cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
THCA	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-38.13	5.9e-146	7.79e-140	-1.05	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-37.95	3.32e-145	2.59e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-37.95	3.32e-145	2.59e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-37.95	3.32e-145	2.59e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-37.95	3.32e-145	2.59e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-37.91	4.62e-145	3.49e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-37.91	4.92e-145	3.49e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-37.91	4.92e-145	3.49e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	37.91	4.92e-145	3.49e-139	1.04	0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-37.85	8.54e-145	5.84e-139	-1.05	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-37.78	1.54e-144	1.02e-138	-1.05	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-37.75	2.21e-144	1.41e-138	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-37.75	2.21e-144	1.41e-138	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-37.68	4.03e-144	2.53e-138	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-37.21	3.42e-142	2.02e-136	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-37.21	3.42e-142	2.02e-136	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	37.19	4.25e-142	2.47e-136	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-37.1	9.34e-142	5.19e-136	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-37.06	1.37e-141	7.49e-136	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-36.83	1.27e-140	6.18e-135	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-36.78	1.94e-140	9.28e-135	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-36.44	5.16e-139	2.2e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-36.44	5.16e-139	2.2e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-36.44	5.16e-139	2.2e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-36.44	5.16e-139	2.2e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	36.41	7.07e-139	2.91e-133	1.03	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	36.41	7.07e-139	2.91e-133	1.03	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	36.41	7.07e-139	2.91e-133	1.03	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-36.26	2.88e-138	1.07e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-36.26	2.88e-138	1.07e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-36.26	2.88e-138	1.07e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	36.23	3.61e-138	1.23e-132	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	36.23	3.61e-138	1.23e-132	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	36.23	3.61e-138	1.23e-132	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	36.17	6.65e-138	2.18e-132	1.03	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-36.09	1.48e-137	4.76e-132	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	35.97	4.59e-137	1.44e-131	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-35.95	5.59e-137	1.74e-131	-1.02	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	35.93	6.55e-137	2.02e-131	1.05	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-35.74	4.13e-136	1.24e-130	-1.04	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-35.68	7.11e-136	2.09e-130	-1.03	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	35.57	2.08e-135	5.94e-130	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
THCA	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	35.52	3.4e-135	9.64e-130	1.06	0.85	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-35.3	2.85e-134	7.79e-129	-1.04	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	34.87	1.95e-132	4.85e-127	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	34.87	1.95e-132	4.85e-127	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	34.87	1.95e-132	4.85e-127	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-34.82	3.11e-132	7.68e-127	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	34.67	1.36e-131	3.33e-126	1.02	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	34.39	2e-130	4.7e-125	1.08	0.85	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	34.29	5.58e-130	1.3e-124	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
THCA	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-34.09	3.77e-129	8.75e-124	-1.05	-0.84	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-34.07	4.78e-129	1.1e-123	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	34.06	5.37e-129	1.23e-123	1.03	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	33.98	1.14e-128	2.58e-123	1.05	0.84	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-33.79	7.18e-128	1.55e-122	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-33.76	9.62e-128	2.05e-122	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-33.76	1.04e-127	2.2e-122	-1	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	33.57	6.33e-127	1.3e-121	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-33.57	6.59e-127	1.33e-121	-1.14	-0.84	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
THCA	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	33.51	1.23e-126	2.45e-121	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	33.49	1.42e-126	2.82e-121	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
THCA	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	33.41	3.25e-126	6.34e-121	1.14	0.84	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
THCA	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	33.38	4.29e-126	8.26e-121	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-33.37	4.56e-126	8.74e-121	-1.04	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	33.32	7.67e-126	1.43e-120	1.06	0.84	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	33.3	8.94e-126	1.65e-120	1.06	0.84	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
THCA	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-33.3	9.75e-126	1.79e-120	-1.14	-0.84	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	33.3	9.84e-126	1.8e-120	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	33.15	4.24e-125	7.63e-120	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	33.12	5.41e-125	9.68e-120	1.05	0.84	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	33.1	6.74e-125	1.2e-119	1.06	0.84	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-32.97	2.46e-124	4.12e-119	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-32.97	2.56e-124	4.27e-119	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-32.96	2.78e-124	4.53e-119	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-32.96	2.78e-124	4.53e-119	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	32.95	3.09e-124	5.02e-119	1.03	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	32.94	3.37e-124	5.45e-119	0.98	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
THCA	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	32.92	4.2e-124	6.7e-119	1	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	32.92	4.2e-124	6.7e-119	1	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	32.91	4.73e-124	7.51e-119	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-32.84	9.21e-124	1.43e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-32.84	9.21e-124	1.43e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-32.82	1.14e-123	1.76e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	32.82	1.16e-123	1.79e-118	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
THCA	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-32.81	1.22e-123	1.88e-118	-1.05	-0.83	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	32.73	2.64e-123	4e-118	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	32.71	3.34e-123	4.97e-118	1.03	0.83	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	32.71	3.34e-123	4.97e-118	1.03	0.83	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	32.71	3.34e-123	4.97e-118	1.03	0.83	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-32.69	4.08e-123	5.96e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-32.69	4.08e-123	5.96e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-32.66	5.31e-123	7.74e-118	-0.97	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	32.65	6.07e-123	8.81e-118	1.02	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	32.62	7.81e-123	1.13e-117	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	32.58	1.22e-122	1.74e-117	1.05	0.83	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	32.58	1.22e-122	1.74e-117	1.05	0.83	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
THCA	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-32.56	1.52e-122	2.16e-117	-1.12	-0.83	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-32.55	1.58e-122	2.23e-117	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	32.52	2.25e-122	3.15e-117	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
THCA	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	32.52	2.33e-122	3.26e-117	1.04	0.83	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-32.51	2.43e-122	3.39e-117	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	32.5	2.75e-122	3.82e-117	0.99	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	32.48	3.36e-122	4.65e-117	1.02	0.83	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	32.45	4.7e-122	6.44e-117	1.02	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-32.43	5.59e-122	7.52e-117	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	32.31	1.91e-121	2.53e-116	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	32.31	1.91e-121	2.53e-116	1.04	0.83	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-32.27	2.68e-121	3.45e-116	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	32.25	3.28e-121	4.02e-116	1.02	0.83	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
THCA	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-32.23	4.03e-121	4.92e-116	-1.12	-0.83	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	32.2	5.33e-121	6.42e-116	1	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-32.2	5.6e-121	6.66e-116	-1.12	-0.83	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-32.2	5.6e-121	6.66e-116	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
THCA	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-32.17	7.36e-121	8.73e-116	-1.11	-0.83	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	32.13	1.16e-120	1.36e-115	1	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	32.1	1.52e-120	1.76e-115	1.02	0.83	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
THCA	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-32.04	2.64e-120	3e-115	-1.03	-0.83	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
THCA	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-31.98	5.01e-120	5.15e-115	-1.12	-0.83	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	31.91	9.77e-120	9.93e-115	0.98	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
THCA	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	31.91	1.03e-119	1.03e-114	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	31.91	1.03e-119	1.03e-114	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	31.91	1.03e-119	1.03e-114	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	31.91	1.03e-119	1.03e-114	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	31.91	1.04e-119	1.04e-114	0.97	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	31.9	1.19e-119	1.16e-114	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	31.88	1.38e-119	1.33e-114	0.95	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
THCA	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-31.87	1.61e-119	1.54e-114	-1.03	-0.83	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	31.82	2.52e-119	2.41e-114	1	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	31.78	4.01e-119	3.79e-114	0.97	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
THCA	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	31.72	6.87e-119	6.42e-114	1.02	0.83	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-31.72	7.18e-119	6.69e-114	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-31.71	7.81e-119	7.24e-114	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	31.65	1.37e-118	1.27e-113	1	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	31.6	2.47e-118	2.23e-113	1.11	0.82	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-31.59	2.62e-118	2.37e-113	-1.01	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
THCA	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-31.58	2.91e-118	2.62e-113	-1.11	-0.82	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
THCA	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-31.58	2.91e-118	2.62e-113	-1.11	-0.82	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	31.58	3.02e-118	2.71e-113	0.96	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
THCA	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-31.57	3.07e-118	2.75e-113	-1.11	-0.82	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
THCA	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	31.55	3.83e-118	3.42e-113	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	31.52	5.26e-118	4.69e-113	1.01	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	31.51	5.78e-118	5.14e-113	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	31.51	6.06e-118	5.35e-113	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	31.51	6.06e-118	5.35e-113	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	31.51	6.06e-118	5.35e-113	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	31.5	6.34e-118	5.56e-113	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	31.5	6.34e-118	5.56e-113	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
THCA	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	31.5	6.34e-118	5.56e-113	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-31.49	7.19e-118	6.29e-113	-1.01	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-31.45	1.03e-117	8.96e-113	-1	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-31.45	1.13e-117	9.8e-113	-1.1	-0.82	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	31.42	1.4e-117	1.21e-112	1.1	0.82	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-31.42	1.52e-117	1.31e-112	-1.11	-0.82	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
THCA	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-31.4	1.73e-117	1.49e-112	-1.11	-0.82	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	31.38	2.12e-117	1.82e-112	0.99	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	31.38	2.19e-117	1.88e-112	1.01	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	31.34	3.34e-117	2.85e-112	0.95	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	31.32	3.99e-117	3.39e-112	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	31.32	4.15e-117	3.52e-112	1.1	0.82	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	31.31	4.52e-117	3.79e-112	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	31.31	4.52e-117	3.79e-112	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	31.31	4.52e-117	3.79e-112	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	31.29	5.24e-117	4.38e-112	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	31.16	1.98e-116	1.63e-111	1.01	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	31.13	2.71e-116	2.21e-111	1.09	0.82	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	31.13	2.71e-116	2.21e-111	1.09	0.82	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	31.13	2.71e-116	2.21e-111	1.09	0.82	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-31.12	3.24e-116	2.55e-111	-1.09	-0.82	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
THCA	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-31.11	3.39e-116	2.65e-111	-1.02	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	31.11	3.46e-116	2.7e-111	1.09	0.82	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	31.1	3.61e-116	2.81e-111	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
THCA	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	31.07	5.33e-116	4.13e-111	1.1	0.82	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
THCA	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-31.06	5.41e-116	4.19e-111	-1.12	-0.82	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
THCA	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	31.02	8.93e-116	6.88e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
THCA	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	30.99	1.19e-115	9.14e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
THCA	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	30.98	1.27e-115	9.78e-111	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	30.98	1.29e-115	9.87e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
THCA	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-30.96	1.55e-115	1.18e-110	-1.03	-0.82	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	30.96	1.64e-115	1.25e-110	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	30.95	1.68e-115	1.28e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	30.94	2.03e-115	1.53e-110	1.09	0.82	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	30.93	2.05e-115	1.55e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	30.93	2.15e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	30.93	2.15e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	30.93	2.15e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	30.93	2.15e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	30.93	2.16e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	30.92	2.27e-115	1.69e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
THCA	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	30.91	2.7e-115	1.94e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
THCA	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	30.91	2.7e-115	1.94e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-30.91	2.74e-115	1.97e-110	-1.01	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	30.89	3.05e-115	2.14e-110	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	30.87	3.82e-115	2.67e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	30.86	4.29e-115	3e-110	1.03	0.82	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	30.85	4.88e-115	3.4e-110	1.09	0.82	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	30.85	4.88e-115	3.4e-110	1.09	0.82	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-30.84	5.55e-115	3.85e-110	-0.96	-0.82	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
THCA	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	30.82	6.58e-115	4.53e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	30.82	6.58e-115	4.53e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-30.8	8.26e-115	5.66e-110	-1.01	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-30.78	9.45e-115	6.45e-110	-1.01	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	30.76	1.24e-114	8.32e-110	1.08	0.82	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	30.76	1.24e-114	8.32e-110	1.08	0.82	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	30.74	1.43e-114	9.57e-110	0.99	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	30.73	1.65e-114	1.1e-109	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
THCA	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-30.72	1.82e-114	1.21e-109	-1.01	-0.82	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
THCA	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	30.71	1.96e-114	1.3e-109	1.08	0.82	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	30.71	1.96e-114	1.3e-109	1.08	0.82	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-30.71	2.05e-114	1.35e-109	-0.96	-0.82	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
THCA	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
THCA	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-30.7	2.29e-114	1.47e-109	-1.02	-0.82	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-30.7	2.29e-114	1.47e-109	-1.02	-0.82	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-30.7	2.29e-114	1.47e-109	-1.02	-0.82	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	30.69	2.52e-114	1.62e-109	0.95	0.82	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
THCA	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	30.67	3e-114	1.93e-109	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	30.67	3.1e-114	1.99e-109	1.08	0.82	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	30.63	4.36e-114	2.79e-109	1.08	0.82	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	30.63	4.36e-114	2.79e-109	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	30.63	4.43e-114	2.82e-109	1.08	0.82	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	30.63	4.43e-114	2.82e-109	1.08	0.82	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	30.63	4.43e-114	2.82e-109	1.08	0.82	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	30.61	5.67e-114	3.61e-109	1.03	0.82	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
THCA	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	30.59	6.95e-114	4.4e-109	1.02	0.82	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	30.59	6.95e-114	4.4e-109	1.02	0.82	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
THCA	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	30.58	7.56e-114	4.78e-109	1.03	0.82	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	30.57	8.66e-114	5.45e-109	1.08	0.82	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	30.57	8.73e-114	5.46e-109	1.08	0.82	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	30.57	8.73e-114	5.46e-109	1.08	0.82	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	30.57	8.73e-114	5.46e-109	1.08	0.82	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	30.52	1.4e-113	8.75e-109	1.07	0.82	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
THCA	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	30.49	1.99e-113	1.23e-108	1.03	0.81	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	30.46	2.71e-113	1.67e-108	1.08	0.81	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	30.4	4.61e-113	2.82e-108	1.03	0.81	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	30.4	4.61e-113	2.82e-108	1.03	0.81	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-30.39	5.19e-113	3.17e-108	-0.97	-0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	30.32	1.04e-112	6.28e-108	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
THCA	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	30.32	1.08e-112	6.5e-108	0.95	0.81	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
THCA	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	30.32	1.1e-112	6.57e-108	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	30.26	1.95e-112	1.15e-107	1.08	0.81	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	30.26	1.95e-112	1.15e-107	1.08	0.81	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	30.24	2.58e-112	1.5e-107	1.08	0.81	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	30.24	2.58e-112	1.5e-107	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	30.23	2.76e-112	1.61e-107	1.02	0.81	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	30.21	3.26e-112	1.89e-107	1.02	0.81	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	30.2	3.75e-112	2.16e-107	1.08	0.81	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
THCA	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-30.2	3.78e-112	2.17e-107	-1.02	-0.81	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
THCA	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-30.2	3.78e-112	2.17e-107	-1.02	-0.81	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
THCA	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	30.18	4.42e-112	2.48e-107	1.08	0.81	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
THCA	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	30.18	4.87e-112	2.72e-107	1.03	0.81	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	30.12	8.9e-112	4.94e-107	1.07	0.81	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	30.11	9.4e-112	5.21e-107	1.08	0.81	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
THCA	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-30.1	1.05e-111	5.81e-107	-1.01	-0.81	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	30.1	1.07e-111	5.93e-107	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
THCA	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-30.1	1.09e-111	5.99e-107	-1.12	-0.81	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
THCA	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	30.1	1.09e-111	6.02e-107	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-30.08	1.28e-111	7.03e-107	-0.97	-0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	30.07	1.4e-111	7.7e-107	1.08	0.81	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	30.07	1.4e-111	7.7e-107	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	30.07	1.43e-111	7.84e-107	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	30.05	1.79e-111	9.74e-107	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	30.05	1.79e-111	9.74e-107	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
THCA	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-30.04	1.93e-111	1.05e-106	-0.95	-0.81	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
THCA	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	30.02	2.42e-111	1.32e-106	1.08	0.81	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	30.02	2.46e-111	1.34e-106	1.02	0.81	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	30	2.88e-111	1.55e-106	1.01	0.81	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-30	2.88e-111	1.55e-106	-1.01	-0.81	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
THCA	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	29.98	3.51e-111	1.88e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	29.98	3.51e-111	1.88e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	29.98	3.51e-111	1.88e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	29.98	3.51e-111	1.88e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
THCA	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	29.97	4.03e-111	2.15e-106	0.94	0.81	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	29.96	4.39e-111	2.34e-106	0.95	0.81	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
THCA	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	29.88	1.04e-110	5.51e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	29.86	1.22e-110	6.41e-106	1.08	0.81	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	29.86	1.24e-110	6.55e-106	1.08	0.81	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
THCA	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-29.85	1.39e-110	7.28e-106	-1.01	-0.81	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	29.85	1.41e-110	7.38e-106	1.08	0.81	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	29.85	1.44e-110	7.56e-106	1.08	0.81	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	29.85	1.45e-110	7.56e-106	0.94	0.81	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	29.83	1.63e-110	8.51e-106	1.08	0.81	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	29.81	2.16e-110	1.12e-105	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
THCA	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-29.79	2.62e-110	1.36e-105	-1.01	-0.81	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	29.79	2.66e-110	1.37e-105	0.97	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	29.78	2.74e-110	1.41e-105	1.08	0.81	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	29.78	2.87e-110	1.47e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	29.78	2.87e-110	1.47e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
THCA	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	29.78	2.87e-110	1.47e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	29.77	3.08e-110	1.56e-105	1.02	0.81	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
THCA	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	29.72	5.2e-110	2.63e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	29.7	6.28e-110	3.16e-105	1.07	0.81	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
THCA	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-29.69	7.07e-110	3.55e-105	-1.09	-0.81	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
THCA	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	29.68	7.89e-110	3.95e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
THCA	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-29.68	7.99e-110	3.99e-105	-1.01	-0.81	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-29.68	7.99e-110	3.99e-105	-1.01	-0.81	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-29.68	7.99e-110	3.99e-105	-1.01	-0.81	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	29.61	1.65e-109	8.18e-105	1.07	0.81	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	29.61	1.69e-109	8.38e-105	0.96	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	29.6	1.85e-109	9.13e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
THCA	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-29.58	2.27e-109	1.12e-104	-1.01	-0.81	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-29.56	2.9e-109	1.38e-104	-1.01	-0.81	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
THCA	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-29.46	7.51e-109	3.53e-104	-1.01	-0.81	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-29.46	7.51e-109	3.53e-104	-1.01	-0.81	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-29.46	7.51e-109	3.53e-104	-1.01	-0.81	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-29.46	7.51e-109	3.53e-104	-1.01	-0.81	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-29.46	7.9e-109	3.71e-104	-1.01	-0.81	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	29.45	8.76e-109	4.11e-104	1.07	0.81	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
THCA	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	29.4	1.45e-108	6.77e-104	1.07	0.8	Shingles;	chr7:38346957	chr7:38343894~38350022:-
THCA	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-29.36	2.19e-108	1.02e-103	-1.02	-0.8	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
THCA	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	29.35	2.5e-108	1.15e-103	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	29.34	2.58e-108	1.19e-103	1.06	0.8	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	29.34	2.58e-108	1.19e-103	1.06	0.8	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	29.34	2.64e-108	1.21e-103	0.98	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-29.25	6.6e-108	3.01e-103	-1.01	-0.8	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
THCA	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	29.25	6.7e-108	3.06e-103	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
THCA	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-29.24	8.03e-108	3.66e-103	-1	-0.8	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	29.21	1.01e-107	4.57e-103	0.93	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
THCA	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-29.21	1.01e-107	4.57e-103	-1.01	-0.8	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	29.14	2.23e-107	1.01e-102	1.08	0.8	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-29.1	3.24e-107	1.46e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-29.02	7.32e-107	3.18e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-29.02	7.32e-107	3.18e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-29.02	7.32e-107	3.18e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-29.02	7.32e-107	3.18e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-29.02	7.45e-107	3.23e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-28.99	9.81e-107	4.24e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-28.96	1.36e-106	5.84e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
THCA	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	28.96	1.39e-106	5.96e-102	1.03	0.8	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	28.93	2.02e-106	8.62e-102	1.06	0.8	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
THCA	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	28.9	2.77e-106	1.17e-101	1.06	0.8	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
THCA	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-28.86	3.98e-106	1.68e-101	-1	-0.8	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-28.85	4.24e-106	1.77e-101	-1	-0.8	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	28.84	5.05e-106	2.1e-101	0.93	0.8	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	28.83	5.24e-106	2.17e-101	1.06	0.8	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	28.81	6.53e-106	2.69e-101	1.06	0.8	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-28.8	7.81e-106	3.22e-101	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-28.79	8.05e-106	3.31e-101	-0.98	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-28.79	8.05e-106	3.31e-101	-0.98	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-28.79	8.05e-106	3.31e-101	-0.98	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-28.79	8.33e-106	3.42e-101	-1	-0.8	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-28.77	1.03e-105	4.21e-101	-1	-0.8	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-28.76	1.09e-105	4.37e-101	-1	-0.8	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-28.76	1.09e-105	4.37e-101	-1	-0.8	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	28.76	1.09e-105	4.37e-101	1	0.8	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	28.76	1.09e-105	4.37e-101	1	0.8	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	28.76	1.09e-105	4.37e-101	1	0.8	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	28.7	2.04e-105	8.13e-101	1.07	0.8	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	28.7	2.21e-105	8.81e-101	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
THCA	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-28.69	2.34e-105	9.3e-101	-0.87	-0.8	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	28.67	2.94e-105	1.17e-100	1.05	0.8	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
THCA	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-28.6	5.9e-105	2.33e-100	-0.87	-0.8	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	28.6	6.14e-105	2.42e-100	1.06	0.8	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
THCA	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	28.59	6.77e-105	2.66e-100	1.03	0.8	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
THCA	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-28.58	7.67e-105	3.01e-100	-0.87	-0.8	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-28.57	8.4e-105	3.29e-100	-1.06	-0.8	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	28.57	8.59e-105	3.36e-100	0.97	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-28.56	9.57e-105	3.73e-100	-1.01	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-28.55	1.05e-104	4.07e-100	-1.02	-0.8	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	28.54	1.14e-104	4.42e-100	1.07	0.8	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	28.53	1.2e-104	4.65e-100	1.06	0.8	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
THCA	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	28.53	1.2e-104	4.65e-100	1.06	0.8	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-28.52	1.46e-104	5.66e-100	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
THCA	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	28.51	1.62e-104	6.27e-100	1	0.8	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	28.49	1.93e-104	7.42e-100	0.98	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
THCA	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	28.4	4.89e-104	1.86e-99	1.01	0.79	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	28.4	4.93e-104	1.87e-99	1.06	0.79	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	28.4	5.02e-104	1.9e-99	1.17	0.79	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
THCA	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	28.36	7.41e-104	2.79e-99	1	0.79	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
THCA	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	28.36	7.51e-104	2.82e-99	1.17	0.79	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
THCA	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-28.36	7.7e-104	2.88e-99	-0.87	-0.79	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
THCA	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-28.34	9.17e-104	3.42e-99	-0.87	-0.79	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
THCA	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	28.34	9.26e-104	3.45e-99	1	0.79	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	28.33	9.96e-104	3.7e-99	1.04	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
THCA	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	28.31	1.21e-103	4.48e-99	0.95	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
THCA	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	28.29	1.57e-103	5.79e-99	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
THCA	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	28.29	1.57e-103	5.79e-99	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
THCA	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	28.25	2.39e-103	8.69e-99	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	28.22	3.36e-103	1.21e-98	1.05	0.79	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	28.22	3.36e-103	1.21e-98	1.05	0.79	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	28.21	3.52e-103	1.27e-98	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
THCA	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-28.21	3.53e-103	1.27e-98	-0.92	-0.79	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	28.19	4.4e-103	1.58e-98	1	0.79	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	28.19	4.59e-103	1.65e-98	1	0.79	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
THCA	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	28.17	5.44e-103	1.95e-98	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	28.16	5.92e-103	2.12e-98	1.01	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
THCA	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	28.13	8.04e-103	2.86e-98	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	28.08	1.41e-102	4.93e-98	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
THCA	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	28.07	1.6e-102	5.6e-98	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
THCA	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	28.06	1.78e-102	6.2e-98	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	28.05	1.97e-102	6.83e-98	1	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
THCA	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-28.03	2.27e-102	7.84e-98	-0.99	-0.79	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	28.01	2.92e-102	1.01e-97	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	28	3.23e-102	1.11e-97	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	27.98	3.95e-102	1.36e-97	1.04	0.79	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	27.96	4.77e-102	1.63e-97	1.04	0.79	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	27.95	5.59e-102	1.91e-97	1.05	0.79	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	27.93	6.57e-102	2.24e-97	1.15	0.79	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
THCA	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-27.93	6.78e-102	2.27e-97	-0.94	-0.79	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	27.93	7.01e-102	2.35e-97	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
THCA	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	27.92	7.25e-102	2.42e-97	0.99	0.79	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	27.9	9.18e-102	3.05e-97	0.96	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
THCA	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	27.89	9.8e-102	3.25e-97	0.94	0.79	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
THCA	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	27.88	1.13e-101	3.74e-97	0.99	0.79	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
THCA	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	27.87	1.23e-101	4.04e-97	1.15	0.79	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
THCA	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	27.87	1.23e-101	4.04e-97	1.15	0.79	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	27.85	1.55e-101	5.1e-97	0.99	0.79	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
THCA	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	27.85	1.61e-101	5.3e-97	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
THCA	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	27.85	1.61e-101	5.3e-97	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
THCA	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	27.84	1.77e-101	5.79e-97	0.99	0.79	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	27.84	1.77e-101	5.79e-97	0.99	0.79	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	27.84	1.77e-101	5.79e-97	0.99	0.79	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	27.82	2.06e-101	6.73e-97	1.03	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
THCA	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	27.8	2.7e-101	8.78e-97	0.99	0.79	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-27.79	2.81e-101	9.08e-97	-0.93	-0.79	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-27.79	2.81e-101	9.08e-97	-0.93	-0.79	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-27.79	2.81e-101	9.08e-97	-0.93	-0.79	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-27.79	2.81e-101	9.08e-97	-0.93	-0.79	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
THCA	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	27.78	3.36e-101	1.08e-96	1.19	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
THCA	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	27.76	3.85e-101	1.24e-96	1.19	0.79	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
THCA	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	27.76	4.17e-101	1.34e-96	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	27.74	4.87e-101	1.56e-96	1.04	0.79	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
THCA	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	27.72	5.92e-101	1.9e-96	1.01	0.79	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
THCA	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-27.71	6.88e-101	2.2e-96	-0.87	-0.79	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
THCA	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	27.67	1.01e-100	3.23e-96	1.18	0.79	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
THCA	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	27.66	1.22e-100	3.86e-96	1	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
THCA	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-27.62	1.74e-100	5.49e-96	-0.99	-0.79	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-27.62	1.85e-100	5.83e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	27.61	1.96e-100	6.16e-96	0.92	0.79	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	27.6	2.25e-100	7e-96	0.93	0.79	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
THCA	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-27.58	2.58e-100	8e-96	-0.99	-0.79	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	27.57	3.13e-100	9.68e-96	0.99	0.79	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	27.57	3.13e-100	9.68e-96	0.99	0.79	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
THCA	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	27.56	3.16e-100	9.77e-96	0.99	0.79	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	27.56	3.34e-100	1.03e-95	1.05	0.79	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	27.55	3.78e-100	1.16e-95	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
THCA	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	27.55	3.78e-100	1.16e-95	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-27.55	3.8e-100	1.17e-95	-1	-0.79	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
THCA	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	27.54	4.07e-100	1.25e-95	1.19	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	27.54	4.27e-100	1.31e-95	1.03	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
THCA	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-27.53	4.71e-100	1.44e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-27.53	4.71e-100	1.44e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-27.53	4.71e-100	1.44e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-27.52	5.23e-100	1.59e-95	-0.92	-0.79	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
THCA	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	27.5	6.17e-100	1.88e-95	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
THCA	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-27.5	6.48e-100	1.97e-95	-0.87	-0.79	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
THCA	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-27.49	6.67e-100	2.03e-95	-1	-0.79	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-27.49	6.83e-100	2.07e-95	-0.92	-0.79	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-27.49	6.83e-100	2.07e-95	-0.92	-0.79	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
THCA	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	27.48	7.44e-100	2.25e-95	0.99	0.79	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-27.48	7.68e-100	2.32e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-27.48	7.68e-100	2.32e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-27.48	7.68e-100	2.32e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-27.48	7.68e-100	2.32e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-27.47	8.24e-100	2.48e-95	-0.92	-0.79	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	27.46	9.25e-100	2.78e-95	0.94	0.78	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-27.42	1.4e-99	4.2e-95	-0.93	-0.78	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-27.42	1.43e-99	4.29e-95	-0.92	-0.78	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-27.41	1.61e-99	4.8e-95	-0.92	-0.78	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-27.41	1.61e-99	4.8e-95	-0.92	-0.78	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
THCA	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	27.4	1.8e-99	5.38e-95	0.96	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
THCA	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-27.39	2.07e-99	6.14e-95	-0.93	-0.78	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	27.38	2.16e-99	6.42e-95	1.14	0.78	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
THCA	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	27.36	2.78e-99	8.23e-95	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-27.34	3.39e-99	1e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-27.34	3.39e-99	1e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	27.32	4.37e-99	1.28e-94	0.94	0.78	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	27.32	4.37e-99	1.28e-94	0.94	0.78	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	27.31	4.77e-99	1.4e-94	0.94	0.78	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-27.26	8e-99	2.33e-94	-0.93	-0.78	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-27.22	1.23e-98	3.54e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-27.21	1.35e-98	3.87e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-27.21	1.35e-98	3.87e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-27.21	1.35e-98	3.87e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	27.19	1.66e-98	4.75e-94	0.94	0.78	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
THCA	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-27.16	2.3e-98	6.52e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-27.16	2.3e-98	6.52e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
THCA	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	27.16	2.34e-98	6.61e-94	0.98	0.78	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
THCA	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-27.15	2.48e-98	6.99e-94	-0.86	-0.78	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
THCA	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-27.13	3.07e-98	8.51e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-27.13	3.07e-98	8.51e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-27.13	3.07e-98	8.51e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-27.13	3.1e-98	8.56e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	27.13	3.1e-98	8.56e-94	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	27.13	3.1e-98	8.56e-94	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
THCA	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	27.13	3.26e-98	9e-94	0.94	0.78	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
THCA	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-27.13	3.26e-98	9.01e-94	-1.07	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
THCA	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	27.12	3.6e-98	9.91e-94	0.97	0.78	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
THCA	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-27.1	4.16e-98	1.14e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	27.1	4.18e-98	1.15e-93	0.94	0.78	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
THCA	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-27.1	4.48e-98	1.23e-93	-1.06	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
THCA	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-27.08	5.1e-98	1.39e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-27.08	5.1e-98	1.39e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-27.08	5.1e-98	1.39e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-27.08	5.1e-98	1.39e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	27.08	5.31e-98	1.45e-93	1.15	0.78	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
THCA	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-27.07	5.82e-98	1.58e-93	-0.87	-0.78	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
THCA	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
THCA	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-27.04	8.17e-98	2.18e-93	-1.06	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
THCA	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	27.03	9.02e-98	2.41e-93	0.93	0.78	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	27.03	9.02e-98	2.41e-93	0.93	0.78	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
THCA	cis	rs4853012	0.793	rs6723185	ENSG00000217702.2	RP11-287D1.4	27.01	1.07e-97	2.82e-93	1.15	0.78	Gestational age at birth (maternal effect);	chr2:74117757	chr2:74130583~74135395:+
THCA	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-27.01	1.12e-97	2.96e-93	-1.07	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
THCA	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-26.99	1.33e-97	3.48e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	26.98	1.57e-97	4.11e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
THCA	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-26.97	1.77e-97	4.61e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	26.96	1.82e-97	4.73e-93	1	0.78	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-26.96	1.93e-97	4.99e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
THCA	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	26.95	2.08e-97	5.36e-93	0.99	0.78	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	26.95	2.17e-97	5.59e-93	0.95	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	26.94	2.24e-97	5.77e-93	0.99	0.78	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-26.94	2.38e-97	6.1e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-26.94	2.38e-97	6.1e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-26.94	2.38e-97	6.1e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-26.94	2.38e-97	6.1e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-26.92	3.02e-97	7.67e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-26.91	3.15e-97	8e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-26.91	3.29e-97	8.35e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-26.91	3.29e-97	8.35e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	26.9	3.73e-97	9.44e-93	0.93	0.78	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
THCA	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-26.89	4.15e-97	1.05e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-26.89	4.15e-97	1.05e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
THCA	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	26.87	4.86e-97	1.22e-92	0.94	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
THCA	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-26.86	5.19e-97	1.31e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-26.86	5.58e-97	1.38e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-26.86	5.63e-97	1.38e-92	-0.84	-0.78	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
THCA	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-26.82	8.6e-97	2.09e-92	-0.99	-0.78	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
THCA	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-26.82	8.69e-97	2.11e-92	-1.07	-0.78	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
THCA	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-26.81	9.14e-97	2.21e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-26.8	9.88e-97	2.39e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	26.79	1.16e-96	2.8e-92	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	26.79	1.16e-96	2.8e-92	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
THCA	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	26.78	1.32e-96	3.17e-92	1.12	0.78	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
THCA	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-26.78	1.35e-96	3.23e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	26.75	1.79e-96	4.27e-92	0.93	0.78	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
THCA	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-26.73	2.16e-96	5.14e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-26.73	2.28e-96	5.41e-92	-0.86	-0.78	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
THCA	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-26.73	2.28e-96	5.41e-92	-0.86	-0.78	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
THCA	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-26.72	2.54e-96	6.02e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
THCA	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	26.69	3.34e-96	7.86e-92	1.17	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	26.69	3.34e-96	7.86e-92	1.17	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
THCA	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-26.65	4.92e-96	1.15e-91	-0.96	-0.78	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
THCA	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-26.65	4.98e-96	1.16e-91	-0.92	-0.78	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-26.65	4.98e-96	1.16e-91	-0.92	-0.78	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	26.65	5.29e-96	1.23e-91	1.22	0.78	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
THCA	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-26.64	5.74e-96	1.33e-91	-0.93	-0.78	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-26.64	5.74e-96	1.33e-91	-0.93	-0.78	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-26.63	6.46e-96	1.49e-91	-0.92	-0.78	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-26.62	6.8e-96	1.57e-91	-0.92	-0.78	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-26.59	9.17e-96	2.11e-91	-0.93	-0.78	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-26.57	1.17e-95	2.69e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	26.56	1.32e-95	3.02e-91	0.9	0.77	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	26.56	1.36e-95	3.11e-91	0.95	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-26.55	1.42e-95	3.24e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	26.54	1.56e-95	3.56e-91	0.92	0.77	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-26.53	1.82e-95	4.15e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
THCA	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-26.53	1.89e-95	4.3e-91	-0.87	-0.77	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
THCA	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	26.52	2.04e-95	4.63e-91	0.98	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
THCA	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-26.52	2.09e-95	4.73e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-26.52	2.09e-95	4.73e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-26.5	2.51e-95	5.68e-91	-0.92	-0.77	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	26.48	3.15e-95	7.1e-91	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-26.46	3.85e-95	8.65e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
THCA	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	26.46	3.92e-95	8.8e-91	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
THCA	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	26.45	4.16e-95	9.33e-91	1.05	0.77	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
THCA	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-26.45	4.2e-95	9.41e-91	-0.92	-0.77	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-26.45	4.33e-95	9.69e-91	-0.85	-0.77	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
THCA	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-26.45	4.47e-95	1e-90	-0.86	-0.77	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
THCA	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-26.43	5.32e-95	1.19e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-26.43	5.32e-95	1.19e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	26.39	7.9e-95	1.75e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-26.39	8.05e-95	1.79e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-26.37	9.62e-95	2.13e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	26.37	9.63e-95	2.13e-90	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-26.36	1.08e-94	2.39e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-26.36	1.16e-94	2.56e-90	-0.93	-0.77	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	26.34	1.35e-94	2.95e-90	0.93	0.77	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
THCA	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
THCA	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	26.34	1.37e-94	2.99e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	26.34	1.37e-94	2.99e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
THCA	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	26.34	1.37e-94	2.99e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
THCA	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	26.34	1.37e-94	2.99e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	26.33	1.52e-94	3.32e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	26.33	1.52e-94	3.32e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
THCA	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	26.32	1.65e-94	3.56e-90	1.19	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
THCA	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-26.32	1.71e-94	3.7e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-26.32	1.71e-94	3.7e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-26.32	1.71e-94	3.7e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
THCA	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	26.32	1.74e-94	3.75e-90	0.95	0.77	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
THCA	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	26.32	1.74e-94	3.75e-90	0.95	0.77	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
THCA	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	26.32	1.74e-94	3.75e-90	0.95	0.77	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
THCA	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-26.32	1.74e-94	3.75e-90	-0.95	-0.77	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-26.31	1.9e-94	4.07e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-26.31	1.9e-94	4.07e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-26.31	1.9e-94	4.07e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-26.31	1.96e-94	4.2e-90	-0.87	-0.77	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
THCA	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-26.3	2.2e-94	4.73e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
THCA	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-26.29	2.47e-94	5.3e-90	-0.94	-0.77	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
THCA	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	26.27	2.92e-94	6.24e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-26.27	2.97e-94	6.35e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-26.24	3.92e-94	8.34e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
THCA	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	26.23	4.4e-94	9.33e-90	0.94	0.77	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
THCA	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	26.23	4.4e-94	9.33e-90	0.94	0.77	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-26.23	4.66e-94	9.89e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-26.22	4.77e-94	1.01e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-26.15	1.01e-93	2.12e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-26.15	1.01e-93	2.12e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-26.15	1.01e-93	2.12e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-26.15	1.01e-93	2.12e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-26.14	1.13e-93	2.36e-89	-0.91	-0.77	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-26.11	1.53e-93	3.19e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-26.1	1.74e-93	3.62e-89	-0.91	-0.77	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-26.08	2.15e-93	4.45e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
THCA	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	26.06	2.86e-93	5.92e-89	0.94	0.77	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
THCA	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	26.04	3.27e-93	6.75e-89	1.2	0.77	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
THCA	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	26.01	4.62e-93	9.53e-89	1.18	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
THCA	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-26.01	4.8e-93	9.88e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-26.01	4.8e-93	9.88e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	25.91	1.43e-92	2.91e-88	0.97	0.77	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	25.89	1.59e-92	3.24e-88	0.85	0.77	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
THCA	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	25.89	1.73e-92	3.53e-88	0.96	0.77	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
THCA	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-25.87	2.01e-92	4.09e-88	-0.92	-0.77	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
THCA	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-25.86	2.32e-92	4.72e-88	-0.93	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
THCA	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	25.85	2.57e-92	5.21e-88	0.96	0.77	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
THCA	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	25.82	3.4e-92	6.88e-88	0.96	0.77	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
THCA	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	25.81	4e-92	8.08e-88	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-25.74	8.18e-92	1.65e-87	-0.92	-0.76	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
THCA	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-25.74	8.61e-92	1.73e-87	-0.97	-0.76	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
THCA	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	25.74	8.72e-92	1.75e-87	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
THCA	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	25.72	1.05e-91	2.1e-87	0.91	0.76	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
THCA	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	25.72	1.08e-91	2.16e-87	1.13	0.76	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	25.71	1.19e-91	2.38e-87	1.02	0.76	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	25.68	1.57e-91	3.13e-87	0.96	0.76	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-25.67	1.85e-91	3.69e-87	-0.92	-0.76	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-25.65	2.1e-91	4.18e-87	-0.91	-0.76	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-25.65	2.1e-91	4.18e-87	-0.91	-0.76	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	25.63	2.83e-91	5.64e-87	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	25.61	3.23e-91	6.41e-87	1.02	0.76	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	25.56	5.66e-91	1.12e-86	1.02	0.76	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
THCA	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	25.56	5.75e-91	1.14e-86	0.97	0.76	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-25.55	6.52e-91	1.29e-86	-0.96	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
THCA	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-25.54	6.84e-91	1.35e-86	-0.91	-0.76	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-25.53	8.23e-91	1.62e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-25.53	8.23e-91	1.62e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
THCA	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	25.51	9.68e-91	1.9e-86	0.96	0.76	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-25.5	1.13e-90	2.22e-86	-0.93	-0.76	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	25.49	1.16e-90	2.28e-86	0.98	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
THCA	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-25.48	1.37e-90	2.68e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	25.41	2.73e-90	5.34e-86	1.02	0.76	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
THCA	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	25.4	3.32e-90	6.45e-86	0.93	0.76	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
THCA	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	25.4	3.32e-90	6.45e-86	0.93	0.76	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
THCA	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	25.4	3.32e-90	6.45e-86	0.93	0.76	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
THCA	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	25.39	3.38e-90	6.57e-86	0.93	0.76	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	25.39	3.44e-90	6.69e-86	1.01	0.76	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	25.39	3.44e-90	6.69e-86	1.01	0.76	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
THCA	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-25.38	3.93e-90	7.61e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	25.38	4.07e-90	7.87e-86	0.93	0.76	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
THCA	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	25.37	4.32e-90	8.37e-86	1.19	0.76	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
THCA	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	25.35	5.59e-90	1.08e-85	0.92	0.76	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	25.35	5.62e-90	1.09e-85	1.01	0.76	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-25.35	5.66e-90	1.09e-85	-0.92	-0.76	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-25.33	6.43e-90	1.24e-85	-0.9	-0.76	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	25.32	7.28e-90	1.4e-85	1.01	0.76	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	25.3	8.83e-90	1.69e-85	1.01	0.76	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	25.3	9.15e-90	1.75e-85	1.01	0.76	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	25.3	9.15e-90	1.75e-85	1.01	0.76	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	25.3	9.15e-90	1.75e-85	1.01	0.76	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	25.3	9.15e-90	1.75e-85	1.01	0.76	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	25.3	9.75e-90	1.86e-85	1.02	0.76	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	25.3	9.75e-90	1.86e-85	1.02	0.76	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	25.3	9.75e-90	1.86e-85	1.02	0.76	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	25.3	9.75e-90	1.86e-85	1.02	0.76	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
THCA	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-25.26	1.39e-89	2.64e-85	-0.86	-0.76	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	25.26	1.45e-89	2.75e-85	1.02	0.76	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	25.25	1.55e-89	2.95e-85	0.9	0.76	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	25.25	1.65e-89	3.12e-85	0.92	0.76	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	25.24	1.71e-89	3.22e-85	0.92	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	25.24	1.81e-89	3.42e-85	1.02	0.76	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	25.23	2.06e-89	3.89e-85	1.02	0.76	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-25.22	2.15e-89	4.05e-85	-0.89	-0.76	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-25.22	2.23e-89	4.21e-85	-0.9	-0.76	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	25.22	2.24e-89	4.22e-85	1.02	0.76	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	25.22	2.24e-89	4.22e-85	1.02	0.76	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-25.21	2.39e-89	4.49e-85	-0.89	-0.76	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	25.2	2.71e-89	5.07e-85	1.02	0.76	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	25.2	2.72e-89	5.1e-85	1.13	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
THCA	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	25.2	2.72e-89	5.1e-85	1.13	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	25.2	2.75e-89	5.14e-85	0.9	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
THCA	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	25.2	2.85e-89	5.34e-85	1.19	0.76	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
THCA	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-25.19	3.1e-89	5.79e-85	-0.85	-0.76	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
THCA	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-25.18	3.43e-89	6.41e-85	-0.86	-0.76	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	25.18	3.54e-89	6.6e-85	1.01	0.76	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	25.18	3.54e-89	6.6e-85	1.01	0.76	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	25.17	3.6e-89	6.72e-85	1.02	0.76	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	25.17	3.63e-89	6.76e-85	1.02	0.76	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	25.17	3.71e-89	6.9e-85	1.01	0.76	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	25.16	4.02e-89	7.46e-85	1.01	0.76	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	25.16	4.03e-89	7.48e-85	1.02	0.76	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	25.16	4.03e-89	7.48e-85	1.02	0.76	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
THCA	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	25.16	4.21e-89	7.81e-85	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	25.15	4.42e-89	8.17e-85	0.9	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	25.15	4.53e-89	8.36e-85	1.01	0.76	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	25.14	4.94e-89	9.1e-85	1.01	0.76	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	25.14	4.94e-89	9.1e-85	1.01	0.76	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	25.13	5.59e-89	1.03e-84	1.01	0.76	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	25.13	5.87e-89	1.08e-84	1.01	0.76	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	25.13	5.87e-89	1.08e-84	1.01	0.76	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	25.13	5.9e-89	1.08e-84	1.01	0.76	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	25.13	6.03e-89	1.11e-84	1.13	0.76	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	25.11	6.79e-89	1.24e-84	1.01	0.76	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
THCA	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	25.09	8.77e-89	1.6e-84	0.96	0.76	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	25.09	9.24e-89	1.68e-84	1.01	0.76	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	25.08	9.55e-89	1.74e-84	1.01	0.76	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-25.08	1.01e-88	1.82e-84	-0.89	-0.76	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	25.06	1.2e-88	2.16e-84	1.01	0.76	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	25.06	1.26e-88	2.26e-84	0.91	0.76	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	25.06	1.28e-88	2.3e-84	1.01	0.76	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	25.05	1.31e-88	2.35e-84	1.01	0.76	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	25.05	1.34e-88	2.41e-84	1.01	0.76	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	25.05	1.34e-88	2.41e-84	1.01	0.76	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	25.05	1.35e-88	2.42e-84	1.01	0.76	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	25.05	1.35e-88	2.42e-84	1.01	0.76	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	25.05	1.4e-88	2.51e-84	1.01	0.76	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	25.05	1.4e-88	2.51e-84	1.01	0.76	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	25.05	1.4e-88	2.51e-84	1.01	0.76	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	25.04	1.55e-88	2.76e-84	1.01	0.76	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	25.04	1.55e-88	2.76e-84	1.01	0.76	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	25.02	1.79e-88	3.18e-84	1.02	0.76	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-25.02	1.82e-88	3.24e-84	-0.89	-0.76	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	25.02	1.91e-88	3.4e-84	1.11	0.76	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	25.02	1.93e-88	3.42e-84	1.01	0.76	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
THCA	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	25.01	2.04e-88	3.61e-84	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	25.01	2.09e-88	3.7e-84	1.01	0.76	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	25.01	2.19e-88	3.87e-84	1.01	0.76	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	25.01	2.2e-88	3.89e-84	0.88	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	25	2.43e-88	4.3e-84	0.88	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	24.99	2.67e-88	4.71e-84	0.9	0.76	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	24.98	2.9e-88	5.1e-84	1.02	0.76	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
THCA	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	24.98	2.9e-88	5.11e-84	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
THCA	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	24.98	2.9e-88	5.11e-84	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	24.97	3.11e-88	5.46e-84	1.01	0.76	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	24.97	3.12e-88	5.48e-84	1.01	0.76	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	24.97	3.28e-88	5.75e-84	1.02	0.76	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	24.97	3.32e-88	5.83e-84	0.91	0.76	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	24.95	3.95e-88	6.92e-84	1.01	0.75	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	24.95	4.09e-88	7.16e-84	0.89	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	24.95	4.2e-88	7.34e-84	1.01	0.75	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	24.95	4.2e-88	7.34e-84	1.01	0.75	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	24.94	4.23e-88	7.38e-84	1.01	0.75	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	24.94	4.23e-88	7.39e-84	0.91	0.75	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	24.94	4.33e-88	7.55e-84	1.01	0.75	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	24.94	4.33e-88	7.55e-84	1.01	0.75	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	24.93	4.79e-88	8.33e-84	1.11	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-24.93	5.05e-88	8.77e-84	-1.01	-0.75	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	24.91	6.24e-88	1.08e-83	1	0.75	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	24.9	6.93e-88	1.19e-83	1	0.75	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	24.89	7.7e-88	1.33e-83	1	0.75	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	24.89	7.94e-88	1.37e-83	1	0.75	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	24.88	8.57e-88	1.47e-83	1.01	0.75	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	24.87	9.35e-88	1.61e-83	1	0.75	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	24.87	9.9e-88	1.7e-83	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	24.87	9.93e-88	1.7e-83	1.01	0.75	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	24.86	9.97e-88	1.71e-83	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
THCA	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	24.85	1.16e-87	1.98e-83	0.89	0.75	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
THCA	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	24.85	1.16e-87	1.98e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
THCA	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	24.85	1.16e-87	1.98e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	24.85	1.19e-87	2.03e-83	1.01	0.75	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	24.85	1.23e-87	2.09e-83	1.01	0.75	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	24.84	1.27e-87	2.18e-83	0.9	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
THCA	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-24.84	1.29e-87	2.21e-83	-0.84	-0.75	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
THCA	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	24.84	1.29e-87	2.21e-83	1	0.75	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	24.83	1.39e-87	2.37e-83	1.02	0.75	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-24.83	1.42e-87	2.42e-83	-1.02	-0.75	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	24.83	1.44e-87	2.45e-83	1.01	0.75	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	24.82	1.67e-87	2.83e-83	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	24.81	1.72e-87	2.92e-83	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-24.8	1.92e-87	3.25e-83	-0.89	-0.75	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
THCA	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	24.79	2.14e-87	3.62e-83	0.98	0.75	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
THCA	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	24.78	2.39e-87	4.04e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
THCA	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	24.78	2.53e-87	4.27e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
THCA	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	24.78	2.53e-87	4.27e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
THCA	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	24.77	2.67e-87	4.51e-83	0.91	0.75	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	24.77	2.9e-87	4.89e-83	1.01	0.75	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	24.75	3.33e-87	5.61e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	24.73	4.08e-87	6.87e-83	1.02	0.75	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	24.72	4.64e-87	7.8e-83	1.01	0.75	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	24.72	4.69e-87	7.88e-83	1	0.75	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	24.72	4.69e-87	7.88e-83	1	0.75	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	24.72	4.69e-87	7.88e-83	1	0.75	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-24.71	5.1e-87	8.57e-83	-0.9	-0.75	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	24.71	5.31e-87	8.91e-83	1	0.75	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	24.71	5.32e-87	8.91e-83	1.01	0.75	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	24.7	5.86e-87	9.81e-83	1.13	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
THCA	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	24.68	6.92e-87	1.16e-82	0.89	0.75	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	24.67	8.14e-87	1.36e-82	1.03	0.75	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	24.67	8.32e-87	1.39e-82	0.91	0.75	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	24.65	9.61e-87	1.6e-82	0.89	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-24.62	1.35e-86	2.25e-82	-0.89	-0.75	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.832	rs2070835	ENSG00000198496.9	NBR2	-24.6	1.67e-86	2.78e-82	-0.9	-0.75	Menopause (age at onset);	chr17:43022008	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	24.6	1.74e-86	2.89e-82	1	0.75	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-24.59	2.03e-86	3.36e-82	-0.89	-0.75	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	24.58	2.16e-86	3.58e-82	1.03	0.75	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	24.58	2.16e-86	3.58e-82	1.03	0.75	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	24.57	2.39e-86	3.96e-82	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	24.56	2.61e-86	4.32e-82	1	0.75	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	24.56	2.64e-86	4.36e-82	0.9	0.75	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	24.55	2.81e-86	4.64e-82	1.02	0.75	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	24.55	2.81e-86	4.64e-82	1.02	0.75	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	24.55	2.81e-86	4.64e-82	1.02	0.75	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-24.5	4.98e-86	8.17e-82	-0.89	-0.75	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-24.5	4.98e-86	8.17e-82	-0.89	-0.75	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
THCA	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	24.5	4.98e-86	8.17e-82	1.3	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	24.5	5.21e-86	8.56e-82	1.02	0.75	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	24.49	5.74e-86	9.4e-82	1.01	0.75	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	24.49	5.74e-86	9.4e-82	1.01	0.75	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	24.44	9.36e-86	1.52e-81	0.89	0.75	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	24.44	9.68e-86	1.58e-81	1	0.75	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-24.43	1.11e-85	1.81e-81	-0.9	-0.75	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
THCA	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	24.43	1.13e-85	1.84e-81	1.12	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	24.4	1.46e-85	2.37e-81	1.02	0.75	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	24.4	1.46e-85	2.37e-81	1.02	0.75	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	24.38	1.94e-85	3.14e-81	1.03	0.75	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-24.37	2.05e-85	3.31e-81	-0.87	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
THCA	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	24.37	2.13e-85	3.45e-81	1.16	0.75	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
THCA	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	24.37	2.13e-85	3.45e-81	1.16	0.75	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	24.35	2.62e-85	4.24e-81	1.03	0.75	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-24.34	2.9e-85	4.68e-81	-0.89	-0.75	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	24.33	3.22e-85	5.19e-81	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
THCA	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-24.32	3.58e-85	5.77e-81	-0.84	-0.75	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
THCA	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	24.31	3.78e-85	6.1e-81	0.89	0.75	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
THCA	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	24.3	4.4e-85	7.06e-81	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-24.3	4.41e-85	7.06e-81	-0.89	-0.75	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	24.3	4.41e-85	7.06e-81	1.1	0.75	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
THCA	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	24.3	4.57e-85	7.31e-81	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	24.28	5.62e-85	8.98e-81	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	24.27	6.26e-85	9.99e-81	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	24.27	6.26e-85	9.99e-81	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	24.23	9.55e-85	1.52e-80	1.02	0.75	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	24.22	1.07e-84	1.71e-80	1.03	0.75	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	24.22	1.07e-84	1.71e-80	1.03	0.75	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	24.21	1.19e-84	1.89e-80	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	24.21	1.19e-84	1.89e-80	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	24.21	1.2e-84	1.9e-80	1	0.74	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-24.2	1.26e-84	2e-80	-0.92	-0.74	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
THCA	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	24.2	1.31e-84	2.08e-80	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
THCA	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	24.2	1.35e-84	2.14e-80	0.82	0.74	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
THCA	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-24.19	1.41e-84	2.23e-80	-0.89	-0.74	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	24.19	1.44e-84	2.28e-80	1.02	0.74	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	24.18	1.52e-84	2.4e-80	1.02	0.74	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	24.18	1.67e-84	2.64e-80	1.02	0.74	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	24.17	1.85e-84	2.92e-80	1.12	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	24.17	1.88e-84	2.96e-80	1.02	0.74	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	24.16	2.02e-84	3.19e-80	1.02	0.74	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	24.16	2.02e-84	3.19e-80	1.02	0.74	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	24.15	2.16e-84	3.4e-80	1.03	0.74	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	24.14	2.34e-84	3.68e-80	0.9	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
THCA	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	24.14	2.44e-84	3.83e-80	0.79	0.74	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	24.11	3.4e-84	5.31e-80	1	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	24.11	3.4e-84	5.31e-80	1	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
THCA	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	24.1	3.66e-84	5.72e-80	0.89	0.74	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	24.07	5.33e-84	8.27e-80	0.89	0.74	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	24.07	5.41e-84	8.39e-80	0.89	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
THCA	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	24.04	7.22e-84	1.12e-79	0.86	0.74	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	24.04	7.29e-84	1.13e-79	0.88	0.74	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	24.02	9.36e-84	1.43e-79	0.89	0.74	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	24.02	9.39e-84	1.44e-79	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	24.01	9.51e-84	1.46e-79	0.98	0.74	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-24	1.13e-83	1.73e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-23.99	1.29e-83	1.98e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
THCA	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	23.98	1.43e-83	2.19e-79	0.93	0.74	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-23.96	1.68e-83	2.56e-79	-0.87	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-23.96	1.7e-83	2.58e-79	-0.89	-0.74	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	23.95	1.89e-83	2.87e-79	0.89	0.74	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	23.94	2.05e-83	3.11e-79	1	0.74	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
THCA	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-23.94	2.07e-83	3.14e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	23.92	2.57e-83	3.87e-79	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	23.9	3.13e-83	4.65e-79	0.98	0.74	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	23.9	3.17e-83	4.7e-79	0.94	0.74	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	23.9	3.17e-83	4.7e-79	0.94	0.74	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
THCA	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-23.89	3.76e-83	5.56e-79	-1.04	-0.74	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	23.87	4.79e-83	7.06e-79	1.02	0.74	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
THCA	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	23.86	5.24e-83	7.72e-79	0.94	0.74	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
THCA	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	23.86	5.32e-83	7.82e-79	0.94	0.74	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-23.85	5.58e-83	8.19e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	23.85	5.64e-83	8.27e-79	0.88	0.74	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	23.85	5.64e-83	8.27e-79	0.88	0.74	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	23.85	5.64e-83	8.27e-79	0.88	0.74	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-23.85	5.82e-83	8.53e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-23.84	6.28e-83	9.2e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-23.84	6.45e-83	9.44e-79	-0.83	-0.74	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	23.84	6.51e-83	9.53e-79	1.01	0.74	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
THCA	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	23.82	7.41e-83	1.08e-78	0.8	0.74	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
THCA	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	23.82	7.62e-83	1.11e-78	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-23.81	8.96e-83	1.3e-78	-0.87	-0.74	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	23.8	9.32e-83	1.35e-78	0.97	0.74	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
THCA	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-23.8	9.77e-83	1.42e-78	-0.83	-0.74	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	23.79	1.05e-82	1.52e-78	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
THCA	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	23.79	1.08e-82	1.57e-78	0.98	0.74	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-23.79	1.08e-82	1.57e-78	-0.87	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
THCA	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	23.77	1.31e-82	1.9e-78	0.98	0.74	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	23.76	1.52e-82	2.2e-78	1	0.74	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
THCA	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	23.75	1.74e-82	2.5e-78	0.94	0.74	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
THCA	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	23.73	2.04e-82	2.91e-78	1.28	0.74	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	23.73	2.04e-82	2.91e-78	1.28	0.74	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	23.73	2.04e-82	2.91e-78	1.28	0.74	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	23.73	2.04e-82	2.91e-78	1.28	0.74	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	23.73	2.15e-82	3.08e-78	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-23.72	2.26e-82	3.23e-78	-0.88	-0.74	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	23.68	3.52e-82	5e-78	0.88	0.74	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	23.67	3.84e-82	5.44e-78	0.88	0.74	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	23.67	3.84e-82	5.44e-78	0.88	0.74	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
THCA	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	23.66	4.33e-82	6.11e-78	0.93	0.74	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-23.66	4.45e-82	6.27e-78	-0.95	-0.74	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	23.64	5.66e-82	7.95e-78	0.99	0.74	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	23.6	8.44e-82	1.18e-77	0.85	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	23.52	1.97e-81	2.72e-77	0.94	0.74	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	23.52	2.04e-81	2.81e-77	1	0.74	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-23.5	2.55e-81	3.5e-77	-0.87	-0.73	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-23.49	2.88e-81	3.94e-77	-0.87	-0.73	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	23.48	3.03e-81	4.14e-77	0.94	0.73	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
THCA	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	23.43	5.24e-81	7.09e-77	1.28	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	23.43	5.24e-81	7.09e-77	1.28	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	23.43	5.33e-81	7.2e-77	1.02	0.73	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-23.43	5.51e-81	7.45e-77	-0.99	-0.73	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-23.41	6.64e-81	8.97e-77	-0.86	-0.73	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
THCA	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	23.41	6.8e-81	9.17e-77	0.79	0.73	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	23.41	6.8e-81	9.17e-77	0.79	0.73	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	23.41	6.8e-81	9.17e-77	0.79	0.73	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
THCA	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-23.39	7.89e-81	1.06e-76	-0.86	-0.73	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
THCA	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	23.39	8.53e-81	1.15e-76	0.8	0.73	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	23.39	8.53e-81	1.15e-76	0.8	0.73	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	23.39	8.53e-81	1.15e-76	0.8	0.73	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	23.39	8.53e-81	1.15e-76	0.8	0.73	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
THCA	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	23.38	9e-81	1.21e-76	0.86	0.73	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	23.38	9.08e-81	1.22e-76	0.98	0.73	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	23.37	1.03e-80	1.38e-76	1.3	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-23.36	1.09e-80	1.46e-76	-0.94	-0.73	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	23.3	2.11e-80	2.8e-76	1.01	0.73	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
THCA	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-23.29	2.54e-80	3.35e-76	-1.09	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
THCA	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-23.26	3.22e-80	4.25e-76	-0.82	-0.73	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
THCA	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	23.25	3.71e-80	4.88e-76	0.98	0.73	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	23.24	4.09e-80	5.39e-76	0.88	0.73	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	23.24	4.24e-80	5.58e-76	0.87	0.73	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
THCA	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	23.23	4.42e-80	5.8e-76	1.3	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	23.21	5.54e-80	7.26e-76	1.01	0.73	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	23.21	5.54e-80	7.26e-76	1.01	0.73	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
THCA	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	23.18	8.22e-80	1.07e-75	0.79	0.73	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	23.18	8.22e-80	1.07e-75	0.79	0.73	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	23.18	8.22e-80	1.07e-75	0.79	0.73	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
THCA	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-23.15	1.04e-79	1.36e-75	-1.06	-0.73	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
THCA	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	23.14	1.27e-79	1.65e-75	0.79	0.73	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
THCA	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-23.13	1.41e-79	1.83e-75	-0.87	-0.73	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-23.1	1.92e-79	2.47e-75	-0.87	-0.73	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
THCA	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	23.04	3.58e-79	4.56e-75	0.79	0.73	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
THCA	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-23.02	4.57e-79	5.8e-75	-0.86	-0.73	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
THCA	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	22.97	7.79e-79	9.82e-75	1.05	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	22.96	8.57e-79	1.08e-74	0.98	0.73	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	22.94	1.11e-78	1.39e-74	0.88	0.73	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-22.94	1.13e-78	1.41e-74	-0.86	-0.73	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	22.85	2.7e-78	3.34e-74	0.92	0.73	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	22.85	2.77e-78	3.42e-74	1	0.73	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	22.85	2.97e-78	3.65e-74	1.25	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
THCA	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	22.85	2.97e-78	3.65e-74	1.25	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
THCA	cis	rs10256972	0.527	rs2949170	ENSG00000229043.2	AC091729.9	-22.83	3.54e-78	4.33e-74	-0.83	-0.73	Endometriosis;Longevity;	chr7:1176802	chr7:1160374~1165267:+
THCA	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-22.83	3.58e-78	4.37e-74	-1.06	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
THCA	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-22.81	4.22e-78	5.14e-74	-0.88	-0.72	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
THCA	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	22.81	4.46e-78	5.44e-74	1.3	0.72	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
THCA	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	22.8	4.85e-78	5.87e-74	0.99	0.72	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
THCA	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-22.8	4.86e-78	5.88e-74	-1.07	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-22.8	4.86e-78	5.88e-74	-1.07	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
THCA	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	22.8	5.05e-78	6.11e-74	0.81	0.72	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
THCA	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	22.75	8.12e-78	9.72e-74	1.1	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
THCA	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-22.73	1.05e-77	1.24e-73	-0.86	-0.72	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-22.68	1.86e-77	2.15e-73	-0.92	-0.72	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-22.66	2.33e-77	2.69e-73	-0.92	-0.72	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-22.66	2.35e-77	2.71e-73	-0.86	-0.72	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
THCA	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	22.65	2.62e-77	3.02e-73	0.78	0.72	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
THCA	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-22.63	3.05e-77	3.49e-73	-1.07	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	22.63	3.13e-77	3.59e-73	1	0.72	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-22.63	3.18e-77	3.64e-73	-0.92	-0.72	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-22.62	3.37e-77	3.84e-73	-0.85	-0.72	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
THCA	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	22.62	3.55e-77	4.04e-73	1.26	0.72	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-22.6	4.24e-77	4.81e-73	-0.92	-0.72	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
THCA	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	22.59	4.57e-77	5.18e-73	0.78	0.72	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
THCA	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-22.59	4.75e-77	5.39e-73	-0.9	-0.72	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-22.56	6.41e-77	7.14e-73	-0.92	-0.72	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-22.56	6.55e-77	7.3e-73	-0.92	-0.72	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-22.56	6.55e-77	7.3e-73	-0.92	-0.72	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
THCA	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-22.55	7.55e-77	8.39e-73	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
THCA	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-22.55	7.55e-77	8.39e-73	-0.92	-0.72	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
THCA	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	22.54	7.97e-77	8.85e-73	0.92	0.72	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-22.52	1.06e-76	1.17e-72	-0.84	-0.72	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
THCA	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-22.51	1.16e-76	1.28e-72	-0.92	-0.72	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-22.51	1.16e-76	1.28e-72	-0.92	-0.72	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-22.51	1.16e-76	1.28e-72	-0.92	-0.72	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
THCA	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	22.5	1.22e-76	1.34e-72	0.92	0.72	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
THCA	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-22.5	1.23e-76	1.35e-72	-0.92	-0.72	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
THCA	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	22.5	1.27e-76	1.4e-72	0.92	0.72	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	22.5	1.27e-76	1.4e-72	0.92	0.72	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
THCA	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-22.49	1.41e-76	1.54e-72	-0.96	-0.72	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	22.48	1.51e-76	1.65e-72	0.99	0.72	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-22.47	1.8e-76	1.97e-72	-0.92	-0.72	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
THCA	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-22.47	1.81e-76	1.98e-72	-1.06	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
THCA	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-22.47	1.81e-76	1.98e-72	-1.06	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-22.46	1.94e-76	2.11e-72	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	22.45	2.21e-76	2.41e-72	0.93	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
THCA	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	22.44	2.39e-76	2.61e-72	0.97	0.72	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	22.44	2.49e-76	2.71e-72	1.22	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-22.43	2.71e-76	2.94e-72	-0.91	-0.72	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-22.43	2.71e-76	2.94e-72	-0.91	-0.72	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-22.43	2.79e-76	3.02e-72	-0.91	-0.72	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-22.42	2.87e-76	3.11e-72	-0.91	-0.72	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	22.42	3.04e-76	3.29e-72	0.92	0.72	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	22.41	3.43e-76	3.71e-72	0.99	0.72	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-22.4	3.58e-76	3.87e-72	-0.91	-0.72	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
THCA	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-22.36	6.07e-76	6.52e-72	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-22.36	6.07e-76	6.52e-72	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-22.36	6.07e-76	6.52e-72	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-22.33	7.74e-76	8.29e-72	-0.92	-0.72	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
THCA	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	22.33	7.81e-76	8.36e-72	1.25	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-22.32	8.54e-76	9.12e-72	-0.92	-0.72	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-22.32	9.29e-76	9.91e-72	-0.91	-0.72	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
THCA	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	22.29	1.26e-75	1.35e-71	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
THCA	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	22.29	1.27e-75	1.35e-71	0.91	0.72	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-22.28	1.37e-75	1.46e-71	-0.92	-0.72	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-22.28	1.37e-75	1.46e-71	-0.92	-0.72	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
THCA	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	22.27	1.59e-75	1.69e-71	0.78	0.72	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	22.26	1.67e-75	1.77e-71	0.77	0.72	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
THCA	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-22.26	1.73e-75	1.83e-71	-0.82	-0.72	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
THCA	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	22.24	2.03e-75	2.15e-71	1.28	0.72	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
THCA	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-22.22	2.69e-75	2.85e-71	-0.82	-0.72	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-22.22	2.69e-75	2.85e-71	-0.82	-0.72	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-22.21	3.05e-75	3.22e-71	-0.85	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
THCA	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	22.2	3.38e-75	3.56e-71	1.23	0.72	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
THCA	cis	rs9322193	0.923	rs2184370	ENSG00000231760.4	RP11-350J20.5	22.18	3.99e-75	4.2e-71	0.98	0.72	Lung cancer;	chr6:149843242	chr6:149796151~149826294:-
THCA	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	22.18	4.01e-75	4.22e-71	1.23	0.72	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	22.16	5.06e-75	5.32e-71	1.26	0.71	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
THCA	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	22.16	5.37e-75	5.64e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-22.15	5.64e-75	5.92e-71	-0.91	-0.71	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	22.09	1.04e-74	1.09e-70	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	22.09	1.15e-74	1.2e-70	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	22.04	1.93e-74	2.01e-70	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	22.03	1.99e-74	2.07e-70	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	22.03	1.99e-74	2.07e-70	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	22.03	2.05e-74	2.13e-70	0.86	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
THCA	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	22.03	2.05e-74	2.13e-70	0.76	0.71	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	22.03	2.11e-74	2.19e-70	0.94	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
THCA	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	22	2.88e-74	2.98e-70	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
THCA	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	22	2.94e-74	3.04e-70	0.77	0.71	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	21.99	3.34e-74	3.44e-70	0.77	0.71	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	21.99	3.34e-74	3.44e-70	0.77	0.71	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	21.99	3.34e-74	3.44e-70	0.77	0.71	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
THCA	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	21.97	3.84e-74	3.94e-70	1.26	0.71	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
THCA	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-21.97	4.1e-74	4.2e-70	-1.04	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
THCA	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	21.95	5.13e-74	5.23e-70	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
THCA	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-21.94	5.28e-74	5.39e-70	-0.87	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
THCA	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-21.94	5.36e-74	5.46e-70	-0.83	-0.71	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
THCA	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	21.92	6.88e-74	7e-70	0.76	0.71	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
THCA	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	21.91	7.4e-74	7.53e-70	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
THCA	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	21.91	7.82e-74	7.95e-70	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
THCA	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	21.91	7.97e-74	8.08e-70	0.76	0.71	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
THCA	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-21.88	1.05e-73	1.06e-69	-0.82	-0.71	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
THCA	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	21.87	1.16e-73	1.17e-69	0.83	0.71	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
THCA	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-21.86	1.32e-73	1.32e-69	-0.88	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	21.86	1.34e-73	1.34e-69	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
THCA	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	21.86	1.35e-73	1.35e-69	0.9	0.71	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
THCA	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	21.85	1.41e-73	1.41e-69	0.81	0.71	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	21.85	1.5e-73	1.5e-69	0.86	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
THCA	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-21.84	1.56e-73	1.56e-69	-0.76	-0.71	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-21.84	1.56e-73	1.56e-69	-0.76	-0.71	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	21.83	1.91e-73	1.91e-69	0.76	0.71	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	21.83	1.92e-73	1.91e-69	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	21.83	1.92e-73	1.91e-69	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
THCA	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-21.83	1.93e-73	1.93e-69	-0.76	-0.71	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	21.82	2.05e-73	2.04e-69	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
THCA	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	21.81	2.21e-73	2.19e-69	0.92	0.71	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
THCA	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-21.8	2.61e-73	2.59e-69	-0.81	-0.71	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-21.8	2.61e-73	2.59e-69	-0.81	-0.71	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-21.8	2.61e-73	2.59e-69	-0.81	-0.71	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-21.79	2.71e-73	2.68e-69	-0.76	-0.71	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-21.78	3.09e-73	3.05e-69	-1.06	-0.71	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-21.78	3.09e-73	3.05e-69	-1.06	-0.71	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-21.78	3.22e-73	3.18e-69	-0.81	-0.71	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	21.77	3.67e-73	3.62e-69	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
THCA	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	21.75	4.16e-73	4.1e-69	0.76	0.71	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	21.75	4.33e-73	4.26e-69	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
THCA	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-21.75	4.5e-73	4.42e-69	-0.75	-0.71	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
THCA	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	21.74	4.91e-73	4.82e-69	1.2	0.71	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
THCA	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-21.74	4.92e-73	4.83e-69	-0.81	-0.71	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
THCA	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	21.71	6.46e-73	6.31e-69	0.86	0.71	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
THCA	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-21.71	6.71e-73	6.55e-69	-1.22	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	21.71	6.79e-73	6.63e-69	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
THCA	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	21.7	7.36e-73	7.18e-69	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	21.7	7.45e-73	7.26e-69	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
THCA	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-21.68	9.43e-73	9.17e-69	-0.91	-0.71	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	21.67	1.06e-72	1.03e-68	0.77	0.71	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
THCA	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-21.66	1.22e-72	1.19e-68	-0.92	-0.71	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	21.65	1.25e-72	1.21e-68	0.76	0.71	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	21.62	1.71e-72	1.66e-68	0.76	0.71	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-21.62	1.83e-72	1.77e-68	-0.75	-0.71	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
THCA	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-21.62	1.88e-72	1.81e-68	-0.75	-0.71	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
THCA	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-21.61	1.96e-72	1.89e-68	-0.81	-0.71	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
THCA	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	21.61	1.98e-72	1.92e-68	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	21.6	2.16e-72	2.08e-68	0.91	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
THCA	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-21.6	2.28e-72	2.19e-68	-0.86	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
THCA	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-21.59	2.5e-72	2.41e-68	-0.75	-0.71	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-21.59	2.5e-72	2.41e-68	-0.75	-0.71	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	21.59	2.53e-72	2.43e-68	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	21.59	2.53e-72	2.43e-68	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
THCA	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-21.59	2.53e-72	2.44e-68	-0.78	-0.71	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
THCA	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	21.58	2.67e-72	2.57e-68	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-21.58	2.81e-72	2.71e-68	-0.78	-0.71	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
THCA	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-21.58	2.92e-72	2.8e-68	-1.04	-0.71	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
THCA	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	21.57	2.97e-72	2.85e-68	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
THCA	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-21.57	2.97e-72	2.86e-68	-0.91	-0.71	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	21.57	3.03e-72	2.91e-68	0.98	0.71	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	21.55	3.77e-72	3.62e-68	0.86	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
THCA	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-21.55	3.92e-72	3.75e-68	-1.05	-0.7	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-21.55	3.92e-72	3.75e-68	-1.05	-0.7	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-21.55	3.92e-72	3.75e-68	-1.05	-0.7	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-21.55	3.92e-72	3.75e-68	-1.05	-0.7	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
THCA	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	21.54	4.42e-72	4.23e-68	0.89	0.7	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
THCA	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-21.53	4.83e-72	4.62e-68	-0.92	-0.7	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
THCA	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-21.53	4.92e-72	4.7e-68	-0.82	-0.7	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	21.53	4.96e-72	4.73e-68	0.84	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
THCA	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	21.52	5.5e-72	5.25e-68	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-21.5	6.47e-72	6.17e-68	-0.78	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
THCA	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-21.49	6.98e-72	6.65e-68	-0.82	-0.7	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
THCA	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-21.49	7.22e-72	6.87e-68	-1.05	-0.7	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
THCA	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	21.49	7.5e-72	7.14e-68	0.92	0.7	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
THCA	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	21.48	7.97e-72	7.58e-68	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
THCA	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	21.48	8.04e-72	7.64e-68	0.89	0.7	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-21.48	8.31e-72	7.89e-68	-1.06	-0.7	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
THCA	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
THCA	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-21.46	9.84e-72	9.28e-68	-1.05	-0.7	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
THCA	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	21.46	1.04e-71	9.81e-68	0.76	0.7	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-21.45	1.13e-71	1.06e-67	-1.05	-0.7	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	21.43	1.36e-71	1.28e-67	0.81	0.7	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-21.43	1.37e-71	1.29e-67	-0.92	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
THCA	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	21.43	1.46e-71	1.37e-67	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-21.42	1.59e-71	1.49e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-21.42	1.59e-71	1.49e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-21.42	1.59e-71	1.49e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-21.42	1.59e-71	1.49e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
THCA	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	21.41	1.71e-71	1.6e-67	0.95	0.7	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
THCA	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-21.41	1.75e-71	1.65e-67	-0.86	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	21.39	2.17e-71	2.03e-67	0.77	0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-21.39	2.28e-71	2.14e-67	-0.92	-0.7	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
THCA	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-21.38	2.33e-71	2.18e-67	-1.05	-0.7	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-21.38	2.36e-71	2.21e-67	-1.05	-0.7	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
THCA	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-21.35	3.3e-71	3.08e-67	-0.78	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
THCA	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	21.35	3.39e-71	3.16e-67	0.82	0.7	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
THCA	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	21.35	3.47e-71	3.23e-67	0.81	0.7	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
THCA	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-21.34	3.73e-71	3.47e-67	-0.79	-0.7	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
THCA	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	21.34	3.96e-71	3.68e-67	0.88	0.7	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	21.34	3.96e-71	3.68e-67	0.88	0.7	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
THCA	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	21.33	4.09e-71	3.8e-67	0.8	0.7	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
THCA	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	21.33	4.31e-71	4.01e-67	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	21.31	5.27e-71	4.9e-67	0.94	0.7	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
THCA	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	21.31	5.31e-71	4.93e-67	0.88	0.7	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
THCA	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	21.3	5.75e-71	5.34e-67	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
THCA	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-21.3	5.82e-71	5.4e-67	-1.19	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	21.3	5.83e-71	5.4e-67	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	21.3	5.83e-71	5.4e-67	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
THCA	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	21.3	5.91e-71	5.48e-67	0.75	0.7	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
THCA	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	21.3	6.12e-71	5.68e-67	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	21.29	6.32e-71	5.86e-67	0.95	0.7	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
THCA	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-21.29	6.35e-71	5.89e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
THCA	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	21.29	6.54e-71	6.06e-67	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-21.29	6.57e-71	6.08e-67	-0.95	-0.7	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
THCA	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-21.28	7.56e-71	7e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
THCA	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-21.27	7.82e-71	7.23e-67	-1.05	-0.7	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
THCA	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-21.26	8.78e-71	8.12e-67	-0.8	-0.7	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
THCA	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-21.26	9.09e-71	8.4e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-21.26	9.09e-71	8.4e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
THCA	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-21.25	1.02e-70	9.42e-67	-0.81	-0.7	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
THCA	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	21.23	1.23e-70	1.13e-66	1.21	0.7	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
THCA	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	21.22	1.44e-70	1.32e-66	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
THCA	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	21.21	1.58e-70	1.45e-66	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	21.2	1.71e-70	1.57e-66	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
THCA	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	21.2	1.71e-70	1.58e-66	0.86	0.7	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
THCA	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	21.2	1.75e-70	1.61e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
THCA	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	21.19	1.97e-70	1.81e-66	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	21.18	2.11e-70	1.94e-66	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
THCA	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	21.16	2.72e-70	2.49e-66	0.93	0.7	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	21.14	3.18e-70	2.91e-66	0.96	0.7	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-21.13	3.57e-70	3.26e-66	-0.91	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
THCA	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	21.1	4.96e-70	4.52e-66	0.82	0.7	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
THCA	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-21.09	5.45e-70	4.96e-66	-1.03	-0.7	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
THCA	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	21.09	5.72e-70	5.2e-66	0.83	0.7	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
THCA	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	21.08	6.28e-70	5.71e-66	0.8	0.7	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
THCA	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	21.05	8.31e-70	7.54e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	21.05	8.35e-70	7.58e-66	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
THCA	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-21.04	9.32e-70	8.45e-66	-1.18	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
THCA	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	21.03	1.04e-69	9.45e-66	0.8	0.7	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
THCA	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-21.02	1.19e-69	1.08e-65	-1.18	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-21	1.43e-69	1.29e-65	-1.19	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-21	1.43e-69	1.29e-65	-1.19	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
THCA	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-20.99	1.69e-69	1.52e-65	-0.78	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
THCA	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	20.99	1.7e-69	1.53e-65	0.89	0.7	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	20.97	2.03e-69	1.82e-65	0.8	0.7	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	20.97	2.04e-69	1.83e-65	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
THCA	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-20.96	2.27e-69	2.04e-65	-0.87	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-20.95	2.54e-69	2.28e-65	-0.76	-0.69	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
THCA	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-20.95	2.6e-69	2.33e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
THCA	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-20.95	2.6e-69	2.33e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	20.94	2.78e-69	2.49e-65	0.92	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
THCA	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	20.94	2.92e-69	2.62e-65	0.8	0.69	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-20.94	3.02e-69	2.71e-65	-0.9	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
THCA	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-20.94	3.05e-69	2.73e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-20.94	3.05e-69	2.73e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-20.94	3.05e-69	2.73e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-20.93	3.39e-69	3.04e-65	-0.95	-0.69	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	20.92	3.53e-69	3.16e-65	0.8	0.69	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
THCA	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-20.92	3.6e-69	3.22e-65	-0.75	-0.69	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
THCA	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	20.89	4.79e-69	4.28e-65	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
THCA	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	20.87	5.99e-69	5.34e-65	0.74	0.69	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	20.85	7.96e-69	7.07e-65	0.91	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
THCA	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-20.83	9.6e-69	8.5e-65	-0.77	-0.69	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
THCA	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	20.81	1.18e-68	1.04e-64	0.78	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
THCA	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	20.81	1.2e-68	1.06e-64	0.87	0.69	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
THCA	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	20.81	1.22e-68	1.08e-64	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	20.79	1.43e-68	1.26e-64	0.78	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
THCA	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	20.78	1.64e-68	1.44e-64	0.79	0.69	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
THCA	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	20.77	1.76e-68	1.55e-64	1.27	0.69	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
THCA	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-20.77	1.81e-68	1.58e-64	-0.85	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
THCA	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	20.77	1.84e-68	1.61e-64	0.82	0.69	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	20.76	2.14e-68	1.87e-64	0.91	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	20.75	2.35e-68	2.05e-64	0.92	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
THCA	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-20.74	2.5e-68	2.18e-64	-0.87	-0.69	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-20.74	2.5e-68	2.18e-64	-0.87	-0.69	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
THCA	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-20.73	2.88e-68	2.51e-64	-0.77	-0.69	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000273295.1	AP000350.5	20.73	2.92e-68	2.54e-64	0.81	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23901432~23907068:-
THCA	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-20.73	2.96e-68	2.58e-64	-0.89	-0.69	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
THCA	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-20.7	3.94e-68	3.42e-64	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
THCA	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	20.69	4.21e-68	3.65e-64	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
THCA	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	20.68	4.7e-68	4.07e-64	0.89	0.69	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
THCA	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-20.68	4.99e-68	4.32e-64	-0.73	-0.69	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
THCA	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	20.67	5.56e-68	4.81e-64	0.89	0.69	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
THCA	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	20.66	5.96e-68	5.15e-64	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
THCA	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	20.66	5.99e-68	5.18e-64	0.75	0.69	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
THCA	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-20.65	6.81e-68	5.88e-64	-0.77	-0.69	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	20.65	7.02e-68	6.06e-64	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	20.63	8.47e-68	7.31e-64	0.79	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
THCA	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-20.61	1.03e-67	8.86e-64	-0.88	-0.69	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
THCA	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	20.59	1.3e-67	1.12e-63	0.84	0.69	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
THCA	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-20.58	1.43e-67	1.22e-63	-0.89	-0.69	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	20.58	1.49e-67	1.28e-63	0.8	0.69	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
THCA	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-20.57	1.56e-67	1.34e-63	-0.76	-0.69	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	20.54	2.2e-67	1.88e-63	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
THCA	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	20.53	2.45e-67	2.09e-63	0.74	0.69	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	20.53	2.45e-67	2.09e-63	0.74	0.69	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	20.53	2.45e-67	2.09e-63	0.74	0.69	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	20.5	3.35e-67	2.85e-63	0.93	0.69	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
THCA	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	20.49	3.76e-67	3.19e-63	0.75	0.69	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	20.48	4.18e-67	3.54e-63	0.74	0.69	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	20.48	4.18e-67	3.54e-63	0.74	0.69	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-20.46	5.12e-67	4.33e-63	-0.73	-0.69	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-20.46	5.49e-67	4.63e-63	-0.73	-0.69	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-20.46	5.54e-67	4.67e-63	-0.74	-0.69	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
THCA	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-20.45	5.63e-67	4.75e-63	-1.04	-0.69	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
THCA	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	20.43	7e-67	5.89e-63	0.86	0.69	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
THCA	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-20.43	7.69e-67	6.46e-63	-0.74	-0.69	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	20.43	7.71e-67	6.48e-63	0.83	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
THCA	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-20.42	8.18e-67	6.86e-63	-0.73	-0.69	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
THCA	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	20.41	9.26e-67	7.75e-63	0.86	0.69	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-20.4	1.02e-66	8.57e-63	-1.04	-0.69	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
THCA	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	20.4	1.03e-66	8.61e-63	0.73	0.69	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-20.4	1.05e-66	8.75e-63	-0.73	-0.69	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
THCA	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	20.4	1.05e-66	8.81e-63	0.88	0.69	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
THCA	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	20.4	1.06e-66	8.84e-63	0.79	0.69	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
THCA	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	20.39	1.12e-66	9.35e-63	1.14	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
THCA	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	20.39	1.12e-66	9.36e-63	0.73	0.69	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	20.39	1.17e-66	9.76e-63	0.74	0.69	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-20.38	1.3e-66	1.08e-62	-0.89	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
THCA	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-20.38	1.31e-66	1.09e-62	-0.77	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
THCA	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-20.37	1.34e-66	1.11e-62	-0.73	-0.68	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
THCA	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	20.37	1.37e-66	1.13e-62	0.74	0.68	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
THCA	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	20.37	1.45e-66	1.2e-62	0.91	0.68	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
THCA	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-20.37	1.46e-66	1.21e-62	-0.73	-0.68	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
THCA	cis	rs7569084	0.687	rs934731	ENSG00000204929.10	AC074391.1	20.36	1.51e-66	1.25e-62	0.86	0.68	Sum eosinophil basophil counts;	chr2:65456353	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs7577452	ENSG00000204929.10	AC074391.1	20.36	1.51e-66	1.25e-62	0.86	0.68	Sum eosinophil basophil counts;	chr2:65456694	chr2:65436711~66084639:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	20.36	1.54e-66	1.28e-62	0.88	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
THCA	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	20.36	1.58e-66	1.31e-62	0.81	0.68	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	20.36	1.62e-66	1.34e-62	0.83	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
THCA	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	20.36	1.65e-66	1.36e-62	0.77	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
THCA	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-20.35	1.72e-66	1.42e-62	-0.76	-0.68	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
THCA	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-20.35	1.84e-66	1.52e-62	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
THCA	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-20.34	1.98e-66	1.64e-62	-0.73	-0.68	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-20.34	1.98e-66	1.64e-62	-0.73	-0.68	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-20.32	2.41e-66	1.98e-62	-0.73	-0.68	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	20.3	3.08e-66	2.53e-62	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
THCA	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	20.27	4.03e-66	3.3e-62	0.88	0.68	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
THCA	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	20.27	4.14e-66	3.38e-62	0.76	0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
THCA	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-20.27	4.27e-66	3.49e-62	-0.73	-0.68	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-20.27	4.27e-66	3.49e-62	-0.73	-0.68	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	20.27	4.35e-66	3.55e-62	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
THCA	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-20.26	4.52e-66	3.69e-62	-0.73	-0.68	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
THCA	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-20.26	4.6e-66	3.75e-62	-0.73	-0.68	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-20.26	4.6e-66	3.75e-62	-0.73	-0.68	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
THCA	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	20.26	4.64e-66	3.78e-62	0.74	0.68	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	20.26	4.83e-66	3.94e-62	0.92	0.68	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
THCA	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	20.25	5.12e-66	4.17e-62	0.73	0.68	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	20.24	6.04e-66	4.92e-62	0.83	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
THCA	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	20.23	6.2e-66	5.04e-62	0.93	0.68	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	20.23	6.2e-66	5.04e-62	0.93	0.68	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	20.23	6.2e-66	5.04e-62	0.93	0.68	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
THCA	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	20.23	6.23e-66	5.07e-62	0.73	0.68	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
THCA	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-20.22	7.1e-66	5.65e-62	-0.75	-0.68	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
THCA	cis	rs7569084	0.687	rs35839762	ENSG00000204929.10	AC074391.1	20.21	7.88e-66	6.26e-62	0.86	0.68	Sum eosinophil basophil counts;	chr2:65441318	chr2:65436711~66084639:+
THCA	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
THCA	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
THCA	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
THCA	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
THCA	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
THCA	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
THCA	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-20.19	9.48e-66	7.49e-62	-0.76	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-20.19	9.51e-66	7.51e-62	-0.76	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
THCA	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	20.19	9.71e-66	7.67e-62	0.73	0.68	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
THCA	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	20.19	1.03e-65	8.1e-62	0.74	0.68	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
THCA	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	20.18	1.12e-65	8.84e-62	0.87	0.68	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-20.16	1.32e-65	1.04e-61	-0.9	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
THCA	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-20.16	1.41e-65	1.1e-61	-0.96	-0.68	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	20.16	1.43e-65	1.12e-61	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
THCA	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	20.14	1.67e-65	1.31e-61	0.91	0.68	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	20.11	2.32e-65	1.81e-61	0.86	0.68	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
THCA	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	20.1	2.59e-65	2.01e-61	0.73	0.68	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
THCA	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
THCA	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-20.09	2.9e-65	2.22e-61	-0.87	-0.68	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
THCA	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-20.09	2.93e-65	2.25e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-20.09	2.93e-65	2.25e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-20.09	2.93e-65	2.25e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
THCA	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-20.09	2.98e-65	2.28e-61	-0.95	-0.68	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
THCA	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-20.07	3.59e-65	2.75e-61	-0.73	-0.68	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
THCA	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	20.07	3.75e-65	2.87e-61	0.82	0.68	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
THCA	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-20.07	3.77e-65	2.89e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	20.06	4.11e-65	3.14e-61	0.82	0.68	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
THCA	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-20.06	4.23e-65	3.23e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-20.06	4.23e-65	3.23e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-20.06	4.23e-65	3.23e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
THCA	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-20.04	5.02e-65	3.82e-61	-0.75	-0.68	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
THCA	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-20.04	5.23e-65	3.98e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	20.04	5.3e-65	4.03e-61	0.82	0.68	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
THCA	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	20.03	5.33e-65	4.05e-61	0.87	0.68	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	20.03	5.33e-65	4.05e-61	0.87	0.68	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
THCA	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	20.03	5.64e-65	4.29e-61	0.82	0.68	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	20.03	5.89e-65	4.47e-61	0.82	0.68	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	20.02	6.21e-65	4.72e-61	1.32	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
THCA	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-20.02	6.52e-65	4.95e-61	-0.72	-0.68	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
THCA	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	20.01	6.68e-65	5.07e-61	0.86	0.68	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
THCA	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-20.01	7.33e-65	5.56e-61	-1.15	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	20	7.36e-65	5.58e-61	0.92	0.68	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	20	7.53e-65	5.71e-61	0.82	0.68	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	20	7.57e-65	5.73e-61	0.82	0.68	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	20	7.57e-65	5.73e-61	0.82	0.68	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
THCA	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	20	8.01e-65	6.06e-61	0.92	0.68	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	20	8.01e-65	6.06e-61	0.92	0.68	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs644498	ENSG00000255239.1	AP002954.6	20	8.01e-65	6.06e-61	0.92	0.68	Serum metabolite levels;	chr11:118696777	chr11:118688039~118690600:-
THCA	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-19.99	8.98e-65	6.78e-61	-0.76	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
THCA	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	19.98	9.24e-65	6.98e-61	0.81	0.68	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
THCA	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-19.98	9.84e-65	7.42e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
THCA	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-19.98	9.84e-65	7.42e-61	-0.76	-0.68	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-19.98	9.84e-65	7.42e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.59e-61	0.82	0.68	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.59e-61	0.82	0.68	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.59e-61	0.82	0.68	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.59e-61	0.82	0.68	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.64e-61	0.82	0.68	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.64e-61	0.82	0.68	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	19.97	1.07e-64	8.09e-61	0.82	0.68	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
THCA	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-19.97	1.08e-64	8.11e-61	-0.9	-0.68	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
THCA	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	19.96	1.14e-64	8.55e-61	0.91	0.68	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
THCA	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-19.96	1.18e-64	8.9e-61	-0.85	-0.68	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
THCA	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	19.96	1.25e-64	9.37e-61	0.9	0.68	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	19.95	1.29e-64	9.71e-61	0.82	0.68	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
THCA	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-19.95	1.3e-64	9.73e-61	-0.76	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
THCA	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	19.95	1.34e-64	1.01e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	19.95	1.35e-64	1.01e-60	0.91	0.68	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
THCA	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	19.94	1.41e-64	1.06e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	19.94	1.46e-64	1.1e-60	0.84	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
THCA	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	19.93	1.63e-64	1.22e-60	0.91	0.68	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
THCA	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	19.93	1.66e-64	1.24e-60	0.91	0.68	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	19.92	1.8e-64	1.35e-60	0.91	0.68	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
THCA	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	19.92	1.8e-64	1.35e-60	0.91	0.68	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
THCA	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	19.92	1.86e-64	1.39e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
THCA	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-19.91	1.97e-64	1.47e-60	-0.75	-0.68	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
THCA	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	19.91	2.03e-64	1.52e-60	0.82	0.68	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-19.89	2.66e-64	1.98e-60	-0.81	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	19.88	2.86e-64	2.13e-60	0.81	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
THCA	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	19.88	2.9e-64	2.16e-60	1.32	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-19.88	3e-64	2.23e-60	-0.78	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
THCA	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	19.87	3.1e-64	2.3e-60	0.81	0.68	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
THCA	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-19.87	3.15e-64	2.34e-60	-0.75	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
THCA	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	19.87	3.21e-64	2.38e-60	0.9	0.68	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-19.86	3.41e-64	2.53e-60	-0.87	-0.68	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
THCA	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	19.86	3.67e-64	2.72e-60	1.13	0.68	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
THCA	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-19.85	3.88e-64	2.87e-60	-0.82	-0.68	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
THCA	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	19.85	3.99e-64	2.95e-60	0.91	0.68	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
THCA	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	19.84	4.45e-64	3.28e-60	0.81	0.68	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	19.84	4.45e-64	3.28e-60	0.81	0.68	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
THCA	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	19.83	4.67e-64	3.44e-60	0.9	0.68	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	19.83	4.67e-64	3.44e-60	0.9	0.68	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
THCA	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	19.83	4.97e-64	3.66e-60	0.78	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
THCA	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-19.82	5.44e-64	4e-60	-0.73	-0.67	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
THCA	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-19.82	5.73e-64	4.22e-60	-0.73	-0.67	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
THCA	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	19.81	5.88e-64	4.33e-60	0.81	0.67	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	19.81	5.88e-64	4.33e-60	0.81	0.67	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
THCA	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-19.81	6.13e-64	4.51e-60	-0.72	-0.67	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
THCA	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	19.81	6.18e-64	4.54e-60	0.9	0.67	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	19.81	6.18e-64	4.54e-60	0.9	0.67	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	19.81	6.18e-64	4.54e-60	0.9	0.67	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
THCA	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-19.79	7.33e-64	5.38e-60	-0.75	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	19.79	7.53e-64	5.52e-60	0.78	0.67	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	19.78	8e-64	5.86e-60	0.81	0.67	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
THCA	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	19.78	8.08e-64	5.91e-60	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
THCA	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	19.78	8.18e-64	5.99e-60	0.9	0.67	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	19.78	8.42e-64	6.16e-60	0.91	0.67	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	19.78	8.76e-64	6.41e-60	0.9	0.67	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
THCA	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	19.77	9.84e-64	7.19e-60	0.9	0.67	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
THCA	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-19.76	1.01e-63	7.39e-60	-0.73	-0.67	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
THCA	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	19.75	1.16e-63	8.43e-60	0.91	0.67	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
THCA	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	19.75	1.17e-63	8.53e-60	0.9	0.67	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
THCA	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	19.75	1.17e-63	8.53e-60	0.9	0.67	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
THCA	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-19.74	1.27e-63	9.25e-60	-0.73	-0.67	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	19.74	1.28e-63	9.31e-60	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
THCA	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	19.74	1.3e-63	9.42e-60	0.77	0.67	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
THCA	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	19.74	1.3e-63	9.44e-60	0.78	0.67	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
THCA	cis	rs858239	0.669	rs56400441	ENSG00000230658.1	KLHL7-AS1	19.73	1.4e-63	1.02e-59	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23101228~23105703:-
THCA	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-19.73	1.43e-63	1.04e-59	-0.72	-0.67	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-19.73	1.43e-63	1.04e-59	-0.72	-0.67	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
THCA	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	19.73	1.45e-63	1.05e-59	0.81	0.67	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
THCA	cis	rs858239	0.614	rs2014816	ENSG00000230658.1	KLHL7-AS1	19.72	1.67e-63	1.21e-59	0.82	0.67	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23101228~23105703:-
THCA	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	19.71	1.77e-63	1.28e-59	0.81	0.67	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
THCA	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	19.71	1.78e-63	1.28e-59	0.91	0.67	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	19.71	1.79e-63	1.29e-59	0.86	0.67	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
THCA	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	19.71	1.81e-63	1.31e-59	0.91	0.67	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	19.71	1.81e-63	1.31e-59	0.91	0.67	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
THCA	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	19.7	1.94e-63	1.4e-59	1.12	0.67	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
THCA	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	19.68	2.45e-63	1.76e-59	0.92	0.67	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
THCA	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	19.68	2.52e-63	1.81e-59	0.85	0.67	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
THCA	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	19.68	2.55e-63	1.83e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	19.68	2.55e-63	1.83e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	19.68	2.55e-63	1.83e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	19.68	2.55e-63	1.83e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-19.68	2.55e-63	1.83e-59	-1.31	-0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	19.68	2.59e-63	1.86e-59	1.3	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
THCA	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-19.67	2.78e-63	2e-59	-0.72	-0.67	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
THCA	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	19.67	2.8e-63	2.01e-59	1.32	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
THCA	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	19.67	2.88e-63	2.07e-59	0.92	0.67	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
THCA	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-19.66	2.94e-63	2.11e-59	-0.74	-0.67	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
THCA	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	19.66	3.03e-63	2.17e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
THCA	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-19.64	3.68e-63	2.63e-59	-0.75	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
THCA	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	19.64	3.79e-63	2.71e-59	0.91	0.67	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	19.64	3.79e-63	2.71e-59	0.91	0.67	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	19.62	4.55e-63	3.25e-59	1.32	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
THCA	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	19.61	5.46e-63	3.9e-59	0.91	0.67	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	19.61	5.48e-63	3.91e-59	0.89	0.67	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
THCA	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	19.61	5.48e-63	3.91e-59	0.89	0.67	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	19.61	5.48e-63	3.91e-59	0.89	0.67	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
THCA	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	19.6	5.84e-63	4.13e-59	0.77	0.67	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	19.59	6.22e-63	4.39e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
THCA	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
THCA	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
THCA	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-19.58	7.57e-63	5.33e-59	-0.84	-0.67	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
THCA	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-19.57	7.77e-63	5.47e-59	-0.73	-0.67	Breast cancer;	chr11:743813	chr11:779617~780755:+
THCA	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	19.57	7.79e-63	5.48e-59	0.91	0.67	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	19.57	7.82e-63	5.5e-59	0.91	0.67	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	19.56	9.12e-63	6.4e-59	0.9	0.67	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
THCA	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	19.56	9.31e-63	6.54e-59	0.85	0.67	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
THCA	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	19.55	9.88e-63	6.94e-59	1.17	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
THCA	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	19.53	1.25e-62	8.68e-59	0.73	0.67	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
THCA	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	19.53	1.27e-62	8.82e-59	0.9	0.67	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
THCA	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	19.53	1.29e-62	8.91e-59	0.91	0.67	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	19.52	1.41e-62	9.76e-59	0.93	0.67	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	19.51	1.59e-62	1.1e-58	0.85	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	19.5	1.75e-62	1.2e-58	0.82	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
THCA	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
THCA	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-19.46	2.56e-62	1.75e-58	-0.78	-0.67	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-19.46	2.56e-62	1.75e-58	-0.78	-0.67	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
THCA	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	19.46	2.73e-62	1.87e-58	0.9	0.67	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	19.46	2.74e-62	1.87e-58	0.9	0.67	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	19.46	2.74e-62	1.87e-58	0.9	0.67	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	19.46	2.74e-62	1.87e-58	0.9	0.67	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	19.46	2.76e-62	1.88e-58	0.89	0.67	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
THCA	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-19.46	2.79e-62	1.91e-58	-0.84	-0.67	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
THCA	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-19.45	2.94e-62	2e-58	-0.83	-0.67	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
THCA	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
THCA	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	19.45	3.03e-62	2.07e-58	0.91	0.67	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	19.43	3.89e-62	2.64e-58	0.79	0.67	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	19.43	3.89e-62	2.64e-58	0.79	0.67	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
THCA	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	19.42	4e-62	2.72e-58	0.71	0.67	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
THCA	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	19.41	4.81e-62	3.23e-58	0.8	0.67	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	19.41	4.81e-62	3.23e-58	0.8	0.67	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	19.39	5.41e-62	3.62e-58	0.8	0.67	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	19.39	5.41e-62	3.62e-58	0.8	0.67	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	19.39	5.41e-62	3.62e-58	0.8	0.67	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	19.39	5.41e-62	3.62e-58	0.8	0.67	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
THCA	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	19.39	5.5e-62	3.69e-58	0.84	0.67	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
THCA	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	19.39	5.82e-62	3.9e-58	1.11	0.67	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
THCA	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	19.38	6.17e-62	4.13e-58	0.8	0.67	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	19.38	6.17e-62	4.13e-58	0.8	0.67	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
THCA	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	19.37	6.88e-62	4.6e-58	0.71	0.67	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	19.37	7.29e-62	4.87e-58	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
THCA	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-19.35	8.36e-62	5.58e-58	-0.7	-0.67	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
THCA	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	19.35	8.46e-62	5.65e-58	0.89	0.67	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
THCA	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-19.35	8.49e-62	5.67e-58	-0.79	-0.67	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
THCA	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-19.35	8.55e-62	5.7e-58	-0.82	-0.67	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-19.35	8.81e-62	5.88e-58	-0.84	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
THCA	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	19.35	9.19e-62	6.12e-58	0.79	0.67	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
THCA	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	19.35	9.24e-62	6.16e-58	0.9	0.67	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
THCA	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-19.34	1.01e-61	6.69e-58	-0.83	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
THCA	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	19.33	1.07e-61	7.13e-58	0.85	0.67	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	19.33	1.07e-61	7.13e-58	0.85	0.67	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	19.33	1.13e-61	7.48e-58	0.85	0.67	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	19.33	1.13e-61	7.48e-58	0.85	0.67	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	19.33	1.13e-61	7.48e-58	0.85	0.67	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-19.33	1.13e-61	7.48e-58	-0.85	-0.67	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	19.33	1.14e-61	7.57e-58	0.8	0.67	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
THCA	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-19.32	1.19e-61	7.9e-58	-0.89	-0.67	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	19.32	1.2e-61	7.99e-58	0.85	0.67	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	19.32	1.2e-61	7.99e-58	0.85	0.67	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	19.32	1.24e-61	8.25e-58	1.27	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
THCA	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-19.32	1.25e-61	8.28e-58	-0.85	-0.67	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-19.31	1.33e-61	8.79e-58	-0.85	-0.67	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-19.31	1.33e-61	8.79e-58	-0.85	-0.67	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
THCA	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-19.3	1.44e-61	9.49e-58	-0.74	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
THCA	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	19.3	1.46e-61	9.67e-58	1.3	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
THCA	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-19.3	1.5e-61	9.92e-58	-0.73	-0.66	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
THCA	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	19.3	1.51e-61	9.99e-58	0.8	0.66	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
THCA	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-19.29	1.6e-61	1.06e-57	-0.84	-0.66	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
THCA	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	19.29	1.62e-61	1.07e-57	0.9	0.66	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
THCA	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-19.29	1.67e-61	1.1e-57	-0.85	-0.66	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
THCA	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-19.28	1.78e-61	1.17e-57	-0.72	-0.66	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
THCA	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-19.28	1.79e-61	1.18e-57	-0.85	-0.66	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
THCA	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-19.28	1.83e-61	1.2e-57	-0.75	-0.66	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
THCA	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	19.28	1.84e-61	1.21e-57	0.84	0.66	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
THCA	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	19.28	1.87e-61	1.23e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	19.28	1.87e-61	1.23e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	19.28	1.87e-61	1.23e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
THCA	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-19.28	1.95e-61	1.28e-57	-0.73	-0.66	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
THCA	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	19.27	2.05e-61	1.35e-57	0.85	0.66	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	19.27	2.05e-61	1.35e-57	0.85	0.66	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	19.27	2.05e-61	1.35e-57	0.85	0.66	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	19.27	2.09e-61	1.37e-57	0.79	0.66	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	19.27	2.09e-61	1.37e-57	0.79	0.66	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	19.27	2.09e-61	1.37e-57	0.79	0.66	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
THCA	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-19.27	2.13e-61	1.39e-57	-0.85	-0.66	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-19.27	2.13e-61	1.39e-57	-0.85	-0.66	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-19.27	2.18e-61	1.43e-57	-0.85	-0.66	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-19.27	2.18e-61	1.43e-57	-0.85	-0.66	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
THCA	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	19.25	2.5e-61	1.62e-57	0.85	0.66	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-19.25	2.5e-61	1.62e-57	-0.85	-0.66	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-19.25	2.5e-61	1.62e-57	-0.85	-0.66	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
THCA	cis	rs7195287	0.591	rs63744561	ENSG00000276791.1	CTD-2270P14.5	19.25	2.5e-61	1.62e-57	0.79	0.66	Eosinophil counts;	chr16:2778171	chr16:2777319~2780568:+
THCA	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
THCA	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-19.25	2.62e-61	1.7e-57	-0.85	-0.66	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-19.24	2.72e-61	1.77e-57	-0.84	-0.66	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-19.24	2.83e-61	1.83e-57	-0.84	-0.66	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-19.24	2.83e-61	1.84e-57	-0.85	-0.66	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	19.24	2.86e-61	1.85e-57	0.81	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
THCA	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	19.24	2.87e-61	1.86e-57	0.79	0.66	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	19.24	2.87e-61	1.86e-57	0.79	0.66	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	19.24	2.87e-61	1.86e-57	0.79	0.66	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	19.24	2.87e-61	1.86e-57	0.79	0.66	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
THCA	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
THCA	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	19.23	3.05e-61	1.97e-57	0.88	0.66	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
THCA	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	19.23	3.16e-61	2.04e-57	0.85	0.66	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
THCA	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.846	rs240051	ENSG00000224086.5	LL22NC03-86G7.1	-19.23	3.27e-61	2.1e-57	-0.78	-0.66	Multiple sclerosis;	chr22:21909763	chr22:21938293~21977632:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
THCA	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-19.23	3.31e-61	2.12e-57	-0.78	-0.66	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
THCA	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-19.22	3.4e-61	2.18e-57	-0.85	-0.66	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-19.22	3.43e-61	2.2e-57	-0.84	-0.66	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	19.22	3.47e-61	2.22e-57	0.79	0.66	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	19.21	3.79e-61	2.43e-57	0.85	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
THCA	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	19.21	4.01e-61	2.56e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
THCA	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-19.2	4.53e-61	2.88e-57	-0.84	-0.66	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	19.19	4.73e-61	3.01e-57	0.79	0.66	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	19.18	5.23e-61	3.32e-57	0.79	0.66	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
THCA	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-19.18	5.61e-61	3.56e-57	-0.75	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
THCA	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-19.18	5.65e-61	3.58e-57	-0.8	-0.66	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
THCA	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-19.17	5.85e-61	3.7e-57	-0.83	-0.66	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
THCA	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	19.17	6.12e-61	3.87e-57	0.8	0.66	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-19.16	6.88e-61	4.35e-57	-0.8	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
THCA	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	19.15	7.2e-61	4.55e-57	0.79	0.66	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
THCA	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-19.15	7.22e-61	4.56e-57	-0.84	-0.66	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-19.15	7.7e-61	4.86e-57	-0.8	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
THCA	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	19.15	7.72e-61	4.87e-57	0.8	0.66	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
THCA	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-19.15	7.85e-61	4.95e-57	-0.73	-0.66	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
THCA	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	19.14	8.35e-61	5.26e-57	0.7	0.66	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
THCA	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	19.14	8.35e-61	5.26e-57	0.7	0.66	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
THCA	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-19.14	8.58e-61	5.41e-57	-0.85	-0.66	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
THCA	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-19.14	8.77e-61	5.52e-57	-0.71	-0.66	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
THCA	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	19.14	8.78e-61	5.53e-57	1.32	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
THCA	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	19.13	9.64e-61	6.07e-57	0.78	0.66	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
THCA	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-19.12	1.08e-60	6.82e-57	-0.7	-0.66	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
THCA	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	19.11	1.12e-60	7.02e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
THCA	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	19.11	1.16e-60	7.32e-57	1.11	0.66	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
THCA	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	19.1	1.26e-60	7.9e-57	0.84	0.66	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
THCA	cis	rs6597981	0.592	rs28625355	ENSG00000279672.1	CMB9-55F22.1	19.1	1.27e-60	7.98e-57	0.72	0.66	Breast cancer;	chr11:736334	chr11:779617~780755:+
THCA	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-19.08	1.61e-60	1.01e-56	-0.74	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
THCA	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-19.07	1.84e-60	1.16e-56	-0.8	-0.66	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
THCA	cis	rs11428934	1	rs11428934	ENSG00000232871.7	SEC1P	19.07	1.89e-60	1.19e-56	0.81	0.66	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr19:48640988	chr19:48638071~48682245:+
THCA	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	19.06	1.98e-60	1.24e-56	0.83	0.66	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	19.06	1.99e-60	1.24e-56	1.26	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
THCA	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	19.06	2.08e-60	1.3e-56	0.69	0.66	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
THCA	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-19.05	2.29e-60	1.43e-56	-0.7	-0.66	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
THCA	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	19.04	2.43e-60	1.52e-56	0.84	0.66	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	19.04	2.47e-60	1.55e-56	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
THCA	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	19.04	2.58e-60	1.61e-56	0.84	0.66	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
THCA	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-19.04	2.6e-60	1.63e-56	-0.69	-0.66	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
THCA	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-19.04	2.62e-60	1.64e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
THCA	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-19.02	2.94e-60	1.83e-56	-0.84	-0.66	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-19.02	2.94e-60	1.83e-56	-0.84	-0.66	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
THCA	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
THCA	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
THCA	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-19.02	3.19e-60	1.99e-56	-0.7	-0.66	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
THCA	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-19.02	3.19e-60	1.99e-56	-0.7	-0.66	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
THCA	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
THCA	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
THCA	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	19.01	3.56e-60	2.21e-56	0.79	0.66	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	19	3.72e-60	2.31e-56	0.8	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
THCA	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	19	3.85e-60	2.39e-56	0.84	0.66	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
THCA	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-19	3.94e-60	2.44e-56	-0.82	-0.66	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
THCA	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	18.99	4.36e-60	2.7e-56	0.84	0.66	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	18.99	4.36e-60	2.7e-56	0.84	0.66	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	18.99	4.36e-60	2.7e-56	0.84	0.66	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
THCA	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	18.98	4.59e-60	2.84e-56	0.84	0.66	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
THCA	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	18.98	4.86e-60	3e-56	0.84	0.66	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
THCA	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	18.97	5.06e-60	3.13e-56	1.09	0.66	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
THCA	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-18.97	5.25e-60	3.24e-56	-0.7	-0.66	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
THCA	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
THCA	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
THCA	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-18.95	6.23e-60	3.83e-56	-0.7	-0.66	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
THCA	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-18.95	6.23e-60	3.83e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-18.95	6.23e-60	3.83e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
THCA	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-18.95	6.32e-60	3.89e-56	-0.84	-0.66	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	18.95	6.61e-60	4.06e-56	0.78	0.66	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	18.94	7.2e-60	4.42e-56	0.78	0.66	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	18.94	7.2e-60	4.42e-56	0.78	0.66	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	18.94	7.2e-60	4.42e-56	0.78	0.66	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
THCA	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	18.94	7.48e-60	4.59e-56	0.84	0.66	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	18.94	7.48e-60	4.59e-56	0.84	0.66	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	18.93	8.03e-60	4.92e-56	0.78	0.66	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
THCA	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	18.93	8.16e-60	5e-56	0.78	0.66	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
THCA	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	18.92	8.82e-60	5.41e-56	0.7	0.66	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
THCA	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	18.92	9.43e-60	5.78e-56	0.84	0.66	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
THCA	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	18.92	9.53e-60	5.84e-56	0.7	0.66	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
THCA	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-18.91	9.91e-60	6.07e-56	-0.84	-0.66	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
THCA	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-18.91	9.93e-60	6.08e-56	-0.68	-0.66	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
THCA	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-18.91	9.95e-60	6.09e-56	-0.84	-0.66	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
THCA	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	18.91	1.03e-59	6.31e-56	0.83	0.66	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
THCA	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	18.9	1.14e-59	7e-56	0.78	0.66	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
THCA	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-18.89	1.25e-59	7.65e-56	-0.84	-0.66	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	18.89	1.27e-59	7.78e-56	0.83	0.66	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	18.89	1.28e-59	7.83e-56	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
THCA	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	18.89	1.31e-59	8e-56	0.78	0.66	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
THCA	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-18.88	1.32e-59	8.06e-56	-0.91	-0.66	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
THCA	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
THCA	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	18.88	1.44e-59	8.74e-56	0.84	0.66	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
THCA	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-18.88	1.45e-59	8.8e-56	-0.7	-0.66	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
THCA	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	18.88	1.45e-59	8.82e-56	1.09	0.66	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
THCA	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
THCA	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-18.88	1.46e-59	8.87e-56	-0.84	-0.66	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	18.87	1.47e-59	8.93e-56	0.76	0.66	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	18.87	1.49e-59	9.08e-56	0.78	0.66	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
THCA	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	18.87	1.5e-59	9.09e-56	0.84	0.66	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-18.86	1.64e-59	9.95e-56	-0.78	-0.66	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
THCA	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-18.86	1.74e-59	1.06e-55	-0.7	-0.66	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
THCA	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	18.86	1.82e-59	1.1e-55	0.84	0.66	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
THCA	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	18.85	1.97e-59	1.19e-55	1.09	0.66	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
THCA	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	18.83	2.33e-59	1.41e-55	1.25	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
THCA	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-18.83	2.34e-59	1.41e-55	-1.06	-0.66	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
THCA	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	18.83	2.38e-59	1.43e-55	0.85	0.66	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
THCA	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	18.83	2.39e-59	1.44e-55	0.83	0.66	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
THCA	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	18.82	2.65e-59	1.6e-55	0.82	0.66	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
THCA	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-18.81	2.98e-59	1.79e-55	-0.84	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-18.8	3.18e-59	1.91e-55	-0.87	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
THCA	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-18.8	3.37e-59	2.02e-55	-0.71	-0.66	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
THCA	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-18.8	3.37e-59	2.02e-55	-0.71	-0.66	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
THCA	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-18.8	3.44e-59	2.06e-55	-0.84	-0.66	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-18.8	3.44e-59	2.06e-55	-0.84	-0.66	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-18.79	3.54e-59	2.12e-55	-0.84	-0.66	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	18.79	3.57e-59	2.14e-55	0.78	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
THCA	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	18.79	3.6e-59	2.16e-55	1.08	0.65	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
THCA	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	18.78	3.99e-59	2.39e-55	0.83	0.65	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	18.78	4.23e-59	2.54e-55	0.83	0.65	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	18.77	4.35e-59	2.6e-55	0.89	0.65	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
THCA	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-18.77	4.43e-59	2.64e-55	-0.84	-0.65	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
THCA	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-18.77	4.43e-59	2.64e-55	-0.84	-0.65	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
THCA	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-18.77	4.43e-59	2.64e-55	-0.84	-0.65	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	18.77	4.55e-59	2.71e-55	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
THCA	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	18.77	4.68e-59	2.79e-55	0.83	0.65	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
THCA	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-18.76	5.08e-59	3.02e-55	-0.83	-0.65	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-18.76	5.08e-59	3.02e-55	-0.83	-0.65	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	18.76	5.22e-59	3.11e-55	0.78	0.65	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	18.75	5.79e-59	3.44e-55	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
THCA	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-18.75	5.83e-59	3.47e-55	-0.91	-0.65	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
THCA	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-18.74	5.97e-59	3.55e-55	-0.69	-0.65	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
THCA	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	18.74	5.99e-59	3.56e-55	0.84	0.65	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	18.74	6.08e-59	3.61e-55	0.89	0.65	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
THCA	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	18.73	6.65e-59	3.9e-55	0.84	0.65	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
THCA	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	18.72	7.4e-59	4.33e-55	0.89	0.65	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	18.72	7.4e-59	4.33e-55	0.89	0.65	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
THCA	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	18.7	9.55e-59	5.58e-55	1.08	0.65	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
THCA	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-18.69	1.02e-58	5.96e-55	-0.84	-0.65	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	18.69	1.06e-58	6.18e-55	0.83	0.65	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
THCA	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	18.69	1.07e-58	6.26e-55	0.85	0.65	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
THCA	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	18.69	1.08e-58	6.28e-55	0.89	0.65	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
THCA	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	18.69	1.11e-58	6.48e-55	0.84	0.65	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
THCA	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-18.68	1.21e-58	7.03e-55	-0.83	-0.65	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	18.68	1.24e-58	7.24e-55	0.91	0.65	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
THCA	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	18.67	1.28e-58	7.48e-55	0.83	0.65	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
THCA	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	18.66	1.47e-58	8.54e-55	0.69	0.65	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
THCA	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	18.66	1.47e-58	8.54e-55	0.69	0.65	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
THCA	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	18.66	1.47e-58	8.54e-55	0.69	0.65	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	18.65	1.57e-58	9.13e-55	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
THCA	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-18.65	1.59e-58	9.25e-55	-0.83	-0.65	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
THCA	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-18.65	1.65e-58	9.57e-55	-0.88	-0.65	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-18.63	2.02e-58	1.17e-54	-0.72	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
THCA	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-18.63	2.03e-58	1.17e-54	-0.69	-0.65	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-18.63	2.03e-58	1.17e-54	-0.69	-0.65	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-18.62	2.21e-58	1.28e-54	-0.7	-0.65	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
THCA	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	18.62	2.24e-58	1.29e-54	0.78	0.65	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
THCA	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-18.62	2.27e-58	1.31e-54	-0.71	-0.65	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
THCA	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	18.62	2.36e-58	1.36e-54	0.79	0.65	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	18.62	2.36e-58	1.36e-54	0.79	0.65	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
THCA	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	18.61	2.59e-58	1.49e-54	0.85	0.65	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
THCA	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-18.61	2.67e-58	1.53e-54	-0.82	-0.65	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
THCA	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	18.59	3.08e-58	1.77e-54	0.85	0.65	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
THCA	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	18.59	3.18e-58	1.82e-54	0.69	0.65	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
THCA	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-18.59	3.28e-58	1.89e-54	-0.84	-0.65	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
THCA	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	18.58	3.35e-58	1.92e-54	0.77	0.65	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
THCA	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	18.58	3.43e-58	1.97e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	18.58	3.43e-58	1.97e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	18.58	3.43e-58	1.97e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	18.58	3.43e-58	1.97e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
THCA	cis	rs67180937	0.844	rs4846384	ENSG00000272750.1	RP11-378J18.8	-18.58	3.51e-58	2.01e-54	-0.73	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222624272	chr1:222658867~222661512:-
THCA	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	18.58	3.56e-58	2.04e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	18.58	3.56e-58	2.04e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	18.58	3.56e-58	2.04e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
THCA	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	18.58	3.56e-58	2.04e-54	0.84	0.65	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
THCA	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	18.57	3.9e-58	2.23e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	18.57	3.9e-58	2.23e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	18.57	3.9e-58	2.23e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	18.57	3.9e-58	2.23e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
THCA	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	18.57	3.98e-58	2.28e-54	0.83	0.65	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
THCA	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	18.56	4.15e-58	2.37e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	18.56	4.31e-58	2.46e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
THCA	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	18.54	5.14e-58	2.93e-54	0.79	0.65	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
THCA	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	18.54	5.24e-58	2.99e-54	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
THCA	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	18.54	5.55e-58	3.16e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
THCA	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	18.54	5.65e-58	3.22e-54	0.83	0.65	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
THCA	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-18.53	6.01e-58	3.42e-54	-0.71	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
THCA	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	18.53	6.17e-58	3.51e-54	0.82	0.65	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	18.53	6.17e-58	3.51e-54	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	18.53	6.23e-58	3.54e-54	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
THCA	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	18.53	6.28e-58	3.57e-54	1.26	0.65	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
THCA	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-18.53	6.29e-58	3.58e-54	-0.74	-0.65	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
THCA	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	18.52	6.33e-58	3.6e-54	0.84	0.65	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	18.52	6.48e-58	3.69e-54	0.83	0.65	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	18.52	6.48e-58	3.69e-54	0.83	0.65	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
THCA	cis	rs67180937	0.844	rs4846770	ENSG00000272750.1	RP11-378J18.8	-18.52	6.55e-58	3.72e-54	-0.72	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622227	chr1:222658867~222661512:-
THCA	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	18.51	7.11e-58	4.04e-54	0.74	0.65	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
THCA	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	18.51	7.12e-58	4.04e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
THCA	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	18.51	7.13e-58	4.04e-54	0.83	0.65	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
THCA	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	18.51	7.14e-58	4.05e-54	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
THCA	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	18.51	7.21e-58	4.09e-54	0.69	0.65	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
THCA	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	18.51	7.26e-58	4.12e-54	0.77	0.65	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
THCA	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	18.51	7.27e-58	4.12e-54	0.72	0.65	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
THCA	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	18.5	8.16e-58	4.62e-54	0.79	0.65	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
THCA	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	18.5	8.45e-58	4.79e-54	0.84	0.65	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
THCA	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	18.49	8.8e-58	4.98e-54	0.83	0.65	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
THCA	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	18.49	9.01e-58	5.1e-54	0.86	0.65	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
THCA	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	18.49	9.07e-58	5.13e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	18.49	9.07e-58	5.13e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	18.49	9.07e-58	5.13e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	18.49	9.07e-58	5.13e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
THCA	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-18.49	9.1e-58	5.14e-54	-0.82	-0.65	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
THCA	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-18.49	9.43e-58	5.32e-54	-0.7	-0.65	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
THCA	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-18.49	9.65e-58	5.44e-54	-0.7	-0.65	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-18.49	9.65e-58	5.44e-54	-0.7	-0.65	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-18.49	9.65e-58	5.44e-54	-0.7	-0.65	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
THCA	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-18.48	9.75e-58	5.5e-54	-0.74	-0.65	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
THCA	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-18.48	9.8e-58	5.52e-54	-0.75	-0.65	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
THCA	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-18.48	1.07e-57	6.04e-54	-0.74	-0.65	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-18.47	1.19e-57	6.68e-54	-0.74	-0.65	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
THCA	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-18.46	1.21e-57	6.82e-54	-0.85	-0.65	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
THCA	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-18.46	1.21e-57	6.82e-54	-0.85	-0.65	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-18.46	1.3e-57	7.3e-54	-0.74	-0.65	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
THCA	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	18.45	1.35e-57	7.58e-54	0.78	0.65	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
THCA	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	18.45	1.36e-57	7.65e-54	0.89	0.65	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-18.45	1.38e-57	7.75e-54	-0.76	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
THCA	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	18.45	1.42e-57	7.97e-54	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
THCA	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-18.45	1.42e-57	7.99e-54	-0.74	-0.65	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
THCA	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	18.45	1.46e-57	8.17e-54	0.89	0.65	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
THCA	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-18.44	1.62e-57	9.06e-54	-0.79	-0.65	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
THCA	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	18.43	1.68e-57	9.44e-54	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
THCA	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-18.43	1.76e-57	9.84e-54	-0.74	-0.65	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	18.42	1.87e-57	1.05e-53	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
THCA	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-18.42	1.89e-57	1.06e-53	-0.79	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
THCA	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	18.42	1.93e-57	1.08e-53	0.67	0.65	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
THCA	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	18.42	1.93e-57	1.08e-53	0.85	0.65	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
THCA	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	18.41	2.07e-57	1.15e-53	0.82	0.65	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
THCA	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	18.41	2.09e-57	1.16e-53	0.84	0.65	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
THCA	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	18.41	2.13e-57	1.19e-53	0.78	0.65	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	18.41	2.13e-57	1.19e-53	0.78	0.65	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
THCA	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	18.41	2.28e-57	1.27e-53	0.83	0.65	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	18.4	2.45e-57	1.36e-53	0.79	0.65	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	18.4	2.49e-57	1.39e-53	0.78	0.65	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	18.4	2.49e-57	1.39e-53	0.78	0.65	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-18.38	2.87e-57	1.6e-53	-0.74	-0.65	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-18.38	2.87e-57	1.6e-53	-0.74	-0.65	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-18.38	2.93e-57	1.63e-53	-0.74	-0.65	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
THCA	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	18.38	2.96e-57	1.65e-53	0.83	0.65	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
THCA	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	18.37	3.21e-57	1.78e-53	0.84	0.65	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
THCA	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	18.37	3.32e-57	1.84e-53	0.83	0.65	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	18.37	3.32e-57	1.84e-53	0.83	0.65	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000218537.1	MIF-AS1	18.36	3.58e-57	1.99e-53	0.84	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23894426~23898930:-
THCA	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	18.36	3.64e-57	2.02e-53	0.67	0.65	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
THCA	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	18.36	3.69e-57	2.04e-53	0.83	0.65	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
THCA	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	18.36	3.71e-57	2.05e-53	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
THCA	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-18.36	3.75e-57	2.08e-53	-0.82	-0.65	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
THCA	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-18.36	3.87e-57	2.14e-53	-0.82	-0.65	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
THCA	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	18.36	3.91e-57	2.16e-53	0.74	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
THCA	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-18.35	4e-57	2.21e-53	-0.73	-0.65	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-18.35	4.03e-57	2.23e-53	-0.73	-0.65	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
THCA	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-18.35	4.03e-57	2.23e-53	-0.73	-0.65	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-18.35	4.03e-57	2.23e-53	-0.73	-0.65	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-18.35	4.03e-57	2.23e-53	-0.73	-0.65	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-18.35	4.06e-57	2.24e-53	-0.74	-0.65	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
THCA	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	18.35	4.13e-57	2.28e-53	0.75	0.65	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
THCA	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-18.34	4.61e-57	2.53e-53	-0.82	-0.65	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
THCA	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-18.34	4.8e-57	2.63e-53	-0.76	-0.65	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
THCA	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	18.34	4.84e-57	2.66e-53	0.74	0.65	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-18.33	5.09e-57	2.79e-53	-0.74	-0.65	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
THCA	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	18.33	5.13e-57	2.81e-53	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	18.33	5.13e-57	2.81e-53	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	18.33	5.13e-57	2.81e-53	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
THCA	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	18.33	5.31e-57	2.91e-53	0.87	0.65	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
THCA	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	18.33	5.38e-57	2.95e-53	0.83	0.65	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	18.33	5.38e-57	2.95e-53	0.83	0.65	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	18.33	5.38e-57	2.95e-53	0.83	0.65	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-18.32	5.96e-57	3.26e-53	-0.74	-0.65	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-18.32	5.97e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-18.32	5.97e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-18.32	5.97e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-18.32	5.99e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-18.32	5.99e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
THCA	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	18.32	6e-57	3.28e-53	0.83	0.65	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	18.32	6e-57	3.28e-53	0.83	0.65	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	18.32	6e-57	3.28e-53	0.83	0.65	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	18.31	6.38e-57	3.48e-53	0.84	0.65	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
THCA	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-18.31	6.43e-57	3.51e-53	-0.82	-0.65	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-18.31	6.65e-57	3.63e-53	-0.82	-0.65	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
THCA	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-18.31	6.65e-57	3.63e-53	-0.82	-0.65	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
THCA	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	18.3	6.91e-57	3.76e-53	0.67	0.65	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
THCA	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	18.3	7.03e-57	3.83e-53	0.79	0.65	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
THCA	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-18.3	7.46e-57	4.06e-53	-0.82	-0.64	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
THCA	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-18.29	7.47e-57	4.07e-53	-0.82	-0.64	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	18.29	7.56e-57	4.12e-53	0.84	0.64	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	18.29	7.56e-57	4.12e-53	0.84	0.64	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	18.28	8.99e-57	4.88e-53	0.82	0.64	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
THCA	cis	rs67180937	0.882	rs17163313	ENSG00000272750.1	RP11-378J18.8	-18.28	9.17e-57	4.99e-53	-0.72	-0.64	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222626283	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	18.27	9.28e-57	5.04e-53	0.78	0.64	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-18.27	9.39e-57	5.1e-53	-0.74	-0.64	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-18.27	9.39e-57	5.1e-53	-0.74	-0.64	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
THCA	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	18.27	9.78e-57	5.31e-53	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
THCA	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-18.27	9.81e-57	5.33e-53	-0.73	-0.64	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
THCA	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	18.27	9.98e-57	5.42e-53	0.83	0.64	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
THCA	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-18.27	1e-56	5.45e-53	-0.83	-0.64	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
THCA	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-18.27	1.02e-56	5.54e-53	-0.72	-0.64	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
THCA	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	18.26	1.03e-56	5.6e-53	0.83	0.64	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	18.26	1.07e-56	5.81e-53	0.85	0.64	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-18.26	1.09e-56	5.89e-53	-0.73	-0.64	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-18.26	1.09e-56	5.89e-53	-0.73	-0.64	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
THCA	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	18.26	1.09e-56	5.9e-53	0.85	0.64	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
THCA	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-18.26	1.13e-56	6.09e-53	-0.82	-0.64	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
THCA	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-18.25	1.24e-56	6.7e-53	-0.74	-0.64	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	18.24	1.33e-56	7.16e-53	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
THCA	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	18.24	1.34e-56	7.22e-53	0.75	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
THCA	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-18.24	1.37e-56	7.39e-53	-0.73	-0.64	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
THCA	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-18.23	1.56e-56	8.43e-53	-0.78	-0.64	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
THCA	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-18.22	1.61e-56	8.71e-53	-0.82	-0.64	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
THCA	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-18.22	1.68e-56	9.05e-53	-0.73	-0.64	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-18.22	1.68e-56	9.05e-53	-0.73	-0.64	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-18.22	1.68e-56	9.05e-53	-0.73	-0.64	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-18.22	1.68e-56	9.05e-53	-0.73	-0.64	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-18.22	1.69e-56	9.07e-53	-0.74	-0.64	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-18.22	1.72e-56	9.24e-53	-0.77	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
THCA	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-18.22	1.73e-56	9.29e-53	-0.73	-0.64	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
THCA	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	18.22	1.74e-56	9.34e-53	1.21	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
THCA	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	18.22	1.76e-56	9.43e-53	1.05	0.64	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
THCA	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-18.21	1.87e-56	1e-52	-0.73	-0.64	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	18.21	1.88e-56	1.01e-52	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
THCA	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-18.21	1.93e-56	1.04e-52	-0.73	-0.64	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
THCA	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	18.21	1.93e-56	1.04e-52	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
THCA	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-18.21	1.96e-56	1.05e-52	-0.73	-0.64	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
THCA	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-18.2	1.98e-56	1.06e-52	-0.85	-0.64	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
THCA	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-18.2	1.99e-56	1.07e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
THCA	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-18.2	1.99e-56	1.07e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-18.2	2.06e-56	1.1e-52	-0.73	-0.64	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-18.2	2.09e-56	1.12e-52	-0.73	-0.64	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-18.2	2.09e-56	1.12e-52	-0.73	-0.64	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
THCA	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	18.2	2.12e-56	1.13e-52	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	18.2	2.12e-56	1.13e-52	1.22	0.64	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	18.2	2.12e-56	1.13e-52	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	18.2	2.12e-56	1.13e-52	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
THCA	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	18.19	2.23e-56	1.19e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	18.19	2.23e-56	1.19e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	18.19	2.23e-56	1.19e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	18.19	2.23e-56	1.19e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	18.19	2.25e-56	1.2e-52	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	18.19	2.25e-56	1.2e-52	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	18.19	2.37e-56	1.26e-52	0.86	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
THCA	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	18.18	2.44e-56	1.31e-52	0.78	0.64	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-18.18	2.53e-56	1.35e-52	-0.74	-0.64	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-18.18	2.53e-56	1.35e-52	-0.74	-0.64	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
THCA	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-18.18	2.54e-56	1.36e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
THCA	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-18.18	2.54e-56	1.36e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
THCA	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	18.18	2.65e-56	1.41e-52	1.07	0.64	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
THCA	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	18.18	2.69e-56	1.44e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	18.18	2.69e-56	1.44e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	18.18	2.69e-56	1.44e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
THCA	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-18.18	2.7e-56	1.44e-52	-0.74	-0.64	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
THCA	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	18.17	2.73e-56	1.45e-52	1.06	0.64	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
THCA	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-18.17	2.9e-56	1.54e-52	-0.82	-0.64	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
THCA	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-18.17	2.92e-56	1.56e-52	-0.82	-0.64	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
THCA	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-18.16	3.01e-56	1.6e-52	-0.82	-0.64	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-18.16	3.16e-56	1.68e-52	-0.75	-0.64	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	18.15	3.35e-56	1.78e-52	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	18.15	3.35e-56	1.78e-52	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
THCA	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-18.15	3.36e-56	1.78e-52	-0.82	-0.64	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	18.14	4.01e-56	2.13e-52	0.82	0.64	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.638	rs7644414	ENSG00000229759.1	MRPS18AP1	18.14	4.03e-56	2.14e-52	0.78	0.64	Coronary artery disease;	chr3:48257589	chr3:48256350~48256938:-
THCA	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-18.13	4.17e-56	2.22e-52	-0.74	-0.64	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
THCA	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	18.13	4.22e-56	2.24e-52	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
THCA	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-18.13	4.27e-56	2.27e-52	-0.73	-0.64	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
THCA	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-18.13	4.28e-56	2.27e-52	-0.77	-0.64	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-18.13	4.28e-56	2.27e-52	-0.77	-0.64	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-18.13	4.28e-56	2.27e-52	-0.77	-0.64	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-18.13	4.28e-56	2.27e-52	-0.77	-0.64	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
THCA	cis	rs7617773	0.962	rs6797587	ENSG00000229759.1	MRPS18AP1	-18.13	4.28e-56	2.27e-52	-0.76	-0.64	Coronary artery disease;	chr3:48156124	chr3:48256350~48256938:-
THCA	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	18.13	4.39e-56	2.33e-52	1.05	0.64	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
THCA	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-18.13	4.4e-56	2.33e-52	-0.74	-0.64	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-18.13	4.4e-56	2.33e-52	-0.74	-0.64	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-18.13	4.4e-56	2.33e-52	-0.74	-0.64	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-18.13	4.4e-56	2.33e-52	-0.74	-0.64	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
THCA	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	18.13	4.41e-56	2.34e-52	0.85	0.64	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
THCA	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	18.13	4.46e-56	2.36e-52	0.82	0.64	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-18.13	4.53e-56	2.4e-52	-0.73	-0.64	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
THCA	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-18.12	4.72e-56	2.5e-52	-0.74	-0.64	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
THCA	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	18.12	4.8e-56	2.54e-52	1.15	0.64	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	18.12	4.86e-56	2.57e-52	0.82	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
THCA	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-18.12	4.87e-56	2.57e-52	-0.73	-0.64	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-18.12	4.87e-56	2.57e-52	-0.73	-0.64	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-18.12	4.87e-56	2.57e-52	-0.73	-0.64	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
THCA	cis	rs55720021	1	rs55720021	ENSG00000232871.7	SEC1P	18.12	4.89e-56	2.58e-52	0.79	0.64	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr19:48640984	chr19:48638071~48682245:+
THCA	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-18.12	5.08e-56	2.68e-52	-0.81	-0.64	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
THCA	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-18.11	5.18e-56	2.73e-52	-0.71	-0.64	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
THCA	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	18.11	5.27e-56	2.78e-52	0.78	0.64	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
THCA	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	18.11	5.27e-56	2.78e-52	0.84	0.64	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
THCA	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-18.11	5.36e-56	2.83e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	18.11	5.42e-56	2.86e-52	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
THCA	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-18.11	5.51e-56	2.91e-52	-0.8	-0.64	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
THCA	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-18.1	5.79e-56	3.04e-52	-0.73	-0.64	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
THCA	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-18.1	6.01e-56	3.16e-52	-0.75	-0.64	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
THCA	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	18.1	6.22e-56	3.27e-52	0.78	0.64	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-18.09	6.38e-56	3.35e-52	-0.73	-0.64	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
THCA	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	18.09	6.41e-56	3.36e-52	0.69	0.64	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
THCA	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-18.09	6.57e-56	3.45e-52	-0.82	-0.64	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
THCA	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-18.09	6.8e-56	3.57e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
THCA	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-18.08	7.38e-56	3.87e-52	-0.81	-0.64	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
THCA	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-18.08	7.4e-56	3.88e-52	-0.73	-0.64	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
THCA	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-18.08	7.75e-56	4.05e-52	-0.74	-0.64	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-18.08	7.83e-56	4.1e-52	-0.71	-0.64	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
THCA	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-18.07	8.02e-56	4.19e-52	-0.74	-0.64	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
THCA	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	18.07	8.16e-56	4.27e-52	1.03	0.64	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
THCA	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-18.07	8.27e-56	4.32e-52	-0.71	-0.64	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
THCA	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-18.07	8.45e-56	4.42e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
THCA	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-18.07	8.45e-56	4.42e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
THCA	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	18.07	8.45e-56	4.42e-52	0.82	0.64	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-18.07	8.74e-56	4.57e-52	-0.73	-0.64	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
THCA	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-18.06	8.88e-56	4.64e-52	-0.74	-0.64	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-18.06	8.88e-56	4.64e-52	-0.74	-0.64	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-18.06	8.94e-56	4.66e-52	-0.73	-0.64	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
THCA	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-18.06	9.36e-56	4.89e-52	-0.83	-0.64	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-18.06	9.37e-56	4.89e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-18.06	9.42e-56	4.91e-52	-0.73	-0.64	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
THCA	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	18.06	9.67e-56	5.04e-52	0.94	0.64	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
THCA	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-18.05	9.78e-56	5.1e-52	-0.74	-0.64	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-18.05	9.83e-56	5.12e-52	-0.73	-0.64	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-18.05	9.83e-56	5.12e-52	-0.73	-0.64	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
THCA	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-18.05	1.02e-55	5.31e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-18.05	1.02e-55	5.31e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
THCA	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-18.05	1.04e-55	5.43e-52	-0.8	-0.64	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
THCA	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-18.05	1.06e-55	5.52e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
THCA	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-18.05	1.06e-55	5.52e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-18.05	1.06e-55	5.52e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-18.05	1.06e-55	5.52e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
THCA	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	18.04	1.12e-55	5.8e-52	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
THCA	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	18.04	1.17e-55	6.08e-52	0.8	0.64	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
THCA	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-18.04	1.17e-55	6.08e-52	-0.73	-0.64	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-18.04	1.2e-55	6.22e-52	-0.73	-0.64	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
THCA	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-18.03	1.21e-55	6.28e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
THCA	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-18.03	1.24e-55	6.44e-52	-0.83	-0.64	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-18.03	1.27e-55	6.56e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
THCA	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-18.03	1.27e-55	6.6e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-18.03	1.28e-55	6.61e-52	-0.74	-0.64	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
THCA	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-18.03	1.3e-55	6.71e-52	-0.77	-0.64	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-18.03	1.32e-55	6.83e-52	-0.77	-0.64	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	18.03	1.32e-55	6.83e-52	0.77	0.64	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
THCA	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-18.02	1.37e-55	7.1e-52	-0.73	-0.64	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
THCA	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	18.02	1.43e-55	7.38e-52	1.06	0.64	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	18.02	1.43e-55	7.38e-52	1.06	0.64	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
THCA	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-18.02	1.43e-55	7.41e-52	-0.74	-0.64	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
THCA	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-18.02	1.44e-55	7.43e-52	-0.82	-0.64	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
THCA	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-18.02	1.45e-55	7.51e-52	-0.73	-0.64	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
THCA	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-18.01	1.52e-55	7.84e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-18.01	1.58e-55	8.15e-52	-0.73	-0.64	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
THCA	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	18.01	1.62e-55	8.38e-52	0.83	0.64	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
THCA	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	18	1.69e-55	8.71e-52	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
THCA	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-17.99	1.99e-55	1.02e-51	-0.82	-0.64	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	17.99	1.99e-55	1.02e-51	0.82	0.64	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	17.99	1.99e-55	1.02e-51	0.82	0.64	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	17.99	1.99e-55	1.02e-51	0.82	0.64	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	17.99	1.99e-55	1.02e-51	0.82	0.64	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-17.98	2.12e-55	1.08e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
THCA	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-17.98	2.12e-55	1.08e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
THCA	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-17.98	2.18e-55	1.12e-51	-0.79	-0.64	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
THCA	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-17.98	2.24e-55	1.15e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
THCA	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	17.98	2.25e-55	1.15e-51	1.04	0.64	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
THCA	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	17.98	2.27e-55	1.16e-51	0.83	0.64	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-17.98	2.27e-55	1.16e-51	-0.77	-0.64	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
THCA	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-17.97	2.38e-55	1.22e-51	-0.75	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
THCA	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-17.97	2.52e-55	1.29e-51	-0.77	-0.64	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
THCA	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	17.96	2.72e-55	1.39e-51	0.81	0.64	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-17.95	2.85e-55	1.46e-51	-0.81	-0.64	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
THCA	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	17.95	2.9e-55	1.48e-51	0.67	0.64	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
THCA	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-17.95	2.91e-55	1.49e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-17.95	2.95e-55	1.5e-51	-0.73	-0.64	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	17.95	2.96e-55	1.51e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
THCA	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-17.95	2.99e-55	1.52e-51	-0.76	-0.64	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
THCA	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-17.95	3.03e-55	1.55e-51	-0.67	-0.64	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
THCA	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	17.95	3.12e-55	1.59e-51	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
THCA	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-17.95	3.14e-55	1.6e-51	-0.77	-0.64	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
THCA	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
THCA	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
THCA	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
THCA	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
THCA	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	17.94	3.45e-55	1.75e-51	0.77	0.64	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
THCA	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-17.93	3.52e-55	1.79e-51	-0.75	-0.64	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
THCA	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-17.93	3.88e-55	1.97e-51	-1.05	-0.64	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
THCA	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-17.92	4.04e-55	2.05e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-17.92	4.04e-55	2.05e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-17.92	4.23e-55	2.14e-51	-0.82	-0.64	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-17.92	4.23e-55	2.14e-51	-0.82	-0.64	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-17.92	4.23e-55	2.14e-51	-0.82	-0.64	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-17.92	4.23e-55	2.14e-51	-0.82	-0.64	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-17.92	4.25e-55	2.15e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-17.92	4.25e-55	2.15e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	17.91	4.39e-55	2.22e-51	0.74	0.64	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-17.91	4.46e-55	2.25e-51	-0.73	-0.64	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
THCA	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-17.91	4.47e-55	2.26e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-17.91	4.65e-55	2.35e-51	-0.73	-0.64	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-17.91	4.65e-55	2.35e-51	-0.73	-0.64	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
THCA	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-17.91	4.72e-55	2.38e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-17.9	4.84e-55	2.44e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	17.9	4.84e-55	2.44e-51	0.8	0.64	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
THCA	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	17.9	4.9e-55	2.47e-51	0.81	0.64	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
THCA	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	17.9	4.96e-55	2.5e-51	0.8	0.64	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	17.9	5.01e-55	2.53e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
THCA	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	17.9	5.16e-55	2.6e-51	0.77	0.64	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
THCA	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-17.9	5.2e-55	2.62e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
THCA	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	17.9	5.21e-55	2.62e-51	0.82	0.64	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	17.9	5.21e-55	2.62e-51	0.82	0.64	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-17.9	5.26e-55	2.65e-51	-0.77	-0.64	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
THCA	cis	rs7617773	0.823	rs9839446	ENSG00000229759.1	MRPS18AP1	-17.89	5.52e-55	2.78e-51	-0.75	-0.64	Coronary artery disease;	chr3:48153176	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.823	rs9839447	ENSG00000229759.1	MRPS18AP1	-17.89	5.52e-55	2.78e-51	-0.75	-0.64	Coronary artery disease;	chr3:48153177	chr3:48256350~48256938:-
THCA	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	17.89	5.6e-55	2.81e-51	1.04	0.64	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
THCA	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	17.89	5.73e-55	2.88e-51	0.84	0.64	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-17.89	5.85e-55	2.94e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
THCA	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
THCA	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
THCA	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-17.88	6.07e-55	3.04e-51	-0.77	-0.64	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-17.88	6.07e-55	3.04e-51	-0.77	-0.64	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
THCA	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-17.88	6.24e-55	3.13e-51	-0.73	-0.64	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
THCA	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-17.88	6.31e-55	3.16e-51	-0.73	-0.64	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
THCA	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-17.88	6.36e-55	3.18e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-17.88	6.36e-55	3.18e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-17.88	6.39e-55	3.2e-51	-0.75	-0.64	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
THCA	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-17.88	6.39e-55	3.2e-51	-0.75	-0.64	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
THCA	cis	rs507080	0.733	rs497678	ENSG00000255239.1	AP002954.6	17.88	6.39e-55	3.2e-51	0.87	0.64	Serum metabolite levels;	chr11:118697172	chr11:118688039~118690600:-
THCA	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	17.88	6.48e-55	3.24e-51	0.84	0.64	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
THCA	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-17.88	6.53e-55	3.27e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
THCA	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-17.88	6.53e-55	3.27e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-17.88	6.54e-55	3.27e-51	-0.72	-0.64	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
THCA	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	17.88	6.56e-55	3.28e-51	0.82	0.64	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	17.88	6.56e-55	3.28e-51	0.82	0.64	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-17.87	6.67e-55	3.33e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	17.87	6.75e-55	3.37e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
THCA	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-17.87	6.78e-55	3.39e-51	-0.8	-0.64	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
THCA	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-17.87	6.93e-55	3.45e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
THCA	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
THCA	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-17.87	7.18e-55	3.57e-51	-0.82	-0.64	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
THCA	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-17.87	7.18e-55	3.57e-51	-0.82	-0.64	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	17.87	7.34e-55	3.64e-51	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	17.87	7.34e-55	3.64e-51	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
THCA	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-17.86	7.42e-55	3.69e-51	-0.82	-0.64	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-17.86	7.42e-55	3.69e-51	-0.82	-0.64	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
THCA	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	17.86	7.55e-55	3.75e-51	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
THCA	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-17.86	7.71e-55	3.82e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-17.86	7.71e-55	3.82e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-17.86	7.71e-55	3.82e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-17.86	7.71e-55	3.82e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	17.86	7.82e-55	3.88e-51	0.84	0.64	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-17.85	8.36e-55	4.15e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-17.85	8.36e-55	4.15e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	17.85	8.42e-55	4.17e-51	0.84	0.64	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	17.85	8.42e-55	4.17e-51	0.84	0.64	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	17.85	8.42e-55	4.17e-51	0.84	0.64	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	17.85	8.42e-55	4.17e-51	0.84	0.64	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
THCA	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-17.85	8.47e-55	4.19e-51	-0.81	-0.64	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
THCA	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-17.85	8.59e-55	4.25e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
THCA	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-17.85	8.62e-55	4.27e-51	-0.8	-0.64	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
THCA	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	17.85	8.67e-55	4.29e-51	1.06	0.64	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
THCA	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-17.85	8.78e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-17.85	8.78e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-17.85	8.78e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	17.85	8.78e-55	4.34e-51	0.8	0.64	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-17.85	8.79e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-17.85	8.79e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-17.85	8.79e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-17.85	8.79e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-17.85	8.81e-55	4.35e-51	-0.8	-0.64	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-17.85	8.81e-55	4.35e-51	-0.8	-0.64	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-17.85	8.81e-55	4.35e-51	-0.8	-0.64	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
THCA	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	17.85	9.05e-55	4.46e-51	1.05	0.64	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
THCA	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	17.84	9.37e-55	4.61e-51	0.84	0.64	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	17.84	9.37e-55	4.61e-51	0.84	0.64	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	17.84	9.37e-55	4.61e-51	0.84	0.64	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	17.84	9.39e-55	4.62e-51	0.75	0.64	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	17.84	9.51e-55	4.68e-51	0.84	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
THCA	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-17.84	1e-54	4.91e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
THCA	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-17.83	1.04e-54	5.11e-51	-0.8	-0.64	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-17.83	1.04e-54	5.11e-51	-0.8	-0.64	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-17.83	1.04e-54	5.11e-51	-0.8	-0.64	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-17.83	1.04e-54	5.11e-51	-0.8	-0.64	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
THCA	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-17.83	1.06e-54	5.2e-51	-0.75	-0.64	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
THCA	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-17.83	1.06e-54	5.2e-51	-0.75	-0.64	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
THCA	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	17.83	1.07e-54	5.25e-51	0.83	0.64	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-17.83	1.07e-54	5.25e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-17.83	1.08e-54	5.27e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-17.83	1.09e-54	5.33e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-17.83	1.09e-54	5.33e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-17.83	1.09e-54	5.33e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-17.83	1.11e-54	5.4e-51	-0.81	-0.64	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-17.83	1.11e-54	5.4e-51	-0.81	-0.64	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
THCA	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-17.83	1.11e-54	5.4e-51	-0.81	-0.64	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
THCA	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	17.83	1.11e-54	5.4e-51	0.81	0.64	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
THCA	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	17.82	1.15e-54	5.62e-51	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
THCA	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-17.82	1.16e-54	5.67e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-17.82	1.22e-54	5.94e-51	-0.81	-0.63	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-17.82	1.22e-54	5.94e-51	-0.81	-0.63	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
THCA	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-17.82	1.22e-54	5.94e-51	-0.75	-0.63	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
THCA	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-17.82	1.22e-54	5.95e-51	-0.81	-0.63	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-17.82	1.22e-54	5.95e-51	-0.81	-0.63	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
THCA	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	17.82	1.26e-54	6.13e-51	0.84	0.63	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-17.81	1.32e-54	6.42e-51	-0.76	-0.63	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
THCA	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-17.81	1.33e-54	6.48e-51	-0.82	-0.63	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	17.81	1.35e-54	6.58e-51	0.81	0.63	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
THCA	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-17.81	1.38e-54	6.73e-51	-0.75	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
THCA	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-17.8	1.51e-54	7.34e-51	-0.81	-0.63	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
THCA	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	17.8	1.53e-54	7.43e-51	0.82	0.63	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	17.8	1.56e-54	7.6e-51	0.81	0.63	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
THCA	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	17.79	1.57e-54	7.64e-51	1.05	0.63	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
THCA	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	17.79	1.71e-54	8.3e-51	0.82	0.63	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
THCA	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-17.79	1.73e-54	8.37e-51	-0.83	-0.63	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-17.78	1.79e-54	8.69e-51	-0.8	-0.63	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	17.78	1.81e-54	8.78e-51	0.74	0.63	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
THCA	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-17.78	1.83e-54	8.85e-51	-0.85	-0.63	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-17.77	1.97e-54	9.53e-51	-0.83	-0.63	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
THCA	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-17.77	2.11e-54	1.02e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	17.77	2.15e-54	1.04e-50	0.82	0.63	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
THCA	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	17.76	2.21e-54	1.07e-50	1.11	0.63	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
THCA	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	17.76	2.23e-54	1.08e-50	0.8	0.63	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
THCA	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-17.76	2.28e-54	1.1e-50	-0.81	-0.63	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-17.76	2.28e-54	1.1e-50	-0.81	-0.63	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
THCA	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-17.76	2.28e-54	1.1e-50	-0.81	-0.63	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
THCA	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-17.76	2.28e-54	1.1e-50	-0.81	-0.63	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-17.76	2.34e-54	1.13e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.41e-54	1.16e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
THCA	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
THCA	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-17.75	2.44e-54	1.18e-50	-0.74	-0.63	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
THCA	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-17.75	2.54e-54	1.23e-50	-0.73	-0.63	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
THCA	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	17.75	2.55e-54	1.23e-50	0.81	0.63	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
THCA	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-17.74	2.69e-54	1.29e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
THCA	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	17.73	3.06e-54	1.47e-50	0.81	0.63	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
THCA	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-17.73	3.06e-54	1.47e-50	-0.85	-0.63	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-17.73	3.09e-54	1.49e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-17.73	3.26e-54	1.56e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
THCA	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	17.72	3.43e-54	1.65e-50	0.68	0.63	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
THCA	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-17.72	3.64e-54	1.75e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
THCA	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-17.71	3.69e-54	1.77e-50	-0.78	-0.63	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
THCA	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	17.71	3.71e-54	1.78e-50	0.67	0.63	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
THCA	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-17.71	3.81e-54	1.83e-50	-0.75	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
THCA	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	17.71	3.84e-54	1.84e-50	0.68	0.63	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
THCA	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	17.71	3.87e-54	1.86e-50	0.82	0.63	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
THCA	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	17.71	3.87e-54	1.86e-50	0.82	0.63	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	17.71	3.87e-54	1.86e-50	0.82	0.63	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
THCA	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-17.71	4.07e-54	1.95e-50	-0.82	-0.63	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
THCA	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	17.7	4.27e-54	2.04e-50	0.82	0.63	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-17.69	4.83e-54	2.31e-50	-0.77	-0.63	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-17.69	4.83e-54	2.31e-50	-0.77	-0.63	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
THCA	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-17.69	4.89e-54	2.34e-50	-0.83	-0.63	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-17.69	4.9e-54	2.34e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
THCA	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-17.69	4.9e-54	2.34e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-17.68	5.06e-54	2.41e-50	-0.81	-0.63	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-17.68	5.23e-54	2.49e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
THCA	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	17.68	5.38e-54	2.57e-50	0.73	0.63	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
THCA	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-17.68	5.46e-54	2.6e-50	-0.84	-0.63	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
THCA	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	17.67	5.89e-54	2.8e-50	0.84	0.63	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
THCA	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-17.67	5.95e-54	2.83e-50	-0.82	-0.63	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
THCA	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-17.67	6.25e-54	2.97e-50	-0.84	-0.63	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	17.66	6.4e-54	3.04e-50	0.78	0.63	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
THCA	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	17.66	6.45e-54	3.06e-50	0.82	0.63	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-17.66	6.54e-54	3.1e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	17.65	7.19e-54	3.41e-50	0.74	0.63	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
THCA	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-17.65	7.63e-54	3.62e-50	-0.75	-0.63	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
THCA	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	17.64	8.27e-54	3.91e-50	0.81	0.63	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
THCA	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-17.64	8.32e-54	3.93e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-17.63	8.96e-54	4.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-17.63	8.96e-54	4.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-17.63	8.96e-54	4.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-17.63	8.96e-54	4.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
THCA	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-17.63	9.13e-54	4.31e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-17.63	9.36e-54	4.41e-50	-0.81	-0.63	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
THCA	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-17.62	9.58e-54	4.51e-50	-0.77	-0.63	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
THCA	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-17.62	1.06e-53	4.97e-50	-0.73	-0.63	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
THCA	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	17.61	1.17e-53	5.5e-50	0.79	0.63	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
THCA	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-17.6	1.2e-53	5.63e-50	-0.74	-0.63	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
THCA	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-17.6	1.23e-53	5.77e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-17.6	1.27e-53	5.95e-50	-0.82	-0.63	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
THCA	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-17.6	1.27e-53	5.96e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-17.6	1.27e-53	5.96e-50	-0.74	-0.63	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
THCA	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-17.59	1.39e-53	6.51e-50	-1	-0.63	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-17.59	1.39e-53	6.52e-50	-0.82	-0.63	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
THCA	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-17.59	1.44e-53	6.74e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-17.59	1.45e-53	6.76e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-17.59	1.46e-53	6.84e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-17.58	1.49e-53	6.98e-50	-0.82	-0.63	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
THCA	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	17.58	1.54e-53	7.18e-50	0.79	0.63	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
THCA	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	17.58	1.55e-53	7.25e-50	0.81	0.63	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-17.58	1.56e-53	7.3e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
THCA	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-17.58	1.56e-53	7.3e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
THCA	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-17.58	1.57e-53	7.34e-50	-0.85	-0.63	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-17.56	1.84e-53	8.54e-50	-0.82	-0.63	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
THCA	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	17.56	1.84e-53	8.56e-50	0.67	0.63	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
THCA	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	17.56	1.98e-53	9.2e-50	0.8	0.63	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
THCA	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	17.55	2.17e-53	1.01e-49	0.8	0.63	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
THCA	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	17.55	2.2e-53	1.02e-49	0.82	0.63	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	17.54	2.27e-53	1.05e-49	0.8	0.63	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
THCA	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-17.54	2.29e-53	1.06e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-17.54	2.38e-53	1.1e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-17.54	2.38e-53	1.1e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-17.54	2.38e-53	1.1e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	17.54	2.48e-53	1.15e-49	0.78	0.63	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
THCA	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-17.53	2.51e-53	1.16e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
THCA	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-17.53	2.55e-53	1.18e-49	-0.84	-0.63	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
THCA	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	17.53	2.58e-53	1.19e-49	0.79	0.63	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
THCA	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-17.53	2.76e-53	1.27e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
THCA	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-17.53	2.76e-53	1.27e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
THCA	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-17.53	2.76e-53	1.27e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
THCA	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	17.52	2.91e-53	1.34e-49	0.67	0.63	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	17.52	2.91e-53	1.34e-49	0.67	0.63	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
THCA	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-17.51	3.12e-53	1.43e-49	-0.74	-0.63	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	17.51	3.19e-53	1.46e-49	1.18	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
THCA	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-17.51	3.22e-53	1.48e-49	-0.72	-0.63	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
THCA	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-17.51	3.3e-53	1.52e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
THCA	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-17.51	3.32e-53	1.52e-49	-0.7	-0.63	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
THCA	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	17.51	3.38e-53	1.55e-49	0.79	0.63	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
THCA	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	17.51	3.4e-53	1.56e-49	0.79	0.63	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
THCA	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-17.49	4.12e-53	1.89e-49	-0.79	-0.63	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
THCA	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-17.49	4.21e-53	1.93e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
THCA	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-17.48	4.3e-53	1.97e-49	-0.76	-0.63	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
THCA	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-17.48	4.32e-53	1.98e-49	-0.8	-0.63	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
THCA	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	17.48	4.33e-53	1.98e-49	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
THCA	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	17.48	4.47e-53	2.04e-49	0.71	0.63	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
THCA	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-17.47	4.93e-53	2.25e-49	-0.85	-0.63	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
THCA	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-17.47	4.99e-53	2.28e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-17.47	5.08e-53	2.32e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
THCA	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-17.47	5.08e-53	2.32e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-17.47	5.08e-53	2.32e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-17.47	5.08e-53	2.32e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
THCA	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-17.46	5.59e-53	2.55e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
THCA	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	17.46	5.71e-53	2.6e-49	0.71	0.63	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
THCA	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-17.46	5.79e-53	2.64e-49	-0.75	-0.63	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
THCA	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	17.45	6.18e-53	2.81e-49	0.8	0.63	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	17.45	6.21e-53	2.82e-49	1.16	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	17.45	6.21e-53	2.82e-49	1.16	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
THCA	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-17.45	6.22e-53	2.82e-49	-0.71	-0.63	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
THCA	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-17.45	6.42e-53	2.91e-49	-0.76	-0.63	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
THCA	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-17.44	6.64e-53	3.01e-49	-1	-0.63	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
THCA	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-17.44	6.7e-53	3.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-17.44	6.7e-53	3.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
THCA	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-17.44	6.7e-53	3.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-17.44	6.7e-53	3.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-17.44	6.71e-53	3.04e-49	-0.74	-0.63	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
THCA	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-17.44	6.74e-53	3.05e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-17.44	6.91e-53	3.13e-49	-0.79	-0.63	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-17.44	6.91e-53	3.13e-49	-0.79	-0.63	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
THCA	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
THCA	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
THCA	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
THCA	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
THCA	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
THCA	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
THCA	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-17.44	7.11e-53	3.21e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-17.43	7.29e-53	3.29e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
THCA	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-17.43	7.56e-53	3.41e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	17.42	8.06e-53	3.64e-49	0.79	0.63	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-17.42	8.07e-53	3.64e-49	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
THCA	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	17.42	8.08e-53	3.64e-49	0.73	0.63	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
THCA	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	17.42	8.24e-53	3.71e-49	0.82	0.63	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-17.42	8.41e-53	3.79e-49	-0.77	-0.63	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
THCA	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-17.42	8.45e-53	3.81e-49	-0.74	-0.63	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-17.42	8.85e-53	3.98e-49	-0.73	-0.63	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	17.41	9.07e-53	4.08e-49	1.17	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
THCA	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	17.41	9.33e-53	4.2e-49	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
THCA	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	17.41	9.4e-53	4.23e-49	1	0.63	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
THCA	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-17.4	9.95e-53	4.47e-49	-0.74	-0.63	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
THCA	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-17.4	9.96e-53	4.48e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-17.4	1.01e-52	4.55e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
THCA	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	17.4	1.1e-52	4.93e-49	0.67	0.63	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
THCA	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-17.4	1.1e-52	4.95e-49	-0.81	-0.63	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-17.39	1.13e-52	5.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-17.39	1.13e-52	5.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-17.39	1.13e-52	5.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-17.39	1.13e-52	5.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
THCA	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-17.39	1.14e-52	5.11e-49	-0.82	-0.63	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
THCA	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-17.39	1.15e-52	5.16e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
THCA	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-17.39	1.16e-52	5.19e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
THCA	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	17.39	1.17e-52	5.22e-49	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
THCA	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-17.38	1.25e-52	5.57e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	17.38	1.26e-52	5.62e-49	0.78	0.63	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
THCA	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	17.38	1.27e-52	5.67e-49	0.96	0.63	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
THCA	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
THCA	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	17.38	1.32e-52	5.85e-49	0.81	0.63	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	17.38	1.32e-52	5.85e-49	0.81	0.63	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
THCA	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	17.37	1.37e-52	6.1e-49	0.81	0.63	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	17.37	1.38e-52	6.15e-49	0.81	0.63	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
THCA	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-17.37	1.4e-52	6.2e-49	-0.78	-0.63	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
THCA	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	17.37	1.4e-52	6.2e-49	0.83	0.63	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	17.37	1.4e-52	6.2e-49	0.83	0.63	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	17.37	1.4e-52	6.2e-49	0.83	0.63	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
THCA	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-17.37	1.4e-52	6.22e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	17.37	1.51e-52	6.68e-49	0.8	0.63	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	17.37	1.51e-52	6.68e-49	0.8	0.63	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
THCA	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-17.36	1.56e-52	6.92e-49	-0.81	-0.63	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-17.36	1.56e-52	6.92e-49	-0.72	-0.63	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
THCA	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-17.36	1.58e-52	6.99e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
THCA	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-17.36	1.58e-52	6.99e-49	-0.73	-0.63	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
THCA	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-17.36	1.63e-52	7.21e-49	-0.79	-0.63	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
THCA	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-17.36	1.63e-52	7.21e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-17.35	1.81e-52	8.03e-49	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
THCA	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-17.35	1.82e-52	8.03e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	17.35	1.85e-52	8.2e-49	0.81	0.62	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	17.35	1.85e-52	8.2e-49	0.81	0.62	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	17.35	1.85e-52	8.2e-49	0.81	0.62	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-17.34	1.88e-52	8.31e-49	-0.72	-0.62	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-17.34	1.88e-52	8.31e-49	-0.72	-0.62	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
THCA	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-17.34	1.95e-52	8.61e-49	-0.78	-0.62	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
THCA	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-17.34	1.98e-52	8.74e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-17.34	1.98e-52	8.74e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-17.34	1.98e-52	8.74e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-17.34	1.98e-52	8.74e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-17.33	2.19e-52	9.64e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-17.33	2.2e-52	9.72e-49	-0.7	-0.62	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
THCA	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	17.33	2.24e-52	9.87e-49	0.96	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
THCA	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	17.32	2.44e-52	1.07e-48	1	0.62	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
THCA	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	17.32	2.44e-52	1.07e-48	0.79	0.62	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
THCA	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-17.32	2.46e-52	1.08e-48	-0.73	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
THCA	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-17.32	2.46e-52	1.08e-48	-0.73	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-17.32	2.46e-52	1.08e-48	-0.73	-0.62	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-17.31	2.84e-52	1.25e-48	-0.8	-0.62	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
THCA	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-17.3	2.88e-52	1.27e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-17.3	2.89e-52	1.27e-48	-0.8	-0.62	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-17.3	2.97e-52	1.3e-48	-0.72	-0.62	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
THCA	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-17.3	2.97e-52	1.3e-48	-0.72	-0.62	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
THCA	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-17.29	3.27e-52	1.43e-48	-0.83	-0.62	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-17.29	3.27e-52	1.43e-48	-0.83	-0.62	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
THCA	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-17.29	3.4e-52	1.49e-48	-0.8	-0.62	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-17.28	3.56e-52	1.56e-48	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
THCA	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	17.28	3.57e-52	1.56e-48	0.82	0.62	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
THCA	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-17.28	3.6e-52	1.58e-48	-0.8	-0.62	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
THCA	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-17.28	3.64e-52	1.59e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-17.28	3.69e-52	1.62e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-17.28	3.71e-52	1.62e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
THCA	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	17.28	3.81e-52	1.67e-48	0.66	0.62	Breast cancer;	chr11:750849	chr11:779617~780755:+
THCA	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-17.28	3.84e-52	1.68e-48	-0.78	-0.62	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
THCA	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	17.28	3.92e-52	1.72e-48	0.81	0.62	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-17.28	3.94e-52	1.72e-48	-0.82	-0.62	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-17.27	4e-52	1.75e-48	-0.74	-0.62	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
THCA	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-17.27	4.17e-52	1.82e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
THCA	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	17.27	4.19e-52	1.83e-48	0.81	0.62	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	17.27	4.19e-52	1.83e-48	0.81	0.62	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	17.27	4.19e-52	1.83e-48	0.81	0.62	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
THCA	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-17.27	4.26e-52	1.86e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-17.26	4.4e-52	1.92e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
THCA	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-17.26	4.54e-52	1.98e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-17.26	4.77e-52	2.07e-48	-0.81	-0.62	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-17.26	4.77e-52	2.07e-48	-0.81	-0.62	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-17.26	4.77e-52	2.07e-48	-0.81	-0.62	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
THCA	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-17.26	4.77e-52	2.07e-48	-0.81	-0.62	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
THCA	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-17.26	4.79e-52	2.08e-48	-0.82	-0.62	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
THCA	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-17.26	4.84e-52	2.11e-48	-0.72	-0.62	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
THCA	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-17.25	5.09e-52	2.21e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
THCA	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-17.25	5.09e-52	2.21e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
THCA	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	17.25	5.28e-52	2.29e-48	0.76	0.62	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
THCA	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-17.25	5.34e-52	2.32e-48	-0.5	-0.62	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
THCA	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-17.24	5.49e-52	2.39e-48	-0.81	-0.62	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
THCA	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-17.24	5.56e-52	2.41e-48	-0.69	-0.62	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
THCA	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-17.24	5.61e-52	2.43e-48	-0.83	-0.62	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
THCA	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-17.24	5.76e-52	2.5e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
THCA	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	17.24	5.82e-52	2.53e-48	0.94	0.62	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	17.24	5.82e-52	2.53e-48	0.94	0.62	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
THCA	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-17.24	5.83e-52	2.53e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
THCA	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	17.23	6.13e-52	2.66e-48	1	0.62	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
THCA	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-17.23	6.35e-52	2.75e-48	-0.83	-0.62	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
THCA	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-17.22	6.75e-52	2.93e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
THCA	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-17.22	7.16e-52	3.09e-48	-0.72	-0.62	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
THCA	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	17.22	7.22e-52	3.11e-48	0.78	0.62	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
THCA	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-17.21	7.56e-52	3.26e-48	-0.74	-0.62	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
THCA	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-17.21	7.81e-52	3.37e-48	-0.71	-0.62	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
THCA	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	17.21	7.93e-52	3.42e-48	0.67	0.62	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
THCA	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	17.2	8.53e-52	3.67e-48	0.94	0.62	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	17.2	8.53e-52	3.67e-48	0.94	0.62	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	17.2	8.53e-52	3.67e-48	0.94	0.62	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	17.2	8.53e-52	3.67e-48	0.94	0.62	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
THCA	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	17.2	9.1e-52	3.91e-48	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-17.19	9.5e-52	4.09e-48	-0.72	-0.62	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
THCA	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	17.19	9.8e-52	4.21e-48	0.66	0.62	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
THCA	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-17.18	1.06e-51	4.53e-48	-0.8	-0.62	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-17.18	1.06e-51	4.53e-48	-0.8	-0.62	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
THCA	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-17.18	1.09e-51	4.66e-48	-0.98	-0.62	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
THCA	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	17.17	1.19e-51	5.08e-48	0.7	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
THCA	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-17.17	1.2e-51	5.14e-48	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-17.17	1.2e-51	5.14e-48	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
THCA	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-17.17	1.23e-51	5.28e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
THCA	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-17.17	1.24e-51	5.32e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
THCA	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	17.16	1.38e-51	5.88e-48	0.8	0.62	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-17.15	1.42e-51	6.09e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
THCA	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	17.15	1.45e-51	6.18e-48	0.67	0.62	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	17.15	1.45e-51	6.18e-48	0.67	0.62	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
THCA	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-17.15	1.48e-51	6.33e-48	-0.82	-0.62	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
THCA	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-17.15	1.54e-51	6.57e-48	-0.7	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
THCA	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	17.14	1.64e-51	6.98e-48	0.94	0.62	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
THCA	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-17.14	1.69e-51	7.22e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-17.13	1.78e-51	7.6e-48	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
THCA	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-17.13	1.81e-51	7.72e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
THCA	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-17.13	1.92e-51	8.16e-48	-0.8	-0.62	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	17.12	1.95e-51	8.29e-48	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
THCA	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-17.12	2.08e-51	8.86e-48	-0.76	-0.62	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
THCA	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-17.12	2.09e-51	8.9e-48	-0.8	-0.62	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
THCA	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-17.12	2.1e-51	8.91e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-17.12	2.1e-51	8.91e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-17.12	2.14e-51	9.09e-48	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	17.1	2.54e-51	1.08e-47	0.67	0.62	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-17.1	2.57e-51	1.09e-47	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
THCA	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-17.1	2.58e-51	1.09e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	17.09	2.68e-51	1.14e-47	0.77	0.62	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
THCA	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	17.09	2.73e-51	1.16e-47	0.82	0.62	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
THCA	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	17.08	2.97e-51	1.26e-47	0.7	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
THCA	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-17.08	2.99e-51	1.26e-47	-0.8	-0.62	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-17.08	2.99e-51	1.26e-47	-0.8	-0.62	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-17.08	2.99e-51	1.26e-47	-0.8	-0.62	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-17.08	3.08e-51	1.3e-47	-0.73	-0.62	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
THCA	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-17.08	3.15e-51	1.33e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
THCA	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-17.07	3.29e-51	1.39e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-17.07	3.35e-51	1.41e-47	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
THCA	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	17.07	3.44e-51	1.45e-47	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	17.07	3.5e-51	1.47e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
THCA	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-17.07	3.51e-51	1.48e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
THCA	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-17.07	3.51e-51	1.48e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-17.07	3.51e-51	1.48e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
THCA	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-17.06	3.71e-51	1.56e-47	-0.79	-0.62	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	17.06	3.76e-51	1.58e-47	0.7	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-17.06	4.05e-51	1.7e-47	-0.76	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
THCA	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	17.05	4.5e-51	1.89e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
THCA	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	17.04	4.5e-51	1.89e-47	0.76	0.62	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
THCA	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	17.04	4.66e-51	1.96e-47	0.82	0.62	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	17.04	4.66e-51	1.96e-47	1.13	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	17.04	4.66e-51	1.96e-47	1.13	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-17.04	4.8e-51	2.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-17.04	4.8e-51	2.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
THCA	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	17.04	4.97e-51	2.08e-47	0.82	0.62	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
THCA	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	17.04	4.97e-51	2.08e-47	0.82	0.62	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-17.03	5.03e-51	2.11e-47	-0.81	-0.62	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	17.03	5.03e-51	2.11e-47	0.81	0.62	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
THCA	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-17.03	5.3e-51	2.22e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-17.03	5.3e-51	2.22e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
THCA	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	17.03	5.43e-51	2.27e-47	0.83	0.62	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
THCA	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	17.03	5.49e-51	2.29e-47	0.98	0.62	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
THCA	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-17.02	5.75e-51	2.4e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
THCA	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-17.02	5.79e-51	2.42e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-17.02	5.95e-51	2.48e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-17.02	5.95e-51	2.48e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-17.02	5.95e-51	2.48e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-17.02	5.96e-51	2.49e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-17.02	6.01e-51	2.51e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	17.01	6.24e-51	2.6e-47	1.13	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-17.01	6.25e-51	2.6e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
THCA	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	17.01	6.45e-51	2.69e-47	1	0.62	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
THCA	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	17.01	6.74e-51	2.81e-47	0.65	0.62	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
THCA	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-17	7.01e-51	2.91e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-17	7.03e-51	2.92e-47	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
THCA	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-17	7.05e-51	2.93e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
THCA	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-17	7.05e-51	2.93e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	17	7.62e-51	3.16e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	17	7.62e-51	3.16e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-16.99	7.91e-51	3.28e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-16.99	7.91e-51	3.28e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	16.99	8.02e-51	3.32e-47	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
THCA	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-16.98	8.75e-51	3.61e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	16.98	8.82e-51	3.64e-47	1.14	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-16.98	9.15e-51	3.78e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
THCA	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-16.98	9.21e-51	3.79e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-16.98	9.29e-51	3.82e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
THCA	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-16.97	9.7e-51	3.98e-47	-0.71	-0.62	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
THCA	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-16.97	9.76e-51	4.01e-47	-0.8	-0.62	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-16.97	9.76e-51	4.01e-47	-0.8	-0.62	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-16.97	9.76e-51	4.01e-47	-0.8	-0.62	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
THCA	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-16.97	9.79e-51	4.02e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-16.97	9.89e-51	4.06e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-16.97	1e-50	4.11e-47	-1.14	-0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	16.97	1e-50	4.11e-47	1.15	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-16.97	1.01e-50	4.13e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	16.97	1.02e-50	4.18e-47	1.12	0.62	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	16.97	1.02e-50	4.18e-47	1.12	0.62	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	16.97	1.02e-50	4.18e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-16.96	1.09e-50	4.45e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-16.96	1.09e-50	4.45e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-16.96	1.12e-50	4.59e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-16.96	1.15e-50	4.7e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-16.96	1.15e-50	4.7e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	16.95	1.18e-50	4.79e-47	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	16.95	1.19e-50	4.85e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
THCA	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-16.95	1.25e-50	5.07e-47	-0.8	-0.62	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
THCA	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-16.95	1.25e-50	5.08e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-16.95	1.27e-50	5.15e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
THCA	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	16.94	1.33e-50	5.39e-47	0.93	0.62	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	16.94	1.33e-50	5.39e-47	0.93	0.62	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	16.94	1.33e-50	5.39e-47	0.93	0.62	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	16.94	1.33e-50	5.39e-47	0.93	0.62	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
THCA	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-16.94	1.34e-50	5.42e-47	-0.71	-0.62	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
THCA	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-16.94	1.39e-50	5.63e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
THCA	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	16.94	1.41e-50	5.71e-47	0.77	0.62	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-16.94	1.42e-50	5.76e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-16.93	1.45e-50	5.87e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	16.93	1.55e-50	6.27e-47	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-16.93	1.56e-50	6.3e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-16.93	1.56e-50	6.3e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-16.93	1.56e-50	6.3e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	16.93	1.57e-50	6.36e-47	1.15	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
THCA	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	16.93	1.58e-50	6.39e-47	0.63	0.62	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
THCA	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	16.92	1.61e-50	6.5e-47	0.82	0.62	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	16.92	1.61e-50	6.51e-47	0.76	0.62	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
THCA	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-16.92	1.62e-50	6.55e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-16.92	1.67e-50	6.72e-47	-0.71	-0.62	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
THCA	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-16.92	1.7e-50	6.87e-47	-0.81	-0.62	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	16.92	1.71e-50	6.9e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
THCA	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-16.92	1.72e-50	6.91e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
THCA	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-16.92	1.75e-50	7.04e-47	-0.71	-0.62	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	16.92	1.75e-50	7.05e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
THCA	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	16.92	1.76e-50	7.06e-47	0.83	0.62	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	16.91	1.8e-50	7.24e-47	0.76	0.62	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	16.91	1.82e-50	7.34e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
THCA	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	16.91	1.86e-50	7.46e-47	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
THCA	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-16.91	1.87e-50	7.51e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-16.91	1.87e-50	7.51e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
THCA	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-16.91	1.89e-50	7.58e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
THCA	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	16.91	1.93e-50	7.69e-47	0.99	0.61	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
THCA	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	16.91	1.94e-50	7.75e-47	0.99	0.61	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
THCA	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-16.9	2.05e-50	8.15e-47	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
THCA	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	16.9	2.09e-50	8.32e-47	0.81	0.61	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	16.9	2.09e-50	8.32e-47	0.81	0.61	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	16.9	2.1e-50	8.35e-47	1.15	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	16.9	2.1e-50	8.35e-47	1.15	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
THCA	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	16.9	2.13e-50	8.43e-47	0.57	0.61	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
THCA	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	16.9	2.13e-50	8.44e-47	0.66	0.61	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-16.9	2.16e-50	8.55e-47	-0.88	-0.61	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
THCA	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-16.89	2.25e-50	8.88e-47	-0.78	-0.61	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	16.89	2.25e-50	8.89e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	16.89	2.31e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-16.89	2.36e-50	9.29e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	16.89	2.37e-50	9.34e-47	0.79	0.61	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	16.89	2.44e-50	9.6e-47	0.65	0.61	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
THCA	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	16.88	2.51e-50	9.88e-47	0.76	0.61	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
THCA	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-16.88	2.55e-50	1e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
THCA	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	16.88	2.64e-50	1.04e-46	0.79	0.61	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
THCA	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-16.88	2.69e-50	1.06e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-16.87	2.78e-50	1.09e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-16.87	2.84e-50	1.11e-46	-1.12	-0.61	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
THCA	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	16.87	2.88e-50	1.12e-46	0.72	0.61	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
THCA	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	16.87	2.95e-50	1.15e-46	0.7	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	16.87	2.95e-50	1.15e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
THCA	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-16.87	2.96e-50	1.15e-46	-0.77	-0.61	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-16.86	3.04e-50	1.18e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-16.86	3.04e-50	1.18e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-16.86	3.08e-50	1.2e-46	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
THCA	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-16.86	3.12e-50	1.21e-46	-0.81	-0.61	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
THCA	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	16.86	3.18e-50	1.24e-46	0.95	0.61	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	16.86	3.18e-50	1.24e-46	0.95	0.61	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-16.86	3.21e-50	1.25e-46	-0.79	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
THCA	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-16.86	3.26e-50	1.27e-46	-0.81	-0.61	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-16.86	3.34e-50	1.3e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-16.85	3.5e-50	1.36e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	16.85	3.51e-50	1.36e-46	0.77	0.61	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
THCA	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	16.85	3.55e-50	1.38e-46	0.72	0.61	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
THCA	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-16.84	3.84e-50	1.49e-46	-0.65	-0.61	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
THCA	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-16.84	3.84e-50	1.49e-46	-0.81	-0.61	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
THCA	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	16.84	3.86e-50	1.49e-46	0.65	0.61	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	16.84	3.99e-50	1.54e-46	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
THCA	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-16.84	3.99e-50	1.54e-46	-0.81	-0.61	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	16.84	4.02e-50	1.56e-46	1.12	0.61	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-16.83	4.16e-50	1.61e-46	-0.8	-0.61	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
THCA	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	16.83	4.18e-50	1.62e-46	0.94	0.61	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
THCA	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	16.83	4.29e-50	1.66e-46	0.65	0.61	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
THCA	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	16.82	4.76e-50	1.83e-46	0.82	0.61	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	16.82	4.76e-50	1.83e-46	0.82	0.61	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	16.82	4.76e-50	1.83e-46	0.82	0.61	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	16.82	4.76e-50	1.83e-46	0.82	0.61	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	16.82	5.04e-50	1.94e-46	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	16.81	5.27e-50	2.03e-46	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
THCA	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-16.81	5.28e-50	2.03e-46	-0.79	-0.61	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
THCA	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	16.81	5.48e-50	2.11e-46	0.62	0.61	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
THCA	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-16.8	5.72e-50	2.2e-46	-0.78	-0.61	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
THCA	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-16.8	5.91e-50	2.27e-46	-0.78	-0.61	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
THCA	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-16.8	5.91e-50	2.27e-46	-0.8	-0.61	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	16.8	5.99e-50	2.3e-46	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
THCA	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-16.8	6.03e-50	2.31e-46	-0.81	-0.61	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	16.8	6.19e-50	2.38e-46	0.71	0.61	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
THCA	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-16.79	6.38e-50	2.45e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	16.79	6.39e-50	2.45e-46	1.13	0.61	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
THCA	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	16.79	6.68e-50	2.56e-46	0.75	0.61	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
THCA	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-16.78	7.32e-50	2.8e-46	-0.77	-0.61	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
THCA	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	16.78	7.47e-50	2.86e-46	0.81	0.61	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
THCA	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-16.78	7.55e-50	2.89e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-16.78	7.76e-50	2.97e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
THCA	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-16.77	7.9e-50	3.02e-46	-0.72	-0.61	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
THCA	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-16.77	7.9e-50	3.02e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
THCA	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	16.77	8.22e-50	3.14e-46	0.98	0.61	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
THCA	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-16.76	8.96e-50	3.42e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-16.76	8.96e-50	3.42e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
THCA	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-16.76	9.21e-50	3.51e-46	-0.78	-0.61	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
THCA	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-16.76	9.4e-50	3.58e-46	-0.78	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
THCA	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	16.76	9.4e-50	3.59e-46	0.78	0.61	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
THCA	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-16.76	9.41e-50	3.59e-46	-0.79	-0.61	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-16.76	9.41e-50	3.59e-46	-0.79	-0.61	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
THCA	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-16.76	9.55e-50	3.64e-46	-0.77	-0.61	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	16.75	9.6e-50	3.66e-46	0.8	0.61	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	16.75	9.75e-50	3.71e-46	0.65	0.61	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
THCA	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	16.75	9.82e-50	3.74e-46	0.64	0.61	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
THCA	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	16.75	1e-49	3.81e-46	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	16.75	1.01e-49	3.85e-46	0.71	0.61	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
THCA	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	16.75	1.03e-49	3.91e-46	0.71	0.61	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
THCA	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-16.75	1.04e-49	3.98e-46	-0.79	-0.61	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	16.74	1.1e-49	4.18e-46	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-16.74	1.1e-49	4.2e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	16.74	1.12e-49	4.25e-46	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
THCA	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	16.74	1.14e-49	4.33e-46	0.76	0.61	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
THCA	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-16.74	1.17e-49	4.43e-46	-0.79	-0.61	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
THCA	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-16.73	1.27e-49	4.83e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-16.73	1.31e-49	4.98e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-16.72	1.35e-49	5.13e-46	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
THCA	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-16.72	1.36e-49	5.15e-46	-0.78	-0.61	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
THCA	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	16.72	1.37e-49	5.18e-46	0.81	0.61	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	16.72	1.38e-49	5.23e-46	1.12	0.61	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	16.72	1.38e-49	5.23e-46	1.12	0.61	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	16.72	1.38e-49	5.23e-46	1.12	0.61	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
THCA	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	16.72	1.38e-49	5.24e-46	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
THCA	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-16.72	1.39e-49	5.27e-46	-0.7	-0.61	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
THCA	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-16.72	1.39e-49	5.28e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-16.72	1.39e-49	5.28e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
THCA	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-16.72	1.42e-49	5.37e-46	-0.81	-0.61	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
THCA	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-16.72	1.42e-49	5.37e-46	-0.74	-0.61	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	16.72	1.42e-49	5.38e-46	1.13	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
THCA	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-16.72	1.43e-49	5.39e-46	-0.78	-0.61	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-16.72	1.43e-49	5.42e-46	-0.79	-0.61	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
THCA	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	16.72	1.46e-49	5.52e-46	0.82	0.61	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
THCA	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-16.71	1.48e-49	5.6e-46	-0.81	-0.61	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	16.71	1.57e-49	5.94e-46	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	16.7	1.71e-49	6.45e-46	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-16.69	1.82e-49	6.83e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-16.69	1.86e-49	6.96e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
THCA	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-16.69	1.88e-49	7.05e-46	-0.77	-0.61	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-16.69	1.93e-49	7.22e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
THCA	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-16.69	1.97e-49	7.35e-46	-0.79	-0.61	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-16.69	1.97e-49	7.35e-46	-0.79	-0.61	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-16.69	1.97e-49	7.35e-46	-0.79	-0.61	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-16.69	1.97e-49	7.36e-46	-0.79	-0.61	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
THCA	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	16.68	2.07e-49	7.75e-46	0.72	0.61	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
THCA	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-16.68	2.12e-49	7.94e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	16.68	2.14e-49	8.01e-46	0.77	0.61	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
THCA	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	16.68	2.15e-49	8.02e-46	0.68	0.61	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
THCA	cis	rs9402673	0.58	rs2297339	ENSG00000232876.1	CTA-212D2.2	-16.68	2.23e-49	8.31e-46	-0.71	-0.61	High light scatter reticulocyte count;Reticulocyte count;	chr6:135054853	chr6:135055033~135060550:+
THCA	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-16.67	2.24e-49	8.35e-46	-0.77	-0.61	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-16.67	2.24e-49	8.35e-46	-0.77	-0.61	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
THCA	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	16.67	2.24e-49	8.37e-46	0.63	0.61	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
THCA	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-16.67	2.33e-49	8.71e-46	-0.81	-0.61	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
THCA	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-16.67	2.35e-49	8.75e-46	-0.72	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	16.67	2.38e-49	8.89e-46	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
THCA	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	16.67	2.43e-49	9.07e-46	0.91	0.61	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
THCA	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-16.66	2.51e-49	9.34e-46	-0.78	-0.61	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
THCA	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	16.66	2.66e-49	9.93e-46	0.72	0.61	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
THCA	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	16.66	2.74e-49	1.02e-45	0.72	0.61	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
THCA	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	16.65	2.81e-49	1.05e-45	0.65	0.61	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-16.65	2.9e-49	1.08e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-16.65	2.9e-49	1.08e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-16.65	2.99e-49	1.11e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-16.65	2.99e-49	1.11e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-16.65	3.02e-49	1.12e-45	-1.13	-0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
THCA	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	16.64	3.24e-49	1.2e-45	0.94	0.61	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
THCA	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-16.63	3.56e-49	1.32e-45	-1.08	-0.61	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
THCA	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-16.63	3.59e-49	1.33e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	16.63	3.6e-49	1.33e-45	1.11	0.61	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	16.63	3.62e-49	1.34e-45	0.62	0.61	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	16.63	3.64e-49	1.35e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
THCA	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-16.63	3.65e-49	1.35e-45	-0.77	-0.61	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
THCA	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	16.63	3.66e-49	1.35e-45	0.79	0.61	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	16.63	3.66e-49	1.35e-45	0.79	0.61	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
THCA	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	16.62	3.87e-49	1.43e-45	0.79	0.61	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-16.62	3.92e-49	1.45e-45	-0.7	-0.61	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
THCA	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-16.62	3.96e-49	1.46e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
THCA	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-16.62	3.97e-49	1.47e-45	-0.79	-0.61	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
THCA	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	16.61	4.37e-49	1.61e-45	0.81	0.61	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
THCA	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	16.61	4.4e-49	1.62e-45	0.94	0.61	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
THCA	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
THCA	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	16.61	4.57e-49	1.68e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	16.61	4.59e-49	1.69e-45	0.61	0.61	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	16.6	4.67e-49	1.72e-45	0.62	0.61	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	16.6	4.71e-49	1.73e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
THCA	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-16.6	4.77e-49	1.75e-45	-0.73	-0.61	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
THCA	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	16.6	5.01e-49	1.84e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	16.6	5.04e-49	1.85e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
THCA	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	16.59	5.22e-49	1.91e-45	0.76	0.61	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
THCA	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-16.59	5.45e-49	2e-45	-0.8	-0.61	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
THCA	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	16.59	5.47e-49	2.01e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-16.59	5.63e-49	2.06e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
THCA	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	16.58	6.08e-49	2.23e-45	1.06	0.61	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
THCA	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-16.58	6.09e-49	2.23e-45	-0.67	-0.61	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
THCA	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	16.58	6.12e-49	2.24e-45	0.64	0.61	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-16.58	6.29e-49	2.3e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
THCA	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-16.57	6.48e-49	2.37e-45	-0.81	-0.61	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-16.57	6.61e-49	2.41e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-16.57	6.83e-49	2.5e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-16.56	7.09e-49	2.59e-45	-0.62	-0.61	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
THCA	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	16.56	7.27e-49	2.65e-45	0.71	0.61	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
THCA	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	16.56	7.38e-49	2.69e-45	0.78	0.61	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-16.56	7.47e-49	2.73e-45	-0.77	-0.61	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	16.56	7.68e-49	2.8e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	16.55	8.29e-49	3.02e-45	1.1	0.61	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
THCA	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	16.54	9.01e-49	3.27e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	16.54	9.01e-49	3.27e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	16.54	9.01e-49	3.27e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
THCA	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	16.54	9.02e-49	3.27e-45	0.71	0.61	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
THCA	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	16.54	9.04e-49	3.28e-45	0.79	0.61	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
THCA	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-16.54	9.44e-49	3.42e-45	-0.78	-0.61	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-16.53	1.01e-48	3.67e-45	-0.99	-0.61	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	16.53	1.01e-48	3.68e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	16.53	1.01e-48	3.68e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
THCA	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	16.53	1.03e-48	3.72e-45	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
THCA	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-16.53	1.07e-48	3.88e-45	-0.77	-0.61	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
THCA	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	16.52	1.11e-48	4.01e-45	0.79	0.61	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	16.52	1.11e-48	4.01e-45	0.79	0.61	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	16.52	1.11e-48	4.01e-45	0.79	0.61	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-16.52	1.14e-48	4.11e-45	-0.68	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
THCA	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-16.52	1.15e-48	4.14e-45	-0.65	-0.61	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
THCA	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	16.52	1.16e-48	4.2e-45	0.7	0.61	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
THCA	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-16.51	1.2e-48	4.32e-45	-0.46	-0.61	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
THCA	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	16.51	1.25e-48	4.5e-45	0.98	0.61	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
THCA	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-16.51	1.3e-48	4.67e-45	-0.71	-0.61	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
THCA	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-16.5	1.39e-48	5.02e-45	-0.76	-0.61	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
THCA	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	16.5	1.41e-48	5.08e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-16.5	1.42e-48	5.11e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	16.5	1.43e-48	5.16e-45	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	16.5	1.43e-48	5.16e-45	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	16.5	1.43e-48	5.16e-45	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	16.5	1.46e-48	5.24e-45	1.14	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
THCA	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-16.49	1.48e-48	5.33e-45	-0.77	-0.61	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-16.49	1.48e-48	5.33e-45	-0.77	-0.61	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	16.49	1.51e-48	5.45e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
THCA	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-16.49	1.55e-48	5.59e-45	-0.98	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
THCA	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	16.48	1.73e-48	6.22e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
THCA	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-16.47	1.82e-48	6.53e-45	-0.73	-0.61	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
THCA	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-16.47	1.85e-48	6.65e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-16.47	1.87e-48	6.72e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-16.47	1.89e-48	6.77e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	16.47	1.93e-48	6.91e-45	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
THCA	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	16.47	1.93e-48	6.91e-45	0.7	0.6	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
THCA	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	16.47	1.95e-48	7e-45	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
THCA	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	16.47	1.98e-48	7.09e-45	0.71	0.6	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
THCA	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	16.46	2.1e-48	7.52e-45	0.63	0.6	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	16.46	2.1e-48	7.52e-45	0.63	0.6	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
THCA	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	16.46	2.16e-48	7.75e-45	0.71	0.6	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
THCA	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-16.46	2.19e-48	7.82e-45	-0.77	-0.6	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-16.46	2.19e-48	7.82e-45	-0.77	-0.6	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
THCA	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-16.46	2.21e-48	7.92e-45	-0.77	-0.6	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
THCA	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-16.45	2.26e-48	8.1e-45	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
THCA	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-16.45	2.32e-48	8.28e-45	-0.76	-0.6	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
THCA	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-16.45	2.35e-48	8.41e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-16.45	2.44e-48	8.72e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-16.45	2.45e-48	8.73e-45	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
THCA	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-16.45	2.48e-48	8.85e-45	-0.61	-0.6	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
THCA	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	16.44	2.49e-48	8.88e-45	1.15	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
THCA	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-16.44	2.51e-48	8.96e-45	-0.77	-0.6	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
THCA	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	16.44	2.52e-48	9e-45	0.93	0.6	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
THCA	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	16.44	2.64e-48	9.4e-45	0.68	0.6	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	16.44	2.64e-48	9.4e-45	0.68	0.6	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
THCA	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	16.44	2.72e-48	9.7e-45	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-16.43	2.79e-48	9.95e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
THCA	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-16.43	2.79e-48	9.95e-45	-0.69	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
THCA	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-16.43	2.87e-48	1.02e-44	-0.64	-0.6	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
THCA	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-16.42	3.12e-48	1.11e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-16.42	3.12e-48	1.11e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
THCA	cis	rs7104764	0.701	rs3782115	ENSG00000277290.1	RP11-326C3.16	-16.42	3.14e-48	1.12e-44	-0.63	-0.6	Menarche (age at onset);	chr11:223272	chr11:243099~243483:-
THCA	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-16.42	3.21e-48	1.14e-44	-0.69	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
THCA	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	16.42	3.26e-48	1.16e-44	1.01	0.6	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	16.42	3.26e-48	1.16e-44	1.01	0.6	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	16.42	3.26e-48	1.16e-44	1.01	0.6	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
THCA	cis	rs17111396	1	rs10873333	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034469	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs726627	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034540	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs726626	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034770	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs726625	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034805	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs726628	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034855	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159483	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034967	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs61978725	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81035378	chr14:81032529~81033404:+
THCA	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	16.41	3.43e-48	1.22e-44	0.92	0.6	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	16.41	3.43e-48	1.22e-44	0.92	0.6	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	16.41	3.43e-48	1.22e-44	0.92	0.6	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	16.41	3.43e-48	1.22e-44	0.92	0.6	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
THCA	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-16.41	3.44e-48	1.22e-44	-0.49	-0.6	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
THCA	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-16.41	3.55e-48	1.26e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
THCA	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-16.41	3.67e-48	1.3e-44	-0.61	-0.6	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
THCA	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-16.41	3.7e-48	1.31e-44	-0.77	-0.6	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
THCA	cis	rs17111396	1	rs12323481	ENSG00000259167.2	NMNAT1P1	16.4	3.8e-48	1.34e-44	0.8	0.6	Uric acid levels;	chr14:81035702	chr14:81032529~81033404:+
THCA	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-16.4	3.96e-48	1.4e-44	-0.62	-0.6	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
THCA	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	16.4	4.08e-48	1.44e-44	0.8	0.6	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
THCA	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	16.4	4.08e-48	1.44e-44	0.8	0.6	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
THCA	cis	rs17111396	1	rs12323693	ENSG00000259167.2	NMNAT1P1	16.4	4.12e-48	1.46e-44	0.8	0.6	Uric acid levels;	chr14:81038613	chr14:81032529~81033404:+
THCA	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-16.4	4.16e-48	1.47e-44	-0.7	-0.6	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
THCA	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	16.39	4.22e-48	1.49e-44	0.76	0.6	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
THCA	cis	rs7240205	0.853	rs58806199	ENSG00000275805.1	RP11-349H17.2	-16.39	4.3e-48	1.52e-44	-0.7	-0.6	Breast cancer;	chr18:26562683	chr18:26565723~26575626:-
THCA	cis	rs17111396	1	rs12323785	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81035726	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159484	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81037209	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12323893	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81037309	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159487	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81037812	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159488	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81037815	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs13353103	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038031	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs13353125	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038079	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs13353104	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038207	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs12323355	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038516	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12323350	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038588	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12323762	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038745	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs12184961	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81039207	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12185035	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81039335	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12184963	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81039393	chr14:81032529~81033404:+
THCA	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	16.39	4.37e-48	1.54e-44	0.92	0.6	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
THCA	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	16.39	4.53e-48	1.59e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
THCA	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-16.39	4.53e-48	1.59e-44	-0.73	-0.6	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
THCA	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-16.38	4.76e-48	1.67e-44	-0.85	-0.6	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
THCA	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	16.38	4.77e-48	1.68e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	16.38	4.77e-48	1.68e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	16.38	4.77e-48	1.68e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-16.38	4.99e-48	1.75e-44	-0.69	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
THCA	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	16.38	5.09e-48	1.79e-44	0.87	0.6	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
THCA	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	16.37	5.29e-48	1.86e-44	0.8	0.6	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	16.37	5.29e-48	1.86e-44	0.8	0.6	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
THCA	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-16.37	5.47e-48	1.92e-44	-0.71	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
THCA	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-16.37	5.52e-48	1.93e-44	-0.78	-0.6	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
THCA	cis	rs17111396	1	rs12323790	ENSG00000259167.2	NMNAT1P1	16.37	5.71e-48	2e-44	0.8	0.6	Uric acid levels;	chr14:81035933	chr14:81032529~81033404:+
THCA	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	16.36	5.98e-48	2.09e-44	0.79	0.6	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
THCA	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	16.36	6.31e-48	2.21e-44	0.89	0.6	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
THCA	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	16.36	6.31e-48	2.21e-44	0.89	0.6	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
THCA	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-16.36	6.37e-48	2.23e-44	-0.6	-0.6	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
THCA	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	16.35	6.41e-48	2.24e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-16.35	6.5e-48	2.27e-44	-0.71	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
THCA	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-16.35	6.8e-48	2.37e-44	-0.78	-0.6	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-16.35	7.01e-48	2.45e-44	-0.68	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
THCA	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	16.34	7.11e-48	2.48e-44	0.71	0.6	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
THCA	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	16.34	7.11e-48	2.48e-44	0.71	0.6	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
THCA	cis	rs1431005	0.793	rs7695310	ENSG00000250620.1	RP11-91J3.3	16.34	7.31e-48	2.55e-44	0.76	0.6	Response to statin therapy;	chr4:187415987	chr4:187413564~187415697:+
THCA	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	16.34	7.32e-48	2.55e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
THCA	cis	rs17111396	0.95	rs2192727	ENSG00000259167.2	NMNAT1P1	16.34	7.4e-48	2.58e-44	0.8	0.6	Uric acid levels;	chr14:81032811	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159485	ENSG00000259167.2	NMNAT1P1	16.34	7.67e-48	2.67e-44	0.8	0.6	Uric acid levels;	chr14:81037775	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs11159486	ENSG00000259167.2	NMNAT1P1	16.34	7.67e-48	2.67e-44	0.8	0.6	Uric acid levels;	chr14:81037780	chr14:81032529~81033404:+
THCA	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-16.34	7.78e-48	2.71e-44	-0.7	-0.6	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
THCA	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	16.33	7.94e-48	2.76e-44	0.67	0.6	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
THCA	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-16.33	8.14e-48	2.83e-44	-0.6	-0.6	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
THCA	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-16.33	8.56e-48	2.98e-44	-0.48	-0.6	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
THCA	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	16.33	8.63e-48	3e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
THCA	cis	rs17111396	1	rs61978742	ENSG00000259167.2	NMNAT1P1	16.32	8.76e-48	3.04e-44	0.8	0.6	Uric acid levels;	chr14:81039023	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.951	rs61978743	ENSG00000259167.2	NMNAT1P1	16.32	8.76e-48	3.04e-44	0.8	0.6	Uric acid levels;	chr14:81039047	chr14:81032529~81033404:+
THCA	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	16.32	8.85e-48	3.08e-44	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
THCA	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-16.32	8.9e-48	3.09e-44	-1.01	-0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
THCA	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	16.32	9.31e-48	3.23e-44	0.85	0.6	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
THCA	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	16.32	9.37e-48	3.25e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	16.32	9.61e-48	3.33e-44	0.62	0.6	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	16.32	9.64e-48	3.35e-44	0.8	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
THCA	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-16.32	9.66e-48	3.35e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
THCA	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-16.32	9.67e-48	3.35e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
THCA	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-16.31	9.7e-48	3.36e-44	-0.73	-0.6	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
THCA	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-16.31	9.75e-48	3.38e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
THCA	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	16.31	9.77e-48	3.39e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
THCA	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	16.31	1.02e-47	3.53e-44	0.67	0.6	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
THCA	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	16.31	1.02e-47	3.54e-44	0.61	0.6	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
THCA	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	16.31	1.02e-47	3.55e-44	0.87	0.6	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
THCA	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	16.31	1.02e-47	3.55e-44	0.87	0.6	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
THCA	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	16.31	1.07e-47	3.71e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
THCA	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-16.3	1.1e-47	3.79e-44	-0.49	-0.6	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
THCA	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	16.3	1.1e-47	3.81e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
THCA	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	16.3	1.12e-47	3.86e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
THCA	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	16.3	1.13e-47	3.9e-44	0.7	0.6	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
THCA	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-16.3	1.17e-47	4.03e-44	-0.76	-0.6	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
THCA	cis	rs17111396	0.95	rs28478356	ENSG00000259167.2	NMNAT1P1	16.3	1.19e-47	4.09e-44	0.79	0.6	Uric acid levels;	chr14:81034034	chr14:81032529~81033404:+
THCA	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	16.29	1.2e-47	4.14e-44	0.63	0.6	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
THCA	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-16.29	1.21e-47	4.17e-44	-0.76	-0.6	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-16.29	1.21e-47	4.17e-44	-0.76	-0.6	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-16.29	1.21e-47	4.17e-44	-0.76	-0.6	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-16.29	1.21e-47	4.17e-44	-0.76	-0.6	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
THCA	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-16.29	1.23e-47	4.23e-44	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
THCA	cis	rs1431005	0.893	rs7663709	ENSG00000250620.1	RP11-91J3.3	16.29	1.23e-47	4.24e-44	0.76	0.6	Response to statin therapy;	chr4:187414777	chr4:187413564~187415697:+
THCA	cis	rs1431005	0.784	rs67451289	ENSG00000250620.1	RP11-91J3.3	16.29	1.23e-47	4.24e-44	0.76	0.6	Response to statin therapy;	chr4:187415295	chr4:187413564~187415697:+
THCA	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
THCA	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-16.29	1.24e-47	4.28e-44	-0.64	-0.6	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
THCA	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	16.29	1.25e-47	4.31e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
THCA	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	16.29	1.26e-47	4.34e-44	0.76	0.6	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-16.29	1.27e-47	4.35e-44	-0.79	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
THCA	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-16.29	1.28e-47	4.41e-44	-0.76	-0.6	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
THCA	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-16.29	1.29e-47	4.44e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
THCA	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-16.29	1.31e-47	4.49e-44	-0.77	-0.6	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
THCA	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	16.29	1.31e-47	4.5e-44	1.09	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
THCA	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	16.28	1.4e-47	4.8e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	16.28	1.41e-47	4.84e-44	1.13	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	16.28	1.41e-47	4.84e-44	0.79	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
THCA	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-16.28	1.42e-47	4.85e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-16.28	1.45e-47	4.96e-44	-0.79	-0.6	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
THCA	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-16.28	1.45e-47	4.98e-44	-0.62	-0.6	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
THCA	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	16.27	1.47e-47	5.05e-44	0.84	0.6	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
THCA	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-16.27	1.5e-47	5.14e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-16.27	1.5e-47	5.14e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
THCA	cis	rs17111396	1	rs12323799	ENSG00000259167.2	NMNAT1P1	16.27	1.52e-47	5.2e-44	0.79	0.6	Uric acid levels;	chr14:81036183	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12323491	ENSG00000259167.2	NMNAT1P1	16.27	1.52e-47	5.2e-44	0.79	0.6	Uric acid levels;	chr14:81036333	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs112548722	ENSG00000259167.2	NMNAT1P1	16.27	1.52e-47	5.2e-44	0.79	0.6	Uric acid levels;	chr14:81044512	chr14:81032529~81033404:+
THCA	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	16.27	1.54e-47	5.26e-44	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	16.27	1.54e-47	5.26e-44	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	16.27	1.54e-47	5.26e-44	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
THCA	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-16.27	1.54e-47	5.27e-44	-0.67	-0.6	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
THCA	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-16.27	1.58e-47	5.39e-44	-0.76	-0.6	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
THCA	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	16.27	1.61e-47	5.49e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
THCA	cis	rs17111396	1	rs28416942	ENSG00000259167.2	NMNAT1P1	16.26	1.66e-47	5.66e-44	0.79	0.6	Uric acid levels;	chr14:81033965	chr14:81032529~81033404:+
THCA	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-16.26	1.72e-47	5.86e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-16.26	1.72e-47	5.86e-44	-0.7	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
THCA	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	16.26	1.81e-47	6.19e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
THCA	cis	rs17111396	1	rs61978724	ENSG00000259167.2	NMNAT1P1	16.25	1.86e-47	6.36e-44	0.79	0.6	Uric acid levels;	chr14:81031959	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs2268470	ENSG00000259167.2	NMNAT1P1	16.25	1.86e-47	6.36e-44	0.79	0.6	Uric acid levels;	chr14:81033151	chr14:81032529~81033404:+
THCA	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-16.24	2.02e-47	6.87e-44	-0.61	-0.6	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
THCA	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-16.24	2.04e-47	6.93e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-16.24	2.04e-47	6.93e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-16.24	2.09e-47	7.09e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	16.24	2.15e-47	7.3e-44	0.69	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
THCA	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-16.24	2.16e-47	7.33e-44	-0.6	-0.6	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	16.24	2.19e-47	7.44e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
THCA	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-16.24	2.21e-47	7.49e-44	-0.89	-0.6	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
THCA	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	16.23	2.38e-47	8.08e-44	0.77	0.6	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
THCA	cis	rs17111396	1	rs2268472	ENSG00000259167.2	NMNAT1P1	16.23	2.39e-47	8.1e-44	0.79	0.6	Uric acid levels;	chr14:81033802	chr14:81032529~81033404:+
THCA	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	16.23	2.4e-47	8.13e-44	0.92	0.6	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
THCA	cis	rs977987	0.732	rs999675	ENSG00000261783.1	RP11-252K23.2	-16.23	2.46e-47	8.33e-44	-0.82	-0.6	Dupuytren's disease;	chr16:75272504	chr16:75379818~75381260:-
THCA	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	16.22	2.49e-47	8.43e-44	0.63	0.6	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
THCA	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	16.22	2.52e-47	8.53e-44	0.78	0.6	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	16.22	2.52e-47	8.53e-44	0.78	0.6	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	16.22	2.52e-47	8.53e-44	0.78	0.6	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	16.22	2.52e-47	8.53e-44	0.78	0.6	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
THCA	cis	rs17111396	1	rs2268471	ENSG00000259167.2	NMNAT1P1	16.22	2.59e-47	8.78e-44	0.79	0.6	Uric acid levels;	chr14:81033195	chr14:81032529~81033404:+
THCA	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-16.22	2.6e-47	8.81e-44	-0.77	-0.6	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-16.22	2.61e-47	8.83e-44	-0.79	-0.6	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
THCA	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	16.22	2.62e-47	8.86e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
THCA	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	16.22	2.65e-47	8.98e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
THCA	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-16.22	2.75e-47	9.3e-44	-0.67	-0.6	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
THCA	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-16.22	2.76e-47	9.32e-44	-0.72	-0.6	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
THCA	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-16.22	2.76e-47	9.32e-44	-0.79	-0.6	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
THCA	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-16.21	2.86e-47	9.67e-44	-0.89	-0.6	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
THCA	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	16.21	2.87e-47	9.71e-44	0.87	0.6	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
THCA	cis	rs7240205	0.853	rs4555225	ENSG00000275805.1	RP11-349H17.2	-16.21	2.91e-47	9.83e-44	-0.69	-0.6	Breast cancer;	chr18:26561892	chr18:26565723~26575626:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	16.21	2.95e-47	9.93e-44	0.74	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
THCA	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-16.21	3.03e-47	1.02e-43	-0.46	-0.6	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-16.2	3.06e-47	1.03e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	16.2	3.08e-47	1.04e-43	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
THCA	cis	rs17111396	1	rs2300525	ENSG00000259167.2	NMNAT1P1	-16.2	3.16e-47	1.06e-43	-0.79	-0.6	Uric acid levels;	chr14:81031049	chr14:81032529~81033404:+
THCA	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-16.2	3.29e-47	1.11e-43	-0.6	-0.6	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-16.2	3.29e-47	1.11e-43	-0.6	-0.6	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
THCA	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
THCA	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	16.2	3.35e-47	1.12e-43	0.67	0.6	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
THCA	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	16.2	3.39e-47	1.14e-43	0.85	0.6	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
THCA	cis	rs17111396	1	rs72689918	ENSG00000259167.2	NMNAT1P1	16.19	3.47e-47	1.16e-43	0.79	0.6	Uric acid levels;	chr14:81035599	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs72689919	ENSG00000259167.2	NMNAT1P1	16.19	3.47e-47	1.16e-43	0.79	0.6	Uric acid levels;	chr14:81035600	chr14:81032529~81033404:+
THCA	cis	rs7104764	0.719	rs3782116	ENSG00000277290.1	RP11-326C3.16	-16.19	3.61e-47	1.21e-43	-0.62	-0.6	Menarche (age at onset);	chr11:223119	chr11:243099~243483:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	16.19	3.65e-47	1.22e-43	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
THCA	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-16.19	3.76e-47	1.26e-43	-0.8	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
THCA	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-16.18	3.84e-47	1.29e-43	-0.87	-0.6	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
THCA	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	16.18	3.86e-47	1.29e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-16.18	3.92e-47	1.31e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
THCA	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-16.18	3.99e-47	1.33e-43	-0.49	-0.6	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
THCA	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
THCA	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-16.18	4.13e-47	1.38e-43	-0.75	-0.6	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-16.18	4.13e-47	1.38e-43	-0.75	-0.6	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-16.18	4.14e-47	1.38e-43	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	16.18	4.15e-47	1.38e-43	0.79	0.6	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
THCA	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	16.17	4.23e-47	1.41e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	16.17	4.55e-47	1.52e-43	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
THCA	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	16.17	4.63e-47	1.54e-43	0.67	0.6	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-16.16	4.72e-47	1.57e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-16.16	4.72e-47	1.57e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-16.16	4.72e-47	1.57e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-16.16	4.72e-47	1.57e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
THCA	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	16.16	4.83e-47	1.6e-43	0.46	0.6	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
THCA	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-16.16	4.9e-47	1.63e-43	-0.75	-0.6	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
THCA	cis	rs17111396	1	rs17628249	ENSG00000259167.2	NMNAT1P1	16.16	4.93e-47	1.64e-43	0.8	0.6	Uric acid levels;	chr14:81031636	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs17545722	ENSG00000259167.2	NMNAT1P1	16.16	5.07e-47	1.68e-43	0.79	0.6	Uric acid levels;	chr14:81031658	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs61978723	ENSG00000259167.2	NMNAT1P1	16.16	5.07e-47	1.68e-43	0.79	0.6	Uric acid levels;	chr14:81031781	chr14:81032529~81033404:+
THCA	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	16.16	5.09e-47	1.69e-43	0.67	0.6	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	16.16	5.09e-47	1.69e-43	0.67	0.6	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
THCA	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-16.15	5.17e-47	1.71e-43	-0.87	-0.6	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
THCA	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-16.15	5.21e-47	1.73e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
THCA	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-16.15	5.25e-47	1.74e-43	-0.71	-0.6	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
THCA	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-16.15	5.3e-47	1.76e-43	-0.63	-0.6	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
THCA	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	16.15	5.36e-47	1.78e-43	0.84	0.6	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
THCA	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-16.15	5.46e-47	1.81e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
THCA	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	16.15	5.61e-47	1.86e-43	0.7	0.6	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
THCA	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	16.15	5.69e-47	1.89e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
THCA	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-16.15	5.69e-47	1.89e-43	-0.92	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
THCA	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	16.14	6.03e-47	2e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	16.14	6.03e-47	2e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	16.14	6.03e-47	2e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000250470.1	AP000351.3	16.14	6.11e-47	2.02e-43	0.77	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23976904~23977585:-
THCA	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-16.14	6.22e-47	2.06e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-16.14	6.22e-47	2.06e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
THCA	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-16.14	6.23e-47	2.06e-43	-0.78	-0.6	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-16.14	6.23e-47	2.06e-43	-0.78	-0.6	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-16.14	6.25e-47	2.07e-43	-0.78	-0.6	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	16.14	6.29e-47	2.08e-43	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
THCA	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	16.14	6.29e-47	2.08e-43	0.78	0.6	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
THCA	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-16.13	6.37e-47	2.11e-43	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
THCA	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	16.13	6.38e-47	2.11e-43	0.78	0.6	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-16.13	6.39e-47	2.11e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	16.13	6.64e-47	2.19e-43	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-16.13	6.82e-47	2.25e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	16.13	6.88e-47	2.27e-43	1.17	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
THCA	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
THCA	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	16.13	6.97e-47	2.3e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
THCA	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-16.12	7.21e-47	2.38e-43	-0.69	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
THCA	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-16.12	7.23e-47	2.38e-43	-0.71	-0.6	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
THCA	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
THCA	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-16.12	7.41e-47	2.44e-43	-0.75	-0.6	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-16.12	7.41e-47	2.44e-43	-0.75	-0.6	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
THCA	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-16.12	7.81e-47	2.57e-43	-0.9	-0.6	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
THCA	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	16.11	8e-47	2.63e-43	0.6	0.6	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	16.11	8e-47	2.63e-43	0.6	0.6	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	16.11	8.23e-47	2.7e-43	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
THCA	cis	rs17111396	0.951	rs2300522	ENSG00000259167.2	NMNAT1P1	16.11	8.25e-47	2.71e-43	0.79	0.6	Uric acid levels;	chr14:81030296	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs2300523	ENSG00000259167.2	NMNAT1P1	16.11	8.25e-47	2.71e-43	0.79	0.6	Uric acid levels;	chr14:81030476	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs2300524	ENSG00000259167.2	NMNAT1P1	16.11	8.25e-47	2.71e-43	0.79	0.6	Uric acid levels;	chr14:81030592	chr14:81032529~81033404:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000231271.1	AP000350.8	16.11	8.29e-47	2.72e-43	0.75	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23949918~23954042:+
THCA	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	16.11	8.56e-47	2.81e-43	0.68	0.6	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.677	rs17011666	ENSG00000272750.1	RP11-378J18.8	-16.1	8.72e-47	2.86e-43	-0.68	-0.6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222625623	chr1:222658867~222661512:-
THCA	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-16.1	8.75e-47	2.87e-43	-0.75	-0.6	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
THCA	cis	rs17111396	1	rs12147797	ENSG00000259167.2	NMNAT1P1	16.1	8.93e-47	2.92e-43	0.79	0.6	Uric acid levels;	chr14:81031290	chr14:81032529~81033404:+
THCA	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	16.1	8.94e-47	2.93e-43	0.48	0.6	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
THCA	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-16.1	9.08e-47	2.97e-43	-0.77	-0.6	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
THCA	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	16.1	9.19e-47	3.01e-43	0.7	0.6	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
THCA	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	16.1	9.44e-47	3.09e-43	0.46	0.6	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-16.1	9.5e-47	3.11e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-16.1	9.5e-47	3.11e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-16.1	9.52e-47	3.11e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-16.1	9.54e-47	3.12e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-16.1	9.54e-47	3.12e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-16.1	9.54e-47	3.12e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-16.1	9.54e-47	3.12e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
THCA	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-16.09	9.81e-47	3.21e-43	-0.72	-0.6	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
THCA	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	16.09	9.92e-47	3.24e-43	0.7	0.6	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
THCA	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-16.08	1.07e-46	3.5e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-16.08	1.08e-46	3.54e-43	-0.72	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
THCA	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-16.08	1.12e-46	3.66e-43	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
THCA	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	16.08	1.13e-46	3.67e-43	0.73	0.6	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
THCA	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-16.08	1.13e-46	3.69e-43	-0.48	-0.6	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
THCA	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	16.07	1.24e-46	4.03e-43	0.75	0.6	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
THCA	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-16.07	1.26e-46	4.1e-43	-0.71	-0.6	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
THCA	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	16.07	1.28e-46	4.16e-43	0.46	0.6	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	16.06	1.35e-46	4.39e-43	1.11	0.6	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
THCA	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	16.06	1.36e-46	4.43e-43	0.46	0.6	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	16.06	1.36e-46	4.43e-43	0.46	0.6	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
THCA	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-16.06	1.41e-46	4.57e-43	-0.86	-0.6	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
THCA	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-16.06	1.44e-46	4.68e-43	-0.69	-0.6	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
THCA	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-16.05	1.5e-46	4.85e-43	-0.75	-0.6	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
THCA	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-16.05	1.59e-46	5.17e-43	-0.48	-0.59	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
THCA	cis	rs7240205	0.853	rs10432165	ENSG00000275805.1	RP11-349H17.2	-16.04	1.66e-46	5.37e-43	-0.69	-0.59	Breast cancer;	chr18:26555361	chr18:26565723~26575626:-
THCA	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-16.04	1.67e-46	5.4e-43	-0.59	-0.59	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
THCA	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	16.04	1.67e-46	5.41e-43	0.87	0.59	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
THCA	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-16.04	1.69e-46	5.46e-43	-0.59	-0.59	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-16.04	1.69e-46	5.46e-43	-0.59	-0.59	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
THCA	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
THCA	cis	rs17111396	0.95	rs12323422	ENSG00000259167.2	NMNAT1P1	16.04	1.71e-46	5.53e-43	0.79	0.59	Uric acid levels;	chr14:81038629	chr14:81032529~81033404:+
THCA	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-16.04	1.78e-46	5.76e-43	-0.75	-0.59	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
THCA	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-16.04	1.79e-46	5.78e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
THCA	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-16.04	1.79e-46	5.79e-43	-0.73	-0.59	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
THCA	cis	rs17111396	1	rs13353102	ENSG00000259167.2	NMNAT1P1	16.03	1.82e-46	5.89e-43	0.79	0.59	Uric acid levels;	chr14:81037923	chr14:81032529~81033404:+
THCA	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	16.03	1.98e-46	6.38e-43	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
THCA	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-16.02	2.01e-46	6.47e-43	-0.75	-0.59	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
THCA	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	16.02	2.07e-46	6.66e-43	0.8	0.59	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
THCA	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-16.02	2.11e-46	6.8e-43	-0.82	-0.59	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
THCA	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-16.02	2.14e-46	6.91e-43	-0.75	-0.59	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-16.02	2.19e-46	7.05e-43	-0.75	-0.59	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
THCA	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-16.02	2.19e-46	7.06e-43	-0.78	-0.59	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
THCA	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	16.02	2.21e-46	7.12e-43	1.04	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
THCA	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-16.01	2.27e-46	7.3e-43	-0.97	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-16.01	2.31e-46	7.44e-43	-0.73	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
THCA	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-16.01	2.31e-46	7.44e-43	-0.76	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
THCA	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	16.01	2.38e-46	7.64e-43	0.67	0.59	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
THCA	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	16	2.5e-46	8.02e-43	1.04	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
THCA	cis	rs1431005	0.893	rs7676864	ENSG00000250620.1	RP11-91J3.3	16	2.58e-46	8.28e-43	0.75	0.59	Response to statin therapy;	chr4:187400331	chr4:187413564~187415697:+
THCA	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	15.99	2.78e-46	8.91e-43	0.74	0.59	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
THCA	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-15.99	2.81e-46	9.03e-43	-0.76	-0.59	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-15.99	2.89e-46	9.27e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-15.99	2.89e-46	9.27e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-15.99	2.89e-46	9.27e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
THCA	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	15.99	2.93e-46	9.4e-43	0.77	0.59	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
THCA	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	15.99	3.01e-46	9.63e-43	0.69	0.59	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
THCA	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	15.98	3.18e-46	1.02e-42	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
THCA	cis	rs7569084	0.687	rs12614851	ENSG00000281920.1	RP11-418H16.1	15.98	3.21e-46	1.03e-42	0.75	0.59	Sum eosinophil basophil counts;	chr2:65458050	chr2:65623272~65628424:+
THCA	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-15.98	3.23e-46	1.03e-42	-0.75	-0.59	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-15.98	3.23e-46	1.03e-42	-0.75	-0.59	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
THCA	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	15.98	3.35e-46	1.07e-42	0.84	0.59	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
THCA	cis	rs1431005	0.893	rs998344	ENSG00000250620.1	RP11-91J3.3	15.97	3.53e-46	1.13e-42	0.76	0.59	Response to statin therapy;	chr4:187413335	chr4:187413564~187415697:+
THCA	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.58e-46	1.14e-42	-0.75	-0.59	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.69e-46	1.17e-42	-0.75	-0.59	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.69e-46	1.17e-42	-0.75	-0.59	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.69e-46	1.17e-42	-0.75	-0.59	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
THCA	cis	rs7569084	0.663	rs1437461	ENSG00000281920.1	RP11-418H16.1	15.96	3.81e-46	1.21e-42	0.75	0.59	Sum eosinophil basophil counts;	chr2:65452578	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs7562559	ENSG00000281920.1	RP11-418H16.1	15.96	3.81e-46	1.21e-42	0.75	0.59	Sum eosinophil basophil counts;	chr2:65452719	chr2:65623272~65628424:+
THCA	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	15.96	3.85e-46	1.23e-42	0.79	0.59	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
THCA	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	15.96	3.93e-46	1.25e-42	0.45	0.59	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	15.96	3.93e-46	1.25e-42	0.45	0.59	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-15.96	3.96e-46	1.26e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-15.96	3.96e-46	1.26e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
THCA	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-15.96	3.96e-46	1.26e-42	-0.74	-0.59	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
THCA	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-15.95	4.38e-46	1.39e-42	-0.73	-0.59	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
THCA	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	15.95	4.48e-46	1.42e-42	0.75	0.59	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
THCA	cis	rs977987	0.669	rs1001861	ENSG00000261783.1	RP11-252K23.2	-15.94	4.67e-46	1.48e-42	-0.8	-0.59	Dupuytren's disease;	chr16:75272557	chr16:75379818~75381260:-
THCA	cis	rs17111396	1	rs2268473	ENSG00000259167.2	NMNAT1P1	15.94	4.73e-46	1.5e-42	0.79	0.59	Uric acid levels;	chr14:81034052	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs28448639	ENSG00000259167.2	NMNAT1P1	15.94	4.73e-46	1.5e-42	0.79	0.59	Uric acid levels;	chr14:81034053	chr14:81032529~81033404:+
THCA	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	15.94	4.74e-46	1.5e-42	0.79	0.59	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
THCA	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	15.94	4.92e-46	1.56e-42	1.03	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
THCA	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	15.94	4.96e-46	1.57e-42	0.73	0.59	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
THCA	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-15.94	5.03e-46	1.59e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-15.93	5.1e-46	1.61e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
THCA	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-15.93	5.11e-46	1.62e-42	-0.8	-0.59	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
THCA	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	15.93	5.14e-46	1.63e-42	0.74	0.59	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
THCA	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-15.93	5.17e-46	1.64e-42	-0.66	-0.59	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
THCA	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
THCA	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	15.92	5.97e-46	1.88e-42	0.67	0.59	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
THCA	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-15.92	6.14e-46	1.94e-42	-0.74	-0.59	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
THCA	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-15.92	6.16e-46	1.94e-42	-0.48	-0.59	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
THCA	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-15.91	6.27e-46	1.98e-42	-0.63	-0.59	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
THCA	cis	rs7240205	0.818	rs4264473	ENSG00000275805.1	RP11-349H17.2	15.91	6.32e-46	2e-42	0.68	0.59	Breast cancer;	chr18:26565915	chr18:26565723~26575626:-
THCA	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	15.91	6.34e-46	2e-42	0.46	0.59	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-15.91	6.75e-46	2.13e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
THCA	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	15.91	6.91e-46	2.18e-42	0.67	0.59	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
THCA	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	15.9	6.99e-46	2.2e-42	0.46	0.59	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	15.9	6.99e-46	2.2e-42	0.46	0.59	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-15.9	7.1e-46	2.23e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
THCA	cis	rs17111396	1	rs2268469	ENSG00000259167.2	NMNAT1P1	15.9	7.16e-46	2.25e-42	0.79	0.59	Uric acid levels;	chr14:81032435	chr14:81032529~81033404:+
THCA	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
THCA	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	15.89	7.81e-46	2.46e-42	0.77	0.59	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
THCA	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	15.89	7.87e-46	2.47e-42	0.67	0.59	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
THCA	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	15.89	7.94e-46	2.5e-42	0.7	0.59	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
THCA	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-15.89	8.07e-46	2.53e-42	-0.46	-0.59	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
THCA	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-15.89	8.16e-46	2.56e-42	-0.74	-0.59	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-15.89	8.16e-46	2.56e-42	-0.74	-0.59	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
THCA	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	15.89	8.27e-46	2.6e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	15.89	8.27e-46	2.6e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	15.89	8.27e-46	2.6e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	15.89	8.27e-46	2.6e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
THCA	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	15.89	8.35e-46	2.62e-42	0.46	0.59	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
THCA	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	15.88	9.43e-46	2.95e-42	1.03	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
THCA	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	15.87	9.61e-46	3.01e-42	0.79	0.59	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	15.87	9.66e-46	3.02e-42	0.6	0.59	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
THCA	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-15.87	9.96e-46	3.12e-42	-0.72	-0.59	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
THCA	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	15.86	1.07e-45	3.36e-42	0.75	0.59	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
THCA	cis	rs7240205	0.853	rs6508448	ENSG00000275805.1	RP11-349H17.2	15.86	1.08e-45	3.37e-42	0.68	0.59	Breast cancer;	chr18:26556863	chr18:26565723~26575626:-
THCA	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-15.86	1.09e-45	3.39e-42	-0.75	-0.59	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
THCA	cis	rs7240205	0.853	rs1941160	ENSG00000275805.1	RP11-349H17.2	15.86	1.13e-45	3.53e-42	0.68	0.59	Breast cancer;	chr18:26553529	chr18:26565723~26575626:-
THCA	cis	rs1431005	0.893	rs67136716	ENSG00000250620.1	RP11-91J3.3	15.86	1.14e-45	3.56e-42	0.76	0.59	Response to statin therapy;	chr4:187414928	chr4:187413564~187415697:+
THCA	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	15.86	1.15e-45	3.59e-42	0.67	0.59	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
THCA	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-15.85	1.17e-45	3.66e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	15.85	1.23e-45	3.82e-42	0.78	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
THCA	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	15.85	1.23e-45	3.84e-42	0.66	0.59	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
THCA	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	15.85	1.28e-45	3.99e-42	1.03	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
THCA	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	15.84	1.3e-45	4.05e-42	0.77	0.59	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
THCA	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	15.84	1.33e-45	4.14e-42	0.84	0.59	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
THCA	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	15.84	1.33e-45	4.15e-42	0.45	0.59	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
THCA	cis	rs7240205	0.853	rs2000649	ENSG00000275805.1	RP11-349H17.2	15.84	1.36e-45	4.22e-42	0.68	0.59	Breast cancer;	chr18:26552897	chr18:26565723~26575626:-
THCA	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	15.84	1.36e-45	4.25e-42	0.73	0.59	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
THCA	cis	rs7240205	0.853	rs4404156	ENSG00000275805.1	RP11-349H17.2	15.84	1.42e-45	4.42e-42	0.68	0.59	Breast cancer;	chr18:26563490	chr18:26565723~26575626:-
THCA	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-15.84	1.42e-45	4.43e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-15.84	1.42e-45	4.43e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
THCA	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	15.84	1.44e-45	4.46e-42	0.98	0.59	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
THCA	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	15.83	1.44e-45	4.48e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	15.83	1.5e-45	4.66e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
THCA	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	15.83	1.51e-45	4.7e-42	0.84	0.59	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
THCA	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-15.83	1.56e-45	4.84e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
THCA	cis	rs7569084	0.687	rs1437462	ENSG00000281920.1	RP11-418H16.1	15.82	1.63e-45	5.07e-42	0.74	0.59	Sum eosinophil basophil counts;	chr2:65449559	chr2:65623272~65628424:+
THCA	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-15.82	1.64e-45	5.08e-42	-0.74	-0.59	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-15.82	1.64e-45	5.08e-42	-0.74	-0.59	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-15.82	1.65e-45	5.13e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-15.82	1.65e-45	5.13e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
THCA	cis	rs7240205	0.818	rs12964926	ENSG00000275805.1	RP11-349H17.2	15.81	1.84e-45	5.7e-42	0.68	0.59	Breast cancer;	chr18:26567363	chr18:26565723~26575626:-
THCA	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
THCA	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	15.81	1.91e-45	5.91e-42	0.69	0.59	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
THCA	cis	rs7240205	0.816	rs2019480	ENSG00000275805.1	RP11-349H17.2	15.8	2.04e-45	6.3e-42	0.68	0.59	Breast cancer;	chr18:26545720	chr18:26565723~26575626:-
THCA	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	15.8	2.12e-45	6.54e-42	1.01	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	15.8	2.12e-45	6.54e-42	1.01	0.59	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
THCA	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-15.8	2.17e-45	6.72e-42	-0.59	-0.59	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-15.8	2.17e-45	6.72e-42	-0.59	-0.59	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
THCA	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-15.79	2.23e-45	6.9e-42	-0.68	-0.59	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
THCA	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	15.79	2.24e-45	6.92e-42	0.69	0.59	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
THCA	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	15.79	2.24e-45	6.92e-42	0.69	0.59	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
THCA	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	15.79	2.41e-45	7.44e-42	0.47	0.59	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
THCA	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	15.78	2.51e-45	7.74e-42	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
THCA	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-15.78	2.56e-45	7.89e-42	-0.58	-0.59	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-15.78	2.6e-45	8e-42	-0.58	-0.59	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000204929.10	AC074391.1	-15.78	2.62e-45	8.06e-42	-0.73	-0.59	Sum eosinophil basophil counts;	chr2:65438139	chr2:65436711~66084639:+
THCA	cis	rs7240205	0.853	rs10454719	ENSG00000275805.1	RP11-349H17.2	-15.77	2.76e-45	8.51e-42	-0.68	-0.59	Breast cancer;	chr18:26559666	chr18:26565723~26575626:-
THCA	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-15.77	2.78e-45	8.57e-42	-0.58	-0.59	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
THCA	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-15.77	2.87e-45	8.85e-42	-0.68	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
THCA	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-15.77	2.88e-45	8.87e-42	-0.74	-0.59	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	15.76	3e-45	9.24e-42	0.74	0.59	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	15.76	3.01e-45	9.25e-42	0.69	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
THCA	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-15.76	3.09e-45	9.51e-42	-0.48	-0.59	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
THCA	cis	rs17111396	0.95	rs10143800	ENSG00000259167.2	NMNAT1P1	15.76	3.12e-45	9.59e-42	0.79	0.59	Uric acid levels;	chr14:81029998	chr14:81032529~81033404:+
THCA	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	15.76	3.15e-45	9.69e-42	0.83	0.59	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
THCA	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-15.76	3.16e-45	9.73e-42	-0.63	-0.59	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
THCA	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	15.76	3.16e-45	9.73e-42	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
THCA	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	15.75	3.32e-45	1.02e-41	0.74	0.59	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
THCA	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	15.75	3.5e-45	1.08e-41	0.45	0.59	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
THCA	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-15.74	3.73e-45	1.15e-41	-0.58	-0.59	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
THCA	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	15.74	3.83e-45	1.17e-41	0.45	0.59	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
THCA	cis	rs7569084	0.663	rs4671128	ENSG00000281920.1	RP11-418H16.1	15.73	4.19e-45	1.29e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65438130	chr2:65623272~65628424:+
THCA	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	15.73	4.25e-45	1.3e-41	0.77	0.59	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
THCA	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-15.73	4.37e-45	1.34e-41	-0.58	-0.59	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
THCA	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	15.73	4.41e-45	1.35e-41	0.45	0.59	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	15.73	4.41e-45	1.35e-41	0.45	0.59	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	15.72	4.49e-45	1.38e-41	0.45	0.59	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
THCA	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	15.72	4.51e-45	1.38e-41	0.67	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
THCA	cis	rs7569084	0.687	rs4671663	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65434400	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs11692813	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65435172	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.663	rs11126037	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65436024	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs11126038	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65436100	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.663	rs11694714	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65436802	chr2:65623272~65628424:+
THCA	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-15.72	4.8e-45	1.47e-41	-0.6	-0.59	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
THCA	cis	rs7569084	0.687	rs1344891	ENSG00000281920.1	RP11-418H16.1	15.72	4.95e-45	1.51e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65458890	chr2:65623272~65628424:+
THCA	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	15.71	5.31e-45	1.62e-41	1.02	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
THCA	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-15.71	5.5e-45	1.68e-41	-0.74	-0.59	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
THCA	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	15.7	5.56e-45	1.7e-41	0.66	0.59	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
THCA	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	15.7	5.71e-45	1.74e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
THCA	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-15.7	5.72e-45	1.75e-41	-0.74	-0.59	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
THCA	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-15.7	5.93e-45	1.81e-41	-0.47	-0.59	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
THCA	cis	rs7569084	0.64	rs11126039	ENSG00000281920.1	RP11-418H16.1	15.7	5.94e-45	1.82e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65457953	chr2:65623272~65628424:+
THCA	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-15.7	5.95e-45	1.82e-41	-0.59	-0.59	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
THCA	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-15.69	6.12e-45	1.87e-41	-0.74	-0.59	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-15.69	6.2e-45	1.89e-41	-0.74	-0.59	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
THCA	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	15.69	6.38e-45	1.95e-41	0.77	0.59	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
THCA	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	15.69	6.63e-45	2.02e-41	0.45	0.59	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	15.69	6.67e-45	2.03e-41	0.45	0.59	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
THCA	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-15.68	6.86e-45	2.09e-41	-0.58	-0.59	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
THCA	cis	rs17111396	1	rs2300526	ENSG00000259167.2	NMNAT1P1	15.68	7.34e-45	2.24e-41	0.79	0.59	Uric acid levels;	chr14:81031123	chr14:81032529~81033404:+
THCA	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-15.67	7.69e-45	2.34e-41	-0.74	-0.59	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
THCA	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	15.67	8.14e-45	2.48e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	15.67	8.14e-45	2.48e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	15.67	8.14e-45	2.48e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	15.67	8.14e-45	2.48e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
THCA	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	15.66	8.7e-45	2.65e-41	1.02	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
THCA	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-15.66	9.02e-45	2.74e-41	-0.73	-0.59	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
THCA	cis	rs7569084	0.687	rs11675538	ENSG00000281920.1	RP11-418H16.1	15.65	9.35e-45	2.84e-41	0.73	0.59	Sum eosinophil basophil counts;	chr2:65459327	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs934731	ENSG00000281920.1	RP11-418H16.1	15.65	1.02e-44	3.08e-41	0.73	0.59	Sum eosinophil basophil counts;	chr2:65456353	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs7577452	ENSG00000281920.1	RP11-418H16.1	15.65	1.02e-44	3.08e-41	0.73	0.59	Sum eosinophil basophil counts;	chr2:65456694	chr2:65623272~65628424:+
THCA	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-15.63	1.16e-44	3.53e-41	-0.78	-0.58	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
THCA	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-15.63	1.16e-44	3.53e-41	-0.58	-0.58	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
THCA	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-15.63	1.17e-44	3.57e-41	-0.98	-0.58	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
THCA	cis	rs1431005	0.893	rs12501227	ENSG00000250620.1	RP11-91J3.3	15.63	1.19e-44	3.62e-41	0.76	0.58	Response to statin therapy;	chr4:187401223	chr4:187413564~187415697:+
THCA	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	15.63	1.21e-44	3.67e-41	0.63	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	15.63	1.21e-44	3.67e-41	0.63	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
THCA	cis	rs1431005	0.893	rs68010462	ENSG00000250620.1	RP11-91J3.3	15.63	1.24e-44	3.77e-41	0.76	0.58	Response to statin therapy;	chr4:187418181	chr4:187413564~187415697:+
THCA	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	15.63	1.25e-44	3.78e-41	0.66	0.58	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
THCA	cis	rs7569084	0.687	rs1370394	ENSG00000281920.1	RP11-418H16.1	15.62	1.31e-44	3.96e-41	0.74	0.58	Sum eosinophil basophil counts;	chr2:65453176	chr2:65623272~65628424:+
THCA	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	15.62	1.39e-44	4.22e-41	0.79	0.58	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
THCA	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	15.61	1.4e-44	4.25e-41	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	15.61	1.4e-44	4.25e-41	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
THCA	cis	rs7569084	1	rs7569084	ENSG00000204929.10	AC074391.1	-15.61	1.44e-44	4.38e-41	-0.72	-0.58	Sum eosinophil basophil counts;	chr2:65429835	chr2:65436711~66084639:+
THCA	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-15.6	1.58e-44	4.79e-41	-0.81	-0.58	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
THCA	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	15.6	1.6e-44	4.83e-41	0.63	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
THCA	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-15.6	1.67e-44	5.05e-41	-0.58	-0.58	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
THCA	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	15.59	1.8e-44	5.44e-41	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	15.59	1.8e-44	5.44e-41	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
THCA	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	15.58	1.94e-44	5.86e-41	0.83	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
THCA	cis	rs7569084	0.687	rs12993075	ENSG00000281920.1	RP11-418H16.1	15.58	2.11e-44	6.36e-41	0.74	0.58	Sum eosinophil basophil counts;	chr2:65431010	chr2:65623272~65628424:+
THCA	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-15.57	2.15e-44	6.47e-41	-0.62	-0.58	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
THCA	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	15.57	2.23e-44	6.72e-41	0.81	0.58	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
THCA	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	15.57	2.23e-44	6.72e-41	0.81	0.58	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
THCA	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	15.57	2.25e-44	6.78e-41	0.83	0.58	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
THCA	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	15.57	2.28e-44	6.86e-41	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
THCA	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	15.56	2.49e-44	7.48e-41	0.58	0.58	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
THCA	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-15.56	2.54e-44	7.63e-41	-0.66	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
THCA	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-15.56	2.54e-44	7.63e-41	-0.66	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
THCA	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-15.56	2.54e-44	7.63e-41	-0.66	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
THCA	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-15.55	2.7e-44	8.12e-41	-0.75	-0.58	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
THCA	cis	rs1431005	0.893	rs9684748	ENSG00000250620.1	RP11-91J3.3	15.55	2.72e-44	8.19e-41	0.74	0.58	Response to statin therapy;	chr4:187398070	chr4:187413564~187415697:+
THCA	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	15.55	2.86e-44	8.6e-41	0.45	0.58	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
THCA	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	15.54	2.91e-44	8.74e-41	0.57	0.58	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-15.54	2.94e-44	8.83e-41	-0.57	-0.58	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
THCA	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-15.54	3.01e-44	9.04e-41	-0.96	-0.58	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
THCA	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-15.53	3.26e-44	9.79e-41	-0.81	-0.58	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
THCA	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-15.53	3.38e-44	1.01e-40	-0.6	-0.58	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	15.52	3.61e-44	1.08e-40	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
THCA	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	15.52	3.7e-44	1.11e-40	0.62	0.58	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
THCA	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-15.52	3.79e-44	1.13e-40	-0.74	-0.58	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-15.52	3.83e-44	1.14e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-15.52	3.83e-44	1.14e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
THCA	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	15.52	3.86e-44	1.15e-40	0.45	0.58	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
THCA	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-15.51	3.97e-44	1.19e-40	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
THCA	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-15.51	3.97e-44	1.19e-40	-0.75	-0.58	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
THCA	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-15.51	4.02e-44	1.2e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
THCA	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-15.51	4.09e-44	1.22e-40	-0.58	-0.58	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
THCA	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-15.51	4.29e-44	1.28e-40	-0.77	-0.58	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
THCA	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	15.5	4.41e-44	1.31e-40	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	15.5	4.41e-44	1.31e-40	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	15.5	4.41e-44	1.31e-40	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	15.5	4.41e-44	1.31e-40	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
THCA	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-15.5	4.45e-44	1.33e-40	-0.77	-0.58	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
THCA	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	15.5	4.55e-44	1.35e-40	0.62	0.58	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
THCA	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-15.5	4.72e-44	1.41e-40	-0.75	-0.58	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
THCA	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-15.49	5.04e-44	1.5e-40	-0.65	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
THCA	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-15.49	5.04e-44	1.5e-40	-0.65	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
THCA	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-15.48	5.65e-44	1.68e-40	-0.47	-0.58	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	15.48	5.67e-44	1.68e-40	0.74	0.58	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
THCA	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-15.47	5.93e-44	1.76e-40	-0.73	-0.58	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
THCA	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	15.47	6.2e-44	1.84e-40	0.73	0.58	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
THCA	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-15.47	6.4e-44	1.9e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
THCA	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	15.47	6.53e-44	1.94e-40	0.94	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
THCA	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-15.46	6.58e-44	1.95e-40	-0.74	-0.58	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
THCA	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	15.46	6.62e-44	1.97e-40	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	15.46	6.85e-44	2.03e-40	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
THCA	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-15.46	6.88e-44	2.04e-40	-0.47	-0.58	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-15.46	6.9e-44	2.05e-40	-0.6	-0.58	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
THCA	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-15.46	6.93e-44	2.06e-40	-0.65	-0.58	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
THCA	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	15.45	7.54e-44	2.23e-40	0.98	0.58	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
THCA	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	15.45	7.74e-44	2.29e-40	0.65	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-15.44	8.06e-44	2.39e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	15.44	8.08e-44	2.39e-40	0.73	0.58	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
THCA	cis	rs7569084	0.687	rs35839762	ENSG00000281920.1	RP11-418H16.1	15.44	8.16e-44	2.41e-40	0.73	0.58	Sum eosinophil basophil counts;	chr2:65441318	chr2:65623272~65628424:+
THCA	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	15.44	8.19e-44	2.42e-40	0.59	0.58	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	15.44	8.25e-44	2.44e-40	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
THCA	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	15.44	8.37e-44	2.47e-40	0.59	0.58	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-15.44	8.48e-44	2.51e-40	-0.57	-0.58	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
THCA	cis	rs17111396	1	rs17111398	ENSG00000259167.2	NMNAT1P1	15.44	8.73e-44	2.58e-40	0.77	0.58	Uric acid levels;	chr14:81057911	chr14:81032529~81033404:+
THCA	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-15.43	9.1e-44	2.69e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
THCA	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	15.43	9.49e-44	2.8e-40	0.45	0.58	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
THCA	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	15.43	9.63e-44	2.84e-40	0.76	0.58	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
THCA	cis	rs17111396	1	rs2268474	ENSG00000259167.2	NMNAT1P1	-15.43	9.83e-44	2.9e-40	-0.76	-0.58	Uric acid levels;	chr14:81058063	chr14:81032529~81033404:+
THCA	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-15.43	9.9e-44	2.92e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-15.42	1.01e-43	2.98e-40	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	15.42	1.09e-43	3.22e-40	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	15.42	1.1e-43	3.23e-40	0.66	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
THCA	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-15.41	1.11e-43	3.26e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
THCA	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-15.41	1.11e-43	3.27e-40	-0.57	-0.58	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
THCA	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-15.41	1.11e-43	3.28e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
THCA	cis	rs992157	0.932	rs1870125	ENSG00000261338.2	RP11-378A13.1	15.41	1.12e-43	3.29e-40	0.63	0.58	Colorectal cancer;	chr2:218323178	chr2:218255319~218257366:+
THCA	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	15.41	1.12e-43	3.3e-40	0.45	0.58	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
THCA	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-15.41	1.13e-43	3.33e-40	-0.68	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000225282.1	AP000350.6	15.41	1.16e-43	3.41e-40	0.7	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23926900~23929574:+
THCA	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	15.41	1.18e-43	3.47e-40	0.61	0.58	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
THCA	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-15.41	1.2e-43	3.54e-40	-0.65	-0.58	Height;	chr3:53074760	chr3:53064283~53065091:-
THCA	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	15.41	1.21e-43	3.57e-40	0.62	0.58	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
THCA	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	15.41	1.22e-43	3.57e-40	0.88	0.58	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
THCA	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-15.4	1.33e-43	3.9e-40	-0.63	-0.58	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
THCA	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-15.39	1.38e-43	4.06e-40	-1.03	-0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
THCA	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	15.39	1.4e-43	4.11e-40	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	15.39	1.4e-43	4.11e-40	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-15.39	1.42e-43	4.14e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-15.39	1.42e-43	4.14e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-15.39	1.42e-43	4.14e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-15.39	1.42e-43	4.14e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	15.38	1.52e-43	4.45e-40	0.72	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
THCA	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-15.37	1.69e-43	4.94e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-15.37	1.69e-43	4.94e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
THCA	cis	rs992157	0.932	rs10203039	ENSG00000261338.2	RP11-378A13.1	15.37	1.72e-43	5.03e-40	0.62	0.58	Colorectal cancer;	chr2:218322644	chr2:218255319~218257366:+
THCA	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	15.37	1.78e-43	5.19e-40	0.62	0.58	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
THCA	cis	rs80028505	0.908	rs56056710	ENSG00000271304.1	DPRXP2	15.36	1.85e-43	5.4e-40	1.01	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36068575	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs58237753	ENSG00000271304.1	DPRXP2	15.36	1.85e-43	5.4e-40	1.01	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36068578	chr6:35989515~35990436:-
THCA	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-15.36	1.86e-43	5.43e-40	-0.7	-0.58	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
THCA	cis	rs7569084	0.687	rs6755006	ENSG00000281920.1	RP11-418H16.1	-15.36	1.89e-43	5.51e-40	-0.73	-0.58	Sum eosinophil basophil counts;	chr2:65426008	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs6755128	ENSG00000281920.1	RP11-418H16.1	-15.36	1.89e-43	5.51e-40	-0.73	-0.58	Sum eosinophil basophil counts;	chr2:65426065	chr2:65623272~65628424:+
THCA	cis	rs1431005	0.892	rs72725289	ENSG00000250620.1	RP11-91J3.3	15.36	1.96e-43	5.71e-40	0.71	0.58	Response to statin therapy;	chr4:187477579	chr4:187413564~187415697:+
THCA	cis	rs992157	0.932	rs10194082	ENSG00000261338.2	RP11-378A13.1	15.36	1.96e-43	5.72e-40	0.62	0.58	Colorectal cancer;	chr2:218323854	chr2:218255319~218257366:+
THCA	cis	rs992157	0.932	rs1473901	ENSG00000261338.2	RP11-378A13.1	15.36	1.96e-43	5.72e-40	0.62	0.58	Colorectal cancer;	chr2:218324115	chr2:218255319~218257366:+
THCA	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	15.36	1.99e-43	5.79e-40	0.65	0.58	Height;	chr3:53073764	chr3:53064283~53065091:-
THCA	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-15.36	2e-43	5.82e-40	-0.76	-0.58	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
THCA	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-15.35	2.2e-43	6.4e-40	-0.73	-0.58	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
THCA	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	15.35	2.21e-43	6.43e-40	0.64	0.58	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
THCA	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-15.35	2.24e-43	6.51e-40	-0.46	-0.58	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
THCA	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-15.35	2.24e-43	6.51e-40	-0.46	-0.58	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
THCA	cis	rs80028505	0.908	rs56413204	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36037125	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs58390233	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36037323	chr6:35989515~35990436:-
THCA	cis	rs80028505	1	rs2237096	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36040225	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.808	rs61195139	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36078449	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs7748078	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36080233	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.71	rs80032177	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36081939	chr6:35989515~35990436:-
THCA	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-15.34	2.3e-43	6.68e-40	-0.7	-0.58	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
THCA	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	15.34	2.37e-43	6.9e-40	0.63	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
THCA	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	15.34	2.41e-43	7e-40	0.68	0.58	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
THCA	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	15.34	2.41e-43	7e-40	0.68	0.58	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
THCA	cis	rs1431005	0.892	rs72725288	ENSG00000250620.1	RP11-91J3.3	15.33	2.53e-43	7.33e-40	0.71	0.58	Response to statin therapy;	chr4:187477411	chr4:187413564~187415697:+
THCA	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	15.33	2.67e-43	7.73e-40	0.61	0.58	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	15.33	2.75e-43	7.97e-40	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
THCA	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	15.32	2.86e-43	8.29e-40	0.75	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
THCA	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-15.32	2.9e-43	8.42e-40	-0.57	-0.58	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
THCA	cis	rs80028505	0.908	rs7759175	ENSG00000271304.1	DPRXP2	15.32	2.93e-43	8.5e-40	0.97	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36045247	chr6:35989515~35990436:-
THCA	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	15.32	3.02e-43	8.76e-40	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	15.32	3.02e-43	8.76e-40	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
THCA	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	15.32	3.04e-43	8.79e-40	0.47	0.58	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
THCA	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-15.31	3.11e-43	8.99e-40	-0.57	-0.58	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
THCA	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	15.31	3.12e-43	9.02e-40	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-15.31	3.14e-43	9.08e-40	-0.76	-0.58	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
THCA	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-15.31	3.16e-43	9.15e-40	-0.57	-0.58	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
THCA	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-15.31	3.18e-43	9.19e-40	-0.84	-0.58	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
THCA	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	15.31	3.19e-43	9.23e-40	0.6	0.58	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-15.3	3.42e-43	9.9e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
THCA	cis	rs62388641	0.636	rs35412353	ENSG00000272279.1	RP11-157J24.2	15.3	3.51e-43	1.01e-39	0.99	0.58	Daytime sleep phenotypes;	chr6:1529209	chr6:1528364~1528911:-
THCA	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-15.3	3.52e-43	1.02e-39	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-15.3	3.52e-43	1.02e-39	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
THCA	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	15.3	3.73e-43	1.08e-39	0.75	0.58	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
THCA	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-15.3	3.73e-43	1.08e-39	-0.72	-0.58	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
THCA	cis	rs1431005	0.964	rs978629	ENSG00000250620.1	RP11-91J3.3	15.29	3.88e-43	1.12e-39	0.74	0.58	Response to statin therapy;	chr4:187426241	chr4:187413564~187415697:+
THCA	cis	rs7569084	0.663	rs10190233	ENSG00000281920.1	RP11-418H16.1	-15.29	4.08e-43	1.18e-39	-0.72	-0.58	Sum eosinophil basophil counts;	chr2:65413095	chr2:65623272~65628424:+
THCA	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-15.29	4.08e-43	1.18e-39	-0.58	-0.58	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-15.29	4.08e-43	1.18e-39	-0.58	-0.58	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
THCA	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-15.28	4.18e-43	1.21e-39	-0.73	-0.58	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
THCA	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	15.28	4.24e-43	1.22e-39	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
THCA	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-15.28	4.25e-43	1.23e-39	-0.73	-0.58	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-15.28	4.25e-43	1.23e-39	-0.73	-0.58	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-15.28	4.25e-43	1.23e-39	-0.73	-0.58	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	15.28	4.25e-43	1.23e-39	0.73	0.58	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
THCA	cis	rs80028505	0.808	rs73729685	ENSG00000271304.1	DPRXP2	15.28	4.28e-43	1.23e-39	0.97	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36043296	chr6:35989515~35990436:-
THCA	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-15.28	4.3e-43	1.24e-39	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-15.28	4.39e-43	1.26e-39	-0.76	-0.58	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
THCA	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-15.28	4.55e-43	1.31e-39	-0.47	-0.58	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-15.28	4.55e-43	1.31e-39	-0.47	-0.58	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
THCA	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-15.28	4.57e-43	1.32e-39	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-15.28	4.57e-43	1.32e-39	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-15.28	4.57e-43	1.32e-39	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
THCA	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	15.27	4.64e-43	1.34e-39	0.67	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
THCA	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	15.27	4.72e-43	1.36e-39	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	15.27	4.72e-43	1.36e-39	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
THCA	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	15.27	4.76e-43	1.37e-39	0.46	0.58	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
THCA	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	15.27	4.86e-43	1.4e-39	0.75	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
THCA	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	15.27	4.86e-43	1.4e-39	0.75	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
THCA	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	15.27	4.92e-43	1.41e-39	0.46	0.58	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	15.27	4.92e-43	1.41e-39	0.46	0.58	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
THCA	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-15.27	4.97e-43	1.43e-39	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
THCA	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	15.26	5.25e-43	1.51e-39	0.76	0.58	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
THCA	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-15.26	5.31e-43	1.53e-39	-0.46	-0.58	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
THCA	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	15.26	5.44e-43	1.56e-39	0.58	0.58	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	15.26	5.49e-43	1.58e-39	0.73	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
THCA	cis	rs1431005	0.963	rs6553064	ENSG00000250620.1	RP11-91J3.3	15.26	5.49e-43	1.58e-39	0.73	0.58	Response to statin therapy;	chr4:187423507	chr4:187413564~187415697:+
THCA	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-15.26	5.6e-43	1.61e-39	-0.78	-0.58	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
THCA	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	15.26	5.67e-43	1.63e-39	0.61	0.58	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
THCA	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-15.25	5.7e-43	1.64e-39	-0.64	-0.58	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
THCA	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-15.25	5.74e-43	1.65e-39	-0.7	-0.58	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-15.25	5.74e-43	1.65e-39	-0.7	-0.58	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
THCA	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	15.25	6.26e-43	1.79e-39	0.74	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
THCA	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	15.24	6.49e-43	1.86e-39	0.67	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
THCA	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-15.24	6.59e-43	1.89e-39	-0.73	-0.58	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
THCA	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-15.24	6.73e-43	1.92e-39	-0.47	-0.58	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
THCA	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-15.24	6.73e-43	1.92e-39	-0.47	-0.58	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-15.24	6.73e-43	1.92e-39	-0.47	-0.58	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
THCA	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-15.24	6.73e-43	1.92e-39	-0.47	-0.58	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	15.24	6.77e-43	1.94e-39	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
THCA	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-15.24	6.79e-43	1.94e-39	-0.69	-0.58	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-15.24	6.79e-43	1.94e-39	-0.69	-0.58	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-15.24	6.79e-43	1.94e-39	-0.69	-0.58	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
THCA	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-15.23	7.38e-43	2.11e-39	-0.47	-0.57	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-15.23	7.38e-43	2.11e-39	-0.47	-0.57	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
THCA	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-15.23	7.63e-43	2.18e-39	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
THCA	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-15.23	7.66e-43	2.19e-39	-0.61	-0.57	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
THCA	cis	rs1431005	0.963	rs72725286	ENSG00000250620.1	RP11-91J3.3	15.23	7.69e-43	2.2e-39	0.72	0.57	Response to statin therapy;	chr4:187475655	chr4:187413564~187415697:+
THCA	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	15.22	7.99e-43	2.28e-39	0.72	0.57	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	15.22	8.1e-43	2.31e-39	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
THCA	cis	rs17111396	0.95	rs12323621	ENSG00000259167.2	NMNAT1P1	15.22	8.2e-43	2.34e-39	0.75	0.57	Uric acid levels;	chr14:81034254	chr14:81032529~81033404:+
THCA	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	15.22	8.28e-43	2.36e-39	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
THCA	cis	rs62388641	0.636	rs62388638	ENSG00000272279.1	RP11-157J24.2	15.22	8.38e-43	2.39e-39	0.99	0.57	Daytime sleep phenotypes;	chr6:1529224	chr6:1528364~1528911:-
THCA	cis	rs17111396	1	rs2024422	ENSG00000259167.2	NMNAT1P1	15.21	9.24e-43	2.63e-39	0.77	0.57	Uric acid levels;	chr14:81050593	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs10131847	ENSG00000259167.2	NMNAT1P1	15.21	9.24e-43	2.63e-39	0.77	0.57	Uric acid levels;	chr14:81051134	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs72689928	ENSG00000259167.2	NMNAT1P1	15.21	9.24e-43	2.63e-39	0.77	0.57	Uric acid levels;	chr14:81051689	chr14:81032529~81033404:+
THCA	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-15.21	9.25e-43	2.63e-39	-0.86	-0.57	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
THCA	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	15.21	9.4e-43	2.68e-39	0.47	0.57	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
THCA	cis	rs80028505	0.908	rs7760578	ENSG00000271304.1	DPRXP2	15.2	9.58e-43	2.73e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36040286	chr6:35989515~35990436:-
THCA	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	15.2	9.61e-43	2.74e-39	0.58	0.57	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	15.2	9.69e-43	2.76e-39	0.73	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
THCA	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	15.2	9.69e-43	2.76e-39	0.81	0.57	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
THCA	cis	rs1431005	0.928	rs4623072	ENSG00000250620.1	RP11-91J3.3	15.2	9.92e-43	2.82e-39	0.73	0.57	Response to statin therapy;	chr4:187459164	chr4:187413564~187415697:+
THCA	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	15.2	9.96e-43	2.83e-39	0.61	0.57	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
THCA	cis	rs80028505	0.908	rs6910685	ENSG00000271304.1	DPRXP2	15.2	1.01e-42	2.88e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36080640	chr6:35989515~35990436:-
THCA	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	15.2	1.02e-42	2.89e-39	0.45	0.57	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
THCA	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-15.2	1.02e-42	2.9e-39	-0.71	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
THCA	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	15.2	1.03e-42	2.92e-39	0.71	0.57	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
THCA	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-15.2	1.04e-42	2.95e-39	-0.71	-0.57	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
THCA	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	15.2	1.04e-42	2.96e-39	0.73	0.57	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
THCA	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-15.2	1.04e-42	2.96e-39	-0.61	-0.57	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
THCA	cis	rs1431005	0.927	rs12651176	ENSG00000250620.1	RP11-91J3.3	15.19	1.05e-42	2.99e-39	0.73	0.57	Response to statin therapy;	chr4:187439724	chr4:187413564~187415697:+
THCA	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-15.19	1.07e-42	3.04e-39	-0.76	-0.57	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-15.19	1.07e-42	3.04e-39	-0.76	-0.57	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
THCA	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	15.19	1.09e-42	3.09e-39	0.68	0.57	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
THCA	cis	rs1431005	0.927	rs72725278	ENSG00000250620.1	RP11-91J3.3	15.19	1.11e-42	3.14e-39	0.72	0.57	Response to statin therapy;	chr4:187465625	chr4:187413564~187415697:+
THCA	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	15.19	1.14e-42	3.24e-39	0.79	0.57	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
THCA	cis	rs80028505	0.908	rs73730440	ENSG00000271304.1	DPRXP2	15.18	1.2e-42	3.38e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36069449	chr6:35989515~35990436:-
THCA	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	15.18	1.22e-42	3.45e-39	0.6	0.57	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
THCA	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-15.18	1.22e-42	3.46e-39	-0.7	-0.57	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
THCA	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-15.18	1.25e-42	3.54e-39	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
THCA	cis	rs80028505	0.908	rs56362075	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36073360	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs3730366	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36076448	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs76703794	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36083422	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs76171341	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36083423	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs73409842	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36083636	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs6908622	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36085370	chr6:35989515~35990436:-
THCA	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-15.17	1.33e-42	3.77e-39	-0.47	-0.57	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-15.17	1.34e-42	3.79e-39	-0.68	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
THCA	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	15.17	1.38e-42	3.88e-39	0.46	0.57	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
THCA	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	15.17	1.4e-42	3.94e-39	0.81	0.57	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
THCA	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	15.17	1.4e-42	3.94e-39	0.81	0.57	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
THCA	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-15.16	1.46e-42	4.11e-39	-0.47	-0.57	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
THCA	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-15.16	1.55e-42	4.36e-39	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
THCA	cis	rs17111396	1	rs4619328	ENSG00000259167.2	NMNAT1P1	15.16	1.55e-42	4.38e-39	0.77	0.57	Uric acid levels;	chr14:81053576	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs2024424	ENSG00000259167.2	NMNAT1P1	15.16	1.55e-42	4.38e-39	0.77	0.57	Uric acid levels;	chr14:81054035	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.951	rs28855991	ENSG00000259167.2	NMNAT1P1	15.16	1.55e-42	4.38e-39	0.77	0.57	Uric acid levels;	chr14:81054218	chr14:81032529~81033404:+
THCA	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-15.16	1.57e-42	4.42e-39	-0.72	-0.57	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	15.15	1.58e-42	4.45e-39	0.58	0.57	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
THCA	cis	rs1431005	1	rs72723291	ENSG00000250620.1	RP11-91J3.3	15.15	1.61e-42	4.53e-39	0.73	0.57	Response to statin therapy;	chr4:187425714	chr4:187413564~187415697:+
THCA	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	15.15	1.61e-42	4.53e-39	0.66	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
THCA	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	15.15	1.71e-42	4.81e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	15.15	1.71e-42	4.81e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	15.15	1.71e-42	4.81e-39	1.07	0.57	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-15.14	1.78e-42	4.99e-39	-0.57	-0.57	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
THCA	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-15.14	1.8e-42	5.06e-39	-0.71	-0.57	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
THCA	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-15.14	1.8e-42	5.06e-39	-0.71	-0.57	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
THCA	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	15.14	1.84e-42	5.16e-39	0.76	0.57	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	15.14	1.84e-42	5.16e-39	0.76	0.57	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
THCA	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	15.14	1.85e-42	5.2e-39	0.81	0.57	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
THCA	cis	rs992157	0.932	rs4672884	ENSG00000261338.2	RP11-378A13.1	-15.14	1.9e-42	5.33e-39	-0.61	-0.57	Colorectal cancer;	chr2:218317758	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-15.14	1.91e-42	5.35e-39	-0.54	-0.57	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
THCA	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	15.14	1.91e-42	5.37e-39	0.6	0.57	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
THCA	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-15.13	1.99e-42	5.57e-39	-0.69	-0.57	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
THCA	cis	rs1431005	1	rs12650667	ENSG00000250620.1	RP11-91J3.3	15.13	2.01e-42	5.63e-39	0.73	0.57	Response to statin therapy;	chr4:187424873	chr4:187413564~187415697:+
THCA	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-15.13	2.03e-42	5.69e-39	-0.69	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
THCA	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	15.13	2.08e-42	5.82e-39	0.46	0.57	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
THCA	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	15.13	2.09e-42	5.85e-39	0.6	0.57	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
THCA	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	15.13	2.14e-42	5.98e-39	0.96	0.57	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
THCA	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	15.12	2.15e-42	6.02e-39	0.68	0.57	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
THCA	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-15.12	2.26e-42	6.32e-39	-0.73	-0.57	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
THCA	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-15.12	2.32e-42	6.47e-39	-0.61	-0.57	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
THCA	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-15.12	2.36e-42	6.6e-39	-0.59	-0.57	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000235689.1	AP000351.13	15.11	2.41e-42	6.72e-39	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:24006305~24008258:-
THCA	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-15.11	2.41e-42	6.73e-39	-0.86	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
THCA	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	15.11	2.46e-42	6.86e-39	0.82	0.57	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
THCA	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	15.11	2.53e-42	7.06e-39	0.46	0.57	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
THCA	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	15.11	2.54e-42	7.1e-39	0.73	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
THCA	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	15.11	2.55e-42	7.12e-39	0.46	0.57	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
THCA	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	15.11	2.62e-42	7.31e-39	0.69	0.57	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
THCA	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-15.1	2.67e-42	7.44e-39	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	15.1	2.72e-42	7.6e-39	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
THCA	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	15.1	2.75e-42	7.65e-39	0.46	0.57	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
THCA	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	15.1	2.78e-42	7.76e-39	0.68	0.57	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	15.1	2.78e-42	7.76e-39	0.68	0.57	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
THCA	cis	rs80028505	1	rs16883989	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36043181	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs6930333	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36046811	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs6921999	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36052151	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.71	rs6934216	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36059856	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.731	rs61364424	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36064129	chr6:35989515~35990436:-
THCA	cis	rs2945232	1	rs2945232	ENSG00000253893.2	FAM85B	-15.1	2.79e-42	7.79e-39	-0.71	-0.57	Schizophrenia;	chr8:8240516	chr8:8167819~8226614:-
THCA	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	15.1	2.87e-42	7.98e-39	0.63	0.57	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	15.1	2.87e-42	7.98e-39	0.63	0.57	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	15.1	2.87e-42	7.98e-39	0.63	0.57	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	15.1	2.87e-42	7.98e-39	0.63	0.57	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
THCA	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	15.1	2.9e-42	8.08e-39	0.45	0.57	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
THCA	cis	rs80028505	0.908	rs56059109	ENSG00000271304.1	DPRXP2	15.09	2.93e-42	8.16e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36057530	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs73407870	ENSG00000271304.1	DPRXP2	15.09	2.93e-42	8.16e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36060470	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs73407871	ENSG00000271304.1	DPRXP2	15.09	2.93e-42	8.16e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36060866	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs60100837	ENSG00000271304.1	DPRXP2	15.09	2.93e-42	8.16e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36064311	chr6:35989515~35990436:-
THCA	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	15.09	3e-42	8.34e-39	0.68	0.57	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	15.09	3e-42	8.34e-39	0.68	0.57	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
THCA	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-15.09	3.03e-42	8.42e-39	-0.46	-0.57	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
THCA	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-15.09	3.03e-42	8.43e-39	-0.71	-0.57	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
THCA	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-15.09	3.04e-42	8.46e-39	-0.69	-0.57	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
THCA	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-15.09	3.16e-42	8.77e-39	-0.79	-0.57	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
THCA	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	15.08	3.28e-42	9.11e-39	0.46	0.57	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	15.08	3.28e-42	9.11e-39	0.46	0.57	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	15.08	3.28e-42	9.11e-39	0.46	0.57	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	15.08	3.28e-42	9.11e-39	0.46	0.57	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
THCA	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	15.08	3.36e-42	9.32e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	15.08	3.36e-42	9.32e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	15.08	3.36e-42	9.32e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
THCA	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	15.08	3.41e-42	9.45e-39	0.75	0.57	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
THCA	cis	rs992157	0.644	rs6741757	ENSG00000261338.2	RP11-378A13.1	15.08	3.47e-42	9.61e-39	0.61	0.57	Colorectal cancer;	chr2:218318025	chr2:218255319~218257366:+
THCA	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-15.08	3.48e-42	9.66e-39	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	15.07	3.6e-42	9.98e-39	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-15.07	3.61e-42	1e-38	-1.07	-0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
THCA	cis	rs80028505	1	rs61212706	ENSG00000271304.1	DPRXP2	15.07	3.75e-42	1.04e-38	0.94	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36071654	chr6:35989515~35990436:-
THCA	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-15.07	3.82e-42	1.06e-38	-0.74	-0.57	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
THCA	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-15.07	3.87e-42	1.07e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
THCA	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	15.07	3.95e-42	1.09e-38	0.64	0.57	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
THCA	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	15.06	4.23e-42	1.17e-38	0.55	0.57	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
THCA	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-15.06	4.24e-42	1.17e-38	-0.74	-0.57	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
THCA	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-15.06	4.26e-42	1.18e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
THCA	cis	rs1431005	1	rs60320548	ENSG00000250620.1	RP11-91J3.3	15.06	4.33e-42	1.2e-38	0.72	0.57	Response to statin therapy;	chr4:187436265	chr4:187413564~187415697:+
THCA	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	15.05	4.39e-42	1.21e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-15.05	4.43e-42	1.22e-38	-0.57	-0.57	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
THCA	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	15.05	4.45e-42	1.23e-38	0.78	0.57	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
THCA	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-15.05	4.49e-42	1.24e-38	-0.7	-0.57	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-15.05	4.49e-42	1.24e-38	-0.7	-0.57	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
THCA	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
THCA	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-15.05	4.82e-42	1.33e-38	-0.73	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
THCA	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-15.04	4.88e-42	1.34e-38	-0.73	-0.57	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
THCA	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-15.04	4.9e-42	1.35e-38	-0.56	-0.57	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
THCA	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-15.04	4.97e-42	1.37e-38	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-15.04	5.02e-42	1.38e-38	-0.74	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
THCA	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-15.04	5.18e-42	1.43e-38	-0.7	-0.57	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-15.04	5.18e-42	1.43e-38	-0.7	-0.57	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
THCA	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	15.04	5.36e-42	1.48e-38	0.57	0.57	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
THCA	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	15.04	5.37e-42	1.48e-38	0.91	0.57	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
THCA	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	15.03	5.43e-42	1.49e-38	0.6	0.57	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
THCA	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	15.03	5.64e-42	1.55e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
THCA	cis	rs1431005	0.964	rs59345911	ENSG00000250620.1	RP11-91J3.3	15.03	5.66e-42	1.56e-38	0.72	0.57	Response to statin therapy;	chr4:187436078	chr4:187413564~187415697:+
THCA	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-15.03	5.8e-42	1.6e-38	-0.69	-0.57	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
THCA	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-15.03	5.82e-42	1.6e-38	-0.65	-0.57	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	15.03	5.89e-42	1.62e-38	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
THCA	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	15.02	5.97e-42	1.64e-38	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
THCA	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	15.02	6.09e-42	1.67e-38	0.68	0.57	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
THCA	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-15.02	6.27e-42	1.72e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-15.02	6.27e-42	1.72e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-15.02	6.27e-42	1.72e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-15.02	6.27e-42	1.72e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
THCA	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
THCA	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-15.02	6.29e-42	1.73e-38	-0.74	-0.57	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
THCA	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	15.02	6.32e-42	1.73e-38	0.46	0.57	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
THCA	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	15.02	6.32e-42	1.73e-38	0.46	0.57	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	15.02	6.32e-42	1.73e-38	0.46	0.57	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000235689.1	AP000351.13	15.02	6.4e-42	1.75e-38	0.71	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:24006305~24008258:-
THCA	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-15.02	6.42e-42	1.76e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
THCA	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
THCA	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
THCA	cis	rs992157	0.764	rs3731861	ENSG00000261338.2	RP11-378A13.1	-15.01	6.81e-42	1.86e-38	-0.61	-0.57	Colorectal cancer;	chr2:218326533	chr2:218255319~218257366:+
THCA	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	15.01	6.84e-42	1.87e-38	0.64	0.57	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
THCA	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-15.01	6.93e-42	1.9e-38	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
THCA	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-15.01	6.94e-42	1.9e-38	-0.74	-0.57	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
THCA	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-15.01	6.95e-42	1.9e-38	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
THCA	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	15.01	7.01e-42	1.92e-38	1	0.57	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
THCA	cis	rs80028505	0.908	rs73407868	ENSG00000271304.1	DPRXP2	15.01	7.13e-42	1.95e-38	0.94	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36054534	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs3730327	ENSG00000271304.1	DPRXP2	15.01	7.13e-42	1.95e-38	0.94	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36059365	chr6:35989515~35990436:-
THCA	cis	rs80028505	1	rs73407876	ENSG00000271304.1	DPRXP2	15.01	7.13e-42	1.95e-38	0.94	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36066143	chr6:35989515~35990436:-
THCA	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-15.01	7.25e-42	1.98e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
THCA	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-15	7.33e-42	2e-38	-0.46	-0.57	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
THCA	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	15	7.34e-42	2e-38	0.68	0.57	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
THCA	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-15	7.49e-42	2.05e-38	-0.84	-0.57	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	15	7.61e-42	2.08e-38	0.73	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
THCA	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-15	7.81e-42	2.13e-38	-0.46	-0.57	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-15	7.86e-42	2.15e-38	-0.74	-0.57	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
THCA	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	15	7.88e-42	2.15e-38	0.69	0.57	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
THCA	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-15	8.04e-42	2.19e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
THCA	cis	rs1431005	0.964	rs112852905	ENSG00000250620.1	RP11-91J3.3	15	8.05e-42	2.2e-38	0.72	0.57	Response to statin therapy;	chr4:187427031	chr4:187413564~187415697:+
THCA	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	14.99	8.19e-42	2.23e-38	0.73	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
THCA	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	14.99	8.22e-42	2.24e-38	0.74	0.57	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
THCA	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-14.99	8.31e-42	2.26e-38	-0.68	-0.57	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
THCA	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	14.99	8.51e-42	2.32e-38	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
THCA	cis	rs80028505	0.908	rs73730437	ENSG00000271304.1	DPRXP2	14.99	8.6e-42	2.34e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36068735	chr6:35989515~35990436:-
THCA	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	14.99	8.61e-42	2.35e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	14.99	8.65e-42	2.35e-38	1.08	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
THCA	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-14.99	8.65e-42	2.35e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
THCA	cis	rs992157	0.764	rs1870124	ENSG00000261338.2	RP11-378A13.1	14.99	8.66e-42	2.36e-38	0.6	0.57	Colorectal cancer;	chr2:218323017	chr2:218255319~218257366:+
THCA	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-14.99	8.73e-42	2.38e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
THCA	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	14.99	8.94e-42	2.43e-38	0.78	0.57	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
THCA	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	14.98	8.95e-42	2.43e-38	0.95	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
THCA	cis	rs80028505	0.803	rs7745927	ENSG00000271304.1	DPRXP2	14.98	8.95e-42	2.43e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36037898	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs7745536	ENSG00000271304.1	DPRXP2	14.98	8.95e-42	2.43e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36037914	chr6:35989515~35990436:-
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	14.98	9.02e-42	2.45e-38	1.08	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	14.98	9.02e-42	2.45e-38	1.08	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
THCA	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	14.98	9.24e-42	2.51e-38	0.64	0.57	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	14.98	9.24e-42	2.51e-38	0.64	0.57	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
THCA	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-14.98	9.4e-42	2.55e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
THCA	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	14.98	9.41e-42	2.56e-38	0.66	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
THCA	cis	rs80028505	0.908	rs7775290	ENSG00000271304.1	DPRXP2	14.98	9.46e-42	2.57e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36069132	chr6:35989515~35990436:-
THCA	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	14.98	9.61e-42	2.61e-38	0.57	0.57	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
THCA	cis	rs7569084	0.663	rs6546150	ENSG00000281920.1	RP11-418H16.1	-14.98	9.76e-42	2.65e-38	-0.71	-0.57	Sum eosinophil basophil counts;	chr2:65415066	chr2:65623272~65628424:+
THCA	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-14.98	9.81e-42	2.67e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-14.98	9.81e-42	2.67e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
THCA	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-14.98	9.88e-42	2.68e-38	-0.57	-0.57	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
THCA	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-14.97	9.95e-42	2.7e-38	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
THCA	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	14.97	9.97e-42	2.71e-38	0.6	0.57	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
THCA	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	14.97	1e-41	2.72e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	14.97	1e-41	2.72e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
THCA	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-14.97	1e-41	2.73e-38	-0.61	-0.57	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
THCA	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	14.97	1.03e-41	2.79e-38	0.63	0.57	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
THCA	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-14.97	1.06e-41	2.86e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
THCA	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-14.97	1.07e-41	2.89e-38	-0.64	-0.57	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
THCA	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	14.97	1.07e-41	2.9e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	14.97	1.07e-41	2.9e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	14.97	1.07e-41	2.9e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	14.96	1.1e-41	2.98e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
THCA	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	14.96	1.12e-41	3.03e-38	0.54	0.57	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	14.96	1.13e-41	3.05e-38	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
THCA	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-14.96	1.15e-41	3.11e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-14.96	1.15e-41	3.11e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
THCA	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-14.96	1.2e-41	3.23e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-14.96	1.2e-41	3.23e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-14.96	1.2e-41	3.23e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
THCA	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	14.95	1.22e-41	3.28e-38	1.01	0.57	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	14.95	1.23e-41	3.31e-38	1.08	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
THCA	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-14.95	1.25e-41	3.36e-38	-0.72	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	14.95	1.26e-41	3.39e-38	0.66	0.57	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
THCA	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-14.95	1.27e-41	3.41e-38	-0.64	-0.57	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
THCA	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	14.95	1.31e-41	3.52e-38	0.68	0.57	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
THCA	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-14.95	1.31e-41	3.53e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-14.95	1.31e-41	3.53e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-14.95	1.31e-41	3.53e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
THCA	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-14.94	1.41e-41	3.8e-38	-0.97	-0.57	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
THCA	cis	rs1431005	1	rs72499925	ENSG00000250620.1	RP11-91J3.3	14.94	1.42e-41	3.81e-38	0.72	0.57	Response to statin therapy;	chr4:187432596	chr4:187413564~187415697:+
THCA	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-14.94	1.44e-41	3.88e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
THCA	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-14.94	1.46e-41	3.93e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-14.94	1.46e-41	3.93e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
THCA	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-14.93	1.53e-41	4.12e-38	-0.45	-0.57	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
THCA	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	14.93	1.57e-41	4.2e-38	1.07	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
THCA	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	14.93	1.57e-41	4.22e-38	0.54	0.57	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
THCA	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-14.93	1.59e-41	4.26e-38	-0.65	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
THCA	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	14.93	1.61e-41	4.31e-38	0.66	0.57	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
THCA	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-14.92	1.66e-41	4.43e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-14.92	1.66e-41	4.43e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-14.92	1.66e-41	4.43e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-14.92	1.66e-41	4.43e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
THCA	cis	rs17111396	1	rs17111396	ENSG00000259167.2	NMNAT1P1	14.92	1.71e-41	4.57e-38	0.76	0.57	Uric acid levels;	chr14:81057710	chr14:81032529~81033404:+
THCA	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-14.91	1.83e-41	4.88e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
THCA	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-14.91	1.87e-41	4.98e-38	-0.68	-0.57	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
THCA	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	14.91	1.87e-41	5e-38	0.72	0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
THCA	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-14.91	1.89e-41	5.03e-38	-0.68	-0.57	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
THCA	cis	rs992157	0.764	rs1870123	ENSG00000261338.2	RP11-378A13.1	14.91	1.9e-41	5.07e-38	0.6	0.57	Colorectal cancer;	chr2:218322975	chr2:218255319~218257366:+
THCA	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	14.91	1.9e-41	5.07e-38	0.55	0.57	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
THCA	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	14.91	1.93e-41	5.15e-38	0.62	0.57	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
THCA	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	14.91	1.94e-41	5.18e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
THCA	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	14.91	1.96e-41	5.21e-38	0.75	0.57	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
THCA	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	14.91	1.97e-41	5.24e-38	0.46	0.57	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-14.91	1.99e-41	5.3e-38	-1	-0.57	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
THCA	cis	rs80028505	0.908	rs60909394	ENSG00000271304.1	DPRXP2	14.91	1.99e-41	5.3e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36087155	chr6:35989515~35990436:-
THCA	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
THCA	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
THCA	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
THCA	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
THCA	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
THCA	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-14.9	2.02e-41	5.37e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-14.9	2.02e-41	5.37e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
THCA	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-14.9	2.06e-41	5.47e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-14.9	2.09e-41	5.55e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-14.9	2.09e-41	5.55e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
THCA	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	14.9	2.1e-41	5.57e-38	0.6	0.57	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
THCA	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	14.9	2.19e-41	5.81e-38	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
THCA	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-14.9	2.21e-41	5.85e-38	-0.64	-0.57	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
THCA	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	14.9	2.23e-41	5.9e-38	1.07	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
THCA	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	14.89	2.27e-41	6e-38	0.74	0.57	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
THCA	cis	rs7240205	0.816	rs7233016	ENSG00000275805.1	RP11-349H17.2	-14.89	2.32e-41	6.13e-38	-0.65	-0.57	Breast cancer;	chr18:26541387	chr18:26565723~26575626:-
THCA	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	14.89	2.36e-41	6.25e-38	0.75	0.57	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
THCA	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-14.89	2.45e-41	6.48e-38	-0.76	-0.57	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
THCA	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-14.89	2.46e-41	6.5e-38	-0.69	-0.57	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
THCA	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-14.89	2.47e-41	6.54e-38	-0.74	-0.57	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
THCA	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-14.88	2.5e-41	6.61e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
THCA	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	14.88	2.55e-41	6.74e-38	0.59	0.57	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-14.88	2.56e-41	6.77e-38	-0.53	-0.57	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-14.88	2.59e-41	6.85e-38	-0.72	-0.57	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
THCA	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-14.88	2.6e-41	6.86e-38	-0.59	-0.57	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
THCA	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-14.88	2.62e-41	6.91e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
THCA	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	14.88	2.62e-41	6.92e-38	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	14.88	2.62e-41	6.92e-38	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
THCA	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-14.88	2.66e-41	7.03e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-14.88	2.66e-41	7.03e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
THCA	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-14.88	2.71e-41	7.14e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-14.88	2.71e-41	7.14e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-14.88	2.71e-41	7.14e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
THCA	cis	rs7569084	0.687	rs963539	ENSG00000281920.1	RP11-418H16.1	-14.88	2.72e-41	7.18e-38	-0.71	-0.57	Sum eosinophil basophil counts;	chr2:65421413	chr2:65623272~65628424:+
THCA	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	14.88	2.73e-41	7.21e-38	0.85	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
THCA	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-14.87	2.81e-41	7.42e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
THCA	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-14.87	2.88e-41	7.59e-38	-0.46	-0.57	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
THCA	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	14.87	2.91e-41	7.67e-38	0.95	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
THCA	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	14.87	3.02e-41	7.94e-38	0.85	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
THCA	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	14.87	3.02e-41	7.94e-38	0.85	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
THCA	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-14.86	3.05e-41	8.03e-38	-0.73	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
THCA	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-14.86	3.07e-41	8.07e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
THCA	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	14.86	3.13e-41	8.24e-38	0.55	0.57	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
THCA	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	14.86	3.24e-41	8.53e-38	0.74	0.57	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
THCA	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-14.86	3.28e-41	8.62e-38	-0.54	-0.57	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
THCA	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-14.86	3.3e-41	8.67e-38	-0.69	-0.57	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
THCA	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	14.86	3.31e-41	8.69e-38	0.74	0.57	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
THCA	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	14.86	3.31e-41	8.69e-38	0.87	0.57	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	14.86	3.32e-41	8.72e-38	0.73	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
THCA	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	14.85	3.44e-41	9.01e-38	0.45	0.57	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
THCA	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	14.85	3.44e-41	9.02e-38	0.59	0.57	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
THCA	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	14.85	3.46e-41	9.06e-38	0.71	0.57	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	14.85	3.48e-41	9.11e-38	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
THCA	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-14.85	3.52e-41	9.21e-38	-0.59	-0.57	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
THCA	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-14.85	3.56e-41	9.32e-38	-0.67	-0.57	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-14.85	3.58e-41	9.38e-38	-0.67	-0.57	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
THCA	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	14.85	3.64e-41	9.52e-38	0.76	0.57	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
THCA	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-14.85	3.64e-41	9.53e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-14.85	3.64e-41	9.53e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
THCA	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-14.84	3.9e-41	1.02e-37	-0.67	-0.56	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
THCA	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-14.84	3.99e-41	1.04e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-14.84	3.99e-41	1.04e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-14.84	4.05e-41	1.06e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-14.84	4.05e-41	1.06e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-14.84	4.05e-41	1.06e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
THCA	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	14.83	4.21e-41	1.1e-37	0.67	0.56	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
THCA	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-14.83	4.29e-41	1.12e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
THCA	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-14.83	4.36e-41	1.14e-37	-0.68	-0.56	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
THCA	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-14.83	4.45e-41	1.16e-37	-0.71	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
THCA	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	14.83	4.46e-41	1.16e-37	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
THCA	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	14.83	4.52e-41	1.18e-37	0.59	0.56	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
THCA	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	14.82	4.58e-41	1.19e-37	0.54	0.56	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
THCA	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-14.82	4.61e-41	1.2e-37	-0.54	-0.56	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
THCA	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	14.82	4.81e-41	1.25e-37	0.46	0.56	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-14.82	4.87e-41	1.27e-37	-0.97	-0.56	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
THCA	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	14.81	5.07e-41	1.32e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
THCA	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-14.81	5.3e-41	1.38e-37	-0.67	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
THCA	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	14.81	5.54e-41	1.43e-37	0.96	0.56	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
THCA	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-14.81	5.55e-41	1.44e-37	-0.66	-0.56	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
THCA	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-14.8	5.59e-41	1.45e-37	-0.69	-0.56	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
THCA	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	14.8	5.65e-41	1.46e-37	0.45	0.56	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	14.8	5.65e-41	1.46e-37	0.45	0.56	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
THCA	cis	rs7188445	1	rs11646791	ENSG00000261390.4	RP11-345M22.2	-14.8	5.77e-41	1.49e-37	-0.67	-0.56	Urate levels;	chr16:79667641	chr16:79715232~79770563:-
THCA	cis	rs17111396	1	rs10150860	ENSG00000259167.2	NMNAT1P1	14.8	5.83e-41	1.51e-37	0.77	0.56	Uric acid levels;	chr14:81055208	chr14:81032529~81033404:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-14.8	6.12e-41	1.58e-37	-0.73	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
THCA	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	14.79	6.19e-41	1.6e-37	0.59	0.56	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
THCA	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	14.79	6.21e-41	1.61e-37	0.84	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
THCA	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-14.79	6.32e-41	1.63e-37	-0.54	-0.56	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
THCA	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	14.79	6.32e-41	1.63e-37	0.67	0.56	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
THCA	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	14.79	6.42e-41	1.66e-37	0.8	0.56	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
THCA	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	14.79	6.42e-41	1.66e-37	0.8	0.56	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
THCA	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-14.79	6.45e-41	1.67e-37	-0.45	-0.56	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-14.79	6.45e-41	1.67e-37	-0.45	-0.56	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
THCA	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-14.79	6.62e-41	1.71e-37	-0.65	-0.56	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-14.79	6.63e-41	1.71e-37	-0.72	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
THCA	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	14.79	6.78e-41	1.75e-37	0.55	0.56	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
THCA	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-14.78	6.87e-41	1.77e-37	-0.76	-0.56	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
THCA	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	14.78	6.94e-41	1.79e-37	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
THCA	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	14.78	7.22e-41	1.86e-37	0.46	0.56	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
THCA	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	14.78	7.22e-41	1.86e-37	0.46	0.56	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
THCA	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	14.78	7.31e-41	1.88e-37	0.54	0.56	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
THCA	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-14.78	7.45e-41	1.92e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
THCA	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	14.78	7.46e-41	1.92e-37	0.46	0.56	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
THCA	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-14.77	7.62e-41	1.96e-37	-0.63	-0.56	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
THCA	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	14.77	7.62e-41	1.96e-37	0.98	0.56	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
THCA	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
THCA	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	14.77	7.76e-41	2e-37	0.71	0.56	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
THCA	cis	rs80028505	0.908	rs56156688	ENSG00000271304.1	DPRXP2	14.77	7.93e-41	2.04e-37	0.95	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36027856	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs61763101	ENSG00000271304.1	DPRXP2	14.77	7.93e-41	2.04e-37	0.95	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36028636	chr6:35989515~35990436:-
THCA	cis	rs80028505	1	rs80028505	ENSG00000271304.1	DPRXP2	14.77	7.93e-41	2.04e-37	0.95	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36030611	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs6932598	ENSG00000271304.1	DPRXP2	14.77	7.93e-41	2.04e-37	0.95	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36031303	chr6:35989515~35990436:-
THCA	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-14.77	8.22e-41	2.11e-37	-0.72	-0.56	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
THCA	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
THCA	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	14.76	8.65e-41	2.22e-37	0.68	0.56	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
THCA	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	14.76	8.81e-41	2.26e-37	0.45	0.56	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
THCA	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	14.76	8.96e-41	2.3e-37	0.75	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
THCA	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	14.76	8.99e-41	2.31e-37	0.8	0.56	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
THCA	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-14.76	9.21e-41	2.36e-37	-0.95	-0.56	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
THCA	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-14.75	9.26e-41	2.37e-37	-0.64	-0.56	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
THCA	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	14.75	9.35e-41	2.4e-37	0.46	0.56	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
THCA	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	14.75	9.58e-41	2.45e-37	0.45	0.56	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-14.75	9.64e-41	2.47e-37	-0.52	-0.56	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	14.75	9.67e-41	2.48e-37	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
THCA	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-14.75	9.68e-41	2.48e-37	-0.64	-0.56	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-14.75	9.68e-41	2.48e-37	-0.64	-0.56	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-14.75	9.68e-41	2.48e-37	-0.64	-0.56	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
THCA	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	14.75	9.88e-41	2.53e-37	0.74	0.56	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
THCA	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-14.75	1.01e-40	2.58e-37	-0.72	-0.56	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-14.75	1.01e-40	2.58e-37	-0.72	-0.56	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	14.75	1.01e-40	2.59e-37	1.07	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	14.75	1.01e-40	2.59e-37	1.07	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	14.75	1.01e-40	2.59e-37	1.07	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
THCA	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-14.75	1.01e-40	2.59e-37	-0.73	-0.56	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
THCA	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	14.74	1.02e-40	2.62e-37	0.46	0.56	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
THCA	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	14.74	1.03e-40	2.62e-37	0.54	0.56	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
THCA	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	14.74	1.05e-40	2.67e-37	0.54	0.56	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
THCA	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	14.74	1.06e-40	2.71e-37	0.45	0.56	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
THCA	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-14.74	1.07e-40	2.74e-37	-0.55	-0.56	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
THCA	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
THCA	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-14.74	1.11e-40	2.83e-37	-0.68	-0.56	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
THCA	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-14.74	1.12e-40	2.85e-37	-0.54	-0.56	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
THCA	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-14.73	1.13e-40	2.89e-37	-0.66	-0.56	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
THCA	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-14.73	1.14e-40	2.89e-37	-0.67	-0.56	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
THCA	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	14.73	1.17e-40	2.97e-37	0.66	0.56	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	14.73	1.17e-40	2.97e-37	0.66	0.56	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000235689.1	AP000351.13	-14.73	1.17e-40	2.98e-37	-0.7	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:24006305~24008258:-
THCA	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	14.73	1.18e-40	3e-37	0.64	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
THCA	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-14.73	1.2e-40	3.05e-37	-0.64	-0.56	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-14.73	1.2e-40	3.05e-37	-0.64	-0.56	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
THCA	cis	rs80028505	0.908	rs56133220	ENSG00000271304.1	DPRXP2	14.73	1.21e-40	3.07e-37	0.94	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36064891	chr6:35989515~35990436:-
THCA	cis	rs1431005	1	rs56063429	ENSG00000250620.1	RP11-91J3.3	14.73	1.21e-40	3.07e-37	0.71	0.56	Response to statin therapy;	chr4:187450476	chr4:187413564~187415697:+
THCA	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-14.73	1.22e-40	3.09e-37	-0.6	-0.56	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
THCA	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-14.73	1.24e-40	3.14e-37	-0.6	-0.56	Breast cancer;	chr11:825777	chr11:779617~780755:+
THCA	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	14.73	1.25e-40	3.18e-37	0.62	0.56	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	14.72	1.26e-40	3.21e-37	0.62	0.56	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
THCA	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	14.72	1.26e-40	3.21e-37	0.45	0.56	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
THCA	cis	rs12429206	0.587	rs17589481	ENSG00000233672.5	RNASEH2B-AS1	-14.72	1.27e-40	3.21e-37	-0.85	-0.56	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50892028	chr13:50862172~50910764:-
THCA	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-14.72	1.28e-40	3.26e-37	-0.72	-0.56	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-14.72	1.32e-40	3.35e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
THCA	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-14.72	1.34e-40	3.38e-37	-0.73	-0.56	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
THCA	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-14.72	1.35e-40	3.41e-37	-0.66	-0.56	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
THCA	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	14.72	1.35e-40	3.42e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
THCA	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	14.72	1.37e-40	3.46e-37	0.6	0.56	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
THCA	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	14.72	1.37e-40	3.47e-37	0.65	0.56	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
THCA	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-14.72	1.38e-40	3.5e-37	-0.98	-0.56	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
THCA	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	14.72	1.38e-40	3.5e-37	0.59	0.56	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-14.71	1.39e-40	3.52e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
THCA	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	14.71	1.47e-40	3.72e-37	0.67	0.56	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
THCA	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	14.71	1.51e-40	3.81e-37	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
THCA	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-14.71	1.52e-40	3.82e-37	-0.7	-0.56	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
THCA	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-14.71	1.53e-40	3.85e-37	-0.63	-0.56	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
THCA	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	14.7	1.55e-40	3.92e-37	0.99	0.56	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
THCA	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-14.7	1.58e-40	3.99e-37	-0.64	-0.56	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
THCA	cis	rs17111396	0.951	rs12323890	ENSG00000259167.2	NMNAT1P1	14.7	1.59e-40	4e-37	0.78	0.56	Uric acid levels;	chr14:81037408	chr14:81032529~81033404:+
THCA	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-14.7	1.63e-40	4.1e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
THCA	cis	rs10793273	1	rs10793273	ENSG00000254675.1	RP11-7I15.4	-14.7	1.64e-40	4.14e-37	-0.61	-0.56	Pelvic organ prolapse;	chr11:78031549	chr11:78022933~78023721:+
THCA	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	14.7	1.66e-40	4.18e-37	0.71	0.56	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
THCA	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	14.69	1.74e-40	4.38e-37	0.61	0.56	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
THCA	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	14.69	1.8e-40	4.53e-37	0.45	0.56	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	14.69	1.8e-40	4.53e-37	0.45	0.56	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
THCA	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	14.69	1.82e-40	4.57e-37	0.65	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
THCA	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	14.69	1.83e-40	4.59e-37	0.63	0.56	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
THCA	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	14.68	1.9e-40	4.77e-37	0.54	0.56	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	14.68	1.9e-40	4.77e-37	0.53	0.56	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
THCA	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	14.68	1.91e-40	4.79e-37	0.6	0.56	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-14.68	1.94e-40	4.86e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	14.68	1.95e-40	4.89e-37	0.62	0.56	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
THCA	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-14.68	1.96e-40	4.93e-37	-0.67	-0.56	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
THCA	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-14.68	2e-40	5.01e-37	-0.65	-0.56	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
THCA	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	14.68	2e-40	5.02e-37	0.59	0.56	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
THCA	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-14.68	2.02e-40	5.07e-37	-0.59	-0.56	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
THCA	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	14.68	2.05e-40	5.13e-37	0.89	0.56	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
THCA	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-14.68	2.05e-40	5.14e-37	-0.64	-0.56	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-14.67	2.08e-40	5.22e-37	-0.63	-0.56	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
THCA	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-14.67	2.14e-40	5.37e-37	-0.67	-0.56	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
THCA	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	14.67	2.17e-40	5.42e-37	0.8	0.56	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
THCA	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-14.67	2.18e-40	5.46e-37	-0.67	-0.56	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-14.67	2.18e-40	5.46e-37	-0.67	-0.56	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
THCA	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	14.67	2.21e-40	5.53e-37	0.76	0.56	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
THCA	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-14.67	2.22e-40	5.55e-37	-0.59	-0.56	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
THCA	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-14.67	2.22e-40	5.55e-37	-0.59	-0.56	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
THCA	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-14.67	2.23e-40	5.58e-37	-0.65	-0.56	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
THCA	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	14.67	2.26e-40	5.66e-37	0.66	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
THCA	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-14.67	2.26e-40	5.67e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
THCA	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-14.67	2.28e-40	5.7e-37	-0.5	-0.56	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
THCA	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-14.67	2.28e-40	5.7e-37	-0.73	-0.56	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
THCA	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	14.66	2.3e-40	5.76e-37	0.65	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
THCA	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-14.66	2.34e-40	5.84e-37	-0.5	-0.56	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-14.66	2.34e-40	5.84e-37	-0.5	-0.56	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
THCA	cis	rs1431005	0.964	rs79181778	ENSG00000250620.1	RP11-91J3.3	14.66	2.44e-40	6.09e-37	0.71	0.56	Response to statin therapy;	chr4:187425756	chr4:187413564~187415697:+
THCA	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-14.66	2.51e-40	6.27e-37	-0.5	-0.56	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
THCA	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	14.65	2.55e-40	6.38e-37	0.78	0.56	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
THCA	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-14.65	2.59e-40	6.47e-37	-0.7	-0.56	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
THCA	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	14.65	2.62e-40	6.55e-37	0.64	0.56	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
THCA	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-14.65	2.63e-40	6.56e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
THCA	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
THCA	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-14.65	2.67e-40	6.66e-37	-0.63	-0.56	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-14.65	2.67e-40	6.66e-37	-0.63	-0.56	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-14.65	2.67e-40	6.66e-37	-0.63	-0.56	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
THCA	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	14.65	2.73e-40	6.81e-37	0.99	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
THCA	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-14.65	2.75e-40	6.85e-37	-0.73	-0.56	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
THCA	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-14.65	2.77e-40	6.91e-37	-0.67	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-14.65	2.77e-40	6.91e-37	-0.73	-0.56	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-14.65	2.81e-40	7.01e-37	-0.81	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
THCA	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	14.65	2.81e-40	7.01e-37	0.76	0.56	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
THCA	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-14.64	2.91e-40	7.24e-37	-0.59	-0.56	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
THCA	cis	rs1431005	0.963	rs58289169	ENSG00000250620.1	RP11-91J3.3	14.64	2.91e-40	7.25e-37	0.7	0.56	Response to statin therapy;	chr4:187476388	chr4:187413564~187415697:+
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	14.64	2.97e-40	7.39e-37	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	14.64	2.97e-40	7.39e-37	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
THCA	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	14.64	3.02e-40	7.5e-37	0.88	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
THCA	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-14.64	3.02e-40	7.51e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
THCA	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-14.64	3.08e-40	7.65e-37	-0.98	-0.56	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	14.63	3.12e-40	7.77e-37	0.66	0.56	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
THCA	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-14.63	3.18e-40	7.9e-37	-0.6	-0.56	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
THCA	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-14.63	3.2e-40	7.95e-37	-0.73	-0.56	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
THCA	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	14.63	3.23e-40	8.03e-37	0.76	0.56	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	14.63	3.28e-40	8.15e-37	0.74	0.56	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
THCA	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	14.63	3.3e-40	8.2e-37	0.55	0.56	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
THCA	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	14.62	3.47e-40	8.62e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	14.62	3.47e-40	8.62e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	14.62	3.55e-40	8.8e-37	0.97	0.56	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
THCA	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-14.62	3.55e-40	8.81e-37	-0.71	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
THCA	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	14.62	3.57e-40	8.85e-37	0.74	0.56	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
THCA	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-14.62	3.63e-40	9e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
THCA	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	14.62	3.69e-40	9.14e-37	0.74	0.56	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	14.62	3.7e-40	9.16e-37	0.72	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
THCA	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-14.62	3.75e-40	9.28e-37	-0.7	-0.56	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
THCA	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-14.61	3.87e-40	9.58e-37	-0.66	-0.56	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
THCA	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-14.61	3.91e-40	9.67e-37	-0.73	-0.56	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
THCA	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-14.61	4.03e-40	9.97e-37	-0.82	-0.56	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
THCA	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	14.61	4.1e-40	1.01e-36	0.67	0.56	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
THCA	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-14.61	4.22e-40	1.04e-36	-0.64	-0.56	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-14.61	4.22e-40	1.04e-36	-0.64	-0.56	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-14.61	4.22e-40	1.04e-36	-0.64	-0.56	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
THCA	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-14.6	4.23e-40	1.05e-36	-0.98	-0.56	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	14.6	4.31e-40	1.06e-36	0.76	0.56	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
THCA	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-14.6	4.5e-40	1.11e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-14.6	4.5e-40	1.11e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
THCA	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	14.6	4.59e-40	1.13e-36	0.86	0.56	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
THCA	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	14.59	4.67e-40	1.15e-36	0.65	0.56	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
THCA	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	14.59	4.74e-40	1.17e-36	0.86	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
THCA	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	14.59	4.75e-40	1.17e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
THCA	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	14.59	4.81e-40	1.19e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
THCA	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-14.59	4.92e-40	1.21e-36	-0.71	-0.56	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
THCA	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	14.59	4.95e-40	1.22e-36	0.88	0.56	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
THCA	cis	rs9660180	0.819	rs4648629	ENSG00000231050.1	RP1-140A9.1	-14.59	4.98e-40	1.23e-36	-0.7	-0.56	Body mass index;	chr1:1764023	chr1:1891471~1892658:+
THCA	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-14.59	5.09e-40	1.25e-36	-0.5	-0.56	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
THCA	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	14.59	5.1e-40	1.26e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
THCA	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	14.58	5.19e-40	1.28e-36	0.74	0.56	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
THCA	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	14.58	5.23e-40	1.29e-36	0.66	0.56	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
THCA	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-14.58	5.33e-40	1.31e-36	-0.74	-0.56	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
THCA	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	14.58	5.33e-40	1.31e-36	0.54	0.56	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
THCA	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	14.58	5.34e-40	1.31e-36	0.66	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
THCA	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	14.58	5.38e-40	1.32e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	14.58	5.38e-40	1.32e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	14.58	5.38e-40	1.32e-36	0.64	0.56	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	14.58	5.38e-40	1.32e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
THCA	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-14.58	5.44e-40	1.34e-36	-0.8	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
THCA	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	14.58	5.51e-40	1.35e-36	0.74	0.56	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
THCA	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	14.58	5.61e-40	1.38e-36	1.06	0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
THCA	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-14.57	5.89e-40	1.45e-36	-0.5	-0.56	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-14.57	5.89e-40	1.45e-36	-0.5	-0.56	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
THCA	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	14.57	5.95e-40	1.46e-36	0.65	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-14.57	6.01e-40	1.48e-36	-0.53	-0.56	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
THCA	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	14.57	6.11e-40	1.5e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	14.57	6.11e-40	1.5e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	14.57	6.11e-40	1.5e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
THCA	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	14.57	6.15e-40	1.51e-36	0.7	0.56	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
THCA	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-14.56	6.33e-40	1.55e-36	-0.99	-0.56	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-14.56	6.33e-40	1.55e-36	-0.99	-0.56	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
THCA	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-14.56	6.34e-40	1.55e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
THCA	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-14.56	6.38e-40	1.56e-36	-0.73	-0.56	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
THCA	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-14.56	6.43e-40	1.57e-36	-0.53	-0.56	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
THCA	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	14.56	6.51e-40	1.59e-36	0.82	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
THCA	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	14.56	6.55e-40	1.6e-36	0.76	0.56	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
THCA	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-14.56	6.59e-40	1.61e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-14.56	6.59e-40	1.61e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
THCA	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	14.56	6.8e-40	1.66e-36	0.59	0.56	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	14.56	6.8e-40	1.66e-36	0.59	0.56	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
THCA	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-14.56	6.81e-40	1.67e-36	-0.73	-0.56	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
THCA	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-14.56	6.93e-40	1.7e-36	-0.49	-0.56	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
THCA	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	14.56	6.96e-40	1.7e-36	0.65	0.56	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
THCA	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	14.55	7.07e-40	1.73e-36	0.65	0.56	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
THCA	cis	rs992157	0.764	rs2891077	ENSG00000261338.2	RP11-378A13.1	14.55	7.08e-40	1.73e-36	0.59	0.56	Colorectal cancer;	chr2:218319707	chr2:218255319~218257366:+
THCA	cis	rs992157	0.73	rs2891078	ENSG00000261338.2	RP11-378A13.1	14.55	7.08e-40	1.73e-36	0.59	0.56	Colorectal cancer;	chr2:218319709	chr2:218255319~218257366:+
THCA	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-14.55	7.1e-40	1.73e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
THCA	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	14.55	7.11e-40	1.74e-36	0.98	0.56	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
THCA	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	14.55	7.3e-40	1.78e-36	0.71	0.56	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
THCA	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	14.55	7.34e-40	1.79e-36	0.72	0.56	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	14.55	7.36e-40	1.8e-36	0.72	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
THCA	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	14.55	7.39e-40	1.8e-36	1.07	0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
THCA	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-14.55	7.51e-40	1.83e-36	-0.74	-0.56	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
THCA	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	14.55	7.54e-40	1.84e-36	0.66	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
THCA	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-14.55	7.6e-40	1.85e-36	-0.74	-0.56	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
THCA	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	14.55	7.67e-40	1.87e-36	0.71	0.56	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
THCA	cis	rs9660180	0.819	rs4648629	ENSG00000268575.1	RP1-283E3.8	14.54	7.85e-40	1.92e-36	0.59	0.56	Body mass index;	chr1:1764023	chr1:1702736~1737688:-
THCA	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-14.54	8.22e-40	2e-36	-0.59	-0.56	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
THCA	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	14.54	8.23e-40	2e-36	0.49	0.56	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
THCA	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-14.54	8.24e-40	2.01e-36	-0.7	-0.56	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
THCA	cis	rs6519955	0.866	rs9626920	ENSG00000231711.2	LINC00899	-14.54	8.3e-40	2.02e-36	-0.46	-0.56	Dupuytren's disease;	chr22:46033113	chr22:46039907~46044853:-
THCA	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-14.54	8.31e-40	2.02e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
THCA	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-14.53	8.85e-40	2.15e-36	-0.68	-0.56	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
THCA	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
THCA	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
THCA	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	14.52	9.47e-40	2.3e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
THCA	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-14.52	9.48e-40	2.3e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
THCA	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	14.52	9.53e-40	2.31e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
THCA	cis	rs7188445	0.898	rs11644758	ENSG00000261390.4	RP11-345M22.2	-14.52	9.53e-40	2.31e-36	-0.67	-0.56	Urate levels;	chr16:79675094	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-14.52	9.53e-40	2.31e-36	-0.67	-0.56	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-14.52	9.53e-40	2.31e-36	-0.67	-0.56	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-14.52	9.53e-40	2.31e-36	-0.67	-0.56	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
THCA	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	14.52	9.54e-40	2.32e-36	0.72	0.56	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
THCA	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-14.52	9.72e-40	2.36e-36	-0.82	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-14.52	1.03e-39	2.49e-36	-0.79	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
THCA	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-14.52	1.04e-39	2.51e-36	-0.81	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
THCA	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-14.51	1.05e-39	2.53e-36	-0.98	-0.56	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
THCA	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	14.51	1.05e-39	2.55e-36	0.71	0.56	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
THCA	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	14.51	1.06e-39	2.57e-36	0.77	0.56	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
THCA	cis	rs2581828	0.931	rs2336722	ENSG00000242142.1	SERBP1P3	14.51	1.07e-39	2.59e-36	0.62	0.56	Crohn's disease;	chr3:53105961	chr3:53064283~53065091:-
THCA	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	14.51	1.09e-39	2.63e-36	0.68	0.56	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
THCA	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-14.51	1.13e-39	2.74e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
THCA	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-14.5	1.19e-39	2.88e-36	-0.7	-0.56	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
THCA	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-14.5	1.2e-39	2.89e-36	-0.98	-0.56	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
THCA	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	14.5	1.2e-39	2.9e-36	0.68	0.56	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
THCA	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	14.5	1.21e-39	2.92e-36	0.7	0.56	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
THCA	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-14.5	1.21e-39	2.93e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
THCA	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	14.5	1.21e-39	2.93e-36	0.56	0.56	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
THCA	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-14.5	1.22e-39	2.93e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-14.5	1.22e-39	2.93e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
THCA	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-14.5	1.25e-39	3.02e-36	-0.89	-0.56	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
THCA	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	14.49	1.28e-39	3.09e-36	0.71	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
THCA	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	14.49	1.3e-39	3.12e-36	0.98	0.56	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
THCA	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-14.49	1.3e-39	3.13e-36	-0.7	-0.56	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-14.49	1.32e-39	3.18e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
THCA	cis	rs80028505	0.908	rs79062678	ENSG00000271304.1	DPRXP2	14.49	1.33e-39	3.2e-36	0.94	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36090426	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs7766032	ENSG00000271304.1	DPRXP2	14.49	1.33e-39	3.2e-36	0.94	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36101212	chr6:35989515~35990436:-
THCA	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	14.49	1.36e-39	3.27e-36	0.87	0.56	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
THCA	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-14.49	1.36e-39	3.28e-36	-0.73	-0.56	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
THCA	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	14.49	1.36e-39	3.29e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	14.49	1.37e-39	3.31e-36	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
THCA	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-14.49	1.41e-39	3.39e-36	-0.53	-0.56	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
THCA	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-14.49	1.41e-39	3.4e-36	-0.5	-0.56	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	14.48	1.43e-39	3.43e-36	0.74	0.56	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	14.48	1.47e-39	3.54e-36	0.63	0.56	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
THCA	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	14.48	1.49e-39	3.59e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
THCA	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-14.48	1.51e-39	3.62e-36	-0.65	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
THCA	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	14.48	1.56e-39	3.73e-36	0.67	0.56	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
THCA	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-14.47	1.58e-39	3.78e-36	-0.97	-0.56	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-14.47	1.58e-39	3.78e-36	-0.97	-0.56	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
THCA	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-14.47	1.58e-39	3.78e-36	-0.97	-0.56	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
THCA	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	14.47	1.58e-39	3.78e-36	0.97	0.56	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
THCA	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-14.47	1.59e-39	3.8e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
THCA	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-14.47	1.59e-39	3.8e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
THCA	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	14.47	1.6e-39	3.84e-36	0.61	0.56	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-14.47	1.62e-39	3.89e-36	-0.97	-0.56	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
THCA	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-14.47	1.68e-39	4.03e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
THCA	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-14.46	1.74e-39	4.15e-36	-0.89	-0.56	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
THCA	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-14.46	1.75e-39	4.19e-36	-0.5	-0.55	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
THCA	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	14.46	1.86e-39	4.45e-36	0.72	0.55	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	14.46	1.86e-39	4.45e-36	0.72	0.55	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
THCA	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	14.45	1.92e-39	4.59e-36	0.83	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
THCA	cis	rs1431005	1	rs55849435	ENSG00000250620.1	RP11-91J3.3	14.45	1.98e-39	4.72e-36	0.7	0.55	Response to statin therapy;	chr4:187455185	chr4:187413564~187415697:+
THCA	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-14.45	2.01e-39	4.78e-36	-0.68	-0.55	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
THCA	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-14.45	2.03e-39	4.85e-36	-0.68	-0.55	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
THCA	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	14.45	2.04e-39	4.87e-36	0.72	0.55	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
THCA	cis	rs2980439	0.729	rs2955585	ENSG00000253893.2	FAM85B	-14.45	2.05e-39	4.88e-36	-0.68	-0.55	Neuroticism;	chr8:8235989	chr8:8167819~8226614:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	14.45	2.05e-39	4.89e-36	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
THCA	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-14.45	2.1e-39	5e-36	-0.67	-0.55	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
THCA	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-14.44	2.17e-39	5.17e-36	-0.56	-0.55	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
THCA	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	14.44	2.18e-39	5.18e-36	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
THCA	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-14.44	2.19e-39	5.19e-36	-0.7	-0.55	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
THCA	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	14.44	2.19e-39	5.19e-36	0.87	0.55	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	14.44	2.19e-39	5.19e-36	0.87	0.55	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
THCA	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	14.44	2.23e-39	5.27e-36	0.96	0.55	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
THCA	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-14.44	2.23e-39	5.28e-36	-0.68	-0.55	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-14.44	2.25e-39	5.31e-36	-0.68	-0.55	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-14.44	2.25e-39	5.31e-36	-0.68	-0.55	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	14.44	2.3e-39	5.42e-36	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
THCA	cis	rs80028505	0.908	rs16883860	ENSG00000271304.1	DPRXP2	-14.43	2.41e-39	5.69e-36	-0.92	-0.55	Foot ulcer in diabetes and neuropathy;	chr6:36034685	chr6:35989515~35990436:-
THCA	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	14.43	2.55e-39	6.02e-36	0.72	0.55	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	14.42	2.7e-39	6.36e-36	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
THCA	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	14.42	2.7e-39	6.36e-36	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
THCA	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	14.42	2.73e-39	6.43e-36	0.75	0.55	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
THCA	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	14.42	2.75e-39	6.47e-36	0.54	0.55	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
THCA	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-14.42	2.76e-39	6.49e-36	-0.97	-0.55	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
THCA	cis	rs732716	0.785	rs7769	ENSG00000267769.1	CTB-50L17.9	-14.41	2.87e-39	6.75e-36	-0.74	-0.55	Mean corpuscular volume;	chr19:4360546	chr19:4454014~4455286:+
THCA	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	14.41	2.96e-39	6.97e-36	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
THCA	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-14.41	3.01e-39	7.08e-36	-0.7	-0.55	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
THCA	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-14.41	3.11e-39	7.31e-36	-0.68	-0.55	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
THCA	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-14.41	3.15e-39	7.4e-36	-0.57	-0.55	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
THCA	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	14.4	3.17e-39	7.45e-36	0.91	0.55	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
THCA	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-14.4	3.34e-39	7.85e-36	-0.96	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
THCA	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-14.4	3.37e-39	7.92e-36	-0.49	-0.55	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
THCA	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-14.39	3.5e-39	8.21e-36	-0.77	-0.55	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
THCA	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-14.39	3.61e-39	8.46e-36	-0.49	-0.55	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
THCA	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
THCA	cis	rs80028505	0.614	rs3761980	ENSG00000271304.1	DPRXP2	-14.39	3.78e-39	8.86e-36	-0.92	-0.55	Foot ulcer in diabetes and neuropathy;	chr6:36026129	chr6:35989515~35990436:-
THCA	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	14.39	3.8e-39	8.88e-36	0.72	0.55	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	14.39	3.8e-39	8.88e-36	0.72	0.55	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	14.39	3.8e-39	8.88e-36	0.72	0.55	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	14.39	3.8e-39	8.88e-36	0.72	0.55	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
THCA	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-14.39	3.81e-39	8.91e-36	-0.67	-0.55	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
THCA	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	14.39	3.81e-39	8.91e-36	0.67	0.55	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
THCA	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	14.39	3.81e-39	8.91e-36	0.67	0.55	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
THCA	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	14.39	3.81e-39	8.91e-36	0.67	0.55	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
THCA	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-14.38	3.87e-39	9.04e-36	-0.7	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
THCA	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-14.38	3.87e-39	9.05e-36	-0.73	-0.55	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-14.38	3.87e-39	9.05e-36	-0.73	-0.55	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-14.38	3.87e-39	9.05e-36	-0.73	-0.55	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-14.38	3.87e-39	9.05e-36	-0.73	-0.55	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
THCA	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	14.38	3.98e-39	9.31e-36	0.96	0.55	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
THCA	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	14.38	4.12e-39	9.63e-36	0.88	0.55	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
THCA	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	14.38	4.13e-39	9.64e-36	0.54	0.55	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
THCA	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-14.37	4.27e-39	9.98e-36	-0.67	-0.55	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
THCA	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-14.37	4.35e-39	1.02e-35	-0.64	-0.55	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
THCA	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-14.37	4.36e-39	1.02e-35	-0.72	-0.55	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
THCA	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	14.37	4.38e-39	1.02e-35	0.59	0.55	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
THCA	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-14.37	4.39e-39	1.03e-35	-0.68	-0.55	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
THCA	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-14.37	4.51e-39	1.05e-35	-1	-0.55	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
THCA	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	14.37	4.54e-39	1.06e-35	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
THCA	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	14.37	4.54e-39	1.06e-35	0.52	0.55	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
THCA	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
THCA	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-14.37	4.58e-39	1.07e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
THCA	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	14.37	4.58e-39	1.07e-35	0.67	0.55	Height;	chr11:118703185	chr11:118688039~118690600:-
THCA	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	14.37	4.58e-39	1.07e-35	0.67	0.55	Height;	chr11:118703207	chr11:118688039~118690600:-
THCA	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	14.37	4.6e-39	1.07e-35	0.45	0.55	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	14.37	4.6e-39	1.07e-35	0.45	0.55	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
THCA	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-14.37	4.61e-39	1.07e-35	-0.49	-0.55	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
THCA	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-14.37	4.64e-39	1.08e-35	-0.68	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
THCA	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	14.36	4.74e-39	1.1e-35	0.94	0.55	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
THCA	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-14.36	4.76e-39	1.11e-35	-0.58	-0.55	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
THCA	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	14.36	4.76e-39	1.11e-35	0.7	0.55	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
THCA	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-14.36	4.77e-39	1.11e-35	-0.67	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
THCA	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-14.36	4.84e-39	1.13e-35	-0.61	-0.55	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
THCA	cis	rs80028505	1	rs7770183	ENSG00000271304.1	DPRXP2	14.36	4.94e-39	1.15e-35	0.94	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36114796	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs56044978	ENSG00000271304.1	DPRXP2	14.36	4.94e-39	1.15e-35	0.94	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36115327	chr6:35989515~35990436:-
THCA	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	14.36	4.95e-39	1.15e-35	0.65	0.55	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
THCA	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	14.36	5.04e-39	1.17e-35	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
THCA	cis	rs80028505	0.908	rs16884628	ENSG00000271304.1	DPRXP2	14.36	5.12e-39	1.19e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36090191	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs16884660	ENSG00000271304.1	DPRXP2	14.36	5.12e-39	1.19e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36092434	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs7745082	ENSG00000271304.1	DPRXP2	14.36	5.12e-39	1.19e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36097845	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs16884906	ENSG00000271304.1	DPRXP2	14.36	5.12e-39	1.19e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36102922	chr6:35989515~35990436:-
THCA	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-14.35	5.35e-39	1.24e-35	-0.66	-0.55	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
THCA	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-14.35	5.38e-39	1.25e-35	-0.45	-0.55	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
THCA	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	14.35	5.38e-39	1.25e-35	0.7	0.55	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	14.35	5.42e-39	1.26e-35	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
THCA	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	14.35	5.52e-39	1.28e-35	0.75	0.55	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
THCA	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-14.35	5.52e-39	1.28e-35	-0.67	-0.55	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
THCA	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	14.35	5.52e-39	1.28e-35	1.05	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
THCA	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	14.35	5.58e-39	1.29e-35	0.73	0.55	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
THCA	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	14.35	5.58e-39	1.29e-35	0.65	0.55	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
THCA	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
THCA	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-14.34	5.89e-39	1.36e-35	-0.81	-0.55	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
THCA	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	14.34	5.9e-39	1.36e-35	0.65	0.55	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
THCA	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-14.34	6.17e-39	1.42e-35	-0.71	-0.55	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
THCA	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	14.33	6.43e-39	1.48e-35	0.64	0.55	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
THCA	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-14.33	6.49e-39	1.5e-35	-0.61	-0.55	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-14.33	6.49e-39	1.5e-35	-0.61	-0.55	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
THCA	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	14.33	6.51e-39	1.5e-35	1.04	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
THCA	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	14.33	6.62e-39	1.53e-35	1.04	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
THCA	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-14.33	6.71e-39	1.55e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
THCA	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-14.33	6.99e-39	1.61e-35	-0.54	-0.55	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
THCA	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-14.32	7.13e-39	1.64e-35	-0.61	-0.55	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-14.32	7.13e-39	1.64e-35	-0.61	-0.55	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-14.32	7.17e-39	1.65e-35	-0.53	-0.55	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
THCA	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	14.32	7.28e-39	1.68e-35	0.7	0.55	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
THCA	cis	rs2980439	0.729	rs2955586	ENSG00000253893.2	FAM85B	-14.32	7.33e-39	1.69e-35	-0.68	-0.55	Neuroticism;	chr8:8236445	chr8:8167819~8226614:-
THCA	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	14.32	7.34e-39	1.69e-35	1.04	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
THCA	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-14.31	7.82e-39	1.8e-35	-0.68	-0.55	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-14.31	7.86e-39	1.81e-35	-0.67	-0.55	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
THCA	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	14.31	7.91e-39	1.82e-35	0.55	0.55	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
THCA	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	14.31	8e-39	1.84e-35	0.44	0.55	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
THCA	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	14.31	8.2e-39	1.88e-35	0.72	0.55	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
THCA	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	14.31	8.36e-39	1.92e-35	0.44	0.55	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	14.31	8.36e-39	1.92e-35	0.44	0.55	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
THCA	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	14.31	8.45e-39	1.94e-35	0.61	0.55	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
THCA	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-14.31	8.49e-39	1.95e-35	-0.82	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
THCA	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-14.3	8.88e-39	2.03e-35	-0.7	-0.55	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
THCA	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	14.3	8.98e-39	2.05e-35	0.7	0.55	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	14.3	8.98e-39	2.05e-35	0.7	0.55	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	14.3	8.98e-39	2.05e-35	0.7	0.55	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	14.3	8.98e-39	2.05e-35	0.7	0.55	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
THCA	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	14.3	9.17e-39	2.1e-35	0.9	0.55	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
THCA	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	14.3	9.18e-39	2.1e-35	0.74	0.55	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
THCA	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	14.3	9.46e-39	2.16e-35	0.71	0.55	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
THCA	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-14.3	9.47e-39	2.16e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	14.29	9.58e-39	2.19e-35	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
THCA	cis	rs1431005	0.963	rs72725287	ENSG00000250620.1	RP11-91J3.3	14.29	9.8e-39	2.24e-35	0.67	0.55	Response to statin therapy;	chr4:187477151	chr4:187413564~187415697:+
THCA	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-14.29	9.84e-39	2.25e-35	-0.52	-0.55	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
THCA	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-14.29	9.88e-39	2.25e-35	-0.61	-0.55	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
THCA	cis	rs80028505	0.908	rs73729698	ENSG00000271304.1	DPRXP2	14.29	1e-38	2.28e-35	0.97	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36054864	chr6:35989515~35990436:-
THCA	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-14.29	1.01e-38	2.31e-35	-0.7	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
THCA	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-14.28	1.06e-38	2.42e-35	-0.67	-0.55	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
THCA	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	14.28	1.07e-38	2.45e-35	0.72	0.55	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	14.28	1.08e-38	2.47e-35	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
THCA	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	14.28	1.11e-38	2.54e-35	0.7	0.55	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
THCA	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	14.28	1.12e-38	2.55e-35	0.6	0.55	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
THCA	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	14.28	1.14e-38	2.6e-35	0.63	0.55	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
THCA	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-14.28	1.15e-38	2.61e-35	-0.67	-0.55	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
THCA	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-14.27	1.17e-38	2.65e-35	-0.49	-0.55	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
THCA	cis	rs80028505	0.908	rs58583792	ENSG00000271304.1	DPRXP2	14.27	1.21e-38	2.76e-35	0.9	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36032925	chr6:35989515~35990436:-
THCA	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-14.27	1.22e-38	2.78e-35	-0.7	-0.55	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
THCA	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	14.27	1.23e-38	2.79e-35	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	14.27	1.23e-38	2.79e-35	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	14.27	1.23e-38	2.79e-35	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
THCA	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	14.26	1.31e-38	2.96e-35	0.76	0.55	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
THCA	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	14.26	1.32e-38	3e-35	0.45	0.55	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
THCA	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	14.26	1.35e-38	3.06e-35	0.77	0.55	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
THCA	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	14.26	1.41e-38	3.19e-35	0.44	0.55	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
THCA	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-14.26	1.42e-38	3.21e-35	-0.58	-0.55	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
THCA	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	14.25	1.44e-38	3.25e-35	0.67	0.55	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-14.25	1.45e-38	3.28e-35	-0.69	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
THCA	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	14.25	1.45e-38	3.29e-35	0.64	0.55	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
THCA	cis	rs80028505	0.908	rs16883819	ENSG00000271304.1	DPRXP2	14.25	1.45e-38	3.29e-35	0.89	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36029991	chr6:35989515~35990436:-
THCA	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	14.25	1.5e-38	3.4e-35	0.44	0.55	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
THCA	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-14.25	1.51e-38	3.42e-35	-0.92	-0.55	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
THCA	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	14.25	1.51e-38	3.42e-35	0.96	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
THCA	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	14.25	1.52e-38	3.44e-35	0.71	0.55	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
THCA	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	14.25	1.56e-38	3.52e-35	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
THCA	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	14.25	1.56e-38	3.53e-35	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
THCA	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-14.25	1.56e-38	3.53e-35	-0.73	-0.55	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
THCA	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	14.24	1.62e-38	3.66e-35	0.79	0.55	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
THCA	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	14.24	1.66e-38	3.74e-35	0.73	0.55	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
THCA	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-14.24	1.72e-38	3.87e-35	-0.44	-0.55	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
THCA	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	14.23	1.75e-38	3.93e-35	0.75	0.55	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
THCA	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-14.23	1.75e-38	3.95e-35	-0.7	-0.55	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
THCA	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	14.23	1.88e-38	4.24e-35	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
THCA	cis	rs80028505	0.908	rs16884919	ENSG00000271304.1	DPRXP2	-14.23	1.89e-38	4.26e-35	-0.92	-0.55	Foot ulcer in diabetes and neuropathy;	chr6:36103740	chr6:35989515~35990436:-
THCA	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-14.23	1.9e-38	4.28e-35	-0.6	-0.55	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-14.23	1.9e-38	4.28e-35	-0.6	-0.55	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
THCA	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-14.22	1.94e-38	4.36e-35	-0.96	-0.55	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
THCA	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	14.22	1.96e-38	4.42e-35	0.62	0.55	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
THCA	cis	rs80028505	0.908	rs3804451	ENSG00000271304.1	DPRXP2	14.22	1.99e-38	4.48e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36110184	chr6:35989515~35990436:-
THCA	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	14.22	2.05e-38	4.61e-35	0.52	0.55	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
THCA	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-14.22	2.08e-38	4.67e-35	-0.43	-0.55	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
THCA	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	14.22	2.11e-38	4.75e-35	0.72	0.55	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
THCA	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	14.21	2.15e-38	4.82e-35	1.02	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
THCA	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	14.21	2.15e-38	4.83e-35	0.63	0.55	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
THCA	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-14.2	2.35e-38	5.26e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
THCA	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	14.2	2.4e-38	5.38e-35	0.7	0.55	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
THCA	cis	rs2980439	0.558	rs2955584	ENSG00000253893.2	FAM85B	-14.2	2.42e-38	5.42e-35	-0.68	-0.55	Neuroticism;	chr8:8234652	chr8:8167819~8226614:-
THCA	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	14.2	2.48e-38	5.54e-35	0.6	0.55	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
THCA	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	14.2	2.49e-38	5.56e-35	0.75	0.55	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
THCA	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	14.2	2.5e-38	5.59e-35	0.64	0.55	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
THCA	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	14.2	2.52e-38	5.64e-35	0.58	0.55	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
THCA	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-14.19	2.81e-38	6.26e-35	-0.95	-0.55	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
THCA	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-14.19	2.81e-38	6.27e-35	-0.6	-0.55	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
THCA	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-14.19	2.82e-38	6.3e-35	-0.7	-0.55	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
THCA	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	14.19	2.83e-38	6.3e-35	0.7	0.55	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
THCA	cis	rs80028505	0.908	rs6457878	ENSG00000271304.1	DPRXP2	14.19	2.84e-38	6.32e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36108503	chr6:35989515~35990436:-
THCA	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	14.18	2.96e-38	6.59e-35	0.76	0.55	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
THCA	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	14.18	2.97e-38	6.62e-35	0.73	0.55	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	14.18	2.97e-38	6.62e-35	0.73	0.55	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
THCA	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-14.18	3.06e-38	6.8e-35	-0.58	-0.55	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
THCA	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	14.17	3.16e-38	7.03e-35	0.44	0.55	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
THCA	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	14.17	3.23e-38	7.18e-35	0.7	0.55	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	14.17	3.23e-38	7.18e-35	0.7	0.55	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
THCA	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-14.17	3.35e-38	7.44e-35	-0.58	-0.55	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
THCA	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-14.17	3.41e-38	7.56e-35	-0.71	-0.55	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
THCA	cis	rs2980439	0.783	rs2948305	ENSG00000253893.2	FAM85B	-14.16	3.53e-38	7.83e-35	-0.69	-0.55	Neuroticism;	chr8:8241055	chr8:8167819~8226614:-
THCA	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-14.16	3.58e-38	7.95e-35	-0.58	-0.55	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
THCA	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-14.16	3.59e-38	7.96e-35	-0.93	-0.55	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-14.16	3.71e-38	8.23e-35	-0.93	-0.55	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-14.16	3.71e-38	8.23e-35	-0.93	-0.55	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
THCA	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-14.16	3.76e-38	8.32e-35	-0.78	-0.55	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
THCA	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-14.16	3.79e-38	8.4e-35	-0.64	-0.55	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
THCA	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-14.16	3.81e-38	8.43e-35	-0.69	-0.55	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
THCA	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-14.16	3.84e-38	8.51e-35	-0.45	-0.55	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
THCA	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-14.15	3.85e-38	8.53e-35	-0.95	-0.55	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
THCA	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	14.15	3.86e-38	8.54e-35	0.6	0.55	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-14.15	3.88e-38	8.58e-35	-0.52	-0.55	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	14.15	3.92e-38	8.68e-35	0.69	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
THCA	cis	rs12220777	1	rs72644212	ENSG00000230091.5	TMEM254-AS1	14.15	4.03e-38	8.91e-35	1.04	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80022758	chr10:80046860~80078912:-
THCA	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	14.15	4.17e-38	9.21e-35	0.7	0.55	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
THCA	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	14.15	4.22e-38	9.33e-35	0.58	0.55	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
THCA	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-14.14	4.28e-38	9.46e-35	-0.71	-0.55	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
THCA	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	14.14	4.32e-38	9.54e-35	0.6	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
THCA	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-14.14	4.6e-38	1.01e-34	-0.69	-0.55	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
THCA	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-14.14	4.66e-38	1.03e-34	-0.58	-0.55	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
THCA	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-14.13	4.78e-38	1.05e-34	-0.72	-0.55	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
THCA	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	14.13	4.79e-38	1.06e-34	0.54	0.55	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
THCA	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-14.13	4.85e-38	1.07e-34	-0.67	-0.55	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
THCA	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
THCA	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-14.13	5.03e-38	1.11e-34	-0.6	-0.55	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
THCA	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	14.13	5.04e-38	1.11e-34	0.52	0.55	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
THCA	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	14.13	5.05e-38	1.11e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
THCA	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-14.13	5.19e-38	1.14e-34	-0.93	-0.55	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
THCA	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	14.12	5.27e-38	1.16e-34	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	14.12	5.27e-38	1.16e-34	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
THCA	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	14.12	5.45e-38	1.2e-34	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
THCA	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-14.12	5.47e-38	1.2e-34	-0.67	-0.55	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
THCA	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	14.12	5.48e-38	1.2e-34	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
THCA	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-14.12	5.57e-38	1.22e-34	-0.9	-0.55	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
THCA	cis	rs12220777	1	rs11201297	ENSG00000230091.5	TMEM254-AS1	14.11	5.76e-38	1.26e-34	1.01	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033993	chr10:80046860~80078912:-
THCA	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	14.11	5.76e-38	1.26e-34	0.7	0.55	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
THCA	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
THCA	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-14.11	5.9e-38	1.29e-34	-0.7	-0.55	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
THCA	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-14.11	5.93e-38	1.3e-34	-0.67	-0.55	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
THCA	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-14.11	6.03e-38	1.32e-34	-0.69	-0.55	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
THCA	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	14.11	6.09e-38	1.34e-34	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
THCA	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	14.11	6.12e-38	1.34e-34	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
THCA	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	14.11	6.24e-38	1.37e-34	0.44	0.55	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
THCA	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-14.11	6.33e-38	1.39e-34	-0.71	-0.55	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
THCA	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-14.1	6.38e-38	1.4e-34	-0.7	-0.55	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
THCA	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-14.1	6.54e-38	1.43e-34	-0.93	-0.55	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-14.1	6.54e-38	1.43e-34	-0.93	-0.55	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
THCA	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
THCA	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
THCA	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-14.09	7.21e-38	1.58e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-14.09	7.21e-38	1.58e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
THCA	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-14.09	7.48e-38	1.63e-34	-0.7	-0.54	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
THCA	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	14.09	7.52e-38	1.64e-34	0.51	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
THCA	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-14.09	7.61e-38	1.66e-34	-0.71	-0.54	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-14.09	7.61e-38	1.66e-34	-0.71	-0.54	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-14.09	7.61e-38	1.66e-34	-0.71	-0.54	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
THCA	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-14.08	7.75e-38	1.69e-34	-0.64	-0.54	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
THCA	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-14.08	7.81e-38	1.7e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	14.08	8e-38	1.74e-34	0.59	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
THCA	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	14.08	8.21e-38	1.78e-34	0.44	0.54	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	14.08	8.24e-38	1.79e-34	0.44	0.54	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
THCA	cis	rs9890032	0.57	rs8068504	ENSG00000266490.1	CTD-2349P21.9	14.08	8.52e-38	1.85e-34	0.54	0.54	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30792372~30792833:+
THCA	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	14.07	8.79e-38	1.91e-34	0.82	0.54	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
THCA	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-14.07	8.82e-38	1.91e-34	-0.66	-0.54	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-14.07	8.82e-38	1.91e-34	-0.66	-0.54	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
THCA	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	14.07	9.04e-38	1.96e-34	0.73	0.54	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
THCA	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-14.07	9.15e-38	1.99e-34	-0.69	-0.54	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
THCA	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	14.07	9.25e-38	2.01e-34	0.7	0.54	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
THCA	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	14.06	9.56e-38	2.07e-34	0.64	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	14.06	9.56e-38	2.07e-34	0.64	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
THCA	cis	rs1431005	0.858	rs77580406	ENSG00000250620.1	RP11-91J3.3	14.06	9.83e-38	2.13e-34	0.69	0.54	Response to statin therapy;	chr4:187493654	chr4:187413564~187415697:+
THCA	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-14.06	1.01e-37	2.18e-34	-0.48	-0.54	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
THCA	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	14.06	1.01e-37	2.18e-34	0.95	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
THCA	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-14.06	1.01e-37	2.2e-34	-0.66	-0.54	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
THCA	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
THCA	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-14.06	1.03e-37	2.22e-34	-0.71	-0.54	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
THCA	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	14.06	1.03e-37	2.23e-34	0.57	0.54	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
THCA	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	14.05	1.05e-37	2.28e-34	0.61	0.54	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
THCA	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-14.05	1.06e-37	2.29e-34	-0.6	-0.54	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
THCA	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-14.05	1.07e-37	2.31e-34	-0.66	-0.54	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-14.05	1.07e-37	2.31e-34	-0.66	-0.54	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-14.05	1.07e-37	2.31e-34	-0.66	-0.54	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
THCA	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-14.05	1.07e-37	2.31e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-14.05	1.07e-37	2.31e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
THCA	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-14.05	1.07e-37	2.31e-34	-0.69	-0.54	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
THCA	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	14.05	1.08e-37	2.33e-34	0.7	0.54	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
THCA	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	14.05	1.09e-37	2.34e-34	0.78	0.54	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
THCA	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	14.05	1.09e-37	2.35e-34	0.69	0.54	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
THCA	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-14.05	1.12e-37	2.41e-34	-0.66	-0.54	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
THCA	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	14.05	1.13e-37	2.43e-34	0.81	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
THCA	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-14.05	1.13e-37	2.44e-34	-0.66	-0.54	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-14.05	1.13e-37	2.44e-34	-0.66	-0.54	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-14.05	1.13e-37	2.44e-34	-0.66	-0.54	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
THCA	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	14.04	1.18e-37	2.55e-34	0.73	0.54	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
THCA	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-14.04	1.19e-37	2.56e-34	-0.57	-0.54	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
THCA	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-14.04	1.21e-37	2.61e-34	-0.74	-0.54	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
THCA	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-14.02	1.42e-37	3.05e-34	-0.64	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
THCA	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	14.02	1.43e-37	3.07e-34	0.44	0.54	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	14.02	1.43e-37	3.08e-34	0.44	0.54	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
THCA	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-14.02	1.44e-37	3.1e-34	-0.52	-0.54	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-14.02	1.44e-37	3.1e-34	-0.52	-0.54	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-14.02	1.53e-37	3.28e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
THCA	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	14.01	1.57e-37	3.36e-34	0.86	0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
THCA	cis	rs9890032	0.618	rs1979507	ENSG00000266490.1	CTD-2349P21.9	14.01	1.59e-37	3.4e-34	0.54	0.54	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30792372~30792833:+
THCA	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-14.01	1.61e-37	3.45e-34	-0.57	-0.54	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
THCA	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	14.01	1.63e-37	3.49e-34	0.83	0.54	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
THCA	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	14.01	1.66e-37	3.54e-34	0.7	0.54	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
THCA	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-14	1.82e-37	3.89e-34	-0.57	-0.54	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
THCA	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-14	1.89e-37	4.04e-34	-0.57	-0.54	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
THCA	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	13.99	1.92e-37	4.1e-34	0.62	0.54	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
THCA	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-13.99	1.93e-37	4.11e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-13.99	1.93e-37	4.11e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
THCA	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-13.99	1.98e-37	4.22e-34	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-13.99	1.98e-37	4.22e-34	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-13.99	2.04e-37	4.35e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
THCA	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	13.99	2.07e-37	4.41e-34	0.75	0.54	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
THCA	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-13.98	2.12e-37	4.51e-34	-0.96	-0.54	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-13.98	2.12e-37	4.51e-34	-0.96	-0.54	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-13.98	2.12e-37	4.51e-34	-0.96	-0.54	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-13.98	2.12e-37	4.51e-34	-0.96	-0.54	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
THCA	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-13.98	2.14e-37	4.56e-34	-0.72	-0.54	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
THCA	cis	rs80028505	0.808	rs41271263	ENSG00000271304.1	DPRXP2	13.98	2.16e-37	4.59e-34	0.94	0.54	Foot ulcer in diabetes and neuropathy;	chr6:36052382	chr6:35989515~35990436:-
THCA	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-13.98	2.22e-37	4.73e-34	-1.01	-0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
THCA	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	13.98	2.25e-37	4.78e-34	0.71	0.54	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
THCA	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-13.98	2.3e-37	4.89e-34	-0.8	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
THCA	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-13.97	2.37e-37	5.03e-34	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-13.97	2.37e-37	5.03e-34	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
THCA	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-13.97	2.43e-37	5.15e-34	-0.71	-0.54	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
THCA	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-13.97	2.46e-37	5.22e-34	-0.55	-0.54	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
THCA	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	13.97	2.49e-37	5.28e-34	0.7	0.54	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
THCA	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	13.97	2.5e-37	5.31e-34	0.71	0.54	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
THCA	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-13.97	2.54e-37	5.39e-34	-0.7	-0.54	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
THCA	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	13.96	2.57e-37	5.44e-34	0.82	0.54	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
THCA	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	13.96	2.59e-37	5.48e-34	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
THCA	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	13.96	2.67e-37	5.65e-34	0.67	0.54	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
THCA	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	13.96	2.68e-37	5.68e-34	0.81	0.54	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
THCA	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	13.96	2.76e-37	5.83e-34	0.63	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
THCA	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-13.95	2.83e-37	5.98e-34	-0.78	-0.54	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
THCA	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-13.95	2.85e-37	6.03e-34	-0.67	-0.54	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
THCA	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-13.95	2.9e-37	6.11e-34	-0.44	-0.54	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
THCA	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	13.95	2.99e-37	6.32e-34	0.78	0.54	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
THCA	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	13.95	2.99e-37	6.32e-34	0.78	0.54	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
THCA	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	13.95	3.04e-37	6.41e-34	0.63	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
THCA	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-13.95	3.05e-37	6.43e-34	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
THCA	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-13.95	3.05e-37	6.44e-34	-0.8	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
THCA	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	13.95	3.08e-37	6.5e-34	0.81	0.54	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
THCA	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-13.94	3.12e-37	6.58e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-13.94	3.12e-37	6.58e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
THCA	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-13.94	3.16e-37	6.66e-34	-0.92	-0.54	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
THCA	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	13.94	3.19e-37	6.73e-34	0.68	0.54	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
THCA	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	13.94	3.41e-37	7.18e-34	1.03	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
THCA	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	13.94	3.42e-37	7.19e-34	0.64	0.54	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
THCA	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-13.94	3.42e-37	7.19e-34	-0.86	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
THCA	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	13.93	3.48e-37	7.33e-34	0.52	0.54	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	13.93	3.48e-37	7.33e-34	0.52	0.54	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
THCA	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-13.93	3.5e-37	7.36e-34	-0.69	-0.54	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
THCA	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-13.93	3.6e-37	7.56e-34	-0.92	-0.54	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
THCA	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-13.93	3.7e-37	7.77e-34	-0.54	-0.54	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-13.93	3.7e-37	7.77e-34	-0.54	-0.54	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-13.93	3.7e-37	7.77e-34	-0.54	-0.54	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-13.93	3.7e-37	7.77e-34	-0.54	-0.54	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
THCA	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-13.92	3.86e-37	8.1e-34	-0.69	-0.54	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
THCA	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-13.92	3.89e-37	8.15e-34	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
THCA	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	13.92	3.96e-37	8.3e-34	0.6	0.54	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
THCA	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-13.92	4.08e-37	8.55e-34	-0.64	-0.54	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
THCA	cis	rs62158211	0.955	rs1823125	ENSG00000234997.1	AC016745.3	13.92	4.16e-37	8.7e-34	0.63	0.54	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113424495~113425324:+
THCA	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	13.92	4.17e-37	8.74e-34	0.63	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
THCA	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-13.91	4.2e-37	8.8e-34	-0.93	-0.54	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	13.91	4.3e-37	8.99e-34	0.7	0.54	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
THCA	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	13.91	4.34e-37	9.07e-34	0.9	0.54	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
THCA	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-13.91	4.4e-37	9.19e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
THCA	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	13.91	4.44e-37	9.28e-34	0.73	0.54	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
THCA	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	13.91	4.44e-37	9.29e-34	0.81	0.54	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
THCA	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	13.91	4.59e-37	9.59e-34	0.44	0.54	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
THCA	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-13.9	4.84e-37	1.01e-33	-0.57	-0.54	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
THCA	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-13.9	4.9e-37	1.02e-33	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	13.9	4.96e-37	1.03e-33	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
THCA	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	13.89	5.26e-37	1.09e-33	0.56	0.54	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	13.89	5.26e-37	1.09e-33	0.56	0.54	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
THCA	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-13.89	5.53e-37	1.15e-33	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-13.88	5.65e-37	1.17e-33	-0.69	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	13.88	5.7e-37	1.18e-33	0.67	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
THCA	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	13.88	5.77e-37	1.2e-33	0.98	0.54	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
THCA	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	13.88	5.9e-37	1.23e-33	0.61	0.54	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	13.88	6.01e-37	1.25e-33	0.67	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
THCA	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	13.88	6.08e-37	1.26e-33	0.83	0.54	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
THCA	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	13.88	6.13e-37	1.27e-33	0.6	0.54	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
THCA	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-13.87	6.28e-37	1.3e-33	-0.94	-0.54	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
THCA	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	13.87	6.31e-37	1.31e-33	0.81	0.54	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	13.87	6.33e-37	1.31e-33	0.69	0.54	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
THCA	cis	rs7569084	1	rs7583469	ENSG00000204929.10	AC074391.1	13.87	6.46e-37	1.34e-33	0.66	0.54	Sum eosinophil basophil counts;	chr2:65424222	chr2:65436711~66084639:+
THCA	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-13.87	6.49e-37	1.34e-33	-0.92	-0.54	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
THCA	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	13.87	6.62e-37	1.37e-33	0.78	0.54	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	13.87	6.62e-37	1.37e-33	0.78	0.54	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
THCA	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-13.87	6.65e-37	1.38e-33	-0.63	-0.54	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
THCA	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-13.87	6.84e-37	1.42e-33	-0.61	-0.54	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	13.87	6.86e-37	1.42e-33	0.6	0.54	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
THCA	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-13.86	7.04e-37	1.46e-33	-0.92	-0.54	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
THCA	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-13.86	7.1e-37	1.47e-33	-0.63	-0.54	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
THCA	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-13.86	7.11e-37	1.47e-33	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-13.86	7.13e-37	1.47e-33	-0.78	-0.54	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
THCA	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-13.86	7.29e-37	1.51e-33	-0.92	-0.54	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
THCA	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	13.86	7.39e-37	1.53e-33	0.82	0.54	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
THCA	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-13.86	7.5e-37	1.55e-33	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
THCA	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	13.85	7.7e-37	1.59e-33	0.77	0.54	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	13.85	7.7e-37	1.59e-33	0.77	0.54	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
THCA	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	13.85	7.93e-37	1.64e-33	0.6	0.54	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	13.85	7.93e-37	1.64e-33	0.6	0.54	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
THCA	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-13.85	7.99e-37	1.65e-33	-0.78	-0.54	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
THCA	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-13.85	7.99e-37	1.65e-33	-0.78	-0.54	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-13.85	7.99e-37	1.65e-33	-0.78	-0.54	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-13.85	8.03e-37	1.66e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
THCA	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-13.85	8.12e-37	1.67e-33	-0.7	-0.54	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
THCA	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-13.84	8.41e-37	1.73e-33	-0.8	-0.54	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
THCA	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	13.84	8.55e-37	1.76e-33	0.57	0.54	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
THCA	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-13.84	8.66e-37	1.78e-33	-0.7	-0.54	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
THCA	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	13.84	8.67e-37	1.78e-33	0.5	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
THCA	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	13.83	9.31e-37	1.91e-33	0.94	0.54	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
THCA	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-13.83	9.36e-37	1.92e-33	-0.49	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-13.83	9.36e-37	1.92e-33	-0.49	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
THCA	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	13.83	9.5e-37	1.95e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
THCA	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	13.83	9.91e-37	2.03e-33	0.47	0.54	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
THCA	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	13.83	1e-36	2.06e-33	0.6	0.54	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
THCA	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	13.82	1.04e-36	2.13e-33	0.88	0.54	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
THCA	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-13.82	1.08e-36	2.21e-33	-0.57	-0.54	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
THCA	cis	rs1431005	1	rs1431005	ENSG00000250620.1	RP11-91J3.3	-13.82	1.1e-36	2.26e-33	-0.67	-0.54	Response to statin therapy;	chr4:187424214	chr4:187413564~187415697:+
THCA	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-13.82	1.12e-36	2.29e-33	-0.71	-0.54	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
THCA	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-13.81	1.16e-36	2.37e-33	-0.85	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
THCA	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-13.81	1.17e-36	2.39e-33	-0.59	-0.54	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-13.81	1.18e-36	2.41e-33	-0.53	-0.54	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
THCA	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	13.81	1.18e-36	2.41e-33	0.71	0.54	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
THCA	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	13.81	1.2e-36	2.44e-33	0.51	0.54	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
THCA	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-13.81	1.2e-36	2.45e-33	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
THCA	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-13.81	1.2e-36	2.45e-33	-0.7	-0.54	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
THCA	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	13.81	1.21e-36	2.48e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	13.81	1.21e-36	2.48e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
THCA	cis	rs12220777	1	rs72644211	ENSG00000230091.5	TMEM254-AS1	13.81	1.22e-36	2.48e-33	1.02	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80021939	chr10:80046860~80078912:-
THCA	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	13.81	1.24e-36	2.52e-33	0.52	0.54	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
THCA	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	13.8	1.26e-36	2.57e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
THCA	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-13.8	1.26e-36	2.57e-33	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
THCA	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	13.8	1.28e-36	2.61e-33	0.49	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
THCA	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	13.8	1.32e-36	2.68e-33	0.96	0.54	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
THCA	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	13.8	1.33e-36	2.72e-33	0.68	0.54	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
THCA	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-13.8	1.34e-36	2.73e-33	-0.57	-0.54	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
THCA	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	13.8	1.35e-36	2.75e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	13.8	1.35e-36	2.75e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
THCA	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	13.79	1.38e-36	2.8e-33	0.81	0.54	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
THCA	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-13.79	1.39e-36	2.82e-33	-0.67	-0.54	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
THCA	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-13.79	1.42e-36	2.88e-33	-0.58	-0.54	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
THCA	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-13.79	1.42e-36	2.89e-33	-0.63	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
THCA	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	13.79	1.42e-36	2.89e-33	0.8	0.54	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
THCA	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	13.79	1.43e-36	2.91e-33	0.7	0.54	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
THCA	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	13.79	1.43e-36	2.91e-33	0.6	0.54	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	13.79	1.43e-36	2.91e-33	0.6	0.54	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	13.79	1.43e-36	2.91e-33	0.6	0.54	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
THCA	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-13.79	1.44e-36	2.93e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
THCA	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	13.79	1.47e-36	2.98e-33	0.8	0.54	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
THCA	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
THCA	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	13.79	1.48e-36	3.01e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
THCA	cis	rs732716	0.752	rs11085072	ENSG00000267769.1	CTB-50L17.9	-13.78	1.51e-36	3.07e-33	-0.73	-0.54	Mean corpuscular volume;	chr19:4368145	chr19:4454014~4455286:+
THCA	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-13.78	1.53e-36	3.11e-33	-0.63	-0.54	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
THCA	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	13.78	1.54e-36	3.13e-33	0.51	0.54	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
THCA	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-13.78	1.56e-36	3.15e-33	-0.51	-0.54	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
THCA	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
THCA	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	13.78	1.57e-36	3.19e-33	0.73	0.54	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
THCA	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
THCA	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-13.77	1.78e-36	3.61e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	13.77	1.79e-36	3.61e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	13.77	1.79e-36	3.61e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	13.77	1.84e-36	3.72e-33	0.81	0.54	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
THCA	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	13.77	1.84e-36	3.72e-33	0.77	0.54	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-13.76	1.86e-36	3.76e-33	-0.54	-0.54	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
THCA	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	13.76	1.87e-36	3.78e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
THCA	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	13.76	1.92e-36	3.87e-33	0.92	0.54	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
THCA	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	13.76	1.94e-36	3.91e-33	0.8	0.54	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	13.76	1.97e-36	3.98e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
THCA	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-13.76	2.02e-36	4.08e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
THCA	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	13.75	2.08e-36	4.18e-33	0.77	0.54	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
THCA	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-13.75	2.16e-36	4.35e-33	-0.78	-0.54	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-13.75	2.16e-36	4.35e-33	-0.74	-0.54	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	13.74	2.26e-36	4.56e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
THCA	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-13.74	2.3e-36	4.63e-33	-0.64	-0.54	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	13.74	2.34e-36	4.71e-33	0.5	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
THCA	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	13.74	2.38e-36	4.78e-33	0.53	0.54	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
THCA	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-13.74	2.43e-36	4.88e-33	-0.95	-0.54	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
THCA	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	13.74	2.45e-36	4.91e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	13.74	2.45e-36	4.91e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	13.74	2.45e-36	4.91e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
THCA	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-13.74	2.45e-36	4.92e-33	-0.57	-0.54	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
THCA	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	13.74	2.46e-36	4.94e-33	0.81	0.54	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	13.74	2.46e-36	4.94e-33	0.81	0.54	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	13.74	2.46e-36	4.94e-33	0.81	0.54	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	13.74	2.46e-36	4.94e-33	0.81	0.54	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
THCA	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-13.73	2.49e-36	4.99e-33	-0.68	-0.54	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
THCA	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-13.73	2.57e-36	5.15e-33	-0.78	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-13.73	2.57e-36	5.15e-33	-0.78	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
THCA	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-13.73	2.58e-36	5.17e-33	-0.57	-0.54	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
THCA	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	13.73	2.65e-36	5.3e-33	0.51	0.53	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
THCA	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-13.73	2.73e-36	5.46e-33	-0.63	-0.53	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
THCA	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-13.72	2.78e-36	5.57e-33	-0.95	-0.53	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
THCA	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-13.72	2.82e-36	5.64e-33	-0.78	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
THCA	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-13.72	2.86e-36	5.73e-33	-0.57	-0.53	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-13.72	2.86e-36	5.73e-33	-0.57	-0.53	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
THCA	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	13.72	2.88e-36	5.75e-33	0.75	0.53	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-13.72	2.88e-36	5.77e-33	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
THCA	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-13.72	2.89e-36	5.79e-33	-0.81	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
THCA	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	13.72	2.94e-36	5.88e-33	0.78	0.53	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-13.71	3.04e-36	6.07e-33	-0.5	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
THCA	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-13.71	3.06e-36	6.11e-33	-0.57	-0.53	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
THCA	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	13.71	3.06e-36	6.11e-33	0.64	0.53	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
THCA	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	13.71	3.08e-36	6.15e-33	0.76	0.53	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
THCA	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-13.71	3.08e-36	6.15e-33	-0.48	-0.53	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
THCA	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	13.71	3.12e-36	6.23e-33	0.8	0.53	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
THCA	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	13.71	3.13e-36	6.26e-33	0.6	0.53	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
THCA	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-13.71	3.19e-36	6.37e-33	-0.56	-0.53	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
THCA	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-13.71	3.2e-36	6.39e-33	-0.85	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
THCA	cis	rs17111396	0.773	rs10147243	ENSG00000259167.2	NMNAT1P1	13.71	3.22e-36	6.43e-33	0.67	0.53	Uric acid levels;	chr14:81044834	chr14:81032529~81033404:+
THCA	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	13.71	3.25e-36	6.49e-33	0.51	0.53	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
THCA	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-13.7	3.37e-36	6.72e-33	-0.5	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
THCA	cis	rs9481169	0.717	rs13191781	ENSG00000255389.1	C6orf3	-13.7	3.44e-36	6.85e-33	-1.03	-0.53	Inflammatory skin disease;	chr6:111620083	chr6:111599875~111602295:+
THCA	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	13.7	3.61e-36	7.19e-33	0.7	0.53	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
THCA	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-13.7	3.65e-36	7.27e-33	-0.68	-0.53	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
THCA	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	13.7	3.67e-36	7.3e-33	0.52	0.53	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
THCA	cis	rs9890032	0.618	rs55872374	ENSG00000266490.1	CTD-2349P21.9	13.69	3.71e-36	7.38e-33	0.53	0.53	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30792372~30792833:+
THCA	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	13.69	3.72e-36	7.4e-33	0.91	0.53	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
THCA	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	13.69	3.72e-36	7.4e-33	0.91	0.53	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
THCA	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	13.69	3.72e-36	7.41e-33	0.77	0.53	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-13.69	3.77e-36	7.51e-33	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
THCA	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-13.69	3.82e-36	7.6e-33	-0.57	-0.53	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
THCA	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-13.69	3.82e-36	7.61e-33	-0.85	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
THCA	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-13.69	3.85e-36	7.66e-33	-0.6	-0.53	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-13.69	3.85e-36	7.66e-33	-0.6	-0.53	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
THCA	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	13.69	3.87e-36	7.7e-33	0.69	0.53	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
THCA	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-13.69	3.91e-36	7.77e-33	-0.56	-0.53	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
THCA	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	13.69	3.95e-36	7.86e-33	0.71	0.53	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
THCA	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	13.69	3.96e-36	7.87e-33	0.65	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
THCA	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	13.68	4.06e-36	8.07e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
THCA	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	13.68	4.23e-36	8.39e-33	0.67	0.53	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
THCA	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	13.68	4.31e-36	8.55e-33	0.8	0.53	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	13.68	4.31e-36	8.55e-33	0.8	0.53	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
THCA	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-13.68	4.45e-36	8.83e-33	-0.84	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
THCA	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	13.68	4.46e-36	8.84e-33	0.82	0.53	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	13.68	4.46e-36	8.84e-33	0.82	0.53	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
THCA	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	13.67	4.48e-36	8.89e-33	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
THCA	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-13.67	4.53e-36	8.98e-33	-0.66	-0.53	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
THCA	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	13.67	4.59e-36	9.11e-33	0.91	0.53	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
THCA	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	13.67	4.61e-36	9.13e-33	0.7	0.53	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
THCA	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-13.67	4.68e-36	9.28e-33	-0.53	-0.53	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
THCA	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-13.67	4.77e-36	9.44e-33	-0.76	-0.53	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
THCA	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-13.67	4.8e-36	9.5e-33	-0.91	-0.53	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
THCA	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	13.66	4.98e-36	9.86e-33	0.59	0.53	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
THCA	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-13.66	5.08e-36	1.01e-32	-0.52	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
THCA	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-13.66	5.08e-36	1.01e-32	-0.52	-0.53	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-13.66	5.08e-36	1.01e-32	-0.52	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-13.66	5.08e-36	1.01e-32	-0.52	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
THCA	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	13.66	5.12e-36	1.01e-32	0.53	0.53	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
THCA	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-13.66	5.36e-36	1.06e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
THCA	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	13.65	5.64e-36	1.11e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	13.65	5.64e-36	1.11e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
THCA	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-13.65	5.78e-36	1.14e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-13.65	5.78e-36	1.14e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-13.65	5.78e-36	1.14e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
THCA	cis	rs80028505	0.908	rs73730459	ENSG00000271304.1	DPRXP2	13.65	5.88e-36	1.16e-32	0.9	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36117226	chr6:35989515~35990436:-
THCA	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-13.64	6.01e-36	1.19e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
THCA	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	13.64	6.05e-36	1.19e-32	0.82	0.53	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	13.64	6.26e-36	1.23e-32	0.79	0.53	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000206090.4	AP000350.7	13.64	6.29e-36	1.24e-32	0.66	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23939998~23942798:+
THCA	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	13.64	6.41e-36	1.26e-32	0.57	0.53	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
THCA	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-13.64	6.52e-36	1.28e-32	-0.58	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
THCA	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-13.64	6.54e-36	1.29e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-13.64	6.62e-36	1.3e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-13.64	6.62e-36	1.3e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
THCA	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	13.63	6.79e-36	1.34e-32	0.57	0.53	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
THCA	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-13.63	6.88e-36	1.35e-32	-0.58	-0.53	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-13.63	6.88e-36	1.35e-32	-0.58	-0.53	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
THCA	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	13.63	6.93e-36	1.36e-32	0.64	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
THCA	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	13.63	7.06e-36	1.39e-32	0.79	0.53	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	13.63	7.2e-36	1.41e-32	0.71	0.53	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
THCA	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-13.62	7.37e-36	1.45e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
THCA	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-13.62	7.44e-36	1.46e-32	-0.78	-0.53	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
THCA	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	13.62	7.46e-36	1.46e-32	0.61	0.53	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
THCA	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-13.62	7.61e-36	1.49e-32	-0.47	-0.53	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
THCA	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	13.62	7.74e-36	1.52e-32	0.9	0.53	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000206090.4	AP000350.7	13.61	8.18e-36	1.6e-32	0.67	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23939998~23942798:+
THCA	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	13.61	8.29e-36	1.62e-32	0.52	0.53	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
THCA	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	13.61	8.32e-36	1.63e-32	0.49	0.53	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
THCA	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	13.61	8.41e-36	1.65e-32	0.51	0.53	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
THCA	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	13.61	8.45e-36	1.65e-32	0.64	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
THCA	cis	rs7240205	0.724	rs6508447	ENSG00000275805.1	RP11-349H17.2	13.61	8.56e-36	1.68e-32	0.61	0.53	Breast cancer;	chr18:26552657	chr18:26565723~26575626:-
THCA	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	13.61	8.61e-36	1.68e-32	0.8	0.53	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
THCA	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-13.61	8.64e-36	1.69e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
THCA	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	13.61	8.67e-36	1.69e-32	0.76	0.53	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	13.61	8.67e-36	1.69e-32	0.76	0.53	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	13.61	8.67e-36	1.69e-32	0.76	0.53	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	13.61	8.67e-36	1.69e-32	0.76	0.53	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
THCA	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-13.61	8.77e-36	1.71e-32	-0.63	-0.53	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
THCA	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-13.6	8.98e-36	1.76e-32	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-13.6	8.98e-36	1.76e-32	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
THCA	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	13.6	9.35e-36	1.83e-32	0.82	0.53	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
THCA	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	13.6	9.65e-36	1.88e-32	0.54	0.53	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
THCA	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	13.6	9.66e-36	1.89e-32	0.58	0.53	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
THCA	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	13.59	9.82e-36	1.91e-32	0.76	0.53	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
THCA	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
THCA	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-13.59	9.84e-36	1.92e-32	-0.61	-0.53	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
THCA	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	13.59	9.85e-36	1.92e-32	0.67	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
THCA	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-13.59	1.01e-35	1.96e-32	-0.73	-0.53	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
THCA	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	13.59	1.02e-35	1.98e-32	0.8	0.53	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
THCA	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	13.59	1.05e-35	2.05e-32	0.9	0.53	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
THCA	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	13.59	1.06e-35	2.05e-32	0.68	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
THCA	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	13.59	1.06e-35	2.06e-32	0.63	0.53	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
THCA	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	13.59	1.07e-35	2.07e-32	0.57	0.53	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
THCA	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	13.59	1.07e-35	2.09e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	13.59	1.07e-35	2.09e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	13.59	1.07e-35	2.09e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
THCA	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-13.59	1.08e-35	2.09e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-13.59	1.08e-35	2.09e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
THCA	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-13.58	1.08e-35	2.11e-32	-0.91	-0.53	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
THCA	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	13.58	1.09e-35	2.12e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
THCA	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	13.58	1.11e-35	2.15e-32	0.7	0.53	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
THCA	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	13.58	1.11e-35	2.16e-32	0.63	0.53	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	13.58	1.13e-35	2.2e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
THCA	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-13.58	1.16e-35	2.25e-32	-0.55	-0.53	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
THCA	cis	rs17111396	0.865	rs7158224	ENSG00000259167.2	NMNAT1P1	13.58	1.16e-35	2.25e-32	0.67	0.53	Uric acid levels;	chr14:81052863	chr14:81032529~81033404:+
THCA	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	13.58	1.17e-35	2.26e-32	0.56	0.53	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
THCA	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-13.58	1.18e-35	2.28e-32	-0.96	-0.53	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
THCA	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	13.58	1.19e-35	2.3e-32	0.67	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
THCA	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	13.58	1.19e-35	2.31e-32	0.62	0.53	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
THCA	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-13.57	1.2e-35	2.32e-32	-0.56	-0.53	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
THCA	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
THCA	cis	rs1263173	0.91	rs1263170	ENSG00000254851.1	RP11-109L13.1	-13.57	1.28e-35	2.47e-32	-0.74	-0.53	HDL cholesterol;	chr11:116807697	chr11:117135528~117138582:+
THCA	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	13.57	1.28e-35	2.48e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	13.57	1.28e-35	2.48e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
THCA	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	13.57	1.3e-35	2.5e-32	0.72	0.53	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
THCA	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	13.57	1.31e-35	2.53e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	13.57	1.31e-35	2.54e-32	0.43	0.53	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
THCA	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-13.56	1.32e-35	2.55e-32	-0.61	-0.53	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
THCA	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-13.56	1.33e-35	2.56e-32	-0.6	-0.53	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
THCA	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-13.56	1.33e-35	2.56e-32	-0.59	-0.53	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
THCA	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	13.56	1.34e-35	2.59e-32	0.54	0.53	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
THCA	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-13.56	1.36e-35	2.63e-32	-0.78	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
THCA	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	13.56	1.36e-35	2.63e-32	0.43	0.53	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000206090.4	AP000350.7	-13.56	1.43e-35	2.76e-32	-0.66	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23939998~23942798:+
THCA	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	13.55	1.51e-35	2.9e-32	0.8	0.53	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
THCA	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-13.55	1.55e-35	2.99e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-13.55	1.55e-35	2.99e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
THCA	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	13.55	1.56e-35	3.01e-32	0.66	0.53	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
THCA	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-13.55	1.58e-35	3.03e-32	-0.83	-0.53	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
THCA	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-13.55	1.58e-35	3.05e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-13.55	1.58e-35	3.05e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	13.54	1.61e-35	3.1e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
THCA	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	13.54	1.62e-35	3.11e-32	0.67	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
THCA	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-13.54	1.63e-35	3.13e-32	-0.56	-0.53	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
THCA	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-13.54	1.65e-35	3.17e-32	-0.47	-0.53	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
THCA	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-13.54	1.67e-35	3.21e-32	-0.64	-0.53	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
THCA	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	13.54	1.67e-35	3.21e-32	0.58	0.53	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
THCA	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-13.54	1.69e-35	3.25e-32	-0.79	-0.53	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
THCA	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	13.54	1.7e-35	3.27e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	13.54	1.71e-35	3.29e-32	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
THCA	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	13.54	1.73e-35	3.31e-32	0.69	0.53	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	13.54	1.73e-35	3.31e-32	0.69	0.53	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
THCA	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	13.54	1.74e-35	3.33e-32	0.69	0.53	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
THCA	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-13.54	1.74e-35	3.34e-32	-0.6	-0.53	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
THCA	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	13.54	1.75e-35	3.35e-32	0.55	0.53	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
THCA	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	13.54	1.75e-35	3.35e-32	0.68	0.53	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	13.54	1.75e-35	3.35e-32	0.68	0.53	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
THCA	cis	rs80028505	0.908	rs7762483	ENSG00000271304.1	DPRXP2	13.54	1.75e-35	3.36e-32	0.85	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36088164	chr6:35989515~35990436:-
THCA	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-13.54	1.76e-35	3.38e-32	-0.52	-0.53	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
THCA	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-13.53	1.8e-35	3.45e-32	-0.67	-0.53	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
THCA	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-13.53	1.8e-35	3.46e-32	-0.55	-0.53	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
THCA	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	13.53	1.81e-35	3.47e-32	0.78	0.53	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
THCA	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-13.53	1.83e-35	3.5e-32	-0.5	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
THCA	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	13.53	1.83e-35	3.51e-32	0.9	0.53	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
THCA	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	13.53	1.86e-35	3.57e-32	0.79	0.53	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	13.53	1.87e-35	3.58e-32	0.8	0.53	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
THCA	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-13.53	1.88e-35	3.6e-32	-0.47	-0.53	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
THCA	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	13.53	1.88e-35	3.6e-32	0.81	0.53	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
THCA	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	13.53	1.89e-35	3.62e-32	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
THCA	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	13.53	1.94e-35	3.72e-32	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
THCA	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	13.52	1.95e-35	3.74e-32	0.53	0.53	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
THCA	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	13.52	1.97e-35	3.77e-32	0.77	0.53	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
THCA	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	13.52	1.97e-35	3.77e-32	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	13.52	2.05e-35	3.92e-32	0.7	0.53	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
THCA	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	13.52	2.06e-35	3.93e-32	0.6	0.53	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	13.52	2.07e-35	3.96e-32	0.82	0.53	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
THCA	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-13.52	2.11e-35	4.02e-32	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-13.52	2.12e-35	4.05e-32	-0.6	-0.53	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	13.52	2.14e-35	4.08e-32	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	13.52	2.14e-35	4.08e-32	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
THCA	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	13.51	2.19e-35	4.19e-32	0.5	0.53	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
THCA	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-13.51	2.21e-35	4.22e-32	-0.54	-0.53	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
THCA	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	13.51	2.22e-35	4.24e-32	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
THCA	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	13.51	2.27e-35	4.33e-32	0.79	0.53	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	13.51	2.27e-35	4.33e-32	0.79	0.53	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
THCA	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
THCA	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
THCA	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
THCA	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
THCA	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
THCA	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
THCA	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
THCA	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	13.51	2.28e-35	4.33e-32	0.43	0.53	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
THCA	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-13.51	2.29e-35	4.36e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
THCA	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	13.51	2.35e-35	4.47e-32	0.82	0.53	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	13.51	2.36e-35	4.5e-32	0.71	0.53	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
THCA	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	13.5	2.38e-35	4.53e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
THCA	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	13.5	2.42e-35	4.6e-32	0.55	0.53	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
THCA	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-13.5	2.43e-35	4.61e-32	-0.69	-0.53	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
THCA	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	13.5	2.47e-35	4.7e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	13.5	2.48e-35	4.71e-32	0.42	0.53	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
THCA	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	13.5	2.57e-35	4.88e-32	0.77	0.53	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
THCA	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-13.5	2.59e-35	4.92e-32	-0.56	-0.53	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
THCA	cis	rs80028505	0.908	rs7764494	ENSG00000271304.1	DPRXP2	13.49	2.64e-35	5.02e-32	0.86	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36113563	chr6:35989515~35990436:-
THCA	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-13.49	2.67e-35	5.06e-32	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
THCA	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	13.49	2.71e-35	5.14e-32	0.68	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
THCA	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-13.49	2.73e-35	5.18e-32	-0.7	-0.53	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
THCA	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	13.49	2.75e-35	5.21e-32	0.48	0.53	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
THCA	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-13.49	2.76e-35	5.23e-32	-0.66	-0.53	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
THCA	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
THCA	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	13.49	2.76e-35	5.23e-32	0.64	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
THCA	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-13.49	2.79e-35	5.29e-32	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	13.49	2.85e-35	5.4e-32	0.75	0.53	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
THCA	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	13.49	2.88e-35	5.46e-32	0.49	0.53	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
THCA	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	13.48	2.97e-35	5.62e-32	0.64	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
THCA	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-13.48	3.02e-35	5.71e-32	-0.77	-0.53	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
THCA	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-13.48	3.04e-35	5.75e-32	-0.75	-0.53	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-13.48	3.04e-35	5.75e-32	-0.75	-0.53	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
THCA	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	13.48	3.04e-35	5.75e-32	0.65	0.53	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
THCA	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-13.48	3.05e-35	5.77e-32	-0.77	-0.53	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
THCA	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-13.48	3.07e-35	5.8e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
THCA	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	13.48	3.08e-35	5.82e-32	0.76	0.53	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-13.48	3.08e-35	5.82e-32	-0.76	-0.53	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-13.48	3.08e-35	5.82e-32	-0.76	-0.53	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
THCA	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	13.48	3.11e-35	5.89e-32	0.71	0.53	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
THCA	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	13.48	3.13e-35	5.92e-32	0.76	0.53	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
THCA	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	13.48	3.13e-35	5.92e-32	0.79	0.53	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
THCA	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
THCA	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-13.47	3.2e-35	6.06e-32	-0.56	-0.53	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
THCA	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	13.47	3.23e-35	6.1e-32	0.8	0.53	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	13.47	3.23e-35	6.11e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
THCA	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-13.47	3.32e-35	6.26e-32	-0.69	-0.53	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
THCA	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	13.47	3.33e-35	6.28e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
THCA	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-13.47	3.36e-35	6.34e-32	-0.59	-0.53	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
THCA	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-13.47	3.43e-35	6.46e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
THCA	cis	rs7617773	0.502	rs6804828	ENSG00000229759.1	MRPS18AP1	13.47	3.43e-35	6.48e-32	0.63	0.53	Coronary artery disease;	chr3:48352066	chr3:48256350~48256938:-
THCA	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	13.47	3.45e-35	6.51e-32	0.76	0.53	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
THCA	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	13.47	3.48e-35	6.57e-32	0.92	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
THCA	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	13.47	3.49e-35	6.58e-32	0.59	0.53	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
THCA	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	13.47	3.5e-35	6.59e-32	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
THCA	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-13.47	3.5e-35	6.6e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
THCA	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-13.46	3.51e-35	6.62e-32	-0.66	-0.53	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
THCA	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	13.46	3.52e-35	6.63e-32	0.55	0.53	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
THCA	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	13.46	3.69e-35	6.96e-32	0.79	0.53	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	13.46	3.69e-35	6.96e-32	0.79	0.53	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	13.46	3.69e-35	6.96e-32	0.79	0.53	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	13.46	3.69e-35	6.96e-32	0.79	0.53	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
THCA	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-13.46	3.7e-35	6.98e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-13.46	3.71e-35	6.99e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
THCA	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-13.46	3.77e-35	7.08e-32	-0.8	-0.53	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
THCA	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-13.46	3.78e-35	7.11e-32	-0.42	-0.53	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
THCA	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-13.46	3.79e-35	7.12e-32	-0.74	-0.53	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
THCA	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	13.46	3.81e-35	7.16e-32	0.58	0.53	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
THCA	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	13.46	3.84e-35	7.21e-32	0.53	0.53	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
THCA	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	13.45	3.88e-35	7.29e-32	0.79	0.53	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	13.45	3.97e-35	7.45e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
THCA	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
THCA	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	13.45	3.99e-35	7.48e-32	0.81	0.53	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
THCA	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-13.45	4.07e-35	7.64e-32	-0.46	-0.53	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
THCA	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	13.45	4.09e-35	7.68e-32	0.8	0.53	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
THCA	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-13.45	4.14e-35	7.77e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
THCA	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-13.45	4.16e-35	7.79e-32	-0.6	-0.53	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
THCA	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	13.45	4.19e-35	7.84e-32	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
THCA	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	13.45	4.19e-35	7.85e-32	0.54	0.53	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
THCA	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-13.45	4.22e-35	7.9e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-13.45	4.22e-35	7.9e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-13.45	4.22e-35	7.9e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
THCA	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	13.44	4.31e-35	8.07e-32	0.58	0.53	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
THCA	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-13.44	4.36e-35	8.16e-32	-0.66	-0.53	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
THCA	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	13.44	4.4e-35	8.24e-32	0.79	0.53	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
THCA	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-13.44	4.44e-35	8.32e-32	-0.93	-0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
THCA	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	13.44	4.5e-35	8.42e-32	0.79	0.53	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-13.44	4.6e-35	8.6e-32	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
THCA	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-13.44	4.6e-35	8.61e-32	-0.69	-0.53	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-13.44	4.6e-35	8.61e-32	-0.69	-0.53	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
THCA	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-13.44	4.63e-35	8.66e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
THCA	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-13.44	4.64e-35	8.67e-32	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
THCA	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-13.44	4.69e-35	8.77e-32	-1.01	-0.53	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
THCA	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	13.43	4.7e-35	8.79e-32	0.76	0.53	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
THCA	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	13.43	4.75e-35	8.88e-32	0.92	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
THCA	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-13.43	4.78e-35	8.93e-32	-0.65	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
THCA	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	13.43	4.8e-35	8.96e-32	0.42	0.53	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
THCA	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-13.43	4.8e-35	8.97e-32	-0.55	-0.53	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
THCA	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-13.43	4.87e-35	9.09e-32	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
THCA	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	13.43	4.89e-35	9.12e-32	0.59	0.53	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
THCA	cis	rs8062405	0.789	rs151174	ENSG00000259982.1	CDC37P1	13.43	4.94e-35	9.22e-32	0.64	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28700294~28701540:-
THCA	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	13.43	5e-35	9.33e-32	0.77	0.53	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
THCA	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-13.43	5.04e-35	9.41e-32	-0.66	-0.53	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
THCA	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-13.43	5.06e-35	9.43e-32	-0.64	-0.53	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
THCA	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-13.43	5.11e-35	9.52e-32	-0.83	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
THCA	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-13.43	5.12e-35	9.53e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-13.43	5.12e-35	9.53e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
THCA	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-13.43	5.13e-35	9.55e-32	-0.9	-0.53	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
THCA	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	13.43	5.15e-35	9.58e-32	0.67	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
THCA	cis	rs80028505	1	rs6936327	ENSG00000271304.1	DPRXP2	13.42	5.21e-35	9.7e-32	0.85	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36102098	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs16884857	ENSG00000271304.1	DPRXP2	13.42	5.21e-35	9.7e-32	0.85	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36102450	chr6:35989515~35990436:-
THCA	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-13.42	5.3e-35	9.85e-32	-0.55	-0.53	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
THCA	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	13.42	5.35e-35	9.95e-32	0.61	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
THCA	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	13.42	5.35e-35	9.96e-32	0.76	0.53	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
THCA	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	13.42	5.44e-35	1.01e-31	0.7	0.53	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
THCA	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	13.42	5.47e-35	1.02e-31	0.63	0.53	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	13.42	5.47e-35	1.02e-31	0.63	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
THCA	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-13.42	5.52e-35	1.03e-31	-0.64	-0.53	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
THCA	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	13.42	5.6e-35	1.04e-31	0.77	0.53	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
THCA	cis	rs17111396	0.826	rs10138781	ENSG00000259167.2	NMNAT1P1	13.42	5.66e-35	1.05e-31	0.67	0.53	Uric acid levels;	chr14:81053518	chr14:81032529~81033404:+
THCA	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-13.41	5.72e-35	1.06e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	13.41	5.72e-35	1.06e-31	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-13.41	5.77e-35	1.07e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
THCA	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	13.41	5.83e-35	1.08e-31	0.48	0.53	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
THCA	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-13.41	5.83e-35	1.08e-31	-0.5	-0.53	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
THCA	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	13.41	5.84e-35	1.08e-31	0.62	0.53	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
THCA	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-13.41	5.85e-35	1.08e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
THCA	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-13.41	5.87e-35	1.09e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
THCA	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-13.41	5.89e-35	1.09e-31	-0.47	-0.53	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-13.41	5.89e-35	1.09e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
THCA	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-13.41	5.99e-35	1.11e-31	-0.66	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	13.41	6e-35	1.11e-31	0.63	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
THCA	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	13.41	6.07e-35	1.12e-31	0.69	0.53	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
THCA	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	13.41	6.08e-35	1.13e-31	0.82	0.53	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	13.41	6.11e-35	1.13e-31	0.71	0.53	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	13.41	6.11e-35	1.13e-31	0.71	0.53	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
THCA	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-13.41	6.22e-35	1.15e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
THCA	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-13.41	6.23e-35	1.15e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-13.41	6.23e-35	1.15e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-13.41	6.29e-35	1.16e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	13.4	6.32e-35	1.17e-31	0.5	0.53	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	13.4	6.33e-35	1.17e-31	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	13.4	6.33e-35	1.17e-31	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-13.4	6.34e-35	1.17e-31	-0.65	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
THCA	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-13.4	6.4e-35	1.18e-31	-0.58	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
THCA	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	13.4	6.41e-35	1.18e-31	0.48	0.53	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
THCA	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-13.4	6.49e-35	1.2e-31	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
THCA	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-13.4	6.5e-35	1.2e-31	-0.42	-0.53	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
THCA	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-13.4	6.55e-35	1.21e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-13.4	6.55e-35	1.21e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-13.4	6.55e-35	1.21e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
THCA	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	13.4	6.56e-35	1.21e-31	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
THCA	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-13.4	6.63e-35	1.23e-31	-0.66	-0.53	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
THCA	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-13.4	6.66e-35	1.23e-31	-0.47	-0.53	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
THCA	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-13.4	6.7e-35	1.24e-31	-0.79	-0.53	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
THCA	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	13.4	6.77e-35	1.25e-31	0.79	0.53	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
THCA	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-13.4	6.79e-35	1.25e-31	-0.64	-0.53	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
THCA	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	13.4	6.8e-35	1.26e-31	0.49	0.53	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
THCA	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	13.4	6.82e-35	1.26e-31	0.63	0.53	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
THCA	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	13.4	6.83e-35	1.26e-31	0.6	0.53	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
THCA	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	13.4	6.86e-35	1.27e-31	0.67	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
THCA	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	13.4	6.88e-35	1.27e-31	0.8	0.53	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
THCA	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-13.4	6.91e-35	1.28e-31	-0.73	-0.53	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
THCA	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	13.4	6.92e-35	1.28e-31	0.49	0.53	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
THCA	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	13.39	6.94e-35	1.28e-31	0.75	0.53	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	13.39	6.95e-35	1.28e-31	0.75	0.53	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	13.39	6.95e-35	1.28e-31	0.75	0.53	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-13.39	7.05e-35	1.3e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
THCA	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-13.39	7.22e-35	1.33e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
THCA	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	13.39	7.27e-35	1.34e-31	0.47	0.53	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
THCA	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-13.39	7.3e-35	1.34e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-13.39	7.3e-35	1.34e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
THCA	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-13.39	7.32e-35	1.35e-31	-0.9	-0.53	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
THCA	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-13.39	7.33e-35	1.35e-31	-0.63	-0.53	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
THCA	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	13.39	7.39e-35	1.36e-31	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
THCA	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	13.39	7.41e-35	1.36e-31	0.65	0.53	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
THCA	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	13.39	7.48e-35	1.38e-31	0.54	0.53	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
THCA	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-13.39	7.57e-35	1.39e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-13.38	7.68e-35	1.41e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
THCA	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	13.38	7.74e-35	1.42e-31	0.76	0.53	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-13.38	7.77e-35	1.43e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
THCA	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	13.38	7.77e-35	1.43e-31	0.78	0.53	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-13.38	7.79e-35	1.43e-31	-0.5	-0.53	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-13.38	7.79e-35	1.43e-31	-0.5	-0.53	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
THCA	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	13.38	7.8e-35	1.43e-31	0.54	0.53	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
THCA	cis	rs6519955	0.897	rs4073601	ENSG00000231711.2	LINC00899	13.38	7.82e-35	1.44e-31	0.44	0.53	Dupuytren's disease;	chr22:46038806	chr22:46039907~46044853:-
THCA	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	13.38	7.84e-35	1.44e-31	0.59	0.53	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
THCA	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-13.38	7.85e-35	1.44e-31	-0.68	-0.53	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
THCA	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	13.38	7.99e-35	1.47e-31	0.77	0.53	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
THCA	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-13.38	8.03e-35	1.48e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
THCA	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	13.38	8.07e-35	1.48e-31	0.86	0.53	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
THCA	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-13.38	8.12e-35	1.49e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-13.38	8.12e-35	1.49e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
THCA	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	13.38	8.13e-35	1.49e-31	0.55	0.53	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
THCA	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-13.38	8.17e-35	1.5e-31	-0.54	-0.53	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
THCA	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
THCA	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	13.38	8.37e-35	1.54e-31	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-13.38	8.41e-35	1.54e-31	-0.68	-0.53	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	13.38	8.42e-35	1.55e-31	0.79	0.53	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
THCA	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	13.37	8.44e-35	1.55e-31	0.51	0.53	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
THCA	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-13.37	8.47e-35	1.55e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-13.37	8.47e-35	1.55e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-13.37	8.47e-35	1.55e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-13.37	8.47e-35	1.55e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
THCA	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	13.37	8.5e-35	1.56e-31	0.63	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
THCA	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	13.37	8.5e-35	1.56e-31	0.55	0.53	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
THCA	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-13.37	8.5e-35	1.56e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-13.37	8.5e-35	1.56e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-13.37	8.5e-35	1.56e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
THCA	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-13.37	8.5e-35	1.56e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
THCA	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-13.37	8.71e-35	1.59e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
THCA	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-13.37	8.74e-35	1.6e-31	-0.67	-0.52	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
THCA	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-13.37	8.75e-35	1.6e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
THCA	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	13.37	8.87e-35	1.62e-31	0.42	0.52	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
THCA	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-13.37	9e-35	1.65e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-13.37	9e-35	1.65e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
THCA	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	13.37	9.04e-35	1.65e-31	0.51	0.52	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-13.37	9.11e-35	1.66e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-13.37	9.28e-35	1.69e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-13.37	9.28e-35	1.69e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
THCA	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-13.36	9.29e-35	1.69e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
THCA	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	13.36	9.36e-35	1.71e-31	0.79	0.52	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
THCA	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	13.36	9.43e-35	1.72e-31	0.58	0.52	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
THCA	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-13.36	9.45e-35	1.72e-31	-0.79	-0.52	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
THCA	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	13.36	9.45e-35	1.72e-31	0.54	0.52	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
THCA	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-13.36	9.49e-35	1.73e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
THCA	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-13.36	9.51e-35	1.73e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
THCA	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-13.36	9.56e-35	1.74e-31	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
THCA	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-13.36	9.57e-35	1.74e-31	-0.83	-0.52	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
THCA	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-13.36	9.6e-35	1.75e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-13.36	9.61e-35	1.75e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
THCA	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	13.36	9.62e-35	1.75e-31	0.48	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
THCA	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	13.36	9.66e-35	1.76e-31	0.81	0.52	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
THCA	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-13.36	9.66e-35	1.76e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-13.36	9.66e-35	1.76e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-13.36	9.66e-35	1.76e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
THCA	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	13.36	9.76e-35	1.78e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
THCA	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	13.36	1e-34	1.82e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
THCA	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	13.36	1e-34	1.82e-31	0.67	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
THCA	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-13.36	1.01e-34	1.84e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	13.36	1.02e-34	1.85e-31	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
THCA	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-13.35	1.02e-34	1.86e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
THCA	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	13.35	1.03e-34	1.87e-31	0.69	0.52	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	13.35	1.03e-34	1.87e-31	0.69	0.52	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	13.35	1.03e-34	1.87e-31	0.69	0.52	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	13.35	1.03e-34	1.87e-31	0.69	0.52	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
THCA	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-13.35	1.04e-34	1.89e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-13.35	1.04e-34	1.89e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-13.35	1.04e-34	1.89e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
THCA	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-13.35	1.09e-34	1.98e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
THCA	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	13.35	1.09e-34	1.98e-31	0.63	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
THCA	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	13.35	1.11e-34	2.01e-31	0.8	0.52	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	13.35	1.11e-34	2.01e-31	0.78	0.52	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
THCA	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-13.35	1.11e-34	2.02e-31	-0.68	-0.52	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
THCA	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-13.35	1.12e-34	2.03e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
THCA	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-13.35	1.12e-34	2.04e-31	-0.46	-0.52	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
THCA	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-13.34	1.13e-34	2.05e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
THCA	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-13.34	1.14e-34	2.07e-31	-0.59	-0.52	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
THCA	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	13.34	1.15e-34	2.09e-31	0.57	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
THCA	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	13.34	1.15e-34	2.09e-31	0.49	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
THCA	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-13.34	1.16e-34	2.11e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	13.34	1.18e-34	2.14e-31	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	13.34	1.18e-34	2.14e-31	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
THCA	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-13.34	1.2e-34	2.18e-31	-0.69	-0.52	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
THCA	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	13.34	1.22e-34	2.21e-31	0.68	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
THCA	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-13.34	1.22e-34	2.21e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
THCA	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
THCA	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	13.34	1.24e-34	2.25e-31	0.75	0.52	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
THCA	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	13.33	1.25e-34	2.27e-31	0.59	0.52	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
THCA	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	13.33	1.27e-34	2.3e-31	0.58	0.52	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
THCA	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	13.33	1.28e-34	2.31e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
THCA	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	13.33	1.28e-34	2.32e-31	0.75	0.52	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
THCA	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-13.33	1.29e-34	2.33e-31	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
THCA	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-13.33	1.31e-34	2.37e-31	-0.52	-0.52	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
THCA	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-13.33	1.33e-34	2.4e-31	-0.68	-0.52	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
THCA	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-13.33	1.33e-34	2.4e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
THCA	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-13.33	1.35e-34	2.43e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-13.33	1.35e-34	2.43e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-13.33	1.35e-34	2.43e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-13.33	1.35e-34	2.43e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
THCA	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-13.33	1.35e-34	2.44e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
THCA	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-13.33	1.35e-34	2.44e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-13.33	1.35e-34	2.44e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-13.33	1.35e-34	2.44e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-13.33	1.35e-34	2.44e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	13.33	1.35e-34	2.44e-31	0.68	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
THCA	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	13.33	1.36e-34	2.45e-31	0.65	0.52	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
THCA	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	13.32	1.39e-34	2.51e-31	0.56	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
THCA	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-13.32	1.4e-34	2.52e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-13.32	1.4e-34	2.52e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-13.32	1.4e-34	2.52e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-13.32	1.4e-34	2.52e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
THCA	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
THCA	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-13.32	1.4e-34	2.52e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
THCA	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
THCA	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
THCA	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	13.32	1.42e-34	2.55e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
THCA	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	13.32	1.42e-34	2.56e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	13.32	1.42e-34	2.56e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
THCA	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	13.32	1.43e-34	2.57e-31	0.61	0.52	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
THCA	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-13.32	1.45e-34	2.6e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
THCA	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-13.32	1.47e-34	2.65e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
THCA	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
THCA	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	13.32	1.48e-34	2.65e-31	0.61	0.52	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
THCA	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	13.32	1.48e-34	2.67e-31	0.55	0.52	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
THCA	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	13.32	1.49e-34	2.68e-31	0.49	0.52	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
THCA	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	13.32	1.51e-34	2.71e-31	0.95	0.52	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
THCA	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	13.32	1.51e-34	2.71e-31	0.95	0.52	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
THCA	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	13.31	1.52e-34	2.73e-31	0.81	0.52	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
THCA	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-13.31	1.52e-34	2.73e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
THCA	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	13.31	1.53e-34	2.74e-31	0.62	0.52	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
THCA	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-13.31	1.55e-34	2.78e-31	-0.47	-0.52	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
THCA	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-13.31	1.55e-34	2.79e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
THCA	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-13.31	1.56e-34	2.81e-31	-0.63	-0.52	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
THCA	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	13.31	1.57e-34	2.81e-31	0.65	0.52	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
THCA	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-13.31	1.57e-34	2.81e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-13.31	1.57e-34	2.81e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
THCA	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	13.31	1.59e-34	2.86e-31	0.55	0.52	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-13.31	1.64e-34	2.94e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-13.31	1.65e-34	2.96e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-13.31	1.65e-34	2.96e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
THCA	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-13.31	1.66e-34	2.97e-31	-0.55	-0.52	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
THCA	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	13.3	1.68e-34	3e-31	0.52	0.52	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
THCA	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	13.3	1.7e-34	3.05e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	13.3	1.7e-34	3.05e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	13.3	1.7e-34	3.05e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	13.3	1.7e-34	3.05e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
THCA	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-13.3	1.72e-34	3.08e-31	-0.46	-0.52	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
THCA	cis	rs80028505	0.908	rs7752459	ENSG00000271304.1	DPRXP2	13.3	1.79e-34	3.21e-31	0.87	0.52	Foot ulcer in diabetes and neuropathy;	chr6:36116895	chr6:35989515~35990436:-
THCA	cis	rs62158211	0.955	rs7556815	ENSG00000234997.1	AC016745.3	-13.3	1.83e-34	3.28e-31	-0.63	-0.52	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr2:113424495~113425324:+
THCA	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-13.29	1.86e-34	3.34e-31	-0.47	-0.52	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
THCA	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	13.29	1.87e-34	3.35e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
THCA	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	13.29	1.89e-34	3.38e-31	0.49	0.52	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
THCA	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-13.29	1.9e-34	3.39e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
THCA	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	13.29	1.91e-34	3.41e-31	0.42	0.52	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
THCA	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-13.29	1.91e-34	3.42e-31	-0.74	-0.52	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
THCA	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	13.29	1.99e-34	3.56e-31	0.78	0.52	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
THCA	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	13.29	2e-34	3.57e-31	0.46	0.52	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
THCA	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	13.29	2.01e-34	3.58e-31	0.55	0.52	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
THCA	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	13.29	2.02e-34	3.61e-31	0.67	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
THCA	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-13.28	2.03e-34	3.62e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-13.28	2.03e-34	3.62e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	13.28	2.03e-34	3.63e-31	0.66	0.52	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
THCA	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	13.28	2.07e-34	3.69e-31	0.68	0.52	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
THCA	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-13.28	2.08e-34	3.72e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	13.28	2.09e-34	3.73e-31	0.81	0.52	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
THCA	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	13.28	2.1e-34	3.74e-31	0.76	0.52	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	13.28	2.1e-34	3.74e-31	0.76	0.52	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
THCA	cis	rs8062405	0.728	rs9931989	ENSG00000259982.1	CDC37P1	-13.28	2.1e-34	3.74e-31	-0.65	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28700294~28701540:-
THCA	cis	rs17111396	0.826	rs10134487	ENSG00000259167.2	NMNAT1P1	13.28	2.11e-34	3.77e-31	0.66	0.52	Uric acid levels;	chr14:81057542	chr14:81032529~81033404:+
THCA	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-13.28	2.11e-34	3.77e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-13.28	2.14e-34	3.81e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
THCA	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	13.28	2.16e-34	3.85e-31	0.55	0.52	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
THCA	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	13.28	2.17e-34	3.86e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	13.28	2.17e-34	3.86e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-13.28	2.21e-34	3.93e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-13.28	2.21e-34	3.93e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
THCA	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	13.28	2.22e-34	3.96e-31	0.42	0.52	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
THCA	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	13.28	2.23e-34	3.96e-31	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
THCA	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
THCA	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	13.27	2.26e-34	4.02e-31	0.65	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	13.27	2.26e-34	4.02e-31	0.65	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-13.27	2.27e-34	4.03e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
THCA	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	13.27	2.3e-34	4.09e-31	0.48	0.52	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
THCA	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	13.27	2.3e-34	4.1e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
THCA	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-13.27	2.31e-34	4.1e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	13.27	2.31e-34	4.11e-31	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
THCA	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	13.27	2.32e-34	4.12e-31	0.78	0.52	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
THCA	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-13.27	2.34e-34	4.16e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
THCA	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-13.27	2.35e-34	4.17e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
THCA	cis	rs1075265	0.584	rs2357954	ENSG00000233266.1	HMGB1P31	13.27	2.37e-34	4.21e-31	0.69	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54051334~54051760:+
THCA	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-13.27	2.39e-34	4.24e-31	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	13.27	2.39e-34	4.24e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
THCA	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	13.27	2.39e-34	4.25e-31	0.55	0.52	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
THCA	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	13.27	2.42e-34	4.29e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
THCA	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	13.27	2.46e-34	4.35e-31	0.48	0.52	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
THCA	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	13.26	2.46e-34	4.36e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
THCA	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-13.26	2.49e-34	4.41e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-13.26	2.49e-34	4.41e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-13.26	2.49e-34	4.41e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-13.26	2.5e-34	4.43e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
THCA	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	13.26	2.52e-34	4.45e-31	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	13.26	2.52e-34	4.45e-31	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
THCA	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-13.26	2.52e-34	4.45e-31	-0.91	-0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
THCA	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-13.26	2.52e-34	4.45e-31	-0.62	-0.52	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
THCA	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	13.26	2.52e-34	4.46e-31	0.82	0.52	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
THCA	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-13.26	2.56e-34	4.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
THCA	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	13.26	2.58e-34	4.56e-31	0.81	0.52	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
THCA	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	13.26	2.58e-34	4.56e-31	0.81	0.52	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
THCA	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-13.26	2.59e-34	4.58e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-13.26	2.59e-34	4.58e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	13.26	2.59e-34	4.58e-31	0.51	0.52	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
THCA	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-13.26	2.64e-34	4.66e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-13.26	2.64e-34	4.66e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
THCA	cis	rs80028505	0.908	rs7771484	ENSG00000271304.1	DPRXP2	-13.26	2.68e-34	4.73e-31	-0.83	-0.52	Foot ulcer in diabetes and neuropathy;	chr6:36095214	chr6:35989515~35990436:-
THCA	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-13.26	2.7e-34	4.76e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
THCA	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	13.25	2.75e-34	4.85e-31	1.08	0.52	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
THCA	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-13.25	2.77e-34	4.89e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
THCA	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-13.25	2.81e-34	4.97e-31	-0.64	-0.52	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
THCA	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	13.25	2.82e-34	4.97e-31	0.61	0.52	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
THCA	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	13.25	2.84e-34	5e-31	0.93	0.52	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
THCA	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	13.25	2.91e-34	5.13e-31	0.59	0.52	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
THCA	cis	rs80028505	1	rs16884694	ENSG00000271304.1	DPRXP2	13.25	2.97e-34	5.23e-31	0.83	0.52	Foot ulcer in diabetes and neuropathy;	chr6:36095385	chr6:35989515~35990436:-
THCA	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	13.25	2.98e-34	5.25e-31	0.79	0.52	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
THCA	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	13.24	3e-34	5.28e-31	0.64	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
THCA	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	13.24	3.03e-34	5.34e-31	0.68	0.52	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
THCA	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	13.24	3.06e-34	5.39e-31	0.67	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
THCA	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	13.24	3.13e-34	5.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
THCA	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-13.24	3.15e-34	5.55e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
THCA	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-13.24	3.19e-34	5.61e-31	-0.77	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
THCA	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-13.24	3.22e-34	5.67e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
THCA	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	13.24	3.23e-34	5.68e-31	0.66	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
THCA	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	13.24	3.25e-34	5.72e-31	0.54	0.52	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
THCA	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	13.24	3.26e-34	5.73e-31	0.48	0.52	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
THCA	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-13.23	3.33e-34	5.86e-31	-0.46	-0.52	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
THCA	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	13.23	3.4e-34	5.98e-31	0.53	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	13.23	3.4e-34	5.98e-31	0.53	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
THCA	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	13.23	3.44e-34	6.04e-31	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
THCA	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	13.23	3.45e-34	6.05e-31	0.6	0.52	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
THCA	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	13.23	3.5e-34	6.14e-31	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
THCA	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-13.23	3.6e-34	6.31e-31	-0.66	-0.52	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
THCA	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-13.22	3.63e-34	6.37e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
THCA	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	13.22	3.65e-34	6.4e-31	0.42	0.52	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	13.22	3.65e-34	6.4e-31	0.42	0.52	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	13.22	3.65e-34	6.4e-31	0.42	0.52	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
THCA	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-13.22	3.8e-34	6.66e-31	-0.49	-0.52	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
THCA	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-13.22	3.87e-34	6.78e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
THCA	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-13.22	3.89e-34	6.81e-31	-0.64	-0.52	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-13.22	3.89e-34	6.81e-31	-0.64	-0.52	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
THCA	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
THCA	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	13.22	3.92e-34	6.86e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
THCA	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	13.22	3.92e-34	6.86e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
THCA	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-13.22	3.92e-34	6.87e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
THCA	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-13.22	3.98e-34	6.97e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
THCA	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	13.21	4.02e-34	7.03e-31	0.79	0.52	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
THCA	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-13.21	4.09e-34	7.15e-31	-0.51	-0.52	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
THCA	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	13.21	4.11e-34	7.18e-31	0.42	0.52	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
THCA	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	13.21	4.11e-34	7.19e-31	0.76	0.52	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
THCA	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-13.21	4.12e-34	7.21e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
THCA	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-13.21	4.16e-34	7.28e-31	-0.66	-0.52	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
THCA	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-13.21	4.18e-34	7.3e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	13.21	4.2e-34	7.34e-31	0.52	0.52	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
THCA	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-13.21	4.21e-34	7.36e-31	-0.53	-0.52	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
THCA	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-13.21	4.27e-34	7.47e-31	-0.89	-0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
THCA	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-13.21	4.3e-34	7.51e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-13.21	4.3e-34	7.51e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
THCA	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
THCA	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	13.21	4.34e-34	7.57e-31	0.75	0.52	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
THCA	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	13.21	4.34e-34	7.58e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
THCA	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	13.2	4.4e-34	7.67e-31	0.54	0.52	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
THCA	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	13.2	4.4e-34	7.67e-31	0.54	0.52	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
THCA	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-13.2	4.47e-34	7.79e-31	-0.65	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
THCA	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	13.2	4.55e-34	7.93e-31	0.55	0.52	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
THCA	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	13.2	4.55e-34	7.93e-31	0.53	0.52	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
THCA	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-13.2	4.57e-34	7.97e-31	-0.53	-0.52	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
THCA	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	13.2	4.76e-34	8.3e-31	0.48	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
THCA	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-13.2	4.77e-34	8.31e-31	-0.62	-0.52	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
THCA	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-13.2	4.77e-34	8.31e-31	-0.46	-0.52	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-13.2	4.77e-34	8.31e-31	-0.46	-0.52	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
THCA	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-13.2	4.84e-34	8.43e-31	-0.65	-0.52	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
THCA	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	13.19	4.87e-34	8.49e-31	0.75	0.52	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-13.19	4.88e-34	8.49e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-13.19	4.88e-34	8.49e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	13.19	4.9e-34	8.53e-31	0.51	0.52	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	13.19	5.02e-34	8.73e-31	0.67	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
THCA	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	13.19	5.04e-34	8.77e-31	0.74	0.52	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
THCA	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-13.19	5.07e-34	8.82e-31	-0.61	-0.52	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
THCA	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-13.19	5.12e-34	8.9e-31	-0.56	-0.52	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
THCA	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	13.19	5.13e-34	8.93e-31	0.6	0.52	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
THCA	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	13.19	5.17e-34	9e-31	0.68	0.52	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
THCA	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	13.19	5.18e-34	9.01e-31	0.68	0.52	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
THCA	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-13.19	5.21e-34	9.05e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
THCA	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	13.19	5.21e-34	9.05e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
THCA	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	13.19	5.21e-34	9.05e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
THCA	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	13.19	5.3e-34	9.21e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
THCA	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	13.18	5.45e-34	9.47e-31	0.53	0.52	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
THCA	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	13.18	5.47e-34	9.51e-31	0.63	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
THCA	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-13.18	5.47e-34	9.51e-31	-0.6	-0.52	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
THCA	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-13.18	5.49e-34	9.53e-31	-0.63	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
THCA	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-13.18	5.54e-34	9.62e-31	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
THCA	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	13.18	5.55e-34	9.63e-31	0.61	0.52	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
THCA	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	13.18	5.59e-34	9.7e-31	0.64	0.52	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	13.18	5.59e-34	9.7e-31	0.64	0.52	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
THCA	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-13.18	5.63e-34	9.76e-31	-0.61	-0.52	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
THCA	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-13.18	5.63e-34	9.78e-31	-0.68	-0.52	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
THCA	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-13.18	5.64e-34	9.79e-31	-0.46	-0.52	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
THCA	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	13.18	5.75e-34	9.97e-31	0.61	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
THCA	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-13.18	5.76e-34	9.99e-31	-0.66	-0.52	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
THCA	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	13.17	5.93e-34	1.03e-30	0.59	0.52	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
THCA	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-13.17	6e-34	1.04e-30	-0.79	-0.52	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
THCA	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-13.17	6e-34	1.04e-30	-0.4	-0.52	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	13.17	6.02e-34	1.04e-30	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
THCA	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-13.17	6.15e-34	1.07e-30	-0.76	-0.52	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
THCA	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-13.17	6.2e-34	1.07e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
THCA	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	13.17	6.24e-34	1.08e-30	0.67	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
THCA	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	13.17	6.29e-34	1.09e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	13.17	6.29e-34	1.09e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
THCA	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	13.17	6.31e-34	1.09e-30	0.66	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	13.17	6.31e-34	1.09e-30	0.66	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
THCA	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-13.17	6.33e-34	1.1e-30	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
THCA	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	13.17	6.38e-34	1.1e-30	0.55	0.52	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
THCA	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	13.17	6.38e-34	1.1e-30	0.55	0.52	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
THCA	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	13.17	6.46e-34	1.12e-30	0.54	0.52	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
THCA	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-13.16	6.57e-34	1.14e-30	-0.66	-0.52	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
THCA	cis	rs944289	0.616	rs1742867	ENSG00000257826.1	RP11-116N8.4	13.16	6.57e-34	1.14e-30	0.54	0.52	Thyroid cancer;	chr14:36067937	chr14:36061026~36067190:-
THCA	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	13.16	6.6e-34	1.14e-30	0.64	0.52	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
THCA	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
THCA	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	13.16	6.74e-34	1.16e-30	0.68	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-13.16	6.74e-34	1.16e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
THCA	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-13.16	6.77e-34	1.17e-30	-0.55	-0.52	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-13.16	6.82e-34	1.18e-30	-0.52	-0.52	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
THCA	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-13.16	6.85e-34	1.18e-30	-0.4	-0.52	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
THCA	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-13.16	6.85e-34	1.18e-30	-0.59	-0.52	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
THCA	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-13.16	6.86e-34	1.18e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
THCA	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-13.16	6.89e-34	1.19e-30	-0.57	-0.52	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	13.16	6.91e-34	1.19e-30	0.49	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
THCA	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
THCA	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	13.16	6.96e-34	1.2e-30	0.74	0.52	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	13.16	6.97e-34	1.2e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
THCA	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-13.16	6.97e-34	1.2e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
THCA	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	13.16	7.03e-34	1.21e-30	0.42	0.52	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
THCA	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	13.16	7.06e-34	1.22e-30	0.61	0.52	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
THCA	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-13.16	7.08e-34	1.22e-30	-0.63	-0.52	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
THCA	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-13.16	7.09e-34	1.22e-30	-0.65	-0.52	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
THCA	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-13.15	7.28e-34	1.25e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-13.15	7.28e-34	1.25e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	13.15	7.33e-34	1.26e-30	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
THCA	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
THCA	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-13.15	7.51e-34	1.29e-30	-0.65	-0.52	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
THCA	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-13.15	7.53e-34	1.3e-30	-0.65	-0.52	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
THCA	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
THCA	cis	rs1061377	0.965	rs1137714	ENSG00000249207.1	RP11-360F5.1	-13.15	7.7e-34	1.32e-30	-0.64	-0.52	Uric acid levels;	chr4:39143105	chr4:39112677~39126818:-
THCA	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-13.15	7.7e-34	1.32e-30	-0.72	-0.52	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
THCA	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	13.15	7.77e-34	1.34e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
THCA	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-13.15	7.77e-34	1.34e-30	-0.61	-0.52	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-13.15	7.77e-34	1.34e-30	-0.61	-0.52	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
THCA	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	13.15	7.83e-34	1.35e-30	0.52	0.52	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-13.14	7.86e-34	1.35e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	13.14	7.88e-34	1.36e-30	0.57	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
THCA	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	13.14	7.96e-34	1.37e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
THCA	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-13.14	7.96e-34	1.37e-30	-0.65	-0.52	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
THCA	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	13.14	7.99e-34	1.37e-30	0.62	0.52	Depression;	chr6:28240757	chr6:28176188~28176674:+
THCA	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-13.14	8.17e-34	1.4e-30	-0.61	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
THCA	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	13.14	8.19e-34	1.41e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-13.14	8.21e-34	1.41e-30	-0.65	-0.52	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
THCA	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	13.14	8.23e-34	1.41e-30	0.8	0.52	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
THCA	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	13.14	8.23e-34	1.41e-30	0.8	0.52	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
THCA	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	13.14	8.27e-34	1.42e-30	0.74	0.52	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
THCA	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	13.14	8.4e-34	1.44e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
THCA	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-13.14	8.42e-34	1.45e-30	-0.51	-0.52	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
THCA	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-13.14	8.47e-34	1.45e-30	-0.66	-0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
THCA	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	13.14	8.49e-34	1.46e-30	0.89	0.52	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
THCA	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	13.14	8.59e-34	1.47e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	13.14	8.59e-34	1.47e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	13.14	8.59e-34	1.47e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
THCA	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-13.13	8.69e-34	1.49e-30	-0.51	-0.52	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
THCA	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	13.13	8.72e-34	1.49e-30	0.8	0.52	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
THCA	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-13.13	8.73e-34	1.5e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	13.13	8.85e-34	1.52e-30	0.51	0.52	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-13.13	8.86e-34	1.52e-30	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
THCA	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-13.13	8.96e-34	1.54e-30	-0.52	-0.52	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
THCA	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-13.13	9.09e-34	1.56e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-13.13	9.09e-34	1.56e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-13.13	9.13e-34	1.56e-30	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
THCA	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	13.13	9.21e-34	1.58e-30	0.69	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
THCA	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-13.13	9.27e-34	1.59e-30	-0.63	-0.52	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
THCA	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	13.13	9.31e-34	1.59e-30	0.77	0.52	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-13.13	9.34e-34	1.6e-30	-0.51	-0.52	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
THCA	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	13.13	9.41e-34	1.61e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
THCA	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	13.13	9.47e-34	1.62e-30	0.66	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
THCA	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-13.13	9.47e-34	1.62e-30	-0.74	-0.52	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
THCA	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-13.12	9.58e-34	1.64e-30	-0.67	-0.52	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
THCA	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-13.12	9.69e-34	1.66e-30	-0.63	-0.52	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
THCA	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	13.12	9.71e-34	1.66e-30	0.68	0.52	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-13.12	9.73e-34	1.67e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
THCA	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	13.12	9.75e-34	1.67e-30	0.62	0.52	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
THCA	cis	rs748404	0.518	rs2927085	ENSG00000249839.1	AC011330.5	-13.12	9.92e-34	1.7e-30	-0.61	-0.52	Lung cancer;	chr15:43697332	chr15:43663654~43684339:-
THCA	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	13.12	1.02e-33	1.74e-30	0.64	0.52	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	13.12	1.02e-33	1.74e-30	0.64	0.52	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	13.12	1.02e-33	1.74e-30	0.64	0.52	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
THCA	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	13.12	1.02e-33	1.74e-30	0.59	0.52	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
THCA	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
THCA	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-13.12	1.03e-33	1.75e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
THCA	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	13.12	1.03e-33	1.76e-30	0.68	0.52	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
THCA	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-13.12	1.04e-33	1.78e-30	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
THCA	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-13.11	1.06e-33	1.81e-30	-0.67	-0.52	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
THCA	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	13.11	1.07e-33	1.82e-30	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	13.11	1.07e-33	1.82e-30	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	13.11	1.07e-33	1.82e-30	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
THCA	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	13.11	1.07e-33	1.83e-30	0.54	0.52	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
THCA	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	13.11	1.07e-33	1.83e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	13.11	1.07e-33	1.83e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
THCA	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	13.11	1.08e-33	1.84e-30	0.81	0.52	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
THCA	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-13.11	1.08e-33	1.84e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
THCA	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	13.11	1.08e-33	1.84e-30	0.75	0.52	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	13.11	1.08e-33	1.84e-30	0.75	0.52	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	13.11	1.08e-33	1.85e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
THCA	cis	rs1061377	0.748	rs12506723	ENSG00000249207.1	RP11-360F5.1	-13.11	1.09e-33	1.87e-30	-0.64	-0.52	Uric acid levels;	chr4:39103152	chr4:39112677~39126818:-
THCA	cis	rs4853012	0.793	rs6723185	ENSG00000257800.1	FNBP1P1	13.11	1.12e-33	1.91e-30	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117757	chr2:74120680~74123218:+
THCA	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	13.11	1.13e-33	1.92e-30	0.75	0.52	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
THCA	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	13.11	1.14e-33	1.95e-30	0.54	0.52	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	13.11	1.14e-33	1.95e-30	0.54	0.52	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-13.11	1.14e-33	1.95e-30	-0.52	-0.52	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
THCA	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-13.11	1.15e-33	1.95e-30	-0.67	-0.52	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
THCA	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-13.11	1.15e-33	1.95e-30	-0.64	-0.52	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-13.11	1.15e-33	1.95e-30	-0.64	-0.52	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
THCA	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	13.11	1.15e-33	1.96e-30	0.74	0.52	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
THCA	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	13.1	1.17e-33	1.99e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	13.1	1.17e-33	1.99e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	13.1	1.17e-33	1.99e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	13.1	1.17e-33	1.99e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
THCA	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-13.1	1.17e-33	2e-30	-0.64	-0.52	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
THCA	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	13.1	1.18e-33	2e-30	0.67	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
THCA	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	13.1	1.18e-33	2e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	13.1	1.18e-33	2e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
THCA	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-13.1	1.19e-33	2.02e-30	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
THCA	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	13.1	1.19e-33	2.02e-30	0.54	0.52	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
THCA	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-13.1	1.19e-33	2.02e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
THCA	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-13.1	1.19e-33	2.03e-30	-0.57	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
THCA	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	13.1	1.2e-33	2.04e-30	0.63	0.52	Height;	chr11:118781100	chr11:118688039~118690600:-
THCA	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-13.1	1.2e-33	2.04e-30	-0.65	-0.52	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
THCA	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
THCA	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	13.1	1.24e-33	2.11e-30	0.65	0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	13.1	1.25e-33	2.13e-30	0.65	0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
THCA	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-13.1	1.26e-33	2.14e-30	-0.47	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.901	rs1039786	ENSG00000249664.1	CTD-2227C6.2	13.1	1.27e-33	2.15e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83012285~83013109:-
THCA	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-13.1	1.27e-33	2.15e-30	-0.65	-0.52	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
THCA	cis	rs9928842	0.823	rs2870472	ENSG00000280152.1	RP11-331F4.5	13.1	1.27e-33	2.16e-30	0.73	0.52	Alcoholic chronic pancreatitis;	chr16:75244943	chr16:75245994~75250077:-
THCA	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	13.09	1.28e-33	2.17e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
THCA	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-13.09	1.3e-33	2.2e-30	-0.61	-0.52	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
THCA	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-13.09	1.31e-33	2.22e-30	-0.52	-0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	13.09	1.31e-33	2.22e-30	0.52	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
THCA	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	13.09	1.31e-33	2.22e-30	0.54	0.52	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
THCA	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	13.09	1.31e-33	2.22e-30	0.89	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	13.09	1.31e-33	2.22e-30	0.89	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
THCA	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	13.09	1.32e-33	2.23e-30	0.66	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
THCA	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	13.09	1.32e-33	2.24e-30	0.42	0.52	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
THCA	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	13.09	1.33e-33	2.25e-30	0.75	0.52	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
THCA	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	13.09	1.33e-33	2.25e-30	0.51	0.52	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
THCA	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	13.09	1.34e-33	2.27e-30	0.76	0.52	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	13.09	1.34e-33	2.28e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	13.09	1.34e-33	2.28e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	13.09	1.36e-33	2.3e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
THCA	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-13.09	1.36e-33	2.3e-30	-0.64	-0.52	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
THCA	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	13.09	1.37e-33	2.33e-30	0.48	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-13.09	1.39e-33	2.36e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
THCA	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	13.08	1.42e-33	2.4e-30	0.8	0.52	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-13.08	1.44e-33	2.44e-30	-0.67	-0.52	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
THCA	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-13.08	1.45e-33	2.45e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
THCA	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-13.08	1.45e-33	2.46e-30	-0.51	-0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
THCA	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-13.08	1.5e-33	2.53e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-13.08	1.51e-33	2.54e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-13.08	1.51e-33	2.54e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-13.08	1.51e-33	2.56e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	13.08	1.52e-33	2.56e-30	0.47	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	13.08	1.52e-33	2.56e-30	0.47	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
THCA	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	13.08	1.52e-33	2.56e-30	0.61	0.52	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
THCA	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	13.08	1.52e-33	2.58e-30	0.42	0.52	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
THCA	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-13.08	1.53e-33	2.58e-30	-0.52	-0.52	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
THCA	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-13.08	1.53e-33	2.58e-30	-0.52	-0.52	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
THCA	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-13.07	1.55e-33	2.61e-30	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-13.07	1.55e-33	2.61e-30	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
THCA	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	13.07	1.56e-33	2.64e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
THCA	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-13.07	1.56e-33	2.64e-30	-0.65	-0.52	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
THCA	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-13.07	1.59e-33	2.68e-30	-0.54	-0.52	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
THCA	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	13.07	1.59e-33	2.68e-30	0.63	0.52	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
THCA	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-13.07	1.59e-33	2.69e-30	-0.78	-0.52	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
THCA	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	13.07	1.63e-33	2.75e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	13.07	1.63e-33	2.75e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
THCA	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	13.07	1.65e-33	2.78e-30	0.76	0.52	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-13.07	1.65e-33	2.79e-30	-0.65	-0.52	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
THCA	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	13.07	1.66e-33	2.81e-30	0.65	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
THCA	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-13.07	1.67e-33	2.82e-30	-0.59	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
THCA	cis	rs9525916	0.967	rs9533775	ENSG00000227258.4	SMIM2-AS1	-13.07	1.68e-33	2.83e-30	-0.53	-0.52	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44110451~44240517:+
THCA	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	13.07	1.69e-33	2.84e-30	0.64	0.52	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	13.07	1.69e-33	2.84e-30	0.64	0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
THCA	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	13.06	1.7e-33	2.87e-30	0.62	0.52	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
THCA	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-13.06	1.74e-33	2.93e-30	-0.46	-0.52	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-13.06	1.74e-33	2.93e-30	-0.46	-0.52	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
THCA	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-13.06	1.75e-33	2.95e-30	-0.61	-0.52	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
THCA	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-13.06	1.75e-33	2.95e-30	-0.57	-0.52	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
THCA	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-13.06	1.77e-33	2.99e-30	-0.63	-0.52	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
THCA	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	13.06	1.78e-33	3e-30	0.75	0.52	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
THCA	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	13.06	1.78e-33	3e-30	0.93	0.52	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
THCA	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	13.06	1.79e-33	3.02e-30	0.74	0.52	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	13.06	1.79e-33	3.02e-30	0.74	0.52	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	13.06	1.79e-33	3.02e-30	0.74	0.52	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
THCA	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	13.06	1.8e-33	3.04e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
THCA	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	13.06	1.81e-33	3.05e-30	0.58	0.52	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
THCA	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-13.06	1.85e-33	3.11e-30	-0.78	-0.52	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
THCA	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	13.06	1.85e-33	3.12e-30	0.8	0.52	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
THCA	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-13.06	1.86e-33	3.13e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
THCA	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
THCA	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-13.06	1.87e-33	3.15e-30	-0.66	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	13.05	1.89e-33	3.17e-30	0.61	0.52	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
THCA	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-13.05	1.89e-33	3.17e-30	-0.74	-0.52	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
THCA	cis	rs8062405	0.728	rs11642449	ENSG00000259982.1	CDC37P1	13.05	1.89e-33	3.18e-30	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28700294~28701540:-
THCA	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-13.05	1.89e-33	3.18e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
THCA	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-13.05	1.9e-33	3.19e-30	-0.61	-0.52	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
THCA	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	13.05	1.9e-33	3.2e-30	0.42	0.52	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	13.05	1.9e-33	3.2e-30	0.42	0.52	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	13.05	1.9e-33	3.2e-30	0.42	0.52	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
THCA	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
THCA	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-13.05	1.91e-33	3.22e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
THCA	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-13.05	1.91e-33	3.22e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
THCA	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	13.05	1.92e-33	3.22e-30	0.64	0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
THCA	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	13.05	1.93e-33	3.24e-30	0.53	0.52	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
THCA	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-13.05	1.98e-33	3.32e-30	-0.97	-0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
THCA	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	13.05	2e-33	3.35e-30	0.58	0.52	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
THCA	cis	rs6519955	0.86	rs8136098	ENSG00000231711.2	LINC00899	13.05	2.01e-33	3.37e-30	0.44	0.52	Dupuytren's disease;	chr22:46029766	chr22:46039907~46044853:-
THCA	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	13.05	2.04e-33	3.42e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
THCA	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-13.04	2.07e-33	3.47e-30	-0.62	-0.52	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
THCA	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	13.04	2.08e-33	3.48e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	13.04	2.08e-33	3.48e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
THCA	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-13.04	2.08e-33	3.49e-30	-0.75	-0.52	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	13.04	2.09e-33	3.51e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	13.04	2.09e-33	3.51e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
THCA	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	13.04	2.1e-33	3.52e-30	0.57	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
THCA	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	13.04	2.11e-33	3.53e-30	0.62	0.52	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
THCA	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-13.04	2.22e-33	3.71e-30	-0.55	-0.52	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
THCA	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	13.04	2.23e-33	3.74e-30	0.54	0.52	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
THCA	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	13.04	2.24e-33	3.74e-30	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
THCA	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	13.04	2.24e-33	3.75e-30	0.65	0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
THCA	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-13.03	2.29e-33	3.82e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
THCA	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-13.03	2.31e-33	3.87e-30	-0.62	-0.52	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
THCA	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	13.03	2.32e-33	3.88e-30	0.6	0.52	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
THCA	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	13.03	2.33e-33	3.9e-30	0.53	0.52	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
THCA	cis	rs9928842	0.722	rs1035540	ENSG00000280152.1	RP11-331F4.5	13.03	2.35e-33	3.92e-30	0.72	0.52	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75245994~75250077:-
THCA	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	13.03	2.4e-33	4.02e-30	0.62	0.52	Height;	chr11:118764443	chr11:118688039~118690600:-
THCA	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-13.03	2.4e-33	4.02e-30	-0.64	-0.52	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
THCA	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	13.03	2.42e-33	4.04e-30	0.62	0.52	Height;	chr3:53073584	chr3:53064283~53065091:-
THCA	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	13.03	2.44e-33	4.07e-30	0.53	0.52	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
THCA	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-13.03	2.44e-33	4.08e-30	-0.64	-0.52	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
THCA	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	13.03	2.45e-33	4.08e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	13.03	2.45e-33	4.08e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
THCA	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-13.03	2.46e-33	4.11e-30	-0.65	-0.52	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
THCA	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	13.03	2.47e-33	4.13e-30	0.61	0.52	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
THCA	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	13.03	2.49e-33	4.16e-30	0.93	0.52	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
THCA	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	13.02	2.52e-33	4.21e-30	0.62	0.51	Height;	chr11:118773873	chr11:118688039~118690600:-
THCA	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	13.02	2.53e-33	4.22e-30	0.51	0.51	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
THCA	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-13.02	2.53e-33	4.23e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
THCA	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	13.02	2.55e-33	4.25e-30	0.54	0.51	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
THCA	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-13.02	2.55e-33	4.25e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
THCA	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	13.02	2.58e-33	4.3e-30	0.65	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
THCA	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	13.02	2.6e-33	4.34e-30	0.54	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
THCA	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	13.02	2.6e-33	4.34e-30	0.65	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
THCA	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-13.02	2.69e-33	4.48e-30	-0.5	-0.51	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	13.02	2.73e-33	4.55e-30	0.67	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
THCA	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-13.02	2.74e-33	4.57e-30	-0.69	-0.51	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
THCA	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	13.02	2.74e-33	4.57e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
THCA	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-13.01	2.76e-33	4.6e-30	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
THCA	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	13.01	2.85e-33	4.75e-30	0.54	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
THCA	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-13.01	2.87e-33	4.78e-30	-0.41	-0.51	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-13.01	2.87e-33	4.78e-30	-0.41	-0.51	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
THCA	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-13.01	2.91e-33	4.83e-30	-0.64	-0.51	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
THCA	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	13.01	2.92e-33	4.86e-30	0.61	0.51	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
THCA	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-13.01	2.95e-33	4.9e-30	-0.48	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
THCA	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	13.01	2.97e-33	4.94e-30	0.65	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
THCA	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-13.01	2.99e-33	4.97e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
THCA	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	13.01	3.03e-33	5.03e-30	0.54	0.51	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
THCA	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-13	3.03e-33	5.04e-30	-0.88	-0.51	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
THCA	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	13	3.05e-33	5.08e-30	0.67	0.51	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	13	3.05e-33	5.08e-30	0.67	0.51	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
THCA	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	13	3.09e-33	5.14e-30	0.74	0.51	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
THCA	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	13	3.13e-33	5.2e-30	0.4	0.51	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
THCA	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	13	3.15e-33	5.23e-30	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
THCA	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	13	3.25e-33	5.4e-30	0.65	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	13	3.25e-33	5.4e-30	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
THCA	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-13	3.32e-33	5.5e-30	-0.46	-0.51	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
THCA	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	13	3.32e-33	5.51e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
THCA	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-12.99	3.36e-33	5.57e-30	-0.65	-0.51	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-12.99	3.36e-33	5.57e-30	-0.65	-0.51	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-12.99	3.36e-33	5.57e-30	-0.65	-0.51	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-12.99	3.36e-33	5.57e-30	-0.65	-0.51	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
THCA	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	12.99	3.37e-33	5.58e-30	0.55	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	12.99	3.37e-33	5.58e-30	0.55	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
THCA	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	12.99	3.41e-33	5.66e-30	0.62	0.51	Height;	chr11:118760944	chr11:118688039~118690600:-
THCA	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	12.99	3.42e-33	5.68e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
THCA	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-12.99	3.43e-33	5.69e-30	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-12.99	3.46e-33	5.73e-30	-0.61	-0.51	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
THCA	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	12.99	3.47e-33	5.76e-30	0.67	0.51	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
THCA	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	12.99	3.49e-33	5.79e-30	0.49	0.51	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
THCA	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	12.99	3.54e-33	5.86e-30	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
THCA	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	12.99	3.54e-33	5.87e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
THCA	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-12.99	3.55e-33	5.88e-30	-0.45	-0.51	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-12.99	3.56e-33	5.89e-30	-0.46	-0.51	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
THCA	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	12.99	3.56e-33	5.9e-30	0.93	0.51	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
THCA	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	12.99	3.59e-33	5.95e-30	0.41	0.51	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
THCA	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	12.99	3.63e-33	6.01e-30	0.77	0.51	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
THCA	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	12.99	3.66e-33	6.06e-30	0.66	0.51	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
THCA	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	12.98	3.69e-33	6.11e-30	0.46	0.51	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
THCA	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	12.98	3.74e-33	6.19e-30	0.66	0.51	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
THCA	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	12.98	3.76e-33	6.22e-30	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
THCA	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	12.98	3.77e-33	6.25e-30	0.8	0.51	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
THCA	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	12.98	3.8e-33	6.29e-30	0.67	0.51	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
THCA	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	12.98	3.82e-33	6.32e-30	0.6	0.51	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
THCA	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-12.98	3.82e-33	6.33e-30	-0.64	-0.51	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
THCA	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-12.98	3.84e-33	6.35e-30	-0.46	-0.51	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
THCA	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-12.98	3.84e-33	6.36e-30	-0.4	-0.51	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
THCA	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	12.98	3.97e-33	6.56e-30	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	12.97	4.05e-33	6.69e-30	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
THCA	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	12.97	4.08e-33	6.75e-30	0.92	0.51	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
THCA	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-12.97	4.1e-33	6.78e-30	-0.52	-0.51	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
THCA	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	12.97	4.12e-33	6.81e-30	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
THCA	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	12.97	4.18e-33	6.9e-30	0.85	0.51	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	12.97	4.18e-33	6.9e-30	0.85	0.51	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
THCA	cis	rs934734	0.532	rs6752053	ENSG00000204929.10	AC074391.1	-12.97	4.22e-33	6.96e-30	-0.61	-0.51	Rheumatoid arthritis;	chr2:65439540	chr2:65436711~66084639:+
THCA	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	12.97	4.23e-33	6.99e-30	0.6	0.51	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
THCA	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	12.97	4.24e-33	7.01e-30	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
THCA	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	12.97	4.35e-33	7.18e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	12.97	4.35e-33	7.18e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
THCA	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	12.96	4.46e-33	7.36e-30	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
THCA	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	12.96	4.53e-33	7.46e-30	0.58	0.51	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
THCA	cis	rs9928842	0.823	rs4888365	ENSG00000280152.1	RP11-331F4.5	12.96	4.56e-33	7.52e-30	0.73	0.51	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75245994~75250077:-
THCA	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	12.96	4.6e-33	7.58e-30	0.54	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
THCA	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	12.96	4.6e-33	7.58e-30	0.74	0.51	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
THCA	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	12.96	4.65e-33	7.66e-30	0.65	0.51	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
THCA	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	12.96	4.66e-33	7.68e-30	0.94	0.51	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
THCA	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	12.96	4.67e-33	7.7e-30	0.78	0.51	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
THCA	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-12.96	4.69e-33	7.73e-30	-0.65	-0.51	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
THCA	cis	rs9890032	0.509	rs11656986	ENSG00000266490.1	CTD-2349P21.9	12.96	4.78e-33	7.87e-30	0.51	0.51	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30792372~30792833:+
THCA	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	12.96	4.79e-33	7.89e-30	0.59	0.51	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
THCA	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	12.96	4.8e-33	7.91e-30	0.53	0.51	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
THCA	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	12.96	4.8e-33	7.91e-30	0.53	0.51	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
THCA	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	12.96	4.87e-33	8.02e-30	0.64	0.51	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
THCA	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-12.96	4.89e-33	8.05e-30	-0.64	-0.51	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
THCA	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	12.95	4.93e-33	8.11e-30	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
THCA	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	12.95	4.97e-33	8.18e-30	0.75	0.51	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	12.95	4.97e-33	8.18e-30	0.75	0.51	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	12.95	4.97e-33	8.18e-30	0.75	0.51	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
THCA	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-12.95	5.02e-33	8.26e-30	-0.62	-0.51	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
THCA	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	12.95	5.05e-33	8.31e-30	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
THCA	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-12.95	5.07e-33	8.34e-30	-0.52	-0.51	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
THCA	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	12.95	5.08e-33	8.35e-30	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
THCA	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	12.95	5.14e-33	8.45e-30	0.54	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
THCA	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	12.95	5.15e-33	8.46e-30	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
THCA	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	12.95	5.17e-33	8.5e-30	0.63	0.51	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
THCA	cis	rs934734	0.532	rs7569113	ENSG00000204929.10	AC074391.1	12.95	5.18e-33	8.52e-30	0.62	0.51	Rheumatoid arthritis;	chr2:65429907	chr2:65436711~66084639:+
THCA	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-12.95	5.22e-33	8.57e-30	-0.52	-0.51	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
THCA	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-12.95	5.23e-33	8.59e-30	-0.52	-0.51	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
THCA	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
THCA	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	12.95	5.32e-33	8.73e-30	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
THCA	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	12.95	5.38e-33	8.83e-30	0.63	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
THCA	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-12.94	5.43e-33	8.91e-30	-0.63	-0.51	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
THCA	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-12.94	5.43e-33	8.91e-30	-0.63	-0.51	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
THCA	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	12.94	5.5e-33	9.02e-30	0.68	0.51	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
THCA	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	12.94	5.73e-33	9.39e-30	0.74	0.51	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
THCA	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	12.94	5.74e-33	9.41e-30	0.68	0.51	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
THCA	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	12.94	5.76e-33	9.44e-30	0.66	0.51	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
THCA	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	12.94	5.79e-33	9.49e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
THCA	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	12.94	5.81e-33	9.52e-30	0.59	0.51	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
THCA	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-12.94	5.81e-33	9.52e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
THCA	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	12.94	5.84e-33	9.58e-30	0.63	0.51	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
THCA	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	12.94	5.84e-33	9.58e-30	0.63	0.51	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
THCA	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-12.94	5.87e-33	9.62e-30	-0.45	-0.51	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
THCA	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	12.93	5.96e-33	9.76e-30	0.49	0.51	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
THCA	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
THCA	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-12.93	6.07e-33	9.95e-30	-0.7	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
THCA	cis	rs587080	0.624	rs674485	ENSG00000245532.5	NEAT1	-12.93	6.08e-33	9.95e-30	-0.38	-0.51	Plateletcrit;	chr11:65429922	chr11:65422774~65445540:+
THCA	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	12.93	6.18e-33	1.01e-29	0.68	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
THCA	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-12.93	6.21e-33	1.02e-29	-0.63	-0.51	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-12.93	6.21e-33	1.02e-29	-0.63	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
THCA	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-12.93	6.22e-33	1.02e-29	-0.6	-0.51	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
THCA	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	12.93	6.23e-33	1.02e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	12.93	6.23e-33	1.02e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
THCA	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-12.93	6.23e-33	1.02e-29	-0.68	-0.51	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
THCA	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	12.93	6.33e-33	1.03e-29	0.75	0.51	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
THCA	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	12.93	6.43e-33	1.05e-29	0.72	0.51	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
THCA	cis	rs10853057	0.541	rs8082708	ENSG00000214174.7	AMZ2P1	-12.92	6.69e-33	1.09e-29	-0.78	-0.51	White matter microstructure (global fractional anisotropy);	chr17:65046182	chr17:64966550~64975576:-
THCA	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	12.92	6.72e-33	1.1e-29	0.78	0.51	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
THCA	cis	rs7829975	0.511	rs2980512	ENSG00000253893.2	FAM85B	-12.92	6.77e-33	1.11e-29	-0.65	-0.51	Mood instability;	chr8:8283379	chr8:8167819~8226614:-
THCA	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	12.92	6.87e-33	1.12e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
THCA	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-12.92	6.87e-33	1.12e-29	-0.7	-0.51	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
THCA	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	12.92	6.99e-33	1.14e-29	0.58	0.51	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
THCA	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	12.92	7.03e-33	1.15e-29	0.62	0.51	Height;	chr11:118749988	chr11:118688039~118690600:-
THCA	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	12.92	7.06e-33	1.15e-29	0.74	0.51	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	12.92	7.17e-33	1.17e-29	0.74	0.51	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
THCA	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-12.91	7.22e-33	1.18e-29	-0.54	-0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
THCA	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	12.91	7.22e-33	1.18e-29	0.58	0.51	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	12.91	7.23e-33	1.18e-29	0.59	0.51	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
THCA	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	12.91	7.25e-33	1.18e-29	0.68	0.51	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
THCA	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	12.91	7.43e-33	1.21e-29	0.79	0.51	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
THCA	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	12.91	7.56e-33	1.23e-29	0.54	0.51	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
THCA	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	12.91	7.64e-33	1.24e-29	0.67	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
THCA	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-12.91	7.64e-33	1.24e-29	-0.45	-0.51	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
THCA	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-12.91	7.65e-33	1.25e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
THCA	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-12.91	7.67e-33	1.25e-29	-0.63	-0.51	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-12.91	7.67e-33	1.25e-29	-0.63	-0.51	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-12.91	7.67e-33	1.25e-29	-0.63	-0.51	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
THCA	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	12.91	7.7e-33	1.25e-29	0.6	0.51	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
THCA	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-12.91	7.71e-33	1.25e-29	-0.83	-0.51	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
THCA	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-12.91	7.75e-33	1.26e-29	-0.64	-0.51	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
THCA	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-12.91	7.75e-33	1.26e-29	-0.64	-0.51	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
THCA	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-12.91	7.81e-33	1.27e-29	-0.89	-0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
THCA	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-12.91	7.88e-33	1.28e-29	-0.63	-0.51	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
THCA	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	12.91	7.9e-33	1.28e-29	0.75	0.51	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
THCA	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	12.9	7.97e-33	1.3e-29	0.47	0.51	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
THCA	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	12.9	8.16e-33	1.33e-29	0.49	0.51	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
THCA	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-12.9	8.22e-33	1.34e-29	-0.65	-0.51	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-12.9	8.22e-33	1.34e-29	-0.65	-0.51	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
THCA	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	12.9	8.33e-33	1.35e-29	0.61	0.51	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
THCA	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	12.9	8.34e-33	1.36e-29	0.76	0.51	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
THCA	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	12.9	8.36e-33	1.36e-29	0.93	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
THCA	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-12.9	8.56e-33	1.39e-29	-0.63	-0.51	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-12.9	8.56e-33	1.39e-29	-0.63	-0.51	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-12.9	8.56e-33	1.39e-29	-0.63	-0.51	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-12.9	8.56e-33	1.39e-29	-0.63	-0.51	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
THCA	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	12.9	8.58e-33	1.39e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	12.9	8.58e-33	1.39e-29	0.49	0.51	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
THCA	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	12.9	8.58e-33	1.39e-29	0.61	0.51	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
THCA	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	12.9	8.61e-33	1.4e-29	0.64	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
THCA	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-12.9	8.64e-33	1.4e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
THCA	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	12.89	9.01e-33	1.46e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
THCA	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	12.89	9.38e-33	1.52e-29	0.48	0.51	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
THCA	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-12.89	9.39e-33	1.52e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
THCA	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-12.89	9.4e-33	1.52e-29	-0.61	-0.51	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
THCA	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-12.89	9.41e-33	1.52e-29	-0.51	-0.51	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
THCA	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	12.89	9.44e-33	1.53e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	12.89	9.44e-33	1.53e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
THCA	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	12.89	9.44e-33	1.53e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	12.89	9.44e-33	1.53e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
THCA	cis	rs9928842	0.823	rs6564243	ENSG00000280152.1	RP11-331F4.5	12.89	9.53e-33	1.54e-29	0.72	0.51	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75245994~75250077:-
THCA	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	12.89	9.54e-33	1.54e-29	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
THCA	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	12.88	9.62e-33	1.56e-29	0.52	0.51	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
THCA	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-12.88	9.64e-33	1.56e-29	-0.45	-0.51	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
THCA	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	12.88	9.75e-33	1.58e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	12.88	9.76e-33	1.58e-29	0.48	0.51	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000204929.10	AC074391.1	-12.88	9.78e-33	1.58e-29	-0.62	-0.51	Rheumatoid arthritis;	chr2:65427878	chr2:65436711~66084639:+
THCA	cis	rs934734	0.532	rs2028151	ENSG00000204929.10	AC074391.1	-12.88	9.78e-33	1.58e-29	-0.62	-0.51	Rheumatoid arthritis;	chr2:65428479	chr2:65436711~66084639:+
THCA	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	12.88	9.83e-33	1.59e-29	0.47	0.51	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
THCA	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	12.88	9.92e-33	1.61e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	12.88	9.92e-33	1.61e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
THCA	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	12.88	9.94e-33	1.61e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	12.88	1e-32	1.62e-29	0.48	0.51	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
THCA	cis	rs587080	0.654	rs595366	ENSG00000245532.5	NEAT1	-12.88	1e-32	1.62e-29	-0.38	-0.51	Plateletcrit;	chr11:65429460	chr11:65422774~65445540:+
THCA	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-12.88	1.01e-32	1.63e-29	-0.4	-0.51	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-12.88	1.01e-32	1.63e-29	-0.4	-0.51	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-12.88	1.03e-32	1.66e-29	-0.38	-0.51	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	12.88	1.03e-32	1.66e-29	0.41	0.51	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
THCA	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-12.88	1.03e-32	1.67e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
THCA	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	12.88	1.04e-32	1.67e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	12.88	1.04e-32	1.67e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	12.88	1.04e-32	1.69e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-12.88	1.05e-32	1.69e-29	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-12.88	1.05e-32	1.69e-29	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
THCA	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	12.88	1.05e-32	1.7e-29	0.76	0.51	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
THCA	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
THCA	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	12.87	1.06e-32	1.71e-29	0.73	0.51	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
THCA	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	12.87	1.06e-32	1.71e-29	0.53	0.51	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
THCA	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	12.87	1.06e-32	1.71e-29	0.38	0.51	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	12.87	1.06e-32	1.71e-29	0.38	0.51	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	12.87	1.06e-32	1.71e-29	0.38	0.51	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
THCA	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	12.87	1.06e-32	1.72e-29	0.48	0.51	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
THCA	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
THCA	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	12.87	1.08e-32	1.74e-29	0.54	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
THCA	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	12.87	1.08e-32	1.74e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	12.87	1.08e-32	1.74e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	12.87	1.08e-32	1.74e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
THCA	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
THCA	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-12.87	1.12e-32	1.8e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
THCA	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	12.87	1.12e-32	1.8e-29	0.74	0.51	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
THCA	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	12.87	1.13e-32	1.82e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-12.87	1.15e-32	1.85e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
THCA	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	12.87	1.15e-32	1.85e-29	0.62	0.51	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
THCA	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	12.86	1.17e-32	1.88e-29	0.62	0.51	Height;	chr11:118761813	chr11:118688039~118690600:-
THCA	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	12.86	1.17e-32	1.88e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
THCA	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	12.86	1.18e-32	1.9e-29	0.67	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
THCA	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	12.86	1.18e-32	1.9e-29	0.52	0.51	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
THCA	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-12.86	1.19e-32	1.92e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
THCA	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
THCA	cis	rs7576126	1	rs7576126	ENSG00000204929.10	AC074391.1	-12.86	1.2e-32	1.92e-29	-0.61	-0.51	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65436711~66084639:+
THCA	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	12.86	1.2e-32	1.93e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
THCA	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	12.86	1.22e-32	1.95e-29	0.63	0.51	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	12.86	1.22e-32	1.96e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
THCA	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	12.86	1.23e-32	1.97e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
THCA	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-12.86	1.23e-32	1.98e-29	-0.65	-0.51	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
THCA	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	12.86	1.24e-32	1.99e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	12.86	1.24e-32	1.99e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
THCA	cis	rs934734	0.673	rs754110	ENSG00000204929.10	AC074391.1	12.86	1.25e-32	2e-29	0.61	0.51	Rheumatoid arthritis;	chr2:65464626	chr2:65436711~66084639:+
THCA	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-12.86	1.26e-32	2.03e-29	-0.45	-0.51	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
THCA	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	12.85	1.3e-32	2.09e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
THCA	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	12.85	1.3e-32	2.09e-29	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
THCA	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	12.85	1.33e-32	2.13e-29	0.62	0.51	Height;	chr11:118737823	chr11:118688039~118690600:-
THCA	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	12.85	1.34e-32	2.15e-29	0.74	0.51	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
THCA	cis	rs934734	0.532	rs7569257	ENSG00000204929.10	AC074391.1	-12.85	1.34e-32	2.15e-29	-0.62	-0.51	Rheumatoid arthritis;	chr2:65429842	chr2:65436711~66084639:+
THCA	cis	rs2288884	0.515	rs9676397	ENSG00000275055.1	CTC-471J1.11	-12.85	1.35e-32	2.16e-29	-0.39	-0.51	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52076750	chr19:52049007~52049754:+
THCA	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-12.85	1.35e-32	2.16e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
THCA	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	12.85	1.37e-32	2.2e-29	0.52	0.51	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
THCA	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	12.85	1.4e-32	2.24e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
THCA	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-12.84	1.42e-32	2.27e-29	-0.67	-0.51	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
THCA	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-12.84	1.42e-32	2.27e-29	-0.67	-0.51	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
THCA	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-12.84	1.44e-32	2.3e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-12.84	1.44e-32	2.3e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-12.84	1.47e-32	2.35e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
THCA	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	12.84	1.48e-32	2.37e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
THCA	cis	rs934734	0.532	rs10184881	ENSG00000204929.10	AC074391.1	-12.84	1.48e-32	2.37e-29	-0.61	-0.51	Rheumatoid arthritis;	chr2:65457018	chr2:65436711~66084639:+
THCA	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	12.84	1.5e-32	2.4e-29	0.6	0.51	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-12.84	1.52e-32	2.43e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.66	rs56131703	ENSG00000163016.8	ALMS1P	12.84	1.53e-32	2.45e-29	0.9	0.51	Metabolite levels;	chr2:73620133	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	12.84	1.53e-32	2.45e-29	0.62	0.51	Height;	chr11:118737916	chr11:118688039~118690600:-
THCA	cis	rs6496932	0.802	rs6497006	ENSG00000218052.5	ADAMTS7P4	12.84	1.55e-32	2.47e-29	0.66	0.51	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85255369~85330334:-
THCA	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-12.83	1.56e-32	2.49e-29	-0.67	-0.51	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
THCA	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-12.83	1.56e-32	2.5e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-12.83	1.56e-32	2.5e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-12.83	1.56e-32	2.5e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	12.83	1.57e-32	2.5e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	12.83	1.58e-32	2.51e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	12.83	1.58e-32	2.51e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	12.83	1.58e-32	2.51e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	12.83	1.58e-32	2.51e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
THCA	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	12.83	1.59e-32	2.53e-29	0.94	0.51	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
THCA	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	12.83	1.59e-32	2.53e-29	0.77	0.51	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
THCA	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	12.83	1.59e-32	2.54e-29	0.85	0.51	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
THCA	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-12.83	1.6e-32	2.56e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-12.83	1.6e-32	2.56e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-12.83	1.6e-32	2.56e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-12.83	1.64e-32	2.62e-29	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
THCA	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-12.83	1.65e-32	2.64e-29	-0.37	-0.51	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
THCA	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-12.83	1.66e-32	2.64e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
THCA	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	12.83	1.66e-32	2.64e-29	0.6	0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
THCA	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-12.83	1.66e-32	2.64e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
THCA	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	12.83	1.67e-32	2.67e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	12.83	1.67e-32	2.67e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
THCA	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-12.83	1.69e-32	2.69e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
THCA	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	12.82	1.73e-32	2.75e-29	0.62	0.51	Height;	chr11:118746590	chr11:118688039~118690600:-
THCA	cis	rs8062405	0.728	rs8056890	ENSG00000259982.1	CDC37P1	12.82	1.73e-32	2.75e-29	0.64	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28700294~28701540:-
THCA	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-12.82	1.75e-32	2.79e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
THCA	cis	rs9309473	0.95	rs13391258	ENSG00000163016.8	ALMS1P	12.82	1.76e-32	2.8e-29	0.76	0.51	Metabolite levels;	chr2:73621806	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs6546861	ENSG00000163016.8	ALMS1P	12.82	1.76e-32	2.8e-29	0.76	0.51	Metabolite levels;	chr2:73622734	chr2:73644919~73685576:+
THCA	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-12.82	1.78e-32	2.84e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
THCA	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-12.82	1.8e-32	2.87e-29	-0.72	-0.51	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
THCA	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
THCA	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
THCA	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
THCA	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
THCA	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
THCA	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
THCA	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	12.82	1.83e-32	2.91e-29	0.59	0.51	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
THCA	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-12.82	1.85e-32	2.93e-29	-0.39	-0.51	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
THCA	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-12.82	1.85e-32	2.94e-29	-0.52	-0.51	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
THCA	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	12.82	1.86e-32	2.95e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	12.82	1.86e-32	2.95e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	12.82	1.86e-32	2.95e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	12.82	1.86e-32	2.95e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
THCA	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	12.81	1.88e-32	2.99e-29	0.46	0.51	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
THCA	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	12.81	1.89e-32	3e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	12.81	1.89e-32	3e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	12.81	1.89e-32	3e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
THCA	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	12.81	1.92e-32	3.05e-29	0.56	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
THCA	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-12.81	1.92e-32	3.05e-29	-0.64	-0.51	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
THCA	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	12.81	1.93e-32	3.07e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	12.81	1.96e-32	3.1e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
THCA	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-12.81	1.99e-32	3.16e-29	-0.54	-0.51	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
THCA	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	12.81	2e-32	3.18e-29	0.49	0.51	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
THCA	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	12.81	2.01e-32	3.18e-29	0.61	0.51	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
THCA	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	12.8	2.07e-32	3.28e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	12.8	2.07e-32	3.28e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
THCA	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	12.8	2.08e-32	3.3e-29	0.62	0.51	Height;	chr11:118747911	chr11:118688039~118690600:-
THCA	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-12.8	2.08e-32	3.3e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-12.8	2.08e-32	3.3e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-12.8	2.1e-32	3.33e-29	-0.5	-0.51	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-12.8	2.1e-32	3.33e-29	-0.5	-0.51	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-12.8	2.1e-32	3.33e-29	-0.5	-0.51	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
THCA	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-12.8	2.1e-32	3.33e-29	-0.75	-0.51	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
THCA	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-12.8	2.1e-32	3.33e-29	-0.62	-0.51	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
THCA	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	12.8	2.13e-32	3.37e-29	0.66	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
THCA	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-12.8	2.19e-32	3.47e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
THCA	cis	rs9309473	0.95	rs6711001	ENSG00000163016.8	ALMS1P	12.8	2.22e-32	3.51e-29	0.76	0.51	Metabolite levels;	chr2:73623693	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	12.8	2.24e-32	3.54e-29	0.73	0.51	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	12.8	2.24e-32	3.54e-29	0.73	0.51	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
THCA	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	12.8	2.25e-32	3.55e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	12.8	2.25e-32	3.55e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
THCA	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	12.8	2.25e-32	3.56e-29	0.67	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
THCA	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-12.79	2.27e-32	3.59e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
THCA	cis	rs9928842	0.77	rs8048371	ENSG00000280152.1	RP11-331F4.5	12.79	2.28e-32	3.61e-29	0.73	0.51	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75245994~75250077:-
THCA	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-12.79	2.31e-32	3.65e-29	-0.64	-0.51	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
THCA	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-12.79	2.32e-32	3.66e-29	-0.64	-0.51	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
THCA	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	12.79	2.32e-32	3.67e-29	0.46	0.51	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
THCA	cis	rs7829975	0.539	rs35571782	ENSG00000253893.2	FAM85B	-12.79	2.33e-32	3.68e-29	-0.65	-0.51	Mood instability;	chr8:8284301	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	12.79	2.33e-32	3.68e-29	0.7	0.51	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
THCA	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	12.79	2.34e-32	3.7e-29	0.67	0.51	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	12.79	2.35e-32	3.72e-29	0.73	0.51	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	12.79	2.35e-32	3.72e-29	0.73	0.51	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	12.79	2.36e-32	3.73e-29	0.61	0.51	Height;	chr11:118742526	chr11:118688039~118690600:-
THCA	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-12.79	2.37e-32	3.74e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
THCA	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-12.79	2.37e-32	3.74e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
THCA	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	12.79	2.37e-32	3.74e-29	0.6	0.51	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
THCA	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	12.79	2.37e-32	3.74e-29	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
THCA	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	12.79	2.38e-32	3.76e-29	0.61	0.51	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	12.79	2.38e-32	3.77e-29	0.65	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
THCA	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-12.79	2.4e-32	3.79e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
THCA	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-12.79	2.4e-32	3.8e-29	-0.77	-0.51	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
THCA	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-12.79	2.45e-32	3.87e-29	-0.62	-0.51	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
THCA	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	12.79	2.46e-32	3.89e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
THCA	cis	rs934734	0.673	rs7575614	ENSG00000204929.10	AC074391.1	12.79	2.46e-32	3.89e-29	0.6	0.51	Rheumatoid arthritis;	chr2:65462666	chr2:65436711~66084639:+
THCA	cis	rs934734	0.673	rs6742215	ENSG00000204929.10	AC074391.1	12.79	2.46e-32	3.89e-29	0.6	0.51	Rheumatoid arthritis;	chr2:65463362	chr2:65436711~66084639:+
THCA	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	12.78	2.51e-32	3.96e-29	0.74	0.51	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	12.78	2.51e-32	3.97e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
THCA	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	12.78	2.54e-32	4e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	12.78	2.54e-32	4e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	12.78	2.54e-32	4e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
THCA	cis	rs934734	0.532	rs6546151	ENSG00000204929.10	AC074391.1	-12.78	2.54e-32	4.01e-29	-0.61	-0.51	Rheumatoid arthritis;	chr2:65449449	chr2:65436711~66084639:+
THCA	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	12.78	2.61e-32	4.12e-29	0.59	0.51	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
THCA	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	12.78	2.63e-32	4.15e-29	0.66	0.51	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
THCA	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	12.78	2.63e-32	4.15e-29	0.61	0.51	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
THCA	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	12.78	2.63e-32	4.15e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
THCA	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	12.78	2.63e-32	4.15e-29	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	12.78	2.63e-32	4.15e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	12.78	2.64e-32	4.16e-29	0.58	0.51	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	12.78	2.64e-32	4.17e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
THCA	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	12.78	2.64e-32	4.17e-29	0.62	0.51	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
THCA	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	12.78	2.68e-32	4.23e-29	0.7	0.51	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
THCA	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	12.78	2.7e-32	4.25e-29	0.73	0.51	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
THCA	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	12.78	2.73e-32	4.3e-29	0.56	0.51	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	12.78	2.73e-32	4.31e-29	0.6	0.51	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
THCA	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	12.78	2.74e-32	4.31e-29	0.38	0.51	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-12.77	2.79e-32	4.39e-29	-0.62	-0.51	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
THCA	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	12.77	2.81e-32	4.43e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
THCA	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-12.77	2.86e-32	4.51e-29	-0.72	-0.51	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
THCA	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-12.77	2.86e-32	4.51e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-12.77	2.86e-32	4.51e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-12.77	2.86e-32	4.51e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-12.77	2.86e-32	4.51e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
THCA	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	12.77	2.87e-32	4.51e-29	0.93	0.51	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-12.77	2.87e-32	4.52e-29	-0.51	-0.51	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	12.77	2.89e-32	4.55e-29	0.59	0.51	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
THCA	cis	rs7188445	0.688	rs4889015	ENSG00000261390.4	RP11-345M22.2	12.77	2.9e-32	4.56e-29	0.6	0.51	Urate levels;	chr16:79684833	chr16:79715232~79770563:-
THCA	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-12.77	2.91e-32	4.57e-29	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
THCA	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	12.77	2.91e-32	4.58e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
THCA	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	12.77	3e-32	4.72e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
THCA	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	12.77	3.01e-32	4.74e-29	0.66	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
THCA	cis	rs6683071	0.601	rs3002129	ENSG00000272750.1	RP11-378J18.8	12.76	3.05e-32	4.79e-29	0.62	0.51	Cognitive performance;	chr1:222681993	chr1:222658867~222661512:-
THCA	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	12.76	3.05e-32	4.79e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	12.76	3.05e-32	4.79e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	12.76	3.05e-32	4.79e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
THCA	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-12.76	3.05e-32	4.8e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
THCA	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-12.76	3.07e-32	4.82e-29	-0.62	-0.51	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
THCA	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	12.76	3.07e-32	4.83e-29	0.62	0.51	Height;	chr3:53085313	chr3:53064283~53065091:-
THCA	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	12.76	3.08e-32	4.84e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	12.76	3.08e-32	4.84e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	12.76	3.08e-32	4.84e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
THCA	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	12.76	3.08e-32	4.84e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	12.76	3.1e-32	4.87e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	12.76	3.1e-32	4.87e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-12.76	3.1e-32	4.87e-29	-0.74	-0.51	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
THCA	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	12.76	3.12e-32	4.9e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	12.76	3.12e-32	4.9e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	12.76	3.12e-32	4.9e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	12.76	3.12e-32	4.9e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
THCA	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-12.76	3.2e-32	5.02e-29	-0.37	-0.51	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
THCA	cis	rs2288884	0.515	rs11882053	ENSG00000275055.1	CTC-471J1.11	-12.76	3.23e-32	5.06e-29	-0.39	-0.51	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047687	chr19:52049007~52049754:+
THCA	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	12.76	3.3e-32	5.17e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	12.76	3.3e-32	5.17e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	12.76	3.3e-32	5.17e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	12.76	3.3e-32	5.17e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
THCA	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-12.75	3.38e-32	5.3e-29	-0.63	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
THCA	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	12.75	3.39e-32	5.31e-29	0.53	0.51	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
THCA	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	12.75	3.45e-32	5.4e-29	0.59	0.51	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-12.75	3.49e-32	5.47e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-12.75	3.49e-32	5.47e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
THCA	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	12.75	3.51e-32	5.5e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
THCA	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	12.75	3.54e-32	5.54e-29	0.53	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
THCA	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-12.75	3.55e-32	5.55e-29	-0.5	-0.51	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-12.75	3.6e-32	5.64e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-12.75	3.6e-32	5.64e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-12.75	3.6e-32	5.64e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	12.74	3.72e-32	5.82e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	12.74	3.76e-32	5.88e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
THCA	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	12.74	3.76e-32	5.89e-29	0.68	0.51	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
THCA	cis	rs9309473	0.95	rs6705977	ENSG00000163016.8	ALMS1P	12.74	3.79e-32	5.93e-29	0.76	0.51	Metabolite levels;	chr2:73622043	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	12.74	3.81e-32	5.96e-29	0.68	0.51	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
THCA	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-12.74	3.82e-32	5.97e-29	-0.49	-0.51	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
THCA	cis	rs62158211	1	rs62158211	ENSG00000234997.1	AC016745.3	-12.74	3.85e-32	6.01e-29	-0.62	-0.51	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348562	chr2:113424495~113425324:+
THCA	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	12.74	3.89e-32	6.08e-29	0.56	0.51	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	12.74	3.89e-32	6.09e-29	0.84	0.51	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
THCA	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	12.74	3.95e-32	6.17e-29	0.76	0.51	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
THCA	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-12.74	3.96e-32	6.2e-29	-0.56	-0.51	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
THCA	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-12.74	4e-32	6.25e-29	-0.61	-0.51	Height;	chr11:118758322	chr11:118688039~118690600:-
THCA	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-12.74	4.01e-32	6.26e-29	-0.64	-0.51	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
THCA	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	12.73	4.04e-32	6.31e-29	0.59	0.51	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
THCA	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	12.73	4.05e-32	6.33e-29	0.76	0.51	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
THCA	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	12.73	4.08e-32	6.37e-29	0.59	0.51	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
THCA	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	12.73	4.11e-32	6.41e-29	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
THCA	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-12.73	4.12e-32	6.43e-29	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-12.73	4.12e-32	6.43e-29	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
THCA	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-12.73	4.27e-32	6.66e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
THCA	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	12.73	4.29e-32	6.68e-29	0.49	0.51	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
THCA	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	12.73	4.32e-32	6.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	12.73	4.32e-32	6.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	12.73	4.32e-32	6.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
THCA	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	12.73	4.33e-32	6.75e-29	0.38	0.51	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
THCA	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	12.73	4.35e-32	6.79e-29	0.41	0.51	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	12.73	4.35e-32	6.79e-29	0.41	0.51	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
THCA	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	12.73	4.39e-32	6.84e-29	0.63	0.51	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	12.73	4.39e-32	6.84e-29	0.63	0.51	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
THCA	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	12.72	4.59e-32	7.15e-29	0.37	0.51	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	12.72	4.59e-32	7.15e-29	0.37	0.51	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-12.72	4.59e-32	7.15e-29	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
THCA	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	12.72	4.63e-32	7.2e-29	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
THCA	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	12.72	4.67e-32	7.28e-29	0.53	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
THCA	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-12.72	4.69e-32	7.3e-29	-0.64	-0.51	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
THCA	cis	rs6504950	0.679	rs9908752	ENSG00000275710.1	RP11-257O5.4	12.72	4.81e-32	7.48e-29	0.66	0.51	Breast cancer;	chr17:54905855	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-12.72	4.81e-32	7.49e-29	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-12.72	4.81e-32	7.49e-29	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-12.72	4.81e-32	7.49e-29	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	12.72	4.82e-32	7.5e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
THCA	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	12.72	4.82e-32	7.5e-29	0.64	0.51	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
THCA	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-12.72	4.84e-32	7.53e-29	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
THCA	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	12.72	4.84e-32	7.53e-29	0.37	0.51	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	12.72	4.84e-32	7.53e-29	0.37	0.51	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
THCA	cis	rs944289	0.616	rs408783	ENSG00000257826.1	RP11-116N8.4	12.72	4.84e-32	7.53e-29	0.53	0.51	Thyroid cancer;	chr14:36065667	chr14:36061026~36067190:-
THCA	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-12.71	5.02e-32	7.81e-29	-0.88	-0.51	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
THCA	cis	rs6452524	0.901	rs2662238	ENSG00000249664.1	CTD-2227C6.2	12.71	5.14e-32	7.98e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	12.71	5.25e-32	8.15e-29	0.72	0.51	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
THCA	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	12.71	5.27e-32	8.18e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	12.71	5.28e-32	8.19e-29	0.59	0.51	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
THCA	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	12.71	5.29e-32	8.21e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-12.71	5.32e-32	8.25e-29	-0.48	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
THCA	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	12.71	5.33e-32	8.27e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
THCA	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-12.7	5.38e-32	8.34e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
THCA	cis	rs12220777	0.585	rs75995665	ENSG00000230091.5	TMEM254-AS1	12.7	5.41e-32	8.39e-29	0.9	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80017462	chr10:80046860~80078912:-
THCA	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-12.7	5.42e-32	8.41e-29	-0.62	-0.51	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
THCA	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	12.7	5.43e-32	8.42e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
THCA	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	12.7	5.45e-32	8.45e-29	0.73	0.51	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
THCA	cis	rs9928842	0.77	rs4888364	ENSG00000280152.1	RP11-331F4.5	12.7	5.47e-32	8.48e-29	0.71	0.51	Alcoholic chronic pancreatitis;	chr16:75245612	chr16:75245994~75250077:-
THCA	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	12.7	5.47e-32	8.48e-29	0.61	0.51	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
THCA	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	12.7	5.51e-32	8.54e-29	0.73	0.51	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
THCA	cis	rs9481169	0.557	rs13190932	ENSG00000255389.1	C6orf3	-12.7	5.7e-32	8.83e-29	-1	-0.51	Inflammatory skin disease;	chr6:111591867	chr6:111599875~111602295:+
THCA	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	12.7	5.71e-32	8.85e-29	0.46	0.51	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
THCA	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-12.7	5.75e-32	8.91e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-12.7	5.75e-32	8.91e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-12.7	5.75e-32	8.91e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
THCA	cis	rs62158211	0.908	rs62158169	ENSG00000234997.1	AC016745.3	-12.7	5.82e-32	9.01e-29	-0.61	-0.51	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113324250	chr2:113424495~113425324:+
THCA	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	12.69	6.02e-32	9.31e-29	0.62	0.51	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
THCA	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	12.69	6.05e-32	9.36e-29	0.59	0.51	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
THCA	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-12.69	6.12e-32	9.46e-29	-0.48	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
THCA	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	12.69	6.14e-32	9.49e-29	0.62	0.51	Depression;	chr6:28142370	chr6:28170845~28172521:+
THCA	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	12.69	6.28e-32	9.69e-29	0.6	0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
THCA	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-12.69	6.42e-32	9.91e-29	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
THCA	cis	rs9309473	0.653	rs6718843	ENSG00000163016.8	ALMS1P	12.68	6.47e-32	9.98e-29	0.76	0.51	Metabolite levels;	chr2:73625378	chr2:73644919~73685576:+
THCA	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-12.68	6.49e-32	1e-28	-0.86	-0.51	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
THCA	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	12.68	6.62e-32	1.02e-28	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
THCA	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-12.68	6.63e-32	1.02e-28	-0.61	-0.5	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
THCA	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-12.68	6.65e-32	1.02e-28	-0.37	-0.5	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
THCA	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-12.68	6.74e-32	1.04e-28	-0.86	-0.5	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
THCA	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-12.68	6.78e-32	1.04e-28	-0.84	-0.5	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-12.68	6.78e-32	1.04e-28	-0.84	-0.5	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
THCA	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-12.68	6.8e-32	1.05e-28	-0.51	-0.5	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
THCA	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	12.68	6.81e-32	1.05e-28	0.73	0.5	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
THCA	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	12.68	6.83e-32	1.05e-28	0.56	0.5	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	12.68	6.85e-32	1.05e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-12.68	6.92e-32	1.06e-28	-0.5	-0.5	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-12.68	7e-32	1.08e-28	-0.69	-0.5	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
THCA	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	12.67	7.16e-32	1.1e-28	0.45	0.5	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
THCA	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	12.67	7.25e-32	1.11e-28	0.74	0.5	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
THCA	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-12.67	7.36e-32	1.13e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
THCA	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	12.67	7.42e-32	1.14e-28	0.42	0.5	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
THCA	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-12.67	7.44e-32	1.14e-28	-0.55	-0.5	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
THCA	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-12.67	7.47e-32	1.15e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
THCA	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	12.67	7.48e-32	1.15e-28	0.37	0.5	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	12.67	7.48e-32	1.15e-28	0.37	0.5	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	12.67	7.48e-32	1.15e-28	0.37	0.5	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
THCA	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	12.67	7.48e-32	1.15e-28	0.37	0.5	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
THCA	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	12.67	7.57e-32	1.16e-28	0.64	0.5	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
THCA	cis	rs934734	0.532	rs10153675	ENSG00000204929.10	AC074391.1	-12.67	7.6e-32	1.17e-28	-0.62	-0.5	Rheumatoid arthritis;	chr2:65422446	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-12.67	7.65e-32	1.17e-28	-0.88	-0.5	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
THCA	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	12.67	7.66e-32	1.17e-28	0.48	0.5	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
THCA	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	12.67	7.76e-32	1.19e-28	0.59	0.5	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
THCA	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	12.66	7.99e-32	1.22e-28	0.48	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
THCA	cis	rs62158211	1	rs1807282	ENSG00000234997.1	AC016745.3	-12.66	8e-32	1.23e-28	-0.61	-0.5	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113352459	chr2:113424495~113425324:+
THCA	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-12.66	8e-32	1.23e-28	-0.69	-0.5	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
THCA	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	12.66	8.02e-32	1.23e-28	0.66	0.5	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
THCA	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	12.66	8.09e-32	1.24e-28	0.61	0.5	Height;	chr11:118786602	chr11:118688039~118690600:-
THCA	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-12.66	8.15e-32	1.25e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-12.66	8.2e-32	1.26e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
THCA	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	12.66	8.24e-32	1.26e-28	0.4	0.5	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
THCA	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-12.66	8.27e-32	1.27e-28	-0.37	-0.5	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
THCA	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
THCA	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	12.66	8.39e-32	1.28e-28	0.65	0.5	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
THCA	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-12.66	8.47e-32	1.3e-28	-0.37	-0.5	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-12.66	8.47e-32	1.3e-28	-0.37	-0.5	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
THCA	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	12.66	8.5e-32	1.3e-28	0.59	0.5	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
THCA	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-12.66	8.53e-32	1.3e-28	-0.84	-0.5	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
THCA	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
THCA	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-12.65	8.79e-32	1.34e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
THCA	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-12.65	8.88e-32	1.36e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
THCA	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	12.65	9.02e-32	1.38e-28	0.67	0.5	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
THCA	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	12.65	9.05e-32	1.38e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-12.65	9.07e-32	1.38e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
THCA	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	12.65	9.17e-32	1.4e-28	0.63	0.5	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
THCA	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	12.65	9.17e-32	1.4e-28	0.59	0.5	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
THCA	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-12.65	9.32e-32	1.42e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-12.65	9.32e-32	1.42e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
THCA	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-12.65	9.36e-32	1.43e-28	-0.56	-0.5	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
THCA	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	12.65	9.39e-32	1.43e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
THCA	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	12.65	9.39e-32	1.43e-28	0.93	0.5	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
THCA	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-12.65	9.41e-32	1.43e-28	-0.72	-0.5	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-12.64	9.47e-32	1.44e-28	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
THCA	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-12.64	9.49e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
THCA	cis	rs7829975	0.511	rs2980423	ENSG00000253893.2	FAM85B	-12.64	9.6e-32	1.46e-28	-0.65	-0.5	Mood instability;	chr8:8285053	chr8:8167819~8226614:-
THCA	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-12.64	9.67e-32	1.47e-28	-0.7	-0.5	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
THCA	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	12.64	9.73e-32	1.48e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	12.64	9.73e-32	1.48e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
THCA	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-12.64	9.76e-32	1.49e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
THCA	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
THCA	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-12.64	9.77e-32	1.49e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
THCA	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
THCA	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-12.64	9.95e-32	1.51e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-12.64	1e-31	1.52e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
THCA	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-12.64	1e-31	1.53e-28	-0.56	-0.5	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
THCA	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	12.64	1.01e-31	1.53e-28	0.42	0.5	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
THCA	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-12.64	1.01e-31	1.54e-28	-0.49	-0.5	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
THCA	cis	rs2288884	0.537	rs12151270	ENSG00000275055.1	CTC-471J1.11	-12.64	1.02e-31	1.55e-28	-0.39	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058984	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-12.64	1.02e-31	1.55e-28	-0.39	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
THCA	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-12.64	1.02e-31	1.55e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-12.64	1.02e-31	1.56e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
THCA	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-12.64	1.03e-31	1.57e-28	-0.39	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
THCA	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	12.64	1.03e-31	1.57e-28	0.62	0.5	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
THCA	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	12.64	1.03e-31	1.57e-28	0.77	0.5	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
THCA	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	12.63	1.04e-31	1.58e-28	0.59	0.5	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
THCA	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-12.63	1.05e-31	1.6e-28	-0.84	-0.5	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
THCA	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-12.63	1.05e-31	1.6e-28	-0.62	-0.5	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
THCA	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-12.63	1.06e-31	1.61e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	12.63	1.06e-31	1.61e-28	0.61	0.5	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
THCA	cis	rs934734	0.532	rs13383320	ENSG00000204929.10	AC074391.1	-12.63	1.06e-31	1.62e-28	-0.61	-0.5	Rheumatoid arthritis;	chr2:65418003	chr2:65436711~66084639:+
THCA	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	12.63	1.08e-31	1.64e-28	0.58	0.5	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	12.63	1.08e-31	1.64e-28	0.58	0.5	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	12.63	1.08e-31	1.64e-28	0.58	0.5	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
THCA	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-12.63	1.08e-31	1.64e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
THCA	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	12.63	1.09e-31	1.65e-28	0.8	0.5	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
THCA	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	12.63	1.09e-31	1.65e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
THCA	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	12.63	1.09e-31	1.65e-28	0.61	0.5	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
THCA	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	12.63	1.09e-31	1.65e-28	0.73	0.5	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	12.63	1.09e-31	1.65e-28	0.73	0.5	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
THCA	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	12.63	1.09e-31	1.66e-28	0.51	0.5	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
THCA	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-12.63	1.09e-31	1.66e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
THCA	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-12.63	1.1e-31	1.66e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
THCA	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-12.63	1.1e-31	1.66e-28	-0.7	-0.5	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
THCA	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-12.63	1.1e-31	1.66e-28	-0.7	-0.5	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
THCA	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-12.63	1.1e-31	1.67e-28	-0.62	-0.5	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
THCA	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	12.63	1.12e-31	1.7e-28	0.46	0.5	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
THCA	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-12.63	1.13e-31	1.71e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.583	rs2936054	ENSG00000272750.1	RP11-378J18.8	12.63	1.13e-31	1.71e-28	0.6	0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222627290	chr1:222658867~222661512:-
THCA	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	12.63	1.14e-31	1.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	12.63	1.14e-31	1.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	12.62	1.16e-31	1.76e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	12.62	1.16e-31	1.76e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
THCA	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-12.62	1.18e-31	1.78e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
THCA	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-12.62	1.21e-31	1.83e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
THCA	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-12.62	1.21e-31	1.83e-28	-0.61	-0.5	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
THCA	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-12.62	1.22e-31	1.84e-28	-0.67	-0.5	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
THCA	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	12.62	1.22e-31	1.84e-28	0.67	0.5	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
THCA	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
THCA	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	12.61	1.26e-31	1.9e-28	0.63	0.5	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
THCA	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-12.61	1.26e-31	1.91e-28	-0.56	-0.5	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
THCA	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-12.61	1.27e-31	1.92e-28	-0.72	-0.5	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
THCA	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	12.61	1.27e-31	1.92e-28	0.62	0.5	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	12.61	1.27e-31	1.93e-28	0.62	0.5	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
THCA	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-12.61	1.27e-31	1.93e-28	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
THCA	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
THCA	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-12.61	1.31e-31	1.98e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
THCA	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	12.61	1.33e-31	2.01e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	12.61	1.33e-31	2.01e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
THCA	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	12.61	1.33e-31	2.01e-28	0.9	0.5	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
THCA	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-12.61	1.34e-31	2.03e-28	-0.63	-0.5	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
THCA	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-12.61	1.35e-31	2.03e-28	-0.64	-0.5	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
THCA	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	12.61	1.35e-31	2.03e-28	0.75	0.5	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
THCA	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	12.61	1.35e-31	2.04e-28	0.61	0.5	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
THCA	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	12.61	1.36e-31	2.05e-28	0.42	0.5	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
THCA	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-12.61	1.38e-31	2.08e-28	-0.37	-0.5	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
THCA	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	12.6	1.38e-31	2.09e-28	0.66	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
THCA	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-12.6	1.39e-31	2.1e-28	-0.61	-0.5	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	12.6	1.39e-31	2.1e-28	0.64	0.5	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
THCA	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	12.6	1.42e-31	2.13e-28	0.68	0.5	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000223768.1	LINC00205	-12.6	1.45e-31	2.19e-28	-0.47	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45293285~45297354:+
THCA	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-12.6	1.45e-31	2.19e-28	-0.73	-0.5	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
THCA	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	12.6	1.45e-31	2.19e-28	0.7	0.5	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
THCA	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	12.6	1.47e-31	2.21e-28	0.41	0.5	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
THCA	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-12.6	1.47e-31	2.21e-28	-0.58	-0.5	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
THCA	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	12.6	1.47e-31	2.21e-28	0.73	0.5	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
THCA	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	12.6	1.48e-31	2.23e-28	0.71	0.5	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
THCA	cis	rs9928842	0.882	rs11641896	ENSG00000280152.1	RP11-331F4.5	12.6	1.49e-31	2.25e-28	0.73	0.5	Alcoholic chronic pancreatitis;	chr16:75266281	chr16:75245994~75250077:-
THCA	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	12.6	1.51e-31	2.27e-28	0.58	0.5	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
THCA	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-12.6	1.51e-31	2.27e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-12.6	1.51e-31	2.27e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
THCA	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-12.59	1.52e-31	2.29e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-12.59	1.52e-31	2.29e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-12.59	1.52e-31	2.29e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-12.59	1.52e-31	2.29e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
THCA	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	12.59	1.53e-31	2.31e-28	0.87	0.5	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
THCA	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	12.59	1.54e-31	2.32e-28	0.37	0.5	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
THCA	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
THCA	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	12.59	1.54e-31	2.32e-28	0.73	0.5	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-12.59	1.54e-31	2.32e-28	-0.66	-0.5	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
THCA	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	12.59	1.56e-31	2.35e-28	0.58	0.5	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
THCA	cis	rs944289	0.616	rs395212	ENSG00000257826.1	RP11-116N8.4	-12.59	1.57e-31	2.36e-28	-0.53	-0.5	Thyroid cancer;	chr14:36065759	chr14:36061026~36067190:-
THCA	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-12.59	1.57e-31	2.36e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-12.59	1.57e-31	2.36e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
THCA	cis	rs80028505	0.764	rs1967966	ENSG00000271304.1	DPRXP2	12.59	1.58e-31	2.37e-28	0.84	0.5	Foot ulcer in diabetes and neuropathy;	chr6:36104395	chr6:35989515~35990436:-
THCA	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	12.59	1.58e-31	2.38e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
THCA	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	12.59	1.6e-31	2.4e-28	0.6	0.5	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
THCA	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	12.59	1.6e-31	2.4e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
THCA	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	12.59	1.6e-31	2.4e-28	0.71	0.5	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
THCA	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-12.59	1.6e-31	2.4e-28	-0.85	-0.5	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
THCA	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	12.59	1.61e-31	2.42e-28	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	12.59	1.62e-31	2.42e-28	0.65	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
THCA	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	12.59	1.62e-31	2.43e-28	0.58	0.5	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	12.59	1.62e-31	2.43e-28	0.58	0.5	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	12.59	1.62e-31	2.43e-28	0.58	0.5	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
THCA	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	12.58	1.68e-31	2.52e-28	0.71	0.5	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
THCA	cis	rs934734	0.532	rs7557569	ENSG00000204929.10	AC074391.1	-12.58	1.69e-31	2.54e-28	-0.61	-0.5	Rheumatoid arthritis;	chr2:65417427	chr2:65436711~66084639:+
THCA	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-12.58	1.71e-31	2.57e-28	-0.52	-0.5	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
THCA	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	12.58	1.75e-31	2.62e-28	0.77	0.5	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
THCA	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-12.58	1.75e-31	2.62e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
THCA	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-12.58	1.75e-31	2.63e-28	-0.64	-0.5	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
THCA	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	12.58	1.76e-31	2.63e-28	0.88	0.5	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
THCA	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	12.58	1.77e-31	2.65e-28	0.73	0.5	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-12.58	1.77e-31	2.66e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-12.58	1.77e-31	2.66e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
THCA	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
THCA	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-12.58	1.79e-31	2.69e-28	-0.68	-0.5	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
THCA	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	12.58	1.8e-31	2.69e-28	0.72	0.5	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	12.58	1.8e-31	2.69e-28	0.72	0.5	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
THCA	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	12.58	1.8e-31	2.7e-28	0.88	0.5	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
THCA	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	12.58	1.8e-31	2.7e-28	0.73	0.5	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
THCA	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	12.58	1.81e-31	2.71e-28	0.72	0.5	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
THCA	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	12.58	1.81e-31	2.71e-28	0.58	0.5	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
THCA	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-12.58	1.83e-31	2.74e-28	-0.83	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	12.57	1.84e-31	2.76e-28	0.59	0.5	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
THCA	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-12.57	1.85e-31	2.76e-28	-0.85	-0.5	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-12.57	1.85e-31	2.76e-28	-0.85	-0.5	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
THCA	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
THCA	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-12.57	1.86e-31	2.78e-28	-0.85	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
THCA	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-12.57	1.88e-31	2.81e-28	-0.4	-0.5	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
THCA	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-12.57	1.92e-31	2.87e-28	-0.84	-0.5	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
THCA	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	12.57	1.92e-31	2.87e-28	0.7	0.5	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
THCA	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	12.57	1.94e-31	2.9e-28	0.58	0.5	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
THCA	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	12.57	1.96e-31	2.92e-28	0.72	0.5	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	12.57	1.97e-31	2.95e-28	0.65	0.5	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
THCA	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	12.57	1.99e-31	2.97e-28	0.83	0.5	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
THCA	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	12.57	2e-31	2.99e-28	0.37	0.5	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	12.57	2e-31	2.99e-28	0.37	0.5	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
THCA	cis	rs934734	0.532	rs1437466	ENSG00000204929.10	AC074391.1	-12.57	2e-31	2.99e-28	-0.6	-0.5	Rheumatoid arthritis;	chr2:65437216	chr2:65436711~66084639:+
THCA	cis	rs9928842	0.823	rs11149811	ENSG00000280152.1	RP11-331F4.5	12.57	2.01e-31	3e-28	0.73	0.5	Alcoholic chronic pancreatitis;	chr16:75266810	chr16:75245994~75250077:-
THCA	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	12.56	2.03e-31	3.03e-28	0.61	0.5	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
THCA	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-12.56	2.04e-31	3.05e-28	-0.62	-0.5	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
THCA	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	12.56	2.05e-31	3.06e-28	0.74	0.5	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
THCA	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	12.56	2.08e-31	3.1e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
THCA	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	12.56	2.09e-31	3.11e-28	0.42	0.5	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
THCA	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-12.56	2.09e-31	3.12e-28	-0.63	-0.5	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-12.56	2.09e-31	3.12e-28	-0.63	-0.5	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
THCA	cis	rs67180937	0.583	rs3008616	ENSG00000272750.1	RP11-378J18.8	12.56	2.11e-31	3.15e-28	0.6	0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623831	chr1:222658867~222661512:-
THCA	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	12.56	2.12e-31	3.15e-28	0.41	0.5	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
THCA	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	12.56	2.12e-31	3.16e-28	0.62	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
THCA	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
THCA	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-12.56	2.14e-31	3.18e-28	-0.4	-0.5	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
THCA	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-12.56	2.15e-31	3.2e-28	-0.37	-0.5	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
THCA	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	12.56	2.16e-31	3.22e-28	0.89	0.5	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
THCA	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	12.56	2.16e-31	3.22e-28	0.89	0.5	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
THCA	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	12.56	2.16e-31	3.22e-28	0.89	0.5	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
THCA	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	12.56	2.17e-31	3.23e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-12.56	2.18e-31	3.24e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
THCA	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	12.56	2.18e-31	3.24e-28	0.37	0.5	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
THCA	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	12.56	2.18e-31	3.24e-28	0.37	0.5	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
THCA	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	12.56	2.18e-31	3.24e-28	0.37	0.5	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
THCA	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-12.56	2.21e-31	3.29e-28	-0.55	-0.5	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-12.55	2.23e-31	3.31e-28	-0.47	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	12.55	2.23e-31	3.31e-28	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
THCA	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	12.55	2.24e-31	3.34e-28	0.37	0.5	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
THCA	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	12.55	2.27e-31	3.38e-28	0.61	0.5	Height;	chr11:118791319	chr11:118688039~118690600:-
THCA	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	12.55	2.27e-31	3.38e-28	0.58	0.5	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
THCA	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-12.55	2.29e-31	3.4e-28	-0.53	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
THCA	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-12.55	2.32e-31	3.44e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-12.55	2.32e-31	3.44e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-12.55	2.34e-31	3.48e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-12.55	2.34e-31	3.48e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
THCA	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-12.55	2.34e-31	3.48e-28	-0.38	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
THCA	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	12.55	2.35e-31	3.49e-28	0.61	0.5	Height;	chr11:118808920	chr11:118688039~118690600:-
THCA	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-12.55	2.36e-31	3.51e-28	-0.38	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
THCA	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	12.55	2.36e-31	3.51e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	12.55	2.36e-31	3.51e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
THCA	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	12.55	2.37e-31	3.51e-28	0.71	0.5	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
THCA	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	12.55	2.38e-31	3.53e-28	0.62	0.5	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	12.55	2.38e-31	3.53e-28	0.62	0.5	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	12.55	2.38e-31	3.53e-28	0.62	0.5	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
THCA	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	12.55	2.41e-31	3.58e-28	0.58	0.5	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
THCA	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-12.55	2.43e-31	3.6e-28	-0.38	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
THCA	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	12.55	2.43e-31	3.61e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000228039.3	KB-1125A3.10	12.54	2.44e-31	3.62e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23963780~23964374:+
THCA	cis	rs9928842	0.882	rs9927264	ENSG00000280152.1	RP11-331F4.5	12.54	2.45e-31	3.64e-28	0.72	0.5	Alcoholic chronic pancreatitis;	chr16:75226343	chr16:75245994~75250077:-
THCA	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	12.54	2.46e-31	3.65e-28	0.7	0.5	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
THCA	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-12.54	2.46e-31	3.65e-28	-0.58	-0.5	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
THCA	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-12.54	2.52e-31	3.73e-28	-0.85	-0.5	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-12.54	2.52e-31	3.73e-28	-0.85	-0.5	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
THCA	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	12.54	2.53e-31	3.75e-28	0.59	0.5	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
THCA	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-12.54	2.59e-31	3.83e-28	-0.64	-0.5	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
THCA	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	12.54	2.6e-31	3.86e-28	0.58	0.5	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
THCA	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-12.54	2.64e-31	3.91e-28	-0.47	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	12.54	2.65e-31	3.93e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
THCA	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	12.54	2.65e-31	3.93e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	12.54	2.65e-31	3.93e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
THCA	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	12.54	2.65e-31	3.93e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	12.54	2.65e-31	3.93e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
THCA	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	12.53	2.72e-31	4.02e-28	0.59	0.5	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
THCA	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-12.53	2.73e-31	4.04e-28	-0.58	-0.5	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
THCA	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	12.53	2.75e-31	4.06e-28	0.57	0.5	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
THCA	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	12.53	2.75e-31	4.07e-28	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
THCA	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	12.53	2.79e-31	4.13e-28	0.59	0.5	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
THCA	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-12.53	2.81e-31	4.15e-28	-0.62	-0.5	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-12.53	2.81e-31	4.15e-28	-0.62	-0.5	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
THCA	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	12.53	2.81e-31	4.15e-28	0.41	0.5	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	12.53	2.81e-31	4.15e-28	0.41	0.5	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
THCA	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	12.53	2.82e-31	4.16e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	12.53	2.82e-31	4.16e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
THCA	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	12.53	2.82e-31	4.16e-28	0.41	0.5	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	12.53	2.82e-31	4.16e-28	0.41	0.5	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	12.53	2.87e-31	4.24e-28	0.41	0.5	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
THCA	cis	rs9309473	0.606	rs62149804	ENSG00000163016.8	ALMS1P	12.53	2.87e-31	4.24e-28	0.87	0.5	Metabolite levels;	chr2:73609879	chr2:73644919~73685576:+
THCA	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	12.53	2.88e-31	4.26e-28	0.62	0.5	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
THCA	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	12.53	2.89e-31	4.27e-28	0.63	0.5	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
THCA	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	12.53	2.93e-31	4.33e-28	0.58	0.5	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
THCA	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	12.53	2.93e-31	4.33e-28	0.57	0.5	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	12.53	2.93e-31	4.33e-28	0.57	0.5	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	12.53	2.94e-31	4.34e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
THCA	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	12.53	2.95e-31	4.35e-28	0.63	0.5	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
THCA	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	12.52	2.98e-31	4.4e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
THCA	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	12.52	2.99e-31	4.41e-28	0.57	0.5	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
THCA	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-12.52	3e-31	4.43e-28	-0.74	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000216901.1	AL022393.7	12.52	3.01e-31	4.44e-28	0.59	0.5	Pubertal anthropometrics;	chr6:28128502	chr6:28176188~28176674:+
THCA	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	12.52	3.03e-31	4.47e-28	0.37	0.5	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	12.52	3.07e-31	4.53e-28	0.47	0.5	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-12.52	3.08e-31	4.55e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
THCA	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-12.52	3.11e-31	4.59e-28	-0.59	-0.5	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
THCA	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	12.52	3.13e-31	4.62e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	12.52	3.13e-31	4.62e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	12.52	3.13e-31	4.62e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	12.52	3.14e-31	4.62e-28	0.6	0.5	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
THCA	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	12.52	3.14e-31	4.63e-28	0.37	0.5	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
THCA	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-12.52	3.15e-31	4.64e-28	-0.4	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
THCA	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-12.52	3.15e-31	4.65e-28	-0.61	-0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
THCA	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	12.52	3.19e-31	4.7e-28	0.63	0.5	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
THCA	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	12.52	3.19e-31	4.71e-28	0.36	0.5	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-12.52	3.22e-31	4.75e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	12.52	3.23e-31	4.75e-28	0.61	0.5	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
THCA	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-12.51	3.24e-31	4.78e-28	-0.84	-0.5	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
THCA	cis	rs944289	0.589	rs847514	ENSG00000257826.1	RP11-116N8.4	12.51	3.24e-31	4.78e-28	0.52	0.5	Thyroid cancer;	chr14:36060904	chr14:36061026~36067190:-
THCA	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	12.51	3.25e-31	4.79e-28	0.41	0.5	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
THCA	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	12.51	3.29e-31	4.84e-28	0.57	0.5	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	12.51	3.29e-31	4.85e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	12.51	3.29e-31	4.85e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
THCA	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	12.51	3.31e-31	4.87e-28	0.62	0.5	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
THCA	cis	rs9309473	1	rs2421555	ENSG00000163016.8	ALMS1P	12.51	3.32e-31	4.88e-28	0.72	0.5	Metabolite levels;	chr2:73589828	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-12.51	3.39e-31	4.99e-28	-0.45	-0.5	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
THCA	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	12.51	3.39e-31	4.99e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	12.51	3.39e-31	4.99e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	12.51	3.39e-31	4.99e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-12.51	3.42e-31	5.04e-28	-0.61	-0.5	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
THCA	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	12.51	3.43e-31	5.04e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	12.51	3.43e-31	5.04e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
THCA	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-12.51	3.45e-31	5.08e-28	-0.37	-0.5	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
THCA	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-12.51	3.48e-31	5.12e-28	-0.56	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
THCA	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	12.51	3.5e-31	5.15e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
THCA	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	12.51	3.55e-31	5.21e-28	0.75	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
THCA	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-12.5	3.59e-31	5.28e-28	-0.62	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
THCA	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	12.5	3.63e-31	5.34e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	12.5	3.64e-31	5.34e-28	0.57	0.5	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
THCA	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	12.5	3.64e-31	5.35e-28	0.72	0.5	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	12.5	3.71e-31	5.45e-28	0.64	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
THCA	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-12.5	3.73e-31	5.47e-28	-0.64	-0.5	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
THCA	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	12.5	3.75e-31	5.51e-28	0.58	0.5	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	12.5	3.75e-31	5.51e-28	0.58	0.5	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
THCA	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	12.5	3.76e-31	5.52e-28	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
THCA	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-12.5	3.8e-31	5.58e-28	-0.53	-0.5	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
THCA	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	12.5	3.88e-31	5.69e-28	0.65	0.5	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
THCA	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-12.5	3.89e-31	5.7e-28	-0.53	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
THCA	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	12.5	3.89e-31	5.7e-28	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
THCA	cis	rs12468226	1	rs77435512	ENSG00000273456.1	RP11-686O6.2	12.49	3.97e-31	5.83e-28	0.58	0.5	Urate levels;	chr2:202334165	chr2:202374932~202375604:-
THCA	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	12.49	4.01e-31	5.88e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
THCA	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	12.49	4.11e-31	6.02e-28	0.88	0.5	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
THCA	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-12.49	4.11e-31	6.03e-28	-0.37	-0.5	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-12.49	4.11e-31	6.03e-28	-0.37	-0.5	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-12.49	4.11e-31	6.03e-28	-0.37	-0.5	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
THCA	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-12.49	4.11e-31	6.03e-28	-0.83	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
THCA	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	12.49	4.16e-31	6.09e-28	0.57	0.5	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000216901.1	AL022393.7	12.49	4.29e-31	6.27e-28	0.59	0.5	Pubertal anthropometrics;	chr6:28197520	chr6:28176188~28176674:+
THCA	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	12.48	4.33e-31	6.34e-28	0.41	0.5	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
THCA	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	12.48	4.33e-31	6.34e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
THCA	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-12.48	4.35e-31	6.37e-28	-0.52	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
THCA	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-12.48	4.35e-31	6.37e-28	-0.36	-0.5	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
THCA	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	12.48	4.35e-31	6.37e-28	0.72	0.5	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	12.48	4.35e-31	6.37e-28	0.72	0.5	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
THCA	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-12.48	4.39e-31	6.42e-28	-0.52	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
THCA	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	12.48	4.39e-31	6.43e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	12.48	4.39e-31	6.43e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	12.48	4.39e-31	6.43e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
THCA	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	12.48	4.43e-31	6.48e-28	0.57	0.5	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
THCA	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	12.48	4.44e-31	6.49e-28	0.72	0.5	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
THCA	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	12.48	4.45e-31	6.51e-28	0.53	0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
THCA	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
THCA	cis	rs67311347	1	rs67311347	ENSG00000223797.4	ENTPD3-AS1	12.48	4.54e-31	6.64e-28	0.41	0.5	Renal cell carcinoma;	chr3:40491752	chr3:40313802~40453329:-
THCA	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	12.48	4.55e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
THCA	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-12.48	4.61e-31	6.73e-28	-0.54	-0.5	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-12.48	4.61e-31	6.73e-28	-0.54	-0.5	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
THCA	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
THCA	cis	rs6496932	0.802	rs12441698	ENSG00000218052.5	ADAMTS7P4	12.48	4.64e-31	6.77e-28	0.65	0.5	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85255369~85330334:-
THCA	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	12.48	4.69e-31	6.85e-28	0.63	0.5	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
THCA	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	12.47	4.75e-31	6.92e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	12.47	4.75e-31	6.92e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	12.47	4.77e-31	6.96e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	12.47	4.77e-31	6.96e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
THCA	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-12.47	4.78e-31	6.98e-28	-0.62	-0.5	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
THCA	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-12.47	4.8e-31	7.01e-28	-0.59	-0.5	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
THCA	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	12.47	4.85e-31	7.07e-28	0.62	0.5	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
THCA	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	12.47	4.86e-31	7.09e-28	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
THCA	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	12.47	4.89e-31	7.12e-28	0.63	0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
THCA	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	12.47	4.89e-31	7.13e-28	0.6	0.5	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
THCA	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	12.47	4.89e-31	7.13e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
THCA	cis	rs324126	0.78	rs60935857	ENSG00000277977.1	CTD-3018O17.5	12.47	4.94e-31	7.21e-28	0.47	0.5	Colonoscopy-negative controls vs population controls;	chr19:52382606	chr19:52392659~52392755:+
THCA	cis	rs934734	0.532	rs10166100	ENSG00000204929.10	AC074391.1	-12.47	4.98e-31	7.25e-28	-0.61	-0.5	Rheumatoid arthritis;	chr2:65418616	chr2:65436711~66084639:+
THCA	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	12.47	4.99e-31	7.27e-28	0.4	0.5	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	12.47	4.99e-31	7.27e-28	0.4	0.5	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	12.47	5.03e-31	7.32e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
THCA	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	12.47	5.04e-31	7.34e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
THCA	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-12.47	5.08e-31	7.4e-28	-0.84	-0.5	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
THCA	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-12.47	5.08e-31	7.4e-28	-0.84	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-12.47	5.08e-31	7.4e-28	-0.84	-0.5	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
THCA	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	12.47	5.13e-31	7.47e-28	0.63	0.5	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
THCA	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	12.46	5.21e-31	7.58e-28	0.65	0.5	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
THCA	cis	rs944289	0.589	rs63360860	ENSG00000257826.1	RP11-116N8.4	12.46	5.21e-31	7.58e-28	0.53	0.5	Thyroid cancer;	chr14:36068846	chr14:36061026~36067190:-
THCA	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-12.46	5.22e-31	7.59e-28	-0.5	-0.5	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
THCA	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-12.46	5.24e-31	7.62e-28	-0.59	-0.5	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
THCA	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	12.46	5.25e-31	7.63e-28	0.66	0.5	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
THCA	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	12.46	5.38e-31	7.83e-28	0.62	0.5	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
THCA	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-12.46	5.39e-31	7.83e-28	-0.62	-0.5	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
THCA	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	12.46	5.39e-31	7.84e-28	0.75	0.5	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
THCA	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	12.46	5.42e-31	7.87e-28	0.41	0.5	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
THCA	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	12.46	5.42e-31	7.88e-28	0.59	0.5	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
THCA	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	12.46	5.42e-31	7.88e-28	0.59	0.5	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
THCA	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	12.46	5.43e-31	7.9e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	12.46	5.43e-31	7.9e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	12.46	5.43e-31	7.9e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	12.46	5.43e-31	7.9e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-12.46	5.44e-31	7.91e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-12.46	5.44e-31	7.91e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-12.46	5.44e-31	7.91e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-12.46	5.44e-31	7.91e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
THCA	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	12.46	5.46e-31	7.93e-28	0.62	0.5	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
THCA	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-12.46	5.49e-31	7.97e-28	-0.6	-0.5	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
THCA	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	12.46	5.49e-31	7.97e-28	0.41	0.5	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
THCA	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	12.46	5.5e-31	7.98e-28	0.57	0.5	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
THCA	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	12.46	5.55e-31	8.05e-28	0.72	0.5	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
THCA	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-12.46	5.61e-31	8.14e-28	-0.52	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
THCA	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	12.46	5.61e-31	8.14e-28	0.41	0.5	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
THCA	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	12.46	5.68e-31	8.25e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	12.46	5.68e-31	8.25e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	12.46	5.68e-31	8.25e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
THCA	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	12.46	5.68e-31	8.25e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	12.45	5.77e-31	8.37e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
THCA	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	12.45	5.78e-31	8.39e-28	0.41	0.5	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	12.45	5.81e-31	8.43e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
THCA	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	12.45	5.83e-31	8.46e-28	0.62	0.5	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	12.45	5.87e-31	8.5e-28	0.61	0.5	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	12.45	5.87e-31	8.5e-28	0.61	0.5	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
THCA	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-12.45	5.88e-31	8.52e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-12.45	5.88e-31	8.52e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-12.45	5.88e-31	8.52e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
THCA	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-12.45	5.94e-31	8.61e-28	-0.59	-0.5	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
THCA	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-12.45	5.95e-31	8.62e-28	-0.65	-0.5	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
THCA	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-12.45	5.97e-31	8.64e-28	-0.62	-0.5	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
THCA	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	12.45	5.97e-31	8.65e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
THCA	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	12.45	6e-31	8.68e-28	0.62	0.5	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	12.45	6e-31	8.68e-28	0.62	0.5	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	12.45	6e-31	8.68e-28	0.62	0.5	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	12.45	6e-31	8.68e-28	0.62	0.5	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
THCA	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	12.45	6.02e-31	8.72e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-12.45	6.04e-31	8.74e-28	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
THCA	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	12.45	6.07e-31	8.79e-28	0.48	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
THCA	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	12.45	6.09e-31	8.81e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	12.45	6.09e-31	8.81e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
THCA	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-12.45	6.09e-31	8.82e-28	-0.62	-0.5	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
THCA	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	12.45	6.14e-31	8.89e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
THCA	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	12.45	6.18e-31	8.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
THCA	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-12.45	6.2e-31	8.97e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
THCA	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	12.45	6.2e-31	8.98e-28	0.72	0.5	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs11126403	ENSG00000163016.8	ALMS1P	12.45	6.2e-31	8.98e-28	0.72	0.5	Metabolite levels;	chr2:73569796	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs11126404	ENSG00000163016.8	ALMS1P	12.45	6.2e-31	8.98e-28	0.72	0.5	Metabolite levels;	chr2:73569797	chr2:73644919~73685576:+
THCA	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	12.45	6.25e-31	9.04e-28	0.71	0.5	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
THCA	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-12.45	6.25e-31	9.04e-28	-0.7	-0.5	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
THCA	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	12.45	6.25e-31	9.05e-28	0.61	0.5	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
THCA	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	12.44	6.3e-31	9.11e-28	0.61	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-12.44	6.32e-31	9.14e-28	-0.61	-0.5	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
THCA	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-12.44	6.33e-31	9.15e-28	-0.65	-0.5	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
THCA	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	12.44	6.33e-31	9.15e-28	0.66	0.5	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	12.44	6.33e-31	9.15e-28	0.66	0.5	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	12.44	6.33e-31	9.15e-28	0.66	0.5	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
THCA	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-12.44	6.37e-31	9.2e-28	-0.59	-0.5	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
THCA	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-12.44	6.37e-31	9.2e-28	-0.37	-0.5	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	12.44	6.4e-31	9.25e-28	0.36	0.5	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
THCA	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
THCA	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	12.44	6.41e-31	9.26e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
THCA	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-12.44	6.44e-31	9.3e-28	-0.36	-0.5	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
THCA	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	12.44	6.45e-31	9.32e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
THCA	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	12.44	6.49e-31	9.38e-28	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	12.44	6.58e-31	9.51e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
THCA	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-12.44	6.77e-31	9.77e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
THCA	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-12.44	6.82e-31	9.84e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-12.44	6.82e-31	9.84e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
THCA	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	12.44	6.83e-31	9.86e-28	0.4	0.5	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
THCA	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	12.44	6.86e-31	9.9e-28	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
THCA	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	12.44	6.87e-31	9.92e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	12.44	6.87e-31	9.92e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	12.44	6.87e-31	9.92e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
THCA	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	12.43	6.98e-31	1.01e-27	0.72	0.5	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
THCA	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	12.43	7.05e-31	1.02e-27	0.59	0.5	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-12.43	7.05e-31	1.02e-27	-0.59	-0.5	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-12.43	7.05e-31	1.02e-27	-0.59	-0.5	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
THCA	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	12.43	7.06e-31	1.02e-27	0.7	0.5	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
THCA	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-12.43	7.07e-31	1.02e-27	-0.76	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-12.43	7.18e-31	1.03e-27	-0.76	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
THCA	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-12.43	7.25e-31	1.04e-27	-0.84	-0.5	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
THCA	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	12.43	7.37e-31	1.06e-27	0.59	0.5	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
THCA	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	12.43	7.45e-31	1.07e-27	0.47	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
THCA	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	12.43	7.46e-31	1.07e-27	0.62	0.5	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	12.43	7.51e-31	1.08e-27	0.58	0.5	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
THCA	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-12.43	7.53e-31	1.08e-27	-0.75	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
THCA	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	12.43	7.54e-31	1.09e-27	0.61	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	12.43	7.55e-31	1.09e-27	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	12.42	7.75e-31	1.11e-27	0.59	0.5	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-12.42	7.75e-31	1.11e-27	-0.59	-0.5	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
THCA	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	12.42	7.83e-31	1.13e-27	0.57	0.5	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
THCA	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-12.42	7.87e-31	1.13e-27	-0.48	-0.5	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
THCA	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	12.42	7.88e-31	1.13e-27	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	12.42	7.88e-31	1.13e-27	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	12.42	7.88e-31	1.13e-27	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
THCA	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	12.42	7.98e-31	1.15e-27	0.87	0.5	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
THCA	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	12.42	8.05e-31	1.16e-27	0.57	0.5	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
THCA	cis	rs6496932	0.755	rs56909106	ENSG00000218052.5	ADAMTS7P4	12.42	8.12e-31	1.17e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85255369~85330334:-
THCA	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-12.42	8.22e-31	1.18e-27	-0.83	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
THCA	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	12.41	8.4e-31	1.21e-27	0.57	0.5	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	12.41	8.4e-31	1.21e-27	0.57	0.5	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	12.41	8.44e-31	1.21e-27	0.41	0.5	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
THCA	cis	rs944289	0.561	rs371191	ENSG00000257826.1	RP11-116N8.4	12.41	8.48e-31	1.22e-27	0.52	0.5	Thyroid cancer;	chr14:36064000	chr14:36061026~36067190:-
THCA	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	12.41	8.51e-31	1.22e-27	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
THCA	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-12.41	8.53e-31	1.23e-27	-0.53	-0.5	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
THCA	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	12.41	8.62e-31	1.24e-27	0.47	0.5	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
THCA	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	12.41	8.67e-31	1.24e-27	0.72	0.5	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
THCA	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	12.41	8.68e-31	1.25e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
THCA	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-12.41	8.73e-31	1.25e-27	-0.37	-0.5	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-12.41	8.73e-31	1.25e-27	-0.37	-0.5	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
THCA	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	12.41	8.75e-31	1.26e-27	0.72	0.5	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
THCA	cis	rs6496932	0.755	rs12905673	ENSG00000218052.5	ADAMTS7P4	-12.41	8.84e-31	1.27e-27	-0.64	-0.5	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85255369~85330334:-
THCA	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-12.41	8.87e-31	1.27e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-12.41	8.87e-31	1.27e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-12.41	8.87e-31	1.27e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
THCA	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	12.41	8.88e-31	1.27e-27	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
THCA	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	12.41	8.93e-31	1.28e-27	0.71	0.5	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	12.41	8.95e-31	1.28e-27	0.47	0.5	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
THCA	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	12.41	8.97e-31	1.29e-27	0.62	0.5	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
THCA	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	12.41	9.11e-31	1.31e-27	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
THCA	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	12.41	9.11e-31	1.31e-27	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
THCA	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-12.4	9.18e-31	1.32e-27	-0.38	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
THCA	cis	rs934734	0.532	rs2860773	ENSG00000204929.10	AC074391.1	-12.4	9.31e-31	1.33e-27	-0.59	-0.5	Rheumatoid arthritis;	chr2:65438507	chr2:65436711~66084639:+
THCA	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	12.4	9.34e-31	1.34e-27	0.57	0.5	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
THCA	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-12.4	9.35e-31	1.34e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
THCA	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-12.4	9.39e-31	1.35e-27	-0.62	-0.5	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	12.4	9.53e-31	1.36e-27	0.7	0.5	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
THCA	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	12.4	9.64e-31	1.38e-27	0.4	0.5	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	12.4	9.7e-31	1.39e-27	0.59	0.5	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
THCA	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	12.4	9.71e-31	1.39e-27	0.41	0.5	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
THCA	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	12.4	9.73e-31	1.39e-27	0.57	0.5	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
THCA	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	12.4	9.75e-31	1.4e-27	0.61	0.5	Height;	chr3:53072864	chr3:53064283~53065091:-
THCA	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	12.4	9.78e-31	1.4e-27	0.62	0.5	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
THCA	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	12.4	9.83e-31	1.41e-27	0.57	0.5	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
THCA	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	12.4	9.86e-31	1.41e-27	0.59	0.5	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	12.4	9.86e-31	1.41e-27	0.59	0.5	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
THCA	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	12.4	9.87e-31	1.41e-27	0.45	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	12.4	9.87e-31	1.41e-27	0.45	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
THCA	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	12.4	9.88e-31	1.41e-27	0.61	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
THCA	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	12.4	9.97e-31	1.43e-27	0.72	0.5	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	12.4	9.98e-31	1.43e-27	0.65	0.5	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	12.4	9.98e-31	1.43e-27	0.65	0.5	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
THCA	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	12.4	1e-30	1.43e-27	0.57	0.5	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	12.4	1e-30	1.43e-27	0.57	0.5	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	12.4	1e-30	1.43e-27	0.57	0.5	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	12.39	1.01e-30	1.44e-27	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
THCA	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	12.39	1.01e-30	1.45e-27	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-12.39	1.02e-30	1.45e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-12.39	1.02e-30	1.45e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
THCA	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-12.39	1.02e-30	1.45e-27	-0.6	-0.5	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
THCA	cis	rs7188445	0.712	rs6564688	ENSG00000261390.4	RP11-345M22.2	12.39	1.02e-30	1.45e-27	0.59	0.5	Urate levels;	chr16:79680061	chr16:79715232~79770563:-
THCA	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	12.39	1.03e-30	1.47e-27	0.64	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
THCA	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
THCA	cis	rs6496932	0.802	rs4843047	ENSG00000218052.5	ADAMTS7P4	12.39	1.04e-30	1.48e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85255369~85330334:-
THCA	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	12.39	1.05e-30	1.5e-27	0.65	0.5	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
THCA	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	12.39	1.05e-30	1.5e-27	0.63	0.5	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	12.39	1.05e-30	1.5e-27	0.36	0.5	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
THCA	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	12.39	1.05e-30	1.5e-27	0.64	0.5	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
THCA	cis	rs853679	0.517	rs9393891	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28111382	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28111650	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Parkinson's disease;	chr6:28112168	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28112175	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28113851	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28114487	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28114933	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28115743	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28116411	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Parkinson's disease;	chr6:28118700	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Parkinson's disease;	chr6:28118701	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Parkinson's disease;	chr6:28119896	chr6:28170845~28172521:+
THCA	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-12.39	1.06e-30	1.52e-27	-0.68	-0.5	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
THCA	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-12.39	1.06e-30	1.52e-27	-0.68	-0.5	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
THCA	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	12.39	1.07e-30	1.52e-27	0.6	0.5	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	12.39	1.07e-30	1.52e-27	0.6	0.5	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	12.39	1.07e-30	1.52e-27	0.6	0.5	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
THCA	cis	rs6496932	0.802	rs2063442	ENSG00000218052.5	ADAMTS7P4	12.39	1.07e-30	1.53e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85255369~85330334:-
THCA	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	12.39	1.07e-30	1.53e-27	0.59	0.5	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
THCA	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	12.39	1.08e-30	1.53e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
THCA	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-12.39	1.08e-30	1.54e-27	-0.81	-0.5	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
THCA	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	12.39	1.08e-30	1.54e-27	0.61	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
THCA	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	12.39	1.09e-30	1.55e-27	0.87	0.5	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
THCA	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-12.39	1.09e-30	1.55e-27	-0.47	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
THCA	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-12.39	1.1e-30	1.57e-27	-0.55	-0.5	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
THCA	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
THCA	cis	rs944289	0.561	rs395660	ENSG00000257826.1	RP11-116N8.4	12.38	1.11e-30	1.57e-27	0.52	0.5	Thyroid cancer;	chr14:36063593	chr14:36061026~36067190:-
THCA	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	12.38	1.11e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
THCA	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-12.38	1.11e-30	1.58e-27	-0.37	-0.5	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
THCA	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
THCA	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-12.38	1.12e-30	1.59e-27	-0.74	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
THCA	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-12.38	1.12e-30	1.59e-27	-0.84	-0.5	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
THCA	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-12.38	1.12e-30	1.6e-27	-0.37	-0.5	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-12.38	1.12e-30	1.6e-27	-0.37	-0.5	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-12.38	1.12e-30	1.6e-27	-0.37	-0.5	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
THCA	cis	rs6496932	0.802	rs12442399	ENSG00000218052.5	ADAMTS7P4	12.38	1.13e-30	1.6e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.802	rs8038403	ENSG00000218052.5	ADAMTS7P4	12.38	1.13e-30	1.6e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85255369~85330334:-
THCA	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	12.38	1.15e-30	1.63e-27	0.35	0.5	Height;	chr11:118758322	chr11:118791254~118793137:+
THCA	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	12.38	1.15e-30	1.63e-27	0.53	0.5	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
THCA	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	12.38	1.16e-30	1.65e-27	0.63	0.5	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
THCA	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-12.38	1.16e-30	1.65e-27	-0.45	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
THCA	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-12.38	1.18e-30	1.67e-27	-0.63	-0.5	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
THCA	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	12.38	1.18e-30	1.68e-27	0.56	0.5	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
THCA	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	12.38	1.19e-30	1.68e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	12.38	1.19e-30	1.68e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
THCA	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	12.38	1.2e-30	1.69e-27	0.58	0.5	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
THCA	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	12.38	1.2e-30	1.69e-27	0.58	0.5	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
THCA	cis	rs944289	0.616	rs448145	ENSG00000257826.1	RP11-116N8.4	12.38	1.2e-30	1.7e-27	0.52	0.5	Thyroid cancer;	chr14:36069722	chr14:36061026~36067190:-
THCA	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-12.37	1.21e-30	1.72e-27	-0.37	-0.5	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
THCA	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-12.37	1.21e-30	1.72e-27	-0.37	-0.5	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-12.37	1.21e-30	1.72e-27	-0.37	-0.5	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	12.37	1.21e-30	1.72e-27	0.56	0.5	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
THCA	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	12.37	1.21e-30	1.72e-27	0.41	0.5	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
THCA	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-12.37	1.22e-30	1.72e-27	-0.4	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
THCA	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	12.37	1.22e-30	1.73e-27	0.53	0.5	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
THCA	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	12.37	1.25e-30	1.77e-27	0.65	0.5	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	12.37	1.25e-30	1.77e-27	0.65	0.5	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
THCA	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-12.37	1.25e-30	1.77e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	12.37	1.25e-30	1.78e-27	0.59	0.5	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-12.37	1.25e-30	1.78e-27	-0.72	-0.5	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-12.37	1.28e-30	1.81e-27	-0.58	-0.5	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
THCA	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-12.37	1.28e-30	1.81e-27	-0.63	-0.5	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
THCA	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	12.37	1.29e-30	1.83e-27	0.57	0.5	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
THCA	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	12.37	1.31e-30	1.85e-27	0.62	0.5	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
THCA	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	12.37	1.31e-30	1.86e-27	0.57	0.5	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
THCA	cis	rs6860806	0.507	rs2631372	ENSG00000233006.5	AC034220.3	12.37	1.32e-30	1.87e-27	0.39	0.5	Breast cancer;	chr5:132367886	chr5:132311285~132369916:-
THCA	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	12.37	1.32e-30	1.87e-27	0.63	0.5	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-12.37	1.33e-30	1.88e-27	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
THCA	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	12.36	1.33e-30	1.88e-27	0.71	0.5	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
THCA	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	12.36	1.33e-30	1.89e-27	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
THCA	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	12.36	1.35e-30	1.9e-27	0.41	0.5	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-12.36	1.37e-30	1.93e-27	-0.69	-0.5	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
THCA	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	12.36	1.38e-30	1.94e-27	0.62	0.5	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
THCA	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	12.36	1.38e-30	1.95e-27	0.66	0.5	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
THCA	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
THCA	cis	rs324126	0.78	rs2059817	ENSG00000277977.1	CTD-3018O17.5	12.36	1.4e-30	1.97e-27	0.47	0.5	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52392659~52392755:+
THCA	cis	rs1150668	1	rs1150668	ENSG00000216901.1	AL022393.7	12.36	1.4e-30	1.98e-27	0.59	0.5	Pubertal anthropometrics;	chr6:28162011	chr6:28176188~28176674:+
THCA	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	12.36	1.4e-30	1.98e-27	0.55	0.5	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
THCA	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-12.36	1.42e-30	2e-27	-0.58	-0.5	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
THCA	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	12.36	1.42e-30	2.01e-27	0.63	0.5	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	12.36	1.42e-30	2.01e-27	0.63	0.5	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	12.36	1.42e-30	2.01e-27	0.63	0.5	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
THCA	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-12.36	1.43e-30	2.02e-27	-0.56	-0.5	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
THCA	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-12.36	1.44e-30	2.03e-27	-0.37	-0.5	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
THCA	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	12.36	1.46e-30	2.06e-27	0.72	0.5	Migraine;	chr16:75350086	chr16:75379818~75381260:-
THCA	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	12.35	1.46e-30	2.06e-27	0.56	0.5	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
THCA	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	12.35	1.48e-30	2.08e-27	0.62	0.5	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
THCA	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-12.35	1.48e-30	2.09e-27	-0.6	-0.5	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
THCA	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	12.35	1.5e-30	2.11e-27	0.37	0.5	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
THCA	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
THCA	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	12.35	1.51e-30	2.13e-27	0.84	0.5	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	12.35	1.51e-30	2.13e-27	0.58	0.5	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	12.35	1.51e-30	2.13e-27	0.57	0.5	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
THCA	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	12.35	1.52e-30	2.14e-27	0.59	0.5	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
THCA	cis	rs934734	0.509	rs12185577	ENSG00000204929.10	AC074391.1	-12.35	1.52e-30	2.14e-27	-0.6	-0.5	Rheumatoid arthritis;	chr2:65432354	chr2:65436711~66084639:+
THCA	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	12.35	1.53e-30	2.16e-27	0.59	0.49	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
THCA	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	12.35	1.53e-30	2.16e-27	0.63	0.49	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
THCA	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-12.35	1.54e-30	2.17e-27	-0.65	-0.49	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
THCA	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	12.35	1.55e-30	2.18e-27	0.66	0.49	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
THCA	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	12.35	1.55e-30	2.18e-27	0.66	0.49	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
THCA	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-12.35	1.55e-30	2.18e-27	-0.61	-0.49	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	12.35	1.55e-30	2.19e-27	0.64	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
THCA	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-12.35	1.55e-30	2.19e-27	-0.65	-0.49	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
THCA	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	12.35	1.56e-30	2.19e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
THCA	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	12.35	1.56e-30	2.19e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	12.35	1.56e-30	2.19e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
THCA	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	12.35	1.56e-30	2.19e-27	0.58	0.49	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
THCA	cis	rs62158211	1	rs4618068	ENSG00000234997.1	AC016745.3	-12.35	1.56e-30	2.19e-27	-0.6	-0.49	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113351778	chr2:113424495~113425324:+
THCA	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	12.35	1.56e-30	2.2e-27	0.59	0.49	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
THCA	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-12.35	1.59e-30	2.23e-27	-0.61	-0.49	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
THCA	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-12.34	1.61e-30	2.26e-27	-0.47	-0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
THCA	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-12.34	1.63e-30	2.29e-27	-0.36	-0.49	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000231464.1	AC024937.4	12.34	1.65e-30	2.31e-27	0.62	0.49	Pancreatic cancer;	chr3:196009869	chr3:195996738~195998233:+
THCA	cis	rs4927850	1	rs4927704	ENSG00000231464.1	AC024937.4	12.34	1.65e-30	2.31e-27	0.62	0.49	Pancreatic cancer;	chr3:196011357	chr3:195996738~195998233:+
THCA	cis	rs4927850	1	rs4927848	ENSG00000231464.1	AC024937.4	12.34	1.65e-30	2.31e-27	0.62	0.49	Pancreatic cancer;	chr3:196011535	chr3:195996738~195998233:+
THCA	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	12.34	1.65e-30	2.32e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
THCA	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-12.34	1.65e-30	2.32e-27	-0.64	-0.49	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
THCA	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-12.34	1.65e-30	2.32e-27	-0.64	-0.49	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
THCA	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-12.34	1.66e-30	2.33e-27	-0.6	-0.49	Height;	chr3:53085518	chr3:53064283~53065091:-
THCA	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-12.34	1.66e-30	2.33e-27	-0.36	-0.49	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	12.34	1.66e-30	2.34e-27	0.37	0.49	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	12.34	1.66e-30	2.34e-27	0.56	0.49	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	12.34	1.66e-30	2.34e-27	0.56	0.49	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
THCA	cis	rs853679	0.517	rs9380047	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28070115	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28071237	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28074687	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28076559	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28076704	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28078391	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28080757	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28080760	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28082231	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28082261	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Parkinson's disease;	chr6:28082269	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28082984	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28083994	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28084025	chr6:28170845~28172521:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28085319	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28096855	chr6:28170845~28172521:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28099759	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Parkinson's disease;	chr6:28100173	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28100648	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28104824	chr6:28170845~28172521:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28107222	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28108492	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28110254	chr6:28170845~28172521:+
THCA	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	12.34	1.71e-30	2.4e-27	0.36	0.49	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-12.34	1.72e-30	2.41e-27	-0.6	-0.49	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
THCA	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-12.34	1.73e-30	2.42e-27	-0.62	-0.49	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
THCA	cis	rs4927850	1	rs6799572	ENSG00000231464.1	AC024937.4	12.34	1.75e-30	2.45e-27	0.61	0.49	Pancreatic cancer;	chr3:196013537	chr3:195996738~195998233:+
THCA	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	12.34	1.75e-30	2.45e-27	0.86	0.49	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
THCA	cis	rs324126	0.78	rs4802926	ENSG00000277977.1	CTD-3018O17.5	-12.34	1.76e-30	2.47e-27	-0.46	-0.49	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52392659~52392755:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-12.33	1.77e-30	2.47e-27	-0.72	-0.49	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
THCA	cis	rs6496932	0.802	rs12439958	ENSG00000218052.5	ADAMTS7P4	12.33	1.77e-30	2.49e-27	0.64	0.49	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85255369~85330334:-
THCA	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	12.33	1.78e-30	2.49e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
THCA	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-12.33	1.78e-30	2.5e-27	-0.63	-0.49	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
THCA	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	12.33	1.79e-30	2.51e-27	0.57	0.49	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
THCA	cis	rs17111396	0.627	rs61978744	ENSG00000259167.2	NMNAT1P1	12.33	1.79e-30	2.51e-27	0.76	0.49	Uric acid levels;	chr14:81045140	chr14:81032529~81033404:+
THCA	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-12.33	1.79e-30	2.51e-27	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
THCA	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	12.33	1.8e-30	2.52e-27	0.36	0.49	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-12.33	1.81e-30	2.54e-27	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	12.33	1.82e-30	2.54e-27	0.57	0.49	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	12.33	1.83e-30	2.56e-27	0.41	0.49	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
THCA	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-12.33	1.86e-30	2.6e-27	-0.94	-0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
THCA	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-12.33	1.86e-30	2.61e-27	-0.47	-0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
THCA	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	12.33	1.88e-30	2.63e-27	0.57	0.49	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
THCA	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-12.33	1.89e-30	2.64e-27	-0.62	-0.49	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
THCA	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	12.33	1.91e-30	2.66e-27	0.4	0.49	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	12.33	1.91e-30	2.66e-27	0.4	0.49	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
THCA	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	12.33	1.93e-30	2.7e-27	0.6	0.49	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
THCA	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-12.32	1.95e-30	2.72e-27	-0.63	-0.49	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	12.32	1.95e-30	2.72e-27	0.63	0.49	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	12.32	1.95e-30	2.72e-27	0.63	0.49	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	12.32	1.95e-30	2.72e-27	0.63	0.49	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
THCA	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
THCA	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	12.32	1.95e-30	2.73e-27	0.63	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
THCA	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	12.32	1.96e-30	2.74e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
THCA	cis	rs853679	0.542	rs9393892	ENSG00000280107.1	AL022393.9	-12.32	1.96e-30	2.74e-27	-0.6	-0.49	Depression;	chr6:28113616	chr6:28170845~28172521:+
THCA	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
THCA	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	12.32	1.97e-30	2.75e-27	0.37	0.49	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
THCA	cis	rs324126	0.78	rs11084150	ENSG00000277977.1	CTD-3018O17.5	-12.32	1.97e-30	2.75e-27	-0.46	-0.49	Colonoscopy-negative controls vs population controls;	chr19:52381851	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs1993531	ENSG00000277977.1	CTD-3018O17.5	12.32	1.97e-30	2.75e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52392659~52392755:+
THCA	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-12.32	1.98e-30	2.76e-27	-0.76	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
THCA	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	12.32	1.99e-30	2.77e-27	0.49	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
THCA	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	12.32	2.01e-30	2.8e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	12.32	2.01e-30	2.8e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
THCA	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-12.32	2.03e-30	2.84e-27	-0.36	-0.49	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
THCA	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	12.32	2.03e-30	2.84e-27	0.53	0.49	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	12.32	2.03e-30	2.84e-27	0.53	0.49	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
THCA	cis	rs853679	0.517	rs9393895	ENSG00000280107.1	AL022393.9	-12.32	2.04e-30	2.84e-27	-0.6	-0.49	Depression;	chr6:28159843	chr6:28170845~28172521:+
THCA	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	12.32	2.06e-30	2.88e-27	0.71	0.49	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
THCA	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-12.32	2.06e-30	2.88e-27	-0.37	-0.49	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
THCA	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	12.32	2.09e-30	2.91e-27	0.58	0.49	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
THCA	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	12.32	2.11e-30	2.94e-27	0.4	0.49	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
THCA	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	12.32	2.11e-30	2.95e-27	0.69	0.49	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
THCA	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	12.32	2.12e-30	2.96e-27	0.42	0.49	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
THCA	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	12.31	2.13e-30	2.97e-27	0.86	0.49	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
THCA	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	12.31	2.14e-30	2.97e-27	0.58	0.49	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
THCA	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-12.31	2.14e-30	2.99e-27	-0.71	-0.49	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
THCA	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	12.31	2.15e-30	2.99e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	12.31	2.15e-30	2.99e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
THCA	cis	rs3931020	0.705	rs28482086	ENSG00000272864.1	RP11-17E13.2	-12.31	2.15e-30	2.99e-27	-0.54	-0.49	Resistin levels;	chr1:74760568	chr1:74698769~74699333:-
THCA	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-12.31	2.16e-30	3e-27	-0.61	-0.49	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
THCA	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-12.31	2.16e-30	3.01e-27	-0.65	-0.49	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
THCA	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	12.31	2.17e-30	3.02e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
THCA	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	12.31	2.17e-30	3.02e-27	0.69	0.49	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
THCA	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
THCA	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
THCA	cis	rs324126	0.78	rs11084153	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs11084154	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs11084155	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52392659~52392755:+
THCA	cis	rs324126	0.752	rs11084156	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs11084157	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs8104808	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs8104812	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52392659~52392755:+
THCA	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-12.31	2.21e-30	3.07e-27	-0.36	-0.49	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
THCA	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-12.31	2.21e-30	3.08e-27	-0.53	-0.49	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
THCA	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	12.31	2.25e-30	3.12e-27	0.72	0.49	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
THCA	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	12.31	2.29e-30	3.18e-27	0.47	0.49	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	12.31	2.29e-30	3.18e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	12.31	2.29e-30	3.18e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
THCA	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	12.31	2.31e-30	3.21e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
THCA	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	12.3	2.33e-30	3.24e-27	0.65	0.49	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	12.3	2.34e-30	3.25e-27	0.72	0.49	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
THCA	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	12.3	2.35e-30	3.26e-27	0.6	0.49	Depression;	chr6:28110525	chr6:28170845~28172521:+
THCA	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	12.3	2.36e-30	3.28e-27	0.73	0.49	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
THCA	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	12.3	2.36e-30	3.28e-27	0.6	0.49	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	12.3	2.36e-30	3.28e-27	0.6	0.49	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	12.3	2.36e-30	3.28e-27	0.6	0.49	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	12.3	2.36e-30	3.28e-27	0.6	0.49	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
THCA	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	12.3	2.36e-30	3.28e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
THCA	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	12.3	2.38e-30	3.3e-27	0.56	0.49	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
THCA	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	12.3	2.39e-30	3.31e-27	0.58	0.49	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
THCA	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-12.3	2.39e-30	3.31e-27	-0.47	-0.49	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
THCA	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	12.3	2.4e-30	3.33e-27	0.4	0.49	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
THCA	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-12.3	2.41e-30	3.35e-27	-0.36	-0.49	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
THCA	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	12.3	2.42e-30	3.35e-27	0.66	0.49	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
THCA	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	12.3	2.42e-30	3.35e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
THCA	cis	rs853679	0.517	rs16893666	ENSG00000280107.1	AL022393.9	12.3	2.44e-30	3.39e-27	0.6	0.49	Depression;	chr6:28086929	chr6:28170845~28172521:+
THCA	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	12.3	2.45e-30	3.39e-27	0.6	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000280107.1	AL022393.9	-12.3	2.45e-30	3.4e-27	-0.6	-0.49	Depression;	chr6:28079011	chr6:28170845~28172521:+
THCA	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-12.3	2.46e-30	3.41e-27	-0.53	-0.49	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
THCA	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	12.3	2.47e-30	3.42e-27	0.6	0.49	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
THCA	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-12.3	2.47e-30	3.42e-27	-0.65	-0.49	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-12.3	2.47e-30	3.42e-27	-0.65	-0.49	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	12.3	2.47e-30	3.42e-27	0.65	0.49	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	12.3	2.47e-30	3.42e-27	0.65	0.49	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	12.3	2.47e-30	3.42e-27	0.65	0.49	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	12.3	2.47e-30	3.42e-27	0.65	0.49	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
THCA	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	12.3	2.48e-30	3.43e-27	0.56	0.49	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
THCA	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-12.3	2.48e-30	3.43e-27	-0.36	-0.49	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
THCA	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
THCA	cis	rs944289	0.616	rs410546	ENSG00000257826.1	RP11-116N8.4	12.3	2.49e-30	3.45e-27	0.51	0.49	Thyroid cancer;	chr14:36071858	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	12.3	2.5e-30	3.47e-27	0.57	0.49	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
THCA	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-12.3	2.51e-30	3.47e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
THCA	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	12.3	2.51e-30	3.47e-27	0.86	0.49	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
THCA	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-12.3	2.51e-30	3.48e-27	-0.53	-0.49	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-12.3	2.53e-30	3.5e-27	-0.71	-0.49	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-12.3	2.53e-30	3.5e-27	-0.71	-0.49	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
THCA	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-12.3	2.53e-30	3.5e-27	-0.74	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
THCA	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-12.3	2.54e-30	3.51e-27	-0.61	-0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
THCA	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-12.3	2.54e-30	3.52e-27	-0.84	-0.49	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
THCA	cis	rs3002131	0.522	rs2378583	ENSG00000225265.1	TAF1A-AS1	-12.3	2.55e-30	3.52e-27	-0.71	-0.49	Interleukin-10 levels;	chr1:222565958	chr1:222589825~222593032:+
THCA	cis	rs324126	0.78	rs1993530	ENSG00000277977.1	CTD-3018O17.5	-12.29	2.58e-30	3.57e-27	-0.47	-0.49	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52392659~52392755:+
THCA	cis	rs11673344	0.801	rs112263309	ENSG00000226686.6	LINC01535	12.29	2.6e-30	3.6e-27	0.58	0.49	Obesity-related traits;	chr19:37160333	chr19:37251912~37265535:+
THCA	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	12.29	2.61e-30	3.6e-27	0.63	0.49	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
THCA	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	12.29	2.61e-30	3.61e-27	0.41	0.49	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000280107.1	AL022393.9	-12.29	2.62e-30	3.62e-27	-0.6	-0.49	Depression;	chr6:28151096	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000280107.1	AL022393.9	-12.29	2.62e-30	3.62e-27	-0.6	-0.49	Depression;	chr6:28152885	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000280107.1	AL022393.9	-12.29	2.62e-30	3.62e-27	-0.6	-0.49	Depression;	chr6:28153120	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000280107.1	AL022393.9	-12.29	2.62e-30	3.62e-27	-0.6	-0.49	Depression;	chr6:28161802	chr6:28170845~28172521:+
THCA	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	12.29	2.63e-30	3.64e-27	0.49	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-12.29	2.64e-30	3.65e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
THCA	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-12.29	2.64e-30	3.65e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-12.29	2.64e-30	3.65e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
THCA	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	12.29	2.65e-30	3.66e-27	0.41	0.49	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
THCA	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-12.29	2.66e-30	3.67e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-12.29	2.66e-30	3.67e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
THCA	cis	rs9309473	1	rs11689392	ENSG00000163016.8	ALMS1P	12.29	2.67e-30	3.69e-27	0.71	0.49	Metabolite levels;	chr2:73394898	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-12.29	2.67e-30	3.69e-27	-0.64	-0.49	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-12.29	2.67e-30	3.69e-27	-0.64	-0.49	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-12.29	2.67e-30	3.69e-27	-0.64	-0.49	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
THCA	cis	rs934734	0.532	rs12185610	ENSG00000204929.10	AC074391.1	-12.29	2.68e-30	3.7e-27	-0.59	-0.49	Rheumatoid arthritis;	chr2:65434334	chr2:65436711~66084639:+
THCA	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	12.29	2.71e-30	3.74e-27	0.36	0.49	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
THCA	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	12.29	2.73e-30	3.77e-27	0.56	0.49	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
THCA	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	12.29	2.75e-30	3.79e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	12.29	2.75e-30	3.79e-27	0.63	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
THCA	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-12.29	2.78e-30	3.83e-27	-0.61	-0.49	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
THCA	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	12.29	2.81e-30	3.87e-27	0.7	0.49	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
THCA	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	12.29	2.81e-30	3.88e-27	0.58	0.49	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
THCA	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-12.28	2.81e-30	3.88e-27	-0.37	-0.49	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-12.28	2.81e-30	3.88e-27	-0.37	-0.49	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-12.28	2.81e-30	3.88e-27	-0.37	-0.49	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
THCA	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	12.28	2.83e-30	3.9e-27	0.71	0.49	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
THCA	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	12.28	2.83e-30	3.9e-27	0.74	0.49	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000204929.10	AC074391.1	-12.28	2.84e-30	3.91e-27	-0.6	-0.49	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65436711~66084639:+
THCA	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	12.28	2.84e-30	3.91e-27	0.4	0.49	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
THCA	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-12.28	2.84e-30	3.92e-27	-0.61	-0.49	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
THCA	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	12.28	2.85e-30	3.93e-27	0.57	0.49	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
THCA	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	12.28	2.87e-30	3.95e-27	0.85	0.49	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-12.28	2.88e-30	3.96e-27	-0.65	-0.49	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
THCA	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-12.28	2.89e-30	3.98e-27	-0.61	-0.49	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
THCA	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-12.28	2.91e-30	4.01e-27	-0.62	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
THCA	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	12.28	2.92e-30	4.02e-27	0.6	0.49	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
THCA	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-12.28	2.92e-30	4.02e-27	-0.37	-0.49	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	12.28	2.93e-30	4.03e-27	0.56	0.49	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
THCA	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	12.28	2.95e-30	4.06e-27	0.41	0.49	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
THCA	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	12.28	2.97e-30	4.09e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
THCA	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	12.28	2.98e-30	4.1e-27	0.61	0.49	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
THCA	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-12.28	2.98e-30	4.1e-27	-0.59	-0.49	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
THCA	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-12.28	3e-30	4.12e-27	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	12.28	3e-30	4.12e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	12.28	3e-30	4.12e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	12.28	3e-30	4.12e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	12.28	3.01e-30	4.14e-27	0.49	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	12.28	3.01e-30	4.14e-27	0.49	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
THCA	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	12.28	3.04e-30	4.17e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
THCA	cis	rs1858037	0.836	rs2576923	ENSG00000204929.10	AC074391.1	-12.28	3.04e-30	4.18e-27	-0.64	-0.49	Rheumatoid arthritis;	chr2:65406750	chr2:65436711~66084639:+
THCA	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	12.28	3.04e-30	4.18e-27	0.85	0.49	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
THCA	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	12.28	3.04e-30	4.18e-27	0.74	0.49	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
THCA	cis	rs853679	0.517	rs4713150	ENSG00000280107.1	AL022393.9	-12.28	3.05e-30	4.19e-27	-0.6	-0.49	Depression;	chr6:28168434	chr6:28170845~28172521:+
THCA	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	12.28	3.07e-30	4.22e-27	0.65	0.49	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	12.28	3.07e-30	4.22e-27	0.65	0.49	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
THCA	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	12.27	3.1e-30	4.26e-27	0.56	0.49	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
THCA	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	12.27	3.1e-30	4.27e-27	0.4	0.49	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
THCA	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	12.27	3.11e-30	4.27e-27	0.41	0.49	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
THCA	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	12.27	3.11e-30	4.27e-27	0.66	0.49	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	12.27	3.12e-30	4.29e-27	0.41	0.49	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	12.27	3.12e-30	4.29e-27	0.41	0.49	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
THCA	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	12.27	3.13e-30	4.3e-27	0.4	0.49	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
THCA	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-12.27	3.14e-30	4.32e-27	-0.61	-0.49	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
THCA	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	12.27	3.18e-30	4.37e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
THCA	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	12.27	3.19e-30	4.38e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
THCA	cis	rs1061377	0.585	rs1367296	ENSG00000249207.1	RP11-360F5.1	-12.27	3.25e-30	4.46e-27	-0.6	-0.49	Uric acid levels;	chr4:39066895	chr4:39112677~39126818:-
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-12.27	3.25e-30	4.46e-27	-0.72	-0.49	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-12.27	3.25e-30	4.46e-27	-0.72	-0.49	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
THCA	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	12.27	3.28e-30	4.5e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	12.27	3.28e-30	4.5e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
THCA	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	12.27	3.29e-30	4.52e-27	0.74	0.49	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
THCA	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	12.27	3.34e-30	4.57e-27	0.65	0.49	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	12.27	3.34e-30	4.57e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	12.27	3.34e-30	4.57e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
THCA	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-12.27	3.34e-30	4.58e-27	-0.83	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
THCA	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	12.27	3.35e-30	4.59e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
THCA	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	12.27	3.38e-30	4.63e-27	0.72	0.49	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
THCA	cis	rs853679	0.513	rs9468296	ENSG00000280107.1	AL022393.9	-12.27	3.38e-30	4.63e-27	-0.6	-0.49	Depression;	chr6:28145952	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000280107.1	AL022393.9	-12.27	3.38e-30	4.63e-27	-0.6	-0.49	Depression;	chr6:28147378	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000280107.1	AL022393.9	-12.27	3.38e-30	4.63e-27	-0.6	-0.49	Depression;	chr6:28147406	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000280107.1	AL022393.9	-12.27	3.38e-30	4.63e-27	-0.6	-0.49	Depression;	chr6:28148143	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs2273564	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28089816	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28090857	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28091439	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28092227	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28093966	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28094014	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28096077	chr6:28170845~28172521:+
THCA	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	12.26	3.43e-30	4.7e-27	0.65	0.49	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-12.26	3.45e-30	4.72e-27	-0.7	-0.49	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
THCA	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-12.26	3.46e-30	4.73e-27	-0.55	-0.49	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
THCA	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	12.26	3.5e-30	4.79e-27	0.74	0.49	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	12.26	3.5e-30	4.79e-27	0.74	0.49	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
THCA	cis	rs9928842	1	rs9928842	ENSG00000280152.1	RP11-331F4.5	12.26	3.54e-30	4.85e-27	0.69	0.49	Alcoholic chronic pancreatitis;	chr16:75208969	chr16:75245994~75250077:-
THCA	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	12.26	3.56e-30	4.88e-27	0.36	0.49	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	12.26	3.56e-30	4.88e-27	0.36	0.49	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	12.26	3.57e-30	4.89e-27	0.56	0.49	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	12.26	3.61e-30	4.93e-27	0.39	0.49	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
THCA	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	12.26	3.61e-30	4.94e-27	0.55	0.49	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
THCA	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	12.26	3.65e-30	5e-27	0.66	0.49	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-12.26	3.66e-30	5.01e-27	-0.6	-0.49	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
THCA	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-12.26	3.68e-30	5.03e-27	-0.62	-0.49	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
THCA	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-12.26	3.68e-30	5.04e-27	-0.4	-0.49	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
THCA	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	12.26	3.7e-30	5.05e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	12.26	3.7e-30	5.05e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
THCA	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	12.25	3.75e-30	5.12e-27	0.85	0.49	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
THCA	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-12.25	3.75e-30	5.13e-27	-0.62	-0.49	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
THCA	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	12.25	3.75e-30	5.13e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
THCA	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	12.25	3.76e-30	5.13e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
THCA	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-12.25	3.76e-30	5.14e-27	-0.57	-0.49	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
THCA	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	12.25	3.76e-30	5.14e-27	0.62	0.49	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	12.25	3.76e-30	5.14e-27	0.62	0.49	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	12.25	3.76e-30	5.14e-27	0.62	0.49	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
THCA	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	12.25	3.79e-30	5.18e-27	0.61	0.49	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
THCA	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-12.25	3.8e-30	5.19e-27	-0.47	-0.49	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	12.25	3.81e-30	5.2e-27	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
THCA	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	12.25	3.81e-30	5.2e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	12.25	3.82e-30	5.21e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
THCA	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	12.25	3.86e-30	5.27e-27	0.62	0.49	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
THCA	cis	rs934734	0.511	rs62141115	ENSG00000204929.10	AC074391.1	-12.25	3.86e-30	5.27e-27	-0.59	-0.49	Rheumatoid arthritis;	chr2:65445058	chr2:65436711~66084639:+
THCA	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-12.25	3.87e-30	5.28e-27	-0.41	-0.49	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
THCA	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-12.25	3.87e-30	5.28e-27	-0.61	-0.49	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
THCA	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	12.25	3.88e-30	5.29e-27	0.65	0.49	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
THCA	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-12.25	3.88e-30	5.29e-27	-0.56	-0.49	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	12.25	3.89e-30	5.31e-27	0.56	0.49	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-12.25	3.91e-30	5.33e-27	-0.56	-0.49	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	12.25	3.92e-30	5.35e-27	0.41	0.49	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	12.25	3.92e-30	5.35e-27	0.41	0.49	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	12.25	3.92e-30	5.35e-27	0.41	0.49	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
THCA	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	12.25	3.93e-30	5.36e-27	0.56	0.49	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	12.25	3.93e-30	5.36e-27	0.56	0.49	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	12.25	3.94e-30	5.37e-27	0.4	0.49	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
THCA	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-12.25	4e-30	5.46e-27	-0.61	-0.49	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
THCA	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	12.25	4e-30	5.46e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	12.25	4e-30	5.46e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-12.25	4.01e-30	5.46e-27	-0.46	-0.49	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
THCA	cis	rs9481169	0.85	rs4947129	ENSG00000255389.1	C6orf3	-12.25	4.04e-30	5.51e-27	-0.9	-0.49	Inflammatory skin disease;	chr6:111609703	chr6:111599875~111602295:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-12.25	4.05e-30	5.51e-27	-0.71	-0.49	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	12.25	4.05e-30	5.52e-27	0.63	0.49	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
THCA	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-12.25	4.05e-30	5.52e-27	-0.46	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
THCA	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	12.24	4.09e-30	5.58e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	12.24	4.09e-30	5.58e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	12.24	4.09e-30	5.58e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
THCA	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	12.24	4.1e-30	5.58e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
THCA	cis	rs853679	0.517	rs9468298	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28154567	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28156691	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28158424	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28159056	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28159925	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28159932	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28162053	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28163375	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28163759	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28164580	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28164825	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28164948	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28165025	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28165528	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Parkinson's disease;	chr6:28165750	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Parkinson's disease;	chr6:28168578	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28169019	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28169249	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28169755	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28169791	chr6:28170845~28172521:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28170075	chr6:28170845~28172521:+
THCA	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	12.24	4.13e-30	5.62e-27	0.58	0.49	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
THCA	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-12.24	4.17e-30	5.67e-27	-0.57	-0.49	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
THCA	cis	rs853679	0.517	rs4713152	ENSG00000280107.1	AL022393.9	-12.24	4.18e-30	5.68e-27	-0.6	-0.49	Depression;	chr6:28169676	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000280107.1	AL022393.9	-12.24	4.18e-30	5.68e-27	-0.6	-0.49	Depression;	chr6:28149979	chr6:28170845~28172521:+
THCA	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	12.24	4.19e-30	5.7e-27	0.65	0.49	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	12.24	4.2e-30	5.71e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	12.24	4.2e-30	5.71e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	12.24	4.2e-30	5.71e-27	0.4	0.49	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
THCA	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	12.24	4.2e-30	5.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
THCA	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	12.24	4.21e-30	5.72e-27	0.62	0.49	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	12.24	4.21e-30	5.72e-27	0.62	0.49	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
THCA	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	12.24	4.26e-30	5.79e-27	0.59	0.49	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	12.24	4.26e-30	5.79e-27	0.59	0.49	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	12.24	4.26e-30	5.79e-27	0.59	0.49	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
THCA	cis	rs1061377	0.621	rs11096974	ENSG00000249207.1	RP11-360F5.1	-12.24	4.28e-30	5.81e-27	-0.59	-0.49	Uric acid levels;	chr4:39062039	chr4:39112677~39126818:-
THCA	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	12.24	4.29e-30	5.84e-27	0.62	0.49	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
THCA	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	12.24	4.3e-30	5.84e-27	0.65	0.49	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	12.24	4.31e-30	5.86e-27	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
THCA	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	12.24	4.44e-30	6.03e-27	0.56	0.49	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-12.24	4.45e-30	6.04e-27	-0.56	-0.49	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
THCA	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-12.24	4.45e-30	6.05e-27	-0.51	-0.49	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
THCA	cis	rs324126	0.78	rs55748277	ENSG00000277977.1	CTD-3018O17.5	12.23	4.5e-30	6.11e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52384992	chr19:52392659~52392755:+
THCA	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	12.23	4.53e-30	6.15e-27	0.36	0.49	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	12.23	4.53e-30	6.15e-27	0.36	0.49	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	12.23	4.53e-30	6.15e-27	0.36	0.49	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
THCA	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	12.23	4.53e-30	6.16e-27	0.41	0.49	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
THCA	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-12.23	4.56e-30	6.19e-27	-0.48	-0.49	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
THCA	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	12.23	4.59e-30	6.23e-27	0.41	0.49	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	12.23	4.59e-30	6.23e-27	0.41	0.49	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	12.23	4.59e-30	6.23e-27	0.41	0.49	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
THCA	cis	rs853679	0.517	rs9380058	ENSG00000280107.1	AL022393.9	-12.23	4.67e-30	6.33e-27	-0.6	-0.49	Depression;	chr6:28159666	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000280107.1	AL022393.9	-12.23	4.67e-30	6.33e-27	-0.6	-0.49	Depression;	chr6:28162598	chr6:28170845~28172521:+
THCA	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	12.23	4.67e-30	6.33e-27	0.41	0.49	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
THCA	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	12.23	4.67e-30	6.33e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
THCA	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	12.23	4.68e-30	6.35e-27	0.71	0.49	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
THCA	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-12.23	4.71e-30	6.39e-27	-0.67	-0.49	Depression;	chr6:28091659	chr6:28115628~28116551:+
THCA	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	12.23	4.73e-30	6.41e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	12.23	4.73e-30	6.42e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	12.23	4.73e-30	6.42e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
THCA	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	12.23	4.74e-30	6.42e-27	0.41	0.49	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	12.23	4.74e-30	6.42e-27	0.41	0.49	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
THCA	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-12.23	4.75e-30	6.44e-27	-0.7	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
THCA	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-12.23	4.76e-30	6.46e-27	-0.65	-0.49	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
THCA	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	12.23	4.79e-30	6.49e-27	0.62	0.49	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
THCA	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
THCA	cis	rs853679	0.517	rs3734573	ENSG00000280107.1	AL022393.9	-12.23	4.81e-30	6.52e-27	-0.6	-0.49	Depression;	chr6:28091659	chr6:28170845~28172521:+
THCA	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	12.23	4.85e-30	6.57e-27	0.56	0.49	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
THCA	cis	rs853679	0.517	rs9393887	ENSG00000280107.1	AL022393.9	-12.23	4.85e-30	6.57e-27	-0.6	-0.49	Depression;	chr6:28091242	chr6:28170845~28172521:+
THCA	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	12.23	4.92e-30	6.66e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
THCA	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-12.22	4.94e-30	6.68e-27	-0.53	-0.49	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-12.22	4.94e-30	6.68e-27	-0.53	-0.49	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
THCA	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	12.22	4.94e-30	6.68e-27	0.58	0.49	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
THCA	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	12.22	4.94e-30	6.69e-27	0.85	0.49	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
THCA	cis	rs62158211	0.826	rs62158168	ENSG00000234997.1	AC016745.3	-12.22	4.98e-30	6.74e-27	-0.58	-0.49	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113320804	chr2:113424495~113425324:+
THCA	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	12.22	4.99e-30	6.75e-27	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	12.22	5e-30	6.76e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
THCA	cis	rs324126	0.78	rs3170100	ENSG00000277977.1	CTD-3018O17.5	12.22	5.01e-30	6.78e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52385367	chr19:52392659~52392755:+
THCA	cis	rs324126	0.743	rs34221182	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs10445583	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52392659~52392755:+
THCA	cis	rs324126	0.752	rs10445584	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs10445585	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs10445586	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs62108317	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52392659~52392755:+
THCA	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	12.22	5.09e-30	6.89e-27	0.74	0.49	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	12.22	5.09e-30	6.89e-27	0.74	0.49	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	12.22	5.1e-30	6.9e-27	0.73	0.49	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000280107.1	AL022393.9	-12.22	5.11e-30	6.91e-27	-0.59	-0.49	Parkinson's disease;	chr6:28110633	chr6:28170845~28172521:+
THCA	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	12.22	5.11e-30	6.91e-27	0.62	0.49	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
THCA	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
THCA	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
THCA	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
THCA	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-12.22	5.18e-30	7e-27	-0.62	-0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
THCA	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	12.22	5.19e-30	7.01e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	12.22	5.19e-30	7.01e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	12.22	5.19e-30	7.01e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
THCA	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	12.22	5.2e-30	7.03e-27	0.73	0.49	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	12.22	5.21e-30	7.03e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	12.22	5.21e-30	7.03e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	12.22	5.21e-30	7.03e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
THCA	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	12.22	5.28e-30	7.13e-27	0.4	0.49	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	12.22	5.28e-30	7.13e-27	0.4	0.49	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
THCA	cis	rs11148252	0.512	rs9526950	ENSG00000235660.1	LINC00345	-12.22	5.29e-30	7.13e-27	-0.63	-0.49	Lewy body disease;	chr13:52600328	chr13:52484161~52484680:-
THCA	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	12.22	5.33e-30	7.19e-27	0.61	0.49	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
THCA	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	12.22	5.33e-30	7.19e-27	0.61	0.49	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000224205.1	AP000351.4	12.22	5.37e-30	7.23e-27	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23987320~23991421:-
THCA	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	12.22	5.38e-30	7.25e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
THCA	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	12.21	5.42e-30	7.31e-27	0.56	0.49	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	12.21	5.42e-30	7.31e-27	0.56	0.49	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	12.21	5.42e-30	7.31e-27	0.56	0.49	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
THCA	cis	rs465969	0.744	rs34659678	ENSG00000255389.1	C6orf3	-12.21	5.45e-30	7.34e-27	-0.95	-0.49	Psoriasis;	chr6:111567337	chr6:111599875~111602295:+
THCA	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-12.21	5.48e-30	7.38e-27	-0.62	-0.49	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
THCA	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-12.21	5.51e-30	7.42e-27	-0.46	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-12.21	5.51e-30	7.42e-27	-0.46	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
THCA	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	12.21	5.58e-30	7.51e-27	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
THCA	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	12.21	5.6e-30	7.54e-27	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	12.21	5.6e-30	7.54e-27	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000280107.1	AL022393.9	-12.21	5.6e-30	7.54e-27	-0.6	-0.49	Depression;	chr6:28071808	chr6:28170845~28172521:+
THCA	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-12.21	5.62e-30	7.56e-27	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
THCA	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-12.21	5.64e-30	7.6e-27	-0.74	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
THCA	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	12.21	5.65e-30	7.6e-27	0.62	0.49	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
THCA	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	12.21	5.65e-30	7.61e-27	0.73	0.49	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
THCA	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	12.21	5.66e-30	7.62e-27	0.41	0.49	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
THCA	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	12.21	5.67e-30	7.64e-27	0.6	0.49	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
THCA	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	12.21	5.69e-30	7.65e-27	0.74	0.49	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
THCA	cis	rs80028505	0.908	rs7760405	ENSG00000271304.1	DPRXP2	12.21	5.69e-30	7.66e-27	0.81	0.49	Foot ulcer in diabetes and neuropathy;	chr6:36106054	chr6:35989515~35990436:-
THCA	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	12.21	5.74e-30	7.72e-27	0.85	0.49	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
THCA	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	12.21	5.75e-30	7.73e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	12.21	5.75e-30	7.73e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
THCA	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-12.21	5.75e-30	7.73e-27	-0.63	-0.49	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
THCA	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	12.21	5.75e-30	7.74e-27	0.57	0.49	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
THCA	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-12.21	5.79e-30	7.79e-27	-0.51	-0.49	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
THCA	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	12.21	5.8e-30	7.8e-27	0.61	0.49	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
THCA	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	12.21	5.91e-30	7.94e-27	0.73	0.49	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
THCA	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	12.21	5.93e-30	7.97e-27	0.41	0.49	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	12.21	5.93e-30	7.97e-27	0.41	0.49	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	12.21	5.93e-30	7.97e-27	0.41	0.49	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
THCA	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	12.21	5.94e-30	7.98e-27	0.62	0.49	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
THCA	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-12.2	5.95e-30	8e-27	-0.36	-0.49	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
THCA	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	12.2	5.99e-30	8.05e-27	0.6	0.49	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
THCA	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-12.2	6e-30	8.06e-27	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	12.2	6.01e-30	8.07e-27	0.56	0.49	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
THCA	cis	rs1858037	0.867	rs72621551	ENSG00000204929.10	AC074391.1	12.2	6.03e-30	8.09e-27	0.64	0.49	Rheumatoid arthritis;	chr2:65388087	chr2:65436711~66084639:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-12.2	6.1e-30	8.19e-27	-0.46	-0.49	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
THCA	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
THCA	cis	rs7569084	1	rs13385171	ENSG00000281920.1	RP11-418H16.1	-12.2	6.24e-30	8.36e-27	-0.6	-0.49	Sum eosinophil basophil counts;	chr2:65434709	chr2:65623272~65628424:+
THCA	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	12.2	6.24e-30	8.36e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
THCA	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	12.2	6.27e-30	8.41e-27	0.61	0.49	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	12.2	6.27e-30	8.41e-27	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-12.2	6.28e-30	8.42e-27	-0.45	-0.49	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
THCA	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	12.2	6.3e-30	8.44e-27	0.36	0.49	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
THCA	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	12.2	6.3e-30	8.44e-27	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
THCA	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-12.2	6.3e-30	8.45e-27	-0.36	-0.49	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-12.2	6.33e-30	8.48e-27	-0.48	-0.49	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-12.2	6.33e-30	8.48e-27	-0.48	-0.49	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
THCA	cis	rs324126	0.78	rs62108319	ENSG00000277977.1	CTD-3018O17.5	12.2	6.34e-30	8.49e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52392659~52392755:+
THCA	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-12.2	6.34e-30	8.49e-27	-0.56	-0.49	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
THCA	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	12.2	6.39e-30	8.56e-27	0.36	0.49	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	12.2	6.39e-30	8.56e-27	0.36	0.49	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
THCA	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	12.2	6.42e-30	8.6e-27	0.59	0.49	Height;	chr3:53091453	chr3:53064283~53065091:-
THCA	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
THCA	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
THCA	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-12.2	6.48e-30	8.68e-27	-0.51	-0.49	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45293285~45297354:+
THCA	cis	rs324126	0.78	rs62108320	ENSG00000277977.1	CTD-3018O17.5	12.2	6.5e-30	8.7e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52392659~52392755:+
THCA	cis	rs324126	0.752	rs62108321	ENSG00000277977.1	CTD-3018O17.5	12.2	6.5e-30	8.7e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52392659~52392755:+
THCA	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	12.2	6.5e-30	8.7e-27	0.47	0.49	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
THCA	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	12.2	6.5e-30	8.7e-27	0.47	0.49	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
THCA	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	12.2	6.52e-30	8.72e-27	0.58	0.49	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
THCA	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	12.19	6.56e-30	8.78e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
THCA	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	12.19	6.6e-30	8.83e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
THCA	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	12.19	6.6e-30	8.83e-27	0.36	0.49	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
THCA	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-12.19	6.62e-30	8.85e-27	-0.59	-0.49	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
THCA	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	12.19	6.63e-30	8.87e-27	0.36	0.49	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-12.19	6.76e-30	9.04e-27	-0.71	-0.49	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-12.19	6.76e-30	9.04e-27	-0.71	-0.49	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-12.19	6.76e-30	9.04e-27	-0.71	-0.49	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
THCA	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-12.19	6.79e-30	9.08e-27	-0.75	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
THCA	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
THCA	cis	rs17111396	0.627	rs59741121	ENSG00000259167.2	NMNAT1P1	12.19	6.87e-30	9.18e-27	0.75	0.49	Uric acid levels;	chr14:81036434	chr14:81032529~81033404:+
THCA	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
THCA	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	12.19	6.91e-30	9.23e-27	0.61	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	12.19	6.91e-30	9.23e-27	0.61	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
THCA	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	12.19	6.94e-30	9.27e-27	0.73	0.49	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
THCA	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	12.19	7.02e-30	9.37e-27	0.85	0.49	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
THCA	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-12.19	7.03e-30	9.39e-27	-0.37	-0.49	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
THCA	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	12.19	7.06e-30	9.42e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-12.19	7.06e-30	9.43e-27	-0.71	-0.49	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
THCA	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	12.19	7.1e-30	9.47e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	12.19	7.1e-30	9.47e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	12.19	7.14e-30	9.52e-27	0.4	0.49	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
THCA	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	12.19	7.16e-30	9.55e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
THCA	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-12.18	7.17e-30	9.56e-27	-0.61	-0.49	Height;	chr3:53080524	chr3:53064283~53065091:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000224205.1	AP000351.4	-12.18	7.2e-30	9.6e-27	-0.59	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23987320~23991421:-
THCA	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	12.18	7.23e-30	9.64e-27	0.39	0.49	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
THCA	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	12.18	7.24e-30	9.65e-27	0.61	0.49	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
THCA	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	12.18	7.25e-30	9.66e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-12.18	7.26e-30	9.68e-27	-0.72	-0.49	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
THCA	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	12.18	7.35e-30	9.79e-27	0.61	0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
THCA	cis	rs6496932	0.802	rs67928464	ENSG00000218052.5	ADAMTS7P4	12.18	7.41e-30	9.87e-27	0.63	0.49	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85255369~85330334:-
THCA	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-12.18	7.43e-30	9.89e-27	-0.51	-0.49	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
THCA	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	12.18	7.46e-30	9.93e-27	0.4	0.49	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
THCA	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	12.18	7.5e-30	9.99e-27	0.59	0.49	Height;	chr11:118809363	chr11:118688039~118690600:-
THCA	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	12.18	7.52e-30	1e-26	0.56	0.49	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
THCA	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	12.18	7.57e-30	1.01e-26	0.57	0.49	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	12.18	7.57e-30	1.01e-26	0.57	0.49	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
THCA	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	12.18	7.6e-30	1.01e-26	0.65	0.49	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-12.18	7.68e-30	1.02e-26	-0.45	-0.49	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-12.18	7.68e-30	1.02e-26	-0.45	-0.49	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
THCA	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-12.18	7.68e-30	1.02e-26	-0.41	-0.49	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000223768.1	LINC00205	-12.18	7.69e-30	1.02e-26	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45293285~45297354:+
THCA	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
THCA	cis	rs853679	0.517	rs3757187	ENSG00000280107.1	AL022393.9	-12.18	7.7e-30	1.02e-26	-0.6	-0.49	Depression;	chr6:28139876	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000280107.1	AL022393.9	-12.18	7.7e-30	1.02e-26	-0.6	-0.49	Depression;	chr6:28139998	chr6:28170845~28172521:+
THCA	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	12.18	7.8e-30	1.04e-26	0.36	0.49	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
THCA	cis	rs9928842	0.824	rs889515	ENSG00000280152.1	RP11-331F4.5	12.18	7.82e-30	1.04e-26	0.69	0.49	Alcoholic chronic pancreatitis;	chr16:75217401	chr16:75245994~75250077:-
THCA	cis	rs853679	0.517	rs1904840	ENSG00000280107.1	AL022393.9	-12.18	7.86e-30	1.05e-26	-0.6	-0.49	Depression;	chr6:28140454	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000280107.1	AL022393.9	-12.18	7.86e-30	1.05e-26	-0.6	-0.49	Depression;	chr6:28141189	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000280107.1	AL022393.9	-12.18	7.86e-30	1.05e-26	-0.6	-0.49	Depression;	chr6:28141484	chr6:28170845~28172521:+
THCA	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
THCA	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28089816	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28090857	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28091439	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28092227	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28093966	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28094014	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28096077	chr6:28115628~28116551:+
THCA	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	12.17	7.89e-30	1.05e-26	0.64	0.49	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
THCA	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-12.17	7.92e-30	1.05e-26	-0.36	-0.49	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-12.17	7.92e-30	1.05e-26	-0.36	-0.49	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
THCA	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	12.17	8e-30	1.06e-26	0.71	0.49	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
THCA	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-12.17	8e-30	1.06e-26	-0.63	-0.49	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
THCA	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	12.17	8.03e-30	1.07e-26	0.36	0.49	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
THCA	cis	rs7240205	0.657	rs1111207	ENSG00000275805.1	RP11-349H17.2	-12.17	8.06e-30	1.07e-26	-0.56	-0.49	Breast cancer;	chr18:26545893	chr18:26565723~26575626:-
THCA	cis	rs7240205	0.657	rs1111208	ENSG00000275805.1	RP11-349H17.2	-12.17	8.06e-30	1.07e-26	-0.56	-0.49	Breast cancer;	chr18:26545901	chr18:26565723~26575626:-
THCA	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	12.17	8.08e-30	1.07e-26	0.36	0.49	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
THCA	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
THCA	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	12.17	8.11e-30	1.08e-26	0.4	0.49	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
THCA	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	12.17	8.14e-30	1.08e-26	0.56	0.49	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	12.17	8.14e-30	1.08e-26	0.56	0.49	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	12.17	8.14e-30	1.08e-26	0.56	0.49	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
THCA	cis	rs7773456	0.576	rs6924929	ENSG00000228412.5	RP4-625H18.2	-12.17	8.14e-30	1.08e-26	-0.74	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19802164~19804752:-
THCA	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	12.17	8.24e-30	1.09e-26	0.61	0.49	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
THCA	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	12.17	8.29e-30	1.1e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
THCA	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	12.17	8.33e-30	1.1e-26	0.61	0.49	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-12.17	8.36e-30	1.11e-26	-0.7	-0.49	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
THCA	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	12.17	8.38e-30	1.11e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	12.17	8.38e-30	1.11e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
THCA	cis	rs11148252	0.532	rs9536185	ENSG00000235660.1	LINC00345	-12.17	8.39e-30	1.11e-26	-0.63	-0.49	Lewy body disease;	chr13:52605666	chr13:52484161~52484680:-
THCA	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	12.17	8.46e-30	1.12e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-12.17	8.46e-30	1.12e-26	-0.6	-0.49	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
THCA	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	12.17	8.47e-30	1.12e-26	0.56	0.49	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
THCA	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
THCA	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
THCA	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	12.17	8.52e-30	1.13e-26	0.54	0.49	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
THCA	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	12.17	8.55e-30	1.13e-26	0.41	0.49	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
THCA	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	12.17	8.57e-30	1.14e-26	0.56	0.49	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
THCA	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	12.17	8.59e-30	1.14e-26	0.56	0.49	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
THCA	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-12.17	8.61e-30	1.14e-26	-0.46	-0.49	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
THCA	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	12.17	8.61e-30	1.14e-26	0.36	0.49	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-12.16	8.63e-30	1.14e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-12.16	8.63e-30	1.14e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-12.16	8.63e-30	1.14e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
THCA	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	12.16	8.69e-30	1.15e-26	0.65	0.49	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-12.16	8.7e-30	1.15e-26	-0.72	-0.49	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-12.16	8.7e-30	1.15e-26	-0.72	-0.49	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
THCA	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-12.16	8.72e-30	1.15e-26	-0.84	-0.49	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
THCA	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-12.16	8.83e-30	1.17e-26	-0.56	-0.49	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	12.16	8.84e-30	1.17e-26	0.58	0.49	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
THCA	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	12.16	8.95e-30	1.18e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	12.16	8.95e-30	1.18e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
THCA	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	12.16	8.98e-30	1.19e-26	0.73	0.49	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	12.16	8.98e-30	1.19e-26	0.73	0.49	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
THCA	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-12.16	9.04e-30	1.2e-26	-0.37	-0.49	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-12.16	9.04e-30	1.2e-26	-0.37	-0.49	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-12.16	9.04e-30	1.2e-26	-0.37	-0.49	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
THCA	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-12.16	9.04e-30	1.2e-26	-0.36	-0.49	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
THCA	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-12.16	9.09e-30	1.2e-26	-0.62	-0.49	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
THCA	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	12.16	9.13e-30	1.21e-26	0.56	0.49	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-12.16	9.2e-30	1.22e-26	-0.45	-0.49	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-12.16	9.29e-30	1.23e-26	-0.72	-0.49	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
THCA	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	12.16	9.31e-30	1.23e-26	0.59	0.49	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
THCA	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	12.16	9.33e-30	1.23e-26	0.69	0.49	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
THCA	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	12.16	9.35e-30	1.24e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	12.16	9.38e-30	1.24e-26	0.56	0.49	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
THCA	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28111382	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28111650	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28112175	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28113851	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28114487	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28114933	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28115743	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28116411	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
THCA	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	12.16	9.43e-30	1.25e-26	0.36	0.49	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
THCA	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-12.15	9.53e-30	1.26e-26	-0.58	-0.49	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
THCA	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	12.15	9.55e-30	1.26e-26	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
THCA	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	12.15	9.56e-30	1.26e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-12.15	9.59e-30	1.27e-26	-0.65	-0.49	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
THCA	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-12.15	9.61e-30	1.27e-26	-0.56	-0.49	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
THCA	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	12.15	9.7e-30	1.28e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
THCA	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-12.15	9.75e-30	1.29e-26	-0.69	-0.49	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
THCA	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	12.15	9.8e-30	1.29e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
THCA	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-12.15	9.8e-30	1.29e-26	-0.61	-0.49	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-12.15	9.8e-30	1.29e-26	-0.61	-0.49	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000224205.1	AP000351.4	12.15	9.87e-30	1.3e-26	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23987320~23991421:-
THCA	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-12.15	9.87e-30	1.3e-26	-0.83	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
THCA	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	12.15	9.94e-30	1.31e-26	0.73	0.49	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	12.15	9.94e-30	1.31e-26	0.73	0.49	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	12.15	9.94e-30	1.31e-26	0.73	0.49	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
THCA	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	12.15	1e-29	1.32e-26	0.6	0.49	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
THCA	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-12.15	1e-29	1.32e-26	-0.74	-0.49	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
THCA	cis	rs7208859	0.673	rs216411	ENSG00000263531.1	RP13-753N3.1	-12.15	1.01e-29	1.33e-26	-0.83	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30863921~30864940:-
THCA	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	12.15	1.02e-29	1.35e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-12.15	1.03e-29	1.35e-26	-0.7	-0.49	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
THCA	cis	rs324126	0.78	rs2059818	ENSG00000277977.1	CTD-3018O17.5	12.14	1.04e-29	1.37e-26	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379267	chr19:52392659~52392755:+
THCA	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-12.14	1.04e-29	1.37e-26	-0.6	-0.49	Height;	chr3:53070344	chr3:53064283~53065091:-
THCA	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-12.14	1.04e-29	1.38e-26	-0.66	-0.49	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
THCA	cis	rs324126	0.78	rs34425941	ENSG00000277977.1	CTD-3018O17.5	12.14	1.05e-29	1.38e-26	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52377359	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs62108318	ENSG00000277977.1	CTD-3018O17.5	12.14	1.05e-29	1.38e-26	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380322	chr19:52392659~52392755:+
THCA	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	12.14	1.05e-29	1.38e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
THCA	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-12.14	1.05e-29	1.39e-26	-0.61	-0.49	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-12.14	1.05e-29	1.39e-26	-0.61	-0.49	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-12.14	1.05e-29	1.39e-26	-0.61	-0.49	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
THCA	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-12.14	1.05e-29	1.39e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
THCA	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	12.14	1.06e-29	1.39e-26	0.55	0.49	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-12.14	1.06e-29	1.39e-26	-0.39	-0.49	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	12.14	1.06e-29	1.39e-26	0.39	0.49	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	12.14	1.06e-29	1.39e-26	0.39	0.49	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-12.14	1.06e-29	1.4e-26	-0.45	-0.49	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
THCA	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-12.14	1.06e-29	1.4e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-12.14	1.07e-29	1.4e-26	-0.61	-0.49	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
THCA	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	12.14	1.08e-29	1.42e-26	0.69	0.49	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-12.14	1.09e-29	1.43e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
THCA	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-12.14	1.11e-29	1.46e-26	-0.64	-0.49	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-12.14	1.11e-29	1.46e-26	-0.64	-0.49	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-12.14	1.11e-29	1.46e-26	-0.64	-0.49	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
THCA	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	12.14	1.12e-29	1.47e-26	0.85	0.49	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-12.14	1.13e-29	1.49e-26	-0.45	-0.49	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
THCA	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-12.13	1.15e-29	1.51e-26	-0.61	-0.49	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
THCA	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	12.13	1.15e-29	1.52e-26	0.65	0.49	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
THCA	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	12.13	1.17e-29	1.53e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	12.13	1.17e-29	1.54e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	12.13	1.17e-29	1.54e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	12.13	1.17e-29	1.54e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
THCA	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	12.13	1.19e-29	1.56e-26	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
THCA	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
THCA	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
THCA	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-12.13	1.2e-29	1.57e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-12.13	1.2e-29	1.57e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-12.13	1.2e-29	1.57e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
THCA	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-12.13	1.2e-29	1.57e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
THCA	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	12.13	1.2e-29	1.57e-26	0.58	0.49	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
THCA	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	12.13	1.2e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
THCA	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	12.13	1.2e-29	1.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	12.13	1.2e-29	1.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
THCA	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	12.13	1.2e-29	1.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
THCA	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28070115	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28071237	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28074687	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28076559	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28076704	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28078391	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28080757	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28080760	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28082231	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28082261	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28082984	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28083994	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28084025	chr6:28115628~28116551:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28085319	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28096855	chr6:28115628~28116551:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28099759	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28100648	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28104824	chr6:28115628~28116551:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28107222	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28108492	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28110254	chr6:28115628~28116551:+
THCA	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	12.13	1.21e-29	1.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
THCA	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-12.13	1.21e-29	1.59e-26	-0.58	-0.49	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
THCA	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	12.13	1.21e-29	1.59e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
THCA	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-12.13	1.22e-29	1.59e-26	-0.36	-0.49	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-12.13	1.22e-29	1.59e-26	-0.36	-0.49	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	12.13	1.22e-29	1.6e-26	0.56	0.49	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	12.13	1.22e-29	1.6e-26	0.56	0.49	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	12.13	1.22e-29	1.6e-26	0.56	0.49	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
THCA	cis	rs4819052	1	rs2297286	ENSG00000223768.1	LINC00205	-12.13	1.23e-29	1.61e-26	-0.5	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45293285~45297354:+
THCA	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	12.13	1.23e-29	1.61e-26	0.61	0.49	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
THCA	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	12.13	1.23e-29	1.61e-26	0.58	0.49	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-12.13	1.23e-29	1.61e-26	-0.71	-0.49	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
THCA	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	12.13	1.24e-29	1.63e-26	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
THCA	cis	rs1858037	0.867	rs55945621	ENSG00000204929.10	AC074391.1	12.12	1.25e-29	1.64e-26	0.64	0.49	Rheumatoid arthritis;	chr2:65388220	chr2:65436711~66084639:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-12.12	1.26e-29	1.64e-26	-0.45	-0.49	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
THCA	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-12.12	1.26e-29	1.64e-26	-0.6	-0.49	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-12.12	1.26e-29	1.64e-26	-0.6	-0.49	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
THCA	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-12.12	1.26e-29	1.66e-26	-0.59	-0.49	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
THCA	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-12.12	1.27e-29	1.66e-26	-0.36	-0.49	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
THCA	cis	rs853679	0.517	rs1904841	ENSG00000280107.1	AL022393.9	-12.12	1.27e-29	1.66e-26	-0.6	-0.49	Depression;	chr6:28140307	chr6:28170845~28172521:+
THCA	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-12.12	1.28e-29	1.67e-26	-0.6	-0.49	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
THCA	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	12.12	1.28e-29	1.68e-26	0.56	0.49	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
THCA	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-12.12	1.28e-29	1.68e-26	-0.62	-0.49	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
THCA	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-12.12	1.29e-29	1.69e-26	-0.63	-0.49	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
THCA	cis	rs4819052	0.851	rs914218	ENSG00000223768.1	LINC00205	-12.12	1.3e-29	1.69e-26	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45293285~45297354:+
THCA	cis	rs4819052	1	rs2297285	ENSG00000223768.1	LINC00205	12.12	1.3e-29	1.69e-26	0.54	0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45293285~45297354:+
THCA	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	12.12	1.31e-29	1.71e-26	0.61	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
THCA	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	12.12	1.31e-29	1.72e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	12.12	1.31e-29	1.72e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
THCA	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	12.12	1.31e-29	1.72e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	12.12	1.31e-29	1.72e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	12.12	1.31e-29	1.72e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
THCA	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	12.12	1.32e-29	1.73e-26	0.36	0.49	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	12.12	1.32e-29	1.73e-26	0.36	0.49	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-12.12	1.34e-29	1.74e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
THCA	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.74e-26	-0.36	-0.49	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.74e-26	-0.36	-0.49	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.75e-26	-0.36	-0.49	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.75e-26	-0.36	-0.49	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.75e-26	-0.36	-0.49	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	12.12	1.34e-29	1.75e-26	0.36	0.49	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
THCA	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	12.12	1.34e-29	1.75e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
THCA	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	12.12	1.35e-29	1.76e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
THCA	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-12.12	1.36e-29	1.77e-26	-0.56	-0.49	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
THCA	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	12.12	1.36e-29	1.77e-26	0.6	0.49	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	12.12	1.37e-29	1.78e-26	0.6	0.49	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	12.12	1.37e-29	1.78e-26	0.6	0.49	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	12.12	1.37e-29	1.78e-26	0.6	0.49	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
THCA	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	12.12	1.37e-29	1.79e-26	0.39	0.49	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
THCA	cis	rs6496932	0.755	rs6497021	ENSG00000218052.5	ADAMTS7P4	-12.11	1.37e-29	1.79e-26	-0.63	-0.49	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85255369~85330334:-
THCA	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-12.11	1.38e-29	1.8e-26	-0.6	-0.49	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
THCA	cis	rs765787	0.53	rs2413775	ENSG00000259520.4	CTD-2651B20.3	12.11	1.38e-29	1.8e-26	0.59	0.49	Uric acid levels;	chr15:45252090	chr15:45251580~45279251:-
THCA	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	12.11	1.38e-29	1.8e-26	0.65	0.49	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
THCA	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	12.11	1.41e-29	1.83e-26	0.6	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
THCA	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-12.11	1.41e-29	1.84e-26	-0.53	-0.49	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
THCA	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	12.11	1.42e-29	1.86e-26	0.63	0.49	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
THCA	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-12.11	1.42e-29	1.86e-26	-0.64	-0.49	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
THCA	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	12.11	1.44e-29	1.88e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	12.11	1.44e-29	1.88e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	12.11	1.44e-29	1.88e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	12.11	1.44e-29	1.88e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
THCA	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
THCA	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-12.11	1.46e-29	1.9e-26	-0.61	-0.49	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
THCA	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-12.11	1.47e-29	1.91e-26	-0.49	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	12.11	1.47e-29	1.92e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	12.11	1.48e-29	1.92e-26	0.77	0.49	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
THCA	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	12.11	1.5e-29	1.95e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
THCA	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-12.11	1.5e-29	1.96e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-12.11	1.5e-29	1.96e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	12.11	1.5e-29	1.96e-26	0.45	0.49	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
THCA	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	12.1	1.51e-29	1.97e-26	0.61	0.49	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
THCA	cis	rs9928842	0.882	rs3169330	ENSG00000280152.1	RP11-331F4.5	12.1	1.51e-29	1.97e-26	0.72	0.49	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75245994~75250077:-
THCA	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	12.1	1.52e-29	1.98e-26	0.63	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
THCA	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	12.1	1.52e-29	1.98e-26	0.61	0.49	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
THCA	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	12.1	1.52e-29	1.98e-26	0.72	0.49	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
THCA	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	12.1	1.53e-29	1.98e-26	0.39	0.49	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
THCA	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	12.1	1.53e-29	1.98e-26	0.56	0.49	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	12.1	1.53e-29	1.98e-26	0.56	0.49	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
THCA	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	12.1	1.53e-29	1.99e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	12.1	1.53e-29	1.99e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	12.1	1.54e-29	2e-26	0.39	0.49	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
THCA	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-12.1	1.54e-29	2e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-12.1	1.54e-29	2e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
THCA	cis	rs56145559	1	rs56145559	ENSG00000163016.8	ALMS1P	12.1	1.56e-29	2.03e-26	0.73	0.49	Schizophrenia;	chr2:73396311	chr2:73644919~73685576:+
THCA	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-12.1	1.58e-29	2.05e-26	-0.36	-0.49	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
THCA	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	12.1	1.59e-29	2.07e-26	0.84	0.49	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
THCA	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-12.1	1.6e-29	2.08e-26	-0.73	-0.49	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
THCA	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-12.1	1.61e-29	2.09e-26	-0.35	-0.49	Height;	chr11:118749988	chr11:118791254~118793137:+
THCA	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-12.1	1.61e-29	2.09e-26	-0.62	-0.49	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs7145727	ENSG00000258413.1	RP11-665C16.6	-12.1	1.61e-29	2.09e-26	-0.63	-0.49	Protein biomarker;	chr14:55380855	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-12.1	1.62e-29	2.1e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-12.1	1.62e-29	2.1e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	12.1	1.62e-29	2.1e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
THCA	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-12.1	1.62e-29	2.11e-26	-0.36	-0.49	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-12.1	1.62e-29	2.11e-26	-0.36	-0.49	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
THCA	cis	rs9928842	0.941	rs1808427	ENSG00000280152.1	RP11-331F4.5	12.1	1.64e-29	2.12e-26	0.68	0.49	Alcoholic chronic pancreatitis;	chr16:75207496	chr16:75245994~75250077:-
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-12.09	1.66e-29	2.15e-26	-0.45	-0.49	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-12.09	1.66e-29	2.15e-26	-0.45	-0.49	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
THCA	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	12.09	1.67e-29	2.16e-26	0.61	0.49	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
THCA	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	12.09	1.67e-29	2.17e-26	0.57	0.49	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
THCA	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-12.09	1.69e-29	2.19e-26	-0.36	-0.49	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-12.09	1.71e-29	2.22e-26	-0.45	-0.49	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
THCA	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	12.09	1.74e-29	2.26e-26	0.66	0.49	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
THCA	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	12.09	1.76e-29	2.28e-26	0.73	0.49	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
THCA	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-12.09	1.76e-29	2.28e-26	-0.63	-0.49	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
THCA	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-12.09	1.77e-29	2.29e-26	-0.58	-0.49	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
THCA	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-12.09	1.78e-29	2.3e-26	-0.6	-0.49	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
THCA	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-12.09	1.78e-29	2.31e-26	-0.51	-0.49	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
THCA	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-12.09	1.78e-29	2.31e-26	-0.36	-0.49	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-12.09	1.79e-29	2.32e-26	-0.45	-0.49	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
THCA	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-12.09	1.79e-29	2.32e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
THCA	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	12.09	1.79e-29	2.32e-26	0.61	0.49	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
THCA	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-12.09	1.8e-29	2.33e-26	-0.46	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	12.09	1.81e-29	2.34e-26	0.56	0.49	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
THCA	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-12.08	1.83e-29	2.36e-26	-0.37	-0.49	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-12.08	1.83e-29	2.36e-26	-0.37	-0.49	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000280107.1	AL022393.9	-12.08	1.83e-29	2.37e-26	-0.58	-0.49	Parkinson's disease;	chr6:28069254	chr6:28170845~28172521:+
THCA	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	12.08	1.84e-29	2.38e-26	0.84	0.49	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
THCA	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	12.08	1.84e-29	2.39e-26	0.63	0.49	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
THCA	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	12.08	1.86e-29	2.4e-26	0.36	0.49	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	12.08	1.86e-29	2.4e-26	0.36	0.49	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	12.08	1.87e-29	2.42e-26	0.36	0.49	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-12.08	1.89e-29	2.44e-26	-0.36	-0.49	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-12.08	1.89e-29	2.44e-26	-0.36	-0.49	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-12.08	1.89e-29	2.44e-26	-0.36	-0.49	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
THCA	cis	rs1431005	0.858	rs11132461	ENSG00000250620.1	RP11-91J3.3	-12.08	1.89e-29	2.45e-26	-0.62	-0.49	Response to statin therapy;	chr4:187509161	chr4:187413564~187415697:+
THCA	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-12.08	1.89e-29	2.45e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
THCA	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.48e-26	0.61	0.49	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.48e-26	0.61	0.49	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
THCA	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.48e-26	0.61	0.49	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.49e-26	0.6	0.49	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
THCA	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.49e-26	0.6	0.49	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
THCA	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.49e-26	0.6	0.49	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.49e-26	0.6	0.49	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
THCA	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	12.08	1.94e-29	2.51e-26	0.48	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	12.08	1.94e-29	2.51e-26	0.48	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-12.08	1.96e-29	2.53e-26	-0.62	-0.49	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
THCA	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	12.08	1.96e-29	2.54e-26	0.39	0.49	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-12.08	1.98e-29	2.56e-26	-0.7	-0.49	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
THCA	cis	rs853679	0.517	rs1947863	ENSG00000280107.1	AL022393.9	-12.08	1.98e-29	2.56e-26	-0.6	-0.49	Depression;	chr6:28131566	chr6:28170845~28172521:+
THCA	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	12.08	1.99e-29	2.57e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	12.08	1.99e-29	2.57e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
THCA	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	12.07	2e-29	2.58e-26	0.56	0.49	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
THCA	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	12.07	2.02e-29	2.61e-26	0.63	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
THCA	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	12.07	2.02e-29	2.61e-26	0.63	0.49	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	12.07	2.02e-29	2.61e-26	0.63	0.49	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
THCA	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-12.07	2.03e-29	2.62e-26	-0.52	-0.49	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
THCA	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-12.07	2.03e-29	2.62e-26	-0.46	-0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	12.07	2.03e-29	2.62e-26	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
THCA	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	12.07	2.05e-29	2.65e-26	0.73	0.49	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	12.07	2.09e-29	2.69e-26	0.73	0.49	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
THCA	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-12.07	2.13e-29	2.75e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-12.07	2.13e-29	2.75e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-12.07	2.13e-29	2.75e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
THCA	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-12.07	2.14e-29	2.76e-26	-0.35	-0.49	Height;	chr11:118747911	chr11:118791254~118793137:+
THCA	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	12.07	2.15e-29	2.77e-26	0.36	0.49	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	12.07	2.15e-29	2.77e-26	0.36	0.49	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
THCA	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	12.07	2.15e-29	2.77e-26	0.36	0.49	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
THCA	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-12.07	2.15e-29	2.77e-26	-0.36	-0.49	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-12.07	2.15e-29	2.77e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
THCA	cis	rs934734	0.532	rs62141075	ENSG00000204929.10	AC074391.1	-12.07	2.16e-29	2.79e-26	-0.59	-0.49	Rheumatoid arthritis;	chr2:65417482	chr2:65436711~66084639:+
THCA	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	12.07	2.18e-29	2.82e-26	0.56	0.49	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
THCA	cis	rs1858037	0.867	rs964505	ENSG00000204929.10	AC074391.1	12.07	2.19e-29	2.82e-26	0.63	0.49	Rheumatoid arthritis;	chr2:65396055	chr2:65436711~66084639:+
THCA	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	12.06	2.19e-29	2.82e-26	0.85	0.49	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
THCA	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	12.06	2.19e-29	2.83e-26	0.6	0.49	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	12.06	2.19e-29	2.83e-26	0.6	0.49	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	12.06	2.19e-29	2.83e-26	0.6	0.49	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	12.06	2.19e-29	2.83e-26	0.6	0.49	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
THCA	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	12.06	2.2e-29	2.83e-26	0.61	0.49	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-12.06	2.2e-29	2.84e-26	-0.71	-0.49	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
THCA	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	12.06	2.2e-29	2.84e-26	0.64	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
THCA	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-12.06	2.23e-29	2.87e-26	-0.65	-0.49	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
THCA	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	12.06	2.24e-29	2.88e-26	0.4	0.49	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	12.06	2.24e-29	2.88e-26	0.4	0.49	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
THCA	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	12.06	2.24e-29	2.88e-26	0.57	0.49	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
THCA	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	12.06	2.26e-29	2.91e-26	0.61	0.49	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
THCA	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-12.06	2.29e-29	2.95e-26	-0.83	-0.49	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
THCA	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-12.06	2.3e-29	2.96e-26	-0.6	-0.49	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
THCA	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	12.06	2.3e-29	2.97e-26	0.36	0.49	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
THCA	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	12.06	2.3e-29	2.97e-26	0.54	0.49	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
THCA	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	12.06	2.31e-29	2.97e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
THCA	cis	rs12458462	0.812	rs34583578	ENSG00000274828.1	RP11-567M16.6	12.06	2.31e-29	2.98e-26	0.41	0.49	Monocyte count;	chr18:79731070	chr18:79677287~79679358:-
THCA	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-12.06	2.32e-29	2.99e-26	-0.54	-0.49	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
THCA	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	12.06	2.32e-29	2.99e-26	0.61	0.49	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
THCA	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	12.06	2.33e-29	2.99e-26	0.51	0.49	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	12.06	2.33e-29	2.99e-26	0.35	0.49	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
THCA	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	12.06	2.36e-29	3.03e-26	0.59	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
THCA	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	12.06	2.37e-29	3.04e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
THCA	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-12.06	2.38e-29	3.06e-26	-0.69	-0.49	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-12.06	2.39e-29	3.07e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
THCA	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-12.05	2.4e-29	3.09e-26	-0.54	-0.49	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
THCA	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-12.05	2.42e-29	3.11e-26	-0.35	-0.49	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	12.05	2.42e-29	3.11e-26	0.35	0.49	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	12.05	2.42e-29	3.11e-26	0.35	0.49	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	12.05	2.43e-29	3.12e-26	0.56	0.49	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000223768.1	LINC00205	12.05	2.45e-29	3.15e-26	0.45	0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-12.05	2.45e-29	3.15e-26	-0.44	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-12.05	2.45e-29	3.15e-26	-0.44	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
THCA	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	12.05	2.45e-29	3.15e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
THCA	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-12.05	2.46e-29	3.16e-26	-0.35	-0.49	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-12.05	2.46e-29	3.16e-26	-0.35	-0.49	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
THCA	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
THCA	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	12.05	2.47e-29	3.17e-26	0.58	0.49	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
THCA	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	12.05	2.49e-29	3.2e-26	0.61	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
THCA	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-12.05	2.49e-29	3.2e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
THCA	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	12.05	2.51e-29	3.23e-26	0.66	0.49	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	12.05	2.51e-29	3.23e-26	0.66	0.49	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
THCA	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	12.05	2.52e-29	3.24e-26	0.57	0.49	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
THCA	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
THCA	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	12.05	2.55e-29	3.27e-26	0.58	0.49	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
THCA	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-12.05	2.56e-29	3.28e-26	-0.52	-0.49	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
THCA	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	12.05	2.58e-29	3.3e-26	0.59	0.49	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
THCA	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-12.05	2.61e-29	3.34e-26	-0.45	-0.49	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	12.04	2.64e-29	3.38e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
THCA	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	12.04	2.67e-29	3.42e-26	0.66	0.49	Depression;	chr6:28086929	chr6:28115628~28116551:+
THCA	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	12.04	2.69e-29	3.43e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
THCA	cis	rs9928842	0.823	rs8061356	ENSG00000280152.1	RP11-331F4.5	12.04	2.7e-29	3.45e-26	0.66	0.49	Alcoholic chronic pancreatitis;	chr16:75260334	chr16:75245994~75250077:-
THCA	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	12.04	2.71e-29	3.47e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
THCA	cis	rs944289	0.557	rs8016147	ENSG00000257826.1	RP11-116N8.4	-12.04	2.73e-29	3.48e-26	-0.53	-0.49	Thyroid cancer;	chr14:36111685	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.879	rs13017585	ENSG00000228389.1	AC068039.4	12.04	2.73e-29	3.48e-26	0.57	0.49	Schizophrenia;	chr2:171865298	chr2:171773482~171775844:+
THCA	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	12.04	2.73e-29	3.49e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	12.04	2.73e-29	3.49e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	12.04	2.73e-29	3.49e-26	0.61	0.49	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	12.04	2.73e-29	3.49e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
THCA	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-12.04	2.73e-29	3.49e-26	-0.54	-0.49	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
THCA	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	12.04	2.74e-29	3.5e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
THCA	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	12.04	2.76e-29	3.53e-26	0.55	0.49	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
THCA	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-12.04	2.8e-29	3.57e-26	-0.36	-0.49	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
THCA	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	12.04	2.81e-29	3.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
THCA	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-12.04	2.82e-29	3.6e-26	-0.92	-0.49	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
THCA	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	12.04	2.84e-29	3.62e-26	0.59	0.49	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
THCA	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	12.04	2.84e-29	3.62e-26	0.39	0.49	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
THCA	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-12.04	2.88e-29	3.68e-26	-0.6	-0.49	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
THCA	cis	rs6496932	1	rs34434405	ENSG00000218052.5	ADAMTS7P4	12.03	2.93e-29	3.73e-26	0.67	0.49	Central corneal thickness;Corneal structure;	chr15:85281437	chr15:85255369~85330334:-
THCA	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	12.03	2.95e-29	3.77e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	12.03	2.95e-29	3.77e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	12.03	2.95e-29	3.77e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
THCA	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-12.03	2.97e-29	3.78e-26	-0.6	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
THCA	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	12.03	3.04e-29	3.88e-26	0.35	0.49	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	12.03	3.04e-29	3.88e-26	0.35	0.49	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
THCA	cis	rs11148252	0.532	rs9536190	ENSG00000235660.1	LINC00345	-12.03	3.05e-29	3.89e-26	-0.63	-0.49	Lewy body disease;	chr13:52606909	chr13:52484161~52484680:-
THCA	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	12.03	3.06e-29	3.89e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
THCA	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-12.03	3.08e-29	3.92e-26	-0.54	-0.49	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
THCA	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	12.03	3.11e-29	3.96e-26	0.69	0.49	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
THCA	cis	rs934734	0.532	rs12470883	ENSG00000204929.10	AC074391.1	-12.03	3.12e-29	3.98e-26	-0.59	-0.49	Rheumatoid arthritis;	chr2:65424717	chr2:65436711~66084639:+
THCA	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	12.03	3.14e-29	3.99e-26	0.64	0.49	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
THCA	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	12.03	3.14e-29	4e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
THCA	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	12.02	3.18e-29	4.05e-26	0.35	0.49	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
THCA	cis	rs934734	0.571	rs7572922	ENSG00000204929.10	AC074391.1	-12.02	3.19e-29	4.05e-26	-0.59	-0.49	Rheumatoid arthritis;	chr2:65425022	chr2:65436711~66084639:+
THCA	cis	rs9928842	0.882	rs9319481	ENSG00000280152.1	RP11-331F4.5	12.02	3.22e-29	4.09e-26	0.7	0.48	Alcoholic chronic pancreatitis;	chr16:75225580	chr16:75245994~75250077:-
THCA	cis	rs9928842	0.882	rs1107593	ENSG00000280152.1	RP11-331F4.5	12.02	3.22e-29	4.09e-26	0.7	0.48	Alcoholic chronic pancreatitis;	chr16:75227431	chr16:75245994~75250077:-
THCA	cis	rs9928842	0.824	rs12924999	ENSG00000280152.1	RP11-331F4.5	12.02	3.22e-29	4.09e-26	0.7	0.48	Alcoholic chronic pancreatitis;	chr16:75228527	chr16:75245994~75250077:-
THCA	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	12.02	3.26e-29	4.14e-26	0.56	0.48	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	12.02	3.26e-29	4.14e-26	0.56	0.48	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	12.02	3.26e-29	4.14e-26	0.56	0.48	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
THCA	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	12.02	3.28e-29	4.17e-26	0.49	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
THCA	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-12.02	3.28e-29	4.17e-26	-0.84	-0.48	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
THCA	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	12.02	3.31e-29	4.21e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
THCA	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	12.02	3.31e-29	4.21e-26	0.73	0.48	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
THCA	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	12.02	3.33e-29	4.24e-26	0.61	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	12.02	3.33e-29	4.24e-26	0.61	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	12.02	3.33e-29	4.24e-26	0.61	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
THCA	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-12.02	3.33e-29	4.24e-26	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
THCA	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-12.02	3.35e-29	4.25e-26	-0.35	-0.48	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
THCA	cis	rs4819052	0.851	rs914214	ENSG00000223768.1	LINC00205	-12.02	3.36e-29	4.26e-26	-0.46	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45293285~45297354:+
THCA	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	12.02	3.38e-29	4.29e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	12.02	3.38e-29	4.29e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	12.02	3.38e-29	4.29e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
THCA	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-12.02	3.38e-29	4.29e-26	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
THCA	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	12.02	3.38e-29	4.3e-26	0.63	0.48	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
THCA	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	12.02	3.42e-29	4.34e-26	0.71	0.48	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
THCA	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-12.02	3.42e-29	4.35e-26	-0.6	-0.48	Height;	chr3:53093751	chr3:53064283~53065091:-
THCA	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	12.02	3.43e-29	4.36e-26	0.58	0.48	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	12.02	3.45e-29	4.38e-26	0.61	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	12.02	3.45e-29	4.38e-26	0.61	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
THCA	cis	rs7182621	0.883	rs10468181	ENSG00000259363.4	CTD-2054N24.2	-12.02	3.45e-29	4.38e-26	-0.59	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99885244	chr15:99807023~99877148:+
THCA	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-12.02	3.46e-29	4.39e-26	-0.45	-0.48	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
THCA	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-12.01	3.5e-29	4.44e-26	-0.55	-0.48	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
THCA	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	12.01	3.5e-29	4.44e-26	0.56	0.48	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	12.01	3.5e-29	4.44e-26	0.56	0.48	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	12.01	3.5e-29	4.44e-26	0.56	0.48	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
THCA	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-12.01	3.52e-29	4.46e-26	-0.36	-0.48	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-12.01	3.52e-29	4.46e-26	-0.36	-0.48	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-12.01	3.52e-29	4.46e-26	-0.36	-0.48	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-12.01	3.52e-29	4.46e-26	-0.36	-0.48	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	12.01	3.52e-29	4.46e-26	0.36	0.48	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	12.01	3.53e-29	4.48e-26	0.36	0.48	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	12.01	3.53e-29	4.48e-26	0.36	0.48	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	12.01	3.53e-29	4.48e-26	0.36	0.48	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	12.01	3.53e-29	4.48e-26	0.36	0.48	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
THCA	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
THCA	cis	rs853679	0.517	rs9380056	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28136698	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28136856	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28137418	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28138363	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Parkinson's disease;	chr6:28138569	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28138981	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28139012	chr6:28170845~28172521:+
THCA	cis	rs4819052	1	rs2297284	ENSG00000223768.1	LINC00205	-12.01	3.55e-29	4.5e-26	-0.5	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45293285~45297354:+
THCA	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-12.01	3.57e-29	4.52e-26	-0.64	-0.48	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	12.01	3.58e-29	4.53e-26	0.7	0.48	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
THCA	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-12.01	3.59e-29	4.55e-26	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
THCA	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-12.01	3.6e-29	4.56e-26	-0.36	-0.48	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
THCA	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-12.01	3.6e-29	4.56e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
THCA	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	12.01	3.62e-29	4.58e-26	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
THCA	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-12.01	3.64e-29	4.61e-26	-0.35	-0.48	Height;	chr11:118746590	chr11:118791254~118793137:+
THCA	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	12.01	3.66e-29	4.63e-26	0.61	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-12.01	3.67e-29	4.65e-26	-0.65	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
THCA	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-12.01	3.67e-29	4.65e-26	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
THCA	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-12.01	3.68e-29	4.66e-26	-0.59	-0.48	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
THCA	cis	rs10853057	0.85	rs35151435	ENSG00000214174.7	AMZ2P1	12.01	3.68e-29	4.66e-26	0.94	0.48	White matter microstructure (global fractional anisotropy);	chr17:65000600	chr17:64966550~64975576:-
THCA	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	12.01	3.69e-29	4.67e-26	0.46	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
THCA	cis	rs944289	0.646	rs1742868	ENSG00000257826.1	RP11-116N8.4	-12.01	3.69e-29	4.67e-26	-0.49	-0.48	Thyroid cancer;	chr14:36067743	chr14:36061026~36067190:-
THCA	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	12.01	3.74e-29	4.73e-26	0.72	0.48	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
THCA	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-12.01	3.75e-29	4.75e-26	-0.36	-0.48	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-12.01	3.75e-29	4.75e-26	-0.36	-0.48	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
THCA	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-12.01	3.78e-29	4.78e-26	-0.56	-0.48	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
THCA	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	12.01	3.78e-29	4.78e-26	0.36	0.48	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
THCA	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	12.01	3.78e-29	4.78e-26	0.36	0.48	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
THCA	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-12.01	3.79e-29	4.79e-26	-0.69	-0.48	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
THCA	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-12	3.84e-29	4.86e-26	-0.56	-0.48	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
THCA	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-12	3.84e-29	4.86e-26	-0.52	-0.48	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000223768.1	LINC00205	12	3.89e-29	4.92e-26	0.46	0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-12	3.93e-29	4.97e-26	-0.69	-0.48	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
THCA	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	12	3.94e-29	4.97e-26	0.36	0.48	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000280107.1	AL022393.9	-12	3.95e-29	4.99e-26	-0.6	-0.48	Depression;	chr6:28143758	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000280107.1	AL022393.9	-12	3.95e-29	4.99e-26	-0.6	-0.48	Depression;	chr6:28144784	chr6:28170845~28172521:+
THCA	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-12	3.96e-29	5.01e-26	-0.68	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
THCA	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-12	3.99e-29	5.04e-26	-0.47	-0.48	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
THCA	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	12	4e-29	5.05e-26	0.58	0.48	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	12	4e-29	5.05e-26	0.58	0.48	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	12	4e-29	5.05e-26	0.58	0.48	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	12	4e-29	5.05e-26	0.58	0.48	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
THCA	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-12	4.07e-29	5.13e-26	-0.54	-0.48	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
THCA	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	12	4.08e-29	5.15e-26	0.65	0.48	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-12	4.09e-29	5.16e-26	-0.39	-0.48	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
THCA	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	12	4.1e-29	5.17e-26	0.6	0.48	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
THCA	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	12	4.12e-29	5.2e-26	0.62	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
THCA	cis	rs853679	0.517	rs4713145	ENSG00000280107.1	AL022393.9	-12	4.17e-29	5.26e-26	-0.59	-0.48	Depression;	chr6:28139049	chr6:28170845~28172521:+
THCA	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	11.99	4.18e-29	5.27e-26	0.56	0.48	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
THCA	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-11.99	4.2e-29	5.3e-26	-0.64	-0.48	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	11.99	4.21e-29	5.31e-26	0.7	0.48	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
THCA	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	11.99	4.21e-29	5.31e-26	0.57	0.48	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
THCA	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	11.99	4.24e-29	5.34e-26	0.55	0.48	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	11.99	4.24e-29	5.35e-26	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	11.99	4.27e-29	5.38e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
THCA	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	11.99	4.31e-29	5.43e-26	0.64	0.48	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-11.99	4.32e-29	5.45e-26	-0.64	-0.48	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
THCA	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-11.99	4.37e-29	5.51e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
THCA	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-11.99	4.37e-29	5.51e-26	-0.35	-0.48	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
THCA	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	11.99	4.42e-29	5.57e-26	0.55	0.48	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	11.99	4.42e-29	5.57e-26	0.55	0.48	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
THCA	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	11.99	4.43e-29	5.58e-26	0.58	0.48	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
THCA	cis	rs1858037	0.867	rs876933	ENSG00000204929.10	AC074391.1	11.99	4.44e-29	5.59e-26	0.63	0.48	Rheumatoid arthritis;	chr2:65382303	chr2:65436711~66084639:+
THCA	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	11.99	4.48e-29	5.64e-26	0.58	0.48	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
THCA	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-11.99	4.48e-29	5.64e-26	-0.54	-0.48	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
THCA	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-11.99	4.49e-29	5.65e-26	-0.64	-0.48	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
THCA	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-11.99	4.54e-29	5.72e-26	-0.35	-0.48	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
THCA	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	11.99	4.55e-29	5.73e-26	0.64	0.48	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	11.99	4.55e-29	5.73e-26	0.64	0.48	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
THCA	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
THCA	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	11.98	4.6e-29	5.79e-26	0.6	0.48	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
THCA	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	11.98	4.63e-29	5.83e-26	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	11.98	4.63e-29	5.83e-26	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
THCA	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-11.98	4.65e-29	5.85e-26	-0.59	-0.48	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
THCA	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	11.98	4.67e-29	5.87e-26	0.6	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
THCA	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	11.98	4.73e-29	5.95e-26	0.56	0.48	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
THCA	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	11.98	4.75e-29	5.97e-26	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	11.98	4.81e-29	6.05e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
THCA	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	11.98	4.85e-29	6.1e-26	0.56	0.48	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
THCA	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-11.98	4.87e-29	6.12e-26	-0.53	-0.48	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
THCA	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-11.98	4.93e-29	6.2e-26	-0.54	-0.48	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
THCA	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	11.98	4.99e-29	6.26e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	11.98	4.99e-29	6.26e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	11.98	4.99e-29	6.26e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	11.98	4.99e-29	6.26e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
THCA	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	11.98	4.99e-29	6.26e-26	0.47	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
THCA	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	11.98	5.02e-29	6.3e-26	0.59	0.48	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	11.98	5.02e-29	6.3e-26	0.59	0.48	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
THCA	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-11.98	5.03e-29	6.31e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
THCA	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-11.97	5.05e-29	6.34e-26	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
THCA	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	11.97	5.07e-29	6.37e-26	0.47	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
THCA	cis	rs12458462	0.851	rs2169249	ENSG00000274828.1	RP11-567M16.6	11.97	5.1e-29	6.4e-26	0.4	0.48	Monocyte count;	chr18:79729649	chr18:79677287~79679358:-
THCA	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	11.97	5.11e-29	6.41e-26	0.69	0.48	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
THCA	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	11.97	5.12e-29	6.43e-26	0.35	0.48	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
THCA	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	11.97	5.14e-29	6.46e-26	0.5	0.48	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
THCA	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-11.97	5.15e-29	6.47e-26	-0.35	-0.48	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-11.97	5.15e-29	6.47e-26	-0.35	-0.48	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-11.97	5.15e-29	6.47e-26	-0.35	-0.48	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-11.97	5.16e-29	6.48e-26	-0.47	-0.48	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
THCA	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-11.97	5.21e-29	6.53e-26	-0.56	-0.48	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
THCA	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
THCA	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-11.97	5.29e-29	6.64e-26	-0.4	-0.48	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
THCA	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-11.97	5.31e-29	6.67e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000280107.1	AL022393.9	-11.97	5.32e-29	6.67e-26	-0.59	-0.48	Depression;	chr6:28096845	chr6:28170845~28172521:+
THCA	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-11.97	5.38e-29	6.74e-26	-0.45	-0.48	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
THCA	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-11.97	5.38e-29	6.75e-26	-0.75	-0.48	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-11.97	5.38e-29	6.75e-26	-0.75	-0.48	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
THCA	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-11.97	5.39e-29	6.75e-26	-0.36	-0.48	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
THCA	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	11.97	5.4e-29	6.76e-26	0.74	0.48	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
THCA	cis	rs67311347	0.955	rs73080163	ENSG00000223797.4	ENTPD3-AS1	11.97	5.44e-29	6.82e-26	0.4	0.48	Renal cell carcinoma;	chr3:40491570	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73080165	ENSG00000223797.4	ENTPD3-AS1	11.97	5.44e-29	6.82e-26	0.4	0.48	Renal cell carcinoma;	chr3:40491571	chr3:40313802~40453329:-
THCA	cis	rs9928842	0.54	rs8051363	ENSG00000280152.1	RP11-331F4.5	11.97	5.45e-29	6.83e-26	0.56	0.48	Alcoholic chronic pancreatitis;	chr16:75221319	chr16:75245994~75250077:-
THCA	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-11.97	5.46e-29	6.84e-26	-0.83	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
THCA	cis	rs80028505	0.908	rs7761118	ENSG00000271304.1	DPRXP2	11.97	5.49e-29	6.87e-26	0.78	0.48	Foot ulcer in diabetes and neuropathy;	chr6:36100526	chr6:35989515~35990436:-
THCA	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-11.97	5.49e-29	6.88e-26	-0.83	-0.48	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	11.97	5.5e-29	6.89e-26	0.65	0.48	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
THCA	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	11.97	5.5e-29	6.89e-26	0.56	0.48	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
THCA	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	11.96	5.53e-29	6.93e-26	0.48	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	11.96	5.53e-29	6.93e-26	0.65	0.48	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	11.96	5.53e-29	6.93e-26	0.65	0.48	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	11.96	5.53e-29	6.93e-26	0.65	0.48	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	11.96	5.53e-29	6.93e-26	0.65	0.48	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
THCA	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-11.96	5.54e-29	6.93e-26	-0.35	-0.48	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
THCA	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
THCA	cis	rs944289	0.646	rs394246	ENSG00000257826.1	RP11-116N8.4	11.96	5.58e-29	6.98e-26	0.49	0.48	Thyroid cancer;	chr14:36066074	chr14:36061026~36067190:-
THCA	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-11.96	5.61e-29	7.02e-26	-0.54	-0.48	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
THCA	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	11.96	5.61e-29	7.02e-26	0.61	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
THCA	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-11.96	5.65e-29	7.07e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
THCA	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	11.96	5.66e-29	7.08e-26	0.65	0.48	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
THCA	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
THCA	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	11.96	5.71e-29	7.14e-26	0.41	0.48	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
THCA	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
THCA	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-11.96	5.77e-29	7.21e-26	-0.59	-0.48	Height;	chr3:53069965	chr3:53064283~53065091:-
THCA	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	11.96	5.85e-29	7.31e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
THCA	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	11.96	5.88e-29	7.34e-26	0.6	0.48	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
THCA	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	11.96	5.91e-29	7.37e-26	0.63	0.48	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
THCA	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	11.96	5.91e-29	7.37e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	11.96	5.94e-29	7.4e-26	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs2838864	ENSG00000223768.1	LINC00205	11.96	5.95e-29	7.41e-26	0.45	0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45293285~45297354:+
THCA	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-11.96	5.98e-29	7.44e-26	-0.35	-0.48	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
THCA	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-11.96	6.04e-29	7.51e-26	-0.64	-0.48	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	11.95	6.06e-29	7.54e-26	0.67	0.48	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-11.95	6.11e-29	7.6e-26	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
THCA	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	11.95	6.14e-29	7.63e-26	0.61	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
THCA	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	11.95	6.14e-29	7.64e-26	0.52	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	11.95	6.14e-29	7.64e-26	0.52	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
THCA	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-11.95	6.15e-29	7.65e-26	-0.35	-0.48	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	11.95	6.15e-29	7.65e-26	0.35	0.48	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
THCA	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	11.95	6.16e-29	7.66e-26	0.5	0.48	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
THCA	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	11.95	6.16e-29	7.66e-26	0.66	0.48	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
THCA	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-11.95	6.16e-29	7.66e-26	-0.75	-0.48	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
THCA	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-11.95	6.16e-29	7.66e-26	-0.75	-0.48	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
THCA	cis	rs853679	0.517	rs4713141	ENSG00000280107.1	AL022393.9	-11.95	6.19e-29	7.7e-26	-0.59	-0.48	Depression;	chr6:28133900	chr6:28170845~28172521:+
THCA	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-11.95	6.2e-29	7.71e-26	-0.65	-0.48	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
THCA	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	11.95	6.26e-29	7.78e-26	0.56	0.48	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
THCA	cis	rs944289	0.646	rs375095	ENSG00000257826.1	RP11-116N8.4	11.95	6.34e-29	7.89e-26	0.49	0.48	Thyroid cancer;	chr14:36066043	chr14:36061026~36067190:-
THCA	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	11.95	6.53e-29	8.11e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
THCA	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-11.95	6.53e-29	8.11e-26	-0.36	-0.48	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
THCA	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-11.95	6.54e-29	8.12e-26	-0.45	-0.48	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
THCA	cis	rs12458462	0.859	rs34242155	ENSG00000274828.1	RP11-567M16.6	11.95	6.54e-29	8.12e-26	0.39	0.48	Monocyte count;	chr18:79665192	chr18:79677287~79679358:-
THCA	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-11.95	6.56e-29	8.14e-26	-0.6	-0.48	Height;	chr3:53094335	chr3:53064283~53065091:-
THCA	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-11.95	6.58e-29	8.17e-26	-0.68	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
THCA	cis	rs4819052	1	rs9306123	ENSG00000223768.1	LINC00205	-11.95	6.58e-29	8.17e-26	-0.49	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45293285~45297354:+
THCA	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	11.95	6.6e-29	8.19e-26	0.64	0.48	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
THCA	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	11.95	6.6e-29	8.19e-26	0.89	0.48	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
THCA	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	11.94	6.65e-29	8.25e-26	0.54	0.48	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
THCA	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	11.94	6.65e-29	8.26e-26	0.7	0.48	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	11.94	6.65e-29	8.26e-26	0.7	0.48	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	11.94	6.67e-29	8.28e-26	0.69	0.48	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
THCA	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	11.94	6.73e-29	8.34e-26	0.66	0.48	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
THCA	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	11.94	6.74e-29	8.35e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
THCA	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	11.94	6.74e-29	8.35e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
THCA	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-11.94	6.75e-29	8.37e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
THCA	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-11.94	6.79e-29	8.42e-26	-0.77	-0.48	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-11.94	6.91e-29	8.57e-26	-0.45	-0.48	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
THCA	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	11.94	6.93e-29	8.59e-26	0.55	0.48	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
THCA	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	11.94	6.97e-29	8.64e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	11.94	6.97e-29	8.64e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-11.94	6.99e-29	8.66e-26	-0.71	-0.48	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-11.94	7.03e-29	8.71e-26	-0.46	-0.48	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
THCA	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	11.94	7.03e-29	8.71e-26	0.5	0.48	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
THCA	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-11.94	7.05e-29	8.73e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
THCA	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
THCA	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-11.94	7.09e-29	8.78e-26	-0.84	-0.48	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
THCA	cis	rs853679	0.517	rs9295761	ENSG00000280107.1	AL022393.9	-11.94	7.12e-29	8.82e-26	-0.59	-0.48	Depression;	chr6:28180209	chr6:28170845~28172521:+
THCA	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	11.94	7.12e-29	8.82e-26	0.62	0.48	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
THCA	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	11.94	7.13e-29	8.83e-26	0.54	0.48	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
THCA	cis	rs4819052	0.684	rs914216	ENSG00000223768.1	LINC00205	-11.94	7.14e-29	8.84e-26	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45293285~45297354:+
THCA	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	11.94	7.15e-29	8.86e-26	0.35	0.48	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-11.94	7.2e-29	8.91e-26	-0.59	-0.48	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
THCA	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	11.94	7.27e-29	9e-26	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
THCA	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	11.93	7.31e-29	9.04e-26	0.46	0.48	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
THCA	cis	rs853679	0.517	rs12332979	ENSG00000280107.1	AL022393.9	-11.93	7.32e-29	9.06e-26	-0.59	-0.48	Depression;	chr6:28173770	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000280107.1	AL022393.9	-11.93	7.32e-29	9.06e-26	-0.59	-0.48	Depression;	chr6:28174809	chr6:28170845~28172521:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000280107.1	AL022393.9	-11.93	7.32e-29	9.06e-26	-0.59	-0.48	Depression;	chr6:28175233	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000280107.1	AL022393.9	-11.93	7.32e-29	9.06e-26	-0.59	-0.48	Depression;	chr6:28176973	chr6:28170845~28172521:+
THCA	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	11.93	7.39e-29	9.14e-26	0.49	0.48	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
THCA	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-11.93	7.49e-29	9.27e-26	-0.56	-0.48	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
THCA	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	11.93	7.54e-29	9.32e-26	0.64	0.48	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
THCA	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-11.93	7.59e-29	9.38e-26	-0.84	-0.48	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
THCA	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-11.93	7.61e-29	9.4e-26	-0.45	-0.48	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
THCA	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-11.93	7.65e-29	9.46e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-11.93	7.65e-29	9.46e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	11.93	7.68e-29	9.49e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
THCA	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-11.93	7.69e-29	9.51e-26	-0.63	-0.48	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-11.93	7.69e-29	9.51e-26	-0.63	-0.48	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
THCA	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	11.93	7.7e-29	9.52e-26	0.64	0.48	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
THCA	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-11.93	7.71e-29	9.53e-26	-0.79	-0.48	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
THCA	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	11.93	7.74e-29	9.56e-26	0.72	0.48	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
THCA	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	11.93	7.76e-29	9.58e-26	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	11.93	7.76e-29	9.58e-26	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
THCA	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	11.93	7.76e-29	9.59e-26	0.52	0.48	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-11.93	7.79e-29	9.63e-26	-0.71	-0.48	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
THCA	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-11.93	7.8e-29	9.63e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-11.93	7.8e-29	9.63e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-11.93	7.8e-29	9.63e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-11.93	7.8e-29	9.63e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
THCA	cis	rs9309473	0.513	rs62149782	ENSG00000163016.8	ALMS1P	11.93	7.83e-29	9.66e-26	0.82	0.48	Metabolite levels;	chr2:73591901	chr2:73644919~73685576:+
THCA	cis	rs240993	0.809	rs11153277	ENSG00000230177.1	RP5-1112D6.4	-11.93	7.84e-29	9.68e-26	-0.43	-0.48	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111277932~111278742:+
THCA	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	11.93	7.87e-29	9.71e-26	0.63	0.48	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
THCA	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	11.93	7.91e-29	9.77e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
THCA	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-11.93	7.92e-29	9.78e-26	-0.48	-0.48	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
THCA	cis	rs9389248	0.623	rs2142725	ENSG00000232876.1	CTA-212D2.2	11.92	8.13e-29	1e-25	0.61	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134937804	chr6:135055033~135060550:+
THCA	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	11.92	8.14e-29	1e-25	0.6	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
THCA	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-11.92	8.25e-29	1.02e-25	-0.5	-0.48	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
THCA	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-11.92	8.26e-29	1.02e-25	-0.46	-0.48	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	11.92	8.31e-29	1.03e-25	0.66	0.48	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
THCA	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	11.92	8.34e-29	1.03e-25	0.84	0.48	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
THCA	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
THCA	cis	rs9928842	0.679	rs4888361	ENSG00000280152.1	RP11-331F4.5	11.92	8.44e-29	1.04e-25	0.68	0.48	Alcoholic chronic pancreatitis;	chr16:75233778	chr16:75245994~75250077:-
THCA	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-11.92	8.48e-29	1.04e-25	-0.35	-0.48	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-11.92	8.49e-29	1.05e-25	-0.62	-0.48	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	11.92	8.58e-29	1.06e-25	0.65	0.48	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
THCA	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.59e-29	1.06e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
THCA	cis	rs12458462	0.851	rs62097746	ENSG00000274828.1	RP11-567M16.6	11.92	8.59e-29	1.06e-25	0.4	0.48	Monocyte count;	chr18:79727508	chr18:79677287~79679358:-
THCA	cis	rs12458462	0.851	rs60298379	ENSG00000274828.1	RP11-567M16.6	11.92	8.59e-29	1.06e-25	0.4	0.48	Monocyte count;	chr18:79728422	chr18:79677287~79679358:-
THCA	cis	rs12458462	0.812	rs36073957	ENSG00000274828.1	RP11-567M16.6	11.92	8.59e-29	1.06e-25	0.4	0.48	Monocyte count;	chr18:79728441	chr18:79677287~79679358:-
THCA	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	11.92	8.65e-29	1.06e-25	0.56	0.48	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	11.92	8.65e-29	1.06e-25	0.56	0.48	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
THCA	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	11.92	8.66e-29	1.07e-25	0.64	0.48	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	11.92	8.66e-29	1.07e-25	0.64	0.48	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	11.92	8.66e-29	1.07e-25	0.64	0.48	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000204929.10	AC074391.1	-11.92	8.67e-29	1.07e-25	-0.59	-0.48	Rheumatoid arthritis;	chr2:65423730	chr2:65436711~66084639:+
THCA	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-11.92	8.67e-29	1.07e-25	-0.64	-0.48	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
THCA	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-11.92	8.67e-29	1.07e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-11.92	8.67e-29	1.07e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
THCA	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-11.92	8.68e-29	1.07e-25	-0.43	-0.48	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
THCA	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-11.92	8.69e-29	1.07e-25	-0.61	-0.48	Height;	chr3:53097932	chr3:53064283~53065091:-
THCA	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	11.92	8.71e-29	1.07e-25	0.55	0.48	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
THCA	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-11.91	8.76e-29	1.08e-25	-0.5	-0.48	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
THCA	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-11.91	8.79e-29	1.08e-25	-0.35	-0.48	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-11.91	8.97e-29	1.1e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-11.91	8.97e-29	1.1e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
THCA	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	11.91	9e-29	1.11e-25	0.83	0.48	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
THCA	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-11.91	9.04e-29	1.11e-25	-0.54	-0.48	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
THCA	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	11.91	9.13e-29	1.12e-25	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
THCA	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	11.91	9.14e-29	1.12e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000223768.1	LINC00205	-11.91	9.18e-29	1.13e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.654	rs4896829	ENSG00000235652.6	RP11-545I5.3	11.91	9.22e-29	1.13e-25	0.46	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-11.91	9.27e-29	1.14e-25	-0.46	-0.48	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-11.91	9.27e-29	1.14e-25	-0.46	-0.48	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-11.91	9.27e-29	1.14e-25	-0.46	-0.48	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-11.91	9.27e-29	1.14e-25	-0.46	-0.48	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-11.91	9.28e-29	1.14e-25	-0.45	-0.48	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
THCA	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-11.91	9.28e-29	1.14e-25	-0.35	-0.48	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	11.91	9.31e-29	1.14e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
THCA	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	11.91	9.34e-29	1.15e-25	0.65	0.48	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-11.91	9.38e-29	1.15e-25	-0.62	-0.48	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
THCA	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-11.91	9.42e-29	1.16e-25	-0.72	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
THCA	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	11.91	9.45e-29	1.16e-25	0.6	0.48	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
THCA	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	11.91	9.5e-29	1.17e-25	0.64	0.48	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	11.91	9.5e-29	1.17e-25	0.64	0.48	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	11.91	9.5e-29	1.17e-25	0.64	0.48	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
THCA	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-11.91	9.52e-29	1.17e-25	-0.5	-0.48	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
THCA	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-11.91	9.53e-29	1.17e-25	-0.62	-0.48	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-11.91	9.54e-29	1.17e-25	-0.69	-0.48	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	11.91	9.55e-29	1.17e-25	0.66	0.48	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000223768.1	LINC00205	-11.91	9.57e-29	1.17e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45293285~45297354:+
THCA	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	11.9	9.6e-29	1.18e-25	0.61	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
THCA	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-11.9	9.64e-29	1.18e-25	-0.46	-0.48	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
THCA	cis	rs9659323	0.67	rs12096179	ENSG00000231365.4	RP11-418J17.1	-11.9	9.66e-29	1.18e-25	-0.48	-0.48	Body mass index;	chr1:119093100	chr1:119140396~119275973:+
THCA	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	11.9	9.84e-29	1.21e-25	0.59	0.48	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	11.9	9.93e-29	1.22e-25	0.59	0.48	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	11.9	9.93e-29	1.22e-25	0.59	0.48	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
THCA	cis	rs6496932	1	rs35156762	ENSG00000218052.5	ADAMTS7P4	11.9	9.98e-29	1.22e-25	0.66	0.48	Central corneal thickness;Corneal structure;	chr15:85281243	chr15:85255369~85330334:-
THCA	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	11.9	9.99e-29	1.22e-25	0.58	0.48	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
THCA	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-11.9	1e-28	1.23e-25	-0.66	-0.48	Depression;	chr6:28091242	chr6:28115628~28116551:+
THCA	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	11.9	1.01e-28	1.23e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	11.9	1.01e-28	1.24e-25	0.58	0.48	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	11.9	1.01e-28	1.24e-25	0.58	0.48	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
THCA	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-11.9	1.01e-28	1.24e-25	-0.64	-0.48	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
THCA	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	11.9	1.03e-28	1.27e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
THCA	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-11.9	1.04e-28	1.27e-25	-0.55	-0.48	Temperament;	chr17:14007232	chr17:14024514~14025488:+
THCA	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-11.9	1.04e-28	1.27e-25	-0.34	-0.48	Height;	chr11:118773873	chr11:118791254~118793137:+
THCA	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	11.9	1.04e-28	1.27e-25	0.64	0.48	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
THCA	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-11.9	1.04e-28	1.27e-25	-0.54	-0.48	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
THCA	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	11.9	1.04e-28	1.27e-25	0.59	0.48	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
THCA	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	11.9	1.05e-28	1.29e-25	0.59	0.48	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	11.9	1.05e-28	1.29e-25	0.59	0.48	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
THCA	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	11.9	1.05e-28	1.29e-25	0.59	0.48	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
THCA	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	11.89	1.05e-28	1.29e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	11.89	1.05e-28	1.29e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
THCA	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	11.89	1.06e-28	1.29e-25	0.6	0.48	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
THCA	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-11.89	1.07e-28	1.31e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-11.89	1.07e-28	1.31e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	11.89	1.07e-28	1.31e-25	0.64	0.48	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	11.89	1.07e-28	1.31e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	11.89	1.07e-28	1.31e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	11.89	1.07e-28	1.31e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	11.89	1.07e-28	1.31e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
THCA	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	11.89	1.07e-28	1.31e-25	0.59	0.48	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
THCA	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	11.89	1.08e-28	1.32e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
THCA	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	11.89	1.08e-28	1.32e-25	0.35	0.48	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	11.89	1.08e-28	1.32e-25	0.35	0.48	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-11.89	1.09e-28	1.33e-25	-0.62	-0.48	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
THCA	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	11.89	1.09e-28	1.34e-25	0.35	0.48	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
THCA	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-11.89	1.1e-28	1.34e-25	-0.7	-0.48	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
THCA	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-11.89	1.1e-28	1.34e-25	-0.38	-0.48	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
THCA	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-11.89	1.1e-28	1.35e-25	-0.53	-0.48	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
THCA	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-11.89	1.11e-28	1.35e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-11.89	1.11e-28	1.35e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
THCA	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-11.89	1.11e-28	1.36e-25	-0.59	-0.48	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
THCA	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	11.89	1.11e-28	1.36e-25	0.61	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
THCA	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
THCA	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-11.89	1.12e-28	1.37e-25	-0.65	-0.48	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
THCA	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	11.89	1.14e-28	1.39e-25	0.58	0.48	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	11.89	1.14e-28	1.39e-25	0.58	0.48	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	11.89	1.14e-28	1.39e-25	0.58	0.48	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
THCA	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	11.89	1.14e-28	1.39e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
THCA	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-11.89	1.14e-28	1.39e-25	-0.35	-0.48	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
THCA	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	11.89	1.14e-28	1.39e-25	0.63	0.48	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	11.89	1.14e-28	1.39e-25	0.63	0.48	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	11.89	1.14e-28	1.39e-25	0.63	0.48	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	11.89	1.14e-28	1.39e-25	0.63	0.48	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
THCA	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	11.89	1.14e-28	1.4e-25	0.39	0.48	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-11.88	1.16e-28	1.41e-25	-0.61	-0.48	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
THCA	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	11.88	1.16e-28	1.41e-25	0.54	0.48	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
THCA	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	11.88	1.17e-28	1.42e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
THCA	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-11.88	1.17e-28	1.43e-25	-0.54	-0.48	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
THCA	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	11.88	1.17e-28	1.43e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	11.88	1.17e-28	1.43e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	11.88	1.18e-28	1.44e-25	0.64	0.48	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	11.88	1.2e-28	1.46e-25	0.64	0.48	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
THCA	cis	rs853679	0.517	rs17711344	ENSG00000280107.1	AL022393.9	11.88	1.23e-28	1.49e-25	0.59	0.48	Depression;	chr6:28109824	chr6:28170845~28172521:+
THCA	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	11.88	1.24e-28	1.5e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000280107.1	AL022393.9	-11.88	1.24e-28	1.51e-25	-0.57	-0.48	Parkinson's disease;	chr6:28066959	chr6:28170845~28172521:+
THCA	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
THCA	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-11.88	1.25e-28	1.52e-25	-0.58	-0.48	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
THCA	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-11.88	1.25e-28	1.52e-25	-0.66	-0.48	Depression;	chr6:28113616	chr6:28115628~28116551:+
THCA	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	11.88	1.25e-28	1.52e-25	0.64	0.48	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-11.88	1.25e-28	1.53e-25	-0.61	-0.48	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
THCA	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	11.88	1.26e-28	1.53e-25	0.36	0.48	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	11.88	1.26e-28	1.53e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
THCA	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	11.87	1.28e-28	1.56e-25	0.69	0.48	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
THCA	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-11.87	1.29e-28	1.57e-25	-0.67	-0.48	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
THCA	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	11.87	1.3e-28	1.58e-25	0.55	0.48	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
THCA	cis	rs9309473	1	rs10184268	ENSG00000163016.8	ALMS1P	11.87	1.3e-28	1.58e-25	0.7	0.48	Metabolite levels;	chr2:73399916	chr2:73644919~73685576:+
THCA	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	11.87	1.32e-28	1.6e-25	0.59	0.48	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
THCA	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	11.87	1.32e-28	1.6e-25	0.64	0.48	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	11.87	1.33e-28	1.61e-25	0.58	0.48	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	11.87	1.33e-28	1.61e-25	0.64	0.48	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	11.87	1.33e-28	1.61e-25	0.64	0.48	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
THCA	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-11.87	1.34e-28	1.62e-25	-0.46	-0.48	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-11.87	1.34e-28	1.63e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-11.87	1.34e-28	1.63e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-11.87	1.35e-28	1.63e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-11.87	1.35e-28	1.63e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-11.87	1.35e-28	1.64e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-11.87	1.35e-28	1.64e-25	-0.69	-0.48	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	11.87	1.36e-28	1.64e-25	0.7	0.48	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	11.87	1.36e-28	1.64e-25	0.7	0.48	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
THCA	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-11.87	1.36e-28	1.65e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-11.87	1.36e-28	1.65e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-11.87	1.36e-28	1.65e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
THCA	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-11.87	1.37e-28	1.66e-25	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
THCA	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	11.87	1.37e-28	1.66e-25	0.61	0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
THCA	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	11.87	1.37e-28	1.66e-25	0.65	0.48	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
THCA	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.39e-28	1.68e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
THCA	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	11.86	1.4e-28	1.7e-25	0.7	0.48	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
THCA	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	11.86	1.42e-28	1.72e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	11.86	1.43e-28	1.73e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-11.86	1.43e-28	1.74e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
THCA	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.44e-28	1.74e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
THCA	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	11.86	1.44e-28	1.74e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-11.86	1.44e-28	1.74e-25	-0.6	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
THCA	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-11.86	1.44e-28	1.75e-25	-0.34	-0.48	Height;	chr11:118742526	chr11:118791254~118793137:+
THCA	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	11.86	1.44e-28	1.75e-25	0.6	0.48	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	11.86	1.44e-28	1.75e-25	0.6	0.48	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
THCA	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-11.86	1.46e-28	1.77e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-11.86	1.46e-28	1.77e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-11.86	1.46e-28	1.77e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	11.86	1.46e-28	1.77e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
THCA	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	11.86	1.47e-28	1.78e-25	0.56	0.48	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
THCA	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	11.86	1.48e-28	1.79e-25	0.57	0.48	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
THCA	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-11.86	1.48e-28	1.8e-25	-0.35	-0.48	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
THCA	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
THCA	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	11.86	1.49e-28	1.8e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
THCA	cis	rs1263173	0.566	rs4225	ENSG00000254851.1	RP11-109L13.1	-11.86	1.5e-28	1.81e-25	-0.64	-0.48	HDL cholesterol;	chr11:116832955	chr11:117135528~117138582:+
THCA	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	11.86	1.5e-28	1.81e-25	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
THCA	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-11.86	1.5e-28	1.82e-25	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-11.86	1.51e-28	1.83e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-11.86	1.52e-28	1.83e-25	-0.65	-0.48	Depression;	chr6:28079011	chr6:28115628~28116551:+
THCA	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-11.86	1.52e-28	1.84e-25	-0.34	-0.48	Height;	chr11:118764443	chr11:118791254~118793137:+
THCA	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-11.85	1.52e-28	1.84e-25	-0.64	-0.48	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-11.85	1.52e-28	1.84e-25	-0.64	-0.48	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
THCA	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	11.85	1.53e-28	1.85e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	11.85	1.53e-28	1.85e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
THCA	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	11.85	1.55e-28	1.87e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000235689.1	AP000351.13	11.85	1.55e-28	1.87e-25	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:24006305~24008258:-
THCA	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-11.85	1.55e-28	1.88e-25	-0.49	-0.48	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
THCA	cis	rs934734	0.571	rs7565437	ENSG00000204929.10	AC074391.1	-11.85	1.56e-28	1.88e-25	-0.59	-0.48	Rheumatoid arthritis;	chr2:65419832	chr2:65436711~66084639:+
THCA	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	11.85	1.56e-28	1.88e-25	0.53	0.48	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
THCA	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	11.85	1.56e-28	1.89e-25	0.59	0.48	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
THCA	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	11.85	1.57e-28	1.9e-25	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
THCA	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	11.85	1.58e-28	1.9e-25	0.6	0.48	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
THCA	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-11.85	1.58e-28	1.9e-25	-0.6	-0.48	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
THCA	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	11.85	1.58e-28	1.91e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
THCA	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	11.85	1.58e-28	1.91e-25	0.59	0.48	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
THCA	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	11.85	1.58e-28	1.91e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
THCA	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	11.85	1.59e-28	1.92e-25	0.73	0.48	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
THCA	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-11.85	1.61e-28	1.94e-25	-0.59	-0.48	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-11.85	1.61e-28	1.94e-25	-0.59	-0.48	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
THCA	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	11.85	1.61e-28	1.94e-25	0.66	0.48	Depression;	chr6:28109824	chr6:28115628~28116551:+
THCA	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-11.85	1.62e-28	1.95e-25	-0.62	-0.48	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
THCA	cis	rs6496932	1	rs6496932	ENSG00000218052.5	ADAMTS7P4	11.85	1.63e-28	1.96e-25	0.65	0.48	Central corneal thickness;Corneal structure;	chr15:85282336	chr15:85255369~85330334:-
THCA	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	11.85	1.63e-28	1.97e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
THCA	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.64e-28	1.97e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.64e-28	1.97e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.64e-28	1.97e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000281920.1	RP11-418H16.1	-11.85	1.64e-28	1.98e-25	-0.59	-0.48	Sum eosinophil basophil counts;	chr2:65438139	chr2:65623272~65628424:+
THCA	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-11.85	1.64e-28	1.98e-25	-0.61	-0.48	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-11.85	1.64e-28	1.98e-25	-0.61	-0.48	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
THCA	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	11.84	1.67e-28	2.02e-25	0.56	0.48	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
THCA	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	11.84	1.68e-28	2.02e-25	0.9	0.48	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	11.84	1.69e-28	2.03e-25	0.57	0.48	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
THCA	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-11.84	1.69e-28	2.03e-25	-0.55	-0.48	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
THCA	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	11.84	1.72e-28	2.07e-25	0.59	0.48	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	11.84	1.72e-28	2.07e-25	0.59	0.48	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-11.84	1.72e-28	2.07e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
THCA	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	11.84	1.73e-28	2.08e-25	0.55	0.48	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
THCA	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-11.84	1.73e-28	2.08e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
THCA	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-11.84	1.73e-28	2.09e-25	-0.69	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
THCA	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-11.84	1.75e-28	2.11e-25	-0.57	-0.48	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
THCA	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-11.84	1.77e-28	2.12e-25	-0.46	-0.48	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-11.84	1.77e-28	2.12e-25	-0.46	-0.48	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
THCA	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	11.84	1.77e-28	2.12e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	11.84	1.77e-28	2.12e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
THCA	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-11.84	1.77e-28	2.12e-25	-0.44	-0.48	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
THCA	cis	rs9928842	1	rs7202566	ENSG00000280152.1	RP11-331F4.5	11.84	1.77e-28	2.13e-25	0.66	0.48	Alcoholic chronic pancreatitis;	chr16:75213746	chr16:75245994~75250077:-
THCA	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	11.84	1.78e-28	2.13e-25	0.71	0.48	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
THCA	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-11.84	1.78e-28	2.13e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000206090.4	AP000350.7	11.84	1.8e-28	2.16e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23939998~23942798:+
THCA	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-11.84	1.8e-28	2.16e-25	-0.58	-0.48	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
THCA	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-11.84	1.81e-28	2.18e-25	-0.47	-0.48	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
THCA	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-11.84	1.81e-28	2.18e-25	-0.53	-0.48	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
THCA	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-11.84	1.82e-28	2.18e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
THCA	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-11.84	1.82e-28	2.18e-25	-0.43	-0.48	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
THCA	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-11.84	1.82e-28	2.18e-25	-0.64	-0.48	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
THCA	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-11.84	1.82e-28	2.19e-25	-0.44	-0.48	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
THCA	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	11.83	1.84e-28	2.21e-25	0.55	0.48	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
THCA	cis	rs4964805	0.954	rs10861104	ENSG00000257681.1	RP11-341G23.4	11.83	1.86e-28	2.23e-25	0.59	0.48	Attention deficit hyperactivity disorder;	chr12:103796145	chr12:103746315~103768858:-
THCA	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	11.83	1.88e-28	2.26e-25	0.55	0.48	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
THCA	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-11.83	1.88e-28	2.26e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-11.83	1.88e-28	2.26e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-11.83	1.88e-28	2.26e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000223768.1	LINC00205	-11.83	1.88e-28	2.26e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45293285~45297354:+
THCA	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-11.83	1.89e-28	2.27e-25	-0.47	-0.48	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
THCA	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-11.83	1.89e-28	2.27e-25	-0.4	-0.48	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
THCA	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	11.83	1.9e-28	2.27e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	11.83	1.9e-28	2.27e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
THCA	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-11.83	1.9e-28	2.27e-25	-0.34	-0.48	Height;	chr11:118760944	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	11.83	1.91e-28	2.29e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	11.83	1.91e-28	2.29e-25	0.64	0.48	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
THCA	cis	rs853679	0.542	rs6934769	ENSG00000280107.1	AL022393.9	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Depression;	chr6:28123153	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs17711801	ENSG00000280107.1	AL022393.9	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Depression;	chr6:28124529	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000280107.1	AL022393.9	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Parkinson's disease;	chr6:28127394	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9468292	ENSG00000280107.1	AL022393.9	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Depression;	chr6:28127577	chr6:28170845~28172521:+
THCA	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	11.83	1.91e-28	2.29e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
THCA	cis	rs1858037	0.867	rs1553675	ENSG00000204929.10	AC074391.1	-11.83	1.93e-28	2.32e-25	-0.63	-0.48	Rheumatoid arthritis;	chr2:65343173	chr2:65436711~66084639:+
THCA	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	11.83	1.93e-28	2.32e-25	0.63	0.48	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	11.83	1.97e-28	2.36e-25	0.62	0.48	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
THCA	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	11.83	1.99e-28	2.38e-25	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
THCA	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-11.83	1.99e-28	2.38e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
THCA	cis	rs2288884	0.559	rs9636139	ENSG00000275055.1	CTC-471J1.11	-11.83	2e-28	2.39e-25	-0.38	-0.48	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018043	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12610953	ENSG00000275055.1	CTC-471J1.11	-11.83	2e-28	2.39e-25	-0.38	-0.48	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018675	chr19:52049007~52049754:+
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000223768.1	LINC00205	-11.82	2.02e-28	2.42e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45293285~45297354:+
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	11.82	2.03e-28	2.43e-25	0.57	0.48	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
THCA	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-11.82	2.05e-28	2.46e-25	-0.55	-0.48	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-11.82	2.05e-28	2.46e-25	-0.55	-0.48	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-11.82	2.05e-28	2.46e-25	-0.55	-0.48	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
THCA	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	11.82	2.08e-28	2.49e-25	0.66	0.48	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-11.82	2.08e-28	2.49e-25	-0.66	-0.48	Depression;	chr6:28071808	chr6:28115628~28116551:+
THCA	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	11.82	2.09e-28	2.5e-25	0.55	0.48	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
THCA	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-11.82	2.1e-28	2.52e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-11.82	2.1e-28	2.52e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-11.82	2.1e-28	2.52e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-11.82	2.1e-28	2.52e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
THCA	cis	rs1858037	0.867	rs1039765	ENSG00000204929.10	AC074391.1	-11.82	2.13e-28	2.54e-25	-0.62	-0.48	Rheumatoid arthritis;	chr2:65387228	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-11.82	2.15e-28	2.57e-25	-0.82	-0.48	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
THCA	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	11.82	2.16e-28	2.59e-25	0.9	0.48	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
THCA	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-11.82	2.17e-28	2.6e-25	-0.46	-0.48	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
THCA	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-11.81	2.2e-28	2.63e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-11.81	2.2e-28	2.63e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-11.81	2.2e-28	2.63e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-11.81	2.2e-28	2.63e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
THCA	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-11.81	2.23e-28	2.67e-25	-0.61	-0.48	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-11.81	2.23e-28	2.67e-25	-0.61	-0.48	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-11.81	2.23e-28	2.67e-25	-0.61	-0.48	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-11.81	2.23e-28	2.67e-25	-0.61	-0.48	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
THCA	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	11.81	2.24e-28	2.68e-25	0.65	0.48	Depression;	chr6:28110525	chr6:28115628~28116551:+
THCA	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	11.81	2.24e-28	2.68e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
THCA	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-11.81	2.25e-28	2.68e-25	-0.55	-0.48	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
THCA	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	11.81	2.25e-28	2.69e-25	0.48	0.48	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
THCA	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	11.81	2.26e-28	2.7e-25	0.66	0.48	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
THCA	cis	rs853679	0.517	rs9283884	ENSG00000280107.1	AL022393.9	11.81	2.27e-28	2.71e-25	0.58	0.48	Depression;	chr6:28167882	chr6:28170845~28172521:+
THCA	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-11.81	2.29e-28	2.74e-25	-0.46	-0.48	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-11.81	2.29e-28	2.74e-25	-0.46	-0.48	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-11.81	2.29e-28	2.74e-25	-0.46	-0.48	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
THCA	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	11.81	2.29e-28	2.74e-25	0.55	0.48	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
THCA	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-11.81	2.3e-28	2.74e-25	-0.51	-0.48	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
THCA	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	11.81	2.32e-28	2.77e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-11.81	2.34e-28	2.79e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-11.81	2.34e-28	2.79e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-11.81	2.34e-28	2.79e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-11.81	2.34e-28	2.79e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
THCA	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	11.81	2.36e-28	2.82e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
THCA	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	11.81	2.37e-28	2.82e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
THCA	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-11.81	2.37e-28	2.82e-25	-0.61	-0.48	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-11.81	2.37e-28	2.82e-25	-0.61	-0.48	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
THCA	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-11.81	2.39e-28	2.85e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-11.81	2.39e-28	2.85e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
THCA	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-11.81	2.39e-28	2.85e-25	-0.62	-0.48	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
THCA	cis	rs9928842	0.882	rs8048956	ENSG00000280152.1	RP11-331F4.5	-11.81	2.39e-28	2.85e-25	-0.63	-0.48	Alcoholic chronic pancreatitis;	chr16:75221068	chr16:75245994~75250077:-
THCA	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-11.81	2.4e-28	2.86e-25	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
THCA	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-11.81	2.4e-28	2.86e-25	-0.92	-0.48	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
THCA	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	11.8	2.41e-28	2.87e-25	0.65	0.48	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	11.8	2.41e-28	2.87e-25	0.65	0.48	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	11.8	2.42e-28	2.88e-25	0.7	0.48	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
THCA	cis	rs9659323	0.67	rs17023223	ENSG00000231365.4	RP11-418J17.1	-11.8	2.42e-28	2.88e-25	-0.47	-0.48	Body mass index;	chr1:119088551	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.67	rs61808898	ENSG00000231365.4	RP11-418J17.1	-11.8	2.42e-28	2.88e-25	-0.47	-0.48	Body mass index;	chr1:119096232	chr1:119140396~119275973:+
THCA	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-11.8	2.43e-28	2.89e-25	-0.56	-0.48	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
THCA	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	11.8	2.44e-28	2.9e-25	0.57	0.48	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
THCA	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-11.8	2.44e-28	2.9e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
THCA	cis	rs6496932	1	rs12917518	ENSG00000218052.5	ADAMTS7P4	11.8	2.45e-28	2.92e-25	0.65	0.48	Central corneal thickness;Corneal structure;	chr15:85284018	chr15:85255369~85330334:-
THCA	cis	rs6496932	1	rs28374025	ENSG00000218052.5	ADAMTS7P4	11.8	2.45e-28	2.92e-25	0.65	0.48	Central corneal thickness;Corneal structure;	chr15:85284107	chr15:85255369~85330334:-
THCA	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	11.8	2.48e-28	2.95e-25	0.73	0.48	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
THCA	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	11.8	2.48e-28	2.95e-25	0.66	0.48	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	11.8	2.48e-28	2.95e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	11.8	2.48e-28	2.95e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-11.8	2.48e-28	2.95e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000223768.1	LINC00205	-11.8	2.48e-28	2.96e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45293285~45297354:+
THCA	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-11.8	2.49e-28	2.96e-25	-0.46	-0.48	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
THCA	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-11.8	2.49e-28	2.97e-25	-0.56	-0.48	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
THCA	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-11.8	2.51e-28	2.99e-25	-0.56	-0.48	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
THCA	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	11.8	2.51e-28	2.99e-25	0.56	0.48	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-11.8	2.53e-28	3.01e-25	-0.47	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-11.8	2.53e-28	3.01e-25	-0.61	-0.48	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-11.8	2.53e-28	3.01e-25	-0.61	-0.48	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
THCA	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	11.8	2.54e-28	3.02e-25	0.59	0.48	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
THCA	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-11.8	2.54e-28	3.02e-25	-0.45	-0.48	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
THCA	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-11.8	2.54e-28	3.03e-25	-0.6	-0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
THCA	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	11.8	2.56e-28	3.04e-25	0.57	0.48	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	11.8	2.56e-28	3.04e-25	0.59	0.48	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
THCA	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-11.8	2.58e-28	3.07e-25	-0.46	-0.48	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
THCA	cis	rs1858037	0.867	rs67453645	ENSG00000204929.10	AC074391.1	11.8	2.6e-28	3.09e-25	0.63	0.48	Rheumatoid arthritis;	chr2:65358908	chr2:65436711~66084639:+
THCA	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-11.8	2.61e-28	3.1e-25	-0.61	-0.48	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-11.8	2.61e-28	3.1e-25	-0.61	-0.48	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-11.8	2.61e-28	3.1e-25	-0.61	-0.48	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
THCA	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-11.8	2.61e-28	3.1e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-11.8	2.61e-28	3.1e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
THCA	cis	rs1858037	0.867	rs61226353	ENSG00000204929.10	AC074391.1	11.8	2.62e-28	3.11e-25	0.63	0.48	Rheumatoid arthritis;	chr2:65363637	chr2:65436711~66084639:+
THCA	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-11.8	2.62e-28	3.12e-25	-0.47	-0.48	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-11.8	2.62e-28	3.12e-25	-0.47	-0.48	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
THCA	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	11.79	2.65e-28	3.14e-25	0.64	0.48	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	11.79	2.65e-28	3.14e-25	0.64	0.48	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
THCA	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-11.79	2.66e-28	3.15e-25	-0.46	-0.48	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-11.79	2.67e-28	3.17e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-11.79	2.67e-28	3.18e-25	-0.61	-0.48	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
THCA	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	11.79	2.68e-28	3.18e-25	0.6	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
THCA	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	11.79	2.7e-28	3.21e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
THCA	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-11.79	2.71e-28	3.22e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
THCA	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	11.79	2.75e-28	3.26e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-11.79	2.78e-28	3.3e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
THCA	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-11.79	2.8e-28	3.32e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
THCA	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	11.79	2.8e-28	3.32e-25	0.58	0.48	Depression;	chr6:28301886	chr6:28176188~28176674:+
THCA	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
THCA	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
THCA	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	11.79	2.83e-28	3.35e-25	0.83	0.48	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
THCA	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-11.79	2.84e-28	3.36e-25	-0.66	-0.48	Depression;	chr6:28139049	chr6:28115628~28116551:+
THCA	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	11.79	2.84e-28	3.37e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	11.79	2.84e-28	3.37e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
THCA	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	11.79	2.86e-28	3.39e-25	0.64	0.48	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	11.79	2.86e-28	3.39e-25	0.64	0.48	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
THCA	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-11.79	2.87e-28	3.4e-25	-0.45	-0.48	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
THCA	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-11.79	2.88e-28	3.41e-25	-0.58	-0.48	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
THCA	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-11.78	2.91e-28	3.45e-25	-0.56	-0.48	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
THCA	cis	rs853679	0.517	rs6922063	ENSG00000280107.1	AL022393.9	-11.78	2.91e-28	3.45e-25	-0.58	-0.48	Depression;	chr6:28126588	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000280107.1	AL022393.9	-11.78	2.91e-28	3.45e-25	-0.58	-0.48	Depression;	chr6:28126953	chr6:28170845~28172521:+
THCA	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-11.78	2.93e-28	3.47e-25	-0.44	-0.48	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.84	rs914217	ENSG00000223768.1	LINC00205	-11.78	2.93e-28	3.47e-25	-0.49	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	11.78	2.94e-28	3.48e-25	0.64	0.48	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
THCA	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-11.78	2.94e-28	3.48e-25	-0.46	-0.48	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
THCA	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	11.78	2.95e-28	3.5e-25	0.4	0.48	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
THCA	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-11.78	2.96e-28	3.51e-25	-0.65	-0.48	Depression;	chr6:28123153	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-11.78	2.96e-28	3.51e-25	-0.65	-0.48	Depression;	chr6:28124529	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-11.78	2.96e-28	3.51e-25	-0.65	-0.48	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-11.78	2.96e-28	3.51e-25	-0.65	-0.48	Depression;	chr6:28127577	chr6:28115628~28116551:+
THCA	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
THCA	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	11.78	3.02e-28	3.57e-25	0.73	0.48	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
THCA	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	11.78	3.04e-28	3.6e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	11.78	3.05e-28	3.61e-25	0.66	0.48	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	11.78	3.05e-28	3.61e-25	0.66	0.48	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	11.78	3.05e-28	3.61e-25	0.67	0.48	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
THCA	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-11.78	3.05e-28	3.61e-25	-0.64	-0.48	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
THCA	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	11.78	3.05e-28	3.61e-25	0.64	0.48	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	11.78	3.05e-28	3.61e-25	0.63	0.48	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
THCA	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	11.78	3.07e-28	3.64e-25	0.57	0.48	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
THCA	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-11.78	3.08e-28	3.64e-25	-0.46	-0.48	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
THCA	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-11.78	3.08e-28	3.65e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-11.78	3.08e-28	3.65e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
THCA	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	11.78	3.09e-28	3.66e-25	0.49	0.48	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	11.78	3.1e-28	3.67e-25	0.64	0.48	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
THCA	cis	rs7188445	0.736	rs4889012	ENSG00000261390.4	RP11-345M22.2	11.78	3.11e-28	3.68e-25	0.56	0.48	Urate levels;	chr16:79667485	chr16:79715232~79770563:-
THCA	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	11.78	3.13e-28	3.7e-25	0.79	0.48	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
THCA	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-11.78	3.14e-28	3.71e-25	-0.54	-0.48	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
THCA	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
THCA	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	11.78	3.16e-28	3.73e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
THCA	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-11.77	3.2e-28	3.78e-25	-0.58	-0.48	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
THCA	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	11.77	3.25e-28	3.84e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
THCA	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	11.77	3.26e-28	3.85e-25	0.57	0.48	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
THCA	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-11.77	3.27e-28	3.86e-25	-0.72	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
THCA	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	11.77	3.28e-28	3.87e-25	0.58	0.48	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
THCA	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-11.77	3.28e-28	3.88e-25	-0.63	-0.48	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
THCA	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-11.77	3.32e-28	3.92e-25	-0.55	-0.48	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
THCA	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-11.77	3.33e-28	3.93e-25	-0.6	-0.48	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
THCA	cis	rs944289	0.617	rs1958617	ENSG00000257826.1	RP11-116N8.4	-11.77	3.34e-28	3.95e-25	-0.52	-0.48	Thyroid cancer;	chr14:36118418	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-11.77	3.35e-28	3.95e-25	-0.67	-0.48	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
THCA	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	11.77	3.35e-28	3.95e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
THCA	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	11.77	3.37e-28	3.97e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	11.77	3.37e-28	3.97e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
THCA	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	11.77	3.39e-28	4e-25	0.56	0.48	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
THCA	cis	rs6570726	0.846	rs446031	ENSG00000235652.6	RP11-545I5.3	11.77	3.4e-28	4.01e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	11.77	3.43e-28	4.05e-25	0.55	0.48	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
THCA	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	11.77	3.44e-28	4.06e-25	0.56	0.48	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
THCA	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	11.77	3.45e-28	4.06e-25	0.63	0.48	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	11.77	3.45e-28	4.06e-25	0.63	0.48	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	11.77	3.45e-28	4.06e-25	0.63	0.48	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	11.77	3.45e-28	4.06e-25	0.63	0.48	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
THCA	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-11.76	3.47e-28	4.09e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
THCA	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-11.76	3.48e-28	4.1e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
THCA	cis	rs7569084	1	rs7569084	ENSG00000281920.1	RP11-418H16.1	-11.76	3.48e-28	4.1e-25	-0.59	-0.48	Sum eosinophil basophil counts;	chr2:65429835	chr2:65623272~65628424:+
THCA	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-11.76	3.48e-28	4.11e-25	-0.46	-0.48	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-11.76	3.49e-28	4.12e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-11.76	3.49e-28	4.12e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-11.76	3.5e-28	4.12e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-11.76	3.5e-28	4.12e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
THCA	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-11.76	3.51e-28	4.13e-25	-0.56	-0.48	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
THCA	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	11.76	3.53e-28	4.15e-25	0.62	0.48	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
THCA	cis	rs2288884	0.559	rs6509611	ENSG00000275055.1	CTC-471J1.11	-11.76	3.56e-28	4.19e-25	-0.37	-0.48	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006953	chr19:52049007~52049754:+
THCA	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-11.76	3.59e-28	4.23e-25	-0.63	-0.48	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	11.76	3.59e-28	4.23e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-11.76	3.61e-28	4.25e-25	-0.6	-0.48	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-11.76	3.61e-28	4.25e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-11.76	3.61e-28	4.25e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
THCA	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	11.76	3.61e-28	4.25e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	11.76	3.66e-28	4.3e-25	0.67	0.48	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-11.76	3.66e-28	4.31e-25	-0.56	-0.48	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
THCA	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-11.76	3.68e-28	4.33e-25	-0.5	-0.48	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
THCA	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-11.76	3.71e-28	4.37e-25	-0.71	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
THCA	cis	rs12458462	0.665	rs2035085	ENSG00000274828.1	RP11-567M16.6	11.76	3.72e-28	4.37e-25	0.39	0.48	Monocyte count;	chr18:79725280	chr18:79677287~79679358:-
THCA	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	11.76	3.74e-28	4.4e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
THCA	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-11.76	3.77e-28	4.43e-25	-0.51	-0.48	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
THCA	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-11.76	3.77e-28	4.43e-25	-0.51	-0.48	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
THCA	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	11.76	3.78e-28	4.44e-25	0.57	0.48	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	11.76	3.79e-28	4.46e-25	0.64	0.48	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	11.76	3.79e-28	4.46e-25	0.64	0.48	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	11.76	3.79e-28	4.46e-25	0.64	0.48	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-11.75	3.82e-28	4.49e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000223768.1	LINC00205	-11.75	3.83e-28	4.51e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45293285~45297354:+
THCA	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	11.75	3.86e-28	4.54e-25	0.53	0.48	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
THCA	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-11.75	3.88e-28	4.56e-25	-0.46	-0.48	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000223768.1	LINC00205	-11.75	3.88e-28	4.57e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45293285~45297354:+
THCA	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-11.75	3.92e-28	4.6e-25	-0.36	-0.48	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
THCA	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	11.75	3.96e-28	4.65e-25	0.65	0.48	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
THCA	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-11.75	4e-28	4.7e-25	-0.56	-0.48	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
THCA	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	11.75	4.03e-28	4.73e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
THCA	cis	rs1858037	0.806	rs12612780	ENSG00000204929.10	AC074391.1	11.75	4.03e-28	4.73e-25	0.63	0.48	Rheumatoid arthritis;	chr2:65355967	chr2:65436711~66084639:+
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-11.75	4.05e-28	4.75e-25	-0.65	-0.48	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-11.75	4.05e-28	4.75e-25	-0.59	-0.48	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
THCA	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	11.75	4.05e-28	4.76e-25	0.59	0.48	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
THCA	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	11.75	4.09e-28	4.8e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
THCA	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	11.75	4.09e-28	4.8e-25	0.57	0.48	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	11.75	4.12e-28	4.83e-25	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
THCA	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	11.75	4.12e-28	4.83e-25	0.46	0.48	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-11.75	4.13e-28	4.85e-25	-0.61	-0.48	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
THCA	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-11.75	4.14e-28	4.86e-25	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
THCA	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-11.75	4.14e-28	4.86e-25	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
THCA	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	11.75	4.16e-28	4.88e-25	0.45	0.48	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
THCA	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-11.74	4.19e-28	4.91e-25	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	11.74	4.25e-28	4.98e-25	0.63	0.48	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
THCA	cis	rs9659323	0.67	rs6701378	ENSG00000231365.4	RP11-418J17.1	-11.74	4.27e-28	5e-25	-0.47	-0.48	Body mass index;	chr1:119095930	chr1:119140396~119275973:+
THCA	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	11.74	4.27e-28	5e-25	0.59	0.48	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
THCA	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	11.74	4.3e-28	5.04e-25	0.55	0.48	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
THCA	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	11.74	4.3e-28	5.04e-25	0.59	0.48	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
THCA	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-11.74	4.3e-28	5.04e-25	-0.61	-0.48	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
THCA	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	11.74	4.31e-28	5.04e-25	0.65	0.48	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000235689.1	AP000351.13	11.74	4.31e-28	5.05e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:24006305~24008258:-
THCA	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-11.74	4.34e-28	5.08e-25	-0.72	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000235689.1	AP000351.13	11.74	4.35e-28	5.1e-25	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:24006305~24008258:-
THCA	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-11.74	4.37e-28	5.12e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-11.74	4.37e-28	5.12e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
THCA	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-11.74	4.38e-28	5.12e-25	-0.59	-0.48	Height;	chr3:53064759	chr3:53064283~53065091:-
THCA	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	11.74	4.4e-28	5.15e-25	0.64	0.48	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
THCA	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-11.74	4.43e-28	5.18e-25	-0.57	-0.48	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-11.74	4.43e-28	5.18e-25	-0.57	-0.48	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
THCA	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-11.74	4.48e-28	5.23e-25	-0.59	-0.48	Height;	chr3:53052712	chr3:53064283~53065091:-
THCA	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-11.74	4.52e-28	5.28e-25	-0.45	-0.48	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
THCA	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-11.74	4.53e-28	5.29e-25	-0.57	-0.48	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
THCA	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28136698	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28136856	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28137418	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28138363	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28138981	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28139012	chr6:28115628~28116551:+
THCA	cis	rs1858037	0.867	rs4671660	ENSG00000204929.10	AC074391.1	11.74	4.55e-28	5.31e-25	0.62	0.48	Rheumatoid arthritis;	chr2:65349302	chr2:65436711~66084639:+
THCA	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-11.73	4.64e-28	5.42e-25	-0.61	-0.48	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
THCA	cis	rs12460587	0.547	rs56244227	ENSG00000275055.1	CTC-471J1.11	-11.73	4.72e-28	5.51e-25	-0.37	-0.48	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080439	chr19:52049007~52049754:+
THCA	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	11.73	4.79e-28	5.58e-25	0.63	0.48	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-11.73	4.79e-28	5.59e-25	-0.58	-0.48	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
THCA	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-11.73	4.82e-28	5.62e-25	-0.44	-0.48	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-11.73	4.82e-28	5.62e-25	-0.44	-0.48	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
THCA	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	11.73	4.85e-28	5.66e-25	0.59	0.48	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
THCA	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-11.73	4.88e-28	5.69e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-11.73	4.88e-28	5.69e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-11.73	4.88e-28	5.69e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-11.73	4.88e-28	5.69e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
THCA	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	11.73	4.89e-28	5.7e-25	0.55	0.48	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
THCA	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	11.73	4.89e-28	5.7e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
THCA	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	11.73	4.89e-28	5.7e-25	0.38	0.48	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
THCA	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	11.73	4.91e-28	5.72e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000223768.1	LINC00205	-11.73	4.94e-28	5.75e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	11.73	4.94e-28	5.75e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
THCA	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	11.73	4.96e-28	5.78e-25	0.84	0.48	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
THCA	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-11.73	4.97e-28	5.8e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
THCA	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	11.72	5.02e-28	5.85e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
THCA	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	11.72	5.04e-28	5.87e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000223768.1	LINC00205	-11.72	5.05e-28	5.88e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45293285~45297354:+
THCA	cis	rs1858037	0.867	rs57913336	ENSG00000204929.10	AC074391.1	11.72	5.05e-28	5.89e-25	0.63	0.48	Rheumatoid arthritis;	chr2:65360485	chr2:65436711~66084639:+
THCA	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	11.72	5.06e-28	5.89e-25	0.55	0.48	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
THCA	cis	rs4819052	0.918	rs34886433	ENSG00000223768.1	LINC00205	-11.72	5.09e-28	5.93e-25	-0.52	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.791	rs6902404	ENSG00000235652.6	RP11-545I5.3	11.72	5.12e-28	5.96e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	11.72	5.14e-28	5.98e-25	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
THCA	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-11.72	5.18e-28	6.03e-25	-0.34	-0.48	Height;	chr11:118761813	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	11.72	5.22e-28	6.08e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	11.72	5.28e-28	6.14e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	11.72	5.29e-28	6.15e-25	0.63	0.48	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
THCA	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-11.72	5.29e-28	6.15e-25	-0.35	-0.48	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
THCA	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	11.72	5.32e-28	6.18e-25	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
THCA	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-11.72	5.33e-28	6.19e-25	-0.35	-0.48	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	11.72	5.33e-28	6.19e-25	0.64	0.48	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
THCA	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-11.72	5.4e-28	6.28e-25	-0.35	-0.48	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-11.72	5.4e-28	6.28e-25	-0.35	-0.48	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-11.72	5.4e-28	6.28e-25	-0.35	-0.48	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
THCA	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	11.72	5.4e-28	6.28e-25	0.64	0.48	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
THCA	cis	rs6496932	0.663	rs7183764	ENSG00000218052.5	ADAMTS7P4	-11.72	5.44e-28	6.32e-25	-0.61	-0.48	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.663	rs4842878	ENSG00000218052.5	ADAMTS7P4	-11.72	5.44e-28	6.32e-25	-0.61	-0.48	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.663	rs8040940	ENSG00000218052.5	ADAMTS7P4	-11.72	5.44e-28	6.32e-25	-0.61	-0.48	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85255369~85330334:-
THCA	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	11.71	5.51e-28	6.4e-25	0.55	0.48	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
THCA	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-11.71	5.58e-28	6.48e-25	-0.53	-0.48	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-11.71	5.58e-28	6.48e-25	-0.53	-0.48	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
THCA	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-11.71	5.65e-28	6.56e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-11.71	5.66e-28	6.56e-25	-0.46	-0.48	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs1340004	ENSG00000280107.1	AL022393.9	-11.71	5.68e-28	6.59e-25	-0.59	-0.48	Depression;	chr6:28135913	chr6:28170845~28172521:+
THCA	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	11.71	5.7e-28	6.61e-25	0.6	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
THCA	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	11.71	5.76e-28	6.68e-25	0.58	0.48	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-11.71	5.76e-28	6.68e-25	-0.6	-0.48	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-11.71	5.78e-28	6.7e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
THCA	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-11.71	5.79e-28	6.71e-25	-0.78	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
THCA	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	11.71	5.83e-28	6.76e-25	0.57	0.48	Depression;	chr6:28323463	chr6:28176188~28176674:+
THCA	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-11.71	5.83e-28	6.76e-25	-0.56	-0.48	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
THCA	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	11.71	5.93e-28	6.87e-25	0.54	0.48	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
THCA	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	11.71	5.94e-28	6.88e-25	0.57	0.48	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
THCA	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-11.71	5.98e-28	6.93e-25	-0.57	-0.48	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-11.71	5.98e-28	6.93e-25	-0.57	-0.48	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-11.71	5.98e-28	6.93e-25	-0.57	-0.48	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
THCA	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	11.7	6.03e-28	6.98e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
THCA	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	11.7	6.11e-28	7.07e-25	0.63	0.48	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	11.7	6.11e-28	7.07e-25	0.63	0.48	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	11.7	6.12e-28	7.09e-25	0.64	0.48	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
THCA	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-11.7	6.16e-28	7.13e-25	-0.65	-0.47	Depression;	chr6:28133900	chr6:28115628~28116551:+
THCA	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-11.7	6.21e-28	7.18e-25	-0.5	-0.47	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
THCA	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-11.7	6.21e-28	7.19e-25	-0.54	-0.47	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
THCA	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-11.7	6.23e-28	7.21e-25	-0.58	-0.47	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
THCA	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	11.7	6.23e-28	7.21e-25	0.56	0.47	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
THCA	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-11.7	6.24e-28	7.22e-25	-0.53	-0.47	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-11.7	6.24e-28	7.22e-25	-0.53	-0.47	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
THCA	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-11.7	6.28e-28	7.26e-25	-0.56	-0.47	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
THCA	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-11.7	6.3e-28	7.29e-25	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
THCA	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	11.7	6.43e-28	7.43e-25	0.64	0.47	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	11.7	6.43e-28	7.43e-25	0.64	0.47	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
THCA	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-11.7	6.44e-28	7.44e-25	-0.58	-0.47	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
THCA	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-11.7	6.49e-28	7.51e-25	-0.72	-0.47	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
THCA	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	11.7	6.51e-28	7.53e-25	0.63	0.47	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	11.7	6.51e-28	7.53e-25	0.63	0.47	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	11.7	6.51e-28	7.53e-25	0.63	0.47	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	11.7	6.52e-28	7.54e-25	0.63	0.47	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
THCA	cis	rs853679	0.55	rs6901017	ENSG00000280107.1	AL022393.9	-11.7	6.53e-28	7.55e-25	-0.56	-0.47	Depression;	chr6:28184805	chr6:28170845~28172521:+
THCA	cis	rs6496932	1	rs2002642	ENSG00000218052.5	ADAMTS7P4	11.69	6.63e-28	7.66e-25	0.65	0.47	Central corneal thickness;Corneal structure;	chr15:85284513	chr15:85255369~85330334:-
THCA	cis	rs6496932	1	rs4842872	ENSG00000218052.5	ADAMTS7P4	11.69	6.63e-28	7.66e-25	0.65	0.47	Central corneal thickness;Corneal structure;	chr15:85284825	chr15:85255369~85330334:-
THCA	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	11.69	6.65e-28	7.68e-25	0.65	0.47	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-11.69	6.71e-28	7.75e-25	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	11.69	6.79e-28	7.85e-25	0.63	0.47	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
THCA	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	11.69	6.82e-28	7.87e-25	0.41	0.47	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
THCA	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-11.69	6.84e-28	7.89e-25	-0.61	-0.47	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
THCA	cis	rs1858037	0.836	rs1396209	ENSG00000204929.10	AC074391.1	11.69	6.85e-28	7.91e-25	0.63	0.47	Rheumatoid arthritis;	chr2:65374100	chr2:65436711~66084639:+
THCA	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-11.69	6.88e-28	7.94e-25	-0.61	-0.47	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
THCA	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-11.69	6.88e-28	7.94e-25	-0.59	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
THCA	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	11.69	6.89e-28	7.95e-25	0.62	0.47	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	11.69	6.89e-28	7.95e-25	0.62	0.47	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
THCA	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-11.69	6.91e-28	7.97e-25	-0.45	-0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	11.69	6.94e-28	8.01e-25	0.56	0.47	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
THCA	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	11.69	6.95e-28	8.02e-25	0.62	0.47	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	11.69	6.95e-28	8.02e-25	0.62	0.47	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	11.69	6.96e-28	8.03e-25	0.64	0.47	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
THCA	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	11.69	6.99e-28	8.06e-25	0.63	0.47	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
THCA	cis	rs9545047	0.904	rs2760105	ENSG00000227676.3	LINC01068	11.69	7.02e-28	8.09e-25	0.61	0.47	Schizophrenia;	chr13:79535732	chr13:79566727~79571436:+
THCA	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	11.69	7.11e-28	8.2e-25	0.48	0.47	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	11.69	7.19e-28	8.28e-25	0.69	0.47	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs4819052	ENSG00000223768.1	LINC00205	-11.69	7.19e-28	8.29e-25	-0.48	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-11.69	7.2e-28	8.29e-25	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	11.69	7.2e-28	8.3e-25	0.64	0.47	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
THCA	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-11.68	7.22e-28	8.32e-25	-0.73	-0.47	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-11.68	7.22e-28	8.32e-25	-0.73	-0.47	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
THCA	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-11.68	7.22e-28	8.32e-25	-0.64	-0.47	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
THCA	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-11.68	7.23e-28	8.33e-25	-0.43	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
THCA	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-11.68	7.31e-28	8.42e-25	-0.34	-0.47	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
THCA	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-11.68	7.31e-28	8.43e-25	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
THCA	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-11.68	7.32e-28	8.44e-25	-0.7	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
THCA	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-11.68	7.34e-28	8.45e-25	-0.72	-0.47	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
THCA	cis	rs17111396	0.627	rs12100732	ENSG00000259167.2	NMNAT1P1	11.68	7.34e-28	8.46e-25	0.74	0.47	Uric acid levels;	chr14:81040141	chr14:81032529~81033404:+
THCA	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	11.68	7.36e-28	8.48e-25	0.36	0.47	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
THCA	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-11.68	7.37e-28	8.49e-25	-0.38	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
THCA	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-11.68	7.39e-28	8.51e-25	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
THCA	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	11.68	7.41e-28	8.54e-25	0.59	0.47	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
THCA	cis	rs6496932	1	rs12917495	ENSG00000218052.5	ADAMTS7P4	11.68	7.51e-28	8.65e-25	0.65	0.47	Central corneal thickness;Corneal structure;	chr15:85286330	chr15:85255369~85330334:-
THCA	cis	rs10740039	0.583	rs9415613	ENSG00000254271.1	RP11-131N11.4	-11.68	7.59e-28	8.74e-25	-0.64	-0.47	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60747636	chr10:60734342~60741828:+
THCA	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	11.68	7.6e-28	8.75e-25	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
THCA	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-11.68	7.64e-28	8.79e-25	-0.65	-0.47	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
THCA	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-11.68	7.65e-28	8.81e-25	-0.6	-0.47	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
THCA	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-11.68	7.67e-28	8.83e-25	-0.71	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
THCA	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-11.68	7.68e-28	8.83e-25	-0.44	-0.47	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-11.68	7.68e-28	8.83e-25	-0.45	-0.47	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000223768.1	LINC00205	-11.68	7.74e-28	8.9e-25	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45293285~45297354:+
THCA	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-11.68	7.85e-28	9.03e-25	-0.73	-0.47	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	11.67	7.93e-28	9.11e-25	0.61	0.47	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
THCA	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-11.67	8.01e-28	9.21e-25	-0.38	-0.47	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
THCA	cis	rs8062405	0.625	rs8060365	ENSG00000259982.1	CDC37P1	-11.67	8.02e-28	9.21e-25	-0.6	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-11.67	8.12e-28	9.33e-25	-0.6	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
THCA	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	11.67	8.14e-28	9.35e-25	0.62	0.47	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-11.67	8.2e-28	9.42e-25	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-11.67	8.2e-28	9.42e-25	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-11.67	8.2e-28	9.42e-25	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
THCA	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-11.67	8.2e-28	9.42e-25	-0.35	-0.47	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
THCA	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	11.67	8.25e-28	9.47e-25	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
THCA	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	11.67	8.25e-28	9.47e-25	0.55	0.47	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
THCA	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	11.67	8.25e-28	9.48e-25	0.82	0.47	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-11.67	8.33e-28	9.56e-25	-0.34	-0.47	Height;	chr11:118737823	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	11.67	8.33e-28	9.57e-25	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
THCA	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-11.67	8.38e-28	9.62e-25	-0.59	-0.47	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
THCA	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	11.67	8.4e-28	9.64e-25	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	11.67	8.41e-28	9.65e-25	0.63	0.47	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	11.67	8.41e-28	9.65e-25	0.63	0.47	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
THCA	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	11.67	8.49e-28	9.74e-25	0.67	0.47	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
THCA	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	11.67	8.56e-28	9.82e-25	0.58	0.47	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	11.67	8.59e-28	9.85e-25	0.63	0.47	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
THCA	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	11.66	8.68e-28	9.95e-25	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	11.66	8.68e-28	9.95e-25	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	11.66	8.68e-28	9.95e-25	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
THCA	cis	rs1858037	0.765	rs67404371	ENSG00000204929.10	AC074391.1	11.66	8.75e-28	1e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65370137	chr2:65436711~66084639:+
THCA	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	11.66	8.82e-28	1.01e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	11.66	8.82e-28	1.01e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	11.66	8.82e-28	1.01e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-11.66	8.82e-28	1.01e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-11.66	8.82e-28	1.01e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-11.66	8.82e-28	1.01e-24	-0.45	-0.47	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-11.66	8.82e-28	1.01e-24	-0.45	-0.47	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-11.66	8.82e-28	1.01e-24	-0.45	-0.47	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-11.66	8.82e-28	1.01e-24	-0.45	-0.47	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
THCA	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-11.66	8.83e-28	1.01e-24	-0.64	-0.47	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-11.66	8.83e-28	1.01e-24	-0.64	-0.47	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-11.66	8.86e-28	1.01e-24	-0.65	-0.47	Depression;	chr6:28096845	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000235689.1	AP000351.13	11.66	8.87e-28	1.02e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:24006305~24008258:-
THCA	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-11.66	8.9e-28	1.02e-24	-0.7	-0.47	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
THCA	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-11.66	8.91e-28	1.02e-24	-0.65	-0.47	Depression;	chr6:28131566	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.923	rs2184370	ENSG00000223701.3	RAET1E-AS1	11.66	8.92e-28	1.02e-24	0.65	0.47	Lung cancer;	chr6:149843242	chr6:149884431~149919508:+
THCA	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-11.66	9.02e-28	1.03e-24	-0.4	-0.47	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000223768.1	LINC00205	-11.66	9.04e-28	1.03e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000223768.1	LINC00205	-11.66	9.04e-28	1.03e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-11.66	9.05e-28	1.04e-24	-0.65	-0.47	Depression;	chr6:28139876	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-11.66	9.05e-28	1.04e-24	-0.65	-0.47	Depression;	chr6:28139998	chr6:28115628~28116551:+
THCA	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	11.66	9.06e-28	1.04e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
THCA	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	11.66	9.07e-28	1.04e-24	0.64	0.47	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
THCA	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-11.66	9.18e-28	1.05e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-11.66	9.18e-28	1.05e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
THCA	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	11.66	9.19e-28	1.05e-24	0.59	0.47	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
THCA	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	11.66	9.28e-28	1.06e-24	0.71	0.47	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
THCA	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
THCA	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	11.66	9.39e-28	1.07e-24	0.61	0.47	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
THCA	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	11.65	9.53e-28	1.09e-24	0.61	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
THCA	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	11.65	9.54e-28	1.09e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
THCA	cis	rs17111396	0.627	rs61978745	ENSG00000259167.2	NMNAT1P1	11.65	9.58e-28	1.09e-24	0.75	0.47	Uric acid levels;	chr14:81048940	chr14:81032529~81033404:+
THCA	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	11.65	9.64e-28	1.1e-24	0.68	0.47	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
THCA	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-11.65	9.76e-28	1.11e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-11.65	9.76e-28	1.11e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-11.65	9.81e-28	1.12e-24	-0.46	-0.47	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
THCA	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	11.65	9.86e-28	1.12e-24	0.5	0.47	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
THCA	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-11.65	9.86e-28	1.12e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
THCA	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	11.65	9.91e-28	1.13e-24	0.59	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
THCA	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	11.65	9.92e-28	1.13e-24	0.57	0.47	Depression;	chr6:28303421	chr6:28176188~28176674:+
THCA	cis	rs944289	0.646	rs367883	ENSG00000257826.1	RP11-116N8.4	11.65	1e-27	1.14e-24	0.48	0.47	Thyroid cancer;	chr14:36063400	chr14:36061026~36067190:-
THCA	cis	rs944289	0.646	rs368181	ENSG00000257826.1	RP11-116N8.4	11.65	1e-27	1.14e-24	0.48	0.47	Thyroid cancer;	chr14:36065621	chr14:36061026~36067190:-
THCA	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-11.65	1e-27	1.14e-24	-0.44	-0.47	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-11.65	1e-27	1.14e-24	-0.44	-0.47	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
THCA	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-11.65	1e-27	1.14e-24	-0.4	-0.47	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
THCA	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-11.65	1e-27	1.14e-24	-0.6	-0.47	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-11.65	1e-27	1.14e-24	-0.6	-0.47	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	11.65	1e-27	1.14e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
THCA	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-11.65	1e-27	1.14e-24	-0.43	-0.47	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
THCA	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	11.65	1e-27	1.14e-24	0.63	0.47	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
THCA	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-11.65	1.01e-27	1.15e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000223768.1	LINC00205	-11.65	1.01e-27	1.15e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45293285~45297354:+
THCA	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-11.65	1.01e-27	1.15e-24	-0.58	-0.47	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
THCA	cis	rs944289	0.589	rs847516	ENSG00000257826.1	RP11-116N8.4	11.65	1.01e-27	1.15e-24	0.48	0.47	Thyroid cancer;	chr14:36060593	chr14:36061026~36067190:-
THCA	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-11.65	1.01e-27	1.15e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
THCA	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	11.65	1.02e-27	1.16e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
THCA	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	11.65	1.02e-27	1.16e-24	0.57	0.47	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	11.65	1.02e-27	1.16e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	11.65	1.02e-27	1.16e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
THCA	cis	rs9481169	0.557	rs34896684	ENSG00000255389.1	C6orf3	-11.65	1.03e-27	1.18e-24	-0.88	-0.47	Inflammatory skin disease;	chr6:111572034	chr6:111599875~111602295:+
THCA	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-11.65	1.03e-27	1.18e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
THCA	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-11.64	1.04e-27	1.19e-24	-0.7	-0.47	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
THCA	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-11.64	1.05e-27	1.19e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-11.64	1.05e-27	1.19e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
THCA	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	11.64	1.05e-27	1.19e-24	0.65	0.47	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	11.64	1.05e-27	1.19e-24	0.65	0.47	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
THCA	cis	rs1858037	0.867	rs2118305	ENSG00000204929.10	AC074391.1	11.64	1.06e-27	1.21e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65378086	chr2:65436711~66084639:+
THCA	cis	rs4964805	1	rs12228207	ENSG00000257681.1	RP11-341G23.4	11.64	1.06e-27	1.21e-24	0.58	0.47	Attention deficit hyperactivity disorder;	chr12:103802956	chr12:103746315~103768858:-
THCA	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-11.64	1.07e-27	1.22e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000223768.1	LINC00205	-11.64	1.07e-27	1.22e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45293285~45297354:+
THCA	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	11.64	1.08e-27	1.22e-24	0.54	0.47	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
THCA	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-11.64	1.08e-27	1.23e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	11.64	1.08e-27	1.23e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	11.64	1.08e-27	1.23e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
THCA	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	11.64	1.08e-27	1.23e-24	0.6	0.47	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
THCA	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	11.64	1.08e-27	1.23e-24	0.63	0.47	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000223768.1	LINC00205	-11.64	1.09e-27	1.24e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45293285~45297354:+
THCA	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	11.64	1.09e-27	1.24e-24	0.49	0.47	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
THCA	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	11.64	1.1e-27	1.24e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	11.64	1.11e-27	1.26e-24	0.62	0.47	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	11.64	1.12e-27	1.27e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	11.63	1.14e-27	1.3e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
THCA	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-11.63	1.14e-27	1.3e-24	-0.46	-0.47	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	11.63	1.15e-27	1.31e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
THCA	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	11.63	1.16e-27	1.31e-24	0.69	0.47	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
THCA	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-11.63	1.16e-27	1.31e-24	-0.69	-0.47	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	11.63	1.16e-27	1.32e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
THCA	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-11.63	1.16e-27	1.32e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
THCA	cis	rs2288884	0.559	rs12459268	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52002719	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs8109948	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004796	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs8109964	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004835	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs8109854	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004866	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12461141	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005712	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12459079	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005741	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12461226	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005996	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12461230	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006051	chr19:52049007~52049754:+
THCA	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-11.63	1.17e-27	1.33e-24	-0.68	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
THCA	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-11.63	1.17e-27	1.33e-24	-0.68	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
THCA	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	11.63	1.17e-27	1.33e-24	0.57	0.47	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	11.63	1.17e-27	1.33e-24	0.57	0.47	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
THCA	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	11.63	1.17e-27	1.33e-24	0.57	0.47	Depression;	chr6:28317705	chr6:28176188~28176674:+
THCA	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-11.63	1.2e-27	1.36e-24	-0.44	-0.47	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
THCA	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	11.63	1.21e-27	1.37e-24	0.49	0.47	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
THCA	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-11.63	1.21e-27	1.38e-24	-0.58	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
THCA	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	11.63	1.22e-27	1.39e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
THCA	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-11.63	1.23e-27	1.39e-24	-0.44	-0.47	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-11.63	1.23e-27	1.39e-24	-0.44	-0.47	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	11.63	1.23e-27	1.4e-24	0.65	0.47	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	11.63	1.24e-27	1.41e-24	0.65	0.47	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
THCA	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-11.62	1.25e-27	1.41e-24	-0.34	-0.47	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-11.62	1.25e-27	1.42e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	11.62	1.25e-27	1.42e-24	0.64	0.47	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
THCA	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	11.62	1.26e-27	1.43e-24	0.56	0.47	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000223768.1	LINC00205	11.62	1.26e-27	1.43e-24	0.44	0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	11.62	1.27e-27	1.44e-24	0.65	0.47	Depression;	chr6:28142370	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
THCA	cis	rs17111396	0.627	rs55947533	ENSG00000259167.2	NMNAT1P1	11.62	1.28e-27	1.45e-24	0.75	0.47	Uric acid levels;	chr14:81052482	chr14:81032529~81033404:+
THCA	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-11.62	1.28e-27	1.45e-24	-0.45	-0.47	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
THCA	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-11.62	1.28e-27	1.45e-24	-0.61	-0.47	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
THCA	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	11.62	1.29e-27	1.46e-24	0.64	0.47	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
THCA	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-11.62	1.29e-27	1.46e-24	-0.71	-0.47	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
THCA	cis	rs1858037	0.836	rs17475335	ENSG00000204929.10	AC074391.1	11.62	1.29e-27	1.46e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65378646	chr2:65436711~66084639:+
THCA	cis	rs4819052	0.851	rs28442024	ENSG00000223768.1	LINC00205	-11.62	1.29e-27	1.46e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45293285~45297354:+
THCA	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	11.62	1.3e-27	1.47e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-11.62	1.31e-27	1.48e-24	-0.64	-0.47	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
THCA	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	11.62	1.32e-27	1.49e-24	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
THCA	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	11.62	1.32e-27	1.5e-24	0.66	0.47	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
THCA	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-11.62	1.34e-27	1.51e-24	-0.45	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
THCA	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-11.62	1.34e-27	1.51e-24	-0.56	-0.47	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
THCA	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	11.62	1.34e-27	1.52e-24	0.56	0.47	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
THCA	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	11.62	1.35e-27	1.52e-24	0.63	0.47	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	11.62	1.35e-27	1.52e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
THCA	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-11.62	1.35e-27	1.53e-24	-0.59	-0.47	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
THCA	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	11.62	1.36e-27	1.54e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
THCA	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	11.61	1.38e-27	1.56e-24	0.51	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
THCA	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	11.61	1.38e-27	1.56e-24	0.59	0.47	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
THCA	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-11.61	1.39e-27	1.56e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-11.61	1.39e-27	1.56e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
THCA	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-11.61	1.39e-27	1.57e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
THCA	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	11.61	1.39e-27	1.57e-24	0.53	0.47	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
THCA	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-11.61	1.4e-27	1.58e-24	-0.7	-0.47	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
THCA	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-11.61	1.4e-27	1.58e-24	-0.7	-0.47	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
THCA	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-11.61	1.4e-27	1.58e-24	-0.7	-0.47	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
THCA	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	11.61	1.41e-27	1.59e-24	0.35	0.47	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
THCA	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	11.61	1.41e-27	1.59e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	11.61	1.41e-27	1.59e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
THCA	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	11.61	1.41e-27	1.59e-24	0.56	0.47	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000223768.1	LINC00205	-11.61	1.42e-27	1.6e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	11.61	1.43e-27	1.61e-24	0.63	0.47	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	11.61	1.43e-27	1.61e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-11.61	1.43e-27	1.61e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-11.61	1.43e-27	1.61e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-11.61	1.43e-27	1.61e-24	-0.48	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-11.61	1.43e-27	1.61e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
THCA	cis	rs853679	0.55	rs1233699	ENSG00000280107.1	AL022393.9	-11.61	1.43e-27	1.61e-24	-0.56	-0.47	Depression;	chr6:28201380	chr6:28170845~28172521:+
THCA	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-11.61	1.44e-27	1.62e-24	-0.58	-0.47	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	11.61	1.44e-27	1.62e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	11.61	1.44e-27	1.62e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	11.61	1.44e-27	1.62e-24	0.54	0.47	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.791	rs4896820	ENSG00000235652.6	RP11-545I5.3	11.61	1.45e-27	1.64e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs4896821	ENSG00000235652.6	RP11-545I5.3	11.61	1.45e-27	1.64e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-11.61	1.45e-27	1.64e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
THCA	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-11.61	1.46e-27	1.64e-24	-0.6	-0.47	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	11.61	1.46e-27	1.65e-24	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	11.61	1.46e-27	1.65e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
THCA	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	11.61	1.47e-27	1.66e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
THCA	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	11.61	1.47e-27	1.66e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
THCA	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	11.61	1.48e-27	1.67e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	11.61	1.48e-27	1.67e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	11.61	1.48e-27	1.67e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	11.61	1.48e-27	1.67e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-11.61	1.48e-27	1.67e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	11.61	1.48e-27	1.67e-24	0.64	0.47	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
THCA	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	11.6	1.5e-27	1.69e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	11.6	1.5e-27	1.69e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
THCA	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	11.6	1.51e-27	1.7e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	11.6	1.51e-27	1.7e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	11.6	1.51e-27	1.7e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	11.6	1.51e-27	1.7e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
THCA	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-11.6	1.51e-27	1.7e-24	-0.71	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
THCA	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-11.6	1.52e-27	1.71e-24	-0.57	-0.47	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
THCA	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-11.6	1.52e-27	1.71e-24	-0.83	-0.47	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
THCA	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	11.6	1.54e-27	1.73e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	11.6	1.54e-27	1.73e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	11.6	1.54e-27	1.73e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	11.6	1.54e-27	1.73e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
THCA	cis	rs17111396	0.627	rs17111394	ENSG00000259167.2	NMNAT1P1	11.6	1.55e-27	1.74e-24	0.73	0.47	Uric acid levels;	chr14:81056784	chr14:81032529~81033404:+
THCA	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-11.6	1.56e-27	1.75e-24	-0.5	-0.47	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
THCA	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	11.6	1.56e-27	1.75e-24	0.64	0.47	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
THCA	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	11.6	1.56e-27	1.75e-24	0.57	0.47	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
THCA	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	11.6	1.56e-27	1.76e-24	0.45	0.47	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
THCA	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	11.6	1.56e-27	1.76e-24	0.45	0.47	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
THCA	cis	rs4819052	0.851	rs2236444	ENSG00000223768.1	LINC00205	-11.6	1.57e-27	1.76e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45293285~45297354:+
THCA	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-11.6	1.59e-27	1.79e-24	-0.52	-0.47	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
THCA	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	11.6	1.6e-27	1.8e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-11.6	1.6e-27	1.8e-24	-0.61	-0.47	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
THCA	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-11.6	1.61e-27	1.8e-24	-0.7	-0.47	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
THCA	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-11.6	1.61e-27	1.8e-24	-0.7	-0.47	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-11.6	1.61e-27	1.8e-24	-0.7	-0.47	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
THCA	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-11.6	1.61e-27	1.8e-24	-0.7	-0.47	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
THCA	cis	rs6496932	0.635	rs12900455	ENSG00000218052.5	ADAMTS7P4	-11.6	1.61e-27	1.81e-24	-0.61	-0.47	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85255369~85330334:-
THCA	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-11.6	1.61e-27	1.81e-24	-0.48	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
THCA	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	11.6	1.61e-27	1.81e-24	0.58	0.47	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
THCA	cis	rs944289	0.51	rs2780314	ENSG00000257826.1	RP11-116N8.4	-11.6	1.63e-27	1.83e-24	-0.5	-0.47	Thyroid cancer;	chr14:36059286	chr14:36061026~36067190:-
THCA	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
THCA	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	11.59	1.65e-27	1.85e-24	0.57	0.47	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000226824.5	RP4-756H11.3	-11.59	1.66e-27	1.86e-24	-0.71	-0.47	Corneal structure;	chr7:66801919	chr7:66654538~66669855:+
THCA	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	11.59	1.67e-27	1.87e-24	0.59	0.47	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
THCA	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-11.59	1.67e-27	1.87e-24	-0.69	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
THCA	cis	rs7772486	0.743	rs1292339	ENSG00000235652.6	RP11-545I5.3	-11.59	1.68e-27	1.88e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000223768.1	LINC00205	-11.59	1.68e-27	1.88e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45293285~45297354:+
THCA	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-11.59	1.68e-27	1.89e-24	-0.7	-0.47	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
THCA	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	11.59	1.69e-27	1.89e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	11.59	1.69e-27	1.89e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs453834	ENSG00000235652.6	RP11-545I5.3	11.59	1.69e-27	1.89e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000223768.1	LINC00205	-11.59	1.7e-27	1.9e-24	-0.48	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45293285~45297354:+
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000280107.1	AL022393.9	-11.59	1.7e-27	1.9e-24	-0.56	-0.47	Parkinson's disease;	chr6:28065618	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	11.59	1.71e-27	1.91e-24	0.63	0.47	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	11.59	1.71e-27	1.91e-24	0.63	0.47	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
THCA	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-11.59	1.71e-27	1.91e-24	-0.34	-0.47	Height;	chr11:118737916	chr11:118791254~118793137:+
THCA	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	11.59	1.71e-27	1.92e-24	0.63	0.47	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
THCA	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	11.59	1.71e-27	1.92e-24	0.54	0.47	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.962	rs2275045	ENSG00000223701.3	RAET1E-AS1	11.59	1.72e-27	1.92e-24	0.65	0.47	Lung cancer;	chr6:149842775	chr6:149884431~149919508:+
THCA	cis	rs4819052	1	rs3746980	ENSG00000223768.1	LINC00205	-11.59	1.75e-27	1.96e-24	-0.48	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45293285~45297354:+
THCA	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-11.59	1.76e-27	1.97e-24	-0.59	-0.47	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
THCA	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	11.59	1.77e-27	1.98e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	11.59	1.78e-27	1.99e-24	0.63	0.47	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	11.59	1.78e-27	1.99e-24	0.63	0.47	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
THCA	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-11.59	1.78e-27	2e-24	-0.6	-0.47	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.743	rs9376955	ENSG00000235652.6	RP11-545I5.3	11.58	1.8e-27	2.01e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.805	rs4896831	ENSG00000235652.6	RP11-545I5.3	11.58	1.8e-27	2.01e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	11.58	1.8e-27	2.01e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	11.58	1.8e-27	2.01e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
THCA	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-11.58	1.82e-27	2.04e-24	-0.56	-0.47	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
THCA	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-11.58	1.82e-27	2.04e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	11.58	1.82e-27	2.04e-24	0.63	0.47	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	11.58	1.83e-27	2.05e-24	0.63	0.47	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
THCA	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-11.58	1.84e-27	2.05e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
THCA	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	11.58	1.84e-27	2.06e-24	0.63	0.47	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-11.58	1.84e-27	2.06e-24	-0.58	-0.47	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
THCA	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-11.58	1.85e-27	2.07e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
THCA	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
THCA	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
THCA	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
THCA	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
THCA	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
THCA	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
THCA	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
THCA	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	11.58	1.86e-27	2.08e-24	0.65	0.47	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	11.58	1.86e-27	2.08e-24	0.65	0.47	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	11.58	1.86e-27	2.08e-24	0.63	0.47	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
THCA	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	11.58	1.86e-27	2.08e-24	0.64	0.47	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
THCA	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	11.58	1.87e-27	2.09e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	11.58	1.87e-27	2.09e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
THCA	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	11.58	1.88e-27	2.1e-24	0.53	0.47	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
THCA	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-11.58	1.88e-27	2.1e-24	-0.57	-0.47	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	11.58	1.89e-27	2.11e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	11.58	1.89e-27	2.11e-24	0.63	0.47	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	11.58	1.9e-27	2.12e-24	0.63	0.47	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
THCA	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.9e-27	2.12e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
THCA	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-11.58	1.92e-27	2.14e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-11.58	1.92e-27	2.14e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-11.58	1.92e-27	2.14e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	11.58	1.92e-27	2.14e-24	0.69	0.47	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
THCA	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	11.58	1.93e-27	2.15e-24	0.58	0.47	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
THCA	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	11.58	1.93e-27	2.15e-24	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
THCA	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-11.58	1.95e-27	2.17e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
THCA	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-11.57	1.96e-27	2.19e-24	-0.61	-0.47	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
THCA	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	11.57	1.97e-27	2.2e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
THCA	cis	rs853679	0.55	rs1233704	ENSG00000280107.1	AL022393.9	11.57	1.98e-27	2.2e-24	0.56	0.47	Depression;	chr6:28199145	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1237875	ENSG00000280107.1	AL022393.9	11.57	1.98e-27	2.2e-24	0.56	0.47	Depression;	chr6:28205232	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1225598	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28193021	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1150689	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28197321	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1225599	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28197412	chr6:28170845~28172521:+
THCA	cis	rs853679	0.574	rs1233705	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28198669	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1233707	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28205175	chr6:28170845~28172521:+
THCA	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-11.57	1.98e-27	2.21e-24	-0.62	-0.47	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
THCA	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	11.57	1.99e-27	2.21e-24	0.63	0.47	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
THCA	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-11.57	2e-27	2.23e-24	-0.52	-0.47	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
THCA	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	11.57	2.03e-27	2.26e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	11.57	2.03e-27	2.26e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000223768.1	LINC00205	-11.57	2.03e-27	2.27e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45293285~45297354:+
THCA	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-11.57	2.04e-27	2.27e-24	-0.58	-0.47	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
THCA	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	11.57	2.05e-27	2.28e-24	0.61	0.47	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	11.57	2.05e-27	2.28e-24	0.61	0.47	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
THCA	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-11.57	2.06e-27	2.29e-24	-0.6	-0.47	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000223768.1	LINC00205	-11.57	2.06e-27	2.29e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45293285~45297354:+
THCA	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-11.57	2.07e-27	2.3e-24	-0.69	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
THCA	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	11.57	2.07e-27	2.3e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	11.57	2.07e-27	2.3e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
THCA	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-11.57	2.08e-27	2.31e-24	-0.34	-0.47	Height;	chr11:118786602	chr11:118791254~118793137:+
THCA	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-11.57	2.08e-27	2.31e-24	-0.7	-0.47	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
THCA	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-11.57	2.08e-27	2.31e-24	-0.61	-0.47	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	11.57	2.08e-27	2.32e-24	0.63	0.47	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.846	rs409553	ENSG00000235652.6	RP11-545I5.3	11.57	2.09e-27	2.33e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs371186	ENSG00000235652.6	RP11-545I5.3	11.57	2.09e-27	2.33e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs439035	ENSG00000235652.6	RP11-545I5.3	11.57	2.09e-27	2.33e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145799409~145886585:+
THCA	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-11.57	2.13e-27	2.37e-24	-0.58	-0.47	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
THCA	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	11.57	2.14e-27	2.38e-24	0.56	0.47	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.967	rs6903252	ENSG00000235652.6	RP11-545I5.3	11.56	2.16e-27	2.4e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145799409~145886585:+
THCA	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-11.56	2.16e-27	2.4e-24	-0.69	-0.47	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
THCA	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-11.56	2.16e-27	2.4e-24	-0.69	-0.47	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
THCA	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	11.56	2.16e-27	2.41e-24	0.67	0.47	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
THCA	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-11.56	2.17e-27	2.41e-24	-0.35	-0.47	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
THCA	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-11.56	2.17e-27	2.42e-24	-0.7	-0.47	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	11.56	2.19e-27	2.43e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	11.56	2.19e-27	2.43e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	11.56	2.19e-27	2.44e-24	0.54	0.47	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	11.56	2.2e-27	2.44e-24	0.63	0.47	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-11.56	2.2e-27	2.45e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
THCA	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	11.56	2.2e-27	2.45e-24	0.45	0.47	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
THCA	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	11.56	2.2e-27	2.45e-24	0.57	0.47	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
THCA	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-11.56	2.22e-27	2.47e-24	-0.34	-0.47	Height;	chr11:118809363	chr11:118791254~118793137:+
THCA	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-11.56	2.23e-27	2.47e-24	-0.44	-0.47	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	11.56	2.23e-27	2.48e-24	0.64	0.47	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
THCA	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-11.56	2.25e-27	2.5e-24	-0.51	-0.47	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
THCA	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	11.56	2.28e-27	2.52e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	11.56	2.28e-27	2.52e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000223768.1	LINC00205	-11.56	2.3e-27	2.54e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000223768.1	LINC00205	-11.56	2.3e-27	2.54e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000223768.1	LINC00205	-11.56	2.3e-27	2.54e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000223768.1	LINC00205	-11.56	2.3e-27	2.54e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs875621	ENSG00000223768.1	LINC00205	-11.56	2.33e-27	2.57e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45293285~45297354:+
THCA	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-11.56	2.33e-27	2.57e-24	-0.57	-0.47	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
THCA	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
THCA	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	11.55	2.36e-27	2.61e-24	0.57	0.47	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	11.55	2.37e-27	2.62e-24	0.56	0.47	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
THCA	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	11.55	2.39e-27	2.64e-24	0.58	0.47	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
THCA	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	11.55	2.39e-27	2.64e-24	0.63	0.47	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
THCA	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-11.55	2.4e-27	2.65e-24	-0.62	-0.47	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
THCA	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-11.55	2.45e-27	2.7e-24	-0.57	-0.47	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
THCA	cis	rs227275	0.525	rs7660298	ENSG00000246560.2	RP11-10L12.4	11.55	2.47e-27	2.73e-24	0.59	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102828055~102844075:+
THCA	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-11.55	2.48e-27	2.74e-24	-0.64	-0.47	Depression;	chr6:28126588	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-11.55	2.48e-27	2.74e-24	-0.64	-0.47	Depression;	chr6:28126953	chr6:28115628~28116551:+
THCA	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	11.55	2.48e-27	2.74e-24	0.54	0.47	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
THCA	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-11.55	2.48e-27	2.74e-24	-0.44	-0.47	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
THCA	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	11.55	2.49e-27	2.74e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	11.55	2.49e-27	2.74e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	11.55	2.51e-27	2.76e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
THCA	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-11.55	2.51e-27	2.77e-24	-0.69	-0.47	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
THCA	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-11.55	2.53e-27	2.78e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
THCA	cis	rs7569084	0.687	rs1437462	ENSG00000237979.1	AC007389.1	11.55	2.53e-27	2.79e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65449559	chr2:65500993~65502138:-
THCA	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	11.55	2.55e-27	2.81e-24	0.63	0.47	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	11.55	2.55e-27	2.81e-24	0.64	0.47	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
THCA	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-11.55	2.56e-27	2.82e-24	-0.34	-0.47	Height;	chr11:118781100	chr11:118791254~118793137:+
THCA	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-11.54	2.6e-27	2.87e-24	-0.62	-0.47	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
THCA	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	11.54	2.61e-27	2.87e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
THCA	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-11.54	2.61e-27	2.87e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
THCA	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	11.54	2.61e-27	2.87e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	11.54	2.61e-27	2.87e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	11.54	2.61e-27	2.87e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
THCA	cis	rs11722779	0.844	rs7694724	ENSG00000246560.2	RP11-10L12.4	11.54	2.61e-27	2.87e-24	0.59	0.47	Schizophrenia;	chr4:103041375	chr4:102828055~102844075:+
THCA	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-11.54	2.64e-27	2.91e-24	-0.64	-0.47	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000223768.1	LINC00205	-11.54	2.66e-27	2.93e-24	-0.48	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	11.54	2.71e-27	2.98e-24	0.64	0.47	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	11.54	2.72e-27	3e-24	0.63	0.47	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
THCA	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	11.54	2.72e-27	3e-24	0.48	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
THCA	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-11.54	2.73e-27	3e-24	-0.44	-0.47	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
THCA	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	11.54	2.73e-27	3e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	11.54	2.73e-27	3e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
THCA	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	11.54	2.74e-27	3.01e-24	0.56	0.47	Depression;	chr6:28200948	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	11.54	2.74e-27	3.02e-24	0.56	0.47	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
THCA	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-11.54	2.79e-27	3.06e-24	-0.65	-0.47	Depression;	chr6:28140454	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-11.54	2.79e-27	3.06e-24	-0.65	-0.47	Depression;	chr6:28141189	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-11.54	2.79e-27	3.06e-24	-0.65	-0.47	Depression;	chr6:28141484	chr6:28115628~28116551:+
THCA	cis	rs4819052	0.851	rs2838867	ENSG00000223768.1	LINC00205	-11.53	2.82e-27	3.1e-24	-0.45	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:45293285~45297354:+
THCA	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-11.53	2.83e-27	3.11e-24	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
THCA	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	11.53	2.84e-27	3.12e-24	0.61	0.47	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
THCA	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	11.53	2.84e-27	3.12e-24	0.61	0.47	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
THCA	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-11.53	2.85e-27	3.13e-24	-0.78	-0.47	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-11.53	2.85e-27	3.13e-24	-0.78	-0.47	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000223768.1	LINC00205	-11.53	2.87e-27	3.15e-24	-0.45	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45293285~45297354:+
THCA	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-11.53	2.87e-27	3.15e-24	-0.61	-0.47	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
THCA	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-11.53	2.87e-27	3.16e-24	-0.62	-0.47	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
THCA	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-11.53	2.88e-27	3.16e-24	-0.57	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
THCA	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	11.53	2.89e-27	3.18e-24	0.58	0.47	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
THCA	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	11.53	2.91e-27	3.2e-24	0.57	0.47	Depression;	chr6:28327262	chr6:28176188~28176674:+
THCA	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-11.53	2.92e-27	3.2e-24	-0.59	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
THCA	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-11.53	2.92e-27	3.2e-24	-0.34	-0.47	Height;	chr11:118791319	chr11:118791254~118793137:+
THCA	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	11.53	2.92e-27	3.21e-24	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	11.53	2.92e-27	3.21e-24	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
THCA	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
THCA	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	11.53	2.97e-27	3.26e-24	0.74	0.47	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
THCA	cis	rs4819052	0.765	rs2838868	ENSG00000223768.1	LINC00205	11.53	2.98e-27	3.27e-24	0.47	0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45293285~45297354:+
THCA	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	11.53	2.98e-27	3.27e-24	0.61	0.47	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
THCA	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-11.53	2.98e-27	3.27e-24	-0.65	-0.47	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
THCA	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	11.53	3e-27	3.29e-24	0.51	0.47	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	11.53	3e-27	3.29e-24	0.51	0.47	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
THCA	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	11.53	3.01e-27	3.3e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-11.53	3.01e-27	3.3e-24	-0.44	-0.47	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
THCA	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	11.53	3.07e-27	3.36e-24	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
THCA	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	11.52	3.08e-27	3.38e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
THCA	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	11.52	3.09e-27	3.38e-24	0.45	0.47	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
THCA	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-11.52	3.1e-27	3.4e-24	-0.73	-0.47	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
THCA	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-11.52	3.1e-27	3.4e-24	-0.64	-0.47	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
THCA	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-11.52	3.11e-27	3.41e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
THCA	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-11.52	3.11e-27	3.41e-24	-0.57	-0.47	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
THCA	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	11.52	3.12e-27	3.42e-24	0.62	0.47	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
THCA	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	11.52	3.13e-27	3.42e-24	0.6	0.47	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
THCA	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	11.52	3.13e-27	3.43e-24	0.6	0.47	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
THCA	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-11.52	3.14e-27	3.44e-24	-0.69	-0.47	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	11.52	3.17e-27	3.47e-24	0.69	0.47	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	11.52	3.17e-27	3.47e-24	0.69	0.47	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	11.52	3.17e-27	3.47e-24	0.69	0.47	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
THCA	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
THCA	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	11.52	3.18e-27	3.48e-24	0.6	0.47	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
THCA	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	11.52	3.18e-27	3.48e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
THCA	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-11.52	3.19e-27	3.49e-24	-0.57	-0.47	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
THCA	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	11.52	3.2e-27	3.5e-24	0.54	0.47	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
THCA	cis	rs12468226	1	rs111542497	ENSG00000273456.1	RP11-686O6.2	11.52	3.21e-27	3.51e-24	0.53	0.47	Urate levels;	chr2:202330369	chr2:202374932~202375604:-
THCA	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	11.52	3.21e-27	3.52e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
THCA	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	11.52	3.22e-27	3.53e-24	0.56	0.47	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	11.52	3.23e-27	3.53e-24	0.62	0.47	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
THCA	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-11.52	3.23e-27	3.54e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
THCA	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-11.52	3.28e-27	3.59e-24	-0.64	-0.47	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-11.52	3.28e-27	3.59e-24	-0.64	-0.47	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
THCA	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	11.52	3.29e-27	3.6e-24	0.44	0.47	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
THCA	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	11.52	3.29e-27	3.6e-24	0.44	0.47	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
THCA	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-11.52	3.3e-27	3.6e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
THCA	cis	rs7569084	0.687	rs4671663	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65434400	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs11692813	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65435172	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.663	rs11126037	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65436024	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs11126038	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65436100	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.663	rs11694714	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65436802	chr2:65500993~65502138:-
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000223768.1	LINC00205	11.52	3.31e-27	3.62e-24	0.44	0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45293285~45297354:+
THCA	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	11.52	3.32e-27	3.62e-24	0.68	0.47	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
THCA	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	11.52	3.33e-27	3.64e-24	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
THCA	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-11.52	3.34e-27	3.64e-24	-0.62	-0.47	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-11.52	3.34e-27	3.64e-24	-0.62	-0.47	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	11.52	3.34e-27	3.65e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
THCA	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	11.52	3.35e-27	3.66e-24	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	11.52	3.35e-27	3.66e-24	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	11.52	3.35e-27	3.66e-24	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000223768.1	LINC00205	-11.52	3.36e-27	3.67e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45293285~45297354:+
THCA	cis	rs7569084	0.663	rs1437461	ENSG00000237979.1	AC007389.1	11.51	3.38e-27	3.69e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65452578	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs7562559	ENSG00000237979.1	AC007389.1	11.51	3.38e-27	3.69e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65452719	chr2:65500993~65502138:-
THCA	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-11.51	3.43e-27	3.74e-24	-0.44	-0.47	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
THCA	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	11.51	3.46e-27	3.77e-24	0.44	0.47	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
THCA	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-11.51	3.49e-27	3.8e-24	-0.38	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
THCA	cis	rs9659323	0.622	rs6689568	ENSG00000231365.4	RP11-418J17.1	-11.51	3.5e-27	3.81e-24	-0.5	-0.47	Body mass index;	chr1:118960338	chr1:119140396~119275973:+
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000223768.1	LINC00205	-11.51	3.53e-27	3.85e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45293285~45297354:+
THCA	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-11.51	3.53e-27	3.85e-24	-0.61	-0.47	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
THCA	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-11.51	3.55e-27	3.87e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
THCA	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-11.51	3.57e-27	3.89e-24	-0.6	-0.47	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
THCA	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	11.51	3.59e-27	3.91e-24	0.53	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
THCA	cis	rs7569084	0.687	rs12614851	ENSG00000237979.1	AC007389.1	11.51	3.61e-27	3.93e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65458050	chr2:65500993~65502138:-
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000280107.1	AL022393.9	-11.51	3.62e-27	3.94e-24	-0.55	-0.47	Parkinson's disease;	chr6:28066257	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000280107.1	AL022393.9	-11.51	3.62e-27	3.94e-24	-0.55	-0.47	Parkinson's disease;	chr6:28066263	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000280107.1	AL022393.9	-11.51	3.62e-27	3.94e-24	-0.55	-0.47	Parkinson's disease;	chr6:28066343	chr6:28170845~28172521:+
THCA	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-11.51	3.63e-27	3.95e-24	-0.57	-0.47	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
THCA	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	11.51	3.65e-27	3.98e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
THCA	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-11.5	3.72e-27	4.05e-24	-0.43	-0.47	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
THCA	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-11.5	3.73e-27	4.06e-24	-0.74	-0.47	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
THCA	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	11.5	3.75e-27	4.08e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
THCA	cis	rs17111396	0.627	rs2371467	ENSG00000259167.2	NMNAT1P1	11.5	3.75e-27	4.08e-24	0.74	0.47	Uric acid levels;	chr14:81055088	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.627	rs61978747	ENSG00000259167.2	NMNAT1P1	11.5	3.75e-27	4.08e-24	0.74	0.47	Uric acid levels;	chr14:81056707	chr14:81032529~81033404:+
THCA	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-11.5	3.78e-27	4.12e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
THCA	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	11.5	3.8e-27	4.13e-24	0.69	0.47	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.654	rs9376958	ENSG00000235652.6	RP11-545I5.3	-11.5	3.8e-27	4.13e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145701904	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	11.5	3.83e-27	4.17e-24	0.62	0.47	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	11.5	3.83e-27	4.17e-24	0.62	0.47	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	11.5	3.83e-27	4.17e-24	0.62	0.47	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
THCA	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	11.5	3.85e-27	4.18e-24	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	11.5	3.85e-27	4.19e-24	0.61	0.47	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	11.5	3.85e-27	4.19e-24	0.61	0.47	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
THCA	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	11.5	3.89e-27	4.23e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	11.5	3.9e-27	4.24e-24	0.64	0.47	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
THCA	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	11.5	3.91e-27	4.25e-24	0.45	0.47	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
THCA	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	11.5	3.92e-27	4.26e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
THCA	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	11.5	3.92e-27	4.26e-24	0.56	0.47	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
THCA	cis	rs853679	0.628	rs9368560	ENSG00000280107.1	AL022393.9	-11.5	3.93e-27	4.28e-24	-0.57	-0.47	Depression;	chr6:28192182	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	11.5	3.95e-27	4.3e-24	0.62	0.47	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
THCA	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	11.5	3.97e-27	4.31e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
THCA	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	11.5	3.97e-27	4.31e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
THCA	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	11.5	3.98e-27	4.32e-24	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	11.5	3.98e-27	4.33e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	11.5	4.02e-27	4.37e-24	0.63	0.47	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	11.5	4.02e-27	4.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
THCA	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-11.5	4.02e-27	4.37e-24	-0.49	-0.47	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
THCA	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	11.5	4.03e-27	4.38e-24	0.63	0.47	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
THCA	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	11.49	4.05e-27	4.4e-24	0.64	0.47	Depression;	chr6:28167882	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	11.49	4.05e-27	4.4e-24	0.63	0.47	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	11.49	4.07e-27	4.42e-24	0.63	0.47	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-11.49	4.11e-27	4.46e-24	-0.62	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
THCA	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	11.49	4.12e-27	4.47e-24	0.63	0.47	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	11.49	4.12e-27	4.47e-24	0.63	0.47	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	11.49	4.12e-27	4.47e-24	0.63	0.47	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	11.49	4.12e-27	4.47e-24	0.63	0.47	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
THCA	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-11.49	4.12e-27	4.48e-24	-0.64	-0.47	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
THCA	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-11.49	4.14e-27	4.49e-24	-0.73	-0.47	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
THCA	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-11.49	4.14e-27	4.49e-24	-0.6	-0.47	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
THCA	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	11.49	4.14e-27	4.5e-24	0.58	0.47	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
THCA	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	11.49	4.15e-27	4.51e-24	0.54	0.47	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	11.49	4.15e-27	4.51e-24	0.57	0.47	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
THCA	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	11.49	4.18e-27	4.54e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
THCA	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-11.49	4.2e-27	4.56e-24	-0.55	-0.47	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
THCA	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-11.49	4.2e-27	4.56e-24	-0.55	-0.47	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
THCA	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	11.49	4.2e-27	4.56e-24	0.35	0.47	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
THCA	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	11.49	4.21e-27	4.56e-24	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
THCA	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	11.49	4.22e-27	4.58e-24	0.56	0.47	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	11.49	4.22e-27	4.58e-24	0.56	0.47	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
THCA	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	11.49	4.22e-27	4.58e-24	0.58	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
THCA	cis	rs1153858	0.848	rs9806699	ENSG00000259520.4	CTD-2651B20.3	-11.49	4.24e-27	4.6e-24	-0.61	-0.47	Homoarginine levels;	chr15:45448194	chr15:45251580~45279251:-
THCA	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	11.49	4.25e-27	4.6e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
THCA	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-11.49	4.25e-27	4.61e-24	-0.62	-0.47	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
THCA	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-11.49	4.26e-27	4.62e-24	-0.49	-0.47	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
THCA	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	11.49	4.3e-27	4.67e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
THCA	cis	rs1858037	0.867	rs67817304	ENSG00000204929.10	AC074391.1	11.49	4.35e-27	4.72e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65346982	chr2:65436711~66084639:+
THCA	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-11.49	4.36e-27	4.72e-24	-0.7	-0.47	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	11.49	4.42e-27	4.79e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
THCA	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-11.48	4.43e-27	4.8e-24	-0.34	-0.47	Height;	chr11:118808920	chr11:118791254~118793137:+
THCA	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-11.48	4.45e-27	4.82e-24	-0.59	-0.47	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
THCA	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-11.48	4.47e-27	4.84e-24	-0.58	-0.47	Height;	chr3:53047596	chr3:53064283~53065091:-
THCA	cis	rs7772486	0.681	rs9390343	ENSG00000235652.6	RP11-545I5.3	-11.48	4.49e-27	4.86e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000223768.1	LINC00205	-11.48	4.49e-27	4.86e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	11.48	4.49e-27	4.86e-24	0.62	0.47	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
THCA	cis	rs6496932	0.663	rs12915663	ENSG00000218052.5	ADAMTS7P4	-11.48	4.49e-27	4.86e-24	-0.6	-0.47	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85255369~85330334:-
THCA	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	11.48	4.51e-27	4.89e-24	0.61	0.47	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	11.48	4.51e-27	4.89e-24	0.61	0.47	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	11.48	4.53e-27	4.9e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	11.48	4.53e-27	4.91e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	11.48	4.53e-27	4.91e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	11.48	4.53e-27	4.91e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-11.48	4.57e-27	4.95e-24	-0.64	-0.47	Depression;	chr6:28143758	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-11.48	4.57e-27	4.95e-24	-0.64	-0.47	Depression;	chr6:28144784	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs9295762	ENSG00000280107.1	AL022393.9	11.48	4.59e-27	4.96e-24	0.55	0.47	Depression;	chr6:28187640	chr6:28170845~28172521:+
THCA	cis	rs6519955	0.765	rs7292527	ENSG00000231711.2	LINC00899	-11.48	4.61e-27	4.98e-24	-0.42	-0.47	Dupuytren's disease;	chr22:46027245	chr22:46039907~46044853:-
THCA	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-11.48	4.65e-27	5.03e-24	-0.7	-0.47	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000223768.1	LINC00205	-11.48	4.66e-27	5.04e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	11.48	4.67e-27	5.05e-24	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	11.48	4.67e-27	5.05e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
THCA	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	11.48	4.73e-27	5.12e-24	0.56	0.47	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
THCA	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-11.48	4.76e-27	5.15e-24	-0.61	-0.47	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
THCA	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-11.48	4.79e-27	5.18e-24	-0.6	-0.47	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
THCA	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	11.48	4.8e-27	5.19e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	11.47	4.85e-27	5.24e-24	0.62	0.47	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	11.47	4.85e-27	5.24e-24	0.62	0.47	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
THCA	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-11.47	4.87e-27	5.27e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-11.47	4.87e-27	5.27e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
THCA	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-11.47	4.88e-27	5.28e-24	-0.51	-0.47	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-11.47	4.88e-27	5.28e-24	-0.51	-0.47	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
THCA	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	11.47	4.89e-27	5.28e-24	0.88	0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
THCA	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-11.47	4.89e-27	5.29e-24	-0.48	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
THCA	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-11.47	4.89e-27	5.29e-24	-0.48	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
THCA	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-11.47	4.89e-27	5.29e-24	-0.48	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000223768.1	LINC00205	-11.47	4.92e-27	5.32e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000223768.1	LINC00205	11.47	4.94e-27	5.33e-24	0.44	0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45293285~45297354:+
THCA	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	11.47	4.94e-27	5.34e-24	0.71	0.47	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
THCA	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-11.47	4.94e-27	5.34e-24	-0.57	-0.47	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
THCA	cis	rs9928842	0.941	rs8057145	ENSG00000280152.1	RP11-331F4.5	11.47	4.96e-27	5.35e-24	0.65	0.47	Alcoholic chronic pancreatitis;	chr16:75222353	chr16:75245994~75250077:-
THCA	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-11.47	4.97e-27	5.36e-24	-0.7	-0.47	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
THCA	cis	rs8062405	0.625	rs8060365	ENSG00000251417.2	RP11-1348G14.4	11.47	4.97e-27	5.36e-24	0.47	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28802743~28817828:+
THCA	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	11.47	4.99e-27	5.39e-24	0.61	0.47	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
THCA	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	11.47	5.12e-27	5.52e-24	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	11.47	5.14e-27	5.54e-24	0.63	0.47	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000223768.1	LINC00205	-11.47	5.14e-27	5.55e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45293285~45297354:+
THCA	cis	rs6558530	0.666	rs6558520	ENSG00000253982.1	CTD-2336O2.1	11.47	5.14e-27	5.55e-24	0.45	0.47	Systolic blood pressure;	chr8:1749407	chr8:1761990~1764502:-
THCA	cis	rs7569084	0.663	rs4671128	ENSG00000237979.1	AC007389.1	11.47	5.16e-27	5.57e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65438130	chr2:65500993~65502138:-
THCA	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-11.47	5.17e-27	5.58e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	11.47	5.18e-27	5.58e-24	0.63	0.47	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	11.47	5.18e-27	5.58e-24	0.64	0.47	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	11.47	5.18e-27	5.58e-24	0.64	0.47	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
THCA	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-11.47	5.19e-27	5.6e-24	-0.6	-0.47	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
THCA	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-11.47	5.2e-27	5.6e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
THCA	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	11.47	5.2e-27	5.61e-24	0.63	0.47	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
THCA	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-11.47	5.21e-27	5.62e-24	-0.57	-0.47	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-11.47	5.25e-27	5.66e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
THCA	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-11.47	5.26e-27	5.67e-24	-0.43	-0.47	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-11.47	5.26e-27	5.67e-24	-0.43	-0.47	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
THCA	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	11.46	5.41e-27	5.83e-24	0.54	0.47	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	11.46	5.41e-27	5.83e-24	0.54	0.47	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	11.46	5.41e-27	5.83e-24	0.54	0.47	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
THCA	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	11.46	5.46e-27	5.88e-24	0.34	0.47	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
THCA	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-11.46	5.47e-27	5.89e-24	-0.63	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-11.46	5.47e-27	5.89e-24	-0.63	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
THCA	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-11.46	5.6e-27	6.03e-24	-0.43	-0.47	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
THCA	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	11.46	5.6e-27	6.03e-24	0.34	0.47	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	11.46	5.61e-27	6.04e-24	0.59	0.47	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	11.46	5.61e-27	6.04e-24	0.59	0.47	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
THCA	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	11.46	5.63e-27	6.06e-24	0.34	0.47	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
THCA	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-11.46	5.64e-27	6.07e-24	-0.61	-0.47	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
THCA	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	11.46	5.66e-27	6.09e-24	0.43	0.47	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
THCA	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-11.46	5.67e-27	6.1e-24	-0.6	-0.47	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
THCA	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-11.46	5.69e-27	6.12e-24	-0.43	-0.47	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
THCA	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-11.46	5.72e-27	6.16e-24	-0.72	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
THCA	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	11.46	5.75e-27	6.19e-24	0.54	0.47	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
THCA	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	11.46	5.78e-27	6.22e-24	0.61	0.47	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	11.46	5.78e-27	6.22e-24	0.61	0.47	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	11.46	5.8e-27	6.24e-24	0.61	0.47	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
THCA	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-11.45	5.84e-27	6.28e-24	-0.51	-0.47	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-11.45	5.84e-27	6.28e-24	-0.51	-0.47	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	11.45	5.85e-27	6.29e-24	0.66	0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
THCA	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-11.45	5.87e-27	6.32e-24	-0.66	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
THCA	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-11.45	5.88e-27	6.32e-24	-0.45	-0.47	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000223768.1	LINC00205	-11.45	5.93e-27	6.38e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	11.45	5.94e-27	6.39e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	11.45	5.94e-27	6.39e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	11.45	5.94e-27	6.39e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
THCA	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	11.45	5.97e-27	6.42e-24	0.49	0.47	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
THCA	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	11.45	6.02e-27	6.46e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	11.45	6.02e-27	6.46e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
THCA	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	11.45	6.02e-27	6.47e-24	0.62	0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000280107.1	AL022393.9	-11.45	6.1e-27	6.55e-24	-0.56	-0.47	Depression;	chr6:28206179	chr6:28170845~28172521:+
THCA	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-11.45	6.12e-27	6.57e-24	-0.51	-0.47	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
THCA	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	11.45	6.17e-27	6.63e-24	0.54	0.47	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	11.45	6.24e-27	6.7e-24	0.62	0.47	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
THCA	cis	rs6496932	0.77	rs4843040	ENSG00000218052.5	ADAMTS7P4	11.44	6.39e-27	6.86e-24	0.59	0.47	Central corneal thickness;Corneal structure;	chr15:85295405	chr15:85255369~85330334:-
THCA	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-11.44	6.4e-27	6.87e-24	-0.55	-0.47	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000223768.1	LINC00205	-11.44	6.44e-27	6.91e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45293285~45297354:+
THCA	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	11.44	6.47e-27	6.95e-24	0.56	0.47	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
THCA	cis	rs4819052	0.808	rs2838862	ENSG00000223768.1	LINC00205	-11.44	6.48e-27	6.95e-24	-0.42	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45266811	chr21:45293285~45297354:+
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	11.44	6.52e-27	7e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
THCA	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	11.44	6.53e-27	7e-24	0.61	0.47	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
THCA	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-11.44	6.53e-27	7e-24	-0.43	-0.47	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000223768.1	LINC00205	-11.44	6.54e-27	7.01e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45293285~45297354:+
THCA	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	11.44	6.57e-27	7.05e-24	0.56	0.47	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
THCA	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	11.44	6.6e-27	7.08e-24	0.57	0.47	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
THCA	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	11.44	6.63e-27	7.11e-24	0.55	0.47	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
THCA	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-11.44	6.64e-27	7.12e-24	-0.78	-0.47	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-11.44	6.64e-27	7.12e-24	-0.78	-0.47	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
THCA	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-11.44	6.67e-27	7.14e-24	-0.72	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000223768.1	LINC00205	-11.44	6.69e-27	7.17e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45293285~45297354:+
THCA	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-11.44	6.73e-27	7.22e-24	-0.57	-0.47	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
THCA	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-11.44	6.76e-27	7.24e-24	-0.36	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
THCA	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-11.44	6.81e-27	7.3e-24	-0.62	-0.47	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
THCA	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-11.44	6.88e-27	7.37e-24	-0.65	-0.47	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
THCA	cis	rs12458462	0.779	rs34814368	ENSG00000274828.1	RP11-567M16.6	11.44	6.89e-27	7.38e-24	0.4	0.47	Monocyte count;	chr18:79734143	chr18:79677287~79679358:-
THCA	cis	rs12458462	0.779	rs35814220	ENSG00000274828.1	RP11-567M16.6	11.44	6.89e-27	7.38e-24	0.4	0.47	Monocyte count;	chr18:79734190	chr18:79677287~79679358:-
THCA	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	11.44	6.89e-27	7.38e-24	0.37	0.47	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
THCA	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-11.44	6.92e-27	7.41e-24	-0.56	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
THCA	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	11.44	6.92e-27	7.41e-24	0.69	0.47	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
THCA	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-11.44	6.93e-27	7.42e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
THCA	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-11.44	6.93e-27	7.43e-24	-0.67	-0.47	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
THCA	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-11.43	6.95e-27	7.44e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	11.43	6.97e-27	7.46e-24	0.62	0.47	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000223768.1	LINC00205	-11.43	6.98e-27	7.47e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45293285~45297354:+
THCA	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	11.43	7e-27	7.49e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
THCA	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-11.43	7.04e-27	7.54e-24	-0.73	-0.47	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
THCA	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-11.43	7.04e-27	7.54e-24	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-11.43	7.04e-27	7.54e-24	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
THCA	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-11.43	7.05e-27	7.54e-24	-0.62	-0.47	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
THCA	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-11.43	7.08e-27	7.58e-24	-0.43	-0.47	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
THCA	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-11.43	7.12e-27	7.62e-24	-0.6	-0.47	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-11.43	7.16e-27	7.66e-24	-0.69	-0.47	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
THCA	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-11.43	7.18e-27	7.68e-24	-0.57	-0.47	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
THCA	cis	rs944289	0.675	rs398745	ENSG00000257826.1	RP11-116N8.4	11.43	7.2e-27	7.7e-24	0.47	0.47	Thyroid cancer;	chr14:36066975	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	11.43	7.24e-27	7.75e-24	0.54	0.47	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
THCA	cis	rs1858037	0.867	rs953312	ENSG00000204929.10	AC074391.1	11.43	7.33e-27	7.83e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65340556	chr2:65436711~66084639:+
THCA	cis	rs1858037	0.867	rs9789444	ENSG00000204929.10	AC074391.1	11.43	7.33e-27	7.83e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65342093	chr2:65436711~66084639:+
THCA	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-11.43	7.35e-27	7.85e-24	-0.69	-0.47	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
THCA	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	11.43	7.45e-27	7.96e-24	0.43	0.47	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
THCA	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-11.43	7.46e-27	7.97e-24	-0.43	-0.47	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
THCA	cis	rs6558530	0.692	rs12335115	ENSG00000253982.1	CTD-2336O2.1	11.43	7.51e-27	8.03e-24	0.45	0.47	Systolic blood pressure;	chr8:1751686	chr8:1761990~1764502:-
THCA	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	11.43	7.52e-27	8.03e-24	0.64	0.47	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
THCA	cis	rs944289	0.646	rs396043	ENSG00000257826.1	RP11-116N8.4	11.43	7.6e-27	8.12e-24	0.48	0.47	Thyroid cancer;	chr14:36071815	chr14:36061026~36067190:-
THCA	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-11.43	7.6e-27	8.12e-24	-0.48	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
THCA	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-11.42	7.63e-27	8.15e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	11.42	7.65e-27	8.17e-24	0.42	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	11.42	7.69e-27	8.21e-24	0.62	0.47	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
THCA	cis	rs944289	0.646	rs429041	ENSG00000257826.1	RP11-116N8.4	11.42	7.7e-27	8.22e-24	0.48	0.47	Thyroid cancer;	chr14:36071930	chr14:36061026~36067190:-
THCA	cis	rs944289	0.646	rs368772	ENSG00000257826.1	RP11-116N8.4	11.42	7.7e-27	8.22e-24	0.48	0.47	Thyroid cancer;	chr14:36071955	chr14:36061026~36067190:-
THCA	cis	rs944289	0.646	rs4981320	ENSG00000257826.1	RP11-116N8.4	11.42	7.7e-27	8.22e-24	0.48	0.47	Thyroid cancer;	chr14:36072456	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	11.42	7.76e-27	8.29e-24	0.53	0.47	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
THCA	cis	rs9659323	0.65	rs12086486	ENSG00000231365.4	RP11-418J17.1	-11.42	7.79e-27	8.31e-24	-0.5	-0.47	Body mass index;	chr1:118946419	chr1:119140396~119275973:+
THCA	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	11.42	7.92e-27	8.45e-24	0.47	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
THCA	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	11.42	7.92e-27	8.45e-24	0.62	0.47	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
THCA	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	11.42	7.92e-27	8.45e-24	0.56	0.47	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
THCA	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	11.42	7.95e-27	8.47e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	11.42	7.95e-27	8.47e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	11.42	7.95e-27	8.47e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-11.42	7.98e-27	8.51e-24	-0.43	-0.47	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	11.42	7.99e-27	8.52e-24	0.61	0.47	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	11.42	8.03e-27	8.56e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	11.42	8.14e-27	8.67e-24	0.63	0.47	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
THCA	cis	rs10935480	0.802	rs73133996	ENSG00000239445.4	ST3GAL6-AS1	-11.42	8.15e-27	8.68e-24	-0.47	-0.47	Blood protein levels;	chr3:98710375	chr3:98714330~98732651:-
THCA	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-11.42	8.17e-27	8.71e-24	-0.5	-0.47	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
THCA	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	11.42	8.19e-27	8.72e-24	0.37	0.47	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
THCA	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-11.42	8.29e-27	8.84e-24	-0.61	-0.47	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
THCA	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	11.42	8.3e-27	8.84e-24	0.57	0.47	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
THCA	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	11.42	8.3e-27	8.84e-24	0.57	0.47	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
THCA	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	11.41	8.33e-27	8.87e-24	0.43	0.47	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
THCA	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	11.41	8.34e-27	8.88e-24	0.61	0.47	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	11.41	8.34e-27	8.88e-24	0.61	0.47	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	11.41	8.34e-27	8.88e-24	0.61	0.47	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-11.41	8.35e-27	8.9e-24	-0.59	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
THCA	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	11.41	8.42e-27	8.97e-24	0.54	0.47	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	11.41	8.45e-27	9e-24	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
THCA	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-11.41	8.45e-27	9e-24	-0.51	-0.47	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
THCA	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	11.41	8.46e-27	9.01e-24	0.63	0.47	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
THCA	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	11.41	8.48e-27	9.03e-24	0.48	0.47	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
THCA	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	11.41	8.48e-27	9.03e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
THCA	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	11.41	8.5e-27	9.05e-24	0.48	0.47	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
THCA	cis	rs9309473	0.558	rs11679042	ENSG00000163016.8	ALMS1P	11.41	8.52e-27	9.06e-24	0.84	0.47	Metabolite levels;	chr2:73680184	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	11.41	8.53e-27	9.08e-24	0.6	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000235689.1	AP000351.13	11.41	8.57e-27	9.12e-24	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:24006305~24008258:-
THCA	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	11.41	8.63e-27	9.18e-24	0.62	0.47	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	11.41	8.64e-27	9.19e-24	0.64	0.47	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	11.41	8.67e-27	9.22e-24	0.64	0.47	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000280107.1	AL022393.9	-11.41	8.68e-27	9.24e-24	-0.55	-0.47	Parkinson's disease;	chr6:28065745	chr6:28170845~28172521:+
THCA	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-11.41	8.69e-27	9.25e-24	-0.55	-0.47	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
THCA	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-11.41	8.78e-27	9.34e-24	-0.56	-0.47	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
THCA	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-11.41	8.89e-27	9.45e-24	-0.57	-0.47	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
THCA	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-11.41	8.9e-27	9.46e-24	-0.57	-0.47	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-11.41	9.01e-27	9.57e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
THCA	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-11.41	9.01e-27	9.57e-24	-0.59	-0.47	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
THCA	cis	rs9659323	0.65	rs1155949	ENSG00000231365.4	RP11-418J17.1	-11.41	9.05e-27	9.61e-24	-0.5	-0.47	Body mass index;	chr1:118953956	chr1:119140396~119275973:+
THCA	cis	rs4819052	0.807	rs1075788	ENSG00000223768.1	LINC00205	-11.4	9.26e-27	9.83e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45293285~45297354:+
THCA	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	11.4	9.26e-27	9.83e-24	0.63	0.47	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
THCA	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	11.4	9.28e-27	9.85e-24	0.59	0.47	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
THCA	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-11.4	9.37e-27	9.94e-24	-0.47	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
THCA	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-11.4	9.5e-27	1e-23	-0.34	-0.47	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
THCA	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-11.4	9.55e-27	1.01e-23	-0.53	-0.47	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-11.4	9.55e-27	1.01e-23	-0.53	-0.47	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-11.4	9.55e-27	1.01e-23	-0.53	-0.47	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
THCA	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-11.4	9.62e-27	1.02e-23	-0.64	-0.47	Depression;	chr6:28173770	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-11.4	9.62e-27	1.02e-23	-0.64	-0.47	Depression;	chr6:28174809	chr6:28115628~28116551:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-11.4	9.62e-27	1.02e-23	-0.64	-0.47	Depression;	chr6:28175233	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-11.4	9.62e-27	1.02e-23	-0.64	-0.47	Depression;	chr6:28176973	chr6:28115628~28116551:+
THCA	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-11.4	9.67e-27	1.02e-23	-0.6	-0.47	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	11.4	9.7e-27	1.03e-23	0.64	0.47	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
THCA	cis	rs8055167	1	rs8055167	ENSG00000280152.1	RP11-331F4.5	11.4	9.79e-27	1.03e-23	0.51	0.47	Alcoholic chronic pancreatitis;	chr16:75220991	chr16:75245994~75250077:-
THCA	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	11.4	9.79e-27	1.03e-23	0.62	0.47	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
THCA	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	11.4	9.8e-27	1.04e-23	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
THCA	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	11.4	9.8e-27	1.04e-23	0.61	0.47	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
THCA	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-11.4	9.87e-27	1.04e-23	-0.49	-0.47	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
THCA	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-11.4	9.92e-27	1.05e-23	-0.55	-0.47	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	11.4	9.94e-27	1.05e-23	0.43	0.47	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
THCA	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	11.39	9.97e-27	1.05e-23	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	11.39	9.98e-27	1.05e-23	0.65	0.47	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
THCA	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-11.39	9.99e-27	1.05e-23	-0.72	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
THCA	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-11.39	1.01e-26	1.07e-23	-0.42	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
THCA	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	11.39	1.01e-26	1.07e-23	0.5	0.47	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
THCA	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-11.39	1.02e-26	1.07e-23	-0.62	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-11.39	1.03e-26	1.09e-23	-0.62	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
THCA	cis	rs6496932	0.663	rs4843051	ENSG00000218052.5	ADAMTS7P4	-11.39	1.03e-26	1.09e-23	-0.6	-0.47	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85255369~85330334:-
THCA	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	11.39	1.03e-26	1.09e-23	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	11.39	1.03e-26	1.09e-23	0.62	0.47	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	11.39	1.04e-26	1.09e-23	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
THCA	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-11.39	1.04e-26	1.1e-23	-0.57	-0.47	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	11.39	1.04e-26	1.1e-23	0.62	0.47	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
THCA	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	11.39	1.04e-26	1.1e-23	0.56	0.47	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
THCA	cis	rs4819052	1	rs4818769	ENSG00000223768.1	LINC00205	-11.39	1.04e-26	1.1e-23	-0.47	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45293285~45297354:+
THCA	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-11.39	1.05e-26	1.11e-23	-0.43	-0.47	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
THCA	cis	rs11098499	0.913	rs12186259	ENSG00000245958.5	RP11-33B1.1	-11.39	1.06e-26	1.12e-23	-0.46	-0.47	Corneal astigmatism;	chr4:119230884	chr4:119454791~119552025:+
THCA	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-11.39	1.07e-26	1.13e-23	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
THCA	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-11.39	1.08e-26	1.14e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-11.39	1.08e-26	1.14e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-11.39	1.08e-26	1.14e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-11.39	1.08e-26	1.14e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
THCA	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-11.39	1.08e-26	1.14e-23	-0.69	-0.46	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000223768.1	LINC00205	-11.38	1.13e-26	1.19e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45293285~45297354:+
THCA	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-11.38	1.13e-26	1.19e-23	-0.43	-0.46	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
THCA	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-11.38	1.13e-26	1.19e-23	-0.73	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
THCA	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	11.38	1.13e-26	1.19e-23	0.6	0.46	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
THCA	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	11.38	1.13e-26	1.19e-23	0.6	0.46	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
THCA	cis	rs4591358	0.648	rs7557471	ENSG00000223466.1	AC064834.2	-11.38	1.14e-26	1.2e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520713	chr2:195533035~195538681:+
THCA	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	11.38	1.14e-26	1.2e-23	0.43	0.46	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs1056101	ENSG00000223768.1	LINC00205	-11.38	1.15e-26	1.21e-23	-0.44	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45293285~45297354:+
THCA	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-11.38	1.16e-26	1.22e-23	-0.6	-0.46	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
THCA	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-11.38	1.16e-26	1.22e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
THCA	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-11.38	1.17e-26	1.22e-23	-0.38	-0.46	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
THCA	cis	rs9659323	0.65	rs12093893	ENSG00000231365.4	RP11-418J17.1	-11.38	1.17e-26	1.23e-23	-0.5	-0.46	Body mass index;	chr1:118948196	chr1:119140396~119275973:+
THCA	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	11.38	1.17e-26	1.23e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
THCA	cis	rs6558530	0.653	rs7001282	ENSG00000253982.1	CTD-2336O2.1	11.38	1.18e-26	1.24e-23	0.45	0.46	Systolic blood pressure;	chr8:1752022	chr8:1761990~1764502:-
THCA	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-11.38	1.18e-26	1.24e-23	-0.64	-0.46	Depression;	chr6:28135913	chr6:28115628~28116551:+
THCA	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-11.37	1.19e-26	1.25e-23	-0.54	-0.46	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
THCA	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-11.37	1.2e-26	1.26e-23	-0.45	-0.46	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	11.37	1.2e-26	1.27e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
THCA	cis	rs6558530	0.615	rs12674711	ENSG00000253982.1	CTD-2336O2.1	11.37	1.22e-26	1.29e-23	0.45	0.46	Systolic blood pressure;	chr8:1751442	chr8:1761990~1764502:-
THCA	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-11.37	1.23e-26	1.29e-23	-0.89	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
THCA	cis	rs9659323	0.596	rs11589179	ENSG00000231365.4	RP11-418J17.1	-11.37	1.24e-26	1.3e-23	-0.5	-0.46	Body mass index;	chr1:118954962	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.65	rs10923705	ENSG00000231365.4	RP11-418J17.1	-11.37	1.24e-26	1.3e-23	-0.5	-0.46	Body mass index;	chr1:118955781	chr1:119140396~119275973:+
THCA	cis	rs2283792	0.74	rs8138075	ENSG00000224086.5	LL22NC03-86G7.1	-11.37	1.24e-26	1.3e-23	-0.56	-0.46	Multiple sclerosis;	chr22:21755092	chr22:21938293~21977632:+
THCA	cis	rs944289	0.617	rs12431579	ENSG00000257826.1	RP11-116N8.4	-11.37	1.25e-26	1.31e-23	-0.51	-0.46	Thyroid cancer;	chr14:36125191	chr14:36061026~36067190:-
THCA	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	11.37	1.25e-26	1.31e-23	0.55	0.46	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
THCA	cis	rs4819052	1	rs13047688	ENSG00000223768.1	LINC00205	-11.37	1.25e-26	1.31e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45293285~45297354:+
THCA	cis	rs6558530	0.692	rs6981804	ENSG00000253982.1	CTD-2336O2.1	11.37	1.27e-26	1.32e-23	0.44	0.46	Systolic blood pressure;	chr8:1752118	chr8:1761990~1764502:-
THCA	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-11.37	1.27e-26	1.33e-23	-0.49	-0.46	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
THCA	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	11.37	1.28e-26	1.34e-23	0.61	0.46	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
THCA	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-11.37	1.29e-26	1.35e-23	-0.7	-0.46	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
THCA	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	11.37	1.29e-26	1.35e-23	0.39	0.46	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
THCA	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	11.37	1.3e-26	1.36e-23	0.57	0.46	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
THCA	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-11.37	1.3e-26	1.36e-23	-0.63	-0.46	Depression;	chr6:28145952	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-11.37	1.3e-26	1.36e-23	-0.63	-0.46	Depression;	chr6:28147378	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-11.37	1.3e-26	1.36e-23	-0.63	-0.46	Depression;	chr6:28147406	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-11.37	1.3e-26	1.36e-23	-0.63	-0.46	Depression;	chr6:28148143	chr6:28115628~28116551:+
THCA	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	11.37	1.3e-26	1.36e-23	0.68	0.46	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
THCA	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-11.37	1.3e-26	1.36e-23	-0.74	-0.46	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
THCA	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	11.36	1.31e-26	1.37e-23	0.56	0.46	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
THCA	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-11.36	1.31e-26	1.37e-23	-0.45	-0.46	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
THCA	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	11.36	1.32e-26	1.38e-23	0.57	0.46	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	11.36	1.32e-26	1.38e-23	0.57	0.46	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
THCA	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	11.36	1.32e-26	1.38e-23	0.57	0.46	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
THCA	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	11.36	1.32e-26	1.38e-23	0.58	0.46	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
THCA	cis	rs1075265	0.901	rs9808326	ENSG00000233266.1	HMGB1P31	11.36	1.33e-26	1.39e-23	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54115971	chr2:54051334~54051760:+
THCA	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-11.36	1.33e-26	1.39e-23	-0.54	-0.46	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
THCA	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	11.36	1.33e-26	1.39e-23	0.5	0.46	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
THCA	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	11.36	1.34e-26	1.4e-23	0.62	0.46	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
THCA	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	11.36	1.34e-26	1.4e-23	0.62	0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
THCA	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-11.36	1.34e-26	1.4e-23	-0.49	-0.46	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
THCA	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	11.36	1.36e-26	1.42e-23	0.81	0.46	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
THCA	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	11.36	1.36e-26	1.42e-23	0.55	0.46	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	11.36	1.36e-26	1.42e-23	0.55	0.46	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
THCA	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-11.36	1.36e-26	1.42e-23	-0.45	-0.46	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
THCA	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	11.36	1.36e-26	1.42e-23	0.76	0.46	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
THCA	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.37e-26	1.43e-23	-0.56	-0.46	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
THCA	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	11.36	1.38e-26	1.44e-23	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
THCA	cis	rs7829975	0.627	rs876954	ENSG00000253893.2	FAM85B	-11.36	1.38e-26	1.44e-23	-0.61	-0.46	Mood instability;	chr8:8453413	chr8:8167819~8226614:-
THCA	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-11.36	1.38e-26	1.44e-23	-0.63	-0.46	Depression;	chr6:28169676	chr6:28115628~28116551:+
THCA	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	11.36	1.38e-26	1.44e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	11.36	1.38e-26	1.44e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
THCA	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-11.36	1.38e-26	1.44e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
THCA	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	11.36	1.39e-26	1.45e-23	0.64	0.46	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
THCA	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.39e-26	1.45e-23	-0.57	-0.46	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.39e-26	1.45e-23	-0.57	-0.46	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.39e-26	1.45e-23	-0.57	-0.46	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
THCA	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	11.36	1.4e-26	1.46e-23	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
THCA	cis	rs12468226	0.938	rs13392645	ENSG00000273456.1	RP11-686O6.2	11.36	1.4e-26	1.46e-23	0.52	0.46	Urate levels;	chr2:202270116	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs7568159	ENSG00000273456.1	RP11-686O6.2	11.36	1.4e-26	1.46e-23	0.52	0.46	Urate levels;	chr2:202286226	chr2:202374932~202375604:-
THCA	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	11.36	1.41e-26	1.47e-23	0.56	0.46	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
THCA	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-11.36	1.41e-26	1.47e-23	-0.34	-0.46	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
THCA	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-11.36	1.41e-26	1.47e-23	-0.43	-0.46	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	11.36	1.41e-26	1.47e-23	0.43	0.46	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
THCA	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-11.36	1.42e-26	1.48e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-11.36	1.42e-26	1.48e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
THCA	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	11.36	1.42e-26	1.48e-23	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
THCA	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-11.35	1.43e-26	1.49e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
THCA	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	11.35	1.44e-26	1.5e-23	0.6	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
THCA	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	11.35	1.44e-26	1.5e-23	0.6	0.46	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
THCA	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	11.35	1.45e-26	1.5e-23	0.49	0.46	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
THCA	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	11.35	1.45e-26	1.51e-23	0.56	0.46	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
THCA	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-11.35	1.46e-26	1.51e-23	-0.6	-0.46	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
THCA	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-11.35	1.46e-26	1.52e-23	-0.54	-0.46	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
THCA	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-11.35	1.47e-26	1.53e-23	-0.64	-0.46	Depression;	chr6:28180209	chr6:28115628~28116551:+
THCA	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	11.35	1.47e-26	1.53e-23	0.54	0.46	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
THCA	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-11.35	1.48e-26	1.54e-23	-0.58	-0.46	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
THCA	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	11.35	1.48e-26	1.54e-23	0.54	0.46	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	11.35	1.48e-26	1.54e-23	0.54	0.46	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
THCA	cis	rs11159086	0.793	rs11621693	ENSG00000270000.1	RP3-449M8.9	11.35	1.48e-26	1.54e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74472631	chr14:74471930~74472360:-
THCA	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-11.35	1.49e-26	1.55e-23	-0.53	-0.46	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
THCA	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	11.35	1.49e-26	1.55e-23	0.39	0.46	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
THCA	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-11.35	1.51e-26	1.57e-23	-0.68	-0.46	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
THCA	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-11.35	1.51e-26	1.57e-23	-0.43	-0.46	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
THCA	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	11.35	1.52e-26	1.58e-23	0.34	0.46	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
THCA	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	11.35	1.52e-26	1.58e-23	0.34	0.46	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
THCA	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	11.35	1.55e-26	1.61e-23	0.34	0.46	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
THCA	cis	rs6452524	0.901	rs12514607	ENSG00000249664.1	CTD-2227C6.2	-11.35	1.56e-26	1.62e-23	-0.59	-0.46	Hypertension (SNP x SNP interaction);	chr5:83209710	chr5:83012285~83013109:-
THCA	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	11.34	1.57e-26	1.63e-23	0.62	0.46	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	11.34	1.58e-26	1.64e-23	0.43	0.46	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	11.34	1.58e-26	1.64e-23	0.43	0.46	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
THCA	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-11.34	1.58e-26	1.64e-23	-0.61	-0.46	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-11.34	1.58e-26	1.64e-23	-0.61	-0.46	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-11.34	1.58e-26	1.64e-23	-0.61	-0.46	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
THCA	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-11.34	1.58e-26	1.64e-23	-0.61	-0.46	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
THCA	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-11.34	1.58e-26	1.65e-23	-0.43	-0.46	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
THCA	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-11.34	1.61e-26	1.67e-23	-0.71	-0.46	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-11.34	1.62e-26	1.68e-23	-0.71	-0.46	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-11.34	1.62e-26	1.68e-23	-0.71	-0.46	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
THCA	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	11.34	1.63e-26	1.69e-23	0.56	0.46	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
THCA	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	11.34	1.63e-26	1.69e-23	0.56	0.46	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
THCA	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-11.34	1.64e-26	1.7e-23	-0.35	-0.46	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
THCA	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-11.34	1.65e-26	1.71e-23	-0.69	-0.46	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-11.34	1.65e-26	1.71e-23	-0.69	-0.46	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
THCA	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-11.34	1.65e-26	1.71e-23	-0.69	-0.46	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
THCA	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-11.34	1.65e-26	1.71e-23	-0.5	-0.46	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
THCA	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	11.34	1.66e-26	1.72e-23	0.53	0.46	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
THCA	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-11.34	1.66e-26	1.73e-23	-0.72	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
THCA	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	11.34	1.67e-26	1.73e-23	0.62	0.46	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	11.34	1.67e-26	1.73e-23	0.62	0.46	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
THCA	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
THCA	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
THCA	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
THCA	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
THCA	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-11.34	1.68e-26	1.75e-23	-0.63	-0.46	Depression;	chr6:28159666	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-11.34	1.68e-26	1.75e-23	-0.63	-0.46	Depression;	chr6:28162598	chr6:28115628~28116551:+
THCA	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-11.34	1.69e-26	1.75e-23	-0.57	-0.46	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
THCA	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	11.34	1.69e-26	1.75e-23	0.38	0.46	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
THCA	cis	rs9659323	0.622	rs28653656	ENSG00000231365.4	RP11-418J17.1	-11.34	1.7e-26	1.76e-23	-0.49	-0.46	Body mass index;	chr1:118943807	chr1:119140396~119275973:+
THCA	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	11.34	1.7e-26	1.76e-23	0.82	0.46	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
THCA	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	11.34	1.71e-26	1.77e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	11.34	1.71e-26	1.77e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	11.34	1.71e-26	1.77e-23	0.85	0.46	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
THCA	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-11.33	1.71e-26	1.77e-23	-0.57	-0.46	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-11.33	1.71e-26	1.77e-23	-0.57	-0.46	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-11.33	1.71e-26	1.77e-23	-0.57	-0.46	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
THCA	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	11.33	1.71e-26	1.78e-23	0.59	0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
THCA	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	11.33	1.72e-26	1.78e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	11.33	1.72e-26	1.78e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	11.33	1.72e-26	1.78e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	11.33	1.72e-26	1.78e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
THCA	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	11.33	1.72e-26	1.79e-23	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
THCA	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	11.33	1.73e-26	1.79e-23	0.76	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
THCA	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-11.33	1.76e-26	1.82e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
THCA	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	11.33	1.76e-26	1.82e-23	0.58	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
THCA	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-11.33	1.76e-26	1.82e-23	-0.43	-0.46	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-11.33	1.76e-26	1.82e-23	-0.43	-0.46	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
THCA	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.76e-26	1.83e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
THCA	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-11.33	1.77e-26	1.83e-23	-0.45	-0.46	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
THCA	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	11.33	1.78e-26	1.84e-23	0.5	0.46	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
THCA	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-11.33	1.78e-26	1.84e-23	-0.58	-0.46	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
THCA	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-11.33	1.78e-26	1.84e-23	-0.61	-0.46	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
THCA	cis	rs465969	1	rs1407644	ENSG00000255389.1	C6orf3	11.33	1.78e-26	1.84e-23	0.81	0.46	Psoriasis;	chr6:111480895	chr6:111599875~111602295:+
THCA	cis	rs6558530	0.625	rs7459507	ENSG00000253982.1	CTD-2336O2.1	11.33	1.78e-26	1.85e-23	0.45	0.46	Systolic blood pressure;	chr8:1750026	chr8:1761990~1764502:-
THCA	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	11.33	1.78e-26	1.85e-23	0.52	0.46	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
THCA	cis	rs11159086	0.793	rs28612392	ENSG00000270000.1	RP3-449M8.9	11.33	1.8e-26	1.86e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74467894	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs11625502	ENSG00000270000.1	RP3-449M8.9	11.33	1.8e-26	1.86e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74468309	chr14:74471930~74472360:-
THCA	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.81e-26	1.87e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
THCA	cis	rs6496932	0.676	rs7183651	ENSG00000218052.5	ADAMTS7P4	-11.33	1.82e-26	1.88e-23	-0.59	-0.46	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85255369~85330334:-
THCA	cis	rs4819052	1	rs28628220	ENSG00000223768.1	LINC00205	-11.33	1.82e-26	1.89e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45293285~45297354:+
THCA	cis	rs4819052	1	rs2838830	ENSG00000223768.1	LINC00205	-11.33	1.82e-26	1.89e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45293285~45297354:+
THCA	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	11.33	1.84e-26	1.9e-23	0.6	0.46	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	11.33	1.84e-26	1.9e-23	0.6	0.46	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
THCA	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.84e-26	1.9e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
THCA	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.84e-26	1.9e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
THCA	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-11.33	1.85e-26	1.91e-23	-0.35	-0.46	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
THCA	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.85e-26	1.91e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
THCA	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	11.33	1.85e-26	1.92e-23	0.73	0.46	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
THCA	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	11.33	1.87e-26	1.93e-23	0.62	0.46	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
THCA	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-11.33	1.87e-26	1.93e-23	-0.61	-0.46	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
THCA	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	11.32	1.87e-26	1.94e-23	0.79	0.46	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	11.32	1.9e-26	1.97e-23	0.64	0.46	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	11.32	1.91e-26	1.97e-23	0.62	0.46	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
THCA	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-11.32	1.91e-26	1.97e-23	-0.48	-0.46	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-11.32	1.91e-26	1.97e-23	-0.48	-0.46	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	11.32	1.91e-26	1.97e-23	0.58	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
THCA	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-11.32	1.94e-26	2e-23	-0.48	-0.46	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-11.32	1.95e-26	2.01e-23	-0.48	-0.46	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
THCA	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	11.32	1.95e-26	2.01e-23	0.84	0.46	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
THCA	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-11.32	1.96e-26	2.02e-23	-0.61	-0.46	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-11.32	1.96e-26	2.02e-23	-0.61	-0.46	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-11.32	1.96e-26	2.02e-23	-0.61	-0.46	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000280107.1	AL022393.9	11.32	1.98e-26	2.04e-23	0.55	0.46	Parkinson's disease;	chr6:28065396	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	11.32	1.98e-26	2.05e-23	0.62	0.46	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
THCA	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	11.32	2e-26	2.06e-23	0.6	0.46	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	11.32	2e-26	2.06e-23	0.6	0.46	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	11.32	2e-26	2.06e-23	0.6	0.46	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	11.32	2e-26	2.06e-23	0.6	0.46	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
THCA	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-11.32	2e-26	2.06e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-11.32	2e-26	2.06e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-11.32	2e-26	2.06e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-11.32	2e-26	2.06e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
THCA	cis	rs7569084	0.687	rs1344891	ENSG00000237979.1	AC007389.1	11.32	2.01e-26	2.07e-23	0.55	0.46	Sum eosinophil basophil counts;	chr2:65458890	chr2:65500993~65502138:-
THCA	cis	rs2658782	0.507	rs4457713	ENSG00000279684.1	RP11-755E23.2	-11.32	2.02e-26	2.07e-23	-0.74	-0.46	Pulmonary function decline;	chr11:93304264	chr11:93286629~93288903:-
THCA	cis	rs16828019	0.704	rs12743340	ENSG00000235358.1	RP11-399E6.1	11.32	2.02e-26	2.08e-23	0.89	0.46	Intelligence (multi-trait analysis);	chr1:40990360	chr1:41242373~41284861:+
THCA	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	11.32	2.04e-26	2.1e-23	0.53	0.46	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-11.31	2.09e-26	2.15e-23	-0.58	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
THCA	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	11.31	2.1e-26	2.15e-23	0.56	0.46	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
THCA	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-11.31	2.11e-26	2.17e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
THCA	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-11.31	2.11e-26	2.17e-23	-0.56	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-11.31	2.12e-26	2.18e-23	-0.63	-0.46	Depression;	chr6:28151096	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-11.31	2.12e-26	2.18e-23	-0.63	-0.46	Depression;	chr6:28152885	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-11.31	2.12e-26	2.18e-23	-0.63	-0.46	Depression;	chr6:28153120	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-11.31	2.12e-26	2.18e-23	-0.63	-0.46	Depression;	chr6:28161802	chr6:28115628~28116551:+
THCA	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-11.31	2.12e-26	2.18e-23	-0.43	-0.46	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
THCA	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-11.31	2.13e-26	2.19e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
THCA	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-11.31	2.14e-26	2.2e-23	-0.56	-0.46	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
THCA	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	11.31	2.15e-26	2.21e-23	0.5	0.46	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	11.31	2.15e-26	2.21e-23	0.5	0.46	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
THCA	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-11.31	2.15e-26	2.21e-23	-0.55	-0.46	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-11.31	2.15e-26	2.21e-23	-0.55	-0.46	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
THCA	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	11.31	2.16e-26	2.21e-23	0.64	0.46	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
THCA	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	11.31	2.16e-26	2.21e-23	0.53	0.46	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	11.31	2.16e-26	2.21e-23	0.53	0.46	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	11.31	2.16e-26	2.21e-23	0.53	0.46	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	11.31	2.16e-26	2.21e-23	0.53	0.46	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-11.31	2.17e-26	2.23e-23	-0.67	-0.46	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
THCA	cis	rs9659323	0.623	rs12091291	ENSG00000231365.4	RP11-418J17.1	11.31	2.17e-26	2.23e-23	0.5	0.46	Body mass index;	chr1:118936205	chr1:119140396~119275973:+
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000235689.1	AP000351.13	-11.31	2.18e-26	2.23e-23	-0.58	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:24006305~24008258:-
THCA	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-11.31	2.19e-26	2.24e-23	-0.5	-0.46	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
THCA	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	11.31	2.19e-26	2.25e-23	0.56	0.46	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	11.31	2.19e-26	2.25e-23	0.56	0.46	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
THCA	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-11.31	2.19e-26	2.25e-23	-0.59	-0.46	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
THCA	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-11.31	2.19e-26	2.25e-23	-0.56	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	11.31	2.2e-26	2.25e-23	0.56	0.46	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
THCA	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28154567	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28156691	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28158424	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28159056	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28159925	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28159932	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28162053	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28163375	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28163759	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28164580	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28164825	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28164948	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28165025	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28165528	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28169019	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28169249	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28169755	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28169791	chr6:28115628~28116551:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28170075	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	11.3	2.24e-26	2.29e-23	0.62	0.46	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
THCA	cis	rs6558530	0.666	rs7845723	ENSG00000253982.1	CTD-2336O2.1	11.3	2.25e-26	2.31e-23	0.45	0.46	Systolic blood pressure;	chr8:1748920	chr8:1761990~1764502:-
THCA	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	11.3	2.27e-26	2.32e-23	0.64	0.46	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
THCA	cis	rs4591358	0.689	rs72927705	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518341	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927707	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518526	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs16836823	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518785	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs57244991	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519331	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927708	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519789	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927711	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520309	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927717	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520887	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927725	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529140	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs7574191	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529995	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs1500605	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530584	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.648	rs1515877	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530995	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs16837006	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533245	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs16837010	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533302	chr2:195533035~195538681:+
THCA	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-11.3	2.27e-26	2.33e-23	-0.43	-0.46	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
THCA	cis	rs4819052	1	rs733738	ENSG00000223768.1	LINC00205	11.3	2.3e-26	2.35e-23	0.47	0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-11.3	2.3e-26	2.35e-23	-0.64	-0.46	Depression;	chr6:28140307	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	11.3	2.34e-26	2.39e-23	0.64	0.46	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
THCA	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-11.3	2.36e-26	2.42e-23	-0.61	-0.46	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	11.3	2.37e-26	2.43e-23	0.61	0.46	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.851	rs2236445	ENSG00000223768.1	LINC00205	-11.3	2.37e-26	2.43e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-11.3	2.38e-26	2.43e-23	-0.63	-0.46	Depression;	chr6:28149979	chr6:28115628~28116551:+
THCA	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	11.3	2.39e-26	2.44e-23	0.43	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
THCA	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-11.3	2.41e-26	2.46e-23	-0.59	-0.46	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
THCA	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-11.3	2.43e-26	2.48e-23	-0.55	-0.46	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
THCA	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-11.3	2.43e-26	2.48e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
THCA	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-11.3	2.44e-26	2.49e-23	-0.74	-0.46	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
THCA	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	11.3	2.44e-26	2.49e-23	0.61	0.46	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
THCA	cis	rs4819052	1	rs9984901	ENSG00000223768.1	LINC00205	-11.29	2.46e-26	2.52e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	11.29	2.48e-26	2.53e-23	0.62	0.46	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-11.29	2.48e-26	2.53e-23	-0.62	-0.46	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
THCA	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	11.29	2.48e-26	2.54e-23	0.81	0.46	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
THCA	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-11.29	2.5e-26	2.55e-23	-0.68	-0.46	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	11.29	2.52e-26	2.57e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
THCA	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-11.29	2.53e-26	2.58e-23	-0.54	-0.46	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	11.29	2.54e-26	2.59e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	11.29	2.54e-26	2.6e-23	0.64	0.46	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	11.29	2.54e-26	2.6e-23	0.64	0.46	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
THCA	cis	rs1858037	0.867	rs4671658	ENSG00000204929.10	AC074391.1	-11.29	2.55e-26	2.6e-23	-0.61	-0.46	Rheumatoid arthritis;	chr2:65334258	chr2:65436711~66084639:+
THCA	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	11.29	2.55e-26	2.6e-23	0.65	0.46	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
THCA	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	11.29	2.57e-26	2.62e-23	0.37	0.46	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
THCA	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-11.29	2.57e-26	2.62e-23	-0.43	-0.46	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
THCA	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-11.29	2.58e-26	2.63e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
THCA	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	11.29	2.6e-26	2.65e-23	0.66	0.46	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
THCA	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	11.29	2.6e-26	2.65e-23	0.31	0.46	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
THCA	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-11.29	2.6e-26	2.65e-23	-0.57	-0.46	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
THCA	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	11.29	2.61e-26	2.66e-23	0.57	0.46	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
THCA	cis	rs4591358	0.689	rs72927784	ENSG00000223466.1	AC064834.2	-11.29	2.62e-26	2.67e-23	-0.67	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195550329	chr2:195533035~195538681:+
THCA	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-11.29	2.62e-26	2.67e-23	-0.64	-0.46	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
THCA	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-11.29	2.63e-26	2.68e-23	-0.58	-0.46	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
THCA	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-11.29	2.64e-26	2.69e-23	-0.63	-0.46	Depression;	chr6:28159843	chr6:28115628~28116551:+
THCA	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-11.29	2.65e-26	2.7e-23	-0.6	-0.46	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
THCA	cis	rs73219805	0.759	rs3808578	ENSG00000228451.3	SDAD1P1	-11.29	2.66e-26	2.71e-23	-0.66	-0.46	Schizophrenia;	chr8:26393906	chr8:26379259~26382953:-
THCA	cis	rs4819052	0.851	rs1056100	ENSG00000223768.1	LINC00205	-11.28	2.68e-26	2.73e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45293285~45297354:+
THCA	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	11.28	2.68e-26	2.73e-23	0.34	0.46	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
THCA	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	11.28	2.69e-26	2.74e-23	0.47	0.46	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
THCA	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-11.28	2.7e-26	2.75e-23	-0.53	-0.46	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
THCA	cis	rs11098499	0.526	rs10026625	ENSG00000245958.5	RP11-33B1.1	-11.28	2.71e-26	2.75e-23	-0.43	-0.46	Corneal astigmatism;	chr4:119358981	chr4:119454791~119552025:+
THCA	cis	rs4819052	0.851	rs2838857	ENSG00000223768.1	LINC00205	-11.28	2.72e-26	2.76e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45293285~45297354:+
THCA	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-11.28	2.73e-26	2.78e-23	-0.59	-0.46	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
THCA	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-11.28	2.73e-26	2.78e-23	-0.59	-0.46	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-11.28	2.73e-26	2.78e-23	-0.59	-0.46	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
THCA	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	11.28	2.74e-26	2.79e-23	0.77	0.46	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
THCA	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	11.28	2.75e-26	2.79e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	11.28	2.79e-26	2.84e-23	0.53	0.46	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	11.28	2.79e-26	2.84e-23	0.63	0.46	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	11.28	2.79e-26	2.84e-23	0.63	0.46	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
THCA	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-11.28	2.81e-26	2.86e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-11.28	2.81e-26	2.86e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
THCA	cis	rs4819052	0.851	rs2838856	ENSG00000223768.1	LINC00205	-11.28	2.81e-26	2.86e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45293285~45297354:+
THCA	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	11.28	2.82e-26	2.86e-23	0.53	0.46	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
THCA	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	11.28	2.82e-26	2.87e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
THCA	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-11.28	2.83e-26	2.88e-23	-0.6	-0.46	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
THCA	cis	rs9928842	0.771	rs8059190	ENSG00000280152.1	RP11-331F4.5	11.28	2.83e-26	2.88e-23	0.63	0.46	Alcoholic chronic pancreatitis;	chr16:75226899	chr16:75245994~75250077:-
THCA	cis	rs3091242	0.806	rs35189848	ENSG00000224183.1	SDHDP6	11.28	2.85e-26	2.89e-23	0.57	0.46	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.836	rs35346083	ENSG00000224183.1	SDHDP6	11.28	2.85e-26	2.89e-23	0.57	0.46	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25294164~25294643:-
THCA	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-11.28	2.86e-26	2.9e-23	-0.6	-0.46	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
THCA	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	11.28	2.86e-26	2.91e-23	0.61	0.46	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
THCA	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-11.28	2.87e-26	2.92e-23	-0.74	-0.46	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
THCA	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	11.28	2.88e-26	2.93e-23	0.43	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
THCA	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-11.28	2.88e-26	2.93e-23	-0.56	-0.46	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-11.28	2.88e-26	2.93e-23	-0.56	-0.46	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-11.28	2.88e-26	2.93e-23	-0.56	-0.46	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
THCA	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	11.28	2.89e-26	2.94e-23	0.54	0.46	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
THCA	cis	rs9659323	0.596	rs6656528	ENSG00000231365.4	RP11-418J17.1	-11.28	2.9e-26	2.94e-23	-0.49	-0.46	Body mass index;	chr1:118934971	chr1:119140396~119275973:+
THCA	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-11.28	2.91e-26	2.95e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
THCA	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-11.28	2.92e-26	2.96e-23	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
THCA	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-11.27	2.93e-26	2.97e-23	-0.6	-0.46	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
THCA	cis	rs73219805	0.759	rs17055186	ENSG00000228451.3	SDAD1P1	-11.27	2.93e-26	2.97e-23	-0.66	-0.46	Schizophrenia;	chr8:26403394	chr8:26379259~26382953:-
THCA	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-11.27	2.95e-26	2.99e-23	-0.56	-0.46	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
THCA	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	11.27	2.95e-26	2.99e-23	0.34	0.46	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
THCA	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-11.27	2.95e-26	2.99e-23	-0.66	-0.46	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
THCA	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-11.27	2.97e-26	3.01e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
THCA	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-11.27	2.98e-26	3.02e-23	-0.61	-0.46	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
THCA	cis	rs4591358	0.689	rs16836990	ENSG00000223466.1	AC064834.2	-11.27	3e-26	3.04e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195532968	chr2:195533035~195538681:+
THCA	cis	rs1858037	0.867	rs6727013	ENSG00000204929.10	AC074391.1	11.27	3.01e-26	3.06e-23	0.61	0.46	Rheumatoid arthritis;	chr2:65331241	chr2:65436711~66084639:+
THCA	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	11.27	3.03e-26	3.07e-23	0.53	0.46	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
THCA	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	11.27	3.03e-26	3.07e-23	0.55	0.46	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
THCA	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	11.27	3.05e-26	3.09e-23	0.61	0.46	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
THCA	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	11.27	3.05e-26	3.09e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	11.27	3.08e-26	3.12e-23	0.61	0.46	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
THCA	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-11.27	3.09e-26	3.13e-23	-0.54	-0.46	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
THCA	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-11.27	3.1e-26	3.14e-23	-0.63	-0.46	Depression;	chr6:28168434	chr6:28115628~28116551:+
THCA	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	11.27	3.11e-26	3.15e-23	0.53	0.46	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	11.27	3.11e-26	3.15e-23	0.53	0.46	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	11.27	3.12e-26	3.16e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
THCA	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	11.27	3.15e-26	3.19e-23	0.89	0.46	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
THCA	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	11.27	3.15e-26	3.19e-23	0.44	0.46	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
THCA	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	11.27	3.18e-26	3.22e-23	0.56	0.46	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
THCA	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	11.27	3.2e-26	3.23e-23	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
THCA	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-11.26	3.21e-26	3.25e-23	-0.72	-0.46	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
THCA	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-11.26	3.22e-26	3.25e-23	-0.59	-0.46	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
THCA	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.23e-26	3.27e-23	-0.56	-0.46	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.23e-26	3.27e-23	-0.56	-0.46	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
THCA	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.23e-26	3.27e-23	-0.56	-0.46	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
THCA	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	11.26	3.24e-26	3.27e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
THCA	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	11.26	3.24e-26	3.28e-23	0.37	0.46	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
THCA	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-11.26	3.26e-26	3.3e-23	-0.61	-0.46	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
THCA	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-11.26	3.28e-26	3.31e-23	-0.59	-0.46	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-11.26	3.28e-26	3.31e-23	-0.59	-0.46	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	11.26	3.28e-26	3.31e-23	0.59	0.46	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
THCA	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-11.26	3.3e-26	3.33e-23	-0.61	-0.46	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
THCA	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	11.26	3.31e-26	3.34e-23	0.6	0.46	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-11.26	3.32e-26	3.35e-23	-0.61	-0.46	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-11.26	3.32e-26	3.35e-23	-0.61	-0.46	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-11.26	3.32e-26	3.35e-23	-0.61	-0.46	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-11.26	3.32e-26	3.35e-23	-0.61	-0.46	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
THCA	cis	rs4591358	0.689	rs59639651	ENSG00000223466.1	AC064834.2	-11.26	3.32e-26	3.36e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544426	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927766	ENSG00000223466.1	AC064834.2	-11.26	3.32e-26	3.36e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545003	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs7580459	ENSG00000223466.1	AC064834.2	-11.26	3.32e-26	3.36e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545963	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs57555936	ENSG00000223466.1	AC064834.2	-11.26	3.32e-26	3.36e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546440	chr2:195533035~195538681:+
THCA	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	11.26	3.33e-26	3.36e-23	0.6	0.46	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
THCA	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-11.26	3.33e-26	3.37e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
THCA	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-11.26	3.33e-26	3.37e-23	-0.61	-0.46	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-11.26	3.37e-26	3.41e-23	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
THCA	cis	rs11159086	0.793	rs17100414	ENSG00000270000.1	RP3-449M8.9	11.26	3.38e-26	3.42e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74467918	chr14:74471930~74472360:-
THCA	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.39e-26	3.42e-23	-0.56	-0.46	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.39e-26	3.42e-23	-0.56	-0.46	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.39e-26	3.42e-23	-0.56	-0.46	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
THCA	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	11.26	3.41e-26	3.44e-23	0.63	0.46	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
THCA	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	11.26	3.42e-26	3.45e-23	0.6	0.46	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
THCA	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-11.26	3.43e-26	3.46e-23	-0.64	-0.46	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-11.26	3.43e-26	3.46e-23	-0.64	-0.46	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
THCA	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	11.26	3.44e-26	3.47e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
THCA	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	11.26	3.47e-26	3.5e-23	0.65	0.46	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
THCA	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	11.26	3.48e-26	3.52e-23	0.79	0.46	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
THCA	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-11.25	3.55e-26	3.58e-23	-0.35	-0.46	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
THCA	cis	rs4591358	0.689	rs34373729	ENSG00000223466.1	AC064834.2	-11.25	3.61e-26	3.64e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195543775	chr2:195533035~195538681:+
THCA	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-11.25	3.62e-26	3.65e-23	-0.55	-0.46	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
THCA	cis	rs4591358	0.689	rs16837051	ENSG00000223466.1	AC064834.2	-11.25	3.62e-26	3.65e-23	-0.67	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195536281	chr2:195533035~195538681:+
THCA	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	11.25	3.63e-26	3.66e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
THCA	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-11.25	3.66e-26	3.68e-23	-0.79	-0.46	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
THCA	cis	rs853679	0.506	rs1150693	ENSG00000280107.1	AL022393.9	-11.25	3.66e-26	3.69e-23	-0.56	-0.46	Depression;	chr6:28206812	chr6:28170845~28172521:+
THCA	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	11.25	3.69e-26	3.71e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
THCA	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-11.25	3.71e-26	3.74e-23	-0.49	-0.46	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
THCA	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-11.25	3.73e-26	3.75e-23	-0.59	-0.46	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
THCA	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-11.25	3.76e-26	3.78e-23	-0.43	-0.46	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000223701.3	RAET1E-AS1	11.25	3.76e-26	3.79e-23	0.63	0.46	Lung cancer;	chr6:149585576	chr6:149884431~149919508:+
THCA	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-11.25	3.78e-26	3.81e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
THCA	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	11.25	3.79e-26	3.82e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
THCA	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-11.25	3.8e-26	3.83e-23	-0.68	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
THCA	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	11.25	3.8e-26	3.83e-23	0.59	0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000223768.1	LINC00205	-11.25	3.81e-26	3.83e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000223768.1	LINC00205	-11.25	3.81e-26	3.83e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000223768.1	LINC00205	-11.25	3.81e-26	3.83e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000223768.1	LINC00205	-11.25	3.81e-26	3.83e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	11.25	3.82e-26	3.84e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
THCA	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-11.24	3.83e-26	3.86e-23	-0.57	-0.46	Height;	chr3:53084188	chr3:53064283~53065091:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	11.24	3.84e-26	3.86e-23	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
THCA	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	11.24	3.91e-26	3.93e-23	0.48	0.46	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
THCA	cis	rs494459	0.733	rs556437	ENSG00000255239.1	AP002954.6	11.24	3.92e-26	3.95e-23	0.57	0.46	Height;	chr11:118835044	chr11:118688039~118690600:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-11.24	3.95e-26	3.97e-23	-0.34	-0.46	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-11.24	3.95e-26	3.97e-23	-0.34	-0.46	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
THCA	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-11.24	3.96e-26	3.98e-23	-0.5	-0.46	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
THCA	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-11.24	3.96e-26	3.98e-23	-0.5	-0.46	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
THCA	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-11.24	3.99e-26	4.01e-23	-0.51	-0.46	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-11.24	3.99e-26	4.01e-23	-0.51	-0.46	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
THCA	cis	rs12468226	0.938	rs55668474	ENSG00000273456.1	RP11-686O6.2	11.24	3.99e-26	4.01e-23	0.52	0.46	Urate levels;	chr2:202265559	chr2:202374932~202375604:-
THCA	cis	rs11690935	0.959	rs6738445	ENSG00000228389.1	AC068039.4	-11.24	3.99e-26	4.01e-23	-0.54	-0.46	Schizophrenia;	chr2:171743105	chr2:171773482~171775844:+
THCA	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.01e-26	4.03e-23	-0.56	-0.46	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.01e-26	4.03e-23	-0.56	-0.46	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
THCA	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-11.24	4.01e-26	4.03e-23	-0.59	-0.46	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	11.24	4.06e-26	4.08e-23	0.64	0.46	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
THCA	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-11.24	4.06e-26	4.08e-23	-0.72	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-11.24	4.08e-26	4.1e-23	-0.61	-0.46	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
THCA	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-11.24	4.09e-26	4.11e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
THCA	cis	rs6964833	1	rs13227433	ENSG00000277053.3	GTF2IP1	-11.24	4.09e-26	4.11e-23	-0.62	-0.46	Menarche (age at onset);	chr7:74680386	chr7:75185385~75237696:-
THCA	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-11.24	4.14e-26	4.16e-23	-0.68	-0.46	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-11.24	4.14e-26	4.16e-23	-0.68	-0.46	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
THCA	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-11.24	4.16e-26	4.18e-23	-0.49	-0.46	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
THCA	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-11.24	4.16e-26	4.18e-23	-0.56	-0.46	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
THCA	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-11.24	4.16e-26	4.18e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
THCA	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	11.24	4.17e-26	4.19e-23	0.42	0.46	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
THCA	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-11.23	4.18e-26	4.2e-23	-0.61	-0.46	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
THCA	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-11.23	4.2e-26	4.22e-23	-0.48	-0.46	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
THCA	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	11.23	4.21e-26	4.22e-23	0.38	0.46	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	11.23	4.21e-26	4.22e-23	0.38	0.46	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	11.23	4.21e-26	4.22e-23	0.38	0.46	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
THCA	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-11.23	4.21e-26	4.23e-23	-0.6	-0.46	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	11.23	4.23e-26	4.24e-23	0.6	0.46	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-11.23	4.28e-26	4.29e-23	-0.6	-0.46	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-11.23	4.28e-26	4.29e-23	-0.6	-0.46	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
THCA	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-11.23	4.28e-26	4.3e-23	-0.55	-0.46	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
THCA	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	11.23	4.29e-26	4.31e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	11.23	4.29e-26	4.31e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	11.23	4.3e-26	4.32e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
THCA	cis	rs4819052	1	rs2838847	ENSG00000223768.1	LINC00205	-11.23	4.38e-26	4.39e-23	-0.46	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45293285~45297354:+
THCA	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-11.23	4.4e-26	4.41e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
THCA	cis	rs9659323	0.613	rs72705339	ENSG00000231365.4	RP11-418J17.1	-11.23	4.41e-26	4.42e-23	-0.49	-0.46	Body mass index;	chr1:118929246	chr1:119140396~119275973:+
THCA	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-11.23	4.44e-26	4.45e-23	-0.45	-0.46	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
THCA	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	11.23	4.45e-26	4.46e-23	0.66	0.46	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
THCA	cis	rs4591358	0.689	rs2889034	ENSG00000223466.1	AC064834.2	-11.23	4.46e-26	4.47e-23	-0.65	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548022	chr2:195533035~195538681:+
THCA	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	11.23	4.46e-26	4.47e-23	0.56	0.46	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	11.23	4.46e-26	4.47e-23	0.56	0.46	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
THCA	cis	rs9928842	0.771	rs2870471	ENSG00000280152.1	RP11-331F4.5	-11.23	4.49e-26	4.49e-23	-0.61	-0.46	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75245994~75250077:-
THCA	cis	rs9659323	0.689	rs10923716	ENSG00000231365.4	RP11-418J17.1	-11.23	4.5e-26	4.5e-23	-0.49	-0.46	Body mass index;	chr1:118993496	chr1:119140396~119275973:+
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	11.23	4.51e-26	4.52e-23	0.63	0.46	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
THCA	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	11.23	4.52e-26	4.53e-23	0.6	0.46	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
THCA	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-11.23	4.52e-26	4.53e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
THCA	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-11.23	4.53e-26	4.54e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-11.23	4.53e-26	4.54e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
THCA	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-11.23	4.54e-26	4.54e-23	-0.57	-0.46	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
THCA	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
THCA	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-11.22	4.58e-26	4.59e-23	-0.35	-0.46	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-11.22	4.58e-26	4.59e-23	-0.35	-0.46	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-11.22	4.58e-26	4.59e-23	-0.35	-0.46	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-11.22	4.58e-26	4.59e-23	-0.35	-0.46	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	11.22	4.58e-26	4.59e-23	0.56	0.46	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
THCA	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	11.22	4.58e-26	4.59e-23	0.8	0.46	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
THCA	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	11.22	4.58e-26	4.59e-23	0.8	0.46	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000223768.1	LINC00205	-11.22	4.61e-26	4.62e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000223768.1	LINC00205	-11.22	4.61e-26	4.62e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000223768.1	LINC00205	-11.22	4.61e-26	4.62e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-11.22	4.62e-26	4.62e-23	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
THCA	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-11.22	4.71e-26	4.71e-23	-0.49	-0.46	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
THCA	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-11.22	4.71e-26	4.71e-23	-0.49	-0.46	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
THCA	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-11.22	4.73e-26	4.73e-23	-0.47	-0.46	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
THCA	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	11.22	4.75e-26	4.75e-23	0.42	0.46	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.875	rs1331645	ENSG00000235652.6	RP11-545I5.3	11.22	4.78e-26	4.78e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146077271	chr6:145799409~145886585:+
THCA	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	11.22	4.78e-26	4.78e-23	0.55	0.46	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
THCA	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-11.22	4.78e-26	4.78e-23	-0.43	-0.46	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
THCA	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	11.22	4.86e-26	4.85e-23	0.49	0.46	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
THCA	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-11.22	4.88e-26	4.87e-23	-0.47	-0.46	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
THCA	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	11.22	4.99e-26	4.98e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
THCA	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	11.22	4.99e-26	4.99e-23	0.53	0.46	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
THCA	cis	rs4819052	0.851	rs2838866	ENSG00000223768.1	LINC00205	-11.21	5.01e-26	5e-23	-0.44	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	11.21	5.03e-26	5.02e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-11.21	5.04e-26	5.03e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-11.21	5.04e-26	5.03e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-11.21	5.04e-26	5.03e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
THCA	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	11.21	5.05e-26	5.04e-23	0.6	0.46	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
THCA	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	11.21	5.06e-26	5.05e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	11.21	5.06e-26	5.05e-23	0.63	0.46	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
THCA	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	11.21	5.09e-26	5.08e-23	0.59	0.46	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	11.21	5.11e-26	5.1e-23	0.63	0.46	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	11.21	5.11e-26	5.1e-23	0.63	0.46	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	11.21	5.11e-26	5.1e-23	0.63	0.46	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	11.21	5.15e-26	5.14e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	11.21	5.17e-26	5.16e-23	0.38	0.46	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
THCA	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	11.21	5.23e-26	5.21e-23	0.53	0.46	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
THCA	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	11.21	5.25e-26	5.24e-23	0.79	0.46	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
THCA	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	11.21	5.29e-26	5.27e-23	0.56	0.46	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
THCA	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	11.21	5.31e-26	5.29e-23	0.89	0.46	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
THCA	cis	rs11159086	0.793	rs1029703	ENSG00000270000.1	RP3-449M8.9	11.21	5.37e-26	5.35e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74473899	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs1029702	ENSG00000270000.1	RP3-449M8.9	11.21	5.37e-26	5.35e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74473909	chr14:74471930~74472360:-
THCA	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-11.21	5.37e-26	5.35e-23	-0.48	-0.46	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
THCA	cis	rs4591358	0.689	rs59017643	ENSG00000223466.1	AC064834.2	-11.21	5.37e-26	5.35e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546835	chr2:195533035~195538681:+
THCA	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-11.21	5.39e-26	5.37e-23	-0.52	-0.46	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-11.21	5.39e-26	5.37e-23	-0.52	-0.46	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
THCA	cis	rs6558530	0.666	rs28376731	ENSG00000253982.1	CTD-2336O2.1	11.21	5.39e-26	5.37e-23	0.44	0.46	Systolic blood pressure;	chr8:1748086	chr8:1761990~1764502:-
THCA	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	11.21	5.41e-26	5.39e-23	0.51	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
THCA	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-11.21	5.42e-26	5.4e-23	-0.53	-0.46	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
THCA	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	11.21	5.42e-26	5.4e-23	0.6	0.46	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
THCA	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-11.2	5.54e-26	5.51e-23	-0.56	-0.46	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
THCA	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	11.2	5.57e-26	5.54e-23	0.31	0.46	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
THCA	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-11.2	5.61e-26	5.58e-23	-0.42	-0.46	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
THCA	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	11.2	5.62e-26	5.59e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	11.2	5.62e-26	5.59e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
THCA	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	11.2	5.68e-26	5.65e-23	0.39	0.46	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
THCA	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	11.2	5.71e-26	5.67e-23	0.67	0.46	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
THCA	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	11.2	5.73e-26	5.7e-23	0.58	0.46	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
THCA	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	11.2	5.74e-26	5.7e-23	0.6	0.46	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
THCA	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	11.2	5.76e-26	5.72e-23	0.53	0.46	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
THCA	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-11.2	5.76e-26	5.72e-23	-0.33	-0.46	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	11.2	5.82e-26	5.79e-23	0.5	0.46	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
THCA	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	11.2	5.83e-26	5.79e-23	0.5	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
THCA	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	11.2	5.83e-26	5.79e-23	0.63	0.46	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	11.2	5.83e-26	5.79e-23	0.63	0.46	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
THCA	cis	rs4819052	1	rs733739	ENSG00000223768.1	LINC00205	-11.2	5.87e-26	5.83e-23	-0.46	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45293285~45297354:+
THCA	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-11.2	5.88e-26	5.84e-23	-0.35	-0.46	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
THCA	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	11.2	5.89e-26	5.85e-23	0.6	0.46	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	11.2	5.89e-26	5.85e-23	0.6	0.46	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-11.2	5.93e-26	5.89e-23	-0.6	-0.46	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
THCA	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-11.2	5.95e-26	5.91e-23	-0.68	-0.46	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
THCA	cis	rs9659323	0.65	rs12066653	ENSG00000231365.4	RP11-418J17.1	-11.2	5.96e-26	5.92e-23	-0.49	-0.46	Body mass index;	chr1:118939885	chr1:119140396~119275973:+
THCA	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
THCA	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	11.19	5.97e-26	5.93e-23	0.59	0.46	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000235689.1	AP000351.13	11.19	5.98e-26	5.93e-23	0.58	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:24006305~24008258:-
THCA	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	11.19	6.01e-26	5.96e-23	0.59	0.46	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
THCA	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-11.19	6.01e-26	5.97e-23	-0.53	-0.46	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
THCA	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-11.19	6.03e-26	5.99e-23	-0.61	-0.46	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
THCA	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-11.19	6.03e-26	5.99e-23	-0.59	-0.46	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
THCA	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	11.19	6.04e-26	5.99e-23	0.56	0.46	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	11.19	6.04e-26	5.99e-23	0.56	0.46	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	11.19	6.04e-26	5.99e-23	0.56	0.46	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	11.19	6.04e-26	5.99e-23	0.56	0.46	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-11.19	6.09e-26	6.04e-23	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000235689.1	AP000351.13	11.19	6.1e-26	6.05e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:24006305~24008258:-
THCA	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	11.19	6.16e-26	6.11e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	11.19	6.16e-26	6.11e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	11.19	6.19e-26	6.14e-23	0.66	0.46	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	11.19	6.19e-26	6.14e-23	0.66	0.46	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	11.19	6.2e-26	6.15e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	11.19	6.2e-26	6.15e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	11.19	6.2e-26	6.15e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	11.19	6.2e-26	6.15e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	11.19	6.24e-26	6.18e-23	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	11.19	6.24e-26	6.18e-23	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
THCA	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-11.19	6.24e-26	6.19e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
THCA	cis	rs6558530	0.579	rs6558528	ENSG00000253982.1	CTD-2336O2.1	11.19	6.25e-26	6.2e-23	0.43	0.46	Systolic blood pressure;	chr8:1754897	chr8:1761990~1764502:-
THCA	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-11.19	6.28e-26	6.22e-23	-0.56	-0.46	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
THCA	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	11.19	6.3e-26	6.24e-23	0.57	0.46	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	11.19	6.3e-26	6.24e-23	0.57	0.46	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
THCA	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-11.19	6.33e-26	6.27e-23	-0.6	-0.46	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
THCA	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	11.19	6.35e-26	6.29e-23	0.6	0.46	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	11.19	6.38e-26	6.32e-23	0.56	0.46	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-11.19	6.43e-26	6.37e-23	-0.57	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
THCA	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	11.19	6.46e-26	6.39e-23	0.62	0.46	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	11.19	6.5e-26	6.43e-23	0.66	0.46	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	11.19	6.5e-26	6.43e-23	0.66	0.46	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
THCA	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	11.18	6.56e-26	6.49e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
THCA	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	11.18	6.59e-26	6.52e-23	0.56	0.46	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
THCA	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	11.18	6.61e-26	6.54e-23	0.56	0.46	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
THCA	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-11.18	6.61e-26	6.54e-23	-0.54	-0.46	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
THCA	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-11.18	6.61e-26	6.54e-23	-0.54	-0.46	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
THCA	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-11.18	6.62e-26	6.55e-23	-0.81	-0.46	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-11.18	6.62e-26	6.55e-23	-0.81	-0.46	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
THCA	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	11.18	6.63e-26	6.56e-23	0.6	0.46	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
THCA	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-11.18	6.67e-26	6.59e-23	-0.52	-0.46	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
THCA	cis	rs7569084	0.687	rs12993075	ENSG00000237979.1	AC007389.1	11.18	6.7e-26	6.63e-23	0.54	0.46	Sum eosinophil basophil counts;	chr2:65431010	chr2:65500993~65502138:-
THCA	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	11.18	6.76e-26	6.69e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
THCA	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	11.18	6.78e-26	6.71e-23	0.47	0.46	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
THCA	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	11.18	6.79e-26	6.71e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	11.18	6.79e-26	6.71e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
THCA	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-11.18	6.79e-26	6.71e-23	-0.67	-0.46	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
THCA	cis	rs4591358	0.689	rs72927760	ENSG00000223466.1	AC064834.2	-11.18	6.81e-26	6.74e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544584	chr2:195533035~195538681:+
THCA	cis	rs860295	0.702	rs10796946	ENSG00000225855.5	RUSC1-AS1	11.18	6.83e-26	6.76e-23	0.32	0.46	Body mass index;	chr1:155459699	chr1:155316863~155324176:-
THCA	cis	rs860295	0.676	rs10908466	ENSG00000225855.5	RUSC1-AS1	11.18	6.83e-26	6.76e-23	0.32	0.46	Body mass index;	chr1:155459934	chr1:155316863~155324176:-
THCA	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	11.18	6.92e-26	6.84e-23	0.56	0.46	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
THCA	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	11.18	7.04e-26	6.95e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	11.18	7.05e-26	6.96e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
THCA	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	11.18	7.05e-26	6.97e-23	0.6	0.46	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
THCA	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-11.18	7.09e-26	7e-23	-0.54	-0.46	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
THCA	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	11.17	7.15e-26	7.06e-23	0.53	0.46	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-11.17	7.19e-26	7.1e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
THCA	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	11.17	7.21e-26	7.11e-23	0.6	0.46	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
THCA	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	11.17	7.22e-26	7.13e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
THCA	cis	rs12468226	0.938	rs55681656	ENSG00000273456.1	RP11-686O6.2	11.17	7.3e-26	7.21e-23	0.52	0.46	Urate levels;	chr2:202319041	chr2:202374932~202375604:-
THCA	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-11.17	7.31e-26	7.21e-23	-0.68	-0.46	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
THCA	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	11.17	7.36e-26	7.26e-23	0.47	0.46	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
THCA	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	11.17	7.47e-26	7.37e-23	0.41	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	11.17	7.47e-26	7.37e-23	0.41	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	11.17	7.47e-26	7.37e-23	0.41	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	11.17	7.51e-26	7.4e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
THCA	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	11.17	7.57e-26	7.46e-23	0.8	0.46	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
THCA	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	11.17	7.6e-26	7.49e-23	0.42	0.46	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
THCA	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	11.17	7.62e-26	7.51e-23	0.75	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
THCA	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-11.17	7.64e-26	7.53e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
THCA	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	11.17	7.66e-26	7.54e-23	0.6	0.46	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	11.17	7.66e-26	7.54e-23	0.6	0.46	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
THCA	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	11.17	7.67e-26	7.56e-23	0.6	0.46	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	11.17	7.69e-26	7.57e-23	0.54	0.46	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	11.17	7.69e-26	7.58e-23	0.61	0.46	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	11.16	7.82e-26	7.7e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2748485	ENSG00000235652.6	RP11-545I5.3	11.16	7.82e-26	7.7e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2207785	ENSG00000235652.6	RP11-545I5.3	11.16	7.82e-26	7.7e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	11.16	7.83e-26	7.71e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
THCA	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	11.16	7.85e-26	7.72e-23	0.49	0.46	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	11.16	7.85e-26	7.72e-23	0.49	0.46	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
THCA	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-11.16	7.86e-26	7.73e-23	-0.94	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
THCA	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	11.16	7.89e-26	7.76e-23	0.48	0.46	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	11.16	7.89e-26	7.76e-23	0.48	0.46	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	11.16	7.89e-26	7.76e-23	0.48	0.46	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
THCA	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-11.16	7.98e-26	7.84e-23	-0.59	-0.46	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
THCA	cis	rs4964805	0.913	rs11111793	ENSG00000257681.1	RP11-341G23.4	11.16	7.98e-26	7.85e-23	0.55	0.46	Attention deficit hyperactivity disorder;	chr12:103804340	chr12:103746315~103768858:-
THCA	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	11.16	8e-26	7.87e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
THCA	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	11.16	8.07e-26	7.93e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	11.16	8.07e-26	7.93e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-11.16	8.16e-26	8.02e-23	-0.59	-0.46	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
THCA	cis	rs6964833	1	rs6964833	ENSG00000277053.3	GTF2IP1	-11.16	8.16e-26	8.02e-23	-0.62	-0.46	Menarche (age at onset);	chr7:74687575	chr7:75185385~75237696:-
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	11.16	8.19e-26	8.05e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
THCA	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	11.16	8.23e-26	8.08e-23	0.74	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
THCA	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	11.16	8.23e-26	8.09e-23	0.48	0.46	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
THCA	cis	rs12468226	0.938	rs58834901	ENSG00000273456.1	RP11-686O6.2	11.16	8.25e-26	8.1e-23	0.52	0.46	Urate levels;	chr2:202288169	chr2:202374932~202375604:-
THCA	cis	rs6964833	1	rs35203738	ENSG00000277053.3	GTF2IP1	-11.16	8.25e-26	8.11e-23	-0.62	-0.46	Menarche (age at onset);	chr7:74690864	chr7:75185385~75237696:-
THCA	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-11.16	8.27e-26	8.12e-23	-0.58	-0.46	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-11.16	8.27e-26	8.12e-23	-0.58	-0.46	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
THCA	cis	rs10246939	0.544	rs12668089	ENSG00000228775.6	WEE2-AS1	11.16	8.28e-26	8.13e-23	0.55	0.46	Bitter taste perception;	chr7:141875111	chr7:141704338~141738346:-
THCA	cis	rs9659323	0.7	rs10923746	ENSG00000231365.4	RP11-418J17.1	-11.16	8.34e-26	8.19e-23	-0.46	-0.46	Body mass index;	chr1:119073655	chr1:119140396~119275973:+
THCA	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-11.16	8.4e-26	8.24e-23	-0.6	-0.46	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
THCA	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-11.16	8.45e-26	8.29e-23	-0.36	-0.46	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
THCA	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-11.16	8.51e-26	8.35e-23	-0.36	-0.46	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
THCA	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	11.15	8.56e-26	8.4e-23	0.6	0.46	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
THCA	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	11.15	8.59e-26	8.43e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	11.15	8.59e-26	8.43e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
THCA	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-11.15	8.59e-26	8.43e-23	-0.58	-0.46	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
THCA	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-11.15	8.64e-26	8.47e-23	-0.36	-0.46	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
THCA	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	11.15	8.64e-26	8.48e-23	0.61	0.46	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	11.15	8.73e-26	8.56e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
THCA	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	11.15	8.74e-26	8.57e-23	0.53	0.46	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
THCA	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-11.15	8.75e-26	8.58e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
THCA	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-11.15	8.76e-26	8.59e-23	-0.59	-0.46	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
THCA	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	11.15	8.83e-26	8.66e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
THCA	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	11.15	8.94e-26	8.76e-23	0.59	0.46	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
THCA	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	11.15	8.95e-26	8.78e-23	0.51	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
THCA	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-11.15	9.04e-26	8.85e-23	-0.6	-0.46	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
THCA	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-11.15	9.09e-26	8.9e-23	-0.67	-0.46	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
THCA	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-11.15	9.09e-26	8.91e-23	-0.73	-0.46	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
THCA	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	11.15	9.17e-26	8.98e-23	0.6	0.46	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
THCA	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	11.15	9.23e-26	9.03e-23	0.63	0.46	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000206090.4	AP000350.7	11.14	9.36e-26	9.16e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23939998~23942798:+
THCA	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	11.14	9.37e-26	9.18e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
THCA	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-11.14	9.45e-26	9.26e-23	-0.56	-0.46	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-11.14	9.57e-26	9.37e-23	-0.56	-0.46	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
THCA	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	11.14	9.81e-26	9.6e-23	0.62	0.46	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
THCA	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-11.14	9.98e-26	9.75e-23	-0.59	-0.46	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
THCA	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-11.14	1e-25	9.77e-23	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-11.14	1e-25	9.8e-23	-0.59	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
THCA	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-11.14	1e-25	9.81e-23	-0.54	-0.46	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
THCA	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-11.14	1e-25	9.81e-23	-0.47	-0.46	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
THCA	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	11.14	1.01e-25	9.84e-23	0.61	0.46	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
THCA	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	11.14	1.01e-25	9.87e-23	0.33	0.46	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
THCA	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-11.14	1.01e-25	9.9e-23	-0.6	-0.46	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-11.14	1.01e-25	9.9e-23	-0.6	-0.46	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-11.14	1.01e-25	9.9e-23	-0.6	-0.46	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
THCA	cis	rs6496932	0.635	rs28559998	ENSG00000218052.5	ADAMTS7P4	-11.14	1.01e-25	9.9e-23	-0.58	-0.46	Central corneal thickness;Corneal structure;	chr15:85360605	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.635	rs8023859	ENSG00000218052.5	ADAMTS7P4	-11.14	1.01e-25	9.9e-23	-0.58	-0.46	Central corneal thickness;Corneal structure;	chr15:85361540	chr15:85255369~85330334:-
THCA	cis	rs934734	0.532	rs6546151	ENSG00000281920.1	RP11-418H16.1	-11.13	1.02e-25	9.96e-23	-0.55	-0.46	Rheumatoid arthritis;	chr2:65449449	chr2:65623272~65628424:+
THCA	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	11.13	1.04e-25	1.02e-22	0.6	0.46	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	11.13	1.05e-25	1.03e-22	0.59	0.46	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	11.13	1.05e-25	1.03e-22	0.59	0.46	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	11.13	1.05e-25	1.03e-22	0.59	0.46	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
THCA	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-11.13	1.06e-25	1.04e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
THCA	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	11.13	1.06e-25	1.04e-22	0.45	0.46	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
THCA	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-11.13	1.07e-25	1.04e-22	-0.53	-0.46	Temperament;	chr17:14075460	chr17:14024514~14025488:+
THCA	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	11.13	1.07e-25	1.04e-22	0.61	0.46	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
THCA	cis	rs4591358	0.638	rs6732435	ENSG00000223466.1	AC064834.2	-11.13	1.07e-25	1.04e-22	-0.67	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541501	chr2:195533035~195538681:+
THCA	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-11.13	1.07e-25	1.05e-22	-0.57	-0.46	Height;	chr3:53034139	chr3:53064283~53065091:-
THCA	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	11.13	1.08e-25	1.05e-22	0.89	0.46	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
THCA	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	11.13	1.08e-25	1.06e-22	0.48	0.46	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	11.13	1.08e-25	1.06e-22	0.48	0.46	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	11.13	1.08e-25	1.06e-22	0.48	0.46	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
THCA	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	11.13	1.09e-25	1.06e-22	0.62	0.46	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
THCA	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-11.13	1.09e-25	1.06e-22	-0.41	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
THCA	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-11.13	1.09e-25	1.06e-22	-0.53	-0.46	Height;	chr3:52994359	chr3:53064283~53065091:-
THCA	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	11.13	1.09e-25	1.07e-22	0.48	0.46	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
THCA	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	11.13	1.1e-25	1.07e-22	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
THCA	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	11.13	1.1e-25	1.07e-22	0.89	0.46	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
THCA	cis	rs12468226	0.938	rs6753044	ENSG00000273456.1	RP11-686O6.2	11.13	1.1e-25	1.07e-22	0.52	0.46	Urate levels;	chr2:202300710	chr2:202374932~202375604:-
THCA	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-11.13	1.11e-25	1.08e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
THCA	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	11.13	1.11e-25	1.08e-22	0.61	0.46	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	11.13	1.11e-25	1.08e-22	0.61	0.46	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-11.13	1.11e-25	1.08e-22	-0.61	-0.46	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
THCA	cis	rs6558530	0.666	rs10113471	ENSG00000253982.1	CTD-2336O2.1	11.13	1.11e-25	1.08e-22	0.44	0.46	Systolic blood pressure;	chr8:1747661	chr8:1761990~1764502:-
THCA	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	11.13	1.11e-25	1.08e-22	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
THCA	cis	rs860295	0.702	rs10796943	ENSG00000225855.5	RUSC1-AS1	11.12	1.11e-25	1.08e-22	0.32	0.46	Body mass index;	chr1:155444938	chr1:155316863~155324176:-
THCA	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	11.12	1.12e-25	1.09e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
THCA	cis	rs916888	0.773	rs199448	ENSG00000232300.1	FAM215B	11.12	1.12e-25	1.09e-22	0.75	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46558830~46562795:-
THCA	cis	rs916888	0.773	rs199447	ENSG00000232300.1	FAM215B	11.12	1.12e-25	1.09e-22	0.75	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46558830~46562795:-
THCA	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	11.12	1.12e-25	1.09e-22	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
THCA	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-11.12	1.13e-25	1.1e-22	-0.58	-0.46	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
THCA	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-11.12	1.14e-25	1.11e-22	-0.35	-0.46	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
THCA	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	11.12	1.15e-25	1.12e-22	0.54	0.46	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
THCA	cis	rs860295	0.676	rs11264374	ENSG00000225855.5	RUSC1-AS1	11.12	1.16e-25	1.12e-22	0.32	0.46	Body mass index;	chr1:155451721	chr1:155316863~155324176:-
THCA	cis	rs4819052	0.632	rs4819050	ENSG00000223768.1	LINC00205	-11.12	1.16e-25	1.13e-22	-0.42	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45293285~45297354:+
THCA	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-11.12	1.17e-25	1.14e-22	-0.6	-0.46	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-11.12	1.17e-25	1.14e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-11.12	1.17e-25	1.14e-22	-0.62	-0.46	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	11.12	1.17e-25	1.14e-22	0.63	0.46	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
THCA	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	11.12	1.17e-25	1.14e-22	0.6	0.46	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
THCA	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	11.12	1.18e-25	1.14e-22	0.54	0.46	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
THCA	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	11.12	1.18e-25	1.14e-22	0.66	0.46	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
THCA	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-11.12	1.18e-25	1.14e-22	-0.5	-0.46	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
THCA	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-11.12	1.2e-25	1.17e-22	-0.74	-0.46	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
THCA	cis	rs4819052	0.851	rs3673	ENSG00000223768.1	LINC00205	-11.12	1.21e-25	1.17e-22	-0.42	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45293285~45297354:+
THCA	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-11.12	1.21e-25	1.17e-22	-0.49	-0.46	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
THCA	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	11.11	1.22e-25	1.18e-22	0.63	0.46	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	11.11	1.22e-25	1.18e-22	0.63	0.46	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
THCA	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-11.11	1.22e-25	1.18e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-11.11	1.22e-25	1.18e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
THCA	cis	rs4819052	1	rs13052356	ENSG00000223768.1	LINC00205	-11.11	1.22e-25	1.19e-22	-0.46	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45293285~45297354:+
THCA	cis	rs944289	0.615	rs1333312	ENSG00000257826.1	RP11-116N8.4	-11.11	1.22e-25	1.19e-22	-0.48	-0.46	Thyroid cancer;	chr14:36093396	chr14:36061026~36067190:-
THCA	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	11.11	1.23e-25	1.19e-22	0.59	0.46	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	11.11	1.23e-25	1.19e-22	0.62	0.46	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
THCA	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-11.11	1.24e-25	1.2e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
THCA	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-11.11	1.24e-25	1.2e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-11.11	1.24e-25	1.2e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-11.11	1.24e-25	1.2e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
THCA	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-11.11	1.24e-25	1.2e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
THCA	cis	rs2658782	0.547	rs10741464	ENSG00000279684.1	RP11-755E23.2	-11.11	1.25e-25	1.21e-22	-0.65	-0.46	Pulmonary function decline;	chr11:93457586	chr11:93286629~93288903:-
THCA	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-11.11	1.25e-25	1.21e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
THCA	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	11.11	1.25e-25	1.22e-22	0.6	0.46	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
THCA	cis	rs934734	0.673	rs754110	ENSG00000281920.1	RP11-418H16.1	11.11	1.26e-25	1.22e-22	0.55	0.46	Rheumatoid arthritis;	chr2:65464626	chr2:65623272~65628424:+
THCA	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	11.11	1.27e-25	1.23e-22	0.63	0.46	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
THCA	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	11.11	1.27e-25	1.24e-22	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
THCA	cis	rs11159086	0.793	rs4903229	ENSG00000270000.1	RP3-449M8.9	11.11	1.27e-25	1.24e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74489865	chr14:74471930~74472360:-
THCA	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-11.11	1.28e-25	1.25e-22	-0.53	-0.46	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
THCA	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	11.11	1.29e-25	1.25e-22	0.41	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
THCA	cis	rs73219805	0.759	rs3758098	ENSG00000228451.3	SDAD1P1	-11.11	1.29e-25	1.25e-22	-0.66	-0.46	Schizophrenia;	chr8:26381867	chr8:26379259~26382953:-
THCA	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-11.11	1.3e-25	1.26e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
THCA	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-11.11	1.32e-25	1.28e-22	-0.47	-0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
THCA	cis	rs12468226	0.938	rs16824590	ENSG00000273456.1	RP11-686O6.2	11.11	1.32e-25	1.28e-22	0.52	0.46	Urate levels;	chr2:202272624	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs77018809	ENSG00000273456.1	RP11-686O6.2	11.11	1.32e-25	1.28e-22	0.52	0.46	Urate levels;	chr2:202273166	chr2:202374932~202375604:-
THCA	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-11.1	1.34e-25	1.29e-22	-0.6	-0.46	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
THCA	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	11.1	1.34e-25	1.3e-22	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
THCA	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	11.1	1.35e-25	1.31e-22	0.72	0.46	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
THCA	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-11.1	1.36e-25	1.32e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
THCA	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	11.1	1.37e-25	1.33e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
THCA	cis	rs944289	0.617	rs7151738	ENSG00000257826.1	RP11-116N8.4	-11.1	1.37e-25	1.33e-22	-0.49	-0.46	Thyroid cancer;	chr14:36114670	chr14:36061026~36067190:-
THCA	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-11.1	1.39e-25	1.35e-22	-0.58	-0.46	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
THCA	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-11.1	1.4e-25	1.35e-22	-0.59	-0.46	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
THCA	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	11.1	1.4e-25	1.36e-22	0.41	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
THCA	cis	rs240993	0.909	rs240991	ENSG00000230177.1	RP5-1112D6.4	-11.1	1.4e-25	1.36e-22	-0.4	-0.46	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111277932~111278742:+
THCA	cis	rs240993	1	rs240993	ENSG00000230177.1	RP5-1112D6.4	-11.1	1.4e-25	1.36e-22	-0.4	-0.46	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111277932~111278742:+
THCA	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	11.1	1.41e-25	1.36e-22	0.65	0.46	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	11.1	1.41e-25	1.37e-22	0.64	0.46	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
THCA	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-11.1	1.41e-25	1.37e-22	-0.53	-0.46	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
THCA	cis	rs11159086	0.793	rs10147316	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74475688	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.838	rs10147963	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74476091	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs8021664	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74476592	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs10150696	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74476723	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs1860108	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74478562	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs11845370	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74481587	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs3784035	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74482221	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs12433382	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74482940	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs10148268	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74484261	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs11850070	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74487575	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs28378078	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74487940	chr14:74471930~74472360:-
THCA	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	11.1	1.43e-25	1.38e-22	0.48	0.46	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000223768.1	LINC00205	-11.1	1.44e-25	1.39e-22	-0.42	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45293285~45297354:+
THCA	cis	rs9659323	0.65	rs61528304	ENSG00000231365.4	RP11-418J17.1	-11.1	1.44e-25	1.39e-22	-0.49	-0.46	Body mass index;	chr1:118920976	chr1:119140396~119275973:+
THCA	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	11.1	1.44e-25	1.39e-22	0.6	0.46	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	11.1	1.44e-25	1.39e-22	0.6	0.46	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	11.1	1.44e-25	1.39e-22	0.6	0.46	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
THCA	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-11.1	1.44e-25	1.39e-22	-0.54	-0.46	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	11.1	1.45e-25	1.4e-22	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
THCA	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	11.1	1.45e-25	1.4e-22	0.78	0.46	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
THCA	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-11.1	1.45e-25	1.4e-22	-0.42	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
THCA	cis	rs6558530	0.666	rs6558518	ENSG00000253982.1	CTD-2336O2.1	11.09	1.46e-25	1.41e-22	0.44	0.46	Systolic blood pressure;	chr8:1749143	chr8:1761990~1764502:-
THCA	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-11.09	1.47e-25	1.42e-22	-0.48	-0.46	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
THCA	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-11.09	1.48e-25	1.43e-22	-0.73	-0.46	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
THCA	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	11.09	1.48e-25	1.43e-22	0.6	0.46	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
THCA	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	11.09	1.48e-25	1.43e-22	0.55	0.46	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
THCA	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-11.09	1.48e-25	1.43e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-11.09	1.48e-25	1.43e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-11.09	1.48e-25	1.43e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-11.09	1.48e-25	1.43e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
THCA	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	11.09	1.49e-25	1.44e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
THCA	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	11.09	1.49e-25	1.44e-22	0.78	0.46	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
THCA	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-11.09	1.49e-25	1.44e-22	-0.59	-0.46	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-11.09	1.49e-25	1.44e-22	-0.59	-0.46	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
THCA	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	11.09	1.5e-25	1.45e-22	0.6	0.46	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
THCA	cis	rs11159086	0.793	rs9285594	ENSG00000270000.1	RP3-449M8.9	11.09	1.5e-25	1.45e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74489253	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs8016972	ENSG00000270000.1	RP3-449M8.9	11.09	1.5e-25	1.45e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74491833	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs8015894	ENSG00000270000.1	RP3-449M8.9	11.09	1.5e-25	1.45e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74491917	chr14:74471930~74472360:-
THCA	cis	rs7569084	0.687	rs6755006	ENSG00000237979.1	AC007389.1	-11.09	1.5e-25	1.45e-22	-0.54	-0.46	Sum eosinophil basophil counts;	chr2:65426008	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs6755128	ENSG00000237979.1	AC007389.1	-11.09	1.5e-25	1.45e-22	-0.54	-0.46	Sum eosinophil basophil counts;	chr2:65426065	chr2:65500993~65502138:-
THCA	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	11.09	1.51e-25	1.46e-22	0.57	0.46	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	11.09	1.51e-25	1.46e-22	0.57	0.46	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
THCA	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	11.09	1.52e-25	1.46e-22	0.41	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
THCA	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	11.09	1.52e-25	1.47e-22	0.55	0.46	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
THCA	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-11.09	1.53e-25	1.48e-22	-0.6	-0.46	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
THCA	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	11.09	1.54e-25	1.48e-22	0.55	0.46	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
THCA	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-11.09	1.54e-25	1.49e-22	-0.53	-0.46	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	11.09	1.55e-25	1.49e-22	0.61	0.46	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
THCA	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	11.09	1.56e-25	1.51e-22	0.59	0.46	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	11.09	1.56e-25	1.51e-22	0.59	0.46	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
THCA	cis	rs11159086	0.793	rs1029701	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74474112	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs12432412	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74474294	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs1029700	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74474309	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs1029699	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74474790	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.729	rs8015872	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74475529	chr14:74471930~74472360:-
THCA	cis	rs4819052	0.851	rs9974891	ENSG00000223768.1	LINC00205	-11.09	1.58e-25	1.52e-22	-0.42	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-11.09	1.58e-25	1.53e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
THCA	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-11.08	1.59e-25	1.53e-22	-0.58	-0.46	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
THCA	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	11.08	1.6e-25	1.54e-22	0.56	0.46	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
THCA	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	11.08	1.6e-25	1.54e-22	0.6	0.46	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
THCA	cis	rs9659323	0.717	rs61806238	ENSG00000231365.4	RP11-418J17.1	-11.08	1.61e-25	1.55e-22	-0.49	-0.46	Body mass index;	chr1:118993755	chr1:119140396~119275973:+
THCA	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-11.08	1.61e-25	1.55e-22	-0.47	-0.46	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000235689.1	AP000351.13	11.08	1.61e-25	1.56e-22	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:24006305~24008258:-
THCA	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-11.08	1.63e-25	1.57e-22	-0.6	-0.46	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
THCA	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-11.08	1.64e-25	1.58e-22	-0.52	-0.46	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000224205.1	AP000351.4	11.08	1.65e-25	1.58e-22	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23987320~23991421:-
THCA	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-11.08	1.66e-25	1.59e-22	-0.59	-0.46	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	11.08	1.66e-25	1.6e-22	0.61	0.46	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
THCA	cis	rs507080	0.733	rs497678	ENSG00000255422.1	AP002954.4	-11.08	1.67e-25	1.61e-22	-0.52	-0.46	Serum metabolite levels;	chr11:118697172	chr11:118704607~118750263:+
THCA	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-11.08	1.67e-25	1.61e-22	-0.67	-0.46	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
THCA	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-11.08	1.67e-25	1.61e-22	-0.67	-0.46	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
THCA	cis	rs934734	0.532	rs10184881	ENSG00000281920.1	RP11-418H16.1	-11.08	1.67e-25	1.61e-22	-0.55	-0.46	Rheumatoid arthritis;	chr2:65457018	chr2:65623272~65628424:+
THCA	cis	rs12468226	0.938	rs7585867	ENSG00000273456.1	RP11-686O6.2	11.08	1.68e-25	1.62e-22	0.52	0.46	Urate levels;	chr2:202287040	chr2:202374932~202375604:-
THCA	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	11.08	1.68e-25	1.62e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
THCA	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-11.08	1.69e-25	1.63e-22	-0.68	-0.46	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-11.08	1.69e-25	1.63e-22	-0.68	-0.46	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
THCA	cis	rs16828019	0.777	rs35080169	ENSG00000235358.1	RP11-399E6.1	11.08	1.7e-25	1.63e-22	0.89	0.46	Intelligence (multi-trait analysis);	chr1:40989287	chr1:41242373~41284861:+
THCA	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-11.08	1.7e-25	1.64e-22	-0.52	-0.45	Height;	chr6:109432968	chr6:109382795~109383666:+
THCA	cis	rs2283792	0.74	rs8140258	ENSG00000224086.5	LL22NC03-86G7.1	-11.08	1.7e-25	1.64e-22	-0.54	-0.45	Multiple sclerosis;	chr22:21755545	chr22:21938293~21977632:+
THCA	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	11.08	1.71e-25	1.64e-22	0.71	0.45	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
THCA	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	11.08	1.71e-25	1.64e-22	0.59	0.45	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
THCA	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	11.08	1.72e-25	1.65e-22	0.6	0.45	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
THCA	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-11.08	1.73e-25	1.66e-22	-0.36	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-11.08	1.73e-25	1.66e-22	-0.36	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
THCA	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-11.07	1.74e-25	1.68e-22	-0.58	-0.45	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
THCA	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	11.07	1.75e-25	1.68e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
THCA	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	11.07	1.75e-25	1.68e-22	0.45	0.45	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	11.07	1.76e-25	1.69e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	11.07	1.76e-25	1.69e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
THCA	cis	rs4591358	0.689	rs2173773	ENSG00000223466.1	AC064834.2	-11.07	1.77e-25	1.7e-22	-0.67	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549701	chr2:195533035~195538681:+
THCA	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-11.07	1.77e-25	1.7e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
THCA	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	11.07	1.77e-25	1.7e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	11.07	1.78e-25	1.71e-22	0.62	0.45	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	11.07	1.78e-25	1.71e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
THCA	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-11.07	1.8e-25	1.72e-22	-0.58	-0.45	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
THCA	cis	rs7772486	0.875	rs2073287	ENSG00000235652.6	RP11-545I5.3	11.07	1.81e-25	1.74e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145799409~145886585:+
THCA	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	11.07	1.81e-25	1.74e-22	0.66	0.45	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
THCA	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	11.07	1.82e-25	1.75e-22	0.59	0.45	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	11.07	1.83e-25	1.75e-22	0.62	0.45	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
THCA	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	11.07	1.83e-25	1.75e-22	0.88	0.45	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	11.07	1.83e-25	1.76e-22	0.53	0.45	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
THCA	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-11.07	1.83e-25	1.76e-22	-0.58	-0.45	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-11.07	1.83e-25	1.76e-22	-0.58	-0.45	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000273142.1	RP11-458F8.4	-11.07	1.84e-25	1.76e-22	-0.43	-0.45	Corneal structure;	chr7:66801919	chr7:66902857~66906297:+
THCA	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-11.07	1.84e-25	1.76e-22	-0.53	-0.45	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
THCA	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-11.07	1.84e-25	1.77e-22	-0.58	-0.45	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
THCA	cis	rs600231	0.665	rs1784859	ENSG00000245532.5	NEAT1	-11.07	1.85e-25	1.77e-22	-0.31	-0.45	Bone mineral density;	chr11:65453278	chr11:65422774~65445540:+
THCA	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	11.07	1.85e-25	1.78e-22	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
THCA	cis	rs6558530	0.666	rs11136422	ENSG00000253982.1	CTD-2336O2.1	11.07	1.85e-25	1.78e-22	0.44	0.45	Systolic blood pressure;	chr8:1747743	chr8:1761990~1764502:-
THCA	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-11.07	1.86e-25	1.79e-22	-0.47	-0.45	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-11.07	1.86e-25	1.79e-22	-0.47	-0.45	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
THCA	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	11.07	1.86e-25	1.79e-22	0.87	0.45	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.887	rs11155662	ENSG00000223701.3	RAET1E-AS1	11.07	1.87e-25	1.79e-22	0.63	0.45	Lung cancer;	chr6:149592731	chr6:149884431~149919508:+
THCA	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-11.07	1.88e-25	1.8e-22	-0.58	-0.45	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
THCA	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	11.07	1.88e-25	1.8e-22	0.54	0.45	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
THCA	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-11.06	1.89e-25	1.81e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-11.06	1.89e-25	1.81e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
THCA	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-11.06	1.89e-25	1.81e-22	-0.58	-0.45	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
THCA	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	11.06	1.9e-25	1.82e-22	0.59	0.45	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
THCA	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	11.06	1.9e-25	1.82e-22	0.88	0.45	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
THCA	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-11.06	1.9e-25	1.82e-22	-0.58	-0.45	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
THCA	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	11.06	1.92e-25	1.83e-22	0.61	0.45	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
THCA	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-11.06	1.92e-25	1.84e-22	-0.58	-0.45	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
THCA	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-11.06	1.95e-25	1.87e-22	-0.33	-0.45	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-11.06	1.96e-25	1.88e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
THCA	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-11.06	1.97e-25	1.89e-22	-0.51	-0.45	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
THCA	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-11.06	1.97e-25	1.89e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
THCA	cis	rs11159086	1	rs11626856	ENSG00000270000.1	RP3-449M8.9	11.06	1.98e-25	1.89e-22	0.5	0.45	Advanced glycation end-product levels;	chr14:74469665	chr14:74471930~74472360:-
THCA	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-11.06	1.98e-25	1.89e-22	-0.53	-0.45	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	11.06	1.99e-25	1.9e-22	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000223768.1	LINC00205	-11.06	1.99e-25	1.91e-22	-0.43	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45293285~45297354:+
THCA	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	11.06	2e-25	1.91e-22	0.6	0.45	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
THCA	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-11.06	2.01e-25	1.92e-22	-0.53	-0.45	Height;	chr3:52998472	chr3:53064283~53065091:-
THCA	cis	rs4591358	0.689	rs72927780	ENSG00000223466.1	AC064834.2	-11.06	2.04e-25	1.95e-22	-0.64	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548569	chr2:195533035~195538681:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	11.06	2.05e-25	1.96e-22	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
THCA	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	11.06	2.06e-25	1.97e-22	0.59	0.45	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
THCA	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-11.05	2.08e-25	1.99e-22	-0.6	-0.45	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
THCA	cis	rs9928842	0.771	rs4888363	ENSG00000280152.1	RP11-331F4.5	11.05	2.08e-25	1.99e-22	0.6	0.45	Alcoholic chronic pancreatitis;	chr16:75243446	chr16:75245994~75250077:-
THCA	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	11.05	2.08e-25	1.99e-22	0.43	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-11.05	2.1e-25	2e-22	-0.6	-0.45	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-11.05	2.1e-25	2e-22	-0.6	-0.45	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-11.05	2.1e-25	2e-22	-0.6	-0.45	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
THCA	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	11.05	2.1e-25	2.01e-22	0.74	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
THCA	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	11.05	2.1e-25	2.01e-22	0.74	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
THCA	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-11.05	2.1e-25	2.01e-22	-0.58	-0.45	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
THCA	cis	rs1185460	0.547	rs10892323	ENSG00000271751.1	RP11-110I1.14	11.05	2.11e-25	2.01e-22	0.57	0.45	Coronary artery disease;	chr11:119032048	chr11:119065263~119065677:-
THCA	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-11.05	2.12e-25	2.03e-22	-0.58	-0.45	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	11.05	2.12e-25	2.03e-22	0.58	0.45	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-11.05	2.12e-25	2.03e-22	-0.58	-0.45	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	11.05	2.14e-25	2.04e-22	0.61	0.45	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
THCA	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-11.05	2.16e-25	2.07e-22	-0.59	-0.45	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-11.05	2.16e-25	2.07e-22	-0.59	-0.45	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-11.05	2.16e-25	2.07e-22	-0.59	-0.45	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
THCA	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	11.05	2.17e-25	2.07e-22	0.55	0.45	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
THCA	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-11.05	2.19e-25	2.09e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	11.05	2.2e-25	2.1e-22	0.59	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
THCA	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
THCA	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
THCA	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
THCA	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	11.05	2.22e-25	2.12e-22	0.53	0.45	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	11.05	2.22e-25	2.12e-22	0.53	0.45	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
THCA	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-11.05	2.22e-25	2.12e-22	-0.77	-0.45	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
THCA	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	11.05	2.23e-25	2.13e-22	0.53	0.45	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	11.05	2.23e-25	2.13e-22	0.53	0.45	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
THCA	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-11.05	2.23e-25	2.13e-22	-0.6	-0.45	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-11.05	2.23e-25	2.13e-22	-0.6	-0.45	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-11.05	2.23e-25	2.13e-22	-0.6	-0.45	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
THCA	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-11.04	2.26e-25	2.16e-22	-0.36	-0.45	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
THCA	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-11.04	2.26e-25	2.16e-22	-0.36	-0.45	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
THCA	cis	rs9659323	0.65	rs10802064	ENSG00000231365.4	RP11-418J17.1	-11.04	2.29e-25	2.18e-22	-0.49	-0.45	Body mass index;	chr1:118915514	chr1:119140396~119275973:+
THCA	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	11.04	2.3e-25	2.19e-22	0.56	0.45	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
THCA	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-11.04	2.3e-25	2.19e-22	-0.36	-0.45	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
THCA	cis	rs934734	0.532	rs6752053	ENSG00000281920.1	RP11-418H16.1	-11.04	2.3e-25	2.19e-22	-0.54	-0.45	Rheumatoid arthritis;	chr2:65439540	chr2:65623272~65628424:+
THCA	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	11.04	2.31e-25	2.2e-22	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	11.04	2.31e-25	2.2e-22	0.65	0.45	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
THCA	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-11.04	2.31e-25	2.2e-22	-0.58	-0.45	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-11.04	2.31e-25	2.2e-22	-0.58	-0.45	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
THCA	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	11.04	2.32e-25	2.21e-22	0.6	0.45	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	11.04	2.32e-25	2.21e-22	0.6	0.45	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
THCA	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-11.04	2.33e-25	2.22e-22	-0.41	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
THCA	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-11.04	2.35e-25	2.23e-22	-0.42	-0.45	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
THCA	cis	rs1858037	0.867	rs871974	ENSG00000204929.10	AC074391.1	-11.04	2.35e-25	2.24e-22	-0.59	-0.45	Rheumatoid arthritis;	chr2:65330153	chr2:65436711~66084639:+
THCA	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	11.04	2.36e-25	2.25e-22	0.55	0.45	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
THCA	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-11.04	2.37e-25	2.25e-22	-0.6	-0.45	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
THCA	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-11.04	2.37e-25	2.26e-22	-0.66	-0.45	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
THCA	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	11.04	2.38e-25	2.26e-22	0.62	0.45	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
THCA	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	11.04	2.38e-25	2.26e-22	0.6	0.45	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-11.04	2.38e-25	2.26e-22	-0.6	-0.45	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
THCA	cis	rs916888	0.687	rs199456	ENSG00000232300.1	FAM215B	11.04	2.4e-25	2.28e-22	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46558830~46562795:-
THCA	cis	rs916888	0.773	rs199451	ENSG00000232300.1	FAM215B	11.04	2.4e-25	2.28e-22	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46558830~46562795:-
THCA	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-11.04	2.43e-25	2.31e-22	-0.53	-0.45	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
THCA	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-11.04	2.44e-25	2.32e-22	-0.66	-0.45	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
THCA	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	11.04	2.45e-25	2.33e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	11.04	2.45e-25	2.33e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
THCA	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	11.04	2.47e-25	2.34e-22	0.49	0.45	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
THCA	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	11.03	2.48e-25	2.35e-22	0.6	0.45	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
THCA	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-11.03	2.48e-25	2.36e-22	-0.58	-0.45	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
THCA	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-11.03	2.48e-25	2.36e-22	-0.58	-0.45	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
THCA	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-11.03	2.48e-25	2.36e-22	-0.58	-0.45	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
THCA	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-11.03	2.49e-25	2.37e-22	-0.53	-0.45	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
THCA	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-11.03	2.51e-25	2.38e-22	-0.55	-0.45	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
THCA	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-11.03	2.53e-25	2.4e-22	-0.53	-0.45	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
THCA	cis	rs7569084	0.687	rs1370394	ENSG00000237979.1	AC007389.1	11.03	2.53e-25	2.4e-22	0.54	0.45	Sum eosinophil basophil counts;	chr2:65453176	chr2:65500993~65502138:-
THCA	cis	rs1976403	0.633	rs1780322	ENSG00000227001.3	NBPF2P	11.03	2.55e-25	2.42e-22	0.51	0.45	Liver enzyme levels (alkaline phosphatase);	chr1:21496583	chr1:21424625~21427967:-
THCA	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-11.03	2.57e-25	2.44e-22	-0.42	-0.45	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
THCA	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	11.03	2.58e-25	2.45e-22	0.63	0.45	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
THCA	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-11.03	2.58e-25	2.45e-22	-0.42	-0.45	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
THCA	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	11.03	2.58e-25	2.45e-22	0.55	0.45	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
THCA	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-11.03	2.59e-25	2.45e-22	-0.73	-0.45	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
THCA	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	11.03	2.6e-25	2.47e-22	0.62	0.45	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
THCA	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	11.03	2.62e-25	2.48e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
THCA	cis	rs4964805	0.865	rs35371470	ENSG00000257681.1	RP11-341G23.4	11.03	2.67e-25	2.53e-22	0.54	0.45	Attention deficit hyperactivity disorder;	chr12:103809942	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.865	rs4964289	ENSG00000257681.1	RP11-341G23.4	11.03	2.67e-25	2.53e-22	0.54	0.45	Attention deficit hyperactivity disorder;	chr12:103810413	chr12:103746315~103768858:-
THCA	cis	rs6452524	0.837	rs1479569	ENSG00000249664.1	CTD-2227C6.2	11.03	2.67e-25	2.53e-22	0.59	0.45	Hypertension (SNP x SNP interaction);	chr5:83081747	chr5:83012285~83013109:-
THCA	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	11.03	2.67e-25	2.53e-22	0.59	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
THCA	cis	rs860295	0.702	rs10908470	ENSG00000225855.5	RUSC1-AS1	11.03	2.68e-25	2.54e-22	0.32	0.45	Body mass index;	chr1:155557222	chr1:155316863~155324176:-
THCA	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	11.03	2.69e-25	2.54e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
THCA	cis	rs12468226	0.938	rs1474002	ENSG00000273456.1	RP11-686O6.2	11.03	2.7e-25	2.55e-22	0.51	0.45	Urate levels;	chr2:202290195	chr2:202374932~202375604:-
THCA	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	11.02	2.7e-25	2.55e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
THCA	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	11.02	2.73e-25	2.58e-22	0.62	0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
THCA	cis	rs4591358	0.689	rs6760142	ENSG00000223466.1	AC064834.2	-11.02	2.73e-25	2.58e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553911	chr2:195533035~195538681:+
THCA	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-11.02	2.75e-25	2.6e-22	-0.56	-0.45	Height;	chr3:53015087	chr3:53064283~53065091:-
THCA	cis	rs4819052	0.679	rs28623526	ENSG00000223768.1	LINC00205	-11.02	2.8e-25	2.65e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45293285~45297354:+
THCA	cis	rs4591358	0.689	rs55876968	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549015	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs55974440	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549056	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs12471810	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549969	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs2133860	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195551243	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs6759817	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553739	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs6434785	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195554142	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.638	rs16837243	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195556458	chr2:195533035~195538681:+
THCA	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-11.02	2.81e-25	2.66e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
THCA	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-11.02	2.83e-25	2.68e-22	-0.39	-0.45	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
THCA	cis	rs9659323	0.539	rs1750331	ENSG00000231365.4	RP11-418J17.1	-11.02	2.84e-25	2.68e-22	-0.46	-0.45	Body mass index;	chr1:118952350	chr1:119140396~119275973:+
THCA	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	11.02	2.84e-25	2.69e-22	0.63	0.45	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
THCA	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	11.02	2.89e-25	2.73e-22	0.55	0.45	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
THCA	cis	rs17111396	0.627	rs72689920	ENSG00000259167.2	NMNAT1P1	11.02	2.91e-25	2.75e-22	0.74	0.45	Uric acid levels;	chr14:81037364	chr14:81032529~81033404:+
THCA	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-11.02	2.93e-25	2.77e-22	-0.6	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
THCA	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-11.02	2.94e-25	2.78e-22	-0.34	-0.45	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-11.02	2.94e-25	2.78e-22	-0.34	-0.45	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-11.02	2.94e-25	2.78e-22	-0.34	-0.45	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
THCA	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	11.02	2.94e-25	2.78e-22	0.52	0.45	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
THCA	cis	rs916888	0.773	rs199457	ENSG00000232300.1	FAM215B	11.01	2.96e-25	2.8e-22	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46558830~46562795:-
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000235689.1	AP000351.13	11.01	2.96e-25	2.8e-22	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:24006305~24008258:-
THCA	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-11.01	2.99e-25	2.82e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-11.01	2.99e-25	2.82e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-11.01	2.99e-25	2.82e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
THCA	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-11.01	2.99e-25	2.82e-22	-0.49	-0.45	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
THCA	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-11.01	3e-25	2.83e-22	-0.82	-0.45	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000223768.1	LINC00205	-11.01	3e-25	2.83e-22	-0.43	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000223768.1	LINC00205	-11.01	3e-25	2.83e-22	-0.43	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45293285~45297354:+
THCA	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	11.01	3.01e-25	2.84e-22	0.55	0.45	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	11.01	3.01e-25	2.84e-22	0.55	0.45	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
THCA	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	11.01	3.03e-25	2.86e-22	0.62	0.45	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	11.01	3.03e-25	2.86e-22	0.54	0.45	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
THCA	cis	rs9659323	0.7	rs2885226	ENSG00000231365.4	RP11-418J17.1	-11.01	3.05e-25	2.88e-22	-0.45	-0.45	Body mass index;	chr1:119081540	chr1:119140396~119275973:+
THCA	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-11.01	3.05e-25	2.88e-22	-0.53	-0.45	Height;	chr3:52994045	chr3:53064283~53065091:-
THCA	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-11.01	3.05e-25	2.88e-22	-0.53	-0.45	Height;	chr3:52994990	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	11.01	3.06e-25	2.89e-22	0.65	0.45	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
THCA	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-11.01	3.06e-25	2.89e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
THCA	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-11.01	3.07e-25	2.9e-22	-0.49	-0.45	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
THCA	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	11.01	3.09e-25	2.92e-22	0.61	0.45	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
THCA	cis	rs916888	0.773	rs199445	ENSG00000232300.1	FAM215B	11.01	3.11e-25	2.93e-22	0.73	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46558830~46562795:-
THCA	cis	rs916888	0.773	rs199443	ENSG00000232300.1	FAM215B	11.01	3.11e-25	2.93e-22	0.73	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46558830~46562795:-
THCA	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-11.01	3.13e-25	2.95e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-11.01	3.13e-25	2.95e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-11.01	3.13e-25	2.95e-22	-0.6	-0.45	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
THCA	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-11.01	3.14e-25	2.96e-22	-0.59	-0.45	QT interval;	chr16:28824579	chr16:28700294~28701540:-
THCA	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	11.01	3.15e-25	2.97e-22	0.88	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
THCA	cis	rs7772486	0.875	rs9390371	ENSG00000235652.6	RP11-545I5.3	11.01	3.16e-25	2.97e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs6909827	ENSG00000235652.6	RP11-545I5.3	11.01	3.16e-25	2.97e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-11.01	3.19e-25	3.01e-22	-0.57	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
THCA	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-11.01	3.21e-25	3.02e-22	-0.6	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
THCA	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-11.01	3.21e-25	3.02e-22	-0.58	-0.45	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
THCA	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-11.01	3.21e-25	3.02e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
THCA	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-11	3.24e-25	3.05e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-11	3.26e-25	3.07e-22	-0.55	-0.45	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
THCA	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-11	3.26e-25	3.07e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
THCA	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-11	3.26e-25	3.07e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
THCA	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-11	3.26e-25	3.07e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
THCA	cis	rs62158211	0.691	rs1964463	ENSG00000234997.1	AC016745.3	11	3.28e-25	3.09e-22	0.51	0.45	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113311444	chr2:113424495~113425324:+
THCA	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	11	3.3e-25	3.1e-22	0.46	0.45	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000206090.4	AP000350.7	11	3.33e-25	3.13e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23939998~23942798:+
THCA	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-11	3.34e-25	3.14e-22	-0.46	-0.45	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
THCA	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-11	3.39e-25	3.19e-22	-0.57	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
THCA	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	11	3.41e-25	3.21e-22	0.87	0.45	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
THCA	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-11	3.42e-25	3.22e-22	-0.55	-0.45	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
THCA	cis	rs934734	0.673	rs7575614	ENSG00000281920.1	RP11-418H16.1	11	3.44e-25	3.23e-22	0.54	0.45	Rheumatoid arthritis;	chr2:65462666	chr2:65623272~65628424:+
THCA	cis	rs934734	0.673	rs6742215	ENSG00000281920.1	RP11-418H16.1	11	3.44e-25	3.23e-22	0.54	0.45	Rheumatoid arthritis;	chr2:65463362	chr2:65623272~65628424:+
THCA	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-11	3.45e-25	3.24e-22	-0.53	-0.45	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
THCA	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-11	3.45e-25	3.24e-22	-0.53	-0.45	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
THCA	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	11	3.49e-25	3.28e-22	0.55	0.45	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	11	3.49e-25	3.28e-22	0.55	0.45	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
THCA	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-11	3.51e-25	3.29e-22	-0.55	-0.45	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
THCA	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	10.99	3.52e-25	3.31e-22	0.6	0.45	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
THCA	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-10.99	3.56e-25	3.34e-22	-0.66	-0.45	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-10.99	3.56e-25	3.34e-22	-0.66	-0.45	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
THCA	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-10.99	3.56e-25	3.34e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
THCA	cis	rs6496932	0.663	rs7182814	ENSG00000218052.5	ADAMTS7P4	-10.99	3.59e-25	3.37e-22	-0.58	-0.45	Central corneal thickness;Corneal structure;	chr15:85362840	chr15:85255369~85330334:-
THCA	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-10.99	3.61e-25	3.39e-22	-0.53	-0.45	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-10.99	3.61e-25	3.39e-22	-0.53	-0.45	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-10.99	3.61e-25	3.39e-22	-0.53	-0.45	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-10.99	3.61e-25	3.39e-22	-0.53	-0.45	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
THCA	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	10.99	3.61e-25	3.39e-22	0.53	0.45	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	10.99	3.61e-25	3.39e-22	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
THCA	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-10.99	3.62e-25	3.4e-22	-0.61	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
THCA	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	10.99	3.62e-25	3.4e-22	0.61	0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
THCA	cis	rs4266144	0.821	rs4325879	ENSG00000244515.1	KRT18P34	-10.99	3.63e-25	3.41e-22	-0.56	-0.45	Coronary artery disease;	chr3:157134195	chr3:157162663~157163932:-
THCA	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-10.99	3.65e-25	3.43e-22	-0.6	-0.45	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-10.99	3.67e-25	3.44e-22	-0.6	-0.45	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
THCA	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-10.99	3.67e-25	3.45e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
THCA	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	10.99	3.7e-25	3.47e-22	0.62	0.45	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
THCA	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-10.99	3.7e-25	3.47e-22	-0.34	-0.45	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
THCA	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-10.99	3.71e-25	3.48e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
THCA	cis	rs7772486	0.748	rs2748484	ENSG00000235652.6	RP11-545I5.3	10.99	3.71e-25	3.48e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	10.99	3.72e-25	3.49e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	10.99	3.72e-25	3.49e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
THCA	cis	rs934734	0.532	rs7569113	ENSG00000281920.1	RP11-418H16.1	10.99	3.74e-25	3.51e-22	0.55	0.45	Rheumatoid arthritis;	chr2:65429907	chr2:65623272~65628424:+
THCA	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-10.99	3.75e-25	3.52e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
THCA	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	10.99	3.78e-25	3.54e-22	0.37	0.45	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
THCA	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	10.99	3.79e-25	3.56e-22	0.52	0.45	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	10.99	3.79e-25	3.56e-22	0.52	0.45	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
THCA	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-10.99	3.8e-25	3.56e-22	-0.59	-0.45	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-10.99	3.81e-25	3.58e-22	-0.6	-0.45	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
THCA	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-10.99	3.82e-25	3.58e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
THCA	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-10.99	3.82e-25	3.58e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-10.99	3.82e-25	3.58e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
THCA	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	10.99	3.82e-25	3.58e-22	0.47	0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
THCA	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-10.99	3.83e-25	3.59e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
THCA	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-10.98	3.84e-25	3.6e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
THCA	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	10.98	3.85e-25	3.61e-22	0.55	0.45	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	10.98	3.85e-25	3.61e-22	0.55	0.45	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
THCA	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-10.98	3.88e-25	3.64e-22	-0.66	-0.45	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
THCA	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-10.98	3.89e-25	3.65e-22	-0.54	-0.45	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
THCA	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-10.98	3.91e-25	3.66e-22	-0.56	-0.45	Height;	chr3:53009621	chr3:53064283~53065091:-
THCA	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	10.98	3.94e-25	3.69e-22	0.52	0.45	Height;	chr6:109367528	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	10.98	3.94e-25	3.69e-22	0.52	0.45	Height;	chr6:109368704	chr6:109382795~109383666:+
THCA	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-10.98	3.94e-25	3.69e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-10.98	3.94e-25	3.69e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
THCA	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	10.98	3.97e-25	3.72e-22	0.54	0.45	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
THCA	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-10.98	3.98e-25	3.73e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
THCA	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	10.98	4.02e-25	3.76e-22	0.62	0.45	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	10.98	4.02e-25	3.76e-22	0.62	0.45	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	10.98	4.02e-25	3.76e-22	0.62	0.45	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
THCA	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-10.98	4.02e-25	3.76e-22	-0.66	-0.45	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-10.98	4.02e-25	3.76e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-10.98	4.02e-25	3.76e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
THCA	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	10.98	4.07e-25	3.81e-22	0.6	0.45	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	10.98	4.07e-25	3.81e-22	0.6	0.45	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
THCA	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	10.98	4.07e-25	3.81e-22	0.88	0.45	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	10.98	4.1e-25	3.84e-22	0.62	0.45	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
THCA	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	10.98	4.11e-25	3.85e-22	0.59	0.45	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
THCA	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-10.97	4.2e-25	3.93e-22	-0.58	-0.45	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-10.97	4.2e-25	3.93e-22	-0.58	-0.45	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
THCA	cis	rs748404	0.578	rs2584701	ENSG00000249839.1	AC011330.5	-10.97	4.21e-25	3.94e-22	-0.54	-0.45	Lung cancer;	chr15:43392741	chr15:43663654~43684339:-
THCA	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-10.97	4.22e-25	3.94e-22	-0.59	-0.45	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
THCA	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	10.97	4.24e-25	3.96e-22	0.83	0.45	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
THCA	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-10.97	4.25e-25	3.97e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-10.97	4.25e-25	3.97e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000223768.1	LINC00205	-10.97	4.26e-25	3.99e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45293285~45297354:+
THCA	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-10.97	4.28e-25	4e-22	-0.59	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-10.97	4.28e-25	4e-22	-0.59	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-10.97	4.28e-25	4e-22	-0.61	-0.45	Depression;	chr6:28206179	chr6:28115628~28116551:+
THCA	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	10.97	4.29e-25	4.01e-22	0.59	0.45	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
THCA	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	10.97	4.29e-25	4.01e-22	0.48	0.45	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	10.97	4.29e-25	4.01e-22	0.48	0.45	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	10.97	4.29e-25	4.01e-22	0.48	0.45	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
THCA	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-10.97	4.32e-25	4.03e-22	-0.39	-0.45	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs385524	ENSG00000251136.7	RP11-37B2.1	-10.97	4.32e-25	4.03e-22	-0.39	-0.45	Leprosy;	chr8:89754242	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-10.97	4.32e-25	4.03e-22	-0.39	-0.45	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
THCA	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	10.97	4.33e-25	4.05e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
THCA	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-10.97	4.34e-25	4.06e-22	-0.6	-0.45	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
THCA	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-10.97	4.35e-25	4.06e-22	-0.39	-0.45	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
THCA	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-10.97	4.35e-25	4.06e-22	-0.42	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
THCA	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-10.97	4.36e-25	4.07e-22	-0.66	-0.45	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
THCA	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-10.97	4.37e-25	4.08e-22	-0.33	-0.45	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
THCA	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	10.97	4.39e-25	4.1e-22	0.57	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
THCA	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-10.97	4.42e-25	4.13e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000224205.1	AP000351.4	10.97	4.47e-25	4.17e-22	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23987320~23991421:-
THCA	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-10.97	4.49e-25	4.19e-22	-0.59	-0.45	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-10.97	4.49e-25	4.19e-22	-0.59	-0.45	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
THCA	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	10.97	4.5e-25	4.2e-22	0.54	0.45	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
THCA	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	10.97	4.51e-25	4.21e-22	0.52	0.45	Height;	chr6:109391084	chr6:109382795~109383666:+
THCA	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-10.97	4.51e-25	4.21e-22	-0.59	-0.45	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
THCA	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs10112852	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89749257	chr8:89609409~89757727:-
THCA	cis	rs42490	0.934	rs10095743	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89749445	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	10.97	4.51e-25	4.21e-22	0.39	0.45	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	10.97	4.51e-25	4.21e-22	0.39	0.45	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
THCA	cis	rs2599510	0.783	rs13399071	ENSG00000276334.1	AL133243.1	10.97	4.52e-25	4.22e-22	0.5	0.45	Interleukin-18 levels;	chr2:32568716	chr2:32521927~32523547:+
THCA	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-10.97	4.54e-25	4.23e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
THCA	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	10.97	4.55e-25	4.24e-22	0.57	0.45	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
THCA	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	10.97	4.56e-25	4.25e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	10.97	4.56e-25	4.25e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-10.97	4.57e-25	4.26e-22	-0.59	-0.45	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-10.97	4.57e-25	4.26e-22	-0.59	-0.45	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.875	rs2814866	ENSG00000235652.6	RP11-545I5.3	10.96	4.58e-25	4.27e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2328712	ENSG00000235652.6	RP11-545I5.3	10.96	4.58e-25	4.27e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145799409~145886585:+
THCA	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-10.96	4.61e-25	4.3e-22	-0.41	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
THCA	cis	rs11159086	0.793	rs10139029	ENSG00000270000.1	RP3-449M8.9	10.96	4.62e-25	4.3e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74492284	chr14:74471930~74472360:-
THCA	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-10.96	4.63e-25	4.31e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
THCA	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-10.96	4.65e-25	4.34e-22	-0.59	-0.45	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
THCA	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	10.96	4.67e-25	4.35e-22	0.81	0.45	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
THCA	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	10.96	4.67e-25	4.35e-22	0.81	0.45	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
THCA	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	10.96	4.68e-25	4.36e-22	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
THCA	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-10.96	4.68e-25	4.36e-22	-0.59	-0.45	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-10.96	4.68e-25	4.36e-22	-0.59	-0.45	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
THCA	cis	rs11159086	1	rs17100451	ENSG00000270000.1	RP3-449M8.9	10.96	4.69e-25	4.37e-22	0.5	0.45	Advanced glycation end-product levels;	chr14:74476210	chr14:74471930~74472360:-
THCA	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-10.96	4.7e-25	4.38e-22	-0.59	-0.45	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-10.96	4.7e-25	4.38e-22	-0.59	-0.45	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
THCA	cis	rs860295	0.702	rs10752611	ENSG00000225855.5	RUSC1-AS1	10.96	4.71e-25	4.39e-22	0.32	0.45	Body mass index;	chr1:155539316	chr1:155316863~155324176:-
THCA	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-10.96	4.71e-25	4.39e-22	-0.72	-0.45	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-10.96	4.71e-25	4.39e-22	-0.72	-0.45	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-10.96	4.71e-25	4.39e-22	-0.72	-0.45	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
THCA	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	10.96	4.77e-25	4.44e-22	0.58	0.45	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
THCA	cis	rs11159086	0.793	rs10136668	ENSG00000270000.1	RP3-449M8.9	10.96	4.8e-25	4.47e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74492183	chr14:74471930~74472360:-
THCA	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-10.96	4.81e-25	4.48e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
THCA	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	10.96	4.84e-25	4.5e-22	0.55	0.45	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
THCA	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	10.96	4.85e-25	4.52e-22	0.48	0.45	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
THCA	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-10.96	4.86e-25	4.53e-22	-0.41	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
THCA	cis	rs7576126	1	rs7576126	ENSG00000281920.1	RP11-418H16.1	-10.96	4.87e-25	4.53e-22	-0.54	-0.45	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65623272~65628424:+
THCA	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-10.96	4.92e-25	4.57e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
THCA	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-10.96	4.92e-25	4.57e-22	-0.6	-0.45	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
THCA	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-10.96	4.93e-25	4.58e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
THCA	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	10.96	4.93e-25	4.58e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
THCA	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	10.96	4.93e-25	4.58e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
THCA	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-10.96	4.93e-25	4.59e-22	-0.71	-0.45	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
THCA	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-10.96	4.95e-25	4.61e-22	-0.67	-0.45	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
THCA	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-10.96	4.97e-25	4.62e-22	-0.8	-0.45	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
THCA	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-10.96	4.98e-25	4.64e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
THCA	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-10.95	5e-25	4.65e-22	-0.46	-0.45	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
THCA	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	10.95	5.07e-25	4.71e-22	0.45	0.45	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
THCA	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	10.95	5.1e-25	4.74e-22	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000223768.1	LINC00205	-10.95	5.14e-25	4.78e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45293285~45297354:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	10.95	5.16e-25	4.79e-22	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
THCA	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-10.95	5.16e-25	4.8e-22	-0.42	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
THCA	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-10.95	5.17e-25	4.8e-22	-0.61	-0.45	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-10.95	5.19e-25	4.83e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
THCA	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-10.95	5.2e-25	4.84e-22	-0.53	-0.45	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
THCA	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-10.95	5.2e-25	4.84e-22	-0.56	-0.45	Height;	chr3:53029854	chr3:53064283~53065091:-
THCA	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-10.95	5.25e-25	4.87e-22	-0.59	-0.45	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000223768.1	LINC00205	-10.95	5.27e-25	4.89e-22	-0.43	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45293285~45297354:+
THCA	cis	rs6964833	0.873	rs4717905	ENSG00000123965.13	PMS2P5	10.95	5.27e-25	4.9e-22	0.78	0.45	Menarche (age at onset);	chr7:74668903	chr7:74894116~74897835:+
THCA	cis	rs7772486	0.875	rs7739418	ENSG00000235652.6	RP11-545I5.3	10.95	5.28e-25	4.91e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-10.95	5.34e-25	4.96e-22	-0.59	-0.45	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
THCA	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-10.95	5.36e-25	4.98e-22	-0.59	-0.45	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
THCA	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	10.95	5.36e-25	4.98e-22	0.47	0.45	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
THCA	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-10.95	5.37e-25	4.99e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
THCA	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	10.95	5.4e-25	5.01e-22	0.57	0.45	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	10.95	5.42e-25	5.03e-22	0.52	0.45	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
THCA	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-10.94	5.46e-25	5.07e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
THCA	cis	rs3745672	1	rs76403598	ENSG00000219665.7	CTD-2006C1.2	-10.94	5.46e-25	5.07e-22	-1	-0.45	Multiple sclerosis;	chr19:12055367	chr19:11987617~12046275:+
THCA	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-10.94	5.48e-25	5.08e-22	-0.58	-0.45	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
THCA	cis	rs4819052	0.851	rs8126930	ENSG00000223768.1	LINC00205	-10.94	5.52e-25	5.13e-22	-0.41	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45293285~45297354:+
THCA	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	10.94	5.52e-25	5.13e-22	0.51	0.45	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
THCA	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-10.94	5.54e-25	5.14e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
THCA	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-10.94	5.54e-25	5.14e-22	-0.57	-0.45	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
THCA	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-10.94	5.6e-25	5.2e-22	-0.51	-0.45	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
THCA	cis	rs4964805	0.865	rs67825151	ENSG00000257681.1	RP11-341G23.4	10.94	5.61e-25	5.21e-22	0.54	0.45	Attention deficit hyperactivity disorder;	chr12:103811666	chr12:103746315~103768858:-
THCA	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-10.94	5.66e-25	5.25e-22	-0.58	-0.45	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
THCA	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-10.94	5.69e-25	5.28e-22	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-10.94	5.69e-25	5.28e-22	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-10.94	5.69e-25	5.28e-22	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-10.94	5.69e-25	5.28e-22	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
THCA	cis	rs944289	0.617	rs11156905	ENSG00000257826.1	RP11-116N8.4	-10.94	5.71e-25	5.29e-22	-0.48	-0.45	Thyroid cancer;	chr14:36100314	chr14:36061026~36067190:-
THCA	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-10.94	5.71e-25	5.29e-22	-0.35	-0.45	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
THCA	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-10.94	5.71e-25	5.29e-22	-0.35	-0.45	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-10.94	5.71e-25	5.29e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
THCA	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-10.94	5.71e-25	5.29e-22	-0.35	-0.45	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
THCA	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	10.94	5.77e-25	5.34e-22	0.54	0.45	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
THCA	cis	rs7569084	0.687	rs35839762	ENSG00000237979.1	AC007389.1	10.94	5.8e-25	5.37e-22	0.53	0.45	Sum eosinophil basophil counts;	chr2:65441318	chr2:65500993~65502138:-
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000223768.1	LINC00205	-10.94	5.8e-25	5.37e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45293285~45297354:+
THCA	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-10.94	5.8e-25	5.37e-22	-0.47	-0.45	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
THCA	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-10.94	5.8e-25	5.38e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
THCA	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-10.94	5.82e-25	5.39e-22	-0.66	-0.45	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
THCA	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-10.94	5.83e-25	5.4e-22	-0.57	-0.45	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
THCA	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-10.94	5.83e-25	5.41e-22	-0.53	-0.45	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
THCA	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-10.94	5.83e-25	5.41e-22	-0.53	-0.45	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
THCA	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	10.94	5.85e-25	5.42e-22	0.52	0.45	Height;	chr6:109374782	chr6:109382795~109383666:+
THCA	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-10.94	5.85e-25	5.42e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
THCA	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-10.94	5.89e-25	5.45e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
THCA	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	10.94	5.91e-25	5.48e-22	0.61	0.45	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	10.94	5.91e-25	5.48e-22	0.61	0.45	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
THCA	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	10.94	5.92e-25	5.49e-22	0.65	0.45	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
THCA	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	10.94	5.92e-25	5.49e-22	0.65	0.45	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
THCA	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	10.94	5.92e-25	5.49e-22	0.65	0.45	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
THCA	cis	rs10256972	0.9	rs4388364	ENSG00000229043.2	AC091729.9	-10.94	5.93e-25	5.49e-22	-0.48	-0.45	Endometriosis;Longevity;	chr7:993409	chr7:1160374~1165267:+
THCA	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-10.94	5.94e-25	5.5e-22	-0.59	-0.45	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
THCA	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-10.93	5.97e-25	5.53e-22	-0.48	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
THCA	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	10.93	5.98e-25	5.54e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
THCA	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	10.93	5.98e-25	5.54e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
THCA	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-10.93	5.98e-25	5.54e-22	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
THCA	cis	rs944289	0.617	rs1952708	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36113126	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs12432682	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36114058	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs7156229	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36114780	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs7156269	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36114849	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs2415314	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36115335	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs1159048	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36115428	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs1475715	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36116017	chr14:36061026~36067190:-
THCA	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	10.93	6.04e-25	5.59e-22	0.57	0.45	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	10.93	6.07e-25	5.61e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
THCA	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	10.93	6.14e-25	5.68e-22	0.8	0.45	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
THCA	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	10.93	6.18e-25	5.71e-22	0.57	0.45	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
THCA	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-10.93	6.18e-25	5.72e-22	-0.59	-0.45	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	10.93	6.22e-25	5.75e-22	0.65	0.45	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
THCA	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	10.93	6.23e-25	5.76e-22	0.59	0.45	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-10.93	6.23e-25	5.76e-22	-0.59	-0.45	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
THCA	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-10.93	6.24e-25	5.77e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
THCA	cis	rs10246939	0.544	rs2163953	ENSG00000228775.6	WEE2-AS1	10.93	6.27e-25	5.79e-22	0.53	0.45	Bitter taste perception;	chr7:141867769	chr7:141704338~141738346:-
THCA	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-10.93	6.27e-25	5.8e-22	-0.58	-0.45	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
THCA	cis	rs3002131	0.604	rs1319392	ENSG00000225265.1	TAF1A-AS1	-10.93	6.28e-25	5.8e-22	-0.6	-0.45	Interleukin-10 levels;	chr1:222567271	chr1:222589825~222593032:+
THCA	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-10.93	6.28e-25	5.8e-22	-0.59	-0.45	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
THCA	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-10.93	6.29e-25	5.81e-22	-0.59	-0.45	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
THCA	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-10.93	6.29e-25	5.81e-22	-0.59	-0.45	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
THCA	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-10.93	6.33e-25	5.85e-22	-0.66	-0.45	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
THCA	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-10.93	6.36e-25	5.88e-22	-0.67	-0.45	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
THCA	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-10.93	6.38e-25	5.9e-22	-0.59	-0.45	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
THCA	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-10.93	6.41e-25	5.92e-22	-0.59	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
THCA	cis	rs6558530	0.666	rs4242539	ENSG00000253982.1	CTD-2336O2.1	10.93	6.43e-25	5.94e-22	0.43	0.45	Systolic blood pressure;	chr8:1746070	chr8:1761990~1764502:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	10.93	6.43e-25	5.94e-22	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
THCA	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	10.93	6.44e-25	5.94e-22	0.65	0.45	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
THCA	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	10.93	6.45e-25	5.95e-22	0.59	0.45	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	10.93	6.45e-25	5.95e-22	0.61	0.45	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
THCA	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-10.93	6.45e-25	5.96e-22	-0.51	-0.45	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
THCA	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-10.93	6.49e-25	5.99e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
THCA	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	10.93	6.49e-25	5.99e-22	0.42	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-10.93	6.5e-25	6e-22	-0.6	-0.45	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	10.92	6.53e-25	6.03e-22	0.6	0.45	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
THCA	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	10.92	6.54e-25	6.04e-22	0.51	0.45	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
THCA	cis	rs4591358	0.648	rs6732306	ENSG00000223466.1	AC064834.2	-10.92	6.56e-25	6.06e-22	-0.64	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541396	chr2:195533035~195538681:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000223768.1	LINC00205	-10.92	6.64e-25	6.12e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45293285~45297354:+
THCA	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-10.92	6.67e-25	6.15e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-10.92	6.67e-25	6.15e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
THCA	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-10.92	6.67e-25	6.15e-22	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
THCA	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-10.92	6.67e-25	6.15e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	10.92	6.68e-25	6.16e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	10.92	6.68e-25	6.16e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	10.92	6.68e-25	6.16e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
THCA	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-10.92	6.7e-25	6.18e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
THCA	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-10.92	6.73e-25	6.2e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-10.92	6.73e-25	6.2e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
THCA	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-10.92	6.81e-25	6.27e-22	-0.56	-0.45	Height;	chr3:53007328	chr3:53064283~53065091:-
THCA	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	10.92	6.86e-25	6.32e-22	0.53	0.45	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
THCA	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	10.92	6.87e-25	6.33e-22	0.87	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
THCA	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	10.92	6.88e-25	6.34e-22	0.52	0.45	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	10.92	6.88e-25	6.34e-22	0.52	0.45	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
THCA	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	10.92	6.92e-25	6.37e-22	0.53	0.45	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	10.92	6.92e-25	6.38e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	10.92	6.92e-25	6.38e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
THCA	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	10.92	6.95e-25	6.4e-22	0.54	0.45	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000223768.1	LINC00205	10.92	7e-25	6.45e-22	0.42	0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45293285~45297354:+
THCA	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-10.92	7.09e-25	6.52e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
THCA	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-10.91	7.1e-25	6.54e-22	-0.39	-0.45	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
THCA	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-10.91	7.13e-25	6.56e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
THCA	cis	rs860295	0.665	rs12028416	ENSG00000225855.5	RUSC1-AS1	10.91	7.15e-25	6.58e-22	0.31	0.45	Body mass index;	chr1:155431370	chr1:155316863~155324176:-
THCA	cis	rs860295	0.629	rs12026638	ENSG00000225855.5	RUSC1-AS1	10.91	7.15e-25	6.58e-22	0.31	0.45	Body mass index;	chr1:155431469	chr1:155316863~155324176:-
THCA	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-10.91	7.2e-25	6.63e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
THCA	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	10.91	7.21e-25	6.64e-22	0.6	0.45	Depression;	chr6:28200948	chr6:28115628~28116551:+
THCA	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-10.91	7.23e-25	6.65e-22	-0.6	-0.45	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-10.91	7.23e-25	6.65e-22	-0.6	-0.45	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
THCA	cis	rs465969	1	rs34382476	ENSG00000255389.1	C6orf3	-10.91	7.27e-25	6.69e-22	-0.8	-0.45	Psoriasis;	chr6:111423551	chr6:111599875~111602295:+
THCA	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	10.91	7.3e-25	6.71e-22	0.54	0.45	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
THCA	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
THCA	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	10.91	7.32e-25	6.73e-22	0.54	0.45	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
THCA	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-10.91	7.34e-25	6.75e-22	-0.52	-0.45	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
THCA	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-10.91	7.47e-25	6.86e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
THCA	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	10.91	7.54e-25	6.92e-22	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
THCA	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	10.91	7.6e-25	6.98e-22	0.62	0.45	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
THCA	cis	rs4591358	0.689	rs1913894	ENSG00000223466.1	AC064834.2	-10.91	7.61e-25	6.99e-22	-0.67	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195534032	chr2:195533035~195538681:+
THCA	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28193021	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28197321	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28197412	chr6:28115628~28116551:+
THCA	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28198669	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	10.91	7.62e-25	6.99e-22	0.6	0.45	Depression;	chr6:28199145	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28205175	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	10.91	7.62e-25	6.99e-22	0.6	0.45	Depression;	chr6:28205232	chr6:28115628~28116551:+
THCA	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-10.91	7.62e-25	6.99e-22	-0.66	-0.45	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-10.91	7.62e-25	6.99e-22	-0.66	-0.45	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
THCA	cis	rs12468226	0.882	rs116437099	ENSG00000273456.1	RP11-686O6.2	10.91	7.62e-25	7e-22	0.53	0.45	Urate levels;	chr2:202299250	chr2:202374932~202375604:-
THCA	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	10.91	7.65e-25	7.02e-22	0.61	0.45	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-10.91	7.7e-25	7.07e-22	-0.6	-0.45	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
THCA	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-10.91	7.72e-25	7.09e-22	-0.55	-0.45	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	10.91	7.72e-25	7.09e-22	0.6	0.45	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
THCA	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
THCA	cis	rs2658782	0.547	rs2085334	ENSG00000279684.1	RP11-755E23.2	-10.9	7.78e-25	7.14e-22	-0.64	-0.45	Pulmonary function decline;	chr11:93447884	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-10.9	7.8e-25	7.15e-22	-0.59	-0.45	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
THCA	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-10.9	7.86e-25	7.21e-22	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
THCA	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-10.9	7.93e-25	7.26e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
THCA	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-10.9	7.96e-25	7.29e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
THCA	cis	rs916888	0.773	rs199535	ENSG00000232300.1	FAM215B	10.9	7.96e-25	7.3e-22	0.72	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46558830~46562795:-
THCA	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-10.9	7.97e-25	7.3e-22	-0.52	-0.45	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
THCA	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	10.9	8e-25	7.33e-22	0.57	0.45	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
THCA	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-10.9	8.01e-25	7.34e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
THCA	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	10.9	8.05e-25	7.38e-22	0.38	0.45	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-10.9	8.06e-25	7.38e-22	-0.61	-0.45	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
THCA	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	10.9	8.07e-25	7.39e-22	0.58	0.45	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
THCA	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	10.9	8.07e-25	7.39e-22	0.52	0.45	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
THCA	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	10.9	8.08e-25	7.4e-22	0.46	0.45	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
THCA	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-10.9	8.1e-25	7.42e-22	-0.57	-0.45	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
THCA	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-10.9	8.17e-25	7.48e-22	-0.59	-0.45	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
THCA	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-10.9	8.18e-25	7.49e-22	-0.55	-0.45	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
THCA	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	10.9	8.21e-25	7.52e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
THCA	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-10.9	8.22e-25	7.52e-22	-0.6	-0.45	Depression;	chr6:28184805	chr6:28115628~28116551:+
THCA	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-10.9	8.22e-25	7.52e-22	-0.62	-0.45	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
THCA	cis	rs934734	0.532	rs2860773	ENSG00000281920.1	RP11-418H16.1	-10.9	8.26e-25	7.56e-22	-0.54	-0.45	Rheumatoid arthritis;	chr2:65438507	chr2:65623272~65628424:+
THCA	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-10.9	8.26e-25	7.56e-22	-0.6	-0.45	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
THCA	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	10.9	8.28e-25	7.58e-22	0.52	0.45	Height;	chr6:109382188	chr6:109382795~109383666:+
THCA	cis	rs4819052	0.851	rs2236443	ENSG00000223768.1	LINC00205	-10.9	8.31e-25	7.6e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	10.9	8.32e-25	7.61e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.679	rs4819053	ENSG00000223768.1	LINC00205	10.9	8.32e-25	7.61e-22	0.41	0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45293285~45297354:+
THCA	cis	rs4266144	0.632	rs56268334	ENSG00000244515.1	KRT18P34	-10.9	8.34e-25	7.63e-22	-0.63	-0.45	Coronary artery disease;	chr3:157130235	chr3:157162663~157163932:-
THCA	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	10.9	8.36e-25	7.65e-22	0.49	0.45	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
THCA	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-10.9	8.41e-25	7.7e-22	-0.59	-0.45	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
THCA	cis	rs11159086	1	rs4899516	ENSG00000270000.1	RP3-449M8.9	10.9	8.43e-25	7.71e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74492825	chr14:74471930~74472360:-
THCA	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-10.9	8.45e-25	7.73e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-10.9	8.45e-25	7.73e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
THCA	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	10.89	8.5e-25	7.77e-22	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
THCA	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	10.89	8.53e-25	7.8e-22	0.81	0.45	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
THCA	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	10.89	8.54e-25	7.81e-22	0.39	0.45	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	10.89	8.55e-25	7.81e-22	0.55	0.45	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
THCA	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-10.89	8.61e-25	7.87e-22	-0.45	-0.45	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
THCA	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-10.89	8.7e-25	7.95e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
THCA	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-10.89	8.72e-25	7.96e-22	-0.55	-0.45	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
THCA	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	10.89	8.79e-25	8.02e-22	0.6	0.45	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
THCA	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
THCA	cis	rs7569084	0.64	rs11126039	ENSG00000237979.1	AC007389.1	10.89	8.81e-25	8.04e-22	0.53	0.45	Sum eosinophil basophil counts;	chr2:65457953	chr2:65500993~65502138:-
THCA	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	10.89	8.85e-25	8.08e-22	0.54	0.45	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
THCA	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	10.89	8.85e-25	8.08e-22	0.54	0.45	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
THCA	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-10.89	8.86e-25	8.08e-22	-0.6	-0.45	Depression;	chr6:28201380	chr6:28115628~28116551:+
THCA	cis	rs3002131	0.604	rs3008641	ENSG00000225265.1	TAF1A-AS1	-10.89	8.87e-25	8.1e-22	-0.59	-0.45	Interleukin-10 levels;	chr1:222566947	chr1:222589825~222593032:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000206090.4	AP000350.7	10.89	8.88e-25	8.1e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23939998~23942798:+
THCA	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	10.89	8.9e-25	8.12e-22	0.45	0.45	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
THCA	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-10.89	8.9e-25	8.12e-22	-0.59	-0.45	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
THCA	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	10.89	8.94e-25	8.15e-22	0.32	0.45	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
THCA	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-10.89	8.94e-25	8.15e-22	-0.32	-0.45	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
THCA	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-10.89	8.94e-25	8.15e-22	-0.32	-0.45	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
THCA	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-10.89	8.94e-25	8.15e-22	-0.32	-0.45	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
THCA	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-10.89	9.03e-25	8.23e-22	-0.39	-0.45	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-10.89	9.03e-25	8.23e-22	-0.39	-0.45	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	10.89	9.03e-25	8.23e-22	0.39	0.45	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	10.89	9.03e-25	8.23e-22	0.39	0.45	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
THCA	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-10.89	9.04e-25	8.24e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-10.89	9.04e-25	8.24e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-10.89	9.04e-25	8.24e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
THCA	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-10.89	9.07e-25	8.27e-22	-0.56	-0.45	Height;	chr3:52989619	chr3:53064283~53065091:-
THCA	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-10.89	9.08e-25	8.28e-22	-0.39	-0.45	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
THCA	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-10.89	9.09e-25	8.29e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
THCA	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	10.89	9.1e-25	8.29e-22	0.65	0.45	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
THCA	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-10.89	9.1e-25	8.29e-22	-0.64	-0.45	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
THCA	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-10.89	9.11e-25	8.3e-22	-0.39	-0.45	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	10.89	9.12e-25	8.31e-22	0.66	0.45	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.788	rs35323494	ENSG00000223768.1	LINC00205	-10.89	9.13e-25	8.32e-22	-0.45	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45293285~45297354:+
THCA	cis	rs2658782	0.547	rs6483244	ENSG00000279684.1	RP11-755E23.2	-10.89	9.14e-25	8.33e-22	-0.65	-0.45	Pulmonary function decline;	chr11:93464769	chr11:93286629~93288903:-
THCA	cis	rs860295	0.702	rs5005770	ENSG00000225855.5	RUSC1-AS1	-10.89	9.17e-25	8.36e-22	-0.31	-0.45	Body mass index;	chr1:155375252	chr1:155316863~155324176:-
THCA	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-10.89	9.22e-25	8.4e-22	-0.59	-0.45	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
THCA	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	10.89	9.24e-25	8.42e-22	0.37	0.45	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
THCA	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-10.88	9.27e-25	8.45e-22	-0.32	-0.45	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
THCA	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	10.88	9.31e-25	8.48e-22	0.54	0.45	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
THCA	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-10.88	9.36e-25	8.53e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-10.88	9.36e-25	8.53e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	10.88	9.49e-25	8.65e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
THCA	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-10.88	9.52e-25	8.67e-22	-0.5	-0.45	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
THCA	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-10.88	9.57e-25	8.72e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-10.88	9.57e-25	8.72e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-10.88	9.57e-25	8.72e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
THCA	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	10.88	9.58e-25	8.72e-22	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	10.88	9.59e-25	8.73e-22	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
THCA	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	10.88	9.63e-25	8.76e-22	0.48	0.45	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
THCA	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-10.88	9.66e-25	8.79e-22	-0.39	-0.45	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
THCA	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	10.88	9.69e-25	8.81e-22	0.52	0.45	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	10.88	9.69e-25	8.81e-22	0.52	0.45	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	10.88	9.69e-25	8.81e-22	0.52	0.45	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	10.88	9.69e-25	8.81e-22	0.52	0.45	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
THCA	cis	rs6558530	0.863	rs4595147	ENSG00000253982.1	CTD-2336O2.1	10.88	9.71e-25	8.83e-22	0.39	0.45	Systolic blood pressure;	chr8:1755403	chr8:1761990~1764502:-
THCA	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-10.88	9.72e-25	8.84e-22	-0.57	-0.45	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
THCA	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-10.88	9.77e-25	8.89e-22	-0.56	-0.45	Height;	chr3:53027969	chr3:53064283~53065091:-
THCA	cis	rs7772486	0.875	rs2748490	ENSG00000235652.6	RP11-545I5.3	10.88	9.78e-25	8.89e-22	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145799409~145886585:+
THCA	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-10.88	9.78e-25	8.9e-22	-0.55	-0.45	Height;	chr3:52992698	chr3:53064283~53065091:-
THCA	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-10.88	9.82e-25	8.93e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-10.88	9.82e-25	8.93e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-10.88	9.82e-25	8.93e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
THCA	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	10.88	9.83e-25	8.94e-22	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
THCA	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-10.88	9.84e-25	8.95e-22	-0.77	-0.45	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
THCA	cis	rs860295	0.702	rs2025669	ENSG00000225855.5	RUSC1-AS1	10.88	9.92e-25	9.02e-22	0.31	0.45	Body mass index;	chr1:155387818	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs12081067	ENSG00000225855.5	RUSC1-AS1	10.88	9.92e-25	9.02e-22	0.31	0.45	Body mass index;	chr1:155389191	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs10908465	ENSG00000225855.5	RUSC1-AS1	10.88	9.92e-25	9.02e-22	0.31	0.45	Body mass index;	chr1:155419897	chr1:155316863~155324176:-
THCA	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	10.88	9.92e-25	9.02e-22	0.52	0.45	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-10.88	9.95e-25	9.05e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
THCA	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	10.88	1e-24	9.1e-22	0.53	0.45	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
THCA	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-10.88	1e-24	9.11e-22	-0.66	-0.45	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
THCA	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-10.88	1.01e-24	9.16e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
THCA	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	10.87	1.01e-24	9.2e-22	0.52	0.45	Height;	chr6:109440234	chr6:109382795~109383666:+
THCA	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-10.87	1.01e-24	9.2e-22	-0.71	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
THCA	cis	rs11159086	0.793	rs10139122	ENSG00000270000.1	RP3-449M8.9	10.87	1.02e-24	9.23e-22	0.48	0.45	Advanced glycation end-product levels;	chr14:74492353	chr14:74471930~74472360:-
THCA	cis	rs7569084	0.663	rs6546150	ENSG00000237979.1	AC007389.1	-10.87	1.02e-24	9.24e-22	-0.52	-0.45	Sum eosinophil basophil counts;	chr2:65415066	chr2:65500993~65502138:-
THCA	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-10.87	1.02e-24	9.27e-22	-0.66	-0.45	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
THCA	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-10.87	1.04e-24	9.42e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
THCA	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	10.87	1.04e-24	9.46e-22	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
THCA	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	10.87	1.04e-24	9.48e-22	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
THCA	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	10.87	1.05e-24	9.52e-22	0.42	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
THCA	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-10.87	1.06e-24	9.6e-22	-0.55	-0.45	Height;	chr3:52991821	chr3:53064283~53065091:-
THCA	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	10.87	1.06e-24	9.61e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	10.87	1.06e-24	9.61e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
THCA	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	10.87	1.07e-24	9.7e-22	0.58	0.45	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
THCA	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-10.87	1.07e-24	9.74e-22	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	10.87	1.08e-24	9.77e-22	0.62	0.45	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
THCA	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	10.87	1.08e-24	9.79e-22	0.48	0.45	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
THCA	cis	rs7569084	0.687	rs934731	ENSG00000237979.1	AC007389.1	10.87	1.08e-24	9.83e-22	0.52	0.45	Sum eosinophil basophil counts;	chr2:65456353	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs7577452	ENSG00000237979.1	AC007389.1	10.87	1.08e-24	9.83e-22	0.52	0.45	Sum eosinophil basophil counts;	chr2:65456694	chr2:65500993~65502138:-
THCA	cis	rs11159086	1	rs8006909	ENSG00000270000.1	RP3-449M8.9	10.87	1.09e-24	9.87e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74478085	chr14:74471930~74472360:-
THCA	cis	rs11159086	1	rs8006958	ENSG00000270000.1	RP3-449M8.9	10.87	1.09e-24	9.87e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74478148	chr14:74471930~74472360:-
THCA	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-10.87	1.1e-24	9.93e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
THCA	cis	rs934734	0.532	rs1437466	ENSG00000281920.1	RP11-418H16.1	-10.87	1.1e-24	9.97e-22	-0.54	-0.45	Rheumatoid arthritis;	chr2:65437216	chr2:65623272~65628424:+
THCA	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	10.86	1.1e-24	1e-21	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-10.86	1.12e-24	1.01e-21	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
THCA	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-10.86	1.12e-24	1.01e-21	-0.34	-0.45	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-10.86	1.12e-24	1.01e-21	-0.64	-0.45	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
THCA	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-10.86	1.12e-24	1.02e-21	-0.58	-0.45	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
THCA	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	10.86	1.13e-24	1.02e-21	0.59	0.45	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000206090.4	AP000350.7	10.86	1.13e-24	1.02e-21	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23939998~23942798:+
THCA	cis	rs4819052	0.679	rs2236450	ENSG00000223768.1	LINC00205	-10.86	1.13e-24	1.02e-21	-0.41	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45293285~45297354:+
THCA	cis	rs7569084	0.687	rs11675538	ENSG00000237979.1	AC007389.1	10.86	1.13e-24	1.02e-21	0.52	0.45	Sum eosinophil basophil counts;	chr2:65459327	chr2:65500993~65502138:-
THCA	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	10.86	1.13e-24	1.03e-21	0.37	0.45	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	10.86	1.13e-24	1.03e-21	0.37	0.45	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
THCA	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	10.86	1.13e-24	1.03e-21	0.52	0.45	Height;	chr6:109390116	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	10.86	1.13e-24	1.03e-21	0.52	0.45	Height;	chr6:109390638	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	10.86	1.13e-24	1.03e-21	0.52	0.45	Height;	chr6:109391534	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	10.86	1.13e-24	1.03e-21	0.52	0.45	Height;	chr6:109393881	chr6:109382795~109383666:+
THCA	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	10.86	1.13e-24	1.03e-21	0.47	0.45	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	10.86	1.13e-24	1.03e-21	0.47	0.45	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
THCA	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	10.86	1.14e-24	1.03e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	10.86	1.14e-24	1.03e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
THCA	cis	rs860295	0.702	rs12239100	ENSG00000225855.5	RUSC1-AS1	10.86	1.14e-24	1.03e-21	0.32	0.45	Body mass index;	chr1:155458685	chr1:155316863~155324176:-
THCA	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	10.86	1.15e-24	1.04e-21	0.52	0.45	Height;	chr6:109397362	chr6:109382795~109383666:+
THCA	cis	rs7569084	0.663	rs10190233	ENSG00000237979.1	AC007389.1	-10.86	1.15e-24	1.04e-21	-0.52	-0.45	Sum eosinophil basophil counts;	chr2:65413095	chr2:65500993~65502138:-
THCA	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	10.86	1.15e-24	1.04e-21	0.52	0.45	Height;	chr6:109443332	chr6:109382795~109383666:+
THCA	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-10.86	1.15e-24	1.04e-21	-0.39	-0.45	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
THCA	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-10.86	1.15e-24	1.04e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.935	rs388394	ENSG00000235652.6	RP11-545I5.3	10.86	1.16e-24	1.05e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145799409~145886585:+
THCA	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	10.86	1.16e-24	1.05e-21	0.62	0.45	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
THCA	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	10.86	1.16e-24	1.05e-21	0.62	0.45	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
THCA	cis	rs4819052	0.851	rs1056099	ENSG00000223768.1	LINC00205	-10.86	1.17e-24	1.06e-21	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2236446	ENSG00000223768.1	LINC00205	-10.86	1.17e-24	1.06e-21	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45293285~45297354:+
THCA	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-10.86	1.17e-24	1.06e-21	-0.7	-0.45	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-10.86	1.19e-24	1.07e-21	-0.59	-0.45	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-10.86	1.19e-24	1.08e-21	-0.56	-0.45	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	10.86	1.19e-24	1.08e-21	0.61	0.45	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
THCA	cis	rs3002131	0.604	rs2133185	ENSG00000225265.1	TAF1A-AS1	-10.86	1.2e-24	1.08e-21	-0.59	-0.45	Interleukin-10 levels;	chr1:222565628	chr1:222589825~222593032:+
THCA	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-10.86	1.2e-24	1.08e-21	-0.86	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
THCA	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
THCA	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
THCA	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-10.85	1.21e-24	1.09e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-10.85	1.21e-24	1.09e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
THCA	cis	rs9532669	0.89	rs11619117	ENSG00000239827.7	SUGT1P3	-10.85	1.21e-24	1.09e-21	-0.49	-0.45	Cervical cancer;	chr13:40880020	chr13:40908159~40921774:-
THCA	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	10.85	1.21e-24	1.1e-21	0.56	0.45	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
THCA	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	10.85	1.21e-24	1.1e-21	0.54	0.45	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	10.85	1.21e-24	1.1e-21	0.54	0.45	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
THCA	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-10.85	1.22e-24	1.1e-21	-0.61	-0.45	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
THCA	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-10.85	1.22e-24	1.1e-21	-0.61	-0.45	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
THCA	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	10.85	1.22e-24	1.1e-21	0.52	0.45	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
THCA	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-10.85	1.22e-24	1.11e-21	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
THCA	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-10.85	1.23e-24	1.11e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
THCA	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-10.85	1.23e-24	1.11e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
THCA	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	10.85	1.23e-24	1.11e-21	0.61	0.45	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
THCA	cis	rs860295	0.702	rs11264386	ENSG00000225855.5	RUSC1-AS1	10.85	1.24e-24	1.12e-21	0.32	0.45	Body mass index;	chr1:155589379	chr1:155316863~155324176:-
THCA	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-10.85	1.26e-24	1.13e-21	-0.64	-0.45	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
THCA	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-10.85	1.26e-24	1.14e-21	-0.64	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
THCA	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-10.85	1.27e-24	1.15e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-10.85	1.27e-24	1.15e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-10.85	1.27e-24	1.15e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
THCA	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-10.85	1.27e-24	1.15e-21	-0.8	-0.45	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-10.85	1.27e-24	1.15e-21	-0.8	-0.45	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
THCA	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	10.85	1.27e-24	1.15e-21	0.8	0.45	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
THCA	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-10.85	1.28e-24	1.15e-21	-0.68	-0.45	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
THCA	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	10.85	1.29e-24	1.17e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.558	rs702316	ENSG00000235652.6	RP11-545I5.3	-10.85	1.3e-24	1.17e-21	-0.47	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145683541	chr6:145799409~145886585:+
THCA	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	10.85	1.3e-24	1.17e-21	0.63	0.45	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
THCA	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	10.85	1.3e-24	1.17e-21	0.54	0.45	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
THCA	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-10.85	1.3e-24	1.18e-21	-0.56	-0.45	Height;	chr3:52977358	chr3:53064283~53065091:-
THCA	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-10.85	1.31e-24	1.18e-21	-0.69	-0.45	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
THCA	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
THCA	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-10.84	1.32e-24	1.19e-21	-0.32	-0.45	Height;	chr11:118703185	chr11:118791254~118793137:+
THCA	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-10.84	1.32e-24	1.19e-21	-0.32	-0.45	Height;	chr11:118703207	chr11:118791254~118793137:+
THCA	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-10.84	1.32e-24	1.19e-21	-0.76	-0.45	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-10.84	1.32e-24	1.19e-21	-0.76	-0.45	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs7750803	ENSG00000255389.1	C6orf3	10.84	1.33e-24	1.2e-21	0.8	0.45	Psoriasis;	chr6:111478910	chr6:111599875~111602295:+
THCA	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-10.84	1.33e-24	1.2e-21	-0.52	-0.45	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000224205.1	AP000351.4	10.84	1.33e-24	1.2e-21	0.53	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23987320~23991421:-
THCA	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-10.84	1.34e-24	1.21e-21	-0.51	-0.45	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
THCA	cis	rs4591358	0.648	rs17177798	ENSG00000223466.1	AC064834.2	-10.84	1.35e-24	1.21e-21	-0.67	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195521352	chr2:195533035~195538681:+
THCA	cis	rs11159086	0.941	rs12434836	ENSG00000270000.1	RP3-449M8.9	10.84	1.35e-24	1.21e-21	0.5	0.45	Advanced glycation end-product levels;	chr14:74468887	chr14:74471930~74472360:-
THCA	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	10.84	1.35e-24	1.22e-21	0.45	0.45	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
THCA	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	10.84	1.35e-24	1.22e-21	0.54	0.45	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	10.84	1.35e-24	1.22e-21	0.54	0.45	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
THCA	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs17510733	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111389715	chr6:111599875~111602295:+
THCA	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
THCA	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-10.84	1.36e-24	1.23e-21	-0.62	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
THCA	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-10.84	1.36e-24	1.23e-21	-0.62	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
THCA	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	10.84	1.37e-24	1.23e-21	0.59	0.45	Depression;	chr6:28187640	chr6:28115628~28116551:+
THCA	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	10.84	1.38e-24	1.24e-21	0.51	0.45	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
THCA	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	10.84	1.38e-24	1.25e-21	0.52	0.45	Height;	chr6:109358652	chr6:109382795~109383666:+
THCA	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-10.84	1.38e-24	1.25e-21	-0.68	-0.45	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
THCA	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-10.84	1.39e-24	1.25e-21	-0.64	-0.45	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-10.84	1.39e-24	1.25e-21	-0.64	-0.45	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-10.84	1.39e-24	1.25e-21	-0.64	-0.45	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
THCA	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	10.84	1.4e-24	1.26e-21	0.47	0.45	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
THCA	cis	rs6558530	0.64	rs4875889	ENSG00000253982.1	CTD-2336O2.1	10.84	1.42e-24	1.27e-21	0.43	0.45	Systolic blood pressure;	chr8:1747125	chr8:1761990~1764502:-
THCA	cis	rs9532669	0.926	rs9532654	ENSG00000239827.7	SUGT1P3	-10.84	1.42e-24	1.27e-21	-0.49	-0.45	Cervical cancer;	chr13:40909812	chr13:40908159~40921774:-
THCA	cis	rs4819052	0.851	rs2255774	ENSG00000223768.1	LINC00205	-10.84	1.42e-24	1.28e-21	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2256000	ENSG00000223768.1	LINC00205	-10.83	1.43e-24	1.29e-21	-0.41	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45293285~45297354:+
THCA	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	10.83	1.44e-24	1.29e-21	0.54	0.45	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
THCA	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
THCA	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	10.83	1.44e-24	1.3e-21	0.54	0.45	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
THCA	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-10.83	1.44e-24	1.3e-21	-0.65	-0.45	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
THCA	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	10.83	1.45e-24	1.3e-21	0.57	0.45	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.875	rs2492855	ENSG00000235652.6	RP11-545I5.3	10.83	1.45e-24	1.3e-21	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-10.83	1.46e-24	1.31e-21	-0.58	-0.45	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
THCA	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	10.83	1.46e-24	1.31e-21	0.49	0.45	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	10.83	1.46e-24	1.31e-21	0.49	0.45	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
THCA	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-10.83	1.46e-24	1.31e-21	-0.49	-0.45	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
THCA	cis	rs916888	0.773	rs1378358	ENSG00000232300.1	FAM215B	10.83	1.47e-24	1.32e-21	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46558830~46562795:-
THCA	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	10.83	1.47e-24	1.32e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	10.83	1.47e-24	1.32e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	10.83	1.47e-24	1.32e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
THCA	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	10.83	1.47e-24	1.32e-21	0.52	0.45	Height;	chr6:109407238	chr6:109382795~109383666:+
THCA	cis	rs8062405	0.728	rs11642449	ENSG00000251417.2	RP11-1348G14.4	-10.83	1.48e-24	1.33e-21	-0.45	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28802743~28817828:+
THCA	cis	rs860295	0.702	rs10908471	ENSG00000225855.5	RUSC1-AS1	10.83	1.48e-24	1.33e-21	0.32	0.45	Body mass index;	chr1:155573151	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs10908472	ENSG00000225855.5	RUSC1-AS1	10.83	1.48e-24	1.33e-21	0.32	0.45	Body mass index;	chr1:155574465	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs11264383	ENSG00000225855.5	RUSC1-AS1	10.83	1.48e-24	1.33e-21	0.32	0.45	Body mass index;	chr1:155575555	chr1:155316863~155324176:-
THCA	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	10.83	1.49e-24	1.34e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	10.83	1.49e-24	1.34e-21	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
THCA	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-10.83	1.5e-24	1.34e-21	-0.43	-0.45	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
THCA	cis	rs9928842	0.823	rs889514	ENSG00000280152.1	RP11-331F4.5	10.83	1.5e-24	1.35e-21	0.6	0.45	Alcoholic chronic pancreatitis;	chr16:75238614	chr16:75245994~75250077:-
THCA	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-10.83	1.5e-24	1.35e-21	-0.58	-0.45	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
THCA	cis	rs6496932	0.663	rs11074169	ENSG00000218052.5	ADAMTS7P4	-10.83	1.5e-24	1.35e-21	-0.58	-0.45	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85255369~85330334:-
THCA	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	10.83	1.5e-24	1.35e-21	0.37	0.45	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
THCA	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	10.83	1.5e-24	1.35e-21	0.31	0.45	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
THCA	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	10.83	1.5e-24	1.35e-21	0.31	0.45	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
THCA	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	10.83	1.5e-24	1.35e-21	0.5	0.45	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
THCA	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	10.83	1.51e-24	1.35e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-10.83	1.52e-24	1.36e-21	-0.58	-0.45	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-10.83	1.52e-24	1.36e-21	-0.58	-0.45	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
THCA	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	10.83	1.52e-24	1.36e-21	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
THCA	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	10.83	1.52e-24	1.37e-21	0.52	0.45	Height;	chr6:109367335	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	10.83	1.53e-24	1.37e-21	0.59	0.45	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
THCA	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	10.83	1.54e-24	1.38e-21	0.73	0.45	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
THCA	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	10.83	1.54e-24	1.39e-21	0.59	0.45	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
THCA	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	10.83	1.56e-24	1.4e-21	0.62	0.45	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-10.82	1.57e-24	1.4e-21	-0.58	-0.45	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
THCA	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-10.82	1.57e-24	1.41e-21	-0.64	-0.45	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
THCA	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	10.82	1.58e-24	1.41e-21	0.59	0.45	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
THCA	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-10.82	1.58e-24	1.41e-21	-0.51	-0.45	Temperament;	chr17:14003617	chr17:14024514~14025488:+
THCA	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-10.82	1.58e-24	1.42e-21	-0.64	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
THCA	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-10.82	1.59e-24	1.43e-21	-0.45	-0.45	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
THCA	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	10.82	1.59e-24	1.43e-21	0.52	0.45	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
THCA	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-10.82	1.6e-24	1.43e-21	-0.54	-0.45	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	10.82	1.61e-24	1.44e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
THCA	cis	rs465969	0.744	rs574056	ENSG00000255389.1	C6orf3	-10.82	1.61e-24	1.44e-21	-0.85	-0.45	Psoriasis;	chr6:111305787	chr6:111599875~111602295:+
THCA	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	10.82	1.61e-24	1.44e-21	0.58	0.45	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
THCA	cis	rs860295	0.702	rs12746592	ENSG00000225855.5	RUSC1-AS1	10.82	1.61e-24	1.45e-21	0.31	0.45	Body mass index;	chr1:155536176	chr1:155316863~155324176:-
THCA	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	10.82	1.62e-24	1.45e-21	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
THCA	cis	rs600231	0.623	rs3015966	ENSG00000245532.5	NEAT1	10.82	1.62e-24	1.45e-21	0.31	0.45	Bone mineral density;	chr11:65450118	chr11:65422774~65445540:+
THCA	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-10.82	1.62e-24	1.45e-21	-0.51	-0.45	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
THCA	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	10.82	1.63e-24	1.46e-21	0.84	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
THCA	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	10.82	1.63e-24	1.46e-21	0.52	0.45	Height;	chr6:109454233	chr6:109382795~109383666:+
THCA	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-10.82	1.63e-24	1.46e-21	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
THCA	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	10.82	1.63e-24	1.46e-21	0.63	0.45	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
THCA	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-10.82	1.64e-24	1.47e-21	-0.58	-0.45	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
THCA	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-10.82	1.64e-24	1.47e-21	-0.6	-0.45	Depression;	chr6:28206812	chr6:28115628~28116551:+
THCA	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	10.82	1.65e-24	1.47e-21	0.41	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
THCA	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-10.82	1.65e-24	1.48e-21	-0.56	-0.45	Height;	chr3:53029908	chr3:53064283~53065091:-
THCA	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	10.82	1.66e-24	1.49e-21	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	10.82	1.66e-24	1.49e-21	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	10.82	1.66e-24	1.49e-21	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
THCA	cis	rs944289	0.617	rs1958614	ENSG00000257826.1	RP11-116N8.4	-10.82	1.67e-24	1.49e-21	-0.48	-0.45	Thyroid cancer;	chr14:36118107	chr14:36061026~36067190:-
THCA	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-10.82	1.67e-24	1.5e-21	-0.55	-0.45	Height;	chr3:52949886	chr3:53064283~53065091:-
THCA	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	10.82	1.68e-24	1.5e-21	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-10.82	1.68e-24	1.5e-21	-0.64	-0.45	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
THCA	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-10.82	1.69e-24	1.51e-21	-0.71	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
THCA	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-10.82	1.7e-24	1.52e-21	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-10.82	1.7e-24	1.52e-21	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
THCA	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-10.82	1.7e-24	1.52e-21	-0.58	-0.45	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
THCA	cis	rs62103177	0.683	rs62101232	ENSG00000261126.6	RP11-795F19.1	10.81	1.7e-24	1.53e-21	0.53	0.45	Opioid sensitivity;	chr18:79962454	chr18:80046900~80095482:+
THCA	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	10.81	1.71e-24	1.53e-21	0.41	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
THCA	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-10.81	1.71e-24	1.53e-21	-0.59	-0.45	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
THCA	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	10.81	1.71e-24	1.53e-21	0.41	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	10.81	1.72e-24	1.54e-21	0.59	0.45	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
THCA	cis	rs916888	0.773	rs169201	ENSG00000232300.1	FAM215B	10.81	1.72e-24	1.54e-21	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46558830~46562795:-
THCA	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	10.81	1.72e-24	1.54e-21	0.58	0.45	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	10.81	1.72e-24	1.54e-21	0.54	0.45	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
THCA	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	10.81	1.74e-24	1.56e-21	0.52	0.45	Height;	chr6:109371524	chr6:109382795~109383666:+
THCA	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	10.81	1.75e-24	1.56e-21	0.45	0.45	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
THCA	cis	rs8062405	0.728	rs9931989	ENSG00000251417.2	RP11-1348G14.4	10.81	1.75e-24	1.56e-21	0.45	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28802743~28817828:+
THCA	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	10.81	1.75e-24	1.57e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
THCA	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-10.81	1.75e-24	1.57e-21	-0.5	-0.45	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
THCA	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-10.81	1.76e-24	1.57e-21	-0.57	-0.45	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
THCA	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	10.81	1.76e-24	1.58e-21	0.54	0.45	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
THCA	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-10.81	1.77e-24	1.58e-21	-0.48	-0.45	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
THCA	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-10.81	1.78e-24	1.59e-21	-0.5	-0.45	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
THCA	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-10.81	1.78e-24	1.59e-21	-0.64	-0.45	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	10.81	1.79e-24	1.6e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-10.81	1.79e-24	1.6e-21	-0.41	-0.45	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
THCA	cis	rs934734	0.532	rs7569257	ENSG00000281920.1	RP11-418H16.1	-10.81	1.79e-24	1.6e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65429842	chr2:65623272~65628424:+
THCA	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	10.81	1.81e-24	1.61e-21	0.49	0.45	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
THCA	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-10.81	1.81e-24	1.62e-21	-0.52	-0.45	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-10.81	1.81e-24	1.62e-21	-0.52	-0.45	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
THCA	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-10.81	1.81e-24	1.62e-21	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
THCA	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-10.81	1.81e-24	1.62e-21	-0.43	-0.45	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
THCA	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	10.81	1.82e-24	1.62e-21	0.45	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
THCA	cis	rs6558530	0.666	rs4242538	ENSG00000253982.1	CTD-2336O2.1	10.81	1.82e-24	1.63e-21	0.42	0.45	Systolic blood pressure;	chr8:1745844	chr8:1761990~1764502:-
THCA	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-10.81	1.82e-24	1.63e-21	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
THCA	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	10.81	1.83e-24	1.63e-21	0.52	0.45	Height;	chr6:109383239	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	10.81	1.83e-24	1.63e-21	0.52	0.45	Height;	chr6:109383248	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	10.81	1.84e-24	1.64e-21	0.52	0.45	Height;	chr6:109392096	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	10.81	1.85e-24	1.65e-21	0.52	0.45	Height;	chr6:109375548	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	10.81	1.85e-24	1.65e-21	0.52	0.45	Height;	chr6:109383848	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	10.81	1.85e-24	1.65e-21	0.52	0.45	Height;	chr6:109384807	chr6:109382795~109383666:+
THCA	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	10.8	1.88e-24	1.67e-21	0.54	0.45	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
THCA	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	10.8	1.88e-24	1.68e-21	0.43	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
THCA	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-10.8	1.88e-24	1.68e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
THCA	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-10.8	1.89e-24	1.68e-21	-0.5	-0.45	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
THCA	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-10.8	1.89e-24	1.68e-21	-0.38	-0.45	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
THCA	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	10.8	1.9e-24	1.7e-21	0.41	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
THCA	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-10.8	1.91e-24	1.7e-21	-0.58	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
THCA	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-10.8	1.91e-24	1.71e-21	-0.47	-0.45	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
THCA	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-10.8	1.92e-24	1.71e-21	-0.57	-0.45	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
THCA	cis	rs934734	0.532	rs12185610	ENSG00000281920.1	RP11-418H16.1	-10.8	1.93e-24	1.72e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65434334	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs963539	ENSG00000237979.1	AC007389.1	-10.8	1.94e-24	1.73e-21	-0.52	-0.45	Sum eosinophil basophil counts;	chr2:65421413	chr2:65500993~65502138:-
THCA	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	10.8	1.95e-24	1.74e-21	0.52	0.45	Height;	chr6:109361200	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	10.8	1.95e-24	1.74e-21	0.52	0.45	Height;	chr6:109368228	chr6:109382795~109383666:+
THCA	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	10.8	1.97e-24	1.76e-21	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	10.8	1.97e-24	1.76e-21	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
THCA	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	10.8	1.98e-24	1.76e-21	0.52	0.45	Height;	chr6:109360263	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	10.8	1.98e-24	1.76e-21	0.52	0.45	Height;	chr6:109370741	chr6:109382795~109383666:+
THCA	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-10.8	1.98e-24	1.76e-21	-0.57	-0.45	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
THCA	cis	rs7211079	0.833	rs7220523	ENSG00000279259.1	RP11-334C17.3	10.8	1.99e-24	1.78e-21	0.47	0.45	Myocardial infarction;	chr17:80153896	chr17:80147250~80148596:+
THCA	cis	rs7211079	0.879	rs7221505	ENSG00000279259.1	RP11-334C17.3	10.8	1.99e-24	1.78e-21	0.47	0.45	Myocardial infarction;	chr17:80154432	chr17:80147250~80148596:+
THCA	cis	rs6570726	0.967	rs441364	ENSG00000235652.6	RP11-545I5.3	10.8	1.99e-24	1.78e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145532526	chr6:145799409~145886585:+
THCA	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-10.8	2e-24	1.78e-21	-0.49	-0.45	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
THCA	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	10.8	2.02e-24	1.8e-21	0.58	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
THCA	cis	rs7826238	0.535	rs2979179	ENSG00000254153.1	CTA-398F10.2	-10.8	2.03e-24	1.8e-21	-0.47	-0.45	Systolic blood pressure;	chr8:8462519	chr8:8456909~8461337:-
THCA	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	10.79	2.03e-24	1.81e-21	0.6	0.45	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
THCA	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-10.79	2.03e-24	1.81e-21	-0.69	-0.45	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
THCA	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-10.79	2.05e-24	1.83e-21	-0.71	-0.45	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
THCA	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	10.79	2.05e-24	1.83e-21	0.49	0.45	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	10.79	2.07e-24	1.84e-21	0.59	0.45	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
THCA	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	10.79	2.08e-24	1.85e-21	0.46	0.45	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
THCA	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	10.79	2.1e-24	1.87e-21	0.44	0.45	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
THCA	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	10.79	2.1e-24	1.87e-21	0.31	0.45	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
THCA	cis	rs7211079	0.719	rs2289535	ENSG00000279259.1	RP11-334C17.3	10.79	2.12e-24	1.89e-21	0.44	0.45	Myocardial infarction;	chr17:80137650	chr17:80147250~80148596:+
THCA	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	10.79	2.13e-24	1.89e-21	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
THCA	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-10.79	2.14e-24	1.9e-21	-0.57	-0.45	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
THCA	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-10.79	2.16e-24	1.92e-21	-0.58	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000206090.4	AP000350.7	10.79	2.18e-24	1.93e-21	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23939998~23942798:+
THCA	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-10.79	2.18e-24	1.94e-21	-0.66	-0.45	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000224205.1	AP000351.4	10.79	2.19e-24	1.95e-21	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23987320~23991421:-
THCA	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-10.78	2.22e-24	1.97e-21	-0.58	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-10.78	2.22e-24	1.97e-21	-0.58	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-10.78	2.22e-24	1.97e-21	-0.58	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
THCA	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	10.78	2.23e-24	1.99e-21	0.6	0.45	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000281920.1	RP11-418H16.1	-10.78	2.24e-24	1.99e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65427878	chr2:65623272~65628424:+
THCA	cis	rs934734	0.532	rs2028151	ENSG00000281920.1	RP11-418H16.1	-10.78	2.24e-24	1.99e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65428479	chr2:65623272~65628424:+
THCA	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	10.78	2.24e-24	1.99e-21	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	10.78	2.25e-24	2e-21	0.59	0.45	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	10.78	2.26e-24	2.01e-21	0.59	0.45	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	10.78	2.26e-24	2.01e-21	0.59	0.45	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
THCA	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	10.78	2.26e-24	2.01e-21	0.92	0.45	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	10.78	2.26e-24	2.01e-21	0.92	0.45	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
THCA	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-10.78	2.26e-24	2.01e-21	-0.59	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-10.78	2.26e-24	2.01e-21	-0.59	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
THCA	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	10.78	2.27e-24	2.02e-21	0.52	0.45	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
THCA	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-10.78	2.29e-24	2.03e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
THCA	cis	rs4819052	0.565	rs35776291	ENSG00000223768.1	LINC00205	-10.78	2.29e-24	2.03e-21	-0.41	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45293285~45297354:+
THCA	cis	rs3745672	1	rs113033627	ENSG00000219665.7	CTD-2006C1.2	-10.78	2.31e-24	2.05e-21	-0.98	-0.45	Multiple sclerosis;	chr19:12055554	chr19:11987617~12046275:+
THCA	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	10.78	2.33e-24	2.07e-21	0.54	0.45	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
THCA	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	10.78	2.38e-24	2.11e-21	0.51	0.45	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
THCA	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-10.78	2.39e-24	2.12e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-10.78	2.39e-24	2.12e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
THCA	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-10.78	2.4e-24	2.13e-21	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
THCA	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	10.78	2.4e-24	2.13e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
THCA	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-10.77	2.43e-24	2.16e-21	-0.58	-0.45	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
THCA	cis	rs934734	0.532	rs13383320	ENSG00000281920.1	RP11-418H16.1	-10.77	2.46e-24	2.18e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65418003	chr2:65623272~65628424:+
THCA	cis	rs6570726	0.902	rs396681	ENSG00000235652.6	RP11-545I5.3	10.77	2.47e-24	2.19e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145799409~145886585:+
THCA	cis	rs324126	0.752	rs1054612	ENSG00000277977.1	CTD-3018O17.5	-10.77	2.49e-24	2.21e-21	-0.41	-0.44	Colonoscopy-negative controls vs population controls;	chr19:52366799	chr19:52392659~52392755:+
THCA	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-10.77	2.49e-24	2.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-10.77	2.49e-24	2.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-10.77	2.49e-24	2.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-10.77	2.49e-24	2.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
THCA	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
THCA	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
THCA	cis	rs62103177	0.525	rs9949598	ENSG00000261126.6	RP11-795F19.1	-10.77	2.54e-24	2.25e-21	-0.47	-0.44	Opioid sensitivity;	chr18:79993037	chr18:80046900~80095482:+
THCA	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	10.77	2.54e-24	2.25e-21	0.62	0.44	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
THCA	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
THCA	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	10.77	2.55e-24	2.26e-21	0.63	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
THCA	cis	rs10246939	0.544	rs6959360	ENSG00000228775.6	WEE2-AS1	10.77	2.56e-24	2.26e-21	0.53	0.44	Bitter taste perception;	chr7:141869806	chr7:141704338~141738346:-
THCA	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-10.77	2.56e-24	2.26e-21	-0.51	-0.44	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
THCA	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	10.77	2.56e-24	2.27e-21	0.51	0.44	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
THCA	cis	rs6964833	0.873	rs4717905	ENSG00000277053.3	GTF2IP1	-10.77	2.57e-24	2.27e-21	-0.6	-0.44	Menarche (age at onset);	chr7:74668903	chr7:75185385~75237696:-
THCA	cis	rs9659323	0.706	rs1409160	ENSG00000231365.4	RP11-418J17.1	-10.77	2.59e-24	2.29e-21	-0.44	-0.44	Body mass index;	chr1:119041231	chr1:119140396~119275973:+
THCA	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-10.77	2.59e-24	2.29e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
THCA	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	10.77	2.6e-24	2.3e-21	0.54	0.44	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
THCA	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-10.77	2.6e-24	2.3e-21	-0.58	-0.44	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
THCA	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	10.77	2.61e-24	2.31e-21	0.52	0.44	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
THCA	cis	rs4819052	0.655	rs2330103	ENSG00000223768.1	LINC00205	-10.77	2.62e-24	2.31e-21	-0.41	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45293285~45297354:+
THCA	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-10.77	2.63e-24	2.32e-21	-0.58	-0.44	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
THCA	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	10.77	2.63e-24	2.32e-21	0.43	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
THCA	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-10.77	2.63e-24	2.33e-21	-0.55	-0.44	Height;	chr3:52975027	chr3:53064283~53065091:-
THCA	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	10.76	2.67e-24	2.36e-21	0.54	0.44	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
THCA	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	10.76	2.67e-24	2.36e-21	0.54	0.44	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	10.76	2.67e-24	2.36e-21	0.54	0.44	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
THCA	cis	rs916888	0.773	rs199439	ENSG00000232300.1	FAM215B	10.76	2.68e-24	2.37e-21	0.73	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46558830~46562795:-
THCA	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-10.76	2.7e-24	2.39e-21	-0.58	-0.44	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
THCA	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-10.76	2.7e-24	2.39e-21	-0.47	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
THCA	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-10.76	2.7e-24	2.39e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
THCA	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	10.76	2.71e-24	2.39e-21	0.54	0.44	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
THCA	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-10.76	2.71e-24	2.39e-21	-0.4	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-10.76	2.71e-24	2.39e-21	-0.4	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
THCA	cis	rs8062405	0.728	rs8056890	ENSG00000251417.2	RP11-1348G14.4	-10.76	2.71e-24	2.4e-21	-0.45	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28802743~28817828:+
THCA	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-10.76	2.73e-24	2.41e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
THCA	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-10.76	2.73e-24	2.42e-21	-0.58	-0.44	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
THCA	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-10.76	2.78e-24	2.46e-21	-0.55	-0.44	Height;	chr3:52989412	chr3:53064283~53065091:-
THCA	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	10.76	2.79e-24	2.46e-21	0.3	0.44	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
THCA	cis	rs8062405	0.656	rs7189927	ENSG00000251417.2	RP11-1348G14.4	10.76	2.82e-24	2.49e-21	0.44	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28802743~28817828:+
THCA	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	10.76	2.83e-24	2.49e-21	0.63	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000224205.1	AP000351.4	10.76	2.84e-24	2.51e-21	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23987320~23991421:-
THCA	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-10.76	2.85e-24	2.51e-21	-0.7	-0.44	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
THCA	cis	rs11159086	1	rs4903232	ENSG00000270000.1	RP3-449M8.9	10.76	2.85e-24	2.52e-21	0.48	0.44	Advanced glycation end-product levels;	chr14:74496585	chr14:74471930~74472360:-
THCA	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-10.76	2.86e-24	2.52e-21	-0.4	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
THCA	cis	rs4819052	0.679	rs2255761	ENSG00000223768.1	LINC00205	-10.76	2.86e-24	2.53e-21	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.875	rs10872582	ENSG00000235652.6	RP11-545I5.3	10.76	2.87e-24	2.53e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145799409~145886585:+
THCA	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	10.75	2.89e-24	2.55e-21	0.55	0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
THCA	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-10.75	2.9e-24	2.56e-21	-0.71	-0.44	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-10.75	2.9e-24	2.56e-21	-0.71	-0.44	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
THCA	cis	rs4819052	0.679	rs2838860	ENSG00000223768.1	LINC00205	-10.75	2.91e-24	2.57e-21	-0.41	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45293285~45297354:+
THCA	cis	rs860295	0.729	rs11264369	ENSG00000225855.5	RUSC1-AS1	-10.75	2.92e-24	2.57e-21	-0.31	-0.44	Body mass index;	chr1:155390039	chr1:155316863~155324176:-
THCA	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-10.75	2.92e-24	2.58e-21	-0.58	-0.44	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
THCA	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	10.75	2.92e-24	2.58e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
THCA	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-10.75	2.95e-24	2.6e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000224205.1	AP000351.4	10.75	2.95e-24	2.6e-21	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23987320~23991421:-
THCA	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	10.75	2.97e-24	2.61e-21	0.48	0.44	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
THCA	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	10.75	2.98e-24	2.63e-21	0.47	0.44	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
THCA	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-10.75	2.99e-24	2.63e-21	-0.59	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-10.75	2.99e-24	2.63e-21	-0.59	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
THCA	cis	rs180730	0.561	rs3099888	ENSG00000251609.2	SETP12	-10.75	2.99e-24	2.63e-21	-0.62	-0.44	Fasting plasma glucose;	chr4:120882580	chr4:120895494~120897083:-
THCA	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	10.75	3e-24	2.64e-21	0.51	0.44	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	10.75	3e-24	2.64e-21	0.51	0.44	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	10.75	3e-24	2.64e-21	0.51	0.44	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	10.75	3e-24	2.64e-21	0.51	0.44	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	10.75	3.01e-24	2.65e-21	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
THCA	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	10.75	3.02e-24	2.66e-21	0.79	0.44	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
THCA	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-10.75	3.03e-24	2.67e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
THCA	cis	rs9928842	0.882	rs4737	ENSG00000280152.1	RP11-331F4.5	-10.75	3.05e-24	2.68e-21	-0.63	-0.44	Alcoholic chronic pancreatitis;	chr16:75204205	chr16:75245994~75250077:-
THCA	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-10.75	3.07e-24	2.7e-21	-0.66	-0.44	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
THCA	cis	rs465969	0.546	rs7772141	ENSG00000255389.1	C6orf3	10.75	3.07e-24	2.71e-21	0.79	0.44	Psoriasis;	chr6:111472358	chr6:111599875~111602295:+
THCA	cis	rs465969	0.793	rs7776047	ENSG00000255389.1	C6orf3	10.75	3.07e-24	2.71e-21	0.79	0.44	Psoriasis;	chr6:111472391	chr6:111599875~111602295:+
THCA	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-10.75	3.08e-24	2.71e-21	-0.46	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
THCA	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	10.75	3.11e-24	2.74e-21	0.31	0.44	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
THCA	cis	rs600231	0.708	rs3132767	ENSG00000245532.5	NEAT1	10.75	3.11e-24	2.74e-21	0.31	0.44	Bone mineral density;	chr11:65467389	chr11:65422774~65445540:+
THCA	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-10.75	3.12e-24	2.75e-21	-0.65	-0.44	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
THCA	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-10.74	3.17e-24	2.79e-21	-0.38	-0.44	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
THCA	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	10.74	3.19e-24	2.81e-21	0.38	0.44	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
THCA	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-10.74	3.19e-24	2.81e-21	-0.38	-0.44	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
THCA	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	10.74	3.21e-24	2.82e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	10.74	3.21e-24	2.82e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	10.74	3.21e-24	2.83e-21	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000235689.1	AP000351.13	10.74	3.23e-24	2.84e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:24006305~24008258:-
THCA	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-10.74	3.24e-24	2.85e-21	-0.47	-0.44	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
THCA	cis	rs180730	0.509	rs1588521	ENSG00000251609.2	SETP12	-10.74	3.26e-24	2.86e-21	-0.62	-0.44	Fasting plasma glucose;	chr4:120881202	chr4:120895494~120897083:-
THCA	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-10.74	3.27e-24	2.87e-21	-0.54	-0.44	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	10.74	3.27e-24	2.87e-21	0.54	0.44	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	10.74	3.27e-24	2.87e-21	0.54	0.44	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
THCA	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	10.74	3.28e-24	2.89e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
THCA	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-10.74	3.29e-24	2.89e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
THCA	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-10.74	3.3e-24	2.91e-21	-0.56	-0.44	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
THCA	cis	rs9532669	0.926	rs4600337	ENSG00000239827.7	SUGT1P3	-10.74	3.33e-24	2.92e-21	-0.5	-0.44	Cervical cancer;	chr13:40879564	chr13:40908159~40921774:-
THCA	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	10.74	3.33e-24	2.93e-21	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
THCA	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	10.74	3.35e-24	2.95e-21	0.5	0.44	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-10.74	3.35e-24	2.95e-21	-0.64	-0.44	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	10.74	3.36e-24	2.95e-21	0.6	0.44	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
THCA	cis	rs4964805	0.865	rs4964780	ENSG00000257681.1	RP11-341G23.4	10.74	3.38e-24	2.97e-21	0.54	0.44	Attention deficit hyperactivity disorder;	chr12:103813081	chr12:103746315~103768858:-
THCA	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-10.74	3.38e-24	2.97e-21	-0.58	-0.44	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
THCA	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-10.74	3.41e-24	2.99e-21	-0.38	-0.44	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
THCA	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	10.73	3.45e-24	3.03e-21	0.52	0.44	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	10.73	3.45e-24	3.03e-21	0.52	0.44	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
THCA	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	10.73	3.46e-24	3.04e-21	0.37	0.44	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
THCA	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	10.73	3.5e-24	3.07e-21	0.53	0.44	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
THCA	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-10.73	3.5e-24	3.08e-21	-0.69	-0.44	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
THCA	cis	rs9322193	0.887	rs3734295	ENSG00000223701.3	RAET1E-AS1	10.73	3.51e-24	3.08e-21	0.6	0.44	Lung cancer;	chr6:149593917	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	10.73	3.53e-24	3.1e-21	0.63	0.44	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	10.73	3.54e-24	3.11e-21	0.6	0.44	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
THCA	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	10.73	3.54e-24	3.11e-21	0.37	0.44	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
THCA	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-10.73	3.57e-24	3.13e-21	-0.49	-0.44	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
THCA	cis	rs4964805	0.773	rs4964623	ENSG00000257681.1	RP11-341G23.4	10.73	3.57e-24	3.13e-21	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103828964	chr12:103746315~103768858:-
THCA	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-10.73	3.58e-24	3.14e-21	-0.59	-0.44	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-10.73	3.59e-24	3.15e-21	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-10.73	3.59e-24	3.15e-21	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
THCA	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-10.73	3.59e-24	3.15e-21	-0.58	-0.44	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
THCA	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	10.73	3.62e-24	3.18e-21	0.54	0.44	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
THCA	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-10.73	3.64e-24	3.2e-21	-0.56	-0.44	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
THCA	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-10.73	3.67e-24	3.22e-21	-0.42	-0.44	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
THCA	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-10.73	3.71e-24	3.26e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-10.73	3.71e-24	3.26e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
THCA	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	10.73	3.73e-24	3.27e-21	0.5	0.44	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
THCA	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	10.72	3.73e-24	3.27e-21	0.48	0.44	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
THCA	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-10.72	3.75e-24	3.28e-21	-0.56	-0.44	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
THCA	cis	rs11159086	1	rs58384818	ENSG00000270000.1	RP3-449M8.9	10.72	3.75e-24	3.29e-21	0.49	0.44	Advanced glycation end-product levels;	chr14:74487045	chr14:74471930~74472360:-
THCA	cis	rs11159086	1	rs17100588	ENSG00000270000.1	RP3-449M8.9	10.72	3.75e-24	3.29e-21	0.49	0.44	Advanced glycation end-product levels;	chr14:74487624	chr14:74471930~74472360:-
THCA	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	10.72	3.75e-24	3.29e-21	0.58	0.44	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	10.72	3.75e-24	3.29e-21	0.58	0.44	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
THCA	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	10.72	3.77e-24	3.3e-21	0.42	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
THCA	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	10.72	3.77e-24	3.3e-21	0.42	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
THCA	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
THCA	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-10.72	3.77e-24	3.31e-21	-0.57	-0.44	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
THCA	cis	rs9928842	0.882	rs6564241	ENSG00000280152.1	RP11-331F4.5	10.72	3.8e-24	3.33e-21	0.65	0.44	Alcoholic chronic pancreatitis;	chr16:75230076	chr16:75245994~75250077:-
THCA	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-10.72	3.8e-24	3.33e-21	-0.57	-0.44	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
THCA	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-10.72	3.8e-24	3.33e-21	-0.6	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
THCA	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-10.72	3.81e-24	3.33e-21	-0.7	-0.44	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-10.72	3.81e-24	3.33e-21	-0.7	-0.44	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
THCA	cis	rs860295	0.702	rs11264387	ENSG00000225855.5	RUSC1-AS1	10.72	3.82e-24	3.35e-21	0.31	0.44	Body mass index;	chr1:155593361	chr1:155316863~155324176:-
THCA	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	10.72	3.83e-24	3.36e-21	0.52	0.44	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	10.72	3.83e-24	3.36e-21	0.52	0.44	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	10.72	3.83e-24	3.36e-21	0.52	0.44	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	10.72	3.83e-24	3.36e-21	0.6	0.44	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
THCA	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-10.72	3.84e-24	3.36e-21	-0.38	-0.44	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
THCA	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	10.72	3.85e-24	3.37e-21	0.51	0.44	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
THCA	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-10.72	3.85e-24	3.37e-21	-0.6	-0.44	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
THCA	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	10.72	3.89e-24	3.4e-21	0.54	0.44	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
THCA	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	10.72	3.91e-24	3.42e-21	0.52	0.44	Height;	chr6:109402736	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	10.72	3.91e-24	3.42e-21	0.52	0.44	Height;	chr6:109403734	chr6:109382795~109383666:+
THCA	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-10.72	3.94e-24	3.44e-21	-0.7	-0.44	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-10.72	3.94e-24	3.44e-21	-0.7	-0.44	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
THCA	cis	rs12188164	0.932	rs2230437	ENSG00000221990.4	EXOC3-AS1	10.72	3.94e-24	3.44e-21	0.37	0.44	Cystic fibrosis severity;	chr5:476238	chr5:441498~443160:-
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-10.72	3.94e-24	3.45e-21	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
THCA	cis	rs2599510	0.811	rs2710628	ENSG00000276334.1	AL133243.1	10.72	3.95e-24	3.45e-21	0.49	0.44	Interleukin-18 levels;	chr2:32533286	chr2:32521927~32523547:+
THCA	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	10.72	3.96e-24	3.47e-21	0.51	0.44	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
THCA	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-10.72	3.97e-24	3.48e-21	-0.64	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
THCA	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	10.72	3.98e-24	3.48e-21	0.54	0.44	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
THCA	cis	rs6570726	0.902	rs4895678	ENSG00000235652.6	RP11-545I5.3	10.72	3.99e-24	3.49e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145614374	chr6:145799409~145886585:+
THCA	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-10.72	4e-24	3.5e-21	-0.63	-0.44	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
THCA	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-10.72	4e-24	3.5e-21	-0.56	-0.44	Height;	chr3:53027361	chr3:53064283~53065091:-
THCA	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	10.72	4e-24	3.5e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	10.72	4e-24	3.5e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
THCA	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-10.72	4.02e-24	3.52e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-10.72	4.02e-24	3.52e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
THCA	cis	rs7615952	0.8	rs11914298	ENSG00000171084.14	FAM86JP	10.72	4.03e-24	3.52e-21	0.62	0.44	Blood pressure (smoking interaction);	chr3:125924929	chr3:125916620~125930024:+
THCA	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	10.71	4.11e-24	3.59e-21	0.31	0.44	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
THCA	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-10.71	4.12e-24	3.6e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
THCA	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-10.71	4.13e-24	3.61e-21	-0.55	-0.44	Height;	chr3:52967831	chr3:53064283~53065091:-
THCA	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-10.71	4.13e-24	3.61e-21	-0.55	-0.44	Height;	chr3:52971094	chr3:53064283~53065091:-
THCA	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	10.71	4.15e-24	3.63e-21	0.51	0.44	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
THCA	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	10.71	4.16e-24	3.63e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
THCA	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-10.71	4.17e-24	3.65e-21	-0.38	-0.44	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
THCA	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-10.71	4.18e-24	3.65e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
THCA	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	10.71	4.19e-24	3.66e-21	0.55	0.44	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
THCA	cis	rs4591358	0.689	rs17178460	ENSG00000223466.1	AC064834.2	-10.71	4.21e-24	3.68e-21	-0.67	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195555365	chr2:195533035~195538681:+
THCA	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	10.71	4.23e-24	3.7e-21	0.5	0.44	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
THCA	cis	rs9532669	0.926	rs4555012	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40879997	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12871420	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40880034	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12871735	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40880169	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12871895	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40880189	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12872288	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40880268	chr13:40908159~40921774:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	10.71	4.28e-24	3.74e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
THCA	cis	rs934734	0.532	rs7557569	ENSG00000281920.1	RP11-418H16.1	-10.71	4.28e-24	3.74e-21	-0.54	-0.44	Rheumatoid arthritis;	chr2:65417427	chr2:65623272~65628424:+
THCA	cis	rs7772486	0.712	rs1292335	ENSG00000235652.6	RP11-545I5.3	10.71	4.29e-24	3.75e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145799409~145886585:+
THCA	cis	rs950169	0.96	rs12905475	ENSG00000225151.9	GOLGA2P7	-10.71	4.3e-24	3.75e-21	-0.68	-0.44	Schizophrenia;	chr15:84131743	chr15:84199311~84230136:-
THCA	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	10.71	4.36e-24	3.8e-21	0.46	0.44	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
THCA	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-10.71	4.38e-24	3.82e-21	-0.56	-0.44	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-10.71	4.38e-24	3.82e-21	-0.58	-0.44	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
THCA	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-10.71	4.39e-24	3.83e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	10.71	4.4e-24	3.84e-21	0.59	0.44	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
THCA	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-10.71	4.41e-24	3.85e-21	-0.54	-0.44	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
THCA	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	10.7	4.44e-24	3.87e-21	0.53	0.44	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
THCA	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	10.7	4.45e-24	3.88e-21	0.53	0.44	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
THCA	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	10.7	4.48e-24	3.91e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
THCA	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	10.7	4.49e-24	3.92e-21	0.51	0.44	Height;	chr6:109357369	chr6:109382795~109383666:+
THCA	cis	rs860295	0.702	rs56675301	ENSG00000225855.5	RUSC1-AS1	10.7	4.5e-24	3.92e-21	0.31	0.44	Body mass index;	chr1:155394536	chr1:155316863~155324176:-
THCA	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-10.7	4.52e-24	3.94e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-10.7	4.52e-24	3.94e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
THCA	cis	rs9532669	0.926	rs9532646	ENSG00000239827.7	SUGT1P3	-10.7	4.54e-24	3.96e-21	-0.49	-0.44	Cervical cancer;	chr13:40880989	chr13:40908159~40921774:-
THCA	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-10.7	4.55e-24	3.97e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
THCA	cis	rs180730	0.561	rs343194	ENSG00000251609.2	SETP12	-10.7	4.57e-24	3.98e-21	-0.61	-0.44	Fasting plasma glucose;	chr4:120880199	chr4:120895494~120897083:-
THCA	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-10.7	4.58e-24	3.99e-21	-0.41	-0.44	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-10.7	4.63e-24	4.04e-21	-0.63	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
THCA	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	10.7	4.64e-24	4.04e-21	0.47	0.44	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-10.7	4.64e-24	4.04e-21	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
THCA	cis	rs2658782	0.526	rs7127240	ENSG00000279684.1	RP11-755E23.2	-10.7	4.66e-24	4.06e-21	-0.63	-0.44	Pulmonary function decline;	chr11:93451726	chr11:93286629~93288903:-
THCA	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	10.7	4.66e-24	4.06e-21	0.48	0.44	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
THCA	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-10.7	4.66e-24	4.06e-21	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-10.7	4.66e-24	4.06e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-10.7	4.69e-24	4.08e-21	-0.59	-0.44	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-10.7	4.69e-24	4.08e-21	-0.59	-0.44	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-10.7	4.69e-24	4.08e-21	-0.59	-0.44	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
THCA	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-10.7	4.69e-24	4.08e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
THCA	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	10.7	4.71e-24	4.11e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
THCA	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-10.7	4.73e-24	4.12e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-10.7	4.73e-24	4.12e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-10.7	4.73e-24	4.12e-21	-0.58	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	10.7	4.75e-24	4.13e-21	0.59	0.44	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	10.7	4.75e-24	4.13e-21	0.59	0.44	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
THCA	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	10.7	4.75e-24	4.14e-21	0.47	0.44	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
THCA	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-10.7	4.75e-24	4.14e-21	-0.54	-0.44	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
THCA	cis	rs9532669	0.926	rs9532647	ENSG00000239827.7	SUGT1P3	-10.7	4.76e-24	4.15e-21	-0.49	-0.44	Cervical cancer;	chr13:40881799	chr13:40908159~40921774:-
THCA	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	10.7	4.77e-24	4.15e-21	0.43	0.44	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
THCA	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	10.7	4.79e-24	4.17e-21	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	10.7	4.79e-24	4.17e-21	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000206090.4	AP000350.7	10.7	4.79e-24	4.17e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23939998~23942798:+
THCA	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	10.7	4.79e-24	4.17e-21	0.59	0.44	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
THCA	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-10.7	4.83e-24	4.2e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
THCA	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	10.69	4.84e-24	4.22e-21	0.55	0.44	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
THCA	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-10.69	4.85e-24	4.22e-21	-0.64	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
THCA	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-10.69	4.87e-24	4.23e-21	-0.6	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
THCA	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-10.69	4.87e-24	4.24e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
THCA	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-10.69	4.87e-24	4.24e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
THCA	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-10.69	4.88e-24	4.25e-21	-0.58	-0.44	QT interval;	chr16:28857143	chr16:28700294~28701540:-
THCA	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	10.69	4.96e-24	4.31e-21	0.52	0.44	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
THCA	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	10.69	4.97e-24	4.32e-21	0.43	0.44	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
THCA	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	10.69	4.97e-24	4.32e-21	0.47	0.44	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
THCA	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	10.69	4.99e-24	4.34e-21	0.52	0.44	Height;	chr6:109470427	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	10.69	4.99e-24	4.34e-21	0.52	0.44	Height;	chr6:109470900	chr6:109382795~109383666:+
THCA	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-10.69	5.02e-24	4.37e-21	-0.68	-0.44	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
THCA	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	10.69	5.02e-24	4.37e-21	0.57	0.44	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
THCA	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-10.69	5.02e-24	4.37e-21	-0.57	-0.44	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	10.69	5.07e-24	4.4e-21	0.5	0.44	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
THCA	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	10.69	5.09e-24	4.42e-21	0.49	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
THCA	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	10.69	5.18e-24	4.51e-21	0.48	0.44	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
THCA	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-10.69	5.21e-24	4.53e-21	-0.61	-0.44	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
THCA	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	10.69	5.23e-24	4.55e-21	0.51	0.44	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
THCA	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-10.69	5.24e-24	4.55e-21	-0.55	-0.44	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
THCA	cis	rs4964805	0.773	rs35746861	ENSG00000257681.1	RP11-341G23.4	10.69	5.25e-24	4.56e-21	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103831506	chr12:103746315~103768858:-
THCA	cis	rs7772486	0.875	rs9403765	ENSG00000235652.6	RP11-545I5.3	-10.68	5.29e-24	4.6e-21	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145799409~145886585:+
THCA	cis	rs860295	0.665	rs11264367	ENSG00000225855.5	RUSC1-AS1	10.68	5.32e-24	4.62e-21	0.31	0.44	Body mass index;	chr1:155367547	chr1:155316863~155324176:-
THCA	cis	rs2599510	0.811	rs2583713	ENSG00000276334.1	AL133243.1	10.68	5.32e-24	4.62e-21	0.48	0.44	Interleukin-18 levels;	chr2:32597662	chr2:32521927~32523547:+
THCA	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	10.68	5.33e-24	4.63e-21	0.51	0.44	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
THCA	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
THCA	cis	rs16828019	1	rs16828019	ENSG00000235358.1	RP11-399E6.1	10.68	5.34e-24	4.64e-21	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41279363	chr1:41242373~41284861:+
THCA	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	10.68	5.34e-24	4.64e-21	0.47	0.44	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
THCA	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-10.68	5.37e-24	4.66e-21	-0.57	-0.44	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	10.68	5.37e-24	4.66e-21	0.57	0.44	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
THCA	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	10.68	5.37e-24	4.67e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	10.68	5.37e-24	4.67e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
THCA	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	10.68	5.43e-24	4.71e-21	0.78	0.44	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
THCA	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	10.68	5.47e-24	4.75e-21	0.51	0.44	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
THCA	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	10.68	5.54e-24	4.81e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	10.68	5.54e-24	4.81e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
THCA	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	10.68	5.57e-24	4.84e-21	0.38	0.44	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
THCA	cis	rs11159086	1	rs11159086	ENSG00000270000.1	RP3-449M8.9	10.68	5.6e-24	4.85e-21	0.48	0.44	Advanced glycation end-product levels;	chr14:74495572	chr14:74471930~74472360:-
THCA	cis	rs9659323	0.65	rs17013645	ENSG00000231365.4	RP11-418J17.1	-10.68	5.6e-24	4.86e-21	-0.47	-0.44	Body mass index;	chr1:118942226	chr1:119140396~119275973:+
THCA	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-10.68	5.6e-24	4.86e-21	-0.55	-0.44	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-10.68	5.62e-24	4.87e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-10.68	5.62e-24	4.87e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-10.68	5.62e-24	4.87e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
THCA	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	10.68	5.65e-24	4.9e-21	0.47	0.44	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
THCA	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
THCA	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	10.68	5.66e-24	4.9e-21	0.6	0.44	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
THCA	cis	rs62103177	0.608	rs4442895	ENSG00000261126.6	RP11-795F19.1	-10.68	5.66e-24	4.91e-21	-0.47	-0.44	Opioid sensitivity;	chr18:80066399	chr18:80046900~80095482:+
THCA	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	10.68	5.67e-24	4.91e-21	0.51	0.44	Temperament;	chr17:14068990	chr17:14024514~14025488:+
THCA	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	10.68	5.69e-24	4.93e-21	0.37	0.44	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
THCA	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	10.68	5.69e-24	4.94e-21	0.53	0.44	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
THCA	cis	rs3745672	1	rs7248680	ENSG00000219665.7	CTD-2006C1.2	10.68	5.7e-24	4.94e-21	0.96	0.44	Multiple sclerosis;	chr19:12054955	chr19:11987617~12046275:+
THCA	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	10.68	5.71e-24	4.95e-21	0.59	0.44	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
THCA	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	10.68	5.73e-24	4.96e-21	0.52	0.44	Height;	chr6:109462738	chr6:109382795~109383666:+
THCA	cis	rs11159086	1	rs12433848	ENSG00000270000.1	RP3-449M8.9	10.68	5.74e-24	4.97e-21	0.49	0.44	Advanced glycation end-product levels;	chr14:74497570	chr14:74471930~74472360:-
THCA	cis	rs944289	0.646	rs408283	ENSG00000257826.1	RP11-116N8.4	-10.67	5.76e-24	4.99e-21	-0.46	-0.44	Thyroid cancer;	chr14:36073503	chr14:36061026~36067190:-
THCA	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-10.67	5.77e-24	5e-21	-0.46	-0.44	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
THCA	cis	rs7829975	0.501	rs2980769	ENSG00000254153.1	CTA-398F10.2	-10.67	5.8e-24	5.02e-21	-0.47	-0.44	Mood instability;	chr8:8462781	chr8:8456909~8461337:-
THCA	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	10.67	5.8e-24	5.02e-21	0.57	0.44	QT interval;	chr16:28860645	chr16:28700294~28701540:-
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000223768.1	LINC00205	-10.67	5.81e-24	5.03e-21	-0.42	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45293285~45297354:+
THCA	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	10.67	5.9e-24	5.11e-21	0.72	0.44	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
THCA	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-10.67	5.92e-24	5.12e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-10.67	5.92e-24	5.12e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
THCA	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	10.67	5.92e-24	5.13e-21	0.55	0.44	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
THCA	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-10.67	5.95e-24	5.15e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
THCA	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-10.67	5.96e-24	5.16e-21	-0.47	-0.44	Height;	chr2:231516587	chr2:231508426~231514339:-
THCA	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-10.67	5.97e-24	5.17e-21	-0.43	-0.44	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
THCA	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	10.67	6.02e-24	5.21e-21	0.64	0.44	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
THCA	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-10.67	6.02e-24	5.21e-21	-0.77	-0.44	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-10.67	6.02e-24	5.21e-21	-0.77	-0.44	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
THCA	cis	rs4819052	0.851	rs11558445	ENSG00000223768.1	LINC00205	-10.67	6.03e-24	5.22e-21	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45293285~45297354:+
THCA	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-10.67	6.04e-24	5.22e-21	-0.38	-0.44	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	10.67	6.04e-24	5.23e-21	0.59	0.44	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
THCA	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	10.67	6.04e-24	5.23e-21	0.59	0.44	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
THCA	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	10.67	6.06e-24	5.24e-21	0.58	0.44	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
THCA	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-10.67	6.07e-24	5.25e-21	-0.58	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
THCA	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-10.67	6.08e-24	5.26e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
THCA	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-10.67	6.08e-24	5.26e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
THCA	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	10.67	6.09e-24	5.26e-21	0.37	0.44	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
THCA	cis	rs7772486	0.774	rs6930181	ENSG00000235652.6	RP11-545I5.3	-10.67	6.09e-24	5.26e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145799409~145886585:+
THCA	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-10.67	6.09e-24	5.27e-21	-0.6	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
THCA	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-10.67	6.19e-24	5.35e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
THCA	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	10.67	6.26e-24	5.41e-21	0.43	0.44	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000206090.4	AP000350.7	10.66	6.31e-24	5.45e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23939998~23942798:+
THCA	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-10.66	6.36e-24	5.49e-21	-0.57	-0.44	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
THCA	cis	rs73219805	0.597	rs71517887	ENSG00000228451.3	SDAD1P1	-10.66	6.37e-24	5.5e-21	-0.62	-0.44	Schizophrenia;	chr8:26374081	chr8:26379259~26382953:-
THCA	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-10.66	6.39e-24	5.52e-21	-0.58	-0.44	QT interval;	chr16:28877088	chr16:28700294~28701540:-
THCA	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	10.66	6.39e-24	5.52e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
THCA	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-10.66	6.4e-24	5.53e-21	-0.54	-0.44	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
THCA	cis	rs9532669	0.89	rs9525420	ENSG00000239827.7	SUGT1P3	-10.66	6.42e-24	5.55e-21	-0.49	-0.44	Cervical cancer;	chr13:40882628	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7324383	ENSG00000239827.7	SUGT1P3	-10.66	6.42e-24	5.55e-21	-0.49	-0.44	Cervical cancer;	chr13:40882754	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532648	ENSG00000239827.7	SUGT1P3	-10.66	6.42e-24	5.55e-21	-0.49	-0.44	Cervical cancer;	chr13:40882795	chr13:40908159~40921774:-
THCA	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-10.66	6.48e-24	5.6e-21	-0.36	-0.44	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
THCA	cis	rs12664251	0.809	rs6931074	ENSG00000253194.1	RP11-351A11.1	10.66	6.49e-24	5.61e-21	0.62	0.44	Schizophrenia;	chr6:119020840	chr6:118934785~119031541:+
THCA	cis	rs2599510	0.783	rs62136349	ENSG00000276334.1	AL133243.1	10.66	6.52e-24	5.63e-21	0.49	0.44	Interleukin-18 levels;	chr2:32602437	chr2:32521927~32523547:+
THCA	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-10.66	6.6e-24	5.7e-21	-0.57	-0.44	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
THCA	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	10.66	6.63e-24	5.72e-21	0.35	0.44	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
THCA	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-10.66	6.63e-24	5.72e-21	-0.55	-0.44	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-10.66	6.64e-24	5.73e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
THCA	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	10.66	6.67e-24	5.76e-21	0.5	0.44	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	10.66	6.68e-24	5.76e-21	0.59	0.44	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-10.66	6.68e-24	5.77e-21	-0.62	-0.44	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
THCA	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-10.66	6.7e-24	5.78e-21	-0.49	-0.44	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
THCA	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	10.66	6.72e-24	5.8e-21	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
THCA	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	10.66	6.72e-24	5.8e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	10.66	6.72e-24	5.8e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	10.66	6.72e-24	5.8e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	10.66	6.73e-24	5.81e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
THCA	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-10.66	6.78e-24	5.85e-21	-0.68	-0.44	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
THCA	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	10.66	6.8e-24	5.86e-21	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
THCA	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	10.66	6.81e-24	5.87e-21	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	10.66	6.84e-24	5.9e-21	0.59	0.44	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
THCA	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-10.65	6.92e-24	5.96e-21	-0.54	-0.44	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
THCA	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-10.65	6.92e-24	5.96e-21	-0.54	-0.44	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
THCA	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-10.65	6.92e-24	5.96e-21	-0.54	-0.44	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
THCA	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-10.65	6.92e-24	5.96e-21	-0.54	-0.44	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
THCA	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-10.65	6.92e-24	5.96e-21	-0.69	-0.44	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
THCA	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-10.65	6.94e-24	5.98e-21	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-10.65	6.95e-24	5.99e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-10.65	6.95e-24	5.99e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-10.65	6.95e-24	5.99e-21	-0.57	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
THCA	cis	rs9532669	0.926	rs9532640	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880628	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs9532641	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880648	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532643	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880800	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs9532644	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880860	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532645	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880898	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9525419	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40881047	chr13:40908159~40921774:-
THCA	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-10.65	7.03e-24	6.06e-21	-0.58	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-10.65	7.03e-24	6.06e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
THCA	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	10.65	7.04e-24	6.06e-21	0.33	0.44	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.806	rs4243478	ENSG00000235652.6	RP11-545I5.3	-10.65	7.05e-24	6.07e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	10.65	7.05e-24	6.07e-21	0.59	0.44	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	10.65	7.1e-24	6.11e-21	0.53	0.44	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
THCA	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	10.65	7.12e-24	6.13e-21	0.71	0.44	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
THCA	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-10.65	7.12e-24	6.13e-21	-0.56	-0.44	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
THCA	cis	rs6496932	0.663	rs2062238	ENSG00000218052.5	ADAMTS7P4	-10.65	7.13e-24	6.14e-21	-0.57	-0.44	Central corneal thickness;Corneal structure;	chr15:85376002	chr15:85255369~85330334:-
THCA	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	10.65	7.13e-24	6.14e-21	0.53	0.44	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
THCA	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-10.65	7.14e-24	6.15e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-10.65	7.14e-24	6.15e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-10.65	7.14e-24	6.15e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-10.65	7.14e-24	6.15e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
THCA	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-10.65	7.15e-24	6.15e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
THCA	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-10.65	7.23e-24	6.22e-21	-0.57	-0.44	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
THCA	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-10.65	7.24e-24	6.23e-21	-0.58	-0.44	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
THCA	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-10.65	7.39e-24	6.35e-21	-0.69	-0.44	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-10.65	7.39e-24	6.35e-21	-0.69	-0.44	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
THCA	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-10.65	7.39e-24	6.36e-21	-0.4	-0.44	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
THCA	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	10.65	7.41e-24	6.37e-21	0.64	0.44	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
THCA	cis	rs180730	0.561	rs2892917	ENSG00000251609.2	SETP12	-10.65	7.42e-24	6.38e-21	-0.61	-0.44	Fasting plasma glucose;	chr4:120898600	chr4:120895494~120897083:-
THCA	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	10.65	7.47e-24	6.42e-21	0.33	0.44	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
THCA	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-10.64	7.49e-24	6.44e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
THCA	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-10.64	7.5e-24	6.44e-21	-0.69	-0.44	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
THCA	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	10.64	7.5e-24	6.44e-21	0.37	0.44	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	10.64	7.5e-24	6.44e-21	0.37	0.44	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
THCA	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	10.64	7.51e-24	6.46e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-10.64	7.56e-24	6.5e-21	-0.62	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
THCA	cis	rs934734	0.532	rs10166100	ENSG00000281920.1	RP11-418H16.1	-10.64	7.58e-24	6.51e-21	-0.54	-0.44	Rheumatoid arthritis;	chr2:65418616	chr2:65623272~65628424:+
THCA	cis	rs860295	0.651	rs12239114	ENSG00000225855.5	RUSC1-AS1	10.64	7.58e-24	6.51e-21	0.31	0.44	Body mass index;	chr1:155352351	chr1:155316863~155324176:-
THCA	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	10.64	7.63e-24	6.55e-21	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
THCA	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-10.64	7.71e-24	6.62e-21	-0.7	-0.44	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
THCA	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	10.64	7.73e-24	6.64e-21	0.59	0.44	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
THCA	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-10.64	7.79e-24	6.69e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
THCA	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	10.64	7.8e-24	6.7e-21	0.37	0.44	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	10.64	7.8e-24	6.7e-21	0.37	0.44	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
THCA	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-10.64	7.86e-24	6.75e-21	-0.63	-0.44	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
THCA	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	10.64	7.89e-24	6.78e-21	0.48	0.44	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
THCA	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	10.64	7.92e-24	6.8e-21	0.48	0.44	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
THCA	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-10.64	7.96e-24	6.84e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-10.64	7.96e-24	6.84e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
THCA	cis	rs7569084	1	rs7583469	ENSG00000281920.1	RP11-418H16.1	10.64	7.97e-24	6.84e-21	0.54	0.44	Sum eosinophil basophil counts;	chr2:65424222	chr2:65623272~65628424:+
THCA	cis	rs673078	0.607	rs56080343	ENSG00000275409.1	RP11-131L12.4	-10.64	7.97e-24	6.84e-21	-0.46	-0.44	Glucose homeostasis traits;	chr12:118439113	chr12:118430147~118430699:+
THCA	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	10.64	7.98e-24	6.85e-21	0.52	0.44	Height;	chr6:109424139	chr6:109382795~109383666:+
THCA	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	10.64	8e-24	6.87e-21	0.38	0.44	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-10.64	8.04e-24	6.9e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
THCA	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	10.64	8.09e-24	6.94e-21	0.5	0.44	Height;	chr6:109405536	chr6:109382795~109383666:+
THCA	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-10.64	8.13e-24	6.97e-21	-0.58	-0.44	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-10.64	8.13e-24	6.97e-21	-0.58	-0.44	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	10.64	8.14e-24	6.99e-21	0.53	0.44	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
THCA	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	10.63	8.24e-24	7.07e-21	0.69	0.44	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
THCA	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-10.63	8.25e-24	7.08e-21	-0.59	-0.44	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	10.63	8.27e-24	7.1e-21	0.57	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
THCA	cis	rs3745672	1	rs7246419	ENSG00000219665.7	CTD-2006C1.2	-10.63	8.35e-24	7.16e-21	-0.97	-0.44	Multiple sclerosis;	chr19:12051897	chr19:11987617~12046275:+
THCA	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-10.63	8.36e-24	7.17e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
THCA	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-10.63	8.38e-24	7.19e-21	-0.5	-0.44	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
THCA	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	10.63	8.38e-24	7.19e-21	0.58	0.44	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	10.63	8.5e-24	7.29e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
THCA	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-10.63	8.6e-24	7.37e-21	-0.57	-0.44	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
THCA	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	10.63	8.62e-24	7.39e-21	0.53	0.44	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
THCA	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-10.63	8.65e-24	7.41e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-10.63	8.75e-24	7.5e-21	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
THCA	cis	rs9890032	0.934	rs3760318	ENSG00000266490.1	CTD-2349P21.9	10.63	8.78e-24	7.53e-21	0.42	0.44	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30792372~30792833:+
THCA	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	10.63	8.81e-24	7.55e-21	0.52	0.44	Height;	chr6:109409679	chr6:109382795~109383666:+
THCA	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-10.63	8.84e-24	7.58e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
THCA	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	10.62	8.88e-24	7.61e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	10.62	8.91e-24	7.64e-21	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
THCA	cis	rs7772486	0.597	rs9285508	ENSG00000235652.6	RP11-545I5.3	-10.62	8.94e-24	7.66e-21	-0.47	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145941561	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	10.62	8.94e-24	7.66e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
THCA	cis	rs2599510	0.755	rs67257914	ENSG00000276334.1	AL133243.1	10.62	9.16e-24	7.84e-21	0.49	0.44	Interleukin-18 levels;	chr2:32578951	chr2:32521927~32523547:+
THCA	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-10.62	9.16e-24	7.84e-21	-0.7	-0.44	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
THCA	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	10.62	9.23e-24	7.9e-21	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
THCA	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-10.62	9.23e-24	7.9e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
THCA	cis	rs7211079	0.912	rs4889831	ENSG00000279259.1	RP11-334C17.3	10.62	9.25e-24	7.92e-21	0.47	0.44	Myocardial infarction;	chr17:80140854	chr17:80147250~80148596:+
THCA	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-10.62	9.28e-24	7.94e-21	-0.49	-0.44	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
THCA	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-10.62	9.29e-24	7.95e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
THCA	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-10.62	9.29e-24	7.95e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-10.62	9.29e-24	7.95e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
THCA	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-10.62	9.34e-24	7.99e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
THCA	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-10.62	9.34e-24	7.99e-21	-0.58	-0.44	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
THCA	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-10.62	9.43e-24	8.07e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
THCA	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	10.62	9.49e-24	8.12e-21	0.5	0.44	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
THCA	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	10.62	9.51e-24	8.13e-21	0.6	0.44	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
THCA	cis	rs4964805	1	rs34307072	ENSG00000257681.1	RP11-341G23.4	10.62	9.52e-24	8.14e-21	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103802526	chr12:103746315~103768858:-
THCA	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-10.62	9.55e-24	8.16e-21	-0.53	-0.44	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
THCA	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-10.62	9.55e-24	8.16e-21	-0.37	-0.44	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
THCA	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-10.62	9.55e-24	8.16e-21	-0.37	-0.44	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
THCA	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-10.62	9.55e-24	8.16e-21	-0.37	-0.44	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
THCA	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-10.62	9.6e-24	8.2e-21	-0.54	-0.44	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
THCA	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-10.62	9.63e-24	8.23e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
THCA	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	10.62	9.63e-24	8.23e-21	0.52	0.44	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
THCA	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-10.62	9.65e-24	8.24e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
THCA	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-10.62	9.65e-24	8.24e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
THCA	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-10.62	9.65e-24	8.24e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
THCA	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-10.62	9.65e-24	8.24e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
THCA	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-10.61	9.69e-24	8.28e-21	-0.48	-0.44	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
THCA	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	10.61	9.72e-24	8.3e-21	0.52	0.44	Height;	chr6:109351795	chr6:109382795~109383666:+
THCA	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	10.61	9.72e-24	8.3e-21	0.53	0.44	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
THCA	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-10.61	9.8e-24	8.37e-21	-0.56	-0.44	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-10.61	9.82e-24	8.39e-21	-0.58	-0.44	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
THCA	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	10.61	9.86e-24	8.42e-21	0.52	0.44	Height;	chr6:109354092	chr6:109382795~109383666:+
THCA	cis	rs11159086	1	rs4899514	ENSG00000270000.1	RP3-449M8.9	-10.61	9.88e-24	8.44e-21	-0.49	-0.44	Advanced glycation end-product levels;	chr14:74473467	chr14:74471930~74472360:-
THCA	cis	rs9487094	0.644	rs9320288	ENSG00000260273.1	RP11-425D10.10	10.61	9.93e-24	8.48e-21	0.52	0.44	Height;	chr6:109446727	chr6:109382795~109383666:+
THCA	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-10.61	9.99e-24	8.53e-21	-0.53	-0.44	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
THCA	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-10.61	1.01e-23	8.61e-21	-0.55	-0.44	Height;	chr3:52936861	chr3:53064283~53065091:-
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-10.61	1.01e-23	8.65e-21	-0.58	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
THCA	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-10.61	1.02e-23	8.7e-21	-0.53	-0.44	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
THCA	cis	rs7211079	0.843	rs73438138	ENSG00000279259.1	RP11-334C17.3	10.61	1.02e-23	8.7e-21	0.47	0.44	Myocardial infarction;	chr17:80148608	chr17:80147250~80148596:+
THCA	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	10.61	1.02e-23	8.72e-21	0.58	0.44	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
THCA	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-10.61	1.03e-23	8.76e-21	-0.67	-0.44	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-10.61	1.03e-23	8.78e-21	-0.55	-0.44	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
THCA	cis	rs934734	0.532	rs10153675	ENSG00000281920.1	RP11-418H16.1	-10.61	1.03e-23	8.78e-21	-0.54	-0.44	Rheumatoid arthritis;	chr2:65422446	chr2:65623272~65628424:+
THCA	cis	rs7772486	0.846	rs2892453	ENSG00000235652.6	RP11-545I5.3	10.61	1.03e-23	8.79e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145799409~145886585:+
THCA	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-10.61	1.04e-23	8.88e-21	-0.57	-0.44	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-10.61	1.04e-23	8.88e-21	-0.57	-0.44	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-10.61	1.04e-23	8.88e-21	-0.57	-0.44	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
THCA	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-10.61	1.05e-23	8.92e-21	-0.53	-0.44	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
THCA	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-10.61	1.05e-23	8.93e-21	-0.45	-0.44	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
THCA	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-10.61	1.05e-23	8.94e-21	-0.37	-0.44	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
THCA	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	10.61	1.05e-23	8.94e-21	0.41	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
THCA	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	10.61	1.05e-23	8.98e-21	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	10.6	1.06e-23	9.07e-21	0.59	0.44	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
THCA	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	10.6	1.07e-23	9.08e-21	0.53	0.44	Height;	chr6:109332929	chr6:109382795~109383666:+
THCA	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-10.6	1.08e-23	9.18e-21	-0.57	-0.44	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
THCA	cis	rs9659323	0.689	rs7545737	ENSG00000231365.4	RP11-418J17.1	10.6	1.08e-23	9.2e-21	0.48	0.44	Body mass index;	chr1:118991200	chr1:119140396~119275973:+
THCA	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
THCA	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	10.6	1.1e-23	9.36e-21	0.59	0.44	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
THCA	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-10.6	1.1e-23	9.4e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
THCA	cis	rs2980439	0.557	rs2921056	ENSG00000254153.1	CTA-398F10.2	-10.6	1.11e-23	9.43e-21	-0.47	-0.44	Neuroticism;	chr8:8461672	chr8:8456909~8461337:-
THCA	cis	rs2980439	0.557	rs2976876	ENSG00000254153.1	CTA-398F10.2	-10.6	1.11e-23	9.44e-21	-0.47	-0.44	Neuroticism;	chr8:8461340	chr8:8456909~8461337:-
THCA	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-10.6	1.11e-23	9.44e-21	-0.78	-0.44	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
THCA	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-10.6	1.11e-23	9.48e-21	-0.62	-0.44	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
THCA	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-10.6	1.12e-23	9.49e-21	-0.6	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
THCA	cis	rs944289	0.74	rs414155	ENSG00000257826.1	RP11-116N8.4	10.6	1.12e-23	9.52e-21	0.45	0.44	Thyroid cancer;	chr14:36076300	chr14:36061026~36067190:-
THCA	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	10.6	1.12e-23	9.52e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
THCA	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-10.6	1.12e-23	9.53e-21	-0.54	-0.44	Height;	chr3:52972039	chr3:53064283~53065091:-
THCA	cis	rs860295	0.702	rs10796945	ENSG00000225855.5	RUSC1-AS1	10.6	1.12e-23	9.55e-21	0.3	0.44	Body mass index;	chr1:155457897	chr1:155316863~155324176:-
THCA	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-10.6	1.13e-23	9.6e-21	-0.55	-0.44	Height;	chr3:52938846	chr3:53064283~53065091:-
THCA	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-10.6	1.13e-23	9.6e-21	-0.55	-0.44	Height;	chr3:52941053	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	10.6	1.13e-23	9.62e-21	0.61	0.44	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
THCA	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	10.6	1.13e-23	9.65e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
THCA	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-10.6	1.14e-23	9.66e-21	-0.56	-0.44	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	10.6	1.14e-23	9.67e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
THCA	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	10.6	1.14e-23	9.68e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
THCA	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	10.6	1.14e-23	9.68e-21	0.58	0.44	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
THCA	cis	rs860295	0.702	rs12025532	ENSG00000225855.5	RUSC1-AS1	10.6	1.14e-23	9.68e-21	0.31	0.44	Body mass index;	chr1:155399511	chr1:155316863~155324176:-
THCA	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	10.6	1.14e-23	9.71e-21	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
THCA	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-10.6	1.15e-23	9.74e-21	-0.58	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
THCA	cis	rs6570726	1	rs6570699	ENSG00000235652.6	RP11-545I5.3	10.6	1.15e-23	9.76e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs1935615	ENSG00000235652.6	RP11-545I5.3	10.6	1.15e-23	9.76e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145799409~145886585:+
THCA	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	10.59	1.15e-23	9.81e-21	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	10.59	1.15e-23	9.81e-21	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
THCA	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-10.59	1.16e-23	9.82e-21	-0.57	-0.44	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
THCA	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	10.59	1.16e-23	9.83e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-10.59	1.16e-23	9.84e-21	-0.58	-0.44	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-10.59	1.16e-23	9.85e-21	-0.56	-0.44	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
THCA	cis	rs934734	0.511	rs62141115	ENSG00000281920.1	RP11-418H16.1	-10.59	1.16e-23	9.9e-21	-0.53	-0.44	Rheumatoid arthritis;	chr2:65445058	chr2:65623272~65628424:+
THCA	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-10.59	1.17e-23	9.96e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
THCA	cis	rs7826238	0.524	rs2921055	ENSG00000254153.1	CTA-398F10.2	-10.59	1.18e-23	9.99e-21	-0.47	-0.44	Systolic blood pressure;	chr8:8461832	chr8:8456909~8461337:-
THCA	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
THCA	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
THCA	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
THCA	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
THCA	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
THCA	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
THCA	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-10.59	1.18e-23	1.01e-20	-0.43	-0.44	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
THCA	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-10.59	1.19e-23	1.01e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
THCA	cis	rs600231	0.708	rs1784860	ENSG00000245532.5	NEAT1	10.59	1.2e-23	1.02e-20	0.3	0.44	Bone mineral density;	chr11:65473241	chr11:65422774~65445540:+
THCA	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	10.59	1.2e-23	1.02e-20	0.3	0.44	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
THCA	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	10.59	1.2e-23	1.02e-20	0.3	0.44	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
THCA	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-10.59	1.2e-23	1.02e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
THCA	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-10.59	1.2e-23	1.02e-20	-0.56	-0.44	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-10.59	1.2e-23	1.02e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-10.59	1.2e-23	1.02e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
THCA	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	10.59	1.21e-23	1.03e-20	0.52	0.44	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
THCA	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-10.59	1.21e-23	1.03e-20	-0.65	-0.44	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000223768.1	LINC00205	-10.59	1.23e-23	1.04e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45293285~45297354:+
THCA	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-10.59	1.24e-23	1.06e-20	-0.69	-0.44	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
THCA	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-10.59	1.24e-23	1.06e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-10.59	1.24e-23	1.06e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
THCA	cis	rs7221109	0.677	rs4890092	ENSG00000278834.1	RP11-458J1.1	10.59	1.25e-23	1.06e-20	0.47	0.44	Type 1 diabetes;	chr17:40630199	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.633	rs9915135	ENSG00000278834.1	RP11-458J1.1	10.59	1.25e-23	1.06e-20	0.47	0.44	Type 1 diabetes;	chr17:40634823	chr17:40648300~40649718:+
THCA	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-10.59	1.25e-23	1.06e-20	-0.68	-0.44	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
THCA	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	10.58	1.26e-23	1.06e-20	0.52	0.44	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
THCA	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	10.58	1.26e-23	1.07e-20	0.44	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
THCA	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	10.58	1.27e-23	1.08e-20	0.49	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
THCA	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	10.58	1.27e-23	1.08e-20	0.54	0.44	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
THCA	cis	rs1185460	0.547	rs1784559	ENSG00000271751.1	RP11-110I1.14	10.58	1.28e-23	1.09e-20	0.55	0.44	Coronary artery disease;	chr11:119030904	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.527	rs693619	ENSG00000271751.1	RP11-110I1.14	10.58	1.28e-23	1.09e-20	0.55	0.44	Coronary artery disease;	chr11:119031235	chr11:119065263~119065677:-
THCA	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-10.58	1.29e-23	1.09e-20	-0.57	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
THCA	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-10.58	1.29e-23	1.09e-20	-0.59	-0.44	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000206090.4	AP000350.7	-10.58	1.31e-23	1.11e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23939998~23942798:+
THCA	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-10.58	1.31e-23	1.11e-20	-0.46	-0.44	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	10.58	1.31e-23	1.11e-20	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-10.58	1.31e-23	1.11e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
THCA	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-10.58	1.32e-23	1.12e-20	-0.55	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
THCA	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	10.58	1.32e-23	1.12e-20	0.38	0.44	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
THCA	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	10.58	1.33e-23	1.13e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
THCA	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	10.58	1.33e-23	1.13e-20	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	10.58	1.33e-23	1.13e-20	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
THCA	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	10.58	1.34e-23	1.13e-20	0.59	0.44	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
THCA	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-10.58	1.34e-23	1.13e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-10.58	1.34e-23	1.13e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
THCA	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-10.58	1.34e-23	1.14e-20	-0.49	-0.44	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-10.58	1.34e-23	1.14e-20	-0.49	-0.44	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
THCA	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-10.58	1.35e-23	1.14e-20	-0.58	-0.44	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
THCA	cis	rs73219805	0.554	rs13266943	ENSG00000228451.3	SDAD1P1	-10.58	1.35e-23	1.15e-20	-0.62	-0.44	Schizophrenia;	chr8:26336629	chr8:26379259~26382953:-
THCA	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	10.58	1.36e-23	1.15e-20	0.54	0.44	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
THCA	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	10.58	1.36e-23	1.15e-20	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
THCA	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-10.58	1.37e-23	1.16e-20	-0.58	-0.44	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
THCA	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	10.57	1.37e-23	1.16e-20	0.52	0.44	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	10.57	1.37e-23	1.16e-20	0.52	0.44	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-10.57	1.38e-23	1.16e-20	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
THCA	cis	rs11148252	0.904	rs7321964	ENSG00000278238.1	RP11-245D16.4	-10.57	1.38e-23	1.17e-20	-0.48	-0.44	Lewy body disease;	chr13:52466687	chr13:52454775~52455331:-
THCA	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	10.57	1.38e-23	1.17e-20	0.43	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
THCA	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-10.57	1.39e-23	1.17e-20	-0.38	-0.44	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
THCA	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-10.57	1.39e-23	1.17e-20	-0.38	-0.44	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
THCA	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	10.57	1.39e-23	1.18e-20	0.8	0.44	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
THCA	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-10.57	1.4e-23	1.18e-20	-0.44	-0.44	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-10.57	1.4e-23	1.18e-20	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-10.57	1.4e-23	1.18e-20	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
THCA	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-10.57	1.4e-23	1.18e-20	-0.5	-0.44	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
THCA	cis	rs860295	0.702	rs3738590	ENSG00000225855.5	RUSC1-AS1	10.57	1.4e-23	1.18e-20	0.31	0.44	Body mass index;	chr1:155660961	chr1:155316863~155324176:-
THCA	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	10.57	1.41e-23	1.19e-20	0.79	0.44	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
THCA	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	10.57	1.41e-23	1.19e-20	0.79	0.44	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	10.57	1.41e-23	1.19e-20	0.52	0.44	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
THCA	cis	rs494459	0.733	rs556437	ENSG00000278376.1	RP11-158I9.8	-10.57	1.41e-23	1.19e-20	-0.32	-0.44	Height;	chr11:118835044	chr11:118791254~118793137:+
THCA	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	10.57	1.41e-23	1.19e-20	0.63	0.44	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
THCA	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	10.57	1.42e-23	1.2e-20	0.51	0.44	Height;	chr6:109477209	chr6:109382795~109383666:+
THCA	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	10.57	1.43e-23	1.21e-20	0.58	0.44	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.846	rs1474871	ENSG00000235652.6	RP11-545I5.3	10.57	1.43e-23	1.21e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145799409~145886585:+
THCA	cis	rs8100891	0.537	rs10403370	ENSG00000267213.4	AC007773.2	-10.57	1.43e-23	1.21e-20	-0.55	-0.44	Neuroticism;	chr19:32501949	chr19:32390050~32405560:-
THCA	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	10.57	1.44e-23	1.21e-20	0.48	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
THCA	cis	rs916888	0.773	rs538628	ENSG00000232300.1	FAM215B	10.57	1.44e-23	1.22e-20	0.72	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46558830~46562795:-
THCA	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-10.57	1.44e-23	1.22e-20	-0.35	-0.44	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
THCA	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	10.57	1.44e-23	1.22e-20	0.42	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
THCA	cis	rs6570726	0.967	rs9403706	ENSG00000235652.6	RP11-545I5.3	-10.57	1.45e-23	1.22e-20	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.967	rs373527	ENSG00000235652.6	RP11-545I5.3	10.57	1.45e-23	1.22e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145799409~145886585:+
THCA	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	10.57	1.45e-23	1.22e-20	0.54	0.44	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
THCA	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-10.57	1.45e-23	1.22e-20	-0.36	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
THCA	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-10.57	1.45e-23	1.23e-20	-0.5	-0.44	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
THCA	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-10.57	1.45e-23	1.23e-20	-0.49	-0.44	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
THCA	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	10.57	1.46e-23	1.23e-20	0.52	0.44	Height;	chr6:109464011	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	10.57	1.46e-23	1.23e-20	0.52	0.44	Height;	chr6:109465777	chr6:109382795~109383666:+
THCA	cis	rs2274273	0.935	rs3818451	ENSG00000258413.1	RP11-665C16.6	-10.57	1.46e-23	1.23e-20	-0.57	-0.44	Protein biomarker;	chr14:55154398	chr14:55262767~55272075:-
THCA	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-10.57	1.46e-23	1.24e-20	-0.35	-0.44	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
THCA	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-10.57	1.47e-23	1.24e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
THCA	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-10.57	1.49e-23	1.25e-20	-0.37	-0.44	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-10.57	1.49e-23	1.25e-20	-0.37	-0.44	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
THCA	cis	rs600231	0.708	rs1784100	ENSG00000245532.5	NEAT1	10.56	1.49e-23	1.26e-20	0.3	0.44	Bone mineral density;	chr11:65481756	chr11:65422774~65445540:+
THCA	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-10.56	1.49e-23	1.26e-20	-0.58	-0.44	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
THCA	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	10.56	1.5e-23	1.27e-20	0.5	0.44	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000224205.1	AP000351.4	10.56	1.5e-23	1.27e-20	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23987320~23991421:-
THCA	cis	rs7772486	0.558	rs2142980	ENSG00000235652.6	RP11-545I5.3	-10.56	1.52e-23	1.28e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145759543	chr6:145799409~145886585:+
THCA	cis	rs7211079	0.957	rs935117	ENSG00000279259.1	RP11-334C17.3	10.56	1.52e-23	1.28e-20	0.47	0.44	Myocardial infarction;	chr17:80141685	chr17:80147250~80148596:+
THCA	cis	rs7211079	0.957	rs58120535	ENSG00000279259.1	RP11-334C17.3	10.56	1.52e-23	1.28e-20	0.47	0.44	Myocardial infarction;	chr17:80142225	chr17:80147250~80148596:+
THCA	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-10.56	1.53e-23	1.29e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
THCA	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	10.56	1.53e-23	1.29e-20	0.53	0.44	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
THCA	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	10.56	1.54e-23	1.3e-20	0.67	0.44	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
THCA	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-10.56	1.54e-23	1.3e-20	-0.53	-0.44	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
THCA	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	10.56	1.55e-23	1.31e-20	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
THCA	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-10.56	1.55e-23	1.31e-20	-0.55	-0.44	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
THCA	cis	rs600231	0.571	rs10896000	ENSG00000245532.5	NEAT1	10.56	1.55e-23	1.31e-20	0.3	0.44	Bone mineral density;	chr11:65450547	chr11:65422774~65445540:+
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000223768.1	LINC00205	-10.56	1.56e-23	1.32e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45293285~45297354:+
THCA	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	10.56	1.56e-23	1.32e-20	0.76	0.44	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
THCA	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	10.56	1.57e-23	1.32e-20	0.43	0.44	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
THCA	cis	rs944289	0.617	rs1537428	ENSG00000257826.1	RP11-116N8.4	10.56	1.58e-23	1.33e-20	0.47	0.44	Thyroid cancer;	chr14:36117579	chr14:36061026~36067190:-
THCA	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-10.56	1.58e-23	1.33e-20	-0.67	-0.44	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-10.56	1.58e-23	1.33e-20	-0.67	-0.44	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
THCA	cis	rs4819052	0.788	rs9978857	ENSG00000223768.1	LINC00205	-10.56	1.58e-23	1.34e-20	-0.42	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45293285~45297354:+
THCA	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-10.56	1.59e-23	1.34e-20	-0.53	-0.44	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
THCA	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	10.56	1.6e-23	1.35e-20	0.75	0.44	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
THCA	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	10.56	1.61e-23	1.35e-20	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
THCA	cis	rs600231	0.708	rs602838	ENSG00000245532.5	NEAT1	10.56	1.61e-23	1.35e-20	0.3	0.44	Bone mineral density;	chr11:65485776	chr11:65422774~65445540:+
THCA	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	10.56	1.61e-23	1.35e-20	0.58	0.44	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
THCA	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	10.55	1.64e-23	1.38e-20	0.4	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
THCA	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	10.55	1.64e-23	1.38e-20	0.52	0.44	Height;	chr6:109347707	chr6:109382795~109383666:+
THCA	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	10.55	1.65e-23	1.39e-20	0.45	0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
THCA	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-10.55	1.66e-23	1.4e-20	-0.59	-0.44	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
THCA	cis	rs2658782	0.704	rs2605614	ENSG00000279684.1	RP11-755E23.2	-10.55	1.67e-23	1.41e-20	-0.71	-0.44	Pulmonary function decline;	chr11:93499579	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.615	rs2605615	ENSG00000279684.1	RP11-755E23.2	-10.55	1.67e-23	1.41e-20	-0.71	-0.44	Pulmonary function decline;	chr11:93499902	chr11:93286629~93288903:-
THCA	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-10.55	1.68e-23	1.41e-20	-0.53	-0.44	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	10.55	1.68e-23	1.42e-20	0.5	0.44	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
THCA	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-10.55	1.69e-23	1.42e-20	-0.34	-0.44	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000280107.1	AL022393.9	-10.55	1.69e-23	1.42e-20	-0.51	-0.44	Parkinson's disease;	chr6:28055973	chr6:28170845~28172521:+
THCA	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-10.55	1.7e-23	1.43e-20	-0.57	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
THCA	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	10.55	1.71e-23	1.44e-20	0.3	0.44	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
THCA	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-10.55	1.71e-23	1.44e-20	-0.53	-0.44	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
THCA	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-10.55	1.71e-23	1.44e-20	-0.7	-0.44	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
THCA	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	10.55	1.72e-23	1.45e-20	0.36	0.44	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	10.55	1.72e-23	1.45e-20	0.36	0.44	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
THCA	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-10.55	1.72e-23	1.45e-20	-0.57	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
THCA	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-10.55	1.73e-23	1.45e-20	-0.57	-0.44	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
THCA	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-10.55	1.73e-23	1.46e-20	-0.76	-0.44	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
THCA	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-10.55	1.74e-23	1.46e-20	-0.53	-0.44	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
THCA	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	10.55	1.74e-23	1.46e-20	0.43	0.44	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
THCA	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	10.55	1.75e-23	1.47e-20	0.57	0.44	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
THCA	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	10.55	1.76e-23	1.48e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
THCA	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-10.55	1.76e-23	1.48e-20	-0.47	-0.44	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
THCA	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-10.55	1.77e-23	1.48e-20	-0.44	-0.44	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
THCA	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	10.55	1.77e-23	1.48e-20	0.38	0.44	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
THCA	cis	rs9532669	0.926	rs12428966	ENSG00000239827.7	SUGT1P3	-10.55	1.77e-23	1.48e-20	-0.48	-0.44	Cervical cancer;	chr13:40876552	chr13:40908159~40921774:-
THCA	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-10.54	1.78e-23	1.49e-20	-0.56	-0.44	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
THCA	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	10.54	1.79e-23	1.5e-20	0.58	0.44	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-10.54	1.8e-23	1.51e-20	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-10.54	1.8e-23	1.51e-20	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
THCA	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-10.54	1.81e-23	1.52e-20	-0.52	-0.44	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
THCA	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	10.54	1.81e-23	1.52e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
THCA	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	10.54	1.81e-23	1.52e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
THCA	cis	rs62103177	0.564	rs55867755	ENSG00000261126.6	RP11-795F19.1	10.54	1.82e-23	1.52e-20	0.47	0.44	Opioid sensitivity;	chr18:79963434	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.564	rs59188178	ENSG00000261126.6	RP11-795F19.1	10.54	1.82e-23	1.52e-20	0.47	0.44	Opioid sensitivity;	chr18:79963435	chr18:80046900~80095482:+
THCA	cis	rs6570726	0.967	rs9497316	ENSG00000235652.6	RP11-545I5.3	-10.54	1.82e-23	1.53e-20	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145799409~145886585:+
THCA	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-10.54	1.83e-23	1.54e-20	-0.56	-0.44	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
THCA	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	10.54	1.85e-23	1.55e-20	0.61	0.44	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
THCA	cis	rs9532669	0.89	rs9525417	ENSG00000239827.7	SUGT1P3	-10.54	1.87e-23	1.57e-20	-0.49	-0.44	Cervical cancer;	chr13:40878431	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs9532638	ENSG00000239827.7	SUGT1P3	-10.54	1.87e-23	1.57e-20	-0.49	-0.44	Cervical cancer;	chr13:40878471	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7997536	ENSG00000239827.7	SUGT1P3	-10.54	1.87e-23	1.57e-20	-0.49	-0.44	Cervical cancer;	chr13:40878685	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7997560	ENSG00000239827.7	SUGT1P3	-10.54	1.87e-23	1.57e-20	-0.49	-0.44	Cervical cancer;	chr13:40878723	chr13:40908159~40921774:-
THCA	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-10.54	1.88e-23	1.58e-20	-0.44	-0.44	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
THCA	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-10.54	1.88e-23	1.58e-20	-0.44	-0.44	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
THCA	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-10.54	1.89e-23	1.59e-20	-0.55	-0.44	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
THCA	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	10.54	1.91e-23	1.6e-20	0.58	0.44	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
THCA	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-10.53	1.93e-23	1.62e-20	-0.57	-0.44	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
THCA	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	10.53	1.95e-23	1.63e-20	0.46	0.44	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
THCA	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	10.53	1.95e-23	1.63e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
THCA	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-10.53	1.96e-23	1.64e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
THCA	cis	rs860295	0.702	rs12047756	ENSG00000225855.5	RUSC1-AS1	10.53	1.96e-23	1.65e-20	0.31	0.44	Body mass index;	chr1:155655153	chr1:155316863~155324176:-
THCA	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	10.53	1.98e-23	1.66e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	10.53	2e-23	1.67e-20	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
THCA	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	10.53	2.01e-23	1.68e-20	0.48	0.44	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
THCA	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-10.53	2.02e-23	1.7e-20	-0.67	-0.44	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-10.53	2.03e-23	1.7e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
THCA	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	10.53	2.04e-23	1.71e-20	0.5	0.44	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
THCA	cis	rs600231	0.665	rs1621277	ENSG00000245532.5	NEAT1	-10.53	2.04e-23	1.71e-20	-0.3	-0.44	Bone mineral density;	chr11:65454483	chr11:65422774~65445540:+
THCA	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	10.53	2.04e-23	1.71e-20	0.58	0.44	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
THCA	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	10.53	2.05e-23	1.72e-20	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
THCA	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-10.53	2.05e-23	1.72e-20	-0.52	-0.44	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
THCA	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-10.53	2.05e-23	1.72e-20	-0.5	-0.44	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
THCA	cis	rs600231	0.719	rs7114809	ENSG00000245532.5	NEAT1	10.53	2.06e-23	1.72e-20	0.3	0.44	Bone mineral density;	chr11:65483973	chr11:65422774~65445540:+
THCA	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	10.53	2.06e-23	1.73e-20	0.51	0.44	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
THCA	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-10.53	2.07e-23	1.73e-20	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
THCA	cis	rs73219805	0.554	rs3808569	ENSG00000228451.3	SDAD1P1	-10.53	2.07e-23	1.73e-20	-0.63	-0.44	Schizophrenia;	chr8:26356252	chr8:26379259~26382953:-
THCA	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	10.53	2.08e-23	1.74e-20	0.51	0.44	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
THCA	cis	rs7772486	0.875	rs864390	ENSG00000235652.6	RP11-545I5.3	10.53	2.08e-23	1.74e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	10.53	2.08e-23	1.74e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	10.53	2.09e-23	1.75e-20	0.51	0.44	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	10.53	2.09e-23	1.75e-20	0.51	0.44	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
THCA	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-10.53	2.09e-23	1.75e-20	-0.48	-0.44	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
THCA	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-10.52	2.12e-23	1.78e-20	-0.57	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
THCA	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	10.52	2.12e-23	1.78e-20	0.56	0.44	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
THCA	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	10.52	2.14e-23	1.79e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	10.52	2.15e-23	1.8e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
THCA	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-10.52	2.15e-23	1.8e-20	-0.38	-0.44	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
THCA	cis	rs600231	0.623	rs587080	ENSG00000245532.5	NEAT1	10.52	2.18e-23	1.82e-20	0.3	0.44	Bone mineral density;	chr11:65486329	chr11:65422774~65445540:+
THCA	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-10.52	2.19e-23	1.83e-20	-0.41	-0.44	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
THCA	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	10.52	2.2e-23	1.84e-20	0.48	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
THCA	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-10.52	2.2e-23	1.84e-20	-0.36	-0.44	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	10.52	2.21e-23	1.85e-20	0.58	0.44	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	10.52	2.21e-23	1.85e-20	0.58	0.44	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	10.52	2.21e-23	1.85e-20	0.58	0.44	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	10.52	2.21e-23	1.85e-20	0.58	0.44	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
THCA	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	10.52	2.23e-23	1.86e-20	0.52	0.44	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
THCA	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-10.52	2.24e-23	1.87e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
THCA	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	10.52	2.24e-23	1.87e-20	0.54	0.44	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
THCA	cis	rs4819052	0.655	rs2330102	ENSG00000223768.1	LINC00205	-10.52	2.25e-23	1.88e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.679	rs8132135	ENSG00000223768.1	LINC00205	-10.52	2.25e-23	1.88e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45293285~45297354:+
THCA	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-10.52	2.25e-23	1.88e-20	-0.34	-0.44	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
THCA	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	10.52	2.26e-23	1.88e-20	0.43	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
THCA	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	10.52	2.26e-23	1.89e-20	0.5	0.44	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	10.52	2.26e-23	1.89e-20	0.5	0.44	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
THCA	cis	rs12188164	1	rs34453673	ENSG00000221990.4	EXOC3-AS1	10.51	2.29e-23	1.91e-20	0.37	0.44	Cystic fibrosis severity;	chr5:434607	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs72717412	ENSG00000221990.4	EXOC3-AS1	10.51	2.29e-23	1.91e-20	0.37	0.44	Cystic fibrosis severity;	chr5:429266	chr5:441498~443160:-
THCA	cis	rs11159086	1	rs3759745	ENSG00000270000.1	RP3-449M8.9	10.51	2.29e-23	1.91e-20	0.47	0.44	Advanced glycation end-product levels;	chr14:74495967	chr14:74471930~74472360:-
THCA	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	10.51	2.3e-23	1.92e-20	0.33	0.44	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
THCA	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	10.51	2.3e-23	1.92e-20	0.52	0.44	Height;	chr6:109346560	chr6:109382795~109383666:+
THCA	cis	rs7772486	0.875	rs6570738	ENSG00000235652.6	RP11-545I5.3	10.51	2.3e-23	1.92e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1412080	ENSG00000235652.6	RP11-545I5.3	10.51	2.3e-23	1.92e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145799409~145886585:+
THCA	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	10.51	2.31e-23	1.93e-20	0.68	0.44	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	10.51	2.31e-23	1.93e-20	0.68	0.44	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
THCA	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	10.51	2.31e-23	1.93e-20	0.61	0.44	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
THCA	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	10.51	2.32e-23	1.94e-20	0.53	0.44	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
THCA	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.94e-20	0.51	0.44	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	10.51	2.34e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
THCA	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	10.51	2.35e-23	1.96e-20	0.33	0.44	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
THCA	cis	rs6570726	0.935	rs449377	ENSG00000235652.6	RP11-545I5.3	10.51	2.37e-23	1.97e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145799409~145886585:+
THCA	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	10.51	2.38e-23	1.98e-20	0.58	0.44	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
THCA	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	10.51	2.39e-23	2e-20	0.33	0.44	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
THCA	cis	rs4964805	1	rs1866295	ENSG00000257681.1	RP11-341G23.4	10.51	2.4e-23	2e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103793168	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.954	rs11111785	ENSG00000257681.1	RP11-341G23.4	10.51	2.42e-23	2.02e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103795278	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.954	rs11111786	ENSG00000257681.1	RP11-341G23.4	10.51	2.42e-23	2.02e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103795279	chr12:103746315~103768858:-
THCA	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	10.51	2.43e-23	2.03e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	10.51	2.43e-23	2.03e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	10.51	2.43e-23	2.03e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	10.51	2.45e-23	2.04e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
THCA	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	10.51	2.47e-23	2.05e-20	0.51	0.44	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
THCA	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	10.5	2.5e-23	2.08e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	10.5	2.51e-23	2.09e-20	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
THCA	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	10.5	2.51e-23	2.09e-20	0.47	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	10.5	2.51e-23	2.09e-20	0.47	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
THCA	cis	rs12188164	1	rs72717410	ENSG00000221990.4	EXOC3-AS1	10.5	2.51e-23	2.09e-20	0.37	0.44	Cystic fibrosis severity;	chr5:428670	chr5:441498~443160:-
THCA	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-10.5	2.52e-23	2.1e-20	-0.48	-0.44	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
THCA	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-10.5	2.53e-23	2.11e-20	-0.5	-0.44	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
THCA	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	10.5	2.54e-23	2.11e-20	0.53	0.44	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
THCA	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-10.5	2.54e-23	2.12e-20	-0.59	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
THCA	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-10.5	2.54e-23	2.12e-20	-0.59	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
THCA	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-10.5	2.55e-23	2.12e-20	-0.57	-0.44	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
THCA	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-10.5	2.57e-23	2.14e-20	-0.56	-0.44	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
THCA	cis	rs11159086	1	rs4903233	ENSG00000270000.1	RP3-449M8.9	10.5	2.58e-23	2.14e-20	0.47	0.44	Advanced glycation end-product levels;	chr14:74497291	chr14:74471930~74472360:-
THCA	cis	rs12188164	1	rs56104584	ENSG00000221990.4	EXOC3-AS1	10.5	2.58e-23	2.15e-20	0.37	0.44	Cystic fibrosis severity;	chr5:437427	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs55842567	ENSG00000221990.4	EXOC3-AS1	10.5	2.58e-23	2.15e-20	0.37	0.44	Cystic fibrosis severity;	chr5:437471	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs56042615	ENSG00000221990.4	EXOC3-AS1	10.5	2.58e-23	2.15e-20	0.37	0.44	Cystic fibrosis severity;	chr5:437552	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs34847072	ENSG00000221990.4	EXOC3-AS1	10.5	2.58e-23	2.15e-20	0.37	0.44	Cystic fibrosis severity;	chr5:437747	chr5:441498~443160:-
THCA	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	10.5	2.58e-23	2.15e-20	0.57	0.44	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
THCA	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	10.5	2.58e-23	2.15e-20	0.55	0.44	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-10.5	2.59e-23	2.15e-20	-0.58	-0.44	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
THCA	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	10.5	2.59e-23	2.15e-20	0.59	0.44	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
THCA	cis	rs7211079	0.917	rs4243251	ENSG00000279259.1	RP11-334C17.3	10.5	2.6e-23	2.16e-20	0.46	0.44	Myocardial infarction;	chr17:80138811	chr17:80147250~80148596:+
THCA	cis	rs7211079	0.917	rs8067991	ENSG00000279259.1	RP11-334C17.3	10.5	2.6e-23	2.16e-20	0.46	0.44	Myocardial infarction;	chr17:80145503	chr17:80147250~80148596:+
THCA	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	10.5	2.6e-23	2.16e-20	0.36	0.44	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
THCA	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-10.5	2.61e-23	2.17e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-10.5	2.61e-23	2.17e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-10.5	2.61e-23	2.17e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-10.5	2.61e-23	2.17e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
THCA	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	10.5	2.61e-23	2.17e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	10.5	2.61e-23	2.17e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs441477	ENSG00000235652.6	RP11-545I5.3	10.5	2.61e-23	2.17e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000224205.1	AP000351.4	10.5	2.63e-23	2.18e-20	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23987320~23991421:-
THCA	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	10.5	2.63e-23	2.18e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	10.5	2.63e-23	2.19e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	10.5	2.64e-23	2.2e-20	0.52	0.44	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
THCA	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	10.5	2.66e-23	2.21e-20	0.46	0.44	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	10.5	2.66e-23	2.21e-20	0.46	0.44	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-10.5	2.67e-23	2.22e-20	-0.36	-0.44	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	10.5	2.67e-23	2.22e-20	0.36	0.44	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	10.5	2.67e-23	2.22e-20	0.36	0.44	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
THCA	cis	rs1043099	0.871	rs9619104	ENSG00000279699.1	RP1-102K2.9	-10.5	2.67e-23	2.22e-20	-0.62	-0.44	Rheumatoid arthritis;	chr22:30378351	chr22:30275215~30276951:-
THCA	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	10.5	2.67e-23	2.22e-20	0.6	0.44	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
THCA	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	10.5	2.7e-23	2.24e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
THCA	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-10.5	2.7e-23	2.24e-20	-0.5	-0.44	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
THCA	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	10.5	2.72e-23	2.26e-20	0.51	0.44	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	10.5	2.72e-23	2.26e-20	0.51	0.44	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
THCA	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-10.5	2.72e-23	2.26e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
THCA	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-10.49	2.72e-23	2.26e-20	-0.59	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
THCA	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	10.49	2.73e-23	2.27e-20	0.33	0.44	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-10.49	2.75e-23	2.28e-20	-0.58	-0.44	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
THCA	cis	rs9532669	0.926	rs2183144	ENSG00000239827.7	SUGT1P3	10.49	2.76e-23	2.29e-20	0.49	0.44	Cervical cancer;	chr13:40862129	chr13:40908159~40921774:-
THCA	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-10.49	2.76e-23	2.29e-20	-0.76	-0.44	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
THCA	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-10.49	2.77e-23	2.3e-20	-0.59	-0.44	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
THCA	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-10.49	2.77e-23	2.3e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
THCA	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-10.49	2.79e-23	2.31e-20	-0.51	-0.44	Height;	chr6:109360458	chr6:109382795~109383666:+
THCA	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	10.49	2.81e-23	2.33e-20	0.6	0.44	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-10.49	2.81e-23	2.33e-20	-0.56	-0.44	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
THCA	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-10.49	2.83e-23	2.34e-20	-0.61	-0.44	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
THCA	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	10.49	2.84e-23	2.35e-20	0.51	0.44	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-10.49	2.84e-23	2.36e-20	-0.58	-0.44	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	10.49	2.84e-23	2.36e-20	0.52	0.44	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
THCA	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-10.49	2.85e-23	2.36e-20	-0.34	-0.44	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
THCA	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-10.49	2.85e-23	2.36e-20	-0.34	-0.44	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
THCA	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-10.49	2.85e-23	2.36e-20	-0.68	-0.44	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-10.49	2.85e-23	2.36e-20	-0.68	-0.44	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
THCA	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-10.49	2.85e-23	2.37e-20	-0.34	-0.44	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
THCA	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	10.49	2.86e-23	2.37e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
THCA	cis	rs9318086	0.533	rs7325450	ENSG00000205861.10	C1QTNF9B-AS1	-10.49	2.86e-23	2.37e-20	-0.51	-0.44	Myopia (pathological);	chr13:23892865	chr13:23888889~23897263:+
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	10.49	2.89e-23	2.39e-20	0.58	0.44	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.679	rs2838859	ENSG00000223768.1	LINC00205	-10.49	2.89e-23	2.39e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45293285~45297354:+
THCA	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-10.49	2.92e-23	2.42e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
THCA	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-10.49	2.93e-23	2.43e-20	-0.5	-0.44	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
THCA	cis	rs7569084	1	rs13385171	ENSG00000234255.7	AC012370.3	-10.49	2.94e-23	2.43e-20	-0.49	-0.44	Sum eosinophil basophil counts;	chr2:65434709	chr2:65439888~65456571:-
THCA	cis	rs62103177	0.525	rs62101233	ENSG00000261126.6	RP11-795F19.1	10.49	2.95e-23	2.44e-20	0.47	0.44	Opioid sensitivity;	chr18:79964288	chr18:80046900~80095482:+
THCA	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	10.49	2.95e-23	2.45e-20	0.53	0.44	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
THCA	cis	rs934734	0.532	rs62141075	ENSG00000281920.1	RP11-418H16.1	-10.48	2.98e-23	2.47e-20	-0.53	-0.44	Rheumatoid arthritis;	chr2:65417482	chr2:65623272~65628424:+
THCA	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-10.48	3e-23	2.49e-20	-0.51	-0.44	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
THCA	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-10.48	3.01e-23	2.49e-20	-0.48	-0.44	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
THCA	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-10.48	3.06e-23	2.53e-20	-0.57	-0.44	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
THCA	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-10.48	3.07e-23	2.54e-20	-0.5	-0.44	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
THCA	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-10.48	3.07e-23	2.55e-20	-0.57	-0.44	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
THCA	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	10.48	3.08e-23	2.55e-20	0.5	0.44	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000224205.1	AP000351.4	10.48	3.12e-23	2.58e-20	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23987320~23991421:-
THCA	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-10.48	3.14e-23	2.6e-20	-0.42	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000223768.1	LINC00205	-10.48	3.16e-23	2.62e-20	-0.45	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	10.48	3.16e-23	2.62e-20	0.58	0.44	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	10.48	3.16e-23	2.62e-20	0.58	0.44	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-10.48	3.18e-23	2.63e-20	-0.44	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-10.48	3.18e-23	2.63e-20	-0.4	-0.44	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
THCA	cis	rs10078	0.848	rs890985	ENSG00000221990.4	EXOC3-AS1	10.48	3.2e-23	2.65e-20	0.38	0.44	Fat distribution (HIV);	chr5:479631	chr5:441498~443160:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-10.48	3.21e-23	2.65e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
THCA	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-10.47	3.24e-23	2.68e-20	-0.43	-0.44	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
THCA	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	10.47	3.24e-23	2.68e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-10.47	3.25e-23	2.69e-20	-0.57	-0.44	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
THCA	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	10.47	3.26e-23	2.69e-20	0.51	0.44	Height;	chr6:109634847	chr6:109382795~109383666:+
THCA	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-10.47	3.27e-23	2.7e-20	-0.73	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
THCA	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	10.47	3.27e-23	2.7e-20	0.47	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
THCA	cis	rs860295	0.702	rs34620961	ENSG00000225855.5	RUSC1-AS1	10.47	3.31e-23	2.74e-20	0.31	0.43	Body mass index;	chr1:155680036	chr1:155316863~155324176:-
THCA	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	10.47	3.34e-23	2.76e-20	0.51	0.43	Height;	chr6:109476101	chr6:109382795~109383666:+
THCA	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-10.47	3.37e-23	2.78e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
THCA	cis	rs9532669	0.926	rs11147824	ENSG00000239827.7	SUGT1P3	-10.47	3.37e-23	2.78e-20	-0.49	-0.43	Cervical cancer;	chr13:40878183	chr13:40908159~40921774:-
THCA	cis	rs860295	0.702	rs12040100	ENSG00000225855.5	RUSC1-AS1	10.47	3.38e-23	2.79e-20	0.3	0.43	Body mass index;	chr1:155642056	chr1:155316863~155324176:-
THCA	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	10.47	3.39e-23	2.8e-20	0.56	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
THCA	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	10.47	3.4e-23	2.81e-20	0.47	0.43	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
THCA	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-10.47	3.42e-23	2.82e-20	-0.55	-0.43	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
THCA	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	10.47	3.42e-23	2.82e-20	0.75	0.43	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
THCA	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	10.47	3.42e-23	2.83e-20	0.59	0.43	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
THCA	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-10.47	3.43e-23	2.83e-20	-0.55	-0.43	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
THCA	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-10.47	3.49e-23	2.87e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
THCA	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	10.47	3.5e-23	2.89e-20	0.53	0.43	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
THCA	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	10.47	3.5e-23	2.89e-20	0.38	0.43	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
THCA	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-10.46	3.55e-23	2.92e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-10.46	3.58e-23	2.95e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
THCA	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-10.46	3.58e-23	2.95e-20	-0.55	-0.43	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
THCA	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-10.46	3.58e-23	2.95e-20	-0.38	-0.43	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	10.46	3.59e-23	2.95e-20	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
THCA	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	10.46	3.61e-23	2.97e-20	0.45	0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-10.46	3.62e-23	2.98e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
THCA	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	10.46	3.62e-23	2.98e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
THCA	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-10.46	3.64e-23	3e-20	-0.56	-0.43	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
THCA	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	10.46	3.67e-23	3.02e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000224205.1	AP000351.4	10.46	3.67e-23	3.02e-20	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23987320~23991421:-
THCA	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-10.46	3.7e-23	3.05e-20	-0.45	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
THCA	cis	rs4819052	0.788	rs13049700	ENSG00000223768.1	LINC00205	-10.46	3.71e-23	3.06e-20	-0.42	-0.43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45293285~45297354:+
THCA	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	10.46	3.77e-23	3.1e-20	0.61	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
THCA	cis	rs12188164	0.965	rs1056465	ENSG00000221990.4	EXOC3-AS1	10.46	3.77e-23	3.1e-20	0.37	0.43	Cystic fibrosis severity;	chr5:442323	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs56146525	ENSG00000221990.4	EXOC3-AS1	10.46	3.77e-23	3.1e-20	0.37	0.43	Cystic fibrosis severity;	chr5:442456	chr5:441498~443160:-
THCA	cis	rs12188164	0.931	rs115554641	ENSG00000221990.4	EXOC3-AS1	10.46	3.77e-23	3.1e-20	0.37	0.43	Cystic fibrosis severity;	chr5:443121	chr5:441498~443160:-
THCA	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	10.46	3.81e-23	3.13e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000206090.4	AP000350.7	10.45	3.87e-23	3.18e-20	0.53	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23939998~23942798:+
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000234255.7	AC012370.3	-10.45	3.87e-23	3.18e-20	-0.49	-0.43	Sum eosinophil basophil counts;	chr2:65438139	chr2:65439888~65456571:-
THCA	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-10.45	3.89e-23	3.2e-20	-0.52	-0.43	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
THCA	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-10.45	3.9e-23	3.2e-20	-0.47	-0.43	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
THCA	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-10.45	3.91e-23	3.22e-20	-0.67	-0.43	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
THCA	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	10.45	3.94e-23	3.24e-20	0.53	0.43	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
THCA	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	10.45	3.96e-23	3.25e-20	0.52	0.43	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
THCA	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-10.45	3.96e-23	3.25e-20	-0.56	-0.43	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
THCA	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	10.45	3.97e-23	3.26e-20	0.37	0.43	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
THCA	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	10.45	3.97e-23	3.26e-20	0.53	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
THCA	cis	rs73219805	0.597	rs3824232	ENSG00000228451.3	SDAD1P1	-10.45	3.98e-23	3.27e-20	-0.61	-0.43	Schizophrenia;	chr8:26370083	chr8:26379259~26382953:-
THCA	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	10.45	4.03e-23	3.31e-20	0.53	0.43	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
THCA	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	10.45	4.04e-23	3.32e-20	0.58	0.43	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	10.45	4.04e-23	3.32e-20	0.58	0.43	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	10.45	4.04e-23	3.32e-20	0.58	0.43	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
THCA	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-10.45	4.05e-23	3.33e-20	-0.5	-0.43	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
THCA	cis	rs944289	0.706	rs11156904	ENSG00000257826.1	RP11-116N8.4	-10.45	4.07e-23	3.34e-20	-0.45	-0.43	Thyroid cancer;	chr14:36085688	chr14:36061026~36067190:-
THCA	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	10.45	4.08e-23	3.35e-20	0.41	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	10.45	4.11e-23	3.37e-20	0.57	0.43	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
THCA	cis	rs860295	0.702	rs2175391	ENSG00000225855.5	RUSC1-AS1	-10.45	4.12e-23	3.38e-20	-0.3	-0.43	Body mass index;	chr1:155655811	chr1:155316863~155324176:-
THCA	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-10.45	4.15e-23	3.41e-20	-0.69	-0.43	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
THCA	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-10.45	4.15e-23	3.41e-20	-0.65	-0.43	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
THCA	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	10.44	4.18e-23	3.43e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	10.44	4.18e-23	3.43e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
THCA	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-10.44	4.18e-23	3.43e-20	-0.49	-0.43	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-10.44	4.21e-23	3.45e-20	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
THCA	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	10.44	4.21e-23	3.45e-20	0.58	0.43	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
THCA	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	10.44	4.23e-23	3.47e-20	0.75	0.43	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
THCA	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-10.44	4.24e-23	3.48e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
THCA	cis	rs12188164	0.965	rs56182240	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:423054	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs55948934	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:423556	chr5:441498~443160:-
THCA	cis	rs12188164	0.897	rs55932239	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:423791	chr5:441498~443160:-
THCA	cis	rs12188164	0.931	rs72717407	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:424538	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs12188678	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:428116	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs12188164	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:428121	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs72717411	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:429009	chr5:441498~443160:-
THCA	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	10.44	4.3e-23	3.53e-20	0.64	0.43	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
THCA	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-10.44	4.32e-23	3.54e-20	-0.44	-0.43	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
THCA	cis	rs600231	0.708	rs682845	ENSG00000245532.5	NEAT1	10.44	4.33e-23	3.55e-20	0.3	0.43	Bone mineral density;	chr11:65486730	chr11:65422774~65445540:+
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	10.44	4.4e-23	3.6e-20	0.51	0.43	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	10.44	4.4e-23	3.6e-20	0.51	0.43	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	10.44	4.4e-23	3.6e-20	0.51	0.43	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
THCA	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-10.44	4.41e-23	3.61e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
THCA	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-10.44	4.41e-23	3.61e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
THCA	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-10.44	4.41e-23	3.61e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
THCA	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	10.44	4.45e-23	3.64e-20	0.37	0.43	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
THCA	cis	rs4964805	1	rs73192053	ENSG00000257681.1	RP11-341G23.4	10.44	4.47e-23	3.66e-20	0.52	0.43	Attention deficit hyperactivity disorder;	chr12:103797077	chr12:103746315~103768858:-
THCA	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	10.44	4.49e-23	3.68e-20	0.53	0.43	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
THCA	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-10.44	4.51e-23	3.69e-20	-0.42	-0.43	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
THCA	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-10.44	4.51e-23	3.69e-20	-0.34	-0.43	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
THCA	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-10.44	4.52e-23	3.7e-20	-0.56	-0.43	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
THCA	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	10.44	4.53e-23	3.7e-20	0.53	0.43	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
THCA	cis	rs7191700	0.673	rs12325495	ENSG00000262703.1	RP11-485G7.6	10.44	4.54e-23	3.72e-20	0.47	0.43	Multiple sclerosis;	chr16:11324471	chr16:11348143~11349321:-
THCA	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	10.43	4.55e-23	3.73e-20	0.51	0.43	Height;	chr6:109447092	chr6:109382795~109383666:+
THCA	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	10.43	4.56e-23	3.73e-20	0.55	0.43	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
THCA	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	10.43	4.56e-23	3.73e-20	0.63	0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
THCA	cis	rs11148252	0.904	rs9568734	ENSG00000278238.1	RP11-245D16.4	-10.43	4.59e-23	3.75e-20	-0.47	-0.43	Lewy body disease;	chr13:52430087	chr13:52454775~52455331:-
THCA	cis	rs12188164	1	rs72717414	ENSG00000221990.4	EXOC3-AS1	10.43	4.59e-23	3.76e-20	0.37	0.43	Cystic fibrosis severity;	chr5:429703	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs72717415	ENSG00000221990.4	EXOC3-AS1	10.43	4.59e-23	3.76e-20	0.37	0.43	Cystic fibrosis severity;	chr5:429944	chr5:441498~443160:-
THCA	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-10.43	4.61e-23	3.77e-20	-0.48	-0.43	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
THCA	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	10.43	4.61e-23	3.77e-20	0.6	0.43	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	10.43	4.61e-23	3.77e-20	0.53	0.43	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
THCA	cis	rs860295	0.702	rs2048431	ENSG00000225855.5	RUSC1-AS1	10.43	4.62e-23	3.78e-20	0.3	0.43	Body mass index;	chr1:155648839	chr1:155316863~155324176:-
THCA	cis	rs11148252	0.904	rs7990581	ENSG00000278238.1	RP11-245D16.4	-10.43	4.62e-23	3.78e-20	-0.47	-0.43	Lewy body disease;	chr13:52445298	chr13:52454775~52455331:-
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	10.43	4.66e-23	3.81e-20	0.57	0.43	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
THCA	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-10.43	4.67e-23	3.82e-20	-0.54	-0.43	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
THCA	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-10.43	4.68e-23	3.83e-20	-0.54	-0.43	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
THCA	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	10.43	4.69e-23	3.83e-20	0.58	0.43	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
THCA	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	10.43	4.69e-23	3.83e-20	0.41	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
THCA	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-10.43	4.7e-23	3.84e-20	-0.5	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
THCA	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-10.43	4.76e-23	3.89e-20	-0.48	-0.43	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
THCA	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	10.43	4.79e-23	3.91e-20	0.63	0.43	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
THCA	cis	rs11148252	0.904	rs9568732	ENSG00000278238.1	RP11-245D16.4	10.43	4.85e-23	3.96e-20	0.47	0.43	Lewy body disease;	chr13:52419277	chr13:52454775~52455331:-
THCA	cis	rs34375054	0.525	rs7398636	ENSG00000279233.1	RP11-158L12.4	10.43	4.86e-23	3.97e-20	0.42	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125114058	chr12:125138245~125141711:+
THCA	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	10.43	4.89e-23	3.99e-20	0.52	0.43	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
THCA	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	10.43	4.91e-23	4.01e-20	0.48	0.43	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
THCA	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-10.43	4.92e-23	4.01e-20	-0.57	-0.43	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
THCA	cis	rs8062405	0.789	rs240704	ENSG00000251417.2	RP11-1348G14.4	-10.43	4.93e-23	4.02e-20	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28802743~28817828:+
THCA	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-10.42	5e-23	4.08e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	10.42	5.07e-23	4.13e-20	0.58	0.43	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	10.42	5.07e-23	4.13e-20	0.58	0.43	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	10.42	5.07e-23	4.13e-20	0.58	0.43	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-10.42	5.08e-23	4.14e-20	-0.4	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	10.42	5.08e-23	4.14e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	10.42	5.08e-23	4.14e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	10.42	5.08e-23	4.14e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
THCA	cis	rs944289	0.646	rs8003253	ENSG00000257826.1	RP11-116N8.4	-10.42	5.09e-23	4.15e-20	-0.45	-0.43	Thyroid cancer;	chr14:36088485	chr14:36061026~36067190:-
THCA	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-10.42	5.11e-23	4.16e-20	-0.55	-0.43	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-10.42	5.11e-23	4.16e-20	-0.55	-0.43	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
THCA	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	10.42	5.14e-23	4.18e-20	0.51	0.43	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
THCA	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	10.42	5.18e-23	4.22e-20	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
THCA	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	10.42	5.21e-23	4.24e-20	0.58	0.43	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
THCA	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	10.42	5.21e-23	4.25e-20	0.33	0.43	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	10.42	5.22e-23	4.25e-20	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	10.42	5.29e-23	4.31e-20	0.58	0.43	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
THCA	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	10.42	5.33e-23	4.34e-20	0.56	0.43	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-10.41	5.4e-23	4.4e-20	-0.4	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
THCA	cis	rs950169	0.656	rs748455	ENSG00000259728.4	LINC00933	10.41	5.42e-23	4.41e-20	0.6	0.43	Schizophrenia;	chr15:84606344	chr15:84570649~84580175:+
THCA	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	10.41	5.47e-23	4.45e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
THCA	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	10.41	5.49e-23	4.46e-20	0.5	0.43	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
THCA	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-10.41	5.49e-23	4.47e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
THCA	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-10.41	5.51e-23	4.48e-20	-0.58	-0.43	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
THCA	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-10.41	5.53e-23	4.5e-20	-0.66	-0.43	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
THCA	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-10.41	5.53e-23	4.5e-20	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-10.41	5.62e-23	4.57e-20	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
THCA	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	10.41	5.63e-23	4.57e-20	0.6	0.43	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
THCA	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	10.41	5.63e-23	4.58e-20	0.76	0.43	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
THCA	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	10.41	5.66e-23	4.6e-20	0.53	0.43	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	10.41	5.66e-23	4.6e-20	0.53	0.43	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	10.41	5.66e-23	4.6e-20	0.53	0.43	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
THCA	cis	rs4266144	0.562	rs2086667	ENSG00000244515.1	KRT18P34	-10.41	5.68e-23	4.62e-20	-0.57	-0.43	Coronary artery disease;	chr3:157118728	chr3:157162663~157163932:-
THCA	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-10.41	5.7e-23	4.63e-20	-0.59	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
THCA	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
THCA	cis	rs4964805	1	rs11111789	ENSG00000257681.1	RP11-341G23.4	10.41	5.71e-23	4.64e-20	0.52	0.43	Attention deficit hyperactivity disorder;	chr12:103797762	chr12:103746315~103768858:-
THCA	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	10.41	5.71e-23	4.64e-20	0.35	0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
THCA	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	10.41	5.72e-23	4.64e-20	0.63	0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
THCA	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	10.41	5.74e-23	4.67e-20	0.33	0.43	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	10.41	5.79e-23	4.7e-20	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
THCA	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-10.41	5.8e-23	4.71e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-10.41	5.8e-23	4.71e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
THCA	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	10.4	5.88e-23	4.78e-20	0.51	0.43	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
THCA	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	10.4	5.9e-23	4.79e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
THCA	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-10.4	5.91e-23	4.8e-20	-0.47	-0.43	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
THCA	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-10.4	5.92e-23	4.81e-20	-0.51	-0.43	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
THCA	cis	rs9532669	0.889	rs9549302	ENSG00000176268.5	CYCSP34	10.4	5.95e-23	4.83e-20	0.5	0.43	Cervical cancer;	chr13:40843278	chr13:40863599~40863902:-
THCA	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	10.4	5.95e-23	4.83e-20	0.89	0.43	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
THCA	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-10.4	5.96e-23	4.84e-20	-0.46	-0.43	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
THCA	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-10.4	5.98e-23	4.85e-20	-0.61	-0.43	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
THCA	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	10.4	5.99e-23	4.86e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
THCA	cis	rs12188164	0.965	rs11739543	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:443561	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs72717430	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:444387	chr5:441498~443160:-
THCA	cis	rs12188164	0.93	rs72717436	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:448176	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs72717438	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:448548	chr5:441498~443160:-
THCA	cis	rs12188164	0.93	rs72717440	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:449586	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs11743639	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:450595	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs11745789	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:450662	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs11744539	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:451310	chr5:441498~443160:-
THCA	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-10.4	6e-23	4.87e-20	-0.51	-0.43	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
THCA	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	10.4	6.01e-23	4.88e-20	0.51	0.43	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
THCA	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	10.4	6.04e-23	4.9e-20	0.47	0.43	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	10.4	6.04e-23	4.9e-20	0.51	0.43	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-10.4	6.11e-23	4.95e-20	-0.36	-0.43	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
THCA	cis	rs1043099	0.912	rs4820831	ENSG00000279699.1	RP1-102K2.9	10.4	6.17e-23	5e-20	0.61	0.43	Rheumatoid arthritis;	chr22:30315454	chr22:30275215~30276951:-
THCA	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-10.4	6.18e-23	5e-20	-0.67	-0.43	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
THCA	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	10.4	6.18e-23	5.01e-20	0.58	0.43	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
THCA	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-10.4	6.19e-23	5.01e-20	-0.56	-0.43	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-10.4	6.19e-23	5.01e-20	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
THCA	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	10.4	6.2e-23	5.02e-20	0.53	0.43	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
THCA	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	10.4	6.21e-23	5.03e-20	0.35	0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
THCA	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	10.4	6.21e-23	5.03e-20	0.35	0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
THCA	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	10.4	6.21e-23	5.03e-20	0.37	0.43	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
THCA	cis	rs9481169	0.557	rs2179070	ENSG00000255389.1	C6orf3	-10.4	6.22e-23	5.04e-20	-0.79	-0.43	Inflammatory skin disease;	chr6:111564549	chr6:111599875~111602295:+
THCA	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-10.4	6.25e-23	5.06e-20	-0.39	-0.43	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-10.4	6.25e-23	5.06e-20	-0.39	-0.43	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	10.4	6.38e-23	5.16e-20	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
THCA	cis	rs9532669	0.89	rs12865032	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40873801	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs34123829	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40873808	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4488324	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40873864	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4288867	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40873880	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4415896	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874001	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs4415897	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874035	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4389021	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874209	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.824	rs4628828	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874369	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.737	rs34354179	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874424	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9594445	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874859	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9594446	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874863	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4402423	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875010	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs9532628	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875172	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532629	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875193	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7491149	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875216	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532630	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875472	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs4306385	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875641	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4406939	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876108	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4628824	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876217	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532632	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876309	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532633	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876332	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532634	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876369	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532635	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876397	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12428959	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876638	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.895	rs4942009	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40877243	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4334153	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40877737	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4309270	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40877827	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4270044	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40877923	chr13:40908159~40921774:-
THCA	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-10.39	6.41e-23	5.18e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
THCA	cis	rs12594515	0.587	rs8033024	ENSG00000273972.1	CTD-2306A12.1	-10.39	6.46e-23	5.22e-20	-0.51	-0.43	Weight;Waist circumference;	chr15:45705898	chr15:45702640~45703183:+
THCA	cis	rs12188164	0.965	rs41282625	ENSG00000221990.4	EXOC3-AS1	10.39	6.47e-23	5.23e-20	0.37	0.43	Cystic fibrosis severity;	chr5:475511	chr5:441498~443160:-
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
THCA	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	10.39	6.52e-23	5.26e-20	0.6	0.43	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
THCA	cis	rs2581828	0.618	rs6777975	ENSG00000242142.1	SERBP1P3	-10.39	6.54e-23	5.28e-20	-0.54	-0.43	Crohn's disease;	chr3:53132119	chr3:53064283~53065091:-
THCA	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109424305	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109425054	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109426518	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109427644	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109430292	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	10.39	6.56e-23	5.3e-20	0.51	0.43	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
THCA	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-10.39	6.56e-23	5.3e-20	-0.47	-0.43	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-10.39	6.57e-23	5.3e-20	-0.49	-0.43	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
THCA	cis	rs860295	0.702	rs11264381	ENSG00000225855.5	RUSC1-AS1	-10.39	6.57e-23	5.3e-20	-0.31	-0.43	Body mass index;	chr1:155552781	chr1:155316863~155324176:-
THCA	cis	rs7772486	0.754	rs702324	ENSG00000235652.6	RP11-545I5.3	-10.39	6.57e-23	5.3e-20	-0.4	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145799409~145886585:+
THCA	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-10.39	6.57e-23	5.31e-20	-0.39	-0.43	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	10.39	6.58e-23	5.31e-20	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	10.39	6.62e-23	5.34e-20	0.41	0.43	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
THCA	cis	rs6570726	1	rs374464	ENSG00000235652.6	RP11-545I5.3	10.39	6.64e-23	5.36e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs450076	ENSG00000235652.6	RP11-545I5.3	10.39	6.64e-23	5.36e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
THCA	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-10.39	6.66e-23	5.37e-20	-0.53	-0.43	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	10.39	6.73e-23	5.43e-20	0.51	0.43	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	10.39	6.73e-23	5.43e-20	0.51	0.43	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	10.39	6.74e-23	5.43e-20	0.35	0.43	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
THCA	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	10.39	6.78e-23	5.47e-20	0.52	0.43	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
THCA	cis	rs7569084	1	rs7569084	ENSG00000234255.7	AC012370.3	-10.39	6.8e-23	5.49e-20	-0.48	-0.43	Sum eosinophil basophil counts;	chr2:65429835	chr2:65439888~65456571:-
THCA	cis	rs7772486	0.79	rs2243665	ENSG00000235652.6	RP11-545I5.3	10.39	6.81e-23	5.49e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-10.39	6.81e-23	5.49e-20	-0.34	-0.43	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
THCA	cis	rs12188164	0.965	rs72717435	ENSG00000221990.4	EXOC3-AS1	10.39	6.81e-23	5.49e-20	0.37	0.43	Cystic fibrosis severity;	chr5:448087	chr5:441498~443160:-
THCA	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-10.39	6.83e-23	5.5e-20	-0.42	-0.43	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
THCA	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-10.39	6.83e-23	5.51e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
THCA	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-10.39	6.83e-23	5.51e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
THCA	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-10.39	6.86e-23	5.53e-20	-0.54	-0.43	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
THCA	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-10.39	6.86e-23	5.53e-20	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
THCA	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-10.39	6.86e-23	5.53e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
THCA	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-10.39	6.86e-23	5.53e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
THCA	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-10.39	6.86e-23	5.53e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-10.38	6.98e-23	5.62e-20	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
THCA	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	10.38	6.99e-23	5.63e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
THCA	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	10.38	7.01e-23	5.65e-20	0.47	0.43	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
THCA	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	10.38	7.01e-23	5.65e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
THCA	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-10.38	7.01e-23	5.65e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
THCA	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	10.38	7.02e-23	5.66e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.837	rs2474354	ENSG00000235652.6	RP11-545I5.3	10.38	7.02e-23	5.66e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	10.38	7.02e-23	5.66e-20	0.57	0.43	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	10.38	7.02e-23	5.66e-20	0.57	0.43	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	10.38	7.02e-23	5.66e-20	0.57	0.43	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
THCA	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	10.38	7.05e-23	5.67e-20	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	10.38	7.05e-23	5.68e-20	0.57	0.43	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
THCA	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	10.38	7.07e-23	5.69e-20	0.54	0.43	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
THCA	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	10.38	7.11e-23	5.72e-20	0.52	0.43	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
THCA	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-10.38	7.15e-23	5.75e-20	-0.45	-0.43	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
THCA	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-10.38	7.15e-23	5.76e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
THCA	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	10.38	7.2e-23	5.8e-20	0.49	0.43	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	10.38	7.2e-23	5.8e-20	0.49	0.43	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
THCA	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	10.38	7.24e-23	5.83e-20	0.57	0.43	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
THCA	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	10.38	7.27e-23	5.85e-20	0.52	0.43	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	10.38	7.52e-23	6.04e-20	0.52	0.43	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
THCA	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	10.38	7.54e-23	6.06e-20	0.85	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
THCA	cis	rs860295	0.702	rs11264375	ENSG00000225855.5	RUSC1-AS1	-10.38	7.54e-23	6.06e-20	-0.3	-0.43	Body mass index;	chr1:155454274	chr1:155316863~155324176:-
THCA	cis	rs12188164	0.965	rs77101200	ENSG00000221990.4	EXOC3-AS1	10.38	7.54e-23	6.06e-20	0.37	0.43	Cystic fibrosis severity;	chr5:442944	chr5:441498~443160:-
THCA	cis	rs12188164	0.93	rs11743825	ENSG00000221990.4	EXOC3-AS1	10.38	7.55e-23	6.07e-20	0.37	0.43	Cystic fibrosis severity;	chr5:475348	chr5:441498~443160:-
THCA	cis	rs4964805	0.954	rs10861105	ENSG00000257681.1	RP11-341G23.4	10.38	7.55e-23	6.07e-20	0.52	0.43	Attention deficit hyperactivity disorder;	chr12:103796221	chr12:103746315~103768858:-
THCA	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-10.38	7.58e-23	6.09e-20	-0.53	-0.43	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
THCA	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	10.37	7.61e-23	6.12e-20	0.62	0.43	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
THCA	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-10.37	7.64e-23	6.14e-20	-0.5	-0.43	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	10.37	7.65e-23	6.15e-20	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
THCA	cis	rs7665090	0.87	rs228623	ENSG00000246560.2	RP11-10L12.4	-10.37	7.68e-23	6.17e-20	-0.53	-0.43	Primary biliary cholangitis;	chr4:102651163	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.837	rs228624	ENSG00000246560.2	RP11-10L12.4	-10.37	7.68e-23	6.17e-20	-0.53	-0.43	Primary biliary cholangitis;	chr4:102651283	chr4:102828055~102844075:+
THCA	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-10.37	7.69e-23	6.18e-20	-0.47	-0.43	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000224205.1	AP000351.4	-10.37	7.7e-23	6.19e-20	-0.51	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23987320~23991421:-
THCA	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	10.37	7.76e-23	6.23e-20	0.52	0.43	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
THCA	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	10.37	7.77e-23	6.24e-20	0.69	0.43	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
THCA	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	10.37	7.81e-23	6.27e-20	0.51	0.43	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	10.37	7.87e-23	6.32e-20	0.51	0.43	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
THCA	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	10.37	7.88e-23	6.32e-20	0.47	0.43	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
THCA	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-10.37	7.89e-23	6.34e-20	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
THCA	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-10.37	7.94e-23	6.37e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
THCA	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-10.37	7.98e-23	6.41e-20	-0.53	-0.43	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
THCA	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-10.37	8.02e-23	6.43e-20	-0.55	-0.43	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
THCA	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	10.37	8.12e-23	6.52e-20	0.64	0.43	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
THCA	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	10.37	8.14e-23	6.53e-20	0.54	0.43	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
THCA	cis	rs7665090	0.87	rs228616	ENSG00000246560.2	RP11-10L12.4	-10.37	8.14e-23	6.53e-20	-0.53	-0.43	Primary biliary cholangitis;	chr4:102658534	chr4:102828055~102844075:+
THCA	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-10.37	8.17e-23	6.55e-20	-0.46	-0.43	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
THCA	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	10.37	8.18e-23	6.56e-20	0.37	0.43	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	10.36	8.26e-23	6.63e-20	0.51	0.43	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
THCA	cis	rs934734	0.509	rs12185577	ENSG00000281920.1	RP11-418H16.1	-10.36	8.29e-23	6.65e-20	-0.52	-0.43	Rheumatoid arthritis;	chr2:65432354	chr2:65623272~65628424:+
THCA	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	10.36	8.31e-23	6.66e-20	0.54	0.43	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
THCA	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.36e-23	6.7e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.36e-23	6.7e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.36e-23	6.7e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.36e-23	6.7e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
THCA	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	10.36	8.48e-23	6.8e-20	0.49	0.43	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
THCA	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	10.36	8.51e-23	6.82e-20	0.54	0.43	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
THCA	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-10.36	8.51e-23	6.82e-20	-0.49	-0.43	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
THCA	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-10.36	8.55e-23	6.85e-20	-0.34	-0.43	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
THCA	cis	rs8062405	0.824	rs240702	ENSG00000251417.2	RP11-1348G14.4	-10.36	8.65e-23	6.92e-20	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28802743~28817828:+
THCA	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	10.36	8.65e-23	6.93e-20	0.52	0.43	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	10.36	8.66e-23	6.93e-20	0.57	0.43	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
THCA	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-10.36	8.68e-23	6.95e-20	-0.42	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
THCA	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-10.36	8.69e-23	6.96e-20	-0.53	-0.43	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
THCA	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	10.36	8.74e-23	7e-20	0.33	0.43	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
THCA	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	10.36	8.78e-23	7.02e-20	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
THCA	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	10.36	8.83e-23	7.06e-20	0.57	0.43	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
THCA	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-10.36	8.84e-23	7.07e-20	-0.53	-0.43	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	10.36	8.87e-23	7.1e-20	0.57	0.43	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
THCA	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	10.36	8.9e-23	7.12e-20	0.36	0.43	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
THCA	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-10.36	8.92e-23	7.13e-20	-0.5	-0.43	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
THCA	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-10.36	8.93e-23	7.14e-20	-0.39	-0.43	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
THCA	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	10.36	8.97e-23	7.17e-20	0.58	0.43	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
THCA	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-10.36	8.98e-23	7.18e-20	-0.53	-0.43	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
THCA	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	10.36	8.99e-23	7.19e-20	0.36	0.43	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
THCA	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	10.35	9.01e-23	7.21e-20	0.41	0.43	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
THCA	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-10.35	9.04e-23	7.23e-20	-0.47	-0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
THCA	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-10.35	9.1e-23	7.27e-20	-0.58	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
THCA	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-10.35	9.14e-23	7.31e-20	-0.55	-0.43	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
THCA	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	10.35	9.15e-23	7.31e-20	0.52	0.43	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	10.35	9.15e-23	7.31e-20	0.52	0.43	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	10.35	9.15e-23	7.31e-20	0.52	0.43	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	10.35	9.15e-23	7.31e-20	0.52	0.43	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
THCA	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-10.35	9.23e-23	7.38e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
THCA	cis	rs11148252	0.846	rs7333451	ENSG00000278238.1	RP11-245D16.4	-10.35	9.27e-23	7.4e-20	-0.48	-0.43	Lewy body disease;	chr13:52473574	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.846	rs9379	ENSG00000278238.1	RP11-245D16.4	-10.35	9.27e-23	7.4e-20	-0.48	-0.43	Lewy body disease;	chr13:52476344	chr13:52454775~52455331:-
THCA	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	10.35	9.28e-23	7.42e-20	0.36	0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	10.35	9.29e-23	7.42e-20	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
THCA	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	10.35	9.34e-23	7.46e-20	0.57	0.43	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
THCA	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-10.35	9.36e-23	7.47e-20	-0.5	-0.43	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
THCA	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	10.35	9.41e-23	7.51e-20	0.57	0.43	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
THCA	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	10.35	9.46e-23	7.55e-20	0.36	0.43	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
THCA	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	10.35	9.59e-23	7.65e-20	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
THCA	cis	rs11148252	0.904	rs9526927	ENSG00000278238.1	RP11-245D16.4	-10.35	9.63e-23	7.68e-20	-0.47	-0.43	Lewy body disease;	chr13:52477492	chr13:52454775~52455331:-
THCA	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	10.35	9.66e-23	7.71e-20	0.76	0.43	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
THCA	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	10.35	9.69e-23	7.73e-20	0.47	0.43	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
THCA	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-10.35	9.73e-23	7.76e-20	-0.34	-0.43	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	10.35	9.77e-23	7.79e-20	0.57	0.43	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
THCA	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	10.34	9.8e-23	7.82e-20	0.47	0.43	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
THCA	cis	rs7665090	0.87	rs228615	ENSG00000246560.2	RP11-10L12.4	-10.34	9.84e-23	7.85e-20	-0.53	-0.43	Primary biliary cholangitis;	chr4:102658303	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	10.34	9.85e-23	7.86e-20	0.42	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
THCA	cis	rs1043099	0.871	rs10427610	ENSG00000279699.1	RP1-102K2.9	-10.34	9.85e-23	7.86e-20	-0.61	-0.43	Rheumatoid arthritis;	chr22:30352229	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.912	rs4820008	ENSG00000279699.1	RP1-102K2.9	-10.34	9.85e-23	7.86e-20	-0.61	-0.43	Rheumatoid arthritis;	chr22:30353352	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.871	rs5749078	ENSG00000279699.1	RP1-102K2.9	-10.34	9.85e-23	7.86e-20	-0.61	-0.43	Rheumatoid arthritis;	chr22:30365077	chr22:30275215~30276951:-
THCA	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-10.34	9.94e-23	7.93e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
THCA	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	10.34	9.97e-23	7.95e-20	0.55	0.43	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
THCA	cis	rs1043099	0.912	rs4823085	ENSG00000279699.1	RP1-102K2.9	-10.34	1e-22	7.99e-20	-0.6	-0.43	Rheumatoid arthritis;	chr22:30290237	chr22:30275215~30276951:-
THCA	cis	rs12188164	0.965	rs56346498	ENSG00000221990.4	EXOC3-AS1	10.34	1.01e-22	8.04e-20	0.37	0.43	Cystic fibrosis severity;	chr5:423480	chr5:441498~443160:-
THCA	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-10.34	1.01e-22	8.08e-20	-0.54	-0.43	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
THCA	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	10.34	1.02e-22	8.09e-20	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
THCA	cis	rs7191700	0.674	rs12597893	ENSG00000262636.1	CTD-3088G3.4	10.34	1.02e-22	8.1e-20	0.53	0.43	Multiple sclerosis;	chr16:11332474	chr16:11380859~11381118:-
THCA	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-10.34	1.02e-22	8.15e-20	-0.36	-0.43	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
THCA	cis	rs860295	0.58	rs10908463	ENSG00000225855.5	RUSC1-AS1	10.34	1.03e-22	8.22e-20	0.3	0.43	Body mass index;	chr1:155316467	chr1:155316863~155324176:-
THCA	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-10.34	1.04e-22	8.27e-20	-0.34	-0.43	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
THCA	cis	rs860295	0.702	rs12039893	ENSG00000225855.5	RUSC1-AS1	10.34	1.04e-22	8.27e-20	0.3	0.43	Body mass index;	chr1:155645024	chr1:155316863~155324176:-
THCA	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	10.34	1.05e-22	8.35e-20	0.51	0.43	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	10.34	1.05e-22	8.35e-20	0.51	0.43	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000281920.1	RP11-418H16.1	-10.34	1.06e-22	8.41e-20	-0.52	-0.43	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65623272~65628424:+
THCA	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	10.34	1.06e-22	8.41e-20	0.36	0.43	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	10.34	1.06e-22	8.41e-20	0.37	0.43	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	10.34	1.06e-22	8.41e-20	0.37	0.43	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
THCA	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	10.34	1.06e-22	8.45e-20	0.47	0.43	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	10.33	1.07e-22	8.52e-20	0.53	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
THCA	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-10.33	1.07e-22	8.55e-20	-0.48	-0.43	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
THCA	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-10.33	1.08e-22	8.55e-20	-0.55	-0.43	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
THCA	cis	rs9532669	0.926	rs9532657	ENSG00000239827.7	SUGT1P3	10.33	1.09e-22	8.63e-20	0.47	0.43	Cervical cancer;	chr13:40918208	chr13:40908159~40921774:-
THCA	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	10.33	1.09e-22	8.65e-20	0.57	0.43	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
THCA	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-10.33	1.09e-22	8.67e-20	-0.51	-0.43	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
THCA	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-10.33	1.1e-22	8.78e-20	-0.59	-0.43	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
THCA	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	10.33	1.12e-22	8.86e-20	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
THCA	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	10.33	1.14e-22	9.07e-20	0.56	0.43	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
THCA	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-10.33	1.15e-22	9.12e-20	-0.55	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
THCA	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	10.33	1.16e-22	9.18e-20	0.52	0.43	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
THCA	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	10.33	1.16e-22	9.2e-20	0.56	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
THCA	cis	rs944289	0.646	rs8007617	ENSG00000257826.1	RP11-116N8.4	-10.33	1.16e-22	9.2e-20	-0.45	-0.43	Thyroid cancer;	chr14:36088883	chr14:36061026~36067190:-
THCA	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	10.32	1.18e-22	9.37e-20	0.48	0.43	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
THCA	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-10.32	1.19e-22	9.43e-20	-0.52	-0.43	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
THCA	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-10.32	1.19e-22	9.43e-20	-0.52	-0.43	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
THCA	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-10.32	1.19e-22	9.43e-20	-0.52	-0.43	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
THCA	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	10.32	1.19e-22	9.46e-20	0.59	0.43	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
THCA	cis	rs12220777	0.748	rs12259239	ENSG00000230091.5	TMEM254-AS1	10.32	1.19e-22	9.46e-20	0.76	0.43	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103265	chr10:80046860~80078912:-
THCA	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-10.32	1.21e-22	9.55e-20	-0.51	-0.43	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
THCA	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-10.32	1.21e-22	9.56e-20	-0.43	-0.43	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
THCA	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-10.32	1.21e-22	9.63e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
THCA	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-10.32	1.22e-22	9.67e-20	-0.48	-0.43	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
THCA	cis	rs4819052	0.634	rs8128636	ENSG00000223768.1	LINC00205	-10.32	1.22e-22	9.69e-20	-0.4	-0.43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45293285~45297354:+
THCA	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-10.32	1.23e-22	9.71e-20	-0.5	-0.43	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
THCA	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-10.32	1.23e-22	9.71e-20	-0.5	-0.43	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-10.32	1.23e-22	9.72e-20	-0.62	-0.43	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
THCA	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-10.32	1.23e-22	9.75e-20	-0.45	-0.43	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
THCA	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	10.32	1.23e-22	9.77e-20	0.44	0.43	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
THCA	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	10.32	1.24e-22	9.82e-20	0.52	0.43	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
THCA	cis	rs944289	0.646	rs8008989	ENSG00000257826.1	RP11-116N8.4	-10.32	1.26e-22	9.99e-20	-0.44	-0.43	Thyroid cancer;	chr14:36088871	chr14:36061026~36067190:-
THCA	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-10.31	1.28e-22	1.01e-19	-0.39	-0.43	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
THCA	cis	rs12188164	0.762	rs11745923	ENSG00000221990.4	EXOC3-AS1	10.31	1.28e-22	1.01e-19	0.37	0.43	Cystic fibrosis severity;	chr5:475293	chr5:441498~443160:-
THCA	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-10.31	1.28e-22	1.01e-19	-0.43	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
THCA	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	10.31	1.29e-22	1.02e-19	0.42	0.43	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
THCA	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-10.31	1.29e-22	1.02e-19	-0.39	-0.43	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
THCA	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-10.31	1.3e-22	1.03e-19	-0.53	-0.43	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
THCA	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-10.31	1.3e-22	1.03e-19	-0.54	-0.43	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
THCA	cis	rs3091242	0.806	rs35189848	ENSG00000261349.1	RP3-465N24.5	10.31	1.31e-22	1.03e-19	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.836	rs35346083	ENSG00000261349.1	RP3-465N24.5	10.31	1.31e-22	1.03e-19	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25266102~25267136:-
THCA	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	10.31	1.31e-22	1.04e-19	0.52	0.43	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
THCA	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-10.31	1.32e-22	1.05e-19	-0.37	-0.43	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
THCA	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-10.31	1.32e-22	1.05e-19	-0.37	-0.43	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
THCA	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-10.31	1.34e-22	1.06e-19	-0.41	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
THCA	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	10.31	1.35e-22	1.07e-19	0.5	0.43	Height;	chr6:109424122	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	10.31	1.35e-22	1.07e-19	0.59	0.43	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
THCA	cis	rs8062405	0.756	rs151301	ENSG00000251417.2	RP11-1348G14.4	-10.31	1.37e-22	1.08e-19	-0.41	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28802743~28817828:+
THCA	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-10.31	1.37e-22	1.08e-19	-0.68	-0.43	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
THCA	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	10.31	1.37e-22	1.09e-19	0.6	0.43	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	10.3	1.38e-22	1.09e-19	0.57	0.43	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
THCA	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-10.3	1.38e-22	1.09e-19	-0.5	-0.43	Migraine;	chr4:56956882	chr4:56960927~56961373:-
THCA	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-10.3	1.38e-22	1.09e-19	-0.5	-0.43	Migraine;	chr4:56957291	chr4:56960927~56961373:-
THCA	cis	rs11148252	0.744	rs4884354	ENSG00000278238.1	RP11-245D16.4	-10.3	1.38e-22	1.09e-19	-0.47	-0.43	Lewy body disease;	chr13:52443339	chr13:52454775~52455331:-
THCA	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	10.3	1.38e-22	1.09e-19	0.62	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
THCA	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-10.3	1.39e-22	1.09e-19	-0.63	-0.43	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
THCA	cis	rs4819052	0.788	rs2236449	ENSG00000223768.1	LINC00205	-10.3	1.39e-22	1.1e-19	-0.42	-0.43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45293285~45297354:+
THCA	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-10.3	1.39e-22	1.1e-19	-0.68	-0.43	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
THCA	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-10.3	1.42e-22	1.12e-19	-0.47	-0.43	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-10.3	1.42e-22	1.12e-19	-0.47	-0.43	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
THCA	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-10.3	1.43e-22	1.13e-19	-0.48	-0.43	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
THCA	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	10.3	1.43e-22	1.13e-19	0.47	0.43	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-10.3	1.43e-22	1.13e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	10.3	1.44e-22	1.13e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
THCA	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-10.3	1.44e-22	1.14e-19	-0.32	-0.43	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
THCA	cis	rs4654748	0.507	rs10799702	ENSG00000227001.3	NBPF2P	-10.3	1.44e-22	1.14e-19	-0.49	-0.43	Folate pathway vitamin levels;	chr1:21495387	chr1:21424625~21427967:-
THCA	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	10.3	1.45e-22	1.14e-19	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
THCA	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-10.3	1.45e-22	1.14e-19	-0.49	-0.43	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
THCA	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	10.3	1.45e-22	1.14e-19	0.51	0.43	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
THCA	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	10.3	1.46e-22	1.15e-19	0.36	0.43	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
THCA	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-10.3	1.47e-22	1.16e-19	-0.5	-0.43	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-10.3	1.47e-22	1.16e-19	-0.5	-0.43	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-10.3	1.47e-22	1.16e-19	-0.5	-0.43	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
THCA	cis	rs11148252	0.846	rs1056335	ENSG00000278238.1	RP11-245D16.4	-10.3	1.47e-22	1.16e-19	-0.47	-0.43	Lewy body disease;	chr13:52415728	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.846	rs7985262	ENSG00000278238.1	RP11-245D16.4	-10.3	1.47e-22	1.16e-19	-0.47	-0.43	Lewy body disease;	chr13:52423026	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-10.3	1.47e-22	1.16e-19	-0.47	-0.43	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-10.3	1.47e-22	1.16e-19	-0.47	-0.43	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
THCA	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-10.3	1.49e-22	1.17e-19	-0.49	-0.43	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
THCA	cis	rs11148252	0.904	rs3892337	ENSG00000278238.1	RP11-245D16.4	-10.3	1.49e-22	1.18e-19	-0.47	-0.43	Lewy body disease;	chr13:52455350	chr13:52454775~52455331:-
THCA	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	10.29	1.5e-22	1.18e-19	0.67	0.43	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
THCA	cis	rs11148252	0.904	rs9536079	ENSG00000278238.1	RP11-245D16.4	-10.29	1.5e-22	1.18e-19	-0.47	-0.43	Lewy body disease;	chr13:52456430	chr13:52454775~52455331:-
THCA	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-10.29	1.5e-22	1.18e-19	-0.5	-0.43	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
THCA	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	10.29	1.51e-22	1.19e-19	0.43	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	10.29	1.51e-22	1.19e-19	0.43	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
THCA	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-10.29	1.52e-22	1.2e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-10.29	1.53e-22	1.2e-19	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
THCA	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	10.29	1.53e-22	1.21e-19	0.63	0.43	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-10.29	1.54e-22	1.21e-19	-0.59	-0.43	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
THCA	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	10.29	1.54e-22	1.21e-19	0.37	0.43	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
THCA	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	10.29	1.54e-22	1.21e-19	0.37	0.43	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
THCA	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-10.29	1.54e-22	1.21e-19	-0.31	-0.43	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-10.29	1.54e-22	1.21e-19	-0.41	-0.43	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
THCA	cis	rs950169	0.509	rs71395455	ENSG00000259728.4	LINC00933	10.29	1.55e-22	1.22e-19	0.59	0.43	Schizophrenia;	chr15:84610573	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	10.29	1.57e-22	1.23e-19	0.51	0.43	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
THCA	cis	rs1043099	0.912	rs5749066	ENSG00000279699.1	RP1-102K2.9	-10.29	1.57e-22	1.24e-19	-0.61	-0.43	Rheumatoid arthritis;	chr22:30340922	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.912	rs5753080	ENSG00000279699.1	RP1-102K2.9	-10.29	1.57e-22	1.24e-19	-0.61	-0.43	Rheumatoid arthritis;	chr22:30342748	chr22:30275215~30276951:-
THCA	cis	rs950169	0.544	rs12913702	ENSG00000259728.4	LINC00933	10.29	1.58e-22	1.24e-19	0.59	0.43	Schizophrenia;	chr15:84609953	chr15:84570649~84580175:+
THCA	cis	rs9532669	0.857	rs9525427	ENSG00000239827.7	SUGT1P3	-10.29	1.59e-22	1.25e-19	-0.46	-0.43	Cervical cancer;	chr13:40918029	chr13:40908159~40921774:-
THCA	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
THCA	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-10.29	1.6e-22	1.26e-19	-0.62	-0.43	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-10.29	1.6e-22	1.26e-19	-0.62	-0.43	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-10.29	1.61e-22	1.26e-19	-0.36	-0.43	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
THCA	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	10.29	1.61e-22	1.26e-19	0.5	0.43	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
THCA	cis	rs62103177	0.564	rs1864529	ENSG00000261126.6	RP11-795F19.1	-10.29	1.63e-22	1.28e-19	-0.47	-0.43	Opioid sensitivity;	chr18:79988975	chr18:80046900~80095482:+
THCA	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	10.29	1.63e-22	1.28e-19	0.5	0.43	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	10.28	1.63e-22	1.28e-19	0.59	0.43	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
THCA	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	10.28	1.63e-22	1.28e-19	0.54	0.43	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
THCA	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	10.28	1.64e-22	1.29e-19	0.62	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	10.28	1.64e-22	1.29e-19	0.56	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
THCA	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-10.28	1.65e-22	1.29e-19	-0.52	-0.43	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
THCA	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-10.28	1.65e-22	1.3e-19	-0.51	-0.43	Migraine;	chr4:56850720	chr4:56960927~56961373:-
THCA	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	10.28	1.65e-22	1.3e-19	0.56	0.43	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
THCA	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-10.28	1.65e-22	1.3e-19	-0.49	-0.43	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
THCA	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-10.28	1.65e-22	1.3e-19	-0.62	-0.43	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
THCA	cis	rs6452524	0.836	rs4343818	ENSG00000249664.1	CTD-2227C6.2	10.28	1.66e-22	1.3e-19	0.56	0.43	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:83012285~83013109:-
THCA	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-10.28	1.66e-22	1.3e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
THCA	cis	rs12594515	0.625	rs2176866	ENSG00000273972.1	CTD-2306A12.1	-10.28	1.66e-22	1.3e-19	-0.5	-0.43	Weight;Waist circumference;	chr15:45704620	chr15:45702640~45703183:+
THCA	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-10.28	1.67e-22	1.31e-19	-0.62	-0.43	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
THCA	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-10.28	1.67e-22	1.31e-19	-0.51	-0.43	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
THCA	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	10.28	1.67e-22	1.31e-19	0.62	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
THCA	cis	rs7665090	0.87	rs228613	ENSG00000246560.2	RP11-10L12.4	-10.28	1.67e-22	1.31e-19	-0.53	-0.43	Primary biliary cholangitis;	chr4:102656308	chr4:102828055~102844075:+
THCA	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	10.28	1.67e-22	1.31e-19	0.53	0.43	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-10.28	1.68e-22	1.32e-19	-0.41	-0.43	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
THCA	cis	rs944289	0.616	rs6571735	ENSG00000257826.1	RP11-116N8.4	-10.28	1.69e-22	1.33e-19	-0.44	-0.43	Thyroid cancer;	chr14:36089428	chr14:36061026~36067190:-
THCA	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	10.28	1.69e-22	1.33e-19	0.47	0.43	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
THCA	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-10.28	1.7e-22	1.33e-19	-0.39	-0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
THCA	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-10.28	1.7e-22	1.33e-19	-0.56	-0.43	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
THCA	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-10.28	1.7e-22	1.33e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
THCA	cis	rs9659323	0.73	rs10923720	ENSG00000231365.4	RP11-418J17.1	-10.28	1.7e-22	1.33e-19	-0.44	-0.43	Body mass index;	chr1:118999256	chr1:119140396~119275973:+
THCA	cis	rs11148252	0.846	rs13431	ENSG00000278238.1	RP11-245D16.4	-10.28	1.71e-22	1.34e-19	-0.47	-0.43	Lewy body disease;	chr13:52413342	chr13:52454775~52455331:-
THCA	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-10.28	1.71e-22	1.34e-19	-0.4	-0.43	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
THCA	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-10.28	1.71e-22	1.34e-19	-0.37	-0.43	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-10.28	1.72e-22	1.35e-19	-0.41	-0.43	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-10.28	1.72e-22	1.35e-19	-0.41	-0.43	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
THCA	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	10.28	1.73e-22	1.35e-19	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
THCA	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-10.28	1.73e-22	1.36e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
THCA	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	10.28	1.74e-22	1.36e-19	0.47	0.43	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
THCA	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	10.28	1.75e-22	1.37e-19	0.7	0.43	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
THCA	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-10.28	1.76e-22	1.38e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
THCA	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	10.27	1.78e-22	1.4e-19	0.58	0.43	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
THCA	cis	rs42490	1	rs402886	ENSG00000251136.7	RP11-37B2.1	-10.27	1.79e-22	1.4e-19	-0.37	-0.43	Leprosy;	chr8:89760272	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs39500	ENSG00000251136.7	RP11-37B2.1	-10.27	1.79e-22	1.4e-19	-0.37	-0.43	Leprosy;	chr8:89760437	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs39761	ENSG00000251136.7	RP11-37B2.1	-10.27	1.79e-22	1.4e-19	-0.37	-0.43	Leprosy;	chr8:89760692	chr8:89609409~89757727:-
THCA	cis	rs42490	0.934	rs43225	ENSG00000251136.7	RP11-37B2.1	-10.27	1.79e-22	1.4e-19	-0.37	-0.43	Leprosy;	chr8:89760776	chr8:89609409~89757727:-
THCA	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	10.27	1.8e-22	1.41e-19	0.85	0.43	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
THCA	cis	rs860295	0.557	rs10796941	ENSG00000225855.5	RUSC1-AS1	10.27	1.8e-22	1.41e-19	0.3	0.43	Body mass index;	chr1:155314470	chr1:155316863~155324176:-
THCA	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-10.27	1.8e-22	1.41e-19	-0.56	-0.43	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
THCA	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-10.27	1.8e-22	1.41e-19	-0.45	-0.43	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
THCA	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-10.27	1.81e-22	1.42e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
THCA	cis	rs1043099	0.912	rs737950	ENSG00000279699.1	RP1-102K2.9	-10.27	1.82e-22	1.42e-19	-0.61	-0.43	Rheumatoid arthritis;	chr22:30361306	chr22:30275215~30276951:-
THCA	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-10.27	1.82e-22	1.43e-19	-0.56	-0.43	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	10.27	1.82e-22	1.43e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	10.27	1.82e-22	1.43e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
THCA	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
THCA	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	10.27	1.85e-22	1.45e-19	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
THCA	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	10.27	1.85e-22	1.45e-19	0.47	0.43	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	10.27	1.86e-22	1.45e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	10.27	1.86e-22	1.45e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
THCA	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	10.27	1.86e-22	1.45e-19	0.5	0.43	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	10.27	1.86e-22	1.45e-19	0.5	0.43	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-10.27	1.88e-22	1.46e-19	-0.41	-0.43	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-10.27	1.88e-22	1.46e-19	-0.41	-0.43	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
THCA	cis	rs9659323	0.612	rs10923721	ENSG00000231365.4	RP11-418J17.1	-10.27	1.88e-22	1.47e-19	-0.44	-0.43	Body mass index;	chr1:118999564	chr1:119140396~119275973:+
THCA	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	10.27	1.88e-22	1.47e-19	0.52	0.43	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000224205.1	AP000351.4	10.27	1.89e-22	1.47e-19	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23987320~23991421:-
THCA	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-10.27	1.89e-22	1.47e-19	-0.49	-0.43	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
THCA	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	10.27	1.89e-22	1.48e-19	0.52	0.43	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
THCA	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-10.27	1.89e-22	1.48e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-10.27	1.89e-22	1.48e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-10.27	1.9e-22	1.49e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
THCA	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-10.27	1.91e-22	1.49e-19	-0.56	-0.43	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-10.27	1.91e-22	1.49e-19	-0.56	-0.43	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
THCA	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-10.27	1.91e-22	1.49e-19	-0.43	-0.43	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
THCA	cis	rs7665090	0.87	rs228614	ENSG00000246560.2	RP11-10L12.4	-10.27	1.91e-22	1.49e-19	-0.53	-0.43	Primary biliary cholangitis;	chr4:102657480	chr4:102828055~102844075:+
THCA	cis	rs1043099	0.912	rs740219	ENSG00000279699.1	RP1-102K2.9	-10.27	1.92e-22	1.5e-19	-0.6	-0.43	Rheumatoid arthritis;	chr22:30318695	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.912	rs5753071	ENSG00000279699.1	RP1-102K2.9	-10.27	1.92e-22	1.5e-19	-0.6	-0.43	Rheumatoid arthritis;	chr22:30330837	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.912	rs10376	ENSG00000279699.1	RP1-102K2.9	-10.27	1.92e-22	1.5e-19	-0.6	-0.43	Rheumatoid arthritis;	chr22:30332367	chr22:30275215~30276951:-
THCA	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	10.27	1.92e-22	1.5e-19	0.53	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	10.27	1.93e-22	1.5e-19	0.35	0.43	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	10.27	1.93e-22	1.5e-19	0.35	0.43	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	10.27	1.93e-22	1.5e-19	0.35	0.43	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	10.27	1.93e-22	1.5e-19	0.35	0.43	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
THCA	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-10.26	1.93e-22	1.51e-19	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
THCA	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-10.26	1.93e-22	1.51e-19	-0.5	-0.43	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
THCA	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	10.26	1.93e-22	1.51e-19	0.45	0.43	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	10.26	1.93e-22	1.51e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
THCA	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	10.26	1.95e-22	1.52e-19	0.53	0.43	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	10.26	1.95e-22	1.52e-19	0.53	0.43	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	10.26	1.95e-22	1.52e-19	0.53	0.43	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
THCA	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	10.26	1.96e-22	1.53e-19	0.52	0.43	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	10.26	1.96e-22	1.53e-19	0.52	0.43	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000206090.4	AP000350.7	10.26	1.97e-22	1.53e-19	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23939998~23942798:+
THCA	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	10.26	1.98e-22	1.54e-19	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
THCA	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-10.26	1.98e-22	1.54e-19	-0.49	-0.43	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-10.26	1.98e-22	1.54e-19	-0.49	-0.43	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-10.26	1.98e-22	1.54e-19	-0.49	-0.43	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
THCA	cis	rs6558530	0.932	rs9022	ENSG00000253982.1	CTD-2336O2.1	10.26	1.98e-22	1.54e-19	0.38	0.43	Systolic blood pressure;	chr8:1762811	chr8:1761990~1764502:-
THCA	cis	rs7772486	0.875	rs2748497	ENSG00000235652.6	RP11-545I5.3	10.26	1.98e-22	1.55e-19	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145799409~145886585:+
THCA	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	10.26	1.99e-22	1.55e-19	0.51	0.43	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
THCA	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-10.26	2.01e-22	1.57e-19	-0.37	-0.43	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-10.26	2.01e-22	1.57e-19	-0.37	-0.43	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
THCA	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	10.26	2.02e-22	1.57e-19	0.47	0.43	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-10.26	2.02e-22	1.57e-19	-0.47	-0.43	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
THCA	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	10.26	2.02e-22	1.57e-19	0.5	0.43	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
THCA	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-10.26	2.04e-22	1.58e-19	-0.46	-0.43	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
THCA	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	10.26	2.04e-22	1.59e-19	0.36	0.43	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	10.26	2.04e-22	1.59e-19	0.36	0.43	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	10.26	2.04e-22	1.59e-19	0.36	0.43	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
THCA	cis	rs2599510	0.811	rs62136345	ENSG00000276334.1	AL133243.1	10.26	2.05e-22	1.6e-19	0.46	0.43	Interleukin-18 levels;	chr2:32582156	chr2:32521927~32523547:+
THCA	cis	rs2599510	0.811	rs2754520	ENSG00000276334.1	AL133243.1	10.26	2.05e-22	1.6e-19	0.46	0.43	Interleukin-18 levels;	chr2:32585226	chr2:32521927~32523547:+
THCA	cis	rs7211079	0.879	rs66693363	ENSG00000279259.1	RP11-334C17.3	10.26	2.06e-22	1.6e-19	0.46	0.43	Myocardial infarction;	chr17:80155136	chr17:80147250~80148596:+
THCA	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	10.26	2.06e-22	1.6e-19	0.36	0.43	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
THCA	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-10.26	2.06e-22	1.61e-19	-0.51	-0.43	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
THCA	cis	rs916888	0.61	rs199529	ENSG00000232300.1	FAM215B	10.26	2.06e-22	1.61e-19	0.67	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46558830~46562795:-
THCA	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-10.26	2.08e-22	1.62e-19	-0.37	-0.43	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
THCA	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	10.26	2.08e-22	1.62e-19	0.78	0.43	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	10.26	2.09e-22	1.63e-19	0.5	0.43	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	10.26	2.09e-22	1.63e-19	0.5	0.43	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
THCA	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	10.26	2.1e-22	1.63e-19	0.51	0.43	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
THCA	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	10.25	2.11e-22	1.64e-19	0.56	0.43	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	10.25	2.11e-22	1.64e-19	0.5	0.43	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
THCA	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-10.25	2.12e-22	1.65e-19	-0.4	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	10.25	2.12e-22	1.65e-19	0.5	0.43	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
THCA	cis	rs12188164	0.965	rs11742144	ENSG00000221990.4	EXOC3-AS1	10.25	2.12e-22	1.65e-19	0.37	0.43	Cystic fibrosis severity;	chr5:422063	chr5:441498~443160:-
THCA	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	10.25	2.13e-22	1.65e-19	0.52	0.43	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
THCA	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	10.25	2.13e-22	1.66e-19	0.5	0.43	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
THCA	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-10.25	2.14e-22	1.66e-19	-0.82	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
THCA	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-10.25	2.14e-22	1.67e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
THCA	cis	rs7191700	0.673	rs12325495	ENSG00000262636.1	CTD-3088G3.4	10.25	2.14e-22	1.67e-19	0.52	0.43	Multiple sclerosis;	chr16:11324471	chr16:11380859~11381118:-
THCA	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	10.25	2.16e-22	1.68e-19	0.52	0.43	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	10.25	2.16e-22	1.68e-19	0.52	0.43	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
THCA	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	10.25	2.16e-22	1.68e-19	0.67	0.43	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
THCA	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-10.25	2.19e-22	1.7e-19	-0.7	-0.43	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
THCA	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-10.25	2.2e-22	1.7e-19	-0.4	-0.43	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
THCA	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	10.25	2.2e-22	1.71e-19	0.44	0.43	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
THCA	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	10.25	2.21e-22	1.71e-19	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	10.25	2.21e-22	1.71e-19	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	10.25	2.21e-22	1.71e-19	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
THCA	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-10.25	2.22e-22	1.72e-19	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	10.25	2.23e-22	1.73e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
THCA	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-10.25	2.24e-22	1.74e-19	-0.54	-0.43	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
THCA	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-10.25	2.24e-22	1.74e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
THCA	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-10.25	2.26e-22	1.75e-19	-0.37	-0.43	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
THCA	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-10.25	2.26e-22	1.76e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-10.25	2.26e-22	1.76e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
THCA	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-10.25	2.27e-22	1.76e-19	-0.41	-0.43	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
THCA	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	10.25	2.28e-22	1.77e-19	0.62	0.43	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	10.25	2.28e-22	1.77e-19	0.62	0.43	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
THCA	cis	rs860295	0.702	rs12043132	ENSG00000225855.5	RUSC1-AS1	10.24	2.33e-22	1.8e-19	0.3	0.43	Body mass index;	chr1:155592576	chr1:155316863~155324176:-
THCA	cis	rs944289	0.74	rs1742869	ENSG00000257826.1	RP11-116N8.4	10.24	2.33e-22	1.8e-19	0.43	0.43	Thyroid cancer;	chr14:36067601	chr14:36061026~36067190:-
THCA	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	10.24	2.33e-22	1.81e-19	0.32	0.43	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
THCA	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	10.24	2.35e-22	1.82e-19	0.45	0.43	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	10.24	2.35e-22	1.82e-19	0.45	0.43	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
THCA	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	10.24	2.36e-22	1.82e-19	0.56	0.43	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	10.24	2.36e-22	1.83e-19	0.35	0.43	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	10.24	2.37e-22	1.84e-19	0.5	0.43	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
THCA	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-10.24	2.38e-22	1.84e-19	-0.52	-0.43	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
THCA	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	10.24	2.38e-22	1.84e-19	0.5	0.43	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	10.24	2.38e-22	1.84e-19	0.5	0.43	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
THCA	cis	rs1043099	0.912	rs2041199	ENSG00000279699.1	RP1-102K2.9	-10.24	2.38e-22	1.85e-19	-0.61	-0.43	Rheumatoid arthritis;	chr22:30336247	chr22:30275215~30276951:-
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	10.24	2.4e-22	1.86e-19	0.59	0.43	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
THCA	cis	rs42490	1	rs405734	ENSG00000251136.7	RP11-37B2.1	-10.24	2.4e-22	1.86e-19	-0.37	-0.43	Leprosy;	chr8:89756211	chr8:89609409~89757727:-
THCA	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	10.24	2.4e-22	1.86e-19	0.38	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
THCA	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	10.24	2.4e-22	1.86e-19	0.43	0.43	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
THCA	cis	rs1043099	1	rs1043099	ENSG00000279699.1	RP1-102K2.9	-10.24	2.4e-22	1.86e-19	-0.59	-0.43	Rheumatoid arthritis;	chr22:30285268	chr22:30275215~30276951:-
THCA	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	10.24	2.42e-22	1.88e-19	0.45	0.43	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
THCA	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	10.24	2.43e-22	1.88e-19	0.59	0.43	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
THCA	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-10.24	2.43e-22	1.88e-19	-0.53	-0.43	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-10.24	2.43e-22	1.88e-19	-0.53	-0.43	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-10.24	2.43e-22	1.88e-19	-0.53	-0.43	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
THCA	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-10.24	2.43e-22	1.88e-19	-0.48	-0.43	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
THCA	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	10.24	2.43e-22	1.88e-19	0.52	0.43	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	10.24	2.43e-22	1.88e-19	0.52	0.43	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
THCA	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-10.24	2.44e-22	1.88e-19	-0.43	-0.43	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	10.24	2.44e-22	1.89e-19	0.5	0.43	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	10.24	2.45e-22	1.89e-19	0.5	0.43	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	10.24	2.45e-22	1.89e-19	0.5	0.43	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
THCA	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	10.24	2.45e-22	1.9e-19	0.5	0.43	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
THCA	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	10.24	2.46e-22	1.9e-19	0.5	0.43	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	10.24	2.46e-22	1.9e-19	0.5	0.43	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
THCA	cis	rs9926296	0.568	rs417323	ENSG00000260259.1	RP11-368I7.4	10.24	2.48e-22	1.92e-19	0.47	0.43	Vitiligo;	chr16:89679869	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	10.23	2.49e-22	1.92e-19	0.57	0.43	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	10.23	2.49e-22	1.92e-19	0.57	0.43	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
THCA	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-10.23	2.49e-22	1.92e-19	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	10.23	2.49e-22	1.93e-19	0.51	0.43	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
THCA	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-10.23	2.5e-22	1.93e-19	-0.51	-0.43	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-10.23	2.5e-22	1.93e-19	-0.51	-0.43	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
THCA	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-10.23	2.5e-22	1.93e-19	-0.51	-0.43	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000224205.1	AP000351.4	10.23	2.5e-22	1.93e-19	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23987320~23991421:-
THCA	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	10.23	2.51e-22	1.94e-19	0.56	0.43	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	10.23	2.51e-22	1.94e-19	0.56	0.43	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
THCA	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	10.23	2.52e-22	1.95e-19	0.58	0.43	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
THCA	cis	rs10740039	0.768	rs920646	ENSG00000254271.1	RP11-131N11.4	10.23	2.52e-22	1.95e-19	0.53	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703767	chr10:60734342~60741828:+
THCA	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-10.23	2.52e-22	1.95e-19	-0.47	-0.43	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-10.23	2.52e-22	1.95e-19	-0.47	-0.43	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
THCA	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	10.23	2.53e-22	1.96e-19	0.5	0.43	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	10.23	2.54e-22	1.96e-19	0.36	0.43	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
THCA	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-10.23	2.56e-22	1.98e-19	-0.34	-0.43	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
THCA	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-10.23	2.57e-22	1.98e-19	-0.47	-0.43	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-10.23	2.57e-22	1.98e-19	-0.47	-0.43	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
THCA	cis	rs4713118	0.662	rs149900	ENSG00000280107.1	AL022393.9	-10.23	2.57e-22	1.98e-19	-0.49	-0.43	Parkinson's disease;	chr6:28046819	chr6:28170845~28172521:+
THCA	cis	rs9532669	0.89	rs7333274	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40862531	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs2324737	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40862808	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942003	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40863270	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs4942004	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40863598	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs9315791	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40863931	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.824	rs9315792	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40863951	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.684	rs7139788	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40864264	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7338617	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40870787	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.857	rs6560961	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40870878	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs6560962	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40870948	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs1055588	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871306	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs3610	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871334	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942005	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871636	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942006	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871862	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942008	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871989	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs2039118	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40872260	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4356347	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40872516	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7982346	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40873273	chr13:40908159~40921774:-
THCA	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-10.23	2.58e-22	1.99e-19	-0.57	-0.43	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
THCA	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	10.23	2.58e-22	1.99e-19	0.47	0.43	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	10.23	2.59e-22	2e-19	0.62	0.43	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-10.23	2.59e-22	2e-19	-0.62	-0.43	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-10.23	2.59e-22	2e-19	-0.62	-0.43	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
THCA	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-10.23	2.6e-22	2.01e-19	-0.39	-0.43	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
THCA	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	10.23	2.62e-22	2.02e-19	0.52	0.43	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000231464.1	AC024937.4	10.23	2.62e-22	2.02e-19	0.59	0.43	Pancreatic cancer;	chr3:196025182	chr3:195996738~195998233:+
THCA	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	10.23	2.62e-22	2.02e-19	0.46	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	10.23	2.62e-22	2.02e-19	0.46	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
THCA	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	10.23	2.65e-22	2.05e-19	0.67	0.43	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	10.23	2.66e-22	2.05e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
THCA	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-10.23	2.67e-22	2.06e-19	-0.37	-0.43	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
THCA	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-10.23	2.68e-22	2.06e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-10.23	2.7e-22	2.08e-19	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-10.23	2.7e-22	2.08e-19	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
THCA	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	10.23	2.7e-22	2.08e-19	0.36	0.43	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
THCA	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-10.23	2.7e-22	2.08e-19	-0.51	-0.43	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-10.23	2.7e-22	2.08e-19	-0.51	-0.43	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
THCA	cis	rs2946504	0.705	rs1879487	ENSG00000251468.2	RP11-369K16.1	-10.23	2.7e-22	2.08e-19	-0.49	-0.43	Type 2 diabetes;	chr8:12947413	chr8:12958387~12962200:+
THCA	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	10.22	2.71e-22	2.09e-19	0.52	0.43	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
THCA	cis	rs1043099	0.871	rs2108093	ENSG00000279699.1	RP1-102K2.9	-10.22	2.72e-22	2.1e-19	-0.59	-0.43	Rheumatoid arthritis;	chr22:30283398	chr22:30275215~30276951:-
THCA	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	10.22	2.73e-22	2.1e-19	0.5	0.43	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
THCA	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	10.22	2.74e-22	2.11e-19	0.56	0.43	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
THCA	cis	rs9532669	0.889	rs6560964	ENSG00000239827.7	SUGT1P3	-10.22	2.74e-22	2.11e-19	-0.47	-0.43	Cervical cancer;	chr13:40871132	chr13:40908159~40921774:-
THCA	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	10.22	2.75e-22	2.12e-19	0.4	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	10.22	2.75e-22	2.12e-19	0.4	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
THCA	cis	rs6496932	0.635	rs11632761	ENSG00000218052.5	ADAMTS7P4	-10.22	2.76e-22	2.13e-19	-0.56	-0.43	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.635	rs67659163	ENSG00000218052.5	ADAMTS7P4	-10.22	2.76e-22	2.13e-19	-0.56	-0.43	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85255369~85330334:-
THCA	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-10.22	2.79e-22	2.15e-19	-0.41	-0.43	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
THCA	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-10.22	2.79e-22	2.15e-19	-0.41	-0.43	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
THCA	cis	rs6570726	0.967	rs413880	ENSG00000235652.6	RP11-545I5.3	10.22	2.79e-22	2.15e-19	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145799409~145886585:+
THCA	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-10.22	2.79e-22	2.15e-19	-0.55	-0.43	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
THCA	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-10.22	2.79e-22	2.15e-19	-0.57	-0.43	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
THCA	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	10.22	2.83e-22	2.18e-19	0.56	0.43	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
THCA	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-10.22	2.86e-22	2.2e-19	-0.43	-0.43	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
THCA	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	10.22	2.88e-22	2.21e-19	0.45	0.43	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
THCA	cis	rs6558530	0.931	rs4639549	ENSG00000253982.1	CTD-2336O2.1	10.22	2.88e-22	2.22e-19	0.37	0.43	Systolic blood pressure;	chr8:1759878	chr8:1761990~1764502:-
THCA	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	10.22	2.9e-22	2.23e-19	0.45	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
THCA	cis	rs4713118	0.662	rs149961	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28047791	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28056708	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28056792	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28057501	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28057708	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28058299	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28058358	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28059910	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28060612	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28060704	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28062059	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	10.22	2.94e-22	2.26e-19	0.57	0.43	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	10.21	2.95e-22	2.27e-19	0.67	0.43	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	10.21	2.95e-22	2.27e-19	0.67	0.43	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	10.21	2.96e-22	2.27e-19	0.53	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
THCA	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-10.21	2.96e-22	2.27e-19	-0.43	-0.43	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-10.21	2.96e-22	2.27e-19	-0.43	-0.43	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
THCA	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-10.21	2.96e-22	2.28e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
THCA	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	10.21	2.98e-22	2.28e-19	0.51	0.43	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
THCA	cis	rs860295	0.58	rs6672284	ENSG00000225855.5	RUSC1-AS1	10.21	2.99e-22	2.3e-19	0.29	0.43	Body mass index;	chr1:155308172	chr1:155316863~155324176:-
THCA	cis	rs4964805	0.913	rs3812803	ENSG00000257681.1	RP11-341G23.4	10.21	2.99e-22	2.3e-19	0.51	0.43	Attention deficit hyperactivity disorder;	chr12:103806682	chr12:103746315~103768858:-
THCA	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	10.21	2.99e-22	2.3e-19	0.5	0.43	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
THCA	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	10.21	2.99e-22	2.3e-19	0.52	0.43	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
THCA	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-10.21	3e-22	2.31e-19	-0.65	-0.43	Depression;	chr6:28103220	chr6:28115628~28116551:+
THCA	cis	rs944289	0.708	rs34613409	ENSG00000257826.1	RP11-116N8.4	-10.21	3.01e-22	2.31e-19	-0.44	-0.43	Thyroid cancer;	chr14:36096489	chr14:36061026~36067190:-
THCA	cis	rs944289	0.774	rs2415312	ENSG00000257826.1	RP11-116N8.4	-10.21	3.01e-22	2.31e-19	-0.44	-0.43	Thyroid cancer;	chr14:36097145	chr14:36061026~36067190:-
THCA	cis	rs860295	0.702	rs1556488	ENSG00000225855.5	RUSC1-AS1	10.21	3.01e-22	2.31e-19	0.3	0.43	Body mass index;	chr1:155570869	chr1:155316863~155324176:-
THCA	cis	rs4591358	0.689	rs72927794	ENSG00000223466.1	AC064834.2	-10.21	3.01e-22	2.31e-19	-0.61	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195558607	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs2102745	ENSG00000223466.1	AC064834.2	-10.21	3.01e-22	2.31e-19	-0.61	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559315	chr2:195533035~195538681:+
THCA	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	10.21	3.01e-22	2.31e-19	0.51	0.43	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
THCA	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	10.21	3.02e-22	2.32e-19	0.52	0.43	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	10.21	3.02e-22	2.32e-19	0.52	0.43	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	10.21	3.02e-22	2.32e-19	0.52	0.43	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
THCA	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-10.21	3.03e-22	2.33e-19	-0.58	-0.43	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
THCA	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	10.21	3.04e-22	2.33e-19	0.5	0.43	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
THCA	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	10.21	3.07e-22	2.35e-19	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
THCA	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-10.21	3.07e-22	2.36e-19	-0.41	-0.43	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
THCA	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-10.21	3.07e-22	2.36e-19	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
THCA	cis	rs860295	0.702	rs11264380	ENSG00000225855.5	RUSC1-AS1	10.21	3.11e-22	2.38e-19	0.3	0.43	Body mass index;	chr1:155550353	chr1:155316863~155324176:-
THCA	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	10.21	3.12e-22	2.39e-19	0.52	0.43	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-10.21	3.13e-22	2.4e-19	-0.52	-0.43	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-10.21	3.13e-22	2.4e-19	-0.52	-0.43	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-10.21	3.13e-22	2.4e-19	-0.52	-0.43	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	10.21	3.13e-22	2.4e-19	0.52	0.43	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	10.21	3.13e-22	2.4e-19	0.52	0.43	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	10.21	3.13e-22	2.4e-19	0.52	0.43	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
THCA	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-10.21	3.13e-22	2.4e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-10.21	3.13e-22	2.4e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
THCA	cis	rs860295	0.702	rs10908479	ENSG00000225855.5	RUSC1-AS1	10.21	3.14e-22	2.4e-19	0.3	0.43	Body mass index;	chr1:155673612	chr1:155316863~155324176:-
THCA	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	10.21	3.14e-22	2.41e-19	0.53	0.43	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
THCA	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	10.21	3.15e-22	2.42e-19	0.51	0.43	Height;	chr6:109358227	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	10.21	3.16e-22	2.42e-19	0.59	0.43	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
THCA	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-10.21	3.16e-22	2.42e-19	-0.44	-0.43	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
THCA	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-10.21	3.18e-22	2.44e-19	-0.51	-0.43	Migraine;	chr4:56853383	chr4:56960927~56961373:-
THCA	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	10.21	3.2e-22	2.45e-19	0.5	0.43	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
THCA	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	10.21	3.2e-22	2.45e-19	0.55	0.43	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
THCA	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	10.21	3.2e-22	2.45e-19	0.47	0.43	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
THCA	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	10.2	3.21e-22	2.46e-19	0.52	0.43	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	10.2	3.21e-22	2.46e-19	0.52	0.43	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
THCA	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	10.2	3.21e-22	2.46e-19	0.51	0.43	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
THCA	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-10.2	3.21e-22	2.46e-19	-0.48	-0.43	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
THCA	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-10.2	3.23e-22	2.48e-19	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
THCA	cis	rs4774565	0.8	rs34174311	ENSG00000244879.4	GABPB1-AS1	-10.2	3.26e-22	2.49e-19	-0.38	-0.43	Breast cancer;	chr15:50381084	chr15:50354959~50372202:+
THCA	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	10.2	3.26e-22	2.49e-19	0.51	0.43	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
THCA	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-10.2	3.26e-22	2.49e-19	-0.54	-0.43	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
THCA	cis	rs9890032	0.967	rs7342976	ENSG00000266490.1	CTD-2349P21.9	10.2	3.29e-22	2.51e-19	0.41	0.43	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30792372~30792833:+
THCA	cis	rs9890032	1	rs28539246	ENSG00000266490.1	CTD-2349P21.9	10.2	3.29e-22	2.51e-19	0.41	0.43	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30792372~30792833:+
THCA	cis	rs9890032	0.967	rs9897628	ENSG00000266490.1	CTD-2349P21.9	10.2	3.29e-22	2.51e-19	0.41	0.43	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30792372~30792833:+
THCA	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-10.2	3.3e-22	2.52e-19	-0.55	-0.43	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
THCA	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-10.2	3.3e-22	2.52e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
THCA	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-10.2	3.3e-22	2.52e-19	-0.51	-0.43	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
THCA	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	10.2	3.3e-22	2.53e-19	0.39	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
THCA	cis	rs780096	0.587	rs4665969	ENSG00000234072.1	AC074117.10	10.2	3.32e-22	2.54e-19	0.33	0.43	Total body bone mineral density;	chr2:27352086	chr2:27356246~27367622:+
THCA	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	10.2	3.32e-22	2.54e-19	0.54	0.43	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	10.2	3.32e-22	2.54e-19	0.54	0.43	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
THCA	cis	rs860295	0.665	rs12079134	ENSG00000225855.5	RUSC1-AS1	10.2	3.33e-22	2.55e-19	0.3	0.43	Body mass index;	chr1:155496993	chr1:155316863~155324176:-
THCA	cis	rs4713118	0.629	rs203890	ENSG00000280107.1	AL022393.9	-10.2	3.34e-22	2.55e-19	-0.5	-0.43	Parkinson's disease;	chr6:28054470	chr6:28170845~28172521:+
THCA	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	10.2	3.36e-22	2.57e-19	0.37	0.43	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
THCA	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-10.2	3.39e-22	2.59e-19	-0.42	-0.43	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
THCA	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-10.2	3.39e-22	2.59e-19	-0.42	-0.43	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
THCA	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	10.2	3.39e-22	2.59e-19	0.61	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-10.2	3.41e-22	2.61e-19	-0.53	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
THCA	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	10.2	3.41e-22	2.61e-19	0.45	0.43	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
THCA	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	10.2	3.42e-22	2.61e-19	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
THCA	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	10.2	3.42e-22	2.61e-19	0.51	0.43	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
THCA	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	10.2	3.42e-22	2.61e-19	0.45	0.43	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
THCA	cis	rs7429990	0.803	rs13319205	ENSG00000229759.1	MRPS18AP1	10.2	3.43e-22	2.62e-19	0.54	0.43	Educational attainment (years of education);	chr3:47758726	chr3:48256350~48256938:-
THCA	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	10.2	3.43e-22	2.62e-19	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
THCA	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-10.2	3.45e-22	2.63e-19	-0.39	-0.43	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
THCA	cis	rs9532669	0.926	rs2324747	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40988883	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs2324748	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40989452	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4245311	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40990003	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs1543589	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40999064	chr13:40863599~40863902:-
THCA	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-10.2	3.45e-22	2.64e-19	-0.45	-0.43	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	10.2	3.47e-22	2.65e-19	0.51	0.43	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
THCA	cis	rs860295	0.702	rs4971095	ENSG00000225855.5	RUSC1-AS1	-10.2	3.48e-22	2.65e-19	-0.3	-0.43	Body mass index;	chr1:155636433	chr1:155316863~155324176:-
THCA	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	10.19	3.49e-22	2.66e-19	0.48	0.43	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
THCA	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	10.19	3.51e-22	2.68e-19	0.51	0.43	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-10.19	3.52e-22	2.68e-19	-0.62	-0.43	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
THCA	cis	rs3745672	1	rs111259072	ENSG00000219665.7	CTD-2006C1.2	-10.19	3.52e-22	2.68e-19	-0.93	-0.43	Multiple sclerosis;	chr19:12045754	chr19:11987617~12046275:+
THCA	cis	rs3745672	0.661	rs112152876	ENSG00000219665.7	CTD-2006C1.2	-10.19	3.52e-22	2.68e-19	-0.93	-0.43	Multiple sclerosis;	chr19:12045864	chr19:11987617~12046275:+
THCA	cis	rs3745672	1	rs10417006	ENSG00000219665.7	CTD-2006C1.2	-10.19	3.52e-22	2.68e-19	-0.93	-0.43	Multiple sclerosis;	chr19:12046438	chr19:11987617~12046275:+
THCA	cis	rs3745672	1	rs7255420	ENSG00000219665.7	CTD-2006C1.2	-10.19	3.52e-22	2.68e-19	-0.93	-0.43	Multiple sclerosis;	chr19:12047024	chr19:11987617~12046275:+
THCA	cis	rs9322193	0.923	rs2184370	ENSG00000268592.3	RAET1E-AS1	10.19	3.52e-22	2.69e-19	0.59	0.43	Lung cancer;	chr6:149843242	chr6:149863494~149919507:+
THCA	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	10.19	3.53e-22	2.7e-19	0.64	0.43	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	10.19	3.53e-22	2.7e-19	0.64	0.43	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
THCA	cis	rs2599510	0.693	rs2754514	ENSG00000276334.1	AL133243.1	10.19	3.54e-22	2.7e-19	0.45	0.43	Interleukin-18 levels;	chr2:32563769	chr2:32521927~32523547:+
THCA	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-10.19	3.54e-22	2.7e-19	-0.62	-0.43	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
THCA	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	10.19	3.55e-22	2.71e-19	0.52	0.43	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
THCA	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-10.19	3.55e-22	2.71e-19	-0.35	-0.43	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
THCA	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-10.19	3.55e-22	2.71e-19	-0.4	-0.43	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
THCA	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-10.19	3.55e-22	2.71e-19	-0.39	-0.43	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
THCA	cis	rs7826238	0.564	rs2921053	ENSG00000254153.1	CTA-398F10.2	-10.19	3.56e-22	2.71e-19	-0.46	-0.43	Systolic blood pressure;	chr8:8462453	chr8:8456909~8461337:-
THCA	cis	rs673078	0.66	rs9943819	ENSG00000275409.1	RP11-131L12.4	-10.19	3.56e-22	2.71e-19	-0.45	-0.43	Glucose homeostasis traits;	chr12:118298917	chr12:118430147~118430699:+
THCA	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-10.19	3.58e-22	2.73e-19	-0.39	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-10.19	3.58e-22	2.73e-19	-0.39	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-10.19	3.58e-22	2.73e-19	-0.39	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
THCA	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-10.19	3.61e-22	2.75e-19	-0.5	-0.43	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
THCA	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-10.19	3.61e-22	2.75e-19	-0.5	-0.43	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
THCA	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-10.19	3.61e-22	2.75e-19	-0.5	-0.43	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
THCA	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	10.19	3.61e-22	2.75e-19	0.47	0.43	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	10.19	3.61e-22	2.75e-19	0.47	0.43	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	10.19	3.61e-22	2.75e-19	0.47	0.43	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	10.19	3.61e-22	2.75e-19	0.47	0.43	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
THCA	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-10.19	3.61e-22	2.75e-19	-0.52	-0.43	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
THCA	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	10.19	3.62e-22	2.76e-19	0.4	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	10.19	3.67e-22	2.79e-19	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
THCA	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-10.19	3.67e-22	2.8e-19	-0.48	-0.43	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
THCA	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	10.19	3.71e-22	2.83e-19	0.42	0.43	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	10.19	3.72e-22	2.83e-19	0.56	0.43	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	10.19	3.72e-22	2.83e-19	0.56	0.43	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
THCA	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	10.19	3.73e-22	2.84e-19	0.54	0.43	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	10.19	3.75e-22	2.85e-19	0.5	0.43	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
THCA	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	10.19	3.75e-22	2.86e-19	0.45	0.43	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
THCA	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-10.19	3.77e-22	2.87e-19	-0.53	-0.43	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
THCA	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-10.19	3.77e-22	2.87e-19	-0.34	-0.43	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
THCA	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	10.19	3.78e-22	2.87e-19	0.35	0.43	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
THCA	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-10.19	3.79e-22	2.88e-19	-0.39	-0.43	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	10.19	3.79e-22	2.89e-19	0.51	0.43	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
THCA	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-10.18	3.8e-22	2.9e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
THCA	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	10.18	3.81e-22	2.9e-19	0.37	0.43	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
THCA	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	10.18	3.82e-22	2.9e-19	0.61	0.43	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
THCA	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	10.18	3.83e-22	2.91e-19	0.59	0.43	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
THCA	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-10.18	3.85e-22	2.93e-19	-0.5	-0.43	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
THCA	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	10.18	3.85e-22	2.93e-19	0.43	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
THCA	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	10.18	3.85e-22	2.93e-19	0.47	0.43	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
THCA	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-10.18	3.86e-22	2.94e-19	-0.34	-0.43	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
THCA	cis	rs180730	0.561	rs3115313	ENSG00000251609.2	SETP12	-10.18	3.87e-22	2.95e-19	-0.59	-0.43	Fasting plasma glucose;	chr4:120887708	chr4:120895494~120897083:-
THCA	cis	rs9890032	1	rs9890032	ENSG00000266490.1	CTD-2349P21.9	-10.18	3.89e-22	2.96e-19	-0.4	-0.43	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30792372~30792833:+
THCA	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-10.18	3.9e-22	2.96e-19	-0.49	-0.43	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000235689.1	AP000351.13	10.18	3.9e-22	2.97e-19	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:24006305~24008258:-
THCA	cis	rs11148252	0.716	rs3803262	ENSG00000278238.1	RP11-245D16.4	-10.18	3.9e-22	2.97e-19	-0.48	-0.43	Lewy body disease;	chr13:52462263	chr13:52454775~52455331:-
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	10.18	3.91e-22	2.98e-19	0.5	0.43	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
THCA	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-10.18	3.91e-22	2.98e-19	-0.34	-0.43	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
THCA	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-10.18	3.92e-22	2.98e-19	-0.5	-0.43	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	10.18	3.92e-22	2.98e-19	0.5	0.43	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	10.18	3.92e-22	2.98e-19	0.5	0.43	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
THCA	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	10.18	3.93e-22	2.99e-19	0.37	0.43	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
THCA	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-10.18	3.94e-22	3e-19	-0.39	-0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
THCA	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-10.18	3.94e-22	3e-19	-0.39	-0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
THCA	cis	rs9659323	0.804	rs10923722	ENSG00000231365.4	RP11-418J17.1	-10.18	3.94e-22	3e-19	-0.44	-0.43	Body mass index;	chr1:119000863	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.745	rs10923723	ENSG00000231365.4	RP11-418J17.1	-10.18	3.94e-22	3e-19	-0.44	-0.43	Body mass index;	chr1:119001379	chr1:119140396~119275973:+
THCA	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	10.18	3.96e-22	3.01e-19	0.59	0.43	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-10.18	3.96e-22	3.01e-19	-0.56	-0.43	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
THCA	cis	rs9532669	0.926	rs7328139	ENSG00000239827.7	SUGT1P3	-10.18	3.97e-22	3.01e-19	-0.47	-0.43	Cervical cancer;	chr13:40862295	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7328145	ENSG00000239827.7	SUGT1P3	-10.18	3.97e-22	3.01e-19	-0.47	-0.43	Cervical cancer;	chr13:40862307	chr13:40908159~40921774:-
THCA	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-10.18	3.99e-22	3.03e-19	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
THCA	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-10.18	3.99e-22	3.03e-19	-0.62	-0.43	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-10.18	3.99e-22	3.03e-19	-0.62	-0.43	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
THCA	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-10.18	3.99e-22	3.03e-19	-0.5	-0.43	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
THCA	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-10.18	3.99e-22	3.03e-19	-0.39	-0.43	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
THCA	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-10.18	4.03e-22	3.06e-19	-0.59	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
THCA	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	10.18	4.07e-22	3.09e-19	0.48	0.42	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	10.18	4.07e-22	3.09e-19	0.48	0.42	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	10.18	4.07e-22	3.09e-19	0.48	0.42	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	10.18	4.07e-22	3.09e-19	0.48	0.42	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
THCA	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
THCA	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	10.18	4.08e-22	3.09e-19	0.47	0.42	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
THCA	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	10.18	4.11e-22	3.12e-19	0.53	0.42	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
THCA	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	10.18	4.11e-22	3.12e-19	0.51	0.42	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	10.18	4.11e-22	3.12e-19	0.51	0.42	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
THCA	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-10.17	4.15e-22	3.15e-19	-0.45	-0.42	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
THCA	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-10.17	4.15e-22	3.15e-19	-0.35	-0.42	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	10.17	4.17e-22	3.16e-19	0.36	0.42	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
THCA	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	10.17	4.17e-22	3.17e-19	0.45	0.42	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	10.17	4.17e-22	3.17e-19	0.45	0.42	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
THCA	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-10.17	4.18e-22	3.17e-19	-0.47	-0.42	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
THCA	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	10.17	4.19e-22	3.18e-19	0.78	0.42	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	10.17	4.19e-22	3.18e-19	0.51	0.42	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	10.17	4.21e-22	3.19e-19	0.35	0.42	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	10.17	4.21e-22	3.19e-19	0.35	0.42	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	10.17	4.21e-22	3.19e-19	0.35	0.42	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-10.17	4.21e-22	3.19e-19	-0.35	-0.42	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-10.17	4.21e-22	3.19e-19	-0.35	-0.42	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-10.17	4.21e-22	3.19e-19	-0.35	-0.42	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
THCA	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-10.17	4.23e-22	3.21e-19	-0.5	-0.42	Migraine;	chr4:56851192	chr4:56960927~56961373:-
THCA	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-10.17	4.23e-22	3.21e-19	-0.5	-0.42	Migraine;	chr4:56852087	chr4:56960927~56961373:-
THCA	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	10.17	4.24e-22	3.22e-19	0.35	0.42	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
THCA	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-10.17	4.25e-22	3.22e-19	-0.47	-0.42	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	10.17	4.26e-22	3.23e-19	0.59	0.42	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	10.17	4.26e-22	3.23e-19	0.59	0.42	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
THCA	cis	rs860295	0.702	rs11264397	ENSG00000225855.5	RUSC1-AS1	10.17	4.26e-22	3.23e-19	0.3	0.42	Body mass index;	chr1:155641694	chr1:155316863~155324176:-
THCA	cis	rs9532669	0.926	rs7331435	ENSG00000239827.7	SUGT1P3	10.17	4.26e-22	3.23e-19	0.47	0.42	Cervical cancer;	chr13:40862396	chr13:40908159~40921774:-
THCA	cis	rs4591358	0.638	rs6704955	ENSG00000223466.1	AC064834.2	-10.17	4.27e-22	3.23e-19	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559393	chr2:195533035~195538681:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	10.17	4.28e-22	3.24e-19	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
THCA	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-10.17	4.28e-22	3.24e-19	-0.53	-0.42	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-10.17	4.28e-22	3.24e-19	-0.53	-0.42	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
THCA	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-10.17	4.3e-22	3.26e-19	-0.5	-0.42	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-10.17	4.3e-22	3.26e-19	-0.5	-0.42	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
THCA	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-10.17	4.33e-22	3.28e-19	-0.61	-0.42	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	10.17	4.33e-22	3.28e-19	0.5	0.42	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	10.17	4.35e-22	3.3e-19	0.5	0.42	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
THCA	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-10.17	4.35e-22	3.3e-19	-0.56	-0.42	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-10.17	4.35e-22	3.3e-19	-0.56	-0.42	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
THCA	cis	rs916888	0.821	rs70600	ENSG00000232300.1	FAM215B	10.17	4.36e-22	3.3e-19	0.69	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46558830~46562795:-
THCA	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-10.17	4.42e-22	3.35e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
THCA	cis	rs9595066	0.627	rs4942290	ENSG00000227258.4	SMIM2-AS1	10.17	4.43e-22	3.35e-19	0.58	0.42	Schizophrenia;	chr13:44183203	chr13:44110451~44240517:+
THCA	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	10.17	4.44e-22	3.36e-19	0.38	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
THCA	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-10.17	4.44e-22	3.36e-19	-0.48	-0.42	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	10.17	4.45e-22	3.37e-19	0.5	0.42	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
THCA	cis	rs2599510	0.811	rs2710625	ENSG00000276334.1	AL133243.1	10.17	4.47e-22	3.39e-19	0.46	0.42	Interleukin-18 levels;	chr2:32597890	chr2:32521927~32523547:+
THCA	cis	rs2980439	0.517	rs793753	ENSG00000253893.2	FAM85B	10.17	4.49e-22	3.39e-19	0.55	0.42	Neuroticism;	chr8:8247837	chr8:8167819~8226614:-
THCA	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-10.16	4.49e-22	3.4e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
THCA	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-10.16	4.49e-22	3.4e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
THCA	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-10.16	4.49e-22	3.4e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
THCA	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-10.16	4.5e-22	3.4e-19	-0.48	-0.42	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	10.16	4.51e-22	3.41e-19	0.5	0.42	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
THCA	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-10.16	4.51e-22	3.41e-19	-0.53	-0.42	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
THCA	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	10.16	4.53e-22	3.43e-19	0.36	0.42	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	10.16	4.53e-22	3.43e-19	0.5	0.42	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	10.16	4.53e-22	3.43e-19	0.5	0.42	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
THCA	cis	rs4713118	0.629	rs203889	ENSG00000280107.1	AL022393.9	-10.16	4.54e-22	3.43e-19	-0.49	-0.42	Parkinson's disease;	chr6:28053997	chr6:28170845~28172521:+
THCA	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	10.16	4.56e-22	3.45e-19	0.58	0.42	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-10.16	4.56e-22	3.45e-19	-0.58	-0.42	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
THCA	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
THCA	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-10.16	4.58e-22	3.46e-19	-0.34	-0.42	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
THCA	cis	rs9890032	1	rs3764419	ENSG00000266490.1	CTD-2349P21.9	10.16	4.59e-22	3.47e-19	0.4	0.42	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30792372~30792833:+
THCA	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	10.16	4.59e-22	3.47e-19	0.36	0.42	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
THCA	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	10.16	4.6e-22	3.48e-19	0.45	0.42	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
THCA	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-10.16	4.61e-22	3.48e-19	-0.55	-0.42	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-10.16	4.61e-22	3.48e-19	-0.55	-0.42	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
THCA	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-10.16	4.66e-22	3.52e-19	-0.47	-0.42	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
THCA	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	10.16	4.66e-22	3.52e-19	0.48	0.42	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
THCA	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-10.16	4.66e-22	3.52e-19	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
THCA	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	10.16	4.68e-22	3.54e-19	0.49	0.42	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
THCA	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.68e-22	3.54e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.68e-22	3.54e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.68e-22	3.54e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.68e-22	3.54e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
THCA	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-10.16	4.69e-22	3.54e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
THCA	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-10.16	4.69e-22	3.54e-19	-0.34	-0.42	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
THCA	cis	rs7665090	0.87	rs227361	ENSG00000246560.2	RP11-10L12.4	10.16	4.72e-22	3.56e-19	0.51	0.42	Primary biliary cholangitis;	chr4:102665820	chr4:102828055~102844075:+
THCA	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.72e-22	3.57e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.72e-22	3.57e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
THCA	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-10.16	4.75e-22	3.59e-19	-0.52	-0.42	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	10.16	4.78e-22	3.61e-19	0.6	0.42	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
THCA	cis	rs934734	0.532	rs12470883	ENSG00000281920.1	RP11-418H16.1	-10.16	4.79e-22	3.61e-19	-0.51	-0.42	Rheumatoid arthritis;	chr2:65424717	chr2:65623272~65628424:+
THCA	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-10.16	4.8e-22	3.63e-19	-0.57	-0.42	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
THCA	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-10.16	4.82e-22	3.63e-19	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-10.16	4.82e-22	3.63e-19	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-10.16	4.82e-22	3.63e-19	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
THCA	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-10.16	4.86e-22	3.67e-19	-0.48	-0.42	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
THCA	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	10.16	4.88e-22	3.68e-19	0.79	0.42	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
THCA	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	10.15	4.91e-22	3.71e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	10.15	4.91e-22	3.71e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
THCA	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	10.15	4.92e-22	3.71e-19	0.35	0.42	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
THCA	cis	rs4964805	0.913	rs35945096	ENSG00000257681.1	RP11-341G23.4	10.15	4.94e-22	3.72e-19	0.51	0.42	Attention deficit hyperactivity disorder;	chr12:103808151	chr12:103746315~103768858:-
THCA	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-10.15	4.96e-22	3.74e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-10.15	4.96e-22	3.74e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
THCA	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-10.15	5.02e-22	3.78e-19	-0.45	-0.42	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
THCA	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-10.15	5.05e-22	3.8e-19	-0.38	-0.42	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
THCA	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-10.15	5.06e-22	3.81e-19	-0.39	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
THCA	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-10.15	5.1e-22	3.84e-19	-0.32	-0.42	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
THCA	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-10.15	5.11e-22	3.85e-19	-0.37	-0.42	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-10.15	5.11e-22	3.85e-19	-0.37	-0.42	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.962	rs2275045	ENSG00000268592.3	RAET1E-AS1	10.15	5.14e-22	3.87e-19	0.59	0.42	Lung cancer;	chr6:149842775	chr6:149863494~149919507:+
THCA	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.15e-22	3.88e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
THCA	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-10.15	5.15e-22	3.88e-19	-0.32	-0.42	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
THCA	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-10.15	5.16e-22	3.88e-19	-0.57	-0.42	QT interval;	chr16:28845498	chr16:28700294~28701540:-
THCA	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.16e-22	3.88e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
THCA	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	10.15	5.19e-22	3.91e-19	0.51	0.42	Depression;	chr6:28314871	chr6:28176188~28176674:+
THCA	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	10.15	5.2e-22	3.91e-19	0.59	0.42	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
THCA	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.25e-22	3.95e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.25e-22	3.95e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.25e-22	3.95e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	10.15	5.28e-22	3.97e-19	0.49	0.42	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
THCA	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-10.15	5.29e-22	3.98e-19	-0.37	-0.42	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
THCA	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.3e-22	3.98e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
THCA	cis	rs217727	0.524	rs7483477	ENSG00000226416.1	MRPL23-AS1	-10.15	5.3e-22	3.98e-19	-0.53	-0.42	Breast cancer;	chr11:1899025	chr11:1983237~1989920:-
THCA	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-10.14	5.34e-22	4.01e-19	-0.47	-0.42	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	10.14	5.35e-22	4.02e-19	0.5	0.42	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
THCA	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-10.14	5.41e-22	4.07e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	10.14	5.41e-22	4.07e-19	0.51	0.42	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	10.14	5.41e-22	4.07e-19	0.51	0.42	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
THCA	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-10.14	5.48e-22	4.11e-19	-0.37	-0.42	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	10.14	5.48e-22	4.11e-19	0.51	0.42	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	10.14	5.51e-22	4.14e-19	0.56	0.42	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
THCA	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	10.14	5.51e-22	4.14e-19	0.55	0.42	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
THCA	cis	rs11673344	0.667	rs504549	ENSG00000226686.6	LINC01535	10.14	5.51e-22	4.14e-19	0.51	0.42	Obesity-related traits;	chr19:36946299	chr19:37251912~37265535:+
THCA	cis	rs8062405	0.558	rs3743963	ENSG00000259982.1	CDC37P1	10.14	5.52e-22	4.14e-19	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28593365	chr16:28700294~28701540:-
THCA	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-10.14	5.53e-22	4.15e-19	-0.48	-0.42	Temperament;	chr17:14013482	chr17:14024514~14025488:+
THCA	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-10.14	5.55e-22	4.16e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	10.14	5.56e-22	4.17e-19	0.5	0.42	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
THCA	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-10.14	5.57e-22	4.18e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
THCA	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-10.14	5.59e-22	4.2e-19	-0.38	-0.42	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
THCA	cis	rs9532669	0.926	rs6560963	ENSG00000239827.7	SUGT1P3	-10.14	5.6e-22	4.2e-19	-0.47	-0.42	Cervical cancer;	chr13:40871126	chr13:40908159~40921774:-
THCA	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	10.14	5.6e-22	4.2e-19	0.5	0.42	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
THCA	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-10.14	5.61e-22	4.21e-19	-0.52	-0.42	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-10.14	5.61e-22	4.21e-19	-0.52	-0.42	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-10.14	5.61e-22	4.21e-19	-0.52	-0.42	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
THCA	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	10.14	5.61e-22	4.21e-19	0.58	0.42	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
THCA	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	10.14	5.63e-22	4.23e-19	0.47	0.42	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
THCA	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	10.14	5.64e-22	4.23e-19	0.61	0.42	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-10.14	5.68e-22	4.26e-19	-0.4	-0.42	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
THCA	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	10.14	5.69e-22	4.27e-19	0.42	0.42	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
THCA	cis	rs748404	0.534	rs489509	ENSG00000249839.1	AC011330.5	-10.14	5.7e-22	4.27e-19	-0.5	-0.42	Lung cancer;	chr15:43294709	chr15:43663654~43684339:-
THCA	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	10.14	5.72e-22	4.29e-19	0.56	0.42	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
THCA	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-10.14	5.72e-22	4.29e-19	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	10.14	5.73e-22	4.3e-19	0.51	0.42	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
THCA	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-10.14	5.73e-22	4.3e-19	-0.53	-0.42	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
THCA	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	10.14	5.74e-22	4.31e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
THCA	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	10.14	5.75e-22	4.31e-19	0.56	0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
THCA	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-10.14	5.75e-22	4.31e-19	-0.45	-0.42	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
THCA	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-10.13	5.8e-22	4.35e-19	-0.62	-0.42	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
THCA	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-10.13	5.85e-22	4.38e-19	-0.43	-0.42	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
THCA	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	10.13	5.9e-22	4.42e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
THCA	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	10.13	5.95e-22	4.46e-19	0.58	0.42	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
THCA	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	10.13	5.97e-22	4.47e-19	0.47	0.42	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
THCA	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-10.13	5.98e-22	4.47e-19	-0.49	-0.42	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
THCA	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	10.13	6e-22	4.49e-19	0.45	0.42	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
THCA	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-10.13	6e-22	4.49e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-10.13	6e-22	4.49e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
THCA	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	10.13	6e-22	4.49e-19	0.42	0.42	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	10.13	6e-22	4.49e-19	0.42	0.42	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	10.13	6e-22	4.49e-19	0.42	0.42	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
THCA	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	10.13	6.03e-22	4.51e-19	0.5	0.42	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
THCA	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-10.13	6.04e-22	4.52e-19	-0.5	-0.42	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
THCA	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-10.13	6.09e-22	4.56e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-10.13	6.09e-22	4.56e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
THCA	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	10.13	6.16e-22	4.61e-19	0.74	0.42	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
THCA	cis	rs4964805	0.913	rs12830701	ENSG00000257681.1	RP11-341G23.4	10.13	6.17e-22	4.61e-19	0.51	0.42	Attention deficit hyperactivity disorder;	chr12:103807904	chr12:103746315~103768858:-
THCA	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	10.13	6.19e-22	4.63e-19	0.51	0.42	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
THCA	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-10.13	6.19e-22	4.63e-19	-0.39	-0.42	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
THCA	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	10.13	6.22e-22	4.65e-19	0.62	0.42	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
THCA	cis	rs4713118	0.629	rs149899	ENSG00000280107.1	AL022393.9	-10.12	6.31e-22	4.71e-19	-0.49	-0.42	Parkinson's disease;	chr6:28052201	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000280107.1	AL022393.9	-10.12	6.31e-22	4.71e-19	-0.49	-0.42	Parkinson's disease;	chr6:28053036	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000280107.1	AL022393.9	-10.12	6.31e-22	4.71e-19	-0.49	-0.42	Parkinson's disease;	chr6:28053042	chr6:28170845~28172521:+
THCA	cis	rs944289	0.533	rs2780313	ENSG00000257826.1	RP11-116N8.4	10.12	6.31e-22	4.71e-19	0.44	0.42	Thyroid cancer;	chr14:36059216	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	10.12	6.32e-22	4.72e-19	0.5	0.42	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	10.12	6.32e-22	4.72e-19	0.5	0.42	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-10.12	6.36e-22	4.75e-19	-0.5	-0.42	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
THCA	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	10.12	6.37e-22	4.75e-19	0.78	0.42	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
THCA	cis	rs62103177	0.564	rs3930043	ENSG00000261126.6	RP11-795F19.1	10.12	6.39e-22	4.77e-19	0.46	0.42	Opioid sensitivity;	chr18:79963832	chr18:80046900~80095482:+
THCA	cis	rs8062405	0.789	rs28676837	ENSG00000251417.2	RP11-1348G14.4	10.12	6.4e-22	4.77e-19	0.42	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28802743~28817828:+
THCA	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	10.12	6.42e-22	4.79e-19	0.46	0.42	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
THCA	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	10.12	6.43e-22	4.79e-19	0.52	0.42	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
THCA	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	10.12	6.43e-22	4.8e-19	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
THCA	cis	rs6570726	0.905	rs377143	ENSG00000235652.6	RP11-545I5.3	10.12	6.44e-22	4.8e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145799409~145886585:+
THCA	cis	rs944289	0.74	rs414755	ENSG00000257826.1	RP11-116N8.4	10.12	6.48e-22	4.84e-19	0.43	0.42	Thyroid cancer;	chr14:36073387	chr14:36061026~36067190:-
THCA	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	10.12	6.49e-22	4.84e-19	0.52	0.42	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
THCA	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	10.12	6.5e-22	4.85e-19	0.53	0.42	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
THCA	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	10.12	6.51e-22	4.86e-19	0.59	0.42	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	10.12	6.51e-22	4.86e-19	0.59	0.42	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
THCA	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	10.12	6.56e-22	4.89e-19	0.58	0.42	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
THCA	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-10.12	6.56e-22	4.89e-19	-0.48	-0.42	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
THCA	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-10.12	6.63e-22	4.94e-19	-0.51	-0.42	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
THCA	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-10.12	6.63e-22	4.94e-19	-0.51	-0.42	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
THCA	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-10.12	6.64e-22	4.95e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-10.12	6.64e-22	4.95e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-10.12	6.64e-22	4.95e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
THCA	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	10.12	6.68e-22	4.98e-19	0.58	0.42	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	10.12	6.72e-22	5.01e-19	0.58	0.42	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
THCA	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	10.12	6.72e-22	5.01e-19	0.58	0.42	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
THCA	cis	rs860295	0.702	rs12067371	ENSG00000225855.5	RUSC1-AS1	10.12	6.77e-22	5.04e-19	0.29	0.42	Body mass index;	chr1:155467878	chr1:155316863~155324176:-
THCA	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-10.12	6.78e-22	5.05e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
THCA	cis	rs860295	0.702	rs475550	ENSG00000225855.5	RUSC1-AS1	10.12	6.78e-22	5.05e-19	0.3	0.42	Body mass index;	chr1:155682290	chr1:155316863~155324176:-
THCA	cis	rs9532669	0.926	rs2324742	ENSG00000239827.7	SUGT1P3	-10.12	6.81e-22	5.07e-19	-0.46	-0.42	Cervical cancer;	chr13:40919059	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.857	rs9594455	ENSG00000239827.7	SUGT1P3	-10.12	6.81e-22	5.07e-19	-0.46	-0.42	Cervical cancer;	chr13:40919452	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532659	ENSG00000239827.7	SUGT1P3	-10.12	6.81e-22	5.07e-19	-0.46	-0.42	Cervical cancer;	chr13:40920380	chr13:40908159~40921774:-
THCA	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	10.12	6.82e-22	5.07e-19	0.49	0.42	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	10.12	6.82e-22	5.07e-19	0.49	0.42	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
THCA	cis	rs1387259	0.759	rs7960122	ENSG00000258273.1	RP11-370I10.4	10.12	6.83e-22	5.08e-19	0.57	0.42	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48333755~48333901:-
THCA	cis	rs6558530	0.965	rs6558535	ENSG00000253982.1	CTD-2336O2.1	10.11	6.88e-22	5.12e-19	0.37	0.42	Systolic blood pressure;	chr8:1762466	chr8:1761990~1764502:-
THCA	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-10.11	6.89e-22	5.12e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
THCA	cis	rs12220777	0.748	rs11201633	ENSG00000230091.5	TMEM254-AS1	10.11	6.91e-22	5.14e-19	0.78	0.42	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090068	chr10:80046860~80078912:-
THCA	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-10.11	6.98e-22	5.19e-19	-0.49	-0.42	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
THCA	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-10.11	7.01e-22	5.21e-19	-0.65	-0.42	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
THCA	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-10.11	7.08e-22	5.26e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
THCA	cis	rs860295	0.639	rs10908469	ENSG00000225855.5	RUSC1-AS1	10.11	7.1e-22	5.27e-19	0.29	0.42	Body mass index;	chr1:155498941	chr1:155316863~155324176:-
THCA	cis	rs1799949	0.832	rs2070835	ENSG00000267681.1	CTD-3199J23.6	-10.11	7.12e-22	5.29e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43022008	chr17:43144956~43145255:+
THCA	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	10.11	7.13e-22	5.3e-19	0.47	0.42	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
THCA	cis	rs6558530	0.965	rs730379	ENSG00000253982.1	CTD-2336O2.1	10.11	7.2e-22	5.34e-19	0.36	0.42	Systolic blood pressure;	chr8:1759927	chr8:1761990~1764502:-
THCA	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	10.11	7.21e-22	5.35e-19	0.59	0.42	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
THCA	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	10.11	7.21e-22	5.35e-19	0.59	0.42	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
THCA	cis	rs4380275	0.782	rs11127506	ENSG00000272342.1	RP13-539J13.1	-10.11	7.23e-22	5.36e-19	-0.49	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:739588~740164:-
THCA	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	10.11	7.23e-22	5.36e-19	0.52	0.42	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	10.11	7.23e-22	5.36e-19	0.52	0.42	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
THCA	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-10.11	7.24e-22	5.37e-19	-0.49	-0.42	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
THCA	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	10.11	7.25e-22	5.38e-19	0.57	0.42	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	10.11	7.34e-22	5.45e-19	0.49	0.42	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
THCA	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-10.11	7.35e-22	5.45e-19	-0.54	-0.42	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
THCA	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	10.11	7.35e-22	5.45e-19	0.63	0.42	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
THCA	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-10.11	7.35e-22	5.45e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
THCA	cis	rs10759883	0.587	rs2405134	ENSG00000175611.10	LINC00476	-10.11	7.39e-22	5.48e-19	-0.48	-0.42	Nicotine dependence;	chr9:95795179	chr9:95759231~95875977:-
THCA	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-10.11	7.42e-22	5.5e-19	-0.62	-0.42	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-10.11	7.42e-22	5.5e-19	-0.62	-0.42	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	10.1	7.52e-22	5.57e-19	0.5	0.42	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	10.1	7.52e-22	5.58e-19	0.59	0.42	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
THCA	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-10.1	7.53e-22	5.58e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
THCA	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-10.1	7.53e-22	5.58e-19	-0.62	-0.42	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
THCA	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	10.1	7.55e-22	5.6e-19	0.53	0.42	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
THCA	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-10.1	7.6e-22	5.63e-19	-0.46	-0.42	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
THCA	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	10.1	7.65e-22	5.66e-19	0.37	0.42	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
THCA	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	10.1	7.7e-22	5.7e-19	0.45	0.42	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
THCA	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	10.1	7.73e-22	5.72e-19	0.53	0.42	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
THCA	cis	rs9532669	0.89	rs35396630	ENSG00000239827.7	SUGT1P3	-10.1	7.74e-22	5.73e-19	-0.47	-0.42	Cervical cancer;	chr13:40863135	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942001	ENSG00000239827.7	SUGT1P3	-10.1	7.74e-22	5.73e-19	-0.47	-0.42	Cervical cancer;	chr13:40863176	chr13:40908159~40921774:-
THCA	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	10.1	7.75e-22	5.74e-19	0.38	0.42	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
THCA	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	10.1	7.75e-22	5.74e-19	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
THCA	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	10.1	7.8e-22	5.77e-19	0.52	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
THCA	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	10.1	7.8e-22	5.77e-19	0.48	0.42	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
THCA	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-10.1	7.81e-22	5.78e-19	-0.33	-0.42	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	10.1	7.86e-22	5.81e-19	0.49	0.42	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
THCA	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-10.1	7.89e-22	5.84e-19	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-10.1	7.91e-22	5.86e-19	-0.4	-0.42	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-10.1	7.91e-22	5.86e-19	-0.4	-0.42	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
THCA	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	10.1	7.94e-22	5.87e-19	0.52	0.42	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
THCA	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-10.1	7.94e-22	5.88e-19	-0.49	-0.42	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
THCA	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	10.1	7.94e-22	5.88e-19	0.48	0.42	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
THCA	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-10.1	7.97e-22	5.89e-19	-0.5	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
THCA	cis	rs6570726	0.935	rs430561	ENSG00000235652.6	RP11-545I5.3	10.1	7.98e-22	5.91e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145799409~145886585:+
THCA	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	10.1	8e-22	5.92e-19	0.71	0.42	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
THCA	cis	rs9532669	0.89	rs9594457	ENSG00000239827.7	SUGT1P3	-10.1	8e-22	5.92e-19	-0.46	-0.42	Cervical cancer;	chr13:40920439	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9594458	ENSG00000239827.7	SUGT1P3	-10.1	8e-22	5.92e-19	-0.46	-0.42	Cervical cancer;	chr13:40920448	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9590562	ENSG00000239827.7	SUGT1P3	-10.1	8e-22	5.92e-19	-0.46	-0.42	Cervical cancer;	chr13:40920503	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs12857052	ENSG00000239827.7	SUGT1P3	-10.1	8e-22	5.92e-19	-0.46	-0.42	Cervical cancer;	chr13:40920831	chr13:40908159~40921774:-
THCA	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-10.1	8.02e-22	5.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
THCA	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-10.1	8.04e-22	5.94e-19	-0.47	-0.42	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-10.1	8.04e-22	5.94e-19	-0.47	-0.42	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-10.1	8.04e-22	5.94e-19	-0.47	-0.42	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-10.1	8.04e-22	5.94e-19	-0.47	-0.42	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
THCA	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	10.09	8.09e-22	5.98e-19	0.49	0.42	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
THCA	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-10.09	8.09e-22	5.98e-19	-0.38	-0.42	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
THCA	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-10.09	8.1e-22	5.99e-19	-0.5	-0.42	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
THCA	cis	rs67311347	0.577	rs2887951	ENSG00000223797.4	ENTPD3-AS1	10.09	8.1e-22	5.99e-19	0.34	0.42	Renal cell carcinoma;	chr3:40240613	chr3:40313802~40453329:-
THCA	cis	rs6570726	0.967	rs418662	ENSG00000235652.6	RP11-545I5.3	10.09	8.11e-22	5.99e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145799409~145886585:+
THCA	cis	rs944289	0.708	rs11622885	ENSG00000257826.1	RP11-116N8.4	-10.09	8.11e-22	6e-19	-0.44	-0.42	Thyroid cancer;	chr14:36095036	chr14:36061026~36067190:-
THCA	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-10.09	8.15e-22	6.02e-19	-0.47	-0.42	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000281920.1	RP11-418H16.1	-10.09	8.17e-22	6.04e-19	-0.52	-0.42	Rheumatoid arthritis;	chr2:65423730	chr2:65623272~65628424:+
THCA	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	10.09	8.17e-22	6.04e-19	0.5	0.42	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
THCA	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-10.09	8.19e-22	6.05e-19	-0.51	-0.42	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
THCA	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	10.09	8.22e-22	6.07e-19	0.5	0.42	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
THCA	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-10.09	8.27e-22	6.11e-19	-0.34	-0.42	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
THCA	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-10.09	8.31e-22	6.14e-19	-0.58	-0.42	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
THCA	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-10.09	8.34e-22	6.16e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-10.09	8.34e-22	6.16e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	10.09	8.36e-22	6.17e-19	0.5	0.42	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
THCA	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	10.09	8.4e-22	6.2e-19	0.51	0.42	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
THCA	cis	rs4964805	0.586	rs934846	ENSG00000257681.1	RP11-341G23.4	10.09	8.45e-22	6.24e-19	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103791519	chr12:103746315~103768858:-
THCA	cis	rs7191700	0.674	rs12597893	ENSG00000262703.1	RP11-485G7.6	10.09	8.51e-22	6.28e-19	0.47	0.42	Multiple sclerosis;	chr16:11332474	chr16:11348143~11349321:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	10.09	8.55e-22	6.31e-19	0.49	0.42	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
THCA	cis	rs10256972	0.504	rs3735687	ENSG00000229043.2	AC091729.9	-10.09	8.59e-22	6.33e-19	-0.46	-0.42	Endometriosis;Longevity;	chr7:1026661	chr7:1160374~1165267:+
THCA	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	10.09	8.6e-22	6.34e-19	0.52	0.42	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
THCA	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	10.09	8.64e-22	6.37e-19	0.44	0.42	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
THCA	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	10.09	8.66e-22	6.39e-19	0.53	0.42	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
THCA	cis	rs4964805	0.865	rs11111796	ENSG00000257681.1	RP11-341G23.4	10.09	8.72e-22	6.43e-19	0.51	0.42	Attention deficit hyperactivity disorder;	chr12:103812150	chr12:103746315~103768858:-
THCA	cis	rs10853057	0.717	rs62062479	ENSG00000214174.7	AMZ2P1	10.09	8.73e-22	6.43e-19	0.79	0.42	White matter microstructure (global fractional anisotropy);	chr17:65060017	chr17:64966550~64975576:-
THCA	cis	rs7772486	0.902	rs2777480	ENSG00000235652.6	RP11-545I5.3	10.09	8.75e-22	6.45e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145799409~145886585:+
THCA	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-10.08	8.81e-22	6.49e-19	-0.49	-0.42	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
THCA	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-10.08	8.83e-22	6.51e-19	-0.47	-0.42	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
THCA	cis	rs10256972	0.64	rs10271082	ENSG00000229043.2	AC091729.9	-10.08	8.86e-22	6.53e-19	-0.47	-0.42	Endometriosis;Longevity;	chr7:1041926	chr7:1160374~1165267:+
THCA	cis	rs62103177	0.564	rs3930042	ENSG00000261126.6	RP11-795F19.1	10.08	8.87e-22	6.53e-19	0.46	0.42	Opioid sensitivity;	chr18:79963843	chr18:80046900~80095482:+
THCA	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	10.08	8.88e-22	6.54e-19	0.51	0.42	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
THCA	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-10.08	8.97e-22	6.6e-19	-0.48	-0.42	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
THCA	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	10.08	9e-22	6.62e-19	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
THCA	cis	rs9532669	0.963	rs9315794	ENSG00000239827.7	SUGT1P3	-10.08	9.02e-22	6.64e-19	-0.46	-0.42	Cervical cancer;	chr13:40939489	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	10.08	9.02e-22	6.64e-19	0.5	0.42	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
THCA	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-10.08	9.08e-22	6.68e-19	-0.51	-0.42	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
THCA	cis	rs11696845	0.787	rs6017408	ENSG00000276223.1	RP4-781B1.5	-10.08	9.09e-22	6.69e-19	-0.51	-0.42	Obesity-related traits;	chr20:44734888	chr20:44746642~44747201:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-10.08	9.11e-22	6.71e-19	-0.35	-0.42	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
THCA	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-10.08	9.14e-22	6.73e-19	-0.53	-0.42	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
THCA	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	10.08	9.22e-22	6.78e-19	0.36	0.42	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
THCA	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-10.08	9.22e-22	6.78e-19	-0.45	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	10.08	9.23e-22	6.79e-19	0.5	0.42	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	10.08	9.4e-22	6.91e-19	0.48	0.42	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
THCA	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-10.08	9.41e-22	6.92e-19	-0.48	-0.42	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
THCA	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	10.08	9.41e-22	6.92e-19	0.5	0.42	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	10.08	9.41e-22	6.92e-19	0.5	0.42	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
THCA	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-10.08	9.47e-22	6.96e-19	-0.4	-0.42	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000224205.1	AP000351.4	10.08	9.48e-22	6.97e-19	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23987320~23991421:-
THCA	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-10.08	9.5e-22	6.98e-19	-0.61	-0.42	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
THCA	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	10.07	9.6e-22	7.05e-19	0.48	0.42	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
THCA	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-10.07	9.62e-22	7.07e-19	-0.47	-0.42	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
THCA	cis	rs10853057	0.717	rs62062478	ENSG00000214174.7	AMZ2P1	10.07	9.63e-22	7.07e-19	0.78	0.42	White matter microstructure (global fractional anisotropy);	chr17:65059458	chr17:64966550~64975576:-
THCA	cis	rs4964805	0.913	rs7134701	ENSG00000257681.1	RP11-341G23.4	10.07	9.64e-22	7.08e-19	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103808913	chr12:103746315~103768858:-
THCA	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	10.07	9.64e-22	7.08e-19	0.62	0.42	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
THCA	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	10.07	9.65e-22	7.09e-19	0.78	0.42	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
THCA	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-10.07	9.71e-22	7.13e-19	-0.49	-0.42	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
THCA	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	10.07	9.71e-22	7.13e-19	0.79	0.42	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
THCA	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	10.07	9.73e-22	7.14e-19	0.47	0.42	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
THCA	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-10.07	9.82e-22	7.21e-19	-0.41	-0.42	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
THCA	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	10.07	9.85e-22	7.22e-19	0.51	0.42	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
THCA	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	10.07	9.88e-22	7.24e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
THCA	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	10.07	1e-21	7.33e-19	0.59	0.42	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
THCA	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	10.07	1e-21	7.33e-19	0.59	0.42	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
THCA	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	10.07	1.01e-21	7.37e-19	0.49	0.42	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
THCA	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-10.07	1.03e-21	7.51e-19	-0.45	-0.42	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
THCA	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	10.07	1.03e-21	7.52e-19	0.5	0.42	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	10.07	1.03e-21	7.56e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
THCA	cis	rs6558530	0.965	rs7460287	ENSG00000253982.1	CTD-2336O2.1	10.07	1.03e-21	7.56e-19	0.37	0.42	Systolic blood pressure;	chr8:1760108	chr8:1761990~1764502:-
THCA	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-10.07	1.03e-21	7.58e-19	-0.47	-0.42	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
THCA	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-10.07	1.04e-21	7.58e-19	-0.49	-0.42	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	10.06	1.04e-21	7.62e-19	0.49	0.42	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
THCA	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-10.06	1.04e-21	7.62e-19	-0.55	-0.42	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	10.06	1.04e-21	7.64e-19	0.57	0.42	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
THCA	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-10.06	1.05e-21	7.65e-19	-0.47	-0.42	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-10.06	1.05e-21	7.65e-19	-0.47	-0.42	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
THCA	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	10.06	1.05e-21	7.65e-19	0.54	0.42	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
THCA	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-10.06	1.05e-21	7.68e-19	-0.44	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
THCA	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
THCA	cis	rs673078	0.66	rs61943365	ENSG00000275409.1	RP11-131L12.4	-10.06	1.06e-21	7.73e-19	-0.46	-0.42	Glucose homeostasis traits;	chr12:118339166	chr12:118430147~118430699:+
THCA	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	10.06	1.06e-21	7.74e-19	0.36	0.42	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	10.06	1.06e-21	7.74e-19	0.36	0.42	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	10.06	1.06e-21	7.74e-19	0.49	0.42	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
THCA	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-10.06	1.07e-21	7.78e-19	-0.48	-0.42	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
THCA	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-10.06	1.07e-21	7.78e-19	-0.41	-0.42	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
THCA	cis	rs6496932	0.635	rs11074191	ENSG00000218052.5	ADAMTS7P4	-10.06	1.07e-21	7.79e-19	-0.56	-0.42	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85255369~85330334:-
THCA	cis	rs42490	0.899	rs1397308	ENSG00000251136.7	RP11-37B2.1	10.06	1.07e-21	7.8e-19	0.37	0.42	Leprosy;	chr8:89628493	chr8:89609409~89757727:-
THCA	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	10.06	1.08e-21	7.85e-19	0.47	0.42	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	10.06	1.08e-21	7.85e-19	0.47	0.42	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
THCA	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-10.06	1.08e-21	7.89e-19	-0.61	-0.42	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
THCA	cis	rs780096	0.506	rs72819512	ENSG00000234072.1	AC074117.10	-10.06	1.09e-21	7.92e-19	-0.34	-0.42	Total body bone mineral density;	chr2:27391582	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.923	rs2184370	ENSG00000216906.2	RP11-350J20.9	10.06	1.09e-21	7.99e-19	0.51	0.42	Lung cancer;	chr6:149843242	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	10.06	1.1e-21	7.99e-19	0.58	0.42	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	10.06	1.1e-21	7.99e-19	0.58	0.42	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	10.06	1.1e-21	8.04e-19	0.47	0.42	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
THCA	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	10.06	1.11e-21	8.08e-19	0.49	0.42	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	10.06	1.11e-21	8.08e-19	0.49	0.42	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	10.06	1.11e-21	8.08e-19	0.49	0.42	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	10.06	1.11e-21	8.08e-19	0.49	0.42	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	10.06	1.11e-21	8.11e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
THCA	cis	rs4660456	0.504	rs2744805	ENSG00000237899.1	RP4-739H11.3	10.06	1.11e-21	8.12e-19	0.59	0.42	Platelet count;	chr1:40654827	chr1:40669089~40687588:-
THCA	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-10.06	1.12e-21	8.18e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-10.06	1.12e-21	8.18e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-10.06	1.12e-21	8.18e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-10.06	1.12e-21	8.18e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
THCA	cis	rs7772486	0.869	rs2777473	ENSG00000235652.6	RP11-545I5.3	10.06	1.12e-21	8.19e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145799409~145886585:+
THCA	cis	rs71403859	0.502	rs34380814	ENSG00000260886.1	TAT-AS1	10.05	1.13e-21	8.24e-19	0.68	0.42	Post bronchodilator FEV1;	chr16:71454272	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	10.05	1.13e-21	8.26e-19	0.49	0.42	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
THCA	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-10.05	1.13e-21	8.26e-19	-0.34	-0.42	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
THCA	cis	rs6496932	1	rs35796484	ENSG00000218052.5	ADAMTS7P4	10.05	1.13e-21	8.27e-19	0.6	0.42	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85255369~85330334:-
THCA	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	10.05	1.14e-21	8.32e-19	0.57	0.42	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
THCA	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	10.05	1.14e-21	8.33e-19	0.36	0.42	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
THCA	cis	rs1426063	0.748	rs7654088	ENSG00000260265.1	RP11-44F21.5	-10.05	1.14e-21	8.34e-19	-0.62	-0.42	QT interval;	chr4:75107103	chr4:75081702~75084717:-
THCA	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-10.05	1.15e-21	8.34e-19	-0.51	-0.42	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
THCA	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-10.05	1.15e-21	8.37e-19	-0.57	-0.42	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
THCA	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-10.05	1.15e-21	8.39e-19	-0.55	-0.42	Depression;	chr6:28229408	chr6:28115628~28116551:+
THCA	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-10.05	1.16e-21	8.42e-19	-0.46	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
THCA	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	10.05	1.16e-21	8.42e-19	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
THCA	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
THCA	cis	rs9928842	0.941	rs6564239	ENSG00000280152.1	RP11-331F4.5	10.05	1.16e-21	8.48e-19	0.65	0.42	Alcoholic chronic pancreatitis;	chr16:75219906	chr16:75245994~75250077:-
THCA	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-10.05	1.17e-21	8.5e-19	-0.53	-0.42	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
THCA	cis	rs860295	0.702	rs11264366	ENSG00000225855.5	RUSC1-AS1	10.05	1.17e-21	8.51e-19	0.29	0.42	Body mass index;	chr1:155365620	chr1:155316863~155324176:-
THCA	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	10.05	1.17e-21	8.51e-19	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
THCA	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-10.05	1.18e-21	8.55e-19	-0.33	-0.42	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	10.05	1.18e-21	8.61e-19	0.49	0.42	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	10.05	1.18e-21	8.62e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
THCA	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	10.05	1.19e-21	8.63e-19	0.35	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
THCA	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-10.05	1.19e-21	8.63e-19	-0.43	-0.42	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
THCA	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	10.05	1.19e-21	8.66e-19	0.47	0.42	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	10.05	1.19e-21	8.66e-19	0.47	0.42	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	10.05	1.19e-21	8.66e-19	0.47	0.42	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
THCA	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	10.05	1.19e-21	8.68e-19	0.47	0.42	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
THCA	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	10.05	1.19e-21	8.69e-19	0.49	0.42	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
THCA	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.19e-21	8.69e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
THCA	cis	rs11148252	0.819	rs7336679	ENSG00000278238.1	RP11-245D16.4	-10.05	1.2e-21	8.69e-19	-0.47	-0.42	Lewy body disease;	chr13:52469198	chr13:52454775~52455331:-
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	10.05	1.21e-21	8.77e-19	0.49	0.42	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-10.05	1.21e-21	8.79e-19	-0.4	-0.42	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	-10.05	1.21e-21	8.79e-19	-0.57	-0.42	Depression;	chr6:28071808	chr6:28161781~28169594:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-10.05	1.21e-21	8.79e-19	-0.4	-0.42	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
THCA	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	10.05	1.22e-21	8.86e-19	0.49	0.42	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
THCA	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-10.05	1.22e-21	8.89e-19	-0.48	-0.42	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
THCA	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	10.05	1.22e-21	8.89e-19	0.57	0.42	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.75	rs9532598	ENSG00000176268.5	CYCSP34	10.05	1.23e-21	8.9e-19	0.49	0.42	Cervical cancer;	chr13:40860627	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.611	rs9532599	ENSG00000176268.5	CYCSP34	10.05	1.23e-21	8.9e-19	0.49	0.42	Cervical cancer;	chr13:40860633	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.571	rs9525405	ENSG00000176268.5	CYCSP34	10.05	1.23e-21	8.9e-19	0.49	0.42	Cervical cancer;	chr13:40860638	chr13:40863599~40863902:-
THCA	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-10.05	1.23e-21	8.91e-19	-0.62	-0.42	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
THCA	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-10.04	1.23e-21	8.95e-19	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
THCA	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-10.04	1.23e-21	8.95e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
THCA	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-10.04	1.24e-21	8.99e-19	-0.49	-0.42	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000280107.1	AL022393.9	-10.04	1.24e-21	8.99e-19	-0.49	-0.42	Parkinson's disease;	chr6:28062721	chr6:28170845~28172521:+
THCA	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	10.04	1.24e-21	9e-19	0.47	0.42	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	10.04	1.24e-21	9e-19	0.47	0.42	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	10.04	1.24e-21	9e-19	0.47	0.42	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	10.04	1.24e-21	9e-19	0.47	0.42	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
THCA	cis	rs6570726	0.537	rs1280279	ENSG00000235652.6	RP11-545I5.3	10.04	1.26e-21	9.12e-19	0.45	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145562912	chr6:145799409~145886585:+
THCA	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
THCA	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-10.04	1.27e-21	9.18e-19	-0.58	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
THCA	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-10.04	1.27e-21	9.19e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
THCA	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-10.04	1.27e-21	9.2e-19	-0.42	-0.42	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-10.04	1.27e-21	9.2e-19	-0.42	-0.42	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-10.04	1.27e-21	9.22e-19	-0.53	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
THCA	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	10.04	1.27e-21	9.24e-19	0.44	0.42	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	10.04	1.28e-21	9.28e-19	0.49	0.42	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
THCA	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-10.04	1.28e-21	9.28e-19	-0.78	-0.42	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
THCA	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-10.04	1.28e-21	9.28e-19	-0.61	-0.42	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
THCA	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-10.04	1.28e-21	9.29e-19	-0.53	-0.42	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-10.04	1.3e-21	9.39e-19	-0.51	-0.42	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
THCA	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-10.04	1.31e-21	9.46e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
THCA	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-10.04	1.31e-21	9.48e-19	-0.53	-0.42	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-10.04	1.31e-21	9.48e-19	-0.53	-0.42	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
THCA	cis	rs9928842	0.823	rs12918452	ENSG00000280152.1	RP11-331F4.5	10.04	1.31e-21	9.51e-19	0.61	0.42	Alcoholic chronic pancreatitis;	chr16:75201536	chr16:75245994~75250077:-
THCA	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	10.04	1.32e-21	9.54e-19	0.49	0.42	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	10.04	1.32e-21	9.54e-19	0.49	0.42	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	10.04	1.32e-21	9.55e-19	0.49	0.42	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
THCA	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-10.04	1.32e-21	9.55e-19	-0.51	-0.42	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
THCA	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-10.04	1.32e-21	9.57e-19	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
THCA	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-10.04	1.32e-21	9.57e-19	-0.44	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-10.04	1.33e-21	9.59e-19	-0.4	-0.42	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
THCA	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-10.03	1.33e-21	9.65e-19	-0.33	-0.42	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
THCA	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-10.03	1.35e-21	9.73e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
THCA	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	10.03	1.35e-21	9.74e-19	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
THCA	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	10.03	1.35e-21	9.74e-19	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
THCA	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-10.03	1.35e-21	9.77e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
THCA	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	10.03	1.36e-21	9.82e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	10.03	1.36e-21	9.83e-19	0.49	0.42	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
THCA	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-10.03	1.37e-21	9.87e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
THCA	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	10.03	1.37e-21	9.88e-19	0.56	0.42	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
THCA	cis	rs944289	0.74	rs368187	ENSG00000257826.1	RP11-116N8.4	10.03	1.37e-21	9.91e-19	0.42	0.42	Thyroid cancer;	chr14:36063370	chr14:36061026~36067190:-
THCA	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-10.03	1.38e-21	9.95e-19	-0.61	-0.42	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
THCA	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-10.03	1.4e-21	1.01e-18	-0.51	-0.42	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000215447.6	BX322557.10	-10.03	1.4e-21	1.01e-18	-0.35	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45288052~45291738:+
THCA	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-10.03	1.4e-21	1.01e-18	-0.49	-0.42	Height;	chr6:109501793	chr6:109382795~109383666:+
THCA	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	10.03	1.41e-21	1.02e-18	0.36	0.42	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
THCA	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-10.03	1.41e-21	1.02e-18	-0.57	-0.42	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
THCA	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	10.03	1.42e-21	1.03e-18	0.46	0.42	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
THCA	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-10.03	1.42e-21	1.03e-18	-0.52	-0.42	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
THCA	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	10.03	1.42e-21	1.03e-18	0.35	0.42	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-10.03	1.43e-21	1.03e-18	-0.5	-0.42	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
THCA	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-10.03	1.43e-21	1.03e-18	-0.45	-0.42	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
THCA	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-10.03	1.43e-21	1.04e-18	-0.61	-0.42	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-10.03	1.43e-21	1.04e-18	-0.61	-0.42	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
THCA	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	10.03	1.44e-21	1.04e-18	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
THCA	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-10.03	1.45e-21	1.05e-18	-0.55	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
THCA	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-10.02	1.45e-21	1.05e-18	-0.62	-0.42	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
THCA	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-10.02	1.46e-21	1.05e-18	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-10.02	1.48e-21	1.07e-18	-0.6	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
THCA	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-10.02	1.48e-21	1.07e-18	-0.45	-0.42	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
THCA	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	10.02	1.48e-21	1.07e-18	0.44	0.42	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	10.02	1.48e-21	1.07e-18	0.58	0.42	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	10.02	1.49e-21	1.07e-18	0.49	0.42	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	10.02	1.49e-21	1.08e-18	0.47	0.42	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
THCA	cis	rs6558530	0.932	rs10102731	ENSG00000253982.1	CTD-2336O2.1	10.02	1.49e-21	1.08e-18	0.37	0.42	Systolic blood pressure;	chr8:1760854	chr8:1761990~1764502:-
THCA	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	10.02	1.5e-21	1.08e-18	0.45	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
THCA	cis	rs1043099	0.912	rs929454	ENSG00000279699.1	RP1-102K2.9	10.02	1.5e-21	1.08e-18	0.58	0.42	Rheumatoid arthritis;	chr22:30296364	chr22:30275215~30276951:-
THCA	cis	rs6570726	0.934	rs9484995	ENSG00000235652.6	RP11-545I5.3	-10.02	1.51e-21	1.09e-18	-0.39	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145459978	chr6:145799409~145886585:+
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-10.02	1.53e-21	1.1e-18	-0.41	-0.42	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
THCA	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	10.02	1.53e-21	1.1e-18	0.52	0.42	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
THCA	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-10.02	1.53e-21	1.1e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
THCA	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-10.02	1.53e-21	1.1e-18	-0.51	-0.42	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
THCA	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	10.02	1.53e-21	1.1e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
THCA	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-10.02	1.54e-21	1.11e-18	-0.35	-0.42	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
THCA	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-10.02	1.54e-21	1.11e-18	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
THCA	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-10.02	1.55e-21	1.11e-18	-0.45	-0.42	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
THCA	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-10.02	1.56e-21	1.12e-18	-0.5	-0.42	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
THCA	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	10.02	1.56e-21	1.13e-18	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
THCA	cis	rs2599510	0.703	rs58852184	ENSG00000276334.1	AL133243.1	10.01	1.58e-21	1.14e-18	0.46	0.42	Interleukin-18 levels;	chr2:32504696	chr2:32521927~32523547:+
THCA	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	10.01	1.59e-21	1.14e-18	0.36	0.42	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
THCA	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-10.01	1.61e-21	1.16e-18	-0.62	-0.42	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-10.01	1.61e-21	1.16e-18	-0.62	-0.42	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
THCA	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-10.01	1.62e-21	1.16e-18	-0.5	-0.42	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
THCA	cis	rs1043099	0.912	rs4339043	ENSG00000279699.1	RP1-102K2.9	10.01	1.64e-21	1.18e-18	0.6	0.42	Rheumatoid arthritis;	chr22:30339919	chr22:30275215~30276951:-
THCA	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-10.01	1.66e-21	1.19e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-10.01	1.66e-21	1.19e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
THCA	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	10.01	1.66e-21	1.19e-18	0.48	0.42	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	10.01	1.66e-21	1.19e-18	0.49	0.42	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
THCA	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-10.01	1.66e-21	1.19e-18	-0.53	-0.42	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
THCA	cis	rs7598759	0.548	rs6750795	ENSG00000181798.2	LINC00471	-10.01	1.66e-21	1.2e-18	-0.51	-0.42	Noise-induced hearing loss;	chr2:231513520	chr2:231508426~231514339:-
THCA	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	10.01	1.67e-21	1.2e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
THCA	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	10.01	1.67e-21	1.2e-18	0.47	0.42	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
THCA	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-10.01	1.67e-21	1.2e-18	-0.48	-0.42	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-10.01	1.67e-21	1.2e-18	-0.48	-0.42	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-10.01	1.67e-21	1.2e-18	-0.57	-0.42	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	10.01	1.67e-21	1.2e-18	0.49	0.42	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	10.01	1.67e-21	1.2e-18	0.49	0.42	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
THCA	cis	rs10740039	0.804	rs4948424	ENSG00000254271.1	RP11-131N11.4	10.01	1.68e-21	1.21e-18	0.51	0.42	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60681812	chr10:60734342~60741828:+
THCA	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-10.01	1.69e-21	1.21e-18	-0.44	-0.42	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
THCA	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	10.01	1.69e-21	1.21e-18	0.49	0.42	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
THCA	cis	rs4266144	0.821	rs56237906	ENSG00000244515.1	KRT18P34	-10.01	1.69e-21	1.22e-18	-0.5	-0.42	Coronary artery disease;	chr3:157134684	chr3:157162663~157163932:-
THCA	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	10.01	1.7e-21	1.22e-18	0.58	0.42	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
THCA	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-10.01	1.71e-21	1.23e-18	-0.52	-0.42	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
THCA	cis	rs6061231	0.834	rs2427307	ENSG00000273619.1	RP5-908M14.9	-10	1.72e-21	1.23e-18	-0.33	-0.42	Colorectal cancer;	chr20:62391630	chr20:62386303~62386970:-
THCA	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	10	1.72e-21	1.23e-18	0.46	0.42	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
THCA	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-10	1.72e-21	1.24e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-10	1.72e-21	1.24e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
THCA	cis	rs4964805	0.683	rs12424737	ENSG00000257681.1	RP11-341G23.4	10	1.73e-21	1.24e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103802443	chr12:103746315~103768858:-
THCA	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	10	1.73e-21	1.24e-18	0.57	0.42	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
THCA	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-10	1.74e-21	1.25e-18	-0.5	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
THCA	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	10	1.74e-21	1.25e-18	0.5	0.42	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
THCA	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-10	1.74e-21	1.25e-18	-0.49	-0.42	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
THCA	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
THCA	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-10	1.75e-21	1.26e-18	-0.43	-0.42	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
THCA	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	10	1.76e-21	1.26e-18	0.43	0.42	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
THCA	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-10	1.76e-21	1.26e-18	-0.43	-0.42	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
THCA	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-10	1.76e-21	1.26e-18	-0.43	-0.42	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
THCA	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-10	1.76e-21	1.26e-18	-0.43	-0.42	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
THCA	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-10	1.76e-21	1.26e-18	-0.5	-0.42	Migraine;	chr4:56852029	chr4:56960927~56961373:-
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000266490.1	CTD-2349P21.9	10	1.77e-21	1.27e-18	0.56	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30792372~30792833:+
THCA	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	10	1.78e-21	1.28e-18	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
THCA	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-10	1.78e-21	1.28e-18	-0.5	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
THCA	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	10	1.78e-21	1.28e-18	0.51	0.42	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
THCA	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-10	1.78e-21	1.28e-18	-0.49	-0.42	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
THCA	cis	rs4964805	0.657	rs4964813	ENSG00000257681.1	RP11-341G23.4	10	1.8e-21	1.29e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103795776	chr12:103746315~103768858:-
THCA	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	10	1.8e-21	1.29e-18	0.58	0.42	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	10	1.8e-21	1.29e-18	0.58	0.42	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-10	1.81e-21	1.29e-18	-0.49	-0.42	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
THCA	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	10	1.82e-21	1.31e-18	0.47	0.42	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	10	1.82e-21	1.31e-18	0.47	0.42	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
THCA	cis	rs9532669	0.963	rs9562238	ENSG00000239827.7	SUGT1P3	-10	1.83e-21	1.31e-18	-0.45	-0.42	Cervical cancer;	chr13:40924785	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	10	1.84e-21	1.32e-18	0.58	0.42	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	10	1.85e-21	1.32e-18	0.49	0.42	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
THCA	cis	rs1426063	0.748	rs6534607	ENSG00000260265.1	RP11-44F21.5	10	1.86e-21	1.33e-18	0.62	0.42	QT interval;	chr4:75106366	chr4:75081702~75084717:-
THCA	cis	rs737008	0.5	rs7189239	ENSG00000262703.1	RP11-485G7.6	9.99	1.87e-21	1.34e-18	0.47	0.42	Obesity-related traits;	chr16:11308658	chr16:11348143~11349321:-
THCA	cis	rs6908034	0.769	rs6916589	ENSG00000228412.5	RP4-625H18.2	9.99	1.87e-21	1.34e-18	0.89	0.42	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761132	chr6:19802164~19804752:-
THCA	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-9.99	1.88e-21	1.34e-18	-0.32	-0.42	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
THCA	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	9.99	1.88e-21	1.34e-18	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
THCA	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	9.99	1.89e-21	1.35e-18	0.48	0.42	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
THCA	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	9.99	1.89e-21	1.35e-18	0.36	0.42	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	9.99	1.89e-21	1.35e-18	0.57	0.42	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
THCA	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	9.99	1.89e-21	1.35e-18	0.57	0.42	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
THCA	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	9.99	1.9e-21	1.36e-18	0.57	0.42	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
THCA	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	9.99	1.9e-21	1.36e-18	0.57	0.42	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
THCA	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	9.99	1.9e-21	1.36e-18	0.57	0.42	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
THCA	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	9.99	1.9e-21	1.36e-18	0.55	0.42	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
THCA	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-9.99	1.92e-21	1.37e-18	-0.58	-0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
THCA	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	9.99	1.93e-21	1.38e-18	0.56	0.42	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
THCA	cis	rs4964805	0.657	rs73192049	ENSG00000257681.1	RP11-341G23.4	9.99	1.94e-21	1.39e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794215	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.632	rs9706225	ENSG00000257681.1	RP11-341G23.4	9.99	1.94e-21	1.39e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794308	chr12:103746315~103768858:-
THCA	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	9.99	1.95e-21	1.39e-18	0.49	0.42	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
THCA	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-9.99	1.95e-21	1.39e-18	-0.55	-0.42	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
THCA	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	9.99	1.96e-21	1.4e-18	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
THCA	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-9.99	1.96e-21	1.4e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
THCA	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-9.99	1.96e-21	1.4e-18	-0.76	-0.42	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
THCA	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	9.99	1.98e-21	1.41e-18	0.57	0.42	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
THCA	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	9.99	1.98e-21	1.41e-18	0.54	0.42	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
THCA	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	9.99	1.98e-21	1.41e-18	0.58	0.42	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
THCA	cis	rs4964805	0.606	rs7312606	ENSG00000257681.1	RP11-341G23.4	9.99	1.98e-21	1.41e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794607	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.581	rs7312825	ENSG00000257681.1	RP11-341G23.4	9.99	1.98e-21	1.41e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794610	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.657	rs11111783	ENSG00000257681.1	RP11-341G23.4	9.99	1.98e-21	1.41e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794745	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.657	rs4964814	ENSG00000257681.1	RP11-341G23.4	-9.99	1.98e-21	1.41e-18	-0.49	-0.42	Attention deficit hyperactivity disorder;	chr12:103795606	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.657	rs11111787	ENSG00000257681.1	RP11-341G23.4	9.99	1.98e-21	1.41e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103795721	chr12:103746315~103768858:-
THCA	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-9.99	1.99e-21	1.42e-18	-0.52	-0.42	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-9.99	1.99e-21	1.42e-18	-0.52	-0.42	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-9.99	1.99e-21	1.42e-18	-0.52	-0.42	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-9.99	1.99e-21	1.42e-18	-0.52	-0.42	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
THCA	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	9.99	1.99e-21	1.42e-18	0.77	0.42	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	9.99	1.99e-21	1.42e-18	0.5	0.42	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
THCA	cis	rs6570726	0.905	rs1355146	ENSG00000235652.6	RP11-545I5.3	-9.99	2e-21	1.43e-18	-0.39	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-9.99	2.01e-21	1.43e-18	-0.6	-0.42	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
THCA	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-9.99	2.02e-21	1.44e-18	-0.33	-0.42	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
THCA	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	9.98	2.03e-21	1.44e-18	0.67	0.42	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
THCA	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-9.98	2.04e-21	1.46e-18	-0.49	-0.42	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
THCA	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	9.98	2.05e-21	1.46e-18	0.49	0.42	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	9.98	2.06e-21	1.47e-18	0.56	0.42	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
THCA	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	9.98	2.07e-21	1.48e-18	0.58	0.42	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
THCA	cis	rs12931792	0.748	rs11150585	ENSG00000183604.13	SMG1P5	9.98	2.08e-21	1.48e-18	0.44	0.42	Tonsillectomy;	chr16:30172965	chr16:30267553~30335374:-
THCA	cis	rs42490	0.834	rs10102245	ENSG00000251136.7	RP11-37B2.1	9.98	2.09e-21	1.49e-18	0.36	0.42	Leprosy;	chr8:89638317	chr8:89609409~89757727:-
THCA	cis	rs860295	0.541	rs11264359	ENSG00000225855.5	RUSC1-AS1	9.98	2.1e-21	1.5e-18	0.28	0.42	Body mass index;	chr1:155313038	chr1:155316863~155324176:-
THCA	cis	rs6061231	0.958	rs2427305	ENSG00000273619.1	RP5-908M14.9	-9.98	2.1e-21	1.5e-18	-0.34	-0.42	Colorectal cancer;	chr20:62378693	chr20:62386303~62386970:-
THCA	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-9.98	2.11e-21	1.5e-18	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
THCA	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-9.98	2.12e-21	1.51e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
THCA	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	9.98	2.12e-21	1.51e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
THCA	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	9.98	2.12e-21	1.51e-18	0.5	0.42	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
THCA	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	9.98	2.14e-21	1.52e-18	0.56	0.42	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
THCA	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-9.98	2.14e-21	1.52e-18	-0.62	-0.42	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
THCA	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	9.98	2.15e-21	1.53e-18	0.49	0.42	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	9.98	2.15e-21	1.53e-18	0.49	0.42	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
THCA	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-9.98	2.16e-21	1.53e-18	-0.49	-0.42	Migraine;	chr4:56937339	chr4:56960927~56961373:-
THCA	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-9.98	2.16e-21	1.54e-18	-0.5	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
THCA	cis	rs4964805	0.657	rs1866293	ENSG00000257681.1	RP11-341G23.4	9.98	2.17e-21	1.54e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103792877	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.71	rs1866296	ENSG00000257681.1	RP11-341G23.4	9.98	2.17e-21	1.54e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103793314	chr12:103746315~103768858:-
THCA	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-9.98	2.17e-21	1.54e-18	-0.66	-0.42	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-9.98	2.17e-21	1.54e-18	-0.66	-0.42	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-9.98	2.17e-21	1.54e-18	-0.66	-0.42	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
THCA	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-9.98	2.18e-21	1.55e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
THCA	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	9.98	2.19e-21	1.55e-18	0.58	0.42	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
THCA	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-9.98	2.19e-21	1.56e-18	-0.53	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
THCA	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	9.98	2.2e-21	1.56e-18	0.56	0.42	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
THCA	cis	rs12931792	0.687	rs8057425	ENSG00000183604.13	SMG1P5	9.97	2.21e-21	1.57e-18	0.44	0.42	Tonsillectomy;	chr16:30171220	chr16:30267553~30335374:-
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	9.97	2.23e-21	1.58e-18	0.49	0.42	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
THCA	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	9.97	2.24e-21	1.59e-18	0.36	0.42	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
THCA	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	9.97	2.24e-21	1.59e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	9.97	2.24e-21	1.59e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	9.97	2.24e-21	1.59e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
THCA	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-9.97	2.24e-21	1.59e-18	-0.51	-0.42	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
THCA	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	9.97	2.25e-21	1.6e-18	0.77	0.42	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
THCA	cis	rs4964805	0.657	rs1866294	ENSG00000257681.1	RP11-341G23.4	9.97	2.25e-21	1.6e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103793017	chr12:103746315~103768858:-
THCA	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	9.97	2.26e-21	1.61e-18	0.49	0.42	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
THCA	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	9.97	2.27e-21	1.61e-18	0.59	0.42	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
THCA	cis	rs4964805	0.657	rs11111781	ENSG00000257681.1	RP11-341G23.4	9.97	2.27e-21	1.61e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103793662	chr12:103746315~103768858:-
THCA	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-9.97	2.28e-21	1.62e-18	-0.63	-0.42	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
THCA	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-9.97	2.28e-21	1.62e-18	-0.69	-0.42	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
THCA	cis	rs12188164	0.9	rs72717425	ENSG00000221990.4	EXOC3-AS1	9.97	2.28e-21	1.62e-18	0.34	0.42	Cystic fibrosis severity;	chr5:438694	chr5:441498~443160:-
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	9.97	2.28e-21	1.62e-18	0.49	0.42	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
THCA	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-9.97	2.31e-21	1.64e-18	-0.54	-0.42	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
THCA	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-9.97	2.31e-21	1.64e-18	-0.54	-0.42	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
THCA	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	9.97	2.32e-21	1.64e-18	0.57	0.42	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
THCA	cis	rs6496932	1	rs11638110	ENSG00000218052.5	ADAMTS7P4	9.97	2.32e-21	1.65e-18	0.61	0.42	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:85255369~85330334:-
THCA	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	9.97	2.32e-21	1.65e-18	0.57	0.42	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	9.97	2.33e-21	1.65e-18	0.57	0.42	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
THCA	cis	rs4591358	0.53	rs72927723	ENSG00000223466.1	AC064834.2	-9.97	2.33e-21	1.66e-18	-0.66	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522498	chr2:195533035~195538681:+
THCA	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-9.97	2.34e-21	1.66e-18	-0.53	-0.42	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
THCA	cis	rs4964805	0.526	rs934845	ENSG00000257681.1	RP11-341G23.4	9.97	2.34e-21	1.66e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103791479	chr12:103746315~103768858:-
THCA	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	9.97	2.37e-21	1.68e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
THCA	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	9.96	2.41e-21	1.7e-18	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
THCA	cis	rs8062405	0.756	rs151182	ENSG00000251417.2	RP11-1348G14.4	-9.96	2.43e-21	1.72e-18	-0.4	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.789	rs151174	ENSG00000251417.2	RP11-1348G14.4	-9.96	2.45e-21	1.73e-18	-0.41	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28802743~28817828:+
THCA	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	9.96	2.47e-21	1.75e-18	0.52	0.42	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
THCA	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	9.96	2.48e-21	1.75e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
THCA	cis	rs6061231	0.958	rs2379126	ENSG00000273619.1	RP5-908M14.9	-9.96	2.5e-21	1.77e-18	-0.34	-0.42	Colorectal cancer;	chr20:62377949	chr20:62386303~62386970:-
THCA	cis	rs6061231	0.958	rs2427304	ENSG00000273619.1	RP5-908M14.9	-9.96	2.5e-21	1.77e-18	-0.34	-0.42	Colorectal cancer;	chr20:62378528	chr20:62386303~62386970:-
THCA	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	9.96	2.5e-21	1.77e-18	0.77	0.42	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	9.96	2.5e-21	1.77e-18	0.49	0.42	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-9.96	2.51e-21	1.77e-18	-0.44	-0.42	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
THCA	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-9.96	2.53e-21	1.79e-18	-0.54	-0.42	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
THCA	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-9.96	2.56e-21	1.81e-18	-0.53	-0.42	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
THCA	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	9.96	2.57e-21	1.82e-18	0.57	0.42	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	9.96	2.57e-21	1.82e-18	0.57	0.42	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
THCA	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-9.96	2.58e-21	1.82e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
THCA	cis	rs4964805	0.913	rs36034617	ENSG00000257681.1	RP11-341G23.4	9.96	2.59e-21	1.83e-18	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103809837	chr12:103746315~103768858:-
THCA	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
THCA	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
THCA	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
THCA	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
THCA	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
THCA	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
THCA	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
THCA	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-9.95	2.61e-21	1.85e-18	-0.49	-0.42	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
THCA	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
THCA	cis	rs6683071	0.689	rs12063226	ENSG00000272750.1	RP11-378J18.8	-9.95	2.63e-21	1.86e-18	-0.58	-0.42	Cognitive performance;	chr1:222753913	chr1:222658867~222661512:-
THCA	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-9.95	2.64e-21	1.86e-18	-0.47	-0.42	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
THCA	cis	rs6479874	0.681	rs9415727	ENSG00000223502.1	RP11-96B5.3	-9.95	2.64e-21	1.87e-18	-0.45	-0.42	Migraine;	chr10:51126376	chr10:51062579~51068553:-
THCA	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	9.95	2.65e-21	1.87e-18	0.34	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
THCA	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-9.95	2.67e-21	1.89e-18	-0.46	-0.42	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
THCA	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	9.95	2.67e-21	1.89e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	9.95	2.67e-21	1.89e-18	0.55	0.42	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	9.95	2.67e-21	1.89e-18	0.55	0.42	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	9.95	2.71e-21	1.91e-18	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
THCA	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-9.95	2.74e-21	1.93e-18	-0.49	-0.42	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
THCA	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	9.95	2.76e-21	1.94e-18	0.48	0.42	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
THCA	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	9.95	2.76e-21	1.95e-18	0.33	0.42	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
THCA	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	9.95	2.77e-21	1.95e-18	0.44	0.42	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-9.95	2.79e-21	1.97e-18	-0.39	-0.42	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
THCA	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	9.95	2.8e-21	1.97e-18	0.31	0.42	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
THCA	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	9.95	2.8e-21	1.97e-18	0.5	0.42	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-9.95	2.8e-21	1.98e-18	-0.39	-0.42	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-9.95	2.8e-21	1.98e-18	-0.39	-0.42	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
THCA	cis	rs2581828	0.58	rs4687570	ENSG00000242142.1	SERBP1P3	9.95	2.81e-21	1.98e-18	0.52	0.42	Crohn's disease;	chr3:53136484	chr3:53064283~53065091:-
THCA	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-9.95	2.81e-21	1.98e-18	-0.31	-0.42	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
THCA	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	9.95	2.82e-21	1.99e-18	0.56	0.42	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	9.95	2.82e-21	1.99e-18	0.56	0.42	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
THCA	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	9.94	2.82e-21	1.99e-18	0.57	0.42	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	9.94	2.82e-21	1.99e-18	0.57	0.42	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	9.94	2.84e-21	2e-18	0.66	0.42	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
THCA	cis	rs4819052	1	rs2297285	ENSG00000215447.6	BX322557.10	9.94	2.85e-21	2e-18	0.41	0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	9.94	2.85e-21	2.01e-18	0.57	0.42	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	9.94	2.85e-21	2.01e-18	0.49	0.42	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000228039.3	KB-1125A3.10	9.94	2.86e-21	2.01e-18	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23963780~23964374:+
THCA	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	9.94	2.87e-21	2.02e-18	0.32	0.42	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
THCA	cis	rs9659323	0.601	rs12033970	ENSG00000231365.4	RP11-418J17.1	-9.94	2.88e-21	2.02e-18	-0.4	-0.42	Body mass index;	chr1:119097778	chr1:119140396~119275973:+
THCA	cis	rs4591358	0.549	rs10200021	ENSG00000223466.1	AC064834.2	-9.94	2.9e-21	2.04e-18	-0.56	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549863	chr2:195533035~195538681:+
THCA	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-9.94	2.91e-21	2.05e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
THCA	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-9.94	2.91e-21	2.05e-18	-0.4	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
THCA	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109497088	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109498751	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109500687	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109507364	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109507366	chr6:109382795~109383666:+
THCA	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	9.94	2.92e-21	2.06e-18	0.33	0.42	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
THCA	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	9.94	2.97e-21	2.09e-18	0.55	0.42	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
THCA	cis	rs7567389	0.511	rs61185143	ENSG00000236682.1	AC068282.3	9.94	3e-21	2.11e-18	0.58	0.42	Self-rated health;	chr2:127407902	chr2:127389130~127400580:+
THCA	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	9.94	3e-21	2.11e-18	0.35	0.42	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
THCA	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-9.94	3.02e-21	2.13e-18	-0.39	-0.42	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
THCA	cis	rs673078	0.607	rs7295288	ENSG00000275409.1	RP11-131L12.4	-9.94	3.03e-21	2.13e-18	-0.48	-0.42	Glucose homeostasis traits;	chr12:118418008	chr12:118430147~118430699:+
THCA	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	9.94	3.04e-21	2.14e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
THCA	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	9.94	3.04e-21	2.14e-18	0.56	0.42	Depression;	chr6:28142370	chr6:28161781~28169594:+
THCA	cis	rs4819052	1	rs2297284	ENSG00000215447.6	BX322557.10	-9.94	3.04e-21	2.14e-18	-0.38	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	9.94	3.04e-21	2.14e-18	0.56	0.42	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	9.94	3.05e-21	2.14e-18	0.57	0.42	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
THCA	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	9.94	3.06e-21	2.15e-18	0.55	0.42	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
THCA	cis	rs944289	0.708	rs1930765	ENSG00000257826.1	RP11-116N8.4	-9.93	3.08e-21	2.16e-18	-0.42	-0.42	Thyroid cancer;	chr14:36110053	chr14:36061026~36067190:-
THCA	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	9.93	3.08e-21	2.17e-18	0.38	0.42	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
THCA	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	9.93	3.11e-21	2.18e-18	0.43	0.42	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
THCA	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109498586	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109499759	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109501402	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109501429	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109503623	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109507271	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	9.93	3.11e-21	2.18e-18	0.56	0.42	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	9.93	3.11e-21	2.18e-18	0.56	0.42	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
THCA	cis	rs73219805	1	rs73217798	ENSG00000228451.3	SDAD1P1	-9.93	3.12e-21	2.19e-18	-0.53	-0.42	Schizophrenia;	chr8:26406847	chr8:26379259~26382953:-
THCA	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-9.93	3.13e-21	2.2e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
THCA	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	9.93	3.14e-21	2.2e-18	0.57	0.42	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
THCA	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	9.93	3.15e-21	2.21e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	9.93	3.15e-21	2.21e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
THCA	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-9.93	3.15e-21	2.21e-18	-0.49	-0.42	Migraine;	chr4:56940917	chr4:56960927~56961373:-
THCA	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	9.93	3.15e-21	2.21e-18	0.49	0.42	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
THCA	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
THCA	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-9.93	3.19e-21	2.24e-18	-0.53	-0.42	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-9.93	3.19e-21	2.24e-18	-0.53	-0.42	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-9.93	3.19e-21	2.24e-18	-0.53	-0.42	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
THCA	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	9.93	3.19e-21	2.24e-18	0.49	0.42	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
THCA	cis	rs7221109	0.56	rs2429549	ENSG00000278834.1	RP11-458J1.1	-9.93	3.2e-21	2.24e-18	-0.44	-0.42	Type 1 diabetes;	chr17:40698154	chr17:40648300~40649718:+
THCA	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	9.93	3.21e-21	2.25e-18	0.49	0.42	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
THCA	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-9.93	3.22e-21	2.25e-18	-0.38	-0.42	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
THCA	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	9.93	3.24e-21	2.27e-18	0.49	0.42	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	9.93	3.27e-21	2.3e-18	0.49	0.42	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
THCA	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	9.93	3.3e-21	2.31e-18	0.56	0.42	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
THCA	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	9.93	3.31e-21	2.32e-18	0.54	0.42	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
THCA	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-9.93	3.33e-21	2.33e-18	-0.61	-0.42	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
THCA	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	9.92	3.33e-21	2.33e-18	0.55	0.42	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
THCA	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-9.92	3.34e-21	2.34e-18	-0.53	-0.42	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
THCA	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-9.92	3.36e-21	2.35e-18	-0.62	-0.42	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
THCA	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
THCA	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	9.92	3.37e-21	2.36e-18	0.5	0.42	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
THCA	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	9.92	3.37e-21	2.36e-18	0.51	0.42	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
THCA	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	9.92	3.38e-21	2.37e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
THCA	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-9.92	3.41e-21	2.38e-18	-0.77	-0.42	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
THCA	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	9.92	3.41e-21	2.39e-18	0.33	0.42	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
THCA	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-9.92	3.42e-21	2.39e-18	-0.32	-0.42	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
THCA	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-9.92	3.44e-21	2.41e-18	-0.56	-0.42	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
THCA	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	9.92	3.45e-21	2.41e-18	0.55	0.42	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
THCA	cis	rs11159086	1	rs72730186	ENSG00000259005.1	RP3-449M8.6	9.92	3.46e-21	2.42e-18	0.5	0.42	Advanced glycation end-product levels;	chr14:74475610	chr14:74474007~74474864:-
THCA	cis	rs9532669	0.963	rs1571116	ENSG00000239827.7	SUGT1P3	-9.92	3.47e-21	2.42e-18	-0.45	-0.42	Cervical cancer;	chr13:40929765	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs9532673	ENSG00000239827.7	SUGT1P3	-9.92	3.47e-21	2.42e-18	-0.45	-0.42	Cervical cancer;	chr13:40930412	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	9.92	3.49e-21	2.44e-18	0.57	0.42	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
THCA	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-9.92	3.49e-21	2.44e-18	-0.44	-0.42	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
THCA	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	9.92	3.51e-21	2.45e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
THCA	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	9.92	3.51e-21	2.45e-18	0.46	0.42	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
THCA	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-9.92	3.51e-21	2.46e-18	-0.35	-0.42	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
THCA	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	9.92	3.53e-21	2.47e-18	0.43	0.42	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
THCA	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-9.92	3.54e-21	2.47e-18	-0.52	-0.42	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	9.92	3.57e-21	2.49e-18	0.56	0.42	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	9.92	3.57e-21	2.49e-18	0.56	0.42	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	9.92	3.57e-21	2.49e-18	0.56	0.42	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.902	rs2748500	ENSG00000235652.6	RP11-545I5.3	9.92	3.57e-21	2.5e-18	0.38	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145799409~145886585:+
THCA	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	9.92	3.57e-21	2.5e-18	0.51	0.42	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
THCA	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-9.92	3.58e-21	2.5e-18	-0.35	-0.42	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
THCA	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	9.92	3.6e-21	2.51e-18	0.57	0.42	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
THCA	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-9.92	3.61e-21	2.52e-18	-0.53	-0.42	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
THCA	cis	rs73219805	0.818	rs117325001	ENSG00000228451.3	SDAD1P1	-9.91	3.62e-21	2.53e-18	-0.53	-0.42	Schizophrenia;	chr8:26384756	chr8:26379259~26382953:-
THCA	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	9.91	3.63e-21	2.54e-18	0.52	0.42	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
THCA	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	9.91	3.64e-21	2.54e-18	0.4	0.42	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
THCA	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	9.91	3.65e-21	2.55e-18	0.48	0.42	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
THCA	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-9.91	3.65e-21	2.55e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
THCA	cis	rs860295	0.651	rs6692183	ENSG00000225855.5	RUSC1-AS1	9.91	3.66e-21	2.56e-18	0.29	0.42	Body mass index;	chr1:155334536	chr1:155316863~155324176:-
THCA	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-9.91	3.66e-21	2.56e-18	-0.56	-0.42	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	9.91	3.75e-21	2.61e-18	0.57	0.42	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
THCA	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-9.91	3.76e-21	2.62e-18	-0.54	-0.42	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
THCA	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	9.91	3.81e-21	2.65e-18	0.46	0.42	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
THCA	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-9.91	3.81e-21	2.66e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
THCA	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-9.91	3.81e-21	2.66e-18	-0.48	-0.42	Migraine;	chr4:56950140	chr4:56960927~56961373:-
THCA	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	9.91	3.82e-21	2.66e-18	0.49	0.42	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.75	rs9532598	ENSG00000239827.7	SUGT1P3	-9.91	3.85e-21	2.69e-18	-0.47	-0.42	Cervical cancer;	chr13:40860627	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.611	rs9532599	ENSG00000239827.7	SUGT1P3	-9.91	3.85e-21	2.69e-18	-0.47	-0.42	Cervical cancer;	chr13:40860633	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.571	rs9525405	ENSG00000239827.7	SUGT1P3	-9.91	3.85e-21	2.69e-18	-0.47	-0.42	Cervical cancer;	chr13:40860638	chr13:40908159~40921774:-
THCA	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-9.91	3.86e-21	2.69e-18	-0.54	-0.42	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
THCA	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-9.91	3.86e-21	2.69e-18	-0.54	-0.42	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
THCA	cis	rs7772486	0.902	rs2144476	ENSG00000235652.6	RP11-545I5.3	9.91	3.87e-21	2.7e-18	0.38	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145799409~145886585:+
THCA	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-9.91	3.9e-21	2.72e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
THCA	cis	rs9532669	0.926	rs11147823	ENSG00000239827.7	SUGT1P3	9.91	3.9e-21	2.72e-18	0.46	0.42	Cervical cancer;	chr13:40878138	chr13:40908159~40921774:-
THCA	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-9.91	3.9e-21	2.72e-18	-0.5	-0.42	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-9.9	3.94e-21	2.75e-18	-0.57	-0.42	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
THCA	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	9.9	3.95e-21	2.75e-18	0.49	0.42	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-9.9	3.97e-21	2.76e-18	-0.4	-0.42	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
THCA	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	9.9	3.98e-21	2.77e-18	0.48	0.42	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
THCA	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	9.9	3.98e-21	2.77e-18	0.41	0.42	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000232546.1	RP11-458F8.1	-9.9	3.98e-21	2.77e-18	-0.41	-0.42	Corneal structure;	chr7:66801919	chr7:66848496~66858136:+
THCA	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	9.9	4e-21	2.78e-18	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	9.9	4.02e-21	2.79e-18	0.48	0.42	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	9.9	4.04e-21	2.81e-18	0.55	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
THCA	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-9.9	4.06e-21	2.82e-18	-0.61	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
THCA	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-9.9	4.06e-21	2.82e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
THCA	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	9.9	4.06e-21	2.82e-18	0.57	0.42	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
THCA	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	9.9	4.06e-21	2.82e-18	0.57	0.42	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	9.9	4.06e-21	2.82e-18	0.57	0.42	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
THCA	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	9.9	4.06e-21	2.82e-18	0.57	0.42	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	9.9	4.06e-21	2.83e-18	0.56	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
THCA	cis	rs934734	0.532	rs7569113	ENSG00000234255.7	AC012370.3	9.9	4.07e-21	2.83e-18	0.45	0.42	Rheumatoid arthritis;	chr2:65429907	chr2:65439888~65456571:-
THCA	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	9.9	4.08e-21	2.84e-18	0.54	0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
THCA	cis	rs11051970	0.513	rs7972023	ENSG00000274964.1	RP11-817I4.1	-9.9	4.09e-21	2.84e-18	-0.53	-0.42	Response to tocilizumab in rheumatoid arthritis;	chr12:32312174	chr12:32339368~32340724:+
THCA	cis	rs7727544	0.669	rs113823725	ENSG00000237714.1	P4HA2-AS1	9.9	4.1e-21	2.85e-18	0.55	0.42	Blood metabolite levels;	chr5:132227808	chr5:132184876~132192808:+
THCA	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-9.9	4.11e-21	2.85e-18	-0.49	-0.42	Height;	chr6:109497253	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	9.9	4.15e-21	2.88e-18	0.57	0.42	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
THCA	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-9.9	4.17e-21	2.9e-18	-0.41	-0.42	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
THCA	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-9.9	4.17e-21	2.9e-18	-0.47	-0.42	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
THCA	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	9.9	4.18e-21	2.9e-18	0.47	0.42	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
THCA	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
THCA	cis	rs6452524	0.805	rs2731850	ENSG00000249664.1	CTD-2227C6.2	-9.9	4.23e-21	2.93e-18	-0.55	-0.42	Hypertension (SNP x SNP interaction);	chr5:83213024	chr5:83012285~83013109:-
THCA	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-9.9	4.23e-21	2.93e-18	-0.5	-0.42	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
THCA	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-9.9	4.24e-21	2.94e-18	-0.49	-0.42	Height;	chr2:231490121	chr2:231508426~231514339:-
THCA	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-9.9	4.24e-21	2.94e-18	-0.31	-0.42	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
THCA	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	9.9	4.26e-21	2.96e-18	0.57	0.42	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
THCA	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	9.9	4.27e-21	2.96e-18	0.74	0.42	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
THCA	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-9.89	4.28e-21	2.97e-18	-0.42	-0.42	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	9.89	4.3e-21	2.98e-18	0.48	0.42	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
THCA	cis	rs1858037	0.867	rs72621551	ENSG00000281920.1	RP11-418H16.1	9.89	4.34e-21	3.01e-18	0.54	0.42	Rheumatoid arthritis;	chr2:65388087	chr2:65623272~65628424:+
THCA	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	9.89	4.34e-21	3.01e-18	0.47	0.42	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
THCA	cis	rs9532669	0.963	rs4343141	ENSG00000239827.7	SUGT1P3	-9.89	4.35e-21	3.01e-18	-0.45	-0.42	Cervical cancer;	chr13:40940497	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs3887418	ENSG00000239827.7	SUGT1P3	-9.89	4.35e-21	3.01e-18	-0.45	-0.42	Cervical cancer;	chr13:40940560	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs1056820	ENSG00000239827.7	SUGT1P3	-9.89	4.35e-21	3.01e-18	-0.45	-0.42	Cervical cancer;	chr13:40941150	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532678	ENSG00000239827.7	SUGT1P3	-9.89	4.35e-21	3.01e-18	-0.45	-0.42	Cervical cancer;	chr13:40941862	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-9.89	4.35e-21	3.01e-18	-0.49	-0.42	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.89	rs9532676	ENSG00000239827.7	SUGT1P3	-9.89	4.36e-21	3.02e-18	-0.45	-0.42	Cervical cancer;	chr13:40935626	chr13:40908159~40921774:-
THCA	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-9.89	4.37e-21	3.03e-18	-0.57	-0.42	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
THCA	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-9.89	4.4e-21	3.05e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-9.89	4.4e-21	3.05e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-9.89	4.4e-21	3.05e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
THCA	cis	rs180730	0.519	rs13105248	ENSG00000251609.2	SETP12	9.89	4.41e-21	3.05e-18	0.58	0.42	Fasting plasma glucose;	chr4:120945433	chr4:120895494~120897083:-
THCA	cis	rs73219805	1	rs3808581	ENSG00000228451.3	SDAD1P1	-9.89	4.41e-21	3.06e-18	-0.53	-0.42	Schizophrenia;	chr8:26392531	chr8:26379259~26382953:-
THCA	cis	rs1075265	0.73	rs6713088	ENSG00000233266.1	HMGB1P31	9.89	4.44e-21	3.08e-18	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54051334~54051760:+
THCA	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-9.89	4.45e-21	3.08e-18	-0.56	-0.42	Depression;	chr6:28226851	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	9.89	4.46e-21	3.09e-18	0.49	0.42	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
THCA	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	9.89	4.46e-21	3.09e-18	0.55	0.42	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
THCA	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-9.89	4.48e-21	3.1e-18	-0.33	-0.42	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	9.89	4.53e-21	3.14e-18	0.56	0.41	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
THCA	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	9.89	4.53e-21	3.14e-18	0.48	0.41	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
THCA	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	9.89	4.53e-21	3.14e-18	0.49	0.41	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
THCA	cis	rs860295	0.557	rs11264372	ENSG00000225855.5	RUSC1-AS1	9.89	4.54e-21	3.14e-18	0.3	0.41	Body mass index;	chr1:155443139	chr1:155316863~155324176:-
THCA	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	9.89	4.54e-21	3.14e-18	0.61	0.41	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
THCA	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-9.89	4.55e-21	3.15e-18	-0.68	-0.41	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
THCA	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	9.89	4.55e-21	3.15e-18	0.78	0.41	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	9.89	4.56e-21	3.16e-18	0.56	0.41	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
THCA	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-9.89	4.57e-21	3.16e-18	-0.5	-0.41	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-9.89	4.57e-21	3.16e-18	-0.5	-0.41	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
THCA	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	9.89	4.57e-21	3.16e-18	0.36	0.41	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-9.89	4.64e-21	3.21e-18	-0.57	-0.41	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
THCA	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-9.88	4.65e-21	3.21e-18	-0.36	-0.41	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
THCA	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-9.88	4.66e-21	3.22e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	9.88	4.67e-21	3.23e-18	0.56	0.41	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	9.88	4.68e-21	3.24e-18	0.57	0.41	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	9.88	4.68e-21	3.24e-18	0.57	0.41	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	9.88	4.68e-21	3.24e-18	0.57	0.41	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	9.88	4.7e-21	3.25e-18	0.56	0.41	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000280107.1	AL022393.9	9.88	4.72e-21	3.27e-18	0.48	0.41	Parkinson's disease;	chr6:28002253	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs156744	ENSG00000280107.1	AL022393.9	-9.88	4.72e-21	3.27e-18	-0.48	-0.41	Parkinson's disease;	chr6:27999496	chr6:28170845~28172521:+
THCA	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-9.88	4.74e-21	3.27e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
THCA	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-9.88	4.74e-21	3.27e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.851	rs2838864	ENSG00000215447.6	BX322557.10	9.88	4.76e-21	3.29e-18	0.34	0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45288052~45291738:+
THCA	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	9.88	4.77e-21	3.3e-18	0.91	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
THCA	cis	rs240993	0.812	rs6568677	ENSG00000230177.1	RP5-1112D6.4	-9.88	4.77e-21	3.3e-18	-0.41	-0.41	Inflammatory skin disease;Psoriasis;	chr6:111392099	chr6:111277932~111278742:+
THCA	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-9.88	4.79e-21	3.31e-18	-0.56	-0.41	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-9.88	4.79e-21	3.31e-18	-0.56	-0.41	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-9.88	4.79e-21	3.31e-18	-0.56	-0.41	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
THCA	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-9.88	4.8e-21	3.31e-18	-0.33	-0.41	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
THCA	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-9.88	4.82e-21	3.33e-18	-0.51	-0.41	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
THCA	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	9.88	4.85e-21	3.35e-18	0.43	0.41	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
THCA	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	9.88	4.86e-21	3.36e-18	0.47	0.41	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	9.88	4.86e-21	3.36e-18	0.47	0.41	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
THCA	cis	rs1426063	0.668	rs6534595	ENSG00000260265.1	RP11-44F21.5	9.88	4.89e-21	3.38e-18	0.61	0.41	QT interval;	chr4:75104432	chr4:75081702~75084717:-
THCA	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-9.88	4.93e-21	3.4e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-9.88	4.93e-21	3.4e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	9.88	4.93e-21	3.4e-18	0.42	0.41	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
THCA	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-9.88	4.93e-21	3.4e-18	-0.62	-0.41	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30792372~30792833:+
THCA	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-9.88	4.96e-21	3.42e-18	-0.34	-0.41	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
THCA	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
THCA	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	9.88	4.99e-21	3.44e-18	0.58	0.41	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
THCA	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	9.88	5e-21	3.45e-18	0.76	0.41	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
THCA	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-9.88	5.01e-21	3.45e-18	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
THCA	cis	rs2599510	0.783	rs2710626	ENSG00000276334.1	AL133243.1	9.88	5.02e-21	3.46e-18	0.45	0.41	Interleukin-18 levels;	chr2:32533687	chr2:32521927~32523547:+
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	9.88	5.02e-21	3.46e-18	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
THCA	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	9.87	5.04e-21	3.47e-18	0.58	0.41	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
THCA	cis	rs934734	0.532	rs6752053	ENSG00000234255.7	AC012370.3	-9.87	5.04e-21	3.47e-18	-0.45	-0.41	Rheumatoid arthritis;	chr2:65439540	chr2:65439888~65456571:-
THCA	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	9.87	5.05e-21	3.48e-18	0.56	0.41	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	9.87	5.06e-21	3.48e-18	0.48	0.41	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	9.87	5.06e-21	3.48e-18	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	9.87	5.07e-21	3.49e-18	0.49	0.41	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
THCA	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	9.87	5.07e-21	3.49e-18	0.9	0.41	QT interval;	chr4:75125224	chr4:75081702~75084717:-
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	9.87	5.09e-21	3.5e-18	0.56	0.41	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
THCA	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-9.87	5.12e-21	3.52e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-9.87	5.13e-21	3.53e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
THCA	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-9.87	5.15e-21	3.54e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
THCA	cis	rs10256972	0.804	rs10275585	ENSG00000229043.2	AC091729.9	-9.87	5.16e-21	3.55e-18	-0.44	-0.41	Endometriosis;Longevity;	chr7:977703	chr7:1160374~1165267:+
THCA	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-9.87	5.16e-21	3.55e-18	-0.68	-0.41	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
THCA	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	9.87	5.18e-21	3.56e-18	0.49	0.41	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
THCA	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-9.87	5.22e-21	3.59e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
THCA	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	9.87	5.24e-21	3.6e-18	0.33	0.41	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	9.87	5.27e-21	3.62e-18	0.48	0.41	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
THCA	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-9.87	5.28e-21	3.63e-18	-0.48	-0.41	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000266490.1	CTD-2349P21.9	9.87	5.31e-21	3.65e-18	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30792372~30792833:+
THCA	cis	rs7772486	0.902	rs1125462	ENSG00000235652.6	RP11-545I5.3	9.87	5.31e-21	3.65e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145799409~145886585:+
THCA	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	9.87	5.33e-21	3.66e-18	0.52	0.41	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
THCA	cis	rs4819052	0.704	rs2297283	ENSG00000223768.1	LINC00205	-9.87	5.33e-21	3.67e-18	-0.39	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45293285~45297354:+
THCA	cis	rs11051970	0.592	rs12227991	ENSG00000274964.1	RP11-817I4.1	-9.87	5.35e-21	3.67e-18	-0.55	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32387111	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051973	ENSG00000274964.1	RP11-817I4.1	-9.87	5.35e-21	3.67e-18	-0.55	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32388978	chr12:32339368~32340724:+
THCA	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-9.87	5.37e-21	3.69e-18	-0.49	-0.41	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
THCA	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-9.87	5.37e-21	3.69e-18	-0.69	-0.41	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
THCA	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	9.87	5.38e-21	3.7e-18	0.62	0.41	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
THCA	cis	rs9532669	0.926	rs8002809	ENSG00000239827.7	SUGT1P3	-9.87	5.42e-21	3.73e-18	-0.47	-0.41	Cervical cancer;	chr13:40872769	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.929	rs7982421	ENSG00000239827.7	SUGT1P3	-9.87	5.42e-21	3.73e-18	-0.47	-0.41	Cervical cancer;	chr13:40872776	chr13:40908159~40921774:-
THCA	cis	rs1858037	0.836	rs2576923	ENSG00000281920.1	RP11-418H16.1	-9.87	5.45e-21	3.74e-18	-0.54	-0.41	Rheumatoid arthritis;	chr2:65406750	chr2:65623272~65628424:+
THCA	cis	rs2980439	0.556	rs2921059	ENSG00000254153.1	CTA-398F10.2	-9.87	5.45e-21	3.75e-18	-0.45	-0.41	Neuroticism;	chr8:8460377	chr8:8456909~8461337:-
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000266490.1	CTD-2349P21.9	9.87	5.45e-21	3.75e-18	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30792372~30792833:+
THCA	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-9.87	5.46e-21	3.75e-18	-0.62	-0.41	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
THCA	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	9.86	5.48e-21	3.76e-18	0.54	0.41	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-9.86	5.48e-21	3.76e-18	-0.55	-0.41	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Body mass index;	chr17:30772984	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	9.86	5.49e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
THCA	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	9.86	5.53e-21	3.79e-18	0.47	0.41	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	9.86	5.53e-21	3.79e-18	0.47	0.41	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
THCA	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	9.86	5.55e-21	3.8e-18	0.46	0.41	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	9.86	5.55e-21	3.8e-18	0.46	0.41	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
THCA	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	9.86	5.56e-21	3.81e-18	0.56	0.41	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
THCA	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-9.86	5.58e-21	3.82e-18	-0.54	-0.41	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000266490.1	CTD-2349P21.9	9.86	5.59e-21	3.83e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30792372~30792833:+
THCA	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
THCA	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-9.86	5.61e-21	3.84e-18	-0.49	-0.41	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
THCA	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-9.86	5.65e-21	3.87e-18	-0.5	-0.41	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
THCA	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-9.86	5.67e-21	3.88e-18	-0.41	-0.41	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
THCA	cis	rs1426063	0.748	rs10005117	ENSG00000260265.1	RP11-44F21.5	9.86	5.74e-21	3.93e-18	0.6	0.41	QT interval;	chr4:75108281	chr4:75081702~75084717:-
THCA	cis	rs944289	0.74	rs404131	ENSG00000257826.1	RP11-116N8.4	9.86	5.75e-21	3.93e-18	0.42	0.41	Thyroid cancer;	chr14:36075287	chr14:36061026~36067190:-
THCA	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-9.86	5.78e-21	3.96e-18	-0.51	-0.41	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	9.86	5.79e-21	3.96e-18	0.49	0.41	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	9.86	5.79e-21	3.96e-18	0.55	0.41	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
THCA	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	9.86	5.79e-21	3.96e-18	0.41	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
THCA	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-9.86	5.8e-21	3.97e-18	-0.53	-0.41	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
THCA	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	9.86	5.81e-21	3.97e-18	0.49	0.41	Height;	chr6:109518783	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	9.86	5.84e-21	4e-18	0.48	0.41	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	9.86	5.84e-21	4e-18	0.48	0.41	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
THCA	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	9.86	5.9e-21	4.03e-18	0.73	0.41	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
THCA	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-9.86	5.91e-21	4.04e-18	-0.38	-0.41	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
THCA	cis	rs860295	0.58	rs12032720	ENSG00000225855.5	RUSC1-AS1	9.86	5.92e-21	4.05e-18	0.29	0.41	Body mass index;	chr1:155305169	chr1:155316863~155324176:-
THCA	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-9.86	5.92e-21	4.05e-18	-0.57	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
THCA	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	9.85	5.94e-21	4.06e-18	0.56	0.41	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
THCA	cis	rs10740039	0.804	rs1372714	ENSG00000254271.1	RP11-131N11.4	9.85	5.94e-21	4.06e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60686640	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.671	rs7919726	ENSG00000254271.1	RP11-131N11.4	9.85	5.94e-21	4.06e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60689748	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs10821824	ENSG00000254271.1	RP11-131N11.4	9.85	5.94e-21	4.06e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60690449	chr10:60734342~60741828:+
THCA	cis	rs1858037	0.867	rs55945621	ENSG00000281920.1	RP11-418H16.1	9.85	5.96e-21	4.07e-18	0.54	0.41	Rheumatoid arthritis;	chr2:65388220	chr2:65623272~65628424:+
THCA	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	9.85	5.97e-21	4.08e-18	0.54	0.41	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
THCA	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	9.85	5.98e-21	4.09e-18	0.56	0.41	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
THCA	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	9.85	5.99e-21	4.09e-18	0.43	0.41	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-9.85	6.03e-21	4.12e-18	-0.39	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-9.85	6.03e-21	4.12e-18	-0.39	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
THCA	cis	rs944289	0.74	rs7145145	ENSG00000257826.1	RP11-116N8.4	-9.85	6.06e-21	4.14e-18	-0.43	-0.41	Thyroid cancer;	chr14:36110724	chr14:36061026~36067190:-
THCA	cis	rs944289	0.708	rs7145311	ENSG00000257826.1	RP11-116N8.4	-9.85	6.06e-21	4.14e-18	-0.43	-0.41	Thyroid cancer;	chr14:36110738	chr14:36061026~36067190:-
THCA	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-9.85	6.06e-21	4.14e-18	-0.68	-0.41	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
THCA	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	9.85	6.08e-21	4.15e-18	0.46	0.41	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	9.85	6.1e-21	4.17e-18	0.56	0.41	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	9.85	6.1e-21	4.17e-18	0.56	0.41	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
THCA	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-9.85	6.11e-21	4.17e-18	-0.41	-0.41	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-9.85	6.11e-21	4.17e-18	-0.41	-0.41	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-9.85	6.11e-21	4.17e-18	-0.51	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
THCA	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	9.85	6.11e-21	4.17e-18	0.57	0.41	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	9.85	6.11e-21	4.17e-18	0.57	0.41	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.662	rs149947	ENSG00000280107.1	AL022393.9	-9.85	6.12e-21	4.18e-18	-0.48	-0.41	Parkinson's disease;	chr6:28004655	chr6:28170845~28172521:+
THCA	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	9.85	6.13e-21	4.19e-18	0.34	0.41	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
THCA	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	9.85	6.13e-21	4.19e-18	0.35	0.41	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
THCA	cis	rs10935480	0.577	rs10804683	ENSG00000239445.4	ST3GAL6-AS1	-9.85	6.18e-21	4.22e-18	-0.42	-0.41	Blood protein levels;	chr3:98661882	chr3:98714330~98732651:-
THCA	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	9.85	6.2e-21	4.23e-18	0.47	0.41	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
THCA	cis	rs34081947	0.5	rs1930766	ENSG00000257826.1	RP11-116N8.4	-9.85	6.22e-21	4.24e-18	-0.48	-0.41	Papillary thyroid cancer;Differentiated thyroid cancer;	chr14:36081037	chr14:36061026~36067190:-
THCA	cis	rs1537424	0.513	rs944845	ENSG00000257826.1	RP11-116N8.4	-9.85	6.22e-21	4.24e-18	-0.48	-0.41	Thyroid hormone levels;	chr14:36081480	chr14:36061026~36067190:-
THCA	cis	rs1537424	0.513	rs1615453	ENSG00000257826.1	RP11-116N8.4	9.85	6.22e-21	4.24e-18	0.48	0.41	Thyroid hormone levels;	chr14:36077246	chr14:36061026~36067190:-
THCA	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	9.85	6.24e-21	4.26e-18	0.49	0.41	Height;	chr6:109586733	chr6:109382795~109383666:+
THCA	cis	rs17684571	0.687	rs13214893	ENSG00000231441.1	RP11-472M19.2	9.85	6.27e-21	4.28e-18	0.55	0.41	Schizophrenia;	chr6:56865425	chr6:56844002~56864078:+
THCA	cis	rs944289	0.679	rs12050116	ENSG00000257826.1	RP11-116N8.4	-9.85	6.28e-21	4.28e-18	-0.42	-0.41	Thyroid cancer;	chr14:36103725	chr14:36061026~36067190:-
THCA	cis	rs4713118	0.629	rs203888	ENSG00000280107.1	AL022393.9	-9.85	6.29e-21	4.29e-18	-0.47	-0.41	Parkinson's disease;	chr6:28053811	chr6:28170845~28172521:+
THCA	cis	rs934734	0.571	rs7572922	ENSG00000281920.1	RP11-418H16.1	-9.85	6.3e-21	4.3e-18	-0.5	-0.41	Rheumatoid arthritis;	chr2:65425022	chr2:65623272~65628424:+
THCA	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-9.85	6.32e-21	4.31e-18	-0.6	-0.41	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
THCA	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	9.85	6.41e-21	4.37e-18	0.49	0.41	Height;	chr6:109494148	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	9.85	6.41e-21	4.37e-18	0.49	0.41	Height;	chr6:109494760	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	9.85	6.41e-21	4.37e-18	0.49	0.41	Height;	chr6:109495102	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	9.85	6.41e-21	4.37e-18	0.49	0.41	Height;	chr6:109496680	chr6:109382795~109383666:+
THCA	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-9.84	6.46e-21	4.4e-18	-0.52	-0.41	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	9.84	6.46e-21	4.41e-18	0.5	0.41	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	9.84	6.46e-21	4.41e-18	0.5	0.41	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-9.84	6.48e-21	4.41e-18	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
THCA	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	9.84	6.54e-21	4.45e-18	0.48	0.41	Height;	chr6:109526846	chr6:109382795~109383666:+
THCA	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	9.84	6.54e-21	4.46e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
THCA	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	9.84	6.58e-21	4.49e-18	0.56	0.41	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
THCA	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-9.84	6.59e-21	4.49e-18	-0.42	-0.41	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
THCA	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-9.84	6.62e-21	4.51e-18	-0.49	-0.41	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000266490.1	CTD-2349P21.9	9.84	6.64e-21	4.53e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30792372~30792833:+
THCA	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-9.84	6.67e-21	4.54e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-9.84	6.67e-21	4.54e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
THCA	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-9.84	6.67e-21	4.55e-18	-0.38	-0.41	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
THCA	cis	rs7191700	0.644	rs12149160	ENSG00000262703.1	RP11-485G7.6	-9.84	6.67e-21	4.55e-18	-0.47	-0.41	Multiple sclerosis;	chr16:11345446	chr16:11348143~11349321:-
THCA	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-9.84	6.71e-21	4.57e-18	-0.57	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	9.84	6.71e-21	4.57e-18	0.48	0.41	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	9.84	6.73e-21	4.58e-18	0.48	0.41	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.853	rs9315795	ENSG00000239827.7	SUGT1P3	-9.84	6.74e-21	4.59e-18	-0.45	-0.41	Cervical cancer;	chr13:40943382	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs3764056	ENSG00000239827.7	SUGT1P3	-9.84	6.74e-21	4.59e-18	-0.45	-0.41	Cervical cancer;	chr13:40943849	chr13:40908159~40921774:-
THCA	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-9.84	6.77e-21	4.61e-18	-0.49	-0.41	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
THCA	cis	rs673078	0.66	rs11068910	ENSG00000275409.1	RP11-131L12.4	-9.84	6.78e-21	4.62e-18	-0.44	-0.41	Glucose homeostasis traits;	chr12:118336076	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-9.84	6.81e-21	4.64e-18	-0.48	-0.41	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
THCA	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	9.84	6.83e-21	4.65e-18	0.49	0.41	Height;	chr6:109494237	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	9.84	6.83e-21	4.65e-18	0.49	0.41	Height;	chr6:109496073	chr6:109382795~109383666:+
THCA	cis	rs17684571	0.687	rs17752213	ENSG00000231441.1	RP11-472M19.2	9.84	6.83e-21	4.65e-18	0.55	0.41	Schizophrenia;	chr6:56864627	chr6:56844002~56864078:+
THCA	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	9.84	6.85e-21	4.66e-18	0.56	0.41	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
THCA	cis	rs10740039	0.883	rs10761542	ENSG00000254271.1	RP11-131N11.4	9.84	6.88e-21	4.68e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655465	chr10:60734342~60741828:+
THCA	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-9.84	6.9e-21	4.69e-18	-0.5	-0.41	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
THCA	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-9.84	6.9e-21	4.7e-18	-0.61	-0.41	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-9.84	6.9e-21	4.7e-18	-0.61	-0.41	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-9.84	6.9e-21	4.7e-18	-0.61	-0.41	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
THCA	cis	rs12460587	0.622	rs7247612	ENSG00000275055.1	CTC-471J1.11	-9.84	6.96e-21	4.73e-18	-0.32	-0.41	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082336	chr19:52049007~52049754:+
THCA	cis	rs934734	0.571	rs7565437	ENSG00000281920.1	RP11-418H16.1	-9.84	6.97e-21	4.74e-18	-0.51	-0.41	Rheumatoid arthritis;	chr2:65419832	chr2:65623272~65628424:+
THCA	cis	rs9532669	0.963	rs4941391	ENSG00000239827.7	SUGT1P3	-9.84	6.98e-21	4.74e-18	-0.45	-0.41	Cervical cancer;	chr13:40939787	chr13:40908159~40921774:-
THCA	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
THCA	cis	rs1858037	0.867	rs964505	ENSG00000281920.1	RP11-418H16.1	9.83	7.08e-21	4.82e-18	0.54	0.41	Rheumatoid arthritis;	chr2:65396055	chr2:65623272~65628424:+
THCA	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	9.83	7.08e-21	4.82e-18	0.47	0.41	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	9.83	7.08e-21	4.82e-18	0.47	0.41	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	9.83	7.08e-21	4.82e-18	0.47	0.41	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	9.83	7.08e-21	4.82e-18	0.47	0.41	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	9.83	7.1e-21	4.82e-18	0.48	0.41	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
THCA	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	9.83	7.1e-21	4.83e-18	0.46	0.41	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
THCA	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-9.83	7.12e-21	4.84e-18	-0.57	-0.41	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
THCA	cis	rs860295	0.557	rs12035524	ENSG00000225855.5	RUSC1-AS1	9.83	7.14e-21	4.85e-18	0.31	0.41	Body mass index;	chr1:155697311	chr1:155316863~155324176:-
THCA	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	9.83	7.16e-21	4.86e-18	0.49	0.41	Height;	chr6:109506513	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	9.83	7.17e-21	4.87e-18	0.48	0.41	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	9.83	7.17e-21	4.87e-18	0.48	0.41	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	9.83	7.17e-21	4.87e-18	0.48	0.41	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-9.83	7.18e-21	4.88e-18	-0.46	-0.41	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
THCA	cis	rs7727544	0.716	rs72793283	ENSG00000237714.1	P4HA2-AS1	9.83	7.19e-21	4.88e-18	0.55	0.41	Blood metabolite levels;	chr5:132231248	chr5:132184876~132192808:+
THCA	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-9.83	7.2e-21	4.89e-18	-0.5	-0.41	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
THCA	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-9.83	7.27e-21	4.94e-18	-0.43	-0.41	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
THCA	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-9.83	7.3e-21	4.95e-18	-0.57	-0.41	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
THCA	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-9.83	7.34e-21	4.98e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
THCA	cis	rs9926296	0.744	rs6860	ENSG00000260259.1	RP11-368I7.4	9.83	7.35e-21	4.99e-18	0.46	0.41	Vitiligo;	chr16:89644712	chr16:89682620~89686569:-
THCA	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-9.83	7.37e-21	5e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	9.83	7.38e-21	5e-18	0.55	0.41	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	9.83	7.38e-21	5e-18	0.55	0.41	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	9.83	7.38e-21	5e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
THCA	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	9.83	7.38e-21	5e-18	0.33	0.41	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
THCA	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	9.83	7.4e-21	5.02e-18	0.55	0.41	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
THCA	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-9.83	7.43e-21	5.03e-18	-0.42	-0.41	Height;	chr11:118703185	chr11:118704607~118750263:+
THCA	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-9.83	7.43e-21	5.03e-18	-0.42	-0.41	Height;	chr11:118703207	chr11:118704607~118750263:+
THCA	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-9.83	7.44e-21	5.04e-18	-0.44	-0.41	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
THCA	cis	rs17684571	0.683	rs13215883	ENSG00000231441.1	RP11-472M19.2	9.83	7.44e-21	5.04e-18	0.55	0.41	Schizophrenia;	chr6:56858927	chr6:56844002~56864078:+
THCA	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-9.83	7.48e-21	5.07e-18	-0.5	-0.41	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
THCA	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	9.83	7.49e-21	5.08e-18	0.56	0.41	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
THCA	cis	rs10740039	0.804	rs1837950	ENSG00000254271.1	RP11-131N11.4	-9.83	7.5e-21	5.08e-18	-0.51	-0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60685207	chr10:60734342~60741828:+
THCA	cis	rs180730	0.519	rs6822124	ENSG00000251609.2	SETP12	9.83	7.51e-21	5.09e-18	0.57	0.41	Fasting plasma glucose;	chr4:120940658	chr4:120895494~120897083:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000266490.1	CTD-2349P21.9	9.83	7.53e-21	5.1e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000266490.1	CTD-2349P21.9	9.83	7.53e-21	5.1e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30792372~30792833:+
THCA	cis	rs916888	0.697	rs199516	ENSG00000232300.1	FAM215B	-9.83	7.53e-21	5.1e-18	-0.66	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46558830~46562795:-
THCA	cis	rs7772486	0.902	rs1331643	ENSG00000235652.6	RP11-545I5.3	9.83	7.56e-21	5.12e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145799409~145886585:+
THCA	cis	rs1858037	0.867	rs67453645	ENSG00000281920.1	RP11-418H16.1	9.82	7.61e-21	5.15e-18	0.55	0.41	Rheumatoid arthritis;	chr2:65358908	chr2:65623272~65628424:+
THCA	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	9.82	7.63e-21	5.17e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
THCA	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-9.82	7.63e-21	5.17e-18	-0.31	-0.41	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
THCA	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-9.82	7.63e-21	5.17e-18	-0.31	-0.41	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
THCA	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28111382	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28111650	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28112175	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28113851	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28114487	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28114933	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28115743	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28116411	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
THCA	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	9.82	7.64e-21	5.18e-18	0.46	0.41	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	9.82	7.64e-21	5.18e-18	0.46	0.41	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	9.82	7.64e-21	5.18e-18	0.46	0.41	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
THCA	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	9.82	7.64e-21	5.18e-18	0.48	0.41	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	9.82	7.64e-21	5.18e-18	0.48	0.41	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
THCA	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-9.82	7.65e-21	5.18e-18	-0.41	-0.41	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
THCA	cis	rs2599510	0.744	rs2254106	ENSG00000276334.1	AL133243.1	9.82	7.71e-21	5.22e-18	0.43	0.41	Interleukin-18 levels;	chr2:32543730	chr2:32521927~32523547:+
THCA	cis	rs2599510	0.729	rs1135484	ENSG00000276334.1	AL133243.1	9.82	7.73e-21	5.23e-18	0.45	0.41	Interleukin-18 levels;	chr2:32523993	chr2:32521927~32523547:+
THCA	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	9.82	7.73e-21	5.23e-18	0.56	0.41	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	9.82	7.73e-21	5.23e-18	0.56	0.41	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-9.82	7.75e-21	5.24e-18	-0.46	-0.41	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
THCA	cis	rs240993	0.812	rs383022	ENSG00000230177.1	RP5-1112D6.4	-9.82	7.76e-21	5.25e-18	-0.41	-0.41	Inflammatory skin disease;Psoriasis;	chr6:111382506	chr6:111277932~111278742:+
THCA	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	9.82	7.8e-21	5.28e-18	0.48	0.41	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	9.82	7.8e-21	5.28e-18	0.48	0.41	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
THCA	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-9.82	7.8e-21	5.28e-18	-0.5	-0.41	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-9.82	7.8e-21	5.28e-18	-0.5	-0.41	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
THCA	cis	rs1858037	0.867	rs61226353	ENSG00000281920.1	RP11-418H16.1	9.82	7.81e-21	5.28e-18	0.54	0.41	Rheumatoid arthritis;	chr2:65363637	chr2:65623272~65628424:+
THCA	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-9.82	7.87e-21	5.32e-18	-0.47	-0.41	Temperament;	chr17:14046511	chr17:14024514~14025488:+
THCA	cis	rs6570726	0.905	rs442435	ENSG00000235652.6	RP11-545I5.3	9.82	7.87e-21	5.33e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs396492	ENSG00000235652.6	RP11-545I5.3	9.82	7.87e-21	5.33e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs7757387	ENSG00000235652.6	RP11-545I5.3	9.82	7.87e-21	5.33e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145799409~145886585:+
THCA	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	9.82	7.9e-21	5.34e-18	0.66	0.41	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
THCA	cis	rs944289	0.708	rs34232378	ENSG00000257826.1	RP11-116N8.4	-9.82	7.9e-21	5.34e-18	-0.42	-0.41	Thyroid cancer;	chr14:36102879	chr14:36061026~36067190:-
THCA	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	9.82	7.92e-21	5.35e-18	0.51	0.41	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
THCA	cis	rs11051970	0.559	rs2036304	ENSG00000274964.1	RP11-817I4.1	-9.82	7.96e-21	5.38e-18	-0.52	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32325441	chr12:32339368~32340724:+
THCA	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-9.82	7.98e-21	5.39e-18	-0.47	-0.41	Temperament;	chr17:14048649	chr17:14024514~14025488:+
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Body mass index;	chr17:30758740	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Body mass index;	chr17:30774046	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
THCA	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-9.82	8e-21	5.41e-18	-0.47	-0.41	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
THCA	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	9.82	8.05e-21	5.44e-18	0.72	0.41	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
THCA	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	9.82	8.07e-21	5.46e-18	0.56	0.41	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
THCA	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	9.82	8.11e-21	5.48e-18	0.49	0.41	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
THCA	cis	rs9532669	0.963	rs1056835	ENSG00000239827.7	SUGT1P3	-9.82	8.2e-21	5.53e-18	-0.45	-0.41	Cervical cancer;	chr13:40932585	chr13:40908159~40921774:-
THCA	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-9.82	8.2e-21	5.54e-18	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-9.82	8.21e-21	5.54e-18	-0.61	-0.41	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
THCA	cis	rs10740039	0.883	rs7898504	ENSG00000254271.1	RP11-131N11.4	9.81	8.26e-21	5.58e-18	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658233	chr10:60734342~60741828:+
THCA	cis	rs944289	0.74	rs885535	ENSG00000257826.1	RP11-116N8.4	-9.81	8.29e-21	5.6e-18	-0.42	-0.41	Thyroid cancer;	chr14:36082574	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	9.81	8.38e-21	5.66e-18	0.55	0.41	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
THCA	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-9.81	8.4e-21	5.67e-18	-0.54	-0.41	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	9.81	8.44e-21	5.69e-18	0.48	0.41	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
THCA	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-9.81	8.45e-21	5.7e-18	-0.53	-0.41	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
THCA	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-9.81	8.47e-21	5.71e-18	-0.49	-0.41	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
THCA	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	9.81	8.48e-21	5.72e-18	0.43	0.41	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
THCA	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	9.81	8.48e-21	5.72e-18	0.43	0.41	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
THCA	cis	rs9532669	0.963	rs4942012	ENSG00000239827.7	SUGT1P3	-9.81	8.49e-21	5.72e-18	-0.44	-0.41	Cervical cancer;	chr13:40939112	chr13:40908159~40921774:-
THCA	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-9.81	8.53e-21	5.75e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
THCA	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	9.81	8.54e-21	5.76e-18	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
THCA	cis	rs11148252	0.532	rs9526975	ENSG00000235660.1	LINC00345	-9.81	8.62e-21	5.82e-18	-0.52	-0.41	Lewy body disease;	chr13:52681669	chr13:52484161~52484680:-
THCA	cis	rs1858037	0.867	rs1553675	ENSG00000281920.1	RP11-418H16.1	-9.81	8.67e-21	5.85e-18	-0.54	-0.41	Rheumatoid arthritis;	chr2:65343173	chr2:65623272~65628424:+
THCA	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109634150	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109640141	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109642186	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109646187	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109652694	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109655791	chr6:109382795~109383666:+
THCA	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-9.81	8.74e-21	5.89e-18	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
THCA	cis	rs916888	0.821	rs199506	ENSG00000232300.1	FAM215B	-9.81	8.74e-21	5.89e-18	-0.67	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46558830~46562795:-
THCA	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	9.81	8.77e-21	5.91e-18	0.56	0.41	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
THCA	cis	rs9532669	0.929	rs9532601	ENSG00000239827.7	SUGT1P3	-9.81	8.8e-21	5.93e-18	-0.47	-0.41	Cervical cancer;	chr13:40861086	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	9.81	8.82e-21	5.94e-18	0.49	0.41	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	9.81	8.82e-21	5.94e-18	0.49	0.41	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	9.81	8.82e-21	5.94e-18	0.49	0.41	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000228039.3	KB-1125A3.10	9.81	8.83e-21	5.94e-18	0.52	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23963780~23964374:+
THCA	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-9.81	8.83e-21	5.95e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
THCA	cis	rs9532669	1	rs9532669	ENSG00000239827.7	SUGT1P3	-9.81	8.88e-21	5.98e-18	-0.45	-0.41	Cervical cancer;	chr13:40927414	chr13:40908159~40921774:-
THCA	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	9.81	8.89e-21	5.98e-18	0.56	0.41	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
THCA	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	9.81	8.89e-21	5.98e-18	0.46	0.41	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	9.81	8.89e-21	5.98e-18	0.46	0.41	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
THCA	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-9.81	8.96e-21	6.03e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-9.81	8.96e-21	6.03e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-9.81	8.96e-21	6.03e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
THCA	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	9.8	8.98e-21	6.05e-18	0.46	0.41	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
THCA	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-9.8	9.1e-21	6.12e-18	-0.43	-0.41	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
THCA	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	9.8	9.14e-21	6.15e-18	0.73	0.41	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
THCA	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	9.8	9.17e-21	6.17e-18	0.46	0.41	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	9.8	9.18e-21	6.17e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
THCA	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-9.8	9.18e-21	6.17e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
THCA	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-9.8	9.25e-21	6.22e-18	-0.62	-0.41	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
THCA	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-9.8	9.25e-21	6.22e-18	-0.62	-0.41	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
THCA	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	9.8	9.28e-21	6.24e-18	0.56	0.41	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
THCA	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	9.8	9.3e-21	6.25e-18	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
THCA	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	9.8	9.34e-21	6.28e-18	0.57	0.41	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
THCA	cis	rs6452524	0.713	rs2386245	ENSG00000249664.1	CTD-2227C6.2	-9.8	9.38e-21	6.3e-18	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83214866	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.836	rs2731852	ENSG00000249664.1	CTD-2227C6.2	-9.8	9.4e-21	6.32e-18	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83212591	chr5:83012285~83013109:-
THCA	cis	rs7727544	0.642	rs7705189	ENSG00000237714.1	P4HA2-AS1	-9.8	9.41e-21	6.32e-18	-0.54	-0.41	Blood metabolite levels;	chr5:132287665	chr5:132184876~132192808:+
THCA	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-9.8	9.41e-21	6.32e-18	-0.45	-0.41	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
THCA	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	9.8	9.42e-21	6.33e-18	0.45	0.41	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
THCA	cis	rs1858037	0.806	rs12612780	ENSG00000281920.1	RP11-418H16.1	9.8	9.44e-21	6.34e-18	0.54	0.41	Rheumatoid arthritis;	chr2:65355967	chr2:65623272~65628424:+
THCA	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	9.8	9.57e-21	6.42e-18	0.71	0.41	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	9.8	9.57e-21	6.42e-18	0.71	0.41	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	9.8	9.57e-21	6.42e-18	0.71	0.41	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
THCA	cis	rs9595066	0.627	rs9562538	ENSG00000227258.4	SMIM2-AS1	9.8	9.57e-21	6.42e-18	0.57	0.41	Schizophrenia;	chr13:44183532	chr13:44110451~44240517:+
THCA	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-9.8	9.59e-21	6.44e-18	-0.41	-0.41	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
THCA	cis	rs944289	0.74	rs379426	ENSG00000257826.1	RP11-116N8.4	9.8	9.6e-21	6.44e-18	0.42	0.41	Thyroid cancer;	chr14:36075253	chr14:36061026~36067190:-
THCA	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-9.8	9.6e-21	6.44e-18	-0.45	-0.41	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-9.8	9.6e-21	6.44e-18	-0.45	-0.41	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
THCA	cis	rs11051970	0.592	rs7132235	ENSG00000274964.1	RP11-817I4.1	-9.8	9.6e-21	6.44e-18	-0.55	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32383369	chr12:32339368~32340724:+
THCA	cis	rs1799810	0.739	rs13030284	ENSG00000236682.1	AC068282.3	9.8	9.67e-21	6.49e-18	0.61	0.41	Self-rated health;	chr2:127401143	chr2:127389130~127400580:+
THCA	cis	rs7727544	0.647	rs72793280	ENSG00000237714.1	P4HA2-AS1	9.8	9.69e-21	6.5e-18	0.55	0.41	Blood metabolite levels;	chr5:132227207	chr5:132184876~132192808:+
THCA	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-9.8	9.71e-21	6.52e-18	-0.61	-0.41	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	9.79	9.74e-21	6.53e-18	0.48	0.41	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
THCA	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
THCA	cis	rs6570726	0.875	rs368744	ENSG00000235652.6	RP11-545I5.3	9.79	9.86e-21	6.61e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	9.79	9.92e-21	6.65e-18	0.48	0.41	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	9.79	9.92e-21	6.65e-18	0.48	0.41	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	9.79	9.92e-21	6.65e-18	0.48	0.41	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	9.79	9.92e-21	6.65e-18	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	9.79	9.93e-21	6.65e-18	0.35	0.41	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
THCA	cis	rs7665090	0.665	rs227277	ENSG00000246560.2	RP11-10L12.4	-9.79	9.95e-21	6.67e-18	-0.5	-0.41	Primary biliary cholangitis;	chr4:102673781	chr4:102828055~102844075:+
THCA	cis	rs6452524	0.836	rs2089565	ENSG00000249664.1	CTD-2227C6.2	-9.79	9.98e-21	6.69e-18	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83214410	chr5:83012285~83013109:-
THCA	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-9.79	1e-20	6.7e-18	-0.49	-0.41	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
THCA	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	9.79	1e-20	6.72e-18	0.43	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	9.79	1e-20	6.72e-18	0.43	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
THCA	cis	rs860295	0.665	rs11264393	ENSG00000225855.5	RUSC1-AS1	9.79	1e-20	6.72e-18	0.29	0.41	Body mass index;	chr1:155604680	chr1:155316863~155324176:-
THCA	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-9.79	1e-20	6.73e-18	-0.4	-0.41	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
THCA	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-9.79	1e-20	6.73e-18	-0.4	-0.41	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
THCA	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-9.79	1.01e-20	6.75e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
THCA	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-9.79	1.01e-20	6.75e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
THCA	cis	rs4380275	0.782	rs4854369	ENSG00000272342.1	RP13-539J13.1	9.79	1.01e-20	6.76e-18	0.48	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:739588~740164:-
THCA	cis	rs860295	0.702	rs3851912	ENSG00000225855.5	RUSC1-AS1	9.79	1.01e-20	6.77e-18	0.29	0.41	Body mass index;	chr1:155616653	chr1:155316863~155324176:-
THCA	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	9.79	1.01e-20	6.79e-18	0.59	0.41	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
THCA	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	9.79	1.01e-20	6.79e-18	0.59	0.41	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
THCA	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-9.79	1.02e-20	6.81e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	9.79	1.02e-20	6.82e-18	0.56	0.41	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
THCA	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-9.79	1.04e-20	6.93e-18	-0.66	-0.41	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
THCA	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-9.79	1.05e-20	7.04e-18	-0.45	-0.41	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
THCA	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-9.78	1.06e-20	7.09e-18	-0.39	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
THCA	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-9.78	1.06e-20	7.1e-18	-0.6	-0.41	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
THCA	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	9.78	1.06e-20	7.11e-18	0.49	0.41	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
THCA	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	9.78	1.06e-20	7.12e-18	0.56	0.41	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
THCA	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-9.78	1.07e-20	7.13e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-9.78	1.07e-20	7.13e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
THCA	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-9.78	1.07e-20	7.14e-18	-0.33	-0.41	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-9.78	1.07e-20	7.14e-18	-0.33	-0.41	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
THCA	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	9.78	1.07e-20	7.18e-18	0.56	0.41	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
THCA	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-9.78	1.08e-20	7.21e-18	-0.48	-0.41	Migraine;	chr4:56943905	chr4:56960927~56961373:-
THCA	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	9.78	1.08e-20	7.22e-18	0.6	0.41	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	9.78	1.08e-20	7.22e-18	0.6	0.41	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
THCA	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	9.78	1.09e-20	7.26e-18	0.68	0.41	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-9.78	1.09e-20	7.31e-18	-0.62	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	9.78	1.09e-20	7.31e-18	0.55	0.41	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
THCA	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	9.78	1.1e-20	7.34e-18	0.66	0.41	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
THCA	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	9.78	1.1e-20	7.37e-18	0.47	0.41	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
THCA	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-9.78	1.1e-20	7.37e-18	-0.48	-0.41	Height;	chr6:109531713	chr6:109382795~109383666:+
THCA	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	9.78	1.1e-20	7.38e-18	0.46	0.41	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
THCA	cis	rs7576126	1	rs7576126	ENSG00000234255.7	AC012370.3	-9.78	1.11e-20	7.39e-18	-0.45	-0.41	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65439888~65456571:-
THCA	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	9.78	1.11e-20	7.42e-18	0.55	0.41	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
THCA	cis	rs2288884	0.559	rs12611043	ENSG00000275055.1	CTC-471J1.11	-9.78	1.11e-20	7.42e-18	-0.32	-0.41	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52049007~52049754:+
THCA	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	9.78	1.11e-20	7.42e-18	0.46	0.41	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
THCA	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-9.78	1.11e-20	7.43e-18	-0.42	-0.41	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
THCA	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	9.78	1.11e-20	7.43e-18	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
THCA	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-9.78	1.11e-20	7.44e-18	-0.61	-0.41	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
THCA	cis	rs944289	0.74	rs884384	ENSG00000257826.1	RP11-116N8.4	-9.78	1.12e-20	7.44e-18	-0.42	-0.41	Thyroid cancer;	chr14:36081801	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs884383	ENSG00000257826.1	RP11-116N8.4	-9.78	1.12e-20	7.44e-18	-0.42	-0.41	Thyroid cancer;	chr14:36081936	chr14:36061026~36067190:-
THCA	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-9.78	1.12e-20	7.49e-18	-0.44	-0.41	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-9.78	1.12e-20	7.49e-18	-0.44	-0.41	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
THCA	cis	rs944289	0.708	rs8016762	ENSG00000257826.1	RP11-116N8.4	-9.78	1.13e-20	7.52e-18	-0.42	-0.41	Thyroid cancer;	chr14:36108538	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs1623766	ENSG00000257826.1	RP11-116N8.4	9.78	1.13e-20	7.55e-18	0.42	0.41	Thyroid cancer;	chr14:36075632	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs416664	ENSG00000257826.1	RP11-116N8.4	9.78	1.13e-20	7.55e-18	0.42	0.41	Thyroid cancer;	chr14:36076319	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs1617130	ENSG00000257826.1	RP11-116N8.4	9.78	1.13e-20	7.55e-18	0.42	0.41	Thyroid cancer;	chr14:36077059	chr14:36061026~36067190:-
THCA	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-9.78	1.14e-20	7.62e-18	-0.34	-0.41	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-9.78	1.14e-20	7.62e-18	-0.34	-0.41	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
THCA	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	9.78	1.14e-20	7.62e-18	0.6	0.41	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
THCA	cis	rs4380275	0.809	rs6753699	ENSG00000272342.1	RP13-539J13.1	9.78	1.15e-20	7.65e-18	0.48	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:739588~740164:-
THCA	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	9.77	1.15e-20	7.66e-18	0.56	0.41	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
THCA	cis	rs9532669	0.926	rs2875421	ENSG00000239827.7	SUGT1P3	-9.77	1.15e-20	7.66e-18	-0.45	-0.41	Cervical cancer;	chr13:40936536	chr13:40908159~40921774:-
THCA	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	9.77	1.15e-20	7.69e-18	0.45	0.41	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
THCA	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	9.77	1.16e-20	7.75e-18	0.57	0.41	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
THCA	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	9.77	1.16e-20	7.76e-18	0.53	0.41	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
THCA	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-9.77	1.17e-20	7.78e-18	-0.83	-0.41	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-9.77	1.17e-20	7.79e-18	-0.47	-0.41	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
THCA	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-9.77	1.17e-20	7.8e-18	-0.35	-0.41	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-9.77	1.17e-20	7.8e-18	-0.35	-0.41	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
THCA	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	9.77	1.17e-20	7.83e-18	0.56	0.41	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
THCA	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	9.77	1.18e-20	7.88e-18	0.55	0.41	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	9.77	1.18e-20	7.89e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
THCA	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	9.77	1.18e-20	7.89e-18	0.48	0.41	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
THCA	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-9.77	1.19e-20	7.9e-18	-0.53	-0.41	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
THCA	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-9.77	1.19e-20	7.92e-18	-0.46	-0.41	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
THCA	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-9.77	1.19e-20	7.95e-18	-0.56	-0.41	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
THCA	cis	rs10759883	0.627	rs596413	ENSG00000175611.10	LINC00476	9.77	1.19e-20	7.95e-18	0.47	0.41	Nicotine dependence;	chr9:95871561	chr9:95759231~95875977:-
THCA	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	9.77	1.21e-20	8.05e-18	0.65	0.41	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
THCA	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-9.77	1.21e-20	8.06e-18	-0.57	-0.41	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
THCA	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-9.77	1.21e-20	8.08e-18	-0.35	-0.41	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-9.77	1.21e-20	8.08e-18	-0.35	-0.41	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
THCA	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	9.77	1.22e-20	8.1e-18	0.72	0.41	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
THCA	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-9.77	1.23e-20	8.16e-18	-0.38	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
THCA	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	9.77	1.23e-20	8.17e-18	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
THCA	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	9.77	1.23e-20	8.17e-18	0.48	0.41	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	9.77	1.23e-20	8.17e-18	0.48	0.41	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	9.77	1.23e-20	8.17e-18	0.48	0.41	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
THCA	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	9.77	1.23e-20	8.18e-18	0.56	0.41	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
THCA	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	9.77	1.23e-20	8.18e-18	0.51	0.41	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000234255.7	AC012370.3	-9.77	1.23e-20	8.22e-18	-0.45	-0.41	Rheumatoid arthritis;	chr2:65427878	chr2:65439888~65456571:-
THCA	cis	rs934734	0.532	rs2028151	ENSG00000234255.7	AC012370.3	-9.77	1.23e-20	8.22e-18	-0.45	-0.41	Rheumatoid arthritis;	chr2:65428479	chr2:65439888~65456571:-
THCA	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-9.77	1.24e-20	8.26e-18	-0.49	-0.41	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
THCA	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-9.77	1.24e-20	8.26e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
THCA	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	9.76	1.25e-20	8.29e-18	0.59	0.41	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
THCA	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-9.76	1.25e-20	8.32e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
THCA	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-9.76	1.26e-20	8.36e-18	-0.5	-0.41	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-9.76	1.26e-20	8.36e-18	-0.5	-0.41	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
THCA	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	9.76	1.26e-20	8.37e-18	0.61	0.41	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
THCA	cis	rs6570726	0.935	rs398060	ENSG00000235652.6	RP11-545I5.3	-9.76	1.27e-20	8.42e-18	-0.38	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145520379	chr6:145799409~145886585:+
THCA	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-9.76	1.27e-20	8.43e-18	-0.53	-0.41	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
THCA	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	9.76	1.27e-20	8.46e-18	0.6	0.41	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	9.76	1.27e-20	8.46e-18	0.6	0.41	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
THCA	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-9.76	1.27e-20	8.46e-18	-0.71	-0.41	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
THCA	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	9.76	1.27e-20	8.47e-18	0.6	0.41	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
THCA	cis	rs9926296	0.712	rs459920	ENSG00000260259.1	RP11-368I7.4	9.76	1.27e-20	8.47e-18	0.46	0.41	Vitiligo;	chr16:89664419	chr16:89682620~89686569:-
THCA	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	9.76	1.28e-20	8.51e-18	0.34	0.41	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	9.76	1.28e-20	8.51e-18	0.34	0.41	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
THCA	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	9.76	1.28e-20	8.54e-18	0.56	0.41	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	9.76	1.28e-20	8.54e-18	0.48	0.41	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	9.76	1.29e-20	8.54e-18	0.48	0.41	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	9.76	1.29e-20	8.54e-18	0.48	0.41	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	9.76	1.29e-20	8.54e-18	0.48	0.41	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
THCA	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-9.76	1.29e-20	8.55e-18	-0.78	-0.41	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
THCA	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28070115	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28071237	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28074687	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28076559	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28076704	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28078391	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28080757	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28080760	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28082231	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28082261	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28082984	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28083994	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28084025	chr6:28161781~28169594:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28085319	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28096855	chr6:28161781~28169594:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28099759	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28100648	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28104824	chr6:28161781~28169594:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28107222	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28108492	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28110254	chr6:28161781~28169594:+
THCA	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-9.76	1.3e-20	8.62e-18	-0.61	-0.41	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
THCA	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-9.76	1.3e-20	8.62e-18	-0.61	-0.41	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
THCA	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-9.76	1.3e-20	8.62e-18	-0.61	-0.41	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
THCA	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-9.76	1.3e-20	8.62e-18	-0.61	-0.41	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
THCA	cis	rs2274273	0.719	rs17740551	ENSG00000258413.1	RP11-665C16.6	-9.76	1.3e-20	8.66e-18	-0.57	-0.41	Protein biomarker;	chr14:55284607	chr14:55262767~55272075:-
THCA	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-9.76	1.31e-20	8.67e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
THCA	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-9.76	1.31e-20	8.68e-18	-0.45	-0.41	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
THCA	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	9.76	1.31e-20	8.69e-18	0.49	0.41	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
THCA	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	9.76	1.31e-20	8.71e-18	0.46	0.41	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
THCA	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	9.76	1.31e-20	8.71e-18	0.73	0.41	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
THCA	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-9.76	1.31e-20	8.71e-18	-0.61	-0.41	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-9.76	1.31e-20	8.71e-18	-0.61	-0.41	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
THCA	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	9.76	1.32e-20	8.74e-18	0.56	0.41	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
THCA	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-9.76	1.34e-20	8.89e-18	-0.47	-0.41	Height;	chr2:231539118	chr2:231508426~231514339:-
THCA	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-9.76	1.34e-20	8.9e-18	-0.38	-0.41	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
THCA	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
THCA	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
THCA	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-9.76	1.35e-20	8.92e-18	-0.56	-0.41	Depression;	chr6:28192182	chr6:28115628~28116551:+
THCA	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-9.75	1.36e-20	8.98e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
THCA	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-9.75	1.36e-20	8.99e-18	-0.44	-0.41	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
THCA	cis	rs6051080	1	rs6051080	ENSG00000274973.1	RP13-401N8.7	-9.75	1.36e-20	9.01e-18	-0.45	-0.41	Colorectal or endometrial cancer;	chr20:25995038	chr20:25845497~25845862:+
THCA	cis	rs67311347	0.506	rs55962832	ENSG00000223797.4	ENTPD3-AS1	9.75	1.37e-20	9.05e-18	0.34	0.41	Renal cell carcinoma;	chr3:40202960	chr3:40313802~40453329:-
THCA	cis	rs7727544	0.716	rs11955347	ENSG00000237714.1	P4HA2-AS1	9.75	1.37e-20	9.07e-18	0.54	0.41	Blood metabolite levels;	chr5:132232231	chr5:132184876~132192808:+
THCA	cis	rs67311347	0.524	rs11129869	ENSG00000223797.4	ENTPD3-AS1	9.75	1.37e-20	9.1e-18	0.34	0.41	Renal cell carcinoma;	chr3:40218247	chr3:40313802~40453329:-
THCA	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	9.75	1.38e-20	9.13e-18	0.48	0.41	Height;	chr6:109546439	chr6:109382795~109383666:+
THCA	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	9.75	1.38e-20	9.13e-18	0.48	0.41	Height;	chr6:109551060	chr6:109382795~109383666:+
THCA	cis	rs7829975	0.774	rs11249893	ENSG00000253893.2	FAM85B	-9.75	1.38e-20	9.13e-18	-0.54	-0.41	Mood instability;	chr8:8843341	chr8:8167819~8226614:-
THCA	cis	rs10872587	0.555	rs9497426	ENSG00000235652.6	RP11-545I5.3	-9.75	1.38e-20	9.13e-18	-0.47	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145913508	chr6:145799409~145886585:+
THCA	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	9.75	1.38e-20	9.16e-18	0.57	0.41	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
THCA	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	9.75	1.39e-20	9.21e-18	0.45	0.41	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
THCA	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-9.75	1.39e-20	9.22e-18	-0.45	-0.41	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
THCA	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-9.75	1.4e-20	9.24e-18	-0.43	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
THCA	cis	rs673078	0.607	rs7294498	ENSG00000275409.1	RP11-131L12.4	-9.75	1.42e-20	9.38e-18	-0.44	-0.41	Glucose homeostasis traits;	chr12:118321680	chr12:118430147~118430699:+
THCA	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
THCA	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
THCA	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
THCA	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	9.75	1.42e-20	9.4e-18	0.55	0.41	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.751	rs1610157	ENSG00000231441.1	RP11-472M19.2	9.75	1.43e-20	9.44e-18	0.55	0.41	Schizophrenia;	chr6:56844035	chr6:56844002~56864078:+
THCA	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	9.75	1.43e-20	9.45e-18	0.73	0.41	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	9.75	1.44e-20	9.54e-18	0.48	0.41	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
THCA	cis	rs10872587	0.555	rs2265470	ENSG00000235652.6	RP11-545I5.3	9.75	1.45e-20	9.58e-18	0.47	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145898096	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	9.75	1.45e-20	9.59e-18	0.55	0.41	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	9.75	1.45e-20	9.59e-18	0.55	0.41	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	9.75	1.45e-20	9.59e-18	0.55	0.41	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	9.75	1.45e-20	9.59e-18	0.55	0.41	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	9.75	1.46e-20	9.61e-18	0.55	0.41	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
THCA	cis	rs2599510	0.744	rs4952212	ENSG00000276334.1	AL133243.1	-9.75	1.46e-20	9.61e-18	-0.45	-0.41	Interleukin-18 levels;	chr2:32393425	chr2:32521927~32523547:+
THCA	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	9.75	1.46e-20	9.65e-18	0.58	0.41	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
THCA	cis	rs853679	0.517	rs6932109	ENSG00000226314.6	ZNF192P1	9.74	1.47e-20	9.69e-18	0.55	0.41	Depression;	chr6:28110525	chr6:28161781~28169594:+
THCA	cis	rs4380275	0.782	rs4854276	ENSG00000272342.1	RP13-539J13.1	9.74	1.47e-20	9.73e-18	0.46	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:739588~740164:-
THCA	cis	rs7727544	0.654	rs4705849	ENSG00000237714.1	P4HA2-AS1	9.74	1.48e-20	9.74e-18	0.53	0.41	Blood metabolite levels;	chr5:132223506	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.716	rs72793278	ENSG00000237714.1	P4HA2-AS1	9.74	1.48e-20	9.74e-18	0.53	0.41	Blood metabolite levels;	chr5:132225679	chr5:132184876~132192808:+
THCA	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	9.74	1.48e-20	9.76e-18	0.48	0.41	Height;	chr6:109588639	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	9.74	1.48e-20	9.76e-18	0.48	0.41	Height;	chr6:109589051	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	9.74	1.48e-20	9.76e-18	0.48	0.41	Height;	chr6:109592105	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	9.74	1.48e-20	9.76e-18	0.48	0.41	Height;	chr6:109608105	chr6:109382795~109383666:+
THCA	cis	rs10740039	0.804	rs894383	ENSG00000254271.1	RP11-131N11.4	9.74	1.48e-20	9.77e-18	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60683359	chr10:60734342~60741828:+
THCA	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-9.74	1.48e-20	9.78e-18	-0.5	-0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	9.74	1.49e-20	9.8e-18	0.55	0.41	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
THCA	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-9.74	1.49e-20	9.84e-18	-0.38	-0.41	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
THCA	cis	rs7727544	0.716	rs4705926	ENSG00000237714.1	P4HA2-AS1	9.74	1.49e-20	9.84e-18	0.53	0.41	Blood metabolite levels;	chr5:132226065	chr5:132184876~132192808:+
THCA	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	9.74	1.49e-20	9.85e-18	0.51	0.41	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
THCA	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-9.74	1.5e-20	9.88e-18	-0.39	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	9.74	1.51e-20	9.95e-18	0.55	0.41	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
THCA	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	9.74	1.51e-20	9.96e-18	0.56	0.41	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	9.74	1.51e-20	9.96e-18	0.56	0.41	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
THCA	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	9.74	1.51e-20	9.96e-18	0.56	0.41	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
THCA	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-9.74	1.51e-20	9.96e-18	-0.5	-0.41	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
THCA	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-9.74	1.52e-20	1e-17	-0.39	-0.41	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
THCA	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	9.74	1.52e-20	1e-17	0.55	0.41	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
THCA	cis	rs944289	0.718	rs12878623	ENSG00000257826.1	RP11-116N8.4	-9.74	1.53e-20	1.01e-17	-0.42	-0.41	Thyroid cancer;	chr14:36081499	chr14:36061026~36067190:-
THCA	cis	rs1858037	0.867	rs57913336	ENSG00000281920.1	RP11-418H16.1	9.74	1.55e-20	1.02e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65360485	chr2:65623272~65628424:+
THCA	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	-9.74	1.55e-20	1.02e-17	-0.55	-0.41	Depression;	chr6:28113616	chr6:28161781~28169594:+
THCA	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-9.74	1.55e-20	1.02e-17	-0.57	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
THCA	cis	rs853679	0.517	rs6922063	ENSG00000226314.6	ZNF192P1	-9.74	1.55e-20	1.02e-17	-0.55	-0.41	Depression;	chr6:28126588	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000226314.6	ZNF192P1	-9.74	1.55e-20	1.02e-17	-0.55	-0.41	Depression;	chr6:28126953	chr6:28161781~28169594:+
THCA	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-9.74	1.55e-20	1.02e-17	-0.45	-0.41	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
THCA	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-9.74	1.57e-20	1.03e-17	-0.35	-0.41	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
THCA	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-9.74	1.57e-20	1.03e-17	-0.49	-0.41	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000215447.6	BX322557.10	-9.74	1.57e-20	1.04e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45288052~45291738:+
THCA	cis	rs11051970	0.559	rs7956708	ENSG00000274964.1	RP11-817I4.1	-9.74	1.57e-20	1.04e-17	-0.53	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32315908	chr12:32339368~32340724:+
THCA	cis	rs6570726	0.811	rs375873	ENSG00000235652.6	RP11-545I5.3	9.74	1.58e-20	1.04e-17	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145799409~145886585:+
THCA	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	9.74	1.58e-20	1.04e-17	0.48	0.41	Height;	chr6:109576414	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	9.74	1.58e-20	1.04e-17	0.55	0.41	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
THCA	cis	rs57677839	1	rs57677839	ENSG00000184669.7	OR7E14P	-9.74	1.58e-20	1.04e-17	-0.54	-0.41	Coronary artery disease;	chr11:17006642	chr11:17013998~17053024:+
THCA	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	9.74	1.58e-20	1.04e-17	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
THCA	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-9.74	1.59e-20	1.05e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
THCA	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	9.73	1.59e-20	1.05e-17	0.47	0.41	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	9.73	1.59e-20	1.05e-17	0.47	0.41	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
THCA	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-9.73	1.6e-20	1.05e-17	-0.35	-0.41	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
THCA	cis	rs2599510	0.783	rs2038534	ENSG00000276334.1	AL133243.1	9.73	1.6e-20	1.06e-17	0.46	0.41	Interleukin-18 levels;	chr2:32434421	chr2:32521927~32523547:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	-9.73	1.61e-20	1.06e-17	-0.55	-0.41	Depression;	chr6:28079011	chr6:28161781~28169594:+
THCA	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	9.73	1.61e-20	1.06e-17	0.38	0.41	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
THCA	cis	rs7772486	0.774	rs2247571	ENSG00000235652.6	RP11-545I5.3	9.73	1.64e-20	1.08e-17	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145799409~145886585:+
THCA	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	9.73	1.64e-20	1.08e-17	0.52	0.41	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	9.73	1.65e-20	1.08e-17	0.55	0.41	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
THCA	cis	rs9926296	0.712	rs258319	ENSG00000260259.1	RP11-368I7.4	9.73	1.65e-20	1.08e-17	0.46	0.41	Vitiligo;	chr16:89665616	chr16:89682620~89686569:-
THCA	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	9.73	1.66e-20	1.09e-17	0.35	0.41	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
THCA	cis	rs7665090	0.728	rs227275	ENSG00000246560.2	RP11-10L12.4	-9.73	1.66e-20	1.09e-17	-0.5	-0.41	Primary biliary cholangitis;	chr4:102672741	chr4:102828055~102844075:+
THCA	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	9.73	1.69e-20	1.11e-17	0.55	0.41	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
THCA	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	9.73	1.69e-20	1.11e-17	0.38	0.41	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
THCA	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	9.73	1.69e-20	1.11e-17	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-9.73	1.7e-20	1.11e-17	-0.55	-0.41	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
THCA	cis	rs1858037	0.867	rs4671660	ENSG00000281920.1	RP11-418H16.1	9.73	1.7e-20	1.11e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65349302	chr2:65623272~65628424:+
THCA	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-9.73	1.7e-20	1.12e-17	-0.56	-0.41	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
THCA	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-9.73	1.72e-20	1.13e-17	-0.31	-0.41	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
THCA	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-9.73	1.72e-20	1.13e-17	-0.31	-0.41	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
THCA	cis	rs4591358	0.508	rs11884880	ENSG00000223466.1	AC064834.2	-9.73	1.72e-20	1.13e-17	-0.6	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195562897	chr2:195533035~195538681:+
THCA	cis	rs4380275	0.782	rs11691064	ENSG00000272342.1	RP13-539J13.1	9.72	1.73e-20	1.13e-17	0.47	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:739588~740164:-
THCA	cis	rs10740039	0.729	rs6479728	ENSG00000254271.1	RP11-131N11.4	-9.72	1.74e-20	1.14e-17	-0.51	-0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:60734342~60741828:+
THCA	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-9.72	1.75e-20	1.14e-17	-0.49	-0.41	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
THCA	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-9.72	1.77e-20	1.16e-17	-0.35	-0.41	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
THCA	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	9.72	1.78e-20	1.17e-17	0.46	0.41	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	9.72	1.78e-20	1.17e-17	0.55	0.41	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
THCA	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	9.72	1.79e-20	1.17e-17	0.46	0.41	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
THCA	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	9.72	1.79e-20	1.17e-17	0.46	0.41	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
THCA	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	9.72	1.8e-20	1.18e-17	0.56	0.41	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
THCA	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-9.72	1.8e-20	1.18e-17	-0.46	-0.41	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-9.72	1.8e-20	1.18e-17	-0.46	-0.41	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
THCA	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-9.72	1.81e-20	1.18e-17	-0.53	-0.41	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
THCA	cis	rs860295	0.702	rs12041534	ENSG00000225855.5	RUSC1-AS1	-9.72	1.81e-20	1.18e-17	-0.27	-0.41	Body mass index;	chr1:155437305	chr1:155316863~155324176:-
THCA	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	9.72	1.82e-20	1.19e-17	0.55	0.41	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
THCA	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	9.72	1.83e-20	1.2e-17	0.53	0.41	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
THCA	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	9.72	1.83e-20	1.2e-17	0.47	0.41	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
THCA	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-9.72	1.83e-20	1.2e-17	-0.56	-0.41	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	9.72	1.83e-20	1.2e-17	0.56	0.41	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
THCA	cis	rs7191700	0.712	rs7187741	ENSG00000262636.1	CTD-3088G3.4	-9.72	1.83e-20	1.2e-17	-0.52	-0.41	Multiple sclerosis;	chr16:11339246	chr16:11380859~11381118:-
THCA	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-9.72	1.83e-20	1.2e-17	-0.52	-0.41	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
THCA	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-9.72	1.84e-20	1.2e-17	-0.57	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000215447.6	BX322557.10	-9.72	1.84e-20	1.2e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000215447.6	BX322557.10	-9.72	1.84e-20	1.21e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45288052~45291738:+
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000266490.1	CTD-2349P21.9	9.72	1.85e-20	1.21e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30792372~30792833:+
THCA	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	9.72	1.85e-20	1.21e-17	0.55	0.41	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-9.72	1.87e-20	1.22e-17	-0.59	-0.41	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-9.72	1.87e-20	1.22e-17	-0.59	-0.41	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-9.72	1.87e-20	1.22e-17	-0.59	-0.41	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-9.72	1.87e-20	1.22e-17	-0.59	-0.41	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
THCA	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	9.72	1.87e-20	1.22e-17	0.48	0.41	Height;	chr6:109584789	chr6:109382795~109383666:+
THCA	cis	rs73219805	1	rs1042992	ENSG00000228451.3	SDAD1P1	9.71	1.88e-20	1.23e-17	0.52	0.41	Schizophrenia;	chr8:26411675	chr8:26379259~26382953:-
THCA	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	9.71	1.89e-20	1.23e-17	0.55	0.41	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000235689.1	AP000351.13	9.71	1.89e-20	1.24e-17	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:24006305~24008258:-
THCA	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	9.71	1.91e-20	1.25e-17	0.77	0.41	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	9.71	1.93e-20	1.26e-17	0.55	0.41	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
THCA	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-9.71	1.94e-20	1.27e-17	-0.34	-0.41	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
THCA	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	9.71	1.94e-20	1.27e-17	0.48	0.41	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
THCA	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	9.71	1.94e-20	1.27e-17	0.48	0.41	Height;	chr6:109558247	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	9.71	1.94e-20	1.27e-17	0.48	0.41	Height;	chr6:109564443	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	9.71	1.94e-20	1.27e-17	0.48	0.41	Height;	chr6:109571489	chr6:109382795~109383666:+
THCA	cis	rs7211079	0.879	rs61357240	ENSG00000279259.1	RP11-334C17.3	9.71	1.95e-20	1.27e-17	0.43	0.41	Myocardial infarction;	chr17:80157976	chr17:80147250~80148596:+
THCA	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	9.71	1.95e-20	1.28e-17	0.48	0.41	Height;	chr6:109533040	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	9.71	1.95e-20	1.28e-17	0.48	0.41	Height;	chr6:109534269	chr6:109382795~109383666:+
THCA	cis	rs7945705	1	rs7937298	ENSG00000254860.4	TMEM9B-AS1	-9.71	1.96e-20	1.28e-17	-0.46	-0.41	Hemoglobin concentration;	chr11:8845962	chr11:8964675~8977527:+
THCA	cis	rs4819052	0.851	rs914218	ENSG00000215447.6	BX322557.10	-9.71	1.96e-20	1.28e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	9.71	1.97e-20	1.29e-17	0.55	0.41	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
THCA	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	9.71	1.97e-20	1.29e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
THCA	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	9.71	1.97e-20	1.29e-17	0.55	0.41	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45288052~45291738:+
THCA	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	-9.71	1.98e-20	1.29e-17	-0.55	-0.41	Depression;	chr6:28123153	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	-9.71	1.98e-20	1.29e-17	-0.55	-0.41	Depression;	chr6:28124529	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	-9.71	1.98e-20	1.29e-17	-0.55	-0.41	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	-9.71	1.98e-20	1.29e-17	-0.55	-0.41	Depression;	chr6:28127577	chr6:28161781~28169594:+
THCA	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-9.71	1.99e-20	1.3e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-9.71	1.99e-20	1.3e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
THCA	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-9.71	2.01e-20	1.31e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
THCA	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	9.71	2.01e-20	1.31e-17	0.74	0.41	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
THCA	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	9.71	2.02e-20	1.32e-17	0.67	0.41	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	9.71	2.02e-20	1.32e-17	0.67	0.41	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
THCA	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-9.71	2.03e-20	1.32e-17	-0.41	-0.41	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
THCA	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-9.7	2.04e-20	1.33e-17	-0.56	-0.41	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
THCA	cis	rs4964805	0.913	rs12229276	ENSG00000257681.1	RP11-341G23.4	-9.7	2.04e-20	1.33e-17	-0.48	-0.41	Attention deficit hyperactivity disorder;	chr12:103810993	chr12:103746315~103768858:-
THCA	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	9.7	2.05e-20	1.34e-17	0.55	0.41	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	9.7	2.05e-20	1.34e-17	0.55	0.41	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	9.7	2.05e-20	1.34e-17	0.55	0.41	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	9.7	2.05e-20	1.34e-17	0.55	0.41	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
THCA	cis	rs2599510	0.703	rs762023	ENSG00000276334.1	AL133243.1	9.7	2.06e-20	1.34e-17	0.44	0.41	Interleukin-18 levels;	chr2:32488103	chr2:32521927~32523547:+
THCA	cis	rs944289	0.774	rs7150539	ENSG00000257826.1	RP11-116N8.4	-9.7	2.06e-20	1.35e-17	-0.42	-0.41	Thyroid cancer;	chr14:36086408	chr14:36061026~36067190:-
THCA	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-9.7	2.07e-20	1.35e-17	-0.55	-0.41	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
THCA	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	9.7	2.07e-20	1.35e-17	0.55	0.41	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-9.7	2.08e-20	1.35e-17	-0.51	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
THCA	cis	rs4380275	0.782	rs60367761	ENSG00000272342.1	RP13-539J13.1	9.7	2.12e-20	1.38e-17	0.48	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:739588~740164:-
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000215447.6	BX322557.10	-9.7	2.12e-20	1.38e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45288052~45291738:+
THCA	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	9.7	2.12e-20	1.38e-17	0.33	0.41	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
THCA	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	9.7	2.14e-20	1.39e-17	0.59	0.41	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	9.7	2.14e-20	1.39e-17	0.59	0.41	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	9.7	2.14e-20	1.39e-17	0.59	0.41	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-9.7	2.14e-20	1.39e-17	-0.59	-0.41	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-9.7	2.14e-20	1.39e-17	-0.59	-0.41	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-9.7	2.14e-20	1.39e-17	-0.59	-0.41	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
THCA	cis	rs704795	0.775	rs4665975	ENSG00000234072.1	AC074117.10	-9.7	2.15e-20	1.4e-17	-0.33	-0.41	Menopause (age at onset);	chr2:27403150	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	9.7	2.15e-20	1.4e-17	0.48	0.41	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	9.7	2.15e-20	1.4e-17	0.48	0.41	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
THCA	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	9.7	2.15e-20	1.4e-17	0.55	0.41	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
THCA	cis	rs10740039	0.883	rs7905018	ENSG00000254271.1	RP11-131N11.4	9.7	2.15e-20	1.4e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647585	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs10761537	ENSG00000254271.1	RP11-131N11.4	9.7	2.15e-20	1.4e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649263	chr10:60734342~60741828:+
THCA	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-9.7	2.16e-20	1.4e-17	-0.31	-0.41	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
THCA	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	9.7	2.16e-20	1.4e-17	0.35	0.41	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
THCA	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	9.7	2.16e-20	1.41e-17	0.33	0.41	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
THCA	cis	rs944289	0.708	rs6571736	ENSG00000257826.1	RP11-116N8.4	-9.7	2.17e-20	1.41e-17	-0.42	-0.41	Thyroid cancer;	chr14:36111271	chr14:36061026~36067190:-
THCA	cis	rs944289	0.679	rs8016148	ENSG00000257826.1	RP11-116N8.4	-9.7	2.17e-20	1.41e-17	-0.42	-0.41	Thyroid cancer;	chr14:36111688	chr14:36061026~36067190:-
THCA	cis	rs944289	0.708	rs2415315	ENSG00000257826.1	RP11-116N8.4	-9.7	2.17e-20	1.41e-17	-0.42	-0.41	Thyroid cancer;	chr14:36115338	chr14:36061026~36067190:-
THCA	cis	rs944289	0.708	rs1475716	ENSG00000257826.1	RP11-116N8.4	-9.7	2.17e-20	1.41e-17	-0.42	-0.41	Thyroid cancer;	chr14:36116033	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	9.7	2.18e-20	1.42e-17	0.49	0.41	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
THCA	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-9.7	2.2e-20	1.43e-17	-0.61	-0.41	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
THCA	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	9.7	2.2e-20	1.43e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-9.69	2.21e-20	1.44e-17	-0.51	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
THCA	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	9.69	2.22e-20	1.44e-17	0.55	0.41	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
THCA	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	9.69	2.22e-20	1.44e-17	0.55	0.41	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	9.69	2.22e-20	1.44e-17	0.55	0.41	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000228039.3	KB-1125A3.10	9.69	2.22e-20	1.44e-17	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23963780~23964374:+
THCA	cis	rs860295	0.702	rs34124416	ENSG00000225855.5	RUSC1-AS1	9.69	2.23e-20	1.45e-17	0.29	0.41	Body mass index;	chr1:155608258	chr1:155316863~155324176:-
THCA	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	9.69	2.23e-20	1.45e-17	0.54	0.41	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
THCA	cis	rs6061231	0.761	rs2427312	ENSG00000273619.1	RP5-908M14.9	-9.69	2.24e-20	1.45e-17	-0.38	-0.41	Colorectal cancer;	chr20:62395535	chr20:62386303~62386970:-
THCA	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-9.69	2.24e-20	1.46e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
THCA	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-9.69	2.24e-20	1.46e-17	-0.54	-0.41	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
THCA	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	9.69	2.24e-20	1.46e-17	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
THCA	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	9.69	2.26e-20	1.47e-17	0.53	0.41	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
THCA	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-9.69	2.27e-20	1.47e-17	-0.45	-0.41	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
THCA	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	9.69	2.27e-20	1.48e-17	0.47	0.41	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
THCA	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	9.69	2.27e-20	1.48e-17	0.47	0.41	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	9.69	2.27e-20	1.48e-17	0.47	0.41	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
THCA	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	9.69	2.28e-20	1.48e-17	0.46	0.41	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
THCA	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	9.69	2.28e-20	1.48e-17	0.62	0.41	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
THCA	cis	rs11159086	0.941	rs11846588	ENSG00000270000.1	RP3-449M8.9	9.69	2.28e-20	1.48e-17	0.43	0.41	Advanced glycation end-product levels;	chr14:74505398	chr14:74471930~74472360:-
THCA	cis	rs9532669	0.7	rs9525406	ENSG00000239827.7	SUGT1P3	-9.69	2.28e-20	1.48e-17	-0.46	-0.41	Cervical cancer;	chr13:40860812	chr13:40908159~40921774:-
THCA	cis	rs8072100	0.807	rs4561509	ENSG00000228782.6	CTD-2026D20.3	9.69	2.29e-20	1.49e-17	0.37	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704433	chr17:47450568~47492492:-
THCA	cis	rs17684571	0.751	rs13195601	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56836186	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35828379	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56839003	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs71564863	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56840372	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs13192540	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56842637	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs13192931	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56842921	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35242294	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56846131	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35080938	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56847992	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs13207768	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56851277	chr6:56844002~56864078:+
THCA	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	9.69	2.3e-20	1.49e-17	0.35	0.41	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	9.69	2.31e-20	1.5e-17	0.34	0.41	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
THCA	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	9.69	2.31e-20	1.5e-17	0.32	0.41	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
THCA	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	9.69	2.32e-20	1.5e-17	0.35	0.41	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
THCA	cis	rs185968827	1	rs185968827	ENSG00000231441.1	RP11-472M19.2	9.69	2.32e-20	1.5e-17	0.54	0.41	Alzheimer disease and age of onset;	chr6:56843712	chr6:56844002~56864078:+
THCA	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-9.69	2.32e-20	1.51e-17	-0.42	-0.41	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
THCA	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	9.69	2.33e-20	1.51e-17	0.33	0.41	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	9.69	2.34e-20	1.52e-17	0.55	0.41	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	9.69	2.36e-20	1.53e-17	0.55	0.41	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	9.69	2.36e-20	1.53e-17	0.55	0.41	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	9.69	2.36e-20	1.53e-17	0.55	0.41	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.751	rs17684941	ENSG00000231441.1	RP11-472M19.2	-9.69	2.37e-20	1.54e-17	-0.55	-0.41	Schizophrenia;	chr6:56862636	chr6:56844002~56864078:+
THCA	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	9.69	2.37e-20	1.54e-17	0.55	0.41	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.857	rs7327018	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40856376	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7327315	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40856383	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7327059	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40856458	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9594433	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40856935	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9525403	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40858292	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7318768	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40859140	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942000	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40859979	chr13:40908159~40921774:-
THCA	cis	rs7500321	1	rs7500321	ENSG00000251417.2	RP11-1348G14.4	9.69	2.38e-20	1.54e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28802743~28817828:+
THCA	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-9.69	2.38e-20	1.54e-17	-0.44	-0.41	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000235689.1	AP000351.13	9.69	2.39e-20	1.55e-17	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:24006305~24008258:-
THCA	cis	rs10740039	1	rs10994460	ENSG00000254271.1	RP11-131N11.4	9.69	2.39e-20	1.55e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60659033	chr10:60734342~60741828:+
THCA	cis	rs950169	0.509	rs71395455	ENSG00000225151.9	GOLGA2P7	-9.68	2.41e-20	1.56e-17	-0.61	-0.41	Schizophrenia;	chr15:84610573	chr15:84199311~84230136:-
THCA	cis	rs4713118	0.662	rs175954	ENSG00000280107.1	AL022393.9	-9.68	2.43e-20	1.57e-17	-0.47	-0.41	Parkinson's disease;	chr6:28043807	chr6:28170845~28172521:+
THCA	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-9.68	2.43e-20	1.58e-17	-0.56	-0.41	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
THCA	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-9.68	2.43e-20	1.58e-17	-0.51	-0.41	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
THCA	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	9.68	2.44e-20	1.58e-17	0.48	0.41	Height;	chr6:109618620	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	9.68	2.44e-20	1.58e-17	0.48	0.41	Height;	chr6:109620772	chr6:109382795~109383666:+
THCA	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	9.68	2.44e-20	1.58e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	9.68	2.44e-20	1.58e-17	0.55	0.41	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.89	rs2324738	ENSG00000239827.7	SUGT1P3	-9.68	2.46e-20	1.59e-17	-0.44	-0.41	Cervical cancer;	chr13:40925242	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs2324739	ENSG00000239827.7	SUGT1P3	-9.68	2.46e-20	1.59e-17	-0.44	-0.41	Cervical cancer;	chr13:40925479	chr13:40908159~40921774:-
THCA	cis	rs73219805	0.793	rs3808573	ENSG00000228451.3	SDAD1P1	-9.68	2.46e-20	1.59e-17	-0.52	-0.41	Schizophrenia;	chr8:26339117	chr8:26379259~26382953:-
THCA	cis	rs2599510	0.811	rs2243844	ENSG00000276334.1	AL133243.1	9.68	2.47e-20	1.6e-17	0.44	0.41	Interleukin-18 levels;	chr2:32550917	chr2:32521927~32523547:+
THCA	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28089816	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28090857	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28091439	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28092227	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28093966	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28094014	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28096077	chr6:28161781~28169594:+
THCA	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	9.68	2.48e-20	1.61e-17	0.32	0.41	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
THCA	cis	rs6046396	1	rs6046404	ENSG00000275142.1	RP5-999L4.2	-9.68	2.5e-20	1.61e-17	-0.58	-0.41	Bipolar disorder and schizophrenia;	chr20:19882918	chr20:19871891~19872284:+
THCA	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	9.68	2.5e-20	1.62e-17	0.5	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	9.68	2.52e-20	1.63e-17	0.55	0.41	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
THCA	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	9.68	2.52e-20	1.63e-17	0.35	0.41	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	9.68	2.52e-20	1.63e-17	0.55	0.41	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
THCA	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	9.68	2.55e-20	1.65e-17	0.36	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
THCA	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-9.68	2.56e-20	1.66e-17	-0.53	-0.41	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
THCA	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	9.67	2.61e-20	1.69e-17	0.53	0.41	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
THCA	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-9.67	2.62e-20	1.69e-17	-0.46	-0.41	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	9.67	2.62e-20	1.7e-17	0.55	0.41	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.751	rs34896026	ENSG00000231441.1	RP11-472M19.2	9.67	2.65e-20	1.72e-17	0.54	0.41	Schizophrenia;	chr6:56829383	chr6:56844002~56864078:+
THCA	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	9.67	2.66e-20	1.72e-17	0.32	0.41	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
THCA	cis	rs1858037	0.867	rs67817304	ENSG00000281920.1	RP11-418H16.1	9.67	2.66e-20	1.72e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65346982	chr2:65623272~65628424:+
THCA	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	9.67	2.67e-20	1.72e-17	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
THCA	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-9.67	2.67e-20	1.73e-17	-0.54	-0.41	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
THCA	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-9.67	2.68e-20	1.73e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
THCA	cis	rs944289	0.708	rs1958615	ENSG00000257826.1	RP11-116N8.4	-9.67	2.69e-20	1.74e-17	-0.42	-0.41	Thyroid cancer;	chr14:36118282	chr14:36061026~36067190:-
THCA	cis	rs944289	0.708	rs1537426	ENSG00000257826.1	RP11-116N8.4	9.67	2.69e-20	1.74e-17	0.42	0.41	Thyroid cancer;	chr14:36117961	chr14:36061026~36067190:-
THCA	cis	rs34375054	0.525	rs12316499	ENSG00000279233.1	RP11-158L12.4	9.67	2.69e-20	1.74e-17	0.39	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125108772	chr12:125138245~125141711:+
THCA	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-9.67	2.69e-20	1.74e-17	-0.48	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
THCA	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	9.67	2.69e-20	1.74e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	9.67	2.69e-20	1.74e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	9.67	2.69e-20	1.74e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
THCA	cis	rs944289	0.74	rs376927	ENSG00000257826.1	RP11-116N8.4	-9.67	2.7e-20	1.74e-17	-0.42	-0.41	Thyroid cancer;	chr14:36078725	chr14:36061026~36067190:-
THCA	cis	rs4713118	0.662	rs149969	ENSG00000280107.1	AL022393.9	-9.67	2.71e-20	1.75e-17	-0.47	-0.41	Parkinson's disease;	chr6:28009959	chr6:28170845~28172521:+
THCA	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-9.67	2.71e-20	1.75e-17	-0.59	-0.41	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
THCA	cis	rs4964805	0.913	rs11111795	ENSG00000257681.1	RP11-341G23.4	9.67	2.71e-20	1.75e-17	0.48	0.41	Attention deficit hyperactivity disorder;	chr12:103811052	chr12:103746315~103768858:-
THCA	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-9.67	2.72e-20	1.76e-17	-0.56	-0.41	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
THCA	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	9.67	2.73e-20	1.76e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
THCA	cis	rs9926296	0.712	rs2437957	ENSG00000260259.1	RP11-368I7.4	9.67	2.73e-20	1.76e-17	0.46	0.41	Vitiligo;	chr16:89649240	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	9.67	2.74e-20	1.77e-17	0.55	0.41	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	9.67	2.74e-20	1.77e-17	0.55	0.41	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-9.67	2.75e-20	1.77e-17	-0.45	-0.41	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	9.67	2.75e-20	1.78e-17	0.55	0.41	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	9.67	2.75e-20	1.78e-17	0.55	0.41	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	9.67	2.75e-20	1.78e-17	0.55	0.41	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-9.67	2.77e-20	1.79e-17	-0.45	-0.41	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
THCA	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	-9.67	2.77e-20	1.79e-17	-0.55	-0.41	Depression;	chr6:28139876	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	-9.67	2.77e-20	1.79e-17	-0.55	-0.41	Depression;	chr6:28139998	chr6:28161781~28169594:+
THCA	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	9.67	2.79e-20	1.8e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	9.67	2.79e-20	1.8e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	9.67	2.8e-20	1.81e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	9.67	2.8e-20	1.81e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	9.67	2.8e-20	1.81e-17	0.59	0.41	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
THCA	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-9.67	2.81e-20	1.81e-17	-0.48	-0.41	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
THCA	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	9.66	2.82e-20	1.82e-17	0.32	0.41	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
THCA	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-9.66	2.82e-20	1.82e-17	-0.54	-0.41	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	9.66	2.83e-20	1.83e-17	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
THCA	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	9.66	2.84e-20	1.83e-17	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
THCA	cis	rs11986414	1	rs11986414	ENSG00000253982.1	CTD-2336O2.1	9.66	2.84e-20	1.83e-17	0.41	0.41	Gaucher disease severity;	chr8:1798784	chr8:1761990~1764502:-
THCA	cis	rs9532669	0.963	rs4600338	ENSG00000239827.7	SUGT1P3	-9.66	2.85e-20	1.84e-17	-0.44	-0.41	Cervical cancer;	chr13:40925175	chr13:40908159~40921774:-
THCA	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	9.66	2.85e-20	1.84e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	9.66	2.85e-20	1.84e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
THCA	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-9.66	2.86e-20	1.85e-17	-0.48	-0.41	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
THCA	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	9.66	2.86e-20	1.85e-17	0.68	0.41	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000224205.1	AP000351.4	9.66	2.87e-20	1.85e-17	0.48	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23987320~23991421:-
THCA	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	9.66	2.87e-20	1.85e-17	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
THCA	cis	rs10740039	0.883	rs7902632	ENSG00000254271.1	RP11-131N11.4	9.66	2.88e-20	1.86e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643811	chr10:60734342~60741828:+
THCA	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-9.66	2.88e-20	1.86e-17	-0.35	-0.41	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	9.66	2.9e-20	1.87e-17	0.45	0.41	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
THCA	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-9.66	2.91e-20	1.88e-17	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
THCA	cis	rs10971721	0.643	rs7040130	ENSG00000260947.1	RP11-384P7.7	9.66	2.92e-20	1.88e-17	0.97	0.41	Body mass index;	chr9:33785075	chr9:33697459~33700986:+
THCA	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	9.66	2.92e-20	1.88e-17	0.43	0.41	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
THCA	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	9.66	2.92e-20	1.88e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
THCA	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-9.66	2.95e-20	1.9e-17	-0.34	-0.41	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
THCA	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-9.66	2.96e-20	1.91e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
THCA	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-9.66	2.97e-20	1.91e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-9.66	2.97e-20	1.91e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000266490.1	CTD-2349P21.9	9.66	2.98e-20	1.92e-17	0.56	0.41	Body mass index;	chr17:30776148	chr17:30792372~30792833:+
THCA	cis	rs1537424	0.513	rs1953119	ENSG00000257826.1	RP11-116N8.4	-9.66	2.98e-20	1.92e-17	-0.47	-0.41	Thyroid hormone levels;	chr14:36091618	chr14:36061026~36067190:-
THCA	cis	rs916888	0.821	rs199514	ENSG00000232300.1	FAM215B	-9.66	2.99e-20	1.92e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46558830~46562795:-
THCA	cis	rs3743772	0.5	rs2388117	ENSG00000279722.1	RP11-44F14.6	9.66	2.99e-20	1.93e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53487607~53489943:-
THCA	cis	rs3743772	0.5	rs28415605	ENSG00000279722.1	RP11-44F14.6	9.66	2.99e-20	1.93e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53487607~53489943:-
THCA	cis	rs3743772	0.5	rs2160290	ENSG00000279722.1	RP11-44F14.6	9.66	2.99e-20	1.93e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53487607~53489943:-
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	9.66	2.99e-20	1.93e-17	0.55	0.41	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	9.66	2.99e-20	1.93e-17	0.55	0.41	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	9.66	2.99e-20	1.93e-17	0.55	0.41	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
THCA	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-9.66	3e-20	1.93e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	9.66	3.01e-20	1.94e-17	0.55	0.41	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
THCA	cis	rs12554020	0.786	rs3893381	ENSG00000227603.1	RP11-165J3.6	-9.66	3.01e-20	1.94e-17	-0.66	-0.41	Schizophrenia;	chr9:93519576	chr9:93435332~93437121:-
THCA	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	9.66	3.01e-20	1.94e-17	0.59	0.41	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
THCA	cis	rs944289	0.708	rs2755194	ENSG00000257826.1	RP11-116N8.4	-9.66	3.02e-20	1.95e-17	-0.41	-0.41	Thyroid cancer;	chr14:36079176	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs11156902	ENSG00000257826.1	RP11-116N8.4	-9.66	3.02e-20	1.95e-17	-0.41	-0.41	Thyroid cancer;	chr14:36080016	chr14:36061026~36067190:-
THCA	cis	rs944289	0.712	rs35736442	ENSG00000257826.1	RP11-116N8.4	-9.66	3.02e-20	1.95e-17	-0.41	-0.41	Thyroid cancer;	chr14:36081119	chr14:36061026~36067190:-
THCA	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	-9.66	3.04e-20	1.96e-17	-0.54	-0.41	Depression;	chr6:28091242	chr6:28161781~28169594:+
THCA	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-9.66	3.04e-20	1.96e-17	-0.74	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
THCA	cis	rs11051970	0.559	rs11051928	ENSG00000274964.1	RP11-817I4.1	-9.66	3.05e-20	1.97e-17	-0.51	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32319580	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051929	ENSG00000274964.1	RP11-817I4.1	-9.66	3.05e-20	1.97e-17	-0.51	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32319617	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.592	rs58926489	ENSG00000274964.1	RP11-817I4.1	-9.66	3.05e-20	1.97e-17	-0.51	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32319949	chr12:32339368~32340724:+
THCA	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	9.66	3.05e-20	1.97e-17	0.47	0.41	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
THCA	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-9.65	3.06e-20	1.97e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	9.65	3.07e-20	1.97e-17	0.54	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
THCA	cis	rs944289	0.74	rs398501	ENSG00000257826.1	RP11-116N8.4	-9.65	3.07e-20	1.97e-17	-0.41	-0.41	Thyroid cancer;	chr14:36078452	chr14:36061026~36067190:-
THCA	cis	rs10740039	1	rs10740040	ENSG00000254271.1	RP11-131N11.4	9.65	3.08e-20	1.98e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654985	chr10:60734342~60741828:+
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	9.65	3.08e-20	1.98e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
THCA	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-9.65	3.1e-20	1.99e-17	-0.68	-0.41	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
THCA	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-9.65	3.1e-20	1.99e-17	-0.57	-0.41	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	9.65	3.1e-20	2e-17	0.55	0.41	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
THCA	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.13e-20	2.01e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.13e-20	2.01e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	9.65	3.13e-20	2.01e-17	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
THCA	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
THCA	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
THCA	cis	rs934734	0.532	rs7569257	ENSG00000234255.7	AC012370.3	-9.65	3.18e-20	2.04e-17	-0.45	-0.41	Rheumatoid arthritis;	chr2:65429842	chr2:65439888~65456571:-
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	9.65	3.19e-20	2.05e-17	0.55	0.41	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-9.65	3.19e-20	2.05e-17	-0.45	-0.41	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-9.65	3.19e-20	2.05e-17	-0.45	-0.41	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-9.65	3.19e-20	2.05e-17	-0.45	-0.41	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
THCA	cis	rs7727544	0.716	rs10058655	ENSG00000237714.1	P4HA2-AS1	9.65	3.2e-20	2.05e-17	0.54	0.41	Blood metabolite levels;	chr5:132235203	chr5:132184876~132192808:+
THCA	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	9.65	3.21e-20	2.06e-17	0.44	0.41	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-9.65	3.21e-20	2.06e-17	-0.55	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-9.65	3.21e-20	2.06e-17	-0.56	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
THCA	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	9.65	3.23e-20	2.07e-17	0.45	0.41	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	9.65	3.23e-20	2.07e-17	0.45	0.41	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	9.65	3.23e-20	2.07e-17	0.45	0.41	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
THCA	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	9.65	3.23e-20	2.07e-17	0.32	0.41	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
THCA	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	9.65	3.23e-20	2.07e-17	0.32	0.41	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	9.65	3.23e-20	2.07e-17	0.32	0.41	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
THCA	cis	rs6452524	0.836	rs2731849	ENSG00000249664.1	CTD-2227C6.2	-9.65	3.23e-20	2.07e-17	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83214060	chr5:83012285~83013109:-
THCA	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	9.65	3.24e-20	2.08e-17	0.53	0.41	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	9.65	3.24e-20	2.08e-17	0.53	0.41	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	9.65	3.24e-20	2.08e-17	0.55	0.41	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-9.65	3.24e-20	2.08e-17	-0.45	-0.41	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
THCA	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	-9.65	3.25e-20	2.09e-17	-0.54	-0.41	Depression;	chr6:28091659	chr6:28161781~28169594:+
THCA	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-9.65	3.26e-20	2.09e-17	-0.46	-0.41	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
THCA	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	9.65	3.27e-20	2.1e-17	0.45	0.41	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	9.65	3.27e-20	2.1e-17	0.45	0.41	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	9.65	3.27e-20	2.1e-17	0.45	0.41	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	9.65	3.27e-20	2.1e-17	0.45	0.41	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
THCA	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-9.65	3.29e-20	2.11e-17	-0.48	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
THCA	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-9.65	3.29e-20	2.11e-17	-0.41	-0.41	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
THCA	cis	rs9532669	0.926	rs9532671	ENSG00000239827.7	SUGT1P3	-9.65	3.29e-20	2.11e-17	-0.44	-0.41	Cervical cancer;	chr13:40927761	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.833	rs9532672	ENSG00000239827.7	SUGT1P3	-9.65	3.29e-20	2.11e-17	-0.44	-0.41	Cervical cancer;	chr13:40928285	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs7324625	ENSG00000239827.7	SUGT1P3	-9.65	3.29e-20	2.11e-17	-0.44	-0.41	Cervical cancer;	chr13:40928606	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4454835	ENSG00000239827.7	SUGT1P3	-9.65	3.29e-20	2.11e-17	-0.44	-0.41	Cervical cancer;	chr13:40928978	chr13:40908159~40921774:-
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000266490.1	CTD-2349P21.9	9.65	3.3e-20	2.12e-17	0.54	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30792372~30792833:+
THCA	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-9.65	3.3e-20	2.12e-17	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
THCA	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-9.65	3.3e-20	2.12e-17	-0.41	-0.41	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
THCA	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	9.65	3.31e-20	2.12e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
THCA	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	9.64	3.32e-20	2.13e-17	0.55	0.41	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
THCA	cis	rs944289	0.708	rs7158599	ENSG00000257826.1	RP11-116N8.4	-9.64	3.33e-20	2.13e-17	-0.42	-0.41	Thyroid cancer;	chr14:36111976	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	9.64	3.33e-20	2.14e-17	0.48	0.41	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
THCA	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	9.64	3.34e-20	2.14e-17	0.45	0.41	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
THCA	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-9.64	3.34e-20	2.14e-17	-0.32	-0.41	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
THCA	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	9.64	3.34e-20	2.14e-17	0.54	0.41	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
THCA	cis	rs9828933	0.701	rs7621544	ENSG00000280620.1	SCAANT1	9.64	3.34e-20	2.14e-17	0.63	0.41	Type 2 diabetes;	chr3:63943005	chr3:63911518~63911772:-
THCA	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	9.64	3.36e-20	2.15e-17	0.56	0.41	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
THCA	cis	rs10740039	0.842	rs10821819	ENSG00000254271.1	RP11-131N11.4	9.64	3.37e-20	2.16e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658857	chr10:60734342~60741828:+
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000215447.6	BX322557.10	-9.64	3.38e-20	2.17e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45288052~45291738:+
THCA	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	9.64	3.38e-20	2.17e-17	0.51	0.41	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
THCA	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-9.64	3.41e-20	2.19e-17	-0.67	-0.41	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
THCA	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	9.64	3.42e-20	2.19e-17	0.46	0.41	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
THCA	cis	rs73219805	0.838	rs17055172	ENSG00000228451.3	SDAD1P1	-9.64	3.42e-20	2.19e-17	-0.51	-0.41	Schizophrenia;	chr8:26368096	chr8:26379259~26382953:-
THCA	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	9.64	3.43e-20	2.2e-17	0.43	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
THCA	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-9.64	3.44e-20	2.2e-17	-0.51	-0.41	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
THCA	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	9.64	3.44e-20	2.2e-17	0.56	0.41	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
THCA	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	9.64	3.44e-20	2.2e-17	0.44	0.41	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	9.64	3.45e-20	2.21e-17	0.55	0.41	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
THCA	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	9.64	3.45e-20	2.21e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
THCA	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-9.64	3.45e-20	2.21e-17	-0.45	-0.41	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
THCA	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	9.64	3.47e-20	2.22e-17	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
THCA	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-9.64	3.47e-20	2.22e-17	-0.35	-0.41	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
THCA	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	9.64	3.47e-20	2.22e-17	0.49	0.41	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
THCA	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-9.64	3.48e-20	2.23e-17	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
THCA	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
THCA	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-9.64	3.48e-20	2.23e-17	-0.56	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
THCA	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-9.64	3.48e-20	2.23e-17	-0.35	-0.41	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
THCA	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	9.64	3.52e-20	2.25e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
THCA	cis	rs2599510	0.84	rs466146	ENSG00000276334.1	AL133243.1	9.64	3.52e-20	2.25e-17	0.43	0.41	Interleukin-18 levels;	chr2:32314167	chr2:32521927~32523547:+
THCA	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-9.64	3.53e-20	2.26e-17	-0.51	-0.41	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	9.64	3.54e-20	2.26e-17	0.55	0.41	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
THCA	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	9.64	3.55e-20	2.27e-17	0.45	0.41	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
THCA	cis	rs10411161	1	rs8108477	ENSG00000269483.1	AC006272.1	9.64	3.55e-20	2.27e-17	0.57	0.41	Breast cancer;	chr19:51861649	chr19:51839924~51843324:-
THCA	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	9.64	3.56e-20	2.27e-17	0.55	0.41	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
THCA	cis	rs9532669	0.963	rs1056824	ENSG00000239827.7	SUGT1P3	-9.64	3.56e-20	2.28e-17	-0.43	-0.41	Cervical cancer;	chr13:40932748	chr13:40908159~40921774:-
THCA	cis	rs4660456	0.504	rs2253835	ENSG00000237899.1	RP4-739H11.3	9.64	3.57e-20	2.28e-17	0.56	0.41	Platelet count;	chr1:40635900	chr1:40669089~40687588:-
THCA	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-9.64	3.57e-20	2.28e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
THCA	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	9.64	3.57e-20	2.28e-17	0.45	0.41	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
THCA	cis	rs944289	0.708	rs2899845	ENSG00000257826.1	RP11-116N8.4	-9.64	3.58e-20	2.29e-17	-0.42	-0.41	Thyroid cancer;	chr14:36116632	chr14:36061026~36067190:-
THCA	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	9.64	3.59e-20	2.29e-17	0.47	0.41	Height;	chr2:231516534	chr2:231508426~231514339:-
THCA	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	9.63	3.61e-20	2.3e-17	0.45	0.41	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
THCA	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-9.63	3.63e-20	2.32e-17	-0.53	-0.41	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
THCA	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	9.63	3.63e-20	2.32e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
THCA	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-9.63	3.65e-20	2.33e-17	-0.56	-0.41	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
THCA	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-9.63	3.66e-20	2.34e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
THCA	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-9.63	3.67e-20	2.34e-17	-0.5	-0.41	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
THCA	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-9.63	3.67e-20	2.35e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
THCA	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-9.63	3.68e-20	2.35e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
THCA	cis	rs9890032	0.934	rs7225461	ENSG00000266490.1	CTD-2349P21.9	9.63	3.69e-20	2.36e-17	0.39	0.41	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30792372~30792833:+
THCA	cis	rs3743772	0.5	rs35346613	ENSG00000279722.1	RP11-44F14.6	9.63	3.7e-20	2.36e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53487607~53489943:-
THCA	cis	rs3743772	0.5	rs62048485	ENSG00000279722.1	RP11-44F14.6	9.63	3.7e-20	2.36e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53487607~53489943:-
THCA	cis	rs9659323	0.632	rs10923743	ENSG00000231365.4	RP11-418J17.1	-9.63	3.7e-20	2.36e-17	-0.39	-0.41	Body mass index;	chr1:119070009	chr1:119140396~119275973:+
THCA	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-9.63	3.7e-20	2.36e-17	-0.55	-0.41	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
THCA	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	9.63	3.71e-20	2.37e-17	0.47	0.41	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
THCA	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	9.63	3.71e-20	2.37e-17	0.32	0.41	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	9.63	3.71e-20	2.37e-17	0.32	0.41	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	9.63	3.71e-20	2.37e-17	0.32	0.41	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
THCA	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	9.63	3.74e-20	2.39e-17	0.5	0.41	Height;	chr11:118852670	chr11:118688039~118690600:-
THCA	cis	rs1858037	0.836	rs1396209	ENSG00000281920.1	RP11-418H16.1	9.63	3.75e-20	2.39e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65374100	chr2:65623272~65628424:+
THCA	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	9.63	3.76e-20	2.4e-17	0.56	0.41	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
THCA	cis	rs1858037	0.867	rs1039765	ENSG00000281920.1	RP11-418H16.1	-9.63	3.76e-20	2.4e-17	-0.53	-0.41	Rheumatoid arthritis;	chr2:65387228	chr2:65623272~65628424:+
THCA	cis	rs916888	0.821	rs415430	ENSG00000232300.1	FAM215B	-9.63	3.76e-20	2.4e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46558830~46562795:-
THCA	cis	rs916888	0.779	rs430685	ENSG00000232300.1	FAM215B	-9.63	3.76e-20	2.4e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46558830~46562795:-
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000215447.6	BX322557.10	-9.63	3.76e-20	2.4e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	9.63	3.76e-20	2.4e-17	0.55	0.41	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
THCA	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	9.63	3.77e-20	2.4e-17	0.58	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
THCA	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	9.63	3.78e-20	2.41e-17	0.45	0.41	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
THCA	cis	rs10740039	0.961	rs2083696	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60656430	chr10:60734342~60741828:+
THCA	cis	rs10740039	1	rs10821818	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657178	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs6479722	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657923	chr10:60734342~60741828:+
THCA	cis	rs10740039	1	rs6479723	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658127	chr10:60734342~60741828:+
THCA	cis	rs10740039	1	rs10761545	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658811	chr10:60734342~60741828:+
THCA	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	9.63	3.8e-20	2.42e-17	0.33	0.41	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
THCA	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	9.63	3.82e-20	2.44e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
THCA	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-9.63	3.82e-20	2.44e-17	-0.55	-0.41	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
THCA	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	9.63	3.84e-20	2.45e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
THCA	cis	rs2033711	0.87	rs7259841	ENSG00000268912.1	CTD-2619J13.17	-9.63	3.85e-20	2.45e-17	-0.32	-0.41	Uric acid clearance;	chr19:58439756	chr19:58428632~58431148:-
THCA	cis	rs62103177	0.564	rs2115996	ENSG00000261126.6	RP11-795F19.1	9.63	3.87e-20	2.47e-17	0.45	0.41	Opioid sensitivity;	chr18:79941007	chr18:80046900~80095482:+
THCA	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	9.63	3.87e-20	2.47e-17	0.65	0.41	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
THCA	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-9.63	3.87e-20	2.47e-17	-0.56	-0.41	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
THCA	cis	rs2839186	0.585	rs2839154	ENSG00000239415.1	AP001469.9	-9.63	3.88e-20	2.47e-17	-0.43	-0.41	Testicular germ cell tumor;	chr21:46217846	chr21:46251549~46254133:-
THCA	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	9.63	3.9e-20	2.48e-17	0.53	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
THCA	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-9.63	3.9e-20	2.48e-17	-0.56	-0.41	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
THCA	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	9.62	3.9e-20	2.49e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
THCA	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	9.62	3.91e-20	2.49e-17	0.54	0.41	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	9.62	3.91e-20	2.49e-17	0.54	0.41	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
THCA	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-9.62	3.92e-20	2.5e-17	-0.59	-0.41	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
THCA	cis	rs780096	0.546	rs2293572	ENSG00000234072.1	AC074117.10	9.62	3.92e-20	2.5e-17	0.32	0.41	Total body bone mineral density;	chr2:27505910	chr2:27356246~27367622:+
THCA	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-9.62	3.94e-20	2.51e-17	-0.46	-0.41	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
THCA	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	9.62	3.97e-20	2.53e-17	0.55	0.41	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
THCA	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-9.62	3.97e-20	2.53e-17	-0.52	-0.41	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
THCA	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	9.62	3.98e-20	2.54e-17	0.59	0.41	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	9.62	4.01e-20	2.55e-17	0.55	0.41	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
THCA	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-9.62	4.02e-20	2.56e-17	-0.42	-0.41	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
THCA	cis	rs10740039	0.883	rs34168977	ENSG00000254271.1	RP11-131N11.4	9.62	4.02e-20	2.56e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632916	chr10:60734342~60741828:+
THCA	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-9.62	4.02e-20	2.56e-17	-0.46	-0.41	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
THCA	cis	rs944289	0.74	rs2780302	ENSG00000257826.1	RP11-116N8.4	-9.62	4.04e-20	2.57e-17	-0.41	-0.41	Thyroid cancer;	chr14:36079456	chr14:36061026~36067190:-
THCA	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-9.62	4.04e-20	2.57e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
THCA	cis	rs6046396	1	rs2145552	ENSG00000275142.1	RP5-999L4.2	-9.62	4.05e-20	2.58e-17	-0.58	-0.41	Bipolar disorder and schizophrenia;	chr20:19881604	chr20:19871891~19872284:+
THCA	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	9.62	4.06e-20	2.58e-17	0.45	0.41	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
THCA	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-9.62	4.07e-20	2.59e-17	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
THCA	cis	rs9532669	0.824	rs4941998	ENSG00000239827.7	SUGT1P3	-9.62	4.09e-20	2.6e-17	-0.46	-0.41	Cervical cancer;	chr13:40859901	chr13:40908159~40921774:-
THCA	cis	rs11051970	0.592	rs58236386	ENSG00000274964.1	RP11-817I4.1	-9.62	4.11e-20	2.62e-17	-0.51	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32320143	chr12:32339368~32340724:+
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
THCA	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	9.62	4.12e-20	2.62e-17	0.47	0.41	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs12229607	ENSG00000275409.1	RP11-131L12.4	-9.62	4.13e-20	2.63e-17	-0.45	-0.41	Glucose homeostasis traits;	chr12:118338333	chr12:118430147~118430699:+
THCA	cis	rs916888	0.738	rs199515	ENSG00000232300.1	FAM215B	-9.62	4.14e-20	2.63e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46558830~46562795:-
THCA	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	9.62	4.15e-20	2.63e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
THCA	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-9.62	4.17e-20	2.65e-17	-0.35	-0.41	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-9.62	4.17e-20	2.65e-17	-0.35	-0.41	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-9.62	4.18e-20	2.65e-17	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
THCA	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-9.62	4.18e-20	2.65e-17	-0.5	-0.41	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-9.62	4.18e-20	2.65e-17	-0.5	-0.41	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
THCA	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
THCA	cis	rs180730	0.5	rs6810734	ENSG00000251609.2	SETP12	9.62	4.19e-20	2.66e-17	0.56	0.41	Fasting plasma glucose;	chr4:120935625	chr4:120895494~120897083:-
THCA	cis	rs180730	0.519	rs6848268	ENSG00000251609.2	SETP12	9.62	4.19e-20	2.66e-17	0.56	0.41	Fasting plasma glucose;	chr4:120936802	chr4:120895494~120897083:-
THCA	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	9.62	4.19e-20	2.66e-17	0.32	0.41	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
THCA	cis	rs10740039	1	rs10761543	ENSG00000254271.1	RP11-131N11.4	9.62	4.23e-20	2.68e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655633	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10761544	ENSG00000254271.1	RP11-131N11.4	9.62	4.23e-20	2.68e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655647	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs7900848	ENSG00000254271.1	RP11-131N11.4	9.62	4.23e-20	2.68e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655893	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.671	rs7913549	ENSG00000254271.1	RP11-131N11.4	9.62	4.23e-20	2.68e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658474	chr10:60734342~60741828:+
THCA	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	9.61	4.24e-20	2.69e-17	0.53	0.41	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
THCA	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	9.61	4.24e-20	2.69e-17	0.53	0.41	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
THCA	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	9.61	4.25e-20	2.69e-17	0.47	0.41	Height;	chr6:109672088	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	9.61	4.25e-20	2.69e-17	0.47	0.41	Height;	chr6:109676091	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	9.61	4.26e-20	2.7e-17	0.48	0.41	Height;	chr6:109738751	chr6:109382795~109383666:+
THCA	cis	rs67311347	0.503	rs11719968	ENSG00000223797.4	ENTPD3-AS1	9.61	4.27e-20	2.71e-17	0.34	0.41	Renal cell carcinoma;	chr3:40200109	chr3:40313802~40453329:-
THCA	cis	rs17684571	0.751	rs34866877	ENSG00000231441.1	RP11-472M19.2	9.61	4.28e-20	2.72e-17	0.54	0.41	Schizophrenia;	chr6:56829507	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35407078	ENSG00000231441.1	RP11-472M19.2	9.61	4.28e-20	2.72e-17	0.54	0.41	Schizophrenia;	chr6:56830216	chr6:56844002~56864078:+
THCA	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-9.61	4.29e-20	2.72e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-9.61	4.29e-20	2.72e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
THCA	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-9.61	4.33e-20	2.74e-17	-0.56	-0.41	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-9.61	4.33e-20	2.74e-17	-0.56	-0.41	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
THCA	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	9.61	4.34e-20	2.75e-17	0.71	0.41	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
THCA	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-9.61	4.34e-20	2.75e-17	-0.53	-0.41	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
THCA	cis	rs1858037	0.765	rs67404371	ENSG00000281920.1	RP11-418H16.1	9.61	4.35e-20	2.76e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65370137	chr2:65623272~65628424:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	9.61	4.36e-20	2.76e-17	0.57	0.41	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
THCA	cis	rs9926296	0.712	rs258332	ENSG00000260259.1	RP11-368I7.4	9.61	4.37e-20	2.77e-17	0.45	0.41	Vitiligo;	chr16:89661275	chr16:89682620~89686569:-
THCA	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-9.61	4.38e-20	2.78e-17	-0.4	-0.41	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
THCA	cis	rs1858037	0.867	rs2118305	ENSG00000281920.1	RP11-418H16.1	9.61	4.39e-20	2.78e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65378086	chr2:65623272~65628424:+
THCA	cis	rs3743772	0.5	rs28804772	ENSG00000279722.1	RP11-44F14.6	9.61	4.39e-20	2.78e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53411252	chr16:53487607~53489943:-
THCA	cis	rs7727544	0.904	rs58835386	ENSG00000233006.5	AC034220.3	9.61	4.39e-20	2.78e-17	0.32	0.41	Blood metabolite levels;	chr5:132264866	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.904	rs7736102	ENSG00000233006.5	AC034220.3	9.61	4.39e-20	2.78e-17	0.32	0.41	Blood metabolite levels;	chr5:132268564	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.904	rs6897575	ENSG00000233006.5	AC034220.3	9.61	4.39e-20	2.78e-17	0.32	0.41	Blood metabolite levels;	chr5:132268842	chr5:132311285~132369916:-
THCA	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	9.61	4.45e-20	2.82e-17	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
THCA	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-9.61	4.48e-20	2.84e-17	-0.56	-0.41	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
THCA	cis	rs7727544	0.836	rs10463892	ENSG00000233006.5	AC034220.3	9.61	4.51e-20	2.85e-17	0.32	0.41	Blood metabolite levels;	chr5:132263012	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.901	rs55633655	ENSG00000233006.5	AC034220.3	9.61	4.51e-20	2.85e-17	0.32	0.41	Blood metabolite levels;	chr5:132263063	chr5:132311285~132369916:-
THCA	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	9.61	4.51e-20	2.85e-17	0.45	0.41	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
THCA	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	9.61	4.51e-20	2.86e-17	0.44	0.41	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
THCA	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	9.61	4.52e-20	2.86e-17	0.41	0.41	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	9.61	4.52e-20	2.86e-17	0.55	0.41	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
THCA	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	9.61	4.54e-20	2.87e-17	0.45	0.41	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
THCA	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	9.61	4.55e-20	2.88e-17	0.43	0.41	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
THCA	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-9.61	4.55e-20	2.88e-17	-0.53	-0.41	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
THCA	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-9.61	4.55e-20	2.88e-17	-0.45	-0.41	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
THCA	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-9.61	4.56e-20	2.88e-17	-0.31	-0.41	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
THCA	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-9.61	4.56e-20	2.89e-17	-0.51	-0.41	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
THCA	cis	rs17684571	0.7	rs36037734	ENSG00000231441.1	RP11-472M19.2	9.61	4.56e-20	2.89e-17	0.55	0.41	Schizophrenia;	chr6:56801202	chr6:56844002~56864078:+
THCA	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	9.61	4.57e-20	2.89e-17	0.55	0.41	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	9.61	4.57e-20	2.89e-17	0.55	0.41	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
THCA	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	9.6	4.6e-20	2.91e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	9.6	4.62e-20	2.92e-17	0.54	0.41	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	9.6	4.62e-20	2.92e-17	0.54	0.41	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	9.6	4.62e-20	2.92e-17	0.54	0.41	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
THCA	cis	rs916888	0.821	rs199512	ENSG00000232300.1	FAM215B	-9.6	4.63e-20	2.93e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46558830~46562795:-
THCA	cis	rs916888	0.821	rs199509	ENSG00000232300.1	FAM215B	-9.6	4.63e-20	2.93e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46558830~46562795:-
THCA	cis	rs916888	0.821	rs199507	ENSG00000232300.1	FAM215B	-9.6	4.63e-20	2.93e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46558830~46562795:-
THCA	cis	rs73219805	1	rs73219805	ENSG00000228451.3	SDAD1P1	-9.6	4.64e-20	2.93e-17	-0.51	-0.41	Schizophrenia;	chr8:26415252	chr8:26379259~26382953:-
THCA	cis	rs11159086	0.938	rs11623040	ENSG00000259005.1	RP3-449M8.6	9.6	4.64e-20	2.93e-17	0.49	0.41	Advanced glycation end-product levels;	chr14:74496743	chr14:74474007~74474864:-
THCA	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	9.6	4.66e-20	2.95e-17	0.48	0.41	Height;	chr6:109690255	chr6:109382795~109383666:+
THCA	cis	rs1537424	0.513	rs944290	ENSG00000257826.1	RP11-116N8.4	-9.6	4.67e-20	2.95e-17	-0.47	-0.41	Thyroid hormone levels;	chr14:36095493	chr14:36061026~36067190:-
THCA	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-9.6	4.67e-20	2.95e-17	-0.5	-0.4	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-9.6	4.68e-20	2.96e-17	-0.48	-0.4	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
THCA	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-9.6	4.7e-20	2.97e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	9.6	4.7e-20	2.97e-17	0.55	0.4	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000215447.6	BX322557.10	-9.6	4.74e-20	3e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45288052~45291738:+
THCA	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	9.6	4.77e-20	3.01e-17	0.51	0.4	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
THCA	cis	rs10740039	1	rs10761541	ENSG00000254271.1	RP11-131N11.4	9.6	4.81e-20	3.04e-17	0.47	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655383	chr10:60734342~60741828:+
THCA	cis	rs8062405	0.573	rs7140	ENSG00000251417.2	RP11-1348G14.4	9.6	4.83e-20	3.05e-17	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28802743~28817828:+
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000266490.1	CTD-2349P21.9	9.6	4.87e-20	3.07e-17	0.55	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30792372~30792833:+
THCA	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-9.6	4.88e-20	3.08e-17	-0.29	-0.4	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
THCA	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	9.6	4.89e-20	3.09e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
THCA	cis	rs180730	0.519	rs13132472	ENSG00000251609.2	SETP12	9.6	4.91e-20	3.1e-17	0.56	0.4	Fasting plasma glucose;	chr4:120954156	chr4:120895494~120897083:-
THCA	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	9.6	4.92e-20	3.1e-17	0.46	0.4	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
THCA	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-9.6	4.94e-20	3.11e-17	-0.46	-0.4	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
THCA	cis	rs4819052	1	rs4819052	ENSG00000215447.6	BX322557.10	-9.6	4.94e-20	3.11e-17	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45288052~45291738:+
THCA	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	9.6	4.94e-20	3.12e-17	0.54	0.4	Depression;	chr6:28086929	chr6:28161781~28169594:+
THCA	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	9.6	4.94e-20	3.12e-17	0.32	0.4	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
THCA	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-9.6	4.96e-20	3.13e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-9.59	4.98e-20	3.14e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
THCA	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	9.59	4.99e-20	3.15e-17	0.51	0.4	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
THCA	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-9.59	5.02e-20	3.16e-17	-0.6	-0.4	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
THCA	cis	rs1426063	0.614	rs76512224	ENSG00000260265.1	RP11-44F21.5	9.59	5.03e-20	3.17e-17	0.88	0.4	QT interval;	chr4:75144808	chr4:75081702~75084717:-
THCA	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	9.59	5.04e-20	3.18e-17	0.43	0.4	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
THCA	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-9.59	5.07e-20	3.19e-17	-0.45	-0.4	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
THCA	cis	rs1858037	0.867	rs876933	ENSG00000281920.1	RP11-418H16.1	9.59	5.08e-20	3.2e-17	0.53	0.4	Rheumatoid arthritis;	chr2:65382303	chr2:65623272~65628424:+
THCA	cis	rs62158211	0.955	rs1823125	ENSG00000272563.1	RP11-480C16.1	9.59	5.1e-20	3.21e-17	0.53	0.4	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113432600~113436042:+
THCA	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-9.59	5.11e-20	3.22e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
THCA	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-9.59	5.11e-20	3.22e-17	-0.5	-0.4	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
THCA	cis	rs957448	0.687	rs10104041	ENSG00000253704.1	RP11-267M23.4	9.59	5.12e-20	3.23e-17	0.41	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94553722~94569745:+
THCA	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-9.59	5.14e-20	3.24e-17	-0.29	-0.4	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
THCA	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	9.59	5.15e-20	3.24e-17	0.44	0.4	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	9.59	5.15e-20	3.24e-17	0.44	0.4	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
THCA	cis	rs934734	0.532	rs7557569	ENSG00000234255.7	AC012370.3	-9.59	5.18e-20	3.26e-17	-0.45	-0.4	Rheumatoid arthritis;	chr2:65417427	chr2:65439888~65456571:-
THCA	cis	rs950169	0.656	rs748455	ENSG00000225151.9	GOLGA2P7	-9.59	5.19e-20	3.27e-17	-0.61	-0.4	Schizophrenia;	chr15:84606344	chr15:84199311~84230136:-
THCA	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-9.59	5.2e-20	3.27e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-9.59	5.2e-20	3.27e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
THCA	cis	rs7191700	0.644	rs12149160	ENSG00000262636.1	CTD-3088G3.4	-9.59	5.2e-20	3.27e-17	-0.51	-0.4	Multiple sclerosis;	chr16:11345446	chr16:11380859~11381118:-
THCA	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-9.59	5.24e-20	3.3e-17	-0.56	-0.4	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-9.59	5.24e-20	3.3e-17	-0.56	-0.4	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
THCA	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-9.59	5.24e-20	3.3e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-9.59	5.24e-20	3.3e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
THCA	cis	rs7221109	0.884	rs7226035	ENSG00000278834.1	RP11-458J1.1	9.59	5.26e-20	3.31e-17	0.43	0.4	Type 1 diabetes;	chr17:40626034	chr17:40648300~40649718:+
THCA	cis	rs9926296	0.712	rs258330	ENSG00000260259.1	RP11-368I7.4	9.59	5.27e-20	3.32e-17	0.45	0.4	Vitiligo;	chr16:89663166	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	9.59	5.28e-20	3.32e-17	0.54	0.4	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
THCA	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28136698	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28136856	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28137418	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28138363	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28138981	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28139012	chr6:28161781~28169594:+
THCA	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-9.59	5.32e-20	3.35e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
THCA	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-9.59	5.32e-20	3.35e-17	-0.35	-0.4	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.963	rs3736953	ENSG00000239827.7	SUGT1P3	-9.59	5.37e-20	3.38e-17	-0.44	-0.4	Cervical cancer;	chr13:40951450	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7322399	ENSG00000239827.7	SUGT1P3	-9.59	5.37e-20	3.38e-17	-0.44	-0.4	Cervical cancer;	chr13:40952511	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7322097	ENSG00000239827.7	SUGT1P3	-9.59	5.37e-20	3.38e-17	-0.44	-0.4	Cervical cancer;	chr13:40952513	chr13:40908159~40921774:-
THCA	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-9.58	5.44e-20	3.42e-17	-0.42	-0.4	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
THCA	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-9.58	5.44e-20	3.42e-17	-0.45	-0.4	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
THCA	cis	rs9532669	0.963	rs7989303	ENSG00000239827.7	SUGT1P3	-9.58	5.45e-20	3.43e-17	-0.44	-0.4	Cervical cancer;	chr13:40950087	chr13:40908159~40921774:-
THCA	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	9.58	5.47e-20	3.44e-17	0.47	0.4	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
THCA	cis	rs860295	0.812	rs10908481	ENSG00000225855.5	RUSC1-AS1	9.58	5.51e-20	3.47e-17	0.28	0.4	Body mass index;	chr1:155743859	chr1:155316863~155324176:-
THCA	cis	rs944289	0.624	rs55775461	ENSG00000257826.1	RP11-116N8.4	-9.58	5.51e-20	3.47e-17	-0.41	-0.4	Thyroid cancer;	chr14:36108166	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-9.58	5.52e-20	3.47e-17	-0.48	-0.4	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000224205.1	AP000351.4	-9.58	5.52e-20	3.47e-17	-0.47	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23987320~23991421:-
THCA	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	9.58	5.52e-20	3.47e-17	0.48	0.4	Height;	chr6:109738307	chr6:109382795~109383666:+
THCA	cis	rs9532669	0.926	rs11147831	ENSG00000176268.5	CYCSP34	9.58	5.57e-20	3.5e-17	0.45	0.4	Cervical cancer;	chr13:40978593	chr13:40863599~40863902:-
THCA	cis	rs1426063	0.614	rs79750906	ENSG00000260265.1	RP11-44F21.5	9.58	5.6e-20	3.52e-17	0.88	0.4	QT interval;	chr4:75139193	chr4:75081702~75084717:-
THCA	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-9.58	5.61e-20	3.53e-17	-0.28	-0.4	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
THCA	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	9.58	5.62e-20	3.53e-17	0.44	0.4	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	9.58	5.62e-20	3.53e-17	0.44	0.4	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
THCA	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	9.58	5.63e-20	3.54e-17	0.32	0.4	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
THCA	cis	rs10971721	0.643	rs10971699	ENSG00000260947.1	RP11-384P7.7	9.58	5.63e-20	3.54e-17	1.11	0.4	Body mass index;	chr9:33777186	chr9:33697459~33700986:+
THCA	cis	rs860295	0.812	rs2297775	ENSG00000225855.5	RUSC1-AS1	-9.58	5.65e-20	3.55e-17	-0.28	-0.4	Body mass index;	chr1:155765221	chr1:155316863~155324176:-
THCA	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	9.58	5.69e-20	3.57e-17	0.56	0.4	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
THCA	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-9.58	5.7e-20	3.58e-17	-0.45	-0.4	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
THCA	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-9.58	5.73e-20	3.6e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-9.58	5.73e-20	3.6e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
THCA	cis	rs4819052	0.807	rs1075788	ENSG00000215447.6	BX322557.10	-9.58	5.75e-20	3.61e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45288052~45291738:+
THCA	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	9.58	5.75e-20	3.61e-17	0.88	0.4	QT interval;	chr4:75134108	chr4:75081702~75084717:-
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	9.58	5.76e-20	3.62e-17	0.54	0.4	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
THCA	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-9.58	5.78e-20	3.62e-17	-0.45	-0.4	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
THCA	cis	rs17608059	0.611	rs2108591	ENSG00000141028.6	CDRT15P1	-9.58	5.8e-20	3.64e-17	-0.47	-0.4	Temperament;	chr17:14019308	chr17:14024514~14025488:+
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	9.58	5.8e-20	3.64e-17	0.54	0.4	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
THCA	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-9.58	5.83e-20	3.66e-17	-0.52	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
THCA	cis	rs853679	0.517	rs4713145	ENSG00000226314.6	ZNF192P1	-9.58	5.85e-20	3.67e-17	-0.54	-0.4	Depression;	chr6:28139049	chr6:28161781~28169594:+
THCA	cis	rs10411161	1	rs3764540	ENSG00000269483.1	AC006272.1	9.58	5.85e-20	3.67e-17	0.59	0.4	Breast cancer;	chr19:51877428	chr19:51839924~51843324:-
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	9.57	5.87e-20	3.68e-17	0.55	0.4	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	9.57	5.87e-20	3.68e-17	0.55	0.4	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	9.57	5.87e-20	3.68e-17	0.55	0.4	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
THCA	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-9.57	5.89e-20	3.69e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-9.57	5.89e-20	3.69e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
THCA	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	9.57	5.9e-20	3.7e-17	0.48	0.4	Height;	chr6:109693890	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	9.57	5.9e-20	3.7e-17	0.48	0.4	Height;	chr6:109694672	chr6:109382795~109383666:+
THCA	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	9.57	5.91e-20	3.7e-17	0.57	0.4	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
THCA	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	9.57	5.91e-20	3.71e-17	0.55	0.4	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	9.57	5.91e-20	3.71e-17	0.55	0.4	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	9.57	5.91e-20	3.71e-17	0.55	0.4	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
THCA	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	9.57	5.94e-20	3.72e-17	0.54	0.4	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	9.57	5.94e-20	3.72e-17	0.54	0.4	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
THCA	cis	rs944289	0.774	rs7147401	ENSG00000257826.1	RP11-116N8.4	-9.57	5.95e-20	3.73e-17	-0.42	-0.4	Thyroid cancer;	chr14:36089461	chr14:36061026~36067190:-
THCA	cis	rs944289	0.774	rs34081947	ENSG00000257826.1	RP11-116N8.4	-9.57	5.95e-20	3.73e-17	-0.42	-0.4	Thyroid cancer;	chr14:36090325	chr14:36061026~36067190:-
THCA	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-9.57	5.99e-20	3.75e-17	-0.44	-0.4	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
THCA	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-9.57	6e-20	3.76e-17	-0.82	-0.4	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	9.57	6.01e-20	3.76e-17	0.54	0.4	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	9.57	6.01e-20	3.76e-17	0.54	0.4	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	9.57	6.01e-20	3.77e-17	0.54	0.4	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
THCA	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-9.57	6.03e-20	3.77e-17	-0.51	-0.4	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
THCA	cis	rs67311347	0.577	rs2371129	ENSG00000223797.4	ENTPD3-AS1	-9.57	6.04e-20	3.78e-17	-0.33	-0.4	Renal cell carcinoma;	chr3:40206902	chr3:40313802~40453329:-
THCA	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	9.57	6.05e-20	3.79e-17	0.46	0.4	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-9.57	6.06e-20	3.8e-17	-0.45	-0.4	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
THCA	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-9.57	6.06e-20	3.8e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
THCA	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	9.57	6.08e-20	3.81e-17	0.45	0.4	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	9.57	6.08e-20	3.81e-17	0.45	0.4	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
THCA	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-9.57	6.11e-20	3.82e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
THCA	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	9.57	6.12e-20	3.83e-17	0.43	0.4	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
THCA	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	9.57	6.15e-20	3.85e-17	0.45	0.4	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	9.57	6.15e-20	3.85e-17	0.45	0.4	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
THCA	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	9.57	6.18e-20	3.87e-17	0.47	0.4	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
THCA	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	9.57	6.18e-20	3.87e-17	0.49	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
THCA	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-9.57	6.22e-20	3.89e-17	-0.56	-0.4	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-9.57	6.22e-20	3.89e-17	-0.56	-0.4	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
THCA	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	9.57	6.22e-20	3.89e-17	0.68	0.4	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
THCA	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
THCA	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-9.57	6.26e-20	3.91e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
THCA	cis	rs934734	0.532	rs1437466	ENSG00000234255.7	AC012370.3	-9.57	6.28e-20	3.93e-17	-0.44	-0.4	Rheumatoid arthritis;	chr2:65437216	chr2:65439888~65456571:-
THCA	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-9.57	6.28e-20	3.93e-17	-0.45	-0.4	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
THCA	cis	rs957448	0.698	rs116348949	ENSG00000253704.1	RP11-267M23.4	9.57	6.29e-20	3.93e-17	0.41	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94553722~94569745:+
THCA	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	9.57	6.31e-20	3.94e-17	0.47	0.4	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
THCA	cis	rs12550612	0.614	rs6983885	ENSG00000253616.4	RP11-875O11.3	9.57	6.33e-20	3.96e-17	0.57	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23087574	chr8:23071377~23074488:-
THCA	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-9.57	6.33e-20	3.96e-17	-0.56	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
THCA	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-9.57	6.33e-20	3.96e-17	-0.56	-0.4	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
THCA	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	9.57	6.35e-20	3.97e-17	0.61	0.4	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
THCA	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-9.56	6.35e-20	3.97e-17	-0.4	-0.4	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
THCA	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.36e-20	3.97e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.36e-20	3.97e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.36e-20	3.97e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
THCA	cis	rs853679	0.517	rs1904841	ENSG00000226314.6	ZNF192P1	-9.56	6.37e-20	3.98e-17	-0.55	-0.4	Depression;	chr6:28140307	chr6:28161781~28169594:+
THCA	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-9.56	6.38e-20	3.99e-17	-0.49	-0.4	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
THCA	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
THCA	cis	rs10411161	1	rs10402988	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51859851	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs2867318	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51860219	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs6509581	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51860629	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs8109345	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51861680	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs8108583	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51861724	chr19:51839924~51843324:-
THCA	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-9.56	6.41e-20	4e-17	-0.45	-0.4	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
THCA	cis	rs9659323	0.632	rs6658479	ENSG00000231365.4	RP11-418J17.1	-9.56	6.41e-20	4.01e-17	-0.39	-0.4	Body mass index;	chr1:119085233	chr1:119140396~119275973:+
THCA	cis	rs748404	0.518	rs2927085	ENSG00000205771.5	CATSPER2P1	-9.56	6.42e-20	4.01e-17	-0.43	-0.4	Lung cancer;	chr15:43697332	chr15:43726918~43747094:-
THCA	cis	rs4819052	0.684	rs914216	ENSG00000215447.6	BX322557.10	-9.56	6.44e-20	4.02e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	9.56	6.49e-20	4.05e-17	0.54	0.4	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
THCA	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-9.56	6.5e-20	4.06e-17	-0.49	-0.4	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
THCA	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	9.56	6.52e-20	4.07e-17	0.56	0.4	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
THCA	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.52e-20	4.07e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000226314.6	ZNF192P1	-9.56	6.57e-20	4.1e-17	-0.54	-0.4	Depression;	chr6:28096845	chr6:28161781~28169594:+
THCA	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-9.56	6.6e-20	4.12e-17	-0.5	-0.4	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
THCA	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-9.56	6.61e-20	4.12e-17	-0.51	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
THCA	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	9.56	6.62e-20	4.13e-17	0.55	0.4	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
THCA	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	9.56	6.64e-20	4.14e-17	0.56	0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
THCA	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-9.56	6.64e-20	4.14e-17	-0.56	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
THCA	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	9.56	6.66e-20	4.15e-17	0.45	0.4	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
THCA	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.69e-20	4.17e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.69e-20	4.17e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.69e-20	4.17e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.69e-20	4.17e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
THCA	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	9.56	6.72e-20	4.19e-17	0.52	0.4	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
THCA	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	9.56	6.75e-20	4.2e-17	0.37	0.4	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	9.56	6.75e-20	4.2e-17	0.37	0.4	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
THCA	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-9.56	6.75e-20	4.21e-17	-0.5	-0.4	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
THCA	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-9.56	6.76e-20	4.21e-17	-0.32	-0.4	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
THCA	cis	rs860295	0.812	rs3820594	ENSG00000225855.5	RUSC1-AS1	9.56	6.79e-20	4.23e-17	0.28	0.4	Body mass index;	chr1:155859720	chr1:155316863~155324176:-
THCA	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	9.56	6.8e-20	4.24e-17	0.45	0.4	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	9.56	6.8e-20	4.24e-17	0.45	0.4	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	9.56	6.8e-20	4.24e-17	0.45	0.4	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
THCA	cis	rs180730	0.519	rs2122511	ENSG00000251609.2	SETP12	9.56	6.8e-20	4.24e-17	0.56	0.4	Fasting plasma glucose;	chr4:120955639	chr4:120895494~120897083:-
THCA	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.81e-20	4.24e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
THCA	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-9.56	6.84e-20	4.26e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-9.56	6.85e-20	4.26e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
THCA	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-9.56	6.85e-20	4.27e-17	-0.58	-0.4	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
THCA	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	9.56	6.86e-20	4.27e-17	0.45	0.4	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
THCA	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	9.56	6.86e-20	4.27e-17	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
THCA	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	9.56	6.87e-20	4.28e-17	0.45	0.4	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
THCA	cis	rs73219805	0.838	rs7840859	ENSG00000228451.3	SDAD1P1	-9.56	6.88e-20	4.28e-17	-0.51	-0.4	Schizophrenia;	chr8:26377501	chr8:26379259~26382953:-
THCA	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-9.55	6.89e-20	4.29e-17	-0.52	-0.4	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
THCA	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-9.55	6.91e-20	4.3e-17	-0.56	-0.4	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
THCA	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	9.55	6.94e-20	4.32e-17	0.49	0.4	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
THCA	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	9.55	6.94e-20	4.32e-17	0.45	0.4	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
THCA	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-9.55	6.96e-20	4.33e-17	-0.45	-0.4	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-9.55	6.96e-20	4.33e-17	-0.45	-0.4	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-9.55	6.96e-20	4.33e-17	-0.45	-0.4	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
THCA	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-9.55	6.97e-20	4.34e-17	-0.45	-0.4	Height;	chr2:231543307	chr2:231508426~231514339:-
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000215447.6	BX322557.10	-9.55	6.98e-20	4.34e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45288052~45291738:+
THCA	cis	rs1799949	0.827	rs74252763	ENSG00000267681.1	CTD-3199J23.6	-9.55	7.03e-20	4.37e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43324652	chr17:43144956~43145255:+
THCA	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-9.55	7.05e-20	4.39e-17	-0.49	-0.4	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
THCA	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-9.55	7.05e-20	4.39e-17	-0.72	-0.4	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
THCA	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	9.55	7.09e-20	4.41e-17	0.45	0.4	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
THCA	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	9.55	7.12e-20	4.43e-17	0.46	0.4	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
THCA	cis	rs1858037	0.867	rs953312	ENSG00000281920.1	RP11-418H16.1	9.55	7.12e-20	4.43e-17	0.54	0.4	Rheumatoid arthritis;	chr2:65340556	chr2:65623272~65628424:+
THCA	cis	rs1858037	0.867	rs9789444	ENSG00000281920.1	RP11-418H16.1	9.55	7.12e-20	4.43e-17	0.54	0.4	Rheumatoid arthritis;	chr2:65342093	chr2:65623272~65628424:+
THCA	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-9.55	7.15e-20	4.45e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
THCA	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-9.55	7.15e-20	4.45e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
THCA	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	9.55	7.19e-20	4.47e-17	0.57	0.4	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
THCA	cis	rs11696845	0.787	rs6031771	ENSG00000276223.1	RP4-781B1.5	-9.55	7.19e-20	4.47e-17	-0.49	-0.4	Obesity-related traits;	chr20:44734949	chr20:44746642~44747201:+
THCA	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	9.55	7.2e-20	4.47e-17	0.55	0.4	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	9.55	7.2e-20	4.47e-17	0.55	0.4	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000235689.1	AP000351.13	9.55	7.2e-20	4.48e-17	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:24006305~24008258:-
THCA	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	9.55	7.33e-20	4.55e-17	0.45	0.4	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	9.55	7.33e-20	4.55e-17	0.45	0.4	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	9.55	7.33e-20	4.55e-17	0.45	0.4	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
THCA	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-9.55	7.33e-20	4.56e-17	-0.67	-0.4	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
THCA	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	9.55	7.35e-20	4.57e-17	0.88	0.4	QT interval;	chr4:75124631	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	9.55	7.35e-20	4.57e-17	0.88	0.4	QT interval;	chr4:75125677	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	9.55	7.35e-20	4.57e-17	0.88	0.4	QT interval;	chr4:75125682	chr4:75081702~75084717:-
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000215447.6	BX322557.10	9.55	7.36e-20	4.57e-17	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45288052~45291738:+
THCA	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-9.55	7.37e-20	4.58e-17	-0.45	-0.4	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
THCA	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-9.55	7.39e-20	4.59e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
THCA	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-9.55	7.4e-20	4.6e-17	-0.46	-0.4	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
THCA	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-9.55	7.41e-20	4.6e-17	-0.56	-0.4	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-9.55	7.41e-20	4.6e-17	-0.56	-0.4	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-9.55	7.41e-20	4.6e-17	-0.56	-0.4	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-9.55	7.41e-20	4.6e-17	-0.56	-0.4	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
THCA	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	9.55	7.42e-20	4.61e-17	0.45	0.4	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
THCA	cis	rs860295	0.812	rs4278368	ENSG00000225855.5	RUSC1-AS1	9.55	7.46e-20	4.63e-17	0.28	0.4	Body mass index;	chr1:155752766	chr1:155316863~155324176:-
THCA	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-9.54	7.52e-20	4.67e-17	-0.54	-0.4	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
THCA	cis	rs673078	0.66	rs73205551	ENSG00000275409.1	RP11-131L12.4	-9.54	7.57e-20	4.7e-17	-0.43	-0.4	Glucose homeostasis traits;	chr12:118330808	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	9.54	7.58e-20	4.7e-17	0.54	0.4	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000215447.6	BX322557.10	-9.54	7.59e-20	4.71e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000215447.6	BX322557.10	-9.54	7.59e-20	4.71e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45288052~45291738:+
THCA	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-9.54	7.59e-20	4.71e-17	-0.56	-0.4	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
THCA	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
THCA	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-9.54	7.66e-20	4.75e-17	-0.56	-0.4	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-9.54	7.66e-20	4.75e-17	-0.56	-0.4	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-9.54	7.66e-20	4.75e-17	-0.56	-0.4	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-9.54	7.66e-20	4.75e-17	-0.56	-0.4	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000215447.6	BX322557.10	-9.54	7.66e-20	4.75e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45288052~45291738:+
THCA	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	-9.54	7.68e-20	4.76e-17	-0.54	-0.4	Depression;	chr6:28159666	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	-9.54	7.68e-20	4.76e-17	-0.54	-0.4	Depression;	chr6:28162598	chr6:28161781~28169594:+
THCA	cis	rs860295	0.812	rs11264413	ENSG00000225855.5	RUSC1-AS1	9.54	7.69e-20	4.77e-17	0.28	0.4	Body mass index;	chr1:155818865	chr1:155316863~155324176:-
THCA	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	9.54	7.7e-20	4.77e-17	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000266490.1	CTD-2349P21.9	9.54	7.7e-20	4.78e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30792372~30792833:+
THCA	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	9.54	7.72e-20	4.79e-17	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
THCA	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	9.54	7.73e-20	4.79e-17	0.5	0.4	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
THCA	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	9.54	7.74e-20	4.8e-17	0.7	0.4	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
THCA	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-9.54	7.76e-20	4.81e-17	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-9.54	7.76e-20	4.81e-17	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-9.54	7.76e-20	4.81e-17	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	9.54	7.81e-20	4.84e-17	0.54	0.4	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
THCA	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	9.54	7.84e-20	4.86e-17	0.54	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	9.54	7.85e-20	4.86e-17	0.54	0.4	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
THCA	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-9.54	7.87e-20	4.88e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
THCA	cis	rs2033711	0.87	rs11084545	ENSG00000268912.1	CTD-2619J13.17	-9.54	7.88e-20	4.88e-17	-0.31	-0.4	Uric acid clearance;	chr19:58440326	chr19:58428632~58431148:-
THCA	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-9.54	7.89e-20	4.89e-17	-0.32	-0.4	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
THCA	cis	rs9926296	0.682	rs258328	ENSG00000260259.1	RP11-368I7.4	9.54	7.89e-20	4.89e-17	0.45	0.4	Vitiligo;	chr16:89663906	chr16:89682620~89686569:-
THCA	cis	rs62158211	0.955	rs7556815	ENSG00000272563.1	RP11-480C16.1	-9.54	7.9e-20	4.89e-17	-0.54	-0.4	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr2:113432600~113436042:+
THCA	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-9.54	7.91e-20	4.9e-17	-0.56	-0.4	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-9.54	7.91e-20	4.9e-17	-0.56	-0.4	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
THCA	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	-9.54	7.91e-20	4.9e-17	-0.54	-0.4	Depression;	chr6:28140454	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	-9.54	7.91e-20	4.9e-17	-0.54	-0.4	Depression;	chr6:28141189	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	-9.54	7.91e-20	4.9e-17	-0.54	-0.4	Depression;	chr6:28141484	chr6:28161781~28169594:+
THCA	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-9.54	7.93e-20	4.91e-17	-0.56	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
THCA	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	9.54	7.93e-20	4.91e-17	0.51	0.4	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	-9.54	7.99e-20	4.94e-17	-0.54	-0.4	Depression;	chr6:28151096	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	-9.54	7.99e-20	4.94e-17	-0.54	-0.4	Depression;	chr6:28152885	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	-9.54	7.99e-20	4.94e-17	-0.54	-0.4	Depression;	chr6:28153120	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	-9.54	7.99e-20	4.94e-17	-0.54	-0.4	Depression;	chr6:28161802	chr6:28161781~28169594:+
THCA	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-9.54	8e-20	4.95e-17	-0.43	-0.4	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
THCA	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	-9.54	8e-20	4.95e-17	-0.54	-0.4	Depression;	chr6:28145952	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	-9.54	8e-20	4.95e-17	-0.54	-0.4	Depression;	chr6:28147378	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	-9.54	8e-20	4.95e-17	-0.54	-0.4	Depression;	chr6:28147406	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	-9.54	8e-20	4.95e-17	-0.54	-0.4	Depression;	chr6:28148143	chr6:28161781~28169594:+
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
THCA	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-9.54	8.01e-20	4.95e-17	-0.31	-0.4	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
THCA	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-9.54	8.03e-20	4.97e-17	-0.32	-0.4	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	9.54	8.05e-20	4.98e-17	0.54	0.4	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
THCA	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	9.53	8.11e-20	5.02e-17	0.32	0.4	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	9.53	8.12e-20	5.02e-17	0.54	0.4	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	9.53	8.15e-20	5.04e-17	0.54	0.4	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	9.53	8.15e-20	5.04e-17	0.54	0.4	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	9.53	8.16e-20	5.05e-17	0.54	0.4	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
THCA	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	9.53	8.17e-20	5.05e-17	0.55	0.4	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
THCA	cis	rs3743772	0.5	rs4784308	ENSG00000279722.1	RP11-44F14.6	9.53	8.17e-20	5.05e-17	0.54	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53406387	chr16:53487607~53489943:-
THCA	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-9.53	8.19e-20	5.07e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-9.53	8.19e-20	5.07e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
THCA	cis	rs7569084	1	rs7583469	ENSG00000234255.7	AC012370.3	9.53	8.23e-20	5.09e-17	0.45	0.4	Sum eosinophil basophil counts;	chr2:65424222	chr2:65439888~65456571:-
THCA	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-9.53	8.24e-20	5.09e-17	-0.31	-0.4	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
THCA	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	9.53	8.29e-20	5.12e-17	0.55	0.4	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
THCA	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	9.53	8.33e-20	5.15e-17	0.49	0.4	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
THCA	cis	rs7615952	0.866	rs6438949	ENSG00000171084.14	FAM86JP	9.53	8.34e-20	5.15e-17	0.55	0.4	Blood pressure (smoking interaction);	chr3:125931221	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	9.53	8.38e-20	5.18e-17	0.54	0.4	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
THCA	cis	rs7727544	0.716	rs7701414	ENSG00000237714.1	P4HA2-AS1	9.53	8.47e-20	5.23e-17	0.53	0.4	Blood metabolite levels;	chr5:132250265	chr5:132184876~132192808:+
THCA	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-9.53	8.48e-20	5.24e-17	-0.48	-0.4	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
THCA	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-9.53	8.5e-20	5.25e-17	-0.39	-0.4	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	9.53	8.51e-20	5.25e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000266490.1	CTD-2349P21.9	9.53	8.51e-20	5.25e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30792372~30792833:+
THCA	cis	rs860295	0.812	rs12024257	ENSG00000225855.5	RUSC1-AS1	9.53	8.52e-20	5.26e-17	0.28	0.4	Body mass index;	chr1:155810745	chr1:155316863~155324176:-
THCA	cis	rs860295	0.812	rs6657670	ENSG00000225855.5	RUSC1-AS1	9.53	8.52e-20	5.26e-17	0.28	0.4	Body mass index;	chr1:155818076	chr1:155316863~155324176:-
THCA	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-9.53	8.53e-20	5.27e-17	-0.31	-0.4	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000215447.6	BX322557.10	-9.53	8.53e-20	5.27e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45288052~45291738:+
THCA	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	9.53	8.54e-20	5.27e-17	0.54	0.4	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
THCA	cis	rs11159086	1	rs11159087	ENSG00000270000.1	RP3-449M8.9	9.53	8.55e-20	5.28e-17	0.43	0.4	Advanced glycation end-product levels;	chr14:74504671	chr14:74471930~74472360:-
THCA	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	9.53	8.59e-20	5.3e-17	0.45	0.4	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
THCA	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-9.53	8.62e-20	5.32e-17	-0.48	-0.4	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
THCA	cis	rs9532669	0.926	rs4941995	ENSG00000239827.7	SUGT1P3	-9.53	8.64e-20	5.33e-17	-0.45	-0.4	Cervical cancer;	chr13:40850117	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9315789	ENSG00000239827.7	SUGT1P3	-9.53	8.64e-20	5.33e-17	-0.45	-0.4	Cervical cancer;	chr13:40852898	chr13:40908159~40921774:-
THCA	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	9.53	8.69e-20	5.36e-17	0.45	0.4	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
THCA	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-9.53	8.73e-20	5.39e-17	-0.5	-0.4	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-9.53	8.73e-20	5.39e-17	-0.5	-0.4	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	9.53	8.73e-20	5.39e-17	0.47	0.4	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
THCA	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	9.53	8.73e-20	5.39e-17	0.47	0.4	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
THCA	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	9.53	8.74e-20	5.39e-17	0.33	0.4	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
THCA	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-9.53	8.76e-20	5.41e-17	-0.53	-0.4	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
THCA	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	9.53	8.77e-20	5.41e-17	0.47	0.4	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	9.52	8.82e-20	5.44e-17	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
THCA	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-9.52	8.84e-20	5.45e-17	-0.48	-0.4	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-9.52	8.84e-20	5.45e-17	-0.49	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
THCA	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	9.52	8.84e-20	5.46e-17	0.36	0.4	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
THCA	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-9.52	8.86e-20	5.47e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
THCA	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-9.52	8.87e-20	5.47e-17	-0.37	-0.4	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.851	rs914214	ENSG00000215447.6	BX322557.10	-9.52	8.89e-20	5.48e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45288052~45291738:+
THCA	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	9.52	8.94e-20	5.52e-17	0.39	0.4	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45288052~45291738:+
THCA	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	9.52	8.96e-20	5.53e-17	0.46	0.4	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
THCA	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-9.52	8.98e-20	5.54e-17	-0.49	-0.4	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
THCA	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	9.52	8.99e-20	5.54e-17	0.76	0.4	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
THCA	cis	rs7191700	0.712	rs7187741	ENSG00000262703.1	RP11-485G7.6	-9.52	9.01e-20	5.55e-17	-0.45	-0.4	Multiple sclerosis;	chr16:11339246	chr16:11348143~11349321:-
THCA	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-9.52	9.01e-20	5.55e-17	-0.53	-0.4	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
THCA	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-9.52	9.01e-20	5.55e-17	-0.38	-0.4	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
THCA	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	9.52	9.02e-20	5.56e-17	0.59	0.4	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
THCA	cis	rs11051970	0.559	rs3748276	ENSG00000274964.1	RP11-817I4.1	-9.52	9.05e-20	5.58e-17	-0.51	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32328643	chr12:32339368~32340724:+
THCA	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-9.52	9.06e-20	5.58e-17	-0.46	-0.4	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
THCA	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	9.52	9.06e-20	5.58e-17	0.68	0.4	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
THCA	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	9.52	9.08e-20	5.59e-17	0.47	0.4	Height;	chr6:109490935	chr6:109382795~109383666:+
THCA	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	9.52	9.09e-20	5.6e-17	0.37	0.4	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
THCA	cis	rs4964805	0.865	rs3935416	ENSG00000257681.1	RP11-341G23.4	9.52	9.1e-20	5.61e-17	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103813177	chr12:103746315~103768858:-
THCA	cis	rs934734	0.532	rs10166100	ENSG00000234255.7	AC012370.3	-9.52	9.13e-20	5.62e-17	-0.45	-0.4	Rheumatoid arthritis;	chr2:65418616	chr2:65439888~65456571:-
THCA	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-9.52	9.14e-20	5.63e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-9.52	9.14e-20	5.63e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-9.52	9.14e-20	5.63e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-9.52	9.14e-20	5.63e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
THCA	cis	rs916888	0.821	rs199505	ENSG00000232300.1	FAM215B	-9.52	9.16e-20	5.64e-17	-0.64	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46558830~46562795:-
THCA	cis	rs916888	0.821	rs70602	ENSG00000232300.1	FAM215B	-9.52	9.16e-20	5.64e-17	-0.64	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46558830~46562795:-
THCA	cis	rs934734	0.532	rs2860773	ENSG00000234255.7	AC012370.3	-9.52	9.18e-20	5.65e-17	-0.44	-0.4	Rheumatoid arthritis;	chr2:65438507	chr2:65439888~65456571:-
THCA	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	9.52	9.19e-20	5.66e-17	0.49	0.4	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
THCA	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	9.52	9.19e-20	5.66e-17	0.55	0.4	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	9.52	9.19e-20	5.66e-17	0.55	0.4	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
THCA	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-9.52	9.2e-20	5.66e-17	-0.6	-0.4	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
THCA	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	9.52	9.23e-20	5.69e-17	0.54	0.4	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
THCA	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	9.52	9.29e-20	5.72e-17	0.51	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	9.52	9.3e-20	5.72e-17	0.47	0.4	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
THCA	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-9.52	9.3e-20	5.73e-17	-0.55	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
THCA	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	9.52	9.32e-20	5.74e-17	0.44	0.4	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
THCA	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	9.52	9.35e-20	5.75e-17	0.29	0.4	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
THCA	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	9.52	9.41e-20	5.79e-17	0.39	0.4	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
THCA	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-9.52	9.41e-20	5.79e-17	-0.55	-0.4	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
THCA	cis	rs1858037	0.836	rs17475335	ENSG00000281920.1	RP11-418H16.1	9.52	9.42e-20	5.8e-17	0.53	0.4	Rheumatoid arthritis;	chr2:65378646	chr2:65623272~65628424:+
THCA	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
THCA	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-9.52	9.46e-20	5.82e-17	-0.53	-0.4	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
THCA	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-9.51	9.53e-20	5.86e-17	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
THCA	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-9.51	9.55e-20	5.88e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45288052~45291738:+
THCA	cis	rs4591358	0.773	rs13002794	ENSG00000223466.1	AC064834.2	-9.51	9.64e-20	5.93e-17	-0.55	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195517175	chr2:195533035~195538681:+
THCA	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	9.51	9.69e-20	5.96e-17	0.5	0.4	Height;	chr11:118856460	chr11:118688039~118690600:-
THCA	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	9.51	9.69e-20	5.96e-17	0.5	0.4	Height;	chr11:118856623	chr11:118688039~118690600:-
THCA	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	9.51	9.69e-20	5.96e-17	0.5	0.4	Height;	chr11:118857611	chr11:118688039~118690600:-
THCA	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-9.51	9.72e-20	5.97e-17	-0.55	-0.4	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-9.51	9.72e-20	5.97e-17	-0.55	-0.4	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-9.51	9.72e-20	5.97e-17	-0.55	-0.4	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
THCA	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	9.51	9.73e-20	5.98e-17	0.45	0.4	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
THCA	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-9.51	9.83e-20	6.04e-17	-0.56	-0.4	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
THCA	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	9.51	9.84e-20	6.05e-17	0.65	0.4	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
THCA	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	9.51	9.85e-20	6.05e-17	0.45	0.4	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
THCA	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-9.51	9.86e-20	6.06e-17	-0.49	-0.4	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
THCA	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-9.51	9.89e-20	6.08e-17	-0.37	-0.4	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
THCA	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	9.51	9.92e-20	6.1e-17	0.59	0.4	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
THCA	cis	rs12931792	0.782	rs13331817	ENSG00000183604.13	SMG1P5	9.51	9.93e-20	6.1e-17	0.43	0.4	Tonsillectomy;	chr16:30161306	chr16:30267553~30335374:-
THCA	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-9.51	9.96e-20	6.12e-17	-0.48	-0.4	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
THCA	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	9.51	9.97e-20	6.13e-17	0.45	0.4	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
THCA	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	9.51	9.98e-20	6.13e-17	0.54	0.4	Depression;	chr6:28109824	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	-9.51	1e-19	6.15e-17	-0.54	-0.4	Depression;	chr6:28149979	chr6:28161781~28169594:+
THCA	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	9.51	1e-19	6.16e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
THCA	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	9.51	1e-19	6.16e-17	0.45	0.4	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
THCA	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	9.51	1e-19	6.16e-17	0.44	0.4	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
THCA	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-9.51	1.01e-19	6.17e-17	-0.52	-0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	9.51	1.01e-19	6.2e-17	0.38	0.4	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	9.51	1.01e-19	6.22e-17	0.54	0.4	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
THCA	cis	rs4819052	0.84	rs914217	ENSG00000215447.6	BX322557.10	-9.51	1.01e-19	6.23e-17	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45288052~45291738:+
THCA	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	9.51	1.01e-19	6.23e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000266490.1	CTD-2349P21.9	9.51	1.02e-19	6.25e-17	0.56	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30792372~30792833:+
THCA	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-9.51	1.02e-19	6.26e-17	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
THCA	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-9.51	1.02e-19	6.29e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
THCA	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-9.51	1.03e-19	6.3e-17	-0.5	-0.4	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
THCA	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	9.51	1.03e-19	6.3e-17	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
THCA	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-9.51	1.03e-19	6.31e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
THCA	cis	rs4819052	0.851	rs2236444	ENSG00000215447.6	BX322557.10	-9.51	1.03e-19	6.31e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45288052~45291738:+
THCA	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-9.51	1.03e-19	6.31e-17	-0.53	-0.4	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
THCA	cis	rs6496932	0.865	rs4843049	ENSG00000218052.5	ADAMTS7P4	9.51	1.03e-19	6.32e-17	0.59	0.4	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85255369~85330334:-
THCA	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	9.5	1.03e-19	6.34e-17	0.53	0.4	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-9.5	1.03e-19	6.34e-17	-0.56	-0.4	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	9.5	1.03e-19	6.34e-17	0.54	0.4	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
THCA	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	9.5	1.03e-19	6.35e-17	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
THCA	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-9.5	1.04e-19	6.35e-17	-0.52	-0.4	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
THCA	cis	rs934734	0.532	rs10153675	ENSG00000234255.7	AC012370.3	-9.5	1.04e-19	6.36e-17	-0.45	-0.4	Rheumatoid arthritis;	chr2:65422446	chr2:65439888~65456571:-
THCA	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-9.5	1.04e-19	6.38e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-9.5	1.04e-19	6.38e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
THCA	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	9.5	1.04e-19	6.38e-17	0.43	0.4	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
THCA	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-9.5	1.04e-19	6.39e-17	-0.46	-0.4	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-9.5	1.04e-19	6.39e-17	-0.46	-0.4	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-9.5	1.04e-19	6.39e-17	-0.46	-0.4	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
THCA	cis	rs180730	0.519	rs2892920	ENSG00000251609.2	SETP12	9.5	1.04e-19	6.4e-17	0.56	0.4	Fasting plasma glucose;	chr4:120953389	chr4:120895494~120897083:-
THCA	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-9.5	1.05e-19	6.46e-17	-0.55	-0.4	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
THCA	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-9.5	1.06e-19	6.49e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
THCA	cis	rs9926296	0.687	rs258317	ENSG00000260259.1	RP11-368I7.4	9.5	1.06e-19	6.49e-17	0.45	0.4	Vitiligo;	chr16:89665830	chr16:89682620~89686569:-
THCA	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	9.5	1.06e-19	6.5e-17	0.45	0.4	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
THCA	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-9.5	1.06e-19	6.5e-17	-0.42	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
THCA	cis	rs7727544	0.678	rs7735891	ENSG00000237714.1	P4HA2-AS1	9.5	1.06e-19	6.51e-17	0.53	0.4	Blood metabolite levels;	chr5:132261312	chr5:132184876~132192808:+
THCA	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	9.5	1.06e-19	6.52e-17	0.29	0.4	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
THCA	cis	rs11051970	0.559	rs2270786	ENSG00000274964.1	RP11-817I4.1	-9.5	1.06e-19	6.52e-17	-0.53	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32337830	chr12:32339368~32340724:+
THCA	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-9.5	1.06e-19	6.52e-17	-0.32	-0.4	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
THCA	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	9.5	1.07e-19	6.53e-17	0.49	0.4	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
THCA	cis	rs1537424	0.513	rs1333313	ENSG00000257826.1	RP11-116N8.4	-9.5	1.07e-19	6.54e-17	-0.47	-0.4	Thyroid hormone levels;	chr14:36093440	chr14:36061026~36067190:-
THCA	cis	rs11148252	0.774	rs7334583	ENSG00000278238.1	RP11-245D16.4	9.5	1.07e-19	6.54e-17	0.44	0.4	Lewy body disease;	chr13:52356217	chr13:52454775~52455331:-
THCA	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-9.5	1.07e-19	6.55e-17	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
THCA	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-9.5	1.07e-19	6.57e-17	-0.56	-0.4	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
THCA	cis	rs4842666	0.915	rs11105376	ENSG00000258302.2	RP11-981P6.1	9.5	1.08e-19	6.6e-17	0.4	0.4	Blood pressure;	chr12:89694991	chr12:89561129~89594878:+
THCA	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	9.5	1.08e-19	6.63e-17	0.48	0.4	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
THCA	cis	rs7221109	0.921	rs4890117	ENSG00000278834.1	RP11-458J1.1	9.5	1.08e-19	6.63e-17	0.43	0.4	Type 1 diabetes;	chr17:40622236	chr17:40648300~40649718:+
THCA	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-9.5	1.08e-19	6.64e-17	-0.49	-0.4	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
THCA	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	9.5	1.09e-19	6.65e-17	0.37	0.4	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
THCA	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	9.5	1.09e-19	6.66e-17	0.45	0.4	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
THCA	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	9.5	1.09e-19	6.66e-17	0.45	0.4	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	9.5	1.09e-19	6.66e-17	0.45	0.4	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	9.5	1.09e-19	6.66e-17	0.45	0.4	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
THCA	cis	rs4819052	1	rs9306123	ENSG00000215447.6	BX322557.10	-9.5	1.09e-19	6.67e-17	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45288052~45291738:+
THCA	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	9.5	1.09e-19	6.68e-17	0.52	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
THCA	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	9.5	1.09e-19	6.69e-17	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
THCA	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-9.5	1.09e-19	6.69e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
THCA	cis	rs62103177	0.564	rs11874805	ENSG00000261126.6	RP11-795F19.1	9.5	1.09e-19	6.69e-17	0.44	0.4	Opioid sensitivity;	chr18:79937110	chr18:80046900~80095482:+
THCA	cis	rs3743772	0.5	rs9924562	ENSG00000279722.1	RP11-44F14.6	9.5	1.09e-19	6.69e-17	0.54	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53487607~53489943:-
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000215447.6	BX322557.10	-9.5	1.09e-19	6.7e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45288052~45291738:+
THCA	cis	rs10740039	0.883	rs7068934	ENSG00000254271.1	RP11-131N11.4	9.5	1.1e-19	6.74e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636490	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10740038	ENSG00000254271.1	RP11-131N11.4	9.5	1.1e-19	6.74e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643479	chr10:60734342~60741828:+
THCA	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	9.5	1.1e-19	6.75e-17	0.47	0.4	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
THCA	cis	rs7829975	0.533	rs35900578	ENSG00000253893.2	FAM85B	-9.5	1.11e-19	6.77e-17	-0.53	-0.4	Mood instability;	chr8:8862003	chr8:8167819~8226614:-
THCA	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	9.5	1.11e-19	6.78e-17	0.68	0.4	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
THCA	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	9.5	1.11e-19	6.81e-17	0.52	0.4	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
THCA	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	9.5	1.11e-19	6.81e-17	0.76	0.4	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
THCA	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-9.49	1.12e-19	6.85e-17	-0.49	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
THCA	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-9.49	1.13e-19	6.91e-17	-0.54	-0.4	QT interval;	chr16:28884339	chr16:28700294~28701540:-
THCA	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	9.49	1.14e-19	6.95e-17	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
THCA	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	9.49	1.14e-19	6.95e-17	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
THCA	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-9.49	1.14e-19	6.95e-17	-0.48	-0.4	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
THCA	cis	rs934734	0.532	rs13383320	ENSG00000234255.7	AC012370.3	-9.49	1.14e-19	6.97e-17	-0.44	-0.4	Rheumatoid arthritis;	chr2:65418003	chr2:65439888~65456571:-
THCA	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-9.49	1.14e-19	6.99e-17	-0.52	-0.4	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
THCA	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	9.49	1.15e-19	7.01e-17	0.55	0.4	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	9.49	1.15e-19	7.01e-17	0.55	0.4	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
THCA	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-9.49	1.15e-19	7.02e-17	-0.55	-0.4	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-9.49	1.16e-19	7.06e-17	-0.57	-0.4	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
THCA	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	9.49	1.16e-19	7.07e-17	0.55	0.4	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
THCA	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-9.49	1.16e-19	7.08e-17	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-9.49	1.16e-19	7.08e-17	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
THCA	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	9.49	1.16e-19	7.09e-17	0.45	0.4	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
THCA	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28154567	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28156691	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28158424	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28159056	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28159925	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28159932	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28162053	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28163375	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28163759	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28164580	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28164825	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28164948	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28165025	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28165528	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28169019	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28169249	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28169755	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28169791	chr6:28161781~28169594:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28170075	chr6:28161781~28169594:+
THCA	cis	rs9926296	0.744	rs154656	ENSG00000260259.1	RP11-368I7.4	9.49	1.16e-19	7.11e-17	0.43	0.4	Vitiligo;	chr16:89641595	chr16:89682620~89686569:-
THCA	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	9.49	1.16e-19	7.11e-17	0.52	0.4	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
THCA	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-9.49	1.17e-19	7.12e-17	-0.29	-0.4	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
THCA	cis	rs916888	0.821	rs199504	ENSG00000232300.1	FAM215B	-9.49	1.17e-19	7.13e-17	-0.64	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46558830~46562795:-
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000266490.1	CTD-2349P21.9	9.49	1.17e-19	7.16e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000266490.1	CTD-2349P21.9	9.49	1.17e-19	7.16e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30792372~30792833:+
THCA	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-9.49	1.18e-19	7.2e-17	-0.34	-0.4	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
THCA	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-9.49	1.19e-19	7.24e-17	-0.56	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
THCA	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	9.49	1.19e-19	7.26e-17	0.44	0.4	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
THCA	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	9.49	1.19e-19	7.28e-17	0.37	0.4	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	9.49	1.19e-19	7.29e-17	0.46	0.4	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
THCA	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	9.49	1.2e-19	7.31e-17	0.45	0.4	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	9.49	1.2e-19	7.31e-17	0.45	0.4	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
THCA	cis	rs7727544	0.716	rs2089855	ENSG00000237714.1	P4HA2-AS1	9.49	1.2e-19	7.34e-17	0.54	0.4	Blood metabolite levels;	chr5:132237836	chr5:132184876~132192808:+
THCA	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-9.48	1.22e-19	7.42e-17	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
THCA	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-9.48	1.22e-19	7.44e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
THCA	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	9.48	1.22e-19	7.44e-17	0.53	0.4	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
THCA	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
THCA	cis	rs4819052	0.851	rs875621	ENSG00000215447.6	BX322557.10	-9.48	1.22e-19	7.46e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45288052~45291738:+
THCA	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-9.48	1.22e-19	7.46e-17	-0.32	-0.4	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
THCA	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-9.48	1.23e-19	7.46e-17	-0.46	-0.4	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-9.48	1.23e-19	7.47e-17	-0.46	-0.4	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
THCA	cis	rs9402743	0.632	rs9399167	ENSG00000231028.7	LINC00271	-9.48	1.23e-19	7.47e-17	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135792678	chr6:135497801~135716055:+
THCA	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-9.48	1.23e-19	7.49e-17	-0.31	-0.4	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
THCA	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-9.48	1.24e-19	7.54e-17	-0.32	-0.4	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-9.48	1.24e-19	7.54e-17	-0.32	-0.4	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
THCA	cis	rs944289	0.74	rs950319	ENSG00000257826.1	RP11-116N8.4	-9.48	1.24e-19	7.55e-17	-0.41	-0.4	Thyroid cancer;	chr14:36096786	chr14:36061026~36067190:-
THCA	cis	rs11051970	0.559	rs11051932	ENSG00000274964.1	RP11-817I4.1	-9.48	1.24e-19	7.57e-17	-0.5	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32320701	chr12:32339368~32340724:+
THCA	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	9.48	1.25e-19	7.6e-17	0.71	0.4	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
THCA	cis	rs7569084	0.566	rs7584295	ENSG00000204929.10	AC074391.1	9.48	1.25e-19	7.61e-17	0.52	0.4	Sum eosinophil basophil counts;	chr2:65353940	chr2:65436711~66084639:+
THCA	cis	rs934734	0.563	rs11695373	ENSG00000204929.10	AC074391.1	9.48	1.25e-19	7.61e-17	0.52	0.4	Rheumatoid arthritis;	chr2:65354066	chr2:65436711~66084639:+
THCA	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	-9.48	1.25e-19	7.61e-17	-0.54	-0.4	Depression;	chr6:28169676	chr6:28161781~28169594:+
THCA	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-9.48	1.25e-19	7.64e-17	-0.3	-0.4	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
THCA	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	-9.48	1.26e-19	7.65e-17	-0.54	-0.4	Depression;	chr6:28131566	chr6:28161781~28169594:+
THCA	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-9.48	1.26e-19	7.66e-17	-0.48	-0.4	Height;	chr6:109636120	chr6:109382795~109383666:+
THCA	cis	rs6496932	0.865	rs4842874	ENSG00000218052.5	ADAMTS7P4	9.48	1.26e-19	7.67e-17	0.58	0.4	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85255369~85330334:-
THCA	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-9.48	1.27e-19	7.74e-17	-0.45	-0.4	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
THCA	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	9.48	1.27e-19	7.75e-17	0.48	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	9.48	1.27e-19	7.75e-17	0.48	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
THCA	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-9.48	1.28e-19	7.78e-17	-0.55	-0.4	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
THCA	cis	rs11051970	0.559	rs11051925	ENSG00000274964.1	RP11-817I4.1	-9.48	1.28e-19	7.81e-17	-0.51	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32314860	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs10431283	ENSG00000274964.1	RP11-817I4.1	-9.48	1.28e-19	7.81e-17	-0.51	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32315070	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs10431225	ENSG00000274964.1	RP11-817I4.1	-9.48	1.28e-19	7.81e-17	-0.51	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32315177	chr12:32339368~32340724:+
THCA	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-9.48	1.28e-19	7.81e-17	-0.3	-0.4	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
THCA	cis	rs4380275	0.782	rs4335978	ENSG00000272342.1	RP13-539J13.1	9.48	1.29e-19	7.83e-17	0.48	0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:739588~740164:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	9.48	1.31e-19	7.96e-17	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
THCA	cis	rs853679	0.513	rs13437444	ENSG00000280107.1	AL022393.9	-9.48	1.31e-19	7.97e-17	-0.54	-0.4	Depression;	chr6:28103220	chr6:28170845~28172521:+
THCA	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-9.48	1.31e-19	7.98e-17	-0.55	-0.4	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-9.48	1.31e-19	7.98e-17	-0.55	-0.4	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
THCA	cis	rs934734	0.532	rs12185610	ENSG00000234255.7	AC012370.3	-9.47	1.31e-19	7.99e-17	-0.44	-0.4	Rheumatoid arthritis;	chr2:65434334	chr2:65439888~65456571:-
THCA	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
THCA	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-9.47	1.32e-19	8.03e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
THCA	cis	rs934734	0.563	rs1858037	ENSG00000204929.10	AC074391.1	9.47	1.32e-19	8.03e-17	0.52	0.4	Rheumatoid arthritis;	chr2:65371166	chr2:65436711~66084639:+
THCA	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-9.47	1.32e-19	8.03e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
THCA	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	9.47	1.32e-19	8.04e-17	0.49	0.4	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	9.47	1.32e-19	8.04e-17	0.49	0.4	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	9.47	1.33e-19	8.05e-17	0.49	0.4	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
THCA	cis	rs4819052	1	rs2297286	ENSG00000215447.6	BX322557.10	-9.47	1.33e-19	8.08e-17	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45288052~45291738:+
THCA	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-9.47	1.33e-19	8.1e-17	-0.55	-0.4	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000224205.1	AP000351.4	9.47	1.34e-19	8.14e-17	0.47	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23987320~23991421:-
THCA	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	9.47	1.34e-19	8.17e-17	0.45	0.4	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
THCA	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	9.47	1.35e-19	8.18e-17	0.37	0.4	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
THCA	cis	rs4591358	0.773	rs35785148	ENSG00000223466.1	AC064834.2	-9.47	1.35e-19	8.21e-17	-0.55	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195516751	chr2:195533035~195538681:+
THCA	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	9.47	1.36e-19	8.25e-17	0.28	0.4	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.573	rs7187575	ENSG00000251417.2	RP11-1348G14.4	9.47	1.36e-19	8.28e-17	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28802743~28817828:+
THCA	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-9.47	1.36e-19	8.28e-17	-0.36	-0.4	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-9.47	1.36e-19	8.28e-17	-0.36	-0.4	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-9.47	1.36e-19	8.28e-17	-0.36	-0.4	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
THCA	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	9.47	1.37e-19	8.29e-17	0.71	0.4	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-9.47	1.37e-19	8.3e-17	-0.29	-0.4	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
THCA	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-9.47	1.38e-19	8.38e-17	-0.44	-0.4	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
THCA	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	9.47	1.39e-19	8.42e-17	0.49	0.4	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
THCA	cis	rs9659323	0.632	rs10923744	ENSG00000231365.4	RP11-418J17.1	-9.47	1.39e-19	8.42e-17	-0.38	-0.4	Body mass index;	chr1:119071318	chr1:119140396~119275973:+
THCA	cis	rs944289	0.598	rs56359141	ENSG00000257826.1	RP11-116N8.4	-9.47	1.39e-19	8.44e-17	-0.41	-0.4	Thyroid cancer;	chr14:36108167	chr14:36061026~36067190:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-9.47	1.4e-19	8.46e-17	-0.29	-0.4	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-9.47	1.4e-19	8.46e-17	-0.29	-0.4	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-9.47	1.4e-19	8.46e-17	-0.29	-0.4	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
THCA	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-9.47	1.4e-19	8.49e-17	-0.29	-0.4	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000215447.6	BX322557.10	-9.47	1.4e-19	8.5e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000215447.6	BX322557.10	-9.47	1.4e-19	8.5e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000215447.6	BX322557.10	-9.47	1.4e-19	8.5e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000215447.6	BX322557.10	-9.47	1.4e-19	8.5e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45288052~45291738:+
THCA	cis	rs2288884	0.649	rs11667001	ENSG00000275055.1	CTC-471J1.11	-9.47	1.4e-19	8.5e-17	-0.45	-0.4	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049416	chr19:52049007~52049754:+
THCA	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	9.47	1.41e-19	8.55e-17	0.47	0.4	Height;	chr6:109740895	chr6:109382795~109383666:+
THCA	cis	rs860295	0.651	rs6677385	ENSG00000225855.5	RUSC1-AS1	9.47	1.42e-19	8.6e-17	0.28	0.4	Body mass index;	chr1:155334790	chr1:155316863~155324176:-
THCA	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-9.47	1.42e-19	8.61e-17	-0.47	-0.4	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-9.47	1.42e-19	8.61e-17	-0.47	-0.4	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000215447.6	BX322557.10	-9.46	1.42e-19	8.64e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45288052~45291738:+
THCA	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-9.46	1.43e-19	8.67e-17	-0.5	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000215447.6	BX322557.10	9.46	1.43e-19	8.69e-17	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45288052~45291738:+
THCA	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
THCA	cis	rs10740039	0.96	rs10443928	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645718	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10443929	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645852	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs7915540	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60646538	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7920170	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647766	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10761538	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649463	chr10:60734342~60741828:+
THCA	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-9.46	1.44e-19	8.73e-17	-0.5	-0.4	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
THCA	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-9.46	1.45e-19	8.78e-17	-0.4	-0.4	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
THCA	cis	rs11051970	0.559	rs10844179	ENSG00000274964.1	RP11-817I4.1	9.46	1.45e-19	8.8e-17	0.51	0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32316667	chr12:32339368~32340724:+
THCA	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	9.46	1.46e-19	8.83e-17	0.49	0.4	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
THCA	cis	rs934734	0.532	rs6546151	ENSG00000234255.7	AC012370.3	-9.46	1.46e-19	8.83e-17	-0.43	-0.4	Rheumatoid arthritis;	chr2:65449449	chr2:65439888~65456571:-
THCA	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	9.46	1.46e-19	8.84e-17	0.52	0.4	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
THCA	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-9.46	1.46e-19	8.86e-17	-0.38	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
THCA	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	9.46	1.46e-19	8.87e-17	0.37	0.4	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
THCA	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	9.46	1.47e-19	8.87e-17	0.47	0.4	Height;	chr6:109739615	chr6:109382795~109383666:+
THCA	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	9.46	1.47e-19	8.9e-17	0.48	0.4	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
THCA	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	9.46	1.47e-19	8.93e-17	0.54	0.4	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
THCA	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	9.46	1.48e-19	8.94e-17	0.37	0.4	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
THCA	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-9.46	1.48e-19	8.96e-17	-0.44	-0.4	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
THCA	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-9.46	1.49e-19	9e-17	-0.48	-0.4	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
THCA	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-9.46	1.49e-19	9.01e-17	-0.3	-0.4	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
THCA	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	9.46	1.49e-19	9.02e-17	0.49	0.4	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
THCA	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-9.46	1.49e-19	9.03e-17	-0.47	-0.4	Height;	chr6:109731677	chr6:109382795~109383666:+
THCA	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-9.46	1.5e-19	9.06e-17	-0.53	-0.4	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
THCA	cis	rs7221109	0.921	rs1013971	ENSG00000278834.1	RP11-458J1.1	9.46	1.5e-19	9.08e-17	0.42	0.4	Type 1 diabetes;	chr17:40624926	chr17:40648300~40649718:+
THCA	cis	rs3743772	0.5	rs28671196	ENSG00000279722.1	RP11-44F14.6	9.46	1.5e-19	9.1e-17	0.53	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53487607~53489943:-
THCA	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-9.46	1.51e-19	9.13e-17	-0.72	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
THCA	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000215447.6	BX322557.10	-9.46	1.52e-19	9.18e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000215447.6	BX322557.10	-9.46	1.52e-19	9.18e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000215447.6	BX322557.10	-9.46	1.52e-19	9.18e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000215447.6	BX322557.10	-9.46	1.52e-19	9.18e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45288052~45291738:+
THCA	cis	rs10411161	1	rs72626249	ENSG00000269483.1	AC006272.1	9.46	1.52e-19	9.18e-17	0.55	0.4	Breast cancer;	chr19:51861622	chr19:51839924~51843324:-
THCA	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	9.46	1.53e-19	9.23e-17	0.45	0.4	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
THCA	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-9.46	1.53e-19	9.24e-17	-0.66	-0.4	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	9.46	1.53e-19	9.26e-17	0.29	0.4	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	9.46	1.53e-19	9.26e-17	0.29	0.4	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-9.46	1.53e-19	9.26e-17	-0.29	-0.4	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-9.46	1.53e-19	9.26e-17	-0.29	-0.4	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-9.46	1.53e-19	9.26e-17	-0.29	-0.4	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
THCA	cis	rs934734	0.532	rs10184881	ENSG00000234255.7	AC012370.3	-9.46	1.54e-19	9.28e-17	-0.43	-0.4	Rheumatoid arthritis;	chr2:65457018	chr2:65439888~65456571:-
THCA	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	9.45	1.55e-19	9.34e-17	0.49	0.4	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
THCA	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-9.45	1.55e-19	9.35e-17	-0.55	-0.4	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-9.45	1.55e-19	9.35e-17	-0.55	-0.4	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
THCA	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
THCA	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	9.45	1.55e-19	9.38e-17	0.47	0.4	Height;	chr6:109732518	chr6:109382795~109383666:+
THCA	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	9.45	1.55e-19	9.39e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
THCA	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	9.45	1.56e-19	9.4e-17	0.44	0.4	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
THCA	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	9.45	1.56e-19	9.4e-17	0.55	0.4	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
THCA	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	9.45	1.56e-19	9.42e-17	0.45	0.4	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
THCA	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	9.45	1.58e-19	9.53e-17	0.55	0.4	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
THCA	cis	rs673078	0.66	rs11068908	ENSG00000275409.1	RP11-131L12.4	-9.45	1.58e-19	9.54e-17	-0.44	-0.4	Glucose homeostasis traits;	chr12:118327265	chr12:118430147~118430699:+
THCA	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	9.45	1.59e-19	9.61e-17	0.47	0.4	Height;	chr6:109763331	chr6:109382795~109383666:+
THCA	cis	rs950169	0.544	rs12913702	ENSG00000225151.9	GOLGA2P7	-9.45	1.6e-19	9.63e-17	-0.6	-0.4	Schizophrenia;	chr15:84609953	chr15:84199311~84230136:-
THCA	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	9.45	1.6e-19	9.63e-17	0.56	0.4	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	9.45	1.6e-19	9.64e-17	0.53	0.4	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
THCA	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	9.45	1.6e-19	9.65e-17	0.48	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
THCA	cis	rs4842666	0.915	rs117742247	ENSG00000258302.2	RP11-981P6.1	9.45	1.6e-19	9.66e-17	0.42	0.4	Blood pressure;	chr12:89597536	chr12:89561129~89594878:+
THCA	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-9.45	1.6e-19	9.66e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-9.45	1.6e-19	9.66e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
THCA	cis	rs8062405	0.573	rs11645306	ENSG00000251417.2	RP11-1348G14.4	9.45	1.6e-19	9.66e-17	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28802743~28817828:+
THCA	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	9.45	1.61e-19	9.7e-17	0.37	0.4	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
THCA	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-9.45	1.61e-19	9.71e-17	-0.39	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.632	rs12045138	ENSG00000231365.4	RP11-418J17.1	-9.45	1.62e-19	9.79e-17	-0.38	-0.4	Body mass index;	chr1:119076825	chr1:119140396~119275973:+
THCA	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	9.45	1.63e-19	9.84e-17	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000226314.6	ZNF192P1	-9.45	1.63e-19	9.84e-17	-0.52	-0.4	Parkinson's disease;	chr6:28069254	chr6:28161781~28169594:+
THCA	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-9.45	1.64e-19	9.9e-17	-0.45	-0.4	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	9.45	1.64e-19	9.9e-17	0.53	0.4	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	9.45	1.64e-19	9.91e-17	0.54	0.4	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
THCA	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	9.45	1.65e-19	9.97e-17	0.37	0.4	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
THCA	cis	rs934734	0.563	rs1858036	ENSG00000204929.10	AC074391.1	9.45	1.65e-19	9.97e-17	0.52	0.4	Rheumatoid arthritis;	chr2:65371107	chr2:65436711~66084639:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000226314.6	ZNF192P1	-9.45	1.66e-19	9.99e-17	-0.52	-0.4	Parkinson's disease;	chr6:28066959	chr6:28161781~28169594:+
THCA	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-9.45	1.66e-19	1e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
THCA	cis	rs11148252	0.774	rs9596649	ENSG00000278238.1	RP11-245D16.4	9.45	1.66e-19	1e-16	0.44	0.4	Lewy body disease;	chr13:52360475	chr13:52454775~52455331:-
THCA	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-9.44	1.69e-19	1.02e-16	-0.44	-0.4	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
THCA	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-9.44	1.7e-19	1.02e-16	-0.47	-0.4	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	9.44	1.7e-19	1.03e-16	0.29	0.4	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
THCA	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-9.44	1.71e-19	1.03e-16	-0.28	-0.4	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
THCA	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-9.44	1.71e-19	1.03e-16	-0.28	-0.4	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
THCA	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-9.44	1.71e-19	1.03e-16	-0.28	-0.4	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
THCA	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-9.44	1.71e-19	1.03e-16	-0.28	-0.4	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-9.44	1.72e-19	1.03e-16	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000215447.6	BX322557.10	9.44	1.73e-19	1.04e-16	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45288052~45291738:+
THCA	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	9.44	1.73e-19	1.04e-16	0.51	0.4	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
THCA	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-9.44	1.74e-19	1.04e-16	-0.36	-0.4	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
THCA	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-9.44	1.74e-19	1.05e-16	-0.52	-0.4	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
THCA	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-9.44	1.74e-19	1.05e-16	-0.5	-0.4	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
THCA	cis	rs7569084	1	rs13385171	ENSG00000237979.1	AC007389.1	-9.44	1.74e-19	1.05e-16	-0.46	-0.4	Sum eosinophil basophil counts;	chr2:65434709	chr2:65500993~65502138:-
THCA	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-9.44	1.76e-19	1.06e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
THCA	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	9.44	1.76e-19	1.06e-16	0.44	0.4	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
THCA	cis	rs944289	0.74	rs1467794	ENSG00000257826.1	RP11-116N8.4	9.44	1.77e-19	1.06e-16	0.41	0.4	Thyroid cancer;	chr14:36097617	chr14:36061026~36067190:-
THCA	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	9.44	1.77e-19	1.06e-16	0.57	0.4	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
THCA	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-9.44	1.77e-19	1.06e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
THCA	cis	rs7569084	0.522	rs906577	ENSG00000204929.10	AC074391.1	9.44	1.78e-19	1.07e-16	0.52	0.4	Sum eosinophil basophil counts;	chr2:65369523	chr2:65436711~66084639:+
THCA	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-9.44	1.78e-19	1.07e-16	-0.44	-0.4	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
THCA	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
THCA	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-9.44	1.79e-19	1.07e-16	-0.32	-0.4	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
THCA	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	9.44	1.79e-19	1.08e-16	0.48	0.4	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-9.44	1.79e-19	1.08e-16	-0.59	-0.4	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
THCA	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-9.44	1.8e-19	1.08e-16	-0.55	-0.4	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-9.44	1.8e-19	1.08e-16	-0.55	-0.4	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-9.44	1.8e-19	1.08e-16	-0.55	-0.4	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-9.44	1.8e-19	1.08e-16	-0.55	-0.4	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
THCA	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-9.44	1.81e-19	1.09e-16	-0.54	-0.4	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
THCA	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	9.43	1.82e-19	1.09e-16	0.34	0.4	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
THCA	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-9.43	1.82e-19	1.09e-16	-0.33	-0.4	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
THCA	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	9.43	1.82e-19	1.1e-16	0.28	0.4	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
THCA	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-9.43	1.82e-19	1.1e-16	-0.28	-0.4	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
THCA	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-9.43	1.82e-19	1.1e-16	-0.28	-0.4	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
THCA	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-9.43	1.82e-19	1.1e-16	-0.28	-0.4	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.926	rs7799	ENSG00000239827.7	SUGT1P3	-9.43	1.83e-19	1.1e-16	-0.43	-0.4	Cervical cancer;	chr13:40958916	chr13:40908159~40921774:-
THCA	cis	rs7727544	0.716	rs4705928	ENSG00000237714.1	P4HA2-AS1	-9.43	1.83e-19	1.1e-16	-0.52	-0.4	Blood metabolite levels;	chr5:132242944	chr5:132184876~132192808:+
THCA	cis	rs9926296	0.715	rs2115401	ENSG00000260259.1	RP11-368I7.4	-9.43	1.83e-19	1.1e-16	-0.42	-0.4	Vitiligo;	chr16:89674201	chr16:89682620~89686569:-
THCA	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-9.43	1.84e-19	1.1e-16	-0.46	-0.4	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
THCA	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	-9.43	1.84e-19	1.11e-16	-0.54	-0.4	Depression;	chr6:28168434	chr6:28161781~28169594:+
THCA	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
THCA	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	9.43	1.85e-19	1.11e-16	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
THCA	cis	rs1799949	1	rs4793236	ENSG00000267681.1	CTD-3199J23.6	-9.43	1.86e-19	1.11e-16	-0.47	-0.4	Menopause (age at onset);	chr17:43359072	chr17:43144956~43145255:+
THCA	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-9.43	1.86e-19	1.12e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
THCA	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	9.43	1.86e-19	1.12e-16	0.51	0.4	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
THCA	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	9.43	1.87e-19	1.12e-16	0.33	0.4	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-9.43	1.89e-19	1.13e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
THCA	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-9.43	1.9e-19	1.14e-16	-0.28	-0.4	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
THCA	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-9.43	1.9e-19	1.14e-16	-0.28	-0.4	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
THCA	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-9.43	1.9e-19	1.14e-16	-0.44	-0.4	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
THCA	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-9.43	1.9e-19	1.14e-16	-0.79	-0.4	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
THCA	cis	rs10740039	0.883	rs7918897	ENSG00000254271.1	RP11-131N11.4	9.43	1.91e-19	1.14e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643754	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs7902456	ENSG00000254271.1	RP11-131N11.4	9.43	1.91e-19	1.14e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643937	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.96	rs10761536	ENSG00000254271.1	RP11-131N11.4	9.43	1.91e-19	1.14e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644657	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10994455	ENSG00000254271.1	RP11-131N11.4	9.43	1.91e-19	1.14e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645589	chr10:60734342~60741828:+
THCA	cis	rs7189233	0.531	rs8055642	ENSG00000279344.1	RP11-44F14.7	9.43	1.91e-19	1.15e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53503669	chr16:53478957~53481550:-
THCA	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	9.43	1.91e-19	1.15e-16	0.51	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
THCA	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-9.43	1.92e-19	1.15e-16	-0.41	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
THCA	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	9.43	1.93e-19	1.16e-16	0.36	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
THCA	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	9.43	1.93e-19	1.16e-16	0.47	0.4	Height;	chr6:109747119	chr6:109382795~109383666:+
THCA	cis	rs934734	0.563	rs11673956	ENSG00000204929.10	AC074391.1	9.43	1.94e-19	1.16e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65370523	chr2:65436711~66084639:+
THCA	cis	rs934734	0.563	rs11673987	ENSG00000204929.10	AC074391.1	9.43	1.94e-19	1.16e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65370537	chr2:65436711~66084639:+
THCA	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	9.43	1.94e-19	1.16e-16	0.32	0.4	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
THCA	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-9.43	1.95e-19	1.17e-16	-0.48	-0.4	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
THCA	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-9.43	1.95e-19	1.17e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
THCA	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-9.43	1.95e-19	1.17e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
THCA	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-9.43	1.95e-19	1.17e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
THCA	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-9.43	1.95e-19	1.17e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
THCA	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-9.43	1.96e-19	1.17e-16	-0.43	-0.4	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
THCA	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	9.42	1.96e-19	1.17e-16	0.6	0.4	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
THCA	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	9.42	1.97e-19	1.18e-16	0.38	0.4	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	9.42	1.97e-19	1.18e-16	0.38	0.4	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-9.42	1.97e-19	1.18e-16	-0.29	-0.4	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-9.42	1.97e-19	1.18e-16	-0.29	-0.4	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
THCA	cis	rs11148252	0.774	rs6561666	ENSG00000278238.1	RP11-245D16.4	-9.42	1.98e-19	1.19e-16	-0.44	-0.4	Lewy body disease;	chr13:52355910	chr13:52454775~52455331:-
THCA	cis	rs934734	0.563	rs11126035	ENSG00000204929.10	AC074391.1	9.42	1.98e-19	1.19e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65369932	chr2:65436711~66084639:+
THCA	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	9.42	1.99e-19	1.19e-16	0.41	0.4	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
THCA	cis	rs1858037	0.867	rs6727013	ENSG00000281920.1	RP11-418H16.1	9.42	1.99e-19	1.19e-16	0.53	0.4	Rheumatoid arthritis;	chr2:65331241	chr2:65623272~65628424:+
THCA	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-9.42	2e-19	1.19e-16	-0.55	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
THCA	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-9.42	2e-19	1.2e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
THCA	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	9.42	2e-19	1.2e-16	0.47	0.4	Height;	chr6:109747411	chr6:109382795~109383666:+
THCA	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	9.42	2e-19	1.2e-16	0.47	0.4	Height;	chr6:109748819	chr6:109382795~109383666:+
THCA	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	9.42	2e-19	1.2e-16	0.47	0.4	Height;	chr6:109749564	chr6:109382795~109383666:+
THCA	cis	rs11696845	0.787	rs13043441	ENSG00000276223.1	RP4-781B1.5	-9.42	2.03e-19	1.21e-16	-0.49	-0.4	Obesity-related traits;	chr20:44735667	chr20:44746642~44747201:+
THCA	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-9.42	2.03e-19	1.21e-16	-0.67	-0.4	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
THCA	cis	rs8062405	0.573	rs8045689	ENSG00000251417.2	RP11-1348G14.4	9.42	2.03e-19	1.21e-16	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28802743~28817828:+
THCA	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-9.42	2.03e-19	1.21e-16	-0.55	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
THCA	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	9.42	2.03e-19	1.21e-16	0.5	0.4	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
THCA	cis	rs860295	0.627	rs11264410	ENSG00000225855.5	RUSC1-AS1	9.42	2.03e-19	1.21e-16	0.28	0.4	Body mass index;	chr1:155775558	chr1:155316863~155324176:-
THCA	cis	rs17684571	0.7	rs13200768	ENSG00000231441.1	RP11-472M19.2	9.42	2.03e-19	1.21e-16	0.54	0.4	Schizophrenia;	chr6:56786828	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13204466	ENSG00000231441.1	RP11-472M19.2	9.42	2.03e-19	1.21e-16	0.54	0.4	Schizophrenia;	chr6:56787376	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs34612783	ENSG00000231441.1	RP11-472M19.2	9.42	2.03e-19	1.21e-16	0.54	0.4	Schizophrenia;	chr6:56787851	chr6:56844002~56864078:+
THCA	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-9.42	2.03e-19	1.22e-16	-0.52	-0.4	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
THCA	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	9.42	2.05e-19	1.22e-16	0.48	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
THCA	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	9.42	2.05e-19	1.22e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
THCA	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-9.42	2.05e-19	1.22e-16	-0.45	-0.4	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-9.42	2.05e-19	1.22e-16	-0.45	-0.4	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-9.42	2.05e-19	1.22e-16	-0.45	-0.4	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
THCA	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	9.42	2.05e-19	1.23e-16	0.72	0.4	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
THCA	cis	rs916888	0.821	rs199513	ENSG00000232300.1	FAM215B	-9.42	2.06e-19	1.23e-16	-0.63	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46558830~46562795:-
THCA	cis	rs7727544	0.631	rs13357280	ENSG00000237714.1	P4HA2-AS1	9.42	2.07e-19	1.24e-16	0.53	0.4	Blood metabolite levels;	chr5:132264494	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.594	rs10479000	ENSG00000237714.1	P4HA2-AS1	9.42	2.07e-19	1.24e-16	0.53	0.4	Blood metabolite levels;	chr5:132271709	chr5:132184876~132192808:+
THCA	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-9.42	2.07e-19	1.24e-16	-0.59	-0.4	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
THCA	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-9.42	2.1e-19	1.25e-16	-0.49	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
THCA	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	9.42	2.11e-19	1.26e-16	0.49	0.4	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	9.41	2.13e-19	1.27e-16	0.29	0.4	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
THCA	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	9.41	2.14e-19	1.28e-16	0.47	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
THCA	cis	rs62103177	0.535	rs4799109	ENSG00000261126.6	RP11-795F19.1	9.41	2.14e-19	1.28e-16	0.45	0.4	Opioid sensitivity;	chr18:79915188	chr18:80046900~80095482:+
THCA	cis	rs1858037	0.867	rs4671658	ENSG00000281920.1	RP11-418H16.1	-9.41	2.15e-19	1.28e-16	-0.53	-0.4	Rheumatoid arthritis;	chr2:65334258	chr2:65623272~65628424:+
THCA	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	9.41	2.16e-19	1.29e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
THCA	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	9.41	2.16e-19	1.29e-16	0.47	0.4	Height;	chr6:109706740	chr6:109382795~109383666:+
THCA	cis	rs11051970	0.527	rs7977938	ENSG00000274964.1	RP11-817I4.1	-9.41	2.17e-19	1.3e-16	-0.5	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32322406	chr12:32339368~32340724:+
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000215447.6	BX322557.10	-9.41	2.17e-19	1.3e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45288052~45291738:+
THCA	cis	rs6496932	0.909	rs74024818	ENSG00000218052.5	ADAMTS7P4	9.41	2.18e-19	1.3e-16	0.59	0.4	Central corneal thickness;Corneal structure;	chr15:85339299	chr15:85255369~85330334:-
THCA	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	9.41	2.18e-19	1.3e-16	0.47	0.4	Height;	chr6:109741670	chr6:109382795~109383666:+
THCA	cis	rs10740039	0.883	rs1561850	ENSG00000254271.1	RP11-131N11.4	9.41	2.18e-19	1.3e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60631583	chr10:60734342~60741828:+
THCA	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	-9.41	2.19e-19	1.3e-16	-0.54	-0.4	Depression;	chr6:28133900	chr6:28161781~28169594:+
THCA	cis	rs4660456	0.504	rs570671	ENSG00000237899.1	RP4-739H11.3	9.41	2.19e-19	1.3e-16	0.55	0.4	Platelet count;	chr1:40625455	chr1:40669089~40687588:-
THCA	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	9.41	2.19e-19	1.31e-16	0.47	0.4	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
THCA	cis	rs1387259	0.698	rs4579969	ENSG00000258273.1	RP11-370I10.4	9.41	2.2e-19	1.31e-16	0.5	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48333755~48333901:-
THCA	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	9.41	2.2e-19	1.31e-16	0.6	0.4	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
THCA	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-9.41	2.21e-19	1.32e-16	-0.55	-0.4	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
THCA	cis	rs9926296	0.744	rs460984	ENSG00000260259.1	RP11-368I7.4	9.41	2.21e-19	1.32e-16	0.45	0.4	Vitiligo;	chr16:89646766	chr16:89682620~89686569:-
THCA	cis	rs62103177	0.608	rs59300126	ENSG00000261126.6	RP11-795F19.1	9.41	2.22e-19	1.32e-16	0.44	0.4	Opioid sensitivity;	chr18:79934439	chr18:80046900~80095482:+
THCA	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	9.41	2.22e-19	1.32e-16	0.54	0.4	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
THCA	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-9.41	2.22e-19	1.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-9.41	2.22e-19	1.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-9.41	2.22e-19	1.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
THCA	cis	rs10411161	0.935	rs8107422	ENSG00000269483.1	AC006272.1	9.41	2.23e-19	1.33e-16	0.55	0.4	Breast cancer;	chr19:51865522	chr19:51839924~51843324:-
THCA	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	9.41	2.24e-19	1.33e-16	0.51	0.4	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
THCA	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	9.41	2.24e-19	1.33e-16	0.51	0.4	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
THCA	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-9.41	2.24e-19	1.34e-16	-0.48	-0.4	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
THCA	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-9.41	2.25e-19	1.34e-16	-0.53	-0.4	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
THCA	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-9.41	2.28e-19	1.36e-16	-0.78	-0.4	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-9.41	2.28e-19	1.36e-16	-0.78	-0.4	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
THCA	cis	rs934734	0.563	rs11126034	ENSG00000204929.10	AC074391.1	-9.41	2.28e-19	1.36e-16	-0.52	-0.4	Rheumatoid arthritis;	chr2:65353087	chr2:65436711~66084639:+
THCA	cis	rs6046396	1	rs6112627	ENSG00000275142.1	RP5-999L4.2	-9.41	2.29e-19	1.37e-16	-0.54	-0.4	Bipolar disorder and schizophrenia;	chr20:19877342	chr20:19871891~19872284:+
THCA	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	9.41	2.29e-19	1.37e-16	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
THCA	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	9.41	2.3e-19	1.37e-16	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
THCA	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-9.4	2.31e-19	1.38e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
THCA	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	9.4	2.32e-19	1.38e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
THCA	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	9.4	2.33e-19	1.38e-16	0.28	0.4	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
THCA	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-9.4	2.33e-19	1.39e-16	-0.55	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
THCA	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-9.4	2.33e-19	1.39e-16	-0.5	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
THCA	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-9.4	2.34e-19	1.39e-16	-0.32	-0.4	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
THCA	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	9.4	2.34e-19	1.39e-16	0.48	0.4	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
THCA	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-9.4	2.34e-19	1.39e-16	-0.38	-0.4	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
THCA	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	9.4	2.35e-19	1.4e-16	0.52	0.4	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000215447.6	BX322557.10	-9.4	2.35e-19	1.4e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	9.4	2.35e-19	1.4e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
THCA	cis	rs9532669	0.889	rs9549302	ENSG00000239827.7	SUGT1P3	-9.4	2.36e-19	1.4e-16	-0.45	-0.4	Cervical cancer;	chr13:40843278	chr13:40908159~40921774:-
THCA	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	9.4	2.36e-19	1.4e-16	0.47	0.4	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
THCA	cis	rs6908034	0.607	rs73378506	ENSG00000228412.5	RP4-625H18.2	9.4	2.36e-19	1.41e-16	0.8	0.4	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819756	chr6:19802164~19804752:-
THCA	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	9.4	2.36e-19	1.41e-16	0.38	0.4	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
THCA	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-9.4	2.37e-19	1.41e-16	-0.43	-0.4	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
THCA	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	9.4	2.37e-19	1.41e-16	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
THCA	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-9.4	2.37e-19	1.41e-16	-0.63	-0.4	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	9.4	2.37e-19	1.41e-16	0.58	0.4	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
THCA	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	9.4	2.38e-19	1.41e-16	0.46	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
THCA	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	9.4	2.38e-19	1.42e-16	0.43	0.4	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000215447.6	BX322557.10	-9.4	2.39e-19	1.42e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45288052~45291738:+
THCA	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-9.4	2.39e-19	1.42e-16	-0.45	-0.4	Height;	chr2:231541633	chr2:231508426~231514339:-
THCA	cis	rs10740039	0.734	rs10821815	ENSG00000254271.1	RP11-131N11.4	9.4	2.4e-19	1.43e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644843	chr10:60734342~60741828:+
THCA	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-9.4	2.41e-19	1.43e-16	-0.48	-0.4	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
THCA	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-9.4	2.41e-19	1.43e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
THCA	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-9.4	2.42e-19	1.44e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
THCA	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-9.4	2.42e-19	1.44e-16	-0.62	-0.4	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
THCA	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	9.4	2.45e-19	1.46e-16	0.29	0.4	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
THCA	cis	rs10411161	1	rs10414104	ENSG00000269483.1	AC006272.1	9.39	2.51e-19	1.49e-16	0.55	0.4	Breast cancer;	chr19:51864879	chr19:51839924~51843324:-
THCA	cis	rs10740039	0.883	rs10994446	ENSG00000254271.1	RP11-131N11.4	9.39	2.51e-19	1.49e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639433	chr10:60734342~60741828:+
THCA	cis	rs748404	0.697	rs546722	ENSG00000249839.1	AC011330.5	-9.39	2.55e-19	1.51e-16	-0.47	-0.4	Lung cancer;	chr15:43288621	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000215447.6	BX322557.10	-9.39	2.56e-19	1.52e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45288052~45291738:+
THCA	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	9.39	2.59e-19	1.54e-16	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
THCA	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	-9.39	2.6e-19	1.54e-16	-0.53	-0.4	Depression;	chr6:28159843	chr6:28161781~28169594:+
THCA	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	9.39	2.6e-19	1.54e-16	0.55	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
THCA	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	9.39	2.62e-19	1.56e-16	0.29	0.4	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
THCA	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-9.39	2.66e-19	1.58e-16	-0.41	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-9.39	2.67e-19	1.58e-16	-0.41	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
THCA	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	9.39	2.68e-19	1.58e-16	0.63	0.4	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
THCA	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-9.39	2.68e-19	1.59e-16	-0.41	-0.4	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
THCA	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	9.39	2.68e-19	1.59e-16	0.38	0.4	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	9.39	2.69e-19	1.59e-16	0.53	0.4	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
THCA	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-9.39	2.7e-19	1.6e-16	-0.4	-0.4	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
THCA	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-9.38	2.72e-19	1.61e-16	-0.47	-0.4	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000215447.6	BX322557.10	-9.38	2.73e-19	1.61e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45288052~45291738:+
THCA	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	9.38	2.73e-19	1.61e-16	0.51	0.4	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
THCA	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-9.38	2.73e-19	1.61e-16	-0.51	-0.4	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
THCA	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-9.38	2.73e-19	1.61e-16	-0.53	-0.4	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
THCA	cis	rs73219805	0.793	rs1564576	ENSG00000228451.3	SDAD1P1	-9.38	2.73e-19	1.61e-16	-0.5	-0.4	Schizophrenia;	chr8:26333320	chr8:26379259~26382953:-
THCA	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	9.38	2.73e-19	1.62e-16	0.52	0.4	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
THCA	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	9.38	2.75e-19	1.63e-16	0.52	0.4	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
THCA	cis	rs11051970	0.559	rs11536026	ENSG00000274964.1	RP11-817I4.1	-9.38	2.78e-19	1.64e-16	-0.53	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32316593	chr12:32339368~32340724:+
THCA	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-9.38	2.78e-19	1.64e-16	-0.55	-0.4	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
THCA	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	9.38	2.79e-19	1.65e-16	0.5	0.4	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
THCA	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	9.38	2.79e-19	1.65e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
THCA	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-9.38	2.79e-19	1.65e-16	-0.46	-0.4	Temperament;	chr17:14018109	chr17:14024514~14025488:+
THCA	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	9.38	2.79e-19	1.65e-16	0.29	0.4	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
THCA	cis	rs7727544	0.716	rs6863213	ENSG00000237714.1	P4HA2-AS1	9.38	2.8e-19	1.65e-16	0.53	0.4	Blood metabolite levels;	chr5:132240239	chr5:132184876~132192808:+
THCA	cis	rs4819052	0.918	rs34886433	ENSG00000215447.6	BX322557.10	-9.38	2.8e-19	1.66e-16	-0.38	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	9.38	2.8e-19	1.66e-16	0.46	0.4	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
THCA	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-9.38	2.82e-19	1.67e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
THCA	cis	rs9402743	0.6	rs9376151	ENSG00000231028.7	LINC00271	-9.38	2.83e-19	1.67e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135789599	chr6:135497801~135716055:+
THCA	cis	rs7727544	1	rs7727038	ENSG00000233006.5	AC034220.3	9.38	2.83e-19	1.67e-16	0.31	0.4	Blood metabolite levels;	chr5:132254564	chr5:132311285~132369916:-
THCA	cis	rs7727544	1	rs7727544	ENSG00000233006.5	AC034220.3	9.38	2.83e-19	1.67e-16	0.31	0.4	Blood metabolite levels;	chr5:132254841	chr5:132311285~132369916:-
THCA	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	9.38	2.83e-19	1.67e-16	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
THCA	cis	rs73219805	0.671	rs13267955	ENSG00000228451.3	SDAD1P1	-9.38	2.84e-19	1.68e-16	-0.5	-0.4	Schizophrenia;	chr8:26367077	chr8:26379259~26382953:-
THCA	cis	rs7727544	1	rs10076701	ENSG00000233006.5	AC034220.3	9.38	2.85e-19	1.68e-16	0.31	0.4	Blood metabolite levels;	chr5:132260726	chr5:132311285~132369916:-
THCA	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-9.38	2.86e-19	1.69e-16	-0.51	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
THCA	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-9.38	2.86e-19	1.69e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
THCA	cis	rs67311347	0.549	rs60249586	ENSG00000223797.4	ENTPD3-AS1	9.38	2.87e-19	1.7e-16	0.32	0.4	Renal cell carcinoma;	chr3:40205168	chr3:40313802~40453329:-
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	9.38	2.87e-19	1.7e-16	0.55	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
THCA	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	9.38	2.89e-19	1.71e-16	0.47	0.4	Height;	chr6:109706514	chr6:109382795~109383666:+
THCA	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-9.38	2.89e-19	1.71e-16	-0.29	-0.4	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
THCA	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	9.38	2.91e-19	1.72e-16	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
THCA	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-9.38	2.91e-19	1.72e-16	-0.55	-0.4	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	9.38	2.92e-19	1.72e-16	0.57	0.4	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
THCA	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	9.37	2.93e-19	1.73e-16	0.44	0.4	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
THCA	cis	rs944289	0.774	rs12589124	ENSG00000257826.1	RP11-116N8.4	-9.37	2.93e-19	1.73e-16	-0.41	-0.4	Thyroid cancer;	chr14:36094718	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs2183451	ENSG00000257826.1	RP11-116N8.4	-9.37	2.93e-19	1.73e-16	-0.41	-0.4	Thyroid cancer;	chr14:36095227	chr14:36061026~36067190:-
THCA	cis	rs944289	0.774	rs884090	ENSG00000257826.1	RP11-116N8.4	-9.37	2.93e-19	1.73e-16	-0.41	-0.4	Thyroid cancer;	chr14:36095741	chr14:36061026~36067190:-
THCA	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	9.37	2.93e-19	1.73e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	9.37	2.93e-19	1.73e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
THCA	cis	rs11051970	0.559	rs7963887	ENSG00000274964.1	RP11-817I4.1	-9.37	2.93e-19	1.73e-16	-0.5	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32323073	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs10844184	ENSG00000274964.1	RP11-817I4.1	-9.37	2.93e-19	1.73e-16	-0.5	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32323918	chr12:32339368~32340724:+
THCA	cis	rs1577917	0.687	rs13197828	ENSG00000203875.9	SNHG5	-9.37	2.93e-19	1.73e-16	-0.49	-0.4	Response to antipsychotic treatment;	chr6:86095912	chr6:85660950~85678736:-
THCA	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-9.37	2.94e-19	1.74e-16	-0.41	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
THCA	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-9.37	2.95e-19	1.74e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
THCA	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-9.37	2.96e-19	1.75e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-9.37	2.96e-19	1.75e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
THCA	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	9.37	2.96e-19	1.75e-16	0.72	0.4	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
THCA	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-9.37	2.98e-19	1.76e-16	-0.37	-0.4	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-9.37	2.99e-19	1.76e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
THCA	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-9.37	3.01e-19	1.78e-16	-0.44	-0.4	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
THCA	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-9.37	3.02e-19	1.78e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
THCA	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	9.37	3.03e-19	1.79e-16	0.44	0.4	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
THCA	cis	rs860295	0.756	rs7546258	ENSG00000225855.5	RUSC1-AS1	9.37	3.05e-19	1.8e-16	0.28	0.4	Body mass index;	chr1:155728854	chr1:155316863~155324176:-
THCA	cis	rs10740039	0.883	rs1442540	ENSG00000254271.1	RP11-131N11.4	-9.37	3.05e-19	1.8e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653548	chr10:60734342~60741828:+
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000266490.1	CTD-2349P21.9	9.37	3.07e-19	1.81e-16	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30792372~30792833:+
THCA	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-9.37	3.08e-19	1.81e-16	-0.42	-0.4	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
THCA	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-9.37	3.08e-19	1.81e-16	-0.44	-0.4	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
THCA	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	9.37	3.09e-19	1.82e-16	0.44	0.4	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
THCA	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	9.37	3.09e-19	1.82e-16	0.54	0.4	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
THCA	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	9.37	3.09e-19	1.82e-16	0.29	0.4	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
THCA	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-9.37	3.1e-19	1.83e-16	-0.41	-0.4	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
THCA	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-9.37	3.1e-19	1.83e-16	-0.39	-0.4	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
THCA	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	9.37	3.11e-19	1.83e-16	0.55	0.4	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
THCA	cis	rs10411161	1	rs4514789	ENSG00000269483.1	AC006272.1	9.37	3.11e-19	1.83e-16	0.55	0.4	Breast cancer;	chr19:51862401	chr19:51839924~51843324:-
THCA	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-9.37	3.11e-19	1.83e-16	-0.45	-0.4	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
THCA	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	9.37	3.11e-19	1.83e-16	0.32	0.4	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	9.37	3.11e-19	1.83e-16	0.32	0.4	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	9.37	3.11e-19	1.83e-16	0.32	0.4	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
THCA	cis	rs10740039	0.883	rs7088404	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633320	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1837946	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633676	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1837945	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633757	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7089287	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634006	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7089720	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634063	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7093573	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634611	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs7093882	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634863	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7097818	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635106	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs2119913	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635631	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.586	rs7068462	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636240	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7069814	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637001	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10740037	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637747	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs10761531	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638177	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.846	rs2165690	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639609	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs2119912	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639754	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs2119911	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639808	chr10:60734342~60741828:+
THCA	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-9.37	3.12e-19	1.83e-16	-0.78	-0.4	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
THCA	cis	rs10740039	0.842	rs1442541	ENSG00000254271.1	RP11-131N11.4	9.37	3.15e-19	1.85e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626285	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1867081	ENSG00000254271.1	RP11-131N11.4	9.37	3.15e-19	1.85e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626569	chr10:60734342~60741828:+
THCA	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	9.37	3.15e-19	1.86e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
THCA	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-9.37	3.15e-19	1.86e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	9.37	3.16e-19	1.86e-16	0.28	0.4	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
THCA	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	9.36	3.17e-19	1.87e-16	0.49	0.4	Height;	chr11:118854014	chr11:118688039~118690600:-
THCA	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-9.36	3.18e-19	1.87e-16	-0.28	-0.4	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
THCA	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	9.36	3.22e-19	1.89e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
THCA	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	9.36	3.23e-19	1.9e-16	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
THCA	cis	rs944289	0.74	rs1537425	ENSG00000257826.1	RP11-116N8.4	9.36	3.24e-19	1.9e-16	0.4	0.4	Thyroid cancer;	chr14:36098954	chr14:36061026~36067190:-
THCA	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-9.36	3.24e-19	1.9e-16	-0.4	-0.4	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
THCA	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-9.36	3.26e-19	1.91e-16	-0.5	-0.4	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
THCA	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	9.36	3.28e-19	1.93e-16	0.6	0.4	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
THCA	cis	rs944289	0.708	rs1958622	ENSG00000257826.1	RP11-116N8.4	-9.36	3.29e-19	1.93e-16	-0.42	-0.4	Thyroid cancer;	chr14:36127289	chr14:36061026~36067190:-
THCA	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-9.36	3.29e-19	1.93e-16	-0.33	-0.4	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
THCA	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	9.36	3.3e-19	1.94e-16	0.64	0.4	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
THCA	cis	rs4819052	0.851	rs2838866	ENSG00000215447.6	BX322557.10	-9.36	3.3e-19	1.94e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45288052~45291738:+
THCA	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-9.36	3.3e-19	1.94e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
THCA	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-9.36	3.32e-19	1.95e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-9.36	3.32e-19	1.95e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-9.36	3.32e-19	1.95e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-9.36	3.32e-19	1.95e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
THCA	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	9.36	3.33e-19	1.95e-16	0.66	0.4	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
THCA	cis	rs12188164	0.686	rs56279338	ENSG00000221990.4	EXOC3-AS1	9.36	3.33e-19	1.95e-16	0.35	0.4	Cystic fibrosis severity;	chr5:416003	chr5:441498~443160:-
THCA	cis	rs12188164	0.686	rs72711365	ENSG00000221990.4	EXOC3-AS1	9.36	3.33e-19	1.95e-16	0.35	0.4	Cystic fibrosis severity;	chr5:416557	chr5:441498~443160:-
THCA	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	9.36	3.33e-19	1.96e-16	0.48	0.4	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
THCA	cis	rs10740039	0.883	rs10821809	ENSG00000254271.1	RP11-131N11.4	9.36	3.34e-19	1.96e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637612	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10761533	ENSG00000254271.1	RP11-131N11.4	9.36	3.34e-19	1.96e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638573	chr10:60734342~60741828:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	-9.36	3.35e-19	1.96e-16	-0.54	-0.4	Depression;	chr6:28143758	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	-9.36	3.35e-19	1.96e-16	-0.54	-0.4	Depression;	chr6:28144784	chr6:28161781~28169594:+
THCA	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-9.36	3.35e-19	1.97e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
THCA	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	9.36	3.35e-19	1.97e-16	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000215447.6	BX322557.10	9.36	3.37e-19	1.98e-16	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45288052~45291738:+
THCA	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	9.36	3.37e-19	1.98e-16	0.51	0.4	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
THCA	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	9.36	3.39e-19	1.99e-16	0.49	0.4	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	9.36	3.4e-19	1.99e-16	0.47	0.4	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
THCA	cis	rs9402743	0.632	rs6570029	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135757894	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs9399161	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135759326	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.665	rs6933507	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135760018	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.665	rs4896172	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135760664	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs6570031	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135762018	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs4896173	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135762413	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs4896174	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135762421	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs4896175	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135762568	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs2093330	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135763534	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs2104132	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135763810	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs9389324	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135765375	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs6900101	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135773766	chr6:135497801~135716055:+
THCA	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-9.36	3.4e-19	2e-16	-0.4	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-9.36	3.4e-19	2e-16	-0.4	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
THCA	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	9.36	3.41e-19	2e-16	0.45	0.4	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
THCA	cis	rs17772222	0.63	rs12437422	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88529621	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.605	rs4899955	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88530381	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs4904454	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88537777	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs2033418	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88539331	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs10873392	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88545124	chr14:88551597~88552493:+
THCA	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	9.35	3.44e-19	2.02e-16	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
THCA	cis	rs10740039	1	rs10740039	ENSG00000254271.1	RP11-131N11.4	9.35	3.46e-19	2.03e-16	0.46	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654924	chr10:60734342~60741828:+
THCA	cis	rs947583	0.517	rs6935371	ENSG00000231028.7	LINC00271	-9.35	3.46e-19	2.03e-16	-0.31	-0.4	Phosphorus levels;	chr6:135779380	chr6:135497801~135716055:+
THCA	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	9.35	3.46e-19	2.03e-16	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
THCA	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-9.35	3.47e-19	2.03e-16	-0.45	-0.4	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
THCA	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-9.35	3.5e-19	2.05e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000215447.6	BX322557.10	-9.35	3.5e-19	2.05e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45288052~45291738:+
THCA	cis	rs348196	0.767	rs12744132	ENSG00000225855.5	RUSC1-AS1	9.35	3.5e-19	2.05e-16	0.29	0.4	Breast cancer;	chr1:155693535	chr1:155316863~155324176:-
THCA	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	9.35	3.5e-19	2.05e-16	0.37	0.4	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
THCA	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-9.35	3.51e-19	2.06e-16	-0.48	-0.4	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
THCA	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	9.35	3.52e-19	2.06e-16	0.28	0.4	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-9.35	3.53e-19	2.07e-16	-0.51	-0.4	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
THCA	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-9.35	3.53e-19	2.07e-16	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-9.35	3.53e-19	2.07e-16	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-9.35	3.53e-19	2.07e-16	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-9.35	3.53e-19	2.07e-16	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
THCA	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-9.35	3.54e-19	2.08e-16	-0.6	-0.4	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
THCA	cis	rs17684571	0.7	rs35873865	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56790203	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13203327	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56792498	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs71564854	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56794662	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs4457154	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56805653	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13194904	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56811443	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs34805046	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56815813	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.765	rs34425815	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56816040	chr6:56844002~56864078:+
THCA	cis	rs11148252	0.553	rs9536236	ENSG00000235660.1	LINC00345	-9.35	3.59e-19	2.1e-16	-0.51	-0.4	Lewy body disease;	chr13:52680877	chr13:52484161~52484680:-
THCA	cis	rs9532669	0.926	rs4516083	ENSG00000239827.7	SUGT1P3	-9.35	3.6e-19	2.11e-16	-0.43	-0.4	Cervical cancer;	chr13:40951783	chr13:40908159~40921774:-
THCA	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	9.35	3.64e-19	2.13e-16	0.55	0.4	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
THCA	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	9.35	3.67e-19	2.15e-16	0.77	0.4	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000215447.6	BX322557.10	-9.35	3.69e-19	2.16e-16	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45288052~45291738:+
THCA	cis	rs7225151	0.522	rs56229705	ENSG00000234327.6	AC012146.7	-9.35	3.7e-19	2.16e-16	-0.53	-0.4	Alzheimer's disease (late onset);	chr17:5111494	chr17:5111468~5115004:+
THCA	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	9.34	3.72e-19	2.17e-16	0.48	0.4	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
THCA	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	9.34	3.72e-19	2.17e-16	0.3	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
THCA	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	9.34	3.73e-19	2.18e-16	0.51	0.4	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
THCA	cis	rs934734	0.563	rs11684155	ENSG00000204929.10	AC074391.1	9.34	3.74e-19	2.19e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65354166	chr2:65436711~66084639:+
THCA	cis	rs7015263	0.818	rs57644875	ENSG00000254231.1	CTD-2284J15.1	-9.34	3.75e-19	2.19e-16	-0.39	-0.4	Intelligence (multi-trait analysis);	chr8:86371118	chr8:86333274~86343314:-
THCA	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-9.34	3.76e-19	2.2e-16	-0.44	-0.4	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
THCA	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	9.34	3.76e-19	2.2e-16	0.44	0.4	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-9.34	3.78e-19	2.21e-16	-0.29	-0.4	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
THCA	cis	rs17772222	0.63	rs1344747	ENSG00000258789.1	RP11-507K2.3	9.34	3.79e-19	2.22e-16	0.38	0.4	Coronary artery calcification;	chr14:88548091	chr14:88551597~88552493:+
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000215447.6	BX322557.10	-9.34	3.81e-19	2.23e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45288052~45291738:+
THCA	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	9.34	3.81e-19	2.23e-16	0.45	0.4	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.84e-19	2.24e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.84e-19	2.24e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.84e-19	2.24e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-9.34	3.84e-19	2.25e-16	-0.5	-0.4	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
THCA	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-9.34	3.85e-19	2.25e-16	-0.31	-0.4	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
THCA	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	9.34	3.86e-19	2.25e-16	0.59	0.4	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
THCA	cis	rs12550612	0.567	rs7834950	ENSG00000253616.4	RP11-875O11.3	9.34	3.86e-19	2.26e-16	0.56	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084305	chr8:23071377~23074488:-
THCA	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	9.34	3.86e-19	2.26e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
THCA	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	9.34	3.86e-19	2.26e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
THCA	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	9.34	3.86e-19	2.26e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
THCA	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	9.34	3.86e-19	2.26e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
THCA	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	9.34	3.88e-19	2.27e-16	0.45	0.4	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
THCA	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	9.34	3.89e-19	2.27e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
THCA	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.91e-19	2.28e-16	-0.45	-0.4	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
THCA	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	9.34	3.92e-19	2.29e-16	0.51	0.4	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
THCA	cis	rs9402743	0.597	rs9399162	ENSG00000231028.7	LINC00271	-9.34	3.93e-19	2.3e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135759368	chr6:135497801~135716055:+
THCA	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	9.34	3.98e-19	2.32e-16	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
THCA	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
THCA	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
THCA	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
THCA	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-9.34	4.01e-19	2.34e-16	-0.37	-0.4	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
THCA	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-9.34	4.01e-19	2.34e-16	-0.37	-0.4	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
THCA	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-9.34	4.01e-19	2.34e-16	-0.37	-0.4	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
THCA	cis	rs934734	0.563	rs955903	ENSG00000204929.10	AC074391.1	9.34	4.02e-19	2.34e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65348419	chr2:65436711~66084639:+
THCA	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-9.33	4.1e-19	2.39e-16	-0.39	-0.4	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
THCA	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-9.33	4.1e-19	2.39e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
THCA	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-9.33	4.11e-19	2.4e-16	-0.45	-0.4	Temperament;	chr17:14007198	chr17:14024514~14025488:+
THCA	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-9.33	4.12e-19	2.4e-16	-0.41	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
THCA	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	9.33	4.14e-19	2.41e-16	0.37	0.4	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
THCA	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-9.33	4.14e-19	2.42e-16	-0.54	-0.4	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-9.33	4.14e-19	2.42e-16	-0.54	-0.4	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
THCA	cis	rs673078	0.607	rs8467	ENSG00000275409.1	RP11-131L12.4	-9.33	4.15e-19	2.42e-16	-0.47	-0.4	Glucose homeostasis traits;	chr12:118417479	chr12:118430147~118430699:+
THCA	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-9.33	4.16e-19	2.42e-16	-0.5	-0.4	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
THCA	cis	rs4927850	1	rs7627706	ENSG00000273009.1	RP11-352G9.1	-9.33	4.16e-19	2.43e-16	-0.44	-0.4	Pancreatic cancer;	chr3:196026482	chr3:195913078~195913683:-
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000273009.1	RP11-352G9.1	-9.33	4.16e-19	2.43e-16	-0.44	-0.4	Pancreatic cancer;	chr3:196026530	chr3:195913078~195913683:-
THCA	cis	rs4927850	1	rs7627868	ENSG00000273009.1	RP11-352G9.1	-9.33	4.16e-19	2.43e-16	-0.44	-0.4	Pancreatic cancer;	chr3:196026602	chr3:195913078~195913683:-
THCA	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	9.33	4.16e-19	2.43e-16	0.54	0.4	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
THCA	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	9.33	4.2e-19	2.45e-16	1.09	0.4	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	9.33	4.2e-19	2.45e-16	1.09	0.4	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
THCA	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-9.33	4.21e-19	2.45e-16	-0.4	-0.4	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000234255.7	AC012370.3	-9.33	4.21e-19	2.45e-16	-0.43	-0.4	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65439888~65456571:-
THCA	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	9.33	4.21e-19	2.45e-16	0.37	0.4	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
THCA	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-9.33	4.23e-19	2.46e-16	-0.53	-0.4	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
THCA	cis	rs9532669	0.963	rs9532681	ENSG00000239827.7	SUGT1P3	-9.33	4.24e-19	2.47e-16	-0.43	-0.4	Cervical cancer;	chr13:40951633	chr13:40908159~40921774:-
THCA	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	9.33	4.24e-19	2.47e-16	0.47	0.4	Height;	chr6:109471826	chr6:109382795~109383666:+
THCA	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-9.33	4.29e-19	2.5e-16	-0.4	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
THCA	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	9.33	4.32e-19	2.51e-16	0.5	0.4	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
THCA	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	9.33	4.34e-19	2.53e-16	0.55	0.4	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
THCA	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	9.33	4.35e-19	2.54e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	9.33	4.35e-19	2.54e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
THCA	cis	rs17807185	0.653	rs9641271	ENSG00000214293.7	APTR	9.32	4.37e-19	2.55e-16	0.28	0.4	Height;	chr7:77668098	chr7:77657660~77696265:-
THCA	cis	rs9532669	0.889	rs7333447	ENSG00000239827.7	SUGT1P3	-9.32	4.4e-19	2.56e-16	-0.42	-0.4	Cervical cancer;	chr13:40917586	chr13:40908159~40921774:-
THCA	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	9.32	4.4e-19	2.56e-16	0.66	0.4	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
THCA	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	9.32	4.43e-19	2.58e-16	0.41	0.4	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
THCA	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	9.32	4.44e-19	2.58e-16	0.47	0.4	Height;	chr6:109458989	chr6:109382795~109383666:+
THCA	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-9.32	4.44e-19	2.59e-16	-0.37	-0.4	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
THCA	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	9.32	4.46e-19	2.59e-16	0.6	0.4	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-9.32	4.47e-19	2.6e-16	-0.57	-0.4	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
THCA	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	9.32	4.5e-19	2.62e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
THCA	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	9.32	4.52e-19	2.63e-16	0.28	0.39	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	9.32	4.52e-19	2.63e-16	0.28	0.39	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	9.32	4.52e-19	2.63e-16	0.28	0.39	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	9.32	4.52e-19	2.63e-16	0.28	0.39	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
THCA	cis	rs12188164	0.714	rs11741954	ENSG00000221990.4	EXOC3-AS1	9.32	4.53e-19	2.63e-16	0.35	0.39	Cystic fibrosis severity;	chr5:421340	chr5:441498~443160:-
THCA	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	9.32	4.54e-19	2.64e-16	0.47	0.39	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
THCA	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	9.32	4.57e-19	2.66e-16	0.59	0.39	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
THCA	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-9.32	4.58e-19	2.66e-16	-0.49	-0.39	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
THCA	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	9.32	4.59e-19	2.67e-16	0.54	0.39	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
THCA	cis	rs67311347	0.502	rs3924444	ENSG00000223797.4	ENTPD3-AS1	9.32	4.61e-19	2.68e-16	0.32	0.39	Renal cell carcinoma;	chr3:40534570	chr3:40313802~40453329:-
THCA	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	9.32	4.62e-19	2.68e-16	0.4	0.39	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	9.32	4.62e-19	2.68e-16	0.4	0.39	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	9.32	4.62e-19	2.68e-16	0.4	0.39	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
THCA	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	9.32	4.65e-19	2.7e-16	0.47	0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-9.32	4.66e-19	2.71e-16	-0.32	-0.39	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	9.32	4.66e-19	2.71e-16	0.28	0.39	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
THCA	cis	rs10971721	0.643	rs10971702	ENSG00000260947.1	RP11-384P7.7	9.32	4.66e-19	2.71e-16	1.09	0.39	Body mass index;	chr9:33784104	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.643	rs12375483	ENSG00000260947.1	RP11-384P7.7	9.32	4.66e-19	2.71e-16	1.09	0.39	Body mass index;	chr9:33784910	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.643	rs72711741	ENSG00000260947.1	RP11-384P7.7	9.32	4.66e-19	2.71e-16	1.09	0.39	Body mass index;	chr9:33785113	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	9.32	4.66e-19	2.71e-16	1.09	0.39	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
THCA	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	9.32	4.67e-19	2.72e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
THCA	cis	rs9402743	0.632	rs6570038	ENSG00000231028.7	LINC00271	-9.32	4.68e-19	2.72e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135775465	chr6:135497801~135716055:+
THCA	cis	rs28510890	0.754	rs11074080	ENSG00000260337.3	RP11-386M24.6	9.32	4.72e-19	2.74e-16	0.48	0.39	Lung cancer in ever smokers;	chr15:92595272	chr15:92592574~92596462:-
THCA	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-9.31	4.75e-19	2.76e-16	-0.37	-0.39	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
THCA	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-9.31	4.75e-19	2.76e-16	-0.37	-0.39	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000215447.6	BX322557.10	-9.31	4.76e-19	2.77e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45288052~45291738:+
THCA	cis	rs1707322	0.691	rs11211174	ENSG00000234329.1	RP11-767N6.2	9.31	4.76e-19	2.77e-16	0.38	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45651039~45651826:-
THCA	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	9.31	4.77e-19	2.77e-16	0.48	0.39	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
THCA	cis	rs7727544	0.716	rs11949055	ENSG00000237714.1	P4HA2-AS1	9.31	4.77e-19	2.77e-16	0.52	0.39	Blood metabolite levels;	chr5:132241044	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.716	rs3844312	ENSG00000237714.1	P4HA2-AS1	9.31	4.77e-19	2.77e-16	0.52	0.39	Blood metabolite levels;	chr5:132246663	chr5:132184876~132192808:+
THCA	cis	rs12188164	0.686	rs11741946	ENSG00000221990.4	EXOC3-AS1	9.31	4.81e-19	2.79e-16	0.35	0.39	Cystic fibrosis severity;	chr5:421288	chr5:441498~443160:-
THCA	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-9.31	4.81e-19	2.8e-16	-0.48	-0.39	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
THCA	cis	rs11051970	0.559	rs4931012	ENSG00000274964.1	RP11-817I4.1	-9.31	4.82e-19	2.8e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32328970	chr12:32339368~32340724:+
THCA	cis	rs4964805	0.632	rs11111782	ENSG00000257681.1	RP11-341G23.4	-9.31	4.83e-19	2.81e-16	-0.46	-0.39	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103746315~103768858:-
THCA	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	9.31	4.86e-19	2.82e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
THCA	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	9.31	4.87e-19	2.83e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
THCA	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	9.31	4.88e-19	2.83e-16	0.5	0.39	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
THCA	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	9.31	4.89e-19	2.84e-16	0.49	0.39	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	9.31	4.9e-19	2.84e-16	0.48	0.39	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
THCA	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	9.31	4.92e-19	2.86e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
THCA	cis	rs2599510	0.807	rs176416	ENSG00000276334.1	AL133243.1	-9.31	4.92e-19	2.86e-16	-0.43	-0.39	Interleukin-18 levels;	chr2:32427155	chr2:32521927~32523547:+
THCA	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	9.31	4.94e-19	2.87e-16	0.62	0.39	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
THCA	cis	rs11051970	0.559	rs11051939	ENSG00000274964.1	RP11-817I4.1	9.31	4.94e-19	2.87e-16	0.5	0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330107	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs16919727	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32329976	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051940	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330187	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051941	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330338	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051942	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330344	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs4316592	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32331076	chr12:32339368~32340724:+
THCA	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	9.31	4.95e-19	2.87e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
THCA	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	9.31	4.96e-19	2.88e-16	0.44	0.39	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
THCA	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-9.31	4.97e-19	2.88e-16	-0.47	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
THCA	cis	rs17772222	0.63	rs8017811	ENSG00000258789.1	RP11-507K2.3	9.31	4.97e-19	2.89e-16	0.38	0.39	Coronary artery calcification;	chr14:88534559	chr14:88551597~88552493:+
THCA	cis	rs944289	0.74	rs4982333	ENSG00000257826.1	RP11-116N8.4	-9.31	5.04e-19	2.92e-16	-0.41	-0.39	Thyroid cancer;	chr14:36100842	chr14:36061026~36067190:-
THCA	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-9.31	5.04e-19	2.92e-16	-0.44	-0.39	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
THCA	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	9.31	5.06e-19	2.93e-16	0.28	0.39	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
THCA	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-9.31	5.06e-19	2.94e-16	-0.48	-0.39	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
THCA	cis	rs737008	0.5	rs7189239	ENSG00000262636.1	CTD-3088G3.4	9.31	5.07e-19	2.94e-16	0.49	0.39	Obesity-related traits;	chr16:11308658	chr16:11380859~11381118:-
THCA	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	9.31	5.07e-19	2.94e-16	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
THCA	cis	rs12188164	0.686	rs72711369	ENSG00000221990.4	EXOC3-AS1	9.31	5.07e-19	2.94e-16	0.35	0.39	Cystic fibrosis severity;	chr5:420402	chr5:441498~443160:-
THCA	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	9.31	5.08e-19	2.94e-16	0.68	0.39	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
THCA	cis	rs2033711	0.87	rs6510152	ENSG00000268912.1	CTD-2619J13.17	-9.31	5.08e-19	2.95e-16	-0.31	-0.39	Uric acid clearance;	chr19:58441952	chr19:58428632~58431148:-
THCA	cis	rs11051970	0.559	rs3748275	ENSG00000274964.1	RP11-817I4.1	-9.31	5.1e-19	2.96e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32328159	chr12:32339368~32340724:+
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000215447.6	BX322557.10	-9.31	5.1e-19	2.96e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	9.31	5.11e-19	2.96e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	9.31	5.11e-19	2.96e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	9.31	5.11e-19	2.96e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
THCA	cis	rs7849270	0.918	rs746873	ENSG00000268707.1	RP11-247A12.7	9.3	5.12e-19	2.97e-16	0.53	0.39	Blood metabolite ratios;	chr9:129102671	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.959	rs746872	ENSG00000268707.1	RP11-247A12.7	9.3	5.12e-19	2.97e-16	0.53	0.39	Blood metabolite ratios;	chr9:129102748	chr9:129170434~129170940:+
THCA	cis	rs2288884	0.537	rs4145658	ENSG00000275055.1	CTC-471J1.11	-9.3	5.12e-19	2.97e-16	-0.31	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:52049007~52049754:+
THCA	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	9.3	5.13e-19	2.97e-16	0.69	0.39	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
THCA	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	9.3	5.13e-19	2.98e-16	0.55	0.39	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
THCA	cis	rs12188164	0.686	rs72711370	ENSG00000221990.4	EXOC3-AS1	9.3	5.14e-19	2.98e-16	0.35	0.39	Cystic fibrosis severity;	chr5:420942	chr5:441498~443160:-
THCA	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	9.3	5.14e-19	2.98e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-9.3	5.14e-19	2.98e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
THCA	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	9.3	5.15e-19	2.99e-16	0.53	0.39	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
THCA	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-9.3	5.16e-19	2.99e-16	-0.46	-0.39	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-9.3	5.16e-19	2.99e-16	-0.46	-0.39	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
THCA	cis	rs10971721	0.643	rs10971701	ENSG00000260947.1	RP11-384P7.7	9.3	5.17e-19	3e-16	1.09	0.39	Body mass index;	chr9:33781900	chr9:33697459~33700986:+
THCA	cis	rs17684571	0.7	rs17684802	ENSG00000231441.1	RP11-472M19.2	-9.3	5.21e-19	3.02e-16	-0.51	-0.39	Schizophrenia;	chr6:56813854	chr6:56844002~56864078:+
THCA	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	9.3	5.22e-19	3.02e-16	0.64	0.39	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
THCA	cis	rs934734	0.509	rs12185577	ENSG00000234255.7	AC012370.3	-9.3	5.22e-19	3.03e-16	-0.43	-0.39	Rheumatoid arthritis;	chr2:65432354	chr2:65439888~65456571:-
THCA	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-9.3	5.25e-19	3.04e-16	-0.28	-0.39	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
THCA	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-9.3	5.29e-19	3.06e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
THCA	cis	rs673078	0.607	rs11068906	ENSG00000275409.1	RP11-131L12.4	-9.3	5.3e-19	3.07e-16	-0.43	-0.39	Glucose homeostasis traits;	chr12:118315098	chr12:118430147~118430699:+
THCA	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	9.3	5.33e-19	3.09e-16	0.4	0.39	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
THCA	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-9.3	5.34e-19	3.09e-16	-0.41	-0.39	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000206090.4	AP000350.7	9.3	5.37e-19	3.11e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23939998~23942798:+
THCA	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-9.3	5.37e-19	3.11e-16	-0.54	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
THCA	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	9.3	5.41e-19	3.13e-16	0.45	0.39	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
THCA	cis	rs7727544	0.716	rs7720230	ENSG00000237714.1	P4HA2-AS1	9.3	5.42e-19	3.14e-16	0.52	0.39	Blood metabolite levels;	chr5:132256712	chr5:132184876~132192808:+
THCA	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	9.3	5.45e-19	3.15e-16	0.57	0.39	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
THCA	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1442546	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650240	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1442545	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650268	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs7090892	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652093	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
THCA	cis	rs2980439	0.517	rs712253	ENSG00000253893.2	FAM85B	9.3	5.48e-19	3.17e-16	0.51	0.39	Neuroticism;	chr8:8246260	chr8:8167819~8226614:-
THCA	cis	rs8062405	0.508	rs9929088	ENSG00000259982.1	CDC37P1	-9.3	5.51e-19	3.19e-16	-0.51	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28990139	chr16:28700294~28701540:-
THCA	cis	rs9318086	1	rs9318086	ENSG00000205861.10	C1QTNF9B-AS1	9.3	5.51e-19	3.19e-16	0.45	0.39	Myopia (pathological);	chr13:23858328	chr13:23888889~23897263:+
THCA	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-9.3	5.53e-19	3.2e-16	-0.45	-0.39	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
THCA	cis	rs2033711	0.902	rs4801589	ENSG00000268912.1	CTD-2619J13.17	-9.29	5.54e-19	3.2e-16	-0.31	-0.39	Uric acid clearance;	chr19:58442031	chr19:58428632~58431148:-
THCA	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-9.29	5.6e-19	3.24e-16	-0.32	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
THCA	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	9.29	5.61e-19	3.25e-16	0.52	0.39	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
THCA	cis	rs2032366	0.606	rs1377171	ENSG00000267279.1	RP11-879F14.2	-9.29	5.62e-19	3.25e-16	-0.42	-0.39	Obesity-related traits;	chr18:61606810	chr18:61585746~61606916:-
THCA	cis	rs11051970	0.559	rs11051938	ENSG00000274964.1	RP11-817I4.1	-9.29	5.65e-19	3.27e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32329882	chr12:32339368~32340724:+
THCA	cis	rs9402743	0.597	rs34266043	ENSG00000231028.7	LINC00271	-9.29	5.66e-19	3.27e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135763663	chr6:135497801~135716055:+
THCA	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
THCA	cis	rs9402743	0.632	rs9399166	ENSG00000231028.7	LINC00271	-9.29	5.68e-19	3.28e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135776762	chr6:135497801~135716055:+
THCA	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	9.29	5.68e-19	3.28e-16	0.48	0.39	Height;	chr11:118855938	chr11:118688039~118690600:-
THCA	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	9.29	5.68e-19	3.28e-16	0.57	0.39	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
THCA	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	9.29	5.69e-19	3.29e-16	0.42	0.39	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000215447.6	BX322557.10	-9.29	5.7e-19	3.29e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45288052~45291738:+
THCA	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-9.29	5.74e-19	3.32e-16	-0.39	-0.39	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
THCA	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	9.29	5.75e-19	3.32e-16	0.29	0.39	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
THCA	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-9.29	5.76e-19	3.33e-16	-0.44	-0.39	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
THCA	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-9.29	5.76e-19	3.33e-16	-0.29	-0.39	Height;	chr11:118856460	chr11:118791254~118793137:+
THCA	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-9.29	5.76e-19	3.33e-16	-0.29	-0.39	Height;	chr11:118856623	chr11:118791254~118793137:+
THCA	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-9.29	5.76e-19	3.33e-16	-0.29	-0.39	Height;	chr11:118857611	chr11:118791254~118793137:+
THCA	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-9.29	5.78e-19	3.34e-16	-0.39	-0.39	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
THCA	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-9.29	5.78e-19	3.34e-16	-0.41	-0.39	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
THCA	cis	rs748404	0.697	rs513970	ENSG00000249839.1	AC011330.5	-9.29	5.81e-19	3.35e-16	-0.47	-0.39	Lung cancer;	chr15:43287368	chr15:43663654~43684339:-
THCA	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	9.29	5.85e-19	3.38e-16	0.77	0.39	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
THCA	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	9.29	5.86e-19	3.38e-16	0.52	0.39	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
THCA	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	9.29	5.86e-19	3.38e-16	0.53	0.39	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
THCA	cis	rs3743772	0.5	rs11859135	ENSG00000279722.1	RP11-44F14.6	9.29	5.87e-19	3.39e-16	0.53	0.39	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53487607~53489943:-
THCA	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-9.29	5.88e-19	3.39e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	9.29	5.93e-19	3.42e-16	0.8	0.39	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	9.29	5.93e-19	3.42e-16	0.8	0.39	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	9.29	5.93e-19	3.42e-16	0.8	0.39	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000215447.6	BX322557.10	-9.29	5.95e-19	3.44e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45288052~45291738:+
THCA	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-9.29	5.98e-19	3.45e-16	-0.37	-0.39	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
THCA	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	9.28	6.02e-19	3.47e-16	0.48	0.39	Height;	chr11:118855233	chr11:118688039~118690600:-
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	9.28	6.03e-19	3.48e-16	0.53	0.39	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000215447.6	BX322557.10	-9.28	6.05e-19	3.49e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45288052~45291738:+
THCA	cis	rs860295	0.812	rs12407800	ENSG00000225855.5	RUSC1-AS1	9.28	6.08e-19	3.51e-16	0.28	0.39	Body mass index;	chr1:155790951	chr1:155316863~155324176:-
THCA	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	9.28	6.09e-19	3.51e-16	0.45	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
THCA	cis	rs934734	0.511	rs62141115	ENSG00000234255.7	AC012370.3	-9.28	6.11e-19	3.52e-16	-0.43	-0.39	Rheumatoid arthritis;	chr2:65445058	chr2:65439888~65456571:-
THCA	cis	rs4819052	0.851	rs28442024	ENSG00000215447.6	BX322557.10	-9.28	6.13e-19	3.53e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45288052~45291738:+
THCA	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	9.28	6.17e-19	3.55e-16	0.32	0.39	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
THCA	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	9.28	6.18e-19	3.56e-16	0.58	0.39	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
THCA	cis	rs17684571	0.751	rs6918949	ENSG00000231441.1	RP11-472M19.2	-9.28	6.19e-19	3.56e-16	-0.5	-0.39	Schizophrenia;	chr6:56845183	chr6:56844002~56864078:+
THCA	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	9.28	6.21e-19	3.58e-16	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
THCA	cis	rs860295	0.812	rs12081192	ENSG00000225855.5	RUSC1-AS1	9.28	6.24e-19	3.59e-16	0.28	0.39	Body mass index;	chr1:155768253	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	9.28	6.29e-19	3.62e-16	0.8	0.39	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	9.28	6.29e-19	3.62e-16	0.8	0.39	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	9.28	6.29e-19	3.62e-16	0.8	0.39	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
THCA	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	9.28	6.29e-19	3.62e-16	0.4	0.39	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
THCA	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	9.28	6.31e-19	3.63e-16	0.38	0.39	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
THCA	cis	rs17684571	0.7	rs35440822	ENSG00000231441.1	RP11-472M19.2	9.28	6.31e-19	3.63e-16	0.51	0.39	Schizophrenia;	chr6:56801006	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.575	rs71564855	ENSG00000231441.1	RP11-472M19.2	9.28	6.31e-19	3.63e-16	0.51	0.39	Schizophrenia;	chr6:56801117	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13218913	ENSG00000231441.1	RP11-472M19.2	9.28	6.31e-19	3.63e-16	0.51	0.39	Schizophrenia;	chr6:56801247	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs71564856	ENSG00000231441.1	RP11-472M19.2	9.28	6.31e-19	3.63e-16	0.51	0.39	Schizophrenia;	chr6:56803447	chr6:56844002~56864078:+
THCA	cis	rs10411161	1	rs10402727	ENSG00000269483.1	AC006272.1	9.28	6.32e-19	3.64e-16	0.55	0.39	Breast cancer;	chr19:51867126	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs10409331	ENSG00000269483.1	AC006272.1	9.28	6.32e-19	3.64e-16	0.55	0.39	Breast cancer;	chr19:51867709	chr19:51839924~51843324:-
THCA	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	9.28	6.32e-19	3.64e-16	0.48	0.39	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
THCA	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	9.28	6.32e-19	3.64e-16	0.8	0.39	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	9.28	6.32e-19	3.64e-16	0.8	0.39	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	9.28	6.32e-19	3.64e-16	0.8	0.39	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
THCA	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	9.28	6.33e-19	3.65e-16	0.59	0.39	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
THCA	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-9.28	6.36e-19	3.66e-16	-0.37	-0.39	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
THCA	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-9.28	6.38e-19	3.67e-16	-0.59	-0.39	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
THCA	cis	rs2841233	0.692	rs2028416	ENSG00000258701.1	LINC00638	9.28	6.4e-19	3.68e-16	0.41	0.39	IgG glycosylation;	chr14:104882215	chr14:104821201~104823718:+
THCA	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	9.28	6.42e-19	3.69e-16	0.49	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs7069157	ENSG00000254271.1	RP11-131N11.4	9.28	6.42e-19	3.7e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60629475	chr10:60734342~60741828:+
THCA	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-9.28	6.45e-19	3.71e-16	-0.5	-0.39	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
THCA	cis	rs10181042	0.581	rs1177285	ENSG00000271889.1	RP11-493E12.1	9.28	6.46e-19	3.71e-16	0.39	0.39	Crohn's disease;	chr2:61123002	chr2:61151433~61162105:-
THCA	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-9.28	6.47e-19	3.72e-16	-0.48	-0.39	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
THCA	cis	rs2599510	1	rs2599510	ENSG00000276334.1	AL133243.1	9.27	6.49e-19	3.73e-16	0.41	0.39	Interleukin-18 levels;	chr2:32600935	chr2:32521927~32523547:+
THCA	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	9.27	6.52e-19	3.75e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
THCA	cis	rs860295	0.812	rs7556519	ENSG00000225855.5	RUSC1-AS1	9.27	6.54e-19	3.76e-16	0.28	0.39	Body mass index;	chr1:155857755	chr1:155316863~155324176:-
THCA	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	9.27	6.55e-19	3.76e-16	0.57	0.39	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	9.27	6.55e-19	3.77e-16	0.44	0.39	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
THCA	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	9.27	6.57e-19	3.78e-16	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
THCA	cis	rs28510890	0.828	rs56874300	ENSG00000260337.3	RP11-386M24.6	9.27	6.57e-19	3.78e-16	0.48	0.39	Lung cancer in ever smokers;	chr15:92583525	chr15:92592574~92596462:-
THCA	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-9.27	6.58e-19	3.78e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
THCA	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
THCA	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	9.27	6.59e-19	3.79e-16	0.37	0.39	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
THCA	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-9.27	6.59e-19	3.79e-16	-0.37	-0.39	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
THCA	cis	rs934734	0.532	rs12470883	ENSG00000234255.7	AC012370.3	-9.27	6.61e-19	3.8e-16	-0.43	-0.39	Rheumatoid arthritis;	chr2:65424717	chr2:65439888~65456571:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000206090.4	AP000350.7	9.27	6.64e-19	3.82e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23939998~23942798:+
THCA	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	9.27	6.65e-19	3.82e-16	0.5	0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
THCA	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-9.27	6.66e-19	3.83e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
THCA	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	9.27	6.67e-19	3.83e-16	0.51	0.39	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	9.27	6.74e-19	3.87e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	9.27	6.74e-19	3.87e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
THCA	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	9.27	6.75e-19	3.88e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
THCA	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	9.27	6.76e-19	3.88e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-9.27	6.76e-19	3.88e-16	-0.41	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
THCA	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-9.27	6.76e-19	3.88e-16	-0.41	-0.39	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
THCA	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	9.27	6.78e-19	3.89e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
THCA	cis	rs7211079	0.843	rs73438138	ENSG00000275479.1	RP11-334C17.6	9.27	6.81e-19	3.91e-16	0.39	0.39	Myocardial infarction;	chr17:80148608	chr17:80149627~80149798:+
THCA	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-9.27	6.82e-19	3.91e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-9.27	6.83e-19	3.92e-16	-0.56	-0.39	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
THCA	cis	rs4927850	1	rs7614767	ENSG00000273009.1	RP11-352G9.1	-9.27	6.84e-19	3.93e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196026580	chr3:195913078~195913683:-
THCA	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	9.27	6.84e-19	3.93e-16	0.53	0.39	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
THCA	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-9.27	6.86e-19	3.94e-16	-0.44	-0.39	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
THCA	cis	rs1009647	0.961	rs1009648	ENSG00000258413.1	RP11-665C16.6	-9.27	6.87e-19	3.95e-16	-0.58	-0.39	Testicular germ cell tumor;	chr14:55413451	chr14:55262767~55272075:-
THCA	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	9.27	6.98e-19	4e-16	0.47	0.39	Height;	chr6:109370985	chr6:109382795~109383666:+
THCA	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-9.26	7.03e-19	4.04e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
THCA	cis	rs9402743	0.597	rs9483879	ENSG00000231028.7	LINC00271	-9.26	7.07e-19	4.06e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135778024	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs9494383	ENSG00000231028.7	LINC00271	-9.26	7.07e-19	4.06e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135778026	chr6:135497801~135716055:+
THCA	cis	rs11971779	0.68	rs4398844	ENSG00000273391.1	RP11-634H22.1	9.26	7.11e-19	4.08e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139358393	chr7:139359032~139359566:-
THCA	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	9.26	7.11e-19	4.08e-16	0.37	0.39	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
THCA	cis	rs6061231	0.675	rs755726	ENSG00000273619.1	RP5-908M14.9	-9.26	7.17e-19	4.11e-16	-0.3	-0.39	Colorectal cancer;	chr20:62387568	chr20:62386303~62386970:-
THCA	cis	rs9828933	0.938	rs831691	ENSG00000280620.1	SCAANT1	9.26	7.19e-19	4.13e-16	0.61	0.39	Type 2 diabetes;	chr3:64021538	chr3:63911518~63911772:-
THCA	cis	rs9532669	0.926	rs9525438	ENSG00000239827.7	SUGT1P3	-9.26	7.27e-19	4.17e-16	-0.42	-0.39	Cervical cancer;	chr13:40964123	chr13:40908159~40921774:-
THCA	cis	rs2032366	0.63	rs1894094	ENSG00000267279.1	RP11-879F14.2	-9.26	7.27e-19	4.17e-16	-0.42	-0.39	Obesity-related traits;	chr18:61606390	chr18:61585746~61606916:-
THCA	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	9.26	7.31e-19	4.19e-16	0.52	0.39	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
THCA	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-9.26	7.34e-19	4.21e-16	-0.43	-0.39	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
THCA	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	9.26	7.35e-19	4.21e-16	0.59	0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
THCA	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	9.26	7.37e-19	4.22e-16	0.42	0.39	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
THCA	cis	rs5769707	0.967	rs5769698	ENSG00000235111.1	RP1-29C18.8	-9.26	7.37e-19	4.22e-16	-0.45	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49612657~49615716:-
THCA	cis	rs4380275	0.782	rs4468850	ENSG00000272342.1	RP13-539J13.1	9.26	7.38e-19	4.23e-16	0.47	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:739588~740164:-
THCA	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-9.26	7.39e-19	4.24e-16	-0.37	-0.39	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.851	rs2838867	ENSG00000215447.6	BX322557.10	-9.26	7.44e-19	4.26e-16	-0.34	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:45288052~45291738:+
THCA	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	9.26	7.46e-19	4.27e-16	0.41	0.39	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
THCA	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-9.26	7.51e-19	4.3e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-9.26	7.51e-19	4.3e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-9.26	7.51e-19	4.3e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	9.26	7.55e-19	4.33e-16	0.51	0.39	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000273009.1	RP11-352G9.1	-9.26	7.56e-19	4.33e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196024982	chr3:195913078~195913683:-
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000273009.1	RP11-352G9.1	-9.26	7.56e-19	4.33e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196025389	chr3:195913078~195913683:-
THCA	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	9.25	7.61e-19	4.36e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
THCA	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	9.25	7.63e-19	4.37e-16	0.77	0.39	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
THCA	cis	rs9532669	0.89	rs9532593	ENSG00000239827.7	SUGT1P3	-9.25	7.66e-19	4.38e-16	-0.44	-0.39	Cervical cancer;	chr13:40847717	chr13:40908159~40921774:-
THCA	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-9.25	7.74e-19	4.43e-16	-0.32	-0.39	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
THCA	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	-9.25	7.74e-19	4.43e-16	-0.53	-0.39	Depression;	chr6:28173770	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	-9.25	7.74e-19	4.43e-16	-0.53	-0.39	Depression;	chr6:28174809	chr6:28161781~28169594:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	-9.25	7.74e-19	4.43e-16	-0.53	-0.39	Depression;	chr6:28175233	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	-9.25	7.74e-19	4.43e-16	-0.53	-0.39	Depression;	chr6:28176973	chr6:28161781~28169594:+
THCA	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-9.25	7.77e-19	4.44e-16	-0.37	-0.39	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	9.25	7.78e-19	4.45e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
THCA	cis	rs324126	1	rs324126	ENSG00000277977.1	CTD-3018O17.5	-9.25	7.78e-19	4.45e-16	-0.37	-0.39	Colonoscopy-negative controls vs population controls;	chr19:52382884	chr19:52392659~52392755:+
THCA	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-9.25	7.81e-19	4.47e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-9.25	7.81e-19	4.47e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-9.25	7.81e-19	4.47e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
THCA	cis	rs9402743	0.632	rs7766804	ENSG00000231028.7	LINC00271	-9.25	7.81e-19	4.47e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135772118	chr6:135497801~135716055:+
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000275120.1	RP11-182J1.17	-9.25	7.81e-19	4.47e-16	-0.42	-0.39	P wave terminal force;	chr15:84635039	chr15:84599434~84606463:-
THCA	cis	rs17684571	0.687	rs34083827	ENSG00000231441.1	RP11-472M19.2	9.25	7.83e-19	4.48e-16	0.53	0.39	Schizophrenia;	chr6:56866498	chr6:56844002~56864078:+
THCA	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	9.25	7.84e-19	4.48e-16	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
THCA	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	9.25	7.89e-19	4.51e-16	0.44	0.39	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
THCA	cis	rs11051970	0.592	rs11051987	ENSG00000274964.1	RP11-817I4.1	-9.25	7.9e-19	4.52e-16	-0.52	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32402472	chr12:32339368~32340724:+
THCA	cis	rs9402743	0.632	rs6570040	ENSG00000231028.7	LINC00271	-9.25	7.95e-19	4.54e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135779557	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs7754830	ENSG00000231028.7	LINC00271	-9.25	7.95e-19	4.54e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135779904	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs2104133	ENSG00000231028.7	LINC00271	-9.25	7.95e-19	4.54e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135781149	chr6:135497801~135716055:+
THCA	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	9.25	7.97e-19	4.56e-16	0.4	0.39	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
THCA	cis	rs17684571	0.751	rs7775182	ENSG00000231441.1	RP11-472M19.2	9.25	7.97e-19	4.56e-16	0.51	0.39	Schizophrenia;	chr6:56831848	chr6:56844002~56864078:+
THCA	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-9.25	8.02e-19	4.58e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
THCA	cis	rs10411161	1	rs8111316	ENSG00000269483.1	AC006272.1	9.25	8.05e-19	4.6e-16	0.54	0.39	Breast cancer;	chr19:51865816	chr19:51839924~51843324:-
THCA	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	9.25	8.1e-19	4.62e-16	0.5	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000273009.1	RP11-352G9.1	-9.25	8.15e-19	4.65e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196021858	chr3:195913078~195913683:-
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000215447.6	BX322557.10	-9.25	8.2e-19	4.68e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45288052~45291738:+
THCA	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	9.25	8.2e-19	4.68e-16	0.53	0.39	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000215447.6	BX322557.10	-9.25	8.2e-19	4.68e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45288052~45291738:+
THCA	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	9.25	8.2e-19	4.68e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	9.25	8.2e-19	4.68e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	9.25	8.22e-19	4.69e-16	0.52	0.39	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
THCA	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	9.24	8.23e-19	4.7e-16	0.77	0.39	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
THCA	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	9.24	8.23e-19	4.7e-16	0.29	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
THCA	cis	rs28510890	0.547	rs12443027	ENSG00000260337.3	RP11-386M24.6	9.24	8.27e-19	4.72e-16	0.53	0.39	Lung cancer in ever smokers;	chr15:92612013	chr15:92592574~92596462:-
THCA	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-9.24	8.28e-19	4.72e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
THCA	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-9.24	8.34e-19	4.76e-16	-0.39	-0.39	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
THCA	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-9.24	8.41e-19	4.79e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
THCA	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	-9.24	8.43e-19	4.81e-16	-0.53	-0.39	Depression;	chr6:28180209	chr6:28161781~28169594:+
THCA	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-9.24	8.45e-19	4.82e-16	-0.53	-0.39	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
THCA	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-9.24	8.46e-19	4.82e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
THCA	cis	rs4927850	1	rs7630875	ENSG00000273009.1	RP11-352G9.1	-9.24	8.48e-19	4.84e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196026895	chr3:195913078~195913683:-
THCA	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	9.24	8.5e-19	4.85e-16	0.56	0.39	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
THCA	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-9.24	8.5e-19	4.85e-16	-0.45	-0.39	Temperament;	chr17:14007316	chr17:14024514~14025488:+
THCA	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-9.24	8.5e-19	4.85e-16	-0.45	-0.39	Temperament;	chr17:13999319	chr17:14024514~14025488:+
THCA	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-9.24	8.52e-19	4.86e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
THCA	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-9.24	8.52e-19	4.86e-16	-0.47	-0.39	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-9.24	8.52e-19	4.86e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
THCA	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-9.24	8.57e-19	4.88e-16	-0.5	-0.39	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
THCA	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	9.24	8.61e-19	4.91e-16	0.5	0.39	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
THCA	cis	rs7772486	0.742	rs4896851	ENSG00000235652.6	RP11-545I5.3	-9.24	8.62e-19	4.91e-16	-0.36	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145957823	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.544	rs6804545	ENSG00000223797.4	ENTPD3-AS1	9.24	8.65e-19	4.93e-16	0.32	0.39	Renal cell carcinoma;	chr3:40312549	chr3:40313802~40453329:-
THCA	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	9.24	8.66e-19	4.94e-16	0.5	0.39	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
THCA	cis	rs12188164	0.686	rs72711367	ENSG00000221990.4	EXOC3-AS1	9.24	8.74e-19	4.98e-16	0.34	0.39	Cystic fibrosis severity;	chr5:418379	chr5:441498~443160:-
THCA	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	9.24	8.76e-19	4.99e-16	0.28	0.39	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
THCA	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	9.24	8.76e-19	4.99e-16	0.28	0.39	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
THCA	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	9.24	8.77e-19	4.99e-16	0.68	0.39	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
THCA	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	9.24	8.78e-19	5e-16	0.29	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
THCA	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	9.24	8.79e-19	5.01e-16	0.48	0.39	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
THCA	cis	rs860295	0.841	rs7556102	ENSG00000225855.5	RUSC1-AS1	-9.24	8.8e-19	5.01e-16	-0.26	-0.39	Body mass index;	chr1:155398412	chr1:155316863~155324176:-
THCA	cis	rs28510890	0.828	rs77955994	ENSG00000260337.3	RP11-386M24.6	9.24	8.8e-19	5.01e-16	0.48	0.39	Lung cancer in ever smokers;	chr15:92582299	chr15:92592574~92596462:-
THCA	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-9.24	8.82e-19	5.02e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
THCA	cis	rs62103177	0.584	rs9956207	ENSG00000261126.6	RP11-795F19.1	-9.24	8.89e-19	5.06e-16	-0.42	-0.39	Opioid sensitivity;	chr18:80210509	chr18:80046900~80095482:+
THCA	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	9.23	8.92e-19	5.08e-16	0.52	0.39	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
THCA	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	9.23	8.94e-19	5.09e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
THCA	cis	rs9402743	0.632	rs4896178	ENSG00000231028.7	LINC00271	-9.23	8.94e-19	5.09e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135783957	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs7773035	ENSG00000231028.7	LINC00271	-9.23	8.94e-19	5.09e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135784743	chr6:135497801~135716055:+
THCA	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-9.23	8.94e-19	5.09e-16	-0.51	-0.39	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
THCA	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-9.23	8.95e-19	5.09e-16	-0.46	-0.39	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
THCA	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	9.23	9.02e-19	5.13e-16	0.62	0.39	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
THCA	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-9.23	9.02e-19	5.13e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
THCA	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	9.23	9.1e-19	5.18e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
THCA	cis	rs944289	0.774	rs12050449	ENSG00000257826.1	RP11-116N8.4	-9.23	9.11e-19	5.18e-16	-0.4	-0.39	Thyroid cancer;	chr14:36101949	chr14:36061026~36067190:-
THCA	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	9.23	9.11e-19	5.18e-16	0.59	0.39	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
THCA	cis	rs944289	0.708	rs1537424	ENSG00000257826.1	RP11-116N8.4	-9.23	9.11e-19	5.18e-16	-0.4	-0.39	Thyroid cancer;	chr14:36104812	chr14:36061026~36067190:-
THCA	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	9.23	9.14e-19	5.2e-16	0.59	0.39	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
THCA	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-9.23	9.15e-19	5.2e-16	-0.51	-0.39	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
THCA	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	9.23	9.16e-19	5.21e-16	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	9.23	9.16e-19	5.21e-16	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
THCA	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	9.23	9.17e-19	5.21e-16	0.52	0.39	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
THCA	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.687	rs35461301	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56832577	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.687	rs35851452	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56832602	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs17752106	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56837455	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs17684878	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56838178	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs17684884	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56838852	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs7761501	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56839187	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35073881	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56842410	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs1610156	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56844274	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs74777312	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56845568	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs6905603	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56848145	chr6:56844002~56864078:+
THCA	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	9.23	9.21e-19	5.23e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
THCA	cis	rs12444156	1	rs12444156	ENSG00000260886.1	TAT-AS1	9.23	9.22e-19	5.24e-16	0.75	0.39	Post bronchodilator FEV1;	chr16:71807354	chr16:71565789~71578187:+
THCA	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-9.23	9.24e-19	5.25e-16	-0.31	-0.39	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
THCA	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
THCA	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	9.23	9.25e-19	5.25e-16	0.32	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
THCA	cis	rs2033711	0.87	rs11669741	ENSG00000268912.1	CTD-2619J13.17	9.23	9.26e-19	5.26e-16	0.3	0.39	Uric acid clearance;	chr19:58449114	chr19:58428632~58431148:-
THCA	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-9.23	9.26e-19	5.26e-16	-0.56	-0.39	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
THCA	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	9.23	9.29e-19	5.28e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000215447.6	BX322557.10	-9.23	9.29e-19	5.28e-16	-0.36	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45288052~45291738:+
THCA	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-9.23	9.35e-19	5.31e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
THCA	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-9.23	9.37e-19	5.32e-16	-0.49	-0.39	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
THCA	cis	rs4927850	1	rs10881564	ENSG00000273009.1	RP11-352G9.1	-9.23	9.44e-19	5.36e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196023455	chr3:195913078~195913683:-
THCA	cis	rs2033711	0.84	rs4801590	ENSG00000268912.1	CTD-2619J13.17	-9.23	9.49e-19	5.39e-16	-0.31	-0.39	Uric acid clearance;	chr19:58450446	chr19:58428632~58431148:-
THCA	cis	rs17772222	0.63	rs12436642	ENSG00000258789.1	RP11-507K2.3	9.23	9.51e-19	5.4e-16	0.38	0.39	Coronary artery calcification;	chr14:88559032	chr14:88551597~88552493:+
THCA	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	9.23	9.53e-19	5.4e-16	0.28	0.39	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.926	rs9566582	ENSG00000239827.7	SUGT1P3	-9.23	9.53e-19	5.4e-16	-0.43	-0.39	Cervical cancer;	chr13:40852121	chr13:40908159~40921774:-
THCA	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-9.23	9.53e-19	5.41e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
THCA	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-9.23	9.62e-19	5.45e-16	-0.51	-0.39	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000275120.1	RP11-182J1.17	-9.22	9.67e-19	5.48e-16	-0.41	-0.39	P wave terminal force;	chr15:84631400	chr15:84599434~84606463:-
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000275120.1	RP11-182J1.17	-9.22	9.67e-19	5.48e-16	-0.41	-0.39	P wave terminal force;	chr15:84631524	chr15:84599434~84606463:-
THCA	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	9.22	9.67e-19	5.48e-16	0.52	0.39	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
THCA	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	9.22	9.69e-19	5.49e-16	0.38	0.39	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
THCA	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-9.22	9.69e-19	5.49e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
THCA	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-9.22	9.71e-19	5.5e-16	-0.59	-0.39	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
THCA	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-9.22	9.72e-19	5.51e-16	-0.44	-0.39	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
THCA	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-9.22	9.73e-19	5.51e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-9.22	9.73e-19	5.51e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-9.22	9.73e-19	5.51e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
THCA	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	9.22	9.73e-19	5.51e-16	0.52	0.39	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
THCA	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	9.22	9.76e-19	5.53e-16	0.49	0.39	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
THCA	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
THCA	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
THCA	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	9.22	9.81e-19	5.56e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
THCA	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-9.22	9.85e-19	5.58e-16	-0.45	-0.39	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
THCA	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-9.22	9.88e-19	5.59e-16	-0.6	-0.39	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
THCA	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	9.22	9.88e-19	5.59e-16	0.52	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
THCA	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-9.22	9.89e-19	5.6e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
THCA	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	9.22	9.92e-19	5.61e-16	0.46	0.39	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-9.22	1.01e-18	5.69e-16	-0.28	-0.39	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
THCA	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-9.22	1.01e-18	5.73e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-9.22	1.02e-18	5.78e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
THCA	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-9.22	1.03e-18	5.82e-16	-0.43	-0.39	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000237979.1	AC007389.1	-9.22	1.03e-18	5.83e-16	-0.45	-0.39	Sum eosinophil basophil counts;	chr2:65438139	chr2:65500993~65502138:-
THCA	cis	rs7772486	0.777	rs1546966	ENSG00000235652.6	RP11-545I5.3	9.22	1.04e-18	5.85e-16	0.37	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146064882	chr6:145799409~145886585:+
THCA	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	9.22	1.04e-18	5.85e-16	0.28	0.39	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	9.22	1.04e-18	5.85e-16	0.28	0.39	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	9.22	1.04e-18	5.85e-16	0.28	0.39	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
THCA	cis	rs7191700	0.583	rs243314	ENSG00000262703.1	RP11-485G7.6	9.22	1.04e-18	5.86e-16	0.43	0.39	Multiple sclerosis;	chr16:11291247	chr16:11348143~11349321:-
THCA	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-9.22	1.04e-18	5.87e-16	-0.61	-0.39	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
THCA	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	9.21	1.04e-18	5.9e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	9.21	1.04e-18	5.9e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	-9.21	1.04e-18	5.9e-16	-0.52	-0.39	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
THCA	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-9.21	1.05e-18	5.91e-16	-0.48	-0.39	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
THCA	cis	rs6496932	0.874	rs11074061	ENSG00000218052.5	ADAMTS7P4	9.21	1.06e-18	5.96e-16	0.55	0.39	Central corneal thickness;Corneal structure;	chr15:85274962	chr15:85255369~85330334:-
THCA	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	9.21	1.06e-18	5.97e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
THCA	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	6e-16	-0.51	-0.39	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
THCA	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-9.21	1.07e-18	6.02e-16	-0.39	-0.39	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
THCA	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-9.21	1.07e-18	6.02e-16	-0.4	-0.39	QT interval;	chr12:29287150	chr12:29280418~29317848:-
THCA	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	9.21	1.07e-18	6.04e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
THCA	cis	rs875971	0.66	rs10229345	ENSG00000237310.1	GS1-124K5.4	9.21	1.07e-18	6.05e-16	0.29	0.39	Aortic root size;	chr7:66517181	chr7:66493706~66495474:+
THCA	cis	rs748404	0.65	rs556851	ENSG00000249839.1	AC011330.5	-9.21	1.08e-18	6.07e-16	-0.46	-0.39	Lung cancer;	chr15:43279021	chr15:43663654~43684339:-
THCA	cis	rs7727544	0.716	rs4594848	ENSG00000237714.1	P4HA2-AS1	9.21	1.08e-18	6.09e-16	0.52	0.39	Blood metabolite levels;	chr5:132250905	chr5:132184876~132192808:+
THCA	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-9.21	1.08e-18	6.1e-16	-0.49	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
THCA	cis	rs28510890	0.789	rs17704141	ENSG00000260337.3	RP11-386M24.6	-9.21	1.08e-18	6.1e-16	-0.48	-0.39	Lung cancer in ever smokers;	chr15:92593271	chr15:92592574~92596462:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000219392.1	RP1-265C24.5	-9.21	1.08e-18	6.11e-16	-0.43	-0.39	Cardiac Troponin-T levels;	chr6:28200255	chr6:28115628~28116551:+
THCA	cis	rs2032366	0.606	rs9965972	ENSG00000267279.1	RP11-879F14.2	-9.21	1.08e-18	6.11e-16	-0.41	-0.39	Obesity-related traits;	chr18:61609468	chr18:61585746~61606916:-
THCA	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-9.21	1.09e-18	6.12e-16	-0.31	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
THCA	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-9.21	1.09e-18	6.12e-16	-0.31	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
THCA	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	9.21	1.09e-18	6.12e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-9.21	1.09e-18	6.13e-16	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-9.21	1.09e-18	6.13e-16	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
THCA	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-9.21	1.09e-18	6.16e-16	-0.39	-0.39	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
THCA	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	9.21	1.09e-18	6.17e-16	0.72	0.39	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
THCA	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-9.21	1.1e-18	6.2e-16	-0.45	-0.39	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
THCA	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-9.21	1.1e-18	6.21e-16	-0.6	-0.39	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
THCA	cis	rs4591358	0.773	rs35070116	ENSG00000223466.1	AC064834.2	-9.21	1.1e-18	6.22e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515729	chr2:195533035~195538681:+
THCA	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-9.21	1.11e-18	6.25e-16	-0.51	-0.39	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
THCA	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-9.21	1.11e-18	6.26e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
THCA	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.27e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.27e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.27e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.27e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.28e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
THCA	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-9.21	1.12e-18	6.3e-16	-0.48	-0.39	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
THCA	cis	rs944289	0.684	rs8016315	ENSG00000257826.1	RP11-116N8.4	-9.21	1.12e-18	6.31e-16	-0.4	-0.39	Thyroid cancer;	chr14:36101158	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs4982334	ENSG00000257826.1	RP11-116N8.4	-9.21	1.12e-18	6.31e-16	-0.4	-0.39	Thyroid cancer;	chr14:36101396	chr14:36061026~36067190:-
THCA	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	9.21	1.12e-18	6.31e-16	0.54	0.39	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
THCA	cis	rs2288884	0.708	rs61574510	ENSG00000275055.1	CTC-471J1.11	-9.21	1.12e-18	6.33e-16	-0.37	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017354	chr19:52049007~52049754:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000224205.1	AP000351.4	9.21	1.12e-18	6.33e-16	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23987320~23991421:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	9.21	1.12e-18	6.34e-16	0.77	0.39	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	9.21	1.13e-18	6.34e-16	0.52	0.39	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	9.21	1.13e-18	6.34e-16	0.52	0.39	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.751	rs28360570	ENSG00000231441.1	RP11-472M19.2	9.21	1.13e-18	6.34e-16	0.5	0.39	Schizophrenia;	chr6:56852832	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs13198597	ENSG00000231441.1	RP11-472M19.2	9.21	1.13e-18	6.34e-16	0.5	0.39	Schizophrenia;	chr6:56852929	chr6:56844002~56864078:+
THCA	cis	rs11051970	0.592	rs11051985	ENSG00000274964.1	RP11-817I4.1	-9.21	1.13e-18	6.34e-16	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32402156	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051986	ENSG00000274964.1	RP11-817I4.1	-9.21	1.13e-18	6.34e-16	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32402339	chr12:32339368~32340724:+
THCA	cis	rs9532669	0.926	rs9532689	ENSG00000239827.7	SUGT1P3	-9.21	1.13e-18	6.35e-16	-0.42	-0.39	Cervical cancer;	chr13:40957990	chr13:40908159~40921774:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-9.2	1.13e-18	6.37e-16	-0.53	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
THCA	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-9.2	1.13e-18	6.38e-16	-0.58	-0.39	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-9.2	1.14e-18	6.4e-16	-0.28	-0.39	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
THCA	cis	rs950169	0.959	rs12911210	ENSG00000259728.4	LINC00933	9.2	1.14e-18	6.43e-16	0.53	0.39	Schizophrenia;	chr15:84123331	chr15:84570649~84580175:+
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000273009.1	RP11-352G9.1	-9.2	1.14e-18	6.44e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196024568	chr3:195913078~195913683:-
THCA	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	9.2	1.14e-18	6.44e-16	0.52	0.39	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
THCA	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	9.2	1.14e-18	6.44e-16	0.44	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
THCA	cis	rs28510890	0.789	rs10852177	ENSG00000260337.3	RP11-386M24.6	9.2	1.15e-18	6.47e-16	0.48	0.39	Lung cancer in ever smokers;	chr15:92594248	chr15:92592574~92596462:-
THCA	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	9.2	1.15e-18	6.48e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000226314.6	ZNF192P1	-9.2	1.15e-18	6.48e-16	-0.51	-0.39	Parkinson's disease;	chr6:28066257	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000226314.6	ZNF192P1	-9.2	1.15e-18	6.48e-16	-0.51	-0.39	Parkinson's disease;	chr6:28066263	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000226314.6	ZNF192P1	-9.2	1.15e-18	6.48e-16	-0.51	-0.39	Parkinson's disease;	chr6:28066343	chr6:28161781~28169594:+
THCA	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-9.2	1.15e-18	6.5e-16	-0.39	-0.39	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
THCA	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	9.2	1.16e-18	6.52e-16	0.51	0.39	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
THCA	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-9.2	1.16e-18	6.55e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
THCA	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-9.2	1.17e-18	6.56e-16	-0.44	-0.39	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
THCA	cis	rs9928842	0.765	rs6564220	ENSG00000280152.1	RP11-331F4.5	9.2	1.17e-18	6.56e-16	0.57	0.39	Alcoholic chronic pancreatitis;	chr16:75190296	chr16:75245994~75250077:-
THCA	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	9.2	1.17e-18	6.58e-16	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
THCA	cis	rs2980439	0.517	rs17594065	ENSG00000253893.2	FAM85B	9.2	1.17e-18	6.58e-16	0.51	0.39	Neuroticism;	chr8:8247883	chr8:8167819~8226614:-
THCA	cis	rs9928842	0.765	rs2870467	ENSG00000280152.1	RP11-331F4.5	9.2	1.17e-18	6.58e-16	0.57	0.39	Alcoholic chronic pancreatitis;	chr16:75189983	chr16:75245994~75250077:-
THCA	cis	rs944289	0.774	rs1958624	ENSG00000257826.1	RP11-116N8.4	9.2	1.18e-18	6.61e-16	0.4	0.39	Thyroid cancer;	chr14:36128692	chr14:36061026~36067190:-
THCA	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-9.2	1.18e-18	6.62e-16	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
THCA	cis	rs7211079	0.833	rs7220523	ENSG00000275479.1	RP11-334C17.6	9.2	1.19e-18	6.67e-16	0.39	0.39	Myocardial infarction;	chr17:80153896	chr17:80149627~80149798:+
THCA	cis	rs7211079	0.879	rs7221505	ENSG00000275479.1	RP11-334C17.6	9.2	1.19e-18	6.67e-16	0.39	0.39	Myocardial infarction;	chr17:80154432	chr17:80149627~80149798:+
THCA	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	9.2	1.19e-18	6.71e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
THCA	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	9.2	1.19e-18	6.71e-16	0.59	0.39	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
THCA	cis	rs10411161	1	rs10412080	ENSG00000269483.1	AC006272.1	9.2	1.2e-18	6.73e-16	0.55	0.39	Breast cancer;	chr19:51870255	chr19:51839924~51843324:-
THCA	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-9.2	1.2e-18	6.77e-16	-0.32	-0.39	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
THCA	cis	rs67311347	0.521	rs2887963	ENSG00000223797.4	ENTPD3-AS1	-9.2	1.21e-18	6.78e-16	-0.31	-0.39	Renal cell carcinoma;	chr3:40201975	chr3:40313802~40453329:-
THCA	cis	rs17684571	0.751	rs13194625	ENSG00000231441.1	RP11-472M19.2	9.2	1.21e-18	6.78e-16	0.53	0.39	Schizophrenia;	chr6:56820446	chr6:56844002~56864078:+
THCA	cis	rs2033711	0.783	rs11671113	ENSG00000268912.1	CTD-2619J13.17	-9.2	1.21e-18	6.79e-16	-0.3	-0.39	Uric acid clearance;	chr19:58446720	chr19:58428632~58431148:-
THCA	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-9.2	1.21e-18	6.79e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-9.2	1.21e-18	6.79e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-9.2	1.21e-18	6.79e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-9.2	1.21e-18	6.79e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
THCA	cis	rs57481061	1	rs57481061	ENSG00000258302.2	RP11-981P6.1	9.2	1.21e-18	6.81e-16	0.4	0.39	Coronary artery disease;	chr12:89625401	chr12:89561129~89594878:+
THCA	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-9.2	1.21e-18	6.81e-16	-0.45	-0.39	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
THCA	cis	rs7015263	0.875	rs10093238	ENSG00000254231.1	CTD-2284J15.1	-9.2	1.22e-18	6.83e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86454867	chr8:86333274~86343314:-
THCA	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-9.2	1.22e-18	6.84e-16	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
THCA	cis	rs947583	0.517	rs9376144	ENSG00000231028.7	LINC00271	-9.19	1.22e-18	6.87e-16	-0.3	-0.39	Phosphorus levels;	chr6:135756247	chr6:135497801~135716055:+
THCA	cis	rs7429990	0.833	rs2280567	ENSG00000229759.1	MRPS18AP1	-9.19	1.22e-18	6.87e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:47572923	chr3:48256350~48256938:-
THCA	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-9.19	1.22e-18	6.88e-16	-0.32	-0.39	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
THCA	cis	rs860295	0.557	rs11264371	ENSG00000225855.5	RUSC1-AS1	9.19	1.23e-18	6.9e-16	0.28	0.39	Body mass index;	chr1:155442246	chr1:155316863~155324176:-
THCA	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-9.19	1.23e-18	6.9e-16	-0.43	-0.39	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
THCA	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs4732367	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139343356	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7808740	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139344209	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-9.19	1.23e-18	6.9e-16	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
THCA	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-9.19	1.24e-18	6.94e-16	-0.51	-0.39	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
THCA	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-9.19	1.24e-18	6.95e-16	-0.5	-0.39	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
THCA	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-9.19	1.24e-18	6.95e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
THCA	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	9.19	1.25e-18	7.02e-16	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
THCA	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-9.19	1.27e-18	7.15e-16	-0.51	-0.39	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-9.19	1.27e-18	7.15e-16	-0.51	-0.39	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-9.19	1.27e-18	7.15e-16	-0.51	-0.39	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
THCA	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-9.19	1.28e-18	7.16e-16	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
THCA	cis	rs9402743	0.597	rs9483880	ENSG00000231028.7	LINC00271	-9.19	1.28e-18	7.18e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135781474	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs4895458	ENSG00000231028.7	LINC00271	-9.19	1.28e-18	7.18e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135783235	chr6:135497801~135716055:+
THCA	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	9.19	1.28e-18	7.19e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	9.19	1.28e-18	7.19e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	9.19	1.28e-18	7.19e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
THCA	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-9.19	1.28e-18	7.2e-16	-0.28	-0.39	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
THCA	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	9.19	1.29e-18	7.22e-16	0.49	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
THCA	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-9.19	1.29e-18	7.25e-16	-0.46	-0.39	Migraine;	chr4:56879297	chr4:56960927~56961373:-
THCA	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-9.19	1.3e-18	7.26e-16	-0.32	-0.39	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-9.19	1.3e-18	7.29e-16	-0.28	-0.39	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
THCA	cis	rs9402743	0.598	rs2327654	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135758303	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.703	rs6933668	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135760013	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.703	rs7756751	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135761314	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.703	rs6570030	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135761688	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs6909996	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Phosphorus levels;	chr6:135763365	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs9399164	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Phosphorus levels;	chr6:135765408	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs4385331	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Phosphorus levels;	chr6:135772025	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.641	rs9402752	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135772549	chr6:135497801~135716055:+
THCA	cis	rs11148252	0.711	rs61957304	ENSG00000278238.1	RP11-245D16.4	-9.19	1.31e-18	7.33e-16	-0.44	-0.39	Lewy body disease;	chr13:52224288	chr13:52454775~52455331:-
THCA	cis	rs7429990	0.833	rs3732530	ENSG00000229759.1	MRPS18AP1	-9.19	1.31e-18	7.35e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:47577463	chr3:48256350~48256938:-
THCA	cis	rs7851660	0.967	rs13288000	ENSG00000236130.1	PTCSC2	-9.19	1.32e-18	7.37e-16	-0.3	-0.39	Strep throat;	chr9:97846698	chr9:97805935~97810008:-
THCA	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	9.18	1.32e-18	7.39e-16	0.51	0.39	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	9.18	1.32e-18	7.41e-16	0.8	0.39	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
THCA	cis	rs1009647	0.961	rs946056	ENSG00000258413.1	RP11-665C16.6	-9.18	1.33e-18	7.42e-16	-0.57	-0.39	Testicular germ cell tumor;	chr14:55414012	chr14:55262767~55272075:-
THCA	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-9.18	1.33e-18	7.43e-16	-0.4	-0.39	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
THCA	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-9.18	1.33e-18	7.43e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-9.18	1.33e-18	7.43e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-9.18	1.33e-18	7.43e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	9.18	1.33e-18	7.43e-16	0.28	0.39	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
THCA	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	9.18	1.33e-18	7.44e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
THCA	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	9.18	1.33e-18	7.45e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
THCA	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-9.18	1.34e-18	7.48e-16	-0.48	-0.39	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
THCA	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	9.18	1.34e-18	7.49e-16	0.77	0.39	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
THCA	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-9.18	1.34e-18	7.49e-16	-0.37	-0.39	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	9.18	1.34e-18	7.5e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
THCA	cis	rs8062405	0.508	rs9929088	ENSG00000251417.2	RP11-1348G14.4	9.18	1.35e-18	7.53e-16	0.41	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28990139	chr16:28802743~28817828:+
THCA	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	9.18	1.35e-18	7.54e-16	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
THCA	cis	rs7015263	0.875	rs7006017	ENSG00000254231.1	CTD-2284J15.1	-9.18	1.35e-18	7.55e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86399325	chr8:86333274~86343314:-
THCA	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	9.18	1.35e-18	7.56e-16	0.59	0.39	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
THCA	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	9.18	1.35e-18	7.56e-16	0.43	0.39	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
THCA	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	9.18	1.35e-18	7.57e-16	0.48	0.39	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
THCA	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	9.18	1.36e-18	7.59e-16	0.49	0.39	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
THCA	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	9.18	1.36e-18	7.59e-16	0.53	0.39	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
THCA	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	9.18	1.36e-18	7.6e-16	0.45	0.39	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
THCA	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	9.18	1.36e-18	7.61e-16	0.49	0.39	Myopia;	chr6:28302807	chr6:28176188~28176674:+
THCA	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-9.18	1.36e-18	7.62e-16	-0.47	-0.39	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
THCA	cis	rs947583	0.517	rs9376148	ENSG00000231028.7	LINC00271	-9.18	1.36e-18	7.63e-16	-0.3	-0.39	Phosphorus levels;	chr6:135777362	chr6:135497801~135716055:+
THCA	cis	rs11971779	0.616	rs10269683	ENSG00000273391.1	RP11-634H22.1	9.18	1.37e-18	7.64e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139416122	chr7:139359032~139359566:-
THCA	cis	rs7015263	0.875	rs10088739	ENSG00000254231.1	CTD-2284J15.1	9.18	1.37e-18	7.66e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr8:86438922	chr8:86333274~86343314:-
THCA	cis	rs4591358	0.773	rs16836736	ENSG00000223466.1	AC064834.2	-9.18	1.37e-18	7.67e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511283	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.773	rs13035516	ENSG00000223466.1	AC064834.2	-9.18	1.37e-18	7.67e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195513234	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.773	rs34475459	ENSG00000223466.1	AC064834.2	-9.18	1.37e-18	7.67e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515682	chr2:195533035~195538681:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000235689.1	AP000351.13	9.18	1.38e-18	7.71e-16	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:24006305~24008258:-
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000266490.1	CTD-2349P21.9	9.18	1.38e-18	7.71e-16	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30792372~30792833:+
THCA	cis	rs11051970	0.527	rs7962680	ENSG00000274964.1	RP11-817I4.1	-9.18	1.39e-18	7.76e-16	-0.53	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32322377	chr12:32339368~32340724:+
THCA	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-9.18	1.39e-18	7.76e-16	-0.4	-0.39	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
THCA	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-9.18	1.39e-18	7.77e-16	-0.51	-0.39	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
THCA	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-9.18	1.39e-18	7.78e-16	-0.46	-0.39	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-9.18	1.39e-18	7.78e-16	-0.46	-0.39	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
THCA	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-9.18	1.39e-18	7.78e-16	-0.46	-0.39	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
THCA	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	9.18	1.39e-18	7.79e-16	0.47	0.39	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
THCA	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-9.18	1.4e-18	7.83e-16	-0.58	-0.39	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
THCA	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-9.18	1.4e-18	7.84e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	9.18	1.4e-18	7.84e-16	0.51	0.39	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
THCA	cis	rs4819052	1	rs733738	ENSG00000215447.6	BX322557.10	9.18	1.41e-18	7.85e-16	0.35	0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45288052~45291738:+
THCA	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-9.18	1.41e-18	7.86e-16	-0.31	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
THCA	cis	rs950169	0.96	rs12905475	ENSG00000259728.4	LINC00933	9.18	1.42e-18	7.91e-16	0.56	0.39	Schizophrenia;	chr15:84131743	chr15:84570649~84580175:+
THCA	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-9.18	1.42e-18	7.92e-16	-0.36	-0.39	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-9.18	1.42e-18	7.93e-16	-0.55	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
THCA	cis	rs4927850	1	rs7625570	ENSG00000273009.1	RP11-352G9.1	-9.17	1.44e-18	8.02e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196020527	chr3:195913078~195913683:-
THCA	cis	rs28510890	0.547	rs35070516	ENSG00000260337.3	RP11-386M24.6	-9.17	1.44e-18	8.02e-16	-0.5	-0.39	Lung cancer in ever smokers;	chr15:92607968	chr15:92592574~92596462:-
THCA	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-9.17	1.44e-18	8.03e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-9.17	1.44e-18	8.05e-16	-0.56	-0.39	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
THCA	cis	rs9402743	0.632	rs9389329	ENSG00000231028.7	LINC00271	9.17	1.45e-18	8.1e-16	0.3	0.39	Systemic lupus erythematosus;	chr6:135777966	chr6:135497801~135716055:+
THCA	cis	rs934734	0.571	rs7572922	ENSG00000234255.7	AC012370.3	-9.17	1.45e-18	8.11e-16	-0.43	-0.39	Rheumatoid arthritis;	chr2:65425022	chr2:65439888~65456571:-
THCA	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-9.17	1.47e-18	8.2e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-9.17	1.47e-18	8.2e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-9.17	1.47e-18	8.2e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-9.17	1.47e-18	8.2e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
THCA	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	9.17	1.48e-18	8.24e-16	0.5	0.39	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
THCA	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-9.17	1.48e-18	8.26e-16	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
THCA	cis	rs4591358	0.773	rs34480328	ENSG00000223466.1	AC064834.2	-9.17	1.48e-18	8.27e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510684	chr2:195533035~195538681:+
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000226314.6	ZNF192P1	9.17	1.49e-18	8.29e-16	0.51	0.39	Parkinson's disease;	chr6:28065396	chr6:28161781~28169594:+
THCA	cis	rs1707322	0.821	rs11211182	ENSG00000234329.1	RP11-767N6.2	9.17	1.49e-18	8.29e-16	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45651039~45651826:-
THCA	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	9.17	1.49e-18	8.29e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
THCA	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-9.17	1.49e-18	8.32e-16	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
THCA	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-9.17	1.5e-18	8.35e-16	-0.41	-0.39	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
THCA	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	9.17	1.5e-18	8.35e-16	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
THCA	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	9.17	1.5e-18	8.36e-16	0.77	0.39	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
THCA	cis	rs10411161	0.702	rs11879336	ENSG00000269483.1	AC006272.1	9.17	1.51e-18	8.42e-16	0.57	0.39	Breast cancer;	chr19:51886374	chr19:51839924~51843324:-
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000215447.6	BX322557.10	-9.17	1.52e-18	8.45e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000215447.6	BX322557.10	-9.17	1.52e-18	8.45e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000215447.6	BX322557.10	-9.17	1.52e-18	8.45e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45288052~45291738:+
THCA	cis	rs9402743	0.666	rs9385737	ENSG00000231028.7	LINC00271	-9.17	1.52e-18	8.45e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135759379	chr6:135497801~135716055:+
THCA	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-9.17	1.52e-18	8.47e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
THCA	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	9.17	1.52e-18	8.48e-16	0.49	0.39	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
THCA	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	9.17	1.52e-18	8.49e-16	0.41	0.39	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
THCA	cis	rs944289	0.712	rs12050121	ENSG00000257826.1	RP11-116N8.4	-9.17	1.52e-18	8.5e-16	-0.4	-0.39	Thyroid cancer;	chr14:36103742	chr14:36061026~36067190:-
THCA	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	9.17	1.53e-18	8.5e-16	0.47	0.39	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
THCA	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-9.17	1.54e-18	8.55e-16	-0.36	-0.39	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
THCA	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	9.17	1.54e-18	8.56e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
THCA	cis	rs526231	0.697	rs253754	ENSG00000175749.11	EIF3KP1	9.17	1.54e-18	8.56e-16	0.58	0.39	Primary biliary cholangitis;	chr5:103296261	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-9.17	1.54e-18	8.59e-16	-0.56	-0.39	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
THCA	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-9.17	1.55e-18	8.61e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
THCA	cis	rs11971779	0.68	rs10242419	ENSG00000273391.1	RP11-634H22.1	-9.16	1.55e-18	8.61e-16	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139404634	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
THCA	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-9.16	1.56e-18	8.7e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
THCA	cis	rs1707322	0.827	rs6683274	ENSG00000234329.1	RP11-767N6.2	9.16	1.57e-18	8.72e-16	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45651039~45651826:-
THCA	cis	rs4591358	0.773	rs35261538	ENSG00000223466.1	AC064834.2	-9.16	1.57e-18	8.75e-16	-0.54	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509681	chr2:195533035~195538681:+
THCA	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-9.16	1.57e-18	8.76e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
THCA	cis	rs11971779	0.616	rs6467836	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139338771	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467837	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139338829	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
THCA	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	9.16	1.58e-18	8.79e-16	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	9.16	1.58e-18	8.79e-16	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
THCA	cis	rs8062405	0.573	rs6565300	ENSG00000251417.2	RP11-1348G14.4	-9.16	1.59e-18	8.82e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28802743~28817828:+
THCA	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	9.16	1.59e-18	8.86e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
THCA	cis	rs17684571	0.751	rs13190854	ENSG00000231441.1	RP11-472M19.2	9.16	1.6e-18	8.88e-16	0.5	0.39	Schizophrenia;	chr6:56827020	chr6:56844002~56864078:+
THCA	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
THCA	cis	rs944289	0.774	rs1537423	ENSG00000257826.1	RP11-116N8.4	9.16	1.61e-18	8.93e-16	0.4	0.39	Thyroid cancer;	chr14:36104863	chr14:36061026~36067190:-
THCA	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	9.16	1.61e-18	8.95e-16	0.58	0.39	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
THCA	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-9.16	1.61e-18	8.96e-16	-0.4	-0.39	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
THCA	cis	rs7569084	0.687	rs6755006	ENSG00000234255.7	AC012370.3	-9.16	1.62e-18	8.99e-16	-0.44	-0.39	Sum eosinophil basophil counts;	chr2:65426008	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs6755128	ENSG00000234255.7	AC012370.3	-9.16	1.62e-18	8.99e-16	-0.44	-0.39	Sum eosinophil basophil counts;	chr2:65426065	chr2:65439888~65456571:-
THCA	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-9.16	1.62e-18	9e-16	-0.51	-0.39	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
THCA	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-9.16	1.62e-18	9.02e-16	-0.28	-0.39	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000242086.7	LINC00969	9.16	1.63e-18	9.06e-16	0.43	0.39	Pancreatic cancer;	chr3:196025182	chr3:195658062~195739964:+
THCA	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	9.16	1.63e-18	9.06e-16	0.28	0.39	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
THCA	cis	rs17807185	0.653	rs7802732	ENSG00000214293.7	APTR	9.16	1.64e-18	9.09e-16	0.28	0.39	Height;	chr7:77658613	chr7:77657660~77696265:-
THCA	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	9.16	1.64e-18	9.11e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	9.16	1.64e-18	9.11e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
THCA	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	9.16	1.65e-18	9.15e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
THCA	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-9.16	1.65e-18	9.16e-16	-0.45	-0.39	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	9.16	1.65e-18	9.18e-16	0.54	0.39	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
THCA	cis	rs7191700	0.583	rs243314	ENSG00000262636.1	CTD-3088G3.4	9.16	1.66e-18	9.21e-16	0.47	0.39	Multiple sclerosis;	chr16:11291247	chr16:11380859~11381118:-
THCA	cis	rs9532669	0.89	rs4941999	ENSG00000239827.7	SUGT1P3	-9.16	1.66e-18	9.21e-16	-0.43	-0.39	Cervical cancer;	chr13:40859926	chr13:40908159~40921774:-
THCA	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-9.16	1.66e-18	9.23e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-9.16	1.66e-18	9.23e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
THCA	cis	rs748404	0.697	rs530188	ENSG00000249839.1	AC011330.5	-9.15	1.67e-18	9.29e-16	-0.45	-0.39	Lung cancer;	chr15:43253116	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs475227	ENSG00000249839.1	AC011330.5	-9.15	1.67e-18	9.29e-16	-0.45	-0.39	Lung cancer;	chr15:43254248	chr15:43663654~43684339:-
THCA	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-9.15	1.67e-18	9.29e-16	-0.49	-0.39	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
THCA	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	9.15	1.68e-18	9.31e-16	0.48	0.39	Height;	chr11:118860890	chr11:118688039~118690600:-
THCA	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	9.15	1.68e-18	9.31e-16	0.48	0.39	Height;	chr11:118861053	chr11:118688039~118690600:-
THCA	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	9.15	1.68e-18	9.31e-16	0.29	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
THCA	cis	rs17684571	0.7	rs34228698	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56795962	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.637	rs34359353	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56800963	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13198204	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56804057	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13201639	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56804329	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.637	rs17751966	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56804850	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs71564861	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56806793	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs35251663	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56806940	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.654	rs4348308	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56815545	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs34640766	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56815876	chr6:56844002~56864078:+
THCA	cis	rs240993	0.761	rs9400480	ENSG00000230177.1	RP5-1112D6.4	9.15	1.69e-18	9.35e-16	0.39	0.39	Inflammatory skin disease;Psoriasis;	chr6:111529394	chr6:111277932~111278742:+
THCA	cis	rs4380275	0.965	rs12621177	ENSG00000272342.1	RP13-539J13.1	9.15	1.69e-18	9.37e-16	0.46	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs4854376	ENSG00000272342.1	RP13-539J13.1	9.15	1.69e-18	9.37e-16	0.46	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:739588~740164:-
THCA	cis	rs11971779	0.59	rs6467839	ENSG00000273391.1	RP11-634H22.1	9.15	1.7e-18	9.41e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139378044	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-9.15	1.7e-18	9.44e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	9.15	1.7e-18	9.44e-16	0.77	0.39	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
THCA	cis	rs947583	0.517	rs9376147	ENSG00000231028.7	LINC00271	-9.15	1.7e-18	9.45e-16	-0.3	-0.39	Phosphorus levels;	chr6:135774774	chr6:135497801~135716055:+
THCA	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-9.15	1.71e-18	9.5e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
THCA	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-9.15	1.72e-18	9.53e-16	-0.7	-0.39	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
THCA	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-9.15	1.72e-18	9.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-9.15	1.72e-18	9.54e-16	-0.47	-0.39	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
THCA	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	9.15	1.72e-18	9.54e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	9.15	1.73e-18	9.56e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
THCA	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	9.15	1.73e-18	9.56e-16	0.28	0.39	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	9.15	1.73e-18	9.57e-16	0.52	0.39	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
THCA	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-9.15	1.73e-18	9.6e-16	-0.37	-0.39	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
THCA	cis	rs7015263	0.572	rs7830128	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86361011	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.572	rs62509419	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86363013	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.572	rs11787036	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86363647	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.572	rs56122638	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86366036	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.572	rs11775728	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86375722	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.539	rs9642913	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86377719	chr8:86333274~86343314:-
THCA	cis	rs2033711	0.87	rs7409473	ENSG00000268912.1	CTD-2619J13.17	-9.15	1.75e-18	9.68e-16	-0.3	-0.39	Uric acid clearance;	chr19:58427798	chr19:58428632~58431148:-
THCA	cis	rs2033711	0.87	rs7408188	ENSG00000268912.1	CTD-2619J13.17	-9.15	1.75e-18	9.68e-16	-0.3	-0.39	Uric acid clearance;	chr19:58428022	chr19:58428632~58431148:-
THCA	cis	rs2033711	0.87	rs1051500	ENSG00000268912.1	CTD-2619J13.17	-9.15	1.75e-18	9.68e-16	-0.3	-0.39	Uric acid clearance;	chr19:58433035	chr19:58428632~58431148:-
THCA	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	9.15	1.75e-18	9.69e-16	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
THCA	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	9.15	1.75e-18	9.71e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
THCA	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	9.15	1.76e-18	9.76e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000215447.6	BX322557.10	9.15	1.78e-18	9.86e-16	0.32	0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45288052~45291738:+
THCA	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	9.15	1.78e-18	9.88e-16	0.79	0.39	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	9.15	1.78e-18	9.88e-16	0.79	0.39	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
THCA	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	9.15	1.79e-18	9.89e-16	0.45	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
THCA	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	9.15	1.79e-18	9.9e-16	0.46	0.39	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
THCA	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	9.15	1.79e-18	9.92e-16	0.52	0.39	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
THCA	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	9.15	1.79e-18	9.92e-16	0.41	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
THCA	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-9.15	1.79e-18	9.92e-16	-0.5	-0.39	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
THCA	cis	rs11971779	0.666	rs6467847	ENSG00000273391.1	RP11-634H22.1	9.15	1.8e-18	9.94e-16	0.38	0.39	Diisocyanate-induced asthma;	chr7:139394690	chr7:139359032~139359566:-
THCA	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-9.15	1.8e-18	9.95e-16	-0.46	-0.39	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
THCA	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-9.15	1.81e-18	9.99e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
THCA	cis	rs6496932	0.913	rs4843037	ENSG00000218052.5	ADAMTS7P4	9.15	1.81e-18	9.99e-16	0.54	0.39	Central corneal thickness;Corneal structure;	chr15:85274674	chr15:85255369~85330334:-
THCA	cis	rs860295	0.812	rs12131079	ENSG00000225855.5	RUSC1-AS1	-9.14	1.82e-18	1.01e-15	-0.26	-0.39	Body mass index;	chr1:155349877	chr1:155316863~155324176:-
THCA	cis	rs17684571	0.751	rs35225175	ENSG00000231441.1	RP11-472M19.2	9.14	1.82e-18	1.01e-15	0.53	0.39	Schizophrenia;	chr6:56822783	chr6:56844002~56864078:+
THCA	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	9.14	1.82e-18	1.01e-15	0.52	0.39	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
THCA	cis	rs748404	0.697	rs493444	ENSG00000249839.1	AC011330.5	-9.14	1.84e-18	1.02e-15	-0.46	-0.39	Lung cancer;	chr15:43274272	chr15:43663654~43684339:-
THCA	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	9.14	1.85e-18	1.02e-15	0.58	0.39	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	9.14	1.85e-18	1.02e-15	0.58	0.39	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	9.14	1.86e-18	1.03e-15	0.52	0.39	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
THCA	cis	rs10411161	0.702	rs7251571	ENSG00000269483.1	AC006272.1	9.14	1.87e-18	1.03e-15	0.54	0.39	Breast cancer;	chr19:51885804	chr19:51839924~51843324:-
THCA	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	9.14	1.87e-18	1.03e-15	0.45	0.39	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
THCA	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-9.14	1.87e-18	1.04e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
THCA	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	9.14	1.89e-18	1.04e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
THCA	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-9.14	1.89e-18	1.04e-15	-0.5	-0.39	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-9.14	1.89e-18	1.04e-15	-0.5	-0.39	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
THCA	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	9.14	1.89e-18	1.04e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
THCA	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-9.14	1.89e-18	1.04e-15	-0.8	-0.39	Gout;	chr7:66661502	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-9.14	1.89e-18	1.04e-15	-0.8	-0.39	Gout;	chr7:66679692	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	9.14	1.89e-18	1.04e-15	0.8	0.39	Gout;	chr7:66682070	chr7:66654538~66669855:+
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	9.14	1.89e-18	1.04e-15	0.8	0.39	Gout;	chr7:66682162	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs4818769	ENSG00000215447.6	BX322557.10	-9.14	1.89e-18	1.05e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45288052~45291738:+
THCA	cis	rs6565180	0.963	rs4787642	ENSG00000183604.13	SMG1P5	-9.14	1.89e-18	1.05e-15	-0.41	-0.39	Tonsillectomy;	chr16:30348087	chr16:30267553~30335374:-
THCA	cis	rs10411161	0.702	rs7250138	ENSG00000269483.1	AC006272.1	9.14	1.89e-18	1.05e-15	0.55	0.39	Breast cancer;	chr19:51881979	chr19:51839924~51843324:-
THCA	cis	rs2032366	0.606	rs7226896	ENSG00000267279.1	RP11-879F14.2	-9.14	1.9e-18	1.05e-15	-0.41	-0.39	Obesity-related traits;	chr18:61608946	chr18:61585746~61606916:-
THCA	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	9.14	1.9e-18	1.05e-15	0.58	0.39	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
THCA	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-9.14	1.9e-18	1.05e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
THCA	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-9.14	1.9e-18	1.05e-15	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
THCA	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	9.14	1.9e-18	1.05e-15	0.49	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
THCA	cis	rs4819052	0.679	rs28623526	ENSG00000215447.6	BX322557.10	-9.14	1.91e-18	1.05e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45288052~45291738:+
THCA	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	9.14	1.91e-18	1.06e-15	0.5	0.39	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
THCA	cis	rs2032366	0.606	rs713485	ENSG00000267279.1	RP11-879F14.2	-9.14	1.92e-18	1.06e-15	-0.41	-0.39	Obesity-related traits;	chr18:61603692	chr18:61585746~61606916:-
THCA	cis	rs8027521	0.521	rs11631861	ENSG00000280362.1	RP11-643A5.3	-9.14	1.92e-18	1.06e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53925421	chr15:53910769~53914712:+
THCA	cis	rs4591358	0.689	rs7578371	ENSG00000223466.1	AC064834.2	-9.14	1.93e-18	1.06e-15	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510222	chr2:195533035~195538681:+
THCA	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	9.14	1.93e-18	1.06e-15	0.66	0.39	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
THCA	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	9.14	1.94e-18	1.07e-15	0.52	0.39	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
THCA	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	-9.14	1.94e-18	1.07e-15	-0.53	-0.39	Depression;	chr6:28135913	chr6:28161781~28169594:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000206090.4	AP000350.7	9.14	1.95e-18	1.07e-15	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23939998~23942798:+
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	9.14	1.95e-18	1.08e-15	0.51	0.39	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	9.14	1.95e-18	1.08e-15	0.51	0.39	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
THCA	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	9.13	1.96e-18	1.08e-15	0.46	0.39	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
THCA	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	9.13	1.96e-18	1.08e-15	0.58	0.39	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
THCA	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-9.13	1.96e-18	1.08e-15	-0.39	-0.39	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
THCA	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-9.13	1.96e-18	1.08e-15	-0.51	-0.39	Gout;	chr7:66693028	chr7:66902857~66906297:+
THCA	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	9.13	1.97e-18	1.08e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
THCA	cis	rs9532669	0.926	rs9562254	ENSG00000239827.7	SUGT1P3	9.13	1.97e-18	1.09e-15	0.42	0.39	Cervical cancer;	chr13:40960902	chr13:40908159~40921774:-
THCA	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-9.13	1.98e-18	1.09e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
THCA	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	9.13	1.98e-18	1.09e-15	0.66	0.39	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	9.13	1.98e-18	1.09e-15	0.66	0.39	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-9.13	1.98e-18	1.09e-15	-0.66	-0.39	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
THCA	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-9.13	1.99e-18	1.1e-15	-0.38	-0.39	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-9.13	1.99e-18	1.1e-15	-0.56	-0.39	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-9.13	1.99e-18	1.1e-15	-0.56	-0.39	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-9.13	1.99e-18	1.1e-15	-0.56	-0.39	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
THCA	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	9.13	2e-18	1.1e-15	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
THCA	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-9.13	2e-18	1.1e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
THCA	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-9.13	2e-18	1.1e-15	-0.39	-0.39	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
THCA	cis	rs4591358	0.689	rs72925794	ENSG00000223466.1	AC064834.2	-9.13	2e-18	1.1e-15	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511813	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.773	rs72925795	ENSG00000223466.1	AC064834.2	-9.13	2e-18	1.1e-15	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511814	chr2:195533035~195538681:+
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-9.13	2.01e-18	1.11e-15	-0.53	-0.39	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
THCA	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	9.13	2.01e-18	1.11e-15	0.48	0.39	Height;	chr11:118859432	chr11:118688039~118690600:-
THCA	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	9.13	2.01e-18	1.11e-15	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
THCA	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-9.13	2.01e-18	1.11e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
THCA	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-9.13	2.01e-18	1.11e-15	-0.49	-0.39	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	9.13	2.03e-18	1.12e-15	0.48	0.39	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
THCA	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
THCA	cis	rs12682352	0.605	rs60707155	ENSG00000253893.2	FAM85B	-9.13	2.04e-18	1.12e-15	-0.51	-0.39	Neuroticism;	chr8:8866905	chr8:8167819~8226614:-
THCA	cis	rs934734	0.532	rs62141075	ENSG00000234255.7	AC012370.3	-9.13	2.04e-18	1.12e-15	-0.43	-0.39	Rheumatoid arthritis;	chr2:65417482	chr2:65439888~65456571:-
THCA	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-9.13	2.04e-18	1.12e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
THCA	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	9.13	2.05e-18	1.13e-15	0.41	0.39	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000215447.6	BX322557.10	-9.13	2.05e-18	1.13e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-9.13	2.05e-18	1.13e-15	-0.56	-0.39	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
THCA	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	9.13	2.05e-18	1.13e-15	0.67	0.39	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
THCA	cis	rs8027521	0.521	rs12901163	ENSG00000280362.1	RP11-643A5.3	-9.13	2.06e-18	1.13e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53924379	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.521	rs12903076	ENSG00000280362.1	RP11-643A5.3	-9.13	2.06e-18	1.13e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53924766	chr15:53910769~53914712:+
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000224205.1	AP000351.4	9.13	2.06e-18	1.13e-15	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23987320~23991421:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000224205.1	AP000351.4	9.13	2.06e-18	1.13e-15	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23987320~23991421:-
THCA	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	9.13	2.07e-18	1.14e-15	0.45	0.39	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
THCA	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-9.13	2.07e-18	1.14e-15	-0.48	-0.39	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-9.13	2.07e-18	1.14e-15	-0.48	-0.39	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
THCA	cis	rs11051970	0.592	rs73086040	ENSG00000274964.1	RP11-817I4.1	-9.13	2.07e-18	1.14e-15	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32414501	chr12:32339368~32340724:+
THCA	cis	rs7208859	0.623	rs170051	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.51	rs216402	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216434	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216436	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216439	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30792372~30792833:+
THCA	cis	rs8027521	0.521	rs11633302	ENSG00000280362.1	RP11-643A5.3	-9.13	2.07e-18	1.14e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53926595	chr15:53910769~53914712:+
THCA	cis	rs11051970	0.559	rs113700251	ENSG00000274964.1	RP11-817I4.1	-9.13	2.07e-18	1.14e-15	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32409337	chr12:32339368~32340724:+
THCA	cis	rs1707322	0.785	rs10890348	ENSG00000234329.1	RP11-767N6.2	9.13	2.08e-18	1.14e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45651039~45651826:-
THCA	cis	rs11148252	0.774	rs7993748	ENSG00000278238.1	RP11-245D16.4	-9.13	2.08e-18	1.14e-15	-0.42	-0.39	Lewy body disease;	chr13:52367496	chr13:52454775~52455331:-
THCA	cis	rs7291412	0.662	rs7292297	ENSG00000231711.2	LINC00899	9.13	2.08e-18	1.15e-15	0.32	0.39	Dupuytren's disease;Subjective well-being;	chr22:46062243	chr22:46039907~46044853:-
THCA	cis	rs17684571	0.7	rs13200559	ENSG00000231441.1	RP11-472M19.2	9.13	2.09e-18	1.15e-15	0.53	0.39	Schizophrenia;	chr6:56777522	chr6:56844002~56864078:+
THCA	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	9.13	2.1e-18	1.15e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
THCA	cis	rs8027521	0.521	rs35926061	ENSG00000280362.1	RP11-643A5.3	-9.13	2.1e-18	1.15e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53927514	chr15:53910769~53914712:+
THCA	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-9.13	2.1e-18	1.15e-15	-0.43	-0.39	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
THCA	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	9.13	2.1e-18	1.16e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
THCA	cis	rs28510890	0.785	rs11074079	ENSG00000260337.3	RP11-386M24.6	9.13	2.11e-18	1.16e-15	0.45	0.39	Lung cancer in ever smokers;	chr15:92581719	chr15:92592574~92596462:-
THCA	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-9.13	2.11e-18	1.16e-15	-0.45	-0.39	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
THCA	cis	rs7015263	0.776	rs55727343	ENSG00000254231.1	CTD-2284J15.1	-9.13	2.11e-18	1.16e-15	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86384204	chr8:86333274~86343314:-
THCA	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	9.12	2.12e-18	1.17e-15	0.58	0.39	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
THCA	cis	rs17772222	0.63	rs7141608	ENSG00000258789.1	RP11-507K2.3	9.12	2.12e-18	1.17e-15	0.37	0.39	Coronary artery calcification;	chr14:88514045	chr14:88551597~88552493:+
THCA	cis	rs947583	0.517	rs6570039	ENSG00000231028.7	LINC00271	-9.12	2.13e-18	1.17e-15	-0.3	-0.39	Phosphorus levels;	chr6:135775602	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.641	rs6906211	ENSG00000231028.7	LINC00271	-9.12	2.13e-18	1.17e-15	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135778283	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs6906845	ENSG00000231028.7	LINC00271	-9.12	2.13e-18	1.17e-15	-0.3	-0.39	Phosphorus levels;	chr6:135778363	chr6:135497801~135716055:+
THCA	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	9.12	2.14e-18	1.17e-15	0.5	0.39	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
THCA	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-9.12	2.14e-18	1.18e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
THCA	cis	rs4713118	0.662	rs464312	ENSG00000280107.1	AL022393.9	-9.12	2.15e-18	1.18e-15	-0.44	-0.39	Parkinson's disease;	chr6:27999813	chr6:28170845~28172521:+
THCA	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	9.12	2.15e-18	1.18e-15	0.4	0.39	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-9.12	2.16e-18	1.19e-15	-0.51	-0.39	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
THCA	cis	rs11148252	0.74	rs9536046	ENSG00000278238.1	RP11-245D16.4	-9.12	2.16e-18	1.19e-15	-0.44	-0.39	Lewy body disease;	chr13:52381764	chr13:52454775~52455331:-
THCA	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-9.12	2.17e-18	1.19e-15	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
THCA	cis	rs2681472	0.524	rs7314459	ENSG00000258302.2	RP11-981P6.1	9.12	2.17e-18	1.19e-15	0.39	0.39	Hypertension;Coronary artery disease;Myocardial infarction;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Systolic blood pressure;Diastolic blood pressure;	chr12:89562564	chr12:89561129~89594878:+
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-9.12	2.17e-18	1.19e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
THCA	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	9.12	2.17e-18	1.19e-15	0.49	0.39	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	9.12	2.17e-18	1.19e-15	0.52	0.39	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	9.12	2.17e-18	1.19e-15	0.52	0.39	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
THCA	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	9.12	2.18e-18	1.2e-15	0.46	0.39	Height;	chr6:109715504	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	9.12	2.18e-18	1.2e-15	0.46	0.39	Height;	chr6:109715560	chr6:109382795~109383666:+
THCA	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-9.12	2.19e-18	1.2e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
THCA	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	9.12	2.19e-18	1.2e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	9.12	2.19e-18	1.2e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
THCA	cis	rs11971779	0.68	rs10274480	ENSG00000273391.1	RP11-634H22.1	9.12	2.22e-18	1.22e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367682	chr7:139359032~139359566:-
THCA	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-9.12	2.22e-18	1.22e-15	-0.45	-0.39	Temperament;	chr17:14015466	chr17:14024514~14025488:+
THCA	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-9.12	2.22e-18	1.22e-15	-0.41	-0.39	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
THCA	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	9.12	2.22e-18	1.22e-15	0.64	0.39	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
THCA	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-9.12	2.23e-18	1.22e-15	-0.5	-0.39	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
THCA	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-9.12	2.24e-18	1.23e-15	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
THCA	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	9.12	2.24e-18	1.23e-15	0.41	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
THCA	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-9.12	2.24e-18	1.23e-15	-0.45	-0.39	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
THCA	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-9.12	2.24e-18	1.23e-15	-0.49	-0.39	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-9.12	2.24e-18	1.23e-15	-0.49	-0.39	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
THCA	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-9.12	2.24e-18	1.23e-15	-0.44	-0.39	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
THCA	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-9.12	2.24e-18	1.23e-15	-0.78	-0.39	Gout;	chr7:66671562	chr7:66654538~66669855:+
THCA	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-9.12	2.25e-18	1.23e-15	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	9.12	2.25e-18	1.23e-15	0.47	0.39	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
THCA	cis	rs4591358	0.773	rs13008940	ENSG00000223466.1	AC064834.2	-9.12	2.26e-18	1.24e-15	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509828	chr2:195533035~195538681:+
THCA	cis	rs11051970	0.559	rs73086036	ENSG00000274964.1	RP11-817I4.1	-9.12	2.27e-18	1.24e-15	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32411651	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051992	ENSG00000274964.1	RP11-817I4.1	-9.12	2.27e-18	1.24e-15	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32411733	chr12:32339368~32340724:+
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000226314.6	ZNF192P1	-9.12	2.27e-18	1.25e-15	-0.5	-0.39	Parkinson's disease;	chr6:28065618	chr6:28161781~28169594:+
THCA	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-9.12	2.28e-18	1.25e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
THCA	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-9.12	2.28e-18	1.25e-15	-0.39	-0.39	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
THCA	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	9.11	2.29e-18	1.25e-15	0.52	0.39	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
THCA	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-9.11	2.29e-18	1.25e-15	-0.49	-0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
THCA	cis	rs780096	0.565	rs13022659	ENSG00000234072.1	AC074117.10	-9.11	2.29e-18	1.26e-15	-0.31	-0.39	Total body bone mineral density;	chr2:27520763	chr2:27356246~27367622:+
THCA	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
THCA	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	9.11	2.3e-18	1.26e-15	0.66	0.39	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
THCA	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-9.11	2.3e-18	1.26e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-9.11	2.3e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
THCA	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-9.11	2.31e-18	1.27e-15	-0.28	-0.39	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-9.11	2.31e-18	1.27e-15	-0.28	-0.39	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
THCA	cis	rs348196	0.672	rs670876	ENSG00000225855.5	RUSC1-AS1	9.11	2.32e-18	1.27e-15	0.29	0.39	Breast cancer;	chr1:155701887	chr1:155316863~155324176:-
THCA	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-9.11	2.33e-18	1.28e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
THCA	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	9.11	2.33e-18	1.28e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	9.11	2.33e-18	1.28e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
THCA	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-9.11	2.34e-18	1.28e-15	-0.39	-0.39	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
THCA	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-9.11	2.34e-18	1.28e-15	-0.46	-0.39	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
THCA	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	9.11	2.35e-18	1.29e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	9.11	2.35e-18	1.29e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
THCA	cis	rs11148252	0.774	rs9536066	ENSG00000278238.1	RP11-245D16.4	-9.11	2.35e-18	1.29e-15	-0.42	-0.39	Lewy body disease;	chr13:52409846	chr13:52454775~52455331:-
THCA	cis	rs62158211	0.908	rs62158169	ENSG00000272563.1	RP11-480C16.1	-9.11	2.35e-18	1.29e-15	-0.53	-0.39	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113324250	chr2:113432600~113436042:+
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	9.11	2.35e-18	1.29e-15	0.52	0.39	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	9.11	2.35e-18	1.29e-15	0.52	0.39	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
THCA	cis	rs7211079	0.912	rs4889831	ENSG00000275479.1	RP11-334C17.6	9.11	2.36e-18	1.29e-15	0.39	0.39	Myocardial infarction;	chr17:80140854	chr17:80149627~80149798:+
THCA	cis	rs748404	0.65	rs518234	ENSG00000249839.1	AC011330.5	-9.11	2.37e-18	1.3e-15	-0.45	-0.39	Lung cancer;	chr15:43281223	chr15:43663654~43684339:-
THCA	cis	rs748404	0.65	rs518261	ENSG00000249839.1	AC011330.5	-9.11	2.37e-18	1.3e-15	-0.45	-0.39	Lung cancer;	chr15:43281231	chr15:43663654~43684339:-
THCA	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	9.11	2.37e-18	1.3e-15	0.28	0.39	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	9.11	2.37e-18	1.3e-15	0.52	0.39	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
THCA	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-9.11	2.37e-18	1.3e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-9.11	2.37e-18	1.3e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	9.11	2.39e-18	1.31e-15	0.48	0.39	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
THCA	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	9.11	2.39e-18	1.31e-15	0.51	0.39	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
THCA	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-9.11	2.39e-18	1.31e-15	-0.5	-0.39	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
THCA	cis	rs4927850	1	rs6799572	ENSG00000273009.1	RP11-352G9.1	-9.11	2.39e-18	1.31e-15	-0.43	-0.39	Pancreatic cancer;	chr3:196013537	chr3:195913078~195913683:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000235689.1	AP000351.13	9.11	2.39e-18	1.31e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:24006305~24008258:-
THCA	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-9.11	2.4e-18	1.31e-15	-0.5	-0.39	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-9.11	2.4e-18	1.31e-15	-0.51	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
THCA	cis	rs7015263	0.818	rs56096624	ENSG00000254231.1	CTD-2284J15.1	-9.11	2.4e-18	1.32e-15	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86403298	chr8:86333274~86343314:-
THCA	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-9.11	2.4e-18	1.32e-15	-0.28	-0.39	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	9.11	2.4e-18	1.32e-15	0.28	0.39	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
THCA	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	9.11	2.41e-18	1.32e-15	0.62	0.39	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
THCA	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-9.11	2.41e-18	1.32e-15	-0.44	-0.39	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-9.11	2.42e-18	1.32e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
THCA	cis	rs4842666	0.831	rs11105337	ENSG00000258302.2	RP11-981P6.1	9.11	2.42e-18	1.32e-15	0.39	0.39	Blood pressure;	chr12:89599730	chr12:89561129~89594878:+
THCA	cis	rs7191700	0.644	rs918738	ENSG00000262636.1	CTD-3088G3.4	-9.11	2.42e-18	1.32e-15	-0.48	-0.39	Multiple sclerosis;	chr16:11345822	chr16:11380859~11381118:-
THCA	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	9.11	2.42e-18	1.32e-15	0.52	0.39	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
THCA	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	9.11	2.43e-18	1.33e-15	0.52	0.39	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
THCA	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	9.11	2.44e-18	1.34e-15	0.76	0.39	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
THCA	cis	rs17684571	0.751	rs13203148	ENSG00000231441.1	RP11-472M19.2	9.11	2.45e-18	1.34e-15	0.53	0.39	Schizophrenia;	chr6:56822235	chr6:56844002~56864078:+
THCA	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	9.11	2.45e-18	1.34e-15	0.71	0.39	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
THCA	cis	rs2599510	0.934	rs2710634	ENSG00000276334.1	AL133243.1	9.11	2.45e-18	1.34e-15	0.41	0.39	Interleukin-18 levels;	chr2:32583737	chr2:32521927~32523547:+
THCA	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-9.11	2.45e-18	1.34e-15	-0.51	-0.39	Gout;	chr7:66721259	chr7:66902857~66906297:+
THCA	cis	rs8027521	0.521	rs12906405	ENSG00000280362.1	RP11-643A5.3	-9.11	2.46e-18	1.34e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53930395	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.521	rs11633398	ENSG00000280362.1	RP11-643A5.3	-9.11	2.46e-18	1.35e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53926827	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.521	rs11633403	ENSG00000280362.1	RP11-643A5.3	-9.11	2.46e-18	1.35e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53926957	chr15:53910769~53914712:+
THCA	cis	rs944289	0.708	rs1953120	ENSG00000257826.1	RP11-116N8.4	-9.11	2.46e-18	1.35e-15	-0.39	-0.39	Thyroid cancer;	chr14:36105724	chr14:36061026~36067190:-
THCA	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	9.1	2.47e-18	1.35e-15	0.45	0.39	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
THCA	cis	rs2033711	0.87	rs3764534	ENSG00000268912.1	CTD-2619J13.17	-9.1	2.48e-18	1.35e-15	-0.3	-0.39	Uric acid clearance;	chr19:58417769	chr19:58428632~58431148:-
THCA	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-9.1	2.48e-18	1.36e-15	-0.5	-0.39	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-9.1	2.48e-18	1.36e-15	-0.5	-0.39	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-9.1	2.48e-18	1.36e-15	-0.5	-0.39	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
THCA	cis	rs2946505	1	rs2946503	ENSG00000251468.2	RP11-369K16.1	9.1	2.5e-18	1.37e-15	0.5	0.39	Migraine;	chr8:12954366	chr8:12958387~12962200:+
THCA	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-9.1	2.5e-18	1.37e-15	-0.39	-0.39	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	9.1	2.5e-18	1.37e-15	0.51	0.39	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	9.1	2.5e-18	1.37e-15	0.51	0.39	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	9.1	2.5e-18	1.37e-15	0.51	0.39	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-9.1	2.51e-18	1.37e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000215447.6	BX322557.10	-9.1	2.51e-18	1.37e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45288052~45291738:+
THCA	cis	rs7211079	0.879	rs66693363	ENSG00000275479.1	RP11-334C17.6	9.1	2.51e-18	1.37e-15	0.39	0.39	Myocardial infarction;	chr17:80155136	chr17:80149627~80149798:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	9.1	2.52e-18	1.37e-15	0.28	0.39	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
THCA	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	9.1	2.52e-18	1.38e-15	0.32	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
THCA	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-9.1	2.57e-18	1.4e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-9.1	2.57e-18	1.4e-15	-0.28	-0.39	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
THCA	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-9.1	2.58e-18	1.41e-15	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
THCA	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-9.1	2.59e-18	1.41e-15	-0.39	-0.39	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
THCA	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	9.1	2.59e-18	1.41e-15	0.32	0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
THCA	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	9.1	2.59e-18	1.41e-15	0.51	0.39	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000226314.6	ZNF192P1	-9.1	2.6e-18	1.42e-15	-0.5	-0.39	Parkinson's disease;	chr6:28065745	chr6:28161781~28169594:+
THCA	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-9.1	2.61e-18	1.42e-15	-0.69	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
THCA	cis	rs1426063	0.614	rs75345649	ENSG00000260265.1	RP11-44F21.5	9.1	2.61e-18	1.42e-15	0.84	0.39	QT interval;	chr4:75100963	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs77333523	ENSG00000260265.1	RP11-44F21.5	9.1	2.61e-18	1.42e-15	0.84	0.39	QT interval;	chr4:75101024	chr4:75081702~75084717:-
THCA	cis	rs4591358	0.648	rs56906982	ENSG00000223466.1	AC064834.2	-9.1	2.62e-18	1.43e-15	-0.52	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512939	chr2:195533035~195538681:+
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	9.1	2.62e-18	1.43e-15	0.52	0.39	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	9.1	2.63e-18	1.43e-15	0.52	0.39	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
THCA	cis	rs494459	0.536	rs11217063	ENSG00000278376.1	RP11-158I9.8	-9.1	2.65e-18	1.45e-15	-0.28	-0.39	Height;	chr11:118855233	chr11:118791254~118793137:+
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	9.1	2.65e-18	1.45e-15	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
THCA	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-9.1	2.65e-18	1.45e-15	-0.46	-0.39	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
THCA	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	9.1	2.66e-18	1.45e-15	0.35	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
THCA	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	9.1	2.67e-18	1.46e-15	0.61	0.39	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
THCA	cis	rs7727544	0.571	rs12521097	ENSG00000237714.1	P4HA2-AS1	9.1	2.67e-18	1.46e-15	0.51	0.39	Blood metabolite levels;	chr5:132239645	chr5:132184876~132192808:+
THCA	cis	rs860295	0.557	rs12091730	ENSG00000225855.5	RUSC1-AS1	9.09	2.68e-18	1.46e-15	0.3	0.39	Body mass index;	chr1:155587180	chr1:155316863~155324176:-
THCA	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	9.09	2.68e-18	1.46e-15	0.55	0.39	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
THCA	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-9.09	2.69e-18	1.46e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-9.09	2.69e-18	1.46e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-9.09	2.69e-18	1.46e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
THCA	cis	rs62103177	0.525	rs1835410	ENSG00000261126.6	RP11-795F19.1	-9.09	2.7e-18	1.47e-15	-0.43	-0.39	Opioid sensitivity;	chr18:79942025	chr18:80046900~80095482:+
THCA	cis	rs4713118	0.662	rs469228	ENSG00000280107.1	AL022393.9	-9.09	2.7e-18	1.47e-15	-0.44	-0.39	Parkinson's disease;	chr6:28002926	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.54	rs469227	ENSG00000280107.1	AL022393.9	-9.09	2.7e-18	1.47e-15	-0.44	-0.39	Parkinson's disease;	chr6:28002927	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs149948	ENSG00000280107.1	AL022393.9	-9.09	2.7e-18	1.47e-15	-0.44	-0.39	Parkinson's disease;	chr6:28007039	chr6:28170845~28172521:+
THCA	cis	rs860295	0.776	rs11264362	ENSG00000225855.5	RUSC1-AS1	-9.09	2.7e-18	1.47e-15	-0.26	-0.39	Body mass index;	chr1:155345824	chr1:155316863~155324176:-
THCA	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-9.09	2.71e-18	1.48e-15	-0.43	-0.39	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
THCA	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-9.09	2.72e-18	1.48e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
THCA	cis	rs11148252	0.74	rs9596648	ENSG00000278238.1	RP11-245D16.4	9.09	2.72e-18	1.48e-15	0.44	0.39	Lewy body disease;	chr13:52360434	chr13:52454775~52455331:-
THCA	cis	rs934734	0.544	rs4671127	ENSG00000204929.10	AC074391.1	9.09	2.72e-18	1.48e-15	0.51	0.39	Rheumatoid arthritis;	chr2:65335836	chr2:65436711~66084639:+
THCA	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
THCA	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66692349	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66693433	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66694214	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66701371	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66702658	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66706390	chr7:66902857~66906297:+
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66710076	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66715944	chr7:66902857~66906297:+
THCA	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	9.09	2.74e-18	1.49e-15	0.43	0.39	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
THCA	cis	rs62103177	0.535	rs34299914	ENSG00000261126.6	RP11-795F19.1	9.09	2.74e-18	1.49e-15	0.45	0.39	Opioid sensitivity;	chr18:80191353	chr18:80046900~80095482:+
THCA	cis	rs494459	0.536	rs11217065	ENSG00000278376.1	RP11-158I9.8	-9.09	2.74e-18	1.49e-15	-0.28	-0.39	Height;	chr11:118855938	chr11:118791254~118793137:+
THCA	cis	rs17772222	0.56	rs3742681	ENSG00000258789.1	RP11-507K2.3	9.09	2.75e-18	1.5e-15	0.37	0.39	Coronary artery calcification;	chr14:88554903	chr14:88551597~88552493:+
THCA	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-9.09	2.75e-18	1.5e-15	-0.48	-0.39	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-9.09	2.75e-18	1.5e-15	-0.48	-0.39	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
THCA	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-9.09	2.76e-18	1.5e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
THCA	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-9.09	2.76e-18	1.5e-15	-0.44	-0.39	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
THCA	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	9.09	2.77e-18	1.51e-15	0.43	0.39	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
THCA	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	9.09	2.77e-18	1.51e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
THCA	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	9.09	2.79e-18	1.52e-15	0.51	0.39	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
THCA	cis	rs2284219	0.565	rs2284217	ENSG00000244480.1	AC005154.7	-9.09	2.79e-18	1.52e-15	-0.35	-0.39	Type 2 diabetes;	chr7:30673992	chr7:30523143~30524535:-
THCA	cis	rs11971779	0.616	rs1862878	ENSG00000273391.1	RP11-634H22.1	9.09	2.8e-18	1.52e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139335168	chr7:139359032~139359566:-
THCA	cis	rs42490	1	rs431264	ENSG00000251136.7	RP11-37B2.1	-9.09	2.8e-18	1.52e-15	-0.33	-0.39	Leprosy;	chr8:89765282	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs42490	ENSG00000251136.7	RP11-37B2.1	-9.09	2.8e-18	1.52e-15	-0.33	-0.39	Leprosy;	chr8:89766285	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs40544	ENSG00000251136.7	RP11-37B2.1	-9.09	2.8e-18	1.52e-15	-0.33	-0.39	Leprosy;	chr8:89768867	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs40377	ENSG00000251136.7	RP11-37B2.1	-9.09	2.8e-18	1.52e-15	-0.33	-0.39	Leprosy;	chr8:89769725	chr8:89609409~89757727:-
THCA	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	9.09	2.8e-18	1.52e-15	0.52	0.39	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000234255.7	AC012370.3	-9.09	2.8e-18	1.52e-15	-0.43	-0.39	Rheumatoid arthritis;	chr2:65423730	chr2:65439888~65456571:-
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	9.09	2.83e-18	1.54e-15	0.79	0.39	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
THCA	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
THCA	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-9.09	2.85e-18	1.55e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
THCA	cis	rs7015263	0.875	rs17608967	ENSG00000254231.1	CTD-2284J15.1	-9.09	2.87e-18	1.56e-15	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86413780	chr8:86333274~86343314:-
THCA	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-9.09	2.87e-18	1.56e-15	-0.71	-0.39	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
THCA	cis	rs9532669	0.926	rs9532691	ENSG00000239827.7	SUGT1P3	9.09	2.88e-18	1.56e-15	0.41	0.39	Cervical cancer;	chr13:40969358	chr13:40908159~40921774:-
THCA	cis	rs9659323	1	rs10923715	ENSG00000231365.4	RP11-418J17.1	9.09	2.89e-18	1.57e-15	0.39	0.39	Body mass index;	chr1:118992711	chr1:119140396~119275973:+
THCA	cis	rs7015263	0.875	rs10092164	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86440801	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs10096443	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86441374	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs6981299	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86443220	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs10088389	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86446578	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs6471349	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86457559	chr8:86333274~86343314:-
THCA	cis	rs780096	0.565	rs11681351	ENSG00000234072.1	AC074117.10	-9.08	2.9e-18	1.57e-15	-0.31	-0.39	Total body bone mineral density;	chr2:27520556	chr2:27356246~27367622:+
THCA	cis	rs1707322	0.963	rs4630155	ENSG00000234329.1	RP11-767N6.2	9.08	2.91e-18	1.58e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs4508055	ENSG00000234329.1	RP11-767N6.2	9.08	2.91e-18	1.58e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs12076580	ENSG00000234329.1	RP11-767N6.2	9.08	2.91e-18	1.58e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45651039~45651826:-
THCA	cis	rs4819052	1	rs9984901	ENSG00000215447.6	BX322557.10	-9.08	2.92e-18	1.58e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45288052~45291738:+
THCA	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
THCA	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
THCA	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
THCA	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
THCA	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
THCA	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
THCA	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-9.08	2.93e-18	1.59e-15	-0.51	-0.39	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-9.08	2.93e-18	1.59e-15	-0.51	-0.39	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-9.08	2.93e-18	1.59e-15	-0.51	-0.39	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
THCA	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	9.08	2.94e-18	1.6e-15	0.48	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
THCA	cis	rs7191700	0.644	rs918738	ENSG00000262703.1	RP11-485G7.6	-9.08	2.94e-18	1.6e-15	-0.42	-0.39	Multiple sclerosis;	chr16:11345822	chr16:11348143~11349321:-
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000228039.3	KB-1125A3.10	9.08	2.96e-18	1.6e-15	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23963780~23964374:+
THCA	cis	rs7015263	0.875	rs10956853	ENSG00000254231.1	CTD-2284J15.1	9.08	2.96e-18	1.6e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86459496	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs6471352	ENSG00000254231.1	CTD-2284J15.1	9.08	2.96e-18	1.6e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86470095	chr8:86333274~86343314:-
THCA	cis	rs7291412	0.579	rs11090867	ENSG00000231711.2	LINC00899	9.08	2.98e-18	1.61e-15	0.31	0.39	Dupuytren's disease;Subjective well-being;	chr22:46058912	chr22:46039907~46044853:-
THCA	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	9.08	2.98e-18	1.62e-15	0.61	0.39	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
THCA	cis	rs1707322	0.752	rs6678444	ENSG00000234329.1	RP11-767N6.2	9.08	2.98e-18	1.62e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45651039~45651826:-
THCA	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	9.08	2.99e-18	1.62e-15	0.52	0.39	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
THCA	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-9.08	2.99e-18	1.62e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	9.08	3e-18	1.63e-15	0.4	0.39	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
THCA	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	9.08	3.01e-18	1.63e-15	0.52	0.39	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	9.08	3.01e-18	1.63e-15	0.52	0.39	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
THCA	cis	rs17684571	0.7	rs62411376	ENSG00000231441.1	RP11-472M19.2	9.08	3.02e-18	1.64e-15	0.5	0.39	Schizophrenia;	chr6:56794436	chr6:56844002~56864078:+
THCA	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	9.08	3.02e-18	1.64e-15	0.41	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	9.08	3.02e-18	1.64e-15	0.53	0.39	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
THCA	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	9.08	3.03e-18	1.64e-15	0.51	0.39	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
THCA	cis	rs9402743	0.64	rs9494384	ENSG00000231028.7	LINC00271	-9.08	3.03e-18	1.64e-15	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135779072	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs6570041	ENSG00000231028.7	LINC00271	-9.08	3.03e-18	1.64e-15	-0.3	-0.39	Phosphorus levels;	chr6:135780515	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs6923513	ENSG00000231028.7	LINC00271	-9.08	3.03e-18	1.64e-15	-0.3	-0.39	Phosphorus levels;	chr6:135780784	chr6:135497801~135716055:+
THCA	cis	rs4591358	0.773	rs13035226	ENSG00000223466.1	AC064834.2	-9.08	3.03e-18	1.64e-15	-0.52	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512957	chr2:195533035~195538681:+
THCA	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	9.08	3.04e-18	1.64e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-9.08	3.04e-18	1.65e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
THCA	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-9.08	3.04e-18	1.65e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
THCA	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-9.08	3.04e-18	1.65e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
THCA	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-9.08	3.04e-18	1.65e-15	-0.39	-0.39	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
THCA	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-9.08	3.05e-18	1.65e-15	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
THCA	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	9.08	3.05e-18	1.65e-15	0.58	0.39	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
THCA	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-9.08	3.06e-18	1.65e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	9.08	3.06e-18	1.66e-15	0.78	0.39	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
THCA	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	9.08	3.07e-18	1.66e-15	0.83	0.39	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
THCA	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-9.08	3.07e-18	1.66e-15	-0.48	-0.39	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
THCA	cis	rs11971779	0.68	rs10271297	ENSG00000273391.1	RP11-634H22.1	9.08	3.07e-18	1.66e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367564	chr7:139359032~139359566:-
THCA	cis	rs62158211	1	rs62158211	ENSG00000272563.1	RP11-480C16.1	-9.08	3.08e-18	1.66e-15	-0.53	-0.39	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348562	chr2:113432600~113436042:+
THCA	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	9.08	3.08e-18	1.66e-15	0.39	0.39	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
THCA	cis	rs10411161	1	rs10411161	ENSG00000269483.1	AC006272.1	9.08	3.08e-18	1.66e-15	0.54	0.39	Breast cancer;	chr19:51869723	chr19:51839924~51843324:-
THCA	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	9.08	3.08e-18	1.67e-15	0.48	0.39	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
THCA	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-9.08	3.09e-18	1.67e-15	-0.55	-0.39	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
THCA	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	9.08	3.1e-18	1.67e-15	0.29	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
THCA	cis	rs9402743	0.667	rs4896179	ENSG00000231028.7	LINC00271	-9.08	3.1e-18	1.68e-15	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135788352	chr6:135497801~135716055:+
THCA	cis	rs10411161	1	rs8106929	ENSG00000269483.1	AC006272.1	9.08	3.11e-18	1.68e-15	0.54	0.39	Breast cancer;	chr19:51865214	chr19:51839924~51843324:-
THCA	cis	rs6496932	0.913	rs7403354	ENSG00000218052.5	ADAMTS7P4	9.08	3.11e-18	1.68e-15	0.54	0.39	Central corneal thickness;Corneal structure;	chr15:85277624	chr15:85255369~85330334:-
THCA	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-9.08	3.11e-18	1.68e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
THCA	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	9.08	3.12e-18	1.69e-15	0.67	0.39	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	9.08	3.12e-18	1.69e-15	0.67	0.39	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
THCA	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-9.07	3.13e-18	1.69e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-9.07	3.13e-18	1.69e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-9.07	3.13e-18	1.69e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-9.07	3.13e-18	1.69e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-9.07	3.13e-18	1.69e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
THCA	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-9.07	3.13e-18	1.69e-15	-0.3	-0.39	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
THCA	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	9.07	3.14e-18	1.7e-15	0.5	0.39	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
THCA	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	9.07	3.15e-18	1.7e-15	0.48	0.39	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
THCA	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	9.07	3.15e-18	1.7e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
THCA	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	9.07	3.16e-18	1.71e-15	0.52	0.39	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
THCA	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	9.07	3.17e-18	1.71e-15	0.58	0.39	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
THCA	cis	rs9329221	0.512	rs12546887	ENSG00000261451.1	RP11-981G7.1	9.07	3.2e-18	1.73e-15	0.47	0.39	Neuroticism;	chr8:10435366	chr8:10433672~10438312:+
THCA	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-9.07	3.21e-18	1.73e-15	-0.41	-0.39	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
THCA	cis	rs860295	0.836	rs1360554	ENSG00000225855.5	RUSC1-AS1	-9.07	3.22e-18	1.74e-15	-0.25	-0.39	Body mass index;	chr1:155503565	chr1:155316863~155324176:-
THCA	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-9.07	3.22e-18	1.74e-15	-0.54	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
THCA	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-9.07	3.24e-18	1.75e-15	-0.47	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
THCA	cis	rs10740039	0.842	rs7080024	ENSG00000254271.1	RP11-131N11.4	-9.07	3.25e-18	1.75e-15	-0.47	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632033	chr10:60734342~60741828:+
THCA	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
THCA	cis	rs4819052	1	rs3746980	ENSG00000215447.6	BX322557.10	-9.07	3.27e-18	1.76e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45288052~45291738:+
THCA	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	9.07	3.27e-18	1.77e-15	0.53	0.39	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
THCA	cis	rs17684571	0.7	rs13205667	ENSG00000231441.1	RP11-472M19.2	9.07	3.27e-18	1.77e-15	0.53	0.39	Schizophrenia;	chr6:56775176	chr6:56844002~56864078:+
THCA	cis	rs2288884	0.767	rs28379522	ENSG00000275055.1	CTC-471J1.11	-9.07	3.27e-18	1.77e-15	-0.36	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.708	rs11665783	ENSG00000275055.1	CTC-471J1.11	-9.07	3.28e-18	1.77e-15	-0.36	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014641	chr19:52049007~52049754:+
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000275120.1	RP11-182J1.17	-9.07	3.28e-18	1.77e-15	-0.41	-0.39	P wave terminal force;	chr15:84654022	chr15:84599434~84606463:-
THCA	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-9.07	3.29e-18	1.77e-15	-0.58	-0.39	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
THCA	cis	rs11971779	0.616	rs6967932	ENSG00000273391.1	RP11-634H22.1	9.07	3.29e-18	1.78e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139337635	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-9.07	3.29e-18	1.78e-15	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
THCA	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	9.07	3.29e-18	1.78e-15	0.53	0.39	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
THCA	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	9.07	3.29e-18	1.78e-15	0.53	0.39	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
THCA	cis	rs10181042	0.612	rs1177282	ENSG00000271889.1	RP11-493E12.1	9.07	3.3e-18	1.78e-15	0.39	0.39	Crohn's disease;	chr2:61130642	chr2:61151433~61162105:-
THCA	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-9.07	3.31e-18	1.79e-15	-0.63	-0.39	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
THCA	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-9.07	3.33e-18	1.79e-15	-0.41	-0.39	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-9.07	3.33e-18	1.79e-15	-0.41	-0.39	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
THCA	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	9.07	3.33e-18	1.8e-15	0.52	0.39	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000273009.1	RP11-352G9.1	9.07	3.34e-18	1.8e-15	0.43	0.39	Pancreatic cancer;	chr3:196024759	chr3:195913078~195913683:-
THCA	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	9.07	3.37e-18	1.82e-15	0.51	0.39	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
THCA	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-9.07	3.37e-18	1.82e-15	-0.46	-0.39	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
THCA	cis	rs11148252	0.74	rs9596643	ENSG00000278238.1	RP11-245D16.4	9.07	3.37e-18	1.82e-15	0.44	0.39	Lewy body disease;	chr13:52338245	chr13:52454775~52455331:-
THCA	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-9.07	3.37e-18	1.82e-15	-0.42	-0.39	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
THCA	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-9.07	3.38e-18	1.82e-15	-0.42	-0.39	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-9.06	3.39e-18	1.83e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-9.06	3.39e-18	1.83e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-9.06	3.39e-18	1.83e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-9.06	3.39e-18	1.83e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
THCA	cis	rs17684571	0.7	rs17684784	ENSG00000231441.1	RP11-472M19.2	-9.06	3.43e-18	1.85e-15	-0.49	-0.39	Schizophrenia;	chr6:56813644	chr6:56844002~56864078:+
THCA	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-9.06	3.46e-18	1.86e-15	-0.68	-0.39	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
THCA	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-9.06	3.46e-18	1.86e-15	-0.33	-0.39	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
THCA	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-9.06	3.46e-18	1.86e-15	-0.57	-0.39	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
THCA	cis	rs2033711	0.84	rs3764533	ENSG00000268912.1	CTD-2619J13.17	-9.06	3.46e-18	1.86e-15	-0.29	-0.39	Uric acid clearance;	chr19:58417827	chr19:58428632~58431148:-
THCA	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-9.06	3.46e-18	1.86e-15	-0.5	-0.39	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
THCA	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-9.06	3.46e-18	1.86e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
THCA	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	9.06	3.46e-18	1.87e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
THCA	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-9.06	3.47e-18	1.87e-15	-0.63	-0.39	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs2255774	ENSG00000215447.6	BX322557.10	-9.06	3.48e-18	1.88e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45288052~45291738:+
THCA	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-9.06	3.49e-18	1.88e-15	-0.69	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
THCA	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	9.06	3.5e-18	1.88e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
THCA	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	9.06	3.51e-18	1.89e-15	0.45	0.39	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	9.06	3.52e-18	1.89e-15	0.51	0.39	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
THCA	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	9.06	3.52e-18	1.9e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
THCA	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-9.06	3.54e-18	1.9e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-9.06	3.54e-18	1.9e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
THCA	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-9.06	3.55e-18	1.91e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-9.06	3.56e-18	1.92e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-9.06	3.56e-18	1.92e-15	-0.78	-0.39	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
THCA	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-9.06	3.57e-18	1.92e-15	-0.34	-0.39	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
THCA	cis	rs947583	0.517	rs7764412	ENSG00000231028.7	LINC00271	-9.06	3.57e-18	1.92e-15	-0.29	-0.39	Phosphorus levels;	chr6:135787214	chr6:135497801~135716055:+
THCA	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	9.06	3.59e-18	1.93e-15	0.51	0.39	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	9.06	3.6e-18	1.94e-15	0.52	0.39	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	9.06	3.6e-18	1.94e-15	0.52	0.39	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
THCA	cis	rs2033711	0.837	rs3764535	ENSG00000268912.1	CTD-2619J13.17	-9.06	3.61e-18	1.94e-15	-0.29	-0.39	Uric acid clearance;	chr19:58417685	chr19:58428632~58431148:-
THCA	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	9.06	3.63e-18	1.95e-15	0.58	0.39	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	9.06	3.64e-18	1.96e-15	0.54	0.39	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
THCA	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	9.06	3.64e-18	1.96e-15	0.53	0.39	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
THCA	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	9.06	3.64e-18	1.96e-15	0.52	0.39	Depression;	chr6:28167882	chr6:28161781~28169594:+
THCA	cis	rs848490	0.508	rs6975810	ENSG00000214293.7	APTR	9.06	3.65e-18	1.96e-15	0.27	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659701	chr7:77657660~77696265:-
THCA	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-9.06	3.65e-18	1.96e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
THCA	cis	rs494459	0.536	rs57719838	ENSG00000278376.1	RP11-158I9.8	-9.06	3.66e-18	1.96e-15	-0.28	-0.39	Height;	chr11:118854014	chr11:118791254~118793137:+
THCA	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-9.05	3.66e-18	1.97e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-9.05	3.66e-18	1.97e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
THCA	cis	rs860295	0.871	rs34632540	ENSG00000225855.5	RUSC1-AS1	-9.05	3.67e-18	1.97e-15	-0.26	-0.39	Body mass index;	chr1:155642406	chr1:155316863~155324176:-
THCA	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	9.05	3.68e-18	1.98e-15	0.52	0.39	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
THCA	cis	rs17684571	0.7	rs13220851	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56796753	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs59432342	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56797506	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs34171958	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56800000	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13201733	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56804226	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17684730	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56804425	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs4371846	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56805767	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17684748	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56809419	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17751977	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56809820	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17684772	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56810415	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17752002	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56812209	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs4299824	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56815697	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13200166	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56816414	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17752046	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56816550	chr6:56844002~56864078:+
THCA	cis	rs860295	0.557	rs10796944	ENSG00000225855.5	RUSC1-AS1	9.05	3.69e-18	1.98e-15	0.3	0.39	Body mass index;	chr1:155446537	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-9.05	3.69e-18	1.98e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
THCA	cis	rs1858037	0.867	rs871974	ENSG00000281920.1	RP11-418H16.1	-9.05	3.69e-18	1.98e-15	-0.51	-0.39	Rheumatoid arthritis;	chr2:65330153	chr2:65623272~65628424:+
THCA	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-9.05	3.73e-18	2e-15	-0.5	-0.39	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
THCA	cis	rs9543976	1	rs9543976	ENSG00000261553.4	RP11-29G8.3	9.05	3.74e-18	2.01e-15	0.48	0.39	Diabetic retinopathy;	chr13:75562512	chr13:75549773~75807120:+
THCA	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-9.05	3.75e-18	2.01e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-9.05	3.75e-18	2.01e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
THCA	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	9.05	3.76e-18	2.02e-15	0.46	0.39	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	9.05	3.76e-18	2.02e-15	0.46	0.39	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	9.05	3.76e-18	2.02e-15	0.46	0.39	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
THCA	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	9.05	3.76e-18	2.02e-15	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
THCA	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-9.05	3.77e-18	2.02e-15	-0.28	-0.39	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
THCA	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
THCA	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
THCA	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	9.05	3.79e-18	2.03e-15	0.58	0.39	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
THCA	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	9.05	3.8e-18	2.04e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	9.05	3.8e-18	2.04e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
THCA	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-9.05	3.8e-18	2.04e-15	-0.4	-0.39	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
THCA	cis	rs1707322	0.685	rs11211177	ENSG00000234329.1	RP11-767N6.2	9.05	3.8e-18	2.04e-15	0.36	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45651039~45651826:-
THCA	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	9.05	3.82e-18	2.05e-15	0.52	0.39	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
THCA	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-9.05	3.83e-18	2.06e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
THCA	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	9.05	3.83e-18	2.06e-15	0.51	0.39	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
THCA	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-9.05	3.84e-18	2.06e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
THCA	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.84e-18	2.06e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
THCA	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	9.05	3.85e-18	2.06e-15	0.58	0.39	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
THCA	cis	rs947583	0.517	rs9402757	ENSG00000231028.7	LINC00271	9.05	3.85e-18	2.07e-15	0.29	0.39	Phosphorus levels;	chr6:135799947	chr6:135497801~135716055:+
THCA	cis	rs4713118	0.662	rs149901	ENSG00000280107.1	AL022393.9	-9.05	3.85e-18	2.07e-15	-0.43	-0.39	Parkinson's disease;	chr6:27997725	chr6:28170845~28172521:+
THCA	cis	rs7665090	0.806	rs7674004	ENSG00000246560.2	RP11-10L12.4	9.05	3.86e-18	2.07e-15	0.46	0.39	Primary biliary cholangitis;	chr4:102619156	chr4:102828055~102844075:+
THCA	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	9.05	3.87e-18	2.07e-15	0.53	0.39	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
THCA	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	9.05	3.87e-18	2.07e-15	0.53	0.39	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
THCA	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-9.05	3.87e-18	2.07e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
THCA	cis	rs7772486	0.84	rs2814864	ENSG00000235652.6	RP11-545I5.3	9.05	3.87e-18	2.07e-15	0.36	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146023910	chr6:145799409~145886585:+
THCA	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	9.05	3.88e-18	2.08e-15	0.37	0.39	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
THCA	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	9.05	3.88e-18	2.08e-15	0.37	0.39	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
THCA	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	9.05	3.88e-18	2.08e-15	0.37	0.39	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
THCA	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-9.05	3.88e-18	2.08e-15	-0.3	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
THCA	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	9.05	3.89e-18	2.09e-15	0.39	0.39	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
THCA	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	9.05	3.9e-18	2.09e-15	0.78	0.39	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	9.05	3.9e-18	2.09e-15	0.78	0.39	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs28628220	ENSG00000215447.6	BX322557.10	-9.05	3.9e-18	2.09e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45288052~45291738:+
THCA	cis	rs4819052	1	rs2838830	ENSG00000215447.6	BX322557.10	-9.05	3.9e-18	2.09e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45288052~45291738:+
THCA	cis	rs2033711	0.728	rs4801586	ENSG00000268912.1	CTD-2619J13.17	-9.05	3.9e-18	2.09e-15	-0.3	-0.39	Uric acid clearance;	chr19:58423161	chr19:58428632~58431148:-
THCA	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-9.05	3.91e-18	2.09e-15	-0.28	-0.39	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
THCA	cis	rs10411161	0.702	rs8110531	ENSG00000269483.1	AC006272.1	9.05	3.92e-18	2.1e-15	0.54	0.39	Breast cancer;	chr19:51880257	chr19:51839924~51843324:-
THCA	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	9.05	3.92e-18	2.1e-15	0.58	0.39	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
THCA	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	9.05	3.92e-18	2.1e-15	0.65	0.39	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
THCA	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-9.05	3.93e-18	2.11e-15	-0.5	-0.39	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
THCA	cis	rs6496932	0.866	rs4842870	ENSG00000218052.5	ADAMTS7P4	9.05	3.95e-18	2.11e-15	0.54	0.39	Central corneal thickness;Corneal structure;	chr15:85277568	chr15:85255369~85330334:-
THCA	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-9.04	3.95e-18	2.12e-15	-0.34	-0.39	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
THCA	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-9.04	3.98e-18	2.13e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
THCA	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	9.04	3.98e-18	2.13e-15	0.41	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
THCA	cis	rs4819052	0.851	rs2236445	ENSG00000215447.6	BX322557.10	-9.04	3.98e-18	2.13e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45288052~45291738:+
THCA	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-9.04	3.98e-18	2.13e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
THCA	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	9.04	3.99e-18	2.14e-15	0.58	0.39	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	9.04	3.99e-18	2.14e-15	0.58	0.39	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	9.04	3.99e-18	2.14e-15	0.58	0.39	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
THCA	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	9.04	3.99e-18	2.14e-15	0.53	0.39	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
THCA	cis	rs2033711	0.783	rs8113810	ENSG00000268912.1	CTD-2619J13.17	-9.04	3.99e-18	2.14e-15	-0.3	-0.39	Uric acid clearance;	chr19:58420739	chr19:58428632~58431148:-
THCA	cis	rs2033711	0.87	rs4801270	ENSG00000268912.1	CTD-2619J13.17	-9.04	3.99e-18	2.14e-15	-0.3	-0.39	Uric acid clearance;	chr19:58421395	chr19:58428632~58431148:-
THCA	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	9.04	4.01e-18	2.15e-15	0.58	0.38	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
THCA	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-9.04	4.02e-18	2.15e-15	-0.46	-0.38	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
THCA	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-9.04	4.02e-18	2.15e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-9.04	4.02e-18	2.15e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	9.04	4.07e-18	2.18e-15	0.48	0.38	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
THCA	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-9.04	4.07e-18	2.18e-15	-0.43	-0.38	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
THCA	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	9.04	4.08e-18	2.18e-15	0.58	0.38	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	9.04	4.08e-18	2.19e-15	0.51	0.38	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	9.04	4.08e-18	2.19e-15	0.51	0.38	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	9.04	4.08e-18	2.19e-15	0.51	0.38	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
THCA	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	9.04	4.09e-18	2.19e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
THCA	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-9.04	4.09e-18	2.19e-15	-0.51	-0.38	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	9.04	4.1e-18	2.19e-15	0.51	0.38	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
THCA	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-9.04	4.12e-18	2.2e-15	-0.5	-0.38	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000266490.1	CTD-2349P21.9	9.04	4.12e-18	2.2e-15	0.54	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000266490.1	CTD-2349P21.9	9.04	4.12e-18	2.2e-15	0.54	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000266490.1	CTD-2349P21.9	9.04	4.12e-18	2.2e-15	0.54	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30792372~30792833:+
THCA	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-9.04	4.15e-18	2.22e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
THCA	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	9.04	4.16e-18	2.23e-15	0.67	0.38	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
THCA	cis	rs494459	0.536	rs7103067	ENSG00000278376.1	RP11-158I9.8	-9.04	4.17e-18	2.23e-15	-0.28	-0.38	Height;	chr11:118852670	chr11:118791254~118793137:+
THCA	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	9.04	4.19e-18	2.24e-15	0.46	0.38	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
THCA	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-9.04	4.22e-18	2.26e-15	-0.43	-0.38	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
THCA	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-9.04	4.23e-18	2.26e-15	-0.31	-0.38	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
THCA	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-9.04	4.24e-18	2.26e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-9.04	4.24e-18	2.26e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
THCA	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-9.04	4.24e-18	2.27e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000215447.6	BX322557.10	-9.04	4.26e-18	2.28e-15	-0.35	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45288052~45291738:+
THCA	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-9.04	4.26e-18	2.28e-15	-0.51	-0.38	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
THCA	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-9.04	4.27e-18	2.28e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-9.03	4.29e-18	2.29e-15	-0.77	-0.38	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	9.03	4.3e-18	2.3e-15	0.75	0.38	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs733739	ENSG00000215447.6	BX322557.10	-9.03	4.33e-18	2.31e-15	-0.34	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45288052~45291738:+
THCA	cis	rs6496932	0.913	rs34896088	ENSG00000218052.5	ADAMTS7P4	9.03	4.33e-18	2.32e-15	0.54	0.38	Central corneal thickness;Corneal structure;	chr15:85278393	chr15:85255369~85330334:-
THCA	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	9.03	4.35e-18	2.32e-15	0.48	0.38	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
THCA	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-9.03	4.37e-18	2.33e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
THCA	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	9.03	4.37e-18	2.33e-15	0.52	0.38	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
THCA	cis	rs10411161	0.702	rs8110546	ENSG00000269483.1	AC006272.1	9.03	4.37e-18	2.33e-15	0.54	0.38	Breast cancer;	chr19:51880303	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs8110461	ENSG00000269483.1	AC006272.1	9.03	4.37e-18	2.33e-15	0.54	0.38	Breast cancer;	chr19:51880316	chr19:51839924~51843324:-
THCA	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	9.03	4.37e-18	2.33e-15	0.45	0.38	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
THCA	cis	rs944289	0.774	rs1958623	ENSG00000257826.1	RP11-116N8.4	-9.03	4.37e-18	2.34e-15	-0.4	-0.38	Thyroid cancer;	chr14:36128417	chr14:36061026~36067190:-
THCA	cis	rs947583	0.517	rs9494390	ENSG00000231028.7	LINC00271	-9.03	4.38e-18	2.34e-15	-0.29	-0.38	Phosphorus levels;	chr6:135794875	chr6:135497801~135716055:+
THCA	cis	rs7727544	0.617	rs3843503	ENSG00000237714.1	P4HA2-AS1	9.03	4.38e-18	2.34e-15	0.51	0.38	Blood metabolite levels;	chr5:132130936	chr5:132184876~132192808:+
THCA	cis	rs524281	0.731	rs3829937	ENSG00000255320.1	RP11-755F10.1	9.03	4.4e-18	2.35e-15	0.61	0.38	Electroencephalogram traits;	chr11:66020195	chr11:66244840~66246239:-
THCA	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-9.03	4.41e-18	2.35e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
THCA	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	9.03	4.42e-18	2.36e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
THCA	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-9.03	4.42e-18	2.36e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
THCA	cis	rs944289	0.774	rs1958625	ENSG00000257826.1	RP11-116N8.4	-9.03	4.43e-18	2.36e-15	-0.41	-0.38	Thyroid cancer;	chr14:36133470	chr14:36061026~36067190:-
THCA	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-9.03	4.43e-18	2.36e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
THCA	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	9.03	4.45e-18	2.37e-15	0.36	0.38	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
THCA	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	9.03	4.45e-18	2.37e-15	0.52	0.38	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
THCA	cis	rs11051970	0.559	rs56670459	ENSG00000274964.1	RP11-817I4.1	-9.03	4.46e-18	2.38e-15	-0.53	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32390391	chr12:32339368~32340724:+
THCA	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-9.03	4.47e-18	2.39e-15	-0.28	-0.38	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-9.03	4.53e-18	2.42e-15	-0.4	-0.38	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
THCA	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-9.03	4.54e-18	2.42e-15	-0.66	-0.38	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
THCA	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-9.03	4.56e-18	2.43e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
THCA	cis	rs8027521	0.521	rs11629463	ENSG00000280362.1	RP11-643A5.3	-9.03	4.56e-18	2.43e-15	-0.54	-0.38	Circulating chemerin levels;	chr15:53941503	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.502	rs11629468	ENSG00000280362.1	RP11-643A5.3	-9.03	4.56e-18	2.43e-15	-0.54	-0.38	Circulating chemerin levels;	chr15:53941519	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.502	rs7183339	ENSG00000280362.1	RP11-643A5.3	-9.03	4.56e-18	2.43e-15	-0.54	-0.38	Circulating chemerin levels;	chr15:53941796	chr15:53910769~53914712:+
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	9.03	4.58e-18	2.44e-15	0.48	0.38	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
THCA	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	9.03	4.6e-18	2.45e-15	0.46	0.38	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	9.03	4.6e-18	2.45e-15	0.46	0.38	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	9.03	4.6e-18	2.45e-15	0.46	0.38	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
THCA	cis	rs10266483	0.96	rs13221291	ENSG00000227986.1	TRIM60P18	-9.03	4.6e-18	2.45e-15	-0.3	-0.38	Response to statin therapy;	chr7:64279114	chr7:64355078~64356199:+
THCA	cis	rs490608	0.628	rs678157	ENSG00000225855.5	RUSC1-AS1	9.02	4.63e-18	2.47e-15	0.28	0.38	Inflammatory bowel disease;	chr1:155688550	chr1:155316863~155324176:-
THCA	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	9.02	4.63e-18	2.47e-15	0.46	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
THCA	cis	rs10740039	0.81	rs10159646	ENSG00000254271.1	RP11-131N11.4	9.02	4.63e-18	2.47e-15	0.49	0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60620366	chr10:60734342~60741828:+
THCA	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	9.02	4.63e-18	2.47e-15	0.4	0.38	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
THCA	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	9.02	4.64e-18	2.47e-15	0.27	0.38	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	9.02	4.64e-18	2.47e-15	0.27	0.38	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	9.02	4.64e-18	2.47e-15	0.27	0.38	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-9.02	4.65e-18	2.48e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-9.02	4.65e-18	2.48e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-9.02	4.65e-18	2.48e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-9.02	4.65e-18	2.48e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
THCA	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-9.02	4.67e-18	2.49e-15	-0.49	-0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
THCA	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-9.02	4.68e-18	2.49e-15	-0.5	-0.38	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
THCA	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-9.02	4.68e-18	2.49e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000224205.1	AP000351.4	9.02	4.68e-18	2.49e-15	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23987320~23991421:-
THCA	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-9.02	4.7e-18	2.51e-15	-0.5	-0.38	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
THCA	cis	rs17772222	0.63	rs816069	ENSG00000258789.1	RP11-507K2.3	9.02	4.7e-18	2.51e-15	0.37	0.38	Coronary artery calcification;	chr14:88500992	chr14:88551597~88552493:+
THCA	cis	rs947583	0.517	rs4895457	ENSG00000231028.7	LINC00271	-9.02	4.72e-18	2.51e-15	-0.29	-0.38	Phosphorus levels;	chr6:135783172	chr6:135497801~135716055:+
THCA	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	9.02	4.72e-18	2.51e-15	0.46	0.38	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000099984.9	GSTT2	-9.02	4.73e-18	2.52e-15	-0.48	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23980123~23983911:+
THCA	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	9.02	4.73e-18	2.52e-15	0.48	0.38	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
THCA	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-9.02	4.73e-18	2.52e-15	-0.5	-0.38	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
THCA	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-9.02	4.74e-18	2.53e-15	-0.56	-0.38	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
THCA	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	9.02	4.76e-18	2.54e-15	0.45	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
THCA	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-9.02	4.76e-18	2.54e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
THCA	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-9.02	4.76e-18	2.54e-15	-0.4	-0.38	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
THCA	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-9.02	4.77e-18	2.54e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-9.02	4.77e-18	2.54e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
THCA	cis	rs2288884	0.731	rs11673450	ENSG00000275055.1	CTC-471J1.11	-9.02	4.77e-18	2.54e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037441	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.731	rs11673398	ENSG00000275055.1	CTC-471J1.11	-9.02	4.77e-18	2.54e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037444	chr19:52049007~52049754:+
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	9.02	4.78e-18	2.54e-15	0.76	0.38	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
THCA	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	9.02	4.78e-18	2.54e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
THCA	cis	rs1707322	0.752	rs4660313	ENSG00000234329.1	RP11-767N6.2	-9.02	4.78e-18	2.55e-15	-0.37	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
THCA	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	9.02	4.8e-18	2.56e-15	0.58	0.38	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
THCA	cis	rs9532669	0.926	rs9532693	ENSG00000239827.7	SUGT1P3	-9.02	4.84e-18	2.58e-15	-0.41	-0.38	Cervical cancer;	chr13:40980557	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	9.02	4.85e-18	2.58e-15	0.46	0.38	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
THCA	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-9.02	4.86e-18	2.59e-15	-0.79	-0.38	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
THCA	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-9.02	4.86e-18	2.59e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-9.02	4.86e-18	2.59e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
THCA	cis	rs17684571	0.751	rs10498812	ENSG00000231441.1	RP11-472M19.2	9.02	4.86e-18	2.59e-15	0.53	0.38	Schizophrenia;	chr6:56819412	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs13220628	ENSG00000231441.1	RP11-472M19.2	9.02	4.86e-18	2.59e-15	0.53	0.38	Schizophrenia;	chr6:56819445	chr6:56844002~56864078:+
THCA	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-9.02	4.88e-18	2.6e-15	-0.39	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
THCA	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-9.02	4.92e-18	2.62e-15	-0.51	-0.38	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000224205.1	AP000351.4	9.02	4.93e-18	2.62e-15	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23987320~23991421:-
THCA	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-9.02	4.95e-18	2.63e-15	-0.5	-0.38	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
THCA	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	9.02	4.95e-18	2.63e-15	0.67	0.38	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
THCA	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	9.02	4.95e-18	2.63e-15	0.51	0.38	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	9.02	4.95e-18	2.63e-15	0.51	0.38	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
THCA	cis	rs12188164	0.502	rs55929184	ENSG00000221990.4	EXOC3-AS1	9.02	4.97e-18	2.64e-15	0.33	0.38	Cystic fibrosis severity;	chr5:405461	chr5:441498~443160:-
THCA	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-9.01	5.01e-18	2.66e-15	-0.4	-0.38	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
THCA	cis	rs7015263	0.535	rs55754530	ENSG00000254231.1	CTD-2284J15.1	-9.01	5.01e-18	2.66e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86361976	chr8:86333274~86343314:-
THCA	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	9.01	5.02e-18	2.67e-15	0.47	0.38	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
THCA	cis	rs6600671	0.691	rs6600662	ENSG00000223345.3	HIST2H2BA	9.01	5.03e-18	2.68e-15	0.44	0.38	Hip geometry;	chr1:121488992	chr1:121108210~121117257:-
THCA	cis	rs11051970	0.527	rs7313432	ENSG00000274964.1	RP11-817I4.1	-9.01	5.04e-18	2.68e-15	-0.5	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32419335	chr12:32339368~32340724:+
THCA	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-9.01	5.04e-18	2.68e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	9.01	5.05e-18	2.68e-15	0.51	0.38	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
THCA	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	9.01	5.05e-18	2.68e-15	0.27	0.38	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
THCA	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-9.01	5.05e-18	2.68e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
THCA	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	9.01	5.05e-18	2.68e-15	0.46	0.38	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
THCA	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-9.01	5.06e-18	2.69e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
THCA	cis	rs7569084	0.663	rs6546150	ENSG00000234255.7	AC012370.3	-9.01	5.06e-18	2.69e-15	-0.44	-0.38	Sum eosinophil basophil counts;	chr2:65415066	chr2:65439888~65456571:-
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-9.01	5.07e-18	2.69e-15	-0.51	-0.38	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
THCA	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	9.01	5.08e-18	2.7e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
THCA	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-9.01	5.09e-18	2.71e-15	-0.36	-0.38	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
THCA	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	9.01	5.1e-18	2.71e-15	0.48	0.38	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	9.01	5.1e-18	2.71e-15	0.48	0.38	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
THCA	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	9.01	5.13e-18	2.72e-15	0.4	0.38	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
THCA	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	9.01	5.14e-18	2.73e-15	0.46	0.38	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
THCA	cis	rs1707322	0.752	rs7541962	ENSG00000234329.1	RP11-767N6.2	9.01	5.17e-18	2.74e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45651039~45651826:-
THCA	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	9.01	5.18e-18	2.75e-15	0.45	0.38	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
THCA	cis	rs9532669	0.963	rs9532662	ENSG00000239827.7	SUGT1P3	-9.01	5.2e-18	2.76e-15	-0.4	-0.38	Cervical cancer;	chr13:40926215	chr13:40908159~40921774:-
THCA	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-9.01	5.2e-18	2.76e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
THCA	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	9.01	5.21e-18	2.76e-15	0.39	0.38	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	9.01	5.21e-18	2.76e-15	0.49	0.38	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
THCA	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-9.01	5.22e-18	2.77e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
THCA	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-9.01	5.22e-18	2.77e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-9.01	5.22e-18	2.77e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
THCA	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-9.01	5.24e-18	2.78e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
THCA	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-9.01	5.24e-18	2.78e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
THCA	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-9.01	5.24e-18	2.78e-15	-0.79	-0.38	Gout;	chr7:66642037	chr7:66654538~66669855:+
THCA	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	9.01	5.25e-18	2.78e-15	0.28	0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
THCA	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	9.01	5.25e-18	2.78e-15	0.58	0.38	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	9.01	5.25e-18	2.78e-15	0.58	0.38	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
THCA	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-9.01	5.25e-18	2.78e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
THCA	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-9.01	5.25e-18	2.78e-15	-0.28	-0.38	Height;	chr11:118859432	chr11:118791254~118793137:+
THCA	cis	rs853679	0.55	rs6901017	ENSG00000226314.6	ZNF192P1	-9.01	5.26e-18	2.79e-15	-0.5	-0.38	Depression;	chr6:28184805	chr6:28161781~28169594:+
THCA	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-9.01	5.33e-18	2.82e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
THCA	cis	rs947583	0.517	rs4896181	ENSG00000231028.7	LINC00271	-9.01	5.33e-18	2.82e-15	-0.29	-0.38	Phosphorus levels;	chr6:135788742	chr6:135497801~135716055:+
THCA	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	9.01	5.33e-18	2.83e-15	0.51	0.38	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
THCA	cis	rs860295	0.812	rs11264363	ENSG00000225855.5	RUSC1-AS1	9.01	5.33e-18	2.83e-15	0.25	0.38	Body mass index;	chr1:155348517	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-9.01	5.34e-18	2.83e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
THCA	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	9.01	5.37e-18	2.85e-15	0.48	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	9.01	5.37e-18	2.85e-15	0.48	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
THCA	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	9.01	5.38e-18	2.85e-15	0.67	0.38	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
THCA	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-9.01	5.39e-18	2.85e-15	-0.28	-0.38	Height;	chr11:118860890	chr11:118791254~118793137:+
THCA	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-9.01	5.39e-18	2.85e-15	-0.28	-0.38	Height;	chr11:118861053	chr11:118791254~118793137:+
THCA	cis	rs10411161	0.702	rs8113584	ENSG00000269483.1	AC006272.1	9.01	5.39e-18	2.86e-15	0.53	0.38	Breast cancer;	chr19:51880621	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs8113685	ENSG00000269483.1	AC006272.1	9.01	5.39e-18	2.86e-15	0.53	0.38	Breast cancer;	chr19:51880637	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs8113768	ENSG00000269483.1	AC006272.1	9.01	5.39e-18	2.86e-15	0.53	0.38	Breast cancer;	chr19:51880685	chr19:51839924~51843324:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000224205.1	AP000351.4	-9	5.41e-18	2.86e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23987320~23991421:-
THCA	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-9	5.43e-18	2.88e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
THCA	cis	rs10411161	0.702	rs8100716	ENSG00000269483.1	AC006272.1	9	5.46e-18	2.89e-15	0.53	0.38	Breast cancer;	chr19:51880808	chr19:51839924~51843324:-
THCA	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	9	5.5e-18	2.91e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	9	5.5e-18	2.92e-15	0.49	0.38	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
THCA	cis	rs4819052	0.851	rs1056101	ENSG00000215447.6	BX322557.10	-9	5.52e-18	2.93e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000215447.6	BX322557.10	-9	5.54e-18	2.93e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45288052~45291738:+
THCA	cis	rs2522056	0.808	rs1016988	ENSG00000233006.5	AC034220.3	-9	5.54e-18	2.94e-15	-0.34	-0.38	Fibrinogen;Lymphocyte counts;	chr5:132408882	chr5:132311285~132369916:-
THCA	cis	rs11971779	0.68	rs6965212	ENSG00000273391.1	RP11-634H22.1	9	5.55e-18	2.94e-15	0.37	0.38	Diisocyanate-induced asthma;	chr7:139341719	chr7:139359032~139359566:-
THCA	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-9	5.56e-18	2.94e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-9	5.6e-18	2.97e-15	-0.47	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
THCA	cis	rs2946505	1	rs2946505	ENSG00000251468.2	RP11-369K16.1	9	5.61e-18	2.97e-15	0.5	0.38	Migraine;	chr8:12953643	chr8:12958387~12962200:+
THCA	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-9	5.61e-18	2.97e-15	-0.41	-0.38	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
THCA	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-9	5.61e-18	2.97e-15	-0.32	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
THCA	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-9	5.62e-18	2.97e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-9	5.62e-18	2.97e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
THCA	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-9	5.64e-18	2.98e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
THCA	cis	rs748404	0.697	rs567357	ENSG00000249839.1	AC011330.5	-9	5.66e-18	2.99e-15	-0.45	-0.38	Lung cancer;	chr15:43279192	chr15:43663654~43684339:-
THCA	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	9	5.68e-18	3e-15	0.52	0.38	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
THCA	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-9	5.68e-18	3.01e-15	-0.35	-0.38	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
THCA	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	9	5.69e-18	3.01e-15	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	9	5.69e-18	3.01e-15	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
THCA	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-9	5.7e-18	3.02e-15	-0.77	-0.38	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
THCA	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-9	5.72e-18	3.03e-15	-0.5	-0.38	Gout;	chr7:66661502	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-9	5.72e-18	3.03e-15	-0.5	-0.38	Gout;	chr7:66679692	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	9	5.72e-18	3.03e-15	0.5	0.38	Gout;	chr7:66682070	chr7:66902857~66906297:+
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	9	5.72e-18	3.03e-15	0.5	0.38	Gout;	chr7:66682162	chr7:66902857~66906297:+
THCA	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-9	5.76e-18	3.05e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-9	5.76e-18	3.05e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-9	5.76e-18	3.05e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-9	5.76e-18	3.05e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
THCA	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	9	5.76e-18	3.05e-15	0.5	0.38	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
THCA	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-9	5.83e-18	3.08e-15	-0.45	-0.38	Migraine;	chr4:56880007	chr4:56960927~56961373:-
THCA	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-9	5.83e-18	3.08e-15	-0.45	-0.38	Migraine;	chr4:56880190	chr4:56960927~56961373:-
THCA	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-9	5.83e-18	3.08e-15	-0.45	-0.38	Migraine;	chr4:56880659	chr4:56960927~56961373:-
THCA	cis	rs7211079	0.957	rs935117	ENSG00000275479.1	RP11-334C17.6	8.99	5.84e-18	3.09e-15	0.38	0.38	Myocardial infarction;	chr17:80141685	chr17:80149627~80149798:+
THCA	cis	rs7211079	0.957	rs58120535	ENSG00000275479.1	RP11-334C17.6	8.99	5.84e-18	3.09e-15	0.38	0.38	Myocardial infarction;	chr17:80142225	chr17:80149627~80149798:+
THCA	cis	rs4842666	0.915	rs11105364	ENSG00000258302.2	RP11-981P6.1	8.99	5.88e-18	3.11e-15	0.38	0.38	Blood pressure;	chr12:89675499	chr12:89561129~89594878:+
THCA	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	8.99	5.92e-18	3.13e-15	0.57	0.38	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
THCA	cis	rs4842666	0.915	rs73437358	ENSG00000258302.2	RP11-981P6.1	8.99	5.92e-18	3.13e-15	0.38	0.38	Blood pressure;	chr12:89678299	chr12:89561129~89594878:+
THCA	cis	rs4842666	0.915	rs11105368	ENSG00000258302.2	RP11-981P6.1	8.99	5.92e-18	3.13e-15	0.38	0.38	Blood pressure;	chr12:89680664	chr12:89561129~89594878:+
THCA	cis	rs4842666	0.765	rs4842675	ENSG00000258302.2	RP11-981P6.1	8.99	5.92e-18	3.13e-15	0.38	0.38	Blood pressure;	chr12:89681466	chr12:89561129~89594878:+
THCA	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-8.99	5.94e-18	3.14e-15	-0.39	-0.38	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
THCA	cis	rs4819052	0.851	rs2838856	ENSG00000215447.6	BX322557.10	-8.99	5.97e-18	3.15e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	8.99	5.99e-18	3.17e-15	0.39	0.38	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
THCA	cis	rs4819052	0.851	rs2838857	ENSG00000215447.6	BX322557.10	-8.99	5.99e-18	3.17e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	8.99	6.01e-18	3.17e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
THCA	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-8.99	6.02e-18	3.18e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
THCA	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	8.99	6.02e-18	3.18e-15	0.69	0.38	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	8.99	6.02e-18	3.18e-15	0.69	0.38	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
THCA	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	8.99	6.03e-18	3.18e-15	0.52	0.38	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
THCA	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-8.99	6.04e-18	3.19e-15	-0.37	-0.38	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
THCA	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-8.99	6.06e-18	3.2e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
THCA	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-8.99	6.06e-18	3.2e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
THCA	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	8.99	6.07e-18	3.21e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
THCA	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	8.99	6.09e-18	3.21e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000266490.1	CTD-2349P21.9	8.99	6.11e-18	3.23e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30792372~30792833:+
THCA	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	8.99	6.14e-18	3.24e-15	0.31	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
THCA	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	8.99	6.15e-18	3.25e-15	0.83	0.38	QT interval;	chr4:75107557	chr4:75081702~75084717:-
THCA	cis	rs7221109	0.961	rs757411	ENSG00000278834.1	RP11-458J1.1	8.99	6.18e-18	3.26e-15	0.4	0.38	Type 1 diabetes;	chr17:40618898	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.961	rs9911533	ENSG00000278834.1	RP11-458J1.1	8.99	6.18e-18	3.26e-15	0.4	0.38	Type 1 diabetes;	chr17:40619224	chr17:40648300~40649718:+
THCA	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-8.99	6.18e-18	3.26e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
THCA	cis	rs4713118	0.662	rs149970	ENSG00000280107.1	AL022393.9	-8.99	6.2e-18	3.27e-15	-0.43	-0.38	Parkinson's disease;	chr6:28012442	chr6:28170845~28172521:+
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	8.99	6.22e-18	3.28e-15	0.78	0.38	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
THCA	cis	rs11148252	0.74	rs7983971	ENSG00000278238.1	RP11-245D16.4	-8.99	6.23e-18	3.29e-15	-0.44	-0.38	Lewy body disease;	chr13:52216565	chr13:52454775~52455331:-
THCA	cis	rs1707322	0.685	rs56177313	ENSG00000234329.1	RP11-767N6.2	8.99	6.24e-18	3.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211178	ENSG00000234329.1	RP11-767N6.2	8.99	6.24e-18	3.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4660314	ENSG00000234329.1	RP11-767N6.2	8.99	6.24e-18	3.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10890346	ENSG00000234329.1	RP11-767N6.2	-8.99	6.24e-18	3.29e-15	-0.36	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45651039~45651826:-
THCA	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-8.99	6.26e-18	3.3e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
THCA	cis	rs10411161	0.721	rs10401778	ENSG00000269483.1	AC006272.1	8.99	6.27e-18	3.31e-15	0.53	0.38	Breast cancer;	chr19:51881062	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs10402630	ENSG00000269483.1	AC006272.1	8.99	6.27e-18	3.31e-15	0.53	0.38	Breast cancer;	chr19:51881317	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.752	rs10402107	ENSG00000269483.1	AC006272.1	8.99	6.27e-18	3.31e-15	0.53	0.38	Breast cancer;	chr19:51881347	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs16983196	ENSG00000269483.1	AC006272.1	8.99	6.27e-18	3.31e-15	0.53	0.38	Breast cancer;	chr19:51881526	chr19:51839924~51843324:-
THCA	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-8.99	6.29e-18	3.32e-15	-0.43	-0.38	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
THCA	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-8.99	6.29e-18	3.32e-15	-0.43	-0.38	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
THCA	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-8.99	6.3e-18	3.32e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
THCA	cis	rs1426063	0.614	rs114761716	ENSG00000260265.1	RP11-44F21.5	8.99	6.3e-18	3.33e-15	0.82	0.38	QT interval;	chr4:75107209	chr4:75081702~75084717:-
THCA	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	8.99	6.3e-18	3.33e-15	0.49	0.38	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	8.99	6.3e-18	3.33e-15	0.49	0.38	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
THCA	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-8.99	6.3e-18	3.33e-15	-0.34	-0.38	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
THCA	cis	rs12468226	0.574	rs4675271	ENSG00000273456.1	RP11-686O6.2	-8.98	6.35e-18	3.35e-15	-0.42	-0.38	Urate levels;	chr2:202170967	chr2:202374932~202375604:-
THCA	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-8.98	6.36e-18	3.35e-15	-0.45	-0.38	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-8.98	6.36e-18	3.35e-15	-0.45	-0.38	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
THCA	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	8.98	6.36e-18	3.36e-15	0.32	0.38	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
THCA	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	8.98	6.37e-18	3.36e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
THCA	cis	rs2274273	0.743	rs7161656	ENSG00000258413.1	RP11-665C16.6	-8.98	6.37e-18	3.36e-15	-0.51	-0.38	Protein biomarker;	chr14:55057812	chr14:55262767~55272075:-
THCA	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	8.98	6.38e-18	3.37e-15	0.57	0.38	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
THCA	cis	rs7569084	1	rs7569084	ENSG00000237979.1	AC007389.1	-8.98	6.38e-18	3.37e-15	-0.44	-0.38	Sum eosinophil basophil counts;	chr2:65429835	chr2:65500993~65502138:-
THCA	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-8.98	6.43e-18	3.39e-15	-0.47	-0.38	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
THCA	cis	rs2032366	0.606	rs6567225	ENSG00000267279.1	RP11-879F14.2	8.98	6.47e-18	3.41e-15	0.41	0.38	Obesity-related traits;	chr18:61607418	chr18:61585746~61606916:-
THCA	cis	rs28510890	0.547	rs12441705	ENSG00000260337.3	RP11-386M24.6	8.98	6.49e-18	3.42e-15	0.51	0.38	Lung cancer in ever smokers;	chr15:92609319	chr15:92592574~92596462:-
THCA	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-8.98	6.53e-18	3.44e-15	-0.36	-0.38	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
THCA	cis	rs7849270	0.84	rs3118639	ENSG00000268707.1	RP11-247A12.7	8.98	6.53e-18	3.44e-15	0.52	0.38	Blood metabolite ratios;	chr9:129093324	chr9:129170434~129170940:+
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000266490.1	CTD-2349P21.9	8.98	6.56e-18	3.46e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000266490.1	CTD-2349P21.9	8.98	6.56e-18	3.46e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000266490.1	CTD-2349P21.9	8.98	6.56e-18	3.46e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30792372~30792833:+
THCA	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	8.98	6.58e-18	3.47e-15	0.52	0.38	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
THCA	cis	rs1707322	0.752	rs12062535	ENSG00000234329.1	RP11-767N6.2	8.98	6.6e-18	3.48e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-8.98	6.6e-18	3.48e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
THCA	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-8.98	6.6e-18	3.48e-15	-0.47	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
THCA	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-8.98	6.63e-18	3.49e-15	-0.41	-0.38	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-8.98	6.63e-18	3.49e-15	-0.41	-0.38	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	8.98	6.64e-18	3.49e-15	0.51	0.38	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
THCA	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-8.98	6.65e-18	3.5e-15	-0.58	-0.38	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
THCA	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	8.98	6.69e-18	3.52e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
THCA	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	8.98	6.72e-18	3.54e-15	0.36	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
THCA	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-8.98	6.75e-18	3.55e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-8.98	6.75e-18	3.55e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
THCA	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-8.98	6.75e-18	3.55e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-8.98	6.75e-18	3.55e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-8.98	6.78e-18	3.57e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
THCA	cis	rs17684571	0.637	rs35566812	ENSG00000231441.1	RP11-472M19.2	8.98	6.79e-18	3.57e-15	0.49	0.38	Schizophrenia;	chr6:56792077	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs62411375	ENSG00000231441.1	RP11-472M19.2	8.98	6.79e-18	3.57e-15	0.49	0.38	Schizophrenia;	chr6:56794361	chr6:56844002~56864078:+
THCA	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	8.98	6.8e-18	3.58e-15	0.46	0.38	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
THCA	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-8.98	6.81e-18	3.58e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-8.98	6.81e-18	3.58e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
THCA	cis	rs1799949	0.965	rs8070179	ENSG00000267681.1	CTD-3199J23.6	-8.97	6.82e-18	3.59e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43050671	chr17:43144956~43145255:+
THCA	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-8.97	6.82e-18	3.59e-15	-0.4	-0.38	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
THCA	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	8.97	6.89e-18	3.63e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
THCA	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-8.97	6.93e-18	3.65e-15	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
THCA	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	8.97	6.93e-18	3.65e-15	0.51	0.38	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	8.97	6.93e-18	3.65e-15	0.51	0.38	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
THCA	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	8.97	6.93e-18	3.65e-15	0.57	0.38	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	8.97	6.95e-18	3.66e-15	0.48	0.38	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	8.97	6.97e-18	3.66e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	8.97	6.97e-18	3.66e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
THCA	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-8.97	6.97e-18	3.67e-15	-0.32	-0.38	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
THCA	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	8.97	6.98e-18	3.67e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	8.97	6.98e-18	3.67e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	8.97	6.98e-18	3.67e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	8.97	6.98e-18	3.67e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
THCA	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-8.97	6.99e-18	3.68e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-8.97	6.99e-18	3.68e-15	-0.46	-0.38	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000235689.1	AP000351.13	-8.97	7e-18	3.68e-15	-0.53	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:24006305~24008258:-
THCA	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-8.97	7.01e-18	3.69e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
THCA	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	8.97	7.02e-18	3.69e-15	0.5	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
THCA	cis	rs1707322	0.927	rs6690386	ENSG00000234329.1	RP11-767N6.2	8.97	7.02e-18	3.69e-15	0.37	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45651039~45651826:-
THCA	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	8.97	7.03e-18	3.69e-15	0.45	0.38	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
THCA	cis	rs673078	0.571	rs61945220	ENSG00000275409.1	RP11-131L12.4	-8.97	7.03e-18	3.7e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118272924	chr12:118430147~118430699:+
THCA	cis	rs673078	0.571	rs61945221	ENSG00000275409.1	RP11-131L12.4	-8.97	7.03e-18	3.7e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118272926	chr12:118430147~118430699:+
THCA	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	8.97	7.05e-18	3.71e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
THCA	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	8.97	7.07e-18	3.71e-15	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
THCA	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	8.97	7.08e-18	3.72e-15	0.68	0.38	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
THCA	cis	rs2288884	0.767	rs3752119	ENSG00000275055.1	CTC-471J1.11	-8.97	7.08e-18	3.72e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048245	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.767	rs3450	ENSG00000275055.1	CTC-471J1.11	-8.97	7.08e-18	3.72e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049746	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.708	rs59104696	ENSG00000275055.1	CTC-471J1.11	-8.97	7.08e-18	3.72e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52051917	chr19:52049007~52049754:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	8.97	7.1e-18	3.73e-15	0.51	0.38	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	8.97	7.11e-18	3.74e-15	0.45	0.38	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
THCA	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-8.97	7.11e-18	3.74e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-8.97	7.11e-18	3.74e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-8.97	7.11e-18	3.74e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-8.97	7.12e-18	3.74e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-8.97	7.12e-18	3.74e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
THCA	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	8.97	7.13e-18	3.75e-15	0.65	0.38	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	8.97	7.14e-18	3.75e-15	0.65	0.38	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
THCA	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	8.97	7.14e-18	3.75e-15	0.36	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000215447.6	BX322557.10	-8.97	7.15e-18	3.75e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45288052~45291738:+
THCA	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-8.97	7.15e-18	3.76e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	8.97	7.16e-18	3.76e-15	0.48	0.38	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
THCA	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-8.97	7.19e-18	3.77e-15	-0.79	-0.38	Gout;	chr7:66645053	chr7:66654538~66669855:+
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-8.97	7.19e-18	3.77e-15	-0.79	-0.38	Gout;	chr7:66654674	chr7:66654538~66669855:+
THCA	cis	rs860295	0.871	rs6696888	ENSG00000225855.5	RUSC1-AS1	-8.97	7.19e-18	3.78e-15	-0.25	-0.38	Body mass index;	chr1:155539091	chr1:155316863~155324176:-
THCA	cis	rs7646881	0.812	rs74618709	ENSG00000240207.5	RP11-379F4.4	-8.97	7.21e-18	3.79e-15	-0.53	-0.38	Tetralogy of Fallot;	chr3:158737492	chr3:158732263~158784070:+
THCA	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-8.97	7.23e-18	3.79e-15	-0.4	-0.38	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
THCA	cis	rs4819052	0.851	rs1056100	ENSG00000215447.6	BX322557.10	-8.97	7.25e-18	3.81e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45288052~45291738:+
THCA	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	8.97	7.28e-18	3.82e-15	0.49	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
THCA	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	8.97	7.3e-18	3.83e-15	0.52	0.38	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
THCA	cis	rs1426063	0.614	rs17199632	ENSG00000260265.1	RP11-44F21.5	8.97	7.3e-18	3.83e-15	0.83	0.38	QT interval;	chr4:75103663	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs76931926	ENSG00000260265.1	RP11-44F21.5	8.97	7.3e-18	3.83e-15	0.83	0.38	QT interval;	chr4:75106902	chr4:75081702~75084717:-
THCA	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-8.97	7.3e-18	3.83e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
THCA	cis	rs2288884	0.767	rs17835716	ENSG00000275055.1	CTC-471J1.11	-8.97	7.32e-18	3.84e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047789	chr19:52049007~52049754:+
THCA	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	8.97	7.33e-18	3.84e-15	0.68	0.38	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
THCA	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	8.97	7.33e-18	3.85e-15	0.52	0.38	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
THCA	cis	rs944289	0.74	rs56400346	ENSG00000257826.1	RP11-116N8.4	-8.97	7.34e-18	3.85e-15	-0.4	-0.38	Thyroid cancer;	chr14:36114681	chr14:36061026~36067190:-
THCA	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-8.97	7.35e-18	3.85e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
THCA	cis	rs1075265	0.722	rs13414216	ENSG00000233266.1	HMGB1P31	8.97	7.36e-18	3.86e-15	0.49	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53699166	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	8.96	7.36e-18	3.86e-15	0.51	0.38	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
THCA	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	8.96	7.37e-18	3.86e-15	0.5	0.38	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
THCA	cis	rs7208859	0.573	rs216442	ENSG00000266490.1	CTD-2349P21.9	8.96	7.39e-18	3.87e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216445	ENSG00000266490.1	CTD-2349P21.9	8.96	7.39e-18	3.87e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216446	ENSG00000266490.1	CTD-2349P21.9	8.96	7.39e-18	3.87e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30792372~30792833:+
THCA	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	8.96	7.42e-18	3.89e-15	0.57	0.38	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
THCA	cis	rs1061377	0.965	rs1137714	ENSG00000249685.1	RP11-360F5.3	8.96	7.43e-18	3.89e-15	0.47	0.38	Uric acid levels;	chr4:39143105	chr4:39133913~39135608:+
THCA	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-8.96	7.44e-18	3.9e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
THCA	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-8.96	7.44e-18	3.9e-15	-0.39	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
THCA	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	8.96	7.45e-18	3.9e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
THCA	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	8.96	7.45e-18	3.91e-15	0.46	0.38	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
THCA	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
THCA	cis	rs9532669	0.926	rs2039119	ENSG00000239827.7	SUGT1P3	8.96	7.47e-18	3.92e-15	0.42	0.38	Cervical cancer;	chr13:40872432	chr13:40908159~40921774:-
THCA	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-8.96	7.48e-18	3.92e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-8.96	7.48e-18	3.92e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
THCA	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	8.96	7.51e-18	3.93e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	8.96	7.51e-18	3.93e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
THCA	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	8.96	7.53e-18	3.95e-15	0.48	0.38	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	8.96	7.53e-18	3.95e-15	0.48	0.38	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	8.96	7.53e-18	3.95e-15	0.48	0.38	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
THCA	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-8.96	7.56e-18	3.96e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
THCA	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-8.96	7.57e-18	3.96e-15	-0.78	-0.38	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
THCA	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	8.96	7.58e-18	3.97e-15	0.36	0.38	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
THCA	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	8.96	7.58e-18	3.97e-15	0.45	0.38	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
THCA	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-8.96	7.6e-18	3.98e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000237310.1	GS1-124K5.4	-8.96	7.6e-18	3.98e-15	-0.29	-0.38	Aortic root size;	chr7:66597493	chr7:66493706~66495474:+
THCA	cis	rs2033711	0.84	rs10423138	ENSG00000268912.1	CTD-2619J13.17	-8.96	7.6e-18	3.98e-15	-0.29	-0.38	Uric acid clearance;	chr19:58416935	chr19:58428632~58431148:-
THCA	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	8.96	7.63e-18	4e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
THCA	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	8.96	7.65e-18	4.01e-15	0.58	0.38	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
THCA	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-8.96	7.66e-18	4.01e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
THCA	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-8.96	7.66e-18	4.01e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
THCA	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-8.96	7.66e-18	4.01e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-8.96	7.66e-18	4.01e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-8.96	7.66e-18	4.01e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
THCA	cis	rs17684571	0.872	rs13203000	ENSG00000231441.1	RP11-472M19.2	8.96	7.66e-18	4.01e-15	0.54	0.38	Schizophrenia;	chr6:56758921	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs13217390	ENSG00000231441.1	RP11-472M19.2	8.96	7.66e-18	4.01e-15	0.54	0.38	Schizophrenia;	chr6:56758953	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34803237	ENSG00000231441.1	RP11-472M19.2	8.96	7.66e-18	4.01e-15	0.54	0.38	Schizophrenia;	chr6:56759620	chr6:56844002~56864078:+
THCA	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-8.96	7.68e-18	4.02e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-8.96	7.68e-18	4.02e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
THCA	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	8.96	7.68e-18	4.02e-15	0.49	0.38	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	8.96	7.68e-18	4.02e-15	0.49	0.38	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
THCA	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	8.96	7.69e-18	4.03e-15	0.51	0.38	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
THCA	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-8.96	7.74e-18	4.05e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-8.96	7.74e-18	4.05e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
THCA	cis	rs1707322	0.721	rs10430123	ENSG00000234329.1	RP11-767N6.2	8.96	7.74e-18	4.05e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45651039~45651826:-
THCA	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	8.96	7.77e-18	4.06e-15	0.25	0.38	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	8.96	7.79e-18	4.07e-15	0.51	0.38	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	8.96	7.79e-18	4.07e-15	0.51	0.38	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	8.96	7.79e-18	4.07e-15	0.51	0.38	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
THCA	cis	rs1707322	1	rs785484	ENSG00000234329.1	RP11-767N6.2	-8.96	7.82e-18	4.09e-15	-0.37	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45651039~45651826:-
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-8.96	7.82e-18	4.09e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-8.96	7.82e-18	4.09e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
THCA	cis	rs9532669	0.926	rs7329302	ENSG00000239827.7	SUGT1P3	8.96	7.85e-18	4.11e-15	0.41	0.38	Cervical cancer;	chr13:40962396	chr13:40908159~40921774:-
THCA	cis	rs1061377	0.965	rs12511857	ENSG00000249685.1	RP11-360F5.3	8.96	7.87e-18	4.12e-15	0.47	0.38	Uric acid levels;	chr4:39143252	chr4:39133913~39135608:+
THCA	cis	rs7211079	0.917	rs8067991	ENSG00000275479.1	RP11-334C17.6	8.96	7.89e-18	4.12e-15	0.38	0.38	Myocardial infarction;	chr17:80145503	chr17:80149627~80149798:+
THCA	cis	rs17684571	0.872	rs34455199	ENSG00000231441.1	RP11-472M19.2	8.96	7.9e-18	4.13e-15	0.54	0.38	Schizophrenia;	chr6:56759780	chr6:56844002~56864078:+
THCA	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-8.96	7.91e-18	4.13e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
THCA	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	8.96	7.93e-18	4.15e-15	0.61	0.38	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
THCA	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-8.96	7.95e-18	4.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-8.96	7.95e-18	4.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-8.96	7.95e-18	4.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
THCA	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-8.96	7.95e-18	4.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
THCA	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-8.95	7.97e-18	4.17e-15	-0.4	-0.38	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
THCA	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	8.95	8.07e-18	4.21e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs383436	ENSG00000266490.1	CTD-2349P21.9	8.95	8.07e-18	4.21e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000266490.1	CTD-2349P21.9	8.95	8.07e-18	4.21e-15	0.53	0.38	Body mass index;	chr17:30641132	chr17:30792372~30792833:+
THCA	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-8.95	8.08e-18	4.22e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
THCA	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-8.95	8.08e-18	4.22e-15	-0.44	-0.38	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
THCA	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-8.95	8.09e-18	4.23e-15	-0.5	-0.38	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-8.95	8.09e-18	4.23e-15	-0.5	-0.38	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
THCA	cis	rs4266144	1	rs12487629	ENSG00000244515.1	KRT18P34	-8.95	8.11e-18	4.23e-15	-0.44	-0.38	Coronary artery disease;	chr3:157134416	chr3:157162663~157163932:-
THCA	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-8.95	8.11e-18	4.23e-15	-0.44	-0.38	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
THCA	cis	rs8027521	0.521	rs10851550	ENSG00000280362.1	RP11-643A5.3	-8.95	8.11e-18	4.24e-15	-0.53	-0.38	Circulating chemerin levels;	chr15:53949189	chr15:53910769~53914712:+
THCA	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-8.95	8.12e-18	4.24e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-8.95	8.12e-18	4.24e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
THCA	cis	rs860295	0.65	rs28662267	ENSG00000225855.5	RUSC1-AS1	8.95	8.13e-18	4.25e-15	0.26	0.38	Body mass index;	chr1:155710658	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-8.95	8.15e-18	4.26e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
THCA	cis	rs9659323	1	rs6680737	ENSG00000231365.4	RP11-418J17.1	-8.95	8.17e-18	4.27e-15	-0.39	-0.38	Body mass index;	chr1:118979008	chr1:119140396~119275973:+
THCA	cis	rs1707322	0.827	rs12125508	ENSG00000234329.1	RP11-767N6.2	8.95	8.18e-18	4.27e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45651039~45651826:-
THCA	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	8.95	8.19e-18	4.28e-15	0.37	0.38	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
THCA	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	8.95	8.19e-18	4.28e-15	0.37	0.38	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	8.95	8.19e-18	4.28e-15	0.37	0.38	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
THCA	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-8.95	8.2e-18	4.28e-15	-0.4	-0.38	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
THCA	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	8.95	8.21e-18	4.29e-15	0.49	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	8.95	8.21e-18	4.29e-15	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
THCA	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-8.95	8.21e-18	4.29e-15	-0.4	-0.38	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	8.95	8.22e-18	4.29e-15	0.49	0.38	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	8.95	8.22e-18	4.29e-15	0.49	0.38	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
THCA	cis	rs1707322	0.721	rs12069121	ENSG00000234329.1	RP11-767N6.2	8.95	8.25e-18	4.3e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45651039~45651826:-
THCA	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-8.95	8.27e-18	4.32e-15	-0.48	-0.38	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
THCA	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-8.95	8.35e-18	4.36e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
THCA	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-8.95	8.37e-18	4.37e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
THCA	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-8.95	8.37e-18	4.37e-15	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
THCA	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-8.95	8.38e-18	4.37e-15	-0.42	-0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
THCA	cis	rs4266144	0.926	rs4368453	ENSG00000244515.1	KRT18P34	-8.95	8.38e-18	4.37e-15	-0.44	-0.38	Coronary artery disease;	chr3:157134352	chr3:157162663~157163932:-
THCA	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-8.95	8.4e-18	4.38e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
THCA	cis	rs6723226	0.557	rs62136260	ENSG00000276334.1	AL133243.1	-8.95	8.41e-18	4.39e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr2:32350379	chr2:32521927~32523547:+
THCA	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-8.95	8.46e-18	4.41e-15	-0.39	-0.38	QT interval;	chr12:29331030	chr12:29280418~29317848:-
THCA	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	8.95	8.46e-18	4.41e-15	0.25	0.38	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
THCA	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	8.95	8.48e-18	4.42e-15	0.75	0.38	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	8.95	8.48e-18	4.42e-15	0.75	0.38	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	8.95	8.48e-18	4.42e-15	0.75	0.38	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
THCA	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-8.95	8.52e-18	4.44e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-8.95	8.52e-18	4.44e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-8.95	8.53e-18	4.45e-15	-0.75	-0.38	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
THCA	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	8.95	8.59e-18	4.48e-15	0.48	0.38	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
THCA	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	8.94	8.6e-18	4.48e-15	0.35	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
THCA	cis	rs17684571	0.7	rs62411366	ENSG00000231441.1	RP11-472M19.2	8.94	8.61e-18	4.49e-15	0.53	0.38	Schizophrenia;	chr6:56773015	chr6:56844002~56864078:+
THCA	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-8.94	8.61e-18	4.49e-15	-0.38	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
THCA	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-8.94	8.63e-18	4.5e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
THCA	cis	rs11051970	0.559	rs11051944	ENSG00000274964.1	RP11-817I4.1	-8.94	8.63e-18	4.5e-15	-0.47	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32332984	chr12:32339368~32340724:+
THCA	cis	rs11971779	0.68	rs6947215	ENSG00000273391.1	RP11-634H22.1	8.94	8.64e-18	4.5e-15	0.34	0.38	Diisocyanate-induced asthma;	chr7:139341892	chr7:139359032~139359566:-
THCA	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	8.94	8.66e-18	4.51e-15	0.5	0.38	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	8.94	8.66e-18	4.51e-15	0.5	0.38	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
THCA	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-8.94	8.68e-18	4.52e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
THCA	cis	rs7665090	1	rs735403	ENSG00000246560.2	RP11-10L12.4	-8.94	8.68e-18	4.52e-15	-0.46	-0.38	Primary biliary cholangitis;	chr4:102632386	chr4:102828055~102844075:+
THCA	cis	rs4819052	0.765	rs2838868	ENSG00000215447.6	BX322557.10	8.94	8.71e-18	4.54e-15	0.34	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	8.94	8.77e-18	4.57e-15	0.45	0.38	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
THCA	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	8.94	8.78e-18	4.58e-15	0.73	0.38	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
THCA	cis	rs17684571	0.7	rs36022925	ENSG00000231441.1	RP11-472M19.2	8.94	8.79e-18	4.58e-15	0.5	0.38	Schizophrenia;	chr6:56818169	chr6:56844002~56864078:+
THCA	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-8.94	8.8e-18	4.58e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
THCA	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-8.94	8.86e-18	4.62e-15	-0.49	-0.38	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
THCA	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-8.94	8.87e-18	4.62e-15	-0.33	-0.38	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
THCA	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	8.94	8.89e-18	4.63e-15	0.41	0.38	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	8.94	8.89e-18	4.63e-15	0.41	0.38	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
THCA	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-8.94	8.89e-18	4.63e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
THCA	cis	rs2274273	0.522	rs2251366	ENSG00000258413.1	RP11-665C16.6	-8.94	8.92e-18	4.64e-15	-0.5	-0.38	Protein biomarker;	chr14:55051438	chr14:55262767~55272075:-
THCA	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-8.94	8.93e-18	4.65e-15	-0.53	-0.38	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
THCA	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-8.94	8.97e-18	4.67e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-8.94	8.97e-18	4.67e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-8.94	8.97e-18	4.67e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
THCA	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-8.94	8.97e-18	4.67e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
THCA	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-8.94	8.98e-18	4.67e-15	-0.56	-0.38	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
THCA	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-8.94	9e-18	4.69e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-8.94	9e-18	4.69e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
THCA	cis	rs2288884	0.767	rs12462359	ENSG00000275055.1	CTC-471J1.11	-8.94	9.02e-18	4.69e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032168	chr19:52049007~52049754:+
THCA	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-8.94	9.03e-18	4.7e-15	-0.77	-0.38	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
THCA	cis	rs944289	0.745	rs1537427	ENSG00000257826.1	RP11-116N8.4	8.94	9.06e-18	4.71e-15	0.4	0.38	Thyroid cancer;	chr14:36117640	chr14:36061026~36067190:-
THCA	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-8.94	9.08e-18	4.72e-15	-0.51	-0.38	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
THCA	cis	rs1707322	0.682	rs10890335	ENSG00000234329.1	RP11-767N6.2	8.94	9.1e-18	4.73e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45651039~45651826:-
THCA	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	8.94	9.1e-18	4.74e-15	0.66	0.38	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
THCA	cis	rs944289	0.74	rs10498332	ENSG00000257826.1	RP11-116N8.4	-8.94	9.11e-18	4.74e-15	-0.39	-0.38	Thyroid cancer;	chr14:36102348	chr14:36061026~36067190:-
THCA	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	8.94	9.13e-18	4.75e-15	0.57	0.38	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	8.94	9.13e-18	4.75e-15	0.57	0.38	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
THCA	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-8.94	9.2e-18	4.79e-15	-0.45	-0.38	Temperament;	chr17:14033087	chr17:14024514~14025488:+
THCA	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	8.94	9.24e-18	4.81e-15	0.37	0.38	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
THCA	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-8.94	9.26e-18	4.82e-15	-0.44	-0.38	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
THCA	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-8.94	9.28e-18	4.82e-15	-0.5	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
THCA	cis	rs944289	0.774	rs8013429	ENSG00000257826.1	RP11-116N8.4	-8.93	9.31e-18	4.84e-15	-0.4	-0.38	Thyroid cancer;	chr14:36131855	chr14:36061026~36067190:-
THCA	cis	rs4819052	0.851	rs3673	ENSG00000215447.6	BX322557.10	-8.93	9.32e-18	4.84e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45288052~45291738:+
THCA	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-8.93	9.33e-18	4.85e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
THCA	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-8.93	9.33e-18	4.85e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
THCA	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	8.93	9.37e-18	4.87e-15	0.48	0.38	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
THCA	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-8.93	9.39e-18	4.88e-15	-0.45	-0.38	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
THCA	cis	rs217727	0.818	rs2525883	ENSG00000226416.1	MRPL23-AS1	8.93	9.39e-18	4.88e-15	0.53	0.38	Breast cancer;	chr11:2000750	chr11:1983237~1989920:-
THCA	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	8.93	9.41e-18	4.89e-15	0.49	0.38	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
THCA	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-8.93	9.42e-18	4.9e-15	-0.4	-0.38	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
THCA	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-8.93	9.44e-18	4.91e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
THCA	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-8.93	9.44e-18	4.91e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	8.93	9.46e-18	4.91e-15	0.49	0.38	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
THCA	cis	rs17684571	0.751	rs16888184	ENSG00000231441.1	RP11-472M19.2	8.93	9.49e-18	4.93e-15	0.47	0.38	Schizophrenia;	chr6:56861347	chr6:56844002~56864078:+
THCA	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	8.93	9.51e-18	4.94e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
THCA	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	8.93	9.52e-18	4.95e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
THCA	cis	rs7727544	0.625	rs4705916	ENSG00000237714.1	P4HA2-AS1	8.93	9.53e-18	4.95e-15	0.51	0.38	Blood metabolite levels;	chr5:132071800	chr5:132184876~132192808:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-8.93	9.57e-18	4.97e-15	-0.28	-0.38	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
THCA	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-8.93	9.57e-18	4.97e-15	-0.44	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
THCA	cis	rs9928842	0.765	rs4479268	ENSG00000280152.1	RP11-331F4.5	-8.93	9.58e-18	4.97e-15	-0.53	-0.38	Alcoholic chronic pancreatitis;	chr16:75190835	chr16:75245994~75250077:-
THCA	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-8.93	9.59e-18	4.98e-15	-0.74	-0.38	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
THCA	cis	rs7665090	0.84	rs7674640	ENSG00000246560.2	RP11-10L12.4	8.93	9.6e-18	4.99e-15	0.46	0.38	Primary biliary cholangitis;	chr4:102619623	chr4:102828055~102844075:+
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000237664.1	LINC00316	-8.93	9.61e-18	4.99e-15	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45338590~45341990:-
THCA	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	8.93	9.62e-18	5e-15	0.63	0.38	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
THCA	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	8.93	9.63e-18	5e-15	0.49	0.38	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
THCA	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-8.93	9.66e-18	5.02e-15	-0.4	-0.38	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
THCA	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	8.93	9.66e-18	5.02e-15	0.6	0.38	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
THCA	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	8.93	9.66e-18	5.02e-15	0.6	0.38	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
THCA	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-8.93	9.69e-18	5.03e-15	-0.48	-0.38	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
THCA	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	8.93	9.69e-18	5.03e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
THCA	cis	rs1707322	0.752	rs11488313	ENSG00000234329.1	RP11-767N6.2	8.93	9.71e-18	5.04e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45651039~45651826:-
THCA	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-8.93	9.71e-18	5.04e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
THCA	cis	rs4819052	0.851	rs9974891	ENSG00000215447.6	BX322557.10	-8.93	9.73e-18	5.05e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45288052~45291738:+
THCA	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-8.93	9.76e-18	5.07e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	8.93	9.78e-18	5.07e-15	0.78	0.38	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.526	rs17516457	ENSG00000237714.1	P4HA2-AS1	8.93	9.79e-18	5.08e-15	0.52	0.38	Blood metabolite levels;	chr5:132254694	chr5:132184876~132192808:+
THCA	cis	rs673078	0.607	rs7958551	ENSG00000275409.1	RP11-131L12.4	-8.93	9.87e-18	5.12e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118442585	chr12:118430147~118430699:+
THCA	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-8.93	9.88e-18	5.13e-15	-0.38	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
THCA	cis	rs7772486	0.774	rs2748503	ENSG00000235652.6	RP11-545I5.3	8.93	9.89e-18	5.13e-15	0.36	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145973906	chr6:145799409~145886585:+
THCA	cis	rs7851660	0.967	rs10818133	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848066	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.933	rs12341377	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848100	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs7851552	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848370	chr9:97805935~97810008:-
THCA	cis	rs7851660	1	rs7851660	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848477	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs12348304	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848951	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs3758251	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97851418	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs10046805	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97851674	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs3758249	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97851858	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs3758248	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97852319	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs907577	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97852835	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.933	rs13302470	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97853271	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.933	rs1867277	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97853632	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.87	rs1867278	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97853667	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs1867280	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97853784	chr9:97805935~97810008:-
THCA	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	8.93	9.89e-18	5.13e-15	0.46	0.38	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
THCA	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-8.93	9.95e-18	5.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
THCA	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-8.93	9.95e-18	5.16e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
THCA	cis	rs7851660	0.967	rs3021526	ENSG00000236130.1	PTCSC2	-8.93	9.98e-18	5.18e-15	-0.29	-0.38	Strep throat;	chr9:97854739	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs1443434	ENSG00000236130.1	PTCSC2	-8.93	9.98e-18	5.18e-15	-0.29	-0.38	Strep throat;	chr9:97855197	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs1443435	ENSG00000236130.1	PTCSC2	-8.93	9.98e-18	5.18e-15	-0.29	-0.38	Strep throat;	chr9:97855301	chr9:97805935~97810008:-
THCA	cis	rs62103177	0.568	rs2365388	ENSG00000261126.6	RP11-795F19.1	8.93	9.99e-18	5.18e-15	0.42	0.38	Opioid sensitivity;	chr18:80215819	chr18:80046900~80095482:+
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-8.93	1e-17	5.19e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-8.93	1e-17	5.19e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
THCA	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-8.93	1e-17	5.19e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
THCA	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
THCA	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
THCA	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-8.93	1e-17	5.19e-15	-0.39	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-8.93	1e-17	5.19e-15	-0.39	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
THCA	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-8.92	1.01e-17	5.21e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
THCA	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	8.92	1.01e-17	5.23e-15	0.35	0.38	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
THCA	cis	rs2033711	0.811	rs9304814	ENSG00000268912.1	CTD-2619J13.17	-8.92	1.01e-17	5.23e-15	-0.3	-0.38	Uric acid clearance;	chr19:58440444	chr19:58428632~58431148:-
THCA	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	8.92	1.01e-17	5.23e-15	0.72	0.38	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	8.92	1.01e-17	5.23e-15	0.72	0.38	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
THCA	cis	rs17807185	0.676	rs4273781	ENSG00000214293.7	APTR	8.92	1.01e-17	5.25e-15	0.27	0.38	Height;	chr7:77671806	chr7:77657660~77696265:-
THCA	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	8.92	1.01e-17	5.25e-15	0.81	0.38	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
THCA	cis	rs8027521	0.521	rs12905498	ENSG00000280362.1	RP11-643A5.3	-8.92	1.02e-17	5.26e-15	-0.53	-0.38	Circulating chemerin levels;	chr15:53943052	chr15:53910769~53914712:+
THCA	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	8.92	1.02e-17	5.27e-15	0.64	0.38	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
THCA	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-8.92	1.02e-17	5.27e-15	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
THCA	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-8.92	1.02e-17	5.28e-15	-0.42	-0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
THCA	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-8.92	1.02e-17	5.28e-15	-0.27	-0.38	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
THCA	cis	rs1707322	0.682	rs10890334	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs6694889	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.682	rs12041197	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211145	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211146	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211147	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-8.92	1.02e-17	5.29e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-8.92	1.02e-17	5.3e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
THCA	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	8.92	1.03e-17	5.31e-15	0.51	0.38	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
THCA	cis	rs1707322	0.752	rs11211152	ENSG00000234329.1	RP11-767N6.2	8.92	1.03e-17	5.31e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs4607935	ENSG00000234329.1	RP11-767N6.2	8.92	1.03e-17	5.31e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.681	rs12048866	ENSG00000234329.1	RP11-767N6.2	8.92	1.03e-17	5.31e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs3811436	ENSG00000234329.1	RP11-767N6.2	8.92	1.03e-17	5.31e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45651039~45651826:-
THCA	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-8.92	1.03e-17	5.33e-15	-0.38	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
THCA	cis	rs9532669	0.926	rs9532690	ENSG00000239827.7	SUGT1P3	-8.92	1.03e-17	5.34e-15	-0.4	-0.38	Cervical cancer;	chr13:40968654	chr13:40908159~40921774:-
THCA	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-8.92	1.04e-17	5.37e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
THCA	cis	rs11148252	0.712	rs61957257	ENSG00000278238.1	RP11-245D16.4	-8.92	1.04e-17	5.37e-15	-0.43	-0.38	Lewy body disease;	chr13:52195567	chr13:52454775~52455331:-
THCA	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-8.92	1.04e-17	5.38e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
THCA	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	8.92	1.04e-17	5.38e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
THCA	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	8.92	1.04e-17	5.38e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
THCA	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-8.92	1.04e-17	5.39e-15	-0.42	-0.38	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
THCA	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	8.92	1.05e-17	5.41e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
THCA	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-8.92	1.05e-17	5.42e-15	-0.51	-0.38	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
THCA	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	8.92	1.05e-17	5.44e-15	0.54	0.38	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
THCA	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	8.92	1.05e-17	5.44e-15	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
THCA	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-8.92	1.05e-17	5.45e-15	-0.56	-0.38	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
THCA	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	8.92	1.05e-17	5.45e-15	0.25	0.38	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
THCA	cis	rs2288884	0.708	rs12460617	ENSG00000275055.1	CTC-471J1.11	-8.92	1.06e-17	5.46e-15	-0.35	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:52049007~52049754:+
THCA	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-8.92	1.06e-17	5.46e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
THCA	cis	rs4819052	0.851	rs2236443	ENSG00000215447.6	BX322557.10	-8.92	1.06e-17	5.47e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45288052~45291738:+
THCA	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-8.92	1.06e-17	5.49e-15	-0.43	-0.38	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
THCA	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	8.92	1.06e-17	5.5e-15	0.25	0.38	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
THCA	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-8.92	1.06e-17	5.51e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-8.92	1.07e-17	5.52e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000215447.6	BX322557.10	-8.92	1.07e-17	5.53e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45288052~45291738:+
THCA	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-8.92	1.07e-17	5.53e-15	-0.41	-0.38	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
THCA	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-8.92	1.07e-17	5.53e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
THCA	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-8.92	1.07e-17	5.55e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
THCA	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-8.92	1.07e-17	5.55e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	8.92	1.07e-17	5.55e-15	0.5	0.38	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
THCA	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-8.92	1.08e-17	5.57e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-8.92	1.08e-17	5.57e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-8.92	1.08e-17	5.57e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-8.92	1.08e-17	5.57e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-8.92	1.08e-17	5.58e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
THCA	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-8.92	1.08e-17	5.6e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
THCA	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-8.91	1.09e-17	5.61e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-8.91	1.09e-17	5.61e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
THCA	cis	rs7851660	0.933	rs894673	ENSG00000236130.1	PTCSC2	-8.91	1.09e-17	5.62e-15	-0.29	-0.38	Strep throat;	chr9:97849988	chr9:97805935~97810008:-
THCA	cis	rs1707322	0.821	rs10749857	ENSG00000234329.1	RP11-767N6.2	8.91	1.09e-17	5.63e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45651039~45651826:-
THCA	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	8.91	1.09e-17	5.65e-15	0.57	0.38	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
THCA	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-8.91	1.09e-17	5.65e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
THCA	cis	rs9309473	0.607	rs10196402	ENSG00000163016.8	ALMS1P	8.91	1.09e-17	5.65e-15	0.5	0.38	Metabolite levels;	chr2:73344953	chr2:73644919~73685576:+
THCA	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	8.91	1.1e-17	5.67e-15	0.74	0.38	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-8.91	1.1e-17	5.67e-15	-0.27	-0.38	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-8.91	1.1e-17	5.67e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
THCA	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-8.91	1.1e-17	5.67e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
THCA	cis	rs853679	0.628	rs9368560	ENSG00000226314.6	ZNF192P1	-8.91	1.1e-17	5.68e-15	-0.51	-0.38	Depression;	chr6:28192182	chr6:28161781~28169594:+
THCA	cis	rs7851660	0.901	rs7873389	ENSG00000236130.1	PTCSC2	-8.91	1.1e-17	5.69e-15	-0.29	-0.38	Strep throat;	chr9:97846948	chr9:97805935~97810008:-
THCA	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-8.91	1.11e-17	5.71e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-8.91	1.11e-17	5.71e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	8.91	1.11e-17	5.72e-15	0.51	0.38	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
THCA	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-8.91	1.11e-17	5.73e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
THCA	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-8.91	1.11e-17	5.73e-15	-0.5	-0.38	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
THCA	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
THCA	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	8.91	1.11e-17	5.73e-15	0.57	0.38	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	8.91	1.11e-17	5.73e-15	0.57	0.38	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	8.91	1.11e-17	5.73e-15	0.48	0.38	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	8.91	1.11e-17	5.74e-15	0.5	0.38	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	8.91	1.11e-17	5.74e-15	0.5	0.38	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
THCA	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	8.91	1.12e-17	5.75e-15	0.64	0.38	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
THCA	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-8.91	1.12e-17	5.76e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
THCA	cis	rs947583	0.517	rs7756915	ENSG00000231028.7	LINC00271	-8.91	1.12e-17	5.78e-15	-0.29	-0.38	Phosphorus levels;	chr6:135798177	chr6:135497801~135716055:+
THCA	cis	rs73081554	0.611	rs4681852	ENSG00000272360.1	RP11-359I18.5	-8.91	1.12e-17	5.79e-15	-0.54	-0.38	Rheumatoid arthritis;	chr3:58423446	chr3:58490830~58491291:-
THCA	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-8.91	1.12e-17	5.8e-15	-0.48	-0.38	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
THCA	cis	rs860295	0.836	rs35615695	ENSG00000225855.5	RUSC1-AS1	-8.91	1.13e-17	5.81e-15	-0.25	-0.38	Body mass index;	chr1:155531223	chr1:155316863~155324176:-
THCA	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-8.91	1.13e-17	5.81e-15	-0.4	-0.38	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
THCA	cis	rs1707322	0.721	rs7519900	ENSG00000234329.1	RP11-767N6.2	8.91	1.13e-17	5.83e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45651039~45651826:-
THCA	cis	rs10740039	0.81	rs9415605	ENSG00000254271.1	RP11-131N11.4	-8.91	1.13e-17	5.83e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60616809	chr10:60734342~60741828:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000273009.1	RP11-352G9.1	-8.91	1.13e-17	5.84e-15	-0.43	-0.38	Pancreatic cancer;	chr3:196009869	chr3:195913078~195913683:-
THCA	cis	rs4927850	1	rs4927704	ENSG00000273009.1	RP11-352G9.1	-8.91	1.13e-17	5.84e-15	-0.43	-0.38	Pancreatic cancer;	chr3:196011357	chr3:195913078~195913683:-
THCA	cis	rs4927850	1	rs4927848	ENSG00000273009.1	RP11-352G9.1	-8.91	1.13e-17	5.84e-15	-0.43	-0.38	Pancreatic cancer;	chr3:196011535	chr3:195913078~195913683:-
THCA	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-8.91	1.14e-17	5.86e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
THCA	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	8.91	1.14e-17	5.88e-15	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
THCA	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-8.91	1.14e-17	5.89e-15	-0.5	-0.38	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
THCA	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-8.91	1.15e-17	5.91e-15	-0.45	-0.38	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-8.91	1.15e-17	5.91e-15	-0.45	-0.38	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
THCA	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	8.91	1.15e-17	5.93e-15	0.5	0.38	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
THCA	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-8.91	1.15e-17	5.93e-15	-0.34	-0.38	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
THCA	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-8.91	1.15e-17	5.95e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
THCA	cis	rs6600671	0.692	rs11249430	ENSG00000223345.3	HIST2H2BA	8.91	1.15e-17	5.95e-15	0.43	0.38	Hip geometry;	chr1:121547115	chr1:121108210~121117257:-
THCA	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-8.91	1.16e-17	5.97e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
THCA	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	8.91	1.16e-17	5.98e-15	0.25	0.38	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	8.91	1.16e-17	5.98e-15	0.25	0.38	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	8.91	1.16e-17	5.98e-15	0.25	0.38	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	8.91	1.16e-17	5.98e-15	0.25	0.38	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
THCA	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-8.91	1.16e-17	5.99e-15	-0.51	-0.38	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
THCA	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-8.91	1.17e-17	6e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
THCA	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-8.91	1.17e-17	6.02e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
THCA	cis	rs1707322	0.752	rs12024590	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs12027622	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4415615	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs7529699	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs6699444	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs10430105	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45651039~45651826:-
THCA	cis	rs7569084	0.663	rs4671128	ENSG00000234255.7	AC012370.3	8.9	1.17e-17	6.03e-15	0.43	0.38	Sum eosinophil basophil counts;	chr2:65438130	chr2:65439888~65456571:-
THCA	cis	rs17684571	0.688	rs35440408	ENSG00000231441.1	RP11-472M19.2	8.9	1.17e-17	6.04e-15	0.47	0.38	Schizophrenia;	chr6:56866055	chr6:56844002~56864078:+
THCA	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	8.9	1.17e-17	6.04e-15	0.51	0.38	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	8.9	1.17e-17	6.04e-15	0.43	0.38	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
THCA	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-8.9	1.17e-17	6.04e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-8.9	1.17e-17	6.04e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
THCA	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	8.9	1.18e-17	6.06e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
THCA	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-8.9	1.18e-17	6.07e-15	-0.41	-0.38	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
THCA	cis	rs934734	0.571	rs7565437	ENSG00000234255.7	AC012370.3	-8.9	1.18e-17	6.07e-15	-0.42	-0.38	Rheumatoid arthritis;	chr2:65419832	chr2:65439888~65456571:-
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-8.9	1.18e-17	6.09e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
THCA	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	8.9	1.18e-17	6.09e-15	0.42	0.38	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
THCA	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-8.9	1.18e-17	6.09e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
THCA	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-8.9	1.19e-17	6.11e-15	-0.39	-0.38	QT interval;	chr12:29309811	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-8.9	1.19e-17	6.11e-15	-0.39	-0.38	QT interval;	chr12:29310155	chr12:29280418~29317848:-
THCA	cis	rs66887589	0.87	rs10518336	ENSG00000245958.5	RP11-33B1.1	-8.9	1.19e-17	6.12e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119601779	chr4:119454791~119552025:+
THCA	cis	rs4819052	1	rs13052356	ENSG00000215447.6	BX322557.10	-8.9	1.19e-17	6.13e-15	-0.34	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45288052~45291738:+
THCA	cis	rs1707322	0.686	rs61784833	ENSG00000234329.1	RP11-767N6.2	8.9	1.2e-17	6.16e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45651039~45651826:-
THCA	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	8.9	1.2e-17	6.17e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
THCA	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-8.9	1.2e-17	6.18e-15	-0.45	-0.38	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
THCA	cis	rs10740039	0.883	rs2393676	ENSG00000254271.1	RP11-131N11.4	8.9	1.2e-17	6.18e-15	0.46	0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60630500	chr10:60734342~60741828:+
THCA	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-8.9	1.2e-17	6.18e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
THCA	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-8.9	1.2e-17	6.19e-15	-0.75	-0.38	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
THCA	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	8.9	1.2e-17	6.19e-15	0.24	0.38	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
THCA	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	8.9	1.21e-17	6.2e-15	0.36	0.38	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
THCA	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-8.9	1.21e-17	6.2e-15	-0.39	-0.38	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	8.9	1.21e-17	6.21e-15	0.51	0.38	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	8.9	1.21e-17	6.23e-15	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
THCA	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-8.9	1.22e-17	6.27e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-8.9	1.22e-17	6.27e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
THCA	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-8.9	1.22e-17	6.27e-15	-0.44	-0.38	Migraine;	chr4:56879851	chr4:56960927~56961373:-
THCA	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-8.9	1.23e-17	6.3e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
THCA	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	8.9	1.23e-17	6.32e-15	0.39	0.38	QT interval;	chr12:29284120	chr12:29280418~29317848:-
THCA	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-8.9	1.23e-17	6.32e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-8.9	1.23e-17	6.32e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
THCA	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	8.9	1.23e-17	6.33e-15	0.44	0.38	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
THCA	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66692349	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66693433	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66694214	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66701371	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66702658	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66706390	chr7:66654538~66669855:+
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66710076	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66715944	chr7:66654538~66669855:+
THCA	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	8.9	1.23e-17	6.34e-15	0.54	0.38	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
THCA	cis	rs7851660	0.967	rs12348691	ENSG00000236130.1	PTCSC2	-8.9	1.24e-17	6.36e-15	-0.29	-0.38	Strep throat;	chr9:97846400	chr9:97805935~97810008:-
THCA	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-8.9	1.24e-17	6.38e-15	-0.48	-0.38	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
THCA	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	8.9	1.24e-17	6.38e-15	0.43	0.38	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
THCA	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-8.9	1.24e-17	6.39e-15	-0.38	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-8.9	1.24e-17	6.39e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	8.9	1.24e-17	6.39e-15	0.49	0.38	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	8.9	1.24e-17	6.39e-15	0.49	0.38	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	8.9	1.24e-17	6.39e-15	0.49	0.38	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
THCA	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-8.9	1.25e-17	6.41e-15	-0.4	-0.38	QT interval;	chr12:29300845	chr12:29280418~29317848:-
THCA	cis	rs6564219	1	rs6564219	ENSG00000280152.1	RP11-331F4.5	8.9	1.25e-17	6.44e-15	0.54	0.38	Alcoholic chronic pancreatitis;	chr16:75188108	chr16:75245994~75250077:-
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000215447.6	BX322557.10	8.9	1.25e-17	6.44e-15	0.31	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45288052~45291738:+
THCA	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	8.9	1.26e-17	6.45e-15	0.49	0.38	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	8.9	1.26e-17	6.45e-15	0.49	0.38	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	8.9	1.26e-17	6.45e-15	0.49	0.38	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
THCA	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-8.9	1.26e-17	6.45e-15	-0.47	-0.38	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
THCA	cis	rs10411161	0.702	rs10424202	ENSG00000269483.1	AC006272.1	8.9	1.26e-17	6.45e-15	0.53	0.38	Breast cancer;	chr19:51884044	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs10423835	ENSG00000269483.1	AC006272.1	8.9	1.26e-17	6.45e-15	0.53	0.38	Breast cancer;	chr19:51884069	chr19:51839924~51843324:-
THCA	cis	rs9928842	0.712	rs8057843	ENSG00000280152.1	RP11-331F4.5	8.9	1.26e-17	6.47e-15	0.54	0.38	Alcoholic chronic pancreatitis;	chr16:75187657	chr16:75245994~75250077:-
THCA	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	8.9	1.26e-17	6.47e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
THCA	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-8.9	1.26e-17	6.48e-15	-0.39	-0.38	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
THCA	cis	rs1707322	0.827	rs6694302	ENSG00000234329.1	RP11-767N6.2	8.89	1.27e-17	6.51e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45651039~45651826:-
THCA	cis	rs34375054	0.672	rs10400509	ENSG00000279233.1	RP11-158L12.4	8.89	1.27e-17	6.52e-15	0.36	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125107627	chr12:125138245~125141711:+
THCA	cis	rs860295	0.871	rs6688636	ENSG00000225855.5	RUSC1-AS1	-8.89	1.27e-17	6.52e-15	-0.25	-0.38	Body mass index;	chr1:155509106	chr1:155316863~155324176:-
THCA	cis	rs11051970	0.659	rs73088096	ENSG00000274964.1	RP11-817I4.1	-8.89	1.27e-17	6.53e-15	-0.49	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32431469	chr12:32339368~32340724:+
THCA	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-8.89	1.28e-17	6.57e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
THCA	cis	rs11971779	0.553	rs36002669	ENSG00000273391.1	RP11-634H22.1	8.89	1.29e-17	6.59e-15	0.35	0.38	Diisocyanate-induced asthma;	chr7:139428415	chr7:139359032~139359566:-
THCA	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-8.89	1.29e-17	6.6e-15	-0.48	-0.38	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
THCA	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-8.89	1.29e-17	6.62e-15	-0.78	-0.38	Gout;	chr7:66693028	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	8.89	1.29e-17	6.63e-15	0.48	0.38	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	8.89	1.29e-17	6.63e-15	0.48	0.38	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
THCA	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	8.89	1.3e-17	6.66e-15	0.81	0.38	QT interval;	chr4:75108738	chr4:75081702~75084717:-
THCA	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-8.89	1.3e-17	6.67e-15	-0.5	-0.38	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
THCA	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	8.89	1.3e-17	6.67e-15	0.41	0.38	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
THCA	cis	rs12188164	0.515	rs17562461	ENSG00000221990.4	EXOC3-AS1	8.89	1.3e-17	6.68e-15	0.32	0.38	Cystic fibrosis severity;	chr5:411246	chr5:441498~443160:-
THCA	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	8.89	1.3e-17	6.68e-15	0.48	0.38	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
THCA	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-8.89	1.33e-17	6.79e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
THCA	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-8.89	1.33e-17	6.8e-15	-0.5	-0.38	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
THCA	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	8.89	1.33e-17	6.82e-15	0.45	0.38	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-8.89	1.33e-17	6.83e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
THCA	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-8.89	1.33e-17	6.83e-15	-0.54	-0.38	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
THCA	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	8.89	1.33e-17	6.84e-15	0.51	0.38	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.679	rs4819053	ENSG00000215447.6	BX322557.10	8.89	1.33e-17	6.84e-15	0.3	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45288052~45291738:+
THCA	cis	rs7015263	0.689	rs10956803	ENSG00000254231.1	CTD-2284J15.1	-8.89	1.34e-17	6.85e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86350845	chr8:86333274~86343314:-
THCA	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	8.89	1.34e-17	6.88e-15	0.44	0.38	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
THCA	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-8.89	1.34e-17	6.89e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
THCA	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-8.89	1.35e-17	6.94e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-8.89	1.35e-17	6.94e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-8.89	1.35e-17	6.94e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-8.89	1.35e-17	6.94e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
THCA	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	8.89	1.36e-17	6.96e-15	0.53	0.38	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
THCA	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	8.89	1.36e-17	6.97e-15	0.48	0.38	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
THCA	cis	rs6600671	0.693	rs1853731	ENSG00000223345.3	HIST2H2BA	8.89	1.36e-17	6.97e-15	0.43	0.38	Hip geometry;	chr1:121510262	chr1:121108210~121117257:-
THCA	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	8.89	1.36e-17	6.98e-15	0.65	0.38	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
THCA	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	8.89	1.36e-17	6.98e-15	0.51	0.38	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
THCA	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	8.89	1.36e-17	6.98e-15	0.51	0.38	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
THCA	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	8.89	1.36e-17	6.98e-15	0.51	0.38	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
THCA	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-8.88	1.37e-17	7.03e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
THCA	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	8.88	1.38e-17	7.05e-15	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
THCA	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	8.88	1.38e-17	7.05e-15	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	8.88	1.38e-17	7.05e-15	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
THCA	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	8.88	1.38e-17	7.06e-15	0.6	0.38	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
THCA	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	8.88	1.38e-17	7.06e-15	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
THCA	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	8.88	1.38e-17	7.06e-15	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
THCA	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-8.88	1.38e-17	7.08e-15	-0.44	-0.38	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
THCA	cis	rs4713118	0.824	rs9468225	ENSG00000219392.1	RP1-265C24.5	-8.88	1.38e-17	7.09e-15	-0.5	-0.38	Parkinson's disease;	chr6:27777940	chr6:28115628~28116551:+
THCA	cis	rs4819052	1	rs13047688	ENSG00000215447.6	BX322557.10	-8.88	1.39e-17	7.09e-15	-0.34	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45288052~45291738:+
THCA	cis	rs7851660	0.87	rs55960649	ENSG00000236130.1	PTCSC2	-8.88	1.39e-17	7.1e-15	-0.29	-0.38	Strep throat;	chr9:97836413	chr9:97805935~97810008:-
THCA	cis	rs7015263	0.643	rs7460251	ENSG00000254231.1	CTD-2284J15.1	-8.88	1.39e-17	7.1e-15	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:86505759	chr8:86333274~86343314:-
THCA	cis	rs11696845	0.761	rs11698203	ENSG00000276223.1	RP4-781B1.5	8.88	1.39e-17	7.14e-15	0.46	0.38	Obesity-related traits;	chr20:44729258	chr20:44746642~44747201:+
THCA	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	8.88	1.4e-17	7.17e-15	0.87	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	8.88	1.4e-17	7.17e-15	0.87	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
THCA	cis	rs7569084	0.687	rs12993075	ENSG00000234255.7	AC012370.3	8.88	1.41e-17	7.24e-15	0.43	0.38	Sum eosinophil basophil counts;	chr2:65431010	chr2:65439888~65456571:-
THCA	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-8.88	1.42e-17	7.27e-15	-0.56	-0.38	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
THCA	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-8.88	1.42e-17	7.27e-15	-0.39	-0.38	QT interval;	chr12:29297620	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-8.88	1.42e-17	7.27e-15	-0.39	-0.38	QT interval;	chr12:29298788	chr12:29280418~29317848:-
THCA	cis	rs2033711	0.87	rs4801583	ENSG00000268912.1	CTD-2619J13.17	-8.88	1.42e-17	7.28e-15	-0.29	-0.38	Uric acid clearance;	chr19:58407038	chr19:58428632~58431148:-
THCA	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	8.88	1.42e-17	7.28e-15	0.48	0.38	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	8.88	1.43e-17	7.3e-15	0.47	0.38	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
THCA	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	8.88	1.43e-17	7.31e-15	0.49	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
THCA	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-8.88	1.43e-17	7.33e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
THCA	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-8.88	1.43e-17	7.33e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
THCA	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-8.88	1.44e-17	7.37e-15	-0.35	-0.38	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
THCA	cis	rs600231	0.706	rs4244811	ENSG00000245532.5	NEAT1	-8.88	1.44e-17	7.37e-15	-0.27	-0.38	Bone mineral density;	chr11:65553309	chr11:65422774~65445540:+
THCA	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	8.88	1.44e-17	7.38e-15	0.47	0.38	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
THCA	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-8.88	1.44e-17	7.38e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	8.88	1.44e-17	7.38e-15	0.76	0.38	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	8.88	1.44e-17	7.38e-15	0.76	0.38	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	8.88	1.46e-17	7.44e-15	0.5	0.38	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
THCA	cis	rs7211079	0.719	rs2289535	ENSG00000275479.1	RP11-334C17.6	8.88	1.46e-17	7.44e-15	0.35	0.38	Myocardial infarction;	chr17:80137650	chr17:80149627~80149798:+
THCA	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-8.88	1.46e-17	7.44e-15	-0.45	-0.38	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
THCA	cis	rs10411161	0.938	rs17778649	ENSG00000269483.1	AC006272.1	8.88	1.46e-17	7.47e-15	0.55	0.38	Breast cancer;	chr19:51878363	chr19:51839924~51843324:-
THCA	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-8.88	1.46e-17	7.48e-15	-0.67	-0.38	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
THCA	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-8.88	1.47e-17	7.51e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-8.88	1.47e-17	7.51e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-8.88	1.47e-17	7.51e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-8.88	1.47e-17	7.51e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
THCA	cis	rs944289	0.868	rs2415316	ENSG00000257826.1	RP11-116N8.4	-8.88	1.48e-17	7.53e-15	-0.4	-0.38	Thyroid cancer;	chr14:36139806	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-8.87	1.48e-17	7.54e-15	-0.4	-0.38	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
THCA	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	8.87	1.49e-17	7.59e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
THCA	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	8.87	1.49e-17	7.59e-15	0.52	0.38	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
THCA	cis	rs1707322	0.752	rs28550303	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs28375469	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28545085	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28719889	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28812624	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28507722	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28568986	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs28396194	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs28752166	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs10890345	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10789471	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211173	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45651039~45651826:-
THCA	cis	rs780096	0.546	rs2293571	ENSG00000234072.1	AC074117.10	-8.87	1.5e-17	7.67e-15	-0.3	-0.38	Total body bone mineral density;	chr2:27506613	chr2:27356246~27367622:+
THCA	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	8.87	1.51e-17	7.71e-15	0.52	0.38	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
THCA	cis	rs7851660	0.967	rs6478437	ENSG00000236130.1	PTCSC2	-8.87	1.51e-17	7.72e-15	-0.29	-0.38	Strep throat;	chr9:97845215	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.901	rs2401639	ENSG00000236130.1	PTCSC2	-8.87	1.51e-17	7.72e-15	-0.29	-0.38	Strep throat;	chr9:97845555	chr9:97805935~97810008:-
THCA	cis	rs944289	0.74	rs7150440	ENSG00000257826.1	RP11-116N8.4	-8.87	1.51e-17	7.72e-15	-0.39	-0.38	Thyroid cancer;	chr14:36114691	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs7150768	ENSG00000257826.1	RP11-116N8.4	-8.87	1.51e-17	7.72e-15	-0.39	-0.38	Thyroid cancer;	chr14:36114699	chr14:36061026~36067190:-
THCA	cis	rs9341808	0.529	rs2322765	ENSG00000272129.1	RP11-250B2.6	8.87	1.52e-17	7.74e-15	0.47	0.38	Sitting height ratio;	chr6:80354879	chr6:80355424~80356859:+
THCA	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
THCA	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
THCA	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
THCA	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
THCA	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
THCA	cis	rs642803	0.591	rs620088	ENSG00000214659.4	KRT8P26	-8.87	1.53e-17	7.79e-15	-0.33	-0.38	Urate levels;	chr11:65741515	chr11:65726939~65728214:+
THCA	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	8.87	1.53e-17	7.8e-15	0.27	0.38	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-8.87	1.53e-17	7.8e-15	-0.49	-0.38	Gout;	chr7:66645053	chr7:66902857~66906297:+
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-8.87	1.53e-17	7.8e-15	-0.49	-0.38	Gout;	chr7:66654674	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-8.87	1.53e-17	7.82e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-8.87	1.53e-17	7.82e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
THCA	cis	rs1707322	0.826	rs10890349	ENSG00000234329.1	RP11-767N6.2	8.87	1.53e-17	7.82e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.758	rs10789474	ENSG00000234329.1	RP11-767N6.2	8.87	1.53e-17	7.82e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45651039~45651826:-
THCA	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	8.87	1.53e-17	7.82e-15	0.65	0.38	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
THCA	cis	rs11051970	0.592	rs11052002	ENSG00000274964.1	RP11-817I4.1	-8.87	1.54e-17	7.85e-15	-0.5	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32437920	chr12:32339368~32340724:+
THCA	cis	rs944289	0.74	rs12891345	ENSG00000257826.1	RP11-116N8.4	-8.87	1.54e-17	7.86e-15	-0.4	-0.38	Thyroid cancer;	chr14:36126977	chr14:36061026~36067190:-
THCA	cis	rs62103177	0.535	rs62101568	ENSG00000261126.6	RP11-795F19.1	8.87	1.55e-17	7.89e-15	0.43	0.38	Opioid sensitivity;	chr18:80176788	chr18:80046900~80095482:+
THCA	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	8.87	1.55e-17	7.91e-15	0.25	0.38	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	8.87	1.55e-17	7.91e-15	0.25	0.38	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	8.87	1.55e-17	7.91e-15	0.25	0.38	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	8.87	1.55e-17	7.91e-15	0.25	0.38	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-8.87	1.56e-17	7.93e-15	-0.48	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
THCA	cis	rs2288884	0.767	rs58329304	ENSG00000275055.1	CTC-471J1.11	-8.87	1.56e-17	7.95e-15	-0.35	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52031919	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.767	rs12460118	ENSG00000275055.1	CTC-471J1.11	-8.87	1.56e-17	7.95e-15	-0.35	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032550	chr19:52049007~52049754:+
THCA	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-8.87	1.56e-17	7.96e-15	-0.51	-0.38	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
THCA	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	8.87	1.56e-17	7.96e-15	0.36	0.38	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
THCA	cis	rs642803	0.551	rs1308020	ENSG00000214659.4	KRT8P26	-8.87	1.56e-17	7.96e-15	-0.33	-0.38	Urate levels;	chr11:65730087	chr11:65726939~65728214:+
THCA	cis	rs28510890	0.547	rs11853339	ENSG00000260337.3	RP11-386M24.6	8.87	1.58e-17	8.03e-15	0.48	0.38	Lung cancer in ever smokers;	chr15:92605654	chr15:92592574~92596462:-
THCA	cis	rs17684571	0.872	rs34832779	ENSG00000231441.1	RP11-472M19.2	8.87	1.58e-17	8.07e-15	0.53	0.38	Schizophrenia;	chr6:56758350	chr6:56844002~56864078:+
THCA	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-8.87	1.59e-17	8.11e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-8.86	1.6e-17	8.15e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
THCA	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-8.86	1.6e-17	8.15e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
THCA	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	8.86	1.6e-17	8.17e-15	0.5	0.38	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
THCA	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-8.86	1.61e-17	8.18e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
THCA	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-8.86	1.61e-17	8.18e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-8.86	1.61e-17	8.2e-15	-0.47	-0.38	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
THCA	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-8.86	1.62e-17	8.23e-15	-0.5	-0.38	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
THCA	cis	rs848490	0.615	rs2428939	ENSG00000214293.7	APTR	-8.86	1.62e-17	8.26e-15	-0.28	-0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77932977	chr7:77657660~77696265:-
THCA	cis	rs1799949	0.965	rs8071278	ENSG00000267681.1	CTD-3199J23.6	-8.86	1.63e-17	8.29e-15	-0.44	-0.38	Menopause (age at onset);	chr17:43041893	chr17:43144956~43145255:+
THCA	cis	rs12188164	0.515	rs11742006	ENSG00000221990.4	EXOC3-AS1	8.86	1.63e-17	8.29e-15	0.32	0.38	Cystic fibrosis severity;	chr5:408414	chr5:441498~443160:-
THCA	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-8.86	1.64e-17	8.34e-15	-0.47	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
THCA	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	8.86	1.64e-17	8.34e-15	0.71	0.38	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
THCA	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-8.86	1.64e-17	8.36e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
THCA	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	8.86	1.66e-17	8.43e-15	0.36	0.38	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
THCA	cis	rs4842666	0.831	rs11105378	ENSG00000258302.2	RP11-981P6.1	8.86	1.66e-17	8.44e-15	0.37	0.38	Blood pressure;	chr12:89696964	chr12:89561129~89594878:+
THCA	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	8.86	1.67e-17	8.48e-15	0.52	0.38	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
THCA	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-8.86	1.67e-17	8.49e-15	-0.52	-0.38	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
THCA	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-8.86	1.68e-17	8.53e-15	-0.5	-0.38	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
THCA	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-8.86	1.68e-17	8.57e-15	-0.48	-0.38	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
THCA	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	8.86	1.69e-17	8.57e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	8.86	1.69e-17	8.57e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
THCA	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	8.86	1.7e-17	8.63e-15	0.51	0.38	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	8.86	1.7e-17	8.64e-15	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
THCA	cis	rs7015263	0.689	rs56268009	ENSG00000254231.1	CTD-2284J15.1	-8.86	1.71e-17	8.68e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86492358	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs6994005	ENSG00000254231.1	CTD-2284J15.1	-8.86	1.71e-17	8.68e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86495633	chr8:86333274~86343314:-
THCA	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-8.86	1.71e-17	8.7e-15	-0.46	-0.38	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
THCA	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-8.86	1.71e-17	8.7e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-8.86	1.71e-17	8.7e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
THCA	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	8.86	1.72e-17	8.73e-15	0.27	0.38	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
THCA	cis	rs1707322	0.721	rs4660883	ENSG00000234329.1	RP11-767N6.2	8.86	1.72e-17	8.74e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	8.86	1.72e-17	8.74e-15	0.47	0.38	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
THCA	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-8.85	1.74e-17	8.83e-15	-0.36	-0.38	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
THCA	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	8.85	1.75e-17	8.87e-15	0.36	0.38	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
THCA	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
THCA	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
THCA	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-8.85	1.75e-17	8.91e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
THCA	cis	rs11603691	1	rs11603691	ENSG00000254662.1	RP11-872D17.4	-8.85	1.76e-17	8.91e-15	-0.71	-0.38	Low high density lipoprotein cholesterol levels;	chr11:57340143	chr11:57325603~57327958:+
THCA	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-8.85	1.76e-17	8.93e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
THCA	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	8.85	1.76e-17	8.94e-15	0.37	0.38	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
THCA	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-8.85	1.76e-17	8.94e-15	-0.44	-0.38	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
THCA	cis	rs7015263	0.689	rs10956800	ENSG00000254231.1	CTD-2284J15.1	8.85	1.76e-17	8.95e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86324220	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs11997234	ENSG00000254231.1	CTD-2284J15.1	8.85	1.76e-17	8.95e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86326916	chr8:86333274~86343314:-
THCA	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	8.85	1.76e-17	8.96e-15	0.5	0.38	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
THCA	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	8.85	1.77e-17	8.99e-15	0.47	0.38	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
THCA	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	8.85	1.77e-17	8.99e-15	0.74	0.38	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
THCA	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-8.85	1.77e-17	9.01e-15	-0.43	-0.38	Height;	chr2:231549981	chr2:231508426~231514339:-
THCA	cis	rs8114671	0.967	rs6088734	ENSG00000269202.1	RP4-614O4.12	-8.85	1.78e-17	9.03e-15	-0.32	-0.38	Height;	chr20:35157243	chr20:35201747~35203288:-
THCA	cis	rs9532669	0.819	rs9532652	ENSG00000239827.7	SUGT1P3	-8.85	1.78e-17	9.05e-15	-0.45	-0.38	Cervical cancer;	chr13:40903300	chr13:40908159~40921774:-
THCA	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-8.85	1.79e-17	9.06e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
THCA	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	8.85	1.79e-17	9.08e-15	0.51	0.38	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
THCA	cis	rs1707322	0.721	rs10890341	ENSG00000234329.1	RP11-767N6.2	8.85	1.79e-17	9.08e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45651039~45651826:-
THCA	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-8.85	1.79e-17	9.1e-15	-0.43	-0.38	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
THCA	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-8.85	1.8e-17	9.12e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
THCA	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	8.85	1.8e-17	9.12e-15	0.68	0.38	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
THCA	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-8.85	1.8e-17	9.12e-15	-0.39	-0.38	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	8.85	1.8e-17	9.14e-15	0.5	0.38	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.851	rs2256000	ENSG00000215447.6	BX322557.10	-8.85	1.81e-17	9.16e-15	-0.3	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45288052~45291738:+
THCA	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-8.85	1.81e-17	9.17e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-8.85	1.81e-17	9.17e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
THCA	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	8.85	1.81e-17	9.18e-15	0.37	0.38	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
THCA	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-8.85	1.81e-17	9.18e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
THCA	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	8.85	1.82e-17	9.22e-15	0.46	0.38	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
THCA	cis	rs2754412	1	rs2754412	ENSG00000263064.2	RP11-291L22.7	8.85	1.82e-17	9.22e-15	0.43	0.38	Breast cancer;	chr10:38338906	chr10:38448689~38448949:+
THCA	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-8.85	1.82e-17	9.23e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
THCA	cis	rs7015263	0.651	rs7461767	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86330049	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs6471279	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86331563	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs6471281	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86337013	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.614	rs7825405	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86337259	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs7462727	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86338405	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs7824469	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86338693	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs10107072	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86339204	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.651	rs4581032	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86339553	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs7015490	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86342081	chr8:86333274~86343314:-
THCA	cis	rs853679	0.55	rs9295762	ENSG00000226314.6	ZNF192P1	8.85	1.85e-17	9.36e-15	0.49	0.38	Depression;	chr6:28187640	chr6:28161781~28169594:+
THCA	cis	rs7015263	0.689	rs7017719	ENSG00000254231.1	CTD-2284J15.1	-8.84	1.86e-17	9.41e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86321739	chr8:86333274~86343314:-
THCA	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-8.84	1.87e-17	9.45e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
THCA	cis	rs7829975	0.777	rs486781	ENSG00000253893.2	FAM85B	8.84	1.87e-17	9.46e-15	0.48	0.38	Mood instability;	chr8:8782230	chr8:8167819~8226614:-
THCA	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-8.84	1.87e-17	9.48e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
THCA	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-8.84	1.87e-17	9.48e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
THCA	cis	rs673078	0.66	rs73220119	ENSG00000275409.1	RP11-131L12.4	-8.84	1.88e-17	9.51e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118159864	chr12:118430147~118430699:+
THCA	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	8.84	1.89e-17	9.55e-15	0.45	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
THCA	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-8.84	1.89e-17	9.55e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-8.84	1.89e-17	9.55e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
THCA	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-8.84	1.89e-17	9.57e-15	-0.65	-0.38	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
THCA	cis	rs7772486	0.811	rs2777475	ENSG00000235652.6	RP11-545I5.3	8.84	1.9e-17	9.6e-15	0.36	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145983467	chr6:145799409~145886585:+
THCA	cis	rs4927850	1	rs10881563	ENSG00000273009.1	RP11-352G9.1	-8.84	1.91e-17	9.64e-15	-0.42	-0.38	Pancreatic cancer;	chr3:196023354	chr3:195913078~195913683:-
THCA	cis	rs944289	0.774	rs2415313	ENSG00000257826.1	RP11-116N8.4	-8.84	1.91e-17	9.67e-15	-0.39	-0.38	Thyroid cancer;	chr14:36115246	chr14:36061026~36067190:-
THCA	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	8.84	1.91e-17	9.67e-15	0.49	0.38	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
THCA	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-8.84	1.91e-17	9.67e-15	-0.52	-0.38	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
THCA	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-8.84	1.91e-17	9.68e-15	-0.46	-0.38	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
THCA	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-8.84	1.92e-17	9.7e-15	-0.47	-0.38	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000237664.1	LINC00316	8.84	1.92e-17	9.73e-15	0.38	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45338590~45341990:-
THCA	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	8.84	1.92e-17	9.73e-15	0.5	0.38	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
THCA	cis	rs7015263	0.714	rs3883910	ENSG00000254231.1	CTD-2284J15.1	8.84	1.93e-17	9.74e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86503659	chr8:86333274~86343314:-
THCA	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-8.84	1.93e-17	9.74e-15	-0.44	-0.38	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
THCA	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	8.84	1.93e-17	9.74e-15	0.66	0.38	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
THCA	cis	rs7727544	0.544	rs55722650	ENSG00000237714.1	P4HA2-AS1	8.84	1.93e-17	9.75e-15	0.51	0.38	Blood metabolite levels;	chr5:132271607	chr5:132184876~132192808:+
THCA	cis	rs10411161	0.702	rs17835311	ENSG00000269483.1	AC006272.1	8.84	1.93e-17	9.76e-15	0.53	0.38	Breast cancer;	chr19:51883528	chr19:51839924~51843324:-
THCA	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	8.84	1.94e-17	9.79e-15	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
THCA	cis	rs6545883	0.507	rs4411680	ENSG00000271889.1	RP11-493E12.1	-8.84	1.94e-17	9.81e-15	-0.36	-0.38	Tuberculosis;	chr2:61356970	chr2:61151433~61162105:-
THCA	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	8.84	1.95e-17	9.84e-15	0.45	0.38	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
THCA	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	8.84	1.95e-17	9.84e-15	0.48	0.38	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
THCA	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	8.84	1.95e-17	9.85e-15	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
THCA	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	8.84	1.95e-17	9.85e-15	0.65	0.38	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	8.84	1.95e-17	9.85e-15	0.65	0.38	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
THCA	cis	rs6496932	0.874	rs2003294	ENSG00000218052.5	ADAMTS7P4	8.84	1.95e-17	9.85e-15	0.52	0.38	Central corneal thickness;Corneal structure;	chr15:85274141	chr15:85255369~85330334:-
THCA	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-8.84	1.95e-17	9.85e-15	-0.47	-0.38	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000215447.6	BX322557.10	-8.84	1.95e-17	9.87e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45288052~45291738:+
THCA	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-8.84	1.96e-17	9.91e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
THCA	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-8.84	1.96e-17	9.91e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
THCA	cis	rs1707322	0.721	rs28501477	ENSG00000234329.1	RP11-767N6.2	8.84	1.97e-17	9.93e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs10890342	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs6658700	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs12047629	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211169	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211171	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28623463	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs28370457	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45651039~45651826:-
THCA	cis	rs7208859	0.673	rs11653955	ENSG00000266490.1	CTD-2349P21.9	8.84	1.98e-17	1e-14	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30792372~30792833:+
THCA	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-8.84	1.98e-17	1e-14	-0.61	-0.38	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
THCA	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-8.84	1.98e-17	1e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-8.84	1.98e-17	1e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-8.84	1.98e-17	1e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
THCA	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-8.84	1.99e-17	1e-14	-0.5	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
THCA	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-8.84	1.99e-17	1e-14	-0.57	-0.38	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
THCA	cis	rs1707322	0.717	rs11211161	ENSG00000234329.1	RP11-767N6.2	8.84	1.99e-17	1.01e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs61784793	ENSG00000234329.1	RP11-767N6.2	8.84	1.99e-17	1.01e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs4586014	ENSG00000234329.1	RP11-767N6.2	8.84	1.99e-17	1.01e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.648	rs4439382	ENSG00000234329.1	RP11-767N6.2	8.84	1.99e-17	1.01e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45651039~45651826:-
THCA	cis	rs10411161	0.702	rs11878580	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51885232	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs11878586	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51885323	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs7251755	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51885695	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs7251689	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51885864	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.69	rs7252336	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51886261	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs11878583	ENSG00000269483.1	AC006272.1	-8.84	2e-17	1.01e-14	-0.53	-0.38	Breast cancer;	chr19:51885293	chr19:51839924~51843324:-
THCA	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	8.83	2.01e-17	1.02e-14	0.5	0.38	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
THCA	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	8.83	2.01e-17	1.02e-14	0.5	0.38	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-8.83	2.02e-17	1.02e-14	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.766	rs4819035	ENSG00000223768.1	LINC00205	-8.83	2.02e-17	1.02e-14	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45293285~45297354:+
THCA	cis	rs4713118	0.696	rs2394002	ENSG00000219392.1	RP1-265C24.5	-8.83	2.02e-17	1.02e-14	-0.5	-0.38	Parkinson's disease;	chr6:27780236	chr6:28115628~28116551:+
THCA	cis	rs9532669	0.926	rs11147831	ENSG00000239827.7	SUGT1P3	-8.83	2.02e-17	1.02e-14	-0.41	-0.38	Cervical cancer;	chr13:40978593	chr13:40908159~40921774:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000228039.3	KB-1125A3.10	8.83	2.02e-17	1.02e-14	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23963780~23964374:+
THCA	cis	rs7637701	0.517	rs66538320	ENSG00000243926.1	TIPARP-AS1	8.83	2.02e-17	1.02e-14	0.38	0.38	Breast cancer;	chr3:156674346	chr3:156671862~156674378:-
THCA	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	8.83	2.02e-17	1.02e-14	0.48	0.38	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
THCA	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	8.83	2.03e-17	1.02e-14	0.47	0.38	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
THCA	cis	rs10411161	0.579	rs59305384	ENSG00000269483.1	AC006272.1	8.83	2.03e-17	1.02e-14	0.51	0.38	Breast cancer;	chr19:51883811	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs10423838	ENSG00000269483.1	AC006272.1	8.83	2.03e-17	1.02e-14	0.51	0.38	Breast cancer;	chr19:51884030	chr19:51839924~51843324:-
THCA	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-8.83	2.04e-17	1.03e-14	-0.31	-0.38	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
THCA	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-8.83	2.04e-17	1.03e-14	-0.39	-0.38	QT interval;	chr12:29319943	chr12:29280418~29317848:-
THCA	cis	rs7945705	0.967	rs7123429	ENSG00000254860.4	TMEM9B-AS1	8.83	2.05e-17	1.03e-14	0.42	0.38	Hemoglobin concentration;	chr11:8845261	chr11:8964675~8977527:+
THCA	cis	rs5769707	0.967	rs17182154	ENSG00000235111.1	RP1-29C18.8	-8.83	2.05e-17	1.04e-14	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49612657~49615716:-
THCA	cis	rs1707322	0.963	rs6429581	ENSG00000234329.1	RP11-767N6.2	8.83	2.06e-17	1.04e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45651039~45651826:-
THCA	cis	rs7849270	1	rs2768630	ENSG00000268707.1	RP11-247A12.7	8.83	2.07e-17	1.04e-14	0.48	0.38	Blood metabolite ratios;	chr9:129104109	chr9:129170434~129170940:+
THCA	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-8.83	2.07e-17	1.05e-14	-0.39	-0.38	QT interval;	chr12:29314736	chr12:29280418~29317848:-
THCA	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	8.83	2.07e-17	1.05e-14	0.49	0.38	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
THCA	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	8.83	2.08e-17	1.05e-14	0.39	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
THCA	cis	rs34081947	0.521	rs11623102	ENSG00000257826.1	RP11-116N8.4	-8.83	2.09e-17	1.05e-14	-0.45	-0.38	Papillary thyroid cancer;Differentiated thyroid cancer;	chr14:36130459	chr14:36061026~36067190:-
THCA	cis	rs673078	0.66	rs61943524	ENSG00000275409.1	RP11-131L12.4	-8.83	2.1e-17	1.06e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118151530	chr12:118430147~118430699:+
THCA	cis	rs1707322	0.721	rs11211151	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12045096	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4609469	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12049027	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs10789467	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10890337	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs3811435	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45651039~45651826:-
THCA	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-8.83	2.1e-17	1.06e-14	-0.48	-0.38	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
THCA	cis	rs1707322	0.721	rs10890333	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12043945	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12091503	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10890336	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000215447.6	BX322557.10	-8.83	2.1e-17	1.06e-14	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45288052~45291738:+
THCA	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	8.83	2.11e-17	1.06e-14	0.44	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
THCA	cis	rs11148252	1	rs11148252	ENSG00000278238.1	RP11-245D16.4	-8.83	2.11e-17	1.06e-14	-0.42	-0.38	Lewy body disease;	chr13:52434913	chr13:52454775~52455331:-
THCA	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-8.83	2.11e-17	1.06e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-8.83	2.11e-17	1.06e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-8.83	2.11e-17	1.06e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
THCA	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-8.83	2.11e-17	1.07e-14	-0.47	-0.38	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	8.83	2.12e-17	1.07e-14	0.49	0.38	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-8.83	2.12e-17	1.07e-14	-0.71	-0.38	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
THCA	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	8.83	2.13e-17	1.07e-14	0.64	0.38	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	8.83	2.13e-17	1.07e-14	0.64	0.38	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
THCA	cis	rs7727544	0.581	rs10075801	ENSG00000237714.1	P4HA2-AS1	8.83	2.13e-17	1.07e-14	0.49	0.38	Blood metabolite levels;	chr5:132341949	chr5:132184876~132192808:+
THCA	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-8.83	2.15e-17	1.08e-14	-0.3	-0.38	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
THCA	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	8.83	2.15e-17	1.09e-14	0.37	0.38	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
THCA	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-8.83	2.16e-17	1.09e-14	-0.4	-0.38	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
THCA	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-8.83	2.16e-17	1.09e-14	-0.4	-0.38	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
THCA	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	8.83	2.16e-17	1.09e-14	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
THCA	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-8.83	2.16e-17	1.09e-14	-0.31	-0.38	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000275120.1	RP11-182J1.17	-8.83	2.16e-17	1.09e-14	-0.39	-0.38	P wave terminal force;	chr15:84632519	chr15:84599434~84606463:-
THCA	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	8.83	2.16e-17	1.09e-14	0.48	0.38	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
THCA	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	8.83	2.16e-17	1.09e-14	0.37	0.38	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	8.83	2.16e-17	1.09e-14	0.37	0.38	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
THCA	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	8.82	2.17e-17	1.09e-14	0.64	0.38	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
THCA	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-8.82	2.17e-17	1.09e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
THCA	cis	rs673078	0.66	rs17440315	ENSG00000275409.1	RP11-131L12.4	-8.82	2.17e-17	1.09e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118158819	chr12:118430147~118430699:+
THCA	cis	rs2274273	0.661	rs8019978	ENSG00000258413.1	RP11-665C16.6	8.82	2.18e-17	1.1e-14	0.49	0.38	Protein biomarker;	chr14:55090566	chr14:55262767~55272075:-
THCA	cis	rs9847710	0.744	rs2115780	ENSG00000242142.1	SERBP1P3	8.82	2.2e-17	1.11e-14	0.46	0.38	Ulcerative colitis;	chr3:53108964	chr3:53064283~53065091:-
THCA	cis	rs1707322	1	rs6672115	ENSG00000234329.1	RP11-767N6.2	8.82	2.21e-17	1.11e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45651039~45651826:-
THCA	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-8.82	2.21e-17	1.11e-14	-0.48	-0.38	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
THCA	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	8.82	2.21e-17	1.11e-14	0.4	0.38	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-8.82	2.22e-17	1.11e-14	-0.76	-0.38	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	8.82	2.22e-17	1.12e-14	0.51	0.38	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
THCA	cis	rs7569084	0.687	rs963539	ENSG00000234255.7	AC012370.3	-8.82	2.22e-17	1.12e-14	-0.43	-0.38	Sum eosinophil basophil counts;	chr2:65421413	chr2:65439888~65456571:-
THCA	cis	rs12701220	0.503	rs12531999	ENSG00000229043.2	AC091729.9	-8.82	2.22e-17	1.12e-14	-0.56	-0.38	Bronchopulmonary dysplasia;	chr7:1141965	chr7:1160374~1165267:+
THCA	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-8.82	2.22e-17	1.12e-14	-0.41	-0.38	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
THCA	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-8.82	2.23e-17	1.12e-14	-0.45	-0.38	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
THCA	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-8.82	2.23e-17	1.12e-14	-0.51	-0.38	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
THCA	cis	rs10411161	0.702	rs7250193	ENSG00000269483.1	AC006272.1	-8.82	2.24e-17	1.12e-14	-0.52	-0.38	Breast cancer;	chr19:51882267	chr19:51839924~51843324:-
THCA	cis	rs4819052	0.808	rs2838862	ENSG00000215447.6	BX322557.10	-8.82	2.24e-17	1.13e-14	-0.3	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45266811	chr21:45288052~45291738:+
THCA	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-8.82	2.24e-17	1.13e-14	-0.78	-0.38	Gout;	chr7:66721259	chr7:66654538~66669855:+
THCA	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-8.82	2.24e-17	1.13e-14	-0.39	-0.38	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
THCA	cis	rs1707322	0.964	rs785516	ENSG00000234329.1	RP11-767N6.2	-8.82	2.25e-17	1.13e-14	-0.36	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785517	ENSG00000234329.1	RP11-767N6.2	-8.82	2.25e-17	1.13e-14	-0.36	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45651039~45651826:-
THCA	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-8.82	2.25e-17	1.13e-14	-0.48	-0.38	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-8.82	2.25e-17	1.13e-14	-0.48	-0.38	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
THCA	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-8.82	2.25e-17	1.13e-14	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
THCA	cis	rs67311347	0.594	rs12629111	ENSG00000223797.4	ENTPD3-AS1	8.82	2.26e-17	1.13e-14	0.3	0.38	Renal cell carcinoma;	chr3:40243860	chr3:40313802~40453329:-
THCA	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	8.82	2.26e-17	1.14e-14	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
THCA	cis	rs28510890	0.789	rs10852176	ENSG00000260337.3	RP11-386M24.6	8.82	2.27e-17	1.14e-14	0.47	0.38	Lung cancer in ever smokers;	chr15:92588701	chr15:92592574~92596462:-
THCA	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	8.82	2.27e-17	1.14e-14	0.43	0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
THCA	cis	rs11971779	0.752	rs4732371	ENSG00000273391.1	RP11-634H22.1	8.82	2.27e-17	1.14e-14	0.37	0.38	Diisocyanate-induced asthma;	chr7:139392571	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
THCA	cis	rs2274273	0.712	rs1002054	ENSG00000258413.1	RP11-665C16.6	-8.82	2.27e-17	1.14e-14	-0.5	-0.38	Protein biomarker;	chr14:55062195	chr14:55262767~55272075:-
THCA	cis	rs1707322	0.752	rs28890893	ENSG00000234329.1	RP11-767N6.2	8.82	2.28e-17	1.15e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45651039~45651826:-
THCA	cis	rs73607972	0.575	rs12926468	ENSG00000275191.1	RP11-36I17.2	-8.82	2.28e-17	1.15e-14	-0.52	-0.38	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53555488	chr16:53628256~53628816:-
THCA	cis	rs11051970	0.559	rs7300646	ENSG00000274964.1	RP11-817I4.1	-8.82	2.29e-17	1.15e-14	-0.46	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32335695	chr12:32339368~32340724:+
THCA	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-8.82	2.29e-17	1.15e-14	-0.74	-0.38	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
THCA	cis	rs2946505	0.516	rs2954193	ENSG00000251468.2	RP11-369K16.1	8.82	2.29e-17	1.15e-14	0.57	0.38	Migraine;	chr8:12960864	chr8:12958387~12962200:+
THCA	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	8.82	2.29e-17	1.15e-14	0.37	0.38	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	8.82	2.29e-17	1.15e-14	0.37	0.38	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	8.82	2.29e-17	1.15e-14	0.37	0.38	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
THCA	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-8.82	2.3e-17	1.16e-14	-0.37	-0.38	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-8.82	2.3e-17	1.16e-14	-0.37	-0.38	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
THCA	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-8.82	2.31e-17	1.16e-14	-0.6	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
THCA	cis	rs1707322	0.789	rs10789473	ENSG00000234329.1	RP11-767N6.2	8.82	2.31e-17	1.16e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45651039~45651826:-
THCA	cis	rs10266483	0.654	rs6962076	ENSG00000271550.1	BNIP3P11	-8.82	2.31e-17	1.16e-14	-0.52	-0.38	Response to statin therapy;	chr7:64559214	chr7:64678954~64687393:-
THCA	cis	rs4842666	0.831	rs12230074	ENSG00000258302.2	RP11-981P6.1	8.82	2.31e-17	1.16e-14	0.37	0.38	Blood pressure;	chr12:89697090	chr12:89561129~89594878:+
THCA	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	8.82	2.31e-17	1.16e-14	0.47	0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
THCA	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-8.82	2.32e-17	1.16e-14	-0.49	-0.38	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
THCA	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-8.82	2.32e-17	1.17e-14	-0.5	-0.38	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	8.82	2.32e-17	1.17e-14	0.5	0.38	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
THCA	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	8.82	2.32e-17	1.17e-14	0.65	0.38	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
THCA	cis	rs4819052	0.851	rs1056099	ENSG00000215447.6	BX322557.10	-8.82	2.33e-17	1.17e-14	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2236446	ENSG00000215447.6	BX322557.10	-8.82	2.33e-17	1.17e-14	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45288052~45291738:+
THCA	cis	rs11051970	0.559	rs3789975	ENSG00000274964.1	RP11-817I4.1	-8.82	2.33e-17	1.17e-14	-0.46	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32331469	chr12:32339368~32340724:+
THCA	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	8.82	2.33e-17	1.17e-14	0.48	0.38	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000224205.1	AP000351.4	8.81	2.35e-17	1.18e-14	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23987320~23991421:-
THCA	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-8.81	2.36e-17	1.18e-14	-0.41	-0.38	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
THCA	cis	rs11148252	1	rs4886018	ENSG00000278238.1	RP11-245D16.4	-8.81	2.36e-17	1.18e-14	-0.42	-0.38	Lewy body disease;	chr13:52416582	chr13:52454775~52455331:-
THCA	cis	rs13129231	1	rs13129231	ENSG00000206820.1	RNU1-138P	-8.81	2.36e-17	1.18e-14	-0.46	-0.38	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113431725	chr4:113420323~113420486:+
THCA	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-8.81	2.36e-17	1.18e-14	-0.41	-0.38	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
THCA	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	8.81	2.36e-17	1.19e-14	0.86	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
THCA	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-8.81	2.37e-17	1.19e-14	-0.49	-0.38	Gout;	chr7:66642037	chr7:66902857~66906297:+
THCA	cis	rs600231	0.706	rs1111934	ENSG00000245532.5	NEAT1	8.81	2.37e-17	1.19e-14	0.28	0.38	Bone mineral density;	chr11:65561921	chr11:65422774~65445540:+
THCA	cis	rs1707322	0.721	rs9793568	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211157	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211158	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs6429575	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.685	rs6690926	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs8179402	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs8179296	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45651039~45651826:-
THCA	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-8.81	2.37e-17	1.19e-14	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
THCA	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-8.81	2.38e-17	1.19e-14	-0.48	-0.38	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-8.81	2.39e-17	1.2e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-8.81	2.39e-17	1.2e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-8.81	2.39e-17	1.2e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.606	rs17622208	ENSG00000237714.1	P4HA2-AS1	8.81	2.39e-17	1.2e-14	0.49	0.38	Blood metabolite levels;	chr5:132381358	chr5:132184876~132192808:+
THCA	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-8.81	2.4e-17	1.2e-14	-0.44	-0.38	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
THCA	cis	rs7849270	0.879	rs2229419	ENSG00000268707.1	RP11-247A12.7	8.81	2.4e-17	1.2e-14	0.46	0.38	Blood metabolite ratios;	chr9:129095351	chr9:129170434~129170940:+
THCA	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	8.81	2.41e-17	1.21e-14	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
THCA	cis	rs860295	0.871	rs11582072	ENSG00000225855.5	RUSC1-AS1	-8.81	2.41e-17	1.21e-14	-0.25	-0.38	Body mass index;	chr1:155507779	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-8.81	2.41e-17	1.21e-14	-0.48	-0.38	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
THCA	cis	rs848490	0.546	rs7384722	ENSG00000214293.7	APTR	8.81	2.41e-17	1.21e-14	0.26	0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77646106	chr7:77657660~77696265:-
THCA	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	8.81	2.41e-17	1.21e-14	0.52	0.38	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
THCA	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-8.81	2.42e-17	1.21e-14	-0.39	-0.38	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-8.81	2.43e-17	1.22e-14	-0.4	-0.38	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
THCA	cis	rs10411161	0.702	rs16983200	ENSG00000269483.1	AC006272.1	8.81	2.44e-17	1.22e-14	0.53	0.38	Breast cancer;	chr19:51883470	chr19:51839924~51843324:-
THCA	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-8.81	2.44e-17	1.23e-14	-0.44	-0.38	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
THCA	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-8.81	2.45e-17	1.23e-14	-0.44	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
THCA	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-8.81	2.46e-17	1.23e-14	-0.46	-0.38	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
THCA	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	8.81	2.5e-17	1.25e-14	0.49	0.38	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
THCA	cis	rs2408955	0.521	rs10875753	ENSG00000258273.1	RP11-370I10.4	-8.81	2.5e-17	1.25e-14	-0.49	-0.38	Glycated hemoglobin levels;	chr12:48163358	chr12:48333755~48333901:-
THCA	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	8.81	2.51e-17	1.26e-14	0.37	0.38	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
THCA	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
THCA	cis	rs56080343	0.515	rs73222056	ENSG00000275759.1	RP11-131L12.3	-8.81	2.52e-17	1.26e-14	-0.56	-0.38	Neuroticism;	chr12:118215875	chr12:118428281~118428870:+
THCA	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	8.81	2.52e-17	1.26e-14	0.62	0.38	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
THCA	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-8.8	2.53e-17	1.27e-14	-0.41	-0.38	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
THCA	cis	rs1707322	0.964	rs6675259	ENSG00000234329.1	RP11-767N6.2	-8.8	2.53e-17	1.27e-14	-0.36	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45651039~45651826:-
THCA	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	8.8	2.53e-17	1.27e-14	0.36	0.38	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
THCA	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-8.8	2.54e-17	1.27e-14	-0.38	-0.38	Height;	chr11:118737823	chr11:118704607~118750263:+
THCA	cis	rs4842666	0.915	rs111478946	ENSG00000258302.2	RP11-981P6.1	8.8	2.55e-17	1.27e-14	0.37	0.38	Blood pressure;	chr12:89665065	chr12:89561129~89594878:+
THCA	cis	rs8027521	0.521	rs12903875	ENSG00000280362.1	RP11-643A5.3	-8.8	2.55e-17	1.27e-14	-0.52	-0.38	Circulating chemerin levels;	chr15:53951346	chr15:53910769~53914712:+
THCA	cis	rs7015263	0.689	rs55807259	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86355487	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.643	rs17681618	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86356156	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.666	rs56268675	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86358580	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs62509421	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86367267	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs12543856	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86369559	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.643	rs17608598	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86375035	chr8:86333274~86343314:-
THCA	cis	rs5769707	0.846	rs5770610	ENSG00000235111.1	RP1-29C18.8	-8.8	2.57e-17	1.29e-14	-0.44	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49612657~49615716:-
THCA	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-8.8	2.58e-17	1.29e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
THCA	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-8.8	2.58e-17	1.29e-14	-0.49	-0.38	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
THCA	cis	rs7727544	0.557	rs715285	ENSG00000237714.1	P4HA2-AS1	8.8	2.59e-17	1.29e-14	0.47	0.38	Blood metabolite levels;	chr5:132149690	chr5:132184876~132192808:+
THCA	cis	rs11148252	0.669	rs4884320	ENSG00000278238.1	RP11-245D16.4	-8.8	2.6e-17	1.3e-14	-0.44	-0.38	Lewy body disease;	chr13:52432779	chr13:52454775~52455331:-
THCA	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	8.8	2.61e-17	1.3e-14	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	8.8	2.61e-17	1.3e-14	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
THCA	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-8.8	2.61e-17	1.31e-14	-0.39	-0.38	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
THCA	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	8.8	2.62e-17	1.31e-14	0.48	0.38	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
THCA	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	8.8	2.62e-17	1.31e-14	0.48	0.38	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
THCA	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	8.8	2.62e-17	1.31e-14	0.49	0.38	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
THCA	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	8.8	2.62e-17	1.31e-14	0.49	0.38	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
THCA	cis	rs7727544	0.582	rs4361509	ENSG00000237714.1	P4HA2-AS1	-8.8	2.62e-17	1.31e-14	-0.47	-0.38	Blood metabolite levels;	chr5:132201060	chr5:132184876~132192808:+
THCA	cis	rs12188164	0.515	rs11745246	ENSG00000221990.4	EXOC3-AS1	8.8	2.65e-17	1.32e-14	0.32	0.38	Cystic fibrosis severity;	chr5:410828	chr5:441498~443160:-
THCA	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	8.8	2.65e-17	1.32e-14	0.46	0.38	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-8.8	2.66e-17	1.33e-14	-0.47	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
THCA	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	8.8	2.67e-17	1.33e-14	0.51	0.38	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
THCA	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	8.8	2.67e-17	1.33e-14	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
THCA	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	8.8	2.67e-17	1.33e-14	0.36	0.38	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
THCA	cis	rs9532669	0.927	rs9532670	ENSG00000239827.7	SUGT1P3	8.8	2.67e-17	1.34e-14	0.41	0.38	Cervical cancer;	chr13:40927691	chr13:40908159~40921774:-
THCA	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-8.8	2.69e-17	1.34e-14	-0.48	-0.38	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
THCA	cis	rs11603691	0.901	rs11228995	ENSG00000254662.1	RP11-872D17.4	-8.8	2.69e-17	1.34e-14	-0.7	-0.38	Low high density lipoprotein cholesterol levels;	chr11:57316061	chr11:57325603~57327958:+
THCA	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-8.8	2.7e-17	1.35e-14	-0.49	-0.38	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
THCA	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-8.8	2.7e-17	1.35e-14	-0.29	-0.38	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
THCA	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-8.8	2.72e-17	1.36e-14	-0.48	-0.38	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
THCA	cis	rs7015263	0.689	rs12544731	ENSG00000254231.1	CTD-2284J15.1	-8.79	2.77e-17	1.38e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86320785	chr8:86333274~86343314:-
THCA	cis	rs1707322	0.717	rs1135812	ENSG00000234329.1	RP11-767N6.2	8.79	2.77e-17	1.38e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs6703748	ENSG00000234329.1	RP11-767N6.2	8.79	2.77e-17	1.38e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45651039~45651826:-
THCA	cis	rs7569084	0.663	rs10190233	ENSG00000234255.7	AC012370.3	-8.79	2.78e-17	1.38e-14	-0.42	-0.38	Sum eosinophil basophil counts;	chr2:65413095	chr2:65439888~65456571:-
THCA	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	8.79	2.78e-17	1.39e-14	0.37	0.38	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	8.79	2.78e-17	1.39e-14	0.37	0.38	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-8.79	2.81e-17	1.4e-14	-0.48	-0.38	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-8.79	2.81e-17	1.4e-14	-0.48	-0.38	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
THCA	cis	rs28510890	0.547	rs11853583	ENSG00000260337.3	RP11-386M24.6	8.79	2.82e-17	1.4e-14	0.48	0.38	Lung cancer in ever smokers;	chr15:92605846	chr15:92592574~92596462:-
THCA	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-8.79	2.82e-17	1.41e-14	-0.44	-0.38	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-8.79	2.83e-17	1.41e-14	-0.5	-0.38	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
THCA	cis	rs2288884	0.537	rs16983434	ENSG00000275055.1	CTC-471J1.11	-8.79	2.83e-17	1.41e-14	-0.3	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:52049007~52049754:+
THCA	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	8.79	2.83e-17	1.41e-14	0.39	0.38	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
THCA	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-8.79	2.84e-17	1.42e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61946068	ENSG00000275409.1	RP11-131L12.4	-8.79	2.84e-17	1.42e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118305861	chr12:118430147~118430699:+
THCA	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	8.79	2.84e-17	1.42e-14	0.37	0.38	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
THCA	cis	rs9532669	0.926	rs4254182	ENSG00000239827.7	SUGT1P3	-8.79	2.84e-17	1.42e-14	-0.41	-0.38	Cervical cancer;	chr13:40879120	chr13:40908159~40921774:-
THCA	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	8.79	2.86e-17	1.42e-14	0.49	0.38	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
THCA	cis	rs7015263	0.689	rs10096168	ENSG00000254231.1	CTD-2284J15.1	8.79	2.86e-17	1.43e-14	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86321176	chr8:86333274~86343314:-
THCA	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	8.79	2.87e-17	1.43e-14	0.37	0.38	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
THCA	cis	rs7665090	1	rs735404	ENSG00000246560.2	RP11-10L12.4	8.79	2.88e-17	1.43e-14	0.45	0.38	Primary biliary cholangitis;	chr4:102632508	chr4:102828055~102844075:+
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-8.79	2.88e-17	1.43e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
THCA	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-8.79	2.88e-17	1.44e-14	-0.39	-0.38	QT interval;	chr12:29302457	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-8.79	2.88e-17	1.44e-14	-0.39	-0.38	QT interval;	chr12:29302458	chr12:29280418~29317848:-
THCA	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	8.79	2.89e-17	1.44e-14	0.48	0.38	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	8.79	2.89e-17	1.44e-14	0.48	0.38	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	8.79	2.89e-17	1.44e-14	0.48	0.38	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
THCA	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	8.79	2.89e-17	1.44e-14	0.56	0.38	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
THCA	cis	rs7211079	0.917	rs4243251	ENSG00000275479.1	RP11-334C17.6	8.79	2.9e-17	1.44e-14	0.38	0.38	Myocardial infarction;	chr17:80138811	chr17:80149627~80149798:+
THCA	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	8.79	2.91e-17	1.45e-14	0.5	0.38	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
THCA	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	8.79	2.91e-17	1.45e-14	0.5	0.38	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
THCA	cis	rs1707322	1	rs12097761	ENSG00000234329.1	RP11-767N6.2	8.79	2.92e-17	1.45e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs10789478	ENSG00000234329.1	RP11-767N6.2	8.79	2.92e-17	1.45e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10789479	ENSG00000234329.1	RP11-767N6.2	8.79	2.92e-17	1.45e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs7512395	ENSG00000234329.1	RP11-767N6.2	8.79	2.92e-17	1.45e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45651039~45651826:-
THCA	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	8.79	2.93e-17	1.46e-14	0.56	0.38	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
THCA	cis	rs4819052	0.851	rs914214	ENSG00000237664.1	LINC00316	-8.79	2.93e-17	1.46e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45338590~45341990:-
THCA	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-8.79	2.94e-17	1.46e-14	-0.78	-0.38	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
THCA	cis	rs5769707	0.967	rs739248	ENSG00000235111.1	RP1-29C18.8	-8.78	2.94e-17	1.46e-14	-0.44	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49612657~49615716:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000235689.1	AP000351.13	8.78	2.95e-17	1.47e-14	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:24006305~24008258:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000235689.1	AP000351.13	8.78	2.95e-17	1.47e-14	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:24006305~24008258:-
THCA	cis	rs2836950	0.545	rs11700813	ENSG00000255568.3	BRWD1-AS2	-8.78	2.95e-17	1.47e-14	-0.3	-0.38	Menarche (age at onset);	chr21:39145543	chr21:39313935~39314962:+
THCA	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-8.78	2.96e-17	1.47e-14	-0.47	-0.38	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
THCA	cis	rs2946505	1	rs2977086	ENSG00000251468.2	RP11-369K16.1	8.78	2.97e-17	1.48e-14	0.49	0.38	Migraine;	chr8:12953436	chr8:12958387~12962200:+
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45338590~45341990:-
THCA	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	8.78	2.98e-17	1.48e-14	0.5	0.38	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
THCA	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	8.78	2.99e-17	1.49e-14	0.48	0.38	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-8.78	3e-17	1.49e-14	-0.47	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
THCA	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-8.78	3.01e-17	1.5e-14	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
THCA	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-8.78	3.03e-17	1.51e-14	-0.4	-0.38	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
THCA	cis	rs1707322	0.963	rs10890373	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.685	rs28617418	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.682	rs28490344	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs28641748	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs6697821	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4330955	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.691	rs12031182	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45651039~45651826:-
THCA	cis	rs11148252	0.669	rs61958050	ENSG00000278238.1	RP11-245D16.4	-8.78	3.04e-17	1.51e-14	-0.45	-0.38	Lewy body disease;	chr13:52420292	chr13:52454775~52455331:-
THCA	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	8.78	3.05e-17	1.52e-14	0.56	0.38	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000224205.1	AP000351.4	8.78	3.06e-17	1.52e-14	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23987320~23991421:-
THCA	cis	rs4819052	0.679	rs2236450	ENSG00000215447.6	BX322557.10	-8.78	3.07e-17	1.53e-14	-0.3	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45288052~45291738:+
THCA	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-8.78	3.09e-17	1.53e-14	-0.51	-0.38	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
THCA	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-8.78	3.11e-17	1.54e-14	-0.29	-0.38	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000237664.1	LINC00316	-8.78	3.11e-17	1.54e-14	-0.37	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45338590~45341990:-
THCA	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	8.78	3.11e-17	1.54e-14	0.44	0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
THCA	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	8.78	3.13e-17	1.56e-14	0.37	0.38	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	8.78	3.13e-17	1.56e-14	0.37	0.38	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
THCA	cis	rs4819052	0.851	rs11558445	ENSG00000215447.6	BX322557.10	-8.78	3.14e-17	1.56e-14	-0.3	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-8.78	3.14e-17	1.56e-14	-0.47	-0.38	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
THCA	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-8.77	3.18e-17	1.58e-14	-0.3	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
THCA	cis	rs7945705	0.791	rs7944560	ENSG00000254860.4	TMEM9B-AS1	-8.77	3.19e-17	1.58e-14	-0.4	-0.38	Hemoglobin concentration;	chr11:8795729	chr11:8964675~8977527:+
THCA	cis	rs853679	0.55	rs1233704	ENSG00000226314.6	ZNF192P1	8.77	3.19e-17	1.58e-14	0.49	0.38	Depression;	chr6:28199145	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1237875	ENSG00000226314.6	ZNF192P1	8.77	3.19e-17	1.58e-14	0.49	0.38	Depression;	chr6:28205232	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1225598	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28193021	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1150689	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28197321	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1225599	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28197412	chr6:28161781~28169594:+
THCA	cis	rs853679	0.574	rs1233705	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28198669	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1233707	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28205175	chr6:28161781~28169594:+
THCA	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
THCA	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	8.77	3.2e-17	1.59e-14	0.6	0.38	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
THCA	cis	rs10411161	1	rs3848562	ENSG00000269483.1	AC006272.1	-8.77	3.2e-17	1.59e-14	-0.51	-0.38	Breast cancer;	chr19:51876582	chr19:51839924~51843324:-
THCA	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-8.77	3.2e-17	1.59e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
THCA	cis	rs1707322	1	rs11211232	ENSG00000234329.1	RP11-767N6.2	8.77	3.21e-17	1.59e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000215447.6	BX322557.10	-8.77	3.22e-17	1.6e-14	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45288052~45291738:+
THCA	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	8.77	3.22e-17	1.6e-14	0.66	0.38	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
THCA	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-8.77	3.23e-17	1.6e-14	-0.5	-0.38	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	8.77	3.23e-17	1.6e-14	0.5	0.38	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
THCA	cis	rs7646881	1	rs59918529	ENSG00000240207.5	RP11-379F4.4	-8.77	3.23e-17	1.6e-14	-0.5	-0.38	Tetralogy of Fallot;	chr3:158734916	chr3:158732263~158784070:+
THCA	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-8.77	3.25e-17	1.61e-14	-0.4	-0.38	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
THCA	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-8.77	3.26e-17	1.62e-14	-0.29	-0.38	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000237664.1	LINC00316	-8.77	3.26e-17	1.62e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45338590~45341990:-
THCA	cis	rs28510890	0.51	rs3825982	ENSG00000260337.3	RP11-386M24.6	8.77	3.28e-17	1.62e-14	0.52	0.38	Lung cancer in ever smokers;	chr15:92617015	chr15:92592574~92596462:-
THCA	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-8.77	3.28e-17	1.63e-14	-0.38	-0.38	QT interval;	chr12:29319476	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-8.77	3.28e-17	1.63e-14	-0.38	-0.38	QT interval;	chr12:29320175	chr12:29280418~29317848:-
THCA	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	8.77	3.31e-17	1.64e-14	0.5	0.37	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
THCA	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	8.77	3.31e-17	1.64e-14	0.52	0.37	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	8.77	3.31e-17	1.64e-14	0.52	0.37	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	8.77	3.31e-17	1.64e-14	0.52	0.37	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
THCA	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	8.77	3.35e-17	1.66e-14	0.47	0.37	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
THCA	cis	rs1707322	1	rs1707317	ENSG00000234329.1	RP11-767N6.2	-8.77	3.35e-17	1.66e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-8.77	3.35e-17	1.66e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
THCA	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-8.77	3.36e-17	1.66e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-8.77	3.36e-17	1.66e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
THCA	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	8.77	3.36e-17	1.67e-14	0.58	0.37	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
THCA	cis	rs1707322	0.717	rs12023439	ENSG00000234329.1	RP11-767N6.2	8.77	3.38e-17	1.67e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45651039~45651826:-
THCA	cis	rs7727544	0.57	rs7701237	ENSG00000237714.1	P4HA2-AS1	8.77	3.38e-17	1.68e-14	0.47	0.37	Blood metabolite levels;	chr5:132198688	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.582	rs3749756	ENSG00000237714.1	P4HA2-AS1	8.77	3.38e-17	1.68e-14	0.47	0.37	Blood metabolite levels;	chr5:132198806	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.582	rs3805683	ENSG00000237714.1	P4HA2-AS1	8.77	3.38e-17	1.68e-14	0.47	0.37	Blood metabolite levels;	chr5:132199432	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.582	rs2278398	ENSG00000237714.1	P4HA2-AS1	-8.77	3.38e-17	1.68e-14	-0.47	-0.37	Blood metabolite levels;	chr5:132194748	chr5:132184876~132192808:+
THCA	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	8.77	3.39e-17	1.68e-14	0.85	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
THCA	cis	rs7727544	0.508	rs10900804	ENSG00000237714.1	P4HA2-AS1	8.77	3.39e-17	1.68e-14	0.5	0.37	Blood metabolite levels;	chr5:132066152	chr5:132184876~132192808:+
THCA	cis	rs1707322	0.721	rs11211149	ENSG00000234329.1	RP11-767N6.2	8.77	3.4e-17	1.68e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45651039~45651826:-
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-8.77	3.4e-17	1.69e-14	-0.49	-0.37	Gout;	chr7:66732812	chr7:66902857~66906297:+
THCA	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	8.77	3.42e-17	1.69e-14	0.27	0.37	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
THCA	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	8.77	3.42e-17	1.7e-14	0.57	0.37	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
THCA	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-8.76	3.44e-17	1.7e-14	-0.5	-0.37	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-8.76	3.44e-17	1.7e-14	-0.5	-0.37	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
THCA	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	8.76	3.45e-17	1.71e-14	0.64	0.37	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
THCA	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-8.76	3.45e-17	1.71e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-8.76	3.46e-17	1.71e-14	-0.49	-0.37	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
THCA	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-8.76	3.46e-17	1.71e-14	-0.45	-0.37	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
THCA	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	8.76	3.47e-17	1.72e-14	0.4	0.37	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
THCA	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	8.76	3.47e-17	1.72e-14	0.48	0.37	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
THCA	cis	rs748404	0.697	rs493177	ENSG00000249839.1	AC011330.5	-8.76	3.48e-17	1.72e-14	-0.44	-0.37	Lung cancer;	chr15:43251060	chr15:43663654~43684339:-
THCA	cis	rs8027521	0.521	rs17551329	ENSG00000280362.1	RP11-643A5.3	8.76	3.48e-17	1.72e-14	0.51	0.37	Circulating chemerin levels;	chr15:53926069	chr15:53910769~53914712:+
THCA	cis	rs1707322	1	rs785490	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785493	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs785496	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785497	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs785499	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45651039~45651826:-
THCA	cis	rs11148252	0.967	rs4286007	ENSG00000278238.1	RP11-245D16.4	-8.76	3.51e-17	1.74e-14	-0.41	-0.37	Lewy body disease;	chr13:52448383	chr13:52454775~52455331:-
THCA	cis	rs910316	0.692	rs7156586	ENSG00000279594.1	RP11-950C14.10	8.76	3.52e-17	1.74e-14	0.36	0.37	Height;	chr14:75039527	chr14:75011269~75012851:-
THCA	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-8.76	3.54e-17	1.75e-14	-0.55	-0.37	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
THCA	cis	rs2408955	0.5	rs12816820	ENSG00000258273.1	RP11-370I10.4	-8.76	3.54e-17	1.75e-14	-0.49	-0.37	Glycated hemoglobin levels;	chr12:48164542	chr12:48333755~48333901:-
THCA	cis	rs73081554	0.611	rs4681851	ENSG00000272360.1	RP11-359I18.5	-8.76	3.55e-17	1.75e-14	-0.52	-0.37	Rheumatoid arthritis;	chr3:58410164	chr3:58490830~58491291:-
THCA	cis	rs6600671	0.764	rs6600673	ENSG00000223345.3	HIST2H2BA	8.76	3.55e-17	1.76e-14	0.42	0.37	Hip geometry;	chr1:121426988	chr1:121108210~121117257:-
THCA	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	8.76	3.56e-17	1.76e-14	0.51	0.37	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
THCA	cis	rs1426063	0.614	rs17000261	ENSG00000260265.1	RP11-44F21.5	8.76	3.56e-17	1.76e-14	0.8	0.37	QT interval;	chr4:75108766	chr4:75081702~75084717:-
THCA	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-8.76	3.57e-17	1.77e-14	-0.45	-0.37	Temperament;	chr17:14042870	chr17:14024514~14025488:+
THCA	cis	rs5760092	0.755	rs915589	ENSG00000235689.1	AP000351.13	-8.76	3.58e-17	1.77e-14	-0.54	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:24006305~24008258:-
THCA	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	8.76	3.61e-17	1.78e-14	0.43	0.37	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-8.76	3.61e-17	1.78e-14	-0.43	-0.37	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
THCA	cis	rs11971779	0.938	rs11981688	ENSG00000273391.1	RP11-634H22.1	8.76	3.62e-17	1.79e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139404149	chr7:139359032~139359566:-
THCA	cis	rs7015263	0.689	rs7460286	ENSG00000254231.1	CTD-2284J15.1	-8.76	3.62e-17	1.79e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86322968	chr8:86333274~86343314:-
THCA	cis	rs9402743	0.632	rs6570028	ENSG00000231028.7	LINC00271	-8.76	3.62e-17	1.79e-14	-0.3	-0.37	Systemic lupus erythematosus;	chr6:135754784	chr6:135497801~135716055:+
THCA	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	8.76	3.62e-17	1.79e-14	0.37	0.37	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
THCA	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	8.76	3.63e-17	1.79e-14	0.47	0.37	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
THCA	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-8.76	3.63e-17	1.79e-14	-0.45	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
THCA	cis	rs1707322	1	rs4606257	ENSG00000234329.1	RP11-767N6.2	8.76	3.63e-17	1.8e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45651039~45651826:-
THCA	cis	rs10411161	0.657	rs67462252	ENSG00000269483.1	AC006272.1	8.76	3.64e-17	1.8e-14	0.52	0.37	Breast cancer;	chr19:51879598	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs8110073	ENSG00000269483.1	AC006272.1	8.76	3.64e-17	1.8e-14	0.52	0.37	Breast cancer;	chr19:51879870	chr19:51839924~51843324:-
THCA	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-8.76	3.65e-17	1.81e-14	-0.62	-0.37	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
THCA	cis	rs1707322	0.963	rs12145287	ENSG00000234329.1	RP11-767N6.2	8.76	3.66e-17	1.81e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45651039~45651826:-
THCA	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	8.76	3.67e-17	1.81e-14	0.44	0.37	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
THCA	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-8.76	3.67e-17	1.81e-14	-0.53	-0.37	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
THCA	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-8.76	3.67e-17	1.81e-14	-0.76	-0.37	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
THCA	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-8.76	3.7e-17	1.83e-14	-0.39	-0.37	QT interval;	chr12:29344573	chr12:29280418~29317848:-
THCA	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-8.75	3.71e-17	1.83e-14	-0.49	-0.37	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
THCA	cis	rs7015263	0.541	rs61117517	ENSG00000254231.1	CTD-2284J15.1	-8.75	3.71e-17	1.83e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86263167	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.573	rs4425734	ENSG00000254231.1	CTD-2284J15.1	-8.75	3.71e-17	1.83e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86265346	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.573	rs17680608	ENSG00000254231.1	CTD-2284J15.1	-8.75	3.71e-17	1.83e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86270695	chr8:86333274~86343314:-
THCA	cis	rs7727544	0.547	rs10076758	ENSG00000237714.1	P4HA2-AS1	8.75	3.71e-17	1.83e-14	0.47	0.37	Blood metabolite levels;	chr5:132188606	chr5:132184876~132192808:+
THCA	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	8.75	3.71e-17	1.83e-14	0.37	0.37	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
THCA	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	8.75	3.71e-17	1.83e-14	0.56	0.37	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
THCA	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-8.75	3.72e-17	1.84e-14	-0.39	-0.37	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
THCA	cis	rs5769707	0.935	rs5770594	ENSG00000235111.1	RP1-29C18.8	-8.75	3.75e-17	1.85e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.967	rs4524218	ENSG00000235111.1	RP1-29C18.8	-8.75	3.75e-17	1.85e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49612657~49615716:-
THCA	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	8.75	3.82e-17	1.88e-14	0.71	0.37	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	8.75	3.82e-17	1.88e-14	0.71	0.37	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	8.75	3.82e-17	1.88e-14	0.71	0.37	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	8.75	3.82e-17	1.88e-14	0.71	0.37	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
THCA	cis	rs9532669	0.889	rs7320344	ENSG00000239827.7	SUGT1P3	-8.75	3.82e-17	1.89e-14	-0.43	-0.37	Cervical cancer;	chr13:40885502	chr13:40908159~40921774:-
THCA	cis	rs3762637	0.769	rs13317855	ENSG00000272758.4	RP11-299J3.8	-8.75	3.83e-17	1.89e-14	-0.63	-0.37	LDL cholesterol levels;	chr3:122385387	chr3:122416207~122443180:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-8.75	3.84e-17	1.89e-14	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-8.75	3.84e-17	1.9e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
THCA	cis	rs7211079	0.879	rs72852522	ENSG00000275479.1	RP11-334C17.6	8.75	3.85e-17	1.9e-14	0.36	0.37	Myocardial infarction;	chr17:80157691	chr17:80149627~80149798:+
THCA	cis	rs7665090	1	rs7665090	ENSG00000246560.2	RP11-10L12.4	-8.75	3.85e-17	1.9e-14	-0.44	-0.37	Primary biliary cholangitis;	chr4:102630446	chr4:102828055~102844075:+
THCA	cis	rs516805	0.847	rs520046	ENSG00000279453.1	RP3-425C14.4	-8.75	3.85e-17	1.9e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122446048	chr6:122436789~122439223:-
THCA	cis	rs1426063	0.614	rs17000260	ENSG00000260265.1	RP11-44F21.5	8.75	3.87e-17	1.91e-14	0.79	0.37	QT interval;	chr4:75108576	chr4:75081702~75084717:-
THCA	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-8.75	3.88e-17	1.91e-14	-0.45	-0.37	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
THCA	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	8.75	3.91e-17	1.93e-14	0.52	0.37	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000235689.1	AP000351.13	8.75	3.91e-17	1.93e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:24006305~24008258:-
THCA	cis	rs9532669	0.926	rs2324747	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40988883	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs2324748	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40989452	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4245311	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40990003	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9525439	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40992645	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs35073784	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40993428	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs9594473	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40997997	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs1543589	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40999064	chr13:40908159~40921774:-
THCA	cis	rs7772486	0.875	rs2777482	ENSG00000235652.6	RP11-545I5.3	8.75	3.91e-17	1.93e-14	0.35	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145999205	chr6:145799409~145886585:+
THCA	cis	rs853679	0.55	rs1233699	ENSG00000226314.6	ZNF192P1	-8.75	3.92e-17	1.93e-14	-0.49	-0.37	Depression;	chr6:28201380	chr6:28161781~28169594:+
THCA	cis	rs11148252	0.967	rs11620062	ENSG00000278238.1	RP11-245D16.4	-8.75	3.92e-17	1.93e-14	-0.41	-0.37	Lewy body disease;	chr13:52419891	chr13:52454775~52455331:-
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	8.75	3.92e-17	1.93e-14	0.5	0.37	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	8.75	3.92e-17	1.93e-14	0.5	0.37	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
THCA	cis	rs10411161	0.702	rs7251929	ENSG00000269483.1	AC006272.1	8.75	3.93e-17	1.94e-14	0.52	0.37	Breast cancer;	chr19:51886005	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.64	rs7252303	ENSG00000269483.1	AC006272.1	8.75	3.93e-17	1.94e-14	0.52	0.37	Breast cancer;	chr19:51886104	chr19:51839924~51843324:-
THCA	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	8.75	3.93e-17	1.94e-14	0.56	0.37	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
THCA	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	8.75	3.94e-17	1.94e-14	0.4	0.37	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
THCA	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	8.75	3.95e-17	1.95e-14	0.51	0.37	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
THCA	cis	rs1707322	0.721	rs11211163	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12037803	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10789470	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs61784796	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10749856	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10890344	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4564187	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28438704	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs28442079	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.65	rs4553239	ENSG00000234329.1	RP11-767N6.2	8.75	3.97e-17	1.96e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45651039~45651826:-
THCA	cis	rs1799949	0.965	rs4793237	ENSG00000267681.1	CTD-3199J23.6	-8.75	3.98e-17	1.96e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43359227	chr17:43144956~43145255:+
THCA	cis	rs9659323	1	rs12073056	ENSG00000231365.4	RP11-418J17.1	-8.74	4e-17	1.97e-14	-0.37	-0.37	Body mass index;	chr1:118965777	chr1:119140396~119275973:+
THCA	cis	rs1707322	0.721	rs11211165	ENSG00000234329.1	RP11-767N6.2	8.74	4.01e-17	1.97e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211166	ENSG00000234329.1	RP11-767N6.2	8.74	4.01e-17	1.97e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7539800	ENSG00000234329.1	RP11-767N6.2	-8.74	4.02e-17	1.98e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45651039~45651826:-
THCA	cis	rs10411161	0.702	rs1433081	ENSG00000269483.1	AC006272.1	8.74	4.03e-17	1.98e-14	0.53	0.37	Breast cancer;	chr19:51887457	chr19:51839924~51843324:-
THCA	cis	rs11051970	0.559	rs11051991	ENSG00000274964.1	RP11-817I4.1	8.74	4.05e-17	1.99e-14	0.49	0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32410998	chr12:32339368~32340724:+
THCA	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	8.74	4.05e-17	1.99e-14	0.53	0.37	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
THCA	cis	rs9926296	0.744	rs352939	ENSG00000260259.1	RP11-368I7.4	8.74	4.06e-17	2e-14	0.41	0.37	Vitiligo;	chr16:89643970	chr16:89682620~89686569:-
THCA	cis	rs11051970	0.513	rs4931013	ENSG00000274964.1	RP11-817I4.1	-8.74	4.08e-17	2.01e-14	-0.48	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32407788	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.546	rs11051989	ENSG00000274964.1	RP11-817I4.1	-8.74	4.08e-17	2.01e-14	-0.48	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32407956	chr12:32339368~32340724:+
THCA	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	8.74	4.1e-17	2.01e-14	0.71	0.37	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
THCA	cis	rs4713118	0.738	rs200465	ENSG00000219392.1	RP1-265C24.5	-8.74	4.1e-17	2.01e-14	-0.49	-0.37	Parkinson's disease;	chr6:27789875	chr6:28115628~28116551:+
THCA	cis	rs9532669	0.926	rs4942014	ENSG00000239827.7	SUGT1P3	-8.74	4.13e-17	2.03e-14	-0.39	-0.37	Cervical cancer;	chr13:40966366	chr13:40908159~40921774:-
THCA	cis	rs7291412	0.601	rs7292407	ENSG00000231711.2	LINC00899	-8.74	4.13e-17	2.03e-14	-0.3	-0.37	Dupuytren's disease;Subjective well-being;	chr22:46057832	chr22:46039907~46044853:-
THCA	cis	rs17684571	0.751	rs7758867	ENSG00000231441.1	RP11-472M19.2	8.74	4.14e-17	2.04e-14	0.45	0.37	Schizophrenia;	chr6:56836000	chr6:56844002~56864078:+
THCA	cis	rs5769707	0.967	rs9616701	ENSG00000235111.1	RP1-29C18.8	-8.74	4.14e-17	2.04e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49612657~49615716:-
THCA	cis	rs6545883	0.507	rs59981505	ENSG00000271889.1	RP11-493E12.1	-8.74	4.15e-17	2.04e-14	-0.36	-0.37	Tuberculosis;	chr2:61353394	chr2:61151433~61162105:-
THCA	cis	rs4819052	0.565	rs35776291	ENSG00000215447.6	BX322557.10	-8.74	4.16e-17	2.05e-14	-0.3	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45288052~45291738:+
THCA	cis	rs12682352	0.652	rs3789843	ENSG00000253893.2	FAM85B	-8.74	4.17e-17	2.05e-14	-0.5	-0.37	Neuroticism;	chr8:8866747	chr8:8167819~8226614:-
THCA	cis	rs12682352	0.652	rs3827806	ENSG00000253893.2	FAM85B	-8.74	4.17e-17	2.05e-14	-0.5	-0.37	Neuroticism;	chr8:8866766	chr8:8167819~8226614:-
THCA	cis	rs910316	0.646	rs11546525	ENSG00000279594.1	RP11-950C14.10	8.74	4.18e-17	2.05e-14	0.36	0.37	Height;	chr14:75070678	chr14:75011269~75012851:-
THCA	cis	rs11148252	0.74	rs9596642	ENSG00000278238.1	RP11-245D16.4	8.74	4.18e-17	2.06e-14	0.43	0.37	Lewy body disease;	chr13:52326744	chr13:52454775~52455331:-
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000237664.1	LINC00316	-8.74	4.19e-17	2.06e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000237664.1	LINC00316	-8.74	4.19e-17	2.06e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45338590~45341990:-
THCA	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	8.74	4.21e-17	2.07e-14	0.48	0.37	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
THCA	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	8.74	4.21e-17	2.07e-14	0.51	0.37	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
THCA	cis	rs1707322	1	rs4074225	ENSG00000234329.1	RP11-767N6.2	8.74	4.21e-17	2.07e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4134387	ENSG00000234329.1	RP11-767N6.2	8.74	4.21e-17	2.07e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890376	ENSG00000234329.1	RP11-767N6.2	8.74	4.21e-17	2.07e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10789485	ENSG00000234329.1	RP11-767N6.2	8.74	4.21e-17	2.07e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45651039~45651826:-
THCA	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	8.74	4.22e-17	2.07e-14	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
THCA	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-8.74	4.24e-17	2.08e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
THCA	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	8.74	4.25e-17	2.09e-14	0.47	0.37	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
THCA	cis	rs10740039	0.81	rs4440977	ENSG00000254271.1	RP11-131N11.4	8.74	4.26e-17	2.09e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60618163	chr10:60734342~60741828:+
THCA	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-8.74	4.28e-17	2.1e-14	-0.5	-0.37	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
THCA	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-8.74	4.28e-17	2.1e-14	-0.4	-0.37	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
THCA	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	8.74	4.29e-17	2.11e-14	0.73	0.37	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-8.74	4.29e-17	2.11e-14	-0.47	-0.37	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-8.74	4.29e-17	2.11e-14	-0.47	-0.37	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
THCA	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-8.74	4.29e-17	2.11e-14	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
THCA	cis	rs4591358	0.731	rs34634374	ENSG00000223466.1	AC064834.2	-8.74	4.3e-17	2.11e-14	-0.52	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509437	chr2:195533035~195538681:+
THCA	cis	rs5769707	0.839	rs73176988	ENSG00000235111.1	RP1-29C18.8	-8.73	4.31e-17	2.12e-14	-0.45	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49612657~49615716:-
THCA	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-8.73	4.32e-17	2.12e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000237664.1	LINC00316	8.73	4.32e-17	2.12e-14	0.37	0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45338590~45341990:-
THCA	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	8.73	4.33e-17	2.12e-14	0.37	0.37	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	8.73	4.33e-17	2.12e-14	0.37	0.37	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
THCA	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-8.73	4.34e-17	2.13e-14	-0.5	-0.37	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-8.73	4.35e-17	2.14e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-8.73	4.35e-17	2.14e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
THCA	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-8.73	4.37e-17	2.14e-14	-0.46	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
THCA	cis	rs6061231	0.701	rs6061505	ENSG00000273619.1	RP5-908M14.9	-8.73	4.37e-17	2.15e-14	-0.28	-0.37	Colorectal cancer;	chr20:62385155	chr20:62386303~62386970:-
THCA	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-8.73	4.38e-17	2.15e-14	-0.45	-0.37	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-8.73	4.38e-17	2.15e-14	-0.45	-0.37	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-8.73	4.38e-17	2.15e-14	-0.45	-0.37	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-8.73	4.38e-17	2.15e-14	-0.45	-0.37	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000224205.1	AP000351.4	-8.73	4.38e-17	2.15e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23987320~23991421:-
THCA	cis	rs2033711	0.755	rs4801587	ENSG00000268912.1	CTD-2619J13.17	-8.73	4.4e-17	2.16e-14	-0.29	-0.37	Uric acid clearance;	chr19:58425312	chr19:58428632~58431148:-
THCA	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-8.73	4.4e-17	2.16e-14	-0.51	-0.37	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	8.73	4.42e-17	2.17e-14	0.51	0.37	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
THCA	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-8.73	4.43e-17	2.17e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
THCA	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-8.73	4.43e-17	2.17e-14	-0.38	-0.37	QT interval;	chr12:29306799	chr12:29280418~29317848:-
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000237664.1	LINC00316	-8.73	4.43e-17	2.18e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45338590~45341990:-
THCA	cis	rs1707322	0.789	rs7540578	ENSG00000234329.1	RP11-767N6.2	8.73	4.47e-17	2.19e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45651039~45651826:-
THCA	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-8.73	4.47e-17	2.19e-14	-0.3	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
THCA	cis	rs11051970	0.559	rs2291420	ENSG00000274964.1	RP11-817I4.1	-8.73	4.47e-17	2.19e-14	-0.46	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32334816	chr12:32339368~32340724:+
THCA	cis	rs748404	0.723	rs512431	ENSG00000249839.1	AC011330.5	8.73	4.47e-17	2.19e-14	0.44	0.37	Lung cancer;	chr15:43249741	chr15:43663654~43684339:-
THCA	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-8.73	4.48e-17	2.2e-14	-0.53	-0.37	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
THCA	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-8.73	4.5e-17	2.21e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
THCA	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-8.73	4.5e-17	2.21e-14	-0.44	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
THCA	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-8.73	4.5e-17	2.21e-14	-0.44	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
THCA	cis	rs7015263	0.689	rs5024450	ENSG00000254231.1	CTD-2284J15.1	8.73	4.54e-17	2.23e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86352009	chr8:86333274~86343314:-
THCA	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	8.73	4.54e-17	2.23e-14	0.24	0.37	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	8.73	4.54e-17	2.23e-14	0.24	0.37	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	8.73	4.54e-17	2.23e-14	0.24	0.37	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
THCA	cis	rs9659323	1	rs9659323	ENSG00000231365.4	RP11-418J17.1	-8.73	4.54e-17	2.23e-14	-0.38	-0.37	Body mass index;	chr1:118961738	chr1:119140396~119275973:+
THCA	cis	rs9659323	1	rs9658899	ENSG00000231365.4	RP11-418J17.1	-8.73	4.54e-17	2.23e-14	-0.38	-0.37	Body mass index;	chr1:118961920	chr1:119140396~119275973:+
THCA	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	8.73	4.55e-17	2.23e-14	0.46	0.37	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
THCA	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-8.73	4.55e-17	2.23e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
THCA	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-8.73	4.55e-17	2.23e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
THCA	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	8.73	4.55e-17	2.23e-14	0.56	0.37	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	8.73	4.55e-17	2.23e-14	0.56	0.37	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	8.73	4.56e-17	2.23e-14	0.44	0.37	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
THCA	cis	rs1707322	0.691	rs61784803	ENSG00000234329.1	RP11-767N6.2	-8.73	4.56e-17	2.23e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.663	rs3935296	ENSG00000234329.1	RP11-767N6.2	-8.73	4.56e-17	2.23e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs28817701	ENSG00000234329.1	RP11-767N6.2	8.73	4.56e-17	2.23e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.691	rs28495425	ENSG00000234329.1	RP11-767N6.2	8.73	4.56e-17	2.23e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45651039~45651826:-
THCA	cis	rs17684571	0.7	rs34520435	ENSG00000231441.1	RP11-472M19.2	8.73	4.56e-17	2.24e-14	0.48	0.37	Schizophrenia;	chr6:56818319	chr6:56844002~56864078:+
THCA	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-8.73	4.57e-17	2.24e-14	-0.3	-0.37	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
THCA	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-8.73	4.58e-17	2.24e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-8.73	4.58e-17	2.24e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-8.73	4.58e-17	2.24e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-8.73	4.58e-17	2.24e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
THCA	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-8.73	4.58e-17	2.25e-14	-0.56	-0.37	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
THCA	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	8.73	4.58e-17	2.25e-14	0.64	0.37	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
THCA	cis	rs11971779	0.646	rs58682779	ENSG00000273391.1	RP11-634H22.1	8.73	4.59e-17	2.25e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139399966	chr7:139359032~139359566:-
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-8.73	4.59e-17	2.25e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-8.73	4.59e-17	2.25e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
THCA	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	8.73	4.6e-17	2.25e-14	0.51	0.37	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
THCA	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
THCA	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
THCA	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-8.73	4.63e-17	2.27e-14	-0.38	-0.37	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
THCA	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	8.73	4.63e-17	2.27e-14	0.47	0.37	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
THCA	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	8.73	4.64e-17	2.27e-14	0.38	0.37	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
THCA	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	8.73	4.64e-17	2.27e-14	0.42	0.37	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
THCA	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-8.72	4.65e-17	2.28e-14	-0.3	-0.37	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
THCA	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	8.72	4.65e-17	2.28e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
THCA	cis	rs2836950	0.501	rs2070865	ENSG00000255568.3	BRWD1-AS2	-8.72	4.68e-17	2.29e-14	-0.31	-0.37	Menarche (age at onset);	chr21:39343593	chr21:39313935~39314962:+
THCA	cis	rs642803	0.613	rs565427	ENSG00000214659.4	KRT8P26	-8.72	4.69e-17	2.3e-14	-0.33	-0.37	Urate levels;	chr11:65765354	chr11:65726939~65728214:+
THCA	cis	rs6723226	0.572	rs176411	ENSG00000276334.1	AL133243.1	8.72	4.71e-17	2.31e-14	0.41	0.37	Intelligence (multi-trait analysis);	chr2:32418460	chr2:32521927~32523547:+
THCA	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-8.72	4.72e-17	2.31e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	8.72	4.72e-17	2.31e-14	0.48	0.37	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
THCA	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-8.72	4.73e-17	2.31e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
THCA	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-8.72	4.73e-17	2.32e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-8.72	4.73e-17	2.32e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-8.72	4.73e-17	2.32e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
THCA	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-8.72	4.74e-17	2.32e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
THCA	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-8.72	4.75e-17	2.33e-14	-0.46	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
THCA	cis	rs7727544	0.582	rs10478998	ENSG00000237714.1	P4HA2-AS1	8.72	4.76e-17	2.33e-14	0.47	0.37	Blood metabolite levels;	chr5:132180838	chr5:132184876~132192808:+
THCA	cis	rs5769707	0.967	rs2071904	ENSG00000235111.1	RP1-29C18.8	-8.72	4.76e-17	2.33e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49612657~49615716:-
THCA	cis	rs7665090	0.967	rs5026469	ENSG00000246560.2	RP11-10L12.4	8.72	4.76e-17	2.33e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633556	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs5026470	ENSG00000246560.2	RP11-10L12.4	8.72	4.76e-17	2.33e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633565	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs5026471	ENSG00000246560.2	RP11-10L12.4	8.72	4.76e-17	2.33e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633576	chr4:102828055~102844075:+
THCA	cis	rs4819052	0.851	rs914218	ENSG00000237664.1	LINC00316	-8.72	4.78e-17	2.34e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45338590~45341990:-
THCA	cis	rs673078	0.607	rs61944671	ENSG00000275409.1	RP11-131L12.4	-8.72	4.78e-17	2.34e-14	-0.46	-0.37	Glucose homeostasis traits;	chr12:118450046	chr12:118430147~118430699:+
THCA	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-8.72	4.8e-17	2.35e-14	-0.38	-0.37	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
THCA	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-8.72	4.8e-17	2.35e-14	-0.44	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000237664.1	LINC00316	-8.72	4.8e-17	2.35e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45338590~45341990:-
THCA	cis	rs12188164	0.575	rs112126699	ENSG00000221990.4	EXOC3-AS1	8.72	4.81e-17	2.35e-14	0.32	0.37	Cystic fibrosis severity;	chr5:419347	chr5:441498~443160:-
THCA	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-8.72	4.83e-17	2.36e-14	-0.5	-0.37	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-8.72	4.83e-17	2.36e-14	-0.5	-0.37	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
THCA	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-8.72	4.83e-17	2.36e-14	-0.46	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
THCA	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-8.72	4.85e-17	2.37e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
THCA	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	8.72	4.85e-17	2.37e-14	0.48	0.37	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
THCA	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-8.72	4.85e-17	2.37e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
THCA	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	8.72	4.85e-17	2.37e-14	0.47	0.37	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
THCA	cis	rs6844153	0.887	rs62302533	ENSG00000240005.4	RP11-293A21.1	-8.72	4.86e-17	2.38e-14	-0.5	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26955309	chr4:26859806~26860599:-
THCA	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-8.72	4.9e-17	2.39e-14	-0.39	-0.37	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
THCA	cis	rs860295	0.557	rs348196	ENSG00000225855.5	RUSC1-AS1	8.72	4.9e-17	2.4e-14	0.27	0.37	Body mass index;	chr1:155697170	chr1:155316863~155324176:-
THCA	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	8.72	4.9e-17	2.4e-14	0.24	0.37	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
THCA	cis	rs934734	0.673	rs754110	ENSG00000234255.7	AC012370.3	8.72	4.91e-17	2.4e-14	0.41	0.37	Rheumatoid arthritis;	chr2:65464626	chr2:65439888~65456571:-
THCA	cis	rs8114671	0.935	rs6058198	ENSG00000269202.1	RP4-614O4.12	-8.72	4.91e-17	2.4e-14	-0.32	-0.37	Height;	chr20:35160450	chr20:35201747~35203288:-
THCA	cis	rs9532669	0.889	rs1989252	ENSG00000239827.7	SUGT1P3	8.72	4.94e-17	2.41e-14	0.4	0.37	Cervical cancer;	chr13:40911532	chr13:40908159~40921774:-
THCA	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	8.72	4.96e-17	2.42e-14	0.52	0.37	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
THCA	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-8.72	4.98e-17	2.43e-14	-0.43	-0.37	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-8.72	4.98e-17	2.43e-14	-0.43	-0.37	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
THCA	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	8.72	4.98e-17	2.44e-14	0.55	0.37	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
THCA	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	8.72	4.98e-17	2.44e-14	0.42	0.37	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
THCA	cis	rs2522056	0.808	rs7704457	ENSG00000233006.5	AC034220.3	8.72	4.99e-17	2.44e-14	0.33	0.37	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132311285~132369916:-
THCA	cis	rs7015263	0.689	rs56039487	ENSG00000254231.1	CTD-2284J15.1	-8.72	4.99e-17	2.44e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86347208	chr8:86333274~86343314:-
THCA	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	8.72	5e-17	2.44e-14	0.37	0.37	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
THCA	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-8.72	5e-17	2.44e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000237664.1	LINC00316	-8.71	5.04e-17	2.46e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45338590~45341990:-
THCA	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-8.71	5.04e-17	2.46e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-8.71	5.04e-17	2.46e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
THCA	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	8.71	5.05e-17	2.46e-14	0.42	0.37	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
THCA	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	8.71	5.06e-17	2.47e-14	0.51	0.37	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	8.71	5.06e-17	2.47e-14	0.51	0.37	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
THCA	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-8.71	5.08e-17	2.48e-14	-0.36	-0.37	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
THCA	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-8.71	5.1e-17	2.49e-14	-0.46	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
THCA	cis	rs1707322	0.662	rs11211160	ENSG00000234329.1	RP11-767N6.2	8.71	5.1e-17	2.49e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4559551	ENSG00000234329.1	RP11-767N6.2	8.71	5.12e-17	2.5e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45651039~45651826:-
THCA	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	8.71	5.13e-17	2.5e-14	0.43	0.37	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
THCA	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	8.71	5.14e-17	2.51e-14	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	8.71	5.14e-17	2.51e-14	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
THCA	cis	rs4819052	1	rs2838847	ENSG00000215447.6	BX322557.10	-8.71	5.14e-17	2.51e-14	-0.33	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45288052~45291738:+
THCA	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-8.71	5.16e-17	2.52e-14	-0.3	-0.37	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
THCA	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-8.71	5.17e-17	2.52e-14	-0.3	-0.37	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
THCA	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	8.71	5.17e-17	2.52e-14	0.51	0.37	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
THCA	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-8.71	5.17e-17	2.52e-14	-0.37	-0.37	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
THCA	cis	rs28510890	0.828	rs78417563	ENSG00000260337.3	RP11-386M24.6	8.71	5.17e-17	2.52e-14	0.46	0.37	Lung cancer in ever smokers;	chr15:92580224	chr15:92592574~92596462:-
THCA	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-8.71	5.17e-17	2.52e-14	-0.44	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
THCA	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-8.71	5.2e-17	2.54e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-8.71	5.2e-17	2.54e-14	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
THCA	cis	rs7015263	0.689	rs4961190	ENSG00000254231.1	CTD-2284J15.1	-8.71	5.21e-17	2.54e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86402670	chr8:86333274~86343314:-
THCA	cis	rs7727544	0.647	rs7721882	ENSG00000237714.1	P4HA2-AS1	8.71	5.22e-17	2.54e-14	0.5	0.37	Blood metabolite levels;	chr5:132083255	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.625	rs3864277	ENSG00000237714.1	P4HA2-AS1	8.71	5.22e-17	2.54e-14	0.5	0.37	Blood metabolite levels;	chr5:132084556	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.647	rs6898270	ENSG00000237714.1	P4HA2-AS1	8.71	5.22e-17	2.54e-14	0.5	0.37	Blood metabolite levels;	chr5:132085497	chr5:132184876~132192808:+
THCA	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-8.71	5.22e-17	2.55e-14	-0.3	-0.37	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
THCA	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	8.71	5.23e-17	2.55e-14	0.24	0.37	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
THCA	cis	rs7291412	1	rs7291412	ENSG00000231711.2	LINC00899	8.71	5.24e-17	2.55e-14	0.32	0.37	Dupuytren's disease;Subjective well-being;	chr22:46063252	chr22:46039907~46044853:-
THCA	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-8.71	5.26e-17	2.56e-14	-0.47	-0.37	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
THCA	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-8.71	5.27e-17	2.57e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
THCA	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-8.71	5.27e-17	2.57e-14	-0.43	-0.37	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
THCA	cis	rs7851660	0.967	rs4743134	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97836286	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs4743135	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97837211	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs7049054	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97837687	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs7860598	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97838420	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.935	rs10818124	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97840726	chr9:97805935~97810008:-
THCA	cis	rs1799949	0.965	rs8176310	ENSG00000267681.1	CTD-3199J23.6	-8.71	5.28e-17	2.58e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43047896	chr17:43144956~43145255:+
THCA	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-8.71	5.29e-17	2.58e-14	-0.38	-0.37	Height;	chr11:118737916	chr11:118704607~118750263:+
THCA	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
THCA	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-8.71	5.32e-17	2.59e-14	-0.42	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.935	rs1109320	ENSG00000235111.1	RP1-29C18.8	-8.71	5.33e-17	2.6e-14	-0.45	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49612657~49615716:-
THCA	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-8.71	5.34e-17	2.6e-14	-0.48	-0.37	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
THCA	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-8.71	5.34e-17	2.6e-14	-0.48	-0.37	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
THCA	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	8.71	5.34e-17	2.6e-14	0.48	0.37	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	8.71	5.34e-17	2.6e-14	0.48	0.37	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
THCA	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	8.71	5.34e-17	2.6e-14	0.48	0.37	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
THCA	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-8.71	5.37e-17	2.62e-14	-0.41	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
THCA	cis	rs2274273	0.682	rs7151224	ENSG00000258413.1	RP11-665C16.6	-8.71	5.39e-17	2.63e-14	-0.49	-0.37	Protein biomarker;	chr14:55050544	chr14:55262767~55272075:-
THCA	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-8.71	5.4e-17	2.63e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
THCA	cis	rs4713118	0.739	rs2893931	ENSG00000219392.1	RP1-265C24.5	-8.71	5.41e-17	2.63e-14	-0.49	-0.37	Parkinson's disease;	chr6:27780231	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.824	rs2092075	ENSG00000219392.1	RP1-265C24.5	-8.71	5.41e-17	2.63e-14	-0.49	-0.37	Parkinson's disease;	chr6:27781551	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.824	rs13211701	ENSG00000219392.1	RP1-265C24.5	-8.71	5.41e-17	2.63e-14	-0.49	-0.37	Parkinson's disease;	chr6:27782300	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.824	rs9468229	ENSG00000219392.1	RP1-265C24.5	-8.71	5.41e-17	2.63e-14	-0.49	-0.37	Parkinson's disease;	chr6:27782307	chr6:28115628~28116551:+
THCA	cis	rs13129231	0.882	rs6835088	ENSG00000206820.1	RNU1-138P	-8.7	5.42e-17	2.64e-14	-0.46	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113436700	chr4:113420323~113420486:+
THCA	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-8.7	5.46e-17	2.66e-14	-0.55	-0.37	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
THCA	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	8.7	5.47e-17	2.67e-14	0.51	0.37	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
THCA	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-8.7	5.48e-17	2.67e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
THCA	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	8.7	5.48e-17	2.67e-14	0.44	0.37	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
THCA	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-8.7	5.52e-17	2.69e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
THCA	cis	rs673078	0.607	rs7307393	ENSG00000275409.1	RP11-131L12.4	-8.7	5.52e-17	2.69e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118308537	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17440669	ENSG00000275409.1	RP11-131L12.4	-8.7	5.52e-17	2.69e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118310397	chr12:118430147~118430699:+
THCA	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-8.7	5.53e-17	2.69e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
THCA	cis	rs7569084	0.687	rs4671663	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65434400	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs11692813	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65435172	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.663	rs11126037	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65436024	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs11126038	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65436100	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.663	rs11694714	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65436802	chr2:65439888~65456571:-
THCA	cis	rs7015263	0.666	rs10956802	ENSG00000254231.1	CTD-2284J15.1	-8.7	5.54e-17	2.69e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86350477	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs7835743	ENSG00000254231.1	CTD-2284J15.1	-8.7	5.54e-17	2.69e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86365089	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs57326273	ENSG00000254231.1	CTD-2284J15.1	-8.7	5.54e-17	2.69e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86408714	chr8:86333274~86343314:-
THCA	cis	rs1707322	1	rs785510	ENSG00000234329.1	RP11-767N6.2	-8.7	5.55e-17	2.7e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45651039~45651826:-
THCA	cis	rs7015263	0.689	rs56365416	ENSG00000254231.1	CTD-2284J15.1	-8.7	5.56e-17	2.7e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86469187	chr8:86333274~86343314:-
THCA	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-8.7	5.57e-17	2.71e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-8.7	5.57e-17	2.71e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
THCA	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	8.7	5.58e-17	2.71e-14	0.38	0.37	QT interval;	chr12:29310426	chr12:29280418~29317848:-
THCA	cis	rs13129231	0.882	rs2882986	ENSG00000206820.1	RNU1-138P	-8.7	5.58e-17	2.72e-14	-0.46	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113434504	chr4:113420323~113420486:+
THCA	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-8.7	5.59e-17	2.72e-14	-0.38	-0.37	Height;	chr11:118742526	chr11:118704607~118750263:+
THCA	cis	rs2274273	0.623	rs1187877	ENSG00000258413.1	RP11-665C16.6	8.7	5.59e-17	2.72e-14	0.5	0.37	Protein biomarker;	chr14:55028443	chr14:55262767~55272075:-
THCA	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	8.7	5.63e-17	2.74e-14	0.44	0.37	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
THCA	cis	rs1707322	0.827	rs10890347	ENSG00000234329.1	RP11-767N6.2	-8.7	5.64e-17	2.74e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45651039~45651826:-
THCA	cis	rs7727544	0.557	rs2897096	ENSG00000237714.1	P4HA2-AS1	8.7	5.64e-17	2.74e-14	0.47	0.37	Blood metabolite levels;	chr5:132150591	chr5:132184876~132192808:+
THCA	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-8.7	5.66e-17	2.75e-14	-0.47	-0.37	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
THCA	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-8.7	5.67e-17	2.76e-14	-0.38	-0.37	QT interval;	chr12:29321177	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-8.7	5.67e-17	2.76e-14	-0.38	-0.37	QT interval;	chr12:29321323	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-8.7	5.67e-17	2.76e-14	-0.38	-0.37	QT interval;	chr12:29322770	chr12:29280418~29317848:-
THCA	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	8.7	5.67e-17	2.76e-14	0.44	0.37	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
THCA	cis	rs3847687	1	rs3847688	ENSG00000256810.1	RP11-76C10.2	8.7	5.68e-17	2.76e-14	0.44	0.37	Longevity;	chr12:131040765	chr12:131030570~131035487:-
THCA	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	8.7	5.68e-17	2.76e-14	0.44	0.37	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	8.7	5.68e-17	2.76e-14	0.44	0.37	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	8.7	5.68e-17	2.76e-14	0.44	0.37	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	8.7	5.69e-17	2.76e-14	0.5	0.37	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
THCA	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	8.7	5.7e-17	2.77e-14	0.61	0.37	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
THCA	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	8.7	5.7e-17	2.77e-14	0.61	0.37	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
THCA	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-8.7	5.7e-17	2.77e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
THCA	cis	rs11133665	0.683	rs7719875	ENSG00000249201.2	CTD-3080P12.3	8.7	5.71e-17	2.78e-14	0.44	0.37	Urinary metabolites;	chr5:1189973	chr5:1173141~1178605:-
THCA	cis	rs9659323	1	rs56897173	ENSG00000231365.4	RP11-418J17.1	-8.7	5.72e-17	2.78e-14	-0.37	-0.37	Body mass index;	chr1:118973109	chr1:119140396~119275973:+
THCA	cis	rs1707322	0.964	rs12067716	ENSG00000234329.1	RP11-767N6.2	8.7	5.73e-17	2.78e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45651039~45651826:-
THCA	cis	rs853679	0.55	rs1233701	ENSG00000226314.6	ZNF192P1	8.7	5.73e-17	2.79e-14	0.49	0.37	Depression;	chr6:28200948	chr6:28161781~28169594:+
THCA	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-8.7	5.73e-17	2.79e-14	-0.46	-0.37	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
THCA	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-8.7	5.76e-17	2.8e-14	-0.44	-0.37	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
THCA	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	-8.7	5.76e-17	2.8e-14	-0.4	-0.37	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
THCA	cis	rs934734	0.673	rs7575614	ENSG00000234255.7	AC012370.3	8.7	5.79e-17	2.81e-14	0.4	0.37	Rheumatoid arthritis;	chr2:65462666	chr2:65439888~65456571:-
THCA	cis	rs934734	0.673	rs6742215	ENSG00000234255.7	AC012370.3	8.7	5.79e-17	2.81e-14	0.4	0.37	Rheumatoid arthritis;	chr2:65463362	chr2:65439888~65456571:-
THCA	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	8.7	5.81e-17	2.82e-14	0.61	0.37	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
THCA	cis	rs1707322	1	rs10890382	ENSG00000234329.1	RP11-767N6.2	8.7	5.81e-17	2.82e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660335	ENSG00000234329.1	RP11-767N6.2	8.7	5.81e-17	2.82e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45651039~45651826:-
THCA	cis	rs9659323	1	rs10923714	ENSG00000231365.4	RP11-418J17.1	-8.7	5.81e-17	2.82e-14	-0.37	-0.37	Body mass index;	chr1:118970290	chr1:119140396~119275973:+
THCA	cis	rs7586673	0.866	rs747003	ENSG00000227403.1	AC009299.3	8.7	5.81e-17	2.82e-14	0.44	0.37	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161244739~161249050:+
THCA	cis	rs9516	0.544	rs664679	ENSG00000254974.1	RP11-702H23.2	8.7	5.82e-17	2.83e-14	0.4	0.37	Facial morphology (factor 15, philtrum width);	chr11:74475254	chr11:74485580~74486051:-
THCA	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	8.7	5.82e-17	2.83e-14	0.38	0.37	QT interval;	chr12:29292489	chr12:29280418~29317848:-
THCA	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-8.7	5.83e-17	2.83e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-8.7	5.83e-17	2.83e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
THCA	cis	rs2033711	0.87	rs1465789	ENSG00000268912.1	CTD-2619J13.17	-8.69	5.89e-17	2.86e-14	-0.29	-0.37	Uric acid clearance;	chr19:58434689	chr19:58428632~58431148:-
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000237664.1	LINC00316	-8.69	5.92e-17	2.87e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45338590~45341990:-
THCA	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	8.69	5.93e-17	2.88e-14	0.51	0.37	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
THCA	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-8.69	5.95e-17	2.89e-14	-0.36	-0.37	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000224205.1	AP000351.4	8.69	5.95e-17	2.89e-14	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23987320~23991421:-
THCA	cis	rs7851660	0.967	rs7847126	ENSG00000236130.1	PTCSC2	-8.69	5.96e-17	2.89e-14	-0.28	-0.37	Strep throat;	chr9:97838353	chr9:97805935~97810008:-
THCA	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-8.69	5.96e-17	2.9e-14	-0.48	-0.37	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-8.69	5.99e-17	2.91e-14	-0.48	-0.37	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
THCA	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	8.69	6.03e-17	2.93e-14	0.44	0.37	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
THCA	cis	rs2274273	0.712	rs7144652	ENSG00000258413.1	RP11-665C16.6	-8.69	6.04e-17	2.93e-14	-0.49	-0.37	Protein biomarker;	chr14:55071000	chr14:55262767~55272075:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	8.69	6.07e-17	2.94e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
THCA	cis	rs17684571	0.7	rs13208409	ENSG00000231441.1	RP11-472M19.2	8.69	6.07e-17	2.95e-14	0.51	0.37	Schizophrenia;	chr6:56763747	chr6:56844002~56864078:+
THCA	cis	rs12922040	0.607	rs11641649	ENSG00000263335.1	AF001548.5	-8.69	6.08e-17	2.95e-14	-0.41	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15773707	chr16:15726674~15732993:+
THCA	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	8.69	6.08e-17	2.95e-14	0.3	0.37	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
THCA	cis	rs9659323	1	rs6700415	ENSG00000231365.4	RP11-418J17.1	-8.69	6.08e-17	2.95e-14	-0.37	-0.37	Body mass index;	chr1:118973551	chr1:119140396~119275973:+
THCA	cis	rs7665090	0.967	rs6533022	ENSG00000246560.2	RP11-10L12.4	8.69	6.08e-17	2.95e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637794	chr4:102828055~102844075:+
THCA	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-8.69	6.14e-17	2.98e-14	-0.29	-0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
THCA	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	8.69	6.17e-17	2.99e-14	0.39	0.37	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
THCA	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	8.69	6.18e-17	2.99e-14	0.44	0.37	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
THCA	cis	rs7727544	0.606	rs10060615	ENSG00000237714.1	P4HA2-AS1	8.69	6.19e-17	3e-14	0.48	0.37	Blood metabolite levels;	chr5:132373185	chr5:132184876~132192808:+
THCA	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	8.69	6.22e-17	3.02e-14	0.4	0.37	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
THCA	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	8.69	6.23e-17	3.02e-14	0.77	0.37	QT interval;	chr4:75108836	chr4:75081702~75084717:-
THCA	cis	rs7015263	0.689	rs7819454	ENSG00000254231.1	CTD-2284J15.1	8.69	6.24e-17	3.03e-14	0.38	0.37	Intelligence (multi-trait analysis);	chr8:86344120	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs10103691	ENSG00000254231.1	CTD-2284J15.1	8.69	6.24e-17	3.03e-14	0.38	0.37	Intelligence (multi-trait analysis);	chr8:86344683	chr8:86333274~86343314:-
THCA	cis	rs4713118	0.824	rs742046	ENSG00000219392.1	RP1-265C24.5	-8.69	6.27e-17	3.04e-14	-0.5	-0.37	Parkinson's disease;	chr6:27771475	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000235689.1	AP000351.13	-8.69	6.27e-17	3.04e-14	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:24006305~24008258:-
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000237664.1	LINC00316	-8.69	6.29e-17	3.05e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45338590~45341990:-
THCA	cis	rs17684571	0.81	rs41267675	ENSG00000231441.1	RP11-472M19.2	8.69	6.3e-17	3.05e-14	0.52	0.37	Schizophrenia;	chr6:56735323	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34566275	ENSG00000231441.1	RP11-472M19.2	8.69	6.3e-17	3.05e-14	0.52	0.37	Schizophrenia;	chr6:56740130	chr6:56844002~56864078:+
THCA	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-8.68	6.3e-17	3.05e-14	-0.38	-0.37	QT interval;	chr12:29303562	chr12:29280418~29317848:-
THCA	cis	rs516805	0.63	rs499825	ENSG00000279453.1	RP3-425C14.4	-8.68	6.31e-17	3.06e-14	-0.38	-0.37	Lymphocyte counts;	chr6:122454050	chr6:122436789~122439223:-
THCA	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-8.68	6.32e-17	3.06e-14	-0.49	-0.37	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-8.68	6.33e-17	3.07e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
THCA	cis	rs12931792	0.875	rs58175255	ENSG00000183604.13	SMG1P5	8.68	6.33e-17	3.07e-14	0.38	0.37	Tonsillectomy;	chr16:30143969	chr16:30267553~30335374:-
THCA	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-8.68	6.35e-17	3.07e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
THCA	cis	rs2288884	0.579	rs6509603	ENSG00000275055.1	CTC-471J1.11	-8.68	6.35e-17	3.08e-14	-0.36	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51960977	chr19:52049007~52049754:+
THCA	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	8.68	6.35e-17	3.08e-14	0.45	0.37	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
THCA	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	8.68	6.36e-17	3.08e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
THCA	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	8.68	6.36e-17	3.08e-14	0.5	0.37	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
THCA	cis	rs7015263	0.689	rs10093379	ENSG00000254231.1	CTD-2284J15.1	8.68	6.36e-17	3.08e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86435831	chr8:86333274~86343314:-
THCA	cis	rs7665090	1	rs5026472	ENSG00000246560.2	RP11-10L12.4	8.68	6.36e-17	3.08e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633616	chr4:102828055~102844075:+
THCA	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	8.68	6.37e-17	3.09e-14	0.37	0.37	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
THCA	cis	rs2032366	0.63	rs1377172	ENSG00000267279.1	RP11-879F14.2	-8.68	6.38e-17	3.09e-14	-0.39	-0.37	Obesity-related traits;	chr18:61629148	chr18:61585746~61606916:-
THCA	cis	rs2032366	0.63	rs12457579	ENSG00000267279.1	RP11-879F14.2	-8.68	6.38e-17	3.09e-14	-0.39	-0.37	Obesity-related traits;	chr18:61629575	chr18:61585746~61606916:-
THCA	cis	rs7727544	0.606	rs200838	ENSG00000237714.1	P4HA2-AS1	-8.68	6.41e-17	3.1e-14	-0.49	-0.37	Blood metabolite levels;	chr5:132374707	chr5:132184876~132192808:+
THCA	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	8.68	6.41e-17	3.1e-14	0.43	0.37	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
THCA	cis	rs1426063	0.614	rs17000264	ENSG00000260265.1	RP11-44F21.5	8.68	6.41e-17	3.1e-14	0.78	0.37	QT interval;	chr4:75108962	chr4:75081702~75084717:-
THCA	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-8.68	6.42e-17	3.11e-14	-0.3	-0.37	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
THCA	cis	rs7665090	0.934	rs35112949	ENSG00000246560.2	RP11-10L12.4	8.68	6.42e-17	3.11e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102638473	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.87	rs34349956	ENSG00000246560.2	RP11-10L12.4	8.68	6.42e-17	3.11e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102638476	chr4:102828055~102844075:+
THCA	cis	rs1009647	1	rs1009647	ENSG00000258413.1	RP11-665C16.6	-8.68	6.43e-17	3.11e-14	-0.56	-0.37	Testicular germ cell tumor;	chr14:55413329	chr14:55262767~55272075:-
THCA	cis	rs4819052	1	rs3746980	ENSG00000237664.1	LINC00316	-8.68	6.44e-17	3.12e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45338590~45341990:-
THCA	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	8.68	6.44e-17	3.12e-14	0.59	0.37	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
THCA	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-8.68	6.45e-17	3.12e-14	-0.38	-0.37	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
THCA	cis	rs1707322	1	rs785467	ENSG00000234329.1	RP11-767N6.2	-8.68	6.46e-17	3.12e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45651039~45651826:-
THCA	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	8.68	6.46e-17	3.13e-14	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
THCA	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	8.68	6.46e-17	3.13e-14	0.59	0.37	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
THCA	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	8.68	6.47e-17	3.13e-14	0.36	0.37	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
THCA	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-8.68	6.52e-17	3.16e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	8.68	6.53e-17	3.16e-14	0.49	0.37	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
THCA	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	8.68	6.54e-17	3.16e-14	0.36	0.37	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
THCA	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	8.68	6.54e-17	3.16e-14	0.7	0.37	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	8.68	6.54e-17	3.16e-14	0.7	0.37	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	8.68	6.54e-17	3.16e-14	0.7	0.37	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
THCA	cis	rs12922040	0.607	rs8059739	ENSG00000263335.1	AF001548.5	-8.68	6.54e-17	3.17e-14	-0.41	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15772869	chr16:15726674~15732993:+
THCA	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-8.68	6.57e-17	3.18e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
THCA	cis	rs7015263	0.689	rs13251647	ENSG00000254231.1	CTD-2284J15.1	8.68	6.57e-17	3.18e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86465366	chr8:86333274~86343314:-
THCA	cis	rs4819052	0.684	rs914216	ENSG00000237664.1	LINC00316	-8.68	6.57e-17	3.18e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45338590~45341990:-
THCA	cis	rs642803	0.613	rs489574	ENSG00000214659.4	KRT8P26	-8.68	6.58e-17	3.18e-14	-0.33	-0.37	Urate levels;	chr11:65775268	chr11:65726939~65728214:+
THCA	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-8.68	6.58e-17	3.18e-14	-0.45	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
THCA	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-8.68	6.6e-17	3.19e-14	-0.46	-0.37	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
THCA	cis	rs792448	0.581	rs1663626	ENSG00000226251.4	RP11-15I11.3	-8.68	6.63e-17	3.2e-14	-0.48	-0.37	White blood cell count (basophil);	chr1:212249225	chr1:212225278~212238977:-
THCA	cis	rs17684571	0.751	rs7771085	ENSG00000231441.1	RP11-472M19.2	8.68	6.64e-17	3.21e-14	0.49	0.37	Schizophrenia;	chr6:56818631	chr6:56844002~56864078:+
THCA	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-8.68	6.66e-17	3.22e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-8.68	6.66e-17	3.22e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
THCA	cis	rs7665090	1	rs2866406	ENSG00000246560.2	RP11-10L12.4	8.68	6.67e-17	3.22e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632862	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2866407	ENSG00000246560.2	RP11-10L12.4	8.68	6.67e-17	3.22e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632951	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2866408	ENSG00000246560.2	RP11-10L12.4	8.68	6.67e-17	3.22e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632956	chr4:102828055~102844075:+
THCA	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	8.68	6.71e-17	3.24e-14	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
THCA	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	8.68	6.71e-17	3.24e-14	0.45	0.37	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
THCA	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	8.68	6.71e-17	3.24e-14	0.45	0.37	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
THCA	cis	rs4713118	0.824	rs9366702	ENSG00000219392.1	RP1-265C24.5	-8.68	6.72e-17	3.25e-14	-0.5	-0.37	Parkinson's disease;	chr6:27766691	chr6:28115628~28116551:+
THCA	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	8.68	6.72e-17	3.25e-14	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
THCA	cis	rs7665090	1	rs1054029	ENSG00000246560.2	RP11-10L12.4	8.68	6.75e-17	3.26e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631896	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs3194585	ENSG00000246560.2	RP11-10L12.4	8.68	6.75e-17	3.26e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631933	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs735405	ENSG00000246560.2	RP11-10L12.4	8.68	6.75e-17	3.26e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632759	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs1077358	ENSG00000246560.2	RP11-10L12.4	8.68	6.75e-17	3.26e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632769	chr4:102828055~102844075:+
THCA	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-8.68	6.75e-17	3.26e-14	-0.3	-0.37	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
THCA	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-8.68	6.77e-17	3.27e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-8.68	6.77e-17	3.27e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
THCA	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	8.68	6.77e-17	3.27e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
THCA	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-8.68	6.78e-17	3.28e-14	-0.44	-0.37	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-8.68	6.79e-17	3.28e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
THCA	cis	rs1707322	1	rs1612419	ENSG00000234329.1	RP11-767N6.2	-8.67	6.8e-17	3.28e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45651039~45651826:-
THCA	cis	rs17684571	0.7	rs13220618	ENSG00000231441.1	RP11-472M19.2	8.67	6.8e-17	3.28e-14	0.49	0.37	Schizophrenia;	chr6:56819388	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35081015	ENSG00000231441.1	RP11-472M19.2	8.67	6.8e-17	3.29e-14	0.49	0.37	Schizophrenia;	chr6:56819757	chr6:56844002~56864078:+
THCA	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-8.67	6.82e-17	3.29e-14	-0.44	-0.37	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
THCA	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-8.67	6.84e-17	3.31e-14	-0.3	-0.37	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
THCA	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-8.67	6.86e-17	3.31e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-8.67	6.86e-17	3.31e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
THCA	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	8.67	6.87e-17	3.32e-14	0.4	0.37	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
THCA	cis	rs1707322	0.752	rs11211168	ENSG00000234329.1	RP11-767N6.2	8.67	6.89e-17	3.33e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45651039~45651826:-
THCA	cis	rs10208649	0.611	rs12616263	ENSG00000272156.1	RP11-477N3.1	8.67	6.91e-17	3.33e-14	0.51	0.37	Body mass index;	chr2:54039235	chr2:54082554~54085066:+
THCA	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	8.67	6.92e-17	3.34e-14	0.43	0.37	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
THCA	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-8.67	6.93e-17	3.35e-14	-0.49	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
THCA	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	8.67	6.93e-17	3.35e-14	0.37	0.37	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
THCA	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-8.67	6.93e-17	3.35e-14	-0.3	-0.37	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
THCA	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	8.67	6.94e-17	3.35e-14	0.43	0.37	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
THCA	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-8.67	6.96e-17	3.36e-14	-0.44	-0.37	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
THCA	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
THCA	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
THCA	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
THCA	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
THCA	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
THCA	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
THCA	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-8.67	6.98e-17	3.37e-14	-0.49	-0.37	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
THCA	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	8.67	6.99e-17	3.37e-14	0.64	0.37	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
THCA	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	8.67	6.99e-17	3.37e-14	0.38	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
THCA	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-8.67	7e-17	3.38e-14	-0.35	-0.37	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
THCA	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	8.67	7.01e-17	3.39e-14	0.51	0.37	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	8.67	7.01e-17	3.39e-14	0.51	0.37	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	8.67	7.01e-17	3.39e-14	0.51	0.37	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	8.67	7.01e-17	3.39e-14	0.51	0.37	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
THCA	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	8.67	7.05e-17	3.4e-14	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000215447.6	BX322557.10	-8.67	7.05e-17	3.4e-14	-0.31	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000215447.6	BX322557.10	-8.67	7.05e-17	3.4e-14	-0.31	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45288052~45291738:+
THCA	cis	rs4713118	0.866	rs2179094	ENSG00000219392.1	RP1-265C24.5	-8.67	7.05e-17	3.4e-14	-0.49	-0.37	Parkinson's disease;	chr6:27774046	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.824	rs2179095	ENSG00000219392.1	RP1-265C24.5	8.67	7.05e-17	3.4e-14	0.49	0.37	Parkinson's disease;	chr6:27783079	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	8.67	7.07e-17	3.41e-14	0.5	0.37	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
THCA	cis	rs1426063	0.614	rs17199779	ENSG00000260265.1	RP11-44F21.5	-8.67	7.08e-17	3.42e-14	-0.76	-0.37	QT interval;	chr4:75105647	chr4:75081702~75084717:-
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000215447.6	BX322557.10	-8.67	7.08e-17	3.42e-14	-0.31	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45288052~45291738:+
THCA	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-8.67	7.09e-17	3.42e-14	-0.3	-0.37	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
THCA	cis	rs62103177	0.733	rs80114941	ENSG00000261126.6	RP11-795F19.1	8.67	7.12e-17	3.43e-14	0.43	0.37	Opioid sensitivity;	chr18:79911740	chr18:80046900~80095482:+
THCA	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-8.67	7.13e-17	3.44e-14	-0.3	-0.37	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000206090.4	AP000350.7	8.67	7.15e-17	3.45e-14	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23939998~23942798:+
THCA	cis	rs1850744	0.702	rs7434744	ENSG00000250942.1	ENPP7P11	8.67	7.15e-17	3.45e-14	0.48	0.37	Economic and political preferences;	chr4:9671064	chr4:9677308~9677934:+
THCA	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-8.67	7.17e-17	3.46e-14	-0.54	-0.37	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
THCA	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-8.67	7.17e-17	3.46e-14	-0.54	-0.37	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
THCA	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-8.67	7.17e-17	3.46e-14	-0.54	-0.37	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000237664.1	LINC00316	-8.67	7.19e-17	3.46e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45338590~45341990:-
THCA	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	8.67	7.19e-17	3.47e-14	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
THCA	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	8.67	7.19e-17	3.47e-14	0.47	0.37	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
THCA	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
THCA	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
THCA	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
THCA	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
THCA	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
THCA	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
THCA	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
THCA	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
THCA	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
THCA	cis	rs4842666	0.915	rs11105352	ENSG00000258302.2	RP11-981P6.1	8.67	7.2e-17	3.47e-14	0.37	0.37	Blood pressure;	chr12:89632685	chr12:89561129~89594878:+
THCA	cis	rs4842666	0.915	rs11105353	ENSG00000258302.2	RP11-981P6.1	8.67	7.2e-17	3.47e-14	0.37	0.37	Blood pressure;	chr12:89632686	chr12:89561129~89594878:+
THCA	cis	rs4842666	0.915	rs11105354	ENSG00000258302.2	RP11-981P6.1	8.67	7.2e-17	3.47e-14	0.37	0.37	Blood pressure;	chr12:89632746	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000235689.1	AP000351.13	8.67	7.21e-17	3.47e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:24006305~24008258:-
THCA	cis	rs1707322	1	rs785507	ENSG00000234329.1	RP11-767N6.2	-8.67	7.21e-17	3.48e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45651039~45651826:-
THCA	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-8.67	7.23e-17	3.48e-14	-0.43	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
THCA	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	8.67	7.24e-17	3.49e-14	0.37	0.37	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
THCA	cis	rs11971779	0.941	rs6954453	ENSG00000273391.1	RP11-634H22.1	8.67	7.24e-17	3.49e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139347048	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.941	rs4732368	ENSG00000273391.1	RP11-634H22.1	8.67	7.24e-17	3.49e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139349461	chr7:139359032~139359566:-
THCA	cis	rs7646881	0.951	rs6441222	ENSG00000240207.5	RP11-379F4.4	-8.67	7.24e-17	3.49e-14	-0.49	-0.37	Tetralogy of Fallot;	chr3:158731978	chr3:158732263~158784070:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-8.67	7.24e-17	3.49e-14	-0.27	-0.37	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
THCA	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	8.67	7.27e-17	3.5e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
THCA	cis	rs11971779	0.816	rs11979272	ENSG00000273391.1	RP11-634H22.1	8.67	7.27e-17	3.5e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139389323	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.941	rs7800795	ENSG00000273391.1	RP11-634H22.1	8.67	7.27e-17	3.5e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139395602	chr7:139359032~139359566:-
THCA	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-8.67	7.29e-17	3.51e-14	-0.45	-0.37	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
THCA	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-8.67	7.33e-17	3.53e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
THCA	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-8.66	7.35e-17	3.54e-14	-0.54	-0.37	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
THCA	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-8.66	7.36e-17	3.54e-14	-0.36	-0.37	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
THCA	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-8.66	7.36e-17	3.55e-14	-0.49	-0.37	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
THCA	cis	rs9341808	0.559	rs7762895	ENSG00000272129.1	RP11-250B2.6	8.66	7.38e-17	3.55e-14	0.46	0.37	Sitting height ratio;	chr6:80351714	chr6:80355424~80356859:+
THCA	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-8.66	7.41e-17	3.57e-14	-0.43	-0.37	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
THCA	cis	rs2929278	0.617	rs694461	ENSG00000166763.7	STRCP1	-8.66	7.42e-17	3.58e-14	-0.41	-0.37	Schizophrenia;	chr15:43803865	chr15:43699488~43718184:-
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000230295.1	RP11-458F8.2	8.66	7.45e-17	3.59e-14	0.33	0.37	Corneal structure;	chr7:66821880	chr7:66880708~66882981:+
THCA	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-8.66	7.45e-17	3.59e-14	-0.47	-0.37	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
THCA	cis	rs17684571	0.872	rs34587484	ENSG00000231441.1	RP11-472M19.2	8.66	7.46e-17	3.59e-14	0.52	0.37	Schizophrenia;	chr6:56742926	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34465210	ENSG00000231441.1	RP11-472M19.2	8.66	7.46e-17	3.59e-14	0.52	0.37	Schizophrenia;	chr6:56742930	chr6:56844002~56864078:+
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-8.66	7.47e-17	3.6e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-8.66	7.47e-17	3.6e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
THCA	cis	rs7015263	0.573	rs62509370	ENSG00000254231.1	CTD-2284J15.1	-8.66	7.47e-17	3.6e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86275982	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.573	rs62509372	ENSG00000254231.1	CTD-2284J15.1	-8.66	7.47e-17	3.6e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86280971	chr8:86333274~86343314:-
THCA	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	8.66	7.48e-17	3.6e-14	0.4	0.37	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
THCA	cis	rs1009647	1	rs35502084	ENSG00000258413.1	RP11-665C16.6	-8.66	7.49e-17	3.61e-14	-0.57	-0.37	Testicular germ cell tumor;	chr14:55409545	chr14:55262767~55272075:-
THCA	cis	rs9813712	0.571	rs9855777	ENSG00000228252.7	COL6A4P2	8.66	7.51e-17	3.61e-14	0.38	0.37	Response to amphetamines;	chr3:130214805	chr3:130212823~130273806:+
THCA	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	8.66	7.51e-17	3.62e-14	0.47	0.37	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
THCA	cis	rs1707322	0.691	rs61784799	ENSG00000234329.1	RP11-767N6.2	-8.66	7.55e-17	3.63e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45651039~45651826:-
THCA	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	8.66	7.58e-17	3.65e-14	0.45	0.37	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
THCA	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	8.66	7.59e-17	3.65e-14	0.6	0.37	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
THCA	cis	rs1707322	0.752	rs4660880	ENSG00000234329.1	RP11-767N6.2	8.66	7.59e-17	3.65e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45651039~45651826:-
THCA	cis	rs7665090	1	rs4013	ENSG00000246560.2	RP11-10L12.4	8.66	7.6e-17	3.66e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631656	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs4019	ENSG00000246560.2	RP11-10L12.4	8.66	7.6e-17	3.66e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631673	chr4:102828055~102844075:+
THCA	cis	rs1707322	1	rs10890381	ENSG00000234329.1	RP11-767N6.2	8.66	7.62e-17	3.67e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45651039~45651826:-
THCA	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-8.66	7.63e-17	3.67e-14	-0.63	-0.37	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
THCA	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-8.66	7.66e-17	3.69e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
THCA	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	8.66	7.68e-17	3.69e-14	0.43	0.37	Migraine;	chr4:56881468	chr4:56960927~56961373:-
THCA	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-8.66	7.69e-17	3.7e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
THCA	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-8.66	7.73e-17	3.72e-14	-0.49	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
THCA	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-8.66	7.73e-17	3.72e-14	-0.49	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
THCA	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-8.66	7.76e-17	3.73e-14	-0.39	-0.37	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
THCA	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-8.66	7.78e-17	3.74e-14	-0.29	-0.37	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
THCA	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-8.66	7.79e-17	3.74e-14	-0.3	-0.37	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-8.66	7.79e-17	3.74e-14	-0.3	-0.37	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-8.66	7.79e-17	3.74e-14	-0.3	-0.37	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
THCA	cis	rs7849270	0.879	rs7042928	ENSG00000268707.1	RP11-247A12.7	8.66	7.79e-17	3.75e-14	0.45	0.37	Blood metabolite ratios;	chr9:129092996	chr9:129170434~129170940:+
THCA	cis	rs10740039	0.81	rs6479720	ENSG00000254271.1	RP11-131N11.4	8.66	7.79e-17	3.75e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60610935	chr10:60734342~60741828:+
THCA	cis	rs1707322	1	rs4660332	ENSG00000234329.1	RP11-767N6.2	8.66	7.8e-17	3.75e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-8.66	7.82e-17	3.76e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-8.66	7.82e-17	3.76e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-8.66	7.82e-17	3.76e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-8.66	7.82e-17	3.76e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	8.66	7.88e-17	3.78e-14	0.43	0.37	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
THCA	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-8.66	7.88e-17	3.79e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	8.66	7.9e-17	3.79e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
THCA	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-8.65	7.9e-17	3.8e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
THCA	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	8.65	7.91e-17	3.8e-14	0.52	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
THCA	cis	rs17684571	0.751	rs10498813	ENSG00000231441.1	RP11-472M19.2	8.65	7.92e-17	3.81e-14	0.49	0.37	Schizophrenia;	chr6:56819921	chr6:56844002~56864078:+
THCA	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	8.65	7.95e-17	3.82e-14	0.51	0.37	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	8.65	7.95e-17	3.82e-14	0.51	0.37	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	8.65	7.95e-17	3.82e-14	0.51	0.37	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
THCA	cis	rs12554020	0.681	rs78759589	ENSG00000227603.1	RP11-165J3.6	8.65	7.96e-17	3.82e-14	0.62	0.37	Schizophrenia;	chr9:93409518	chr9:93435332~93437121:-
THCA	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	8.65	7.99e-17	3.84e-14	0.45	0.37	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
THCA	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	8.65	8e-17	3.84e-14	0.59	0.37	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
THCA	cis	rs8018967	0.622	rs2041073	ENSG00000258695.2	RP3-414A15.2	8.65	8.01e-17	3.85e-14	0.45	0.37	Blood metabolite ratios;	chr14:73505831	chr14:73522878~73530610:+
THCA	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-8.65	8.01e-17	3.85e-14	-0.3	-0.37	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
THCA	cis	rs934734	0.532	rs6752053	ENSG00000237979.1	AC007389.1	-8.65	8.05e-17	3.86e-14	-0.42	-0.37	Rheumatoid arthritis;	chr2:65439540	chr2:65500993~65502138:-
THCA	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	8.65	8.07e-17	3.87e-14	0.47	0.37	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
THCA	cis	rs1707322	1	rs12124847	ENSG00000234329.1	RP11-767N6.2	8.65	8.07e-17	3.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45651039~45651826:-
THCA	cis	rs7665090	1	rs2866409	ENSG00000246560.2	RP11-10L12.4	8.65	8.1e-17	3.89e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102633104	chr4:102828055~102844075:+
THCA	cis	rs11148252	0.716	rs2760772	ENSG00000278238.1	RP11-245D16.4	-8.65	8.12e-17	3.9e-14	-0.43	-0.37	Lewy body disease;	chr13:52206238	chr13:52454775~52455331:-
THCA	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-8.65	8.13e-17	3.9e-14	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
THCA	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-8.65	8.13e-17	3.9e-14	-0.53	-0.37	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
THCA	cis	rs597539	0.69	rs615644	ENSG00000250508.1	RP11-757G1.6	-8.65	8.16e-17	3.91e-14	-0.45	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68870664~68874542:+
THCA	cis	rs1707322	1	rs12077974	ENSG00000234329.1	RP11-767N6.2	8.65	8.2e-17	3.93e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45651039~45651826:-
THCA	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	8.65	8.21e-17	3.94e-14	0.46	0.37	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
THCA	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-8.65	8.23e-17	3.95e-14	-0.52	-0.37	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-8.65	8.23e-17	3.95e-14	-0.52	-0.37	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.653	rs1209087	ENSG00000258413.1	RP11-665C16.6	8.65	8.24e-17	3.95e-14	0.49	0.37	Protein biomarker;	chr14:55026502	chr14:55262767~55272075:-
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-8.65	8.29e-17	3.98e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
THCA	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-8.65	8.3e-17	3.98e-14	-0.36	-0.37	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
THCA	cis	rs12554020	0.685	rs55893789	ENSG00000227603.1	RP11-165J3.6	8.65	8.3e-17	3.98e-14	0.62	0.37	Schizophrenia;	chr9:93408608	chr9:93435332~93437121:-
THCA	cis	rs9532669	0.926	rs9594450	ENSG00000239827.7	SUGT1P3	-8.65	8.31e-17	3.98e-14	-0.43	-0.37	Cervical cancer;	chr13:40880067	chr13:40908159~40921774:-
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-8.65	8.34e-17	4e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-8.65	8.34e-17	4e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-8.65	8.34e-17	4e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
THCA	cis	rs10740039	0.768	rs10821801	ENSG00000254271.1	RP11-131N11.4	8.65	8.36e-17	4.01e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60612017	chr10:60734342~60741828:+
THCA	cis	rs7665090	1	rs5026473	ENSG00000246560.2	RP11-10L12.4	8.65	8.37e-17	4.01e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633636	chr4:102828055~102844075:+
THCA	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	8.65	8.37e-17	4.02e-14	0.36	0.37	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	8.65	8.37e-17	4.02e-14	0.36	0.37	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
THCA	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	8.65	8.37e-17	4.02e-14	0.36	0.37	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
THCA	cis	rs4780355	0.776	rs9936459	ENSG00000262636.1	CTD-3088G3.4	-8.65	8.39e-17	4.02e-14	-0.49	-0.37	Crohn's disease and psoriasis;	chr16:11343922	chr16:11380859~11381118:-
THCA	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	8.65	8.42e-17	4.04e-14	0.5	0.37	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
THCA	cis	rs526231	0.697	rs422115	ENSG00000175749.11	EIF3KP1	8.65	8.42e-17	4.04e-14	0.56	0.37	Primary biliary cholangitis;	chr5:103298639	chr5:103032376~103033031:+
THCA	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	8.65	8.43e-17	4.04e-14	0.58	0.37	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
THCA	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	8.65	8.43e-17	4.04e-14	0.58	0.37	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
THCA	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	8.65	8.44e-17	4.04e-14	0.36	0.37	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-8.65	8.45e-17	4.05e-14	-0.76	-0.37	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-8.65	8.45e-17	4.05e-14	-0.76	-0.37	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
THCA	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	8.65	8.46e-17	4.05e-14	0.44	0.37	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
THCA	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	8.65	8.46e-17	4.06e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
THCA	cis	rs516805	0.961	rs510283	ENSG00000279453.1	RP3-425C14.4	-8.65	8.46e-17	4.06e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122451547	chr6:122436789~122439223:-
THCA	cis	rs848490	0.762	rs7796089	ENSG00000214293.7	APTR	8.65	8.47e-17	4.06e-14	0.27	0.37	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77882781	chr7:77657660~77696265:-
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000235689.1	AP000351.13	-8.65	8.5e-17	4.08e-14	-0.47	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:24006305~24008258:-
THCA	cis	rs7665090	1	rs5026476	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102633753	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs6812747	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634260	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs6839064	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634519	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2272695	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634646	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2272696	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634664	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2272697	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634835	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2866413	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102635920	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs4547797	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102636035	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2866414	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102636062	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs9996834	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102636372	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2903283	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102636596	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs4579121	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637012	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs6810869	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637357	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.934	rs6533020	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637648	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.934	rs6533021	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637696	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	8.64	8.53e-17	4.08e-14	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
THCA	cis	rs6545883	0.524	rs2463101	ENSG00000271889.1	RP11-493E12.1	-8.64	8.55e-17	4.09e-14	-0.36	-0.37	Tuberculosis;	chr2:61347287	chr2:61151433~61162105:-
THCA	cis	rs2946505	0.608	rs2466257	ENSG00000251468.2	RP11-369K16.1	8.64	8.56e-17	4.1e-14	0.6	0.37	Migraine;	chr8:12954754	chr8:12958387~12962200:+
THCA	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	8.64	8.57e-17	4.11e-14	0.37	0.37	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
THCA	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	8.64	8.57e-17	4.11e-14	0.7	0.37	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
THCA	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-8.64	8.59e-17	4.11e-14	-0.39	-0.37	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
THCA	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-8.64	8.6e-17	4.12e-14	-0.4	-0.37	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
THCA	cis	rs9928842	0.765	rs6564222	ENSG00000280152.1	RP11-331F4.5	8.64	8.63e-17	4.13e-14	0.54	0.37	Alcoholic chronic pancreatitis;	chr16:75191146	chr16:75245994~75250077:-
THCA	cis	rs11971779	0.941	rs1127424	ENSG00000273391.1	RP11-634H22.1	8.64	8.66e-17	4.15e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139422914	chr7:139359032~139359566:-
THCA	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	8.64	8.67e-17	4.15e-14	0.47	0.37	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
THCA	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-8.64	8.67e-17	4.15e-14	-0.46	-0.37	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
THCA	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-8.64	8.67e-17	4.15e-14	-0.46	-0.37	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	8.64	8.69e-17	4.16e-14	0.49	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
THCA	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-8.64	8.72e-17	4.18e-14	-0.49	-0.37	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
THCA	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	8.64	8.73e-17	4.18e-14	0.76	0.37	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
THCA	cis	rs11148252	0.574	rs61958118	ENSG00000235660.1	LINC00345	-8.64	8.82e-17	4.22e-14	-0.46	-0.37	Lewy body disease;	chr13:52596091	chr13:52484161~52484680:-
THCA	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-8.64	8.82e-17	4.22e-14	-0.43	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
THCA	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	8.64	8.85e-17	4.24e-14	0.36	0.37	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
THCA	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-8.64	8.87e-17	4.25e-14	-0.52	-0.37	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-8.64	8.87e-17	4.25e-14	-0.52	-0.37	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
THCA	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-8.64	8.89e-17	4.25e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
THCA	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-8.64	8.89e-17	4.25e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
THCA	cis	rs8114671	0.527	rs6088650	ENSG00000269202.1	RP4-614O4.12	8.64	8.92e-17	4.27e-14	0.31	0.37	Height;	chr20:34926662	chr20:35201747~35203288:-
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000224205.1	AP000351.4	-8.64	8.95e-17	4.28e-14	-0.45	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23987320~23991421:-
THCA	cis	rs2946505	0.569	rs2460359	ENSG00000251468.2	RP11-369K16.1	8.64	8.96e-17	4.29e-14	0.59	0.37	Migraine;	chr8:12955509	chr8:12958387~12962200:+
THCA	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	8.64	8.98e-17	4.3e-14	0.37	0.37	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000237664.1	LINC00316	-8.64	8.99e-17	4.3e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45338590~45341990:-
THCA	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
THCA	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
THCA	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
THCA	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
THCA	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
THCA	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
THCA	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
THCA	cis	rs526231	0.697	rs168820	ENSG00000175749.11	EIF3KP1	8.64	9.05e-17	4.33e-14	0.57	0.37	Primary biliary cholangitis;	chr5:103306972	chr5:103032376~103033031:+
THCA	cis	rs11148252	0.774	rs56033750	ENSG00000278238.1	RP11-245D16.4	-8.64	9.09e-17	4.34e-14	-0.41	-0.37	Lewy body disease;	chr13:52173143	chr13:52454775~52455331:-
THCA	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-8.64	9.09e-17	4.35e-14	-0.35	-0.37	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
THCA	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	8.64	9.1e-17	4.35e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
THCA	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-8.64	9.1e-17	4.35e-14	-0.3	-0.37	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
THCA	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	8.64	9.11e-17	4.35e-14	0.48	0.37	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000215447.6	BX322557.10	-8.64	9.12e-17	4.36e-14	-0.3	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45288052~45291738:+
THCA	cis	rs7826238	0.543	rs2976908	ENSG00000253893.2	FAM85B	-8.64	9.17e-17	4.39e-14	-0.5	-0.37	Systolic blood pressure;	chr8:8488264	chr8:8167819~8226614:-
THCA	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-8.63	9.22e-17	4.41e-14	-0.5	-0.37	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000237664.1	LINC00316	-8.63	9.24e-17	4.42e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45338590~45341990:-
THCA	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-8.63	9.27e-17	4.43e-14	-0.38	-0.37	Height;	chr11:118749988	chr11:118704607~118750263:+
THCA	cis	rs17684571	0.872	rs13198399	ENSG00000231441.1	RP11-472M19.2	8.63	9.27e-17	4.43e-14	0.51	0.37	Schizophrenia;	chr6:56733196	chr6:56844002~56864078:+
THCA	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-8.63	9.37e-17	4.48e-14	-0.36	-0.37	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
THCA	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	8.63	9.37e-17	4.48e-14	0.42	0.37	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	8.63	9.37e-17	4.48e-14	0.42	0.37	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
THCA	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-8.63	9.38e-17	4.48e-14	-0.45	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
THCA	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-8.63	9.38e-17	4.48e-14	-0.45	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-8.63	9.38e-17	4.48e-14	-0.47	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
THCA	cis	rs9659323	1	rs11584380	ENSG00000231365.4	RP11-418J17.1	-8.63	9.41e-17	4.49e-14	-0.37	-0.37	Body mass index;	chr1:118974797	chr1:119140396~119275973:+
THCA	cis	rs10740039	0.81	rs1442543	ENSG00000254271.1	RP11-131N11.4	8.63	9.45e-17	4.51e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613704	chr10:60734342~60741828:+
THCA	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	8.63	9.46e-17	4.52e-14	0.44	0.37	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
THCA	cis	rs11971779	0.818	rs12056045	ENSG00000273391.1	RP11-634H22.1	8.63	9.46e-17	4.52e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139340684	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.941	rs74299967	ENSG00000273391.1	RP11-634H22.1	8.63	9.46e-17	4.52e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139359023	chr7:139359032~139359566:-
THCA	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	8.63	9.52e-17	4.54e-14	0.46	0.37	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
THCA	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-8.63	9.52e-17	4.55e-14	-0.68	-0.37	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
THCA	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	8.63	9.53e-17	4.55e-14	0.36	0.37	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
THCA	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	8.63	9.53e-17	4.55e-14	0.36	0.37	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
THCA	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	8.63	9.53e-17	4.55e-14	0.36	0.37	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
THCA	cis	rs9659323	0.931	rs113197996	ENSG00000231365.4	RP11-418J17.1	-8.63	9.53e-17	4.55e-14	-0.38	-0.37	Body mass index;	chr1:118979803	chr1:119140396~119275973:+
THCA	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	8.63	9.56e-17	4.56e-14	0.36	0.37	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
THCA	cis	rs11148252	0.624	rs6561682	ENSG00000278238.1	RP11-245D16.4	8.63	9.58e-17	4.57e-14	0.45	0.37	Lewy body disease;	chr13:52692162	chr13:52454775~52455331:-
THCA	cis	rs860295	1	rs10908482	ENSG00000225855.5	RUSC1-AS1	8.63	9.58e-17	4.57e-14	0.25	0.37	Body mass index;	chr1:155744082	chr1:155316863~155324176:-
THCA	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	8.63	9.6e-17	4.58e-14	0.42	0.37	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
THCA	cis	rs2274273	0.688	rs6573001	ENSG00000258413.1	RP11-665C16.6	-8.63	9.6e-17	4.58e-14	-0.48	-0.37	Protein biomarker;	chr14:55089784	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.684	rs2340921	ENSG00000258413.1	RP11-665C16.6	-8.63	9.6e-17	4.58e-14	-0.48	-0.37	Protein biomarker;	chr14:55096987	chr14:55262767~55272075:-
THCA	cis	rs7665090	0.875	rs6813322	ENSG00000246560.2	RP11-10L12.4	8.63	9.61e-17	4.59e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634462	chr4:102828055~102844075:+
THCA	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	8.63	9.71e-17	4.64e-14	0.47	0.37	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
THCA	cis	rs2946505	0.608	rs2977083	ENSG00000251468.2	RP11-369K16.1	8.63	9.72e-17	4.64e-14	0.6	0.37	Migraine;	chr8:12957393	chr8:12958387~12962200:+
THCA	cis	rs7727544	0.606	rs10058074	ENSG00000237714.1	P4HA2-AS1	8.63	9.75e-17	4.65e-14	0.48	0.37	Blood metabolite levels;	chr5:132350453	chr5:132184876~132192808:+
THCA	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	8.63	9.8e-17	4.68e-14	0.56	0.37	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
THCA	cis	rs7665090	1	rs7664828	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630219	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs7690123	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630602	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs7665659	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630661	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs7665854	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630752	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.846	rs7690700	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630911	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs13112557	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631096	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs12644381	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631273	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs1054037	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631552	chr4:102828055~102844075:+
THCA	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-8.63	9.83e-17	4.69e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
THCA	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	8.63	9.85e-17	4.7e-14	0.49	0.37	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	8.63	9.85e-17	4.7e-14	0.49	0.37	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
THCA	cis	rs10740039	0.81	rs1372709	ENSG00000254271.1	RP11-131N11.4	8.63	9.88e-17	4.71e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60621666	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.768	rs10994432	ENSG00000254271.1	RP11-131N11.4	8.63	9.88e-17	4.71e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60623831	chr10:60734342~60741828:+
THCA	cis	rs6496932	0.865	rs10520600	ENSG00000218052.5	ADAMTS7P4	8.63	9.91e-17	4.72e-14	0.57	0.37	Central corneal thickness;Corneal structure;	chr15:85365171	chr15:85255369~85330334:-
THCA	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	8.62	9.93e-17	4.74e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
THCA	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-8.62	9.94e-17	4.74e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
THCA	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	8.62	9.97e-17	4.75e-14	0.42	0.37	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
THCA	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-8.62	9.99e-17	4.76e-14	-0.45	-0.37	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-8.62	9.99e-17	4.76e-14	-0.45	-0.37	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
THCA	cis	rs73081554	0.611	rs13071861	ENSG00000272360.1	RP11-359I18.5	-8.62	1e-16	4.77e-14	-0.52	-0.37	Rheumatoid arthritis;	chr3:58385605	chr3:58490830~58491291:-
THCA	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-8.62	1e-16	4.78e-14	-0.49	-0.37	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
THCA	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	8.62	1e-16	4.78e-14	0.54	0.37	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
THCA	cis	rs860295	1	rs7541060	ENSG00000225855.5	RUSC1-AS1	8.62	1.01e-16	4.79e-14	0.25	0.37	Body mass index;	chr1:155758297	chr1:155316863~155324176:-
THCA	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	8.62	1.01e-16	4.81e-14	0.34	0.37	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
THCA	cis	rs17684571	0.872	rs35494794	ENSG00000231441.1	RP11-472M19.2	8.62	1.01e-16	4.82e-14	0.51	0.37	Schizophrenia;	chr6:56716124	chr6:56844002~56864078:+
THCA	cis	rs7015263	0.536	rs7460027	ENSG00000254231.1	CTD-2284J15.1	8.62	1.01e-16	4.83e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86330012	chr8:86333274~86343314:-
THCA	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-8.62	1.02e-16	4.84e-14	-0.38	-0.37	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
THCA	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-8.62	1.02e-16	4.87e-14	-0.55	-0.37	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
THCA	cis	rs1707322	1	rs1622208	ENSG00000234329.1	RP11-767N6.2	-8.62	1.02e-16	4.87e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45651039~45651826:-
THCA	cis	rs4591358	0.636	rs6712400	ENSG00000223466.1	AC064834.2	-8.62	1.03e-16	4.89e-14	-0.48	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506646	chr2:195533035~195538681:+
THCA	cis	rs2929278	0.617	rs693919	ENSG00000166763.7	STRCP1	-8.62	1.03e-16	4.89e-14	-0.4	-0.37	Schizophrenia;	chr15:43810130	chr15:43699488~43718184:-
THCA	cis	rs17772222	0.582	rs1288122	ENSG00000258789.1	RP11-507K2.3	8.62	1.03e-16	4.89e-14	0.35	0.37	Coronary artery calcification;	chr14:88472736	chr14:88551597~88552493:+
THCA	cis	rs12908161	0.959	rs17598603	ENSG00000259728.4	LINC00933	-8.62	1.03e-16	4.9e-14	-0.51	-0.37	Schizophrenia;	chr15:84656980	chr15:84570649~84580175:+
THCA	cis	rs860295	1	rs6427286	ENSG00000225855.5	RUSC1-AS1	8.62	1.03e-16	4.9e-14	0.25	0.37	Body mass index;	chr1:155753506	chr1:155316863~155324176:-
THCA	cis	rs860295	1	rs6427287	ENSG00000225855.5	RUSC1-AS1	8.62	1.03e-16	4.9e-14	0.25	0.37	Body mass index;	chr1:155753629	chr1:155316863~155324176:-
THCA	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	8.62	1.03e-16	4.9e-14	0.35	0.37	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
THCA	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	8.62	1.03e-16	4.9e-14	0.35	0.37	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
THCA	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-8.62	1.03e-16	4.92e-14	-0.45	-0.37	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
THCA	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	8.62	1.03e-16	4.93e-14	0.36	0.37	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
THCA	cis	rs10740039	0.81	rs10821800	ENSG00000254271.1	RP11-131N11.4	8.62	1.04e-16	4.94e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607812	chr10:60734342~60741828:+
THCA	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	8.62	1.04e-16	4.94e-14	0.35	0.37	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
THCA	cis	rs8114671	0.804	rs6060139	ENSG00000269202.1	RP4-614O4.12	-8.62	1.04e-16	4.96e-14	-0.31	-0.37	Height;	chr20:34978696	chr20:35201747~35203288:-
THCA	cis	rs7569084	0.687	rs1344891	ENSG00000234255.7	AC012370.3	8.62	1.04e-16	4.97e-14	0.42	0.37	Sum eosinophil basophil counts;	chr2:65458890	chr2:65439888~65456571:-
THCA	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	8.62	1.04e-16	4.97e-14	0.41	0.37	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
THCA	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-8.62	1.05e-16	4.98e-14	-0.38	-0.37	Height;	chr11:118764443	chr11:118704607~118750263:+
THCA	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-8.62	1.05e-16	5e-14	-0.52	-0.37	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.824	rs9468223	ENSG00000219392.1	RP1-265C24.5	-8.62	1.05e-16	5e-14	-0.49	-0.37	Parkinson's disease;	chr6:27772887	chr6:28115628~28116551:+
THCA	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	8.62	1.05e-16	5.02e-14	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
THCA	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	8.62	1.06e-16	5.02e-14	0.45	0.37	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
THCA	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-8.62	1.06e-16	5.03e-14	-0.39	-0.37	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
THCA	cis	rs9309473	0.687	rs11693531	ENSG00000163016.8	ALMS1P	8.62	1.06e-16	5.04e-14	0.5	0.37	Metabolite levels;	chr2:73381486	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-8.62	1.06e-16	5.05e-14	-0.38	-0.37	Height;	chr11:118791319	chr11:118704607~118750263:+
THCA	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-8.62	1.06e-16	5.05e-14	-0.45	-0.37	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
THCA	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-8.62	1.06e-16	5.05e-14	-0.29	-0.37	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
THCA	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	8.62	1.06e-16	5.05e-14	0.32	0.37	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
THCA	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	8.62	1.06e-16	5.06e-14	0.55	0.37	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
THCA	cis	rs11051970	0.559	rs11051945	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32336191	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051946	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32336335	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.527	rs2388989	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32337341	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs2388988	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32337414	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs4604975	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32337441	chr12:32339368~32340724:+
THCA	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	8.62	1.06e-16	5.06e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
THCA	cis	rs10411161	0.702	rs11879319	ENSG00000269483.1	AC006272.1	8.62	1.07e-16	5.07e-14	0.51	0.37	Breast cancer;	chr19:51886339	chr19:51839924~51843324:-
THCA	cis	rs8114671	0.805	rs4616	ENSG00000269202.1	RP4-614O4.12	8.62	1.07e-16	5.07e-14	0.32	0.37	Height;	chr20:35002555	chr20:35201747~35203288:-
THCA	cis	rs737008	0.922	rs28567501	ENSG00000262703.1	RP11-485G7.6	-8.62	1.07e-16	5.07e-14	-0.42	-0.37	Obesity-related traits;	chr16:11285071	chr16:11348143~11349321:-
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000237664.1	LINC00316	-8.62	1.07e-16	5.08e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45338590~45341990:-
THCA	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-8.61	1.07e-16	5.09e-14	-0.44	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
THCA	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	8.61	1.07e-16	5.1e-14	0.46	0.37	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
THCA	cis	rs13129231	0.842	rs2882987	ENSG00000206820.1	RNU1-138P	-8.61	1.07e-16	5.11e-14	-0.45	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113434406	chr4:113420323~113420486:+
THCA	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-8.61	1.08e-16	5.11e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
THCA	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	8.61	1.08e-16	5.13e-14	0.32	0.37	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
THCA	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-8.61	1.08e-16	5.14e-14	-0.39	-0.37	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
THCA	cis	rs2274273	0.682	rs1187876	ENSG00000258413.1	RP11-665C16.6	8.61	1.08e-16	5.14e-14	0.49	0.37	Protein biomarker;	chr14:55028481	chr14:55262767~55272075:-
THCA	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-8.61	1.08e-16	5.14e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
THCA	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-8.61	1.08e-16	5.15e-14	-0.49	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
THCA	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-8.61	1.09e-16	5.17e-14	-0.42	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
THCA	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-8.61	1.09e-16	5.17e-14	-0.38	-0.37	Height;	chr11:118781100	chr11:118704607~118750263:+
THCA	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-8.61	1.09e-16	5.18e-14	-0.36	-0.37	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
THCA	cis	rs2032366	0.606	rs1452597	ENSG00000267279.1	RP11-879F14.2	-8.61	1.09e-16	5.18e-14	-0.39	-0.37	Obesity-related traits;	chr18:61590985	chr18:61585746~61606916:-
THCA	cis	rs2274273	0.712	rs9806049	ENSG00000258413.1	RP11-665C16.6	-8.61	1.09e-16	5.18e-14	-0.49	-0.37	Protein biomarker;	chr14:55058871	chr14:55262767~55272075:-
THCA	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-8.61	1.09e-16	5.19e-14	-0.47	-0.37	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
THCA	cis	rs7727544	0.582	rs3805681	ENSG00000237714.1	P4HA2-AS1	8.61	1.1e-16	5.21e-14	0.46	0.37	Blood metabolite levels;	chr5:132202167	chr5:132184876~132192808:+
THCA	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
THCA	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	8.61	1.1e-16	5.24e-14	0.36	0.37	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
THCA	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-8.61	1.1e-16	5.24e-14	-0.5	-0.37	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	8.61	1.11e-16	5.26e-14	0.73	0.37	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
THCA	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-8.61	1.11e-16	5.26e-14	-0.48	-0.37	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
THCA	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-8.61	1.11e-16	5.27e-14	-0.3	-0.37	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
THCA	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	8.61	1.11e-16	5.28e-14	0.39	0.37	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
THCA	cis	rs947583	0.663	rs7765436	ENSG00000231028.7	LINC00271	-8.61	1.11e-16	5.3e-14	-0.29	-0.37	Phosphorus levels;	chr6:135804721	chr6:135497801~135716055:+
THCA	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-8.61	1.12e-16	5.3e-14	-0.38	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
THCA	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	8.61	1.12e-16	5.3e-14	0.46	0.37	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
THCA	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	8.61	1.12e-16	5.31e-14	0.64	0.37	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
THCA	cis	rs1707322	0.717	rs2275086	ENSG00000234329.1	RP11-767N6.2	-8.61	1.12e-16	5.32e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45651039~45651826:-
THCA	cis	rs17684571	0.872	rs13219942	ENSG00000231441.1	RP11-472M19.2	8.61	1.12e-16	5.32e-14	0.51	0.37	Schizophrenia;	chr6:56713977	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs35326806	ENSG00000231441.1	RP11-472M19.2	8.61	1.12e-16	5.32e-14	0.51	0.37	Schizophrenia;	chr6:56714216	chr6:56844002~56864078:+
THCA	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-8.61	1.12e-16	5.34e-14	-0.35	-0.37	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
THCA	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-8.61	1.13e-16	5.35e-14	-0.36	-0.37	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	8.61	1.14e-16	5.39e-14	0.36	0.37	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
THCA	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	8.61	1.14e-16	5.4e-14	0.41	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	8.61	1.14e-16	5.4e-14	0.41	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
THCA	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	8.61	1.14e-16	5.4e-14	0.41	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
THCA	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	8.61	1.14e-16	5.4e-14	0.41	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
THCA	cis	rs11148252	0.967	rs11618716	ENSG00000278238.1	RP11-245D16.4	8.61	1.14e-16	5.42e-14	0.41	0.37	Lewy body disease;	chr13:52472701	chr13:52454775~52455331:-
THCA	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-8.61	1.14e-16	5.42e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000206090.4	AP000350.7	8.61	1.14e-16	5.42e-14	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23939998~23942798:+
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000237664.1	LINC00316	-8.61	1.14e-16	5.43e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000237664.1	LINC00316	-8.61	1.15e-16	5.43e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45338590~45341990:-
THCA	cis	rs2946505	0.569	rs2466267	ENSG00000251468.2	RP11-369K16.1	8.61	1.15e-16	5.44e-14	0.59	0.37	Migraine;	chr8:12961793	chr8:12958387~12962200:+
THCA	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-8.61	1.15e-16	5.46e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
THCA	cis	rs741668	0.641	rs9562637	ENSG00000235903.6	CPB2-AS1	-8.61	1.15e-16	5.47e-14	-0.47	-0.37	Cerebrospinal fluid clusterin levels;	chr13:46071410	chr13:46052806~46113332:+
THCA	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-8.61	1.15e-16	5.47e-14	-0.42	-0.37	Height;	chr2:231553603	chr2:231508426~231514339:-
THCA	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	8.6	1.15e-16	5.47e-14	0.82	0.37	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
THCA	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-8.6	1.16e-16	5.48e-14	-0.42	-0.37	Height;	chr2:231551270	chr2:231508426~231514339:-
THCA	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-8.6	1.16e-16	5.49e-14	-0.38	-0.37	Height;	chr11:118773873	chr11:118704607~118750263:+
THCA	cis	rs9659323	0.632	rs10802074	ENSG00000231365.4	RP11-418J17.1	-8.6	1.16e-16	5.5e-14	-0.34	-0.37	Body mass index;	chr1:119082373	chr1:119140396~119275973:+
THCA	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-8.6	1.16e-16	5.51e-14	-0.39	-0.37	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
THCA	cis	rs736801	0.607	rs11739135	ENSG00000237714.1	P4HA2-AS1	8.6	1.16e-16	5.51e-14	0.5	0.37	Mosquito bite size;Breast cancer;	chr5:132397705	chr5:132184876~132192808:+
THCA	cis	rs7665090	0.936	rs5026474	ENSG00000246560.2	RP11-10L12.4	8.6	1.16e-16	5.51e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102633653	chr4:102828055~102844075:+
THCA	cis	rs10411161	0.702	rs10414472	ENSG00000269483.1	AC006272.1	8.6	1.17e-16	5.54e-14	0.51	0.37	Breast cancer;	chr19:51895344	chr19:51839924~51843324:-
THCA	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-8.6	1.18e-16	5.57e-14	-0.3	-0.37	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
THCA	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
THCA	cis	rs7727544	0.547	rs56083751	ENSG00000237714.1	P4HA2-AS1	8.6	1.18e-16	5.59e-14	0.48	0.37	Blood metabolite levels;	chr5:132328945	chr5:132184876~132192808:+
THCA	cis	rs4819052	0.84	rs914217	ENSG00000237664.1	LINC00316	-8.6	1.18e-16	5.59e-14	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45338590~45341990:-
THCA	cis	rs11051970	0.559	rs10844188	ENSG00000274964.1	RP11-817I4.1	-8.6	1.18e-16	5.59e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32334710	chr12:32339368~32340724:+
THCA	cis	rs2929278	0.561	rs62018952	ENSG00000166763.7	STRCP1	-8.6	1.18e-16	5.6e-14	-0.4	-0.37	Schizophrenia;	chr15:43788539	chr15:43699488~43718184:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000235689.1	AP000351.13	8.6	1.18e-16	5.61e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:24006305~24008258:-
THCA	cis	rs1707322	1	rs1707322	ENSG00000234329.1	RP11-767N6.2	8.6	1.19e-16	5.63e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45651039~45651826:-
THCA	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	8.6	1.2e-16	5.68e-14	0.46	0.37	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
THCA	cis	rs516805	0.961	rs483933	ENSG00000279453.1	RP3-425C14.4	-8.6	1.2e-16	5.69e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122460377	chr6:122436789~122439223:-
THCA	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-8.6	1.2e-16	5.69e-14	-0.47	-0.37	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
THCA	cis	rs7665090	1	rs2125211	ENSG00000246560.2	RP11-10L12.4	-8.6	1.2e-16	5.69e-14	-0.44	-0.37	Primary biliary cholangitis;	chr4:102638719	chr4:102828055~102844075:+
THCA	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	8.6	1.2e-16	5.7e-14	0.35	0.37	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
THCA	cis	rs8114671	0.562	rs6120757	ENSG00000269202.1	RP4-614O4.12	-8.6	1.2e-16	5.7e-14	-0.31	-0.37	Height;	chr20:34900968	chr20:35201747~35203288:-
THCA	cis	rs4789693	0.872	rs28612648	ENSG00000265458.1	RP13-20L14.6	8.6	1.2e-16	5.7e-14	0.38	0.37	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82454273~82458521:-
THCA	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	8.6	1.2e-16	5.7e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
THCA	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-8.6	1.2e-16	5.71e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
THCA	cis	rs17772222	0.655	rs816072	ENSG00000258789.1	RP11-507K2.3	8.6	1.21e-16	5.72e-14	0.35	0.37	Coronary artery calcification;	chr14:88484335	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.655	rs1152376	ENSG00000258789.1	RP11-507K2.3	8.6	1.21e-16	5.72e-14	0.35	0.37	Coronary artery calcification;	chr14:88495121	chr14:88551597~88552493:+
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000237664.1	LINC00316	-8.6	1.22e-16	5.79e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45338590~45341990:-
THCA	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	8.6	1.22e-16	5.79e-14	0.6	0.37	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
THCA	cis	rs7646881	1	rs73015652	ENSG00000240207.5	RP11-379F4.4	-8.6	1.23e-16	5.8e-14	-0.49	-0.37	Tetralogy of Fallot;	chr3:158733594	chr3:158732263~158784070:+
THCA	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	8.6	1.23e-16	5.82e-14	0.39	0.37	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
THCA	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-8.6	1.23e-16	5.83e-14	-0.39	-0.37	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
THCA	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	8.6	1.23e-16	5.84e-14	0.48	0.37	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000237664.1	LINC00316	-8.6	1.23e-16	5.84e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45338590~45341990:-
THCA	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-8.6	1.23e-16	5.84e-14	-0.54	-0.37	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
THCA	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-8.6	1.24e-16	5.86e-14	-0.39	-0.37	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
THCA	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-8.6	1.24e-16	5.87e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
THCA	cis	rs7849270	0.84	rs12346996	ENSG00000268707.1	RP11-247A12.7	-8.6	1.24e-16	5.88e-14	-0.5	-0.37	Blood metabolite ratios;	chr9:129078577	chr9:129170434~129170940:+
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45338590~45341990:-
THCA	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-8.59	1.25e-16	5.91e-14	-0.46	-0.37	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
THCA	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-8.59	1.25e-16	5.92e-14	-0.49	-0.37	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-8.59	1.25e-16	5.92e-14	-0.49	-0.37	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-8.59	1.25e-16	5.93e-14	-0.46	-0.37	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
THCA	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-8.59	1.25e-16	5.93e-14	-0.47	-0.37	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
THCA	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-8.59	1.25e-16	5.93e-14	-0.38	-0.37	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
THCA	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	8.59	1.26e-16	5.96e-14	0.46	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
THCA	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	8.59	1.26e-16	5.96e-14	0.38	0.37	QT interval;	chr12:29304617	chr12:29280418~29317848:-
THCA	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-8.59	1.26e-16	5.98e-14	-0.37	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
THCA	cis	rs7849270	0.76	rs882616	ENSG00000268707.1	RP11-247A12.7	8.59	1.27e-16	5.99e-14	0.48	0.37	Blood metabolite ratios;	chr9:129178586	chr9:129170434~129170940:+
THCA	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	8.59	1.27e-16	6e-14	0.44	0.37	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
THCA	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-8.59	1.27e-16	6e-14	-0.64	-0.37	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
THCA	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	8.59	1.27e-16	6.02e-14	0.3	0.37	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-8.59	1.27e-16	6.02e-14	-0.3	-0.37	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-8.59	1.27e-16	6.02e-14	-0.3	-0.37	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
THCA	cis	rs12554020	1	rs55846141	ENSG00000227603.1	RP11-165J3.6	8.59	1.28e-16	6.03e-14	0.62	0.37	Schizophrenia;	chr9:93427679	chr9:93435332~93437121:-
THCA	cis	rs516805	0.924	rs809770	ENSG00000279453.1	RP3-425C14.4	-8.59	1.28e-16	6.03e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122440061	chr6:122436789~122439223:-
THCA	cis	rs516805	0.924	rs476215	ENSG00000279453.1	RP3-425C14.4	-8.59	1.28e-16	6.03e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122440739	chr6:122436789~122439223:-
THCA	cis	rs1707322	0.647	rs6686944	ENSG00000234329.1	RP11-767N6.2	8.59	1.28e-16	6.03e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45651039~45651826:-
THCA	cis	rs17772222	0.63	rs2778936	ENSG00000258789.1	RP11-507K2.3	8.59	1.28e-16	6.05e-14	0.35	0.37	Coronary artery calcification;	chr14:88505959	chr14:88551597~88552493:+
THCA	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	8.59	1.28e-16	6.05e-14	0.35	0.37	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
THCA	cis	rs5769707	0.837	rs5770599	ENSG00000235111.1	RP1-29C18.8	-8.59	1.28e-16	6.05e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49612657~49615716:-
THCA	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	8.59	1.29e-16	6.11e-14	0.45	0.37	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
THCA	cis	rs12554020	0.786	rs17532098	ENSG00000227603.1	RP11-165J3.6	8.59	1.3e-16	6.12e-14	0.7	0.37	Schizophrenia;	chr9:93500443	chr9:93435332~93437121:-
THCA	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	8.59	1.3e-16	6.13e-14	0.32	0.37	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
THCA	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	8.59	1.3e-16	6.13e-14	0.49	0.37	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
THCA	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	8.59	1.3e-16	6.15e-14	0.47	0.37	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
THCA	cis	rs10740039	0.729	rs6479721	ENSG00000254271.1	RP11-131N11.4	8.59	1.31e-16	6.2e-14	0.46	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613364	chr10:60734342~60741828:+
THCA	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-8.59	1.31e-16	6.21e-14	-0.38	-0.37	QT interval;	chr12:29349303	chr12:29280418~29317848:-
THCA	cis	rs10740039	0.732	rs10160182	ENSG00000254271.1	RP11-131N11.4	8.59	1.32e-16	6.23e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602693	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.768	rs10159993	ENSG00000254271.1	RP11-131N11.4	8.59	1.32e-16	6.23e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602788	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.768	rs1372710	ENSG00000254271.1	RP11-131N11.4	8.59	1.32e-16	6.23e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60603200	chr10:60734342~60741828:+
THCA	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-8.59	1.32e-16	6.25e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-8.59	1.32e-16	6.25e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-8.59	1.32e-16	6.25e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-8.59	1.32e-16	6.25e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
THCA	cis	rs12188164	0.515	rs11744936	ENSG00000221990.4	EXOC3-AS1	8.59	1.33e-16	6.26e-14	0.31	0.37	Cystic fibrosis severity;	chr5:411997	chr5:441498~443160:-
THCA	cis	rs11051970	0.559	rs12578899	ENSG00000274964.1	RP11-817I4.1	-8.59	1.33e-16	6.28e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32332017	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs2291421	ENSG00000274964.1	RP11-817I4.1	-8.59	1.33e-16	6.28e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32334173	chr12:32339368~32340724:+
THCA	cis	rs12554020	0.786	rs75395683	ENSG00000227603.1	RP11-165J3.6	8.59	1.33e-16	6.29e-14	0.62	0.37	Schizophrenia;	chr9:93415128	chr9:93435332~93437121:-
THCA	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-8.59	1.33e-16	6.29e-14	-0.5	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
THCA	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-8.59	1.33e-16	6.3e-14	-0.35	-0.37	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
THCA	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-8.59	1.33e-16	6.3e-14	-0.47	-0.37	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
THCA	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	8.59	1.34e-16	6.31e-14	0.28	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
THCA	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-8.59	1.34e-16	6.33e-14	-0.5	-0.37	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-8.59	1.34e-16	6.33e-14	-0.5	-0.37	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
THCA	cis	rs62103177	0.81	rs62103197	ENSG00000261126.6	RP11-795F19.1	8.58	1.34e-16	6.33e-14	0.43	0.37	Opioid sensitivity;	chr18:79872923	chr18:80046900~80095482:+
THCA	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
THCA	cis	rs13068223	0.503	rs34277251	ENSG00000243926.1	TIPARP-AS1	8.58	1.34e-16	6.33e-14	0.38	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156671862~156674378:-
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	8.58	1.34e-16	6.35e-14	0.43	0.37	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
THCA	cis	rs516805	0.961	rs693669	ENSG00000279453.1	RP3-425C14.4	-8.58	1.35e-16	6.35e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122465690	chr6:122436789~122439223:-
THCA	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-8.58	1.35e-16	6.35e-14	-0.42	-0.37	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
THCA	cis	rs7727544	0.548	rs2069614	ENSG00000237714.1	P4HA2-AS1	8.58	1.35e-16	6.37e-14	0.48	0.37	Blood metabolite levels;	chr5:132071908	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.548	rs2069616	ENSG00000237714.1	P4HA2-AS1	8.58	1.35e-16	6.37e-14	0.48	0.37	Blood metabolite levels;	chr5:132072384	chr5:132184876~132192808:+
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000237664.1	LINC00316	-8.58	1.35e-16	6.37e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45338590~45341990:-
THCA	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-8.58	1.35e-16	6.38e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
THCA	cis	rs7015263	0.714	rs56321721	ENSG00000254231.1	CTD-2284J15.1	-8.58	1.35e-16	6.38e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86527798	chr8:86333274~86343314:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000228039.3	KB-1125A3.10	8.58	1.35e-16	6.39e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23963780~23964374:+
THCA	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-8.58	1.36e-16	6.4e-14	-0.58	-0.37	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-8.58	1.36e-16	6.4e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
THCA	cis	rs4591358	0.773	rs17781713	ENSG00000223466.1	AC064834.2	-8.58	1.37e-16	6.45e-14	-0.5	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506827	chr2:195533035~195538681:+
THCA	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-8.58	1.37e-16	6.45e-14	-0.44	-0.37	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
THCA	cis	rs10411161	0.702	rs6509591	ENSG00000269483.1	AC006272.1	8.58	1.37e-16	6.48e-14	0.5	0.37	Breast cancer;	chr19:51888687	chr19:51839924~51843324:-
THCA	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-8.58	1.38e-16	6.49e-14	-0.48	-0.37	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
THCA	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	8.58	1.38e-16	6.49e-14	0.44	0.37	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
THCA	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-8.58	1.38e-16	6.49e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
THCA	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-8.58	1.38e-16	6.5e-14	-0.36	-0.37	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
THCA	cis	rs7727544	0.564	rs3852206	ENSG00000237714.1	P4HA2-AS1	8.58	1.38e-16	6.51e-14	0.5	0.37	Blood metabolite levels;	chr5:132079743	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.618	rs2631367	ENSG00000237714.1	P4HA2-AS1	-8.58	1.38e-16	6.52e-14	-0.48	-0.37	Blood metabolite levels;	chr5:132369766	chr5:132184876~132192808:+
THCA	cis	rs516805	0.781	rs502103	ENSG00000279453.1	RP3-425C14.4	-8.58	1.38e-16	6.53e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122446062	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs511279	ENSG00000279453.1	RP3-425C14.4	-8.58	1.38e-16	6.53e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122451385	chr6:122436789~122439223:-
THCA	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	8.58	1.39e-16	6.53e-14	0.36	0.37	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	8.58	1.39e-16	6.53e-14	0.36	0.37	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
THCA	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	8.58	1.39e-16	6.53e-14	0.5	0.37	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
THCA	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-8.58	1.39e-16	6.55e-14	-0.36	-0.37	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
THCA	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-8.58	1.39e-16	6.56e-14	-0.35	-0.37	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
THCA	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	8.58	1.4e-16	6.58e-14	0.47	0.37	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
THCA	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-8.58	1.4e-16	6.6e-14	-0.52	-0.37	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
THCA	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-8.58	1.4e-16	6.61e-14	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000226314.6	ZNF192P1	-8.58	1.4e-16	6.62e-14	-0.49	-0.37	Depression;	chr6:28206179	chr6:28161781~28169594:+
THCA	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-8.58	1.41e-16	6.64e-14	-0.43	-0.37	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
THCA	cis	rs2274273	0.661	rs2147964	ENSG00000258413.1	RP11-665C16.6	-8.58	1.41e-16	6.66e-14	-0.48	-0.37	Protein biomarker;	chr14:55097677	chr14:55262767~55272075:-
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000235689.1	AP000351.13	8.58	1.41e-16	6.66e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:24006305~24008258:-
THCA	cis	rs17684571	0.751	rs13203681	ENSG00000231441.1	RP11-472M19.2	8.58	1.41e-16	6.67e-14	0.46	0.37	Schizophrenia;	chr6:56841361	chr6:56844002~56864078:+
THCA	cis	rs3847687	0.966	rs3847689	ENSG00000256810.1	RP11-76C10.2	8.58	1.42e-16	6.69e-14	0.43	0.37	Longevity;	chr12:131040989	chr12:131030570~131035487:-
THCA	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-8.58	1.42e-16	6.7e-14	-0.42	-0.37	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
THCA	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	8.58	1.42e-16	6.71e-14	0.46	0.37	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
THCA	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-8.58	1.42e-16	6.71e-14	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
THCA	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-8.58	1.43e-16	6.72e-14	-0.38	-0.37	QT interval;	chr12:29343291	chr12:29280418~29317848:-
THCA	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	8.58	1.43e-16	6.73e-14	0.6	0.37	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	8.58	1.43e-16	6.73e-14	0.6	0.37	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
THCA	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	8.58	1.43e-16	6.74e-14	0.71	0.37	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
THCA	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	8.58	1.44e-16	6.77e-14	0.35	0.37	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
THCA	cis	rs7665090	0.875	rs6813687	ENSG00000246560.2	RP11-10L12.4	8.58	1.44e-16	6.78e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634455	chr4:102828055~102844075:+
THCA	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-8.58	1.44e-16	6.79e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
THCA	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-8.58	1.44e-16	6.79e-14	-0.34	-0.37	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
THCA	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-8.58	1.44e-16	6.8e-14	-0.52	-0.37	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.824	rs7759217	ENSG00000219392.1	RP1-265C24.5	-8.57	1.45e-16	6.81e-14	-0.49	-0.37	Parkinson's disease;	chr6:27762684	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.784	rs9468219	ENSG00000219392.1	RP1-265C24.5	-8.57	1.45e-16	6.81e-14	-0.49	-0.37	Parkinson's disease;	chr6:27763976	chr6:28115628~28116551:+
THCA	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	8.57	1.45e-16	6.81e-14	0.43	0.37	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
THCA	cis	rs748404	0.697	rs555001	ENSG00000249839.1	AC011330.5	-8.57	1.45e-16	6.82e-14	-0.43	-0.37	Lung cancer;	chr15:43253530	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs475261	ENSG00000249839.1	AC011330.5	-8.57	1.45e-16	6.82e-14	-0.43	-0.37	Lung cancer;	chr15:43254258	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000237664.1	LINC00316	-8.57	1.45e-16	6.82e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45338590~45341990:-
THCA	cis	rs6723226	0.521	rs1991626	ENSG00000276334.1	AL133243.1	-8.57	1.45e-16	6.84e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr2:32377382	chr2:32521927~32523547:+
THCA	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.86e-14	-0.52	-0.37	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.86e-14	-0.52	-0.37	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.86e-14	-0.52	-0.37	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.86e-14	-0.52	-0.37	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
THCA	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-8.57	1.46e-16	6.87e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-8.57	1.46e-16	6.87e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-8.57	1.46e-16	6.87e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
THCA	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	8.57	1.46e-16	6.87e-14	0.46	0.37	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
THCA	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.89e-14	-0.49	-0.37	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
THCA	cis	rs516805	0.781	rs477425	ENSG00000279453.1	RP3-425C14.4	-8.57	1.47e-16	6.9e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122393627	chr6:122436789~122439223:-
THCA	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	8.57	1.47e-16	6.91e-14	0.37	0.37	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
THCA	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-8.57	1.47e-16	6.91e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-8.57	1.47e-16	6.91e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-8.57	1.47e-16	6.91e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
THCA	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-8.57	1.47e-16	6.91e-14	-0.41	-0.37	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
THCA	cis	rs9543976	1	rs73223984	ENSG00000261553.4	RP11-29G8.3	-8.57	1.47e-16	6.93e-14	-0.49	-0.37	Diabetic retinopathy;	chr13:75607005	chr13:75549773~75807120:+
THCA	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	8.57	1.48e-16	6.96e-14	0.24	0.37	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
THCA	cis	rs7665090	1	rs7677509	ENSG00000246560.2	RP11-10L12.4	8.57	1.48e-16	6.97e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102628849	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs7699231	ENSG00000246560.2	RP11-10L12.4	8.57	1.48e-16	6.97e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102628918	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs7699678	ENSG00000246560.2	RP11-10L12.4	8.57	1.48e-16	6.97e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102628939	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs11724614	ENSG00000246560.2	RP11-10L12.4	8.57	1.48e-16	6.97e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102629091	chr4:102828055~102844075:+
THCA	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	8.57	1.49e-16	6.99e-14	0.85	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
THCA	cis	rs1153858	0.562	rs8025019	ENSG00000259520.4	CTD-2651B20.3	-8.57	1.49e-16	7.02e-14	-0.7	-0.37	Homoarginine levels;	chr15:45443667	chr15:45251580~45279251:-
THCA	cis	rs7727544	0.606	rs2631360	ENSG00000237714.1	P4HA2-AS1	8.57	1.49e-16	7.02e-14	0.48	0.37	Blood metabolite levels;	chr5:132371737	chr5:132184876~132192808:+
THCA	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	8.57	1.5e-16	7.05e-14	0.39	0.37	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
THCA	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-8.57	1.5e-16	7.05e-14	-0.47	-0.37	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
THCA	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	8.57	1.5e-16	7.07e-14	0.39	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
THCA	cis	rs2032366	0.591	rs7241479	ENSG00000267279.1	RP11-879F14.2	-8.57	1.51e-16	7.1e-14	-0.39	-0.37	Obesity-related traits;	chr18:61631923	chr18:61585746~61606916:-
THCA	cis	rs2032366	0.654	rs7227661	ENSG00000267279.1	RP11-879F14.2	-8.57	1.51e-16	7.1e-14	-0.39	-0.37	Obesity-related traits;	chr18:61632275	chr18:61585746~61606916:-
THCA	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-8.57	1.51e-16	7.11e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
THCA	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-8.57	1.52e-16	7.13e-14	-0.39	-0.37	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
THCA	cis	rs4591358	0.773	rs17781737	ENSG00000223466.1	AC064834.2	-8.57	1.52e-16	7.13e-14	-0.5	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508251	chr2:195533035~195538681:+
THCA	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	8.57	1.52e-16	7.13e-14	0.52	0.37	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
THCA	cis	rs7727544	0.548	rs4705938	ENSG00000237714.1	P4HA2-AS1	8.57	1.52e-16	7.14e-14	0.48	0.37	Blood metabolite levels;	chr5:132358384	chr5:132184876~132192808:+
THCA	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-8.57	1.53e-16	7.17e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
THCA	cis	rs7849270	0.837	rs4642748	ENSG00000268707.1	RP11-247A12.7	-8.57	1.53e-16	7.17e-14	-0.45	-0.37	Blood metabolite ratios;	chr9:129092668	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.692	rs4397510	ENSG00000268707.1	RP11-247A12.7	-8.57	1.53e-16	7.17e-14	-0.45	-0.37	Blood metabolite ratios;	chr9:129092671	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.879	rs10739741	ENSG00000268707.1	RP11-247A12.7	-8.57	1.53e-16	7.17e-14	-0.45	-0.37	Blood metabolite ratios;	chr9:129092881	chr9:129170434~129170940:+
THCA	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-8.57	1.53e-16	7.19e-14	-0.43	-0.37	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	8.57	1.53e-16	7.2e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
THCA	cis	rs736801	0.704	rs56399423	ENSG00000237714.1	P4HA2-AS1	8.57	1.53e-16	7.21e-14	0.5	0.37	Mosquito bite size;Breast cancer;	chr5:132336964	chr5:132184876~132192808:+
THCA	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	8.57	1.54e-16	7.22e-14	0.36	0.37	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
THCA	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	8.57	1.54e-16	7.23e-14	0.45	0.37	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
THCA	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-8.57	1.54e-16	7.23e-14	-0.3	-0.37	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
THCA	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	8.57	1.54e-16	7.25e-14	0.36	0.37	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
THCA	cis	rs17772222	0.675	rs1099698	ENSG00000258789.1	RP11-507K2.3	8.57	1.55e-16	7.26e-14	0.35	0.37	Coronary artery calcification;	chr14:88414904	chr14:88551597~88552493:+
THCA	cis	rs1707322	0.717	rs3014246	ENSG00000234329.1	RP11-767N6.2	-8.57	1.55e-16	7.26e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000237664.1	LINC00316	8.57	1.55e-16	7.28e-14	0.37	0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45338590~45341990:-
THCA	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-8.57	1.55e-16	7.29e-14	-0.49	-0.37	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-8.57	1.55e-16	7.29e-14	-0.49	-0.37	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
THCA	cis	rs42490	0.638	rs28144	ENSG00000251136.7	RP11-37B2.1	-8.56	1.56e-16	7.33e-14	-0.31	-0.37	Leprosy;	chr8:89810531	chr8:89609409~89757727:-
THCA	cis	rs848490	0.674	rs6971555	ENSG00000214293.7	APTR	8.56	1.56e-16	7.33e-14	0.28	0.37	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777422	chr7:77657660~77696265:-
THCA	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	8.56	1.58e-16	7.4e-14	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	8.56	1.58e-16	7.4e-14	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	8.56	1.58e-16	7.4e-14	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	8.56	1.58e-16	7.4e-14	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
THCA	cis	rs516805	0.961	rs1267942	ENSG00000279453.1	RP3-425C14.4	-8.56	1.58e-16	7.43e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122472375	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs471620	ENSG00000279453.1	RP3-425C14.4	-8.56	1.58e-16	7.43e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122473532	chr6:122436789~122439223:-
THCA	cis	rs4819052	0.788	rs35323494	ENSG00000215447.6	BX322557.10	-8.56	1.59e-16	7.45e-14	-0.32	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.55	rs1861350	ENSG00000279344.1	RP11-44F14.7	8.56	1.59e-16	7.45e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr16:53499430	chr16:53478957~53481550:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-8.56	1.59e-16	7.46e-14	-0.45	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
THCA	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-8.56	1.59e-16	7.46e-14	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
THCA	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	8.56	1.59e-16	7.47e-14	0.55	0.37	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
THCA	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	8.56	1.59e-16	7.49e-14	0.24	0.37	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
THCA	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-8.56	1.6e-16	7.53e-14	-0.38	-0.37	Height;	chr11:118786602	chr11:118704607~118750263:+
THCA	cis	rs11051970	0.559	rs4931621	ENSG00000274964.1	RP11-817I4.1	-8.56	1.61e-16	7.54e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32333569	chr12:32339368~32340724:+
THCA	cis	rs2274273	0.588	rs17128145	ENSG00000258413.1	RP11-665C16.6	8.56	1.61e-16	7.54e-14	0.5	0.37	Protein biomarker;	chr14:55069688	chr14:55262767~55272075:-
THCA	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-8.56	1.61e-16	7.56e-14	-0.59	-0.37	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
THCA	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-8.56	1.61e-16	7.56e-14	-0.38	-0.37	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
THCA	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-8.56	1.61e-16	7.57e-14	-0.46	-0.37	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
THCA	cis	rs11051970	0.559	rs3816819	ENSG00000274964.1	RP11-817I4.1	-8.56	1.61e-16	7.58e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32334123	chr12:32339368~32340724:+
THCA	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	8.56	1.62e-16	7.59e-14	0.44	0.37	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000237664.1	LINC00316	-8.56	1.62e-16	7.6e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45338590~45341990:-
THCA	cis	rs11971779	0.793	rs4732366	ENSG00000273391.1	RP11-634H22.1	8.56	1.62e-16	7.6e-14	0.36	0.37	Diisocyanate-induced asthma;	chr7:139343099	chr7:139359032~139359566:-
THCA	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	8.56	1.62e-16	7.61e-14	0.41	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000224205.1	AP000351.4	8.56	1.63e-16	7.63e-14	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23987320~23991421:-
THCA	cis	rs10847980	0.623	rs7955367	ENSG00000256092.2	RP13-942N8.1	8.56	1.64e-16	7.67e-14	0.55	0.37	Adiponectin levels;	chr12:123344245	chr12:123363868~123366113:+
THCA	cis	rs10847980	0.623	rs28613486	ENSG00000256092.2	RP13-942N8.1	8.56	1.64e-16	7.67e-14	0.55	0.37	Adiponectin levels;	chr12:123382721	chr12:123363868~123366113:+
THCA	cis	rs516805	0.59	rs13371	ENSG00000279453.1	RP3-425C14.4	-8.56	1.64e-16	7.67e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122443881	chr6:122436789~122439223:-
THCA	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-8.56	1.64e-16	7.69e-14	-0.54	-0.37	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
THCA	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-8.56	1.65e-16	7.71e-14	-0.47	-0.37	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
THCA	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
THCA	cis	rs853679	0.506	rs1150693	ENSG00000226314.6	ZNF192P1	-8.56	1.66e-16	7.75e-14	-0.49	-0.37	Depression;	chr6:28206812	chr6:28161781~28169594:+
THCA	cis	rs10740039	0.81	rs10761528	ENSG00000254271.1	RP11-131N11.4	8.56	1.66e-16	7.77e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607902	chr10:60734342~60741828:+
THCA	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	8.56	1.66e-16	7.78e-14	0.68	0.37	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
THCA	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-8.56	1.67e-16	7.82e-14	-0.37	-0.37	Height;	chr11:118760944	chr11:118704607~118750263:+
THCA	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-8.56	1.67e-16	7.83e-14	-0.38	-0.37	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
THCA	cis	rs516805	0.961	rs573709	ENSG00000279453.1	RP3-425C14.4	8.55	1.69e-16	7.88e-14	0.33	0.37	Lymphocyte counts;	chr6:122457673	chr6:122436789~122439223:-
THCA	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-8.55	1.69e-16	7.91e-14	-0.42	-0.37	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	8.55	1.7e-16	7.93e-14	0.27	0.37	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
THCA	cis	rs2946505	0.689	rs2977087	ENSG00000251468.2	RP11-369K16.1	8.55	1.7e-16	7.94e-14	0.6	0.37	Migraine;	chr8:12953432	chr8:12958387~12962200:+
THCA	cis	rs7015263	0.689	rs12543887	ENSG00000254231.1	CTD-2284J15.1	-8.55	1.71e-16	7.99e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86408311	chr8:86333274~86343314:-
THCA	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-8.55	1.71e-16	8e-14	-0.43	-0.37	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
THCA	cis	rs737008	0.96	rs11640295	ENSG00000262703.1	RP11-485G7.6	8.55	1.71e-16	8.01e-14	0.43	0.37	Obesity-related traits;	chr16:11296871	chr16:11348143~11349321:-
THCA	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	8.55	1.72e-16	8.02e-14	0.48	0.37	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
THCA	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-8.55	1.72e-16	8.03e-14	-0.53	-0.37	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
THCA	cis	rs516805	0.673	rs561953	ENSG00000279453.1	RP3-425C14.4	-8.55	1.72e-16	8.06e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122440341	chr6:122436789~122439223:-
THCA	cis	rs7727544	0.505	rs721121	ENSG00000237714.1	P4HA2-AS1	8.55	1.73e-16	8.08e-14	0.48	0.37	Blood metabolite levels;	chr5:132070740	chr5:132184876~132192808:+
THCA	cis	rs62103177	0.81	rs62103195	ENSG00000261126.6	RP11-795F19.1	8.55	1.73e-16	8.09e-14	0.43	0.37	Opioid sensitivity;	chr18:79869693	chr18:80046900~80095482:+
THCA	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-8.55	1.74e-16	8.13e-14	-0.47	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
THCA	cis	rs748404	0.578	rs2584701	ENSG00000205771.5	CATSPER2P1	-8.55	1.74e-16	8.13e-14	-0.39	-0.37	Lung cancer;	chr15:43392741	chr15:43726918~43747094:-
THCA	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	8.55	1.74e-16	8.15e-14	0.39	0.37	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
THCA	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	8.55	1.74e-16	8.15e-14	0.39	0.37	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
THCA	cis	rs1009647	1	rs1890256	ENSG00000258413.1	RP11-665C16.6	-8.55	1.75e-16	8.16e-14	-0.55	-0.37	Testicular germ cell tumor;	chr14:55414558	chr14:55262767~55272075:-
THCA	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	8.55	1.75e-16	8.16e-14	0.43	0.37	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
THCA	cis	rs7615952	0.673	rs34072288	ENSG00000171084.14	FAM86JP	8.55	1.75e-16	8.18e-14	0.62	0.37	Blood pressure (smoking interaction);	chr3:125825186	chr3:125916620~125930024:+
THCA	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	8.55	1.75e-16	8.18e-14	0.49	0.37	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	8.55	1.75e-16	8.18e-14	0.49	0.37	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-8.55	1.75e-16	8.2e-14	-0.37	-0.37	Height;	chr11:118746590	chr11:118704607~118750263:+
THCA	cis	rs2929278	0.617	rs575082	ENSG00000166763.7	STRCP1	-8.55	1.76e-16	8.22e-14	-0.4	-0.37	Schizophrenia;	chr15:43817944	chr15:43699488~43718184:-
THCA	cis	rs9813712	0.571	rs9855426	ENSG00000228252.7	COL6A4P2	8.55	1.76e-16	8.22e-14	0.37	0.37	Response to amphetamines;	chr3:130214475	chr3:130212823~130273806:+
THCA	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	8.55	1.76e-16	8.23e-14	0.55	0.37	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
THCA	cis	rs1075265	0.572	rs2193682	ENSG00000233266.1	HMGB1P31	8.55	1.77e-16	8.25e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53695119	chr2:54051334~54051760:+
THCA	cis	rs10411161	0.702	rs6509592	ENSG00000269483.1	AC006272.1	8.55	1.77e-16	8.26e-14	0.51	0.37	Breast cancer;	chr19:51889897	chr19:51839924~51843324:-
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000237664.1	LINC00316	-8.55	1.77e-16	8.26e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45338590~45341990:-
THCA	cis	rs516805	0.961	rs527978	ENSG00000279453.1	RP3-425C14.4	-8.55	1.78e-16	8.29e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122475225	chr6:122436789~122439223:-
THCA	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-8.55	1.78e-16	8.31e-14	-0.44	-0.37	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
THCA	cis	rs516805	0.706	rs1267943	ENSG00000279453.1	RP3-425C14.4	-8.55	1.78e-16	8.32e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122462498	chr6:122436789~122439223:-
THCA	cis	rs35260072	1	rs35260072	ENSG00000237714.1	P4HA2-AS1	8.55	1.78e-16	8.33e-14	0.5	0.37	Itch intensity from mosquito bite;	chr5:132295159	chr5:132184876~132192808:+
THCA	cis	rs7015263	0.689	rs56395805	ENSG00000254231.1	CTD-2284J15.1	-8.55	1.78e-16	8.33e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86401033	chr8:86333274~86343314:-
THCA	cis	rs11148252	0.508	rs6561671	ENSG00000235660.1	LINC00345	-8.55	1.79e-16	8.34e-14	-0.44	-0.37	Lewy body disease;	chr13:52608179	chr13:52484161~52484680:-
THCA	cis	rs7015263	0.579	rs34895735	ENSG00000254231.1	CTD-2284J15.1	-8.55	1.79e-16	8.35e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86393165	chr8:86333274~86343314:-
THCA	cis	rs17684571	0.751	rs36094082	ENSG00000231441.1	RP11-472M19.2	8.55	1.79e-16	8.35e-14	0.46	0.37	Schizophrenia;	chr6:56842153	chr6:56844002~56864078:+
THCA	cis	rs61041384	0.661	rs74240781	ENSG00000256092.2	RP13-942N8.1	-8.55	1.79e-16	8.36e-14	-0.55	-0.37	Schizophrenia;	chr12:123308154	chr12:123363868~123366113:+
THCA	cis	rs6600671	0.719	rs9728991	ENSG00000223345.3	HIST2H2BA	8.55	1.8e-16	8.38e-14	0.41	0.37	Hip geometry;	chr1:121522281	chr1:121108210~121117257:-
THCA	cis	rs9926296	0.744	rs460879	ENSG00000260259.1	RP11-368I7.4	8.55	1.8e-16	8.4e-14	0.39	0.37	Vitiligo;	chr16:89646481	chr16:89682620~89686569:-
THCA	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	8.55	1.8e-16	8.41e-14	0.36	0.37	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
THCA	cis	rs2929278	0.588	rs1975364	ENSG00000166763.7	STRCP1	8.55	1.81e-16	8.42e-14	0.4	0.37	Schizophrenia;	chr15:43857991	chr15:43699488~43718184:-
THCA	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	8.55	1.81e-16	8.43e-14	0.57	0.37	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
THCA	cis	rs16846053	0.515	rs7588198	ENSG00000227403.1	AC009299.3	-8.55	1.81e-16	8.43e-14	-0.59	-0.37	Blood osmolality (transformed sodium);	chr2:161508691	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs10202267	ENSG00000227403.1	AC009299.3	-8.55	1.81e-16	8.43e-14	-0.59	-0.37	Blood osmolality (transformed sodium);	chr2:161509616	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs7595197	ENSG00000227403.1	AC009299.3	-8.55	1.81e-16	8.43e-14	-0.59	-0.37	Blood osmolality (transformed sodium);	chr2:161510325	chr2:161244739~161249050:+
THCA	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	8.55	1.81e-16	8.43e-14	0.48	0.37	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
THCA	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-8.54	1.82e-16	8.48e-14	-0.46	-0.37	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
THCA	cis	rs1707322	0.686	rs2275085	ENSG00000234329.1	RP11-767N6.2	-8.54	1.82e-16	8.5e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45651039~45651826:-
THCA	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	8.54	1.82e-16	8.5e-14	0.46	0.37	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
THCA	cis	rs11603691	0.901	rs11228997	ENSG00000254662.1	RP11-872D17.4	-8.54	1.83e-16	8.53e-14	-0.68	-0.37	Low high density lipoprotein cholesterol levels;	chr11:57316555	chr11:57325603~57327958:+
THCA	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	8.54	1.83e-16	8.55e-14	0.44	0.37	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
THCA	cis	rs8114671	0.836	rs6060140	ENSG00000269202.1	RP4-614O4.12	-8.54	1.84e-16	8.57e-14	-0.31	-0.37	Height;	chr20:34978704	chr20:35201747~35203288:-
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000237664.1	LINC00316	-8.54	1.84e-16	8.57e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45338590~45341990:-
THCA	cis	rs2929278	0.617	rs4617832	ENSG00000166763.7	STRCP1	-8.54	1.84e-16	8.58e-14	-0.4	-0.37	Schizophrenia;	chr15:43738381	chr15:43699488~43718184:-
THCA	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	8.54	1.84e-16	8.59e-14	0.52	0.37	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
THCA	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-8.54	1.85e-16	8.61e-14	-0.54	-0.37	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
THCA	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-8.54	1.85e-16	8.62e-14	-0.33	-0.37	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
THCA	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-8.54	1.86e-16	8.65e-14	-0.35	-0.37	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-8.54	1.86e-16	8.65e-14	-0.35	-0.37	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-8.54	1.86e-16	8.65e-14	-0.35	-0.37	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-8.54	1.86e-16	8.65e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.582	rs10075459	ENSG00000237714.1	P4HA2-AS1	8.54	1.86e-16	8.66e-14	0.46	0.37	Blood metabolite levels;	chr5:132205670	chr5:132184876~132192808:+
THCA	cis	rs7849270	0.879	rs3124496	ENSG00000268707.1	RP11-247A12.7	8.54	1.86e-16	8.69e-14	0.47	0.37	Blood metabolite ratios;	chr9:129094583	chr9:129170434~129170940:+
THCA	cis	rs526231	0.667	rs187580	ENSG00000175749.11	EIF3KP1	8.54	1.87e-16	8.69e-14	0.58	0.37	Primary biliary cholangitis;	chr5:103291654	chr5:103032376~103033031:+
THCA	cis	rs7646881	0.767	rs58152433	ENSG00000240207.5	RP11-379F4.4	-8.54	1.87e-16	8.73e-14	-0.51	-0.37	Tetralogy of Fallot;	chr3:158738851	chr3:158732263~158784070:+
THCA	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	8.54	1.88e-16	8.74e-14	0.43	0.37	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
THCA	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-8.54	1.88e-16	8.74e-14	-0.43	-0.37	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
THCA	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-8.54	1.88e-16	8.74e-14	-0.43	-0.37	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
THCA	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-8.54	1.88e-16	8.75e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
THCA	cis	rs7015263	0.573	rs6983925	ENSG00000254231.1	CTD-2284J15.1	-8.54	1.88e-16	8.76e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86277028	chr8:86333274~86343314:-
THCA	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	8.54	1.89e-16	8.79e-14	0.56	0.37	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
THCA	cis	rs4819052	1	rs9306123	ENSG00000237664.1	LINC00316	-8.54	1.89e-16	8.81e-14	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45338590~45341990:-
THCA	cis	rs17684571	0.872	rs13198938	ENSG00000231441.1	RP11-472M19.2	8.54	1.89e-16	8.82e-14	0.49	0.37	Schizophrenia;	chr6:56733628	chr6:56844002~56864078:+
THCA	cis	rs2929278	0.617	rs2955969	ENSG00000166763.7	STRCP1	-8.54	1.9e-16	8.85e-14	-0.4	-0.37	Schizophrenia;	chr15:43822329	chr15:43699488~43718184:-
THCA	cis	rs1707322	0.721	rs6699418	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4431884	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.65	rs4660879	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10789468	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs6429574	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45651039~45651826:-
THCA	cis	rs7851660	0.967	rs7043885	ENSG00000236130.1	PTCSC2	-8.54	1.91e-16	8.89e-14	-0.28	-0.37	Strep throat;	chr9:97834157	chr9:97805935~97810008:-
THCA	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-8.54	1.91e-16	8.91e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
THCA	cis	rs747687	0.655	rs7218037	ENSG00000262133.1	RP11-676J12.6	8.54	1.92e-16	8.93e-14	0.61	0.37	Blood pressure;	chr17:866227	chr17:877902~880093:+
THCA	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-8.54	1.92e-16	8.96e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
THCA	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-8.54	1.93e-16	8.97e-14	-0.53	-0.37	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
THCA	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
THCA	cis	rs736801	0.569	rs12517950	ENSG00000237714.1	P4HA2-AS1	8.54	1.93e-16	8.97e-14	0.49	0.37	Mosquito bite size;Breast cancer;	chr5:132395634	chr5:132184876~132192808:+
THCA	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-8.54	1.93e-16	8.97e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
THCA	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	8.54	1.93e-16	8.99e-14	0.63	0.37	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	8.54	1.93e-16	8.99e-14	0.63	0.37	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000237664.1	LINC00316	8.54	1.94e-16	9.01e-14	0.37	0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45338590~45341990:-
THCA	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	8.54	1.94e-16	9.02e-14	0.35	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
THCA	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	8.54	1.94e-16	9.02e-14	0.58	0.37	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
THCA	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	8.54	1.95e-16	9.06e-14	0.45	0.37	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
THCA	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	8.53	1.95e-16	9.07e-14	0.27	0.37	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
THCA	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-8.53	1.96e-16	9.1e-14	-0.45	-0.37	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
THCA	cis	rs947583	0.955	rs7760254	ENSG00000231028.7	LINC00271	8.53	1.96e-16	9.12e-14	0.3	0.37	Phosphorus levels;	chr6:135811157	chr6:135497801~135716055:+
THCA	cis	rs7712401	0.765	rs10079941	ENSG00000263432.2	RN7SL689P	8.53	1.97e-16	9.16e-14	0.41	0.37	Mean platelet volume;	chr5:123045668	chr5:123022487~123022783:-
THCA	cis	rs1707322	0.717	rs3014245	ENSG00000234329.1	RP11-767N6.2	-8.53	1.97e-16	9.16e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs1135850	ENSG00000234329.1	RP11-767N6.2	8.53	1.98e-16	9.2e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.655	rs3014240	ENSG00000234329.1	RP11-767N6.2	-8.53	1.98e-16	9.2e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs3014235	ENSG00000234329.1	RP11-767N6.2	-8.53	1.98e-16	9.2e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45651039~45651826:-
THCA	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-8.53	1.98e-16	9.21e-14	-0.38	-0.37	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
THCA	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	8.53	1.99e-16	9.25e-14	0.44	0.37	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
THCA	cis	rs17684571	0.625	rs16888186	ENSG00000231441.1	RP11-472M19.2	8.53	1.99e-16	9.26e-14	0.46	0.37	Schizophrenia;	chr6:56866906	chr6:56844002~56864078:+
THCA	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-8.53	1.99e-16	9.27e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000237664.1	LINC00316	-8.53	2e-16	9.31e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45338590~45341990:-
THCA	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-8.53	2.01e-16	9.33e-14	-0.46	-0.37	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
THCA	cis	rs10971721	0.818	rs10971708	ENSG00000260947.1	RP11-384P7.7	8.53	2.01e-16	9.33e-14	0.93	0.37	Body mass index;	chr9:33803273	chr9:33697459~33700986:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000235689.1	AP000351.13	8.53	2.01e-16	9.35e-14	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:24006305~24008258:-
THCA	cis	rs4819052	0.679	rs2838860	ENSG00000215447.6	BX322557.10	-8.53	2.02e-16	9.39e-14	-0.3	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45288052~45291738:+
THCA	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-8.53	2.03e-16	9.42e-14	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
THCA	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	8.53	2.03e-16	9.44e-14	0.45	0.37	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-8.53	2.04e-16	9.46e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-8.53	2.04e-16	9.46e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
THCA	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-8.53	2.04e-16	9.48e-14	-0.47	-0.37	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
THCA	cis	rs11971779	0.793	rs11543827	ENSG00000273391.1	RP11-634H22.1	8.53	2.05e-16	9.5e-14	0.36	0.37	Diisocyanate-induced asthma;	chr7:139347947	chr7:139359032~139359566:-
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
THCA	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	8.53	2.05e-16	9.5e-14	0.36	0.37	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	8.53	2.05e-16	9.5e-14	0.36	0.37	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
THCA	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	8.53	2.05e-16	9.51e-14	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
THCA	cis	rs2439831	0.85	rs28413881	ENSG00000249839.1	AC011330.5	-8.53	2.06e-16	9.55e-14	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43881901	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000224205.1	AP000351.4	8.53	2.06e-16	9.55e-14	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23987320~23991421:-
THCA	cis	rs7569084	0.687	rs1437462	ENSG00000234255.7	AC012370.3	8.53	2.06e-16	9.56e-14	0.42	0.37	Sum eosinophil basophil counts;	chr2:65449559	chr2:65439888~65456571:-
THCA	cis	rs736801	0.607	rs11746555	ENSG00000237714.1	P4HA2-AS1	8.53	2.06e-16	9.58e-14	0.49	0.37	Mosquito bite size;Breast cancer;	chr5:132391341	chr5:132184876~132192808:+
THCA	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-8.53	2.06e-16	9.58e-14	-0.37	-0.37	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
THCA	cis	rs17772222	0.682	rs1152377	ENSG00000258789.1	RP11-507K2.3	8.53	2.06e-16	9.58e-14	0.35	0.37	Coronary artery calcification;	chr14:88496243	chr14:88551597~88552493:+
THCA	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	8.53	2.07e-16	9.59e-14	0.5	0.37	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
THCA	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	8.53	2.07e-16	9.61e-14	0.36	0.37	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	8.53	2.07e-16	9.61e-14	0.36	0.37	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
THCA	cis	rs7665090	0.967	rs13106325	ENSG00000246560.2	RP11-10L12.4	8.53	2.07e-16	9.62e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102633835	chr4:102828055~102844075:+
THCA	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-8.53	2.07e-16	9.62e-14	-0.35	-0.37	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
THCA	cis	rs4842666	0.915	rs12579302	ENSG00000258302.2	RP11-981P6.1	-8.53	2.08e-16	9.64e-14	-0.36	-0.37	Blood pressure;	chr12:89656726	chr12:89561129~89594878:+
THCA	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	8.53	2.08e-16	9.64e-14	0.41	0.37	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
THCA	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-8.53	2.08e-16	9.67e-14	-0.48	-0.37	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
THCA	cis	rs529866	0.519	rs4451969	ENSG00000262636.1	CTD-3088G3.4	-8.53	2.09e-16	9.68e-14	-0.47	-0.37	Inflammatory bowel disease;Crohn's disease;	chr16:11289662	chr16:11380859~11381118:-
THCA	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	8.53	2.09e-16	9.69e-14	0.3	0.37	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
THCA	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	8.53	2.1e-16	9.73e-14	0.35	0.37	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
THCA	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	8.53	2.1e-16	9.74e-14	0.38	0.37	QT interval;	chr12:29379056	chr12:29280418~29317848:-
THCA	cis	rs10181042	0.514	rs1177288	ENSG00000271889.1	RP11-493E12.1	8.52	2.1e-16	9.75e-14	0.35	0.37	Crohn's disease;	chr2:61125850	chr2:61151433~61162105:-
THCA	cis	rs10181042	0.514	rs1177289	ENSG00000271889.1	RP11-493E12.1	8.52	2.1e-16	9.75e-14	0.35	0.37	Crohn's disease;	chr2:61126121	chr2:61151433~61162105:-
THCA	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-8.52	2.1e-16	9.76e-14	-0.48	-0.37	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-8.52	2.11e-16	9.78e-14	-0.46	-0.37	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-8.52	2.11e-16	9.78e-14	-0.46	-0.37	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-8.52	2.11e-16	9.78e-14	-0.46	-0.37	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs61945217	ENSG00000275409.1	RP11-131L12.4	-8.52	2.11e-16	9.8e-14	-0.49	-0.37	Glucose homeostasis traits;	chr12:118261194	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs117091919	ENSG00000275409.1	RP11-131L12.4	-8.52	2.11e-16	9.8e-14	-0.49	-0.37	Glucose homeostasis traits;	chr12:118273228	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs7314987	ENSG00000275409.1	RP11-131L12.4	-8.52	2.11e-16	9.8e-14	-0.49	-0.37	Glucose homeostasis traits;	chr12:118274072	chr12:118430147~118430699:+
THCA	cis	rs9309473	0.687	rs6546827	ENSG00000163016.8	ALMS1P	8.52	2.11e-16	9.81e-14	0.48	0.37	Metabolite levels;	chr2:73379365	chr2:73644919~73685576:+
THCA	cis	rs4819052	0.851	rs2838867	ENSG00000237664.1	LINC00316	-8.52	2.12e-16	9.81e-14	-0.38	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:45338590~45341990:-
THCA	cis	rs1707322	0.717	rs2253862	ENSG00000234329.1	RP11-767N6.2	-8.52	2.12e-16	9.81e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs2991988	ENSG00000234329.1	RP11-767N6.2	-8.52	2.12e-16	9.81e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs2991989	ENSG00000234329.1	RP11-767N6.2	-8.52	2.12e-16	9.81e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45651039~45651826:-
THCA	cis	rs737008	0.959	rs11865598	ENSG00000262703.1	RP11-485G7.6	8.52	2.12e-16	9.82e-14	0.43	0.37	Obesity-related traits;	chr16:11309575	chr16:11348143~11349321:-
THCA	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-8.52	2.12e-16	9.84e-14	-0.46	-0.37	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
THCA	cis	rs9475752	0.552	rs17685045	ENSG00000231441.1	RP11-472M19.2	8.52	2.12e-16	9.84e-14	0.49	0.37	Menarche (age at onset);	chr6:56880135	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.552	rs13203600	ENSG00000231441.1	RP11-472M19.2	8.52	2.12e-16	9.84e-14	0.49	0.37	Menarche (age at onset);	chr6:56880364	chr6:56844002~56864078:+
THCA	cis	rs7851660	0.935	rs4460498	ENSG00000236130.1	PTCSC2	-8.52	2.13e-16	9.88e-14	-0.28	-0.37	Strep throat;	chr9:97858130	chr9:97805935~97810008:-
THCA	cis	rs2274273	0.745	rs56262555	ENSG00000258413.1	RP11-665C16.6	-8.52	2.13e-16	9.89e-14	-0.49	-0.37	Protein biomarker;	chr14:55095244	chr14:55262767~55272075:-
THCA	cis	rs1707322	0.717	rs1547925	ENSG00000234329.1	RP11-767N6.2	-8.52	2.14e-16	9.92e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45651039~45651826:-
THCA	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-8.52	2.14e-16	9.93e-14	-0.49	-0.37	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
THCA	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	8.52	2.14e-16	9.94e-14	0.48	0.37	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
THCA	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	8.52	2.14e-16	9.94e-14	0.46	0.37	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
THCA	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-8.52	2.15e-16	9.94e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-8.52	2.15e-16	9.94e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
THCA	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	8.52	2.15e-16	9.96e-14	0.47	0.37	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-8.52	2.15e-16	9.96e-14	-0.46	-0.37	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
THCA	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-8.52	2.15e-16	9.96e-14	-0.44	-0.37	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
THCA	cis	rs2408955	0.521	rs10875749	ENSG00000258273.1	RP11-370I10.4	8.52	2.15e-16	9.97e-14	0.48	0.37	Glycated hemoglobin levels;	chr12:48138134	chr12:48333755~48333901:-
THCA	cis	rs2408955	0.521	rs7301003	ENSG00000258273.1	RP11-370I10.4	-8.52	2.15e-16	9.97e-14	-0.48	-0.37	Glycated hemoglobin levels;	chr12:48156444	chr12:48333755~48333901:-
THCA	cis	rs7015263	0.689	rs6471354	ENSG00000254231.1	CTD-2284J15.1	8.52	2.15e-16	9.98e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86473254	chr8:86333274~86343314:-
THCA	cis	rs7727544	0.582	rs10052046	ENSG00000237714.1	P4HA2-AS1	8.52	2.16e-16	1e-13	0.46	0.37	Blood metabolite levels;	chr5:132208773	chr5:132184876~132192808:+
THCA	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	8.52	2.16e-16	1e-13	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
THCA	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	8.52	2.16e-16	1e-13	0.41	0.37	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
THCA	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	8.52	2.16e-16	1e-13	0.41	0.37	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
THCA	cis	rs1707322	0.721	rs11211181	ENSG00000234329.1	RP11-767N6.2	8.52	2.17e-16	1e-13	0.34	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45651039~45651826:-
THCA	cis	rs7665090	1	rs12498722	ENSG00000246560.2	RP11-10L12.4	8.52	2.17e-16	1e-13	0.44	0.37	Primary biliary cholangitis;	chr4:102633365	chr4:102828055~102844075:+
THCA	cis	rs11148252	0.532	rs9536185	ENSG00000278238.1	RP11-245D16.4	-8.52	2.17e-16	1e-13	-0.42	-0.37	Lewy body disease;	chr13:52605666	chr13:52454775~52455331:-
THCA	cis	rs17684571	0.751	rs6910414	ENSG00000231441.1	RP11-472M19.2	8.52	2.17e-16	1.01e-13	0.45	0.37	Schizophrenia;	chr6:56861939	chr6:56844002~56864078:+
THCA	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	8.52	2.17e-16	1.01e-13	0.38	0.37	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
THCA	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-8.52	2.17e-16	1.01e-13	-0.38	-0.37	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
THCA	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	8.52	2.18e-16	1.01e-13	0.43	0.37	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
THCA	cis	rs910316	0.523	rs4026175	ENSG00000279594.1	RP11-950C14.10	8.52	2.18e-16	1.01e-13	0.35	0.37	Height;	chr14:75035537	chr14:75011269~75012851:-
THCA	cis	rs7015263	0.603	rs56102132	ENSG00000254231.1	CTD-2284J15.1	-8.52	2.18e-16	1.01e-13	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86425798	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs62510798	ENSG00000254231.1	CTD-2284J15.1	-8.52	2.18e-16	1.01e-13	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86432337	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.714	rs6471345	ENSG00000254231.1	CTD-2284J15.1	8.52	2.18e-16	1.01e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86445357	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs6988601	ENSG00000254231.1	CTD-2284J15.1	8.52	2.18e-16	1.01e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86451366	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs10095129	ENSG00000254231.1	CTD-2284J15.1	8.52	2.18e-16	1.01e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86454079	chr8:86333274~86343314:-
THCA	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	8.52	2.19e-16	1.01e-13	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
THCA	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-8.52	2.2e-16	1.02e-13	-0.45	-0.37	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
THCA	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	8.52	2.2e-16	1.02e-13	0.36	0.37	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
THCA	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-8.52	2.21e-16	1.02e-13	-0.57	-0.37	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
THCA	cis	rs7727544	0.582	rs3828675	ENSG00000237714.1	P4HA2-AS1	8.52	2.21e-16	1.02e-13	0.46	0.37	Blood metabolite levels;	chr5:132211175	chr5:132184876~132192808:+
THCA	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-8.52	2.21e-16	1.02e-13	-0.38	-0.37	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
THCA	cis	rs516805	0.706	rs541551	ENSG00000279453.1	RP3-425C14.4	-8.52	2.22e-16	1.02e-13	-0.37	-0.37	Lymphocyte counts;	chr6:122462736	chr6:122436789~122439223:-
THCA	cis	rs11464691	1	rs11464691	ENSG00000278834.1	RP11-458J1.1	8.52	2.22e-16	1.03e-13	0.38	0.37	Allergic disease (asthma, hay fever or eczema);	chr17:40614389	chr17:40648300~40649718:+
THCA	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-8.52	2.22e-16	1.03e-13	-0.39	-0.37	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
THCA	cis	rs17826219	0.568	rs59858012	ENSG00000266490.1	CTD-2349P21.9	8.52	2.22e-16	1.03e-13	0.56	0.37	Body mass index;	chr17:30751564	chr17:30792372~30792833:+
THCA	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-8.52	2.22e-16	1.03e-13	-0.44	-0.37	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
THCA	cis	rs12188164	0.61	rs57433159	ENSG00000221990.4	EXOC3-AS1	8.52	2.22e-16	1.03e-13	0.31	0.37	Cystic fibrosis severity;	chr5:418610	chr5:441498~443160:-
THCA	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-8.52	2.22e-16	1.03e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-8.52	2.22e-16	1.03e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
THCA	cis	rs2929278	0.617	rs12908467	ENSG00000166763.7	STRCP1	-8.52	2.22e-16	1.03e-13	-0.4	-0.37	Schizophrenia;	chr15:43755232	chr15:43699488~43718184:-
THCA	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	8.52	2.24e-16	1.04e-13	0.46	0.37	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
THCA	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-8.52	2.24e-16	1.04e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
THCA	cis	rs673078	0.517	rs73205578	ENSG00000275409.1	RP11-131L12.4	-8.52	2.24e-16	1.04e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118385113	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs73205579	ENSG00000275409.1	RP11-131L12.4	-8.52	2.24e-16	1.04e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118385125	chr12:118430147~118430699:+
THCA	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	8.52	2.25e-16	1.04e-13	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	8.52	2.25e-16	1.04e-13	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
THCA	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	8.52	2.25e-16	1.04e-13	0.44	0.37	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
THCA	cis	rs1707322	0.721	rs10430124	ENSG00000234329.1	RP11-767N6.2	8.52	2.25e-16	1.04e-13	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45651039~45651826:-
THCA	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	8.52	2.26e-16	1.04e-13	0.24	0.37	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	8.52	2.26e-16	1.04e-13	0.24	0.37	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
THCA	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	8.52	2.26e-16	1.04e-13	0.41	0.37	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
THCA	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-8.52	2.26e-16	1.04e-13	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
THCA	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	8.52	2.26e-16	1.04e-13	0.24	0.37	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
THCA	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-8.51	2.27e-16	1.05e-13	-0.35	-0.37	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
THCA	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	8.51	2.28e-16	1.05e-13	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
THCA	cis	rs4819052	0.679	rs2255761	ENSG00000215447.6	BX322557.10	-8.51	2.28e-16	1.05e-13	-0.3	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45288052~45291738:+
THCA	cis	rs934734	0.752	rs2661795	ENSG00000204929.10	AC074391.1	-8.51	2.28e-16	1.05e-13	-0.45	-0.37	Rheumatoid arthritis;	chr2:65399672	chr2:65436711~66084639:+
THCA	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-8.51	2.28e-16	1.05e-13	-0.49	-0.37	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
THCA	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	8.51	2.28e-16	1.05e-13	0.41	0.37	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
THCA	cis	rs922182	0.556	rs10851734	ENSG00000275785.1	RP11-111E14.2	-8.51	2.29e-16	1.06e-13	-0.44	-0.37	Blood protein levels;	chr15:63924048	chr15:63890030~63890317:+
THCA	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	8.51	2.29e-16	1.06e-13	0.6	0.37	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
THCA	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-8.51	2.29e-16	1.06e-13	-0.6	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	8.51	2.29e-16	1.06e-13	0.47	0.37	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
THCA	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	8.51	2.29e-16	1.06e-13	0.5	0.37	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
THCA	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	8.51	2.3e-16	1.06e-13	0.71	0.37	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
THCA	cis	rs9659323	0.73	rs10802070	ENSG00000231365.4	RP11-418J17.1	-8.51	2.3e-16	1.06e-13	-0.36	-0.37	Body mass index;	chr1:118998863	chr1:119140396~119275973:+
THCA	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-8.51	2.3e-16	1.06e-13	-0.47	-0.37	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
THCA	cis	rs5769707	0.837	rs1573726	ENSG00000235111.1	RP1-29C18.8	-8.51	2.31e-16	1.07e-13	-0.43	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49612657~49615716:-
THCA	cis	rs736801	0.569	rs11748193	ENSG00000237714.1	P4HA2-AS1	8.51	2.32e-16	1.07e-13	0.49	0.37	Mosquito bite size;Breast cancer;	chr5:132389637	chr5:132184876~132192808:+
THCA	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	8.51	2.33e-16	1.08e-13	0.44	0.37	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
THCA	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	8.51	2.33e-16	1.08e-13	0.44	0.37	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
THCA	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-8.51	2.33e-16	1.08e-13	-0.3	-0.37	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-8.51	2.33e-16	1.08e-13	-0.3	-0.37	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-8.51	2.33e-16	1.08e-13	-0.3	-0.37	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
THCA	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-8.51	2.33e-16	1.08e-13	-0.3	-0.37	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
THCA	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	8.51	2.34e-16	1.08e-13	0.41	0.37	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
THCA	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-8.51	2.34e-16	1.08e-13	-0.47	-0.37	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
THCA	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-8.51	2.35e-16	1.09e-13	-0.49	-0.37	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
THCA	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-8.51	2.36e-16	1.09e-13	-0.54	-0.37	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	8.51	2.37e-16	1.09e-13	0.5	0.37	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
THCA	cis	rs1707322	1	rs1707337	ENSG00000234329.1	RP11-767N6.2	-8.51	2.37e-16	1.09e-13	-0.34	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768807	ENSG00000234329.1	RP11-767N6.2	-8.51	2.37e-16	1.09e-13	-0.34	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45651039~45651826:-
THCA	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-8.51	2.38e-16	1.1e-13	-0.49	-0.37	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
THCA	cis	rs9595066	0.627	rs4432167	ENSG00000227258.4	SMIM2-AS1	-8.51	2.38e-16	1.1e-13	-0.45	-0.37	Schizophrenia;	chr13:44178225	chr13:44110451~44240517:+
THCA	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-8.51	2.38e-16	1.1e-13	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
THCA	cis	rs9532669	0.926	rs4942007	ENSG00000239827.7	SUGT1P3	-8.51	2.39e-16	1.1e-13	-0.41	-0.37	Cervical cancer;	chr13:40871887	chr13:40908159~40921774:-
THCA	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-8.51	2.4e-16	1.11e-13	-0.43	-0.37	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
THCA	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	8.51	2.41e-16	1.11e-13	0.42	0.37	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
THCA	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	8.51	2.42e-16	1.12e-13	0.41	0.37	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
THCA	cis	rs465969	0.793	rs34288099	ENSG00000255389.1	C6orf3	-8.51	2.43e-16	1.12e-13	-0.56	-0.37	Psoriasis;	chr6:111424034	chr6:111599875~111602295:+
THCA	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	8.51	2.44e-16	1.12e-13	0.35	0.37	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
THCA	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-8.5	2.44e-16	1.13e-13	-0.52	-0.37	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-8.5	2.44e-16	1.13e-13	-0.52	-0.37	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-8.5	2.44e-16	1.13e-13	-0.52	-0.37	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
THCA	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	8.5	2.45e-16	1.13e-13	0.44	0.37	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
THCA	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	8.5	2.45e-16	1.13e-13	0.3	0.37	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000237664.1	LINC00316	-8.5	2.45e-16	1.13e-13	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000237664.1	LINC00316	-8.5	2.45e-16	1.13e-13	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000237664.1	LINC00316	-8.5	2.45e-16	1.13e-13	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000237664.1	LINC00316	-8.5	2.45e-16	1.13e-13	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45338590~45341990:-
THCA	cis	rs1043099	0.731	rs5763923	ENSG00000279699.1	RP1-102K2.9	-8.5	2.47e-16	1.14e-13	-0.49	-0.37	Rheumatoid arthritis;	chr22:30279228	chr22:30275215~30276951:-
THCA	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-8.5	2.47e-16	1.14e-13	-0.29	-0.37	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
THCA	cis	rs11971779	0.793	rs11764426	ENSG00000273391.1	RP11-634H22.1	8.5	2.48e-16	1.14e-13	0.36	0.37	Diisocyanate-induced asthma;	chr7:139339304	chr7:139359032~139359566:-
THCA	cis	rs42490	0.664	rs43227	ENSG00000251136.7	RP11-37B2.1	-8.5	2.49e-16	1.15e-13	-0.31	-0.37	Leprosy;	chr8:89809351	chr8:89609409~89757727:-
THCA	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	8.5	2.49e-16	1.15e-13	0.41	0.37	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
THCA	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	8.5	2.49e-16	1.15e-13	0.67	0.37	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
THCA	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-8.5	2.5e-16	1.15e-13	-0.52	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
THCA	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	8.5	2.5e-16	1.15e-13	0.46	0.37	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
THCA	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-8.5	2.5e-16	1.15e-13	-0.47	-0.37	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
THCA	cis	rs10847980	0.623	rs28681105	ENSG00000256092.2	RP13-942N8.1	8.5	2.51e-16	1.16e-13	0.55	0.37	Adiponectin levels;	chr12:123390978	chr12:123363868~123366113:+
THCA	cis	rs10847980	0.623	rs28501453	ENSG00000256092.2	RP13-942N8.1	8.5	2.51e-16	1.16e-13	0.55	0.37	Adiponectin levels;	chr12:123392765	chr12:123363868~123366113:+
THCA	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-8.5	2.51e-16	1.16e-13	-0.54	-0.37	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
THCA	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-8.5	2.51e-16	1.16e-13	-0.48	-0.37	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
THCA	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-8.5	2.52e-16	1.16e-13	-0.3	-0.37	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-8.5	2.52e-16	1.16e-13	-0.3	-0.37	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
THCA	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-8.5	2.52e-16	1.16e-13	-0.47	-0.37	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
THCA	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-8.5	2.53e-16	1.16e-13	-0.29	-0.37	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
THCA	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	8.5	2.53e-16	1.17e-13	0.47	0.37	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
THCA	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	8.5	2.54e-16	1.17e-13	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
THCA	cis	rs673078	0.562	rs61944668	ENSG00000275409.1	RP11-131L12.4	-8.5	2.55e-16	1.17e-13	-0.45	-0.36	Glucose homeostasis traits;	chr12:118448446	chr12:118430147~118430699:+
THCA	cis	rs4842666	0.834	rs2681492	ENSG00000258302.2	RP11-981P6.1	8.5	2.55e-16	1.18e-13	0.36	0.36	Blood pressure;	chr12:89619312	chr12:89561129~89594878:+
THCA	cis	rs7674212	0.507	rs223331	ENSG00000251288.2	RP11-10L12.2	-8.5	2.56e-16	1.18e-13	-0.48	-0.36	Type 2 diabetes;	chr4:102872408	chr4:102751401~102752641:+
THCA	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-8.5	2.57e-16	1.18e-13	-0.44	-0.36	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
THCA	cis	rs4380275	1	rs4450634	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs4380275	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs6548253	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs73143802	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs4359695	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:739588~740164:-
THCA	cis	rs4380275	0.931	rs4538239	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:739588~740164:-
THCA	cis	rs10181042	0.514	rs1177283	ENSG00000271889.1	RP11-493E12.1	8.5	2.57e-16	1.18e-13	0.35	0.36	Crohn's disease;	chr2:61121669	chr2:61151433~61162105:-
THCA	cis	rs7727544	0.606	rs72795121	ENSG00000237714.1	P4HA2-AS1	8.5	2.57e-16	1.18e-13	0.48	0.36	Blood metabolite levels;	chr5:132302631	chr5:132184876~132192808:+
THCA	cis	rs736801	0.729	rs1050152	ENSG00000237714.1	P4HA2-AS1	8.5	2.58e-16	1.18e-13	0.49	0.36	Mosquito bite size;Breast cancer;	chr5:132340627	chr5:132184876~132192808:+
THCA	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	8.5	2.58e-16	1.19e-13	0.44	0.36	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
THCA	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-8.5	2.58e-16	1.19e-13	-0.44	-0.36	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-8.5	2.58e-16	1.19e-13	-0.44	-0.36	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000237664.1	LINC00316	-8.5	2.59e-16	1.19e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45338590~45341990:-
THCA	cis	rs8114671	0.562	rs6088653	ENSG00000269202.1	RP4-614O4.12	-8.5	2.59e-16	1.19e-13	-0.31	-0.36	Height;	chr20:34932518	chr20:35201747~35203288:-
THCA	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-8.5	2.6e-16	1.2e-13	-0.46	-0.36	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
THCA	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-8.5	2.6e-16	1.2e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
THCA	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-8.5	2.6e-16	1.2e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
THCA	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-8.5	2.6e-16	1.2e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
THCA	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-8.5	2.6e-16	1.2e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
THCA	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-8.5	2.61e-16	1.2e-13	-0.44	-0.36	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
THCA	cis	rs848490	0.656	rs55714086	ENSG00000214293.7	APTR	8.5	2.61e-16	1.2e-13	0.26	0.36	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77807168	chr7:77657660~77696265:-
THCA	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	8.5	2.61e-16	1.2e-13	0.45	0.36	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000215447.6	BX322557.10	-8.5	2.61e-16	1.2e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45288052~45291738:+
THCA	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-8.5	2.62e-16	1.2e-13	-0.49	-0.36	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
THCA	cis	rs7665090	1	rs6821119	ENSG00000246560.2	RP11-10L12.4	8.5	2.62e-16	1.2e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102634076	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.934	rs6844332	ENSG00000246560.2	RP11-10L12.4	8.5	2.62e-16	1.2e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102634095	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs6821133	ENSG00000246560.2	RP11-10L12.4	8.5	2.62e-16	1.2e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102634096	chr4:102828055~102844075:+
THCA	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	8.5	2.62e-16	1.2e-13	0.35	0.36	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
THCA	cis	rs7851660	0.935	rs12347191	ENSG00000236130.1	PTCSC2	-8.5	2.63e-16	1.21e-13	-0.28	-0.36	Strep throat;	chr9:97857437	chr9:97805935~97810008:-
THCA	cis	rs11971779	0.793	rs11772447	ENSG00000273391.1	RP11-634H22.1	8.49	2.63e-16	1.21e-13	0.35	0.36	Diisocyanate-induced asthma;	chr7:139348843	chr7:139359032~139359566:-
THCA	cis	rs9532669	0.89	rs9532627	ENSG00000239827.7	SUGT1P3	-8.49	2.64e-16	1.21e-13	-0.4	-0.36	Cervical cancer;	chr13:40874811	chr13:40908159~40921774:-
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000237664.1	LINC00316	8.49	2.64e-16	1.21e-13	0.36	0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45338590~45341990:-
THCA	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	8.49	2.65e-16	1.22e-13	0.33	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	8.49	2.65e-16	1.22e-13	0.33	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
THCA	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	8.49	2.65e-16	1.22e-13	0.36	0.36	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
THCA	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-8.49	2.67e-16	1.23e-13	-0.45	-0.36	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
THCA	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-8.49	2.67e-16	1.23e-13	-0.45	-0.36	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
THCA	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-8.49	2.68e-16	1.23e-13	-0.48	-0.36	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
THCA	cis	rs7665090	1	rs11727546	ENSG00000246560.2	RP11-10L12.4	8.49	2.68e-16	1.23e-13	0.43	0.36	Primary biliary cholangitis;	chr4:102636507	chr4:102828055~102844075:+
THCA	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-8.49	2.68e-16	1.23e-13	-0.47	-0.36	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-8.49	2.68e-16	1.23e-13	-0.47	-0.36	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
THCA	cis	rs11159086	1	rs72730186	ENSG00000270000.1	RP3-449M8.9	8.49	2.68e-16	1.23e-13	0.46	0.36	Advanced glycation end-product levels;	chr14:74475610	chr14:74471930~74472360:-
THCA	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-8.49	2.69e-16	1.23e-13	-0.38	-0.36	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
THCA	cis	rs11051970	0.527	rs7309590	ENSG00000274964.1	RP11-817I4.1	-8.49	2.69e-16	1.24e-13	-0.44	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32337915	chr12:32339368~32340724:+
THCA	cis	rs516805	0.748	rs562616	ENSG00000279453.1	RP3-425C14.4	-8.49	2.7e-16	1.24e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122467041	chr6:122436789~122439223:-
THCA	cis	rs944289	0.966	rs1169124	ENSG00000257826.1	RP11-116N8.4	-8.49	2.7e-16	1.24e-13	-0.39	-0.36	Thyroid cancer;	chr14:36150082	chr14:36061026~36067190:-
THCA	cis	rs944289	0.899	rs1169125	ENSG00000257826.1	RP11-116N8.4	-8.49	2.7e-16	1.24e-13	-0.39	-0.36	Thyroid cancer;	chr14:36150560	chr14:36061026~36067190:-
THCA	cis	rs944289	0.966	rs1169129	ENSG00000257826.1	RP11-116N8.4	-8.49	2.7e-16	1.24e-13	-0.39	-0.36	Thyroid cancer;	chr14:36152619	chr14:36061026~36067190:-
THCA	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-8.49	2.71e-16	1.24e-13	-0.39	-0.36	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-8.49	2.72e-16	1.25e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
THCA	cis	rs1707322	0.506	rs2991983	ENSG00000234329.1	RP11-767N6.2	-8.49	2.72e-16	1.25e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs3014249	ENSG00000234329.1	RP11-767N6.2	-8.49	2.72e-16	1.25e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45651039~45651826:-
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	8.49	2.74e-16	1.26e-13	0.46	0.36	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
THCA	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-8.49	2.74e-16	1.26e-13	-0.29	-0.36	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
THCA	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	8.49	2.74e-16	1.26e-13	0.36	0.36	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000226314.6	ZNF192P1	-8.49	2.74e-16	1.26e-13	-0.47	-0.36	Parkinson's disease;	chr6:28055973	chr6:28161781~28169594:+
THCA	cis	rs11051970	0.918	rs12229856	ENSG00000274964.1	RP11-817I4.1	-8.49	2.75e-16	1.26e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32378286	chr12:32339368~32340724:+
THCA	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-8.49	2.75e-16	1.26e-13	-0.38	-0.36	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
THCA	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-8.49	2.76e-16	1.26e-13	-0.37	-0.36	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-8.49	2.76e-16	1.26e-13	-0.37	-0.36	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000230295.1	RP11-458F8.2	-8.49	2.76e-16	1.27e-13	-0.32	-0.36	Corneal structure;	chr7:66789303	chr7:66880708~66882981:+
THCA	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-8.49	2.76e-16	1.27e-13	-0.48	-0.36	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
THCA	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	8.49	2.76e-16	1.27e-13	0.45	0.36	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
THCA	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	8.49	2.77e-16	1.27e-13	0.6	0.36	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
THCA	cis	rs860295	1	rs822478	ENSG00000225855.5	RUSC1-AS1	-8.49	2.77e-16	1.27e-13	-0.25	-0.36	Body mass index;	chr1:155824178	chr1:155316863~155324176:-
THCA	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	8.49	2.77e-16	1.27e-13	0.35	0.36	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	8.49	2.77e-16	1.27e-13	0.35	0.36	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
THCA	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	8.49	2.77e-16	1.27e-13	0.3	0.36	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-8.49	2.77e-16	1.27e-13	-0.75	-0.36	Gout;	chr7:66732812	chr7:66654538~66669855:+
THCA	cis	rs516805	0.781	rs574462	ENSG00000279453.1	RP3-425C14.4	-8.49	2.78e-16	1.27e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122404863	chr6:122436789~122439223:-
THCA	cis	rs11603691	1	rs11602266	ENSG00000254662.1	RP11-872D17.4	-8.49	2.78e-16	1.27e-13	-0.68	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57327035	chr11:57325603~57327958:+
THCA	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	8.49	2.78e-16	1.27e-13	0.44	0.36	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
THCA	cis	rs16846053	0.515	rs6432688	ENSG00000227403.1	AC009299.3	-8.49	2.78e-16	1.28e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161522146	chr2:161244739~161249050:+
THCA	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-8.49	2.79e-16	1.28e-13	-0.39	-0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
THCA	cis	rs934734	0.532	rs7569113	ENSG00000237979.1	AC007389.1	8.49	2.79e-16	1.28e-13	0.41	0.36	Rheumatoid arthritis;	chr2:65429907	chr2:65500993~65502138:-
THCA	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	8.49	2.8e-16	1.28e-13	0.36	0.36	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
THCA	cis	rs5769707	0.837	rs5769709	ENSG00000235111.1	RP1-29C18.8	-8.49	2.8e-16	1.29e-13	-0.43	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49612657~49615716:-
THCA	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	8.49	2.8e-16	1.29e-13	0.48	0.36	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
THCA	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-8.49	2.81e-16	1.29e-13	-0.41	-0.36	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
THCA	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	8.49	2.81e-16	1.29e-13	0.44	0.36	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
THCA	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	8.49	2.81e-16	1.29e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
THCA	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-8.49	2.81e-16	1.29e-13	-0.38	-0.36	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000230295.1	RP11-458F8.2	-8.49	2.82e-16	1.29e-13	-0.32	-0.36	Corneal structure;	chr7:66790251	chr7:66880708~66882981:+
THCA	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	8.49	2.82e-16	1.29e-13	0.41	0.36	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
THCA	cis	rs8114671	0.869	rs2145559	ENSG00000269202.1	RP4-614O4.12	8.49	2.83e-16	1.3e-13	0.31	0.36	Height;	chr20:35063922	chr20:35201747~35203288:-
THCA	cis	rs673078	0.607	rs17512525	ENSG00000275409.1	RP11-131L12.4	-8.48	2.84e-16	1.3e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118315467	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17440774	ENSG00000275409.1	RP11-131L12.4	-8.48	2.84e-16	1.3e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118316155	chr12:118430147~118430699:+
THCA	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-8.48	2.84e-16	1.3e-13	-0.62	-0.36	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
THCA	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	8.48	2.84e-16	1.3e-13	0.41	0.36	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
THCA	cis	rs516805	0.748	rs563084	ENSG00000279453.1	RP3-425C14.4	8.48	2.84e-16	1.3e-13	0.37	0.36	Lymphocyte counts;	chr6:122397105	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs512063	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122409206	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs572674	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122411239	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs492250	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122421808	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs9320872	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122425438	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs505749	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122425751	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs502252	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122436330	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs577049	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122438204	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs577838	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122438270	chr6:122436789~122439223:-
THCA	cis	rs1707322	0.89	rs2297883	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1707338	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs1707339	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768818	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768817	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785470	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45651039~45651826:-
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-8.48	2.84e-16	1.3e-13	-0.32	-0.36	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-8.48	2.84e-16	1.3e-13	-0.32	-0.36	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
THCA	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	8.48	2.85e-16	1.31e-13	0.45	0.36	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
THCA	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-8.48	2.85e-16	1.31e-13	-0.46	-0.36	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
THCA	cis	rs13129231	0.92	rs17676840	ENSG00000206820.1	RNU1-138P	8.48	2.86e-16	1.31e-13	0.44	0.36	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113439469	chr4:113420323~113420486:+
THCA	cis	rs8114671	0.562	rs6088655	ENSG00000269202.1	RP4-614O4.12	-8.48	2.87e-16	1.31e-13	-0.31	-0.36	Height;	chr20:34940035	chr20:35201747~35203288:-
THCA	cis	rs2032366	0.606	rs9783923	ENSG00000267279.1	RP11-879F14.2	-8.48	2.88e-16	1.32e-13	-0.39	-0.36	Obesity-related traits;	chr18:61635518	chr18:61585746~61606916:-
THCA	cis	rs516805	0.748	rs155460	ENSG00000279453.1	RP3-425C14.4	-8.48	2.88e-16	1.32e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122499180	chr6:122436789~122439223:-
THCA	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-8.48	2.88e-16	1.32e-13	-0.37	-0.36	QT interval;	chr12:29306357	chr12:29280418~29317848:-
THCA	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	8.48	2.89e-16	1.32e-13	0.51	0.36	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
THCA	cis	rs7727544	0.548	rs35696821	ENSG00000237714.1	P4HA2-AS1	8.48	2.91e-16	1.33e-13	0.46	0.36	Blood metabolite levels;	chr5:132172324	chr5:132184876~132192808:+
THCA	cis	rs7665090	0.967	rs13106304	ENSG00000246560.2	RP11-10L12.4	8.48	2.91e-16	1.33e-13	0.43	0.36	Primary biliary cholangitis;	chr4:102633818	chr4:102828055~102844075:+
THCA	cis	rs28510890	0.547	rs10152637	ENSG00000260337.3	RP11-386M24.6	8.48	2.92e-16	1.34e-13	0.47	0.36	Lung cancer in ever smokers;	chr15:92602409	chr15:92592574~92596462:-
THCA	cis	rs4819052	1	rs4819052	ENSG00000237664.1	LINC00316	-8.48	2.92e-16	1.34e-13	-0.39	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45338590~45341990:-
THCA	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	8.48	2.92e-16	1.34e-13	0.35	0.36	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
THCA	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-8.48	2.93e-16	1.34e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.582	rs3792894	ENSG00000237714.1	P4HA2-AS1	8.48	2.93e-16	1.34e-13	0.46	0.36	Blood metabolite levels;	chr5:132211578	chr5:132184876~132192808:+
THCA	cis	rs1707322	0.717	rs1972410	ENSG00000234329.1	RP11-767N6.2	8.48	2.93e-16	1.34e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45651039~45651826:-
THCA	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-8.48	2.93e-16	1.34e-13	-0.49	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
THCA	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-8.48	2.94e-16	1.34e-13	-0.45	-0.36	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
THCA	cis	rs9341808	0.529	rs9350851	ENSG00000272129.1	RP11-250B2.6	8.48	2.94e-16	1.34e-13	0.45	0.36	Sitting height ratio;	chr6:80349471	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.529	rs9352826	ENSG00000272129.1	RP11-250B2.6	8.48	2.94e-16	1.34e-13	0.45	0.36	Sitting height ratio;	chr6:80349654	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	8.48	2.94e-16	1.35e-13	0.45	0.36	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
THCA	cis	rs4819052	0.655	rs2330102	ENSG00000215447.6	BX322557.10	-8.48	2.95e-16	1.35e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.679	rs8132135	ENSG00000215447.6	BX322557.10	-8.48	2.95e-16	1.35e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45288052~45291738:+
THCA	cis	rs9500256	1	rs9500256	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-8.48	2.96e-16	1.35e-13	-0.37	-0.36	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57855891~57856468:-
THCA	cis	rs42490	0.625	rs427854	ENSG00000251136.7	RP11-37B2.1	-8.48	2.96e-16	1.35e-13	-0.32	-0.36	Leprosy;	chr8:89843518	chr8:89609409~89757727:-
THCA	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	8.48	2.96e-16	1.36e-13	0.45	0.36	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
THCA	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-8.48	2.97e-16	1.36e-13	-0.35	-0.36	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
THCA	cis	rs16846053	0.515	rs918964	ENSG00000227403.1	AC009299.3	-8.48	2.98e-16	1.36e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161440405	chr2:161244739~161249050:+
THCA	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	8.48	2.98e-16	1.36e-13	0.35	0.36	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
THCA	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-8.48	2.98e-16	1.36e-13	-0.25	-0.36	Breast cancer;	chr11:743813	chr11:777578~784297:+
THCA	cis	rs2032366	0.63	rs7235404	ENSG00000267279.1	RP11-879F14.2	8.48	2.98e-16	1.36e-13	0.39	0.36	Obesity-related traits;	chr18:61628753	chr18:61585746~61606916:-
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000215447.6	BX322557.10	-8.48	2.99e-16	1.37e-13	-0.31	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45288052~45291738:+
THCA	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-8.48	2.99e-16	1.37e-13	-0.44	-0.36	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000237664.1	LINC00316	-8.48	2.99e-16	1.37e-13	-0.37	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45338590~45341990:-
THCA	cis	rs1707322	0.964	rs785483	ENSG00000234329.1	RP11-767N6.2	-8.48	2.99e-16	1.37e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs796773	ENSG00000234329.1	RP11-767N6.2	-8.48	2.99e-16	1.37e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.896	rs785518	ENSG00000234329.1	RP11-767N6.2	-8.48	2.99e-16	1.37e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785519	ENSG00000234329.1	RP11-767N6.2	-8.48	2.99e-16	1.37e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45651039~45651826:-
THCA	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	8.48	2.99e-16	1.37e-13	0.31	0.36	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
THCA	cis	rs11051970	0.513	rs2892655	ENSG00000274964.1	RP11-817I4.1	-8.48	3e-16	1.37e-13	-0.44	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32337295	chr12:32339368~32340724:+
THCA	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	8.48	3e-16	1.37e-13	0.69	0.36	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	8.48	3e-16	1.37e-13	0.69	0.36	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
THCA	cis	rs17684571	0.751	rs4415160	ENSG00000231441.1	RP11-472M19.2	-8.48	3.02e-16	1.38e-13	-0.47	-0.36	Schizophrenia;	chr6:56821424	chr6:56844002~56864078:+
THCA	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-8.48	3.02e-16	1.38e-13	-0.38	-0.36	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-8.48	3.02e-16	1.38e-13	-0.38	-0.36	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
THCA	cis	rs7945705	0.791	rs6484484	ENSG00000254860.4	TMEM9B-AS1	-8.48	3.02e-16	1.38e-13	-0.39	-0.36	Hemoglobin concentration;	chr11:8795659	chr11:8964675~8977527:+
THCA	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-8.48	3.02e-16	1.38e-13	-0.44	-0.36	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000237979.1	AC007389.1	-8.48	3.03e-16	1.38e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65427878	chr2:65500993~65502138:-
THCA	cis	rs934734	0.532	rs2028151	ENSG00000237979.1	AC007389.1	-8.48	3.03e-16	1.38e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65428479	chr2:65500993~65502138:-
THCA	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-8.48	3.03e-16	1.39e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
THCA	cis	rs2408955	0.541	rs11168428	ENSG00000258273.1	RP11-370I10.4	8.48	3.03e-16	1.39e-13	0.47	0.36	Glycated hemoglobin levels;	chr12:48153345	chr12:48333755~48333901:-
THCA	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.582	rs7703009	ENSG00000237714.1	P4HA2-AS1	8.47	3.06e-16	1.4e-13	0.46	0.36	Blood metabolite levels;	chr5:132216692	chr5:132184876~132192808:+
THCA	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	8.47	3.06e-16	1.4e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
THCA	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-8.47	3.07e-16	1.4e-13	-0.43	-0.36	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
THCA	cis	rs7665090	0.905	rs2866410	ENSG00000246560.2	RP11-10L12.4	8.47	3.08e-16	1.4e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102633178	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.936	rs2866411	ENSG00000246560.2	RP11-10L12.4	8.47	3.08e-16	1.4e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102633183	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.936	rs2866412	ENSG00000246560.2	RP11-10L12.4	8.47	3.08e-16	1.4e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102633193	chr4:102828055~102844075:+
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-8.47	3.08e-16	1.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-8.47	3.08e-16	1.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-8.47	3.08e-16	1.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-8.47	3.08e-16	1.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
THCA	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	8.47	3.08e-16	1.4e-13	0.4	0.36	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
THCA	cis	rs7674212	0.507	rs223361	ENSG00000251288.2	RP11-10L12.2	-8.47	3.09e-16	1.41e-13	-0.49	-0.36	Type 2 diabetes;	chr4:102848147	chr4:102751401~102752641:+
THCA	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-8.47	3.09e-16	1.41e-13	-0.37	-0.36	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-8.47	3.09e-16	1.41e-13	-0.37	-0.36	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-8.47	3.09e-16	1.41e-13	-0.37	-0.36	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
THCA	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-8.47	3.1e-16	1.41e-13	-0.38	-0.36	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
THCA	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	8.47	3.1e-16	1.41e-13	0.39	0.36	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
THCA	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-8.47	3.1e-16	1.41e-13	-0.29	-0.36	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-8.47	3.1e-16	1.41e-13	-0.29	-0.36	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
THCA	cis	rs1005277	0.579	rs2474595	ENSG00000263064.2	RP11-291L22.7	-8.47	3.1e-16	1.42e-13	-0.41	-0.36	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38448689~38448949:+
THCA	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-8.47	3.11e-16	1.42e-13	-0.46	-0.36	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
THCA	cis	rs7569084	0.663	rs1437461	ENSG00000234255.7	AC012370.3	8.47	3.12e-16	1.42e-13	0.42	0.36	Sum eosinophil basophil counts;	chr2:65452578	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs7562559	ENSG00000234255.7	AC012370.3	8.47	3.12e-16	1.42e-13	0.42	0.36	Sum eosinophil basophil counts;	chr2:65452719	chr2:65439888~65456571:-
THCA	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-8.47	3.12e-16	1.42e-13	-0.49	-0.36	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
THCA	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-8.47	3.13e-16	1.43e-13	-0.54	-0.36	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
THCA	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-8.47	3.14e-16	1.43e-13	-0.43	-0.36	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	8.47	3.14e-16	1.43e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
THCA	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	8.47	3.14e-16	1.43e-13	0.49	0.36	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
THCA	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	8.47	3.15e-16	1.44e-13	0.36	0.36	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000230295.1	RP11-458F8.2	-8.47	3.15e-16	1.44e-13	-0.32	-0.36	Corneal structure;	chr7:66813271	chr7:66880708~66882981:+
THCA	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-8.47	3.16e-16	1.44e-13	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
THCA	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-8.47	3.16e-16	1.44e-13	-0.41	-0.36	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
THCA	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-8.47	3.16e-16	1.44e-13	-0.38	-0.36	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
THCA	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	8.47	3.17e-16	1.45e-13	0.6	0.36	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
THCA	cis	rs10463554	0.892	rs1438687	ENSG00000175749.11	EIF3KP1	8.47	3.19e-16	1.46e-13	0.48	0.36	Parkinson's disease;	chr5:102968792	chr5:103032376~103033031:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	8.47	3.2e-16	1.46e-13	0.27	0.36	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	8.47	3.2e-16	1.46e-13	0.27	0.36	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
THCA	cis	rs2439831	0.85	rs7181039	ENSG00000249839.1	AC011330.5	-8.47	3.21e-16	1.46e-13	-0.6	-0.36	Lung cancer in ever smokers;	chr15:43886914	chr15:43663654~43684339:-
THCA	cis	rs7211079	0.879	rs61357240	ENSG00000275479.1	RP11-334C17.6	8.47	3.21e-16	1.46e-13	0.36	0.36	Myocardial infarction;	chr17:80157976	chr17:80149627~80149798:+
THCA	cis	rs73186030	0.591	rs56098325	ENSG00000272758.4	RP11-299J3.8	8.47	3.22e-16	1.47e-13	0.47	0.36	Serum parathyroid hormone levels;	chr3:122342362	chr3:122416207~122443180:+
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000237664.1	LINC00316	-8.47	3.23e-16	1.47e-13	-0.37	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45338590~45341990:-
THCA	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	8.47	3.23e-16	1.47e-13	0.43	0.36	Temperament;	chr17:13996939	chr17:14024514~14025488:+
THCA	cis	rs8114671	0.562	rs725521	ENSG00000269202.1	RP4-614O4.12	-8.47	3.23e-16	1.47e-13	-0.3	-0.36	Height;	chr20:34928268	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6087651	ENSG00000269202.1	RP4-614O4.12	-8.47	3.23e-16	1.47e-13	-0.3	-0.36	Height;	chr20:34930550	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6119545	ENSG00000269202.1	RP4-614O4.12	-8.47	3.23e-16	1.47e-13	-0.3	-0.36	Height;	chr20:34935066	chr20:35201747~35203288:-
THCA	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-8.47	3.24e-16	1.48e-13	-0.42	-0.36	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
THCA	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-8.47	3.24e-16	1.48e-13	-0.49	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
THCA	cis	rs17772222	0.675	rs845769	ENSG00000258789.1	RP11-507K2.3	8.47	3.26e-16	1.48e-13	0.35	0.36	Coronary artery calcification;	chr14:88461455	chr14:88551597~88552493:+
THCA	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	8.47	3.26e-16	1.48e-13	0.71	0.36	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000237664.1	LINC00316	-8.47	3.26e-16	1.49e-13	-0.37	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45338590~45341990:-
THCA	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-8.47	3.27e-16	1.49e-13	-0.46	-0.36	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
THCA	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	8.47	3.28e-16	1.5e-13	0.44	0.36	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
THCA	cis	rs516805	0.748	rs155467	ENSG00000279453.1	RP3-425C14.4	-8.46	3.3e-16	1.5e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122512451	chr6:122436789~122439223:-
THCA	cis	rs1707322	0.686	rs3014242	ENSG00000234329.1	RP11-767N6.2	-8.46	3.3e-16	1.5e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45651039~45651826:-
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000228039.3	KB-1125A3.10	-8.46	3.32e-16	1.51e-13	-0.5	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23963780~23964374:+
THCA	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	8.46	3.33e-16	1.52e-13	0.49	0.36	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
THCA	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-8.46	3.34e-16	1.52e-13	-0.54	-0.36	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
THCA	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-8.46	3.35e-16	1.52e-13	-0.35	-0.36	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
THCA	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	8.46	3.36e-16	1.53e-13	0.41	0.36	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
THCA	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	8.46	3.37e-16	1.53e-13	0.36	0.36	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
THCA	cis	rs11148252	0.774	rs6561666	ENSG00000235660.1	LINC00345	-8.46	3.37e-16	1.53e-13	-0.45	-0.36	Lewy body disease;	chr13:52355910	chr13:52484161~52484680:-
THCA	cis	rs4819052	0.851	rs2838864	ENSG00000237664.1	LINC00316	8.46	3.37e-16	1.53e-13	0.36	0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45338590~45341990:-
THCA	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	8.46	3.37e-16	1.54e-13	0.57	0.36	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
THCA	cis	rs2274273	0.554	rs3742564	ENSG00000258413.1	RP11-665C16.6	8.46	3.38e-16	1.54e-13	0.49	0.36	Protein biomarker;	chr14:55063402	chr14:55262767~55272075:-
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-8.46	3.38e-16	1.54e-13	-0.32	-0.36	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-8.46	3.38e-16	1.54e-13	-0.32	-0.36	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
THCA	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
THCA	cis	rs4819052	0.807	rs1075788	ENSG00000237664.1	LINC00316	-8.46	3.42e-16	1.55e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45338590~45341990:-
THCA	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-8.46	3.42e-16	1.55e-13	-0.49	-0.36	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
THCA	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	8.46	3.42e-16	1.56e-13	0.35	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
THCA	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	8.46	3.43e-16	1.56e-13	0.46	0.36	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
THCA	cis	rs4819052	0.632	rs4819050	ENSG00000215447.6	BX322557.10	-8.46	3.44e-16	1.56e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45288052~45291738:+
THCA	cis	rs7015263	0.714	rs7465350	ENSG00000254231.1	CTD-2284J15.1	8.46	3.45e-16	1.57e-13	0.37	0.36	Intelligence (multi-trait analysis);	chr8:86525480	chr8:86333274~86343314:-
THCA	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	8.46	3.45e-16	1.57e-13	0.24	0.36	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	8.46	3.45e-16	1.57e-13	0.24	0.36	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
THCA	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-8.46	3.45e-16	1.57e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-8.46	3.45e-16	1.57e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
THCA	cis	rs2929278	0.589	rs2411284	ENSG00000166763.7	STRCP1	-8.46	3.46e-16	1.57e-13	-0.39	-0.36	Schizophrenia;	chr15:43746701	chr15:43699488~43718184:-
THCA	cis	rs7727544	0.582	rs2301579	ENSG00000237714.1	P4HA2-AS1	8.46	3.47e-16	1.58e-13	0.46	0.36	Blood metabolite levels;	chr5:132217647	chr5:132184876~132192808:+
THCA	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	8.46	3.49e-16	1.58e-13	0.43	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
THCA	cis	rs11148252	0.532	rs9536190	ENSG00000278238.1	RP11-245D16.4	-8.46	3.49e-16	1.59e-13	-0.42	-0.36	Lewy body disease;	chr13:52606909	chr13:52454775~52455331:-
THCA	cis	rs860295	0.836	rs6684889	ENSG00000225855.5	RUSC1-AS1	-8.46	3.5e-16	1.59e-13	-0.25	-0.36	Body mass index;	chr1:155457271	chr1:155316863~155324176:-
THCA	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-8.46	3.51e-16	1.59e-13	-0.5	-0.36	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
THCA	cis	rs4927850	1	rs10881564	ENSG00000226155.1	AC124944.3	-8.46	3.52e-16	1.6e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196023455	chr3:195912049~195913986:+
THCA	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	8.46	3.53e-16	1.6e-13	0.38	0.36	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
THCA	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	8.46	3.54e-16	1.61e-13	0.35	0.36	Breast size;	chr12:9232939	chr12:9277235~9313241:+
THCA	cis	rs10208649	0.808	rs11886366	ENSG00000272156.1	RP11-477N3.1	8.46	3.54e-16	1.61e-13	0.66	0.36	Body mass index;	chr2:53997126	chr2:54082554~54085066:+
THCA	cis	rs1707322	1	rs6677777	ENSG00000234329.1	RP11-767N6.2	8.45	3.54e-16	1.61e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45651039~45651826:-
THCA	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	8.45	3.55e-16	1.61e-13	0.47	0.36	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
THCA	cis	rs41157	0.528	rs15888	ENSG00000279159.1	RP3-394A18.1	8.45	3.55e-16	1.61e-13	0.36	0.36	Cerebrospinal P-tau181p levels;	chr22:30030346	chr22:29978950~30028236:-
THCA	cis	rs10740039	0.81	rs10740036	ENSG00000254271.1	RP11-131N11.4	8.45	3.55e-16	1.61e-13	0.46	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60606216	chr10:60734342~60741828:+
THCA	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	8.45	3.55e-16	1.61e-13	0.35	0.36	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
THCA	cis	rs600231	0.706	rs3782091	ENSG00000245532.5	NEAT1	-8.45	3.56e-16	1.62e-13	-0.26	-0.36	Bone mineral density;	chr11:65569012	chr11:65422774~65445540:+
THCA	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	8.45	3.57e-16	1.62e-13	0.35	0.36	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
THCA	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-8.45	3.57e-16	1.62e-13	-0.42	-0.36	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
THCA	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	8.45	3.57e-16	1.62e-13	0.48	0.36	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-8.45	3.57e-16	1.62e-13	-0.32	-0.36	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
THCA	cis	rs1707322	0.721	rs10890343	ENSG00000234329.1	RP11-767N6.2	8.45	3.58e-16	1.62e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45651039~45651826:-
THCA	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-8.45	3.58e-16	1.63e-13	-0.44	-0.36	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
THCA	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-8.45	3.59e-16	1.63e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
THCA	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	8.45	3.6e-16	1.63e-13	0.6	0.36	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
THCA	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	8.45	3.61e-16	1.64e-13	0.43	0.36	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
THCA	cis	rs922182	0.595	rs7176387	ENSG00000275785.1	RP11-111E14.2	-8.45	3.62e-16	1.64e-13	-0.43	-0.36	Blood protein levels;	chr15:63926909	chr15:63890030~63890317:+
THCA	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-8.45	3.62e-16	1.64e-13	-0.58	-0.36	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
THCA	cis	rs8114671	0.967	rs1415774	ENSG00000269202.1	RP4-614O4.12	8.45	3.62e-16	1.64e-13	0.3	0.36	Height;	chr20:35177813	chr20:35201747~35203288:-
THCA	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	8.45	3.63e-16	1.65e-13	0.56	0.36	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
THCA	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-8.45	3.63e-16	1.65e-13	-0.38	-0.36	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
THCA	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-8.45	3.63e-16	1.65e-13	-0.38	-0.36	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
THCA	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-8.45	3.63e-16	1.65e-13	-0.38	-0.36	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
THCA	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	8.45	3.65e-16	1.66e-13	0.55	0.36	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
THCA	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-8.45	3.66e-16	1.66e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
THCA	cis	rs10208649	0.611	rs61740458	ENSG00000272156.1	RP11-477N3.1	8.45	3.66e-16	1.66e-13	0.51	0.36	Body mass index;	chr2:54065503	chr2:54082554~54085066:+
THCA	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	8.45	3.68e-16	1.67e-13	0.45	0.36	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
THCA	cis	rs1707322	1	rs785465	ENSG00000234329.1	RP11-767N6.2	8.45	3.68e-16	1.67e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45651039~45651826:-
THCA	cis	rs516805	0.748	rs1267941	ENSG00000279453.1	RP3-425C14.4	-8.45	3.69e-16	1.67e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122471888	chr6:122436789~122439223:-
THCA	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-8.45	3.69e-16	1.67e-13	-0.48	-0.36	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
THCA	cis	rs4819052	0.851	rs875621	ENSG00000237664.1	LINC00316	-8.45	3.71e-16	1.68e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45338590~45341990:-
THCA	cis	rs7569084	0.687	rs12614851	ENSG00000234255.7	AC012370.3	8.45	3.71e-16	1.68e-13	0.42	0.36	Sum eosinophil basophil counts;	chr2:65458050	chr2:65439888~65456571:-
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-8.45	3.73e-16	1.69e-13	-0.32	-0.36	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
THCA	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	8.45	3.74e-16	1.69e-13	0.49	0.36	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
THCA	cis	rs673078	0.607	rs7309671	ENSG00000275409.1	RP11-131L12.4	-8.45	3.75e-16	1.7e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118313188	chr12:118430147~118430699:+
THCA	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-8.45	3.76e-16	1.7e-13	-0.48	-0.36	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
THCA	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-8.45	3.76e-16	1.7e-13	-0.29	-0.36	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
THCA	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-8.45	3.76e-16	1.7e-13	-0.29	-0.36	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
THCA	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-8.45	3.77e-16	1.71e-13	-0.44	-0.36	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
THCA	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	8.45	3.78e-16	1.71e-13	0.5	0.36	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
THCA	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-8.45	3.79e-16	1.72e-13	-0.41	-0.36	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
THCA	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-8.45	3.79e-16	1.72e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
THCA	cis	rs1707322	1	rs785504	ENSG00000234329.1	RP11-767N6.2	-8.45	3.8e-16	1.72e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45651039~45651826:-
THCA	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-8.45	3.81e-16	1.73e-13	-0.29	-0.36	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
THCA	cis	rs4819052	1	rs2297286	ENSG00000237664.1	LINC00316	-8.45	3.81e-16	1.73e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45338590~45341990:-
THCA	cis	rs11148252	0.512	rs9526950	ENSG00000278238.1	RP11-245D16.4	-8.44	3.83e-16	1.73e-13	-0.42	-0.36	Lewy body disease;	chr13:52600328	chr13:52454775~52455331:-
THCA	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-8.44	3.83e-16	1.73e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
THCA	cis	rs4842666	0.667	rs1401981	ENSG00000258302.2	RP11-981P6.1	8.44	3.84e-16	1.74e-13	0.37	0.36	Blood pressure;	chr12:89697669	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-8.44	3.84e-16	1.74e-13	-0.47	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
THCA	cis	rs7015263	0.676	rs7460439	ENSG00000254231.1	CTD-2284J15.1	8.44	3.85e-16	1.74e-13	0.36	0.36	Intelligence (multi-trait analysis);	chr8:86501861	chr8:86333274~86343314:-
THCA	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	8.44	3.87e-16	1.75e-13	0.41	0.36	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
THCA	cis	rs1707322	0.686	rs1547924	ENSG00000234329.1	RP11-767N6.2	8.44	3.89e-16	1.76e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs3014236	ENSG00000234329.1	RP11-767N6.2	-8.44	3.89e-16	1.76e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45651039~45651826:-
THCA	cis	rs4591358	0.773	rs17177580	ENSG00000223466.1	AC064834.2	8.44	3.89e-16	1.76e-13	0.49	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508426	chr2:195533035~195538681:+
THCA	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-8.44	3.92e-16	1.77e-13	-0.27	-0.36	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
THCA	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-8.44	3.92e-16	1.78e-13	-0.35	-0.36	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000237664.1	LINC00316	-8.44	3.93e-16	1.78e-13	-0.37	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000237664.1	LINC00316	-8.44	3.93e-16	1.78e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45338590~45341990:-
THCA	cis	rs3847687	1	rs3847687	ENSG00000256810.1	RP11-76C10.2	8.44	3.94e-16	1.78e-13	0.42	0.36	Longevity;	chr12:131040508	chr12:131030570~131035487:-
THCA	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-8.44	3.94e-16	1.79e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
THCA	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-8.44	3.97e-16	1.8e-13	-0.57	-0.36	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000230295.1	RP11-458F8.2	-8.44	3.97e-16	1.8e-13	-0.32	-0.36	Corneal structure;	chr7:66798563	chr7:66880708~66882981:+
THCA	cis	rs910316	0.575	rs12889133	ENSG00000279594.1	RP11-950C14.10	8.44	3.98e-16	1.8e-13	0.35	0.36	Height;	chr14:74998386	chr14:75011269~75012851:-
THCA	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	8.44	3.98e-16	1.8e-13	0.45	0.36	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
THCA	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-8.44	3.98e-16	1.8e-13	-0.37	-0.36	Height;	chr11:118809363	chr11:118704607~118750263:+
THCA	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	8.44	3.98e-16	1.8e-13	0.41	0.36	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
THCA	cis	rs9595066	0.627	rs4394973	ENSG00000227258.4	SMIM2-AS1	-8.44	3.98e-16	1.8e-13	-0.45	-0.36	Schizophrenia;	chr13:44179173	chr13:44110451~44240517:+
THCA	cis	rs11603691	1	rs11607950	ENSG00000254662.1	RP11-872D17.4	-8.44	3.99e-16	1.81e-13	-0.68	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57339887	chr11:57325603~57327958:+
THCA	cis	rs11603691	1	rs11229003	ENSG00000254662.1	RP11-872D17.4	-8.44	3.99e-16	1.81e-13	-0.68	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57340817	chr11:57325603~57327958:+
THCA	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	8.44	3.99e-16	1.81e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	8.44	3.99e-16	1.81e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	8.44	3.99e-16	1.81e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	8.44	3.99e-16	1.81e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
THCA	cis	rs4819052	0.655	rs2330103	ENSG00000215447.6	BX322557.10	-8.44	3.99e-16	1.81e-13	-0.29	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45288052~45291738:+
THCA	cis	rs1707322	1	rs785469	ENSG00000234329.1	RP11-767N6.2	-8.44	4.01e-16	1.82e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785468	ENSG00000234329.1	RP11-767N6.2	-8.44	4.01e-16	1.82e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45651039~45651826:-
THCA	cis	rs944289	0.966	rs2415317	ENSG00000257826.1	RP11-116N8.4	8.44	4.02e-16	1.82e-13	0.38	0.36	Thyroid cancer;	chr14:36140472	chr14:36061026~36067190:-
THCA	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	8.44	4.02e-16	1.82e-13	0.48	0.36	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
THCA	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	8.44	4.04e-16	1.83e-13	0.25	0.36	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	8.44	4.04e-16	1.83e-13	0.25	0.36	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
THCA	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.44	4.05e-16	1.83e-13	0.47	0.36	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
THCA	cis	rs8114671	0.869	rs1407202	ENSG00000269202.1	RP4-614O4.12	8.44	4.05e-16	1.83e-13	0.31	0.36	Height;	chr20:35064164	chr20:35201747~35203288:-
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-8.44	4.06e-16	1.84e-13	-0.32	-0.36	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
THCA	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	8.44	4.07e-16	1.84e-13	0.49	0.36	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
THCA	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	8.44	4.07e-16	1.84e-13	0.53	0.36	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
THCA	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	8.44	4.09e-16	1.85e-13	0.24	0.36	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
THCA	cis	rs17772222	0.545	rs1758846	ENSG00000258789.1	RP11-507K2.3	8.44	4.09e-16	1.85e-13	0.35	0.36	Coronary artery calcification;	chr14:88449288	chr14:88551597~88552493:+
THCA	cis	rs8114671	0.967	rs6060285	ENSG00000269202.1	RP4-614O4.12	-8.44	4.1e-16	1.85e-13	-0.3	-0.36	Height;	chr20:35182684	chr20:35201747~35203288:-
THCA	cis	rs11148252	0.595	rs4885117	ENSG00000235660.1	LINC00345	-8.44	4.11e-16	1.86e-13	-0.46	-0.36	Lewy body disease;	chr13:52578892	chr13:52484161~52484680:-
THCA	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-8.43	4.11e-16	1.86e-13	-0.48	-0.36	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
THCA	cis	rs8114671	0.935	rs6060282	ENSG00000269202.1	RP4-614O4.12	-8.43	4.12e-16	1.86e-13	-0.3	-0.36	Height;	chr20:35179263	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs2065978	ENSG00000269202.1	RP4-614O4.12	-8.43	4.12e-16	1.86e-13	-0.3	-0.36	Height;	chr20:35179488	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs2065979	ENSG00000269202.1	RP4-614O4.12	-8.43	4.12e-16	1.86e-13	-0.3	-0.36	Height;	chr20:35179887	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs6088753	ENSG00000269202.1	RP4-614O4.12	-8.43	4.12e-16	1.86e-13	-0.3	-0.36	Height;	chr20:35180449	chr20:35201747~35203288:-
THCA	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	8.43	4.13e-16	1.86e-13	0.35	0.36	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
THCA	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-8.43	4.13e-16	1.87e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
THCA	cis	rs934734	0.532	rs7557569	ENSG00000237979.1	AC007389.1	-8.43	4.14e-16	1.87e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65417427	chr2:65500993~65502138:-
THCA	cis	rs8114671	0.562	rs6088646	ENSG00000269202.1	RP4-614O4.12	-8.43	4.15e-16	1.88e-13	-0.3	-0.36	Height;	chr20:34918134	chr20:35201747~35203288:-
THCA	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	8.43	4.15e-16	1.88e-13	0.48	0.36	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	8.43	4.15e-16	1.88e-13	0.48	0.36	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
THCA	cis	rs516805	1	rs516805	ENSG00000279453.1	RP3-425C14.4	-8.43	4.16e-16	1.88e-13	-0.33	-0.36	Lymphocyte counts;	chr6:122398486	chr6:122436789~122439223:-
THCA	cis	rs4718428	0.705	rs11028	ENSG00000230295.1	RP11-458F8.2	-8.43	4.16e-16	1.88e-13	-0.32	-0.36	Corneal structure;	chr7:66811230	chr7:66880708~66882981:+
THCA	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-8.43	4.17e-16	1.88e-13	-0.43	-0.36	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
THCA	cis	rs2929278	0.561	rs3099045	ENSG00000166763.7	STRCP1	8.43	4.18e-16	1.89e-13	0.4	0.36	Schizophrenia;	chr15:43631757	chr15:43699488~43718184:-
THCA	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	8.43	4.19e-16	1.89e-13	0.48	0.36	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000228039.3	KB-1125A3.10	8.43	4.19e-16	1.89e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23963780~23964374:+
THCA	cis	rs1707322	0.686	rs3014239	ENSG00000234329.1	RP11-767N6.2	-8.43	4.2e-16	1.9e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45651039~45651826:-
THCA	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-8.43	4.2e-16	1.9e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
THCA	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-8.43	4.21e-16	1.9e-13	-0.5	-0.36	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
THCA	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	8.43	4.21e-16	1.9e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
THCA	cis	rs2712184	0.846	rs7598172	ENSG00000229352.1	AC007563.3	-8.43	4.21e-16	1.9e-13	-0.44	-0.36	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216813276	chr2:216799608~216805335:+
THCA	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-8.43	4.21e-16	1.9e-13	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
THCA	cis	rs1707322	0.686	rs2230659	ENSG00000234329.1	RP11-767N6.2	-8.43	4.25e-16	1.92e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45651039~45651826:-
THCA	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	8.43	4.29e-16	1.94e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
THCA	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-8.43	4.31e-16	1.94e-13	-0.4	-0.36	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
THCA	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-8.43	4.32e-16	1.95e-13	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-8.43	4.32e-16	1.95e-13	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
THCA	cis	rs7829975	0.658	rs2409096	ENSG00000253893.2	FAM85B	-8.43	4.35e-16	1.96e-13	-0.47	-0.36	Mood instability;	chr8:8834967	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-8.43	4.35e-16	1.96e-13	-0.46	-0.36	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
THCA	cis	rs8114671	0.967	rs1415773	ENSG00000269202.1	RP4-614O4.12	-8.43	4.35e-16	1.96e-13	-0.3	-0.36	Height;	chr20:35177782	chr20:35201747~35203288:-
THCA	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	8.43	4.36e-16	1.97e-13	0.41	0.36	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
THCA	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-8.43	4.36e-16	1.97e-13	-0.36	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
THCA	cis	rs62158211	1	rs4618068	ENSG00000272563.1	RP11-480C16.1	-8.43	4.36e-16	1.97e-13	-0.49	-0.36	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113351778	chr2:113432600~113436042:+
THCA	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	8.43	4.36e-16	1.97e-13	0.68	0.36	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
THCA	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-8.43	4.37e-16	1.97e-13	-0.51	-0.36	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-8.43	4.37e-16	1.97e-13	-0.51	-0.36	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
THCA	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-8.43	4.38e-16	1.97e-13	-0.53	-0.36	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
THCA	cis	rs17772222	0.701	rs1627444	ENSG00000258789.1	RP11-507K2.3	8.43	4.39e-16	1.98e-13	0.34	0.36	Coronary artery calcification;	chr14:88413784	chr14:88551597~88552493:+
THCA	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	8.43	4.39e-16	1.98e-13	0.45	0.36	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
THCA	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	8.43	4.39e-16	1.98e-13	0.45	0.36	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000230295.1	RP11-458F8.2	-8.43	4.4e-16	1.98e-13	-0.32	-0.36	Corneal structure;	chr7:66887678	chr7:66880708~66882981:+
THCA	cis	rs741668	0.641	rs1022951	ENSG00000235903.6	CPB2-AS1	8.43	4.41e-16	1.99e-13	0.46	0.36	Cerebrospinal fluid clusterin levels;	chr13:46075319	chr13:46052806~46113332:+
THCA	cis	rs934734	0.532	rs7569257	ENSG00000237979.1	AC007389.1	-8.43	4.41e-16	1.99e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65429842	chr2:65500993~65502138:-
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000237664.1	LINC00316	-8.43	4.42e-16	1.99e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45338590~45341990:-
THCA	cis	rs10740039	0.846	rs10761529	ENSG00000254271.1	RP11-131N11.4	8.43	4.43e-16	2e-13	0.45	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60627052	chr10:60734342~60741828:+
THCA	cis	rs1707322	0.721	rs56255771	ENSG00000234329.1	RP11-767N6.2	8.43	4.43e-16	2e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45651039~45651826:-
THCA	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	8.42	4.43e-16	2e-13	0.24	0.36	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	8.42	4.43e-16	2e-13	0.24	0.36	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	8.42	4.43e-16	2e-13	0.24	0.36	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
THCA	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	8.42	4.44e-16	2e-13	0.41	0.36	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
THCA	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	8.42	4.45e-16	2.01e-13	0.52	0.36	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
THCA	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	8.42	4.45e-16	2.01e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
THCA	cis	rs1707322	1	rs785486	ENSG00000234329.1	RP11-767N6.2	-8.42	4.46e-16	2.01e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.865	rs785501	ENSG00000234329.1	RP11-767N6.2	-8.42	4.46e-16	2.01e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.929	rs785500	ENSG00000234329.1	RP11-767N6.2	-8.42	4.46e-16	2.01e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45651039~45651826:-
THCA	cis	rs8114671	0.967	rs2378337	ENSG00000269202.1	RP4-614O4.12	-8.42	4.46e-16	2.01e-13	-0.3	-0.36	Height;	chr20:35183632	chr20:35201747~35203288:-
THCA	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	8.42	4.48e-16	2.02e-13	0.45	0.36	Depression;	chr6:28273214	chr6:28176188~28176674:+
THCA	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	8.42	4.48e-16	2.02e-13	0.45	0.36	Depression;	chr6:28273215	chr6:28176188~28176674:+
THCA	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-8.42	4.48e-16	2.02e-13	-0.54	-0.36	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
THCA	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	8.42	4.49e-16	2.02e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
THCA	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-8.42	4.53e-16	2.04e-13	-0.35	-0.36	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
THCA	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	8.42	4.53e-16	2.04e-13	0.24	0.36	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
THCA	cis	rs240993	0.516	rs241004	ENSG00000230177.1	RP5-1112D6.4	-8.42	4.55e-16	2.05e-13	-0.39	-0.36	Inflammatory skin disease;Psoriasis;	chr6:111275341	chr6:111277932~111278742:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000206090.4	AP000350.7	8.42	4.55e-16	2.05e-13	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23939998~23942798:+
THCA	cis	rs8114671	0.935	rs945960	ENSG00000269202.1	RP4-614O4.12	-8.42	4.55e-16	2.05e-13	-0.3	-0.36	Height;	chr20:35175051	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs2069952	ENSG00000269202.1	RP4-614O4.12	-8.42	4.55e-16	2.05e-13	-0.3	-0.36	Height;	chr20:35176148	chr20:35201747~35203288:-
THCA	cis	rs1707322	0.686	rs3014251	ENSG00000234329.1	RP11-767N6.2	-8.42	4.55e-16	2.05e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45651039~45651826:-
THCA	cis	rs737008	0.922	rs2070923	ENSG00000262703.1	RP11-485G7.6	8.42	4.55e-16	2.05e-13	0.42	0.36	Obesity-related traits;	chr16:11275998	chr16:11348143~11349321:-
THCA	cis	rs2946505	0.569	rs2977084	ENSG00000251468.2	RP11-369K16.1	8.42	4.55e-16	2.05e-13	0.58	0.36	Migraine;	chr8:12956634	chr8:12958387~12962200:+
THCA	cis	rs7015263	0.714	rs56122533	ENSG00000254231.1	CTD-2284J15.1	-8.42	4.56e-16	2.05e-13	-0.37	-0.36	Intelligence (multi-trait analysis);	chr8:86517828	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.714	rs7461624	ENSG00000254231.1	CTD-2284J15.1	-8.42	4.56e-16	2.05e-13	-0.37	-0.36	Intelligence (multi-trait analysis);	chr8:86527639	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.714	rs62510845	ENSG00000254231.1	CTD-2284J15.1	-8.42	4.56e-16	2.05e-13	-0.37	-0.36	Intelligence (multi-trait analysis);	chr8:86534823	chr8:86333274~86343314:-
THCA	cis	rs42490	0.7	rs410663	ENSG00000251136.7	RP11-37B2.1	8.42	4.6e-16	2.07e-13	0.32	0.36	Leprosy;	chr8:89859461	chr8:89609409~89757727:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	8.42	4.63e-16	2.08e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
THCA	cis	rs516805	0.847	rs520867	ENSG00000279453.1	RP3-425C14.4	-8.42	4.66e-16	2.1e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122465501	chr6:122436789~122439223:-
THCA	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-8.42	4.66e-16	2.1e-13	-0.61	-0.36	Depression;	chr6:28119105	chr6:28115628~28116551:+
THCA	cis	rs2274273	0.686	rs68083077	ENSG00000258413.1	RP11-665C16.6	-8.42	4.67e-16	2.1e-13	-0.51	-0.36	Protein biomarker;	chr14:55107710	chr14:55262767~55272075:-
THCA	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	8.42	4.67e-16	2.1e-13	0.37	0.36	Height;	chr11:118758322	chr11:118704607~118750263:+
THCA	cis	rs9475752	0.552	rs13205022	ENSG00000231441.1	RP11-472M19.2	-8.42	4.68e-16	2.11e-13	-0.48	-0.36	Menarche (age at onset);	chr6:56875620	chr6:56844002~56864078:+
THCA	cis	rs8114671	0.836	rs6142294	ENSG00000269202.1	RP4-614O4.12	8.42	4.69e-16	2.11e-13	0.31	0.36	Height;	chr20:35083694	chr20:35201747~35203288:-
THCA	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	8.42	4.7e-16	2.12e-13	0.43	0.36	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000224205.1	AP000351.4	8.42	4.71e-16	2.12e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23987320~23991421:-
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-8.42	4.71e-16	2.12e-13	-0.46	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-8.42	4.72e-16	2.12e-13	-0.45	-0.36	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
THCA	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-8.42	4.72e-16	2.12e-13	-0.38	-0.36	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
THCA	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-8.42	4.73e-16	2.13e-13	-0.53	-0.36	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
THCA	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-8.42	4.73e-16	2.13e-13	-0.53	-0.36	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
THCA	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	8.42	4.74e-16	2.13e-13	0.4	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
THCA	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-8.42	4.74e-16	2.13e-13	-0.42	-0.36	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
THCA	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	8.42	4.75e-16	2.13e-13	0.56	0.36	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
THCA	cis	rs42490	0.664	rs453266	ENSG00000251136.7	RP11-37B2.1	-8.42	4.75e-16	2.14e-13	-0.31	-0.36	Leprosy;	chr8:89823789	chr8:89609409~89757727:-
THCA	cis	rs42490	0.638	rs369771	ENSG00000251136.7	RP11-37B2.1	-8.42	4.75e-16	2.14e-13	-0.31	-0.36	Leprosy;	chr8:89823884	chr8:89609409~89757727:-
THCA	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-8.42	4.76e-16	2.14e-13	-0.46	-0.36	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
THCA	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	8.42	4.76e-16	2.14e-13	0.36	0.36	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
THCA	cis	rs11148252	0.774	rs9596649	ENSG00000235660.1	LINC00345	8.41	4.77e-16	2.15e-13	0.45	0.36	Lewy body disease;	chr13:52360475	chr13:52484161~52484680:-
THCA	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	8.41	4.79e-16	2.16e-13	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
THCA	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	8.41	4.81e-16	2.16e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
THCA	cis	rs10740039	0.81	rs2165691	ENSG00000254271.1	RP11-131N11.4	8.41	4.82e-16	2.17e-13	0.46	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60611891	chr10:60734342~60741828:+
THCA	cis	rs6504663	0.558	rs11871603	ENSG00000275897.1	RP11-94C24.13	8.41	4.83e-16	2.17e-13	0.34	0.36	Visceral fat;	chr17:50481676	chr17:50475819~50478391:+
THCA	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
THCA	cis	rs4927850	1	rs7630875	ENSG00000226155.1	AC124944.3	-8.41	4.84e-16	2.17e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196026895	chr3:195912049~195913986:+
THCA	cis	rs1707322	0.686	rs11211179	ENSG00000234329.1	RP11-767N6.2	8.41	4.85e-16	2.18e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10157795	ENSG00000234329.1	RP11-767N6.2	8.41	4.85e-16	2.18e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45651039~45651826:-
THCA	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	8.41	4.85e-16	2.18e-13	0.42	0.36	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
THCA	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	8.41	4.89e-16	2.2e-13	0.32	0.36	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
THCA	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-8.41	4.89e-16	2.2e-13	-0.37	-0.36	Height;	chr11:118808920	chr11:118704607~118750263:+
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-8.41	4.91e-16	2.2e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-8.41	4.91e-16	2.2e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
THCA	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-8.41	4.91e-16	2.2e-13	-0.51	-0.36	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
THCA	cis	rs2408955	0.521	rs1476607	ENSG00000258273.1	RP11-370I10.4	8.41	4.92e-16	2.21e-13	0.48	0.36	Glycated hemoglobin levels;	chr12:48131021	chr12:48333755~48333901:-
THCA	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-8.41	4.92e-16	2.21e-13	-0.29	-0.36	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000235689.1	AP000351.13	8.41	4.92e-16	2.21e-13	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:24006305~24008258:-
THCA	cis	rs2408955	0.568	rs12099462	ENSG00000258273.1	RP11-370I10.4	8.41	4.93e-16	2.21e-13	0.48	0.36	Glycated hemoglobin levels;	chr12:48109321	chr12:48333755~48333901:-
THCA	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-8.41	4.93e-16	2.22e-13	-0.35	-0.36	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
THCA	cis	rs4842666	0.915	rs2681472	ENSG00000258302.2	RP11-981P6.1	8.41	4.94e-16	2.22e-13	0.36	0.36	Blood pressure;	chr12:89615182	chr12:89561129~89594878:+
THCA	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	8.41	4.94e-16	2.22e-13	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
THCA	cis	rs4789693	1	rs4789693	ENSG00000265458.1	RP13-20L14.6	8.41	4.94e-16	2.22e-13	0.36	0.36	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82454273~82458521:-
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000226155.1	AC124944.3	-8.41	4.95e-16	2.22e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196021858	chr3:195912049~195913986:+
THCA	cis	rs860295	1	rs860295	ENSG00000225855.5	RUSC1-AS1	-8.41	4.95e-16	2.22e-13	-0.24	-0.36	Body mass index;	chr1:155797917	chr1:155316863~155324176:-
THCA	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	8.41	4.96e-16	2.23e-13	0.62	0.36	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
THCA	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-8.41	4.97e-16	2.23e-13	-0.38	-0.36	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
THCA	cis	rs8114671	0.562	rs6120763	ENSG00000269202.1	RP4-614O4.12	-8.41	4.98e-16	2.23e-13	-0.3	-0.36	Height;	chr20:34918597	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs3746450	ENSG00000269202.1	RP4-614O4.12	-8.41	4.98e-16	2.23e-13	-0.3	-0.36	Height;	chr20:34920785	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6087649	ENSG00000269202.1	RP4-614O4.12	-8.41	4.98e-16	2.23e-13	-0.3	-0.36	Height;	chr20:34922859	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs4911449	ENSG00000269202.1	RP4-614O4.12	-8.41	4.98e-16	2.23e-13	-0.3	-0.36	Height;	chr20:34924433	chr20:35201747~35203288:-
THCA	cis	rs795484	0.507	rs795482	ENSG00000275759.1	RP11-131L12.3	8.41	4.99e-16	2.24e-13	0.34	0.36	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118153011	chr12:118428281~118428870:+
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-8.41	5e-16	2.24e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
THCA	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	8.41	5e-16	2.25e-13	0.4	0.36	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
THCA	cis	rs4380275	1	rs7562792	ENSG00000272342.1	RP13-539J13.1	8.41	5.02e-16	2.25e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:739588~740164:-
THCA	cis	rs795484	0.507	rs2249624	ENSG00000275759.1	RP11-131L12.3	8.41	5.02e-16	2.25e-13	0.34	0.36	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118151264	chr12:118428281~118428870:+
THCA	cis	rs9902453	0.505	rs11080107	ENSG00000264007.1	RP11-68I3.10	-8.41	5.03e-16	2.26e-13	-0.42	-0.36	Coffee consumption (cups per day);	chr17:29611406	chr17:29621617~29622254:-
THCA	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	8.41	5.05e-16	2.26e-13	0.46	0.36	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
THCA	cis	rs9475752	0.503	rs60563401	ENSG00000231441.1	RP11-472M19.2	8.41	5.05e-16	2.27e-13	0.44	0.36	Menarche (age at onset);	chr6:56873580	chr6:56844002~56864078:+
THCA	cis	rs4380275	1	rs4268954	ENSG00000272342.1	RP13-539J13.1	8.41	5.05e-16	2.27e-13	0.43	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:739588~740164:-
THCA	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-8.41	5.07e-16	2.28e-13	-0.48	-0.36	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
THCA	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	8.41	5.08e-16	2.28e-13	0.69	0.36	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	8.41	5.08e-16	2.28e-13	0.69	0.36	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
THCA	cis	rs7309	0.87	rs2358016	ENSG00000227403.1	AC009299.3	8.41	5.09e-16	2.28e-13	0.39	0.36	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161244739~161249050:+
THCA	cis	rs11148252	0.904	rs7321964	ENSG00000235660.1	LINC00345	-8.41	5.1e-16	2.29e-13	-0.45	-0.36	Lewy body disease;	chr13:52466687	chr13:52484161~52484680:-
THCA	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	8.41	5.12e-16	2.3e-13	0.44	0.36	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
THCA	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	8.41	5.12e-16	2.3e-13	0.24	0.36	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	8.41	5.12e-16	2.3e-13	0.24	0.36	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-8.41	5.13e-16	2.3e-13	-0.32	-0.36	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
THCA	cis	rs4819052	0.634	rs8128636	ENSG00000215447.6	BX322557.10	-8.4	5.14e-16	2.3e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45288052~45291738:+
THCA	cis	rs11148252	0.595	rs4884522	ENSG00000235660.1	LINC00345	-8.4	5.15e-16	2.31e-13	-0.46	-0.36	Lewy body disease;	chr13:52479633	chr13:52484161~52484680:-
THCA	cis	rs1707322	0.964	rs1768802	ENSG00000234329.1	RP11-767N6.2	-8.4	5.16e-16	2.32e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1588663	ENSG00000234329.1	RP11-767N6.2	-8.4	5.16e-16	2.32e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768801	ENSG00000234329.1	RP11-767N6.2	-8.4	5.16e-16	2.32e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768800	ENSG00000234329.1	RP11-767N6.2	-8.4	5.16e-16	2.32e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45651039~45651826:-
THCA	cis	rs11148252	0.74	rs7981050	ENSG00000278238.1	RP11-245D16.4	-8.4	5.17e-16	2.32e-13	-0.41	-0.36	Lewy body disease;	chr13:52181014	chr13:52454775~52455331:-
THCA	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	8.4	5.18e-16	2.32e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	8.4	5.19e-16	2.33e-13	0.58	0.36	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
THCA	cis	rs2712184	0.875	rs1015784	ENSG00000229352.1	AC007563.3	-8.4	5.2e-16	2.33e-13	-0.44	-0.36	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216817110	chr2:216799608~216805335:+
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000237664.1	LINC00316	-8.4	5.21e-16	2.34e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45338590~45341990:-
THCA	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-8.4	5.22e-16	2.34e-13	-0.48	-0.36	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-8.4	5.22e-16	2.34e-13	-0.48	-0.36	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
THCA	cis	rs7849270	0.879	rs7046990	ENSG00000268707.1	RP11-247A12.7	-8.4	5.24e-16	2.35e-13	-0.45	-0.36	Blood metabolite ratios;	chr9:129093859	chr9:129170434~129170940:+
THCA	cis	rs1707322	0.686	rs2230658	ENSG00000234329.1	RP11-767N6.2	-8.4	5.26e-16	2.36e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs2991986	ENSG00000234329.1	RP11-767N6.2	-8.4	5.26e-16	2.36e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs2991987	ENSG00000234329.1	RP11-767N6.2	-8.4	5.26e-16	2.36e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45651039~45651826:-
THCA	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	8.4	5.27e-16	2.36e-13	0.46	0.36	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
THCA	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-8.4	5.28e-16	2.37e-13	-0.57	-0.36	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
THCA	cis	rs8114671	0.967	rs9574	ENSG00000269202.1	RP4-614O4.12	-8.4	5.28e-16	2.37e-13	-0.3	-0.36	Height;	chr20:35176829	chr20:35201747~35203288:-
THCA	cis	rs860295	0.967	rs6665227	ENSG00000225855.5	RUSC1-AS1	8.4	5.3e-16	2.38e-13	0.24	0.36	Body mass index;	chr1:155740669	chr1:155316863~155324176:-
THCA	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-8.4	5.31e-16	2.38e-13	-0.45	-0.36	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-8.4	5.31e-16	2.38e-13	-0.45	-0.36	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
THCA	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-8.4	5.31e-16	2.38e-13	-0.51	-0.36	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
THCA	cis	rs9659323	0.73	rs7512189	ENSG00000231365.4	RP11-418J17.1	-8.4	5.31e-16	2.38e-13	-0.35	-0.36	Body mass index;	chr1:118999909	chr1:119140396~119275973:+
THCA	cis	rs416603	0.967	rs7191538	ENSG00000262636.1	CTD-3088G3.4	-8.4	5.32e-16	2.38e-13	-0.45	-0.36	Type 1 diabetes;	chr16:11269532	chr16:11380859~11381118:-
THCA	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-8.4	5.35e-16	2.39e-13	-0.37	-0.36	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
THCA	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-8.4	5.35e-16	2.39e-13	-0.37	-0.36	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
THCA	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.4	5.36e-16	2.4e-13	0.47	0.36	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
THCA	cis	rs42490	0.59	rs39771	ENSG00000251136.7	RP11-37B2.1	-8.4	5.36e-16	2.4e-13	-0.31	-0.36	Leprosy;	chr8:89826378	chr8:89609409~89757727:-
THCA	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-8.4	5.37e-16	2.4e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
THCA	cis	rs1850744	0.702	rs13104360	ENSG00000250942.1	ENPP7P11	8.4	5.39e-16	2.41e-13	0.49	0.36	Economic and political preferences;	chr4:9683180	chr4:9677308~9677934:+
THCA	cis	rs8114671	0.562	rs4911447	ENSG00000269202.1	RP4-614O4.12	-8.4	5.39e-16	2.41e-13	-0.3	-0.36	Height;	chr20:34891642	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6088642	ENSG00000269202.1	RP4-614O4.12	-8.4	5.39e-16	2.41e-13	-0.3	-0.36	Height;	chr20:34895383	chr20:35201747~35203288:-
THCA	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-8.4	5.41e-16	2.42e-13	-0.48	-0.36	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-8.4	5.41e-16	2.42e-13	-0.48	-0.36	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-8.4	5.41e-16	2.42e-13	-0.48	-0.36	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-8.4	5.41e-16	2.42e-13	-0.48	-0.36	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
THCA	cis	rs8114671	0.967	rs2069948	ENSG00000269202.1	RP4-614O4.12	-8.4	5.42e-16	2.43e-13	-0.3	-0.36	Height;	chr20:35174686	chr20:35201747~35203288:-
THCA	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	8.4	5.42e-16	2.43e-13	0.52	0.36	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
THCA	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	8.4	5.43e-16	2.43e-13	0.45	0.36	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
THCA	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-8.4	5.52e-16	2.47e-13	-0.29	-0.36	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-8.4	5.52e-16	2.47e-13	-0.29	-0.36	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
THCA	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-8.4	5.52e-16	2.47e-13	-0.29	-0.36	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
THCA	cis	rs3747113	1	rs13056719	ENSG00000128262.7	POM121L9P	-8.39	5.54e-16	2.48e-13	-0.4	-0.36	Gut microbiome composition (summer);	chr22:24328131	chr22:24251828~24265525:+
THCA	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	8.39	5.55e-16	2.48e-13	0.62	0.36	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	8.39	5.55e-16	2.48e-13	0.62	0.36	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
THCA	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-8.39	5.55e-16	2.48e-13	-0.53	-0.36	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
THCA	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-8.39	5.55e-16	2.48e-13	-0.53	-0.36	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
THCA	cis	rs7646881	0.904	rs112493023	ENSG00000240207.5	RP11-379F4.4	-8.39	5.56e-16	2.49e-13	-0.48	-0.36	Tetralogy of Fallot;	chr3:158730487	chr3:158732263~158784070:+
THCA	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-8.39	5.57e-16	2.49e-13	-0.37	-0.36	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
THCA	cis	rs934734	0.532	rs10153675	ENSG00000237979.1	AC007389.1	-8.39	5.58e-16	2.5e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65422446	chr2:65500993~65502138:-
THCA	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	8.39	5.6e-16	2.5e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
THCA	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-8.39	5.6e-16	2.5e-13	-0.37	-0.36	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
THCA	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-8.39	5.61e-16	2.51e-13	-0.48	-0.36	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
THCA	cis	rs9595066	0.627	rs2246432	ENSG00000227258.4	SMIM2-AS1	-8.39	5.61e-16	2.51e-13	-0.45	-0.36	Schizophrenia;	chr13:44182648	chr13:44110451~44240517:+
THCA	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-8.39	5.62e-16	2.51e-13	-0.29	-0.36	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-8.39	5.62e-16	2.51e-13	-0.29	-0.36	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000224205.1	AP000351.4	8.39	5.64e-16	2.52e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23987320~23991421:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000224205.1	AP000351.4	8.39	5.64e-16	2.52e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23987320~23991421:-
THCA	cis	rs6504663	0.558	rs7627	ENSG00000275897.1	RP11-94C24.13	8.39	5.64e-16	2.52e-13	0.35	0.36	Visceral fat;	chr17:50474793	chr17:50475819~50478391:+
THCA	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	8.39	5.65e-16	2.52e-13	0.34	0.36	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	8.39	5.65e-16	2.52e-13	0.34	0.36	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
THCA	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	8.39	5.67e-16	2.54e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	8.39	5.67e-16	2.54e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	8.39	5.67e-16	2.54e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	8.39	5.67e-16	2.54e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
THCA	cis	rs2562456	0.876	rs62110202	ENSG00000268555.1	RP11-678G14.3	8.39	5.7e-16	2.55e-13	0.5	0.36	Pain;	chr19:21571799	chr19:21570822~21587322:-
THCA	cis	rs73607972	0.569	rs34115013	ENSG00000275191.1	RP11-36I17.2	-8.39	5.7e-16	2.55e-13	-0.49	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53534324	chr16:53628256~53628816:-
THCA	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-8.39	5.73e-16	2.56e-13	-0.45	-0.36	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
THCA	cis	rs7291412	0.662	rs6520015	ENSG00000231711.2	LINC00899	-8.39	5.75e-16	2.57e-13	-0.3	-0.36	Dupuytren's disease;Subjective well-being;	chr22:46067551	chr22:46039907~46044853:-
THCA	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	8.39	5.75e-16	2.57e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
THCA	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	8.39	5.76e-16	2.57e-13	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
THCA	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	8.39	5.76e-16	2.57e-13	0.45	0.36	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
THCA	cis	rs16846053	0.515	rs4664047	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161649360	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs6432699	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161652729	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs6758760	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161654331	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.551	rs12692640	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161669405	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs3849355	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.57	-0.36	Blood osmolality (transformed sodium);	chr2:161531204	chr2:161244739~161249050:+
THCA	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-8.39	5.79e-16	2.59e-13	-0.29	-0.36	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
THCA	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-8.39	5.8e-16	2.59e-13	-0.37	-0.36	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-8.39	5.8e-16	2.59e-13	-0.37	-0.36	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-8.39	5.8e-16	2.59e-13	-0.37	-0.36	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-8.39	5.8e-16	2.59e-13	-0.37	-0.36	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
THCA	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	8.39	5.8e-16	2.59e-13	0.37	0.36	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
THCA	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	8.39	5.83e-16	2.6e-13	0.48	0.36	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000228039.3	KB-1125A3.10	8.39	5.84e-16	2.61e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23963780~23964374:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000228039.3	KB-1125A3.10	8.39	5.84e-16	2.61e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23963780~23964374:+
THCA	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-8.39	5.88e-16	2.62e-13	-0.38	-0.36	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
THCA	cis	rs848490	0.722	rs4729772	ENSG00000214293.7	APTR	8.39	5.89e-16	2.63e-13	0.26	0.36	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77826582	chr7:77657660~77696265:-
THCA	cis	rs2929278	0.562	rs8033846	ENSG00000166763.7	STRCP1	-8.39	5.9e-16	2.63e-13	-0.39	-0.36	Schizophrenia;	chr15:43743165	chr15:43699488~43718184:-
THCA	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	8.39	5.94e-16	2.65e-13	0.32	0.36	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
THCA	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	8.39	5.94e-16	2.65e-13	0.35	0.36	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
THCA	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	8.39	5.94e-16	2.65e-13	0.35	0.36	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
THCA	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	8.39	5.94e-16	2.65e-13	0.35	0.36	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
THCA	cis	rs16846053	0.515	rs4001644	ENSG00000227403.1	AC009299.3	-8.39	5.95e-16	2.65e-13	-0.57	-0.36	Blood osmolality (transformed sodium);	chr2:161542357	chr2:161244739~161249050:+
THCA	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-8.38	5.96e-16	2.66e-13	-0.46	-0.36	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
THCA	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	8.38	5.96e-16	2.66e-13	0.48	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
THCA	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	8.38	5.97e-16	2.66e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
THCA	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-8.38	5.97e-16	2.66e-13	-0.57	-0.36	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
THCA	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	8.38	5.97e-16	2.66e-13	0.62	0.36	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
THCA	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-8.38	5.97e-16	2.66e-13	-0.38	-0.36	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
THCA	cis	rs910316	1	rs4903289	ENSG00000279594.1	RP11-950C14.10	-8.38	5.98e-16	2.67e-13	-0.34	-0.36	Height;	chr14:75157285	chr14:75011269~75012851:-
THCA	cis	rs516805	0.923	rs491171	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122408021	chr6:122436789~122439223:-
THCA	cis	rs516805	0.923	rs556675	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122408083	chr6:122436789~122439223:-
THCA	cis	rs516805	0.923	rs487487	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122422357	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs556439	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122423864	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs572632	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122437753	chr6:122436789~122439223:-
THCA	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-8.38	6.01e-16	2.68e-13	-0.37	-0.36	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
THCA	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	8.38	6.02e-16	2.68e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
THCA	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-8.38	6.03e-16	2.69e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
THCA	cis	rs11673344	0.523	rs10420330	ENSG00000226686.6	LINC01535	8.38	6.05e-16	2.7e-13	0.39	0.36	Obesity-related traits;	chr19:37111269	chr19:37251912~37265535:+
THCA	cis	rs1707322	0.686	rs2991977	ENSG00000234329.1	RP11-767N6.2	-8.38	6.07e-16	2.71e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.656	rs2991981	ENSG00000234329.1	RP11-767N6.2	-8.38	6.07e-16	2.71e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.656	rs3014210	ENSG00000234329.1	RP11-767N6.2	-8.38	6.07e-16	2.71e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45651039~45651826:-
THCA	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	8.38	6.09e-16	2.71e-13	0.23	0.36	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000224205.1	AP000351.4	8.38	6.1e-16	2.72e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23987320~23991421:-
THCA	cis	rs7714584	1	rs4958422	ENSG00000197083.10	ZNF300P1	8.38	6.14e-16	2.73e-13	0.64	0.36	Crohn's disease;	chr5:150807172	chr5:150930645~150946289:-
THCA	cis	rs507080	0.961	rs642530	ENSG00000278376.1	RP11-158I9.8	-8.38	6.14e-16	2.73e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118680047	chr11:118791254~118793137:+
THCA	cis	rs4819052	0.679	rs2838859	ENSG00000215447.6	BX322557.10	-8.38	6.15e-16	2.74e-13	-0.29	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45288052~45291738:+
THCA	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-8.38	6.18e-16	2.75e-13	-0.45	-0.36	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
THCA	cis	rs8114671	0.562	rs6120758	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34904720	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs7266550	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34907707	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2378294	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34912575	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2076667	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34919161	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs3818273	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34921472	chr20:35201747~35203288:-
THCA	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	8.38	6.18e-16	2.75e-13	0.44	0.36	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
THCA	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	8.38	6.19e-16	2.76e-13	0.45	0.36	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
THCA	cis	rs28510890	0.754	rs8033582	ENSG00000260337.3	RP11-386M24.6	8.38	6.19e-16	2.76e-13	0.4	0.36	Lung cancer in ever smokers;	chr15:92582658	chr15:92592574~92596462:-
THCA	cis	rs737008	0.922	rs2550475	ENSG00000262703.1	RP11-485G7.6	8.38	6.2e-16	2.76e-13	0.42	0.36	Obesity-related traits;	chr16:11278129	chr16:11348143~11349321:-
THCA	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-8.38	6.21e-16	2.76e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
THCA	cis	rs8114671	0.967	rs4911472	ENSG00000269202.1	RP4-614O4.12	-8.38	6.21e-16	2.77e-13	-0.3	-0.36	Height;	chr20:35187574	chr20:35201747~35203288:-
THCA	cis	rs7191700	0.511	rs8043625	ENSG00000262636.1	CTD-3088G3.4	-8.38	6.22e-16	2.77e-13	-0.45	-0.36	Multiple sclerosis;	chr16:11268038	chr16:11380859~11381118:-
THCA	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	8.38	6.23e-16	2.77e-13	0.24	0.36	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
THCA	cis	rs1707322	0.752	rs6662164	ENSG00000234329.1	RP11-767N6.2	8.38	6.24e-16	2.78e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-8.38	6.25e-16	2.78e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-8.38	6.25e-16	2.78e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.625	rs3091338	ENSG00000237714.1	P4HA2-AS1	8.38	6.27e-16	2.79e-13	0.48	0.36	Blood metabolite levels;	chr5:132067045	chr5:132184876~132192808:+
THCA	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	8.38	6.27e-16	2.79e-13	0.46	0.36	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	8.38	6.27e-16	2.79e-13	0.46	0.36	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
THCA	cis	rs3847687	1	rs11061303	ENSG00000256810.1	RP11-76C10.2	8.38	6.27e-16	2.79e-13	0.43	0.36	Longevity;	chr12:131041777	chr12:131030570~131035487:-
THCA	cis	rs984222	0.62	rs10923763	ENSG00000231365.4	RP11-418J17.1	8.38	6.28e-16	2.79e-13	0.35	0.36	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119175597	chr1:119140396~119275973:+
THCA	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	8.38	6.28e-16	2.8e-13	0.38	0.36	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
THCA	cis	rs8114671	0.836	rs6141526	ENSG00000269202.1	RP4-614O4.12	8.38	6.28e-16	2.8e-13	0.31	0.36	Height;	chr20:35027452	chr20:35201747~35203288:-
THCA	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	8.38	6.29e-16	2.8e-13	0.45	0.36	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
THCA	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-8.38	6.32e-16	2.81e-13	-0.37	-0.36	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
THCA	cis	rs7191700	0.578	rs243324	ENSG00000262636.1	CTD-3088G3.4	8.38	6.33e-16	2.82e-13	0.45	0.36	Multiple sclerosis;	chr16:11261113	chr16:11380859~11381118:-
THCA	cis	rs910316	0.763	rs175057	ENSG00000279594.1	RP11-950C14.10	-8.38	6.34e-16	2.82e-13	-0.34	-0.36	Height;	chr14:75022929	chr14:75011269~75012851:-
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000226155.1	AC124944.3	-8.38	6.35e-16	2.82e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196024982	chr3:195912049~195913986:+
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000226155.1	AC124944.3	-8.38	6.35e-16	2.82e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196025389	chr3:195912049~195913986:+
THCA	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-8.38	6.35e-16	2.83e-13	-0.37	-0.36	Height;	chr11:118761813	chr11:118704607~118750263:+
THCA	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-8.37	6.42e-16	2.85e-13	-0.35	-0.36	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
THCA	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	8.37	6.42e-16	2.85e-13	0.35	0.36	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
THCA	cis	rs8114671	0.562	rs1060615	ENSG00000269202.1	RP4-614O4.12	8.37	6.43e-16	2.86e-13	0.3	0.36	Height;	chr20:34890578	chr20:35201747~35203288:-
THCA	cis	rs5769707	0.872	rs5770604	ENSG00000235111.1	RP1-29C18.8	-8.37	6.43e-16	2.86e-13	-0.42	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49612657~49615716:-
THCA	cis	rs4380275	0.965	rs4315562	ENSG00000272342.1	RP13-539J13.1	8.37	6.45e-16	2.87e-13	0.43	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:739588~740164:-
THCA	cis	rs4927850	1	rs7627706	ENSG00000226155.1	AC124944.3	-8.37	6.46e-16	2.87e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196026482	chr3:195912049~195913986:+
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000226155.1	AC124944.3	-8.37	6.46e-16	2.87e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196026530	chr3:195912049~195913986:+
THCA	cis	rs4927850	1	rs7627868	ENSG00000226155.1	AC124944.3	-8.37	6.46e-16	2.87e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196026602	chr3:195912049~195913986:+
THCA	cis	rs1707322	0.656	rs9429172	ENSG00000234329.1	RP11-767N6.2	-8.37	6.47e-16	2.88e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45651039~45651826:-
THCA	cis	rs42490	0.664	rs39515	ENSG00000251136.7	RP11-37B2.1	-8.37	6.5e-16	2.89e-13	-0.31	-0.36	Leprosy;	chr8:89816761	chr8:89609409~89757727:-
THCA	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-8.37	6.5e-16	2.89e-13	-0.48	-0.36	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
THCA	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-8.37	6.5e-16	2.89e-13	-0.48	-0.36	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
THCA	cis	rs10740039	0.732	rs10159808	ENSG00000254271.1	RP11-131N11.4	8.37	6.51e-16	2.89e-13	0.46	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602432	chr10:60734342~60741828:+
THCA	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-8.37	6.51e-16	2.9e-13	-0.39	-0.36	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-8.37	6.51e-16	2.9e-13	-0.39	-0.36	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-8.37	6.51e-16	2.9e-13	-0.39	-0.36	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
THCA	cis	rs61041384	0.661	rs4474478	ENSG00000256092.2	RP13-942N8.1	-8.37	6.54e-16	2.9e-13	-0.55	-0.36	Schizophrenia;	chr12:123249821	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs4759411	ENSG00000256092.2	RP13-942N8.1	-8.37	6.54e-16	2.9e-13	-0.55	-0.36	Schizophrenia;	chr12:123256296	chr12:123363868~123366113:+
THCA	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	8.37	6.55e-16	2.91e-13	0.4	0.36	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	8.37	6.55e-16	2.91e-13	0.4	0.36	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
THCA	cis	rs7247513	0.78	rs4804725	ENSG00000230310.1	CTD-2192J16.11	-8.37	6.57e-16	2.92e-13	-0.44	-0.36	Bipolar disorder;	chr19:12612331	chr19:12552597~12553644:+
THCA	cis	rs8114671	0.562	rs6087653	ENSG00000269202.1	RP4-614O4.12	-8.37	6.58e-16	2.92e-13	-0.3	-0.36	Height;	chr20:34934251	chr20:35201747~35203288:-
THCA	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-8.37	6.59e-16	2.93e-13	-0.48	-0.36	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
THCA	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-8.37	6.6e-16	2.93e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
THCA	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-8.37	6.6e-16	2.93e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
THCA	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-8.37	6.6e-16	2.93e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
THCA	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-8.37	6.6e-16	2.93e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
THCA	cis	rs7727544	0.606	rs11950562	ENSG00000237714.1	P4HA2-AS1	8.37	6.6e-16	2.93e-13	0.47	0.36	Blood metabolite levels;	chr5:132316836	chr5:132184876~132192808:+
THCA	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	8.37	6.61e-16	2.93e-13	0.45	0.36	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
THCA	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-8.37	6.61e-16	2.94e-13	-0.44	-0.36	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
THCA	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-8.37	6.62e-16	2.94e-13	-0.43	-0.36	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
THCA	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-8.37	6.62e-16	2.94e-13	-0.37	-0.36	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
THCA	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-8.37	6.62e-16	2.94e-13	-0.76	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
THCA	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-8.37	6.63e-16	2.94e-13	-0.29	-0.36	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
THCA	cis	rs7665090	1	rs909349	ENSG00000246560.2	RP11-10L12.4	-8.37	6.63e-16	2.95e-13	-0.43	-0.36	Primary biliary cholangitis;	chr4:102635159	chr4:102828055~102844075:+
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000224205.1	AP000351.4	8.37	6.66e-16	2.96e-13	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23987320~23991421:-
THCA	cis	rs42490	0.638	rs40637	ENSG00000251136.7	RP11-37B2.1	-8.37	6.67e-16	2.96e-13	-0.31	-0.36	Leprosy;	chr8:89811082	chr8:89609409~89757727:-
THCA	cis	rs8114671	0.528	rs6119542	ENSG00000269202.1	RP4-614O4.12	-8.37	6.68e-16	2.97e-13	-0.3	-0.36	Height;	chr20:34896742	chr20:35201747~35203288:-
THCA	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	8.37	6.69e-16	2.97e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
THCA	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-8.37	6.7e-16	2.97e-13	-0.45	-0.36	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
THCA	cis	rs8114671	0.562	rs6087642	ENSG00000269202.1	RP4-614O4.12	-8.37	6.71e-16	2.98e-13	-0.3	-0.36	Height;	chr20:34880503	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6088636	ENSG00000269202.1	RP4-614O4.12	-8.37	6.71e-16	2.98e-13	-0.3	-0.36	Height;	chr20:34881943	chr20:35201747~35203288:-
THCA	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
THCA	cis	rs8114671	0.967	rs6058202	ENSG00000269202.1	RP4-614O4.12	-8.37	6.73e-16	2.99e-13	-0.3	-0.36	Height;	chr20:35190180	chr20:35201747~35203288:-
THCA	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	8.37	6.73e-16	2.99e-13	0.63	0.36	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
THCA	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	8.37	6.75e-16	3e-13	0.44	0.36	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
THCA	cis	rs10740039	0.81	rs1006956	ENSG00000254271.1	RP11-131N11.4	-8.37	6.76e-16	3e-13	-0.46	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60608218	chr10:60734342~60741828:+
THCA	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-8.37	6.76e-16	3e-13	-0.5	-0.36	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
THCA	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	8.37	6.77e-16	3e-13	0.42	0.36	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
THCA	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-8.37	6.77e-16	3e-13	-0.42	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
THCA	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	8.37	6.77e-16	3.01e-13	0.4	0.36	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	8.37	6.77e-16	3.01e-13	0.4	0.36	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
THCA	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	8.37	6.78e-16	3.01e-13	0.45	0.36	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
THCA	cis	rs9309473	0.687	rs11126399	ENSG00000163016.8	ALMS1P	8.37	6.8e-16	3.02e-13	0.49	0.36	Metabolite levels;	chr2:73386213	chr2:73644919~73685576:+
THCA	cis	rs7576126	1	rs7576126	ENSG00000237979.1	AC007389.1	-8.37	6.81e-16	3.02e-13	-0.4	-0.36	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65500993~65502138:-
THCA	cis	rs17772222	0.682	rs2401751	ENSG00000258789.1	RP11-507K2.3	8.37	6.81e-16	3.02e-13	0.35	0.36	Coronary artery calcification;	chr14:88480278	chr14:88551597~88552493:+
THCA	cis	rs1707322	0.686	rs1541131	ENSG00000234329.1	RP11-767N6.2	-8.37	6.82e-16	3.03e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45651039~45651826:-
THCA	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-8.37	6.84e-16	3.03e-13	-0.37	-0.36	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
THCA	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-8.37	6.84e-16	3.03e-13	-0.56	-0.36	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
THCA	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-8.37	6.84e-16	3.03e-13	-0.56	-0.36	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
THCA	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-8.37	6.84e-16	3.03e-13	-0.56	-0.36	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
THCA	cis	rs9918079	1	rs9918079	ENSG00000273133.1	RP11-799M12.2	8.37	6.85e-16	3.04e-13	0.56	0.36	Obesity-related traits;	chr4:15543787	chr4:15563698~15564253:-
THCA	cis	rs7727544	0.582	rs6896703	ENSG00000237714.1	P4HA2-AS1	-8.37	6.86e-16	3.04e-13	-0.46	-0.36	Blood metabolite levels;	chr5:132185602	chr5:132184876~132192808:+
THCA	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	8.37	6.9e-16	3.06e-13	0.4	0.36	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-8.37	6.9e-16	3.06e-13	-0.26	-0.36	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
THCA	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-8.36	6.9e-16	3.06e-13	-0.35	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
THCA	cis	rs922182	0.556	rs12443020	ENSG00000275785.1	RP11-111E14.2	8.36	6.9e-16	3.06e-13	0.43	0.36	Blood protein levels;	chr15:63923624	chr15:63890030~63890317:+
THCA	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	8.36	6.92e-16	3.07e-13	0.44	0.36	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
THCA	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	8.36	6.95e-16	3.08e-13	0.4	0.36	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
THCA	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
THCA	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	8.36	6.96e-16	3.08e-13	0.24	0.36	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
THCA	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	8.36	6.96e-16	3.09e-13	0.45	0.36	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	8.36	6.96e-16	3.09e-13	0.45	0.36	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
THCA	cis	rs16846053	0.515	rs6750756	ENSG00000227403.1	AC009299.3	-8.36	6.99e-16	3.1e-13	-0.57	-0.36	Blood osmolality (transformed sodium);	chr2:161659798	chr2:161244739~161249050:+
THCA	cis	rs1850744	0.702	rs10939428	ENSG00000250942.1	ENPP7P11	8.36	7.02e-16	3.11e-13	0.49	0.36	Economic and political preferences;	chr4:9628417	chr4:9677308~9677934:+
THCA	cis	rs4713118	0.629	rs203887	ENSG00000280107.1	AL022393.9	-8.36	7.02e-16	3.11e-13	-0.45	-0.36	Parkinson's disease;	chr6:28053491	chr6:28170845~28172521:+
THCA	cis	rs1707322	1	rs1707303	ENSG00000234329.1	RP11-767N6.2	-8.36	7.02e-16	3.11e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45338590~45341990:-
THCA	cis	rs737008	0.96	rs34764020	ENSG00000262703.1	RP11-485G7.6	-8.36	7.11e-16	3.15e-13	-0.41	-0.36	Obesity-related traits;	chr16:11284502	chr16:11348143~11349321:-
THCA	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-8.36	7.17e-16	3.17e-13	-0.31	-0.36	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
THCA	cis	rs11096990	0.634	rs60016848	ENSG00000249685.1	RP11-360F5.3	-8.36	7.22e-16	3.2e-13	-0.43	-0.36	Cognitive function;	chr4:39281436	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.577	rs6830736	ENSG00000249685.1	RP11-360F5.3	-8.36	7.22e-16	3.2e-13	-0.43	-0.36	Cognitive function;	chr4:39281467	chr4:39133913~39135608:+
THCA	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-8.36	7.22e-16	3.2e-13	-0.58	-0.36	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	8.36	7.23e-16	3.2e-13	0.26	0.36	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
THCA	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	8.36	7.23e-16	3.2e-13	0.31	0.36	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
THCA	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-8.36	7.23e-16	3.2e-13	-0.46	-0.36	Gout;	chr7:66671562	chr7:66902857~66906297:+
THCA	cis	rs270601	0.77	rs10463891	ENSG00000233006.5	AC034220.3	-8.36	7.25e-16	3.21e-13	-0.28	-0.36	Acylcarnitine levels;	chr5:132261699	chr5:132311285~132369916:-
THCA	cis	rs600231	0.706	rs10896016	ENSG00000245532.5	NEAT1	-8.36	7.26e-16	3.21e-13	-0.26	-0.36	Bone mineral density;	chr11:65568234	chr11:65422774~65445540:+
THCA	cis	rs516805	0.961	rs544099	ENSG00000279453.1	RP3-425C14.4	8.36	7.28e-16	3.22e-13	0.32	0.36	Lymphocyte counts;	chr6:122479837	chr6:122436789~122439223:-
THCA	cis	rs8114671	0.933	rs6087683	ENSG00000269202.1	RP4-614O4.12	-8.36	7.28e-16	3.22e-13	-0.3	-0.36	Height;	chr20:35186641	chr20:35201747~35203288:-
THCA	cis	rs934734	0.532	rs13383320	ENSG00000237979.1	AC007389.1	-8.36	7.3e-16	3.23e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65418003	chr2:65500993~65502138:-
THCA	cis	rs853679	0.882	rs9468300	ENSG00000280107.1	AL022393.9	-8.36	7.31e-16	3.24e-13	-0.55	-0.36	Depression;	chr6:28159062	chr6:28170845~28172521:+
THCA	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	8.36	7.31e-16	3.24e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
THCA	cis	rs7646881	1	rs61558956	ENSG00000240207.5	RP11-379F4.4	-8.36	7.31e-16	3.24e-13	-0.48	-0.36	Tetralogy of Fallot;	chr3:158734866	chr3:158732263~158784070:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	8.36	7.32e-16	3.24e-13	0.26	0.36	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	8.36	7.32e-16	3.24e-13	0.26	0.36	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
THCA	cis	rs910316	1	rs10136948	ENSG00000279594.1	RP11-950C14.10	8.36	7.32e-16	3.24e-13	0.33	0.36	Height;	chr14:75044372	chr14:75011269~75012851:-
THCA	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	8.36	7.33e-16	3.25e-13	0.31	0.36	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	8.36	7.33e-16	3.25e-13	0.31	0.36	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
THCA	cis	rs2562456	0.876	rs11085468	ENSG00000268555.1	RP11-678G14.3	8.36	7.35e-16	3.25e-13	0.5	0.36	Pain;	chr19:21569087	chr19:21570822~21587322:-
THCA	cis	rs516805	0.781	rs560717	ENSG00000279453.1	RP3-425C14.4	-8.36	7.36e-16	3.26e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122482909	chr6:122436789~122439223:-
THCA	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	8.36	7.36e-16	3.26e-13	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
THCA	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	8.36	7.38e-16	3.27e-13	0.41	0.36	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
THCA	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-8.36	7.4e-16	3.27e-13	-0.37	-0.36	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
THCA	cis	rs947583	1	rs6570043	ENSG00000231028.7	LINC00271	-8.36	7.4e-16	3.27e-13	-0.29	-0.36	Phosphorus levels;	chr6:135812960	chr6:135497801~135716055:+
THCA	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-8.36	7.4e-16	3.28e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
THCA	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	8.35	7.46e-16	3.3e-13	0.48	0.36	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	8.35	7.46e-16	3.3e-13	0.48	0.36	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
THCA	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	8.35	7.47e-16	3.3e-13	0.44	0.36	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
THCA	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	8.35	7.49e-16	3.31e-13	0.48	0.36	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	8.35	7.52e-16	3.32e-13	0.48	0.36	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
THCA	cis	rs17772222	0.682	rs28711639	ENSG00000258789.1	RP11-507K2.3	-8.35	7.53e-16	3.33e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88482277	chr14:88551597~88552493:+
THCA	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-8.35	7.56e-16	3.34e-13	-0.48	-0.36	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
THCA	cis	rs13129231	0.806	rs17676882	ENSG00000206820.1	RNU1-138P	-8.35	7.58e-16	3.35e-13	-0.44	-0.36	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113451912	chr4:113420323~113420486:+
THCA	cis	rs7221109	1	rs7221109	ENSG00000278834.1	RP11-458J1.1	8.35	7.62e-16	3.37e-13	0.37	0.36	Type 1 diabetes;	chr17:40614034	chr17:40648300~40649718:+
THCA	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	8.35	7.67e-16	3.39e-13	0.43	0.36	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000235689.1	AP000351.13	8.35	7.69e-16	3.4e-13	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:24006305~24008258:-
THCA	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	8.35	7.73e-16	3.41e-13	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
THCA	cis	rs42490	0.664	rs376110	ENSG00000251136.7	RP11-37B2.1	-8.35	7.77e-16	3.43e-13	-0.31	-0.36	Leprosy;	chr8:89819362	chr8:89609409~89757727:-
THCA	cis	rs9813712	0.526	rs13065659	ENSG00000228252.7	COL6A4P2	-8.35	7.79e-16	3.44e-13	-0.37	-0.36	Response to amphetamines;	chr3:130231945	chr3:130212823~130273806:+
THCA	cis	rs42490	0.57	rs454561	ENSG00000251136.7	RP11-37B2.1	-8.35	7.79e-16	3.44e-13	-0.31	-0.36	Leprosy;	chr8:89824387	chr8:89609409~89757727:-
THCA	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	8.35	7.8e-16	3.44e-13	0.24	0.36	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
THCA	cis	rs42490	0.635	rs42186	ENSG00000251136.7	RP11-37B2.1	-8.35	7.81e-16	3.45e-13	-0.31	-0.36	Leprosy;	chr8:89827257	chr8:89609409~89757727:-
THCA	cis	rs42490	0.7	rs40250	ENSG00000251136.7	RP11-37B2.1	-8.35	7.81e-16	3.45e-13	-0.31	-0.36	Leprosy;	chr8:89828779	chr8:89609409~89757727:-
THCA	cis	rs42490	0.7	rs419890	ENSG00000251136.7	RP11-37B2.1	-8.35	7.81e-16	3.45e-13	-0.31	-0.36	Leprosy;	chr8:89829012	chr8:89609409~89757727:-
THCA	cis	rs11051970	0.918	rs11051969	ENSG00000274964.1	RP11-817I4.1	-8.35	7.81e-16	3.45e-13	-0.41	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32384189	chr12:32339368~32340724:+
THCA	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	8.35	7.82e-16	3.46e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	8.35	7.82e-16	3.46e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	8.35	7.82e-16	3.46e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
THCA	cis	rs7569084	0.687	rs35839762	ENSG00000234255.7	AC012370.3	8.35	7.83e-16	3.46e-13	0.41	0.36	Sum eosinophil basophil counts;	chr2:65441318	chr2:65439888~65456571:-
THCA	cis	rs1707322	1	rs2458400	ENSG00000234329.1	RP11-767N6.2	-8.35	7.85e-16	3.47e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45651039~45651826:-
THCA	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-8.35	7.85e-16	3.47e-13	-0.42	-0.36	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
THCA	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-8.35	7.85e-16	3.47e-13	-0.4	-0.36	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
THCA	cis	rs6504108	0.624	rs1860863	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48127316	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs1860862	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48127474	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.602	rs3944039	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48127708	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs2041572	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48127911	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs758999	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48128653	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7225865	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48132602	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs34949267	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48134690	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs12941830	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48141769	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7220768	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48147467	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7220922	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48147546	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7225550	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48147881	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7223867	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48152794	chr17:48066704~48067293:-
THCA	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	8.35	7.91e-16	3.49e-13	0.55	0.36	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	8.35	7.91e-16	3.49e-13	0.55	0.36	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	8.35	7.91e-16	3.49e-13	0.55	0.36	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	8.35	7.91e-16	3.49e-13	0.55	0.36	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000230295.1	RP11-458F8.2	-8.35	7.92e-16	3.5e-13	-0.32	-0.36	Corneal structure;	chr7:66894282	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000230295.1	RP11-458F8.2	-8.35	7.92e-16	3.5e-13	-0.32	-0.36	Corneal structure;	chr7:66896631	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-8.35	7.96e-16	3.51e-13	-0.32	-0.36	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
THCA	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-8.35	7.99e-16	3.53e-13	-0.41	-0.36	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
THCA	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-8.35	7.99e-16	3.53e-13	-0.32	-0.36	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
THCA	cis	rs8114671	0.935	rs633198	ENSG00000269202.1	RP4-614O4.12	8.34	8.01e-16	3.54e-13	0.3	0.36	Height;	chr20:35190631	chr20:35201747~35203288:-
THCA	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	8.34	8.01e-16	3.54e-13	0.34	0.36	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
THCA	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	8.34	8.02e-16	3.54e-13	0.44	0.36	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
THCA	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	8.34	8.03e-16	3.54e-13	0.34	0.36	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
THCA	cis	rs2712184	0.875	rs2541381	ENSG00000229352.1	AC007563.3	-8.34	8.03e-16	3.54e-13	-0.45	-0.36	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216819113	chr2:216799608~216805335:+
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000226155.1	AC124944.3	-8.34	8.04e-16	3.55e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196024568	chr3:195912049~195913986:+
THCA	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	8.34	8.05e-16	3.55e-13	0.38	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
THCA	cis	rs7727544	0.716	rs7701414	ENSG00000224431.1	AC063976.7	8.34	8.06e-16	3.56e-13	0.31	0.36	Blood metabolite levels;	chr5:132250265	chr5:132199456~132203487:+
THCA	cis	rs9928842	0.765	rs6564221	ENSG00000280152.1	RP11-331F4.5	8.34	8.06e-16	3.56e-13	0.51	0.36	Alcoholic chronic pancreatitis;	chr16:75191073	chr16:75245994~75250077:-
THCA	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	8.34	8.09e-16	3.57e-13	0.45	0.36	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
THCA	cis	rs7208859	0.673	rs9915139	ENSG00000266490.1	CTD-2349P21.9	8.34	8.09e-16	3.57e-13	0.5	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30792372~30792833:+
THCA	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	8.34	8.11e-16	3.58e-13	0.63	0.36	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
THCA	cis	rs1707322	0.896	rs809774	ENSG00000234329.1	RP11-767N6.2	-8.34	8.12e-16	3.58e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45651039~45651826:-
THCA	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-8.34	8.13e-16	3.59e-13	-0.32	-0.36	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
THCA	cis	rs2929278	0.589	rs7174732	ENSG00000166763.7	STRCP1	-8.34	8.14e-16	3.59e-13	-0.39	-0.36	Schizophrenia;	chr15:43746265	chr15:43699488~43718184:-
THCA	cis	rs2929278	0.617	rs11070410	ENSG00000166763.7	STRCP1	-8.34	8.15e-16	3.59e-13	-0.39	-0.36	Schizophrenia;	chr15:43764847	chr15:43699488~43718184:-
THCA	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	8.34	8.15e-16	3.59e-13	0.45	0.36	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
THCA	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-8.34	8.15e-16	3.59e-13	-0.71	-0.36	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
THCA	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-8.34	8.18e-16	3.61e-13	-0.52	-0.36	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-8.34	8.18e-16	3.61e-13	-0.52	-0.36	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
THCA	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-8.34	8.18e-16	3.61e-13	-0.48	-0.36	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
THCA	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	8.34	8.18e-16	3.61e-13	0.43	0.36	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
THCA	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	8.34	8.18e-16	3.61e-13	0.39	0.36	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
THCA	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	8.34	8.19e-16	3.61e-13	0.23	0.36	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000215447.6	BX322557.10	-8.34	8.19e-16	3.61e-13	-0.29	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45288052~45291738:+
THCA	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	8.34	8.2e-16	3.61e-13	0.23	0.36	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
THCA	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-8.34	8.2e-16	3.62e-13	-0.29	-0.36	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
THCA	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	8.34	8.2e-16	3.62e-13	0.45	0.36	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
THCA	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-8.34	8.21e-16	3.62e-13	-0.37	-0.36	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
THCA	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-8.34	8.22e-16	3.62e-13	-0.45	-0.36	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
THCA	cis	rs1859596	0.646	rs6964644	ENSG00000234456.6	MAGI2-AS3	8.34	8.25e-16	3.64e-13	0.34	0.36	Reading or mathematical ability;	chr7:79463506	chr7:79452877~79471208:+
THCA	cis	rs11696845	1	rs6073534	ENSG00000276223.1	RP4-781B1.5	-8.34	8.28e-16	3.65e-13	-0.44	-0.36	Obesity-related traits;	chr20:44736863	chr20:44746642~44747201:+
THCA	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	8.34	8.3e-16	3.66e-13	0.4	0.36	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
THCA	cis	rs8114671	0.562	rs6087641	ENSG00000269202.1	RP4-614O4.12	-8.34	8.33e-16	3.67e-13	-0.3	-0.36	Height;	chr20:34879914	chr20:35201747~35203288:-
THCA	cis	rs6601450	0.519	rs34906836	ENSG00000261451.1	RP11-981G7.1	8.34	8.33e-16	3.67e-13	0.43	0.36	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10431482	chr8:10433672~10438312:+
THCA	cis	rs9532669	0.89	rs2149570	ENSG00000176268.5	CYCSP34	8.34	8.34e-16	3.67e-13	0.42	0.36	Cervical cancer;	chr13:40858533	chr13:40863599~40863902:-
THCA	cis	rs507080	0.733	rs497678	ENSG00000278376.1	RP11-158I9.8	-8.34	8.34e-16	3.67e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118697172	chr11:118791254~118793137:+
THCA	cis	rs8114671	0.804	rs6088666	ENSG00000269202.1	RP4-614O4.12	-8.34	8.35e-16	3.68e-13	-0.31	-0.36	Height;	chr20:34976767	chr20:35201747~35203288:-
THCA	cis	rs8027521	0.56	rs1961236	ENSG00000280362.1	RP11-643A5.3	8.34	8.39e-16	3.7e-13	0.47	0.36	Circulating chemerin levels;	chr15:53934476	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.56	rs1961237	ENSG00000280362.1	RP11-643A5.3	8.34	8.39e-16	3.7e-13	0.47	0.36	Circulating chemerin levels;	chr15:53934488	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.56	rs1351095	ENSG00000280362.1	RP11-643A5.3	8.34	8.39e-16	3.7e-13	0.47	0.36	Circulating chemerin levels;	chr15:53934855	chr15:53910769~53914712:+
THCA	cis	rs12931792	0.682	rs12373113	ENSG00000183604.13	SMG1P5	8.34	8.39e-16	3.7e-13	0.36	0.36	Tonsillectomy;	chr16:30176192	chr16:30267553~30335374:-
THCA	cis	rs12931792	0.682	rs12373078	ENSG00000183604.13	SMG1P5	8.34	8.39e-16	3.7e-13	0.36	0.36	Tonsillectomy;	chr16:30176355	chr16:30267553~30335374:-
THCA	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-8.34	8.39e-16	3.7e-13	-0.37	-0.36	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
THCA	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-8.34	8.39e-16	3.7e-13	-0.37	-0.36	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
THCA	cis	rs73607972	0.518	rs8060020	ENSG00000275191.1	RP11-36I17.2	-8.34	8.4e-16	3.7e-13	-0.48	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554152	chr16:53628256~53628816:-
THCA	cis	rs507080	1	rs507080	ENSG00000278376.1	RP11-158I9.8	-8.34	8.4e-16	3.7e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118678873	chr11:118791254~118793137:+
THCA	cis	rs1707322	0.963	rs1768815	ENSG00000234329.1	RP11-767N6.2	-8.34	8.42e-16	3.71e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45651039~45651826:-
THCA	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	8.34	8.46e-16	3.72e-13	0.28	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
THCA	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	8.34	8.47e-16	3.73e-13	0.26	0.36	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
THCA	cis	rs7191700	0.511	rs8058983	ENSG00000262636.1	CTD-3088G3.4	-8.34	8.51e-16	3.75e-13	-0.44	-0.36	Multiple sclerosis;	chr16:11266992	chr16:11380859~11381118:-
THCA	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-8.34	8.55e-16	3.76e-13	-0.43	-0.36	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-8.34	8.55e-16	3.76e-13	-0.43	-0.36	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
THCA	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-8.34	8.56e-16	3.77e-13	-0.43	-0.36	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
THCA	cis	rs516805	0.748	rs72962455	ENSG00000279453.1	RP3-425C14.4	8.34	8.56e-16	3.77e-13	0.37	0.36	Lymphocyte counts;	chr6:122563378	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197685	ENSG00000279453.1	RP3-425C14.4	-8.34	8.56e-16	3.77e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122554622	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs1989254	ENSG00000279453.1	RP3-425C14.4	-8.34	8.56e-16	3.77e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122556317	chr6:122436789~122439223:-
THCA	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-8.34	8.58e-16	3.77e-13	-0.26	-0.36	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
THCA	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-8.34	8.6e-16	3.78e-13	-0.39	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
THCA	cis	rs4713118	0.629	rs203890	ENSG00000226314.6	ZNF192P1	-8.33	8.61e-16	3.79e-13	-0.46	-0.36	Parkinson's disease;	chr6:28054470	chr6:28161781~28169594:+
THCA	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	8.33	8.63e-16	3.8e-13	0.59	0.36	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
THCA	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-8.33	8.64e-16	3.8e-13	-0.28	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
THCA	cis	rs11603691	1	rs7129491	ENSG00000254662.1	RP11-872D17.4	-8.33	8.64e-16	3.8e-13	-0.67	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57327608	chr11:57325603~57327958:+
THCA	cis	rs516805	0.748	rs197693	ENSG00000279453.1	RP3-425C14.4	-8.33	8.64e-16	3.8e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122521294	chr6:122436789~122439223:-
THCA	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
THCA	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	8.33	8.65e-16	3.81e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
THCA	cis	rs516805	0.667	rs197676	ENSG00000279453.1	RP3-425C14.4	-8.33	8.66e-16	3.81e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122532410	chr6:122436789~122439223:-
THCA	cis	rs7191700	0.578	rs243324	ENSG00000262703.1	RP11-485G7.6	8.33	8.66e-16	3.81e-13	0.4	0.36	Multiple sclerosis;	chr16:11261113	chr16:11348143~11349321:-
THCA	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	8.33	8.69e-16	3.82e-13	0.36	0.36	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
THCA	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-8.33	8.7e-16	3.83e-13	-0.47	-0.36	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
THCA	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-8.33	8.7e-16	3.83e-13	-0.26	-0.36	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-8.33	8.7e-16	3.83e-13	-0.26	-0.36	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-8.33	8.73e-16	3.84e-13	-0.52	-0.36	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
THCA	cis	rs4819052	1	rs2297284	ENSG00000237664.1	LINC00316	-8.33	8.75e-16	3.85e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45338590~45341990:-
THCA	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	8.33	8.76e-16	3.85e-13	0.24	0.36	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
THCA	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	8.33	8.77e-16	3.86e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
THCA	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	8.33	8.79e-16	3.86e-13	0.41	0.36	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
THCA	cis	rs9649213	0.502	rs6465680	ENSG00000272950.1	RP11-307C18.1	8.33	8.8e-16	3.87e-13	0.44	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr7:98322853~98323430:+
THCA	cis	rs910316	1	rs7142235	ENSG00000279594.1	RP11-950C14.10	8.33	8.81e-16	3.87e-13	0.33	0.36	Height;	chr14:75093260	chr14:75011269~75012851:-
THCA	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	8.33	8.82e-16	3.88e-13	0.55	0.36	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
THCA	cis	rs11696845	0.966	rs6073535	ENSG00000276223.1	RP4-781B1.5	-8.33	8.87e-16	3.9e-13	-0.44	-0.36	Obesity-related traits;	chr20:44745218	chr20:44746642~44747201:+
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	8.33	9.02e-16	3.96e-13	0.26	0.36	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
THCA	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	8.33	9.06e-16	3.98e-13	0.35	0.36	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	8.33	9.06e-16	3.98e-13	0.35	0.36	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
THCA	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	8.33	9.06e-16	3.98e-13	0.35	0.36	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
THCA	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-8.33	9.07e-16	3.98e-13	-0.49	-0.36	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.507	rs223317	ENSG00000251288.2	RP11-10L12.2	-8.33	9.09e-16	3.99e-13	-0.48	-0.36	Type 2 diabetes;	chr4:102881667	chr4:102751401~102752641:+
THCA	cis	rs1850744	0.702	rs2077679	ENSG00000250942.1	ENPP7P11	-8.33	9.09e-16	3.99e-13	-0.52	-0.36	Economic and political preferences;	chr4:9606465	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs1961552	ENSG00000250942.1	ENPP7P11	-8.33	9.09e-16	3.99e-13	-0.52	-0.36	Economic and political preferences;	chr4:9606682	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs4974816	ENSG00000250942.1	ENPP7P11	-8.33	9.09e-16	3.99e-13	-0.52	-0.36	Economic and political preferences;	chr4:9611443	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs4974812	ENSG00000250942.1	ENPP7P11	-8.33	9.09e-16	3.99e-13	-0.52	-0.36	Economic and political preferences;	chr4:9612974	chr4:9677308~9677934:+
THCA	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-8.33	9.09e-16	3.99e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
THCA	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-8.33	9.12e-16	4e-13	-0.32	-0.36	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
THCA	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	8.33	9.13e-16	4.01e-13	0.42	0.36	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
THCA	cis	rs11148252	0.774	rs7334583	ENSG00000235660.1	LINC00345	8.33	9.18e-16	4.03e-13	0.44	0.36	Lewy body disease;	chr13:52356217	chr13:52484161~52484680:-
THCA	cis	rs2929278	0.546	rs686666	ENSG00000166763.7	STRCP1	8.33	9.18e-16	4.03e-13	0.39	0.36	Schizophrenia;	chr15:43869352	chr15:43699488~43718184:-
THCA	cis	rs947583	0.866	rs7759326	ENSG00000231028.7	LINC00271	-8.33	9.19e-16	4.03e-13	-0.29	-0.36	Phosphorus levels;	chr6:135816421	chr6:135497801~135716055:+
THCA	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-8.33	9.22e-16	4.04e-13	-0.43	-0.36	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
THCA	cis	rs1707322	0.682	rs12037459	ENSG00000234329.1	RP11-767N6.2	8.33	9.23e-16	4.05e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45651039~45651826:-
THCA	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	8.33	9.25e-16	4.06e-13	0.39	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-8.32	9.27e-16	4.07e-13	-0.71	-0.36	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
THCA	cis	rs922182	0.557	rs730589	ENSG00000275785.1	RP11-111E14.2	8.32	9.28e-16	4.07e-13	0.44	0.36	Blood protein levels;	chr15:63901974	chr15:63890030~63890317:+
THCA	cis	rs10208649	0.572	rs7585466	ENSG00000272156.1	RP11-477N3.1	8.32	9.28e-16	4.07e-13	0.49	0.36	Body mass index;	chr2:54098988	chr2:54082554~54085066:+
THCA	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	8.32	9.28e-16	4.07e-13	0.42	0.36	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
THCA	cis	rs8114671	0.901	rs6119581	ENSG00000269202.1	RP4-614O4.12	-8.32	9.3e-16	4.08e-13	-0.3	-0.36	Height;	chr20:35185886	chr20:35201747~35203288:-
THCA	cis	rs10740039	0.81	rs7098097	ENSG00000254271.1	RP11-131N11.4	8.32	9.3e-16	4.08e-13	0.45	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60605233	chr10:60734342~60741828:+
THCA	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-8.32	9.3e-16	4.08e-13	-0.37	-0.36	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
THCA	cis	rs1850744	0.702	rs4974858	ENSG00000250942.1	ENPP7P11	-8.32	9.32e-16	4.09e-13	-0.52	-0.36	Economic and political preferences;	chr4:9605498	chr4:9677308~9677934:+
THCA	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	8.32	9.36e-16	4.1e-13	0.31	0.36	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
THCA	cis	rs910316	0.726	rs175040	ENSG00000279594.1	RP11-950C14.10	-8.32	9.38e-16	4.11e-13	-0.33	-0.36	Height;	chr14:75002852	chr14:75011269~75012851:-
THCA	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	8.32	9.4e-16	4.12e-13	0.46	0.36	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
THCA	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-8.32	9.4e-16	4.12e-13	-0.48	-0.36	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
THCA	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	8.32	9.41e-16	4.13e-13	0.36	0.36	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
THCA	cis	rs516805	0.563	rs571706	ENSG00000279453.1	RP3-425C14.4	-8.32	9.42e-16	4.13e-13	-0.36	-0.36	Lymphocyte counts;	chr6:122393787	chr6:122436789~122439223:-
THCA	cis	rs1799949	0.602	rs8176257	ENSG00000267681.1	CTD-3199J23.6	-8.32	9.42e-16	4.13e-13	-0.44	-0.36	Menopause (age at onset);	chr17:43064188	chr17:43144956~43145255:+
THCA	cis	rs1426063	0.8	rs28861517	ENSG00000260265.1	RP11-44F21.5	8.32	9.43e-16	4.13e-13	0.58	0.36	QT interval;	chr4:75092995	chr4:75081702~75084717:-
THCA	cis	rs17772222	0.582	rs11625009	ENSG00000258789.1	RP11-507K2.3	8.32	9.43e-16	4.13e-13	0.35	0.36	Coronary artery calcification;	chr14:88521018	chr14:88551597~88552493:+
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000266490.1	CTD-2349P21.9	8.32	9.44e-16	4.14e-13	0.46	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000266490.1	CTD-2349P21.9	8.32	9.44e-16	4.14e-13	0.46	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30792372~30792833:+
THCA	cis	rs8114671	0.562	rs4911163	ENSG00000269202.1	RP4-614O4.12	-8.32	9.45e-16	4.14e-13	-0.3	-0.36	Height;	chr20:34882891	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6088640	ENSG00000269202.1	RP4-614O4.12	-8.32	9.45e-16	4.14e-13	-0.3	-0.36	Height;	chr20:34884706	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6087643	ENSG00000269202.1	RP4-614O4.12	-8.32	9.45e-16	4.14e-13	-0.3	-0.36	Height;	chr20:34886659	chr20:35201747~35203288:-
THCA	cis	rs516805	0.923	rs538457	ENSG00000279453.1	RP3-425C14.4	-8.32	9.47e-16	4.15e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122485610	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs9385248	ENSG00000279453.1	RP3-425C14.4	-8.32	9.47e-16	4.15e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122490982	chr6:122436789~122439223:-
THCA	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-8.32	9.48e-16	4.16e-13	-0.36	-0.36	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-8.32	9.48e-16	4.16e-13	-0.36	-0.36	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
THCA	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	8.32	9.48e-16	4.16e-13	0.44	0.36	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
THCA	cis	rs853679	0.527	rs9461443	ENSG00000280107.1	AL022393.9	-8.32	9.49e-16	4.16e-13	-0.43	-0.36	Depression;	chr6:28226851	chr6:28170845~28172521:+
THCA	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	8.32	9.51e-16	4.16e-13	0.56	0.36	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
THCA	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-8.32	9.53e-16	4.17e-13	-0.39	-0.36	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
THCA	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-8.32	9.53e-16	4.17e-13	-0.42	-0.36	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
THCA	cis	rs8027521	0.56	rs2019408	ENSG00000280362.1	RP11-643A5.3	8.32	9.54e-16	4.18e-13	0.47	0.36	Circulating chemerin levels;	chr15:53934014	chr15:53910769~53914712:+
THCA	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-8.32	9.56e-16	4.19e-13	-0.45	-0.36	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
THCA	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-8.32	9.56e-16	4.19e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
THCA	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	8.32	9.57e-16	4.19e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
THCA	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	8.32	9.57e-16	4.19e-13	0.4	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
THCA	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	8.32	9.57e-16	4.19e-13	0.24	0.36	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
THCA	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	8.32	9.59e-16	4.2e-13	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
THCA	cis	rs8114671	0.967	rs3746427	ENSG00000269202.1	RP4-614O4.12	-8.32	9.59e-16	4.2e-13	-0.3	-0.36	Height;	chr20:35142661	chr20:35201747~35203288:-
THCA	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	8.32	9.59e-16	4.2e-13	0.38	0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
THCA	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-8.32	9.6e-16	4.2e-13	-0.43	-0.36	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
THCA	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	8.32	9.63e-16	4.22e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
THCA	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	8.32	9.64e-16	4.22e-13	0.41	0.36	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
THCA	cis	rs11603691	1	rs61888887	ENSG00000254662.1	RP11-872D17.4	-8.32	9.65e-16	4.23e-13	-0.67	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57331577	chr11:57325603~57327958:+
THCA	cis	rs910316	0.763	rs175036	ENSG00000279594.1	RP11-950C14.10	-8.32	9.67e-16	4.23e-13	-0.33	-0.36	Height;	chr14:74997592	chr14:75011269~75012851:-
THCA	cis	rs910316	0.712	rs175037	ENSG00000279594.1	RP11-950C14.10	-8.32	9.67e-16	4.23e-13	-0.33	-0.36	Height;	chr14:74998335	chr14:75011269~75012851:-
THCA	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	8.32	9.69e-16	4.24e-13	0.76	0.36	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
THCA	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	8.32	9.73e-16	4.26e-13	0.31	0.36	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	8.32	9.73e-16	4.26e-13	0.31	0.36	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
THCA	cis	rs7829975	0.653	rs13259070	ENSG00000253893.2	FAM85B	-8.32	9.75e-16	4.27e-13	-0.46	-0.36	Mood instability;	chr8:8833277	chr8:8167819~8226614:-
THCA	cis	rs11168351	0.864	rs12228750	ENSG00000258273.1	RP11-370I10.4	8.32	9.77e-16	4.27e-13	0.47	0.36	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48333755~48333901:-
THCA	cis	rs11168351	0.864	rs10875743	ENSG00000258273.1	RP11-370I10.4	8.32	9.77e-16	4.27e-13	0.47	0.36	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48333755~48333901:-
THCA	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	8.32	9.79e-16	4.28e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
THCA	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	8.32	9.8e-16	4.29e-13	0.47	0.36	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
THCA	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	8.32	9.8e-16	4.29e-13	0.55	0.36	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
THCA	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-8.32	9.85e-16	4.31e-13	-0.5	-0.36	Depression;	chr6:28231053	chr6:28115628~28116551:+
THCA	cis	rs4927850	1	rs7625570	ENSG00000226155.1	AC124944.3	-8.32	9.86e-16	4.31e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196020527	chr3:195912049~195913986:+
THCA	cis	rs17772222	0.682	rs10132554	ENSG00000258789.1	RP11-507K2.3	-8.32	9.86e-16	4.31e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88473090	chr14:88551597~88552493:+
THCA	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	8.32	9.87e-16	4.31e-13	0.4	0.36	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	8.32	9.87e-16	4.31e-13	0.4	0.36	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	8.32	9.87e-16	4.31e-13	0.4	0.36	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	8.32	9.87e-16	4.31e-13	0.4	0.36	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
THCA	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	8.32	9.88e-16	4.32e-13	0.34	0.36	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
THCA	cis	rs1707322	0.721	rs7520123	ENSG00000234329.1	RP11-767N6.2	8.32	9.89e-16	4.33e-13	0.33	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45651039~45651826:-
THCA	cis	rs180730	1	rs343198	ENSG00000251609.2	SETP12	-8.31	9.98e-16	4.36e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120877031	chr4:120895494~120897083:-
THCA	cis	rs11051970	0.918	rs6488050	ENSG00000274964.1	RP11-817I4.1	-8.31	9.98e-16	4.36e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32379565	chr12:32339368~32340724:+
THCA	cis	rs910316	1	rs175512	ENSG00000279594.1	RP11-950C14.10	-8.31	9.98e-16	4.37e-13	-0.33	-0.36	Height;	chr14:75056679	chr14:75011269~75012851:-
THCA	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	8.31	1e-15	4.38e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
THCA	cis	rs507080	0.922	rs533646	ENSG00000278376.1	RP11-158I9.8	-8.31	1e-15	4.39e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118696037	chr11:118791254~118793137:+
THCA	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-8.31	1e-15	4.39e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
THCA	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-8.31	1.01e-15	4.41e-13	-0.71	-0.36	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
THCA	cis	rs8114671	0.662	rs3761143	ENSG00000269202.1	RP4-614O4.12	-8.31	1.01e-15	4.42e-13	-0.31	-0.36	Height;	chr20:34957942	chr20:35201747~35203288:-
THCA	cis	rs910316	1	rs12590452	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75082053	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs1043674	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75082667	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs10142865	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75088921	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs10142626	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75088933	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs2010678	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75100475	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs4899545	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75101435	chr14:75011269~75012851:-
THCA	cis	rs516805	0.667	rs197679	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122548188	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197681	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122551788	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197682	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122551848	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197683	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122552277	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197684	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122553697	chr6:122436789~122439223:-
THCA	cis	rs72807246	1	rs72807246	ENSG00000228701.1	TNKS2-AS1	8.31	1.02e-15	4.45e-13	0.64	0.36	Breast cancer;	chr10:92172529	chr10:91782839~91798291:-
THCA	cis	rs516805	0.748	rs647178	ENSG00000279453.1	RP3-425C14.4	-8.31	1.03e-15	4.48e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122543602	chr6:122436789~122439223:-
THCA	cis	rs180730	1	rs343197	ENSG00000251609.2	SETP12	8.31	1.03e-15	4.49e-13	0.57	0.36	Fasting plasma glucose;	chr4:120877330	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs171069	ENSG00000251609.2	SETP12	-8.31	1.03e-15	4.49e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120880210	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs3115314	ENSG00000251609.2	SETP12	-8.31	1.03e-15	4.49e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120888621	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs184668	ENSG00000251609.2	SETP12	-8.31	1.03e-15	4.49e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120888812	chr4:120895494~120897083:-
THCA	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-8.31	1.03e-15	4.51e-13	-0.49	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
THCA	cis	rs11673344	0.523	rs1402468	ENSG00000226686.6	LINC01535	8.31	1.03e-15	4.52e-13	0.39	0.36	Obesity-related traits;	chr19:37129346	chr19:37251912~37265535:+
THCA	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-8.31	1.03e-15	4.52e-13	-0.29	-0.36	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
THCA	cis	rs11051970	0.918	rs7309115	ENSG00000274964.1	RP11-817I4.1	-8.31	1.04e-15	4.53e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32388307	chr12:32339368~32340724:+
THCA	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	8.31	1.04e-15	4.56e-13	0.46	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
THCA	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	8.31	1.04e-15	4.56e-13	0.42	0.36	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
THCA	cis	rs17684571	0.7	rs35642890	ENSG00000231441.1	RP11-472M19.2	8.31	1.05e-15	4.57e-13	0.43	0.36	Schizophrenia;	chr6:56809919	chr6:56844002~56864078:+
THCA	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-8.31	1.05e-15	4.57e-13	-0.43	-0.36	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
THCA	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-8.31	1.05e-15	4.59e-13	-0.61	-0.36	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
THCA	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	8.31	1.05e-15	4.59e-13	0.5	0.36	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
THCA	cis	rs7945705	0.902	rs11042088	ENSG00000254860.4	TMEM9B-AS1	-8.31	1.05e-15	4.59e-13	-0.41	-0.36	Hemoglobin concentration;	chr11:8821968	chr11:8964675~8977527:+
THCA	cis	rs1707322	0.717	rs3014237	ENSG00000234329.1	RP11-767N6.2	-8.31	1.06e-15	4.61e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45651039~45651826:-
THCA	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-8.31	1.06e-15	4.62e-13	-0.26	-0.36	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
THCA	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	8.31	1.06e-15	4.62e-13	0.32	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
THCA	cis	rs737008	0.922	rs1559394	ENSG00000262703.1	RP11-485G7.6	-8.31	1.06e-15	4.62e-13	-0.41	-0.36	Obesity-related traits;	chr16:11275348	chr16:11348143~11349321:-
THCA	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-8.31	1.06e-15	4.63e-13	-0.48	-0.36	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
THCA	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-8.31	1.07e-15	4.66e-13	-0.43	-0.36	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
THCA	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-8.31	1.07e-15	4.66e-13	-0.35	-0.36	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
THCA	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	8.31	1.07e-15	4.66e-13	0.3	0.36	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
THCA	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	8.31	1.07e-15	4.67e-13	0.4	0.36	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
THCA	cis	rs516805	0.748	rs12211993	ENSG00000279453.1	RP3-425C14.4	8.3	1.07e-15	4.69e-13	0.37	0.36	Lymphocyte counts;	chr6:122570216	chr6:122436789~122439223:-
THCA	cis	rs16846053	0.515	rs7557876	ENSG00000227403.1	AC009299.3	-8.3	1.08e-15	4.69e-13	-0.56	-0.36	Blood osmolality (transformed sodium);	chr2:161633024	chr2:161244739~161249050:+
THCA	cis	rs10411161	0.721	rs1433082	ENSG00000269483.1	AC006272.1	-8.3	1.08e-15	4.7e-13	-0.48	-0.36	Breast cancer;	chr19:51887473	chr19:51839924~51843324:-
THCA	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-8.3	1.08e-15	4.7e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-8.3	1.08e-15	4.7e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
THCA	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-8.3	1.08e-15	4.71e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
THCA	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-8.3	1.08e-15	4.72e-13	-0.43	-0.36	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
THCA	cis	rs4591358	0.678	rs13015934	ENSG00000223466.1	AC064834.2	-8.3	1.08e-15	4.73e-13	-0.5	-0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195504897	chr2:195533035~195538681:+
THCA	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-8.3	1.09e-15	4.73e-13	-0.43	-0.36	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
THCA	cis	rs812925	0.537	rs10865324	ENSG00000271889.1	RP11-493E12.1	-8.3	1.09e-15	4.74e-13	-0.34	-0.36	Immature fraction of reticulocytes;	chr2:61394172	chr2:61151433~61162105:-
THCA	cis	rs11971779	0.878	rs4732378	ENSG00000273391.1	RP11-634H22.1	8.3	1.09e-15	4.75e-13	0.38	0.36	Diisocyanate-induced asthma;	chr7:139435649	chr7:139359032~139359566:-
THCA	cis	rs2274273	0.529	rs7149965	ENSG00000258413.1	RP11-665C16.6	-8.3	1.1e-15	4.77e-13	-0.49	-0.36	Protein biomarker;	chr14:55041473	chr14:55262767~55272075:-
THCA	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	8.3	1.1e-15	4.77e-13	0.4	0.36	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
THCA	cis	rs910316	1	rs12589876	ENSG00000279594.1	RP11-950C14.10	8.3	1.1e-15	4.79e-13	0.33	0.36	Height;	chr14:75077486	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs10246	ENSG00000279594.1	RP11-950C14.10	8.3	1.1e-15	4.79e-13	0.33	0.36	Height;	chr14:75077767	chr14:75011269~75012851:-
THCA	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-8.3	1.1e-15	4.81e-13	-0.57	-0.36	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.702	rs28699233	ENSG00000249839.1	AC011330.5	-8.3	1.1e-15	4.81e-13	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43830668	chr15:43663654~43684339:-
THCA	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	8.3	1.11e-15	4.82e-13	0.42	0.36	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
THCA	cis	rs910316	1	rs4903281	ENSG00000279594.1	RP11-950C14.10	8.3	1.11e-15	4.85e-13	0.33	0.36	Height;	chr14:75087658	chr14:75011269~75012851:-
THCA	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	8.3	1.11e-15	4.85e-13	0.47	0.36	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
THCA	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	8.3	1.12e-15	4.86e-13	0.38	0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
THCA	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	8.3	1.12e-15	4.86e-13	0.38	0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
THCA	cis	rs934734	0.752	rs1039764	ENSG00000204929.10	AC074391.1	-8.3	1.12e-15	4.86e-13	-0.44	-0.36	Rheumatoid arthritis;	chr2:65387479	chr2:65436711~66084639:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-8.3	1.12e-15	4.88e-13	-0.26	-0.36	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
THCA	cis	rs3745672	1	rs279170	ENSG00000219665.7	CTD-2006C1.2	-8.3	1.12e-15	4.88e-13	-0.73	-0.36	Multiple sclerosis;	chr19:12025708	chr19:11987617~12046275:+
THCA	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000237664.1	LINC00316	-8.3	1.12e-15	4.89e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000237664.1	LINC00316	-8.3	1.12e-15	4.89e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000237664.1	LINC00316	-8.3	1.12e-15	4.89e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000237664.1	LINC00316	-8.3	1.12e-15	4.89e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45338590~45341990:-
THCA	cis	rs1707322	1	rs9429186	ENSG00000234329.1	RP11-767N6.2	-8.3	1.13e-15	4.9e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785506	ENSG00000234329.1	RP11-767N6.2	-8.3	1.13e-15	4.9e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45651039~45651826:-
THCA	cis	rs11673344	0.543	rs8108429	ENSG00000226686.6	LINC01535	8.3	1.13e-15	4.91e-13	0.39	0.36	Obesity-related traits;	chr19:37145874	chr19:37251912~37265535:+
THCA	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	8.3	1.13e-15	4.92e-13	0.24	0.36	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
THCA	cis	rs910316	0.763	rs175047	ENSG00000279594.1	RP11-950C14.10	-8.3	1.13e-15	4.92e-13	-0.33	-0.36	Height;	chr14:75012336	chr14:75011269~75012851:-
THCA	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-8.3	1.13e-15	4.93e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
THCA	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	8.3	1.14e-15	4.94e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
THCA	cis	rs9640161	0.83	rs12703061	ENSG00000261305.1	RP4-584D14.7	8.3	1.14e-15	4.96e-13	0.43	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150365456	chr7:150341771~150342607:+
THCA	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	8.3	1.14e-15	4.97e-13	0.55	0.36	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
THCA	cis	rs6723226	0.572	rs176404	ENSG00000276334.1	AL133243.1	-8.3	1.14e-15	4.97e-13	-0.4	-0.36	Intelligence (multi-trait analysis);	chr2:32413778	chr2:32521927~32523547:+
THCA	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	8.3	1.15e-15	5e-13	0.75	0.36	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
THCA	cis	rs7569084	0.687	rs1370394	ENSG00000234255.7	AC012370.3	8.3	1.15e-15	5.01e-13	0.41	0.36	Sum eosinophil basophil counts;	chr2:65453176	chr2:65439888~65456571:-
THCA	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	8.3	1.15e-15	5.01e-13	0.68	0.36	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
THCA	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	8.3	1.16e-15	5.02e-13	0.44	0.36	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
THCA	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	8.29	1.16e-15	5.02e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
THCA	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-8.29	1.16e-15	5.03e-13	-0.42	-0.36	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
THCA	cis	rs4713118	0.699	rs573179	ENSG00000280107.1	AL022393.9	-8.29	1.16e-15	5.04e-13	-0.43	-0.36	Parkinson's disease;	chr6:27881898	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.699	rs200978	ENSG00000280107.1	AL022393.9	-8.29	1.16e-15	5.04e-13	-0.43	-0.36	Parkinson's disease;	chr6:27885390	chr6:28170845~28172521:+
THCA	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	8.29	1.16e-15	5.04e-13	0.24	0.36	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
THCA	cis	rs6504108	0.581	rs55982346	ENSG00000278765.1	RP5-890E16.5	-8.29	1.16e-15	5.05e-13	-0.4	-0.36	Body mass index;	chr17:48198512	chr17:48066704~48067293:-
THCA	cis	rs2712184	0.875	rs2541382	ENSG00000229352.1	AC007563.3	-8.29	1.16e-15	5.06e-13	-0.44	-0.36	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216815311	chr2:216799608~216805335:+
THCA	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-8.29	1.16e-15	5.06e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
THCA	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	8.29	1.16e-15	5.06e-13	0.55	0.36	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
THCA	cis	rs6504108	0.624	rs2278868	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48184809	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs11079814	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48191077	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.602	rs11872095	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48193810	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs12452956	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48196575	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs8075270	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48197648	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs8072282	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48199496	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs8069064	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48203301	chr17:48066704~48067293:-
THCA	cis	rs240993	0.516	rs241006	ENSG00000230177.1	RP5-1112D6.4	-8.29	1.17e-15	5.08e-13	-0.39	-0.36	Inflammatory skin disease;Psoriasis;	chr6:111279910	chr6:111277932~111278742:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-8.29	1.17e-15	5.09e-13	-0.26	-0.36	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
THCA	cis	rs4789693	0.808	rs12935995	ENSG00000265458.1	RP13-20L14.6	8.29	1.17e-15	5.09e-13	0.37	0.36	Glucocorticoid-induced osteonecrosis;	chr17:82437007	chr17:82454273~82458521:-
THCA	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-8.29	1.17e-15	5.09e-13	-0.43	-0.36	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
THCA	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	8.29	1.17e-15	5.09e-13	0.34	0.36	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
THCA	cis	rs8114671	0.967	rs6088747	ENSG00000269202.1	RP4-614O4.12	-8.29	1.18e-15	5.11e-13	-0.3	-0.36	Height;	chr20:35166801	chr20:35201747~35203288:-
THCA	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-8.29	1.18e-15	5.12e-13	-0.47	-0.36	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
THCA	cis	rs3847687	1	rs78233646	ENSG00000256810.1	RP11-76C10.2	8.29	1.18e-15	5.12e-13	0.42	0.36	Longevity;	chr12:131035625	chr12:131030570~131035487:-
THCA	cis	rs7665090	1	rs10027437	ENSG00000246560.2	RP11-10L12.4	8.29	1.18e-15	5.13e-13	0.43	0.36	Primary biliary cholangitis;	chr4:102636094	chr4:102828055~102844075:+
THCA	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	8.29	1.18e-15	5.14e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	8.29	1.18e-15	5.14e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	8.29	1.18e-15	5.14e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	8.29	1.18e-15	5.14e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
THCA	cis	rs11148252	0.712	rs61957257	ENSG00000235660.1	LINC00345	-8.29	1.18e-15	5.14e-13	-0.45	-0.36	Lewy body disease;	chr13:52195567	chr13:52484161~52484680:-
THCA	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-8.29	1.18e-15	5.14e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
THCA	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	8.29	1.19e-15	5.15e-13	0.35	0.36	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
THCA	cis	rs853679	0.882	rs9461432	ENSG00000280107.1	AL022393.9	-8.29	1.19e-15	5.15e-13	-0.54	-0.36	Depression;	chr6:28119105	chr6:28170845~28172521:+
THCA	cis	rs1707322	1	rs785498	ENSG00000234329.1	RP11-767N6.2	-8.29	1.19e-15	5.16e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45651039~45651826:-
THCA	cis	rs180730	0.898	rs343200	ENSG00000251609.2	SETP12	-8.29	1.19e-15	5.17e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120876657	chr4:120895494~120897083:-
THCA	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-8.29	1.2e-15	5.19e-13	-0.42	-0.36	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
THCA	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-8.29	1.2e-15	5.19e-13	-0.34	-0.36	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
THCA	cis	rs1799949	0.602	rs8176235	ENSG00000267681.1	CTD-3199J23.6	-8.29	1.2e-15	5.2e-13	-0.44	-0.36	Menopause (age at onset);	chr17:43067543	chr17:43144956~43145255:+
THCA	cis	rs11673344	0.583	rs7254411	ENSG00000226686.6	LINC01535	8.29	1.21e-15	5.25e-13	0.39	0.36	Obesity-related traits;	chr19:37034969	chr19:37251912~37265535:+
THCA	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	8.29	1.22e-15	5.27e-13	0.45	0.36	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
THCA	cis	rs853679	0.76	rs9468317	ENSG00000219392.1	RP1-265C24.5	-8.29	1.22e-15	5.27e-13	-0.5	-0.36	Depression;	chr6:28230678	chr6:28115628~28116551:+
THCA	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	8.29	1.22e-15	5.29e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	8.29	1.22e-15	5.29e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	8.29	1.22e-15	5.29e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
THCA	cis	rs9549328	0.7	rs2185001	ENSG00000267868.1	RP11-120K24.3	8.29	1.22e-15	5.29e-13	0.37	0.36	Systolic blood pressure;	chr13:112962055	chr13:112964835~112966131:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	8.29	1.22e-15	5.29e-13	0.26	0.36	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	8.29	1.22e-15	5.29e-13	0.26	0.36	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
THCA	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	8.29	1.22e-15	5.31e-13	0.68	0.36	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
THCA	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	8.29	1.23e-15	5.32e-13	0.4	0.36	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
THCA	cis	rs2032366	0.591	rs9783921	ENSG00000267279.1	RP11-879F14.2	8.29	1.23e-15	5.32e-13	0.38	0.36	Obesity-related traits;	chr18:61635219	chr18:61585746~61606916:-
THCA	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	8.29	1.23e-15	5.33e-13	0.43	0.36	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	8.29	1.23e-15	5.33e-13	0.43	0.36	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
THCA	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	8.29	1.23e-15	5.34e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
THCA	cis	rs673078	0.66	rs61943525	ENSG00000275409.1	RP11-131L12.4	-8.29	1.23e-15	5.35e-13	-0.48	-0.36	Glucose homeostasis traits;	chr12:118152927	chr12:118430147~118430699:+
THCA	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	8.29	1.23e-15	5.35e-13	0.45	0.36	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
THCA	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	8.29	1.23e-15	5.35e-13	0.37	0.36	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
THCA	cis	rs180730	1	rs2667176	ENSG00000251609.2	SETP12	-8.29	1.23e-15	5.35e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120881498	chr4:120895494~120897083:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-8.29	1.24e-15	5.36e-13	-0.26	-0.36	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-8.29	1.24e-15	5.36e-13	-0.26	-0.36	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
THCA	cis	rs2120243	0.533	rs1500921	ENSG00000244515.1	KRT18P34	-8.29	1.24e-15	5.37e-13	-0.4	-0.36	Hepatocellular carcinoma in hepatitis B infection;	chr3:157337638	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.533	rs62278578	ENSG00000244515.1	KRT18P34	-8.29	1.24e-15	5.37e-13	-0.4	-0.36	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338078	chr3:157162663~157163932:-
THCA	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	8.29	1.24e-15	5.37e-13	0.26	0.36	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
THCA	cis	rs741668	0.641	rs9534306	ENSG00000235903.6	CPB2-AS1	8.29	1.24e-15	5.38e-13	0.45	0.36	Cerebrospinal fluid clusterin levels;	chr13:46069100	chr13:46052806~46113332:+
THCA	cis	rs12594515	0.625	rs2176866	ENSG00000259200.1	RP11-718O11.1	-8.29	1.24e-15	5.39e-13	-0.46	-0.36	Weight;Waist circumference;	chr15:45704620	chr15:45705078~45931069:+
THCA	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-8.28	1.24e-15	5.39e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-8.28	1.24e-15	5.39e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
THCA	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	8.28	1.25e-15	5.4e-13	0.45	0.36	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
THCA	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	8.28	1.25e-15	5.41e-13	0.45	0.36	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
THCA	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	8.28	1.25e-15	5.42e-13	0.43	0.36	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
THCA	cis	rs7191700	0.511	rs243330	ENSG00000262636.1	CTD-3088G3.4	8.28	1.26e-15	5.45e-13	0.44	0.36	Multiple sclerosis;	chr16:11257134	chr16:11380859~11381118:-
THCA	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	8.28	1.26e-15	5.46e-13	0.4	0.36	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
THCA	cis	rs7015263	0.714	rs3903247	ENSG00000254231.1	CTD-2284J15.1	-8.28	1.26e-15	5.47e-13	-0.36	-0.36	Intelligence (multi-trait analysis);	chr8:86526184	chr8:86333274~86343314:-
THCA	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	8.28	1.26e-15	5.47e-13	0.26	0.36	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
THCA	cis	rs1850744	0.609	rs6448959	ENSG00000250942.1	ENPP7P11	8.28	1.26e-15	5.48e-13	0.49	0.36	Economic and political preferences;	chr4:9682303	chr4:9677308~9677934:+
THCA	cis	rs1858037	0.867	rs4671660	ENSG00000237979.1	AC007389.1	8.28	1.26e-15	5.48e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65349302	chr2:65500993~65502138:-
THCA	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-8.28	1.27e-15	5.49e-13	-0.47	-0.36	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
THCA	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	8.28	1.27e-15	5.5e-13	0.33	0.36	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.59	rs59602547	ENSG00000273391.1	RP11-634H22.1	8.28	1.27e-15	5.5e-13	0.33	0.36	Diisocyanate-induced asthma;	chr7:139432277	chr7:139359032~139359566:-
THCA	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.27e-15	5.5e-13	-0.35	-0.36	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.27e-15	5.5e-13	-0.35	-0.36	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	8.28	1.27e-15	5.5e-13	0.26	0.36	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
THCA	cis	rs10266483	0.741	rs10254313	ENSG00000227986.1	TRIM60P18	-8.28	1.27e-15	5.52e-13	-0.29	-0.36	Response to statin therapy;	chr7:64278935	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.741	rs35244017	ENSG00000227986.1	TRIM60P18	-8.28	1.27e-15	5.52e-13	-0.29	-0.36	Response to statin therapy;	chr7:64278939	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.843	rs10272639	ENSG00000227986.1	TRIM60P18	-8.28	1.27e-15	5.52e-13	-0.29	-0.36	Response to statin therapy;	chr7:64278944	chr7:64355078~64356199:+
THCA	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	8.28	1.27e-15	5.52e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	8.28	1.27e-15	5.52e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	8.28	1.27e-15	5.52e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
THCA	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
THCA	cis	rs2562456	0.917	rs2650825	ENSG00000268555.1	RP11-678G14.3	8.28	1.28e-15	5.53e-13	0.5	0.36	Pain;	chr19:21516423	chr19:21570822~21587322:-
THCA	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.28e-15	5.54e-13	-0.36	-0.36	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.28e-15	5.54e-13	-0.36	-0.36	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
THCA	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	8.28	1.28e-15	5.55e-13	0.45	0.36	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
THCA	cis	rs180730	1	rs343195	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120879311	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs180730	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120880635	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs1901136	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120881574	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs2667175	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120882099	chr4:120895494~120897083:-
THCA	cis	rs180730	0.948	rs3115312	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120882651	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs3106313	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120882815	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs1450472	ENSG00000251609.2	SETP12	8.28	1.28e-15	5.56e-13	0.57	0.36	Fasting plasma glucose;	chr4:120882137	chr4:120895494~120897083:-
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	8.28	1.29e-15	5.57e-13	0.34	0.36	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
THCA	cis	rs934734	0.532	rs10166100	ENSG00000237979.1	AC007389.1	-8.28	1.29e-15	5.58e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65418616	chr2:65500993~65502138:-
THCA	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-8.28	1.29e-15	5.59e-13	-0.33	-0.36	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
THCA	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-8.28	1.29e-15	5.59e-13	-0.33	-0.36	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	8.28	1.29e-15	5.59e-13	0.26	0.36	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
THCA	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-8.28	1.29e-15	5.6e-13	-0.37	-0.36	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
THCA	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-8.28	1.29e-15	5.6e-13	-0.46	-0.36	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
THCA	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-8.28	1.29e-15	5.6e-13	-0.46	-0.36	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
THCA	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-8.28	1.29e-15	5.6e-13	-0.46	-0.36	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
THCA	cis	rs7191700	0.601	rs243329	ENSG00000262636.1	CTD-3088G3.4	8.28	1.29e-15	5.6e-13	0.44	0.36	Multiple sclerosis;	chr16:11258456	chr16:11380859~11381118:-
THCA	cis	rs6504108	0.624	rs4794505	ENSG00000278765.1	RP5-890E16.5	-8.28	1.3e-15	5.62e-13	-0.4	-0.36	Body mass index;	chr17:48205944	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.647	rs12150533	ENSG00000278765.1	RP5-890E16.5	-8.28	1.3e-15	5.62e-13	-0.4	-0.36	Body mass index;	chr17:48210179	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs4794517	ENSG00000278765.1	RP5-890E16.5	-8.28	1.3e-15	5.62e-13	-0.4	-0.36	Body mass index;	chr17:48214491	chr17:48066704~48067293:-
THCA	cis	rs11148252	0.716	rs1887360	ENSG00000278238.1	RP11-245D16.4	-8.28	1.3e-15	5.63e-13	-0.43	-0.36	Lewy body disease;	chr13:52205031	chr13:52454775~52455331:-
THCA	cis	rs1850744	0.702	rs11724183	ENSG00000250942.1	ENPP7P11	-8.28	1.3e-15	5.64e-13	-0.52	-0.36	Economic and political preferences;	chr4:9608270	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.826	rs11735475	ENSG00000250942.1	ENPP7P11	-8.28	1.3e-15	5.64e-13	-0.52	-0.36	Economic and political preferences;	chr4:9613302	chr4:9677308~9677934:+
THCA	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	8.28	1.31e-15	5.66e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	8.28	1.31e-15	5.66e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
THCA	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-8.28	1.31e-15	5.68e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
THCA	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	8.28	1.32e-15	5.7e-13	0.41	0.36	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
THCA	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-8.28	1.32e-15	5.71e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
THCA	cis	rs2562456	0.682	rs11085464	ENSG00000268555.1	RP11-678G14.3	8.28	1.32e-15	5.72e-13	0.49	0.36	Pain;	chr19:21568976	chr19:21570822~21587322:-
THCA	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.32e-15	5.72e-13	-0.34	-0.36	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
THCA	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	8.28	1.33e-15	5.75e-13	0.48	0.36	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
THCA	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-8.28	1.33e-15	5.75e-13	-0.46	-0.36	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
THCA	cis	rs7727544	0.642	rs7705189	ENSG00000224431.1	AC063976.7	-8.28	1.33e-15	5.76e-13	-0.31	-0.36	Blood metabolite levels;	chr5:132287665	chr5:132199456~132203487:+
THCA	cis	rs9500256	0.967	rs1012500	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-8.28	1.33e-15	5.76e-13	-0.36	-0.36	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57855891~57856468:-
THCA	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	8.28	1.34e-15	5.77e-13	0.26	0.36	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	8.28	1.34e-15	5.77e-13	0.26	0.36	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	8.28	1.34e-15	5.77e-13	0.26	0.36	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
THCA	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	8.28	1.34e-15	5.77e-13	0.44	0.36	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
THCA	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	8.28	1.34e-15	5.77e-13	0.5	0.36	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
THCA	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	8.27	1.34e-15	5.79e-13	0.4	0.36	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	8.27	1.34e-15	5.79e-13	0.4	0.36	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
THCA	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	8.27	1.34e-15	5.8e-13	0.33	0.36	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
THCA	cis	rs9928842	0.765	rs6564223	ENSG00000280152.1	RP11-331F4.5	8.27	1.34e-15	5.81e-13	0.54	0.36	Alcoholic chronic pancreatitis;	chr16:75192001	chr16:75245994~75250077:-
THCA	cis	rs42490	0.664	rs394108	ENSG00000251136.7	RP11-37B2.1	-8.27	1.34e-15	5.81e-13	-0.31	-0.36	Leprosy;	chr8:89812991	chr8:89609409~89757727:-
THCA	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-8.27	1.35e-15	5.81e-13	-0.42	-0.36	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	8.27	1.36e-15	5.86e-13	0.26	0.36	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
THCA	cis	rs516805	0.748	rs155463	ENSG00000279453.1	RP3-425C14.4	-8.27	1.36e-15	5.86e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122501474	chr6:122436789~122439223:-
THCA	cis	rs516805	0.715	rs197691	ENSG00000279453.1	RP3-425C14.4	-8.27	1.36e-15	5.86e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122513394	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197692	ENSG00000279453.1	RP3-425C14.4	-8.27	1.36e-15	5.86e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122515260	chr6:122436789~122439223:-
THCA	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-8.27	1.36e-15	5.86e-13	-0.39	-0.36	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
THCA	cis	rs7945705	0.967	rs4554887	ENSG00000254860.4	TMEM9B-AS1	-8.27	1.36e-15	5.89e-13	-0.41	-0.36	Hemoglobin concentration;	chr11:8818776	chr11:8964675~8977527:+
THCA	cis	rs17772222	0.638	rs11159859	ENSG00000258789.1	RP11-507K2.3	-8.27	1.37e-15	5.9e-13	-0.35	-0.36	Coronary artery calcification;	chr14:88561547	chr14:88551597~88552493:+
THCA	cis	rs507080	0.922	rs478371	ENSG00000278376.1	RP11-158I9.8	-8.27	1.37e-15	5.9e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118694627	chr11:118791254~118793137:+
THCA	cis	rs9902453	0.584	rs3809790	ENSG00000264007.1	RP11-68I3.10	-8.27	1.37e-15	5.91e-13	-0.4	-0.36	Coffee consumption (cups per day);	chr17:29628522	chr17:29621617~29622254:-
THCA	cis	rs1005277	0.603	rs1998062	ENSG00000263064.2	RP11-291L22.7	8.27	1.37e-15	5.93e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	8.27	1.37e-15	5.93e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	8.27	1.37e-15	5.93e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	8.27	1.37e-15	5.93e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000237664.1	LINC00316	-8.27	1.38e-15	5.93e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000237664.1	LINC00316	-8.27	1.38e-15	5.93e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000237664.1	LINC00316	-8.27	1.38e-15	5.93e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45338590~45341990:-
THCA	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-8.27	1.38e-15	5.94e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-8.27	1.38e-15	5.94e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.682	rs3783889	ENSG00000258789.1	RP11-507K2.3	-8.27	1.38e-15	5.94e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88475637	chr14:88551597~88552493:+
THCA	cis	rs1707322	0.682	rs28508523	ENSG00000234329.1	RP11-767N6.2	8.27	1.38e-15	5.94e-13	0.33	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.691	rs11211175	ENSG00000234329.1	RP11-767N6.2	8.27	1.38e-15	5.94e-13	0.33	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45651039~45651826:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	8.27	1.38e-15	5.94e-13	0.26	0.36	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
THCA	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-8.27	1.38e-15	5.97e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
THCA	cis	rs10411161	0.702	rs7247017	ENSG00000269483.1	AC006272.1	8.27	1.38e-15	5.97e-13	0.5	0.36	Breast cancer;	chr19:51888516	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs7256926	ENSG00000269483.1	AC006272.1	8.27	1.38e-15	5.97e-13	0.5	0.36	Breast cancer;	chr19:51888735	chr19:51839924~51843324:-
THCA	cis	rs4380275	0.965	rs4375894	ENSG00000272342.1	RP13-539J13.1	8.27	1.39e-15	6e-13	0.43	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:739588~740164:-
THCA	cis	rs4713118	1	rs1139226	ENSG00000219392.1	RP1-265C24.5	-8.27	1.39e-15	6.02e-13	-0.45	-0.36	Parkinson's disease;	chr6:27707511	chr6:28115628~28116551:+
THCA	cis	rs4713118	1	rs9468195	ENSG00000219392.1	RP1-265C24.5	-8.27	1.39e-15	6.02e-13	-0.45	-0.36	Parkinson's disease;	chr6:27708530	chr6:28115628~28116551:+
THCA	cis	rs6504108	0.624	rs17620033	ENSG00000278765.1	RP5-890E16.5	-8.27	1.4e-15	6.03e-13	-0.4	-0.36	Body mass index;	chr17:48214052	chr17:48066704~48067293:-
THCA	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	8.27	1.4e-15	6.04e-13	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000230295.1	RP11-458F8.2	-8.27	1.4e-15	6.05e-13	-0.31	-0.36	Corneal structure;	chr7:66911108	chr7:66880708~66882981:+
THCA	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	8.27	1.4e-15	6.05e-13	0.38	0.36	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
THCA	cis	rs1707322	0.686	rs1084086	ENSG00000234329.1	RP11-767N6.2	-8.27	1.41e-15	6.08e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45651039~45651826:-
THCA	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	8.27	1.42e-15	6.1e-13	0.35	0.36	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
THCA	cis	rs42490	0.625	rs438485	ENSG00000251136.7	RP11-37B2.1	-8.27	1.42e-15	6.12e-13	-0.31	-0.36	Leprosy;	chr8:89831190	chr8:89609409~89757727:-
THCA	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-8.27	1.42e-15	6.14e-13	-0.42	-0.36	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
THCA	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-8.27	1.43e-15	6.15e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
THCA	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-8.27	1.43e-15	6.16e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
THCA	cis	rs11971779	0.688	rs1862880	ENSG00000273391.1	RP11-634H22.1	8.27	1.43e-15	6.17e-13	0.35	0.36	Diisocyanate-induced asthma;	chr7:139335354	chr7:139359032~139359566:-
THCA	cis	rs8114671	0.836	rs6142280	ENSG00000269202.1	RP4-614O4.12	8.27	1.44e-15	6.18e-13	0.3	0.36	Height;	chr20:35034439	chr20:35201747~35203288:-
THCA	cis	rs2522056	1	rs10900807	ENSG00000233006.5	AC034220.3	-8.26	1.44e-15	6.21e-13	-0.32	-0.36	Fibrinogen;Lymphocyte counts;	chr5:132421788	chr5:132311285~132369916:-
THCA	cis	rs638893	0.588	rs2156755	ENSG00000278376.1	RP11-158I9.8	-8.26	1.44e-15	6.22e-13	-0.31	-0.36	Vitiligo;	chr11:118855521	chr11:118791254~118793137:+
THCA	cis	rs7714584	1	rs6874560	ENSG00000197083.10	ZNF300P1	8.26	1.44e-15	6.22e-13	0.63	0.36	Crohn's disease;	chr5:150803151	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11748553	ENSG00000197083.10	ZNF300P1	8.26	1.44e-15	6.22e-13	0.63	0.36	Crohn's disease;	chr5:150804991	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11746560	ENSG00000197083.10	ZNF300P1	8.26	1.44e-15	6.22e-13	0.63	0.36	Crohn's disease;	chr5:150806363	chr5:150930645~150946289:-
THCA	cis	rs1859596	0.646	rs10252126	ENSG00000234456.6	MAGI2-AS3	8.26	1.44e-15	6.22e-13	0.34	0.36	Reading or mathematical ability;	chr7:79468167	chr7:79452877~79471208:+
THCA	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	8.26	1.45e-15	6.23e-13	0.4	0.36	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
THCA	cis	rs6504108	0.624	rs4794525	ENSG00000278765.1	RP5-890E16.5	-8.26	1.45e-15	6.23e-13	-0.4	-0.36	Body mass index;	chr17:48220996	chr17:48066704~48067293:-
THCA	cis	rs7829975	0.593	rs2921077	ENSG00000254153.1	CTA-398F10.2	-8.26	1.45e-15	6.23e-13	-0.38	-0.36	Mood instability;	chr8:8446992	chr8:8456909~8461337:-
THCA	cis	rs507080	0.922	rs7114458	ENSG00000278376.1	RP11-158I9.8	-8.26	1.45e-15	6.23e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118695466	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs7114216	ENSG00000278376.1	RP11-158I9.8	-8.26	1.45e-15	6.23e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118695525	chr11:118791254~118793137:+
THCA	cis	rs1949733	0.628	rs1543246	ENSG00000205959.3	RP11-689P11.2	-8.26	1.45e-15	6.24e-13	-0.28	-0.36	Response to antineoplastic agents;	chr4:8503182	chr4:8482270~8512610:+
THCA	cis	rs8114671	0.662	rs6058146	ENSG00000269202.1	RP4-614O4.12	-8.26	1.45e-15	6.24e-13	-0.31	-0.36	Height;	chr20:34952726	chr20:35201747~35203288:-
THCA	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-8.26	1.45e-15	6.24e-13	-0.44	-0.36	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
THCA	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	8.26	1.45e-15	6.25e-13	0.24	0.36	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
THCA	cis	rs1858037	0.806	rs12612780	ENSG00000237979.1	AC007389.1	8.26	1.46e-15	6.29e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65355967	chr2:65500993~65502138:-
THCA	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	8.26	1.46e-15	6.29e-13	0.48	0.36	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
THCA	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	8.26	1.47e-15	6.33e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
THCA	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-8.26	1.47e-15	6.34e-13	-0.34	-0.36	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
THCA	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-8.26	1.48e-15	6.35e-13	-0.42	-0.36	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
THCA	cis	rs1707322	0.686	rs2050376	ENSG00000234329.1	RP11-767N6.2	8.26	1.48e-15	6.37e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45651039~45651826:-
THCA	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-8.26	1.48e-15	6.38e-13	-0.38	-0.36	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
THCA	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-8.26	1.48e-15	6.38e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-8.26	1.48e-15	6.38e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.637	rs879932	ENSG00000258789.1	RP11-507K2.3	-8.26	1.48e-15	6.38e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88479247	chr14:88551597~88552493:+
THCA	cis	rs947583	0.71	rs6570045	ENSG00000231028.7	LINC00271	-8.26	1.48e-15	6.38e-13	-0.28	-0.36	Phosphorus levels;	chr6:135815734	chr6:135497801~135716055:+
THCA	cis	rs1858037	0.765	rs67404371	ENSG00000237979.1	AC007389.1	8.26	1.48e-15	6.38e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65370137	chr2:65500993~65502138:-
THCA	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-8.26	1.48e-15	6.38e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
THCA	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	8.26	1.48e-15	6.38e-13	0.41	0.36	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
THCA	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-8.26	1.49e-15	6.39e-13	-0.46	-0.36	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
THCA	cis	rs507080	0.922	rs518028	ENSG00000278376.1	RP11-158I9.8	-8.26	1.49e-15	6.39e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118694273	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs519982	ENSG00000278376.1	RP11-158I9.8	-8.26	1.49e-15	6.39e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118694522	chr11:118791254~118793137:+
THCA	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-8.26	1.49e-15	6.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
THCA	cis	rs11051970	0.918	rs7309706	ENSG00000274964.1	RP11-817I4.1	-8.26	1.49e-15	6.41e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32385274	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.918	rs76930558	ENSG00000274964.1	RP11-817I4.1	-8.26	1.49e-15	6.41e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32385905	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.918	rs73084099	ENSG00000274964.1	RP11-817I4.1	-8.26	1.49e-15	6.41e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32386817	chr12:32339368~32340724:+
THCA	cis	rs2288884	0.596	rs12459638	ENSG00000275055.1	CTC-471J1.11	-8.26	1.49e-15	6.41e-13	-0.37	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51998549	chr19:52049007~52049754:+
THCA	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	8.26	1.49e-15	6.42e-13	0.69	0.36	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
THCA	cis	rs673078	0.66	rs61945224	ENSG00000275409.1	RP11-131L12.4	-8.26	1.49e-15	6.42e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118288623	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945225	ENSG00000275409.1	RP11-131L12.4	-8.26	1.49e-15	6.42e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118288960	chr12:118430147~118430699:+
THCA	cis	rs910316	0.737	rs175071	ENSG00000279594.1	RP11-950C14.10	-8.26	1.5e-15	6.43e-13	-0.32	-0.36	Height;	chr14:75031474	chr14:75011269~75012851:-
THCA	cis	rs5769707	0.967	rs763126	ENSG00000235111.1	RP1-29C18.8	8.26	1.5e-15	6.43e-13	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49612657~49615716:-
THCA	cis	rs910316	0.763	rs13712	ENSG00000279594.1	RP11-950C14.10	8.26	1.5e-15	6.45e-13	0.32	0.36	Height;	chr14:75017109	chr14:75011269~75012851:-
THCA	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	8.26	1.5e-15	6.45e-13	0.4	0.36	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	8.26	1.5e-15	6.45e-13	0.4	0.36	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
THCA	cis	rs17684571	0.751	rs7761729	ENSG00000231441.1	RP11-472M19.2	8.26	1.5e-15	6.45e-13	0.44	0.36	Schizophrenia;	chr6:56846478	chr6:56844002~56864078:+
THCA	cis	rs1707322	0.627	rs3014213	ENSG00000234329.1	RP11-767N6.2	-8.26	1.5e-15	6.47e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs2152078	ENSG00000234329.1	RP11-767N6.2	-8.26	1.5e-15	6.47e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs2991979	ENSG00000234329.1	RP11-767N6.2	-8.26	1.5e-15	6.47e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45651039~45651826:-
THCA	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-8.26	1.51e-15	6.48e-13	-0.44	-0.36	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
THCA	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-8.26	1.51e-15	6.48e-13	-0.35	-0.36	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
THCA	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-8.26	1.51e-15	6.48e-13	-0.44	-0.36	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
THCA	cis	rs4819052	0.851	rs28442024	ENSG00000237664.1	LINC00316	-8.26	1.51e-15	6.49e-13	-0.35	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45338590~45341990:-
THCA	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	8.26	1.51e-15	6.51e-13	0.26	0.36	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
THCA	cis	rs7569084	1	rs7583469	ENSG00000237979.1	AC007389.1	8.26	1.52e-15	6.51e-13	0.41	0.36	Sum eosinophil basophil counts;	chr2:65424222	chr2:65500993~65502138:-
THCA	cis	rs1707322	0.721	rs6665808	ENSG00000234329.1	RP11-767N6.2	8.26	1.52e-15	6.52e-13	0.33	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45651039~45651826:-
THCA	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	8.26	1.52e-15	6.52e-13	0.43	0.36	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
THCA	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	8.26	1.52e-15	6.53e-13	0.4	0.36	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	8.26	1.52e-15	6.53e-13	0.4	0.36	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	8.26	1.52e-15	6.53e-13	0.4	0.36	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	8.26	1.52e-15	6.53e-13	0.4	0.36	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
THCA	cis	rs1858037	0.867	rs67453645	ENSG00000237979.1	AC007389.1	8.26	1.52e-15	6.54e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65358908	chr2:65500993~65502138:-
THCA	cis	rs4819052	0.851	rs2838857	ENSG00000237664.1	LINC00316	-8.26	1.52e-15	6.55e-13	-0.35	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45338590~45341990:-
THCA	cis	rs2032366	0.63	rs6567226	ENSG00000267279.1	RP11-879F14.2	-8.26	1.53e-15	6.57e-13	-0.38	-0.36	Obesity-related traits;	chr18:61635689	chr18:61585746~61606916:-
THCA	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-8.26	1.54e-15	6.61e-13	-0.43	-0.36	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
THCA	cis	rs2562456	0.876	rs11085467	ENSG00000268555.1	RP11-678G14.3	8.26	1.55e-15	6.64e-13	0.49	0.36	Pain;	chr19:21569041	chr19:21570822~21587322:-
THCA	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-8.25	1.55e-15	6.67e-13	-0.43	-0.36	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-8.25	1.55e-15	6.67e-13	-0.43	-0.36	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
THCA	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-8.25	1.55e-15	6.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
THCA	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	8.25	1.55e-15	6.67e-13	0.51	0.36	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
THCA	cis	rs7727544	0.716	rs72793283	ENSG00000224431.1	AC063976.7	8.25	1.56e-15	6.68e-13	0.31	0.36	Blood metabolite levels;	chr5:132231248	chr5:132199456~132203487:+
THCA	cis	rs1850744	0.702	rs10939427	ENSG00000250942.1	ENPP7P11	8.25	1.56e-15	6.69e-13	0.52	0.36	Economic and political preferences;	chr4:9626914	chr4:9677308~9677934:+
THCA	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	8.25	1.56e-15	6.69e-13	0.42	0.36	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
THCA	cis	rs507080	0.922	rs642662	ENSG00000278376.1	RP11-158I9.8	-8.25	1.56e-15	6.7e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118696311	chr11:118791254~118793137:+
THCA	cis	rs11673344	0.543	rs1818748	ENSG00000226686.6	LINC01535	8.25	1.56e-15	6.71e-13	0.39	0.36	Obesity-related traits;	chr19:37065416	chr19:37251912~37265535:+
THCA	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	8.25	1.56e-15	6.71e-13	0.26	0.36	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
THCA	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-8.25	1.57e-15	6.72e-13	-0.37	-0.36	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
THCA	cis	rs910316	1	rs4899544	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.72e-13	0.33	0.36	Height;	chr14:75079853	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs4903279	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.72e-13	0.33	0.36	Height;	chr14:75079880	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs1071989	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.72e-13	0.33	0.36	Height;	chr14:75097956	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs9805979	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.72e-13	0.33	0.36	Height;	chr14:75099506	chr14:75011269~75012851:-
THCA	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-8.25	1.57e-15	6.73e-13	-0.37	-0.36	Height;	chr11:118747911	chr11:118704607~118750263:+
THCA	cis	rs16846053	0.515	rs1510094	ENSG00000227403.1	AC009299.3	8.25	1.57e-15	6.74e-13	0.56	0.36	Blood osmolality (transformed sodium);	chr2:161632681	chr2:161244739~161249050:+
THCA	cis	rs910316	1	rs12589376	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.75e-13	0.33	0.36	Height;	chr14:75094449	chr14:75011269~75012851:-
THCA	cis	rs507080	0.883	rs656575	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679199	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs656505	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679245	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs660489	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679255	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs543327	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679276	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs543413	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679308	chr11:118791254~118793137:+
THCA	cis	rs1858037	0.867	rs61226353	ENSG00000237979.1	AC007389.1	8.25	1.58e-15	6.76e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65363637	chr2:65500993~65502138:-
THCA	cis	rs1850744	0.536	rs114344194	ENSG00000250942.1	ENPP7P11	-8.25	1.58e-15	6.76e-13	-0.52	-0.36	Economic and political preferences;	chr4:9605096	chr4:9677308~9677934:+
THCA	cis	rs910316	1	rs12589815	ENSG00000279594.1	RP11-950C14.10	8.25	1.58e-15	6.76e-13	0.33	0.36	Height;	chr14:75077398	chr14:75011269~75012851:-
THCA	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	8.25	1.59e-15	6.8e-13	0.43	0.36	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	8.25	1.59e-15	6.8e-13	0.43	0.36	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	8.25	1.59e-15	6.8e-13	0.43	0.36	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
THCA	cis	rs10411161	0.752	rs10404812	ENSG00000269483.1	AC006272.1	8.25	1.59e-15	6.81e-13	0.51	0.36	Breast cancer;	chr19:51897438	chr19:51839924~51843324:-
THCA	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-8.25	1.59e-15	6.81e-13	-0.45	-0.36	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
THCA	cis	rs9500256	1	rs9500256	ENSG00000215190.7	LINC00680	-8.25	1.59e-15	6.83e-13	-0.41	-0.36	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57946074~57961501:-
THCA	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	8.25	1.59e-15	6.83e-13	0.69	0.36	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
THCA	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-8.25	1.6e-15	6.84e-13	-0.37	-0.36	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
THCA	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-8.25	1.6e-15	6.85e-13	-0.34	-0.36	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
THCA	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-8.25	1.6e-15	6.86e-13	-0.46	-0.36	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
THCA	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-8.25	1.6e-15	6.88e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-8.25	1.6e-15	6.88e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-8.25	1.6e-15	6.88e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
THCA	cis	rs270601	0.77	rs932019	ENSG00000233006.5	AC034220.3	8.25	1.61e-15	6.89e-13	0.28	0.36	Acylcarnitine levels;	chr5:132263677	chr5:132311285~132369916:-
THCA	cis	rs910316	1	rs7156105	ENSG00000279594.1	RP11-950C14.10	8.25	1.61e-15	6.89e-13	0.33	0.36	Height;	chr14:75075251	chr14:75011269~75012851:-
THCA	cis	rs7646881	1	rs73015655	ENSG00000240207.5	RP11-379F4.4	-8.25	1.61e-15	6.91e-13	-0.48	-0.36	Tetralogy of Fallot;	chr3:158734093	chr3:158732263~158784070:+
THCA	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	8.25	1.62e-15	6.93e-13	0.4	0.36	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	8.25	1.62e-15	6.93e-13	0.4	0.36	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	8.25	1.62e-15	6.93e-13	0.4	0.36	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
THCA	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	8.25	1.62e-15	6.94e-13	0.42	0.36	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
THCA	cis	rs7727544	0.669	rs113823725	ENSG00000224431.1	AC063976.7	8.25	1.62e-15	6.95e-13	0.31	0.36	Blood metabolite levels;	chr5:132227808	chr5:132199456~132203487:+
THCA	cis	rs11051970	0.918	rs1055876	ENSG00000274964.1	RP11-817I4.1	-8.25	1.63e-15	6.97e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32383266	chr12:32339368~32340724:+
THCA	cis	rs270601	0.77	rs4361510	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132263954	chr5:132311285~132369916:-
THCA	cis	rs270601	0.77	rs61352298	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132264896	chr5:132311285~132369916:-
THCA	cis	rs270601	0.739	rs1979981	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132266027	chr5:132311285~132369916:-
THCA	cis	rs270601	0.77	rs1007602	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132266473	chr5:132311285~132369916:-
THCA	cis	rs270601	0.71	rs4705852	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132267114	chr5:132311285~132369916:-
THCA	cis	rs673078	0.66	rs17512407	ENSG00000275409.1	RP11-131L12.4	-8.25	1.63e-15	6.97e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118292705	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61946064	ENSG00000275409.1	RP11-131L12.4	-8.25	1.63e-15	6.97e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118294495	chr12:118430147~118430699:+
THCA	cis	rs1075265	0.537	rs2160929	ENSG00000233266.1	HMGB1P31	8.25	1.63e-15	6.99e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53654735	chr2:54051334~54051760:+
THCA	cis	rs507080	0.733	rs601318	ENSG00000278376.1	RP11-158I9.8	-8.25	1.63e-15	6.99e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118648845	chr11:118791254~118793137:+
THCA	cis	rs507080	0.697	rs653008	ENSG00000278376.1	RP11-158I9.8	-8.25	1.63e-15	6.99e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118649775	chr11:118791254~118793137:+
THCA	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	8.25	1.63e-15	6.99e-13	0.34	0.36	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
THCA	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-8.25	1.64e-15	7.01e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
THCA	cis	rs922182	0.535	rs28729238	ENSG00000275785.1	RP11-111E14.2	8.25	1.64e-15	7.04e-13	0.42	0.36	Blood protein levels;	chr15:63902953	chr15:63890030~63890317:+
THCA	cis	rs11603691	0.901	rs61888886	ENSG00000254662.1	RP11-872D17.4	-8.25	1.64e-15	7.04e-13	-0.67	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57325698	chr11:57325603~57327958:+
THCA	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-8.25	1.65e-15	7.05e-13	-0.45	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-8.25	1.65e-15	7.06e-13	-0.26	-0.36	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
THCA	cis	rs7727544	0.716	rs4705928	ENSG00000224431.1	AC063976.7	-8.25	1.65e-15	7.07e-13	-0.31	-0.36	Blood metabolite levels;	chr5:132242944	chr5:132199456~132203487:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-8.25	1.65e-15	7.07e-13	-0.45	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
THCA	cis	rs7714584	0.826	rs12655654	ENSG00000197083.10	ZNF300P1	8.25	1.65e-15	7.08e-13	0.63	0.36	Crohn's disease;	chr5:150794733	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs74955473	ENSG00000197083.10	ZNF300P1	8.25	1.65e-15	7.08e-13	0.63	0.36	Crohn's disease;	chr5:150794996	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs79780973	ENSG00000197083.10	ZNF300P1	8.25	1.65e-15	7.08e-13	0.63	0.36	Crohn's disease;	chr5:150795248	chr5:150930645~150946289:-
THCA	cis	rs1005277	0.54	rs2474598	ENSG00000263064.2	RP11-291L22.7	-8.25	1.65e-15	7.08e-13	-0.4	-0.36	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38448689~38448949:+
THCA	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	8.25	1.65e-15	7.08e-13	0.42	0.36	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
THCA	cis	rs910316	0.967	rs11159116	ENSG00000279594.1	RP11-950C14.10	8.25	1.66e-15	7.1e-13	0.33	0.36	Height;	chr14:75083881	chr14:75011269~75012851:-
THCA	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-8.25	1.67e-15	7.13e-13	-0.37	-0.36	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-8.25	1.67e-15	7.13e-13	-0.37	-0.36	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
THCA	cis	rs1707322	0.929	rs785513	ENSG00000234329.1	RP11-767N6.2	-8.24	1.67e-15	7.15e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45651039~45651826:-
THCA	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
THCA	cis	rs1858037	0.867	rs57913336	ENSG00000237979.1	AC007389.1	8.24	1.68e-15	7.17e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65360485	chr2:65500993~65502138:-
THCA	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-8.24	1.68e-15	7.18e-13	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
THCA	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	8.24	1.68e-15	7.18e-13	0.43	0.36	Depression;	chr6:28363475	chr6:28176188~28176674:+
THCA	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	8.24	1.68e-15	7.19e-13	0.74	0.36	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000224205.1	AP000351.4	8.24	1.68e-15	7.19e-13	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23987320~23991421:-
THCA	cis	rs934734	0.752	rs2661797	ENSG00000204929.10	AC074391.1	-8.24	1.68e-15	7.19e-13	-0.44	-0.36	Rheumatoid arthritis;	chr2:65406056	chr2:65436711~66084639:+
THCA	cis	rs4713118	0.629	rs203889	ENSG00000226314.6	ZNF192P1	-8.24	1.68e-15	7.19e-13	-0.45	-0.36	Parkinson's disease;	chr6:28053997	chr6:28161781~28169594:+
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-8.24	1.68e-15	7.19e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-8.24	1.68e-15	7.19e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
THCA	cis	rs6504108	0.624	rs2021811	ENSG00000278765.1	RP5-890E16.5	-8.24	1.68e-15	7.2e-13	-0.4	-0.36	Body mass index;	chr17:48160420	chr17:48066704~48067293:-
THCA	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-8.24	1.69e-15	7.22e-13	-0.43	-0.36	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
THCA	cis	rs7712401	0.541	rs6867714	ENSG00000263432.2	RN7SL689P	8.24	1.7e-15	7.29e-13	0.42	0.36	Mean platelet volume;	chr5:123046364	chr5:123022487~123022783:-
THCA	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	8.24	1.71e-15	7.31e-13	0.47	0.36	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
THCA	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	8.24	1.71e-15	7.31e-13	0.42	0.36	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
THCA	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-8.24	1.71e-15	7.32e-13	-0.51	-0.36	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	8.24	1.71e-15	7.32e-13	0.26	0.36	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
THCA	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	8.24	1.71e-15	7.33e-13	0.44	0.36	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
THCA	cis	rs73607972	0.518	rs7193898	ENSG00000275191.1	RP11-36I17.2	8.24	1.72e-15	7.35e-13	0.46	0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53551009	chr16:53628256~53628816:-
THCA	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	8.24	1.72e-15	7.36e-13	0.44	0.36	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
THCA	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	8.24	1.72e-15	7.37e-13	0.42	0.36	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
THCA	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-8.24	1.73e-15	7.39e-13	-0.43	-0.36	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-8.24	1.73e-15	7.39e-13	-0.43	-0.36	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000266490.1	CTD-2349P21.9	8.24	1.73e-15	7.41e-13	0.46	0.36	Body mass index;	chr17:30690132	chr17:30792372~30792833:+
THCA	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	8.24	1.73e-15	7.41e-13	0.72	0.36	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
THCA	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	8.24	1.74e-15	7.42e-13	0.33	0.36	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
THCA	cis	rs7191700	0.578	rs243327	ENSG00000262703.1	RP11-485G7.6	-8.24	1.74e-15	7.43e-13	-0.39	-0.36	Multiple sclerosis;	chr16:11259447	chr16:11348143~11349321:-
THCA	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-8.24	1.75e-15	7.46e-13	-0.4	-0.36	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-8.24	1.75e-15	7.46e-13	-0.4	-0.36	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
THCA	cis	rs6504663	0.596	rs7208018	ENSG00000275897.1	RP11-94C24.13	-8.24	1.75e-15	7.47e-13	-0.34	-0.36	Visceral fat;	chr17:50480502	chr17:50475819~50478391:+
THCA	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-8.24	1.75e-15	7.47e-13	-0.35	-0.36	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
THCA	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	8.24	1.75e-15	7.49e-13	0.43	0.36	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
THCA	cis	rs11051970	0.918	rs73084101	ENSG00000274964.1	RP11-817I4.1	-8.24	1.75e-15	7.5e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32391405	chr12:32339368~32340724:+
THCA	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	8.24	1.76e-15	7.51e-13	0.41	0.36	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
THCA	cis	rs9475752	0.552	rs13209099	ENSG00000231441.1	RP11-472M19.2	8.24	1.76e-15	7.51e-13	0.48	0.36	Menarche (age at onset);	chr6:56869254	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.552	rs71564864	ENSG00000231441.1	RP11-472M19.2	8.24	1.76e-15	7.51e-13	0.48	0.36	Menarche (age at onset);	chr6:56869596	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.552	rs13216793	ENSG00000231441.1	RP11-472M19.2	8.24	1.76e-15	7.51e-13	0.48	0.36	Menarche (age at onset);	chr6:56874589	chr6:56844002~56864078:+
THCA	cis	rs6496932	0.563	rs2344083	ENSG00000259630.2	CTD-2262B20.1	-8.24	1.76e-15	7.51e-13	-0.43	-0.36	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85415228~85415633:+
THCA	cis	rs11696845	0.965	rs34485448	ENSG00000276223.1	RP4-781B1.5	-8.24	1.76e-15	7.52e-13	-0.44	-0.36	Obesity-related traits;	chr20:44741878	chr20:44746642~44747201:+
THCA	cis	rs9532669	0.889	rs7339089	ENSG00000239827.7	SUGT1P3	-8.24	1.76e-15	7.53e-13	-0.39	-0.36	Cervical cancer;	chr13:40863790	chr13:40908159~40921774:-
THCA	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
THCA	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-8.24	1.77e-15	7.55e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
THCA	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	8.24	1.77e-15	7.55e-13	0.35	0.36	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
THCA	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	8.24	1.77e-15	7.58e-13	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
THCA	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	8.24	1.78e-15	7.6e-13	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
THCA	cis	rs4789693	0.809	rs8071692	ENSG00000265458.1	RP13-20L14.6	8.24	1.78e-15	7.61e-13	0.36	0.36	Glucocorticoid-induced osteonecrosis;	chr17:82434457	chr17:82454273~82458521:-
THCA	cis	rs6844153	1	rs4557251	ENSG00000240005.4	RP11-293A21.1	-8.24	1.79e-15	7.63e-13	-0.5	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26848285	chr4:26859806~26860599:-
THCA	cis	rs7569084	0.64	rs11126039	ENSG00000234255.7	AC012370.3	8.24	1.79e-15	7.65e-13	0.4	0.36	Sum eosinophil basophil counts;	chr2:65457953	chr2:65439888~65456571:-
THCA	cis	rs910316	1	rs4899546	ENSG00000279594.1	RP11-950C14.10	8.24	1.79e-15	7.65e-13	0.33	0.36	Height;	chr14:75128243	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs11159117	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75118164	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs28626045	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75122492	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs12890371	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75127136	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs12889309	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75127199	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs4322591	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75133994	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs876403	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75136131	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs4903285	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75142565	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs7147118	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75143467	chr14:75011269~75012851:-
THCA	cis	rs507080	0.961	rs600969	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118675087	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs12577485	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118676793	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
THCA	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs673770	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679892	chr11:118791254~118793137:+
THCA	cis	rs2562456	0.561	rs12610883	ENSG00000268555.1	RP11-678G14.3	8.23	1.8e-15	7.69e-13	0.49	0.36	Pain;	chr19:21567257	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs7259708	ENSG00000268555.1	RP11-678G14.3	8.23	1.8e-15	7.69e-13	0.49	0.36	Pain;	chr19:21567846	chr19:21570822~21587322:-
THCA	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	8.23	1.81e-15	7.72e-13	0.42	0.36	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
THCA	cis	rs910316	1	rs12879542	ENSG00000279594.1	RP11-950C14.10	8.23	1.81e-15	7.74e-13	0.33	0.36	Height;	chr14:75040822	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs4903275	ENSG00000279594.1	RP11-950C14.10	8.23	1.81e-15	7.74e-13	0.33	0.36	Height;	chr14:75045806	chr14:75011269~75012851:-
THCA	cis	rs4927850	1	rs6799572	ENSG00000242086.7	LINC00969	8.23	1.82e-15	7.75e-13	0.35	0.36	Pancreatic cancer;	chr3:196013537	chr3:195658062~195739964:+
THCA	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-8.23	1.82e-15	7.76e-13	-0.39	-0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
THCA	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-8.23	1.82e-15	7.79e-13	-0.42	-0.36	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
THCA	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-8.23	1.83e-15	7.82e-13	-0.5	-0.35	Depression;	chr6:28240414	chr6:28115628~28116551:+
THCA	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-8.23	1.83e-15	7.82e-13	-0.5	-0.35	Depression;	chr6:28240780	chr6:28115628~28116551:+
THCA	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-8.23	1.83e-15	7.82e-13	-0.5	-0.35	Depression;	chr6:28241324	chr6:28115628~28116551:+
THCA	cis	rs2439831	0.557	rs13329084	ENSG00000249839.1	AC011330.5	8.23	1.84e-15	7.84e-13	0.64	0.35	Lung cancer in ever smokers;	chr15:43858865	chr15:43663654~43684339:-
THCA	cis	rs2712184	0.756	rs2712163	ENSG00000229352.1	AC007563.3	-8.23	1.84e-15	7.86e-13	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216795623	chr2:216799608~216805335:+
THCA	cis	rs6504108	0.624	rs3792692	ENSG00000278765.1	RP5-890E16.5	-8.23	1.85e-15	7.9e-13	-0.39	-0.35	Body mass index;	chr17:48177730	chr17:48066704~48067293:-
THCA	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-8.23	1.85e-15	7.91e-13	-0.43	-0.35	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
THCA	cis	rs853679	0.766	rs9368561	ENSG00000280107.1	AL022393.9	-8.23	1.86e-15	7.92e-13	-0.55	-0.35	Depression;	chr6:28200565	chr6:28170845~28172521:+
THCA	cis	rs4819052	0.851	rs3673	ENSG00000237664.1	LINC00316	-8.23	1.86e-15	7.93e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45338590~45341990:-
THCA	cis	rs853679	0.55	rs34477097	ENSG00000280107.1	AL022393.9	-8.23	1.86e-15	7.93e-13	-0.41	-0.35	Depression;	chr6:28229408	chr6:28170845~28172521:+
THCA	cis	rs2439831	0.85	rs67541383	ENSG00000249839.1	AC011330.5	-8.23	1.86e-15	7.93e-13	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43880350	chr15:43663654~43684339:-
THCA	cis	rs910316	1	rs10146482	ENSG00000279594.1	RP11-950C14.10	8.23	1.86e-15	7.95e-13	0.33	0.35	Height;	chr14:75107384	chr14:75011269~75012851:-
THCA	cis	rs2522056	0.935	rs1981524	ENSG00000233006.5	AC034220.3	-8.23	1.87e-15	7.96e-13	-0.31	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132311285~132369916:-
THCA	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-8.23	1.87e-15	7.98e-13	-0.5	-0.35	Depression;	chr6:28241753	chr6:28115628~28116551:+
THCA	cis	rs9649213	0.574	rs6961790	ENSG00000272950.1	RP11-307C18.1	8.23	1.88e-15	8.01e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr7:98322853~98323430:+
THCA	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-8.23	1.88e-15	8.03e-13	-0.46	-0.35	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-8.23	1.88e-15	8.03e-13	-0.46	-0.35	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
THCA	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-8.23	1.89e-15	8.04e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
THCA	cis	rs910316	1	rs11845639	ENSG00000279594.1	RP11-950C14.10	8.23	1.9e-15	8.08e-13	0.33	0.35	Height;	chr14:75103590	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs8017642	ENSG00000279594.1	RP11-950C14.10	8.23	1.9e-15	8.08e-13	0.33	0.35	Height;	chr14:75124119	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs2268617	ENSG00000279594.1	RP11-950C14.10	8.23	1.9e-15	8.08e-13	0.33	0.35	Height;	chr14:75142025	chr14:75011269~75012851:-
THCA	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	8.23	1.9e-15	8.1e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
THCA	cis	rs737008	1	rs737008	ENSG00000262703.1	RP11-485G7.6	-8.23	1.9e-15	8.1e-13	-0.41	-0.35	Obesity-related traits;	chr16:11281009	chr16:11348143~11349321:-
THCA	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	8.23	1.91e-15	8.12e-13	0.4	0.35	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
THCA	cis	rs6504108	0.577	rs2109982	ENSG00000278765.1	RP5-890E16.5	-8.23	1.92e-15	8.18e-13	-0.39	-0.35	Body mass index;	chr17:48167407	chr17:48066704~48067293:-
THCA	cis	rs1707322	0.686	rs1250	ENSG00000234329.1	RP11-767N6.2	8.23	1.92e-15	8.19e-13	0.34	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45651039~45651826:-
THCA	cis	rs910316	1	rs3742773	ENSG00000279594.1	RP11-950C14.10	8.23	1.92e-15	8.19e-13	0.33	0.35	Height;	chr14:75112940	chr14:75011269~75012851:-
THCA	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	8.23	1.93e-15	8.2e-13	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
THCA	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-8.23	1.93e-15	8.21e-13	-0.48	-0.35	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
THCA	cis	rs1707322	0.721	rs61784800	ENSG00000234329.1	RP11-767N6.2	-8.22	1.93e-15	8.21e-13	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45651039~45651826:-
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	8.22	1.93e-15	8.22e-13	0.35	0.35	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	8.22	1.93e-15	8.22e-13	0.35	0.35	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
THCA	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	8.22	1.94e-15	8.24e-13	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
THCA	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-8.22	1.94e-15	8.26e-13	-0.43	-0.35	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
THCA	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-8.22	1.94e-15	8.26e-13	-0.58	-0.35	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
THCA	cis	rs7015263	1	rs7459811	ENSG00000254231.1	CTD-2284J15.1	8.22	1.95e-15	8.28e-13	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86493174	chr8:86333274~86343314:-
THCA	cis	rs7191700	0.578	rs243327	ENSG00000262636.1	CTD-3088G3.4	-8.22	1.95e-15	8.28e-13	-0.44	-0.35	Multiple sclerosis;	chr16:11259447	chr16:11380859~11381118:-
THCA	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-8.22	1.96e-15	8.32e-13	-0.42	-0.35	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
THCA	cis	rs180730	1	rs3114955	ENSG00000251609.2	SETP12	-8.22	1.96e-15	8.35e-13	-0.56	-0.35	Fasting plasma glucose;	chr4:120884835	chr4:120895494~120897083:-
THCA	cis	rs9649213	0.593	rs3779194	ENSG00000272950.1	RP11-307C18.1	8.22	1.97e-15	8.37e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr7:98322853~98323430:+
THCA	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-8.22	1.97e-15	8.38e-13	-0.42	-0.35	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
THCA	cis	rs9500256	0.655	rs12209098	ENSG00000215190.7	LINC00680	8.22	1.97e-15	8.38e-13	0.44	0.35	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57946074~57961501:-
THCA	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	8.22	1.97e-15	8.38e-13	0.43	0.35	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
THCA	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-8.22	1.97e-15	8.38e-13	-0.41	-0.35	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
THCA	cis	rs17772222	0.682	rs28482235	ENSG00000258789.1	RP11-507K2.3	-8.22	1.97e-15	8.4e-13	-0.34	-0.35	Coronary artery calcification;	chr14:88472857	chr14:88551597~88552493:+
THCA	cis	rs3745672	1	rs7250427	ENSG00000219665.7	CTD-2006C1.2	-8.22	1.98e-15	8.42e-13	-0.72	-0.35	Multiple sclerosis;	chr19:12036386	chr19:11987617~12046275:+
THCA	cis	rs2712184	0.756	rs2541393	ENSG00000229352.1	AC007563.3	-8.22	1.98e-15	8.43e-13	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216786507	chr2:216799608~216805335:+
THCA	cis	rs6504108	0.602	rs2938483	ENSG00000278765.1	RP5-890E16.5	-8.22	1.98e-15	8.44e-13	-0.4	-0.35	Body mass index;	chr17:48240642	chr17:48066704~48067293:-
THCA	cis	rs910316	1	rs7303	ENSG00000279594.1	RP11-950C14.10	8.22	1.99e-15	8.45e-13	0.33	0.35	Height;	chr14:75053362	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs10143132	ENSG00000279594.1	RP11-950C14.10	8.22	1.99e-15	8.45e-13	0.33	0.35	Height;	chr14:75059147	chr14:75011269~75012851:-
THCA	cis	rs11159086	0.938	rs11623040	ENSG00000270000.1	RP3-449M8.9	8.22	1.99e-15	8.45e-13	0.46	0.35	Advanced glycation end-product levels;	chr14:74496743	chr14:74471930~74472360:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-8.22	1.99e-15	8.46e-13	-0.58	-0.35	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
THCA	cis	rs8114671	0.562	rs1013677	ENSG00000269202.1	RP4-614O4.12	-8.22	1.99e-15	8.46e-13	-0.3	-0.35	Height;	chr20:34880990	chr20:35201747~35203288:-
THCA	cis	rs9532669	0.926	rs4356344	ENSG00000239827.7	SUGT1P3	-8.22	1.99e-15	8.48e-13	-0.41	-0.35	Cervical cancer;	chr13:40874086	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-8.22	2e-15	8.49e-13	-0.44	-0.35	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
THCA	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-8.22	2e-15	8.5e-13	-0.44	-0.35	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
THCA	cis	rs7208859	0.673	rs11652370	ENSG00000266490.1	CTD-2349P21.9	8.22	2e-15	8.51e-13	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30792372~30792833:+
THCA	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	8.22	2.01e-15	8.54e-13	0.32	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
THCA	cis	rs2288884	0.541	rs7508746	ENSG00000275055.1	CTC-471J1.11	-8.22	2.02e-15	8.57e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51990246	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.634	rs74476955	ENSG00000275055.1	CTC-471J1.11	-8.22	2.02e-15	8.57e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997806	chr19:52049007~52049754:+
THCA	cis	rs2522056	1	rs1003533	ENSG00000233006.5	AC034220.3	-8.22	2.02e-15	8.58e-13	-0.31	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132311285~132369916:-
THCA	cis	rs507080	0.961	rs34413584	ENSG00000278376.1	RP11-158I9.8	-8.22	2.02e-15	8.58e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118675072	chr11:118791254~118793137:+
THCA	cis	rs7945705	0.967	rs11042082	ENSG00000254860.4	TMEM9B-AS1	-8.22	2.02e-15	8.6e-13	-0.41	-0.35	Hemoglobin concentration;	chr11:8817682	chr11:8964675~8977527:+
THCA	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-8.22	2.03e-15	8.64e-13	-0.48	-0.35	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
THCA	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-8.22	2.03e-15	8.65e-13	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
THCA	cis	rs2284378	0.506	rs6142059	ENSG00000275784.1	RP5-1125A11.6	-8.22	2.04e-15	8.65e-13	-0.35	-0.35	Breast cancer;	chr20:33956521	chr20:33989480~33991818:-
THCA	cis	rs741668	0.641	rs4942472	ENSG00000235903.6	CPB2-AS1	-8.22	2.04e-15	8.65e-13	-0.46	-0.35	Cerebrospinal fluid clusterin levels;	chr13:46070980	chr13:46052806~46113332:+
THCA	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	8.22	2.04e-15	8.66e-13	0.52	0.35	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
THCA	cis	rs7569084	0.687	rs934731	ENSG00000234255.7	AC012370.3	8.22	2.04e-15	8.66e-13	0.4	0.35	Sum eosinophil basophil counts;	chr2:65456353	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs7577452	ENSG00000234255.7	AC012370.3	8.22	2.04e-15	8.66e-13	0.4	0.35	Sum eosinophil basophil counts;	chr2:65456694	chr2:65439888~65456571:-
THCA	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	8.22	2.04e-15	8.66e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
THCA	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-8.22	2.05e-15	8.7e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
THCA	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-8.22	2.05e-15	8.7e-13	-0.45	-0.35	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
THCA	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-8.22	2.05e-15	8.72e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
THCA	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	8.22	2.05e-15	8.72e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
THCA	cis	rs507080	0.922	rs502601	ENSG00000278376.1	RP11-158I9.8	-8.22	2.05e-15	8.72e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118694970	chr11:118791254~118793137:+
THCA	cis	rs10411161	0.702	rs10403189	ENSG00000269483.1	AC006272.1	-8.22	2.06e-15	8.74e-13	-0.5	-0.35	Breast cancer;	chr19:51897420	chr19:51839924~51843324:-
THCA	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	8.22	2.06e-15	8.75e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	8.22	2.06e-15	8.75e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
THCA	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	8.22	2.06e-15	8.75e-13	0.23	0.35	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
THCA	cis	rs6504108	0.624	rs2021752	ENSG00000278765.1	RP5-890E16.5	8.22	2.06e-15	8.75e-13	0.39	0.35	Body mass index;	chr17:48162901	chr17:48066704~48067293:-
THCA	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	8.22	2.06e-15	8.77e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
THCA	cis	rs910316	1	rs10140851	ENSG00000279594.1	RP11-950C14.10	8.22	2.06e-15	8.77e-13	0.33	0.35	Height;	chr14:75045909	chr14:75011269~75012851:-
THCA	cis	rs9902453	0.542	rs3809789	ENSG00000264007.1	RP11-68I3.10	8.22	2.07e-15	8.78e-13	0.41	0.35	Coffee consumption (cups per day);	chr17:29628743	chr17:29621617~29622254:-
THCA	cis	rs4819052	0.851	rs2236444	ENSG00000237664.1	LINC00316	-8.21	2.08e-15	8.82e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45338590~45341990:-
THCA	cis	rs4713118	0.662	rs149900	ENSG00000226314.6	ZNF192P1	-8.21	2.08e-15	8.83e-13	-0.45	-0.35	Parkinson's disease;	chr6:28046819	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.629	rs149899	ENSG00000226314.6	ZNF192P1	-8.21	2.08e-15	8.83e-13	-0.45	-0.35	Parkinson's disease;	chr6:28052201	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000226314.6	ZNF192P1	-8.21	2.08e-15	8.83e-13	-0.45	-0.35	Parkinson's disease;	chr6:28053036	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000226314.6	ZNF192P1	-8.21	2.08e-15	8.83e-13	-0.45	-0.35	Parkinson's disease;	chr6:28053042	chr6:28161781~28169594:+
THCA	cis	rs910316	1	rs12435391	ENSG00000279594.1	RP11-950C14.10	8.21	2.08e-15	8.84e-13	0.33	0.35	Height;	chr14:75135034	chr14:75011269~75012851:-
THCA	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	8.21	2.08e-15	8.85e-13	0.34	0.35	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
THCA	cis	rs934734	0.752	rs1876518	ENSG00000204929.10	AC074391.1	-8.21	2.08e-15	8.85e-13	-0.44	-0.35	Rheumatoid arthritis;	chr2:65381775	chr2:65436711~66084639:+
THCA	cis	rs9309473	0.528	rs11126395	ENSG00000163016.8	ALMS1P	8.21	2.09e-15	8.88e-13	0.47	0.35	Metabolite levels;	chr2:73337836	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.528	rs11898362	ENSG00000163016.8	ALMS1P	8.21	2.09e-15	8.88e-13	0.47	0.35	Metabolite levels;	chr2:73338165	chr2:73644919~73685576:+
THCA	cis	rs4713118	0.869	rs9283883	ENSG00000219392.1	RP1-265C24.5	-8.21	2.1e-15	8.91e-13	-0.46	-0.35	Parkinson's disease;	chr6:27747691	chr6:28115628~28116551:+
THCA	cis	rs6504108	0.647	rs3805370	ENSG00000278765.1	RP5-890E16.5	-8.21	2.1e-15	8.93e-13	-0.39	-0.35	Body mass index;	chr17:48181731	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.647	rs3805371	ENSG00000278765.1	RP5-890E16.5	-8.21	2.1e-15	8.93e-13	-0.39	-0.35	Body mass index;	chr17:48181739	chr17:48066704~48067293:-
THCA	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-8.21	2.11e-15	8.95e-13	-0.35	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
THCA	cis	rs4927850	1	rs6799572	ENSG00000226155.1	AC124944.3	-8.21	2.11e-15	8.95e-13	-0.42	-0.35	Pancreatic cancer;	chr3:196013537	chr3:195912049~195913986:+
THCA	cis	rs6565180	1	rs11862806	ENSG00000183604.13	SMG1P5	-8.21	2.11e-15	8.96e-13	-0.36	-0.35	Tonsillectomy;	chr16:30352750	chr16:30267553~30335374:-
THCA	cis	rs13068223	0.617	rs13061457	ENSG00000243926.1	TIPARP-AS1	8.21	2.11e-15	8.97e-13	0.37	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156671862~156674378:-
THCA	cis	rs507080	0.961	rs4457789	ENSG00000278376.1	RP11-158I9.8	-8.21	2.11e-15	8.97e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118668461	chr11:118791254~118793137:+
THCA	cis	rs7727544	0.514	rs3846728	ENSG00000237714.1	P4HA2-AS1	8.21	2.12e-15	8.99e-13	0.45	0.35	Blood metabolite levels;	chr5:132100524	chr5:132184876~132192808:+
THCA	cis	rs375066	0.935	rs10414702	ENSG00000267058.1	RP11-15A1.3	-8.21	2.12e-15	9e-13	-0.29	-0.35	Breast cancer;	chr19:43876384	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs10421518	ENSG00000267058.1	RP11-15A1.3	-8.21	2.12e-15	9e-13	-0.29	-0.35	Breast cancer;	chr19:43877134	chr19:43891804~43901805:-
THCA	cis	rs375066	0.87	rs7258418	ENSG00000267058.1	RP11-15A1.3	-8.21	2.12e-15	9e-13	-0.29	-0.35	Breast cancer;	chr19:43878931	chr19:43891804~43901805:-
THCA	cis	rs934734	0.532	rs1437466	ENSG00000237979.1	AC007389.1	-8.21	2.13e-15	9.02e-13	-0.4	-0.35	Rheumatoid arthritis;	chr2:65437216	chr2:65500993~65502138:-
THCA	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-8.21	2.13e-15	9.02e-13	-0.45	-0.35	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
THCA	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-8.21	2.13e-15	9.02e-13	-0.34	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-8.21	2.13e-15	9.03e-13	-0.44	-0.35	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
THCA	cis	rs507080	0.922	rs644867	ENSG00000278376.1	RP11-158I9.8	-8.21	2.13e-15	9.03e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118696836	chr11:118791254~118793137:+
THCA	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	8.21	2.13e-15	9.05e-13	0.58	0.35	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
THCA	cis	rs4072705	0.967	rs6478677	ENSG00000224020.1	MIR181A2HG	-8.21	2.14e-15	9.07e-13	-0.32	-0.35	Menarche (age at onset);	chr9:124659900	chr9:124658467~124698631:+
THCA	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-8.21	2.14e-15	9.08e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
THCA	cis	rs17684571	0.872	rs3002011	ENSG00000231441.1	RP11-472M19.2	8.21	2.15e-15	9.1e-13	0.45	0.35	Schizophrenia;	chr6:56760325	chr6:56844002~56864078:+
THCA	cis	rs11971779	0.65	rs6969699	ENSG00000273391.1	RP11-634H22.1	8.21	2.15e-15	9.11e-13	0.34	0.35	Diisocyanate-induced asthma;	chr7:139443532	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs11772551	ENSG00000273391.1	RP11-634H22.1	8.21	2.15e-15	9.11e-13	0.34	0.35	Diisocyanate-induced asthma;	chr7:139444232	chr7:139359032~139359566:-
THCA	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	8.21	2.15e-15	9.11e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
THCA	cis	rs6504108	0.624	rs3805363	ENSG00000278765.1	RP5-890E16.5	-8.21	2.16e-15	9.15e-13	-0.39	-0.35	Body mass index;	chr17:48164260	chr17:48066704~48067293:-
THCA	cis	rs516805	0.748	rs510471	ENSG00000279453.1	RP3-425C14.4	-8.21	2.16e-15	9.17e-13	-0.35	-0.35	Lymphocyte counts;	chr6:122391714	chr6:122436789~122439223:-
THCA	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	8.21	2.16e-15	9.17e-13	0.31	0.35	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
THCA	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	8.21	2.16e-15	9.17e-13	0.45	0.35	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
THCA	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-8.21	2.17e-15	9.18e-13	-0.42	-0.35	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
THCA	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-8.21	2.17e-15	9.22e-13	-0.34	-0.35	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
THCA	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	8.21	2.17e-15	9.22e-13	0.45	0.35	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000206090.4	AP000350.7	-8.21	2.18e-15	9.24e-13	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23939998~23942798:+
THCA	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	8.21	2.18e-15	9.26e-13	0.43	0.35	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
THCA	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-8.21	2.18e-15	9.26e-13	-0.44	-0.35	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
THCA	cis	rs910316	0.839	rs35977276	ENSG00000279594.1	RP11-950C14.10	-8.21	2.19e-15	9.28e-13	-0.33	-0.35	Height;	chr14:75170656	chr14:75011269~75012851:-
THCA	cis	rs3822625	0.541	rs10042998	ENSG00000271828.1	CTD-2310F14.1	8.21	2.19e-15	9.29e-13	0.75	0.35	Breast cancer (early onset);	chr5:56909472	chr5:56927874~56929573:+
THCA	cis	rs4072705	0.967	rs4838200	ENSG00000224020.1	MIR181A2HG	8.21	2.2e-15	9.31e-13	0.32	0.35	Menarche (age at onset);	chr9:124688778	chr9:124658467~124698631:+
THCA	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.21	2.2e-15	9.32e-13	0.46	0.35	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
THCA	cis	rs7727544	0.678	rs7735891	ENSG00000224431.1	AC063976.7	8.21	2.2e-15	9.34e-13	0.31	0.35	Blood metabolite levels;	chr5:132261312	chr5:132199456~132203487:+
THCA	cis	rs375066	0.935	rs396874	ENSG00000267058.1	RP11-15A1.3	-8.21	2.21e-15	9.35e-13	-0.29	-0.35	Breast cancer;	chr19:43893073	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs397346	ENSG00000267058.1	RP11-15A1.3	-8.21	2.21e-15	9.35e-13	-0.29	-0.35	Breast cancer;	chr19:43894963	chr19:43891804~43901805:-
THCA	cis	rs4819052	0.851	rs2838866	ENSG00000237664.1	LINC00316	-8.21	2.21e-15	9.36e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45338590~45341990:-
THCA	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	8.21	2.21e-15	9.37e-13	0.68	0.35	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
THCA	cis	rs4819052	0.851	rs2255774	ENSG00000237664.1	LINC00316	-8.21	2.21e-15	9.38e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45338590~45341990:-
THCA	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	8.21	2.22e-15	9.39e-13	0.45	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
THCA	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-8.21	2.22e-15	9.41e-13	-0.39	-0.35	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
THCA	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-8.21	2.22e-15	9.41e-13	-0.42	-0.35	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-8.21	2.22e-15	9.41e-13	-0.42	-0.35	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-8.21	2.22e-15	9.41e-13	-0.42	-0.35	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-8.21	2.22e-15	9.41e-13	-0.42	-0.35	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-8.2	2.23e-15	9.45e-13	-0.42	-0.35	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-8.2	2.23e-15	9.45e-13	-0.43	-0.35	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
THCA	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	8.2	2.23e-15	9.46e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
THCA	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-8.2	2.24e-15	9.48e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
THCA	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-8.2	2.24e-15	9.49e-13	-0.42	-0.35	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
THCA	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-8.2	2.24e-15	9.49e-13	-0.42	-0.35	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
THCA	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
THCA	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-8.2	2.24e-15	9.5e-13	-0.23	-0.35	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
THCA	cis	rs375066	0.967	rs8104290	ENSG00000267058.1	RP11-15A1.3	-8.2	2.25e-15	9.52e-13	-0.29	-0.35	Breast cancer;	chr19:43863186	chr19:43891804~43901805:-
THCA	cis	rs375066	0.934	rs2191564	ENSG00000267058.1	RP11-15A1.3	-8.2	2.25e-15	9.52e-13	-0.29	-0.35	Breast cancer;	chr19:43863459	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs11673020	ENSG00000267058.1	RP11-15A1.3	-8.2	2.25e-15	9.52e-13	-0.29	-0.35	Breast cancer;	chr19:43870479	chr19:43891804~43901805:-
THCA	cis	rs2412819	0.599	rs2470120	ENSG00000166763.7	STRCP1	8.2	2.25e-15	9.52e-13	0.39	0.35	Lung cancer;	chr15:43636872	chr15:43699488~43718184:-
THCA	cis	rs9500256	0.966	rs1322446	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-8.2	2.25e-15	9.53e-13	-0.36	-0.35	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57855891~57856468:-
THCA	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	8.2	2.25e-15	9.54e-13	0.47	0.35	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
THCA	cis	rs860295	1	rs708611	ENSG00000225855.5	RUSC1-AS1	-8.2	2.26e-15	9.55e-13	-0.24	-0.35	Body mass index;	chr1:155773519	chr1:155316863~155324176:-
THCA	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-8.2	2.26e-15	9.58e-13	-0.29	-0.35	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
THCA	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-8.2	2.27e-15	9.59e-13	-0.47	-0.35	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
THCA	cis	rs934734	0.752	rs2661796	ENSG00000204929.10	AC074391.1	-8.2	2.27e-15	9.6e-13	-0.43	-0.35	Rheumatoid arthritis;	chr2:65400272	chr2:65436711~66084639:+
THCA	cis	rs2032366	0.583	rs1452594	ENSG00000267279.1	RP11-879F14.2	-8.2	2.27e-15	9.62e-13	-0.37	-0.35	Obesity-related traits;	chr18:61590689	chr18:61585746~61606916:-
THCA	cis	rs934734	0.673	rs7575614	ENSG00000237979.1	AC007389.1	8.2	2.28e-15	9.63e-13	0.39	0.35	Rheumatoid arthritis;	chr2:65462666	chr2:65500993~65502138:-
THCA	cis	rs934734	0.673	rs6742215	ENSG00000237979.1	AC007389.1	8.2	2.28e-15	9.63e-13	0.39	0.35	Rheumatoid arthritis;	chr2:65463362	chr2:65500993~65502138:-
THCA	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-8.2	2.28e-15	9.63e-13	-0.44	-0.35	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
THCA	cis	rs42490	0.738	rs39509	ENSG00000251136.7	RP11-37B2.1	-8.2	2.28e-15	9.63e-13	-0.3	-0.35	Leprosy;	chr8:89791937	chr8:89609409~89757727:-
THCA	cis	rs42490	0.752	rs411279	ENSG00000251136.7	RP11-37B2.1	-8.2	2.28e-15	9.63e-13	-0.3	-0.35	Leprosy;	chr8:89795929	chr8:89609409~89757727:-
THCA	cis	rs10411161	0.702	rs79180893	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51892362	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs11879436	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51894562	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs10420224	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51895702	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs75647161	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51895731	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs17778790	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51896306	chr19:51839924~51843324:-
THCA	cis	rs11148252	0.595	rs4885325	ENSG00000235660.1	LINC00345	-8.2	2.28e-15	9.65e-13	-0.45	-0.35	Lewy body disease;	chr13:52597182	chr13:52484161~52484680:-
THCA	cis	rs6504108	0.647	rs7210149	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48220260	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.602	rs1452667	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48225053	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs4793779	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48229235	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs1452666	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48230388	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs1377201	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48234766	chr17:48066704~48067293:-
THCA	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-8.2	2.29e-15	9.67e-13	-0.37	-0.35	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
THCA	cis	rs9649213	0.593	rs7787858	ENSG00000272950.1	RP11-307C18.1	8.2	2.29e-15	9.67e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs3801254	ENSG00000272950.1	RP11-307C18.1	8.2	2.29e-15	9.67e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr7:98322853~98323430:+
THCA	cis	rs7849270	0.879	rs10988200	ENSG00000268707.1	RP11-247A12.7	-8.2	2.29e-15	9.68e-13	-0.44	-0.35	Blood metabolite ratios;	chr9:129094306	chr9:129170434~129170940:+
THCA	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-8.2	2.29e-15	9.69e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
THCA	cis	rs507080	0.883	rs692750	ENSG00000278376.1	RP11-158I9.8	-8.2	2.29e-15	9.69e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118667599	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-8.2	2.29e-15	9.69e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
THCA	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-8.2	2.29e-15	9.7e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-8.2	2.29e-15	9.7e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
THCA	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	8.2	2.29e-15	9.7e-13	0.34	0.35	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
THCA	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	8.2	2.29e-15	9.7e-13	0.46	0.35	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	8.2	2.29e-15	9.7e-13	0.46	0.35	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
THCA	cis	rs9649213	0.593	rs6961438	ENSG00000272950.1	RP11-307C18.1	8.2	2.3e-15	9.72e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr7:98322853~98323430:+
THCA	cis	rs11696845	0.966	rs1467474	ENSG00000276223.1	RP4-781B1.5	-8.2	2.3e-15	9.75e-13	-0.43	-0.35	Obesity-related traits;	chr20:44743364	chr20:44746642~44747201:+
THCA	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	8.2	2.3e-15	9.75e-13	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
THCA	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	8.2	2.31e-15	9.75e-13	0.42	0.35	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
THCA	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	8.2	2.31e-15	9.75e-13	0.31	0.35	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
THCA	cis	rs6504108	0.602	rs7219967	ENSG00000278765.1	RP5-890E16.5	-8.2	2.31e-15	9.79e-13	-0.4	-0.35	Body mass index;	chr17:48216712	chr17:48066704~48067293:-
THCA	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	8.2	2.32e-15	9.79e-13	0.42	0.35	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
THCA	cis	rs1707322	0.964	rs785508	ENSG00000234329.1	RP11-767N6.2	-8.2	2.32e-15	9.8e-13	-0.34	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs785509	ENSG00000234329.1	RP11-767N6.2	-8.2	2.32e-15	9.8e-13	-0.34	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45651039~45651826:-
THCA	cis	rs910316	1	rs7156328	ENSG00000279594.1	RP11-950C14.10	8.2	2.32e-15	9.8e-13	0.33	0.35	Height;	chr14:75066238	chr14:75011269~75012851:-
THCA	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-8.2	2.32e-15	9.81e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
THCA	cis	rs7208859	0.673	rs1347360	ENSG00000266490.1	CTD-2349P21.9	8.2	2.32e-15	9.81e-13	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30792372~30792833:+
THCA	cis	rs1005277	0.579	rs176880	ENSG00000263064.2	RP11-291L22.7	-8.2	2.32e-15	9.82e-13	-0.4	-0.35	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38448689~38448949:+
THCA	cis	rs62103177	0.713	rs62103186	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79867574	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103187	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79867633	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103188	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79867661	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103189	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79867815	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103191	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79868769	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103192	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79869050	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.733	rs62103193	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79869217	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103194	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79869482	chr18:80046900~80095482:+
THCA	cis	rs2929278	0.588	rs688009	ENSG00000166763.7	STRCP1	8.2	2.33e-15	9.83e-13	0.38	0.35	Schizophrenia;	chr15:43864104	chr15:43699488~43718184:-
THCA	cis	rs42490	0.653	rs40453	ENSG00000251136.7	RP11-37B2.1	-8.2	2.33e-15	9.84e-13	-0.3	-0.35	Leprosy;	chr8:89789817	chr8:89609409~89757727:-
THCA	cis	rs922182	0.617	rs55694045	ENSG00000275785.1	RP11-111E14.2	8.2	2.33e-15	9.84e-13	0.42	0.35	Blood protein levels;	chr15:63953744	chr15:63890030~63890317:+
THCA	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
THCA	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-8.2	2.33e-15	9.84e-13	-0.35	-0.35	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
THCA	cis	rs922182	0.617	rs28737203	ENSG00000275785.1	RP11-111E14.2	8.2	2.33e-15	9.86e-13	0.41	0.35	Blood protein levels;	chr15:63948970	chr15:63890030~63890317:+
THCA	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	8.2	2.34e-15	9.87e-13	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
THCA	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	8.2	2.34e-15	9.87e-13	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
THCA	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	8.2	2.34e-15	9.88e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
THCA	cis	rs42490	0.752	rs400411	ENSG00000251136.7	RP11-37B2.1	-8.2	2.34e-15	9.89e-13	-0.3	-0.35	Leprosy;	chr8:89789871	chr8:89609409~89757727:-
THCA	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	8.2	2.34e-15	9.9e-13	0.42	0.35	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
THCA	cis	rs7714584	0.793	rs2161363	ENSG00000197083.10	ZNF300P1	8.2	2.35e-15	9.91e-13	0.61	0.35	Crohn's disease;	chr5:150802517	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	8.2	2.35e-15	9.91e-13	0.61	0.35	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
THCA	cis	rs910316	1	rs12588240	ENSG00000279594.1	RP11-950C14.10	8.2	2.35e-15	9.91e-13	0.33	0.35	Height;	chr14:75145380	chr14:75011269~75012851:-
THCA	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-8.2	2.35e-15	9.92e-13	-0.43	-0.35	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
THCA	cis	rs2562456	0.724	rs58001930	ENSG00000268555.1	RP11-678G14.3	8.2	2.35e-15	9.93e-13	0.49	0.35	Pain;	chr19:21560061	chr19:21570822~21587322:-
THCA	cis	rs11148252	0.711	rs61957304	ENSG00000235660.1	LINC00345	-8.2	2.36e-15	9.98e-13	-0.45	-0.35	Lewy body disease;	chr13:52224288	chr13:52484161~52484680:-
THCA	cis	rs1707322	0.682	rs3014241	ENSG00000234329.1	RP11-767N6.2	-8.2	2.36e-15	9.99e-13	-0.34	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45651039~45651826:-
THCA	cis	rs910316	1	rs10149880	ENSG00000279594.1	RP11-950C14.10	-8.2	2.37e-15	9.99e-13	-0.33	-0.35	Height;	chr14:75166305	chr14:75011269~75012851:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000235689.1	AP000351.13	8.2	2.38e-15	1e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:24006305~24008258:-
THCA	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-8.2	2.38e-15	1e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-8.2	2.38e-15	1e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
THCA	cis	rs2562456	0.837	rs11085462	ENSG00000268555.1	RP11-678G14.3	8.2	2.38e-15	1e-12	0.49	0.35	Pain;	chr19:21567449	chr19:21570822~21587322:-
THCA	cis	rs7191700	0.511	rs12923756	ENSG00000262636.1	CTD-3088G3.4	-8.2	2.39e-15	1.01e-12	-0.43	-0.35	Multiple sclerosis;	chr16:11265818	chr16:11380859~11381118:-
THCA	cis	rs853679	0.76	rs11967137	ENSG00000219392.1	RP1-265C24.5	-8.2	2.39e-15	1.01e-12	-0.49	-0.35	Depression;	chr6:28231986	chr6:28115628~28116551:+
THCA	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	8.2	2.39e-15	1.01e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
THCA	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-8.2	2.39e-15	1.01e-12	-0.43	-0.35	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
THCA	cis	rs4927850	0.709	rs6783079	ENSG00000242086.7	LINC00969	8.19	2.4e-15	1.01e-12	0.4	0.35	Pancreatic cancer;	chr3:195925837	chr3:195658062~195739964:+
THCA	cis	rs4927850	0.709	rs6765762	ENSG00000242086.7	LINC00969	8.19	2.4e-15	1.01e-12	0.4	0.35	Pancreatic cancer;	chr3:195925980	chr3:195658062~195739964:+
THCA	cis	rs673078	0.66	rs7961312	ENSG00000275409.1	RP11-131L12.4	-8.19	2.4e-15	1.01e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118324431	chr12:118430147~118430699:+
THCA	cis	rs6504108	0.624	rs3792694	ENSG00000278765.1	RP5-890E16.5	8.19	2.4e-15	1.01e-12	0.39	0.35	Body mass index;	chr17:48183080	chr17:48066704~48067293:-
THCA	cis	rs9473147	0.516	rs4715018	ENSG00000270761.1	RP11-385F7.1	-8.19	2.41e-15	1.02e-12	-0.29	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47474135	chr6:47477243~47477572:-
THCA	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-8.19	2.41e-15	1.02e-12	-0.34	-0.35	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
THCA	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-8.19	2.41e-15	1.02e-12	-0.43	-0.35	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
THCA	cis	rs1005277	0.579	rs2505241	ENSG00000263064.2	RP11-291L22.7	8.19	2.41e-15	1.02e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38448689~38448949:+
THCA	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-8.19	2.42e-15	1.02e-12	-0.37	-0.35	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-8.19	2.42e-15	1.02e-12	-0.37	-0.35	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
THCA	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	8.19	2.42e-15	1.02e-12	0.44	0.35	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
THCA	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-8.19	2.42e-15	1.02e-12	-0.42	-0.35	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
THCA	cis	rs910316	1	rs10873275	ENSG00000279594.1	RP11-950C14.10	8.19	2.43e-15	1.02e-12	0.33	0.35	Height;	chr14:75064757	chr14:75011269~75012851:-
THCA	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	8.19	2.44e-15	1.03e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
THCA	cis	rs922182	0.557	rs7161764	ENSG00000275785.1	RP11-111E14.2	-8.19	2.44e-15	1.03e-12	-0.42	-0.35	Blood protein levels;	chr15:63910545	chr15:63890030~63890317:+
THCA	cis	rs7727544	0.716	rs11955347	ENSG00000224431.1	AC063976.7	8.19	2.46e-15	1.04e-12	0.31	0.35	Blood metabolite levels;	chr5:132232231	chr5:132199456~132203487:+
THCA	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-8.19	2.46e-15	1.04e-12	-0.5	-0.35	Depression;	chr6:28242515	chr6:28115628~28116551:+
THCA	cis	rs853679	0.76	rs967005	ENSG00000219392.1	RP1-265C24.5	-8.19	2.46e-15	1.04e-12	-0.5	-0.35	Depression;	chr6:28242910	chr6:28115628~28116551:+
THCA	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-8.19	2.47e-15	1.04e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
THCA	cis	rs2408955	0.522	rs973398	ENSG00000258273.1	RP11-370I10.4	8.19	2.47e-15	1.04e-12	0.47	0.35	Glycated hemoglobin levels;	chr12:48097265	chr12:48333755~48333901:-
THCA	cis	rs910316	1	rs3742780	ENSG00000279594.1	RP11-950C14.10	8.19	2.47e-15	1.04e-12	0.33	0.35	Height;	chr14:75038305	chr14:75011269~75012851:-
THCA	cis	rs3847687	1	rs34853396	ENSG00000256810.1	RP11-76C10.2	8.19	2.48e-15	1.04e-12	0.42	0.35	Longevity;	chr12:131034720	chr12:131030570~131035487:-
THCA	cis	rs2688482	0.512	rs3103954	ENSG00000224769.1	AC069213.1	8.19	2.48e-15	1.05e-12	0.53	0.35	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195614947~195620233:+
THCA	cis	rs9649213	0.555	rs67132564	ENSG00000272950.1	RP11-307C18.1	8.19	2.49e-15	1.05e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98385588	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465682	ENSG00000272950.1	RP11-307C18.1	8.19	2.49e-15	1.05e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98387105	chr7:98322853~98323430:+
THCA	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	8.19	2.49e-15	1.05e-12	0.42	0.35	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
THCA	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	8.19	2.49e-15	1.05e-12	0.42	0.35	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
THCA	cis	rs2439831	0.85	rs16965120	ENSG00000249839.1	AC011330.5	-8.19	2.5e-15	1.05e-12	-0.57	-0.35	Lung cancer in ever smokers;	chr15:43808144	chr15:43663654~43684339:-
THCA	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	8.19	2.5e-15	1.05e-12	0.43	0.35	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
THCA	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	8.19	2.5e-15	1.05e-12	0.48	0.35	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
THCA	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	8.19	2.51e-15	1.06e-12	0.43	0.35	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
THCA	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	8.19	2.51e-15	1.06e-12	0.45	0.35	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
THCA	cis	rs34375054	0.66	rs35941060	ENSG00000279233.1	RP11-158L12.4	8.19	2.51e-15	1.06e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125109699	chr12:125138245~125141711:+
THCA	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-8.19	2.51e-15	1.06e-12	-0.57	-0.35	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
THCA	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-8.19	2.51e-15	1.06e-12	-0.71	-0.35	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	8.19	2.52e-15	1.06e-12	0.26	0.35	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
THCA	cis	rs934734	0.673	rs754110	ENSG00000237979.1	AC007389.1	8.19	2.52e-15	1.06e-12	0.4	0.35	Rheumatoid arthritis;	chr2:65464626	chr2:65500993~65502138:-
THCA	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	8.19	2.52e-15	1.06e-12	0.4	0.35	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
THCA	cis	rs4713118	0.629	rs203888	ENSG00000226314.6	ZNF192P1	-8.19	2.52e-15	1.06e-12	-0.44	-0.35	Parkinson's disease;	chr6:28053811	chr6:28161781~28169594:+
THCA	cis	rs9473147	0.516	rs1931837	ENSG00000270761.1	RP11-385F7.1	-8.19	2.52e-15	1.06e-12	-0.29	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47474641	chr6:47477243~47477572:-
THCA	cis	rs11971779	0.588	rs6969786	ENSG00000273391.1	RP11-634H22.1	8.19	2.53e-15	1.07e-12	0.34	0.35	Diisocyanate-induced asthma;	chr7:139443364	chr7:139359032~139359566:-
THCA	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	8.19	2.53e-15	1.07e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
THCA	cis	rs2712184	0.875	rs7586692	ENSG00000229352.1	AC007563.3	-8.19	2.53e-15	1.07e-12	-0.43	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216809980	chr2:216799608~216805335:+
THCA	cis	rs7176527	1	rs7176527	ENSG00000188388.10	GOLGA6L3	8.19	2.54e-15	1.07e-12	0.53	0.35	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85240472~85247170:+
THCA	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-8.19	2.54e-15	1.07e-12	-0.4	-0.35	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-8.19	2.54e-15	1.07e-12	-0.4	-0.35	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
THCA	cis	rs1707322	0.896	rs785512	ENSG00000234329.1	RP11-767N6.2	-8.19	2.54e-15	1.07e-12	-0.34	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45651039~45651826:-
THCA	cis	rs240993	0.715	rs9400483	ENSG00000230177.1	RP5-1112D6.4	8.19	2.55e-15	1.07e-12	0.35	0.35	Inflammatory skin disease;Psoriasis;	chr6:111535073	chr6:111277932~111278742:+
THCA	cis	rs9649213	0.593	rs62478233	ENSG00000272950.1	RP11-307C18.1	8.19	2.55e-15	1.07e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98393780	chr7:98322853~98323430:+
THCA	cis	rs2562456	0.876	rs62110163	ENSG00000268555.1	RP11-678G14.3	8.19	2.56e-15	1.08e-12	0.49	0.35	Pain;	chr19:21546020	chr19:21570822~21587322:-
THCA	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-8.19	2.56e-15	1.08e-12	-0.46	-0.35	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
THCA	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-8.19	2.57e-15	1.08e-12	-0.42	-0.35	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
THCA	cis	rs4713118	0.662	rs149961	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28047791	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28056708	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28056792	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28057501	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28057708	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28058299	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28058358	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28059910	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28060612	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28060704	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28062059	chr6:28161781~28169594:+
THCA	cis	rs16846053	0.515	rs2892770	ENSG00000227403.1	AC009299.3	-8.19	2.57e-15	1.08e-12	-0.55	-0.35	Blood osmolality (transformed sodium);	chr2:161638321	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs3843853	ENSG00000227403.1	AC009299.3	-8.19	2.57e-15	1.08e-12	-0.55	-0.35	Blood osmolality (transformed sodium);	chr2:161645081	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs1510084	ENSG00000227403.1	AC009299.3	-8.19	2.57e-15	1.08e-12	-0.55	-0.35	Blood osmolality (transformed sodium);	chr2:161647233	chr2:161244739~161249050:+
THCA	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-8.19	2.57e-15	1.08e-12	-0.5	-0.35	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	8.19	2.58e-15	1.08e-12	0.23	0.35	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	8.19	2.58e-15	1.08e-12	0.23	0.35	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	8.19	2.58e-15	1.08e-12	0.23	0.35	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
THCA	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	8.18	2.58e-15	1.09e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
THCA	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-8.18	2.59e-15	1.09e-12	-0.42	-0.35	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
THCA	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-8.18	2.59e-15	1.09e-12	-0.45	-0.35	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
THCA	cis	rs8114671	0.57	rs3761144	ENSG00000269202.1	RP4-614O4.12	-8.18	2.6e-15	1.09e-12	-0.3	-0.35	Height;	chr20:34956272	chr20:35201747~35203288:-
THCA	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	8.18	2.6e-15	1.09e-12	0.73	0.35	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
THCA	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	8.18	2.6e-15	1.09e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
THCA	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
THCA	cis	rs2120243	0.504	rs114107407	ENSG00000244515.1	KRT18P34	-8.18	2.61e-15	1.1e-12	-0.4	-0.35	Hepatocellular carcinoma in hepatitis B infection;	chr3:157344846	chr3:157162663~157163932:-
THCA	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
THCA	cis	rs1859596	0.608	rs2269991	ENSG00000234456.6	MAGI2-AS3	8.18	2.64e-15	1.11e-12	0.34	0.35	Reading or mathematical ability;	chr7:79460820	chr7:79452877~79471208:+
THCA	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-8.18	2.64e-15	1.11e-12	-0.5	-0.35	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
THCA	cis	rs9640161	0.783	rs1132261	ENSG00000261305.1	RP4-584D14.7	8.18	2.64e-15	1.11e-12	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150362898	chr7:150341771~150342607:+
THCA	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	8.18	2.64e-15	1.11e-12	0.37	0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
THCA	cis	rs6723226	0.65	rs6729952	ENSG00000276334.1	AL133243.1	8.18	2.64e-15	1.11e-12	0.39	0.35	Intelligence (multi-trait analysis);	chr2:32539855	chr2:32521927~32523547:+
THCA	cis	rs7015263	0.573	rs4484676	ENSG00000254231.1	CTD-2284J15.1	8.18	2.65e-15	1.11e-12	0.35	0.35	Intelligence (multi-trait analysis);	chr8:86259547	chr8:86333274~86343314:-
THCA	cis	rs4789693	0.938	rs8078595	ENSG00000265458.1	RP13-20L14.6	8.18	2.65e-15	1.12e-12	0.35	0.35	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82454273~82458521:-
THCA	cis	rs9473147	0.543	rs1004173	ENSG00000270761.1	RP11-385F7.1	-8.18	2.66e-15	1.12e-12	-0.28	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47477281	chr6:47477243~47477572:-
THCA	cis	rs7727544	0.716	rs10058655	ENSG00000224431.1	AC063976.7	8.18	2.66e-15	1.12e-12	0.31	0.35	Blood metabolite levels;	chr5:132235203	chr5:132199456~132203487:+
THCA	cis	rs910316	1	rs10138183	ENSG00000279594.1	RP11-950C14.10	8.18	2.66e-15	1.12e-12	0.33	0.35	Height;	chr14:75148524	chr14:75011269~75012851:-
THCA	cis	rs10463554	0.824	rs34374	ENSG00000175749.11	EIF3KP1	8.18	2.66e-15	1.12e-12	0.44	0.35	Parkinson's disease;	chr5:103068317	chr5:103032376~103033031:+
THCA	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-8.18	2.67e-15	1.12e-12	-0.42	-0.35	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
THCA	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	8.18	2.67e-15	1.12e-12	0.43	0.35	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-8.18	2.67e-15	1.12e-12	-0.41	-0.35	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
THCA	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	8.18	2.67e-15	1.12e-12	0.4	0.35	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
THCA	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	8.18	2.7e-15	1.13e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
THCA	cis	rs7727544	0.581	rs10075801	ENSG00000224431.1	AC063976.7	8.18	2.71e-15	1.14e-12	0.31	0.35	Blood metabolite levels;	chr5:132341949	chr5:132199456~132203487:+
THCA	cis	rs12554020	0.581	rs4255201	ENSG00000227603.1	RP11-165J3.6	8.18	2.71e-15	1.14e-12	0.59	0.35	Schizophrenia;	chr9:93401055	chr9:93435332~93437121:-
THCA	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-8.18	2.72e-15	1.14e-12	-0.42	-0.35	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
THCA	cis	rs2562456	0.837	rs62110205	ENSG00000268555.1	RP11-678G14.3	8.18	2.72e-15	1.14e-12	0.49	0.35	Pain;	chr19:21577269	chr19:21570822~21587322:-
THCA	cis	rs8114671	0.869	rs66535333	ENSG00000269202.1	RP4-614O4.12	8.18	2.72e-15	1.14e-12	0.3	0.35	Height;	chr20:35068863	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.869	rs1544047	ENSG00000269202.1	RP4-614O4.12	8.18	2.72e-15	1.14e-12	0.3	0.35	Height;	chr20:35082950	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.836	rs17404569	ENSG00000269202.1	RP4-614O4.12	8.18	2.72e-15	1.14e-12	0.3	0.35	Height;	chr20:35086274	chr20:35201747~35203288:-
THCA	cis	rs910316	1	rs12897094	ENSG00000279594.1	RP11-950C14.10	8.18	2.73e-15	1.15e-12	0.33	0.35	Height;	chr14:75112713	chr14:75011269~75012851:-
THCA	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-8.18	2.73e-15	1.15e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
THCA	cis	rs934734	0.789	rs4303705	ENSG00000204929.10	AC074391.1	-8.18	2.74e-15	1.15e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65392576	chr2:65436711~66084639:+
THCA	cis	rs910316	1	rs4903284	ENSG00000279594.1	RP11-950C14.10	8.18	2.75e-15	1.15e-12	0.33	0.35	Height;	chr14:75125780	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs2024653	ENSG00000279594.1	RP11-950C14.10	8.18	2.75e-15	1.15e-12	0.33	0.35	Height;	chr14:75128451	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs1047418	ENSG00000279594.1	RP11-950C14.10	8.18	2.75e-15	1.15e-12	0.33	0.35	Height;	chr14:75139089	chr14:75011269~75012851:-
THCA	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	8.18	2.75e-15	1.15e-12	0.42	0.35	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000206090.4	AP000350.7	-8.18	2.76e-15	1.16e-12	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23939998~23942798:+
THCA	cis	rs1707322	1	rs4660334	ENSG00000234329.1	RP11-767N6.2	8.18	2.76e-15	1.16e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45651039~45651826:-
THCA	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-8.18	2.77e-15	1.16e-12	-0.52	-0.35	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
THCA	cis	rs2712184	0.729	rs2541390	ENSG00000229352.1	AC007563.3	-8.18	2.77e-15	1.16e-12	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216799297	chr2:216799608~216805335:+
THCA	cis	rs2115630	0.641	rs11073613	ENSG00000225151.9	GOLGA2P7	8.17	2.78e-15	1.17e-12	0.46	0.35	P wave terminal force;	chr15:84642662	chr15:84199311~84230136:-
THCA	cis	rs8027521	0.56	rs2725563	ENSG00000280362.1	RP11-643A5.3	8.17	2.79e-15	1.17e-12	0.46	0.35	Circulating chemerin levels;	chr15:53938222	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.56	rs1119201	ENSG00000280362.1	RP11-643A5.3	8.17	2.79e-15	1.17e-12	0.46	0.35	Circulating chemerin levels;	chr15:53938705	chr15:53910769~53914712:+
THCA	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	8.17	2.83e-15	1.19e-12	0.49	0.35	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
THCA	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-8.17	2.83e-15	1.19e-12	-0.56	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
THCA	cis	rs62158211	1	rs1807282	ENSG00000272563.1	RP11-480C16.1	-8.17	2.84e-15	1.19e-12	-0.48	-0.35	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113352459	chr2:113432600~113436042:+
THCA	cis	rs62103177	0.81	rs3902996	ENSG00000261126.6	RP11-795F19.1	8.17	2.84e-15	1.19e-12	0.4	0.35	Opioid sensitivity;	chr18:79870571	chr18:80046900~80095482:+
THCA	cis	rs17772222	0.682	rs2274736	ENSG00000258789.1	RP11-507K2.3	-8.17	2.84e-15	1.19e-12	-0.33	-0.35	Coronary artery calcification;	chr14:88472308	chr14:88551597~88552493:+
THCA	cis	rs9649213	0.593	rs2394854	ENSG00000272950.1	RP11-307C18.1	8.17	2.84e-15	1.19e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr7:98322853~98323430:+
THCA	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	8.17	2.84e-15	1.19e-12	0.44	0.35	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
THCA	cis	rs736801	0.78	rs12521868	ENSG00000237714.1	P4HA2-AS1	-8.17	2.85e-15	1.19e-12	-0.48	-0.35	Mosquito bite size;Breast cancer;	chr5:132448701	chr5:132184876~132192808:+
THCA	cis	rs4072705	0.967	rs4836986	ENSG00000224020.1	MIR181A2HG	-8.17	2.86e-15	1.2e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124645780	chr9:124658467~124698631:+
THCA	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-8.17	2.86e-15	1.2e-12	-0.4	-0.35	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
THCA	cis	rs6545883	0.507	rs4672427	ENSG00000271889.1	RP11-493E12.1	-8.17	2.87e-15	1.2e-12	-0.34	-0.35	Tuberculosis;	chr2:61242115	chr2:61151433~61162105:-
THCA	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	8.17	2.87e-15	1.2e-12	0.56	0.35	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
THCA	cis	rs6565180	1	rs68051857	ENSG00000183604.13	SMG1P5	-8.17	2.87e-15	1.21e-12	-0.35	-0.35	Tonsillectomy;	chr16:30348690	chr16:30267553~30335374:-
THCA	cis	rs6565180	1	rs6565180	ENSG00000183604.13	SMG1P5	-8.17	2.87e-15	1.21e-12	-0.35	-0.35	Tonsillectomy;	chr16:30350020	chr16:30267553~30335374:-
THCA	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	8.17	2.88e-15	1.21e-12	0.35	0.35	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
THCA	cis	rs9649213	0.593	rs55825602	ENSG00000272950.1	RP11-307C18.1	8.17	2.88e-15	1.21e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr7:98322853~98323430:+
THCA	cis	rs4072705	1	rs4838201	ENSG00000224020.1	MIR181A2HG	-8.17	2.88e-15	1.21e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124698338	chr9:124658467~124698631:+
THCA	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-8.17	2.9e-15	1.21e-12	-0.44	-0.35	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
THCA	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-8.17	2.9e-15	1.21e-12	-0.44	-0.35	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
THCA	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-8.17	2.9e-15	1.21e-12	-0.44	-0.35	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
THCA	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-8.17	2.9e-15	1.22e-12	-0.42	-0.35	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
THCA	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	8.17	2.9e-15	1.22e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
THCA	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	8.17	2.9e-15	1.22e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
THCA	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	8.17	2.9e-15	1.22e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
THCA	cis	rs9649213	0.574	rs3801251	ENSG00000272950.1	RP11-307C18.1	8.17	2.91e-15	1.22e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs3779193	ENSG00000272950.1	RP11-307C18.1	8.17	2.91e-15	1.22e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs12704989	ENSG00000272950.1	RP11-307C18.1	8.17	2.91e-15	1.22e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr7:98322853~98323430:+
THCA	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-8.17	2.92e-15	1.22e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
THCA	cis	rs73607972	0.598	rs35726119	ENSG00000275191.1	RP11-36I17.2	-8.17	2.94e-15	1.23e-12	-0.52	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53521927	chr16:53628256~53628816:-
THCA	cis	rs7015263	0.573	rs6999654	ENSG00000254231.1	CTD-2284J15.1	-8.17	2.95e-15	1.23e-12	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:86275434	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.573	rs17680712	ENSG00000254231.1	CTD-2284J15.1	-8.17	2.95e-15	1.23e-12	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:86288546	chr8:86333274~86343314:-
THCA	cis	rs910316	0.783	rs11850751	ENSG00000279594.1	RP11-950C14.10	8.17	2.96e-15	1.24e-12	0.33	0.35	Height;	chr14:75123410	chr14:75011269~75012851:-
THCA	cis	rs7208859	0.673	rs7211776	ENSG00000266490.1	CTD-2349P21.9	8.17	2.96e-15	1.24e-12	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30792372~30792833:+
THCA	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-8.17	2.97e-15	1.24e-12	-0.42	-0.35	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
THCA	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-8.17	2.97e-15	1.24e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
THCA	cis	rs9649213	0.593	rs56286037	ENSG00000272950.1	RP11-307C18.1	8.17	2.97e-15	1.24e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98390210	chr7:98322853~98323430:+
THCA	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-8.17	2.98e-15	1.25e-12	-0.5	-0.35	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-8.17	2.98e-15	1.25e-12	-0.5	-0.35	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
THCA	cis	rs910316	1	rs2300601	ENSG00000279594.1	RP11-950C14.10	8.17	2.98e-15	1.25e-12	0.33	0.35	Height;	chr14:75172868	chr14:75011269~75012851:-
THCA	cis	rs9473147	0.516	rs9369695	ENSG00000270761.1	RP11-385F7.1	-8.17	2.98e-15	1.25e-12	-0.29	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47472829	chr6:47477243~47477572:-
THCA	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	8.17	2.98e-15	1.25e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	8.17	2.98e-15	1.25e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	8.17	2.98e-15	1.25e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
THCA	cis	rs17684571	0.751	rs1903332	ENSG00000231441.1	RP11-472M19.2	-8.17	2.98e-15	1.25e-12	-0.42	-0.35	Schizophrenia;	chr6:56857437	chr6:56844002~56864078:+
THCA	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	8.16	2.99e-15	1.25e-12	0.39	0.35	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
THCA	cis	rs11673344	0.504	rs8105065	ENSG00000226686.6	LINC01535	8.16	2.99e-15	1.25e-12	0.39	0.35	Obesity-related traits;	chr19:37141003	chr19:37251912~37265535:+
THCA	cis	rs6565180	0.889	rs8051096	ENSG00000183604.13	SMG1P5	-8.16	3.01e-15	1.26e-12	-0.36	-0.35	Tonsillectomy;	chr16:30336410	chr16:30267553~30335374:-
THCA	cis	rs2439831	0.867	rs496584	ENSG00000249839.1	AC011330.5	-8.16	3.01e-15	1.26e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43539725	chr15:43663654~43684339:-
THCA	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	8.16	3.01e-15	1.26e-12	0.33	0.35	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
THCA	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-8.16	3.02e-15	1.26e-12	-0.42	-0.35	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-8.16	3.02e-15	1.26e-12	-0.42	-0.35	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-8.16	3.02e-15	1.26e-12	-0.42	-0.35	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
THCA	cis	rs11673344	0.504	rs2118208	ENSG00000226686.6	LINC01535	8.16	3.02e-15	1.26e-12	0.39	0.35	Obesity-related traits;	chr19:37135573	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs2118209	ENSG00000226686.6	LINC01535	8.16	3.02e-15	1.26e-12	0.39	0.35	Obesity-related traits;	chr19:37135618	chr19:37251912~37265535:+
THCA	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	8.16	3.03e-15	1.27e-12	0.42	0.35	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
THCA	cis	rs6452524	0.522	rs13161662	ENSG00000249664.1	CTD-2227C6.2	-8.16	3.05e-15	1.27e-12	-0.46	-0.35	Hypertension (SNP x SNP interaction);	chr5:83209777	chr5:83012285~83013109:-
THCA	cis	rs9640161	0.83	rs36069544	ENSG00000261305.1	RP4-584D14.7	8.16	3.05e-15	1.27e-12	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150364449	chr7:150341771~150342607:+
THCA	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-8.16	3.06e-15	1.28e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
THCA	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	8.16	3.06e-15	1.28e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
THCA	cis	rs11673344	0.523	rs2891766	ENSG00000226686.6	LINC01535	8.16	3.06e-15	1.28e-12	0.39	0.35	Obesity-related traits;	chr19:37037057	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs7245453	ENSG00000226686.6	LINC01535	8.16	3.06e-15	1.28e-12	0.39	0.35	Obesity-related traits;	chr19:37043447	chr19:37251912~37265535:+
THCA	cis	rs2562456	0.833	rs2562507	ENSG00000268555.1	RP11-678G14.3	-8.16	3.06e-15	1.28e-12	-0.49	-0.35	Pain;	chr19:21543535	chr19:21570822~21587322:-
THCA	cis	rs12594515	0.587	rs8033024	ENSG00000259200.1	RP11-718O11.1	-8.16	3.06e-15	1.28e-12	-0.45	-0.35	Weight;Waist circumference;	chr15:45705898	chr15:45705078~45931069:+
THCA	cis	rs7569084	0.687	rs11675538	ENSG00000234255.7	AC012370.3	8.16	3.07e-15	1.28e-12	0.4	0.35	Sum eosinophil basophil counts;	chr2:65459327	chr2:65439888~65456571:-
THCA	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-8.16	3.07e-15	1.28e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
THCA	cis	rs922182	0.557	rs4776662	ENSG00000275785.1	RP11-111E14.2	-8.16	3.07e-15	1.28e-12	-0.42	-0.35	Blood protein levels;	chr15:63911363	chr15:63890030~63890317:+
THCA	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
THCA	cis	rs673078	0.607	rs2784	ENSG00000275409.1	RP11-131L12.4	-8.16	3.08e-15	1.29e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118311745	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7302387	ENSG00000275409.1	RP11-131L12.4	-8.16	3.08e-15	1.29e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118316546	chr12:118430147~118430699:+
THCA	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-8.16	3.09e-15	1.29e-12	-0.41	-0.35	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
THCA	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	8.16	3.09e-15	1.29e-12	0.5	0.35	Height;	chr4:57019797	chr4:56960927~56961373:-
THCA	cis	rs6504108	0.624	rs1316657	ENSG00000278765.1	RP5-890E16.5	-8.16	3.09e-15	1.29e-12	-0.39	-0.35	Body mass index;	chr17:48174029	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs1002330	ENSG00000278765.1	RP5-890E16.5	-8.16	3.09e-15	1.29e-12	-0.39	-0.35	Body mass index;	chr17:48176153	chr17:48066704~48067293:-
THCA	cis	rs910316	0.763	rs175016	ENSG00000279594.1	RP11-950C14.10	-8.16	3.1e-15	1.29e-12	-0.32	-0.35	Height;	chr14:74992930	chr14:75011269~75012851:-
THCA	cis	rs910316	0.935	rs3742771	ENSG00000279594.1	RP11-950C14.10	8.16	3.1e-15	1.29e-12	0.33	0.35	Height;	chr14:75132944	chr14:75011269~75012851:-
THCA	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-8.16	3.1e-15	1.3e-12	-0.36	-0.35	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
THCA	cis	rs2562456	0.754	rs55771551	ENSG00000268555.1	RP11-678G14.3	8.16	3.1e-15	1.3e-12	0.49	0.35	Pain;	chr19:21563578	chr19:21570822~21587322:-
THCA	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	8.16	3.1e-15	1.3e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
THCA	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	8.16	3.1e-15	1.3e-12	0.31	0.35	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
THCA	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-8.16	3.11e-15	1.3e-12	-0.61	-0.35	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
THCA	cis	rs42490	0.625	rs43229	ENSG00000251136.7	RP11-37B2.1	-8.16	3.11e-15	1.3e-12	-0.3	-0.35	Leprosy;	chr8:89826558	chr8:89609409~89757727:-
THCA	cis	rs3747113	1	rs35303215	ENSG00000128262.7	POM121L9P	-8.16	3.11e-15	1.3e-12	-0.4	-0.35	Gut microbiome composition (summer);	chr22:24405567	chr22:24251828~24265525:+
THCA	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	8.16	3.11e-15	1.3e-12	0.33	0.35	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
THCA	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-8.16	3.12e-15	1.3e-12	-0.42	-0.35	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
THCA	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	8.16	3.13e-15	1.31e-12	0.4	0.35	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
THCA	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-8.16	3.13e-15	1.31e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-8.16	3.13e-15	1.31e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-8.16	3.13e-15	1.31e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
THCA	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	8.16	3.13e-15	1.31e-12	0.61	0.35	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
THCA	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-8.16	3.13e-15	1.31e-12	-0.42	-0.35	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
THCA	cis	rs2839186	0.77	rs2330353	ENSG00000239415.1	AP001469.9	8.16	3.13e-15	1.31e-12	0.37	0.35	Testicular germ cell tumor;	chr21:46249734	chr21:46251549~46254133:-
THCA	cis	rs11673344	0.504	rs4805204	ENSG00000226686.6	LINC01535	8.16	3.14e-15	1.31e-12	0.39	0.35	Obesity-related traits;	chr19:37136666	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs4805205	ENSG00000226686.6	LINC01535	8.16	3.14e-15	1.31e-12	0.39	0.35	Obesity-related traits;	chr19:37136693	chr19:37251912~37265535:+
THCA	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-8.16	3.14e-15	1.31e-12	-0.39	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
THCA	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	8.16	3.14e-15	1.31e-12	0.45	0.35	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.507	rs223322	ENSG00000251288.2	RP11-10L12.2	-8.16	3.15e-15	1.32e-12	-0.47	-0.35	Type 2 diabetes;	chr4:102879037	chr4:102751401~102752641:+
THCA	cis	rs6504108	0.624	rs17681336	ENSG00000278765.1	RP5-890E16.5	-8.16	3.16e-15	1.32e-12	-0.39	-0.35	Body mass index;	chr17:48172430	chr17:48066704~48067293:-
THCA	cis	rs9329221	0.527	rs4452832	ENSG00000261451.1	RP11-981G7.1	-8.16	3.16e-15	1.32e-12	-0.45	-0.35	Neuroticism;	chr8:10463044	chr8:10433672~10438312:+
THCA	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	8.16	3.17e-15	1.32e-12	0.42	0.35	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	8.16	3.17e-15	1.32e-12	0.42	0.35	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	8.16	3.17e-15	1.32e-12	0.42	0.35	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	8.16	3.18e-15	1.33e-12	0.42	0.35	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
THCA	cis	rs11603023	0.569	rs573905	ENSG00000255422.1	AP002954.4	-8.16	3.18e-15	1.33e-12	-0.4	-0.35	Cholesterol, total;	chr11:118701558	chr11:118704607~118750263:+
THCA	cis	rs516805	0.715	rs11154087	ENSG00000279453.1	RP3-425C14.4	8.16	3.18e-15	1.33e-12	0.37	0.35	Lymphocyte counts;	chr6:122575484	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs11968579	ENSG00000279453.1	RP3-425C14.4	8.16	3.18e-15	1.33e-12	0.37	0.35	Lymphocyte counts;	chr6:122575950	chr6:122436789~122439223:-
THCA	cis	rs812925	0.519	rs2463099	ENSG00000271889.1	RP11-493E12.1	-8.16	3.18e-15	1.33e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61391176	chr2:61151433~61162105:-
THCA	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	8.16	3.19e-15	1.33e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
THCA	cis	rs11673344	0.504	rs11666786	ENSG00000226686.6	LINC01535	8.16	3.19e-15	1.33e-12	0.39	0.35	Obesity-related traits;	chr19:37133947	chr19:37251912~37265535:+
THCA	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-8.16	3.19e-15	1.33e-12	-0.47	-0.35	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
THCA	cis	rs2562456	0.761	rs35008138	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21548822	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs2681388	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21549451	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.876	rs2681370	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21554036	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.876	rs11668606	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21554618	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.876	rs2681395	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21555338	chr19:21570822~21587322:-
THCA	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-8.16	3.2e-15	1.34e-12	-0.5	-0.35	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
THCA	cis	rs11696845	0.966	rs1467473	ENSG00000276223.1	RP4-781B1.5	8.15	3.21e-15	1.34e-12	0.43	0.35	Obesity-related traits;	chr20:44743337	chr20:44746642~44747201:+
THCA	cis	rs6545883	0.524	rs2694618	ENSG00000271889.1	RP11-493E12.1	8.15	3.21e-15	1.34e-12	0.34	0.35	Tuberculosis;	chr2:61309849	chr2:61151433~61162105:-
THCA	cis	rs240993	0.812	rs118203	ENSG00000230177.1	RP5-1112D6.4	-8.15	3.22e-15	1.34e-12	-0.36	-0.35	Inflammatory skin disease;Psoriasis;	chr6:111337017	chr6:111277932~111278742:+
THCA	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-8.15	3.22e-15	1.34e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
THCA	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.23e-15	1.35e-12	-0.57	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-8.15	3.24e-15	1.35e-12	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
THCA	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	8.15	3.24e-15	1.35e-12	0.44	0.35	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
THCA	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-8.15	3.26e-15	1.36e-12	-0.42	-0.35	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
THCA	cis	rs62103177	0.81	rs62096745	ENSG00000261126.6	RP11-795F19.1	8.15	3.26e-15	1.36e-12	0.42	0.35	Opioid sensitivity;	chr18:79859135	chr18:80046900~80095482:+
THCA	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000237664.1	LINC00316	-8.15	3.26e-15	1.36e-12	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45338590~45341990:-
THCA	cis	rs10411161	0.702	rs892039	ENSG00000269483.1	AC006272.1	8.15	3.27e-15	1.36e-12	0.5	0.35	Breast cancer;	chr19:51893288	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs2867319	ENSG00000269483.1	AC006272.1	8.15	3.27e-15	1.36e-12	0.5	0.35	Breast cancer;	chr19:51893907	chr19:51839924~51843324:-
THCA	cis	rs42490	0.664	rs43226	ENSG00000251136.7	RP11-37B2.1	-8.15	3.27e-15	1.36e-12	-0.3	-0.35	Leprosy;	chr8:89809048	chr8:89609409~89757727:-
THCA	cis	rs42490	0.664	rs422559	ENSG00000251136.7	RP11-37B2.1	-8.15	3.27e-15	1.36e-12	-0.3	-0.35	Leprosy;	chr8:89809121	chr8:89609409~89757727:-
THCA	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	8.15	3.27e-15	1.36e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
THCA	cis	rs4713118	0.699	rs200969	ENSG00000280107.1	AL022393.9	-8.15	3.27e-15	1.36e-12	-0.42	-0.35	Parkinson's disease;	chr6:27891675	chr6:28170845~28172521:+
THCA	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	8.15	3.27e-15	1.36e-12	0.44	0.35	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
THCA	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-8.15	3.28e-15	1.37e-12	-0.45	-0.35	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
THCA	cis	rs62103177	0.81	rs62103175	ENSG00000261126.6	RP11-795F19.1	8.15	3.28e-15	1.37e-12	0.4	0.35	Opioid sensitivity;	chr18:79862467	chr18:80046900~80095482:+
THCA	cis	rs2408955	0.561	rs9971924	ENSG00000258273.1	RP11-370I10.4	8.15	3.29e-15	1.37e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48086049	chr12:48333755~48333901:-
THCA	cis	rs2408955	0.522	rs7139330	ENSG00000258273.1	RP11-370I10.4	8.15	3.29e-15	1.37e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48089701	chr12:48333755~48333901:-
THCA	cis	rs2408955	0.522	rs2051851	ENSG00000258273.1	RP11-370I10.4	8.15	3.29e-15	1.37e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48092157	chr12:48333755~48333901:-
THCA	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-8.15	3.29e-15	1.37e-12	-0.46	-0.35	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
THCA	cis	rs7849270	1	rs3814492	ENSG00000268707.1	RP11-247A12.7	-8.15	3.29e-15	1.37e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129110943	chr9:129170434~129170940:+
THCA	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	8.15	3.29e-15	1.37e-12	0.4	0.35	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
THCA	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-8.15	3.3e-15	1.37e-12	-0.45	-0.35	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
THCA	cis	rs9813712	0.526	rs62281641	ENSG00000228252.7	COL6A4P2	-8.15	3.3e-15	1.38e-12	-0.35	-0.35	Response to amphetamines;	chr3:130235668	chr3:130212823~130273806:+
THCA	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-8.15	3.31e-15	1.38e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
THCA	cis	rs17684571	0.872	rs3002010	ENSG00000231441.1	RP11-472M19.2	8.15	3.32e-15	1.38e-12	0.45	0.35	Schizophrenia;	chr6:56760050	chr6:56844002~56864078:+
THCA	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	8.15	3.32e-15	1.38e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
THCA	cis	rs910316	1	rs175492	ENSG00000279594.1	RP11-950C14.10	8.15	3.32e-15	1.38e-12	0.32	0.35	Height;	chr14:75078517	chr14:75011269~75012851:-
THCA	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-8.15	3.33e-15	1.39e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
THCA	cis	rs922182	0.557	rs7161953	ENSG00000275785.1	RP11-111E14.2	-8.15	3.33e-15	1.39e-12	-0.42	-0.35	Blood protein levels;	chr15:63910688	chr15:63890030~63890317:+
THCA	cis	rs4819052	0.851	rs9974891	ENSG00000237664.1	LINC00316	-8.15	3.33e-15	1.39e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45338590~45341990:-
THCA	cis	rs4814920	0.818	rs4813376	ENSG00000233895.1	RP1-122P22.2	8.15	3.34e-15	1.39e-12	0.38	0.35	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19757708~19809675:+
THCA	cis	rs853679	0.513	rs13437444	ENSG00000226314.6	ZNF192P1	-8.15	3.34e-15	1.39e-12	-0.53	-0.35	Depression;	chr6:28103220	chr6:28161781~28169594:+
THCA	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-8.15	3.34e-15	1.39e-12	-0.44	-0.35	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
THCA	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	8.15	3.35e-15	1.39e-12	0.33	0.35	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
THCA	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	8.15	3.35e-15	1.39e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
THCA	cis	rs2712184	0.756	rs2712164	ENSG00000229352.1	AC007563.3	-8.15	3.35e-15	1.4e-12	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216795193	chr2:216799608~216805335:+
THCA	cis	rs9828933	0.832	rs3774723	ENSG00000280620.1	SCAANT1	8.15	3.36e-15	1.4e-12	0.56	0.35	Type 2 diabetes;	chr3:63976663	chr3:63911518~63911772:-
THCA	cis	rs9847710	0.524	rs11712910	ENSG00000242142.1	SERBP1P3	8.15	3.36e-15	1.4e-12	0.44	0.35	Ulcerative colitis;	chr3:53060178	chr3:53064283~53065091:-
THCA	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-8.15	3.37e-15	1.4e-12	-0.44	-0.35	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-8.15	3.37e-15	1.4e-12	-0.44	-0.35	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
THCA	cis	rs7208859	0.673	rs2470251	ENSG00000266490.1	CTD-2349P21.9	8.15	3.38e-15	1.41e-12	0.45	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30792372~30792833:+
THCA	cis	rs910316	0.591	rs7157158	ENSG00000279594.1	RP11-950C14.10	8.15	3.38e-15	1.41e-12	0.32	0.35	Height;	chr14:74990535	chr14:75011269~75012851:-
THCA	cis	rs9500256	0.966	rs1322446	ENSG00000215190.7	LINC00680	-8.15	3.38e-15	1.41e-12	-0.4	-0.35	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57946074~57961501:-
THCA	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-8.15	3.39e-15	1.41e-12	-0.37	-0.35	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
THCA	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-8.15	3.41e-15	1.42e-12	-0.42	-0.35	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
THCA	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-8.15	3.41e-15	1.42e-12	-0.42	-0.35	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000237664.1	LINC00316	-8.15	3.41e-15	1.42e-12	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45338590~45341990:-
THCA	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-8.15	3.42e-15	1.42e-12	-0.46	-0.35	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
THCA	cis	rs1707322	1	rs10789486	ENSG00000234329.1	RP11-767N6.2	8.15	3.42e-15	1.42e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45651039~45651826:-
THCA	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	8.15	3.44e-15	1.43e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
THCA	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-8.15	3.45e-15	1.43e-12	-0.41	-0.35	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
THCA	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-8.14	3.45e-15	1.44e-12	-0.43	-0.35	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
THCA	cis	rs375066	0.935	rs396973	ENSG00000267058.1	RP11-15A1.3	8.14	3.46e-15	1.44e-12	0.29	0.35	Breast cancer;	chr19:43895154	chr19:43891804~43901805:-
THCA	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-8.14	3.46e-15	1.44e-12	-0.42	-0.35	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-8.14	3.46e-15	1.44e-12	-0.42	-0.35	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
THCA	cis	rs11148252	0.904	rs9526927	ENSG00000235660.1	LINC00345	-8.14	3.47e-15	1.44e-12	-0.43	-0.35	Lewy body disease;	chr13:52477492	chr13:52484161~52484680:-
THCA	cis	rs4934494	0.911	rs7081788	ENSG00000232936.4	RP11-80H5.2	8.14	3.47e-15	1.44e-12	0.46	0.35	Red blood cell count;	chr10:89648999	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.911	rs34486602	ENSG00000232936.4	RP11-80H5.2	8.14	3.47e-15	1.44e-12	0.46	0.35	Red blood cell count;	chr10:89655895	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.911	rs6586213	ENSG00000232936.4	RP11-80H5.2	8.14	3.47e-15	1.44e-12	0.46	0.35	Red blood cell count;	chr10:89656327	chr10:89645282~89650667:+
THCA	cis	rs4819052	0.851	rs1056100	ENSG00000237664.1	LINC00316	-8.14	3.47e-15	1.44e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45338590~45341990:-
THCA	cis	rs673078	0.607	rs17441214	ENSG00000275409.1	RP11-131L12.4	-8.14	3.48e-15	1.45e-12	-0.45	-0.35	Glucose homeostasis traits;	chr12:118436721	chr12:118430147~118430699:+
THCA	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-8.14	3.48e-15	1.45e-12	-0.45	-0.35	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
THCA	cis	rs1707322	1	rs7538978	ENSG00000234329.1	RP11-767N6.2	-8.14	3.48e-15	1.45e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45651039~45651826:-
THCA	cis	rs416603	0.967	rs11640138	ENSG00000262636.1	CTD-3088G3.4	8.14	3.49e-15	1.45e-12	0.44	0.35	Type 1 diabetes;	chr16:11268872	chr16:11380859~11381118:-
THCA	cis	rs947583	0.588	rs9321530	ENSG00000231028.7	LINC00271	-8.14	3.49e-15	1.45e-12	-0.28	-0.35	Phosphorus levels;	chr6:135790941	chr6:135497801~135716055:+
THCA	cis	rs7811142	0.945	rs6974282	ENSG00000242294.5	STAG3L5P	8.14	3.5e-15	1.45e-12	0.24	0.35	Platelet count;	chr7:100500672	chr7:100336079~100351900:+
THCA	cis	rs9649213	0.593	rs1076272	ENSG00000272950.1	RP11-307C18.1	8.14	3.5e-15	1.46e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr7:98322853~98323430:+
THCA	cis	rs73607972	0.696	rs7194983	ENSG00000275191.1	RP11-36I17.2	-8.14	3.5e-15	1.46e-12	-0.5	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525100	chr16:53628256~53628816:-
THCA	cis	rs7291412	0.54	rs9627391	ENSG00000231711.2	LINC00899	8.14	3.53e-15	1.47e-12	0.29	0.35	Dupuytren's disease;Subjective well-being;	chr22:46051217	chr22:46039907~46044853:-
THCA	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-8.14	3.53e-15	1.47e-12	-0.46	-0.35	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
THCA	cis	rs2712184	0.655	rs1003622	ENSG00000229352.1	AC007563.3	-8.14	3.53e-15	1.47e-12	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216788885	chr2:216799608~216805335:+
THCA	cis	rs7208859	0.673	rs9912122	ENSG00000266490.1	CTD-2349P21.9	8.14	3.53e-15	1.47e-12	0.45	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30792372~30792833:+
THCA	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-8.14	3.54e-15	1.47e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
THCA	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-8.14	3.54e-15	1.47e-12	-0.42	-0.35	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000242086.7	LINC00969	8.14	3.55e-15	1.47e-12	0.35	0.35	Pancreatic cancer;	chr3:196009869	chr3:195658062~195739964:+
THCA	cis	rs4927850	1	rs4927704	ENSG00000242086.7	LINC00969	8.14	3.55e-15	1.47e-12	0.35	0.35	Pancreatic cancer;	chr3:196011357	chr3:195658062~195739964:+
THCA	cis	rs4927850	1	rs4927848	ENSG00000242086.7	LINC00969	8.14	3.55e-15	1.47e-12	0.35	0.35	Pancreatic cancer;	chr3:196011535	chr3:195658062~195739964:+
THCA	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-8.14	3.56e-15	1.48e-12	-0.32	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-8.14	3.58e-15	1.49e-12	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
THCA	cis	rs1858037	0.867	rs55945621	ENSG00000237979.1	AC007389.1	8.14	3.58e-15	1.49e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65388220	chr2:65500993~65502138:-
THCA	cis	rs2562456	0.755	rs1879234	ENSG00000268555.1	RP11-678G14.3	-8.14	3.58e-15	1.49e-12	-0.49	-0.35	Pain;	chr19:21521677	chr19:21570822~21587322:-
THCA	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	8.14	3.59e-15	1.49e-12	0.42	0.35	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
THCA	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-8.14	3.61e-15	1.5e-12	-0.37	-0.35	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
THCA	cis	rs7015263	0.573	rs7007174	ENSG00000254231.1	CTD-2284J15.1	-8.14	3.61e-15	1.5e-12	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:86275422	chr8:86333274~86343314:-
THCA	cis	rs9309473	0.583	rs6718864	ENSG00000163016.8	ALMS1P	8.14	3.61e-15	1.5e-12	0.46	0.35	Metabolite levels;	chr2:73347463	chr2:73644919~73685576:+
THCA	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-8.14	3.61e-15	1.5e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
THCA	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-8.14	3.62e-15	1.5e-12	-0.31	-0.35	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
THCA	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-8.14	3.63e-15	1.51e-12	-0.29	-0.35	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
THCA	cis	rs2929278	0.561	rs2927071	ENSG00000166763.7	STRCP1	8.14	3.63e-15	1.51e-12	0.39	0.35	Schizophrenia;	chr15:43626883	chr15:43699488~43718184:-
THCA	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	8.14	3.63e-15	1.51e-12	0.45	0.35	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
THCA	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-8.14	3.64e-15	1.51e-12	-0.46	-0.35	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
THCA	cis	rs984222	0.617	rs12123458	ENSG00000231365.4	RP11-418J17.1	8.14	3.65e-15	1.51e-12	0.35	0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119211635	chr1:119140396~119275973:+
THCA	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	8.14	3.65e-15	1.52e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
THCA	cis	rs1858037	0.867	rs72621551	ENSG00000237979.1	AC007389.1	8.14	3.66e-15	1.52e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65388087	chr2:65500993~65502138:-
THCA	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	8.14	3.67e-15	1.52e-12	0.59	0.35	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
THCA	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	8.14	3.68e-15	1.53e-12	0.44	0.35	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
THCA	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-8.14	3.68e-15	1.53e-12	-0.44	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
THCA	cis	rs11696845	1	rs1467472	ENSG00000276223.1	RP4-781B1.5	-8.14	3.68e-15	1.53e-12	-0.43	-0.35	Obesity-related traits;	chr20:44742910	chr20:44746642~44747201:+
THCA	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	8.14	3.69e-15	1.53e-12	0.24	0.35	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
THCA	cis	rs42490	0.614	rs445172	ENSG00000251136.7	RP11-37B2.1	-8.14	3.69e-15	1.53e-12	-0.3	-0.35	Leprosy;	chr8:89808322	chr8:89609409~89757727:-
THCA	cis	rs853679	0.723	rs9366718	ENSG00000219392.1	RP1-265C24.5	-8.14	3.7e-15	1.53e-12	-0.49	-0.35	Depression;	chr6:28237724	chr6:28115628~28116551:+
THCA	cis	rs9309473	0.555	rs2901437	ENSG00000163016.8	ALMS1P	8.14	3.7e-15	1.54e-12	0.46	0.35	Metabolite levels;	chr2:73369896	chr2:73644919~73685576:+
THCA	cis	rs11673344	0.504	rs10402907	ENSG00000226686.6	LINC01535	8.13	3.71e-15	1.54e-12	0.39	0.35	Obesity-related traits;	chr19:37112874	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.563	rs4805199	ENSG00000226686.6	LINC01535	8.13	3.71e-15	1.54e-12	0.39	0.35	Obesity-related traits;	chr19:37115527	chr19:37251912~37265535:+
THCA	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	8.13	3.71e-15	1.54e-12	0.36	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
THCA	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	8.13	3.71e-15	1.54e-12	0.36	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000237664.1	LINC00316	-8.13	3.71e-15	1.54e-12	-0.38	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45338590~45341990:-
THCA	cis	rs4072705	0.967	rs10818985	ENSG00000224020.1	MIR181A2HG	-8.13	3.71e-15	1.54e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124688292	chr9:124658467~124698631:+
THCA	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-8.13	3.72e-15	1.54e-12	-0.42	-0.35	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
THCA	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-8.13	3.73e-15	1.55e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-8.13	3.73e-15	1.55e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-8.13	3.73e-15	1.55e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
THCA	cis	rs7208859	0.623	rs8082537	ENSG00000266490.1	CTD-2349P21.9	8.13	3.73e-15	1.55e-12	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30792372~30792833:+
THCA	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	8.13	3.74e-15	1.55e-12	0.4	0.35	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
THCA	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-8.13	3.75e-15	1.55e-12	-0.49	-0.35	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
THCA	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-8.13	3.75e-15	1.55e-12	-0.42	-0.35	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
THCA	cis	rs8114671	0.836	rs6120778	ENSG00000269202.1	RP4-614O4.12	-8.13	3.76e-15	1.56e-12	-0.3	-0.35	Height;	chr20:34977366	chr20:35201747~35203288:-
THCA	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	8.13	3.77e-15	1.56e-12	0.42	0.35	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
THCA	cis	rs4819052	0.851	rs2838856	ENSG00000237664.1	LINC00316	-8.13	3.77e-15	1.56e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45338590~45341990:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000206090.4	AP000350.7	8.13	3.77e-15	1.56e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23939998~23942798:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000206090.4	AP000350.7	8.13	3.77e-15	1.56e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23939998~23942798:+
THCA	cis	rs2522056	0.808	rs17771891	ENSG00000233006.5	AC034220.3	8.13	3.77e-15	1.56e-12	0.31	0.35	Fibrinogen;Lymphocyte counts;	chr5:132408510	chr5:132311285~132369916:-
THCA	cis	rs11148252	0.5	rs342768	ENSG00000235660.1	LINC00345	-8.13	3.78e-15	1.56e-12	-0.42	-0.35	Lewy body disease;	chr13:52634747	chr13:52484161~52484680:-
THCA	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	8.13	3.78e-15	1.57e-12	0.42	0.35	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
THCA	cis	rs2120243	0.533	rs1392798	ENSG00000244515.1	KRT18P34	8.13	3.79e-15	1.57e-12	0.4	0.35	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338498	chr3:157162663~157163932:-
THCA	cis	rs11673344	0.504	rs8110796	ENSG00000226686.6	LINC01535	8.13	3.79e-15	1.57e-12	0.39	0.35	Obesity-related traits;	chr19:37132682	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs8111285	ENSG00000226686.6	LINC01535	8.13	3.79e-15	1.57e-12	0.39	0.35	Obesity-related traits;	chr19:37132747	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs6510591	ENSG00000226686.6	LINC01535	8.13	3.79e-15	1.57e-12	0.39	0.35	Obesity-related traits;	chr19:37133186	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs6510592	ENSG00000226686.6	LINC01535	8.13	3.79e-15	1.57e-12	0.39	0.35	Obesity-related traits;	chr19:37133430	chr19:37251912~37265535:+
THCA	cis	rs947583	0.588	rs9321532	ENSG00000231028.7	LINC00271	8.13	3.79e-15	1.57e-12	0.28	0.35	Phosphorus levels;	chr6:135791078	chr6:135497801~135716055:+
THCA	cis	rs11673344	0.504	rs8099987	ENSG00000226686.6	LINC01535	8.13	3.8e-15	1.58e-12	0.39	0.35	Obesity-related traits;	chr19:37132570	chr19:37251912~37265535:+
THCA	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	8.13	3.81e-15	1.58e-12	0.66	0.35	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
THCA	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-8.13	3.81e-15	1.58e-12	-0.34	-0.35	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
THCA	cis	rs860295	0.966	rs821551	ENSG00000225855.5	RUSC1-AS1	8.13	3.82e-15	1.58e-12	0.24	0.35	Body mass index;	chr1:155718789	chr1:155316863~155324176:-
THCA	cis	rs812925	0.537	rs2593620	ENSG00000271889.1	RP11-493E12.1	-8.13	3.82e-15	1.58e-12	-0.34	-0.35	Immature fraction of reticulocytes;	chr2:61386126	chr2:61151433~61162105:-
THCA	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-8.13	3.82e-15	1.58e-12	-0.36	-0.35	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
THCA	cis	rs6844153	1	rs74642474	ENSG00000240005.4	RP11-293A21.1	-8.13	3.84e-15	1.59e-12	-0.5	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26854979	chr4:26859806~26860599:-
THCA	cis	rs595244	0.706	rs4775770	ENSG00000259705.1	RP11-227D13.1	-8.13	3.85e-15	1.59e-12	-0.51	-0.35	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48652366	chr15:48645951~48652016:+
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-8.13	3.85e-15	1.59e-12	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
THCA	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	8.13	3.85e-15	1.6e-12	0.43	0.35	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	8.13	3.86e-15	1.6e-12	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
THCA	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-8.13	3.86e-15	1.6e-12	-0.34	-0.35	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
THCA	cis	rs910316	0.763	rs1548807	ENSG00000279594.1	RP11-950C14.10	8.13	3.87e-15	1.6e-12	0.32	0.35	Height;	chr14:75012879	chr14:75011269~75012851:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-8.13	3.88e-15	1.6e-12	-0.55	-0.35	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
THCA	cis	rs7727544	0.631	rs13357280	ENSG00000224431.1	AC063976.7	8.13	3.88e-15	1.61e-12	0.31	0.35	Blood metabolite levels;	chr5:132264494	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.594	rs10479000	ENSG00000224431.1	AC063976.7	8.13	3.88e-15	1.61e-12	0.31	0.35	Blood metabolite levels;	chr5:132271709	chr5:132199456~132203487:+
THCA	cis	rs910316	0.874	rs61980828	ENSG00000279594.1	RP11-950C14.10	-8.13	3.89e-15	1.61e-12	-0.33	-0.35	Height;	chr14:75163675	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs910316	ENSG00000279594.1	RP11-950C14.10	8.13	3.89e-15	1.61e-12	0.33	0.35	Height;	chr14:75159339	chr14:75011269~75012851:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	8.13	3.89e-15	1.61e-12	0.42	0.35	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
THCA	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	8.13	3.9e-15	1.61e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
THCA	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	8.13	3.9e-15	1.61e-12	0.47	0.35	Height;	chr4:55401306	chr4:55363971~55395847:-
THCA	cis	rs910316	0.935	rs11159119	ENSG00000279594.1	RP11-950C14.10	-8.13	3.9e-15	1.61e-12	-0.33	-0.35	Height;	chr14:75170264	chr14:75011269~75012851:-
THCA	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	8.13	3.9e-15	1.62e-12	0.22	0.35	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
THCA	cis	rs12188164	0.61	rs6555242	ENSG00000221990.4	EXOC3-AS1	8.13	3.91e-15	1.62e-12	0.29	0.35	Cystic fibrosis severity;	chr5:416431	chr5:441498~443160:-
THCA	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	8.13	3.91e-15	1.62e-12	0.56	0.35	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
THCA	cis	rs62103177	0.683	rs13838	ENSG00000261126.6	RP11-795F19.1	8.13	3.92e-15	1.62e-12	0.4	0.35	Opioid sensitivity;	chr18:79903409	chr18:80046900~80095482:+
THCA	cis	rs812925	0.537	rs10196146	ENSG00000271889.1	RP11-493E12.1	-8.13	3.92e-15	1.62e-12	-0.34	-0.35	Immature fraction of reticulocytes;	chr2:61378244	chr2:61151433~61162105:-
THCA	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-8.13	3.92e-15	1.62e-12	-0.36	-0.35	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
THCA	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	8.13	3.93e-15	1.63e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
THCA	cis	rs11696845	1	rs1555299	ENSG00000276223.1	RP4-781B1.5	-8.13	3.94e-15	1.63e-12	-0.43	-0.35	Obesity-related traits;	chr20:44741465	chr20:44746642~44747201:+
THCA	cis	rs11696845	1	rs13038016	ENSG00000276223.1	RP4-781B1.5	-8.13	3.94e-15	1.63e-12	-0.43	-0.35	Obesity-related traits;	chr20:44741856	chr20:44746642~44747201:+
THCA	cis	rs11696845	1	rs13037759	ENSG00000276223.1	RP4-781B1.5	-8.13	3.94e-15	1.63e-12	-0.43	-0.35	Obesity-related traits;	chr20:44742051	chr20:44746642~44747201:+
THCA	cis	rs11696845	0.965	rs13038381	ENSG00000276223.1	RP4-781B1.5	-8.13	3.94e-15	1.63e-12	-0.43	-0.35	Obesity-related traits;	chr20:44742106	chr20:44746642~44747201:+
THCA	cis	rs4819052	0.765	rs2838868	ENSG00000237664.1	LINC00316	8.13	3.94e-15	1.63e-12	0.37	0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45338590~45341990:-
THCA	cis	rs507080	0.922	rs516153	ENSG00000278376.1	RP11-158I9.8	-8.13	3.95e-15	1.63e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118694053	chr11:118791254~118793137:+
THCA	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-8.13	3.96e-15	1.64e-12	-0.29	-0.35	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
THCA	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-8.13	3.97e-15	1.64e-12	-0.5	-0.35	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
THCA	cis	rs2562456	0.917	rs2562466	ENSG00000268555.1	RP11-678G14.3	-8.13	3.97e-15	1.64e-12	-0.49	-0.35	Pain;	chr19:21531402	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2562468	ENSG00000268555.1	RP11-678G14.3	-8.13	3.97e-15	1.64e-12	-0.49	-0.35	Pain;	chr19:21532048	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2562471	ENSG00000268555.1	RP11-678G14.3	-8.13	3.97e-15	1.64e-12	-0.49	-0.35	Pain;	chr19:21533017	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2681377	ENSG00000268555.1	RP11-678G14.3	-8.13	3.97e-15	1.64e-12	-0.49	-0.35	Pain;	chr19:21533718	chr19:21570822~21587322:-
THCA	cis	rs2288884	0.634	rs80309583	ENSG00000275055.1	CTC-471J1.11	-8.13	3.97e-15	1.64e-12	-0.34	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51996949	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.634	rs17835649	ENSG00000275055.1	CTC-471J1.11	-8.13	3.97e-15	1.64e-12	-0.34	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997362	chr19:52049007~52049754:+
THCA	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-8.13	3.97e-15	1.64e-12	-0.6	-0.35	Depression;	chr6:28129415	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-8.13	3.98e-15	1.64e-12	-0.45	-0.35	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-8.13	3.98e-15	1.64e-12	-0.45	-0.35	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
THCA	cis	rs910316	0.967	rs175479	ENSG00000279594.1	RP11-950C14.10	-8.13	3.98e-15	1.65e-12	-0.33	-0.35	Height;	chr14:75095168	chr14:75011269~75012851:-
THCA	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
THCA	cis	rs910316	1	rs876402	ENSG00000279594.1	RP11-950C14.10	-8.12	3.99e-15	1.65e-12	-0.33	-0.35	Height;	chr14:75135159	chr14:75011269~75012851:-
THCA	cis	rs1707322	1	rs10890365	ENSG00000234329.1	RP11-767N6.2	8.12	4e-15	1.65e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs1056101	ENSG00000237664.1	LINC00316	-8.12	4.01e-15	1.66e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45338590~45341990:-
THCA	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-8.12	4.02e-15	1.66e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
THCA	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	8.12	4.02e-15	1.66e-12	0.24	0.35	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
THCA	cis	rs9640161	0.783	rs35435439	ENSG00000261305.1	RP4-584D14.7	8.12	4.03e-15	1.67e-12	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150366445	chr7:150341771~150342607:+
THCA	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-8.12	4.03e-15	1.67e-12	-0.41	-0.35	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
THCA	cis	rs7208859	0.673	rs56846352	ENSG00000266490.1	CTD-2349P21.9	8.12	4.04e-15	1.67e-12	0.45	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30792372~30792833:+
THCA	cis	rs2562456	0.958	rs2562508	ENSG00000268555.1	RP11-678G14.3	-8.12	4.04e-15	1.67e-12	-0.48	-0.35	Pain;	chr19:21543479	chr19:21570822~21587322:-
THCA	cis	rs10411161	0.752	rs4584941	ENSG00000269483.1	AC006272.1	8.12	4.04e-15	1.67e-12	0.51	0.35	Breast cancer;	chr19:51888888	chr19:51839924~51843324:-
THCA	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	8.12	4.05e-15	1.67e-12	0.45	0.35	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
THCA	cis	rs1858037	0.867	rs2118305	ENSG00000237979.1	AC007389.1	8.12	4.05e-15	1.67e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65378086	chr2:65500993~65502138:-
THCA	cis	rs6723226	0.638	rs6543657	ENSG00000276334.1	AL133243.1	8.12	4.05e-15	1.67e-12	0.39	0.35	Intelligence (multi-trait analysis);	chr2:32480017	chr2:32521927~32523547:+
THCA	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-8.12	4.06e-15	1.68e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
THCA	cis	rs8114671	0.967	rs6142320	ENSG00000269202.1	RP4-614O4.12	8.12	4.06e-15	1.68e-12	0.29	0.35	Height;	chr20:35200390	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs6142321	ENSG00000269202.1	RP4-614O4.12	8.12	4.06e-15	1.68e-12	0.29	0.35	Height;	chr20:35200671	chr20:35201747~35203288:-
THCA	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-8.12	4.07e-15	1.68e-12	-0.4	-0.35	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-8.12	4.07e-15	1.68e-12	-0.4	-0.35	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
THCA	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	8.12	4.08e-15	1.69e-12	0.42	0.35	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
THCA	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-8.12	4.09e-15	1.69e-12	-0.42	-0.35	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
THCA	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-8.12	4.09e-15	1.69e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
THCA	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	8.12	4.09e-15	1.69e-12	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
THCA	cis	rs8114671	0.836	rs734308	ENSG00000269202.1	RP4-614O4.12	8.12	4.1e-15	1.69e-12	0.3	0.35	Height;	chr20:34984293	chr20:35201747~35203288:-
THCA	cis	rs11148252	0.904	rs7990581	ENSG00000235660.1	LINC00345	-8.12	4.12e-15	1.7e-12	-0.43	-0.35	Lewy body disease;	chr13:52445298	chr13:52484161~52484680:-
THCA	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-8.12	4.13e-15	1.7e-12	-0.49	-0.35	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
THCA	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	8.12	4.13e-15	1.7e-12	0.45	0.35	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
THCA	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-8.12	4.13e-15	1.71e-12	-0.42	-0.35	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-8.12	4.13e-15	1.71e-12	-0.45	-0.35	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-8.12	4.13e-15	1.71e-12	-0.45	-0.35	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
THCA	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
THCA	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-8.12	4.14e-15	1.71e-12	-0.42	-0.35	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
THCA	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-8.12	4.14e-15	1.71e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
THCA	cis	rs11148252	0.904	rs9568734	ENSG00000235660.1	LINC00345	-8.12	4.16e-15	1.71e-12	-0.43	-0.35	Lewy body disease;	chr13:52430087	chr13:52484161~52484680:-
THCA	cis	rs4664293	0.528	rs1549386	ENSG00000226266.5	AC009961.3	8.12	4.16e-15	1.72e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159558015	chr2:159670708~159712435:-
THCA	cis	rs7182621	0.509	rs12917012	ENSG00000259363.4	CTD-2054N24.2	-8.12	4.16e-15	1.72e-12	-0.42	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99807023~99877148:+
THCA	cis	rs7247513	0.964	rs12104149	ENSG00000230310.1	CTD-2192J16.11	-8.12	4.18e-15	1.72e-12	-0.42	-0.35	Bipolar disorder;	chr19:12610274	chr19:12552597~12553644:+
THCA	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	8.12	4.18e-15	1.72e-12	0.41	0.35	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
THCA	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-8.12	4.2e-15	1.73e-12	-0.42	-0.35	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-8.12	4.2e-15	1.73e-12	-0.42	-0.35	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-8.12	4.2e-15	1.73e-12	-0.42	-0.35	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-8.12	4.2e-15	1.73e-12	-0.42	-0.35	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
THCA	cis	rs3747113	0.865	rs9620384	ENSG00000128262.7	POM121L9P	-8.12	4.21e-15	1.74e-12	-0.39	-0.35	Gut microbiome composition (summer);	chr22:24379380	chr22:24251828~24265525:+
THCA	cis	rs9309473	0.528	rs11126396	ENSG00000163016.8	ALMS1P	8.12	4.21e-15	1.74e-12	0.47	0.35	Metabolite levels;	chr2:73338015	chr2:73644919~73685576:+
THCA	cis	rs737008	0.922	rs11074957	ENSG00000262703.1	RP11-485G7.6	-8.12	4.22e-15	1.74e-12	-0.41	-0.35	Obesity-related traits;	chr16:11284294	chr16:11348143~11349321:-
THCA	cis	rs526231	0.584	rs246914	ENSG00000175749.11	EIF3KP1	8.12	4.23e-15	1.75e-12	0.55	0.35	Primary biliary cholangitis;	chr5:103223706	chr5:103032376~103033031:+
THCA	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	8.12	4.24e-15	1.75e-12	0.43	0.35	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
THCA	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	8.12	4.24e-15	1.75e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	8.12	4.24e-15	1.75e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
THCA	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	8.12	4.24e-15	1.75e-12	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
THCA	cis	rs7665090	0.846	rs4496586	ENSG00000246560.2	RP11-10L12.4	8.12	4.25e-15	1.75e-12	0.42	0.35	Primary biliary cholangitis;	chr4:102636154	chr4:102828055~102844075:+
THCA	cis	rs17772222	0.701	rs453112	ENSG00000258789.1	RP11-507K2.3	8.12	4.25e-15	1.75e-12	0.34	0.35	Coronary artery calcification;	chr14:88392657	chr14:88551597~88552493:+
THCA	cis	rs11148252	0.904	rs9536079	ENSG00000235660.1	LINC00345	-8.12	4.26e-15	1.76e-12	-0.43	-0.35	Lewy body disease;	chr13:52456430	chr13:52484161~52484680:-
THCA	cis	rs9549328	0.731	rs2873371	ENSG00000267868.1	RP11-120K24.3	8.12	4.26e-15	1.76e-12	0.37	0.35	Systolic blood pressure;	chr13:112961928	chr13:112964835~112966131:-
THCA	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	8.12	4.26e-15	1.76e-12	0.39	0.35	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	8.12	4.26e-15	1.76e-12	0.39	0.35	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
THCA	cis	rs984222	0.648	rs6428801	ENSG00000231365.4	RP11-418J17.1	-8.12	4.26e-15	1.76e-12	-0.34	-0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119145867	chr1:119140396~119275973:+
THCA	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-8.12	4.28e-15	1.76e-12	-0.44	-0.35	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
THCA	cis	rs1858037	0.867	rs1553675	ENSG00000237979.1	AC007389.1	-8.11	4.29e-15	1.77e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65343173	chr2:65500993~65502138:-
THCA	cis	rs7176527	1	rs3762169	ENSG00000188388.10	GOLGA6L3	8.11	4.3e-15	1.77e-12	0.52	0.35	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85240472~85247170:+
THCA	cis	rs11603691	1	rs117981067	ENSG00000254662.1	RP11-872D17.4	-8.11	4.3e-15	1.77e-12	-0.67	-0.35	Low high density lipoprotein cholesterol levels;	chr11:57296638	chr11:57325603~57327958:+
THCA	cis	rs11148252	0.904	rs3892337	ENSG00000235660.1	LINC00345	-8.11	4.3e-15	1.77e-12	-0.43	-0.35	Lewy body disease;	chr13:52455350	chr13:52484161~52484680:-
THCA	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-8.11	4.3e-15	1.77e-12	-0.5	-0.35	Depression;	chr6:28232159	chr6:28115628~28116551:+
THCA	cis	rs8114671	0.628	rs6060130	ENSG00000269202.1	RP4-614O4.12	-8.11	4.31e-15	1.78e-12	-0.3	-0.35	Height;	chr20:34961516	chr20:35201747~35203288:-
THCA	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	8.11	4.31e-15	1.78e-12	0.33	0.35	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
THCA	cis	rs922182	0.617	rs12324438	ENSG00000275785.1	RP11-111E14.2	-8.11	4.32e-15	1.78e-12	-0.42	-0.35	Blood protein levels;	chr15:63951237	chr15:63890030~63890317:+
THCA	cis	rs7727544	0.606	rs10058074	ENSG00000224431.1	AC063976.7	8.11	4.34e-15	1.78e-12	0.31	0.35	Blood metabolite levels;	chr5:132350453	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.604	rs2069803	ENSG00000237714.1	P4HA2-AS1	8.11	4.34e-15	1.79e-12	0.47	0.35	Blood metabolite levels;	chr5:132064740	chr5:132184876~132192808:+
THCA	cis	rs10208649	0.611	rs75340524	ENSG00000272156.1	RP11-477N3.1	8.11	4.35e-15	1.79e-12	0.51	0.35	Body mass index;	chr2:54068793	chr2:54082554~54085066:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000206090.4	AP000350.7	8.11	4.35e-15	1.79e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23939998~23942798:+
THCA	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-8.11	4.36e-15	1.79e-12	-0.42	-0.35	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-8.11	4.36e-15	1.79e-12	-0.42	-0.35	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-8.11	4.36e-15	1.8e-12	-0.42	-0.35	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
THCA	cis	rs240993	0.516	rs173287	ENSG00000230177.1	RP5-1112D6.4	-8.11	4.37e-15	1.8e-12	-0.38	-0.35	Inflammatory skin disease;Psoriasis;	chr6:111276236	chr6:111277932~111278742:+
THCA	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-8.11	4.38e-15	1.8e-12	-0.51	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
THCA	cis	rs7727544	0.513	rs10065787	ENSG00000237714.1	P4HA2-AS1	8.11	4.39e-15	1.81e-12	0.45	0.35	Blood metabolite levels;	chr5:132100793	chr5:132184876~132192808:+
THCA	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	8.11	4.4e-15	1.81e-12	0.43	0.35	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	8.11	4.4e-15	1.81e-12	0.43	0.35	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
THCA	cis	rs10463554	0.675	rs444020	ENSG00000175749.11	EIF3KP1	8.11	4.41e-15	1.81e-12	0.44	0.35	Parkinson's disease;	chr5:103092139	chr5:103032376~103033031:+
THCA	cis	rs1707322	0.964	rs10890358	ENSG00000234329.1	RP11-767N6.2	8.11	4.41e-15	1.81e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45651039~45651826:-
THCA	cis	rs950169	0.614	rs765524	ENSG00000259728.4	LINC00933	8.11	4.42e-15	1.82e-12	0.5	0.35	Schizophrenia;	chr15:84013030	chr15:84570649~84580175:+
THCA	cis	rs1858037	0.836	rs1396209	ENSG00000237979.1	AC007389.1	8.11	4.42e-15	1.82e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65374100	chr2:65500993~65502138:-
THCA	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	8.11	4.44e-15	1.83e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
THCA	cis	rs507080	0.769	rs745663	ENSG00000278376.1	RP11-158I9.8	-8.11	4.45e-15	1.83e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118658886	chr11:118791254~118793137:+
THCA	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	8.11	4.45e-15	1.83e-12	0.27	0.35	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
THCA	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	8.11	4.45e-15	1.83e-12	0.42	0.35	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
THCA	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-8.11	4.46e-15	1.84e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
THCA	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-8.11	4.48e-15	1.84e-12	-0.46	-0.35	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
THCA	cis	rs7208859	0.623	rs122898	ENSG00000266490.1	CTD-2349P21.9	-8.11	4.48e-15	1.84e-12	-0.48	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30792372~30792833:+
THCA	cis	rs10208649	0.908	rs7559651	ENSG00000272156.1	RP11-477N3.1	8.11	4.48e-15	1.84e-12	0.64	0.35	Body mass index;	chr2:53981801	chr2:54082554~54085066:+
THCA	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	8.11	4.48e-15	1.84e-12	0.44	0.35	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
THCA	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	8.11	4.49e-15	1.84e-12	0.42	0.35	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
THCA	cis	rs240993	0.812	rs9487668	ENSG00000230177.1	RP5-1112D6.4	8.11	4.49e-15	1.85e-12	0.36	0.35	Inflammatory skin disease;Psoriasis;	chr6:111553466	chr6:111277932~111278742:+
THCA	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	8.11	4.49e-15	1.85e-12	0.24	0.35	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
THCA	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	8.11	4.5e-15	1.85e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
THCA	cis	rs11673344	0.523	rs36096221	ENSG00000226686.6	LINC01535	8.11	4.51e-15	1.85e-12	0.39	0.35	Obesity-related traits;	chr19:37060838	chr19:37251912~37265535:+
THCA	cis	rs1859596	0.625	rs6946634	ENSG00000234456.6	MAGI2-AS3	8.11	4.52e-15	1.86e-12	0.33	0.35	Reading or mathematical ability;	chr7:79463780	chr7:79452877~79471208:+
THCA	cis	rs1859596	0.646	rs6964015	ENSG00000234456.6	MAGI2-AS3	8.11	4.52e-15	1.86e-12	0.33	0.35	Reading or mathematical ability;	chr7:79463836	chr7:79452877~79471208:+
THCA	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-8.11	4.52e-15	1.86e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
THCA	cis	rs507080	0.845	rs667982	ENSG00000278376.1	RP11-158I9.8	-8.11	4.52e-15	1.86e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118692058	chr11:118791254~118793137:+
THCA	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	8.11	4.54e-15	1.86e-12	0.46	0.35	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
THCA	cis	rs853679	0.882	rs3757188	ENSG00000280107.1	AL022393.9	-8.11	4.54e-15	1.87e-12	-0.54	-0.35	Depression;	chr6:28139579	chr6:28170845~28172521:+
THCA	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	8.11	4.56e-15	1.87e-12	0.24	0.35	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
THCA	cis	rs1850744	0.702	rs116079424	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9591580	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs115282360	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9591752	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.826	rs114657516	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9592233	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs73805540	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9592340	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.826	rs116509172	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9592499	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.59	rs35509001	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9593247	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.793	rs34495260	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9593700	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs9799502	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9594318	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs57171822	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9594831	chr4:9677308~9677934:+
THCA	cis	rs1850744	1	rs76469957	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9595993	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.793	rs75043790	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596032	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.826	rs76738832	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596185	chr4:9677308~9677934:+
THCA	cis	rs1850744	1	rs114290083	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596370	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs114945335	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596567	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs73802906	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596824	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs78422890	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9599141	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs11735905	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9600133	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs73802912	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9600873	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs73802915	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9601576	chr4:9677308~9677934:+
THCA	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-8.11	4.57e-15	1.88e-12	-0.48	-0.35	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-8.11	4.57e-15	1.88e-12	-0.48	-0.35	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-8.11	4.57e-15	1.88e-12	-0.48	-0.35	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
THCA	cis	rs4664293	0.528	rs12466650	ENSG00000226266.5	AC009961.3	8.11	4.58e-15	1.88e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159552252	chr2:159670708~159712435:-
THCA	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs78256546	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100355347	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs41280971	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100356834	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs11761426	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100359270	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs77861211	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100364473	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs11769057	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100367038	chr7:100320992~100341908:-
THCA	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	8.11	4.6e-15	1.89e-12	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
THCA	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-8.1	4.6e-15	1.89e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
THCA	cis	rs11696845	0.899	rs2868198	ENSG00000276223.1	RP4-781B1.5	-8.1	4.61e-15	1.89e-12	-0.43	-0.35	Obesity-related traits;	chr20:44739294	chr20:44746642~44747201:+
THCA	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	8.1	4.62e-15	1.9e-12	0.37	0.35	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
THCA	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	8.1	4.62e-15	1.9e-12	0.47	0.35	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
THCA	cis	rs11673344	0.523	rs7248948	ENSG00000226686.6	LINC01535	8.1	4.63e-15	1.9e-12	0.39	0.35	Obesity-related traits;	chr19:37056317	chr19:37251912~37265535:+
THCA	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	8.1	4.63e-15	1.9e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
THCA	cis	rs73607972	0.501	rs73614583	ENSG00000275191.1	RP11-36I17.2	-8.1	4.63e-15	1.9e-12	-0.51	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554597	chr16:53628256~53628816:-
THCA	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-8.1	4.64e-15	1.9e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
THCA	cis	rs7015263	1	rs6415565	ENSG00000254231.1	CTD-2284J15.1	-8.1	4.66e-15	1.91e-12	-0.34	-0.35	Intelligence (multi-trait analysis);	chr8:86500667	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs7817738	ENSG00000254231.1	CTD-2284J15.1	8.1	4.66e-15	1.91e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86490903	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs7459897	ENSG00000254231.1	CTD-2284J15.1	8.1	4.66e-15	1.91e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86493522	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs12546331	ENSG00000254231.1	CTD-2284J15.1	8.1	4.66e-15	1.91e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86493739	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs9773093	ENSG00000254231.1	CTD-2284J15.1	8.1	4.66e-15	1.91e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86496855	chr8:86333274~86343314:-
THCA	cis	rs9649213	0.593	rs6465683	ENSG00000272950.1	RP11-307C18.1	8.1	4.66e-15	1.91e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98396780	chr7:98322853~98323430:+
THCA	cis	rs7811142	0.83	rs6945952	ENSG00000078319.8	PMS2P1	-8.1	4.67e-15	1.91e-12	-0.49	-0.35	Platelet count;	chr7:100384152	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs73401450	ENSG00000078319.8	PMS2P1	-8.1	4.67e-15	1.91e-12	-0.49	-0.35	Platelet count;	chr7:100384236	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs73401451	ENSG00000078319.8	PMS2P1	-8.1	4.67e-15	1.91e-12	-0.49	-0.35	Platelet count;	chr7:100384272	chr7:100320992~100341908:-
THCA	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-8.1	4.68e-15	1.92e-12	-0.42	-0.35	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
THCA	cis	rs7849270	0.837	rs10819463	ENSG00000268707.1	RP11-247A12.7	-8.1	4.69e-15	1.92e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129100958	chr9:129170434~129170940:+
THCA	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-8.1	4.7e-15	1.92e-12	-0.42	-0.35	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
THCA	cis	rs116175783	0.557	rs62194490	ENSG00000227403.1	AC009299.3	8.1	4.7e-15	1.93e-12	0.62	0.35	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161244739~161249050:+
THCA	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
THCA	cis	rs1061377	0.965	rs7690465	ENSG00000249685.1	RP11-360F5.3	8.1	4.73e-15	1.94e-12	0.43	0.35	Uric acid levels;	chr4:39147015	chr4:39133913~39135608:+
THCA	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	8.1	4.73e-15	1.94e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
THCA	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-8.1	4.73e-15	1.94e-12	-0.39	-0.35	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
THCA	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	8.1	4.73e-15	1.94e-12	0.42	0.35	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
THCA	cis	rs1707322	1	rs11211205	ENSG00000234329.1	RP11-767N6.2	8.1	4.74e-15	1.94e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45651039~45651826:-
THCA	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	8.1	4.75e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
THCA	cis	rs853679	0.882	rs9393908	ENSG00000280107.1	AL022393.9	-8.1	4.75e-15	1.95e-12	-0.55	-0.35	Depression;	chr6:28223052	chr6:28170845~28172521:+
THCA	cis	rs853679	0.882	rs9366717	ENSG00000280107.1	AL022393.9	-8.1	4.75e-15	1.95e-12	-0.55	-0.35	Depression;	chr6:28223279	chr6:28170845~28172521:+
THCA	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	8.1	4.76e-15	1.95e-12	0.24	0.35	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
THCA	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-8.1	4.76e-15	1.95e-12	-0.47	-0.35	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
THCA	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
THCA	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	8.1	4.77e-15	1.95e-12	0.45	0.35	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	8.1	4.77e-15	1.95e-12	0.45	0.35	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
THCA	cis	rs7247513	0.859	rs35945052	ENSG00000230310.1	CTD-2192J16.11	-8.1	4.78e-15	1.96e-12	-0.42	-0.35	Bipolar disorder;	chr19:12592416	chr19:12552597~12553644:+
THCA	cis	rs8114671	0.586	rs734111	ENSG00000269202.1	RP4-614O4.12	-8.1	4.78e-15	1.96e-12	-0.3	-0.35	Height;	chr20:34945933	chr20:35201747~35203288:-
THCA	cis	rs910316	0.726	rs12882664	ENSG00000279594.1	RP11-950C14.10	8.1	4.79e-15	1.96e-12	0.32	0.35	Height;	chr14:74980075	chr14:75011269~75012851:-
THCA	cis	rs9532669	0.889	rs1989252	ENSG00000176268.5	CYCSP34	-8.1	4.79e-15	1.96e-12	-0.39	-0.35	Cervical cancer;	chr13:40911532	chr13:40863599~40863902:-
THCA	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	8.1	4.79e-15	1.96e-12	0.33	0.35	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
THCA	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	8.1	4.8e-15	1.96e-12	0.42	0.35	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-8.1	4.82e-15	1.97e-12	-0.44	-0.35	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
THCA	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	8.1	4.84e-15	1.98e-12	0.34	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
THCA	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	8.1	4.84e-15	1.98e-12	0.43	0.35	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
THCA	cis	rs848490	0.722	rs6976860	ENSG00000214293.7	APTR	8.1	4.84e-15	1.98e-12	0.26	0.35	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77822829	chr7:77657660~77696265:-
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	8.1	4.84e-15	1.98e-12	0.34	0.35	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
THCA	cis	rs3747113	1	rs11703914	ENSG00000128262.7	POM121L9P	-8.1	4.85e-15	1.99e-12	-0.39	-0.35	Gut microbiome composition (summer);	chr22:24371634	chr22:24251828~24265525:+
THCA	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	8.1	4.86e-15	1.99e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
THCA	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	8.1	4.87e-15	1.99e-12	0.48	0.35	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
THCA	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-8.1	4.88e-15	1.99e-12	-0.37	-0.35	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-8.1	4.88e-15	1.99e-12	-0.37	-0.35	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
THCA	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-8.1	4.88e-15	1.99e-12	-0.37	-0.35	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-8.1	4.88e-15	2e-12	-0.44	-0.35	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
THCA	cis	rs507080	0.769	rs527290	ENSG00000278376.1	RP11-158I9.8	-8.1	4.88e-15	2e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118644898	chr11:118791254~118793137:+
THCA	cis	rs8114671	0.662	rs6088664	ENSG00000269202.1	RP4-614O4.12	-8.1	4.88e-15	2e-12	-0.3	-0.35	Height;	chr20:34963297	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.836	rs745849	ENSG00000269202.1	RP4-614O4.12	8.1	4.89e-15	2e-12	0.3	0.35	Height;	chr20:34984375	chr20:35201747~35203288:-
THCA	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	8.1	4.9e-15	2e-12	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
THCA	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-8.1	4.92e-15	2.01e-12	-0.34	-0.35	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
THCA	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	8.1	4.92e-15	2.01e-12	0.56	0.35	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
THCA	cis	rs516805	0.886	rs557528	ENSG00000279453.1	RP3-425C14.4	-8.1	4.92e-15	2.01e-12	-0.32	-0.35	Lymphocyte counts;	chr6:122482793	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs559721	ENSG00000279453.1	RP3-425C14.4	-8.1	4.92e-15	2.01e-12	-0.32	-0.35	Lymphocyte counts;	chr6:122482796	chr6:122436789~122439223:-
THCA	cis	rs7811142	0.83	rs6948685	ENSG00000078319.8	PMS2P1	-8.1	4.92e-15	2.01e-12	-0.49	-0.35	Platelet count;	chr7:100372565	chr7:100320992~100341908:-
THCA	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-8.1	4.94e-15	2.02e-12	-0.34	-0.35	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
THCA	cis	rs7554547	0.667	rs4846072	ENSG00000199347.1	RNU5E-1	8.1	4.94e-15	2.02e-12	0.47	0.35	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr1:11908152~11908271:+
THCA	cis	rs910316	1	rs7145159	ENSG00000279594.1	RP11-950C14.10	8.09	4.96e-15	2.03e-12	0.32	0.35	Height;	chr14:75116565	chr14:75011269~75012851:-
THCA	cis	rs947583	0.588	rs9494389	ENSG00000231028.7	LINC00271	-8.09	4.96e-15	2.03e-12	-0.28	-0.35	Phosphorus levels;	chr6:135794369	chr6:135497801~135716055:+
THCA	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	8.09	4.96e-15	2.03e-12	0.39	0.35	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
THCA	cis	rs66887589	0.87	rs59590064	ENSG00000245958.5	RP11-33B1.1	8.09	4.97e-15	2.03e-12	0.3	0.35	Diastolic blood pressure;	chr4:119618598	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.934	rs6817317	ENSG00000245958.5	RP11-33B1.1	8.09	4.97e-15	2.03e-12	0.3	0.35	Diastolic blood pressure;	chr4:119621672	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.934	rs7672519	ENSG00000245958.5	RP11-33B1.1	8.09	4.97e-15	2.03e-12	0.3	0.35	Diastolic blood pressure;	chr4:119622957	chr4:119454791~119552025:+
THCA	cis	rs11148252	0.904	rs9568732	ENSG00000235660.1	LINC00345	8.09	4.99e-15	2.04e-12	0.43	0.35	Lewy body disease;	chr13:52419277	chr13:52484161~52484680:-
THCA	cis	rs7208859	0.623	rs73271869	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73271872	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.568	rs9907834	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Body mass index;	chr17:30826995	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73271887	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9898858	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs55658077	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9899692	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9906957	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30792372~30792833:+
THCA	cis	rs4819052	0.704	rs2297283	ENSG00000215447.6	BX322557.10	-8.09	5e-15	2.04e-12	-0.29	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45288052~45291738:+
THCA	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	8.09	5e-15	2.04e-12	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
THCA	cis	rs9309473	0.607	rs6720094	ENSG00000163016.8	ALMS1P	8.09	5e-15	2.04e-12	0.46	0.35	Metabolite levels;	chr2:73360948	chr2:73644919~73685576:+
THCA	cis	rs17684571	0.808	rs6938003	ENSG00000231441.1	RP11-472M19.2	8.09	5.01e-15	2.05e-12	0.44	0.35	Schizophrenia;	chr6:56753365	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs3002008	ENSG00000231441.1	RP11-472M19.2	8.09	5.01e-15	2.05e-12	0.44	0.35	Schizophrenia;	chr6:56757527	chr6:56844002~56864078:+
THCA	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	8.09	5.01e-15	2.05e-12	0.45	0.35	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
THCA	cis	rs42490	0.664	rs372981	ENSG00000251136.7	RP11-37B2.1	-8.09	5.02e-15	2.05e-12	-0.3	-0.35	Leprosy;	chr8:89784740	chr8:89609409~89757727:-
THCA	cis	rs11603023	1	rs11603023	ENSG00000255239.1	AP002954.6	8.09	5.03e-15	2.05e-12	0.46	0.35	Cholesterol, total;	chr11:118615352	chr11:118688039~118690600:-
THCA	cis	rs7220401	0.789	rs4794859	ENSG00000264007.1	RP11-68I3.10	-8.09	5.03e-15	2.05e-12	-0.4	-0.35	Coronary artery disease;	chr17:29635375	chr17:29621617~29622254:-
THCA	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	8.09	5.03e-15	2.05e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
THCA	cis	rs1850744	0.702	rs55813730	ENSG00000250942.1	ENPP7P11	-8.09	5.03e-15	2.05e-12	-0.51	-0.35	Economic and political preferences;	chr4:9593994	chr4:9677308~9677934:+
THCA	cis	rs1707322	1	rs11211190	ENSG00000234329.1	RP11-767N6.2	8.09	5.03e-15	2.05e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6429580	ENSG00000234329.1	RP11-767N6.2	8.09	5.03e-15	2.05e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45651039~45651826:-
THCA	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-8.09	5.03e-15	2.06e-12	-0.34	-0.35	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
THCA	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-8.09	5.04e-15	2.06e-12	-0.42	-0.35	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
THCA	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	8.09	5.07e-15	2.07e-12	0.34	0.35	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
THCA	cis	rs934734	0.752	rs268132	ENSG00000204929.10	AC074391.1	8.09	5.08e-15	2.07e-12	0.45	0.35	Rheumatoid arthritis;	chr2:65382543	chr2:65436711~66084639:+
THCA	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	8.09	5.08e-15	2.08e-12	0.26	0.35	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
THCA	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	8.09	5.09e-15	2.08e-12	0.71	0.35	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
THCA	cis	rs17772222	0.701	rs845757	ENSG00000258789.1	RP11-507K2.3	8.09	5.09e-15	2.08e-12	0.33	0.35	Coronary artery calcification;	chr14:88455372	chr14:88551597~88552493:+
THCA	cis	rs270601	0.739	rs3900945	ENSG00000233006.5	AC034220.3	8.09	5.1e-15	2.08e-12	0.27	0.35	Acylcarnitine levels;	chr5:132257177	chr5:132311285~132369916:-
THCA	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	8.09	5.11e-15	2.09e-12	0.44	0.35	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
THCA	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-8.09	5.12e-15	2.09e-12	-0.47	-0.35	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
THCA	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-8.09	5.13e-15	2.1e-12	-0.28	-0.35	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
THCA	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	8.09	5.14e-15	2.1e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
THCA	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-8.09	5.15e-15	2.1e-12	-0.45	-0.35	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	8.09	5.15e-15	2.1e-12	0.45	0.35	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
THCA	cis	rs4072705	0.967	rs4838195	ENSG00000224020.1	MIR181A2HG	-8.09	5.16e-15	2.1e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124588938	chr9:124658467~124698631:+
THCA	cis	rs1707322	0.963	rs11211229	ENSG00000234329.1	RP11-767N6.2	8.09	5.16e-15	2.11e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45651039~45651826:-
THCA	cis	rs5769707	0.967	rs2187891	ENSG00000235111.1	RP1-29C18.8	-8.09	5.17e-15	2.11e-12	-0.41	-0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49612657~49615716:-
THCA	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	8.09	5.19e-15	2.12e-12	0.33	0.35	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
THCA	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-8.09	5.19e-15	2.12e-12	-0.44	-0.35	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	8.09	5.2e-15	2.12e-12	0.34	0.35	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
THCA	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	8.09	5.21e-15	2.12e-12	0.47	0.35	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	8.09	5.21e-15	2.12e-12	0.47	0.35	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
THCA	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-8.09	5.23e-15	2.13e-12	-0.42	-0.35	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
THCA	cis	rs375066	0.935	rs108775	ENSG00000267058.1	RP11-15A1.3	-8.09	5.24e-15	2.14e-12	-0.29	-0.35	Breast cancer;	chr19:43901770	chr19:43891804~43901805:-
THCA	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	8.09	5.24e-15	2.14e-12	0.46	0.35	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
THCA	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	8.09	5.26e-15	2.14e-12	0.85	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
THCA	cis	rs507080	0.845	rs481903	ENSG00000278376.1	RP11-158I9.8	-8.09	5.27e-15	2.15e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118697024	chr11:118791254~118793137:+
THCA	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	8.09	5.27e-15	2.15e-12	0.57	0.35	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
THCA	cis	rs4819052	0.788	rs9978857	ENSG00000215447.6	BX322557.10	-8.09	5.27e-15	2.15e-12	-0.3	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45288052~45291738:+
THCA	cis	rs9309473	0.583	rs6709853	ENSG00000163016.8	ALMS1P	8.09	5.28e-15	2.15e-12	0.46	0.35	Metabolite levels;	chr2:73348937	chr2:73644919~73685576:+
THCA	cis	rs4072705	0.967	rs10760369	ENSG00000224020.1	MIR181A2HG	-8.09	5.28e-15	2.15e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124635121	chr9:124658467~124698631:+
THCA	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	8.09	5.29e-15	2.16e-12	0.36	0.35	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
THCA	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	8.09	5.3e-15	2.16e-12	0.34	0.35	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
THCA	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	8.09	5.3e-15	2.16e-12	0.38	0.35	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
THCA	cis	rs4713118	0.869	rs9468214	ENSG00000219392.1	RP1-265C24.5	-8.09	5.31e-15	2.17e-12	-0.45	-0.35	Parkinson's disease;	chr6:27745520	chr6:28115628~28116551:+
THCA	cis	rs1850744	0.702	rs6836184	ENSG00000250942.1	ENPP7P11	8.08	5.35e-15	2.18e-12	0.48	0.35	Economic and political preferences;	chr4:9632087	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.536	rs6843869	ENSG00000250942.1	ENPP7P11	8.08	5.35e-15	2.18e-12	0.48	0.35	Economic and political preferences;	chr4:9632827	chr4:9677308~9677934:+
THCA	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
THCA	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
THCA	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-8.08	5.35e-15	2.18e-12	-0.64	-0.35	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
THCA	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-8.08	5.36e-15	2.18e-12	-0.48	-0.35	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
THCA	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-8.08	5.37e-15	2.19e-12	-0.43	-0.35	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
THCA	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-8.08	5.37e-15	2.19e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
THCA	cis	rs10266483	0.921	rs687547	ENSG00000227986.1	TRIM60P18	-8.08	5.38e-15	2.19e-12	-0.29	-0.35	Response to statin therapy;	chr7:64284551	chr7:64355078~64356199:+
THCA	cis	rs42490	0.664	rs389848	ENSG00000251136.7	RP11-37B2.1	-8.08	5.38e-15	2.19e-12	-0.3	-0.35	Leprosy;	chr8:89784739	chr8:89609409~89757727:-
THCA	cis	rs934734	0.752	rs268136	ENSG00000204929.10	AC074391.1	-8.08	5.38e-15	2.19e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65380409	chr2:65436711~66084639:+
THCA	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	8.08	5.38e-15	2.19e-12	0.42	0.35	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
THCA	cis	rs934734	0.532	rs6546151	ENSG00000237979.1	AC007389.1	-8.08	5.39e-15	2.2e-12	-0.39	-0.35	Rheumatoid arthritis;	chr2:65449449	chr2:65500993~65502138:-
THCA	cis	rs2274273	0.805	rs8012156	ENSG00000258413.1	RP11-665C16.6	-8.08	5.39e-15	2.2e-12	-0.47	-0.35	Protein biomarker;	chr14:55085782	chr14:55262767~55272075:-
THCA	cis	rs9309473	0.528	rs2091022	ENSG00000163016.8	ALMS1P	8.08	5.41e-15	2.2e-12	0.47	0.35	Metabolite levels;	chr2:73337442	chr2:73644919~73685576:+
THCA	cis	rs1858037	0.867	rs876933	ENSG00000237979.1	AC007389.1	8.08	5.42e-15	2.21e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65382303	chr2:65500993~65502138:-
THCA	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	8.08	5.42e-15	2.21e-12	0.34	0.35	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000235689.1	AP000351.13	8.08	5.44e-15	2.21e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:24006305~24008258:-
THCA	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	8.08	5.44e-15	2.21e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
THCA	cis	rs12168402	0.51	rs1076116	ENSG00000235209.1	CTA-150C2.13	8.08	5.44e-15	2.22e-12	0.45	0.35	Subjective well-being;	chr22:38841832	chr22:38921227~38924708:+
THCA	cis	rs507080	0.922	rs582630	ENSG00000278376.1	RP11-158I9.8	-8.08	5.45e-15	2.22e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118692090	chr11:118791254~118793137:+
THCA	cis	rs507080	0.883	rs527475	ENSG00000278376.1	RP11-158I9.8	-8.08	5.45e-15	2.22e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118692530	chr11:118791254~118793137:+
THCA	cis	rs189798	0.738	rs330911	ENSG00000254340.1	RP11-10A14.3	8.08	5.46e-15	2.22e-12	0.4	0.35	Myopia (pathological);	chr8:9138763	chr8:9141424~9145435:+
THCA	cis	rs922182	0.557	rs6494452	ENSG00000275785.1	RP11-111E14.2	8.08	5.46e-15	2.22e-12	0.41	0.35	Blood protein levels;	chr15:63907009	chr15:63890030~63890317:+
THCA	cis	rs10208649	0.908	rs11887593	ENSG00000272156.1	RP11-477N3.1	8.08	5.47e-15	2.22e-12	0.64	0.35	Body mass index;	chr2:54040638	chr2:54082554~54085066:+
THCA	cis	rs8114671	0.933	rs2103971	ENSG00000269202.1	RP4-614O4.12	8.08	5.48e-15	2.23e-12	0.29	0.35	Height;	chr20:35198453	chr20:35201747~35203288:-
THCA	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	8.08	5.49e-15	2.24e-12	0.35	0.35	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
THCA	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	8.08	5.5e-15	2.24e-12	0.46	0.35	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
THCA	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-8.08	5.51e-15	2.24e-12	-0.52	-0.35	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
THCA	cis	rs10208649	0.908	rs9678301	ENSG00000272156.1	RP11-477N3.1	8.08	5.52e-15	2.24e-12	0.67	0.35	Body mass index;	chr2:54014373	chr2:54082554~54085066:+
THCA	cis	rs736801	0.808	rs72797303	ENSG00000237714.1	P4HA2-AS1	8.08	5.52e-15	2.24e-12	0.47	0.35	Mosquito bite size;Breast cancer;	chr5:132460471	chr5:132184876~132192808:+
THCA	cis	rs736801	0.808	rs72797306	ENSG00000237714.1	P4HA2-AS1	8.08	5.52e-15	2.24e-12	0.47	0.35	Mosquito bite size;Breast cancer;	chr5:132465058	chr5:132184876~132192808:+
THCA	cis	rs7811142	0.83	rs3087502	ENSG00000078319.8	PMS2P1	-8.08	5.52e-15	2.25e-12	-0.49	-0.35	Platelet count;	chr7:100357741	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs61735533	ENSG00000078319.8	PMS2P1	-8.08	5.52e-15	2.25e-12	-0.49	-0.35	Platelet count;	chr7:100358243	chr7:100320992~100341908:-
THCA	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	8.08	5.53e-15	2.25e-12	0.42	0.35	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
THCA	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-8.08	5.56e-15	2.26e-12	-0.34	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000226314.6	ZNF192P1	-8.08	5.58e-15	2.27e-12	-0.44	-0.35	Parkinson's disease;	chr6:28062721	chr6:28161781~28169594:+
THCA	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-8.08	5.59e-15	2.27e-12	-0.44	-0.35	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
THCA	cis	rs7176527	0.519	rs12148368	ENSG00000230373.7	GOLGA6L5P	8.08	5.59e-15	2.27e-12	0.37	0.35	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84507885~84516814:-
THCA	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	8.08	5.6e-15	2.28e-12	0.31	0.35	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
THCA	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	8.08	5.6e-15	2.28e-12	0.43	0.35	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
THCA	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-8.08	5.61e-15	2.28e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
THCA	cis	rs8114671	0.836	rs62213676	ENSG00000269202.1	RP4-614O4.12	8.08	5.61e-15	2.28e-12	0.29	0.35	Height;	chr20:35024873	chr20:35201747~35203288:-
THCA	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	8.08	5.61e-15	2.28e-12	0.42	0.35	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
THCA	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-8.08	5.63e-15	2.29e-12	-0.41	-0.35	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
THCA	cis	rs8114671	0.742	rs6058161	ENSG00000269202.1	RP4-614O4.12	8.08	5.64e-15	2.29e-12	0.29	0.35	Height;	chr20:35032223	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.836	rs4911461	ENSG00000269202.1	RP4-614O4.12	8.08	5.65e-15	2.3e-12	0.29	0.35	Height;	chr20:35042190	chr20:35201747~35203288:-
THCA	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-8.08	5.66e-15	2.3e-12	-0.38	-0.35	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
THCA	cis	rs17772222	0.701	rs376698	ENSG00000258789.1	RP11-507K2.3	8.08	5.68e-15	2.31e-12	0.34	0.35	Coronary artery calcification;	chr14:88391886	chr14:88551597~88552493:+
THCA	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-8.08	5.69e-15	2.31e-12	-0.47	-0.35	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-8.08	5.69e-15	2.31e-12	-0.47	-0.35	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
THCA	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	8.07	5.72e-15	2.32e-12	0.56	0.35	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	8.07	5.72e-15	2.32e-12	0.56	0.35	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
THCA	cis	rs180730	1	rs343166	ENSG00000251609.2	SETP12	-8.07	5.73e-15	2.33e-12	-0.56	-0.35	Fasting plasma glucose;	chr4:120897567	chr4:120895494~120897083:-
THCA	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-8.07	5.73e-15	2.33e-12	-0.44	-0.35	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
THCA	cis	rs11673344	0.504	rs4239587	ENSG00000226686.6	LINC01535	8.07	5.73e-15	2.33e-12	0.38	0.35	Obesity-related traits;	chr19:37136211	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs4805202	ENSG00000226686.6	LINC01535	8.07	5.73e-15	2.33e-12	0.38	0.35	Obesity-related traits;	chr19:37136499	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs4805203	ENSG00000226686.6	LINC01535	8.07	5.73e-15	2.33e-12	0.38	0.35	Obesity-related traits;	chr19:37136586	chr19:37251912~37265535:+
THCA	cis	rs42490	0.653	rs40247	ENSG00000251136.7	RP11-37B2.1	-8.07	5.74e-15	2.33e-12	-0.3	-0.35	Leprosy;	chr8:89789744	chr8:89609409~89757727:-
THCA	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-8.07	5.75e-15	2.33e-12	-0.42	-0.35	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	8.07	5.75e-15	2.33e-12	0.42	0.35	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
THCA	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-8.07	5.75e-15	2.33e-12	-0.4	-0.35	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
THCA	cis	rs984222	0.617	rs4659152	ENSG00000231365.4	RP11-418J17.1	8.07	5.76e-15	2.34e-12	0.34	0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119216235	chr1:119140396~119275973:+
THCA	cis	rs4934494	0.911	rs7098233	ENSG00000232936.4	RP11-80H5.2	-8.07	5.76e-15	2.34e-12	-0.45	-0.35	Red blood cell count;	chr10:89663111	chr10:89645282~89650667:+
THCA	cis	rs11673344	0.504	rs12984458	ENSG00000226686.6	LINC01535	-8.07	5.76e-15	2.34e-12	-0.38	-0.35	Obesity-related traits;	chr19:37138189	chr19:37251912~37265535:+
THCA	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-8.07	5.77e-15	2.34e-12	-0.42	-0.35	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
THCA	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	8.07	5.77e-15	2.34e-12	0.24	0.35	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	8.07	5.77e-15	2.34e-12	0.24	0.35	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
THCA	cis	rs875971	0.522	rs1880556	ENSG00000237310.1	GS1-124K5.4	8.07	5.79e-15	2.35e-12	0.26	0.35	Aortic root size;	chr7:65967557	chr7:66493706~66495474:+
THCA	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	8.07	5.8e-15	2.35e-12	0.42	0.35	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
THCA	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-8.07	5.8e-15	2.36e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
THCA	cis	rs4934494	1	rs4934494	ENSG00000232936.4	RP11-80H5.2	8.07	5.81e-15	2.36e-12	0.46	0.35	Red blood cell count;	chr10:89687662	chr10:89645282~89650667:+
THCA	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	8.07	5.82e-15	2.36e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000237664.1	LINC00316	-8.07	5.82e-15	2.36e-12	-0.38	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45338590~45341990:-
THCA	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-8.07	5.83e-15	2.37e-12	-0.45	-0.35	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-8.07	5.83e-15	2.37e-12	-0.45	-0.35	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
THCA	cis	rs2115630	0.755	rs7169629	ENSG00000225151.9	GOLGA2P7	-8.07	5.84e-15	2.37e-12	-0.44	-0.35	P wave terminal force;	chr15:84648043	chr15:84199311~84230136:-
THCA	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	8.07	5.84e-15	2.37e-12	0.33	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
THCA	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	8.07	5.84e-15	2.37e-12	0.33	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
THCA	cis	rs8114671	0.869	rs2038503	ENSG00000269202.1	RP4-614O4.12	8.07	5.84e-15	2.37e-12	0.29	0.35	Height;	chr20:35088097	chr20:35201747~35203288:-
THCA	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	8.07	5.85e-15	2.37e-12	0.42	0.35	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-8.07	5.85e-15	2.37e-12	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
THCA	cis	rs507080	0.769	rs645637	ENSG00000278376.1	RP11-158I9.8	-8.07	5.86e-15	2.38e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118634373	chr11:118791254~118793137:+
THCA	cis	rs9649213	0.574	rs62478236	ENSG00000272950.1	RP11-307C18.1	8.07	5.86e-15	2.38e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98401065	chr7:98322853~98323430:+
THCA	cis	rs748404	0.534	rs489509	ENSG00000205771.5	CATSPER2P1	-8.07	5.88e-15	2.39e-12	-0.36	-0.35	Lung cancer;	chr15:43294709	chr15:43726918~43747094:-
THCA	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	8.07	5.9e-15	2.39e-12	0.33	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
THCA	cis	rs922182	0.617	rs17777266	ENSG00000275785.1	RP11-111E14.2	8.07	5.9e-15	2.39e-12	0.4	0.35	Blood protein levels;	chr15:63949043	chr15:63890030~63890317:+
THCA	cis	rs11971779	0.554	rs11772686	ENSG00000273391.1	RP11-634H22.1	8.07	5.91e-15	2.4e-12	0.34	0.35	Diisocyanate-induced asthma;	chr7:139444625	chr7:139359032~139359566:-
THCA	cis	rs507080	0.922	rs585039	ENSG00000278376.1	RP11-158I9.8	-8.07	5.91e-15	2.4e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118692672	chr11:118791254~118793137:+
THCA	cis	rs11168351	0.833	rs6580652	ENSG00000258273.1	RP11-370I10.4	8.07	5.92e-15	2.4e-12	0.46	0.35	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48333755~48333901:-
THCA	cis	rs1707322	1	rs10890380	ENSG00000234329.1	RP11-767N6.2	8.07	5.93e-15	2.4e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45651039~45651826:-
THCA	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-8.07	5.93e-15	2.4e-12	-0.45	-0.35	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
THCA	cis	rs367615	0.55	rs10060801	ENSG00000249476.1	CTD-2587M2.1	8.07	5.96e-15	2.42e-12	0.35	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109546081	chr5:109237120~109326369:-
THCA	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	8.07	5.96e-15	2.42e-12	0.38	0.35	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
THCA	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-8.07	5.98e-15	2.42e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-8.07	5.98e-15	2.42e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
THCA	cis	rs8114671	0.904	rs6060197	ENSG00000269202.1	RP4-614O4.12	8.07	5.99e-15	2.43e-12	0.29	0.35	Height;	chr20:35066512	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.839	rs6142290	ENSG00000269202.1	RP4-614O4.12	8.07	5.99e-15	2.43e-12	0.29	0.35	Height;	chr20:35066869	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.869	rs6060199	ENSG00000269202.1	RP4-614O4.12	8.07	5.99e-15	2.43e-12	0.29	0.35	Height;	chr20:35066970	chr20:35201747~35203288:-
THCA	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	8.07	6e-15	2.43e-12	0.5	0.35	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
THCA	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	8.07	6.01e-15	2.43e-12	0.49	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
THCA	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	8.07	6.01e-15	2.44e-12	0.42	0.35	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
THCA	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-8.07	6.03e-15	2.44e-12	-0.34	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
THCA	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	8.07	6.03e-15	2.44e-12	0.38	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
THCA	cis	rs8062405	0.54	rs480400	ENSG00000251417.2	RP11-1348G14.4	-8.07	6.04e-15	2.45e-12	-0.33	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28802743~28817828:+
THCA	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	8.07	6.05e-15	2.45e-12	0.45	0.35	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
THCA	cis	rs4934494	0.822	rs3962370	ENSG00000232936.4	RP11-80H5.2	8.07	6.05e-15	2.45e-12	0.45	0.35	Red blood cell count;	chr10:89777763	chr10:89645282~89650667:+
THCA	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-8.07	6.05e-15	2.45e-12	-0.42	-0.35	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
THCA	cis	rs116175783	0.557	rs72876083	ENSG00000227403.1	AC009299.3	8.07	6.06e-15	2.45e-12	0.62	0.35	Intelligence (multi-trait analysis);	chr2:161327527	chr2:161244739~161249050:+
THCA	cis	rs11673344	0.504	rs7252940	ENSG00000226686.6	LINC01535	8.07	6.06e-15	2.46e-12	0.38	0.35	Obesity-related traits;	chr19:37138589	chr19:37251912~37265535:+
THCA	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	8.07	6.07e-15	2.46e-12	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
THCA	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	8.07	6.08e-15	2.47e-12	0.26	0.35	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
THCA	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-8.07	6.09e-15	2.47e-12	-0.42	-0.35	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
THCA	cis	rs507080	0.883	rs558593	ENSG00000278376.1	RP11-158I9.8	-8.07	6.1e-15	2.47e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118691811	chr11:118791254~118793137:+
THCA	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-8.07	6.1e-15	2.47e-12	-0.42	-0.35	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
THCA	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-8.07	6.11e-15	2.47e-12	-0.48	-0.35	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
THCA	cis	rs934734	0.532	rs10184881	ENSG00000237979.1	AC007389.1	-8.07	6.12e-15	2.48e-12	-0.39	-0.35	Rheumatoid arthritis;	chr2:65457018	chr2:65500993~65502138:-
THCA	cis	rs8114671	0.74	rs3761141	ENSG00000269202.1	RP4-614O4.12	-8.07	6.14e-15	2.49e-12	-0.3	-0.35	Height;	chr20:35150021	chr20:35201747~35203288:-
THCA	cis	rs812925	0.502	rs778150	ENSG00000271889.1	RP11-493E12.1	-8.06	6.16e-15	2.5e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61381237	chr2:61151433~61162105:-
THCA	cis	rs950169	0.649	rs12911612	ENSG00000259728.4	LINC00933	8.06	6.17e-15	2.5e-12	0.5	0.35	Schizophrenia;	chr15:84022262	chr15:84570649~84580175:+
THCA	cis	rs950169	0.649	rs12905952	ENSG00000259728.4	LINC00933	8.06	6.17e-15	2.5e-12	0.5	0.35	Schizophrenia;	chr15:84022509	chr15:84570649~84580175:+
THCA	cis	rs950169	0.61	rs34529571	ENSG00000259728.4	LINC00933	8.06	6.17e-15	2.5e-12	0.5	0.35	Schizophrenia;	chr15:84023055	chr15:84570649~84580175:+
THCA	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	8.06	6.19e-15	2.51e-12	0.45	0.35	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
THCA	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	8.06	6.19e-15	2.51e-12	0.45	0.35	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
THCA	cis	rs910316	0.737	rs175072	ENSG00000279594.1	RP11-950C14.10	-8.06	6.19e-15	2.51e-12	-0.32	-0.35	Height;	chr14:75036124	chr14:75011269~75012851:-
THCA	cis	rs910316	0.712	rs175074	ENSG00000279594.1	RP11-950C14.10	-8.06	6.19e-15	2.51e-12	-0.32	-0.35	Height;	chr14:75037751	chr14:75011269~75012851:-
THCA	cis	rs736801	0.808	rs2248116	ENSG00000237714.1	P4HA2-AS1	-8.06	6.23e-15	2.52e-12	-0.46	-0.35	Mosquito bite size;Breast cancer;	chr5:132468655	chr5:132184876~132192808:+
THCA	cis	rs944289	1	rs944289	ENSG00000257826.1	RP11-116N8.4	-8.06	6.23e-15	2.52e-12	-0.37	-0.35	Thyroid cancer;	chr14:36180040	chr14:36061026~36067190:-
THCA	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	8.06	6.24e-15	2.53e-12	0.44	0.35	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
THCA	cis	rs367615	0.842	rs2578484	ENSG00000249476.1	CTD-2587M2.1	-8.06	6.24e-15	2.53e-12	-0.37	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109615107	chr5:109237120~109326369:-
THCA	cis	rs1707322	0.928	rs7527244	ENSG00000234329.1	RP11-767N6.2	8.06	6.26e-15	2.53e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45651039~45651826:-
THCA	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	8.06	6.27e-15	2.54e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	8.06	6.27e-15	2.54e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	8.06	6.27e-15	2.54e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
THCA	cis	rs62103177	0.81	rs62103178	ENSG00000261126.6	RP11-795F19.1	8.06	6.29e-15	2.55e-12	0.4	0.35	Opioid sensitivity;	chr18:79864555	chr18:80046900~80095482:+
THCA	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-8.06	6.31e-15	2.55e-12	-0.56	-0.35	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
THCA	cis	rs812925	0.519	rs1186706	ENSG00000271889.1	RP11-493E12.1	8.06	6.31e-15	2.56e-12	0.33	0.35	Immature fraction of reticulocytes;	chr2:61446259	chr2:61151433~61162105:-
THCA	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	8.06	6.34e-15	2.57e-12	0.33	0.35	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
THCA	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	8.06	6.36e-15	2.57e-12	0.42	0.35	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
THCA	cis	rs7829975	0.593	rs2921051	ENSG00000254153.1	CTA-398F10.2	-8.06	6.38e-15	2.58e-12	-0.37	-0.35	Mood instability;	chr8:8462594	chr8:8456909~8461337:-
THCA	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-8.06	6.39e-15	2.58e-12	-0.28	-0.35	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
THCA	cis	rs66887589	0.934	rs2389873	ENSG00000245958.5	RP11-33B1.1	8.06	6.4e-15	2.59e-12	0.3	0.35	Diastolic blood pressure;	chr4:119633559	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.934	rs4834792	ENSG00000245958.5	RP11-33B1.1	8.06	6.4e-15	2.59e-12	0.3	0.35	Diastolic blood pressure;	chr4:119634541	chr4:119454791~119552025:+
THCA	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	8.06	6.42e-15	2.59e-12	0.44	0.35	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
THCA	cis	rs1707322	1	rs3922887	ENSG00000234329.1	RP11-767N6.2	8.06	6.42e-15	2.59e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs3922886	ENSG00000234329.1	RP11-767N6.2	8.06	6.42e-15	2.59e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45651039~45651826:-
THCA	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	8.06	6.42e-15	2.59e-12	0.44	0.35	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
THCA	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-8.06	6.44e-15	2.6e-12	-0.37	-0.35	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-8.06	6.44e-15	2.6e-12	-0.37	-0.35	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
THCA	cis	rs7015263	1	rs11781016	ENSG00000254231.1	CTD-2284J15.1	-8.06	6.45e-15	2.61e-12	-0.34	-0.35	Intelligence (multi-trait analysis);	chr8:86517069	chr8:86333274~86343314:-
THCA	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	8.06	6.47e-15	2.61e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
THCA	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	8.06	6.48e-15	2.62e-12	0.41	0.35	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
THCA	cis	rs2712184	0.729	rs4674115	ENSG00000229352.1	AC007563.3	-8.06	6.52e-15	2.63e-12	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216794905	chr2:216799608~216805335:+
THCA	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	8.06	6.58e-15	2.66e-12	0.57	0.35	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
THCA	cis	rs9649213	0.593	rs6465662	ENSG00000272950.1	RP11-307C18.1	8.05	6.61e-15	2.67e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr7:98322853~98323430:+
THCA	cis	rs11673344	0.504	rs4806407	ENSG00000226686.6	LINC01535	-8.05	6.61e-15	2.67e-12	-0.38	-0.35	Obesity-related traits;	chr19:37097849	chr19:37251912~37265535:+
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000242086.7	LINC00969	8.05	6.61e-15	2.67e-12	0.33	0.35	Pancreatic cancer;	chr3:196021659	chr3:195658062~195739964:+
THCA	cis	rs42490	0.716	rs40547	ENSG00000251136.7	RP11-37B2.1	-8.05	6.62e-15	2.67e-12	-0.29	-0.35	Leprosy;	chr8:89817685	chr8:89609409~89757727:-
THCA	cis	rs944289	0.966	rs1169146	ENSG00000257826.1	RP11-116N8.4	-8.05	6.62e-15	2.67e-12	-0.37	-0.35	Thyroid cancer;	chr14:36163563	chr14:36061026~36067190:-
THCA	cis	rs9649213	0.593	rs7458551	ENSG00000272950.1	RP11-307C18.1	8.05	6.63e-15	2.68e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr7:98322853~98323430:+
THCA	cis	rs1859596	0.625	rs7791175	ENSG00000234456.6	MAGI2-AS3	8.05	6.63e-15	2.68e-12	0.33	0.35	Reading or mathematical ability;	chr7:79474901	chr7:79452877~79471208:+
THCA	cis	rs73607972	0.696	rs7201237	ENSG00000275191.1	RP11-36I17.2	-8.05	6.64e-15	2.68e-12	-0.49	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53526005	chr16:53628256~53628816:-
THCA	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	8.05	6.65e-15	2.69e-12	0.47	0.35	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
THCA	cis	rs6545883	0.558	rs7587389	ENSG00000271889.1	RP11-493E12.1	-8.05	6.65e-15	2.69e-12	-0.34	-0.35	Tuberculosis;	chr2:61422656	chr2:61151433~61162105:-
THCA	cis	rs375066	0.901	rs1978723	ENSG00000267058.1	RP11-15A1.3	8.05	6.66e-15	2.69e-12	0.28	0.35	Breast cancer;	chr19:43879648	chr19:43891804~43901805:-
THCA	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	8.05	6.67e-15	2.69e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	8.05	6.67e-15	2.69e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	8.05	6.67e-15	2.69e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
THCA	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-8.05	6.67e-15	2.69e-12	-0.51	-0.35	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000264538.5	SUZ12P1	-8.05	6.68e-15	2.7e-12	-0.36	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30709299~30790908:+
THCA	cis	rs6565180	0.888	rs8060853	ENSG00000183604.13	SMG1P5	8.05	6.68e-15	2.7e-12	0.38	0.35	Tonsillectomy;	chr16:30392537	chr16:30267553~30335374:-
THCA	cis	rs1858037	0.867	rs964505	ENSG00000237979.1	AC007389.1	8.05	6.69e-15	2.7e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65396055	chr2:65500993~65502138:-
THCA	cis	rs1858037	0.867	rs67817304	ENSG00000237979.1	AC007389.1	8.05	6.69e-15	2.7e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65346982	chr2:65500993~65502138:-
THCA	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-8.05	6.72e-15	2.71e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
THCA	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	8.05	6.72e-15	2.71e-12	0.43	0.35	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
THCA	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
THCA	cis	rs8114671	0.836	rs1885114	ENSG00000269202.1	RP4-614O4.12	8.05	6.72e-15	2.71e-12	0.3	0.35	Height;	chr20:34989558	chr20:35201747~35203288:-
THCA	cis	rs42490	0.625	rs39519	ENSG00000251136.7	RP11-37B2.1	8.05	6.72e-15	2.71e-12	0.3	0.35	Leprosy;	chr8:89833814	chr8:89609409~89757727:-
THCA	cis	rs2562456	0.874	rs2562408	ENSG00000268555.1	RP11-678G14.3	-8.05	6.74e-15	2.72e-12	-0.48	-0.35	Pain;	chr19:21527079	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.874	rs2562417	ENSG00000268555.1	RP11-678G14.3	-8.05	6.74e-15	2.72e-12	-0.48	-0.35	Pain;	chr19:21528400	chr19:21570822~21587322:-
THCA	cis	rs1707322	1	rs4660331	ENSG00000234329.1	RP11-767N6.2	8.05	6.76e-15	2.73e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45651039~45651826:-
THCA	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-8.05	6.76e-15	2.73e-12	-0.43	-0.35	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
THCA	cis	rs10266483	0.921	rs624257	ENSG00000227986.1	TRIM60P18	8.05	6.78e-15	2.74e-12	0.28	0.35	Response to statin therapy;	chr7:64284848	chr7:64355078~64356199:+
THCA	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-8.05	6.78e-15	2.74e-12	-0.44	-0.35	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
THCA	cis	rs2712184	0.756	rs2712182	ENSG00000229352.1	AC007563.3	-8.05	6.78e-15	2.74e-12	-0.41	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216782802	chr2:216799608~216805335:+
THCA	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	8.05	6.79e-15	2.74e-12	0.4	0.35	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
THCA	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	8.05	6.79e-15	2.74e-12	0.45	0.35	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
THCA	cis	rs1707322	1	rs4298677	ENSG00000234329.1	RP11-767N6.2	8.05	6.79e-15	2.74e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45651039~45651826:-
THCA	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-8.05	6.8e-15	2.74e-12	-0.5	-0.35	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
THCA	cis	rs910316	1	rs175449	ENSG00000279594.1	RP11-950C14.10	-8.05	6.8e-15	2.74e-12	-0.32	-0.35	Height;	chr14:75124143	chr14:75011269~75012851:-
THCA	cis	rs910316	0.935	rs175448	ENSG00000279594.1	RP11-950C14.10	-8.05	6.8e-15	2.74e-12	-0.32	-0.35	Height;	chr14:75124368	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs175442	ENSG00000279594.1	RP11-950C14.10	-8.05	6.8e-15	2.74e-12	-0.32	-0.35	Height;	chr14:75136861	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-8.05	6.8e-15	2.75e-12	-0.32	-0.35	Height;	chr14:75119585	chr14:75011269~75012851:-
THCA	cis	rs12928939	0.637	rs8046629	ENSG00000260886.1	TAT-AS1	8.05	6.81e-15	2.75e-12	0.46	0.35	Post bronchodilator FEV1;	chr16:71609213	chr16:71565789~71578187:+
THCA	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-8.05	6.81e-15	2.75e-12	-0.47	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
THCA	cis	rs2562456	0.876	rs11085465	ENSG00000268555.1	RP11-678G14.3	-8.05	6.81e-15	2.75e-12	-0.48	-0.35	Pain;	chr19:21568988	chr19:21570822~21587322:-
THCA	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-8.05	6.81e-15	2.75e-12	-0.42	-0.35	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
THCA	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-8.05	6.81e-15	2.75e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-8.05	6.81e-15	2.75e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
THCA	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-8.05	6.82e-15	2.75e-12	-0.42	-0.35	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
THCA	cis	rs910316	0.789	rs12894419	ENSG00000279594.1	RP11-950C14.10	8.05	6.82e-15	2.75e-12	0.32	0.35	Height;	chr14:75005099	chr14:75011269~75012851:-
THCA	cis	rs8114671	0.836	rs6060165	ENSG00000269202.1	RP4-614O4.12	8.05	6.83e-15	2.75e-12	0.29	0.35	Height;	chr20:35031677	chr20:35201747~35203288:-
THCA	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-8.05	6.83e-15	2.76e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
THCA	cis	rs7191700	0.601	rs243329	ENSG00000262703.1	RP11-485G7.6	8.05	6.84e-15	2.76e-12	0.38	0.35	Multiple sclerosis;	chr16:11258456	chr16:11348143~11349321:-
THCA	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	8.05	6.84e-15	2.76e-12	0.44	0.35	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
THCA	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-8.05	6.87e-15	2.77e-12	-0.38	-0.35	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
THCA	cis	rs42490	0.716	rs42346	ENSG00000251136.7	RP11-37B2.1	8.05	6.87e-15	2.77e-12	0.29	0.35	Leprosy;	chr8:89816829	chr8:89609409~89757727:-
THCA	cis	rs910316	0.763	rs12588981	ENSG00000279594.1	RP11-950C14.10	8.05	6.88e-15	2.77e-12	0.32	0.35	Height;	chr14:74993858	chr14:75011269~75012851:-
THCA	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-8.05	6.88e-15	2.77e-12	-0.36	-0.35	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
THCA	cis	rs737008	0.922	rs1559394	ENSG00000262636.1	CTD-3088G3.4	-8.05	6.88e-15	2.78e-12	-0.45	-0.35	Obesity-related traits;	chr16:11275348	chr16:11380859~11381118:-
THCA	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-8.05	6.89e-15	2.78e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-8.05	6.89e-15	2.78e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-8.05	6.89e-15	2.78e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
THCA	cis	rs8114671	0.836	rs3746432	ENSG00000269202.1	RP4-614O4.12	8.05	6.9e-15	2.78e-12	0.29	0.35	Height;	chr20:35004960	chr20:35201747~35203288:-
THCA	cis	rs62103177	0.733	rs62103232	ENSG00000261126.6	RP11-795F19.1	8.05	6.91e-15	2.79e-12	0.4	0.35	Opioid sensitivity;	chr18:79875553	chr18:80046900~80095482:+
THCA	cis	rs8114671	0.836	rs6142284	ENSG00000269202.1	RP4-614O4.12	8.05	6.91e-15	2.79e-12	0.29	0.35	Height;	chr20:35053564	chr20:35201747~35203288:-
THCA	cis	rs9500256	0.967	rs1012500	ENSG00000215190.7	LINC00680	-8.05	6.91e-15	2.79e-12	-0.4	-0.35	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57946074~57961501:-
THCA	cis	rs673078	0.607	rs17512483	ENSG00000275409.1	RP11-131L12.4	8.05	6.93e-15	2.8e-12	0.47	0.35	Glucose homeostasis traits;	chr12:118312380	chr12:118430147~118430699:+
THCA	cis	rs11051970	0.879	rs73081911	ENSG00000274964.1	RP11-817I4.1	-8.05	6.94e-15	2.8e-12	-0.41	-0.35	Response to tocilizumab in rheumatoid arthritis;	chr12:32386190	chr12:32339368~32340724:+
THCA	cis	rs6545883	0.56	rs11677776	ENSG00000271889.1	RP11-493E12.1	-8.05	6.96e-15	2.81e-12	-0.34	-0.35	Tuberculosis;	chr2:61275978	chr2:61151433~61162105:-
THCA	cis	rs42490	0.716	rs43135	ENSG00000251136.7	RP11-37B2.1	-8.05	6.96e-15	2.81e-12	-0.29	-0.35	Leprosy;	chr8:89823722	chr8:89609409~89757727:-
THCA	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-8.05	6.97e-15	2.81e-12	-0.53	-0.35	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
THCA	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	8.05	6.97e-15	2.81e-12	0.42	0.35	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
THCA	cis	rs1707322	1	rs10890350	ENSG00000234329.1	RP11-767N6.2	8.05	6.98e-15	2.81e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-8.05	7.04e-15	2.84e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
THCA	cis	rs73607972	0.696	rs7197014	ENSG00000275191.1	RP11-36I17.2	-8.05	7.05e-15	2.84e-12	-0.49	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525165	chr16:53628256~53628816:-
THCA	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-8.05	7.07e-15	2.85e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-8.05	7.07e-15	2.85e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-8.05	7.07e-15	2.85e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	8.04	7.1e-15	2.86e-12	0.47	0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000235689.1	AP000351.13	8.04	7.11e-15	2.86e-12	0.44	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:24006305~24008258:-
THCA	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-8.04	7.13e-15	2.87e-12	-0.4	-0.35	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
THCA	cis	rs812925	0.537	rs2463097	ENSG00000271889.1	RP11-493E12.1	-8.04	7.13e-15	2.87e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61387166	chr2:61151433~61162105:-
THCA	cis	rs7015263	1	rs4961196	ENSG00000254231.1	CTD-2284J15.1	-8.04	7.15e-15	2.88e-12	-0.34	-0.35	Intelligence (multi-trait analysis);	chr8:86489481	chr8:86333274~86343314:-
THCA	cis	rs2562456	0.917	rs2681376	ENSG00000268555.1	RP11-678G14.3	-8.04	7.16e-15	2.88e-12	-0.49	-0.35	Pain;	chr19:21532723	chr19:21570822~21587322:-
THCA	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-8.04	7.17e-15	2.89e-12	-0.42	-0.35	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
THCA	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	8.04	7.19e-15	2.9e-12	0.49	0.35	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
THCA	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	8.04	7.23e-15	2.91e-12	0.42	0.35	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
THCA	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	8.04	7.23e-15	2.91e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
THCA	cis	rs507080	0.885	rs4938530	ENSG00000278376.1	RP11-158I9.8	-8.04	7.23e-15	2.91e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118689861	chr11:118791254~118793137:+
THCA	cis	rs7727544	0.716	rs7720230	ENSG00000224431.1	AC063976.7	8.04	7.24e-15	2.91e-12	0.31	0.35	Blood metabolite levels;	chr5:132256712	chr5:132199456~132203487:+
THCA	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-8.04	7.26e-15	2.92e-12	-0.45	-0.35	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
THCA	cis	rs910316	0.763	rs4556	ENSG00000279594.1	RP11-950C14.10	8.04	7.26e-15	2.92e-12	0.32	0.35	Height;	chr14:75009368	chr14:75011269~75012851:-
THCA	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-8.04	7.26e-15	2.92e-12	-0.59	-0.35	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
THCA	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	8.04	7.27e-15	2.93e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
THCA	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-8.04	7.28e-15	2.93e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
THCA	cis	rs6545883	0.542	rs7584500	ENSG00000271889.1	RP11-493E12.1	8.04	7.28e-15	2.93e-12	0.33	0.35	Tuberculosis;	chr2:61464980	chr2:61151433~61162105:-
THCA	cis	rs11673344	0.523	rs7258438	ENSG00000226686.6	LINC01535	8.04	7.29e-15	2.93e-12	0.38	0.35	Obesity-related traits;	chr19:37032534	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.503	rs10414520	ENSG00000226686.6	LINC01535	8.04	7.29e-15	2.93e-12	0.38	0.35	Obesity-related traits;	chr19:37057279	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.503	rs1829603	ENSG00000226686.6	LINC01535	8.04	7.29e-15	2.93e-12	0.38	0.35	Obesity-related traits;	chr19:37065396	chr19:37251912~37265535:+
THCA	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-8.04	7.3e-15	2.94e-12	-0.33	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
THCA	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	8.04	7.34e-15	2.95e-12	0.31	0.35	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
THCA	cis	rs9475752	0.552	rs6925518	ENSG00000231441.1	RP11-472M19.2	8.04	7.35e-15	2.96e-12	0.42	0.35	Menarche (age at onset);	chr6:56876405	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.552	rs6905658	ENSG00000231441.1	RP11-472M19.2	8.04	7.35e-15	2.96e-12	0.42	0.35	Menarche (age at onset);	chr6:56876523	chr6:56844002~56864078:+
THCA	cis	rs4927850	1	rs10881563	ENSG00000226155.1	AC124944.3	-8.04	7.35e-15	2.96e-12	-0.42	-0.35	Pancreatic cancer;	chr3:196023354	chr3:195912049~195913986:+
THCA	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-8.04	7.39e-15	2.97e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-8.04	7.39e-15	2.97e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
THCA	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-8.04	7.41e-15	2.98e-12	-0.42	-0.35	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
THCA	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-8.04	7.42e-15	2.98e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-8.04	7.42e-15	2.98e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-8.04	7.42e-15	2.98e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
THCA	cis	rs831571	0.955	rs35839	ENSG00000280620.1	SCAANT1	8.04	7.44e-15	2.99e-12	0.56	0.35	Type 2 diabetes;	chr3:64027741	chr3:63911518~63911772:-
THCA	cis	rs736801	0.74	rs12515180	ENSG00000237714.1	P4HA2-AS1	8.04	7.44e-15	2.99e-12	0.48	0.35	Mosquito bite size;Breast cancer;	chr5:132449992	chr5:132184876~132192808:+
THCA	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-8.04	7.44e-15	2.99e-12	-0.37	-0.35	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
THCA	cis	rs9640161	0.83	rs35840727	ENSG00000261305.1	RP4-584D14.7	8.04	7.46e-15	3e-12	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150366115	chr7:150341771~150342607:+
THCA	cis	rs881375	0.902	rs7021880	ENSG00000226752.6	PSMD5-AS1	8.04	7.47e-15	3e-12	0.46	0.35	Rheumatoid arthritis;	chr9:120911612	chr9:120824828~120854385:+
THCA	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-8.04	7.47e-15	3e-12	-0.28	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
THCA	cis	rs910316	1	rs3742778	ENSG00000279594.1	RP11-950C14.10	-8.04	7.48e-15	3.01e-12	-0.32	-0.35	Height;	chr14:75071514	chr14:75011269~75012851:-
THCA	cis	rs2836950	0.805	rs62223042	ENSG00000255568.3	BRWD1-AS2	-8.04	7.5e-15	3.01e-12	-0.28	-0.35	Menarche (age at onset);	chr21:39311814	chr21:39313935~39314962:+
THCA	cis	rs7247513	0.964	rs4414604	ENSG00000230310.1	CTD-2192J16.11	-8.04	7.5e-15	3.01e-12	-0.42	-0.35	Bipolar disorder;	chr19:12591623	chr19:12552597~12553644:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	8.04	7.51e-15	3.02e-12	0.48	0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
THCA	cis	rs860295	1	rs822527	ENSG00000225855.5	RUSC1-AS1	-8.04	7.56e-15	3.04e-12	-0.23	-0.35	Body mass index;	chr1:155768262	chr1:155316863~155324176:-
THCA	cis	rs507080	0.922	rs558781	ENSG00000278376.1	RP11-158I9.8	-8.04	7.56e-15	3.04e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118693688	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs508640	ENSG00000278376.1	RP11-158I9.8	-8.04	7.56e-15	3.04e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118693704	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs471227	ENSG00000278376.1	RP11-158I9.8	-8.04	7.56e-15	3.04e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118693892	chr11:118791254~118793137:+
THCA	cis	rs4934494	0.727	rs1590566	ENSG00000232936.4	RP11-80H5.2	8.04	7.57e-15	3.04e-12	0.45	0.35	Red blood cell count;	chr10:89778781	chr10:89645282~89650667:+
THCA	cis	rs7247513	0.964	rs2042946	ENSG00000230310.1	CTD-2192J16.11	-8.04	7.57e-15	3.04e-12	-0.42	-0.35	Bipolar disorder;	chr19:12594540	chr19:12552597~12553644:+
THCA	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	8.04	7.58e-15	3.04e-12	0.42	0.35	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
THCA	cis	rs1707322	1	rs7531911	ENSG00000234329.1	RP11-767N6.2	8.04	7.58e-15	3.05e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45651039~45651826:-
THCA	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-8.04	7.58e-15	3.05e-12	-0.37	-0.35	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
THCA	cis	rs7580658	0.711	rs12469035	ENSG00000236682.1	AC068282.3	-8.04	7.59e-15	3.05e-12	-0.45	-0.35	Protein C levels;	chr2:127227341	chr2:127389130~127400580:+
THCA	cis	rs6558530	0.777	rs3812477	ENSG00000253982.1	CTD-2336O2.1	8.04	7.59e-15	3.05e-12	0.31	0.35	Systolic blood pressure;	chr8:1786286	chr8:1761990~1764502:-
THCA	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-8.04	7.59e-15	3.05e-12	-0.34	-0.35	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
THCA	cis	rs1858037	0.836	rs2576923	ENSG00000237979.1	AC007389.1	-8.03	7.62e-15	3.06e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65406750	chr2:65500993~65502138:-
THCA	cis	rs7247513	0.93	rs2861408	ENSG00000230310.1	CTD-2192J16.11	-8.03	7.62e-15	3.06e-12	-0.42	-0.35	Bipolar disorder;	chr19:12591285	chr19:12552597~12553644:+
THCA	cis	rs4073416	0.707	rs8003811	ENSG00000276116.2	FUT8-AS1	8.03	7.64e-15	3.07e-12	0.37	0.35	N-glycan levels;	chr14:65744532	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.707	rs761830	ENSG00000276116.2	FUT8-AS1	8.03	7.64e-15	3.07e-12	0.37	0.35	N-glycan levels;	chr14:65746268	chr14:65411170~65412690:-
THCA	cis	rs9649213	0.593	rs6465673	ENSG00000272950.1	RP11-307C18.1	8.03	7.65e-15	3.07e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465677	ENSG00000272950.1	RP11-307C18.1	8.03	7.66e-15	3.08e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465678	ENSG00000272950.1	RP11-307C18.1	8.03	7.66e-15	3.08e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr7:98322853~98323430:+
THCA	cis	rs4950322	0.542	rs115179956	ENSG00000237188.3	RP11-337C18.8	8.03	7.67e-15	3.08e-12	0.4	0.35	Protein quantitative trait loci;	chr1:147172620	chr1:147172771~147211568:+
THCA	cis	rs7811142	0.945	rs6978739	ENSG00000242294.5	STAG3L5P	8.03	7.67e-15	3.08e-12	0.24	0.35	Platelet count;	chr7:100501057	chr7:100336079~100351900:+
THCA	cis	rs62103177	1	rs62103177	ENSG00000261126.6	RP11-795F19.1	8.03	7.69e-15	3.09e-12	0.4	0.35	Opioid sensitivity;	chr18:79864479	chr18:80046900~80095482:+
THCA	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-8.03	7.71e-15	3.1e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
THCA	cis	rs8114671	0.804	rs3803936	ENSG00000269202.1	RP4-614O4.12	8.03	7.72e-15	3.1e-12	0.29	0.35	Height;	chr20:35044972	chr20:35201747~35203288:-
THCA	cis	rs737008	0.922	rs2550475	ENSG00000262636.1	CTD-3088G3.4	8.03	7.72e-15	3.1e-12	0.45	0.35	Obesity-related traits;	chr16:11278129	chr16:11380859~11381118:-
THCA	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
THCA	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-8.03	7.73e-15	3.1e-12	-0.34	-0.35	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
THCA	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	8.03	7.74e-15	3.1e-12	0.42	0.35	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
THCA	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
THCA	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-8.03	7.77e-15	3.12e-12	-0.35	-0.35	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
THCA	cis	rs9649213	0.593	rs6963210	ENSG00000272950.1	RP11-307C18.1	8.03	7.77e-15	3.12e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs9648908	ENSG00000272950.1	RP11-307C18.1	8.03	7.77e-15	3.12e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7797943	ENSG00000272950.1	RP11-307C18.1	8.03	7.77e-15	3.12e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr7:98322853~98323430:+
THCA	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	8.03	7.78e-15	3.12e-12	0.43	0.35	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
THCA	cis	rs910316	0.763	rs6574205	ENSG00000279594.1	RP11-950C14.10	8.03	7.79e-15	3.12e-12	0.32	0.35	Height;	chr14:74986336	chr14:75011269~75012851:-
THCA	cis	rs1850744	0.826	rs115893429	ENSG00000250942.1	ENPP7P11	-8.03	7.79e-15	3.12e-12	-0.51	-0.35	Economic and political preferences;	chr4:9592194	chr4:9677308~9677934:+
THCA	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	8.03	7.8e-15	3.13e-12	0.56	0.35	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
THCA	cis	rs9649213	0.593	rs3801264	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs1468338	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs2158553	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs10808107	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.613	rs10953256	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.613	rs2286074	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7789380	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6948540	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs6979373	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs34717219	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs62478177	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs3801263	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.555	rs12667634	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr7:98322853~98323430:+
THCA	cis	rs8114671	0.836	rs2425012	ENSG00000269202.1	RP4-614O4.12	8.03	7.8e-15	3.13e-12	0.29	0.35	Height;	chr20:34994152	chr20:35201747~35203288:-
THCA	cis	rs9649213	0.593	rs7795176	ENSG00000272950.1	RP11-307C18.1	8.03	7.81e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs62478200	ENSG00000272950.1	RP11-307C18.1	8.03	7.81e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465675	ENSG00000272950.1	RP11-307C18.1	-8.03	7.81e-15	3.13e-12	-0.42	-0.35	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs2107716	ENSG00000272950.1	RP11-307C18.1	8.03	7.81e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr7:98322853~98323430:+
THCA	cis	rs9309473	0.607	rs1403412	ENSG00000163016.8	ALMS1P	8.03	7.82e-15	3.13e-12	0.46	0.35	Metabolite levels;	chr2:73370964	chr2:73644919~73685576:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-8.03	7.82e-15	3.14e-12	-0.25	-0.35	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
THCA	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	8.03	7.82e-15	3.14e-12	0.42	0.35	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	8.03	7.82e-15	3.14e-12	0.42	0.35	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	8.03	7.82e-15	3.14e-12	0.42	0.35	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	8.03	7.82e-15	3.14e-12	0.42	0.35	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
THCA	cis	rs1707322	1	rs7547189	ENSG00000234329.1	RP11-767N6.2	8.03	7.83e-15	3.14e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7547284	ENSG00000234329.1	RP11-767N6.2	8.03	7.83e-15	3.14e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45651039~45651826:-
THCA	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-8.03	7.84e-15	3.14e-12	-0.41	-0.35	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-8.03	7.84e-15	3.14e-12	-0.41	-0.35	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-8.03	7.84e-15	3.14e-12	-0.41	-0.35	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-8.03	7.84e-15	3.14e-12	-0.41	-0.35	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
THCA	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-8.03	7.84e-15	3.14e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
THCA	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-8.03	7.84e-15	3.14e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
THCA	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-8.03	7.84e-15	3.14e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
THCA	cis	rs2408955	0.522	rs4760679	ENSG00000258273.1	RP11-370I10.4	8.03	7.85e-15	3.14e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48067852	chr12:48333755~48333901:-
THCA	cis	rs9649213	0.593	rs6955647	ENSG00000272950.1	RP11-307C18.1	8.03	7.85e-15	3.14e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr7:98322853~98323430:+
THCA	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	8.03	7.85e-15	3.15e-12	0.42	0.35	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
THCA	cis	rs116175783	0.557	rs62188136	ENSG00000227403.1	AC009299.3	8.03	7.86e-15	3.15e-12	0.61	0.35	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161244739~161249050:+
THCA	cis	rs944289	0.966	rs34992253	ENSG00000257826.1	RP11-116N8.4	-8.03	7.86e-15	3.15e-12	-0.37	-0.35	Thyroid cancer;	chr14:36177957	chr14:36061026~36067190:-
THCA	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	8.03	7.87e-15	3.15e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	8.03	7.87e-15	3.15e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	8.03	7.87e-15	3.15e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
THCA	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	8.03	7.87e-15	3.15e-12	0.44	0.35	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	8.03	7.87e-15	3.15e-12	0.44	0.35	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	8.03	7.87e-15	3.15e-12	0.44	0.35	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
THCA	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-8.03	7.87e-15	3.15e-12	-0.42	-0.35	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
THCA	cis	rs934734	0.789	rs268122	ENSG00000204929.10	AC074391.1	-8.03	7.88e-15	3.16e-12	-0.44	-0.35	Rheumatoid arthritis;	chr2:65374975	chr2:65436711~66084639:+
THCA	cis	rs7674212	0.556	rs6533039	ENSG00000251288.2	RP11-10L12.2	-8.03	7.88e-15	3.16e-12	-0.46	-0.35	Type 2 diabetes;	chr4:102938381	chr4:102751401~102752641:+
THCA	cis	rs4819052	0.788	rs13049700	ENSG00000215447.6	BX322557.10	-8.03	7.88e-15	3.16e-12	-0.3	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45288052~45291738:+
THCA	cis	rs2562456	0.917	rs2681392	ENSG00000268555.1	RP11-678G14.3	-8.03	7.9e-15	3.16e-12	-0.48	-0.35	Pain;	chr19:21513185	chr19:21570822~21587322:-
THCA	cis	rs910316	1	rs13099	ENSG00000279594.1	RP11-950C14.10	-8.03	7.91e-15	3.17e-12	-0.32	-0.35	Height;	chr14:75132452	chr14:75011269~75012851:-
THCA	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	8.03	7.91e-15	3.17e-12	0.43	0.35	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
THCA	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-8.03	7.92e-15	3.17e-12	-0.26	-0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
THCA	cis	rs41307935	0.908	rs17162313	ENSG00000260063.1	RP5-968P14.2	8.03	7.92e-15	3.17e-12	0.65	0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26849628	chr1:26692132~26694131:-
THCA	cis	rs9649213	0.593	rs13232181	ENSG00000272950.1	RP11-307C18.1	8.03	7.92e-15	3.17e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr7:98322853~98323430:+
THCA	cis	rs66887589	0.934	rs7681980	ENSG00000245958.5	RP11-33B1.1	8.03	7.94e-15	3.18e-12	0.3	0.35	Diastolic blood pressure;	chr4:119612068	chr4:119454791~119552025:+
THCA	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	8.03	7.94e-15	3.18e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
THCA	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-8.03	7.95e-15	3.18e-12	-0.42	-0.35	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
THCA	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	8.03	7.97e-15	3.19e-12	0.46	0.35	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
THCA	cis	rs1707322	1	rs6661500	ENSG00000234329.1	RP11-767N6.2	8.03	7.97e-15	3.19e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45651039~45651826:-
THCA	cis	rs2439831	0.867	rs11856184	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43626964	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2927072	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43630200	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2920781	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43632484	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.764	rs2447193	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43637535	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
THCA	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	8.03	7.98e-15	3.19e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	8.03	7.98e-15	3.19e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	8.03	7.98e-15	3.19e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
THCA	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	8.03	7.98e-15	3.2e-12	0.41	0.35	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
THCA	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	8.03	7.99e-15	3.2e-12	0.45	0.35	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
THCA	cis	rs2839186	0.709	rs2156117	ENSG00000239415.1	AP001469.9	8.03	8e-15	3.2e-12	0.36	0.35	Testicular germ cell tumor;	chr21:46249386	chr21:46251549~46254133:-
THCA	cis	rs7221109	0.857	rs11658582	ENSG00000278834.1	RP11-458J1.1	8.03	8e-15	3.2e-12	0.36	0.35	Type 1 diabetes;	chr17:40606948	chr17:40648300~40649718:+
THCA	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	8.03	8.01e-15	3.2e-12	0.44	0.35	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	8.03	8.01e-15	3.2e-12	0.44	0.35	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
THCA	cis	rs9649213	0.537	rs6971825	ENSG00000272950.1	RP11-307C18.1	8.03	8.02e-15	3.21e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr7:98322853~98323430:+
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000215447.6	BX322557.10	-8.03	8.02e-15	3.21e-12	-0.32	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45288052~45291738:+
THCA	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-8.03	8.02e-15	3.21e-12	-0.43	-0.35	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
THCA	cis	rs1707322	1	rs10890359	ENSG00000234329.1	RP11-767N6.2	8.03	8.03e-15	3.21e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45651039~45651826:-
THCA	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	8.03	8.03e-15	3.21e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
THCA	cis	rs7247513	0.866	rs7247171	ENSG00000230310.1	CTD-2192J16.11	-8.03	8.03e-15	3.21e-12	-0.42	-0.35	Bipolar disorder;	chr19:12595186	chr19:12552597~12553644:+
THCA	cis	rs9649213	0.593	rs6973775	ENSG00000272950.1	RP11-307C18.1	8.03	8.05e-15	3.22e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.613	rs7777415	ENSG00000272950.1	RP11-307C18.1	8.03	8.05e-15	3.22e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98329902	chr7:98322853~98323430:+
THCA	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-8.03	8.07e-15	3.23e-12	-0.41	-0.35	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	8.03	8.08e-15	3.23e-12	0.42	0.35	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	8.03	8.08e-15	3.23e-12	0.42	0.35	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
THCA	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-8.03	8.08e-15	3.23e-12	-0.41	-0.35	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-8.03	8.08e-15	3.23e-12	-0.41	-0.35	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
THCA	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	8.03	8.1e-15	3.24e-12	0.41	0.35	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
THCA	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	8.03	8.1e-15	3.24e-12	0.42	0.35	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
THCA	cis	rs11673344	0.504	rs4806409	ENSG00000226686.6	LINC01535	8.03	8.11e-15	3.24e-12	0.38	0.35	Obesity-related traits;	chr19:37097923	chr19:37251912~37265535:+
THCA	cis	rs1707322	1	rs6429588	ENSG00000234329.1	RP11-767N6.2	8.03	8.11e-15	3.24e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12097799	ENSG00000234329.1	RP11-767N6.2	8.03	8.11e-15	3.24e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45651039~45651826:-
THCA	cis	rs507080	0.769	rs12290522	ENSG00000278376.1	RP11-158I9.8	-8.03	8.13e-15	3.25e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118615610	chr11:118791254~118793137:+
THCA	cis	rs7015263	1	rs7823154	ENSG00000254231.1	CTD-2284J15.1	8.03	8.14e-15	3.26e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr8:86524742	chr8:86333274~86343314:-
THCA	cis	rs7291412	0.929	rs7289457	ENSG00000231711.2	LINC00899	8.03	8.14e-15	3.26e-12	0.3	0.35	Dupuytren's disease;Subjective well-being;	chr22:46060723	chr22:46039907~46044853:-
THCA	cis	rs116175783	0.557	rs16845844	ENSG00000227403.1	AC009299.3	-8.03	8.15e-15	3.26e-12	-0.61	-0.35	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161244739~161249050:+
THCA	cis	rs73607972	0.597	rs1111487	ENSG00000275191.1	RP11-36I17.2	8.02	8.2e-15	3.28e-12	0.47	0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53528217	chr16:53628256~53628816:-
THCA	cis	rs2839186	0.721	rs3788252	ENSG00000239415.1	AP001469.9	8.02	8.2e-15	3.28e-12	0.37	0.35	Testicular germ cell tumor;	chr21:46241321	chr21:46251549~46254133:-
THCA	cis	rs7015263	0.936	rs7463186	ENSG00000254231.1	CTD-2284J15.1	8.02	8.2e-15	3.28e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr8:86504972	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs7006629	ENSG00000254231.1	CTD-2284J15.1	8.02	8.2e-15	3.28e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr8:86507313	chr8:86333274~86343314:-
THCA	cis	rs10411161	0.671	rs8105497	ENSG00000269483.1	AC006272.1	8.02	8.21e-15	3.28e-12	0.45	0.35	Breast cancer;	chr19:51847134	chr19:51839924~51843324:-
THCA	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-8.02	8.22e-15	3.28e-12	-0.45	-0.35	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
THCA	cis	rs189798	0.845	rs330904	ENSG00000254340.1	RP11-10A14.3	-8.02	8.24e-15	3.29e-12	-0.39	-0.35	Myopia (pathological);	chr8:9134315	chr8:9141424~9145435:+
THCA	cis	rs16846053	0.748	rs890076	ENSG00000227403.1	AC009299.3	-8.02	8.24e-15	3.29e-12	-0.59	-0.35	Blood osmolality (transformed sodium);	chr2:161424237	chr2:161244739~161249050:+
THCA	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-8.02	8.25e-15	3.3e-12	-0.42	-0.35	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
THCA	cis	rs7430456	0.874	rs7428501	ENSG00000228221.4	LINC00578	8.02	8.25e-15	3.3e-12	0.46	0.35	Breast cancer;	chr3:177751974	chr3:177441921~177752305:+
THCA	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	8.02	8.27e-15	3.3e-12	0.42	0.35	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
THCA	cis	rs1707322	1	rs4660906	ENSG00000234329.1	RP11-767N6.2	8.02	8.27e-15	3.31e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45651039~45651826:-
THCA	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-8.02	8.28e-15	3.31e-12	-0.43	-0.35	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
THCA	cis	rs7727544	0.716	rs6863213	ENSG00000224431.1	AC063976.7	8.02	8.3e-15	3.32e-12	0.31	0.35	Blood metabolite levels;	chr5:132240239	chr5:132199456~132203487:+
THCA	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	8.02	8.3e-15	3.32e-12	0.33	0.35	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
THCA	cis	rs7727544	0.606	rs200838	ENSG00000233006.5	AC034220.3	-8.02	8.31e-15	3.32e-12	-0.27	-0.35	Blood metabolite levels;	chr5:132374707	chr5:132311285~132369916:-
THCA	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-8.02	8.33e-15	3.33e-12	-0.42	-0.35	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
THCA	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	8.02	8.34e-15	3.33e-12	0.51	0.35	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
THCA	cis	rs416603	0.967	rs11644184	ENSG00000262636.1	CTD-3088G3.4	-8.02	8.36e-15	3.34e-12	-0.43	-0.35	Type 1 diabetes;	chr16:11271247	chr16:11380859~11381118:-
THCA	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-8.02	8.38e-15	3.35e-12	-0.54	-0.35	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
THCA	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-8.02	8.39e-15	3.35e-12	-0.41	-0.35	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
THCA	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-8.02	8.43e-15	3.36e-12	-0.48	-0.35	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
THCA	cis	rs42490	0.625	rs425312	ENSG00000251136.7	RP11-37B2.1	-8.02	8.45e-15	3.38e-12	-0.3	-0.35	Leprosy;	chr8:89834127	chr8:89609409~89757727:-
THCA	cis	rs11673344	0.504	rs2385374	ENSG00000226686.6	LINC01535	8.02	8.46e-15	3.38e-12	0.38	0.35	Obesity-related traits;	chr19:37092115	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs4254428	ENSG00000226686.6	LINC01535	8.02	8.46e-15	3.38e-12	0.38	0.35	Obesity-related traits;	chr19:37093748	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs8109501	ENSG00000226686.6	LINC01535	8.02	8.46e-15	3.38e-12	0.38	0.35	Obesity-related traits;	chr19:37102194	chr19:37251912~37265535:+
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-8.02	8.5e-15	3.39e-12	-0.64	-0.35	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
THCA	cis	rs934734	0.752	rs268131	ENSG00000204929.10	AC074391.1	-8.02	8.53e-15	3.4e-12	-0.42	-0.35	Rheumatoid arthritis;	chr2:65383337	chr2:65436711~66084639:+
THCA	cis	rs673078	0.66	rs78690826	ENSG00000275409.1	RP11-131L12.4	-8.02	8.53e-15	3.41e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118176693	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs17512142	ENSG00000275409.1	RP11-131L12.4	-8.02	8.53e-15	3.41e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118186186	chr12:118430147~118430699:+
THCA	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-8.02	8.54e-15	3.41e-12	-0.4	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
THCA	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	8.02	8.54e-15	3.41e-12	0.42	0.35	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
THCA	cis	rs227932	0.614	rs4722260	ENSG00000234286.1	AC006026.13	8.02	8.54e-15	3.41e-12	0.6	0.35	Schizophrenia;	chr7:23719851	chr7:23680195~23680786:-
THCA	cis	rs1707322	1	rs12403666	ENSG00000234329.1	RP11-767N6.2	8.02	8.54e-15	3.41e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45651039~45651826:-
THCA	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-8.02	8.58e-15	3.42e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
THCA	cis	rs1707322	0.964	rs6697830	ENSG00000234329.1	RP11-767N6.2	8.02	8.58e-15	3.43e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12060274	ENSG00000234329.1	RP11-767N6.2	8.02	8.58e-15	3.43e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45651039~45651826:-
THCA	cis	rs2712184	0.729	rs2541397	ENSG00000229352.1	AC007563.3	-8.02	8.6e-15	3.43e-12	-0.41	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216781970	chr2:216799608~216805335:+
THCA	cis	rs7208859	0.623	rs55724095	ENSG00000266490.1	CTD-2349P21.9	8.02	8.6e-15	3.43e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.568	rs9903854	ENSG00000266490.1	CTD-2349P21.9	8.02	8.6e-15	3.43e-12	0.49	0.35	Body mass index;	chr17:30826980	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs80355557	ENSG00000266490.1	CTD-2349P21.9	8.02	8.6e-15	3.43e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9911173	ENSG00000266490.1	CTD-2349P21.9	8.02	8.6e-15	3.43e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30792372~30792833:+
THCA	cis	rs7727544	0.716	rs4594848	ENSG00000224431.1	AC063976.7	8.02	8.6e-15	3.43e-12	0.31	0.35	Blood metabolite levels;	chr5:132250905	chr5:132199456~132203487:+
THCA	cis	rs910316	0.967	rs175502	ENSG00000279594.1	RP11-950C14.10	-8.02	8.63e-15	3.44e-12	-0.32	-0.35	Height;	chr14:75066976	chr14:75011269~75012851:-
THCA	cis	rs3096299	0.542	rs1078578	ENSG00000274627.1	RP11-104N10.2	8.02	8.63e-15	3.44e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89320526	chr16:89516797~89522217:+
THCA	cis	rs7208859	0.673	rs216424	ENSG00000266490.1	CTD-2349P21.9	8.02	8.63e-15	3.44e-12	0.44	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30792372~30792833:+
THCA	cis	rs7247513	0.93	rs34321000	ENSG00000230310.1	CTD-2192J16.11	-8.02	8.64e-15	3.45e-12	-0.42	-0.35	Bipolar disorder;	chr19:12602274	chr19:12552597~12553644:+
THCA	cis	rs9329221	0.527	rs34259385	ENSG00000261451.1	RP11-981G7.1	-8.02	8.65e-15	3.45e-12	-0.44	-0.35	Neuroticism;	chr8:10467946	chr8:10433672~10438312:+
THCA	cis	rs7247513	0.93	rs35275129	ENSG00000230310.1	CTD-2192J16.11	-8.02	8.66e-15	3.45e-12	-0.41	-0.35	Bipolar disorder;	chr19:12605679	chr19:12552597~12553644:+
THCA	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	8.02	8.66e-15	3.45e-12	0.4	0.35	Migraine;	chr4:56861145	chr4:56960927~56961373:-
THCA	cis	rs4780355	0.619	rs918737	ENSG00000262636.1	CTD-3088G3.4	-8.02	8.7e-15	3.47e-12	-0.46	-0.35	Crohn's disease and psoriasis;	chr16:11345782	chr16:11380859~11381118:-
THCA	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-8.02	8.7e-15	3.47e-12	-0.37	-0.35	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-8.02	8.7e-15	3.47e-12	-0.37	-0.35	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
THCA	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	8.02	8.72e-15	3.47e-12	0.23	0.35	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	8.02	8.72e-15	3.47e-12	0.23	0.35	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	8.02	8.72e-15	3.47e-12	0.23	0.35	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	8.02	8.72e-15	3.47e-12	0.23	0.35	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
THCA	cis	rs9649213	0.574	rs3801257	ENSG00000272950.1	RP11-307C18.1	8.02	8.72e-15	3.48e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7803372	ENSG00000272950.1	RP11-307C18.1	8.02	8.72e-15	3.48e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr7:98322853~98323430:+
THCA	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	8.02	8.73e-15	3.48e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
THCA	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	8.02	8.76e-15	3.49e-12	0.33	0.35	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
THCA	cis	rs922182	0.617	rs13329183	ENSG00000275785.1	RP11-111E14.2	8.02	8.77e-15	3.49e-12	0.4	0.35	Blood protein levels;	chr15:63948610	chr15:63890030~63890317:+
THCA	cis	rs922182	0.579	rs13329518	ENSG00000275785.1	RP11-111E14.2	8.02	8.77e-15	3.49e-12	0.4	0.35	Blood protein levels;	chr15:63948881	chr15:63890030~63890317:+
THCA	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	8.02	8.77e-15	3.49e-12	0.24	0.35	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
THCA	cis	rs910316	1	rs12889472	ENSG00000279594.1	RP11-950C14.10	8.02	8.77e-15	3.5e-12	0.32	0.35	Height;	chr14:75077276	chr14:75011269~75012851:-
THCA	cis	rs9649213	0.593	rs7776638	ENSG00000272950.1	RP11-307C18.1	8.01	8.81e-15	3.51e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs36099592	ENSG00000272950.1	RP11-307C18.1	8.01	8.81e-15	3.51e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr7:98322853~98323430:+
THCA	cis	rs2562456	0.917	rs9304987	ENSG00000268555.1	RP11-678G14.3	-8.01	8.82e-15	3.51e-12	-0.48	-0.35	Pain;	chr19:21499472	chr19:21570822~21587322:-
THCA	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	8.01	8.83e-15	3.52e-12	0.42	0.35	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
THCA	cis	rs11696845	0.896	rs61356009	ENSG00000276223.1	RP4-781B1.5	-8.01	8.84e-15	3.52e-12	-0.42	-0.35	Obesity-related traits;	chr20:44743750	chr20:44746642~44747201:+
THCA	cis	rs11673344	0.504	rs11084874	ENSG00000226686.6	LINC01535	8.01	8.87e-15	3.53e-12	0.38	0.35	Obesity-related traits;	chr19:37096667	chr19:37251912~37265535:+
THCA	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-8.01	8.87e-15	3.53e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
THCA	cis	rs9400467	0.528	rs56827	ENSG00000230177.1	RP5-1112D6.4	-8.01	8.88e-15	3.54e-12	-0.27	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111277932~111278742:+
THCA	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	8.01	8.89e-15	3.54e-12	0.42	0.35	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	8.01	8.89e-15	3.54e-12	0.42	0.35	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	8.01	8.89e-15	3.54e-12	0.42	0.35	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
THCA	cis	rs736801	0.78	rs11951091	ENSG00000237714.1	P4HA2-AS1	8.01	8.92e-15	3.55e-12	0.47	0.35	Mosquito bite size;Breast cancer;	chr5:132450903	chr5:132184876~132192808:+
THCA	cis	rs1707322	1	rs785480	ENSG00000234329.1	RP11-767N6.2	8.01	8.93e-15	3.55e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45651039~45651826:-
THCA	cis	rs11971779	0.638	rs77668044	ENSG00000273391.1	RP11-634H22.1	8.01	8.93e-15	3.56e-12	0.4	0.35	Diisocyanate-induced asthma;	chr7:139426339	chr7:139359032~139359566:-
THCA	cis	rs910316	1	rs175426	ENSG00000279594.1	RP11-950C14.10	-8.01	8.95e-15	3.56e-12	-0.32	-0.35	Height;	chr14:75157431	chr14:75011269~75012851:-
THCA	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	8.01	8.95e-15	3.57e-12	0.41	0.35	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
THCA	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-8.01	8.98e-15	3.58e-12	-0.45	-0.35	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
THCA	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-8.01	9e-15	3.58e-12	-0.41	-0.35	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
THCA	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	8.01	9e-15	3.58e-12	0.43	0.35	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
THCA	cis	rs1859596	0.646	rs6957474	ENSG00000234456.6	MAGI2-AS3	8.01	9e-15	3.58e-12	0.33	0.35	Reading or mathematical ability;	chr7:79458308	chr7:79452877~79471208:+
THCA	cis	rs10208649	0.908	rs13395751	ENSG00000272156.1	RP11-477N3.1	8.01	9.02e-15	3.59e-12	0.64	0.35	Body mass index;	chr2:54011657	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs6715161	ENSG00000272156.1	RP11-477N3.1	8.01	9.02e-15	3.59e-12	0.64	0.35	Body mass index;	chr2:54012968	chr2:54082554~54085066:+
THCA	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	8.01	9.03e-15	3.59e-12	0.33	0.35	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
THCA	cis	rs1707322	1	rs4390216	ENSG00000234329.1	RP11-767N6.2	8.01	9.04e-15	3.6e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs10437063	ENSG00000234329.1	RP11-767N6.2	8.01	9.04e-15	3.6e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6676982	ENSG00000234329.1	RP11-767N6.2	8.01	9.04e-15	3.6e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.927	rs11211194	ENSG00000234329.1	RP11-767N6.2	8.01	9.04e-15	3.6e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45651039~45651826:-
THCA	cis	rs9649213	0.593	rs34534766	ENSG00000272950.1	RP11-307C18.1	8.01	9.05e-15	3.6e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr7:98322853~98323430:+
THCA	cis	rs527616	0.93	rs604702	ENSG00000265369.3	PCAT18	8.01	9.06e-15	3.61e-12	0.43	0.35	Breast cancer;	chr18:26751502	chr18:26687621~26703638:-
THCA	cis	rs910316	0.737	rs2098251	ENSG00000279594.1	RP11-950C14.10	8.01	9.07e-15	3.61e-12	0.32	0.35	Height;	chr14:75025993	chr14:75011269~75012851:-
THCA	cis	rs910316	0.664	rs2098252	ENSG00000279594.1	RP11-950C14.10	8.01	9.07e-15	3.61e-12	0.32	0.35	Height;	chr14:75026029	chr14:75011269~75012851:-
THCA	cis	rs910316	0.737	rs28687415	ENSG00000279594.1	RP11-950C14.10	8.01	9.07e-15	3.61e-12	0.32	0.35	Height;	chr14:75028779	chr14:75011269~75012851:-
THCA	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	8.01	9.07e-15	3.61e-12	0.25	0.35	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
THCA	cis	rs507080	0.769	rs570836	ENSG00000278376.1	RP11-158I9.8	-8.01	9.07e-15	3.61e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118641444	chr11:118791254~118793137:+
THCA	cis	rs984222	0.586	rs12742258	ENSG00000231365.4	RP11-418J17.1	8.01	9.08e-15	3.61e-12	0.34	0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119199678	chr1:119140396~119275973:+
THCA	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	8.01	9.1e-15	3.62e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
THCA	cis	rs2562456	0.917	rs11085463	ENSG00000268555.1	RP11-678G14.3	8.01	9.11e-15	3.63e-12	0.47	0.35	Pain;	chr19:21568500	chr19:21570822~21587322:-
THCA	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-8.01	9.12e-15	3.63e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
THCA	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-8.01	9.12e-15	3.63e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
THCA	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.537	rs35997266	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6945554	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr7:98322853~98323430:+
THCA	cis	rs2288884	0.79	rs7253849	ENSG00000275055.1	CTC-471J1.11	-8.01	9.15e-15	3.64e-12	-0.31	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056992	chr19:52049007~52049754:+
THCA	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-8.01	9.18e-15	3.65e-12	-0.44	-0.35	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
THCA	cis	rs1707322	1	rs946527	ENSG00000234329.1	RP11-767N6.2	8.01	9.18e-15	3.65e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45651039~45651826:-
THCA	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	8.01	9.19e-15	3.65e-12	0.33	0.35	Breast size;	chr12:9220132	chr12:9277235~9313241:+
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000230295.1	RP11-458F8.2	-8.01	9.22e-15	3.67e-12	-0.32	-0.35	Corneal structure;	chr7:66801919	chr7:66880708~66882981:+
THCA	cis	rs2929278	0.617	rs663214	ENSG00000166763.7	STRCP1	-8.01	9.23e-15	3.67e-12	-0.37	-0.35	Schizophrenia;	chr15:43821584	chr15:43699488~43718184:-
THCA	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-8.01	9.24e-15	3.67e-12	-0.34	-0.35	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
THCA	cis	rs9649213	0.593	rs1859482	ENSG00000272950.1	RP11-307C18.1	8.01	9.24e-15	3.67e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs13246868	ENSG00000272950.1	RP11-307C18.1	8.01	9.24e-15	3.67e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs12672092	ENSG00000272950.1	RP11-307C18.1	8.01	9.24e-15	3.67e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr7:98322853~98323430:+
THCA	cis	rs853679	0.825	rs8180562	ENSG00000280107.1	AL022393.9	-8.01	9.24e-15	3.68e-12	-0.53	-0.35	Depression;	chr6:28173682	chr6:28170845~28172521:+
THCA	cis	rs853679	0.882	rs9380064	ENSG00000280107.1	AL022393.9	-8.01	9.24e-15	3.68e-12	-0.53	-0.35	Depression;	chr6:28175340	chr6:28170845~28172521:+
THCA	cis	rs11673344	0.504	rs7258360	ENSG00000226686.6	LINC01535	8.01	9.25e-15	3.68e-12	0.38	0.35	Obesity-related traits;	chr19:37115015	chr19:37251912~37265535:+
THCA	cis	rs7727544	0.606	rs10060615	ENSG00000224431.1	AC063976.7	8.01	9.26e-15	3.68e-12	0.3	0.35	Blood metabolite levels;	chr5:132373185	chr5:132199456~132203487:+
THCA	cis	rs7208859	0.673	rs3764420	ENSG00000266490.1	CTD-2349P21.9	8.01	9.26e-15	3.68e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30792372~30792833:+
THCA	cis	rs507080	0.769	rs11603616	ENSG00000278376.1	RP11-158I9.8	-8.01	9.26e-15	3.68e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118625350	chr11:118791254~118793137:+
THCA	cis	rs507080	0.769	rs571001	ENSG00000278376.1	RP11-158I9.8	-8.01	9.26e-15	3.68e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118629457	chr11:118791254~118793137:+
THCA	cis	rs507080	0.769	rs570952	ENSG00000278376.1	RP11-158I9.8	-8.01	9.26e-15	3.68e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118629477	chr11:118791254~118793137:+
THCA	cis	rs507080	0.769	rs483283	ENSG00000278376.1	RP11-158I9.8	-8.01	9.26e-15	3.68e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118635684	chr11:118791254~118793137:+
THCA	cis	rs7727544	0.716	rs11949055	ENSG00000224431.1	AC063976.7	8.01	9.26e-15	3.68e-12	0.31	0.35	Blood metabolite levels;	chr5:132241044	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.716	rs3844312	ENSG00000224431.1	AC063976.7	8.01	9.26e-15	3.68e-12	0.31	0.35	Blood metabolite levels;	chr5:132246663	chr5:132199456~132203487:+
THCA	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	8.01	9.28e-15	3.69e-12	0.41	0.35	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
THCA	cis	rs507080	0.883	rs12798453	ENSG00000278376.1	RP11-158I9.8	-8.01	9.28e-15	3.69e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118690701	chr11:118791254~118793137:+
THCA	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-8.01	9.28e-15	3.69e-12	-0.36	-0.35	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
THCA	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
THCA	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	8.01	9.29e-15	3.69e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
THCA	cis	rs922182	0.595	rs9302232	ENSG00000275785.1	RP11-111E14.2	8.01	9.33e-15	3.71e-12	0.41	0.35	Blood protein levels;	chr15:63913159	chr15:63890030~63890317:+
THCA	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	8.01	9.33e-15	3.71e-12	0.9	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
THCA	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	8.01	9.33e-15	3.71e-12	0.35	0.35	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	8.01	9.33e-15	3.71e-12	0.35	0.35	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
THCA	cis	rs934734	0.967	rs17534670	ENSG00000204929.10	AC074391.1	-8.01	9.33e-15	3.71e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65388294	chr2:65436711~66084639:+
THCA	cis	rs6504108	0.624	rs10853098	ENSG00000278765.1	RP5-890E16.5	-8.01	9.34e-15	3.71e-12	-0.39	-0.35	Body mass index;	chr17:48159219	chr17:48066704~48067293:-
THCA	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	8.01	9.34e-15	3.71e-12	0.33	0.35	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
THCA	cis	rs922182	0.617	rs11852732	ENSG00000275785.1	RP11-111E14.2	8.01	9.35e-15	3.71e-12	0.4	0.35	Blood protein levels;	chr15:63947708	chr15:63890030~63890317:+
THCA	cis	rs922182	0.579	rs11856257	ENSG00000275785.1	RP11-111E14.2	8.01	9.35e-15	3.71e-12	0.4	0.35	Blood protein levels;	chr15:63947742	chr15:63890030~63890317:+
THCA	cis	rs922182	0.617	rs28621460	ENSG00000275785.1	RP11-111E14.2	8.01	9.35e-15	3.71e-12	0.4	0.35	Blood protein levels;	chr15:63948033	chr15:63890030~63890317:+
THCA	cis	rs922182	0.617	rs2899697	ENSG00000275785.1	RP11-111E14.2	8.01	9.35e-15	3.71e-12	0.4	0.35	Blood protein levels;	chr15:63948237	chr15:63890030~63890317:+
THCA	cis	rs9649213	0.593	rs3823740	ENSG00000272950.1	RP11-307C18.1	8.01	9.35e-15	3.72e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs35535338	ENSG00000272950.1	RP11-307C18.1	8.01	9.35e-15	3.72e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs36017146	ENSG00000272950.1	RP11-307C18.1	8.01	9.35e-15	3.72e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr7:98322853~98323430:+
THCA	cis	rs2946504	0.861	rs2946494	ENSG00000251468.2	RP11-369K16.1	-8.01	9.4e-15	3.73e-12	-0.43	-0.35	Type 2 diabetes;	chr8:12962601	chr8:12958387~12962200:+
THCA	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	8	9.45e-15	3.75e-12	0.41	0.35	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
THCA	cis	rs516805	0.748	rs577744	ENSG00000279453.1	RP3-425C14.4	-8	9.47e-15	3.76e-12	-0.36	-0.35	Lymphocyte counts;	chr6:122447712	chr6:122436789~122439223:-
THCA	cis	rs984222	0.617	rs2003365	ENSG00000231365.4	RP11-418J17.1	8	9.47e-15	3.76e-12	0.34	0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119219414	chr1:119140396~119275973:+
THCA	cis	rs1707322	1	rs11211248	ENSG00000234329.1	RP11-767N6.2	8	9.49e-15	3.77e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7532204	ENSG00000234329.1	RP11-767N6.2	-8	9.49e-15	3.77e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.835	rs946525	ENSG00000234329.1	RP11-767N6.2	-8	9.49e-15	3.77e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs946524	ENSG00000234329.1	RP11-767N6.2	-8	9.49e-15	3.77e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660336	ENSG00000234329.1	RP11-767N6.2	-8	9.49e-15	3.77e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45651039~45651826:-
THCA	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	8	9.52e-15	3.78e-12	0.71	0.35	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
THCA	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-8	9.53e-15	3.78e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
THCA	cis	rs6597981	0.592	rs28625355	ENSG00000255284.1	AP006621.5	8	9.55e-15	3.79e-12	0.24	0.35	Breast cancer;	chr11:736334	chr11:777578~784297:+
THCA	cis	rs17459044	1	rs17459044	ENSG00000268707.1	RP11-247A12.7	-8	9.56e-15	3.8e-12	-0.43	-0.35	Pelvic organ prolapse (moderate/severe);	chr9:129091345	chr9:129170434~129170940:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000226314.6	ZNF192P1	8	9.6e-15	3.81e-12	0.44	0.35	Parkinson's disease;	chr6:28002253	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs156744	ENSG00000226314.6	ZNF192P1	-8	9.6e-15	3.81e-12	-0.44	-0.35	Parkinson's disease;	chr6:27999496	chr6:28161781~28169594:+
THCA	cis	rs62158211	0.826	rs62158168	ENSG00000272563.1	RP11-480C16.1	-8	9.61e-15	3.81e-12	-0.46	-0.35	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113320804	chr2:113432600~113436042:+
THCA	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-8	9.61e-15	3.82e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
THCA	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	8	9.66e-15	3.83e-12	0.43	0.35	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
THCA	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	8	9.69e-15	3.85e-12	0.34	0.35	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
THCA	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	8	9.69e-15	3.85e-12	0.34	0.35	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
THCA	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	8	9.69e-15	3.85e-12	0.34	0.35	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
THCA	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-8	9.69e-15	3.85e-12	-0.38	-0.35	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
THCA	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	8	9.78e-15	3.88e-12	0.45	0.35	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
THCA	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	8	9.79e-15	3.88e-12	0.64	0.35	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
THCA	cis	rs7247513	0.964	rs4804200	ENSG00000230310.1	CTD-2192J16.11	-8	9.8e-15	3.89e-12	-0.43	-0.35	Bipolar disorder;	chr19:12599938	chr19:12552597~12553644:+
THCA	cis	rs7247513	0.964	rs4371272	ENSG00000230310.1	CTD-2192J16.11	-8	9.8e-15	3.89e-12	-0.43	-0.35	Bipolar disorder;	chr19:12600467	chr19:12552597~12553644:+
THCA	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	8	9.84e-15	3.9e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
THCA	cis	rs1799949	0.602	rs8176199	ENSG00000267681.1	CTD-3199J23.6	-8	9.86e-15	3.91e-12	-0.46	-0.35	Menopause (age at onset);	chr17:43078507	chr17:43144956~43145255:+
THCA	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	8	9.9e-15	3.92e-12	0.41	0.35	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-8	9.9e-15	3.92e-12	-0.41	-0.35	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
THCA	cis	rs7674212	0.531	rs2866416	ENSG00000251288.2	RP11-10L12.2	-8	9.9e-15	3.93e-12	-0.47	-0.35	Type 2 diabetes;	chr4:102959554	chr4:102751401~102752641:+
THCA	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-8	9.94e-15	3.94e-12	-0.41	-0.35	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
THCA	cis	rs2274273	0.623	rs1187881	ENSG00000258413.1	RP11-665C16.6	8	9.96e-15	3.95e-12	0.47	0.35	Protein biomarker;	chr14:55022479	chr14:55262767~55272075:-
THCA	cis	rs2408955	0.542	rs7975632	ENSG00000258273.1	RP11-370I10.4	-8	9.97e-15	3.95e-12	-0.45	-0.35	Glycated hemoglobin levels;	chr12:48049265	chr12:48333755~48333901:-
THCA	cis	rs7247513	0.964	rs1864083	ENSG00000230310.1	CTD-2192J16.11	-8	9.97e-15	3.95e-12	-0.42	-0.35	Bipolar disorder;	chr19:12596488	chr19:12552597~12553644:+
THCA	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	8	9.98e-15	3.96e-12	0.56	0.35	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
THCA	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	8	9.98e-15	3.96e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
THCA	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	8	9.98e-15	3.96e-12	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
THCA	cis	rs2562456	0.874	rs9304986	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.96e-12	-0.48	-0.35	Pain;	chr19:21499260	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2650805	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.96e-12	-0.48	-0.35	Pain;	chr19:21505137	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs10420016	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.96e-12	-0.48	-0.35	Pain;	chr19:21505800	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2681389	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.97e-12	-0.48	-0.35	Pain;	chr19:21509773	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs6511256	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.97e-12	-0.48	-0.35	Pain;	chr19:21510513	chr19:21570822~21587322:-
THCA	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	8	1.01e-14	3.99e-12	0.42	0.35	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
THCA	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	8	1.01e-14	4e-12	0.49	0.35	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
THCA	cis	rs9649213	0.593	rs6944262	ENSG00000272950.1	RP11-307C18.1	8	1.01e-14	4e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr7:98322853~98323430:+
THCA	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	7.99	1.02e-14	4.04e-12	0.91	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
THCA	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	7.99	1.02e-14	4.04e-12	0.43	0.35	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	7.99	1.02e-14	4.04e-12	0.43	0.35	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
THCA	cis	rs240993	0.516	rs173286	ENSG00000230177.1	RP5-1112D6.4	-7.99	1.02e-14	4.04e-12	-0.38	-0.35	Inflammatory skin disease;Psoriasis;	chr6:111292391	chr6:111277932~111278742:+
THCA	cis	rs116175783	0.557	rs2303318	ENSG00000227403.1	AC009299.3	7.99	1.02e-14	4.04e-12	0.61	0.35	Intelligence (multi-trait analysis);	chr2:161367984	chr2:161244739~161249050:+
THCA	cis	rs2839186	0.77	rs2839171	ENSG00000239415.1	AP001469.9	-7.99	1.02e-14	4.05e-12	-0.36	-0.35	Testicular germ cell tumor;	chr21:46253333	chr21:46251549~46254133:-
THCA	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	7.99	1.02e-14	4.05e-12	0.42	0.35	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
THCA	cis	rs4819052	1	rs4818769	ENSG00000237664.1	LINC00316	-7.99	1.03e-14	4.06e-12	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45338590~45341990:-
THCA	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-7.99	1.03e-14	4.07e-12	-0.43	-0.35	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
THCA	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-7.99	1.03e-14	4.07e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
THCA	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-7.99	1.03e-14	4.08e-12	-0.42	-0.35	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
THCA	cis	rs1707322	1	rs10890353	ENSG00000234329.1	RP11-767N6.2	7.99	1.03e-14	4.08e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45651039~45651826:-
THCA	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-7.99	1.03e-14	4.08e-12	-0.56	-0.35	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
THCA	cis	rs9649213	0.593	rs1468340	ENSG00000272950.1	RP11-307C18.1	7.99	1.03e-14	4.09e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.555	rs6956686	ENSG00000272950.1	RP11-307C18.1	7.99	1.03e-14	4.09e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs13246843	ENSG00000272950.1	RP11-307C18.1	7.99	1.03e-14	4.09e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr7:98322853~98323430:+
THCA	cis	rs4072705	1	rs7874367	ENSG00000224020.1	MIR181A2HG	7.99	1.04e-14	4.1e-12	0.3	0.35	Menarche (age at onset);	chr9:124615501	chr9:124658467~124698631:+
THCA	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	7.99	1.04e-14	4.1e-12	0.33	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
THCA	cis	rs17684571	0.872	rs36068365	ENSG00000231441.1	RP11-472M19.2	7.99	1.04e-14	4.1e-12	0.43	0.35	Schizophrenia;	chr6:56716358	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs11968575	ENSG00000231441.1	RP11-472M19.2	7.99	1.04e-14	4.1e-12	0.43	0.35	Schizophrenia;	chr6:56728107	chr6:56844002~56864078:+
THCA	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-7.99	1.04e-14	4.11e-12	-0.3	-0.35	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
THCA	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	7.99	1.04e-14	4.11e-12	0.56	0.35	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
THCA	cis	rs9309473	0.579	rs1852644	ENSG00000163016.8	ALMS1P	7.99	1.04e-14	4.12e-12	0.46	0.35	Metabolite levels;	chr2:73370590	chr2:73644919~73685576:+
THCA	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	7.99	1.04e-14	4.12e-12	0.33	0.35	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
THCA	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	7.99	1.04e-14	4.12e-12	0.43	0.35	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
THCA	cis	rs4927850	1	rs7614767	ENSG00000226155.1	AC124944.3	-7.99	1.04e-14	4.12e-12	-0.41	-0.35	Pancreatic cancer;	chr3:196026580	chr3:195912049~195913986:+
THCA	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
THCA	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	7.99	1.05e-14	4.13e-12	0.48	0.35	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
THCA	cis	rs2562456	0.792	rs2562398	ENSG00000268555.1	RP11-678G14.3	-7.99	1.05e-14	4.14e-12	-0.48	-0.35	Pain;	chr19:21540147	chr19:21570822~21587322:-
THCA	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	7.99	1.05e-14	4.15e-12	0.53	0.35	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	7.99	1.05e-14	4.15e-12	0.53	0.35	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	7.99	1.05e-14	4.15e-12	0.53	0.35	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	7.99	1.05e-14	4.15e-12	0.53	0.35	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
THCA	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-7.99	1.05e-14	4.16e-12	-0.43	-0.35	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
THCA	cis	rs1707322	1	rs10890370	ENSG00000234329.1	RP11-767N6.2	7.99	1.05e-14	4.17e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45651039~45651826:-
THCA	cis	rs4266144	0.544	rs7340627	ENSG00000244515.1	KRT18P34	-7.99	1.05e-14	4.17e-12	-0.38	-0.35	Coronary artery disease;	chr3:157114604	chr3:157162663~157163932:-
THCA	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-7.99	1.06e-14	4.17e-12	-0.57	-0.35	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
THCA	cis	rs7302981	0.967	rs12815871	ENSG00000272368.2	RP4-605O3.4	7.99	1.06e-14	4.19e-12	0.21	0.35	Systolic blood pressure;	chr12:50157165	chr12:50112197~50165618:+
THCA	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	7.99	1.06e-14	4.2e-12	0.43	0.35	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
THCA	cis	rs9649213	0.593	rs6969234	ENSG00000272950.1	RP11-307C18.1	7.99	1.06e-14	4.2e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs3801256	ENSG00000272950.1	RP11-307C18.1	7.99	1.06e-14	4.2e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr7:98322853~98323430:+
THCA	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-7.99	1.06e-14	4.2e-12	-0.41	-0.35	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
THCA	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	7.99	1.07e-14	4.21e-12	0.39	0.35	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
THCA	cis	rs7727544	0.618	rs2631367	ENSG00000233006.5	AC034220.3	-7.99	1.07e-14	4.21e-12	-0.27	-0.35	Blood metabolite levels;	chr5:132369766	chr5:132311285~132369916:-
THCA	cis	rs9309473	0.583	rs6546822	ENSG00000163016.8	ALMS1P	7.99	1.07e-14	4.22e-12	0.46	0.35	Metabolite levels;	chr2:73347970	chr2:73644919~73685576:+
THCA	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-7.99	1.07e-14	4.22e-12	-0.45	-0.35	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
THCA	cis	rs4713118	1	rs13215072	ENSG00000219392.1	RP1-265C24.5	-7.99	1.07e-14	4.22e-12	-0.44	-0.35	Parkinson's disease;	chr6:27709949	chr6:28115628~28116551:+
THCA	cis	rs507080	0.922	rs514143	ENSG00000278376.1	RP11-158I9.8	-7.99	1.07e-14	4.23e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118687740	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-7.99	1.07e-14	4.23e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
THCA	cis	rs737008	0.922	rs28567501	ENSG00000262636.1	CTD-3088G3.4	-7.99	1.07e-14	4.23e-12	-0.44	-0.35	Obesity-related traits;	chr16:11285071	chr16:11380859~11381118:-
THCA	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-7.99	1.07e-14	4.23e-12	-0.41	-0.35	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
THCA	cis	rs10936632	0.565	rs9865021	ENSG00000242578.1	RP11-469J4.3	-7.99	1.07e-14	4.24e-12	-0.38	-0.35	Prostate cancer;	chr3:170429093	chr3:170410512~170418615:+
THCA	cis	rs507080	0.769	rs2077173	ENSG00000278376.1	RP11-158I9.8	-7.99	1.07e-14	4.24e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118621876	chr11:118791254~118793137:+
THCA	cis	rs10208649	0.71	rs10190353	ENSG00000272156.1	RP11-477N3.1	7.99	1.07e-14	4.24e-12	0.64	0.35	Body mass index;	chr2:54015688	chr2:54082554~54085066:+
THCA	cis	rs3096299	0.583	rs889574	ENSG00000274627.1	RP11-104N10.2	7.99	1.08e-14	4.25e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89320400	chr16:89516797~89522217:+
THCA	cis	rs9649213	0.593	rs3801255	ENSG00000272950.1	RP11-307C18.1	7.99	1.08e-14	4.25e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr7:98322853~98323430:+
THCA	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	7.99	1.08e-14	4.25e-12	0.71	0.35	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
THCA	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-7.99	1.08e-14	4.26e-12	-0.34	-0.35	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
THCA	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	7.99	1.08e-14	4.26e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
THCA	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	7.99	1.08e-14	4.26e-12	0.34	0.35	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
THCA	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	7.99	1.08e-14	4.27e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
THCA	cis	rs28510890	0.72	rs17704001	ENSG00000260337.3	RP11-386M24.6	7.99	1.08e-14	4.28e-12	0.38	0.35	Lung cancer in ever smokers;	chr15:92583935	chr15:92592574~92596462:-
THCA	cis	rs9649213	0.593	rs2240349	ENSG00000272950.1	RP11-307C18.1	7.99	1.09e-14	4.28e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs13307593	ENSG00000272950.1	RP11-307C18.1	7.99	1.09e-14	4.28e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr7:98322853~98323430:+
THCA	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	7.99	1.09e-14	4.29e-12	0.41	0.35	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
THCA	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-7.99	1.09e-14	4.3e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
THCA	cis	rs1707322	1	rs34694458	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6671754	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs6666763	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4489497	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211235	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.893	rs9919275	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211236	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660328	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.928	rs61785614	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs9793167	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211237	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs11211238	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4460583	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs4459051	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211239	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45651039~45651826:-
THCA	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	7.98	1.09e-14	4.31e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	7.98	1.09e-14	4.31e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	7.98	1.09e-14	4.31e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
THCA	cis	rs7727544	0.606	rs10060615	ENSG00000233006.5	AC034220.3	7.98	1.1e-14	4.32e-12	0.27	0.35	Blood metabolite levels;	chr5:132373185	chr5:132311285~132369916:-
THCA	cis	rs2439831	0.867	rs2447208	ENSG00000275601.1	AC011330.13	-7.98	1.1e-14	4.34e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43641697	chr15:43642389~43643023:-
THCA	cis	rs529866	0.5	rs918739	ENSG00000262636.1	CTD-3088G3.4	-7.98	1.1e-14	4.34e-12	-0.45	-0.35	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11380859~11381118:-
THCA	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-7.98	1.1e-14	4.34e-12	-0.41	-0.35	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
THCA	cis	rs1707322	0.964	rs7546237	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211200	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7553924	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4641257	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6693336	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4539075	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211219	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211222	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45651039~45651826:-
THCA	cis	rs8114671	0.805	rs6060168	ENSG00000269202.1	RP4-614O4.12	-7.98	1.1e-14	4.36e-12	-0.29	-0.35	Height;	chr20:35033214	chr20:35201747~35203288:-
THCA	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	7.98	1.11e-14	4.36e-12	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
THCA	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-7.98	1.11e-14	4.36e-12	-0.41	-0.35	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
THCA	cis	rs1707322	1	rs11211243	ENSG00000234329.1	RP11-767N6.2	7.98	1.11e-14	4.37e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211244	ENSG00000234329.1	RP11-767N6.2	7.98	1.11e-14	4.37e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660903	ENSG00000234329.1	RP11-767N6.2	7.98	1.11e-14	4.37e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660905	ENSG00000234329.1	RP11-767N6.2	-7.98	1.11e-14	4.37e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45651039~45651826:-
THCA	cis	rs507080	0.807	rs7926944	ENSG00000278376.1	RP11-158I9.8	-7.98	1.11e-14	4.37e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118689119	chr11:118791254~118793137:+
THCA	cis	rs737008	0.922	rs2070923	ENSG00000262636.1	CTD-3088G3.4	7.98	1.11e-14	4.38e-12	0.45	0.35	Obesity-related traits;	chr16:11275998	chr16:11380859~11381118:-
THCA	cis	rs7621025	0.5	rs4678275	ENSG00000273486.1	RP11-731C17.2	7.98	1.11e-14	4.38e-12	0.35	0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136837338~136839021:-
THCA	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-7.98	1.11e-14	4.38e-12	-0.51	-0.35	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-7.98	1.11e-14	4.38e-12	-0.51	-0.35	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-7.98	1.11e-14	4.38e-12	-0.51	-0.35	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
THCA	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	7.98	1.11e-14	4.39e-12	0.9	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
THCA	cis	rs910316	0.687	rs175059	ENSG00000279594.1	RP11-950C14.10	-7.98	1.11e-14	4.39e-12	-0.31	-0.35	Height;	chr14:75023964	chr14:75011269~75012851:-
THCA	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	7.98	1.11e-14	4.39e-12	0.43	0.35	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	7.98	1.11e-14	4.39e-12	0.43	0.35	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	7.98	1.11e-14	4.39e-12	0.43	0.35	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	7.98	1.11e-14	4.39e-12	0.43	0.35	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
THCA	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-7.98	1.11e-14	4.39e-12	-0.42	-0.35	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
THCA	cis	rs11603691	0.901	rs61888888	ENSG00000254662.1	RP11-872D17.4	-7.98	1.12e-14	4.39e-12	-0.65	-0.35	Low high density lipoprotein cholesterol levels;	chr11:57336210	chr11:57325603~57327958:+
THCA	cis	rs7942368	1	rs1440977	ENSG00000254632.1	RP11-21L23.4	7.98	1.12e-14	4.4e-12	0.5	0.35	Endometriosis;	chr11:76765385	chr11:76759916~76768223:-
THCA	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	7.98	1.12e-14	4.41e-12	0.36	0.35	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
THCA	cis	rs9926296	0.744	rs164749	ENSG00000260259.1	RP11-368I7.4	7.98	1.12e-14	4.41e-12	0.36	0.35	Vitiligo;	chr16:89641816	chr16:89682620~89686569:-
THCA	cis	rs8062405	0.757	rs2411453	ENSG00000251417.2	RP11-1348G14.4	7.98	1.12e-14	4.43e-12	0.32	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28802743~28817828:+
THCA	cis	rs4713118	1	rs4713118	ENSG00000219392.1	RP1-265C24.5	-7.98	1.12e-14	4.43e-12	-0.44	-0.35	Parkinson's disease;	chr6:27709015	chr6:28115628~28116551:+
THCA	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-7.98	1.13e-14	4.43e-12	-0.33	-0.35	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
THCA	cis	rs4072705	1	rs4836991	ENSG00000224020.1	MIR181A2HG	7.98	1.13e-14	4.44e-12	0.31	0.35	Menarche (age at onset);	chr9:124749761	chr9:124658467~124698631:+
THCA	cis	rs7247513	0.927	rs34956595	ENSG00000230310.1	CTD-2192J16.11	-7.98	1.13e-14	4.45e-12	-0.42	-0.35	Bipolar disorder;	chr19:12591983	chr19:12552597~12553644:+
THCA	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	7.98	1.13e-14	4.45e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
THCA	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-7.98	1.13e-14	4.45e-12	-0.56	-0.35	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
THCA	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-7.98	1.13e-14	4.46e-12	-0.36	-0.35	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
THCA	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
THCA	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
THCA	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
THCA	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
THCA	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
THCA	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
THCA	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-7.98	1.14e-14	4.49e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
THCA	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	7.98	1.14e-14	4.49e-12	0.33	0.35	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
THCA	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	7.98	1.14e-14	4.49e-12	0.48	0.35	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
THCA	cis	rs812925	0.519	rs2694638	ENSG00000271889.1	RP11-493E12.1	-7.98	1.14e-14	4.49e-12	-0.34	-0.35	Immature fraction of reticulocytes;	chr2:61408228	chr2:61151433~61162105:-
THCA	cis	rs6840258	0.547	rs17012170	ENSG00000251411.1	RP11-397E7.4	-7.98	1.14e-14	4.49e-12	-0.44	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86939692	chr4:86913266~86914817:-
THCA	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-7.98	1.15e-14	4.52e-12	-0.41	-0.35	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
THCA	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
THCA	cis	rs42490	0.716	rs40638	ENSG00000251136.7	RP11-37B2.1	-7.98	1.15e-14	4.54e-12	-0.29	-0.35	Leprosy;	chr8:89815824	chr8:89609409~89757727:-
THCA	cis	rs42490	0.716	rs370282	ENSG00000251136.7	RP11-37B2.1	-7.98	1.15e-14	4.54e-12	-0.29	-0.35	Leprosy;	chr8:89816117	chr8:89609409~89757727:-
THCA	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	7.98	1.15e-14	4.54e-12	0.37	0.35	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
THCA	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-7.98	1.16e-14	4.55e-12	-0.47	-0.35	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
THCA	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-7.98	1.16e-14	4.56e-12	-0.4	-0.35	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
THCA	cis	rs9309473	0.607	rs1522926	ENSG00000163016.8	ALMS1P	7.98	1.16e-14	4.57e-12	0.46	0.35	Metabolite levels;	chr2:73364113	chr2:73644919~73685576:+
THCA	cis	rs1707322	1	rs10890378	ENSG00000234329.1	RP11-767N6.2	-7.98	1.16e-14	4.58e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785478	ENSG00000234329.1	RP11-767N6.2	-7.98	1.16e-14	4.58e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6657720	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7519181	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890372	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.928	rs6681068	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211228	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs9803784	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs12022335	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890375	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890377	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs10789484	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7527079	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs34446427	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs4660900	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4454479	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7517560	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12077546	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12124291	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45651039~45651826:-
THCA	cis	rs934734	0.532	rs12185610	ENSG00000237979.1	AC007389.1	-7.98	1.17e-14	4.58e-12	-0.39	-0.35	Rheumatoid arthritis;	chr2:65434334	chr2:65500993~65502138:-
THCA	cis	rs3096299	0.583	rs1078577	ENSG00000274627.1	RP11-104N10.2	7.97	1.18e-14	4.62e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89320680	chr16:89516797~89522217:+
THCA	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-7.97	1.18e-14	4.63e-12	-0.41	-0.35	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
THCA	cis	rs1859596	0.625	rs10260483	ENSG00000234456.6	MAGI2-AS3	-7.97	1.18e-14	4.63e-12	-0.33	-0.35	Reading or mathematical ability;	chr7:79470338	chr7:79452877~79471208:+
THCA	cis	rs910316	0.967	rs10142770	ENSG00000279594.1	RP11-950C14.10	7.97	1.18e-14	4.63e-12	0.32	0.35	Height;	chr14:75058746	chr14:75011269~75012851:-
THCA	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-7.97	1.18e-14	4.63e-12	-0.41	-0.35	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
THCA	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	7.97	1.18e-14	4.65e-12	0.51	0.35	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
THCA	cis	rs7247513	0.93	rs1864082	ENSG00000230310.1	CTD-2192J16.11	-7.97	1.18e-14	4.66e-12	-0.42	-0.35	Bipolar disorder;	chr19:12597090	chr19:12552597~12553644:+
THCA	cis	rs11603691	1	rs10896608	ENSG00000254662.1	RP11-872D17.4	-7.97	1.19e-14	4.67e-12	-0.61	-0.35	Low high density lipoprotein cholesterol levels;	chr11:57341437	chr11:57325603~57327958:+
THCA	cis	rs934734	0.789	rs906579	ENSG00000204929.10	AC074391.1	-7.97	1.19e-14	4.67e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65374464	chr2:65436711~66084639:+
THCA	cis	rs934734	0.789	rs906578	ENSG00000204929.10	AC074391.1	-7.97	1.19e-14	4.67e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65374466	chr2:65436711~66084639:+
THCA	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-7.97	1.19e-14	4.67e-12	-0.37	-0.35	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
THCA	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-7.97	1.19e-14	4.67e-12	-0.42	-0.35	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
THCA	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	7.97	1.19e-14	4.68e-12	0.42	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
THCA	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-7.97	1.19e-14	4.68e-12	-0.36	-0.35	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
THCA	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-7.97	1.19e-14	4.68e-12	-0.3	-0.35	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
THCA	cis	rs10208649	0.908	rs114837028	ENSG00000272156.1	RP11-477N3.1	7.97	1.19e-14	4.69e-12	0.72	0.35	Body mass index;	chr2:53983416	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs74930210	ENSG00000272156.1	RP11-477N3.1	7.97	1.19e-14	4.69e-12	0.72	0.35	Body mass index;	chr2:53995287	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.808	rs115322634	ENSG00000272156.1	RP11-477N3.1	7.97	1.19e-14	4.69e-12	0.72	0.35	Body mass index;	chr2:53997572	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs78688150	ENSG00000272156.1	RP11-477N3.1	7.97	1.19e-14	4.69e-12	0.72	0.35	Body mass index;	chr2:53997658	chr2:54082554~54085066:+
THCA	cis	rs42490	0.689	rs43228	ENSG00000251136.7	RP11-37B2.1	-7.97	1.19e-14	4.69e-12	-0.29	-0.35	Leprosy;	chr8:89816790	chr8:89609409~89757727:-
THCA	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	7.97	1.2e-14	4.69e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
THCA	cis	rs10208649	0.908	rs2161083	ENSG00000272156.1	RP11-477N3.1	7.97	1.2e-14	4.71e-12	0.63	0.35	Body mass index;	chr2:54024661	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs2112120	ENSG00000272156.1	RP11-477N3.1	7.97	1.2e-14	4.71e-12	0.63	0.35	Body mass index;	chr2:54024957	chr2:54082554~54085066:+
THCA	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	7.97	1.2e-14	4.72e-12	0.46	0.35	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000206090.4	AP000350.7	-7.97	1.2e-14	4.72e-12	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23939998~23942798:+
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000237664.1	LINC00316	-7.97	1.2e-14	4.73e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000237664.1	LINC00316	-7.97	1.2e-14	4.73e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000237664.1	LINC00316	-7.97	1.2e-14	4.73e-12	-0.34	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45338590~45341990:-
THCA	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	7.97	1.21e-14	4.74e-12	0.46	0.35	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
THCA	cis	rs9649213	0.593	rs10953257	ENSG00000272950.1	RP11-307C18.1	-7.97	1.21e-14	4.76e-12	-0.42	-0.35	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr7:98322853~98323430:+
THCA	cis	rs4950322	0.542	rs4950382	ENSG00000237188.3	RP11-337C18.8	7.97	1.22e-14	4.77e-12	0.39	0.35	Protein quantitative trait loci;	chr1:147176645	chr1:147172771~147211568:+
THCA	cis	rs9532669	0.89	rs2149570	ENSG00000239827.7	SUGT1P3	-7.97	1.22e-14	4.77e-12	-0.39	-0.35	Cervical cancer;	chr13:40858533	chr13:40908159~40921774:-
THCA	cis	rs6840258	0.547	rs72667727	ENSG00000251411.1	RP11-397E7.4	-7.97	1.22e-14	4.79e-12	-0.44	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86936370	chr4:86913266~86914817:-
THCA	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	7.97	1.22e-14	4.8e-12	0.4	0.35	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000206090.4	AP000350.7	7.97	1.22e-14	4.8e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23939998~23942798:+
THCA	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	7.97	1.22e-14	4.81e-12	0.8	0.34	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
THCA	cis	rs736801	0.808	rs4705950	ENSG00000237714.1	P4HA2-AS1	7.97	1.23e-14	4.82e-12	0.46	0.34	Mosquito bite size;Breast cancer;	chr5:132457594	chr5:132184876~132192808:+
THCA	cis	rs11971779	0.838	rs4728468	ENSG00000273391.1	RP11-634H22.1	7.97	1.23e-14	4.83e-12	0.34	0.34	Diisocyanate-induced asthma;	chr7:139438232	chr7:139359032~139359566:-
THCA	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-7.97	1.23e-14	4.83e-12	-0.37	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
THCA	cis	rs9649213	0.593	rs7796611	ENSG00000272950.1	RP11-307C18.1	7.97	1.24e-14	4.86e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs13238610	ENSG00000272950.1	RP11-307C18.1	7.97	1.24e-14	4.86e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr7:98322853~98323430:+
THCA	cis	rs8114671	0.836	rs13042358	ENSG00000269202.1	RP4-614O4.12	7.97	1.24e-14	4.86e-12	0.29	0.34	Height;	chr20:35046676	chr20:35201747~35203288:-
THCA	cis	rs910316	0.836	rs6574212	ENSG00000279594.1	RP11-950C14.10	-7.97	1.24e-14	4.86e-12	-0.32	-0.34	Height;	chr14:75204956	chr14:75011269~75012851:-
THCA	cis	rs1387259	0.64	rs10783243	ENSG00000258273.1	RP11-370I10.4	7.97	1.24e-14	4.88e-12	0.4	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48333755~48333901:-
THCA	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	7.97	1.24e-14	4.88e-12	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
THCA	cis	rs10208649	0.908	rs114242964	ENSG00000272156.1	RP11-477N3.1	7.97	1.24e-14	4.88e-12	0.72	0.34	Body mass index;	chr2:54013985	chr2:54082554~54085066:+
THCA	cis	rs2712184	0.756	rs715049	ENSG00000229352.1	AC007563.3	-7.97	1.24e-14	4.88e-12	-0.41	-0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216792379	chr2:216799608~216805335:+
THCA	cis	rs17695224	0.545	rs8099997	ENSG00000269483.1	AC006272.1	7.97	1.25e-14	4.88e-12	0.37	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51842216	chr19:51839924~51843324:-
THCA	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	7.97	1.25e-14	4.89e-12	0.43	0.34	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
THCA	cis	rs7811142	0.83	rs28495773	ENSG00000078319.8	PMS2P1	-7.97	1.25e-14	4.89e-12	-0.49	-0.34	Platelet count;	chr7:100345960	chr7:100320992~100341908:-
THCA	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-7.97	1.25e-14	4.89e-12	-0.42	-0.34	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
THCA	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-7.97	1.25e-14	4.91e-12	-0.31	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
THCA	cis	rs7772486	0.84	rs854144	ENSG00000235652.6	RP11-545I5.3	-7.97	1.25e-14	4.92e-12	-0.34	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:146039744	chr6:145799409~145886585:+
THCA	cis	rs8114671	0.562	rs1801310	ENSG00000269202.1	RP4-614O4.12	-7.97	1.26e-14	4.92e-12	-0.29	-0.34	Height;	chr20:34929211	chr20:35201747~35203288:-
THCA	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-7.97	1.26e-14	4.92e-12	-0.48	-0.34	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
THCA	cis	rs5752326	0.764	rs5997093	ENSG00000261188.1	CTA-445C9.14	-7.97	1.26e-14	4.92e-12	-0.34	-0.34	Ischemic stroke;	chr22:26455862	chr22:26512537~26514568:+
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000264538.5	SUZ12P1	-7.96	1.26e-14	4.93e-12	-0.35	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000264538.5	SUZ12P1	-7.96	1.26e-14	4.93e-12	-0.35	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30709299~30790908:+
THCA	cis	rs7621025	0.5	rs12629000	ENSG00000273486.1	RP11-731C17.2	7.96	1.26e-14	4.93e-12	0.35	0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136837338~136839021:-
THCA	cis	rs7621025	0.5	rs1965107	ENSG00000273486.1	RP11-731C17.2	7.96	1.26e-14	4.93e-12	0.35	0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136837338~136839021:-
THCA	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	7.96	1.26e-14	4.94e-12	0.29	0.34	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
THCA	cis	rs42490	0.716	rs40636	ENSG00000251136.7	RP11-37B2.1	-7.96	1.26e-14	4.94e-12	-0.29	-0.34	Leprosy;	chr8:89809079	chr8:89609409~89757727:-
THCA	cis	rs4713118	0.662	rs149947	ENSG00000226314.6	ZNF192P1	-7.96	1.26e-14	4.94e-12	-0.44	-0.34	Parkinson's disease;	chr6:28004655	chr6:28161781~28169594:+
THCA	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-7.96	1.26e-14	4.95e-12	-0.45	-0.34	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
THCA	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-7.96	1.27e-14	4.96e-12	-0.44	-0.34	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
THCA	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	7.96	1.27e-14	4.97e-12	0.66	0.34	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
THCA	cis	rs947583	0.955	rs927330	ENSG00000231028.7	LINC00271	7.96	1.27e-14	4.97e-12	0.28	0.34	Phosphorus levels;	chr6:135810618	chr6:135497801~135716055:+
THCA	cis	rs7712401	0.58	rs10066632	ENSG00000263432.2	RN7SL689P	7.96	1.27e-14	4.97e-12	0.41	0.34	Mean platelet volume;	chr5:123028988	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs10076327	ENSG00000263432.2	RN7SL689P	7.96	1.27e-14	4.97e-12	0.41	0.34	Mean platelet volume;	chr5:123031652	chr5:123022487~123022783:-
THCA	cis	rs507080	0.922	rs478296	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	4.98e-12	-0.28	-0.34	Serum metabolite levels;	chr11:118696666	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs493834	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	4.98e-12	-0.28	-0.34	Serum metabolite levels;	chr11:118696735	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs644498	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	4.98e-12	-0.28	-0.34	Serum metabolite levels;	chr11:118696777	chr11:118791254~118793137:+
THCA	cis	rs507080	0.845	rs613377	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	4.99e-12	-0.27	-0.34	Serum metabolite levels;	chr11:118685375	chr11:118791254~118793137:+
THCA	cis	rs10208649	0.908	rs10199995	ENSG00000272156.1	RP11-477N3.1	7.96	1.27e-14	4.99e-12	0.65	0.34	Body mass index;	chr2:53981138	chr2:54082554~54085066:+
THCA	cis	rs11673344	0.523	rs10406110	ENSG00000226686.6	LINC01535	7.96	1.29e-14	5.04e-12	0.38	0.34	Obesity-related traits;	chr19:37160027	chr19:37251912~37265535:+
THCA	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	7.96	1.29e-14	5.05e-12	0.41	0.34	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
THCA	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-7.96	1.29e-14	5.05e-12	-0.43	-0.34	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
THCA	cis	rs8114671	0.967	rs2093058	ENSG00000269202.1	RP4-614O4.12	7.96	1.29e-14	5.05e-12	0.29	0.34	Height;	chr20:35203478	chr20:35201747~35203288:-
THCA	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-7.96	1.29e-14	5.06e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
THCA	cis	rs7849270	0.801	rs6478868	ENSG00000268707.1	RP11-247A12.7	7.96	1.29e-14	5.07e-12	0.44	0.34	Blood metabolite ratios;	chr9:129164813	chr9:129170434~129170940:+
THCA	cis	rs922182	0.557	rs2004231	ENSG00000275785.1	RP11-111E14.2	7.96	1.3e-14	5.08e-12	0.41	0.34	Blood protein levels;	chr15:63903570	chr15:63890030~63890317:+
THCA	cis	rs4789693	0.746	rs4789775	ENSG00000265458.1	RP13-20L14.6	7.96	1.3e-14	5.09e-12	0.35	0.34	Glucocorticoid-induced osteonecrosis;	chr17:82434029	chr17:82454273~82458521:-
THCA	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	7.96	1.3e-14	5.1e-12	0.41	0.34	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
THCA	cis	rs11603691	0.901	rs7111339	ENSG00000254662.1	RP11-872D17.4	-7.96	1.3e-14	5.1e-12	-0.64	-0.34	Low high density lipoprotein cholesterol levels;	chr11:57323498	chr11:57325603~57327958:+
THCA	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-7.96	1.3e-14	5.1e-12	-0.53	-0.34	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
THCA	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	7.96	1.3e-14	5.11e-12	0.31	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
THCA	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	7.96	1.31e-14	5.12e-12	0.37	0.34	Shingles;	chr7:38346957	chr7:38358512~38359162:-
THCA	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	7.96	1.31e-14	5.13e-12	0.33	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
THCA	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
THCA	cis	rs11673344	0.523	rs2562605	ENSG00000226686.6	LINC01535	7.96	1.32e-14	5.15e-12	0.38	0.34	Obesity-related traits;	chr19:37029302	chr19:37251912~37265535:+
THCA	cis	rs1707322	1	rs4660889	ENSG00000234329.1	RP11-767N6.2	7.96	1.32e-14	5.16e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890355	ENSG00000234329.1	RP11-767N6.2	7.96	1.32e-14	5.16e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211204	ENSG00000234329.1	RP11-767N6.2	7.96	1.32e-14	5.16e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211217	ENSG00000234329.1	RP11-767N6.2	7.96	1.32e-14	5.16e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45651039~45651826:-
THCA	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-7.96	1.32e-14	5.17e-12	-0.52	-0.34	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-7.96	1.32e-14	5.17e-12	-0.52	-0.34	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs1056099	ENSG00000237664.1	LINC00316	-7.96	1.33e-14	5.18e-12	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2236446	ENSG00000237664.1	LINC00316	-7.96	1.33e-14	5.18e-12	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45338590~45341990:-
THCA	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-7.96	1.33e-14	5.18e-12	-0.5	-0.34	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000264538.5	SUZ12P1	-7.96	1.33e-14	5.19e-12	-0.35	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30709299~30790908:+
THCA	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	7.96	1.33e-14	5.19e-12	0.43	0.34	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
THCA	cis	rs1707322	1	rs6675222	ENSG00000234329.1	RP11-767N6.2	7.96	1.33e-14	5.19e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660895	ENSG00000234329.1	RP11-767N6.2	7.96	1.33e-14	5.19e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660318	ENSG00000234329.1	RP11-767N6.2	7.96	1.33e-14	5.19e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45651039~45651826:-
THCA	cis	rs2439831	0.867	rs2255051	ENSG00000249839.1	AC011330.5	-7.96	1.33e-14	5.21e-12	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43553963	chr15:43663654~43684339:-
THCA	cis	rs957448	0.503	rs752460	ENSG00000253704.1	RP11-267M23.4	7.96	1.33e-14	5.21e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94477994	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs4735293	ENSG00000253704.1	RP11-267M23.4	7.96	1.33e-14	5.21e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94478175	chr8:94553722~94569745:+
THCA	cis	rs11673344	0.523	rs6510584	ENSG00000226686.6	LINC01535	7.96	1.33e-14	5.21e-12	0.38	0.34	Obesity-related traits;	chr19:37058699	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.503	rs7246720	ENSG00000226686.6	LINC01535	7.96	1.33e-14	5.21e-12	0.38	0.34	Obesity-related traits;	chr19:37073726	chr19:37251912~37265535:+
THCA	cis	rs9473147	0.543	rs4711880	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47512940	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9473126	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47514097	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs4715025	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47515917	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs7767350	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47517390	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs10948363	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47520026	chr6:47477243~47477572:-
THCA	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	7.96	1.34e-14	5.25e-12	0.41	0.34	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
THCA	cis	rs1005277	0.691	rs2474558	ENSG00000263064.2	RP11-291L22.7	-7.96	1.34e-14	5.26e-12	-0.4	-0.34	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38448689~38448949:+
THCA	cis	rs910316	0.663	rs175034	ENSG00000279594.1	RP11-950C14.10	-7.96	1.35e-14	5.26e-12	-0.32	-0.34	Height;	chr14:74996984	chr14:75011269~75012851:-
THCA	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	7.96	1.35e-14	5.26e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
THCA	cis	rs4819052	1	rs733739	ENSG00000237664.1	LINC00316	-7.96	1.35e-14	5.26e-12	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45338590~45341990:-
THCA	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	7.96	1.35e-14	5.27e-12	0.56	0.34	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
THCA	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	7.96	1.35e-14	5.27e-12	0.53	0.34	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
THCA	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-7.96	1.35e-14	5.27e-12	-0.44	-0.34	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
THCA	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-7.95	1.35e-14	5.27e-12	-0.59	-0.34	Depression;	chr6:28124907	chr6:28115628~28116551:+
THCA	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	7.95	1.35e-14	5.28e-12	0.89	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	7.95	1.35e-14	5.28e-12	0.89	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	7.95	1.35e-14	5.28e-12	0.89	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
THCA	cis	rs737008	1	rs737008	ENSG00000262636.1	CTD-3088G3.4	-7.95	1.35e-14	5.28e-12	-0.45	-0.34	Obesity-related traits;	chr16:11281009	chr16:11380859~11381118:-
THCA	cis	rs984222	0.563	rs7518538	ENSG00000231365.4	RP11-418J17.1	7.95	1.35e-14	5.28e-12	0.34	0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119207788	chr1:119140396~119275973:+
THCA	cis	rs116175783	0.557	rs62197081	ENSG00000227403.1	AC009299.3	7.95	1.35e-14	5.29e-12	0.61	0.34	Intelligence (multi-trait analysis);	chr2:161336814	chr2:161244739~161249050:+
THCA	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.35e-14	5.29e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.35e-14	5.29e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
THCA	cis	rs8114671	0.967	rs6142323	ENSG00000269202.1	RP4-614O4.12	7.95	1.36e-14	5.3e-12	0.29	0.34	Height;	chr20:35201180	chr20:35201747~35203288:-
THCA	cis	rs11673344	0.504	rs4806408	ENSG00000226686.6	LINC01535	7.95	1.36e-14	5.31e-12	0.38	0.34	Obesity-related traits;	chr19:37097875	chr19:37251912~37265535:+
THCA	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	7.95	1.36e-14	5.31e-12	0.47	0.34	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	7.95	1.36e-14	5.31e-12	0.47	0.34	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
THCA	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-7.95	1.37e-14	5.34e-12	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
THCA	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	7.95	1.37e-14	5.36e-12	0.91	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	7.95	1.37e-14	5.36e-12	0.91	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	7.95	1.37e-14	5.36e-12	0.91	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	7.95	1.37e-14	5.36e-12	0.91	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
THCA	cis	rs138491296	1	rs138491296	ENSG00000264007.1	RP11-68I3.10	-7.95	1.37e-14	5.37e-12	-0.39	-0.34	White blood cell count;	chr17:29634549	chr17:29621617~29622254:-
THCA	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	7.95	1.37e-14	5.37e-12	0.49	0.34	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
THCA	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-7.95	1.38e-14	5.39e-12	-0.44	-0.34	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
THCA	cis	rs4819052	1	rs2838847	ENSG00000237664.1	LINC00316	-7.95	1.38e-14	5.4e-12	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45338590~45341990:-
THCA	cis	rs910316	0.763	rs175042	ENSG00000279594.1	RP11-950C14.10	-7.95	1.38e-14	5.4e-12	-0.32	-0.34	Height;	chr14:75004130	chr14:75011269~75012851:-
THCA	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-7.95	1.39e-14	5.42e-12	-0.62	-0.34	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
THCA	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	7.95	1.39e-14	5.42e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
THCA	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	7.95	1.39e-14	5.43e-12	0.42	0.34	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
THCA	cis	rs11603691	1	rs10896598	ENSG00000254662.1	RP11-872D17.4	-7.95	1.39e-14	5.43e-12	-0.66	-0.34	Low high density lipoprotein cholesterol levels;	chr11:57284533	chr11:57325603~57327958:+
THCA	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	7.95	1.4e-14	5.44e-12	0.56	0.34	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	7.95	1.4e-14	5.44e-12	0.56	0.34	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
THCA	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-7.95	1.4e-14	5.45e-12	-0.39	-0.34	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
THCA	cis	rs1858037	0.836	rs17475335	ENSG00000237979.1	AC007389.1	7.95	1.4e-14	5.46e-12	0.42	0.34	Rheumatoid arthritis;	chr2:65378646	chr2:65500993~65502138:-
THCA	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	7.95	1.4e-14	5.46e-12	0.43	0.34	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
THCA	cis	rs910316	0.699	rs175039	ENSG00000279594.1	RP11-950C14.10	-7.95	1.4e-14	5.47e-12	-0.32	-0.34	Height;	chr14:75002247	chr14:75011269~75012851:-
THCA	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	7.95	1.4e-14	5.47e-12	0.23	0.34	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
THCA	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	7.95	1.4e-14	5.47e-12	0.33	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
THCA	cis	rs1707322	1	rs10890360	ENSG00000234329.1	RP11-767N6.2	7.95	1.41e-14	5.49e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6682683	ENSG00000234329.1	RP11-767N6.2	7.95	1.41e-14	5.49e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45651039~45651826:-
THCA	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-7.95	1.41e-14	5.5e-12	-0.43	-0.34	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
THCA	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	7.95	1.41e-14	5.51e-12	0.24	0.34	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
THCA	cis	rs2787702	0.5	rs11598488	ENSG00000237233.2	TMEM26-AS1	7.95	1.41e-14	5.51e-12	0.56	0.34	Response to taxane treatment (placlitaxel);	chr10:61576492	chr10:61452639~61481956:+
THCA	cis	rs7811142	0.83	rs7341507	ENSG00000078319.8	PMS2P1	-7.95	1.42e-14	5.51e-12	-0.49	-0.34	Platelet count;	chr7:100353692	chr7:100320992~100341908:-
THCA	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	7.95	1.42e-14	5.51e-12	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
THCA	cis	rs2439831	0.867	rs486301	ENSG00000249839.1	AC011330.5	-7.95	1.42e-14	5.52e-12	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43544751	chr15:43663654~43684339:-
THCA	cis	rs11673344	0.523	rs2562607	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37031358	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs2385415	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37035291	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs7246739	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37040829	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs7260488	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37058883	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs8110158	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37063491	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.562	rs7257320	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37080933	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs10403975	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37082172	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs2385375	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37087620	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs35162188	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37088908	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.562	rs7250507	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37095772	chr19:37251912~37265535:+
THCA	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.42e-14	5.55e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.42e-14	5.55e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.42e-14	5.55e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
THCA	cis	rs736801	0.74	rs17622378	ENSG00000237714.1	P4HA2-AS1	7.95	1.43e-14	5.55e-12	0.47	0.34	Mosquito bite size;Breast cancer;	chr5:132442760	chr5:132184876~132192808:+
THCA	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	7.95	1.43e-14	5.55e-12	0.44	0.34	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
THCA	cis	rs2470135	1	rs2470135	ENSG00000166763.7	STRCP1	7.95	1.43e-14	5.55e-12	0.37	0.34	Diastolic blood pressure;	chr15:43703591	chr15:43699488~43718184:-
THCA	cis	rs10208649	0.656	rs12623097	ENSG00000272156.1	RP11-477N3.1	7.95	1.43e-14	5.56e-12	0.52	0.34	Body mass index;	chr2:54071182	chr2:54082554~54085066:+
THCA	cis	rs7119038	0.615	rs10892274	ENSG00000255239.1	AP002954.6	-7.95	1.43e-14	5.56e-12	-0.48	-0.34	Sjögren's syndrome;	chr11:118734754	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.523	rs7245520	ENSG00000226686.6	LINC01535	7.95	1.43e-14	5.57e-12	0.38	0.34	Obesity-related traits;	chr19:37036416	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs7256380	ENSG00000226686.6	LINC01535	7.95	1.43e-14	5.57e-12	0.38	0.34	Obesity-related traits;	chr19:37041178	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs6510585	ENSG00000226686.6	LINC01535	7.95	1.43e-14	5.57e-12	0.38	0.34	Obesity-related traits;	chr19:37063081	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs17206540	ENSG00000226686.6	LINC01535	7.95	1.43e-14	5.57e-12	0.38	0.34	Obesity-related traits;	chr19:37069009	chr19:37251912~37265535:+
THCA	cis	rs9649213	0.593	rs6975156	ENSG00000272950.1	RP11-307C18.1	7.95	1.44e-14	5.58e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr7:98322853~98323430:+
THCA	cis	rs56080343	0.515	rs73222056	ENSG00000275409.1	RP11-131L12.4	-7.95	1.44e-14	5.58e-12	-0.43	-0.34	Neuroticism;	chr12:118215875	chr12:118430147~118430699:+
THCA	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	7.95	1.44e-14	5.6e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
THCA	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-7.95	1.44e-14	5.6e-12	-0.44	-0.34	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
THCA	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-7.95	1.44e-14	5.6e-12	-0.56	-0.34	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
THCA	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-7.95	1.45e-14	5.62e-12	-0.44	-0.34	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
THCA	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	7.95	1.45e-14	5.62e-12	0.7	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
THCA	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-7.94	1.45e-14	5.63e-12	-0.34	-0.34	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-7.94	1.45e-14	5.63e-12	-0.42	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
THCA	cis	rs9473147	0.516	rs9381564	ENSG00000270761.1	RP11-385F7.1	-7.94	1.45e-14	5.64e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47476070	chr6:47477243~47477572:-
THCA	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-7.94	1.46e-14	5.65e-12	-0.42	-0.34	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
THCA	cis	rs9649213	0.593	rs6465672	ENSG00000272950.1	RP11-307C18.1	-7.94	1.46e-14	5.66e-12	-0.42	-0.34	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr7:98322853~98323430:+
THCA	cis	rs11673344	0.504	rs10403728	ENSG00000226686.6	LINC01535	7.94	1.46e-14	5.66e-12	0.38	0.34	Obesity-related traits;	chr19:37091569	chr19:37251912~37265535:+
THCA	cis	rs9309473	0.583	rs11899517	ENSG00000163016.8	ALMS1P	7.94	1.46e-14	5.67e-12	0.46	0.34	Metabolite levels;	chr2:73346133	chr2:73644919~73685576:+
THCA	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-7.94	1.46e-14	5.68e-12	-0.39	-0.34	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
THCA	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	7.94	1.47e-14	5.71e-12	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
THCA	cis	rs8062405	0.558	rs3743963	ENSG00000251417.2	RP11-1348G14.4	-7.94	1.47e-14	5.71e-12	-0.32	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28593365	chr16:28802743~28817828:+
THCA	cis	rs62103177	0.759	rs7227794	ENSG00000261126.6	RP11-795F19.1	7.94	1.47e-14	5.72e-12	0.4	0.34	Opioid sensitivity;	chr18:79850925	chr18:80046900~80095482:+
THCA	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-7.94	1.47e-14	5.73e-12	-0.5	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
THCA	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	7.94	1.48e-14	5.74e-12	0.33	0.34	Breast size;	chr12:9219433	chr12:9277235~9313241:+
THCA	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	7.94	1.48e-14	5.74e-12	0.33	0.34	Breast size;	chr12:9220266	chr12:9277235~9313241:+
THCA	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-7.94	1.48e-14	5.74e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
THCA	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	7.94	1.48e-14	5.74e-12	0.23	0.34	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
THCA	cis	rs3747113	0.913	rs34999116	ENSG00000128262.7	POM121L9P	-7.94	1.48e-14	5.76e-12	-0.39	-0.34	Gut microbiome composition (summer);	chr22:24418657	chr22:24251828~24265525:+
THCA	cis	rs8113308	0.81	rs55810059	ENSG00000269235.1	ZNF350-AS1	7.94	1.49e-14	5.77e-12	0.53	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51947475	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs7255377	ENSG00000269235.1	ZNF350-AS1	7.94	1.49e-14	5.77e-12	0.53	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948085	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs7254930	ENSG00000269235.1	ZNF350-AS1	7.94	1.49e-14	5.77e-12	0.53	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948274	chr19:51949134~51981367:+
THCA	cis	rs4819052	0.851	rs2236445	ENSG00000237664.1	LINC00316	-7.94	1.49e-14	5.78e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45338590~45341990:-
THCA	cis	rs11715604	1	rs11715604	ENSG00000239213.4	NCK1-AS1	-7.94	1.49e-14	5.78e-12	-0.42	-0.34	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);	chr3:136870707	chr3:136841726~136862054:-
THCA	cis	rs984222	0.559	rs61807010	ENSG00000231365.4	RP11-418J17.1	7.94	1.49e-14	5.79e-12	0.34	0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119200568	chr1:119140396~119275973:+
THCA	cis	rs7811142	0.83	rs6965458	ENSG00000078319.8	PMS2P1	-7.94	1.5e-14	5.81e-12	-0.5	-0.34	Platelet count;	chr7:100375779	chr7:100320992~100341908:-
THCA	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	7.94	1.5e-14	5.81e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
THCA	cis	rs736801	0.78	rs2188962	ENSG00000237714.1	P4HA2-AS1	7.94	1.5e-14	5.82e-12	0.47	0.34	Mosquito bite size;Breast cancer;	chr5:132435113	chr5:132184876~132192808:+
THCA	cis	rs11148252	0.774	rs9536066	ENSG00000235660.1	LINC00345	-7.94	1.5e-14	5.83e-12	-0.42	-0.34	Lewy body disease;	chr13:52409846	chr13:52484161~52484680:-
THCA	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-7.94	1.5e-14	5.84e-12	-0.4	-0.34	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
THCA	cis	rs812925	0.502	rs13028833	ENSG00000271889.1	RP11-493E12.1	-7.94	1.51e-14	5.84e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61417194	chr2:61151433~61162105:-
THCA	cis	rs4713118	0.869	rs2056925	ENSG00000219392.1	RP1-265C24.5	-7.94	1.51e-14	5.84e-12	-0.44	-0.34	Parkinson's disease;	chr6:27723126	chr6:28115628~28116551:+
THCA	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-7.94	1.51e-14	5.84e-12	-0.48	-0.34	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs6953107	ENSG00000242294.5	STAG3L5P	7.94	1.51e-14	5.87e-12	0.23	0.34	Platelet count;	chr7:100498041	chr7:100336079~100351900:+
THCA	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-7.94	1.51e-14	5.87e-12	-0.59	-0.34	Depression;	chr6:28076050	chr6:28115628~28116551:+
THCA	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-7.94	1.51e-14	5.87e-12	-0.59	-0.34	Depression;	chr6:28085045	chr6:28115628~28116551:+
THCA	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-7.94	1.51e-14	5.87e-12	-0.59	-0.34	Depression;	chr6:28111963	chr6:28115628~28116551:+
THCA	cis	rs4789693	0.873	rs8069111	ENSG00000265458.1	RP13-20L14.6	7.94	1.51e-14	5.87e-12	0.35	0.34	Glucocorticoid-induced osteonecrosis;	chr17:82437581	chr17:82454273~82458521:-
THCA	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-7.94	1.52e-14	5.89e-12	-0.37	-0.34	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
THCA	cis	rs737008	0.96	rs34764020	ENSG00000262636.1	CTD-3088G3.4	-7.94	1.52e-14	5.91e-12	-0.44	-0.34	Obesity-related traits;	chr16:11284502	chr16:11380859~11381118:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000235689.1	AP000351.13	-7.94	1.53e-14	5.92e-12	-0.46	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:24006305~24008258:-
THCA	cis	rs2712184	0.875	rs35925637	ENSG00000229352.1	AC007563.3	7.94	1.53e-14	5.92e-12	0.42	0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216811905	chr2:216799608~216805335:+
THCA	cis	rs2921073	0.604	rs2979140	ENSG00000253893.2	FAM85B	-7.94	1.53e-14	5.93e-12	-0.43	-0.34	Parkinson's disease;	chr8:8409692	chr8:8167819~8226614:-
THCA	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	7.94	1.53e-14	5.94e-12	0.43	0.34	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
THCA	cis	rs934734	0.752	rs1194849	ENSG00000204929.10	AC074391.1	-7.94	1.53e-14	5.94e-12	-0.42	-0.34	Rheumatoid arthritis;	chr2:65379519	chr2:65436711~66084639:+
THCA	cis	rs6908034	0.66	rs12525506	ENSG00000228412.5	RP4-625H18.2	7.94	1.53e-14	5.94e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19794003	chr6:19802164~19804752:-
THCA	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-7.94	1.53e-14	5.95e-12	-0.37	-0.34	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
THCA	cis	rs860295	1	rs822490	ENSG00000225855.5	RUSC1-AS1	7.94	1.54e-14	5.96e-12	0.23	0.34	Body mass index;	chr1:155853180	chr1:155316863~155324176:-
THCA	cis	rs10932679	0.532	rs2712162	ENSG00000229352.1	AC007563.3	-7.94	1.54e-14	5.97e-12	-0.43	-0.34	Pulse pressure;	chr2:216797065	chr2:216799608~216805335:+
THCA	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-7.94	1.54e-14	5.97e-12	-0.42	-0.34	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
THCA	cis	rs12655019	0.92	rs16886496	ENSG00000271828.1	CTD-2310F14.1	-7.94	1.54e-14	5.98e-12	-0.78	-0.34	Breast cancer (early onset);	chr5:56921702	chr5:56927874~56929573:+
THCA	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-7.94	1.54e-14	5.99e-12	-0.42	-0.34	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
THCA	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-7.94	1.55e-14	5.99e-12	-0.31	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
THCA	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-7.94	1.55e-14	5.99e-12	-0.54	-0.34	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
THCA	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	7.93	1.56e-14	6.03e-12	0.41	0.34	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000226155.1	AC124944.3	-7.93	1.56e-14	6.04e-12	-0.42	-0.34	Pancreatic cancer;	chr3:196009869	chr3:195912049~195913986:+
THCA	cis	rs4927850	1	rs4927704	ENSG00000226155.1	AC124944.3	-7.93	1.56e-14	6.04e-12	-0.42	-0.34	Pancreatic cancer;	chr3:196011357	chr3:195912049~195913986:+
THCA	cis	rs4927850	1	rs4927848	ENSG00000226155.1	AC124944.3	-7.93	1.56e-14	6.04e-12	-0.42	-0.34	Pancreatic cancer;	chr3:196011535	chr3:195912049~195913986:+
THCA	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	7.93	1.56e-14	6.04e-12	0.39	0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
THCA	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	7.93	1.56e-14	6.06e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
THCA	cis	rs1598856	0.873	rs230510	ENSG00000246560.2	RP11-10L12.4	-7.93	1.57e-14	6.07e-12	-0.41	-0.34	Primary biliary cholangitis;	chr4:102555009	chr4:102828055~102844075:+
THCA	cis	rs934734	0.789	rs11689314	ENSG00000204929.10	AC074391.1	-7.93	1.57e-14	6.08e-12	-0.43	-0.34	Rheumatoid arthritis;	chr2:65378274	chr2:65436711~66084639:+
THCA	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	7.93	1.57e-14	6.09e-12	0.27	0.34	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
THCA	cis	rs7208859	0.673	rs28588622	ENSG00000266490.1	CTD-2349P21.9	7.93	1.58e-14	6.1e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30792372~30792833:+
THCA	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-7.93	1.58e-14	6.12e-12	-0.37	-0.34	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
THCA	cis	rs812925	0.502	rs6545868	ENSG00000271889.1	RP11-493E12.1	-7.93	1.58e-14	6.12e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61428230	chr2:61151433~61162105:-
THCA	cis	rs7851660	0.679	rs7033765	ENSG00000236130.1	PTCSC2	7.93	1.58e-14	6.12e-12	0.27	0.34	Strep throat;	chr9:97829423	chr9:97805935~97810008:-
THCA	cis	rs12701220	0.522	rs868833	ENSG00000229043.2	AC091729.9	-7.93	1.58e-14	6.13e-12	-0.4	-0.34	Bronchopulmonary dysplasia;	chr7:1015337	chr7:1160374~1165267:+
THCA	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-7.93	1.59e-14	6.14e-12	-0.47	-0.34	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
THCA	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	7.93	1.59e-14	6.14e-12	0.56	0.34	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
THCA	cis	rs7945705	0.776	rs11042069	ENSG00000254860.4	TMEM9B-AS1	-7.93	1.59e-14	6.15e-12	-0.38	-0.34	Hemoglobin concentration;	chr11:8795768	chr11:8964675~8977527:+
THCA	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	7.93	1.59e-14	6.15e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
THCA	cis	rs1707322	1	rs11211223	ENSG00000234329.1	RP11-767N6.2	7.93	1.6e-14	6.19e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45651039~45651826:-
THCA	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	7.93	1.6e-14	6.19e-12	0.54	0.34	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	7.93	1.6e-14	6.19e-12	0.54	0.34	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	7.93	1.6e-14	6.19e-12	0.54	0.34	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	7.93	1.6e-14	6.19e-12	0.54	0.34	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
THCA	cis	rs73607972	0.518	rs35618081	ENSG00000275191.1	RP11-36I17.2	-7.93	1.6e-14	6.19e-12	-0.45	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53536855	chr16:53628256~53628816:-
THCA	cis	rs17695224	0.545	rs4802884	ENSG00000269483.1	AC006272.1	7.93	1.6e-14	6.19e-12	0.37	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51845202	chr19:51839924~51843324:-
THCA	cis	rs1387259	0.619	rs7134565	ENSG00000258273.1	RP11-370I10.4	7.93	1.6e-14	6.2e-12	0.4	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.619	rs2130095	ENSG00000258273.1	RP11-370I10.4	7.93	1.6e-14	6.2e-12	0.4	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48333755~48333901:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000235689.1	AP000351.13	-7.93	1.61e-14	6.22e-12	-0.42	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:24006305~24008258:-
THCA	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-7.93	1.61e-14	6.22e-12	-0.44	-0.34	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
THCA	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	7.93	1.61e-14	6.22e-12	0.23	0.34	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
THCA	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	7.93	1.61e-14	6.22e-12	0.41	0.34	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
THCA	cis	rs1858037	0.867	rs953312	ENSG00000237979.1	AC007389.1	7.93	1.61e-14	6.22e-12	0.43	0.34	Rheumatoid arthritis;	chr2:65340556	chr2:65500993~65502138:-
THCA	cis	rs1858037	0.867	rs9789444	ENSG00000237979.1	AC007389.1	7.93	1.61e-14	6.22e-12	0.43	0.34	Rheumatoid arthritis;	chr2:65342093	chr2:65500993~65502138:-
THCA	cis	rs227932	0.51	rs10950957	ENSG00000234286.1	AC006026.13	7.93	1.61e-14	6.25e-12	0.59	0.34	Schizophrenia;	chr7:23723661	chr7:23680195~23680786:-
THCA	cis	rs12681366	0.881	rs2931631	ENSG00000253704.1	RP11-267M23.4	7.93	1.61e-14	6.25e-12	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94401415	chr8:94553722~94569745:+
THCA	cis	rs7208859	0.673	rs11651802	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs17826219	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs61223749	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs3764421	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11651858	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs36056619	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9909497	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11080135	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9894876	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277967	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs60020217	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs73277974	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277978	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs9905827	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Body mass index;	chr17:30865150	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11657391	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs58089675	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73263755	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9899349	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11652358	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11656845	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9891179	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9891413	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73263776	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11650271	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11657270	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73263785	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs55904046	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9889968	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs61348930	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.614	rs28758251	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9899943	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11080138	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73265612	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11658435	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73265624	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs2269915	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs2269916	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11649765	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30792372~30792833:+
THCA	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-7.93	1.63e-14	6.3e-12	-0.42	-0.34	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000230295.1	RP11-458F8.2	-7.93	1.63e-14	6.31e-12	-0.31	-0.34	Corneal structure;	chr7:66950082	chr7:66880708~66882981:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000237979.1	AC007389.1	-7.93	1.63e-14	6.32e-12	-0.39	-0.34	Rheumatoid arthritis;	chr2:65423730	chr2:65500993~65502138:-
THCA	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	7.93	1.64e-14	6.34e-12	0.3	0.34	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
THCA	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-7.93	1.64e-14	6.36e-12	-0.48	-0.34	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
THCA	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-7.93	1.65e-14	6.36e-12	-0.44	-0.34	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
THCA	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-7.93	1.65e-14	6.39e-12	-0.41	-0.34	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
THCA	cis	rs2929278	0.589	rs11638972	ENSG00000166763.7	STRCP1	-7.93	1.66e-14	6.41e-12	-0.37	-0.34	Schizophrenia;	chr15:43782493	chr15:43699488~43718184:-
THCA	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	7.93	1.66e-14	6.42e-12	0.47	0.34	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	7.93	1.66e-14	6.42e-12	0.47	0.34	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
THCA	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	7.93	1.66e-14	6.42e-12	0.52	0.34	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
THCA	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-7.93	1.66e-14	6.43e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
THCA	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-7.93	1.66e-14	6.43e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
THCA	cis	rs2274273	0.623	rs1187883	ENSG00000258413.1	RP11-665C16.6	7.93	1.67e-14	6.44e-12	0.47	0.34	Protein biomarker;	chr14:55021516	chr14:55262767~55272075:-
THCA	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-7.93	1.67e-14	6.44e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
THCA	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-7.93	1.67e-14	6.44e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
THCA	cis	rs9649213	0.593	rs6947340	ENSG00000272950.1	RP11-307C18.1	-7.92	1.67e-14	6.46e-12	-0.42	-0.34	Prostate cancer (SNP x SNP interaction);	chr7:98282929	chr7:98322853~98323430:+
THCA	cis	rs4713118	0.869	rs9295743	ENSG00000219392.1	RP1-265C24.5	-7.92	1.67e-14	6.46e-12	-0.44	-0.34	Parkinson's disease;	chr6:27747323	chr6:28115628~28116551:+
THCA	cis	rs7302981	1	rs7308356	ENSG00000272368.2	RP4-605O3.4	-7.92	1.67e-14	6.46e-12	-0.21	-0.34	Systolic blood pressure;	chr12:50145828	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.934	rs7301649	ENSG00000272368.2	RP4-605O3.4	-7.92	1.67e-14	6.46e-12	-0.21	-0.34	Systolic blood pressure;	chr12:50147087	chr12:50112197~50165618:+
THCA	cis	rs6908034	0.607	rs73376657	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805729	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs74573060	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805801	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs113894708	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805835	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs62404179	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806041	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.546	rs73376662	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806109	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs12529148	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806566	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs112659166	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807178	chr6:19802164~19804752:-
THCA	cis	rs7811142	0.83	rs705866	ENSG00000078319.8	PMS2P1	-7.92	1.67e-14	6.46e-12	-0.5	-0.34	Platelet count;	chr7:100367662	chr7:100320992~100341908:-
THCA	cis	rs9649213	0.574	rs60077733	ENSG00000272950.1	RP11-307C18.1	7.92	1.67e-14	6.47e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr7:98322853~98323430:+
THCA	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-7.92	1.67e-14	6.47e-12	-0.41	-0.34	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
THCA	cis	rs42490	0.664	rs40457	ENSG00000251136.7	RP11-37B2.1	-7.92	1.68e-14	6.49e-12	-0.3	-0.34	Leprosy;	chr8:89811459	chr8:89609409~89757727:-
THCA	cis	rs7811142	0.83	rs7792525	ENSG00000078319.8	PMS2P1	-7.92	1.68e-14	6.49e-12	-0.49	-0.34	Platelet count;	chr7:100374499	chr7:100320992~100341908:-
THCA	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	7.92	1.68e-14	6.49e-12	0.34	0.34	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
THCA	cis	rs7302981	0.934	rs7294548	ENSG00000272368.2	RP4-605O3.4	-7.92	1.68e-14	6.5e-12	-0.2	-0.34	Systolic blood pressure;	chr12:50149418	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.967	rs6580729	ENSG00000272368.2	RP4-605O3.4	7.92	1.68e-14	6.5e-12	0.2	0.34	Systolic blood pressure;	chr12:50153255	chr12:50112197~50165618:+
THCA	cis	rs9928842	0.765	rs8055472	ENSG00000280152.1	RP11-331F4.5	7.92	1.69e-14	6.51e-12	0.45	0.34	Alcoholic chronic pancreatitis;	chr16:75191650	chr16:75245994~75250077:-
THCA	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-7.92	1.69e-14	6.52e-12	-0.42	-0.34	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
THCA	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	7.92	1.69e-14	6.52e-12	0.38	0.34	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
THCA	cis	rs934734	0.509	rs12185577	ENSG00000237979.1	AC007389.1	-7.92	1.69e-14	6.54e-12	-0.39	-0.34	Rheumatoid arthritis;	chr2:65432354	chr2:65500993~65502138:-
THCA	cis	rs910316	1	rs2098297	ENSG00000279594.1	RP11-950C14.10	-7.92	1.69e-14	6.54e-12	-0.32	-0.34	Height;	chr14:75152415	chr14:75011269~75012851:-
THCA	cis	rs2946504	1	rs2946504	ENSG00000251468.2	RP11-369K16.1	-7.92	1.7e-14	6.55e-12	-0.42	-0.34	Type 2 diabetes;	chr8:12954071	chr8:12958387~12962200:+
THCA	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	7.92	1.7e-14	6.55e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	7.92	1.7e-14	6.55e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
THCA	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	7.92	1.7e-14	6.55e-12	0.29	0.34	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
THCA	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-7.92	1.7e-14	6.56e-12	-0.41	-0.34	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
THCA	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	7.92	1.7e-14	6.56e-12	0.34	0.34	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
THCA	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-7.92	1.7e-14	6.58e-12	-0.41	-0.34	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
THCA	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-7.92	1.71e-14	6.6e-12	-0.43	-0.34	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
THCA	cis	rs2522056	1	rs11242113	ENSG00000233006.5	AC034220.3	-7.92	1.71e-14	6.6e-12	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132441542	chr5:132311285~132369916:-
THCA	cis	rs737008	0.821	rs28671554	ENSG00000262703.1	RP11-485G7.6	7.92	1.71e-14	6.61e-12	0.38	0.34	Obesity-related traits;	chr16:11309896	chr16:11348143~11349321:-
THCA	cis	rs11148252	0.5	rs342768	ENSG00000278238.1	RP11-245D16.4	-7.92	1.71e-14	6.61e-12	-0.37	-0.34	Lewy body disease;	chr13:52634747	chr13:52454775~52455331:-
THCA	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-7.92	1.71e-14	6.62e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
THCA	cis	rs8114671	0.935	rs35193912	ENSG00000269202.1	RP4-614O4.12	7.92	1.72e-14	6.62e-12	0.28	0.34	Height;	chr20:35197247	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs34515766	ENSG00000269202.1	RP4-614O4.12	7.92	1.72e-14	6.62e-12	0.28	0.34	Height;	chr20:35197418	chr20:35201747~35203288:-
THCA	cis	rs1707322	1	rs7526369	ENSG00000234329.1	RP11-767N6.2	7.92	1.72e-14	6.63e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs10890371	ENSG00000234329.1	RP11-767N6.2	7.92	1.72e-14	6.63e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45651039~45651826:-
THCA	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-7.92	1.72e-14	6.63e-12	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
THCA	cis	rs7621025	0.5	rs71630059	ENSG00000273486.1	RP11-731C17.2	-7.92	1.72e-14	6.65e-12	-0.36	-0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136837338~136839021:-
THCA	cis	rs6908034	0.66	rs6918235	ENSG00000228412.5	RP4-625H18.2	7.92	1.72e-14	6.65e-12	0.81	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19788196	chr6:19802164~19804752:-
THCA	cis	rs8114671	0.967	rs4911476	ENSG00000269202.1	RP4-614O4.12	7.92	1.72e-14	6.66e-12	0.29	0.34	Height;	chr20:35192965	chr20:35201747~35203288:-
THCA	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
THCA	cis	rs10208649	1	rs72904915	ENSG00000272156.1	RP11-477N3.1	7.92	1.72e-14	6.66e-12	0.63	0.34	Body mass index;	chr2:54000213	chr2:54082554~54085066:+
THCA	cis	rs7208859	0.623	rs426434	ENSG00000266490.1	CTD-2349P21.9	7.92	1.73e-14	6.66e-12	0.44	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30792372~30792833:+
THCA	cis	rs12682352	0.65	rs13265731	ENSG00000253893.2	FAM85B	-7.92	1.73e-14	6.66e-12	-0.45	-0.34	Neuroticism;	chr8:8815810	chr8:8167819~8226614:-
THCA	cis	rs9400467	0.528	rs457492	ENSG00000230177.1	RP5-1112D6.4	-7.92	1.73e-14	6.67e-12	-0.27	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111277932~111278742:+
THCA	cis	rs7208859	0.573	rs73267873	ENSG00000266490.1	CTD-2349P21.9	7.92	1.73e-14	6.69e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.561	rs4085382	ENSG00000266490.1	CTD-2349P21.9	7.92	1.73e-14	6.69e-12	0.43	0.34	Body mass index;	chr17:30744184	chr17:30792372~30792833:+
THCA	cis	rs9649213	0.613	rs6961129	ENSG00000272950.1	RP11-307C18.1	7.92	1.73e-14	6.69e-12	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr7:98322853~98323430:+
THCA	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-7.92	1.74e-14	6.71e-12	-0.64	-0.34	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
THCA	cis	rs7942368	1	rs10437754	ENSG00000254632.1	RP11-21L23.4	7.92	1.74e-14	6.72e-12	0.5	0.34	Endometriosis;	chr11:76766823	chr11:76759916~76768223:-
THCA	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-7.92	1.74e-14	6.72e-12	-0.44	-0.34	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
THCA	cis	rs180730	1	rs1376109	ENSG00000251609.2	SETP12	-7.92	1.76e-14	6.78e-12	-0.54	-0.34	Fasting plasma glucose;	chr4:120917160	chr4:120895494~120897083:-
THCA	cis	rs812925	0.519	rs967968	ENSG00000271889.1	RP11-493E12.1	-7.92	1.76e-14	6.79e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61428921	chr2:61151433~61162105:-
THCA	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	7.92	1.77e-14	6.84e-12	0.46	0.34	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
THCA	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	7.92	1.77e-14	6.84e-12	0.42	0.34	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
THCA	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	7.92	1.77e-14	6.84e-12	0.46	0.34	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
THCA	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-7.92	1.78e-14	6.86e-12	-0.45	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
THCA	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-7.92	1.78e-14	6.86e-12	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
THCA	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	7.92	1.78e-14	6.87e-12	0.23	0.34	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
THCA	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-7.92	1.78e-14	6.88e-12	-0.53	-0.34	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
THCA	cis	rs240993	0.502	rs240966	ENSG00000230177.1	RP5-1112D6.4	-7.92	1.79e-14	6.88e-12	-0.37	-0.34	Inflammatory skin disease;Psoriasis;	chr6:111323462	chr6:111277932~111278742:+
THCA	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-7.92	1.79e-14	6.89e-12	-0.42	-0.34	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
THCA	cis	rs736801	0.808	rs2706396	ENSG00000237714.1	P4HA2-AS1	-7.92	1.79e-14	6.89e-12	-0.46	-0.34	Mosquito bite size;Breast cancer;	chr5:132461117	chr5:132184876~132192808:+
THCA	cis	rs736801	0.836	rs2522052	ENSG00000237714.1	P4HA2-AS1	-7.92	1.79e-14	6.89e-12	-0.46	-0.34	Mosquito bite size;Breast cancer;	chr5:132462795	chr5:132184876~132192808:+
THCA	cis	rs736801	0.808	rs2706403	ENSG00000237714.1	P4HA2-AS1	-7.92	1.79e-14	6.89e-12	-0.46	-0.34	Mosquito bite size;Breast cancer;	chr5:132463320	chr5:132184876~132192808:+
THCA	cis	rs736801	0.754	rs2706336	ENSG00000237714.1	P4HA2-AS1	-7.92	1.79e-14	6.89e-12	-0.46	-0.34	Mosquito bite size;Breast cancer;	chr5:132464269	chr5:132184876~132192808:+
THCA	cis	rs12655019	0.92	rs74455703	ENSG00000271828.1	CTD-2310F14.1	7.92	1.79e-14	6.9e-12	0.79	0.34	Breast cancer (early onset);	chr5:56949442	chr5:56927874~56929573:+
THCA	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	7.91	1.79e-14	6.91e-12	0.4	0.34	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
THCA	cis	rs6908034	0.607	rs76413455	ENSG00000228412.5	RP4-625H18.2	7.91	1.8e-14	6.92e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808733	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs76525593	ENSG00000228412.5	RP4-625H18.2	7.91	1.8e-14	6.92e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808939	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.546	rs74514942	ENSG00000228412.5	RP4-625H18.2	7.91	1.8e-14	6.92e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810289	chr6:19802164~19804752:-
THCA	cis	rs9388451	0.839	rs980014	ENSG00000237742.5	RP11-624M8.1	-7.91	1.8e-14	6.95e-12	-0.29	-0.34	Brugada syndrome;	chr6:125746855	chr6:125578558~125749190:-
THCA	cis	rs7302981	0.967	rs35998534	ENSG00000272368.2	RP4-605O3.4	7.91	1.81e-14	6.96e-12	0.2	0.34	Systolic blood pressure;	chr12:50162999	chr12:50112197~50165618:+
THCA	cis	rs7714584	1	rs1863998	ENSG00000197083.10	ZNF300P1	7.91	1.81e-14	6.98e-12	0.56	0.34	Crohn's disease;	chr5:150892191	chr5:150930645~150946289:-
THCA	cis	rs812925	0.502	rs2084318	ENSG00000271889.1	RP11-493E12.1	-7.91	1.81e-14	6.98e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61425466	chr2:61151433~61162105:-
THCA	cis	rs28510890	0.789	rs11853354	ENSG00000260337.3	RP11-386M24.6	7.91	1.81e-14	6.99e-12	0.45	0.34	Lung cancer in ever smokers;	chr15:92568575	chr15:92592574~92596462:-
THCA	cis	rs4664293	0.718	rs4477859	ENSG00000226266.5	AC009961.3	7.91	1.82e-14	7e-12	0.4	0.34	Monocyte percentage of white cells;	chr2:159738616	chr2:159670708~159712435:-
THCA	cis	rs12655019	0.92	rs12514633	ENSG00000271828.1	CTD-2310F14.1	7.91	1.82e-14	7e-12	0.79	0.34	Breast cancer (early onset);	chr5:56940186	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs16886525	ENSG00000271828.1	CTD-2310F14.1	7.91	1.82e-14	7e-12	0.79	0.34	Breast cancer (early onset);	chr5:56941838	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs75713680	ENSG00000271828.1	CTD-2310F14.1	7.91	1.82e-14	7e-12	0.79	0.34	Breast cancer (early onset);	chr5:56942377	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs76797434	ENSG00000271828.1	CTD-2310F14.1	7.91	1.82e-14	7e-12	0.79	0.34	Breast cancer (early onset);	chr5:56945862	chr5:56927874~56929573:+
THCA	cis	rs12681366	0.881	rs12674614	ENSG00000253704.1	RP11-267M23.4	7.91	1.82e-14	7.01e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94396605	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.881	rs3019155	ENSG00000253704.1	RP11-267M23.4	7.91	1.82e-14	7.01e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94405359	chr8:94553722~94569745:+
THCA	cis	rs7220401	0.789	rs3760456	ENSG00000264007.1	RP11-68I3.10	-7.91	1.82e-14	7.01e-12	-0.39	-0.34	Coronary artery disease;	chr17:29621826	chr17:29621617~29622254:-
THCA	cis	rs17684571	0.872	rs34429594	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56714954	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs11961141	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56717580	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.81	rs60498201	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56718021	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs35807277	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56718783	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34812826	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56721893	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs59085778	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56723357	chr6:56844002~56864078:+
THCA	cis	rs240993	0.715	rs7776346	ENSG00000230177.1	RP5-1112D6.4	7.91	1.83e-14	7.04e-12	0.33	0.34	Inflammatory skin disease;Psoriasis;	chr6:111540162	chr6:111277932~111278742:+
THCA	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-7.91	1.83e-14	7.04e-12	-0.43	-0.34	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
THCA	cis	rs934734	0.511	rs62141115	ENSG00000237979.1	AC007389.1	-7.91	1.83e-14	7.05e-12	-0.39	-0.34	Rheumatoid arthritis;	chr2:65445058	chr2:65500993~65502138:-
THCA	cis	rs12701220	0.522	rs12334290	ENSG00000229043.2	AC091729.9	-7.91	1.83e-14	7.05e-12	-0.4	-0.34	Bronchopulmonary dysplasia;	chr7:1014881	chr7:1160374~1165267:+
THCA	cis	rs7811142	0.83	rs11765869	ENSG00000078319.8	PMS2P1	-7.91	1.84e-14	7.07e-12	-0.5	-0.34	Platelet count;	chr7:100367166	chr7:100320992~100341908:-
THCA	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-7.91	1.85e-14	7.1e-12	-0.41	-0.34	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
THCA	cis	rs13631	0.728	rs7848423	ENSG00000268996.3	MAN1B1-AS1	7.91	1.85e-14	7.11e-12	0.31	0.34	Cerebrospinal fluid biomarker levels;	chr9:137093304	chr9:137084946~137086817:-
THCA	cis	rs7045138	1	rs7045138	ENSG00000236130.1	PTCSC2	-7.91	1.85e-14	7.13e-12	-0.27	-0.34	Thyroid hormone levels;	chr9:97829181	chr9:97805935~97810008:-
THCA	cis	rs11673344	0.523	rs7255724	ENSG00000226686.6	LINC01535	7.91	1.86e-14	7.17e-12	0.38	0.34	Obesity-related traits;	chr19:37158675	chr19:37251912~37265535:+
THCA	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	7.91	1.87e-14	7.18e-12	0.41	0.34	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
THCA	cis	rs910316	0.737	rs175055	ENSG00000279594.1	RP11-950C14.10	-7.91	1.87e-14	7.21e-12	-0.31	-0.34	Height;	chr14:75022243	chr14:75011269~75012851:-
THCA	cis	rs8114671	0.967	rs2069945	ENSG00000269202.1	RP4-614O4.12	-7.91	1.87e-14	7.21e-12	-0.29	-0.34	Height;	chr20:35174034	chr20:35201747~35203288:-
THCA	cis	rs7015263	1	rs7015263	ENSG00000254231.1	CTD-2284J15.1	7.91	1.88e-14	7.24e-12	0.33	0.34	Intelligence (multi-trait analysis);	chr8:86513963	chr8:86333274~86343314:-
THCA	cis	rs2712184	0.756	rs2024489	ENSG00000229352.1	AC007563.3	-7.91	1.89e-14	7.25e-12	-0.41	-0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216796807	chr2:216799608~216805335:+
THCA	cis	rs2712184	0.756	rs2712161	ENSG00000229352.1	AC007563.3	-7.91	1.89e-14	7.25e-12	-0.41	-0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216797661	chr2:216799608~216805335:+
THCA	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	7.91	1.89e-14	7.26e-12	0.44	0.34	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
THCA	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	7.91	1.89e-14	7.26e-12	0.23	0.34	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
THCA	cis	rs1707322	1	rs10158032	ENSG00000234329.1	RP11-767N6.2	7.91	1.89e-14	7.28e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45651039~45651826:-
THCA	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	7.91	1.89e-14	7.28e-12	0.37	0.34	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
THCA	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-7.91	1.89e-14	7.28e-12	-0.47	-0.34	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
THCA	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-7.91	1.9e-14	7.29e-12	-0.34	-0.34	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
THCA	cis	rs910316	0.967	rs175505	ENSG00000279594.1	RP11-950C14.10	-7.91	1.9e-14	7.3e-12	-0.32	-0.34	Height;	chr14:75062916	chr14:75011269~75012851:-
THCA	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	7.91	1.91e-14	7.33e-12	0.3	0.34	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
THCA	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	7.91	1.91e-14	7.34e-12	0.39	0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
THCA	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	7.91	1.91e-14	7.35e-12	0.29	0.34	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
THCA	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	7.91	1.92e-14	7.36e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
THCA	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-7.91	1.92e-14	7.37e-12	-0.43	-0.34	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
THCA	cis	rs17772222	0.675	rs845758	ENSG00000258789.1	RP11-507K2.3	7.91	1.92e-14	7.38e-12	0.32	0.34	Coronary artery calcification;	chr14:88433746	chr14:88551597~88552493:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	7.91	1.92e-14	7.38e-12	0.25	0.34	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
THCA	cis	rs4072705	0.967	rs10818979	ENSG00000224020.1	MIR181A2HG	-7.91	1.92e-14	7.39e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124574634	chr9:124658467~124698631:+
THCA	cis	rs4713118	0.505	rs156740	ENSG00000219392.1	RP1-265C24.5	-7.9	1.92e-14	7.4e-12	-0.37	-0.34	Parkinson's disease;	chr6:27992657	chr6:28115628~28116551:+
THCA	cis	rs4819052	0.788	rs2236449	ENSG00000215447.6	BX322557.10	-7.9	1.93e-14	7.41e-12	-0.3	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45288052~45291738:+
THCA	cis	rs910316	0.875	rs12588099	ENSG00000279594.1	RP11-950C14.10	7.9	1.93e-14	7.41e-12	0.32	0.34	Height;	chr14:75127759	chr14:75011269~75012851:-
THCA	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	7.9	1.93e-14	7.42e-12	0.43	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	7.9	1.93e-14	7.42e-12	0.43	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000264538.5	SUZ12P1	-7.9	1.93e-14	7.42e-12	-0.34	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30709299~30790908:+
THCA	cis	rs2439831	0.867	rs2245715	ENSG00000249839.1	AC011330.5	-7.9	1.93e-14	7.42e-12	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43525854	chr15:43663654~43684339:-
THCA	cis	rs4713118	0.869	rs9283881	ENSG00000219392.1	RP1-265C24.5	-7.9	1.94e-14	7.45e-12	-0.44	-0.34	Parkinson's disease;	chr6:27747476	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9283882	ENSG00000219392.1	RP1-265C24.5	-7.9	1.94e-14	7.45e-12	-0.44	-0.34	Parkinson's disease;	chr6:27747479	chr6:28115628~28116551:+
THCA	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-7.9	1.94e-14	7.45e-12	-0.4	-0.34	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
THCA	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-7.9	1.94e-14	7.46e-12	-0.51	-0.34	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-7.9	1.94e-14	7.46e-12	-0.51	-0.34	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
THCA	cis	rs1707322	0.963	rs34907901	ENSG00000234329.1	RP11-767N6.2	7.9	1.94e-14	7.47e-12	0.33	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45651039~45651826:-
THCA	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-7.9	1.94e-14	7.47e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
THCA	cis	rs6908034	0.607	rs34109983	ENSG00000228412.5	RP4-625H18.2	7.9	1.95e-14	7.48e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807811	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs73376680	ENSG00000228412.5	RP4-625H18.2	7.9	1.95e-14	7.48e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807868	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs73376681	ENSG00000228412.5	RP4-625H18.2	7.9	1.95e-14	7.48e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807944	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs80355837	ENSG00000228412.5	RP4-625H18.2	7.9	1.95e-14	7.48e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808112	chr6:19802164~19804752:-
THCA	cis	rs6723226	0.679	rs116617324	ENSG00000276334.1	AL133243.1	-7.9	1.95e-14	7.49e-12	-0.39	-0.34	Intelligence (multi-trait analysis);	chr2:32397641	chr2:32521927~32523547:+
THCA	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-7.9	1.95e-14	7.49e-12	-0.38	-0.34	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
THCA	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-7.9	1.95e-14	7.5e-12	-0.47	-0.34	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
THCA	cis	rs4713118	0.869	rs9283880	ENSG00000219392.1	RP1-265C24.5	-7.9	1.95e-14	7.5e-12	-0.44	-0.34	Parkinson's disease;	chr6:27747464	chr6:28115628~28116551:+
THCA	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-7.9	1.96e-14	7.51e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
THCA	cis	rs910316	1	rs175425	ENSG00000279594.1	RP11-950C14.10	-7.9	1.96e-14	7.52e-12	-0.32	-0.34	Height;	chr14:75159428	chr14:75011269~75012851:-
THCA	cis	rs910316	0.935	rs175422	ENSG00000279594.1	RP11-950C14.10	-7.9	1.96e-14	7.52e-12	-0.32	-0.34	Height;	chr14:75160616	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs35446981	ENSG00000279594.1	RP11-950C14.10	-7.9	1.96e-14	7.52e-12	-0.32	-0.34	Height;	chr14:75170648	chr14:75011269~75012851:-
THCA	cis	rs934734	0.532	rs2860773	ENSG00000237979.1	AC007389.1	-7.9	1.96e-14	7.52e-12	-0.38	-0.34	Rheumatoid arthritis;	chr2:65438507	chr2:65500993~65502138:-
THCA	cis	rs12682352	0.602	rs13260419	ENSG00000253893.2	FAM85B	-7.9	1.96e-14	7.53e-12	-0.45	-0.34	Neuroticism;	chr8:8817666	chr8:8167819~8226614:-
THCA	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-7.9	1.96e-14	7.53e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
THCA	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-7.9	1.96e-14	7.53e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs6901520	ENSG00000219392.1	RP1-265C24.5	-7.9	1.96e-14	7.54e-12	-0.44	-0.34	Parkinson's disease;	chr6:27746796	chr6:28115628~28116551:+
THCA	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	7.9	1.97e-14	7.56e-12	0.23	0.34	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000237664.1	LINC00316	-7.9	1.97e-14	7.58e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45338590~45341990:-
THCA	cis	rs4072705	0.967	rs4838208	ENSG00000224020.1	MIR181A2HG	-7.9	1.98e-14	7.62e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124765756	chr9:124658467~124698631:+
THCA	cis	rs4072705	0.967	rs4838209	ENSG00000224020.1	MIR181A2HG	-7.9	1.98e-14	7.62e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124766563	chr9:124658467~124698631:+
THCA	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	7.9	1.99e-14	7.62e-12	0.41	0.34	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
THCA	cis	rs9329221	0.527	rs7833781	ENSG00000261451.1	RP11-981G7.1	7.9	1.99e-14	7.63e-12	0.44	0.34	Neuroticism;	chr8:10475967	chr8:10433672~10438312:+
THCA	cis	rs7945705	0.875	rs11042059	ENSG00000254860.4	TMEM9B-AS1	-7.9	1.99e-14	7.64e-12	-0.37	-0.34	Hemoglobin concentration;	chr11:8773533	chr11:8964675~8977527:+
THCA	cis	rs984222	0.677	rs6428792	ENSG00000231365.4	RP11-418J17.1	-7.9	1.99e-14	7.65e-12	-0.34	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119114244	chr1:119140396~119275973:+
THCA	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-7.9	1.99e-14	7.65e-12	-0.53	-0.34	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
THCA	cis	rs7811142	0.945	rs34989573	ENSG00000242294.5	STAG3L5P	7.9	2e-14	7.66e-12	0.23	0.34	Platelet count;	chr7:100500272	chr7:100336079~100351900:+
THCA	cis	rs9847710	0.566	rs2564951	ENSG00000242142.1	SERBP1P3	7.9	2e-14	7.66e-12	0.43	0.34	Ulcerative colitis;	chr3:53026433	chr3:53064283~53065091:-
THCA	cis	rs10411161	0.81	rs4267442	ENSG00000269483.1	AC006272.1	7.9	2e-14	7.67e-12	0.57	0.34	Breast cancer;	chr19:51860474	chr19:51839924~51843324:-
THCA	cis	rs62289301	0.5	rs10007081	ENSG00000273133.1	RP11-799M12.2	-7.9	2e-14	7.67e-12	-0.48	-0.34	Joint mobility (Beighton score);	chr4:15509764	chr4:15563698~15564253:-
THCA	cis	rs4789693	0.938	rs4789694	ENSG00000265458.1	RP13-20L14.6	-7.9	2e-14	7.68e-12	-0.34	-0.34	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82454273~82458521:-
THCA	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-7.9	2e-14	7.68e-12	-0.4	-0.34	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
THCA	cis	rs673078	0.66	rs61943362	ENSG00000275409.1	RP11-131L12.4	-7.9	2e-14	7.68e-12	-0.45	-0.34	Glucose homeostasis traits;	chr12:118322042	chr12:118430147~118430699:+
THCA	cis	rs12655019	0.92	rs1466010	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56917329	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs16886497	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56924887	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs79354983	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56925710	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs113772507	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56929449	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs16886510	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56932618	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs78075120	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56932640	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs76869724	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56932668	chr5:56927874~56929573:+
THCA	cis	rs944289	0.562	rs12431566	ENSG00000257826.1	RP11-116N8.4	7.9	2e-14	7.69e-12	0.36	0.34	Thyroid cancer;	chr14:36051211	chr14:36061026~36067190:-
THCA	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	7.9	2.01e-14	7.69e-12	0.42	0.34	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
THCA	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-7.9	2.01e-14	7.7e-12	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-7.9	2.01e-14	7.7e-12	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-7.9	2.01e-14	7.7e-12	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
THCA	cis	rs6723226	0.75	rs1033751	ENSG00000276334.1	AL133243.1	7.9	2.01e-14	7.71e-12	0.38	0.34	Intelligence (multi-trait analysis);	chr2:32470691	chr2:32521927~32523547:+
THCA	cis	rs944289	0.966	rs1182929	ENSG00000257826.1	RP11-116N8.4	-7.9	2.01e-14	7.71e-12	-0.36	-0.34	Thyroid cancer;	chr14:36165946	chr14:36061026~36067190:-
THCA	cis	rs9329221	0.527	rs10903328	ENSG00000261451.1	RP11-981G7.1	7.9	2.01e-14	7.72e-12	0.44	0.34	Neuroticism;	chr8:10474657	chr8:10433672~10438312:+
THCA	cis	rs910316	1	rs11623413	ENSG00000279594.1	RP11-950C14.10	-7.9	2.01e-14	7.73e-12	-0.32	-0.34	Height;	chr14:75122121	chr14:75011269~75012851:-
THCA	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	7.9	2.02e-14	7.75e-12	0.41	0.34	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
THCA	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	7.9	2.02e-14	7.75e-12	0.46	0.34	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	7.9	2.02e-14	7.75e-12	0.46	0.34	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
THCA	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	7.9	2.03e-14	7.77e-12	0.42	0.34	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
THCA	cis	rs853679	0.882	rs4713140	ENSG00000280107.1	AL022393.9	-7.9	2.03e-14	7.77e-12	-0.52	-0.34	Depression;	chr6:28129415	chr6:28170845~28172521:+
THCA	cis	rs116175783	0.557	rs62188138	ENSG00000227403.1	AC009299.3	7.9	2.03e-14	7.77e-12	0.6	0.34	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161244739~161249050:+
THCA	cis	rs116175783	0.557	rs6710414	ENSG00000227403.1	AC009299.3	7.9	2.03e-14	7.77e-12	0.6	0.34	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161244739~161249050:+
THCA	cis	rs4266144	0.544	rs13080798	ENSG00000244515.1	KRT18P34	-7.9	2.03e-14	7.77e-12	-0.38	-0.34	Coronary artery disease;	chr3:157114612	chr3:157162663~157163932:-
THCA	cis	rs8062405	0.558	rs231976	ENSG00000251417.2	RP11-1348G14.4	-7.9	2.04e-14	7.81e-12	-0.32	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28802743~28817828:+
THCA	cis	rs42490	0.789	rs416324	ENSG00000251136.7	RP11-37B2.1	7.9	2.04e-14	7.81e-12	0.29	0.34	Leprosy;	chr8:89803007	chr8:89609409~89757727:-
THCA	cis	rs12681366	0.881	rs2381793	ENSG00000253704.1	RP11-267M23.4	7.9	2.04e-14	7.83e-12	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94388167	chr8:94553722~94569745:+
THCA	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	7.9	2.05e-14	7.85e-12	0.68	0.34	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
THCA	cis	rs2562456	0.834	rs2173727	ENSG00000268555.1	RP11-678G14.3	-7.9	2.05e-14	7.85e-12	-0.47	-0.34	Pain;	chr19:21491155	chr19:21570822~21587322:-
THCA	cis	rs7674212	0.531	rs4699048	ENSG00000251288.2	RP11-10L12.2	-7.9	2.05e-14	7.85e-12	-0.46	-0.34	Type 2 diabetes;	chr4:103005570	chr4:102751401~102752641:+
THCA	cis	rs2787702	0.5	rs28793568	ENSG00000237233.2	TMEM26-AS1	7.9	2.05e-14	7.85e-12	0.56	0.34	Response to taxane treatment (placlitaxel);	chr10:61584797	chr10:61452639~61481956:+
THCA	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-7.9	2.05e-14	7.86e-12	-0.42	-0.34	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
THCA	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-7.9	2.06e-14	7.9e-12	-0.44	-0.34	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
THCA	cis	rs7811142	0.83	rs76798830	ENSG00000078319.8	PMS2P1	-7.9	2.06e-14	7.91e-12	-0.5	-0.34	Platelet count;	chr7:100355205	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.775	rs6946768	ENSG00000078319.8	PMS2P1	-7.9	2.06e-14	7.91e-12	-0.5	-0.34	Platelet count;	chr7:100356770	chr7:100320992~100341908:-
THCA	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-7.9	2.06e-14	7.91e-12	-0.44	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
THCA	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	7.9	2.06e-14	7.91e-12	0.48	0.34	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
THCA	cis	rs12681366	0.801	rs6981551	ENSG00000253704.1	RP11-267M23.4	7.9	2.06e-14	7.91e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:94553722~94569745:+
THCA	cis	rs6496932	0.503	rs10220820	ENSG00000218052.5	ADAMTS7P4	-7.89	2.07e-14	7.92e-12	-0.45	-0.34	Central corneal thickness;Corneal structure;	chr15:85441932	chr15:85255369~85330334:-
THCA	cis	rs7851660	0.679	rs4297160	ENSG00000236130.1	PTCSC2	-7.89	2.07e-14	7.93e-12	-0.27	-0.34	Strep throat;	chr9:97823224	chr9:97805935~97810008:-
THCA	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-7.89	2.08e-14	7.98e-12	-0.48	-0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
THCA	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	7.89	2.08e-14	7.98e-12	0.46	0.34	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
THCA	cis	rs12681366	0.801	rs12549544	ENSG00000253704.1	RP11-267M23.4	7.89	2.08e-14	7.98e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94553722~94569745:+
THCA	cis	rs9388451	0.839	rs3966775	ENSG00000237742.5	RP11-624M8.1	-7.89	2.09e-14	7.99e-12	-0.29	-0.34	Brugada syndrome;	chr6:125746509	chr6:125578558~125749190:-
THCA	cis	rs10411161	0.81	rs77458785	ENSG00000269483.1	AC006272.1	7.89	2.09e-14	8e-12	0.58	0.34	Breast cancer;	chr19:51881042	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.81	rs60981935	ENSG00000269483.1	AC006272.1	7.89	2.09e-14	8e-12	0.58	0.34	Breast cancer;	chr19:51882028	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.81	rs57171871	ENSG00000269483.1	AC006272.1	7.89	2.09e-14	8e-12	0.58	0.34	Breast cancer;	chr19:51882079	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.81	rs59911578	ENSG00000269483.1	AC006272.1	7.89	2.09e-14	8e-12	0.58	0.34	Breast cancer;	chr19:51882344	chr19:51839924~51843324:-
THCA	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	7.89	2.09e-14	8e-12	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
THCA	cis	rs934734	0.752	rs198478	ENSG00000204929.10	AC074391.1	-7.89	2.09e-14	8.01e-12	-0.42	-0.34	Rheumatoid arthritis;	chr2:65379877	chr2:65436711~66084639:+
THCA	cis	rs7727544	0.647	rs72793280	ENSG00000224431.1	AC063976.7	7.89	2.09e-14	8.02e-12	0.3	0.34	Blood metabolite levels;	chr5:132227207	chr5:132199456~132203487:+
THCA	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-7.89	2.1e-14	8.03e-12	-0.44	-0.34	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
THCA	cis	rs11148252	0.774	rs7993748	ENSG00000235660.1	LINC00345	-7.89	2.1e-14	8.05e-12	-0.42	-0.34	Lewy body disease;	chr13:52367496	chr13:52484161~52484680:-
THCA	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-7.89	2.11e-14	8.07e-12	-0.51	-0.34	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-7.89	2.11e-14	8.07e-12	-0.51	-0.34	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-7.89	2.11e-14	8.07e-12	-0.51	-0.34	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-7.89	2.11e-14	8.07e-12	-0.51	-0.34	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
THCA	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	7.89	2.11e-14	8.07e-12	0.55	0.34	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	7.89	2.11e-14	8.07e-12	0.55	0.34	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	7.89	2.11e-14	8.07e-12	0.55	0.34	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
THCA	cis	rs7727544	0.716	rs2089855	ENSG00000224431.1	AC063976.7	7.89	2.11e-14	8.08e-12	0.31	0.34	Blood metabolite levels;	chr5:132237836	chr5:132199456~132203487:+
THCA	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	7.89	2.12e-14	8.1e-12	0.45	0.34	Height;	chr6:109573151	chr6:109382795~109383666:+
THCA	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	7.89	2.12e-14	8.1e-12	0.55	0.34	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
THCA	cis	rs7918232	0.574	rs10458708	ENSG00000262412.1	RP11-85G18.6	7.89	2.12e-14	8.11e-12	0.4	0.34	Breast cancer;	chr10:27166676	chr10:27243130~27250804:+
THCA	cis	rs10208649	1	rs10208649	ENSG00000272156.1	RP11-477N3.1	-7.89	2.12e-14	8.11e-12	-0.61	-0.34	Body mass index;	chr2:53934226	chr2:54082554~54085066:+
THCA	cis	rs910316	0.935	rs2268620	ENSG00000279594.1	RP11-950C14.10	-7.89	2.12e-14	8.13e-12	-0.32	-0.34	Height;	chr14:75173700	chr14:75011269~75012851:-
THCA	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	7.89	2.13e-14	8.14e-12	0.2	0.34	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
THCA	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-7.89	2.13e-14	8.16e-12	-0.33	-0.34	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-7.89	2.13e-14	8.16e-12	-0.33	-0.34	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
THCA	cis	rs4072705	0.967	rs4144630	ENSG00000224020.1	MIR181A2HG	-7.89	2.14e-14	8.18e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124676921	chr9:124658467~124698631:+
THCA	cis	rs8114671	0.836	rs2425006	ENSG00000269202.1	RP4-614O4.12	7.89	2.15e-14	8.21e-12	0.29	0.34	Height;	chr20:34983425	chr20:35201747~35203288:-
THCA	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	7.89	2.15e-14	8.22e-12	0.63	0.34	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
THCA	cis	rs4713118	0.662	rs149969	ENSG00000226314.6	ZNF192P1	-7.89	2.15e-14	8.23e-12	-0.43	-0.34	Parkinson's disease;	chr6:28009959	chr6:28161781~28169594:+
THCA	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	7.89	2.15e-14	8.23e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
THCA	cis	rs10853057	0.717	rs4791242	ENSG00000214174.7	AMZ2P1	-7.89	2.15e-14	8.24e-12	-0.54	-0.34	White matter microstructure (global fractional anisotropy);	chr17:65061533	chr17:64966550~64975576:-
THCA	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
THCA	cis	rs910316	0.81	rs77939209	ENSG00000279594.1	RP11-950C14.10	-7.89	2.16e-14	8.27e-12	-0.32	-0.34	Height;	chr14:75203367	chr14:75011269~75012851:-
THCA	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-7.89	2.16e-14	8.27e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
THCA	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-7.89	2.16e-14	8.27e-12	-0.41	-0.34	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-7.89	2.16e-14	8.27e-12	-0.41	-0.34	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-7.89	2.16e-14	8.27e-12	-0.41	-0.34	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-7.89	2.16e-14	8.27e-12	-0.41	-0.34	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
THCA	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-7.89	2.18e-14	8.33e-12	-0.44	-0.34	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
THCA	cis	rs1707322	1	rs6687301	ENSG00000234329.1	RP11-767N6.2	7.89	2.18e-14	8.33e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45651039~45651826:-
THCA	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-7.89	2.18e-14	8.35e-12	-0.48	-0.34	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
THCA	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	7.89	2.18e-14	8.35e-12	0.23	0.34	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
THCA	cis	rs78579487	1	rs78579487	ENSG00000240875.4	LINC00886	-7.89	2.19e-14	8.36e-12	-0.28	-0.34	Breast cancer;	chr3:156800879	chr3:156747346~156817062:-
THCA	cis	rs987724	0.551	rs1835372	ENSG00000240875.4	LINC00886	-7.89	2.19e-14	8.36e-12	-0.28	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156801238	chr3:156747346~156817062:-
THCA	cis	rs2712184	0.756	rs2024487	ENSG00000229352.1	AC007563.3	7.89	2.19e-14	8.38e-12	0.4	0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216798548	chr2:216799608~216805335:+
THCA	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-7.89	2.2e-14	8.4e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-7.89	2.2e-14	8.4e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-7.89	2.2e-14	8.4e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
THCA	cis	rs7247513	0.964	rs8105902	ENSG00000230310.1	CTD-2192J16.11	-7.89	2.2e-14	8.42e-12	-0.41	-0.34	Bipolar disorder;	chr19:12607537	chr19:12552597~12553644:+
THCA	cis	rs7646881	0.812	rs73017539	ENSG00000240207.5	RP11-379F4.4	-7.89	2.21e-14	8.42e-12	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742954	chr3:158732263~158784070:+
THCA	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
THCA	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	7.88	2.22e-14	8.47e-12	0.43	0.34	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
THCA	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	7.88	2.22e-14	8.47e-12	0.23	0.34	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	7.88	2.22e-14	8.47e-12	0.23	0.34	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
THCA	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-7.88	2.22e-14	8.47e-12	-0.33	-0.34	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
THCA	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-7.88	2.22e-14	8.49e-12	-0.41	-0.34	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
THCA	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	7.88	2.22e-14	8.5e-12	0.46	0.34	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
THCA	cis	rs910316	0.712	rs175015	ENSG00000279594.1	RP11-950C14.10	-7.88	2.23e-14	8.5e-12	-0.31	-0.34	Height;	chr14:74990372	chr14:75011269~75012851:-
THCA	cis	rs910316	0.763	rs735452	ENSG00000279594.1	RP11-950C14.10	-7.88	2.23e-14	8.52e-12	-0.32	-0.34	Height;	chr14:75031281	chr14:75011269~75012851:-
THCA	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	7.88	2.23e-14	8.52e-12	0.41	0.34	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
THCA	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	7.88	2.23e-14	8.52e-12	0.42	0.34	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
THCA	cis	rs4819052	1	rs13047688	ENSG00000237664.1	LINC00316	-7.88	2.23e-14	8.52e-12	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45338590~45341990:-
THCA	cis	rs6844153	0.941	rs73116683	ENSG00000240005.4	RP11-293A21.1	-7.88	2.23e-14	8.53e-12	-0.44	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26955376	chr4:26859806~26860599:-
THCA	cis	rs8114671	0.836	rs2038504	ENSG00000269202.1	RP4-614O4.12	7.88	2.25e-14	8.58e-12	0.29	0.34	Height;	chr20:35060384	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.836	rs2104083	ENSG00000269202.1	RP4-614O4.12	7.88	2.25e-14	8.58e-12	0.29	0.34	Height;	chr20:35061330	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.839	rs2104084	ENSG00000269202.1	RP4-614O4.12	7.88	2.25e-14	8.58e-12	0.29	0.34	Height;	chr20:35061414	chr20:35201747~35203288:-
THCA	cis	rs934734	0.532	rs62141075	ENSG00000237979.1	AC007389.1	-7.88	2.25e-14	8.6e-12	-0.39	-0.34	Rheumatoid arthritis;	chr2:65417482	chr2:65500993~65502138:-
THCA	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	7.88	2.25e-14	8.6e-12	0.31	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	7.88	2.25e-14	8.6e-12	0.31	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
THCA	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-7.88	2.26e-14	8.61e-12	-0.41	-0.34	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
THCA	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	7.88	2.26e-14	8.61e-12	0.32	0.34	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
THCA	cis	rs2439831	0.717	rs28495368	ENSG00000275601.1	AC011330.13	-7.88	2.26e-14	8.62e-12	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43603444	chr15:43642389~43643023:-
THCA	cis	rs11651753	0.598	rs4794286	ENSG00000264920.1	RP11-6N17.4	-7.88	2.26e-14	8.63e-12	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47913231	chr17:47891255~47895812:-
THCA	cis	rs7208859	0.673	rs78799101	ENSG00000266490.1	CTD-2349P21.9	7.88	2.26e-14	8.64e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30792372~30792833:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000206090.4	AP000350.7	7.88	2.27e-14	8.64e-12	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23939998~23942798:+
THCA	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	7.88	2.27e-14	8.65e-12	0.42	0.34	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
THCA	cis	rs1707322	1	rs4073847	ENSG00000234329.1	RP11-767N6.2	-7.88	2.27e-14	8.66e-12	-0.32	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45651039~45651826:-
THCA	cis	rs7208859	0.562	rs216408	ENSG00000266490.1	CTD-2349P21.9	-7.88	2.27e-14	8.66e-12	-0.44	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30792372~30792833:+
THCA	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-7.88	2.27e-14	8.67e-12	-0.5	-0.34	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
THCA	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	7.88	2.28e-14	8.69e-12	0.34	0.34	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
THCA	cis	rs6908034	0.556	rs113071446	ENSG00000228412.5	RP4-625H18.2	7.88	2.28e-14	8.7e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810604	chr6:19802164~19804752:-
THCA	cis	rs28510890	0.688	rs12593253	ENSG00000260337.3	RP11-386M24.6	7.88	2.28e-14	8.71e-12	0.38	0.34	Lung cancer in ever smokers;	chr15:92587690	chr15:92592574~92596462:-
THCA	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	7.88	2.28e-14	8.71e-12	0.33	0.34	Breast size;	chr12:9228263	chr12:9277235~9313241:+
THCA	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	7.88	2.29e-14	8.74e-12	0.44	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
THCA	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-7.88	2.29e-14	8.74e-12	-0.41	-0.34	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
THCA	cis	rs17684571	0.872	rs3002009	ENSG00000231441.1	RP11-472M19.2	7.88	2.3e-14	8.76e-12	0.43	0.34	Schizophrenia;	chr6:56757983	chr6:56844002~56864078:+
THCA	cis	rs71403859	0.502	rs75986475	ENSG00000260886.1	TAT-AS1	7.88	2.31e-14	8.8e-12	0.62	0.34	Post bronchodilator FEV1;	chr16:71430155	chr16:71565789~71578187:+
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000219392.1	RP1-265C24.5	-7.88	2.31e-14	8.83e-12	-0.38	-0.34	Pubertal anthropometrics;	chr6:28197520	chr6:28115628~28116551:+
THCA	cis	rs62103177	0.759	rs9956512	ENSG00000261126.6	RP11-795F19.1	7.88	2.32e-14	8.84e-12	0.4	0.34	Opioid sensitivity;	chr18:79847517	chr18:80046900~80095482:+
THCA	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	7.88	2.32e-14	8.84e-12	0.43	0.34	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
THCA	cis	rs9500256	0.967	rs4928431	ENSG00000272541.1	XXbac-BPGBPG55C20.1	7.88	2.32e-14	8.85e-12	0.36	0.34	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57855891~57856468:-
THCA	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	7.88	2.32e-14	8.86e-12	0.41	0.34	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	7.88	2.32e-14	8.86e-12	0.41	0.34	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
THCA	cis	rs12681366	0.881	rs10464877	ENSG00000253704.1	RP11-267M23.4	7.88	2.32e-14	8.86e-12	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94385615	chr8:94553722~94569745:+
THCA	cis	rs2466254	0.657	rs2460915	ENSG00000251468.2	RP11-369K16.1	7.88	2.32e-14	8.86e-12	0.54	0.34	Pneumonia;	chr8:12968527	chr8:12958387~12962200:+
THCA	cis	rs2839186	0.708	rs17183123	ENSG00000239415.1	AP001469.9	7.88	2.33e-14	8.87e-12	0.35	0.34	Testicular germ cell tumor;	chr21:46252047	chr21:46251549~46254133:-
THCA	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-7.88	2.33e-14	8.9e-12	-0.39	-0.34	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
THCA	cis	rs7945705	0.738	rs11042067	ENSG00000254860.4	TMEM9B-AS1	7.88	2.34e-14	8.91e-12	0.36	0.34	Hemoglobin concentration;	chr11:8793906	chr11:8964675~8977527:+
THCA	cis	rs736801	0.808	rs6866614	ENSG00000237714.1	P4HA2-AS1	-7.88	2.34e-14	8.91e-12	-0.47	-0.34	Mosquito bite size;Breast cancer;	chr5:132451445	chr5:132184876~132192808:+
THCA	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	7.88	2.34e-14	8.94e-12	0.46	0.34	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
THCA	cis	rs853679	0.824	rs34712084	ENSG00000280107.1	AL022393.9	-7.88	2.35e-14	8.96e-12	-0.53	-0.34	Depression;	chr6:28076050	chr6:28170845~28172521:+
THCA	cis	rs853679	0.824	rs1321505	ENSG00000280107.1	AL022393.9	-7.88	2.35e-14	8.96e-12	-0.53	-0.34	Depression;	chr6:28085045	chr6:28170845~28172521:+
THCA	cis	rs853679	0.882	rs9468287	ENSG00000280107.1	AL022393.9	-7.88	2.35e-14	8.96e-12	-0.53	-0.34	Depression;	chr6:28111963	chr6:28170845~28172521:+
THCA	cis	rs8027521	0.54	rs11639036	ENSG00000280362.1	RP11-643A5.3	7.88	2.35e-14	8.96e-12	0.52	0.34	Circulating chemerin levels;	chr15:53944693	chr15:53910769~53914712:+
THCA	cis	rs12681366	0.881	rs3019145	ENSG00000253704.1	RP11-267M23.4	7.88	2.35e-14	8.97e-12	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94401324	chr8:94553722~94569745:+
THCA	cis	rs10971721	0.584	rs10971938	ENSG00000260947.1	RP11-384P7.7	-7.88	2.35e-14	8.97e-12	-0.78	-0.34	Body mass index;	chr9:34120722	chr9:33697459~33700986:+
THCA	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	7.88	2.36e-14	8.98e-12	0.46	0.34	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
THCA	cis	rs4072705	1	rs6478680	ENSG00000224020.1	MIR181A2HG	-7.88	2.36e-14	8.98e-12	-0.3	-0.34	Menarche (age at onset);	chr9:124696189	chr9:124658467~124698631:+
THCA	cis	rs2712184	0.756	rs2541388	ENSG00000229352.1	AC007563.3	7.88	2.36e-14	8.99e-12	0.4	0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216799561	chr2:216799608~216805335:+
THCA	cis	rs11673344	0.504	rs6510593	ENSG00000226686.6	LINC01535	7.88	2.37e-14	9.03e-12	0.38	0.34	Obesity-related traits;	chr19:37143153	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs7259332	ENSG00000226686.6	LINC01535	7.88	2.37e-14	9.03e-12	0.38	0.34	Obesity-related traits;	chr19:37143389	chr19:37251912~37265535:+
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000237979.1	AC007389.1	-7.88	2.38e-14	9.05e-12	-0.39	-0.34	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65500993~65502138:-
THCA	cis	rs4072705	1	rs7032937	ENSG00000224020.1	MIR181A2HG	-7.88	2.38e-14	9.06e-12	-0.3	-0.34	Menarche (age at onset);	chr9:124575894	chr9:124658467~124698631:+
THCA	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	7.88	2.38e-14	9.06e-12	0.41	0.34	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
THCA	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	7.88	2.38e-14	9.06e-12	0.46	0.34	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
THCA	cis	rs7247513	0.964	rs8100964	ENSG00000230310.1	CTD-2192J16.11	-7.87	2.39e-14	9.11e-12	-0.41	-0.34	Bipolar disorder;	chr19:12609817	chr19:12552597~12553644:+
THCA	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-7.87	2.39e-14	9.12e-12	-0.35	-0.34	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
THCA	cis	rs116175783	0.557	rs16845770	ENSG00000227403.1	AC009299.3	7.87	2.4e-14	9.13e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161325276	chr2:161244739~161249050:+
THCA	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-7.87	2.4e-14	9.14e-12	-0.41	-0.34	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
THCA	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	7.87	2.4e-14	9.14e-12	0.43	0.34	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
THCA	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	7.87	2.4e-14	9.16e-12	0.41	0.34	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
THCA	cis	rs7727544	0.606	rs10058074	ENSG00000233006.5	AC034220.3	7.87	2.41e-14	9.17e-12	0.27	0.34	Blood metabolite levels;	chr5:132350453	chr5:132311285~132369916:-
THCA	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	7.87	2.41e-14	9.17e-12	0.23	0.34	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
THCA	cis	rs34375054	0.623	rs2297478	ENSG00000279233.1	RP11-158L12.4	7.87	2.41e-14	9.18e-12	0.34	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125107298	chr12:125138245~125141711:+
THCA	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	7.87	2.42e-14	9.22e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
THCA	cis	rs11148252	0.774	rs56033750	ENSG00000235660.1	LINC00345	-7.87	2.43e-14	9.25e-12	-0.42	-0.34	Lewy body disease;	chr13:52173143	chr13:52484161~52484680:-
THCA	cis	rs7208859	0.623	rs3752019	ENSG00000266490.1	CTD-2349P21.9	7.87	2.43e-14	9.26e-12	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs56146117	ENSG00000266490.1	CTD-2349P21.9	7.87	2.43e-14	9.26e-12	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30792372~30792833:+
THCA	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-7.87	2.44e-14	9.29e-12	-0.44	-0.34	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
THCA	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	7.87	2.44e-14	9.3e-12	0.43	0.34	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
THCA	cis	rs2018683	0.768	rs10282015	ENSG00000228421.2	AC005013.5	7.87	2.44e-14	9.3e-12	0.38	0.34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.77	rs10951208	ENSG00000228421.2	AC005013.5	7.87	2.44e-14	9.3e-12	0.38	0.34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28957667~28959345:+
THCA	cis	rs9400467	0.528	rs11153280	ENSG00000230177.1	RP5-1112D6.4	-7.87	2.45e-14	9.32e-12	-0.27	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111277932~111278742:+
THCA	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	7.87	2.45e-14	9.34e-12	0.32	0.34	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
THCA	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	7.87	2.45e-14	9.34e-12	0.32	0.34	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
THCA	cis	rs10208649	1	rs72906711	ENSG00000272156.1	RP11-477N3.1	7.87	2.46e-14	9.35e-12	0.62	0.34	Body mass index;	chr2:54036465	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs13387890	ENSG00000272156.1	RP11-477N3.1	7.87	2.46e-14	9.35e-12	0.62	0.34	Body mass index;	chr2:54039249	chr2:54082554~54085066:+
THCA	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-7.87	2.46e-14	9.36e-12	-0.54	-0.34	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
THCA	cis	rs7015263	0.715	rs6999022	ENSG00000254231.1	CTD-2284J15.1	7.87	2.46e-14	9.36e-12	0.34	0.34	Intelligence (multi-trait analysis);	chr8:86510941	chr8:86333274~86343314:-
THCA	cis	rs595244	0.764	rs6493333	ENSG00000259705.1	RP11-227D13.1	-7.87	2.48e-14	9.43e-12	-0.46	-0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48646849	chr15:48645951~48652016:+
THCA	cis	rs732716	0.752	rs11085072	ENSG00000267980.1	AC007292.6	-7.87	2.48e-14	9.44e-12	-0.41	-0.34	Mean corpuscular volume;	chr19:4368145	chr19:4363789~4364640:+
THCA	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	7.87	2.48e-14	9.45e-12	0.42	0.34	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
THCA	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	7.87	2.49e-14	9.47e-12	0.43	0.34	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
THCA	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	7.87	2.5e-14	9.49e-12	0.51	0.34	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
THCA	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-7.87	2.5e-14	9.5e-12	-0.33	-0.34	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
THCA	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	7.87	2.5e-14	9.52e-12	0.44	0.34	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
THCA	cis	rs7430456	0.839	rs9824506	ENSG00000228221.4	LINC00578	-7.87	2.51e-14	9.53e-12	-0.46	-0.34	Breast cancer;	chr3:177751431	chr3:177441921~177752305:+
THCA	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	7.87	2.51e-14	9.54e-12	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	7.87	2.51e-14	9.54e-12	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
THCA	cis	rs6908034	0.607	rs73376650	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805275	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs112599867	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805301	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs73376651	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805328	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs73376655	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805433	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs113592672	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805832	chr6:19802164~19804752:-
THCA	cis	rs11651753	0.561	rs60580012	ENSG00000264920.1	RP11-6N17.4	-7.87	2.51e-14	9.55e-12	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892442	chr17:47891255~47895812:-
THCA	cis	rs11651753	0.561	rs61422354	ENSG00000264920.1	RP11-6N17.4	-7.87	2.51e-14	9.55e-12	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892443	chr17:47891255~47895812:-
THCA	cis	rs1707322	0.963	rs11211202	ENSG00000234329.1	RP11-767N6.2	7.87	2.52e-14	9.57e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-7.87	2.52e-14	9.58e-12	-0.38	-0.34	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
THCA	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	7.87	2.52e-14	9.59e-12	0.44	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
THCA	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-7.87	2.53e-14	9.61e-12	-0.42	-0.34	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
THCA	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-7.87	2.53e-14	9.62e-12	-0.43	-0.34	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
THCA	cis	rs8114671	0.562	rs6088647	ENSG00000269202.1	RP4-614O4.12	-7.87	2.53e-14	9.62e-12	-0.29	-0.34	Height;	chr20:34918194	chr20:35201747~35203288:-
THCA	cis	rs2439831	0.867	rs2255440	ENSG00000249839.1	AC011330.5	-7.87	2.53e-14	9.63e-12	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43538269	chr15:43663654~43684339:-
THCA	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-7.87	2.54e-14	9.67e-12	-0.41	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
THCA	cis	rs2439831	0.717	rs2470132	ENSG00000249839.1	AC011330.5	-7.86	2.56e-14	9.71e-12	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43543283	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2251844	ENSG00000249839.1	AC011330.5	-7.86	2.56e-14	9.71e-12	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43544280	chr15:43663654~43684339:-
THCA	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	7.86	2.56e-14	9.72e-12	0.41	0.34	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
THCA	cis	rs9649213	0.593	rs6465666	ENSG00000272950.1	RP11-307C18.1	-7.86	2.57e-14	9.75e-12	-0.42	-0.34	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr7:98322853~98323430:+
THCA	cis	rs7849270	0.798	rs10988198	ENSG00000268707.1	RP11-247A12.7	-7.86	2.57e-14	9.76e-12	-0.42	-0.34	Blood metabolite ratios;	chr9:129083846	chr9:129170434~129170940:+
THCA	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-7.86	2.57e-14	9.76e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
THCA	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-7.86	2.57e-14	9.76e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-7.86	2.58e-14	9.79e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
THCA	cis	rs11673344	0.543	rs12980849	ENSG00000226686.6	LINC01535	7.86	2.59e-14	9.83e-12	0.38	0.34	Obesity-related traits;	chr19:37160812	chr19:37251912~37265535:+
THCA	cis	rs7621025	0.5	rs9845460	ENSG00000273486.1	RP11-731C17.2	7.86	2.59e-14	9.84e-12	0.34	0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136837338~136839021:-
THCA	cis	rs9388451	0.868	rs10457467	ENSG00000237742.5	RP11-624M8.1	-7.86	2.6e-14	9.87e-12	-0.3	-0.34	Brugada syndrome;	chr6:125724002	chr6:125578558~125749190:-
THCA	cis	rs944289	0.932	rs1169151	ENSG00000257826.1	RP11-116N8.4	7.86	2.6e-14	9.89e-12	0.36	0.34	Thyroid cancer;	chr14:36171395	chr14:36061026~36067190:-
THCA	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-7.86	2.62e-14	9.93e-12	-0.39	-0.34	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
THCA	cis	rs172166	0.538	rs1150686	ENSG00000219392.1	RP1-265C24.5	-7.86	2.62e-14	9.94e-12	-0.37	-0.34	Cardiac Troponin-T levels;	chr6:28193493	chr6:28115628~28116551:+
THCA	cis	rs1150688	1	rs1150688	ENSG00000219392.1	RP1-265C24.5	-7.86	2.62e-14	9.94e-12	-0.37	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28115628~28116551:+
THCA	cis	rs860295	0.676	rs2666826	ENSG00000225855.5	RUSC1-AS1	7.86	2.62e-14	9.94e-12	0.24	0.34	Body mass index;	chr1:155688294	chr1:155316863~155324176:-
THCA	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	7.86	2.62e-14	9.95e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
THCA	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-7.86	2.63e-14	9.97e-12	-0.44	-0.34	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
THCA	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	7.86	2.63e-14	9.99e-12	0.41	0.34	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	7.86	2.63e-14	9.99e-12	0.41	0.34	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	7.86	2.63e-14	9.99e-12	0.41	0.34	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
THCA	cis	rs11148252	0.595	rs9526974	ENSG00000235660.1	LINC00345	-7.86	2.63e-14	9.99e-12	-0.44	-0.34	Lewy body disease;	chr13:52676905	chr13:52484161~52484680:-
THCA	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
THCA	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-7.86	2.65e-14	1.01e-11	-0.43	-0.34	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
THCA	cis	rs11051970	0.559	rs60162504	ENSG00000274964.1	RP11-817I4.1	-7.86	2.65e-14	1.01e-11	-0.45	-0.34	Response to tocilizumab in rheumatoid arthritis;	chr12:32320687	chr12:32339368~32340724:+
THCA	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	7.86	2.66e-14	1.01e-11	0.54	0.34	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
THCA	cis	rs13129231	0.889	rs4833427	ENSG00000206820.1	RNU1-138P	-7.86	2.67e-14	1.01e-11	-0.4	-0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113421407	chr4:113420323~113420486:+
THCA	cis	rs116175783	0.793	rs1267044	ENSG00000227403.1	AC009299.3	7.86	2.67e-14	1.01e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161271100	chr2:161244739~161249050:+
THCA	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-7.86	2.67e-14	1.01e-11	-0.53	-0.34	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
THCA	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-7.86	2.67e-14	1.01e-11	-0.53	-0.34	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000226155.1	AC124944.3	7.86	2.67e-14	1.01e-11	0.41	0.34	Pancreatic cancer;	chr3:196024759	chr3:195912049~195913986:+
THCA	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-7.86	2.68e-14	1.02e-11	-0.41	-0.34	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-7.86	2.68e-14	1.02e-11	-0.41	-0.34	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
THCA	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-7.86	2.69e-14	1.02e-11	-0.51	-0.34	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000235689.1	AP000351.13	7.86	2.69e-14	1.02e-11	0.43	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:24006305~24008258:-
THCA	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	7.86	2.69e-14	1.02e-11	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
THCA	cis	rs7646881	0.812	rs7624408	ENSG00000240207.5	RP11-379F4.4	-7.86	2.7e-14	1.03e-11	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742269	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs7636023	ENSG00000240207.5	RP11-379F4.4	-7.86	2.7e-14	1.03e-11	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742270	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs73017536	ENSG00000240207.5	RP11-379F4.4	-7.86	2.7e-14	1.03e-11	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742813	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs73017540	ENSG00000240207.5	RP11-379F4.4	-7.86	2.7e-14	1.03e-11	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742999	chr3:158732263~158784070:+
THCA	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	7.86	2.71e-14	1.03e-11	0.43	0.34	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
THCA	cis	rs7714584	1	rs1896707	ENSG00000197083.10	ZNF300P1	7.86	2.71e-14	1.03e-11	0.55	0.34	Crohn's disease;	chr5:150865567	chr5:150930645~150946289:-
THCA	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-7.86	2.71e-14	1.03e-11	-0.4	-0.34	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
THCA	cis	rs2120243	0.533	rs34263112	ENSG00000244515.1	KRT18P34	-7.86	2.71e-14	1.03e-11	-0.38	-0.34	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338259	chr3:157162663~157163932:-
THCA	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-7.86	2.72e-14	1.03e-11	-0.36	-0.34	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	7.86	2.72e-14	1.03e-11	0.45	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
THCA	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-7.86	2.72e-14	1.03e-11	-0.4	-0.34	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000230295.1	RP11-458F8.2	7.86	2.72e-14	1.03e-11	0.3	0.34	Corneal structure;	chr7:66872661	chr7:66880708~66882981:+
THCA	cis	rs812925	0.519	rs1186696	ENSG00000271889.1	RP11-493E12.1	7.86	2.73e-14	1.03e-11	0.33	0.34	Immature fraction of reticulocytes;	chr2:61433348	chr2:61151433~61162105:-
THCA	cis	rs7015630	0.618	rs28405481	ENSG00000251136.7	RP11-37B2.1	-7.86	2.73e-14	1.03e-11	-0.37	-0.34	Inflammatory bowel disease;Crohn's disease;	chr8:89807501	chr8:89609409~89757727:-
THCA	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-7.86	2.74e-14	1.04e-11	-0.4	-0.34	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
THCA	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	7.85	2.74e-14	1.04e-11	0.38	0.34	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
THCA	cis	rs9902453	0.9	rs56195309	ENSG00000264007.1	RP11-68I3.10	7.85	2.74e-14	1.04e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:30126735	chr17:29621617~29622254:-
THCA	cis	rs11971779	0.774	rs7785906	ENSG00000273391.1	RP11-634H22.1	7.85	2.75e-14	1.04e-11	0.34	0.34	Diisocyanate-induced asthma;	chr7:139437906	chr7:139359032~139359566:-
THCA	cis	rs2284219	0.894	rs1076291	ENSG00000196295.10	AC005154.6	-7.85	2.75e-14	1.04e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30672979	chr7:30516309~30594809:-
THCA	cis	rs2284219	0.894	rs1076292	ENSG00000196295.10	AC005154.6	-7.85	2.75e-14	1.04e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30673085	chr7:30516309~30594809:-
THCA	cis	rs2284219	0.894	rs2251002	ENSG00000196295.10	AC005154.6	-7.85	2.75e-14	1.04e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30673228	chr7:30516309~30594809:-
THCA	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-7.85	2.76e-14	1.05e-11	-0.5	-0.34	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
THCA	cis	rs6723226	0.75	rs3769597	ENSG00000276334.1	AL133243.1	7.85	2.76e-14	1.05e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr2:32466332	chr2:32521927~32523547:+
THCA	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	7.85	2.77e-14	1.05e-11	0.38	0.34	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
THCA	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	7.85	2.78e-14	1.05e-11	0.41	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
THCA	cis	rs17684571	0.872	rs16888135	ENSG00000231441.1	RP11-472M19.2	7.85	2.78e-14	1.05e-11	0.43	0.34	Schizophrenia;	chr6:56734969	chr6:56844002~56864078:+
THCA	cis	rs7727544	0.548	rs4705938	ENSG00000233006.5	AC034220.3	7.85	2.78e-14	1.05e-11	0.27	0.34	Blood metabolite levels;	chr5:132358384	chr5:132311285~132369916:-
THCA	cis	rs1707322	1	rs4524994	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs9787412	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660896	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.928	rs10732844	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12133129	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs4553121	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs6690652	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6695421	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45651039~45651826:-
THCA	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	7.85	2.79e-14	1.06e-11	0.43	0.34	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
THCA	cis	rs4784934	0.921	rs4784938	ENSG00000260186.4	RP11-481J2.2	7.85	2.8e-14	1.06e-11	0.49	0.34	QT interval;	chr16:58433949	chr16:58421326~58462470:+
THCA	cis	rs2839186	0.77	rs2839984	ENSG00000239415.1	AP001469.9	7.85	2.8e-14	1.06e-11	0.35	0.34	Testicular germ cell tumor;	chr21:46251776	chr21:46251549~46254133:-
THCA	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	7.85	2.81e-14	1.06e-11	0.41	0.34	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
THCA	cis	rs12681366	0.801	rs2919668	ENSG00000253704.1	RP11-267M23.4	7.85	2.81e-14	1.07e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94449193	chr8:94553722~94569745:+
THCA	cis	rs8114671	0.527	rs6060112	ENSG00000269202.1	RP4-614O4.12	-7.85	2.82e-14	1.07e-11	-0.29	-0.34	Height;	chr20:34901473	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2064454	ENSG00000269202.1	RP4-614O4.12	-7.85	2.82e-14	1.07e-11	-0.29	-0.34	Height;	chr20:34908366	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2273683	ENSG00000269202.1	RP4-614O4.12	-7.85	2.82e-14	1.07e-11	-0.29	-0.34	Height;	chr20:34921720	chr20:35201747~35203288:-
THCA	cis	rs12681366	0.881	rs12682038	ENSG00000253704.1	RP11-267M23.4	7.85	2.82e-14	1.07e-11	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94393252	chr8:94553722~94569745:+
THCA	cis	rs10411161	0.81	rs8102738	ENSG00000269483.1	AC006272.1	7.85	2.82e-14	1.07e-11	0.59	0.34	Breast cancer;	chr19:51884976	chr19:51839924~51843324:-
THCA	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	7.85	2.83e-14	1.07e-11	0.43	0.34	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
THCA	cis	rs10411161	0.81	rs77082285	ENSG00000269483.1	AC006272.1	7.85	2.83e-14	1.07e-11	0.59	0.34	Breast cancer;	chr19:51884330	chr19:51839924~51843324:-
THCA	cis	rs6908034	0.66	rs76322282	ENSG00000228412.5	RP4-625H18.2	7.85	2.83e-14	1.07e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801429	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs111533721	ENSG00000228412.5	RP4-625H18.2	7.85	2.83e-14	1.07e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803514	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.505	rs76709285	ENSG00000228412.5	RP4-625H18.2	7.85	2.83e-14	1.07e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804099	chr6:19802164~19804752:-
THCA	cis	rs7945705	0.818	rs4929916	ENSG00000254860.4	TMEM9B-AS1	-7.85	2.83e-14	1.07e-11	-0.37	-0.34	Hemoglobin concentration;	chr11:8803449	chr11:8964675~8977527:+
THCA	cis	rs12681366	0.881	rs3019150	ENSG00000253704.1	RP11-267M23.4	7.85	2.83e-14	1.07e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94420055	chr8:94553722~94569745:+
THCA	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	7.85	2.84e-14	1.07e-11	0.43	0.34	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
THCA	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	7.85	2.84e-14	1.07e-11	0.43	0.34	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
THCA	cis	rs6558530	0.73	rs7341635	ENSG00000253982.1	CTD-2336O2.1	7.85	2.84e-14	1.07e-11	0.29	0.34	Systolic blood pressure;	chr8:1773477	chr8:1761990~1764502:-
THCA	cis	rs934734	0.752	rs268139	ENSG00000204929.10	AC074391.1	-7.85	2.84e-14	1.08e-11	-0.42	-0.34	Rheumatoid arthritis;	chr2:65379857	chr2:65436711~66084639:+
THCA	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-7.85	2.84e-14	1.08e-11	-0.51	-0.34	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
THCA	cis	rs71636778	0.509	rs12760759	ENSG00000260063.1	RP5-968P14.2	7.85	2.86e-14	1.08e-11	0.62	0.34	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26831853	chr1:26692132~26694131:-
THCA	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-7.85	2.87e-14	1.09e-11	-0.44	-0.34	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
THCA	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-7.85	2.87e-14	1.09e-11	-0.43	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
THCA	cis	rs1949733	0.655	rs2631736	ENSG00000205959.3	RP11-689P11.2	7.85	2.87e-14	1.09e-11	0.28	0.34	Response to antineoplastic agents;	chr4:8476694	chr4:8482270~8512610:+
THCA	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-7.85	2.88e-14	1.09e-11	-0.37	-0.34	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-7.85	2.88e-14	1.09e-11	-0.37	-0.34	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-7.85	2.88e-14	1.09e-11	-0.37	-0.34	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
THCA	cis	rs2439831	0.867	rs2255042	ENSG00000249839.1	AC011330.5	7.85	2.89e-14	1.09e-11	0.51	0.34	Lung cancer in ever smokers;	chr15:43542120	chr15:43663654~43684339:-
THCA	cis	rs638893	0.617	rs4938561	ENSG00000278376.1	RP11-158I9.8	-7.85	2.89e-14	1.09e-11	-0.29	-0.34	Vitiligo;	chr11:118847776	chr11:118791254~118793137:+
THCA	cis	rs180730	0.95	rs2198032	ENSG00000251609.2	SETP12	7.85	2.89e-14	1.09e-11	0.54	0.34	Fasting plasma glucose;	chr4:120918993	chr4:120895494~120897083:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000235689.1	AP000351.13	7.85	2.89e-14	1.09e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:24006305~24008258:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000235689.1	AP000351.13	7.85	2.89e-14	1.09e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:24006305~24008258:-
THCA	cis	rs16846053	0.515	rs1567981	ENSG00000227403.1	AC009299.3	-7.85	2.89e-14	1.09e-11	-0.55	-0.34	Blood osmolality (transformed sodium);	chr2:161692589	chr2:161244739~161249050:+
THCA	cis	rs12681366	0.801	rs2919658	ENSG00000253704.1	RP11-267M23.4	7.85	2.9e-14	1.1e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:94553722~94569745:+
THCA	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-7.85	2.91e-14	1.1e-11	-0.2	-0.34	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
THCA	cis	rs853679	0.882	rs4713139	ENSG00000280107.1	AL022393.9	-7.85	2.91e-14	1.1e-11	-0.52	-0.34	Depression;	chr6:28124907	chr6:28170845~28172521:+
THCA	cis	rs9329221	0.502	rs11777364	ENSG00000261451.1	RP11-981G7.1	7.85	2.92e-14	1.1e-11	0.42	0.34	Neuroticism;	chr8:10431036	chr8:10433672~10438312:+
THCA	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	7.85	2.92e-14	1.1e-11	0.3	0.34	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
THCA	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
THCA	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-7.84	2.94e-14	1.11e-11	-0.52	-0.34	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
THCA	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	7.84	2.95e-14	1.12e-11	0.54	0.34	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
THCA	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	7.84	2.95e-14	1.12e-11	0.54	0.34	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
THCA	cis	rs7208859	0.673	rs2433	ENSG00000266490.1	CTD-2349P21.9	7.84	2.96e-14	1.12e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30792372~30792833:+
THCA	cis	rs7945705	0.776	rs2316865	ENSG00000254860.4	TMEM9B-AS1	-7.84	2.96e-14	1.12e-11	-0.37	-0.34	Hemoglobin concentration;	chr11:8793923	chr11:8964675~8977527:+
THCA	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-7.84	2.96e-14	1.12e-11	-0.44	-0.34	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
THCA	cis	rs8113308	0.748	rs7251478	ENSG00000269235.1	ZNF350-AS1	7.84	2.97e-14	1.12e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51979258	chr19:51949134~51981367:+
THCA	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-7.84	2.97e-14	1.12e-11	-0.41	-0.34	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
THCA	cis	rs180730	1	rs1530799	ENSG00000251609.2	SETP12	7.84	2.98e-14	1.13e-11	0.54	0.34	Fasting plasma glucose;	chr4:120923267	chr4:120895494~120897083:-
THCA	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-7.84	2.98e-14	1.13e-11	-0.42	-0.34	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
THCA	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-7.84	2.98e-14	1.13e-11	-0.32	-0.34	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
THCA	cis	rs4814920	0.756	rs6075586	ENSG00000233895.1	RP1-122P22.2	-7.84	2.99e-14	1.13e-11	-0.37	-0.34	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19757708~19809675:+
THCA	cis	rs10971721	0.543	rs72731230	ENSG00000260947.1	RP11-384P7.7	7.84	2.99e-14	1.13e-11	0.77	0.34	Body mass index;	chr9:34133733	chr9:33697459~33700986:+
THCA	cis	rs42490	0.635	rs418634	ENSG00000251136.7	RP11-37B2.1	-7.84	3e-14	1.13e-11	-0.29	-0.34	Leprosy;	chr8:89847469	chr8:89609409~89757727:-
THCA	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-7.84	3e-14	1.13e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-7.84	3e-14	1.13e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-7.84	3e-14	1.13e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
THCA	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-7.84	3e-14	1.13e-11	-0.28	-0.34	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
THCA	cis	rs10208649	1	rs74627832	ENSG00000272156.1	RP11-477N3.1	7.84	3.01e-14	1.14e-11	0.7	0.34	Body mass index;	chr2:53933972	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.731	rs724387	ENSG00000272156.1	RP11-477N3.1	7.84	3.01e-14	1.14e-11	0.71	0.34	Body mass index;	chr2:53672707	chr2:54082554~54085066:+
THCA	cis	rs8114671	0.562	rs2223881	ENSG00000269202.1	RP4-614O4.12	-7.84	3.02e-14	1.14e-11	-0.29	-0.34	Height;	chr20:34918660	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs4911450	ENSG00000269202.1	RP4-614O4.12	-7.84	3.02e-14	1.14e-11	-0.29	-0.34	Height;	chr20:34924603	chr20:35201747~35203288:-
THCA	cis	rs116175783	0.557	rs10490567	ENSG00000227403.1	AC009299.3	7.84	3.02e-14	1.14e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161317267	chr2:161244739~161249050:+
THCA	cis	rs7247513	0.964	rs35235213	ENSG00000230310.1	CTD-2192J16.11	-7.84	3.02e-14	1.14e-11	-0.41	-0.34	Bipolar disorder;	chr19:12602342	chr19:12552597~12553644:+
THCA	cis	rs4072705	1	rs10760372	ENSG00000224020.1	MIR181A2HG	-7.84	3.03e-14	1.14e-11	-0.31	-0.34	Menarche (age at onset);	chr9:124706537	chr9:124658467~124698631:+
THCA	cis	rs116175783	0.557	rs62188123	ENSG00000227403.1	AC009299.3	7.84	3.03e-14	1.14e-11	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161244739~161249050:+
THCA	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-7.84	3.03e-14	1.14e-11	-0.37	-0.34	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-7.84	3.03e-14	1.14e-11	-0.37	-0.34	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
THCA	cis	rs2522056	1	rs7730247	ENSG00000233006.5	AC034220.3	-7.84	3.03e-14	1.15e-11	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132445596	chr5:132311285~132369916:-
THCA	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-7.84	3.04e-14	1.15e-11	-0.2	-0.34	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
THCA	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	7.84	3.04e-14	1.15e-11	0.4	0.34	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
THCA	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-7.84	3.05e-14	1.15e-11	-0.5	-0.34	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
THCA	cis	rs11148252	0.875	rs4884452	ENSG00000278238.1	RP11-245D16.4	7.84	3.05e-14	1.15e-11	0.39	0.34	Lewy body disease;	chr13:52375649	chr13:52454775~52455331:-
THCA	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-7.84	3.05e-14	1.15e-11	-0.3	-0.34	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000237664.1	LINC00316	-7.84	3.05e-14	1.15e-11	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45338590~45341990:-
THCA	cis	rs2288884	0.505	rs11666461	ENSG00000275055.1	CTC-471J1.11	-7.84	3.07e-14	1.16e-11	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51934234	chr19:52049007~52049754:+
THCA	cis	rs7727544	0.571	rs12521097	ENSG00000224431.1	AC063976.7	7.84	3.07e-14	1.16e-11	0.3	0.34	Blood metabolite levels;	chr5:132239645	chr5:132199456~132203487:+
THCA	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-7.84	3.07e-14	1.16e-11	-0.52	-0.34	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
THCA	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-7.84	3.1e-14	1.17e-11	-0.39	-0.34	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
THCA	cis	rs853679	0.713	rs200991	ENSG00000219392.1	RP1-265C24.5	7.84	3.1e-14	1.17e-11	0.49	0.34	Depression;	chr6:27847716	chr6:28115628~28116551:+
THCA	cis	rs7621025	0.5	rs16844241	ENSG00000273486.1	RP11-731C17.2	-7.84	3.11e-14	1.17e-11	-0.35	-0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136837338~136839021:-
THCA	cis	rs2297363	1	rs16888669	ENSG00000213073.4	RP11-288H12.3	-7.84	3.11e-14	1.17e-11	-0.36	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160082862	chr6:160093082~160096212:+
THCA	cis	rs2562456	0.516	rs56072098	ENSG00000268555.1	RP11-678G14.3	-7.84	3.12e-14	1.18e-11	-0.47	-0.34	Pain;	chr19:21469158	chr19:21570822~21587322:-
THCA	cis	rs11971779	0.715	rs6467856	ENSG00000273391.1	RP11-634H22.1	7.84	3.12e-14	1.18e-11	0.33	0.34	Diisocyanate-induced asthma;	chr7:139442553	chr7:139359032~139359566:-
THCA	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-7.84	3.13e-14	1.18e-11	-0.41	-0.34	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
THCA	cis	rs7430456	0.81	rs6443489	ENSG00000228221.4	LINC00578	7.84	3.13e-14	1.18e-11	0.45	0.34	Breast cancer;	chr3:177737489	chr3:177441921~177752305:+
THCA	cis	rs2284219	1	rs2284219	ENSG00000196295.10	AC005154.6	-7.84	3.13e-14	1.18e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30674820	chr7:30516309~30594809:-
THCA	cis	rs2284219	0.964	rs733453	ENSG00000196295.10	AC005154.6	-7.84	3.13e-14	1.18e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30675157	chr7:30516309~30594809:-
THCA	cis	rs2284219	1	rs2267715	ENSG00000196295.10	AC005154.6	-7.84	3.13e-14	1.18e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30676471	chr7:30516309~30594809:-
THCA	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-7.84	3.13e-14	1.18e-11	-0.35	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
THCA	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	7.84	3.13e-14	1.18e-11	0.88	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
THCA	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
THCA	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
THCA	cis	rs686320	1	rs686320	ENSG00000245532.5	NEAT1	7.84	3.14e-14	1.18e-11	0.31	0.34	Hip circumference adjusted for BMI;	chr11:65477067	chr11:65422774~65445540:+
THCA	cis	rs686320	1	rs667196	ENSG00000245532.5	NEAT1	7.84	3.14e-14	1.18e-11	0.31	0.34	Hip circumference adjusted for BMI;	chr11:65479621	chr11:65422774~65445540:+
THCA	cis	rs812925	0.519	rs2922089	ENSG00000271889.1	RP11-493E12.1	-7.84	3.15e-14	1.19e-11	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61397994	chr2:61151433~61162105:-
THCA	cis	rs812925	0.519	rs2694627	ENSG00000271889.1	RP11-493E12.1	-7.84	3.15e-14	1.19e-11	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61398371	chr2:61151433~61162105:-
THCA	cis	rs7714584	1	rs60134818	ENSG00000197083.10	ZNF300P1	7.84	3.15e-14	1.19e-11	0.55	0.34	Crohn's disease;	chr5:150881481	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	7.84	3.15e-14	1.19e-11	0.55	0.34	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
THCA	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-7.83	3.16e-14	1.19e-11	-0.52	-0.34	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
THCA	cis	rs1949733	0.675	rs2010758	ENSG00000205959.3	RP11-689P11.2	-7.83	3.16e-14	1.19e-11	-0.27	-0.34	Response to antineoplastic agents;	chr4:8473896	chr4:8482270~8512610:+
THCA	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-7.83	3.18e-14	1.2e-11	-0.34	-0.34	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
THCA	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	7.83	3.2e-14	1.21e-11	0.45	0.34	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
THCA	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-7.83	3.21e-14	1.21e-11	-0.41	-0.34	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
THCA	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-7.83	3.21e-14	1.21e-11	-0.41	-0.34	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
THCA	cis	rs1949733	0.628	rs2688231	ENSG00000205959.3	RP11-689P11.2	-7.83	3.22e-14	1.21e-11	-0.28	-0.34	Response to antineoplastic agents;	chr4:8489254	chr4:8482270~8512610:+
THCA	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-7.83	3.22e-14	1.21e-11	-0.52	-0.34	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
THCA	cis	rs2562456	0.917	rs6511253	ENSG00000268555.1	RP11-678G14.3	-7.83	3.23e-14	1.22e-11	-0.47	-0.34	Pain;	chr19:21495996	chr19:21570822~21587322:-
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000237664.1	LINC00316	-7.83	3.24e-14	1.22e-11	-0.33	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45338590~45341990:-
THCA	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-7.83	3.24e-14	1.22e-11	-0.42	-0.34	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
THCA	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-7.83	3.25e-14	1.22e-11	-0.43	-0.34	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
THCA	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	7.83	3.25e-14	1.22e-11	0.32	0.34	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
THCA	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	7.83	3.25e-14	1.22e-11	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
THCA	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	7.83	3.25e-14	1.22e-11	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
THCA	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	7.83	3.25e-14	1.22e-11	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
THCA	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-7.83	3.26e-14	1.23e-11	-0.33	-0.34	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
THCA	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-7.83	3.26e-14	1.23e-11	-0.43	-0.34	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
THCA	cis	rs910316	1	rs175436	ENSG00000279594.1	RP11-950C14.10	-7.83	3.27e-14	1.23e-11	-0.32	-0.34	Height;	chr14:75141980	chr14:75011269~75012851:-
THCA	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-7.83	3.29e-14	1.24e-11	-0.58	-0.34	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
THCA	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-7.83	3.29e-14	1.24e-11	-0.29	-0.34	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
THCA	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-7.83	3.29e-14	1.24e-11	-0.29	-0.34	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
THCA	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-7.83	3.29e-14	1.24e-11	-0.29	-0.34	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
THCA	cis	rs12681366	0.763	rs3019277	ENSG00000253704.1	RP11-267M23.4	7.83	3.29e-14	1.24e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94428195	chr8:94553722~94569745:+
THCA	cis	rs17772222	0.606	rs449338	ENSG00000258789.1	RP11-507K2.3	7.83	3.3e-14	1.24e-11	0.31	0.34	Coronary artery calcification;	chr14:88411690	chr14:88551597~88552493:+
THCA	cis	rs10411161	0.748	rs17835306	ENSG00000269483.1	AC006272.1	7.83	3.3e-14	1.24e-11	0.58	0.34	Breast cancer;	chr19:51882013	chr19:51839924~51843324:-
THCA	cis	rs7176527	0.5	rs895571	ENSG00000230373.7	GOLGA6L5P	7.83	3.3e-14	1.24e-11	0.37	0.34	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:84507885~84516814:-
THCA	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-7.83	3.3e-14	1.24e-11	-0.33	-0.34	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
THCA	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	7.83	3.3e-14	1.24e-11	0.54	0.34	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	7.83	3.3e-14	1.24e-11	0.54	0.34	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
THCA	cis	rs8114671	0.562	rs4911164	ENSG00000269202.1	RP4-614O4.12	-7.83	3.31e-14	1.25e-11	-0.29	-0.34	Height;	chr20:34891685	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2378292	ENSG00000269202.1	RP4-614O4.12	-7.83	3.31e-14	1.25e-11	-0.29	-0.34	Height;	chr20:34897375	chr20:35201747~35203288:-
THCA	cis	rs7208859	0.573	rs73277960	ENSG00000266490.1	CTD-2349P21.9	7.83	3.31e-14	1.25e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73263788	ENSG00000266490.1	CTD-2349P21.9	7.83	3.31e-14	1.25e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs12949860	ENSG00000266490.1	CTD-2349P21.9	7.83	3.31e-14	1.25e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30792372~30792833:+
THCA	cis	rs2348418	0.864	rs2137073	ENSG00000247934.4	RP11-967K21.1	-7.83	3.31e-14	1.25e-11	-0.29	-0.34	Lung function (FEV1);Lung function (FVC);	chr12:28564151	chr12:28163298~28190738:-
THCA	cis	rs7208859	0.673	rs11655623	ENSG00000266490.1	CTD-2349P21.9	7.83	3.33e-14	1.25e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30792372~30792833:+
THCA	cis	rs2522056	0.932	rs1012793	ENSG00000233006.5	AC034220.3	-7.83	3.34e-14	1.26e-11	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132445653	chr5:132311285~132369916:-
THCA	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	7.83	3.35e-14	1.26e-11	0.37	0.34	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
THCA	cis	rs7302981	0.809	rs66768395	ENSG00000272368.2	RP4-605O3.4	7.83	3.35e-14	1.26e-11	0.21	0.34	Systolic blood pressure;	chr12:50174482	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.809	rs1044370	ENSG00000272368.2	RP4-605O3.4	7.83	3.35e-14	1.26e-11	0.21	0.34	Systolic blood pressure;	chr12:50176827	chr12:50112197~50165618:+
THCA	cis	rs1598856	1	rs93059	ENSG00000246560.2	RP11-10L12.4	7.83	3.36e-14	1.26e-11	0.41	0.34	Primary biliary cholangitis;	chr4:102547361	chr4:102828055~102844075:+
THCA	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	7.83	3.37e-14	1.27e-11	0.44	0.34	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
THCA	cis	rs9500256	0.655	rs12208465	ENSG00000215190.7	LINC00680	-7.83	3.37e-14	1.27e-11	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57946074~57961501:-
THCA	cis	rs9500256	0.655	rs12210275	ENSG00000215190.7	LINC00680	-7.83	3.37e-14	1.27e-11	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57946074~57961501:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000206090.4	AP000350.7	7.83	3.37e-14	1.27e-11	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23939998~23942798:+
THCA	cis	rs10266483	0.96	rs679883	ENSG00000227986.1	TRIM60P18	7.83	3.38e-14	1.27e-11	0.28	0.34	Response to statin therapy;	chr7:64289990	chr7:64355078~64356199:+
THCA	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	7.82	3.39e-14	1.27e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
THCA	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	7.82	3.39e-14	1.28e-11	0.49	0.34	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-7.82	3.39e-14	1.28e-11	-0.49	-0.34	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
THCA	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.39e-14	1.28e-11	-0.33	-0.34	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
THCA	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.39e-14	1.28e-11	-0.33	-0.34	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
THCA	cis	rs9640161	0.711	rs10259796	ENSG00000261305.1	RP4-584D14.7	7.82	3.39e-14	1.28e-11	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150353338	chr7:150341771~150342607:+
THCA	cis	rs42490	0.652	rs374957	ENSG00000251136.7	RP11-37B2.1	-7.82	3.4e-14	1.28e-11	-0.29	-0.34	Leprosy;	chr8:89825402	chr8:89609409~89757727:-
THCA	cis	rs8113308	0.81	rs11881650	ENSG00000269235.1	ZNF350-AS1	-7.82	3.4e-14	1.28e-11	-0.52	-0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946886	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.688	rs7259507	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942475	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs7259622	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942484	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs73582180	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943284	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8105910	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943815	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs11880193	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51945416	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs16983256	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946228	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8100521	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946390	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8100541	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946442	chr19:51949134~51981367:+
THCA	cis	rs8114671	0.562	rs8117491	ENSG00000269202.1	RP4-614O4.12	-7.82	3.41e-14	1.28e-11	-0.29	-0.34	Height;	chr20:34922317	chr20:35201747~35203288:-
THCA	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	7.82	3.41e-14	1.28e-11	0.44	0.34	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
THCA	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-7.82	3.42e-14	1.28e-11	-0.52	-0.34	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
THCA	cis	rs4819052	1	rs733738	ENSG00000237664.1	LINC00316	7.82	3.42e-14	1.29e-11	0.37	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45338590~45341990:-
THCA	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-7.82	3.42e-14	1.29e-11	-0.43	-0.34	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
THCA	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	7.82	3.42e-14	1.29e-11	0.41	0.34	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
THCA	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-7.82	3.43e-14	1.29e-11	-0.37	-0.34	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
THCA	cis	rs77204473	0.744	rs74955808	ENSG00000254851.1	RP11-109L13.1	7.82	3.43e-14	1.29e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117121969	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs12420361	ENSG00000254851.1	RP11-109L13.1	7.82	3.43e-14	1.29e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117123072	chr11:117135528~117138582:+
THCA	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-7.82	3.45e-14	1.3e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
THCA	cis	rs416603	0.967	rs7191538	ENSG00000262703.1	RP11-485G7.6	-7.82	3.46e-14	1.3e-11	-0.37	-0.34	Type 1 diabetes;	chr16:11269532	chr16:11348143~11349321:-
THCA	cis	rs4072705	0.967	rs4240486	ENSG00000224020.1	MIR181A2HG	-7.82	3.46e-14	1.3e-11	-0.3	-0.34	Menarche (age at onset);	chr9:124578831	chr9:124658467~124698631:+
THCA	cis	rs6908034	0.66	rs111509549	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19798139	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.6	rs79733895	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19799310	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.66	rs111231540	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801995	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.556	rs77486465	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803631	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs112824001	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804460	chr6:19802164~19804752:-
THCA	cis	rs7247513	0.79	rs8112964	ENSG00000230310.1	CTD-2192J16.11	-7.82	3.46e-14	1.3e-11	-0.41	-0.34	Bipolar disorder;	chr19:12641359	chr19:12552597~12553644:+
THCA	cis	rs11672691	0.871	rs2191139	ENSG00000267107.5	PCAT19	7.82	3.46e-14	1.3e-11	0.35	0.34	Prostate cancer;	chr19:41495302	chr19:41454169~41500649:-
THCA	cis	rs7208859	0.673	rs216440	ENSG00000266490.1	CTD-2349P21.9	7.82	3.48e-14	1.31e-11	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30792372~30792833:+
THCA	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	7.82	3.48e-14	1.31e-11	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
THCA	cis	rs7945705	0.791	rs12421789	ENSG00000254860.4	TMEM9B-AS1	7.82	3.48e-14	1.31e-11	0.36	0.34	Hemoglobin concentration;	chr11:8792409	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.791	rs10769958	ENSG00000254860.4	TMEM9B-AS1	7.82	3.48e-14	1.31e-11	0.36	0.34	Hemoglobin concentration;	chr11:8793568	chr11:8964675~8977527:+
THCA	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-7.82	3.49e-14	1.31e-11	-0.48	-0.34	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
THCA	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-7.82	3.49e-14	1.31e-11	-0.48	-0.34	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
THCA	cis	rs2439831	0.85	rs694985	ENSG00000249839.1	AC011330.5	-7.82	3.49e-14	1.31e-11	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43521189	chr15:43663654~43684339:-
THCA	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	7.82	3.5e-14	1.31e-11	0.43	0.34	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
THCA	cis	rs11696845	0.666	rs6073533	ENSG00000276223.1	RP4-781B1.5	7.82	3.51e-14	1.32e-11	0.41	0.34	Obesity-related traits;	chr20:44732441	chr20:44746642~44747201:+
THCA	cis	rs10411161	0.81	rs17778661	ENSG00000269483.1	AC006272.1	7.82	3.51e-14	1.32e-11	0.59	0.34	Breast cancer;	chr19:51880035	chr19:51839924~51843324:-
THCA	cis	rs2522056	1	rs62385693	ENSG00000233006.5	AC034220.3	-7.82	3.51e-14	1.32e-11	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132437982	chr5:132311285~132369916:-
THCA	cis	rs9649213	0.593	rs6465665	ENSG00000272950.1	RP11-307C18.1	7.82	3.51e-14	1.32e-11	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr7:98322853~98323430:+
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000219392.1	RP1-265C24.5	-7.82	3.52e-14	1.32e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28298372	chr6:28115628~28116551:+
THCA	cis	rs6545883	0.501	rs935860	ENSG00000271889.1	RP11-493E12.1	7.82	3.52e-14	1.32e-11	0.32	0.34	Tuberculosis;	chr2:61179426	chr2:61151433~61162105:-
THCA	cis	rs7015630	0.563	rs28461337	ENSG00000251136.7	RP11-37B2.1	-7.82	3.52e-14	1.32e-11	-0.36	-0.34	Inflammatory bowel disease;Crohn's disease;	chr8:89812907	chr8:89609409~89757727:-
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000206090.4	AP000350.7	7.82	3.52e-14	1.32e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23939998~23942798:+
THCA	cis	rs193541	0.632	rs168913	ENSG00000263432.2	RN7SL689P	7.82	3.53e-14	1.33e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122890098	chr5:123022487~123022783:-
THCA	cis	rs947583	0.913	rs2027516	ENSG00000231028.7	LINC00271	-7.82	3.54e-14	1.33e-11	-0.27	-0.34	Phosphorus levels;	chr6:135810750	chr6:135497801~135716055:+
THCA	cis	rs6723226	0.721	rs3769600	ENSG00000276334.1	AL133243.1	-7.82	3.54e-14	1.33e-11	-0.38	-0.34	Intelligence (multi-trait analysis);	chr2:32391811	chr2:32521927~32523547:+
THCA	cis	rs12681366	0.801	rs2011246	ENSG00000253704.1	RP11-267M23.4	7.82	3.54e-14	1.33e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs2043988	ENSG00000253704.1	RP11-267M23.4	7.82	3.54e-14	1.33e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs2930956	ENSG00000253704.1	RP11-267M23.4	7.82	3.54e-14	1.33e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs55963151	ENSG00000253704.1	RP11-267M23.4	7.82	3.54e-14	1.33e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:94553722~94569745:+
THCA	cis	rs77204473	0.744	rs74882651	ENSG00000254851.1	RP11-109L13.1	7.82	3.54e-14	1.33e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117114475	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-7.82	3.54e-14	1.33e-11	-0.89	-0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
THCA	cis	rs7714584	1	rs4958852	ENSG00000197083.10	ZNF300P1	7.82	3.55e-14	1.33e-11	0.62	0.34	Crohn's disease;	chr5:150951069	chr5:150930645~150946289:-
THCA	cis	rs4713118	0.869	rs9366700	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27729172	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs6456802	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27730576	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9393851	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27731802	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9461400	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27732780	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9295742	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27735053	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9461401	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27735512	chr6:28115628~28116551:+
THCA	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-7.82	3.55e-14	1.33e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
THCA	cis	rs7665090	0.528	rs4235405	ENSG00000246560.2	RP11-10L12.4	7.82	3.56e-14	1.34e-11	0.41	0.34	Primary biliary cholangitis;	chr4:102595654	chr4:102828055~102844075:+
THCA	cis	rs7119038	0.609	rs11216999	ENSG00000255239.1	AP002954.6	-7.82	3.56e-14	1.34e-11	-0.48	-0.34	Sjögren's syndrome;	chr11:118734232	chr11:118688039~118690600:-
THCA	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-7.82	3.57e-14	1.34e-11	-0.44	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
THCA	cis	rs524281	0.729	rs12790034	ENSG00000255320.1	RP11-755F10.1	-7.82	3.58e-14	1.34e-11	-0.5	-0.34	Electroencephalogram traits;	chr11:66018268	chr11:66244840~66246239:-
THCA	cis	rs950169	0.545	rs4842841	ENSG00000259728.4	LINC00933	7.82	3.58e-14	1.34e-11	0.49	0.34	Schizophrenia;	chr15:83972373	chr15:84570649~84580175:+
THCA	cis	rs934734	0.967	rs702875	ENSG00000204929.10	AC074391.1	7.82	3.59e-14	1.35e-11	0.42	0.34	Rheumatoid arthritis;	chr2:65387063	chr2:65436711~66084639:+
THCA	cis	rs686320	1	rs679643	ENSG00000245532.5	NEAT1	7.82	3.59e-14	1.35e-11	0.3	0.34	Hip circumference adjusted for BMI;	chr11:65483119	chr11:65422774~65445540:+
THCA	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-7.82	3.6e-14	1.35e-11	-0.39	-0.34	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
THCA	cis	rs1850744	0.826	rs13101880	ENSG00000250942.1	ENPP7P11	7.82	3.6e-14	1.35e-11	0.48	0.34	Economic and political preferences;	chr4:9706203	chr4:9677308~9677934:+
THCA	cis	rs7302981	0.967	rs35549836	ENSG00000272368.2	RP4-605O3.4	7.82	3.61e-14	1.35e-11	0.2	0.34	Systolic blood pressure;	chr12:50159419	chr12:50112197~50165618:+
THCA	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-7.82	3.61e-14	1.35e-11	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
THCA	cis	rs42490	0.59	rs441547	ENSG00000251136.7	RP11-37B2.1	-7.82	3.61e-14	1.35e-11	-0.29	-0.34	Leprosy;	chr8:89807954	chr8:89609409~89757727:-
THCA	cis	rs42490	0.614	rs441548	ENSG00000251136.7	RP11-37B2.1	-7.82	3.61e-14	1.35e-11	-0.29	-0.34	Leprosy;	chr8:89807955	chr8:89609409~89757727:-
THCA	cis	rs4664293	0.967	rs10202187	ENSG00000226266.5	AC009961.3	-7.82	3.61e-14	1.36e-11	-0.4	-0.34	Monocyte percentage of white cells;	chr2:159571135	chr2:159670708~159712435:-
THCA	cis	rs7267979	0.903	rs6050482	ENSG00000274414.1	RP5-965G21.4	-7.82	3.62e-14	1.36e-11	-0.4	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.706	rs6037069	ENSG00000274414.1	RP5-965G21.4	-7.82	3.62e-14	1.36e-11	-0.4	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25239007~25245229:-
THCA	cis	rs4072705	0.934	rs4838194	ENSG00000224020.1	MIR181A2HG	-7.82	3.62e-14	1.36e-11	-0.3	-0.34	Menarche (age at onset);	chr9:124580536	chr9:124658467~124698631:+
THCA	cis	rs1009647	0.592	rs1045004	ENSG00000258413.1	RP11-665C16.6	-7.82	3.62e-14	1.36e-11	-0.56	-0.34	Testicular germ cell tumor;	chr14:55353073	chr14:55262767~55272075:-
THCA	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-7.81	3.63e-14	1.36e-11	-0.29	-0.34	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
THCA	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-7.81	3.63e-14	1.36e-11	-0.38	-0.34	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
THCA	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	7.81	3.63e-14	1.36e-11	0.43	0.34	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000237664.1	LINC00316	7.81	3.64e-14	1.37e-11	0.33	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2236443	ENSG00000237664.1	LINC00316	-7.81	3.65e-14	1.37e-11	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000237664.1	LINC00316	-7.81	3.66e-14	1.37e-11	-0.33	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45338590~45341990:-
THCA	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	7.81	3.67e-14	1.38e-11	0.32	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
THCA	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	7.81	3.68e-14	1.38e-11	0.42	0.34	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
THCA	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-7.81	3.68e-14	1.38e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-7.81	3.68e-14	1.38e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
THCA	cis	rs12681366	0.801	rs72674819	ENSG00000253704.1	RP11-267M23.4	7.81	3.69e-14	1.38e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94468072	chr8:94553722~94569745:+
THCA	cis	rs4713118	0.662	rs175954	ENSG00000226314.6	ZNF192P1	-7.81	3.7e-14	1.38e-11	-0.43	-0.34	Parkinson's disease;	chr6:28043807	chr6:28161781~28169594:+
THCA	cis	rs10208649	0.808	rs6730494	ENSG00000272156.1	RP11-477N3.1	7.81	3.7e-14	1.39e-11	0.63	0.34	Body mass index;	chr2:53992049	chr2:54082554~54085066:+
THCA	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-7.81	3.71e-14	1.39e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
THCA	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	7.81	3.71e-14	1.39e-11	0.38	0.34	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
THCA	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-7.81	3.72e-14	1.39e-11	-0.41	-0.34	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
THCA	cis	rs1707322	1	rs34444543	ENSG00000234329.1	RP11-767N6.2	7.81	3.72e-14	1.39e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45651039~45651826:-
THCA	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	7.81	3.73e-14	1.4e-11	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	7.81	3.73e-14	1.4e-11	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
THCA	cis	rs4789693	0.938	rs12952655	ENSG00000265458.1	RP13-20L14.6	-7.81	3.74e-14	1.4e-11	-0.34	-0.34	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82454273~82458521:-
THCA	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-7.81	3.74e-14	1.4e-11	-0.37	-0.34	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-7.81	3.74e-14	1.4e-11	-0.37	-0.34	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
THCA	cis	rs2562456	0.72	rs6511250	ENSG00000268555.1	RP11-678G14.3	-7.81	3.75e-14	1.4e-11	-0.47	-0.34	Pain;	chr19:21473244	chr19:21570822~21587322:-
THCA	cis	rs116175783	0.557	rs1146025	ENSG00000227403.1	AC009299.3	7.81	3.75e-14	1.41e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161283301	chr2:161244739~161249050:+
THCA	cis	rs116175783	0.557	rs62197071	ENSG00000227403.1	AC009299.3	7.81	3.75e-14	1.41e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161292703	chr2:161244739~161249050:+
THCA	cis	rs116175783	0.557	rs16845757	ENSG00000227403.1	AC009299.3	7.81	3.75e-14	1.41e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161299749	chr2:161244739~161249050:+
THCA	cis	rs17684571	0.872	rs13210876	ENSG00000231441.1	RP11-472M19.2	-7.81	3.76e-14	1.41e-11	-0.43	-0.34	Schizophrenia;	chr6:56739425	chr6:56844002~56864078:+
THCA	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	7.81	3.76e-14	1.41e-11	0.32	0.34	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
THCA	cis	rs2439831	0.867	rs12443102	ENSG00000275601.1	AC011330.13	-7.81	3.77e-14	1.41e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43639905	chr15:43642389~43643023:-
THCA	cis	rs13068223	0.84	rs11709829	ENSG00000243926.1	TIPARP-AS1	7.81	3.77e-14	1.41e-11	0.33	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156716300	chr3:156671862~156674378:-
THCA	cis	rs7942368	0.941	rs12290350	ENSG00000254632.1	RP11-21L23.4	-7.81	3.77e-14	1.41e-11	-0.5	-0.34	Endometriosis;	chr11:76769211	chr11:76759916~76768223:-
THCA	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	7.81	3.78e-14	1.41e-11	0.38	0.34	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
THCA	cis	rs7247513	0.93	rs28368916	ENSG00000230310.1	CTD-2192J16.11	-7.81	3.78e-14	1.41e-11	-0.41	-0.34	Bipolar disorder;	chr19:12590763	chr19:12552597~12553644:+
THCA	cis	rs6723226	0.75	rs762019	ENSG00000276334.1	AL133243.1	7.81	3.78e-14	1.42e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr2:32463533	chr2:32521927~32523547:+
THCA	cis	rs453301	0.686	rs17702602	ENSG00000253893.2	FAM85B	7.81	3.79e-14	1.42e-11	0.44	0.34	Joint mobility (Beighton score);	chr8:9051086	chr8:8167819~8226614:-
THCA	cis	rs11603691	1	rs11228973	ENSG00000254662.1	RP11-872D17.4	-7.81	3.79e-14	1.42e-11	-0.64	-0.34	Low high density lipoprotein cholesterol levels;	chr11:57262770	chr11:57325603~57327958:+
THCA	cis	rs10869777	0.519	rs2501939	ENSG00000234618.1	RPSAP9	7.81	3.8e-14	1.42e-11	0.36	0.34	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76371314	chr9:76398699~76399586:+
THCA	cis	rs728616	0.867	rs61860039	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860041	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860042	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860043	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860044	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12415870	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12414521	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs55666905	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs56008106	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:79663088~79826594:-
THCA	cis	rs11673344	0.504	rs35579954	ENSG00000226686.6	LINC01535	7.81	3.81e-14	1.43e-11	0.37	0.34	Obesity-related traits;	chr19:37139308	chr19:37251912~37265535:+
THCA	cis	rs17826219	0.561	rs562840	ENSG00000266490.1	CTD-2349P21.9	7.81	3.82e-14	1.43e-11	0.43	0.34	Body mass index;	chr17:30622372	chr17:30792372~30792833:+
THCA	cis	rs984222	0.617	rs1891222	ENSG00000231365.4	RP11-418J17.1	-7.81	3.83e-14	1.43e-11	-0.34	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119208379	chr1:119140396~119275973:+
THCA	cis	rs2297363	1	rs1130861	ENSG00000213073.4	RP11-288H12.3	-7.81	3.84e-14	1.44e-11	-0.36	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160090322	chr6:160093082~160096212:+
THCA	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	7.81	3.85e-14	1.44e-11	0.23	0.34	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
THCA	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-7.81	3.86e-14	1.45e-11	-0.52	-0.34	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
THCA	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	7.81	3.88e-14	1.45e-11	0.41	0.34	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
THCA	cis	rs9649213	0.593	rs1468341	ENSG00000272950.1	RP11-307C18.1	7.8	3.9e-14	1.46e-11	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr7:98322853~98323430:+
THCA	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	7.8	3.9e-14	1.46e-11	0.2	0.34	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
THCA	cis	rs950169	0.579	rs12913054	ENSG00000259728.4	LINC00933	7.8	3.91e-14	1.46e-11	0.49	0.34	Schizophrenia;	chr15:83995704	chr15:84570649~84580175:+
THCA	cis	rs910316	0.904	rs7156089	ENSG00000279594.1	RP11-950C14.10	-7.8	3.92e-14	1.47e-11	-0.32	-0.34	Height;	chr14:75178824	chr14:75011269~75012851:-
THCA	cis	rs6908034	0.607	rs78402429	ENSG00000228412.5	RP4-625H18.2	7.8	3.93e-14	1.47e-11	0.81	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19811459	chr6:19802164~19804752:-
THCA	cis	rs62103177	0.713	rs3744886	ENSG00000261126.6	RP11-795F19.1	7.8	3.93e-14	1.47e-11	0.41	0.34	Opioid sensitivity;	chr18:79899561	chr18:80046900~80095482:+
THCA	cis	rs11651753	0.561	rs4794261	ENSG00000264920.1	RP11-6N17.4	-7.8	3.93e-14	1.47e-11	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47904980	chr17:47891255~47895812:-
THCA	cis	rs11651753	0.561	rs7211859	ENSG00000264920.1	RP11-6N17.4	-7.8	3.93e-14	1.47e-11	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47908916	chr17:47891255~47895812:-
THCA	cis	rs9549328	0.577	rs4907477	ENSG00000267868.1	RP11-120K24.3	7.8	3.94e-14	1.47e-11	0.35	0.34	Systolic blood pressure;	chr13:112964170	chr13:112964835~112966131:-
THCA	cis	rs9549328	0.577	rs4907478	ENSG00000267868.1	RP11-120K24.3	7.8	3.94e-14	1.47e-11	0.35	0.34	Systolic blood pressure;	chr13:112964173	chr13:112964835~112966131:-
THCA	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-7.8	3.94e-14	1.47e-11	-0.43	-0.34	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
THCA	cis	rs7208859	0.673	rs11654331	ENSG00000266490.1	CTD-2349P21.9	7.8	3.94e-14	1.47e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30792372~30792833:+
THCA	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-7.8	3.94e-14	1.47e-11	-0.23	-0.34	Breast cancer;	chr11:825777	chr11:777578~784297:+
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-7.8	3.97e-14	1.49e-11	-0.79	-0.34	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
THCA	cis	rs9902453	0.845	rs7501472	ENSG00000264007.1	RP11-68I3.10	7.8	3.98e-14	1.49e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29683610	chr17:29621617~29622254:-
THCA	cis	rs7208859	0.673	rs999797	ENSG00000266490.1	CTD-2349P21.9	7.8	3.98e-14	1.49e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30792372~30792833:+
THCA	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-7.8	3.99e-14	1.49e-11	-0.42	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
THCA	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	7.8	4e-14	1.5e-11	0.22	0.34	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
THCA	cis	rs728616	0.867	rs4633405	ENSG00000225484.5	NUTM2B-AS1	-7.8	4e-14	1.5e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79663088~79826594:-
THCA	cis	rs1858037	0.867	rs6727013	ENSG00000237979.1	AC007389.1	7.8	4.01e-14	1.5e-11	0.42	0.34	Rheumatoid arthritis;	chr2:65331241	chr2:65500993~65502138:-
THCA	cis	rs7191700	0.511	rs8043625	ENSG00000262703.1	RP11-485G7.6	-7.8	4.01e-14	1.5e-11	-0.38	-0.34	Multiple sclerosis;	chr16:11268038	chr16:11348143~11349321:-
THCA	cis	rs7208859	0.673	rs9911989	ENSG00000266490.1	CTD-2349P21.9	-7.8	4.01e-14	1.5e-11	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs12103759	ENSG00000266490.1	CTD-2349P21.9	7.8	4.01e-14	1.5e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs59029591	ENSG00000266490.1	CTD-2349P21.9	7.8	4.01e-14	1.5e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73265633	ENSG00000266490.1	CTD-2349P21.9	7.8	4.01e-14	1.5e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9913782	ENSG00000266490.1	CTD-2349P21.9	7.8	4.01e-14	1.5e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30792372~30792833:+
THCA	cis	rs7714584	0.793	rs11949375	ENSG00000197083.10	ZNF300P1	7.8	4.01e-14	1.5e-11	0.55	0.34	Crohn's disease;	chr5:150823418	chr5:150930645~150946289:-
THCA	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	7.8	4.03e-14	1.5e-11	0.43	0.34	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	7.8	4.03e-14	1.5e-11	0.43	0.34	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	7.8	4.03e-14	1.5e-11	0.43	0.34	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
THCA	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	7.8	4.03e-14	1.51e-11	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
THCA	cis	rs7208859	0.673	rs3816780	ENSG00000266490.1	CTD-2349P21.9	7.8	4.03e-14	1.51e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30792372~30792833:+
THCA	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	7.8	4.04e-14	1.51e-11	0.55	0.34	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
THCA	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	7.8	4.05e-14	1.51e-11	0.38	0.34	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
THCA	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	7.8	4.05e-14	1.51e-11	0.41	0.34	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
THCA	cis	rs11651753	0.561	rs1108833	ENSG00000264920.1	RP11-6N17.4	-7.8	4.05e-14	1.51e-11	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47905431	chr17:47891255~47895812:-
THCA	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-7.8	4.05e-14	1.51e-11	-0.42	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
THCA	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	7.8	4.06e-14	1.52e-11	0.66	0.34	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
THCA	cis	rs12681366	0.843	rs3019147	ENSG00000253704.1	RP11-267M23.4	7.8	4.06e-14	1.52e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94412804	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.881	rs3019149	ENSG00000253704.1	RP11-267M23.4	7.8	4.06e-14	1.52e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94418351	chr8:94553722~94569745:+
THCA	cis	rs934734	0.532	rs12470883	ENSG00000237979.1	AC007389.1	-7.8	4.06e-14	1.52e-11	-0.38	-0.34	Rheumatoid arthritis;	chr2:65424717	chr2:65500993~65502138:-
THCA	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-7.8	4.08e-14	1.52e-11	-0.33	-0.34	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
THCA	cis	rs8114671	1	rs8114671	ENSG00000269202.1	RP4-614O4.12	7.8	4.08e-14	1.52e-11	0.28	0.34	Height;	chr20:35201339	chr20:35201747~35203288:-
THCA	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	7.8	4.09e-14	1.53e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	7.8	4.09e-14	1.53e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
THCA	cis	rs4273100	0.79	rs60606605	ENSG00000228157.4	AC007952.5	7.8	4.1e-14	1.53e-11	0.52	0.34	Schizophrenia;	chr17:19373831	chr17:19092974~19096837:+
THCA	cis	rs6452524	0.836	rs10514249	ENSG00000249664.1	CTD-2227C6.2	-7.8	4.11e-14	1.53e-11	-0.42	-0.34	Hypertension (SNP x SNP interaction);	chr5:83209037	chr5:83012285~83013109:-
THCA	cis	rs17695224	0.545	rs11666614	ENSG00000269483.1	AC006272.1	7.8	4.11e-14	1.53e-11	0.37	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51842833	chr19:51839924~51843324:-
THCA	cis	rs13068223	0.584	rs345986	ENSG00000243926.1	TIPARP-AS1	-7.8	4.11e-14	1.53e-11	-0.33	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156677540	chr3:156671862~156674378:-
THCA	cis	rs8100891	0.922	rs7255223	ENSG00000267213.4	AC007773.2	7.8	4.11e-14	1.54e-11	0.32	0.34	Neuroticism;	chr19:32333404	chr19:32390050~32405560:-
THCA	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	7.8	4.11e-14	1.54e-11	0.41	0.34	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	7.8	4.11e-14	1.54e-11	0.41	0.34	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
THCA	cis	rs12681366	0.801	rs1372048	ENSG00000253704.1	RP11-267M23.4	7.8	4.12e-14	1.54e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94553722~94569745:+
THCA	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-7.8	4.12e-14	1.54e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
THCA	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-7.8	4.12e-14	1.54e-11	-0.35	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
THCA	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-7.8	4.14e-14	1.54e-11	-0.38	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
THCA	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-7.8	4.14e-14	1.54e-11	-0.33	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
THCA	cis	rs934734	0.789	rs2661798	ENSG00000204929.10	AC074391.1	-7.8	4.14e-14	1.55e-11	-0.43	-0.34	Rheumatoid arthritis;	chr2:65408554	chr2:65436711~66084639:+
THCA	cis	rs7208859	0.673	rs79541516	ENSG00000266490.1	CTD-2349P21.9	7.8	4.15e-14	1.55e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30792372~30792833:+
THCA	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-7.8	4.15e-14	1.55e-11	-0.4	-0.34	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
THCA	cis	rs4072705	1	rs4072705	ENSG00000224020.1	MIR181A2HG	-7.8	4.17e-14	1.55e-11	-0.3	-0.34	Menarche (age at onset);	chr9:124611184	chr9:124658467~124698631:+
THCA	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	7.8	4.17e-14	1.56e-11	0.47	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
THCA	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	7.8	4.17e-14	1.56e-11	0.38	0.34	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
THCA	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-7.79	4.18e-14	1.56e-11	-0.48	-0.34	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
THCA	cis	rs4273100	0.85	rs11204306	ENSG00000228157.4	AC007952.5	7.79	4.18e-14	1.56e-11	0.52	0.34	Schizophrenia;	chr17:19364058	chr17:19092974~19096837:+
THCA	cis	rs4273100	0.79	rs2048230	ENSG00000228157.4	AC007952.5	7.79	4.18e-14	1.56e-11	0.52	0.34	Schizophrenia;	chr17:19372886	chr17:19092974~19096837:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000272009.1	RP1-313I6.12	-7.79	4.19e-14	1.56e-11	-0.4	-0.34	Depression;	chr6:28071808	chr6:28078792~28081130:-
THCA	cis	rs2880765	0.506	rs719138	ENSG00000259295.5	CSPG4P12	7.79	4.19e-14	1.56e-11	0.51	0.34	Coronary artery disease;	chr15:85511831	chr15:85191438~85213905:+
THCA	cis	rs2522056	1	rs2106854	ENSG00000233006.5	AC034220.3	-7.79	4.2e-14	1.57e-11	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132433482	chr5:132311285~132369916:-
THCA	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-7.79	4.2e-14	1.57e-11	-0.46	-0.34	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
THCA	cis	rs1667284	0.935	rs1791161	ENSG00000266521.1	RP11-650P15.1	7.79	4.21e-14	1.57e-11	0.42	0.34	Problematic alcohol use in trauma-exposed individuals;	chr18:31624247	chr18:31496645~31497195:-
THCA	cis	rs2466254	0.657	rs2203834	ENSG00000251468.2	RP11-369K16.1	-7.79	4.21e-14	1.57e-11	-0.54	-0.34	Pneumonia;	chr8:12967384	chr8:12958387~12962200:+
THCA	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	7.79	4.22e-14	1.57e-11	0.43	0.34	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
THCA	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	7.79	4.22e-14	1.57e-11	0.54	0.34	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
THCA	cis	rs1850744	0.702	rs13136217	ENSG00000250942.1	ENPP7P11	7.79	4.22e-14	1.57e-11	0.44	0.34	Economic and political preferences;	chr4:9720668	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.609	rs2037315	ENSG00000250942.1	ENPP7P11	7.79	4.22e-14	1.57e-11	0.44	0.34	Economic and political preferences;	chr4:9720784	chr4:9677308~9677934:+
THCA	cis	rs831571	1	rs166230	ENSG00000280620.1	SCAANT1	-7.79	4.23e-14	1.58e-11	-0.52	-0.34	Type 2 diabetes;	chr3:64067531	chr3:63911518~63911772:-
THCA	cis	rs77204473	1	rs17120177	ENSG00000254851.1	RP11-109L13.1	7.79	4.23e-14	1.58e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116956653	chr11:117135528~117138582:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-7.79	4.23e-14	1.58e-11	-0.33	-0.34	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
THCA	cis	rs812925	0.537	rs10208769	ENSG00000271889.1	RP11-493E12.1	-7.79	4.24e-14	1.58e-11	-0.32	-0.34	Immature fraction of reticulocytes;	chr2:61378479	chr2:61151433~61162105:-
THCA	cis	rs62103177	0.789	rs7242289	ENSG00000261126.6	RP11-795F19.1	7.79	4.25e-14	1.58e-11	0.4	0.34	Opioid sensitivity;	chr18:79843291	chr18:80046900~80095482:+
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000219392.1	RP1-265C24.5	-7.79	4.25e-14	1.59e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28294921	chr6:28115628~28116551:+
THCA	cis	rs860295	0.702	rs1325908	ENSG00000225855.5	RUSC1-AS1	7.79	4.25e-14	1.59e-11	0.23	0.34	Body mass index;	chr1:155443513	chr1:155316863~155324176:-
THCA	cis	rs7727544	0.584	rs7714191	ENSG00000237714.1	P4HA2-AS1	7.79	4.26e-14	1.59e-11	0.45	0.34	Blood metabolite levels;	chr5:132005848	chr5:132184876~132192808:+
THCA	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-7.79	4.27e-14	1.59e-11	-0.52	-0.34	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
THCA	cis	rs7208859	0.673	rs216411	ENSG00000266490.1	CTD-2349P21.9	-7.79	4.27e-14	1.59e-11	-0.42	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30792372~30792833:+
THCA	cis	rs17695224	0.545	rs7252508	ENSG00000269483.1	AC006272.1	7.79	4.27e-14	1.59e-11	0.36	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51831530	chr19:51839924~51843324:-
THCA	cis	rs28510890	0.75	rs12592167	ENSG00000260337.3	RP11-386M24.6	7.79	4.28e-14	1.59e-11	0.46	0.34	Lung cancer in ever smokers;	chr15:92565835	chr15:92592574~92596462:-
THCA	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-7.79	4.3e-14	1.6e-11	-0.55	-0.34	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
THCA	cis	rs7727544	0.606	rs17622208	ENSG00000233006.5	AC034220.3	7.79	4.3e-14	1.6e-11	0.26	0.34	Blood metabolite levels;	chr5:132381358	chr5:132311285~132369916:-
THCA	cis	rs9549328	0.577	rs4907571	ENSG00000267868.1	RP11-120K24.3	7.79	4.31e-14	1.6e-11	0.35	0.34	Systolic blood pressure;	chr13:112964182	chr13:112964835~112966131:-
THCA	cis	rs6452524	0.772	rs13156510	ENSG00000249664.1	CTD-2227C6.2	-7.79	4.31e-14	1.6e-11	-0.42	-0.34	Hypertension (SNP x SNP interaction);	chr5:83208668	chr5:83012285~83013109:-
THCA	cis	rs61041384	0.661	rs74240770	ENSG00000256092.2	RP13-942N8.1	-7.79	4.32e-14	1.61e-11	-0.49	-0.34	Schizophrenia;	chr12:123207195	chr12:123363868~123366113:+
THCA	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-7.79	4.32e-14	1.61e-11	-0.35	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
THCA	cis	rs910316	0.967	rs2268619	ENSG00000279594.1	RP11-950C14.10	-7.79	4.33e-14	1.61e-11	-0.32	-0.34	Height;	chr14:75173651	chr14:75011269~75012851:-
THCA	cis	rs7430456	0.87	rs9864169	ENSG00000228221.4	LINC00578	7.79	4.33e-14	1.61e-11	0.45	0.34	Breast cancer;	chr3:177746841	chr3:177441921~177752305:+
THCA	cis	rs7430456	0.901	rs12696448	ENSG00000228221.4	LINC00578	7.79	4.33e-14	1.61e-11	0.45	0.34	Breast cancer;	chr3:177746860	chr3:177441921~177752305:+
THCA	cis	rs7247513	0.856	rs6511828	ENSG00000230310.1	CTD-2192J16.11	-7.79	4.34e-14	1.62e-11	-0.41	-0.34	Bipolar disorder;	chr19:12634985	chr19:12552597~12553644:+
THCA	cis	rs4664293	0.769	rs10171236	ENSG00000226266.5	AC009961.3	-7.79	4.35e-14	1.62e-11	-0.41	-0.34	Monocyte percentage of white cells;	chr2:159729752	chr2:159670708~159712435:-
THCA	cis	rs4819052	1	rs28628220	ENSG00000237664.1	LINC00316	-7.79	4.35e-14	1.62e-11	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45338590~45341990:-
THCA	cis	rs4819052	1	rs2838830	ENSG00000237664.1	LINC00316	-7.79	4.35e-14	1.62e-11	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45338590~45341990:-
THCA	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-7.79	4.36e-14	1.62e-11	-0.36	-0.34	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
THCA	cis	rs17684571	0.872	rs3002007	ENSG00000231441.1	RP11-472M19.2	7.79	4.38e-14	1.63e-11	0.42	0.34	Schizophrenia;	chr6:56753962	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs2967963	ENSG00000231441.1	RP11-472M19.2	7.79	4.38e-14	1.63e-11	0.42	0.34	Schizophrenia;	chr6:56756819	chr6:56844002~56864078:+
THCA	cis	rs6908034	0.607	rs77791009	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812371	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs75060331	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812725	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs77753186	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812749	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs79162793	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812834	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs76245225	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812957	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs75110577	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814292	chr6:19802164~19804752:-
THCA	cis	rs910316	0.935	rs175076	ENSG00000279594.1	RP11-950C14.10	-7.79	4.43e-14	1.65e-11	-0.31	-0.34	Height;	chr14:75038783	chr14:75011269~75012851:-
THCA	cis	rs9500256	0.903	rs726783	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-7.79	4.43e-14	1.65e-11	-0.35	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57855891~57856468:-
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000264538.5	SUZ12P1	7.79	4.46e-14	1.66e-11	0.34	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30709299~30790908:+
THCA	cis	rs7945705	0.875	rs10769955	ENSG00000254860.4	TMEM9B-AS1	-7.79	4.47e-14	1.66e-11	-0.37	-0.34	Hemoglobin concentration;	chr11:8763100	chr11:8964675~8977527:+
THCA	cis	rs8114671	0.935	rs6142313	ENSG00000269202.1	RP4-614O4.12	7.78	4.51e-14	1.68e-11	0.28	0.34	Height;	chr20:35192624	chr20:35201747~35203288:-
THCA	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-7.78	4.51e-14	1.68e-11	-0.51	-0.34	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
THCA	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-7.78	4.52e-14	1.68e-11	-0.37	-0.34	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
THCA	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	7.78	4.54e-14	1.69e-11	0.4	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
THCA	cis	rs42490	0.589	rs39772	ENSG00000251136.7	RP11-37B2.1	-7.78	4.54e-14	1.69e-11	-0.29	-0.34	Leprosy;	chr8:89831636	chr8:89609409~89757727:-
THCA	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	7.78	4.57e-14	1.7e-11	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
THCA	cis	rs10936632	0.565	rs6794467	ENSG00000242578.1	RP11-469J4.3	-7.78	4.59e-14	1.7e-11	-0.37	-0.34	Prostate cancer;	chr3:170430203	chr3:170410512~170418615:+
THCA	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-7.78	4.59e-14	1.71e-11	-0.4	-0.34	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
THCA	cis	rs741668	0.507	rs9567620	ENSG00000235903.6	CPB2-AS1	7.78	4.59e-14	1.71e-11	0.44	0.34	Cerebrospinal fluid clusterin levels;	chr13:46088455	chr13:46052806~46113332:+
THCA	cis	rs9500256	0.683	rs10458024	ENSG00000215190.7	LINC00680	-7.78	4.59e-14	1.71e-11	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57946074~57961501:-
THCA	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	7.78	4.59e-14	1.71e-11	0.44	0.34	Height;	chr6:109372084	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	7.78	4.59e-14	1.71e-11	0.44	0.34	Height;	chr6:109375848	chr6:109382795~109383666:+
THCA	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	7.78	4.61e-14	1.71e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
THCA	cis	rs12681366	0.843	rs3019156	ENSG00000253704.1	RP11-267M23.4	7.78	4.61e-14	1.71e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94409552	chr8:94553722~94569745:+
THCA	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-7.78	4.62e-14	1.72e-11	-0.52	-0.34	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
THCA	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	7.78	4.62e-14	1.72e-11	0.4	0.34	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
THCA	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-7.78	4.63e-14	1.72e-11	-0.4	-0.34	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
THCA	cis	rs10256972	0.605	rs10251094	ENSG00000229043.2	AC091729.9	-7.78	4.63e-14	1.72e-11	-0.37	-0.34	Endometriosis;Longevity;	chr7:977447	chr7:1160374~1165267:+
THCA	cis	rs11148252	0.508	rs6561671	ENSG00000278238.1	RP11-245D16.4	-7.78	4.63e-14	1.72e-11	-0.36	-0.34	Lewy body disease;	chr13:52608179	chr13:52454775~52455331:-
THCA	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	7.78	4.65e-14	1.73e-11	0.23	0.34	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
THCA	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-7.78	4.66e-14	1.73e-11	-0.44	-0.34	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
THCA	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-7.78	4.66e-14	1.73e-11	-0.37	-0.34	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
THCA	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	7.78	4.67e-14	1.74e-11	0.4	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
THCA	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	7.78	4.68e-14	1.74e-11	0.47	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
THCA	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	7.78	4.7e-14	1.75e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
THCA	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	7.78	4.71e-14	1.75e-11	0.44	0.34	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
THCA	cis	rs17684571	0.751	rs11970648	ENSG00000231441.1	RP11-472M19.2	7.78	4.71e-14	1.75e-11	0.43	0.34	Schizophrenia;	chr6:56762797	chr6:56844002~56864078:+
THCA	cis	rs6908034	0.607	rs12525152	ENSG00000228412.5	RP4-625H18.2	7.78	4.71e-14	1.75e-11	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19809193	chr6:19802164~19804752:-
THCA	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-7.78	4.72e-14	1.75e-11	-0.47	-0.34	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
THCA	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-7.78	4.72e-14	1.75e-11	-0.33	-0.34	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
THCA	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	7.78	4.72e-14	1.75e-11	0.61	0.34	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
THCA	cis	rs7727544	0.606	rs2631360	ENSG00000233006.5	AC034220.3	7.78	4.72e-14	1.75e-11	0.26	0.34	Blood metabolite levels;	chr5:132371737	chr5:132311285~132369916:-
THCA	cis	rs4819052	1	rs2297285	ENSG00000237664.1	LINC00316	7.78	4.73e-14	1.76e-11	0.4	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45338590~45341990:-
THCA	cis	rs7247513	0.856	rs2162863	ENSG00000230310.1	CTD-2192J16.11	-7.78	4.74e-14	1.76e-11	-0.42	-0.34	Bipolar disorder;	chr19:12588963	chr19:12552597~12553644:+
THCA	cis	rs7247513	1	rs8104385	ENSG00000230310.1	CTD-2192J16.11	-7.78	4.74e-14	1.76e-11	-0.42	-0.34	Bipolar disorder;	chr19:12589470	chr19:12552597~12553644:+
THCA	cis	rs10411161	0.748	rs58120918	ENSG00000269483.1	AC006272.1	7.78	4.74e-14	1.76e-11	0.56	0.34	Breast cancer;	chr19:51865093	chr19:51839924~51843324:-
THCA	cis	rs8114671	0.562	rs6120746	ENSG00000269202.1	RP4-614O4.12	-7.78	4.74e-14	1.76e-11	-0.29	-0.34	Height;	chr20:34860693	chr20:35201747~35203288:-
THCA	cis	rs17684571	0.872	rs3002004	ENSG00000231441.1	RP11-472M19.2	7.78	4.75e-14	1.76e-11	0.42	0.34	Schizophrenia;	chr6:56743331	chr6:56844002~56864078:+
THCA	cis	rs10208649	0.908	rs11884857	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54033185	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.901	rs6748686	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54037481	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.808	rs77805752	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54037506	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs6719990	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54037515	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs72906714	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54038423	chr2:54082554~54085066:+
THCA	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-7.78	4.77e-14	1.77e-11	-0.5	-0.34	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
THCA	cis	rs7714584	1	rs11167521	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150892223	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10057988	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150892500	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10052606	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150892655	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs57001853	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150892890	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2217266	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150893059	chr5:150930645~150946289:-
THCA	cis	rs7646881	0.812	rs61387735	ENSG00000240207.5	RP11-379F4.4	-7.78	4.78e-14	1.77e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158738372	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.767	rs73015669	ENSG00000240207.5	RP11-379F4.4	-7.78	4.78e-14	1.77e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158738529	chr3:158732263~158784070:+
THCA	cis	rs1009647	0.645	rs17742719	ENSG00000258413.1	RP11-665C16.6	7.78	4.79e-14	1.78e-11	0.56	0.34	Testicular germ cell tumor;	chr14:55388878	chr14:55262767~55272075:-
THCA	cis	rs8113308	0.81	rs8104281	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939766	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8104121	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939810	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8104323	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939992	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8108525	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940883	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs7258701	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51941816	chr19:51949134~51981367:+
THCA	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	7.78	4.79e-14	1.78e-11	0.31	0.34	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
THCA	cis	rs12188164	0.515	rs2672744	ENSG00000221990.4	EXOC3-AS1	-7.78	4.81e-14	1.78e-11	-0.28	-0.34	Cystic fibrosis severity;	chr5:410932	chr5:441498~443160:-
THCA	cis	rs7015263	0.606	rs10102749	ENSG00000254231.1	CTD-2284J15.1	-7.77	4.82e-14	1.79e-11	-0.34	-0.34	Intelligence (multi-trait analysis);	chr8:86395104	chr8:86333274~86343314:-
THCA	cis	rs10208649	0.908	rs60776154	ENSG00000272156.1	RP11-477N3.1	7.77	4.82e-14	1.79e-11	0.62	0.34	Body mass index;	chr2:54026676	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.831	rs72906704	ENSG00000272156.1	RP11-477N3.1	7.77	4.82e-14	1.79e-11	0.62	0.34	Body mass index;	chr2:54028088	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs7556936	ENSG00000272156.1	RP11-477N3.1	7.77	4.82e-14	1.79e-11	0.62	0.34	Body mass index;	chr2:54028594	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs7583508	ENSG00000272156.1	RP11-477N3.1	7.77	4.82e-14	1.79e-11	0.62	0.34	Body mass index;	chr2:54028648	chr2:54082554~54085066:+
THCA	cis	rs1061377	0.748	rs12506723	ENSG00000249685.1	RP11-360F5.3	7.77	4.83e-14	1.79e-11	0.41	0.34	Uric acid levels;	chr4:39103152	chr4:39133913~39135608:+
THCA	cis	rs748404	0.588	rs2255410	ENSG00000166763.7	STRCP1	7.77	4.83e-14	1.79e-11	0.36	0.34	Lung cancer;	chr15:43538899	chr15:43699488~43718184:-
THCA	cis	rs1707322	0.896	rs946528	ENSG00000234329.1	RP11-767N6.2	-7.77	4.83e-14	1.79e-11	-0.32	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45651039~45651826:-
THCA	cis	rs728616	0.867	rs61860034	ENSG00000225484.5	NUTM2B-AS1	-7.77	4.85e-14	1.8e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79663088~79826594:-
THCA	cis	rs227932	0.764	rs78660981	ENSG00000234286.1	AC006026.13	-7.77	4.85e-14	1.8e-11	-0.62	-0.34	Schizophrenia;	chr7:23719296	chr7:23680195~23680786:-
THCA	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	7.77	4.91e-14	1.82e-11	0.4	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
THCA	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	7.77	4.93e-14	1.83e-11	0.33	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
THCA	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	7.77	4.95e-14	1.84e-11	0.54	0.34	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
THCA	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	7.77	4.96e-14	1.84e-11	0.44	0.34	Height;	chr6:109415050	chr6:109382795~109383666:+
THCA	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	7.77	4.96e-14	1.84e-11	0.39	0.34	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	7.77	4.96e-14	1.84e-11	0.39	0.34	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
THCA	cis	rs9902453	0.808	rs1986555	ENSG00000264007.1	RP11-68I3.10	7.77	4.97e-14	1.84e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29687430	chr17:29621617~29622254:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	7.77	4.97e-14	1.84e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
THCA	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-7.77	4.98e-14	1.84e-11	-0.52	-0.34	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
THCA	cis	rs4784934	0.959	rs2042401	ENSG00000260186.4	RP11-481J2.2	7.77	4.98e-14	1.85e-11	0.49	0.34	QT interval;	chr16:58430171	chr16:58421326~58462470:+
THCA	cis	rs17684571	0.7	rs61601344	ENSG00000231441.1	RP11-472M19.2	7.77	4.99e-14	1.85e-11	0.41	0.34	Schizophrenia;	chr6:56797356	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs35609883	ENSG00000231441.1	RP11-472M19.2	7.77	4.99e-14	1.85e-11	0.41	0.34	Schizophrenia;	chr6:56807034	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs35886823	ENSG00000231441.1	RP11-472M19.2	7.77	4.99e-14	1.85e-11	0.41	0.34	Schizophrenia;	chr6:56816682	chr6:56844002~56864078:+
THCA	cis	rs1426063	0.541	rs58959724	ENSG00000260265.1	RP11-44F21.5	7.77	5.01e-14	1.86e-11	0.84	0.34	QT interval;	chr4:75073543	chr4:75081702~75084717:-
THCA	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	7.77	5.02e-14	1.86e-11	0.25	0.34	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
THCA	cis	rs6844153	1	rs74895929	ENSG00000240005.4	RP11-293A21.1	-7.77	5.03e-14	1.86e-11	-0.45	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26846035	chr4:26859806~26860599:-
THCA	cis	rs4713118	0.869	rs6930992	ENSG00000219392.1	RP1-265C24.5	-7.77	5.03e-14	1.87e-11	-0.43	-0.34	Parkinson's disease;	chr6:27744341	chr6:28115628~28116551:+
THCA	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	7.77	5.04e-14	1.87e-11	0.43	0.34	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
THCA	cis	rs9329221	0.527	rs34308302	ENSG00000261451.1	RP11-981G7.1	-7.77	5.04e-14	1.87e-11	-0.44	-0.34	Neuroticism;	chr8:10474512	chr8:10433672~10438312:+
THCA	cis	rs12681366	0.801	rs12682524	ENSG00000253704.1	RP11-267M23.4	7.77	5.04e-14	1.87e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94553722~94569745:+
THCA	cis	rs62103177	0.81	rs62096746	ENSG00000261126.6	RP11-795F19.1	7.77	5.06e-14	1.87e-11	0.39	0.34	Opioid sensitivity;	chr18:79859556	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.733	rs62096747	ENSG00000261126.6	RP11-795F19.1	7.77	5.06e-14	1.87e-11	0.39	0.34	Opioid sensitivity;	chr18:79859568	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.733	rs62096748	ENSG00000261126.6	RP11-795F19.1	7.77	5.06e-14	1.87e-11	0.39	0.34	Opioid sensitivity;	chr18:79859699	chr18:80046900~80095482:+
THCA	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-7.77	5.07e-14	1.88e-11	-0.36	-0.34	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000219392.1	RP1-265C24.5	-7.77	5.08e-14	1.88e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28230503	chr6:28115628~28116551:+
THCA	cis	rs7191700	0.511	rs243330	ENSG00000262703.1	RP11-485G7.6	7.77	5.08e-14	1.88e-11	0.37	0.34	Multiple sclerosis;	chr16:11257134	chr16:11348143~11349321:-
THCA	cis	rs9902453	0.967	rs61240589	ENSG00000264007.1	RP11-68I3.10	7.77	5.08e-14	1.88e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:30122017	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs55748380	ENSG00000264007.1	RP11-68I3.10	7.77	5.08e-14	1.88e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:30142764	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs60694493	ENSG00000264007.1	RP11-68I3.10	7.77	5.08e-14	1.88e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:30146238	chr17:29621617~29622254:-
THCA	cis	rs950169	0.579	rs12912716	ENSG00000259728.4	LINC00933	7.77	5.11e-14	1.89e-11	0.49	0.34	Schizophrenia;	chr15:83995511	chr15:84570649~84580175:+
THCA	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-7.77	5.11e-14	1.89e-11	-0.43	-0.34	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
THCA	cis	rs2439831	0.571	rs689883	ENSG00000249839.1	AC011330.5	-7.77	5.12e-14	1.89e-11	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43520398	chr15:43663654~43684339:-
THCA	cis	rs77204473	0.744	rs77661993	ENSG00000254851.1	RP11-109L13.1	7.77	5.12e-14	1.9e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117139758	chr11:117135528~117138582:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-7.77	5.14e-14	1.9e-11	-0.42	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
THCA	cis	rs7942368	1	rs1440978	ENSG00000254632.1	RP11-21L23.4	7.77	5.14e-14	1.9e-11	0.49	0.34	Endometriosis;	chr11:76765236	chr11:76759916~76768223:-
THCA	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-7.77	5.15e-14	1.91e-11	-0.44	-0.34	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
THCA	cis	rs910316	1	rs175443	ENSG00000279594.1	RP11-950C14.10	-7.77	5.15e-14	1.91e-11	-0.32	-0.34	Height;	chr14:75135260	chr14:75011269~75012851:-
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000264538.5	SUZ12P1	-7.77	5.15e-14	1.91e-11	-0.34	-0.34	Body mass index;	chr17:30778787	chr17:30709299~30790908:+
THCA	cis	rs4460629	0.905	rs4971077	ENSG00000160766.13	GBAP1	-7.76	5.16e-14	1.91e-11	-0.36	-0.34	Serum magnesium levels;	chr1:155156241	chr1:155213821~155227422:-
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000219392.1	RP1-265C24.5	-7.76	5.16e-14	1.91e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28175232	chr6:28115628~28116551:+
THCA	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	7.76	5.18e-14	1.92e-11	0.35	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
THCA	cis	rs7646881	0.812	rs59957986	ENSG00000240207.5	RP11-379F4.4	-7.76	5.18e-14	1.92e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158741124	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs59192661	ENSG00000240207.5	RP11-379F4.4	-7.76	5.18e-14	1.92e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158741238	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs6788069	ENSG00000240207.5	RP11-379F4.4	7.76	5.18e-14	1.92e-11	0.48	0.34	Tetralogy of Fallot;	chr3:158741670	chr3:158732263~158784070:+
THCA	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	7.76	5.19e-14	1.92e-11	0.46	0.34	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	7.76	5.19e-14	1.92e-11	0.46	0.34	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	7.76	5.19e-14	1.92e-11	0.46	0.34	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	7.76	5.19e-14	1.92e-11	0.46	0.34	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
THCA	cis	rs9649213	0.555	rs6948346	ENSG00000272950.1	RP11-307C18.1	7.76	5.21e-14	1.93e-11	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr7:98322853~98323430:+
THCA	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	7.76	5.22e-14	1.93e-11	0.68	0.34	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
THCA	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	7.76	5.22e-14	1.93e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
THCA	cis	rs6496044	0.547	rs1564719	ENSG00000259295.5	CSPG4P12	7.76	5.22e-14	1.93e-11	0.44	0.34	Interstitial lung disease;	chr15:85511035	chr15:85191438~85213905:+
THCA	cis	rs11651753	0.561	rs11654010	ENSG00000264920.1	RP11-6N17.4	7.76	5.22e-14	1.93e-11	0.3	0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47883499	chr17:47891255~47895812:-
THCA	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	7.76	5.23e-14	1.93e-11	0.39	0.34	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	7.76	5.23e-14	1.93e-11	0.39	0.34	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
THCA	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-7.76	5.23e-14	1.94e-11	-0.36	-0.34	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-7.76	5.23e-14	1.94e-11	-0.36	-0.34	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-7.76	5.23e-14	1.94e-11	-0.36	-0.34	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
THCA	cis	rs910316	0.967	rs175451	ENSG00000279594.1	RP11-950C14.10	-7.76	5.26e-14	1.95e-11	-0.32	-0.34	Height;	chr14:75123026	chr14:75011269~75012851:-
THCA	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	7.76	5.27e-14	1.95e-11	0.22	0.34	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	7.76	5.27e-14	1.95e-11	0.22	0.34	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
THCA	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-7.76	5.28e-14	1.95e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
THCA	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	7.76	5.28e-14	1.95e-11	0.39	0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
THCA	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	7.76	5.29e-14	1.96e-11	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
THCA	cis	rs12928939	0.769	rs34680964	ENSG00000260886.1	TAT-AS1	7.76	5.29e-14	1.96e-11	0.44	0.34	Post bronchodilator FEV1;	chr16:71624691	chr16:71565789~71578187:+
THCA	cis	rs516805	0.748	rs6908508	ENSG00000279453.1	RP3-425C14.4	7.76	5.3e-14	1.96e-11	0.33	0.34	Lymphocyte counts;	chr6:122387857	chr6:122436789~122439223:-
THCA	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-7.76	5.3e-14	1.96e-11	-0.49	-0.34	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
THCA	cis	rs4950322	0.542	rs12046706	ENSG00000237188.3	RP11-337C18.8	7.76	5.3e-14	1.96e-11	0.38	0.34	Protein quantitative trait loci;	chr1:147189758	chr1:147172771~147211568:+
THCA	cis	rs812925	0.555	rs12616433	ENSG00000271889.1	RP11-493E12.1	7.76	5.31e-14	1.96e-11	0.32	0.34	Immature fraction of reticulocytes;	chr2:61469353	chr2:61151433~61162105:-
THCA	cis	rs2839186	0.814	rs2839167	ENSG00000239415.1	AP001469.9	7.76	5.31e-14	1.96e-11	0.35	0.34	Testicular germ cell tumor;	chr21:46241673	chr21:46251549~46254133:-
THCA	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	7.76	5.31e-14	1.96e-11	0.54	0.34	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
THCA	cis	rs5769707	0.616	rs135869	ENSG00000235111.1	RP1-29C18.8	-7.76	5.31e-14	1.97e-11	-0.44	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49612657~49615716:-
THCA	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-7.76	5.32e-14	1.97e-11	-0.53	-0.34	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
THCA	cis	rs9388451	0.839	rs3799709	ENSG00000237742.5	RP11-624M8.1	-7.76	5.32e-14	1.97e-11	-0.29	-0.34	Brugada syndrome;	chr6:125757215	chr6:125578558~125749190:-
THCA	cis	rs7191700	0.511	rs8058983	ENSG00000262703.1	RP11-485G7.6	-7.76	5.33e-14	1.97e-11	-0.37	-0.34	Multiple sclerosis;	chr16:11266992	chr16:11348143~11349321:-
THCA	cis	rs910316	0.967	rs175432	ENSG00000279594.1	RP11-950C14.10	-7.76	5.34e-14	1.97e-11	-0.32	-0.34	Height;	chr14:75148543	chr14:75011269~75012851:-
THCA	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	7.76	5.34e-14	1.97e-11	0.34	0.34	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
THCA	cis	rs9500256	0.711	rs6588685	ENSG00000215190.7	LINC00680	-7.76	5.35e-14	1.98e-11	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57946074~57961501:-
THCA	cis	rs11673344	0.523	rs2562609	ENSG00000226686.6	LINC01535	7.76	5.35e-14	1.98e-11	0.37	0.34	Obesity-related traits;	chr19:37036255	chr19:37251912~37265535:+
THCA	cis	rs42490	0.664	rs421411	ENSG00000251136.7	RP11-37B2.1	-7.76	5.35e-14	1.98e-11	-0.29	-0.34	Leprosy;	chr8:89808665	chr8:89609409~89757727:-
THCA	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-7.76	5.36e-14	1.98e-11	-0.58	-0.34	Depression;	chr6:28139579	chr6:28115628~28116551:+
THCA	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	7.76	5.37e-14	1.98e-11	0.35	0.34	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
THCA	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	7.76	5.37e-14	1.98e-11	0.33	0.34	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
THCA	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	7.76	5.37e-14	1.98e-11	0.33	0.34	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
THCA	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	7.76	5.37e-14	1.99e-11	0.46	0.34	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	7.76	5.37e-14	1.99e-11	0.46	0.34	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
THCA	cis	rs4072705	1	rs4838196	ENSG00000224020.1	MIR181A2HG	-7.76	5.37e-14	1.99e-11	-0.29	-0.34	Menarche (age at onset);	chr9:124595399	chr9:124658467~124698631:+
THCA	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-7.76	5.38e-14	1.99e-11	-0.29	-0.34	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
THCA	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-7.76	5.38e-14	1.99e-11	-0.29	-0.34	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
THCA	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-7.76	5.38e-14	1.99e-11	-0.29	-0.34	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
THCA	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-7.76	5.38e-14	1.99e-11	-0.29	-0.34	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
THCA	cis	rs686320	1	rs35940245	ENSG00000245532.5	NEAT1	7.76	5.38e-14	1.99e-11	0.3	0.34	Hip circumference adjusted for BMI;	chr11:65465202	chr11:65422774~65445540:+
THCA	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-7.76	5.39e-14	1.99e-11	-0.47	-0.34	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
THCA	cis	rs42490	0.576	rs432457	ENSG00000251136.7	RP11-37B2.1	-7.76	5.39e-14	1.99e-11	-0.3	-0.34	Leprosy;	chr8:89853680	chr8:89609409~89757727:-
THCA	cis	rs240993	0.812	rs7751272	ENSG00000230177.1	RP5-1112D6.4	-7.76	5.4e-14	1.99e-11	-0.35	-0.34	Inflammatory skin disease;Psoriasis;	chr6:111419068	chr6:111277932~111278742:+
THCA	cis	rs9847710	0.733	rs2581806	ENSG00000242142.1	SERBP1P3	7.76	5.42e-14	2e-11	0.42	0.34	Ulcerative colitis;	chr3:53029344	chr3:53064283~53065091:-
THCA	cis	rs7665090	0.528	rs3774968	ENSG00000246560.2	RP11-10L12.4	7.76	5.43e-14	2e-11	0.41	0.34	Primary biliary cholangitis;	chr4:102609955	chr4:102828055~102844075:+
THCA	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-7.76	5.43e-14	2.01e-11	-0.47	-0.34	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
THCA	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-7.76	5.43e-14	2.01e-11	-0.47	-0.34	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
THCA	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-7.76	5.43e-14	2.01e-11	-0.47	-0.34	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
THCA	cis	rs180730	0.847	rs1450459	ENSG00000251609.2	SETP12	7.76	5.43e-14	2.01e-11	0.53	0.34	Fasting plasma glucose;	chr4:120925312	chr4:120895494~120897083:-
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	7.76	5.44e-14	2.01e-11	0.47	0.34	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
THCA	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	7.76	5.44e-14	2.01e-11	0.41	0.34	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	7.76	5.44e-14	2.01e-11	0.41	0.34	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
THCA	cis	rs1426063	0.614	rs76325897	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75084747	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs76093954	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75087994	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs114977200	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75088736	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs77625282	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75089646	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs75112697	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75089725	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs7684790	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75090873	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs7671634	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75090883	chr4:75081702~75084717:-
THCA	cis	rs8114671	0.967	rs4911478	ENSG00000269202.1	RP4-614O4.12	7.76	5.44e-14	2.01e-11	0.28	0.34	Height;	chr20:35194822	chr20:35201747~35203288:-
THCA	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-7.76	5.45e-14	2.01e-11	-0.35	-0.34	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
THCA	cis	rs11673344	0.523	rs8108509	ENSG00000226686.6	LINC01535	7.76	5.46e-14	2.02e-11	0.37	0.34	Obesity-related traits;	chr19:37060370	chr19:37251912~37265535:+
THCA	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	7.76	5.52e-14	2.04e-11	0.41	0.34	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
THCA	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	7.76	5.53e-14	2.04e-11	0.36	0.34	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
THCA	cis	rs6908034	0.607	rs77386860	ENSG00000228412.5	RP4-625H18.2	7.75	5.57e-14	2.05e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814524	chr6:19802164~19804752:-
THCA	cis	rs7247513	0.759	rs8110545	ENSG00000230310.1	CTD-2192J16.11	-7.75	5.58e-14	2.06e-11	-0.4	-0.34	Bipolar disorder;	chr19:12644084	chr19:12552597~12553644:+
THCA	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	7.75	5.58e-14	2.06e-11	0.32	0.34	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
THCA	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-7.75	5.59e-14	2.06e-11	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
THCA	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-7.75	5.6e-14	2.06e-11	-0.52	-0.34	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
THCA	cis	rs1005277	0.579	rs176838	ENSG00000263064.2	RP11-291L22.7	-7.75	5.6e-14	2.07e-11	-0.38	-0.34	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38448689~38448949:+
THCA	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-7.75	5.61e-14	2.07e-11	-0.4	-0.34	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
THCA	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	7.75	5.62e-14	2.07e-11	0.46	0.34	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	7.75	5.62e-14	2.07e-11	0.46	0.34	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	7.75	5.62e-14	2.07e-11	0.46	0.34	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
THCA	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-7.75	5.63e-14	2.08e-11	-0.4	-0.34	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
THCA	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-7.75	5.64e-14	2.08e-11	-0.52	-0.34	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
THCA	cis	rs8114671	0.562	rs7263157	ENSG00000269202.1	RP4-614O4.12	-7.75	5.65e-14	2.08e-11	-0.29	-0.34	Height;	chr20:34871324	chr20:35201747~35203288:-
THCA	cis	rs7851660	0.527	rs7859751	ENSG00000236130.1	PTCSC2	-7.75	5.65e-14	2.08e-11	-0.27	-0.34	Strep throat;	chr9:97813606	chr9:97805935~97810008:-
THCA	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	7.75	5.65e-14	2.09e-11	0.29	0.34	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
THCA	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-7.75	5.66e-14	2.09e-11	-0.36	-0.34	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
THCA	cis	rs812925	0.519	rs10199672	ENSG00000271889.1	RP11-493E12.1	-7.75	5.66e-14	2.09e-11	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61400499	chr2:61151433~61162105:-
THCA	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	7.75	5.67e-14	2.09e-11	0.2	0.34	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
THCA	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	7.75	5.67e-14	2.09e-11	0.46	0.34	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
THCA	cis	rs831571	0.955	rs35837	ENSG00000280620.1	SCAANT1	7.75	5.69e-14	2.1e-11	0.53	0.34	Type 2 diabetes;	chr3:64027573	chr3:63911518~63911772:-
THCA	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-7.75	5.7e-14	2.1e-11	-0.34	-0.34	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
THCA	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-7.75	5.71e-14	2.11e-11	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
THCA	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	7.75	5.72e-14	2.11e-11	0.51	0.34	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
THCA	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	7.75	5.73e-14	2.11e-11	0.43	0.34	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
THCA	cis	rs5769707	0.667	rs4824069	ENSG00000235111.1	RP1-29C18.8	-7.75	5.75e-14	2.12e-11	-0.44	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49612657~49615716:-
THCA	cis	rs12928939	0.859	rs11670	ENSG00000260886.1	TAT-AS1	7.75	5.77e-14	2.13e-11	0.45	0.34	Post bronchodilator FEV1;	chr16:71645124	chr16:71565789~71578187:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	7.75	5.78e-14	2.13e-11	0.25	0.34	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
THCA	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-7.75	5.78e-14	2.13e-11	-0.41	-0.34	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
THCA	cis	rs16846053	0.515	rs1399650	ENSG00000227403.1	AC009299.3	-7.75	5.78e-14	2.13e-11	-0.54	-0.34	Blood osmolality (transformed sodium);	chr2:161695208	chr2:161244739~161249050:+
THCA	cis	rs62103177	0.513	rs9945153	ENSG00000261126.6	RP11-795F19.1	7.75	5.78e-14	2.13e-11	0.4	0.34	Opioid sensitivity;	chr18:79838450	chr18:80046900~80095482:+
THCA	cis	rs950169	0.579	rs881983	ENSG00000259728.4	LINC00933	7.75	5.79e-14	2.13e-11	0.48	0.34	Schizophrenia;	chr15:83978556	chr15:84570649~84580175:+
THCA	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	7.75	5.79e-14	2.13e-11	0.2	0.34	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
THCA	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	7.75	5.79e-14	2.13e-11	0.42	0.34	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
THCA	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	7.75	5.79e-14	2.13e-11	0.42	0.34	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
THCA	cis	rs11673344	0.504	rs6510588	ENSG00000226686.6	LINC01535	-7.75	5.79e-14	2.13e-11	-0.37	-0.34	Obesity-related traits;	chr19:37106493	chr19:37251912~37265535:+
THCA	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-7.75	5.79e-14	2.13e-11	-0.51	-0.34	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-7.75	5.79e-14	2.13e-11	-0.51	-0.34	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-7.75	5.79e-14	2.13e-11	-0.51	-0.34	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
THCA	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-7.75	5.8e-14	2.13e-11	-0.29	-0.34	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
THCA	cis	rs8114671	0.562	rs6088635	ENSG00000269202.1	RP4-614O4.12	-7.75	5.8e-14	2.14e-11	-0.29	-0.34	Height;	chr20:34878698	chr20:35201747~35203288:-
THCA	cis	rs17684571	0.7	rs16888171	ENSG00000231441.1	RP11-472M19.2	7.75	5.8e-14	2.14e-11	0.41	0.34	Schizophrenia;	chr6:56810369	chr6:56844002~56864078:+
THCA	cis	rs910316	0.87	rs7147712	ENSG00000279594.1	RP11-950C14.10	-7.75	5.8e-14	2.14e-11	-0.32	-0.34	Height;	chr14:75204004	chr14:75011269~75012851:-
THCA	cis	rs7208859	0.614	rs73265646	ENSG00000266490.1	CTD-2349P21.9	7.75	5.81e-14	2.14e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30792372~30792833:+
THCA	cis	rs595244	0.706	rs2289136	ENSG00000259705.1	RP11-227D13.1	-7.75	5.81e-14	2.14e-11	-0.48	-0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48652075	chr15:48645951~48652016:+
THCA	cis	rs710216	0.571	rs11210772	ENSG00000227533.4	SLC2A1-AS1	-7.75	5.83e-14	2.14e-11	-0.46	-0.34	Red cell distribution width;	chr1:42982828	chr1:42959049~42983358:+
THCA	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	7.75	5.83e-14	2.15e-11	0.82	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
THCA	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-7.75	5.83e-14	2.15e-11	-0.3	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
THCA	cis	rs1426063	0.614	rs115690958	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75078364	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs78681370	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75081556	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs17000212	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75081611	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs77018380	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75081621	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs75846524	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75083172	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs78046076	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75091818	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs74670563	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75094656	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs115338890	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75094719	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.541	rs116304289	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75095072	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs76204704	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75097804	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs80030693	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75099929	chr4:75081702~75084717:-
THCA	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-7.75	5.84e-14	2.15e-11	-0.29	-0.34	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
THCA	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	7.75	5.86e-14	2.16e-11	0.46	0.34	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
THCA	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	7.75	5.86e-14	2.16e-11	0.46	0.34	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	7.75	5.86e-14	2.16e-11	0.46	0.34	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
THCA	cis	rs741668	0.759	rs12428399	ENSG00000235903.6	CPB2-AS1	7.75	5.86e-14	2.16e-11	0.44	0.34	Cerebrospinal fluid clusterin levels;	chr13:46060804	chr13:46052806~46113332:+
THCA	cis	rs73607972	0.696	rs9931018	ENSG00000275191.1	RP11-36I17.2	-7.75	5.86e-14	2.16e-11	-0.47	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53529205	chr16:53628256~53628816:-
THCA	cis	rs172166	0.516	rs1150670	ENSG00000219392.1	RP1-265C24.5	-7.75	5.87e-14	2.16e-11	-0.37	-0.34	Cardiac Troponin-T levels;	chr6:28162781	chr6:28115628~28116551:+
THCA	cis	rs7674212	0.833	rs61075040	ENSG00000251288.2	RP11-10L12.2	-7.75	5.88e-14	2.16e-11	-0.46	-0.34	Type 2 diabetes;	chr4:103052804	chr4:102751401~102752641:+
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000264538.5	SUZ12P1	-7.75	5.88e-14	2.16e-11	-0.34	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30709299~30790908:+
THCA	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	7.75	5.91e-14	2.17e-11	0.2	0.34	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
THCA	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-7.75	5.92e-14	2.18e-11	-0.42	-0.34	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
THCA	cis	rs728616	0.867	rs726289	ENSG00000225484.5	NUTM2B-AS1	-7.75	5.92e-14	2.18e-11	-0.64	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79663088~79826594:-
THCA	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-7.75	5.92e-14	2.18e-11	-0.5	-0.34	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000237664.1	LINC00316	-7.75	5.92e-14	2.18e-11	-0.36	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45338590~45341990:-
THCA	cis	rs7829975	0.593	rs2979241	ENSG00000254153.1	CTA-398F10.2	-7.75	5.93e-14	2.18e-11	-0.35	-0.34	Mood instability;	chr8:8445843	chr8:8456909~8461337:-
THCA	cis	rs17772222	0.727	rs3179969	ENSG00000258789.1	RP11-507K2.3	-7.75	5.93e-14	2.18e-11	-0.32	-0.34	Coronary artery calcification;	chr14:88396185	chr14:88551597~88552493:+
THCA	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	7.74	5.95e-14	2.19e-11	0.2	0.34	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
THCA	cis	rs11971779	0.793	rs4728464	ENSG00000273391.1	RP11-634H22.1	-7.74	5.95e-14	2.19e-11	-0.33	-0.34	Diisocyanate-induced asthma;	chr7:139332924	chr7:139359032~139359566:-
THCA	cis	rs8114671	0.967	rs1577924	ENSG00000269202.1	RP4-614O4.12	7.74	5.96e-14	2.19e-11	0.28	0.34	Height;	chr20:35196485	chr20:35201747~35203288:-
THCA	cis	rs12928939	0.815	rs61753635	ENSG00000260886.1	TAT-AS1	7.74	5.96e-14	2.19e-11	0.43	0.34	Post bronchodilator FEV1;	chr16:71626501	chr16:71565789~71578187:+
THCA	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
THCA	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-7.74	5.99e-14	2.2e-11	-0.47	-0.34	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
THCA	cis	rs6496932	0.503	rs4564526	ENSG00000218052.5	ADAMTS7P4	-7.74	6e-14	2.2e-11	-0.45	-0.34	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85255369~85330334:-
THCA	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-7.74	6e-14	2.21e-11	-0.4	-0.34	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
THCA	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-7.74	6e-14	2.21e-11	-0.48	-0.34	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
THCA	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-7.74	6.01e-14	2.21e-11	-0.36	-0.34	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
THCA	cis	rs10971721	0.584	rs72731218	ENSG00000260947.1	RP11-384P7.7	7.74	6.01e-14	2.21e-11	0.76	0.34	Body mass index;	chr9:34119678	chr9:33697459~33700986:+
THCA	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-7.74	6.01e-14	2.21e-11	-0.41	-0.34	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
THCA	cis	rs8081395	0.899	rs2645477	ENSG00000266992.1	DHX40P1	-7.74	6.02e-14	2.21e-11	-0.39	-0.34	White blood cell count;	chr17:59768263	chr17:59976009~60002384:-
THCA	cis	rs2288884	0.505	rs6509602	ENSG00000275055.1	CTC-471J1.11	-7.74	6.02e-14	2.21e-11	-0.34	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51956892	chr19:52049007~52049754:+
THCA	cis	rs7727544	0.716	rs4705926	ENSG00000224431.1	AC063976.7	7.74	6.02e-14	2.21e-11	0.29	0.34	Blood metabolite levels;	chr5:132226065	chr5:132199456~132203487:+
THCA	cis	rs934734	0.571	rs7565437	ENSG00000237979.1	AC007389.1	-7.74	6.05e-14	2.23e-11	-0.39	-0.34	Rheumatoid arthritis;	chr2:65419832	chr2:65500993~65502138:-
THCA	cis	rs12280210	0.655	rs76169968	ENSG00000254851.1	RP11-109L13.1	7.74	6.06e-14	2.23e-11	0.74	0.34	Lobe attachment (rater-scored or self-reported);	chr11:117212250	chr11:117135528~117138582:+
THCA	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	7.74	6.07e-14	2.23e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
THCA	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	7.74	6.08e-14	2.23e-11	0.3	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
THCA	cis	rs9500256	0.655	rs12191043	ENSG00000215190.7	LINC00680	-7.74	6.08e-14	2.24e-11	-0.43	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57946074~57961501:-
THCA	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	7.74	6.09e-14	2.24e-11	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
THCA	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	7.74	6.1e-14	2.24e-11	0.55	0.34	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	7.74	6.1e-14	2.24e-11	0.55	0.34	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
THCA	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-7.74	6.11e-14	2.24e-11	-0.52	-0.34	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
THCA	cis	rs13068223	0.568	rs7636965	ENSG00000243926.1	TIPARP-AS1	7.74	6.11e-14	2.25e-11	0.33	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156700615	chr3:156671862~156674378:-
THCA	cis	rs42490	0.614	rs402434	ENSG00000251136.7	RP11-37B2.1	-7.74	6.12e-14	2.25e-11	-0.29	-0.34	Leprosy;	chr8:89808088	chr8:89609409~89757727:-
THCA	cis	rs42490	0.614	rs452694	ENSG00000251136.7	RP11-37B2.1	-7.74	6.12e-14	2.25e-11	-0.29	-0.34	Leprosy;	chr8:89808293	chr8:89609409~89757727:-
THCA	cis	rs42490	0.59	rs447611	ENSG00000251136.7	RP11-37B2.1	-7.74	6.12e-14	2.25e-11	-0.29	-0.34	Leprosy;	chr8:89808359	chr8:89609409~89757727:-
THCA	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	7.74	6.12e-14	2.25e-11	0.42	0.34	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
THCA	cis	rs853679	1	rs7740487	ENSG00000280107.1	AL022393.9	-7.74	6.13e-14	2.25e-11	-0.49	-0.34	Depression;	chr6:28248708	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs68141011	ENSG00000280107.1	AL022393.9	-7.74	6.13e-14	2.25e-11	-0.49	-0.34	Depression;	chr6:28250019	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs13200462	ENSG00000280107.1	AL022393.9	-7.74	6.13e-14	2.25e-11	-0.49	-0.34	Depression;	chr6:28250421	chr6:28170845~28172521:+
THCA	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-7.74	6.15e-14	2.26e-11	-0.32	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
THCA	cis	rs6840258	0.66	rs72667736	ENSG00000251411.1	RP11-397E7.4	-7.74	6.15e-14	2.26e-11	-0.42	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86954803	chr4:86913266~86914817:-
THCA	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-7.74	6.15e-14	2.26e-11	-0.43	-0.34	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
THCA	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	7.74	6.17e-14	2.26e-11	0.33	0.34	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
THCA	cis	rs193541	0.632	rs1903260	ENSG00000263432.2	RN7SL689P	7.74	6.2e-14	2.28e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122799493	chr5:123022487~123022783:-
THCA	cis	rs11603691	1	rs2155233	ENSG00000254662.1	RP11-872D17.4	-7.74	6.2e-14	2.28e-11	-0.61	-0.34	Low high density lipoprotein cholesterol levels;	chr11:57274518	chr11:57325603~57327958:+
THCA	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-7.74	6.21e-14	2.28e-11	-0.36	-0.34	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
THCA	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-7.74	6.22e-14	2.28e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
THCA	cis	rs17684571	0.7	rs6904535	ENSG00000231441.1	RP11-472M19.2	7.74	6.22e-14	2.28e-11	0.41	0.34	Schizophrenia;	chr6:56767178	chr6:56844002~56864078:+
THCA	cis	rs11971779	0.715	rs6467854	ENSG00000273391.1	RP11-634H22.1	7.74	6.23e-14	2.29e-11	0.32	0.34	Diisocyanate-induced asthma;	chr7:139442337	chr7:139359032~139359566:-
THCA	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	7.74	6.25e-14	2.3e-11	0.43	0.34	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000235689.1	AP000351.13	7.74	6.26e-14	2.3e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:24006305~24008258:-
THCA	cis	rs34375054	0.687	rs12303572	ENSG00000279233.1	RP11-158L12.4	7.74	6.26e-14	2.3e-11	0.34	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125126725	chr12:125138245~125141711:+
THCA	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	7.74	6.26e-14	2.3e-11	0.41	0.34	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
THCA	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-7.74	6.27e-14	2.3e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-7.74	6.27e-14	2.3e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-7.74	6.27e-14	2.3e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
THCA	cis	rs7646881	0.812	rs61696028	ENSG00000240207.5	RP11-379F4.4	-7.74	6.27e-14	2.3e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158737914	chr3:158732263~158784070:+
THCA	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-7.74	6.28e-14	2.31e-11	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
THCA	cis	rs934734	0.571	rs7572922	ENSG00000237979.1	AC007389.1	-7.74	6.29e-14	2.31e-11	-0.38	-0.34	Rheumatoid arthritis;	chr2:65425022	chr2:65500993~65502138:-
THCA	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-7.74	6.29e-14	2.31e-11	-0.4	-0.34	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
THCA	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	7.74	6.33e-14	2.32e-11	0.54	0.34	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
THCA	cis	rs910316	0.737	rs175065	ENSG00000279594.1	RP11-950C14.10	-7.74	6.35e-14	2.33e-11	-0.31	-0.34	Height;	chr14:75028280	chr14:75011269~75012851:-
THCA	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-7.74	6.36e-14	2.33e-11	-0.35	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
THCA	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	7.73	6.36e-14	2.33e-11	0.2	0.34	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
THCA	cis	rs4780355	0.918	rs243318	ENSG00000262636.1	CTD-3088G3.4	7.73	6.37e-14	2.34e-11	0.44	0.34	Crohn's disease and psoriasis;	chr16:11264161	chr16:11380859~11381118:-
THCA	cis	rs7727544	0.654	rs4705849	ENSG00000224431.1	AC063976.7	7.73	6.38e-14	2.34e-11	0.29	0.34	Blood metabolite levels;	chr5:132223506	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.716	rs72793278	ENSG00000224431.1	AC063976.7	7.73	6.38e-14	2.34e-11	0.29	0.34	Blood metabolite levels;	chr5:132225679	chr5:132199456~132203487:+
THCA	cis	rs11148252	0.538	rs2408609	ENSG00000235660.1	LINC00345	-7.73	6.39e-14	2.34e-11	-0.41	-0.34	Lewy body disease;	chr13:52139907	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.538	rs2897976	ENSG00000235660.1	LINC00345	-7.73	6.39e-14	2.34e-11	-0.41	-0.34	Lewy body disease;	chr13:52141808	chr13:52484161~52484680:-
THCA	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	7.73	6.39e-14	2.34e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
THCA	cis	rs9902453	0.899	rs1979572	ENSG00000264007.1	RP11-68I3.10	7.73	6.39e-14	2.34e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30184960	chr17:29621617~29622254:-
THCA	cis	rs9640161	0.789	rs34495356	ENSG00000261305.1	RP4-584D14.7	7.73	6.39e-14	2.34e-11	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150360702	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.789	rs36035506	ENSG00000261305.1	RP4-584D14.7	7.73	6.39e-14	2.34e-11	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150360754	chr7:150341771~150342607:+
THCA	cis	rs7760535	0.794	rs12529158	ENSG00000230177.1	RP5-1112D6.4	7.73	6.4e-14	2.35e-11	0.27	0.34	Metabolic traits;	chr6:111501244	chr6:111277932~111278742:+
THCA	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-7.73	6.42e-14	2.36e-11	-0.4	-0.34	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-7.73	6.42e-14	2.36e-11	-0.4	-0.34	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
THCA	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	7.73	6.43e-14	2.36e-11	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
THCA	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-7.73	6.44e-14	2.36e-11	-0.38	-0.34	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
THCA	cis	rs2274273	0.662	rs4525413	ENSG00000258413.1	RP11-665C16.6	-7.73	6.44e-14	2.36e-11	-0.47	-0.34	Protein biomarker;	chr14:55194420	chr14:55262767~55272075:-
THCA	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-7.73	6.45e-14	2.36e-11	-0.54	-0.34	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
THCA	cis	rs4072705	0.967	rs10739651	ENSG00000224020.1	MIR181A2HG	-7.73	6.45e-14	2.36e-11	-0.31	-0.34	Menarche (age at onset);	chr9:124561794	chr9:124658467~124698631:+
THCA	cis	rs2688608	0.592	rs7923045	ENSG00000271816.1	BMS1P4	7.73	6.46e-14	2.37e-11	0.34	0.34	Inflammatory bowel disease;	chr10:73727740	chr10:73699151~73730487:-
THCA	cis	rs3820443	0.83	rs57294801	ENSG00000234020.1	CHIAP3	-7.73	6.46e-14	2.37e-11	-0.43	-0.34	Late-onset Alzheimer's disease;	chr1:111353909	chr1:111353275~111367409:-
THCA	cis	rs910316	0.967	rs175498	ENSG00000279594.1	RP11-950C14.10	-7.73	6.46e-14	2.37e-11	-0.31	-0.34	Height;	chr14:75069666	chr14:75011269~75012851:-
THCA	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-7.73	6.47e-14	2.37e-11	-0.51	-0.34	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
THCA	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-7.73	6.49e-14	2.38e-11	-0.4	-0.34	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
THCA	cis	rs7851660	0.527	rs7870540	ENSG00000236130.1	PTCSC2	-7.73	6.5e-14	2.38e-11	-0.27	-0.34	Strep throat;	chr9:97811643	chr9:97805935~97810008:-
THCA	cis	rs9902453	0.845	rs72823935	ENSG00000264007.1	RP11-68I3.10	7.73	6.52e-14	2.39e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29681577	chr17:29621617~29622254:-
THCA	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-7.73	6.52e-14	2.39e-11	-0.44	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000264538.5	SUZ12P1	-7.73	6.52e-14	2.39e-11	-0.34	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30709299~30790908:+
THCA	cis	rs1858037	0.867	rs1039765	ENSG00000237979.1	AC007389.1	-7.73	6.53e-14	2.39e-11	-0.41	-0.34	Rheumatoid arthritis;	chr2:65387228	chr2:65500993~65502138:-
THCA	cis	rs9813712	0.597	rs11711883	ENSG00000228252.7	COL6A4P2	-7.73	6.54e-14	2.4e-11	-0.33	-0.34	Response to amphetamines;	chr3:130241367	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.574	rs62281647	ENSG00000228252.7	COL6A4P2	-7.73	6.54e-14	2.4e-11	-0.33	-0.34	Response to amphetamines;	chr3:130242670	chr3:130212823~130273806:+
THCA	cis	rs17684571	0.748	rs3002006	ENSG00000231441.1	RP11-472M19.2	7.73	6.54e-14	2.4e-11	0.42	0.34	Schizophrenia;	chr6:56750916	chr6:56844002~56864078:+
THCA	cis	rs910316	0.737	rs91144	ENSG00000279594.1	RP11-950C14.10	-7.73	6.54e-14	2.4e-11	-0.31	-0.34	Height;	chr14:74982814	chr14:75011269~75012851:-
THCA	cis	rs6597981	0.592	rs28625355	ENSG00000255142.1	AP006621.6	7.73	6.55e-14	2.4e-11	0.24	0.34	Breast cancer;	chr11:736334	chr11:781645~782105:+
THCA	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-7.73	6.57e-14	2.41e-11	-0.43	-0.34	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
THCA	cis	rs2284219	0.929	rs12533248	ENSG00000196295.10	AC005154.6	-7.73	6.57e-14	2.41e-11	-0.24	-0.34	Type 2 diabetes;	chr7:30678973	chr7:30516309~30594809:-
THCA	cis	rs7945705	0.846	rs4929911	ENSG00000254860.4	TMEM9B-AS1	-7.73	6.58e-14	2.41e-11	-0.37	-0.34	Hemoglobin concentration;	chr11:8794948	chr11:8964675~8977527:+
THCA	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	7.73	6.58e-14	2.41e-11	0.4	0.34	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
THCA	cis	rs10411161	0.81	rs11667971	ENSG00000269483.1	AC006272.1	7.73	6.58e-14	2.41e-11	0.57	0.34	Breast cancer;	chr19:51904441	chr19:51839924~51843324:-
THCA	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	7.73	6.58e-14	2.41e-11	0.43	0.34	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
THCA	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	7.73	6.6e-14	2.42e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
THCA	cis	rs12928939	0.769	rs1056303	ENSG00000260886.1	TAT-AS1	7.73	6.61e-14	2.42e-11	0.43	0.34	Post bronchodilator FEV1;	chr16:71636163	chr16:71565789~71578187:+
THCA	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-7.73	6.61e-14	2.42e-11	-0.42	-0.34	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
THCA	cis	rs984222	0.501	rs1325943	ENSG00000231365.4	RP11-418J17.1	-7.73	6.65e-14	2.43e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942984	chr1:119140396~119275973:+
THCA	cis	rs984222	0.501	rs1325945	ENSG00000231365.4	RP11-418J17.1	-7.73	6.65e-14	2.43e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943148	chr1:119140396~119275973:+
THCA	cis	rs984222	0.501	rs1779420	ENSG00000231365.4	RP11-418J17.1	-7.73	6.65e-14	2.43e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943840	chr1:119140396~119275973:+
THCA	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	7.73	6.66e-14	2.44e-11	0.67	0.34	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
THCA	cis	rs984222	0.529	rs1325946	ENSG00000231365.4	RP11-418J17.1	-7.73	6.67e-14	2.44e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943299	chr1:119140396~119275973:+
THCA	cis	rs7247513	0.897	rs12979146	ENSG00000230310.1	CTD-2192J16.11	-7.73	6.67e-14	2.44e-11	-0.4	-0.34	Bipolar disorder;	chr19:12607090	chr19:12552597~12553644:+
THCA	cis	rs6558530	0.73	rs13256424	ENSG00000253982.1	CTD-2336O2.1	7.73	6.68e-14	2.44e-11	0.29	0.34	Systolic blood pressure;	chr8:1776838	chr8:1761990~1764502:-
THCA	cis	rs380904	0.963	rs410822	ENSG00000254859.1	RP11-661A12.5	-7.73	6.68e-14	2.44e-11	-0.49	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:143492441	chr8:143541973~143549729:-
THCA	cis	rs2787702	0.5	rs72822011	ENSG00000237233.2	TMEM26-AS1	7.73	6.68e-14	2.44e-11	0.57	0.34	Response to taxane treatment (placlitaxel);	chr10:61573852	chr10:61452639~61481956:+
THCA	cis	rs11148252	0.508	rs11148260	ENSG00000278238.1	RP11-245D16.4	-7.73	6.69e-14	2.45e-11	-0.37	-0.34	Lewy body disease;	chr13:52588508	chr13:52454775~52455331:-
THCA	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-7.73	6.69e-14	2.45e-11	-0.44	-0.34	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
THCA	cis	rs11673344	0.504	rs7245882	ENSG00000226686.6	LINC01535	-7.73	6.7e-14	2.45e-11	-0.37	-0.34	Obesity-related traits;	chr19:37089513	chr19:37251912~37265535:+
THCA	cis	rs416603	0.901	rs149597	ENSG00000262636.1	CTD-3088G3.4	-7.73	6.71e-14	2.46e-11	-0.42	-0.34	Type 1 diabetes;	chr16:11250085	chr16:11380859~11381118:-
THCA	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	7.73	6.71e-14	2.46e-11	0.43	0.34	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
THCA	cis	rs984222	0.501	rs1325941	ENSG00000231365.4	RP11-418J17.1	-7.73	6.73e-14	2.46e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941193	chr1:119140396~119275973:+
THCA	cis	rs984222	0.501	rs1750333	ENSG00000231365.4	RP11-418J17.1	-7.73	6.73e-14	2.46e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941315	chr1:119140396~119275973:+
THCA	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-7.73	6.73e-14	2.46e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
THCA	cis	rs116175783	0.557	rs3769963	ENSG00000227403.1	AC009299.3	7.73	6.74e-14	2.47e-11	0.61	0.34	Intelligence (multi-trait analysis);	chr2:161350999	chr2:161244739~161249050:+
THCA	cis	rs11096990	0.613	rs12643415	ENSG00000249685.1	RP11-360F5.3	-7.73	6.75e-14	2.47e-11	-0.41	-0.34	Cognitive function;	chr4:39270375	chr4:39133913~39135608:+
THCA	cis	rs1949733	0.701	rs1880024	ENSG00000205959.3	RP11-689P11.2	-7.73	6.78e-14	2.48e-11	-0.28	-0.34	Response to antineoplastic agents;	chr4:8452912	chr4:8482270~8512610:+
THCA	cis	rs8114671	0.562	rs6058137	ENSG00000269202.1	RP4-614O4.12	-7.73	6.78e-14	2.48e-11	-0.29	-0.34	Height;	chr20:34887271	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs8116657	ENSG00000269202.1	RP4-614O4.12	-7.73	6.78e-14	2.48e-11	-0.29	-0.34	Height;	chr20:34888671	chr20:35201747~35203288:-
THCA	cis	rs12928939	0.815	rs12446005	ENSG00000260886.1	TAT-AS1	7.73	6.79e-14	2.48e-11	0.43	0.34	Post bronchodilator FEV1;	chr16:71621132	chr16:71565789~71578187:+
THCA	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	7.73	6.79e-14	2.48e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
THCA	cis	rs1858037	0.867	rs4671658	ENSG00000237979.1	AC007389.1	-7.73	6.81e-14	2.49e-11	-0.42	-0.34	Rheumatoid arthritis;	chr2:65334258	chr2:65500993~65502138:-
THCA	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	7.72	6.82e-14	2.49e-11	0.43	0.34	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
THCA	cis	rs77204473	0.744	rs12417098	ENSG00000254851.1	RP11-109L13.1	7.72	6.82e-14	2.5e-11	0.89	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117134137	chr11:117135528~117138582:+
THCA	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	7.72	6.83e-14	2.5e-11	0.45	0.34	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	7.72	6.83e-14	2.5e-11	0.45	0.34	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
THCA	cis	rs13068223	0.663	rs12107178	ENSG00000243926.1	TIPARP-AS1	7.72	6.83e-14	2.5e-11	0.34	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156671862~156674378:-
THCA	cis	rs2274273	1	rs10140857	ENSG00000258413.1	RP11-665C16.6	-7.72	6.83e-14	2.5e-11	-0.45	-0.34	Protein biomarker;	chr14:55152893	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs74617736	ENSG00000258413.1	RP11-665C16.6	-7.72	6.83e-14	2.5e-11	-0.45	-0.34	Protein biomarker;	chr14:55154201	chr14:55262767~55272075:-
THCA	cis	rs11148252	0.538	rs2296349	ENSG00000235660.1	LINC00345	-7.72	6.84e-14	2.5e-11	-0.41	-0.34	Lewy body disease;	chr13:52135922	chr13:52484161~52484680:-
THCA	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	7.72	6.86e-14	2.51e-11	0.4	0.34	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
THCA	cis	rs947583	0.588	rs6925090	ENSG00000231028.7	LINC00271	-7.72	6.88e-14	2.51e-11	-0.26	-0.34	Phosphorus levels;	chr6:135795339	chr6:135497801~135716055:+
THCA	cis	rs7942368	1	rs1440977	ENSG00000254761.1	RP11-672A2.1	7.72	6.89e-14	2.52e-11	0.47	0.34	Endometriosis;	chr11:76765385	chr11:76712396~76719608:-
THCA	cis	rs9388451	0.839	rs3757217	ENSG00000237742.5	RP11-624M8.1	-7.72	6.89e-14	2.52e-11	-0.29	-0.34	Brugada syndrome;	chr6:125748490	chr6:125578558~125749190:-
THCA	cis	rs1150668	0.799	rs853684	ENSG00000219392.1	RP1-265C24.5	-7.72	6.91e-14	2.53e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28326773	chr6:28115628~28116551:+
THCA	cis	rs4072705	0.967	rs4076333	ENSG00000224020.1	MIR181A2HG	-7.72	6.91e-14	2.53e-11	-0.3	-0.34	Menarche (age at onset);	chr9:124623330	chr9:124658467~124698631:+
THCA	cis	rs710216	0.595	rs4660697	ENSG00000227533.4	SLC2A1-AS1	-7.72	6.91e-14	2.53e-11	-0.48	-0.34	Red cell distribution width;	chr1:42992579	chr1:42959049~42983358:+
THCA	cis	rs11971779	0.941	rs7802779	ENSG00000273391.1	RP11-634H22.1	7.72	6.91e-14	2.53e-11	0.34	0.34	Diisocyanate-induced asthma;	chr7:139437833	chr7:139359032~139359566:-
THCA	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-7.72	6.94e-14	2.54e-11	-0.31	-0.34	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
THCA	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	7.72	6.98e-14	2.55e-11	0.43	0.34	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
THCA	cis	rs9543976	0.623	rs8192764	ENSG00000261553.4	RP11-29G8.3	7.72	6.99e-14	2.56e-11	0.41	0.34	Diabetic retinopathy;	chr13:75605079	chr13:75549773~75807120:+
THCA	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-7.72	6.99e-14	2.56e-11	-0.51	-0.34	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
THCA	cis	rs9902453	0.967	rs8067576	ENSG00000264007.1	RP11-68I3.10	7.72	7e-14	2.56e-11	0.38	0.34	Coffee consumption (cups per day);	chr17:30117236	chr17:29621617~29622254:-
THCA	cis	rs9388451	0.839	rs1811852	ENSG00000237742.5	RP11-624M8.1	-7.72	7.02e-14	2.56e-11	-0.29	-0.34	Brugada syndrome;	chr6:125750429	chr6:125578558~125749190:-
THCA	cis	rs910316	0.737	rs175424	ENSG00000279594.1	RP11-950C14.10	-7.72	7.03e-14	2.57e-11	-0.31	-0.34	Height;	chr14:75159554	chr14:75011269~75012851:-
THCA	cis	rs910316	0.763	rs2080201	ENSG00000279594.1	RP11-950C14.10	-7.72	7.03e-14	2.57e-11	-0.31	-0.34	Height;	chr14:75163269	chr14:75011269~75012851:-
THCA	cis	rs2839186	0.814	rs12482209	ENSG00000239415.1	AP001469.9	-7.72	7.03e-14	2.57e-11	-0.35	-0.34	Testicular germ cell tumor;	chr21:46244361	chr21:46251549~46254133:-
THCA	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	7.72	7.05e-14	2.58e-11	0.42	0.34	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
THCA	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-7.72	7.05e-14	2.58e-11	-0.42	-0.34	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
THCA	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-7.72	7.05e-14	2.58e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
THCA	cis	rs9902453	0.845	rs3102558	ENSG00000264007.1	RP11-68I3.10	7.72	7.06e-14	2.58e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29696124	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs2321331	ENSG00000264007.1	RP11-68I3.10	7.72	7.06e-14	2.58e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29698510	chr17:29621617~29622254:-
THCA	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-7.72	7.07e-14	2.58e-11	-0.35	-0.34	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
THCA	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	7.72	7.07e-14	2.58e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
THCA	cis	rs10208649	0.908	rs11904365	ENSG00000272156.1	RP11-477N3.1	-7.72	7.08e-14	2.59e-11	-0.61	-0.34	Body mass index;	chr2:53998444	chr2:54082554~54085066:+
THCA	cis	rs9813712	0.597	rs62281648	ENSG00000228252.7	COL6A4P2	-7.72	7.1e-14	2.59e-11	-0.33	-0.34	Response to amphetamines;	chr3:130244794	chr3:130212823~130273806:+
THCA	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	7.72	7.1e-14	2.59e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
THCA	cis	rs1150668	0.799	rs9301	ENSG00000219392.1	RP1-265C24.5	-7.72	7.1e-14	2.59e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28324929	chr6:28115628~28116551:+
THCA	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-7.72	7.12e-14	2.6e-11	-0.32	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
THCA	cis	rs7727544	0.606	rs72795121	ENSG00000224431.1	AC063976.7	7.72	7.13e-14	2.6e-11	0.3	0.34	Blood metabolite levels;	chr5:132302631	chr5:132199456~132203487:+
THCA	cis	rs5769707	0.605	rs9616702	ENSG00000235111.1	RP1-29C18.8	-7.72	7.13e-14	2.61e-11	-0.44	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49612657~49615716:-
THCA	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-7.72	7.15e-14	2.61e-11	-0.52	-0.34	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
THCA	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	7.72	7.15e-14	2.61e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
THCA	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	7.72	7.15e-14	2.61e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	7.72	7.15e-14	2.61e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	7.72	7.15e-14	2.61e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
THCA	cis	rs2288884	0.676	rs58197197	ENSG00000275055.1	CTC-471J1.11	-7.72	7.16e-14	2.61e-11	-0.34	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52000405	chr19:52049007~52049754:+
THCA	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	7.72	7.16e-14	2.62e-11	0.48	0.34	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
THCA	cis	rs42490	0.557	rs426240	ENSG00000251136.7	RP11-37B2.1	-7.72	7.17e-14	2.62e-11	-0.29	-0.34	Leprosy;	chr8:89834573	chr8:89609409~89757727:-
THCA	cis	rs9902453	0.934	rs4427857	ENSG00000264007.1	RP11-68I3.10	7.72	7.17e-14	2.62e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30130971	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.868	rs9896012	ENSG00000264007.1	RP11-68I3.10	7.72	7.17e-14	2.62e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30143073	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.868	rs9890075	ENSG00000264007.1	RP11-68I3.10	7.72	7.17e-14	2.62e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30143446	chr17:29621617~29622254:-
THCA	cis	rs4780355	0.843	rs243325	ENSG00000262636.1	CTD-3088G3.4	7.72	7.17e-14	2.62e-11	0.44	0.34	Crohn's disease and psoriasis;	chr16:11260640	chr16:11380859~11381118:-
THCA	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-7.72	7.19e-14	2.62e-11	-0.36	-0.34	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
THCA	cis	rs4820539	1	rs3827316	ENSG00000221069.1	AC000029.1	-7.72	7.19e-14	2.63e-11	-0.4	-0.34	Bone mineral density;	chr22:23126351	chr22:23136620~23136710:+
THCA	cis	rs7714584	1	rs1428552	ENSG00000197083.10	ZNF300P1	7.72	7.2e-14	2.63e-11	0.54	0.34	Crohn's disease;	chr5:150880269	chr5:150930645~150946289:-
THCA	cis	rs1667284	0.935	rs1791171	ENSG00000266521.1	RP11-650P15.1	7.72	7.22e-14	2.64e-11	0.42	0.34	Problematic alcohol use in trauma-exposed individuals;	chr18:31636194	chr18:31496645~31497195:-
THCA	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
THCA	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6579806	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150891522	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs4958848	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150891560	chr5:150930645~150946289:-
THCA	cis	rs922182	0.557	rs8039736	ENSG00000275785.1	RP11-111E14.2	7.72	7.26e-14	2.65e-11	0.41	0.34	Blood protein levels;	chr15:63896052	chr15:63890030~63890317:+
THCA	cis	rs7247513	0.866	rs2861405	ENSG00000230310.1	CTD-2192J16.11	-7.72	7.29e-14	2.66e-11	-0.4	-0.34	Bipolar disorder;	chr19:12611518	chr19:12552597~12553644:+
THCA	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-7.72	7.3e-14	2.66e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
THCA	cis	rs17684571	0.872	rs34824960	ENSG00000231441.1	RP11-472M19.2	7.71	7.31e-14	2.67e-11	0.42	0.34	Schizophrenia;	chr6:56722732	chr6:56844002~56864078:+
THCA	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	7.71	7.34e-14	2.68e-11	0.49	0.34	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
THCA	cis	rs3847687	1	rs3847688	ENSG00000279128.1	RP11-76C10.4	7.71	7.35e-14	2.68e-11	0.38	0.34	Longevity;	chr12:131040765	chr12:131022769~131024741:-
THCA	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	7.71	7.35e-14	2.68e-11	0.51	0.34	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
THCA	cis	rs17772222	0.565	rs845759	ENSG00000258789.1	RP11-507K2.3	7.71	7.36e-14	2.68e-11	0.32	0.34	Coronary artery calcification;	chr14:88415538	chr14:88551597~88552493:+
THCA	cis	rs12681366	0.881	rs2960121	ENSG00000253704.1	RP11-267M23.4	7.71	7.36e-14	2.68e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94417678	chr8:94553722~94569745:+
THCA	cis	rs747687	0.655	rs9674522	ENSG00000262133.1	RP11-676J12.6	-7.71	7.37e-14	2.69e-11	-0.56	-0.34	Blood pressure;	chr17:864995	chr17:877902~880093:+
THCA	cis	rs17772222	0.651	rs12586714	ENSG00000258789.1	RP11-507K2.3	-7.71	7.37e-14	2.69e-11	-0.31	-0.34	Coronary artery calcification;	chr14:88360497	chr14:88551597~88552493:+
THCA	cis	rs10853057	0.717	rs11079553	ENSG00000214174.7	AMZ2P1	-7.71	7.37e-14	2.69e-11	-0.54	-0.34	White matter microstructure (global fractional anisotropy);	chr17:65061877	chr17:64966550~64975576:-
THCA	cis	rs7727544	0.581	rs10075801	ENSG00000233006.5	AC034220.3	7.71	7.38e-14	2.69e-11	0.26	0.34	Blood metabolite levels;	chr5:132341949	chr5:132311285~132369916:-
THCA	cis	rs8113308	0.81	rs11879040	ENSG00000269235.1	ZNF350-AS1	7.71	7.39e-14	2.69e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946856	chr19:51949134~51981367:+
THCA	cis	rs9902453	0.845	rs2617865	ENSG00000264007.1	RP11-68I3.10	-7.71	7.39e-14	2.69e-11	-0.39	-0.34	Coffee consumption (cups per day);	chr17:29722786	chr17:29621617~29622254:-
THCA	cis	rs11018904	0.636	rs61903695	ENSG00000280385.1	AP000648.5	-7.71	7.4e-14	2.7e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90193614~90198120:+
THCA	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	7.71	7.41e-14	2.7e-11	0.51	0.34	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	7.71	7.41e-14	2.7e-11	0.51	0.34	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
THCA	cis	rs860295	0.719	rs490608	ENSG00000225855.5	RUSC1-AS1	7.71	7.43e-14	2.71e-11	0.22	0.34	Body mass index;	chr1:155713079	chr1:155316863~155324176:-
THCA	cis	rs11148252	0.532	rs9536262	ENSG00000235660.1	LINC00345	7.71	7.43e-14	2.71e-11	0.43	0.34	Lewy body disease;	chr13:52728939	chr13:52484161~52484680:-
THCA	cis	rs8114671	0.836	rs6058154	ENSG00000269202.1	RP4-614O4.12	7.71	7.45e-14	2.71e-11	0.28	0.34	Height;	chr20:34998031	chr20:35201747~35203288:-
THCA	cis	rs9902453	0.845	rs3115101	ENSG00000264007.1	RP11-68I3.10	7.71	7.49e-14	2.73e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29714609	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs3102556	ENSG00000264007.1	RP11-68I3.10	7.71	7.49e-14	2.73e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29715524	chr17:29621617~29622254:-
THCA	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	7.71	7.5e-14	2.73e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
THCA	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	7.71	7.5e-14	2.73e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
THCA	cis	rs9902453	0.967	rs4493117	ENSG00000264007.1	RP11-68I3.10	7.71	7.51e-14	2.73e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30162752	chr17:29621617~29622254:-
THCA	cis	rs9341808	0.556	rs1535075	ENSG00000272129.1	RP11-250B2.6	7.71	7.51e-14	2.73e-11	0.42	0.34	Sitting height ratio;	chr6:80325089	chr6:80355424~80356859:+
THCA	cis	rs2288884	0.505	rs75919042	ENSG00000275055.1	CTC-471J1.11	-7.71	7.53e-14	2.74e-11	-0.36	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51973246	chr19:52049007~52049754:+
THCA	cis	rs66887589	0.87	rs2389875	ENSG00000245958.5	RP11-33B1.1	7.71	7.53e-14	2.74e-11	0.3	0.34	Diastolic blood pressure;	chr4:119635859	chr4:119454791~119552025:+
THCA	cis	rs10208649	0.908	rs11889527	ENSG00000272156.1	RP11-477N3.1	7.71	7.58e-14	2.76e-11	0.62	0.34	Body mass index;	chr2:53999178	chr2:54082554~54085066:+
THCA	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	7.71	7.59e-14	2.76e-11	0.43	0.34	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
THCA	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	7.71	7.59e-14	2.76e-11	0.46	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
THCA	cis	rs4820539	1	rs2157710	ENSG00000221069.1	AC000029.1	-7.71	7.61e-14	2.77e-11	-0.4	-0.34	Bone mineral density;	chr22:23115299	chr22:23136620~23136710:+
THCA	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	7.71	7.61e-14	2.77e-11	0.29	0.34	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
THCA	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	7.71	7.61e-14	2.77e-11	0.3	0.34	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
THCA	cis	rs10411161	0.81	rs72626248	ENSG00000269483.1	AC006272.1	7.71	7.62e-14	2.77e-11	0.55	0.34	Breast cancer;	chr19:51853993	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.63	rs7252101	ENSG00000269483.1	AC006272.1	7.71	7.62e-14	2.77e-11	0.55	0.34	Breast cancer;	chr19:51856119	chr19:51839924~51843324:-
THCA	cis	rs2839186	0.709	rs2839176	ENSG00000239415.1	AP001469.9	7.71	7.63e-14	2.78e-11	0.34	0.34	Testicular germ cell tumor;	chr21:46258259	chr21:46251549~46254133:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000224205.1	AP000351.4	7.71	7.66e-14	2.79e-11	0.39	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23987320~23991421:-
THCA	cis	rs934734	0.563	rs1858037	ENSG00000281920.1	RP11-418H16.1	7.71	7.66e-14	2.79e-11	0.44	0.34	Rheumatoid arthritis;	chr2:65371166	chr2:65623272~65628424:+
THCA	cis	rs9902453	0.933	rs7221154	ENSG00000264007.1	RP11-68I3.10	-7.71	7.67e-14	2.79e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30178006	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	7.71	7.68e-14	2.79e-11	0.39	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
THCA	cis	rs9902453	0.791	rs3115086	ENSG00000264007.1	RP11-68I3.10	7.71	7.69e-14	2.8e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29698931	chr17:29621617~29622254:-
THCA	cis	rs910316	0.763	rs175490	ENSG00000279594.1	RP11-950C14.10	7.71	7.7e-14	2.8e-11	0.31	0.33	Height;	chr14:75078982	chr14:75011269~75012851:-
THCA	cis	rs910316	0.737	rs175048	ENSG00000279594.1	RP11-950C14.10	-7.71	7.7e-14	2.8e-11	-0.31	-0.33	Height;	chr14:75013191	chr14:75011269~75012851:-
THCA	cis	rs2274273	0.686	rs66842809	ENSG00000258413.1	RP11-665C16.6	-7.71	7.71e-14	2.8e-11	-0.47	-0.33	Protein biomarker;	chr14:55163853	chr14:55262767~55272075:-
THCA	cis	rs7942368	1	rs7933092	ENSG00000254632.1	RP11-21L23.4	7.71	7.72e-14	2.81e-11	0.48	0.33	Endometriosis;	chr11:76764444	chr11:76759916~76768223:-
THCA	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	7.71	7.72e-14	2.81e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	7.71	7.72e-14	2.81e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	7.71	7.72e-14	2.81e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000224205.1	AP000351.4	-7.71	7.73e-14	2.81e-11	-0.44	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23987320~23991421:-
THCA	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-7.71	7.75e-14	2.82e-11	-0.36	-0.33	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-7.71	7.75e-14	2.82e-11	-0.36	-0.33	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
THCA	cis	rs914615	0.552	rs11264339	ENSG00000160766.13	GBAP1	7.71	7.76e-14	2.82e-11	0.36	0.33	Urinary albumin-to-creatinine ratio;	chr1:155168172	chr1:155213821~155227422:-
THCA	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	7.71	7.78e-14	2.83e-11	0.39	0.33	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
THCA	cis	rs11673344	0.562	rs6510580	ENSG00000226686.6	LINC01535	7.71	7.79e-14	2.83e-11	0.37	0.33	Obesity-related traits;	chr19:37038452	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs2082009	ENSG00000226686.6	LINC01535	7.71	7.79e-14	2.83e-11	0.37	0.33	Obesity-related traits;	chr19:37039834	chr19:37251912~37265535:+
THCA	cis	rs10208649	0.831	rs76039968	ENSG00000272156.1	RP11-477N3.1	7.71	7.79e-14	2.83e-11	0.7	0.33	Body mass index;	chr2:53694900	chr2:54082554~54085066:+
THCA	cis	rs1850744	0.536	rs2037313	ENSG00000250942.1	ENPP7P11	7.71	7.81e-14	2.84e-11	0.43	0.33	Economic and political preferences;	chr4:9723087	chr4:9677308~9677934:+
THCA	cis	rs10208649	1	rs75213010	ENSG00000272156.1	RP11-477N3.1	7.71	7.81e-14	2.84e-11	0.71	0.33	Body mass index;	chr2:53709320	chr2:54082554~54085066:+
THCA	cis	rs11673344	0.523	rs2082010	ENSG00000226686.6	LINC01535	7.7	7.83e-14	2.85e-11	0.37	0.33	Obesity-related traits;	chr19:37039874	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.563	rs55825113	ENSG00000226686.6	LINC01535	7.7	7.84e-14	2.85e-11	0.37	0.33	Obesity-related traits;	chr19:37191523	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	7.7	7.85e-14	2.85e-11	0.43	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
THCA	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-7.7	7.86e-14	2.86e-11	-0.32	-0.33	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
THCA	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-7.7	7.89e-14	2.87e-11	-0.67	-0.33	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-7.7	7.9e-14	2.87e-11	-0.63	-0.33	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
THCA	cis	rs1949733	0.666	rs3103070	ENSG00000205959.3	RP11-689P11.2	7.7	7.9e-14	2.87e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8507098	chr4:8482270~8512610:+
THCA	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	7.7	7.91e-14	2.87e-11	0.38	0.33	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
THCA	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	7.7	7.91e-14	2.87e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
THCA	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	7.7	7.91e-14	2.88e-11	0.2	0.33	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
THCA	cis	rs66823261	0.741	rs7841786	ENSG00000223508.5	RPL23AP53	7.7	7.97e-14	2.9e-11	0.42	0.33	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:213186~232231:-
THCA	cis	rs7191700	0.511	rs12923756	ENSG00000262703.1	RP11-485G7.6	-7.7	7.98e-14	2.9e-11	-0.37	-0.33	Multiple sclerosis;	chr16:11265818	chr16:11348143~11349321:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-7.7	7.98e-14	2.9e-11	-0.49	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
THCA	cis	rs9400467	0.528	rs456865	ENSG00000230177.1	RP5-1112D6.4	-7.7	7.99e-14	2.9e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs1676863	ENSG00000230177.1	RP5-1112D6.4	-7.7	7.99e-14	2.9e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111277932~111278742:+
THCA	cis	rs10208649	1	rs10188834	ENSG00000272156.1	RP11-477N3.1	7.7	8.02e-14	2.92e-11	0.62	0.33	Body mass index;	chr2:53937236	chr2:54082554~54085066:+
THCA	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	7.7	8.03e-14	2.92e-11	0.45	0.33	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
THCA	cis	rs172166	0.516	rs2791333	ENSG00000219392.1	RP1-265C24.5	-7.7	8.03e-14	2.92e-11	-0.37	-0.33	Cardiac Troponin-T levels;	chr6:28143336	chr6:28115628~28116551:+
THCA	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	7.7	8.04e-14	2.92e-11	0.31	0.33	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
THCA	cis	rs10971721	0.822	rs56160720	ENSG00000260947.1	RP11-384P7.7	7.7	8.07e-14	2.93e-11	0.82	0.33	Body mass index;	chr9:33899827	chr9:33697459~33700986:+
THCA	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	7.7	8.08e-14	2.94e-11	0.42	0.33	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
THCA	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-7.7	8.09e-14	2.94e-11	-0.51	-0.33	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
THCA	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-7.7	8.09e-14	2.94e-11	-0.51	-0.33	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
THCA	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-7.7	8.09e-14	2.94e-11	-0.51	-0.33	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
THCA	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-7.7	8.09e-14	2.94e-11	-0.51	-0.33	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
THCA	cis	rs1043099	0.571	rs5753111	ENSG00000279699.1	RP1-102K2.9	-7.7	8.11e-14	2.94e-11	-0.42	-0.33	Rheumatoid arthritis;	chr22:30383222	chr22:30275215~30276951:-
THCA	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	7.7	8.12e-14	2.95e-11	0.4	0.33	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
THCA	cis	rs4950322	0.57	rs4950315	ENSG00000237188.3	RP11-337C18.8	-7.7	8.12e-14	2.95e-11	-0.42	-0.33	Protein quantitative trait loci;	chr1:147264433	chr1:147172771~147211568:+
THCA	cis	rs10411161	0.671	rs10412377	ENSG00000269483.1	AC006272.1	-7.7	8.12e-14	2.95e-11	-0.43	-0.33	Breast cancer;	chr19:51847419	chr19:51839924~51843324:-
THCA	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	7.7	8.13e-14	2.95e-11	0.43	0.33	Height;	chr6:109351533	chr6:109382795~109383666:+
THCA	cis	rs7942368	0.818	rs10793194	ENSG00000254761.1	RP11-672A2.1	7.7	8.14e-14	2.96e-11	0.47	0.33	Endometriosis;	chr11:76764685	chr11:76712396~76719608:-
THCA	cis	rs66887589	0.776	rs10518337	ENSG00000245958.5	RP11-33B1.1	7.7	8.15e-14	2.96e-11	0.29	0.33	Diastolic blood pressure;	chr4:119653719	chr4:119454791~119552025:+
THCA	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-7.7	8.16e-14	2.96e-11	-0.36	-0.33	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
THCA	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	7.7	8.17e-14	2.97e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
THCA	cis	rs7727544	0.606	rs17622208	ENSG00000224431.1	AC063976.7	7.7	8.18e-14	2.97e-11	0.29	0.33	Blood metabolite levels;	chr5:132381358	chr5:132199456~132203487:+
THCA	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	7.7	8.18e-14	2.97e-11	0.43	0.33	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
THCA	cis	rs6496932	0.503	rs4842882	ENSG00000218052.5	ADAMTS7P4	-7.7	8.2e-14	2.98e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85440952	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.503	rs7176605	ENSG00000218052.5	ADAMTS7P4	-7.7	8.2e-14	2.98e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85443491	chr15:85255369~85330334:-
THCA	cis	rs8081395	0.729	rs12453125	ENSG00000266992.1	DHX40P1	-7.7	8.2e-14	2.98e-11	-0.39	-0.33	White blood cell count;	chr17:59968715	chr17:59976009~60002384:-
THCA	cis	rs2288884	0.505	rs12459170	ENSG00000275055.1	CTC-471J1.11	-7.7	8.23e-14	2.99e-11	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51955005	chr19:52049007~52049754:+
THCA	cis	rs17684571	0.751	rs6934714	ENSG00000231441.1	RP11-472M19.2	7.7	8.23e-14	2.99e-11	0.41	0.33	Schizophrenia;	chr6:56821811	chr6:56844002~56864078:+
THCA	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-7.7	8.25e-14	2.99e-11	-0.22	-0.33	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
THCA	cis	rs9400467	0.528	rs6933627	ENSG00000230177.1	RP5-1112D6.4	-7.7	8.26e-14	3e-11	-0.27	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111277932~111278742:+
THCA	cis	rs801193	0.66	rs2659914	ENSG00000232559.3	GS1-124K5.12	7.7	8.29e-14	3.01e-11	0.31	0.33	Aortic root size;	chr7:66691927	chr7:66554588~66576923:-
THCA	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	7.7	8.29e-14	3.01e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
THCA	cis	rs9902453	0.765	rs9890747	ENSG00000264007.1	RP11-68I3.10	7.7	8.29e-14	3.01e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29680424	chr17:29621617~29622254:-
THCA	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	7.7	8.33e-14	3.02e-11	0.4	0.33	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
THCA	cis	rs10971721	1	rs10971721	ENSG00000260947.1	RP11-384P7.7	7.7	8.33e-14	3.02e-11	0.8	0.33	Body mass index;	chr9:33827696	chr9:33697459~33700986:+
THCA	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-7.7	8.35e-14	3.03e-11	-0.42	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-7.7	8.35e-14	3.03e-11	-0.42	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
THCA	cis	rs11673344	0.542	rs826327	ENSG00000226686.6	LINC01535	7.7	8.36e-14	3.03e-11	0.37	0.33	Obesity-related traits;	chr19:37004397	chr19:37251912~37265535:+
THCA	cis	rs9902453	0.935	rs4310926	ENSG00000264007.1	RP11-68I3.10	7.7	8.38e-14	3.04e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30106257	chr17:29621617~29622254:-
THCA	cis	rs2466254	0.657	rs2460351	ENSG00000251468.2	RP11-369K16.1	7.7	8.38e-14	3.04e-11	0.54	0.33	Pneumonia;	chr8:12968785	chr8:12958387~12962200:+
THCA	cis	rs17772222	1	rs74071851	ENSG00000258983.2	RP11-507K2.2	7.7	8.39e-14	3.04e-11	0.43	0.33	Coronary artery calcification;	chr14:88415858	chr14:88499334~88515502:+
THCA	cis	rs910316	0.789	rs175457	ENSG00000279594.1	RP11-950C14.10	-7.69	8.41e-14	3.05e-11	-0.31	-0.33	Height;	chr14:75117804	chr14:75011269~75012851:-
THCA	cis	rs368187	0.71	rs2780303	ENSG00000257826.1	RP11-116N8.4	7.69	8.41e-14	3.05e-11	0.36	0.33	Thyroid cancer;	chr14:36045580	chr14:36061026~36067190:-
THCA	cis	rs8114671	0.562	rs6058120	ENSG00000269202.1	RP4-614O4.12	-7.69	8.42e-14	3.05e-11	-0.28	-0.33	Height;	chr20:34815026	chr20:35201747~35203288:-
THCA	cis	rs180730	1	rs1450479	ENSG00000251609.2	SETP12	7.69	8.43e-14	3.06e-11	0.53	0.33	Fasting plasma glucose;	chr4:120916718	chr4:120895494~120897083:-
THCA	cis	rs12681366	0.839	rs3019282	ENSG00000253704.1	RP11-267M23.4	7.69	8.43e-14	3.06e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94439898	chr8:94553722~94569745:+
THCA	cis	rs9640161	0.789	rs13223702	ENSG00000261305.1	RP4-584D14.7	7.69	8.43e-14	3.06e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150361879	chr7:150341771~150342607:+
THCA	cis	rs11971779	0.527	rs1076349	ENSG00000273391.1	RP11-634H22.1	7.69	8.44e-14	3.06e-11	0.31	0.33	Diisocyanate-induced asthma;	chr7:139441748	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.65	rs4732380	ENSG00000273391.1	RP11-634H22.1	7.69	8.44e-14	3.06e-11	0.31	0.33	Diisocyanate-induced asthma;	chr7:139442113	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs6467853	ENSG00000273391.1	RP11-634H22.1	7.69	8.44e-14	3.06e-11	0.31	0.33	Diisocyanate-induced asthma;	chr7:139442281	chr7:139359032~139359566:-
THCA	cis	rs7942368	0.941	rs10160769	ENSG00000254761.1	RP11-672A2.1	7.69	8.44e-14	3.06e-11	0.47	0.33	Endometriosis;	chr11:76763783	chr11:76712396~76719608:-
THCA	cis	rs11651753	0.561	rs17616603	ENSG00000264920.1	RP11-6N17.4	-7.69	8.44e-14	3.06e-11	-0.3	-0.33	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47882254	chr17:47891255~47895812:-
THCA	cis	rs7208859	0.623	rs9914242	ENSG00000266490.1	CTD-2349P21.9	7.69	8.44e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277964	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11652409	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9896095	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs58920731	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277984	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277986	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs12103588	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.614	rs9914534	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs4131618	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11658344	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9900144	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs11656121	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11650973	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs56085216	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11650305	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11654914	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9914271	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30792372~30792833:+
THCA	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	7.69	8.47e-14	3.07e-11	0.4	0.33	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	7.69	8.47e-14	3.07e-11	0.4	0.33	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	7.69	8.47e-14	3.07e-11	0.4	0.33	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
THCA	cis	rs9400467	0.528	rs465796	ENSG00000230177.1	RP5-1112D6.4	-7.69	8.49e-14	3.08e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111277932~111278742:+
THCA	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-7.69	8.49e-14	3.08e-11	-0.38	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
THCA	cis	rs9902453	0.967	rs28792710	ENSG00000264007.1	RP11-68I3.10	7.69	8.5e-14	3.08e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30122997	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs8074028	ENSG00000264007.1	RP11-68I3.10	7.69	8.5e-14	3.08e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30134669	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs9908901	ENSG00000264007.1	RP11-68I3.10	7.69	8.5e-14	3.08e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30142695	chr17:29621617~29622254:-
THCA	cis	rs7942368	0.941	rs10160769	ENSG00000254632.1	RP11-21L23.4	7.69	8.51e-14	3.08e-11	0.48	0.33	Endometriosis;	chr11:76763783	chr11:76759916~76768223:-
THCA	cis	rs812925	0.537	rs778139	ENSG00000271889.1	RP11-493E12.1	-7.69	8.51e-14	3.09e-11	-0.32	-0.33	Immature fraction of reticulocytes;	chr2:61457429	chr2:61151433~61162105:-
THCA	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-7.69	8.52e-14	3.09e-11	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
THCA	cis	rs42490	0.536	rs365871	ENSG00000251136.7	RP11-37B2.1	-7.69	8.55e-14	3.1e-11	-0.3	-0.33	Leprosy;	chr8:89861458	chr8:89609409~89757727:-
THCA	cis	rs42490	0.536	rs386857	ENSG00000251136.7	RP11-37B2.1	-7.69	8.55e-14	3.1e-11	-0.3	-0.33	Leprosy;	chr8:89862824	chr8:89609409~89757727:-
THCA	cis	rs2712184	0.756	rs2712181	ENSG00000229352.1	AC007563.3	7.69	8.56e-14	3.1e-11	0.39	0.33	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216790146	chr2:216799608~216805335:+
THCA	cis	rs7208859	0.673	rs75142521	ENSG00000264538.5	SUZ12P1	-7.69	8.56e-14	3.1e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30709299~30790908:+
THCA	cis	rs4950322	0.542	rs2883434	ENSG00000237188.3	RP11-337C18.8	7.69	8.58e-14	3.11e-11	0.38	0.33	Protein quantitative trait loci;	chr1:147177505	chr1:147172771~147211568:+
THCA	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	7.69	8.6e-14	3.11e-11	0.3	0.33	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
THCA	cis	rs4950322	0.542	rs1932977	ENSG00000237188.3	RP11-337C18.8	7.69	8.6e-14	3.11e-11	0.39	0.33	Protein quantitative trait loci;	chr1:147217371	chr1:147172771~147211568:+
THCA	cis	rs812925	0.502	rs2053750	ENSG00000271889.1	RP11-493E12.1	-7.69	8.6e-14	3.11e-11	-0.32	-0.33	Immature fraction of reticulocytes;	chr2:61429138	chr2:61151433~61162105:-
THCA	cis	rs9902453	0.933	rs9898353	ENSG00000264007.1	RP11-68I3.10	7.69	8.62e-14	3.12e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30124847	chr17:29621617~29622254:-
THCA	cis	rs829880	0.57	rs4488248	ENSG00000227825.4	SLC9A7P1	7.69	8.64e-14	3.13e-11	0.3	0.33	Colonoscopy-negative controls vs population controls;	chr12:98459910	chr12:98453835~98457145:-
THCA	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-7.69	8.64e-14	3.13e-11	-0.36	-0.33	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-7.69	8.64e-14	3.13e-11	-0.36	-0.33	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-7.69	8.64e-14	3.13e-11	-0.36	-0.33	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
THCA	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-7.69	8.65e-14	3.13e-11	-0.4	-0.33	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
THCA	cis	rs6487679	1	rs6487679	ENSG00000111788.10	RP11-22B23.1	7.69	8.67e-14	3.14e-11	0.4	0.33	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9277235~9313241:+
THCA	cis	rs7208859	0.673	rs11656462	ENSG00000266490.1	CTD-2349P21.9	7.69	8.67e-14	3.14e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs216418	ENSG00000266490.1	CTD-2349P21.9	7.69	8.7e-14	3.15e-11	0.43	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216423	ENSG00000266490.1	CTD-2349P21.9	7.69	8.7e-14	3.15e-11	0.43	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30792372~30792833:+
THCA	cis	rs9543976	0.623	rs9318361	ENSG00000261553.4	RP11-29G8.3	7.69	8.72e-14	3.16e-11	0.4	0.33	Diabetic retinopathy;	chr13:75602944	chr13:75549773~75807120:+
THCA	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	7.69	8.72e-14	3.16e-11	0.29	0.33	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
THCA	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	7.69	8.76e-14	3.17e-11	0.3	0.33	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
THCA	cis	rs7942368	1	rs10437754	ENSG00000254761.1	RP11-672A2.1	7.69	8.76e-14	3.17e-11	0.48	0.33	Endometriosis;	chr11:76766823	chr11:76712396~76719608:-
THCA	cis	rs10411161	0.552	rs2191668	ENSG00000269483.1	AC006272.1	7.69	8.78e-14	3.18e-11	0.48	0.33	Breast cancer;	chr19:51832524	chr19:51839924~51843324:-
THCA	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-7.69	8.8e-14	3.18e-11	-0.29	-0.33	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-7.69	8.8e-14	3.18e-11	-0.29	-0.33	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
THCA	cis	rs9902453	0.967	rs9913074	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30154181	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs7211246	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30158744	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs7216487	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30175624	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs7216494	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30175633	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs1532042	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30177371	chr17:29621617~29622254:-
THCA	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-7.69	8.82e-14	3.19e-11	-0.49	-0.33	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-7.69	8.82e-14	3.19e-11	-0.49	-0.33	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
THCA	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-7.69	8.84e-14	3.2e-11	-0.35	-0.33	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
THCA	cis	rs849141	0.925	rs508347	ENSG00000234336.5	JAZF1-AS1	-7.69	8.84e-14	3.2e-11	-0.37	-0.33	Height;Hip circumference adjusted for BMI;	chr7:28173205	chr7:28180322~28243917:+
THCA	cis	rs2976388	0.647	rs13272904	ENSG00000253741.1	CTD-2292P10.4	-7.69	8.84e-14	3.2e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142701196	chr8:142702252~142726973:-
THCA	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-7.69	8.85e-14	3.2e-11	-0.35	-0.33	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
THCA	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	7.69	8.85e-14	3.2e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
THCA	cis	rs667920	0.573	rs9682783	ENSG00000273486.1	RP11-731C17.2	7.69	8.89e-14	3.21e-11	0.34	0.33	Coronary artery disease;	chr3:136820847	chr3:136837338~136839021:-
THCA	cis	rs7247513	0.639	rs12984441	ENSG00000230310.1	CTD-2192J16.11	-7.69	8.9e-14	3.22e-11	-0.39	-0.33	Bipolar disorder;	chr19:12649473	chr19:12552597~12553644:+
THCA	cis	rs8113308	0.81	rs17695737	ENSG00000269235.1	ZNF350-AS1	7.69	8.91e-14	3.22e-11	0.51	0.33	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:51949134~51981367:+
THCA	cis	rs240993	0.516	rs181294	ENSG00000230177.1	RP5-1112D6.4	-7.69	8.91e-14	3.22e-11	-0.36	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111298999	chr6:111277932~111278742:+
THCA	cis	rs17695224	0.606	rs10411054	ENSG00000269483.1	AC006272.1	7.69	8.91e-14	3.22e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831208	chr19:51839924~51843324:-
THCA	cis	rs10208649	0.831	rs77308271	ENSG00000272156.1	RP11-477N3.1	7.69	8.92e-14	3.22e-11	0.71	0.33	Body mass index;	chr2:54075827	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.831	rs75447473	ENSG00000272156.1	RP11-477N3.1	7.69	8.92e-14	3.22e-11	0.71	0.33	Body mass index;	chr2:54077507	chr2:54082554~54085066:+
THCA	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
THCA	cis	rs6487679	1	rs7298108	ENSG00000111788.10	RP11-22B23.1	-7.69	8.94e-14	3.23e-11	-0.39	-0.33	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9277235~9313241:+
THCA	cis	rs73219805	0.536	rs77690628	ENSG00000228451.3	SDAD1P1	-7.69	8.97e-14	3.24e-11	-0.75	-0.33	Schizophrenia;	chr8:26331707	chr8:26379259~26382953:-
THCA	cis	rs73219805	0.536	rs73217710	ENSG00000228451.3	SDAD1P1	-7.69	8.97e-14	3.24e-11	-0.75	-0.33	Schizophrenia;	chr8:26340717	chr8:26379259~26382953:-
THCA	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	7.69	8.98e-14	3.25e-11	0.34	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
THCA	cis	rs7674212	0.865	rs13149311	ENSG00000251288.2	RP11-10L12.2	-7.69	8.98e-14	3.25e-11	-0.45	-0.33	Type 2 diabetes;	chr4:103056543	chr4:102751401~102752641:+
THCA	cis	rs11971779	0.588	rs2003531	ENSG00000273391.1	RP11-634H22.1	7.69	8.99e-14	3.25e-11	0.32	0.33	Diisocyanate-induced asthma;	chr7:139441832	chr7:139359032~139359566:-
THCA	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-7.68	9e-14	3.25e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-7.68	9e-14	3.25e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
THCA	cis	rs11148252	0.811	rs9536030	ENSG00000278238.1	RP11-245D16.4	7.68	9e-14	3.25e-11	0.38	0.33	Lewy body disease;	chr13:52364156	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.875	rs9596651	ENSG00000278238.1	RP11-245D16.4	7.68	9e-14	3.25e-11	0.38	0.33	Lewy body disease;	chr13:52364447	chr13:52454775~52455331:-
THCA	cis	rs4820539	1	rs6003518	ENSG00000221069.1	AC000029.1	-7.68	9.03e-14	3.26e-11	-0.39	-0.33	Bone mineral density;	chr22:23129346	chr22:23136620~23136710:+
THCA	cis	rs910316	0.934	rs4903278	ENSG00000279594.1	RP11-950C14.10	7.68	9.04e-14	3.27e-11	0.31	0.33	Height;	chr14:75068316	chr14:75011269~75012851:-
THCA	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-7.68	9.04e-14	3.27e-11	-0.42	-0.33	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
THCA	cis	rs11672691	0.829	rs8112363	ENSG00000267107.5	PCAT19	7.68	9.04e-14	3.27e-11	0.35	0.33	Prostate cancer;	chr19:41483803	chr19:41454169~41500649:-
THCA	cis	rs984222	0.501	rs1419289	ENSG00000231365.4	RP11-418J17.1	-7.68	9.05e-14	3.27e-11	-0.32	-0.33	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118944613	chr1:119140396~119275973:+
THCA	cis	rs7714584	1	rs7734778	ENSG00000197083.10	ZNF300P1	7.68	9.05e-14	3.27e-11	0.52	0.33	Crohn's disease;	chr5:150876994	chr5:150930645~150946289:-
THCA	cis	rs270601	0.721	rs162894	ENSG00000233006.5	AC034220.3	7.68	9.06e-14	3.27e-11	0.26	0.33	Acylcarnitine levels;	chr5:132276179	chr5:132311285~132369916:-
THCA	cis	rs77204473	0.744	rs12421425	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117131244	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs17120367	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132112	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs17120370	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132672	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs74735277	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132702	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs75208249	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132907	chr11:117135528~117138582:+
THCA	cis	rs10971721	0.643	rs7040130	ENSG00000281128.1	PTENP1-AS	7.68	9.1e-14	3.29e-11	0.73	0.33	Body mass index;	chr9:33785075	chr9:33677268~33688011:+
THCA	cis	rs28510890	0.75	rs12591974	ENSG00000260337.3	RP11-386M24.6	7.68	9.12e-14	3.29e-11	0.46	0.33	Lung cancer in ever smokers;	chr15:92565541	chr15:92592574~92596462:-
THCA	cis	rs7727544	0.526	rs4705908	ENSG00000237714.1	P4HA2-AS1	7.68	9.13e-14	3.3e-11	0.45	0.33	Blood metabolite levels;	chr5:132011827	chr5:132184876~132192808:+
THCA	cis	rs6908034	0.607	rs79406203	ENSG00000228412.5	RP4-625H18.2	7.68	9.15e-14	3.31e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19815990	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs74559916	ENSG00000228412.5	RP4-625H18.2	7.68	9.15e-14	3.31e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818486	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.505	rs76391302	ENSG00000228412.5	RP4-625H18.2	7.68	9.15e-14	3.31e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818885	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.505	rs77880623	ENSG00000228412.5	RP4-625H18.2	7.68	9.15e-14	3.31e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819223	chr6:19802164~19804752:-
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000264538.5	SUZ12P1	-7.68	9.16e-14	3.31e-11	-0.33	-0.33	Body mass index;	chr17:30806554	chr17:30709299~30790908:+
THCA	cis	rs9902453	0.845	rs3115099	ENSG00000264007.1	RP11-68I3.10	7.68	9.16e-14	3.31e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29692275	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs58606097	ENSG00000264007.1	RP11-68I3.10	7.68	9.16e-14	3.31e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29693361	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs3102559	ENSG00000264007.1	RP11-68I3.10	7.68	9.16e-14	3.31e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29702705	chr17:29621617~29622254:-
THCA	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	7.68	9.2e-14	3.32e-11	0.25	0.33	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
THCA	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-7.68	9.21e-14	3.32e-11	-0.49	-0.33	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
THCA	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	7.68	9.26e-14	3.34e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
THCA	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-7.68	9.27e-14	3.34e-11	-0.36	-0.33	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
THCA	cis	rs686320	1	rs2957267	ENSG00000245532.5	NEAT1	7.68	9.3e-14	3.36e-11	0.31	0.33	Hip circumference adjusted for BMI;	chr11:65468321	chr11:65422774~65445540:+
THCA	cis	rs950169	0.579	rs62027818	ENSG00000259728.4	LINC00933	7.68	9.32e-14	3.36e-11	0.48	0.33	Schizophrenia;	chr15:83992393	chr15:84570649~84580175:+
THCA	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	7.68	9.33e-14	3.36e-11	0.43	0.33	Height;	chr6:109382480	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	7.68	9.33e-14	3.36e-11	0.43	0.33	Height;	chr6:109387972	chr6:109382795~109383666:+
THCA	cis	rs1598856	0.932	rs230530	ENSG00000246560.2	RP11-10L12.4	-7.68	9.34e-14	3.37e-11	-0.4	-0.33	Primary biliary cholangitis;	chr4:102532823	chr4:102828055~102844075:+
THCA	cis	rs1198430	0.789	rs1198423	ENSG00000232482.2	RP4-654C18.1	-7.68	9.36e-14	3.38e-11	-0.57	-0.33	Total cholesterol levels;	chr1:23408748	chr1:23410832~23412146:+
THCA	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-7.68	9.36e-14	3.38e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
THCA	cis	rs10936632	0.565	rs7610584	ENSG00000242578.1	RP11-469J4.3	-7.68	9.37e-14	3.38e-11	-0.38	-0.33	Prostate cancer;	chr3:170435395	chr3:170410512~170418615:+
THCA	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-7.68	9.39e-14	3.39e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
THCA	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	7.68	9.42e-14	3.4e-11	0.4	0.33	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	7.68	9.42e-14	3.4e-11	0.4	0.33	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	7.68	9.42e-14	3.4e-11	0.4	0.33	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	7.68	9.42e-14	3.4e-11	0.4	0.33	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
THCA	cis	rs910316	0.737	rs175080	ENSG00000279594.1	RP11-950C14.10	-7.68	9.44e-14	3.4e-11	-0.31	-0.33	Height;	chr14:75047125	chr14:75011269~75012851:-
THCA	cis	rs7829975	0.559	rs4841025	ENSG00000253893.2	FAM85B	7.68	9.47e-14	3.42e-11	0.42	0.33	Mood instability;	chr8:8745650	chr8:8167819~8226614:-
THCA	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	7.68	9.48e-14	3.42e-11	0.39	0.33	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
THCA	cis	rs1949733	0.701	rs940134	ENSG00000205959.3	RP11-689P11.2	-7.68	9.5e-14	3.42e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8453143	chr4:8482270~8512610:+
THCA	cis	rs1949733	0.701	rs871768	ENSG00000205959.3	RP11-689P11.2	-7.68	9.5e-14	3.42e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8453211	chr4:8482270~8512610:+
THCA	cis	rs77204473	1	rs17120099	ENSG00000254851.1	RP11-109L13.1	7.68	9.5e-14	3.43e-11	0.87	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116864744	chr11:117135528~117138582:+
THCA	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-7.68	9.5e-14	3.43e-11	-0.35	-0.33	QT interval;	chr12:29357436	chr12:29280418~29317848:-
THCA	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-7.68	9.53e-14	3.44e-11	-0.36	-0.33	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
THCA	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	7.68	9.54e-14	3.44e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
THCA	cis	rs801193	0.66	rs974239	ENSG00000232559.3	GS1-124K5.12	7.68	9.58e-14	3.45e-11	0.32	0.33	Aortic root size;	chr7:66748504	chr7:66554588~66576923:-
THCA	cis	rs9543976	0.623	rs7986566	ENSG00000261553.4	RP11-29G8.3	7.68	9.6e-14	3.46e-11	0.4	0.33	Diabetic retinopathy;	chr13:75623795	chr13:75549773~75807120:+
THCA	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-7.68	9.61e-14	3.46e-11	-0.4	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
THCA	cis	rs4780355	0.918	rs243323	ENSG00000262636.1	CTD-3088G3.4	7.68	9.64e-14	3.47e-11	0.44	0.33	Crohn's disease and psoriasis;	chr16:11267345	chr16:11380859~11381118:-
THCA	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	7.68	9.64e-14	3.47e-11	0.36	0.33	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
THCA	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	7.67	9.66e-14	3.48e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
THCA	cis	rs4819052	1	rs9984901	ENSG00000237664.1	LINC00316	-7.67	9.67e-14	3.48e-11	-0.36	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45338590~45341990:-
THCA	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-7.67	9.67e-14	3.48e-11	-0.58	-0.33	Depression;	chr6:28173682	chr6:28115628~28116551:+
THCA	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-7.67	9.67e-14	3.48e-11	-0.58	-0.33	Depression;	chr6:28175340	chr6:28115628~28116551:+
THCA	cis	rs1667284	1	rs1667275	ENSG00000266521.1	RP11-650P15.1	7.67	9.69e-14	3.49e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31633302	chr18:31496645~31497195:-
THCA	cis	rs7945705	0.806	rs12224436	ENSG00000254860.4	TMEM9B-AS1	-7.67	9.7e-14	3.49e-11	-0.37	-0.33	Hemoglobin concentration;	chr11:8794278	chr11:8964675~8977527:+
THCA	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	7.67	9.72e-14	3.5e-11	0.42	0.33	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
THCA	cis	rs1150668	1	rs1150668	ENSG00000219392.1	RP1-265C24.5	-7.67	9.72e-14	3.5e-11	-0.37	-0.33	Pubertal anthropometrics;	chr6:28162011	chr6:28115628~28116551:+
THCA	cis	rs4591358	0.608	rs72927762	ENSG00000223466.1	AC064834.2	-7.67	9.72e-14	3.5e-11	-0.6	-0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544921	chr2:195533035~195538681:+
THCA	cis	rs34375054	0.66	rs12305181	ENSG00000279233.1	RP11-158L12.4	7.67	9.73e-14	3.5e-11	0.33	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125109610	chr12:125138245~125141711:+
THCA	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	7.67	9.74e-14	3.51e-11	0.43	0.33	Height;	chr6:109769861	chr6:109382795~109383666:+
THCA	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	7.67	9.74e-14	3.51e-11	0.32	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
THCA	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	7.67	9.74e-14	3.51e-11	0.32	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
THCA	cis	rs910316	0.967	rs119076	ENSG00000279594.1	RP11-950C14.10	-7.67	9.75e-14	3.51e-11	-0.31	-0.33	Height;	chr14:75105716	chr14:75011269~75012851:-
THCA	cis	rs12681366	0.801	rs2919657	ENSG00000253704.1	RP11-267M23.4	7.67	9.76e-14	3.52e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94460724	chr8:94553722~94569745:+
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000264538.5	SUZ12P1	-7.67	9.77e-14	3.52e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000264538.5	SUZ12P1	-7.67	9.77e-14	3.52e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30709299~30790908:+
THCA	cis	rs17695224	0.545	rs7252805	ENSG00000269483.1	AC006272.1	7.67	9.8e-14	3.53e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51840169	chr19:51839924~51843324:-
THCA	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-7.67	9.8e-14	3.53e-11	-0.38	-0.33	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
THCA	cis	rs1275468	0.798	rs2366987	ENSG00000257497.2	RP11-585P4.5	-7.67	9.8e-14	3.53e-11	-0.47	-0.33	Polycystic ovary syndrome;	chr12:75536346	chr12:75483454~75489820:-
THCA	cis	rs728616	0.867	rs1923534	ENSG00000225484.5	NUTM2B-AS1	-7.67	9.82e-14	3.53e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12414096	ENSG00000225484.5	NUTM2B-AS1	-7.67	9.82e-14	3.53e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:79663088~79826594:-
THCA	cis	rs728616	0.557	rs17107449	ENSG00000225484.5	NUTM2B-AS1	-7.67	9.82e-14	3.53e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:79663088~79826594:-
THCA	cis	rs9902453	0.757	rs12453308	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30114586	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs60176674	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30152836	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs61014003	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30158215	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs56326816	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30165787	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs4533341	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30168654	chr17:29621617~29622254:-
THCA	cis	rs8114671	0.585	rs2236271	ENSG00000269202.1	RP4-614O4.12	7.67	9.83e-14	3.54e-11	0.29	0.33	Height;	chr20:34936037	chr20:35201747~35203288:-
THCA	cis	rs9388451	0.839	rs3799711	ENSG00000237742.5	RP11-624M8.1	7.67	9.84e-14	3.54e-11	0.29	0.33	Brugada syndrome;	chr6:125754167	chr6:125578558~125749190:-
THCA	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-7.67	9.84e-14	3.54e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
THCA	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	7.67	9.85e-14	3.54e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
THCA	cis	rs10971721	0.908	rs10971722	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33828166	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971723	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33829604	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs12376055	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33831957	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs55684780	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33833210	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs10971728	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33834635	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.642	rs114466241	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33835731	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs12378261	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33837174	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725374	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33840651	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.749	rs72725375	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33840706	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725376	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33841931	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725377	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33842228	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725378	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33842896	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs12380143	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33847588	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725381	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33851167	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971735	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33851801	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.642	rs10971736	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33854376	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.749	rs10971741	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33856869	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs56253239	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33860068	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs115554740	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33860888	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725387	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33863673	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs72725388	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33864624	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs117687546	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33864931	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs56172788	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33865752	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10971750	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33869783	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971753	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33870438	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971754	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33871714	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971755	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33872007	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725398	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33875920	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971758	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33876071	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs72725402	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33878358	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs72727303	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33878378	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971763	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33879779	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971764	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33880102	chr9:33697459~33700986:+
THCA	cis	rs172166	0.56	rs203878	ENSG00000219392.1	RP1-265C24.5	-7.67	9.85e-14	3.55e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28081218	chr6:28115628~28116551:+
THCA	cis	rs9388451	0.872	rs2008027	ENSG00000237742.5	RP11-624M8.1	-7.67	9.88e-14	3.56e-11	-0.29	-0.33	Brugada syndrome;	chr6:125731213	chr6:125578558~125749190:-
THCA	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	7.67	9.89e-14	3.56e-11	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
THCA	cis	rs1667284	0.967	rs895888	ENSG00000266521.1	RP11-650P15.1	7.67	9.89e-14	3.56e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31648224	chr18:31496645~31497195:-
THCA	cis	rs10971721	0.822	rs10971773	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33898781	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971774	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33900111	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727318	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33901802	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10971782	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33909466	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs10971787	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33914414	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727327	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33918818	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971791	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33920912	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971792	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33920955	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727329	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33921666	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs11848	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33921921	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727332	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33929479	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727335	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33931720	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727336	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33931795	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971802	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33933284	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971803	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33933289	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs41314578	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33933943	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs56274755	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33934273	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs118115128	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33935451	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727340	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33936736	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727341	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33936878	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727342	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33938084	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs117733169	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33938101	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727344	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33939122	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971807	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33939557	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727345	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33940200	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727346	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33940420	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727350	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33944732	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727351	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33950434	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727353	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33950824	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971817	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33951886	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10971819	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33954149	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727362	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33957324	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727367	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33965180	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727369	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33965777	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971826	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33972035	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971827	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33972469	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971828	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33973417	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727378	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33975792	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727389	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33987030	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs72727392	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33988921	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727399	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33997271	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971838	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33997948	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.686	rs10971839	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33998410	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729305	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34000293	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729316	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34008175	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971845	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34009879	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971847	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34011460	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971848	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34012504	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971850	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34013910	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10814061	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34014032	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs12380173	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34018500	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs12377970	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34021269	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10971857	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34021621	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs72729329	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34022884	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs10971858	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34023693	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729341	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34031693	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729344	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34034032	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971866	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34043163	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971867	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34046758	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729361	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34047525	chr9:33697459~33700986:+
THCA	cis	rs10181042	0.565	rs2564117	ENSG00000271889.1	RP11-493E12.1	7.67	9.92e-14	3.57e-11	0.31	0.33	Crohn's disease;	chr2:61005887	chr2:61151433~61162105:-
THCA	cis	rs9902453	0.967	rs1906450	ENSG00000264007.1	RP11-68I3.10	7.67	9.94e-14	3.57e-11	0.39	0.33	Coffee consumption (cups per day);	chr17:30188726	chr17:29621617~29622254:-
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000219392.1	RP1-265C24.5	-7.67	9.94e-14	3.57e-11	-0.37	-0.33	Pubertal anthropometrics;	chr6:28128502	chr6:28115628~28116551:+
THCA	cis	rs9640161	0.789	rs11767409	ENSG00000261305.1	RP4-584D14.7	7.67	9.95e-14	3.58e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150360954	chr7:150341771~150342607:+
THCA	cis	rs934734	0.563	rs11126034	ENSG00000281920.1	RP11-418H16.1	-7.67	9.96e-14	3.58e-11	-0.43	-0.33	Rheumatoid arthritis;	chr2:65353087	chr2:65623272~65628424:+
THCA	cis	rs8081395	0.834	rs11650106	ENSG00000266992.1	DHX40P1	-7.67	9.96e-14	3.58e-11	-0.39	-0.33	White blood cell count;	chr17:59772890	chr17:59976009~60002384:-
THCA	cis	rs11148252	0.875	rs4885953	ENSG00000278238.1	RP11-245D16.4	-7.67	9.97e-14	3.58e-11	-0.38	-0.33	Lewy body disease;	chr13:52402356	chr13:52454775~52455331:-
THCA	cis	rs12681366	0.839	rs2931632	ENSG00000253704.1	RP11-267M23.4	7.67	9.98e-14	3.59e-11	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:94553722~94569745:+
THCA	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	7.67	9.98e-14	3.59e-11	0.43	0.33	Height;	chr6:109403951	chr6:109382795~109383666:+
THCA	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	7.67	9.98e-14	3.59e-11	0.4	0.33	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
THCA	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	7.67	1e-13	3.59e-11	0.38	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
THCA	cis	rs7176527	1	rs3762168	ENSG00000188388.10	GOLGA6L3	7.67	1e-13	3.6e-11	0.5	0.33	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85240472~85247170:+
THCA	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	7.67	1e-13	3.6e-11	0.41	0.33	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
THCA	cis	rs10971721	0.822	rs72725392	ENSG00000260947.1	RP11-384P7.7	7.67	1e-13	3.61e-11	0.82	0.33	Body mass index;	chr9:33867780	chr9:33697459~33700986:+
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000264538.5	SUZ12P1	-7.67	1e-13	3.61e-11	-0.33	-0.33	Body mass index;	chr17:30741407	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000264538.5	SUZ12P1	-7.67	1e-13	3.61e-11	-0.33	-0.33	Body mass index;	chr17:30745674	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000264538.5	SUZ12P1	-7.67	1e-13	3.61e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30709299~30790908:+
THCA	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-7.67	1e-13	3.61e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-7.67	1e-13	3.61e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
THCA	cis	rs4718428	1	rs4718428	ENSG00000273142.1	RP11-458F8.4	-7.67	1e-13	3.61e-11	-0.27	-0.33	Corneal structure;	chr7:66956459	chr7:66902857~66906297:+
THCA	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-7.67	1.01e-13	3.61e-11	-0.42	-0.33	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
THCA	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	7.67	1.01e-13	3.61e-11	0.32	0.33	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
THCA	cis	rs16846053	0.515	rs971027	ENSG00000227403.1	AC009299.3	-7.67	1.01e-13	3.61e-11	-0.53	-0.33	Blood osmolality (transformed sodium);	chr2:161588104	chr2:161244739~161249050:+
THCA	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	7.67	1.01e-13	3.62e-11	0.4	0.33	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
THCA	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	7.67	1.01e-13	3.62e-11	0.33	0.33	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
THCA	cis	rs10971721	0.584	rs72731221	ENSG00000260947.1	RP11-384P7.7	7.67	1.01e-13	3.63e-11	0.75	0.33	Body mass index;	chr9:34122376	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731222	ENSG00000260947.1	RP11-384P7.7	7.67	1.01e-13	3.63e-11	0.75	0.33	Body mass index;	chr9:34122864	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971939	ENSG00000260947.1	RP11-384P7.7	7.67	1.01e-13	3.63e-11	0.75	0.33	Body mass index;	chr9:34123437	chr9:33697459~33700986:+
THCA	cis	rs2976388	0.647	rs2572898	ENSG00000253741.1	CTD-2292P10.4	-7.67	1.01e-13	3.63e-11	-0.42	-0.33	Urinary tract infection frequency;	chr8:142700856	chr8:142702252~142726973:-
THCA	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-7.67	1.01e-13	3.64e-11	-0.36	-0.33	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
THCA	cis	rs7665090	0.603	rs17033015	ENSG00000246560.2	RP11-10L12.4	7.67	1.01e-13	3.64e-11	0.4	0.33	Primary biliary cholangitis;	chr4:102625147	chr4:102828055~102844075:+
THCA	cis	rs2522056	1	rs2057655	ENSG00000233006.5	AC034220.3	7.67	1.01e-13	3.64e-11	0.29	0.33	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132311285~132369916:-
THCA	cis	rs748404	0.516	rs523156	ENSG00000166763.7	STRCP1	-7.67	1.02e-13	3.64e-11	-0.36	-0.33	Lung cancer;	chr15:43519645	chr15:43699488~43718184:-
THCA	cis	rs7208859	0.623	rs58908911	ENSG00000266490.1	CTD-2349P21.9	7.67	1.02e-13	3.65e-11	0.49	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30792372~30792833:+
THCA	cis	rs7302981	0.741	rs76919525	ENSG00000272368.2	RP4-605O3.4	-7.67	1.02e-13	3.65e-11	-0.21	-0.33	Systolic blood pressure;	chr12:50147950	chr12:50112197~50165618:+
THCA	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	7.67	1.02e-13	3.65e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
THCA	cis	rs12681366	0.839	rs3019278	ENSG00000253704.1	RP11-267M23.4	7.67	1.02e-13	3.66e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.839	rs2930964	ENSG00000253704.1	RP11-267M23.4	7.67	1.02e-13	3.66e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94553722~94569745:+
THCA	cis	rs2408955	0.522	rs4760612	ENSG00000258273.1	RP11-370I10.4	7.67	1.02e-13	3.67e-11	0.44	0.33	Glycated hemoglobin levels;	chr12:48028073	chr12:48333755~48333901:-
THCA	cis	rs5769707	0.681	rs2071902	ENSG00000235111.1	RP1-29C18.8	-7.67	1.02e-13	3.68e-11	-0.44	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49612657~49615716:-
THCA	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	7.67	1.03e-13	3.69e-11	0.41	0.33	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
THCA	cis	rs7267979	0.903	rs6132819	ENSG00000274414.1	RP5-965G21.4	-7.67	1.03e-13	3.7e-11	-0.4	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25239007~25245229:-
THCA	cis	rs4784934	0.879	rs9931547	ENSG00000260186.4	RP11-481J2.2	7.67	1.03e-13	3.71e-11	0.49	0.33	QT interval;	chr16:58432203	chr16:58421326~58462470:+
THCA	cis	rs736801	0.808	rs2522057	ENSG00000237714.1	P4HA2-AS1	7.66	1.04e-13	3.72e-11	0.44	0.33	Mosquito bite size;Breast cancer;	chr5:132466255	chr5:132184876~132192808:+
THCA	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	7.66	1.04e-13	3.72e-11	0.31	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
THCA	cis	rs10971721	0.584	rs10971900	ENSG00000260947.1	RP11-384P7.7	7.66	1.04e-13	3.74e-11	0.77	0.33	Body mass index;	chr9:34085079	chr9:33697459~33700986:+
THCA	cis	rs853679	1	rs11965538	ENSG00000219392.1	RP1-265C24.5	-7.66	1.04e-13	3.74e-11	-0.53	-0.33	Depression;	chr6:28272137	chr6:28115628~28116551:+
THCA	cis	rs853679	0.882	rs2743555	ENSG00000219392.1	RP1-265C24.5	-7.66	1.04e-13	3.74e-11	-0.53	-0.33	Depression;	chr6:28273304	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs1419183	ENSG00000219392.1	RP1-265C24.5	-7.66	1.04e-13	3.74e-11	-0.53	-0.33	Depression;	chr6:28275017	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs6901575	ENSG00000219392.1	RP1-265C24.5	-7.66	1.04e-13	3.74e-11	-0.53	-0.33	Depression;	chr6:28283207	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs1679709	ENSG00000219392.1	RP1-265C24.5	7.66	1.04e-13	3.74e-11	0.53	0.33	Depression;	chr6:28260564	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs1778511	ENSG00000219392.1	RP1-265C24.5	7.66	1.04e-13	3.74e-11	0.53	0.33	Depression;	chr6:28261633	chr6:28115628~28116551:+
THCA	cis	rs1949733	0.701	rs4696828	ENSG00000205959.3	RP11-689P11.2	7.66	1.05e-13	3.77e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8453877	chr4:8482270~8512610:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000219392.1	RP1-265C24.5	-7.66	1.05e-13	3.77e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28164978	chr6:28115628~28116551:+
THCA	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	7.66	1.05e-13	3.77e-11	0.43	0.33	Height;	chr6:109339681	chr6:109382795~109383666:+
THCA	cis	rs516805	0.748	rs155458	ENSG00000279453.1	RP3-425C14.4	7.66	1.05e-13	3.77e-11	0.34	0.33	Lymphocyte counts;	chr6:122493636	chr6:122436789~122439223:-
THCA	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-7.66	1.06e-13	3.78e-11	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
THCA	cis	rs10971721	0.822	rs56370320	ENSG00000260947.1	RP11-384P7.7	7.66	1.06e-13	3.79e-11	0.81	0.33	Body mass index;	chr9:33865630	chr9:33697459~33700986:+
THCA	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
THCA	cis	rs9649213	0.574	rs7802560	ENSG00000272950.1	RP11-307C18.1	-7.66	1.06e-13	3.79e-11	-0.41	-0.33	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr7:98322853~98323430:+
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000264538.5	SUZ12P1	-7.66	1.06e-13	3.79e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30709299~30790908:+
THCA	cis	rs7851660	0.548	rs1156850	ENSG00000236130.1	PTCSC2	-7.66	1.06e-13	3.79e-11	-0.27	-0.33	Strep throat;	chr9:97810882	chr9:97805935~97810008:-
THCA	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	7.66	1.06e-13	3.8e-11	0.43	0.33	Height;	chr6:109381443	chr6:109382795~109383666:+
THCA	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-7.66	1.06e-13	3.8e-11	-0.42	-0.33	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
THCA	cis	rs11024102	0.83	rs11024110	ENSG00000184669.7	OR7E14P	-7.66	1.06e-13	3.8e-11	-0.43	-0.33	Glaucoma (primary angle closure);	chr11:17006843	chr11:17013998~17053024:+
THCA	cis	rs9329221	0.506	rs6993610	ENSG00000261451.1	RP11-981G7.1	-7.66	1.06e-13	3.8e-11	-0.43	-0.33	Neuroticism;	chr8:10473484	chr8:10433672~10438312:+
THCA	cis	rs2466254	0.657	rs2466265	ENSG00000251468.2	RP11-369K16.1	7.66	1.06e-13	3.81e-11	0.54	0.33	Pneumonia;	chr8:12972212	chr8:12958387~12962200:+
THCA	cis	rs6496932	0.503	rs8037726	ENSG00000218052.5	ADAMTS7P4	-7.66	1.06e-13	3.81e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85255369~85330334:-
THCA	cis	rs2562456	0.917	rs2650804	ENSG00000268555.1	RP11-678G14.3	7.66	1.07e-13	3.82e-11	0.46	0.33	Pain;	chr19:21497382	chr19:21570822~21587322:-
THCA	cis	rs8062405	0.558	rs151228	ENSG00000251417.2	RP11-1348G14.4	-7.66	1.07e-13	3.82e-11	-0.31	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28802743~28817828:+
THCA	cis	rs6908034	0.556	rs79028848	ENSG00000228412.5	RP4-625H18.2	7.66	1.07e-13	3.82e-11	0.8	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782922	chr6:19802164~19804752:-
THCA	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-7.66	1.07e-13	3.83e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
THCA	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-7.66	1.07e-13	3.84e-11	-0.38	-0.33	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
THCA	cis	rs9400467	0.528	rs10872066	ENSG00000230177.1	RP5-1112D6.4	-7.66	1.07e-13	3.84e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111277932~111278742:+
THCA	cis	rs2712184	0.721	rs2541401	ENSG00000229352.1	AC007563.3	-7.66	1.07e-13	3.84e-11	-0.4	-0.33	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216776283	chr2:216799608~216805335:+
THCA	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	7.66	1.08e-13	3.86e-11	0.38	0.33	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
THCA	cis	rs17684571	0.872	rs13219546	ENSG00000231441.1	RP11-472M19.2	7.66	1.08e-13	3.86e-11	0.42	0.33	Schizophrenia;	chr6:56741480	chr6:56844002~56864078:+
THCA	cis	rs2284219	0.964	rs2284218	ENSG00000196295.10	AC005154.6	-7.66	1.08e-13	3.86e-11	-0.24	-0.33	Type 2 diabetes;	chr7:30674717	chr7:30516309~30594809:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000206090.4	AP000350.7	7.66	1.08e-13	3.86e-11	0.42	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23939998~23942798:+
THCA	cis	rs7942368	0.941	rs10899279	ENSG00000254632.1	RP11-21L23.4	7.66	1.08e-13	3.86e-11	0.48	0.33	Endometriosis;	chr11:76766200	chr11:76759916~76768223:-
THCA	cis	rs66823261	0.778	rs2906332	ENSG00000223508.5	RPL23AP53	7.66	1.08e-13	3.87e-11	0.43	0.33	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:213186~232231:-
THCA	cis	rs2562456	0.833	rs8106025	ENSG00000268555.1	RP11-678G14.3	-7.66	1.08e-13	3.88e-11	-0.47	-0.33	Pain;	chr19:21451922	chr19:21570822~21587322:-
THCA	cis	rs9543976	0.623	rs9544004	ENSG00000261553.4	RP11-29G8.3	7.66	1.08e-13	3.88e-11	0.4	0.33	Diabetic retinopathy;	chr13:75617748	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.588	rs7324195	ENSG00000261553.4	RP11-29G8.3	7.66	1.08e-13	3.88e-11	0.4	0.33	Diabetic retinopathy;	chr13:75618386	chr13:75549773~75807120:+
THCA	cis	rs10411161	0.748	rs56705839	ENSG00000269483.1	AC006272.1	7.66	1.09e-13	3.89e-11	0.54	0.33	Breast cancer;	chr19:51873983	chr19:51839924~51843324:-
THCA	cis	rs9329221	0.527	rs4841351	ENSG00000261451.1	RP11-981G7.1	-7.66	1.09e-13	3.89e-11	-0.43	-0.33	Neuroticism;	chr8:10469857	chr8:10433672~10438312:+
THCA	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-7.66	1.09e-13	3.9e-11	-0.84	-0.33	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
THCA	cis	rs2288884	0.505	rs8110213	ENSG00000275055.1	CTC-471J1.11	-7.66	1.09e-13	3.9e-11	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51958730	chr19:52049007~52049754:+
THCA	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	7.66	1.09e-13	3.9e-11	0.2	0.33	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
THCA	cis	rs737008	0.922	rs376374	ENSG00000262703.1	RP11-485G7.6	-7.66	1.09e-13	3.91e-11	-0.38	-0.33	Obesity-related traits;	chr16:11276759	chr16:11348143~11349321:-
THCA	cis	rs13129231	0.847	rs12499647	ENSG00000206820.1	RNU1-138P	-7.66	1.09e-13	3.91e-11	-0.38	-0.33	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113447561	chr4:113420323~113420486:+
THCA	cis	rs8062405	0.54	rs151226	ENSG00000251417.2	RP11-1348G14.4	-7.66	1.09e-13	3.92e-11	-0.31	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28802743~28817828:+
THCA	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	7.66	1.1e-13	3.92e-11	0.4	0.33	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
THCA	cis	rs9902453	0.933	rs4470197	ENSG00000264007.1	RP11-68I3.10	7.66	1.1e-13	3.93e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30137456	chr17:29621617~29622254:-
THCA	cis	rs75422866	0.558	rs73104190	ENSG00000257433.4	RP1-197B17.3	7.66	1.1e-13	3.93e-11	0.5	0.33	Pneumonia;	chr12:47716040	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs73104197	ENSG00000257433.4	RP1-197B17.3	7.66	1.1e-13	3.93e-11	0.5	0.33	Pneumonia;	chr12:47717273	chr12:47706085~47742294:+
THCA	cis	rs4819052	1	rs13052356	ENSG00000237664.1	LINC00316	-7.66	1.1e-13	3.95e-11	-0.36	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45338590~45341990:-
THCA	cis	rs10971721	0.584	rs55857848	ENSG00000260947.1	RP11-384P7.7	7.66	1.1e-13	3.95e-11	0.75	0.33	Body mass index;	chr9:34121512	chr9:33697459~33700986:+
THCA	cis	rs748404	0.56	rs689797	ENSG00000166763.7	STRCP1	7.65	1.11e-13	3.97e-11	0.36	0.33	Lung cancer;	chr15:43534359	chr15:43699488~43718184:-
THCA	cis	rs748404	0.56	rs2255663	ENSG00000166763.7	STRCP1	-7.65	1.11e-13	3.97e-11	-0.36	-0.33	Lung cancer;	chr15:43536810	chr15:43699488~43718184:-
THCA	cis	rs42490	0.536	rs400571	ENSG00000251136.7	RP11-37B2.1	-7.65	1.11e-13	3.97e-11	-0.3	-0.33	Leprosy;	chr8:89863336	chr8:89609409~89757727:-
THCA	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-7.65	1.11e-13	3.97e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000264538.5	SUZ12P1	-7.65	1.11e-13	3.97e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30709299~30790908:+
THCA	cis	rs172166	0.516	rs2622322	ENSG00000219392.1	RP1-265C24.5	-7.65	1.11e-13	3.98e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28149665	chr6:28115628~28116551:+
THCA	cis	rs11148252	0.875	rs9568728	ENSG00000278238.1	RP11-245D16.4	-7.65	1.11e-13	3.98e-11	-0.38	-0.33	Lewy body disease;	chr13:52372458	chr13:52454775~52455331:-
THCA	cis	rs2929278	0.617	rs3087657	ENSG00000166763.7	STRCP1	7.65	1.12e-13	3.99e-11	0.37	0.33	Schizophrenia;	chr15:43771661	chr15:43699488~43718184:-
THCA	cis	rs11148252	0.538	rs2274202	ENSG00000235660.1	LINC00345	-7.65	1.12e-13	4e-11	-0.41	-0.33	Lewy body disease;	chr13:52148663	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.538	rs9526842	ENSG00000235660.1	LINC00345	-7.65	1.12e-13	4e-11	-0.41	-0.33	Lewy body disease;	chr13:52153588	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.538	rs9535887	ENSG00000235660.1	LINC00345	-7.65	1.12e-13	4e-11	-0.41	-0.33	Lewy body disease;	chr13:52156626	chr13:52484161~52484680:-
THCA	cis	rs9902453	0.967	rs1906451	ENSG00000264007.1	RP11-68I3.10	7.65	1.12e-13	4.01e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30188461	chr17:29621617~29622254:-
THCA	cis	rs172166	0.61	rs276369	ENSG00000219392.1	RP1-265C24.5	-7.65	1.12e-13	4.01e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:27951465	chr6:28115628~28116551:+
THCA	cis	rs193541	0.632	rs246276	ENSG00000263432.2	RN7SL689P	7.65	1.13e-13	4.02e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122904262	chr5:123022487~123022783:-
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000237664.1	LINC00316	-7.65	1.13e-13	4.03e-11	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45338590~45341990:-
THCA	cis	rs8113308	0.81	rs8104626	ENSG00000269235.1	ZNF350-AS1	7.65	1.13e-13	4.04e-11	0.52	0.33	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51977364	chr19:51949134~51981367:+
THCA	cis	rs5769707	0.681	rs8140095	ENSG00000235111.1	RP1-29C18.8	-7.65	1.13e-13	4.04e-11	-0.44	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49612657~49615716:-
THCA	cis	rs9500256	0.903	rs726783	ENSG00000215190.7	LINC00680	-7.65	1.13e-13	4.04e-11	-0.38	-0.33	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57946074~57961501:-
THCA	cis	rs516805	0.748	rs11154070	ENSG00000279453.1	RP3-425C14.4	7.65	1.13e-13	4.04e-11	0.34	0.33	Lymphocyte counts;	chr6:122362886	chr6:122436789~122439223:-
THCA	cis	rs934734	0.563	rs1858036	ENSG00000281920.1	RP11-418H16.1	7.65	1.14e-13	4.06e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65371107	chr2:65623272~65628424:+
THCA	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-7.65	1.14e-13	4.07e-11	-0.36	-0.33	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-7.65	1.14e-13	4.07e-11	-0.36	-0.33	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-7.65	1.14e-13	4.07e-11	-0.36	-0.33	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
THCA	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	7.65	1.14e-13	4.08e-11	0.45	0.33	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
THCA	cis	rs8114671	0.539	rs2064453	ENSG00000269202.1	RP4-614O4.12	-7.65	1.15e-13	4.09e-11	-0.29	-0.33	Height;	chr20:34873007	chr20:35201747~35203288:-
THCA	cis	rs686320	1	rs1787666	ENSG00000245532.5	NEAT1	7.65	1.15e-13	4.09e-11	0.3	0.33	Hip circumference adjusted for BMI;	chr11:65481618	chr11:65422774~65445540:+
THCA	cis	rs728616	0.867	rs723191	ENSG00000225484.5	NUTM2B-AS1	-7.65	1.15e-13	4.09e-11	-0.63	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs723193	ENSG00000225484.5	NUTM2B-AS1	-7.65	1.15e-13	4.09e-11	-0.63	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:79663088~79826594:-
THCA	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-7.65	1.15e-13	4.1e-11	-0.47	-0.33	Depression;	chr6:27871968	chr6:28115628~28116551:+
THCA	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-7.65	1.15e-13	4.11e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
THCA	cis	rs7942368	0.818	rs10793194	ENSG00000254632.1	RP11-21L23.4	7.65	1.15e-13	4.12e-11	0.48	0.33	Endometriosis;	chr11:76764685	chr11:76759916~76768223:-
THCA	cis	rs11603691	1	rs2155232	ENSG00000254662.1	RP11-872D17.4	-7.65	1.15e-13	4.12e-11	-0.59	-0.33	Low high density lipoprotein cholesterol levels;	chr11:57273904	chr11:57325603~57327958:+
THCA	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	7.65	1.16e-13	4.13e-11	0.42	0.33	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
THCA	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	7.65	1.16e-13	4.13e-11	0.42	0.33	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
THCA	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-7.65	1.16e-13	4.14e-11	-0.36	-0.33	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
THCA	cis	rs11148252	0.875	rs7987115	ENSG00000278238.1	RP11-245D16.4	-7.65	1.16e-13	4.14e-11	-0.37	-0.33	Lewy body disease;	chr13:52387962	chr13:52454775~52455331:-
THCA	cis	rs10971721	0.822	rs12376279	ENSG00000260947.1	RP11-384P7.7	7.65	1.16e-13	4.14e-11	0.81	0.33	Body mass index;	chr9:33804256	chr9:33697459~33700986:+
THCA	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-7.65	1.16e-13	4.14e-11	-0.36	-0.33	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
THCA	cis	rs9902453	0.9	rs9910970	ENSG00000264007.1	RP11-68I3.10	7.65	1.16e-13	4.14e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30151311	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs8079028	ENSG00000264007.1	RP11-68I3.10	7.65	1.16e-13	4.14e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30157216	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.833	rs7216631	ENSG00000264007.1	RP11-68I3.10	7.65	1.16e-13	4.14e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30168094	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.868	rs9902340	ENSG00000264007.1	RP11-68I3.10	-7.65	1.16e-13	4.14e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30149440	chr17:29621617~29622254:-
THCA	cis	rs1667284	1	rs1667284	ENSG00000266521.1	RP11-650P15.1	-7.65	1.16e-13	4.14e-11	-0.42	-0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31646245	chr18:31496645~31497195:-
THCA	cis	rs17695224	0.545	rs10500309	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51829123	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs8111469	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51829272	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.565	rs61681419	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51830726	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs13346095	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831092	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs13346104	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831173	chr19:51839924~51843324:-
THCA	cis	rs860295	0.871	rs12724079	ENSG00000225855.5	RUSC1-AS1	-7.65	1.16e-13	4.15e-11	-0.21	-0.33	Body mass index;	chr1:155464151	chr1:155316863~155324176:-
THCA	cis	rs922182	0.663	rs7180057	ENSG00000275785.1	RP11-111E14.2	7.65	1.17e-13	4.16e-11	0.39	0.33	Blood protein levels;	chr15:63971596	chr15:63890030~63890317:+
THCA	cis	rs6496932	0.503	rs10520588	ENSG00000218052.5	ADAMTS7P4	-7.65	1.17e-13	4.17e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85255369~85330334:-
THCA	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-7.65	1.17e-13	4.18e-11	-0.41	-0.33	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
THCA	cis	rs11673344	0.542	rs1667380	ENSG00000226686.6	LINC01535	7.65	1.17e-13	4.19e-11	0.37	0.33	Obesity-related traits;	chr19:37001848	chr19:37251912~37265535:+
THCA	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	7.65	1.18e-13	4.19e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
THCA	cis	rs9813712	0.574	rs35856399	ENSG00000228252.7	COL6A4P2	-7.65	1.18e-13	4.19e-11	-0.32	-0.33	Response to amphetamines;	chr3:130241961	chr3:130212823~130273806:+
THCA	cis	rs11603691	0.901	rs10896604	ENSG00000254662.1	RP11-872D17.4	7.65	1.18e-13	4.2e-11	0.59	0.33	Low high density lipoprotein cholesterol levels;	chr11:57317739	chr11:57325603~57327958:+
THCA	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-7.65	1.18e-13	4.2e-11	-0.36	-0.33	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
THCA	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-7.65	1.18e-13	4.2e-11	-0.27	-0.33	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
THCA	cis	rs17695224	0.5	rs4801897	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831942	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs4802876	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831964	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs4802877	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831991	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.52	rs4801898	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51832064	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs17761960	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51832275	chr19:51839924~51843324:-
THCA	cis	rs10971721	0.822	rs10971793	ENSG00000260947.1	RP11-384P7.7	7.65	1.18e-13	4.21e-11	0.82	0.33	Body mass index;	chr9:33922628	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971794	ENSG00000260947.1	RP11-384P7.7	7.65	1.18e-13	4.21e-11	0.82	0.33	Body mass index;	chr9:33924314	chr9:33697459~33700986:+
THCA	cis	rs61041384	1	rs76872194	ENSG00000256092.2	RP13-942N8.1	-7.65	1.18e-13	4.21e-11	-0.49	-0.33	Schizophrenia;	chr12:123208816	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs74240771	ENSG00000256092.2	RP13-942N8.1	-7.65	1.18e-13	4.21e-11	-0.49	-0.33	Schizophrenia;	chr12:123212416	chr12:123363868~123366113:+
THCA	cis	rs4950322	0.542	rs17159914	ENSG00000237188.3	RP11-337C18.8	-7.65	1.19e-13	4.23e-11	-0.38	-0.33	Protein quantitative trait loci;	chr1:147183226	chr1:147172771~147211568:+
THCA	cis	rs2562456	0.917	rs2650793	ENSG00000268555.1	RP11-678G14.3	-7.65	1.19e-13	4.23e-11	-0.45	-0.33	Pain;	chr19:21493313	chr19:21570822~21587322:-
THCA	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	7.64	1.19e-13	4.24e-11	0.4	0.33	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
THCA	cis	rs9400467	0.508	rs11153283	ENSG00000230177.1	RP5-1112D6.4	-7.64	1.19e-13	4.24e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111277932~111278742:+
THCA	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-7.64	1.19e-13	4.24e-11	-0.32	-0.33	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
THCA	cis	rs4073416	0.707	rs1054218	ENSG00000276116.2	FUT8-AS1	-7.64	1.19e-13	4.25e-11	-0.35	-0.33	N-glycan levels;	chr14:65742472	chr14:65411170~65412690:-
THCA	cis	rs2439831	0.867	rs3101443	ENSG00000275601.1	AC011330.13	-7.64	1.19e-13	4.25e-11	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43620174	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2614811	ENSG00000275601.1	AC011330.13	-7.64	1.19e-13	4.25e-11	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43621289	chr15:43642389~43643023:-
THCA	cis	rs10971721	0.731	rs12377117	ENSG00000260947.1	RP11-384P7.7	7.64	1.19e-13	4.25e-11	0.81	0.33	Body mass index;	chr9:33806586	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.73	rs72725361	ENSG00000260947.1	RP11-384P7.7	7.64	1.19e-13	4.25e-11	0.81	0.33	Body mass index;	chr9:33806615	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs12376664	ENSG00000260947.1	RP11-384P7.7	7.64	1.19e-13	4.25e-11	0.81	0.33	Body mass index;	chr9:33808705	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725368	ENSG00000260947.1	RP11-384P7.7	7.64	1.19e-13	4.25e-11	0.81	0.33	Body mass index;	chr9:33815457	chr9:33697459~33700986:+
THCA	cis	rs9309473	0.528	rs10191517	ENSG00000163016.8	ALMS1P	7.64	1.19e-13	4.25e-11	0.44	0.33	Metabolite levels;	chr2:73331275	chr2:73644919~73685576:+
THCA	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-7.64	1.19e-13	4.26e-11	-0.38	-0.33	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-7.64	1.19e-13	4.26e-11	-0.38	-0.33	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
THCA	cis	rs12681366	0.761	rs2930963	ENSG00000253704.1	RP11-267M23.4	7.64	1.2e-13	4.26e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94553722~94569745:+
THCA	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-7.64	1.2e-13	4.28e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-7.64	1.2e-13	4.28e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
THCA	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
THCA	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	7.64	1.2e-13	4.28e-11	0.43	0.33	Height;	chr6:109436760	chr6:109382795~109383666:+
THCA	cis	rs853679	0.882	rs9380069	ENSG00000280107.1	AL022393.9	-7.64	1.2e-13	4.28e-11	-0.48	-0.33	Depression;	chr6:28235522	chr6:28170845~28172521:+
THCA	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	7.64	1.2e-13	4.28e-11	0.53	0.33	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
THCA	cis	rs6504663	0.525	rs557	ENSG00000275897.1	RP11-94C24.13	7.64	1.2e-13	4.29e-11	0.32	0.33	Visceral fat;	chr17:50485873	chr17:50475819~50478391:+
THCA	cis	rs686320	1	rs3132770	ENSG00000245532.5	NEAT1	7.64	1.2e-13	4.29e-11	0.3	0.33	Hip circumference adjusted for BMI;	chr11:65483846	chr11:65422774~65445540:+
THCA	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	7.64	1.2e-13	4.29e-11	0.2	0.33	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
THCA	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-7.64	1.2e-13	4.29e-11	-0.32	-0.33	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
THCA	cis	rs737008	0.96	rs11640295	ENSG00000262636.1	CTD-3088G3.4	7.64	1.21e-13	4.3e-11	0.44	0.33	Obesity-related traits;	chr16:11296871	chr16:11380859~11381118:-
THCA	cis	rs67180937	0.778	rs3002126	ENSG00000272750.1	RP11-378J18.8	-7.64	1.21e-13	4.31e-11	-0.48	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222676939	chr1:222658867~222661512:-
THCA	cis	rs728616	0.867	rs76239460	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860400	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860412	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12412257	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs117139504	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12412226	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs4387301	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79663088~79826594:-
THCA	cis	rs728616	0.764	rs117833443	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs116994688	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860420	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs75447386	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs4520539	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860421	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs118134654	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79663088~79826594:-
THCA	cis	rs730566	0.64	rs6442112	ENSG00000229759.1	MRPS18AP1	7.64	1.21e-13	4.31e-11	0.42	0.33	Prion diseases;	chr3:48274544	chr3:48256350~48256938:-
THCA	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-7.64	1.21e-13	4.31e-11	-0.33	-0.33	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
THCA	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-7.64	1.21e-13	4.32e-11	-0.58	-0.33	Depression;	chr6:28200565	chr6:28115628~28116551:+
THCA	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	7.64	1.21e-13	4.32e-11	0.41	0.33	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
THCA	cis	rs7160336	0.604	rs4903150	ENSG00000259065.1	RP5-1021I20.1	7.64	1.22e-13	4.33e-11	0.39	0.33	Blood protein levels;	chr14:73844725	chr14:73787360~73803270:+
THCA	cis	rs2581794	1	rs2581794	ENSG00000242142.1	SERBP1P3	7.64	1.22e-13	4.35e-11	0.39	0.33	Schizophrenia;	chr3:53002190	chr3:53064283~53065091:-
THCA	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	7.64	1.22e-13	4.35e-11	0.43	0.33	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
THCA	cis	rs516805	0.748	rs12189881	ENSG00000279453.1	RP3-425C14.4	7.64	1.22e-13	4.35e-11	0.34	0.33	Lymphocyte counts;	chr6:122375109	chr6:122436789~122439223:-
THCA	cis	rs2288884	0.945	rs78336183	ENSG00000275055.1	CTC-471J1.11	-7.64	1.22e-13	4.35e-11	-0.31	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058230	chr19:52049007~52049754:+
THCA	cis	rs7945705	0.875	rs10769947	ENSG00000254860.4	TMEM9B-AS1	-7.64	1.22e-13	4.36e-11	-0.36	-0.33	Hemoglobin concentration;	chr11:8736567	chr11:8964675~8977527:+
THCA	cis	rs2787702	0.5	rs11591943	ENSG00000237233.2	TMEM26-AS1	7.64	1.23e-13	4.36e-11	0.54	0.33	Response to taxane treatment (placlitaxel);	chr10:61560817	chr10:61452639~61481956:+
THCA	cis	rs9341808	0.754	rs3805907	ENSG00000272129.1	RP11-250B2.6	-7.64	1.23e-13	4.37e-11	-0.42	-0.33	Sitting height ratio;	chr6:80263948	chr6:80355424~80356859:+
THCA	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-7.64	1.23e-13	4.38e-11	-0.54	-0.33	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
THCA	cis	rs2562456	0.755	rs2562421	ENSG00000268119.4	CTD-2561J22.5	-7.64	1.23e-13	4.38e-11	-0.42	-0.33	Pain;	chr19:21448502	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs2562420	ENSG00000268119.4	CTD-2561J22.5	-7.64	1.23e-13	4.38e-11	-0.42	-0.33	Pain;	chr19:21448503	chr19:21444241~21463908:-
THCA	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	7.64	1.23e-13	4.39e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
THCA	cis	rs11696845	1	rs11696845	ENSG00000276223.1	RP4-781B1.5	-7.64	1.24e-13	4.4e-11	-0.42	-0.33	Obesity-related traits;	chr20:44742679	chr20:44746642~44747201:+
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000237664.1	LINC00316	-7.64	1.24e-13	4.4e-11	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45338590~45341990:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000264538.5	SUZ12P1	-7.64	1.24e-13	4.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000264538.5	SUZ12P1	-7.64	1.24e-13	4.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30709299~30790908:+
THCA	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-7.64	1.24e-13	4.41e-11	-0.51	-0.33	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
THCA	cis	rs1949733	1	rs1357481	ENSG00000205959.3	RP11-689P11.2	-7.64	1.24e-13	4.41e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8494494	chr4:8482270~8512610:+
THCA	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-7.64	1.24e-13	4.41e-11	-0.54	-0.33	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
THCA	cis	rs10971721	0.749	rs72725371	ENSG00000260947.1	RP11-384P7.7	7.64	1.24e-13	4.41e-11	0.81	0.33	Body mass index;	chr9:33825013	chr9:33697459~33700986:+
THCA	cis	rs9902453	1	rs28664971	ENSG00000264007.1	RP11-68I3.10	7.64	1.24e-13	4.42e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30110392	chr17:29621617~29622254:-
THCA	cis	rs12681366	0.761	rs2197003	ENSG00000253704.1	RP11-267M23.4	7.64	1.24e-13	4.42e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94444758	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs2921386	ENSG00000253704.1	RP11-267M23.4	7.64	1.24e-13	4.42e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94446672	chr8:94553722~94569745:+
THCA	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	7.64	1.25e-13	4.43e-11	0.42	0.33	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000207650.1	MIR570	7.64	1.25e-13	4.43e-11	0.4	0.33	Pancreatic cancer;	chr3:196025182	chr3:195699401~195699497:+
THCA	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	7.64	1.25e-13	4.44e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
THCA	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-7.64	1.25e-13	4.44e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
THCA	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-7.64	1.25e-13	4.44e-11	-0.41	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
THCA	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	7.64	1.25e-13	4.45e-11	0.32	0.33	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
THCA	cis	rs9388451	0.874	rs3734634	ENSG00000237742.5	RP11-624M8.1	-7.64	1.25e-13	4.45e-11	-0.29	-0.33	Brugada syndrome;	chr6:125790654	chr6:125578558~125749190:-
THCA	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-7.64	1.25e-13	4.46e-11	-0.35	-0.33	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
THCA	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	7.64	1.26e-13	4.46e-11	0.42	0.33	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
THCA	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	7.64	1.26e-13	4.47e-11	0.82	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
THCA	cis	rs8114671	0.647	rs1124511	ENSG00000269202.1	RP4-614O4.12	-7.64	1.26e-13	4.5e-11	-0.28	-0.33	Height;	chr20:35148894	chr20:35201747~35203288:-
THCA	cis	rs9902453	0.967	rs55744550	ENSG00000264007.1	RP11-68I3.10	7.64	1.27e-13	4.5e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30148711	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	7.64	1.27e-13	4.51e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	7.64	1.27e-13	4.51e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Body mass index;	chr17:30739311	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Body mass index;	chr17:30745415	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Body mass index;	chr17:30745654	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30709299~30790908:+
THCA	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-7.64	1.27e-13	4.51e-11	-0.35	-0.33	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
THCA	cis	rs1150668	0.83	rs213240	ENSG00000219392.1	RP1-265C24.5	-7.64	1.27e-13	4.52e-11	-0.37	-0.33	Pubertal anthropometrics;	chr6:28348098	chr6:28115628~28116551:+
THCA	cis	rs9902453	0.78	rs3115093	ENSG00000264007.1	RP11-68I3.10	7.64	1.27e-13	4.52e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:29712737	chr17:29621617~29622254:-
THCA	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-7.63	1.27e-13	4.52e-11	-0.32	-0.33	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
THCA	cis	rs9393777	0.92	rs13196692	ENSG00000280107.1	AL022393.9	-7.63	1.27e-13	4.52e-11	-0.65	-0.33	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28170845~28172521:+
THCA	cis	rs9393777	0.92	rs34150729	ENSG00000280107.1	AL022393.9	-7.63	1.27e-13	4.52e-11	-0.65	-0.33	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28170845~28172521:+
THCA	cis	rs9393777	0.92	rs13191227	ENSG00000280107.1	AL022393.9	-7.63	1.27e-13	4.52e-11	-0.65	-0.33	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28170845~28172521:+
THCA	cis	rs11673344	0.542	rs826325	ENSG00000226686.6	LINC01535	7.63	1.27e-13	4.53e-11	0.36	0.33	Obesity-related traits;	chr19:37003580	chr19:37251912~37265535:+
THCA	cis	rs8114671	0.967	rs6142322	ENSG00000269202.1	RP4-614O4.12	7.63	1.28e-13	4.53e-11	0.28	0.33	Height;	chr20:35200735	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs6142324	ENSG00000269202.1	RP4-614O4.12	7.63	1.28e-13	4.53e-11	0.28	0.33	Height;	chr20:35201240	chr20:35201747~35203288:-
THCA	cis	rs10971721	0.584	rs10971901	ENSG00000260947.1	RP11-384P7.7	7.63	1.28e-13	4.54e-11	0.77	0.33	Body mass index;	chr9:34085149	chr9:33697459~33700986:+
THCA	cis	rs7646881	0.812	rs73015665	ENSG00000240207.5	RP11-379F4.4	-7.63	1.28e-13	4.54e-11	-0.47	-0.33	Tetralogy of Fallot;	chr3:158736145	chr3:158732263~158784070:+
THCA	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	7.63	1.28e-13	4.54e-11	0.23	0.33	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
THCA	cis	rs801193	0.66	rs1962050	ENSG00000232559.3	GS1-124K5.12	-7.63	1.28e-13	4.54e-11	-0.31	-0.33	Aortic root size;	chr7:66775021	chr7:66554588~66576923:-
THCA	cis	rs2915864	0.8	rs13172358	ENSG00000280047.1	CTC-463A16.1	7.63	1.28e-13	4.56e-11	0.51	0.33	Facial morphology (factor 20);	chr5:142104560	chr5:142165767~142168387:+
THCA	cis	rs875971	0.929	rs4122249	ENSG00000232559.3	GS1-124K5.12	7.63	1.29e-13	4.57e-11	0.31	0.33	Aortic root size;	chr7:66455949	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000264538.5	SUZ12P1	-7.63	1.29e-13	4.57e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000264538.5	SUZ12P1	-7.63	1.29e-13	4.57e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30709299~30790908:+
THCA	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-7.63	1.29e-13	4.59e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-7.63	1.29e-13	4.59e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-7.63	1.29e-13	4.59e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
THCA	cis	rs9388451	0.869	rs7764016	ENSG00000237742.5	RP11-624M8.1	-7.63	1.29e-13	4.59e-11	-0.29	-0.33	Brugada syndrome;	chr6:125749643	chr6:125578558~125749190:-
THCA	cis	rs601999	1	rs601999	ENSG00000108785.7	HSD17B1P1	7.63	1.29e-13	4.59e-11	0.34	0.33	Parkinson's disease;	chr17:42546140	chr17:42546764~42548706:+
THCA	cis	rs737008	0.922	rs376374	ENSG00000262636.1	CTD-3088G3.4	-7.63	1.29e-13	4.59e-11	-0.43	-0.33	Obesity-related traits;	chr16:11276759	chr16:11380859~11381118:-
THCA	cis	rs737008	0.922	rs11074957	ENSG00000262636.1	CTD-3088G3.4	-7.63	1.29e-13	4.6e-11	-0.43	-0.33	Obesity-related traits;	chr16:11284294	chr16:11380859~11381118:-
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000264538.5	SUZ12P1	-7.63	1.29e-13	4.6e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30709299~30790908:+
THCA	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	7.63	1.3e-13	4.6e-11	0.38	0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
THCA	cis	rs7208859	0.623	rs122898	ENSG00000264538.5	SUZ12P1	7.63	1.3e-13	4.6e-11	0.34	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30709299~30790908:+
THCA	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	7.63	1.3e-13	4.6e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	7.63	1.3e-13	4.6e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	7.63	1.3e-13	4.6e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
THCA	cis	rs10181042	0.535	rs2441465	ENSG00000271889.1	RP11-493E12.1	7.63	1.3e-13	4.6e-11	0.3	0.33	Crohn's disease;	chr2:61084052	chr2:61151433~61162105:-
THCA	cis	rs9649213	0.574	rs34830366	ENSG00000272950.1	RP11-307C18.1	7.63	1.3e-13	4.61e-11	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs34776142	ENSG00000272950.1	RP11-307C18.1	7.63	1.3e-13	4.61e-11	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr7:98322853~98323430:+
THCA	cis	rs4780355	0.877	rs243317	ENSG00000262636.1	CTD-3088G3.4	-7.63	1.3e-13	4.62e-11	-0.44	-0.33	Crohn's disease and psoriasis;	chr16:11263474	chr16:11380859~11381118:-
THCA	cis	rs42490	0.609	rs367640	ENSG00000251136.7	RP11-37B2.1	-7.63	1.3e-13	4.62e-11	-0.3	-0.33	Leprosy;	chr8:89852168	chr8:89609409~89757727:-
THCA	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-7.63	1.3e-13	4.62e-11	-0.36	-0.33	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
THCA	cis	rs4820539	1	rs5751589	ENSG00000221069.1	AC000029.1	7.63	1.3e-13	4.62e-11	0.4	0.33	Bone mineral density;	chr22:23133575	chr22:23136620~23136710:+
THCA	cis	rs9902453	0.716	rs3098949	ENSG00000264007.1	RP11-68I3.10	7.63	1.31e-13	4.64e-11	0.36	0.33	Coffee consumption (cups per day);	chr17:29651676	chr17:29621617~29622254:-
THCA	cis	rs11673344	0.523	rs2562599	ENSG00000226686.6	LINC01535	-7.63	1.31e-13	4.64e-11	-0.37	-0.33	Obesity-related traits;	chr19:37025472	chr19:37251912~37265535:+
THCA	cis	rs9640161	0.789	rs34728606	ENSG00000261305.1	RP4-584D14.7	7.63	1.31e-13	4.64e-11	0.42	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150357605	chr7:150341771~150342607:+
THCA	cis	rs9543976	0.623	rs6562914	ENSG00000261553.4	RP11-29G8.3	7.63	1.31e-13	4.64e-11	0.39	0.33	Diabetic retinopathy;	chr13:75593401	chr13:75549773~75807120:+
THCA	cis	rs1667284	0.967	rs1791221	ENSG00000266521.1	RP11-650P15.1	7.63	1.31e-13	4.65e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31639928	chr18:31496645~31497195:-
THCA	cis	rs1667284	0.967	rs1667281	ENSG00000266521.1	RP11-650P15.1	7.63	1.31e-13	4.65e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31640793	chr18:31496645~31497195:-
THCA	cis	rs1667284	1	rs1612691	ENSG00000266521.1	RP11-650P15.1	7.63	1.31e-13	4.65e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31640955	chr18:31496645~31497195:-
THCA	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	7.63	1.31e-13	4.65e-11	0.4	0.33	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
THCA	cis	rs10971721	0.822	rs12376145	ENSG00000260947.1	RP11-384P7.7	7.63	1.31e-13	4.67e-11	0.81	0.33	Body mass index;	chr9:34050408	chr9:33697459~33700986:+
THCA	cis	rs7674212	1	rs7674212	ENSG00000251288.2	RP11-10L12.2	-7.63	1.32e-13	4.67e-11	-0.45	-0.33	Type 2 diabetes;	chr4:103067742	chr4:102751401~102752641:+
THCA	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	7.63	1.32e-13	4.67e-11	0.4	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
THCA	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-7.63	1.32e-13	4.68e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-7.63	1.32e-13	4.68e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-7.63	1.32e-13	4.68e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
THCA	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-7.63	1.32e-13	4.68e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
THCA	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
THCA	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	7.63	1.32e-13	4.69e-11	0.42	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000264538.5	SUZ12P1	-7.63	1.32e-13	4.69e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30709299~30790908:+
THCA	cis	rs2032366	0.967	rs6650736	ENSG00000267279.1	RP11-879F14.2	-7.63	1.32e-13	4.69e-11	-0.34	-0.33	Obesity-related traits;	chr18:61601711	chr18:61585746~61606916:-
THCA	cis	rs2032366	0.967	rs9965804	ENSG00000267279.1	RP11-879F14.2	-7.63	1.32e-13	4.69e-11	-0.34	-0.33	Obesity-related traits;	chr18:61602021	chr18:61585746~61606916:-
THCA	cis	rs2032366	1	rs1894095	ENSG00000267279.1	RP11-879F14.2	-7.63	1.32e-13	4.69e-11	-0.34	-0.33	Obesity-related traits;	chr18:61605988	chr18:61585746~61606916:-
THCA	cis	rs10208649	1	rs78542544	ENSG00000272156.1	RP11-477N3.1	7.63	1.32e-13	4.69e-11	0.69	0.33	Body mass index;	chr2:53879589	chr2:54082554~54085066:+
THCA	cis	rs4780355	0.918	rs1646019	ENSG00000262636.1	CTD-3088G3.4	7.63	1.32e-13	4.69e-11	0.44	0.33	Crohn's disease and psoriasis;	chr16:11265823	chr16:11380859~11381118:-
THCA	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-7.63	1.33e-13	4.7e-11	-0.51	-0.33	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
THCA	cis	rs9640161	0.789	rs10248490	ENSG00000261305.1	RP4-584D14.7	7.63	1.33e-13	4.7e-11	0.4	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150354329	chr7:150341771~150342607:+
THCA	cis	rs950169	0.579	rs11633088	ENSG00000259728.4	LINC00933	-7.63	1.33e-13	4.7e-11	-0.47	-0.33	Schizophrenia;	chr15:84003429	chr15:84570649~84580175:+
THCA	cis	rs7942368	0.878	rs1866843	ENSG00000254632.1	RP11-21L23.4	7.63	1.33e-13	4.7e-11	0.48	0.33	Endometriosis;	chr11:76778292	chr11:76759916~76768223:-
THCA	cis	rs17684571	0.872	rs6926134	ENSG00000231441.1	RP11-472M19.2	7.63	1.33e-13	4.71e-11	0.42	0.33	Schizophrenia;	chr6:56723974	chr6:56844002~56864078:+
THCA	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	7.63	1.33e-13	4.72e-11	0.43	0.33	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
THCA	cis	rs3847687	1	rs34853396	ENSG00000279128.1	RP11-76C10.4	7.63	1.33e-13	4.72e-11	0.37	0.33	Longevity;	chr12:131034720	chr12:131022769~131024741:-
THCA	cis	rs1949733	1	rs6447875	ENSG00000205959.3	RP11-689P11.2	-7.63	1.33e-13	4.73e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8501479	chr4:8482270~8512610:+
THCA	cis	rs2115630	0.691	rs8040066	ENSG00000275120.1	RP11-182J1.17	-7.63	1.34e-13	4.74e-11	-0.34	-0.33	P wave terminal force;	chr15:84633234	chr15:84599434~84606463:-
THCA	cis	rs9902453	0.9	rs12451122	ENSG00000264007.1	RP11-68I3.10	7.63	1.34e-13	4.74e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30159358	chr17:29621617~29622254:-
THCA	cis	rs17772222	0.74	rs61975276	ENSG00000258789.1	RP11-507K2.3	-7.63	1.34e-13	4.75e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511193	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs61975277	ENSG00000258789.1	RP11-507K2.3	-7.63	1.34e-13	4.75e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511202	chr14:88551597~88552493:+
THCA	cis	rs6600671	1	rs10794671	ENSG00000223345.3	HIST2H2BA	7.63	1.34e-13	4.76e-11	0.36	0.33	Hip geometry;	chr1:121426382	chr1:121108210~121117257:-
THCA	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	7.63	1.34e-13	4.76e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
THCA	cis	rs9388451	0.903	rs9388446	ENSG00000237742.5	RP11-624M8.1	-7.63	1.35e-13	4.79e-11	-0.29	-0.33	Brugada syndrome;	chr6:125743774	chr6:125578558~125749190:-
THCA	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	7.63	1.35e-13	4.79e-11	0.45	0.33	Height;	chr4:55501955	chr4:55363971~55395847:-
THCA	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-7.63	1.35e-13	4.79e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
THCA	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	7.63	1.35e-13	4.8e-11	0.42	0.33	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	7.63	1.35e-13	4.8e-11	0.42	0.33	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
THCA	cis	rs2348418	0.864	rs7314984	ENSG00000247934.4	RP11-967K21.1	7.63	1.35e-13	4.8e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28557936	chr12:28163298~28190738:-
THCA	cis	rs2562456	0.793	rs2650819	ENSG00000268119.4	CTD-2561J22.5	-7.63	1.36e-13	4.8e-11	-0.42	-0.33	Pain;	chr19:21456071	chr19:21444241~21463908:-
THCA	cis	rs748404	0.56	rs570933	ENSG00000166763.7	STRCP1	7.63	1.36e-13	4.81e-11	0.36	0.33	Lung cancer;	chr15:43531832	chr15:43699488~43718184:-
THCA	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	7.63	1.36e-13	4.81e-11	0.2	0.33	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
THCA	cis	rs10208649	0.908	rs76073574	ENSG00000272156.1	RP11-477N3.1	7.63	1.36e-13	4.82e-11	0.71	0.33	Body mass index;	chr2:53980525	chr2:54082554~54085066:+
THCA	cis	rs2348418	0.864	rs11049716	ENSG00000247934.4	RP11-967K21.1	7.63	1.36e-13	4.82e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28564713	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7136843	ENSG00000247934.4	RP11-967K21.1	7.63	1.36e-13	4.82e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28564875	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7957495	ENSG00000247934.4	RP11-967K21.1	-7.63	1.36e-13	4.82e-11	-0.29	-0.33	Lung function (FEV1);Lung function (FVC);	chr12:28564522	chr12:28163298~28190738:-
THCA	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-7.62	1.37e-13	4.85e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-7.62	1.37e-13	4.85e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-7.62	1.37e-13	4.85e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-7.62	1.37e-13	4.85e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
THCA	cis	rs1949733	0.701	rs2631735	ENSG00000205959.3	RP11-689P11.2	-7.62	1.37e-13	4.86e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8474391	chr4:8482270~8512610:+
THCA	cis	rs2712184	0.66	rs10164732	ENSG00000229352.1	AC007563.3	7.62	1.37e-13	4.86e-11	0.39	0.33	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216780946	chr2:216799608~216805335:+
THCA	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-7.62	1.37e-13	4.87e-11	-0.41	-0.33	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
THCA	cis	rs10971721	0.822	rs7856487	ENSG00000260947.1	RP11-384P7.7	7.62	1.37e-13	4.87e-11	0.81	0.33	Body mass index;	chr9:33870942	chr9:33697459~33700986:+
THCA	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-7.62	1.38e-13	4.87e-11	-0.32	-0.33	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
THCA	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-7.62	1.38e-13	4.87e-11	-0.36	-0.33	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
THCA	cis	rs2348418	0.831	rs7137119	ENSG00000247934.4	RP11-967K21.1	7.62	1.38e-13	4.87e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28565058	chr12:28163298~28190738:-
THCA	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-7.62	1.38e-13	4.88e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
THCA	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-7.62	1.38e-13	4.88e-11	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
THCA	cis	rs7727544	0.547	rs56083751	ENSG00000233006.5	AC034220.3	7.62	1.38e-13	4.9e-11	0.26	0.33	Blood metabolite levels;	chr5:132328945	chr5:132311285~132369916:-
THCA	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-7.62	1.38e-13	4.9e-11	-0.29	-0.33	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
THCA	cis	rs9813712	0.597	rs1453255	ENSG00000228252.7	COL6A4P2	-7.62	1.39e-13	4.9e-11	-0.33	-0.33	Response to amphetamines;	chr3:130258815	chr3:130212823~130273806:+
THCA	cis	rs6908034	0.66	rs74795718	ENSG00000228412.5	RP4-625H18.2	7.62	1.39e-13	4.93e-11	0.81	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782068	chr6:19802164~19804752:-
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000219392.1	RP1-265C24.5	-7.62	1.4e-13	4.94e-11	-0.36	-0.33	Pubertal anthropometrics;	chr6:28271903	chr6:28115628~28116551:+
THCA	cis	rs17695224	0.565	rs7248523	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51833888	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.585	rs10406893	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51833901	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs10406732	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51833974	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.519	rs2159654	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51834004	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs2159655	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51834006	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.527	rs2903546	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51834082	chr19:51839924~51843324:-
THCA	cis	rs728616	0.867	rs34870056	ENSG00000225484.5	NUTM2B-AS1	-7.62	1.4e-13	4.95e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79663088~79826594:-
THCA	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	7.62	1.4e-13	4.96e-11	0.44	0.33	Height;	chr4:55361200	chr4:55363971~55395847:-
THCA	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-7.62	1.4e-13	4.97e-11	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-7.62	1.4e-13	4.97e-11	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
THCA	cis	rs7430456	1	rs7430456	ENSG00000228221.4	LINC00578	-7.62	1.4e-13	4.97e-11	-0.42	-0.33	Breast cancer;	chr3:177768082	chr3:177441921~177752305:+
THCA	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	7.62	1.41e-13	4.98e-11	0.43	0.33	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
THCA	cis	rs9400467	0.528	rs459403	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.41e-13	4.98e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111277932~111278742:+
THCA	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	7.62	1.41e-13	4.99e-11	0.39	0.33	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
THCA	cis	rs416603	0.967	rs11644184	ENSG00000262703.1	RP11-485G7.6	-7.62	1.41e-13	4.99e-11	-0.37	-0.33	Type 1 diabetes;	chr16:11271247	chr16:11348143~11349321:-
THCA	cis	rs11148252	0.538	rs2408611	ENSG00000235660.1	LINC00345	-7.62	1.41e-13	4.99e-11	-0.41	-0.33	Lewy body disease;	chr13:52135606	chr13:52484161~52484680:-
THCA	cis	rs9400467	0.528	rs462432	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.41e-13	4.99e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.931	rs466923	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.41e-13	4.99e-11	-0.26	-0.33	Metabolic traits;	chr6:111341774	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs1623806	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.41e-13	4.99e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111277932~111278742:+
THCA	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	7.62	1.41e-13	5e-11	0.39	0.33	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
THCA	cis	rs17695224	0.527	rs7250063	ENSG00000269483.1	AC006272.1	7.62	1.42e-13	5.01e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51834447	chr19:51839924~51843324:-
THCA	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	7.62	1.42e-13	5.01e-11	0.32	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
THCA	cis	rs9400467	0.528	rs455247	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.811	rs464401	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Metabolic traits;	chr6:111347804	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.509	rs463854	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.509	rs463853	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs456569	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs455335	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs465795	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs110732	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.592	rs462493	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs456871	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.811	rs455732	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Metabolic traits;	chr6:111374065	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs458486	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs455726	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111277932~111278742:+
THCA	cis	rs11148252	0.777	rs9535889	ENSG00000278238.1	RP11-245D16.4	-7.62	1.42e-13	5.02e-11	-0.38	-0.33	Lewy body disease;	chr13:52159499	chr13:52454775~52455331:-
THCA	cis	rs9902453	0.967	rs62070344	ENSG00000264007.1	RP11-68I3.10	7.62	1.42e-13	5.03e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30149979	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs4356528	ENSG00000264007.1	RP11-68I3.10	7.62	1.42e-13	5.03e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30162652	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.872	rs34698290	ENSG00000264007.1	RP11-68I3.10	7.62	1.42e-13	5.03e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30173447	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.866	rs4795529	ENSG00000264007.1	RP11-68I3.10	7.62	1.43e-13	5.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30116531	chr17:29621617~29622254:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000224205.1	AP000351.4	-7.62	1.43e-13	5.06e-11	-0.46	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23987320~23991421:-
THCA	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-7.62	1.43e-13	5.06e-11	-0.38	-0.33	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
THCA	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-7.62	1.43e-13	5.06e-11	-0.35	-0.33	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
THCA	cis	rs4660456	0.572	rs1008204	ENSG00000237899.1	RP4-739H11.3	7.62	1.44e-13	5.08e-11	0.4	0.33	Platelet count;	chr1:40700189	chr1:40669089~40687588:-
THCA	cis	rs7646881	1	rs59217052	ENSG00000240207.5	RP11-379F4.4	-7.62	1.44e-13	5.08e-11	-0.45	-0.33	Tetralogy of Fallot;	chr3:158734667	chr3:158732263~158784070:+
THCA	cis	rs7646881	1	rs7646881	ENSG00000240207.5	RP11-379F4.4	-7.62	1.44e-13	5.08e-11	-0.45	-0.33	Tetralogy of Fallot;	chr3:158735490	chr3:158732263~158784070:+
THCA	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	7.62	1.44e-13	5.09e-11	0.4	0.33	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	7.62	1.44e-13	5.09e-11	0.4	0.33	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
THCA	cis	rs172166	0.516	rs1225618	ENSG00000219392.1	RP1-265C24.5	-7.62	1.44e-13	5.09e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28161935	chr6:28115628~28116551:+
THCA	cis	rs172166	0.61	rs156737	ENSG00000219392.1	RP1-265C24.5	-7.62	1.44e-13	5.1e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:27927435	chr6:28115628~28116551:+
THCA	cis	rs7942368	1	rs12282785	ENSG00000254632.1	RP11-21L23.4	7.62	1.44e-13	5.1e-11	0.47	0.33	Endometriosis;	chr11:76764986	chr11:76759916~76768223:-
THCA	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	7.62	1.44e-13	5.1e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
THCA	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-7.62	1.44e-13	5.1e-11	-0.29	-0.33	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
THCA	cis	rs11148252	0.538	rs3368	ENSG00000235660.1	LINC00345	-7.62	1.45e-13	5.11e-11	-0.41	-0.33	Lewy body disease;	chr13:52133104	chr13:52484161~52484680:-
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30750419	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30753533	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30794616	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30815122	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30815823	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30709299~30790908:+
THCA	cis	rs7015263	0.581	rs1142528	ENSG00000254231.1	CTD-2284J15.1	7.62	1.45e-13	5.12e-11	0.33	0.33	Intelligence (multi-trait analysis);	chr8:86469071	chr8:86333274~86343314:-
THCA	cis	rs801193	0.613	rs2659900	ENSG00000232559.3	GS1-124K5.12	7.62	1.45e-13	5.12e-11	0.32	0.33	Aortic root size;	chr7:66719456	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000264538.5	SUZ12P1	-7.62	1.46e-13	5.14e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30709299~30790908:+
THCA	cis	rs7942368	0.941	rs737185	ENSG00000254632.1	RP11-21L23.4	7.62	1.46e-13	5.15e-11	0.48	0.33	Endometriosis;	chr11:76774314	chr11:76759916~76768223:-
THCA	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-7.62	1.46e-13	5.15e-11	-0.36	-0.33	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
THCA	cis	rs516805	0.706	rs9490427	ENSG00000279453.1	RP3-425C14.4	7.62	1.46e-13	5.15e-11	0.34	0.33	Lymphocyte counts;	chr6:122353084	chr6:122436789~122439223:-
THCA	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	7.62	1.46e-13	5.15e-11	0.83	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
THCA	cis	rs9309473	0.528	rs7573275	ENSG00000163016.8	ALMS1P	7.61	1.46e-13	5.16e-11	0.45	0.33	Metabolite levels;	chr2:73325414	chr2:73644919~73685576:+
THCA	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	7.61	1.46e-13	5.16e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
THCA	cis	rs2839186	0.771	rs2280957	ENSG00000239415.1	AP001469.9	-7.61	1.46e-13	5.16e-11	-0.34	-0.33	Testicular germ cell tumor;	chr21:46222358	chr21:46251549~46254133:-
THCA	cis	rs2562456	0.793	rs627522	ENSG00000268555.1	RP11-678G14.3	7.61	1.46e-13	5.16e-11	0.45	0.33	Pain;	chr19:21313002	chr19:21570822~21587322:-
THCA	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
THCA	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
THCA	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10463240	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150877291	chr5:150930645~150946289:-
THCA	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-7.61	1.47e-13	5.17e-11	-0.41	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
THCA	cis	rs17772222	0.696	rs28666030	ENSG00000258789.1	RP11-507K2.3	-7.61	1.47e-13	5.18e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511463	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs28493481	ENSG00000258789.1	RP11-507K2.3	-7.61	1.47e-13	5.18e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511491	chr14:88551597~88552493:+
THCA	cis	rs910316	0.967	rs4903292	ENSG00000279594.1	RP11-950C14.10	7.61	1.47e-13	5.19e-11	0.31	0.33	Height;	chr14:75189542	chr14:75011269~75012851:-
THCA	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	7.61	1.47e-13	5.2e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
THCA	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-7.61	1.48e-13	5.21e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
THCA	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	7.61	1.48e-13	5.22e-11	0.4	0.33	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
THCA	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	7.61	1.48e-13	5.22e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
THCA	cis	rs7743045	0.548	rs2357023	ENSG00000253194.1	RP11-351A11.1	-7.61	1.48e-13	5.23e-11	-0.46	-0.33	Mean platelet volume;	chr6:119023364	chr6:118934785~119031541:+
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000264538.5	SUZ12P1	-7.61	1.48e-13	5.23e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30709299~30790908:+
THCA	cis	rs11148252	0.538	rs9535879	ENSG00000235660.1	LINC00345	-7.61	1.48e-13	5.23e-11	-0.41	-0.33	Lewy body disease;	chr13:52130488	chr13:52484161~52484680:-
THCA	cis	rs42490	0.576	rs390536	ENSG00000251136.7	RP11-37B2.1	-7.61	1.48e-13	5.23e-11	-0.3	-0.33	Leprosy;	chr8:89857122	chr8:89609409~89757727:-
THCA	cis	rs3822625	0.541	rs112793966	ENSG00000271828.1	CTD-2310F14.1	7.61	1.49e-13	5.24e-11	0.76	0.33	Breast cancer (early onset);	chr5:56908291	chr5:56927874~56929573:+
THCA	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	7.61	1.49e-13	5.25e-11	0.2	0.33	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	7.61	1.49e-13	5.25e-11	0.2	0.33	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	7.61	1.49e-13	5.25e-11	0.2	0.33	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
THCA	cis	rs914615	0.508	rs7535292	ENSG00000160766.13	GBAP1	-7.61	1.49e-13	5.25e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155155273	chr1:155213821~155227422:-
THCA	cis	rs2562456	0.755	rs2562421	ENSG00000268555.1	RP11-678G14.3	-7.61	1.49e-13	5.25e-11	-0.47	-0.33	Pain;	chr19:21448502	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs2562420	ENSG00000268555.1	RP11-678G14.3	-7.61	1.49e-13	5.25e-11	-0.47	-0.33	Pain;	chr19:21448503	chr19:21570822~21587322:-
THCA	cis	rs10411161	0.808	rs892040	ENSG00000269483.1	AC006272.1	7.61	1.49e-13	5.25e-11	0.58	0.33	Breast cancer;	chr19:51893392	chr19:51839924~51843324:-
THCA	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	7.61	1.49e-13	5.26e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
THCA	cis	rs4660456	0.597	rs7518568	ENSG00000237899.1	RP4-739H11.3	7.61	1.5e-13	5.28e-11	0.4	0.33	Platelet count;	chr1:40708508	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	7.61	1.5e-13	5.28e-11	0.4	0.33	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
THCA	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-7.61	1.5e-13	5.28e-11	-0.48	-0.33	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-7.61	1.5e-13	5.28e-11	-0.48	-0.33	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-7.61	1.5e-13	5.28e-11	-0.48	-0.33	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-7.61	1.5e-13	5.28e-11	-0.48	-0.33	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
THCA	cis	rs10971721	0.822	rs72725370	ENSG00000260947.1	RP11-384P7.7	7.61	1.5e-13	5.29e-11	0.81	0.33	Body mass index;	chr9:33818459	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.554	rs10971712	ENSG00000260947.1	RP11-384P7.7	7.61	1.5e-13	5.29e-11	0.81	0.33	Body mass index;	chr9:33820940	chr9:33697459~33700986:+
THCA	cis	rs950169	0.614	rs12903883	ENSG00000259728.4	LINC00933	7.61	1.5e-13	5.3e-11	0.47	0.33	Schizophrenia;	chr15:84011801	chr15:84570649~84580175:+
THCA	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-7.61	1.5e-13	5.3e-11	-0.33	-0.33	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
THCA	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	7.61	1.5e-13	5.3e-11	0.19	0.33	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
THCA	cis	rs7688540	0.8	rs10003142	ENSG00000211553.1	AC253576.2	-7.61	1.51e-13	5.33e-11	-0.45	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs11723803	ENSG00000211553.1	AC253576.2	-7.61	1.51e-13	5.33e-11	-0.45	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:136461~136568:+
THCA	cis	rs17684571	0.872	rs4275049	ENSG00000231441.1	RP11-472M19.2	7.61	1.51e-13	5.33e-11	0.42	0.33	Schizophrenia;	chr6:56737530	chr6:56844002~56864078:+
THCA	cis	rs4934494	0.813	rs12775783	ENSG00000232936.4	RP11-80H5.2	7.61	1.51e-13	5.33e-11	0.45	0.33	Red blood cell count;	chr10:89646494	chr10:89645282~89650667:+
THCA	cis	rs11971779	0.68	rs4732379	ENSG00000273391.1	RP11-634H22.1	7.61	1.52e-13	5.35e-11	0.31	0.33	Diisocyanate-induced asthma;	chr7:139438068	chr7:139359032~139359566:-
THCA	cis	rs10208649	0.908	rs78244745	ENSG00000272156.1	RP11-477N3.1	7.61	1.53e-13	5.4e-11	0.7	0.33	Body mass index;	chr2:54056137	chr2:54082554~54085066:+
THCA	cis	rs2522056	1	rs6874639	ENSG00000233006.5	AC034220.3	7.61	1.53e-13	5.4e-11	0.29	0.33	Fibrinogen;Lymphocyte counts;	chr5:132443024	chr5:132311285~132369916:-
THCA	cis	rs853679	0.769	rs17720293	ENSG00000280107.1	AL022393.9	-7.61	1.53e-13	5.4e-11	-0.59	-0.33	Depression;	chr6:28246920	chr6:28170845~28172521:+
THCA	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	7.61	1.54e-13	5.41e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
THCA	cis	rs10208649	0.611	rs58851686	ENSG00000272156.1	RP11-477N3.1	7.61	1.54e-13	5.41e-11	0.48	0.33	Body mass index;	chr2:54057179	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.611	rs1363060	ENSG00000272156.1	RP11-477N3.1	7.61	1.54e-13	5.41e-11	0.48	0.33	Body mass index;	chr2:54057447	chr2:54082554~54085066:+
THCA	cis	rs1426063	0.61	rs72862239	ENSG00000260265.1	RP11-44F21.5	7.61	1.54e-13	5.41e-11	0.8	0.33	QT interval;	chr4:75071967	chr4:75081702~75084717:-
THCA	cis	rs61041384	0.661	rs74917517	ENSG00000256092.2	RP13-942N8.1	-7.61	1.54e-13	5.42e-11	-0.49	-0.33	Schizophrenia;	chr12:123204258	chr12:123363868~123366113:+
THCA	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-7.61	1.54e-13	5.42e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-7.61	1.54e-13	5.42e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
THCA	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	7.61	1.54e-13	5.42e-11	0.33	0.33	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
THCA	cis	rs6723226	0.721	rs10172510	ENSG00000276334.1	AL133243.1	7.61	1.54e-13	5.44e-11	0.37	0.33	Intelligence (multi-trait analysis);	chr2:32395820	chr2:32521927~32523547:+
THCA	cis	rs1426063	0.614	rs6534447	ENSG00000260265.1	RP11-44F21.5	-7.61	1.54e-13	5.44e-11	-0.82	-0.33	QT interval;	chr4:75080682	chr4:75081702~75084717:-
THCA	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-7.61	1.55e-13	5.45e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
THCA	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	7.61	1.55e-13	5.46e-11	0.43	0.33	Height;	chr6:109333018	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	7.61	1.56e-13	5.48e-11	0.43	0.33	Height;	chr6:109365409	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	7.61	1.56e-13	5.48e-11	0.43	0.33	Height;	chr6:109373851	chr6:109382795~109383666:+
THCA	cis	rs516805	0.748	rs72974455	ENSG00000279453.1	RP3-425C14.4	7.61	1.56e-13	5.49e-11	0.34	0.33	Lymphocyte counts;	chr6:122377134	chr6:122436789~122439223:-
THCA	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-7.61	1.56e-13	5.49e-11	-0.36	-0.33	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
THCA	cis	rs17772222	0.74	rs10150986	ENSG00000258789.1	RP11-507K2.3	-7.61	1.56e-13	5.5e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88517326	chr14:88551597~88552493:+
THCA	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	7.61	1.56e-13	5.5e-11	0.41	0.33	Height;	chr6:109332622	chr6:109382795~109383666:+
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000264538.5	SUZ12P1	-7.61	1.56e-13	5.5e-11	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30709299~30790908:+
THCA	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	7.61	1.56e-13	5.51e-11	0.32	0.33	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
THCA	cis	rs7942368	0.941	rs10899279	ENSG00000254761.1	RP11-672A2.1	7.6	1.57e-13	5.54e-11	0.47	0.33	Endometriosis;	chr11:76766200	chr11:76712396~76719608:-
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000264538.5	SUZ12P1	-7.6	1.57e-13	5.54e-11	-0.33	-0.33	Body mass index;	chr17:30752751	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000266490.1	CTD-2349P21.9	7.6	1.58e-13	5.54e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216433	ENSG00000266490.1	CTD-2349P21.9	7.6	1.58e-13	5.54e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30792372~30792833:+
THCA	cis	rs516805	0.748	rs6930548	ENSG00000279453.1	RP3-425C14.4	-7.6	1.58e-13	5.54e-11	-0.34	-0.33	Lymphocyte counts;	chr6:122375807	chr6:122436789~122439223:-
THCA	cis	rs12681366	0.806	rs72672679	ENSG00000253704.1	RP11-267M23.4	7.6	1.58e-13	5.55e-11	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94368956	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.881	rs12675415	ENSG00000253704.1	RP11-267M23.4	7.6	1.58e-13	5.55e-11	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94371332	chr8:94553722~94569745:+
THCA	cis	rs10208649	0.611	rs7583626	ENSG00000272156.1	RP11-477N3.1	7.6	1.58e-13	5.55e-11	0.49	0.33	Body mass index;	chr2:54063635	chr2:54082554~54085066:+
THCA	cis	rs71636778	0.509	rs17162311	ENSG00000260063.1	RP5-968P14.2	7.6	1.58e-13	5.56e-11	0.61	0.33	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26848475	chr1:26692132~26694131:-
THCA	cis	rs2562456	0.92	rs2650784	ENSG00000268555.1	RP11-678G14.3	-7.6	1.58e-13	5.56e-11	-0.45	-0.33	Pain;	chr19:21483795	chr19:21570822~21587322:-
THCA	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	7.6	1.58e-13	5.56e-11	0.4	0.33	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	7.6	1.58e-13	5.57e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
THCA	cis	rs7247513	0.964	rs1007352	ENSG00000230310.1	CTD-2192J16.11	-7.6	1.59e-13	5.58e-11	-0.4	-0.33	Bipolar disorder;	chr19:12611731	chr19:12552597~12553644:+
THCA	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	7.6	1.59e-13	5.59e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	7.6	1.59e-13	5.59e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
THCA	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	7.6	1.59e-13	5.59e-11	0.43	0.33	Height;	chr6:109441837	chr6:109382795~109383666:+
THCA	cis	rs10916248	0.559	rs56023673	ENSG00000232628.4	RP11-365O16.3	7.6	1.59e-13	5.59e-11	0.52	0.33	QT interval (drug interaction);	chr1:224180821	chr1:224208747~224213279:-
THCA	cis	rs6723108	0.517	rs3739029	ENSG00000224043.6	CCNT2-AS1	-7.6	1.59e-13	5.6e-11	-0.34	-0.33	Type 2 diabetes;	chr2:134841837	chr2:134735464~134918710:-
THCA	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-7.6	1.59e-13	5.6e-11	-0.47	-0.33	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
THCA	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	7.6	1.59e-13	5.6e-11	0.43	0.33	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	7.6	1.59e-13	5.6e-11	0.43	0.33	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
THCA	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
THCA	cis	rs12681366	1	rs12681366	ENSG00000253704.1	RP11-267M23.4	7.6	1.6e-13	5.62e-11	0.33	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94389037	chr8:94553722~94569745:+
THCA	cis	rs2284219	1	rs2284219	ENSG00000244480.1	AC005154.7	-7.6	1.6e-13	5.63e-11	-0.26	-0.33	Type 2 diabetes;	chr7:30674820	chr7:30523143~30524535:-
THCA	cis	rs2284219	0.964	rs733453	ENSG00000244480.1	AC005154.7	-7.6	1.6e-13	5.63e-11	-0.26	-0.33	Type 2 diabetes;	chr7:30675157	chr7:30523143~30524535:-
THCA	cis	rs2284219	1	rs2267715	ENSG00000244480.1	AC005154.7	-7.6	1.6e-13	5.63e-11	-0.26	-0.33	Type 2 diabetes;	chr7:30676471	chr7:30523143~30524535:-
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000264538.5	SUZ12P1	-7.6	1.6e-13	5.63e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30709299~30790908:+
THCA	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	7.6	1.6e-13	5.63e-11	0.31	0.33	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
THCA	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-7.6	1.61e-13	5.64e-11	-0.36	-0.33	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
THCA	cis	rs728616	0.867	rs61860417	ENSG00000225484.5	NUTM2B-AS1	-7.6	1.61e-13	5.64e-11	-0.64	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79663088~79826594:-
THCA	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	7.6	1.61e-13	5.64e-11	0.71	0.33	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	7.6	1.61e-13	5.64e-11	0.71	0.33	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	7.6	1.61e-13	5.64e-11	0.71	0.33	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	7.6	1.61e-13	5.64e-11	0.71	0.33	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
THCA	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	7.6	1.61e-13	5.65e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
THCA	cis	rs3812049	0.826	rs34576922	ENSG00000245937.6	LINC01184	-7.6	1.61e-13	5.65e-11	-0.37	-0.33	Lymphocyte counts;Red cell distribution width;	chr5:128028411	chr5:127940426~128083172:-
THCA	cis	rs9902453	0.817	rs2628170	ENSG00000264007.1	RP11-68I3.10	-7.6	1.61e-13	5.66e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29729594	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2874505	ENSG00000264007.1	RP11-68I3.10	7.6	1.61e-13	5.66e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29710905	chr17:29621617~29622254:-
THCA	cis	rs9329221	0.527	rs4841352	ENSG00000261451.1	RP11-981G7.1	7.6	1.61e-13	5.66e-11	0.43	0.33	Neuroticism;	chr8:10470080	chr8:10433672~10438312:+
THCA	cis	rs240993	0.516	rs369594	ENSG00000230177.1	RP5-1112D6.4	-7.6	1.62e-13	5.67e-11	-0.36	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111303197	chr6:111277932~111278742:+
THCA	cis	rs4713118	0.911	rs9295746	ENSG00000280107.1	AL022393.9	-7.6	1.62e-13	5.67e-11	-0.4	-0.33	Parkinson's disease;	chr6:27762285	chr6:28170845~28172521:+
THCA	cis	rs42490	0.536	rs379015	ENSG00000251136.7	RP11-37B2.1	-7.6	1.62e-13	5.68e-11	-0.3	-0.33	Leprosy;	chr8:89856245	chr8:89609409~89757727:-
THCA	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-7.6	1.62e-13	5.68e-11	-0.32	-0.33	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
THCA	cis	rs11673344	0.542	rs826324	ENSG00000226686.6	LINC01535	7.6	1.62e-13	5.69e-11	0.36	0.33	Obesity-related traits;	chr19:37014343	chr19:37251912~37265535:+
THCA	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-7.6	1.62e-13	5.7e-11	-0.78	-0.33	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
THCA	cis	rs6496932	0.503	rs2086756	ENSG00000218052.5	ADAMTS7P4	-7.6	1.63e-13	5.71e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85255369~85330334:-
THCA	cis	rs1949733	1	rs2631740	ENSG00000205959.3	RP11-689P11.2	7.6	1.63e-13	5.72e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8482379	chr4:8482270~8512610:+
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000264538.5	SUZ12P1	-7.6	1.63e-13	5.72e-11	-0.34	-0.33	Body mass index;	chr17:30776148	chr17:30709299~30790908:+
THCA	cis	rs4072705	0.967	rs4287038	ENSG00000224020.1	MIR181A2HG	7.6	1.63e-13	5.73e-11	0.3	0.33	Menarche (age at onset);	chr9:124607400	chr9:124658467~124698631:+
THCA	cis	rs494459	0.733	rs556437	ENSG00000255422.1	AP002954.4	-7.6	1.63e-13	5.74e-11	-0.35	-0.33	Height;	chr11:118835044	chr11:118704607~118750263:+
THCA	cis	rs12817211	0.502	rs7961065	ENSG00000272368.2	RP4-605O3.4	-7.6	1.64e-13	5.75e-11	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50119904	chr12:50112197~50165618:+
THCA	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	7.6	1.64e-13	5.75e-11	0.41	0.33	Height;	chr6:109403287	chr6:109382795~109383666:+
THCA	cis	rs1150668	0.699	rs13408	ENSG00000219392.1	RP1-265C24.5	-7.6	1.64e-13	5.75e-11	-0.36	-0.33	Pubertal anthropometrics;	chr6:28244970	chr6:28115628~28116551:+
THCA	cis	rs2115630	0.691	rs61322921	ENSG00000275120.1	RP11-182J1.17	-7.6	1.64e-13	5.75e-11	-0.34	-0.33	P wave terminal force;	chr15:84620407	chr15:84599434~84606463:-
THCA	cis	rs853679	0.517	rs6922063	ENSG00000220721.1	OR1F12	7.6	1.64e-13	5.77e-11	0.46	0.33	Depression;	chr6:28126588	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000220721.1	OR1F12	7.6	1.64e-13	5.77e-11	0.46	0.33	Depression;	chr6:28126953	chr6:28073316~28074233:+
THCA	cis	rs4604234	0.573	rs11961361	ENSG00000272129.1	RP11-250B2.6	-7.6	1.64e-13	5.77e-11	-0.72	-0.33	Cancer;	chr6:80294840	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.541	rs11963917	ENSG00000272129.1	RP11-250B2.6	-7.6	1.64e-13	5.77e-11	-0.72	-0.33	Cancer;	chr6:80294843	chr6:80355424~80356859:+
THCA	cis	rs12681366	1	rs2930971	ENSG00000253704.1	RP11-267M23.4	7.6	1.65e-13	5.78e-11	0.33	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94420319	chr8:94553722~94569745:+
THCA	cis	rs3812049	0.826	rs6860245	ENSG00000245937.6	LINC01184	-7.6	1.65e-13	5.79e-11	-0.37	-0.33	Lymphocyte counts;Red cell distribution width;	chr5:128032306	chr5:127940426~128083172:-
THCA	cis	rs7267979	0.903	rs6115101	ENSG00000274414.1	RP5-965G21.4	-7.6	1.65e-13	5.79e-11	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.868	rs6107019	ENSG00000274414.1	RP5-965G21.4	-7.6	1.65e-13	5.79e-11	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25239007~25245229:-
THCA	cis	rs2562456	0.833	rs8106025	ENSG00000268119.4	CTD-2561J22.5	-7.6	1.65e-13	5.8e-11	-0.41	-0.33	Pain;	chr19:21451922	chr19:21444241~21463908:-
THCA	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-7.6	1.66e-13	5.82e-11	-0.32	-0.33	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000264538.5	SUZ12P1	-7.6	1.67e-13	5.84e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30709299~30790908:+
THCA	cis	rs10971721	0.584	rs12375716	ENSG00000260947.1	RP11-384P7.7	7.6	1.67e-13	5.86e-11	0.75	0.33	Body mass index;	chr9:34100034	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs12379730	ENSG00000260947.1	RP11-384P7.7	7.6	1.67e-13	5.86e-11	0.75	0.33	Body mass index;	chr9:34100072	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs55672700	ENSG00000260947.1	RP11-384P7.7	7.6	1.67e-13	5.86e-11	0.75	0.33	Body mass index;	chr9:34102723	chr9:33697459~33700986:+
THCA	cis	rs1949733	0.585	rs2631768	ENSG00000205959.3	RP11-689P11.2	7.6	1.67e-13	5.87e-11	0.26	0.33	Response to antineoplastic agents;	chr4:8471323	chr4:8482270~8512610:+
THCA	cis	rs950169	0.614	rs12911536	ENSG00000259728.4	LINC00933	7.6	1.68e-13	5.88e-11	0.47	0.33	Schizophrenia;	chr15:84004278	chr15:84570649~84580175:+
THCA	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	7.6	1.68e-13	5.88e-11	0.43	0.33	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
THCA	cis	rs6762	0.55	rs8672	ENSG00000279672.1	CMB9-55F22.1	7.6	1.68e-13	5.88e-11	0.37	0.33	Mean platelet volume;	chr11:838634	chr11:779617~780755:+
THCA	cis	rs950169	0.526	rs698620	ENSG00000275120.1	RP11-182J1.17	-7.59	1.68e-13	5.89e-11	-0.34	-0.33	Schizophrenia;	chr15:84633977	chr15:84599434~84606463:-
THCA	cis	rs11673344	0.503	rs703531	ENSG00000226686.6	LINC01535	7.59	1.68e-13	5.9e-11	0.36	0.33	Obesity-related traits;	chr19:37010050	chr19:37251912~37265535:+
THCA	cis	rs728616	0.558	rs116434658	ENSG00000225484.5	NUTM2B-AS1	-7.59	1.68e-13	5.9e-11	-0.48	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chr10:79663088~79826594:-
THCA	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	7.59	1.68e-13	5.9e-11	0.38	0.33	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
THCA	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	7.59	1.68e-13	5.91e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
THCA	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	7.59	1.69e-13	5.91e-11	0.43	0.33	Height;	chr6:109416945	chr6:109382795~109383666:+
THCA	cis	rs9902453	0.791	rs6505141	ENSG00000264007.1	RP11-68I3.10	7.59	1.69e-13	5.92e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:29671169	chr17:29621617~29622254:-
THCA	cis	rs1949733	1	rs3103071	ENSG00000205959.3	RP11-689P11.2	7.59	1.69e-13	5.93e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8506852	chr4:8482270~8512610:+
THCA	cis	rs240993	0.812	rs459809	ENSG00000230177.1	RP5-1112D6.4	-7.59	1.69e-13	5.93e-11	-0.34	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111277932~111278742:+
THCA	cis	rs7208859	0.673	rs450585	ENSG00000266490.1	CTD-2349P21.9	7.59	1.69e-13	5.93e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30792372~30792833:+
THCA	cis	rs9902453	0.904	rs4461132	ENSG00000264007.1	RP11-68I3.10	7.59	1.69e-13	5.94e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30096412	chr17:29621617~29622254:-
THCA	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-7.59	1.7e-13	5.95e-11	-0.34	-0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
THCA	cis	rs2688608	0.592	rs11814282	ENSG00000271816.1	BMS1P4	7.59	1.7e-13	5.95e-11	0.34	0.33	Inflammatory bowel disease;	chr10:73730459	chr10:73699151~73730487:-
THCA	cis	rs914615	0.507	rs4971085	ENSG00000160766.13	GBAP1	-7.59	1.7e-13	5.96e-11	-0.36	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155165746	chr1:155213821~155227422:-
THCA	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-7.59	1.7e-13	5.97e-11	-0.36	-0.33	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-7.59	1.7e-13	5.97e-11	-0.36	-0.33	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
THCA	cis	rs7945705	0.875	rs10769957	ENSG00000254860.4	TMEM9B-AS1	7.59	1.7e-13	5.97e-11	0.36	0.33	Hemoglobin concentration;	chr11:8787469	chr11:8964675~8977527:+
THCA	cis	rs10181042	0.565	rs3108630	ENSG00000271889.1	RP11-493E12.1	-7.59	1.71e-13	5.98e-11	-0.3	-0.33	Crohn's disease;	chr2:61041025	chr2:61151433~61162105:-
THCA	cis	rs1949733	1	rs1949733	ENSG00000205959.3	RP11-689P11.2	7.59	1.71e-13	5.98e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8501632	chr4:8482270~8512610:+
THCA	cis	rs74233809	1	rs74233809	ENSG00000213277.3	MARCKSL1P1	7.59	1.71e-13	5.98e-11	0.54	0.33	Birth weight;	chr10:103154183	chr10:103175554~103176094:+
THCA	cis	rs832187	0.594	rs832197	ENSG00000280620.1	SCAANT1	-7.59	1.71e-13	6.01e-11	-0.45	-0.33	Schizophrenia;	chr3:63898616	chr3:63911518~63911772:-
THCA	cis	rs947583	1	rs947583	ENSG00000231028.7	LINC00271	-7.59	1.71e-13	6.01e-11	-0.28	-0.33	Phosphorus levels;	chr6:135812521	chr6:135497801~135716055:+
THCA	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	7.59	1.72e-13	6.01e-11	0.48	0.33	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	7.59	1.72e-13	6.01e-11	0.48	0.33	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
THCA	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	7.59	1.72e-13	6.03e-11	0.22	0.33	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000266490.1	CTD-2349P21.9	7.59	1.72e-13	6.03e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30792372~30792833:+
THCA	cis	rs9388451	0.903	rs7758115	ENSG00000237742.5	RP11-624M8.1	-7.59	1.72e-13	6.04e-11	-0.29	-0.33	Brugada syndrome;	chr6:125740356	chr6:125578558~125749190:-
THCA	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-7.59	1.73e-13	6.06e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-7.59	1.73e-13	6.06e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
THCA	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	7.59	1.73e-13	6.06e-11	0.2	0.33	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
THCA	cis	rs4273100	0.79	rs60166680	ENSG00000228157.4	AC007952.5	7.59	1.73e-13	6.07e-11	0.52	0.33	Schizophrenia;	chr17:19374231	chr17:19092974~19096837:+
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000237664.1	LINC00316	-7.59	1.73e-13	6.07e-11	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45338590~45341990:-
THCA	cis	rs11148252	0.538	rs9535885	ENSG00000235660.1	LINC00345	-7.59	1.74e-13	6.08e-11	-0.4	-0.33	Lewy body disease;	chr13:52152389	chr13:52484161~52484680:-
THCA	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-7.59	1.74e-13	6.08e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
THCA	cis	rs914615	0.552	rs4276914	ENSG00000160766.13	GBAP1	-7.59	1.74e-13	6.09e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155169753	chr1:155213821~155227422:-
THCA	cis	rs914615	0.552	rs4971088	ENSG00000160766.13	GBAP1	-7.59	1.74e-13	6.09e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155170407	chr1:155213821~155227422:-
THCA	cis	rs914615	0.552	rs4971089	ENSG00000160766.13	GBAP1	-7.59	1.74e-13	6.09e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155170451	chr1:155213821~155227422:-
THCA	cis	rs2361718	0.521	rs2361724	ENSG00000279259.1	RP11-334C17.3	7.59	1.74e-13	6.1e-11	0.33	0.33	Yeast infection;	chr17:80125315	chr17:80147250~80148596:+
THCA	cis	rs7811142	1	rs7783550	ENSG00000078319.8	PMS2P1	7.59	1.74e-13	6.1e-11	0.46	0.33	Platelet count;	chr7:100390182	chr7:100320992~100341908:-
THCA	cis	rs6723226	0.598	rs2710629	ENSG00000276334.1	AL133243.1	7.59	1.74e-13	6.1e-11	0.36	0.33	Intelligence (multi-trait analysis);	chr2:32540777	chr2:32521927~32523547:+
THCA	cis	rs934734	0.563	rs11126035	ENSG00000281920.1	RP11-418H16.1	7.59	1.74e-13	6.1e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65369932	chr2:65623272~65628424:+
THCA	cis	rs61041384	0.661	rs74240768	ENSG00000256092.2	RP13-942N8.1	-7.59	1.75e-13	6.11e-11	-0.48	-0.33	Schizophrenia;	chr12:123199429	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs74240769	ENSG00000256092.2	RP13-942N8.1	-7.59	1.75e-13	6.11e-11	-0.48	-0.33	Schizophrenia;	chr12:123203681	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs4759407	ENSG00000256092.2	RP13-942N8.1	-7.59	1.75e-13	6.11e-11	-0.48	-0.33	Schizophrenia;	chr12:123205127	chr12:123363868~123366113:+
THCA	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-7.59	1.75e-13	6.12e-11	-0.41	-0.33	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
THCA	cis	rs7811142	0.779	rs111312383	ENSG00000078319.8	PMS2P1	-7.59	1.75e-13	6.12e-11	-0.46	-0.33	Platelet count;	chr7:100307702	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.779	rs28680963	ENSG00000078319.8	PMS2P1	-7.59	1.75e-13	6.12e-11	-0.46	-0.33	Platelet count;	chr7:100307852	chr7:100320992~100341908:-
THCA	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-7.59	1.75e-13	6.13e-11	-0.41	-0.33	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
THCA	cis	rs1318937	1	rs2046725	ENSG00000224660.1	SH3BP5-AS1	7.59	1.75e-13	6.14e-11	0.24	0.33	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253651	chr3:15254184~15264493:+
THCA	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	7.59	1.75e-13	6.14e-11	0.42	0.33	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
THCA	cis	rs10181042	0.565	rs1177234	ENSG00000271889.1	RP11-493E12.1	7.59	1.75e-13	6.14e-11	0.31	0.33	Crohn's disease;	chr2:61032928	chr2:61151433~61162105:-
THCA	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-7.59	1.75e-13	6.14e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Body mass index;	chr17:30758740	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Body mass index;	chr17:30774046	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs12006	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30709299~30790908:+
THCA	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	7.59	1.76e-13	6.15e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
THCA	cis	rs2284219	0.929	rs12533248	ENSG00000244480.1	AC005154.7	-7.59	1.76e-13	6.15e-11	-0.26	-0.33	Type 2 diabetes;	chr7:30678973	chr7:30523143~30524535:-
THCA	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-7.59	1.76e-13	6.15e-11	-0.35	-0.33	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
THCA	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-7.59	1.76e-13	6.15e-11	-0.35	-0.33	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
THCA	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-7.59	1.76e-13	6.18e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
THCA	cis	rs1850744	0.702	rs10805314	ENSG00000250942.1	ENPP7P11	7.59	1.77e-13	6.18e-11	0.46	0.33	Economic and political preferences;	chr4:9701557	chr4:9677308~9677934:+
THCA	cis	rs7208859	0.673	rs216409	ENSG00000266490.1	CTD-2349P21.9	-7.59	1.77e-13	6.19e-11	-0.42	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30792372~30792833:+
THCA	cis	rs12928939	0.815	rs7185575	ENSG00000260886.1	TAT-AS1	7.59	1.77e-13	6.2e-11	0.43	0.33	Post bronchodilator FEV1;	chr16:71638666	chr16:71565789~71578187:+
THCA	cis	rs41307935	0.908	rs111707709	ENSG00000260063.1	RP5-968P14.2	-7.59	1.77e-13	6.21e-11	-0.61	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26848285	chr1:26692132~26694131:-
THCA	cis	rs10208649	0.656	rs60191560	ENSG00000272156.1	RP11-477N3.1	7.59	1.78e-13	6.21e-11	0.48	0.33	Body mass index;	chr2:54058661	chr2:54082554~54085066:+
THCA	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.22e-11	0.19	0.33	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.22e-11	0.19	0.33	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.22e-11	0.19	0.33	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.22e-11	0.19	0.33	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.23e-11	0.19	0.33	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
THCA	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-7.59	1.78e-13	6.23e-11	-0.41	-0.33	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
THCA	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-7.59	1.78e-13	6.23e-11	-0.41	-0.33	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
THCA	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-7.59	1.78e-13	6.23e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-7.59	1.78e-13	6.23e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
THCA	cis	rs7208859	0.614	rs73265646	ENSG00000264538.5	SUZ12P1	-7.59	1.78e-13	6.23e-11	-0.36	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30709299~30790908:+
THCA	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.23e-11	0.19	0.33	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
THCA	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	7.59	1.78e-13	6.23e-11	0.42	0.33	Height;	chr6:109773423	chr6:109382795~109383666:+
THCA	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-7.59	1.78e-13	6.24e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
THCA	cis	rs516805	0.706	rs11752939	ENSG00000279453.1	RP3-425C14.4	7.59	1.79e-13	6.24e-11	0.34	0.33	Lymphocyte counts;	chr6:122350062	chr6:122436789~122439223:-
THCA	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-7.59	1.79e-13	6.25e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-7.59	1.79e-13	6.25e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-7.59	1.79e-13	6.25e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2717602	ENSG00000253741.1	CTD-2292P10.4	-7.59	1.79e-13	6.25e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142724265	chr8:142702252~142726973:-
THCA	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-7.59	1.79e-13	6.25e-11	-0.28	-0.33	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-7.59	1.79e-13	6.25e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-7.59	1.79e-13	6.25e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000264538.5	SUZ12P1	-7.59	1.79e-13	6.26e-11	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30709299~30790908:+
THCA	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	7.59	1.79e-13	6.26e-11	0.42	0.33	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
THCA	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-7.59	1.79e-13	6.27e-11	-0.48	-0.33	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
THCA	cis	rs6762	0.692	rs5030778	ENSG00000279672.1	CMB9-55F22.1	7.58	1.8e-13	6.28e-11	0.37	0.33	Mean platelet volume;	chr11:836008	chr11:779617~780755:+
THCA	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	7.58	1.8e-13	6.28e-11	0.49	0.33	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000264538.5	SUZ12P1	-7.58	1.8e-13	6.29e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30709299~30790908:+
THCA	cis	rs5769707	0.604	rs1018814	ENSG00000235111.1	RP1-29C18.8	-7.58	1.8e-13	6.29e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49612657~49615716:-
THCA	cis	rs1667284	1	rs1667283	ENSG00000266521.1	RP11-650P15.1	7.58	1.81e-13	6.32e-11	0.41	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31643658	chr18:31496645~31497195:-
THCA	cis	rs728616	0.558	rs55803802	ENSG00000225484.5	NUTM2B-AS1	-7.58	1.81e-13	6.32e-11	-0.48	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79663088~79826594:-
THCA	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-7.58	1.81e-13	6.32e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
THCA	cis	rs3847687	0.966	rs3847689	ENSG00000279128.1	RP11-76C10.4	7.58	1.81e-13	6.33e-11	0.37	0.33	Longevity;	chr12:131040989	chr12:131022769~131024741:-
THCA	cis	rs79349575	0.716	rs595767	ENSG00000248278.1	SUMO2P17	7.58	1.81e-13	6.33e-11	0.39	0.33	Type 2 diabetes;	chr17:48880625	chr17:48874860~48908983:-
THCA	cis	rs9828933	0.752	rs12633353	ENSG00000280620.1	SCAANT1	7.58	1.82e-13	6.35e-11	0.66	0.33	Type 2 diabetes;	chr3:63984604	chr3:63911518~63911772:-
THCA	cis	rs1858037	0.867	rs871974	ENSG00000237979.1	AC007389.1	-7.58	1.82e-13	6.35e-11	-0.41	-0.33	Rheumatoid arthritis;	chr2:65330153	chr2:65500993~65502138:-
THCA	cis	rs28510890	0.658	rs12442454	ENSG00000260337.3	RP11-386M24.6	7.58	1.82e-13	6.35e-11	0.36	0.33	Lung cancer in ever smokers;	chr15:92615762	chr15:92592574~92596462:-
THCA	cis	rs13129231	0.924	rs2037675	ENSG00000206820.1	RNU1-138P	-7.58	1.82e-13	6.35e-11	-0.39	-0.33	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113422785	chr4:113420323~113420486:+
THCA	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-7.58	1.82e-13	6.36e-11	-0.41	-0.33	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
THCA	cis	rs11971779	0.793	rs9632774	ENSG00000273391.1	RP11-634H22.1	7.58	1.82e-13	6.36e-11	0.33	0.33	Diisocyanate-induced asthma;	chr7:139452816	chr7:139359032~139359566:-
THCA	cis	rs7247513	0.658	rs4804728	ENSG00000230310.1	CTD-2192J16.11	-7.58	1.82e-13	6.37e-11	-0.4	-0.33	Bipolar disorder;	chr19:12642114	chr19:12552597~12553644:+
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000266490.1	CTD-2349P21.9	7.58	1.82e-13	6.37e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30792372~30792833:+
THCA	cis	rs944289	0.562	rs860200	ENSG00000257826.1	RP11-116N8.4	-7.58	1.82e-13	6.37e-11	-0.34	-0.33	Thyroid cancer;	chr14:36057079	chr14:36061026~36067190:-
THCA	cis	rs9902453	0.967	rs12450956	ENSG00000264007.1	RP11-68I3.10	7.58	1.83e-13	6.38e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30202007	chr17:29621617~29622254:-
THCA	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	7.58	1.83e-13	6.38e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
THCA	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	7.58	1.83e-13	6.38e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
THCA	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	7.58	1.83e-13	6.38e-11	0.44	0.33	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
THCA	cis	rs801193	0.636	rs2659895	ENSG00000232559.3	GS1-124K5.12	7.58	1.83e-13	6.38e-11	0.31	0.33	Aortic root size;	chr7:66731484	chr7:66554588~66576923:-
THCA	cis	rs7829975	0.6	rs1719381	ENSG00000253893.2	FAM85B	7.58	1.83e-13	6.38e-11	0.42	0.33	Mood instability;	chr8:8744834	chr8:8167819~8226614:-
THCA	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-7.58	1.83e-13	6.38e-11	-0.4	-0.33	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
THCA	cis	rs9640161	0.83	rs17173702	ENSG00000261305.1	RP4-584D14.7	7.58	1.83e-13	6.39e-11	0.42	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150371516	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.83	rs17173703	ENSG00000261305.1	RP4-584D14.7	7.58	1.83e-13	6.39e-11	0.42	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150371531	chr7:150341771~150342607:+
THCA	cis	rs2032366	1	rs2032366	ENSG00000267279.1	RP11-879F14.2	-7.58	1.83e-13	6.39e-11	-0.33	-0.33	Obesity-related traits;	chr18:61599138	chr18:61585746~61606916:-
THCA	cis	rs1949733	1	rs2688233	ENSG00000205959.3	RP11-689P11.2	-7.58	1.83e-13	6.39e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8490158	chr4:8482270~8512610:+
THCA	cis	rs1949733	1	rs2631758	ENSG00000205959.3	RP11-689P11.2	7.58	1.83e-13	6.39e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8493577	chr4:8482270~8512610:+
THCA	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	7.58	1.83e-13	6.4e-11	0.85	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Body mass index;	chr17:30751280	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30709299~30790908:+
THCA	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	7.58	1.84e-13	6.41e-11	0.43	0.33	Height;	chr6:109359125	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	7.58	1.84e-13	6.41e-11	0.43	0.33	Height;	chr6:109360679	chr6:109382795~109383666:+
THCA	cis	rs17772222	0.74	rs3783885	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88510714	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs11159857	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88510796	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs4390529	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88510853	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.771	rs4516145	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88510953	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs4594187	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511071	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs4514599	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511083	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs73317739	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511400	chr14:88551597~88552493:+
THCA	cis	rs910316	0.967	rs4903293	ENSG00000279594.1	RP11-950C14.10	-7.58	1.84e-13	6.42e-11	-0.31	-0.33	Height;	chr14:75189865	chr14:75011269~75012851:-
THCA	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-7.58	1.84e-13	6.43e-11	-0.32	-0.33	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000264538.5	SUZ12P1	-7.58	1.85e-13	6.45e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30709299~30790908:+
THCA	cis	rs2274273	0.686	rs66782529	ENSG00000258413.1	RP11-665C16.6	-7.58	1.85e-13	6.45e-11	-0.46	-0.33	Protein biomarker;	chr14:55121149	chr14:55262767~55272075:-
THCA	cis	rs690037	0.641	rs538525	ENSG00000272498.1	RP11-415F23.3	-7.58	1.85e-13	6.45e-11	-0.36	-0.33	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334772	chr3:16339308~16339871:+
THCA	cis	rs7646881	1	rs59313096	ENSG00000240207.5	RP11-379F4.4	-7.58	1.85e-13	6.46e-11	-0.45	-0.33	Tetralogy of Fallot;	chr3:158734453	chr3:158732263~158784070:+
THCA	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	7.58	1.85e-13	6.46e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
THCA	cis	rs9847710	0.696	rs62253605	ENSG00000242142.1	SERBP1P3	7.58	1.85e-13	6.46e-11	0.4	0.33	Ulcerative colitis;	chr3:52944402	chr3:53064283~53065091:-
THCA	cis	rs1949733	1	rs1880023	ENSG00000205959.3	RP11-689P11.2	7.58	1.86e-13	6.47e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8479104	chr4:8482270~8512610:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000206090.4	AP000350.7	7.58	1.86e-13	6.48e-11	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23939998~23942798:+
THCA	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	7.58	1.86e-13	6.48e-11	0.26	0.33	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
THCA	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-7.58	1.87e-13	6.51e-11	-0.46	-0.33	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
THCA	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	7.58	1.87e-13	6.52e-11	0.36	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
THCA	cis	rs6558530	0.698	rs7015858	ENSG00000253982.1	CTD-2336O2.1	7.58	1.87e-13	6.52e-11	0.29	0.33	Systolic blood pressure;	chr8:1776141	chr8:1761990~1764502:-
THCA	cis	rs1318937	1	rs1318937	ENSG00000224660.1	SH3BP5-AS1	-7.58	1.87e-13	6.53e-11	-0.21	-0.33	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253857	chr3:15254184~15264493:+
THCA	cis	rs116175783	0.557	rs3731768	ENSG00000227403.1	AC009299.3	7.58	1.87e-13	6.53e-11	0.6	0.33	Intelligence (multi-trait analysis);	chr2:161250809	chr2:161244739~161249050:+
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000219392.1	RP1-265C24.5	7.58	1.88e-13	6.54e-11	0.36	0.33	Pubertal anthropometrics;	chr6:28255953	chr6:28115628~28116551:+
THCA	cis	rs240993	0.809	rs11153277	ENSG00000271789.1	RP5-1112D6.7	-7.58	1.88e-13	6.56e-11	-0.36	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111297126~111298510:+
THCA	cis	rs914615	0.552	rs11264337	ENSG00000160766.13	GBAP1	-7.58	1.89e-13	6.57e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155165974	chr1:155213821~155227422:-
THCA	cis	rs6496932	0.503	rs7164354	ENSG00000218052.5	ADAMTS7P4	-7.58	1.89e-13	6.59e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85405217	chr15:85255369~85330334:-
THCA	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-7.58	1.89e-13	6.59e-11	-0.35	-0.33	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
THCA	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	7.58	1.89e-13	6.6e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	7.58	1.89e-13	6.6e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
THCA	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-7.58	1.89e-13	6.6e-11	-0.23	-0.33	Breast cancer;	chr11:743813	chr11:781645~782105:+
THCA	cis	rs2135507	0.501	rs10030631	ENSG00000270480.1	RP11-57B24.1	-7.58	1.9e-13	6.6e-11	-0.5	-0.33	Juvenile osteochondritis dissecans;	chr4:82675592	chr4:82691737~82692468:+
THCA	cis	rs9902453	0.904	rs7213076	ENSG00000264007.1	RP11-68I3.10	-7.58	1.9e-13	6.62e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30092410	chr17:29621617~29622254:-
THCA	cis	rs7569084	0.522	rs906577	ENSG00000281920.1	RP11-418H16.1	7.58	1.9e-13	6.62e-11	0.43	0.33	Sum eosinophil basophil counts;	chr2:65369523	chr2:65623272~65628424:+
THCA	cis	rs934734	0.563	rs11673956	ENSG00000281920.1	RP11-418H16.1	7.58	1.9e-13	6.62e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65370523	chr2:65623272~65628424:+
THCA	cis	rs934734	0.563	rs11673987	ENSG00000281920.1	RP11-418H16.1	7.58	1.9e-13	6.62e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65370537	chr2:65623272~65628424:+
THCA	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	7.58	1.9e-13	6.64e-11	0.4	0.33	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
THCA	cis	rs5769707	0.681	rs2319346	ENSG00000235111.1	RP1-29C18.8	-7.58	1.91e-13	6.66e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49612657~49615716:-
THCA	cis	rs9902453	1	rs62070312	ENSG00000264007.1	RP11-68I3.10	7.58	1.91e-13	6.66e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30111859	chr17:29621617~29622254:-
THCA	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-7.58	1.92e-13	6.69e-11	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
THCA	cis	rs2688608	0.592	rs7908825	ENSG00000271816.1	BMS1P4	-7.57	1.93e-13	6.71e-11	-0.33	-0.33	Inflammatory bowel disease;	chr10:73794783	chr10:73699151~73730487:-
THCA	cis	rs8100891	0.665	rs7259259	ENSG00000267213.4	AC007773.2	-7.57	1.93e-13	6.72e-11	-0.29	-0.33	Neuroticism;	chr19:32328935	chr19:32390050~32405560:-
THCA	cis	rs11148252	0.583	rs9536048	ENSG00000278238.1	RP11-245D16.4	-7.57	1.93e-13	6.73e-11	-0.41	-0.33	Lewy body disease;	chr13:52384653	chr13:52454775~52455331:-
THCA	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
THCA	cis	rs12681366	0.919	rs13248829	ENSG00000253704.1	RP11-267M23.4	7.57	1.93e-13	6.73e-11	0.32	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94476750	chr8:94553722~94569745:+
THCA	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-7.57	1.93e-13	6.73e-11	-0.27	-0.33	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
THCA	cis	rs116175783	0.557	rs1146024	ENSG00000227403.1	AC009299.3	7.57	1.93e-13	6.73e-11	0.58	0.33	Intelligence (multi-trait analysis);	chr2:161282740	chr2:161244739~161249050:+
THCA	cis	rs5769707	0.749	rs8137251	ENSG00000235111.1	RP1-29C18.8	-7.57	1.93e-13	6.73e-11	-0.4	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49612657~49615716:-
THCA	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-7.57	1.94e-13	6.75e-11	-0.36	-0.33	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
THCA	cis	rs875971	1	rs10244498	ENSG00000232559.3	GS1-124K5.12	7.57	1.94e-13	6.75e-11	0.31	0.33	Aortic root size;	chr7:66651069	chr7:66554588~66576923:-
THCA	cis	rs9890032	0.57	rs8068504	ENSG00000263531.1	RP13-753N3.1	7.57	1.95e-13	6.77e-11	0.45	0.33	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30863921~30864940:-
THCA	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	7.57	1.95e-13	6.77e-11	0.32	0.33	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
THCA	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	7.57	1.95e-13	6.8e-11	0.41	0.33	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
THCA	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	7.57	1.96e-13	6.81e-11	0.4	0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
THCA	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	7.57	1.96e-13	6.81e-11	0.37	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
THCA	cis	rs7208859	0.673	rs216435	ENSG00000266490.1	CTD-2349P21.9	7.57	1.96e-13	6.81e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30792372~30792833:+
THCA	cis	rs12655019	0.92	rs75167082	ENSG00000271828.1	CTD-2310F14.1	7.57	1.96e-13	6.82e-11	0.75	0.33	Breast cancer (early onset);	chr5:56915577	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs1466007	ENSG00000271828.1	CTD-2310F14.1	7.57	1.96e-13	6.82e-11	0.75	0.33	Breast cancer (early onset);	chr5:56917812	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs74865790	ENSG00000271828.1	CTD-2310F14.1	7.57	1.96e-13	6.82e-11	0.75	0.33	Breast cancer (early onset);	chr5:56923871	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs12657064	ENSG00000271828.1	CTD-2310F14.1	7.57	1.96e-13	6.82e-11	0.75	0.33	Breast cancer (early onset);	chr5:56925172	chr5:56927874~56929573:+
THCA	cis	rs7267979	0.873	rs7453	ENSG00000274414.1	RP5-965G21.4	-7.57	1.96e-13	6.83e-11	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25239007~25245229:-
THCA	cis	rs17772222	0.71	rs1028455	ENSG00000258789.1	RP11-507K2.3	-7.57	1.96e-13	6.83e-11	-0.31	-0.33	Coronary artery calcification;	chr14:88363631	chr14:88551597~88552493:+
THCA	cis	rs10971721	0.643	rs10971699	ENSG00000281128.1	PTENP1-AS	7.57	1.97e-13	6.84e-11	0.84	0.33	Body mass index;	chr9:33777186	chr9:33677268~33688011:+
THCA	cis	rs6600671	1	rs1856572	ENSG00000223345.3	HIST2H2BA	7.57	1.97e-13	6.84e-11	0.36	0.33	Hip geometry;	chr1:121427719	chr1:121108210~121117257:-
THCA	cis	rs11673344	0.542	rs2562598	ENSG00000226686.6	LINC01535	7.57	1.97e-13	6.85e-11	0.36	0.33	Obesity-related traits;	chr19:37025318	chr19:37251912~37265535:+
THCA	cis	rs1949733	1	rs1916326	ENSG00000205959.3	RP11-689P11.2	7.57	1.98e-13	6.87e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8498296	chr4:8482270~8512610:+
THCA	cis	rs1949733	1	rs2140337	ENSG00000205959.3	RP11-689P11.2	-7.57	1.98e-13	6.87e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8500385	chr4:8482270~8512610:+
THCA	cis	rs1949733	1	rs6837429	ENSG00000205959.3	RP11-689P11.2	-7.57	1.98e-13	6.87e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8500647	chr4:8482270~8512610:+
THCA	cis	rs6745190	1	rs6745190	ENSG00000236153.1	AC104076.3	-7.57	1.98e-13	6.9e-11	-0.4	-0.33	White blood cell count;	chr2:181042998	chr2:180979427~180980090:-
THCA	cis	rs7208859	0.673	rs216420	ENSG00000266490.1	CTD-2349P21.9	7.57	1.99e-13	6.9e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30792372~30792833:+
THCA	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	7.57	1.99e-13	6.91e-11	0.42	0.33	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
THCA	cis	rs3847687	0.966	rs3847689	ENSG00000279993.1	RP11-76C10.3	7.57	1.99e-13	6.91e-11	0.36	0.33	Longevity;	chr12:131040989	chr12:131025561~131028060:-
THCA	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-7.57	1.99e-13	6.91e-11	-0.56	-0.33	Depression;	chr6:28159062	chr6:28115628~28116551:+
THCA	cis	rs6745190	0.953	rs10171108	ENSG00000236153.1	AC104076.3	7.57	1.99e-13	6.92e-11	0.39	0.33	White blood cell count;	chr2:181046944	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.953	rs6744130	ENSG00000236153.1	AC104076.3	7.57	1.99e-13	6.92e-11	0.39	0.33	White blood cell count;	chr2:181048088	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.953	rs6731268	ENSG00000236153.1	AC104076.3	7.57	1.99e-13	6.92e-11	0.39	0.33	White blood cell count;	chr2:181048264	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.953	rs10171998	ENSG00000236153.1	AC104076.3	7.57	1.99e-13	6.92e-11	0.39	0.33	White blood cell count;	chr2:181054763	chr2:180979427~180980090:-
THCA	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	7.57	1.99e-13	6.92e-11	0.61	0.33	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
THCA	cis	rs516805	0.748	rs11154072	ENSG00000279453.1	RP3-425C14.4	7.57	1.99e-13	6.93e-11	0.34	0.33	Lymphocyte counts;	chr6:122374632	chr6:122436789~122439223:-
THCA	cis	rs7176527	0.784	rs62021162	ENSG00000188388.10	GOLGA6L3	7.57	2e-13	6.94e-11	0.48	0.33	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85240472~85247170:+
THCA	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	7.57	2e-13	6.94e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
THCA	cis	rs10055631	0.518	rs2662226	ENSG00000229666.1	MAST4-AS1	-7.57	2e-13	6.95e-11	-0.38	-0.33	Coronary artery disease;	chr5:67017390	chr5:67001383~67003953:-
THCA	cis	rs7015630	0.505	rs11989430	ENSG00000251136.7	RP11-37B2.1	-7.57	2.01e-13	6.97e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr8:89806387	chr8:89609409~89757727:-
THCA	cis	rs7208859	0.673	rs9895684	ENSG00000264538.5	SUZ12P1	-7.57	2.01e-13	6.98e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30709299~30790908:+
THCA	cis	rs957448	0.561	rs12679785	ENSG00000253704.1	RP11-267M23.4	7.57	2.02e-13	7e-11	0.34	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94553722~94569745:+
THCA	cis	rs957448	0.561	rs13258635	ENSG00000253704.1	RP11-267M23.4	7.57	2.02e-13	7e-11	0.34	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94553722~94569745:+
THCA	cis	rs12680842	0.842	rs34691145	ENSG00000253704.1	RP11-267M23.4	7.57	2.02e-13	7e-11	0.34	0.33	Body mass index;	chr8:94597715	chr8:94553722~94569745:+
THCA	cis	rs2688608	0.592	rs10824032	ENSG00000271816.1	BMS1P4	7.57	2.02e-13	7.02e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73768372	chr10:73699151~73730487:-
THCA	cis	rs1009647	0.614	rs60726667	ENSG00000258413.1	RP11-665C16.6	-7.57	2.02e-13	7.03e-11	-0.59	-0.33	Testicular germ cell tumor;	chr14:55391205	chr14:55262767~55272075:-
THCA	cis	rs7942368	0.941	rs1465900	ENSG00000254632.1	RP11-21L23.4	7.57	2.03e-13	7.04e-11	0.47	0.33	Endometriosis;	chr11:76762094	chr11:76759916~76768223:-
THCA	cis	rs7942368	1	rs10160660	ENSG00000254632.1	RP11-21L23.4	7.57	2.03e-13	7.04e-11	0.47	0.33	Endometriosis;	chr11:76763493	chr11:76759916~76768223:-
THCA	cis	rs6496932	0.503	rs7170085	ENSG00000218052.5	ADAMTS7P4	-7.57	2.03e-13	7.05e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85255369~85330334:-
THCA	cis	rs10208649	0.731	rs6760038	ENSG00000272156.1	RP11-477N3.1	7.57	2.03e-13	7.06e-11	0.7	0.33	Body mass index;	chr2:53661017	chr2:54082554~54085066:+
THCA	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	7.57	2.04e-13	7.09e-11	0.41	0.33	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
THCA	cis	rs12928939	0.774	rs7192860	ENSG00000260886.1	TAT-AS1	7.57	2.05e-13	7.11e-11	0.43	0.33	Post bronchodilator FEV1;	chr16:71609719	chr16:71565789~71578187:+
THCA	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-7.57	2.05e-13	7.11e-11	-0.31	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
THCA	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-7.57	2.05e-13	7.13e-11	-0.47	-0.33	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
THCA	cis	rs4820539	1	rs4822357	ENSG00000221069.1	AC000029.1	-7.56	2.06e-13	7.16e-11	-0.4	-0.33	Bone mineral density;	chr22:23131044	chr22:23136620~23136710:+
THCA	cis	rs9549328	0.731	rs55804996	ENSG00000267868.1	RP11-120K24.3	7.56	2.07e-13	7.17e-11	0.34	0.33	Systolic blood pressure;	chr13:112971053	chr13:112964835~112966131:-
THCA	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-7.56	2.07e-13	7.17e-11	-0.35	-0.33	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
THCA	cis	rs172166	0.516	rs1225710	ENSG00000219392.1	RP1-265C24.5	7.56	2.07e-13	7.17e-11	0.36	0.33	Cardiac Troponin-T levels;	chr6:28132862	chr6:28115628~28116551:+
THCA	cis	rs7942368	1	rs1440978	ENSG00000254761.1	RP11-672A2.1	7.56	2.07e-13	7.17e-11	0.46	0.33	Endometriosis;	chr11:76765236	chr11:76712396~76719608:-
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000237664.1	LINC00316	-7.56	2.07e-13	7.18e-11	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45338590~45341990:-
THCA	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-7.56	2.07e-13	7.18e-11	-0.48	-0.33	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-7.56	2.07e-13	7.18e-11	-0.48	-0.33	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
THCA	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	7.56	2.07e-13	7.19e-11	0.39	0.33	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	7.56	2.07e-13	7.19e-11	0.39	0.33	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
THCA	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	7.56	2.07e-13	7.19e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
THCA	cis	rs7727544	0.606	rs72795121	ENSG00000233006.5	AC034220.3	7.56	2.07e-13	7.19e-11	0.26	0.33	Blood metabolite levels;	chr5:132302631	chr5:132311285~132369916:-
THCA	cis	rs853679	1	rs1778508	ENSG00000219392.1	RP1-265C24.5	7.56	2.08e-13	7.2e-11	0.51	0.33	Depression;	chr6:28262103	chr6:28115628~28116551:+
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000264538.5	SUZ12P1	-7.56	2.08e-13	7.21e-11	-0.33	-0.33	Body mass index;	chr17:30730179	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000264538.5	SUZ12P1	-7.56	2.08e-13	7.21e-11	-0.33	-0.33	Body mass index;	chr17:30730744	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000264538.5	SUZ12P1	-7.56	2.08e-13	7.21e-11	-0.33	-0.33	Body mass index;	chr17:30731712	chr17:30709299~30790908:+
THCA	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	7.56	2.08e-13	7.23e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	7.56	2.08e-13	7.23e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
THCA	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	7.56	2.08e-13	7.23e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
THCA	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	7.56	2.08e-13	7.23e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000206090.4	AP000350.7	7.56	2.09e-13	7.24e-11	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23939998~23942798:+
THCA	cis	rs944289	0.536	rs1951375	ENSG00000257826.1	RP11-116N8.4	-7.56	2.09e-13	7.25e-11	-0.34	-0.33	Thyroid cancer;	chr14:36051569	chr14:36061026~36067190:-
THCA	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	7.56	2.09e-13	7.25e-11	0.44	0.33	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
THCA	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	7.56	2.1e-13	7.29e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
THCA	cis	rs73607972	0.501	rs4784317	ENSG00000275191.1	RP11-36I17.2	-7.56	2.1e-13	7.29e-11	-0.48	-0.33	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53552273	chr16:53628256~53628816:-
THCA	cis	rs875971	1	rs2420820	ENSG00000232559.3	GS1-124K5.12	-7.56	2.1e-13	7.29e-11	-0.31	-0.33	Aortic root size;	chr7:66626920	chr7:66554588~66576923:-
THCA	cis	rs2839186	0.605	rs2839173	ENSG00000239415.1	AP001469.9	7.56	2.11e-13	7.3e-11	0.35	0.33	Testicular germ cell tumor;	chr21:46256797	chr21:46251549~46254133:-
THCA	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	7.56	2.11e-13	7.31e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000264538.5	SUZ12P1	-7.56	2.11e-13	7.32e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30709299~30790908:+
THCA	cis	rs10971721	0.584	rs56145814	ENSG00000260947.1	RP11-384P7.7	7.56	2.11e-13	7.32e-11	0.75	0.33	Body mass index;	chr9:34088953	chr9:33697459~33700986:+
THCA	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-7.56	2.11e-13	7.33e-11	-0.47	-0.33	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
THCA	cis	rs116175783	0.557	rs1267058	ENSG00000227403.1	AC009299.3	-7.56	2.11e-13	7.33e-11	-0.58	-0.33	Intelligence (multi-trait analysis);	chr2:161264934	chr2:161244739~161249050:+
THCA	cis	rs4718428	1	rs12534637	ENSG00000273142.1	RP11-458F8.4	-7.56	2.12e-13	7.34e-11	-0.27	-0.33	Corneal structure;	chr7:66862667	chr7:66902857~66906297:+
THCA	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	7.56	2.12e-13	7.34e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
THCA	cis	rs1009647	0.633	rs11626485	ENSG00000258413.1	RP11-665C16.6	-7.56	2.12e-13	7.35e-11	-0.58	-0.33	Testicular germ cell tumor;	chr14:55360046	chr14:55262767~55272075:-
THCA	cis	rs10971721	0.584	rs72731212	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34109710	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs12376939	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34110139	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731214	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34113019	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs117997985	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34113176	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731216	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34115066	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971933	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34117073	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971935	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34118147	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971936	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34118988	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731217	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34119555	chr9:33697459~33700986:+
THCA	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-7.56	2.13e-13	7.37e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
THCA	cis	rs17826219	0.706	rs609472	ENSG00000266490.1	CTD-2349P21.9	7.56	2.13e-13	7.38e-11	0.41	0.33	Body mass index;	chr17:30624409	chr17:30792372~30792833:+
THCA	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-7.56	2.13e-13	7.38e-11	-0.3	-0.33	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
THCA	cis	rs9902453	0.817	rs880749	ENSG00000264007.1	RP11-68I3.10	-7.56	2.13e-13	7.39e-11	-0.38	-0.33	Coffee consumption (cups per day);	chr17:29732952	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs4473252	ENSG00000264007.1	RP11-68I3.10	7.56	2.13e-13	7.39e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30127405	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.836	rs62070337	ENSG00000264007.1	RP11-68I3.10	7.56	2.13e-13	7.39e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30139239	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.899	rs8067580	ENSG00000264007.1	RP11-68I3.10	7.56	2.13e-13	7.39e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30144230	chr17:29621617~29622254:-
THCA	cis	rs12817211	0.502	rs34167640	ENSG00000272368.2	RP4-605O3.4	-7.56	2.14e-13	7.41e-11	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50123208	chr12:50112197~50165618:+
THCA	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	7.56	2.14e-13	7.43e-11	0.43	0.33	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
THCA	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	7.56	2.14e-13	7.43e-11	0.43	0.33	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
THCA	cis	rs593531	0.614	rs596976	ENSG00000212961.4	HNRNPA1P40	-7.56	2.15e-13	7.45e-11	-0.42	-0.33	Neuroticism;	chr11:74332663	chr11:74354443~74355720:+
THCA	cis	rs4073416	0.712	rs11624104	ENSG00000276116.2	FUT8-AS1	-7.56	2.15e-13	7.46e-11	-0.33	-0.33	N-glycan levels;	chr14:65729419	chr14:65411170~65412690:-
THCA	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	7.56	2.15e-13	7.46e-11	0.35	0.33	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
THCA	cis	rs28510890	0.688	rs28438060	ENSG00000260337.3	RP11-386M24.6	7.56	2.16e-13	7.47e-11	0.36	0.33	Lung cancer in ever smokers;	chr15:92616176	chr15:92592574~92596462:-
THCA	cis	rs651907	0.557	rs11712748	ENSG00000256628.3	ZBTB11-AS1	7.56	2.16e-13	7.48e-11	0.39	0.33	Colorectal cancer;	chr3:101664718	chr3:101676475~101679217:+
THCA	cis	rs853679	1	rs2799077	ENSG00000219392.1	RP1-265C24.5	-7.56	2.17e-13	7.5e-11	-0.52	-0.33	Depression;	chr6:28266819	chr6:28115628~28116551:+
THCA	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-7.56	2.17e-13	7.51e-11	-0.32	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
THCA	cis	rs6600671	1	rs2185281	ENSG00000223345.3	HIST2H2BA	7.56	2.17e-13	7.52e-11	0.36	0.33	Hip geometry;	chr1:121438132	chr1:121108210~121117257:-
THCA	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-7.56	2.17e-13	7.52e-11	-0.4	-0.33	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
THCA	cis	rs9640161	0.789	rs66688634	ENSG00000261305.1	RP4-584D14.7	7.56	2.17e-13	7.52e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150356717	chr7:150341771~150342607:+
THCA	cis	rs9902453	0.933	rs7224199	ENSG00000264007.1	RP11-68I3.10	7.56	2.17e-13	7.53e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30196708	chr17:29621617~29622254:-
THCA	cis	rs1318937	0.915	rs78365740	ENSG00000224660.1	SH3BP5-AS1	7.56	2.17e-13	7.53e-11	0.25	0.33	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15258339	chr3:15254184~15264493:+
THCA	cis	rs6496932	0.503	rs7170370	ENSG00000218052.5	ADAMTS7P4	-7.56	2.18e-13	7.55e-11	-0.43	-0.33	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85255369~85330334:-
THCA	cis	rs7267979	0.903	rs6107015	ENSG00000274414.1	RP5-965G21.4	-7.56	2.18e-13	7.55e-11	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25239007~25245229:-
THCA	cis	rs2522056	1	rs2706383	ENSG00000233006.5	AC034220.3	-7.56	2.19e-13	7.57e-11	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132456710	chr5:132311285~132369916:-
THCA	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	7.56	2.19e-13	7.58e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
THCA	cis	rs1015362	0.503	rs4911371	ENSG00000276073.1	RP5-1125A11.7	-7.56	2.19e-13	7.59e-11	-0.35	-0.33	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33985617~33988989:-
THCA	cis	rs9500256	0.515	rs12207710	ENSG00000215190.7	LINC00680	-7.56	2.2e-13	7.6e-11	-0.42	-0.33	Eosinophilic esophagitis (pediatric);	chr6:57943175	chr6:57946074~57961501:-
THCA	cis	rs193541	0.564	rs62377434	ENSG00000263432.2	RN7SL689P	-7.56	2.2e-13	7.6e-11	-0.4	-0.33	Glucose homeostasis traits;	chr5:123004874	chr5:123022487~123022783:-
THCA	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
THCA	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
THCA	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	7.56	2.2e-13	7.62e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
THCA	cis	rs11673344	0.523	rs2562594	ENSG00000226686.6	LINC01535	7.56	2.2e-13	7.62e-11	0.36	0.33	Obesity-related traits;	chr19:37023783	chr19:37251912~37265535:+
THCA	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	7.55	2.21e-13	7.63e-11	0.41	0.33	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	7.55	2.21e-13	7.63e-11	0.41	0.33	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
THCA	cis	rs1150668	0.745	rs213238	ENSG00000219392.1	RP1-265C24.5	-7.55	2.21e-13	7.64e-11	-0.37	-0.33	Pubertal anthropometrics;	chr6:28354216	chr6:28115628~28116551:+
THCA	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	7.55	2.21e-13	7.64e-11	0.42	0.33	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
THCA	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-7.55	2.21e-13	7.65e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
THCA	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-7.55	2.21e-13	7.65e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
THCA	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-7.55	2.22e-13	7.67e-11	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
THCA	cis	rs2297363	0.841	rs13220323	ENSG00000213073.4	RP11-288H12.3	-7.55	2.22e-13	7.67e-11	-0.35	-0.33	Total cholesterol levels;Blood protein levels;	chr6:160085723	chr6:160093082~160096212:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Body mass index;	chr17:30756962	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Body mass index;	chr17:30758695	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Body mass index;	chr17:30772984	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Body mass index;	chr17:30779631	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000264538.5	SUZ12P1	7.55	2.22e-13	7.68e-11	0.33	0.33	Body mass index;	chr17:30767864	chr17:30709299~30790908:+
THCA	cis	rs42490	0.536	rs366867	ENSG00000251136.7	RP11-37B2.1	-7.55	2.22e-13	7.68e-11	-0.3	-0.33	Leprosy;	chr8:89851946	chr8:89609409~89757727:-
THCA	cis	rs42490	0.576	rs425140	ENSG00000251136.7	RP11-37B2.1	-7.55	2.22e-13	7.68e-11	-0.3	-0.33	Leprosy;	chr8:89852397	chr8:89609409~89757727:-
THCA	cis	rs42490	0.576	rs377897	ENSG00000251136.7	RP11-37B2.1	-7.55	2.22e-13	7.68e-11	-0.3	-0.33	Leprosy;	chr8:89852734	chr8:89609409~89757727:-
THCA	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	7.55	2.23e-13	7.7e-11	0.19	0.33	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
THCA	cis	rs11673344	0.542	rs2562585	ENSG00000226686.6	LINC01535	7.55	2.23e-13	7.7e-11	0.36	0.33	Obesity-related traits;	chr19:37018321	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs8101392	ENSG00000226686.6	LINC01535	7.55	2.23e-13	7.7e-11	0.36	0.33	Obesity-related traits;	chr19:37024416	chr19:37251912~37265535:+
THCA	cis	rs6504108	0.624	rs2305433	ENSG00000278765.1	RP5-890E16.5	7.55	2.23e-13	7.7e-11	0.37	0.33	Body mass index;	chr17:48188071	chr17:48066704~48067293:-
THCA	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	7.55	2.23e-13	7.71e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	7.55	2.23e-13	7.71e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	7.55	2.23e-13	7.71e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
THCA	cis	rs7942368	1	rs1440979	ENSG00000254632.1	RP11-21L23.4	7.55	2.23e-13	7.71e-11	0.47	0.33	Endometriosis;	chr11:76784085	chr11:76759916~76768223:-
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000264538.5	SUZ12P1	-7.55	2.24e-13	7.72e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30709299~30790908:+
THCA	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	7.55	2.24e-13	7.72e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	7.55	2.24e-13	7.72e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
THCA	cis	rs910316	0.967	rs4384542	ENSG00000279594.1	RP11-950C14.10	-7.55	2.24e-13	7.73e-11	-0.31	-0.33	Height;	chr14:75191310	chr14:75011269~75012851:-
THCA	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	7.55	2.24e-13	7.73e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
THCA	cis	rs6745190	0.953	rs6433883	ENSG00000236153.1	AC104076.3	7.55	2.24e-13	7.73e-11	0.38	0.33	White blood cell count;	chr2:181046155	chr2:180979427~180980090:-
THCA	cis	rs910316	0.934	rs7141705	ENSG00000279594.1	RP11-950C14.10	-7.55	2.24e-13	7.73e-11	-0.31	-0.33	Height;	chr14:75188649	chr14:75011269~75012851:-
THCA	cis	rs9902453	0.904	rs12952179	ENSG00000264007.1	RP11-68I3.10	-7.55	2.24e-13	7.75e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30085669	chr17:29621617~29622254:-
THCA	cis	rs2288884	0.541	rs8107827	ENSG00000275055.1	CTC-471J1.11	-7.55	2.25e-13	7.76e-11	-0.33	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51962228	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.505	rs4988334	ENSG00000275055.1	CTC-471J1.11	-7.55	2.25e-13	7.76e-11	-0.33	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965745	chr19:52049007~52049754:+
THCA	cis	rs9640161	0.658	rs74348353	ENSG00000261305.1	RP4-584D14.7	7.55	2.25e-13	7.76e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150356566	chr7:150341771~150342607:+
THCA	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
THCA	cis	rs240993	0.812	rs10214442	ENSG00000230177.1	RP5-1112D6.4	-7.55	2.25e-13	7.77e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111277932~111278742:+
THCA	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-7.55	2.25e-13	7.77e-11	-0.41	-0.33	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
THCA	cis	rs193541	0.53	rs6595405	ENSG00000263432.2	RN7SL689P	7.55	2.25e-13	7.77e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122749050	chr5:123022487~123022783:-
THCA	cis	rs829883	0.738	rs249854	ENSG00000227825.4	SLC9A7P1	7.55	2.25e-13	7.78e-11	0.28	0.33	Colorectal adenoma (advanced);	chr12:98468994	chr12:98453835~98457145:-
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000264538.5	SUZ12P1	-7.55	2.26e-13	7.79e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30709299~30790908:+
THCA	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-7.55	2.26e-13	7.8e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-7.55	2.26e-13	7.8e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-7.55	2.26e-13	7.8e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-7.55	2.26e-13	7.8e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
THCA	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-7.55	2.26e-13	7.81e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
THCA	cis	rs9813712	0.597	rs10934931	ENSG00000228252.7	COL6A4P2	-7.55	2.26e-13	7.81e-11	-0.32	-0.33	Response to amphetamines;	chr3:130261365	chr3:130212823~130273806:+
THCA	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	7.55	2.27e-13	7.82e-11	0.44	0.33	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.572	rs7519348	ENSG00000237899.1	RP4-739H11.3	-7.55	2.27e-13	7.82e-11	-0.4	-0.33	Platelet count;	chr1:40694532	chr1:40669089~40687588:-
THCA	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	7.55	2.27e-13	7.83e-11	0.43	0.33	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
THCA	cis	rs6840258	0.66	rs55851914	ENSG00000251411.1	RP11-397E7.4	-7.55	2.27e-13	7.84e-11	-0.41	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955903	chr4:86913266~86914817:-
THCA	cis	rs17684571	0.748	rs13192478	ENSG00000231441.1	RP11-472M19.2	7.55	2.27e-13	7.84e-11	0.41	0.33	Schizophrenia;	chr6:56719979	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs13213878	ENSG00000231441.1	RP11-472M19.2	7.55	2.27e-13	7.84e-11	0.41	0.33	Schizophrenia;	chr6:56725043	chr6:56844002~56864078:+
THCA	cis	rs42490	0.576	rs381456	ENSG00000251136.7	RP11-37B2.1	-7.55	2.27e-13	7.84e-11	-0.3	-0.33	Leprosy;	chr8:89865176	chr8:89609409~89757727:-
THCA	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	7.55	2.28e-13	7.85e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
THCA	cis	rs9388451	0.839	rs9321054	ENSG00000237742.5	RP11-624M8.1	7.55	2.28e-13	7.87e-11	0.28	0.33	Brugada syndrome;	chr6:125758822	chr6:125578558~125749190:-
THCA	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	7.55	2.28e-13	7.87e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
THCA	cis	rs240993	0.812	rs9487639	ENSG00000230177.1	RP5-1112D6.4	-7.55	2.29e-13	7.89e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111426791	chr6:111277932~111278742:+
THCA	cis	rs7302981	0.967	rs11831413	ENSG00000272368.2	RP4-605O3.4	7.55	2.29e-13	7.89e-11	0.2	0.33	Systolic blood pressure;	chr12:50156600	chr12:50112197~50165618:+
THCA	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	7.55	2.29e-13	7.91e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
THCA	cis	rs12928939	0.815	rs10500560	ENSG00000260886.1	TAT-AS1	7.55	2.29e-13	7.91e-11	0.43	0.33	Post bronchodilator FEV1;	chr16:71647250	chr16:71565789~71578187:+
THCA	cis	rs9329221	0.527	rs6989657	ENSG00000261451.1	RP11-981G7.1	7.55	2.3e-13	7.94e-11	0.43	0.33	Neuroticism;	chr8:10473363	chr8:10433672~10438312:+
THCA	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-7.55	2.3e-13	7.95e-11	-0.47	-0.33	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
THCA	cis	rs2562456	0.793	rs2650819	ENSG00000268555.1	RP11-678G14.3	-7.55	2.31e-13	7.95e-11	-0.47	-0.33	Pain;	chr19:21456071	chr19:21570822~21587322:-
THCA	cis	rs10208649	1	rs78887562	ENSG00000272156.1	RP11-477N3.1	7.55	2.31e-13	7.95e-11	0.68	0.33	Body mass index;	chr2:53904409	chr2:54082554~54085066:+
THCA	cis	rs9388451	0.874	rs7739566	ENSG00000237742.5	RP11-624M8.1	-7.55	2.31e-13	7.96e-11	-0.28	-0.33	Brugada syndrome;	chr6:125773611	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.839	rs4897155	ENSG00000237742.5	RP11-624M8.1	-7.55	2.31e-13	7.96e-11	-0.28	-0.33	Brugada syndrome;	chr6:125773998	chr6:125578558~125749190:-
THCA	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	7.55	2.31e-13	7.96e-11	0.21	0.33	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
THCA	cis	rs8027521	0.54	rs2725582	ENSG00000280362.1	RP11-643A5.3	-7.55	2.31e-13	7.96e-11	-0.45	-0.33	Circulating chemerin levels;	chr15:53971770	chr15:53910769~53914712:+
THCA	cis	rs7247513	0.797	rs3815914	ENSG00000230310.1	CTD-2192J16.11	-7.55	2.31e-13	7.97e-11	-0.39	-0.33	Bipolar disorder;	chr19:12649850	chr19:12552597~12553644:+
THCA	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	7.55	2.31e-13	7.98e-11	0.7	0.33	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
THCA	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-7.55	2.32e-13	7.98e-11	-0.4	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-7.55	2.32e-13	7.98e-11	-0.4	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-7.55	2.32e-13	7.98e-11	-0.4	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-7.55	2.32e-13	7.98e-11	-0.4	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
THCA	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	7.55	2.32e-13	7.98e-11	0.41	0.33	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
THCA	cis	rs957448	0.748	rs12680342	ENSG00000253704.1	RP11-267M23.4	7.55	2.32e-13	7.99e-11	0.38	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94347410	chr8:94553722~94569745:+
THCA	cis	rs748404	0.518	rs480108	ENSG00000166763.7	STRCP1	7.55	2.32e-13	7.99e-11	0.35	0.33	Lung cancer;	chr15:43525208	chr15:43699488~43718184:-
THCA	cis	rs748404	0.56	rs572837	ENSG00000166763.7	STRCP1	7.55	2.32e-13	7.99e-11	0.35	0.33	Lung cancer;	chr15:43531615	chr15:43699488~43718184:-
THCA	cis	rs116175783	0.557	rs3769968	ENSG00000227403.1	AC009299.3	7.55	2.32e-13	7.99e-11	0.57	0.33	Intelligence (multi-trait analysis);	chr2:161309640	chr2:161244739~161249050:+
THCA	cis	rs116175783	0.557	rs1733180	ENSG00000227403.1	AC009299.3	-7.55	2.32e-13	7.99e-11	-0.57	-0.33	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161244739~161249050:+
THCA	cis	rs801193	0.548	rs2659904	ENSG00000232559.3	GS1-124K5.12	7.55	2.32e-13	8e-11	0.32	0.33	Aortic root size;	chr7:66713615	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000264538.5	SUZ12P1	-7.55	2.32e-13	8e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30709299~30790908:+
THCA	cis	rs9902453	0.967	rs11080121	ENSG00000264007.1	RP11-68I3.10	7.55	2.32e-13	8e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30201824	chr17:29621617~29622254:-
THCA	cis	rs6539288	0.901	rs7974499	ENSG00000260329.1	RP11-412D9.4	-7.55	2.32e-13	8.01e-11	-0.3	-0.33	Total body bone mineral density;	chr12:106947607	chr12:106954029~106955497:-
THCA	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-7.55	2.33e-13	8.02e-11	-0.35	-0.33	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
THCA	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	7.55	2.33e-13	8.03e-11	0.42	0.33	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
THCA	cis	rs950169	0.545	rs4354897	ENSG00000259728.4	LINC00933	7.55	2.33e-13	8.03e-11	0.47	0.33	Schizophrenia;	chr15:83976219	chr15:84570649~84580175:+
THCA	cis	rs2439831	0.867	rs12443102	ENSG00000249839.1	AC011330.5	-7.55	2.33e-13	8.04e-11	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43639905	chr15:43663654~43684339:-
THCA	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	7.55	2.33e-13	8.04e-11	0.31	0.33	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
THCA	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	7.55	2.34e-13	8.05e-11	0.41	0.33	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
THCA	cis	rs9902453	0.967	rs12602065	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30155470	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs4343336	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30161218	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs7223645	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30164011	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs12450441	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30168003	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs7222685	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30169412	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs34433787	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30169762	chr17:29621617~29622254:-
THCA	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-7.55	2.34e-13	8.05e-11	-0.36	-0.33	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
THCA	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-7.55	2.34e-13	8.05e-11	-0.39	-0.33	Migraine;	chr4:56881195	chr4:56960927~56961373:-
THCA	cis	rs42490	0.576	rs376962	ENSG00000251136.7	RP11-37B2.1	-7.55	2.34e-13	8.06e-11	-0.3	-0.33	Leprosy;	chr8:89862004	chr8:89609409~89757727:-
THCA	cis	rs42490	0.576	rs386587	ENSG00000251136.7	RP11-37B2.1	-7.55	2.34e-13	8.06e-11	-0.3	-0.33	Leprosy;	chr8:89862772	chr8:89609409~89757727:-
THCA	cis	rs2688608	0.592	rs11000757	ENSG00000271816.1	BMS1P4	7.55	2.34e-13	8.07e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73727057	chr10:73699151~73730487:-
THCA	cis	rs4950322	0.542	rs4950384	ENSG00000237188.3	RP11-337C18.8	7.55	2.34e-13	8.07e-11	0.4	0.33	Protein quantitative trait loci;	chr1:147177310	chr1:147172771~147211568:+
THCA	cis	rs3847687	1	rs3847687	ENSG00000279128.1	RP11-76C10.4	7.55	2.35e-13	8.07e-11	0.36	0.33	Longevity;	chr12:131040508	chr12:131022769~131024741:-
THCA	cis	rs6908034	0.607	rs12526109	ENSG00000228412.5	RP4-625H18.2	7.55	2.35e-13	8.08e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819858	chr6:19802164~19804752:-
THCA	cis	rs9890032	0.618	rs1979507	ENSG00000263531.1	RP13-753N3.1	7.55	2.35e-13	8.08e-11	0.45	0.33	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30863921~30864940:-
THCA	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-7.55	2.36e-13	8.11e-11	-0.38	-0.33	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
THCA	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-7.55	2.36e-13	8.11e-11	-0.41	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
THCA	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	7.54	2.36e-13	8.14e-11	0.22	0.33	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
THCA	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	7.54	2.37e-13	8.14e-11	0.44	0.33	Height;	chr4:55566291	chr4:55363971~55395847:-
THCA	cis	rs9902453	0.935	rs9905950	ENSG00000264007.1	RP11-68I3.10	7.54	2.37e-13	8.14e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30104180	chr17:29621617~29622254:-
THCA	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	7.54	2.37e-13	8.14e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
THCA	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-7.54	2.37e-13	8.16e-11	-0.47	-0.33	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
THCA	cis	rs914615	0.529	rs11264338	ENSG00000160766.13	GBAP1	-7.54	2.37e-13	8.16e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155166081	chr1:155213821~155227422:-
THCA	cis	rs7247513	0.701	rs8107642	ENSG00000230310.1	CTD-2192J16.11	-7.54	2.38e-13	8.19e-11	-0.38	-0.33	Bipolar disorder;	chr19:12655556	chr19:12552597~12553644:+
THCA	cis	rs2562456	0.876	rs7252585	ENSG00000268555.1	RP11-678G14.3	-7.54	2.38e-13	8.2e-11	-0.45	-0.33	Pain;	chr19:21475141	chr19:21570822~21587322:-
THCA	cis	rs1150668	0.835	rs203869	ENSG00000219392.1	RP1-265C24.5	-7.54	2.38e-13	8.2e-11	-0.36	-0.33	Pubertal anthropometrics;	chr6:28073041	chr6:28115628~28116551:+
THCA	cis	rs9902453	0.934	rs12453172	ENSG00000264007.1	RP11-68I3.10	7.54	2.39e-13	8.21e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30114572	chr17:29621617~29622254:-
THCA	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	7.54	2.39e-13	8.22e-11	0.19	0.33	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
THCA	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-7.54	2.39e-13	8.22e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
THCA	cis	rs9847710	0.545	rs2952830	ENSG00000242142.1	SERBP1P3	7.54	2.39e-13	8.23e-11	0.41	0.33	Ulcerative colitis;	chr3:52948280	chr3:53064283~53065091:-
THCA	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	7.54	2.39e-13	8.23e-11	0.42	0.33	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
THCA	cis	rs934734	0.967	rs1866051	ENSG00000204929.10	AC074391.1	7.54	2.39e-13	8.23e-11	0.41	0.33	Rheumatoid arthritis;	chr2:65375015	chr2:65436711~66084639:+
THCA	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-7.54	2.4e-13	8.24e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
THCA	cis	rs42490	0.664	rs39516	ENSG00000251136.7	RP11-37B2.1	-7.54	2.41e-13	8.29e-11	-0.28	-0.33	Leprosy;	chr8:89822157	chr8:89609409~89757727:-
THCA	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-7.54	2.41e-13	8.29e-11	-0.36	-0.33	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
THCA	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-7.54	2.42e-13	8.3e-11	-0.32	-0.33	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-7.54	2.42e-13	8.3e-11	-0.32	-0.33	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
THCA	cis	rs875971	1	rs1544549	ENSG00000232559.3	GS1-124K5.12	-7.54	2.42e-13	8.31e-11	-0.31	-0.33	Aortic root size;	chr7:66625676	chr7:66554588~66576923:-
THCA	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
THCA	cis	rs2562456	0.833	rs2968076	ENSG00000268555.1	RP11-678G14.3	-7.54	2.43e-13	8.34e-11	-0.47	-0.33	Pain;	chr19:21454299	chr19:21570822~21587322:-
THCA	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	7.54	2.43e-13	8.35e-11	0.19	0.33	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
THCA	cis	rs10411161	0.81	rs17778711	ENSG00000269483.1	AC006272.1	7.54	2.44e-13	8.37e-11	0.55	0.33	Breast cancer;	chr19:51882047	chr19:51839924~51843324:-
THCA	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-7.54	2.44e-13	8.37e-11	-0.58	-0.33	Depression;	chr6:28223052	chr6:28115628~28116551:+
THCA	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-7.54	2.44e-13	8.37e-11	-0.58	-0.33	Depression;	chr6:28223279	chr6:28115628~28116551:+
THCA	cis	rs7302981	0.934	rs7532	ENSG00000272368.2	RP4-605O3.4	-7.54	2.44e-13	8.38e-11	-0.2	-0.33	Systolic blood pressure;	chr12:50130181	chr12:50112197~50165618:+
THCA	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	7.54	2.44e-13	8.38e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	7.54	2.44e-13	8.38e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
THCA	cis	rs12817211	0.502	rs7135322	ENSG00000272368.2	RP4-605O3.4	-7.54	2.44e-13	8.39e-11	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50118065	chr12:50112197~50165618:+
THCA	cis	rs193541	0.53	rs2125857	ENSG00000263432.2	RN7SL689P	7.54	2.44e-13	8.4e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122747461	chr5:123022487~123022783:-
THCA	cis	rs8114671	0.527	rs2253484	ENSG00000269202.1	RP4-614O4.12	7.54	2.44e-13	8.4e-11	0.27	0.33	Height;	chr20:34817460	chr20:35201747~35203288:-
THCA	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-7.54	2.45e-13	8.43e-11	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
THCA	cis	rs9902453	0.933	rs8080343	ENSG00000264007.1	RP11-68I3.10	7.54	2.46e-13	8.44e-11	0.36	0.33	Coffee consumption (cups per day);	chr17:30129740	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	7.54	2.46e-13	8.44e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
THCA	cis	rs9902453	0.933	rs1128156	ENSG00000264007.1	RP11-68I3.10	7.54	2.46e-13	8.45e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30186158	chr17:29621617~29622254:-
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000264538.5	SUZ12P1	-7.54	2.46e-13	8.46e-11	-0.32	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30709299~30790908:+
THCA	cis	rs9902453	0.967	rs4325622	ENSG00000264007.1	RP11-68I3.10	7.54	2.46e-13	8.46e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30199457	chr17:29621617~29622254:-
THCA	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-7.54	2.46e-13	8.46e-11	-0.5	-0.33	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
THCA	cis	rs728616	0.85	rs3889823	ENSG00000225484.5	NUTM2B-AS1	-7.54	2.46e-13	8.47e-11	-0.66	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79663088~79826594:-
THCA	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-7.54	2.47e-13	8.48e-11	-0.38	-0.33	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
THCA	cis	rs7208859	0.673	rs9895684	ENSG00000266490.1	CTD-2349P21.9	7.54	2.47e-13	8.5e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30792372~30792833:+
THCA	cis	rs4820539	0.934	rs3788348	ENSG00000221069.1	AC000029.1	-7.54	2.48e-13	8.5e-11	-0.39	-0.33	Bone mineral density;	chr22:23125759	chr22:23136620~23136710:+
THCA	cis	rs4820539	0.932	rs3788349	ENSG00000221069.1	AC000029.1	-7.54	2.48e-13	8.5e-11	-0.39	-0.33	Bone mineral density;	chr22:23125763	chr22:23136620~23136710:+
THCA	cis	rs9902453	0.967	rs17825877	ENSG00000264007.1	RP11-68I3.10	7.54	2.48e-13	8.5e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30188170	chr17:29621617~29622254:-
THCA	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-7.54	2.48e-13	8.5e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
THCA	cis	rs6496932	0.503	rs11074205	ENSG00000218052.5	ADAMTS7P4	-7.54	2.48e-13	8.51e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85401381	chr15:85255369~85330334:-
THCA	cis	rs11673344	0.504	rs2595555	ENSG00000226686.6	LINC01535	7.54	2.48e-13	8.52e-11	0.36	0.33	Obesity-related traits;	chr19:37000219	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs1667377	ENSG00000226686.6	LINC01535	7.54	2.48e-13	8.52e-11	0.36	0.33	Obesity-related traits;	chr19:37000966	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs1667379	ENSG00000226686.6	LINC01535	7.54	2.48e-13	8.52e-11	0.36	0.33	Obesity-related traits;	chr19:37001192	chr19:37251912~37265535:+
THCA	cis	rs2787702	0.5	rs72827301	ENSG00000237233.2	TMEM26-AS1	7.54	2.48e-13	8.52e-11	0.55	0.33	Response to taxane treatment (placlitaxel);	chr10:61550794	chr10:61452639~61481956:+
THCA	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-7.54	2.49e-13	8.56e-11	-0.48	-0.33	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
THCA	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-7.54	2.5e-13	8.58e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
THCA	cis	rs2839186	0.605	rs2839170	ENSG00000239415.1	AP001469.9	7.54	2.5e-13	8.59e-11	0.34	0.33	Testicular germ cell tumor;	chr21:46251391	chr21:46251549~46254133:-
THCA	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	7.54	2.51e-13	8.6e-11	0.49	0.33	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
THCA	cis	rs849141	0.925	rs520161	ENSG00000234336.5	JAZF1-AS1	-7.54	2.51e-13	8.6e-11	-0.36	-0.33	Height;Hip circumference adjusted for BMI;	chr7:28171041	chr7:28180322~28243917:+
THCA	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	7.54	2.51e-13	8.6e-11	0.3	0.33	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
THCA	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
THCA	cis	rs2361718	0.5	rs8068856	ENSG00000279259.1	RP11-334C17.3	7.54	2.51e-13	8.61e-11	0.33	0.33	Yeast infection;	chr17:80126932	chr17:80147250~80148596:+
THCA	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	7.54	2.51e-13	8.61e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
THCA	cis	rs12554020	0.786	rs12349299	ENSG00000227603.1	RP11-165J3.6	7.54	2.51e-13	8.62e-11	0.5	0.33	Schizophrenia;	chr9:93412482	chr9:93435332~93437121:-
THCA	cis	rs1949733	0.656	rs2688243	ENSG00000205959.3	RP11-689P11.2	-7.54	2.51e-13	8.62e-11	-0.27	-0.33	Response to antineoplastic agents;	chr4:8434559	chr4:8482270~8512610:+
THCA	cis	rs1799949	0.628	rs4474733	ENSG00000267681.1	CTD-3199J23.6	-7.54	2.52e-13	8.63e-11	-0.41	-0.33	Menopause (age at onset);	chr17:43356292	chr17:43144956~43145255:+
THCA	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-7.54	2.52e-13	8.63e-11	-0.51	-0.33	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-7.54	2.52e-13	8.63e-11	-0.51	-0.33	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-7.54	2.52e-13	8.63e-11	-0.51	-0.33	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
THCA	cis	rs7208859	0.673	rs12103759	ENSG00000264538.5	SUZ12P1	-7.53	2.53e-13	8.68e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs59029591	ENSG00000264538.5	SUZ12P1	-7.53	2.53e-13	8.68e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73265633	ENSG00000264538.5	SUZ12P1	-7.53	2.53e-13	8.68e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9913782	ENSG00000264538.5	SUZ12P1	-7.53	2.53e-13	8.68e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9911989	ENSG00000264538.5	SUZ12P1	7.53	2.53e-13	8.68e-11	0.35	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30709299~30790908:+
THCA	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	7.53	2.53e-13	8.68e-11	0.3	0.33	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
THCA	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-7.53	2.54e-13	8.69e-11	-0.4	-0.33	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
THCA	cis	rs4073416	0.684	rs883081	ENSG00000276116.2	FUT8-AS1	7.53	2.54e-13	8.7e-11	0.34	0.33	N-glycan levels;	chr14:65413903	chr14:65411170~65412690:-
THCA	cis	rs2688608	0.62	rs12253408	ENSG00000271816.1	BMS1P4	7.53	2.54e-13	8.7e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73736198	chr10:73699151~73730487:-
THCA	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-7.53	2.55e-13	8.73e-11	-0.31	-0.33	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-7.53	2.55e-13	8.73e-11	-0.31	-0.33	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
THCA	cis	rs2348418	0.864	rs6487687	ENSG00000247934.4	RP11-967K21.1	7.53	2.55e-13	8.75e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28558230	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs6487689	ENSG00000247934.4	RP11-967K21.1	7.53	2.55e-13	8.75e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28560101	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7304540	ENSG00000247934.4	RP11-967K21.1	7.53	2.55e-13	8.75e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28560489	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7304776	ENSG00000247934.4	RP11-967K21.1	7.53	2.55e-13	8.75e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28560634	chr12:28163298~28190738:-
THCA	cis	rs11168351	1	rs11168351	ENSG00000258273.1	RP11-370I10.4	-7.53	2.56e-13	8.78e-11	-0.43	-0.33	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48333755~48333901:-
THCA	cis	rs934734	0.563	rs11684155	ENSG00000281920.1	RP11-418H16.1	7.53	2.57e-13	8.79e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65354166	chr2:65623272~65628424:+
THCA	cis	rs10181042	0.528	rs2564118	ENSG00000271889.1	RP11-493E12.1	7.53	2.57e-13	8.79e-11	0.31	0.33	Crohn's disease;	chr2:61006154	chr2:61151433~61162105:-
THCA	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-7.53	2.57e-13	8.8e-11	-0.41	-0.33	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
THCA	cis	rs7208859	0.673	rs79541516	ENSG00000264538.5	SUZ12P1	-7.53	2.58e-13	8.82e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30709299~30790908:+
THCA	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	7.53	2.58e-13	8.82e-11	0.42	0.33	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
THCA	cis	rs6723226	0.75	rs10182170	ENSG00000276334.1	AL133243.1	7.53	2.58e-13	8.84e-11	0.37	0.33	Intelligence (multi-trait analysis);	chr2:32479118	chr2:32521927~32523547:+
THCA	cis	rs2348418	0.864	rs11049714	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28561162	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7960369	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28561569	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7977817	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28562549	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.831	rs7977525	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28562584	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7977850	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28562715	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7978086	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28562761	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs11609924	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28563197	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs2137071	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28563797	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7968563	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28563844	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs2137072	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28563872	chr12:28163298~28190738:-
THCA	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	7.53	2.58e-13	8.85e-11	0.29	0.33	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
THCA	cis	rs2439831	1	rs527921	ENSG00000275601.1	AC011330.13	7.53	2.58e-13	8.85e-11	0.5	0.33	Lung cancer in ever smokers;	chr15:43478218	chr15:43642389~43643023:-
THCA	cis	rs4927850	0.521	rs4927679	ENSG00000231464.1	AC024937.4	-7.53	2.58e-13	8.85e-11	-0.36	-0.33	Pancreatic cancer;	chr3:195931489	chr3:195996738~195998233:+
THCA	cis	rs801193	0.591	rs2707839	ENSG00000232559.3	GS1-124K5.12	7.53	2.59e-13	8.88e-11	0.31	0.33	Aortic root size;	chr7:66728097	chr7:66554588~66576923:-
THCA	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	7.53	2.59e-13	8.88e-11	0.37	0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
THCA	cis	rs11146838	1	rs11146838	ENSG00000276805.1	RP11-291L22.6	7.53	2.59e-13	8.88e-11	0.35	0.33	Breast cancer;	chr10:38856846	chr10:38451030~38451785:+
THCA	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-7.53	2.6e-13	8.89e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-7.53	2.6e-13	8.89e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-7.53	2.6e-13	8.89e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-7.53	2.6e-13	8.89e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
THCA	cis	rs2675662	0.525	rs12264025	ENSG00000271816.1	BMS1P4	7.53	2.6e-13	8.9e-11	0.33	0.33	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.592	rs12253429	ENSG00000271816.1	BMS1P4	7.53	2.6e-13	8.9e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73736403	chr10:73699151~73730487:-
THCA	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	7.53	2.6e-13	8.9e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000226155.1	AC124944.3	-7.53	2.61e-13	8.93e-11	-0.38	-0.33	Pancreatic cancer;	chr3:196022690	chr3:195912049~195913986:+
THCA	cis	rs6065	0.618	rs16954342	ENSG00000234203.1	RP5-1050D4.2	7.53	2.61e-13	8.94e-11	0.71	0.33	Platelet count;	chr17:5003808	chr17:4972851~4974681:+
THCA	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	7.53	2.61e-13	8.94e-11	0.32	0.33	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
THCA	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	7.53	2.62e-13	8.95e-11	0.27	0.33	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
THCA	cis	rs2688608	0.592	rs10762563	ENSG00000271816.1	BMS1P4	7.53	2.63e-13	9.01e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73765044	chr10:73699151~73730487:-
THCA	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	7.53	2.64e-13	9.02e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	7.53	2.64e-13	9.02e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
THCA	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	7.53	2.64e-13	9.03e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
THCA	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	7.53	2.64e-13	9.03e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
THCA	cis	rs4820539	1	rs916584	ENSG00000221069.1	AC000029.1	-7.53	2.64e-13	9.04e-11	-0.39	-0.33	Bone mineral density;	chr22:23127246	chr22:23136620~23136710:+
THCA	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-7.53	2.65e-13	9.05e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
THCA	cis	rs75422866	0.558	rs73104190	ENSG00000274902.1	RP1-197B17.4	7.53	2.65e-13	9.06e-11	0.68	0.33	Pneumonia;	chr12:47716040	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.51	rs73104197	ENSG00000274902.1	RP1-197B17.4	7.53	2.65e-13	9.06e-11	0.68	0.33	Pneumonia;	chr12:47717273	chr12:47731908~47732351:+
THCA	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	7.53	2.65e-13	9.06e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	7.53	2.65e-13	9.06e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30709299~30790908:+
THCA	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	7.53	2.66e-13	9.08e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
THCA	cis	rs910316	0.737	rs175510	ENSG00000279594.1	RP11-950C14.10	-7.53	2.66e-13	9.09e-11	-0.3	-0.33	Height;	chr14:75058136	chr14:75011269~75012851:-
THCA	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-7.53	2.66e-13	9.1e-11	-0.47	-0.33	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
THCA	cis	rs9902453	0.967	rs56129908	ENSG00000264007.1	RP11-68I3.10	7.53	2.66e-13	9.1e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30094364	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs4350617	ENSG00000264007.1	RP11-68I3.10	7.53	2.66e-13	9.1e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30096070	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs55971458	ENSG00000264007.1	RP11-68I3.10	7.53	2.66e-13	9.1e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30099998	chr17:29621617~29622254:-
THCA	cis	rs10208649	0.611	rs12620667	ENSG00000272156.1	RP11-477N3.1	7.53	2.66e-13	9.1e-11	0.48	0.33	Body mass index;	chr2:54063860	chr2:54082554~54085066:+
THCA	cis	rs7569084	0.566	rs7584295	ENSG00000281920.1	RP11-418H16.1	7.53	2.67e-13	9.12e-11	0.43	0.33	Sum eosinophil basophil counts;	chr2:65353940	chr2:65623272~65628424:+
THCA	cis	rs934734	0.563	rs11695373	ENSG00000281920.1	RP11-418H16.1	7.53	2.67e-13	9.12e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65354066	chr2:65623272~65628424:+
THCA	cis	rs2032366	1	rs8088329	ENSG00000267279.1	RP11-879F14.2	-7.53	2.67e-13	9.14e-11	-0.33	-0.33	Obesity-related traits;	chr18:61595758	chr18:61585746~61606916:-
THCA	cis	rs12817211	0.502	rs1554844	ENSG00000272368.2	RP4-605O3.4	-7.53	2.68e-13	9.16e-11	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50120582	chr12:50112197~50165618:+
THCA	cis	rs2688608	0.53	rs71507081	ENSG00000271816.1	BMS1P4	7.53	2.68e-13	9.16e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73733378	chr10:73699151~73730487:-
THCA	cis	rs9388451	0.874	rs1159974	ENSG00000237742.5	RP11-624M8.1	7.53	2.68e-13	9.16e-11	0.28	0.33	Brugada syndrome;	chr6:125769131	chr6:125578558~125749190:-
THCA	cis	rs2032366	1	rs10439023	ENSG00000267279.1	RP11-879F14.2	-7.53	2.68e-13	9.16e-11	-0.33	-0.33	Obesity-related traits;	chr18:61597073	chr18:61585746~61606916:-
THCA	cis	rs9902453	0.791	rs3098950	ENSG00000264007.1	RP11-68I3.10	7.53	2.68e-13	9.17e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:29671367	chr17:29621617~29622254:-
THCA	cis	rs7015263	0.727	rs4961194	ENSG00000254231.1	CTD-2284J15.1	-7.53	2.68e-13	9.17e-11	-0.32	-0.33	Intelligence (multi-trait analysis);	chr8:86482745	chr8:86333274~86343314:-
THCA	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	7.53	2.69e-13	9.19e-11	0.46	0.33	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
THCA	cis	rs914615	0.552	rs4421576	ENSG00000160766.13	GBAP1	-7.53	2.69e-13	9.19e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155169734	chr1:155213821~155227422:-
THCA	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	7.53	2.69e-13	9.19e-11	0.48	0.33	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	7.53	2.69e-13	9.19e-11	0.48	0.33	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	7.53	2.69e-13	9.19e-11	0.48	0.33	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	7.53	2.69e-13	9.19e-11	0.48	0.33	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
THCA	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	7.53	2.69e-13	9.2e-11	0.36	0.33	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
THCA	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	7.53	2.69e-13	9.21e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
THCA	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-7.53	2.7e-13	9.21e-11	-0.32	-0.33	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
THCA	cis	rs2712184	0.687	rs62180470	ENSG00000229352.1	AC007563.3	7.53	2.7e-13	9.23e-11	0.39	0.33	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216780728	chr2:216799608~216805335:+
THCA	cis	rs10932679	0.532	rs2024488	ENSG00000229352.1	AC007563.3	-7.52	2.71e-13	9.25e-11	-0.41	-0.33	Pulse pressure;	chr2:216798245	chr2:216799608~216805335:+
THCA	cis	rs11148252	0.564	rs2296350	ENSG00000235660.1	LINC00345	-7.52	2.71e-13	9.25e-11	-0.4	-0.33	Lewy body disease;	chr13:52135908	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.538	rs2296348	ENSG00000235660.1	LINC00345	-7.52	2.71e-13	9.25e-11	-0.4	-0.33	Lewy body disease;	chr13:52136000	chr13:52484161~52484680:-
THCA	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	7.52	2.71e-13	9.26e-11	0.48	0.33	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
THCA	cis	rs2880765	0.835	rs7161880	ENSG00000259295.5	CSPG4P12	7.52	2.71e-13	9.27e-11	0.41	0.33	Coronary artery disease;	chr15:85475515	chr15:85191438~85213905:+
THCA	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	7.52	2.72e-13	9.28e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
THCA	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	7.52	2.72e-13	9.28e-11	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
THCA	cis	rs5769707	0.706	rs2071903	ENSG00000235111.1	RP1-29C18.8	-7.52	2.72e-13	9.29e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49612657~49615716:-
THCA	cis	rs2562456	0.833	rs516519	ENSG00000268119.4	CTD-2561J22.5	-7.52	2.73e-13	9.31e-11	-0.41	-0.33	Pain;	chr19:21298730	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs552800	ENSG00000268119.4	CTD-2561J22.5	-7.52	2.73e-13	9.31e-11	-0.41	-0.33	Pain;	chr19:21301840	chr19:21444241~21463908:-
THCA	cis	rs3822625	0.541	rs12655019	ENSG00000271828.1	CTD-2310F14.1	7.52	2.73e-13	9.31e-11	0.76	0.33	Breast cancer (early onset);	chr5:56899963	chr5:56927874~56929573:+
THCA	cis	rs748404	0.518	rs2927085	ENSG00000166763.7	STRCP1	7.52	2.73e-13	9.32e-11	0.35	0.33	Lung cancer;	chr15:43697332	chr15:43699488~43718184:-
THCA	cis	rs7833787	0.502	rs6586783	ENSG00000278886.1	RP11-108A14.1	-7.52	2.74e-13	9.35e-11	-0.43	-0.33	Obesity-related traits;	chr8:18884042	chr8:18864681~18865247:-
THCA	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	7.52	2.74e-13	9.35e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
THCA	cis	rs12681366	0.839	rs3019280	ENSG00000253704.1	RP11-267M23.4	7.52	2.74e-13	9.36e-11	0.34	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.839	rs3019281	ENSG00000253704.1	RP11-267M23.4	7.52	2.74e-13	9.36e-11	0.34	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94553722~94569745:+
THCA	cis	rs9500256	0.934	rs1343391	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-7.52	2.74e-13	9.36e-11	-0.34	-0.33	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57855891~57856468:-
THCA	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	7.52	2.76e-13	9.42e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
THCA	cis	rs11673344	0.598	rs826326	ENSG00000226686.6	LINC01535	7.52	2.76e-13	9.43e-11	0.36	0.33	Obesity-related traits;	chr19:37003863	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.542	rs826328	ENSG00000226686.6	LINC01535	7.52	2.76e-13	9.43e-11	0.36	0.33	Obesity-related traits;	chr19:37004479	chr19:37251912~37265535:+
THCA	cis	rs2522056	1	rs2405528	ENSG00000233006.5	AC034220.3	-7.52	2.76e-13	9.43e-11	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132458606	chr5:132311285~132369916:-
THCA	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-7.52	2.76e-13	9.44e-11	-0.36	-0.33	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
THCA	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	7.52	2.77e-13	9.44e-11	0.19	0.33	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	7.52	2.77e-13	9.44e-11	0.19	0.33	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
THCA	cis	rs12681366	1	rs2960122	ENSG00000253704.1	RP11-267M23.4	7.52	2.78e-13	9.49e-11	0.32	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94419858	chr8:94553722~94569745:+
THCA	cis	rs6745190	0.953	rs7371639	ENSG00000236153.1	AC104076.3	7.52	2.79e-13	9.52e-11	0.38	0.33	White blood cell count;	chr2:181057272	chr2:180979427~180980090:-
THCA	cis	rs10971721	0.596	rs9650704	ENSG00000260947.1	RP11-384P7.7	7.52	2.79e-13	9.52e-11	0.74	0.33	Body mass index;	chr9:34141956	chr9:33697459~33700986:+
THCA	cis	rs17684571	0.872	rs2967960	ENSG00000231441.1	RP11-472M19.2	7.52	2.79e-13	9.52e-11	0.41	0.33	Schizophrenia;	chr6:56745971	chr6:56844002~56864078:+
THCA	cis	rs3847687	1	rs78233646	ENSG00000279128.1	RP11-76C10.4	7.52	2.79e-13	9.52e-11	0.37	0.33	Longevity;	chr12:131035625	chr12:131022769~131024741:-
THCA	cis	rs116175783	0.557	rs62197075	ENSG00000227403.1	AC009299.3	7.52	2.8e-13	9.55e-11	0.59	0.33	Intelligence (multi-trait analysis);	chr2:161312613	chr2:161244739~161249050:+
THCA	cis	rs11673344	0.542	rs826331	ENSG00000226686.6	LINC01535	7.52	2.8e-13	9.56e-11	0.36	0.33	Obesity-related traits;	chr19:37007360	chr19:37251912~37265535:+
THCA	cis	rs9400467	0.528	rs1989574	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.56e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.811	rs1002475	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Metabolic traits;	chr6:111388386	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs11153288	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs11153290	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs11153291	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs11153292	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs12190634	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs11153294	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs9487632	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs11153295	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs6915753	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs4620159	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111277932~111278742:+
THCA	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-7.52	2.81e-13	9.58e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-7.52	2.81e-13	9.58e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
THCA	cis	rs2348418	0.864	rs7312339	ENSG00000247934.4	RP11-967K21.1	7.52	2.81e-13	9.58e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28558751	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs1343859	ENSG00000247934.4	RP11-967K21.1	7.52	2.81e-13	9.58e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28559537	chr12:28163298~28190738:-
THCA	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.81e-13	9.6e-11	-0.35	-0.33	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
THCA	cis	rs2562456	1	rs2562456	ENSG00000268555.1	RP11-678G14.3	7.52	2.82e-13	9.6e-11	0.44	0.33	Pain;	chr19:21483408	chr19:21570822~21587322:-
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000219392.1	RP1-265C24.5	-7.52	2.82e-13	9.61e-11	-0.36	-0.33	Pubertal anthropometrics;	chr6:28259100	chr6:28115628~28116551:+
THCA	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	7.52	2.83e-13	9.63e-11	0.39	0.33	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
THCA	cis	rs10208649	0.706	rs75833613	ENSG00000272156.1	RP11-477N3.1	7.52	2.83e-13	9.64e-11	0.48	0.33	Body mass index;	chr2:54065224	chr2:54082554~54085066:+
THCA	cis	rs7847628	0.587	rs1060817	ENSG00000270917.1	RP11-27I1.6	-7.52	2.83e-13	9.64e-11	-0.45	-0.33	Birth weight;	chr9:120820914	chr9:120812475~120812845:-
THCA	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	7.52	2.83e-13	9.64e-11	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
THCA	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	7.52	2.83e-13	9.65e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
THCA	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-7.52	2.83e-13	9.66e-11	-0.32	-0.33	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-7.52	2.83e-13	9.66e-11	-0.32	-0.33	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
THCA	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	7.52	2.84e-13	9.68e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
THCA	cis	rs853679	0.882	rs9461432	ENSG00000226314.6	ZNF192P1	-7.52	2.84e-13	9.69e-11	-0.54	-0.33	Depression;	chr6:28119105	chr6:28161781~28169594:+
THCA	cis	rs9506514	0.712	rs11838795	ENSG00000222726.1	RNU2-7P	7.52	2.85e-13	9.7e-11	0.4	0.33	Coronary artery calcification;	chr13:20684189	chr13:20612161~20612338:+
THCA	cis	rs910316	0.967	rs8013444	ENSG00000279594.1	RP11-950C14.10	-7.52	2.85e-13	9.71e-11	-0.31	-0.33	Height;	chr14:75195278	chr14:75011269~75012851:-
THCA	cis	rs1009647	0.583	rs72715746	ENSG00000258413.1	RP11-665C16.6	-7.52	2.85e-13	9.71e-11	-0.59	-0.33	Testicular germ cell tumor;	chr14:55274652	chr14:55262767~55272075:-
THCA	cis	rs9890032	0.618	rs55872374	ENSG00000263531.1	RP13-753N3.1	7.52	2.85e-13	9.71e-11	0.45	0.33	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30863921~30864940:-
THCA	cis	rs11148252	0.84	rs3886077	ENSG00000278238.1	RP11-245D16.4	-7.52	2.85e-13	9.72e-11	-0.36	-0.33	Lewy body disease;	chr13:52374918	chr13:52454775~52455331:-
THCA	cis	rs7302981	0.934	rs7279	ENSG00000272368.2	RP4-605O3.4	-7.52	2.86e-13	9.73e-11	-0.2	-0.33	Systolic blood pressure;	chr12:50130164	chr12:50112197~50165618:+
THCA	cis	rs9400467	0.528	rs7451051	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.86e-13	9.74e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs6913769	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.86e-13	9.74e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111277932~111278742:+
THCA	cis	rs910316	0.737	rs108621	ENSG00000279594.1	RP11-950C14.10	-7.52	2.86e-13	9.75e-11	-0.3	-0.33	Height;	chr14:75013934	chr14:75011269~75012851:-
THCA	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-7.52	2.87e-13	9.77e-11	-0.32	-0.33	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
THCA	cis	rs17772222	0.74	rs11847417	ENSG00000258789.1	RP11-507K2.3	7.52	2.87e-13	9.77e-11	0.31	0.33	Coronary artery calcification;	chr14:88510606	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs10138309	ENSG00000258789.1	RP11-507K2.3	-7.52	2.87e-13	9.77e-11	-0.31	-0.33	Coronary artery calcification;	chr14:88510352	chr14:88551597~88552493:+
THCA	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	7.52	2.87e-13	9.77e-11	0.42	0.33	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
THCA	cis	rs7945705	0.791	rs4579928	ENSG00000254860.4	TMEM9B-AS1	-7.52	2.88e-13	9.81e-11	-0.35	-0.33	Hemoglobin concentration;	chr11:8794157	chr11:8964675~8977527:+
THCA	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-7.52	2.88e-13	9.81e-11	-0.51	-0.33	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
THCA	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	7.52	2.88e-13	9.82e-11	0.32	0.33	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
THCA	cis	rs7948661	1	rs2276045	ENSG00000278376.1	RP11-158I9.8	7.52	2.89e-13	9.84e-11	0.56	0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118494453	chr11:118791254~118793137:+
THCA	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	7.52	2.89e-13	9.85e-11	0.45	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
THCA	cis	rs875971	1	rs6979382	ENSG00000232559.3	GS1-124K5.12	7.52	2.89e-13	9.86e-11	0.31	0.33	Aortic root size;	chr7:66421388	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6961990	ENSG00000232559.3	GS1-124K5.12	7.52	2.89e-13	9.86e-11	0.31	0.33	Aortic root size;	chr7:66423583	chr7:66554588~66576923:-
THCA	cis	rs9902453	0.753	rs3097118	ENSG00000264007.1	RP11-68I3.10	7.52	2.9e-13	9.87e-11	0.36	0.33	Coffee consumption (cups per day);	chr17:29651448	chr17:29621617~29622254:-
THCA	cis	rs270601	0.721	rs270621	ENSG00000233006.5	AC034220.3	7.51	2.91e-13	9.89e-11	0.26	0.33	Acylcarnitine levels;	chr5:132270128	chr5:132311285~132369916:-
THCA	cis	rs7247513	1	rs7247513	ENSG00000230310.1	CTD-2192J16.11	-7.51	2.91e-13	9.9e-11	-0.4	-0.33	Bipolar disorder;	chr19:12580371	chr19:12552597~12553644:+
THCA	cis	rs7942368	1	rs10899280	ENSG00000254761.1	RP11-672A2.1	7.51	2.92e-13	9.92e-11	0.46	0.33	Endometriosis;	chr11:76785693	chr11:76712396~76719608:-
THCA	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	7.51	2.92e-13	9.94e-11	0.32	0.33	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
THCA	cis	rs527616	0.965	rs1667550	ENSG00000265369.3	PCAT18	7.51	2.92e-13	9.95e-11	0.4	0.33	Breast cancer;	chr18:26752512	chr18:26687621~26703638:-
THCA	cis	rs9902453	0.765	rs2264303	ENSG00000264007.1	RP11-68I3.10	-7.51	2.92e-13	9.95e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29728330	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2264302	ENSG00000264007.1	RP11-68I3.10	-7.51	2.92e-13	9.95e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29730077	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2447935	ENSG00000264007.1	RP11-68I3.10	-7.51	2.92e-13	9.95e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29730506	chr17:29621617~29622254:-
THCA	cis	rs12554020	0.892	rs10217595	ENSG00000227603.1	RP11-165J3.6	7.51	2.93e-13	9.97e-11	0.5	0.33	Schizophrenia;	chr9:93418609	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs10117236	ENSG00000227603.1	RP11-165J3.6	7.51	2.93e-13	9.97e-11	0.5	0.33	Schizophrenia;	chr9:93419731	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs7863760	ENSG00000227603.1	RP11-165J3.6	7.51	2.93e-13	9.97e-11	0.5	0.33	Schizophrenia;	chr9:93420287	chr9:93435332~93437121:-
THCA	cis	rs240993	0.812	rs7766610	ENSG00000230177.1	RP5-1112D6.4	-7.51	2.93e-13	9.97e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111386618	chr6:111277932~111278742:+
THCA	cis	rs934734	0.563	rs955903	ENSG00000281920.1	RP11-418H16.1	7.51	2.93e-13	9.98e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65348419	chr2:65623272~65628424:+
THCA	cis	rs11696845	0.626	rs1111032	ENSG00000276223.1	RP4-781B1.5	-7.51	2.94e-13	1e-10	-0.39	-0.33	Obesity-related traits;	chr20:44750129	chr20:44746642~44747201:+
THCA	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-7.51	2.94e-13	1e-10	-0.5	-0.33	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
THCA	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-7.51	2.94e-13	1e-10	-0.48	-0.33	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-7.51	2.94e-13	1e-10	-0.48	-0.33	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-7.51	2.94e-13	1e-10	-0.48	-0.33	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
THCA	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-7.51	2.94e-13	1e-10	-0.36	-0.33	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
THCA	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-7.51	2.95e-13	1e-10	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	7.51	2.95e-13	1e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	7.51	2.95e-13	1e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	7.51	2.95e-13	1e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
THCA	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-7.51	2.95e-13	1e-10	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
THCA	cis	rs12681366	0.881	rs16916760	ENSG00000253704.1	RP11-267M23.4	7.51	2.95e-13	1e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94356881	chr8:94553722~94569745:+
THCA	cis	rs4073416	0.712	rs8010876	ENSG00000276116.2	FUT8-AS1	7.51	2.95e-13	1e-10	0.33	0.33	N-glycan levels;	chr14:65740258	chr14:65411170~65412690:-
THCA	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
THCA	cis	rs7727544	0.547	rs56083751	ENSG00000224431.1	AC063976.7	7.51	2.96e-13	1.01e-10	0.29	0.33	Blood metabolite levels;	chr5:132328945	chr5:132199456~132203487:+
THCA	cis	rs801193	0.66	rs2659897	ENSG00000232559.3	GS1-124K5.12	-7.51	2.96e-13	1.01e-10	-0.31	-0.33	Aortic root size;	chr7:66722728	chr7:66554588~66576923:-
THCA	cis	rs9393777	0.92	rs13207689	ENSG00000280107.1	AL022393.9	-7.51	2.96e-13	1.01e-10	-0.64	-0.33	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28170845~28172521:+
THCA	cis	rs11148252	0.875	rs9526913	ENSG00000278238.1	RP11-245D16.4	-7.51	2.96e-13	1.01e-10	-0.36	-0.33	Lewy body disease;	chr13:52401702	chr13:52454775~52455331:-
THCA	cis	rs2562456	0.793	rs627522	ENSG00000268119.4	CTD-2561J22.5	7.51	2.97e-13	1.01e-10	0.4	0.33	Pain;	chr19:21313002	chr19:21444241~21463908:-
THCA	cis	rs910316	0.763	rs175014	ENSG00000279594.1	RP11-950C14.10	-7.51	2.97e-13	1.01e-10	-0.3	-0.33	Height;	chr14:74990224	chr14:75011269~75012851:-
THCA	cis	rs2839186	0.605	rs2839174	ENSG00000239415.1	AP001469.9	7.51	2.98e-13	1.01e-10	0.34	0.33	Testicular germ cell tumor;	chr21:46257020	chr21:46251549~46254133:-
THCA	cis	rs7302981	0.967	rs2178173	ENSG00000272368.2	RP4-605O3.4	-7.51	2.98e-13	1.01e-10	-0.2	-0.33	Systolic blood pressure;	chr12:50124146	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.967	rs7297421	ENSG00000272368.2	RP4-605O3.4	-7.51	2.98e-13	1.01e-10	-0.2	-0.33	Systolic blood pressure;	chr12:50125143	chr12:50112197~50165618:+
THCA	cis	rs2688608	0.587	rs2894040	ENSG00000271816.1	BMS1P4	7.51	2.98e-13	1.01e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73718401	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.592	rs3849967	ENSG00000271816.1	BMS1P4	7.51	2.98e-13	1.01e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73723608	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.592	rs7909802	ENSG00000271816.1	BMS1P4	7.51	2.98e-13	1.01e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73724428	chr10:73699151~73730487:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000213640.3	EEF1DP4	-7.51	2.99e-13	1.01e-10	-0.38	-0.33	Calcium levels;	chr7:65751755	chr7:64862999~64864370:+
THCA	cis	rs914615	0.552	rs12752585	ENSG00000160766.13	GBAP1	-7.51	3e-13	1.02e-10	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155162930	chr1:155213821~155227422:-
THCA	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	7.51	3e-13	1.02e-10	0.31	0.33	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
THCA	cis	rs10411161	0.552	rs2109657	ENSG00000269483.1	AC006272.1	7.51	3.01e-13	1.02e-10	0.47	0.33	Breast cancer;	chr19:51837473	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.552	rs721891	ENSG00000269483.1	AC006272.1	7.51	3.01e-13	1.02e-10	0.47	0.33	Breast cancer;	chr19:51838218	chr19:51839924~51843324:-
THCA	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-7.51	3.01e-13	1.02e-10	-0.39	-0.33	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
THCA	cis	rs2408955	0.522	rs10875721	ENSG00000258273.1	RP11-370I10.4	7.51	3.01e-13	1.02e-10	0.44	0.33	Glycated hemoglobin levels;	chr12:48019810	chr12:48333755~48333901:-
THCA	cis	rs2288884	0.505	rs17835435	ENSG00000275055.1	CTC-471J1.11	-7.51	3.02e-13	1.03e-10	-0.34	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51931453	chr19:52049007~52049754:+
THCA	cis	rs72772090	0.539	rs17484359	ENSG00000248734.2	CTD-2260A17.1	-7.51	3.03e-13	1.03e-10	-0.56	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96861310	chr5:96784777~96785999:+
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000226155.1	AC124944.3	-7.51	3.03e-13	1.03e-10	-0.38	-0.33	Pancreatic cancer;	chr3:196021659	chr3:195912049~195913986:+
THCA	cis	rs651907	0.557	rs7629753	ENSG00000256628.3	ZBTB11-AS1	-7.51	3.03e-13	1.03e-10	-0.38	-0.33	Colorectal cancer;	chr3:101653078	chr3:101676475~101679217:+
THCA	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	7.51	3.03e-13	1.03e-10	0.42	0.33	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
THCA	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	7.51	3.03e-13	1.03e-10	0.42	0.33	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
THCA	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	7.51	3.03e-13	1.03e-10	0.42	0.33	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
THCA	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	7.51	3.04e-13	1.03e-10	0.48	0.33	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
THCA	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-7.51	3.04e-13	1.03e-10	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
THCA	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-7.51	3.04e-13	1.03e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-7.51	3.04e-13	1.03e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
THCA	cis	rs748404	0.56	rs1060939	ENSG00000166763.7	STRCP1	7.51	3.04e-13	1.03e-10	0.35	0.33	Lung cancer;	chr15:43524719	chr15:43699488~43718184:-
THCA	cis	rs17684571	0.872	rs59247267	ENSG00000231441.1	RP11-472M19.2	7.51	3.05e-13	1.03e-10	0.41	0.33	Schizophrenia;	chr6:56733965	chr6:56844002~56864078:+
THCA	cis	rs8113308	0.81	rs10411484	ENSG00000269235.1	ZNF350-AS1	7.51	3.06e-13	1.04e-10	0.5	0.33	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940152	chr19:51949134~51981367:+
THCA	cis	rs11971779	0.68	rs7785903	ENSG00000273391.1	RP11-634H22.1	7.51	3.06e-13	1.04e-10	0.3	0.33	Diisocyanate-induced asthma;	chr7:139437897	chr7:139359032~139359566:-
THCA	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	7.51	3.06e-13	1.04e-10	0.48	0.33	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
THCA	cis	rs17772222	0.651	rs1950280	ENSG00000258789.1	RP11-507K2.3	7.51	3.07e-13	1.04e-10	0.31	0.33	Coronary artery calcification;	chr14:88366259	chr14:88551597~88552493:+
THCA	cis	rs7208859	0.673	rs75142521	ENSG00000266490.1	CTD-2349P21.9	7.51	3.07e-13	1.04e-10	0.46	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30792372~30792833:+
THCA	cis	rs7851660	0.654	rs2120264	ENSG00000236130.1	PTCSC2	-7.51	3.07e-13	1.04e-10	-0.26	-0.33	Strep throat;	chr9:97883446	chr9:97805935~97810008:-
THCA	cis	rs42490	0.664	rs368812	ENSG00000251136.7	RP11-37B2.1	-7.51	3.07e-13	1.04e-10	-0.28	-0.33	Leprosy;	chr8:89822269	chr8:89609409~89757727:-
THCA	cis	rs7646881	1	rs73015649	ENSG00000240207.5	RP11-379F4.4	-7.51	3.08e-13	1.04e-10	-0.44	-0.33	Tetralogy of Fallot;	chr3:158732509	chr3:158732263~158784070:+
THCA	cis	rs7646881	1	rs73015654	ENSG00000240207.5	RP11-379F4.4	-7.51	3.08e-13	1.04e-10	-0.44	-0.33	Tetralogy of Fallot;	chr3:158733865	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.953	rs73015657	ENSG00000240207.5	RP11-379F4.4	-7.51	3.08e-13	1.04e-10	-0.44	-0.33	Tetralogy of Fallot;	chr3:158734143	chr3:158732263~158784070:+
THCA	cis	rs17772222	0.74	rs61975278	ENSG00000258789.1	RP11-507K2.3	-7.51	3.08e-13	1.05e-10	-0.32	-0.33	Coronary artery calcification;	chr14:88511223	chr14:88551597~88552493:+
THCA	cis	rs516805	0.667	rs7767993	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122343192	chr6:122436789~122439223:-
THCA	cis	rs516805	0.667	rs10457432	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122344699	chr6:122436789~122439223:-
THCA	cis	rs516805	0.673	rs12201010	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122345675	chr6:122436789~122439223:-
THCA	cis	rs516805	0.64	rs12208084	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122345745	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs17662514	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122346013	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs9320863	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122347086	chr6:122436789~122439223:-
THCA	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-7.51	3.08e-13	1.05e-10	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.681	rs8137111	ENSG00000235111.1	RP1-29C18.8	-7.51	3.08e-13	1.05e-10	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49612657~49615716:-
THCA	cis	rs853679	1	rs2799079	ENSG00000219392.1	RP1-265C24.5	-7.51	3.08e-13	1.05e-10	-0.52	-0.33	Depression;	chr6:28267398	chr6:28115628~28116551:+
THCA	cis	rs7208859	0.623	rs609063	ENSG00000264538.5	SUZ12P1	-7.51	3.09e-13	1.05e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs383436	ENSG00000264538.5	SUZ12P1	-7.51	3.09e-13	1.05e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000264538.5	SUZ12P1	-7.51	3.09e-13	1.05e-10	-0.34	-0.33	Body mass index;	chr17:30641132	chr17:30709299~30790908:+
THCA	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	7.51	3.09e-13	1.05e-10	0.43	0.33	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
THCA	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	7.51	3.1e-13	1.05e-10	0.19	0.33	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	7.51	3.1e-13	1.05e-10	0.19	0.33	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
THCA	cis	rs9506514	0.722	rs4769124	ENSG00000222726.1	RNU2-7P	7.5	3.11e-13	1.05e-10	0.4	0.33	Coronary artery calcification;	chr13:20652706	chr13:20612161~20612338:+
THCA	cis	rs11051970	0.625	rs2728709	ENSG00000274964.1	RP11-817I4.1	-7.5	3.11e-13	1.06e-10	-0.4	-0.33	Response to tocilizumab in rheumatoid arthritis;	chr12:32414782	chr12:32339368~32340724:+
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000263603.1	CTD-2349P21.5	-7.5	3.11e-13	1.06e-10	-0.58	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30729469~30731202:+
THCA	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	7.5	3.11e-13	1.06e-10	0.48	0.33	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	7.5	3.11e-13	1.06e-10	0.48	0.33	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
THCA	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-7.5	3.11e-13	1.06e-10	-0.32	-0.33	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
THCA	cis	rs2839186	0.771	rs13046451	ENSG00000239415.1	AP001469.9	-7.5	3.12e-13	1.06e-10	-0.34	-0.33	Testicular germ cell tumor;	chr21:46221459	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.77	rs2280956	ENSG00000239415.1	AP001469.9	-7.5	3.12e-13	1.06e-10	-0.34	-0.33	Testicular germ cell tumor;	chr21:46222409	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.771	rs2839155	ENSG00000239415.1	AP001469.9	7.5	3.12e-13	1.06e-10	0.34	0.33	Testicular germ cell tumor;	chr21:46220078	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.771	rs2280959	ENSG00000239415.1	AP001469.9	7.5	3.12e-13	1.06e-10	0.34	0.33	Testicular germ cell tumor;	chr21:46222082	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.739	rs2280958	ENSG00000239415.1	AP001469.9	7.5	3.12e-13	1.06e-10	0.34	0.33	Testicular germ cell tumor;	chr21:46222102	chr21:46251549~46254133:-
THCA	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	7.5	3.12e-13	1.06e-10	0.43	0.33	Height;	chr6:109427303	chr6:109382795~109383666:+
THCA	cis	rs910316	0.763	rs175450	ENSG00000279594.1	RP11-950C14.10	-7.5	3.14e-13	1.06e-10	-0.3	-0.33	Height;	chr14:75123637	chr14:75011269~75012851:-
THCA	cis	rs910316	0.789	rs175444	ENSG00000279594.1	RP11-950C14.10	-7.5	3.14e-13	1.06e-10	-0.3	-0.33	Height;	chr14:75135079	chr14:75011269~75012851:-
THCA	cis	rs651907	0.557	rs7651406	ENSG00000256628.3	ZBTB11-AS1	7.5	3.14e-13	1.06e-10	0.38	0.33	Colorectal cancer;	chr3:101674452	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs3864012	ENSG00000256628.3	ZBTB11-AS1	7.5	3.14e-13	1.06e-10	0.38	0.33	Colorectal cancer;	chr3:101678779	chr3:101676475~101679217:+
THCA	cis	rs4820539	0.966	rs5751587	ENSG00000221069.1	AC000029.1	-7.5	3.14e-13	1.07e-10	-0.38	-0.33	Bone mineral density;	chr22:23127903	chr22:23136620~23136710:+
THCA	cis	rs4820539	0.966	rs5759594	ENSG00000221069.1	AC000029.1	-7.5	3.14e-13	1.07e-10	-0.38	-0.33	Bone mineral density;	chr22:23128473	chr22:23136620~23136710:+
THCA	cis	rs4820539	1	rs5759595	ENSG00000221069.1	AC000029.1	-7.5	3.14e-13	1.07e-10	-0.38	-0.33	Bone mineral density;	chr22:23129437	chr22:23136620~23136710:+
THCA	cis	rs2288884	0.505	rs2278415	ENSG00000275055.1	CTC-471J1.11	-7.5	3.15e-13	1.07e-10	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964950	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.505	rs3764538	ENSG00000275055.1	CTC-471J1.11	-7.5	3.15e-13	1.07e-10	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965334	chr19:52049007~52049754:+
THCA	cis	rs2946505	0.871	rs2466244	ENSG00000251468.2	RP11-369K16.1	7.5	3.15e-13	1.07e-10	0.44	0.33	Migraine;	chr8:12964370	chr8:12958387~12962200:+
THCA	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	7.5	3.16e-13	1.07e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
THCA	cis	rs7942368	1	rs7107409	ENSG00000254761.1	RP11-672A2.1	7.5	3.16e-13	1.07e-10	0.46	0.33	Endometriosis;	chr11:76781151	chr11:76712396~76719608:-
THCA	cis	rs11148252	0.538	rs9535880	ENSG00000235660.1	LINC00345	-7.5	3.17e-13	1.07e-10	-0.4	-0.33	Lewy body disease;	chr13:52132007	chr13:52484161~52484680:-
THCA	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-7.5	3.17e-13	1.08e-10	-0.32	-0.33	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000264538.5	SUZ12P1	-7.5	3.18e-13	1.08e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30709299~30790908:+
THCA	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-7.5	3.19e-13	1.08e-10	-0.36	-0.33	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
THCA	cis	rs9902453	1	rs4581755	ENSG00000264007.1	RP11-68I3.10	7.5	3.19e-13	1.08e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:30100880	chr17:29621617~29622254:-
THCA	cis	rs957448	0.561	rs7459558	ENSG00000253704.1	RP11-267M23.4	7.5	3.19e-13	1.08e-10	0.33	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94553722~94569745:+
THCA	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	7.5	3.19e-13	1.08e-10	0.43	0.33	Height;	chr4:55413708	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	7.5	3.19e-13	1.08e-10	0.43	0.33	Height;	chr4:55415153	chr4:55363971~55395847:-
THCA	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	7.5	3.19e-13	1.08e-10	0.37	0.33	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
THCA	cis	rs7942368	1	rs1440979	ENSG00000254761.1	RP11-672A2.1	7.5	3.2e-13	1.08e-10	0.46	0.33	Endometriosis;	chr11:76784085	chr11:76712396~76719608:-
THCA	cis	rs2976388	0.647	rs2585136	ENSG00000253741.1	CTD-2292P10.4	-7.5	3.2e-13	1.08e-10	-0.41	-0.33	Urinary tract infection frequency;	chr8:142730723	chr8:142702252~142726973:-
THCA	cis	rs1198430	1	rs1198434	ENSG00000232482.2	RP4-654C18.1	-7.5	3.2e-13	1.09e-10	-0.58	-0.33	Total cholesterol levels;	chr1:23431641	chr1:23410832~23412146:+
THCA	cis	rs780096	1	rs780095	ENSG00000234072.1	AC074117.10	-7.5	3.2e-13	1.09e-10	-0.25	-0.33	Total body bone mineral density;	chr2:27518238	chr2:27356246~27367622:+
THCA	cis	rs6504108	0.624	rs3897986	ENSG00000278765.1	RP5-890E16.5	7.5	3.21e-13	1.09e-10	0.37	0.33	Body mass index;	chr17:48184177	chr17:48066704~48067293:-
THCA	cis	rs910316	0.763	rs175044	ENSG00000279594.1	RP11-950C14.10	-7.5	3.21e-13	1.09e-10	-0.3	-0.33	Height;	chr14:75005406	chr14:75011269~75012851:-
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000226155.1	AC124944.3	-7.5	3.22e-13	1.09e-10	-0.38	-0.33	Pancreatic cancer;	chr3:196026869	chr3:195912049~195913986:+
THCA	cis	rs11971779	1	rs75919582	ENSG00000273391.1	RP11-634H22.1	7.5	3.22e-13	1.09e-10	0.36	0.33	Diisocyanate-induced asthma;	chr7:139370173	chr7:139359032~139359566:-
THCA	cis	rs7247513	0.79	rs17476839	ENSG00000230310.1	CTD-2192J16.11	7.5	3.22e-13	1.09e-10	0.39	0.33	Bipolar disorder;	chr19:12651969	chr19:12552597~12553644:+
THCA	cis	rs67340775	0.541	rs200965	ENSG00000219392.1	RP1-265C24.5	-7.5	3.22e-13	1.09e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27898606	chr6:28115628~28116551:+
THCA	cis	rs11672691	0.792	rs7248215	ENSG00000267107.5	PCAT19	7.5	3.23e-13	1.09e-10	0.34	0.33	Prostate cancer;	chr19:41493212	chr19:41454169~41500649:-
THCA	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-7.5	3.24e-13	1.1e-10	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
THCA	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	7.5	3.24e-13	1.1e-10	0.33	0.33	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-7.5	3.24e-13	1.1e-10	-0.33	-0.33	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
THCA	cis	rs6762	0.748	rs1130719	ENSG00000279672.1	CMB9-55F22.1	7.5	3.24e-13	1.1e-10	0.36	0.33	Mean platelet volume;	chr11:838760	chr11:779617~780755:+
THCA	cis	rs10208649	1	rs13401719	ENSG00000272156.1	RP11-477N3.1	7.5	3.24e-13	1.1e-10	0.59	0.33	Body mass index;	chr2:53958510	chr2:54082554~54085066:+
THCA	cis	rs4820539	0.966	rs2301554	ENSG00000221069.1	AC000029.1	-7.5	3.25e-13	1.1e-10	-0.39	-0.33	Bone mineral density;	chr22:23142067	chr22:23136620~23136710:+
THCA	cis	rs944289	0.53	rs2755193	ENSG00000257826.1	RP11-116N8.4	7.5	3.25e-13	1.1e-10	0.35	0.33	Thyroid cancer;	chr14:36049416	chr14:36061026~36067190:-
THCA	cis	rs67340775	0.541	rs200964	ENSG00000219392.1	RP1-265C24.5	-7.5	3.25e-13	1.1e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27899165	chr6:28115628~28116551:+
THCA	cis	rs4072705	1	rs722477	ENSG00000224020.1	MIR181A2HG	-7.5	3.26e-13	1.1e-10	-0.29	-0.33	Menarche (age at onset);	chr9:124712315	chr9:124658467~124698631:+
THCA	cis	rs914615	0.552	rs4460629	ENSG00000160766.13	GBAP1	-7.5	3.26e-13	1.1e-10	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155162859	chr1:155213821~155227422:-
THCA	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-7.5	3.27e-13	1.11e-10	-0.34	-0.33	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-7.5	3.27e-13	1.11e-10	-0.34	-0.33	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-7.5	3.27e-13	1.11e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-7.5	3.27e-13	1.11e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
THCA	cis	rs2562456	0.833	rs2968076	ENSG00000268119.4	CTD-2561J22.5	-7.5	3.27e-13	1.11e-10	-0.41	-0.33	Pain;	chr19:21454299	chr19:21444241~21463908:-
THCA	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-7.5	3.27e-13	1.11e-10	-0.31	-0.33	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
THCA	cis	rs950169	0.512	rs4374136	ENSG00000259728.4	LINC00933	7.5	3.28e-13	1.11e-10	0.47	0.33	Schizophrenia;	chr15:83976255	chr15:84570649~84580175:+
THCA	cis	rs6504108	0.624	rs2060876	ENSG00000278765.1	RP5-890E16.5	-7.5	3.28e-13	1.11e-10	-0.37	-0.33	Body mass index;	chr17:48245604	chr17:48066704~48067293:-
THCA	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
THCA	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	7.5	3.28e-13	1.11e-10	0.27	0.33	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
THCA	cis	rs801193	0.66	rs10950049	ENSG00000232559.3	GS1-124K5.12	7.5	3.3e-13	1.12e-10	0.31	0.33	Aortic root size;	chr7:66765873	chr7:66554588~66576923:-
THCA	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	7.5	3.3e-13	1.12e-10	0.36	0.33	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
THCA	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
THCA	cis	rs651907	0.557	rs3806654	ENSG00000256628.3	ZBTB11-AS1	7.5	3.3e-13	1.12e-10	0.38	0.33	Colorectal cancer;	chr3:101677685	chr3:101676475~101679217:+
THCA	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
THCA	cis	rs7942368	0.793	rs12273016	ENSG00000254761.1	RP11-672A2.1	-7.5	3.31e-13	1.12e-10	-0.45	-0.33	Endometriosis;	chr11:76779672	chr11:76712396~76719608:-
THCA	cis	rs6600671	1	rs10903159	ENSG00000223345.3	HIST2H2BA	7.5	3.31e-13	1.12e-10	0.36	0.33	Hip geometry;	chr1:121440138	chr1:121108210~121117257:-
THCA	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	7.5	3.31e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-7.5	3.31e-13	1.12e-10	-0.19	-0.33	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	7.5	3.31e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
THCA	cis	rs2284219	0.964	rs2284218	ENSG00000244480.1	AC005154.7	-7.5	3.31e-13	1.12e-10	-0.26	-0.33	Type 2 diabetes;	chr7:30674717	chr7:30523143~30524535:-
THCA	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	7.5	3.32e-13	1.12e-10	0.45	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
THCA	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-7.5	3.32e-13	1.12e-10	-0.35	-0.33	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
THCA	cis	rs2688608	0.592	rs10762560	ENSG00000271816.1	BMS1P4	7.49	3.33e-13	1.13e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73735647	chr10:73699151~73730487:-
THCA	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-7.49	3.33e-13	1.13e-10	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
THCA	cis	rs11673344	0.504	rs1667378	ENSG00000226686.6	LINC01535	7.49	3.33e-13	1.13e-10	0.36	0.33	Obesity-related traits;	chr19:37001171	chr19:37251912~37265535:+
THCA	cis	rs7119038	0.609	rs11216998	ENSG00000255239.1	AP002954.6	-7.49	3.33e-13	1.13e-10	-0.46	-0.33	Sjögren's syndrome;	chr11:118734128	chr11:118688039~118690600:-
THCA	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	7.49	3.33e-13	1.13e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	7.49	3.33e-13	1.13e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	7.49	3.33e-13	1.13e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
THCA	cis	rs10208649	1	rs11886024	ENSG00000272156.1	RP11-477N3.1	7.49	3.33e-13	1.13e-10	0.59	0.33	Body mass index;	chr2:53917682	chr2:54082554~54085066:+
THCA	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	7.49	3.34e-13	1.13e-10	0.19	0.33	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
THCA	cis	rs1198430	1	rs1198432	ENSG00000232482.2	RP4-654C18.1	7.49	3.34e-13	1.13e-10	0.58	0.33	Total cholesterol levels;	chr1:23429662	chr1:23410832~23412146:+
THCA	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	7.49	3.34e-13	1.13e-10	0.41	0.33	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
THCA	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-7.49	3.35e-13	1.13e-10	-0.32	-0.33	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
THCA	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	7.49	3.36e-13	1.13e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
THCA	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-7.49	3.36e-13	1.13e-10	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
THCA	cis	rs944289	0.53	rs2780308	ENSG00000257826.1	RP11-116N8.4	7.49	3.36e-13	1.14e-10	0.35	0.33	Thyroid cancer;	chr14:36050062	chr14:36061026~36067190:-
THCA	cis	rs9902453	0.967	rs12449783	ENSG00000264007.1	RP11-68I3.10	7.49	3.38e-13	1.14e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:30200635	chr17:29621617~29622254:-
THCA	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	7.49	3.38e-13	1.14e-10	0.41	0.33	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
THCA	cis	rs12928939	0.815	rs8049163	ENSG00000260886.1	TAT-AS1	7.49	3.39e-13	1.14e-10	0.43	0.33	Post bronchodilator FEV1;	chr16:71685450	chr16:71565789~71578187:+
THCA	cis	rs690037	0.551	rs690522	ENSG00000272498.1	RP11-415F23.3	7.49	3.39e-13	1.14e-10	0.36	0.33	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16335560	chr3:16339308~16339871:+
THCA	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	7.49	3.39e-13	1.15e-10	0.19	0.33	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
THCA	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	7.49	3.39e-13	1.15e-10	0.38	0.33	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
THCA	cis	rs67340775	0.541	rs200975	ENSG00000219392.1	RP1-265C24.5	-7.49	3.4e-13	1.15e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27887847	chr6:28115628~28116551:+
THCA	cis	rs67340775	0.541	rs200974	ENSG00000219392.1	RP1-265C24.5	-7.49	3.4e-13	1.15e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27888067	chr6:28115628~28116551:+
THCA	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	7.49	3.4e-13	1.15e-10	0.19	0.33	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
THCA	cis	rs7945705	0.846	rs4929912	ENSG00000254860.4	TMEM9B-AS1	7.49	3.4e-13	1.15e-10	0.37	0.33	Hemoglobin concentration;	chr11:8795148	chr11:8964675~8977527:+
THCA	cis	rs11148252	0.87	rs11148246	ENSG00000278238.1	RP11-245D16.4	-7.49	3.41e-13	1.15e-10	-0.37	-0.33	Lewy body disease;	chr13:52223402	chr13:52454775~52455331:-
THCA	cis	rs875971	1	rs709597	ENSG00000232559.3	GS1-124K5.12	-7.49	3.41e-13	1.15e-10	-0.31	-0.33	Aortic root size;	chr7:66360996	chr7:66554588~66576923:-
THCA	cis	rs7726414	1	rs115808154	ENSG00000279469.1	RP11-215P8.2	7.49	3.41e-13	1.15e-10	0.67	0.33	Systemic lupus erythematosus;	chr5:134128584	chr5:134394360~134395008:-
THCA	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	7.49	3.41e-13	1.15e-10	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
THCA	cis	rs2688608	0.592	rs7080579	ENSG00000271816.1	BMS1P4	7.49	3.42e-13	1.15e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73744271	chr10:73699151~73730487:-
THCA	cis	rs853679	1	rs853676	ENSG00000219392.1	RP1-265C24.5	-7.49	3.42e-13	1.15e-10	-0.51	-0.33	Depression;	chr6:28331910	chr6:28115628~28116551:+
THCA	cis	rs17695224	0.545	rs4802875	ENSG00000269483.1	AC006272.1	7.49	3.42e-13	1.16e-10	0.35	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51827056	chr19:51839924~51843324:-
THCA	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-7.49	3.43e-13	1.16e-10	-0.4	-0.33	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-7.49	3.43e-13	1.16e-10	-0.4	-0.33	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
THCA	cis	rs2688608	0.592	rs11000758	ENSG00000271816.1	BMS1P4	7.49	3.43e-13	1.16e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73733852	chr10:73699151~73730487:-
THCA	cis	rs4820539	1	rs5759598	ENSG00000221069.1	AC000029.1	-7.49	3.43e-13	1.16e-10	-0.38	-0.33	Bone mineral density;	chr22:23138775	chr22:23136620~23136710:+
THCA	cis	rs728616	0.717	rs61860016	ENSG00000225484.5	NUTM2B-AS1	-7.49	3.43e-13	1.16e-10	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:79663088~79826594:-
THCA	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	7.49	3.44e-13	1.16e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
THCA	cis	rs224278	0.51	rs1888967	ENSG00000238280.1	RP11-436D10.3	-7.49	3.44e-13	1.16e-10	-0.41	-0.33	Ewing sarcoma;	chr10:62819700	chr10:62793562~62805887:-
THCA	cis	rs651907	0.557	rs3094297	ENSG00000256628.3	ZBTB11-AS1	7.49	3.45e-13	1.16e-10	0.38	0.33	Colorectal cancer;	chr3:101680416	chr3:101676475~101679217:+
THCA	cis	rs2348418	0.864	rs2175464	ENSG00000247934.4	RP11-967K21.1	-7.49	3.45e-13	1.16e-10	-0.28	-0.33	Lung function (FEV1);Lung function (FVC);	chr12:28564178	chr12:28163298~28190738:-
THCA	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-7.49	3.45e-13	1.16e-10	-0.48	-0.33	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-7.49	3.45e-13	1.16e-10	-0.48	-0.33	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
THCA	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	7.49	3.45e-13	1.16e-10	0.43	0.33	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-7.49	3.45e-13	1.17e-10	-0.41	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
THCA	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-7.49	3.46e-13	1.17e-10	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-7.49	3.46e-13	1.17e-10	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
THCA	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	7.49	3.46e-13	1.17e-10	0.49	0.33	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	7.49	3.47e-13	1.17e-10	0.49	0.33	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000232559.3	GS1-124K5.12	7.49	3.47e-13	1.17e-10	0.31	0.33	Aortic root size;	chr7:66749580	chr7:66554588~66576923:-
THCA	cis	rs801193	0.66	rs4610622	ENSG00000232559.3	GS1-124K5.12	7.49	3.47e-13	1.17e-10	0.31	0.33	Aortic root size;	chr7:66759510	chr7:66554588~66576923:-
THCA	cis	rs17772222	0.74	rs61984675	ENSG00000258789.1	RP11-507K2.3	-7.49	3.48e-13	1.17e-10	-0.32	-0.33	Coronary artery calcification;	chr14:88511236	chr14:88551597~88552493:+
THCA	cis	rs1198430	0.714	rs946265	ENSG00000232482.2	RP4-654C18.1	-7.49	3.48e-13	1.17e-10	-0.51	-0.33	Total cholesterol levels;	chr1:23448803	chr1:23410832~23412146:+
THCA	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-7.49	3.48e-13	1.18e-10	-0.36	-0.33	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
THCA	cis	rs831571	1	rs831571	ENSG00000280620.1	SCAANT1	-7.49	3.48e-13	1.18e-10	-0.5	-0.33	Type 2 diabetes;	chr3:64062621	chr3:63911518~63911772:-
THCA	cis	rs7942368	1	rs1440980	ENSG00000254632.1	RP11-21L23.4	7.49	3.49e-13	1.18e-10	0.47	0.33	Endometriosis;	chr11:76784032	chr11:76759916~76768223:-
THCA	cis	rs2562456	0.833	rs2968078	ENSG00000268555.1	RP11-678G14.3	-7.49	3.49e-13	1.18e-10	-0.47	-0.33	Pain;	chr19:21458942	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.755	rs2650773	ENSG00000268555.1	RP11-678G14.3	-7.49	3.49e-13	1.18e-10	-0.47	-0.33	Pain;	chr19:21461286	chr19:21570822~21587322:-
THCA	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-7.49	3.5e-13	1.18e-10	-0.32	-0.33	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
THCA	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-7.49	3.5e-13	1.18e-10	-0.32	-0.33	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-7.49	3.5e-13	1.18e-10	-0.32	-0.33	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-7.49	3.5e-13	1.18e-10	-0.32	-0.33	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
THCA	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-7.49	3.51e-13	1.18e-10	-0.35	-0.33	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
THCA	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	7.49	3.51e-13	1.18e-10	0.83	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
THCA	cis	rs9828933	0.507	rs56030924	ENSG00000280620.1	SCAANT1	7.49	3.51e-13	1.18e-10	0.46	0.33	Type 2 diabetes;	chr3:64009887	chr3:63911518~63911772:-
THCA	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	7.49	3.53e-13	1.19e-10	0.42	0.33	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
THCA	cis	rs2688608	0.592	rs11000760	ENSG00000271816.1	BMS1P4	7.49	3.54e-13	1.19e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73733976	chr10:73699151~73730487:-
THCA	cis	rs9388451	0.839	rs10457469	ENSG00000237742.5	RP11-624M8.1	-7.49	3.54e-13	1.19e-10	-0.28	-0.33	Brugada syndrome;	chr6:125762512	chr6:125578558~125749190:-
THCA	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	7.49	3.56e-13	1.2e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
THCA	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	7.48	3.56e-13	1.2e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	7.48	3.56e-13	1.2e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
THCA	cis	rs7208859	0.673	rs9889755	ENSG00000266490.1	CTD-2349P21.9	-7.48	3.56e-13	1.2e-10	-0.43	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30792372~30792833:+
THCA	cis	rs9902453	0.933	rs2054846	ENSG00000264007.1	RP11-68I3.10	-7.48	3.57e-13	1.2e-10	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30180675	chr17:29621617~29622254:-
THCA	cis	rs910316	0.967	rs7146523	ENSG00000279594.1	RP11-950C14.10	-7.48	3.57e-13	1.2e-10	-0.3	-0.33	Height;	chr14:75193177	chr14:75011269~75012851:-
THCA	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	7.48	3.58e-13	1.21e-10	0.37	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
THCA	cis	rs9902453	0.904	rs12951836	ENSG00000264007.1	RP11-68I3.10	-7.48	3.58e-13	1.21e-10	-0.36	-0.33	Coffee consumption (cups per day);	chr17:30083259	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs12948898	ENSG00000264007.1	RP11-68I3.10	-7.48	3.58e-13	1.21e-10	-0.36	-0.33	Coffee consumption (cups per day);	chr17:30083306	chr17:29621617~29622254:-
THCA	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	7.48	3.58e-13	1.21e-10	0.38	0.33	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
THCA	cis	rs11168351	0.927	rs7971880	ENSG00000258273.1	RP11-370I10.4	-7.48	3.59e-13	1.21e-10	-0.44	-0.33	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48333755~48333901:-
THCA	cis	rs947583	1	rs7742626	ENSG00000231028.7	LINC00271	7.48	3.59e-13	1.21e-10	0.27	0.33	Phosphorus levels;	chr6:135811358	chr6:135497801~135716055:+
THCA	cis	rs516805	0.64	rs55768410	ENSG00000279453.1	RP3-425C14.4	7.48	3.59e-13	1.21e-10	0.34	0.33	Lymphocyte counts;	chr6:122358588	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs9490431	ENSG00000279453.1	RP3-425C14.4	7.48	3.59e-13	1.21e-10	0.34	0.33	Lymphocyte counts;	chr6:122361132	chr6:122436789~122439223:-
THCA	cis	rs8027521	0.54	rs2725583	ENSG00000280362.1	RP11-643A5.3	-7.48	3.59e-13	1.21e-10	-0.45	-0.33	Circulating chemerin levels;	chr15:53972311	chr15:53910769~53914712:+
THCA	cis	rs7302981	0.51	rs860698	ENSG00000272368.2	RP4-605O3.4	7.48	3.61e-13	1.21e-10	0.2	0.33	Systolic blood pressure;	chr12:50092539	chr12:50112197~50165618:+
THCA	cis	rs9813712	0.574	rs11718032	ENSG00000228252.7	COL6A4P2	7.48	3.61e-13	1.21e-10	0.32	0.33	Response to amphetamines;	chr3:130257749	chr3:130212823~130273806:+
THCA	cis	rs4820539	1	rs916583	ENSG00000221069.1	AC000029.1	-7.48	3.61e-13	1.22e-10	-0.38	-0.33	Bone mineral density;	chr22:23127080	chr22:23136620~23136710:+
THCA	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-7.48	3.61e-13	1.22e-10	-0.38	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
THCA	cis	rs9902453	0.967	rs34323226	ENSG00000264007.1	RP11-68I3.10	7.48	3.61e-13	1.22e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:30190436	chr17:29621617~29622254:-
THCA	cis	rs6539288	0.901	rs4964506	ENSG00000260329.1	RP11-412D9.4	-7.48	3.61e-13	1.22e-10	-0.3	-0.33	Total body bone mineral density;	chr12:106953307	chr12:106954029~106955497:-
THCA	cis	rs12460587	0.587	rs10415150	ENSG00000275055.1	CTC-471J1.11	-7.48	3.62e-13	1.22e-10	-0.26	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52101372	chr19:52049007~52049754:+
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000263603.1	CTD-2349P21.5	-7.48	3.62e-13	1.22e-10	-0.57	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30729469~30731202:+
THCA	cis	rs4820539	0.902	rs9612237	ENSG00000221069.1	AC000029.1	-7.48	3.62e-13	1.22e-10	-0.38	-0.33	Bone mineral density;	chr22:23130767	chr22:23136620~23136710:+
THCA	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-7.48	3.62e-13	1.22e-10	-0.29	-0.33	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
THCA	cis	rs728616	0.717	rs12412999	ENSG00000225484.5	NUTM2B-AS1	-7.48	3.63e-13	1.22e-10	-0.64	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:79663088~79826594:-
THCA	cis	rs9828933	0.577	rs832194	ENSG00000280620.1	SCAANT1	-7.48	3.63e-13	1.22e-10	-0.55	-0.33	Type 2 diabetes;	chr3:63871395	chr3:63911518~63911772:-
THCA	cis	rs9902453	0.765	rs3115087	ENSG00000264007.1	RP11-68I3.10	7.48	3.65e-13	1.23e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29703249	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.817	rs3115089	ENSG00000264007.1	RP11-68I3.10	7.48	3.65e-13	1.23e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29704863	chr17:29621617~29622254:-
THCA	cis	rs67340775	0.541	rs200979	ENSG00000219392.1	RP1-265C24.5	-7.48	3.65e-13	1.23e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27884579	chr6:28115628~28116551:+
THCA	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	7.48	3.65e-13	1.23e-10	0.41	0.33	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
THCA	cis	rs7302981	0.746	rs836177	ENSG00000272368.2	RP4-605O3.4	7.48	3.65e-13	1.23e-10	0.2	0.33	Systolic blood pressure;	chr12:50098038	chr12:50112197~50165618:+
THCA	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	7.48	3.66e-13	1.23e-10	0.4	0.33	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	7.48	3.66e-13	1.23e-10	0.4	0.33	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
THCA	cis	rs914615	0.552	rs7556304	ENSG00000160766.13	GBAP1	-7.48	3.66e-13	1.23e-10	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155167033	chr1:155213821~155227422:-
THCA	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	7.48	3.66e-13	1.23e-10	0.19	0.33	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	7.48	3.66e-13	1.23e-10	0.19	0.33	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000263603.1	CTD-2349P21.5	7.48	3.66e-13	1.23e-10	0.57	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30729469~30731202:+
THCA	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	7.48	3.66e-13	1.23e-10	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
THCA	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	7.48	3.66e-13	1.23e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	7.48	3.66e-13	1.23e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	7.48	3.66e-13	1.23e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
THCA	cis	rs71636778	0.509	rs17162387	ENSG00000260063.1	RP5-968P14.2	-7.48	3.66e-13	1.23e-10	-0.59	-0.33	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26966865	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34976021	ENSG00000260063.1	RP5-968P14.2	-7.48	3.66e-13	1.23e-10	-0.59	-0.33	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26972073	chr1:26692132~26694131:-
THCA	cis	rs2115630	0.691	rs2292462	ENSG00000275120.1	RP11-182J1.17	-7.48	3.67e-13	1.23e-10	-0.33	-0.33	P wave terminal force;	chr15:84657523	chr15:84599434~84606463:-
THCA	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-7.48	3.68e-13	1.24e-10	-0.41	-0.33	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
THCA	cis	rs67340775	0.541	rs169287	ENSG00000219392.1	RP1-265C24.5	-7.48	3.68e-13	1.24e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27886982	chr6:28115628~28116551:+
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000273009.1	RP11-352G9.1	-7.48	3.69e-13	1.24e-10	-0.35	-0.33	Pancreatic cancer;	chr3:196026869	chr3:195913078~195913683:-
THCA	cis	rs12928939	0.723	rs71403864	ENSG00000260886.1	TAT-AS1	7.48	3.69e-13	1.24e-10	0.42	0.33	Post bronchodilator FEV1;	chr16:71661127	chr16:71565789~71578187:+
THCA	cis	rs6504108	0.624	rs954226	ENSG00000278765.1	RP5-890E16.5	-7.48	3.69e-13	1.24e-10	-0.37	-0.33	Body mass index;	chr17:48227450	chr17:48066704~48067293:-
THCA	cis	rs748404	0.697	rs530188	ENSG00000205771.5	CATSPER2P1	-7.48	3.7e-13	1.24e-10	-0.34	-0.33	Lung cancer;	chr15:43253116	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs475227	ENSG00000205771.5	CATSPER2P1	-7.48	3.7e-13	1.24e-10	-0.34	-0.33	Lung cancer;	chr15:43254248	chr15:43726918~43747094:-
THCA	cis	rs9649213	0.531	rs35216698	ENSG00000272950.1	RP11-307C18.1	7.48	3.7e-13	1.24e-10	0.4	0.33	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr7:98322853~98323430:+
THCA	cis	rs507080	0.922	rs525485	ENSG00000278376.1	RP11-158I9.8	-7.48	3.71e-13	1.25e-10	-0.26	-0.33	Serum metabolite levels;	chr11:118685045	chr11:118791254~118793137:+
THCA	cis	rs4664293	0.565	rs10165197	ENSG00000226266.5	AC009961.3	7.48	3.71e-13	1.25e-10	0.38	0.33	Monocyte percentage of white cells;	chr2:159537137	chr2:159670708~159712435:-
THCA	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-7.48	3.71e-13	1.25e-10	-0.4	-0.33	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
THCA	cis	rs4604234	0.518	rs73463537	ENSG00000272129.1	RP11-250B2.6	-7.48	3.72e-13	1.25e-10	-0.69	-0.33	Cancer;	chr6:80275314	chr6:80355424~80356859:+
THCA	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	7.48	3.72e-13	1.25e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	7.48	3.72e-13	1.25e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
THCA	cis	rs7942368	1	rs7107409	ENSG00000254632.1	RP11-21L23.4	7.48	3.72e-13	1.25e-10	0.47	0.33	Endometriosis;	chr11:76781151	chr11:76759916~76768223:-
THCA	cis	rs193541	0.53	rs1466371	ENSG00000263432.2	RN7SL689P	7.48	3.72e-13	1.25e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122748093	chr5:123022487~123022783:-
THCA	cis	rs5769707	0.681	rs135879	ENSG00000235111.1	RP1-29C18.8	-7.48	3.73e-13	1.25e-10	-0.4	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.642	rs135880	ENSG00000235111.1	RP1-29C18.8	-7.48	3.73e-13	1.25e-10	-0.4	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49612657~49615716:-
THCA	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-7.48	3.74e-13	1.26e-10	-0.48	-0.33	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
THCA	cis	rs11971779	0.68	rs73154134	ENSG00000273391.1	RP11-634H22.1	7.48	3.75e-13	1.26e-10	0.32	0.33	Diisocyanate-induced asthma;	chr7:139355205	chr7:139359032~139359566:-
THCA	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	7.48	3.75e-13	1.26e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
THCA	cis	rs8027521	0.58	rs2725567	ENSG00000280362.1	RP11-643A5.3	-7.48	3.75e-13	1.26e-10	-0.41	-0.33	Circulating chemerin levels;	chr15:53944858	chr15:53910769~53914712:+
THCA	cis	rs2688608	0.592	rs3933085	ENSG00000271816.1	BMS1P4	7.48	3.76e-13	1.26e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73723573	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.592	rs7909544	ENSG00000271816.1	BMS1P4	7.48	3.76e-13	1.26e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73724246	chr10:73699151~73730487:-
THCA	cis	rs13068223	0.584	rs344018	ENSG00000243926.1	TIPARP-AS1	-7.48	3.76e-13	1.26e-10	-0.32	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156698204	chr3:156671862~156674378:-
THCA	cis	rs6745190	0.953	rs4990275	ENSG00000236153.1	AC104076.3	7.48	3.76e-13	1.26e-10	0.38	0.33	White blood cell count;	chr2:181008934	chr2:180979427~180980090:-
THCA	cis	rs690037	0.528	rs568833	ENSG00000272498.1	RP11-415F23.3	7.48	3.76e-13	1.27e-10	0.35	0.33	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16326329	chr3:16339308~16339871:+
THCA	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-7.48	3.77e-13	1.27e-10	-0.38	-0.33	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
THCA	cis	rs10971721	0.584	rs1378	ENSG00000260947.1	RP11-384P7.7	7.48	3.77e-13	1.27e-10	0.74	0.33	Body mass index;	chr9:34107506	chr9:33697459~33700986:+
THCA	cis	rs910316	0.737	rs175077	ENSG00000279594.1	RP11-950C14.10	-7.48	3.77e-13	1.27e-10	-0.3	-0.33	Height;	chr14:75040172	chr14:75011269~75012851:-
THCA	cis	rs9902453	0.967	rs4429345	ENSG00000264007.1	RP11-68I3.10	-7.48	3.77e-13	1.27e-10	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30131087	chr17:29621617~29622254:-
THCA	cis	rs12928939	0.815	rs1345868	ENSG00000260886.1	TAT-AS1	7.48	3.77e-13	1.27e-10	0.42	0.33	Post bronchodilator FEV1;	chr16:71635721	chr16:71565789~71578187:+
THCA	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
THCA	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
THCA	cis	rs947583	0.588	rs12204523	ENSG00000231028.7	LINC00271	-7.48	3.78e-13	1.27e-10	-0.27	-0.33	Phosphorus levels;	chr6:135753856	chr6:135497801~135716055:+
THCA	cis	rs1962073	0.528	rs4582610	ENSG00000261451.1	RP11-981G7.1	-7.48	3.78e-13	1.27e-10	-0.41	-0.33	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10460833	chr8:10433672~10438312:+
THCA	cis	rs853679	1	rs1679732	ENSG00000219392.1	RP1-265C24.5	7.48	3.79e-13	1.27e-10	0.52	0.33	Depression;	chr6:28253486	chr6:28115628~28116551:+
THCA	cis	rs516805	0.706	rs9490430	ENSG00000279453.1	RP3-425C14.4	7.48	3.79e-13	1.27e-10	0.34	0.33	Lymphocyte counts;	chr6:122360951	chr6:122436789~122439223:-
THCA	cis	rs193541	0.621	rs898391	ENSG00000263432.2	RN7SL689P	7.48	3.8e-13	1.28e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122746471	chr5:123022487~123022783:-
THCA	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-7.48	3.8e-13	1.28e-10	-0.42	-0.33	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
THCA	cis	rs9902453	0.765	rs3102555	ENSG00000264007.1	RP11-68I3.10	7.48	3.8e-13	1.28e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29717083	chr17:29621617~29622254:-
THCA	cis	rs934734	1	rs934734	ENSG00000204929.10	AC074391.1	-7.48	3.8e-13	1.28e-10	-0.4	-0.33	Rheumatoid arthritis;	chr2:65368452	chr2:65436711~66084639:+
THCA	cis	rs6430549	0.518	rs41521049	ENSG00000224043.6	CCNT2-AS1	-7.48	3.8e-13	1.28e-10	-0.35	-0.33	Hematocrit;	chr2:134935499	chr2:134735464~134918710:-
THCA	cis	rs9487605	1	rs9487605	ENSG00000271789.1	RP5-1112D6.7	-7.47	3.81e-13	1.28e-10	-0.35	-0.33	Inflammatory skin disease;	chr6:111261682	chr6:111297126~111298510:+
THCA	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-7.47	3.82e-13	1.28e-10	-0.47	-0.33	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
THCA	cis	rs12817211	0.502	rs12369049	ENSG00000272368.2	RP4-605O3.4	-7.47	3.83e-13	1.29e-10	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50116679	chr12:50112197~50165618:+
THCA	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-7.47	3.83e-13	1.29e-10	-0.6	-0.33	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
THCA	cis	rs6539288	0.901	rs4964507	ENSG00000260329.1	RP11-412D9.4	-7.47	3.83e-13	1.29e-10	-0.3	-0.33	Total body bone mineral density;	chr12:106954979	chr12:106954029~106955497:-
THCA	cis	rs12701220	0.595	rs12532837	ENSG00000229043.2	AC091729.9	-7.47	3.84e-13	1.29e-10	-0.49	-0.33	Bronchopulmonary dysplasia;	chr7:1083215	chr7:1160374~1165267:+
THCA	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.84e-13	1.29e-10	-0.32	-0.33	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
THCA	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-7.47	3.85e-13	1.29e-10	-0.35	-0.33	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
THCA	cis	rs240993	0.516	rs240968	ENSG00000230177.1	RP5-1112D6.4	-7.47	3.85e-13	1.29e-10	-0.36	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111311517	chr6:111277932~111278742:+
THCA	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	7.47	3.86e-13	1.3e-10	0.58	0.33	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
THCA	cis	rs2522056	0.808	rs2706373	ENSG00000233006.5	AC034220.3	-7.47	3.86e-13	1.3e-10	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132468564	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs2522062	ENSG00000233006.5	AC034220.3	-7.47	3.86e-13	1.3e-10	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132469724	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs2522063	ENSG00000233006.5	AC034220.3	-7.47	3.86e-13	1.3e-10	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132469899	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs2706379	ENSG00000233006.5	AC034220.3	-7.47	3.86e-13	1.3e-10	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132470043	chr5:132311285~132369916:-
THCA	cis	rs748404	0.56	rs529611	ENSG00000166763.7	STRCP1	7.47	3.87e-13	1.3e-10	0.35	0.33	Lung cancer;	chr15:43513790	chr15:43699488~43718184:-
THCA	cis	rs9388451	0.626	rs3799708	ENSG00000237742.5	RP11-624M8.1	-7.47	3.87e-13	1.3e-10	-0.29	-0.33	Brugada syndrome;	chr6:125757384	chr6:125578558~125749190:-
THCA	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-7.47	3.88e-13	1.3e-10	-0.34	-0.33	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-7.47	3.88e-13	1.3e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
THCA	cis	rs9902453	0.933	rs9303628	ENSG00000264007.1	RP11-68I3.10	7.47	3.89e-13	1.31e-10	0.36	0.33	Coffee consumption (cups per day);	chr17:30200210	chr17:29621617~29622254:-
THCA	cis	rs7015630	0.648	rs62530862	ENSG00000251136.7	RP11-37B2.1	-7.47	3.89e-13	1.31e-10	-0.35	-0.33	Inflammatory bowel disease;Crohn's disease;	chr8:89822659	chr8:89609409~89757727:-
THCA	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-7.47	3.9e-13	1.31e-10	-0.44	-0.33	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
THCA	cis	rs12188164	0.582	rs80273890	ENSG00000221990.4	EXOC3-AS1	7.47	3.91e-13	1.31e-10	0.31	0.33	Cystic fibrosis severity;	chr5:482942	chr5:441498~443160:-
THCA	cis	rs5760842	0.933	rs5760837	ENSG00000279110.1	CTA-243E7.1	-7.47	3.91e-13	1.31e-10	-0.4	-0.33	Recurrent major depressive disorder;	chr22:25085119	chr22:25052122~25065241:-
THCA	cis	rs12817211	0.502	rs12819883	ENSG00000272368.2	RP4-605O3.4	-7.47	3.92e-13	1.31e-10	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50140005	chr12:50112197~50165618:+
THCA	cis	rs6545883	0.525	rs2049747	ENSG00000271889.1	RP11-493E12.1	-7.47	3.92e-13	1.32e-10	-0.31	-0.33	Tuberculosis;	chr2:61137019	chr2:61151433~61162105:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000206090.4	AP000350.7	7.47	3.93e-13	1.32e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23939998~23942798:+
THCA	cis	rs6504108	0.624	rs8069263	ENSG00000278765.1	RP5-890E16.5	-7.47	3.93e-13	1.32e-10	-0.36	-0.33	Body mass index;	chr17:48209416	chr17:48066704~48067293:-
THCA	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	7.47	3.93e-13	1.32e-10	0.43	0.33	Height;	chr6:109618283	chr6:109382795~109383666:+
THCA	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-7.47	3.93e-13	1.32e-10	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
THCA	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-7.47	3.93e-13	1.32e-10	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
THCA	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-7.47	3.94e-13	1.32e-10	-0.35	-0.33	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
THCA	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	7.47	3.94e-13	1.32e-10	0.31	0.33	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
THCA	cis	rs9816784	0.696	rs6778081	ENSG00000242086.7	LINC00969	-7.47	3.95e-13	1.32e-10	-0.3	-0.33	Mean corpuscular hemoglobin;	chr3:196092334	chr3:195658062~195739964:+
THCA	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	7.47	3.97e-13	1.33e-10	0.65	0.33	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
THCA	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	7.47	3.98e-13	1.33e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
THCA	cis	rs12655019	0.92	rs2271202	ENSG00000271828.1	CTD-2310F14.1	7.47	3.98e-13	1.34e-10	0.75	0.33	Breast cancer (early onset);	chr5:56912714	chr5:56927874~56929573:+
THCA	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
THCA	cis	rs2562456	1	rs2359155	ENSG00000268555.1	RP11-678G14.3	-7.47	4e-13	1.34e-10	-0.45	-0.33	Pain;	chr19:21489067	chr19:21570822~21587322:-
THCA	cis	rs9902453	0.74	rs2617867	ENSG00000264007.1	RP11-68I3.10	-7.47	4e-13	1.34e-10	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29722381	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2628191	ENSG00000264007.1	RP11-68I3.10	-7.47	4e-13	1.34e-10	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29724122	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	7.47	4.01e-13	1.34e-10	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
THCA	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-7.47	4.01e-13	1.35e-10	-0.34	-0.33	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
THCA	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	7.47	4.01e-13	1.35e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
THCA	cis	rs728616	0.51	rs12416084	ENSG00000225484.5	NUTM2B-AS1	-7.47	4.02e-13	1.35e-10	-0.48	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79663088~79826594:-
THCA	cis	rs728616	0.51	rs34817075	ENSG00000225484.5	NUTM2B-AS1	-7.47	4.02e-13	1.35e-10	-0.48	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79663088~79826594:-
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000219392.1	RP1-265C24.5	-7.47	4.02e-13	1.35e-10	-0.36	-0.33	Pubertal anthropometrics;	chr6:28219323	chr6:28115628~28116551:+
THCA	cis	rs6723108	0.603	rs4953938	ENSG00000224043.6	CCNT2-AS1	7.47	4.04e-13	1.35e-10	0.35	0.33	Type 2 diabetes;	chr2:134937278	chr2:134735464~134918710:-
THCA	cis	rs686320	1	rs616599	ENSG00000245532.5	NEAT1	7.47	4.04e-13	1.35e-10	0.29	0.33	Hip circumference adjusted for BMI;	chr11:65486554	chr11:65422774~65445540:+
THCA	cis	rs6840258	0.66	rs10516786	ENSG00000251411.1	RP11-397E7.4	-7.47	4.05e-13	1.36e-10	-0.39	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86971189	chr4:86913266~86914817:-
THCA	cis	rs9902453	0.791	rs3115100	ENSG00000264007.1	RP11-68I3.10	7.47	4.05e-13	1.36e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29718726	chr17:29621617~29622254:-
THCA	cis	rs6600671	1	rs7532615	ENSG00000223345.3	HIST2H2BA	-7.47	4.05e-13	1.36e-10	-0.36	-0.33	Hip geometry;	chr1:121430980	chr1:121108210~121117257:-
THCA	cis	rs6539288	0.835	rs2041893	ENSG00000260329.1	RP11-412D9.4	-7.47	4.06e-13	1.36e-10	-0.3	-0.33	Total body bone mineral density;	chr12:106956598	chr12:106954029~106955497:-
THCA	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	7.47	4.06e-13	1.36e-10	0.48	0.33	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	7.47	4.06e-13	1.36e-10	0.48	0.33	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	7.47	4.06e-13	1.36e-10	0.48	0.33	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
THCA	cis	rs12817211	0.502	rs7294618	ENSG00000272368.2	RP4-605O3.4	-7.47	4.07e-13	1.36e-10	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50119192	chr12:50112197~50165618:+
THCA	cis	rs12817211	0.502	rs7961112	ENSG00000272368.2	RP4-605O3.4	-7.47	4.07e-13	1.36e-10	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50119736	chr12:50112197~50165618:+
THCA	cis	rs9341808	0.754	rs1015158	ENSG00000272129.1	RP11-250B2.6	7.47	4.07e-13	1.36e-10	0.42	0.33	Sitting height ratio;	chr6:80236028	chr6:80355424~80356859:+
THCA	cis	rs4950322	0.57	rs17356184	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147262943	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs80270233	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147263320	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs4950392	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147264889	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs17356219	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147265684	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72691041	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147267084	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs17356233	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147268843	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs17356240	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147269877	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs1999820	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147270329	chr1:147172771~147211568:+
THCA	cis	rs1198430	0.929	rs1210852	ENSG00000232482.2	RP4-654C18.1	-7.46	4.09e-13	1.37e-10	-0.58	-0.33	Total cholesterol levels;	chr1:23427040	chr1:23410832~23412146:+
THCA	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	7.46	4.09e-13	1.37e-10	0.41	0.33	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
THCA	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-7.46	4.09e-13	1.37e-10	-0.32	-0.33	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
THCA	cis	rs9902453	0.868	rs8066602	ENSG00000264007.1	RP11-68I3.10	7.46	4.1e-13	1.37e-10	0.36	0.33	Coffee consumption (cups per day);	chr17:30196067	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.868	rs8066731	ENSG00000264007.1	RP11-68I3.10	7.46	4.1e-13	1.37e-10	0.36	0.33	Coffee consumption (cups per day);	chr17:30196103	chr17:29621617~29622254:-
THCA	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-7.46	4.1e-13	1.37e-10	-0.41	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
THCA	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-7.46	4.1e-13	1.37e-10	-0.35	-0.33	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
THCA	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	7.46	4.1e-13	1.37e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	7.46	4.1e-13	1.37e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
THCA	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	7.46	4.12e-13	1.38e-10	0.19	0.33	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
THCA	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-7.46	4.12e-13	1.38e-10	-0.37	-0.33	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
THCA	cis	rs10181042	0.565	rs62150982	ENSG00000271889.1	RP11-493E12.1	-7.46	4.13e-13	1.38e-10	-0.3	-0.33	Crohn's disease;	chr2:61053540	chr2:61151433~61162105:-
THCA	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-7.46	4.13e-13	1.38e-10	-0.53	-0.33	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-7.46	4.13e-13	1.38e-10	-0.53	-0.33	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
THCA	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	7.46	4.13e-13	1.38e-10	0.37	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
THCA	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	7.46	4.13e-13	1.38e-10	0.37	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
THCA	cis	rs9876781	0.56	rs2362451	ENSG00000229759.1	MRPS18AP1	-7.46	4.13e-13	1.38e-10	-0.39	-0.33	Longevity;	chr3:48358338	chr3:48256350~48256938:-
THCA	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-7.46	4.14e-13	1.39e-10	-0.42	-0.33	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
THCA	cis	rs7646881	1	rs73015651	ENSG00000240207.5	RP11-379F4.4	-7.46	4.14e-13	1.39e-10	-0.45	-0.33	Tetralogy of Fallot;	chr3:158733133	chr3:158732263~158784070:+
THCA	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-7.46	4.15e-13	1.39e-10	-0.32	-0.33	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
THCA	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	7.46	4.15e-13	1.39e-10	0.19	0.33	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
THCA	cis	rs9388451	0.626	rs1935983	ENSG00000237742.5	RP11-624M8.1	-7.46	4.16e-13	1.39e-10	-0.29	-0.33	Brugada syndrome;	chr6:125747768	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.626	rs1343116	ENSG00000237742.5	RP11-624M8.1	-7.46	4.16e-13	1.39e-10	-0.29	-0.33	Brugada syndrome;	chr6:125748556	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.626	rs1343115	ENSG00000237742.5	RP11-624M8.1	-7.46	4.16e-13	1.39e-10	-0.29	-0.33	Brugada syndrome;	chr6:125748671	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.626	rs2875881	ENSG00000237742.5	RP11-624M8.1	-7.46	4.16e-13	1.39e-10	-0.29	-0.33	Brugada syndrome;	chr6:125751707	chr6:125578558~125749190:-
THCA	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	7.46	4.16e-13	1.39e-10	0.19	0.33	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
THCA	cis	rs9902453	0.791	rs3115090	ENSG00000264007.1	RP11-68I3.10	7.46	4.16e-13	1.39e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29707996	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.726	rs3115092	ENSG00000264007.1	RP11-68I3.10	7.46	4.16e-13	1.39e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29709332	chr17:29621617~29622254:-
THCA	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-7.46	4.18e-13	1.4e-10	-0.38	-0.33	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
THCA	cis	rs4713118	0.581	rs200504	ENSG00000219392.1	RP1-265C24.5	-7.46	4.18e-13	1.4e-10	-0.45	-0.33	Parkinson's disease;	chr6:27818042	chr6:28115628~28116551:+
THCA	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	7.46	4.18e-13	1.4e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	7.46	4.18e-13	1.4e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
THCA	cis	rs2288884	0.579	rs6509609	ENSG00000275055.1	CTC-471J1.11	-7.46	4.19e-13	1.4e-10	-0.32	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51970353	chr19:52049007~52049754:+
THCA	cis	rs7208859	0.623	rs55724095	ENSG00000264538.5	SUZ12P1	-7.46	4.2e-13	1.41e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs9903854	ENSG00000264538.5	SUZ12P1	-7.46	4.2e-13	1.41e-10	-0.34	-0.33	Body mass index;	chr17:30826980	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs80355557	ENSG00000264538.5	SUZ12P1	-7.46	4.2e-13	1.41e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9911173	ENSG00000264538.5	SUZ12P1	-7.46	4.2e-13	1.41e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30709299~30790908:+
THCA	cis	rs9902453	0.765	rs3102560	ENSG00000264007.1	RP11-68I3.10	7.46	4.21e-13	1.41e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29702920	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.726	rs3115088	ENSG00000264007.1	RP11-68I3.10	7.46	4.21e-13	1.41e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29704257	chr17:29621617~29622254:-
THCA	cis	rs9847710	0.901	rs2564964	ENSG00000242142.1	SERBP1P3	7.46	4.21e-13	1.41e-10	0.39	0.33	Ulcerative colitis;	chr3:53004102	chr3:53064283~53065091:-
THCA	cis	rs853679	1	rs9986596	ENSG00000280107.1	AL022393.9	-7.46	4.21e-13	1.41e-10	-0.47	-0.33	Depression;	chr6:28251883	chr6:28170845~28172521:+
THCA	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-7.46	4.22e-13	1.41e-10	-0.42	-0.33	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-7.46	4.22e-13	1.41e-10	-0.42	-0.33	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
THCA	cis	rs6487679	1	rs1017302	ENSG00000111788.10	RP11-22B23.1	7.46	4.22e-13	1.41e-10	0.39	0.33	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9277235~9313241:+
THCA	cis	rs6487679	1	rs10734765	ENSG00000111788.10	RP11-22B23.1	7.46	4.22e-13	1.41e-10	0.39	0.33	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9277235~9313241:+
THCA	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	7.46	4.24e-13	1.42e-10	0.19	0.33	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
THCA	cis	rs4072705	1	rs10818983	ENSG00000224020.1	MIR181A2HG	-7.46	4.25e-13	1.42e-10	-0.29	-0.33	Menarche (age at onset);	chr9:124649298	chr9:124658467~124698631:+
THCA	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	7.46	4.25e-13	1.42e-10	0.43	0.33	Height;	chr6:109564272	chr6:109382795~109383666:+
THCA	cis	rs8114671	0.562	rs959829	ENSG00000269202.1	RP4-614O4.12	7.46	4.25e-13	1.42e-10	0.28	0.33	Height;	chr20:34758244	chr20:35201747~35203288:-
THCA	cis	rs7267979	0.868	rs6138553	ENSG00000274414.1	RP5-965G21.4	-7.46	4.25e-13	1.42e-10	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.903	rs6115109	ENSG00000274414.1	RP5-965G21.4	-7.46	4.25e-13	1.42e-10	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25239007~25245229:-
THCA	cis	rs853679	0.517	rs1904841	ENSG00000220721.1	OR1F12	7.46	4.26e-13	1.42e-10	0.45	0.33	Depression;	chr6:28140307	chr6:28073316~28074233:+
THCA	cis	rs6745190	0.953	rs6433878	ENSG00000236153.1	AC104076.3	7.46	4.27e-13	1.43e-10	0.38	0.33	White blood cell count;	chr2:180973227	chr2:180979427~180980090:-
THCA	cis	rs17684571	0.872	rs3002003	ENSG00000231441.1	RP11-472M19.2	7.46	4.27e-13	1.43e-10	0.41	0.33	Schizophrenia;	chr6:56743274	chr6:56844002~56864078:+
THCA	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	7.46	4.27e-13	1.43e-10	0.34	0.33	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
THCA	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-7.46	4.29e-13	1.43e-10	-0.38	-0.33	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
THCA	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-7.46	4.29e-13	1.43e-10	-0.38	-0.33	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
THCA	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
THCA	cis	rs4950322	0.542	rs17159924	ENSG00000237188.3	RP11-337C18.8	7.46	4.3e-13	1.44e-10	0.4	0.33	Protein quantitative trait loci;	chr1:147199463	chr1:147172771~147211568:+
THCA	cis	rs2688608	0.592	rs7076585	ENSG00000271816.1	BMS1P4	7.46	4.31e-13	1.44e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73743934	chr10:73699151~73730487:-
THCA	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	7.46	4.31e-13	1.44e-10	0.32	0.33	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
THCA	cis	rs2348418	0.864	rs2203088	ENSG00000247934.4	RP11-967K21.1	7.46	4.32e-13	1.44e-10	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28556767	chr12:28163298~28190738:-
THCA	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-7.46	4.33e-13	1.44e-10	-0.5	-0.33	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
THCA	cis	rs10936632	0.728	rs10804840	ENSG00000242578.1	RP11-469J4.3	-7.46	4.33e-13	1.45e-10	-0.36	-0.33	Prostate cancer;	chr3:170354019	chr3:170410512~170418615:+
THCA	cis	rs2688608	0.592	rs10762559	ENSG00000271816.1	BMS1P4	7.46	4.33e-13	1.45e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73726695	chr10:73699151~73730487:-
THCA	cis	rs10971721	0.584	rs10971940	ENSG00000260947.1	RP11-384P7.7	7.46	4.34e-13	1.45e-10	0.73	0.33	Body mass index;	chr9:34127213	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731226	ENSG00000260947.1	RP11-384P7.7	7.46	4.34e-13	1.45e-10	0.73	0.33	Body mass index;	chr9:34128832	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971944	ENSG00000260947.1	RP11-384P7.7	7.46	4.34e-13	1.45e-10	0.73	0.33	Body mass index;	chr9:34129008	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.631	rs74450404	ENSG00000260947.1	RP11-384P7.7	7.46	4.34e-13	1.45e-10	0.73	0.33	Body mass index;	chr9:34134666	chr9:33697459~33700986:+
THCA	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	7.46	4.34e-13	1.45e-10	0.41	0.33	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
THCA	cis	rs10936632	0.755	rs10804839	ENSG00000242578.1	RP11-469J4.3	-7.46	4.35e-13	1.45e-10	-0.36	-0.33	Prostate cancer;	chr3:170353995	chr3:170410512~170418615:+
THCA	cis	rs7208859	0.623	rs73271869	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73271872	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs9907834	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Body mass index;	chr17:30826995	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73271887	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9898858	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs55658077	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9899692	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9906957	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30709299~30790908:+
THCA	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	7.46	4.35e-13	1.45e-10	0.31	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
THCA	cis	rs4950322	0.547	rs6660507	ENSG00000237188.3	RP11-337C18.8	7.46	4.35e-13	1.45e-10	0.37	0.33	Protein quantitative trait loci;	chr1:147148574	chr1:147172771~147211568:+
THCA	cis	rs6907340	0.517	rs9465531	ENSG00000227116.1	RP3-471C18.1	-7.46	4.35e-13	1.45e-10	-0.35	-0.33	Endometriosis;	chr6:19798418	chr6:19730427~19734567:-
THCA	cis	rs8114671	0.647	rs6060267	ENSG00000269202.1	RP4-614O4.12	-7.46	4.35e-13	1.45e-10	-0.27	-0.33	Height;	chr20:35146209	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.647	rs6060268	ENSG00000269202.1	RP4-614O4.12	-7.46	4.35e-13	1.45e-10	-0.27	-0.33	Height;	chr20:35146490	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.647	rs1415771	ENSG00000269202.1	RP4-614O4.12	-7.46	4.35e-13	1.45e-10	-0.27	-0.33	Height;	chr20:35146690	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.647	rs945959	ENSG00000269202.1	RP4-614O4.12	-7.46	4.35e-13	1.45e-10	-0.27	-0.33	Height;	chr20:35147102	chr20:35201747~35203288:-
THCA	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	7.45	4.37e-13	1.46e-10	0.47	0.33	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
THCA	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-7.45	4.37e-13	1.46e-10	-0.35	-0.33	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
THCA	cis	rs34375054	0.66	rs12303416	ENSG00000279233.1	RP11-158L12.4	7.45	4.37e-13	1.46e-10	0.32	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125108812	chr12:125138245~125141711:+
THCA	cis	rs944289	0.53	rs2780309	ENSG00000257826.1	RP11-116N8.4	7.45	4.38e-13	1.46e-10	0.34	0.33	Thyroid cancer;	chr14:36050646	chr14:36061026~36067190:-
THCA	cis	rs10971721	0.822	rs117703548	ENSG00000260947.1	RP11-384P7.7	7.45	4.38e-13	1.46e-10	0.8	0.33	Body mass index;	chr9:34041199	chr9:33697459~33700986:+
THCA	cis	rs467650	0.509	rs2591443	ENSG00000246763.5	RGMB-AS1	-7.45	4.38e-13	1.46e-10	-0.31	-0.33	Venous thromboembolism (SNP x SNP interaction);	chr5:98661785	chr5:98769618~98773469:-
THCA	cis	rs240993	0.812	rs7764543	ENSG00000230177.1	RP5-1112D6.4	-7.45	4.38e-13	1.46e-10	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111277932~111278742:+
THCA	cis	rs7746199	0.736	rs58616630	ENSG00000280107.1	AL022393.9	-7.45	4.39e-13	1.47e-10	-0.64	-0.33	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs34573979	ENSG00000280107.1	AL022393.9	-7.45	4.39e-13	1.47e-10	-0.64	-0.33	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28170845~28172521:+
THCA	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	7.45	4.39e-13	1.47e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	7.45	4.4e-13	1.47e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	7.45	4.4e-13	1.47e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
THCA	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	7.45	4.4e-13	1.47e-10	0.32	0.33	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
THCA	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-7.45	4.4e-13	1.47e-10	-0.22	-0.33	Breast cancer;	chr11:825777	chr11:781645~782105:+
THCA	cis	rs2361718	0.5	rs4889970	ENSG00000279259.1	RP11-334C17.3	-7.45	4.41e-13	1.47e-10	-0.33	-0.33	Yeast infection;	chr17:80122287	chr17:80147250~80148596:+
THCA	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-7.45	4.41e-13	1.47e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
THCA	cis	rs9549328	0.8	rs9549620	ENSG00000267868.1	RP11-120K24.3	7.45	4.42e-13	1.47e-10	0.34	0.33	Systolic blood pressure;	chr13:112979107	chr13:112964835~112966131:-
THCA	cis	rs6908034	0.607	rs78774173	ENSG00000228412.5	RP4-625H18.2	7.45	4.42e-13	1.48e-10	0.81	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19820455	chr6:19802164~19804752:-
THCA	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-7.45	4.43e-13	1.48e-10	-0.38	-0.33	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
THCA	cis	rs6539288	0.901	rs4964193	ENSG00000260329.1	RP11-412D9.4	-7.45	4.44e-13	1.48e-10	-0.29	-0.33	Total body bone mineral density;	chr12:106927970	chr12:106954029~106955497:-
THCA	cis	rs6696239	0.531	rs2644150	ENSG00000227711.2	RP11-275O4.5	-7.45	4.44e-13	1.48e-10	-0.35	-0.33	Height;	chr1:227514120	chr1:227509028~227520477:-
THCA	cis	rs4266144	0.558	rs7623382	ENSG00000244515.1	KRT18P34	-7.45	4.44e-13	1.48e-10	-0.37	-0.33	Coronary artery disease;	chr3:157115105	chr3:157162663~157163932:-
THCA	cis	rs7430456	0.901	rs9824206	ENSG00000228221.4	LINC00578	7.45	4.45e-13	1.48e-10	0.42	0.33	Breast cancer;	chr3:177742093	chr3:177441921~177752305:+
THCA	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-7.45	4.45e-13	1.48e-10	-0.34	-0.33	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-7.45	4.45e-13	1.48e-10	-0.34	-0.33	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
THCA	cis	rs2688608	0.592	rs11000759	ENSG00000271816.1	BMS1P4	7.45	4.46e-13	1.49e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73733968	chr10:73699151~73730487:-
THCA	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-7.45	4.46e-13	1.49e-10	-0.43	-0.33	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-7.45	4.46e-13	1.49e-10	-0.43	-0.33	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
THCA	cis	rs910316	0.967	rs4899551	ENSG00000279594.1	RP11-950C14.10	-7.45	4.46e-13	1.49e-10	-0.3	-0.33	Height;	chr14:75193543	chr14:75011269~75012851:-
THCA	cis	rs984222	0.775	rs2645294	ENSG00000231365.4	RP11-418J17.1	-7.45	4.49e-13	1.5e-10	-0.31	-0.33	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119031964	chr1:119140396~119275973:+
THCA	cis	rs1949733	1	rs2631745	ENSG00000205959.3	RP11-689P11.2	7.45	4.5e-13	1.5e-10	0.27	0.33	Response to antineoplastic agents;	chr4:8488803	chr4:8482270~8512610:+
THCA	cis	rs2361718	0.5	rs4889818	ENSG00000279259.1	RP11-334C17.3	7.45	4.5e-13	1.5e-10	0.33	0.33	Yeast infection;	chr17:80111429	chr17:80147250~80148596:+
THCA	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-7.45	4.5e-13	1.5e-10	-0.53	-0.32	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000263603.1	CTD-2349P21.5	-7.45	4.5e-13	1.5e-10	-0.58	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs8078182	ENSG00000264538.5	SUZ12P1	-7.45	4.51e-13	1.5e-10	-0.31	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30709299~30790908:+
THCA	cis	rs12188164	0.62	rs1043356	ENSG00000221990.4	EXOC3-AS1	-7.45	4.51e-13	1.5e-10	-0.3	-0.32	Cystic fibrosis severity;	chr5:480833	chr5:441498~443160:-
THCA	cis	rs1962073	0.528	rs12544112	ENSG00000261451.1	RP11-981G7.1	7.45	4.53e-13	1.51e-10	0.41	0.32	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10461305	chr8:10433672~10438312:+
THCA	cis	rs9649213	0.555	rs7785612	ENSG00000272950.1	RP11-307C18.1	7.45	4.53e-13	1.51e-10	0.4	0.32	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr7:98322853~98323430:+
THCA	cis	rs1949733	0.701	rs940136	ENSG00000205959.3	RP11-689P11.2	-7.45	4.53e-13	1.51e-10	-0.27	-0.32	Response to antineoplastic agents;	chr4:8447265	chr4:8482270~8512610:+
THCA	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	7.45	4.54e-13	1.51e-10	0.47	0.32	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	7.45	4.54e-13	1.51e-10	0.47	0.32	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
THCA	cis	rs9847710	0.838	rs2564962	ENSG00000242142.1	SERBP1P3	7.45	4.54e-13	1.51e-10	0.39	0.32	Ulcerative colitis;	chr3:52997622	chr3:53064283~53065091:-
THCA	cis	rs9847710	0.869	rs11708675	ENSG00000242142.1	SERBP1P3	7.45	4.54e-13	1.51e-10	0.39	0.32	Ulcerative colitis;	chr3:52997896	chr3:53064283~53065091:-
THCA	cis	rs9847710	0.869	rs2564920	ENSG00000242142.1	SERBP1P3	7.45	4.54e-13	1.51e-10	0.39	0.32	Ulcerative colitis;	chr3:52999041	chr3:53064283~53065091:-
THCA	cis	rs9847710	0.838	rs12635298	ENSG00000242142.1	SERBP1P3	7.45	4.54e-13	1.51e-10	0.39	0.32	Ulcerative colitis;	chr3:52999780	chr3:53064283~53065091:-
THCA	cis	rs9388451	0.874	rs13209968	ENSG00000237742.5	RP11-624M8.1	-7.45	4.55e-13	1.52e-10	-0.28	-0.32	Brugada syndrome;	chr6:125768139	chr6:125578558~125749190:-
THCA	cis	rs990871	0.927	rs1460943	ENSG00000227207.2	RPL31P12	-7.45	4.55e-13	1.52e-10	-0.4	-0.32	Subcutaneous adipose tissue;	chr1:72347446	chr1:72301472~72301829:+
THCA	cis	rs416603	0.901	rs149597	ENSG00000262703.1	RP11-485G7.6	-7.45	4.55e-13	1.52e-10	-0.36	-0.32	Type 1 diabetes;	chr16:11250085	chr16:11348143~11349321:-
THCA	cis	rs4820539	1	rs13054985	ENSG00000221069.1	AC000029.1	-7.45	4.55e-13	1.52e-10	-0.39	-0.32	Bone mineral density;	chr22:23116390	chr22:23136620~23136710:+
THCA	cis	rs910316	0.737	rs175049	ENSG00000279594.1	RP11-950C14.10	-7.45	4.56e-13	1.52e-10	-0.3	-0.32	Height;	chr14:75014665	chr14:75011269~75012851:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000206090.4	AP000350.7	7.45	4.56e-13	1.52e-10	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23939998~23942798:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000206090.4	AP000350.7	7.45	4.56e-13	1.52e-10	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23939998~23942798:+
THCA	cis	rs1198430	1	rs946268	ENSG00000232482.2	RP4-654C18.1	-7.45	4.56e-13	1.52e-10	-0.58	-0.32	Total cholesterol levels;	chr1:23421273	chr1:23410832~23412146:+
THCA	cis	rs9902453	0.904	rs8078638	ENSG00000264007.1	RP11-68I3.10	7.45	4.58e-13	1.52e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29963340	chr17:29621617~29622254:-
THCA	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-7.45	4.6e-13	1.53e-10	-0.41	-0.32	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-7.45	4.6e-13	1.53e-10	-0.41	-0.32	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
THCA	cis	rs4713118	0.619	rs200486	ENSG00000219392.1	RP1-265C24.5	-7.45	4.6e-13	1.53e-10	-0.45	-0.32	Parkinson's disease;	chr6:27811728	chr6:28115628~28116551:+
THCA	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	7.45	4.62e-13	1.54e-10	0.4	0.32	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	7.45	4.62e-13	1.54e-10	0.4	0.32	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
THCA	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-7.45	4.62e-13	1.54e-10	-0.74	-0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
THCA	cis	rs7302981	0.681	rs706792	ENSG00000272368.2	RP4-605O3.4	7.45	4.62e-13	1.54e-10	0.2	0.32	Systolic blood pressure;	chr12:50073861	chr12:50112197~50165618:+
THCA	cis	rs9902453	1	rs59274738	ENSG00000264007.1	RP11-68I3.10	7.45	4.62e-13	1.54e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:30110617	chr17:29621617~29622254:-
THCA	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-7.45	4.63e-13	1.54e-10	-0.51	-0.32	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
THCA	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-7.45	4.63e-13	1.54e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
THCA	cis	rs12928939	0.815	rs11648483	ENSG00000260886.1	TAT-AS1	7.45	4.64e-13	1.54e-10	0.42	0.32	Post bronchodilator FEV1;	chr16:71673495	chr16:71565789~71578187:+
THCA	cis	rs6600671	0.967	rs4844613	ENSG00000223345.3	HIST2H2BA	7.45	4.64e-13	1.54e-10	0.36	0.32	Hip geometry;	chr1:121431913	chr1:121108210~121117257:-
THCA	cis	rs7208859	0.573	rs8078182	ENSG00000266490.1	CTD-2349P21.9	7.45	4.64e-13	1.54e-10	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30792372~30792833:+
THCA	cis	rs801193	0.613	rs2016325	ENSG00000237310.1	GS1-124K5.4	-7.45	4.64e-13	1.55e-10	-0.24	-0.32	Aortic root size;	chr7:66858513	chr7:66493706~66495474:+
THCA	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	7.45	4.65e-13	1.55e-10	0.37	0.32	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
THCA	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	7.45	4.65e-13	1.55e-10	0.37	0.32	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
THCA	cis	rs7302981	0.967	rs7972842	ENSG00000272368.2	RP4-605O3.4	-7.45	4.66e-13	1.55e-10	-0.19	-0.32	Systolic blood pressure;	chr12:50122540	chr12:50112197~50165618:+
THCA	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	7.45	4.66e-13	1.55e-10	0.35	0.32	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
THCA	cis	rs9902453	0.845	rs2259855	ENSG00000264007.1	RP11-68I3.10	-7.44	4.67e-13	1.55e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:29770842	chr17:29621617~29622254:-
THCA	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-7.44	4.67e-13	1.55e-10	-0.27	-0.32	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
THCA	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-7.44	4.67e-13	1.55e-10	-0.35	-0.32	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-7.44	4.67e-13	1.55e-10	-0.35	-0.32	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
THCA	cis	rs6696239	0.531	rs2644151	ENSG00000227711.2	RP11-275O4.5	-7.44	4.67e-13	1.55e-10	-0.35	-0.32	Height;	chr1:227514993	chr1:227509028~227520477:-
THCA	cis	rs7208859	0.573	rs216442	ENSG00000264538.5	SUZ12P1	-7.44	4.68e-13	1.56e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs216445	ENSG00000264538.5	SUZ12P1	-7.44	4.68e-13	1.56e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs216446	ENSG00000264538.5	SUZ12P1	-7.44	4.68e-13	1.56e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30709299~30790908:+
THCA	cis	rs6600671	0.934	rs12131379	ENSG00000223345.3	HIST2H2BA	7.44	4.69e-13	1.56e-10	0.35	0.32	Hip geometry;	chr1:121551639	chr1:121108210~121117257:-
THCA	cis	rs4820539	0.966	rs2157709	ENSG00000221069.1	AC000029.1	-7.44	4.69e-13	1.56e-10	-0.39	-0.32	Bone mineral density;	chr22:23115233	chr22:23136620~23136710:+
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000273009.1	RP11-352G9.1	-7.44	4.7e-13	1.56e-10	-0.35	-0.32	Pancreatic cancer;	chr3:196022690	chr3:195913078~195913683:-
THCA	cis	rs3096299	0.583	rs2965949	ENSG00000274627.1	RP11-104N10.2	7.44	4.7e-13	1.56e-10	0.36	0.32	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89516797~89522217:+
THCA	cis	rs2688608	0.588	rs10128205	ENSG00000271816.1	BMS1P4	7.44	4.71e-13	1.57e-10	0.33	0.32	Inflammatory bowel disease;	chr10:73709890	chr10:73699151~73730487:-
THCA	cis	rs8113308	1	rs8104737	ENSG00000269235.1	ZNF350-AS1	7.44	4.72e-13	1.57e-10	0.46	0.32	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938444	chr19:51949134~51981367:+
THCA	cis	rs6545883	0.525	rs1177274	ENSG00000271889.1	RP11-493E12.1	7.44	4.72e-13	1.57e-10	0.3	0.32	Tuberculosis;	chr2:61141397	chr2:61151433~61162105:-
THCA	cis	rs6539288	0.865	rs2888893	ENSG00000260329.1	RP11-412D9.4	-7.44	4.74e-13	1.58e-10	-0.3	-0.32	Total body bone mineral density;	chr12:106944853	chr12:106954029~106955497:-
THCA	cis	rs12655019	0.92	rs7731829	ENSG00000271828.1	CTD-2310F14.1	7.44	4.74e-13	1.58e-10	0.74	0.32	Breast cancer (early onset);	chr5:56911884	chr5:56927874~56929573:+
THCA	cis	rs7554547	0.667	rs2336377	ENSG00000199347.1	RNU5E-1	-7.44	4.75e-13	1.58e-10	-0.42	-0.32	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr1:11908152~11908271:+
THCA	cis	rs11148252	0.553	rs9536219	ENSG00000235660.1	LINC00345	-7.44	4.75e-13	1.58e-10	-0.42	-0.32	Lewy body disease;	chr13:52653166	chr13:52484161~52484680:-
THCA	cis	rs6600671	1	rs11249350	ENSG00000223345.3	HIST2H2BA	7.44	4.75e-13	1.58e-10	0.35	0.32	Hip geometry;	chr1:121436587	chr1:121108210~121117257:-
THCA	cis	rs2018683	1	rs160837	ENSG00000228421.2	AC005013.5	7.44	4.75e-13	1.58e-10	0.36	0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28973116	chr7:28957667~28959345:+
THCA	cis	rs7942368	0.941	rs10793195	ENSG00000254761.1	RP11-672A2.1	7.44	4.76e-13	1.58e-10	0.46	0.32	Endometriosis;	chr11:76793688	chr11:76712396~76719608:-
THCA	cis	rs6723108	0.603	rs3814355	ENSG00000224043.6	CCNT2-AS1	-7.44	4.76e-13	1.58e-10	-0.35	-0.32	Type 2 diabetes;	chr2:134953946	chr2:134735464~134918710:-
THCA	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-7.44	4.77e-13	1.58e-10	-0.26	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-7.44	4.77e-13	1.58e-10	-0.26	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
THCA	cis	rs875971	0.898	rs6977501	ENSG00000232559.3	GS1-124K5.12	-7.44	4.77e-13	1.59e-10	-0.31	-0.32	Aortic root size;	chr7:66228355	chr7:66554588~66576923:-
THCA	cis	rs2348418	0.864	rs6487690	ENSG00000247934.4	RP11-967K21.1	7.44	4.78e-13	1.59e-10	0.29	0.32	Lung function (FEV1);Lung function (FVC);	chr12:28560407	chr12:28163298~28190738:-
THCA	cis	rs4820539	1	rs885964	ENSG00000221069.1	AC000029.1	-7.44	4.78e-13	1.59e-10	-0.39	-0.32	Bone mineral density;	chr22:23118816	chr22:23136620~23136710:+
THCA	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	7.44	4.79e-13	1.59e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
THCA	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-7.44	4.79e-13	1.59e-10	-0.27	-0.32	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
THCA	cis	rs2688608	0.56	rs10128354	ENSG00000271816.1	BMS1P4	7.44	4.79e-13	1.59e-10	0.33	0.32	Inflammatory bowel disease;	chr10:73710287	chr10:73699151~73730487:-
THCA	cis	rs690037	0.673	rs690573	ENSG00000272498.1	RP11-415F23.3	7.44	4.8e-13	1.59e-10	0.36	0.32	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334933	chr3:16339308~16339871:+
THCA	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	7.44	4.8e-13	1.6e-10	0.6	0.32	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
THCA	cis	rs17772222	0.74	rs10150311	ENSG00000258789.1	RP11-507K2.3	-7.44	4.83e-13	1.6e-10	-0.31	-0.32	Coronary artery calcification;	chr14:88510128	chr14:88551597~88552493:+
THCA	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	7.44	4.84e-13	1.61e-10	0.19	0.32	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
THCA	cis	rs9902453	0.74	rs2254414	ENSG00000264007.1	RP11-68I3.10	-7.44	4.85e-13	1.61e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:29734112	chr17:29621617~29622254:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000206090.4	AP000350.7	7.44	4.85e-13	1.61e-10	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23939998~23942798:+
THCA	cis	rs12817211	0.524	rs1554845	ENSG00000272368.2	RP4-605O3.4	-7.44	4.85e-13	1.61e-10	-0.19	-0.32	Colorectal or endometrial cancer;	chr12:50129721	chr12:50112197~50165618:+
THCA	cis	rs4073416	0.712	rs11627067	ENSG00000276116.2	FUT8-AS1	7.44	4.86e-13	1.61e-10	0.33	0.32	N-glycan levels;	chr14:65716235	chr14:65411170~65412690:-
THCA	cis	rs193541	0.632	rs30036	ENSG00000263432.2	RN7SL689P	7.44	4.86e-13	1.61e-10	0.39	0.32	Glucose homeostasis traits;	chr5:122942565	chr5:123022487~123022783:-
THCA	cis	rs6539288	0.739	rs4964511	ENSG00000260329.1	RP11-412D9.4	-7.44	4.88e-13	1.62e-10	-0.3	-0.32	Total body bone mineral density;	chr12:106966468	chr12:106954029~106955497:-
THCA	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-7.44	4.89e-13	1.62e-10	-0.37	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
THCA	cis	rs2288884	0.505	rs12460506	ENSG00000275055.1	CTC-471J1.11	-7.44	4.89e-13	1.62e-10	-0.33	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51980340	chr19:52049007~52049754:+
THCA	cis	rs2522056	0.932	rs2522064	ENSG00000233006.5	AC034220.3	-7.44	4.91e-13	1.63e-10	-0.28	-0.32	Fibrinogen;Lymphocyte counts;	chr5:132470796	chr5:132311285~132369916:-
THCA	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	7.44	4.91e-13	1.63e-10	0.3	0.32	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
THCA	cis	rs56751865	1	rs56751865	ENSG00000254851.1	RP11-109L13.1	7.44	4.92e-13	1.63e-10	0.77	0.32	Lobe attachment (rater scored);	chr11:117066155	chr11:117135528~117138582:+
THCA	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-7.44	4.92e-13	1.63e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-7.44	4.92e-13	1.63e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-7.44	4.92e-13	1.63e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-7.44	4.92e-13	1.63e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-7.44	4.92e-13	1.63e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-7.44	4.92e-13	1.63e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
THCA	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-7.44	4.93e-13	1.63e-10	-0.38	-0.32	Height;	chr2:231559006	chr2:231508426~231514339:-
THCA	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	7.44	4.93e-13	1.64e-10	0.45	0.32	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
THCA	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	7.44	4.93e-13	1.64e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	7.44	4.93e-13	1.64e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
THCA	cis	rs957448	0.539	rs9643346	ENSG00000253704.1	RP11-267M23.4	7.44	4.93e-13	1.64e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94553722~94569745:+
THCA	cis	rs9500256	0.602	rs62414342	ENSG00000215190.7	LINC00680	-7.44	4.94e-13	1.64e-10	-0.42	-0.32	Eosinophilic esophagitis (pediatric);	chr6:57917905	chr6:57946074~57961501:-
THCA	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	7.44	4.94e-13	1.64e-10	0.35	0.32	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-7.44	4.94e-13	1.64e-10	-0.35	-0.32	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-7.44	4.94e-13	1.64e-10	-0.35	-0.32	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-7.44	4.94e-13	1.64e-10	-0.35	-0.32	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
THCA	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-7.44	4.96e-13	1.65e-10	-0.29	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
THCA	cis	rs10971721	0.822	rs307673	ENSG00000260947.1	RP11-384P7.7	7.44	4.98e-13	1.65e-10	0.78	0.32	Body mass index;	chr9:33968821	chr9:33697459~33700986:+
THCA	cis	rs2253762	0.507	rs11200310	ENSG00000276742.1	RP11-500G22.4	7.44	4.98e-13	1.65e-10	0.48	0.32	Breast cancer;	chr10:121989944	chr10:121956782~121957098:+
THCA	cis	rs922182	0.663	rs55929105	ENSG00000275785.1	RP11-111E14.2	7.43	5e-13	1.66e-10	0.38	0.32	Blood protein levels;	chr15:63973605	chr15:63890030~63890317:+
THCA	cis	rs10971721	0.584	rs72731224	ENSG00000260947.1	RP11-384P7.7	7.43	5e-13	1.66e-10	0.73	0.32	Body mass index;	chr9:34122888	chr9:33697459~33700986:+
THCA	cis	rs6600671	1	rs4844607	ENSG00000223345.3	HIST2H2BA	-7.43	5e-13	1.66e-10	-0.35	-0.32	Hip geometry;	chr1:121442201	chr1:121108210~121117257:-
THCA	cis	rs875971	1	rs6961717	ENSG00000232559.3	GS1-124K5.12	-7.43	5.01e-13	1.66e-10	-0.31	-0.32	Aortic root size;	chr7:66122550	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs2087647	ENSG00000232559.3	GS1-124K5.12	-7.43	5.01e-13	1.66e-10	-0.31	-0.32	Aortic root size;	chr7:66128201	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6958484	ENSG00000232559.3	GS1-124K5.12	-7.43	5.01e-13	1.66e-10	-0.31	-0.32	Aortic root size;	chr7:66134459	chr7:66554588~66576923:-
THCA	cis	rs1949733	1	rs868105	ENSG00000205959.3	RP11-689P11.2	7.43	5.01e-13	1.66e-10	0.28	0.32	Response to antineoplastic agents;	chr4:8499303	chr4:8482270~8512610:+
THCA	cis	rs2522056	1	rs2706339	ENSG00000233006.5	AC034220.3	-7.43	5.01e-13	1.66e-10	-0.28	-0.32	Fibrinogen;Lymphocyte counts;	chr5:132464413	chr5:132311285~132369916:-
THCA	cis	rs2562456	0.793	rs2562474	ENSG00000268555.1	RP11-678G14.3	-7.43	5.01e-13	1.66e-10	-0.46	-0.32	Pain;	chr19:21463480	chr19:21570822~21587322:-
THCA	cis	rs7208859	0.573	rs11654035	ENSG00000264538.5	SUZ12P1	-7.43	5.04e-13	1.67e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30709299~30790908:+
THCA	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-7.43	5.05e-13	1.67e-10	-0.34	-0.32	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
THCA	cis	rs2976388	0.632	rs2585139	ENSG00000253741.1	CTD-2292P10.4	-7.43	5.06e-13	1.68e-10	-0.41	-0.32	Urinary tract infection frequency;	chr8:142726757	chr8:142702252~142726973:-
THCA	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	7.43	5.06e-13	1.68e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
THCA	cis	rs7942368	1	rs12282785	ENSG00000254761.1	RP11-672A2.1	7.43	5.07e-13	1.68e-10	0.46	0.32	Endometriosis;	chr11:76764986	chr11:76712396~76719608:-
THCA	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-7.43	5.07e-13	1.68e-10	-0.5	-0.32	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
THCA	cis	rs875971	1	rs11971949	ENSG00000232559.3	GS1-124K5.12	-7.43	5.07e-13	1.68e-10	-0.31	-0.32	Aortic root size;	chr7:66161027	chr7:66554588~66576923:-
THCA	cis	rs9473147	0.516	rs7749271	ENSG00000270761.1	RP11-385F7.1	-7.43	5.08e-13	1.68e-10	-0.26	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47517266	chr6:47477243~47477572:-
THCA	cis	rs7208859	0.673	rs2433	ENSG00000264538.5	SUZ12P1	-7.43	5.1e-13	1.69e-10	-0.35	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30709299~30790908:+
THCA	cis	rs7851660	0.844	rs10984103	ENSG00000236130.1	PTCSC2	7.43	5.1e-13	1.69e-10	0.25	0.32	Strep throat;	chr9:97876993	chr9:97805935~97810008:-
THCA	cis	rs732716	0.853	rs12459922	ENSG00000267980.1	AC007292.6	-7.43	5.11e-13	1.69e-10	-0.36	-0.32	Mean corpuscular volume;	chr19:4455865	chr19:4363789~4364640:+
THCA	cis	rs9649213	0.574	rs34817002	ENSG00000272950.1	RP11-307C18.1	7.43	5.11e-13	1.69e-10	0.4	0.32	Prostate cancer (SNP x SNP interaction);	chr7:98257739	chr7:98322853~98323430:+
THCA	cis	rs3847687	1	rs3847687	ENSG00000279993.1	RP11-76C10.3	7.43	5.12e-13	1.7e-10	0.35	0.32	Longevity;	chr12:131040508	chr12:131025561~131028060:-
THCA	cis	rs8113308	0.81	rs8105110	ENSG00000269235.1	ZNF350-AS1	7.43	5.12e-13	1.7e-10	0.49	0.32	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948863	chr19:51949134~51981367:+
THCA	cis	rs35934224	0.891	rs33997573	ENSG00000232926.1	AC000078.5	7.43	5.14e-13	1.7e-10	0.4	0.32	Glaucoma (primary open-angle);	chr22:19881428	chr22:19887289~19887970:+
THCA	cis	rs4072705	1	rs10760370	ENSG00000224020.1	MIR181A2HG	-7.43	5.15e-13	1.7e-10	-0.28	-0.32	Menarche (age at onset);	chr9:124655724	chr9:124658467~124698631:+
THCA	cis	rs1150668	0.796	rs1005125	ENSG00000219392.1	RP1-265C24.5	-7.43	5.15e-13	1.71e-10	-0.35	-0.32	Pubertal anthropometrics;	chr6:28399578	chr6:28115628~28116551:+
THCA	cis	rs45509595	0.556	rs34409918	ENSG00000280107.1	AL022393.9	-7.43	5.15e-13	1.71e-10	-0.65	-0.32	Breast cancer;	chr6:27717569	chr6:28170845~28172521:+
THCA	cis	rs6723108	0.603	rs12469411	ENSG00000224043.6	CCNT2-AS1	-7.43	5.15e-13	1.71e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134906986	chr2:134735464~134918710:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000206090.4	AP000350.7	-7.43	5.15e-13	1.71e-10	-0.4	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23939998~23942798:+
THCA	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	7.43	5.16e-13	1.71e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
THCA	cis	rs71636778	0.509	rs41307935	ENSG00000260063.1	RP5-968P14.2	-7.43	5.17e-13	1.71e-10	-0.61	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26854576	chr1:26692132~26694131:-
THCA	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-7.43	5.17e-13	1.71e-10	-0.34	-0.32	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000263603.1	CTD-2349P21.5	-7.43	5.17e-13	1.71e-10	-0.55	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30729469~30731202:+
THCA	cis	rs17684571	0.872	rs11961342	ENSG00000231441.1	RP11-472M19.2	7.43	5.17e-13	1.71e-10	0.41	0.32	Schizophrenia;	chr6:56714550	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34703847	ENSG00000231441.1	RP11-472M19.2	7.43	5.17e-13	1.71e-10	0.41	0.32	Schizophrenia;	chr6:56722130	chr6:56844002~56864078:+
THCA	cis	rs2712184	0.967	rs11892032	ENSG00000229352.1	AC007563.3	-7.43	5.18e-13	1.72e-10	-0.38	-0.32	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216804258	chr2:216799608~216805335:+
THCA	cis	rs7688540	0.771	rs10005733	ENSG00000211553.1	AC253576.2	-7.43	5.18e-13	1.72e-10	-0.46	-0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:136461~136568:+
THCA	cis	rs2348418	0.831	rs7296538	ENSG00000247934.4	RP11-967K21.1	-7.43	5.2e-13	1.72e-10	-0.28	-0.32	Lung function (FEV1);Lung function (FVC);	chr12:28558850	chr12:28163298~28190738:-
THCA	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	7.43	5.21e-13	1.72e-10	0.41	0.32	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
THCA	cis	rs2439831	0.867	rs2447196	ENSG00000275601.1	AC011330.13	7.43	5.21e-13	1.73e-10	0.5	0.32	Lung cancer in ever smokers;	chr15:43601620	chr15:43642389~43643023:-
THCA	cis	rs10208649	1	rs7599335	ENSG00000272156.1	RP11-477N3.1	7.43	5.22e-13	1.73e-10	0.59	0.32	Body mass index;	chr2:53914500	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs7560575	ENSG00000272156.1	RP11-477N3.1	7.43	5.22e-13	1.73e-10	0.59	0.32	Body mass index;	chr2:53914893	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs13389673	ENSG00000272156.1	RP11-477N3.1	7.43	5.22e-13	1.73e-10	0.59	0.32	Body mass index;	chr2:53916185	chr2:54082554~54085066:+
THCA	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-7.43	5.23e-13	1.73e-10	-0.26	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
THCA	cis	rs875971	1	rs6946143	ENSG00000232559.3	GS1-124K5.12	7.43	5.25e-13	1.74e-10	0.32	0.32	Aortic root size;	chr7:66114735	chr7:66554588~66576923:-
THCA	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	7.43	5.25e-13	1.74e-10	0.37	0.32	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
THCA	cis	rs8113308	1	rs8105440	ENSG00000269235.1	ZNF350-AS1	7.43	5.26e-13	1.74e-10	0.44	0.32	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948647	chr19:51949134~51981367:+
THCA	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-7.43	5.26e-13	1.74e-10	-0.4	-0.32	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
THCA	cis	rs2911132	1	rs2911140	ENSG00000248734.2	CTD-2260A17.1	7.43	5.26e-13	1.74e-10	0.35	0.32	Urate levels (BMI interaction);	chr5:96844240	chr5:96784777~96785999:+
THCA	cis	rs875971	1	rs4718307	ENSG00000232559.3	GS1-124K5.12	-7.43	5.27e-13	1.74e-10	-0.31	-0.32	Aortic root size;	chr7:66146001	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs7801282	ENSG00000232559.3	GS1-124K5.12	-7.43	5.27e-13	1.74e-10	-0.31	-0.32	Aortic root size;	chr7:66148700	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs55962648	ENSG00000232559.3	GS1-124K5.12	-7.43	5.27e-13	1.74e-10	-0.31	-0.32	Aortic root size;	chr7:66160764	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs2420168	ENSG00000232559.3	GS1-124K5.12	-7.43	5.27e-13	1.74e-10	-0.31	-0.32	Aortic root size;	chr7:66165644	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs11974219	ENSG00000232559.3	GS1-124K5.12	-7.43	5.27e-13	1.74e-10	-0.31	-0.32	Aortic root size;	chr7:66182423	chr7:66554588~66576923:-
THCA	cis	rs4273100	1	rs868698	ENSG00000265185.4	SNORD3B-1	7.43	5.27e-13	1.74e-10	0.48	0.32	Schizophrenia;	chr17:19281898	chr17:19061912~19062669:+
THCA	cis	rs7646881	0.812	rs73017541	ENSG00000240207.5	RP11-379F4.4	-7.43	5.28e-13	1.75e-10	-0.46	-0.32	Tetralogy of Fallot;	chr3:158743007	chr3:158732263~158784070:+
THCA	cis	rs5769707	0.681	rs9616329	ENSG00000235111.1	RP1-29C18.8	-7.43	5.28e-13	1.75e-10	-0.4	-0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49612657~49615716:-
THCA	cis	rs9902453	0.845	rs2628165	ENSG00000264007.1	RP11-68I3.10	7.43	5.28e-13	1.75e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29794148	chr17:29621617~29622254:-
THCA	cis	rs17695224	0.545	rs7253924	ENSG00000269483.1	AC006272.1	7.43	5.3e-13	1.75e-10	0.34	0.32	HDL cholesterol;HDL cholesterol levels;	chr19:51824960	chr19:51839924~51843324:-
THCA	cis	rs8114671	0.551	rs4911162	ENSG00000269202.1	RP4-614O4.12	-7.43	5.3e-13	1.75e-10	-0.28	-0.32	Height;	chr20:34823622	chr20:35201747~35203288:-
THCA	cis	rs853679	0.517	rs6932109	ENSG00000220721.1	OR1F12	-7.43	5.3e-13	1.75e-10	-0.44	-0.32	Depression;	chr6:28110525	chr6:28073316~28074233:+
THCA	cis	rs4072705	0.967	rs10217141	ENSG00000224020.1	MIR181A2HG	-7.43	5.31e-13	1.75e-10	-0.29	-0.32	Menarche (age at onset);	chr9:124641656	chr9:124658467~124698631:+
THCA	cis	rs1949733	0.675	rs2688219	ENSG00000205959.3	RP11-689P11.2	-7.43	5.31e-13	1.75e-10	-0.27	-0.32	Response to antineoplastic agents;	chr4:8442904	chr4:8482270~8512610:+
THCA	cis	rs17684571	0.872	rs4640889	ENSG00000231441.1	RP11-472M19.2	-7.43	5.31e-13	1.76e-10	-0.41	-0.32	Schizophrenia;	chr6:56740534	chr6:56844002~56864078:+
THCA	cis	rs7302981	0.746	rs646782	ENSG00000272368.2	RP4-605O3.4	7.43	5.31e-13	1.76e-10	0.2	0.32	Systolic blood pressure;	chr12:50088428	chr12:50112197~50165618:+
THCA	cis	rs4934494	0.768	rs2094214	ENSG00000232936.4	RP11-80H5.2	7.43	5.32e-13	1.76e-10	0.44	0.32	Red blood cell count;	chr10:89649624	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.635	rs12572869	ENSG00000232936.4	RP11-80H5.2	7.43	5.32e-13	1.76e-10	0.44	0.32	Red blood cell count;	chr10:89653611	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs67111731	ENSG00000232936.4	RP11-80H5.2	7.43	5.32e-13	1.76e-10	0.44	0.32	Red blood cell count;	chr10:89659528	chr10:89645282~89650667:+
THCA	cis	rs9388451	0.839	rs4897157	ENSG00000237742.5	RP11-624M8.1	-7.43	5.34e-13	1.76e-10	-0.28	-0.32	Brugada syndrome;	chr6:125781835	chr6:125578558~125749190:-
THCA	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-7.43	5.34e-13	1.77e-10	-0.32	-0.32	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
THCA	cis	rs853679	1	rs2799079	ENSG00000280107.1	AL022393.9	-7.42	5.34e-13	1.77e-10	-0.46	-0.32	Depression;	chr6:28267398	chr6:28170845~28172521:+
THCA	cis	rs17772222	0.74	rs11845147	ENSG00000258789.1	RP11-507K2.3	-7.42	5.35e-13	1.77e-10	-0.31	-0.32	Coronary artery calcification;	chr14:88502804	chr14:88551597~88552493:+
THCA	cis	rs7773456	1	rs7773456	ENSG00000228412.5	RP4-625H18.2	7.42	5.35e-13	1.77e-10	0.39	0.32	Lupus nephritis in systemic lupus erythematosus;	chr6:19823007	chr6:19802164~19804752:-
THCA	cis	rs193541	0.632	rs400207	ENSG00000263432.2	RN7SL689P	-7.42	5.36e-13	1.77e-10	-0.39	-0.32	Glucose homeostasis traits;	chr5:122982802	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs415417	ENSG00000263432.2	RN7SL689P	-7.42	5.36e-13	1.77e-10	-0.39	-0.32	Glucose homeostasis traits;	chr5:122987189	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs62377425	ENSG00000263432.2	RN7SL689P	-7.42	5.36e-13	1.77e-10	-0.39	-0.32	Glucose homeostasis traits;	chr5:122996930	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs34714850	ENSG00000263432.2	RN7SL689P	-7.42	5.36e-13	1.77e-10	-0.39	-0.32	Glucose homeostasis traits;	chr5:122997000	chr5:123022487~123022783:-
THCA	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-7.42	5.37e-13	1.78e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
THCA	cis	rs12908161	0.959	rs17534709	ENSG00000225151.9	GOLGA2P7	-7.42	5.39e-13	1.78e-10	-0.48	-0.32	Schizophrenia;	chr15:84771166	chr15:84199311~84230136:-
THCA	cis	rs240993	0.812	rs6937734	ENSG00000230177.1	RP5-1112D6.4	7.42	5.39e-13	1.78e-10	0.33	0.32	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111277932~111278742:+
THCA	cis	rs193541	0.632	rs430069	ENSG00000263432.2	RN7SL689P	7.42	5.4e-13	1.79e-10	0.39	0.32	Glucose homeostasis traits;	chr5:122927656	chr5:123022487~123022783:-
THCA	cis	rs12188164	0.62	rs56070387	ENSG00000221990.4	EXOC3-AS1	7.42	5.4e-13	1.79e-10	0.3	0.32	Cystic fibrosis severity;	chr5:482416	chr5:441498~443160:-
THCA	cis	rs4789693	0.518	rs6502108	ENSG00000265458.1	RP13-20L14.6	-7.42	5.41e-13	1.79e-10	-0.32	-0.32	Glucocorticoid-induced osteonecrosis;	chr17:82417023	chr17:82454273~82458521:-
THCA	cis	rs7727544	0.545	rs10074490	ENSG00000237714.1	P4HA2-AS1	7.42	5.42e-13	1.79e-10	0.44	0.32	Blood metabolite levels;	chr5:132004339	chr5:132184876~132192808:+
THCA	cis	rs9649213	0.593	rs7812180	ENSG00000272950.1	RP11-307C18.1	-7.42	5.43e-13	1.79e-10	-0.42	-0.32	Prostate cancer (SNP x SNP interaction);	chr7:98339828	chr7:98322853~98323430:+
THCA	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	7.42	5.43e-13	1.79e-10	0.4	0.32	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
THCA	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	7.42	5.43e-13	1.79e-10	0.46	0.32	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
THCA	cis	rs910316	0.763	rs175435	ENSG00000279594.1	RP11-950C14.10	7.42	5.43e-13	1.8e-10	0.3	0.32	Height;	chr14:75145322	chr14:75011269~75012851:-
THCA	cis	rs947583	0.588	rs12211505	ENSG00000231028.7	LINC00271	-7.42	5.44e-13	1.8e-10	-0.26	-0.32	Phosphorus levels;	chr6:135753683	chr6:135497801~135716055:+
THCA	cis	rs180730	0.861	rs4833694	ENSG00000251609.2	SETP12	7.42	5.44e-13	1.8e-10	0.51	0.32	Fasting plasma glucose;	chr4:120928563	chr4:120895494~120897083:-
THCA	cis	rs2688608	0.592	rs12253482	ENSG00000271816.1	BMS1P4	7.42	5.44e-13	1.8e-10	0.33	0.32	Inflammatory bowel disease;	chr10:73736372	chr10:73699151~73730487:-
THCA	cis	rs7302981	0.9	rs836179	ENSG00000272368.2	RP4-605O3.4	7.42	5.46e-13	1.8e-10	0.19	0.32	Systolic blood pressure;	chr12:50109299	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.9	rs836180	ENSG00000272368.2	RP4-605O3.4	7.42	5.46e-13	1.8e-10	0.19	0.32	Systolic blood pressure;	chr12:50109486	chr12:50112197~50165618:+
THCA	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	7.42	5.46e-13	1.8e-10	0.61	0.32	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	7.42	5.46e-13	1.8e-10	0.61	0.32	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
THCA	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-7.42	5.46e-13	1.8e-10	-0.35	-0.32	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-7.42	5.46e-13	1.8e-10	-0.35	-0.32	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-7.42	5.46e-13	1.8e-10	-0.35	-0.32	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-7.42	5.46e-13	1.8e-10	-0.35	-0.32	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000273009.1	RP11-352G9.1	-7.42	5.46e-13	1.8e-10	-0.35	-0.32	Pancreatic cancer;	chr3:196021659	chr3:195913078~195913683:-
THCA	cis	rs1850744	1	rs1850744	ENSG00000250942.1	ENPP7P11	7.42	5.47e-13	1.81e-10	0.45	0.32	Economic and political preferences;	chr4:9789088	chr4:9677308~9677934:+
THCA	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-7.42	5.47e-13	1.81e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
THCA	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-7.42	5.47e-13	1.81e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
THCA	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-7.42	5.47e-13	1.81e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
THCA	cis	rs10208649	0.764	rs7583005	ENSG00000272156.1	RP11-477N3.1	7.42	5.48e-13	1.81e-10	0.66	0.32	Body mass index;	chr2:54019051	chr2:54082554~54085066:+
THCA	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	7.42	5.48e-13	1.81e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
THCA	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-7.42	5.48e-13	1.81e-10	-0.37	-0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
THCA	cis	rs11168351	0.927	rs10875716	ENSG00000258273.1	RP11-370I10.4	-7.42	5.49e-13	1.81e-10	-0.43	-0.32	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48333755~48333901:-
THCA	cis	rs6745190	0.906	rs11692072	ENSG00000236153.1	AC104076.3	7.42	5.49e-13	1.81e-10	0.38	0.32	White blood cell count;	chr2:181037735	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.953	rs10930950	ENSG00000236153.1	AC104076.3	7.42	5.49e-13	1.81e-10	0.38	0.32	White blood cell count;	chr2:181039677	chr2:180979427~180980090:-
THCA	cis	rs6600671	1	rs4844381	ENSG00000223345.3	HIST2H2BA	7.42	5.5e-13	1.82e-10	0.35	0.32	Hip geometry;	chr1:121443040	chr1:121108210~121117257:-
THCA	cis	rs2562456	0.833	rs516519	ENSG00000268555.1	RP11-678G14.3	-7.42	5.51e-13	1.82e-10	-0.46	-0.32	Pain;	chr19:21298730	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs552800	ENSG00000268555.1	RP11-678G14.3	-7.42	5.51e-13	1.82e-10	-0.46	-0.32	Pain;	chr19:21301840	chr19:21570822~21587322:-
THCA	cis	rs7208859	0.673	rs73277964	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11652409	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9896095	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs58920731	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73277984	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73277986	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs12103588	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.614	rs9914534	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs4131618	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11658344	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9900144	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs11656121	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11650973	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs56085216	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11650305	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11654914	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9914271	ENSG00000264538.5	SUZ12P1	-7.42	5.51e-13	1.82e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30709299~30790908:+
THCA	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-7.42	5.51e-13	1.82e-10	-0.35	-0.32	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
THCA	cis	rs6745190	0.906	rs12621277	ENSG00000236153.1	AC104076.3	7.42	5.52e-13	1.82e-10	0.38	0.32	White blood cell count;	chr2:180966460	chr2:180979427~180980090:-
THCA	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	7.42	5.52e-13	1.82e-10	0.37	0.32	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
THCA	cis	rs77204473	0.744	rs116861530	ENSG00000254851.1	RP11-109L13.1	7.42	5.52e-13	1.82e-10	0.81	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117091945	chr11:117135528~117138582:+
THCA	cis	rs875971	0.965	rs10267430	ENSG00000232559.3	GS1-124K5.12	-7.42	5.52e-13	1.82e-10	-0.31	-0.32	Aortic root size;	chr7:66278036	chr7:66554588~66576923:-
THCA	cis	rs957448	0.561	rs58663902	ENSG00000253704.1	RP11-267M23.4	7.42	5.54e-13	1.83e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94553722~94569745:+
THCA	cis	rs6745190	0.862	rs10187842	ENSG00000236153.1	AC104076.3	7.42	5.56e-13	1.83e-10	0.38	0.32	White blood cell count;	chr2:181034788	chr2:180979427~180980090:-
THCA	cis	rs1830074	1	rs1830074	ENSG00000187953.9	PMS2CL	-7.42	5.56e-13	1.83e-10	-0.34	-0.32	Body mass index;	chr7:6679043	chr7:6710128~6753862:+
THCA	cis	rs9902453	0.967	rs3813034	ENSG00000264007.1	RP11-68I3.10	7.42	5.56e-13	1.83e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:30197786	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs1042173	ENSG00000264007.1	RP11-68I3.10	7.42	5.56e-13	1.83e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:30197993	chr17:29621617~29622254:-
THCA	cis	rs728616	0.867	rs61859763	ENSG00000225484.5	NUTM2B-AS1	-7.42	5.59e-13	1.84e-10	-0.67	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:79663088~79826594:-
THCA	cis	rs2839186	0.708	rs6518285	ENSG00000239415.1	AP001469.9	7.42	5.59e-13	1.84e-10	0.33	0.32	Testicular germ cell tumor;	chr21:46224753	chr21:46251549~46254133:-
THCA	cis	rs9549328	0.718	rs7139939	ENSG00000267868.1	RP11-120K24.3	7.42	5.6e-13	1.85e-10	0.34	0.32	Systolic blood pressure;	chr13:112980095	chr13:112964835~112966131:-
THCA	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-7.42	5.61e-13	1.85e-10	-0.46	-0.32	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
THCA	cis	rs1198430	0.714	rs1198437	ENSG00000232482.2	RP4-654C18.1	-7.42	5.61e-13	1.85e-10	-0.49	-0.32	Total cholesterol levels;	chr1:23420931	chr1:23410832~23412146:+
THCA	cis	rs947583	0.588	rs2208574	ENSG00000231028.7	LINC00271	-7.42	5.62e-13	1.85e-10	-0.26	-0.32	Phosphorus levels;	chr6:135754479	chr6:135497801~135716055:+
THCA	cis	rs9473147	0.516	rs2151974	ENSG00000270761.1	RP11-385F7.1	-7.42	5.62e-13	1.85e-10	-0.26	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47547894	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs9367284	ENSG00000270761.1	RP11-385F7.1	-7.42	5.62e-13	1.85e-10	-0.26	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47548633	chr6:47477243~47477572:-
THCA	cis	rs9902453	0.845	rs62068583	ENSG00000264007.1	RP11-68I3.10	7.42	5.63e-13	1.86e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29674464	chr17:29621617~29622254:-
THCA	cis	rs2562456	0.833	rs2928211	ENSG00000268555.1	RP11-678G14.3	-7.42	5.64e-13	1.86e-10	-0.46	-0.32	Pain;	chr19:21358495	chr19:21570822~21587322:-
THCA	cis	rs75422866	0.51	rs73105803	ENSG00000274902.1	RP1-197B17.4	7.42	5.64e-13	1.86e-10	0.67	0.32	Pneumonia;	chr12:47722135	chr12:47731908~47732351:+
THCA	cis	rs4073416	0.738	rs11851576	ENSG00000276116.2	FUT8-AS1	7.42	5.64e-13	1.86e-10	0.33	0.32	N-glycan levels;	chr14:65433565	chr14:65411170~65412690:-
THCA	cis	rs1962073	0.528	rs9329223	ENSG00000261451.1	RP11-981G7.1	-7.42	5.67e-13	1.87e-10	-0.4	-0.32	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10474244	chr8:10433672~10438312:+
THCA	cis	rs4950322	0.57	rs72691054	ENSG00000237188.3	RP11-337C18.8	7.42	5.67e-13	1.87e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147277942	chr1:147172771~147211568:+
THCA	cis	rs9532669	0.819	rs9532652	ENSG00000176268.5	CYCSP34	7.42	5.67e-13	1.87e-10	0.4	0.32	Cervical cancer;	chr13:40903300	chr13:40863599~40863902:-
THCA	cis	rs4073416	0.718	rs2268962	ENSG00000276116.2	FUT8-AS1	-7.42	5.69e-13	1.87e-10	-0.33	-0.32	N-glycan levels;	chr14:65680555	chr14:65411170~65412690:-
THCA	cis	rs9341808	0.727	rs4706834	ENSG00000272129.1	RP11-250B2.6	7.42	5.69e-13	1.88e-10	0.41	0.32	Sitting height ratio;	chr6:80302888	chr6:80355424~80356859:+
THCA	cis	rs1949733	1	rs2688223	ENSG00000205959.3	RP11-689P11.2	-7.42	5.7e-13	1.88e-10	-0.27	-0.32	Response to antineoplastic agents;	chr4:8469671	chr4:8482270~8512610:+
THCA	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	7.42	5.71e-13	1.88e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
THCA	cis	rs3847687	0.546	rs6486621	ENSG00000256810.1	RP11-76C10.2	7.42	5.72e-13	1.88e-10	0.39	0.32	Longevity;	chr12:131035663	chr12:131030570~131035487:-
THCA	cis	rs853679	0.542	rs6934769	ENSG00000220721.1	OR1F12	7.41	5.72e-13	1.89e-10	0.45	0.32	Depression;	chr6:28123153	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs17711801	ENSG00000220721.1	OR1F12	7.41	5.72e-13	1.89e-10	0.45	0.32	Depression;	chr6:28124529	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000220721.1	OR1F12	7.41	5.72e-13	1.89e-10	0.45	0.32	Parkinson's disease;	chr6:28127394	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9468292	ENSG00000220721.1	OR1F12	7.41	5.72e-13	1.89e-10	0.45	0.32	Depression;	chr6:28127577	chr6:28073316~28074233:+
THCA	cis	rs6745190	0.953	rs6433879	ENSG00000236153.1	AC104076.3	7.41	5.72e-13	1.89e-10	0.38	0.32	White blood cell count;	chr2:180990735	chr2:180979427~180980090:-
THCA	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	7.41	5.73e-13	1.89e-10	0.19	0.32	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
THCA	cis	rs6539288	0.739	rs1053050	ENSG00000260329.1	RP11-412D9.4	-7.41	5.74e-13	1.89e-10	-0.29	-0.32	Total body bone mineral density;	chr12:106973446	chr12:106954029~106955497:-
THCA	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	7.41	5.75e-13	1.89e-10	0.39	0.32	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	7.41	5.75e-13	1.89e-10	0.39	0.32	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
THCA	cis	rs1150668	0.799	rs1150707	ENSG00000219392.1	RP1-265C24.5	-7.41	5.75e-13	1.9e-10	-0.35	-0.32	Pubertal anthropometrics;	chr6:28229827	chr6:28115628~28116551:+
THCA	cis	rs2288884	0.505	rs57637334	ENSG00000275055.1	CTC-471J1.11	-7.41	5.76e-13	1.9e-10	-0.36	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51977572	chr19:52049007~52049754:+
THCA	cis	rs62355901	0.556	rs2897972	ENSG00000271828.1	CTD-2310F14.1	7.41	5.77e-13	1.9e-10	0.65	0.32	Breast cancer;	chr5:56750525	chr5:56927874~56929573:+
THCA	cis	rs9309473	0.607	rs1522927	ENSG00000163016.8	ALMS1P	7.41	5.78e-13	1.9e-10	0.43	0.32	Metabolite levels;	chr2:73329027	chr2:73644919~73685576:+
THCA	cis	rs990871	0.962	rs1460942	ENSG00000227207.2	RPL31P12	-7.41	5.78e-13	1.9e-10	-0.4	-0.32	Subcutaneous adipose tissue;	chr1:72347573	chr1:72301472~72301829:+
THCA	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-7.41	5.78e-13	1.9e-10	-0.5	-0.32	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
THCA	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-7.41	5.78e-13	1.9e-10	-0.37	-0.32	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
THCA	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	7.41	5.79e-13	1.91e-10	0.19	0.32	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
THCA	cis	rs9816784	0.901	rs12490036	ENSG00000242086.7	LINC00969	-7.41	5.79e-13	1.91e-10	-0.3	-0.32	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195658062~195739964:+
THCA	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	7.41	5.8e-13	1.91e-10	0.4	0.32	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	7.41	5.8e-13	1.91e-10	0.4	0.32	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	7.41	5.8e-13	1.91e-10	0.39	0.32	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
THCA	cis	rs224090	0.54	rs11592442	ENSG00000238280.1	RP11-436D10.3	-7.41	5.8e-13	1.91e-10	-0.41	-0.32	Crohn's disease;	chr10:62774144	chr10:62793562~62805887:-
THCA	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	7.41	5.81e-13	1.91e-10	0.37	0.32	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
THCA	cis	rs2288884	0.541	rs72483948	ENSG00000275055.1	CTC-471J1.11	-7.41	5.81e-13	1.91e-10	-0.33	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51971668	chr19:52049007~52049754:+
THCA	cis	rs172166	0.694	rs1150666	ENSG00000280107.1	AL022393.9	-7.41	5.84e-13	1.92e-10	-0.36	-0.32	Cardiac Troponin-T levels;	chr6:28156150	chr6:28170845~28172521:+
THCA	cis	rs9388451	0.874	rs9398787	ENSG00000237742.5	RP11-624M8.1	-7.41	5.84e-13	1.92e-10	-0.27	-0.32	Brugada syndrome;	chr6:125769462	chr6:125578558~125749190:-
THCA	cis	rs1949733	0.701	rs2688222	ENSG00000205959.3	RP11-689P11.2	-7.41	5.84e-13	1.92e-10	-0.27	-0.32	Response to antineoplastic agents;	chr4:8472008	chr4:8482270~8512610:+
THCA	cis	rs17772222	0.651	rs865285	ENSG00000258789.1	RP11-507K2.3	7.41	5.86e-13	1.93e-10	0.3	0.32	Coronary artery calcification;	chr14:88391138	chr14:88551597~88552493:+
THCA	cis	rs7746199	0.736	rs34965299	ENSG00000280107.1	AL022393.9	-7.41	5.86e-13	1.93e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28170845~28172521:+
THCA	cis	rs35491132	1	rs35491132	ENSG00000280107.1	AL022393.9	-7.41	5.86e-13	1.93e-10	-0.64	-0.32	Urinary tract infection frequency;	chr6:27559449	chr6:28170845~28172521:+
THCA	cis	rs4660456	0.572	rs10789191	ENSG00000237899.1	RP4-739H11.3	7.41	5.87e-13	1.93e-10	0.4	0.32	Platelet count;	chr1:40690819	chr1:40669089~40687588:-
THCA	cis	rs4820539	1	rs916585	ENSG00000221069.1	AC000029.1	-7.41	5.89e-13	1.94e-10	-0.38	-0.32	Bone mineral density;	chr22:23127251	chr22:23136620~23136710:+
THCA	cis	rs6565180	0.632	rs8050812	ENSG00000183604.13	SMG1P5	-7.41	5.89e-13	1.94e-10	-0.36	-0.32	Tonsillectomy;	chr16:30374516	chr16:30267553~30335374:-
THCA	cis	rs7208859	0.673	rs11653955	ENSG00000263603.1	CTD-2349P21.5	-7.41	5.89e-13	1.94e-10	-0.58	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30729469~30731202:+
THCA	cis	rs7760535	0.763	rs10457240	ENSG00000230177.1	RP5-1112D6.4	-7.41	5.89e-13	1.94e-10	-0.26	-0.32	Metabolic traits;	chr6:111527671	chr6:111277932~111278742:+
THCA	cis	rs875971	1	rs875971	ENSG00000232559.3	GS1-124K5.12	-7.41	5.94e-13	1.95e-10	-0.31	-0.32	Aortic root size;	chr7:66152608	chr7:66554588~66576923:-
THCA	cis	rs17695224	0.545	rs8109098	ENSG00000269483.1	AC006272.1	7.41	5.95e-13	1.96e-10	0.34	0.32	HDL cholesterol;HDL cholesterol levels;	chr19:51825363	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs10853846	ENSG00000269483.1	AC006272.1	7.41	5.95e-13	1.96e-10	0.34	0.32	HDL cholesterol;HDL cholesterol levels;	chr19:51826595	chr19:51839924~51843324:-
THCA	cis	rs4948275	0.55	rs10994742	ENSG00000237233.2	TMEM26-AS1	7.41	5.97e-13	1.96e-10	0.44	0.32	Night sleep phenotypes;	chr10:61372482	chr10:61452639~61481956:+
THCA	cis	rs516805	0.748	rs197680	ENSG00000279453.1	RP3-425C14.4	-7.41	5.97e-13	1.96e-10	-0.37	-0.32	Lymphocyte counts;	chr6:122548987	chr6:122436789~122439223:-
THCA	cis	rs2911132	1	rs2911130	ENSG00000248734.2	CTD-2260A17.1	7.41	5.98e-13	1.96e-10	0.34	0.32	Urate levels (BMI interaction);	chr5:96847724	chr5:96784777~96785999:+
THCA	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-7.41	5.98e-13	1.97e-10	-0.37	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
THCA	cis	rs1198430	0.759	rs1198427	ENSG00000232482.2	RP4-654C18.1	-7.41	5.99e-13	1.97e-10	-0.49	-0.32	Total cholesterol levels;	chr1:23426405	chr1:23410832~23412146:+
THCA	cis	rs6762	0.719	rs1130698	ENSG00000279672.1	CMB9-55F22.1	7.41	6e-13	1.97e-10	0.36	0.32	Mean platelet volume;	chr11:838542	chr11:779617~780755:+
THCA	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	7.41	6e-13	1.97e-10	0.34	0.32	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
THCA	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-7.41	6.01e-13	1.97e-10	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
THCA	cis	rs875971	1	rs2077593	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66427543	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs4717292	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66430611	chr7:66554588~66576923:-
THCA	cis	rs875971	0.895	rs10755833	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66448930	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs12668936	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66449417	chr7:66554588~66576923:-
THCA	cis	rs875971	0.895	rs1833495	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66456608	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs6945032	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66457499	chr7:66554588~66576923:-
THCA	cis	rs875971	0.929	rs12673810	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66458866	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6961155	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66468308	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs7789768	ENSG00000232559.3	GS1-124K5.12	7.41	6.01e-13	1.98e-10	0.3	0.32	Aortic root size;	chr7:66473993	chr7:66554588~66576923:-
THCA	cis	rs748404	0.697	rs546722	ENSG00000205771.5	CATSPER2P1	-7.41	6.01e-13	1.98e-10	-0.34	-0.32	Lung cancer;	chr15:43288621	chr15:43726918~43747094:-
THCA	cis	rs9902453	0.765	rs3102562	ENSG00000264007.1	RP11-68I3.10	7.41	6.02e-13	1.98e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29713385	chr17:29621617~29622254:-
THCA	cis	rs12025262	0.934	rs10924961	ENSG00000227671.4	RP11-488L18.4	7.41	6.02e-13	1.98e-10	0.19	0.32	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247198985	chr1:247189851~247210856:-
THCA	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	7.41	6.02e-13	1.98e-10	0.39	0.32	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
THCA	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-7.41	6.03e-13	1.98e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
THCA	cis	rs7131987	0.65	rs4331146	ENSG00000275476.1	RP11-996F15.4	-7.41	6.03e-13	1.98e-10	-0.33	-0.32	QT interval;	chr12:29287150	chr12:29277397~29277882:-
THCA	cis	rs36051354	0.592	rs2710332	ENSG00000242142.1	SERBP1P3	7.41	6.03e-13	1.98e-10	0.4	0.32	Intelligence (multi-trait analysis);	chr3:52944675	chr3:53064283~53065091:-
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000264538.5	SUZ12P1	-7.41	6.04e-13	1.98e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000264538.5	SUZ12P1	-7.41	6.04e-13	1.98e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30709299~30790908:+
THCA	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-7.41	6.05e-13	1.99e-10	-0.37	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
THCA	cis	rs7942368	1	rs3758711	ENSG00000254761.1	RP11-672A2.1	7.41	6.06e-13	1.99e-10	0.46	0.32	Endometriosis;	chr11:76784516	chr11:76712396~76719608:-
THCA	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	7.41	6.07e-13	1.99e-10	0.81	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
THCA	cis	rs17695224	0.545	rs66634805	ENSG00000269483.1	AC006272.1	7.41	6.07e-13	1.99e-10	0.35	0.32	HDL cholesterol;HDL cholesterol levels;	chr19:51816080	chr19:51839924~51843324:-
THCA	cis	rs12681366	0.96	rs2930961	ENSG00000253704.1	RP11-267M23.4	7.41	6.07e-13	1.99e-10	0.32	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94431578	chr8:94553722~94569745:+
THCA	cis	rs2562456	0.793	rs2562428	ENSG00000268555.1	RP11-678G14.3	-7.41	6.09e-13	2e-10	-0.46	-0.32	Pain;	chr19:21442652	chr19:21570822~21587322:-
THCA	cis	rs686320	0.748	rs550894	ENSG00000245532.5	NEAT1	7.41	6.1e-13	2e-10	0.32	0.32	Hip circumference adjusted for BMI;	chr11:65444469	chr11:65422774~65445540:+
THCA	cis	rs910316	0.967	rs11624893	ENSG00000279594.1	RP11-950C14.10	-7.41	6.1e-13	2e-10	-0.3	-0.32	Height;	chr14:75193421	chr14:75011269~75012851:-
THCA	cis	rs10971721	0.596	rs72731236	ENSG00000260947.1	RP11-384P7.7	7.41	6.11e-13	2.01e-10	0.75	0.32	Body mass index;	chr9:34147214	chr9:33697459~33700986:+
THCA	cis	rs4662750	0.583	rs2244880	ENSG00000236682.1	AC068282.3	7.4	6.12e-13	2.01e-10	0.41	0.32	Renal cell carcinoma;	chr2:127629069	chr2:127389130~127400580:+
THCA	cis	rs944289	0.562	rs2780310	ENSG00000257826.1	RP11-116N8.4	7.4	6.14e-13	2.01e-10	0.34	0.32	Thyroid cancer;	chr14:36050852	chr14:36061026~36067190:-
THCA	cis	rs74233809	1	rs11191580	ENSG00000213277.3	MARCKSL1P1	-7.4	6.14e-13	2.01e-10	-0.53	-0.32	Birth weight;	chr10:103146454	chr10:103175554~103176094:+
THCA	cis	rs9902453	0.904	rs12939344	ENSG00000264007.1	RP11-68I3.10	-7.4	6.15e-13	2.02e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30001801	chr17:29621617~29622254:-
THCA	cis	rs2439831	1	rs28628574	ENSG00000249839.1	AC011330.5	-7.4	6.15e-13	2.02e-10	-0.55	-0.32	Lung cancer in ever smokers;	chr15:43509840	chr15:43663654~43684339:-
THCA	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	7.4	6.16e-13	2.02e-10	0.78	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
THCA	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	7.4	6.18e-13	2.03e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
THCA	cis	rs7945705	0.967	rs7943377	ENSG00000254860.4	TMEM9B-AS1	-7.4	6.18e-13	2.03e-10	-0.37	-0.32	Hemoglobin concentration;	chr11:8827153	chr11:8964675~8977527:+
THCA	cis	rs5758659	0.692	rs5751251	ENSG00000182057.4	OGFRP1	7.4	6.2e-13	2.03e-10	0.36	0.32	Cognitive function;	chr22:42244600	chr22:42269753~42275196:+
THCA	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	7.4	6.2e-13	2.03e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
THCA	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-7.4	6.21e-13	2.04e-10	-0.31	-0.32	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
THCA	cis	rs7727544	0.606	rs11950562	ENSG00000233006.5	AC034220.3	7.4	6.21e-13	2.04e-10	0.25	0.32	Blood metabolite levels;	chr5:132316836	chr5:132311285~132369916:-
THCA	cis	rs240993	0.715	rs9487627	ENSG00000230177.1	RP5-1112D6.4	-7.4	6.22e-13	2.04e-10	-0.33	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111408846	chr6:111277932~111278742:+
THCA	cis	rs7851660	0.874	rs7037175	ENSG00000236130.1	PTCSC2	-7.4	6.22e-13	2.04e-10	-0.25	-0.32	Strep throat;	chr9:97869380	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs7868534	ENSG00000236130.1	PTCSC2	-7.4	6.22e-13	2.04e-10	-0.25	-0.32	Strep throat;	chr9:97870324	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs10818175	ENSG00000236130.1	PTCSC2	-7.4	6.22e-13	2.04e-10	-0.25	-0.32	Strep throat;	chr9:97871104	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs1955144	ENSG00000236130.1	PTCSC2	-7.4	6.22e-13	2.04e-10	-0.25	-0.32	Strep throat;	chr9:97872307	chr9:97805935~97810008:-
THCA	cis	rs4964805	0.559	rs1469999	ENSG00000257681.1	RP11-341G23.4	-7.4	6.22e-13	2.04e-10	-0.42	-0.32	Attention deficit hyperactivity disorder;	chr12:103814333	chr12:103746315~103768858:-
THCA	cis	rs1850744	0.826	rs7659176	ENSG00000250942.1	ENPP7P11	7.4	6.23e-13	2.04e-10	0.44	0.32	Economic and political preferences;	chr4:9719442	chr4:9677308~9677934:+
THCA	cis	rs10181042	0.565	rs1177233	ENSG00000271889.1	RP11-493E12.1	-7.4	6.24e-13	2.04e-10	-0.3	-0.32	Crohn's disease;	chr2:61034999	chr2:61151433~61162105:-
THCA	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	7.4	6.24e-13	2.05e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
THCA	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	7.4	6.24e-13	2.05e-10	0.19	0.32	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	7.4	6.24e-13	2.05e-10	0.19	0.32	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
THCA	cis	rs9388451	0.513	rs1268069	ENSG00000237742.5	RP11-624M8.1	-7.4	6.26e-13	2.05e-10	-0.29	-0.32	Brugada syndrome;	chr6:125718848	chr6:125578558~125749190:-
THCA	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	7.4	6.27e-13	2.05e-10	0.31	0.32	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
THCA	cis	rs5769707	0.681	rs4622843	ENSG00000235111.1	RP1-29C18.8	-7.4	6.28e-13	2.06e-10	-0.4	-0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49612657~49615716:-
THCA	cis	rs6723108	0.627	rs7593370	ENSG00000224043.6	CCNT2-AS1	7.4	6.29e-13	2.06e-10	0.34	0.32	Type 2 diabetes;	chr2:134865947	chr2:134735464~134918710:-
THCA	cis	rs795484	0.507	rs1726407	ENSG00000275759.1	RP11-131L12.3	7.4	6.29e-13	2.06e-10	0.3	0.32	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118145921	chr12:118428281~118428870:+
THCA	cis	rs4073416	0.712	rs11158602	ENSG00000276116.2	FUT8-AS1	7.4	6.3e-13	2.06e-10	0.34	0.32	N-glycan levels;	chr14:65605015	chr14:65411170~65412690:-
THCA	cis	rs6696239	0.513	rs12042653	ENSG00000227711.2	RP11-275O4.5	7.4	6.31e-13	2.07e-10	0.34	0.32	Height;	chr1:227524509	chr1:227509028~227520477:-
THCA	cis	rs240993	0.516	rs240981	ENSG00000230177.1	RP5-1112D6.4	-7.4	6.31e-13	2.07e-10	-0.35	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111289990	chr6:111277932~111278742:+
THCA	cis	rs7267979	1	rs1888999	ENSG00000274414.1	RP5-965G21.4	-7.4	6.31e-13	2.07e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25239007~25245229:-
THCA	cis	rs67340775	0.541	rs200966	ENSG00000219392.1	RP1-265C24.5	-7.4	6.32e-13	2.07e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr6:27894374	chr6:28115628~28116551:+
THCA	cis	rs17695224	0.545	rs763782	ENSG00000269483.1	AC006272.1	7.4	6.32e-13	2.07e-10	0.35	0.32	HDL cholesterol;HDL cholesterol levels;	chr19:51821841	chr19:51839924~51843324:-
THCA	cis	rs9649213	0.574	rs7789440	ENSG00000272950.1	RP11-307C18.1	7.4	6.33e-13	2.07e-10	0.4	0.32	Prostate cancer (SNP x SNP interaction);	chr7:98259486	chr7:98322853~98323430:+
THCA	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	7.4	6.33e-13	2.07e-10	0.18	0.32	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
THCA	cis	rs10971721	0.822	rs10971788	ENSG00000260947.1	RP11-384P7.7	7.4	6.33e-13	2.07e-10	0.78	0.32	Body mass index;	chr9:33915087	chr9:33697459~33700986:+
THCA	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	7.4	6.34e-13	2.08e-10	0.45	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
THCA	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-7.4	6.35e-13	2.08e-10	-0.39	-0.32	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-7.4	6.35e-13	2.08e-10	-0.39	-0.32	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
THCA	cis	rs2880765	0.835	rs7180213	ENSG00000259295.5	CSPG4P12	7.4	6.35e-13	2.08e-10	0.41	0.32	Coronary artery disease;	chr15:85477956	chr15:85191438~85213905:+
THCA	cis	rs9902453	0.868	rs11080118	ENSG00000264007.1	RP11-68I3.10	-7.4	6.35e-13	2.08e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30148361	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs8065261	ENSG00000264007.1	RP11-68I3.10	-7.4	6.35e-13	2.08e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30091023	chr17:29621617~29622254:-
THCA	cis	rs12928939	0.815	rs12448022	ENSG00000260886.1	TAT-AS1	7.4	6.35e-13	2.08e-10	0.42	0.32	Post bronchodilator FEV1;	chr16:71690466	chr16:71565789~71578187:+
THCA	cis	rs6539288	0.901	rs4964505	ENSG00000260329.1	RP11-412D9.4	-7.4	6.36e-13	2.08e-10	-0.29	-0.32	Total body bone mineral density;	chr12:106948062	chr12:106954029~106955497:-
THCA	cis	rs7727544	0.544	rs55722650	ENSG00000224431.1	AC063976.7	7.4	6.36e-13	2.08e-10	0.29	0.32	Blood metabolite levels;	chr5:132271607	chr5:132199456~132203487:+
THCA	cis	rs4072705	1	rs6478671	ENSG00000224020.1	MIR181A2HG	-7.4	6.36e-13	2.08e-10	-0.29	-0.32	Menarche (age at onset);	chr9:124611716	chr9:124658467~124698631:+
THCA	cis	rs9902453	1	rs12600993	ENSG00000264007.1	RP11-68I3.10	7.4	6.37e-13	2.08e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29964204	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	7.4	6.37e-13	2.09e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
THCA	cis	rs6723108	0.559	rs1942051	ENSG00000224043.6	CCNT2-AS1	-7.4	6.38e-13	2.09e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134846120	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs10928519	ENSG00000224043.6	CCNT2-AS1	-7.4	6.38e-13	2.09e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134846389	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs4954191	ENSG00000224043.6	CCNT2-AS1	-7.4	6.38e-13	2.09e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134854878	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs6430550	ENSG00000224043.6	CCNT2-AS1	-7.4	6.38e-13	2.09e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134858815	chr2:134735464~134918710:-
THCA	cis	rs2562456	0.833	rs2968078	ENSG00000268119.4	CTD-2561J22.5	-7.4	6.39e-13	2.09e-10	-0.41	-0.32	Pain;	chr19:21458942	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.755	rs2650773	ENSG00000268119.4	CTD-2561J22.5	-7.4	6.39e-13	2.09e-10	-0.41	-0.32	Pain;	chr19:21461286	chr19:21444241~21463908:-
THCA	cis	rs9549328	0.921	rs9549623	ENSG00000267868.1	RP11-120K24.3	7.4	6.41e-13	2.1e-10	0.33	0.32	Systolic blood pressure;	chr13:112985979	chr13:112964835~112966131:-
THCA	cis	rs6504108	0.624	rs882380	ENSG00000278765.1	RP5-890E16.5	-7.4	6.42e-13	2.1e-10	-0.36	-0.32	Body mass index;	chr17:48216874	chr17:48066704~48067293:-
THCA	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	7.4	6.42e-13	2.1e-10	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
THCA	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	7.4	6.43e-13	2.1e-10	0.53	0.32	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
THCA	cis	rs9902453	1	rs56280226	ENSG00000264007.1	RP11-68I3.10	7.4	6.43e-13	2.11e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:30102557	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs8082175	ENSG00000264007.1	RP11-68I3.10	7.4	6.43e-13	2.11e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:30103285	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	7.4	6.45e-13	2.11e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
THCA	cis	rs6723108	0.517	rs1530555	ENSG00000224043.6	CCNT2-AS1	-7.4	6.45e-13	2.11e-10	-0.33	-0.32	Type 2 diabetes;	chr2:134842169	chr2:134735464~134918710:-
THCA	cis	rs6504663	0.558	rs2412325	ENSG00000275897.1	RP11-94C24.13	7.4	6.46e-13	2.11e-10	0.31	0.32	Visceral fat;	chr17:50468871	chr17:50475819~50478391:+
THCA	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-7.4	6.47e-13	2.12e-10	-0.35	-0.32	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
THCA	cis	rs1949733	1	rs3103072	ENSG00000205959.3	RP11-689P11.2	7.4	6.47e-13	2.12e-10	0.28	0.32	Response to antineoplastic agents;	chr4:8506704	chr4:8482270~8512610:+
THCA	cis	rs9902453	0.838	rs3110495	ENSG00000264007.1	RP11-68I3.10	-7.4	6.47e-13	2.12e-10	-0.35	-0.32	Coffee consumption (cups per day);	chr17:29651437	chr17:29621617~29622254:-
THCA	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	7.4	6.48e-13	2.12e-10	0.78	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
THCA	cis	rs116139393	0.536	rs13247186	ENSG00000187953.9	PMS2CL	-7.4	6.48e-13	2.12e-10	-0.4	-0.32	Alzheimer's disease (APOE e4 interaction);	chr7:6729524	chr7:6710128~6753862:+
THCA	cis	rs6504622	0.818	rs28451958	ENSG00000262879.4	RP11-156P1.3	7.4	6.48e-13	2.12e-10	0.3	0.32	Orofacial clefts;	chr17:46968528	chr17:46984045~47100323:-
THCA	cis	rs910316	0.737	rs175043	ENSG00000279594.1	RP11-950C14.10	-7.4	6.49e-13	2.12e-10	-0.3	-0.32	Height;	chr14:75005100	chr14:75011269~75012851:-
THCA	cis	rs8114671	0.562	rs6087644	ENSG00000269202.1	RP4-614O4.12	-7.4	6.49e-13	2.12e-10	-0.28	-0.32	Height;	chr20:34893114	chr20:35201747~35203288:-
THCA	cis	rs1850744	1	rs2280208	ENSG00000250942.1	ENPP7P11	7.4	6.49e-13	2.12e-10	0.45	0.32	Economic and political preferences;	chr4:9798419	chr4:9677308~9677934:+
THCA	cis	rs7302981	1	rs7302981	ENSG00000272368.2	RP4-605O3.4	-7.4	6.5e-13	2.13e-10	-0.19	-0.32	Systolic blood pressure;	chr12:50144032	chr12:50112197~50165618:+
THCA	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-7.4	6.51e-13	2.13e-10	-0.34	-0.32	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
THCA	cis	rs12681366	1	rs66787185	ENSG00000253704.1	RP11-267M23.4	7.4	6.51e-13	2.13e-10	0.32	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94365254	chr8:94553722~94569745:+
THCA	cis	rs12681366	1	rs67808321	ENSG00000253704.1	RP11-267M23.4	7.4	6.51e-13	2.13e-10	0.32	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94373317	chr8:94553722~94569745:+
THCA	cis	rs67340775	0.541	rs200968	ENSG00000219392.1	RP1-265C24.5	-7.4	6.52e-13	2.13e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr6:27891790	chr6:28115628~28116551:+
THCA	cis	rs77204473	1	rs77204473	ENSG00000254851.1	RP11-109L13.1	7.4	6.53e-13	2.14e-10	0.9	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934348	chr11:117135528~117138582:+
THCA	cis	rs4934494	0.768	rs1409357	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89669719	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs17125834	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89673405	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs12571918	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89674920	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs12776306	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89676300	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs7078321	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89678341	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs34379399	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89683526	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs17126269	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89694974	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs768805	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89695448	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs12571268	ENSG00000232936.4	RP11-80H5.2	7.4	6.53e-13	2.14e-10	0.44	0.32	Red blood cell count;	chr10:89698830	chr10:89645282~89650667:+
THCA	cis	rs9902453	0.904	rs12936302	ENSG00000264007.1	RP11-68I3.10	-7.4	6.53e-13	2.14e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30022458	chr17:29621617~29622254:-
THCA	cis	rs10971721	0.584	rs10971951	ENSG00000260947.1	RP11-384P7.7	7.4	6.54e-13	2.14e-10	0.74	0.32	Body mass index;	chr9:34146527	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.686	rs10971952	ENSG00000260947.1	RP11-384P7.7	7.4	6.54e-13	2.14e-10	0.74	0.32	Body mass index;	chr9:34146604	chr9:33697459~33700986:+
THCA	cis	rs7923837	0.687	rs11187139	ENSG00000236493.2	EIF2S2P3	7.39	6.54e-13	2.14e-10	0.33	0.32	Multiple sclerosis;Body mass index;	chr10:92706670	chr10:92668745~92669743:-
THCA	cis	rs17772222	0.793	rs7143853	ENSG00000258983.2	RP11-507K2.2	7.39	6.57e-13	2.15e-10	0.4	0.32	Coronary artery calcification;	chr14:88578477	chr14:88499334~88515502:+
THCA	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	7.39	6.57e-13	2.15e-10	0.39	0.32	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	7.39	6.57e-13	2.15e-10	0.39	0.32	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	7.39	6.57e-13	2.15e-10	0.39	0.32	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
THCA	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-7.39	6.57e-13	2.15e-10	-0.35	-0.32	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
THCA	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-7.39	6.58e-13	2.15e-10	-0.37	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
THCA	cis	rs875971	1	rs35149210	ENSG00000232559.3	GS1-124K5.12	7.39	6.58e-13	2.15e-10	0.3	0.32	Aortic root size;	chr7:66464938	chr7:66554588~66576923:-
THCA	cis	rs4718428	1	rs1830070	ENSG00000273142.1	RP11-458F8.4	-7.39	6.6e-13	2.16e-10	-0.27	-0.32	Corneal structure;	chr7:66884684	chr7:66902857~66906297:+
THCA	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-7.39	6.61e-13	2.16e-10	-0.41	-0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
THCA	cis	rs957448	0.561	rs4734282	ENSG00000253704.1	RP11-267M23.4	7.39	6.62e-13	2.17e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94553722~94569745:+
THCA	cis	rs4664293	0.967	rs13000070	ENSG00000226266.5	AC009961.3	-7.39	6.64e-13	2.17e-10	-0.38	-0.32	Monocyte percentage of white cells;	chr2:159669263	chr2:159670708~159712435:-
THCA	cis	rs957448	0.561	rs34471170	ENSG00000253704.1	RP11-267M23.4	7.39	6.64e-13	2.17e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94553722~94569745:+
THCA	cis	rs957448	0.561	rs9642927	ENSG00000253704.1	RP11-267M23.4	7.39	6.64e-13	2.17e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94553722~94569745:+
THCA	cis	rs957448	0.529	rs9642928	ENSG00000253704.1	RP11-267M23.4	7.39	6.64e-13	2.17e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94553722~94569745:+
THCA	cis	rs957448	0.561	rs1808488	ENSG00000253704.1	RP11-267M23.4	7.39	6.64e-13	2.17e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94553722~94569745:+
THCA	cis	rs957448	0.583	rs754275	ENSG00000253704.1	RP11-267M23.4	7.39	6.64e-13	2.17e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94553722~94569745:+
THCA	cis	rs957448	0.561	rs1426172	ENSG00000253704.1	RP11-267M23.4	7.39	6.64e-13	2.17e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94553722~94569745:+
THCA	cis	rs9902453	0.838	rs8064689	ENSG00000264007.1	RP11-68I3.10	7.39	6.65e-13	2.17e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29890035	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.769	rs7210288	ENSG00000264007.1	RP11-68I3.10	7.39	6.65e-13	2.17e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29916455	chr17:29621617~29622254:-
THCA	cis	rs4073416	0.712	rs883082	ENSG00000276116.2	FUT8-AS1	7.39	6.65e-13	2.17e-10	0.33	0.32	N-glycan levels;	chr14:65414222	chr14:65411170~65412690:-
THCA	cis	rs74233809	1	rs34747231	ENSG00000213277.3	MARCKSL1P1	7.39	6.65e-13	2.17e-10	0.54	0.32	Birth weight;	chr10:103182487	chr10:103175554~103176094:+
THCA	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-7.39	6.66e-13	2.18e-10	-0.37	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
THCA	cis	rs9902453	0.817	rs2617881	ENSG00000264007.1	RP11-68I3.10	-7.39	6.68e-13	2.18e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:29736257	chr17:29621617~29622254:-
THCA	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	7.39	6.68e-13	2.18e-10	0.4	0.32	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000263603.1	CTD-2349P21.5	-7.39	6.69e-13	2.18e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30729469~30731202:+
THCA	cis	rs1150668	0.799	rs7206	ENSG00000219392.1	RP1-265C24.5	-7.39	6.69e-13	2.18e-10	-0.35	-0.32	Pubertal anthropometrics;	chr6:28233360	chr6:28115628~28116551:+
THCA	cis	rs9902453	0.902	rs4075014	ENSG00000264007.1	RP11-68I3.10	7.39	6.71e-13	2.19e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29978656	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs12602258	ENSG00000264007.1	RP11-68I3.10	7.39	6.71e-13	2.19e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29990639	chr17:29621617~29622254:-
THCA	cis	rs1023500	0.506	rs6002625	ENSG00000205702.9	CYP2D7	-7.39	6.72e-13	2.2e-10	-0.27	-0.32	Schizophrenia;	chr22:42121685	chr22:42140203~42144577:-
THCA	cis	rs12817211	0.502	rs59262224	ENSG00000272368.2	RP4-605O3.4	-7.39	6.73e-13	2.2e-10	-0.19	-0.32	Colorectal or endometrial cancer;	chr12:50117164	chr12:50112197~50165618:+
THCA	cis	rs4835473	0.932	rs12505628	ENSG00000251600.4	RP11-673E1.1	-7.39	6.73e-13	2.2e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143758468	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs12505663	ENSG00000251600.4	RP11-673E1.1	-7.39	6.73e-13	2.2e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143758491	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs12513078	ENSG00000251600.4	RP11-673E1.1	-7.39	6.73e-13	2.2e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143758494	chr4:143912331~143982454:+
THCA	cis	rs7267979	0.868	rs6138550	ENSG00000274414.1	RP5-965G21.4	-7.39	6.74e-13	2.2e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.903	rs6050481	ENSG00000274414.1	RP5-965G21.4	-7.39	6.74e-13	2.2e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.834	rs6115100	ENSG00000274414.1	RP5-965G21.4	-7.39	6.74e-13	2.2e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25239007~25245229:-
THCA	cis	rs3847687	1	rs3847688	ENSG00000279993.1	RP11-76C10.3	7.39	6.74e-13	2.2e-10	0.36	0.32	Longevity;	chr12:131040765	chr12:131025561~131028060:-
THCA	cis	rs6745190	0.953	rs9808318	ENSG00000236153.1	AC104076.3	7.39	6.75e-13	2.2e-10	0.38	0.32	White blood cell count;	chr2:181025478	chr2:180979427~180980090:-
THCA	cis	rs3806843	0.705	rs35614340	ENSG00000202515.1	VTRNA1-3	7.39	6.76e-13	2.21e-10	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr5:140726158~140726246:+
THCA	cis	rs7615952	0.8	rs2062773	ENSG00000241288.6	RP11-379B18.5	-7.39	6.77e-13	2.21e-10	-0.4	-0.32	Blood pressure (smoking interaction);	chr3:125920805	chr3:125827238~125916384:-
THCA	cis	rs7015263	0.754	rs7820697	ENSG00000254231.1	CTD-2284J15.1	7.39	6.8e-13	2.22e-10	0.31	0.32	Intelligence (multi-trait analysis);	chr8:86490626	chr8:86333274~86343314:-
THCA	cis	rs4835473	0.9	rs12505665	ENSG00000251600.4	RP11-673E1.1	-7.39	6.8e-13	2.22e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143758515	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs12509716	ENSG00000251600.4	RP11-673E1.1	-7.39	6.8e-13	2.22e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143758520	chr4:143912331~143982454:+
THCA	cis	rs7746199	0.736	rs13209332	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs34105070	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.673	rs72845046	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs67652222	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs13212093	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs34038546	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28170845~28172521:+
THCA	cis	rs141342723	1	rs141342723	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs34543938	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs56405707	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs13210634	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs13215275	ENSG00000280107.1	AL022393.9	-7.39	6.81e-13	2.22e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28170845~28172521:+
THCA	cis	rs7847628	0.587	rs10760117	ENSG00000270917.1	RP11-27I1.6	-7.39	6.81e-13	2.22e-10	-0.44	-0.32	Birth weight;	chr9:120824459	chr9:120812475~120812845:-
THCA	cis	rs12908161	1	rs35808647	ENSG00000225151.9	GOLGA2P7	-7.39	6.81e-13	2.22e-10	-0.47	-0.32	Schizophrenia;	chr15:84834210	chr15:84199311~84230136:-
THCA	cis	rs7727544	0.571	rs12521097	ENSG00000233006.5	AC034220.3	7.39	6.81e-13	2.22e-10	0.25	0.32	Blood metabolite levels;	chr5:132239645	chr5:132311285~132369916:-
THCA	cis	rs74233809	1	rs12219901	ENSG00000213277.3	MARCKSL1P1	7.39	6.81e-13	2.22e-10	0.53	0.32	Birth weight;	chr10:103081210	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs10458729	ENSG00000213277.3	MARCKSL1P1	7.39	6.81e-13	2.22e-10	0.53	0.32	Birth weight;	chr10:103081722	chr10:103175554~103176094:+
THCA	cis	rs6504108	0.624	rs12947089	ENSG00000278765.1	RP5-890E16.5	-7.39	6.81e-13	2.22e-10	-0.36	-0.32	Body mass index;	chr17:48160628	chr17:48066704~48067293:-
THCA	cis	rs4819052	0.918	rs34886433	ENSG00000237664.1	LINC00316	-7.39	6.81e-13	2.22e-10	-0.37	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45338590~45341990:-
THCA	cis	rs11696845	0.666	rs6103849	ENSG00000276223.1	RP4-781B1.5	7.39	6.82e-13	2.23e-10	0.39	0.32	Obesity-related traits;	chr20:44737046	chr20:44746642~44747201:+
THCA	cis	rs9341808	0.791	rs1324122	ENSG00000272129.1	RP11-250B2.6	7.39	6.83e-13	2.23e-10	0.41	0.32	Sitting height ratio;	chr6:80236344	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.754	rs10806185	ENSG00000272129.1	RP11-250B2.6	7.39	6.83e-13	2.23e-10	0.41	0.32	Sitting height ratio;	chr6:80244794	chr6:80355424~80356859:+
THCA	cis	rs7302981	0.899	rs1862043	ENSG00000272368.2	RP4-605O3.4	-7.39	6.84e-13	2.23e-10	-0.19	-0.32	Systolic blood pressure;	chr12:50182533	chr12:50112197~50165618:+
THCA	cis	rs801193	0.569	rs6978178	ENSG00000232559.3	GS1-124K5.12	-7.39	6.84e-13	2.23e-10	-0.31	-0.32	Aortic root size;	chr7:66658097	chr7:66554588~66576923:-
THCA	cis	rs2911132	1	rs2549803	ENSG00000248734.2	CTD-2260A17.1	7.39	6.86e-13	2.24e-10	0.34	0.32	Urate levels (BMI interaction);	chr5:96839226	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-7.39	6.86e-13	2.24e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-7.39	6.86e-13	2.24e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
THCA	cis	rs728616	0.867	rs12414877	ENSG00000225484.5	NUTM2B-AS1	-7.39	6.87e-13	2.24e-10	-0.64	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80020952	chr10:79663088~79826594:-
THCA	cis	rs748404	0.56	rs1869258	ENSG00000166763.7	STRCP1	7.39	6.87e-13	2.24e-10	0.35	0.32	Lung cancer;	chr15:43511423	chr15:43699488~43718184:-
THCA	cis	rs12681366	0.62	rs2930968	ENSG00000253704.1	RP11-267M23.4	7.39	6.87e-13	2.24e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94450467	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.663	rs2930970	ENSG00000253704.1	RP11-267M23.4	7.39	6.87e-13	2.24e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94452109	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.663	rs2921389	ENSG00000253704.1	RP11-267M23.4	7.39	6.87e-13	2.24e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94454138	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.663	rs2043987	ENSG00000253704.1	RP11-267M23.4	7.39	6.87e-13	2.24e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94457465	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.663	rs2919662	ENSG00000253704.1	RP11-267M23.4	7.39	6.87e-13	2.24e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94458044	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.663	rs2919660	ENSG00000253704.1	RP11-267M23.4	7.39	6.87e-13	2.24e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94458469	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.663	rs1561648	ENSG00000253704.1	RP11-267M23.4	7.39	6.87e-13	2.24e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94462209	chr8:94553722~94569745:+
THCA	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	7.39	6.87e-13	2.24e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
THCA	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	7.39	6.87e-13	2.24e-10	0.33	0.32	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000206090.4	AP000350.7	7.39	6.88e-13	2.25e-10	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23939998~23942798:+
THCA	cis	rs10869777	0.591	rs13288968	ENSG00000234618.1	RPSAP9	-7.39	6.89e-13	2.25e-10	-0.33	-0.32	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76371615	chr9:76398699~76399586:+
THCA	cis	rs1198430	0.759	rs946267	ENSG00000232482.2	RP4-654C18.1	-7.39	6.89e-13	2.25e-10	-0.49	-0.32	Total cholesterol levels;	chr1:23421210	chr1:23410832~23412146:+
THCA	cis	rs1198430	0.759	rs1198438	ENSG00000232482.2	RP4-654C18.1	-7.39	6.89e-13	2.25e-10	-0.49	-0.32	Total cholesterol levels;	chr1:23423064	chr1:23410832~23412146:+
THCA	cis	rs6723108	0.627	rs2053726	ENSG00000224043.6	CCNT2-AS1	-7.39	6.91e-13	2.25e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134852584	chr2:134735464~134918710:-
THCA	cis	rs1150668	0.699	rs1736895	ENSG00000219392.1	RP1-265C24.5	-7.39	6.91e-13	2.25e-10	-0.35	-0.32	Pubertal anthropometrics;	chr6:28252048	chr6:28115628~28116551:+
THCA	cis	rs7208859	0.573	rs11654035	ENSG00000263603.1	CTD-2349P21.5	-7.39	6.91e-13	2.25e-10	-0.57	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30729469~30731202:+
THCA	cis	rs9400467	0.528	rs6568680	ENSG00000230177.1	RP5-1112D6.4	-7.39	6.92e-13	2.26e-10	-0.26	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111277932~111278742:+
THCA	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-7.39	6.92e-13	2.26e-10	-0.38	-0.32	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
THCA	cis	rs6840258	0.825	rs72667751	ENSG00000251411.1	RP11-397E7.4	-7.39	6.92e-13	2.26e-10	-0.38	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87015227	chr4:86913266~86914817:-
THCA	cis	rs4820539	1	rs4822362	ENSG00000221069.1	AC000029.1	-7.39	6.93e-13	2.26e-10	-0.38	-0.32	Bone mineral density;	chr22:23140557	chr22:23136620~23136710:+
THCA	cis	rs1061377	0.748	rs6816202	ENSG00000249685.1	RP11-360F5.3	7.39	6.93e-13	2.26e-10	0.4	0.32	Uric acid levels;	chr4:39106868	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.748	rs6842561	ENSG00000249685.1	RP11-360F5.3	7.39	6.93e-13	2.26e-10	0.4	0.32	Uric acid levels;	chr4:39106873	chr4:39133913~39135608:+
THCA	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-7.39	6.94e-13	2.26e-10	-0.41	-0.32	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
THCA	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	7.39	6.95e-13	2.27e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	7.39	6.95e-13	2.27e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	7.39	6.95e-13	2.27e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	7.39	6.95e-13	2.27e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	7.39	6.95e-13	2.27e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
THCA	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	7.39	6.95e-13	2.27e-10	0.49	0.32	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	7.39	6.95e-13	2.27e-10	0.49	0.32	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
THCA	cis	rs5758659	0.716	rs2143138	ENSG00000182057.4	OGFRP1	7.39	6.95e-13	2.27e-10	0.36	0.32	Cognitive function;	chr22:42222334	chr22:42269753~42275196:+
THCA	cis	rs12928939	0.769	rs12445161	ENSG00000260886.1	TAT-AS1	7.39	6.97e-13	2.27e-10	0.42	0.32	Post bronchodilator FEV1;	chr16:71708025	chr16:71565789~71578187:+
THCA	cis	rs12928939	0.815	rs34731378	ENSG00000260886.1	TAT-AS1	7.39	6.97e-13	2.27e-10	0.42	0.32	Post bronchodilator FEV1;	chr16:71711845	chr16:71565789~71578187:+
THCA	cis	rs7942368	1	rs1440980	ENSG00000254761.1	RP11-672A2.1	7.39	6.97e-13	2.27e-10	0.45	0.32	Endometriosis;	chr11:76784032	chr11:76712396~76719608:-
THCA	cis	rs875971	1	rs6958271	ENSG00000232559.3	GS1-124K5.12	7.39	6.98e-13	2.27e-10	0.31	0.32	Aortic root size;	chr7:66514344	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6958277	ENSG00000232559.3	GS1-124K5.12	7.39	6.98e-13	2.27e-10	0.31	0.32	Aortic root size;	chr7:66514362	chr7:66554588~66576923:-
THCA	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-7.39	6.98e-13	2.27e-10	-0.47	-0.32	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-7.39	6.98e-13	2.27e-10	-0.47	-0.32	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-7.39	6.98e-13	2.27e-10	-0.47	-0.32	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-7.39	6.98e-13	2.27e-10	-0.47	-0.32	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-7.39	6.98e-13	2.27e-10	-0.47	-0.32	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
THCA	cis	rs4073416	0.712	rs12879971	ENSG00000276116.2	FUT8-AS1	7.39	6.99e-13	2.28e-10	0.33	0.32	N-glycan levels;	chr14:65434886	chr14:65411170~65412690:-
THCA	cis	rs7615952	0.8	rs11915699	ENSG00000241288.6	RP11-379B18.5	-7.38	7e-13	2.28e-10	-0.4	-0.32	Blood pressure (smoking interaction);	chr3:125913841	chr3:125827238~125916384:-
THCA	cis	rs4950322	0.57	rs72691032	ENSG00000237188.3	RP11-337C18.8	7.38	7.01e-13	2.28e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147261120	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72691033	ENSG00000237188.3	RP11-337C18.8	7.38	7.01e-13	2.28e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147261267	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs111370771	ENSG00000237188.3	RP11-337C18.8	7.38	7.01e-13	2.28e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147261420	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs4301678	ENSG00000237188.3	RP11-337C18.8	7.38	7.01e-13	2.28e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147261907	chr1:147172771~147211568:+
THCA	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-7.38	7.01e-13	2.28e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
THCA	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-7.38	7.02e-13	2.29e-10	-0.31	-0.32	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
THCA	cis	rs7208859	0.614	rs216412	ENSG00000266490.1	CTD-2349P21.9	-7.38	7.03e-13	2.29e-10	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30792372~30792833:+
THCA	cis	rs2033711	0.728	rs4801586	ENSG00000269473.1	CTD-2619J13.19	7.38	7.04e-13	2.29e-10	0.3	0.32	Uric acid clearance;	chr19:58423161	chr19:58440448~58445849:+
THCA	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-7.38	7.04e-13	2.29e-10	-0.32	-0.32	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
THCA	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	7.38	7.04e-13	2.29e-10	0.42	0.32	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
THCA	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	7.38	7.06e-13	2.3e-10	0.49	0.32	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
THCA	cis	rs875971	1	rs937495	ENSG00000232559.3	GS1-124K5.12	-7.38	7.06e-13	2.3e-10	-0.31	-0.32	Aortic root size;	chr7:66314811	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs2036264	ENSG00000232559.3	GS1-124K5.12	-7.38	7.06e-13	2.3e-10	-0.31	-0.32	Aortic root size;	chr7:66334917	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs7783613	ENSG00000232559.3	GS1-124K5.12	-7.38	7.06e-13	2.3e-10	-0.31	-0.32	Aortic root size;	chr7:66340274	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs778735	ENSG00000232559.3	GS1-124K5.12	7.38	7.06e-13	2.3e-10	0.31	0.32	Aortic root size;	chr7:66349822	chr7:66554588~66576923:-
THCA	cis	rs13068223	0.905	rs344027	ENSG00000243926.1	TIPARP-AS1	-7.38	7.06e-13	2.3e-10	-0.31	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156750604	chr3:156671862~156674378:-
THCA	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-7.38	7.07e-13	2.3e-10	-0.37	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
THCA	cis	rs9902453	1	rs4465650	ENSG00000264007.1	RP11-68I3.10	7.38	7.08e-13	2.31e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:30069703	chr17:29621617~29622254:-
THCA	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-7.38	7.08e-13	2.31e-10	-0.47	-0.32	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
THCA	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-7.38	7.08e-13	2.31e-10	-0.47	-0.32	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-7.38	7.08e-13	2.31e-10	-0.47	-0.32	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
THCA	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	7.38	7.11e-13	2.31e-10	0.3	0.32	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
THCA	cis	rs2018683	1	rs4719963	ENSG00000228421.2	AC005013.5	-7.38	7.11e-13	2.32e-10	-0.36	-0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28971448	chr7:28957667~28959345:+
THCA	cis	rs4073416	0.712	rs2411822	ENSG00000276116.2	FUT8-AS1	7.38	7.12e-13	2.32e-10	0.33	0.32	N-glycan levels;	chr14:65411677	chr14:65411170~65412690:-
THCA	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-7.38	7.14e-13	2.32e-10	-0.41	-0.32	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
THCA	cis	rs875971	0.895	rs12698520	ENSG00000232559.3	GS1-124K5.12	7.38	7.14e-13	2.33e-10	0.3	0.32	Aortic root size;	chr7:66453720	chr7:66554588~66576923:-
THCA	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-7.38	7.14e-13	2.33e-10	-0.39	-0.32	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
THCA	cis	rs1949733	0.656	rs2631762	ENSG00000205959.3	RP11-689P11.2	-7.38	7.14e-13	2.33e-10	-0.27	-0.32	Response to antineoplastic agents;	chr4:8421395	chr4:8482270~8512610:+
THCA	cis	rs2033711	0.783	rs8113810	ENSG00000269473.1	CTD-2619J13.19	7.38	7.14e-13	2.33e-10	0.3	0.32	Uric acid clearance;	chr19:58420739	chr19:58440448~58445849:+
THCA	cis	rs2033711	0.87	rs4801270	ENSG00000269473.1	CTD-2619J13.19	7.38	7.14e-13	2.33e-10	0.3	0.32	Uric acid clearance;	chr19:58421395	chr19:58440448~58445849:+
THCA	cis	rs4820539	1	rs5759596	ENSG00000221069.1	AC000029.1	-7.38	7.15e-13	2.33e-10	-0.38	-0.32	Bone mineral density;	chr22:23133563	chr22:23136620~23136710:+
THCA	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-7.38	7.16e-13	2.33e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
THCA	cis	rs62158211	0.565	rs2121243	ENSG00000234997.1	AC016745.3	-7.38	7.18e-13	2.34e-10	-0.33	-0.32	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113341769	chr2:113424495~113425324:+
THCA	cis	rs6600671	1	rs4844616	ENSG00000223345.3	HIST2H2BA	7.38	7.18e-13	2.34e-10	0.35	0.32	Hip geometry;	chr1:121429348	chr1:121108210~121117257:-
THCA	cis	rs9902453	0.874	rs4474741	ENSG00000264007.1	RP11-68I3.10	-7.38	7.18e-13	2.34e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:29821099	chr17:29621617~29622254:-
THCA	cis	rs4819052	0.851	rs8126930	ENSG00000237664.1	LINC00316	-7.38	7.19e-13	2.34e-10	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45338590~45341990:-
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000272009.1	RP1-313I6.12	-7.38	7.19e-13	2.34e-10	-0.37	-0.32	Parkinson's disease;	chr6:28069254	chr6:28078792~28081130:-
THCA	cis	rs7945705	0.875	rs4929914	ENSG00000254860.4	TMEM9B-AS1	7.38	7.19e-13	2.34e-10	0.35	0.32	Hemoglobin concentration;	chr11:8802841	chr11:8964675~8977527:+
THCA	cis	rs4819052	0.766	rs4819035	ENSG00000215447.6	BX322557.10	-7.38	7.2e-13	2.34e-10	-0.3	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45288052~45291738:+
THCA	cis	rs7302981	0.845	rs56709084	ENSG00000272368.2	RP4-605O3.4	7.38	7.21e-13	2.35e-10	0.19	0.32	Systolic blood pressure;	chr12:50170107	chr12:50112197~50165618:+
THCA	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	7.38	7.22e-13	2.35e-10	0.41	0.32	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
THCA	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	7.38	7.23e-13	2.35e-10	0.39	0.32	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
THCA	cis	rs911555	0.504	rs4906340	ENSG00000269958.1	RP11-73M18.8	-7.38	7.27e-13	2.37e-10	-0.32	-0.32	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103696353~103697163:+
THCA	cis	rs9388451	0.839	rs9401845	ENSG00000237742.5	RP11-624M8.1	-7.38	7.28e-13	2.37e-10	-0.28	-0.32	Brugada syndrome;	chr6:125782972	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.805	rs1028481	ENSG00000237742.5	RP11-624M8.1	-7.38	7.28e-13	2.37e-10	-0.28	-0.32	Brugada syndrome;	chr6:125785427	chr6:125578558~125749190:-
THCA	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-7.38	7.28e-13	2.37e-10	-0.33	-0.32	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-7.38	7.28e-13	2.37e-10	-0.33	-0.32	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
THCA	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	7.38	7.28e-13	2.37e-10	0.41	0.32	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
THCA	cis	rs240993	0.669	rs6935759	ENSG00000230177.1	RP5-1112D6.4	-7.38	7.29e-13	2.37e-10	-0.33	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111457517	chr6:111277932~111278742:+
THCA	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	7.38	7.29e-13	2.37e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
THCA	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	7.38	7.29e-13	2.37e-10	0.45	0.32	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
THCA	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	7.38	7.29e-13	2.37e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
THCA	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-7.38	7.3e-13	2.37e-10	-0.78	-0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
THCA	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-7.38	7.31e-13	2.38e-10	-0.37	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
THCA	cis	rs875971	1	rs2420591	ENSG00000232559.3	GS1-124K5.12	7.38	7.33e-13	2.38e-10	0.3	0.32	Aortic root size;	chr7:66447394	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000263603.1	CTD-2349P21.5	-7.38	7.34e-13	2.39e-10	-0.57	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000263603.1	CTD-2349P21.5	-7.38	7.34e-13	2.39e-10	-0.57	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11656462	ENSG00000264538.5	SUZ12P1	-7.38	7.34e-13	2.39e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30709299~30790908:+
THCA	cis	rs9549328	0.8	rs9549616	ENSG00000267868.1	RP11-120K24.3	7.38	7.35e-13	2.39e-10	0.33	0.32	Systolic blood pressure;	chr13:112973448	chr13:112964835~112966131:-
THCA	cis	rs4820539	1	rs4822358	ENSG00000221069.1	AC000029.1	-7.38	7.35e-13	2.39e-10	-0.38	-0.32	Bone mineral density;	chr22:23132608	chr22:23136620~23136710:+
THCA	cis	rs12817211	0.502	rs3741562	ENSG00000272368.2	RP4-605O3.4	-7.38	7.36e-13	2.39e-10	-0.19	-0.32	Colorectal or endometrial cancer;	chr12:50135953	chr12:50112197~50165618:+
THCA	cis	rs12817211	0.502	rs12369104	ENSG00000272368.2	RP4-605O3.4	-7.38	7.36e-13	2.39e-10	-0.19	-0.32	Colorectal or endometrial cancer;	chr12:50141207	chr12:50112197~50165618:+
THCA	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-7.38	7.36e-13	2.39e-10	-0.4	-0.32	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
THCA	cis	rs71636778	0.509	rs17162339	ENSG00000260063.1	RP5-968P14.2	7.38	7.36e-13	2.39e-10	0.58	0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26926332	chr1:26692132~26694131:-
THCA	cis	rs2288884	1	rs17779301	ENSG00000275055.1	CTC-471J1.11	7.38	7.37e-13	2.4e-10	0.32	0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035990	chr19:52049007~52049754:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000228039.3	KB-1125A3.10	7.38	7.38e-13	2.4e-10	0.41	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23963780~23964374:+
THCA	cis	rs4664293	1	rs4665083	ENSG00000226266.5	AC009961.3	7.38	7.38e-13	2.4e-10	0.37	0.32	Monocyte percentage of white cells;	chr2:159573616	chr2:159670708~159712435:-
THCA	cis	rs875971	1	rs778726	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66363744	chr7:66554588~66576923:-
THCA	cis	rs875971	0.767	rs1695815	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66366357	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs778685	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66371189	chr7:66554588~66576923:-
THCA	cis	rs875971	0.929	rs778682	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66372947	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs11765965	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66377234	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs1643388	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66379575	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs778722	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66379841	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs778721	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66380410	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs778706	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66395437	chr7:66554588~66576923:-
THCA	cis	rs875971	0.895	rs778700	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66401463	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs778699	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66403303	chr7:66554588~66576923:-
THCA	cis	rs875971	0.929	rs778692	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66407462	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs4718343	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66409301	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs1968225	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66409786	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6460295	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66417741	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs6978721	ENSG00000232559.3	GS1-124K5.12	7.38	7.38e-13	2.4e-10	0.3	0.32	Aortic root size;	chr7:66418217	chr7:66554588~66576923:-
THCA	cis	rs7811142	0.72	rs112622797	ENSG00000078319.8	PMS2P1	-7.38	7.4e-13	2.4e-10	-0.47	-0.32	Platelet count;	chr7:100319793	chr7:100320992~100341908:-
THCA	cis	rs6570726	0.526	rs7755237	ENSG00000235652.6	RP11-545I5.3	-7.38	7.4e-13	2.4e-10	-0.3	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145410716	chr6:145799409~145886585:+
THCA	cis	rs9388451	0.626	rs3799712	ENSG00000237742.5	RP11-624M8.1	-7.38	7.4e-13	2.4e-10	-0.29	-0.32	Brugada syndrome;	chr6:125753957	chr6:125578558~125749190:-
THCA	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	7.38	7.4e-13	2.41e-10	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
THCA	cis	rs7247513	0.78	rs4804725	ENSG00000213290.4	PGK1P2	-7.38	7.4e-13	2.41e-10	-0.39	-0.32	Bipolar disorder;	chr19:12612331	chr19:12559571~12561105:+
THCA	cis	rs910316	0.726	rs61979167	ENSG00000279594.1	RP11-950C14.10	-7.38	7.41e-13	2.41e-10	-0.3	-0.32	Height;	chr14:75196907	chr14:75011269~75012851:-
THCA	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-7.38	7.43e-13	2.41e-10	-0.32	-0.32	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-7.38	7.44e-13	2.42e-10	-0.32	-0.32	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-7.38	7.44e-13	2.42e-10	-0.32	-0.32	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-7.38	7.44e-13	2.42e-10	-0.32	-0.32	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
THCA	cis	rs910316	0.737	rs398896	ENSG00000279594.1	RP11-950C14.10	-7.38	7.44e-13	2.42e-10	-0.29	-0.32	Height;	chr14:75016124	chr14:75011269~75012851:-
THCA	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-7.38	7.47e-13	2.43e-10	-0.35	-0.32	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-7.38	7.47e-13	2.43e-10	-0.35	-0.32	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
THCA	cis	rs9388451	0.807	rs1269175	ENSG00000237742.5	RP11-624M8.1	7.38	7.47e-13	2.43e-10	0.28	0.32	Brugada syndrome;	chr6:125719289	chr6:125578558~125749190:-
THCA	cis	rs7942368	1	rs7933092	ENSG00000254761.1	RP11-672A2.1	7.38	7.48e-13	2.43e-10	0.45	0.32	Endometriosis;	chr11:76764444	chr11:76712396~76719608:-
THCA	cis	rs2274273	0.624	rs2026633	ENSG00000258413.1	RP11-665C16.6	-7.38	7.48e-13	2.43e-10	-0.46	-0.32	Protein biomarker;	chr14:55322459	chr14:55262767~55272075:-
THCA	cis	rs9876781	0.507	rs1824362	ENSG00000229759.1	MRPS18AP1	-7.37	7.49e-13	2.43e-10	-0.38	-0.32	Longevity;	chr3:48360459	chr3:48256350~48256938:-
THCA	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	7.37	7.49e-13	2.43e-10	0.4	0.32	Height;	chr6:109655182	chr6:109382795~109383666:+
THCA	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-7.37	7.51e-13	2.44e-10	-0.41	-0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
THCA	cis	rs875971	1	rs4717300	ENSG00000232559.3	GS1-124K5.12	7.37	7.51e-13	2.44e-10	0.3	0.32	Aortic root size;	chr7:66482393	chr7:66554588~66576923:-
THCA	cis	rs7674212	0.833	rs61075040	ENSG00000246560.2	RP11-10L12.4	7.37	7.51e-13	2.44e-10	0.41	0.32	Type 2 diabetes;	chr4:103052804	chr4:102828055~102844075:+
THCA	cis	rs875971	0.838	rs2173570	ENSG00000232559.3	GS1-124K5.12	-7.37	7.52e-13	2.44e-10	-0.31	-0.32	Aortic root size;	chr7:66297976	chr7:66554588~66576923:-
THCA	cis	rs7746199	0.736	rs17749927	ENSG00000280107.1	AL022393.9	-7.37	7.53e-13	2.45e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs13192965	ENSG00000280107.1	AL022393.9	-7.37	7.53e-13	2.45e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28170845~28172521:+
THCA	cis	rs7208859	0.673	rs423151	ENSG00000266490.1	CTD-2349P21.9	7.37	7.54e-13	2.45e-10	0.41	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30792372~30792833:+
THCA	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	7.37	7.55e-13	2.45e-10	0.51	0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
THCA	cis	rs7247513	1	rs2042947	ENSG00000230310.1	CTD-2192J16.11	-7.37	7.55e-13	2.45e-10	-0.39	-0.32	Bipolar disorder;	chr19:12582289	chr19:12552597~12553644:+
THCA	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-7.37	7.58e-13	2.46e-10	-0.31	-0.32	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
THCA	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-7.37	7.6e-13	2.47e-10	-0.35	-0.32	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-7.37	7.6e-13	2.47e-10	-0.35	-0.32	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-7.37	7.6e-13	2.47e-10	-0.35	-0.32	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
THCA	cis	rs7246657	0.943	rs7259968	ENSG00000226686.6	LINC01535	-7.37	7.61e-13	2.47e-10	-0.45	-0.32	Coronary artery calcification;	chr19:37320952	chr19:37251912~37265535:+
THCA	cis	rs4820539	0.966	rs5996470	ENSG00000221069.1	AC000029.1	-7.37	7.61e-13	2.47e-10	-0.38	-0.32	Bone mineral density;	chr22:23141068	chr22:23136620~23136710:+
THCA	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-7.37	7.64e-13	2.48e-10	-0.47	-0.32	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-7.37	7.64e-13	2.48e-10	-0.47	-0.32	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
THCA	cis	rs7246657	0.943	rs2045908	ENSG00000226686.6	LINC01535	-7.37	7.64e-13	2.48e-10	-0.46	-0.32	Coronary artery calcification;	chr19:37488866	chr19:37251912~37265535:+
THCA	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-7.37	7.65e-13	2.48e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-7.37	7.65e-13	2.48e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
THCA	cis	rs416603	0.967	rs11640138	ENSG00000262703.1	RP11-485G7.6	7.37	7.66e-13	2.49e-10	0.36	0.32	Type 1 diabetes;	chr16:11268872	chr16:11348143~11349321:-
THCA	cis	rs6745190	0.953	rs4366861	ENSG00000236153.1	AC104076.3	-7.37	7.67e-13	2.49e-10	-0.38	-0.32	White blood cell count;	chr2:180988301	chr2:180979427~180980090:-
THCA	cis	rs8114671	0.562	rs4911161	ENSG00000269202.1	RP4-614O4.12	-7.37	7.68e-13	2.49e-10	-0.27	-0.32	Height;	chr20:34814428	chr20:35201747~35203288:-
THCA	cis	rs875971	1	rs1363055	ENSG00000232559.3	GS1-124K5.12	7.37	7.68e-13	2.49e-10	0.3	0.32	Aortic root size;	chr7:66478288	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs9691480	ENSG00000232559.3	GS1-124K5.12	7.37	7.68e-13	2.49e-10	0.3	0.32	Aortic root size;	chr7:66479319	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs7789554	ENSG00000232559.3	GS1-124K5.12	7.37	7.68e-13	2.49e-10	0.3	0.32	Aortic root size;	chr7:66481051	chr7:66554588~66576923:-
THCA	cis	rs875971	0.895	rs1974769	ENSG00000232559.3	GS1-124K5.12	7.37	7.68e-13	2.49e-10	0.3	0.32	Aortic root size;	chr7:66485627	chr7:66554588~66576923:-
THCA	cis	rs875971	0.895	rs6460300	ENSG00000232559.3	GS1-124K5.12	7.37	7.68e-13	2.49e-10	0.3	0.32	Aortic root size;	chr7:66487937	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs7803416	ENSG00000232559.3	GS1-124K5.12	7.37	7.68e-13	2.49e-10	0.3	0.32	Aortic root size;	chr7:66489212	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs1981799	ENSG00000232559.3	GS1-124K5.12	7.37	7.68e-13	2.49e-10	0.3	0.32	Aortic root size;	chr7:66490572	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs2277911	ENSG00000232559.3	GS1-124K5.12	7.37	7.68e-13	2.49e-10	0.3	0.32	Aortic root size;	chr7:66493638	chr7:66554588~66576923:-
THCA	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-7.37	7.69e-13	2.49e-10	-0.32	-0.32	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
THCA	cis	rs9902453	1	rs8065059	ENSG00000264007.1	RP11-68I3.10	-7.37	7.71e-13	2.5e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30090358	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs12600855	ENSG00000264007.1	RP11-68I3.10	7.37	7.71e-13	2.5e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29952573	chr17:29621617~29622254:-
THCA	cis	rs4950322	0.57	rs3737855	ENSG00000237188.3	RP11-337C18.8	7.37	7.72e-13	2.51e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147271257	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs4950316	ENSG00000237188.3	RP11-337C18.8	7.37	7.72e-13	2.51e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147273712	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs2354428	ENSG00000237188.3	RP11-337C18.8	7.37	7.72e-13	2.51e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147277512	chr1:147172771~147211568:+
THCA	cis	rs9928842	0.712	rs10871304	ENSG00000280152.1	RP11-331F4.5	7.37	7.74e-13	2.51e-10	0.38	0.32	Alcoholic chronic pancreatitis;	chr16:75189593	chr16:75245994~75250077:-
THCA	cis	rs7131987	0.65	rs67146951	ENSG00000275476.1	RP11-996F15.4	-7.37	7.75e-13	2.51e-10	-0.33	-0.32	QT interval;	chr12:29297620	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.65	rs10843382	ENSG00000275476.1	RP11-996F15.4	-7.37	7.75e-13	2.51e-10	-0.33	-0.32	QT interval;	chr12:29298788	chr12:29277397~29277882:-
THCA	cis	rs2281636	0.723	rs3740078	ENSG00000233690.1	EBAG9P1	7.37	7.76e-13	2.51e-10	0.34	0.32	Obesity-related traits;	chr10:99685834	chr10:99697407~99697949:-
THCA	cis	rs2281636	0.723	rs11190246	ENSG00000233690.1	EBAG9P1	7.37	7.76e-13	2.51e-10	0.34	0.32	Obesity-related traits;	chr10:99691854	chr10:99697407~99697949:-
THCA	cis	rs4664293	0.903	rs10185155	ENSG00000226266.5	AC009961.3	-7.37	7.77e-13	2.52e-10	-0.38	-0.32	Monocyte percentage of white cells;	chr2:159696717	chr2:159670708~159712435:-
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000263603.1	CTD-2349P21.5	7.37	7.79e-13	2.53e-10	0.56	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30729469~30731202:+
THCA	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-7.37	7.8e-13	2.53e-10	-0.34	-0.32	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
THCA	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-7.37	7.81e-13	2.53e-10	-0.35	-0.32	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
THCA	cis	rs11603691	1	rs518272	ENSG00000254662.1	RP11-872D17.4	-7.37	7.81e-13	2.53e-10	-0.58	-0.32	Low high density lipoprotein cholesterol levels;	chr11:57250083	chr11:57325603~57327958:+
THCA	cis	rs9309473	0.528	rs6546820	ENSG00000163016.8	ALMS1P	7.37	7.82e-13	2.53e-10	0.43	0.32	Metabolite levels;	chr2:73326269	chr2:73644919~73685576:+
THCA	cis	rs9402743	0.671	rs9373138	ENSG00000231028.7	LINC00271	-7.37	7.82e-13	2.53e-10	-0.26	-0.32	Systemic lupus erythematosus;	chr6:135630343	chr6:135497801~135716055:+
THCA	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-7.37	7.83e-13	2.54e-10	-0.32	-0.32	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
THCA	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	7.37	7.83e-13	2.54e-10	0.39	0.32	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
THCA	cis	rs75422866	0.51	rs73105812	ENSG00000274902.1	RP1-197B17.4	7.37	7.83e-13	2.54e-10	0.67	0.32	Pneumonia;	chr12:47724404	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.51	rs74733564	ENSG00000274902.1	RP1-197B17.4	7.37	7.83e-13	2.54e-10	0.67	0.32	Pneumonia;	chr12:47724644	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.51	rs73105814	ENSG00000274902.1	RP1-197B17.4	7.37	7.83e-13	2.54e-10	0.67	0.32	Pneumonia;	chr12:47725817	chr12:47731908~47732351:+
THCA	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-7.37	7.84e-13	2.54e-10	-0.33	-0.32	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-7.37	7.84e-13	2.54e-10	-0.33	-0.32	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
THCA	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-7.37	7.84e-13	2.54e-10	-0.33	-0.32	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
THCA	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-7.37	7.84e-13	2.54e-10	-0.19	-0.32	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
THCA	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	7.37	7.85e-13	2.54e-10	0.43	0.32	Height;	chr4:55482360	chr4:55363971~55395847:-
THCA	cis	rs7246657	0.943	rs10415358	ENSG00000226686.6	LINC01535	-7.37	7.86e-13	2.55e-10	-0.47	-0.32	Coronary artery calcification;	chr19:37317961	chr19:37251912~37265535:+
THCA	cis	rs7746199	0.736	rs13193542	ENSG00000280107.1	AL022393.9	-7.37	7.86e-13	2.55e-10	-0.65	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs13193480	ENSG00000280107.1	AL022393.9	-7.37	7.86e-13	2.55e-10	-0.65	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28170845~28172521:+
THCA	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	7.37	7.86e-13	2.55e-10	0.41	0.32	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
THCA	cis	rs875971	1	rs4718357	ENSG00000232559.3	GS1-124K5.12	7.37	7.86e-13	2.55e-10	0.3	0.32	Aortic root size;	chr7:66495891	chr7:66554588~66576923:-
THCA	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-7.37	7.87e-13	2.55e-10	-0.46	-0.32	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
THCA	cis	rs8113308	0.81	rs56029016	ENSG00000269235.1	ZNF350-AS1	7.37	7.87e-13	2.55e-10	0.48	0.32	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949209	chr19:51949134~51981367:+
THCA	cis	rs227932	0.764	rs76349338	ENSG00000234286.1	AC006026.13	-7.37	7.88e-13	2.55e-10	-0.61	-0.32	Schizophrenia;	chr7:23709138	chr7:23680195~23680786:-
THCA	cis	rs829883	0.664	rs829864	ENSG00000227825.4	SLC9A7P1	7.37	7.89e-13	2.56e-10	0.27	0.32	Colorectal adenoma (advanced);	chr12:98456417	chr12:98453835~98457145:-
THCA	cis	rs829883	0.664	rs1096148	ENSG00000227825.4	SLC9A7P1	7.37	7.89e-13	2.56e-10	0.27	0.32	Colorectal adenoma (advanced);	chr12:98457227	chr12:98453835~98457145:-
THCA	cis	rs829883	0.664	rs865509	ENSG00000227825.4	SLC9A7P1	7.37	7.89e-13	2.56e-10	0.27	0.32	Colorectal adenoma (advanced);	chr12:98460666	chr12:98453835~98457145:-
THCA	cis	rs829883	0.639	rs829898	ENSG00000227825.4	SLC9A7P1	7.37	7.89e-13	2.56e-10	0.27	0.32	Colorectal adenoma (advanced);	chr12:98463897	chr12:98453835~98457145:-
THCA	cis	rs910316	0.967	rs8007539	ENSG00000279594.1	RP11-950C14.10	-7.37	7.9e-13	2.56e-10	-0.3	-0.32	Height;	chr14:75198250	chr14:75011269~75012851:-
THCA	cis	rs853679	0.517	rs9295761	ENSG00000220721.1	OR1F12	7.37	7.91e-13	2.56e-10	0.45	0.32	Depression;	chr6:28180209	chr6:28073316~28074233:+
THCA	cis	rs7615952	0.932	rs13321217	ENSG00000241288.6	RP11-379B18.5	-7.37	7.91e-13	2.56e-10	-0.39	-0.32	Blood pressure (smoking interaction);	chr3:125912928	chr3:125827238~125916384:-
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000264538.5	SUZ12P1	7.37	7.91e-13	2.56e-10	0.33	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs7211776	ENSG00000264538.5	SUZ12P1	-7.37	7.93e-13	2.57e-10	-0.31	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30709299~30790908:+
THCA	cis	rs516805	0.748	rs155466	ENSG00000279453.1	RP3-425C14.4	-7.37	7.95e-13	2.57e-10	-0.37	-0.32	Lymphocyte counts;	chr6:122512286	chr6:122436789~122439223:-
THCA	cis	rs875971	0.929	rs34406470	ENSG00000232559.3	GS1-124K5.12	7.37	7.96e-13	2.58e-10	0.3	0.32	Aortic root size;	chr7:66464969	chr7:66554588~66576923:-
THCA	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	7.37	7.97e-13	2.58e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
THCA	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	7.37	7.97e-13	2.58e-10	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
THCA	cis	rs7267979	0.833	rs6138556	ENSG00000274414.1	RP5-965G21.4	-7.37	7.98e-13	2.58e-10	-0.39	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25239007~25245229:-
THCA	cis	rs4718428	1	rs4718421	ENSG00000273142.1	RP11-458F8.4	-7.37	7.99e-13	2.59e-10	-0.27	-0.32	Corneal structure;	chr7:66885313	chr7:66902857~66906297:+
THCA	cis	rs4948275	0.53	rs10994747	ENSG00000237233.2	TMEM26-AS1	7.36	8.02e-13	2.6e-10	0.43	0.32	Night sleep phenotypes;	chr10:61390164	chr10:61452639~61481956:+
THCA	cis	rs9473147	0.516	rs10948367	ENSG00000270761.1	RP11-385F7.1	-7.36	8.03e-13	2.6e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47617879	chr6:47477243~47477572:-
THCA	cis	rs6907340	0.517	rs6939160	ENSG00000227116.1	RP3-471C18.1	-7.36	8.04e-13	2.6e-10	-0.34	-0.32	Endometriosis;	chr6:19802086	chr6:19730427~19734567:-
THCA	cis	rs7208859	0.673	rs9912122	ENSG00000264538.5	SUZ12P1	-7.36	8.04e-13	2.6e-10	-0.31	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30709299~30790908:+
THCA	cis	rs4073416	0.647	rs11628196	ENSG00000276116.2	FUT8-AS1	7.36	8.05e-13	2.61e-10	0.33	0.32	N-glycan levels;	chr14:65424523	chr14:65411170~65412690:-
THCA	cis	rs9902453	0.934	rs11080120	ENSG00000264007.1	RP11-68I3.10	7.36	8.05e-13	2.61e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:30180003	chr17:29621617~29622254:-
THCA	cis	rs7851660	0.844	rs12342417	ENSG00000236130.1	PTCSC2	-7.36	8.06e-13	2.61e-10	-0.25	-0.32	Strep throat;	chr9:97876783	chr9:97805935~97810008:-
THCA	cis	rs7829975	0.777	rs6989926	ENSG00000253893.2	FAM85B	7.36	8.08e-13	2.61e-10	0.41	0.32	Mood instability;	chr8:8689803	chr8:8167819~8226614:-
THCA	cis	rs2712184	0.868	rs1548946	ENSG00000229352.1	AC007563.3	-7.36	8.09e-13	2.62e-10	-0.38	-0.32	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216800645	chr2:216799608~216805335:+
THCA	cis	rs2712184	0.935	rs2541387	ENSG00000229352.1	AC007563.3	-7.36	8.09e-13	2.62e-10	-0.38	-0.32	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216801451	chr2:216799608~216805335:+
THCA	cis	rs932287	0.651	rs1111010	ENSG00000254860.4	TMEM9B-AS1	-7.36	8.1e-13	2.62e-10	-0.35	-0.32	Colonoscopy-negative controls vs population controls;	chr11:9028388	chr11:8964675~8977527:+
THCA	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-7.36	8.1e-13	2.62e-10	-0.31	-0.32	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-7.36	8.1e-13	2.62e-10	-0.31	-0.32	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000263603.1	CTD-2349P21.5	-7.36	8.1e-13	2.62e-10	-0.57	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30729469~30731202:+
THCA	cis	rs172166	0.561	rs149971	ENSG00000219392.1	RP1-265C24.5	-7.36	8.11e-13	2.62e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28014374	chr6:28115628~28116551:+
THCA	cis	rs2712184	0.652	rs13000985	ENSG00000229352.1	AC007563.3	7.36	8.12e-13	2.63e-10	0.38	0.32	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216779638	chr2:216799608~216805335:+
THCA	cis	rs875971	0.83	rs4718358	ENSG00000232559.3	GS1-124K5.12	7.36	8.12e-13	2.63e-10	0.31	0.32	Aortic root size;	chr7:66508681	chr7:66554588~66576923:-
THCA	cis	rs9309473	0.607	rs58962779	ENSG00000163016.8	ALMS1P	7.36	8.13e-13	2.63e-10	0.43	0.32	Metabolite levels;	chr2:73328673	chr2:73644919~73685576:+
THCA	cis	rs9516	0.564	rs10898993	ENSG00000254974.1	RP11-702H23.2	7.36	8.13e-13	2.63e-10	0.34	0.32	Facial morphology (factor 15, philtrum width);	chr11:74463919	chr11:74485580~74486051:-
THCA	cis	rs9400467	0.528	rs445349	ENSG00000230177.1	RP5-1112D6.4	7.36	8.13e-13	2.63e-10	0.26	0.32	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111277932~111278742:+
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000263603.1	CTD-2349P21.5	-7.36	8.15e-13	2.64e-10	-0.57	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000263603.1	CTD-2349P21.5	-7.36	8.15e-13	2.64e-10	-0.57	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30729469~30731202:+
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000273142.1	RP11-458F8.4	-7.36	8.15e-13	2.64e-10	-0.27	-0.32	Corneal structure;	chr7:66925268	chr7:66902857~66906297:+
THCA	cis	rs75422866	0.51	rs73105819	ENSG00000274902.1	RP1-197B17.4	7.36	8.16e-13	2.64e-10	0.67	0.32	Pneumonia;	chr12:47727190	chr12:47731908~47732351:+
THCA	cis	rs1150668	0.799	rs1150705	ENSG00000219392.1	RP1-265C24.5	-7.36	8.17e-13	2.64e-10	-0.35	-0.32	Pubertal anthropometrics;	chr6:28226008	chr6:28115628~28116551:+
THCA	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-7.36	8.17e-13	2.64e-10	-0.37	-0.32	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
THCA	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-7.36	8.17e-13	2.64e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
THCA	cis	rs34381861	0.52	rs74382390	ENSG00000260886.1	TAT-AS1	7.36	8.19e-13	2.65e-10	0.56	0.32	Post bronchodilator FEV1;	chr16:71424623	chr16:71565789~71578187:+
THCA	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	7.36	8.2e-13	2.65e-10	0.44	0.32	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000220721.1	OR1F12	7.36	8.2e-13	2.65e-10	0.45	0.32	Depression;	chr6:28143758	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000220721.1	OR1F12	7.36	8.2e-13	2.65e-10	0.45	0.32	Depression;	chr6:28144784	chr6:28073316~28074233:+
THCA	cis	rs116139393	0.656	rs10244591	ENSG00000187953.9	PMS2CL	-7.36	8.21e-13	2.65e-10	-0.4	-0.32	Alzheimer's disease (APOE e4 interaction);	chr7:6731467	chr7:6710128~6753862:+
THCA	cis	rs910316	0.737	rs175499	ENSG00000279594.1	RP11-950C14.10	-7.36	8.22e-13	2.66e-10	-0.29	-0.32	Height;	chr14:75069224	chr14:75011269~75012851:-
THCA	cis	rs875971	0.929	rs6970860	ENSG00000232559.3	GS1-124K5.12	7.36	8.22e-13	2.66e-10	0.3	0.32	Aortic root size;	chr7:66511647	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6957199	ENSG00000232559.3	GS1-124K5.12	7.36	8.22e-13	2.66e-10	0.3	0.32	Aortic root size;	chr7:66513532	chr7:66554588~66576923:-
THCA	cis	rs4713118	0.512	rs2622319	ENSG00000280107.1	AL022393.9	-7.36	8.22e-13	2.66e-10	-0.35	-0.32	Parkinson's disease;	chr6:28152623	chr6:28170845~28172521:+
THCA	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	7.36	8.24e-13	2.66e-10	0.49	0.32	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
THCA	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	7.36	8.26e-13	2.67e-10	0.6	0.32	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
THCA	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-7.36	8.27e-13	2.67e-10	-0.32	-0.32	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
THCA	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-7.36	8.28e-13	2.67e-10	-0.35	-0.32	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-7.36	8.28e-13	2.67e-10	-0.35	-0.32	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
THCA	cis	rs4072705	1	rs4836980	ENSG00000224020.1	MIR181A2HG	-7.36	8.28e-13	2.68e-10	-0.29	-0.32	Menarche (age at onset);	chr9:124576884	chr9:124658467~124698631:+
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000213640.3	EEF1DP4	-7.36	8.28e-13	2.68e-10	-0.38	-0.32	Calcium levels;	chr7:65800652	chr7:64862999~64864370:+
THCA	cis	rs2439831	0.571	rs689883	ENSG00000275601.1	AC011330.13	-7.36	8.29e-13	2.68e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43520398	chr15:43642389~43643023:-
THCA	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-7.36	8.31e-13	2.68e-10	-0.26	-0.32	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
THCA	cis	rs71636778	0.509	rs35962879	ENSG00000260063.1	RP5-968P14.2	-7.36	8.32e-13	2.69e-10	-0.58	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26956965	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs61457762	ENSG00000260063.1	RP5-968P14.2	-7.36	8.32e-13	2.69e-10	-0.58	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26957666	chr1:26692132~26694131:-
THCA	cis	rs75422866	0.51	rs73105818	ENSG00000274902.1	RP1-197B17.4	7.36	8.33e-13	2.69e-10	0.67	0.32	Pneumonia;	chr12:47726538	chr12:47731908~47732351:+
THCA	cis	rs9902453	1	rs6505158	ENSG00000264007.1	RP11-68I3.10	-7.36	8.34e-13	2.69e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30076330	chr17:29621617~29622254:-
THCA	cis	rs2115630	0.653	rs61394864	ENSG00000275120.1	RP11-182J1.17	-7.36	8.35e-13	2.7e-10	-0.33	-0.32	P wave terminal force;	chr15:84626943	chr15:84599434~84606463:-
THCA	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	7.36	8.36e-13	2.7e-10	0.41	0.32	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
THCA	cis	rs853679	0.585	rs201001	ENSG00000219392.1	RP1-265C24.5	-7.36	8.36e-13	2.7e-10	-0.45	-0.32	Depression;	chr6:27841121	chr6:28115628~28116551:+
THCA	cis	rs853679	0.585	rs201000	ENSG00000219392.1	RP1-265C24.5	-7.36	8.36e-13	2.7e-10	-0.45	-0.32	Depression;	chr6:27841381	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.539	rs200988	ENSG00000219392.1	RP1-265C24.5	-7.36	8.36e-13	2.7e-10	-0.39	-0.32	Parkinson's disease;	chr6:27851575	chr6:28115628~28116551:+
THCA	cis	rs200986	1	rs200986	ENSG00000219392.1	RP1-265C24.5	-7.36	8.36e-13	2.7e-10	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28115628~28116551:+
THCA	cis	rs2839186	0.771	rs13049175	ENSG00000239415.1	AP001469.9	-7.36	8.37e-13	2.7e-10	-0.33	-0.32	Testicular germ cell tumor;	chr21:46221412	chr21:46251549~46254133:-
THCA	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-7.36	8.39e-13	2.71e-10	-0.32	-0.32	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
THCA	cis	rs860295	0.58	rs7528441	ENSG00000225855.5	RUSC1-AS1	7.36	8.39e-13	2.71e-10	0.23	0.32	Body mass index;	chr1:155873465	chr1:155316863~155324176:-
THCA	cis	rs17684571	0.938	rs71564849	ENSG00000231441.1	RP11-472M19.2	7.36	8.4e-13	2.71e-10	0.41	0.32	Schizophrenia;	chr6:56709421	chr6:56844002~56864078:+
THCA	cis	rs7727544	0.606	rs2631360	ENSG00000224431.1	AC063976.7	7.36	8.4e-13	2.71e-10	0.28	0.32	Blood metabolite levels;	chr5:132371737	chr5:132199456~132203487:+
THCA	cis	rs11662586	0.517	rs11663082	ENSG00000261126.6	RP11-795F19.1	7.36	8.41e-13	2.71e-10	0.27	0.32	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79953494	chr18:80046900~80095482:+
THCA	cis	rs11662586	0.517	rs11662894	ENSG00000261126.6	RP11-795F19.1	7.36	8.41e-13	2.71e-10	0.27	0.32	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79953591	chr18:80046900~80095482:+
THCA	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-7.36	8.41e-13	2.71e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-7.36	8.41e-13	2.71e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-7.36	8.41e-13	2.71e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-7.36	8.41e-13	2.71e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-7.36	8.41e-13	2.71e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-7.36	8.41e-13	2.71e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	7.36	8.41e-13	2.71e-10	0.51	0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
THCA	cis	rs9402743	0.671	rs2327650	ENSG00000231028.7	LINC00271	-7.36	8.42e-13	2.72e-10	-0.26	-0.32	Systemic lupus erythematosus;	chr6:135630279	chr6:135497801~135716055:+
THCA	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	7.36	8.43e-13	2.72e-10	0.49	0.32	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	7.36	8.43e-13	2.72e-10	0.49	0.32	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
THCA	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-7.36	8.44e-13	2.72e-10	-0.47	-0.32	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
THCA	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	7.36	8.44e-13	2.72e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
THCA	cis	rs2562456	0.755	rs2914646	ENSG00000268555.1	RP11-678G14.3	-7.36	8.45e-13	2.72e-10	-0.46	-0.32	Pain;	chr19:21454359	chr19:21570822~21587322:-
THCA	cis	rs6762	0.719	rs28655651	ENSG00000279672.1	CMB9-55F22.1	7.36	8.46e-13	2.73e-10	0.36	0.32	Mean platelet volume;	chr11:837121	chr11:779617~780755:+
THCA	cis	rs6762	0.748	rs1130663	ENSG00000279672.1	CMB9-55F22.1	7.36	8.46e-13	2.73e-10	0.36	0.32	Mean platelet volume;	chr11:837582	chr11:779617~780755:+
THCA	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	7.36	8.48e-13	2.73e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	7.36	8.48e-13	2.73e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	7.36	8.48e-13	2.73e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	7.36	8.48e-13	2.73e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
THCA	cis	rs728616	0.51	rs61860860	ENSG00000225484.5	NUTM2B-AS1	-7.36	8.48e-13	2.73e-10	-0.48	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79998816	chr10:79663088~79826594:-
THCA	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-7.36	8.5e-13	2.74e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
THCA	cis	rs2439831	0.85	rs2957637	ENSG00000249839.1	AC011330.5	-7.36	8.5e-13	2.74e-10	-0.5	-0.32	Lung cancer in ever smokers;	chr15:43658920	chr15:43663654~43684339:-
THCA	cis	rs9890032	0.532	rs1808257	ENSG00000263531.1	RP13-753N3.1	7.36	8.53e-13	2.75e-10	0.43	0.32	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30863921~30864940:-
THCA	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-7.36	8.54e-13	2.75e-10	-0.31	-0.32	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
THCA	cis	rs2439831	0.867	rs11856184	ENSG00000249839.1	AC011330.5	-7.36	8.54e-13	2.75e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43626964	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2927072	ENSG00000249839.1	AC011330.5	-7.36	8.54e-13	2.75e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43630200	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2920781	ENSG00000249839.1	AC011330.5	-7.36	8.54e-13	2.75e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43632484	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.764	rs2447193	ENSG00000249839.1	AC011330.5	-7.36	8.54e-13	2.75e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43637535	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2447211	ENSG00000249839.1	AC011330.5	-7.36	8.54e-13	2.75e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43644153	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.571	rs2470121	ENSG00000249839.1	AC011330.5	-7.36	8.54e-13	2.75e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43645420	chr15:43663654~43684339:-
THCA	cis	rs5771242	0.776	rs6010198	ENSG00000273253.2	RP3-402G11.26	7.36	8.54e-13	2.75e-10	0.36	0.32	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50172199	chr22:50199090~50200837:-
THCA	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	7.35	8.57e-13	2.76e-10	0.49	0.32	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
THCA	cis	rs7302981	0.746	rs706793	ENSG00000272368.2	RP4-605O3.4	7.35	8.58e-13	2.77e-10	0.2	0.32	Systolic blood pressure;	chr12:50073986	chr12:50112197~50165618:+
THCA	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-7.35	8.59e-13	2.77e-10	-0.35	-0.32	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-7.35	8.59e-13	2.77e-10	-0.35	-0.32	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
THCA	cis	rs4820539	0.902	rs4822359	ENSG00000221069.1	AC000029.1	-7.35	8.59e-13	2.77e-10	-0.38	-0.32	Bone mineral density;	chr22:23132785	chr22:23136620~23136710:+
THCA	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	7.35	8.6e-13	2.77e-10	0.38	0.32	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
THCA	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	7.35	8.6e-13	2.77e-10	0.37	0.32	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
THCA	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	7.35	8.61e-13	2.77e-10	0.4	0.32	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
THCA	cis	rs12655019	0.92	rs3756586	ENSG00000271828.1	CTD-2310F14.1	7.35	8.61e-13	2.77e-10	0.73	0.32	Breast cancer (early onset);	chr5:56921369	chr5:56927874~56929573:+
THCA	cis	rs875971	1	rs3735148	ENSG00000232559.3	GS1-124K5.12	7.35	8.61e-13	2.78e-10	0.3	0.32	Aortic root size;	chr7:66506022	chr7:66554588~66576923:-
THCA	cis	rs17684571	0.7	rs34966024	ENSG00000231441.1	RP11-472M19.2	7.35	8.62e-13	2.78e-10	0.4	0.32	Schizophrenia;	chr6:56766213	chr6:56844002~56864078:+
THCA	cis	rs7847628	0.551	rs10818476	ENSG00000270917.1	RP11-27I1.6	-7.35	8.62e-13	2.78e-10	-0.44	-0.32	Birth weight;	chr9:120809760	chr9:120812475~120812845:-
THCA	cis	rs4073416	0.679	rs2002692	ENSG00000276116.2	FUT8-AS1	7.35	8.62e-13	2.78e-10	0.33	0.32	N-glycan levels;	chr14:65432736	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.679	rs11620749	ENSG00000276116.2	FUT8-AS1	7.35	8.62e-13	2.78e-10	0.33	0.32	N-glycan levels;	chr14:65433086	chr14:65411170~65412690:-
THCA	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-7.35	8.63e-13	2.78e-10	-0.4	-0.32	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
THCA	cis	rs7786410	1	rs7786410	ENSG00000275875.1	RP11-613E4.5	7.35	8.63e-13	2.78e-10	0.51	0.32	Age-related hearing impairment;	chr7:55854630	chr7:55741525~55741869:+
THCA	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	7.35	8.64e-13	2.79e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
THCA	cis	rs853679	1	rs1679709	ENSG00000280107.1	AL022393.9	7.35	8.67e-13	2.79e-10	0.45	0.32	Depression;	chr6:28260564	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs1778511	ENSG00000280107.1	AL022393.9	7.35	8.67e-13	2.79e-10	0.45	0.32	Depression;	chr6:28261633	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs11965538	ENSG00000280107.1	AL022393.9	-7.35	8.67e-13	2.79e-10	-0.45	-0.32	Depression;	chr6:28272137	chr6:28170845~28172521:+
THCA	cis	rs853679	0.882	rs2743555	ENSG00000280107.1	AL022393.9	-7.35	8.67e-13	2.79e-10	-0.45	-0.32	Depression;	chr6:28273304	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs1419183	ENSG00000280107.1	AL022393.9	-7.35	8.67e-13	2.79e-10	-0.45	-0.32	Depression;	chr6:28275017	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs6901575	ENSG00000280107.1	AL022393.9	-7.35	8.67e-13	2.79e-10	-0.45	-0.32	Depression;	chr6:28283207	chr6:28170845~28172521:+
THCA	cis	rs453301	0.631	rs11779804	ENSG00000253893.2	FAM85B	7.35	8.68e-13	2.8e-10	0.44	0.32	Joint mobility (Beighton score);	chr8:8940442	chr8:8167819~8226614:-
THCA	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-7.35	8.68e-13	2.8e-10	-0.41	-0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
THCA	cis	rs6844153	0.941	rs75656258	ENSG00000240005.4	RP11-293A21.1	-7.35	8.68e-13	2.8e-10	-0.43	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26843577	chr4:26859806~26860599:-
THCA	cis	rs2929278	0.617	rs533143	ENSG00000166763.7	STRCP1	7.35	8.68e-13	2.8e-10	0.35	0.32	Schizophrenia;	chr15:43896656	chr15:43699488~43718184:-
THCA	cis	rs6762	0.748	rs7929032	ENSG00000279672.1	CMB9-55F22.1	7.35	8.69e-13	2.8e-10	0.36	0.32	Mean platelet volume;	chr11:839078	chr11:779617~780755:+
THCA	cis	rs6762	0.748	rs7936838	ENSG00000279672.1	CMB9-55F22.1	7.35	8.69e-13	2.8e-10	0.36	0.32	Mean platelet volume;	chr11:839093	chr11:779617~780755:+
THCA	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-7.35	8.7e-13	2.8e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
THCA	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-7.35	8.7e-13	2.8e-10	-0.31	-0.32	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
THCA	cis	rs3847687	1	rs11061303	ENSG00000279128.1	RP11-76C10.4	7.35	8.7e-13	2.8e-10	0.36	0.32	Longevity;	chr12:131041777	chr12:131022769~131024741:-
THCA	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-7.35	8.71e-13	2.81e-10	-0.35	-0.32	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
THCA	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	7.35	8.71e-13	2.81e-10	0.4	0.32	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
THCA	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	7.35	8.71e-13	2.81e-10	0.42	0.32	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
THCA	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	7.35	8.71e-13	2.81e-10	0.19	0.32	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
THCA	cis	rs2439831	0.702	rs3784275	ENSG00000249839.1	AC011330.5	-7.35	8.73e-13	2.81e-10	-0.54	-0.32	Lung cancer in ever smokers;	chr15:43799188	chr15:43663654~43684339:-
THCA	cis	rs4713118	0.513	rs149878	ENSG00000219392.1	RP1-265C24.5	-7.35	8.73e-13	2.81e-10	-0.38	-0.32	Parkinson's disease;	chr6:27910960	chr6:28115628~28116551:+
THCA	cis	rs2712184	0.967	rs2541385	ENSG00000229352.1	AC007563.3	-7.35	8.73e-13	2.81e-10	-0.38	-0.32	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216804872	chr2:216799608~216805335:+
THCA	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-7.35	8.74e-13	2.81e-10	-0.31	-0.32	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
THCA	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	7.35	8.74e-13	2.82e-10	0.3	0.32	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
THCA	cis	rs11051970	1	rs6488051	ENSG00000274964.1	RP11-817I4.1	-7.35	8.74e-13	2.82e-10	-0.36	-0.32	Response to tocilizumab in rheumatoid arthritis;	chr12:32379799	chr12:32339368~32340724:+
THCA	cis	rs853679	0.517	rs868987	ENSG00000220721.1	OR1F12	-7.35	8.74e-13	2.82e-10	-0.44	-0.32	Depression;	chr6:28142370	chr6:28073316~28074233:+
THCA	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	7.35	8.76e-13	2.82e-10	0.41	0.32	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
THCA	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-7.35	8.76e-13	2.82e-10	-0.37	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
THCA	cis	rs9326248	0.861	rs4938348	ENSG00000280143.1	AP000892.6	7.35	8.76e-13	2.82e-10	0.45	0.32	Blood protein levels;	chr11:117151161	chr11:117204967~117210292:+
THCA	cis	rs2712184	1	rs2712184	ENSG00000229352.1	AC007563.3	-7.35	8.76e-13	2.82e-10	-0.38	-0.32	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216818056	chr2:216799608~216805335:+
THCA	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-7.35	8.77e-13	2.82e-10	-0.35	-0.32	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-7.35	8.78e-13	2.83e-10	-0.35	-0.32	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
THCA	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	7.35	8.78e-13	2.83e-10	0.37	0.32	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
THCA	cis	rs9902453	1	rs60967688	ENSG00000264007.1	RP11-68I3.10	7.35	8.79e-13	2.83e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:30110034	chr17:29621617~29622254:-
THCA	cis	rs6907340	0.517	rs9465533	ENSG00000227116.1	RP3-471C18.1	-7.35	8.8e-13	2.83e-10	-0.34	-0.32	Endometriosis;	chr6:19801477	chr6:19730427~19734567:-
THCA	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	7.35	8.8e-13	2.83e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
THCA	cis	rs6762	0.692	rs7928925	ENSG00000279672.1	CMB9-55F22.1	7.35	8.81e-13	2.83e-10	0.36	0.32	Mean platelet volume;	chr11:839155	chr11:779617~780755:+
THCA	cis	rs6762	0.719	rs7936806	ENSG00000279672.1	CMB9-55F22.1	7.35	8.81e-13	2.83e-10	0.36	0.32	Mean platelet volume;	chr11:839186	chr11:779617~780755:+
THCA	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-7.35	8.82e-13	2.84e-10	-0.35	-0.32	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
THCA	cis	rs7131987	0.65	rs3782509	ENSG00000275476.1	RP11-996F15.4	-7.35	8.82e-13	2.84e-10	-0.33	-0.32	QT interval;	chr12:29300845	chr12:29277397~29277882:-
THCA	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	7.35	8.83e-13	2.84e-10	0.34	0.32	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
THCA	cis	rs6745190	0.953	rs4510177	ENSG00000236153.1	AC104076.3	7.35	8.84e-13	2.84e-10	0.38	0.32	White blood cell count;	chr2:180976518	chr2:180979427~180980090:-
THCA	cis	rs713477	0.712	rs72717779	ENSG00000258413.1	RP11-665C16.6	7.35	8.85e-13	2.85e-10	0.42	0.32	Pediatric bone mineral content (femoral neck);	chr14:55426722	chr14:55262767~55272075:-
THCA	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-7.35	8.85e-13	2.85e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
THCA	cis	rs73219805	0.536	rs17055142	ENSG00000228451.3	SDAD1P1	7.35	8.85e-13	2.85e-10	0.63	0.32	Schizophrenia;	chr8:26344085	chr8:26379259~26382953:-
THCA	cis	rs7302981	0.899	rs4883481	ENSG00000272368.2	RP4-605O3.4	-7.35	8.86e-13	2.85e-10	-0.19	-0.32	Systolic blood pressure;	chr12:50180528	chr12:50112197~50165618:+
THCA	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-7.35	8.86e-13	2.85e-10	-0.35	-0.32	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
THCA	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-7.35	8.86e-13	2.85e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-7.35	8.86e-13	2.85e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
THCA	cis	rs6600671	1	rs12047116	ENSG00000223345.3	HIST2H2BA	7.35	8.87e-13	2.85e-10	0.35	0.32	Hip geometry;	chr1:121443912	chr1:121108210~121117257:-
THCA	cis	rs6600671	0.967	rs11249347	ENSG00000223345.3	HIST2H2BA	7.35	8.87e-13	2.85e-10	0.35	0.32	Hip geometry;	chr1:121446489	chr1:121108210~121117257:-
THCA	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	7.35	8.87e-13	2.85e-10	0.31	0.32	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
THCA	cis	rs9549328	0.879	rs12428058	ENSG00000267868.1	RP11-120K24.3	7.35	8.87e-13	2.85e-10	0.33	0.32	Systolic blood pressure;	chr13:112982190	chr13:112964835~112966131:-
THCA	cis	rs875971	0.964	rs6978429	ENSG00000232559.3	GS1-124K5.12	7.35	8.88e-13	2.86e-10	0.3	0.32	Aortic root size;	chr7:66494889	chr7:66554588~66576923:-
THCA	cis	rs875971	0.929	rs12535036	ENSG00000232559.3	GS1-124K5.12	7.35	8.88e-13	2.86e-10	0.3	0.32	Aortic root size;	chr7:66499076	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs12698523	ENSG00000232559.3	GS1-124K5.12	7.35	8.88e-13	2.86e-10	0.3	0.32	Aortic root size;	chr7:66503126	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6970030	ENSG00000232559.3	GS1-124K5.12	7.35	8.88e-13	2.86e-10	0.3	0.32	Aortic root size;	chr7:66503692	chr7:66554588~66576923:-
THCA	cis	rs875971	0.928	rs6970357	ENSG00000232559.3	GS1-124K5.12	7.35	8.88e-13	2.86e-10	0.3	0.32	Aortic root size;	chr7:66503891	chr7:66554588~66576923:-
THCA	cis	rs7674212	0.772	rs13113099	ENSG00000251288.2	RP11-10L12.2	-7.35	8.88e-13	2.86e-10	-0.43	-0.32	Type 2 diabetes;	chr4:103052965	chr4:102751401~102752641:+
THCA	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-7.35	8.89e-13	2.86e-10	-0.35	-0.32	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-7.35	8.89e-13	2.86e-10	-0.35	-0.32	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	7.35	8.89e-13	2.86e-10	0.35	0.32	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-7.35	8.89e-13	2.86e-10	-0.35	-0.32	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
THCA	cis	rs6496044	0.547	rs7173125	ENSG00000259295.5	CSPG4P12	-7.35	8.89e-13	2.86e-10	-0.42	-0.32	Interstitial lung disease;	chr15:85512214	chr15:85191438~85213905:+
THCA	cis	rs9402743	0.671	rs4896158	ENSG00000231028.7	LINC00271	-7.35	8.9e-13	2.86e-10	-0.26	-0.32	Systemic lupus erythematosus;	chr6:135630087	chr6:135497801~135716055:+
THCA	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	7.35	8.92e-13	2.87e-10	0.7	0.32	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs117388682	ENSG00000274902.1	RP1-197B17.4	7.35	8.92e-13	2.87e-10	0.7	0.32	Pneumonia;	chr12:47599713	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	7.35	8.92e-13	2.87e-10	0.7	0.32	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	7.35	8.92e-13	2.87e-10	0.7	0.32	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
THCA	cis	rs4820539	1	rs885965	ENSG00000221069.1	AC000029.1	-7.35	8.92e-13	2.87e-10	-0.38	-0.32	Bone mineral density;	chr22:23119238	chr22:23136620~23136710:+
THCA	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	7.35	8.93e-13	2.87e-10	0.3	0.32	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
THCA	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	7.35	8.93e-13	2.87e-10	0.3	0.32	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
THCA	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	7.35	8.93e-13	2.87e-10	0.3	0.32	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
THCA	cis	rs17767294	0.612	rs9461425	ENSG00000280107.1	AL022393.9	-7.35	8.93e-13	2.87e-10	-0.52	-0.32	Parkinson's disease;	chr6:27951910	chr6:28170845~28172521:+
THCA	cis	rs6539288	0.901	rs2041894	ENSG00000260329.1	RP11-412D9.4	-7.35	8.96e-13	2.88e-10	-0.29	-0.32	Total body bone mineral density;	chr12:106956389	chr12:106954029~106955497:-
THCA	cis	rs7615952	0.799	rs13315434	ENSG00000241288.6	RP11-379B18.5	-7.35	8.96e-13	2.88e-10	-0.39	-0.32	Blood pressure (smoking interaction);	chr3:125922551	chr3:125827238~125916384:-
THCA	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	7.35	9e-13	2.89e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
THCA	cis	rs7942368	0.878	rs1866843	ENSG00000254761.1	RP11-672A2.1	7.35	9e-13	2.89e-10	0.45	0.32	Endometriosis;	chr11:76778292	chr11:76712396~76719608:-
THCA	cis	rs741668	0.759	rs3736943	ENSG00000235903.6	CPB2-AS1	7.35	9.01e-13	2.9e-10	0.42	0.32	Cerebrospinal fluid clusterin levels;	chr13:46044936	chr13:46052806~46113332:+
THCA	cis	rs741668	0.795	rs1041167	ENSG00000235903.6	CPB2-AS1	7.35	9.01e-13	2.9e-10	0.42	0.32	Cerebrospinal fluid clusterin levels;	chr13:46046000	chr13:46052806~46113332:+
THCA	cis	rs741668	0.795	rs17600555	ENSG00000235903.6	CPB2-AS1	7.35	9.01e-13	2.9e-10	0.42	0.32	Cerebrospinal fluid clusterin levels;	chr13:46049527	chr13:46052806~46113332:+
THCA	cis	rs741668	0.795	rs7324938	ENSG00000235903.6	CPB2-AS1	7.35	9.01e-13	2.9e-10	0.42	0.32	Cerebrospinal fluid clusterin levels;	chr13:46049937	chr13:46052806~46113332:+
THCA	cis	rs11148252	0.553	rs9536236	ENSG00000278238.1	RP11-245D16.4	-7.35	9.01e-13	2.9e-10	-0.37	-0.32	Lewy body disease;	chr13:52680877	chr13:52454775~52455331:-
THCA	cis	rs7942368	0.887	rs10899282	ENSG00000254761.1	RP11-672A2.1	7.35	9.01e-13	2.9e-10	0.46	0.32	Endometriosis;	chr11:76793654	chr11:76712396~76719608:-
THCA	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	7.35	9.01e-13	2.9e-10	0.39	0.32	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
THCA	cis	rs875971	0.965	rs6971509	ENSG00000232559.3	GS1-124K5.12	-7.35	9.02e-13	2.9e-10	-0.3	-0.32	Aortic root size;	chr7:66249983	chr7:66554588~66576923:-
THCA	cis	rs2712184	0.967	rs7587010	ENSG00000229352.1	AC007563.3	-7.35	9.03e-13	2.9e-10	-0.38	-0.32	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216810266	chr2:216799608~216805335:+
THCA	cis	rs74233809	1	rs11191582	ENSG00000213277.3	MARCKSL1P1	7.35	9.06e-13	2.91e-10	0.54	0.32	Birth weight;	chr10:103153896	chr10:103175554~103176094:+
THCA	cis	rs728616	0.867	rs1054054	ENSG00000225484.5	NUTM2B-AS1	-7.35	9.06e-13	2.91e-10	-0.65	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61859766	ENSG00000225484.5	NUTM2B-AS1	-7.35	9.06e-13	2.91e-10	-0.65	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:79663088~79826594:-
THCA	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	7.35	9.07e-13	2.91e-10	0.37	0.32	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
THCA	cis	rs3745672	1	rs624976	ENSG00000219665.7	CTD-2006C1.2	7.35	9.09e-13	2.92e-10	0.67	0.32	Multiple sclerosis;	chr19:11999423	chr19:11987617~12046275:+
THCA	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-7.35	9.1e-13	2.92e-10	-0.31	-0.32	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
THCA	cis	rs8114671	0.527	rs2295352	ENSG00000269202.1	RP4-614O4.12	7.35	9.11e-13	2.92e-10	0.27	0.32	Height;	chr20:34732251	chr20:35201747~35203288:-
THCA	cis	rs4073416	0.598	rs34357872	ENSG00000276116.2	FUT8-AS1	7.35	9.12e-13	2.93e-10	0.33	0.32	N-glycan levels;	chr14:65597197	chr14:65411170~65412690:-
THCA	cis	rs910316	0.737	rs108622	ENSG00000279594.1	RP11-950C14.10	-7.35	9.13e-13	2.93e-10	-0.29	-0.32	Height;	chr14:75015205	chr14:75011269~75012851:-
THCA	cis	rs910316	0.737	rs424120	ENSG00000279594.1	RP11-950C14.10	-7.35	9.13e-13	2.93e-10	-0.29	-0.32	Height;	chr14:75016125	chr14:75011269~75012851:-
THCA	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	7.35	9.15e-13	2.94e-10	0.49	0.32	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
THCA	cis	rs9475752	0.552	rs13190784	ENSG00000231441.1	RP11-472M19.2	7.35	9.15e-13	2.94e-10	0.38	0.32	Menarche (age at onset);	chr6:56868254	chr6:56844002~56864078:+
THCA	cis	rs4820539	0.933	rs2267004	ENSG00000221069.1	AC000029.1	-7.34	9.17e-13	2.95e-10	-0.38	-0.32	Bone mineral density;	chr22:23117676	chr22:23136620~23136710:+
THCA	cis	rs6723226	0.806	rs2249109	ENSG00000276334.1	AL133243.1	7.34	9.18e-13	2.95e-10	0.36	0.32	Intelligence (multi-trait analysis);	chr2:32525812	chr2:32521927~32523547:+
THCA	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	7.34	9.18e-13	2.95e-10	0.19	0.32	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
THCA	cis	rs4073416	0.842	rs4080329	ENSG00000276116.2	FUT8-AS1	-7.34	9.18e-13	2.95e-10	-0.34	-0.32	N-glycan levels;	chr14:65766772	chr14:65411170~65412690:-
THCA	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	7.34	9.19e-13	2.95e-10	0.45	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
THCA	cis	rs7760535	0.826	rs10872068	ENSG00000230177.1	RP5-1112D6.4	7.34	9.19e-13	2.95e-10	0.26	0.32	Metabolic traits;	chr6:111528657	chr6:111277932~111278742:+
THCA	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-7.34	9.2e-13	2.95e-10	-0.26	-0.32	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
THCA	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	7.34	9.22e-13	2.96e-10	0.48	0.32	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
THCA	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	7.34	9.25e-13	2.97e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	7.34	9.25e-13	2.97e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	7.34	9.25e-13	2.97e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	7.34	9.25e-13	2.97e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	7.34	9.25e-13	2.97e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	7.34	9.25e-13	2.97e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	7.34	9.25e-13	2.97e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	7.34	9.25e-13	2.97e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
THCA	cis	rs1850744	0.826	rs9291607	ENSG00000250942.1	ENPP7P11	-7.34	9.25e-13	2.97e-10	-0.4	-0.32	Economic and political preferences;	chr4:9707174	chr4:9677308~9677934:+
THCA	cis	rs11148252	0.564	rs2296350	ENSG00000278238.1	RP11-245D16.4	-7.34	9.26e-13	2.97e-10	-0.35	-0.32	Lewy body disease;	chr13:52135908	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.538	rs2296348	ENSG00000278238.1	RP11-245D16.4	-7.34	9.26e-13	2.97e-10	-0.35	-0.32	Lewy body disease;	chr13:52136000	chr13:52454775~52455331:-
THCA	cis	rs651907	0.557	rs59596156	ENSG00000256628.3	ZBTB11-AS1	7.34	9.27e-13	2.98e-10	0.38	0.32	Colorectal cancer;	chr3:101675373	chr3:101676475~101679217:+
THCA	cis	rs7615952	0.641	rs4490307	ENSG00000171084.14	FAM86JP	7.34	9.27e-13	2.98e-10	0.38	0.32	Blood pressure (smoking interaction);	chr3:125993833	chr3:125916620~125930024:+
THCA	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-7.34	9.28e-13	2.98e-10	-0.31	-0.32	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
THCA	cis	rs7267979	0.868	rs6138546	ENSG00000274414.1	RP5-965G21.4	-7.34	9.28e-13	2.98e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25239007~25245229:-
THCA	cis	rs4718428	0.924	rs6971897	ENSG00000273142.1	RP11-458F8.4	-7.34	9.29e-13	2.98e-10	-0.26	-0.32	Corneal structure;	chr7:66947787	chr7:66902857~66906297:+
THCA	cis	rs516805	0.748	rs572261	ENSG00000279453.1	RP3-425C14.4	-7.34	9.3e-13	2.99e-10	-0.36	-0.32	Lymphocyte counts;	chr6:122408877	chr6:122436789~122439223:-
THCA	cis	rs12681366	1	rs10956911	ENSG00000253704.1	RP11-267M23.4	7.34	9.31e-13	2.99e-10	0.32	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94371647	chr8:94553722~94569745:+
THCA	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-7.34	9.32e-13	2.99e-10	-0.4	-0.32	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
THCA	cis	rs7942368	1	rs10899280	ENSG00000254632.1	RP11-21L23.4	7.34	9.32e-13	2.99e-10	0.46	0.32	Endometriosis;	chr11:76785693	chr11:76759916~76768223:-
THCA	cis	rs9549328	0.8	rs9549326	ENSG00000267868.1	RP11-120K24.3	7.34	9.33e-13	2.99e-10	0.33	0.32	Systolic blood pressure;	chr13:112976139	chr13:112964835~112966131:-
THCA	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-7.34	9.33e-13	2.99e-10	-0.33	-0.32	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
THCA	cis	rs7942368	0.941	rs10899283	ENSG00000254761.1	RP11-672A2.1	7.34	9.33e-13	2.99e-10	0.46	0.32	Endometriosis;	chr11:76794158	chr11:76712396~76719608:-
THCA	cis	rs5758659	0.716	rs5758661	ENSG00000182057.4	OGFRP1	7.34	9.33e-13	3e-10	0.36	0.32	Cognitive function;	chr22:42228439	chr22:42269753~42275196:+
THCA	cis	rs42490	0.664	rs39767	ENSG00000251136.7	RP11-37B2.1	-7.34	9.34e-13	3e-10	-0.27	-0.32	Leprosy;	chr8:89807770	chr8:89609409~89757727:-
THCA	cis	rs6840258	1	rs72667753	ENSG00000251411.1	RP11-397E7.4	-7.34	9.35e-13	3e-10	-0.38	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019860	chr4:86913266~86914817:-
THCA	cis	rs9473147	0.543	rs4711878	ENSG00000270761.1	RP11-385F7.1	-7.34	9.37e-13	3.01e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47488382	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs6931478	ENSG00000270761.1	RP11-385F7.1	-7.34	9.37e-13	3.01e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47494177	chr6:47477243~47477572:-
THCA	cis	rs9369695	0.881	rs9349409	ENSG00000270761.1	RP11-385F7.1	-7.34	9.37e-13	3.01e-10	-0.25	-0.32	Reticulocyte count;	chr6:47495390	chr6:47477243~47477572:-
THCA	cis	rs9369695	0.842	rs9395262	ENSG00000270761.1	RP11-385F7.1	-7.34	9.37e-13	3.01e-10	-0.25	-0.32	Reticulocyte count;	chr6:47497531	chr6:47477243~47477572:-
THCA	cis	rs7727544	0.526	rs17516457	ENSG00000224431.1	AC063976.7	7.34	9.38e-13	3.01e-10	0.29	0.32	Blood metabolite levels;	chr5:132254694	chr5:132199456~132203487:+
THCA	cis	rs9400467	0.508	rs11153293	ENSG00000230177.1	RP5-1112D6.4	-7.34	9.4e-13	3.01e-10	-0.26	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs11756643	ENSG00000230177.1	RP5-1112D6.4	-7.34	9.4e-13	3.01e-10	-0.26	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111277932~111278742:+
THCA	cis	rs9549328	0.842	rs6577024	ENSG00000267868.1	RP11-120K24.3	7.34	9.4e-13	3.01e-10	0.33	0.32	Systolic blood pressure;	chr13:112979777	chr13:112964835~112966131:-
THCA	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	7.34	9.41e-13	3.02e-10	0.4	0.32	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
THCA	cis	rs240993	0.715	rs4947122	ENSG00000230177.1	RP5-1112D6.4	-7.34	9.43e-13	3.03e-10	-0.31	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111548887	chr6:111277932~111278742:+
THCA	cis	rs5769707	0.642	rs4824070	ENSG00000235111.1	RP1-29C18.8	-7.34	9.43e-13	3.03e-10	-0.42	-0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49612657~49615716:-
THCA	cis	rs2522056	1	rs2522054	ENSG00000233006.5	AC034220.3	-7.34	9.44e-13	3.03e-10	-0.28	-0.32	Fibrinogen;Lymphocyte counts;	chr5:132463834	chr5:132311285~132369916:-
THCA	cis	rs2688608	0.592	rs13013	ENSG00000271816.1	BMS1P4	7.34	9.47e-13	3.04e-10	0.33	0.32	Inflammatory bowel disease;	chr10:73802403	chr10:73699151~73730487:-
THCA	cis	rs8027521	0.54	rs11857317	ENSG00000280362.1	RP11-643A5.3	-7.34	9.48e-13	3.04e-10	-0.45	-0.32	Circulating chemerin levels;	chr15:53964654	chr15:53910769~53914712:+
THCA	cis	rs227932	0.618	rs3807888	ENSG00000234286.1	AC006026.13	-7.34	9.52e-13	3.05e-10	-0.6	-0.32	Schizophrenia;	chr7:23710213	chr7:23680195~23680786:-
THCA	cis	rs1949733	0.675	rs2688235	ENSG00000205959.3	RP11-689P11.2	-7.34	9.52e-13	3.05e-10	-0.27	-0.32	Response to antineoplastic agents;	chr4:8448819	chr4:8482270~8512610:+
THCA	cis	rs9902453	0.967	rs4294864	ENSG00000264007.1	RP11-68I3.10	7.34	9.52e-13	3.05e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:30113120	chr17:29621617~29622254:-
THCA	cis	rs11148252	0.532	rs9526975	ENSG00000278238.1	RP11-245D16.4	-7.34	9.53e-13	3.05e-10	-0.36	-0.32	Lewy body disease;	chr13:52681669	chr13:52454775~52455331:-
THCA	cis	rs516805	0.667	rs9482234	ENSG00000279453.1	RP3-425C14.4	7.34	9.53e-13	3.06e-10	0.33	0.32	Lymphocyte counts;	chr6:122313998	chr6:122436789~122439223:-
THCA	cis	rs651907	0.557	rs12629954	ENSG00000256628.3	ZBTB11-AS1	7.34	9.56e-13	3.07e-10	0.38	0.32	Colorectal cancer;	chr3:101641779	chr3:101676475~101679217:+
THCA	cis	rs9902453	1	rs4075623	ENSG00000264007.1	RP11-68I3.10	-7.34	9.56e-13	3.07e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30059508	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs4795525	ENSG00000264007.1	RP11-68I3.10	-7.34	9.56e-13	3.07e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30061469	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs4239227	ENSG00000264007.1	RP11-68I3.10	-7.34	9.56e-13	3.07e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30062085	chr17:29621617~29622254:-
THCA	cis	rs2439831	0.85	rs3097773	ENSG00000249839.1	AC011330.5	7.34	9.58e-13	3.07e-10	0.48	0.32	Lung cancer in ever smokers;	chr15:43600874	chr15:43663654~43684339:-
THCA	cis	rs9902453	0.838	rs9646436	ENSG00000264007.1	RP11-68I3.10	7.34	9.6e-13	3.08e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29882041	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.838	rs9646437	ENSG00000264007.1	RP11-68I3.10	7.34	9.6e-13	3.08e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29882047	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.838	rs9646438	ENSG00000264007.1	RP11-68I3.10	7.34	9.6e-13	3.08e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29882073	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.808	rs56216220	ENSG00000264007.1	RP11-68I3.10	7.34	9.6e-13	3.08e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29882164	chr17:29621617~29622254:-
THCA	cis	rs61041384	0.661	rs3759111	ENSG00000256092.2	RP13-942N8.1	7.34	9.61e-13	3.08e-10	0.47	0.32	Schizophrenia;	chr12:123203227	chr12:123363868~123366113:+
THCA	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	7.34	9.61e-13	3.08e-10	0.44	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	7.34	9.61e-13	3.08e-10	0.44	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
THCA	cis	rs1150668	0.796	rs1124132	ENSG00000219392.1	RP1-265C24.5	-7.34	9.61e-13	3.08e-10	-0.35	-0.32	Pubertal anthropometrics;	chr6:28412544	chr6:28115628~28116551:+
THCA	cis	rs8114671	0.562	rs6119536	ENSG00000269202.1	RP4-614O4.12	7.34	9.62e-13	3.08e-10	0.26	0.32	Height;	chr20:34862238	chr20:35201747~35203288:-
THCA	cis	rs7208859	0.673	rs11655623	ENSG00000264538.5	SUZ12P1	-7.34	9.62e-13	3.08e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs3752019	ENSG00000264538.5	SUZ12P1	-7.34	9.65e-13	3.09e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs56146117	ENSG00000264538.5	SUZ12P1	-7.34	9.65e-13	3.09e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs3816780	ENSG00000264538.5	SUZ12P1	-7.34	9.66e-13	3.09e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30709299~30790908:+
THCA	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	7.34	9.69e-13	3.11e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
THCA	cis	rs7811142	1	rs11771419	ENSG00000078319.8	PMS2P1	-7.34	9.71e-13	3.11e-10	-0.45	-0.32	Platelet count;	chr7:100390780	chr7:100320992~100341908:-
THCA	cis	rs9549328	0.878	rs9577407	ENSG00000267868.1	RP11-120K24.3	7.34	9.72e-13	3.11e-10	0.33	0.32	Systolic blood pressure;	chr13:112985357	chr13:112964835~112966131:-
THCA	cis	rs12817211	0.502	rs7307230	ENSG00000272368.2	RP4-605O3.4	7.34	9.72e-13	3.11e-10	0.19	0.32	Colorectal or endometrial cancer;	chr12:50118849	chr12:50112197~50165618:+
THCA	cis	rs713477	1	rs10782426	ENSG00000258413.1	RP11-665C16.6	7.34	9.73e-13	3.12e-10	0.42	0.32	Pediatric bone mineral content (femoral neck);	chr14:55423984	chr14:55262767~55272075:-
THCA	cis	rs2281636	0.723	rs11190245	ENSG00000233690.1	EBAG9P1	7.34	9.75e-13	3.12e-10	0.35	0.32	Obesity-related traits;	chr10:99691502	chr10:99697407~99697949:-
THCA	cis	rs7851660	0.805	rs10759981	ENSG00000236130.1	PTCSC2	-7.34	9.75e-13	3.12e-10	-0.25	-0.32	Strep throat;	chr9:97873498	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs925487	ENSG00000236130.1	PTCSC2	-7.34	9.75e-13	3.12e-10	-0.25	-0.32	Strep throat;	chr9:97874116	chr9:97805935~97810008:-
THCA	cis	rs9473147	0.516	rs9349413	ENSG00000270761.1	RP11-385F7.1	-7.34	9.76e-13	3.13e-10	-0.26	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47543755	chr6:47477243~47477572:-
THCA	cis	rs7746199	0.673	rs35501037	ENSG00000280107.1	AL022393.9	-7.34	9.76e-13	3.13e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28170845~28172521:+
THCA	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-7.34	9.77e-13	3.13e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
THCA	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-7.34	9.77e-13	3.13e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
THCA	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	7.34	9.79e-13	3.13e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
THCA	cis	rs10208649	1	rs73937421	ENSG00000272156.1	RP11-477N3.1	7.33	9.82e-13	3.14e-10	0.67	0.32	Body mass index;	chr2:53861798	chr2:54082554~54085066:+
THCA	cis	rs990871	1	rs2568960	ENSG00000227207.2	RPL31P12	-7.33	9.83e-13	3.15e-10	-0.39	-0.32	Subcutaneous adipose tissue;	chr1:72346566	chr1:72301472~72301829:+
THCA	cis	rs990871	1	rs2815753	ENSG00000227207.2	RPL31P12	-7.33	9.83e-13	3.15e-10	-0.39	-0.32	Subcutaneous adipose tissue;	chr1:72346641	chr1:72301472~72301829:+
THCA	cis	rs732716	0.853	rs1127888	ENSG00000267980.1	AC007292.6	-7.33	9.84e-13	3.15e-10	-0.36	-0.32	Mean corpuscular volume;	chr19:4454086	chr19:4363789~4364640:+
THCA	cis	rs7267979	0.866	rs2424698	ENSG00000274414.1	RP5-965G21.4	-7.33	9.85e-13	3.15e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25239007~25245229:-
THCA	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	7.33	9.86e-13	3.15e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
THCA	cis	rs957448	0.507	rs1984711	ENSG00000253704.1	RP11-267M23.4	7.33	9.86e-13	3.16e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94553722~94569745:+
THCA	cis	rs2911132	1	rs2911132	ENSG00000248734.2	CTD-2260A17.1	7.33	9.87e-13	3.16e-10	0.34	0.32	Urate levels (BMI interaction);	chr5:96851285	chr5:96784777~96785999:+
THCA	cis	rs875971	1	rs7792762	ENSG00000232559.3	GS1-124K5.12	7.33	9.87e-13	3.16e-10	0.3	0.32	Aortic root size;	chr7:66539151	chr7:66554588~66576923:-
THCA	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	7.33	9.87e-13	3.16e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
THCA	cis	rs12817211	0.549	rs7398567	ENSG00000272368.2	RP4-605O3.4	7.33	9.88e-13	3.16e-10	0.19	0.32	Colorectal or endometrial cancer;	chr12:50157375	chr12:50112197~50165618:+
THCA	cis	rs12817211	0.549	rs10783338	ENSG00000272368.2	RP4-605O3.4	7.33	9.88e-13	3.16e-10	0.19	0.32	Colorectal or endometrial cancer;	chr12:50158746	chr12:50112197~50165618:+
THCA	cis	rs4934494	0.681	rs1129777	ENSG00000232936.4	RP11-80H5.2	7.33	9.88e-13	3.16e-10	0.44	0.32	Red blood cell count;	chr10:89709168	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.727	rs3824607	ENSG00000232936.4	RP11-80H5.2	7.33	9.88e-13	3.16e-10	0.44	0.32	Red blood cell count;	chr10:89711258	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.681	rs3740035	ENSG00000232936.4	RP11-80H5.2	7.33	9.88e-13	3.16e-10	0.44	0.32	Red blood cell count;	chr10:89716708	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.681	rs34591435	ENSG00000232936.4	RP11-80H5.2	7.33	9.88e-13	3.16e-10	0.44	0.32	Red blood cell count;	chr10:89721691	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.727	rs12783845	ENSG00000232936.4	RP11-80H5.2	7.33	9.88e-13	3.16e-10	0.44	0.32	Red blood cell count;	chr10:89722872	chr10:89645282~89650667:+
THCA	cis	rs240993	0.761	rs6920014	ENSG00000230177.1	RP5-1112D6.4	-7.33	9.89e-13	3.16e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111385198	chr6:111277932~111278742:+
THCA	cis	rs853679	0.517	rs3757187	ENSG00000272009.1	RP1-313I6.12	-7.33	9.89e-13	3.16e-10	-0.38	-0.32	Depression;	chr6:28139876	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs3757185	ENSG00000272009.1	RP1-313I6.12	-7.33	9.89e-13	3.16e-10	-0.38	-0.32	Depression;	chr6:28139998	chr6:28078792~28081130:-
THCA	cis	rs4073416	0.684	rs2184603	ENSG00000276116.2	FUT8-AS1	7.33	9.89e-13	3.17e-10	0.33	0.32	N-glycan levels;	chr14:65463952	chr14:65411170~65412690:-
THCA	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	7.33	9.9e-13	3.17e-10	0.35	0.32	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
THCA	cis	rs651907	0.557	rs11924013	ENSG00000256628.3	ZBTB11-AS1	7.33	9.96e-13	3.19e-10	0.38	0.32	Colorectal cancer;	chr3:101647854	chr3:101676475~101679217:+
THCA	cis	rs172166	0.694	rs1225716	ENSG00000280107.1	AL022393.9	-7.33	9.96e-13	3.19e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28145968	chr6:28170845~28172521:+
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000263603.1	CTD-2349P21.5	-7.33	9.97e-13	3.19e-10	-0.55	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30729469~30731202:+
THCA	cis	rs1043099	0.571	rs5749082	ENSG00000279699.1	RP1-102K2.9	-7.33	1e-12	3.2e-10	-0.38	-0.32	Rheumatoid arthritis;	chr22:30374614	chr22:30275215~30276951:-
THCA	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-7.33	1e-12	3.2e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-7.33	1e-12	3.2e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-7.33	1e-12	3.2e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-7.33	1e-12	3.2e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-7.33	1e-12	3.2e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-7.33	1e-12	3.2e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-7.33	1e-12	3.2e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-7.33	1e-12	3.2e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
THCA	cis	rs270601	0.633	rs733300	ENSG00000233006.5	AC034220.3	7.33	1e-12	3.21e-10	0.25	0.32	Acylcarnitine levels;	chr5:132236550	chr5:132311285~132369916:-
THCA	cis	rs270601	0.633	rs4535443	ENSG00000233006.5	AC034220.3	7.33	1e-12	3.21e-10	0.25	0.32	Acylcarnitine levels;	chr5:132236868	chr5:132311285~132369916:-
THCA	cis	rs12681366	0.734	rs6991077	ENSG00000253704.1	RP11-267M23.4	7.33	1e-12	3.21e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94375577	chr8:94553722~94569745:+
THCA	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-7.33	1e-12	3.21e-10	-0.46	-0.32	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
THCA	cis	rs853679	0.517	rs12332979	ENSG00000220721.1	OR1F12	7.33	1e-12	3.21e-10	0.44	0.32	Depression;	chr6:28173770	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000220721.1	OR1F12	7.33	1e-12	3.21e-10	0.44	0.32	Depression;	chr6:28174809	chr6:28073316~28074233:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000220721.1	OR1F12	7.33	1e-12	3.21e-10	0.44	0.32	Depression;	chr6:28175233	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000220721.1	OR1F12	7.33	1e-12	3.21e-10	0.44	0.32	Depression;	chr6:28176973	chr6:28073316~28074233:+
THCA	cis	rs77204473	0.744	rs76567973	ENSG00000254851.1	RP11-109L13.1	7.33	1e-12	3.21e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100045	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs78135964	ENSG00000254851.1	RP11-109L13.1	7.33	1e-12	3.21e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100961	chr11:117135528~117138582:+
THCA	cis	rs10971721	0.822	rs72729357	ENSG00000260947.1	RP11-384P7.7	7.33	1.01e-12	3.21e-10	0.79	0.32	Body mass index;	chr9:34041170	chr9:33697459~33700986:+
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000263603.1	CTD-2349P21.5	-7.33	1.01e-12	3.22e-10	-0.57	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30729469~30731202:+
THCA	cis	rs67340775	0.541	rs200973	ENSG00000219392.1	RP1-265C24.5	-7.33	1.01e-12	3.22e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr6:27890643	chr6:28115628~28116551:+
THCA	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
THCA	cis	rs74233809	1	rs11191587	ENSG00000213277.3	MARCKSL1P1	7.33	1.01e-12	3.23e-10	0.53	0.32	Birth weight;	chr10:103169959	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191593	ENSG00000213277.3	MARCKSL1P1	7.33	1.01e-12	3.23e-10	0.53	0.32	Birth weight;	chr10:103179458	chr10:103175554~103176094:+
THCA	cis	rs4460629	0.901	rs4745	ENSG00000160766.13	GBAP1	7.33	1.01e-12	3.23e-10	0.35	0.32	Serum magnesium levels;	chr1:155133751	chr1:155213821~155227422:-
THCA	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-7.33	1.01e-12	3.23e-10	-0.34	-0.32	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
THCA	cis	rs4073416	0.684	rs4902400	ENSG00000276116.2	FUT8-AS1	7.33	1.01e-12	3.23e-10	0.33	0.32	N-glycan levels;	chr14:65490397	chr14:65411170~65412690:-
THCA	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-7.33	1.01e-12	3.24e-10	-0.37	-0.32	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
THCA	cis	rs10208649	1	rs10199444	ENSG00000272156.1	RP11-477N3.1	7.33	1.01e-12	3.24e-10	0.57	0.32	Body mass index;	chr2:53934939	chr2:54082554~54085066:+
THCA	cis	rs77204473	0.744	rs74420345	ENSG00000254851.1	RP11-109L13.1	7.33	1.02e-12	3.25e-10	0.81	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117092561	chr11:117135528~117138582:+
THCA	cis	rs9549328	0.67	rs2873372	ENSG00000267868.1	RP11-120K24.3	7.33	1.02e-12	3.25e-10	0.32	0.32	Systolic blood pressure;	chr13:112959069	chr13:112964835~112966131:-
THCA	cis	rs875971	1	rs1565531	ENSG00000232559.3	GS1-124K5.12	-7.33	1.02e-12	3.25e-10	-0.3	-0.32	Aortic root size;	chr7:66198126	chr7:66554588~66576923:-
THCA	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-7.33	1.02e-12	3.25e-10	-0.32	-0.32	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-7.33	1.02e-12	3.25e-10	-0.32	-0.32	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
THCA	cis	rs11148252	0.538	rs2408611	ENSG00000278238.1	RP11-245D16.4	-7.33	1.02e-12	3.26e-10	-0.35	-0.32	Lewy body disease;	chr13:52135606	chr13:52454775~52455331:-
THCA	cis	rs2522056	0.935	rs757104	ENSG00000233006.5	AC034220.3	-7.33	1.02e-12	3.26e-10	-0.28	-0.32	Fibrinogen;Lymphocyte counts;	chr5:132459537	chr5:132311285~132369916:-
THCA	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	7.33	1.02e-12	3.26e-10	0.4	0.32	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
THCA	cis	rs8027521	0.846	rs4776192	ENSG00000280362.1	RP11-643A5.3	7.33	1.02e-12	3.27e-10	0.39	0.32	Circulating chemerin levels;	chr15:53932311	chr15:53910769~53914712:+
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000224205.1	AP000351.4	-7.33	1.02e-12	3.27e-10	-0.41	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23987320~23991421:-
THCA	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	7.33	1.02e-12	3.27e-10	0.41	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
THCA	cis	rs193541	0.632	rs26370	ENSG00000263432.2	RN7SL689P	7.33	1.02e-12	3.27e-10	0.39	0.32	Glucose homeostasis traits;	chr5:122899497	chr5:123022487~123022783:-
THCA	cis	rs240993	0.812	rs118202	ENSG00000230177.1	RP5-1112D6.4	-7.33	1.03e-12	3.28e-10	-0.33	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111337168	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs240955	ENSG00000230177.1	RP5-1112D6.4	-7.33	1.03e-12	3.28e-10	-0.33	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111339440	chr6:111277932~111278742:+
THCA	cis	rs240993	0.761	rs453776	ENSG00000230177.1	RP5-1112D6.4	-7.33	1.03e-12	3.28e-10	-0.33	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111342260	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs240990	ENSG00000230177.1	RP5-1112D6.4	-7.33	1.03e-12	3.28e-10	-0.33	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111343820	chr6:111277932~111278742:+
THCA	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-7.33	1.03e-12	3.29e-10	-0.8	-0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
THCA	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	7.33	1.03e-12	3.29e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
THCA	cis	rs4604234	0.708	rs11966262	ENSG00000272129.1	RP11-250B2.6	-7.33	1.03e-12	3.29e-10	-0.7	-0.32	Cancer;	chr6:80294867	chr6:80355424~80356859:+
THCA	cis	rs2880765	0.835	rs7162502	ENSG00000259295.5	CSPG4P12	7.33	1.03e-12	3.29e-10	0.4	0.32	Coronary artery disease;	chr15:85501242	chr15:85191438~85213905:+
THCA	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	7.33	1.03e-12	3.29e-10	0.31	0.32	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
THCA	cis	rs1061377	0.748	rs1964345	ENSG00000249685.1	RP11-360F5.3	7.33	1.03e-12	3.29e-10	0.39	0.32	Uric acid levels;	chr4:39104793	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.748	rs1964347	ENSG00000249685.1	RP11-360F5.3	7.33	1.03e-12	3.29e-10	0.39	0.32	Uric acid levels;	chr4:39104956	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.748	rs1036033	ENSG00000249685.1	RP11-360F5.3	7.33	1.03e-12	3.29e-10	0.39	0.32	Uric acid levels;	chr4:39105295	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.748	rs4974933	ENSG00000249685.1	RP11-360F5.3	7.33	1.03e-12	3.29e-10	0.39	0.32	Uric acid levels;	chr4:39105636	chr4:39133913~39135608:+
THCA	cis	rs1043099	0.571	rs757869	ENSG00000279699.1	RP1-102K2.9	-7.33	1.03e-12	3.3e-10	-0.38	-0.32	Rheumatoid arthritis;	chr22:30368464	chr22:30275215~30276951:-
THCA	cis	rs829880	0.57	rs844205	ENSG00000227825.4	SLC9A7P1	7.33	1.03e-12	3.3e-10	0.29	0.32	Colonoscopy-negative controls vs population controls;	chr12:98452275	chr12:98453835~98457145:-
THCA	cis	rs42490	0.789	rs51331	ENSG00000251136.7	RP11-37B2.1	-7.33	1.03e-12	3.3e-10	-0.27	-0.32	Leprosy;	chr8:89801900	chr8:89609409~89757727:-
THCA	cis	rs7646881	0.812	rs73015644	ENSG00000240207.5	RP11-379F4.4	-7.33	1.04e-12	3.31e-10	-0.46	-0.32	Tetralogy of Fallot;	chr3:158729955	chr3:158732263~158784070:+
THCA	cis	rs7189233	1	rs62048543	ENSG00000279722.1	RP11-44F14.6	-7.33	1.04e-12	3.33e-10	-0.34	-0.32	Intelligence (multi-trait analysis);	chr16:53500712	chr16:53487607~53489943:-
THCA	cis	rs516805	0.59	rs1430816	ENSG00000279453.1	RP3-425C14.4	-7.33	1.04e-12	3.33e-10	-0.34	-0.32	Lymphocyte counts;	chr6:122591978	chr6:122436789~122439223:-
THCA	cis	rs4950322	0.57	rs17360443	ENSG00000237188.3	RP11-337C18.8	7.32	1.05e-12	3.34e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147279737	chr1:147172771~147211568:+
THCA	cis	rs7942368	1	rs3758711	ENSG00000254632.1	RP11-21L23.4	7.32	1.05e-12	3.35e-10	0.46	0.32	Endometriosis;	chr11:76784516	chr11:76759916~76768223:-
THCA	cis	rs7208859	0.673	rs2470251	ENSG00000264538.5	SUZ12P1	-7.32	1.05e-12	3.35e-10	-0.31	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30709299~30790908:+
THCA	cis	rs831571	0.915	rs6797912	ENSG00000280620.1	SCAANT1	-7.32	1.05e-12	3.35e-10	-0.5	-0.32	Type 2 diabetes;	chr3:64072564	chr3:63911518~63911772:-
THCA	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-7.32	1.05e-12	3.35e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-7.32	1.05e-12	3.35e-10	-0.52	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
THCA	cis	rs7208859	0.673	rs11654331	ENSG00000264538.5	SUZ12P1	-7.32	1.05e-12	3.36e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30709299~30790908:+
THCA	cis	rs728616	0.867	rs41298231	ENSG00000225484.5	NUTM2B-AS1	-7.32	1.05e-12	3.36e-10	-0.65	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922705	chr10:79663088~79826594:-
THCA	cis	rs9640161	0.83	rs7800196	ENSG00000261305.1	RP4-584D14.7	7.32	1.05e-12	3.36e-10	0.38	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150364445	chr7:150341771~150342607:+
THCA	cis	rs368187	0.721	rs1759760	ENSG00000257826.1	RP11-116N8.4	7.32	1.05e-12	3.36e-10	0.34	0.32	Thyroid cancer;	chr14:36052560	chr14:36061026~36067190:-
THCA	cis	rs2236295	0.618	rs224285	ENSG00000238280.1	RP11-436D10.3	7.32	1.05e-12	3.36e-10	0.4	0.32	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62825050	chr10:62793562~62805887:-
THCA	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-7.32	1.05e-12	3.36e-10	-0.52	-0.32	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
THCA	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	7.32	1.06e-12	3.37e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
THCA	cis	rs9928842	0.664	rs8053265	ENSG00000280152.1	RP11-331F4.5	7.32	1.06e-12	3.37e-10	0.38	0.32	Alcoholic chronic pancreatitis;	chr16:75187953	chr16:75245994~75250077:-
THCA	cis	rs4073416	0.746	rs12882200	ENSG00000276116.2	FUT8-AS1	7.32	1.06e-12	3.37e-10	0.33	0.32	N-glycan levels;	chr14:65691143	chr14:65411170~65412690:-
THCA	cis	rs2880765	0.835	rs11638498	ENSG00000259295.5	CSPG4P12	7.32	1.06e-12	3.37e-10	0.4	0.32	Coronary artery disease;	chr15:85479787	chr15:85191438~85213905:+
THCA	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-7.32	1.06e-12	3.38e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
THCA	cis	rs1949733	0.701	rs2631754	ENSG00000205959.3	RP11-689P11.2	-7.32	1.06e-12	3.38e-10	-0.27	-0.32	Response to antineoplastic agents;	chr4:8447506	chr4:8482270~8512610:+
THCA	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-7.32	1.06e-12	3.38e-10	-0.31	-0.32	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
THCA	cis	rs4713118	0.911	rs9461406	ENSG00000280107.1	AL022393.9	7.32	1.06e-12	3.39e-10	0.38	0.32	Parkinson's disease;	chr6:27751985	chr6:28170845~28172521:+
THCA	cis	rs4820539	0.966	rs2283803	ENSG00000221069.1	AC000029.1	-7.32	1.07e-12	3.4e-10	-0.38	-0.32	Bone mineral density;	chr22:23112694	chr22:23136620~23136710:+
THCA	cis	rs7208859	0.573	rs73277960	ENSG00000264538.5	SUZ12P1	-7.32	1.07e-12	3.4e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73263788	ENSG00000264538.5	SUZ12P1	-7.32	1.07e-12	3.4e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs12949860	ENSG00000264538.5	SUZ12P1	-7.32	1.07e-12	3.4e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30709299~30790908:+
THCA	cis	rs2880765	0.835	rs7174323	ENSG00000259295.5	CSPG4P12	7.32	1.07e-12	3.41e-10	0.41	0.32	Coronary artery disease;	chr15:85506488	chr15:85191438~85213905:+
THCA	cis	rs2018683	1	rs4719962	ENSG00000228421.2	AC005013.5	7.32	1.07e-12	3.41e-10	0.36	0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959621	chr7:28957667~28959345:+
THCA	cis	rs9902453	0.765	rs2628167	ENSG00000264007.1	RP11-68I3.10	-7.32	1.07e-12	3.41e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:29737480	chr17:29621617~29622254:-
THCA	cis	rs4073416	0.712	rs11627084	ENSG00000276116.2	FUT8-AS1	7.32	1.07e-12	3.42e-10	0.33	0.32	N-glycan levels;	chr14:65512118	chr14:65411170~65412690:-
THCA	cis	rs9500256	0.934	rs1343391	ENSG00000215190.7	LINC00680	-7.32	1.07e-12	3.42e-10	-0.37	-0.32	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57946074~57961501:-
THCA	cis	rs10208649	0.901	rs11894028	ENSG00000272156.1	RP11-477N3.1	7.32	1.07e-12	3.42e-10	0.58	0.32	Body mass index;	chr2:53926743	chr2:54082554~54085066:+
THCA	cis	rs6509701	1	rs6509701	ENSG00000268225.1	CTD-2331H12.5	-7.32	1.07e-12	3.42e-10	-0.34	-0.32	Psychosis in Alzheimer's disease;	chr19:52880932	chr19:52861807~52862866:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	7.32	1.07e-12	3.42e-10	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
THCA	cis	rs71403859	0.57	rs76231867	ENSG00000260886.1	TAT-AS1	7.32	1.07e-12	3.42e-10	0.54	0.32	Post bronchodilator FEV1;	chr16:71416023	chr16:71565789~71578187:+
THCA	cis	rs71403859	0.57	rs78972826	ENSG00000260886.1	TAT-AS1	7.32	1.07e-12	3.42e-10	0.54	0.32	Post bronchodilator FEV1;	chr16:71420361	chr16:71565789~71578187:+
THCA	cis	rs4073416	0.691	rs10483785	ENSG00000276116.2	FUT8-AS1	7.32	1.07e-12	3.42e-10	0.32	0.32	N-glycan levels;	chr14:65752799	chr14:65411170~65412690:-
THCA	cis	rs324126	0.527	rs17780009	ENSG00000277977.1	CTD-3018O17.5	-7.32	1.07e-12	3.42e-10	-0.35	-0.32	Colonoscopy-negative controls vs population controls;	chr19:52370365	chr19:52392659~52392755:+
THCA	cis	rs6600671	0.934	rs11249429	ENSG00000223345.3	HIST2H2BA	-7.32	1.08e-12	3.43e-10	-0.35	-0.32	Hip geometry;	chr1:121549282	chr1:121108210~121117257:-
THCA	cis	rs934734	0.789	rs174847	ENSG00000204929.10	AC074391.1	-7.32	1.08e-12	3.43e-10	-0.41	-0.32	Rheumatoid arthritis;	chr2:65378060	chr2:65436711~66084639:+
THCA	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	7.32	1.08e-12	3.43e-10	0.4	0.32	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	7.32	1.08e-12	3.43e-10	0.39	0.32	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
THCA	cis	rs442309	0.551	rs1509966	ENSG00000238280.1	RP11-436D10.3	-7.32	1.08e-12	3.44e-10	-0.38	-0.32	Vogt-Koyanagi-Harada syndrome;	chr10:62792847	chr10:62793562~62805887:-
THCA	cis	rs853679	1	rs7740487	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	3.44e-10	-0.52	-0.32	Depression;	chr6:28248708	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs68141011	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	3.44e-10	-0.52	-0.32	Depression;	chr6:28250019	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs13200462	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	3.44e-10	-0.52	-0.32	Depression;	chr6:28250421	chr6:28115628~28116551:+
THCA	cis	rs7189233	1	rs7194519	ENSG00000279722.1	RP11-44F14.6	-7.32	1.08e-12	3.44e-10	-0.34	-0.32	Intelligence (multi-trait analysis);	chr16:53501364	chr16:53487607~53489943:-
THCA	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	7.32	1.08e-12	3.45e-10	0.48	0.32	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	7.32	1.08e-12	3.45e-10	0.48	0.32	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000207650.1	MIR570	7.32	1.09e-12	3.46e-10	0.35	0.32	Pancreatic cancer;	chr3:196009869	chr3:195699401~195699497:+
THCA	cis	rs4927850	1	rs4927704	ENSG00000207650.1	MIR570	7.32	1.09e-12	3.46e-10	0.35	0.32	Pancreatic cancer;	chr3:196011357	chr3:195699401~195699497:+
THCA	cis	rs4927850	1	rs4927848	ENSG00000207650.1	MIR570	7.32	1.09e-12	3.46e-10	0.35	0.32	Pancreatic cancer;	chr3:196011535	chr3:195699401~195699497:+
THCA	cis	rs4934494	0.681	rs12572928	ENSG00000232936.4	RP11-80H5.2	7.32	1.09e-12	3.46e-10	0.44	0.32	Red blood cell count;	chr10:89793792	chr10:89645282~89650667:+
THCA	cis	rs8027521	0.54	rs17793691	ENSG00000280362.1	RP11-643A5.3	-7.32	1.09e-12	3.46e-10	-0.45	-0.32	Circulating chemerin levels;	chr15:53959720	chr15:53910769~53914712:+
THCA	cis	rs853679	0.542	rs6934769	ENSG00000272009.1	RP1-313I6.12	-7.32	1.09e-12	3.46e-10	-0.38	-0.32	Depression;	chr6:28123153	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs17711801	ENSG00000272009.1	RP1-313I6.12	-7.32	1.09e-12	3.46e-10	-0.38	-0.32	Depression;	chr6:28124529	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000272009.1	RP1-313I6.12	-7.32	1.09e-12	3.46e-10	-0.38	-0.32	Parkinson's disease;	chr6:28127394	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9468292	ENSG00000272009.1	RP1-313I6.12	-7.32	1.09e-12	3.46e-10	-0.38	-0.32	Depression;	chr6:28127577	chr6:28078792~28081130:-
THCA	cis	rs7208859	0.623	rs170051	ENSG00000264538.5	SUZ12P1	-7.32	1.09e-12	3.46e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.51	rs216402	ENSG00000264538.5	SUZ12P1	-7.32	1.09e-12	3.46e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs216434	ENSG00000264538.5	SUZ12P1	-7.32	1.09e-12	3.46e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs216436	ENSG00000264538.5	SUZ12P1	-7.32	1.09e-12	3.46e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000264538.5	SUZ12P1	-7.32	1.09e-12	3.46e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs216439	ENSG00000264538.5	SUZ12P1	-7.32	1.09e-12	3.46e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30709299~30790908:+
THCA	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	7.32	1.09e-12	3.47e-10	0.37	0.32	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	7.32	1.09e-12	3.47e-10	0.37	0.32	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	7.32	1.09e-12	3.47e-10	0.37	0.32	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	7.32	1.09e-12	3.47e-10	0.37	0.32	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
THCA	cis	rs2253762	0.507	rs4752630	ENSG00000276742.1	RP11-500G22.4	7.32	1.09e-12	3.47e-10	0.46	0.32	Breast cancer;	chr10:121991440	chr10:121956782~121957098:+
THCA	cis	rs2281636	0.691	rs6584306	ENSG00000233690.1	EBAG9P1	7.32	1.09e-12	3.47e-10	0.35	0.32	Obesity-related traits;	chr10:99662739	chr10:99697407~99697949:-
THCA	cis	rs6600671	0.899	rs11249432	ENSG00000223345.3	HIST2H2BA	7.32	1.09e-12	3.47e-10	0.35	0.32	Hip geometry;	chr1:121541678	chr1:121108210~121117257:-
THCA	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	7.32	1.09e-12	3.47e-10	0.22	0.32	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
THCA	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	7.32	1.09e-12	3.48e-10	0.42	0.32	Height;	chr6:109708527	chr6:109382795~109383666:+
THCA	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	7.32	1.09e-12	3.48e-10	0.39	0.32	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	7.32	1.09e-12	3.48e-10	0.39	0.32	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000206090.4	AP000350.7	-7.32	1.09e-12	3.48e-10	-0.44	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23939998~23942798:+
THCA	cis	rs17772222	0.917	rs77382318	ENSG00000258983.2	RP11-507K2.2	7.32	1.09e-12	3.48e-10	0.41	0.32	Coronary artery calcification;	chr14:88355785	chr14:88499334~88515502:+
THCA	cis	rs1150668	0.764	rs9368565	ENSG00000219392.1	RP1-265C24.5	7.32	1.09e-12	3.48e-10	0.35	0.32	Pubertal anthropometrics;	chr6:28377433	chr6:28115628~28116551:+
THCA	cis	rs270601	0.69	rs162904	ENSG00000233006.5	AC034220.3	-7.32	1.09e-12	3.48e-10	-0.25	-0.32	Acylcarnitine levels;	chr5:132260091	chr5:132311285~132369916:-
THCA	cis	rs9341808	0.754	rs9294173	ENSG00000272129.1	RP11-250B2.6	7.32	1.1e-12	3.49e-10	0.4	0.32	Sitting height ratio;	chr6:80281913	chr6:80355424~80356859:+
THCA	cis	rs11148252	0.538	rs2408609	ENSG00000278238.1	RP11-245D16.4	-7.32	1.1e-12	3.49e-10	-0.35	-0.32	Lewy body disease;	chr13:52139907	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.538	rs2897976	ENSG00000278238.1	RP11-245D16.4	-7.32	1.1e-12	3.49e-10	-0.35	-0.32	Lewy body disease;	chr13:52141808	chr13:52454775~52455331:-
THCA	cis	rs9902453	1	rs9890205	ENSG00000264007.1	RP11-68I3.10	-7.32	1.1e-12	3.49e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30055686	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs4994355	ENSG00000264007.1	RP11-68I3.10	-7.32	1.1e-12	3.49e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30059266	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs9890886	ENSG00000264007.1	RP11-68I3.10	-7.32	1.1e-12	3.49e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30064058	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.935	rs9898424	ENSG00000264007.1	RP11-68I3.10	-7.32	1.1e-12	3.49e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30065928	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs4465649	ENSG00000264007.1	RP11-68I3.10	-7.32	1.1e-12	3.49e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30067729	chr17:29621617~29622254:-
THCA	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-7.32	1.1e-12	3.49e-10	-0.41	-0.32	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
THCA	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	7.32	1.1e-12	3.5e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	7.32	1.1e-12	3.5e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
THCA	cis	rs6723108	0.603	rs10187990	ENSG00000224043.6	CCNT2-AS1	-7.32	1.1e-12	3.5e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134939987	chr2:134735464~134918710:-
THCA	cis	rs832187	0.64	rs704367	ENSG00000280620.1	SCAANT1	-7.32	1.1e-12	3.51e-10	-0.44	-0.32	Schizophrenia;	chr3:63883101	chr3:63911518~63911772:-
THCA	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	7.32	1.1e-12	3.51e-10	0.37	0.32	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
THCA	cis	rs4934494	0.727	rs67827533	ENSG00000232936.4	RP11-80H5.2	7.32	1.1e-12	3.51e-10	0.43	0.32	Red blood cell count;	chr10:89745626	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.768	rs1926139	ENSG00000232936.4	RP11-80H5.2	7.32	1.1e-12	3.51e-10	0.43	0.32	Red blood cell count;	chr10:89753395	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.727	rs55823491	ENSG00000232936.4	RP11-80H5.2	7.32	1.1e-12	3.51e-10	0.43	0.32	Red blood cell count;	chr10:89757598	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.727	rs12570750	ENSG00000232936.4	RP11-80H5.2	7.32	1.1e-12	3.51e-10	0.43	0.32	Red blood cell count;	chr10:89761273	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.723	rs17127001	ENSG00000232936.4	RP11-80H5.2	7.32	1.1e-12	3.51e-10	0.43	0.32	Red blood cell count;	chr10:89762932	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.727	rs36019294	ENSG00000232936.4	RP11-80H5.2	7.32	1.1e-12	3.51e-10	0.43	0.32	Red blood cell count;	chr10:89777822	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.636	rs34408087	ENSG00000232936.4	RP11-80H5.2	7.32	1.1e-12	3.51e-10	0.43	0.32	Red blood cell count;	chr10:89783794	chr10:89645282~89650667:+
THCA	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	7.32	1.11e-12	3.52e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
THCA	cis	rs270601	0.661	rs10036208	ENSG00000233006.5	AC034220.3	7.32	1.11e-12	3.52e-10	0.25	0.32	Acylcarnitine levels;	chr5:132235630	chr5:132311285~132369916:-
THCA	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	7.32	1.11e-12	3.53e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	7.32	1.11e-12	3.53e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	7.32	1.11e-12	3.53e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
THCA	cis	rs6723108	0.604	rs6430551	ENSG00000224043.6	CCNT2-AS1	-7.32	1.11e-12	3.53e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134863986	chr2:134735464~134918710:-
THCA	cis	rs7851660	0.844	rs12343182	ENSG00000236130.1	PTCSC2	-7.32	1.11e-12	3.54e-10	-0.25	-0.32	Strep throat;	chr9:97861977	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs7860144	ENSG00000236130.1	PTCSC2	-7.32	1.11e-12	3.54e-10	-0.25	-0.32	Strep throat;	chr9:97864602	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs10120412	ENSG00000236130.1	PTCSC2	-7.32	1.11e-12	3.54e-10	-0.25	-0.32	Strep throat;	chr9:97865956	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs2417576	ENSG00000236130.1	PTCSC2	-7.32	1.11e-12	3.54e-10	-0.25	-0.32	Strep throat;	chr9:97866425	chr9:97805935~97810008:-
THCA	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	7.32	1.11e-12	3.54e-10	0.45	0.32	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	7.32	1.11e-12	3.54e-10	0.45	0.32	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	7.32	1.11e-12	3.54e-10	0.45	0.32	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	7.32	1.11e-12	3.54e-10	0.45	0.32	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
THCA	cis	rs9902453	0.765	rs6505143	ENSG00000264007.1	RP11-68I3.10	7.32	1.11e-12	3.54e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29823567	chr17:29621617~29622254:-
THCA	cis	rs9847710	0.808	rs2564919	ENSG00000242142.1	SERBP1P3	7.32	1.12e-12	3.55e-10	0.38	0.32	Ulcerative colitis;	chr3:52999279	chr3:53064283~53065091:-
THCA	cis	rs7189233	0.91	rs3809634	ENSG00000279722.1	RP11-44F14.6	-7.31	1.12e-12	3.56e-10	-0.33	-0.32	Intelligence (multi-trait analysis);	chr16:53504245	chr16:53487607~53489943:-
THCA	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	7.31	1.12e-12	3.56e-10	0.59	0.32	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	7.31	1.12e-12	3.56e-10	0.59	0.32	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
THCA	cis	rs2880765	0.835	rs4843063	ENSG00000259295.5	CSPG4P12	7.31	1.12e-12	3.57e-10	0.4	0.32	Coronary artery disease;	chr15:85505517	chr15:85191438~85213905:+
THCA	cis	rs6600671	1	rs10903161	ENSG00000223345.3	HIST2H2BA	7.31	1.12e-12	3.57e-10	0.35	0.32	Hip geometry;	chr1:121436882	chr1:121108210~121117257:-
THCA	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-7.31	1.12e-12	3.58e-10	-0.34	-0.32	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
THCA	cis	rs9549328	0.837	rs4907572	ENSG00000267868.1	RP11-120K24.3	7.31	1.13e-12	3.58e-10	0.33	0.32	Systolic blood pressure;	chr13:112993007	chr13:112964835~112966131:-
THCA	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	7.31	1.13e-12	3.59e-10	0.41	0.32	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
THCA	cis	rs875971	1	rs6460296	ENSG00000232559.3	GS1-124K5.12	7.31	1.13e-12	3.59e-10	0.3	0.32	Aortic root size;	chr7:66430152	chr7:66554588~66576923:-
THCA	cis	rs875971	0.895	rs4718349	ENSG00000232559.3	GS1-124K5.12	7.31	1.13e-12	3.59e-10	0.3	0.32	Aortic root size;	chr7:66444024	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs2042133	ENSG00000232559.3	GS1-124K5.12	7.31	1.13e-12	3.59e-10	0.3	0.32	Aortic root size;	chr7:66466935	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs2161065	ENSG00000232559.3	GS1-124K5.12	7.31	1.13e-12	3.59e-10	0.3	0.32	Aortic root size;	chr7:66467918	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs12698521	ENSG00000232559.3	GS1-124K5.12	7.31	1.13e-12	3.59e-10	0.3	0.32	Aortic root size;	chr7:66474502	chr7:66554588~66576923:-
THCA	cis	rs829880	0.789	rs1096146	ENSG00000227825.4	SLC9A7P1	7.31	1.13e-12	3.59e-10	0.28	0.32	Colonoscopy-negative controls vs population controls;	chr12:98457188	chr12:98453835~98457145:-
THCA	cis	rs34864796	0.547	rs200476	ENSG00000219392.1	RP1-265C24.5	-7.31	1.13e-12	3.59e-10	-0.44	-0.32	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28115628~28116551:+
THCA	cis	rs7267979	0.833	rs4619688	ENSG00000274414.1	RP5-965G21.4	-7.31	1.13e-12	3.59e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25239007~25245229:-
THCA	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-7.31	1.13e-12	3.59e-10	-0.4	-0.32	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
THCA	cis	rs8114671	0.562	rs2889861	ENSG00000269202.1	RP4-614O4.12	-7.31	1.13e-12	3.59e-10	-0.27	-0.32	Height;	chr20:34817861	chr20:35201747~35203288:-
THCA	cis	rs1150668	0.83	rs2023493	ENSG00000219392.1	RP1-265C24.5	-7.31	1.13e-12	3.6e-10	-0.35	-0.32	Pubertal anthropometrics;	chr6:28432385	chr6:28115628~28116551:+
THCA	cis	rs9532669	0.926	rs4356344	ENSG00000176268.5	CYCSP34	7.31	1.13e-12	3.6e-10	0.39	0.32	Cervical cancer;	chr13:40874086	chr13:40863599~40863902:-
THCA	cis	rs7646881	0.504	rs4264773	ENSG00000240207.5	RP11-379F4.4	-7.31	1.13e-12	3.6e-10	-0.39	-0.32	Tetralogy of Fallot;	chr3:158745436	chr3:158732263~158784070:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000228039.3	KB-1125A3.10	7.31	1.13e-12	3.61e-10	0.41	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23963780~23964374:+
THCA	cis	rs6723108	0.627	rs1374292	ENSG00000224043.6	CCNT2-AS1	-7.31	1.14e-12	3.61e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134896598	chr2:134735464~134918710:-
THCA	cis	rs990871	1	rs2613494	ENSG00000227207.2	RPL31P12	-7.31	1.14e-12	3.62e-10	-0.39	-0.32	Subcutaneous adipose tissue;	chr1:72346974	chr1:72301472~72301829:+
THCA	cis	rs990871	0.927	rs2568961	ENSG00000227207.2	RPL31P12	-7.31	1.14e-12	3.62e-10	-0.39	-0.32	Subcutaneous adipose tissue;	chr1:72347064	chr1:72301472~72301829:+
THCA	cis	rs2976388	0.609	rs2244152	ENSG00000253741.1	CTD-2292P10.4	-7.31	1.14e-12	3.62e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142703467	chr8:142702252~142726973:-
THCA	cis	rs801193	0.569	rs13242290	ENSG00000232559.3	GS1-124K5.12	-7.31	1.14e-12	3.62e-10	-0.31	-0.32	Aortic root size;	chr7:66656898	chr7:66554588~66576923:-
THCA	cis	rs2288884	0.505	rs2278414	ENSG00000275055.1	CTC-471J1.11	-7.31	1.14e-12	3.63e-10	-0.36	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964569	chr19:52049007~52049754:+
THCA	cis	rs2880765	0.835	rs6497202	ENSG00000259295.5	CSPG4P12	7.31	1.14e-12	3.63e-10	0.4	0.32	Coronary artery disease;	chr15:85478144	chr15:85191438~85213905:+
THCA	cis	rs6600671	1	rs4844380	ENSG00000223345.3	HIST2H2BA	7.31	1.14e-12	3.63e-10	0.35	0.32	Hip geometry;	chr1:121451764	chr1:121108210~121117257:-
THCA	cis	rs1009647	0.645	rs67773067	ENSG00000258413.1	RP11-665C16.6	-7.31	1.15e-12	3.64e-10	-0.57	-0.32	Testicular germ cell tumor;	chr14:55230489	chr14:55262767~55272075:-
THCA	cis	rs1009647	0.645	rs17672298	ENSG00000258413.1	RP11-665C16.6	-7.31	1.15e-12	3.64e-10	-0.57	-0.32	Testicular germ cell tumor;	chr14:55233566	chr14:55262767~55272075:-
THCA	cis	rs1009647	0.645	rs68153899	ENSG00000258413.1	RP11-665C16.6	-7.31	1.15e-12	3.64e-10	-0.57	-0.32	Testicular germ cell tumor;	chr14:55236190	chr14:55262767~55272075:-
THCA	cis	rs737008	0.959	rs11865598	ENSG00000262636.1	CTD-3088G3.4	7.31	1.15e-12	3.64e-10	0.42	0.32	Obesity-related traits;	chr16:11309575	chr16:11380859~11381118:-
THCA	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-7.31	1.15e-12	3.64e-10	-0.35	-0.32	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
THCA	cis	rs944289	0.504	rs107196	ENSG00000257826.1	RP11-116N8.4	7.31	1.15e-12	3.65e-10	0.34	0.32	Thyroid cancer;	chr14:36054892	chr14:36061026~36067190:-
THCA	cis	rs853679	0.607	rs13194781	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27847861	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs36116761	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27850704	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs34194357	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27850757	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13199772	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27866307	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13199906	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27866361	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs17763089	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27867440	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs17695758	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27869405	chr6:28170845~28172521:+
THCA	cis	rs6723108	0.627	rs1446524	ENSG00000224043.6	CCNT2-AS1	-7.31	1.15e-12	3.65e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134873761	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs10928522	ENSG00000224043.6	CCNT2-AS1	-7.31	1.15e-12	3.65e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134875292	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs4954193	ENSG00000224043.6	CCNT2-AS1	-7.31	1.15e-12	3.65e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134884610	chr2:134735464~134918710:-
THCA	cis	rs45509595	0.841	rs17751184	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Breast cancer;	chr6:27807250	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs67101035	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27831109	chr6:28170845~28172521:+
THCA	cis	rs853679	0.556	rs34706883	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27837477	chr6:28170845~28172521:+
THCA	cis	rs67340775	0.748	rs13212651	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Lung cancer in ever smokers;	chr6:27839207	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs35819751	ENSG00000280107.1	AL022393.9	-7.31	1.15e-12	3.65e-10	-0.64	-0.32	Depression;	chr6:27842791	chr6:28170845~28172521:+
THCA	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-7.31	1.15e-12	3.66e-10	-0.21	-0.32	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
THCA	cis	rs7811142	1	rs11771241	ENSG00000078319.8	PMS2P1	-7.31	1.15e-12	3.66e-10	-0.45	-0.32	Platelet count;	chr7:100397162	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.943	rs10241492	ENSG00000078319.8	PMS2P1	-7.31	1.15e-12	3.66e-10	-0.45	-0.32	Platelet count;	chr7:100397190	chr7:100320992~100341908:-
THCA	cis	rs6570726	0.526	rs9403699	ENSG00000235652.6	RP11-545I5.3	7.31	1.15e-12	3.66e-10	0.3	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145409549	chr6:145799409~145886585:+
THCA	cis	rs7746199	0.736	rs34064842	ENSG00000280107.1	AL022393.9	-7.31	1.16e-12	3.67e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28170845~28172521:+
THCA	cis	rs2522056	1	rs2522056	ENSG00000233006.5	AC034220.3	-7.31	1.16e-12	3.67e-10	-0.28	-0.32	Fibrinogen;Lymphocyte counts;	chr5:132466034	chr5:132311285~132369916:-
THCA	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-7.31	1.16e-12	3.68e-10	-0.31	-0.32	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
THCA	cis	rs8114671	0.527	rs3736802	ENSG00000269202.1	RP4-614O4.12	7.31	1.16e-12	3.68e-10	0.27	0.32	Height;	chr20:35016239	chr20:35201747~35203288:-
THCA	cis	rs71636778	0.509	rs6656815	ENSG00000260063.1	RP5-968P14.2	-7.31	1.16e-12	3.69e-10	-0.59	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26965971	chr1:26692132~26694131:-
THCA	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	7.31	1.16e-12	3.69e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
THCA	cis	rs6430553	0.964	rs10496731	ENSG00000224043.6	CCNT2-AS1	-7.31	1.16e-12	3.69e-10	-0.32	-0.32	Blood metabolite levels;	chr2:134840058	chr2:134735464~134918710:-
THCA	cis	rs9549328	0.8	rs9549621	ENSG00000267868.1	RP11-120K24.3	7.31	1.16e-12	3.69e-10	0.33	0.32	Systolic blood pressure;	chr13:112979265	chr13:112964835~112966131:-
THCA	cis	rs198389	0.568	rs12406667	ENSG00000242349.4	NPPA-AS1	7.31	1.16e-12	3.69e-10	0.3	0.32	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813794	chr1:11841017~11848079:+
THCA	cis	rs12681366	0.881	rs12676373	ENSG00000253704.1	RP11-267M23.4	7.31	1.16e-12	3.7e-10	0.35	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94349890	chr8:94553722~94569745:+
THCA	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	7.31	1.17e-12	3.7e-10	0.39	0.32	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
THCA	cis	rs9341808	0.718	rs10943699	ENSG00000272129.1	RP11-250B2.6	7.31	1.17e-12	3.7e-10	0.41	0.32	Sitting height ratio;	chr6:80230824	chr6:80355424~80356859:+
THCA	cis	rs74233809	1	rs9633712	ENSG00000213277.3	MARCKSL1P1	7.31	1.17e-12	3.7e-10	0.52	0.32	Birth weight;	chr10:103114004	chr10:103175554~103176094:+
THCA	cis	rs74233809	0.786	rs11191564	ENSG00000213277.3	MARCKSL1P1	7.31	1.17e-12	3.7e-10	0.52	0.32	Birth weight;	chr10:103118786	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs1060240	ENSG00000213277.3	MARCKSL1P1	7.31	1.17e-12	3.7e-10	0.52	0.32	Birth weight;	chr10:103123580	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs10883835	ENSG00000213277.3	MARCKSL1P1	7.31	1.17e-12	3.7e-10	0.52	0.32	Birth weight;	chr10:103124451	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs732998	ENSG00000213277.3	MARCKSL1P1	-7.31	1.17e-12	3.7e-10	-0.52	-0.32	Birth weight;	chr10:103138144	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191575	ENSG00000213277.3	MARCKSL1P1	7.31	1.17e-12	3.7e-10	0.52	0.32	Birth weight;	chr10:103138580	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs79993475	ENSG00000213277.3	MARCKSL1P1	7.31	1.17e-12	3.7e-10	0.52	0.32	Birth weight;	chr10:103141274	chr10:103175554~103176094:+
THCA	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-7.31	1.17e-12	3.71e-10	-0.36	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-7.31	1.17e-12	3.71e-10	-0.36	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
THCA	cis	rs1043099	0.549	rs9608904	ENSG00000279699.1	RP1-102K2.9	-7.31	1.17e-12	3.71e-10	-0.39	-0.32	Rheumatoid arthritis;	chr22:30412772	chr22:30275215~30276951:-
THCA	cis	rs4934494	0.727	rs12572012	ENSG00000232936.4	RP11-80H5.2	7.31	1.17e-12	3.71e-10	0.43	0.32	Red blood cell count;	chr10:89727892	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.727	rs3758388	ENSG00000232936.4	RP11-80H5.2	7.31	1.17e-12	3.71e-10	0.43	0.32	Red blood cell count;	chr10:89729222	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.727	rs12783582	ENSG00000232936.4	RP11-80H5.2	7.31	1.17e-12	3.71e-10	0.43	0.32	Red blood cell count;	chr10:89735210	chr10:89645282~89650667:+
THCA	cis	rs7665090	0.714	rs5026475	ENSG00000246560.2	RP11-10L12.4	7.31	1.17e-12	3.71e-10	0.38	0.32	Primary biliary cholangitis;	chr4:102633664	chr4:102828055~102844075:+
THCA	cis	rs853679	0.585	rs201004	ENSG00000219392.1	RP1-265C24.5	-7.31	1.17e-12	3.71e-10	-0.45	-0.32	Depression;	chr6:27837156	chr6:28115628~28116551:+
THCA	cis	rs6696239	0.513	rs2492634	ENSG00000227711.2	RP11-275O4.5	7.31	1.17e-12	3.71e-10	0.34	0.32	Height;	chr1:227517157	chr1:227509028~227520477:-
THCA	cis	rs12681366	0.663	rs4735294	ENSG00000253704.1	RP11-267M23.4	7.31	1.17e-12	3.71e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94478313	chr8:94553722~94569745:+
THCA	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	7.31	1.17e-12	3.72e-10	0.4	0.32	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
THCA	cis	rs914615	0.508	rs4390169	ENSG00000160766.13	GBAP1	7.31	1.17e-12	3.72e-10	0.35	0.32	Urinary albumin-to-creatinine ratio;	chr1:155133578	chr1:155213821~155227422:-
THCA	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-7.31	1.17e-12	3.72e-10	-0.36	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-7.31	1.17e-12	3.72e-10	-0.36	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-7.31	1.17e-12	3.72e-10	-0.36	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-7.31	1.17e-12	3.72e-10	-0.36	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
THCA	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-7.31	1.17e-12	3.72e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
THCA	cis	rs6696239	0.513	rs903684	ENSG00000227711.2	RP11-275O4.5	-7.31	1.17e-12	3.72e-10	-0.34	-0.32	Height;	chr1:227509398	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.531	rs2644140	ENSG00000227711.2	RP11-275O4.5	-7.31	1.17e-12	3.72e-10	-0.34	-0.32	Height;	chr1:227509680	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.531	rs2018401	ENSG00000227711.2	RP11-275O4.5	-7.31	1.17e-12	3.72e-10	-0.34	-0.32	Height;	chr1:227509952	chr1:227509028~227520477:-
THCA	cis	rs853679	0.517	rs3757187	ENSG00000220721.1	OR1F12	7.31	1.17e-12	3.73e-10	0.44	0.32	Depression;	chr6:28139876	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000220721.1	OR1F12	7.31	1.17e-12	3.73e-10	0.44	0.32	Depression;	chr6:28139998	chr6:28073316~28074233:+
THCA	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-7.31	1.18e-12	3.73e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
THCA	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-7.31	1.18e-12	3.73e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
THCA	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-7.31	1.18e-12	3.73e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
THCA	cis	rs829883	0.714	rs249847	ENSG00000227825.4	SLC9A7P1	7.31	1.18e-12	3.73e-10	0.27	0.32	Colorectal adenoma (advanced);	chr12:98473938	chr12:98453835~98457145:-
THCA	cis	rs9341808	0.754	rs6907729	ENSG00000272129.1	RP11-250B2.6	-7.31	1.18e-12	3.74e-10	-0.4	-0.32	Sitting height ratio;	chr6:80295205	chr6:80355424~80356859:+
THCA	cis	rs17695224	0.585	rs7252487	ENSG00000269483.1	AC006272.1	7.31	1.18e-12	3.75e-10	0.34	0.32	HDL cholesterol;HDL cholesterol levels;	chr19:51821490	chr19:51839924~51843324:-
THCA	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-7.31	1.18e-12	3.75e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
THCA	cis	rs7208859	0.673	rs11653955	ENSG00000264538.5	SUZ12P1	-7.31	1.18e-12	3.76e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30709299~30790908:+
THCA	cis	rs9341808	0.718	rs9343978	ENSG00000272129.1	RP11-250B2.6	7.31	1.19e-12	3.76e-10	0.41	0.32	Sitting height ratio;	chr6:80262261	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.754	rs9341810	ENSG00000272129.1	RP11-250B2.6	7.31	1.19e-12	3.76e-10	0.41	0.32	Sitting height ratio;	chr6:80265121	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.7	rs12215236	ENSG00000272129.1	RP11-250B2.6	7.31	1.19e-12	3.76e-10	0.41	0.32	Sitting height ratio;	chr6:80265341	chr6:80355424~80356859:+
THCA	cis	rs2688608	0.653	rs12775558	ENSG00000271816.1	BMS1P4	7.31	1.19e-12	3.76e-10	0.33	0.32	Inflammatory bowel disease;	chr10:73811110	chr10:73699151~73730487:-
THCA	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-7.31	1.19e-12	3.77e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
THCA	cis	rs2976388	0.669	rs2585135	ENSG00000253741.1	CTD-2292P10.4	7.31	1.19e-12	3.78e-10	0.4	0.32	Urinary tract infection frequency;	chr8:142732775	chr8:142702252~142726973:-
THCA	cis	rs11148252	0.538	rs2296349	ENSG00000278238.1	RP11-245D16.4	-7.31	1.19e-12	3.78e-10	-0.35	-0.32	Lewy body disease;	chr13:52135922	chr13:52454775~52455331:-
THCA	cis	rs651907	0.557	rs13069443	ENSG00000256628.3	ZBTB11-AS1	7.31	1.19e-12	3.78e-10	0.38	0.32	Colorectal cancer;	chr3:101654461	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs11925001	ENSG00000256628.3	ZBTB11-AS1	7.31	1.19e-12	3.78e-10	0.38	0.32	Colorectal cancer;	chr3:101655122	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs34624546	ENSG00000256628.3	ZBTB11-AS1	7.31	1.19e-12	3.78e-10	0.38	0.32	Colorectal cancer;	chr3:101655382	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs56291106	ENSG00000256628.3	ZBTB11-AS1	7.31	1.19e-12	3.78e-10	0.38	0.32	Colorectal cancer;	chr3:101658630	chr3:101676475~101679217:+
THCA	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	7.3	1.2e-12	3.8e-10	0.39	0.32	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	7.3	1.2e-12	3.8e-10	0.39	0.32	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
THCA	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-7.3	1.2e-12	3.8e-10	-0.33	-0.32	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
THCA	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	7.3	1.2e-12	3.8e-10	0.41	0.32	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
THCA	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	7.3	1.2e-12	3.8e-10	0.48	0.32	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
THCA	cis	rs5760842	0.967	rs5760830	ENSG00000279110.1	CTA-243E7.1	-7.3	1.2e-12	3.81e-10	-0.39	-0.32	Recurrent major depressive disorder;	chr22:25081637	chr22:25052122~25065241:-
THCA	cis	rs2911132	1	rs2617433	ENSG00000248734.2	CTD-2260A17.1	7.3	1.2e-12	3.81e-10	0.34	0.32	Urate levels (BMI interaction);	chr5:96840738	chr5:96784777~96785999:+
THCA	cis	rs4073416	0.771	rs11158596	ENSG00000276116.2	FUT8-AS1	7.3	1.2e-12	3.81e-10	0.33	0.32	N-glycan levels;	chr14:65445257	chr14:65411170~65412690:-
THCA	cis	rs7430456	0.967	rs6780021	ENSG00000228221.4	LINC00578	7.3	1.2e-12	3.81e-10	0.42	0.32	Breast cancer;	chr3:177739677	chr3:177441921~177752305:+
THCA	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-7.3	1.21e-12	3.82e-10	-0.39	-0.32	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
THCA	cis	rs3812049	0.784	rs3749748	ENSG00000245937.6	LINC01184	-7.3	1.21e-12	3.83e-10	-0.36	-0.32	Lymphocyte counts;Red cell distribution width;	chr5:128014857	chr5:127940426~128083172:-
THCA	cis	rs4713118	0.866	rs9468217	ENSG00000280107.1	AL022393.9	-7.3	1.21e-12	3.83e-10	-0.38	-0.32	Parkinson's disease;	chr6:27758688	chr6:28170845~28172521:+
THCA	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	7.3	1.21e-12	3.84e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
THCA	cis	rs875971	1	rs7781698	ENSG00000232559.3	GS1-124K5.12	7.3	1.22e-12	3.86e-10	0.3	0.32	Aortic root size;	chr7:66431325	chr7:66554588~66576923:-
THCA	cis	rs17572109	0.666	rs4674297	ENSG00000261338.2	RP11-378A13.1	7.3	1.22e-12	3.86e-10	0.39	0.32	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218255319~218257366:+
THCA	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	7.3	1.22e-12	3.87e-10	0.38	0.32	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
THCA	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	7.3	1.22e-12	3.87e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	7.3	1.22e-12	3.87e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	7.3	1.22e-12	3.87e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	7.3	1.22e-12	3.87e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	7.3	1.22e-12	3.87e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
THCA	cis	rs7746199	0.673	rs72847313	ENSG00000280107.1	AL022393.9	-7.3	1.22e-12	3.87e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.611	rs17750747	ENSG00000280107.1	AL022393.9	-7.3	1.22e-12	3.87e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28170845~28172521:+
THCA	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-7.3	1.22e-12	3.88e-10	-0.41	-0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
THCA	cis	rs7567389	0.568	rs7568070	ENSG00000236682.1	AC068282.3	-7.3	1.22e-12	3.88e-10	-0.46	-0.32	Self-rated health;	chr2:127195478	chr2:127389130~127400580:+
THCA	cis	rs240993	0.812	rs9487626	ENSG00000230177.1	RP5-1112D6.4	-7.3	1.23e-12	3.88e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111395665	chr6:111277932~111278742:+
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000263603.1	CTD-2349P21.5	-7.3	1.23e-12	3.88e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30729469~30731202:+
THCA	cis	rs17695224	0.545	rs12459256	ENSG00000269483.1	AC006272.1	7.3	1.23e-12	3.88e-10	0.34	0.32	HDL cholesterol;HDL cholesterol levels;	chr19:51819835	chr19:51839924~51843324:-
THCA	cis	rs2929278	0.617	rs524908	ENSG00000166763.7	STRCP1	-7.3	1.23e-12	3.88e-10	-0.35	-0.32	Schizophrenia;	chr15:43895793	chr15:43699488~43718184:-
THCA	cis	rs240993	0.761	rs462832	ENSG00000230177.1	RP5-1112D6.4	-7.3	1.23e-12	3.88e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111365088	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs455645	ENSG00000230177.1	RP5-1112D6.4	-7.3	1.23e-12	3.88e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111373870	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs462779	ENSG00000230177.1	RP5-1112D6.4	-7.3	1.23e-12	3.88e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111374684	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs461646	ENSG00000230177.1	RP5-1112D6.4	-7.3	1.23e-12	3.88e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111375054	chr6:111277932~111278742:+
THCA	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	7.3	1.23e-12	3.89e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
THCA	cis	rs2836974	0.583	rs2735307	ENSG00000255568.3	BRWD1-AS2	7.3	1.23e-12	3.89e-10	0.26	0.32	Cognitive function;	chr21:39341432	chr21:39313935~39314962:+
THCA	cis	rs6452524	0.544	rs2126989	ENSG00000249664.1	CTD-2227C6.2	-7.3	1.23e-12	3.89e-10	-0.42	-0.32	Hypertension (SNP x SNP interaction);	chr5:83092120	chr5:83012285~83013109:-
THCA	cis	rs6723108	0.627	rs1348790	ENSG00000224043.6	CCNT2-AS1	-7.3	1.23e-12	3.9e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134882405	chr2:134735464~134918710:-
THCA	cis	rs9902453	0.726	rs3110494	ENSG00000264007.1	RP11-68I3.10	7.3	1.23e-12	3.9e-10	0.35	0.32	Coffee consumption (cups per day);	chr17:29649579	chr17:29621617~29622254:-
THCA	cis	rs74233809	1	rs12412038	ENSG00000213277.3	MARCKSL1P1	7.3	1.23e-12	3.9e-10	0.53	0.32	Birth weight;	chr10:103096405	chr10:103175554~103176094:+
THCA	cis	rs240993	0.715	rs7752418	ENSG00000230177.1	RP5-1112D6.4	7.3	1.24e-12	3.92e-10	0.31	0.32	Inflammatory skin disease;Psoriasis;	chr6:111466682	chr6:111277932~111278742:+
THCA	cis	rs2976388	0.692	rs1435453	ENSG00000253741.1	CTD-2292P10.4	-7.3	1.24e-12	3.92e-10	-0.4	-0.32	Urinary tract infection frequency;	chr8:142699357	chr8:142702252~142726973:-
THCA	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	7.3	1.24e-12	3.93e-10	0.4	0.32	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
THCA	cis	rs9341808	0.754	rs6918172	ENSG00000272129.1	RP11-250B2.6	7.3	1.25e-12	3.94e-10	0.4	0.32	Sitting height ratio;	chr6:80309525	chr6:80355424~80356859:+
THCA	cis	rs2281636	0.723	rs11190255	ENSG00000233690.1	EBAG9P1	7.3	1.25e-12	3.94e-10	0.34	0.32	Obesity-related traits;	chr10:99714742	chr10:99697407~99697949:-
THCA	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-7.3	1.25e-12	3.94e-10	-0.46	-0.32	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
THCA	cis	rs741668	0.759	rs73188488	ENSG00000235903.6	CPB2-AS1	7.3	1.25e-12	3.95e-10	0.42	0.32	Cerebrospinal fluid clusterin levels;	chr13:46050849	chr13:46052806~46113332:+
THCA	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-7.3	1.25e-12	3.95e-10	-0.48	-0.32	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
THCA	cis	rs7302981	0.967	rs7136570	ENSG00000272368.2	RP4-605O3.4	-7.3	1.25e-12	3.96e-10	-0.19	-0.32	Systolic blood pressure;	chr12:50136153	chr12:50112197~50165618:+
THCA	cis	rs6600671	1	rs1591882	ENSG00000223345.3	HIST2H2BA	7.3	1.25e-12	3.96e-10	0.34	0.32	Hip geometry;	chr1:121441455	chr1:121108210~121117257:-
THCA	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-7.3	1.25e-12	3.97e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
THCA	cis	rs2439831	0.867	rs2260160	ENSG00000275601.1	AC011330.13	-7.3	1.25e-12	3.97e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43603445	chr15:43642389~43643023:-
THCA	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-7.3	1.25e-12	3.97e-10	-0.42	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
THCA	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-7.3	1.25e-12	3.97e-10	-0.42	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
THCA	cis	rs9341808	0.727	rs1324120	ENSG00000272129.1	RP11-250B2.6	7.3	1.25e-12	3.97e-10	0.41	0.32	Sitting height ratio;	chr6:80266408	chr6:80355424~80356859:+
THCA	cis	rs6600671	0.899	rs6674392	ENSG00000223345.3	HIST2H2BA	7.3	1.26e-12	3.97e-10	0.35	0.32	Hip geometry;	chr1:121518864	chr1:121108210~121117257:-
THCA	cis	rs17345786	0.511	rs1138818	ENSG00000256628.3	ZBTB11-AS1	7.3	1.26e-12	3.97e-10	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101676475~101679217:+
THCA	cis	rs4072705	1	rs10760373	ENSG00000224020.1	MIR181A2HG	-7.3	1.26e-12	3.98e-10	-0.28	-0.32	Menarche (age at onset);	chr9:124723166	chr9:124658467~124698631:+
THCA	cis	rs7945705	0.846	rs905290	ENSG00000254860.4	TMEM9B-AS1	-7.3	1.26e-12	3.99e-10	-0.35	-0.32	Hemoglobin concentration;	chr11:8732182	chr11:8964675~8977527:+
THCA	cis	rs984222	0.501	rs1361906	ENSG00000231365.4	RP11-418J17.1	-7.3	1.26e-12	3.99e-10	-0.31	-0.32	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942021	chr1:119140396~119275973:+
THCA	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	7.3	1.27e-12	4.01e-10	0.45	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
THCA	cis	rs7942368	0.941	rs737185	ENSG00000254761.1	RP11-672A2.1	7.3	1.27e-12	4.01e-10	0.45	0.32	Endometriosis;	chr11:76774314	chr11:76712396~76719608:-
THCA	cis	rs6745190	0.953	rs4667005	ENSG00000236153.1	AC104076.3	-7.3	1.27e-12	4.01e-10	-0.37	-0.32	White blood cell count;	chr2:180997852	chr2:180979427~180980090:-
THCA	cis	rs7942368	0.941	rs1465900	ENSG00000254761.1	RP11-672A2.1	7.3	1.27e-12	4.01e-10	0.45	0.32	Endometriosis;	chr11:76762094	chr11:76712396~76719608:-
THCA	cis	rs7942368	1	rs10160660	ENSG00000254761.1	RP11-672A2.1	7.3	1.27e-12	4.01e-10	0.45	0.32	Endometriosis;	chr11:76763493	chr11:76712396~76719608:-
THCA	cis	rs9388451	0.626	rs7748729	ENSG00000237742.5	RP11-624M8.1	-7.3	1.27e-12	4.01e-10	-0.28	-0.32	Brugada syndrome;	chr6:125756235	chr6:125578558~125749190:-
THCA	cis	rs651907	0.557	rs3094295	ENSG00000256628.3	ZBTB11-AS1	7.3	1.27e-12	4.02e-10	0.38	0.32	Colorectal cancer;	chr3:101683151	chr3:101676475~101679217:+
THCA	cis	rs453301	0.631	rs7843369	ENSG00000253893.2	FAM85B	7.3	1.27e-12	4.02e-10	0.44	0.32	Joint mobility (Beighton score);	chr8:8940276	chr8:8167819~8226614:-
THCA	cis	rs853679	1	rs1679732	ENSG00000280107.1	AL022393.9	7.3	1.27e-12	4.03e-10	0.45	0.32	Depression;	chr6:28253486	chr6:28170845~28172521:+
THCA	cis	rs7120173	0.693	rs12799198	ENSG00000254851.1	RP11-109L13.1	-7.3	1.28e-12	4.03e-10	-0.51	-0.32	Visceral adipose tissue adjusted for BMI;	chr11:116930706	chr11:117135528~117138582:+
THCA	cis	rs4947019	0.609	rs17070590	ENSG00000260273.1	RP11-425D10.10	7.3	1.28e-12	4.04e-10	0.69	0.32	Hematological parameters;	chr6:109424420	chr6:109382795~109383666:+
THCA	cis	rs2302464	1	rs4395498	ENSG00000214846.4	RP11-115L11.1	7.29	1.28e-12	4.04e-10	0.79	0.32	Cerebrospinal fluid biomarker levels;	chr4:15731674	chr4:15730962~15731627:-
THCA	cis	rs9902453	0.845	rs12602426	ENSG00000264007.1	RP11-68I3.10	7.29	1.28e-12	4.04e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29831797	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs10853135	ENSG00000264007.1	RP11-68I3.10	7.29	1.28e-12	4.04e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29861657	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.808	rs76515799	ENSG00000264007.1	RP11-68I3.10	7.29	1.28e-12	4.04e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29842473	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.808	rs78154346	ENSG00000264007.1	RP11-68I3.10	7.29	1.28e-12	4.04e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29842475	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.808	rs56088359	ENSG00000264007.1	RP11-68I3.10	7.29	1.28e-12	4.04e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29846641	chr17:29621617~29622254:-
THCA	cis	rs6762	0.642	rs28692469	ENSG00000279672.1	CMB9-55F22.1	7.29	1.28e-12	4.04e-10	0.36	0.32	Mean platelet volume;	chr11:839675	chr11:779617~780755:+
THCA	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	7.29	1.28e-12	4.05e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000263603.1	CTD-2349P21.5	-7.29	1.28e-12	4.06e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30729469~30731202:+
THCA	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	7.29	1.28e-12	4.06e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	7.29	1.28e-12	4.06e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	7.29	1.28e-12	4.06e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	7.29	1.28e-12	4.06e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	7.29	1.28e-12	4.06e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	7.29	1.28e-12	4.06e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	7.29	1.28e-12	4.06e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	7.29	1.28e-12	4.06e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
THCA	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-7.29	1.29e-12	4.06e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
THCA	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-7.29	1.29e-12	4.08e-10	-0.34	-0.32	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-7.29	1.29e-12	4.08e-10	-0.34	-0.32	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-7.29	1.29e-12	4.08e-10	-0.34	-0.32	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-7.29	1.29e-12	4.08e-10	-0.34	-0.32	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
THCA	cis	rs651907	0.557	rs11917569	ENSG00000256628.3	ZBTB11-AS1	7.29	1.3e-12	4.1e-10	0.38	0.32	Colorectal cancer;	chr3:101636219	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs11917682	ENSG00000256628.3	ZBTB11-AS1	7.29	1.3e-12	4.1e-10	0.38	0.32	Colorectal cancer;	chr3:101636583	chr3:101676475~101679217:+
THCA	cis	rs6723108	0.603	rs6733130	ENSG00000224043.6	CCNT2-AS1	-7.29	1.3e-12	4.1e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134908983	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs1374287	ENSG00000224043.6	CCNT2-AS1	-7.29	1.3e-12	4.1e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134909631	chr2:134735464~134918710:-
THCA	cis	rs910316	0.967	rs11159121	ENSG00000279594.1	RP11-950C14.10	-7.29	1.3e-12	4.1e-10	-0.29	-0.32	Height;	chr14:75199326	chr14:75011269~75012851:-
THCA	cis	rs4639966	0.589	rs480958	ENSG00000255239.1	AP002954.6	7.29	1.3e-12	4.1e-10	0.41	0.32	Systemic lupus erythematosus;	chr11:118707281	chr11:118688039~118690600:-
THCA	cis	rs240993	0.715	rs399219	ENSG00000230177.1	RP5-1112D6.4	-7.29	1.3e-12	4.1e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111371880	chr6:111277932~111278742:+
THCA	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-7.29	1.3e-12	4.11e-10	-0.4	-0.32	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
THCA	cis	rs728616	0.614	rs10887235	ENSG00000225484.5	NUTM2B-AS1	-7.29	1.3e-12	4.11e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955890	chr10:79663088~79826594:-
THCA	cis	rs12681366	1	rs7825731	ENSG00000253704.1	RP11-267M23.4	7.29	1.3e-12	4.12e-10	0.32	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94362147	chr8:94553722~94569745:+
THCA	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-7.29	1.31e-12	4.12e-10	-0.31	-0.32	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
THCA	cis	rs9902453	0.817	rs2617880	ENSG00000264007.1	RP11-68I3.10	-7.29	1.31e-12	4.13e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:29779100	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.808	rs62068617	ENSG00000264007.1	RP11-68I3.10	7.29	1.31e-12	4.13e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29817710	chr17:29621617~29622254:-
THCA	cis	rs651907	0.557	rs13081846	ENSG00000256628.3	ZBTB11-AS1	7.29	1.31e-12	4.13e-10	0.38	0.32	Colorectal cancer;	chr3:101664477	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs11711079	ENSG00000256628.3	ZBTB11-AS1	7.29	1.31e-12	4.13e-10	0.38	0.32	Colorectal cancer;	chr3:101668074	chr3:101676475~101679217:+
THCA	cis	rs17345786	0.511	rs13061565	ENSG00000256628.3	ZBTB11-AS1	7.29	1.31e-12	4.13e-10	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs7651404	ENSG00000256628.3	ZBTB11-AS1	7.29	1.31e-12	4.13e-10	0.38	0.32	Colorectal cancer;	chr3:101674450	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs3806653	ENSG00000256628.3	ZBTB11-AS1	7.29	1.31e-12	4.13e-10	0.38	0.32	Colorectal cancer;	chr3:101678128	chr3:101676475~101679217:+
THCA	cis	rs71636778	0.509	rs34460334	ENSG00000260063.1	RP5-968P14.2	-7.29	1.31e-12	4.13e-10	-0.62	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26888588	chr1:26692132~26694131:-
THCA	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-7.29	1.31e-12	4.13e-10	-0.47	-0.32	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
THCA	cis	rs4266144	0.558	rs34696078	ENSG00000244515.1	KRT18P34	-7.29	1.31e-12	4.13e-10	-0.36	-0.32	Coronary artery disease;	chr3:157114875	chr3:157162663~157163932:-
THCA	cis	rs2880765	0.835	rs6496027	ENSG00000259295.5	CSPG4P12	7.29	1.31e-12	4.14e-10	0.41	0.32	Coronary artery disease;	chr15:85506757	chr15:85191438~85213905:+
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000263603.1	CTD-2349P21.5	-7.29	1.31e-12	4.14e-10	-0.54	-0.32	Body mass index;	chr17:30806554	chr17:30729469~30731202:+
THCA	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	7.29	1.31e-12	4.14e-10	0.32	0.32	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
THCA	cis	rs910316	0.737	rs175084	ENSG00000279594.1	RP11-950C14.10	-7.29	1.31e-12	4.15e-10	-0.29	-0.32	Height;	chr14:75052472	chr14:75011269~75012851:-
THCA	cis	rs9902453	1	rs4533340	ENSG00000264007.1	RP11-68I3.10	7.29	1.32e-12	4.15e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29950933	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	7.29	1.32e-12	4.15e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	7.29	1.32e-12	4.15e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
THCA	cis	rs748404	0.646	rs2253268	ENSG00000166763.7	STRCP1	7.29	1.32e-12	4.15e-10	0.34	0.32	Lung cancer;	chr15:43508770	chr15:43699488~43718184:-
THCA	cis	rs801193	0.569	rs2659907	ENSG00000232559.3	GS1-124K5.12	7.29	1.32e-12	4.15e-10	0.3	0.32	Aortic root size;	chr7:66699045	chr7:66554588~66576923:-
THCA	cis	rs593531	0.592	rs598869	ENSG00000212961.4	HNRNPA1P40	7.29	1.32e-12	4.15e-10	0.4	0.32	Neuroticism;	chr11:74335930	chr11:74354443~74355720:+
THCA	cis	rs7208859	0.623	rs9914242	ENSG00000264538.5	SUZ12P1	-7.29	1.32e-12	4.16e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30709299~30790908:+
THCA	cis	rs3806843	0.735	rs778596	ENSG00000202515.1	VTRNA1-3	7.29	1.32e-12	4.16e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr5:140726158~140726246:+
THCA	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-7.29	1.32e-12	4.17e-10	-0.31	-0.32	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
THCA	cis	rs6545883	0.503	rs1665272	ENSG00000271889.1	RP11-493E12.1	7.29	1.33e-12	4.18e-10	0.3	0.32	Tuberculosis;	chr2:61152151	chr2:61151433~61162105:-
THCA	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-7.29	1.33e-12	4.18e-10	-0.31	-0.32	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-7.29	1.33e-12	4.18e-10	-0.31	-0.32	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-7.29	1.33e-12	4.18e-10	-0.31	-0.32	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
THCA	cis	rs853679	0.517	rs4713145	ENSG00000272009.1	RP1-313I6.12	-7.29	1.33e-12	4.18e-10	-0.38	-0.32	Depression;	chr6:28139049	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs149901	ENSG00000226314.6	ZNF192P1	-7.29	1.33e-12	4.18e-10	-0.39	-0.32	Parkinson's disease;	chr6:27997725	chr6:28161781~28169594:+
THCA	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	7.29	1.33e-12	4.18e-10	0.49	0.32	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
THCA	cis	rs1198430	1	rs1198431	ENSG00000232482.2	RP4-654C18.1	7.29	1.33e-12	4.18e-10	0.56	0.32	Total cholesterol levels;	chr1:23429223	chr1:23410832~23412146:+
THCA	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-7.29	1.33e-12	4.19e-10	-0.31	-0.32	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000263603.1	CTD-2349P21.5	-7.29	1.33e-12	4.19e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30729469~30731202:+
THCA	cis	rs2439831	0.85	rs2957637	ENSG00000275601.1	AC011330.13	-7.29	1.33e-12	4.19e-10	-0.5	-0.32	Lung cancer in ever smokers;	chr15:43658920	chr15:43642389~43643023:-
THCA	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	7.29	1.33e-12	4.19e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	7.29	1.33e-12	4.19e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
THCA	cis	rs10208649	1	rs75237140	ENSG00000272156.1	RP11-477N3.1	7.29	1.33e-12	4.19e-10	0.58	0.32	Body mass index;	chr2:53953570	chr2:54082554~54085066:+
THCA	cis	rs240993	0.812	rs460594	ENSG00000230177.1	RP5-1112D6.4	-7.29	1.33e-12	4.2e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111348602	chr6:111277932~111278742:+
THCA	cis	rs6762	0.748	rs28735718	ENSG00000279672.1	CMB9-55F22.1	7.29	1.33e-12	4.2e-10	0.36	0.32	Mean platelet volume;	chr11:839629	chr11:779617~780755:+
THCA	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-7.29	1.34e-12	4.21e-10	-0.31	-0.32	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
THCA	cis	rs12681366	0.734	rs1872889	ENSG00000253704.1	RP11-267M23.4	7.29	1.34e-12	4.21e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94406193	chr8:94553722~94569745:+
THCA	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-7.29	1.34e-12	4.21e-10	-0.34	-0.32	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
THCA	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	7.29	1.34e-12	4.21e-10	0.36	0.32	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
THCA	cis	rs1023500	0.573	rs133381	ENSG00000205702.9	CYP2D7	7.29	1.34e-12	4.22e-10	0.26	0.32	Schizophrenia;	chr22:42074604	chr22:42140203~42144577:-
THCA	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-7.29	1.34e-12	4.22e-10	-0.36	-0.32	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
THCA	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-7.29	1.34e-12	4.23e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-7.29	1.34e-12	4.23e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
THCA	cis	rs651907	0.557	rs7651721	ENSG00000256628.3	ZBTB11-AS1	7.29	1.34e-12	4.23e-10	0.38	0.32	Colorectal cancer;	chr3:101674739	chr3:101676475~101679217:+
THCA	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	7.29	1.35e-12	4.24e-10	0.33	0.32	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
THCA	cis	rs7674212	1	rs7691873	ENSG00000251288.2	RP11-10L12.2	7.29	1.35e-12	4.24e-10	0.43	0.32	Type 2 diabetes;	chr4:103066742	chr4:102751401~102752641:+
THCA	cis	rs2018683	1	rs2018683	ENSG00000228421.2	AC005013.5	7.29	1.35e-12	4.24e-10	0.35	0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28974579	chr7:28957667~28959345:+
THCA	cis	rs442309	0.583	rs10995307	ENSG00000238280.1	RP11-436D10.3	7.29	1.35e-12	4.24e-10	0.38	0.32	Vogt-Koyanagi-Harada syndrome;	chr10:62792482	chr10:62793562~62805887:-
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000263603.1	CTD-2349P21.5	-7.29	1.35e-12	4.25e-10	-0.54	-0.32	Body mass index;	chr17:30778787	chr17:30729469~30731202:+
THCA	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-7.29	1.35e-12	4.25e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
THCA	cis	rs7746199	0.736	rs13212318	ENSG00000280107.1	AL022393.9	-7.29	1.35e-12	4.26e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs13202291	ENSG00000280107.1	AL022393.9	-7.29	1.35e-12	4.26e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs17750424	ENSG00000280107.1	AL022393.9	-7.29	1.35e-12	4.26e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28170845~28172521:+
THCA	cis	rs6430553	0.964	rs1530556	ENSG00000224043.6	CCNT2-AS1	-7.29	1.35e-12	4.26e-10	-0.32	-0.32	Blood metabolite levels;	chr2:134842164	chr2:134735464~134918710:-
THCA	cis	rs853679	0.517	rs9393891	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Depression;	chr6:28111382	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9468286	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Depression;	chr6:28111650	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Parkinson's disease;	chr6:28112168	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs35512245	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Depression;	chr6:28112175	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380055	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Depression;	chr6:28113851	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368553	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Depression;	chr6:28114487	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368554	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Depression;	chr6:28114933	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs4713137	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Depression;	chr6:28115743	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9348793	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Depression;	chr6:28116411	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Parkinson's disease;	chr6:28118700	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Parkinson's disease;	chr6:28118701	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000272009.1	RP1-313I6.12	-7.29	1.36e-12	4.27e-10	-0.37	-0.32	Parkinson's disease;	chr6:28119896	chr6:28078792~28081130:-
THCA	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-7.29	1.36e-12	4.27e-10	-0.34	-0.32	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-7.29	1.36e-12	4.27e-10	-0.34	-0.32	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-7.29	1.36e-12	4.27e-10	-0.34	-0.32	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000263603.1	CTD-2349P21.5	-7.29	1.36e-12	4.27e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30729469~30731202:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-7.29	1.36e-12	4.27e-10	-0.41	-0.32	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
THCA	cis	rs7851660	0.809	rs7866436	ENSG00000236130.1	PTCSC2	-7.29	1.36e-12	4.28e-10	-0.25	-0.32	Strep throat;	chr9:97887814	chr9:97805935~97810008:-
THCA	cis	rs3806843	0.735	rs2563314	ENSG00000202515.1	VTRNA1-3	7.29	1.36e-12	4.28e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs2530240	ENSG00000202515.1	VTRNA1-3	7.29	1.36e-12	4.28e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs801189	ENSG00000202515.1	VTRNA1-3	7.29	1.36e-12	4.28e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.706	rs1089305	ENSG00000202515.1	VTRNA1-3	7.29	1.36e-12	4.28e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs801185	ENSG00000202515.1	VTRNA1-3	7.29	1.36e-12	4.28e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.676	rs2563304	ENSG00000202515.1	VTRNA1-3	7.29	1.36e-12	4.28e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs3776129	ENSG00000202515.1	VTRNA1-3	7.29	1.36e-12	4.28e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr5:140726158~140726246:+
THCA	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-7.29	1.36e-12	4.28e-10	-0.37	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
THCA	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	7.29	1.36e-12	4.29e-10	0.42	0.32	Height;	chr6:109712525	chr6:109382795~109383666:+
THCA	cis	rs7246657	0.943	rs4803347	ENSG00000226686.6	LINC01535	-7.29	1.36e-12	4.29e-10	-0.45	-0.32	Coronary artery calcification;	chr19:37357115	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000263603.1	CTD-2349P21.5	-7.29	1.36e-12	4.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000263603.1	CTD-2349P21.5	-7.29	1.36e-12	4.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30729469~30731202:+
THCA	cis	rs7246657	1	rs12709812	ENSG00000226686.6	LINC01535	7.29	1.37e-12	4.3e-10	0.46	0.32	Coronary artery calcification;	chr19:37303948	chr19:37251912~37265535:+
THCA	cis	rs467650	0.509	rs2545678	ENSG00000246763.5	RGMB-AS1	-7.29	1.37e-12	4.3e-10	-0.3	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr5:98664664	chr5:98769618~98773469:-
THCA	cis	rs516805	0.667	rs1339532	ENSG00000279453.1	RP3-425C14.4	7.28	1.37e-12	4.3e-10	0.33	0.32	Lymphocyte counts;	chr6:122345249	chr6:122436789~122439223:-
THCA	cis	rs6723226	0.708	rs2754513	ENSG00000276334.1	AL133243.1	7.28	1.37e-12	4.31e-10	0.36	0.32	Intelligence (multi-trait analysis);	chr2:32557696	chr2:32521927~32523547:+
THCA	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-7.28	1.37e-12	4.32e-10	-0.46	-0.32	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
THCA	cis	rs7851660	0.874	rs1955143	ENSG00000236130.1	PTCSC2	-7.28	1.37e-12	4.32e-10	-0.25	-0.32	Strep throat;	chr9:97872297	chr9:97805935~97810008:-
THCA	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-7.28	1.37e-12	4.32e-10	-0.56	-0.32	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
THCA	cis	rs728616	0.571	rs113030473	ENSG00000225484.5	NUTM2B-AS1	-7.28	1.38e-12	4.33e-10	-0.65	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79889275	chr10:79663088~79826594:-
THCA	cis	rs6840258	1	rs56390363	ENSG00000251411.1	RP11-397E7.4	-7.28	1.38e-12	4.33e-10	-0.38	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87021935	chr4:86913266~86914817:-
THCA	cis	rs651907	0.557	rs1056579	ENSG00000256628.3	ZBTB11-AS1	7.28	1.38e-12	4.33e-10	0.38	0.32	Colorectal cancer;	chr3:101679033	chr3:101676475~101679217:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66364510	chr7:66554588~66576923:-
THCA	cis	rs875971	0.929	rs778712	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66384991	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs778710	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66389847	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs778708	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66391332	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs778696	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66405826	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs778694	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66406571	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs4718344	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66409394	chr7:66554588~66576923:-
THCA	cis	rs875971	0.737	rs7803424	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66415618	chr7:66554588~66576923:-
THCA	cis	rs875971	0.83	rs7799834	ENSG00000232559.3	GS1-124K5.12	7.28	1.38e-12	4.34e-10	0.3	0.32	Aortic root size;	chr7:66415707	chr7:66554588~66576923:-
THCA	cis	rs2880765	0.805	rs34598679	ENSG00000259295.5	CSPG4P12	7.28	1.38e-12	4.34e-10	0.4	0.32	Coronary artery disease;	chr15:85498974	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs4344688	ENSG00000259295.5	CSPG4P12	7.28	1.38e-12	4.34e-10	0.4	0.32	Coronary artery disease;	chr15:85499776	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs4280192	ENSG00000259295.5	CSPG4P12	7.28	1.38e-12	4.34e-10	0.4	0.32	Coronary artery disease;	chr15:85499789	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs7169632	ENSG00000259295.5	CSPG4P12	7.28	1.38e-12	4.34e-10	0.4	0.32	Coronary artery disease;	chr15:85501436	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs12910373	ENSG00000259295.5	CSPG4P12	7.28	1.38e-12	4.34e-10	0.4	0.32	Coronary artery disease;	chr15:85503571	chr15:85191438~85213905:+
THCA	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	7.28	1.38e-12	4.35e-10	0.39	0.32	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
THCA	cis	rs875971	0.964	rs6945019	ENSG00000232559.3	GS1-124K5.12	7.28	1.39e-12	4.35e-10	0.3	0.32	Aortic root size;	chr7:66457471	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.673	rs999797	ENSG00000264538.5	SUZ12P1	-7.28	1.39e-12	4.36e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30709299~30790908:+
THCA	cis	rs6723108	0.592	rs10928523	ENSG00000224043.6	CCNT2-AS1	-7.28	1.39e-12	4.36e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134907891	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs1374288	ENSG00000224043.6	CCNT2-AS1	-7.28	1.39e-12	4.36e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134909483	chr2:134735464~134918710:-
THCA	cis	rs6928977	0.675	rs12206850	ENSG00000231028.7	LINC00271	-7.28	1.39e-12	4.37e-10	-0.27	-0.32	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135476670	chr6:135497801~135716055:+
THCA	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	7.28	1.39e-12	4.37e-10	0.39	0.32	Height;	chr6:109582583	chr6:109382795~109383666:+
THCA	cis	rs4073416	0.806	rs7148737	ENSG00000276116.2	FUT8-AS1	7.28	1.39e-12	4.37e-10	0.33	0.32	N-glycan levels;	chr14:65763314	chr14:65411170~65412690:-
THCA	cis	rs2976388	0.609	rs2257796	ENSG00000253741.1	CTD-2292P10.4	-7.28	1.39e-12	4.37e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142727249	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.647	rs2585138	ENSG00000253741.1	CTD-2292P10.4	-7.28	1.39e-12	4.37e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142727533	chr8:142702252~142726973:-
THCA	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	7.28	1.39e-12	4.38e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	7.28	1.39e-12	4.38e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	7.28	1.39e-12	4.38e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
THCA	cis	rs7131987	0.903	rs7308125	ENSG00000257176.2	RP11-996F15.2	-7.28	1.39e-12	4.38e-10	-0.31	-0.32	QT interval;	chr12:29272278	chr12:29280418~29317848:-
THCA	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-7.28	1.39e-12	4.38e-10	-0.31	-0.32	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
THCA	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	7.28	1.4e-12	4.38e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	7.28	1.4e-12	4.38e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	7.28	1.4e-12	4.38e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	7.28	1.4e-12	4.38e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	7.28	1.4e-12	4.38e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	7.28	1.4e-12	4.38e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
THCA	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-7.28	1.4e-12	4.39e-10	-0.34	-0.32	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-7.28	1.4e-12	4.39e-10	-0.34	-0.32	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-7.28	1.4e-12	4.39e-10	-0.34	-0.32	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-7.28	1.4e-12	4.39e-10	-0.34	-0.32	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-7.28	1.4e-12	4.39e-10	-0.34	-0.32	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
THCA	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	7.28	1.4e-12	4.39e-10	0.25	0.32	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
THCA	cis	rs172166	0.538	rs149956	ENSG00000219392.1	RP1-265C24.5	-7.28	1.4e-12	4.41e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28068473	chr6:28115628~28116551:+
THCA	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-7.28	1.4e-12	4.41e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-7.28	1.4e-12	4.41e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
THCA	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-7.28	1.4e-12	4.41e-10	-0.39	-0.32	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
THCA	cis	rs7189233	0.955	rs72801821	ENSG00000279722.1	RP11-44F14.6	-7.28	1.41e-12	4.42e-10	-0.34	-0.32	Intelligence (multi-trait analysis);	chr16:53445740	chr16:53487607~53489943:-
THCA	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	7.28	1.41e-12	4.42e-10	0.61	0.32	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	7.28	1.41e-12	4.42e-10	0.61	0.32	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Body mass index;	chr17:30751280	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.42e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30729469~30731202:+
THCA	cis	rs9828933	0.808	rs3733125	ENSG00000280620.1	SCAANT1	7.28	1.41e-12	4.43e-10	0.7	0.32	Type 2 diabetes;	chr3:63995959	chr3:63911518~63911772:-
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Body mass index;	chr17:30739311	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Body mass index;	chr17:30745415	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Body mass index;	chr17:30745654	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000263603.1	CTD-2349P21.5	-7.28	1.41e-12	4.43e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30729469~30731202:+
THCA	cis	rs2976388	0.609	rs2717601	ENSG00000253741.1	CTD-2292P10.4	-7.28	1.42e-12	4.44e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142726506	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2572909	ENSG00000253741.1	CTD-2292P10.4	-7.28	1.42e-12	4.44e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142725046	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2585140	ENSG00000253741.1	CTD-2292P10.4	-7.28	1.42e-12	4.44e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142725478	chr8:142702252~142726973:-
THCA	cis	rs193541	0.53	rs2045626	ENSG00000263432.2	RN7SL689P	7.28	1.42e-12	4.45e-10	0.38	0.32	Glucose homeostasis traits;	chr5:122745558	chr5:123022487~123022783:-
THCA	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	7.28	1.42e-12	4.45e-10	0.48	0.32	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
THCA	cis	rs6672530	0.518	rs7551459	ENSG00000227711.2	RP11-275O4.5	7.28	1.42e-12	4.45e-10	0.33	0.32	Hip circumference adjusted for BMI;	chr1:227536317	chr1:227509028~227520477:-
THCA	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	7.28	1.42e-12	4.45e-10	0.4	0.32	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
THCA	cis	rs7208859	0.673	rs11651802	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs17826219	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs61223749	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs3764421	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11651858	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs36056619	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9909497	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11080135	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9894876	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73277967	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs60020217	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs73277974	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73277978	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs9905827	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Body mass index;	chr17:30865150	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11657391	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs58089675	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73263755	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9899349	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11652358	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11656845	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9891179	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9891413	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73263776	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11650271	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11657270	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73263785	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs55904046	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9889968	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs61348930	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.614	rs28758251	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9899943	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11080138	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73265612	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11658435	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73265624	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs2269915	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs2269916	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs11649765	ENSG00000264538.5	SUZ12P1	-7.28	1.42e-12	4.45e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30709299~30790908:+
THCA	cis	rs172166	0.611	rs203883	ENSG00000280107.1	AL022393.9	-7.28	1.42e-12	4.46e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28110578	chr6:28170845~28172521:+
THCA	cis	rs11133665	1	rs11133665	ENSG00000249201.2	CTD-3080P12.3	7.28	1.42e-12	4.46e-10	0.43	0.32	Urinary metabolites;	chr5:1188170	chr5:1173141~1178605:-
THCA	cis	rs6840258	0.607	rs56023922	ENSG00000251411.1	RP11-397E7.4	-7.28	1.43e-12	4.47e-10	-0.4	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86994934	chr4:86913266~86914817:-
THCA	cis	rs9876781	0.56	rs4558783	ENSG00000229759.1	MRPS18AP1	-7.28	1.43e-12	4.47e-10	-0.39	-0.32	Longevity;	chr3:48365972	chr3:48256350~48256938:-
THCA	cis	rs7760535	0.763	rs10457241	ENSG00000230177.1	RP5-1112D6.4	-7.28	1.43e-12	4.47e-10	-0.26	-0.32	Metabolic traits;	chr6:111527831	chr6:111277932~111278742:+
THCA	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
THCA	cis	rs651907	0.557	rs17411983	ENSG00000256628.3	ZBTB11-AS1	-7.28	1.43e-12	4.47e-10	-0.37	-0.32	Colorectal cancer;	chr3:101680282	chr3:101676475~101679217:+
THCA	cis	rs7428	0.527	rs1053560	ENSG00000246575.2	AC093162.5	7.28	1.43e-12	4.47e-10	0.29	0.32	Ear protrusion;	chr2:85319069	chr2:85315041~85316529:+
THCA	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	7.28	1.43e-12	4.47e-10	0.59	0.32	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
THCA	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	7.28	1.43e-12	4.47e-10	0.81	0.32	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
THCA	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-7.28	1.43e-12	4.47e-10	-0.34	-0.32	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
THCA	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	7.28	1.43e-12	4.47e-10	0.43	0.32	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
THCA	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-7.28	1.43e-12	4.47e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
THCA	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	7.28	1.43e-12	4.47e-10	0.4	0.32	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
THCA	cis	rs3020736	0.5	rs5996111	ENSG00000205702.9	CYP2D7	-7.28	1.43e-12	4.48e-10	-0.26	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42140203~42144577:-
THCA	cis	rs77204473	0.744	rs11216252	ENSG00000254851.1	RP11-109L13.1	7.28	1.43e-12	4.48e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057507	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs11216253	ENSG00000254851.1	RP11-109L13.1	7.28	1.43e-12	4.48e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057509	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	7.28	1.43e-12	4.48e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
THCA	cis	rs1949733	0.958	rs3103069	ENSG00000205959.3	RP11-689P11.2	7.28	1.43e-12	4.48e-10	0.27	0.32	Response to antineoplastic agents;	chr4:8507724	chr4:8482270~8512610:+
THCA	cis	rs7688540	0.713	rs4624608	ENSG00000275426.1	CH17-262A2.1	7.28	1.43e-12	4.48e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:149738~150317:+
THCA	cis	rs7428	0.527	rs7608892	ENSG00000246575.2	AC093162.5	7.28	1.43e-12	4.48e-10	0.29	0.32	Ear protrusion;	chr2:85315595	chr2:85315041~85316529:+
THCA	cis	rs7208859	0.673	rs11652370	ENSG00000264538.5	SUZ12P1	-7.28	1.44e-12	4.5e-10	-0.3	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30709299~30790908:+
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000237664.1	LINC00316	-7.28	1.44e-12	4.5e-10	-0.35	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45338590~45341990:-
THCA	cis	rs853679	0.517	rs1904840	ENSG00000220721.1	OR1F12	7.28	1.44e-12	4.5e-10	0.44	0.32	Depression;	chr6:28140454	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000220721.1	OR1F12	7.28	1.44e-12	4.5e-10	0.44	0.32	Depression;	chr6:28141189	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000220721.1	OR1F12	7.28	1.44e-12	4.5e-10	0.44	0.32	Depression;	chr6:28141484	chr6:28073316~28074233:+
THCA	cis	rs699371	0.507	rs10149787	ENSG00000270000.1	RP3-449M8.9	-7.28	1.44e-12	4.5e-10	-0.3	-0.32	Height;	chr14:74458749	chr14:74471930~74472360:-
THCA	cis	rs7260598	0.71	rs10423819	ENSG00000268442.1	CTD-2027I19.2	7.28	1.44e-12	4.51e-10	0.38	0.32	Response to taxane treatment (placlitaxel);	chr19:24153857	chr19:24162370~24163425:-
THCA	cis	rs7727544	0.548	rs4705938	ENSG00000224431.1	AC063976.7	7.28	1.44e-12	4.51e-10	0.28	0.32	Blood metabolite levels;	chr5:132358384	chr5:132199456~132203487:+
THCA	cis	rs9635231	1	rs9635231	ENSG00000258413.1	RP11-665C16.6	7.28	1.44e-12	4.52e-10	0.42	0.32	Pediatric bone mineral density (femoral neck);	chr14:55420985	chr14:55262767~55272075:-
THCA	cis	rs7829975	0.684	rs546603	ENSG00000253893.2	FAM85B	7.28	1.44e-12	4.52e-10	0.39	0.32	Mood instability;	chr8:8738328	chr8:8167819~8226614:-
THCA	cis	rs853679	0.517	rs868987	ENSG00000272009.1	RP1-313I6.12	7.28	1.45e-12	4.52e-10	0.37	0.32	Depression;	chr6:28142370	chr6:28078792~28081130:-
THCA	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	7.28	1.45e-12	4.53e-10	0.36	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
THCA	cis	rs467650	0.549	rs2547958	ENSG00000246763.5	RGMB-AS1	-7.28	1.45e-12	4.53e-10	-0.3	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr5:98658249	chr5:98769618~98773469:-
THCA	cis	rs7942368	1	rs4309181	ENSG00000254761.1	RP11-672A2.1	7.28	1.45e-12	4.53e-10	0.45	0.32	Endometriosis;	chr11:76790661	chr11:76712396~76719608:-
THCA	cis	rs2976388	0.609	rs2717603	ENSG00000253741.1	CTD-2292P10.4	-7.28	1.45e-12	4.53e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142721775	chr8:142702252~142726973:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000213640.3	EEF1DP4	-7.28	1.45e-12	4.54e-10	-0.37	-0.32	Calcium levels;	chr7:65806798	chr7:64862999~64864370:+
THCA	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-7.28	1.45e-12	4.54e-10	-0.34	-0.32	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
THCA	cis	rs71636778	0.509	rs34556682	ENSG00000260063.1	RP5-968P14.2	-7.28	1.45e-12	4.54e-10	-0.61	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26859658	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34889971	ENSG00000260063.1	RP5-968P14.2	-7.28	1.45e-12	4.54e-10	-0.61	-0.32	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26861566	chr1:26692132~26694131:-
THCA	cis	rs2562456	0.833	rs2562487	ENSG00000268555.1	RP11-678G14.3	7.28	1.45e-12	4.54e-10	0.45	0.32	Pain;	chr19:21468580	chr19:21570822~21587322:-
THCA	cis	rs13129231	0.739	rs79232065	ENSG00000206820.1	RNU1-138P	-7.28	1.45e-12	4.54e-10	-0.42	-0.32	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113424263	chr4:113420323~113420486:+
THCA	cis	rs1949733	0.656	rs2688224	ENSG00000205959.3	RP11-689P11.2	-7.28	1.45e-12	4.54e-10	-0.26	-0.32	Response to antineoplastic agents;	chr4:8402973	chr4:8482270~8512610:+
THCA	cis	rs2439831	0.618	rs8023508	ENSG00000249839.1	AC011330.5	7.28	1.45e-12	4.54e-10	0.45	0.32	Lung cancer in ever smokers;	chr15:43883905	chr15:43663654~43684339:-
THCA	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-7.28	1.45e-12	4.55e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
THCA	cis	rs4947019	0.609	rs9487099	ENSG00000260273.1	RP11-425D10.10	7.28	1.45e-12	4.55e-10	0.7	0.32	Hematological parameters;	chr6:109423803	chr6:109382795~109383666:+
THCA	cis	rs9902453	0.791	rs2729451	ENSG00000264007.1	RP11-68I3.10	-7.28	1.45e-12	4.55e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:29804316	chr17:29621617~29622254:-
THCA	cis	rs77204473	0.744	rs12273545	ENSG00000254851.1	RP11-109L13.1	7.28	1.45e-12	4.55e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040296	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs77999164	ENSG00000254851.1	RP11-109L13.1	7.28	1.45e-12	4.55e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117041401	chr11:117135528~117138582:+
THCA	cis	rs2880765	0.835	rs7169429	ENSG00000259295.5	CSPG4P12	7.28	1.46e-12	4.56e-10	0.4	0.32	Coronary artery disease;	chr15:85493417	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs7168860	ENSG00000259295.5	CSPG4P12	7.28	1.46e-12	4.56e-10	0.4	0.32	Coronary artery disease;	chr15:85493799	chr15:85191438~85213905:+
THCA	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-7.28	1.46e-12	4.56e-10	-0.34	-0.32	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
THCA	cis	rs7131987	0.65	rs7973786	ENSG00000275476.1	RP11-996F15.4	-7.27	1.46e-12	4.57e-10	-0.32	-0.32	QT interval;	chr12:29309811	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.718	rs7976961	ENSG00000275476.1	RP11-996F15.4	-7.27	1.46e-12	4.57e-10	-0.32	-0.32	QT interval;	chr12:29310155	chr12:29277397~29277882:-
THCA	cis	rs8040855	0.582	rs10775252	ENSG00000259295.5	CSPG4P12	-7.27	1.46e-12	4.57e-10	-0.41	-0.32	Bulimia nervosa;	chr15:85173793	chr15:85191438~85213905:+
THCA	cis	rs2976388	0.609	rs2585145	ENSG00000253741.1	CTD-2292P10.4	-7.27	1.46e-12	4.57e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142718039	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.587	rs2717606	ENSG00000253741.1	CTD-2292P10.4	-7.27	1.46e-12	4.57e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142718078	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2585144	ENSG00000253741.1	CTD-2292P10.4	-7.27	1.46e-12	4.57e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142718851	chr8:142702252~142726973:-
THCA	cis	rs875971	0.965	rs7794930	ENSG00000232559.3	GS1-124K5.12	-7.27	1.46e-12	4.57e-10	-0.3	-0.32	Aortic root size;	chr7:66313559	chr7:66554588~66576923:-
THCA	cis	rs651907	0.514	rs34301719	ENSG00000256628.3	ZBTB11-AS1	7.27	1.47e-12	4.59e-10	0.38	0.32	Colorectal cancer;	chr3:101699149	chr3:101676475~101679217:+
THCA	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	7.27	1.47e-12	4.59e-10	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
THCA	cis	rs4820539	1	rs756631	ENSG00000221069.1	AC000029.1	-7.27	1.47e-12	4.6e-10	-0.38	-0.32	Bone mineral density;	chr22:23120996	chr22:23136620~23136710:+
THCA	cis	rs2288884	1	rs2043298	ENSG00000275055.1	CTC-471J1.11	7.27	1.47e-12	4.6e-10	0.32	0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069814	chr19:52049007~52049754:+
THCA	cis	rs2281636	0.6	rs56901709	ENSG00000233690.1	EBAG9P1	7.27	1.47e-12	4.6e-10	0.34	0.32	Obesity-related traits;	chr10:99639205	chr10:99697407~99697949:-
THCA	cis	rs11168351	1	rs11168351	ENSG00000240399.1	RP1-228P16.1	7.27	1.47e-12	4.61e-10	0.32	0.32	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48054813~48055591:-
THCA	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-7.27	1.48e-12	4.61e-10	-0.31	-0.32	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
THCA	cis	rs7428	0.527	rs4832164	ENSG00000246575.2	AC093162.5	7.27	1.48e-12	4.62e-10	0.29	0.32	Ear protrusion;	chr2:85319809	chr2:85315041~85316529:+
THCA	cis	rs875971	1	rs1167612	ENSG00000232559.3	GS1-124K5.12	-7.27	1.48e-12	4.62e-10	-0.31	-0.32	Aortic root size;	chr7:66102989	chr7:66554588~66576923:-
THCA	cis	rs9473147	0.543	rs7738044	ENSG00000270761.1	RP11-385F7.1	-7.27	1.48e-12	4.64e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47501537	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9473122	ENSG00000270761.1	RP11-385F7.1	-7.27	1.48e-12	4.64e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47507226	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.503	rs9473123	ENSG00000270761.1	RP11-385F7.1	-7.27	1.48e-12	4.64e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47507603	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs13211285	ENSG00000270761.1	RP11-385F7.1	-7.27	1.48e-12	4.64e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47511882	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs1872505	ENSG00000270761.1	RP11-385F7.1	-7.27	1.48e-12	4.64e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47513239	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs9296561	ENSG00000270761.1	RP11-385F7.1	-7.27	1.48e-12	4.64e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47521202	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs7749167	ENSG00000270761.1	RP11-385F7.1	-7.27	1.48e-12	4.64e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47526204	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs9296564	ENSG00000270761.1	RP11-385F7.1	-7.27	1.48e-12	4.64e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47527023	chr6:47477243~47477572:-
THCA	cis	rs10899021	0.92	rs11236181	ENSG00000279353.1	RP11-864N7.4	7.27	1.48e-12	4.64e-10	0.64	0.32	Response to metformin (IC50);	chr11:74634778	chr11:74698231~74699658:-
THCA	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-7.27	1.48e-12	4.64e-10	-0.34	-0.32	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-7.27	1.48e-12	4.64e-10	-0.34	-0.32	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
THCA	cis	rs172166	0.611	rs203882	ENSG00000280107.1	AL022393.9	-7.27	1.49e-12	4.65e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28110724	chr6:28170845~28172521:+
THCA	cis	rs172166	0.694	rs1770131	ENSG00000280107.1	AL022393.9	-7.27	1.49e-12	4.65e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28118635	chr6:28170845~28172521:+
THCA	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	7.27	1.49e-12	4.66e-10	0.31	0.32	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
THCA	cis	rs9341808	0.727	rs9352809	ENSG00000272129.1	RP11-250B2.6	7.27	1.49e-12	4.66e-10	0.4	0.32	Sitting height ratio;	chr6:80289599	chr6:80355424~80356859:+
THCA	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	7.27	1.5e-12	4.67e-10	0.41	0.32	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
THCA	cis	rs9902453	0.74	rs2628189	ENSG00000264007.1	RP11-68I3.10	-7.27	1.5e-12	4.67e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:29761795	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2729448	ENSG00000264007.1	RP11-68I3.10	-7.27	1.5e-12	4.67e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:29764935	chr17:29621617~29622254:-
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	7.27	1.5e-12	4.67e-10	0.54	0.32	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Body mass index;	chr17:30756962	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Body mass index;	chr17:30758695	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Body mass index;	chr17:30772984	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Body mass index;	chr17:30779631	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000263603.1	CTD-2349P21.5	-7.27	1.5e-12	4.67e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30729469~30731202:+
THCA	cis	rs2562456	0.793	rs2562474	ENSG00000268119.4	CTD-2561J22.5	-7.27	1.5e-12	4.67e-10	-0.4	-0.32	Pain;	chr19:21463480	chr19:21444241~21463908:-
THCA	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-7.27	1.5e-12	4.68e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
THCA	cis	rs9902453	0.765	rs2259857	ENSG00000264007.1	RP11-68I3.10	-7.27	1.5e-12	4.68e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:29770762	chr17:29621617~29622254:-
THCA	cis	rs875971	0.895	rs3857684	ENSG00000232559.3	GS1-124K5.12	7.27	1.5e-12	4.68e-10	0.3	0.32	Aortic root size;	chr7:66473171	chr7:66554588~66576923:-
THCA	cis	rs7324557	0.684	rs58663560	ENSG00000205861.10	C1QTNF9B-AS1	-7.27	1.5e-12	4.69e-10	-0.39	-0.32	Visceral adipose tissue adjusted for BMI;	chr13:23830800	chr13:23888889~23897263:+
THCA	cis	rs9549328	0.8	rs9549619	ENSG00000267868.1	RP11-120K24.3	7.27	1.51e-12	4.69e-10	0.33	0.32	Systolic blood pressure;	chr13:112978306	chr13:112964835~112966131:-
THCA	cis	rs2880765	0.835	rs4842886	ENSG00000259295.5	CSPG4P12	7.27	1.51e-12	4.7e-10	0.4	0.32	Coronary artery disease;	chr15:85492542	chr15:85191438~85213905:+
THCA	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-7.27	1.51e-12	4.7e-10	-0.42	-0.32	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
THCA	cis	rs9902453	1	rs57411618	ENSG00000264007.1	RP11-68I3.10	7.27	1.51e-12	4.7e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29946034	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs7222308	ENSG00000264007.1	RP11-68I3.10	7.27	1.51e-12	4.7e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29950023	chr17:29621617~29622254:-
THCA	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-7.27	1.51e-12	4.7e-10	-0.34	-0.32	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-7.27	1.51e-12	4.7e-10	-0.34	-0.32	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-7.27	1.51e-12	4.7e-10	-0.34	-0.32	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
THCA	cis	rs7246657	1	rs7247672	ENSG00000226686.6	LINC01535	-7.27	1.51e-12	4.71e-10	-0.46	-0.32	Coronary artery calcification;	chr19:37253026	chr19:37251912~37265535:+
THCA	cis	rs7246657	1	rs8110011	ENSG00000226686.6	LINC01535	-7.27	1.51e-12	4.71e-10	-0.46	-0.32	Coronary artery calcification;	chr19:37254911	chr19:37251912~37265535:+
THCA	cis	rs34375054	0.752	rs35505608	ENSG00000279233.1	RP11-158L12.4	7.27	1.51e-12	4.71e-10	0.33	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125177706	chr12:125138245~125141711:+
THCA	cis	rs9902453	0.808	rs8069669	ENSG00000264007.1	RP11-68I3.10	7.27	1.51e-12	4.71e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29912484	chr17:29621617~29622254:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000206090.4	AP000350.7	7.27	1.51e-12	4.72e-10	0.39	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23939998~23942798:+
THCA	cis	rs7267979	0.933	rs2424708	ENSG00000274414.1	RP5-965G21.4	-7.27	1.52e-12	4.73e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs884613	ENSG00000274414.1	RP5-965G21.4	7.27	1.52e-12	4.73e-10	0.38	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs1888998	ENSG00000274414.1	RP5-965G21.4	7.27	1.52e-12	4.73e-10	0.38	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2500433	ENSG00000274414.1	RP5-965G21.4	7.27	1.52e-12	4.73e-10	0.38	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2482948	ENSG00000274414.1	RP5-965G21.4	7.27	1.52e-12	4.73e-10	0.38	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2482919	ENSG00000274414.1	RP5-965G21.4	7.27	1.52e-12	4.73e-10	0.38	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6037086	ENSG00000274414.1	RP5-965G21.4	7.27	1.52e-12	4.73e-10	0.38	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2482923	ENSG00000274414.1	RP5-965G21.4	7.27	1.52e-12	4.73e-10	0.38	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25239007~25245229:-
THCA	cis	rs7247513	0.639	rs12984441	ENSG00000213290.4	PGK1P2	-7.27	1.52e-12	4.73e-10	-0.37	-0.32	Bipolar disorder;	chr19:12649473	chr19:12559571~12561105:+
THCA	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-7.27	1.52e-12	4.73e-10	-0.31	-0.32	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-7.27	1.52e-12	4.73e-10	-0.31	-0.32	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-7.27	1.52e-12	4.73e-10	-0.31	-0.32	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-7.27	1.52e-12	4.73e-10	-0.31	-0.32	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
THCA	cis	rs4073416	0.771	rs4902412	ENSG00000276116.2	FUT8-AS1	7.27	1.52e-12	4.74e-10	0.32	0.32	N-glycan levels;	chr14:65720349	chr14:65411170~65412690:-
THCA	cis	rs6866614	0.627	rs27437	ENSG00000237714.1	P4HA2-AS1	7.27	1.52e-12	4.74e-10	0.4	0.32	Perceived unattractiveness to mosquitoes;	chr5:132101268	chr5:132184876~132192808:+
THCA	cis	rs74233809	0.901	rs12416331	ENSG00000213277.3	MARCKSL1P1	7.27	1.52e-12	4.74e-10	0.53	0.32	Birth weight;	chr10:103169157	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs79237883	ENSG00000213277.3	MARCKSL1P1	7.27	1.52e-12	4.74e-10	0.53	0.32	Birth weight;	chr10:103181189	chr10:103175554~103176094:+
THCA	cis	rs12348691	0.503	rs7023267	ENSG00000236130.1	PTCSC2	-7.27	1.52e-12	4.75e-10	-0.26	-0.32	Alopecia areata;	chr9:97841653	chr9:97805935~97810008:-
THCA	cis	rs75422866	0.541	rs12425816	ENSG00000274902.1	RP1-197B17.4	7.27	1.52e-12	4.75e-10	0.66	0.32	Pneumonia;	chr12:47731419	chr12:47731908~47732351:+
THCA	cis	rs240993	0.812	rs459147	ENSG00000230177.1	RP5-1112D6.4	-7.27	1.53e-12	4.76e-10	-0.32	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111370285	chr6:111277932~111278742:+
THCA	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	7.27	1.53e-12	4.76e-10	0.39	0.32	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
THCA	cis	rs3806843	0.735	rs801167	ENSG00000202515.1	VTRNA1-3	-7.27	1.53e-12	4.76e-10	-0.36	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs801183	ENSG00000202515.1	VTRNA1-3	-7.27	1.53e-12	4.76e-10	-0.36	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.706	rs2563302	ENSG00000202515.1	VTRNA1-3	7.27	1.53e-12	4.76e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs801168	ENSG00000202515.1	VTRNA1-3	7.27	1.53e-12	4.76e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs809635	ENSG00000202515.1	VTRNA1-3	7.27	1.53e-12	4.76e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.648	rs2530233	ENSG00000202515.1	VTRNA1-3	7.27	1.53e-12	4.76e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs702394	ENSG00000202515.1	VTRNA1-3	7.27	1.53e-12	4.76e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs801180	ENSG00000202515.1	VTRNA1-3	7.27	1.53e-12	4.76e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr5:140726158~140726246:+
THCA	cis	rs9902453	1	rs62070270	ENSG00000264007.1	RP11-68I3.10	7.27	1.53e-12	4.77e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29936962	chr17:29621617~29622254:-
THCA	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	7.27	1.53e-12	4.77e-10	0.5	0.32	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
THCA	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-7.27	1.53e-12	4.77e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	7.27	1.53e-12	4.77e-10	0.41	0.32	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
THCA	cis	rs4073416	0.712	rs3825640	ENSG00000276116.2	FUT8-AS1	-7.27	1.53e-12	4.77e-10	-0.33	-0.32	N-glycan levels;	chr14:65494486	chr14:65411170~65412690:-
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-7.27	1.53e-12	4.77e-10	-0.4	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
THCA	cis	rs61041384	0.661	rs79033960	ENSG00000256092.2	RP13-942N8.1	-7.27	1.53e-12	4.78e-10	-0.47	-0.32	Schizophrenia;	chr12:123196388	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs77015199	ENSG00000256092.2	RP13-942N8.1	-7.27	1.53e-12	4.78e-10	-0.47	-0.32	Schizophrenia;	chr12:123197090	chr12:123363868~123366113:+
THCA	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	7.27	1.54e-12	4.78e-10	0.38	0.32	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
THCA	cis	rs2839186	0.656	rs8128380	ENSG00000239415.1	AP001469.9	7.27	1.54e-12	4.78e-10	0.34	0.32	Testicular germ cell tumor;	chr21:46245779	chr21:46251549~46254133:-
THCA	cis	rs875971	0.964	rs60193905	ENSG00000232559.3	GS1-124K5.12	7.27	1.54e-12	4.78e-10	0.3	0.32	Aortic root size;	chr7:66506273	chr7:66554588~66576923:-
THCA	cis	rs875971	0.929	rs10950041	ENSG00000232559.3	GS1-124K5.12	7.27	1.54e-12	4.78e-10	0.3	0.32	Aortic root size;	chr7:66508888	chr7:66554588~66576923:-
THCA	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	7.27	1.54e-12	4.78e-10	0.59	0.32	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	7.27	1.54e-12	4.78e-10	0.59	0.32	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	7.27	1.54e-12	4.78e-10	0.59	0.32	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
THCA	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-7.27	1.54e-12	4.78e-10	-0.38	-0.32	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-7.27	1.54e-12	4.78e-10	-0.38	-0.32	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-7.27	1.54e-12	4.78e-10	-0.38	-0.32	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
THCA	cis	rs4073416	0.712	rs10483780	ENSG00000276116.2	FUT8-AS1	7.27	1.54e-12	4.79e-10	0.33	0.32	N-glycan levels;	chr14:65513452	chr14:65411170~65412690:-
THCA	cis	rs7829975	0.564	rs2976855	ENSG00000254153.1	CTA-398F10.2	-7.27	1.54e-12	4.79e-10	-0.33	-0.32	Mood instability;	chr8:8444284	chr8:8456909~8461337:-
THCA	cis	rs853679	0.542	rs9393892	ENSG00000220721.1	OR1F12	7.27	1.54e-12	4.79e-10	0.44	0.32	Depression;	chr6:28113616	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs464312	ENSG00000226314.6	ZNF192P1	-7.27	1.54e-12	4.8e-10	-0.39	-0.32	Parkinson's disease;	chr6:27999813	chr6:28161781~28169594:+
THCA	cis	rs10208649	0.611	rs1974771	ENSG00000272156.1	RP11-477N3.1	7.27	1.54e-12	4.8e-10	0.48	0.32	Body mass index;	chr2:54051406	chr2:54082554~54085066:+
THCA	cis	rs6723226	0.739	rs2754525	ENSG00000276334.1	AL133243.1	7.27	1.55e-12	4.81e-10	0.36	0.32	Intelligence (multi-trait analysis);	chr2:32580219	chr2:32521927~32523547:+
THCA	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-7.27	1.55e-12	4.81e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-7.27	1.55e-12	4.81e-10	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
THCA	cis	rs7554547	0.667	rs4846072	ENSG00000201801.1	RNU5E-4P	7.27	1.55e-12	4.81e-10	0.37	0.32	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr1:11909808~11909927:-
THCA	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-7.27	1.55e-12	4.81e-10	-0.35	-0.32	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
THCA	cis	rs910316	0.967	rs4899549	ENSG00000279594.1	RP11-950C14.10	-7.27	1.55e-12	4.82e-10	-0.3	-0.32	Height;	chr14:75180791	chr14:75011269~75012851:-
THCA	cis	rs9549328	0.8	rs9549617	ENSG00000267868.1	RP11-120K24.3	7.27	1.55e-12	4.82e-10	0.33	0.32	Systolic blood pressure;	chr13:112973756	chr13:112964835~112966131:-
THCA	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-7.27	1.55e-12	4.82e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-7.27	1.55e-12	4.82e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
THCA	cis	rs12681366	0.734	rs13281619	ENSG00000253704.1	RP11-267M23.4	7.27	1.55e-12	4.83e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94384658	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.708	rs13280849	ENSG00000253704.1	RP11-267M23.4	7.27	1.55e-12	4.83e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94384731	chr8:94553722~94569745:+
THCA	cis	rs9902453	0.612	rs2617868	ENSG00000264007.1	RP11-68I3.10	-7.27	1.55e-12	4.83e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:29746229	chr17:29621617~29622254:-
THCA	cis	rs6762	0.748	rs5030780	ENSG00000279672.1	CMB9-55F22.1	7.27	1.55e-12	4.83e-10	0.35	0.32	Mean platelet volume;	chr11:838110	chr11:779617~780755:+
THCA	cis	rs8012947	1	rs7153897	ENSG00000279636.2	LINC00216	-7.27	1.55e-12	4.83e-10	-0.33	-0.32	Alcohol consumption in current drinkers;	chr14:58295479	chr14:58288033~58289158:+
THCA	cis	rs7727544	0.606	rs200838	ENSG00000224431.1	AC063976.7	-7.27	1.55e-12	4.83e-10	-0.28	-0.32	Blood metabolite levels;	chr5:132374707	chr5:132199456~132203487:+
THCA	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-7.27	1.55e-12	4.83e-10	-0.38	-0.32	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
THCA	cis	rs4950322	0.57	rs72692980	ENSG00000237188.3	RP11-337C18.8	7.27	1.56e-12	4.84e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147337830	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.634	rs7542951	ENSG00000237188.3	RP11-337C18.8	7.27	1.56e-12	4.84e-10	0.4	0.32	Protein quantitative trait loci;	chr1:147340308	chr1:147172771~147211568:+
THCA	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-7.27	1.56e-12	4.84e-10	-0.41	-0.32	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
THCA	cis	rs7851660	0.874	rs13299924	ENSG00000236130.1	PTCSC2	-7.27	1.56e-12	4.85e-10	-0.25	-0.32	Strep throat;	chr9:97865280	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs10122541	ENSG00000236130.1	PTCSC2	-7.27	1.56e-12	4.85e-10	-0.25	-0.32	Strep throat;	chr9:97865986	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.839	rs2417575	ENSG00000236130.1	PTCSC2	-7.27	1.56e-12	4.85e-10	-0.25	-0.32	Strep throat;	chr9:97866360	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.874	rs1443436	ENSG00000236130.1	PTCSC2	-7.27	1.56e-12	4.85e-10	-0.25	-0.32	Strep throat;	chr9:97869016	chr9:97805935~97810008:-
THCA	cis	rs4639966	0.569	rs603486	ENSG00000255239.1	AP002954.6	7.27	1.56e-12	4.85e-10	0.4	0.32	Systemic lupus erythematosus;	chr11:118716638	chr11:118688039~118690600:-
THCA	cis	rs9902453	0.765	rs2628185	ENSG00000264007.1	RP11-68I3.10	-7.27	1.56e-12	4.85e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:29743089	chr17:29621617~29622254:-
THCA	cis	rs875971	0.965	rs28682868	ENSG00000232559.3	GS1-124K5.12	-7.27	1.56e-12	4.85e-10	-0.3	-0.32	Aortic root size;	chr7:66224822	chr7:66554588~66576923:-
THCA	cis	rs728616	0.614	rs10887218	ENSG00000225484.5	NUTM2B-AS1	-7.26	1.57e-12	4.87e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951268	chr10:79663088~79826594:-
THCA	cis	rs74233809	1	rs75970938	ENSG00000213277.3	MARCKSL1P1	7.26	1.57e-12	4.87e-10	0.53	0.32	Birth weight;	chr10:103033891	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs79668541	ENSG00000213277.3	MARCKSL1P1	7.26	1.57e-12	4.87e-10	0.53	0.32	Birth weight;	chr10:103034147	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs3781285	ENSG00000213277.3	MARCKSL1P1	7.26	1.57e-12	4.87e-10	0.53	0.32	Birth weight;	chr10:103065908	chr10:103175554~103176094:+
THCA	cis	rs2562456	0.755	rs2914646	ENSG00000268119.4	CTD-2561J22.5	-7.26	1.57e-12	4.88e-10	-0.4	-0.32	Pain;	chr19:21454359	chr19:21444241~21463908:-
THCA	cis	rs651907	0.557	rs2303474	ENSG00000256628.3	ZBTB11-AS1	7.26	1.57e-12	4.88e-10	0.38	0.32	Colorectal cancer;	chr3:101653055	chr3:101676475~101679217:+
THCA	cis	rs9816784	0.696	rs6778081	ENSG00000231464.1	AC024937.4	-7.26	1.57e-12	4.88e-10	-0.37	-0.32	Mean corpuscular hemoglobin;	chr3:196092334	chr3:195996738~195998233:+
THCA	cis	rs74233809	1	rs12220743	ENSG00000213277.3	MARCKSL1P1	7.26	1.57e-12	4.88e-10	0.52	0.32	Birth weight;	chr10:103092155	chr10:103175554~103176094:+
THCA	cis	rs6600671	0.967	rs11249349	ENSG00000223345.3	HIST2H2BA	7.26	1.57e-12	4.89e-10	0.35	0.32	Hip geometry;	chr1:121437310	chr1:121108210~121117257:-
THCA	cis	rs699371	0.507	rs10149538	ENSG00000270000.1	RP3-449M8.9	7.26	1.58e-12	4.9e-10	0.3	0.32	Height;	chr14:74458694	chr14:74471930~74472360:-
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000263603.1	CTD-2349P21.5	-7.26	1.58e-12	4.9e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30729469~30731202:+
THCA	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-7.26	1.58e-12	4.9e-10	-0.34	-0.32	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-7.26	1.58e-12	4.9e-10	-0.34	-0.32	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
THCA	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	7.26	1.58e-12	4.91e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-7.26	1.58e-12	4.91e-10	-0.46	-0.32	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
THCA	cis	rs4073416	0.746	rs12887673	ENSG00000276116.2	FUT8-AS1	7.26	1.58e-12	4.92e-10	0.32	0.32	N-glycan levels;	chr14:65755053	chr14:65411170~65412690:-
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000264538.5	SUZ12P1	-7.26	1.59e-12	4.93e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000264538.5	SUZ12P1	-7.26	1.59e-12	4.93e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000264538.5	SUZ12P1	-7.26	1.59e-12	4.93e-10	-0.33	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30709299~30790908:+
THCA	cis	rs9341808	0.754	rs9341811	ENSG00000272129.1	RP11-250B2.6	7.26	1.59e-12	4.93e-10	0.4	0.32	Sitting height ratio;	chr6:80272984	chr6:80355424~80356859:+
THCA	cis	rs4072705	1	rs4836985	ENSG00000224020.1	MIR181A2HG	-7.26	1.59e-12	4.93e-10	-0.28	-0.32	Menarche (age at onset);	chr9:124645615	chr9:124658467~124698631:+
THCA	cis	rs4073416	0.684	rs3783709	ENSG00000276116.2	FUT8-AS1	7.26	1.59e-12	4.94e-10	0.33	0.32	N-glycan levels;	chr14:65591946	chr14:65411170~65412690:-
THCA	cis	rs2839186	0.872	rs2250213	ENSG00000239415.1	AP001469.9	7.26	1.59e-12	4.95e-10	0.33	0.32	Testicular germ cell tumor;	chr21:46254361	chr21:46251549~46254133:-
THCA	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-7.26	1.59e-12	4.95e-10	-0.51	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
THCA	cis	rs2976388	0.692	rs2978983	ENSG00000253741.1	CTD-2292P10.4	-7.26	1.59e-12	4.95e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142684424	chr8:142702252~142726973:-
THCA	cis	rs3806843	0.735	rs2563306	ENSG00000202515.1	VTRNA1-3	7.26	1.6e-12	4.96e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs813897	ENSG00000202515.1	VTRNA1-3	7.26	1.6e-12	4.96e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr5:140726158~140726246:+
THCA	cis	rs74233809	1	rs77420391	ENSG00000213277.3	MARCKSL1P1	7.26	1.6e-12	4.96e-10	0.53	0.32	Birth weight;	chr10:103186066	chr10:103175554~103176094:+
THCA	cis	rs17772222	0.653	rs1346996	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88507174	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs7160471	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88507241	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs9323830	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88507260	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs7160647	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88507340	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs7143642	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88507616	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs10143744	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88508073	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs1999177	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88508298	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs1999176	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88508371	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs1864746	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88508455	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs1864747	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88508523	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs7151164	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88509329	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs12433026	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88509495	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs10138139	ENSG00000258789.1	RP11-507K2.3	-7.26	1.6e-12	4.97e-10	-0.3	-0.32	Coronary artery calcification;	chr14:88510027	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs10138002	ENSG00000258789.1	RP11-507K2.3	7.26	1.6e-12	4.97e-10	0.3	0.32	Coronary artery calcification;	chr14:88510071	chr14:88551597~88552493:+
THCA	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	7.26	1.6e-12	4.97e-10	0.33	0.32	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
THCA	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-7.26	1.6e-12	4.97e-10	-0.52	-0.32	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
THCA	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	7.26	1.6e-12	4.98e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
THCA	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	7.26	1.6e-12	4.98e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
THCA	cis	rs10050311	0.858	rs1985944	ENSG00000251411.1	RP11-397E7.4	-7.26	1.6e-12	4.98e-10	-0.4	-0.32	Insulin-related traits;	chr4:86898130	chr4:86913266~86914817:-
THCA	cis	rs6745190	0.953	rs4346343	ENSG00000236153.1	AC104076.3	7.26	1.6e-12	4.98e-10	0.37	0.32	White blood cell count;	chr2:181002320	chr2:180979427~180980090:-
THCA	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	7.26	1.61e-12	4.99e-10	0.29	0.32	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
THCA	cis	rs7246657	1	rs35398388	ENSG00000226686.6	LINC01535	-7.26	1.61e-12	4.99e-10	-0.46	-0.32	Coronary artery calcification;	chr19:37249456	chr19:37251912~37265535:+
THCA	cis	rs4073416	0.712	rs12890978	ENSG00000276116.2	FUT8-AS1	7.26	1.61e-12	5e-10	0.33	0.32	N-glycan levels;	chr14:65516172	chr14:65411170~65412690:-
THCA	cis	rs9369695	0.842	rs2396825	ENSG00000270761.1	RP11-385F7.1	-7.26	1.61e-12	5e-10	-0.25	-0.32	Reticulocyte count;	chr6:47600960	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs9395286	ENSG00000270761.1	RP11-385F7.1	-7.26	1.61e-12	5e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47607596	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9349417	ENSG00000270761.1	RP11-385F7.1	-7.26	1.61e-12	5e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47612921	chr6:47477243~47477572:-
THCA	cis	rs9369695	0.883	rs9381581	ENSG00000270761.1	RP11-385F7.1	-7.26	1.61e-12	5e-10	-0.25	-0.32	Reticulocyte count;	chr6:47612959	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs9463342	ENSG00000270761.1	RP11-385F7.1	-7.26	1.61e-12	5e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47617370	chr6:47477243~47477572:-
THCA	cis	rs16846053	0.551	rs1515186	ENSG00000227403.1	AC009299.3	-7.26	1.61e-12	5e-10	-0.54	-0.32	Blood osmolality (transformed sodium);	chr2:161699850	chr2:161244739~161249050:+
THCA	cis	rs2018683	1	rs740252	ENSG00000228421.2	AC005013.5	7.26	1.62e-12	5.01e-10	0.35	0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28958149	chr7:28957667~28959345:+
THCA	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	7.26	1.62e-12	5.02e-10	0.38	0.32	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
THCA	cis	rs651907	0.557	rs12629658	ENSG00000256628.3	ZBTB11-AS1	7.26	1.62e-12	5.03e-10	0.38	0.32	Colorectal cancer;	chr3:101637691	chr3:101676475~101679217:+
THCA	cis	rs6762	0.748	rs7928935	ENSG00000279672.1	CMB9-55F22.1	7.26	1.62e-12	5.03e-10	0.35	0.32	Mean platelet volume;	chr11:839127	chr11:779617~780755:+
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000263603.1	CTD-2349P21.5	-7.26	1.62e-12	5.03e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30729469~30731202:+
THCA	cis	rs11051970	1	rs11051970	ENSG00000274964.1	RP11-817I4.1	-7.26	1.62e-12	5.03e-10	-0.36	-0.32	Response to tocilizumab in rheumatoid arthritis;	chr12:32384554	chr12:32339368~32340724:+
THCA	cis	rs7746199	0.736	rs13195636	ENSG00000280107.1	AL022393.9	-7.26	1.62e-12	5.04e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28170845~28172521:+
THCA	cis	rs7760535	0.794	rs3851225	ENSG00000230177.1	RP5-1112D6.4	-7.26	1.63e-12	5.04e-10	-0.25	-0.32	Metabolic traits;	chr6:111503929	chr6:111277932~111278742:+
THCA	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-7.26	1.63e-12	5.04e-10	-0.39	-0.32	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
THCA	cis	rs801193	0.548	rs2659891	ENSG00000232559.3	GS1-124K5.12	7.26	1.63e-12	5.05e-10	0.3	0.32	Aortic root size;	chr7:66736127	chr7:66554588~66576923:-
THCA	cis	rs801193	0.548	rs7805152	ENSG00000232559.3	GS1-124K5.12	7.26	1.63e-12	5.05e-10	0.3	0.32	Aortic root size;	chr7:66744266	chr7:66554588~66576923:-
THCA	cis	rs56114371	0.53	rs169262	ENSG00000219392.1	RP1-265C24.5	-7.26	1.63e-12	5.05e-10	-0.44	-0.32	Breast cancer;	chr6:27803112	chr6:28115628~28116551:+
THCA	cis	rs4950322	0.58	rs7515160	ENSG00000237188.3	RP11-337C18.8	7.26	1.63e-12	5.05e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147120714	chr1:147172771~147211568:+
THCA	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-7.26	1.63e-12	5.06e-10	-0.4	-0.32	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
THCA	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-7.26	1.63e-12	5.06e-10	-0.38	-0.32	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
THCA	cis	rs4948275	0.53	rs2139778	ENSG00000237233.2	TMEM26-AS1	7.26	1.63e-12	5.07e-10	0.43	0.32	Night sleep phenotypes;	chr10:61375185	chr10:61452639~61481956:+
THCA	cis	rs9902453	1	rs11080114	ENSG00000264007.1	RP11-68I3.10	-7.26	1.64e-12	5.07e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30080269	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs7221743	ENSG00000264007.1	RP11-68I3.10	-7.26	1.64e-12	5.07e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30080858	chr17:29621617~29622254:-
THCA	cis	rs7131987	0.65	rs7301398	ENSG00000275476.1	RP11-996F15.4	-7.26	1.64e-12	5.07e-10	-0.33	-0.32	QT interval;	chr12:29302457	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.65	rs7301188	ENSG00000275476.1	RP11-996F15.4	-7.26	1.64e-12	5.07e-10	-0.33	-0.32	QT interval;	chr12:29302458	chr12:29277397~29277882:-
THCA	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	7.26	1.64e-12	5.08e-10	0.4	0.32	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
THCA	cis	rs3806843	0.741	rs4912597	ENSG00000202515.1	VTRNA1-3	7.26	1.64e-12	5.08e-10	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140727272	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.771	rs2563334	ENSG00000202515.1	VTRNA1-3	7.26	1.64e-12	5.08e-10	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140727480	chr5:140726158~140726246:+
THCA	cis	rs875971	1	rs6963646	ENSG00000232559.3	GS1-124K5.12	-7.26	1.64e-12	5.08e-10	-0.3	-0.32	Aortic root size;	chr7:66220780	chr7:66554588~66576923:-
THCA	cis	rs7267979	0.873	rs6115093	ENSG00000274414.1	RP5-965G21.4	-7.26	1.64e-12	5.09e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25239007~25245229:-
THCA	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-7.26	1.65e-12	5.11e-10	-0.35	-0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
THCA	cis	rs2439831	0.85	rs694985	ENSG00000275601.1	AC011330.13	-7.26	1.65e-12	5.11e-10	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43521189	chr15:43642389~43643023:-
THCA	cis	rs737008	0.96	rs949429	ENSG00000262636.1	CTD-3088G3.4	-7.26	1.65e-12	5.11e-10	-0.41	-0.32	Obesity-related traits;	chr16:11282172	chr16:11380859~11381118:-
THCA	cis	rs6061231	0.74	rs11698650	ENSG00000275437.1	RP5-908M14.10	7.26	1.65e-12	5.12e-10	0.28	0.32	Colorectal cancer;	chr20:62383318	chr20:62402236~62405935:-
THCA	cis	rs853679	0.542	rs9393892	ENSG00000272009.1	RP1-313I6.12	-7.26	1.65e-12	5.12e-10	-0.37	-0.32	Depression;	chr6:28113616	chr6:28078792~28081130:-
THCA	cis	rs10129255	0.576	rs2157616	ENSG00000223648.3	IGHV3-64	7.26	1.65e-12	5.13e-10	0.19	0.32	Kawasaki disease;	chr14:106767802	chr14:106643132~106658258:-
THCA	cis	rs11971779	1	rs11971779	ENSG00000273391.1	RP11-634H22.1	-7.26	1.65e-12	5.13e-10	-0.34	-0.32	Diisocyanate-induced asthma;	chr7:139355512	chr7:139359032~139359566:-
THCA	cis	rs875971	1	rs12533997	ENSG00000232559.3	GS1-124K5.12	7.26	1.65e-12	5.13e-10	0.3	0.32	Aortic root size;	chr7:66500390	chr7:66554588~66576923:-
THCA	cis	rs853679	0.723	rs1736904	ENSG00000219392.1	RP1-265C24.5	-7.26	1.66e-12	5.13e-10	-0.41	-0.32	Depression;	chr6:28251492	chr6:28115628~28116551:+
THCA	cis	rs34375054	0.752	rs12582808	ENSG00000279233.1	RP11-158L12.4	7.26	1.66e-12	5.14e-10	0.34	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125176913	chr12:125138245~125141711:+
THCA	cis	rs12817211	0.502	rs17124432	ENSG00000272368.2	RP4-605O3.4	7.26	1.66e-12	5.14e-10	0.19	0.32	Colorectal or endometrial cancer;	chr12:50116994	chr12:50112197~50165618:+
THCA	cis	rs1150668	0.796	rs1052215	ENSG00000219392.1	RP1-265C24.5	7.26	1.66e-12	5.14e-10	0.35	0.32	Pubertal anthropometrics;	chr6:28380381	chr6:28115628~28116551:+
THCA	cis	rs1150668	0.796	rs2531832	ENSG00000219392.1	RP1-265C24.5	-7.26	1.66e-12	5.15e-10	-0.35	-0.32	Pubertal anthropometrics;	chr6:28421445	chr6:28115628~28116551:+
THCA	cis	rs9828933	0.577	rs832193	ENSG00000280620.1	SCAANT1	-7.26	1.66e-12	5.15e-10	-0.54	-0.32	Type 2 diabetes;	chr3:63868769	chr3:63911518~63911772:-
THCA	cis	rs17684571	1	rs17684571	ENSG00000231441.1	RP11-472M19.2	7.26	1.66e-12	5.15e-10	0.4	0.32	Schizophrenia;	chr6:56710873	chr6:56844002~56864078:+
THCA	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	7.26	1.66e-12	5.15e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
THCA	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-7.26	1.66e-12	5.16e-10	-0.34	-0.32	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
THCA	cis	rs3806843	0.735	rs801188	ENSG00000202515.1	VTRNA1-3	7.26	1.67e-12	5.16e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140687331	chr5:140726158~140726246:+
THCA	cis	rs6600671	1	rs1832558	ENSG00000223345.3	HIST2H2BA	7.26	1.67e-12	5.17e-10	0.35	0.32	Hip geometry;	chr1:121435521	chr1:121108210~121117257:-
THCA	cis	rs1198430	1	rs1198439	ENSG00000232482.2	RP4-654C18.1	-7.25	1.67e-12	5.18e-10	-0.56	-0.32	Total cholesterol levels;	chr1:23423100	chr1:23410832~23412146:+
THCA	cis	rs8100891	0.734	rs4804990	ENSG00000267213.4	AC007773.2	-7.25	1.67e-12	5.18e-10	-0.29	-0.32	Neuroticism;	chr19:32346523	chr19:32390050~32405560:-
THCA	cis	rs10208649	1	rs6756424	ENSG00000272156.1	RP11-477N3.1	7.25	1.67e-12	5.18e-10	0.57	0.32	Body mass index;	chr2:53903698	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs6731911	ENSG00000272156.1	RP11-477N3.1	7.25	1.67e-12	5.18e-10	0.57	0.32	Body mass index;	chr2:53904575	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs9309251	ENSG00000272156.1	RP11-477N3.1	7.25	1.67e-12	5.18e-10	0.57	0.32	Body mass index;	chr2:53906501	chr2:54082554~54085066:+
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000263603.1	CTD-2349P21.5	-7.25	1.67e-12	5.18e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30729469~30731202:+
THCA	cis	rs11696845	0.666	rs13042905	ENSG00000276223.1	RP4-781B1.5	-7.25	1.67e-12	5.19e-10	-0.38	-0.32	Obesity-related traits;	chr20:44750813	chr20:44746642~44747201:+
THCA	cis	rs7302981	0.746	rs836172	ENSG00000272368.2	RP4-605O3.4	7.25	1.68e-12	5.19e-10	0.19	0.32	Systolic blood pressure;	chr12:50096316	chr12:50112197~50165618:+
THCA	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-7.25	1.68e-12	5.19e-10	-0.48	-0.32	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
THCA	cis	rs6723108	0.603	rs56271357	ENSG00000224043.6	CCNT2-AS1	-7.25	1.68e-12	5.2e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134963145	chr2:134735464~134918710:-
THCA	cis	rs9473147	0.516	rs2151975	ENSG00000270761.1	RP11-385F7.1	-7.25	1.68e-12	5.2e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47547927	chr6:47477243~47477572:-
THCA	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-7.25	1.68e-12	5.2e-10	-0.37	-0.32	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
THCA	cis	rs4820539	0.902	rs737846	ENSG00000221069.1	AC000029.1	-7.25	1.68e-12	5.21e-10	-0.38	-0.32	Bone mineral density;	chr22:23118482	chr22:23136620~23136710:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000220721.1	OR1F12	7.25	1.69e-12	5.23e-10	0.44	0.32	Depression;	chr6:28149979	chr6:28073316~28074233:+
THCA	cis	rs984222	0.587	rs11577739	ENSG00000231365.4	RP11-418J17.1	7.25	1.69e-12	5.23e-10	0.32	0.32	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119220628	chr1:119140396~119275973:+
THCA	cis	rs9506514	0.722	rs10400670	ENSG00000222726.1	RNU2-7P	7.25	1.69e-12	5.24e-10	0.39	0.32	Coronary artery calcification;	chr13:20679350	chr13:20612161~20612338:+
THCA	cis	rs73219805	0.536	rs3200031	ENSG00000228451.3	SDAD1P1	-7.25	1.7e-12	5.25e-10	-0.72	-0.32	Schizophrenia;	chr8:26369968	chr8:26379259~26382953:-
THCA	cis	rs73219805	0.536	rs1048527	ENSG00000228451.3	SDAD1P1	-7.25	1.7e-12	5.25e-10	-0.72	-0.32	Schizophrenia;	chr8:26372177	chr8:26379259~26382953:-
THCA	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-7.25	1.7e-12	5.25e-10	-0.37	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
THCA	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-7.25	1.7e-12	5.26e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000263603.1	CTD-2349P21.5	-7.25	1.7e-12	5.26e-10	-0.54	-0.32	Body mass index;	chr17:30752751	chr17:30729469~30731202:+
THCA	cis	rs7267979	1	rs2424710	ENSG00000274414.1	RP5-965G21.4	-7.25	1.7e-12	5.26e-10	-0.37	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6115140	ENSG00000274414.1	RP5-965G21.4	-7.25	1.7e-12	5.26e-10	-0.37	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs1888997	ENSG00000274414.1	RP5-965G21.4	7.25	1.7e-12	5.26e-10	0.37	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs3002698	ENSG00000274414.1	RP5-965G21.4	7.25	1.7e-12	5.26e-10	0.37	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25239007~25245229:-
THCA	cis	rs9381040	0.748	rs9357348	ENSG00000161912.16	ADCY10P1	7.25	1.7e-12	5.27e-10	0.21	0.32	Alzheimer's disease (late onset);	chr6:41186494	chr6:41101022~41140835:+
THCA	cis	rs7247513	0.897	rs12972944	ENSG00000230310.1	CTD-2192J16.11	-7.25	1.71e-12	5.28e-10	-0.39	-0.32	Bipolar disorder;	chr19:12602994	chr19:12552597~12553644:+
THCA	cis	rs8114671	0.967	rs12481169	ENSG00000269202.1	RP4-614O4.12	7.25	1.71e-12	5.3e-10	0.26	0.32	Height;	chr20:35206707	chr20:35201747~35203288:-
THCA	cis	rs853679	1	rs2799077	ENSG00000280107.1	AL022393.9	-7.25	1.71e-12	5.3e-10	-0.45	-0.32	Depression;	chr6:28266819	chr6:28170845~28172521:+
THCA	cis	rs651907	0.535	rs13059470	ENSG00000256628.3	ZBTB11-AS1	-7.25	1.71e-12	5.3e-10	-0.37	-0.32	Colorectal cancer;	chr3:101705956	chr3:101676475~101679217:+
THCA	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	7.25	1.71e-12	5.3e-10	0.26	0.32	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
THCA	cis	rs453301	0.682	rs2929451	ENSG00000254153.1	CTA-398F10.2	-7.25	1.71e-12	5.3e-10	-0.34	-0.32	Joint mobility (Beighton score);	chr8:9227785	chr8:8456909~8461337:-
THCA	cis	rs74233809	1	rs11191607	ENSG00000213277.3	MARCKSL1P1	7.25	1.72e-12	5.32e-10	0.51	0.32	Birth weight;	chr10:103199431	chr10:103175554~103176094:+
THCA	cis	rs77204473	0.744	rs75890305	ENSG00000254851.1	RP11-109L13.1	7.25	1.72e-12	5.32e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117049253	chr11:117135528~117138582:+
THCA	cis	rs4073416	0.746	rs12879202	ENSG00000276116.2	FUT8-AS1	7.25	1.72e-12	5.32e-10	0.33	0.32	N-glycan levels;	chr14:65510464	chr14:65411170~65412690:-
THCA	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-7.25	1.73e-12	5.35e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-7.25	1.73e-12	5.35e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-7.25	1.73e-12	5.35e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
THCA	cis	rs4820539	0.966	rs5759600	ENSG00000221069.1	AC000029.1	-7.25	1.73e-12	5.35e-10	-0.37	-0.32	Bone mineral density;	chr22:23141582	chr22:23136620~23136710:+
THCA	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-7.25	1.73e-12	5.35e-10	-0.37	-0.32	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
THCA	cis	rs8012947	1	rs7154076	ENSG00000279636.2	LINC00216	-7.25	1.73e-12	5.35e-10	-0.33	-0.32	Alcohol consumption in current drinkers;	chr14:58295564	chr14:58288033~58289158:+
THCA	cis	rs2976388	0.669	rs1836633	ENSG00000253741.1	CTD-2292P10.4	-7.25	1.74e-12	5.37e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142693174	chr8:142702252~142726973:-
THCA	cis	rs172166	0.585	rs149963	ENSG00000219392.1	RP1-265C24.5	-7.25	1.74e-12	5.37e-10	-0.34	-0.32	Cardiac Troponin-T levels;	chr6:28049354	chr6:28115628~28116551:+
THCA	cis	rs4947019	0.609	rs9487109	ENSG00000260273.1	RP11-425D10.10	7.25	1.74e-12	5.37e-10	0.69	0.32	Hematological parameters;	chr6:109436323	chr6:109382795~109383666:+
THCA	cis	rs853679	0.517	rs9380056	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.37e-10	-0.37	-0.32	Depression;	chr6:28136698	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380057	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.37e-10	-0.37	-0.32	Depression;	chr6:28136856	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs1947862	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.37e-10	-0.37	-0.32	Depression;	chr6:28137418	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs6941992	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.37e-10	-0.37	-0.32	Depression;	chr6:28138363	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.37e-10	-0.37	-0.32	Parkinson's disease;	chr6:28138569	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs4713143	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.37e-10	-0.37	-0.32	Depression;	chr6:28138981	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs4713144	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.37e-10	-0.37	-0.32	Depression;	chr6:28139012	chr6:28078792~28081130:-
THCA	cis	rs74233809	1	rs11191560	ENSG00000213277.3	MARCKSL1P1	7.25	1.74e-12	5.38e-10	0.52	0.32	Birth weight;	chr10:103109281	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs12413046	ENSG00000213277.3	MARCKSL1P1	7.25	1.74e-12	5.38e-10	0.52	0.32	Birth weight;	chr10:103111447	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs10883832	ENSG00000213277.3	MARCKSL1P1	7.25	1.74e-12	5.38e-10	0.52	0.32	Birth weight;	chr10:103111522	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs79082900	ENSG00000213277.3	MARCKSL1P1	7.25	1.74e-12	5.38e-10	0.52	0.32	Birth weight;	chr10:103117545	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs12220375	ENSG00000213277.3	MARCKSL1P1	7.25	1.74e-12	5.38e-10	0.52	0.32	Birth weight;	chr10:103141734	chr10:103175554~103176094:+
THCA	cis	rs2976388	0.625	rs2257840	ENSG00000253741.1	CTD-2292P10.4	-7.25	1.74e-12	5.38e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142727775	chr8:142702252~142726973:-
THCA	cis	rs875971	1	rs10257427	ENSG00000232559.3	GS1-124K5.12	-7.25	1.74e-12	5.38e-10	-0.3	-0.32	Aortic root size;	chr7:66278221	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs10215948	ENSG00000232559.3	GS1-124K5.12	-7.25	1.74e-12	5.38e-10	-0.3	-0.32	Aortic root size;	chr7:66282799	chr7:66554588~66576923:-
THCA	cis	rs875971	0.964	rs55748098	ENSG00000232559.3	GS1-124K5.12	-7.25	1.74e-12	5.38e-10	-0.3	-0.32	Aortic root size;	chr7:66298631	chr7:66554588~66576923:-
THCA	cis	rs75422866	0.51	rs73105829	ENSG00000274902.1	RP1-197B17.4	7.25	1.74e-12	5.39e-10	0.66	0.32	Pneumonia;	chr12:47734162	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.51	rs75424057	ENSG00000274902.1	RP1-197B17.4	7.25	1.74e-12	5.39e-10	0.66	0.32	Pneumonia;	chr12:47737294	chr12:47731908~47732351:+
THCA	cis	rs853679	0.517	rs9380047	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28070115	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs7755442	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28071237	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs12174753	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28074687	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs55747925	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28076559	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs56310871	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28076704	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs34716816	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28078391	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380049	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28080757	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380050	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28080760	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393885	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28082231	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393886	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28082261	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Parkinson's disease;	chr6:28082269	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs56364346	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28082984	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9357061	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28083994	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368550	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28084025	chr6:28078792~28081130:-
THCA	cis	rs853679	0.542	rs2295594	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28085319	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9366715	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28096855	chr6:28078792~28081130:-
THCA	cis	rs853679	0.598	rs9380054	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28099759	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Parkinson's disease;	chr6:28100173	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368552	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28100648	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs2281588	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28104824	chr6:28078792~28081130:-
THCA	cis	rs853679	0.542	rs34131763	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28107222	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs35193936	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28108492	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs36078605	ENSG00000272009.1	RP1-313I6.12	-7.25	1.74e-12	5.39e-10	-0.37	-0.32	Depression;	chr6:28110254	chr6:28078792~28081130:-
THCA	cis	rs2562456	0.755	rs2562421	ENSG00000213976.4	CTD-2561J22.2	7.25	1.74e-12	5.39e-10	0.35	0.32	Pain;	chr19:21448502	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.793	rs2562420	ENSG00000213976.4	CTD-2561J22.2	7.25	1.74e-12	5.39e-10	0.35	0.32	Pain;	chr19:21448503	chr19:21382865~21387177:+
THCA	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	7.25	1.74e-12	5.39e-10	0.6	0.32	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
THCA	cis	rs1198430	0.683	rs7551124	ENSG00000232482.2	RP4-654C18.1	-7.25	1.74e-12	5.39e-10	-0.5	-0.32	Total cholesterol levels;	chr1:23459267	chr1:23410832~23412146:+
THCA	cis	rs7811142	0.943	rs3900792	ENSG00000078319.8	PMS2P1	-7.25	1.74e-12	5.39e-10	-0.44	-0.32	Platelet count;	chr7:100406954	chr7:100320992~100341908:-
THCA	cis	rs733592	0.599	rs12819124	ENSG00000240399.1	RP1-228P16.1	7.25	1.75e-12	5.39e-10	0.31	0.32	Plateletcrit;	chr12:48015271	chr12:48054813~48055591:-
THCA	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-7.25	1.75e-12	5.39e-10	-0.31	-0.32	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-7.25	1.75e-12	5.39e-10	-0.31	-0.32	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
THCA	cis	rs9890032	0.52	rs2321926	ENSG00000263531.1	RP13-753N3.1	7.25	1.75e-12	5.39e-10	0.43	0.32	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30863921~30864940:-
THCA	cis	rs8012947	1	rs7155580	ENSG00000279636.2	LINC00216	-7.25	1.75e-12	5.4e-10	-0.33	-0.32	Alcohol consumption in current drinkers;	chr14:58304914	chr14:58288033~58289158:+
THCA	cis	rs10050311	0.858	rs72667703	ENSG00000251411.1	RP11-397E7.4	-7.25	1.75e-12	5.4e-10	-0.4	-0.32	Insulin-related traits;	chr4:86891825	chr4:86913266~86914817:-
THCA	cis	rs875971	1	rs12532998	ENSG00000232559.3	GS1-124K5.12	7.25	1.75e-12	5.4e-10	0.3	0.32	Aortic root size;	chr7:66502472	chr7:66554588~66576923:-
THCA	cis	rs1198430	1	rs1198430	ENSG00000232482.2	RP4-654C18.1	7.25	1.75e-12	5.42e-10	0.55	0.32	Total cholesterol levels;	chr1:23429020	chr1:23410832~23412146:+
THCA	cis	rs875971	0.965	rs9969301	ENSG00000232559.3	GS1-124K5.12	-7.25	1.75e-12	5.42e-10	-0.3	-0.32	Aortic root size;	chr7:66316668	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs709595	ENSG00000232559.3	GS1-124K5.12	7.25	1.75e-12	5.42e-10	0.3	0.32	Aortic root size;	chr7:66352346	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs811880	ENSG00000232559.3	GS1-124K5.12	7.25	1.75e-12	5.42e-10	0.3	0.32	Aortic root size;	chr7:66353659	chr7:66554588~66576923:-
THCA	cis	rs9287719	0.601	rs6755281	ENSG00000243819.4	RN7SL832P	7.25	1.75e-12	5.42e-10	0.26	0.32	Prostate cancer;	chr2:10629729	chr2:10690344~10692099:+
THCA	cis	rs748404	0.723	rs512431	ENSG00000205771.5	CATSPER2P1	7.25	1.75e-12	5.42e-10	0.33	0.32	Lung cancer;	chr15:43249741	chr15:43726918~43747094:-
THCA	cis	rs9467773	0.869	rs1796520	ENSG00000124549.13	BTN2A3P	-7.25	1.76e-12	5.42e-10	-0.3	-0.32	Intelligence (multi-trait analysis);	chr6:26410572	chr6:26421391~26432383:+
THCA	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	7.25	1.76e-12	5.42e-10	0.33	0.32	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000263603.1	CTD-2349P21.5	-7.25	1.76e-12	5.43e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30729469~30731202:+
THCA	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-7.25	1.76e-12	5.43e-10	-0.52	-0.32	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
THCA	cis	rs12928939	0.727	rs8053623	ENSG00000260886.1	TAT-AS1	7.25	1.76e-12	5.43e-10	0.41	0.32	Post bronchodilator FEV1;	chr16:71613626	chr16:71565789~71578187:+
THCA	cis	rs160451	0.966	rs28374917	ENSG00000251136.7	RP11-37B2.1	7.25	1.76e-12	5.44e-10	0.27	0.32	Leprosy;	chr8:89666525	chr8:89609409~89757727:-
THCA	cis	rs914615	0.508	rs4971079	ENSG00000160766.13	GBAP1	-7.25	1.76e-12	5.44e-10	-0.34	-0.32	Urinary albumin-to-creatinine ratio;	chr1:155157915	chr1:155213821~155227422:-
THCA	cis	rs1009647	0.677	rs11851870	ENSG00000258413.1	RP11-665C16.6	-7.25	1.77e-12	5.46e-10	-0.55	-0.32	Testicular germ cell tumor;	chr14:55349264	chr14:55262767~55272075:-
THCA	cis	rs853679	0.517	rs9393887	ENSG00000220721.1	OR1F12	7.25	1.77e-12	5.46e-10	0.44	0.32	Depression;	chr6:28091242	chr6:28073316~28074233:+
THCA	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-7.25	1.77e-12	5.46e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
THCA	cis	rs875971	0.755	rs76288834	ENSG00000232559.3	GS1-124K5.12	-7.25	1.77e-12	5.46e-10	-0.31	-0.32	Aortic root size;	chr7:66604815	chr7:66554588~66576923:-
THCA	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-7.25	1.77e-12	5.46e-10	-0.33	-0.32	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
THCA	cis	rs7851660	0.844	rs10123699	ENSG00000236130.1	PTCSC2	-7.25	1.77e-12	5.46e-10	-0.25	-0.32	Strep throat;	chr9:97875577	chr9:97805935~97810008:-
THCA	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-7.25	1.77e-12	5.47e-10	-0.33	-0.32	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
THCA	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	7.25	1.77e-12	5.47e-10	0.4	0.32	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
THCA	cis	rs7267979	0.903	rs2474766	ENSG00000274414.1	RP5-965G21.4	-7.25	1.77e-12	5.47e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25239007~25245229:-
THCA	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	7.25	1.77e-12	5.47e-10	0.38	0.32	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
THCA	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-7.25	1.77e-12	5.47e-10	-0.37	-0.32	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
THCA	cis	rs8114671	0.562	rs6088621	ENSG00000269202.1	RP4-614O4.12	-7.25	1.78e-12	5.48e-10	-0.27	-0.32	Height;	chr20:34830937	chr20:35201747~35203288:-
THCA	cis	rs12594515	1	rs57299255	ENSG00000259200.1	RP11-718O11.1	-7.25	1.78e-12	5.48e-10	-0.38	-0.32	Weight;Waist circumference;	chr15:45704334	chr15:45705078~45931069:+
THCA	cis	rs3020736	0.5	rs7292241	ENSG00000205702.9	CYP2D7	-7.25	1.78e-12	5.49e-10	-0.26	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42140203~42144577:-
THCA	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-7.25	1.78e-12	5.5e-10	-0.46	-0.32	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-7.25	1.78e-12	5.5e-10	-0.46	-0.32	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
THCA	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-7.25	1.78e-12	5.51e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-7.25	1.78e-12	5.51e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
THCA	cis	rs7945705	0.715	rs10840123	ENSG00000254860.4	TMEM9B-AS1	-7.24	1.78e-12	5.51e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8797468	chr11:8964675~8977527:+
THCA	cis	rs12908161	1	rs3803405	ENSG00000259728.4	LINC00933	7.24	1.79e-12	5.51e-10	0.44	0.32	Schizophrenia;	chr15:84840409	chr15:84570649~84580175:+
THCA	cis	rs7948661	1	rs9332809	ENSG00000278376.1	RP11-158I9.8	7.24	1.79e-12	5.52e-10	0.55	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118490757	chr11:118791254~118793137:+
THCA	cis	rs77204473	0.744	rs12970	ENSG00000254851.1	RP11-109L13.1	7.24	1.79e-12	5.52e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117203393	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	7.24	1.79e-12	5.52e-10	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	7.24	1.79e-12	5.52e-10	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
THCA	cis	rs9388451	0.626	rs3734637	ENSG00000237742.5	RP11-624M8.1	-7.24	1.79e-12	5.53e-10	-0.28	-0.32	Brugada syndrome;	chr6:125760173	chr6:125578558~125749190:-
THCA	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	7.24	1.79e-12	5.53e-10	0.47	0.32	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000220721.1	OR1F12	7.24	1.79e-12	5.53e-10	0.43	0.32	Depression;	chr6:28079011	chr6:28073316~28074233:+
THCA	cis	rs7942368	1	rs1837680	ENSG00000254761.1	RP11-672A2.1	7.24	1.79e-12	5.53e-10	0.45	0.32	Endometriosis;	chr11:76790407	chr11:76712396~76719608:-
THCA	cis	rs910316	0.967	rs4899550	ENSG00000279594.1	RP11-950C14.10	-7.24	1.79e-12	5.54e-10	-0.3	-0.32	Height;	chr14:75180963	chr14:75011269~75012851:-
THCA	cis	rs79349575	0.87	rs12941262	ENSG00000248278.1	SUMO2P17	7.24	1.8e-12	5.54e-10	0.38	0.32	Type 2 diabetes;	chr17:48889675	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.778	rs12950328	ENSG00000248278.1	SUMO2P17	7.24	1.8e-12	5.54e-10	0.38	0.32	Type 2 diabetes;	chr17:48889699	chr17:48874860~48908983:-
THCA	cis	rs35934224	0.891	rs13054713	ENSG00000232926.1	AC000078.5	7.24	1.8e-12	5.54e-10	0.39	0.32	Glaucoma (primary open-angle);	chr22:19880391	chr22:19887289~19887970:+
THCA	cis	rs12681366	0.734	rs716770	ENSG00000253704.1	RP11-267M23.4	7.24	1.8e-12	5.54e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94378693	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.734	rs10504936	ENSG00000253704.1	RP11-267M23.4	7.24	1.8e-12	5.54e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94379827	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.734	rs10112606	ENSG00000253704.1	RP11-267M23.4	7.24	1.8e-12	5.54e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94383838	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.708	rs12680029	ENSG00000253704.1	RP11-267M23.4	7.24	1.8e-12	5.54e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94392418	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.647	rs12545262	ENSG00000253704.1	RP11-267M23.4	7.24	1.8e-12	5.54e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94392813	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.734	rs28641679	ENSG00000253704.1	RP11-267M23.4	7.24	1.8e-12	5.54e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94394465	chr8:94553722~94569745:+
THCA	cis	rs875971	0.867	rs1002053	ENSG00000232559.3	GS1-124K5.12	-7.24	1.8e-12	5.55e-10	-0.3	-0.32	Aortic root size;	chr7:66333558	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6460292	ENSG00000232559.3	GS1-124K5.12	-7.24	1.8e-12	5.55e-10	-0.3	-0.32	Aortic root size;	chr7:66345088	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs2659893	ENSG00000232559.3	GS1-124K5.12	7.24	1.8e-12	5.55e-10	0.3	0.32	Aortic root size;	chr7:66735006	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs2659892	ENSG00000232559.3	GS1-124K5.12	7.24	1.8e-12	5.55e-10	0.3	0.32	Aortic root size;	chr7:66735318	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs2707847	ENSG00000232559.3	GS1-124K5.12	7.24	1.8e-12	5.55e-10	0.3	0.32	Aortic root size;	chr7:66737884	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs11761542	ENSG00000232559.3	GS1-124K5.12	7.24	1.8e-12	5.55e-10	0.3	0.32	Aortic root size;	chr7:66753209	chr7:66554588~66576923:-
THCA	cis	rs7942368	0.941	rs11236936	ENSG00000254761.1	RP11-672A2.1	7.24	1.8e-12	5.55e-10	0.45	0.32	Endometriosis;	chr11:76789786	chr11:76712396~76719608:-
THCA	cis	rs1850744	1	rs7664572	ENSG00000250942.1	ENPP7P11	-7.24	1.8e-12	5.57e-10	-0.45	-0.32	Economic and political preferences;	chr4:9807085	chr4:9677308~9677934:+
THCA	cis	rs853679	0.517	rs9380058	ENSG00000220721.1	OR1F12	7.24	1.81e-12	5.58e-10	0.44	0.32	Depression;	chr6:28159666	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000220721.1	OR1F12	7.24	1.81e-12	5.58e-10	0.44	0.32	Depression;	chr6:28162598	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs35848276	ENSG00000280107.1	AL022393.9	-7.24	1.81e-12	5.59e-10	-0.64	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28170845~28172521:+
THCA	cis	rs2439831	0.867	rs2255042	ENSG00000275601.1	AC011330.13	7.24	1.81e-12	5.59e-10	0.48	0.32	Lung cancer in ever smokers;	chr15:43542120	chr15:43642389~43643023:-
THCA	cis	rs4273100	0.834	rs59415593	ENSG00000228157.4	AC007952.5	7.24	1.82e-12	5.6e-10	0.51	0.32	Schizophrenia;	chr17:19319911	chr17:19092974~19096837:+
THCA	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	7.24	1.82e-12	5.6e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
THCA	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	7.24	1.82e-12	5.6e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	7.24	1.82e-12	5.6e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	7.24	1.82e-12	5.6e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	7.24	1.82e-12	5.6e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	7.24	1.82e-12	5.6e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	7.24	1.82e-12	5.6e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
THCA	cis	rs9902453	0.934	rs7213902	ENSG00000264007.1	RP11-68I3.10	7.24	1.82e-12	5.61e-10	0.37	0.32	Coffee consumption (cups per day);	chr17:29995917	chr17:29621617~29622254:-
THCA	cis	rs4073416	0.746	rs12883382	ENSG00000276116.2	FUT8-AS1	7.24	1.82e-12	5.61e-10	0.33	0.32	N-glycan levels;	chr14:65678678	chr14:65411170~65412690:-
THCA	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	7.24	1.82e-12	5.62e-10	0.58	0.32	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	7.24	1.82e-12	5.62e-10	0.58	0.32	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	7.24	1.82e-12	5.62e-10	0.58	0.32	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
THCA	cis	rs7208859	0.673	rs78799101	ENSG00000264538.5	SUZ12P1	-7.24	1.83e-12	5.63e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30709299~30790908:+
THCA	cis	rs12908161	0.959	rs61074241	ENSG00000259728.4	LINC00933	7.24	1.83e-12	5.63e-10	0.45	0.32	Schizophrenia;	chr15:84790165	chr15:84570649~84580175:+
THCA	cis	rs4073416	0.712	rs12892058	ENSG00000276116.2	FUT8-AS1	7.24	1.83e-12	5.64e-10	0.33	0.32	N-glycan levels;	chr14:65436723	chr14:65411170~65412690:-
THCA	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	7.24	1.83e-12	5.64e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
THCA	cis	rs910316	0.934	rs8016330	ENSG00000279594.1	RP11-950C14.10	-7.24	1.83e-12	5.64e-10	-0.3	-0.32	Height;	chr14:75190804	chr14:75011269~75012851:-
THCA	cis	rs4073416	0.712	rs1535173	ENSG00000276116.2	FUT8-AS1	-7.24	1.83e-12	5.65e-10	-0.32	-0.32	N-glycan levels;	chr14:65732421	chr14:65411170~65412690:-
THCA	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-7.24	1.84e-12	5.66e-10	-0.35	-0.32	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000263603.1	CTD-2349P21.5	-7.24	1.84e-12	5.66e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000263603.1	CTD-2349P21.5	-7.24	1.84e-12	5.66e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30729469~30731202:+
THCA	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-7.24	1.84e-12	5.66e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-7.24	1.84e-12	5.66e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
THCA	cis	rs2284219	0.894	rs1076291	ENSG00000244480.1	AC005154.7	-7.24	1.84e-12	5.67e-10	-0.25	-0.32	Type 2 diabetes;	chr7:30672979	chr7:30523143~30524535:-
THCA	cis	rs2284219	0.894	rs1076292	ENSG00000244480.1	AC005154.7	-7.24	1.84e-12	5.67e-10	-0.25	-0.32	Type 2 diabetes;	chr7:30673085	chr7:30523143~30524535:-
THCA	cis	rs2284219	0.894	rs2251002	ENSG00000244480.1	AC005154.7	-7.24	1.84e-12	5.67e-10	-0.25	-0.32	Type 2 diabetes;	chr7:30673228	chr7:30523143~30524535:-
THCA	cis	rs2836974	0.604	rs2854727	ENSG00000255568.3	BRWD1-AS2	7.24	1.84e-12	5.67e-10	0.25	0.32	Cognitive function;	chr21:39341861	chr21:39313935~39314962:+
THCA	cis	rs6061231	0.701	rs6061505	ENSG00000275437.1	RP5-908M14.10	7.24	1.84e-12	5.68e-10	0.28	0.32	Colorectal cancer;	chr20:62385155	chr20:62402236~62405935:-
THCA	cis	rs12030196	0.536	rs2716130	ENSG00000230812.4	LINC01358	7.24	1.85e-12	5.69e-10	0.33	0.32	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59021456	chr1:59020387~59044614:+
THCA	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-7.24	1.85e-12	5.69e-10	-0.31	-0.32	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
THCA	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	7.24	1.85e-12	5.69e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
THCA	cis	rs12681366	0.734	rs4735292	ENSG00000253704.1	RP11-267M23.4	7.24	1.85e-12	5.69e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94396503	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.734	rs3019146	ENSG00000253704.1	RP11-267M23.4	7.24	1.85e-12	5.69e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94401878	chr8:94553722~94569745:+
THCA	cis	rs4073416	0.712	rs1953416	ENSG00000276116.2	FUT8-AS1	7.24	1.85e-12	5.7e-10	0.33	0.32	N-glycan levels;	chr14:65412089	chr14:65411170~65412690:-
THCA	cis	rs4950322	0.57	rs4950409	ENSG00000237188.3	RP11-337C18.8	7.24	1.85e-12	5.71e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147335879	chr1:147172771~147211568:+
THCA	cis	rs7646881	0.812	rs75267618	ENSG00000240207.5	RP11-379F4.4	-7.24	1.86e-12	5.72e-10	-0.45	-0.32	Tetralogy of Fallot;	chr3:158726027	chr3:158732263~158784070:+
THCA	cis	rs4820539	1	rs2267002	ENSG00000221069.1	AC000029.1	-7.24	1.86e-12	5.72e-10	-0.37	-0.32	Bone mineral density;	chr22:23114515	chr22:23136620~23136710:+
THCA	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	7.24	1.86e-12	5.73e-10	0.3	0.32	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
THCA	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-7.24	1.86e-12	5.74e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-7.24	1.86e-12	5.74e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
THCA	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	7.24	1.86e-12	5.74e-10	0.45	0.32	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
THCA	cis	rs728616	0.614	rs1885552	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952336	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs1885551	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952597	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs12253608	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952727	chr10:79663088~79826594:-
THCA	cis	rs728616	0.764	rs1885549	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952794	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs12245076	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953675	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs10788319	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953754	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs11200859	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953805	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs10887229	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954018	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs10788321	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954039	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs61858839	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954162	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs61858841	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954420	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs61858842	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955283	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs10887233	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955596	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs10887234	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955666	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs2146192	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955982	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs2146191	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955998	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs10887243	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957339	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs10887244	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957352	chr10:79663088~79826594:-
THCA	cis	rs728616	0.541	rs61860401	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs61860413	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs61860414	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.87e-12	5.74e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:79663088~79826594:-
THCA	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	7.24	1.87e-12	5.76e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	7.24	1.87e-12	5.76e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
THCA	cis	rs3806843	0.705	rs2530230	ENSG00000202515.1	VTRNA1-3	7.24	1.87e-12	5.77e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140708546	chr5:140726158~140726246:+
THCA	cis	rs6539288	0.933	rs6539285	ENSG00000260329.1	RP11-412D9.4	-7.24	1.88e-12	5.77e-10	-0.29	-0.32	Total body bone mineral density;	chr12:106903683	chr12:106954029~106955497:-
THCA	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	7.24	1.88e-12	5.77e-10	0.45	0.32	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
THCA	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-7.24	1.88e-12	5.78e-10	-0.34	-0.32	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
THCA	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	7.24	1.88e-12	5.78e-10	0.35	0.32	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
THCA	cis	rs728616	0.867	rs55690691	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.88e-12	5.78e-10	-0.65	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79899186	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs1983775	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.88e-12	5.78e-10	-0.65	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903819	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs1983776	ENSG00000225484.5	NUTM2B-AS1	-7.24	1.88e-12	5.78e-10	-0.65	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903939	chr10:79663088~79826594:-
THCA	cis	rs910316	0.737	rs175045	ENSG00000279594.1	RP11-950C14.10	-7.24	1.88e-12	5.79e-10	-0.29	-0.32	Height;	chr14:75008572	chr14:75011269~75012851:-
THCA	cis	rs6723226	0.698	rs13409142	ENSG00000276334.1	AL133243.1	7.24	1.88e-12	5.79e-10	0.36	0.32	Intelligence (multi-trait analysis);	chr2:32441069	chr2:32521927~32523547:+
THCA	cis	rs853679	0.517	rs3734573	ENSG00000220721.1	OR1F12	7.24	1.88e-12	5.79e-10	0.44	0.32	Depression;	chr6:28091659	chr6:28073316~28074233:+
THCA	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-7.24	1.88e-12	5.8e-10	-0.4	-0.32	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
THCA	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-7.24	1.88e-12	5.8e-10	-0.44	-0.32	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
THCA	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-7.24	1.89e-12	5.8e-10	-0.34	-0.32	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-7.24	1.89e-12	5.8e-10	-0.34	-0.32	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-7.24	1.89e-12	5.8e-10	-0.34	-0.32	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
THCA	cis	rs853679	0.882	rs9468300	ENSG00000226314.6	ZNF192P1	-7.24	1.89e-12	5.81e-10	-0.53	-0.32	Depression;	chr6:28159062	chr6:28161781~28169594:+
THCA	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.81e-10	-0.31	-0.32	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.81e-10	-0.31	-0.32	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
THCA	cis	rs2522056	1	rs2706395	ENSG00000233006.5	AC034220.3	-7.24	1.89e-12	5.82e-10	-0.27	-0.32	Fibrinogen;Lymphocyte counts;	chr5:132461111	chr5:132311285~132369916:-
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000263603.1	CTD-2349P21.5	-7.24	1.89e-12	5.82e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30729469~30731202:+
THCA	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-7.24	1.89e-12	5.82e-10	-0.32	-0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
THCA	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-7.24	1.89e-12	5.82e-10	-0.31	-0.32	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
THCA	cis	rs748404	0.588	rs506120	ENSG00000166763.7	STRCP1	7.24	1.89e-12	5.83e-10	0.34	0.32	Lung cancer;	chr15:43509826	chr15:43699488~43718184:-
THCA	cis	rs6840258	1	rs72667752	ENSG00000251411.1	RP11-397E7.4	-7.24	1.9e-12	5.84e-10	-0.38	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87018379	chr4:86913266~86914817:-
THCA	cis	rs6840258	1	rs72667754	ENSG00000251411.1	RP11-397E7.4	-7.24	1.9e-12	5.84e-10	-0.38	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87020909	chr4:86913266~86914817:-
THCA	cis	rs6840258	1	rs56050898	ENSG00000251411.1	RP11-397E7.4	-7.24	1.9e-12	5.84e-10	-0.38	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87024223	chr4:86913266~86914817:-
THCA	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	7.24	1.9e-12	5.84e-10	0.33	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
THCA	cis	rs77204473	0.744	rs80143284	ENSG00000254851.1	RP11-109L13.1	7.24	1.9e-12	5.84e-10	0.76	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117042854	chr11:117135528~117138582:+
THCA	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	7.24	1.9e-12	5.85e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	7.24	1.9e-12	5.85e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	7.24	1.9e-12	5.85e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
THCA	cis	rs10208649	1	rs6545367	ENSG00000272156.1	RP11-477N3.1	7.24	1.9e-12	5.85e-10	0.59	0.32	Body mass index;	chr2:53810148	chr2:54082554~54085066:+
THCA	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-7.24	1.9e-12	5.85e-10	-0.4	-0.32	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
THCA	cis	rs7120173	0.571	rs634044	ENSG00000254851.1	RP11-109L13.1	-7.24	1.9e-12	5.85e-10	-0.52	-0.32	Visceral adipose tissue adjusted for BMI;	chr11:116881842	chr11:117135528~117138582:+
THCA	cis	rs74233809	1	rs11191555	ENSG00000213277.3	MARCKSL1P1	7.24	1.9e-12	5.85e-10	0.52	0.32	Birth weight;	chr10:103097766	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191557	ENSG00000213277.3	MARCKSL1P1	7.24	1.9e-12	5.85e-10	0.52	0.32	Birth weight;	chr10:103104857	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191558	ENSG00000213277.3	MARCKSL1P1	7.24	1.9e-12	5.85e-10	0.52	0.32	Birth weight;	chr10:103104921	chr10:103175554~103176094:+
THCA	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-7.24	1.9e-12	5.85e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-7.24	1.9e-12	5.85e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
THCA	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-7.24	1.9e-12	5.86e-10	-0.33	-0.32	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
THCA	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-7.24	1.9e-12	5.86e-10	-0.33	-0.32	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
THCA	cis	rs990871	0.924	rs2568956	ENSG00000227207.2	RPL31P12	-7.24	1.91e-12	5.86e-10	-0.39	-0.32	Subcutaneous adipose tissue;	chr1:72298693	chr1:72301472~72301829:+
THCA	cis	rs36051354	0.573	rs2581792	ENSG00000242142.1	SERBP1P3	7.23	1.91e-12	5.87e-10	0.39	0.32	Intelligence (multi-trait analysis);	chr3:53001028	chr3:53064283~53065091:-
THCA	cis	rs17684571	0.938	rs17751682	ENSG00000231441.1	RP11-472M19.2	-7.23	1.91e-12	5.88e-10	-0.4	-0.32	Schizophrenia;	chr6:56695732	chr6:56844002~56864078:+
THCA	cis	rs9902453	1	rs4328498	ENSG00000264007.1	RP11-68I3.10	-7.23	1.91e-12	5.89e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30017258	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs6505152	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30004448	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs7223786	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30005089	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs8072664	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30006367	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.791	rs57719820	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30008070	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.935	rs9911794	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30022448	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs9896062	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30030029	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs9904336	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30030062	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs8071742	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30034651	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs4575590	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30034951	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs4074170	ENSG00000264007.1	RP11-68I3.10	-7.23	1.92e-12	5.89e-10	-0.37	-0.32	Coffee consumption (cups per day);	chr17:30054123	chr17:29621617~29622254:-
THCA	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	7.23	1.92e-12	5.9e-10	0.39	0.32	Height;	chr6:109656105	chr6:109382795~109383666:+
THCA	cis	rs947583	0.588	rs9494360	ENSG00000231028.7	LINC00271	-7.23	1.92e-12	5.9e-10	-0.26	-0.32	Phosphorus levels;	chr6:135755906	chr6:135497801~135716055:+
THCA	cis	rs990871	0.962	rs2815752	ENSG00000227207.2	RPL31P12	7.23	1.92e-12	5.9e-10	0.39	0.32	Subcutaneous adipose tissue;	chr1:72346757	chr1:72301472~72301829:+
THCA	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	7.23	1.93e-12	5.92e-10	0.4	0.32	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
THCA	cis	rs9859260	0.614	rs493661	ENSG00000231464.1	AC024937.4	-7.23	1.93e-12	5.93e-10	-0.4	-0.32	Mean corpuscular volume;	chr3:196059618	chr3:195996738~195998233:+
THCA	cis	rs853679	0.55	rs6901017	ENSG00000272009.1	RP1-313I6.12	-7.23	1.93e-12	5.93e-10	-0.36	-0.32	Depression;	chr6:28184805	chr6:28078792~28081130:-
THCA	cis	rs9990333	1	rs9990333	ENSG00000242086.7	LINC00969	-7.23	1.93e-12	5.94e-10	-0.3	-0.32	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195658062~195739964:+
THCA	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	7.23	1.93e-12	5.94e-10	0.38	0.32	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
THCA	cis	rs4784934	1	rs1424077	ENSG00000260186.4	RP11-481J2.2	7.23	1.93e-12	5.94e-10	0.48	0.32	QT interval;	chr16:58428723	chr16:58421326~58462470:+
THCA	cis	rs990871	1	rs11209948	ENSG00000227207.2	RPL31P12	7.23	1.93e-12	5.94e-10	0.39	0.32	Subcutaneous adipose tissue;	chr1:72346221	chr1:72301472~72301829:+
THCA	cis	rs9649213	0.574	rs7802541	ENSG00000272950.1	RP11-307C18.1	7.23	1.94e-12	5.95e-10	0.39	0.32	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr7:98322853~98323430:+
THCA	cis	rs172166	0.694	rs203876	ENSG00000280107.1	AL022393.9	-7.23	1.94e-12	5.95e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28078895	chr6:28170845~28172521:+
THCA	cis	rs172166	0.694	rs203877	ENSG00000280107.1	AL022393.9	-7.23	1.94e-12	5.95e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28080846	chr6:28170845~28172521:+
THCA	cis	rs172166	0.652	rs476167	ENSG00000280107.1	AL022393.9	-7.23	1.94e-12	5.95e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28098110	chr6:28170845~28172521:+
THCA	cis	rs172166	0.694	rs203892	ENSG00000280107.1	AL022393.9	-7.23	1.94e-12	5.95e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28099418	chr6:28170845~28172521:+
THCA	cis	rs75422866	0.51	rs35784744	ENSG00000274902.1	RP1-197B17.4	7.23	1.94e-12	5.95e-10	0.66	0.32	Pneumonia;	chr12:47729646	chr12:47731908~47732351:+
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Body mass index;	chr17:30750419	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Body mass index;	chr17:30753533	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Body mass index;	chr17:30794616	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Body mass index;	chr17:30815122	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Body mass index;	chr17:30815823	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.94e-12	5.95e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30729469~30731202:+
THCA	cis	rs2439831	0.867	rs2447208	ENSG00000249839.1	AC011330.5	-7.23	1.94e-12	5.96e-10	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43641697	chr15:43663654~43684339:-
THCA	cis	rs516805	0.667	rs7771090	ENSG00000279453.1	RP3-425C14.4	-7.23	1.94e-12	5.97e-10	-0.33	-0.32	Lymphocyte counts;	chr6:122339732	chr6:122436789~122439223:-
THCA	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	7.23	1.95e-12	5.97e-10	0.38	0.32	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
THCA	cis	rs4073416	0.619	rs867972	ENSG00000276116.2	FUT8-AS1	7.23	1.95e-12	5.98e-10	0.33	0.32	N-glycan levels;	chr14:65429043	chr14:65411170~65412690:-
THCA	cis	rs7246657	0.943	rs10415024	ENSG00000226686.6	LINC01535	-7.23	1.95e-12	5.98e-10	-0.46	-0.32	Coronary artery calcification;	chr19:37323822	chr19:37251912~37265535:+
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.95e-12	5.98e-10	-0.54	-0.32	Body mass index;	chr17:30741407	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.95e-12	5.98e-10	-0.54	-0.32	Body mass index;	chr17:30745674	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.95e-12	5.98e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30729469~30731202:+
THCA	cis	rs8027521	0.54	rs2711592	ENSG00000280362.1	RP11-643A5.3	-7.23	1.95e-12	5.98e-10	-0.43	-0.32	Circulating chemerin levels;	chr15:53979486	chr15:53910769~53914712:+
THCA	cis	rs2836974	0.545	rs8128901	ENSG00000255568.3	BRWD1-AS2	7.23	1.95e-12	5.98e-10	0.25	0.32	Cognitive function;	chr21:39338493	chr21:39313935~39314962:+
THCA	cis	rs4713118	0.662	rs469228	ENSG00000226314.6	ZNF192P1	-7.23	1.95e-12	5.98e-10	-0.39	-0.32	Parkinson's disease;	chr6:28002926	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.54	rs469227	ENSG00000226314.6	ZNF192P1	-7.23	1.95e-12	5.98e-10	-0.39	-0.32	Parkinson's disease;	chr6:28002927	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs149948	ENSG00000226314.6	ZNF192P1	-7.23	1.95e-12	5.98e-10	-0.39	-0.32	Parkinson's disease;	chr6:28007039	chr6:28161781~28169594:+
THCA	cis	rs11148252	0.683	rs9536006	ENSG00000278238.1	RP11-245D16.4	-7.23	1.95e-12	5.98e-10	-0.36	-0.32	Lewy body disease;	chr13:52313572	chr13:52454775~52455331:-
THCA	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-7.23	1.95e-12	5.99e-10	-0.34	-0.32	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-7.23	1.95e-12	5.99e-10	-0.34	-0.32	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
THCA	cis	rs10971721	0.631	rs10971945	ENSG00000260947.1	RP11-384P7.7	7.23	1.95e-12	5.99e-10	0.71	0.32	Body mass index;	chr9:34129397	chr9:33697459~33700986:+
THCA	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-7.23	1.95e-12	6e-10	-0.3	-0.32	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
THCA	cis	rs6723226	0.708	rs2710627	ENSG00000276334.1	AL133243.1	7.23	1.95e-12	6e-10	0.36	0.32	Intelligence (multi-trait analysis);	chr2:32533560	chr2:32521927~32523547:+
THCA	cis	rs2836974	0.583	rs2776306	ENSG00000255568.3	BRWD1-AS2	7.23	1.96e-12	6.01e-10	0.25	0.32	Cognitive function;	chr21:39341828	chr21:39313935~39314962:+
THCA	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	7.23	1.96e-12	6.01e-10	0.3	0.32	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
THCA	cis	rs801193	0.569	rs2707824	ENSG00000232559.3	GS1-124K5.12	7.23	1.96e-12	6.01e-10	0.3	0.32	Aortic root size;	chr7:66724256	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs10274883	ENSG00000232559.3	GS1-124K5.12	-7.23	1.96e-12	6.01e-10	-0.3	-0.32	Aortic root size;	chr7:66651104	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs881285	ENSG00000232559.3	GS1-124K5.12	-7.23	1.96e-12	6.01e-10	-0.3	-0.32	Aortic root size;	chr7:66654433	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs3846973	ENSG00000232559.3	GS1-124K5.12	-7.23	1.96e-12	6.01e-10	-0.3	-0.32	Aortic root size;	chr7:66655048	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs2013908	ENSG00000232559.3	GS1-124K5.12	-7.23	1.96e-12	6.01e-10	-0.3	-0.32	Aortic root size;	chr7:66656082	chr7:66554588~66576923:-
THCA	cis	rs7646881	1	rs7646987	ENSG00000240207.5	RP11-379F4.4	7.23	1.96e-12	6.03e-10	0.43	0.32	Tetralogy of Fallot;	chr3:158735653	chr3:158732263~158784070:+
THCA	cis	rs74233809	1	rs76752100	ENSG00000213277.3	MARCKSL1P1	7.23	1.97e-12	6.03e-10	0.52	0.32	Birth weight;	chr10:103034329	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191454	ENSG00000213277.3	MARCKSL1P1	7.23	1.97e-12	6.04e-10	0.52	0.32	Birth weight;	chr10:102900247	chr10:103175554~103176094:+
THCA	cis	rs832187	0.679	rs9879045	ENSG00000280620.1	SCAANT1	7.23	1.97e-12	6.05e-10	0.43	0.32	Schizophrenia;	chr3:64016249	chr3:63911518~63911772:-
THCA	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-7.23	1.98e-12	6.06e-10	-0.34	-0.32	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
THCA	cis	rs12681366	0.734	rs2046664	ENSG00000253704.1	RP11-267M23.4	7.23	1.98e-12	6.07e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94375713	chr8:94553722~94569745:+
THCA	cis	rs8067545	0.641	rs397969	ENSG00000270091.1	RP11-78O7.2	-7.23	1.98e-12	6.07e-10	-0.23	-0.32	Schizophrenia;	chr17:19900934	chr17:19896590~19897287:-
THCA	cis	rs240993	0.672	rs6922226	ENSG00000230177.1	RP5-1112D6.4	-7.23	1.98e-12	6.08e-10	-0.33	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111403281	chr6:111277932~111278742:+
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000263603.1	CTD-2349P21.5	-7.23	1.98e-12	6.08e-10	-0.55	-0.32	Body mass index;	chr17:30776148	chr17:30729469~30731202:+
THCA	cis	rs2033711	0.87	rs6510152	ENSG00000269473.1	CTD-2619J13.19	7.23	1.98e-12	6.08e-10	0.3	0.32	Uric acid clearance;	chr19:58441952	chr19:58440448~58445849:+
THCA	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-7.23	1.99e-12	6.09e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-7.23	1.99e-12	6.09e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-7.23	1.99e-12	6.09e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-7.23	1.99e-12	6.09e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
THCA	cis	rs4073416	0.712	rs7493004	ENSG00000276116.2	FUT8-AS1	7.23	1.99e-12	6.1e-10	0.33	0.32	N-glycan levels;	chr14:65657386	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.712	rs7142651	ENSG00000276116.2	FUT8-AS1	7.23	1.99e-12	6.1e-10	0.33	0.32	N-glycan levels;	chr14:65666003	chr14:65411170~65412690:-
THCA	cis	rs9287719	0.649	rs6732429	ENSG00000243819.4	RN7SL832P	-7.23	1.99e-12	6.1e-10	-0.26	-0.32	Prostate cancer;	chr2:10618846	chr2:10690344~10692099:+
THCA	cis	rs728616	0.614	rs58606426	ENSG00000225484.5	NUTM2B-AS1	-7.23	1.99e-12	6.1e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs57966752	ENSG00000225484.5	NUTM2B-AS1	-7.23	1.99e-12	6.1e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:79663088~79826594:-
THCA	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	7.23	1.99e-12	6.1e-10	0.35	0.32	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
THCA	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	7.23	1.99e-12	6.11e-10	0.45	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
THCA	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-7.23	2e-12	6.12e-10	-0.31	-0.32	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
THCA	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-7.23	2e-12	6.13e-10	-0.4	-0.32	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
THCA	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	7.23	2e-12	6.13e-10	0.3	0.32	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
THCA	cis	rs30380	0.69	rs2042381	ENSG00000248734.2	CTD-2260A17.1	7.23	2e-12	6.14e-10	0.35	0.32	Cerebrospinal fluid biomarker levels;	chr5:96852963	chr5:96784777~96785999:+
THCA	cis	rs7923837	0.687	rs10882102	ENSG00000236493.2	EIF2S2P3	7.23	2.01e-12	6.15e-10	0.33	0.32	Multiple sclerosis;Body mass index;	chr10:92706738	chr10:92668745~92669743:-
THCA	cis	rs10869777	0.905	rs10869776	ENSG00000234618.1	RPSAP9	-7.23	2.01e-12	6.17e-10	-0.34	-0.32	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76433936	chr9:76398699~76399586:+
THCA	cis	rs11051970	1	rs1872829	ENSG00000274964.1	RP11-817I4.1	-7.23	2.01e-12	6.17e-10	-0.36	-0.32	Response to tocilizumab in rheumatoid arthritis;	chr12:32382166	chr12:32339368~32340724:+
THCA	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-7.23	2.02e-12	6.18e-10	-0.46	-0.32	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-7.23	2.02e-12	6.18e-10	-0.46	-0.32	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
THCA	cis	rs4073416	0.684	rs12890902	ENSG00000276116.2	FUT8-AS1	7.23	2.02e-12	6.18e-10	0.33	0.32	N-glycan levels;	chr14:65649904	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.712	rs2300865	ENSG00000276116.2	FUT8-AS1	7.23	2.02e-12	6.18e-10	0.33	0.32	N-glycan levels;	chr14:65653297	chr14:65411170~65412690:-
THCA	cis	rs198389	0.589	rs198401	ENSG00000242349.4	NPPA-AS1	-7.23	2.02e-12	6.19e-10	-0.29	-0.32	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11828327	chr1:11841017~11848079:+
THCA	cis	rs728616	0.614	rs59169164	ENSG00000225484.5	NUTM2B-AS1	-7.23	2.02e-12	6.2e-10	-0.47	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952159	chr10:79663088~79826594:-
THCA	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	7.23	2.02e-12	6.2e-10	0.38	0.32	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
THCA	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	7.23	2.02e-12	6.2e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
THCA	cis	rs11148252	0.538	rs3368	ENSG00000278238.1	RP11-245D16.4	-7.23	2.02e-12	6.21e-10	-0.35	-0.32	Lewy body disease;	chr13:52133104	chr13:52454775~52455331:-
THCA	cis	rs172166	0.694	rs188105	ENSG00000280107.1	AL022393.9	-7.23	2.03e-12	6.21e-10	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28103615	chr6:28170845~28172521:+
THCA	cis	rs12681366	0.683	rs56285115	ENSG00000253704.1	RP11-267M23.4	7.23	2.03e-12	6.22e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94389244	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.734	rs16916796	ENSG00000253704.1	RP11-267M23.4	7.23	2.03e-12	6.22e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94390001	chr8:94553722~94569745:+
THCA	cis	rs516805	0.748	rs155461	ENSG00000279453.1	RP3-425C14.4	-7.23	2.03e-12	6.22e-10	-0.35	-0.32	Lymphocyte counts;	chr6:122499547	chr6:122436789~122439223:-
THCA	cis	rs7221109	0.711	rs11651694	ENSG00000278834.1	RP11-458J1.1	7.23	2.03e-12	6.22e-10	0.34	0.32	Type 1 diabetes;	chr17:40602009	chr17:40648300~40649718:+
THCA	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	7.23	2.03e-12	6.23e-10	0.49	0.32	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
THCA	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	7.22	2.04e-12	6.26e-10	0.4	0.32	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
THCA	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	7.22	2.04e-12	6.26e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
THCA	cis	rs9902453	0.817	rs59420007	ENSG00000264007.1	RP11-68I3.10	7.22	2.05e-12	6.29e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29869096	chr17:29621617~29622254:-
THCA	cis	rs2033711	0.902	rs4801589	ENSG00000269473.1	CTD-2619J13.19	7.22	2.05e-12	6.29e-10	0.3	0.32	Uric acid clearance;	chr19:58442031	chr19:58440448~58445849:+
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Body mass index;	chr17:30758740	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Body mass index;	chr17:30774046	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs12006	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000263603.1	CTD-2349P21.5	-7.22	2.05e-12	6.29e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30729469~30731202:+
THCA	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-7.22	2.06e-12	6.29e-10	-0.34	-0.32	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
THCA	cis	rs4072705	1	rs4836981	ENSG00000224020.1	MIR181A2HG	-7.22	2.06e-12	6.29e-10	-0.28	-0.32	Menarche (age at onset);	chr9:124577866	chr9:124658467~124698631:+
THCA	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-7.22	2.06e-12	6.3e-10	-0.25	-0.32	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
THCA	cis	rs4780355	1	rs4780355	ENSG00000262636.1	CTD-3088G3.4	7.22	2.06e-12	6.3e-10	0.41	0.32	Crohn's disease and psoriasis;	chr16:11254001	chr16:11380859~11381118:-
THCA	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-7.22	2.06e-12	6.3e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-7.22	2.06e-12	6.3e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
THCA	cis	rs5758659	0.633	rs762995	ENSG00000182057.4	OGFRP1	7.22	2.06e-12	6.31e-10	0.35	0.32	Cognitive function;	chr22:42276118	chr22:42269753~42275196:+
THCA	cis	rs6723108	0.603	rs6708336	ENSG00000224043.6	CCNT2-AS1	-7.22	2.06e-12	6.31e-10	-0.34	-0.32	Type 2 diabetes;	chr2:134961562	chr2:134735464~134918710:-
THCA	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	7.22	2.06e-12	6.31e-10	0.33	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
THCA	cis	rs34375054	0.624	rs12832525	ENSG00000279233.1	RP11-158L12.4	7.22	2.06e-12	6.31e-10	0.33	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125195820	chr12:125138245~125141711:+
THCA	cis	rs6723108	0.627	rs12469941	ENSG00000224043.6	CCNT2-AS1	7.22	2.06e-12	6.32e-10	0.33	0.32	Type 2 diabetes;	chr2:134872357	chr2:134735464~134918710:-
THCA	cis	rs801193	0.591	rs721717	ENSG00000232559.3	GS1-124K5.12	-7.22	2.07e-12	6.33e-10	-0.3	-0.32	Aortic root size;	chr7:66665305	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs6951302	ENSG00000232559.3	GS1-124K5.12	-7.22	2.07e-12	6.33e-10	-0.3	-0.32	Aortic root size;	chr7:66667525	chr7:66554588~66576923:-
THCA	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-7.22	2.07e-12	6.33e-10	-0.34	-0.32	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
THCA	cis	rs2408955	0.522	rs6580650	ENSG00000258273.1	RP11-370I10.4	7.22	2.07e-12	6.34e-10	0.43	0.32	Glycated hemoglobin levels;	chr12:48024773	chr12:48333755~48333901:-
THCA	cis	rs9902453	0.808	rs10445400	ENSG00000264007.1	RP11-68I3.10	7.22	2.07e-12	6.34e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29856041	chr17:29621617~29622254:-
THCA	cis	rs7208859	0.673	rs216410	ENSG00000264538.5	SUZ12P1	7.22	2.08e-12	6.35e-10	0.31	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30709299~30790908:+
THCA	cis	rs713477	1	rs8010013	ENSG00000258413.1	RP11-665C16.6	7.22	2.09e-12	6.38e-10	0.42	0.32	Pediatric bone mineral content (femoral neck);	chr14:55418110	chr14:55262767~55272075:-
THCA	cis	rs77204473	0.744	rs75216569	ENSG00000254851.1	RP11-109L13.1	7.22	2.09e-12	6.38e-10	0.8	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117036999	chr11:117135528~117138582:+
THCA	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-7.22	2.09e-12	6.38e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
THCA	cis	rs9287719	0.572	rs1038690	ENSG00000234818.1	AC092687.5	-7.22	2.09e-12	6.39e-10	-0.38	-0.32	Prostate cancer;	chr2:10673118	chr2:10589166~10604830:+
THCA	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	7.22	2.09e-12	6.4e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	7.22	2.09e-12	6.4e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
THCA	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-7.22	2.09e-12	6.4e-10	-0.51	-0.32	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
THCA	cis	rs7044106	0.615	rs10818470	ENSG00000238181.2	AHCYP2	-7.22	2.09e-12	6.41e-10	-0.4	-0.32	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120720673~120721972:+
THCA	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	7.22	2.09e-12	6.41e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
THCA	cis	rs2880765	0.835	rs2170735	ENSG00000259295.5	CSPG4P12	7.22	2.1e-12	6.42e-10	0.4	0.32	Coronary artery disease;	chr15:85500254	chr15:85191438~85213905:+
THCA	cis	rs3747113	0.732	rs11704465	ENSG00000128262.7	POM121L9P	-7.22	2.1e-12	6.42e-10	-0.36	-0.32	Gut microbiome composition (summer);	chr22:24466629	chr22:24251828~24265525:+
THCA	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	7.22	2.1e-12	6.42e-10	0.37	0.32	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
THCA	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-7.22	2.1e-12	6.42e-10	-0.34	-0.32	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-7.22	2.1e-12	6.42e-10	-0.34	-0.32	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
THCA	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	7.22	2.1e-12	6.43e-10	0.3	0.32	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
THCA	cis	rs875971	0.862	rs6944374	ENSG00000232559.3	GS1-124K5.12	-7.22	2.11e-12	6.44e-10	-0.3	-0.32	Aortic root size;	chr7:66221942	chr7:66554588~66576923:-
THCA	cis	rs9902453	0.967	rs7212741	ENSG00000264007.1	RP11-68I3.10	7.22	2.11e-12	6.44e-10	0.36	0.32	Coffee consumption (cups per day);	chr17:29995923	chr17:29621617~29622254:-
THCA	cis	rs853679	0.517	rs9393891	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Depression;	chr6:28111382	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Depression;	chr6:28111650	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Parkinson's disease;	chr6:28112168	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Depression;	chr6:28112175	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Depression;	chr6:28113851	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Depression;	chr6:28114487	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Depression;	chr6:28114933	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Depression;	chr6:28115743	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Depression;	chr6:28116411	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Parkinson's disease;	chr6:28118700	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Parkinson's disease;	chr6:28118701	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000220721.1	OR1F12	7.22	2.11e-12	6.45e-10	0.43	0.32	Parkinson's disease;	chr6:28119896	chr6:28073316~28074233:+
THCA	cis	rs4073416	0.712	rs2268961	ENSG00000276116.2	FUT8-AS1	7.22	2.11e-12	6.45e-10	0.33	0.32	N-glycan levels;	chr14:65680047	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.746	rs2064694	ENSG00000276116.2	FUT8-AS1	7.22	2.11e-12	6.45e-10	0.33	0.32	N-glycan levels;	chr14:65681528	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.657	rs11622271	ENSG00000276116.2	FUT8-AS1	7.22	2.11e-12	6.45e-10	0.33	0.32	N-glycan levels;	chr14:65682347	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.712	rs12588838	ENSG00000276116.2	FUT8-AS1	7.22	2.11e-12	6.45e-10	0.33	0.32	N-glycan levels;	chr14:65695920	chr14:65411170~65412690:-
THCA	cis	rs4950322	0.57	rs17356492	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147296089	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72691093	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147297977	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs76236344	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147297989	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72691095	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147298305	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72691097	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147299711	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72691098	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147300142	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72691102	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147301189	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692904	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147301437	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692905	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147301560	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692907	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147301921	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692914	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147302946	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692917	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147304389	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692920	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147308501	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs66580541	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147308828	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs945742	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147313437	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.543	rs4950318	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147316240	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.543	rs4950319	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147316250	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.543	rs4453096	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147316574	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.571	rs4373796	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147316747	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.543	rs4568882	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147316885	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.543	rs2883323	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147316995	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.543	rs2883324	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147317157	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.542	rs72692942	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147318467	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs4950399	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147319302	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs4950403	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147319723	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.517	rs116479391	ENSG00000237188.3	RP11-337C18.8	7.22	2.11e-12	6.46e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147320940	chr1:147172771~147211568:+
THCA	cis	rs957448	0.561	rs71532325	ENSG00000253704.1	RP11-267M23.4	7.22	2.12e-12	6.48e-10	0.33	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94553722~94569745:+
THCA	cis	rs651907	0.514	rs55654108	ENSG00000256628.3	ZBTB11-AS1	7.22	2.13e-12	6.51e-10	0.37	0.32	Colorectal cancer;	chr3:101706859	chr3:101676475~101679217:+
THCA	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-7.22	2.14e-12	6.53e-10	-0.33	-0.32	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
THCA	cis	rs9467773	0.869	rs1796521	ENSG00000124549.13	BTN2A3P	-7.22	2.14e-12	6.53e-10	-0.3	-0.32	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26421391~26432383:+
THCA	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-7.22	2.14e-12	6.54e-10	-0.33	-0.32	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
THCA	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	7.22	2.14e-12	6.55e-10	0.42	0.32	Height;	chr6:109331033	chr6:109382795~109383666:+
THCA	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-7.22	2.14e-12	6.55e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
THCA	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	7.22	2.14e-12	6.55e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	7.22	2.14e-12	6.55e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	7.22	2.14e-12	6.55e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	7.22	2.14e-12	6.55e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	7.22	2.14e-12	6.55e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	7.22	2.14e-12	6.55e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
THCA	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	7.22	2.15e-12	6.55e-10	0.59	0.32	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
THCA	cis	rs9341808	0.754	rs9361591	ENSG00000272129.1	RP11-250B2.6	7.22	2.15e-12	6.56e-10	0.4	0.32	Sitting height ratio;	chr6:80243538	chr6:80355424~80356859:+
THCA	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-7.22	2.15e-12	6.56e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-7.22	2.15e-12	6.56e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-7.22	2.15e-12	6.56e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
THCA	cis	rs7727544	0.836	rs10463892	ENSG00000237714.1	P4HA2-AS1	7.22	2.15e-12	6.57e-10	0.41	0.32	Blood metabolite levels;	chr5:132263012	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.901	rs55633655	ENSG00000237714.1	P4HA2-AS1	7.22	2.15e-12	6.57e-10	0.41	0.32	Blood metabolite levels;	chr5:132263063	chr5:132184876~132192808:+
THCA	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-7.22	2.15e-12	6.57e-10	-0.3	-0.32	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-7.22	2.15e-12	6.57e-10	-0.3	-0.32	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-7.22	2.15e-12	6.57e-10	-0.3	-0.32	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
THCA	cis	rs2836974	0.545	rs3167757	ENSG00000255568.3	BRWD1-AS2	7.22	2.15e-12	6.58e-10	0.25	0.32	Cognitive function;	chr21:39342552	chr21:39313935~39314962:+
THCA	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-7.22	2.15e-12	6.58e-10	-0.58	-0.32	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
THCA	cis	rs10869777	0.967	rs10869779	ENSG00000234618.1	RPSAP9	-7.22	2.16e-12	6.6e-10	-0.34	-0.32	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76440227	chr9:76398699~76399586:+
THCA	cis	rs7267979	0.706	rs6138542	ENSG00000274414.1	RP5-965G21.4	-7.22	2.17e-12	6.61e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25239007~25245229:-
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000220721.1	OR1F12	7.22	2.17e-12	6.61e-10	0.43	0.32	Parkinson's disease;	chr6:28110633	chr6:28073316~28074233:+
THCA	cis	rs8012947	1	rs56208804	ENSG00000279636.2	LINC00216	-7.22	2.17e-12	6.61e-10	-0.33	-0.32	Alcohol consumption in current drinkers;	chr14:58313408	chr14:58288033~58289158:+
THCA	cis	rs8012947	0.959	rs3945957	ENSG00000279636.2	LINC00216	-7.22	2.17e-12	6.61e-10	-0.33	-0.32	Alcohol consumption in current drinkers;	chr14:58316335	chr14:58288033~58289158:+
THCA	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-7.22	2.17e-12	6.62e-10	-0.36	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
THCA	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-7.22	2.17e-12	6.63e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-7.22	2.17e-12	6.63e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
THCA	cis	rs6539288	0.933	rs4964498	ENSG00000260329.1	RP11-412D9.4	-7.22	2.17e-12	6.63e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106912945	chr12:106954029~106955497:-
THCA	cis	rs1198430	0.673	rs7511979	ENSG00000232482.2	RP4-654C18.1	-7.22	2.17e-12	6.64e-10	-0.47	-0.32	Total cholesterol levels;	chr1:23420932	chr1:23410832~23412146:+
THCA	cis	rs934734	0.544	rs4671127	ENSG00000281920.1	RP11-418H16.1	7.22	2.18e-12	6.64e-10	0.42	0.32	Rheumatoid arthritis;	chr2:65335836	chr2:65623272~65628424:+
THCA	cis	rs17684571	0.938	rs4262190	ENSG00000231441.1	RP11-472M19.2	7.21	2.18e-12	6.66e-10	0.38	0.32	Schizophrenia;	chr6:56702404	chr6:56844002~56864078:+
THCA	cis	rs467650	0.529	rs1508791	ENSG00000246763.5	RGMB-AS1	-7.21	2.18e-12	6.66e-10	-0.29	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr5:98660173	chr5:98769618~98773469:-
THCA	cis	rs853679	1	rs9986596	ENSG00000219392.1	RP1-265C24.5	-7.21	2.18e-12	6.66e-10	-0.51	-0.32	Depression;	chr6:28251883	chr6:28115628~28116551:+
THCA	cis	rs4073416	0.691	rs11628765	ENSG00000276116.2	FUT8-AS1	7.21	2.19e-12	6.67e-10	0.33	0.32	N-glycan levels;	chr14:65701731	chr14:65411170~65412690:-
THCA	cis	rs9341808	0.754	rs10733162	ENSG00000272129.1	RP11-250B2.6	7.21	2.19e-12	6.69e-10	0.4	0.32	Sitting height ratio;	chr6:80313672	chr6:80355424~80356859:+
THCA	cis	rs875971	0.862	rs6952182	ENSG00000232559.3	GS1-124K5.12	-7.21	2.19e-12	6.69e-10	-0.31	-0.32	Aortic root size;	chr7:66218330	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6964437	ENSG00000232559.3	GS1-124K5.12	-7.21	2.19e-12	6.69e-10	-0.31	-0.32	Aortic root size;	chr7:66221457	chr7:66554588~66576923:-
THCA	cis	rs4950322	0.57	rs72691090	ENSG00000237188.3	RP11-337C18.8	7.21	2.19e-12	6.69e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147297884	chr1:147172771~147211568:+
THCA	cis	rs17772222	0.755	rs12435019	ENSG00000258789.1	RP11-507K2.3	-7.21	2.2e-12	6.7e-10	-0.29	-0.32	Coronary artery calcification;	chr14:88365074	chr14:88551597~88552493:+
THCA	cis	rs7948661	1	rs9332781	ENSG00000278376.1	RP11-158I9.8	7.21	2.2e-12	6.7e-10	0.54	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118475884	chr11:118791254~118793137:+
THCA	cis	rs9902453	0.967	rs9900911	ENSG00000264007.1	RP11-68I3.10	-7.21	2.2e-12	6.7e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30003262	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.935	rs7220151	ENSG00000264007.1	RP11-68I3.10	-7.21	2.2e-12	6.7e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30007692	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.838	rs7217638	ENSG00000264007.1	RP11-68I3.10	-7.21	2.2e-12	6.7e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30009754	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs9912741	ENSG00000264007.1	RP11-68I3.10	-7.21	2.2e-12	6.7e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30032493	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs9891871	ENSG00000264007.1	RP11-68I3.10	-7.21	2.2e-12	6.7e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30043173	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs6505155	ENSG00000264007.1	RP11-68I3.10	-7.21	2.2e-12	6.7e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30045765	chr17:29621617~29622254:-
THCA	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-7.21	2.2e-12	6.72e-10	-0.51	-0.32	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
THCA	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-7.21	2.2e-12	6.72e-10	-0.34	-0.32	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
THCA	cis	rs7208859	0.673	rs216410	ENSG00000266490.1	CTD-2349P21.9	-7.21	2.2e-12	6.72e-10	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30792372~30792833:+
THCA	cis	rs2880765	0.835	rs2170736	ENSG00000259295.5	CSPG4P12	7.21	2.21e-12	6.74e-10	0.4	0.32	Coronary artery disease;	chr15:85500167	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs4340287	ENSG00000259295.5	CSPG4P12	7.21	2.21e-12	6.74e-10	0.4	0.32	Coronary artery disease;	chr15:85500506	chr15:85191438~85213905:+
THCA	cis	rs7727544	0.904	rs58835386	ENSG00000237714.1	P4HA2-AS1	7.21	2.21e-12	6.74e-10	0.41	0.32	Blood metabolite levels;	chr5:132264866	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.904	rs7736102	ENSG00000237714.1	P4HA2-AS1	7.21	2.21e-12	6.74e-10	0.41	0.32	Blood metabolite levels;	chr5:132268564	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.904	rs6897575	ENSG00000237714.1	P4HA2-AS1	7.21	2.21e-12	6.74e-10	0.41	0.32	Blood metabolite levels;	chr5:132268842	chr5:132184876~132192808:+
THCA	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-7.21	2.22e-12	6.75e-10	-0.38	-0.32	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-7.21	2.22e-12	6.75e-10	-0.38	-0.32	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
THCA	cis	rs7568498	0.517	rs11678856	ENSG00000235724.7	AC009299.2	7.21	2.22e-12	6.75e-10	0.36	0.32	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161068932	chr2:161222785~161308303:-
THCA	cis	rs7189233	0.955	rs16952242	ENSG00000279722.1	RP11-44F14.6	-7.21	2.22e-12	6.76e-10	-0.33	-0.32	Intelligence (multi-trait analysis);	chr16:53440338	chr16:53487607~53489943:-
THCA	cis	rs7948661	0.661	rs113028342	ENSG00000278376.1	RP11-158I9.8	7.21	2.22e-12	6.77e-10	0.54	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118462822	chr11:118791254~118793137:+
THCA	cis	rs9473147	0.516	rs6904764	ENSG00000270761.1	RP11-385F7.1	-7.21	2.22e-12	6.77e-10	-0.25	-0.32	Platelet distribution width;Mean platelet volume;	chr6:47535761	chr6:47477243~47477572:-
THCA	cis	rs9369695	0.883	rs9473128	ENSG00000270761.1	RP11-385F7.1	-7.21	2.22e-12	6.77e-10	-0.25	-0.32	Reticulocyte count;	chr6:47537274	chr6:47477243~47477572:-
THCA	cis	rs9902453	0.817	rs2729449	ENSG00000264007.1	RP11-68I3.10	-7.21	2.22e-12	6.78e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:29762733	chr17:29621617~29622254:-
THCA	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.79e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.79e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.79e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.79e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.79e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.79e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
THCA	cis	rs875971	0.862	rs6460293	ENSG00000232559.3	GS1-124K5.12	-7.21	2.23e-12	6.8e-10	-0.3	-0.32	Aortic root size;	chr7:66345205	chr7:66554588~66576923:-
THCA	cis	rs2236295	0.597	rs7477765	ENSG00000238280.1	RP11-436D10.3	-7.21	2.23e-12	6.8e-10	-0.39	-0.32	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62831984	chr10:62793562~62805887:-
THCA	cis	rs467650	0.529	rs2549200	ENSG00000246763.5	RGMB-AS1	-7.21	2.23e-12	6.8e-10	-0.3	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr5:98660644	chr5:98769618~98773469:-
THCA	cis	rs7727544	0.506	rs10040809	ENSG00000237714.1	P4HA2-AS1	7.21	2.23e-12	6.81e-10	0.42	0.32	Blood metabolite levels;	chr5:132007324	chr5:132184876~132192808:+
THCA	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.81e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.81e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.81e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-7.21	2.23e-12	6.81e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
THCA	cis	rs2263638	0.565	rs2488794	ENSG00000228701.1	TNKS2-AS1	-7.21	2.24e-12	6.81e-10	-0.41	-0.32	Airflow obstruction;	chr10:92408060	chr10:91782839~91798291:-
THCA	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-7.21	2.24e-12	6.82e-10	-0.31	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
THCA	cis	rs9506514	0.722	rs11147813	ENSG00000222726.1	RNU2-7P	7.21	2.24e-12	6.82e-10	0.38	0.32	Coronary artery calcification;	chr13:20684419	chr13:20612161~20612338:+
THCA	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	7.21	2.24e-12	6.83e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
THCA	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-7.21	2.24e-12	6.83e-10	-0.4	-0.32	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
THCA	cis	rs853679	0.517	rs4713150	ENSG00000220721.1	OR1F12	7.21	2.24e-12	6.84e-10	0.44	0.32	Depression;	chr6:28168434	chr6:28073316~28074233:+
THCA	cis	rs7189233	1	rs62048544	ENSG00000279722.1	RP11-44F14.6	-7.21	2.25e-12	6.84e-10	-0.33	-0.32	Intelligence (multi-trait analysis);	chr16:53503829	chr16:53487607~53489943:-
THCA	cis	rs12701220	0.744	rs2030958	ENSG00000229043.2	AC091729.9	-7.21	2.25e-12	6.84e-10	-0.44	-0.32	Bronchopulmonary dysplasia;	chr7:1036374	chr7:1160374~1165267:+
THCA	cis	rs12681366	0.734	rs10102496	ENSG00000253704.1	RP11-267M23.4	7.21	2.25e-12	6.85e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94385953	chr8:94553722~94569745:+
THCA	cis	rs8012947	1	rs10151828	ENSG00000279636.2	LINC00216	-7.21	2.25e-12	6.85e-10	-0.33	-0.32	Alcohol consumption in current drinkers;	chr14:58282711	chr14:58288033~58289158:+
THCA	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	7.21	2.25e-12	6.87e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
THCA	cis	rs9402743	0.634	rs9321512	ENSG00000231028.7	LINC00271	7.21	2.25e-12	6.87e-10	0.25	0.32	Systemic lupus erythematosus;	chr6:135603299	chr6:135497801~135716055:+
THCA	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-7.21	2.26e-12	6.87e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
THCA	cis	rs875971	1	rs9986696	ENSG00000232559.3	GS1-124K5.12	-7.21	2.26e-12	6.88e-10	-0.3	-0.32	Aortic root size;	chr7:66239589	chr7:66554588~66576923:-
THCA	cis	rs832187	0.704	rs832195	ENSG00000280620.1	SCAANT1	-7.21	2.26e-12	6.88e-10	-0.43	-0.32	Schizophrenia;	chr3:63878936	chr3:63911518~63911772:-
THCA	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	7.21	2.26e-12	6.88e-10	0.37	0.32	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
THCA	cis	rs2439831	0.867	rs2245715	ENSG00000275601.1	AC011330.13	-7.21	2.26e-12	6.88e-10	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43525854	chr15:43642389~43643023:-
THCA	cis	rs3806843	0.657	rs2563283	ENSG00000202515.1	VTRNA1-3	7.21	2.26e-12	6.88e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.771	rs2563336	ENSG00000202515.1	VTRNA1-3	7.21	2.26e-12	6.88e-10	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr5:140726158~140726246:+
THCA	cis	rs801193	0.591	rs4506088	ENSG00000232559.3	GS1-124K5.12	-7.21	2.26e-12	6.89e-10	-0.3	-0.32	Aortic root size;	chr7:66670470	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs2659908	ENSG00000232559.3	GS1-124K5.12	7.21	2.26e-12	6.89e-10	0.3	0.32	Aortic root size;	chr7:66695835	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs4717315	ENSG00000232559.3	GS1-124K5.12	7.21	2.26e-12	6.89e-10	0.3	0.32	Aortic root size;	chr7:66713338	chr7:66554588~66576923:-
THCA	cis	rs801193	0.527	rs2707837	ENSG00000232559.3	GS1-124K5.12	7.21	2.26e-12	6.89e-10	0.3	0.32	Aortic root size;	chr7:66716086	chr7:66554588~66576923:-
THCA	cis	rs9329221	0.521	rs17693945	ENSG00000261451.1	RP11-981G7.1	-7.21	2.26e-12	6.89e-10	-0.41	-0.32	Neuroticism;	chr8:10248500	chr8:10433672~10438312:+
THCA	cis	rs1949733	0.656	rs6845969	ENSG00000205959.3	RP11-689P11.2	-7.21	2.26e-12	6.9e-10	-0.26	-0.32	Response to antineoplastic agents;	chr4:8400738	chr4:8482270~8512610:+
THCA	cis	rs6600671	1	rs11249351	ENSG00000223345.3	HIST2H2BA	7.21	2.27e-12	6.91e-10	0.34	0.32	Hip geometry;	chr1:121430082	chr1:121108210~121117257:-
THCA	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	7.21	2.27e-12	6.92e-10	0.3	0.32	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
THCA	cis	rs6745190	0.953	rs4595925	ENSG00000236153.1	AC104076.3	7.21	2.27e-12	6.92e-10	0.38	0.32	White blood cell count;	chr2:180979589	chr2:180979427~180980090:-
THCA	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	7.21	2.27e-12	6.92e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	7.21	2.27e-12	6.92e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	7.21	2.27e-12	6.92e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	7.21	2.27e-12	6.92e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	7.21	2.27e-12	6.92e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	7.21	2.27e-12	6.92e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	7.21	2.27e-12	6.92e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	7.21	2.27e-12	6.92e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
THCA	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-7.21	2.28e-12	6.93e-10	-0.34	-0.32	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
THCA	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	7.21	2.28e-12	6.93e-10	0.25	0.32	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
THCA	cis	rs6600671	0.967	rs12069545	ENSG00000223345.3	HIST2H2BA	7.21	2.28e-12	6.93e-10	0.34	0.32	Hip geometry;	chr1:121430343	chr1:121108210~121117257:-
THCA	cis	rs853679	0.517	rs6922063	ENSG00000272009.1	RP1-313I6.12	-7.21	2.28e-12	6.94e-10	-0.37	-0.32	Depression;	chr6:28126588	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs2275508	ENSG00000272009.1	RP1-313I6.12	-7.21	2.28e-12	6.94e-10	-0.37	-0.32	Depression;	chr6:28126953	chr6:28078792~28081130:-
THCA	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	7.21	2.28e-12	6.95e-10	0.34	0.32	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
THCA	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	7.21	2.28e-12	6.95e-10	0.41	0.32	Height;	chr6:109713188	chr6:109382795~109383666:+
THCA	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-7.21	2.29e-12	6.96e-10	-0.56	-0.32	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
THCA	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-7.21	2.29e-12	6.97e-10	-0.39	-0.32	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
THCA	cis	rs7131987	0.65	rs10843377	ENSG00000275476.1	RP11-996F15.4	7.21	2.29e-12	6.98e-10	0.32	0.32	QT interval;	chr12:29284120	chr12:29277397~29277882:-
THCA	cis	rs853679	0.517	rs3734573	ENSG00000272009.1	RP1-313I6.12	-7.21	2.3e-12	6.99e-10	-0.37	-0.32	Depression;	chr6:28091659	chr6:28078792~28081130:-
THCA	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	7.21	2.3e-12	6.99e-10	0.38	0.32	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
THCA	cis	rs7246657	0.943	rs10405064	ENSG00000226686.6	LINC01535	-7.21	2.3e-12	6.99e-10	-0.47	-0.32	Coronary artery calcification;	chr19:37370959	chr19:37251912~37265535:+
THCA	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-7.21	2.3e-12	7e-10	-0.34	-0.32	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
THCA	cis	rs12817211	0.524	rs7967979	ENSG00000272368.2	RP4-605O3.4	-7.21	2.3e-12	7e-10	-0.18	-0.32	Colorectal or endometrial cancer;	chr12:50126893	chr12:50112197~50165618:+
THCA	cis	rs12817211	0.548	rs2204684	ENSG00000272368.2	RP4-605O3.4	-7.21	2.3e-12	7e-10	-0.18	-0.32	Colorectal or endometrial cancer;	chr12:50128689	chr12:50112197~50165618:+
THCA	cis	rs11148252	0.538	rs9535880	ENSG00000278238.1	RP11-245D16.4	-7.21	2.3e-12	7e-10	-0.34	-0.32	Lewy body disease;	chr13:52132007	chr13:52454775~52455331:-
THCA	cis	rs875971	0.825	rs6951503	ENSG00000232559.3	GS1-124K5.12	-7.21	2.3e-12	7e-10	-0.3	-0.32	Aortic root size;	chr7:66253949	chr7:66554588~66576923:-
THCA	cis	rs6762	0.748	rs3059	ENSG00000279672.1	CMB9-55F22.1	7.21	2.3e-12	7e-10	0.36	0.32	Mean platelet volume;	chr11:840319	chr11:779617~780755:+
THCA	cis	rs9400467	0.509	rs11153287	ENSG00000230177.1	RP5-1112D6.4	-7.21	2.3e-12	7.01e-10	-0.25	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111383334	chr6:111277932~111278742:+
THCA	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-7.21	2.3e-12	7.01e-10	-0.23	-0.32	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
THCA	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-7.21	2.31e-12	7.02e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-7.21	2.31e-12	7.02e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
THCA	cis	rs10050311	0.858	rs72667705	ENSG00000251411.1	RP11-397E7.4	-7.21	2.31e-12	7.03e-10	-0.39	-0.32	Insulin-related traits;	chr4:86892986	chr4:86913266~86914817:-
THCA	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-7.21	2.31e-12	7.03e-10	-0.39	-0.32	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
THCA	cis	rs12681366	0.734	rs16916802	ENSG00000253704.1	RP11-267M23.4	7.21	2.31e-12	7.03e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94397280	chr8:94553722~94569745:+
THCA	cis	rs7131987	0.621	rs57803026	ENSG00000275476.1	RP11-996F15.4	-7.21	2.31e-12	7.04e-10	-0.32	-0.32	QT interval;	chr12:29344573	chr12:29277397~29277882:-
THCA	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-7.21	2.31e-12	7.04e-10	-0.23	-0.32	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
THCA	cis	rs6908034	0.607	rs12527834	ENSG00000228412.5	RP4-625H18.2	7.21	2.31e-12	7.04e-10	0.8	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821550	chr6:19802164~19804752:-
THCA	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-7.21	2.32e-12	7.05e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-7.21	2.32e-12	7.05e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-7.21	2.32e-12	7.05e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-7.21	2.32e-12	7.05e-10	-0.41	-0.32	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	7.21	2.32e-12	7.05e-10	0.4	0.32	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
THCA	cis	rs160451	0.934	rs34036322	ENSG00000251136.7	RP11-37B2.1	7.21	2.32e-12	7.05e-10	0.27	0.32	Leprosy;	chr8:89654670	chr8:89609409~89757727:-
THCA	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-7.21	2.32e-12	7.05e-10	-0.38	-0.32	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
THCA	cis	rs853679	0.517	rs4713141	ENSG00000272009.1	RP1-313I6.12	-7.21	2.32e-12	7.06e-10	-0.37	-0.32	Depression;	chr6:28133900	chr6:28078792~28081130:-
THCA	cis	rs7131987	0.65	rs16934135	ENSG00000275476.1	RP11-996F15.4	-7.21	2.32e-12	7.06e-10	-0.32	-0.32	QT interval;	chr12:29331030	chr12:29277397~29277882:-
THCA	cis	rs4950322	0.57	rs72692979	ENSG00000237188.3	RP11-337C18.8	7.21	2.32e-12	7.06e-10	0.39	0.32	Protein quantitative trait loci;	chr1:147336094	chr1:147172771~147211568:+
THCA	cis	rs6545883	0.525	rs1729658	ENSG00000271889.1	RP11-493E12.1	7.21	2.32e-12	7.06e-10	0.29	0.32	Tuberculosis;	chr2:61146385	chr2:61151433~61162105:-
THCA	cis	rs79349575	0.783	rs28409394	ENSG00000248278.1	SUMO2P17	7.21	2.32e-12	7.06e-10	0.37	0.32	Type 2 diabetes;	chr17:48920756	chr17:48874860~48908983:-
THCA	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-7.2	2.33e-12	7.07e-10	-0.25	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-7.2	2.33e-12	7.07e-10	-0.25	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
THCA	cis	rs4948275	0.55	rs10994749	ENSG00000237233.2	TMEM26-AS1	7.2	2.33e-12	7.08e-10	0.43	0.32	Night sleep phenotypes;	chr10:61396464	chr10:61452639~61481956:+
THCA	cis	rs74233809	1	rs12219027	ENSG00000213277.3	MARCKSL1P1	7.2	2.33e-12	7.08e-10	0.52	0.32	Birth weight;	chr10:103051446	chr10:103175554~103176094:+
THCA	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-7.2	2.33e-12	7.08e-10	-0.43	-0.32	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
THCA	cis	rs7176527	0.579	rs366717	ENSG00000188388.10	GOLGA6L3	7.2	2.33e-12	7.08e-10	0.44	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85240472~85247170:+
THCA	cis	rs8027521	0.501	rs2711588	ENSG00000280362.1	RP11-643A5.3	-7.2	2.33e-12	7.08e-10	-0.42	-0.32	Circulating chemerin levels;	chr15:53982129	chr15:53910769~53914712:+
THCA	cis	rs4072705	1	rs2416949	ENSG00000224020.1	MIR181A2HG	-7.2	2.34e-12	7.11e-10	-0.28	-0.32	Menarche (age at onset);	chr9:124712832	chr9:124658467~124698631:+
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000264538.5	SUZ12P1	-7.2	2.34e-12	7.11e-10	-0.32	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30709299~30790908:+
THCA	cis	rs74233809	1	rs12217501	ENSG00000213277.3	MARCKSL1P1	7.2	2.34e-12	7.11e-10	0.52	0.32	Birth weight;	chr10:103092132	chr10:103175554~103176094:+
THCA	cis	rs9341808	0.754	rs1324121	ENSG00000272129.1	RP11-250B2.6	7.2	2.34e-12	7.11e-10	0.4	0.32	Sitting height ratio;	chr6:80236360	chr6:80355424~80356859:+
THCA	cis	rs4073416	0.712	rs11158601	ENSG00000276116.2	FUT8-AS1	7.2	2.34e-12	7.11e-10	0.33	0.32	N-glycan levels;	chr14:65558645	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.651	rs1958561	ENSG00000276116.2	FUT8-AS1	7.2	2.34e-12	7.11e-10	0.33	0.32	N-glycan levels;	chr14:65570043	chr14:65411170~65412690:-
THCA	cis	rs6908034	0.607	rs79842087	ENSG00000228412.5	RP4-625H18.2	7.2	2.34e-12	7.12e-10	0.8	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821085	chr6:19802164~19804752:-
THCA	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	7.2	2.34e-12	7.12e-10	0.35	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
THCA	cis	rs79349575	0.594	rs1985785	ENSG00000248278.1	SUMO2P17	7.2	2.34e-12	7.12e-10	0.37	0.32	Type 2 diabetes;	chr17:48890426	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.685	rs1124829	ENSG00000248278.1	SUMO2P17	7.2	2.34e-12	7.12e-10	0.37	0.32	Type 2 diabetes;	chr17:48890435	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.721	rs1008834	ENSG00000248278.1	SUMO2P17	7.2	2.34e-12	7.12e-10	0.37	0.32	Type 2 diabetes;	chr17:48890646	chr17:48874860~48908983:-
THCA	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-7.2	2.34e-12	7.12e-10	-0.41	-0.32	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
THCA	cis	rs6908034	0.66	rs74457659	ENSG00000228412.5	RP4-625H18.2	7.2	2.35e-12	7.13e-10	0.77	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19760494	chr6:19802164~19804752:-
THCA	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	7.2	2.35e-12	7.13e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	7.2	2.35e-12	7.13e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
THCA	cis	rs990871	1	rs2815765	ENSG00000227207.2	RPL31P12	-7.2	2.35e-12	7.13e-10	-0.39	-0.32	Subcutaneous adipose tissue;	chr1:72286547	chr1:72301472~72301829:+
THCA	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	7.2	2.35e-12	7.14e-10	0.21	0.32	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	7.2	2.35e-12	7.14e-10	0.21	0.32	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
THCA	cis	rs2946505	0.59	rs2203836	ENSG00000251468.2	RP11-369K16.1	7.2	2.36e-12	7.16e-10	0.44	0.32	Migraine;	chr8:12967279	chr8:12958387~12962200:+
THCA	cis	rs9902453	0.904	rs4994353	ENSG00000264007.1	RP11-68I3.10	-7.2	2.36e-12	7.17e-10	-0.36	-0.32	Coffee consumption (cups per day);	chr17:30059262	chr17:29621617~29622254:-
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000264538.5	SUZ12P1	-7.2	2.36e-12	7.17e-10	-0.32	-0.32	Body mass index;	chr17:30737900	chr17:30709299~30790908:+
THCA	cis	rs4948275	0.55	rs7904815	ENSG00000237233.2	TMEM26-AS1	7.2	2.36e-12	7.18e-10	0.43	0.32	Night sleep phenotypes;	chr10:61376854	chr10:61452639~61481956:+
THCA	cis	rs12928939	0.774	rs7205340	ENSG00000260886.1	TAT-AS1	-7.2	2.37e-12	7.19e-10	-0.4	-0.32	Post bronchodilator FEV1;	chr16:71611767	chr16:71565789~71578187:+
THCA	cis	rs7131987	0.622	rs7294598	ENSG00000275476.1	RP11-996F15.4	7.2	2.37e-12	7.2e-10	0.32	0.32	QT interval;	chr12:29379056	chr12:29277397~29277882:-
THCA	cis	rs4820539	0.966	rs2267000	ENSG00000221069.1	AC000029.1	-7.2	2.37e-12	7.2e-10	-0.37	-0.32	Bone mineral density;	chr22:23113179	chr22:23136620~23136710:+
THCA	cis	rs6539288	0.933	rs7961366	ENSG00000260329.1	RP11-412D9.4	-7.2	2.37e-12	7.2e-10	-0.29	-0.32	Total body bone mineral density;	chr12:106902263	chr12:106954029~106955497:-
THCA	cis	rs2288884	0.943	rs1433089	ENSG00000275055.1	CTC-471J1.11	-7.2	2.38e-12	7.22e-10	-0.31	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52003732	chr19:52049007~52049754:+
THCA	cis	rs4072705	1	rs10760374	ENSG00000224020.1	MIR181A2HG	-7.2	2.38e-12	7.22e-10	-0.28	-0.32	Menarche (age at onset);	chr9:124733229	chr9:124658467~124698631:+
THCA	cis	rs12594515	1	rs8029209	ENSG00000259200.1	RP11-718O11.1	-7.2	2.38e-12	7.23e-10	-0.38	-0.32	Weight;Waist circumference;	chr15:45701291	chr15:45705078~45931069:+
THCA	cis	rs516805	0.706	rs1339533	ENSG00000279453.1	RP3-425C14.4	-7.2	2.38e-12	7.24e-10	-0.32	-0.32	Lymphocyte counts;	chr6:122348687	chr6:122436789~122439223:-
THCA	cis	rs860295	0.557	rs915181	ENSG00000225855.5	RUSC1-AS1	7.2	2.38e-12	7.24e-10	0.22	0.32	Body mass index;	chr1:155944981	chr1:155316863~155324176:-
THCA	cis	rs7945705	0.782	rs3763918	ENSG00000254860.4	TMEM9B-AS1	-7.2	2.39e-12	7.25e-10	-0.34	-0.32	Hemoglobin concentration;	chr11:8798136	chr11:8964675~8977527:+
THCA	cis	rs227932	0.681	rs7776862	ENSG00000234286.1	AC006026.13	7.2	2.39e-12	7.25e-10	0.57	0.32	Schizophrenia;	chr7:23736607	chr7:23680195~23680786:-
THCA	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	7.2	2.39e-12	7.25e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	7.2	2.39e-12	7.25e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	7.2	2.39e-12	7.25e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	7.2	2.39e-12	7.25e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	7.2	2.39e-12	7.25e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
THCA	cis	rs875971	0.862	rs6960446	ENSG00000232559.3	GS1-124K5.12	-7.2	2.39e-12	7.26e-10	-0.3	-0.32	Aortic root size;	chr7:66268272	chr7:66554588~66576923:-
THCA	cis	rs875971	0.789	rs10260426	ENSG00000232559.3	GS1-124K5.12	-7.2	2.39e-12	7.26e-10	-0.3	-0.32	Aortic root size;	chr7:66271055	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs7796162	ENSG00000232559.3	GS1-124K5.12	-7.2	2.39e-12	7.26e-10	-0.3	-0.32	Aortic root size;	chr7:66280771	chr7:66554588~66576923:-
THCA	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	7.2	2.39e-12	7.26e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	7.2	2.39e-12	7.26e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	7.2	2.39e-12	7.26e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	7.2	2.39e-12	7.26e-10	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
THCA	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	7.2	2.39e-12	7.26e-10	0.39	0.32	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
THCA	cis	rs12681366	0.734	rs2931633	ENSG00000253704.1	RP11-267M23.4	7.2	2.39e-12	7.27e-10	0.31	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94410492	chr8:94553722~94569745:+
THCA	cis	rs2976388	0.647	rs2082801	ENSG00000253741.1	CTD-2292P10.4	-7.2	2.39e-12	7.27e-10	-0.39	-0.32	Urinary tract infection frequency;	chr8:142705043	chr8:142702252~142726973:-
THCA	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-7.2	2.39e-12	7.27e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
THCA	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	7.2	2.4e-12	7.27e-10	0.38	0.32	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
THCA	cis	rs910316	0.673	rs2012627	ENSG00000279594.1	RP11-950C14.10	7.2	2.4e-12	7.27e-10	0.28	0.32	Height;	chr14:74976400	chr14:75011269~75012851:-
THCA	cis	rs2880765	0.835	rs4360874	ENSG00000259295.5	CSPG4P12	7.2	2.4e-12	7.28e-10	0.4	0.32	Coronary artery disease;	chr15:85497589	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs4514633	ENSG00000259295.5	CSPG4P12	7.2	2.4e-12	7.28e-10	0.4	0.32	Coronary artery disease;	chr15:85497786	chr15:85191438~85213905:+
THCA	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	7.2	2.4e-12	7.28e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
THCA	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	7.2	2.4e-12	7.28e-10	0.4	0.32	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
THCA	cis	rs11096990	0.613	rs12643415	ENSG00000249207.1	RP11-360F5.1	7.2	2.4e-12	7.29e-10	0.38	0.32	Cognitive function;	chr4:39270375	chr4:39112677~39126818:-
THCA	cis	rs4820539	1	rs4820539	ENSG00000221069.1	AC000029.1	7.2	2.4e-12	7.29e-10	0.36	0.32	Bone mineral density;	chr22:23135783	chr22:23136620~23136710:+
THCA	cis	rs7554547	0.871	rs6661289	ENSG00000199347.1	RNU5E-1	7.2	2.41e-12	7.3e-10	0.42	0.32	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr1:11908152~11908271:+
THCA	cis	rs947583	0.588	rs981580	ENSG00000231028.7	LINC00271	-7.2	2.41e-12	7.3e-10	-0.26	-0.32	Phosphorus levels;	chr6:135786492	chr6:135497801~135716055:+
THCA	cis	rs3806843	0.735	rs2563335	ENSG00000202515.1	VTRNA1-3	-7.2	2.41e-12	7.31e-10	-0.36	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr5:140726158~140726246:+
THCA	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-7.2	2.41e-12	7.32e-10	-0.34	-0.32	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000272009.1	RP1-313I6.12	-7.2	2.41e-12	7.32e-10	-0.37	-0.32	Depression;	chr6:28079011	chr6:28078792~28081130:-
THCA	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	7.2	2.41e-12	7.33e-10	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
THCA	cis	rs6723108	0.517	rs1530557	ENSG00000224043.6	CCNT2-AS1	7.2	2.42e-12	7.34e-10	0.33	0.32	Type 2 diabetes;	chr2:134849309	chr2:134735464~134918710:-
THCA	cis	rs7208859	0.623	rs58908911	ENSG00000264538.5	SUZ12P1	-7.2	2.42e-12	7.35e-10	-0.34	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30709299~30790908:+
THCA	cis	rs6539288	0.677	rs7315989	ENSG00000260329.1	RP11-412D9.4	-7.2	2.43e-12	7.36e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106946010	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.641	rs12318060	ENSG00000260329.1	RP11-412D9.4	-7.2	2.43e-12	7.36e-10	-0.28	-0.32	Total body bone mineral density;	chr12:106946834	chr12:106954029~106955497:-
THCA	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-7.2	2.43e-12	7.37e-10	-0.3	-0.32	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
THCA	cis	rs72772090	0.539	rs11742261	ENSG00000248734.2	CTD-2260A17.1	-7.2	2.43e-12	7.38e-10	-0.5	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96831905	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11748795	ENSG00000248734.2	CTD-2260A17.1	-7.2	2.43e-12	7.38e-10	-0.5	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96832353	chr5:96784777~96785999:+
THCA	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	7.2	2.44e-12	7.4e-10	0.41	0.32	Height;	chr6:109737797	chr6:109382795~109383666:+
THCA	cis	rs10899021	1	rs11236202	ENSG00000279353.1	RP11-864N7.4	7.2	2.44e-12	7.41e-10	0.69	0.32	Response to metformin (IC50);	chr11:74665647	chr11:74698231~74699658:-
THCA	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	7.2	2.44e-12	7.41e-10	0.35	0.32	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
THCA	cis	rs9341808	0.727	rs10943697	ENSG00000272129.1	RP11-250B2.6	7.2	2.45e-12	7.44e-10	0.4	0.32	Sitting height ratio;	chr6:80221789	chr6:80355424~80356859:+
THCA	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-7.2	2.45e-12	7.44e-10	-0.29	-0.32	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
THCA	cis	rs7246657	0.941	rs7259618	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.44e-10	-0.46	-0.32	Coronary artery calcification;	chr19:37259817	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000263603.1	CTD-2349P21.5	-7.2	2.46e-12	7.44e-10	-0.54	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30729469~30731202:+
THCA	cis	rs733592	0.599	rs12819124	ENSG00000258273.1	RP11-370I10.4	-7.2	2.46e-12	7.45e-10	-0.39	-0.32	Plateletcrit;	chr12:48015271	chr12:48333755~48333901:-
THCA	cis	rs7246657	0.882	rs59224125	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.45e-10	-0.44	-0.32	Coronary artery calcification;	chr19:37472303	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10414904	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.47e-10	-0.44	-0.32	Coronary artery calcification;	chr19:37339186	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10417844	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.47e-10	-0.44	-0.32	Coronary artery calcification;	chr19:37346685	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs1373991	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.47e-10	-0.44	-0.32	Coronary artery calcification;	chr19:37348009	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10405407	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.47e-10	-0.44	-0.32	Coronary artery calcification;	chr19:37348262	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs12709813	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.47e-10	-0.44	-0.32	Coronary artery calcification;	chr19:37354081	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs13345116	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.47e-10	-0.44	-0.32	Coronary artery calcification;	chr19:37356196	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.765	rs7247259	ENSG00000226686.6	LINC01535	-7.2	2.46e-12	7.47e-10	-0.44	-0.32	Coronary artery calcification;	chr19:37360188	chr19:37251912~37265535:+
THCA	cis	rs7942368	0.715	rs12788118	ENSG00000254761.1	RP11-672A2.1	7.2	2.46e-12	7.47e-10	0.43	0.32	Endometriosis;	chr11:76783176	chr11:76712396~76719608:-
THCA	cis	rs2880765	0.835	rs28874135	ENSG00000259295.5	CSPG4P12	7.2	2.46e-12	7.47e-10	0.4	0.32	Coronary artery disease;	chr15:85488272	chr15:85191438~85213905:+
THCA	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-7.2	2.47e-12	7.47e-10	-0.37	-0.32	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
THCA	cis	rs736801	0.729	rs1050152	ENSG00000224431.1	AC063976.7	7.2	2.47e-12	7.48e-10	0.28	0.32	Mosquito bite size;Breast cancer;	chr5:132340627	chr5:132199456~132203487:+
THCA	cis	rs17684571	0.938	rs55742092	ENSG00000231441.1	RP11-472M19.2	7.2	2.47e-12	7.48e-10	0.4	0.32	Schizophrenia;	chr6:56708377	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs17684553	ENSG00000231441.1	RP11-472M19.2	7.2	2.47e-12	7.48e-10	0.4	0.32	Schizophrenia;	chr6:56708858	chr6:56844002~56864078:+
THCA	cis	rs5760842	0.967	rs5752054	ENSG00000279110.1	CTA-243E7.1	-7.2	2.47e-12	7.49e-10	-0.38	-0.32	Recurrent major depressive disorder;	chr22:25084905	chr22:25052122~25065241:-
THCA	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-7.2	2.47e-12	7.49e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-7.2	2.47e-12	7.49e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-7.2	2.47e-12	7.49e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-7.2	2.47e-12	7.49e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-7.2	2.47e-12	7.49e-10	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
THCA	cis	rs4713118	0.669	rs200997	ENSG00000219392.1	RP1-265C24.5	-7.2	2.47e-12	7.49e-10	-0.38	-0.32	Parkinson's disease;	chr6:27844037	chr6:28115628~28116551:+
THCA	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-7.2	2.47e-12	7.5e-10	-0.3	-0.32	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-7.2	2.47e-12	7.5e-10	-0.3	-0.32	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-7.2	2.47e-12	7.5e-10	-0.3	-0.32	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-7.2	2.47e-12	7.5e-10	-0.3	-0.32	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-7.2	2.47e-12	7.5e-10	-0.3	-0.32	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
THCA	cis	rs9341808	0.754	rs9352808	ENSG00000272129.1	RP11-250B2.6	7.2	2.48e-12	7.5e-10	0.4	0.32	Sitting height ratio;	chr6:80287625	chr6:80355424~80356859:+
THCA	cis	rs651907	0.535	rs11707250	ENSG00000256628.3	ZBTB11-AS1	-7.2	2.48e-12	7.5e-10	-0.37	-0.32	Colorectal cancer;	chr3:101790527	chr3:101676475~101679217:+
THCA	cis	rs240993	0.812	rs9400476	ENSG00000230177.1	RP5-1112D6.4	7.2	2.48e-12	7.51e-10	0.32	0.32	Inflammatory skin disease;Psoriasis;	chr6:111463172	chr6:111277932~111278742:+
THCA	cis	rs2522056	1	rs886286	ENSG00000233006.5	AC034220.3	-7.2	2.48e-12	7.51e-10	-0.27	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132459905	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs757105	ENSG00000233006.5	AC034220.3	-7.2	2.48e-12	7.51e-10	-0.27	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132459971	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs2522047	ENSG00000233006.5	AC034220.3	-7.2	2.48e-12	7.51e-10	-0.27	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132460190	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs2706393	ENSG00000233006.5	AC034220.3	-7.2	2.48e-12	7.51e-10	-0.27	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132460375	chr5:132311285~132369916:-
THCA	cis	rs8113308	0.515	rs68124997	ENSG00000269235.1	ZNF350-AS1	7.2	2.48e-12	7.52e-10	0.56	0.31	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949276	chr19:51949134~51981367:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	7.2	2.48e-12	7.52e-10	0.38	0.31	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
THCA	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	7.19	2.48e-12	7.53e-10	0.38	0.31	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
THCA	cis	rs7267979	0.932	rs2387891	ENSG00000274414.1	RP5-965G21.4	-7.19	2.49e-12	7.53e-10	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25239007~25245229:-
THCA	cis	rs4073416	0.712	rs12889002	ENSG00000276116.2	FUT8-AS1	7.19	2.49e-12	7.53e-10	0.33	0.31	N-glycan levels;	chr14:65596864	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.684	rs743085	ENSG00000276116.2	FUT8-AS1	7.19	2.49e-12	7.53e-10	0.33	0.31	N-glycan levels;	chr14:65601415	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.712	rs12886334	ENSG00000276116.2	FUT8-AS1	7.19	2.49e-12	7.53e-10	0.33	0.31	N-glycan levels;	chr14:65627953	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.679	rs12896663	ENSG00000276116.2	FUT8-AS1	7.19	2.49e-12	7.53e-10	0.33	0.31	N-glycan levels;	chr14:65638251	chr14:65411170~65412690:-
THCA	cis	rs853679	0.517	rs2273564	ENSG00000272009.1	RP1-313I6.12	-7.19	2.49e-12	7.53e-10	-0.37	-0.31	Depression;	chr6:28089816	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs1853097	ENSG00000272009.1	RP1-313I6.12	-7.19	2.49e-12	7.53e-10	-0.37	-0.31	Depression;	chr6:28090857	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393888	ENSG00000272009.1	RP1-313I6.12	-7.19	2.49e-12	7.53e-10	-0.37	-0.31	Depression;	chr6:28091439	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9357063	ENSG00000272009.1	RP1-313I6.12	-7.19	2.49e-12	7.53e-10	-0.37	-0.31	Depression;	chr6:28092227	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs3823180	ENSG00000272009.1	RP1-313I6.12	-7.19	2.49e-12	7.53e-10	-0.37	-0.31	Depression;	chr6:28093966	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368551	ENSG00000272009.1	RP1-313I6.12	-7.19	2.49e-12	7.53e-10	-0.37	-0.31	Depression;	chr6:28094014	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393890	ENSG00000272009.1	RP1-313I6.12	-7.19	2.49e-12	7.53e-10	-0.37	-0.31	Depression;	chr6:28096077	chr6:28078792~28081130:-
THCA	cis	rs7646881	0.812	rs75107964	ENSG00000240207.5	RP11-379F4.4	-7.19	2.49e-12	7.53e-10	-0.47	-0.31	Tetralogy of Fallot;	chr3:158740962	chr3:158732263~158784070:+
THCA	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	7.19	2.49e-12	7.53e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
THCA	cis	rs7267979	0.903	rs6115118	ENSG00000274414.1	RP5-965G21.4	-7.19	2.49e-12	7.55e-10	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.903	rs1118963	ENSG00000274414.1	RP5-965G21.4	-7.19	2.49e-12	7.55e-10	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25239007~25245229:-
THCA	cis	rs2348418	0.715	rs1581076	ENSG00000247934.4	RP11-967K21.1	7.19	2.49e-12	7.55e-10	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28570724	chr12:28163298~28190738:-
THCA	cis	rs8027521	0.501	rs2253111	ENSG00000280362.1	RP11-643A5.3	-7.19	2.49e-12	7.55e-10	-0.43	-0.31	Circulating chemerin levels;	chr15:53982741	chr15:53910769~53914712:+
THCA	cis	rs780096	0.967	rs1260333	ENSG00000234072.1	AC074117.10	-7.19	2.49e-12	7.55e-10	-0.24	-0.31	Total body bone mineral density;	chr2:27525757	chr2:27356246~27367622:+
THCA	cis	rs12681366	0.734	rs10102233	ENSG00000253704.1	RP11-267M23.4	7.19	2.5e-12	7.56e-10	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94389429	chr8:94553722~94569745:+
THCA	cis	rs4950322	0.57	rs7554833	ENSG00000237188.3	RP11-337C18.8	-7.19	2.5e-12	7.56e-10	-0.39	-0.31	Protein quantitative trait loci;	chr1:147289362	chr1:147172771~147211568:+
THCA	cis	rs42490	0.576	rs388866	ENSG00000251136.7	RP11-37B2.1	-7.19	2.5e-12	7.56e-10	-0.28	-0.31	Leprosy;	chr8:89856604	chr8:89609409~89757727:-
THCA	cis	rs3806843	0.801	rs2531358	ENSG00000202515.1	VTRNA1-3	7.19	2.5e-12	7.57e-10	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr5:140726158~140726246:+
THCA	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	7.19	2.5e-12	7.57e-10	0.4	0.31	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
THCA	cis	rs10266483	0.883	rs683689	ENSG00000227986.1	TRIM60P18	-7.19	2.5e-12	7.57e-10	-0.26	-0.31	Response to statin therapy;	chr7:64282165	chr7:64355078~64356199:+
THCA	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-7.19	2.5e-12	7.58e-10	-0.31	-0.31	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
THCA	cis	rs987724	0.519	rs9820830	ENSG00000240875.4	LINC00886	-7.19	2.5e-12	7.58e-10	-0.25	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824915	chr3:156747346~156817062:-
THCA	cis	rs6723108	0.603	rs10166142	ENSG00000224043.6	CCNT2-AS1	-7.19	2.5e-12	7.58e-10	-0.34	-0.31	Type 2 diabetes;	chr2:134952752	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.603	rs3814354	ENSG00000224043.6	CCNT2-AS1	-7.19	2.5e-12	7.58e-10	-0.34	-0.31	Type 2 diabetes;	chr2:134954087	chr2:134735464~134918710:-
THCA	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-7.19	2.51e-12	7.59e-10	-0.43	-0.31	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
THCA	cis	rs875971	0.862	rs778736	ENSG00000232559.3	GS1-124K5.12	7.19	2.51e-12	7.6e-10	0.3	0.31	Aortic root size;	chr7:66348861	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs1875057	ENSG00000232559.3	GS1-124K5.12	-7.19	2.51e-12	7.6e-10	-0.3	-0.31	Aortic root size;	chr7:66266868	chr7:66554588~66576923:-
THCA	cis	rs875971	0.755	rs10228885	ENSG00000232559.3	GS1-124K5.12	-7.19	2.51e-12	7.6e-10	-0.3	-0.31	Aortic root size;	chr7:66315542	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs3893216	ENSG00000232559.3	GS1-124K5.12	-7.19	2.51e-12	7.6e-10	-0.3	-0.31	Aortic root size;	chr7:66325720	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6958294	ENSG00000232559.3	GS1-124K5.12	-7.19	2.51e-12	7.6e-10	-0.3	-0.31	Aortic root size;	chr7:66329809	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs2088655	ENSG00000232559.3	GS1-124K5.12	-7.19	2.51e-12	7.6e-10	-0.3	-0.31	Aortic root size;	chr7:66330724	chr7:66554588~66576923:-
THCA	cis	rs875971	0.895	rs10447522	ENSG00000232559.3	GS1-124K5.12	-7.19	2.51e-12	7.6e-10	-0.3	-0.31	Aortic root size;	chr7:66331087	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs7783779	ENSG00000232559.3	GS1-124K5.12	-7.19	2.51e-12	7.6e-10	-0.3	-0.31	Aortic root size;	chr7:66331639	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs2088653	ENSG00000232559.3	GS1-124K5.12	-7.19	2.51e-12	7.6e-10	-0.3	-0.31	Aortic root size;	chr7:66343621	chr7:66554588~66576923:-
THCA	cis	rs11603023	0.569	rs573905	ENSG00000278376.1	RP11-158I9.8	-7.19	2.51e-12	7.6e-10	-0.25	-0.31	Cholesterol, total;	chr11:118701558	chr11:118791254~118793137:+
THCA	cis	rs8114671	0.562	rs1018447	ENSG00000269202.1	RP4-614O4.12	7.19	2.51e-12	7.6e-10	0.27	0.31	Height;	chr20:34813904	chr20:35201747~35203288:-
THCA	cis	rs990871	0.962	rs3101337	ENSG00000227207.2	RPL31P12	-7.19	2.51e-12	7.6e-10	-0.39	-0.31	Subcutaneous adipose tissue;	chr1:72285451	chr1:72301472~72301829:+
THCA	cis	rs990871	1	rs3101336	ENSG00000227207.2	RPL31P12	-7.19	2.51e-12	7.6e-10	-0.39	-0.31	Subcutaneous adipose tissue;	chr1:72285502	chr1:72301472~72301829:+
THCA	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	7.19	2.52e-12	7.62e-10	0.36	0.31	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
THCA	cis	rs9902453	0.765	rs2169810	ENSG00000264007.1	RP11-68I3.10	7.19	2.52e-12	7.62e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29840923	chr17:29621617~29622254:-
THCA	cis	rs270601	0.69	rs162907	ENSG00000233006.5	AC034220.3	-7.19	2.52e-12	7.62e-10	-0.24	-0.31	Acylcarnitine levels;	chr5:132244459	chr5:132311285~132369916:-
THCA	cis	rs270601	0.71	rs371709	ENSG00000233006.5	AC034220.3	7.19	2.52e-12	7.62e-10	0.24	0.31	Acylcarnitine levels;	chr5:132247547	chr5:132311285~132369916:-
THCA	cis	rs4784934	0.842	rs1895522	ENSG00000260186.4	RP11-481J2.2	-7.19	2.52e-12	7.63e-10	-0.44	-0.31	QT interval;	chr16:58425134	chr16:58421326~58462470:+
THCA	cis	rs2880765	0.835	rs4842884	ENSG00000259295.5	CSPG4P12	7.19	2.53e-12	7.65e-10	0.4	0.31	Coronary artery disease;	chr15:85491943	chr15:85191438~85213905:+
THCA	cis	rs934734	0.736	rs10186240	ENSG00000204929.10	AC074391.1	7.19	2.53e-12	7.66e-10	0.39	0.31	Rheumatoid arthritis;	chr2:65350517	chr2:65436711~66084639:+
THCA	cis	rs10899021	1	rs11236190	ENSG00000279353.1	RP11-864N7.4	7.19	2.53e-12	7.66e-10	0.67	0.31	Response to metformin (IC50);	chr11:74655710	chr11:74698231~74699658:-
THCA	cis	rs875971	1	rs697970	ENSG00000232559.3	GS1-124K5.12	-7.19	2.53e-12	7.67e-10	-0.31	-0.31	Aortic root size;	chr7:66095065	chr7:66554588~66576923:-
THCA	cis	rs2033711	0.811	rs9304814	ENSG00000269473.1	CTD-2619J13.19	7.19	2.54e-12	7.69e-10	0.3	0.31	Uric acid clearance;	chr19:58440444	chr19:58440448~58445849:+
THCA	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	7.19	2.55e-12	7.7e-10	0.4	0.31	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
THCA	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	7.19	2.55e-12	7.72e-10	0.38	0.31	Height;	chr6:109640682	chr6:109382795~109383666:+
THCA	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	7.19	2.56e-12	7.73e-10	0.77	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	7.19	2.56e-12	7.73e-10	0.77	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
THCA	cis	rs2880765	0.835	rs11074276	ENSG00000259295.5	CSPG4P12	7.19	2.56e-12	7.74e-10	0.4	0.31	Coronary artery disease;	chr15:85487132	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.805	rs11858817	ENSG00000259295.5	CSPG4P12	7.19	2.56e-12	7.74e-10	0.4	0.31	Coronary artery disease;	chr15:85488029	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs11633604	ENSG00000259295.5	CSPG4P12	7.19	2.56e-12	7.74e-10	0.4	0.31	Coronary artery disease;	chr15:85488348	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs7164106	ENSG00000259295.5	CSPG4P12	7.19	2.56e-12	7.74e-10	0.4	0.31	Coronary artery disease;	chr15:85489359	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs1872074	ENSG00000259295.5	CSPG4P12	7.19	2.56e-12	7.74e-10	0.4	0.31	Coronary artery disease;	chr15:85489953	chr15:85191438~85213905:+
THCA	cis	rs7208859	0.673	rs56846352	ENSG00000264538.5	SUZ12P1	-7.19	2.56e-12	7.74e-10	-0.3	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30709299~30790908:+
THCA	cis	rs17695224	0.545	rs7247613	ENSG00000269483.1	AC006272.1	7.19	2.56e-12	7.74e-10	0.34	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51819940	chr19:51839924~51843324:-
THCA	cis	rs4820539	0.934	rs3788351	ENSG00000221069.1	AC000029.1	-7.19	2.57e-12	7.76e-10	-0.38	-0.31	Bone mineral density;	chr22:23126994	chr22:23136620~23136710:+
THCA	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-7.19	2.57e-12	7.76e-10	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-7.19	2.57e-12	7.76e-10	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
THCA	cis	rs4073416	0.684	rs12879805	ENSG00000276116.2	FUT8-AS1	7.19	2.57e-12	7.76e-10	0.33	0.31	N-glycan levels;	chr14:65581077	chr14:65411170~65412690:-
THCA	cis	rs853679	1	rs1936365	ENSG00000219392.1	RP1-265C24.5	7.19	2.57e-12	7.76e-10	0.48	0.31	Depression;	chr6:28300675	chr6:28115628~28116551:+
THCA	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	7.19	2.57e-12	7.76e-10	0.39	0.31	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	7.19	2.57e-12	7.76e-10	0.39	0.31	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
THCA	cis	rs651907	0.557	rs35850993	ENSG00000256628.3	ZBTB11-AS1	7.19	2.57e-12	7.76e-10	0.37	0.31	Colorectal cancer;	chr3:101718589	chr3:101676475~101679217:+
THCA	cis	rs4950322	0.57	rs80070044	ENSG00000237188.3	RP11-337C18.8	7.19	2.57e-12	7.76e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147330238	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692963	ENSG00000237188.3	RP11-337C18.8	7.19	2.57e-12	7.76e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147331090	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.518	rs72692965	ENSG00000237188.3	RP11-337C18.8	7.19	2.57e-12	7.76e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147332085	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.518	rs72692968	ENSG00000237188.3	RP11-337C18.8	7.19	2.57e-12	7.76e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147332884	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.518	rs72692970	ENSG00000237188.3	RP11-337C18.8	7.19	2.57e-12	7.76e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147332887	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692971	ENSG00000237188.3	RP11-337C18.8	7.19	2.57e-12	7.76e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147333088	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692973	ENSG00000237188.3	RP11-337C18.8	7.19	2.57e-12	7.76e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147333281	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692975	ENSG00000237188.3	RP11-337C18.8	7.19	2.57e-12	7.76e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147333506	chr1:147172771~147211568:+
THCA	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	7.19	2.57e-12	7.78e-10	0.4	0.31	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
THCA	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	7.19	2.58e-12	7.78e-10	0.76	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
THCA	cis	rs9388451	1	rs9388451	ENSG00000237742.5	RP11-624M8.1	-7.19	2.58e-12	7.79e-10	-0.27	-0.31	Brugada syndrome;	chr6:125769231	chr6:125578558~125749190:-
THCA	cis	rs12594515	0.967	rs11070466	ENSG00000259200.1	RP11-718O11.1	-7.19	2.58e-12	7.79e-10	-0.38	-0.31	Weight;Waist circumference;	chr15:45692757	chr15:45705078~45931069:+
THCA	cis	rs6509701	0.922	rs8109094	ENSG00000268225.1	CTD-2331H12.5	-7.19	2.59e-12	7.81e-10	-0.33	-0.31	Psychosis in Alzheimer's disease;	chr19:52892050	chr19:52861807~52862866:-
THCA	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	7.19	2.59e-12	7.83e-10	0.79	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	7.19	2.59e-12	7.83e-10	0.79	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
THCA	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	7.19	2.59e-12	7.83e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	7.19	2.59e-12	7.83e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	7.19	2.59e-12	7.83e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	7.19	2.59e-12	7.83e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	7.19	2.59e-12	7.83e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	7.19	2.59e-12	7.83e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
THCA	cis	rs2921036	0.529	rs2979192	ENSG00000254153.1	CTA-398F10.2	-7.19	2.59e-12	7.84e-10	-0.35	-0.31	Neuroticism;	chr8:8480637	chr8:8456909~8461337:-
THCA	cis	rs2439831	0.867	rs2255440	ENSG00000275601.1	AC011330.13	-7.19	2.59e-12	7.84e-10	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43538269	chr15:43642389~43643023:-
THCA	cis	rs4073416	0.712	rs8012278	ENSG00000276116.2	FUT8-AS1	7.19	2.6e-12	7.84e-10	0.33	0.31	N-glycan levels;	chr14:65615855	chr14:65411170~65412690:-
THCA	cis	rs12681366	0.762	rs67639046	ENSG00000253704.1	RP11-267M23.4	7.19	2.6e-12	7.85e-10	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94373552	chr8:94553722~94569745:+
THCA	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-7.19	2.6e-12	7.86e-10	-0.3	-0.31	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
THCA	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-7.19	2.61e-12	7.87e-10	-0.35	-0.31	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
THCA	cis	rs7267979	0.932	rs433352	ENSG00000274414.1	RP5-965G21.4	7.19	2.61e-12	7.88e-10	0.38	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25239007~25245229:-
THCA	cis	rs4072705	0.967	rs7020358	ENSG00000224020.1	MIR181A2HG	-7.19	2.61e-12	7.88e-10	-0.28	-0.31	Menarche (age at onset);	chr9:124720192	chr9:124658467~124698631:+
THCA	cis	rs651907	0.535	rs61396602	ENSG00000256628.3	ZBTB11-AS1	7.19	2.61e-12	7.88e-10	0.37	0.31	Colorectal cancer;	chr3:101790202	chr3:101676475~101679217:+
THCA	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-7.19	2.61e-12	7.89e-10	-0.34	-0.31	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
THCA	cis	rs172166	0.694	rs203893	ENSG00000280107.1	AL022393.9	-7.19	2.61e-12	7.89e-10	-0.34	-0.31	Cardiac Troponin-T levels;	chr6:28094288	chr6:28170845~28172521:+
THCA	cis	rs853679	0.882	rs9380069	ENSG00000219392.1	RP1-265C24.5	-7.19	2.61e-12	7.89e-10	-0.51	-0.31	Depression;	chr6:28235522	chr6:28115628~28116551:+
THCA	cis	rs12935418	0.887	rs3743503	ENSG00000261061.1	RP11-303E16.2	-7.19	2.62e-12	7.9e-10	-0.41	-0.31	Mean corpuscular volume;	chr16:81022836	chr16:81030770~81031485:+
THCA	cis	rs7260598	0.792	rs17620029	ENSG00000268442.1	CTD-2027I19.2	7.19	2.62e-12	7.9e-10	0.44	0.31	Response to taxane treatment (placlitaxel);	chr19:24171510	chr19:24162370~24163425:-
THCA	cis	rs10899021	1	rs11236186	ENSG00000279353.1	RP11-864N7.4	7.19	2.62e-12	7.9e-10	0.62	0.31	Response to metformin (IC50);	chr11:74651820	chr11:74698231~74699658:-
THCA	cis	rs10899021	1	rs7935426	ENSG00000279353.1	RP11-864N7.4	7.19	2.62e-12	7.9e-10	0.62	0.31	Response to metformin (IC50);	chr11:74652845	chr11:74698231~74699658:-
THCA	cis	rs2976388	0.625	rs2717600	ENSG00000253741.1	CTD-2292P10.4	7.19	2.62e-12	7.91e-10	0.4	0.31	Urinary tract infection frequency;	chr8:142732570	chr8:142702252~142726973:-
THCA	cis	rs12908161	1	rs3803405	ENSG00000225151.9	GOLGA2P7	-7.19	2.62e-12	7.91e-10	-0.47	-0.31	Schizophrenia;	chr15:84840409	chr15:84199311~84230136:-
THCA	cis	rs4073416	0.684	rs7153297	ENSG00000276116.2	FUT8-AS1	7.19	2.62e-12	7.91e-10	0.33	0.31	N-glycan levels;	chr14:65536748	chr14:65411170~65412690:-
THCA	cis	rs74233809	1	rs11191543	ENSG00000213277.3	MARCKSL1P1	7.19	2.62e-12	7.92e-10	0.52	0.31	Birth weight;	chr10:103064630	chr10:103175554~103176094:+
THCA	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	7.19	2.62e-12	7.92e-10	0.39	0.31	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
THCA	cis	rs1850744	1	rs1533615	ENSG00000250942.1	ENPP7P11	-7.19	2.62e-12	7.92e-10	-0.43	-0.31	Economic and political preferences;	chr4:9802900	chr4:9677308~9677934:+
THCA	cis	rs2688608	0.592	rs10824031	ENSG00000271816.1	BMS1P4	7.19	2.63e-12	7.93e-10	0.33	0.31	Inflammatory bowel disease;	chr10:73749515	chr10:73699151~73730487:-
THCA	cis	rs651907	0.557	rs62284198	ENSG00000256628.3	ZBTB11-AS1	7.19	2.63e-12	7.93e-10	0.37	0.31	Colorectal cancer;	chr3:101755855	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs2318090	ENSG00000256628.3	ZBTB11-AS1	7.19	2.63e-12	7.93e-10	0.37	0.31	Colorectal cancer;	chr3:101756089	chr3:101676475~101679217:+
THCA	cis	rs7811142	1	rs76913697	ENSG00000078319.8	PMS2P1	-7.19	2.63e-12	7.93e-10	-0.44	-0.31	Platelet count;	chr7:100405149	chr7:100320992~100341908:-
THCA	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	7.19	2.63e-12	7.93e-10	0.38	0.31	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
THCA	cis	rs9500256	0.967	rs4928431	ENSG00000215190.7	LINC00680	7.19	2.63e-12	7.94e-10	0.37	0.31	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57946074~57961501:-
THCA	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	7.19	2.63e-12	7.95e-10	0.39	0.31	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	7.19	2.63e-12	7.95e-10	0.39	0.31	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
THCA	cis	rs7246657	0.943	rs10404602	ENSG00000226686.6	LINC01535	-7.19	2.64e-12	7.97e-10	-0.47	-0.31	Coronary artery calcification;	chr19:37334731	chr19:37251912~37265535:+
THCA	cis	rs3806843	0.735	rs6849	ENSG00000202515.1	VTRNA1-3	7.19	2.64e-12	7.98e-10	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr5:140726158~140726246:+
THCA	cis	rs4950322	0.547	rs17355509	ENSG00000237188.3	RP11-337C18.8	7.19	2.65e-12	7.99e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147123139	chr1:147172771~147211568:+
THCA	cis	rs7849270	0.679	rs10988217	ENSG00000268707.1	RP11-247A12.7	-7.19	2.65e-12	7.99e-10	-0.36	-0.31	Blood metabolite ratios;	chr9:129125837	chr9:129170434~129170940:+
THCA	cis	rs3847687	0.507	rs10773838	ENSG00000256810.1	RP11-76C10.2	7.19	2.65e-12	8e-10	0.38	0.31	Longevity;	chr12:131039287	chr12:131030570~131035487:-
THCA	cis	rs911555	0.546	rs28798508	ENSG00000269958.1	RP11-73M18.8	7.19	2.65e-12	8e-10	0.3	0.31	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103696353~103697163:+
THCA	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	7.18	2.65e-12	8.01e-10	0.4	0.31	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
THCA	cis	rs10899021	0.79	rs59958321	ENSG00000279353.1	RP11-864N7.4	7.18	2.66e-12	8.01e-10	0.63	0.31	Response to metformin (IC50);	chr11:74643569	chr11:74698231~74699658:-
THCA	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-7.18	2.66e-12	8.03e-10	-0.34	-0.31	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-7.18	2.66e-12	8.03e-10	-0.34	-0.31	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-7.18	2.66e-12	8.03e-10	-0.34	-0.31	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-7.18	2.66e-12	8.03e-10	-0.34	-0.31	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-7.18	2.66e-12	8.03e-10	-0.34	-0.31	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-7.18	2.66e-12	8.03e-10	-0.34	-0.31	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-7.18	2.66e-12	8.03e-10	-0.34	-0.31	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
THCA	cis	rs1015362	0.503	rs1883708	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.66e-12	8.04e-10	-0.33	-0.31	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33985617~33988989:-
THCA	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-7.18	2.67e-12	8.05e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
THCA	cis	rs2688608	0.62	rs7076525	ENSG00000271816.1	BMS1P4	7.18	2.67e-12	8.05e-10	0.33	0.31	Inflammatory bowel disease;	chr10:73753039	chr10:73699151~73730487:-
THCA	cis	rs4664293	0.867	rs6720304	ENSG00000226266.5	AC009961.3	-7.18	2.67e-12	8.05e-10	-0.39	-0.31	Monocyte percentage of white cells;	chr2:159787321	chr2:159670708~159712435:-
THCA	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	7.18	2.67e-12	8.05e-10	0.51	0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
THCA	cis	rs6539288	0.899	rs4964192	ENSG00000260329.1	RP11-412D9.4	-7.18	2.67e-12	8.06e-10	-0.28	-0.31	Total body bone mineral density;	chr12:106915014	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.899	rs6539290	ENSG00000260329.1	RP11-412D9.4	-7.18	2.67e-12	8.06e-10	-0.28	-0.31	Total body bone mineral density;	chr12:106915871	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.933	rs6539291	ENSG00000260329.1	RP11-412D9.4	-7.18	2.67e-12	8.06e-10	-0.28	-0.31	Total body bone mineral density;	chr12:106916033	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.834	rs1545097	ENSG00000260329.1	RP11-412D9.4	-7.18	2.67e-12	8.06e-10	-0.28	-0.31	Total body bone mineral density;	chr12:106919918	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.899	rs6539292	ENSG00000260329.1	RP11-412D9.4	-7.18	2.67e-12	8.06e-10	-0.28	-0.31	Total body bone mineral density;	chr12:106919935	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.901	rs1444580	ENSG00000260329.1	RP11-412D9.4	-7.18	2.67e-12	8.06e-10	-0.28	-0.31	Total body bone mineral density;	chr12:106920780	chr12:106954029~106955497:-
THCA	cis	rs172166	0.694	rs9295760	ENSG00000280107.1	AL022393.9	-7.18	2.67e-12	8.06e-10	-0.35	-0.31	Cardiac Troponin-T levels;	chr6:28179607	chr6:28170845~28172521:+
THCA	cis	rs6723108	0.517	rs4954192	ENSG00000224043.6	CCNT2-AS1	-7.18	2.68e-12	8.07e-10	-0.33	-0.31	Type 2 diabetes;	chr2:134875411	chr2:134735464~134918710:-
THCA	cis	rs42490	0.51	rs218885	ENSG00000251136.7	RP11-37B2.1	7.18	2.68e-12	8.07e-10	0.27	0.31	Leprosy;	chr8:89678313	chr8:89609409~89757727:-
THCA	cis	rs2880765	0.835	rs6497206	ENSG00000259295.5	CSPG4P12	7.18	2.68e-12	8.08e-10	0.39	0.31	Coronary artery disease;	chr15:85485994	chr15:85191438~85213905:+
THCA	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	7.18	2.68e-12	8.08e-10	0.18	0.31	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
THCA	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-7.18	2.68e-12	8.08e-10	-0.37	-0.31	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
THCA	cis	rs853679	0.517	rs2273564	ENSG00000220721.1	OR1F12	7.18	2.68e-12	8.08e-10	0.43	0.31	Depression;	chr6:28089816	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000220721.1	OR1F12	7.18	2.68e-12	8.08e-10	0.43	0.31	Depression;	chr6:28090857	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000220721.1	OR1F12	7.18	2.68e-12	8.08e-10	0.43	0.31	Depression;	chr6:28091439	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000220721.1	OR1F12	7.18	2.68e-12	8.08e-10	0.43	0.31	Depression;	chr6:28092227	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000220721.1	OR1F12	7.18	2.68e-12	8.08e-10	0.43	0.31	Depression;	chr6:28093966	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000220721.1	OR1F12	7.18	2.68e-12	8.08e-10	0.43	0.31	Depression;	chr6:28094014	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000220721.1	OR1F12	7.18	2.68e-12	8.08e-10	0.43	0.31	Depression;	chr6:28096077	chr6:28073316~28074233:+
THCA	cis	rs4273100	1	rs868698	ENSG00000228157.4	AC007952.5	7.18	2.69e-12	8.1e-10	0.49	0.31	Schizophrenia;	chr17:19281898	chr17:19092974~19096837:+
THCA	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	7.18	2.69e-12	8.11e-10	0.47	0.31	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
THCA	cis	rs12681366	0.592	rs4735291	ENSG00000253704.1	RP11-267M23.4	7.18	2.7e-12	8.13e-10	0.33	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94394914	chr8:94553722~94569745:+
THCA	cis	rs853679	0.517	rs1947863	ENSG00000272009.1	RP1-313I6.12	-7.18	2.7e-12	8.13e-10	-0.37	-0.31	Depression;	chr6:28131566	chr6:28078792~28081130:-
THCA	cis	rs12594515	1	rs11070467	ENSG00000259200.1	RP11-718O11.1	7.18	2.7e-12	8.14e-10	0.38	0.31	Weight;Waist circumference;	chr15:45692803	chr15:45705078~45931069:+
THCA	cis	rs74233809	1	rs11191551	ENSG00000213277.3	MARCKSL1P1	7.18	2.7e-12	8.14e-10	0.51	0.31	Birth weight;	chr10:103091078	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs17094683	ENSG00000213277.3	MARCKSL1P1	7.18	2.7e-12	8.14e-10	0.51	0.31	Birth weight;	chr10:103091544	chr10:103175554~103176094:+
THCA	cis	rs12681366	0.959	rs58826082	ENSG00000253704.1	RP11-267M23.4	7.18	2.71e-12	8.15e-10	0.32	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94351487	chr8:94553722~94569745:+
THCA	cis	rs853679	0.517	rs9380047	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28070115	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28071237	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28074687	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28076559	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28076704	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28078391	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28080757	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28080760	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28082231	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28082261	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Parkinson's disease;	chr6:28082269	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28082984	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28083994	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28084025	chr6:28073316~28074233:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28085319	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28096855	chr6:28073316~28074233:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28099759	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Parkinson's disease;	chr6:28100173	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28100648	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28104824	chr6:28073316~28074233:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28107222	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28108492	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000220721.1	OR1F12	7.18	2.71e-12	8.16e-10	0.43	0.31	Depression;	chr6:28110254	chr6:28073316~28074233:+
THCA	cis	rs8012947	1	rs7149735	ENSG00000279636.2	LINC00216	-7.18	2.71e-12	8.16e-10	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58289703	chr14:58288033~58289158:+
THCA	cis	rs8012947	0.959	rs6573198	ENSG00000279636.2	LINC00216	-7.18	2.71e-12	8.16e-10	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58293044	chr14:58288033~58289158:+
THCA	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	7.18	2.71e-12	8.17e-10	0.37	0.31	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
THCA	cis	rs875971	0.862	rs2901152	ENSG00000232559.3	GS1-124K5.12	-7.18	2.72e-12	8.19e-10	-0.3	-0.31	Aortic root size;	chr7:66300017	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs10263690	ENSG00000232559.3	GS1-124K5.12	-7.18	2.72e-12	8.19e-10	-0.3	-0.31	Aortic root size;	chr7:66301466	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs10250544	ENSG00000232559.3	GS1-124K5.12	-7.18	2.72e-12	8.19e-10	-0.3	-0.31	Aortic root size;	chr7:66301574	chr7:66554588~66576923:-
THCA	cis	rs4073416	0.708	rs7146742	ENSG00000276116.2	FUT8-AS1	7.18	2.73e-12	8.21e-10	0.33	0.31	N-glycan levels;	chr14:65566216	chr14:65411170~65412690:-
THCA	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-7.18	2.73e-12	8.21e-10	-0.46	-0.31	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-7.18	2.73e-12	8.21e-10	-0.46	-0.31	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-7.18	2.73e-12	8.21e-10	-0.46	-0.31	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
THCA	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	7.18	2.73e-12	8.23e-10	0.41	0.31	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
THCA	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	7.18	2.74e-12	8.24e-10	0.4	0.31	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
THCA	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-7.18	2.74e-12	8.24e-10	-0.41	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
THCA	cis	rs728616	0.614	rs3934643	ENSG00000225484.5	NUTM2B-AS1	-7.18	2.74e-12	8.24e-10	-0.47	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79663088~79826594:-
THCA	cis	rs792448	0.743	rs351373	ENSG00000226251.4	RP11-15I11.3	-7.18	2.74e-12	8.24e-10	-0.4	-0.31	White blood cell count (basophil);	chr1:212253289	chr1:212225278~212238977:-
THCA	cis	rs12594515	1	rs6493169	ENSG00000259200.1	RP11-718O11.1	7.18	2.74e-12	8.24e-10	0.38	0.31	Weight;Waist circumference;	chr15:45694796	chr15:45705078~45931069:+
THCA	cis	rs9902453	0.817	rs4794861	ENSG00000264007.1	RP11-68I3.10	7.18	2.75e-12	8.27e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29856156	chr17:29621617~29622254:-
THCA	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-7.18	2.75e-12	8.28e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
THCA	cis	rs42490	0.51	rs4961157	ENSG00000251136.7	RP11-37B2.1	-7.18	2.75e-12	8.28e-10	-0.27	-0.31	Leprosy;	chr8:89684800	chr8:89609409~89757727:-
THCA	cis	rs7247513	0.964	rs12104149	ENSG00000213290.4	PGK1P2	-7.18	2.75e-12	8.29e-10	-0.38	-0.31	Bipolar disorder;	chr19:12610274	chr19:12559571~12561105:+
THCA	cis	rs4073416	0.746	rs11624045	ENSG00000276116.2	FUT8-AS1	7.18	2.76e-12	8.31e-10	0.32	0.31	N-glycan levels;	chr14:65641300	chr14:65411170~65412690:-
THCA	cis	rs9902453	1	rs7212497	ENSG00000264007.1	RP11-68I3.10	-7.18	2.76e-12	8.31e-10	-0.36	-0.31	Coffee consumption (cups per day);	chr17:30008931	chr17:29621617~29622254:-
THCA	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	7.18	2.76e-12	8.31e-10	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
THCA	cis	rs7267979	1	rs2500432	ENSG00000274414.1	RP5-965G21.4	-7.18	2.76e-12	8.31e-10	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25239007~25245229:-
THCA	cis	rs5760842	0.967	rs5760834	ENSG00000279110.1	CTA-243E7.1	-7.18	2.76e-12	8.32e-10	-0.38	-0.31	Recurrent major depressive disorder;	chr22:25083512	chr22:25052122~25065241:-
THCA	cis	rs453301	0.631	rs28572014	ENSG00000253893.2	FAM85B	7.18	2.77e-12	8.33e-10	0.43	0.31	Joint mobility (Beighton score);	chr8:8936097	chr8:8167819~8226614:-
THCA	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-7.18	2.77e-12	8.34e-10	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
THCA	cis	rs1015362	0.504	rs6059552	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.78e-12	8.37e-10	-0.33	-0.31	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33985617~33988989:-
THCA	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-7.18	2.8e-12	8.41e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
THCA	cis	rs9902453	0.817	rs17226179	ENSG00000264007.1	RP11-68I3.10	7.18	2.8e-12	8.42e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29841555	chr17:29621617~29622254:-
THCA	cis	rs6600671	1	rs12145080	ENSG00000223345.3	HIST2H2BA	-7.18	2.8e-12	8.42e-10	-0.34	-0.31	Hip geometry;	chr1:121443673	chr1:121108210~121117257:-
THCA	cis	rs11148252	0.538	rs9535879	ENSG00000278238.1	RP11-245D16.4	-7.18	2.8e-12	8.42e-10	-0.34	-0.31	Lewy body disease;	chr13:52130488	chr13:52454775~52455331:-
THCA	cis	rs651907	0.535	rs4342086	ENSG00000256628.3	ZBTB11-AS1	7.18	2.8e-12	8.42e-10	0.37	0.31	Colorectal cancer;	chr3:101784921	chr3:101676475~101679217:+
THCA	cis	rs732716	0.853	rs72990643	ENSG00000267980.1	AC007292.6	-7.18	2.8e-12	8.42e-10	-0.35	-0.31	Mean corpuscular volume;	chr19:4454739	chr19:4363789~4364640:+
THCA	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	7.18	2.8e-12	8.42e-10	0.4	0.31	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	7.18	2.8e-12	8.42e-10	0.4	0.31	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
THCA	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	7.18	2.8e-12	8.42e-10	0.4	0.31	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
THCA	cis	rs4950322	0.517	rs114823926	ENSG00000237188.3	RP11-337C18.8	7.18	2.8e-12	8.43e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147281805	chr1:147172771~147211568:+
THCA	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-7.18	2.81e-12	8.44e-10	-0.3	-0.31	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-7.18	2.81e-12	8.44e-10	-0.3	-0.31	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-7.18	2.81e-12	8.44e-10	-0.3	-0.31	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-7.18	2.81e-12	8.44e-10	-0.3	-0.31	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
THCA	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-7.18	2.81e-12	8.45e-10	-0.34	-0.31	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
THCA	cis	rs17767294	0.612	rs9461424	ENSG00000280107.1	AL022393.9	-7.18	2.81e-12	8.46e-10	-0.51	-0.31	Parkinson's disease;	chr6:27951623	chr6:28170845~28172521:+
THCA	cis	rs6723226	0.806	rs6543658	ENSG00000276334.1	AL133243.1	7.18	2.81e-12	8.46e-10	0.36	0.31	Intelligence (multi-trait analysis);	chr2:32493782	chr2:32521927~32523547:+
THCA	cis	rs1198430	0.639	rs1767147	ENSG00000232482.2	RP4-654C18.1	-7.18	2.82e-12	8.46e-10	-0.48	-0.31	Total cholesterol levels;	chr1:23444023	chr1:23410832~23412146:+
THCA	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-7.18	2.82e-12	8.48e-10	-0.49	-0.31	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-7.18	2.82e-12	8.48e-10	-0.49	-0.31	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
THCA	cis	rs77204473	1	rs12292278	ENSG00000254851.1	RP11-109L13.1	-7.18	2.82e-12	8.49e-10	-0.78	-0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117135528~117138582:+
THCA	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	7.18	2.83e-12	8.49e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
THCA	cis	rs9341808	0.754	rs3793000	ENSG00000272129.1	RP11-250B2.6	7.18	2.83e-12	8.5e-10	0.4	0.31	Sitting height ratio;	chr6:80285420	chr6:80355424~80356859:+
THCA	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	7.18	2.83e-12	8.5e-10	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	7.18	2.83e-12	8.5e-10	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
THCA	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	7.18	2.83e-12	8.51e-10	0.48	0.31	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	7.18	2.83e-12	8.51e-10	0.48	0.31	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
THCA	cis	rs6723108	0.604	rs1893396	ENSG00000224043.6	CCNT2-AS1	-7.18	2.83e-12	8.52e-10	-0.33	-0.31	Type 2 diabetes;	chr2:134841439	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.603	rs3739030	ENSG00000224043.6	CCNT2-AS1	-7.18	2.83e-12	8.52e-10	-0.33	-0.31	Type 2 diabetes;	chr2:134841811	chr2:134735464~134918710:-
THCA	cis	rs9816784	0.901	rs12490036	ENSG00000226155.1	AC124944.3	7.17	2.84e-12	8.52e-10	0.35	0.31	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195912049~195913986:+
THCA	cis	rs651907	0.557	rs7645391	ENSG00000256628.3	ZBTB11-AS1	7.17	2.84e-12	8.53e-10	0.37	0.31	Colorectal cancer;	chr3:101642662	chr3:101676475~101679217:+
THCA	cis	rs9902453	0.765	rs2127001	ENSG00000264007.1	RP11-68I3.10	-7.17	2.85e-12	8.55e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29771201	chr17:29621617~29622254:-
THCA	cis	rs922182	0.763	rs1380841	ENSG00000275785.1	RP11-111E14.2	7.17	2.85e-12	8.56e-10	0.37	0.31	Blood protein levels;	chr15:63969713	chr15:63890030~63890317:+
THCA	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-7.17	2.85e-12	8.57e-10	-0.38	-0.31	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
THCA	cis	rs3761847	0.5	rs10760132	ENSG00000226752.6	PSMD5-AS1	-7.17	2.85e-12	8.57e-10	-0.37	-0.31	Rheumatoid arthritis;	chr9:120977715	chr9:120824828~120854385:+
THCA	cis	rs9902453	0.765	rs1531553	ENSG00000264007.1	RP11-68I3.10	-7.17	2.86e-12	8.58e-10	-0.36	-0.31	Coffee consumption (cups per day);	chr17:29739734	chr17:29621617~29622254:-
THCA	cis	rs79349575	0.721	rs9904645	ENSG00000248278.1	SUMO2P17	7.17	2.86e-12	8.59e-10	0.37	0.31	Type 2 diabetes;	chr17:48892303	chr17:48874860~48908983:-
THCA	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-7.17	2.86e-12	8.59e-10	-0.3	-0.31	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-7.17	2.86e-12	8.59e-10	-0.3	-0.31	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-7.17	2.86e-12	8.59e-10	-0.3	-0.31	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-7.17	2.86e-12	8.59e-10	-0.3	-0.31	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-7.17	2.86e-12	8.59e-10	-0.3	-0.31	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
THCA	cis	rs7131987	0.903	rs67517901	ENSG00000257176.2	RP11-996F15.2	-7.17	2.86e-12	8.6e-10	-0.31	-0.31	QT interval;	chr12:29268413	chr12:29280418~29317848:-
THCA	cis	rs8027521	0.54	rs2616878	ENSG00000280362.1	RP11-643A5.3	-7.17	2.87e-12	8.62e-10	-0.42	-0.31	Circulating chemerin levels;	chr15:53980770	chr15:53910769~53914712:+
THCA	cis	rs11668609	0.81	rs10407383	ENSG00000268442.1	CTD-2027I19.2	7.17	2.88e-12	8.64e-10	0.38	0.31	Response to taxane treatment (docetaxel);	chr19:24134099	chr19:24162370~24163425:-
THCA	cis	rs7246657	0.882	rs10412043	ENSG00000226686.6	LINC01535	-7.17	2.88e-12	8.64e-10	-0.44	-0.31	Coronary artery calcification;	chr19:37335724	chr19:37251912~37265535:+
THCA	cis	rs6723108	0.603	rs62168897	ENSG00000224043.6	CCNT2-AS1	-7.17	2.88e-12	8.64e-10	-0.33	-0.31	Type 2 diabetes;	chr2:134960427	chr2:134735464~134918710:-
THCA	cis	rs8027521	0.54	rs12909079	ENSG00000280362.1	RP11-643A5.3	-7.17	2.89e-12	8.67e-10	-0.45	-0.31	Circulating chemerin levels;	chr15:53964564	chr15:53910769~53914712:+
THCA	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	7.17	2.89e-12	8.67e-10	0.26	0.31	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
THCA	cis	rs875971	0.862	rs6971059	ENSG00000232559.3	GS1-124K5.12	-7.17	2.89e-12	8.68e-10	-0.3	-0.31	Aortic root size;	chr7:66602045	chr7:66554588~66576923:-
THCA	cis	rs875971	0.825	rs7384021	ENSG00000232559.3	GS1-124K5.12	-7.17	2.89e-12	8.68e-10	-0.3	-0.31	Aortic root size;	chr7:66612917	chr7:66554588~66576923:-
THCA	cis	rs875971	0.825	rs66981195	ENSG00000232559.3	GS1-124K5.12	-7.17	2.89e-12	8.68e-10	-0.3	-0.31	Aortic root size;	chr7:66614048	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs3926380	ENSG00000232559.3	GS1-124K5.12	-7.17	2.89e-12	8.68e-10	-0.3	-0.31	Aortic root size;	chr7:66615658	chr7:66554588~66576923:-
THCA	cis	rs875971	0.825	rs1860472	ENSG00000232559.3	GS1-124K5.12	-7.17	2.89e-12	8.68e-10	-0.3	-0.31	Aortic root size;	chr7:66617736	chr7:66554588~66576923:-
THCA	cis	rs7247513	0.759	rs8110545	ENSG00000213290.4	PGK1P2	-7.17	2.89e-12	8.68e-10	-0.37	-0.31	Bipolar disorder;	chr19:12644084	chr19:12559571~12561105:+
THCA	cis	rs7182621	0.546	rs11635811	ENSG00000182397.13	DNM1P46	7.17	2.9e-12	8.7e-10	0.41	0.31	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99790156~99806927:-
THCA	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	7.17	2.9e-12	8.7e-10	0.43	0.31	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
THCA	cis	rs74233809	1	rs11191548	ENSG00000213277.3	MARCKSL1P1	-7.17	2.9e-12	8.71e-10	-0.52	-0.31	Birth weight;	chr10:103086421	chr10:103175554~103176094:+
THCA	cis	rs853679	0.517	rs4713152	ENSG00000220721.1	OR1F12	7.17	2.9e-12	8.71e-10	0.43	0.31	Depression;	chr6:28169676	chr6:28073316~28074233:+
THCA	cis	rs10208649	0.611	rs3929001	ENSG00000272156.1	RP11-477N3.1	-7.17	2.9e-12	8.71e-10	-0.45	-0.31	Body mass index;	chr2:54055750	chr2:54082554~54085066:+
THCA	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	7.17	2.9e-12	8.71e-10	0.44	0.31	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
THCA	cis	rs10208649	0.536	rs10190578	ENSG00000272156.1	RP11-477N3.1	-7.17	2.9e-12	8.71e-10	-0.42	-0.31	Body mass index;	chr2:53707014	chr2:54082554~54085066:+
THCA	cis	rs853679	0.517	rs1904840	ENSG00000272009.1	RP1-313I6.12	-7.17	2.9e-12	8.71e-10	-0.37	-0.31	Depression;	chr6:28140454	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368555	ENSG00000272009.1	RP1-313I6.12	-7.17	2.9e-12	8.71e-10	-0.37	-0.31	Depression;	chr6:28141189	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393893	ENSG00000272009.1	RP1-313I6.12	-7.17	2.9e-12	8.71e-10	-0.37	-0.31	Depression;	chr6:28141484	chr6:28078792~28081130:-
THCA	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	7.17	2.9e-12	8.72e-10	0.35	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
THCA	cis	rs736801	0.704	rs56399423	ENSG00000224431.1	AC063976.7	7.17	2.9e-12	8.72e-10	0.28	0.31	Mosquito bite size;Breast cancer;	chr5:132336964	chr5:132199456~132203487:+
THCA	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	7.17	2.91e-12	8.73e-10	0.28	0.31	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
THCA	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	7.17	2.91e-12	8.73e-10	0.28	0.31	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
THCA	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-7.17	2.91e-12	8.74e-10	-0.29	-0.31	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
THCA	cis	rs7267979	0.932	rs6115200	ENSG00000274414.1	RP5-965G21.4	-7.17	2.91e-12	8.74e-10	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.932	rs6138588	ENSG00000274414.1	RP5-965G21.4	-7.17	2.91e-12	8.74e-10	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25239007~25245229:-
THCA	cis	rs72772090	0.539	rs72773981	ENSG00000248734.2	CTD-2260A17.1	-7.17	2.92e-12	8.76e-10	-0.5	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96820356	chr5:96784777~96785999:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	7.17	2.92e-12	8.76e-10	0.37	0.31	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
THCA	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	7.17	2.92e-12	8.76e-10	0.6	0.31	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	7.17	2.92e-12	8.76e-10	0.6	0.31	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
THCA	cis	rs875971	0.895	rs12531677	ENSG00000232559.3	GS1-124K5.12	-7.17	2.92e-12	8.76e-10	-0.3	-0.31	Aortic root size;	chr7:66304099	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs7798630	ENSG00000232559.3	GS1-124K5.12	-7.17	2.92e-12	8.76e-10	-0.3	-0.31	Aortic root size;	chr7:66306492	chr7:66554588~66576923:-
THCA	cis	rs853679	0.882	rs4713140	ENSG00000226314.6	ZNF192P1	-7.17	2.92e-12	8.76e-10	-0.53	-0.31	Depression;	chr6:28129415	chr6:28161781~28169594:+
THCA	cis	rs4950322	0.57	rs4950401	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147319571	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs4950402	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147319684	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs4950404	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147319834	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692946	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147319966	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692948	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147320298	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692951	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147320551	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs77118461	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147320718	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs78681047	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147321013	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72692953	ENSG00000237188.3	RP11-337C18.8	7.17	2.92e-12	8.77e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147321416	chr1:147172771~147211568:+
THCA	cis	rs12681366	0.734	rs16916788	ENSG00000253704.1	RP11-267M23.4	7.17	2.92e-12	8.77e-10	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94387390	chr8:94553722~94569745:+
THCA	cis	rs875971	0.79	rs10257911	ENSG00000232559.3	GS1-124K5.12	-7.17	2.93e-12	8.78e-10	-0.3	-0.31	Aortic root size;	chr7:66278783	chr7:66554588~66576923:-
THCA	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	7.17	2.93e-12	8.78e-10	0.38	0.31	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	7.17	2.93e-12	8.78e-10	0.38	0.31	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
THCA	cis	rs4664293	0.867	rs3764968	ENSG00000226266.5	AC009961.3	-7.17	2.93e-12	8.79e-10	-0.39	-0.31	Monocyte percentage of white cells;	chr2:159790579	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs6740910	ENSG00000226266.5	AC009961.3	-7.17	2.93e-12	8.79e-10	-0.39	-0.31	Monocyte percentage of white cells;	chr2:159792709	chr2:159670708~159712435:-
THCA	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-7.17	2.93e-12	8.79e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-7.17	2.93e-12	8.79e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-7.17	2.93e-12	8.8e-10	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
THCA	cis	rs2562456	0.833	rs2562487	ENSG00000213976.4	CTD-2561J22.2	-7.17	2.93e-12	8.8e-10	-0.34	-0.31	Pain;	chr19:21468580	chr19:21382865~21387177:+
THCA	cis	rs7811142	0.887	rs35111986	ENSG00000078319.8	PMS2P1	-7.17	2.94e-12	8.8e-10	-0.45	-0.31	Platelet count;	chr7:100402651	chr7:100320992~100341908:-
THCA	cis	rs4950322	0.58	rs17359629	ENSG00000237188.3	RP11-337C18.8	7.17	2.94e-12	8.82e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147121537	chr1:147172771~147211568:+
THCA	cis	rs2712184	0.967	rs1014680	ENSG00000229352.1	AC007563.3	7.17	2.95e-12	8.83e-10	0.37	0.31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216808101	chr2:216799608~216805335:+
THCA	cis	rs7246657	0.882	rs13345148	ENSG00000226686.6	LINC01535	-7.17	2.95e-12	8.83e-10	-0.44	-0.31	Coronary artery calcification;	chr19:37328729	chr19:37251912~37265535:+
THCA	cis	rs2281636	0.691	rs11190218	ENSG00000233690.1	EBAG9P1	7.17	2.95e-12	8.85e-10	0.34	0.31	Obesity-related traits;	chr10:99650305	chr10:99697407~99697949:-
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000264538.5	SUZ12P1	-7.17	2.96e-12	8.86e-10	-0.32	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30709299~30790908:+
THCA	cis	rs651907	0.535	rs34648996	ENSG00000256628.3	ZBTB11-AS1	7.17	2.96e-12	8.87e-10	0.37	0.31	Colorectal cancer;	chr3:101792358	chr3:101676475~101679217:+
THCA	cis	rs875971	0.862	rs1968126	ENSG00000232559.3	GS1-124K5.12	-7.17	2.97e-12	8.89e-10	-0.3	-0.31	Aortic root size;	chr7:66592017	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6460306	ENSG00000232559.3	GS1-124K5.12	-7.17	2.97e-12	8.89e-10	-0.3	-0.31	Aortic root size;	chr7:66595806	chr7:66554588~66576923:-
THCA	cis	rs875971	0.789	rs7808013	ENSG00000232559.3	GS1-124K5.12	-7.17	2.97e-12	8.89e-10	-0.3	-0.31	Aortic root size;	chr7:66606209	chr7:66554588~66576923:-
THCA	cis	rs7247513	1	rs12459123	ENSG00000230310.1	CTD-2192J16.11	-7.17	2.97e-12	8.9e-10	-0.39	-0.31	Bipolar disorder;	chr19:12578927	chr19:12552597~12553644:+
THCA	cis	rs7246657	0.943	rs10415937	ENSG00000226686.6	LINC01535	-7.17	2.97e-12	8.91e-10	-0.44	-0.31	Coronary artery calcification;	chr19:37339162	chr19:37251912~37265535:+
THCA	cis	rs8114671	0.562	rs6120739	ENSG00000269202.1	RP4-614O4.12	-7.17	2.97e-12	8.91e-10	-0.26	-0.31	Height;	chr20:34817424	chr20:35201747~35203288:-
THCA	cis	rs3812049	0.826	rs17764730	ENSG00000245937.6	LINC01184	7.17	2.98e-12	8.93e-10	0.36	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128021834	chr5:127940426~128083172:-
THCA	cis	rs6539288	0.933	rs1822736	ENSG00000260329.1	RP11-412D9.4	7.17	2.98e-12	8.93e-10	0.28	0.31	Total body bone mineral density;	chr12:106915481	chr12:106954029~106955497:-
THCA	cis	rs7246657	0.943	rs10426666	ENSG00000226686.6	LINC01535	-7.17	2.98e-12	8.93e-10	-0.46	-0.31	Coronary artery calcification;	chr19:37337612	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs4969487	ENSG00000226686.6	LINC01535	-7.17	2.98e-12	8.93e-10	-0.46	-0.31	Coronary artery calcification;	chr19:37340137	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs28402338	ENSG00000226686.6	LINC01535	-7.17	2.98e-12	8.93e-10	-0.46	-0.31	Coronary artery calcification;	chr19:37343021	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10417503	ENSG00000226686.6	LINC01535	-7.17	2.98e-12	8.93e-10	-0.46	-0.31	Coronary artery calcification;	chr19:37351833	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10403613	ENSG00000226686.6	LINC01535	-7.17	2.98e-12	8.93e-10	-0.46	-0.31	Coronary artery calcification;	chr19:37353404	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs9304566	ENSG00000226686.6	LINC01535	-7.17	2.98e-12	8.93e-10	-0.46	-0.31	Coronary artery calcification;	chr19:37354602	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs4417644	ENSG00000226686.6	LINC01535	-7.17	2.98e-12	8.93e-10	-0.46	-0.31	Coronary artery calcification;	chr19:37361570	chr19:37251912~37265535:+
THCA	cis	rs1598856	0.932	rs2168803	ENSG00000246560.2	RP11-10L12.4	7.17	2.99e-12	8.94e-10	0.38	0.31	Primary biliary cholangitis;	chr4:102507458	chr4:102828055~102844075:+
THCA	cis	rs1198430	0.683	rs1077514	ENSG00000232482.2	RP4-654C18.1	7.17	2.99e-12	8.94e-10	0.48	0.31	Total cholesterol levels;	chr1:23439740	chr1:23410832~23412146:+
THCA	cis	rs4950322	0.57	rs113498894	ENSG00000237188.3	RP11-337C18.8	7.17	2.99e-12	8.95e-10	0.39	0.31	Protein quantitative trait loci;	chr1:147318880	chr1:147172771~147211568:+
THCA	cis	rs728616	0.867	rs28365998	ENSG00000225484.5	NUTM2B-AS1	-7.17	2.99e-12	8.95e-10	-0.63	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:79663088~79826594:-
THCA	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	7.17	2.99e-12	8.95e-10	0.28	0.31	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
THCA	cis	rs4073416	0.712	rs2149841	ENSG00000276116.2	FUT8-AS1	7.17	2.99e-12	8.97e-10	0.33	0.31	N-glycan levels;	chr14:65543601	chr14:65411170~65412690:-
THCA	cis	rs8012947	0.959	rs10137327	ENSG00000279636.2	LINC00216	-7.17	3e-12	8.98e-10	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58287183	chr14:58288033~58289158:+
THCA	cis	rs2749592	0.513	rs1208708	ENSG00000263064.2	RP11-291L22.7	7.17	3e-12	8.99e-10	0.36	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38448689~38448949:+
THCA	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	7.17	3e-12	8.99e-10	0.18	0.31	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
THCA	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	7.17	3e-12	8.99e-10	0.18	0.31	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
THCA	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	7.17	3e-12	8.99e-10	0.46	0.31	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
THCA	cis	rs61041384	1	rs4759367	ENSG00000256092.2	RP13-942N8.1	-7.17	3e-12	9e-10	-0.46	-0.31	Schizophrenia;	chr12:123171997	chr12:123363868~123366113:+
THCA	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-7.17	3.01e-12	9e-10	-0.36	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
THCA	cis	rs4820539	1	rs4822361	ENSG00000221069.1	AC000029.1	7.17	3.01e-12	9.02e-10	0.36	0.31	Bone mineral density;	chr22:23140531	chr22:23136620~23136710:+
THCA	cis	rs42490	0.528	rs7004089	ENSG00000251136.7	RP11-37B2.1	7.17	3.01e-12	9.03e-10	0.26	0.31	Leprosy;	chr8:89688329	chr8:89609409~89757727:-
THCA	cis	rs8012947	1	rs8009579	ENSG00000279636.2	LINC00216	-7.17	3.02e-12	9.03e-10	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58246841	chr14:58288033~58289158:+
THCA	cis	rs6539288	0.901	rs11113143	ENSG00000260329.1	RP11-412D9.4	-7.17	3.02e-12	9.04e-10	-0.28	-0.31	Total body bone mineral density;	chr12:106910081	chr12:106954029~106955497:-
THCA	cis	rs240993	0.812	rs455650	ENSG00000230177.1	RP5-1112D6.4	-7.17	3.02e-12	9.04e-10	-0.32	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111370320	chr6:111277932~111278742:+
THCA	cis	rs801193	0.569	rs11772819	ENSG00000232559.3	GS1-124K5.12	7.17	3.02e-12	9.05e-10	0.3	0.31	Aortic root size;	chr7:66752983	chr7:66554588~66576923:-
THCA	cis	rs801193	0.569	rs7800620	ENSG00000232559.3	GS1-124K5.12	7.17	3.02e-12	9.05e-10	0.3	0.31	Aortic root size;	chr7:66758701	chr7:66554588~66576923:-
THCA	cis	rs6539288	0.933	rs1444583	ENSG00000260329.1	RP11-412D9.4	7.17	3.02e-12	9.05e-10	0.28	0.31	Total body bone mineral density;	chr12:106919068	chr12:106954029~106955497:-
THCA	cis	rs7247513	0.964	rs12979795	ENSG00000230310.1	CTD-2192J16.11	7.16	3.03e-12	9.07e-10	0.37	0.31	Bipolar disorder;	chr19:12607033	chr19:12552597~12553644:+
THCA	cis	rs8114671	0.562	rs34837802	ENSG00000269202.1	RP4-614O4.12	-7.16	3.04e-12	9.09e-10	-0.27	-0.31	Height;	chr20:34837105	chr20:35201747~35203288:-
THCA	cis	rs737008	0.96	rs949429	ENSG00000262703.1	RP11-485G7.6	-7.16	3.04e-12	9.11e-10	-0.36	-0.31	Obesity-related traits;	chr16:11282172	chr16:11348143~11349321:-
THCA	cis	rs4934494	0.768	rs12572608	ENSG00000232936.4	RP11-80H5.2	-7.16	3.05e-12	9.11e-10	-0.43	-0.31	Red blood cell count;	chr10:89647170	chr10:89645282~89650667:+
THCA	cis	rs10411161	0.748	rs78410648	ENSG00000269483.1	AC006272.1	7.16	3.05e-12	9.12e-10	0.54	0.31	Breast cancer;	chr19:51896148	chr19:51839924~51843324:-
THCA	cis	rs9341808	0.69	rs9448909	ENSG00000272129.1	RP11-250B2.6	7.16	3.05e-12	9.12e-10	0.39	0.31	Sitting height ratio;	chr6:80199314	chr6:80355424~80356859:+
THCA	cis	rs74233809	0.892	rs11191447	ENSG00000213277.3	MARCKSL1P1	7.16	3.06e-12	9.14e-10	0.51	0.31	Birth weight;	chr10:102892566	chr10:103175554~103176094:+
THCA	cis	rs875971	1	rs6956179	ENSG00000232559.3	GS1-124K5.12	-7.16	3.06e-12	9.15e-10	-0.3	-0.31	Aortic root size;	chr7:66341672	chr7:66554588~66576923:-
THCA	cis	rs7267979	0.966	rs910996	ENSG00000274414.1	RP5-965G21.4	-7.16	3.06e-12	9.17e-10	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25239007~25245229:-
THCA	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	7.16	3.06e-12	9.17e-10	0.4	0.31	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
THCA	cis	rs6676180	0.555	rs12060730	ENSG00000231365.4	RP11-418J17.1	-7.16	3.07e-12	9.17e-10	-0.31	-0.31	Monobrow;	chr1:119228079	chr1:119140396~119275973:+
THCA	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-7.16	3.07e-12	9.17e-10	-0.37	-0.31	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
THCA	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-7.16	3.07e-12	9.17e-10	-0.34	-0.31	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-7.16	3.07e-12	9.17e-10	-0.34	-0.31	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
THCA	cis	rs12594515	1	rs56220882	ENSG00000259200.1	RP11-718O11.1	-7.16	3.07e-12	9.18e-10	-0.38	-0.31	Weight;Waist circumference;	chr15:45704877	chr15:45705078~45931069:+
THCA	cis	rs875971	0.862	rs11984115	ENSG00000232559.3	GS1-124K5.12	-7.16	3.07e-12	9.18e-10	-0.3	-0.31	Aortic root size;	chr7:66308872	chr7:66554588~66576923:-
THCA	cis	rs1009647	0.614	rs17253702	ENSG00000258413.1	RP11-665C16.6	-7.16	3.07e-12	9.19e-10	-0.55	-0.31	Testicular germ cell tumor;	chr14:55117165	chr14:55262767~55272075:-
THCA	cis	rs651907	0.557	rs13099674	ENSG00000256628.3	ZBTB11-AS1	7.16	3.08e-12	9.21e-10	0.37	0.31	Colorectal cancer;	chr3:101770785	chr3:101676475~101679217:+
THCA	cis	rs9400467	0.528	rs240954	ENSG00000230177.1	RP5-1112D6.4	-7.16	3.09e-12	9.24e-10	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111338619	chr6:111277932~111278742:+
THCA	cis	rs728616	0.867	rs7893241	ENSG00000225484.5	NUTM2B-AS1	-7.16	3.09e-12	9.25e-10	-0.6	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194582	chr10:79663088~79826594:-
THCA	cis	rs7615952	0.736	rs11921945	ENSG00000241288.6	RP11-379B18.5	-7.16	3.09e-12	9.25e-10	-0.39	-0.31	Blood pressure (smoking interaction);	chr3:125924876	chr3:125827238~125916384:-
THCA	cis	rs853679	0.882	rs4713139	ENSG00000226314.6	ZNF192P1	-7.16	3.09e-12	9.25e-10	-0.53	-0.31	Depression;	chr6:28124907	chr6:28161781~28169594:+
THCA	cis	rs4780355	1	rs1111186	ENSG00000262636.1	CTD-3088G3.4	7.16	3.09e-12	9.25e-10	0.41	0.31	Crohn's disease and psoriasis;	chr16:11253191	chr16:11380859~11381118:-
THCA	cis	rs74233809	1	rs74233296	ENSG00000213277.3	MARCKSL1P1	7.16	3.1e-12	9.26e-10	0.51	0.31	Birth weight;	chr10:102895593	chr10:103175554~103176094:+
THCA	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	7.16	3.1e-12	9.26e-10	0.35	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
THCA	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	7.16	3.1e-12	9.27e-10	0.44	0.31	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	7.16	3.1e-12	9.27e-10	0.44	0.31	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
THCA	cis	rs4072705	1	rs4524900	ENSG00000224020.1	MIR181A2HG	-7.16	3.1e-12	9.27e-10	-0.28	-0.31	Menarche (age at onset);	chr9:124580930	chr9:124658467~124698631:+
THCA	cis	rs12681366	0.708	rs2930962	ENSG00000253704.1	RP11-267M23.4	7.16	3.1e-12	9.28e-10	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94433277	chr8:94553722~94569745:+
THCA	cis	rs1949733	1	rs3103067	ENSG00000205959.3	RP11-689P11.2	-7.16	3.1e-12	9.28e-10	-0.26	-0.31	Response to antineoplastic agents;	chr4:8509496	chr4:8482270~8512610:+
THCA	cis	rs7942368	1	rs1837679	ENSG00000254761.1	RP11-672A2.1	7.16	3.11e-12	9.29e-10	0.46	0.31	Endometriosis;	chr11:76790513	chr11:76712396~76719608:-
THCA	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	7.16	3.12e-12	9.31e-10	0.38	0.31	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
THCA	cis	rs4073416	0.741	rs4143898	ENSG00000276116.2	FUT8-AS1	-7.16	3.12e-12	9.33e-10	-0.31	-0.31	N-glycan levels;	chr14:65722164	chr14:65411170~65412690:-
THCA	cis	rs1322639	0.55	rs9505943	ENSG00000261039.2	RP11-417E7.2	-7.16	3.13e-12	9.34e-10	-0.34	-0.31	Pulse pressure;	chr6:169192824	chr6:169175304~169182740:-
THCA	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	7.16	3.13e-12	9.36e-10	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
THCA	cis	rs7760535	0.764	rs240994	ENSG00000230177.1	RP5-1112D6.4	-7.16	3.13e-12	9.36e-10	-0.25	-0.31	Metabolic traits;	chr6:111354554	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.794	rs463860	ENSG00000230177.1	RP5-1112D6.4	-7.16	3.13e-12	9.36e-10	-0.25	-0.31	Metabolic traits;	chr6:111370518	chr6:111277932~111278742:+
THCA	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-7.16	3.13e-12	9.36e-10	-0.52	-0.31	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
THCA	cis	rs6496932	0.774	rs12901648	ENSG00000218052.5	ADAMTS7P4	-7.16	3.14e-12	9.37e-10	-0.48	-0.31	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:85255369~85330334:-
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000263603.1	CTD-2349P21.5	-7.16	3.14e-12	9.38e-10	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000263603.1	CTD-2349P21.5	-7.16	3.14e-12	9.38e-10	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000263603.1	CTD-2349P21.5	-7.16	3.14e-12	9.38e-10	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000263603.1	CTD-2349P21.5	-7.16	3.14e-12	9.38e-10	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000263603.1	CTD-2349P21.5	-7.16	3.14e-12	9.38e-10	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000263603.1	CTD-2349P21.5	-7.16	3.14e-12	9.38e-10	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000263603.1	CTD-2349P21.5	-7.16	3.14e-12	9.38e-10	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30729469~30731202:+
THCA	cis	rs911555	0.504	rs4444269	ENSG00000269958.1	RP11-73M18.8	7.16	3.14e-12	9.38e-10	0.3	0.31	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103696353~103697163:+
THCA	cis	rs7221109	0.682	rs9893132	ENSG00000278834.1	RP11-458J1.1	7.16	3.14e-12	9.38e-10	0.33	0.31	Type 1 diabetes;	chr17:40598769	chr17:40648300~40649718:+
THCA	cis	rs4713118	0.513	rs149955	ENSG00000280107.1	AL022393.9	-7.16	3.14e-12	9.39e-10	-0.34	-0.31	Parkinson's disease;	chr6:28068447	chr6:28170845~28172521:+
THCA	cis	rs8012947	1	rs6573199	ENSG00000279636.2	LINC00216	-7.16	3.14e-12	9.39e-10	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58318063	chr14:58288033~58289158:+
THCA	cis	rs2712184	0.873	rs1548945	ENSG00000229352.1	AC007563.3	-7.16	3.14e-12	9.39e-10	-0.37	-0.31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216801065	chr2:216799608~216805335:+
THCA	cis	rs172166	0.637	rs1233691	ENSG00000280107.1	AL022393.9	-7.16	3.15e-12	9.41e-10	-0.33	-0.31	Cardiac Troponin-T levels;	chr6:28186119	chr6:28170845~28172521:+
THCA	cis	rs8067545	0.641	rs203450	ENSG00000270091.1	RP11-78O7.2	-7.16	3.15e-12	9.41e-10	-0.23	-0.31	Schizophrenia;	chr17:19919757	chr17:19896590~19897287:-
THCA	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	7.16	3.16e-12	9.42e-10	0.47	0.31	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	7.16	3.16e-12	9.42e-10	0.47	0.31	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	7.16	3.16e-12	9.42e-10	0.47	0.31	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	7.16	3.16e-12	9.42e-10	0.47	0.31	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
THCA	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	7.16	3.16e-12	9.43e-10	0.29	0.31	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
THCA	cis	rs4073416	0.746	rs12895074	ENSG00000276116.2	FUT8-AS1	7.16	3.16e-12	9.43e-10	0.33	0.31	N-glycan levels;	chr14:65510075	chr14:65411170~65412690:-
THCA	cis	rs8100891	0.734	rs741445	ENSG00000267213.4	AC007773.2	-7.16	3.16e-12	9.44e-10	-0.29	-0.31	Neuroticism;	chr19:32345686	chr19:32390050~32405560:-
THCA	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-7.16	3.16e-12	9.45e-10	-0.38	-0.31	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
THCA	cis	rs4845875	0.557	rs4846054	ENSG00000242349.4	NPPA-AS1	7.16	3.17e-12	9.46e-10	0.3	0.31	Midregional pro atrial natriuretic peptide levels;	chr1:11809173	chr1:11841017~11848079:+
THCA	cis	rs9467773	0.836	rs1624440	ENSG00000124549.13	BTN2A3P	-7.16	3.17e-12	9.46e-10	-0.29	-0.31	Intelligence (multi-trait analysis);	chr6:26433101	chr6:26421391~26432383:+
THCA	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	7.16	3.17e-12	9.47e-10	0.78	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
THCA	cis	rs516805	0.706	rs1034060	ENSG00000279453.1	RP3-425C14.4	7.16	3.17e-12	9.47e-10	0.32	0.31	Lymphocyte counts;	chr6:122319181	chr6:122436789~122439223:-
THCA	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	7.16	3.18e-12	9.49e-10	0.37	0.31	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
THCA	cis	rs12653396	0.609	rs2194027	ENSG00000247828.6	TMEM161B-AS1	7.16	3.19e-12	9.52e-10	0.23	0.31	Educational attainment (years of education);	chr5:88526854	chr5:88268895~88436685:+
THCA	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-7.16	3.19e-12	9.53e-10	-0.51	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-7.16	3.19e-12	9.53e-10	-0.51	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
THCA	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-7.16	3.2e-12	9.54e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000235689.1	AP000351.13	-7.16	3.2e-12	9.54e-10	-0.4	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:24006305~24008258:-
THCA	cis	rs10971721	0.643	rs10971701	ENSG00000281128.1	PTENP1-AS	7.16	3.2e-12	9.55e-10	0.8	0.31	Body mass index;	chr9:33781900	chr9:33677268~33688011:+
THCA	cis	rs6840258	0.943	rs72667748	ENSG00000251411.1	RP11-397E7.4	-7.16	3.2e-12	9.55e-10	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87005882	chr4:86913266~86914817:-
THCA	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-7.16	3.2e-12	9.55e-10	-0.25	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
THCA	cis	rs875971	1	rs3981131	ENSG00000232559.3	GS1-124K5.12	7.16	3.2e-12	9.56e-10	0.3	0.31	Aortic root size;	chr7:66486690	chr7:66554588~66576923:-
THCA	cis	rs6745190	0.906	rs6706565	ENSG00000236153.1	AC104076.3	7.16	3.2e-12	9.56e-10	0.37	0.31	White blood cell count;	chr2:181065685	chr2:180979427~180980090:-
THCA	cis	rs2032366	1	rs1840047	ENSG00000267279.1	RP11-879F14.2	-7.16	3.21e-12	9.57e-10	-0.31	-0.31	Obesity-related traits;	chr18:61591312	chr18:61585746~61606916:-
THCA	cis	rs9341808	0.718	rs10080237	ENSG00000272129.1	RP11-250B2.6	7.16	3.21e-12	9.58e-10	0.4	0.31	Sitting height ratio;	chr6:80144753	chr6:80355424~80356859:+
THCA	cis	rs875971	0.895	rs6460278	ENSG00000232559.3	GS1-124K5.12	-7.16	3.21e-12	9.58e-10	-0.3	-0.31	Aortic root size;	chr7:66197749	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6460279	ENSG00000232559.3	GS1-124K5.12	-7.16	3.21e-12	9.58e-10	-0.3	-0.31	Aortic root size;	chr7:66197774	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs28491091	ENSG00000232559.3	GS1-124K5.12	-7.16	3.21e-12	9.58e-10	-0.3	-0.31	Aortic root size;	chr7:66204077	chr7:66554588~66576923:-
THCA	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-7.16	3.21e-12	9.58e-10	-0.74	-0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
THCA	cis	rs12681366	0.663	rs6980687	ENSG00000253704.1	RP11-267M23.4	7.16	3.21e-12	9.58e-10	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94469685	chr8:94553722~94569745:+
THCA	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-7.16	3.21e-12	9.59e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-7.16	3.21e-12	9.59e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-7.16	3.21e-12	9.59e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-7.16	3.21e-12	9.59e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-7.16	3.21e-12	9.59e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-7.16	3.21e-12	9.59e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
THCA	cis	rs12935418	0.832	rs79957369	ENSG00000261061.1	RP11-303E16.2	-7.16	3.21e-12	9.59e-10	-0.41	-0.31	Mean corpuscular volume;	chr16:81025654	chr16:81030770~81031485:+
THCA	cis	rs6762	0.719	rs28620453	ENSG00000279672.1	CMB9-55F22.1	7.16	3.22e-12	9.6e-10	0.35	0.31	Mean platelet volume;	chr11:836971	chr11:779617~780755:+
THCA	cis	rs7246657	0.943	rs2081096	ENSG00000226686.6	LINC01535	-7.16	3.22e-12	9.61e-10	-0.44	-0.31	Coronary artery calcification;	chr19:37473798	chr19:37251912~37265535:+
THCA	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	7.16	3.22e-12	9.61e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	7.16	3.22e-12	9.61e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	7.16	3.22e-12	9.61e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	7.16	3.22e-12	9.61e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
THCA	cis	rs9341808	0.718	rs6910201	ENSG00000272129.1	RP11-250B2.6	7.16	3.22e-12	9.61e-10	0.39	0.31	Sitting height ratio;	chr6:80195221	chr6:80355424~80356859:+
THCA	cis	rs11148252	0.51	rs7337430	ENSG00000235660.1	LINC00345	-7.16	3.22e-12	9.61e-10	-0.39	-0.31	Lewy body disease;	chr13:52010108	chr13:52484161~52484680:-
THCA	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-7.16	3.23e-12	9.62e-10	-0.38	-0.31	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
THCA	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-7.16	3.23e-12	9.62e-10	-0.31	-0.31	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
THCA	cis	rs8067545	0.641	rs2108978	ENSG00000270091.1	RP11-78O7.2	-7.16	3.23e-12	9.63e-10	-0.23	-0.31	Schizophrenia;	chr17:19958145	chr17:19896590~19897287:-
THCA	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-7.16	3.23e-12	9.63e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-7.16	3.23e-12	9.63e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-7.16	3.23e-12	9.63e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-7.16	3.23e-12	9.63e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-7.16	3.23e-12	9.63e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-7.16	3.23e-12	9.63e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
THCA	cis	rs801193	0.569	rs10950050	ENSG00000232559.3	GS1-124K5.12	7.16	3.23e-12	9.64e-10	0.3	0.31	Aortic root size;	chr7:66774601	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.673	rs3764420	ENSG00000264538.5	SUZ12P1	-7.15	3.23e-12	9.64e-10	-0.33	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30709299~30790908:+
THCA	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-7.15	3.23e-12	9.65e-10	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
THCA	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-7.15	3.24e-12	9.65e-10	-0.35	-0.31	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
THCA	cis	rs4073416	0.712	rs12888212	ENSG00000276116.2	FUT8-AS1	7.15	3.24e-12	9.65e-10	0.32	0.31	N-glycan levels;	chr14:65733740	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.712	rs927004	ENSG00000276116.2	FUT8-AS1	7.15	3.24e-12	9.65e-10	0.32	0.31	N-glycan levels;	chr14:65734193	chr14:65411170~65412690:-
THCA	cis	rs2976388	0.609	rs2164308	ENSG00000253741.1	CTD-2292P10.4	7.15	3.24e-12	9.66e-10	0.38	0.31	Urinary tract infection frequency;	chr8:142704241	chr8:142702252~142726973:-
THCA	cis	rs4948275	0.55	rs7082786	ENSG00000237233.2	TMEM26-AS1	7.15	3.24e-12	9.67e-10	0.43	0.31	Night sleep phenotypes;	chr10:61417232	chr10:61452639~61481956:+
THCA	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-7.15	3.24e-12	9.67e-10	-0.41	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
THCA	cis	rs160451	0.966	rs1603289	ENSG00000251136.7	RP11-37B2.1	7.15	3.24e-12	9.67e-10	0.27	0.31	Leprosy;	chr8:89655405	chr8:89609409~89757727:-
THCA	cis	rs160451	0.966	rs12216864	ENSG00000251136.7	RP11-37B2.1	7.15	3.24e-12	9.67e-10	0.27	0.31	Leprosy;	chr8:89665895	chr8:89609409~89757727:-
THCA	cis	rs42490	0.528	rs10956209	ENSG00000251136.7	RP11-37B2.1	7.15	3.24e-12	9.67e-10	0.27	0.31	Leprosy;	chr8:89670923	chr8:89609409~89757727:-
THCA	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-7.15	3.24e-12	9.67e-10	-0.37	-0.31	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
THCA	cis	rs2439831	0.867	rs2255051	ENSG00000275601.1	AC011330.13	-7.15	3.25e-12	9.68e-10	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43553963	chr15:43642389~43643023:-
THCA	cis	rs9902453	0.765	rs2729447	ENSG00000264007.1	RP11-68I3.10	-7.15	3.25e-12	9.68e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29771984	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2628180	ENSG00000264007.1	RP11-68I3.10	-7.15	3.25e-12	9.68e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29774705	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.74	rs2729446	ENSG00000264007.1	RP11-68I3.10	-7.15	3.25e-12	9.68e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29775481	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2729440	ENSG00000264007.1	RP11-68I3.10	-7.15	3.25e-12	9.68e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29779856	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.74	rs2244247	ENSG00000264007.1	RP11-68I3.10	-7.15	3.25e-12	9.68e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29783156	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.74	rs2617884	ENSG00000264007.1	RP11-68I3.10	-7.15	3.25e-12	9.68e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29793412	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2617883	ENSG00000264007.1	RP11-68I3.10	-7.15	3.25e-12	9.68e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29793470	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2729436	ENSG00000264007.1	RP11-68I3.10	-7.15	3.25e-12	9.68e-10	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29793652	chr17:29621617~29622254:-
THCA	cis	rs780096	0.967	rs1260334	ENSG00000234072.1	AC074117.10	-7.15	3.25e-12	9.68e-10	-0.24	-0.31	Total body bone mineral density;	chr2:27525730	chr2:27356246~27367622:+
THCA	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	7.15	3.25e-12	9.69e-10	0.4	0.31	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
THCA	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	7.15	3.25e-12	9.69e-10	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
THCA	cis	rs2880765	0.835	rs7163958	ENSG00000259295.5	CSPG4P12	7.15	3.25e-12	9.7e-10	0.39	0.31	Coronary artery disease;	chr15:85501984	chr15:85191438~85213905:+
THCA	cis	rs4820539	1	rs2267003	ENSG00000221069.1	AC000029.1	-7.15	3.26e-12	9.7e-10	-0.37	-0.31	Bone mineral density;	chr22:23114911	chr22:23136620~23136710:+
THCA	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	7.15	3.26e-12	9.71e-10	0.38	0.31	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
THCA	cis	rs12594515	0.506	rs74199860	ENSG00000259200.1	RP11-718O11.1	-7.15	3.26e-12	9.71e-10	-0.38	-0.31	Weight;Waist circumference;	chr15:45696992	chr15:45705078~45931069:+
THCA	cis	rs728616	0.614	rs726014	ENSG00000225484.5	NUTM2B-AS1	-7.15	3.26e-12	9.72e-10	-0.46	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948988	chr10:79663088~79826594:-
THCA	cis	rs7568498	0.517	rs11678856	ENSG00000227403.1	AC009299.3	7.15	3.26e-12	9.72e-10	0.39	0.31	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161068932	chr2:161244739~161249050:+
THCA	cis	rs72772090	0.539	rs72773991	ENSG00000248734.2	CTD-2260A17.1	-7.15	3.26e-12	9.73e-10	-0.49	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96828072	chr5:96784777~96785999:+
THCA	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	7.15	3.27e-12	9.73e-10	0.44	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
THCA	cis	rs9902453	0.845	rs12452201	ENSG00000264007.1	RP11-68I3.10	7.15	3.27e-12	9.74e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29887155	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.817	rs55974138	ENSG00000264007.1	RP11-68I3.10	7.15	3.27e-12	9.74e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29888528	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs58575982	ENSG00000264007.1	RP11-68I3.10	7.15	3.27e-12	9.74e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29894758	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs2321493	ENSG00000264007.1	RP11-68I3.10	7.15	3.27e-12	9.74e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29903341	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.808	rs12452288	ENSG00000264007.1	RP11-68I3.10	7.15	3.27e-12	9.74e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29908202	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.791	rs55655651	ENSG00000264007.1	RP11-68I3.10	7.15	3.27e-12	9.74e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29917268	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs12601963	ENSG00000264007.1	RP11-68I3.10	7.15	3.27e-12	9.74e-10	0.36	0.31	Coffee consumption (cups per day);	chr17:29919340	chr17:29621617~29622254:-
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000220721.1	OR1F12	7.15	3.27e-12	9.74e-10	0.42	0.31	Parkinson's disease;	chr6:28069254	chr6:28073316~28074233:+
THCA	cis	rs801193	0.569	rs13226966	ENSG00000232559.3	GS1-124K5.12	7.15	3.27e-12	9.74e-10	0.3	0.31	Aortic root size;	chr7:66768636	chr7:66554588~66576923:-
THCA	cis	rs17695224	0.545	rs4802871	ENSG00000269483.1	AC006272.1	7.15	3.27e-12	9.74e-10	0.33	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51817487	chr19:51839924~51843324:-
THCA	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-7.15	3.27e-12	9.74e-10	-0.25	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
THCA	cis	rs990871	0.962	rs6661921	ENSG00000227207.2	RPL31P12	-7.15	3.28e-12	9.77e-10	-0.38	-0.31	Subcutaneous adipose tissue;	chr1:72359172	chr1:72301472~72301829:+
THCA	cis	rs990871	0.962	rs6687024	ENSG00000227207.2	RPL31P12	-7.15	3.28e-12	9.77e-10	-0.38	-0.31	Subcutaneous adipose tissue;	chr1:72359177	chr1:72301472~72301829:+
THCA	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	7.15	3.28e-12	9.77e-10	0.34	0.31	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
THCA	cis	rs10050311	0.858	rs55698195	ENSG00000251411.1	RP11-397E7.4	-7.15	3.28e-12	9.77e-10	-0.4	-0.31	Insulin-related traits;	chr4:86872297	chr4:86913266~86914817:-
THCA	cis	rs11696845	0.626	rs6073537	ENSG00000276223.1	RP4-781B1.5	7.15	3.28e-12	9.78e-10	0.37	0.31	Obesity-related traits;	chr20:44749629	chr20:44746642~44747201:+
THCA	cis	rs651907	0.535	rs11717638	ENSG00000256628.3	ZBTB11-AS1	7.15	3.29e-12	9.79e-10	0.37	0.31	Colorectal cancer;	chr3:101786624	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs34263427	ENSG00000256628.3	ZBTB11-AS1	7.15	3.29e-12	9.79e-10	0.37	0.31	Colorectal cancer;	chr3:101788961	chr3:101676475~101679217:+
THCA	cis	rs651907	0.514	rs11706494	ENSG00000256628.3	ZBTB11-AS1	7.15	3.29e-12	9.79e-10	0.37	0.31	Colorectal cancer;	chr3:101790631	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs34063583	ENSG00000256628.3	ZBTB11-AS1	7.15	3.29e-12	9.79e-10	0.37	0.31	Colorectal cancer;	chr3:101791104	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs34161138	ENSG00000256628.3	ZBTB11-AS1	7.15	3.29e-12	9.79e-10	0.37	0.31	Colorectal cancer;	chr3:101791544	chr3:101676475~101679217:+
THCA	cis	rs7044106	0.762	rs10760112	ENSG00000238181.2	AHCYP2	-7.15	3.29e-12	9.81e-10	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120720673~120721972:+
THCA	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	7.15	3.29e-12	9.81e-10	0.39	0.31	Height;	chr6:109347085	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	7.15	3.29e-12	9.81e-10	0.39	0.31	Height;	chr6:109347277	chr6:109382795~109383666:+
THCA	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	7.15	3.3e-12	9.82e-10	0.35	0.31	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
THCA	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-7.15	3.3e-12	9.82e-10	-0.25	-0.31	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
THCA	cis	rs7849973	0.637	rs12349560	ENSG00000224549.1	RP11-370B11.3	-7.15	3.3e-12	9.82e-10	-0.4	-0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22763159	chr9:22767175~22768316:+
THCA	cis	rs12681366	0.734	rs2919672	ENSG00000253704.1	RP11-267M23.4	7.15	3.3e-12	9.83e-10	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94424919	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.708	rs2930958	ENSG00000253704.1	RP11-267M23.4	7.15	3.3e-12	9.83e-10	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94428325	chr8:94553722~94569745:+
THCA	cis	rs56114371	0.568	rs200468	ENSG00000219392.1	RP1-265C24.5	-7.15	3.3e-12	9.83e-10	-0.44	-0.31	Breast cancer;	chr6:27790076	chr6:28115628~28116551:+
THCA	cis	rs728616	0.867	rs17884637	ENSG00000225484.5	NUTM2B-AS1	-7.15	3.3e-12	9.84e-10	-0.63	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928166	chr10:79663088~79826594:-
THCA	cis	rs853679	0.517	rs9380056	ENSG00000220721.1	OR1F12	7.15	3.31e-12	9.84e-10	0.43	0.31	Depression;	chr6:28136698	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000220721.1	OR1F12	7.15	3.31e-12	9.84e-10	0.43	0.31	Depression;	chr6:28136856	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000220721.1	OR1F12	7.15	3.31e-12	9.84e-10	0.43	0.31	Depression;	chr6:28137418	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000220721.1	OR1F12	7.15	3.31e-12	9.84e-10	0.43	0.31	Depression;	chr6:28138363	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000220721.1	OR1F12	7.15	3.31e-12	9.84e-10	0.43	0.31	Parkinson's disease;	chr6:28138569	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000220721.1	OR1F12	7.15	3.31e-12	9.84e-10	0.43	0.31	Depression;	chr6:28138981	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000220721.1	OR1F12	7.15	3.31e-12	9.84e-10	0.43	0.31	Depression;	chr6:28139012	chr6:28073316~28074233:+
THCA	cis	rs4835473	0.897	rs13145976	ENSG00000251600.4	RP11-673E1.1	-7.15	3.31e-12	9.84e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143735710	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs13114071	ENSG00000251600.4	RP11-673E1.1	-7.15	3.31e-12	9.84e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143735728	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs13140654	ENSG00000251600.4	RP11-673E1.1	-7.15	3.31e-12	9.84e-10	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143735733	chr4:143912331~143982454:+
THCA	cis	rs8012947	1	rs10145437	ENSG00000279636.2	LINC00216	-7.15	3.31e-12	9.85e-10	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58294485	chr14:58288033~58289158:+
THCA	cis	rs2281636	0.66	rs11190184	ENSG00000233690.1	EBAG9P1	7.15	3.31e-12	9.87e-10	0.35	0.31	Obesity-related traits;	chr10:99608442	chr10:99697407~99697949:-
THCA	cis	rs651907	0.513	rs34963630	ENSG00000256628.3	ZBTB11-AS1	7.15	3.31e-12	9.87e-10	0.37	0.31	Colorectal cancer;	chr3:101785973	chr3:101676475~101679217:+
THCA	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	7.15	3.32e-12	9.87e-10	0.38	0.31	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	7.15	3.32e-12	9.87e-10	0.38	0.31	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000224205.1	AP000351.4	-7.15	3.32e-12	9.89e-10	-0.38	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23987320~23991421:-
THCA	cis	rs12594515	0.935	rs8042519	ENSG00000259200.1	RP11-718O11.1	-7.15	3.32e-12	9.89e-10	-0.38	-0.31	Weight;Waist circumference;	chr15:45704143	chr15:45705078~45931069:+
THCA	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	7.15	3.33e-12	9.91e-10	0.43	0.31	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
THCA	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-7.15	3.33e-12	9.92e-10	-0.36	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
THCA	cis	rs6723108	0.627	rs2197579	ENSG00000224043.6	CCNT2-AS1	-7.15	3.33e-12	9.92e-10	-0.33	-0.31	Type 2 diabetes;	chr2:134887408	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs4954197	ENSG00000224043.6	CCNT2-AS1	-7.15	3.33e-12	9.92e-10	-0.33	-0.31	Type 2 diabetes;	chr2:134904674	chr2:134735464~134918710:-
THCA	cis	rs10899021	1	rs11236201	ENSG00000279353.1	RP11-864N7.4	7.15	3.33e-12	9.92e-10	0.68	0.31	Response to metformin (IC50);	chr11:74664588	chr11:74698231~74699658:-
THCA	cis	rs593531	0.614	rs623065	ENSG00000212961.4	HNRNPA1P40	7.15	3.34e-12	9.93e-10	0.4	0.31	Neuroticism;	chr11:74360165	chr11:74354443~74355720:+
THCA	cis	rs4072705	1	rs4838206	ENSG00000224020.1	MIR181A2HG	-7.15	3.34e-12	9.95e-10	-0.28	-0.31	Menarche (age at onset);	chr9:124749645	chr9:124658467~124698631:+
THCA	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	7.15	3.34e-12	9.95e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
THCA	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	7.15	3.34e-12	9.95e-10	0.39	0.31	Height;	chr6:109613205	chr6:109382795~109383666:+
THCA	cis	rs651907	0.535	rs11919389	ENSG00000256628.3	ZBTB11-AS1	7.15	3.34e-12	9.95e-10	0.37	0.31	Colorectal cancer;	chr3:101705614	chr3:101676475~101679217:+
THCA	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-7.15	3.34e-12	9.95e-10	-0.38	-0.31	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
THCA	cis	rs651907	0.535	rs17412601	ENSG00000256628.3	ZBTB11-AS1	7.15	3.35e-12	9.97e-10	0.37	0.31	Colorectal cancer;	chr3:101780431	chr3:101676475~101679217:+
THCA	cis	rs12655019	0.92	rs12654125	ENSG00000271828.1	CTD-2310F14.1	7.15	3.35e-12	9.97e-10	0.72	0.31	Breast cancer (early onset);	chr5:56919926	chr5:56927874~56929573:+
THCA	cis	rs4591358	0.527	rs16836742	ENSG00000223466.1	AC064834.2	7.15	3.35e-12	9.98e-10	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512919	chr2:195533035~195538681:+
THCA	cis	rs7727544	1	rs10076701	ENSG00000237714.1	P4HA2-AS1	7.15	3.35e-12	9.98e-10	0.4	0.31	Blood metabolite levels;	chr5:132260726	chr5:132184876~132192808:+
THCA	cis	rs9388451	0.839	rs11154331	ENSG00000237742.5	RP11-624M8.1	-7.15	3.35e-12	9.98e-10	-0.27	-0.31	Brugada syndrome;	chr6:125790283	chr6:125578558~125749190:-
THCA	cis	rs7948661	1	rs9332793	ENSG00000278376.1	RP11-158I9.8	7.15	3.36e-12	9.98e-10	0.54	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118483743	chr11:118791254~118793137:+
THCA	cis	rs832187	0.615	rs9865811	ENSG00000280620.1	SCAANT1	7.15	3.36e-12	1e-09	0.42	0.31	Schizophrenia;	chr3:64008829	chr3:63911518~63911772:-
THCA	cis	rs12681366	0.708	rs12680213	ENSG00000253704.1	RP11-267M23.4	7.15	3.36e-12	1e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94387588	chr8:94553722~94569745:+
THCA	cis	rs4073416	0.712	rs12589698	ENSG00000276116.2	FUT8-AS1	-7.15	3.36e-12	1e-09	-0.33	-0.31	N-glycan levels;	chr14:65453717	chr14:65411170~65412690:-
THCA	cis	rs9902453	0.845	rs7209622	ENSG00000264007.1	RP11-68I3.10	7.15	3.36e-12	1e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29929789	chr17:29621617~29622254:-
THCA	cis	rs7267979	0.932	rs4280527	ENSG00000274414.1	RP5-965G21.4	-7.15	3.37e-12	1e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25239007~25245229:-
THCA	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	7.15	3.37e-12	1e-09	0.28	0.31	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
THCA	cis	rs853679	0.517	rs16893666	ENSG00000272009.1	RP1-313I6.12	7.15	3.37e-12	1e-09	0.37	0.31	Depression;	chr6:28086929	chr6:28078792~28081130:-
THCA	cis	rs7045881	0.558	rs62542707	ENSG00000254396.1	RP11-56F10.3	7.15	3.37e-12	1e-09	0.49	0.31	Schizophrenia;	chr9:27066936	chr9:27102630~27104728:+
THCA	cis	rs12594515	1	rs12592190	ENSG00000259200.1	RP11-718O11.1	-7.15	3.37e-12	1e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45701830	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs11854554	ENSG00000259200.1	RP11-718O11.1	-7.15	3.37e-12	1e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45702348	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs35182335	ENSG00000259200.1	RP11-718O11.1	-7.15	3.37e-12	1e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45702986	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs11855509	ENSG00000259200.1	RP11-718O11.1	-7.15	3.37e-12	1e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45703276	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs11855562	ENSG00000259200.1	RP11-718O11.1	-7.15	3.37e-12	1e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45703461	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs8043291	ENSG00000259200.1	RP11-718O11.1	-7.15	3.37e-12	1e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45704049	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs56412446	ENSG00000259200.1	RP11-718O11.1	-7.15	3.37e-12	1e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45704226	chr15:45705078~45931069:+
THCA	cis	rs4073416	0.684	rs78230848	ENSG00000276116.2	FUT8-AS1	7.15	3.38e-12	1.01e-09	0.33	0.31	N-glycan levels;	chr14:65549666	chr14:65411170~65412690:-
THCA	cis	rs7727544	1	rs7727038	ENSG00000237714.1	P4HA2-AS1	7.15	3.38e-12	1.01e-09	0.4	0.31	Blood metabolite levels;	chr5:132254564	chr5:132184876~132192808:+
THCA	cis	rs7727544	1	rs7727544	ENSG00000237714.1	P4HA2-AS1	7.15	3.38e-12	1.01e-09	0.4	0.31	Blood metabolite levels;	chr5:132254841	chr5:132184876~132192808:+
THCA	cis	rs10971721	0.643	rs10971702	ENSG00000281128.1	PTENP1-AS	7.15	3.38e-12	1.01e-09	0.8	0.31	Body mass index;	chr9:33784104	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.643	rs12375483	ENSG00000281128.1	PTENP1-AS	7.15	3.38e-12	1.01e-09	0.8	0.31	Body mass index;	chr9:33784910	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.643	rs72711741	ENSG00000281128.1	PTENP1-AS	7.15	3.38e-12	1.01e-09	0.8	0.31	Body mass index;	chr9:33785113	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.554	rs55917897	ENSG00000281128.1	PTENP1-AS	7.15	3.38e-12	1.01e-09	0.8	0.31	Body mass index;	chr9:33795952	chr9:33677268~33688011:+
THCA	cis	rs10899021	1	rs61900636	ENSG00000279353.1	RP11-864N7.4	7.15	3.39e-12	1.01e-09	0.63	0.31	Response to metformin (IC50);	chr11:74648546	chr11:74698231~74699658:-
THCA	cis	rs3806843	0.676	rs1583005	ENSG00000202515.1	VTRNA1-3	7.15	3.39e-12	1.01e-09	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140651952	chr5:140726158~140726246:+
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000228409.4	CCT6P1	-7.15	3.39e-12	1.01e-09	-0.23	-0.31	Calcium levels;	chr7:65751755	chr7:65751142~65763354:+
THCA	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-7.15	3.4e-12	1.01e-09	-0.34	-0.31	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
THCA	cis	rs7044106	0.708	rs2416760	ENSG00000238181.2	AHCYP2	-7.15	3.4e-12	1.01e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120720673~120721972:+
THCA	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	7.15	3.4e-12	1.01e-09	0.61	0.31	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
THCA	cis	rs6840258	0.941	rs7665282	ENSG00000251411.1	RP11-397E7.4	-7.15	3.41e-12	1.01e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86979698	chr4:86913266~86914817:-
THCA	cis	rs6840258	1	rs56201818	ENSG00000251411.1	RP11-397E7.4	-7.15	3.41e-12	1.01e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031481	chr4:86913266~86914817:-
THCA	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	7.15	3.41e-12	1.01e-09	0.43	0.31	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
THCA	cis	rs2439831	0.717	rs2470132	ENSG00000275601.1	AC011330.13	-7.15	3.41e-12	1.01e-09	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43543283	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2251844	ENSG00000275601.1	AC011330.13	-7.15	3.41e-12	1.01e-09	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43544280	chr15:43642389~43643023:-
THCA	cis	rs7851660	0.874	rs1955145	ENSG00000236130.1	PTCSC2	7.15	3.41e-12	1.01e-09	0.25	0.31	Strep throat;	chr9:97872469	chr9:97805935~97810008:-
THCA	cis	rs853679	0.517	rs9393887	ENSG00000272009.1	RP1-313I6.12	-7.15	3.42e-12	1.02e-09	-0.37	-0.31	Depression;	chr6:28091242	chr6:28078792~28081130:-
THCA	cis	rs2880765	0.835	rs56406982	ENSG00000259295.5	CSPG4P12	7.15	3.42e-12	1.02e-09	0.39	0.31	Coronary artery disease;	chr15:85493148	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.835	rs900573	ENSG00000259295.5	CSPG4P12	-7.15	3.42e-12	1.02e-09	-0.39	-0.31	Coronary artery disease;	chr15:85494762	chr15:85191438~85213905:+
THCA	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	7.15	3.42e-12	1.02e-09	0.38	0.31	Height;	chr6:109415411	chr6:109382795~109383666:+
THCA	cis	rs74233809	1	rs35125602	ENSG00000213277.3	MARCKSL1P1	7.15	3.43e-12	1.02e-09	0.51	0.31	Birth weight;	chr10:102896282	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191453	ENSG00000213277.3	MARCKSL1P1	7.15	3.43e-12	1.02e-09	0.51	0.31	Birth weight;	chr10:102900095	chr10:103175554~103176094:+
THCA	cis	rs7688540	0.8	rs61792060	ENSG00000211553.1	AC253576.2	-7.15	3.43e-12	1.02e-09	-0.43	-0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:136461~136568:+
THCA	cis	rs9318086	0.534	rs10507334	ENSG00000205861.10	C1QTNF9B-AS1	7.15	3.43e-12	1.02e-09	0.37	0.31	Myopia (pathological);	chr13:23795648	chr13:23888889~23897263:+
THCA	cis	rs2688608	0.618	rs28553894	ENSG00000271816.1	BMS1P4	7.15	3.45e-12	1.02e-09	0.32	0.31	Inflammatory bowel disease;	chr10:73730085	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.618	rs28718766	ENSG00000271816.1	BMS1P4	7.15	3.45e-12	1.02e-09	0.32	0.31	Inflammatory bowel disease;	chr10:73730086	chr10:73699151~73730487:-
THCA	cis	rs7942368	0.887	rs10899282	ENSG00000254632.1	RP11-21L23.4	7.15	3.45e-12	1.02e-09	0.45	0.31	Endometriosis;	chr11:76793654	chr11:76759916~76768223:-
THCA	cis	rs6539288	0.899	rs7956807	ENSG00000260329.1	RP11-412D9.4	-7.15	3.45e-12	1.03e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106906748	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.899	rs7298423	ENSG00000260329.1	RP11-412D9.4	-7.15	3.45e-12	1.03e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106908202	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.933	rs1037011	ENSG00000260329.1	RP11-412D9.4	-7.15	3.45e-12	1.03e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106909000	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.933	rs4964497	ENSG00000260329.1	RP11-412D9.4	-7.15	3.45e-12	1.03e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106910711	chr12:106954029~106955497:-
THCA	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-7.14	3.45e-12	1.03e-09	-0.38	-0.31	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
THCA	cis	rs6061231	0.755	rs11699160	ENSG00000275437.1	RP5-908M14.10	7.14	3.46e-12	1.03e-09	0.28	0.31	Colorectal cancer;	chr20:62383595	chr20:62402236~62405935:-
THCA	cis	rs4072705	0.967	rs2148787	ENSG00000224020.1	MIR181A2HG	-7.14	3.46e-12	1.03e-09	-0.28	-0.31	Menarche (age at onset);	chr9:124705925	chr9:124658467~124698631:+
THCA	cis	rs7131987	0.903	rs6487796	ENSG00000257176.2	RP11-996F15.2	-7.14	3.46e-12	1.03e-09	-0.31	-0.31	QT interval;	chr12:29269831	chr12:29280418~29317848:-
THCA	cis	rs12681366	0.762	rs10109060	ENSG00000253704.1	RP11-267M23.4	7.14	3.46e-12	1.03e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94365140	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.762	rs1598713	ENSG00000253704.1	RP11-267M23.4	7.14	3.46e-12	1.03e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94369061	chr8:94553722~94569745:+
THCA	cis	rs6539288	0.866	rs6539286	ENSG00000260329.1	RP11-412D9.4	-7.14	3.47e-12	1.03e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106903845	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.899	rs6539287	ENSG00000260329.1	RP11-412D9.4	-7.14	3.47e-12	1.03e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106903872	chr12:106954029~106955497:-
THCA	cis	rs3806843	0.771	rs801174	ENSG00000202515.1	VTRNA1-3	7.14	3.47e-12	1.03e-09	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140733127	chr5:140726158~140726246:+
THCA	cis	rs832187	0.704	rs704364	ENSG00000280620.1	SCAANT1	-7.14	3.48e-12	1.03e-09	-0.42	-0.31	Schizophrenia;	chr3:63889058	chr3:63911518~63911772:-
THCA	cis	rs7246657	0.943	rs28373708	ENSG00000226686.6	LINC01535	-7.14	3.48e-12	1.03e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37485757	chr19:37251912~37265535:+
THCA	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	7.14	3.49e-12	1.04e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	7.14	3.49e-12	1.04e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	7.14	3.49e-12	1.04e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
THCA	cis	rs1850744	1	rs1519095	ENSG00000250942.1	ENPP7P11	7.14	3.49e-12	1.04e-09	0.45	0.31	Economic and political preferences;	chr4:9809307	chr4:9677308~9677934:+
THCA	cis	rs12594515	1	rs7162201	ENSG00000259200.1	RP11-718O11.1	-7.14	3.49e-12	1.04e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45700460	chr15:45705078~45931069:+
THCA	cis	rs6539288	0.677	rs10778515	ENSG00000260329.1	RP11-412D9.4	-7.14	3.5e-12	1.04e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106938703	chr12:106954029~106955497:-
THCA	cis	rs2439831	0.867	rs486301	ENSG00000275601.1	AC011330.13	-7.14	3.5e-12	1.04e-09	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43544751	chr15:43642389~43643023:-
THCA	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	7.14	3.51e-12	1.04e-09	0.25	0.31	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
THCA	cis	rs17684571	0.938	rs35619924	ENSG00000231441.1	RP11-472M19.2	7.14	3.51e-12	1.04e-09	0.4	0.31	Schizophrenia;	chr6:56695868	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.938	rs10498811	ENSG00000231441.1	RP11-472M19.2	7.14	3.51e-12	1.04e-09	0.4	0.31	Schizophrenia;	chr6:56696475	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.938	rs13196211	ENSG00000231441.1	RP11-472M19.2	7.14	3.51e-12	1.04e-09	0.4	0.31	Schizophrenia;	chr6:56697697	chr6:56844002~56864078:+
THCA	cis	rs17684571	1	rs5024547	ENSG00000231441.1	RP11-472M19.2	7.14	3.51e-12	1.04e-09	0.4	0.31	Schizophrenia;	chr6:56698295	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.938	rs13206849	ENSG00000231441.1	RP11-472M19.2	7.14	3.51e-12	1.04e-09	0.4	0.31	Schizophrenia;	chr6:56701823	chr6:56844002~56864078:+
THCA	cis	rs990871	1	rs2012697	ENSG00000227207.2	RPL31P12	-7.14	3.52e-12	1.04e-09	-0.38	-0.31	Subcutaneous adipose tissue;	chr1:72353929	chr1:72301472~72301829:+
THCA	cis	rs74233809	1	rs11191531	ENSG00000213277.3	MARCKSL1P1	7.14	3.52e-12	1.04e-09	0.52	0.31	Birth weight;	chr10:103047141	chr10:103175554~103176094:+
THCA	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	7.14	3.52e-12	1.04e-09	0.34	0.31	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
THCA	cis	rs848490	0.855	rs67745553	ENSG00000214293.7	APTR	7.14	3.52e-12	1.05e-09	0.25	0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77674781	chr7:77657660~77696265:-
THCA	cis	rs12594515	1	rs8032835	ENSG00000259200.1	RP11-718O11.1	-7.14	3.52e-12	1.05e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45705699	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs8033148	ENSG00000259200.1	RP11-718O11.1	-7.14	3.52e-12	1.05e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45705731	chr15:45705078~45931069:+
THCA	cis	rs7811142	1	rs66632384	ENSG00000078319.8	PMS2P1	-7.14	3.52e-12	1.05e-09	-0.44	-0.31	Platelet count;	chr7:100421281	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs67163493	ENSG00000078319.8	PMS2P1	-7.14	3.52e-12	1.05e-09	-0.44	-0.31	Platelet count;	chr7:100426215	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.943	rs73403312	ENSG00000078319.8	PMS2P1	-7.14	3.52e-12	1.05e-09	-0.44	-0.31	Platelet count;	chr7:100426530	chr7:100320992~100341908:-
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000263603.1	CTD-2349P21.5	-7.14	3.53e-12	1.05e-09	-0.53	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30729469~30731202:+
THCA	cis	rs2522056	1	rs2522050	ENSG00000233006.5	AC034220.3	-7.14	3.53e-12	1.05e-09	-0.27	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132460917	chr5:132311285~132369916:-
THCA	cis	rs4820539	0.966	rs2267001	ENSG00000221069.1	AC000029.1	-7.14	3.53e-12	1.05e-09	-0.37	-0.31	Bone mineral density;	chr22:23114509	chr22:23136620~23136710:+
THCA	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-7.14	3.54e-12	1.05e-09	-0.39	-0.31	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
THCA	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-7.14	3.54e-12	1.05e-09	-0.38	-0.31	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
THCA	cis	rs9902453	0.817	rs2321333	ENSG00000264007.1	RP11-68I3.10	7.14	3.54e-12	1.05e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29813839	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2250320	ENSG00000264007.1	RP11-68I3.10	-7.14	3.54e-12	1.05e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29801639	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2467334	ENSG00000264007.1	RP11-68I3.10	-7.14	3.54e-12	1.05e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29808490	chr17:29621617~29622254:-
THCA	cis	rs7246657	0.943	rs4803229	ENSG00000226686.6	LINC01535	-7.14	3.55e-12	1.05e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37373780	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs1559229	ENSG00000226686.6	LINC01535	-7.14	3.55e-12	1.05e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37385295	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.882	rs6508719	ENSG00000226686.6	LINC01535	-7.14	3.55e-12	1.05e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37386517	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs4452075	ENSG00000226686.6	LINC01535	-7.14	3.55e-12	1.05e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37388687	chr19:37251912~37265535:+
THCA	cis	rs2880765	0.835	rs4842887	ENSG00000259295.5	CSPG4P12	7.14	3.56e-12	1.06e-09	0.39	0.31	Coronary artery disease;	chr15:85492579	chr15:85191438~85213905:+
THCA	cis	rs4713118	0.539	rs510987	ENSG00000219392.1	RP1-265C24.5	-7.14	3.56e-12	1.06e-09	-0.39	-0.31	Parkinson's disease;	chr6:27879739	chr6:28115628~28116551:+
THCA	cis	rs41307935	0.73	rs12753968	ENSG00000260063.1	RP5-968P14.2	-7.14	3.57e-12	1.06e-09	-0.61	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26870872	chr1:26692132~26694131:-
THCA	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-7.14	3.57e-12	1.06e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
THCA	cis	rs2976388	0.967	rs2976397	ENSG00000253741.1	CTD-2292P10.4	7.14	3.57e-12	1.06e-09	0.39	0.31	Urinary tract infection frequency;	chr8:142683195	chr8:142702252~142726973:-
THCA	cis	rs10971721	0.643	rs12378415	ENSG00000281128.1	PTENP1-AS	7.14	3.58e-12	1.06e-09	0.8	0.31	Body mass index;	chr9:33797335	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.643	rs41315997	ENSG00000281128.1	PTENP1-AS	7.14	3.58e-12	1.06e-09	0.8	0.31	Body mass index;	chr9:33798840	chr9:33677268~33688011:+
THCA	cis	rs6723108	0.603	rs1947112	ENSG00000224043.6	CCNT2-AS1	-7.14	3.58e-12	1.06e-09	-0.33	-0.31	Type 2 diabetes;	chr2:134958387	chr2:134735464~134918710:-
THCA	cis	rs6539288	0.933	rs6539289	ENSG00000260329.1	RP11-412D9.4	7.14	3.59e-12	1.07e-09	0.28	0.31	Total body bone mineral density;	chr12:106915538	chr12:106954029~106955497:-
THCA	cis	rs4664293	1	rs6745766	ENSG00000226266.5	AC009961.3	-7.14	3.59e-12	1.07e-09	-0.36	-0.31	Monocyte percentage of white cells;	chr2:159598284	chr2:159670708~159712435:-
THCA	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-7.14	3.6e-12	1.07e-09	-0.38	-0.31	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
THCA	cis	rs1198430	0.683	rs1198440	ENSG00000232482.2	RP4-654C18.1	-7.14	3.61e-12	1.07e-09	-0.49	-0.31	Total cholesterol levels;	chr1:23454368	chr1:23410832~23412146:+
THCA	cis	rs9813712	0.571	rs9866568	ENSG00000228252.7	COL6A4P2	-7.14	3.62e-12	1.07e-09	-0.32	-0.31	Response to amphetamines;	chr3:130297539	chr3:130212823~130273806:+
THCA	cis	rs9341808	0.754	rs6916405	ENSG00000272129.1	RP11-250B2.6	7.14	3.62e-12	1.07e-09	0.39	0.31	Sitting height ratio;	chr6:80314471	chr6:80355424~80356859:+
THCA	cis	rs9813712	0.595	rs1453239	ENSG00000228252.7	COL6A4P2	-7.14	3.62e-12	1.07e-09	-0.31	-0.31	Response to amphetamines;	chr3:130288915	chr3:130212823~130273806:+
THCA	cis	rs9287719	0.649	rs6721857	ENSG00000243819.4	RN7SL832P	-7.14	3.62e-12	1.07e-09	-0.25	-0.31	Prostate cancer;	chr2:10581084	chr2:10690344~10692099:+
THCA	cis	rs7267979	1	rs7267979	ENSG00000274414.1	RP5-965G21.4	-7.14	3.64e-12	1.08e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25239007~25245229:-
THCA	cis	rs3822625	0.541	rs76679228	ENSG00000271828.1	CTD-2310F14.1	7.14	3.64e-12	1.08e-09	0.72	0.31	Breast cancer (early onset);	chr5:56903684	chr5:56927874~56929573:+
THCA	cis	rs240993	0.812	rs6942129	ENSG00000230177.1	RP5-1112D6.4	-7.14	3.64e-12	1.08e-09	-0.32	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111442417	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs9487644	ENSG00000230177.1	RP5-1112D6.4	-7.14	3.64e-12	1.08e-09	-0.32	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111443064	chr6:111277932~111278742:+
THCA	cis	rs240993	0.761	rs9487645	ENSG00000230177.1	RP5-1112D6.4	-7.14	3.64e-12	1.08e-09	-0.32	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111443065	chr6:111277932~111278742:+
THCA	cis	rs7015630	0.657	rs2338882	ENSG00000251136.7	RP11-37B2.1	-7.14	3.64e-12	1.08e-09	-0.34	-0.31	Inflammatory bowel disease;Crohn's disease;	chr8:89809970	chr8:89609409~89757727:-
THCA	cis	rs2880765	0.835	rs730372	ENSG00000259295.5	CSPG4P12	-7.14	3.65e-12	1.08e-09	-0.39	-0.31	Coronary artery disease;	chr15:85494962	chr15:85191438~85213905:+
THCA	cis	rs9902453	0.868	rs7212162	ENSG00000264007.1	RP11-68I3.10	7.14	3.65e-12	1.08e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29994310	chr17:29621617~29622254:-
THCA	cis	rs72772090	0.539	rs72773986	ENSG00000248734.2	CTD-2260A17.1	-7.14	3.65e-12	1.08e-09	-0.49	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96824014	chr5:96784777~96785999:+
THCA	cis	rs6745190	0.953	rs6704750	ENSG00000236153.1	AC104076.3	7.14	3.66e-12	1.08e-09	0.37	0.31	White blood cell count;	chr2:180964847	chr2:180979427~180980090:-
THCA	cis	rs6539288	0.933	rs2053205	ENSG00000260329.1	RP11-412D9.4	-7.14	3.66e-12	1.08e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106912489	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.933	rs759605	ENSG00000260329.1	RP11-412D9.4	-7.14	3.66e-12	1.08e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106913401	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.933	rs759604	ENSG00000260329.1	RP11-412D9.4	-7.14	3.66e-12	1.08e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106913518	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.899	rs759603	ENSG00000260329.1	RP11-412D9.4	-7.14	3.66e-12	1.08e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106913613	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.933	rs2075289	ENSG00000260329.1	RP11-412D9.4	-7.14	3.66e-12	1.08e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106913860	chr12:106954029~106955497:-
THCA	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-7.14	3.66e-12	1.08e-09	-0.3	-0.31	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
THCA	cis	rs6539288	0.677	rs11113144	ENSG00000260329.1	RP11-412D9.4	-7.14	3.66e-12	1.08e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106929644	chr12:106954029~106955497:-
THCA	cis	rs7044106	0.791	rs2416799	ENSG00000238181.2	AHCYP2	-7.14	3.67e-12	1.09e-09	-0.41	-0.31	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120720673~120721972:+
THCA	cis	rs8012947	1	rs1957038	ENSG00000279636.2	LINC00216	-7.14	3.67e-12	1.09e-09	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58299899	chr14:58288033~58289158:+
THCA	cis	rs651907	0.557	rs34181125	ENSG00000256628.3	ZBTB11-AS1	7.14	3.67e-12	1.09e-09	0.37	0.31	Colorectal cancer;	chr3:101771434	chr3:101676475~101679217:+
THCA	cis	rs728616	0.558	rs61859793	ENSG00000242600.5	MBL1P	7.14	3.68e-12	1.09e-09	0.4	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927007	chr10:79904898~79950336:+
THCA	cis	rs801193	0.548	rs2109297	ENSG00000232559.3	GS1-124K5.12	-7.14	3.68e-12	1.09e-09	-0.3	-0.31	Aortic root size;	chr7:66657397	chr7:66554588~66576923:-
THCA	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	7.13	3.69e-12	1.09e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
THCA	cis	rs7208859	0.623	rs609063	ENSG00000263603.1	CTD-2349P21.5	-7.13	3.69e-12	1.09e-09	-0.55	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs383436	ENSG00000263603.1	CTD-2349P21.5	-7.13	3.69e-12	1.09e-09	-0.55	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000263603.1	CTD-2349P21.5	-7.13	3.69e-12	1.09e-09	-0.55	-0.31	Body mass index;	chr17:30641132	chr17:30729469~30731202:+
THCA	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	7.13	3.7e-12	1.09e-09	0.39	0.31	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	7.13	3.7e-12	1.09e-09	0.39	0.31	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
THCA	cis	rs1949733	0.877	rs940133	ENSG00000205959.3	RP11-689P11.2	-7.13	3.7e-12	1.09e-09	-0.27	-0.31	Response to antineoplastic agents;	chr4:8471887	chr4:8482270~8512610:+
THCA	cis	rs9318086	0.534	rs1011362	ENSG00000205861.10	C1QTNF9B-AS1	-7.13	3.71e-12	1.1e-09	-0.36	-0.31	Myopia (pathological);	chr13:23803018	chr13:23888889~23897263:+
THCA	cis	rs4664293	0.802	rs7563417	ENSG00000226266.5	AC009961.3	-7.13	3.72e-12	1.1e-09	-0.38	-0.31	Monocyte percentage of white cells;	chr2:159727762	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs13022404	ENSG00000226266.5	AC009961.3	-7.13	3.72e-12	1.1e-09	-0.38	-0.31	Monocyte percentage of white cells;	chr2:159732981	chr2:159670708~159712435:-
THCA	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-7.13	3.72e-12	1.1e-09	-0.3	-0.31	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
THCA	cis	rs467650	0.549	rs720859	ENSG00000246763.5	RGMB-AS1	-7.13	3.72e-12	1.1e-09	-0.29	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr5:98659713	chr5:98769618~98773469:-
THCA	cis	rs651907	0.557	rs11710533	ENSG00000256628.3	ZBTB11-AS1	7.13	3.72e-12	1.1e-09	0.37	0.31	Colorectal cancer;	chr3:101632628	chr3:101676475~101679217:+
THCA	cis	rs10050311	0.858	rs76283582	ENSG00000251411.1	RP11-397E7.4	-7.13	3.72e-12	1.1e-09	-0.39	-0.31	Insulin-related traits;	chr4:86878202	chr4:86913266~86914817:-
THCA	cis	rs4820539	1	rs4822360	ENSG00000221069.1	AC000029.1	-7.13	3.72e-12	1.1e-09	-0.36	-0.31	Bone mineral density;	chr22:23140273	chr22:23136620~23136710:+
THCA	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	7.13	3.72e-12	1.1e-09	0.38	0.31	Height;	chr6:109478720	chr6:109382795~109383666:+
THCA	cis	rs651907	0.535	rs11714444	ENSG00000256628.3	ZBTB11-AS1	7.13	3.73e-12	1.1e-09	0.37	0.31	Colorectal cancer;	chr3:101794838	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs12631513	ENSG00000256628.3	ZBTB11-AS1	7.13	3.73e-12	1.1e-09	0.37	0.31	Colorectal cancer;	chr3:101798632	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs13094911	ENSG00000256628.3	ZBTB11-AS1	7.13	3.73e-12	1.1e-09	0.37	0.31	Colorectal cancer;	chr3:101800177	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs11712309	ENSG00000256628.3	ZBTB11-AS1	7.13	3.73e-12	1.1e-09	0.37	0.31	Colorectal cancer;	chr3:101800253	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs35799195	ENSG00000256628.3	ZBTB11-AS1	7.13	3.73e-12	1.1e-09	0.37	0.31	Colorectal cancer;	chr3:101803083	chr3:101676475~101679217:+
THCA	cis	rs5006884	0.568	rs12803469	ENSG00000167355.6	AC104389.28	-7.13	3.74e-12	1.11e-09	-0.4	-0.31	Fetal hemoglobin levels;	chr11:5361553	chr11:5304976~5505652:-
THCA	cis	rs9473147	0.503	rs2171086	ENSG00000270761.1	RP11-385F7.1	-7.13	3.74e-12	1.11e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47622368	chr6:47477243~47477572:-
THCA	cis	rs947583	0.545	rs9494364	ENSG00000231028.7	LINC00271	-7.13	3.74e-12	1.11e-09	-0.26	-0.31	Phosphorus levels;	chr6:135759549	chr6:135497801~135716055:+
THCA	cis	rs2712184	0.683	rs2541403	ENSG00000229352.1	AC007563.3	7.13	3.74e-12	1.11e-09	0.38	0.31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216773162	chr2:216799608~216805335:+
THCA	cis	rs9467773	0.869	rs742090	ENSG00000124549.13	BTN2A3P	-7.13	3.74e-12	1.11e-09	-0.29	-0.31	Intelligence (multi-trait analysis);	chr6:26415409	chr6:26421391~26432383:+
THCA	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	7.13	3.75e-12	1.11e-09	0.37	0.31	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
THCA	cis	rs1150668	0.796	rs213237	ENSG00000219392.1	RP1-265C24.5	-7.13	3.75e-12	1.11e-09	-0.34	-0.31	Pubertal anthropometrics;	chr6:28356161	chr6:28115628~28116551:+
THCA	cis	rs12594515	0.967	rs11070465	ENSG00000259200.1	RP11-718O11.1	-7.13	3.76e-12	1.11e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45692701	chr15:45705078~45931069:+
THCA	cis	rs801193	0.569	rs7782587	ENSG00000232559.3	GS1-124K5.12	7.13	3.76e-12	1.11e-09	0.3	0.31	Aortic root size;	chr7:66701485	chr7:66554588~66576923:-
THCA	cis	rs4713118	0.868	rs2893928	ENSG00000280107.1	AL022393.9	-7.13	3.76e-12	1.11e-09	-0.39	-0.31	Parkinson's disease;	chr6:27770651	chr6:28170845~28172521:+
THCA	cis	rs516805	0.667	rs9320856	ENSG00000279453.1	RP3-425C14.4	-7.13	3.76e-12	1.11e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122219888	chr6:122436789~122439223:-
THCA	cis	rs7246657	0.943	rs8111782	ENSG00000226686.6	LINC01535	-7.13	3.76e-12	1.11e-09	-0.47	-0.31	Coronary artery calcification;	chr19:37377002	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10404920	ENSG00000226686.6	LINC01535	-7.13	3.76e-12	1.11e-09	-0.47	-0.31	Coronary artery calcification;	chr19:37390654	chr19:37251912~37265535:+
THCA	cis	rs74233809	1	rs12219304	ENSG00000213277.3	MARCKSL1P1	7.13	3.77e-12	1.11e-09	0.52	0.31	Birth weight;	chr10:103171827	chr10:103175554~103176094:+
THCA	cis	rs651907	0.557	rs34376498	ENSG00000256628.3	ZBTB11-AS1	7.13	3.77e-12	1.11e-09	0.37	0.31	Colorectal cancer;	chr3:101761312	chr3:101676475~101679217:+
THCA	cis	rs728616	0.558	rs723192	ENSG00000225484.5	NUTM2B-AS1	-7.13	3.77e-12	1.12e-09	-0.45	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948257	chr10:79663088~79826594:-
THCA	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-7.13	3.78e-12	1.12e-09	-0.31	-0.31	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
THCA	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	7.13	3.78e-12	1.12e-09	0.39	0.31	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	7.13	3.78e-12	1.12e-09	0.39	0.31	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	7.13	3.78e-12	1.12e-09	0.39	0.31	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	7.13	3.78e-12	1.12e-09	0.39	0.31	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
THCA	cis	rs7044106	0.762	rs10984972	ENSG00000238181.2	AHCYP2	-7.13	3.78e-12	1.12e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120720673~120721972:+
THCA	cis	rs1426063	1	rs28515115	ENSG00000260265.1	RP11-44F21.5	7.13	3.79e-12	1.12e-09	0.55	0.31	QT interval;	chr4:75101904	chr4:75081702~75084717:-
THCA	cis	rs1426063	1	rs10026801	ENSG00000260265.1	RP11-44F21.5	7.13	3.79e-12	1.12e-09	0.55	0.31	QT interval;	chr4:75103167	chr4:75081702~75084717:-
THCA	cis	rs6866614	0.608	rs17132288	ENSG00000237714.1	P4HA2-AS1	7.13	3.79e-12	1.12e-09	0.41	0.31	Perceived unattractiveness to mosquitoes;	chr5:132000412	chr5:132184876~132192808:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-7.13	3.81e-12	1.12e-09	-0.4	-0.31	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
THCA	cis	rs736801	0.704	rs56399423	ENSG00000233006.5	AC034220.3	7.13	3.81e-12	1.13e-09	0.25	0.31	Mosquito bite size;Breast cancer;	chr5:132336964	chr5:132311285~132369916:-
THCA	cis	rs9473147	0.516	rs9395279	ENSG00000270761.1	RP11-385F7.1	-7.13	3.81e-12	1.13e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47575128	chr6:47477243~47477572:-
THCA	cis	rs4073416	0.679	rs11622829	ENSG00000276116.2	FUT8-AS1	7.13	3.83e-12	1.13e-09	0.32	0.31	N-glycan levels;	chr14:65725064	chr14:65411170~65412690:-
THCA	cis	rs9902453	0.817	rs9909128	ENSG00000264007.1	RP11-68I3.10	7.13	3.83e-12	1.13e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29834464	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs12601647	ENSG00000264007.1	RP11-68I3.10	7.13	3.83e-12	1.13e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29837935	chr17:29621617~29622254:-
THCA	cis	rs17684571	0.938	rs35668437	ENSG00000231441.1	RP11-472M19.2	7.13	3.83e-12	1.13e-09	0.4	0.31	Schizophrenia;	chr6:56701058	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.938	rs17684511	ENSG00000231441.1	RP11-472M19.2	7.13	3.83e-12	1.13e-09	0.4	0.31	Schizophrenia;	chr6:56701217	chr6:56844002~56864078:+
THCA	cis	rs7044106	0.69	rs10739569	ENSG00000238181.2	AHCYP2	-7.13	3.83e-12	1.13e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120720673~120721972:+
THCA	cis	rs9543976	0.688	rs56084319	ENSG00000261553.4	RP11-29G8.3	-7.13	3.83e-12	1.13e-09	-0.48	-0.31	Diabetic retinopathy;	chr13:75536543	chr13:75549773~75807120:+
THCA	cis	rs3812049	0.784	rs2250127	ENSG00000245937.6	LINC01184	-7.13	3.83e-12	1.13e-09	-0.36	-0.31	Lymphocyte counts;Red cell distribution width;	chr5:128053152	chr5:127940426~128083172:-
THCA	cis	rs9813712	0.595	rs1453240	ENSG00000228252.7	COL6A4P2	-7.13	3.84e-12	1.14e-09	-0.31	-0.31	Response to amphetamines;	chr3:130282849	chr3:130212823~130273806:+
THCA	cis	rs9902453	1	rs9902453	ENSG00000264007.1	RP11-68I3.10	-7.13	3.85e-12	1.14e-09	-0.36	-0.31	Coffee consumption (cups per day);	chr17:30022077	chr17:29621617~29622254:-
THCA	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-7.13	3.85e-12	1.14e-09	-0.34	-0.31	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
THCA	cis	rs42490	0.528	rs2840206	ENSG00000251136.7	RP11-37B2.1	7.13	3.85e-12	1.14e-09	0.26	0.31	Leprosy;	chr8:89670184	chr8:89609409~89757727:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000220721.1	OR1F12	7.13	3.86e-12	1.14e-09	0.43	0.31	Depression;	chr6:28151096	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000220721.1	OR1F12	7.13	3.86e-12	1.14e-09	0.43	0.31	Depression;	chr6:28152885	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000220721.1	OR1F12	7.13	3.86e-12	1.14e-09	0.43	0.31	Depression;	chr6:28153120	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000220721.1	OR1F12	7.13	3.86e-12	1.14e-09	0.43	0.31	Depression;	chr6:28161802	chr6:28073316~28074233:+
THCA	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-7.13	3.86e-12	1.14e-09	-0.41	-0.31	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
THCA	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	7.13	3.86e-12	1.14e-09	0.55	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-7.13	3.86e-12	1.14e-09	-0.4	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
THCA	cis	rs71636778	0.509	rs56139710	ENSG00000260063.1	RP5-968P14.2	-7.13	3.87e-12	1.14e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26943297	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs11807824	ENSG00000260063.1	RP5-968P14.2	-7.13	3.87e-12	1.14e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26943847	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34473788	ENSG00000260063.1	RP5-968P14.2	-7.13	3.87e-12	1.14e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26945028	chr1:26692132~26694131:-
THCA	cis	rs1322639	0.592	rs7743597	ENSG00000261039.2	RP11-417E7.2	-7.13	3.88e-12	1.14e-09	-0.34	-0.31	Pulse pressure;	chr6:169191583	chr6:169175304~169182740:-
THCA	cis	rs12681366	0.734	rs2291439	ENSG00000253704.1	RP11-267M23.4	7.13	3.88e-12	1.15e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94407470	chr8:94553722~94569745:+
THCA	cis	rs875971	0.862	rs6460302	ENSG00000232559.3	GS1-124K5.12	7.13	3.88e-12	1.15e-09	0.3	0.31	Aortic root size;	chr7:66495270	chr7:66554588~66576923:-
THCA	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	7.13	3.88e-12	1.15e-09	0.43	0.31	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
THCA	cis	rs4950322	0.542	rs56080828	ENSG00000237188.3	RP11-337C18.8	7.13	3.89e-12	1.15e-09	0.39	0.31	Protein quantitative trait loci;	chr1:147183447	chr1:147172771~147211568:+
THCA	cis	rs453301	0.631	rs4840376	ENSG00000253893.2	FAM85B	7.13	3.89e-12	1.15e-09	0.43	0.31	Joint mobility (Beighton score);	chr8:8944591	chr8:8167819~8226614:-
THCA	cis	rs2439831	0.85	rs28509275	ENSG00000249839.1	AC011330.5	-7.13	3.89e-12	1.15e-09	-0.56	-0.31	Lung cancer in ever smokers;	chr15:43805907	chr15:43663654~43684339:-
THCA	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-7.13	3.89e-12	1.15e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-7.13	3.89e-12	1.15e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
THCA	cis	rs4073416	0.684	rs4581615	ENSG00000276116.2	FUT8-AS1	7.13	3.89e-12	1.15e-09	0.32	0.31	N-glycan levels;	chr14:65589225	chr14:65411170~65412690:-
THCA	cis	rs853679	0.517	rs9468298	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28154567	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28156691	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28158424	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28159056	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28159925	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28159932	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28162053	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28163375	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28163759	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28164580	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28164825	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28164948	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28165025	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28165528	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Parkinson's disease;	chr6:28165750	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Parkinson's disease;	chr6:28168578	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28169019	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28169249	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28169755	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28169791	chr6:28073316~28074233:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000220721.1	OR1F12	7.13	3.9e-12	1.15e-09	0.43	0.31	Depression;	chr6:28170075	chr6:28073316~28074233:+
THCA	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-7.13	3.9e-12	1.15e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
THCA	cis	rs990871	1	rs2568958	ENSG00000227207.2	RPL31P12	-7.13	3.9e-12	1.15e-09	-0.39	-0.31	Subcutaneous adipose tissue;	chr1:72299433	chr1:72301472~72301829:+
THCA	cis	rs7247513	0.93	rs34321000	ENSG00000213290.4	PGK1P2	-7.13	3.91e-12	1.15e-09	-0.38	-0.31	Bipolar disorder;	chr19:12602274	chr19:12559571~12561105:+
THCA	cis	rs12594515	1	rs12185095	ENSG00000259200.1	RP11-718O11.1	-7.13	3.92e-12	1.16e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45702437	chr15:45705078~45931069:+
THCA	cis	rs1198430	0.639	rs685059	ENSG00000232482.2	RP4-654C18.1	-7.13	3.92e-12	1.16e-09	-0.48	-0.31	Total cholesterol levels;	chr1:23456692	chr1:23410832~23412146:+
THCA	cis	rs7044106	0.708	rs959558	ENSG00000238181.2	AHCYP2	-7.13	3.92e-12	1.16e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120720673~120721972:+
THCA	cis	rs853679	0.517	rs6932109	ENSG00000272009.1	RP1-313I6.12	7.13	3.92e-12	1.16e-09	0.36	0.31	Depression;	chr6:28110525	chr6:28078792~28081130:-
THCA	cis	rs651907	0.535	rs11711903	ENSG00000256628.3	ZBTB11-AS1	7.13	3.93e-12	1.16e-09	0.37	0.31	Colorectal cancer;	chr3:101781904	chr3:101676475~101679217:+
THCA	cis	rs4073416	0.712	rs12586842	ENSG00000276116.2	FUT8-AS1	7.13	3.93e-12	1.16e-09	0.32	0.31	N-glycan levels;	chr14:65678304	chr14:65411170~65412690:-
THCA	cis	rs9400467	0.528	rs7752361	ENSG00000230177.1	RP5-1112D6.4	-7.13	3.93e-12	1.16e-09	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.811	rs7764591	ENSG00000230177.1	RP5-1112D6.4	-7.13	3.93e-12	1.16e-09	-0.25	-0.31	Metabolic traits;	chr6:111462211	chr6:111277932~111278742:+
THCA	cis	rs6840258	1	rs6840258	ENSG00000251411.1	RP11-397E7.4	-7.12	3.94e-12	1.16e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87052516	chr4:86913266~86914817:-
THCA	cis	rs3806843	0.676	rs2569159	ENSG00000202515.1	VTRNA1-3	7.12	3.94e-12	1.16e-09	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140651125	chr5:140726158~140726246:+
THCA	cis	rs9902453	0.817	rs1038089	ENSG00000264007.1	RP11-68I3.10	7.12	3.94e-12	1.16e-09	0.36	0.31	Coffee consumption (cups per day);	chr17:29851706	chr17:29621617~29622254:-
THCA	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	7.12	3.95e-12	1.16e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
THCA	cis	rs7246657	0.943	rs6508711	ENSG00000226686.6	LINC01535	-7.12	3.95e-12	1.16e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37324232	chr19:37251912~37265535:+
THCA	cis	rs11148252	0.51	rs35895576	ENSG00000235660.1	LINC00345	-7.12	3.95e-12	1.16e-09	-0.38	-0.31	Lewy body disease;	chr13:52010764	chr13:52484161~52484680:-
THCA	cis	rs7760535	0.831	rs62420437	ENSG00000230177.1	RP5-1112D6.4	-7.12	3.95e-12	1.17e-09	-0.25	-0.31	Metabolic traits;	chr6:111427577	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs4276544	ENSG00000230177.1	RP5-1112D6.4	-7.12	3.95e-12	1.17e-09	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs12211763	ENSG00000230177.1	RP5-1112D6.4	-7.12	3.95e-12	1.17e-09	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs10872067	ENSG00000230177.1	RP5-1112D6.4	-7.12	3.95e-12	1.17e-09	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs9689727	ENSG00000230177.1	RP5-1112D6.4	-7.12	3.95e-12	1.17e-09	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs12214380	ENSG00000230177.1	RP5-1112D6.4	-7.12	3.95e-12	1.17e-09	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs61269242	ENSG00000230177.1	RP5-1112D6.4	-7.12	3.95e-12	1.17e-09	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:111277932~111278742:+
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000272009.1	RP1-313I6.12	-7.12	3.95e-12	1.17e-09	-0.36	-0.31	Parkinson's disease;	chr6:28066257	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000272009.1	RP1-313I6.12	-7.12	3.95e-12	1.17e-09	-0.36	-0.31	Parkinson's disease;	chr6:28066263	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000272009.1	RP1-313I6.12	-7.12	3.95e-12	1.17e-09	-0.36	-0.31	Parkinson's disease;	chr6:28066343	chr6:28078792~28081130:-
THCA	cis	rs6928977	0.675	rs9399148	ENSG00000231028.7	LINC00271	7.12	3.96e-12	1.17e-09	0.26	0.31	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135497801~135716055:+
THCA	cis	rs10208649	1	rs6745729	ENSG00000272156.1	RP11-477N3.1	7.12	3.96e-12	1.17e-09	0.56	0.31	Body mass index;	chr2:53888676	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs13432387	ENSG00000272156.1	RP11-477N3.1	7.12	3.96e-12	1.17e-09	0.56	0.31	Body mass index;	chr2:53889150	chr2:54082554~54085066:+
THCA	cis	rs7246657	0.882	rs6508716	ENSG00000226686.6	LINC01535	-7.12	3.97e-12	1.17e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37328108	chr19:37251912~37265535:+
THCA	cis	rs6723108	0.603	rs1592	ENSG00000224043.6	CCNT2-AS1	-7.12	3.97e-12	1.17e-09	-0.33	-0.31	Type 2 diabetes;	chr2:134964573	chr2:134735464~134918710:-
THCA	cis	rs9341808	0.718	rs1324123	ENSG00000272129.1	RP11-250B2.6	7.12	3.98e-12	1.17e-09	0.39	0.31	Sitting height ratio;	chr6:80223177	chr6:80355424~80356859:+
THCA	cis	rs4835473	0.932	rs12509579	ENSG00000251600.4	RP11-673E1.1	-7.12	3.98e-12	1.17e-09	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143736821	chr4:143912331~143982454:+
THCA	cis	rs848490	0.889	rs11769259	ENSG00000214293.7	APTR	7.12	3.98e-12	1.17e-09	0.25	0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77666013	chr7:77657660~77696265:-
THCA	cis	rs7182621	0.639	rs35049216	ENSG00000182397.13	DNM1P46	7.12	3.98e-12	1.17e-09	0.43	0.31	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99790156~99806927:-
THCA	cis	rs77204473	1	rs2044426	ENSG00000254851.1	RP11-109L13.1	7.12	3.98e-12	1.17e-09	0.74	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116885467	chr11:117135528~117138582:+
THCA	cis	rs5006884	0.507	rs12802792	ENSG00000167355.6	AC104389.28	-7.12	3.99e-12	1.18e-09	-0.39	-0.31	Fetal hemoglobin levels;	chr11:5361541	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.507	rs17270517	ENSG00000167355.6	AC104389.28	-7.12	3.99e-12	1.18e-09	-0.39	-0.31	Fetal hemoglobin levels;	chr11:5361604	chr11:5304976~5505652:-
THCA	cis	rs9813712	0.571	rs9846596	ENSG00000228252.7	COL6A4P2	-7.12	4e-12	1.18e-09	-0.32	-0.31	Response to amphetamines;	chr3:130288318	chr3:130212823~130273806:+
THCA	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	7.12	4.01e-12	1.18e-09	0.39	0.31	Height;	chr6:109446728	chr6:109382795~109383666:+
THCA	cis	rs4835473	0.9	rs4054634	ENSG00000251600.4	RP11-673E1.1	-7.12	4.02e-12	1.19e-09	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143787045	chr4:143912331~143982454:+
THCA	cis	rs7246657	0.943	rs7253091	ENSG00000226686.6	LINC01535	-7.12	4.03e-12	1.19e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37476312	chr19:37251912~37265535:+
THCA	cis	rs4073416	0.712	rs1998036	ENSG00000276116.2	FUT8-AS1	7.12	4.04e-12	1.19e-09	0.32	0.31	N-glycan levels;	chr14:65671481	chr14:65411170~65412690:-
THCA	cis	rs516805	0.748	rs12211888	ENSG00000279453.1	RP3-425C14.4	7.12	4.04e-12	1.19e-09	0.31	0.31	Lymphocyte counts;	chr6:122384621	chr6:122436789~122439223:-
THCA	cis	rs853679	0.513	rs9468296	ENSG00000220721.1	OR1F12	7.12	4.05e-12	1.19e-09	0.43	0.31	Depression;	chr6:28145952	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000220721.1	OR1F12	7.12	4.05e-12	1.19e-09	0.43	0.31	Depression;	chr6:28147378	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000220721.1	OR1F12	7.12	4.05e-12	1.19e-09	0.43	0.31	Depression;	chr6:28147406	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000220721.1	OR1F12	7.12	4.05e-12	1.19e-09	0.43	0.31	Depression;	chr6:28148143	chr6:28073316~28074233:+
THCA	cis	rs853679	1	rs853694	ENSG00000219392.1	RP1-265C24.5	-7.12	4.05e-12	1.19e-09	-0.48	-0.31	Depression;	chr6:28311323	chr6:28115628~28116551:+
THCA	cis	rs7637701	0.818	rs10936038	ENSG00000240875.4	LINC00886	-7.12	4.05e-12	1.19e-09	-0.25	-0.31	Breast cancer;	chr3:156814877	chr3:156747346~156817062:-
THCA	cis	rs7637701	0.818	rs11711674	ENSG00000240875.4	LINC00886	-7.12	4.05e-12	1.19e-09	-0.25	-0.31	Breast cancer;	chr3:156815164	chr3:156747346~156817062:-
THCA	cis	rs7637701	0.818	rs1560415	ENSG00000240875.4	LINC00886	-7.12	4.05e-12	1.19e-09	-0.25	-0.31	Breast cancer;	chr3:156819569	chr3:156747346~156817062:-
THCA	cis	rs7637701	0.818	rs1560416	ENSG00000240875.4	LINC00886	-7.12	4.05e-12	1.19e-09	-0.25	-0.31	Breast cancer;	chr3:156819630	chr3:156747346~156817062:-
THCA	cis	rs7637701	0.818	rs9837271	ENSG00000240875.4	LINC00886	-7.12	4.05e-12	1.19e-09	-0.25	-0.31	Breast cancer;	chr3:156820949	chr3:156747346~156817062:-
THCA	cis	rs832187	0.615	rs2037119	ENSG00000280620.1	SCAANT1	7.12	4.05e-12	1.19e-09	0.43	0.31	Schizophrenia;	chr3:64009203	chr3:63911518~63911772:-
THCA	cis	rs7267979	1	rs7019	ENSG00000274414.1	RP5-965G21.4	-7.12	4.06e-12	1.19e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25239007~25245229:-
THCA	cis	rs4072705	0.9	rs4836993	ENSG00000224020.1	MIR181A2HG	-7.12	4.06e-12	1.2e-09	-0.28	-0.31	Menarche (age at onset);	chr9:124796091	chr9:124658467~124698631:+
THCA	cis	rs6539288	0.677	rs2216221	ENSG00000260329.1	RP11-412D9.4	-7.12	4.06e-12	1.2e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106933453	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.677	rs1348565	ENSG00000260329.1	RP11-412D9.4	-7.12	4.06e-12	1.2e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106935326	chr12:106954029~106955497:-
THCA	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	7.12	4.06e-12	1.2e-09	0.4	0.31	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	7.12	4.06e-12	1.2e-09	0.4	0.31	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
THCA	cis	rs3213758	0.588	rs12928335	ENSG00000275191.1	RP11-36I17.2	-7.12	4.07e-12	1.2e-09	-0.54	-0.31	Vitiligo (non-segmental);	chr16:53580834	chr16:53628256~53628816:-
THCA	cis	rs6723108	0.627	rs766270	ENSG00000224043.6	CCNT2-AS1	-7.12	4.07e-12	1.2e-09	-0.33	-0.31	Type 2 diabetes;	chr2:134909356	chr2:134735464~134918710:-
THCA	cis	rs9902453	0.715	rs2628176	ENSG00000264007.1	RP11-68I3.10	-7.12	4.08e-12	1.2e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29812274	chr17:29621617~29622254:-
THCA	cis	rs7942368	1	rs11236924	ENSG00000254632.1	RP11-21L23.4	7.12	4.09e-12	1.2e-09	0.47	0.31	Endometriosis;	chr11:76756303	chr11:76759916~76768223:-
THCA	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	7.12	4.09e-12	1.2e-09	0.42	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
THCA	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	7.12	4.1e-12	1.21e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
THCA	cis	rs9341808	0.754	rs978814	ENSG00000272129.1	RP11-250B2.6	7.12	4.1e-12	1.21e-09	0.4	0.31	Sitting height ratio;	chr6:80250195	chr6:80355424~80356859:+
THCA	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-7.12	4.11e-12	1.21e-09	-0.28	-0.31	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
THCA	cis	rs12681366	0.537	rs10956913	ENSG00000253704.1	RP11-267M23.4	7.12	4.11e-12	1.21e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94471459	chr8:94553722~94569745:+
THCA	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-7.12	4.11e-12	1.21e-09	-0.41	-0.31	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
THCA	cis	rs4266144	0.581	rs1806867	ENSG00000244515.1	KRT18P34	-7.12	4.11e-12	1.21e-09	-0.36	-0.31	Coronary artery disease;	chr3:157110513	chr3:157162663~157163932:-
THCA	cis	rs651907	0.557	rs62284199	ENSG00000256628.3	ZBTB11-AS1	7.12	4.11e-12	1.21e-09	0.37	0.31	Colorectal cancer;	chr3:101759687	chr3:101676475~101679217:+
THCA	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-7.12	4.11e-12	1.21e-09	-0.39	-0.31	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
THCA	cis	rs7246657	0.943	rs7252325	ENSG00000226686.6	LINC01535	-7.12	4.12e-12	1.21e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37439743	chr19:37251912~37265535:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000272009.1	RP1-313I6.12	-7.12	4.12e-12	1.21e-09	-0.37	-0.31	Depression;	chr6:28149979	chr6:28078792~28081130:-
THCA	cis	rs4073416	0.712	rs11627184	ENSG00000276116.2	FUT8-AS1	7.12	4.12e-12	1.21e-09	0.32	0.31	N-glycan levels;	chr14:65654725	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.684	rs11627185	ENSG00000276116.2	FUT8-AS1	7.12	4.12e-12	1.21e-09	0.32	0.31	N-glycan levels;	chr14:65654774	chr14:65411170~65412690:-
THCA	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	7.12	4.13e-12	1.21e-09	0.32	0.31	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
THCA	cis	rs10869777	0.875	rs35889208	ENSG00000234618.1	RPSAP9	-7.12	4.13e-12	1.22e-09	-0.33	-0.31	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76436756	chr9:76398699~76399586:+
THCA	cis	rs2976388	0.967	rs2585183	ENSG00000253741.1	CTD-2292P10.4	7.12	4.14e-12	1.22e-09	0.39	0.31	Urinary tract infection frequency;	chr8:142684641	chr8:142702252~142726973:-
THCA	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	7.12	4.15e-12	1.22e-09	0.25	0.31	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
THCA	cis	rs41307935	0.915	rs34696599	ENSG00000260063.1	RP5-968P14.2	-7.12	4.15e-12	1.22e-09	-0.62	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26877237	chr1:26692132~26694131:-
THCA	cis	rs516805	0.667	rs2606617	ENSG00000279453.1	RP3-425C14.4	-7.12	4.17e-12	1.23e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122182619	chr6:122436789~122439223:-
THCA	cis	rs860295	0.58	rs2016251	ENSG00000225855.5	RUSC1-AS1	7.12	4.17e-12	1.23e-09	0.21	0.31	Body mass index;	chr1:155945197	chr1:155316863~155324176:-
THCA	cis	rs7044106	0.708	rs1324472	ENSG00000238181.2	AHCYP2	-7.12	4.19e-12	1.23e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120720673~120721972:+
THCA	cis	rs987724	0.727	rs6776157	ENSG00000240875.4	LINC00886	-7.12	4.19e-12	1.23e-09	-0.25	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156825693	chr3:156747346~156817062:-
THCA	cis	rs2562456	0.755	rs2914646	ENSG00000213976.4	CTD-2561J22.2	7.12	4.19e-12	1.23e-09	0.34	0.31	Pain;	chr19:21454359	chr19:21382865~21387177:+
THCA	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-7.12	4.2e-12	1.23e-09	-0.43	-0.31	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
THCA	cis	rs848490	0.889	rs6960913	ENSG00000214293.7	APTR	7.12	4.2e-12	1.23e-09	0.24	0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77647943	chr7:77657660~77696265:-
THCA	cis	rs1850744	0.826	rs6858644	ENSG00000250942.1	ENPP7P11	7.11	4.2e-12	1.24e-09	0.42	0.31	Economic and political preferences;	chr4:9740057	chr4:9677308~9677934:+
THCA	cis	rs9549328	0.837	rs9549618	ENSG00000267868.1	RP11-120K24.3	7.11	4.21e-12	1.24e-09	0.32	0.31	Systolic blood pressure;	chr13:112974334	chr13:112964835~112966131:-
THCA	cis	rs736801	0.569	rs11748193	ENSG00000224431.1	AC063976.7	7.11	4.21e-12	1.24e-09	0.28	0.31	Mosquito bite size;Breast cancer;	chr5:132389637	chr5:132199456~132203487:+
THCA	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	7.11	4.21e-12	1.24e-09	0.36	0.31	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
THCA	cis	rs10208649	1	rs13402778	ENSG00000272156.1	RP11-477N3.1	7.11	4.21e-12	1.24e-09	0.58	0.31	Body mass index;	chr2:53900883	chr2:54082554~54085066:+
THCA	cis	rs8007846	0.539	rs67957534	ENSG00000276116.2	FUT8-AS1	7.11	4.21e-12	1.24e-09	0.32	0.31	Multiple sclerosis--Brain Glutamate Levels;	chr14:65657867	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs113075795	ENSG00000276116.2	FUT8-AS1	-7.11	4.21e-12	1.24e-09	-0.49	-0.31	Ischemic stroke;	chr14:65502237	chr14:65411170~65412690:-
THCA	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	7.11	4.21e-12	1.24e-09	0.4	0.31	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
THCA	cis	rs12701220	0.503	rs12702047	ENSG00000229043.2	AC091729.9	-7.11	4.23e-12	1.24e-09	-0.49	-0.31	Bronchopulmonary dysplasia;	chr7:1093084	chr7:1160374~1165267:+
THCA	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-7.11	4.23e-12	1.24e-09	-0.47	-0.31	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
THCA	cis	rs172166	0.561	rs149973	ENSG00000219392.1	RP1-265C24.5	-7.11	4.23e-12	1.24e-09	-0.34	-0.31	Cardiac Troponin-T levels;	chr6:28015835	chr6:28115628~28116551:+
THCA	cis	rs172166	0.561	rs149974	ENSG00000219392.1	RP1-265C24.5	-7.11	4.23e-12	1.24e-09	-0.34	-0.31	Cardiac Troponin-T levels;	chr6:28017318	chr6:28115628~28116551:+
THCA	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	7.11	4.24e-12	1.25e-09	0.38	0.31	Height;	chr6:109617741	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	7.11	4.24e-12	1.25e-09	0.38	0.31	Height;	chr6:109619295	chr6:109382795~109383666:+
THCA	cis	rs9287719	0.578	rs62127189	ENSG00000243819.4	RN7SL832P	7.11	4.24e-12	1.25e-09	0.26	0.31	Prostate cancer;	chr2:10621200	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.601	rs1861299	ENSG00000243819.4	RN7SL832P	7.11	4.24e-12	1.25e-09	0.26	0.31	Prostate cancer;	chr2:10623631	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.601	rs1861300	ENSG00000243819.4	RN7SL832P	7.11	4.24e-12	1.25e-09	0.26	0.31	Prostate cancer;	chr2:10623835	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.601	rs10084172	ENSG00000243819.4	RN7SL832P	7.11	4.24e-12	1.25e-09	0.26	0.31	Prostate cancer;	chr2:10631102	chr2:10690344~10692099:+
THCA	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-7.11	4.24e-12	1.25e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-7.11	4.24e-12	1.25e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-7.11	4.24e-12	1.25e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
THCA	cis	rs848490	0.928	rs55919387	ENSG00000214293.7	APTR	7.11	4.25e-12	1.25e-09	0.25	0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77686304	chr7:77657660~77696265:-
THCA	cis	rs79349575	0.729	rs62075824	ENSG00000248278.1	SUMO2P17	7.11	4.25e-12	1.25e-09	0.37	0.31	Type 2 diabetes;	chr17:48909317	chr17:48874860~48908983:-
THCA	cis	rs9388451	0.772	rs1268064	ENSG00000237742.5	RP11-624M8.1	7.11	4.25e-12	1.25e-09	0.27	0.31	Brugada syndrome;	chr6:125721432	chr6:125578558~125749190:-
THCA	cis	rs12817211	0.524	rs10876000	ENSG00000272368.2	RP4-605O3.4	-7.11	4.25e-12	1.25e-09	-0.18	-0.31	Colorectal or endometrial cancer;	chr12:50128431	chr12:50112197~50165618:+
THCA	cis	rs12817211	0.524	rs2204683	ENSG00000272368.2	RP4-605O3.4	-7.11	4.25e-12	1.25e-09	-0.18	-0.31	Colorectal or endometrial cancer;	chr12:50128593	chr12:50112197~50165618:+
THCA	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	7.11	4.26e-12	1.25e-09	0.38	0.31	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	7.11	4.26e-12	1.25e-09	0.38	0.31	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
THCA	cis	rs74233809	1	rs12413409	ENSG00000213277.3	MARCKSL1P1	7.11	4.26e-12	1.25e-09	0.5	0.31	Birth weight;	chr10:102959339	chr10:103175554~103176094:+
THCA	cis	rs9473147	0.516	rs7754971	ENSG00000270761.1	RP11-385F7.1	-7.11	4.26e-12	1.25e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47622740	chr6:47477243~47477572:-
THCA	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	7.11	4.26e-12	1.25e-09	0.25	0.31	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
THCA	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	7.11	4.27e-12	1.25e-09	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
THCA	cis	rs516805	0.667	rs2606650	ENSG00000279453.1	RP3-425C14.4	-7.11	4.27e-12	1.26e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122123443	chr6:122436789~122439223:-
THCA	cis	rs516805	0.562	rs2816156	ENSG00000279453.1	RP3-425C14.4	-7.11	4.27e-12	1.26e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122124569	chr6:122436789~122439223:-
THCA	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	7.11	4.28e-12	1.26e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	7.11	4.28e-12	1.26e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
THCA	cis	rs62158211	0.565	rs57611236	ENSG00000234997.1	AC016745.3	-7.11	4.28e-12	1.26e-09	-0.33	-0.31	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113346227	chr2:113424495~113425324:+
THCA	cis	rs160451	1	rs160441	ENSG00000251136.7	RP11-37B2.1	7.11	4.28e-12	1.26e-09	0.27	0.31	Leprosy;	chr8:89644760	chr8:89609409~89757727:-
THCA	cis	rs4950322	0.518	rs55697094	ENSG00000237188.3	RP11-337C18.8	7.11	4.28e-12	1.26e-09	0.38	0.31	Protein quantitative trait loci;	chr1:147121205	chr1:147172771~147211568:+
THCA	cis	rs9287719	0.649	rs10929683	ENSG00000243819.4	RN7SL832P	-7.11	4.29e-12	1.26e-09	-0.26	-0.31	Prostate cancer;	chr2:10592082	chr2:10690344~10692099:+
THCA	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	7.11	4.29e-12	1.26e-09	0.26	0.31	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000263603.1	CTD-2349P21.5	-7.11	4.29e-12	1.26e-09	-0.54	-0.31	Body mass index;	chr17:30730179	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000263603.1	CTD-2349P21.5	-7.11	4.29e-12	1.26e-09	-0.54	-0.31	Body mass index;	chr17:30730744	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000263603.1	CTD-2349P21.5	-7.11	4.29e-12	1.26e-09	-0.54	-0.31	Body mass index;	chr17:30731712	chr17:30729469~30731202:+
THCA	cis	rs6745190	0.748	rs6735373	ENSG00000236153.1	AC104076.3	7.11	4.3e-12	1.26e-09	0.36	0.31	White blood cell count;	chr2:181065907	chr2:180979427~180980090:-
THCA	cis	rs1009647	0.529	rs56098354	ENSG00000258413.1	RP11-665C16.6	-7.11	4.3e-12	1.26e-09	-0.56	-0.31	Testicular germ cell tumor;	chr14:55201452	chr14:55262767~55272075:-
THCA	cis	rs6486730	1	rs6486730	ENSG00000274695.1	RP11-21K12.3	-7.11	4.31e-12	1.27e-09	-0.36	-0.31	Systemic lupus erythematosus;	chr12:128790482	chr12:128826836~128827579:+
THCA	cis	rs4950322	0.57	rs6703892	ENSG00000237188.3	RP11-337C18.8	7.11	4.31e-12	1.27e-09	0.39	0.31	Protein quantitative trait loci;	chr1:147287627	chr1:147172771~147211568:+
THCA	cis	rs2657294	0.603	rs11543	ENSG00000233313.2	HMGA1P5	-7.11	4.31e-12	1.27e-09	-0.44	-0.31	Pneumonia;	chr10:75210855	chr10:75276376~75276646:-
THCA	cis	rs9318086	0.534	rs1962469	ENSG00000205861.10	C1QTNF9B-AS1	-7.11	4.32e-12	1.27e-09	-0.36	-0.31	Myopia (pathological);	chr13:23803405	chr13:23888889~23897263:+
THCA	cis	rs7246657	0.943	rs9917081	ENSG00000226686.6	LINC01535	-7.11	4.32e-12	1.27e-09	-0.46	-0.31	Coronary artery calcification;	chr19:37385714	chr19:37251912~37265535:+
THCA	cis	rs367615	0.68	rs253247	ENSG00000249476.1	CTD-2587M2.1	7.11	4.32e-12	1.27e-09	0.36	0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109648265	chr5:109237120~109326369:-
THCA	cis	rs9902453	0.845	rs7222842	ENSG00000264007.1	RP11-68I3.10	7.11	4.32e-12	1.27e-09	0.36	0.31	Coffee consumption (cups per day);	chr17:29919925	chr17:29621617~29622254:-
THCA	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-7.11	4.32e-12	1.27e-09	-0.49	-0.31	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
THCA	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-7.11	4.33e-12	1.27e-09	-0.37	-0.31	Height;	chr2:231556448	chr2:231508426~231514339:-
THCA	cis	rs6840258	1	rs7695426	ENSG00000251411.1	RP11-397E7.4	-7.11	4.36e-12	1.28e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000125	chr4:86913266~86914817:-
THCA	cis	rs10869777	1	rs10869778	ENSG00000234618.1	RPSAP9	-7.11	4.36e-12	1.28e-09	-0.33	-0.31	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76435422	chr9:76398699~76399586:+
THCA	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-7.11	4.37e-12	1.28e-09	-0.3	-0.31	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
THCA	cis	rs4273100	1	rs16960158	ENSG00000228157.4	AC007952.5	7.11	4.38e-12	1.28e-09	0.5	0.31	Schizophrenia;	chr17:19259739	chr17:19092974~19096837:+
THCA	cis	rs13230714	0.858	rs2888075	ENSG00000204959.4	ARHGEF34P	7.11	4.38e-12	1.28e-09	0.34	0.31	Breast cancer;	chr7:144456786	chr7:144272445~144286966:-
THCA	cis	rs853679	0.517	rs4713145	ENSG00000220721.1	OR1F12	7.11	4.38e-12	1.29e-09	0.43	0.31	Depression;	chr6:28139049	chr6:28073316~28074233:+
THCA	cis	rs4950322	0.542	rs28381210	ENSG00000237188.3	RP11-337C18.8	7.11	4.39e-12	1.29e-09	0.38	0.31	Protein quantitative trait loci;	chr1:147201925	chr1:147172771~147211568:+
THCA	cis	rs2287838	0.638	rs62105751	ENSG00000267289.1	CTD-2623N2.11	7.11	4.39e-12	1.29e-09	0.39	0.31	Sleep duration;	chr19:9847213	chr19:9834079~9835013:-
THCA	cis	rs7760535	0.757	rs10456875	ENSG00000230177.1	RP5-1112D6.4	-7.11	4.4e-12	1.29e-09	-0.25	-0.31	Metabolic traits;	chr6:111428522	chr6:111277932~111278742:+
THCA	cis	rs12130219	0.543	rs11204988	ENSG00000237975.5	FLG-AS1	7.11	4.4e-12	1.29e-09	0.49	0.31	Inflammatory skin disease;	chr1:152371417	chr1:152168125~152445456:+
THCA	cis	rs7044106	0.718	rs10616	ENSG00000238181.2	AHCYP2	-7.11	4.4e-12	1.29e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120720673~120721972:+
THCA	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	7.11	4.41e-12	1.29e-09	0.32	0.31	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
THCA	cis	rs227932	0.681	rs79586340	ENSG00000234286.1	AC006026.13	-7.11	4.41e-12	1.29e-09	-0.58	-0.31	Schizophrenia;	chr7:23746122	chr7:23680195~23680786:-
THCA	cis	rs227932	0.681	rs75405201	ENSG00000234286.1	AC006026.13	-7.11	4.41e-12	1.29e-09	-0.58	-0.31	Schizophrenia;	chr7:23746123	chr7:23680195~23680786:-
THCA	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	7.11	4.41e-12	1.29e-09	0.38	0.31	Height;	chr6:109581800	chr6:109382795~109383666:+
THCA	cis	rs62158211	0.565	rs62158212	ENSG00000234997.1	AC016745.3	-7.11	4.42e-12	1.29e-09	-0.32	-0.31	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348749	chr2:113424495~113425324:+
THCA	cis	rs6430553	0.964	rs62168869	ENSG00000224043.6	CCNT2-AS1	-7.11	4.42e-12	1.3e-09	-0.31	-0.31	Blood metabolite levels;	chr2:134889209	chr2:134735464~134918710:-
THCA	cis	rs911555	0.504	rs8021368	ENSG00000269958.1	RP11-73M18.8	7.11	4.42e-12	1.3e-09	0.3	0.31	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103696353~103697163:+
THCA	cis	rs17772222	0.92	rs61975260	ENSG00000258983.2	RP11-507K2.2	7.11	4.42e-12	1.3e-09	0.4	0.31	Coronary artery calcification;	chr14:88429597	chr14:88499334~88515502:+
THCA	cis	rs8012947	1	rs1885133	ENSG00000279636.2	LINC00216	-7.11	4.43e-12	1.3e-09	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58270684	chr14:58288033~58289158:+
THCA	cis	rs8012947	1	rs8009527	ENSG00000279636.2	LINC00216	-7.11	4.43e-12	1.3e-09	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58285394	chr14:58288033~58289158:+
THCA	cis	rs3806843	0.868	rs2531349	ENSG00000202515.1	VTRNA1-3	7.11	4.43e-12	1.3e-09	0.35	0.31	Depressive symptoms (multi-trait analysis);	chr5:140741368	chr5:140726158~140726246:+
THCA	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	7.11	4.44e-12	1.3e-09	0.4	0.31	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
THCA	cis	rs2554380	0.657	rs4530091	ENSG00000230373.7	GOLGA6L5P	-7.11	4.44e-12	1.3e-09	-0.35	-0.31	Height;	chr15:83814026	chr15:84507885~84516814:-
THCA	cis	rs12594515	0.904	rs8032875	ENSG00000259200.1	RP11-718O11.1	-7.11	4.45e-12	1.3e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45705812	chr15:45705078~45931069:+
THCA	cis	rs12594515	0.874	rs8032878	ENSG00000259200.1	RP11-718O11.1	-7.11	4.45e-12	1.3e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45705817	chr15:45705078~45931069:+
THCA	cis	rs11971779	0.938	rs28477480	ENSG00000273391.1	RP11-634H22.1	-7.11	4.45e-12	1.3e-09	-0.33	-0.31	Diisocyanate-induced asthma;	chr7:139351312	chr7:139359032~139359566:-
THCA	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	7.11	4.45e-12	1.3e-09	0.25	0.31	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
THCA	cis	rs6540731	1	rs7518329	ENSG00000226251.4	RP11-15I11.3	-7.11	4.45e-12	1.3e-09	-0.39	-0.31	Intelligence (childhood);	chr1:212225191	chr1:212225278~212238977:-
THCA	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	7.11	4.45e-12	1.3e-09	0.38	0.31	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
THCA	cis	rs6600671	0.934	rs11249348	ENSG00000223345.3	HIST2H2BA	7.11	4.46e-12	1.31e-09	0.34	0.31	Hip geometry;	chr1:121446444	chr1:121108210~121117257:-
THCA	cis	rs7131987	0.903	rs2194519	ENSG00000257176.2	RP11-996F15.2	7.11	4.46e-12	1.31e-09	0.3	0.31	QT interval;	chr12:29270650	chr12:29280418~29317848:-
THCA	cis	rs7615952	0.688	rs7624806	ENSG00000241288.6	RP11-379B18.5	-7.11	4.46e-12	1.31e-09	-0.38	-0.31	Blood pressure (smoking interaction);	chr3:125880231	chr3:125827238~125916384:-
THCA	cis	rs7208859	0.573	rs216443	ENSG00000264538.5	SUZ12P1	-7.11	4.47e-12	1.31e-09	-0.33	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30709299~30790908:+
THCA	cis	rs6840258	1	rs17752307	ENSG00000251411.1	RP11-397E7.4	-7.11	4.48e-12	1.31e-09	-0.39	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86978133	chr4:86913266~86914817:-
THCA	cis	rs9813712	0.523	rs9866942	ENSG00000228252.7	COL6A4P2	-7.11	4.49e-12	1.31e-09	-0.32	-0.31	Response to amphetamines;	chr3:130297796	chr3:130212823~130273806:+
THCA	cis	rs11168351	0.926	rs10875719	ENSG00000240399.1	RP1-228P16.1	7.1	4.49e-12	1.32e-09	0.32	0.31	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48054813~48055591:-
THCA	cis	rs728616	0.867	rs56198874	ENSG00000225484.5	NUTM2B-AS1	-7.1	4.49e-12	1.32e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:79663088~79826594:-
THCA	cis	rs728616	1	rs12414891	ENSG00000225484.5	NUTM2B-AS1	-7.1	4.49e-12	1.32e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79930629	chr10:79663088~79826594:-
THCA	cis	rs728616	0.717	rs12415523	ENSG00000225484.5	NUTM2B-AS1	-7.1	4.49e-12	1.32e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79932220	chr10:79663088~79826594:-
THCA	cis	rs728616	0.764	rs75385771	ENSG00000225484.5	NUTM2B-AS1	-7.1	4.49e-12	1.32e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79933023	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs17883671	ENSG00000225484.5	NUTM2B-AS1	-7.1	4.49e-12	1.32e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs17885031	ENSG00000225484.5	NUTM2B-AS1	-7.1	4.49e-12	1.32e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs3088308	ENSG00000225484.5	NUTM2B-AS1	-7.1	4.49e-12	1.32e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs17879726	ENSG00000225484.5	NUTM2B-AS1	-7.1	4.49e-12	1.32e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:79663088~79826594:-
THCA	cis	rs6840258	1	rs7682652	ENSG00000251411.1	RP11-397E7.4	-7.1	4.49e-12	1.32e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86992292	chr4:86913266~86914817:-
THCA	cis	rs453301	0.624	rs330058	ENSG00000254153.1	CTA-398F10.2	7.1	4.51e-12	1.32e-09	0.33	0.31	Joint mobility (Beighton score);	chr8:9232299	chr8:8456909~8461337:-
THCA	cis	rs10899021	1	rs10899025	ENSG00000279353.1	RP11-864N7.4	7.1	4.51e-12	1.32e-09	0.63	0.31	Response to metformin (IC50);	chr11:74655995	chr11:74698231~74699658:-
THCA	cis	rs651907	0.535	rs17347156	ENSG00000256628.3	ZBTB11-AS1	7.1	4.51e-12	1.32e-09	0.37	0.31	Colorectal cancer;	chr3:101785830	chr3:101676475~101679217:+
THCA	cis	rs4950322	0.58	rs2083720	ENSG00000237188.3	RP11-337C18.8	7.1	4.51e-12	1.32e-09	0.38	0.31	Protein quantitative trait loci;	chr1:147122296	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.58	rs72706441	ENSG00000237188.3	RP11-337C18.8	7.1	4.51e-12	1.32e-09	0.38	0.31	Protein quantitative trait loci;	chr1:147122601	chr1:147172771~147211568:+
THCA	cis	rs1667284	1	rs1667286	ENSG00000266521.1	RP11-650P15.1	7.1	4.52e-12	1.32e-09	0.4	0.31	Problematic alcohol use in trauma-exposed individuals;	chr18:31649190	chr18:31496645~31497195:-
THCA	cis	rs9473147	0.516	rs9395283	ENSG00000270761.1	RP11-385F7.1	-7.1	4.52e-12	1.32e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47583708	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs6903331	ENSG00000270761.1	RP11-385F7.1	-7.1	4.52e-12	1.32e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47595179	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs13212790	ENSG00000270761.1	RP11-385F7.1	-7.1	4.52e-12	1.32e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47608631	chr6:47477243~47477572:-
THCA	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-7.1	4.53e-12	1.33e-09	-0.34	-0.31	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000263603.1	CTD-2349P21.5	-7.1	4.53e-12	1.33e-09	-0.53	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30729469~30731202:+
THCA	cis	rs7015630	0.542	rs13280951	ENSG00000251136.7	RP11-37B2.1	-7.1	4.55e-12	1.33e-09	-0.34	-0.31	Inflammatory bowel disease;Crohn's disease;	chr8:89809746	chr8:89609409~89757727:-
THCA	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-7.1	4.55e-12	1.33e-09	-0.3	-0.31	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
THCA	cis	rs6479901	0.947	rs7910662	ENSG00000232075.1	MRPL35P2	-7.1	4.55e-12	1.33e-09	-0.49	-0.31	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-7.1	4.55e-12	1.33e-09	-0.49	-0.31	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
THCA	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-7.1	4.55e-12	1.33e-09	-0.49	-0.31	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-7.1	4.55e-12	1.33e-09	-0.49	-0.31	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-7.1	4.55e-12	1.33e-09	-0.49	-0.31	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
THCA	cis	rs112521149	1	rs112521149	ENSG00000242349.4	NPPA-AS1	-7.1	4.55e-12	1.33e-09	-0.47	-0.31	Mean corpuscular volume;	chr1:11829758	chr1:11841017~11848079:+
THCA	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	7.1	4.56e-12	1.33e-09	0.39	0.31	Height;	chr6:109449796	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	7.1	4.56e-12	1.33e-09	0.38	0.31	Height;	chr6:109530435	chr6:109382795~109383666:+
THCA	cis	rs516805	0.748	rs11154077	ENSG00000279453.1	RP3-425C14.4	7.1	4.56e-12	1.34e-09	0.31	0.31	Lymphocyte counts;	chr6:122386994	chr6:122436789~122439223:-
THCA	cis	rs2915864	0.8	rs36061508	ENSG00000280047.1	CTC-463A16.1	7.1	4.57e-12	1.34e-09	0.5	0.31	Facial morphology (factor 20);	chr5:142107638	chr5:142165767~142168387:+
THCA	cis	rs8012947	0.959	rs6573196	ENSG00000279636.2	LINC00216	-7.1	4.57e-12	1.34e-09	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58255821	chr14:58288033~58289158:+
THCA	cis	rs8012947	1	rs9743908	ENSG00000279636.2	LINC00216	-7.1	4.57e-12	1.34e-09	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58256828	chr14:58288033~58289158:+
THCA	cis	rs10208649	0.831	rs75123794	ENSG00000272156.1	RP11-477N3.1	7.1	4.57e-12	1.34e-09	0.61	0.31	Body mass index;	chr2:53684845	chr2:54082554~54085066:+
THCA	cis	rs8113308	1	rs7246064	ENSG00000269235.1	ZNF350-AS1	7.1	4.57e-12	1.34e-09	0.43	0.31	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939009	chr19:51949134~51981367:+
THCA	cis	rs831571	0.668	rs17069879	ENSG00000280620.1	SCAANT1	-7.1	4.58e-12	1.34e-09	-0.5	-0.31	Type 2 diabetes;	chr3:64097741	chr3:63911518~63911772:-
THCA	cis	rs1275468	1	rs1275468	ENSG00000257497.2	RP11-585P4.5	-7.1	4.58e-12	1.34e-09	-0.45	-0.31	Polycystic ovary syndrome;	chr12:75541377	chr12:75483454~75489820:-
THCA	cis	rs41307935	0.822	rs71636786	ENSG00000260063.1	RP5-968P14.2	-7.1	4.58e-12	1.34e-09	-0.6	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26851434	chr1:26692132~26694131:-
THCA	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	7.1	4.59e-12	1.34e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
THCA	cis	rs7246657	0.943	rs10422967	ENSG00000226686.6	LINC01535	-7.1	4.6e-12	1.34e-09	-0.46	-0.31	Coronary artery calcification;	chr19:37359235	chr19:37251912~37265535:+
THCA	cis	rs4073416	0.712	rs12890123	ENSG00000276116.2	FUT8-AS1	7.1	4.61e-12	1.35e-09	0.32	0.31	N-glycan levels;	chr14:65531351	chr14:65411170~65412690:-
THCA	cis	rs4072705	1	rs10760371	ENSG00000224020.1	MIR181A2HG	-7.1	4.62e-12	1.35e-09	-0.28	-0.31	Menarche (age at onset);	chr9:124690698	chr9:124658467~124698631:+
THCA	cis	rs12681366	0.537	rs10956914	ENSG00000253704.1	RP11-267M23.4	-7.1	4.62e-12	1.35e-09	-0.31	-0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94471495	chr8:94553722~94569745:+
THCA	cis	rs7851660	0.527	rs7870795	ENSG00000236130.1	PTCSC2	-7.1	4.62e-12	1.35e-09	-0.25	-0.31	Strep throat;	chr9:97811838	chr9:97805935~97810008:-
THCA	cis	rs79349575	0.783	rs62075818	ENSG00000248278.1	SUMO2P17	7.1	4.62e-12	1.35e-09	0.37	0.31	Type 2 diabetes;	chr17:48904965	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs9912829	ENSG00000248278.1	SUMO2P17	7.1	4.62e-12	1.35e-09	0.37	0.31	Type 2 diabetes;	chr17:48905387	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs62075820	ENSG00000248278.1	SUMO2P17	7.1	4.62e-12	1.35e-09	0.37	0.31	Type 2 diabetes;	chr17:48905809	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs4294857	ENSG00000248278.1	SUMO2P17	7.1	4.62e-12	1.35e-09	0.37	0.31	Type 2 diabetes;	chr17:48906029	chr17:48874860~48908983:-
THCA	cis	rs7760535	0.735	rs240974	ENSG00000230177.1	RP5-1112D6.4	-7.1	4.62e-12	1.35e-09	-0.25	-0.31	Metabolic traits;	chr6:111328113	chr6:111277932~111278742:+
THCA	cis	rs7131987	0.65	rs6487808	ENSG00000275476.1	RP11-996F15.4	7.1	4.63e-12	1.35e-09	0.31	0.31	QT interval;	chr12:29310426	chr12:29277397~29277882:-
THCA	cis	rs2976388	0.669	rs2976391	ENSG00000253741.1	CTD-2292P10.4	-7.1	4.63e-12	1.36e-09	-0.39	-0.31	Urinary tract infection frequency;	chr8:142681306	chr8:142702252~142726973:-
THCA	cis	rs2439831	0.717	rs28495368	ENSG00000249839.1	AC011330.5	-7.1	4.64e-12	1.36e-09	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43603444	chr15:43663654~43684339:-
THCA	cis	rs875971	1	rs6945843	ENSG00000232559.3	GS1-124K5.12	-7.1	4.64e-12	1.36e-09	-0.29	-0.31	Aortic root size;	chr7:66269796	chr7:66554588~66576923:-
THCA	cis	rs79349575	0.783	rs61576918	ENSG00000248278.1	SUMO2P17	7.1	4.65e-12	1.36e-09	0.37	0.31	Type 2 diabetes;	chr17:48908231	chr17:48874860~48908983:-
THCA	cis	rs6539288	0.933	rs10861672	ENSG00000260329.1	RP11-412D9.4	-7.1	4.65e-12	1.36e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106906222	chr12:106954029~106955497:-
THCA	cis	rs198389	0.589	rs198399	ENSG00000242349.4	NPPA-AS1	-7.1	4.65e-12	1.36e-09	-0.29	-0.31	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11823572	chr1:11841017~11848079:+
THCA	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	7.1	4.66e-12	1.36e-09	0.4	0.31	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
THCA	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	7.1	4.66e-12	1.36e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	7.1	4.66e-12	1.36e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	7.1	4.66e-12	1.36e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
THCA	cis	rs9928842	0.664	rs7205074	ENSG00000280152.1	RP11-331F4.5	-7.1	4.66e-12	1.36e-09	-0.36	-0.31	Alcoholic chronic pancreatitis;	chr16:75186111	chr16:75245994~75250077:-
THCA	cis	rs79349575	0.783	rs962272	ENSG00000248278.1	SUMO2P17	7.1	4.67e-12	1.36e-09	0.37	0.31	Type 2 diabetes;	chr17:48900921	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs903567	ENSG00000248278.1	SUMO2P17	7.1	4.67e-12	1.36e-09	0.37	0.31	Type 2 diabetes;	chr17:48902956	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs318095	ENSG00000248278.1	SUMO2P17	7.1	4.67e-12	1.36e-09	0.37	0.31	Type 2 diabetes;	chr17:48897372	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs318096	ENSG00000248278.1	SUMO2P17	7.1	4.67e-12	1.36e-09	0.37	0.31	Type 2 diabetes;	chr17:48898008	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.777	rs28517720	ENSG00000248278.1	SUMO2P17	7.1	4.67e-12	1.36e-09	0.37	0.31	Type 2 diabetes;	chr17:48899394	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.749	rs2546491	ENSG00000248278.1	SUMO2P17	7.1	4.67e-12	1.36e-09	0.37	0.31	Type 2 diabetes;	chr17:48900554	chr17:48874860~48908983:-
THCA	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	7.1	4.67e-12	1.37e-09	0.25	0.31	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
THCA	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	7.1	4.67e-12	1.37e-09	0.26	0.31	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.556	rs10168351	ENSG00000243819.4	RN7SL832P	7.1	4.67e-12	1.37e-09	0.26	0.31	Prostate cancer;	chr2:10596684	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.578	rs10168852	ENSG00000243819.4	RN7SL832P	7.1	4.67e-12	1.37e-09	0.26	0.31	Prostate cancer;	chr2:10606197	chr2:10690344~10692099:+
THCA	cis	rs12220777	0.818	rs7918223	ENSG00000230091.5	TMEM254-AS1	7.1	4.67e-12	1.37e-09	0.49	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090023	chr10:80046860~80078912:-
THCA	cis	rs7246657	0.943	rs7257672	ENSG00000226686.6	LINC01535	-7.1	4.67e-12	1.37e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37332957	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.891	rs7257495	ENSG00000226686.6	LINC01535	-7.1	4.67e-12	1.37e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37332974	chr19:37251912~37265535:+
THCA	cis	rs79349575	0.749	rs519537	ENSG00000248278.1	SUMO2P17	7.1	4.68e-12	1.37e-09	0.37	0.31	Type 2 diabetes;	chr17:48893778	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs832410	ENSG00000248278.1	SUMO2P17	7.1	4.68e-12	1.37e-09	0.37	0.31	Type 2 diabetes;	chr17:48895503	chr17:48874860~48908983:-
THCA	cis	rs10899021	1	rs61900635	ENSG00000279353.1	RP11-864N7.4	7.1	4.68e-12	1.37e-09	0.63	0.31	Response to metformin (IC50);	chr11:74647965	chr11:74698231~74699658:-
THCA	cis	rs12701220	0.948	rs10275712	ENSG00000229043.2	AC091729.9	-7.1	4.68e-12	1.37e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:1043282	chr7:1160374~1165267:+
THCA	cis	rs8114671	0.586	rs6087634	ENSG00000269202.1	RP4-614O4.12	-7.1	4.69e-12	1.37e-09	-0.27	-0.31	Height;	chr20:34826006	chr20:35201747~35203288:-
THCA	cis	rs651907	0.535	rs13094753	ENSG00000256628.3	ZBTB11-AS1	7.1	4.69e-12	1.37e-09	0.37	0.31	Colorectal cancer;	chr3:101806238	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs11716558	ENSG00000256628.3	ZBTB11-AS1	7.1	4.69e-12	1.37e-09	0.37	0.31	Colorectal cancer;	chr3:101809637	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs12633089	ENSG00000256628.3	ZBTB11-AS1	7.1	4.69e-12	1.37e-09	0.37	0.31	Colorectal cancer;	chr3:101809919	chr3:101676475~101679217:+
THCA	cis	rs10899021	0.915	rs11236198	ENSG00000279353.1	RP11-864N7.4	7.1	4.69e-12	1.37e-09	0.63	0.31	Response to metformin (IC50);	chr11:74661155	chr11:74698231~74699658:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-7.1	4.7e-12	1.37e-09	-0.23	-0.31	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
THCA	cis	rs11603691	0.711	rs10792091	ENSG00000254662.1	RP11-872D17.4	-7.1	4.7e-12	1.37e-09	-0.57	-0.31	Low high density lipoprotein cholesterol levels;	chr11:57351682	chr11:57325603~57327958:+
THCA	cis	rs7131987	0.617	rs3764953	ENSG00000275476.1	RP11-996F15.4	-7.1	4.71e-12	1.38e-09	-0.32	-0.31	QT interval;	chr12:29349303	chr12:29277397~29277882:-
THCA	cis	rs6928977	0.675	rs6908428	ENSG00000231028.7	LINC00271	-7.1	4.72e-12	1.38e-09	-0.26	-0.31	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135497801~135716055:+
THCA	cis	rs72843506	0.586	rs75374787	ENSG00000270091.1	RP11-78O7.2	-7.1	4.72e-12	1.38e-09	-0.37	-0.31	Schizophrenia;	chr17:19900805	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.586	rs79829757	ENSG00000270091.1	RP11-78O7.2	-7.1	4.72e-12	1.38e-09	-0.37	-0.31	Schizophrenia;	chr17:19900844	chr17:19896590~19897287:-
THCA	cis	rs12681366	0.563	rs6999103	ENSG00000253704.1	RP11-267M23.4	7.1	4.73e-12	1.38e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94470309	chr8:94553722~94569745:+
THCA	cis	rs34375054	0.687	rs35540170	ENSG00000279233.1	RP11-158L12.4	7.1	4.73e-12	1.38e-09	0.34	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125184576	chr12:125138245~125141711:+
THCA	cis	rs593531	0.55	rs592644	ENSG00000212961.4	HNRNPA1P40	7.1	4.74e-12	1.38e-09	0.39	0.31	Neuroticism;	chr11:74342502	chr11:74354443~74355720:+
THCA	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	7.1	4.74e-12	1.38e-09	0.38	0.31	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	7.1	4.74e-12	1.38e-09	0.38	0.31	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	7.1	4.74e-12	1.38e-09	0.38	0.31	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
THCA	cis	rs2281636	0.723	rs11190195	ENSG00000233690.1	EBAG9P1	-7.1	4.75e-12	1.39e-09	-0.33	-0.31	Obesity-related traits;	chr10:99626710	chr10:99697407~99697949:-
THCA	cis	rs875971	0.862	rs6460307	ENSG00000232559.3	GS1-124K5.12	7.1	4.76e-12	1.39e-09	0.29	0.31	Aortic root size;	chr7:66595884	chr7:66554588~66576923:-
THCA	cis	rs651907	0.535	rs58658478	ENSG00000256628.3	ZBTB11-AS1	7.1	4.76e-12	1.39e-09	0.37	0.31	Colorectal cancer;	chr3:101792823	chr3:101676475~101679217:+
THCA	cis	rs4934494	0.727	rs2418929	ENSG00000232936.4	RP11-80H5.2	7.1	4.77e-12	1.39e-09	0.42	0.31	Red blood cell count;	chr10:89741720	chr10:89645282~89650667:+
THCA	cis	rs2439831	0.867	rs3101443	ENSG00000249839.1	AC011330.5	-7.1	4.77e-12	1.39e-09	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43620174	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2614811	ENSG00000249839.1	AC011330.5	-7.1	4.77e-12	1.39e-09	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43621289	chr15:43663654~43684339:-
THCA	cis	rs12594515	1	rs8039622	ENSG00000259200.1	RP11-718O11.1	-7.1	4.77e-12	1.39e-09	-0.38	-0.31	Weight;Waist circumference;	chr15:45694233	chr15:45705078~45931069:+
THCA	cis	rs7727544	0.618	rs2631367	ENSG00000224431.1	AC063976.7	-7.1	4.78e-12	1.4e-09	-0.27	-0.31	Blood metabolite levels;	chr5:132369766	chr5:132199456~132203487:+
THCA	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-7.1	4.78e-12	1.4e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
THCA	cis	rs4073416	0.712	rs8018278	ENSG00000276116.2	FUT8-AS1	7.1	4.78e-12	1.4e-09	0.32	0.31	N-glycan levels;	chr14:65713370	chr14:65411170~65412690:-
THCA	cis	rs17695224	0.675	rs10422421	ENSG00000269483.1	AC006272.1	7.1	4.79e-12	1.4e-09	0.34	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51836479	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.675	rs10422984	ENSG00000269483.1	AC006272.1	7.1	4.79e-12	1.4e-09	0.34	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51836492	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.675	rs10422606	ENSG00000269483.1	AC006272.1	7.1	4.79e-12	1.4e-09	0.34	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51836494	chr19:51839924~51843324:-
THCA	cis	rs12681366	0.708	rs1011249	ENSG00000253704.1	RP11-267M23.4	7.1	4.79e-12	1.4e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94425833	chr8:94553722~94569745:+
THCA	cis	rs10050311	0.858	rs1010903	ENSG00000251411.1	RP11-397E7.4	-7.1	4.79e-12	1.4e-09	-0.38	-0.31	Insulin-related traits;	chr4:86898040	chr4:86913266~86914817:-
THCA	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	7.1	4.79e-12	1.4e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	7.1	4.79e-12	1.4e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	7.1	4.79e-12	1.4e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	7.1	4.79e-12	1.4e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
THCA	cis	rs944289	0.515	rs1755768	ENSG00000257826.1	RP11-116N8.4	-7.09	4.79e-12	1.4e-09	-0.35	-0.31	Thyroid cancer;	chr14:36192691	chr14:36061026~36067190:-
THCA	cis	rs3204270	0.639	rs6565620	ENSG00000262049.1	RP13-1032I1.7	7.09	4.8e-12	1.4e-09	0.28	0.31	Dental caries;	chr17:81691070	chr17:81701324~81703300:-
THCA	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	7.09	4.8e-12	1.4e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
THCA	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-7.09	4.81e-12	1.4e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
THCA	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-7.09	4.81e-12	1.4e-09	-0.34	-0.31	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
THCA	cis	rs7267979	0.899	rs2179459	ENSG00000274414.1	RP5-965G21.4	-7.09	4.82e-12	1.41e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25239007~25245229:-
THCA	cis	rs7576126	0.515	rs1866050	ENSG00000204929.10	AC074391.1	7.09	4.82e-12	1.41e-09	0.43	0.31	Severe influenza A (H1N1) infection;	chr2:65450595	chr2:65436711~66084639:+
THCA	cis	rs17684571	0.938	rs56101897	ENSG00000231441.1	RP11-472M19.2	7.09	4.82e-12	1.41e-09	0.4	0.31	Schizophrenia;	chr6:56687628	chr6:56844002~56864078:+
THCA	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	7.09	4.82e-12	1.41e-09	0.41	0.31	Height;	chr6:109762861	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	7.09	4.82e-12	1.41e-09	0.41	0.31	Height;	chr6:109764163	chr6:109382795~109383666:+
THCA	cis	rs6840258	1	rs72667750	ENSG00000251411.1	RP11-397E7.4	-7.09	4.83e-12	1.41e-09	-0.38	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87009273	chr4:86913266~86914817:-
THCA	cis	rs6840258	1	rs56406125	ENSG00000251411.1	RP11-397E7.4	-7.09	4.83e-12	1.41e-09	-0.38	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019053	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.941	rs72667757	ENSG00000251411.1	RP11-397E7.4	-7.09	4.83e-12	1.41e-09	-0.38	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87025842	chr4:86913266~86914817:-
THCA	cis	rs4814920	0.756	rs1543472	ENSG00000233895.1	RP1-122P22.2	7.09	4.83e-12	1.41e-09	0.33	0.31	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19757708~19809675:+
THCA	cis	rs9876781	0.559	rs7630053	ENSG00000229759.1	MRPS18AP1	7.09	4.83e-12	1.41e-09	0.38	0.31	Longevity;	chr3:48357096	chr3:48256350~48256938:-
THCA	cis	rs9473147	0.516	rs9381575	ENSG00000270761.1	RP11-385F7.1	-7.09	4.84e-12	1.41e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47561028	chr6:47477243~47477572:-
THCA	cis	rs4713118	0.662	rs149970	ENSG00000226314.6	ZNF192P1	-7.09	4.85e-12	1.41e-09	-0.38	-0.31	Parkinson's disease;	chr6:28012442	chr6:28161781~28169594:+
THCA	cis	rs9902453	0.808	rs4595850	ENSG00000264007.1	RP11-68I3.10	7.09	4.86e-12	1.42e-09	0.36	0.31	Coffee consumption (cups per day);	chr17:29879308	chr17:29621617~29622254:-
THCA	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	7.09	4.86e-12	1.42e-09	0.79	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	7.09	4.86e-12	1.42e-09	0.79	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	7.09	4.86e-12	1.42e-09	0.79	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	7.09	4.86e-12	1.42e-09	0.79	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	7.09	4.86e-12	1.42e-09	0.79	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	7.09	4.86e-12	1.42e-09	0.79	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
THCA	cis	rs2287838	0.686	rs1862472	ENSG00000267289.1	CTD-2623N2.11	-7.09	4.86e-12	1.42e-09	-0.38	-0.31	Sleep duration;	chr19:9847181	chr19:9834079~9835013:-
THCA	cis	rs6539288	0.77	rs1468908	ENSG00000260329.1	RP11-412D9.4	-7.09	4.87e-12	1.42e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106904539	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.933	rs1470380	ENSG00000260329.1	RP11-412D9.4	-7.09	4.87e-12	1.42e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106904961	chr12:106954029~106955497:-
THCA	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	7.09	4.87e-12	1.42e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
THCA	cis	rs7189233	0.955	rs72801853	ENSG00000279722.1	RP11-44F14.6	-7.09	4.88e-12	1.42e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr16:53482912	chr16:53487607~53489943:-
THCA	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-7.09	4.89e-12	1.43e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
THCA	cis	rs516805	0.667	rs225080	ENSG00000279453.1	RP3-425C14.4	-7.09	4.89e-12	1.43e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122295949	chr6:122436789~122439223:-
THCA	cis	rs6539288	0.677	rs10735418	ENSG00000260329.1	RP11-412D9.4	-7.09	4.9e-12	1.43e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106949598	chr12:106954029~106955497:-
THCA	cis	rs736801	0.607	rs11739135	ENSG00000224431.1	AC063976.7	7.09	4.9e-12	1.43e-09	0.28	0.31	Mosquito bite size;Breast cancer;	chr5:132397705	chr5:132199456~132203487:+
THCA	cis	rs12594515	0.967	rs11854477	ENSG00000259200.1	RP11-718O11.1	-7.09	4.9e-12	1.43e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45706147	chr15:45705078~45931069:+
THCA	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	7.09	4.9e-12	1.43e-09	0.25	0.31	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000272009.1	RP1-313I6.12	-7.09	4.9e-12	1.43e-09	-0.35	-0.31	Parkinson's disease;	chr6:28065745	chr6:28078792~28081130:-
THCA	cis	rs4073416	0.712	rs6573624	ENSG00000276116.2	FUT8-AS1	7.09	4.91e-12	1.43e-09	0.32	0.31	N-glycan levels;	chr14:65760167	chr14:65411170~65412690:-
THCA	cis	rs7131987	0.65	rs11050187	ENSG00000275476.1	RP11-996F15.4	-7.09	4.91e-12	1.43e-09	-0.31	-0.31	QT interval;	chr12:29319943	chr12:29277397~29277882:-
THCA	cis	rs6540731	1	rs12402397	ENSG00000226251.4	RP11-15I11.3	-7.09	4.91e-12	1.43e-09	-0.39	-0.31	Intelligence (childhood);	chr1:212222602	chr1:212225278~212238977:-
THCA	cis	rs651907	0.535	rs36060163	ENSG00000256628.3	ZBTB11-AS1	7.09	4.92e-12	1.43e-09	0.37	0.31	Colorectal cancer;	chr3:101642119	chr3:101676475~101679217:+
THCA	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	7.09	4.92e-12	1.43e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
THCA	cis	rs4934494	0.862	rs12246250	ENSG00000232936.4	RP11-80H5.2	7.09	4.92e-12	1.44e-09	0.4	0.31	Red blood cell count;	chr10:89629540	chr10:89645282~89650667:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000272009.1	RP1-313I6.12	-7.09	4.92e-12	1.44e-09	-0.37	-0.31	Depression;	chr6:28143758	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393894	ENSG00000272009.1	RP1-313I6.12	-7.09	4.92e-12	1.44e-09	-0.37	-0.31	Depression;	chr6:28144784	chr6:28078792~28081130:-
THCA	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-7.09	4.93e-12	1.44e-09	-0.37	-0.31	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
THCA	cis	rs516805	0.665	rs517427	ENSG00000279453.1	RP3-425C14.4	-7.09	4.93e-12	1.44e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122291180	chr6:122436789~122439223:-
THCA	cis	rs2341534	1	rs2341534	ENSG00000258413.1	RP11-665C16.6	-7.09	4.93e-12	1.44e-09	-0.48	-0.31	Morning vs. evening chronotype;	chr14:55318019	chr14:55262767~55272075:-
THCA	cis	rs780096	0.967	rs1313566	ENSG00000234072.1	AC074117.10	-7.09	4.93e-12	1.44e-09	-0.24	-0.31	Total body bone mineral density;	chr2:27526037	chr2:27356246~27367622:+
THCA	cis	rs875971	0.862	rs2909688	ENSG00000232559.3	GS1-124K5.12	7.09	4.93e-12	1.44e-09	0.3	0.31	Aortic root size;	chr7:66376625	chr7:66554588~66576923:-
THCA	cis	rs6745190	0.906	rs13019038	ENSG00000236153.1	AC104076.3	-7.09	4.94e-12	1.44e-09	-0.36	-0.31	White blood cell count;	chr2:181082907	chr2:180979427~180980090:-
THCA	cis	rs77204473	0.793	rs543819	ENSG00000254851.1	RP11-109L13.1	7.09	4.94e-12	1.44e-09	0.75	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116879357	chr11:117135528~117138582:+
THCA	cis	rs853679	1	rs6905391	ENSG00000219392.1	RP1-265C24.5	-7.09	4.94e-12	1.44e-09	-0.48	-0.31	Depression;	chr6:28294909	chr6:28115628~28116551:+
THCA	cis	rs3745672	1	rs442446	ENSG00000219665.7	CTD-2006C1.2	-7.09	4.95e-12	1.44e-09	-0.67	-0.31	Multiple sclerosis;	chr19:11999259	chr19:11987617~12046275:+
THCA	cis	rs7811142	1	rs73161762	ENSG00000078319.8	PMS2P1	-7.09	4.95e-12	1.44e-09	-0.46	-0.31	Platelet count;	chr7:100417223	chr7:100320992~100341908:-
THCA	cis	rs71403859	0.685	rs12927044	ENSG00000260886.1	TAT-AS1	7.09	4.95e-12	1.44e-09	0.72	0.31	Post bronchodilator FEV1;	chr16:71896202	chr16:71565789~71578187:+
THCA	cis	rs17695224	0.545	rs4802872	ENSG00000269483.1	AC006272.1	7.09	4.96e-12	1.45e-09	0.33	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51817790	chr19:51839924~51843324:-
THCA	cis	rs7131987	0.621	rs11050181	ENSG00000275476.1	RP11-996F15.4	-7.09	4.96e-12	1.45e-09	-0.31	-0.31	QT interval;	chr12:29314736	chr12:29277397~29277882:-
THCA	cis	rs160451	0.934	rs160422	ENSG00000251136.7	RP11-37B2.1	7.09	4.97e-12	1.45e-09	0.27	0.31	Leprosy;	chr8:89657610	chr8:89609409~89757727:-
THCA	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	7.09	4.98e-12	1.45e-09	0.26	0.31	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
THCA	cis	rs7208859	0.673	rs999798	ENSG00000266490.1	CTD-2349P21.9	7.09	4.99e-12	1.45e-09	0.4	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30792372~30792833:+
THCA	cis	rs7131987	0.65	rs7954871	ENSG00000275476.1	RP11-996F15.4	-7.09	5e-12	1.46e-09	-0.31	-0.31	QT interval;	chr12:29306799	chr12:29277397~29277882:-
THCA	cis	rs75422866	0.764	rs73104177	ENSG00000274902.1	RP1-197B17.4	7.09	5e-12	1.46e-09	0.69	0.31	Pneumonia;	chr12:47713550	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.764	rs73104184	ENSG00000274902.1	RP1-197B17.4	7.09	5e-12	1.46e-09	0.69	0.31	Pneumonia;	chr12:47715623	chr12:47731908~47732351:+
THCA	cis	rs910316	0.967	rs12147532	ENSG00000279594.1	RP11-950C14.10	-7.09	5e-12	1.46e-09	-0.29	-0.31	Height;	chr14:75185155	chr14:75011269~75012851:-
THCA	cis	rs7583236	0.5	rs7601899	ENSG00000179818.12	PCBP1-AS1	-7.09	5e-12	1.46e-09	-0.39	-0.31	Obesity-related traits;	chr2:70108841	chr2:69962263~70103220:-
THCA	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-7.09	5e-12	1.46e-09	-0.3	-0.31	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
THCA	cis	rs12594515	1	rs12594515	ENSG00000259200.1	RP11-718O11.1	7.09	5e-12	1.46e-09	0.38	0.31	Weight;Waist circumference;	chr15:45692873	chr15:45705078~45931069:+
THCA	cis	rs2712184	0.935	rs2712169	ENSG00000229352.1	AC007563.3	-7.09	5e-12	1.46e-09	-0.37	-0.31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216806626	chr2:216799608~216805335:+
THCA	cis	rs853679	0.599	rs202906	ENSG00000219392.1	RP1-265C24.5	7.09	5e-12	1.46e-09	0.48	0.31	Depression;	chr6:28043874	chr6:28115628~28116551:+
THCA	cis	rs9902453	1	rs7207021	ENSG00000264007.1	RP11-68I3.10	-7.09	5.01e-12	1.46e-09	-0.36	-0.31	Coffee consumption (cups per day);	chr17:30073498	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs9897206	ENSG00000264007.1	RP11-68I3.10	-7.09	5.01e-12	1.46e-09	-0.36	-0.31	Coffee consumption (cups per day);	chr17:30079090	chr17:29621617~29622254:-
THCA	cis	rs12701220	0.948	rs12690826	ENSG00000229043.2	AC091729.9	-7.09	5.01e-12	1.46e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:1041982	chr7:1160374~1165267:+
THCA	cis	rs853679	0.769	rs17720293	ENSG00000226314.6	ZNF192P1	-7.09	5.01e-12	1.46e-09	-0.6	-0.31	Depression;	chr6:28246920	chr6:28161781~28169594:+
THCA	cis	rs875971	0.895	rs7782806	ENSG00000232559.3	GS1-124K5.12	-7.09	5.02e-12	1.46e-09	-0.3	-0.31	Aortic root size;	chr7:66192910	chr7:66554588~66576923:-
THCA	cis	rs4072705	0.933	rs10760376	ENSG00000224020.1	MIR181A2HG	7.09	5.03e-12	1.47e-09	0.27	0.31	Menarche (age at onset);	chr9:124791791	chr9:124658467~124698631:+
THCA	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	7.09	5.04e-12	1.47e-09	0.34	0.31	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
THCA	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-7.09	5.04e-12	1.47e-09	-0.3	-0.31	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
THCA	cis	rs7665090	0.517	rs1585214	ENSG00000246560.2	RP11-10L12.4	7.09	5.05e-12	1.47e-09	0.38	0.31	Primary biliary cholangitis;	chr4:102523376	chr4:102828055~102844075:+
THCA	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	7.09	5.06e-12	1.47e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
THCA	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-7.09	5.06e-12	1.47e-09	-0.48	-0.31	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-7.09	5.06e-12	1.47e-09	-0.48	-0.31	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
THCA	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	7.09	5.06e-12	1.47e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	7.09	5.06e-12	1.47e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	7.09	5.06e-12	1.47e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
THCA	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-7.09	5.06e-12	1.47e-09	-0.38	-0.31	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
THCA	cis	rs172166	0.637	rs1225597	ENSG00000280107.1	AL022393.9	-7.09	5.06e-12	1.47e-09	-0.33	-0.31	Cardiac Troponin-T levels;	chr6:28194309	chr6:28170845~28172521:+
THCA	cis	rs172166	0.637	rs1071893	ENSG00000280107.1	AL022393.9	-7.09	5.06e-12	1.47e-09	-0.33	-0.31	Cardiac Troponin-T levels;	chr6:28199857	chr6:28170845~28172521:+
THCA	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	7.09	5.07e-12	1.48e-09	0.33	0.31	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	7.09	5.07e-12	1.48e-09	0.33	0.31	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
THCA	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	7.09	5.07e-12	1.48e-09	0.33	0.31	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
THCA	cis	rs7208859	0.573	rs216442	ENSG00000263603.1	CTD-2349P21.5	-7.09	5.07e-12	1.48e-09	-0.55	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs216445	ENSG00000263603.1	CTD-2349P21.5	-7.09	5.07e-12	1.48e-09	-0.55	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs216446	ENSG00000263603.1	CTD-2349P21.5	-7.09	5.07e-12	1.48e-09	-0.55	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30729469~30731202:+
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-7.09	5.07e-12	1.48e-09	-0.23	-0.31	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
THCA	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-7.09	5.07e-12	1.48e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
THCA	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-7.09	5.07e-12	1.48e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
THCA	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-7.09	5.07e-12	1.48e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
THCA	cis	rs9402743	0.671	rs9376115	ENSG00000231028.7	LINC00271	7.09	5.08e-12	1.48e-09	0.25	0.31	Systemic lupus erythematosus;	chr6:135616579	chr6:135497801~135716055:+
THCA	cis	rs172166	0.637	rs1225592	ENSG00000280107.1	AL022393.9	-7.09	5.08e-12	1.48e-09	-0.33	-0.31	Cardiac Troponin-T levels;	chr6:28182464	chr6:28170845~28172521:+
THCA	cis	rs172166	0.637	rs1225595	ENSG00000280107.1	AL022393.9	-7.09	5.08e-12	1.48e-09	-0.33	-0.31	Cardiac Troponin-T levels;	chr6:28183562	chr6:28170845~28172521:+
THCA	cis	rs728616	0.867	rs17606361	ENSG00000225484.5	NUTM2B-AS1	-7.09	5.09e-12	1.48e-09	-0.61	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80085655	chr10:79663088~79826594:-
THCA	cis	rs728616	0.764	rs61859016	ENSG00000225484.5	NUTM2B-AS1	-7.09	5.09e-12	1.48e-09	-0.61	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80092744	chr10:79663088~79826594:-
THCA	cis	rs4713118	0.513	rs149954	ENSG00000280107.1	AL022393.9	-7.09	5.09e-12	1.48e-09	-0.34	-0.31	Parkinson's disease;	chr6:28067468	chr6:28170845~28172521:+
THCA	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-7.09	5.1e-12	1.48e-09	-0.4	-0.31	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
THCA	cis	rs7015263	0.689	rs6996052	ENSG00000254231.1	CTD-2284J15.1	-7.09	5.1e-12	1.48e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:86417643	chr8:86333274~86343314:-
THCA	cis	rs516805	0.748	rs55863504	ENSG00000279453.1	RP3-425C14.4	7.09	5.1e-12	1.48e-09	0.31	0.31	Lymphocyte counts;	chr6:122376339	chr6:122436789~122439223:-
THCA	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-7.09	5.1e-12	1.48e-09	-0.34	-0.31	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
THCA	cis	rs4819052	0.808	rs2838862	ENSG00000237664.1	LINC00316	-7.09	5.1e-12	1.48e-09	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45266811	chr21:45338590~45341990:-
THCA	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	7.09	5.11e-12	1.49e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
THCA	cis	rs7260598	0.792	rs73029291	ENSG00000268442.1	CTD-2027I19.2	7.09	5.11e-12	1.49e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24171866	chr19:24162370~24163425:-
THCA	cis	rs7015263	0.714	rs7822494	ENSG00000254231.1	CTD-2284J15.1	7.09	5.11e-12	1.49e-09	0.3	0.31	Intelligence (multi-trait analysis);	chr8:86464210	chr8:86333274~86343314:-
THCA	cis	rs1075265	0.518	rs13414393	ENSG00000233266.1	HMGB1P31	7.08	5.12e-12	1.49e-09	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54051334~54051760:+
THCA	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	7.08	5.12e-12	1.49e-09	0.39	0.31	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
THCA	cis	rs1150668	0.796	rs213236	ENSG00000219392.1	RP1-265C24.5	-7.08	5.12e-12	1.49e-09	-0.33	-0.31	Pubertal anthropometrics;	chr6:28356620	chr6:28115628~28116551:+
THCA	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	7.08	5.13e-12	1.49e-09	0.38	0.31	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	7.08	5.13e-12	1.49e-09	0.38	0.31	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	7.08	5.13e-12	1.49e-09	0.38	0.31	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	7.08	5.13e-12	1.49e-09	0.38	0.31	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	7.08	5.13e-12	1.49e-09	0.38	0.31	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	7.08	5.13e-12	1.49e-09	0.38	0.31	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	7.08	5.13e-12	1.49e-09	0.38	0.31	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
THCA	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-7.08	5.13e-12	1.49e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
THCA	cis	rs9473147	0.516	rs9357546	ENSG00000270761.1	RP11-385F7.1	-7.08	5.13e-12	1.49e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47581759	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs9349415	ENSG00000270761.1	RP11-385F7.1	-7.08	5.13e-12	1.49e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47584125	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs9349416	ENSG00000270761.1	RP11-385F7.1	-7.08	5.13e-12	1.49e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47584202	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs1485780	ENSG00000270761.1	RP11-385F7.1	-7.08	5.13e-12	1.49e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47588894	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9381578	ENSG00000270761.1	RP11-385F7.1	-7.08	5.13e-12	1.49e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47588898	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs9381579	ENSG00000270761.1	RP11-385F7.1	-7.08	5.13e-12	1.49e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47588944	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs10456570	ENSG00000270761.1	RP11-385F7.1	-7.08	5.13e-12	1.49e-09	-0.25	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47591715	chr6:47477243~47477572:-
THCA	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	7.08	5.13e-12	1.49e-09	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
THCA	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-7.08	5.14e-12	1.49e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-7.08	5.14e-12	1.49e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
THCA	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-7.08	5.14e-12	1.5e-09	-0.61	-0.31	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
THCA	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-7.08	5.15e-12	1.5e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
THCA	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-7.08	5.17e-12	1.5e-09	-0.49	-0.31	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
THCA	cis	rs2361718	0.522	rs11867921	ENSG00000279259.1	RP11-334C17.3	7.08	5.17e-12	1.5e-09	0.32	0.31	Yeast infection;	chr17:80147371	chr17:80147250~80148596:+
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000213640.3	EEF1DP4	7.08	5.18e-12	1.5e-09	0.36	0.31	Calcium levels;	chr7:65733651	chr7:64862999~64864370:+
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000263603.1	CTD-2349P21.5	-7.08	5.18e-12	1.51e-09	-0.55	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000263603.1	CTD-2349P21.5	-7.08	5.18e-12	1.51e-09	-0.55	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000263603.1	CTD-2349P21.5	-7.08	5.18e-12	1.51e-09	-0.55	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30729469~30731202:+
THCA	cis	rs7945705	0.818	rs10769948	ENSG00000254860.4	TMEM9B-AS1	7.08	5.18e-12	1.51e-09	0.34	0.31	Hemoglobin concentration;	chr11:8740235	chr11:8964675~8977527:+
THCA	cis	rs853679	0.517	rs9295761	ENSG00000272009.1	RP1-313I6.12	-7.08	5.18e-12	1.51e-09	-0.37	-0.31	Depression;	chr6:28180209	chr6:28078792~28081130:-
THCA	cis	rs523522	0.962	rs2393590	ENSG00000278344.1	RP11-18C24.8	7.08	5.18e-12	1.51e-09	0.34	0.31	High light scatter reticulocyte count;	chr12:120476097	chr12:120500735~120501090:-
THCA	cis	rs593531	0.571	rs3862799	ENSG00000212961.4	HNRNPA1P40	7.08	5.19e-12	1.51e-09	0.4	0.31	Neuroticism;	chr11:74339217	chr11:74354443~74355720:+
THCA	cis	rs9902453	0.874	rs3936006	ENSG00000264007.1	RP11-68I3.10	7.08	5.2e-12	1.51e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29930642	chr17:29621617~29622254:-
THCA	cis	rs7226408	0.857	rs2162389	ENSG00000267707.2	RP11-95O2.5	-7.08	5.2e-12	1.51e-09	-0.41	-0.31	Obesity-related traits;	chr18:36857070	chr18:37243776~37247506:+
THCA	cis	rs75422866	0.867	rs73104163	ENSG00000274902.1	RP1-197B17.4	7.08	5.21e-12	1.51e-09	0.69	0.31	Pneumonia;	chr12:47706187	chr12:47731908~47732351:+
THCA	cis	rs75422866	1	rs12423045	ENSG00000274902.1	RP1-197B17.4	7.08	5.21e-12	1.51e-09	0.69	0.31	Pneumonia;	chr12:47706275	chr12:47731908~47732351:+
THCA	cis	rs9847710	0.838	rs2581795	ENSG00000242142.1	SERBP1P3	-7.08	5.22e-12	1.52e-09	-0.34	-0.31	Ulcerative colitis;	chr3:53004770	chr3:53064283~53065091:-
THCA	cis	rs2735413	0.564	rs11863954	ENSG00000276007.1	RP11-358L22.3	-7.08	5.22e-12	1.52e-09	-0.35	-0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78093252	chr16:78123243~78124332:+
THCA	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-7.08	5.22e-12	1.52e-09	-0.38	-0.31	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
THCA	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-7.08	5.23e-12	1.52e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000272009.1	RP1-313I6.12	7.08	5.23e-12	1.52e-09	0.35	0.31	Parkinson's disease;	chr6:28065396	chr6:28078792~28081130:-
THCA	cis	rs9402743	0.564	rs6570020	ENSG00000231028.7	LINC00271	-7.08	5.23e-12	1.52e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135604607	chr6:135497801~135716055:+
THCA	cis	rs8030379	1	rs10152139	ENSG00000230373.7	GOLGA6L5P	-7.08	5.23e-12	1.52e-09	-0.29	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901510	chr15:84507885~84516814:-
THCA	cis	rs2839186	0.807	rs2032226	ENSG00000239415.1	AP001469.9	7.08	5.23e-12	1.52e-09	0.33	0.31	Testicular germ cell tumor;	chr21:46260438	chr21:46251549~46254133:-
THCA	cis	rs7189233	0.955	rs60420081	ENSG00000279344.1	RP11-44F14.7	7.08	5.24e-12	1.52e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr16:53486892	chr16:53478957~53481550:-
THCA	cis	rs6430553	0.964	rs56383182	ENSG00000224043.6	CCNT2-AS1	-7.08	5.24e-12	1.52e-09	-0.31	-0.31	Blood metabolite levels;	chr2:134850641	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.534	rs6430546	ENSG00000224043.6	CCNT2-AS1	-7.08	5.24e-12	1.52e-09	-0.31	-0.31	Type 2 diabetes;	chr2:134851231	chr2:134735464~134918710:-
THCA	cis	rs6430553	0.964	rs60793693	ENSG00000224043.6	CCNT2-AS1	-7.08	5.24e-12	1.52e-09	-0.31	-0.31	Blood metabolite levels;	chr2:134852125	chr2:134735464~134918710:-
THCA	cis	rs9475752	1	rs34812189	ENSG00000231441.1	RP11-472M19.2	7.08	5.24e-12	1.52e-09	0.4	0.31	Menarche (age at onset);	chr6:56941929	chr6:56844002~56864078:+
THCA	cis	rs7246657	0.943	rs7255785	ENSG00000226686.6	LINC01535	-7.08	5.24e-12	1.52e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37480781	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs7255996	ENSG00000226686.6	LINC01535	-7.08	5.24e-12	1.52e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37480797	chr19:37251912~37265535:+
THCA	cis	rs4664293	0.867	rs2059698	ENSG00000226266.5	AC009961.3	7.08	5.25e-12	1.53e-09	0.38	0.31	Monocyte percentage of white cells;	chr2:159785905	chr2:159670708~159712435:-
THCA	cis	rs875971	0.83	rs778711	ENSG00000232559.3	GS1-124K5.12	7.08	5.26e-12	1.53e-09	0.3	0.31	Aortic root size;	chr7:66386670	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs1083554	ENSG00000232559.3	GS1-124K5.12	7.08	5.26e-12	1.53e-09	0.3	0.31	Aortic root size;	chr7:66387354	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs778707	ENSG00000232559.3	GS1-124K5.12	7.08	5.26e-12	1.53e-09	0.3	0.31	Aortic root size;	chr7:66392040	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs778705	ENSG00000232559.3	GS1-124K5.12	7.08	5.26e-12	1.53e-09	0.3	0.31	Aortic root size;	chr7:66396128	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs778697	ENSG00000232559.3	GS1-124K5.12	7.08	5.26e-12	1.53e-09	0.3	0.31	Aortic root size;	chr7:66405439	chr7:66554588~66576923:-
THCA	cis	rs875971	0.798	rs7789615	ENSG00000232559.3	GS1-124K5.12	7.08	5.26e-12	1.53e-09	0.3	0.31	Aortic root size;	chr7:66413674	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6978028	ENSG00000232559.3	GS1-124K5.12	7.08	5.26e-12	1.53e-09	0.3	0.31	Aortic root size;	chr7:66421313	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6947339	ENSG00000232559.3	GS1-124K5.12	7.08	5.26e-12	1.53e-09	0.3	0.31	Aortic root size;	chr7:66423483	chr7:66554588~66576923:-
THCA	cis	rs17684571	0.938	rs35408048	ENSG00000231441.1	RP11-472M19.2	7.08	5.26e-12	1.53e-09	0.4	0.31	Schizophrenia;	chr6:56694746	chr6:56844002~56864078:+
THCA	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	7.08	5.26e-12	1.53e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
THCA	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-7.08	5.26e-12	1.53e-09	-0.52	-0.31	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
THCA	cis	rs8067545	0.641	rs203482	ENSG00000270091.1	RP11-78O7.2	-7.08	5.26e-12	1.53e-09	-0.23	-0.31	Schizophrenia;	chr17:19923897	chr17:19896590~19897287:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000232559.3	GS1-124K5.12	-7.08	5.27e-12	1.53e-09	-0.3	-0.31	Aortic root size;	chr7:66093491	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs1182882	ENSG00000232559.3	GS1-124K5.12	-7.08	5.27e-12	1.53e-09	-0.3	-0.31	Aortic root size;	chr7:66097076	chr7:66554588~66576923:-
THCA	cis	rs9902453	0.817	rs62068620	ENSG00000264007.1	RP11-68I3.10	7.08	5.27e-12	1.53e-09	0.36	0.31	Coffee consumption (cups per day);	chr17:29840656	chr17:29621617~29622254:-
THCA	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	7.08	5.27e-12	1.53e-09	0.25	0.31	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
THCA	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	7.08	5.28e-12	1.53e-09	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
THCA	cis	rs10869777	1	rs10869777	ENSG00000234618.1	RPSAP9	-7.08	5.28e-12	1.53e-09	-0.33	-0.31	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76434241	chr9:76398699~76399586:+
THCA	cis	rs6723108	0.517	rs10928520	ENSG00000224043.6	CCNT2-AS1	-7.08	5.29e-12	1.53e-09	-0.31	-0.31	Type 2 diabetes;	chr2:134846613	chr2:134735464~134918710:-
THCA	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	7.08	5.29e-12	1.53e-09	0.33	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
THCA	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	7.08	5.29e-12	1.53e-09	0.33	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
THCA	cis	rs453301	0.686	rs4840389	ENSG00000253893.2	FAM85B	7.08	5.29e-12	1.53e-09	0.4	0.31	Joint mobility (Beighton score);	chr8:9026993	chr8:8167819~8226614:-
THCA	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	7.08	5.29e-12	1.53e-09	0.4	0.31	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
THCA	cis	rs957448	0.561	rs4735302	ENSG00000253704.1	RP11-267M23.4	-7.08	5.3e-12	1.54e-09	-0.32	-0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94553722~94569745:+
THCA	cis	rs4713118	0.513	rs1225591	ENSG00000280107.1	AL022393.9	-7.08	5.3e-12	1.54e-09	-0.34	-0.31	Parkinson's disease;	chr6:28180974	chr6:28170845~28172521:+
THCA	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	7.08	5.31e-12	1.54e-09	0.39	0.31	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
THCA	cis	rs8012947	1	rs12323535	ENSG00000279636.2	LINC00216	-7.08	5.32e-12	1.54e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58303137	chr14:58288033~58289158:+
THCA	cis	rs8012947	1	rs10145481	ENSG00000279636.2	LINC00216	-7.08	5.32e-12	1.54e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58303671	chr14:58288033~58289158:+
THCA	cis	rs8012947	0.959	rs1951204	ENSG00000279636.2	LINC00216	-7.08	5.32e-12	1.54e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58303983	chr14:58288033~58289158:+
THCA	cis	rs4660456	0.529	rs61779237	ENSG00000237899.1	RP4-739H11.3	7.08	5.32e-12	1.54e-09	0.38	0.31	Platelet count;	chr1:40685300	chr1:40669089~40687588:-
THCA	cis	rs9902453	0.817	rs12941382	ENSG00000264007.1	RP11-68I3.10	-7.08	5.32e-12	1.54e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:30083106	chr17:29621617~29622254:-
THCA	cis	rs10411161	0.81	rs76098421	ENSG00000269483.1	AC006272.1	7.08	5.32e-12	1.54e-09	0.52	0.31	Breast cancer;	chr19:51901392	chr19:51839924~51843324:-
THCA	cis	rs853679	1	rs853679	ENSG00000219392.1	RP1-265C24.5	-7.08	5.33e-12	1.55e-09	-0.48	-0.31	Depression;	chr6:28329086	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs853678	ENSG00000219392.1	RP1-265C24.5	-7.08	5.33e-12	1.55e-09	-0.48	-0.31	Depression;	chr6:28329536	chr6:28115628~28116551:+
THCA	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-7.08	5.33e-12	1.55e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-7.08	5.33e-12	1.55e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-7.08	5.33e-12	1.55e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
THCA	cis	rs9902453	0.933	rs7225462	ENSG00000264007.1	RP11-68I3.10	7.08	5.33e-12	1.55e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29994208	chr17:29621617~29622254:-
THCA	cis	rs11168351	0.926	rs10875719	ENSG00000258273.1	RP11-370I10.4	-7.08	5.33e-12	1.55e-09	-0.41	-0.31	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48333755~48333901:-
THCA	cis	rs853679	0.517	rs12332979	ENSG00000272009.1	RP1-313I6.12	-7.08	5.33e-12	1.55e-09	-0.37	-0.31	Depression;	chr6:28173770	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs67878650	ENSG00000272009.1	RP1-313I6.12	-7.08	5.33e-12	1.55e-09	-0.37	-0.31	Depression;	chr6:28174809	chr6:28078792~28081130:-
THCA	cis	rs853679	0.569	rs9348798	ENSG00000272009.1	RP1-313I6.12	-7.08	5.33e-12	1.55e-09	-0.37	-0.31	Depression;	chr6:28175233	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380065	ENSG00000272009.1	RP1-313I6.12	-7.08	5.33e-12	1.55e-09	-0.37	-0.31	Depression;	chr6:28176973	chr6:28078792~28081130:-
THCA	cis	rs6600671	1	rs1986111	ENSG00000223345.3	HIST2H2BA	7.08	5.34e-12	1.55e-09	0.34	0.31	Hip geometry;	chr1:121462934	chr1:121108210~121117257:-
THCA	cis	rs9902453	0.845	rs2617875	ENSG00000264007.1	RP11-68I3.10	7.08	5.34e-12	1.55e-09	0.36	0.31	Coffee consumption (cups per day);	chr17:29763006	chr17:29621617~29622254:-
THCA	cis	rs1198430	0.925	rs487859	ENSG00000232482.2	RP4-654C18.1	-7.08	5.35e-12	1.55e-09	-0.57	-0.31	Total cholesterol levels;	chr1:23474608	chr1:23410832~23412146:+
THCA	cis	rs17695224	0.5	rs56083320	ENSG00000269483.1	AC006272.1	7.08	5.35e-12	1.55e-09	0.33	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51818005	chr19:51839924~51843324:-
THCA	cis	rs651907	0.535	rs35810977	ENSG00000256628.3	ZBTB11-AS1	7.08	5.35e-12	1.55e-09	0.37	0.31	Colorectal cancer;	chr3:101812536	chr3:101676475~101679217:+
THCA	cis	rs74233809	1	rs11191472	ENSG00000213277.3	MARCKSL1P1	7.08	5.36e-12	1.55e-09	0.51	0.31	Birth weight;	chr10:102947259	chr10:103175554~103176094:+
THCA	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	7.08	5.37e-12	1.56e-09	0.26	0.31	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
THCA	cis	rs4947019	0.534	rs75527655	ENSG00000260273.1	RP11-425D10.10	7.08	5.37e-12	1.56e-09	0.68	0.31	Hematological parameters;	chr6:109392693	chr6:109382795~109383666:+
THCA	cis	rs7246657	0.943	rs4803460	ENSG00000226686.6	LINC01535	-7.08	5.38e-12	1.56e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37394326	chr19:37251912~37265535:+
THCA	cis	rs42490	0.528	rs1040327	ENSG00000251136.7	RP11-37B2.1	7.08	5.38e-12	1.56e-09	0.26	0.31	Leprosy;	chr8:89669585	chr8:89609409~89757727:-
THCA	cis	rs9902453	0.74	rs1382391	ENSG00000264007.1	RP11-68I3.10	-7.08	5.38e-12	1.56e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29784968	chr17:29621617~29622254:-
THCA	cis	rs7727544	0.716	rs10058655	ENSG00000233006.5	AC034220.3	7.08	5.39e-12	1.56e-09	0.25	0.31	Blood metabolite levels;	chr5:132235203	chr5:132311285~132369916:-
THCA	cis	rs6539288	0.63	rs1055332	ENSG00000260329.1	RP11-412D9.4	-7.08	5.4e-12	1.56e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106954847	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.677	rs2287163	ENSG00000260329.1	RP11-412D9.4	-7.08	5.4e-12	1.56e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106955516	chr12:106954029~106955497:-
THCA	cis	rs240993	0.909	rs11153279	ENSG00000271789.1	RP5-1112D6.7	7.08	5.4e-12	1.57e-09	0.33	0.31	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111297126~111298510:+
THCA	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-7.08	5.41e-12	1.57e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
THCA	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-7.08	5.41e-12	1.57e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
THCA	cis	rs200972	1	rs200972	ENSG00000219392.1	RP1-265C24.5	-7.08	5.42e-12	1.57e-09	-0.36	-0.31	Urinary tract infection frequency;	chr6:27891059	chr6:28115628~28116551:+
THCA	cis	rs7208859	0.673	rs28588622	ENSG00000264538.5	SUZ12P1	-7.08	5.43e-12	1.57e-09	-0.33	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30709299~30790908:+
THCA	cis	rs6840258	0.66	rs55816619	ENSG00000251411.1	RP11-397E7.4	-7.08	5.44e-12	1.58e-09	-0.39	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87038653	chr4:86913266~86914817:-
THCA	cis	rs7045881	0.674	rs62542706	ENSG00000254396.1	RP11-56F10.3	7.08	5.45e-12	1.58e-09	0.49	0.31	Schizophrenia;	chr9:27054959	chr9:27102630~27104728:+
THCA	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	7.08	5.45e-12	1.58e-09	0.36	0.31	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
THCA	cis	rs6928977	0.675	rs11154803	ENSG00000231028.7	LINC00271	-7.08	5.45e-12	1.58e-09	-0.26	-0.31	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135497801~135716055:+
THCA	cis	rs12594515	1	rs11070464	ENSG00000259200.1	RP11-718O11.1	-7.08	5.46e-12	1.58e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45692578	chr15:45705078~45931069:+
THCA	cis	rs74233809	1	rs12411886	ENSG00000213277.3	MARCKSL1P1	7.07	5.46e-12	1.58e-09	0.51	0.31	Birth weight;	chr10:102925542	chr10:103175554~103176094:+
THCA	cis	rs7942368	0.715	rs12788118	ENSG00000254632.1	RP11-21L23.4	7.07	5.47e-12	1.58e-09	0.44	0.31	Endometriosis;	chr11:76783176	chr11:76759916~76768223:-
THCA	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	7.07	5.47e-12	1.58e-09	0.4	0.31	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
THCA	cis	rs6723108	0.517	rs6729702	ENSG00000224043.6	CCNT2-AS1	-7.07	5.47e-12	1.58e-09	-0.31	-0.31	Type 2 diabetes;	chr2:134844586	chr2:134735464~134918710:-
THCA	cis	rs875971	1	rs2220626	ENSG00000232559.3	GS1-124K5.12	-7.07	5.49e-12	1.59e-09	-0.3	-0.31	Aortic root size;	chr7:66081075	chr7:66554588~66576923:-
THCA	cis	rs651907	0.535	rs13084113	ENSG00000256628.3	ZBTB11-AS1	7.07	5.49e-12	1.59e-09	0.37	0.31	Colorectal cancer;	chr3:101815195	chr3:101676475~101679217:+
THCA	cis	rs736801	0.569	rs12517950	ENSG00000224431.1	AC063976.7	7.07	5.5e-12	1.59e-09	0.28	0.31	Mosquito bite size;Breast cancer;	chr5:132395634	chr5:132199456~132203487:+
THCA	cis	rs8030379	1	rs4842838	ENSG00000230373.7	GOLGA6L5P	7.07	5.5e-12	1.59e-09	0.29	0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84507885~84516814:-
THCA	cis	rs160451	0.899	rs218887	ENSG00000251136.7	RP11-37B2.1	7.07	5.5e-12	1.59e-09	0.26	0.31	Leprosy;	chr8:89679295	chr8:89609409~89757727:-
THCA	cis	rs7189233	1	rs62048491	ENSG00000279722.1	RP11-44F14.6	-7.07	5.5e-12	1.59e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr16:53422479	chr16:53487607~53489943:-
THCA	cis	rs7260598	0.792	rs17620072	ENSG00000268442.1	CTD-2027I19.2	7.07	5.51e-12	1.6e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24177850	chr19:24162370~24163425:-
THCA	cis	rs12681366	0.537	rs10095298	ENSG00000253704.1	RP11-267M23.4	7.07	5.51e-12	1.6e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94472353	chr8:94553722~94569745:+
THCA	cis	rs467650	0.549	rs162676	ENSG00000246763.5	RGMB-AS1	-7.07	5.53e-12	1.6e-09	-0.29	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr5:98655799	chr5:98769618~98773469:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000228039.3	KB-1125A3.10	-7.07	5.53e-12	1.6e-09	-0.42	-0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23963780~23964374:+
THCA	cis	rs6061231	0.675	rs755726	ENSG00000275437.1	RP5-908M14.10	7.07	5.54e-12	1.6e-09	0.27	0.31	Colorectal cancer;	chr20:62387568	chr20:62402236~62405935:-
THCA	cis	rs2380205	0.58	rs980230	ENSG00000232807.2	RP11-536K7.3	7.07	5.54e-12	1.6e-09	0.29	0.31	Breast cancer;	chr10:5863268	chr10:5934270~5945900:-
THCA	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-7.07	5.54e-12	1.6e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
THCA	cis	rs42490	0.553	rs380425	ENSG00000251136.7	RP11-37B2.1	-7.07	5.54e-12	1.61e-09	-0.28	-0.31	Leprosy;	chr8:89849814	chr8:89609409~89757727:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000272009.1	RP1-313I6.12	-7.07	5.55e-12	1.61e-09	-0.36	-0.31	Depression;	chr6:28151096	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9295758	ENSG00000272009.1	RP1-313I6.12	-7.07	5.55e-12	1.61e-09	-0.36	-0.31	Depression;	chr6:28152885	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs17774663	ENSG00000272009.1	RP1-313I6.12	-7.07	5.55e-12	1.61e-09	-0.36	-0.31	Depression;	chr6:28153120	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9357065	ENSG00000272009.1	RP1-313I6.12	-7.07	5.55e-12	1.61e-09	-0.36	-0.31	Depression;	chr6:28161802	chr6:28078792~28081130:-
THCA	cis	rs741668	0.897	rs41284147	ENSG00000235903.6	CPB2-AS1	7.07	5.56e-12	1.61e-09	0.42	0.31	Cerebrospinal fluid clusterin levels;	chr13:45957558	chr13:46052806~46113332:+
THCA	cis	rs7044106	0.762	rs10760110	ENSG00000238181.2	AHCYP2	7.07	5.56e-12	1.61e-09	0.39	0.31	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120720673~120721972:+
THCA	cis	rs4934494	0.768	rs58163515	ENSG00000232936.4	RP11-80H5.2	7.07	5.57e-12	1.61e-09	0.42	0.31	Red blood cell count;	chr10:89637807	chr10:89645282~89650667:+
THCA	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	7.07	5.57e-12	1.61e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
THCA	cis	rs74233809	1	rs943037	ENSG00000213277.3	MARCKSL1P1	7.07	5.58e-12	1.61e-09	0.52	0.31	Birth weight;	chr10:103076162	chr10:103175554~103176094:+
THCA	cis	rs853679	0.882	rs3757188	ENSG00000226314.6	ZNF192P1	-7.07	5.58e-12	1.61e-09	-0.52	-0.31	Depression;	chr6:28139579	chr6:28161781~28169594:+
THCA	cis	rs8114671	0.967	rs2180568	ENSG00000269202.1	RP4-614O4.12	7.07	5.58e-12	1.61e-09	0.26	0.31	Height;	chr20:35206991	chr20:35201747~35203288:-
THCA	cis	rs7942368	1	rs1837679	ENSG00000254632.1	RP11-21L23.4	7.07	5.59e-12	1.62e-09	0.46	0.31	Endometriosis;	chr11:76790513	chr11:76759916~76768223:-
THCA	cis	rs6723108	0.517	rs6430548	ENSG00000224043.6	CCNT2-AS1	-7.07	5.59e-12	1.62e-09	-0.31	-0.31	Type 2 diabetes;	chr2:134854869	chr2:134735464~134918710:-
THCA	cis	rs11148252	0.811	rs9535895	ENSG00000278238.1	RP11-245D16.4	-7.07	5.59e-12	1.62e-09	-0.35	-0.31	Lewy body disease;	chr13:52191712	chr13:52454775~52455331:-
THCA	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-7.07	5.59e-12	1.62e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
THCA	cis	rs42490	0.51	rs218890	ENSG00000251136.7	RP11-37B2.1	-7.07	5.6e-12	1.62e-09	-0.26	-0.31	Leprosy;	chr8:89680848	chr8:89609409~89757727:-
THCA	cis	rs10899021	1	rs11236193	ENSG00000279353.1	RP11-864N7.4	7.07	5.6e-12	1.62e-09	0.64	0.31	Response to metformin (IC50);	chr11:74657262	chr11:74698231~74699658:-
THCA	cis	rs8012947	1	rs8011191	ENSG00000279636.2	LINC00216	-7.07	5.6e-12	1.62e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58250295	chr14:58288033~58289158:+
THCA	cis	rs8012947	1	rs6573197	ENSG00000279636.2	LINC00216	-7.07	5.6e-12	1.62e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58257490	chr14:58288033~58289158:+
THCA	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	7.07	5.6e-12	1.62e-09	0.28	0.31	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
THCA	cis	rs7246657	0.943	rs8106839	ENSG00000226686.6	LINC01535	-7.07	5.6e-12	1.62e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37467573	chr19:37251912~37265535:+
THCA	cis	rs9813712	0.595	rs1993217	ENSG00000228252.7	COL6A4P2	-7.07	5.61e-12	1.62e-09	-0.31	-0.31	Response to amphetamines;	chr3:130284832	chr3:130212823~130273806:+
THCA	cis	rs875971	0.798	rs57739047	ENSG00000232559.3	GS1-124K5.12	7.07	5.61e-12	1.62e-09	0.29	0.31	Aortic root size;	chr7:66507579	chr7:66554588~66576923:-
THCA	cis	rs875971	0.83	rs6950137	ENSG00000232559.3	GS1-124K5.12	7.07	5.61e-12	1.62e-09	0.29	0.31	Aortic root size;	chr7:66511623	chr7:66554588~66576923:-
THCA	cis	rs7044106	0.664	rs7861679	ENSG00000238181.2	AHCYP2	7.07	5.61e-12	1.62e-09	0.4	0.31	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120720673~120721972:+
THCA	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-7.07	5.62e-12	1.62e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
THCA	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-7.07	5.62e-12	1.62e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
THCA	cis	rs7942368	1	rs1440977	ENSG00000204529.3	GUCY2EP	7.07	5.62e-12	1.63e-09	0.44	0.31	Endometriosis;	chr11:76765385	chr11:76694043~76707641:-
THCA	cis	rs8114671	0.562	rs6060064	ENSG00000269202.1	RP4-614O4.12	7.07	5.62e-12	1.63e-09	0.26	0.31	Height;	chr20:34818536	chr20:35201747~35203288:-
THCA	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-7.07	5.62e-12	1.63e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
THCA	cis	rs2836974	0.544	rs8128919	ENSG00000255568.3	BRWD1-AS2	7.07	5.62e-12	1.63e-09	0.25	0.31	Cognitive function;	chr21:39339936	chr21:39313935~39314962:+
THCA	cis	rs8012947	1	rs12878264	ENSG00000279636.2	LINC00216	-7.07	5.62e-12	1.63e-09	-0.33	-0.31	Alcohol consumption in current drinkers;	chr14:58254250	chr14:58288033~58289158:+
THCA	cis	rs12594515	1	rs6493170	ENSG00000259200.1	RP11-718O11.1	-7.07	5.62e-12	1.63e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45694821	chr15:45705078~45931069:+
THCA	cis	rs7267979	0.718	rs2983489	ENSG00000274414.1	RP5-965G21.4	-7.07	5.64e-12	1.63e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25239007~25245229:-
THCA	cis	rs12681366	0.537	rs6999976	ENSG00000253704.1	RP11-267M23.4	7.07	5.65e-12	1.63e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94470194	chr8:94553722~94569745:+
THCA	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	7.07	5.65e-12	1.63e-09	0.38	0.31	Height;	chr6:109352730	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	7.07	5.65e-12	1.63e-09	0.38	0.31	Height;	chr6:109353355	chr6:109382795~109383666:+
THCA	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-7.07	5.65e-12	1.63e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
THCA	cis	rs6539288	0.677	rs1348566	ENSG00000260329.1	RP11-412D9.4	-7.07	5.66e-12	1.64e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106931870	chr12:106954029~106955497:-
THCA	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-7.07	5.66e-12	1.64e-09	-0.4	-0.31	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
THCA	cis	rs7044106	0.762	rs1867254	ENSG00000238181.2	AHCYP2	-7.07	5.66e-12	1.64e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120720673~120721972:+
THCA	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-7.07	5.66e-12	1.64e-09	-0.34	-0.31	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
THCA	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	7.07	5.66e-12	1.64e-09	0.31	0.31	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
THCA	cis	rs7727544	0.716	rs6863213	ENSG00000233006.5	AC034220.3	7.07	5.67e-12	1.64e-09	0.25	0.31	Blood metabolite levels;	chr5:132240239	chr5:132311285~132369916:-
THCA	cis	rs3812049	0.737	rs790155	ENSG00000245937.6	LINC01184	7.07	5.67e-12	1.64e-09	0.35	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128162688	chr5:127940426~128083172:-
THCA	cis	rs3812049	0.737	rs790154	ENSG00000245937.6	LINC01184	7.07	5.67e-12	1.64e-09	0.35	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128165543	chr5:127940426~128083172:-
THCA	cis	rs2439831	0.867	rs2447196	ENSG00000249839.1	AC011330.5	7.07	5.67e-12	1.64e-09	0.47	0.31	Lung cancer in ever smokers;	chr15:43601620	chr15:43663654~43684339:-
THCA	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-7.07	5.7e-12	1.65e-09	-0.25	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
THCA	cis	rs7942368	0.941	rs12290350	ENSG00000254761.1	RP11-672A2.1	-7.07	5.7e-12	1.65e-09	-0.44	-0.31	Endometriosis;	chr11:76769211	chr11:76712396~76719608:-
THCA	cis	rs3847687	1	rs78233646	ENSG00000279993.1	RP11-76C10.3	7.07	5.7e-12	1.65e-09	0.34	0.31	Longevity;	chr12:131035625	chr12:131025561~131028060:-
THCA	cis	rs17695224	0.5	rs55899451	ENSG00000269483.1	AC006272.1	7.07	5.71e-12	1.65e-09	0.33	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51818058	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs55843033	ENSG00000269483.1	AC006272.1	7.07	5.71e-12	1.65e-09	0.33	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51818280	chr19:51839924~51843324:-
THCA	cis	rs6540731	1	rs35209719	ENSG00000226251.4	RP11-15I11.3	-7.07	5.71e-12	1.65e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212228335	chr1:212225278~212238977:-
THCA	cis	rs6540731	0.967	rs4951581	ENSG00000226251.4	RP11-15I11.3	-7.07	5.71e-12	1.65e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212228770	chr1:212225278~212238977:-
THCA	cis	rs7045881	0.674	rs73438223	ENSG00000254396.1	RP11-56F10.3	7.07	5.71e-12	1.65e-09	0.48	0.31	Schizophrenia;	chr9:27041663	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.674	rs78770866	ENSG00000254396.1	RP11-56F10.3	7.07	5.71e-12	1.65e-09	0.48	0.31	Schizophrenia;	chr9:27046470	chr9:27102630~27104728:+
THCA	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	7.07	5.71e-12	1.65e-09	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
THCA	cis	rs7512898	0.9	rs6427848	ENSG00000260088.1	RP11-92G12.3	-7.07	5.72e-12	1.65e-09	-0.39	-0.31	Electrocardiographic conduction measures;	chr1:200701253	chr1:200669507~200694250:+
THCA	cis	rs7189233	1	rs7189233	ENSG00000279722.1	RP11-44F14.6	-7.07	5.73e-12	1.66e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr16:53421471	chr16:53487607~53489943:-
THCA	cis	rs853679	0.599	rs156743	ENSG00000219392.1	RP1-265C24.5	-7.07	5.74e-12	1.66e-09	-0.49	-0.31	Depression;	chr6:27999311	chr6:28115628~28116551:+
THCA	cis	rs12594515	1	rs6493172	ENSG00000259200.1	RP11-718O11.1	-7.07	5.75e-12	1.66e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45695015	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs8025258	ENSG00000259200.1	RP11-718O11.1	-7.07	5.75e-12	1.66e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45695356	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs8027000	ENSG00000259200.1	RP11-718O11.1	-7.07	5.75e-12	1.66e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45695597	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs8026221	ENSG00000259200.1	RP11-718O11.1	-7.07	5.75e-12	1.66e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45695712	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs8031128	ENSG00000259200.1	RP11-718O11.1	-7.07	5.75e-12	1.66e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45696330	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs8032361	ENSG00000259200.1	RP11-718O11.1	-7.07	5.75e-12	1.66e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45696355	chr15:45705078~45931069:+
THCA	cis	rs12594515	0.967	rs71405295	ENSG00000259200.1	RP11-718O11.1	-7.07	5.75e-12	1.66e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45696723	chr15:45705078~45931069:+
THCA	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-7.07	5.75e-12	1.66e-09	-0.37	-0.31	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
THCA	cis	rs990871	0.927	rs6699744	ENSG00000227207.2	RPL31P12	-7.07	5.76e-12	1.66e-09	-0.38	-0.31	Subcutaneous adipose tissue;	chr1:72359461	chr1:72301472~72301829:+
THCA	cis	rs75422866	0.867	rs7303895	ENSG00000274902.1	RP1-197B17.4	7.07	5.76e-12	1.66e-09	0.63	0.31	Pneumonia;	chr12:47683290	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs7304743	ENSG00000274902.1	RP1-197B17.4	-7.07	5.76e-12	1.66e-09	-0.63	-0.31	Pneumonia;	chr12:47683658	chr12:47731908~47732351:+
THCA	cis	rs6723226	0.842	rs2754522	ENSG00000276334.1	AL133243.1	7.07	5.76e-12	1.66e-09	0.35	0.31	Intelligence (multi-trait analysis);	chr2:32576190	chr2:32521927~32523547:+
THCA	cis	rs9341808	0.718	rs2874829	ENSG00000272129.1	RP11-250B2.6	7.07	5.77e-12	1.67e-09	0.39	0.31	Sitting height ratio;	chr6:80146380	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.618	rs6916507	ENSG00000272129.1	RP11-250B2.6	7.07	5.77e-12	1.67e-09	0.39	0.31	Sitting height ratio;	chr6:80152548	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.65	rs6909546	ENSG00000272129.1	RP11-250B2.6	7.07	5.77e-12	1.67e-09	0.39	0.31	Sitting height ratio;	chr6:80160206	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.69	rs2322634	ENSG00000272129.1	RP11-250B2.6	7.07	5.77e-12	1.67e-09	0.39	0.31	Sitting height ratio;	chr6:80164297	chr6:80355424~80356859:+
THCA	cis	rs875971	0.862	rs2420174	ENSG00000232559.3	GS1-124K5.12	-7.07	5.77e-12	1.67e-09	-0.29	-0.31	Aortic root size;	chr7:66180374	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs2420173	ENSG00000232559.3	GS1-124K5.12	-7.07	5.77e-12	1.67e-09	-0.29	-0.31	Aortic root size;	chr7:66180412	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs4718319	ENSG00000232559.3	GS1-124K5.12	-7.07	5.77e-12	1.67e-09	-0.29	-0.31	Aortic root size;	chr7:66187797	chr7:66554588~66576923:-
THCA	cis	rs7044106	0.791	rs10984998	ENSG00000238181.2	AHCYP2	-7.07	5.77e-12	1.67e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120720673~120721972:+
THCA	cis	rs7727544	0.716	rs2089855	ENSG00000233006.5	AC034220.3	7.07	5.78e-12	1.67e-09	0.25	0.31	Blood metabolite levels;	chr5:132237836	chr5:132311285~132369916:-
THCA	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	7.07	5.78e-12	1.67e-09	0.26	0.31	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
THCA	cis	rs12701220	0.901	rs12701713	ENSG00000229043.2	AC091729.9	-7.07	5.78e-12	1.67e-09	-0.41	-0.31	Bronchopulmonary dysplasia;	chr7:1050869	chr7:1160374~1165267:+
THCA	cis	rs9902453	0.704	rs2628179	ENSG00000264007.1	RP11-68I3.10	-7.07	5.79e-12	1.67e-09	-0.36	-0.31	Coffee consumption (cups per day);	chr17:29744778	chr17:29621617~29622254:-
THCA	cis	rs7044106	0.762	rs10984974	ENSG00000238181.2	AHCYP2	-7.07	5.79e-12	1.67e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120720673~120721972:+
THCA	cis	rs875971	0.83	rs6967708	ENSG00000232559.3	GS1-124K5.12	-7.07	5.8e-12	1.67e-09	-0.3	-0.31	Aortic root size;	chr7:66192326	chr7:66554588~66576923:-
THCA	cis	rs516805	0.63	rs2606656	ENSG00000279453.1	RP3-425C14.4	-7.07	5.82e-12	1.68e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122153088	chr6:122436789~122439223:-
THCA	cis	rs728616	0.867	rs12413715	ENSG00000225484.5	NUTM2B-AS1	-7.07	5.82e-12	1.68e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:79663088~79826594:-
THCA	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	7.07	5.82e-12	1.68e-09	0.42	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
THCA	cis	rs7260598	0.792	rs17620048	ENSG00000268442.1	CTD-2027I19.2	7.06	5.83e-12	1.68e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24174677	chr19:24162370~24163425:-
THCA	cis	rs4927850	1	rs6799572	ENSG00000207650.1	MIR570	7.06	5.83e-12	1.68e-09	0.33	0.31	Pancreatic cancer;	chr3:196013537	chr3:195699401~195699497:+
THCA	cis	rs2976388	1	rs2572910	ENSG00000253741.1	CTD-2292P10.4	7.06	5.83e-12	1.68e-09	0.38	0.31	Urinary tract infection frequency;	chr8:142688717	chr8:142702252~142726973:-
THCA	cis	rs2562456	0.833	rs2928211	ENSG00000268119.4	CTD-2561J22.5	-7.06	5.83e-12	1.68e-09	-0.39	-0.31	Pain;	chr19:21358495	chr19:21444241~21463908:-
THCA	cis	rs728616	0.614	rs55768100	ENSG00000225484.5	NUTM2B-AS1	-7.06	5.83e-12	1.68e-09	-0.46	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:79663088~79826594:-
THCA	cis	rs6600671	0.966	rs6600664	ENSG00000223345.3	HIST2H2BA	7.06	5.84e-12	1.69e-09	0.34	0.31	Hip geometry;	chr1:121480638	chr1:121108210~121117257:-
THCA	cis	rs6600671	0.932	rs6600663	ENSG00000223345.3	HIST2H2BA	7.06	5.84e-12	1.69e-09	0.34	0.31	Hip geometry;	chr1:121480639	chr1:121108210~121117257:-
THCA	cis	rs4947019	0.609	rs9487082	ENSG00000260273.1	RP11-425D10.10	7.06	5.84e-12	1.69e-09	0.67	0.31	Hematological parameters;	chr6:109388333	chr6:109382795~109383666:+
THCA	cis	rs9902453	0.874	rs7213517	ENSG00000264007.1	RP11-68I3.10	-7.06	5.86e-12	1.69e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:30074722	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs7218379	ENSG00000264007.1	RP11-68I3.10	-7.06	5.86e-12	1.69e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:30075719	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.817	rs7217961	ENSG00000264007.1	RP11-68I3.10	-7.06	5.86e-12	1.69e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:30076094	chr17:29621617~29622254:-
THCA	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	7.06	5.87e-12	1.69e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
THCA	cis	rs853679	0.824	rs34712084	ENSG00000226314.6	ZNF192P1	-7.06	5.87e-12	1.69e-09	-0.52	-0.31	Depression;	chr6:28076050	chr6:28161781~28169594:+
THCA	cis	rs853679	0.824	rs1321505	ENSG00000226314.6	ZNF192P1	-7.06	5.87e-12	1.69e-09	-0.52	-0.31	Depression;	chr6:28085045	chr6:28161781~28169594:+
THCA	cis	rs853679	0.882	rs9468287	ENSG00000226314.6	ZNF192P1	-7.06	5.87e-12	1.69e-09	-0.52	-0.31	Depression;	chr6:28111963	chr6:28161781~28169594:+
THCA	cis	rs2288884	0.943	rs75722407	ENSG00000275055.1	CTC-471J1.11	-7.06	5.88e-12	1.7e-09	-0.31	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021989	chr19:52049007~52049754:+
THCA	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-7.06	5.88e-12	1.7e-09	-0.3	-0.31	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
THCA	cis	rs860295	0.535	rs2297649	ENSG00000225855.5	RUSC1-AS1	-7.06	5.88e-12	1.7e-09	-0.21	-0.31	Body mass index;	chr1:155965453	chr1:155316863~155324176:-
THCA	cis	rs728616	0.717	rs116884206	ENSG00000225484.5	NUTM2B-AS1	-7.06	5.89e-12	1.7e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80230790	chr10:79663088~79826594:-
THCA	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	7.06	5.89e-12	1.7e-09	0.39	0.31	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
THCA	cis	rs728616	0.867	rs56000427	ENSG00000225484.5	NUTM2B-AS1	-7.06	5.9e-12	1.7e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80227190	chr10:79663088~79826594:-
THCA	cis	rs651907	0.514	rs12636046	ENSG00000256628.3	ZBTB11-AS1	7.06	5.9e-12	1.7e-09	0.37	0.31	Colorectal cancer;	chr3:101715604	chr3:101676475~101679217:+
THCA	cis	rs1125355	0.964	rs11673825	ENSG00000251491.2	OR7E28P	-7.06	5.91e-12	1.7e-09	-0.48	-0.31	Alzheimer's disease in APOE e4+ carriers;	chr2:158816114	chr2:158862311~158863285:+
THCA	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	7.06	5.91e-12	1.7e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
THCA	cis	rs12594515	1	rs8039974	ENSG00000259200.1	RP11-718O11.1	-7.06	5.92e-12	1.71e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45694467	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs6493167	ENSG00000259200.1	RP11-718O11.1	-7.06	5.92e-12	1.71e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45694611	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs6493168	ENSG00000259200.1	RP11-718O11.1	-7.06	5.92e-12	1.71e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45694613	chr15:45705078~45931069:+
THCA	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-7.06	5.92e-12	1.71e-09	-0.22	-0.31	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
THCA	cis	rs8012947	1	rs10133305	ENSG00000279636.2	LINC00216	-7.06	5.92e-12	1.71e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58294411	chr14:58288033~58289158:+
THCA	cis	rs7267979	0.934	rs2261115	ENSG00000274414.1	RP5-965G21.4	-7.06	5.92e-12	1.71e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2261747	ENSG00000274414.1	RP5-965G21.4	-7.06	5.92e-12	1.71e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25239007~25245229:-
THCA	cis	rs7942368	1	rs56228827	ENSG00000254632.1	RP11-21L23.4	7.06	5.93e-12	1.71e-09	0.46	0.31	Endometriosis;	chr11:76756479	chr11:76759916~76768223:-
THCA	cis	rs12817211	0.549	rs7138945	ENSG00000272368.2	RP4-605O3.4	-7.06	5.93e-12	1.71e-09	-0.18	-0.31	Colorectal or endometrial cancer;	chr12:50145636	chr12:50112197~50165618:+
THCA	cis	rs4789693	0.679	rs7217570	ENSG00000265458.1	RP13-20L14.6	-7.06	5.94e-12	1.71e-09	-0.31	-0.31	Glucocorticoid-induced osteonecrosis;	chr17:82421456	chr17:82454273~82458521:-
THCA	cis	rs7267979	1	rs2482927	ENSG00000274414.1	RP5-965G21.4	7.06	5.94e-12	1.71e-09	0.37	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25239007~25245229:-
THCA	cis	rs4947019	0.686	rs3757229	ENSG00000260273.1	RP11-425D10.10	7.06	5.95e-12	1.72e-09	0.67	0.31	Hematological parameters;	chr6:109382935	chr6:109382795~109383666:+
THCA	cis	rs4947019	0.686	rs17070554	ENSG00000260273.1	RP11-425D10.10	7.06	5.95e-12	1.72e-09	0.67	0.31	Hematological parameters;	chr6:109383183	chr6:109382795~109383666:+
THCA	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	7.06	5.95e-12	1.72e-09	0.28	0.31	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
THCA	cis	rs1125355	0.964	rs11694423	ENSG00000251491.2	OR7E28P	-7.06	5.97e-12	1.72e-09	-0.49	-0.31	Alzheimer's disease in APOE e4+ carriers;	chr2:158820019	chr2:158862311~158863285:+
THCA	cis	rs6745190	0.906	rs6743720	ENSG00000236153.1	AC104076.3	-7.06	5.98e-12	1.72e-09	-0.36	-0.31	White blood cell count;	chr2:181095771	chr2:180979427~180980090:-
THCA	cis	rs853679	0.599	rs149990	ENSG00000219392.1	RP1-265C24.5	-7.06	5.99e-12	1.73e-09	-0.5	-0.31	Depression;	chr6:28030480	chr6:28115628~28116551:+
THCA	cis	rs792448	0.603	rs4951588	ENSG00000226251.4	RP11-15I11.3	-7.06	5.99e-12	1.73e-09	-0.36	-0.31	White blood cell count (basophil);	chr1:212327091	chr1:212225278~212238977:-
THCA	cis	rs7189233	0.955	rs8054299	ENSG00000279344.1	RP11-44F14.7	-7.06	6e-12	1.73e-09	-0.35	-0.31	Intelligence (multi-trait analysis);	chr16:53464743	chr16:53478957~53481550:-
THCA	cis	rs7208859	0.615	rs216462	ENSG00000264538.5	SUZ12P1	7.06	6.01e-12	1.73e-09	0.32	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30709299~30790908:+
THCA	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	7.06	6.01e-12	1.73e-09	0.25	0.31	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
THCA	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	7.06	6.01e-12	1.73e-09	0.25	0.31	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
THCA	cis	rs9287719	0.686	rs10174605	ENSG00000243819.4	RN7SL832P	7.06	6.01e-12	1.73e-09	0.25	0.31	Prostate cancer;	chr2:10585106	chr2:10690344~10692099:+
THCA	cis	rs9341808	0.718	rs9352806	ENSG00000272129.1	RP11-250B2.6	7.06	6.02e-12	1.73e-09	0.39	0.31	Sitting height ratio;	chr6:80270340	chr6:80355424~80356859:+
THCA	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-7.06	6.02e-12	1.73e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
THCA	cis	rs7267979	1	rs7018	ENSG00000274414.1	RP5-965G21.4	-7.06	6.02e-12	1.74e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4815404	ENSG00000274414.1	RP5-965G21.4	7.06	6.02e-12	1.74e-09	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6083805	ENSG00000274414.1	RP5-965G21.4	7.06	6.02e-12	1.74e-09	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25239007~25245229:-
THCA	cis	rs4072705	1	rs10986391	ENSG00000224020.1	MIR181A2HG	-7.06	6.03e-12	1.74e-09	-0.27	-0.31	Menarche (age at onset);	chr9:124665956	chr9:124658467~124698631:+
THCA	cis	rs7580658	0.534	rs2089109	ENSG00000236682.1	AC068282.3	-7.06	6.04e-12	1.74e-09	-0.39	-0.31	Protein C levels;	chr2:127193882	chr2:127389130~127400580:+
THCA	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-7.06	6.04e-12	1.74e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
THCA	cis	rs9341808	0.754	rs3805885	ENSG00000272129.1	RP11-250B2.6	-7.06	6.04e-12	1.74e-09	-0.39	-0.31	Sitting height ratio;	chr6:80287034	chr6:80355424~80356859:+
THCA	cis	rs4835473	0.662	rs4340756	ENSG00000251600.4	RP11-673E1.1	7.06	6.04e-12	1.74e-09	0.4	0.31	Immature fraction of reticulocytes;	chr4:144017063	chr4:143912331~143982454:+
THCA	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-7.06	6.04e-12	1.74e-09	-0.3	-0.31	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-7.06	6.04e-12	1.74e-09	-0.3	-0.31	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
THCA	cis	rs6570726	0.526	rs4896805	ENSG00000235652.6	RP11-545I5.3	-7.06	6.05e-12	1.74e-09	-0.29	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145414293	chr6:145799409~145886585:+
THCA	cis	rs780096	1	rs780096	ENSG00000234072.1	AC074117.10	-7.06	6.05e-12	1.74e-09	-0.23	-0.31	Total body bone mineral density;	chr2:27518205	chr2:27356246~27367622:+
THCA	cis	rs6723108	0.517	rs6430552	ENSG00000224043.6	CCNT2-AS1	-7.06	6.05e-12	1.74e-09	-0.31	-0.31	Type 2 diabetes;	chr2:134865238	chr2:134735464~134918710:-
THCA	cis	rs9902453	0.791	rs62068629	ENSG00000264007.1	RP11-68I3.10	7.06	6.06e-12	1.75e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29860578	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.817	rs1842026	ENSG00000264007.1	RP11-68I3.10	7.06	6.06e-12	1.75e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29861093	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.78	rs7210991	ENSG00000264007.1	RP11-68I3.10	7.06	6.06e-12	1.75e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29863943	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.817	rs12051834	ENSG00000264007.1	RP11-68I3.10	7.06	6.06e-12	1.75e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29865767	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.78	rs62068621	ENSG00000264007.1	RP11-68I3.10	7.06	6.06e-12	1.75e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29843364	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.78	rs57037139	ENSG00000264007.1	RP11-68I3.10	7.06	6.06e-12	1.75e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29846265	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.817	rs55758314	ENSG00000264007.1	RP11-68I3.10	7.06	6.06e-12	1.75e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29846960	chr17:29621617~29622254:-
THCA	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-7.06	6.07e-12	1.75e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-7.06	6.07e-12	1.75e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
THCA	cis	rs7044106	0.762	rs1470307	ENSG00000238181.2	AHCYP2	-7.06	6.07e-12	1.75e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120720673~120721972:+
THCA	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	7.06	6.07e-12	1.75e-09	0.57	0.31	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
THCA	cis	rs12908161	0.959	rs61074241	ENSG00000225151.9	GOLGA2P7	-7.06	6.07e-12	1.75e-09	-0.47	-0.31	Schizophrenia;	chr15:84790165	chr15:84199311~84230136:-
THCA	cis	rs651907	0.557	rs36002990	ENSG00000256628.3	ZBTB11-AS1	7.06	6.07e-12	1.75e-09	0.37	0.31	Colorectal cancer;	chr3:101719018	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs11720745	ENSG00000256628.3	ZBTB11-AS1	7.06	6.07e-12	1.75e-09	0.37	0.31	Colorectal cancer;	chr3:101722846	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs35117343	ENSG00000256628.3	ZBTB11-AS1	7.06	6.07e-12	1.75e-09	0.37	0.31	Colorectal cancer;	chr3:101726282	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs11914318	ENSG00000256628.3	ZBTB11-AS1	7.06	6.07e-12	1.75e-09	0.37	0.31	Colorectal cancer;	chr3:101735014	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs1031710	ENSG00000256628.3	ZBTB11-AS1	7.06	6.07e-12	1.75e-09	0.37	0.31	Colorectal cancer;	chr3:101745051	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs13065944	ENSG00000256628.3	ZBTB11-AS1	7.06	6.07e-12	1.75e-09	0.37	0.31	Colorectal cancer;	chr3:101754244	chr3:101676475~101679217:+
THCA	cis	rs728616	0.614	rs958865	ENSG00000225484.5	NUTM2B-AS1	-7.06	6.08e-12	1.75e-09	-0.45	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948273	chr10:79663088~79826594:-
THCA	cis	rs9902453	0.791	rs2628166	ENSG00000264007.1	RP11-68I3.10	-7.06	6.08e-12	1.75e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29786105	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.817	rs2729435	ENSG00000264007.1	RP11-68I3.10	-7.06	6.08e-12	1.75e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:29794514	chr17:29621617~29622254:-
THCA	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-7.06	6.09e-12	1.75e-09	-0.39	-0.31	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
THCA	cis	rs853679	0.599	rs149943	ENSG00000219392.1	RP1-265C24.5	-7.06	6.09e-12	1.75e-09	-0.5	-0.31	Depression;	chr6:28034610	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs1904841	ENSG00000272009.1	RP1-313I6.12	-7.06	6.11e-12	1.76e-09	-0.37	-0.31	Depression;	chr6:28140307	chr6:28078792~28081130:-
THCA	cis	rs7246657	0.943	rs10405325	ENSG00000226686.6	LINC01535	-7.06	6.12e-12	1.76e-09	-0.46	-0.31	Coronary artery calcification;	chr19:37392575	chr19:37251912~37265535:+
THCA	cis	rs7267979	0.966	rs4813557	ENSG00000274414.1	RP5-965G21.4	7.06	6.13e-12	1.76e-09	0.37	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25239007~25245229:-
THCA	cis	rs593531	0.614	rs486758	ENSG00000212961.4	HNRNPA1P40	7.06	6.13e-12	1.76e-09	0.39	0.31	Neuroticism;	chr11:74347887	chr11:74354443~74355720:+
THCA	cis	rs71403859	0.502	rs8053720	ENSG00000260886.1	TAT-AS1	7.06	6.13e-12	1.76e-09	0.52	0.31	Post bronchodilator FEV1;	chr16:71422239	chr16:71565789~71578187:+
THCA	cis	rs12435908	1	rs17246042	ENSG00000276116.2	FUT8-AS1	-7.06	6.14e-12	1.77e-09	-0.49	-0.31	Ischemic stroke;	chr14:65407612	chr14:65411170~65412690:-
THCA	cis	rs7260598	0.792	rs73031010	ENSG00000268442.1	CTD-2027I19.2	7.06	6.14e-12	1.77e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24178160	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs7260592	ENSG00000268442.1	CTD-2027I19.2	7.06	6.14e-12	1.77e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24178786	chr19:24162370~24163425:-
THCA	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-7.06	6.15e-12	1.77e-09	-0.34	-0.31	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
THCA	cis	rs2288884	1	rs76768215	ENSG00000275055.1	CTC-471J1.11	-7.06	6.15e-12	1.77e-09	-0.31	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069370	chr19:52049007~52049754:+
THCA	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-7.06	6.15e-12	1.77e-09	-0.25	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
THCA	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	7.06	6.15e-12	1.77e-09	0.38	0.31	Height;	chr6:109340338	chr6:109382795~109383666:+
THCA	cis	rs4947019	0.609	rs79097132	ENSG00000260273.1	RP11-425D10.10	7.06	6.16e-12	1.77e-09	0.68	0.31	Hematological parameters;	chr6:109404619	chr6:109382795~109383666:+
THCA	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	7.06	6.16e-12	1.77e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
THCA	cis	rs1949733	1	rs3103099	ENSG00000205959.3	RP11-689P11.2	7.06	6.17e-12	1.77e-09	0.27	0.31	Response to antineoplastic agents;	chr4:8509840	chr4:8482270~8512610:+
THCA	cis	rs6745190	0.953	rs4667008	ENSG00000236153.1	AC104076.3	7.06	6.18e-12	1.78e-09	0.36	0.31	White blood cell count;	chr2:181000876	chr2:180979427~180980090:-
THCA	cis	rs6740322	0.901	rs2163228	ENSG00000234936.1	AC010883.5	7.06	6.18e-12	1.78e-09	0.33	0.31	Coronary artery disease;	chr2:43322107	chr2:43229573~43233394:+
THCA	cis	rs9902453	0.704	rs2617874	ENSG00000264007.1	RP11-68I3.10	7.06	6.19e-12	1.78e-09	0.36	0.31	Coffee consumption (cups per day);	chr17:29758154	chr17:29621617~29622254:-
THCA	cis	rs160451	0.966	rs2101854	ENSG00000251136.7	RP11-37B2.1	7.06	6.2e-12	1.78e-09	0.26	0.31	Leprosy;	chr8:89663517	chr8:89609409~89757727:-
THCA	cis	rs736801	0.729	rs1050152	ENSG00000233006.5	AC034220.3	7.06	6.2e-12	1.78e-09	0.25	0.31	Mosquito bite size;Breast cancer;	chr5:132340627	chr5:132311285~132369916:-
THCA	cis	rs651907	0.557	rs13077925	ENSG00000256628.3	ZBTB11-AS1	7.06	6.2e-12	1.78e-09	0.36	0.31	Colorectal cancer;	chr3:101769337	chr3:101676475~101679217:+
THCA	cis	rs7247513	0.927	rs34956595	ENSG00000213290.4	PGK1P2	-7.06	6.21e-12	1.79e-09	-0.38	-0.31	Bipolar disorder;	chr19:12591983	chr19:12559571~12561105:+
THCA	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	7.05	6.22e-12	1.79e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	7.05	6.22e-12	1.79e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
THCA	cis	rs2562456	0.793	rs2562474	ENSG00000213976.4	CTD-2561J22.2	7.05	6.22e-12	1.79e-09	0.34	0.31	Pain;	chr19:21463480	chr19:21382865~21387177:+
THCA	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-7.05	6.22e-12	1.79e-09	-0.36	-0.31	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
THCA	cis	rs9388451	0.807	rs1268070	ENSG00000237742.5	RP11-624M8.1	-7.05	6.23e-12	1.79e-09	-0.27	-0.31	Brugada syndrome;	chr6:125720018	chr6:125578558~125749190:-
THCA	cis	rs848490	0.889	rs11764525	ENSG00000214293.7	APTR	7.05	6.23e-12	1.79e-09	0.24	0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77648608	chr7:77657660~77696265:-
THCA	cis	rs728616	0.614	rs2181204	ENSG00000225484.5	NUTM2B-AS1	-7.05	6.24e-12	1.79e-09	-0.45	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79663088~79826594:-
THCA	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	7.05	6.24e-12	1.79e-09	0.4	0.31	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
THCA	cis	rs7044106	0.762	rs4837789	ENSG00000238181.2	AHCYP2	-7.05	6.24e-12	1.79e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120720673~120721972:+
THCA	cis	rs42490	0.789	rs383592	ENSG00000251136.7	RP11-37B2.1	-7.05	6.25e-12	1.8e-09	-0.26	-0.31	Leprosy;	chr8:89792100	chr8:89609409~89757727:-
THCA	cis	rs9813712	0.595	rs16825656	ENSG00000228252.7	COL6A4P2	-7.05	6.25e-12	1.8e-09	-0.31	-0.31	Response to amphetamines;	chr3:130286225	chr3:130212823~130273806:+
THCA	cis	rs5760842	0.967	rs5760844	ENSG00000279110.1	CTA-243E7.1	-7.05	6.25e-12	1.8e-09	-0.38	-0.31	Recurrent major depressive disorder;	chr22:25087218	chr22:25052122~25065241:-
THCA	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-7.05	6.25e-12	1.8e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
THCA	cis	rs2287838	0.638	rs55975644	ENSG00000267289.1	CTD-2623N2.11	7.05	6.26e-12	1.8e-09	0.38	0.31	Sleep duration;	chr19:9850311	chr19:9834079~9835013:-
THCA	cis	rs2880765	0.835	rs4536419	ENSG00000259295.5	CSPG4P12	7.05	6.26e-12	1.8e-09	0.39	0.31	Coronary artery disease;	chr15:85496240	chr15:85191438~85213905:+
THCA	cis	rs1198430	0.639	rs2297841	ENSG00000232482.2	RP4-654C18.1	-7.05	6.26e-12	1.8e-09	-0.47	-0.31	Total cholesterol levels;	chr1:23437656	chr1:23410832~23412146:+
THCA	cis	rs4660456	0.619	rs753753	ENSG00000237899.1	RP4-739H11.3	-7.05	6.27e-12	1.8e-09	-0.38	-0.31	Platelet count;	chr1:40771716	chr1:40669089~40687588:-
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000272009.1	RP1-313I6.12	-7.05	6.27e-12	1.8e-09	-0.35	-0.31	Parkinson's disease;	chr6:28065618	chr6:28078792~28081130:-
THCA	cis	rs853679	1	rs853676	ENSG00000280107.1	AL022393.9	-7.05	6.28e-12	1.8e-09	-0.43	-0.31	Depression;	chr6:28331910	chr6:28170845~28172521:+
THCA	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-7.05	6.28e-12	1.81e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
THCA	cis	rs686320	1	rs1194758	ENSG00000245532.5	NEAT1	-7.05	6.29e-12	1.81e-09	-0.27	-0.31	Hip circumference adjusted for BMI;	chr11:65470614	chr11:65422774~65445540:+
THCA	cis	rs832187	0.64	rs831692	ENSG00000280620.1	SCAANT1	7.05	6.29e-12	1.81e-09	0.42	0.31	Schizophrenia;	chr3:64018307	chr3:63911518~63911772:-
THCA	cis	rs12681366	0.708	rs3019154	ENSG00000253704.1	RP11-267M23.4	7.05	6.29e-12	1.81e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94434280	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.708	rs3019279	ENSG00000253704.1	RP11-267M23.4	7.05	6.29e-12	1.81e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94435677	chr8:94553722~94569745:+
THCA	cis	rs516805	0.667	rs1456706	ENSG00000279453.1	RP3-425C14.4	-7.05	6.29e-12	1.81e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122134801	chr6:122436789~122439223:-
THCA	cis	rs516805	0.667	rs2606651	ENSG00000279453.1	RP3-425C14.4	-7.05	6.29e-12	1.81e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122136475	chr6:122436789~122439223:-
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000263603.1	CTD-2349P21.5	-7.05	6.3e-12	1.81e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30729469~30731202:+
THCA	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	7.05	6.31e-12	1.81e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
THCA	cis	rs7324557	0.683	rs9510884	ENSG00000205861.10	C1QTNF9B-AS1	7.05	6.31e-12	1.81e-09	0.38	0.31	Visceral adipose tissue adjusted for BMI;	chr13:23830873	chr13:23888889~23897263:+
THCA	cis	rs6840258	1	rs55787557	ENSG00000251411.1	RP11-397E7.4	-7.05	6.31e-12	1.81e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87029673	chr4:86913266~86914817:-
THCA	cis	rs6840258	1	rs72667759	ENSG00000251411.1	RP11-397E7.4	-7.05	6.31e-12	1.81e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031047	chr4:86913266~86914817:-
THCA	cis	rs6509701	1	rs2162919	ENSG00000268225.1	CTD-2331H12.5	7.05	6.33e-12	1.82e-09	0.32	0.31	Psychosis in Alzheimer's disease;	chr19:52878176	chr19:52861807~52862866:-
THCA	cis	rs7586673	0.893	rs889925	ENSG00000235724.7	AC009299.2	-7.05	6.33e-12	1.82e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161222785~161308303:-
THCA	cis	rs7586673	0.93	rs2884364	ENSG00000235724.7	AC009299.2	-7.05	6.33e-12	1.82e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161222785~161308303:-
THCA	cis	rs12594515	1	rs8038058	ENSG00000259200.1	RP11-718O11.1	-7.05	6.33e-12	1.82e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45698074	chr15:45705078~45931069:+
THCA	cis	rs7923837	0.687	rs10882101	ENSG00000236493.2	EIF2S2P3	7.05	6.33e-12	1.82e-09	0.31	0.31	Multiple sclerosis;Body mass index;	chr10:92702670	chr10:92668745~92669743:-
THCA	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	7.05	6.34e-12	1.82e-09	0.35	0.31	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
THCA	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	7.05	6.37e-12	1.83e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
THCA	cis	rs2562456	0.833	rs8106025	ENSG00000213976.4	CTD-2561J22.2	7.05	6.37e-12	1.83e-09	0.34	0.31	Pain;	chr19:21451922	chr19:21382865~21387177:+
THCA	cis	rs7044106	0.762	rs3903886	ENSG00000238181.2	AHCYP2	7.05	6.37e-12	1.83e-09	0.4	0.31	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120720673~120721972:+
THCA	cis	rs10266483	0.881	rs636242	ENSG00000227986.1	TRIM60P18	-7.05	6.38e-12	1.83e-09	-0.26	-0.31	Response to statin therapy;	chr7:64284377	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.921	rs653746	ENSG00000227986.1	TRIM60P18	-7.05	6.38e-12	1.83e-09	-0.26	-0.31	Response to statin therapy;	chr7:64284399	chr7:64355078~64356199:+
THCA	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	7.05	6.38e-12	1.83e-09	0.38	0.31	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	7.05	6.38e-12	1.83e-09	0.38	0.31	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
THCA	cis	rs7246657	0.891	rs7253114	ENSG00000226686.6	LINC01535	-7.05	6.38e-12	1.83e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37497823	chr19:37251912~37265535:+
THCA	cis	rs9341808	0.718	rs2322636	ENSG00000272129.1	RP11-250B2.6	7.05	6.38e-12	1.83e-09	0.39	0.31	Sitting height ratio;	chr6:80187719	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9448908	ENSG00000272129.1	RP11-250B2.6	7.05	6.38e-12	1.83e-09	0.39	0.31	Sitting height ratio;	chr6:80188352	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs3828754	ENSG00000272129.1	RP11-250B2.6	7.05	6.38e-12	1.83e-09	0.39	0.31	Sitting height ratio;	chr6:80190923	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs10943696	ENSG00000272129.1	RP11-250B2.6	7.05	6.38e-12	1.83e-09	0.39	0.31	Sitting height ratio;	chr6:80191555	chr6:80355424~80356859:+
THCA	cis	rs8114671	0.527	rs6060068	ENSG00000269202.1	RP4-614O4.12	-7.05	6.38e-12	1.83e-09	-0.27	-0.31	Height;	chr20:34828017	chr20:35201747~35203288:-
THCA	cis	rs829883	0.738	rs249846	ENSG00000227825.4	SLC9A7P1	7.05	6.38e-12	1.83e-09	0.27	0.31	Colorectal adenoma (advanced);	chr12:98474961	chr12:98453835~98457145:-
THCA	cis	rs9902453	0.817	rs62068625	ENSG00000264007.1	RP11-68I3.10	7.05	6.39e-12	1.84e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29849563	chr17:29621617~29622254:-
THCA	cis	rs7267979	1	rs6083828	ENSG00000274414.1	RP5-965G21.4	7.05	6.4e-12	1.84e-09	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25239007~25245229:-
THCA	cis	rs875971	0.798	rs6460304	ENSG00000232559.3	GS1-124K5.12	7.05	6.41e-12	1.84e-09	0.29	0.31	Aortic root size;	chr7:66499741	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6945775	ENSG00000232559.3	GS1-124K5.12	7.05	6.41e-12	1.84e-09	0.29	0.31	Aortic root size;	chr7:66503987	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.673	rs9915139	ENSG00000264538.5	SUZ12P1	-7.05	6.41e-12	1.84e-09	-0.32	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30709299~30790908:+
THCA	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-7.05	6.41e-12	1.84e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
THCA	cis	rs7246657	0.943	rs1035479	ENSG00000226686.6	LINC01535	7.05	6.42e-12	1.84e-09	0.44	0.31	Coronary artery calcification;	chr19:37402398	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.882	rs4803539	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37406620	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10406177	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37417045	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.882	rs28623164	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37422551	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs7252346	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37423780	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs2891699	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37429335	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs9676967	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37437187	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs8109632	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37440223	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs7255407	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37443034	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.941	rs7256130	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37443079	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs2112923	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37449425	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs3760825	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37454699	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10420754	ENSG00000226686.6	LINC01535	-7.05	6.42e-12	1.84e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37468470	chr19:37251912~37265535:+
THCA	cis	rs875971	0.862	rs13226170	ENSG00000232559.3	GS1-124K5.12	7.05	6.43e-12	1.85e-09	0.3	0.31	Aortic root size;	chr7:66534311	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs2420611	ENSG00000232559.3	GS1-124K5.12	7.05	6.43e-12	1.85e-09	0.3	0.31	Aortic root size;	chr7:66534333	chr7:66554588~66576923:-
THCA	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	7.05	6.44e-12	1.85e-09	0.34	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
THCA	cis	rs3847687	1	rs11061303	ENSG00000279993.1	RP11-76C10.3	7.05	6.44e-12	1.85e-09	0.34	0.31	Longevity;	chr12:131041777	chr12:131025561~131028060:-
THCA	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	7.05	6.44e-12	1.85e-09	0.38	0.31	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
THCA	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	7.05	6.44e-12	1.85e-09	0.33	0.31	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
THCA	cis	rs6539288	1	rs6539288	ENSG00000260329.1	RP11-412D9.4	-7.05	6.44e-12	1.85e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106904084	chr12:106954029~106955497:-
THCA	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	7.05	6.44e-12	1.85e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
THCA	cis	rs9876781	0.539	rs9809695	ENSG00000229759.1	MRPS18AP1	-7.05	6.45e-12	1.85e-09	-0.37	-0.31	Longevity;	chr3:48364654	chr3:48256350~48256938:-
THCA	cis	rs9902453	0.619	rs2255489	ENSG00000264007.1	RP11-68I3.10	-7.05	6.45e-12	1.85e-09	-0.36	-0.31	Coffee consumption (cups per day);	chr17:29757956	chr17:29621617~29622254:-
THCA	cis	rs6479901	0.947	rs10740128	ENSG00000232075.1	MRPL35P2	-7.05	6.45e-12	1.85e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63634317~63634827:-
THCA	cis	rs5760842	1	rs5760842	ENSG00000279110.1	CTA-243E7.1	-7.05	6.45e-12	1.85e-09	-0.38	-0.31	Recurrent major depressive disorder;	chr22:25087024	chr22:25052122~25065241:-
THCA	cis	rs9890032	0.581	rs62070592	ENSG00000263531.1	RP13-753N3.1	7.05	6.46e-12	1.85e-09	0.42	0.31	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30863921~30864940:-
THCA	cis	rs8030379	1	rs11259928	ENSG00000230373.7	GOLGA6L5P	-7.05	6.47e-12	1.86e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899343	chr15:84507885~84516814:-
THCA	cis	rs8114671	0.562	rs2424999	ENSG00000269202.1	RP4-614O4.12	-7.05	6.47e-12	1.86e-09	-0.26	-0.31	Height;	chr20:34798627	chr20:35201747~35203288:-
THCA	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	7.05	6.47e-12	1.86e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
THCA	cis	rs72480748	0.509	rs3865457	ENSG00000256612.6	CYP2B7P	-7.05	6.48e-12	1.86e-09	-0.37	-0.31	Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);Post bronchodilator FEV1;	chr19:40893064	chr19:40924219~40950660:+
THCA	cis	rs7267979	0.933	rs1130694	ENSG00000274414.1	RP5-965G21.4	-7.05	6.49e-12	1.86e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25239007~25245229:-
THCA	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-7.05	6.5e-12	1.86e-09	-0.23	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
THCA	cis	rs12655019	0.92	rs6450410	ENSG00000271828.1	CTD-2310F14.1	7.05	6.5e-12	1.87e-09	0.71	0.31	Breast cancer (early onset);	chr5:56910874	chr5:56927874~56929573:+
THCA	cis	rs7247513	0.964	rs1864083	ENSG00000213290.4	PGK1P2	-7.05	6.5e-12	1.87e-09	-0.38	-0.31	Bipolar disorder;	chr19:12596488	chr19:12559571~12561105:+
THCA	cis	rs12594515	1	rs6493175	ENSG00000259200.1	RP11-718O11.1	-7.05	6.51e-12	1.87e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45697700	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs6493176	ENSG00000259200.1	RP11-718O11.1	-7.05	6.51e-12	1.87e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45697828	chr15:45705078~45931069:+
THCA	cis	rs12594515	0.967	rs8039088	ENSG00000259200.1	RP11-718O11.1	-7.05	6.51e-12	1.87e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45697980	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs8038320	ENSG00000259200.1	RP11-718O11.1	-7.05	6.51e-12	1.87e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45698069	chr15:45705078~45931069:+
THCA	cis	rs12594515	0.967	rs67854274	ENSG00000259200.1	RP11-718O11.1	-7.05	6.51e-12	1.87e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45698320	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs58368732	ENSG00000259200.1	RP11-718O11.1	-7.05	6.51e-12	1.87e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45698333	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs7172161	ENSG00000259200.1	RP11-718O11.1	-7.05	6.51e-12	1.87e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45698582	chr15:45705078~45931069:+
THCA	cis	rs12594515	1	rs7173144	ENSG00000259200.1	RP11-718O11.1	-7.05	6.51e-12	1.87e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45698998	chr15:45705078~45931069:+
THCA	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-7.05	6.52e-12	1.87e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
THCA	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-7.05	6.52e-12	1.87e-09	-0.23	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
THCA	cis	rs2688608	0.62	rs7098444	ENSG00000271816.1	BMS1P4	7.05	6.53e-12	1.87e-09	0.31	0.31	Inflammatory bowel disease;	chr10:73820284	chr10:73699151~73730487:-
THCA	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	7.05	6.53e-12	1.87e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	7.05	6.53e-12	1.87e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
THCA	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-7.05	6.53e-12	1.87e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
THCA	cis	rs8030379	1	rs1471552	ENSG00000230373.7	GOLGA6L5P	-7.05	6.54e-12	1.88e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901982	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs7178962	ENSG00000230373.7	GOLGA6L5P	-7.05	6.54e-12	1.88e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904496	chr15:84507885~84516814:-
THCA	cis	rs9318086	0.512	rs4769290	ENSG00000205861.10	C1QTNF9B-AS1	7.05	6.54e-12	1.88e-09	0.36	0.31	Myopia (pathological);	chr13:23799304	chr13:23888889~23897263:+
THCA	cis	rs9318086	0.534	rs7996675	ENSG00000205861.10	C1QTNF9B-AS1	7.05	6.54e-12	1.88e-09	0.36	0.31	Myopia (pathological);	chr13:23799791	chr13:23888889~23897263:+
THCA	cis	rs516805	0.667	rs2045352	ENSG00000279453.1	RP3-425C14.4	-7.05	6.56e-12	1.88e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122119694	chr6:122436789~122439223:-
THCA	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	7.05	6.56e-12	1.88e-09	0.31	0.31	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
THCA	cis	rs7849973	0.624	rs1349150	ENSG00000224549.1	RP11-370B11.3	-7.05	6.57e-12	1.88e-09	-0.39	-0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22757187	chr9:22767175~22768316:+
THCA	cis	rs11148252	0.538	rs2274202	ENSG00000278238.1	RP11-245D16.4	-7.05	6.58e-12	1.89e-09	-0.34	-0.31	Lewy body disease;	chr13:52148663	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.538	rs9526842	ENSG00000278238.1	RP11-245D16.4	-7.05	6.58e-12	1.89e-09	-0.34	-0.31	Lewy body disease;	chr13:52153588	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.538	rs9535887	ENSG00000278238.1	RP11-245D16.4	-7.05	6.58e-12	1.89e-09	-0.34	-0.31	Lewy body disease;	chr13:52156626	chr13:52454775~52455331:-
THCA	cis	rs11089937	0.926	rs5750601	ENSG00000211639.2	IGLV4-60	7.05	6.58e-12	1.89e-09	0.21	0.31	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22162199~22162681:+
THCA	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	7.05	6.58e-12	1.89e-09	0.28	0.31	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
THCA	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	7.05	6.58e-12	1.89e-09	0.28	0.31	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
THCA	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	7.05	6.58e-12	1.89e-09	0.28	0.31	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
THCA	cis	rs17684571	0.938	rs16888130	ENSG00000231441.1	RP11-472M19.2	7.05	6.59e-12	1.89e-09	0.36	0.31	Schizophrenia;	chr6:56709382	chr6:56844002~56864078:+
THCA	cis	rs17684571	1	rs16888133	ENSG00000231441.1	RP11-472M19.2	7.05	6.59e-12	1.89e-09	0.36	0.31	Schizophrenia;	chr6:56709593	chr6:56844002~56864078:+
THCA	cis	rs6430553	0.821	rs12477502	ENSG00000224043.6	CCNT2-AS1	-7.05	6.59e-12	1.89e-09	-0.32	-0.31	Blood metabolite levels;	chr2:134871682	chr2:134735464~134918710:-
THCA	cis	rs8030379	0.967	rs62027761	ENSG00000230373.7	GOLGA6L5P	-7.05	6.59e-12	1.89e-09	-0.29	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903845	chr15:84507885~84516814:-
THCA	cis	rs8114671	0.933	rs6142327	ENSG00000269202.1	RP4-614O4.12	7.05	6.6e-12	1.89e-09	0.26	0.31	Height;	chr20:35205344	chr20:35201747~35203288:-
THCA	cis	rs172166	0.561	rs149976	ENSG00000219392.1	RP1-265C24.5	7.05	6.6e-12	1.89e-09	0.34	0.31	Cardiac Troponin-T levels;	chr6:28019998	chr6:28115628~28116551:+
THCA	cis	rs9902453	0.904	rs55866125	ENSG00000264007.1	RP11-68I3.10	7.05	6.61e-12	1.9e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29985975	chr17:29621617~29622254:-
THCA	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-7.05	6.63e-12	1.9e-09	-0.28	-0.31	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
THCA	cis	rs10129255	0.517	rs11625572	ENSG00000223648.3	IGHV3-64	7.05	6.63e-12	1.9e-09	0.19	0.31	Kawasaki disease;	chr14:106656426	chr14:106643132~106658258:-
THCA	cis	rs7045881	0.674	rs62542704	ENSG00000254396.1	RP11-56F10.3	7.05	6.63e-12	1.9e-09	0.48	0.31	Schizophrenia;	chr9:27047243	chr9:27102630~27104728:+
THCA	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	7.04	6.64e-12	1.9e-09	0.4	0.31	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
THCA	cis	rs736801	0.607	rs11746555	ENSG00000224431.1	AC063976.7	7.04	6.64e-12	1.9e-09	0.28	0.31	Mosquito bite size;Breast cancer;	chr5:132391341	chr5:132199456~132203487:+
THCA	cis	rs74233809	1	rs11191499	ENSG00000213277.3	MARCKSL1P1	7.04	6.64e-12	1.9e-09	0.5	0.31	Birth weight;	chr10:103004514	chr10:103175554~103176094:+
THCA	cis	rs12449000	1	rs12449000	ENSG00000260259.1	RP11-368I7.4	-7.04	6.65e-12	1.9e-09	-0.34	-0.31	Schizophrenia;	chr16:89806562	chr16:89682620~89686569:-
THCA	cis	rs9467773	0.869	rs9295689	ENSG00000124549.13	BTN2A3P	7.04	6.65e-12	1.9e-09	0.3	0.31	Intelligence (multi-trait analysis);	chr6:26455583	chr6:26421391~26432383:+
THCA	cis	rs9341808	0.718	rs11962614	ENSG00000272129.1	RP11-250B2.6	7.04	6.66e-12	1.91e-09	0.39	0.31	Sitting height ratio;	chr6:80113589	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs12208016	ENSG00000272129.1	RP11-250B2.6	7.04	6.66e-12	1.91e-09	0.39	0.31	Sitting height ratio;	chr6:80113846	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9448886	ENSG00000272129.1	RP11-250B2.6	7.04	6.66e-12	1.91e-09	0.39	0.31	Sitting height ratio;	chr6:80116184	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.683	rs9359409	ENSG00000272129.1	RP11-250B2.6	7.04	6.66e-12	1.91e-09	0.39	0.31	Sitting height ratio;	chr6:80117180	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs4437429	ENSG00000272129.1	RP11-250B2.6	7.04	6.66e-12	1.91e-09	0.39	0.31	Sitting height ratio;	chr6:80118875	chr6:80355424~80356859:+
THCA	cis	rs4664293	0.707	rs7563956	ENSG00000226266.5	AC009961.3	7.04	6.66e-12	1.91e-09	0.37	0.31	Monocyte percentage of white cells;	chr2:159815943	chr2:159670708~159712435:-
THCA	cis	rs4947019	0.609	rs116647873	ENSG00000260273.1	RP11-425D10.10	7.04	6.66e-12	1.91e-09	0.67	0.31	Hematological parameters;	chr6:109398216	chr6:109382795~109383666:+
THCA	cis	rs853679	0.517	rs17711344	ENSG00000220721.1	OR1F12	-7.04	6.67e-12	1.91e-09	-0.43	-0.31	Depression;	chr6:28109824	chr6:28073316~28074233:+
THCA	cis	rs8030379	1	rs10152119	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901629	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs1471553	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83902286	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs1564475	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903477	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs7183263	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904289	chr15:84507885~84516814:-
THCA	cis	rs8030379	0.967	rs899926	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904739	chr15:84507885~84516814:-
THCA	cis	rs8030379	0.967	rs8029387	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906523	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs940934	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906776	chr15:84507885~84516814:-
THCA	cis	rs8030379	0.935	rs1815172	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907080	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs1810049	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907300	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs11853052	ENSG00000230373.7	GOLGA6L5P	-7.04	6.68e-12	1.91e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907407	chr15:84507885~84516814:-
THCA	cis	rs6142102	0.812	rs6120440	ENSG00000275784.1	RP5-1125A11.6	7.04	6.69e-12	1.92e-09	0.33	0.31	Skin pigmentation;	chr20:33929779	chr20:33989480~33991818:-
THCA	cis	rs6539288	0.691	rs10746071	ENSG00000260329.1	RP11-412D9.4	7.04	6.69e-12	1.92e-09	0.28	0.31	Total body bone mineral density;	chr12:106959817	chr12:106954029~106955497:-
THCA	cis	rs79349575	0.756	rs2643361	ENSG00000248278.1	SUMO2P17	7.04	6.69e-12	1.92e-09	0.36	0.31	Type 2 diabetes;	chr17:48900100	chr17:48874860~48908983:-
THCA	cis	rs875971	0.723	rs28391294	ENSG00000232559.3	GS1-124K5.12	-7.04	6.7e-12	1.92e-09	-0.29	-0.31	Aortic root size;	chr7:66189328	chr7:66554588~66576923:-
THCA	cis	rs2911132	0.714	rs13167972	ENSG00000248734.2	CTD-2260A17.1	7.04	6.7e-12	1.92e-09	0.32	0.31	Urate levels (BMI interaction);	chr5:96761124	chr5:96784777~96785999:+
THCA	cis	rs853679	1	rs853685	ENSG00000280107.1	AL022393.9	-7.04	6.7e-12	1.92e-09	-0.42	-0.31	Depression;	chr6:28321008	chr6:28170845~28172521:+
THCA	cis	rs3847687	0.686	rs71448229	ENSG00000256810.1	RP11-76C10.2	7.04	6.72e-12	1.92e-09	0.37	0.31	Longevity;	chr12:131036984	chr12:131030570~131035487:-
THCA	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-7.04	6.73e-12	1.92e-09	-0.3	-0.31	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
THCA	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-7.04	6.73e-12	1.93e-09	-0.3	-0.31	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
THCA	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-7.04	6.73e-12	1.93e-09	-0.38	-0.31	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-7.04	6.73e-12	1.93e-09	-0.38	-0.31	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-7.04	6.73e-12	1.93e-09	-0.38	-0.31	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-7.04	6.73e-12	1.93e-09	-0.38	-0.31	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
THCA	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	7.04	6.74e-12	1.93e-09	0.4	0.31	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
THCA	cis	rs17695224	0.545	rs55883913	ENSG00000269483.1	AC006272.1	7.04	6.75e-12	1.93e-09	0.33	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51818071	chr19:51839924~51843324:-
THCA	cis	rs2412819	0.559	rs8040336	ENSG00000249839.1	AC011330.5	-7.04	6.75e-12	1.93e-09	-0.35	-0.31	Lung cancer;	chr15:43761419	chr15:43663654~43684339:-
THCA	cis	rs11148252	0.84	rs4369550	ENSG00000278238.1	RP11-245D16.4	-7.04	6.75e-12	1.93e-09	-0.35	-0.31	Lewy body disease;	chr13:52170775	chr13:52454775~52455331:-
THCA	cis	rs4947019	0.534	rs9487087	ENSG00000260273.1	RP11-425D10.10	7.04	6.77e-12	1.94e-09	0.67	0.31	Hematological parameters;	chr6:109401184	chr6:109382795~109383666:+
THCA	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	7.04	6.77e-12	1.94e-09	0.39	0.31	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
THCA	cis	rs6539288	0.933	rs10861673	ENSG00000260329.1	RP11-412D9.4	-7.04	6.77e-12	1.94e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106906293	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.933	rs1037012	ENSG00000260329.1	RP11-412D9.4	-7.04	6.77e-12	1.94e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106908899	chr12:106954029~106955497:-
THCA	cis	rs7267979	0.899	rs6115213	ENSG00000274414.1	RP5-965G21.4	-7.04	6.78e-12	1.94e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25239007~25245229:-
THCA	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-7.04	6.8e-12	1.94e-09	-0.35	-0.31	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
THCA	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	7.04	6.8e-12	1.94e-09	0.74	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
THCA	cis	rs651907	0.514	rs10936744	ENSG00000256628.3	ZBTB11-AS1	7.04	6.8e-12	1.95e-09	0.37	0.31	Colorectal cancer;	chr3:101714596	chr3:101676475~101679217:+
THCA	cis	rs651907	0.514	rs12636047	ENSG00000256628.3	ZBTB11-AS1	7.04	6.8e-12	1.95e-09	0.37	0.31	Colorectal cancer;	chr3:101715605	chr3:101676475~101679217:+
THCA	cis	rs12906542	0.507	rs4395040	ENSG00000260776.4	RP11-114H24.2	7.04	6.81e-12	1.95e-09	0.45	0.31	Breast cancer;	chr15:77990191	chr15:77914217~77926846:-
THCA	cis	rs6723226	0.772	rs2366894	ENSG00000276334.1	AL133243.1	7.04	6.82e-12	1.95e-09	0.34	0.31	Intelligence (multi-trait analysis);	chr2:32488639	chr2:32521927~32523547:+
THCA	cis	rs7131987	0.903	rs11050161	ENSG00000257176.2	RP11-996F15.2	-7.04	6.82e-12	1.95e-09	-0.3	-0.31	QT interval;	chr12:29267116	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.903	rs11050162	ENSG00000257176.2	RP11-996F15.2	-7.04	6.82e-12	1.95e-09	-0.3	-0.31	QT interval;	chr12:29267121	chr12:29280418~29317848:-
THCA	cis	rs7182621	0.639	rs12906068	ENSG00000182397.13	DNM1P46	7.04	6.82e-12	1.95e-09	0.43	0.31	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99790156~99806927:-
THCA	cis	rs74233809	1	rs11191519	ENSG00000213277.3	MARCKSL1P1	7.04	6.83e-12	1.95e-09	0.51	0.31	Birth weight;	chr10:103025161	chr10:103175554~103176094:+
THCA	cis	rs6600671	0.934	rs11249431	ENSG00000275538.1	RNVU1-19	-7.04	6.83e-12	1.95e-09	-0.41	-0.31	Hip geometry;	chr1:121544405	chr1:120850819~120850985:-
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-7.04	6.83e-12	1.95e-09	-0.4	-0.31	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
THCA	cis	rs847577	0.715	rs12665986	ENSG00000272950.1	RP11-307C18.1	-7.04	6.85e-12	1.96e-09	-0.39	-0.31	Breast cancer;	chr7:98090364	chr7:98322853~98323430:+
THCA	cis	rs3847687	0.901	rs12370258	ENSG00000256810.1	RP11-76C10.2	7.04	6.85e-12	1.96e-09	0.37	0.31	Longevity;	chr12:131042756	chr12:131030570~131035487:-
THCA	cis	rs7727544	0.606	rs11950562	ENSG00000224431.1	AC063976.7	7.04	6.85e-12	1.96e-09	0.27	0.31	Blood metabolite levels;	chr5:132316836	chr5:132199456~132203487:+
THCA	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	7.04	6.85e-12	1.96e-09	0.38	0.31	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
THCA	cis	rs12701220	0.901	rs12701708	ENSG00000229043.2	AC091729.9	-7.04	6.85e-12	1.96e-09	-0.41	-0.31	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1160374~1165267:+
THCA	cis	rs6539288	0.677	rs10778518	ENSG00000260329.1	RP11-412D9.4	7.04	6.86e-12	1.96e-09	0.28	0.31	Total body bone mineral density;	chr12:106950172	chr12:106954029~106955497:-
THCA	cis	rs3806843	0.568	rs2530232	ENSG00000202515.1	VTRNA1-3	7.04	6.86e-12	1.96e-09	0.35	0.31	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr5:140726158~140726246:+
THCA	cis	rs7942368	0.941	rs10793195	ENSG00000254632.1	RP11-21L23.4	7.04	6.86e-12	1.96e-09	0.45	0.31	Endometriosis;	chr11:76793688	chr11:76759916~76768223:-
THCA	cis	rs10899021	1	rs7102084	ENSG00000279353.1	RP11-864N7.4	7.04	6.87e-12	1.96e-09	0.61	0.31	Response to metformin (IC50);	chr11:74647087	chr11:74698231~74699658:-
THCA	cis	rs9388451	0.868	rs1268083	ENSG00000237742.5	RP11-624M8.1	7.04	6.87e-12	1.96e-09	0.27	0.31	Brugada syndrome;	chr6:125727894	chr6:125578558~125749190:-
THCA	cis	rs10411161	0.752	rs9973239	ENSG00000269483.1	AC006272.1	7.04	6.87e-12	1.96e-09	0.45	0.31	Breast cancer;	chr19:51903526	chr19:51839924~51843324:-
THCA	cis	rs6545883	0.525	rs1621048	ENSG00000271889.1	RP11-493E12.1	-7.04	6.87e-12	1.97e-09	-0.29	-0.31	Tuberculosis;	chr2:61137081	chr2:61151433~61162105:-
THCA	cis	rs8030379	1	rs2401175	ENSG00000230373.7	GOLGA6L5P	7.04	6.88e-12	1.97e-09	0.28	0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909465	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs1564474	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901281	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2401172	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908205	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2401173	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908218	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2401174	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908240	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs11259929	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908450	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs11259930	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908598	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs1480827	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909040	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2401176	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909612	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2401179	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910196	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2401180	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910434	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs11259932	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911305	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs11259934	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911419	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs11259935	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911675	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs12914857	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912414	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2055712	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912853	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2061999	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913988	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs3934135	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915047	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2030838	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915058	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2030839	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915207	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2030840	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915382	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs1880730	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915432	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs7496814	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916207	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs8024418	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917556	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs8042970	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917616	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs11259937	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919081	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs11637866	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919206	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2135880	ENSG00000230373.7	GOLGA6L5P	-7.04	6.88e-12	1.97e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83920861	chr15:84507885~84516814:-
THCA	cis	rs2408955	0.522	rs3997	ENSG00000240399.1	RP1-228P16.1	-7.04	6.88e-12	1.97e-09	-0.32	-0.31	Glycated hemoglobin levels;	chr12:48087804	chr12:48054813~48055591:-
THCA	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	7.04	6.88e-12	1.97e-09	0.4	0.31	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
THCA	cis	rs829880	0.858	rs733180	ENSG00000227825.4	SLC9A7P1	7.04	6.9e-12	1.97e-09	0.27	0.31	Colonoscopy-negative controls vs population controls;	chr12:98448810	chr12:98453835~98457145:-
THCA	cis	rs6065	0.618	rs16942618	ENSG00000234203.1	RP5-1050D4.2	7.04	6.9e-12	1.97e-09	0.63	0.31	Platelet count;	chr17:4974063	chr17:4972851~4974681:+
THCA	cis	rs516805	0.748	rs6912610	ENSG00000279453.1	RP3-425C14.4	7.04	6.9e-12	1.97e-09	0.31	0.31	Lymphocyte counts;	chr6:122379961	chr6:122436789~122439223:-
THCA	cis	rs2288884	1	rs11673286	ENSG00000275055.1	CTC-471J1.11	-7.04	6.91e-12	1.98e-09	-0.31	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037065	chr19:52049007~52049754:+
THCA	cis	rs9341808	0.718	rs3805922	ENSG00000272129.1	RP11-250B2.6	7.04	6.92e-12	1.98e-09	0.39	0.31	Sitting height ratio;	chr6:80182272	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs3805920	ENSG00000272129.1	RP11-250B2.6	7.04	6.92e-12	1.98e-09	0.39	0.31	Sitting height ratio;	chr6:80183028	chr6:80355424~80356859:+
THCA	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	7.04	6.93e-12	1.98e-09	0.27	0.31	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
THCA	cis	rs9543976	0.623	rs974373	ENSG00000261553.4	RP11-29G8.3	7.04	6.93e-12	1.98e-09	0.38	0.31	Diabetic retinopathy;	chr13:75589660	chr13:75549773~75807120:+
THCA	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	7.04	6.94e-12	1.98e-09	0.55	0.31	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
THCA	cis	rs4934494	0.689	rs17127596	ENSG00000232936.4	RP11-80H5.2	-7.04	6.94e-12	1.98e-09	-0.4	-0.31	Red blood cell count;	chr10:89816128	chr10:89645282~89650667:+
THCA	cis	rs875971	0.862	rs11763189	ENSG00000232559.3	GS1-124K5.12	7.04	6.94e-12	1.98e-09	0.29	0.31	Aortic root size;	chr7:66518542	chr7:66554588~66576923:-
THCA	cis	rs79349575	0.783	rs4255820	ENSG00000248278.1	SUMO2P17	7.04	6.94e-12	1.98e-09	0.36	0.31	Type 2 diabetes;	chr17:48919221	chr17:48874860~48908983:-
THCA	cis	rs6840258	0.825	rs79998318	ENSG00000251411.1	RP11-397E7.4	-7.04	6.94e-12	1.98e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87033014	chr4:86913266~86914817:-
THCA	cis	rs6545883	0.525	rs1729662	ENSG00000271889.1	RP11-493E12.1	7.04	6.95e-12	1.98e-09	0.29	0.31	Tuberculosis;	chr2:61164170	chr2:61151433~61162105:-
THCA	cis	rs8030379	1	rs1564473	ENSG00000230373.7	GOLGA6L5P	-7.04	6.97e-12	1.99e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901190	chr15:84507885~84516814:-
THCA	cis	rs7727544	0.507	rs10051679	ENSG00000233006.5	AC034220.3	7.04	6.97e-12	1.99e-09	0.23	0.31	Blood metabolite levels;	chr5:132235238	chr5:132311285~132369916:-
THCA	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-7.04	6.98e-12	1.99e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
THCA	cis	rs1850744	1	rs1519094	ENSG00000250942.1	ENPP7P11	7.04	6.99e-12	2e-09	0.44	0.31	Economic and political preferences;	chr4:9815662	chr4:9677308~9677934:+
THCA	cis	rs6600671	1	rs6600669	ENSG00000223345.3	HIST2H2BA	7.04	6.99e-12	2e-09	0.34	0.31	Hip geometry;	chr1:121471785	chr1:121108210~121117257:-
THCA	cis	rs8062405	0.722	rs3785354	ENSG00000278665.1	RP11-666O2.4	7.04	7e-12	2e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28599241~28601881:-
THCA	cis	rs4950322	0.542	rs3766520	ENSG00000237188.3	RP11-337C18.8	7.04	7.01e-12	2e-09	0.39	0.31	Protein quantitative trait loci;	chr1:147214658	chr1:147172771~147211568:+
THCA	cis	rs9400467	0.528	rs7750792	ENSG00000230177.1	RP5-1112D6.4	-7.04	7.01e-12	2e-09	-0.25	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:111277932~111278742:+
THCA	cis	rs8100891	0.734	rs8104048	ENSG00000267213.4	AC007773.2	-7.04	7.02e-12	2e-09	-0.28	-0.31	Neuroticism;	chr19:32338400	chr19:32390050~32405560:-
THCA	cis	rs4664293	0.967	rs35975814	ENSG00000226266.5	AC009961.3	-7.04	7.02e-12	2e-09	-0.35	-0.31	Monocyte percentage of white cells;	chr2:159691280	chr2:159670708~159712435:-
THCA	cis	rs6065	0.618	rs16942630	ENSG00000234203.1	RP5-1050D4.2	7.04	7.03e-12	2.01e-09	0.63	0.31	Platelet count;	chr17:4975142	chr17:4972851~4974681:+
THCA	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-7.04	7.05e-12	2.01e-09	-0.22	-0.31	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
THCA	cis	rs6840258	0.941	rs55913164	ENSG00000251411.1	RP11-397E7.4	-7.04	7.05e-12	2.01e-09	-0.38	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86977778	chr4:86913266~86914817:-
THCA	cis	rs9341808	0.718	rs9294171	ENSG00000272129.1	RP11-250B2.6	7.04	7.06e-12	2.01e-09	0.39	0.31	Sitting height ratio;	chr6:80130098	chr6:80355424~80356859:+
THCA	cis	rs7948661	0.661	rs7116876	ENSG00000278376.1	RP11-158I9.8	7.04	7.07e-12	2.02e-09	0.52	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118500310	chr11:118791254~118793137:+
THCA	cis	rs832187	0.615	rs9875198	ENSG00000280620.1	SCAANT1	7.04	7.08e-12	2.02e-09	0.42	0.31	Schizophrenia;	chr3:64010239	chr3:63911518~63911772:-
THCA	cis	rs7221109	0.682	rs1358175	ENSG00000278834.1	RP11-458J1.1	7.03	7.1e-12	2.02e-09	0.33	0.31	Type 1 diabetes;	chr17:40601537	chr17:40648300~40649718:+
THCA	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-7.03	7.1e-12	2.03e-09	-0.28	-0.31	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
THCA	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	7.03	7.11e-12	2.03e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
THCA	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	7.03	7.12e-12	2.03e-09	0.38	0.31	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
THCA	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	7.03	7.13e-12	2.04e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
THCA	cis	rs7191700	0.509	rs415595	ENSG00000262703.1	RP11-485G7.6	7.03	7.14e-12	2.04e-09	0.33	0.31	Multiple sclerosis;	chr16:11269835	chr16:11348143~11349321:-
THCA	cis	rs7191700	0.509	rs416603	ENSG00000262703.1	RP11-485G7.6	-7.03	7.14e-12	2.04e-09	-0.33	-0.31	Multiple sclerosis;	chr16:11270222	chr16:11348143~11349321:-
THCA	cis	rs453301	0.605	rs7843024	ENSG00000253893.2	FAM85B	7.03	7.15e-12	2.04e-09	0.42	0.31	Joint mobility (Beighton score);	chr8:8942466	chr8:8167819~8226614:-
THCA	cis	rs453301	0.631	rs7843789	ENSG00000253893.2	FAM85B	7.03	7.15e-12	2.04e-09	0.42	0.31	Joint mobility (Beighton score);	chr8:8943051	chr8:8167819~8226614:-
THCA	cis	rs7324557	0.717	rs7318360	ENSG00000205861.10	C1QTNF9B-AS1	-7.03	7.15e-12	2.04e-09	-0.38	-0.31	Visceral adipose tissue adjusted for BMI;	chr13:23818143	chr13:23888889~23897263:+
THCA	cis	rs8062405	0.755	rs4787457	ENSG00000278665.1	RP11-666O2.4	7.03	7.16e-12	2.04e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.755	rs4788080	ENSG00000278665.1	RP11-666O2.4	7.03	7.16e-12	2.04e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.755	rs4787456	ENSG00000278665.1	RP11-666O2.4	7.03	7.16e-12	2.04e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.755	rs4788078	ENSG00000278665.1	RP11-666O2.4	7.03	7.16e-12	2.04e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28599241~28601881:-
THCA	cis	rs1426063	1	rs10022563	ENSG00000260265.1	RP11-44F21.5	7.03	7.18e-12	2.05e-09	0.54	0.31	QT interval;	chr4:75100989	chr4:75081702~75084717:-
THCA	cis	rs1426063	1	rs10033857	ENSG00000260265.1	RP11-44F21.5	7.03	7.18e-12	2.05e-09	0.54	0.31	QT interval;	chr4:75103208	chr4:75081702~75084717:-
THCA	cis	rs2712184	0.683	rs2541406	ENSG00000229352.1	AC007563.3	-7.03	7.19e-12	2.05e-09	-0.37	-0.31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216771124	chr2:216799608~216805335:+
THCA	cis	rs4934494	0.736	rs10881613	ENSG00000232936.4	RP11-80H5.2	7.03	7.2e-12	2.05e-09	0.4	0.31	Red blood cell count;	chr10:89629468	chr10:89645282~89650667:+
THCA	cis	rs7267979	1	rs7020	ENSG00000274414.1	RP5-965G21.4	-7.03	7.2e-12	2.05e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25239007~25245229:-
THCA	cis	rs12906542	0.529	rs62008651	ENSG00000260776.4	RP11-114H24.2	7.03	7.2e-12	2.05e-09	0.46	0.31	Breast cancer;	chr15:77984075	chr15:77914217~77926846:-
THCA	cis	rs7247513	0.79	rs8112964	ENSG00000213290.4	PGK1P2	-7.03	7.2e-12	2.05e-09	-0.37	-0.31	Bipolar disorder;	chr19:12641359	chr19:12559571~12561105:+
THCA	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	7.03	7.21e-12	2.05e-09	0.61	0.31	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
THCA	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	7.03	7.21e-12	2.05e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
THCA	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-7.03	7.21e-12	2.06e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
THCA	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	7.03	7.21e-12	2.06e-09	0.38	0.31	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
THCA	cis	rs4950322	0.542	rs3766519	ENSG00000237188.3	RP11-337C18.8	7.03	7.22e-12	2.06e-09	0.39	0.31	Protein quantitative trait loci;	chr1:147214802	chr1:147172771~147211568:+
THCA	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	7.03	7.22e-12	2.06e-09	0.38	0.31	Height;	chr6:109454855	chr6:109382795~109383666:+
THCA	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-7.03	7.23e-12	2.06e-09	-0.38	-0.31	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
THCA	cis	rs12701220	0.847	rs10272002	ENSG00000229043.2	AC091729.9	-7.03	7.23e-12	2.06e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:1007979	chr7:1160374~1165267:+
THCA	cis	rs4664293	0.867	rs13432	ENSG00000226266.5	AC009961.3	-7.03	7.23e-12	2.06e-09	-0.38	-0.31	Monocyte percentage of white cells;	chr2:159769216	chr2:159670708~159712435:-
THCA	cis	rs74233809	1	rs12221193	ENSG00000213277.3	MARCKSL1P1	7.03	7.24e-12	2.06e-09	0.5	0.31	Birth weight;	chr10:102905510	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs77180047	ENSG00000213277.3	MARCKSL1P1	7.03	7.24e-12	2.06e-09	0.5	0.31	Birth weight;	chr10:102907000	chr10:103175554~103176094:+
THCA	cis	rs7015630	0.648	rs6996564	ENSG00000251136.7	RP11-37B2.1	-7.03	7.24e-12	2.06e-09	-0.33	-0.31	Inflammatory bowel disease;Crohn's disease;	chr8:89838537	chr8:89609409~89757727:-
THCA	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	7.03	7.24e-12	2.06e-09	0.37	0.31	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
THCA	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	7.03	7.26e-12	2.07e-09	0.4	0.31	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
THCA	cis	rs9475752	0.947	rs35961728	ENSG00000231441.1	RP11-472M19.2	7.03	7.26e-12	2.07e-09	0.4	0.31	Menarche (age at onset);	chr6:56941764	chr6:56844002~56864078:+
THCA	cis	rs6840258	0.6	rs1447994	ENSG00000251411.1	RP11-397E7.4	7.03	7.27e-12	2.07e-09	0.35	0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86966902	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.66	rs6531941	ENSG00000251411.1	RP11-397E7.4	7.03	7.27e-12	2.07e-09	0.35	0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86974808	chr4:86913266~86914817:-
THCA	cis	rs4664293	1	rs13014418	ENSG00000226266.5	AC009961.3	-7.03	7.27e-12	2.07e-09	-0.35	-0.31	Monocyte percentage of white cells;	chr2:159627174	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-7.03	7.27e-12	2.07e-09	-0.35	-0.31	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-7.03	7.27e-12	2.07e-09	-0.35	-0.31	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-7.03	7.27e-12	2.07e-09	-0.35	-0.31	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
THCA	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	7.03	7.28e-12	2.07e-09	0.21	0.31	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
THCA	cis	rs728616	0.867	rs61859022	ENSG00000225484.5	NUTM2B-AS1	-7.03	7.28e-12	2.07e-09	-0.6	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:79663088~79826594:-
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000264538.5	SUZ12P1	-7.03	7.29e-12	2.08e-09	-0.3	-0.31	Body mass index;	chr17:30690132	chr17:30709299~30790908:+
THCA	cis	rs4664293	0.836	rs2556102	ENSG00000226266.5	AC009961.3	-7.03	7.29e-12	2.08e-09	-0.38	-0.31	Monocyte percentage of white cells;	chr2:159798611	chr2:159670708~159712435:-
THCA	cis	rs6840258	1	rs767315	ENSG00000251411.1	RP11-397E7.4	-7.03	7.3e-12	2.08e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87039283	chr4:86913266~86914817:-
THCA	cis	rs4950322	0.748	rs17356680	ENSG00000237188.3	RP11-337C18.8	7.03	7.3e-12	2.08e-09	0.38	0.31	Protein quantitative trait loci;	chr1:147354934	chr1:147172771~147211568:+
THCA	cis	rs7246657	1	rs6508710	ENSG00000226686.6	LINC01535	-7.03	7.31e-12	2.08e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37258984	chr19:37251912~37265535:+
THCA	cis	rs9376098	0.825	rs7764187	ENSG00000232876.1	CTA-212D2.2	-7.03	7.31e-12	2.08e-09	-0.37	-0.31	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135162604	chr6:135055033~135060550:+
THCA	cis	rs853679	1	rs853685	ENSG00000219392.1	RP1-265C24.5	-7.03	7.31e-12	2.08e-09	-0.48	-0.31	Depression;	chr6:28321008	chr6:28115628~28116551:+
THCA	cis	rs9380516	0.786	rs1413896	ENSG00000228559.1	RP3-340B19.3	-7.03	7.32e-12	2.08e-09	-0.45	-0.31	Hepatitis C induced liver fibrosis;	chr6:35555130	chr6:35544632~35545669:+
THCA	cis	rs11668609	1	rs8100931	ENSG00000268442.1	CTD-2027I19.2	7.03	7.32e-12	2.08e-09	0.36	0.31	Response to taxane treatment (docetaxel);	chr19:24175770	chr19:24162370~24163425:-
THCA	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	7.03	7.33e-12	2.09e-09	0.37	0.31	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
THCA	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-7.03	7.34e-12	2.09e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-7.03	7.34e-12	2.09e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-7.03	7.34e-12	2.09e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-7.03	7.34e-12	2.09e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-7.03	7.34e-12	2.09e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
THCA	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-7.03	7.34e-12	2.09e-09	-0.25	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
THCA	cis	rs853679	0.517	rs9468298	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28154567	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9295759	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28156691	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9348796	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28158424	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs11552219	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28159056	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393896	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28159925	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393897	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28159932	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9357066	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28162053	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368556	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28163375	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368557	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28163759	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380059	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28164580	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380060	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28164825	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs35227624	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28164948	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380061	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28165025	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9368558	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28165528	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Parkinson's disease;	chr6:28165750	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Parkinson's disease;	chr6:28168578	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393901	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28169019	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs3173443	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28169249	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9348797	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28169755	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9380062	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28169791	chr6:28078792~28081130:-
THCA	cis	rs853679	0.542	rs9380063	ENSG00000272009.1	RP1-313I6.12	-7.03	7.35e-12	2.09e-09	-0.36	-0.31	Depression;	chr6:28170075	chr6:28078792~28081130:-
THCA	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-7.03	7.35e-12	2.09e-09	-0.52	-0.31	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
THCA	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-7.03	7.35e-12	2.09e-09	-0.34	-0.31	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-7.03	7.35e-12	2.09e-09	-0.34	-0.31	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
THCA	cis	rs3806843	0.741	rs2563293	ENSG00000202515.1	VTRNA1-3	7.03	7.36e-12	2.09e-09	0.35	0.31	Depressive symptoms (multi-trait analysis);	chr5:140730951	chr5:140726158~140726246:+
THCA	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	7.03	7.37e-12	2.1e-09	0.4	0.31	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
THCA	cis	rs7246657	0.943	rs3803895	ENSG00000226686.6	LINC01535	-7.03	7.37e-12	2.1e-09	-0.43	-0.31	Coronary artery calcification;	chr19:37407767	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs6508732	ENSG00000226686.6	LINC01535	-7.03	7.37e-12	2.1e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37509566	chr19:37251912~37265535:+
THCA	cis	rs467650	0.509	rs27575	ENSG00000246763.5	RGMB-AS1	7.03	7.38e-12	2.1e-09	0.3	0.31	Venous thromboembolism (SNP x SNP interaction);	chr5:98649207	chr5:98769618~98773469:-
THCA	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	7.03	7.38e-12	2.1e-09	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
THCA	cis	rs990871	1	rs2568952	ENSG00000227207.2	RPL31P12	-7.03	7.38e-12	2.1e-09	-0.38	-0.31	Subcutaneous adipose tissue;	chr1:72289422	chr1:72301472~72301829:+
THCA	cis	rs4072705	1	rs4240487	ENSG00000224020.1	MIR181A2HG	-7.03	7.39e-12	2.1e-09	-0.27	-0.31	Menarche (age at onset);	chr9:124608028	chr9:124658467~124698631:+
THCA	cis	rs651907	0.557	rs7612283	ENSG00000256628.3	ZBTB11-AS1	7.03	7.39e-12	2.1e-09	0.37	0.31	Colorectal cancer;	chr3:101716075	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs34457525	ENSG00000256628.3	ZBTB11-AS1	7.03	7.39e-12	2.1e-09	0.37	0.31	Colorectal cancer;	chr3:101716381	chr3:101676475~101679217:+
THCA	cis	rs6928977	0.714	rs11154801	ENSG00000231028.7	LINC00271	-7.03	7.4e-12	2.1e-09	-0.26	-0.31	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135418217	chr6:135497801~135716055:+
THCA	cis	rs9341808	0.754	rs9343973	ENSG00000272129.1	RP11-250B2.6	7.03	7.4e-12	2.11e-09	0.39	0.31	Sitting height ratio;	chr6:80203499	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs7740627	ENSG00000272129.1	RP11-250B2.6	7.03	7.4e-12	2.11e-09	0.39	0.31	Sitting height ratio;	chr6:80206630	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs2143887	ENSG00000272129.1	RP11-250B2.6	7.03	7.4e-12	2.11e-09	0.39	0.31	Sitting height ratio;	chr6:80207570	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.683	rs7771449	ENSG00000272129.1	RP11-250B2.6	7.03	7.4e-12	2.11e-09	0.39	0.31	Sitting height ratio;	chr6:80210260	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs910266	ENSG00000272129.1	RP11-250B2.6	7.03	7.4e-12	2.11e-09	0.39	0.31	Sitting height ratio;	chr6:80211453	chr6:80355424~80356859:+
THCA	cis	rs523522	0.962	rs4767903	ENSG00000278344.1	RP11-18C24.8	7.03	7.41e-12	2.11e-09	0.33	0.31	High light scatter reticulocyte count;	chr12:120492243	chr12:120500735~120501090:-
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000263603.1	CTD-2349P21.5	-7.03	7.41e-12	2.11e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30729469~30731202:+
THCA	cis	rs2688608	0.617	rs6480709	ENSG00000271816.1	BMS1P4	7.03	7.42e-12	2.11e-09	0.32	0.31	Inflammatory bowel disease;	chr10:73719367	chr10:73699151~73730487:-
THCA	cis	rs853679	0.517	rs4713141	ENSG00000220721.1	OR1F12	7.03	7.43e-12	2.11e-09	0.43	0.31	Depression;	chr6:28133900	chr6:28073316~28074233:+
THCA	cis	rs11024102	1	rs11024102	ENSG00000184669.7	OR7E14P	-7.03	7.44e-12	2.11e-09	-0.42	-0.31	Glaucoma (primary angle closure);	chr11:16987058	chr11:17013998~17053024:+
THCA	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-7.03	7.44e-12	2.12e-09	-0.45	-0.31	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
THCA	cis	rs62103177	0.561	rs891488	ENSG00000261126.6	RP11-795F19.1	-7.03	7.44e-12	2.12e-09	-0.3	-0.31	Opioid sensitivity;	chr18:79877424	chr18:80046900~80095482:+
THCA	cis	rs1198430	0.599	rs946269	ENSG00000232482.2	RP4-654C18.1	-7.03	7.44e-12	2.12e-09	-0.47	-0.31	Total cholesterol levels;	chr1:23442866	chr1:23410832~23412146:+
THCA	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	7.03	7.45e-12	2.12e-09	0.38	0.31	Height;	chr6:109361318	chr6:109382795~109383666:+
THCA	cis	rs6723108	0.627	rs4954189	ENSG00000224043.6	CCNT2-AS1	-7.03	7.48e-12	2.13e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134849763	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs10432371	ENSG00000224043.6	CCNT2-AS1	-7.03	7.48e-12	2.13e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134852176	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs6430549	ENSG00000224043.6	CCNT2-AS1	-7.03	7.48e-12	2.13e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134858776	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs1446523	ENSG00000224043.6	CCNT2-AS1	-7.03	7.48e-12	2.13e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134859051	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs6706537	ENSG00000224043.6	CCNT2-AS1	-7.03	7.48e-12	2.13e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134861412	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs6430545	ENSG00000224043.6	CCNT2-AS1	7.03	7.48e-12	2.13e-09	0.32	0.31	Type 2 diabetes;	chr2:134845031	chr2:134735464~134918710:-
THCA	cis	rs1395	0.744	rs1975384	ENSG00000234072.1	AC074117.10	-7.03	7.48e-12	2.13e-09	-0.28	-0.31	Blood metabolite levels;	chr2:27319174	chr2:27356246~27367622:+
THCA	cis	rs7119038	0.509	rs11216956	ENSG00000255239.1	AP002954.6	-7.03	7.48e-12	2.13e-09	-0.47	-0.31	Sjögren's syndrome;	chr11:118704617	chr11:118688039~118690600:-
THCA	cis	rs2287838	0.638	rs55832059	ENSG00000267289.1	CTD-2623N2.11	7.03	7.5e-12	2.13e-09	0.39	0.31	Sleep duration;	chr19:9845000	chr19:9834079~9835013:-
THCA	cis	rs2839186	0.559	rs2277826	ENSG00000239415.1	AP001469.9	-7.03	7.5e-12	2.13e-09	-0.32	-0.31	Testicular germ cell tumor;	chr21:46219578	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.587	rs35679325	ENSG00000239415.1	AP001469.9	-7.03	7.5e-12	2.13e-09	-0.32	-0.31	Testicular germ cell tumor;	chr21:46221066	chr21:46251549~46254133:-
THCA	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	7.03	7.51e-12	2.14e-09	0.4	0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
THCA	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-7.03	7.52e-12	2.14e-09	-0.32	-0.31	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
THCA	cis	rs7208859	0.673	rs9915139	ENSG00000263603.1	CTD-2349P21.5	-7.03	7.54e-12	2.14e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30729469~30731202:+
THCA	cis	rs9287719	0.624	rs6740245	ENSG00000243819.4	RN7SL832P	7.03	7.54e-12	2.14e-09	0.25	0.31	Prostate cancer;	chr2:10620776	chr2:10690344~10692099:+
THCA	cis	rs7942368	1	rs10437754	ENSG00000204529.3	GUCY2EP	7.03	7.55e-12	2.15e-09	0.44	0.31	Endometriosis;	chr11:76766823	chr11:76694043~76707641:-
THCA	cis	rs2412819	0.571	rs8038068	ENSG00000249839.1	AC011330.5	-7.03	7.55e-12	2.15e-09	-0.48	-0.31	Lung cancer;	chr15:43622175	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs56246169	ENSG00000249839.1	AC011330.5	-7.03	7.55e-12	2.15e-09	-0.48	-0.31	Lung cancer;	chr15:43628358	chr15:43663654~43684339:-
THCA	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	7.02	7.55e-12	2.15e-09	0.55	0.31	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
THCA	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-7.02	7.56e-12	2.15e-09	-0.39	-0.31	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
THCA	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-7.02	7.56e-12	2.15e-09	-0.3	-0.31	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
THCA	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	7.02	7.57e-12	2.15e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
THCA	cis	rs1009647	0.583	rs68175860	ENSG00000258413.1	RP11-665C16.6	-7.02	7.57e-12	2.15e-09	-0.56	-0.31	Testicular germ cell tumor;	chr14:55166872	chr14:55262767~55272075:-
THCA	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	7.02	7.58e-12	2.15e-09	0.48	0.31	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-7.02	7.58e-12	2.15e-09	-0.48	-0.31	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-7.02	7.58e-12	2.15e-09	-0.48	-0.31	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-7.02	7.58e-12	2.15e-09	-0.48	-0.31	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-7.02	7.58e-12	2.15e-09	-0.48	-0.31	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-7.02	7.58e-12	2.15e-09	-0.48	-0.31	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
THCA	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	7.02	7.58e-12	2.15e-09	0.44	0.31	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
THCA	cis	rs6504622	0.934	rs3760377	ENSG00000262879.4	RP11-156P1.3	-7.02	7.58e-12	2.15e-09	-0.29	-0.31	Orofacial clefts;	chr17:46964713	chr17:46984045~47100323:-
THCA	cis	rs6504622	1	rs11079745	ENSG00000262879.4	RP11-156P1.3	-7.02	7.58e-12	2.15e-09	-0.29	-0.31	Orofacial clefts;	chr17:46966781	chr17:46984045~47100323:-
THCA	cis	rs6672530	0.5	rs10916185	ENSG00000227711.2	RP11-275O4.5	-7.02	7.58e-12	2.15e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr1:227634997	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.5	rs10799434	ENSG00000227711.2	RP11-275O4.5	-7.02	7.58e-12	2.15e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr1:227635214	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.5	rs10916187	ENSG00000227711.2	RP11-275O4.5	-7.02	7.58e-12	2.15e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr1:227635217	chr1:227509028~227520477:-
THCA	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	7.02	7.59e-12	2.16e-09	0.46	0.31	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
THCA	cis	rs2976388	0.692	rs2585175	ENSG00000253741.1	CTD-2292P10.4	-7.02	7.59e-12	2.16e-09	-0.38	-0.31	Urinary tract infection frequency;	chr8:142699871	chr8:142702252~142726973:-
THCA	cis	rs990871	0.962	rs11209950	ENSG00000227207.2	RPL31P12	-7.02	7.6e-12	2.16e-09	-0.38	-0.31	Subcutaneous adipose tissue;	chr1:72363997	chr1:72301472~72301829:+
THCA	cis	rs2439831	0.867	rs935901	ENSG00000249839.1	AC011330.5	-7.02	7.6e-12	2.16e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43359058	chr15:43663654~43684339:-
THCA	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	7.02	7.61e-12	2.16e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
THCA	cis	rs7044106	0.791	rs4837792	ENSG00000238181.2	AHCYP2	-7.02	7.63e-12	2.17e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120720673~120721972:+
THCA	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-7.02	7.64e-12	2.17e-09	-0.25	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
THCA	cis	rs11662586	0.517	rs7230837	ENSG00000261126.6	RP11-795F19.1	7.02	7.65e-12	2.17e-09	0.25	0.31	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79935384	chr18:80046900~80095482:+
THCA	cis	rs6504622	0.935	rs17608961	ENSG00000262879.4	RP11-156P1.3	-7.02	7.65e-12	2.17e-09	-0.29	-0.31	Orofacial clefts;	chr17:46952302	chr17:46984045~47100323:-
THCA	cis	rs7131987	0.621	rs3782506	ENSG00000275476.1	RP11-996F15.4	7.02	7.65e-12	2.17e-09	0.31	0.31	QT interval;	chr12:29292489	chr12:29277397~29277882:-
THCA	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-7.02	7.66e-12	2.17e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-7.02	7.66e-12	2.17e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-7.02	7.66e-12	2.17e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-7.02	7.66e-12	2.17e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
THCA	cis	rs73186030	0.623	rs16832958	ENSG00000272758.4	RP11-299J3.8	7.02	7.66e-12	2.17e-09	0.33	0.31	Serum parathyroid hormone levels;	chr3:122299646	chr3:122416207~122443180:+
THCA	cis	rs1075232	1	rs1075232	ENSG00000270055.1	CTD-3092A11.2	-7.02	7.66e-12	2.18e-09	-0.59	-0.31	Survival in colorectal cancer (non-distant metastatic);	chr15:31449013	chr15:30487963~30490313:+
THCA	cis	rs6539288	0.63	rs10778519	ENSG00000260329.1	RP11-412D9.4	-7.02	7.67e-12	2.18e-09	-0.28	-0.31	Total body bone mineral density;	chr12:106963551	chr12:106954029~106955497:-
THCA	cis	rs7131987	0.683	rs3782511	ENSG00000275476.1	RP11-996F15.4	-7.02	7.67e-12	2.18e-09	-0.31	-0.31	QT interval;	chr12:29343291	chr12:29277397~29277882:-
THCA	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	7.02	7.67e-12	2.18e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
THCA	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-7.02	7.68e-12	2.18e-09	-0.3	-0.31	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
THCA	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-7.02	7.68e-12	2.18e-09	-0.22	-0.31	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
THCA	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-7.02	7.68e-12	2.18e-09	-0.39	-0.31	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-7.02	7.68e-12	2.18e-09	-0.39	-0.31	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
THCA	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-7.02	7.68e-12	2.18e-09	-0.4	-0.31	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
THCA	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	7.02	7.69e-12	2.18e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
THCA	cis	rs7182621	0.546	rs11632596	ENSG00000182397.13	DNM1P46	7.02	7.7e-12	2.18e-09	0.4	0.31	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99790156~99806927:-
THCA	cis	rs9902453	0.904	rs4375718	ENSG00000264007.1	RP11-68I3.10	-7.02	7.7e-12	2.19e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:30036624	chr17:29621617~29622254:-
THCA	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-7.02	7.7e-12	2.19e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000263603.1	CTD-2349P21.5	-7.02	7.7e-12	2.19e-09	-0.53	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30729469~30731202:+
THCA	cis	rs3822625	0.541	rs12657353	ENSG00000271828.1	CTD-2310F14.1	7.02	7.71e-12	2.19e-09	0.72	0.31	Breast cancer (early onset);	chr5:56900449	chr5:56927874~56929573:+
THCA	cis	rs8007846	0.523	rs12894902	ENSG00000276116.2	FUT8-AS1	7.02	7.71e-12	2.19e-09	0.32	0.31	Multiple sclerosis--Brain Glutamate Levels;	chr14:65695081	chr14:65411170~65412690:-
THCA	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	7.02	7.72e-12	2.19e-09	0.47	0.31	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
THCA	cis	rs7044106	0.762	rs3904197	ENSG00000238181.2	AHCYP2	-7.02	7.72e-12	2.19e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120720673~120721972:+
THCA	cis	rs74233809	1	rs77860422	ENSG00000213277.3	MARCKSL1P1	7.02	7.73e-12	2.19e-09	0.5	0.31	Birth weight;	chr10:102988252	chr10:103175554~103176094:+
THCA	cis	rs950027	0.516	rs12916762	ENSG00000259520.4	CTD-2651B20.3	-7.02	7.73e-12	2.19e-09	-0.38	-0.31	Response to fenofibrate (adiponectin levels);	chr15:45656104	chr15:45251580~45279251:-
THCA	cis	rs829880	1	rs829880	ENSG00000227825.4	SLC9A7P1	7.02	7.74e-12	2.19e-09	0.27	0.31	Colonoscopy-negative controls vs population controls;	chr12:98451553	chr12:98453835~98457145:-
THCA	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	7.02	7.74e-12	2.2e-09	0.36	0.31	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000224205.1	AP000351.4	7.02	7.74e-12	2.2e-09	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23987320~23991421:-
THCA	cis	rs12817211	0.502	rs11169282	ENSG00000272368.2	RP4-605O3.4	7.02	7.75e-12	2.2e-09	0.18	0.31	Colorectal or endometrial cancer;	chr12:50136188	chr12:50112197~50165618:+
THCA	cis	rs7474896	0.616	rs1985260	ENSG00000263064.2	RP11-291L22.7	7.02	7.75e-12	2.2e-09	0.44	0.31	Obesity (extreme);	chr10:38145162	chr10:38448689~38448949:+
THCA	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-7.02	7.75e-12	2.2e-09	-0.3	-0.31	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
THCA	cis	rs875971	0.862	rs4236208	ENSG00000232559.3	GS1-124K5.12	-7.02	7.75e-12	2.2e-09	-0.29	-0.31	Aortic root size;	chr7:66284091	chr7:66554588~66576923:-
THCA	cis	rs9467773	0.595	rs6907924	ENSG00000124549.13	BTN2A3P	-7.02	7.76e-12	2.2e-09	-0.29	-0.31	Intelligence (multi-trait analysis);	chr6:26438589	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.55	rs9379874	ENSG00000124549.13	BTN2A3P	-7.02	7.76e-12	2.2e-09	-0.29	-0.31	Intelligence (multi-trait analysis);	chr6:26440201	chr6:26421391~26432383:+
THCA	cis	rs72843506	0.586	rs61749865	ENSG00000270091.1	RP11-78O7.2	-7.02	7.76e-12	2.2e-09	-0.36	-0.31	Schizophrenia;	chr17:19931799	chr17:19896590~19897287:-
THCA	cis	rs74233809	1	rs5011520	ENSG00000213277.3	MARCKSL1P1	7.02	7.77e-12	2.2e-09	0.5	0.31	Birth weight;	chr10:102937759	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs10883808	ENSG00000213277.3	MARCKSL1P1	7.02	7.77e-12	2.2e-09	0.5	0.31	Birth weight;	chr10:102961369	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191479	ENSG00000213277.3	MARCKSL1P1	7.02	7.77e-12	2.2e-09	0.5	0.31	Birth weight;	chr10:102963863	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs10883815	ENSG00000213277.3	MARCKSL1P1	7.02	7.77e-12	2.2e-09	0.5	0.31	Birth weight;	chr10:102979422	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs112390216	ENSG00000213277.3	MARCKSL1P1	7.02	7.77e-12	2.2e-09	0.5	0.31	Birth weight;	chr10:102981274	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191502	ENSG00000213277.3	MARCKSL1P1	7.02	7.77e-12	2.2e-09	0.5	0.31	Birth weight;	chr10:103005737	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs74444347	ENSG00000213277.3	MARCKSL1P1	7.02	7.77e-12	2.2e-09	0.5	0.31	Birth weight;	chr10:103009518	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs12221335	ENSG00000213277.3	MARCKSL1P1	7.02	7.77e-12	2.2e-09	0.5	0.31	Birth weight;	chr10:103009635	chr10:103175554~103176094:+
THCA	cis	rs2562456	0.793	rs2650819	ENSG00000213976.4	CTD-2561J22.2	7.02	7.78e-12	2.21e-09	0.33	0.31	Pain;	chr19:21456071	chr19:21382865~21387177:+
THCA	cis	rs9287719	0.649	rs10184776	ENSG00000243819.4	RN7SL832P	7.02	7.79e-12	2.21e-09	0.25	0.31	Prostate cancer;	chr2:10586320	chr2:10690344~10692099:+
THCA	cis	rs453301	0.631	rs11780774	ENSG00000253893.2	FAM85B	7.02	7.8e-12	2.21e-09	0.42	0.31	Joint mobility (Beighton score);	chr8:8941601	chr8:8167819~8226614:-
THCA	cis	rs7246657	0.943	rs3745765	ENSG00000226686.6	LINC01535	-7.02	7.8e-12	2.21e-09	-0.43	-0.31	Coronary artery calcification;	chr19:37363333	chr19:37251912~37265535:+
THCA	cis	rs875971	0.83	rs6976714	ENSG00000232559.3	GS1-124K5.12	7.02	7.81e-12	2.21e-09	0.29	0.31	Aortic root size;	chr7:66426474	chr7:66554588~66576923:-
THCA	cis	rs875971	0.651	rs2420596	ENSG00000232559.3	GS1-124K5.12	7.02	7.81e-12	2.21e-09	0.29	0.31	Aortic root size;	chr7:66450996	chr7:66554588~66576923:-
THCA	cis	rs875971	0.52	rs2420597	ENSG00000232559.3	GS1-124K5.12	7.02	7.81e-12	2.21e-09	0.29	0.31	Aortic root size;	chr7:66450999	chr7:66554588~66576923:-
THCA	cis	rs8012947	0.877	rs10136481	ENSG00000279636.2	LINC00216	-7.02	7.81e-12	2.21e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58302690	chr14:58288033~58289158:+
THCA	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-7.02	7.82e-12	2.22e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
THCA	cis	rs875971	0.862	rs10282433	ENSG00000232559.3	GS1-124K5.12	-7.02	7.83e-12	2.22e-09	-0.29	-0.31	Aortic root size;	chr7:66256452	chr7:66554588~66576923:-
THCA	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	7.02	7.84e-12	2.22e-09	0.48	0.31	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
THCA	cis	rs74233809	1	rs12221064	ENSG00000213277.3	MARCKSL1P1	7.02	7.85e-12	2.22e-09	0.5	0.31	Birth weight;	chr10:102917369	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs77602510	ENSG00000213277.3	MARCKSL1P1	7.02	7.85e-12	2.22e-09	0.5	0.31	Birth weight;	chr10:102922845	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs78821730	ENSG00000213277.3	MARCKSL1P1	7.02	7.85e-12	2.22e-09	0.5	0.31	Birth weight;	chr10:102924787	chr10:103175554~103176094:+
THCA	cis	rs7189233	1	rs16952251	ENSG00000279722.1	RP11-44F14.6	-7.02	7.85e-12	2.22e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr16:53449226	chr16:53487607~53489943:-
THCA	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-7.02	7.85e-12	2.23e-09	-0.3	-0.31	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
THCA	cis	rs17695224	0.63	rs4802879	ENSG00000269483.1	AC006272.1	7.02	7.88e-12	2.23e-09	0.34	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51837122	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.611	rs4802880	ENSG00000269483.1	AC006272.1	7.02	7.88e-12	2.23e-09	0.34	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51837123	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.675	rs2109656	ENSG00000269483.1	AC006272.1	7.02	7.88e-12	2.23e-09	0.34	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51837424	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.675	rs3948650	ENSG00000269483.1	AC006272.1	7.02	7.88e-12	2.23e-09	0.34	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51837446	chr19:51839924~51843324:-
THCA	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	7.02	7.88e-12	2.23e-09	0.32	0.31	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
THCA	cis	rs3745672	1	rs7256759	ENSG00000219665.7	CTD-2006C1.2	-7.02	7.88e-12	2.23e-09	-0.68	-0.31	Multiple sclerosis;	chr19:11954195	chr19:11987617~12046275:+
THCA	cis	rs62103177	0.636	rs9958792	ENSG00000261126.6	RP11-795F19.1	-7.02	7.9e-12	2.24e-09	-0.3	-0.31	Opioid sensitivity;	chr18:79867876	chr18:80046900~80095482:+
THCA	cis	rs3806843	0.735	rs778595	ENSG00000202515.1	VTRNA1-3	7.02	7.9e-12	2.24e-09	0.35	0.31	Depressive symptoms (multi-trait analysis);	chr5:140657096	chr5:140726158~140726246:+
THCA	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-7.02	7.91e-12	2.24e-09	-0.33	-0.31	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
THCA	cis	rs848490	0.889	rs35392227	ENSG00000214293.7	APTR	7.02	7.91e-12	2.24e-09	0.24	0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77648452	chr7:77657660~77696265:-
THCA	cis	rs4273100	1	rs16960499	ENSG00000228157.4	AC007952.5	7.02	7.91e-12	2.24e-09	0.5	0.31	Schizophrenia;	chr17:19299719	chr17:19092974~19096837:+
THCA	cis	rs3806843	0.735	rs778597	ENSG00000202515.1	VTRNA1-3	-7.02	7.92e-12	2.24e-09	-0.35	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140661080	chr5:140726158~140726246:+
THCA	cis	rs7131987	0.65	rs10843384	ENSG00000275476.1	RP11-996F15.4	-7.02	7.92e-12	2.24e-09	-0.31	-0.31	QT interval;	chr12:29319476	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.65	rs11050188	ENSG00000275476.1	RP11-996F15.4	-7.02	7.92e-12	2.24e-09	-0.31	-0.31	QT interval;	chr12:29320175	chr12:29277397~29277882:-
THCA	cis	rs453301	0.624	rs330056	ENSG00000254153.1	CTA-398F10.2	7.02	7.93e-12	2.25e-09	0.33	0.31	Joint mobility (Beighton score);	chr8:9232185	chr8:8456909~8461337:-
THCA	cis	rs12594515	1	rs12906442	ENSG00000259200.1	RP11-718O11.1	-7.02	7.94e-12	2.25e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45693056	chr15:45705078~45931069:+
THCA	cis	rs16846053	0.551	rs1515185	ENSG00000227403.1	AC009299.3	-7.02	7.96e-12	2.25e-09	-0.53	-0.31	Blood osmolality (transformed sodium);	chr2:161702916	chr2:161244739~161249050:+
THCA	cis	rs9341808	0.754	rs3812126	ENSG00000272129.1	RP11-250B2.6	-7.02	7.96e-12	2.25e-09	-0.39	-0.31	Sitting height ratio;	chr6:80242984	chr6:80355424~80356859:+
THCA	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	7.02	7.96e-12	2.26e-09	0.57	0.31	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
THCA	cis	rs7267979	0.932	rs6132848	ENSG00000274414.1	RP5-965G21.4	-7.02	7.96e-12	2.26e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25239007~25245229:-
THCA	cis	rs6504622	0.721	rs11079748	ENSG00000262879.4	RP11-156P1.3	-7.02	7.97e-12	2.26e-09	-0.28	-0.31	Orofacial clefts;	chr17:47055097	chr17:46984045~47100323:-
THCA	cis	rs8081395	0.603	rs1292047	ENSG00000266992.1	DHX40P1	7.02	7.99e-12	2.26e-09	0.36	0.31	White blood cell count;	chr17:59877805	chr17:59976009~60002384:-
THCA	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	7.02	7.99e-12	2.26e-09	0.38	0.31	Height;	chr6:109352852	chr6:109382795~109383666:+
THCA	cis	rs6723108	0.627	rs62168872	ENSG00000224043.6	CCNT2-AS1	-7.02	7.99e-12	2.26e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134904177	chr2:134735464~134918710:-
THCA	cis	rs792448	0.743	rs351378	ENSG00000226251.4	RP11-15I11.3	-7.02	7.99e-12	2.26e-09	-0.38	-0.31	White blood cell count (basophil);	chr1:212251854	chr1:212225278~212238977:-
THCA	cis	rs2976388	0.647	rs1048831	ENSG00000253741.1	CTD-2292P10.4	-7.02	8e-12	2.26e-09	-0.38	-0.31	Urinary tract infection frequency;	chr8:142700440	chr8:142702252~142726973:-
THCA	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-7.02	8e-12	2.27e-09	-0.28	-0.31	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
THCA	cis	rs8014204	0.544	rs2286913	ENSG00000279594.1	RP11-950C14.10	7.02	8e-12	2.27e-09	0.31	0.31	Caffeine consumption;	chr14:74919873	chr14:75011269~75012851:-
THCA	cis	rs10208649	0.831	rs6545368	ENSG00000272156.1	RP11-477N3.1	7.02	8e-12	2.27e-09	0.44	0.31	Body mass index;	chr2:53813267	chr2:54082554~54085066:+
THCA	cis	rs7246657	1	rs34544865	ENSG00000226686.6	LINC01535	-7.02	8.01e-12	2.27e-09	-0.48	-0.31	Coronary artery calcification;	chr19:37310340	chr19:37251912~37265535:+
THCA	cis	rs4660456	0.556	rs823674	ENSG00000237899.1	RP4-739H11.3	-7.02	8.02e-12	2.27e-09	-0.36	-0.31	Platelet count;	chr1:40774799	chr1:40669089~40687588:-
THCA	cis	rs564343	0.765	rs1558974	ENSG00000255320.1	RP11-755F10.1	7.02	8.02e-12	2.27e-09	0.38	0.31	Obesity (early onset extreme);	chr11:66110303	chr11:66244840~66246239:-
THCA	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-7.02	8.02e-12	2.27e-09	-0.52	-0.31	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
THCA	cis	rs9902453	0.904	rs7212292	ENSG00000264007.1	RP11-68I3.10	-7.02	8.03e-12	2.27e-09	-0.35	-0.31	Coffee consumption (cups per day);	chr17:30082246	chr17:29621617~29622254:-
THCA	cis	rs3806843	0.735	rs2530242	ENSG00000202515.1	VTRNA1-3	7.02	8.03e-12	2.27e-09	0.35	0.31	Depressive symptoms (multi-trait analysis);	chr5:140673766	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs2530241	ENSG00000202515.1	VTRNA1-3	7.02	8.03e-12	2.27e-09	0.35	0.31	Depressive symptoms (multi-trait analysis);	chr5:140674900	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.735	rs2530235	ENSG00000202515.1	VTRNA1-3	7.02	8.03e-12	2.27e-09	0.35	0.31	Depressive symptoms (multi-trait analysis);	chr5:140693062	chr5:140726158~140726246:+
THCA	cis	rs8030379	1	rs11633301	ENSG00000230373.7	GOLGA6L5P	7.02	8.03e-12	2.27e-09	0.29	0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916286	chr15:84507885~84516814:-
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000264538.5	SUZ12P1	-7.02	8.04e-12	2.28e-09	-0.29	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000264538.5	SUZ12P1	-7.02	8.04e-12	2.28e-09	-0.29	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30709299~30790908:+
THCA	cis	rs8012947	0.959	rs2233752	ENSG00000279636.2	LINC00216	-7.02	8.05e-12	2.28e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58288762	chr14:58288033~58289158:+
THCA	cis	rs8012947	0.959	rs10132929	ENSG00000279636.2	LINC00216	-7.02	8.05e-12	2.28e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58292289	chr14:58288033~58289158:+
THCA	cis	rs8012947	0.959	rs7146801	ENSG00000279636.2	LINC00216	-7.02	8.05e-12	2.28e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58292769	chr14:58288033~58289158:+
THCA	cis	rs2033711	0.783	rs11671113	ENSG00000269473.1	CTD-2619J13.19	7.02	8.05e-12	2.28e-09	0.29	0.31	Uric acid clearance;	chr19:58446720	chr19:58440448~58445849:+
THCA	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	7.02	8.05e-12	2.28e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
THCA	cis	rs860295	0.58	rs10908483	ENSG00000225855.5	RUSC1-AS1	7.02	8.05e-12	2.28e-09	0.21	0.31	Body mass index;	chr1:155897043	chr1:155316863~155324176:-
THCA	cis	rs9902453	0.904	rs9900112	ENSG00000264007.1	RP11-68I3.10	7.02	8.06e-12	2.28e-09	0.34	0.31	Coffee consumption (cups per day);	chr17:29955892	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs6505148	ENSG00000264007.1	RP11-68I3.10	7.01	8.07e-12	2.29e-09	0.34	0.31	Coffee consumption (cups per day);	chr17:29962800	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs4077465	ENSG00000264007.1	RP11-68I3.10	7.01	8.07e-12	2.29e-09	0.34	0.31	Coffee consumption (cups per day);	chr17:29973126	chr17:29621617~29622254:-
THCA	cis	rs1198430	0.925	rs2510072	ENSG00000232482.2	RP4-654C18.1	-7.01	8.08e-12	2.29e-09	-0.56	-0.31	Total cholesterol levels;	chr1:23443181	chr1:23410832~23412146:+
THCA	cis	rs9990333	0.862	rs6806599	ENSG00000242086.7	LINC00969	-7.01	8.08e-12	2.29e-09	-0.3	-0.31	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195658062~195739964:+
THCA	cis	rs4664293	0.74	rs12464577	ENSG00000226266.5	AC009961.3	7.01	8.08e-12	2.29e-09	0.37	0.31	Monocyte percentage of white cells;	chr2:159816321	chr2:159670708~159712435:-
THCA	cis	rs12681366	0.564	rs2165405	ENSG00000253704.1	RP11-267M23.4	7.01	8.1e-12	2.29e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94442079	chr8:94553722~94569745:+
THCA	cis	rs9402743	0.67	rs7769840	ENSG00000231028.7	LINC00271	7.01	8.11e-12	2.29e-09	0.25	0.31	Systemic lupus erythematosus;	chr6:135605412	chr6:135497801~135716055:+
THCA	cis	rs651907	0.557	rs34947019	ENSG00000256628.3	ZBTB11-AS1	7.01	8.12e-12	2.3e-09	0.36	0.31	Colorectal cancer;	chr3:101813391	chr3:101676475~101679217:+
THCA	cis	rs651907	0.535	rs34743741	ENSG00000256628.3	ZBTB11-AS1	7.01	8.12e-12	2.3e-09	0.36	0.31	Colorectal cancer;	chr3:101813604	chr3:101676475~101679217:+
THCA	cis	rs8114671	0.562	rs6088622	ENSG00000269202.1	RP4-614O4.12	-7.01	8.13e-12	2.3e-09	-0.26	-0.31	Height;	chr20:34832174	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.552	rs2024635	ENSG00000269202.1	RP4-614O4.12	-7.01	8.13e-12	2.3e-09	-0.26	-0.31	Height;	chr20:34834811	chr20:35201747~35203288:-
THCA	cis	rs860295	0.58	rs867549	ENSG00000225855.5	RUSC1-AS1	7.01	8.14e-12	2.3e-09	0.21	0.31	Body mass index;	chr1:155910368	chr1:155316863~155324176:-
THCA	cis	rs2018683	0.899	rs10479817	ENSG00000228421.2	AC005013.5	7.01	8.14e-12	2.3e-09	0.34	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938531	chr7:28957667~28959345:+
THCA	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	7.01	8.15e-12	2.3e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
THCA	cis	rs1198430	0.639	rs16860685	ENSG00000232482.2	RP4-654C18.1	-7.01	8.15e-12	2.31e-09	-0.47	-0.31	Total cholesterol levels;	chr1:23440151	chr1:23410832~23412146:+
THCA	cis	rs9543976	0.614	rs4885308	ENSG00000261553.4	RP11-29G8.3	-7.01	8.16e-12	2.31e-09	-0.48	-0.31	Diabetic retinopathy;	chr13:75532357	chr13:75549773~75807120:+
THCA	cis	rs7044106	0.708	rs920745	ENSG00000238181.2	AHCYP2	-7.01	8.16e-12	2.31e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120720673~120721972:+
THCA	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-7.01	8.16e-12	2.31e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-7.01	8.16e-12	2.31e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
THCA	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-7.01	8.16e-12	2.31e-09	-0.48	-0.31	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
THCA	cis	rs875971	0.862	rs778720	ENSG00000232559.3	GS1-124K5.12	-7.01	8.17e-12	2.31e-09	-0.29	-0.31	Aortic root size;	chr7:66381288	chr7:66554588~66576923:-
THCA	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-7.01	8.17e-12	2.31e-09	-0.3	-0.31	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
THCA	cis	rs8030379	1	rs11259933	ENSG00000230373.7	GOLGA6L5P	-7.01	8.17e-12	2.31e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911404	chr15:84507885~84516814:-
THCA	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	7.01	8.18e-12	2.31e-09	0.38	0.31	Height;	chr6:109438349	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	7.01	8.18e-12	2.31e-09	0.38	0.31	Height;	chr6:109441033	chr6:109382795~109383666:+
THCA	cis	rs4950322	0.58	rs7514970	ENSG00000237188.3	RP11-337C18.8	7.01	8.18e-12	2.31e-09	0.37	0.31	Protein quantitative trait loci;	chr1:147120516	chr1:147172771~147211568:+
THCA	cis	rs5006884	0.547	rs2647601	ENSG00000167355.6	AC104389.28	7.01	8.19e-12	2.32e-09	0.39	0.31	Fetal hemoglobin levels;	chr11:5355626	chr11:5304976~5505652:-
THCA	cis	rs8030379	1	rs10906983	ENSG00000230373.7	GOLGA6L5P	-7.01	8.19e-12	2.32e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900431	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs922664	ENSG00000230373.7	GOLGA6L5P	-7.01	8.19e-12	2.32e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900803	chr15:84507885~84516814:-
THCA	cis	rs651907	0.557	rs2288272	ENSG00000256628.3	ZBTB11-AS1	7.01	8.19e-12	2.32e-09	0.36	0.31	Colorectal cancer;	chr3:101659632	chr3:101676475~101679217:+
THCA	cis	rs7657257	1	rs4267735	ENSG00000214846.4	RP11-115L11.1	7.01	8.2e-12	2.32e-09	0.77	0.31	Blood protein levels;	chr4:15731625	chr4:15730962~15731627:-
THCA	cis	rs9467773	0.595	rs9366657	ENSG00000124549.13	BTN2A3P	7.01	8.21e-12	2.32e-09	0.29	0.31	Intelligence (multi-trait analysis);	chr6:26434686	chr6:26421391~26432383:+
THCA	cis	rs2135507	0.501	rs7657237	ENSG00000270480.1	RP11-57B24.1	7.01	8.23e-12	2.33e-09	0.49	0.31	Juvenile osteochondritis dissecans;	chr4:82674085	chr4:82691737~82692468:+
THCA	cis	rs453301	0.631	rs13250781	ENSG00000253893.2	FAM85B	7.01	8.23e-12	2.33e-09	0.42	0.31	Joint mobility (Beighton score);	chr8:8935833	chr8:8167819~8226614:-
THCA	cis	rs7267979	0.932	rs6115215	ENSG00000274414.1	RP5-965G21.4	-7.01	8.24e-12	2.33e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25239007~25245229:-
THCA	cis	rs7247513	0.93	rs35275129	ENSG00000213290.4	PGK1P2	-7.01	8.24e-12	2.33e-09	-0.37	-0.31	Bipolar disorder;	chr19:12605679	chr19:12559571~12561105:+
THCA	cis	rs10799445	0.547	rs2093609	ENSG00000227711.2	RP11-275O4.5	-7.01	8.25e-12	2.33e-09	-0.32	-0.31	Height;	chr1:227633282	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs10916182	ENSG00000227711.2	RP11-275O4.5	-7.01	8.25e-12	2.33e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr1:227634239	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs10916183	ENSG00000227711.2	RP11-275O4.5	-7.01	8.25e-12	2.33e-09	-0.32	-0.31	Height;	chr1:227634583	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs10916184	ENSG00000227711.2	RP11-275O4.5	-7.01	8.25e-12	2.33e-09	-0.32	-0.31	Hip circumference adjusted for BMI;	chr1:227634684	chr1:227509028~227520477:-
THCA	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	7.01	8.26e-12	2.34e-09	0.39	0.31	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
THCA	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	7.01	8.27e-12	2.34e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	7.01	8.27e-12	2.34e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	7.01	8.27e-12	2.34e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	7.01	8.27e-12	2.34e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	7.01	8.27e-12	2.34e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
THCA	cis	rs62103177	0.683	rs13745	ENSG00000261126.6	RP11-795F19.1	-7.01	8.3e-12	2.34e-09	-0.34	-0.31	Opioid sensitivity;	chr18:79903896	chr18:80046900~80095482:+
THCA	cis	rs853679	0.666	rs200956	ENSG00000280107.1	AL022393.9	-7.01	8.3e-12	2.35e-09	-0.38	-0.31	Depression;	chr6:27871968	chr6:28170845~28172521:+
THCA	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	7.01	8.3e-12	2.35e-09	0.38	0.31	Height;	chr6:109357908	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	7.01	8.3e-12	2.35e-09	0.38	0.31	Height;	chr6:109359747	chr6:109382795~109383666:+
THCA	cis	rs860295	0.58	rs66466805	ENSG00000225855.5	RUSC1-AS1	7.01	8.3e-12	2.35e-09	0.21	0.31	Body mass index;	chr1:155918875	chr1:155316863~155324176:-
THCA	cis	rs9532669	0.889	rs7320344	ENSG00000176268.5	CYCSP34	7.01	8.33e-12	2.35e-09	0.37	0.31	Cervical cancer;	chr13:40885502	chr13:40863599~40863902:-
THCA	cis	rs853679	0.55	rs9295762	ENSG00000272009.1	RP1-313I6.12	7.01	8.34e-12	2.36e-09	0.35	0.31	Depression;	chr6:28187640	chr6:28078792~28081130:-
THCA	cis	rs9402743	0.631	rs9376112	ENSG00000231028.7	LINC00271	-7.01	8.34e-12	2.36e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135606862	chr6:135497801~135716055:+
THCA	cis	rs1850744	0.702	rs7668469	ENSG00000250942.1	ENPP7P11	7.01	8.35e-12	2.36e-09	0.43	0.31	Economic and political preferences;	chr4:9742906	chr4:9677308~9677934:+
THCA	cis	rs7773456	0.711	rs9358277	ENSG00000237404.1	RP3-471C18.2	7.01	8.36e-12	2.36e-09	0.38	0.31	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19689825~19753113:-
THCA	cis	rs7267979	0.866	rs6138609	ENSG00000274414.1	RP5-965G21.4	-7.01	8.37e-12	2.36e-09	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25239007~25245229:-
THCA	cis	rs7044106	0.762	rs1547268	ENSG00000238181.2	AHCYP2	-7.01	8.39e-12	2.37e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120720673~120721972:+
THCA	cis	rs8062405	0.69	rs7187604	ENSG00000278665.1	RP11-666O2.4	7.01	8.39e-12	2.37e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28599241~28601881:-
THCA	cis	rs8030379	1	rs10906982	ENSG00000230373.7	GOLGA6L5P	-7.01	8.4e-12	2.37e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899406	chr15:84507885~84516814:-
THCA	cis	rs7688540	0.713	rs12511388	ENSG00000275426.1	CH17-262A2.1	7.01	8.4e-12	2.37e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:149738~150317:+
THCA	cis	rs6840258	0.941	rs6854749	ENSG00000251411.1	RP11-397E7.4	-7.01	8.4e-12	2.37e-09	-0.36	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87047646	chr4:86913266~86914817:-
THCA	cis	rs4073416	0.712	rs2411351	ENSG00000276116.2	FUT8-AS1	7.01	8.4e-12	2.37e-09	0.31	0.31	N-glycan levels;	chr14:65704823	chr14:65411170~65412690:-
THCA	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-7.01	8.41e-12	2.38e-09	-0.3	-0.31	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-7.01	8.41e-12	2.38e-09	-0.3	-0.31	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
THCA	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	7.01	8.41e-12	2.38e-09	0.36	0.31	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
THCA	cis	rs7247513	0.964	rs4804202	ENSG00000230310.1	CTD-2192J16.11	-7.01	8.42e-12	2.38e-09	-0.37	-0.31	Bipolar disorder;	chr19:12607805	chr19:12552597~12553644:+
THCA	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	7.01	8.42e-12	2.38e-09	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
THCA	cis	rs3847687	1	rs34853396	ENSG00000279993.1	RP11-76C10.3	7.01	8.44e-12	2.38e-09	0.34	0.31	Longevity;	chr12:131034720	chr12:131025561~131028060:-
THCA	cis	rs6723108	0.603	rs3769023	ENSG00000224043.6	CCNT2-AS1	-7.01	8.44e-12	2.38e-09	-0.33	-0.31	Type 2 diabetes;	chr2:134956133	chr2:134735464~134918710:-
THCA	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	7.01	8.46e-12	2.39e-09	0.38	0.31	Height;	chr6:109354040	chr6:109382795~109383666:+
THCA	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	7.01	8.47e-12	2.39e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	7.01	8.47e-12	2.39e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
THCA	cis	rs2288884	0.943	rs11084131	ENSG00000275055.1	CTC-471J1.11	-7.01	8.47e-12	2.39e-09	-0.31	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011193	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.943	rs11084132	ENSG00000275055.1	CTC-471J1.11	-7.01	8.47e-12	2.39e-09	-0.31	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011327	chr19:52049007~52049754:+
THCA	cis	rs9402743	0.671	rs4896157	ENSG00000231028.7	LINC00271	-7.01	8.47e-12	2.39e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135620981	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.599	rs6919741	ENSG00000231028.7	LINC00271	-7.01	8.47e-12	2.39e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135622057	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs9321516	ENSG00000231028.7	LINC00271	-7.01	8.47e-12	2.39e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135622150	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.598	rs7761716	ENSG00000231028.7	LINC00271	-7.01	8.47e-12	2.39e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135623243	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs7762139	ENSG00000231028.7	LINC00271	-7.01	8.47e-12	2.39e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135623289	chr6:135497801~135716055:+
THCA	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-7.01	8.47e-12	2.39e-09	-0.24	-0.31	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
THCA	cis	rs12594515	0.967	rs11856523	ENSG00000259200.1	RP11-718O11.1	-7.01	8.47e-12	2.39e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45697297	chr15:45705078~45931069:+
THCA	cis	rs2033711	0.84	rs4801590	ENSG00000269473.1	CTD-2619J13.19	7.01	8.47e-12	2.39e-09	0.29	0.31	Uric acid clearance;	chr19:58450446	chr19:58440448~58445849:+
THCA	cis	rs1949733	0.958	rs2631731	ENSG00000205959.3	RP11-689P11.2	-7.01	8.47e-12	2.39e-09	-0.26	-0.31	Response to antineoplastic agents;	chr4:8428090	chr4:8482270~8512610:+
THCA	cis	rs79349575	0.783	rs62075838	ENSG00000248278.1	SUMO2P17	7.01	8.48e-12	2.39e-09	0.36	0.31	Type 2 diabetes;	chr17:48919070	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs62075839	ENSG00000248278.1	SUMO2P17	7.01	8.48e-12	2.39e-09	0.36	0.31	Type 2 diabetes;	chr17:48919072	chr17:48874860~48908983:-
THCA	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-7.01	8.48e-12	2.39e-09	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs61390361	ENSG00000275601.1	AC011330.13	-7.01	8.48e-12	2.39e-09	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43867644	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-7.01	8.48e-12	2.39e-09	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
THCA	cis	rs10916248	0.612	rs10916304	ENSG00000232628.4	RP11-365O16.3	7.01	8.49e-12	2.4e-09	0.49	0.31	QT interval (drug interaction);	chr1:224110166	chr1:224208747~224213279:-
THCA	cis	rs9402743	0.671	rs7767066	ENSG00000231028.7	LINC00271	-7.01	8.49e-12	2.4e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135623970	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.598	rs9483856	ENSG00000231028.7	LINC00271	-7.01	8.49e-12	2.4e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135624088	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.635	rs9376118	ENSG00000231028.7	LINC00271	-7.01	8.49e-12	2.4e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135624521	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs742738	ENSG00000231028.7	LINC00271	-7.01	8.49e-12	2.4e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135625301	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs9402728	ENSG00000231028.7	LINC00271	-7.01	8.49e-12	2.4e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135626450	chr6:135497801~135716055:+
THCA	cis	rs2880765	0.835	rs4360875	ENSG00000259295.5	CSPG4P12	7.01	8.49e-12	2.4e-09	0.39	0.31	Coronary artery disease;	chr15:85497163	chr15:85191438~85213905:+
THCA	cis	rs9902453	0.904	rs12103671	ENSG00000264007.1	RP11-68I3.10	-7.01	8.49e-12	2.4e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30081199	chr17:29621617~29622254:-
THCA	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	7.01	8.49e-12	2.4e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
THCA	cis	rs79349575	0.749	rs46521	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48911167	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.749	rs318093	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48911992	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.745	rs170319	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48914169	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs318090	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48914390	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.651	rs4378658	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48916008	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs12453374	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48917484	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs12453394	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48917608	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.811	rs12601072	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48920636	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.749	rs58838744	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48921540	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.811	rs60708039	ENSG00000248278.1	SUMO2P17	7.01	8.5e-12	2.4e-09	0.36	0.31	Type 2 diabetes;	chr17:48922011	chr17:48874860~48908983:-
THCA	cis	rs12435908	0.786	rs12434854	ENSG00000276116.2	FUT8-AS1	-7.01	8.51e-12	2.4e-09	-0.49	-0.31	Ischemic stroke;	chr14:65429516	chr14:65411170~65412690:-
THCA	cis	rs7189233	1	rs7194519	ENSG00000279344.1	RP11-44F14.7	7.01	8.51e-12	2.4e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr16:53501364	chr16:53478957~53481550:-
THCA	cis	rs7267979	1	rs2482928	ENSG00000274414.1	RP5-965G21.4	7.01	8.51e-12	2.4e-09	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25239007~25245229:-
THCA	cis	rs853679	0.513	rs9468296	ENSG00000272009.1	RP1-313I6.12	-7.01	8.52e-12	2.4e-09	-0.36	-0.31	Depression;	chr6:28145952	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs4711164	ENSG00000272009.1	RP1-313I6.12	-7.01	8.52e-12	2.4e-09	-0.36	-0.31	Depression;	chr6:28147378	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs4711165	ENSG00000272009.1	RP1-313I6.12	-7.01	8.52e-12	2.4e-09	-0.36	-0.31	Depression;	chr6:28147406	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs4713148	ENSG00000272009.1	RP1-313I6.12	-7.01	8.52e-12	2.4e-09	-0.36	-0.31	Depression;	chr6:28148143	chr6:28078792~28081130:-
THCA	cis	rs1862618	0.853	rs10051747	ENSG00000271828.1	CTD-2310F14.1	7.01	8.52e-12	2.41e-09	0.46	0.31	Initial pursuit acceleration;	chr5:56787462	chr5:56927874~56929573:+
THCA	cis	rs1823874	0.886	rs2123933	ENSG00000182397.13	DNM1P46	-7.01	8.53e-12	2.41e-09	-0.34	-0.31	IgG glycosylation;	chr15:99824131	chr15:99790156~99806927:-
THCA	cis	rs71636778	0.509	rs36053809	ENSG00000260063.1	RP5-968P14.2	-7.01	8.54e-12	2.41e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26756602	chr1:26692132~26694131:-
THCA	cis	rs7044106	0.5	rs56725168	ENSG00000238181.2	AHCYP2	-7.01	8.55e-12	2.41e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120720673~120721972:+
THCA	cis	rs7189233	0.956	rs62048490	ENSG00000279722.1	RP11-44F14.6	-7.01	8.55e-12	2.41e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr16:53422364	chr16:53487607~53489943:-
THCA	cis	rs7044106	0.791	rs4836830	ENSG00000238181.2	AHCYP2	-7.01	8.55e-12	2.41e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120720673~120721972:+
THCA	cis	rs2288884	1	rs76368799	ENSG00000275055.1	CTC-471J1.11	-7.01	8.56e-12	2.42e-09	-0.3	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058254	chr19:52049007~52049754:+
THCA	cis	rs2288884	1	rs72483951	ENSG00000275055.1	CTC-471J1.11	-7.01	8.56e-12	2.42e-09	-0.3	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52070429	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.943	rs12611112	ENSG00000275055.1	CTC-471J1.11	-7.01	8.56e-12	2.42e-09	-0.3	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52071686	chr19:52049007~52049754:+
THCA	cis	rs2288884	1	rs56808319	ENSG00000275055.1	CTC-471J1.11	-7.01	8.56e-12	2.42e-09	-0.3	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074621	chr19:52049007~52049754:+
THCA	cis	rs7208859	0.725	rs9891656	ENSG00000266490.1	CTD-2349P21.9	7.01	8.57e-12	2.42e-09	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30792372~30792833:+
THCA	cis	rs853679	0.766	rs9368561	ENSG00000226314.6	ZNF192P1	-7.01	8.59e-12	2.42e-09	-0.52	-0.31	Depression;	chr6:28200565	chr6:28161781~28169594:+
THCA	cis	rs12594515	0.967	rs11857628	ENSG00000259200.1	RP11-718O11.1	-7	8.61e-12	2.43e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45706008	chr15:45705078~45931069:+
THCA	cis	rs6840258	0.66	rs10015639	ENSG00000251411.1	RP11-397E7.4	7	8.62e-12	2.43e-09	0.35	0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970413	chr4:86913266~86914817:-
THCA	cis	rs848490	0.889	rs17156247	ENSG00000214293.7	APTR	-7	8.62e-12	2.43e-09	-0.24	-0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77668224	chr7:77657660~77696265:-
THCA	cis	rs934734	0.736	rs7559283	ENSG00000204929.10	AC074391.1	7	8.63e-12	2.43e-09	0.39	0.31	Rheumatoid arthritis;	chr2:65351234	chr2:65436711~66084639:+
THCA	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-7	8.63e-12	2.43e-09	-0.38	-0.31	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
THCA	cis	rs7189233	1	rs7189819	ENSG00000279722.1	RP11-44F14.6	-7	8.64e-12	2.44e-09	-0.32	-0.31	Intelligence (multi-trait analysis);	chr16:53502433	chr16:53487607~53489943:-
THCA	cis	rs11722228	0.549	rs73212863	ENSG00000261490.1	RP11-448G15.3	7	8.64e-12	2.44e-09	0.23	0.31	Urate levels;Serum uric acid levels;Gout;	chr4:10102549	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.508	rs73212864	ENSG00000261490.1	RP11-448G15.3	7	8.64e-12	2.44e-09	0.23	0.31	Urate levels;Serum uric acid levels;Gout;	chr4:10102567	chr4:10068089~10073019:-
THCA	cis	rs7044106	0.762	rs7024046	ENSG00000238181.2	AHCYP2	-7	8.64e-12	2.44e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120720673~120721972:+
THCA	cis	rs12701220	0.894	rs34712249	ENSG00000229043.2	AC091729.9	-7	8.65e-12	2.44e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:996998	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.894	rs10257744	ENSG00000229043.2	AC091729.9	-7	8.65e-12	2.44e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:1005976	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.894	rs12701406	ENSG00000229043.2	AC091729.9	-7	8.65e-12	2.44e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:1010647	chr7:1160374~1165267:+
THCA	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-7	8.65e-12	2.44e-09	-0.58	-0.31	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
THCA	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-7	8.65e-12	2.44e-09	-0.58	-0.31	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
THCA	cis	rs1075232	1	rs34959140	ENSG00000270055.1	CTD-3092A11.2	-7	8.65e-12	2.44e-09	-0.58	-0.31	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30487963~30490313:+
THCA	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	7	8.65e-12	2.44e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000272009.1	RP1-313I6.12	-7	8.65e-12	2.44e-09	-0.36	-0.31	Depression;	chr6:28096845	chr6:28078792~28081130:-
THCA	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-7	8.66e-12	2.44e-09	-0.39	-0.31	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
THCA	cis	rs11603023	0.569	rs573905	ENSG00000255239.1	AP002954.6	7	8.66e-12	2.44e-09	0.41	0.31	Cholesterol, total;	chr11:118701558	chr11:118688039~118690600:-
THCA	cis	rs9467773	0.838	rs3734540	ENSG00000124549.13	BTN2A3P	7	8.68e-12	2.45e-09	0.3	0.31	Intelligence (multi-trait analysis);	chr6:26463093	chr6:26421391~26432383:+
THCA	cis	rs4950322	0.58	rs17355474	ENSG00000237188.3	RP11-337C18.8	7	8.68e-12	2.45e-09	0.37	0.31	Protein quantitative trait loci;	chr1:147120541	chr1:147172771~147211568:+
THCA	cis	rs10799445	0.527	rs10799435	ENSG00000227711.2	RP11-275O4.5	-7	8.7e-12	2.45e-09	-0.32	-0.31	Height;	chr1:227636221	chr1:227509028~227520477:-
THCA	cis	rs12701220	0.894	rs12539012	ENSG00000229043.2	AC091729.9	-7	8.7e-12	2.45e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:1012497	chr7:1160374~1165267:+
THCA	cis	rs227932	0.571	rs12536173	ENSG00000234286.1	AC006026.13	-7	8.71e-12	2.45e-09	-0.57	-0.31	Schizophrenia;	chr7:23834413	chr7:23680195~23680786:-
THCA	cis	rs9402743	0.671	rs9373137	ENSG00000231028.7	LINC00271	-7	8.71e-12	2.45e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135629059	chr6:135497801~135716055:+
THCA	cis	rs4713118	0.629	rs203887	ENSG00000226314.6	ZNF192P1	-7	8.74e-12	2.46e-09	-0.43	-0.31	Parkinson's disease;	chr6:28053491	chr6:28161781~28169594:+
THCA	cis	rs8030379	1	rs117031571	ENSG00000230373.7	GOLGA6L5P	-7	8.74e-12	2.46e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903902	chr15:84507885~84516814:-
THCA	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-7	8.75e-12	2.47e-09	-0.34	-0.31	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-7	8.75e-12	2.47e-09	-0.34	-0.31	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
THCA	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	7	8.76e-12	2.47e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
THCA	cis	rs7044106	0.791	rs10984995	ENSG00000238181.2	AHCYP2	-7	8.76e-12	2.47e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120720673~120721972:+
THCA	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-7	8.78e-12	2.47e-09	-0.48	-0.31	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
THCA	cis	rs875971	0.862	rs7786892	ENSG00000232559.3	GS1-124K5.12	-7	8.79e-12	2.48e-09	-0.29	-0.31	Aortic root size;	chr7:66163889	chr7:66554588~66576923:-
THCA	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	7	8.79e-12	2.48e-09	0.38	0.31	Height;	chr6:109395761	chr6:109382795~109383666:+
THCA	cis	rs7267979	0.932	rs6115214	ENSG00000274414.1	RP5-965G21.4	7	8.79e-12	2.48e-09	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25239007~25245229:-
THCA	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	7	8.81e-12	2.48e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
THCA	cis	rs2439831	0.85	rs28513374	ENSG00000275601.1	AC011330.13	-7	8.81e-12	2.48e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43833297	chr15:43642389~43643023:-
THCA	cis	rs7580658	0.545	rs59318157	ENSG00000236682.1	AC068282.3	-7	8.81e-12	2.48e-09	-0.4	-0.31	Protein C levels;	chr2:127192498	chr2:127389130~127400580:+
THCA	cis	rs516805	0.667	rs17729938	ENSG00000279453.1	RP3-425C14.4	7	8.81e-12	2.48e-09	0.31	0.31	Lymphocyte counts;	chr6:122340364	chr6:122436789~122439223:-
THCA	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	7	8.81e-12	2.48e-09	0.38	0.31	Height;	chr6:109366911	chr6:109382795~109383666:+
THCA	cis	rs7044106	0.762	rs10760107	ENSG00000238181.2	AHCYP2	-7	8.85e-12	2.49e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120720673~120721972:+
THCA	cis	rs8030379	0.967	rs11857009	ENSG00000230373.7	GOLGA6L5P	-7	8.87e-12	2.5e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83898661	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs2046120	ENSG00000230373.7	GOLGA6L5P	-7	8.87e-12	2.5e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899010	chr15:84507885~84516814:-
THCA	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.894	rs9919452	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs10761776	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.624	rs10822175	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7097698	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63513635	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-7	8.87e-12	2.5e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
THCA	cis	rs8062405	0.755	rs62034350	ENSG00000278665.1	RP11-666O2.4	7	8.87e-12	2.5e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28599241~28601881:-
THCA	cis	rs7267979	0.816	rs6115094	ENSG00000274414.1	RP5-965G21.4	-7	8.89e-12	2.5e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25239007~25245229:-
THCA	cis	rs3745672	1	rs10405348	ENSG00000219665.7	CTD-2006C1.2	-7	8.89e-12	2.5e-09	-0.67	-0.31	Multiple sclerosis;	chr19:11952038	chr19:11987617~12046275:+
THCA	cis	rs10266483	0.843	rs667644	ENSG00000227986.1	TRIM60P18	-7	8.89e-12	2.5e-09	-0.26	-0.31	Response to statin therapy;	chr7:64290180	chr7:64355078~64356199:+
THCA	cis	rs713477	1	rs8014526	ENSG00000258413.1	RP11-665C16.6	7	8.91e-12	2.51e-09	0.41	0.31	Pediatric bone mineral content (femoral neck);	chr14:55418336	chr14:55262767~55272075:-
THCA	cis	rs2287838	0.686	rs730554	ENSG00000267289.1	CTD-2623N2.11	-7	8.92e-12	2.51e-09	-0.37	-0.31	Sleep duration;	chr19:9850870	chr19:9834079~9835013:-
THCA	cis	rs9902453	0.791	rs28492945	ENSG00000264007.1	RP11-68I3.10	7	8.94e-12	2.52e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29896964	chr17:29621617~29622254:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000206090.4	AP000350.7	-7	8.95e-12	2.52e-09	-0.39	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23939998~23942798:+
THCA	cis	rs7674212	0.865	rs1481279	ENSG00000251288.2	RP11-10L12.2	7	8.96e-12	2.52e-09	0.41	0.31	Type 2 diabetes;	chr4:103056781	chr4:102751401~102752641:+
THCA	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-7	8.97e-12	2.52e-09	-0.38	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-7	8.97e-12	2.52e-09	-0.38	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
THCA	cis	rs832187	0.593	rs3774713	ENSG00000280620.1	SCAANT1	7	8.98e-12	2.52e-09	0.41	0.31	Schizophrenia;	chr3:63932016	chr3:63911518~63911772:-
THCA	cis	rs728616	0.764	rs56122289	ENSG00000225484.5	NUTM2B-AS1	-7	8.98e-12	2.52e-09	-0.62	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79986271	chr10:79663088~79826594:-
THCA	cis	rs7608910	0.578	rs2564114	ENSG00000271889.1	RP11-493E12.1	7	8.99e-12	2.53e-09	0.3	0.31	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:61003512	chr2:61151433~61162105:-
THCA	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	7	8.99e-12	2.53e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
THCA	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	7	9e-12	2.53e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
THCA	cis	rs7189233	0.955	rs60420081	ENSG00000279722.1	RP11-44F14.6	-7	9e-12	2.53e-09	-0.32	-0.31	Intelligence (multi-trait analysis);	chr16:53486892	chr16:53487607~53489943:-
THCA	cis	rs2439831	1	rs471229	ENSG00000249839.1	AC011330.5	-7	9e-12	2.53e-09	-0.45	-0.31	Lung cancer in ever smokers;	chr15:43441796	chr15:43663654~43684339:-
THCA	cis	rs4664293	0.836	rs13032500	ENSG00000226266.5	AC009961.3	-7	9.01e-12	2.53e-09	-0.37	-0.31	Monocyte percentage of white cells;	chr2:159749740	chr2:159670708~159712435:-
THCA	cis	rs7267979	1	rs2482911	ENSG00000274414.1	RP5-965G21.4	7	9.02e-12	2.54e-09	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25239007~25245229:-
THCA	cis	rs7189233	0.955	rs72801817	ENSG00000279722.1	RP11-44F14.6	-7	9.04e-12	2.54e-09	-0.32	-0.31	Intelligence (multi-trait analysis);	chr16:53440656	chr16:53487607~53489943:-
THCA	cis	rs4845875	0.514	rs198393	ENSG00000242349.4	NPPA-AS1	-7	9.04e-12	2.54e-09	-0.29	-0.31	Midregional pro atrial natriuretic peptide levels;	chr1:11819628	chr1:11841017~11848079:+
THCA	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	7	9.04e-12	2.54e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
THCA	cis	rs7015630	0.657	rs12155807	ENSG00000251136.7	RP11-37B2.1	-7	9.06e-12	2.55e-09	-0.33	-0.31	Inflammatory bowel disease;Crohn's disease;	chr8:89835484	chr8:89609409~89757727:-
THCA	cis	rs7246657	0.943	rs713256	ENSG00000226686.6	LINC01535	-7	9.06e-12	2.55e-09	-0.46	-0.31	Coronary artery calcification;	chr19:37374463	chr19:37251912~37265535:+
THCA	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-7	9.08e-12	2.55e-09	-0.39	-0.31	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
THCA	cis	rs853679	1	rs853694	ENSG00000280107.1	AL022393.9	-7	9.08e-12	2.55e-09	-0.42	-0.31	Depression;	chr6:28311323	chr6:28170845~28172521:+
THCA	cis	rs8012947	1	rs4595719	ENSG00000279636.2	LINC00216	-7	9.08e-12	2.55e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58302084	chr14:58288033~58289158:+
THCA	cis	rs797680	0.964	rs12038699	ENSG00000223745.6	RP4-717I23.3	7	9.09e-12	2.55e-09	0.19	0.31	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93093261	chr1:93262186~93346025:-
THCA	cis	rs380904	1	rs380904	ENSG00000254859.1	RP11-661A12.5	-7	9.09e-12	2.55e-09	-0.45	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:143483735	chr8:143541973~143549729:-
THCA	cis	rs7045881	0.61	rs62542672	ENSG00000254396.1	RP11-56F10.3	7	9.1e-12	2.56e-09	0.48	0.31	Schizophrenia;	chr9:27022938	chr9:27102630~27104728:+
THCA	cis	rs4664293	1	rs6753181	ENSG00000226266.5	AC009961.3	-7	9.12e-12	2.56e-09	-0.35	-0.31	Monocyte percentage of white cells;	chr2:159635927	chr2:159670708~159712435:-
THCA	cis	rs6723226	0.803	rs176415	ENSG00000276334.1	AL133243.1	-7	9.12e-12	2.56e-09	-0.35	-0.31	Intelligence (multi-trait analysis);	chr2:32424710	chr2:32521927~32523547:+
THCA	cis	rs853679	0.599	rs188015	ENSG00000219392.1	RP1-265C24.5	-7	9.13e-12	2.57e-09	-0.5	-0.31	Depression;	chr6:27909668	chr6:28115628~28116551:+
THCA	cis	rs9287719	0.649	rs12104950	ENSG00000243819.4	RN7SL832P	7	9.14e-12	2.57e-09	0.25	0.31	Prostate cancer;	chr2:10591979	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10803724	ENSG00000243819.4	RN7SL832P	7	9.14e-12	2.57e-09	0.25	0.31	Prostate cancer;	chr2:10592197	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10803725	ENSG00000243819.4	RN7SL832P	7	9.14e-12	2.57e-09	0.25	0.31	Prostate cancer;	chr2:10592220	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10929685	ENSG00000243819.4	RN7SL832P	7	9.14e-12	2.57e-09	0.25	0.31	Prostate cancer;	chr2:10592673	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10183359	ENSG00000243819.4	RN7SL832P	7	9.14e-12	2.57e-09	0.25	0.31	Prostate cancer;	chr2:10592918	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.624	rs10172926	ENSG00000243819.4	RN7SL832P	7	9.14e-12	2.57e-09	0.25	0.31	Prostate cancer;	chr2:10593128	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.601	rs10178751	ENSG00000243819.4	RN7SL832P	7	9.14e-12	2.57e-09	0.25	0.31	Prostate cancer;	chr2:10594077	chr2:10690344~10692099:+
THCA	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	7	9.14e-12	2.57e-09	0.33	0.31	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
THCA	cis	rs875971	0.862	rs778684	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66371416	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs778680	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66375427	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs11769079	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66377141	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs1695820	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66379576	chr7:66554588~66576923:-
THCA	cis	rs875971	0.83	rs778715	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66384222	chr7:66554588~66576923:-
THCA	cis	rs875971	0.83	rs809025	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66384832	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs778702	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66399848	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs1643375	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66407690	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6962717	ENSG00000232559.3	GS1-124K5.12	7	9.15e-12	2.57e-09	0.29	0.31	Aortic root size;	chr7:66418748	chr7:66554588~66576923:-
THCA	cis	rs4947019	0.686	rs9487083	ENSG00000260273.1	RP11-425D10.10	7	9.15e-12	2.57e-09	0.66	0.31	Hematological parameters;	chr6:109394399	chr6:109382795~109383666:+
THCA	cis	rs193541	0.53	rs9327272	ENSG00000263432.2	RN7SL689P	7	9.16e-12	2.57e-09	0.37	0.31	Glucose homeostasis traits;	chr5:122737853	chr5:123022487~123022783:-
THCA	cis	rs2562456	0.793	rs2562428	ENSG00000268119.4	CTD-2561J22.5	-7	9.17e-12	2.57e-09	-0.39	-0.31	Pain;	chr19:21442652	chr19:21444241~21463908:-
THCA	cis	rs7267979	0.744	rs6050463	ENSG00000274414.1	RP5-965G21.4	-6.99	9.18e-12	2.58e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25239007~25245229:-
THCA	cis	rs7208859	0.623	rs170051	ENSG00000263603.1	CTD-2349P21.5	-6.99	9.21e-12	2.59e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.51	rs216402	ENSG00000263603.1	CTD-2349P21.5	-6.99	9.21e-12	2.59e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs216434	ENSG00000263603.1	CTD-2349P21.5	-6.99	9.21e-12	2.59e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs216436	ENSG00000263603.1	CTD-2349P21.5	-6.99	9.21e-12	2.59e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000263603.1	CTD-2349P21.5	-6.99	9.21e-12	2.59e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs216439	ENSG00000263603.1	CTD-2349P21.5	-6.99	9.21e-12	2.59e-09	-0.54	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30729469~30731202:+
THCA	cis	rs748404	0.723	rs11853991	ENSG00000205771.5	CATSPER2P1	-6.99	9.21e-12	2.59e-09	-0.31	-0.31	Lung cancer;	chr15:43265351	chr15:43726918~43747094:-
THCA	cis	rs9341808	0.718	rs9352803	ENSG00000272129.1	RP11-250B2.6	6.99	9.21e-12	2.59e-09	0.39	0.31	Sitting height ratio;	chr6:80154950	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.655	rs9350846	ENSG00000272129.1	RP11-250B2.6	6.99	9.21e-12	2.59e-09	0.39	0.31	Sitting height ratio;	chr6:80155764	chr6:80355424~80356859:+
THCA	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-6.99	9.21e-12	2.59e-09	-0.39	-0.31	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-6.99	9.21e-12	2.59e-09	-0.39	-0.31	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
THCA	cis	rs8012947	0.92	rs7154498	ENSG00000279636.2	LINC00216	-6.99	9.24e-12	2.59e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58295814	chr14:58288033~58289158:+
THCA	cis	rs8012947	0.92	rs7155825	ENSG00000279636.2	LINC00216	-6.99	9.24e-12	2.59e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58295819	chr14:58288033~58289158:+
THCA	cis	rs9467773	0.595	rs3846845	ENSG00000124549.13	BTN2A3P	-6.99	9.24e-12	2.59e-09	-0.29	-0.31	Intelligence (multi-trait analysis);	chr6:26444687	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.572	rs3846846	ENSG00000124549.13	BTN2A3P	-6.99	9.24e-12	2.59e-09	-0.29	-0.31	Intelligence (multi-trait analysis);	chr6:26444811	chr6:26421391~26432383:+
THCA	cis	rs7811142	1	rs73161759	ENSG00000078319.8	PMS2P1	-6.99	9.25e-12	2.6e-09	-0.43	-0.31	Platelet count;	chr7:100412371	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs67315960	ENSG00000078319.8	PMS2P1	-6.99	9.25e-12	2.6e-09	-0.43	-0.31	Platelet count;	chr7:100417501	chr7:100320992~100341908:-
THCA	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-6.99	9.27e-12	2.6e-09	-0.32	-0.31	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
THCA	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-6.99	9.27e-12	2.6e-09	-0.32	-0.31	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
THCA	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-6.99	9.27e-12	2.6e-09	-0.32	-0.31	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
THCA	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	6.99	9.27e-12	2.6e-09	0.32	0.31	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
THCA	cis	rs4664293	0.967	rs13020365	ENSG00000226266.5	AC009961.3	-6.99	9.27e-12	2.6e-09	-0.35	-0.31	Monocyte percentage of white cells;	chr2:159619893	chr2:159670708~159712435:-
THCA	cis	rs6597981	0.604	rs7945912	ENSG00000255284.1	AP006621.5	6.99	9.28e-12	2.6e-09	0.2	0.31	Breast cancer;	chr11:750849	chr11:777578~784297:+
THCA	cis	rs7044106	0.791	rs4836829	ENSG00000238181.2	AHCYP2	-6.99	9.29e-12	2.61e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120720673~120721972:+
THCA	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-6.99	9.3e-12	2.61e-09	-0.33	-0.31	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
THCA	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	6.99	9.31e-12	2.61e-09	0.38	0.31	Height;	chr6:109387685	chr6:109382795~109383666:+
THCA	cis	rs8062405	0.723	rs4788079	ENSG00000278665.1	RP11-666O2.4	6.99	9.31e-12	2.61e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28599241~28601881:-
THCA	cis	rs7646881	0.812	rs79303235	ENSG00000240207.5	RP11-379F4.4	-6.99	9.32e-12	2.62e-09	-0.43	-0.31	Tetralogy of Fallot;	chr3:158727004	chr3:158732263~158784070:+
THCA	cis	rs7131987	0.65	rs7957339	ENSG00000275476.1	RP11-996F15.4	-6.99	9.33e-12	2.62e-09	-0.31	-0.31	QT interval;	chr12:29303562	chr12:29277397~29277882:-
THCA	cis	rs7044106	0.791	rs3904196	ENSG00000238181.2	AHCYP2	-6.99	9.33e-12	2.62e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120720673~120721972:+
THCA	cis	rs1501911	0.509	rs327786	ENSG00000246763.5	RGMB-AS1	6.99	9.34e-12	2.62e-09	0.29	0.31	Lung function (FEV1/FVC);	chr5:98878301	chr5:98769618~98773469:-
THCA	cis	rs7267979	0.903	rs2474769	ENSG00000274414.1	RP5-965G21.4	-6.99	9.34e-12	2.62e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25239007~25245229:-
THCA	cis	rs2439831	0.867	rs496584	ENSG00000275601.1	AC011330.13	-6.99	9.35e-12	2.62e-09	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43539725	chr15:43642389~43643023:-
THCA	cis	rs8081395	0.775	rs2526355	ENSG00000266992.1	DHX40P1	6.99	9.35e-12	2.62e-09	0.35	0.31	White blood cell count;	chr17:59875872	chr17:59976009~60002384:-
THCA	cis	rs7189233	1	rs7189819	ENSG00000279344.1	RP11-44F14.7	6.99	9.35e-12	2.62e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr16:53502433	chr16:53478957~53481550:-
THCA	cis	rs7044106	0.791	rs4837793	ENSG00000238181.2	AHCYP2	-6.99	9.35e-12	2.62e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120720673~120721972:+
THCA	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	6.99	9.36e-12	2.63e-09	0.36	0.31	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
THCA	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-6.99	9.36e-12	2.63e-09	-0.3	-0.31	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-6.99	9.36e-12	2.63e-09	-0.3	-0.31	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
THCA	cis	rs5769707	0.521	rs739244	ENSG00000235111.1	RP1-29C18.8	-6.99	9.37e-12	2.63e-09	-0.38	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49612657~49615716:-
THCA	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	6.99	9.37e-12	2.63e-09	0.38	0.31	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	6.99	9.37e-12	2.63e-09	0.33	0.31	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	6.99	9.37e-12	2.63e-09	0.33	0.31	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
THCA	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-6.99	9.38e-12	2.63e-09	-0.38	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-6.99	9.38e-12	2.63e-09	-0.38	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
THCA	cis	rs7246657	0.882	rs8112610	ENSG00000226686.6	LINC01535	-6.99	9.39e-12	2.63e-09	-0.43	-0.31	Coronary artery calcification;	chr19:37437828	chr19:37251912~37265535:+
THCA	cis	rs516805	0.597	rs2816157	ENSG00000279453.1	RP3-425C14.4	-6.99	9.39e-12	2.63e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122124400	chr6:122436789~122439223:-
THCA	cis	rs12681366	0.537	rs2919659	ENSG00000253704.1	RP11-267M23.4	6.99	9.39e-12	2.63e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94459544	chr8:94553722~94569745:+
THCA	cis	rs2408955	0.515	rs10875742	ENSG00000258273.1	RP11-370I10.4	6.99	9.4e-12	2.64e-09	0.38	0.31	Glycated hemoglobin levels;	chr12:48099591	chr12:48333755~48333901:-
THCA	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	6.99	9.41e-12	2.64e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	6.99	9.41e-12	2.64e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
THCA	cis	rs7851660	0.805	rs4255258	ENSG00000236130.1	PTCSC2	-6.99	9.41e-12	2.64e-09	-0.25	-0.31	Strep throat;	chr9:97885263	chr9:97805935~97810008:-
THCA	cis	rs7208859	0.614	rs216412	ENSG00000264538.5	SUZ12P1	6.99	9.42e-12	2.64e-09	0.29	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30709299~30790908:+
THCA	cis	rs1292048	1	rs1292048	ENSG00000266992.1	DHX40P1	6.99	9.43e-12	2.64e-09	0.35	0.31	Red cell distribution width;	chr17:59877710	chr17:59976009~60002384:-
THCA	cis	rs7246657	1	rs1529957	ENSG00000226686.6	LINC01535	-6.99	9.43e-12	2.64e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37248899	chr19:37251912~37265535:+
THCA	cis	rs5742933	0.725	rs1132360	ENSG00000273240.1	RP11-455J20.3	6.99	9.44e-12	2.65e-09	0.32	0.31	Ferritin levels;	chr2:189661498	chr2:189763859~189764456:-
THCA	cis	rs12348691	0.503	rs4743138	ENSG00000236130.1	PTCSC2	6.99	9.47e-12	2.66e-09	0.26	0.31	Alopecia areata;	chr9:97852014	chr9:97805935~97810008:-
THCA	cis	rs7131987	0.621	rs6487805	ENSG00000275476.1	RP11-996F15.4	6.99	9.48e-12	2.66e-09	0.31	0.31	QT interval;	chr12:29304617	chr12:29277397~29277882:-
THCA	cis	rs10971721	0.822	rs10971818	ENSG00000260947.1	RP11-384P7.7	-6.99	9.48e-12	2.66e-09	-0.73	-0.31	Body mass index;	chr9:33952155	chr9:33697459~33700986:+
THCA	cis	rs7044106	0.762	rs1324473	ENSG00000238181.2	AHCYP2	6.99	9.48e-12	2.66e-09	0.39	0.31	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120720673~120721972:+
THCA	cis	rs11024102	1	rs10766368	ENSG00000184669.7	OR7E14P	-6.99	9.48e-12	2.66e-09	-0.42	-0.31	Glaucoma (primary angle closure);	chr11:16993335	chr11:17013998~17053024:+
THCA	cis	rs4266144	0.632	rs56268334	ENSG00000241770.1	RP11-555M1.3	-6.99	9.48e-12	2.66e-09	-0.47	-0.31	Coronary artery disease;	chr3:157130235	chr3:157163452~157169133:+
THCA	cis	rs7246657	0.941	rs67293224	ENSG00000226686.6	LINC01535	-6.99	9.5e-12	2.66e-09	-0.46	-0.31	Coronary artery calcification;	chr19:37312346	chr19:37251912~37265535:+
THCA	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	6.99	9.51e-12	2.66e-09	0.25	0.31	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
THCA	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-6.99	9.51e-12	2.67e-09	-0.38	-0.31	Height;	chr6:109485060	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	6.99	9.52e-12	2.67e-09	0.38	0.31	Height;	chr6:109382524	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	6.99	9.52e-12	2.67e-09	0.38	0.31	Height;	chr6:109384228	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	6.99	9.52e-12	2.67e-09	0.38	0.31	Height;	chr6:109385087	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	6.99	9.52e-12	2.67e-09	0.38	0.31	Height;	chr6:109388256	chr6:109382795~109383666:+
THCA	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-6.99	9.53e-12	2.67e-09	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
THCA	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-6.99	9.53e-12	2.67e-09	-0.38	-0.31	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
THCA	cis	rs911555	0.504	rs8006526	ENSG00000269958.1	RP11-73M18.8	6.99	9.54e-12	2.67e-09	0.29	0.31	Intelligence (multi-trait analysis);	chr14:103608678	chr14:103696353~103697163:+
THCA	cis	rs74233809	1	rs11191514	ENSG00000213277.3	MARCKSL1P1	6.99	9.55e-12	2.67e-09	0.5	0.31	Birth weight;	chr10:103013607	chr10:103175554~103176094:+
THCA	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-6.99	9.55e-12	2.68e-09	-0.29	-0.31	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
THCA	cis	rs4072705	1	rs721862	ENSG00000224020.1	MIR181A2HG	-6.99	9.55e-12	2.68e-09	-0.27	-0.31	Menarche (age at onset);	chr9:124773713	chr9:124658467~124698631:+
THCA	cis	rs10869777	0.967	rs7847904	ENSG00000234618.1	RPSAP9	-6.99	9.55e-12	2.68e-09	-0.33	-0.31	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76440097	chr9:76398699~76399586:+
THCA	cis	rs6840258	1	rs114701347	ENSG00000251411.1	RP11-397E7.4	-6.99	9.56e-12	2.68e-09	-0.36	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87043849	chr4:86913266~86914817:-
THCA	cis	rs6840258	1	rs72667765	ENSG00000251411.1	RP11-397E7.4	-6.99	9.56e-12	2.68e-09	-0.36	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87044790	chr4:86913266~86914817:-
THCA	cis	rs1850744	0.826	rs10939514	ENSG00000250942.1	ENPP7P11	6.99	9.57e-12	2.68e-09	0.46	0.31	Economic and political preferences;	chr4:9771572	chr4:9677308~9677934:+
THCA	cis	rs1850744	1	rs1878275	ENSG00000250942.1	ENPP7P11	6.99	9.57e-12	2.68e-09	0.46	0.31	Economic and political preferences;	chr4:9775777	chr4:9677308~9677934:+
THCA	cis	rs1850744	1	rs9685502	ENSG00000250942.1	ENPP7P11	6.99	9.57e-12	2.68e-09	0.46	0.31	Economic and political preferences;	chr4:9778012	chr4:9677308~9677934:+
THCA	cis	rs17684571	0.938	rs4074102	ENSG00000231441.1	RP11-472M19.2	6.99	9.59e-12	2.68e-09	0.39	0.31	Schizophrenia;	chr6:56697497	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.938	rs4074101	ENSG00000231441.1	RP11-472M19.2	6.99	9.59e-12	2.68e-09	0.39	0.31	Schizophrenia;	chr6:56697654	chr6:56844002~56864078:+
THCA	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	6.99	9.59e-12	2.69e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
THCA	cis	rs12928939	0.911	rs11645725	ENSG00000260886.1	TAT-AS1	6.99	9.6e-12	2.69e-09	0.41	0.31	Post bronchodilator FEV1;	chr16:71792980	chr16:71565789~71578187:+
THCA	cis	rs2439831	1	rs2439841	ENSG00000249839.1	AC011330.5	-6.99	9.6e-12	2.69e-09	-0.45	-0.31	Lung cancer in ever smokers;	chr15:43442551	chr15:43663654~43684339:-
THCA	cis	rs8114671	0.773	rs3746438	ENSG00000269202.1	RP4-614O4.12	6.99	9.61e-12	2.69e-09	0.26	0.31	Height;	chr20:34996486	chr20:35201747~35203288:-
THCA	cis	rs853679	0.517	rs1340004	ENSG00000220721.1	OR1F12	6.99	9.61e-12	2.69e-09	0.43	0.31	Depression;	chr6:28135913	chr6:28073316~28074233:+
THCA	cis	rs74233809	1	rs3740390	ENSG00000213277.3	MARCKSL1P1	6.99	9.61e-12	2.69e-09	0.48	0.31	Birth weight;	chr10:102878723	chr10:103175554~103176094:+
THCA	cis	rs9876781	0.559	rs1903144	ENSG00000229759.1	MRPS18AP1	6.99	9.65e-12	2.7e-09	0.37	0.31	Longevity;	chr3:48364907	chr3:48256350~48256938:-
THCA	cis	rs7811142	1	rs11763414	ENSG00000078319.8	PMS2P1	-6.99	9.65e-12	2.7e-09	-0.43	-0.31	Platelet count;	chr7:100419221	chr7:100320992~100341908:-
THCA	cis	rs507080	0.922	rs4936433	ENSG00000278376.1	RP11-158I9.8	6.99	9.65e-12	2.7e-09	0.26	0.31	Serum metabolite levels;	chr11:118681711	chr11:118791254~118793137:+
THCA	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-6.99	9.66e-12	2.7e-09	-0.32	-0.31	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
THCA	cis	rs3847687	0.901	rs12370258	ENSG00000279128.1	RP11-76C10.4	6.99	9.66e-12	2.7e-09	0.35	0.31	Longevity;	chr12:131042756	chr12:131022769~131024741:-
THCA	cis	rs7267979	0.873	rs6037062	ENSG00000274414.1	RP5-965G21.4	-6.99	9.67e-12	2.71e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25239007~25245229:-
THCA	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-6.99	9.67e-12	2.71e-09	-0.28	-0.31	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
THCA	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-6.99	9.7e-12	2.71e-09	-0.37	-0.31	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
THCA	cis	rs848490	0.889	rs11489585	ENSG00000214293.7	APTR	6.99	9.71e-12	2.72e-09	0.24	0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685535	chr7:77657660~77696265:-
THCA	cis	rs9402743	0.671	rs9399151	ENSG00000231028.7	LINC00271	-6.99	9.72e-12	2.72e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135617920	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs9376116	ENSG00000231028.7	LINC00271	-6.99	9.72e-12	2.72e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135618763	chr6:135497801~135716055:+
THCA	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	6.99	9.73e-12	2.72e-09	0.34	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	6.99	9.73e-12	2.72e-09	0.34	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	6.99	9.73e-12	2.72e-09	0.34	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
THCA	cis	rs7324557	0.683	rs9507167	ENSG00000205861.10	C1QTNF9B-AS1	6.99	9.73e-12	2.72e-09	0.38	0.31	Visceral adipose tissue adjusted for BMI;	chr13:23829525	chr13:23888889~23897263:+
THCA	cis	rs4950322	0.58	rs4950308	ENSG00000237188.3	RP11-337C18.8	6.99	9.73e-12	2.72e-09	0.37	0.31	Protein quantitative trait loci;	chr1:147120092	chr1:147172771~147211568:+
THCA	cis	rs875971	0.862	rs2024192	ENSG00000232559.3	GS1-124K5.12	-6.99	9.74e-12	2.72e-09	-0.3	-0.31	Aortic root size;	chr7:66576460	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6955837	ENSG00000232559.3	GS1-124K5.12	-6.99	9.74e-12	2.72e-09	-0.3	-0.31	Aortic root size;	chr7:66578155	chr7:66554588~66576923:-
THCA	cis	rs875971	0.825	rs10281499	ENSG00000232559.3	GS1-124K5.12	-6.99	9.74e-12	2.72e-09	-0.3	-0.31	Aortic root size;	chr7:66583979	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs4718377	ENSG00000232559.3	GS1-124K5.12	-6.99	9.74e-12	2.72e-09	-0.3	-0.31	Aortic root size;	chr7:66584691	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs10278014	ENSG00000232559.3	GS1-124K5.12	-6.99	9.74e-12	2.72e-09	-0.3	-0.31	Aortic root size;	chr7:66586277	chr7:66554588~66576923:-
THCA	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-6.99	9.74e-12	2.72e-09	-0.32	-0.31	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
THCA	cis	rs2688608	0.592	rs2306328	ENSG00000271816.1	BMS1P4	6.99	9.75e-12	2.73e-09	0.31	0.31	Inflammatory bowel disease;	chr10:73819752	chr10:73699151~73730487:-
THCA	cis	rs2348418	0.715	rs12307612	ENSG00000247934.4	RP11-967K21.1	6.99	9.78e-12	2.73e-09	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28566713	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.715	rs12307709	ENSG00000247934.4	RP11-967K21.1	6.99	9.78e-12	2.73e-09	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28566767	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.715	rs11049719	ENSG00000247934.4	RP11-967K21.1	6.99	9.78e-12	2.73e-09	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28567446	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.715	rs11049720	ENSG00000247934.4	RP11-967K21.1	6.99	9.78e-12	2.73e-09	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28567477	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.715	rs10843206	ENSG00000247934.4	RP11-967K21.1	6.99	9.78e-12	2.73e-09	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28569823	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.681	rs10843207	ENSG00000247934.4	RP11-967K21.1	6.99	9.78e-12	2.73e-09	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28569929	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.715	rs7971717	ENSG00000247934.4	RP11-967K21.1	6.99	9.78e-12	2.73e-09	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28570087	chr12:28163298~28190738:-
THCA	cis	rs6723108	0.517	rs7580655	ENSG00000224043.6	CCNT2-AS1	-6.99	9.78e-12	2.74e-09	-0.31	-0.31	Type 2 diabetes;	chr2:134869605	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.517	rs6711390	ENSG00000224043.6	CCNT2-AS1	-6.99	9.78e-12	2.74e-09	-0.31	-0.31	Type 2 diabetes;	chr2:134871869	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.517	rs6430553	ENSG00000224043.6	CCNT2-AS1	-6.99	9.78e-12	2.74e-09	-0.31	-0.31	Type 2 diabetes;	chr2:134873830	chr2:134735464~134918710:-
THCA	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-6.98	9.8e-12	2.74e-09	-0.38	-0.31	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
THCA	cis	rs853679	0.517	rs4713152	ENSG00000272009.1	RP1-313I6.12	-6.98	9.81e-12	2.74e-09	-0.36	-0.31	Depression;	chr6:28169676	chr6:28078792~28081130:-
THCA	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	6.98	9.82e-12	2.75e-09	0.38	0.31	Height;	chr6:109375003	chr6:109382795~109383666:+
THCA	cis	rs240993	0.812	rs9400481	ENSG00000230177.1	RP5-1112D6.4	6.98	9.82e-12	2.75e-09	0.32	0.31	Inflammatory skin disease;Psoriasis;	chr6:111529539	chr6:111277932~111278742:+
THCA	cis	rs6600671	0.934	rs67718113	ENSG00000275538.1	RNVU1-19	-6.98	9.83e-12	2.75e-09	-0.4	-0.31	Hip geometry;	chr1:121497112	chr1:120850819~120850985:-
THCA	cis	rs72772090	0.634	rs12186366	ENSG00000248734.2	CTD-2260A17.1	-6.98	9.83e-12	2.75e-09	-0.49	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96784777~96785999:+
THCA	cis	rs8030379	1	rs6603004	ENSG00000230373.7	GOLGA6L5P	6.98	9.84e-12	2.75e-09	0.28	0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899752	chr15:84507885~84516814:-
THCA	cis	rs41307935	0.908	rs12735646	ENSG00000260063.1	RP5-968P14.2	-6.98	9.84e-12	2.75e-09	-0.58	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26751875	chr1:26692132~26694131:-
THCA	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	6.98	9.85e-12	2.75e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	6.98	9.85e-12	2.75e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
THCA	cis	rs2562456	0.833	rs2968076	ENSG00000213976.4	CTD-2561J22.2	6.98	9.85e-12	2.75e-09	0.33	0.31	Pain;	chr19:21454299	chr19:21382865~21387177:+
THCA	cis	rs4713118	0.505	rs276371	ENSG00000219392.1	RP1-265C24.5	-6.98	9.86e-12	2.76e-09	-0.34	-0.31	Parkinson's disease;	chr6:27942930	chr6:28115628~28116551:+
THCA	cis	rs9402743	0.634	rs4896156	ENSG00000231028.7	LINC00271	-6.98	9.86e-12	2.76e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135605725	chr6:135497801~135716055:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000272009.1	RP1-313I6.12	-6.98	9.88e-12	2.76e-09	-0.35	-0.31	Parkinson's disease;	chr6:28066959	chr6:28078792~28081130:-
THCA	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	6.98	9.89e-12	2.77e-09	0.42	0.31	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	6.98	9.9e-12	2.77e-09	0.36	0.31	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
THCA	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-6.98	9.92e-12	2.77e-09	-0.28	-0.31	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
THCA	cis	rs6539288	0.899	rs2053206	ENSG00000260329.1	RP11-412D9.4	-6.98	9.93e-12	2.77e-09	-0.27	-0.31	Total body bone mineral density;	chr12:106912401	chr12:106954029~106955497:-
THCA	cis	rs7044106	0.791	rs2416797	ENSG00000238181.2	AHCYP2	-6.98	9.93e-12	2.77e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120720673~120721972:+
THCA	cis	rs7044106	0.791	rs2416798	ENSG00000238181.2	AHCYP2	-6.98	9.93e-12	2.77e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120720673~120721972:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000220721.1	OR1F12	6.98	9.93e-12	2.78e-09	0.42	0.31	Depression;	chr6:28096845	chr6:28073316~28074233:+
THCA	cis	rs73186030	1	rs73186030	ENSG00000272758.4	RP11-299J3.8	6.98	9.94e-12	2.78e-09	0.39	0.31	Serum parathyroid hormone levels;	chr3:122294618	chr3:122416207~122443180:+
THCA	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	6.98	9.95e-12	2.78e-09	0.3	0.31	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
THCA	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	6.98	9.96e-12	2.78e-09	0.47	0.31	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
THCA	cis	rs9388451	0.807	rs1268065	ENSG00000237742.5	RP11-624M8.1	6.98	9.97e-12	2.79e-09	0.27	0.31	Brugada syndrome;	chr6:125721637	chr6:125578558~125749190:-
THCA	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	6.98	9.97e-12	2.79e-09	0.38	0.31	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
THCA	cis	rs7131987	0.683	rs12366505	ENSG00000275476.1	RP11-996F15.4	-6.98	9.98e-12	2.79e-09	-0.31	-0.31	QT interval;	chr12:29321177	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.65	rs12366527	ENSG00000275476.1	RP11-996F15.4	-6.98	9.98e-12	2.79e-09	-0.31	-0.31	QT interval;	chr12:29321323	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.65	rs7311912	ENSG00000275476.1	RP11-996F15.4	-6.98	9.98e-12	2.79e-09	-0.31	-0.31	QT interval;	chr12:29322770	chr12:29277397~29277882:-
THCA	cis	rs9318086	0.534	rs7319884	ENSG00000205861.10	C1QTNF9B-AS1	6.98	9.98e-12	2.79e-09	0.36	0.31	Myopia (pathological);	chr13:23813273	chr13:23888889~23897263:+
THCA	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-6.98	1e-11	2.79e-09	-0.53	-0.31	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
THCA	cis	rs13113518	0.557	rs13142096	ENSG00000273257.1	RP11-177J6.1	6.98	1e-11	2.79e-09	0.44	0.31	Height;	chr4:55566291	chr4:55387949~55388271:+
THCA	cis	rs12701220	0.817	rs1058729	ENSG00000229043.2	AC091729.9	-6.98	1e-11	2.8e-09	-0.4	-0.31	Bronchopulmonary dysplasia;	chr7:1047647	chr7:1160374~1165267:+
THCA	cis	rs516805	0.63	rs1379098	ENSG00000279453.1	RP3-425C14.4	-6.98	1e-11	2.8e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122121672	chr6:122436789~122439223:-
THCA	cis	rs7811142	1	rs11764818	ENSG00000078319.8	PMS2P1	-6.98	1.01e-11	2.81e-09	-0.43	-0.31	Platelet count;	chr7:100445432	chr7:100320992~100341908:-
THCA	cis	rs4947019	0.609	rs749621	ENSG00000260273.1	RP11-425D10.10	6.98	1.01e-11	2.81e-09	0.66	0.31	Hematological parameters;	chr6:109441397	chr6:109382795~109383666:+
THCA	cis	rs7246657	0.943	rs1382357	ENSG00000226686.6	LINC01535	-6.98	1.01e-11	2.81e-09	-0.43	-0.31	Coronary artery calcification;	chr19:37486707	chr19:37251912~37265535:+
THCA	cis	rs853679	1	rs853679	ENSG00000280107.1	AL022393.9	-6.98	1.01e-11	2.81e-09	-0.42	-0.31	Depression;	chr6:28329086	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs853678	ENSG00000280107.1	AL022393.9	-6.98	1.01e-11	2.81e-09	-0.42	-0.31	Depression;	chr6:28329536	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs16893666	ENSG00000220721.1	OR1F12	-6.98	1.01e-11	2.81e-09	-0.42	-0.31	Depression;	chr6:28086929	chr6:28073316~28074233:+
THCA	cis	rs2348418	0.647	rs938081	ENSG00000247934.4	RP11-967K21.1	6.98	1.01e-11	2.81e-09	0.27	0.31	Lung function (FEV1);Lung function (FVC);	chr12:28567680	chr12:28163298~28190738:-
THCA	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	6.98	1.01e-11	2.82e-09	0.3	0.31	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
THCA	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	6.98	1.01e-11	2.82e-09	0.3	0.31	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
THCA	cis	rs12817211	0.549	rs6580728	ENSG00000272368.2	RP4-605O3.4	-6.98	1.01e-11	2.82e-09	-0.18	-0.31	Colorectal or endometrial cancer;	chr12:50147344	chr12:50112197~50165618:+
THCA	cis	rs11148252	0.538	rs9535885	ENSG00000278238.1	RP11-245D16.4	-6.98	1.01e-11	2.82e-09	-0.33	-0.31	Lewy body disease;	chr13:52152389	chr13:52454775~52455331:-
THCA	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	6.98	1.01e-11	2.83e-09	0.4	0.31	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
THCA	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	6.98	1.02e-11	2.83e-09	0.41	0.31	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
THCA	cis	rs12435908	1	rs11844747	ENSG00000276116.2	FUT8-AS1	6.98	1.02e-11	2.83e-09	0.48	0.31	Ischemic stroke;	chr14:65403410	chr14:65411170~65412690:-
THCA	cis	rs875971	0.756	rs4718328	ENSG00000232559.3	GS1-124K5.12	-6.98	1.02e-11	2.84e-09	-0.29	-0.31	Aortic root size;	chr7:66228350	chr7:66554588~66576923:-
THCA	cis	rs9475752	1	rs1451707	ENSG00000231441.1	RP11-472M19.2	6.98	1.02e-11	2.84e-09	0.39	0.31	Menarche (age at onset);	chr6:56937079	chr6:56844002~56864078:+
THCA	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	6.98	1.02e-11	2.84e-09	0.24	0.31	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
THCA	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-6.98	1.02e-11	2.85e-09	-0.39	-0.31	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-6.98	1.02e-11	2.85e-09	-0.39	-0.31	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-6.98	1.02e-11	2.85e-09	-0.39	-0.31	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-6.98	1.02e-11	2.85e-09	-0.39	-0.31	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
THCA	cis	rs7324557	0.717	rs7325423	ENSG00000205861.10	C1QTNF9B-AS1	-6.98	1.02e-11	2.85e-09	-0.38	-0.31	Visceral adipose tissue adjusted for BMI;	chr13:23827670	chr13:23888889~23897263:+
THCA	cis	rs944289	0.561	rs1755769	ENSG00000257826.1	RP11-116N8.4	-6.98	1.02e-11	2.85e-09	-0.35	-0.31	Thyroid cancer;	chr14:36193617	chr14:36061026~36067190:-
THCA	cis	rs453301	0.657	rs36056437	ENSG00000253893.2	FAM85B	6.98	1.02e-11	2.86e-09	0.41	0.31	Joint mobility (Beighton score);	chr8:8935355	chr8:8167819~8226614:-
THCA	cis	rs74233809	1	rs77787671	ENSG00000213277.3	MARCKSL1P1	6.98	1.03e-11	2.86e-09	0.5	0.31	Birth weight;	chr10:103016448	chr10:103175554~103176094:+
THCA	cis	rs8062405	0.755	rs4788076	ENSG00000278665.1	RP11-666O2.4	6.98	1.03e-11	2.87e-09	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28599241~28601881:-
THCA	cis	rs1859596	0.565	rs2886361	ENSG00000234456.6	MAGI2-AS3	6.98	1.03e-11	2.87e-09	0.3	0.31	Reading or mathematical ability;	chr7:79485381	chr7:79452877~79471208:+
THCA	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-6.98	1.03e-11	2.87e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
THCA	cis	rs9287719	0.649	rs12618726	ENSG00000243819.4	RN7SL832P	6.98	1.03e-11	2.87e-09	0.25	0.31	Prostate cancer;	chr2:10588249	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs6714787	ENSG00000243819.4	RN7SL832P	6.98	1.03e-11	2.87e-09	0.25	0.31	Prostate cancer;	chr2:10588906	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs2024432	ENSG00000243819.4	RN7SL832P	6.98	1.03e-11	2.87e-09	0.25	0.31	Prostate cancer;	chr2:10591348	chr2:10690344~10692099:+
THCA	cis	rs7945705	0.846	rs11042055	ENSG00000254860.4	TMEM9B-AS1	-6.98	1.03e-11	2.87e-09	-0.34	-0.31	Hemoglobin concentration;	chr11:8735309	chr11:8964675~8977527:+
THCA	cis	rs9402743	0.671	rs6901733	ENSG00000231028.7	LINC00271	-6.98	1.03e-11	2.88e-09	-0.25	-0.31	Systemic lupus erythematosus;	chr6:135619407	chr6:135497801~135716055:+
THCA	cis	rs516805	0.667	rs9632500	ENSG00000279453.1	RP3-425C14.4	6.98	1.03e-11	2.88e-09	0.33	0.31	Lymphocyte counts;	chr6:122251472	chr6:122436789~122439223:-
THCA	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	6.98	1.03e-11	2.88e-09	0.47	0.31	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
THCA	cis	rs4713118	0.715	rs200480	ENSG00000219392.1	RP1-265C24.5	-6.98	1.04e-11	2.89e-09	-0.35	-0.31	Parkinson's disease;	chr6:27805886	chr6:28115628~28116551:+
THCA	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-6.98	1.04e-11	2.89e-09	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
THCA	cis	rs4845875	0.534	rs6541003	ENSG00000242349.4	NPPA-AS1	6.98	1.04e-11	2.89e-09	0.29	0.31	Midregional pro atrial natriuretic peptide levels;	chr1:11795810	chr1:11841017~11848079:+
THCA	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-6.98	1.04e-11	2.89e-09	-0.4	-0.31	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
THCA	cis	rs1125355	0.964	rs78599894	ENSG00000251491.2	OR7E28P	-6.98	1.04e-11	2.9e-09	-0.47	-0.31	Alzheimer's disease in APOE e4+ carriers;	chr2:158817912	chr2:158862311~158863285:+
THCA	cis	rs7247513	0.859	rs35945052	ENSG00000213290.4	PGK1P2	-6.98	1.04e-11	2.9e-09	-0.37	-0.31	Bipolar disorder;	chr19:12592416	chr19:12559571~12561105:+
THCA	cis	rs7044106	0.762	rs7044226	ENSG00000238181.2	AHCYP2	-6.98	1.04e-11	2.9e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120720673~120721972:+
THCA	cis	rs6540731	1	rs4500383	ENSG00000226251.4	RP11-15I11.3	-6.98	1.04e-11	2.9e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212218254	chr1:212225278~212238977:-
THCA	cis	rs2348418	0.715	rs1355471	ENSG00000247934.4	RP11-967K21.1	-6.98	1.04e-11	2.9e-09	-0.27	-0.31	Lung function (FEV1);Lung function (FVC);	chr12:28568792	chr12:28163298~28190738:-
THCA	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-6.98	1.04e-11	2.91e-09	-0.32	-0.31	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
THCA	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-6.98	1.04e-11	2.91e-09	-0.32	-0.31	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
THCA	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-6.97	1.04e-11	2.91e-09	-0.39	-0.31	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
THCA	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	6.97	1.04e-11	2.91e-09	0.38	0.31	Height;	chr6:109380457	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	6.97	1.04e-11	2.91e-09	0.38	0.31	Height;	chr6:109380990	chr6:109382795~109383666:+
THCA	cis	rs12701220	0.725	rs13242971	ENSG00000229043.2	AC091729.9	-6.97	1.04e-11	2.91e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:1015879	chr7:1160374~1165267:+
THCA	cis	rs8030379	1	rs11259936	ENSG00000230373.7	GOLGA6L5P	6.97	1.04e-11	2.91e-09	0.28	0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911830	chr15:84507885~84516814:-
THCA	cis	rs7849973	0.579	rs13285009	ENSG00000224549.1	RP11-370B11.3	-6.97	1.05e-11	2.92e-09	-0.39	-0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22763642	chr9:22767175~22768316:+
THCA	cis	rs7189233	1	rs62048544	ENSG00000279344.1	RP11-44F14.7	6.97	1.05e-11	2.92e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr16:53503829	chr16:53478957~53481550:-
THCA	cis	rs9287719	0.614	rs12329184	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10582638	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.614	rs10929679	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10582982	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.614	rs10929680	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10583000	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.614	rs10929681	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10583157	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.614	rs6711473	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10583248	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.624	rs10211190	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10585302	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10166765	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10585547	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs6720112	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10585593	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs6730247	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10585762	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.6	rs10197187	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10586513	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.624	rs10199635	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10586514	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.624	rs10199831	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10586737	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.624	rs10187659	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10586834	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10202370	ENSG00000243819.4	RN7SL832P	6.97	1.05e-11	2.92e-09	0.25	0.31	Prostate cancer;	chr2:10586917	chr2:10690344~10692099:+
THCA	cis	rs728616	0.702	rs78734698	ENSG00000225484.5	NUTM2B-AS1	-6.97	1.05e-11	2.92e-09	-0.61	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:79663088~79826594:-
THCA	cis	rs12701220	0.894	rs8591	ENSG00000229043.2	AC091729.9	-6.97	1.05e-11	2.92e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:997163	chr7:1160374~1165267:+
THCA	cis	rs875971	0.862	rs4718330	ENSG00000232559.3	GS1-124K5.12	-6.97	1.05e-11	2.92e-09	-0.29	-0.31	Aortic root size;	chr7:66250256	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs313814	ENSG00000229886.1	RP5-1132H15.3	6.97	1.05e-11	2.92e-09	0.49	0.31	Diabetic kidney disease;	chr7:66038306	chr7:66025126~66031544:-
THCA	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	6.97	1.05e-11	2.92e-09	0.4	0.31	Height;	chr6:109732047	chr6:109382795~109383666:+
THCA	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	6.97	1.05e-11	2.92e-09	0.31	0.31	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
THCA	cis	rs17695224	0.675	rs10405314	ENSG00000269483.1	AC006272.1	6.97	1.05e-11	2.92e-09	0.33	0.31	HDL cholesterol;HDL cholesterol levels;	chr19:51839450	chr19:51839924~51843324:-
THCA	cis	rs7260598	0.792	rs11669171	ENSG00000268442.1	CTD-2027I19.2	6.97	1.05e-11	2.93e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24153957	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs11669295	ENSG00000268442.1	CTD-2027I19.2	6.97	1.05e-11	2.93e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24154184	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs11670299	ENSG00000268442.1	CTD-2027I19.2	6.97	1.05e-11	2.93e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24154959	chr19:24162370~24163425:-
THCA	cis	rs9287719	0.649	rs2024433	ENSG00000243819.4	RN7SL832P	6.97	1.06e-11	2.94e-09	0.25	0.31	Prostate cancer;	chr2:10591378	chr2:10690344~10692099:+
THCA	cis	rs847577	1	rs847577	ENSG00000272950.1	RP11-307C18.1	-6.97	1.06e-11	2.94e-09	-0.39	-0.31	Breast cancer;	chr7:98065546	chr7:98322853~98323430:+
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000263603.1	CTD-2349P21.5	-6.97	1.06e-11	2.94e-09	-0.53	-0.31	Body mass index;	chr17:30737900	chr17:30729469~30731202:+
THCA	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-6.97	1.06e-11	2.95e-09	-0.28	-0.31	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
THCA	cis	rs4950322	0.57	rs4950400	ENSG00000237188.3	RP11-337C18.8	-6.97	1.06e-11	2.95e-09	-0.38	-0.31	Protein quantitative trait loci;	chr1:147319383	chr1:147172771~147211568:+
THCA	cis	rs1387259	0.839	rs7486941	ENSG00000240399.1	RP1-228P16.1	-6.97	1.06e-11	2.95e-09	-0.3	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48054813~48055591:-
THCA	cis	rs7260598	0.792	rs73031013	ENSG00000268442.1	CTD-2027I19.2	6.97	1.06e-11	2.96e-09	0.44	0.31	Response to taxane treatment (placlitaxel);	chr19:24182049	chr19:24162370~24163425:-
THCA	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	6.97	1.06e-11	2.96e-09	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
THCA	cis	rs797680	0.964	rs1856027	ENSG00000223745.6	RP4-717I23.3	6.97	1.06e-11	2.96e-09	0.19	0.31	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93078574	chr1:93262186~93346025:-
THCA	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-6.97	1.06e-11	2.96e-09	-0.28	-0.31	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
THCA	cis	rs5760092	0.572	rs738806	ENSG00000235689.1	AP000351.13	6.97	1.06e-11	2.96e-09	0.41	0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:24006305~24008258:-
THCA	cis	rs17684571	0.872	rs35206656	ENSG00000231441.1	RP11-472M19.2	6.97	1.06e-11	2.96e-09	0.36	0.31	Schizophrenia;	chr6:56706662	chr6:56844002~56864078:+
THCA	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	6.97	1.06e-11	2.96e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
THCA	cis	rs651907	0.535	rs2290859	ENSG00000256628.3	ZBTB11-AS1	6.97	1.06e-11	2.96e-09	0.36	0.31	Colorectal cancer;	chr3:101806781	chr3:101676475~101679217:+
THCA	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-6.97	1.06e-11	2.96e-09	-0.38	-0.31	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
THCA	cis	rs7727544	0.716	rs4705928	ENSG00000233006.5	AC034220.3	-6.97	1.07e-11	2.96e-09	-0.24	-0.31	Blood metabolite levels;	chr5:132242944	chr5:132311285~132369916:-
THCA	cis	rs7267979	1	rs2500424	ENSG00000274414.1	RP5-965G21.4	6.97	1.07e-11	2.97e-09	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25239007~25245229:-
THCA	cis	rs453301	0.598	rs10104303	ENSG00000253893.2	FAM85B	-6.97	1.07e-11	2.97e-09	-0.38	-0.31	Joint mobility (Beighton score);	chr8:8977018	chr8:8167819~8226614:-
THCA	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	6.97	1.07e-11	2.97e-09	0.47	0.31	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
THCA	cis	rs12681366	0.537	rs9297939	ENSG00000253704.1	RP11-267M23.4	6.97	1.07e-11	2.97e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94467961	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.564	rs10808669	ENSG00000253704.1	RP11-267M23.4	6.97	1.07e-11	2.97e-09	0.31	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94468833	chr8:94553722~94569745:+
THCA	cis	rs240993	0.812	rs28770304	ENSG00000230177.1	RP5-1112D6.4	6.97	1.07e-11	2.97e-09	0.31	0.31	Inflammatory skin disease;Psoriasis;	chr6:111461586	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs9387012	ENSG00000230177.1	RP5-1112D6.4	6.97	1.07e-11	2.97e-09	0.31	0.31	Inflammatory skin disease;Psoriasis;	chr6:111465824	chr6:111277932~111278742:+
THCA	cis	rs699371	0.55	rs11851117	ENSG00000270000.1	RP3-449M8.9	6.97	1.07e-11	2.97e-09	0.29	0.31	Height;	chr14:74454856	chr14:74471930~74472360:-
THCA	cis	rs9902453	0.904	rs10853136	ENSG00000264007.1	RP11-68I3.10	-6.97	1.07e-11	2.98e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30079000	chr17:29621617~29622254:-
THCA	cis	rs7044106	0.762	rs1547267	ENSG00000238181.2	AHCYP2	-6.97	1.07e-11	2.98e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120720673~120721972:+
THCA	cis	rs7044106	0.762	rs4142158	ENSG00000238181.2	AHCYP2	-6.97	1.07e-11	2.98e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120720673~120721972:+
THCA	cis	rs12701220	0.894	rs13224488	ENSG00000229043.2	AC091729.9	-6.97	1.07e-11	2.98e-09	-0.42	-0.31	Bronchopulmonary dysplasia;	chr7:1012717	chr7:1160374~1165267:+
THCA	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	6.97	1.07e-11	2.98e-09	0.48	0.31	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
THCA	cis	rs516805	0.665	rs2606648	ENSG00000279453.1	RP3-425C14.4	-6.97	1.07e-11	2.98e-09	-0.33	-0.31	Lymphocyte counts;	chr6:122119554	chr6:122436789~122439223:-
THCA	cis	rs1385374	0.858	rs10847696	ENSG00000274695.1	RP11-21K12.3	6.97	1.07e-11	2.98e-09	0.54	0.31	Systemic lupus erythematosus;	chr12:128812608	chr12:128826836~128827579:+
THCA	cis	rs516805	0.667	rs928011	ENSG00000279453.1	RP3-425C14.4	6.97	1.07e-11	2.98e-09	0.32	0.31	Lymphocyte counts;	chr6:122248991	chr6:122436789~122439223:-
THCA	cis	rs853679	0.517	rs1947863	ENSG00000220721.1	OR1F12	6.97	1.07e-11	2.98e-09	0.42	0.31	Depression;	chr6:28131566	chr6:28073316~28074233:+
THCA	cis	rs172166	0.694	rs2791332	ENSG00000280107.1	AL022393.9	-6.97	1.07e-11	2.99e-09	-0.34	-0.31	Cardiac Troponin-T levels;	chr6:28141010	chr6:28170845~28172521:+
THCA	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-6.97	1.08e-11	3e-09	-0.38	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
THCA	cis	rs7811142	0.943	rs28660238	ENSG00000078319.8	PMS2P1	-6.97	1.08e-11	3.01e-09	-0.43	-0.31	Platelet count;	chr7:100425685	chr7:100320992~100341908:-
THCA	cis	rs17772222	0.715	rs10139921	ENSG00000258983.2	RP11-507K2.2	6.97	1.08e-11	3.01e-09	0.42	0.31	Coronary artery calcification;	chr14:88468512	chr14:88499334~88515502:+
THCA	cis	rs875971	0.83	rs12673450	ENSG00000232559.3	GS1-124K5.12	6.97	1.08e-11	3.01e-09	0.3	0.31	Aortic root size;	chr7:66544233	chr7:66554588~66576923:-
THCA	cis	rs7044106	0.791	rs7036196	ENSG00000238181.2	AHCYP2	-6.97	1.08e-11	3.01e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120720673~120721972:+
THCA	cis	rs853679	0.517	rs17711344	ENSG00000272009.1	RP1-313I6.12	6.97	1.08e-11	3.01e-09	0.36	0.31	Depression;	chr6:28109824	chr6:28078792~28081130:-
THCA	cis	rs12701220	0.817	rs59471534	ENSG00000229043.2	AC091729.9	-6.97	1.08e-11	3.02e-09	-0.39	-0.31	Bronchopulmonary dysplasia;	chr7:1045588	chr7:1160374~1165267:+
THCA	cis	rs9475752	1	rs1451708	ENSG00000231441.1	RP11-472M19.2	6.97	1.09e-11	3.02e-09	0.39	0.31	Menarche (age at onset);	chr6:56937403	chr6:56844002~56864078:+
THCA	cis	rs41307935	0.643	rs34909427	ENSG00000260063.1	RP5-968P14.2	-6.97	1.09e-11	3.03e-09	-0.58	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26750763	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs59715866	ENSG00000260063.1	RP5-968P14.2	-6.97	1.09e-11	3.03e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26752685	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12737946	ENSG00000260063.1	RP5-968P14.2	-6.97	1.09e-11	3.03e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753403	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.57	rs71636776	ENSG00000260063.1	RP5-968P14.2	-6.97	1.09e-11	3.03e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26756557	chr1:26692132~26694131:-
THCA	cis	rs1949733	0.959	rs2688242	ENSG00000205959.3	RP11-689P11.2	-6.97	1.09e-11	3.03e-09	-0.26	-0.31	Response to antineoplastic agents;	chr4:8428216	chr4:8482270~8512610:+
THCA	cis	rs853679	0.517	rs9393895	ENSG00000272009.1	RP1-313I6.12	-6.97	1.09e-11	3.03e-09	-0.36	-0.31	Depression;	chr6:28159843	chr6:28078792~28081130:-
THCA	cis	rs792448	0.717	rs1389371	ENSG00000226251.4	RP11-15I11.3	-6.97	1.09e-11	3.03e-09	-0.38	-0.31	White blood cell count (basophil);	chr1:212236813	chr1:212225278~212238977:-
THCA	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	6.97	1.09e-11	3.03e-09	0.39	0.31	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
THCA	cis	rs860295	0.557	rs6696019	ENSG00000225855.5	RUSC1-AS1	6.97	1.09e-11	3.04e-09	0.21	0.31	Body mass index;	chr1:155895186	chr1:155316863~155324176:-
THCA	cis	rs4934494	0.834	rs1359624	ENSG00000232936.4	RP11-80H5.2	6.97	1.09e-11	3.04e-09	0.38	0.31	Red blood cell count;	chr10:89635671	chr10:89645282~89650667:+
THCA	cis	rs9902453	0.765	rs34585141	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30009414	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs4528633	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30029118	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs7225686	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30029726	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs4547389	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30037750	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs55633288	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30041178	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.874	rs7220004	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30042530	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs11654983	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30043024	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs7218113	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30045112	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs7219456	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30047094	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.874	rs11653805	ENSG00000264007.1	RP11-68I3.10	-6.97	1.09e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30051258	chr17:29621617~29622254:-
THCA	cis	rs2408955	0.522	rs11168408	ENSG00000240399.1	RP1-228P16.1	-6.97	1.09e-11	3.04e-09	-0.32	-0.31	Glycated hemoglobin levels;	chr12:48104544	chr12:48054813~48055591:-
THCA	cis	rs9902453	0.904	rs11080115	ENSG00000264007.1	RP11-68I3.10	-6.97	1.1e-11	3.04e-09	-0.34	-0.31	Coffee consumption (cups per day);	chr17:30081052	chr17:29621617~29622254:-
THCA	cis	rs848490	0.851	rs1130039	ENSG00000214293.7	APTR	6.97	1.1e-11	3.05e-09	0.24	0.31	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77657810	chr7:77657660~77696265:-
THCA	cis	rs9341808	0.718	rs12203867	ENSG00000272129.1	RP11-250B2.6	6.97	1.1e-11	3.05e-09	0.39	0.31	Sitting height ratio;	chr6:80111116	chr6:80355424~80356859:+
THCA	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	6.97	1.1e-11	3.05e-09	0.2	0.31	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
THCA	cis	rs7246657	0.943	rs7255952	ENSG00000226686.6	LINC01535	-6.97	1.1e-11	3.05e-09	-0.44	-0.31	Coronary artery calcification;	chr19:37497895	chr19:37251912~37265535:+
THCA	cis	rs6540731	1	rs4362041	ENSG00000226251.4	RP11-15I11.3	-6.97	1.1e-11	3.05e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212227127	chr1:212225278~212238977:-
THCA	cis	rs6540731	1	rs1389369	ENSG00000226251.4	RP11-15I11.3	-6.97	1.1e-11	3.05e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212227194	chr1:212225278~212238977:-
THCA	cis	rs6540731	1	rs1389370	ENSG00000226251.4	RP11-15I11.3	-6.97	1.1e-11	3.05e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212227275	chr1:212225278~212238977:-
THCA	cis	rs6540731	1	rs6540735	ENSG00000226251.4	RP11-15I11.3	-6.97	1.1e-11	3.05e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212227418	chr1:212225278~212238977:-
THCA	cis	rs6540731	1	rs6657900	ENSG00000226251.4	RP11-15I11.3	-6.97	1.1e-11	3.05e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212227524	chr1:212225278~212238977:-
THCA	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-6.97	1.1e-11	3.05e-09	-0.22	-0.31	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
THCA	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-6.97	1.1e-11	3.05e-09	-0.22	-0.31	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
THCA	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-6.97	1.1e-11	3.05e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
THCA	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	6.97	1.1e-11	3.06e-09	0.38	0.31	Height;	chr6:109480428	chr6:109382795~109383666:+
THCA	cis	rs8067545	0.641	rs203457	ENSG00000270091.1	RP11-78O7.2	6.97	1.1e-11	3.06e-09	0.23	0.31	Schizophrenia;	chr17:19915025	chr17:19896590~19897287:-
THCA	cis	rs9902453	0.726	rs4795523	ENSG00000264007.1	RP11-68I3.10	6.97	1.1e-11	3.06e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29849296	chr17:29621617~29622254:-
THCA	cis	rs9341808	0.69	rs6930534	ENSG00000272129.1	RP11-250B2.6	6.97	1.1e-11	3.06e-09	0.39	0.31	Sitting height ratio;	chr6:80186333	chr6:80355424~80356859:+
THCA	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	6.97	1.1e-11	3.07e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
THCA	cis	rs2281636	0.63	rs12355655	ENSG00000233690.1	EBAG9P1	6.97	1.1e-11	3.07e-09	0.33	0.31	Obesity-related traits;	chr10:99616982	chr10:99697407~99697949:-
THCA	cis	rs2018683	0.803	rs12700920	ENSG00000228421.2	AC005013.5	6.97	1.11e-11	3.07e-09	0.35	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.933	rs12536127	ENSG00000228421.2	AC005013.5	6.97	1.11e-11	3.07e-09	0.35	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28957667~28959345:+
THCA	cis	rs3745672	1	rs60697554	ENSG00000219665.7	CTD-2006C1.2	-6.97	1.11e-11	3.07e-09	-0.67	-0.31	Multiple sclerosis;	chr19:11946944	chr19:11987617~12046275:+
THCA	cis	rs3745672	1	rs58336952	ENSG00000219665.7	CTD-2006C1.2	-6.97	1.11e-11	3.07e-09	-0.67	-0.31	Multiple sclerosis;	chr19:11947101	chr19:11987617~12046275:+
THCA	cis	rs9990333	0.622	rs57783901	ENSG00000242086.7	LINC00969	6.97	1.11e-11	3.07e-09	0.3	0.31	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195658062~195739964:+
THCA	cis	rs7811142	1	rs7803454	ENSG00000078319.8	PMS2P1	-6.97	1.11e-11	3.07e-09	-0.45	-0.31	Platelet count;	chr7:100393925	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.943	rs11769886	ENSG00000078319.8	PMS2P1	-6.97	1.11e-11	3.07e-09	-0.45	-0.31	Platelet count;	chr7:100400984	chr7:100320992~100341908:-
THCA	cis	rs6539288	0.933	rs10778513	ENSG00000260329.1	RP11-412D9.4	-6.97	1.11e-11	3.08e-09	-0.27	-0.31	Total body bone mineral density;	chr12:106908405	chr12:106954029~106955497:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	6.97	1.11e-11	3.08e-09	0.45	0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
THCA	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	6.97	1.11e-11	3.08e-09	0.46	0.31	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	6.97	1.11e-11	3.08e-09	0.46	0.31	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	6.97	1.11e-11	3.08e-09	0.46	0.31	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
THCA	cis	rs853679	0.517	rs9380058	ENSG00000272009.1	RP1-313I6.12	-6.97	1.11e-11	3.08e-09	-0.36	-0.31	Depression;	chr6:28159666	chr6:28078792~28081130:-
THCA	cis	rs853679	0.517	rs9393898	ENSG00000272009.1	RP1-313I6.12	-6.97	1.11e-11	3.08e-09	-0.36	-0.31	Depression;	chr6:28162598	chr6:28078792~28081130:-
THCA	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-6.97	1.11e-11	3.08e-09	-0.35	-0.31	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
THCA	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	6.97	1.11e-11	3.09e-09	0.36	0.31	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
THCA	cis	rs6991838	0.806	rs11781358	ENSG00000200714.1	Y_RNA	6.97	1.11e-11	3.09e-09	0.38	0.31	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65592731~65592820:+
THCA	cis	rs4908760	0.811	rs301802	ENSG00000232912.4	RP5-1115A15.1	6.97	1.11e-11	3.09e-09	0.3	0.31	Vitiligo;	chr1:8437247	chr1:8424645~8434838:+
THCA	cis	rs7044106	0.762	rs10739570	ENSG00000238181.2	AHCYP2	-6.96	1.11e-11	3.09e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120720673~120721972:+
THCA	cis	rs6540731	1	rs11119885	ENSG00000226251.4	RP11-15I11.3	-6.96	1.11e-11	3.09e-09	-0.38	-0.31	Intelligence (childhood);	chr1:212227656	chr1:212225278~212238977:-
THCA	cis	rs7811142	0.887	rs111972532	ENSG00000078319.8	PMS2P1	-6.96	1.11e-11	3.09e-09	-0.43	-0.31	Platelet count;	chr7:100471465	chr7:100320992~100341908:-
THCA	cis	rs7942368	0.818	rs10793194	ENSG00000204529.3	GUCY2EP	6.96	1.11e-11	3.09e-09	0.43	0.31	Endometriosis;	chr11:76764685	chr11:76694043~76707641:-
THCA	cis	rs2243480	1	rs7804223	ENSG00000228409.4	CCT6P1	-6.96	1.11e-11	3.1e-09	-0.36	-0.31	Diabetic kidney disease;	chr7:66199572	chr7:65751142~65763354:+
THCA	cis	rs860295	0.58	rs2282301	ENSG00000225855.5	RUSC1-AS1	-6.96	1.12e-11	3.1e-09	-0.21	-0.31	Body mass index;	chr1:155898834	chr1:155316863~155324176:-
THCA	cis	rs7267979	1	rs2424704	ENSG00000274414.1	RP5-965G21.4	-6.96	1.12e-11	3.1e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25239007~25245229:-
THCA	cis	rs7942368	0.793	rs12273016	ENSG00000254632.1	RP11-21L23.4	-6.96	1.12e-11	3.11e-09	-0.43	-0.31	Endometriosis;	chr11:76779672	chr11:76759916~76768223:-
THCA	cis	rs4819052	0.59	rs414743	ENSG00000223768.1	LINC00205	-6.96	1.12e-11	3.12e-09	-0.33	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45092160	chr21:45293285~45297354:+
THCA	cis	rs11971779	0.941	rs28395455	ENSG00000273391.1	RP11-634H22.1	6.96	1.12e-11	3.12e-09	0.32	0.31	Diisocyanate-induced asthma;	chr7:139351240	chr7:139359032~139359566:-
THCA	cis	rs9341808	0.718	rs35447745	ENSG00000272129.1	RP11-250B2.6	6.96	1.12e-11	3.12e-09	0.39	0.31	Sitting height ratio;	chr6:80107031	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9352801	ENSG00000272129.1	RP11-250B2.6	6.96	1.12e-11	3.12e-09	0.39	0.31	Sitting height ratio;	chr6:80107751	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9361584	ENSG00000272129.1	RP11-250B2.6	6.96	1.12e-11	3.12e-09	0.39	0.31	Sitting height ratio;	chr6:80110229	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9359408	ENSG00000272129.1	RP11-250B2.6	6.96	1.12e-11	3.12e-09	0.39	0.31	Sitting height ratio;	chr6:80110415	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9443734	ENSG00000272129.1	RP11-250B2.6	6.96	1.12e-11	3.12e-09	0.39	0.31	Sitting height ratio;	chr6:80110576	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9443735	ENSG00000272129.1	RP11-250B2.6	6.96	1.12e-11	3.12e-09	0.39	0.31	Sitting height ratio;	chr6:80110757	chr6:80355424~80356859:+
THCA	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-6.96	1.13e-11	3.13e-09	-0.39	-0.31	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
THCA	cis	rs7044106	0.762	rs1886337	ENSG00000238181.2	AHCYP2	-6.96	1.13e-11	3.13e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120720673~120721972:+
THCA	cis	rs7615952	0.8	rs11914298	ENSG00000241288.6	RP11-379B18.5	-6.96	1.13e-11	3.13e-09	-0.39	-0.31	Blood pressure (smoking interaction);	chr3:125924929	chr3:125827238~125916384:-
THCA	cis	rs7403037	0.837	rs11857739	ENSG00000259905.4	PWRN1	6.96	1.13e-11	3.14e-09	0.33	0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24330727	chr15:24493137~24652130:+
THCA	cis	rs7267979	1	rs2257991	ENSG00000274414.1	RP5-965G21.4	6.96	1.13e-11	3.14e-09	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25239007~25245229:-
THCA	cis	rs797680	0.93	rs12128131	ENSG00000223745.6	RP4-717I23.3	6.96	1.13e-11	3.14e-09	0.19	0.31	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93080742	chr1:93262186~93346025:-
THCA	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	6.96	1.13e-11	3.14e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	6.96	1.13e-11	3.14e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	6.96	1.13e-11	3.14e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
THCA	cis	rs2562456	0.833	rs2968078	ENSG00000213976.4	CTD-2561J22.2	6.96	1.13e-11	3.14e-09	0.33	0.31	Pain;	chr19:21458942	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.755	rs2650773	ENSG00000213976.4	CTD-2561J22.2	6.96	1.13e-11	3.14e-09	0.33	0.31	Pain;	chr19:21461286	chr19:21382865~21387177:+
THCA	cis	rs8067545	0.616	rs203465	ENSG00000270091.1	RP11-78O7.2	-6.96	1.13e-11	3.15e-09	-0.23	-0.31	Schizophrenia;	chr17:19907407	chr17:19896590~19897287:-
THCA	cis	rs7554547	0.667	rs2336377	ENSG00000201801.1	RNU5E-4P	-6.96	1.14e-11	3.15e-09	-0.35	-0.31	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr1:11909808~11909927:-
THCA	cis	rs8012947	1	rs2348072	ENSG00000279636.2	LINC00216	-6.96	1.14e-11	3.15e-09	-0.32	-0.31	Alcohol consumption in current drinkers;	chr14:58277034	chr14:58288033~58289158:+
THCA	cis	rs4073416	0.679	rs7155541	ENSG00000276116.2	FUT8-AS1	6.96	1.14e-11	3.16e-09	0.32	0.31	N-glycan levels;	chr14:65579524	chr14:65411170~65412690:-
THCA	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-6.96	1.14e-11	3.16e-09	-0.54	-0.31	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
THCA	cis	rs516805	0.568	rs56290570	ENSG00000279453.1	RP3-425C14.4	6.96	1.14e-11	3.16e-09	0.32	0.31	Lymphocyte counts;	chr6:122240177	chr6:122436789~122439223:-
THCA	cis	rs516805	0.633	rs9490414	ENSG00000279453.1	RP3-425C14.4	6.96	1.14e-11	3.16e-09	0.32	0.31	Lymphocyte counts;	chr6:122245612	chr6:122436789~122439223:-
THCA	cis	rs6840258	0.825	rs72667747	ENSG00000251411.1	RP11-397E7.4	-6.96	1.14e-11	3.17e-09	-0.38	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000911	chr4:86913266~86914817:-
THCA	cis	rs9287719	0.649	rs11684537	ENSG00000243819.4	RN7SL832P	6.96	1.14e-11	3.17e-09	0.25	0.31	Prostate cancer;	chr2:10594706	chr2:10690344~10692099:+
THCA	cis	rs4950322	0.748	rs56392137	ENSG00000237188.3	RP11-337C18.8	6.96	1.14e-11	3.17e-09	0.38	0.31	Protein quantitative trait loci;	chr1:147352450	chr1:147172771~147211568:+
THCA	cis	rs2018683	0.899	rs10269454	ENSG00000228421.2	AC005013.5	6.96	1.14e-11	3.17e-09	0.34	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938783	chr7:28957667~28959345:+
THCA	cis	rs4713118	0.868	rs35069907	ENSG00000280107.1	AL022393.9	-6.96	1.14e-11	3.17e-09	-0.37	-0.31	Parkinson's disease;	chr6:27778913	chr6:28170845~28172521:+
THCA	cis	rs2929278	0.736	rs2412823	ENSG00000166763.7	STRCP1	-6.96	1.14e-11	3.17e-09	-0.33	-0.31	Schizophrenia;	chr15:43935072	chr15:43699488~43718184:-
THCA	cis	rs6570726	0.526	rs72994723	ENSG00000235652.6	RP11-545I5.3	-6.96	1.15e-11	3.18e-09	-0.28	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145401812	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.526	rs9376928	ENSG00000235652.6	RP11-545I5.3	-6.96	1.15e-11	3.18e-09	-0.28	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145403267	chr6:145799409~145886585:+
THCA	cis	rs12931792	0.712	rs2887799	ENSG00000183604.13	SMG1P5	6.96	1.15e-11	3.18e-09	0.3	0.31	Tonsillectomy;	chr16:30152512	chr16:30267553~30335374:-
THCA	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	6.96	1.15e-11	3.18e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
THCA	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	6.96	1.15e-11	3.18e-09	0.76	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
THCA	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	6.96	1.15e-11	3.18e-09	0.76	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
THCA	cis	rs7044106	0.708	rs10760113	ENSG00000238181.2	AHCYP2	-6.96	1.15e-11	3.19e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120720673~120721972:+
THCA	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	6.96	1.15e-11	3.19e-09	0.4	0.31	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
THCA	cis	rs7811142	1	rs60257855	ENSG00000078319.8	PMS2P1	-6.96	1.15e-11	3.19e-09	-0.43	-0.31	Platelet count;	chr7:100429157	chr7:100320992~100341908:-
THCA	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-6.96	1.15e-11	3.19e-09	-0.47	-0.31	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
THCA	cis	rs11722228	0.508	rs9732	ENSG00000261490.1	RP11-448G15.3	6.96	1.15e-11	3.2e-09	0.23	0.31	Urate levels;Serum uric acid levels;Gout;	chr4:10075034	chr4:10068089~10073019:-
THCA	cis	rs7727544	0.507	rs11741341	ENSG00000233006.5	AC034220.3	6.96	1.15e-11	3.2e-09	0.23	0.31	Blood metabolite levels;	chr5:132234525	chr5:132311285~132369916:-
THCA	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-6.96	1.15e-11	3.2e-09	-0.33	-0.31	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
THCA	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	6.96	1.15e-11	3.2e-09	0.34	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
THCA	cis	rs6479901	0.947	rs7083823	ENSG00000232075.1	MRPL35P2	-6.96	1.15e-11	3.2e-09	-0.48	-0.31	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63634317~63634827:-
THCA	cis	rs8030379	1	rs1480823	ENSG00000230373.7	GOLGA6L5P	-6.96	1.16e-11	3.2e-09	-0.28	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916994	chr15:84507885~84516814:-
THCA	cis	rs7811142	1	rs74460138	ENSG00000078319.8	PMS2P1	-6.96	1.16e-11	3.21e-09	-0.43	-0.31	Platelet count;	chr7:100429716	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs6975729	ENSG00000078319.8	PMS2P1	-6.96	1.16e-11	3.21e-09	-0.43	-0.31	Platelet count;	chr7:100430564	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs1073	ENSG00000078319.8	PMS2P1	-6.96	1.16e-11	3.21e-09	-0.43	-0.31	Platelet count;	chr7:100433989	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs4989959	ENSG00000078319.8	PMS2P1	-6.96	1.16e-11	3.21e-09	-0.43	-0.31	Platelet count;	chr7:100434665	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.887	rs4074838	ENSG00000078319.8	PMS2P1	-6.96	1.16e-11	3.21e-09	-0.43	-0.31	Platelet count;	chr7:100435042	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.945	rs6955362	ENSG00000078319.8	PMS2P1	-6.96	1.16e-11	3.21e-09	-0.43	-0.31	Platelet count;	chr7:100458543	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs6975514	ENSG00000078319.8	PMS2P1	-6.96	1.16e-11	3.21e-09	-0.43	-0.31	Platelet count;	chr7:100458597	chr7:100320992~100341908:-
THCA	cis	rs2243480	1	rs35396113	ENSG00000229886.1	RP5-1132H15.3	6.96	1.16e-11	3.21e-09	0.49	0.31	Diabetic kidney disease;	chr7:66030474	chr7:66025126~66031544:-
THCA	cis	rs74233809	1	rs10509759	ENSG00000213277.3	MARCKSL1P1	6.96	1.16e-11	3.21e-09	0.5	0.31	Birth weight;	chr10:102929908	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs10883806	ENSG00000213277.3	MARCKSL1P1	6.96	1.16e-11	3.21e-09	0.5	0.31	Birth weight;	chr10:102953319	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs78260931	ENSG00000213277.3	MARCKSL1P1	6.96	1.16e-11	3.21e-09	0.5	0.31	Birth weight;	chr10:102962205	chr10:103175554~103176094:+
THCA	cis	rs74233809	1	rs11191505	ENSG00000213277.3	MARCKSL1P1	6.96	1.16e-11	3.21e-09	0.5	0.31	Birth weight;	chr10:103007134	chr10:103175554~103176094:+
THCA	cis	rs7208859	0.623	rs8082537	ENSG00000264538.5	SUZ12P1	-6.96	1.16e-11	3.21e-09	-0.3	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30709299~30790908:+
THCA	cis	rs9467773	0.595	rs4320356	ENSG00000124549.13	BTN2A3P	-6.96	1.16e-11	3.21e-09	-0.29	-0.31	Intelligence (multi-trait analysis);	chr6:26423332	chr6:26421391~26432383:+
THCA	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	6.96	1.16e-11	3.22e-09	0.34	0.31	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
THCA	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-6.96	1.16e-11	3.22e-09	-0.36	-0.31	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
THCA	cis	rs4072705	1	rs13283284	ENSG00000224020.1	MIR181A2HG	-6.96	1.16e-11	3.22e-09	-0.27	-0.31	Menarche (age at onset);	chr9:124753898	chr9:124658467~124698631:+
THCA	cis	rs71636778	0.509	rs12742115	ENSG00000260063.1	RP5-968P14.2	-6.96	1.16e-11	3.22e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753440	chr1:26692132~26694131:-
THCA	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	6.96	1.16e-11	3.23e-09	0.32	0.31	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
THCA	cis	rs45509595	0.822	rs200484	ENSG00000219392.1	RP1-265C24.5	-6.96	1.17e-11	3.23e-09	-0.52	-0.31	Breast cancer;	chr6:27807896	chr6:28115628~28116551:+
THCA	cis	rs1552244	0.882	rs13089863	ENSG00000232901.1	CYCSP10	-6.96	1.17e-11	3.23e-09	-0.4	-0.31	Alzheimer's disease;	chr3:9990575	chr3:10000647~10000940:-
THCA	cis	rs160451	1	rs160446	ENSG00000251136.7	RP11-37B2.1	6.96	1.17e-11	3.23e-09	0.26	0.31	Leprosy;	chr8:89647035	chr8:89609409~89757727:-
THCA	cis	rs160451	0.966	rs160450	ENSG00000251136.7	RP11-37B2.1	6.96	1.17e-11	3.23e-09	0.26	0.31	Leprosy;	chr8:89650354	chr8:89609409~89757727:-
THCA	cis	rs160451	1	rs160451	ENSG00000251136.7	RP11-37B2.1	6.96	1.17e-11	3.23e-09	0.26	0.31	Leprosy;	chr8:89650713	chr8:89609409~89757727:-
THCA	cis	rs7267979	0.773	rs6132821	ENSG00000274414.1	RP5-965G21.4	-6.96	1.17e-11	3.24e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.844	rs1555330	ENSG00000274414.1	RP5-965G21.4	-6.96	1.17e-11	3.24e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.844	rs6107017	ENSG00000274414.1	RP5-965G21.4	-6.96	1.17e-11	3.24e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.844	rs6132824	ENSG00000274414.1	RP5-965G21.4	-6.96	1.17e-11	3.24e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25239007~25245229:-
THCA	cis	rs8113308	1	rs8113308	ENSG00000269235.1	ZNF350-AS1	6.96	1.17e-11	3.24e-09	0.41	0.31	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942133	chr19:51949134~51981367:+
THCA	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-6.96	1.17e-11	3.24e-09	-0.72	-0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
THCA	cis	rs853679	1	rs735765	ENSG00000280107.1	AL022393.9	-6.96	1.17e-11	3.24e-09	-0.46	-0.31	Depression;	chr6:28202519	chr6:28170845~28172521:+
THCA	cis	rs7324557	0.717	rs7330646	ENSG00000205861.10	C1QTNF9B-AS1	6.96	1.17e-11	3.24e-09	0.38	0.31	Visceral adipose tissue adjusted for BMI;	chr13:23828025	chr13:23888889~23897263:+
THCA	cis	rs7260598	0.792	rs11670331	ENSG00000268442.1	CTD-2027I19.2	6.96	1.17e-11	3.24e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24155040	chr19:24162370~24163425:-
THCA	cis	rs7811142	1	rs7811142	ENSG00000078319.8	PMS2P1	-6.96	1.17e-11	3.24e-09	-0.43	-0.31	Platelet count;	chr7:100467820	chr7:100320992~100341908:-
THCA	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-6.96	1.17e-11	3.25e-09	-0.36	-0.31	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
THCA	cis	rs11673344	0.503	rs1667370	ENSG00000226686.6	LINC01535	6.96	1.17e-11	3.25e-09	0.33	0.31	Obesity-related traits;	chr19:36999318	chr19:37251912~37265535:+
THCA	cis	rs1198430	0.683	rs534417	ENSG00000232482.2	RP4-654C18.1	-6.96	1.17e-11	3.25e-09	-0.47	-0.31	Total cholesterol levels;	chr1:23458472	chr1:23410832~23412146:+
THCA	cis	rs2880765	0.743	rs8032488	ENSG00000259295.5	CSPG4P12	6.96	1.17e-11	3.25e-09	0.39	0.31	Coronary artery disease;	chr15:85469537	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.743	rs8028240	ENSG00000259295.5	CSPG4P12	6.96	1.17e-11	3.25e-09	0.39	0.31	Coronary artery disease;	chr15:85470017	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.743	rs6497194	ENSG00000259295.5	CSPG4P12	6.96	1.17e-11	3.25e-09	0.39	0.31	Coronary artery disease;	chr15:85470885	chr15:85191438~85213905:+
THCA	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-6.96	1.17e-11	3.25e-09	-0.38	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
THCA	cis	rs6840258	1	rs75550773	ENSG00000251411.1	RP11-397E7.4	-6.96	1.17e-11	3.25e-09	-0.37	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87034271	chr4:86913266~86914817:-
THCA	cis	rs2688608	0.62	rs7080350	ENSG00000271816.1	BMS1P4	-6.96	1.17e-11	3.25e-09	-0.31	-0.31	Inflammatory bowel disease;	chr10:73818085	chr10:73699151~73730487:-
THCA	cis	rs6723108	0.581	rs1446525	ENSG00000224043.6	CCNT2-AS1	-6.96	1.17e-11	3.25e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134880277	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs6430554	ENSG00000224043.6	CCNT2-AS1	-6.96	1.17e-11	3.25e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134880891	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs2053727	ENSG00000224043.6	CCNT2-AS1	-6.96	1.17e-11	3.25e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134885728	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs7589297	ENSG00000224043.6	CCNT2-AS1	-6.96	1.17e-11	3.25e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134894829	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.604	rs1374291	ENSG00000224043.6	CCNT2-AS1	-6.96	1.17e-11	3.25e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134896768	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.627	rs4954196	ENSG00000224043.6	CCNT2-AS1	-6.96	1.17e-11	3.25e-09	-0.32	-0.31	Type 2 diabetes;	chr2:134904446	chr2:134735464~134918710:-
THCA	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	6.96	1.18e-11	3.25e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
THCA	cis	rs516805	0.667	rs2606624	ENSG00000279453.1	RP3-425C14.4	-6.96	1.18e-11	3.25e-09	-0.32	-0.31	Lymphocyte counts;	chr6:122168693	chr6:122436789~122439223:-
THCA	cis	rs74233809	1	rs17115213	ENSG00000213277.3	MARCKSL1P1	6.96	1.18e-11	3.26e-09	0.5	0.31	Birth weight;	chr10:102921386	chr10:103175554~103176094:+
THCA	cis	rs12348691	0.503	rs10983975	ENSG00000236130.1	PTCSC2	-6.96	1.18e-11	3.26e-09	-0.26	-0.31	Alopecia areata;	chr9:97851906	chr9:97805935~97810008:-
THCA	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-6.96	1.18e-11	3.27e-09	-0.54	-0.31	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
THCA	cis	rs7688540	0.723	rs7687112	ENSG00000275426.1	CH17-262A2.1	6.96	1.18e-11	3.27e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:149738~150317:+
THCA	cis	rs4934494	0.689	rs17127588	ENSG00000232936.4	RP11-80H5.2	6.96	1.18e-11	3.27e-09	0.4	0.31	Red blood cell count;	chr10:89815887	chr10:89645282~89650667:+
THCA	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-6.96	1.18e-11	3.27e-09	-0.24	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-6.96	1.18e-11	3.27e-09	-0.24	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-6.96	1.18e-11	3.27e-09	-0.24	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-6.96	1.18e-11	3.27e-09	-0.24	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-6.96	1.18e-11	3.27e-09	-0.24	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-6.96	1.18e-11	3.27e-09	-0.24	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-6.96	1.18e-11	3.27e-09	-0.24	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
THCA	cis	rs12681366	0.511	rs2919670	ENSG00000253704.1	RP11-267M23.4	6.96	1.18e-11	3.27e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94444390	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.537	rs2197004	ENSG00000253704.1	RP11-267M23.4	6.96	1.18e-11	3.27e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94444748	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.537	rs2919667	ENSG00000253704.1	RP11-267M23.4	6.96	1.18e-11	3.27e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94452974	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.537	rs2919656	ENSG00000253704.1	RP11-267M23.4	6.96	1.18e-11	3.27e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94460806	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.537	rs3019284	ENSG00000253704.1	RP11-267M23.4	6.96	1.18e-11	3.27e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94460848	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.537	rs2381886	ENSG00000253704.1	RP11-267M23.4	6.96	1.18e-11	3.27e-09	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94464825	chr8:94553722~94569745:+
THCA	cis	rs12594515	1	rs12911309	ENSG00000259200.1	RP11-718O11.1	-6.96	1.18e-11	3.27e-09	-0.37	-0.31	Weight;Waist circumference;	chr15:45693521	chr15:45705078~45931069:+
THCA	cis	rs7267979	0.727	rs2474765	ENSG00000274414.1	RP5-965G21.4	-6.96	1.18e-11	3.27e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.764	rs2474767	ENSG00000274414.1	RP5-965G21.4	-6.96	1.18e-11	3.27e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25239007~25245229:-
THCA	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-6.96	1.18e-11	3.27e-09	-0.38	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
THCA	cis	rs72949976	0.511	rs11903721	ENSG00000270659.1	RP11-105N14.1	6.96	1.18e-11	3.27e-09	0.25	0.31	Squamous cell lung carcinoma;Lung cancer;	chr2:213152028	chr2:213152970~213153659:+
THCA	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	6.96	1.18e-11	3.28e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	6.96	1.18e-11	3.28e-09	0.39	0.31	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
THCA	cis	rs1198430	0.852	rs909537	ENSG00000232482.2	RP4-654C18.1	-6.96	1.19e-11	3.28e-09	-0.57	-0.31	Total cholesterol levels;	chr1:23483570	chr1:23410832~23412146:+
THCA	cis	rs748404	0.66	rs2467738	ENSG00000166763.7	STRCP1	6.96	1.19e-11	3.28e-09	0.32	0.31	Lung cancer;	chr15:43447738	chr15:43699488~43718184:-
THCA	cis	rs2243480	1	rs313807	ENSG00000229886.1	RP5-1132H15.3	6.95	1.19e-11	3.29e-09	0.49	0.31	Diabetic kidney disease;	chr7:66034494	chr7:66025126~66031544:-
THCA	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-6.95	1.19e-11	3.29e-09	-0.33	-0.31	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
THCA	cis	rs9487094	0.677	rs13203636	ENSG00000260273.1	RP11-425D10.10	6.95	1.19e-11	3.29e-09	0.41	0.31	Height;	chr6:109741085	chr6:109382795~109383666:+
THCA	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-6.95	1.19e-11	3.3e-09	-0.24	-0.31	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
THCA	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	6.95	1.19e-11	3.3e-09	0.24	0.31	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
THCA	cis	rs7646881	0.504	rs61080878	ENSG00000240207.5	RP11-379F4.4	-6.95	1.19e-11	3.3e-09	-0.38	-0.31	Tetralogy of Fallot;	chr3:158745108	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.504	rs67305172	ENSG00000240207.5	RP11-379F4.4	-6.95	1.19e-11	3.3e-09	-0.38	-0.31	Tetralogy of Fallot;	chr3:158746485	chr3:158732263~158784070:+
THCA	cis	rs2243480	0.901	rs313808	ENSG00000229886.1	RP5-1132H15.3	6.95	1.19e-11	3.3e-09	0.49	0.31	Diabetic kidney disease;	chr7:66034886	chr7:66025126~66031544:-
THCA	cis	rs6600671	0.934	rs7528274	ENSG00000223345.3	HIST2H2BA	6.95	1.19e-11	3.3e-09	0.34	0.31	Hip geometry;	chr1:121545103	chr1:121108210~121117257:-
THCA	cis	rs71636778	0.642	rs12752833	ENSG00000260063.1	RP5-968P14.2	-6.95	1.19e-11	3.3e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26747433	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs115772301	ENSG00000260063.1	RP5-968P14.2	-6.95	1.19e-11	3.3e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26749193	chr1:26692132~26694131:-
THCA	cis	rs2018683	0.899	rs10479816	ENSG00000228421.2	AC005013.5	6.95	1.19e-11	3.3e-09	0.34	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938404	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.834	rs2012754	ENSG00000228421.2	AC005013.5	6.95	1.2e-11	3.31e-09	0.35	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28957667~28959345:+
THCA	cis	rs71636778	0.509	rs12743862	ENSG00000260063.1	RP5-968P14.2	-6.95	1.2e-11	3.31e-09	-0.58	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701730	chr1:26692132~26694131:-
THCA	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-6.95	1.2e-11	3.31e-09	-0.3	-0.31	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
THCA	cis	rs7760535	0.826	rs7753887	ENSG00000230177.1	RP5-1112D6.4	-6.95	1.2e-11	3.31e-09	-0.25	-0.31	Metabolic traits;	chr6:111533904	chr6:111277932~111278742:+
THCA	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-6.95	1.2e-11	3.31e-09	-0.41	-0.31	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
THCA	cis	rs2834188	1	rs4408796	ENSG00000272659.1	AP000295.10	6.95	1.2e-11	3.32e-09	0.42	0.31	Narcolepsy;	chr21:33326436	chr21:33309491~33310181:+
THCA	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-6.95	1.2e-11	3.32e-09	-0.39	-0.31	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
THCA	cis	rs853679	0.769	rs17720293	ENSG00000219392.1	RP1-265C24.5	-6.95	1.2e-11	3.32e-09	-0.61	-0.31	Depression;	chr6:28246920	chr6:28115628~28116551:+
THCA	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	6.95	1.2e-11	3.32e-09	0.32	0.31	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
THCA	cis	rs990871	0.962	rs1841499	ENSG00000227207.2	RPL31P12	-6.95	1.2e-11	3.33e-09	-0.37	-0.31	Subcutaneous adipose tissue;	chr1:72370773	chr1:72301472~72301829:+
THCA	cis	rs990871	1	rs10789336	ENSG00000227207.2	RPL31P12	-6.95	1.2e-11	3.33e-09	-0.37	-0.31	Subcutaneous adipose tissue;	chr1:72372723	chr1:72301472~72301829:+
THCA	cis	rs7826238	0.502	rs10503377	ENSG00000253893.2	FAM85B	-6.95	1.2e-11	3.33e-09	-0.43	-0.31	Systolic blood pressure;	chr8:8520912	chr8:8167819~8226614:-
THCA	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-6.95	1.2e-11	3.33e-09	-0.38	-0.31	Height;	chr6:109380015	chr6:109382795~109383666:+
THCA	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-6.95	1.21e-11	3.33e-09	-0.3	-0.31	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
THCA	cis	rs6676180	0.514	rs868675	ENSG00000231365.4	RP11-418J17.1	-6.95	1.21e-11	3.33e-09	-0.29	-0.31	Monobrow;	chr1:119230973	chr1:119140396~119275973:+
THCA	cis	rs2243480	1	rs313813	ENSG00000229886.1	RP5-1132H15.3	6.95	1.21e-11	3.33e-09	0.49	0.31	Diabetic kidney disease;	chr7:66038513	chr7:66025126~66031544:-
THCA	cis	rs7044106	0.762	rs1411158	ENSG00000238181.2	AHCYP2	-6.95	1.21e-11	3.34e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120720673~120721972:+
THCA	cis	rs453301	0.624	rs330060	ENSG00000254153.1	CTA-398F10.2	6.95	1.21e-11	3.34e-09	0.33	0.31	Joint mobility (Beighton score);	chr8:9233392	chr8:8456909~8461337:-
THCA	cis	rs7428	0.527	rs7607284	ENSG00000246575.2	AC093162.5	6.95	1.21e-11	3.35e-09	0.28	0.31	Ear protrusion;	chr2:85320253	chr2:85315041~85316529:+
THCA	cis	rs7428	0.527	rs4459734	ENSG00000246575.2	AC093162.5	6.95	1.21e-11	3.35e-09	0.28	0.31	Ear protrusion;	chr2:85320306	chr2:85315041~85316529:+
THCA	cis	rs7428	0.527	rs1554110	ENSG00000246575.2	AC093162.5	6.95	1.21e-11	3.35e-09	0.28	0.31	Ear protrusion;	chr2:85320840	chr2:85315041~85316529:+
THCA	cis	rs7428	0.545	rs7572750	ENSG00000246575.2	AC093162.5	6.95	1.21e-11	3.35e-09	0.28	0.31	Ear protrusion;	chr2:85325063	chr2:85315041~85316529:+
THCA	cis	rs4266144	0.821	rs4325879	ENSG00000241770.1	RP11-555M1.3	-6.95	1.21e-11	3.35e-09	-0.42	-0.31	Coronary artery disease;	chr3:157134195	chr3:157163452~157169133:+
THCA	cis	rs911555	0.504	rs745079	ENSG00000269958.1	RP11-73M18.8	6.95	1.21e-11	3.35e-09	0.29	0.31	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103696353~103697163:+
THCA	cis	rs911555	0.504	rs61995761	ENSG00000269958.1	RP11-73M18.8	6.95	1.21e-11	3.35e-09	0.29	0.31	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103696353~103697163:+
THCA	cis	rs2115630	0.641	rs11073613	ENSG00000275120.1	RP11-182J1.17	-6.95	1.22e-11	3.36e-09	-0.32	-0.31	P wave terminal force;	chr15:84642662	chr15:84599434~84606463:-
THCA	cis	rs10055631	0.5	rs706702	ENSG00000229666.1	MAST4-AS1	6.95	1.22e-11	3.36e-09	0.35	0.31	Coronary artery disease;	chr5:67009622	chr5:67001383~67003953:-
THCA	cis	rs2976388	1	rs2976398	ENSG00000253741.1	CTD-2292P10.4	6.95	1.22e-11	3.36e-09	0.38	0.31	Urinary tract infection frequency;	chr8:142683461	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2920294	ENSG00000253741.1	CTD-2292P10.4	6.95	1.22e-11	3.36e-09	0.38	0.31	Urinary tract infection frequency;	chr8:142683908	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2920293	ENSG00000253741.1	CTD-2292P10.4	6.95	1.22e-11	3.36e-09	0.38	0.31	Urinary tract infection frequency;	chr8:142683996	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2920292	ENSG00000253741.1	CTD-2292P10.4	6.95	1.22e-11	3.36e-09	0.38	0.31	Urinary tract infection frequency;	chr8:142684281	chr8:142702252~142726973:-
THCA	cis	rs11148252	0.514	rs3783242	ENSG00000278238.1	RP11-245D16.4	-6.95	1.22e-11	3.36e-09	-0.35	-0.31	Lewy body disease;	chr13:52143814	chr13:52454775~52455331:-
THCA	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-6.95	1.22e-11	3.37e-09	-0.56	-0.31	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
THCA	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-6.95	1.22e-11	3.37e-09	-0.39	-0.31	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
THCA	cis	rs8067545	0.616	rs203477	ENSG00000270091.1	RP11-78O7.2	-6.95	1.22e-11	3.37e-09	-0.23	-0.31	Schizophrenia;	chr17:19928506	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.641	rs850623	ENSG00000270091.1	RP11-78O7.2	-6.95	1.22e-11	3.37e-09	-0.23	-0.31	Schizophrenia;	chr17:19933817	chr17:19896590~19897287:-
THCA	cis	rs12188164	0.582	rs72700694	ENSG00000221990.4	EXOC3-AS1	6.95	1.22e-11	3.37e-09	0.29	0.31	Cystic fibrosis severity;	chr5:483152	chr5:441498~443160:-
THCA	cis	rs6504622	0.875	rs2316330	ENSG00000262879.4	RP11-156P1.3	6.95	1.22e-11	3.37e-09	0.28	0.31	Orofacial clefts;	chr17:46962666	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.905	rs3851785	ENSG00000262879.4	RP11-156P1.3	6.95	1.22e-11	3.37e-09	0.28	0.31	Orofacial clefts;	chr17:46962781	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.875	rs11652318	ENSG00000262879.4	RP11-156P1.3	6.95	1.22e-11	3.37e-09	0.28	0.31	Orofacial clefts;	chr17:46963728	chr17:46984045~47100323:-
THCA	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	6.95	1.22e-11	3.37e-09	0.38	0.31	Height;	chr6:109371573	chr6:109382795~109383666:+
THCA	cis	rs2439831	1	rs7173487	ENSG00000249839.1	AC011330.5	-6.95	1.22e-11	3.38e-09	-0.49	-0.31	Lung cancer in ever smokers;	chr15:43458041	chr15:43663654~43684339:-
THCA	cis	rs1385374	1	rs12311303	ENSG00000274695.1	RP11-21K12.3	6.95	1.22e-11	3.38e-09	0.53	0.31	Systemic lupus erythematosus;	chr12:128817047	chr12:128826836~128827579:+
THCA	cis	rs4835473	0.932	rs9308176	ENSG00000251600.4	RP11-673E1.1	-6.95	1.22e-11	3.38e-09	-0.39	-0.31	Immature fraction of reticulocytes;	chr4:144072718	chr4:143912331~143982454:+
THCA	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	6.95	1.23e-11	3.38e-09	0.34	0.31	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
THCA	cis	rs2033711	0.87	rs11669741	ENSG00000269473.1	CTD-2619J13.19	-6.95	1.23e-11	3.38e-09	-0.29	-0.31	Uric acid clearance;	chr19:58449114	chr19:58440448~58445849:+
THCA	cis	rs7044106	0.708	rs991121	ENSG00000238181.2	AHCYP2	-6.95	1.23e-11	3.39e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120720673~120721972:+
THCA	cis	rs7727544	0.545	rs17674015	ENSG00000237714.1	P4HA2-AS1	6.95	1.23e-11	3.39e-09	0.43	0.31	Blood metabolite levels;	chr5:132026085	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.545	rs3916443	ENSG00000237714.1	P4HA2-AS1	6.95	1.23e-11	3.39e-09	0.43	0.31	Blood metabolite levels;	chr5:132033386	chr5:132184876~132192808:+
THCA	cis	rs71636778	0.509	rs11555809	ENSG00000260063.1	RP5-968P14.2	-6.95	1.23e-11	3.39e-09	-0.6	-0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26890178	chr1:26692132~26694131:-
THCA	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	6.95	1.23e-11	3.39e-09	0.34	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
THCA	cis	rs741668	0.931	rs17428874	ENSG00000235903.6	CPB2-AS1	6.95	1.23e-11	3.39e-09	0.41	0.31	Cerebrospinal fluid clusterin levels;	chr13:45955427	chr13:46052806~46113332:+
THCA	cis	rs916888	0.779	rs199526	ENSG00000232300.1	FAM215B	-6.95	1.23e-11	3.39e-09	-0.44	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46558830~46562795:-
THCA	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	6.95	1.23e-11	3.39e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
THCA	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-6.95	1.23e-11	3.39e-09	-0.29	-0.31	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
THCA	cis	rs138024639	1	rs138024639	ENSG00000280107.1	AL022393.9	-6.95	1.23e-11	3.39e-09	-0.6	-0.31	Breast cancer;	chr6:28468244	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs55690788	ENSG00000280107.1	AL022393.9	-6.95	1.23e-11	3.39e-09	-0.6	-0.31	Depression;	chr6:28468368	chr6:28170845~28172521:+
THCA	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-6.95	1.23e-11	3.4e-09	-0.37	-0.31	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
THCA	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-6.95	1.23e-11	3.4e-09	-0.37	-0.31	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
THCA	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-6.95	1.23e-11	3.4e-09	-0.24	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
THCA	cis	rs9388451	0.626	rs9385383	ENSG00000237742.5	RP11-624M8.1	-6.95	1.23e-11	3.4e-09	-0.27	-0.31	Brugada syndrome;	chr6:125765144	chr6:125578558~125749190:-
THCA	cis	rs1125355	0.964	rs72943123	ENSG00000251491.2	OR7E28P	-6.95	1.23e-11	3.4e-09	-0.47	-0.31	Alzheimer's disease in APOE e4+ carriers;	chr2:158818711	chr2:158862311~158863285:+
THCA	cis	rs1125355	0.964	rs74556943	ENSG00000251491.2	OR7E28P	-6.95	1.23e-11	3.4e-09	-0.47	-0.31	Alzheimer's disease in APOE e4+ carriers;	chr2:158819211	chr2:158862311~158863285:+
THCA	cis	rs7045881	0.674	rs62542705	ENSG00000254396.1	RP11-56F10.3	6.95	1.23e-11	3.4e-09	0.48	0.31	Schizophrenia;	chr9:27050025	chr9:27102630~27104728:+
THCA	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-6.95	1.23e-11	3.41e-09	-0.59	-0.31	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
THCA	cis	rs7260598	0.792	rs73021412	ENSG00000268442.1	CTD-2027I19.2	6.95	1.24e-11	3.42e-09	0.43	0.31	Response to taxane treatment (placlitaxel);	chr19:24070755	chr19:24162370~24163425:-
THCA	cis	rs2288884	1	rs2288884	ENSG00000275055.1	CTC-471J1.11	-6.95	1.24e-11	3.42e-09	-0.3	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52029018	chr19:52049007~52049754:+
THCA	cis	rs9380516	0.786	rs9470055	ENSG00000228559.1	RP3-340B19.3	-6.95	1.24e-11	3.42e-09	-0.44	-0.31	Hepatitis C induced liver fibrosis;	chr6:35554184	chr6:35544632~35545669:+
THCA	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	6.95	1.24e-11	3.42e-09	0.24	0.31	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
THCA	cis	rs9393777	0.92	rs67859638	ENSG00000280107.1	AL022393.9	-6.95	1.24e-11	3.42e-09	-0.63	-0.31	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28170845~28172521:+
THCA	cis	rs4789693	0.679	rs7213057	ENSG00000265458.1	RP13-20L14.6	6.95	1.24e-11	3.43e-09	0.31	0.31	Glucocorticoid-induced osteonecrosis;	chr17:82421063	chr17:82454273~82458521:-
THCA	cis	rs2348418	0.715	rs4931083	ENSG00000247934.4	RP11-967K21.1	-6.95	1.24e-11	3.43e-09	-0.26	-0.31	Lung function (FEV1);Lung function (FVC);	chr12:28568952	chr12:28163298~28190738:-
THCA	cis	rs7189233	0.955	rs7189726	ENSG00000279722.1	RP11-44F14.6	-6.95	1.24e-11	3.43e-09	-0.32	-0.31	Intelligence (multi-trait analysis);	chr16:53463862	chr16:53487607~53489943:-
THCA	cis	rs853679	0.825	rs8180562	ENSG00000226314.6	ZNF192P1	-6.95	1.24e-11	3.43e-09	-0.52	-0.31	Depression;	chr6:28173682	chr6:28161781~28169594:+
THCA	cis	rs853679	0.882	rs9380064	ENSG00000226314.6	ZNF192P1	-6.95	1.24e-11	3.43e-09	-0.52	-0.31	Depression;	chr6:28175340	chr6:28161781~28169594:+
THCA	cis	rs7646881	0.812	rs9864589	ENSG00000240207.5	RP11-379F4.4	-6.95	1.25e-11	3.44e-09	-0.43	-0.31	Tetralogy of Fallot;	chr3:158712917	chr3:158732263~158784070:+
THCA	cis	rs7727544	0.716	rs11949055	ENSG00000233006.5	AC034220.3	6.95	1.25e-11	3.44e-09	0.24	0.31	Blood metabolite levels;	chr5:132241044	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.716	rs3844312	ENSG00000233006.5	AC034220.3	6.95	1.25e-11	3.44e-09	0.24	0.31	Blood metabolite levels;	chr5:132246663	chr5:132311285~132369916:-
THCA	cis	rs875971	0.767	rs1643394	ENSG00000232559.3	GS1-124K5.12	6.95	1.25e-11	3.44e-09	0.29	0.31	Aortic root size;	chr7:66371107	chr7:66554588~66576923:-
THCA	cis	rs9902453	0.904	rs9897794	ENSG00000264007.1	RP11-68I3.10	6.95	1.25e-11	3.44e-09	0.34	0.31	Coffee consumption (cups per day);	chr17:29969309	chr17:29621617~29622254:-
THCA	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-6.95	1.25e-11	3.44e-09	-0.49	-0.31	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
THCA	cis	rs5006884	0.507	rs17270832	ENSG00000167355.6	AC104389.28	-6.95	1.25e-11	3.45e-09	-0.39	-0.31	Fetal hemoglobin levels;	chr11:5362910	chr11:5304976~5505652:-
THCA	cis	rs6600671	0.902	rs2222371	ENSG00000275538.1	RNVU1-19	-6.95	1.25e-11	3.45e-09	-0.4	-0.31	Hip geometry;	chr1:121547320	chr1:120850819~120850985:-
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000272009.1	RP1-313I6.12	-6.95	1.25e-11	3.46e-09	-0.35	-0.31	Parkinson's disease;	chr6:28110633	chr6:28078792~28081130:-
THCA	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-6.95	1.25e-11	3.46e-09	-0.28	-0.31	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
THCA	cis	rs3745672	1	rs157184	ENSG00000219665.7	CTD-2006C1.2	-6.95	1.26e-11	3.46e-09	-0.64	-0.31	Multiple sclerosis;	chr19:12017502	chr19:11987617~12046275:+
THCA	cis	rs3745672	0.661	rs157185	ENSG00000219665.7	CTD-2006C1.2	-6.95	1.26e-11	3.46e-09	-0.64	-0.31	Multiple sclerosis;	chr19:12019662	chr19:11987617~12046275:+
THCA	cis	rs1426063	0.614	rs17266308	ENSG00000260265.1	RP11-44F21.5	-6.95	1.26e-11	3.46e-09	-0.6	-0.31	QT interval;	chr4:75137695	chr4:75081702~75084717:-
THCA	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	6.95	1.26e-11	3.47e-09	0.38	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
THCA	cis	rs2562456	0.617	rs34203148	ENSG00000268555.1	RP11-678G14.3	6.95	1.26e-11	3.48e-09	0.45	0.31	Pain;	chr19:21590743	chr19:21570822~21587322:-
THCA	cis	rs4072705	0.967	rs10739650	ENSG00000224020.1	MIR181A2HG	-6.95	1.26e-11	3.48e-09	-0.28	-0.31	Menarche (age at onset);	chr9:124561497	chr9:124658467~124698631:+
THCA	cis	rs7044106	0.762	rs10818471	ENSG00000238181.2	AHCYP2	-6.95	1.26e-11	3.48e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120720673~120721972:+
THCA	cis	rs7044106	0.718	rs1960421	ENSG00000238181.2	AHCYP2	-6.95	1.26e-11	3.48e-09	-0.39	-0.31	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120720673~120721972:+
THCA	cis	rs8067545	0.641	rs1479129	ENSG00000270091.1	RP11-78O7.2	-6.95	1.26e-11	3.48e-09	-0.23	-0.31	Schizophrenia;	chr17:19942456	chr17:19896590~19897287:-
THCA	cis	rs6840258	1	rs17604480	ENSG00000251411.1	RP11-397E7.4	-6.95	1.26e-11	3.49e-09	-0.36	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87048975	chr4:86913266~86914817:-
THCA	cis	rs17684571	0.938	rs71564848	ENSG00000231441.1	RP11-472M19.2	6.95	1.26e-11	3.49e-09	0.39	0.31	Schizophrenia;	chr6:56684255	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.938	rs34576803	ENSG00000231441.1	RP11-472M19.2	6.95	1.26e-11	3.49e-09	0.39	0.31	Schizophrenia;	chr6:56684609	chr6:56844002~56864078:+
THCA	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	6.94	1.27e-11	3.49e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	6.94	1.27e-11	3.49e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	6.94	1.27e-11	3.49e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	6.94	1.27e-11	3.49e-09	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
THCA	cis	rs860295	0.557	rs12037177	ENSG00000225855.5	RUSC1-AS1	-6.94	1.27e-11	3.5e-09	-0.21	-0.31	Body mass index;	chr1:155907238	chr1:155316863~155324176:-
THCA	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-6.94	1.27e-11	3.5e-09	-0.28	-0.31	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-6.94	1.27e-11	3.5e-09	-0.28	-0.31	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-6.94	1.27e-11	3.5e-09	-0.28	-0.31	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-6.94	1.27e-11	3.5e-09	-0.28	-0.31	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
THCA	cis	rs7267979	1	rs13038834	ENSG00000274414.1	RP5-965G21.4	-6.94	1.27e-11	3.51e-09	-0.36	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25239007~25245229:-
THCA	cis	rs9902453	0.689	rs56788338	ENSG00000264007.1	RP11-68I3.10	6.94	1.27e-11	3.51e-09	0.35	0.31	Coffee consumption (cups per day);	chr17:29859539	chr17:29621617~29622254:-
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000213640.3	EEF1DP4	-6.94	1.28e-11	3.52e-09	-0.36	-0.31	Calcium levels;	chr7:65829754	chr7:64862999~64864370:+
THCA	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-6.94	1.28e-11	3.52e-09	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
THCA	cis	rs1598856	0.966	rs11097788	ENSG00000246560.2	RP11-10L12.4	6.94	1.28e-11	3.52e-09	0.37	0.31	Primary biliary cholangitis;	chr4:102486271	chr4:102828055~102844075:+
THCA	cis	rs9287719	0.649	rs12473957	ENSG00000243819.4	RN7SL832P	-6.94	1.28e-11	3.52e-09	-0.25	-0.31	Prostate cancer;	chr2:10577588	chr2:10690344~10692099:+
THCA	cis	rs12130219	0.588	rs2282302	ENSG00000237975.5	FLG-AS1	6.94	1.28e-11	3.53e-09	0.48	0.31	Inflammatory skin disease;	chr1:152356893	chr1:152168125~152445456:+
THCA	cis	rs11722228	0.549	rs3796818	ENSG00000261490.1	RP11-448G15.3	6.94	1.28e-11	3.53e-09	0.23	0.31	Urate levels;Serum uric acid levels;Gout;	chr4:10096352	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.549	rs41268389	ENSG00000261490.1	RP11-448G15.3	6.94	1.28e-11	3.53e-09	0.23	0.31	Urate levels;Serum uric acid levels;Gout;	chr4:10097653	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.521	rs62288520	ENSG00000261490.1	RP11-448G15.3	6.94	1.28e-11	3.53e-09	0.23	0.31	Urate levels;Serum uric acid levels;Gout;	chr4:10098050	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.549	rs62288521	ENSG00000261490.1	RP11-448G15.3	6.94	1.28e-11	3.53e-09	0.23	0.31	Urate levels;Serum uric acid levels;Gout;	chr4:10098148	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.549	rs2241488	ENSG00000261490.1	RP11-448G15.3	6.94	1.28e-11	3.53e-09	0.23	0.31	Urate levels;Serum uric acid levels;Gout;	chr4:10099507	chr4:10068089~10073019:-
THCA	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-6.94	1.28e-11	3.53e-09	-0.39	-0.31	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
THCA	cis	rs7851660	0.506	rs1912996	ENSG00000236130.1	PTCSC2	-6.94	1.28e-11	3.53e-09	-0.26	-0.3	Strep throat;	chr9:97835979	chr9:97805935~97810008:-
THCA	cis	rs12435908	1	rs7145574	ENSG00000276116.2	FUT8-AS1	-6.94	1.28e-11	3.53e-09	-0.48	-0.3	Ischemic stroke;	chr14:65417684	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs59822422	ENSG00000276116.2	FUT8-AS1	-6.94	1.28e-11	3.53e-09	-0.48	-0.3	Ischemic stroke;	chr14:65422848	chr14:65411170~65412690:-
THCA	cis	rs9876781	0.53	rs35516531	ENSG00000229759.1	MRPS18AP1	6.94	1.28e-11	3.54e-09	0.37	0.3	Longevity;	chr3:48364275	chr3:48256350~48256938:-
THCA	cis	rs7580658	0.545	rs13006847	ENSG00000236682.1	AC068282.3	6.94	1.29e-11	3.54e-09	0.39	0.3	Protein C levels;	chr2:127194687	chr2:127389130~127400580:+
THCA	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-6.94	1.29e-11	3.54e-09	-0.26	-0.3	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
THCA	cis	rs7811142	1	rs28490152	ENSG00000078319.8	PMS2P1	-6.94	1.29e-11	3.54e-09	-0.43	-0.3	Platelet count;	chr7:100423359	chr7:100320992~100341908:-
THCA	cis	rs7246657	0.943	rs10420430	ENSG00000226686.6	LINC01535	-6.94	1.29e-11	3.55e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37403292	chr19:37251912~37265535:+
THCA	cis	rs8067545	0.641	rs203462	ENSG00000270091.1	RP11-78O7.2	-6.94	1.29e-11	3.55e-09	-0.23	-0.3	Schizophrenia;	chr17:19909228	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.641	rs203460	ENSG00000270091.1	RP11-78O7.2	-6.94	1.29e-11	3.55e-09	-0.23	-0.3	Schizophrenia;	chr17:19911973	chr17:19896590~19897287:-
THCA	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	6.94	1.29e-11	3.55e-09	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
THCA	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	6.94	1.29e-11	3.55e-09	0.37	0.3	Depression;	chr6:28399886	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	6.94	1.29e-11	3.55e-09	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
THCA	cis	rs7044106	0.734	rs10491784	ENSG00000238181.2	AHCYP2	-6.94	1.29e-11	3.55e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120720673~120721972:+
THCA	cis	rs12928939	0.911	rs12919271	ENSG00000260886.1	TAT-AS1	6.94	1.29e-11	3.55e-09	0.41	0.3	Post bronchodilator FEV1;	chr16:71758793	chr16:71565789~71578187:+
THCA	cis	rs8081395	0.58	rs180515	ENSG00000266992.1	DHX40P1	6.94	1.29e-11	3.55e-09	0.36	0.3	White blood cell count;	chr17:59946914	chr17:59976009~60002384:-
THCA	cis	rs6723108	0.517	rs6430543	ENSG00000224043.6	CCNT2-AS1	6.94	1.29e-11	3.56e-09	0.31	0.3	Type 2 diabetes;	chr2:134844839	chr2:134735464~134918710:-
THCA	cis	rs240993	0.812	rs9387013	ENSG00000230177.1	RP5-1112D6.4	6.94	1.29e-11	3.56e-09	0.31	0.3	Inflammatory skin disease;Psoriasis;	chr6:111512517	chr6:111277932~111278742:+
THCA	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-6.94	1.29e-11	3.56e-09	-0.24	-0.3	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
THCA	cis	rs4784934	0.655	rs12932631	ENSG00000260186.4	RP11-481J2.2	6.94	1.29e-11	3.56e-09	0.43	0.3	QT interval;	chr16:58435506	chr16:58421326~58462470:+
THCA	cis	rs4784934	0.655	rs12927589	ENSG00000260186.4	RP11-481J2.2	6.94	1.29e-11	3.56e-09	0.43	0.3	QT interval;	chr16:58435775	chr16:58421326~58462470:+
THCA	cis	rs4784934	0.655	rs4577076	ENSG00000260186.4	RP11-481J2.2	6.94	1.29e-11	3.56e-09	0.43	0.3	QT interval;	chr16:58435933	chr16:58421326~58462470:+
THCA	cis	rs2120243	0.539	rs1568609	ENSG00000244515.1	KRT18P34	-6.94	1.29e-11	3.56e-09	-0.35	-0.3	Hepatocellular carcinoma in hepatitis B infection;	chr3:157349050	chr3:157162663~157163932:-
THCA	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-6.94	1.3e-11	3.57e-09	-0.59	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
THCA	cis	rs79349575	0.721	rs3744608	ENSG00000248278.1	SUMO2P17	6.94	1.3e-11	3.57e-09	0.36	0.3	Type 2 diabetes;	chr17:48915871	chr17:48874860~48908983:-
THCA	cis	rs7580658	0.891	rs55998967	ENSG00000236682.1	AC068282.3	-6.94	1.3e-11	3.57e-09	-0.4	-0.3	Protein C levels;	chr2:127291098	chr2:127389130~127400580:+
THCA	cis	rs4073416	0.712	rs11622014	ENSG00000276116.2	FUT8-AS1	6.94	1.3e-11	3.57e-09	0.32	0.3	N-glycan levels;	chr14:65574927	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.712	rs12887134	ENSG00000276116.2	FUT8-AS1	6.94	1.3e-11	3.57e-09	0.32	0.3	N-glycan levels;	chr14:65578825	chr14:65411170~65412690:-
THCA	cis	rs4266144	0.563	rs61124401	ENSG00000241770.1	RP11-555M1.3	-6.94	1.3e-11	3.57e-09	-0.44	-0.3	Coronary artery disease;	chr3:157123130	chr3:157163452~157169133:+
THCA	cis	rs2439831	1	rs2439841	ENSG00000275601.1	AC011330.13	-6.94	1.3e-11	3.57e-09	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43442551	chr15:43642389~43643023:-
THCA	cis	rs172166	0.516	rs1225715	ENSG00000219392.1	RP1-265C24.5	6.94	1.3e-11	3.57e-09	0.34	0.3	Cardiac Troponin-T levels;	chr6:28145595	chr6:28115628~28116551:+
THCA	cis	rs6696239	0.513	rs12040302	ENSG00000227711.2	RP11-275O4.5	6.94	1.3e-11	3.58e-09	0.32	0.3	Height;	chr1:227509464	chr1:227509028~227520477:-
THCA	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	6.94	1.3e-11	3.59e-09	0.39	0.3	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
THCA	cis	rs13191038	1	rs13191038	ENSG00000280107.1	AL022393.9	-6.94	1.3e-11	3.59e-09	-0.61	-0.3	Urinary tract infection frequency;	chr6:28515140	chr6:28170845~28172521:+
THCA	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	6.94	1.3e-11	3.59e-09	0.39	0.3	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	6.94	1.3e-11	3.59e-09	0.39	0.3	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
THCA	cis	rs9341808	0.718	rs3812121	ENSG00000272129.1	RP11-250B2.6	6.94	1.3e-11	3.59e-09	0.39	0.3	Sitting height ratio;	chr6:80259010	chr6:80355424~80356859:+
THCA	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-6.94	1.3e-11	3.59e-09	-0.33	-0.3	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
THCA	cis	rs12348691	0.503	rs7048394	ENSG00000236130.1	PTCSC2	-6.94	1.31e-11	3.59e-09	-0.26	-0.3	Alopecia areata;	chr9:97843151	chr9:97805935~97810008:-
THCA	cis	rs12348691	0.503	rs7849834	ENSG00000236130.1	PTCSC2	-6.94	1.31e-11	3.59e-09	-0.26	-0.3	Alopecia areata;	chr9:97843906	chr9:97805935~97810008:-
THCA	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-6.94	1.31e-11	3.59e-09	-0.35	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
THCA	cis	rs7044106	0.762	rs10491783	ENSG00000238181.2	AHCYP2	-6.94	1.31e-11	3.59e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120720673~120721972:+
THCA	cis	rs7044106	0.762	rs966397	ENSG00000238181.2	AHCYP2	-6.94	1.31e-11	3.59e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120720673~120721972:+
THCA	cis	rs875971	0.825	rs1000464	ENSG00000232559.3	GS1-124K5.12	-6.94	1.31e-11	3.6e-09	-0.29	-0.3	Aortic root size;	chr7:66312922	chr7:66554588~66576923:-
THCA	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	6.94	1.31e-11	3.6e-09	0.28	0.3	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
THCA	cis	rs375066	0.762	rs171238	ENSG00000267058.1	RP11-15A1.3	-6.94	1.31e-11	3.6e-09	-0.26	-0.3	Breast cancer;	chr19:43875402	chr19:43891804~43901805:-
THCA	cis	rs12348691	0.503	rs7848950	ENSG00000236130.1	PTCSC2	-6.94	1.31e-11	3.6e-09	-0.25	-0.3	Alopecia areata;	chr9:97850492	chr9:97805935~97810008:-
THCA	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-6.94	1.31e-11	3.6e-09	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
THCA	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-6.94	1.31e-11	3.6e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
THCA	cis	rs6540731	0.935	rs903120	ENSG00000226251.4	RP11-15I11.3	-6.94	1.31e-11	3.61e-09	-0.37	-0.3	Intelligence (childhood);	chr1:212231830	chr1:212225278~212238977:-
THCA	cis	rs6540731	1	rs2087946	ENSG00000226251.4	RP11-15I11.3	-6.94	1.31e-11	3.61e-09	-0.37	-0.3	Intelligence (childhood);	chr1:212232054	chr1:212225278~212238977:-
THCA	cis	rs6540731	1	rs903121	ENSG00000226251.4	RP11-15I11.3	-6.94	1.31e-11	3.61e-09	-0.37	-0.3	Intelligence (childhood);	chr1:212232113	chr1:212225278~212238977:-
THCA	cis	rs6540731	1	rs2012917	ENSG00000226251.4	RP11-15I11.3	-6.94	1.31e-11	3.61e-09	-0.37	-0.3	Intelligence (childhood);	chr1:212232429	chr1:212225278~212238977:-
THCA	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	6.94	1.31e-11	3.61e-09	0.39	0.3	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
THCA	cis	rs7267979	1	rs2482931	ENSG00000274414.1	RP5-965G21.4	6.94	1.31e-11	3.61e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25239007~25245229:-
THCA	cis	rs8067545	0.641	rs169412	ENSG00000270091.1	RP11-78O7.2	-6.94	1.31e-11	3.61e-09	-0.23	-0.3	Schizophrenia;	chr17:19948562	chr17:19896590~19897287:-
THCA	cis	rs7580658	0.963	rs12463451	ENSG00000236682.1	AC068282.3	-6.94	1.31e-11	3.62e-09	-0.4	-0.3	Protein C levels;	chr2:127296307	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.963	rs4233583	ENSG00000236682.1	AC068282.3	-6.94	1.31e-11	3.62e-09	-0.4	-0.3	Protein C levels;	chr2:127302492	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.963	rs4233584	ENSG00000236682.1	AC068282.3	-6.94	1.31e-11	3.62e-09	-0.4	-0.3	Protein C levels;	chr2:127302587	chr2:127389130~127400580:+
THCA	cis	rs1318937	1	rs3821639	ENSG00000224660.1	SH3BP5-AS1	6.94	1.31e-11	3.62e-09	0.22	0.3	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15264159	chr3:15254184~15264493:+
THCA	cis	rs6600671	0.934	rs67718113	ENSG00000223345.3	HIST2H2BA	-6.94	1.32e-11	3.63e-09	-0.35	-0.3	Hip geometry;	chr1:121497112	chr1:121108210~121117257:-
THCA	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-6.94	1.32e-11	3.63e-09	-0.28	-0.3	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
THCA	cis	rs9876781	0.559	rs7610524	ENSG00000229759.1	MRPS18AP1	6.94	1.32e-11	3.63e-09	0.38	0.3	Longevity;	chr3:48353882	chr3:48256350~48256938:-
THCA	cis	rs11722228	0.549	rs73212828	ENSG00000261490.1	RP11-448G15.3	6.94	1.32e-11	3.63e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10077132	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.549	rs73212830	ENSG00000261490.1	RP11-448G15.3	6.94	1.32e-11	3.63e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10077135	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.549	rs56146302	ENSG00000261490.1	RP11-448G15.3	6.94	1.32e-11	3.63e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10079428	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.549	rs55848383	ENSG00000261490.1	RP11-448G15.3	6.94	1.32e-11	3.63e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10079493	chr4:10068089~10073019:-
THCA	cis	rs792448	0.603	rs12024665	ENSG00000226251.4	RP11-15I11.3	-6.94	1.32e-11	3.63e-09	-0.36	-0.3	White blood cell count (basophil);	chr1:212326553	chr1:212225278~212238977:-
THCA	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	6.94	1.32e-11	3.64e-09	0.34	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
THCA	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-6.94	1.33e-11	3.64e-09	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
THCA	cis	rs16846053	0.591	rs13014399	ENSG00000227403.1	AC009299.3	-6.94	1.33e-11	3.65e-09	-0.52	-0.3	Blood osmolality (transformed sodium);	chr2:161706641	chr2:161244739~161249050:+
THCA	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-6.94	1.33e-11	3.65e-09	-0.37	-0.3	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.791	rs10985008	ENSG00000238181.2	AHCYP2	-6.94	1.33e-11	3.65e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120720673~120721972:+
THCA	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-6.94	1.33e-11	3.65e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-6.94	1.33e-11	3.65e-09	-0.47	-0.3	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
THCA	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-6.94	1.33e-11	3.65e-09	-0.38	-0.3	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
THCA	cis	rs6672530	0.518	rs903683	ENSG00000227711.2	RP11-275O4.5	6.94	1.33e-11	3.65e-09	0.32	0.3	Hip circumference adjusted for BMI;	chr1:227508809	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs1495842	ENSG00000227711.2	RP11-275O4.5	6.94	1.33e-11	3.65e-09	0.32	0.3	Height;	chr1:227508893	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs11580570	ENSG00000227711.2	RP11-275O4.5	6.94	1.33e-11	3.65e-09	0.32	0.3	Height;	chr1:227509139	chr1:227509028~227520477:-
THCA	cis	rs12594515	1	rs12595137	ENSG00000259200.1	RP11-718O11.1	-6.94	1.33e-11	3.66e-09	-0.37	-0.3	Weight;Waist circumference;	chr15:45693907	chr15:45705078~45931069:+
THCA	cis	rs12594515	0.967	rs12595138	ENSG00000259200.1	RP11-718O11.1	-6.94	1.33e-11	3.66e-09	-0.37	-0.3	Weight;Waist circumference;	chr15:45693910	chr15:45705078~45931069:+
THCA	cis	rs9287719	0.649	rs10929684	ENSG00000243819.4	RN7SL832P	-6.94	1.33e-11	3.66e-09	-0.25	-0.3	Prostate cancer;	chr2:10592098	chr2:10690344~10692099:+
THCA	cis	rs12594515	0.694	rs2068294	ENSG00000259200.1	RP11-718O11.1	-6.94	1.33e-11	3.66e-09	-0.37	-0.3	Weight;Waist circumference;	chr15:45693350	chr15:45705078~45931069:+
THCA	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-6.94	1.33e-11	3.66e-09	-0.47	-0.3	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
THCA	cis	rs829883	0.664	rs829874	ENSG00000227825.4	SLC9A7P1	6.94	1.33e-11	3.67e-09	0.26	0.3	Colorectal adenoma (advanced);	chr12:98446837	chr12:98453835~98457145:-
THCA	cis	rs12817211	0.549	rs7972465	ENSG00000272368.2	RP4-605O3.4	6.94	1.34e-11	3.67e-09	0.18	0.3	Colorectal or endometrial cancer;	chr12:50152342	chr12:50112197~50165618:+
THCA	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	6.94	1.34e-11	3.68e-09	0.4	0.3	Height;	chr4:55457922	chr4:55363971~55395847:-
THCA	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-6.94	1.34e-11	3.68e-09	-0.41	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
THCA	cis	rs11696845	0.626	rs4810439	ENSG00000276223.1	RP4-781B1.5	6.94	1.34e-11	3.68e-09	0.37	0.3	Obesity-related traits;	chr20:44749229	chr20:44746642~44747201:+
THCA	cis	rs9902453	0.765	rs8071576	ENSG00000264007.1	RP11-68I3.10	6.94	1.34e-11	3.68e-09	0.35	0.3	Coffee consumption (cups per day);	chr17:29861536	chr17:29621617~29622254:-
THCA	cis	rs1009647	0.645	rs72715709	ENSG00000258413.1	RP11-665C16.6	-6.94	1.34e-11	3.68e-09	-0.55	-0.3	Testicular germ cell tumor;	chr14:55244974	chr14:55262767~55272075:-
THCA	cis	rs7246657	1	rs7246657	ENSG00000226686.6	LINC01535	6.94	1.34e-11	3.69e-09	0.43	0.3	Coronary artery calcification;	chr19:37256206	chr19:37251912~37265535:+
THCA	cis	rs7044106	0.762	rs1530370	ENSG00000238181.2	AHCYP2	-6.94	1.34e-11	3.69e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120720673~120721972:+
THCA	cis	rs9341808	0.69	rs9343970	ENSG00000272129.1	RP11-250B2.6	6.94	1.34e-11	3.69e-09	0.38	0.3	Sitting height ratio;	chr6:80171572	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9343971	ENSG00000272129.1	RP11-250B2.6	6.94	1.34e-11	3.69e-09	0.38	0.3	Sitting height ratio;	chr6:80172339	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.754	rs3805925	ENSG00000272129.1	RP11-250B2.6	6.94	1.34e-11	3.69e-09	0.38	0.3	Sitting height ratio;	chr6:80174116	chr6:80355424~80356859:+
THCA	cis	rs1552244	0.882	rs13084194	ENSG00000232901.1	CYCSP10	6.94	1.34e-11	3.69e-09	0.4	0.3	Alzheimer's disease;	chr3:9989808	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs13099507	ENSG00000232901.1	CYCSP10	6.94	1.34e-11	3.69e-09	0.4	0.3	Alzheimer's disease;	chr3:9989919	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs55962400	ENSG00000232901.1	CYCSP10	6.94	1.34e-11	3.69e-09	0.4	0.3	Alzheimer's disease;	chr3:10002773	chr3:10000647~10000940:-
THCA	cis	rs8067545	0.641	rs4925060	ENSG00000270091.1	RP11-78O7.2	-6.94	1.34e-11	3.7e-09	-0.23	-0.3	Schizophrenia;	chr17:19959945	chr17:19896590~19897287:-
THCA	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-6.94	1.35e-11	3.7e-09	-0.26	-0.3	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
THCA	cis	rs7688540	0.8	rs12506277	ENSG00000211553.1	AC253576.2	-6.94	1.35e-11	3.7e-09	-0.42	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:136461~136568:+
THCA	cis	rs7688540	0.8	rs12501727	ENSG00000211553.1	AC253576.2	-6.94	1.35e-11	3.7e-09	-0.42	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:136461~136568:+
THCA	cis	rs7267979	0.932	rs417130	ENSG00000274414.1	RP5-965G21.4	-6.94	1.35e-11	3.7e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.932	rs372678	ENSG00000274414.1	RP5-965G21.4	-6.94	1.35e-11	3.7e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25239007~25245229:-
THCA	cis	rs79349575	0.783	rs15563	ENSG00000248278.1	SUMO2P17	6.94	1.35e-11	3.71e-09	0.35	0.3	Type 2 diabetes;	chr17:48927831	chr17:48874860~48908983:-
THCA	cis	rs496547	0.719	rs598373	ENSG00000255239.1	AP002954.6	6.93	1.35e-11	3.71e-09	0.39	0.3	Hip minimal joint space width;	chr11:118793668	chr11:118688039~118690600:-
THCA	cis	rs7637701	0.818	rs4680305	ENSG00000240875.4	LINC00886	-6.93	1.35e-11	3.71e-09	-0.24	-0.3	Breast cancer;	chr3:156815614	chr3:156747346~156817062:-
THCA	cis	rs2439831	0.681	rs28653441	ENSG00000249839.1	AC011330.5	-6.93	1.35e-11	3.71e-09	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43385064	chr15:43663654~43684339:-
THCA	cis	rs160451	1	rs160424	ENSG00000251136.7	RP11-37B2.1	6.93	1.35e-11	3.71e-09	0.26	0.3	Leprosy;	chr8:89658452	chr8:89609409~89757727:-
THCA	cis	rs10208649	0.831	rs10209918	ENSG00000272156.1	RP11-477N3.1	6.93	1.36e-11	3.72e-09	0.58	0.3	Body mass index;	chr2:53688174	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.731	rs78472090	ENSG00000272156.1	RP11-477N3.1	6.93	1.36e-11	3.72e-09	0.58	0.3	Body mass index;	chr2:53688318	chr2:54082554~54085066:+
THCA	cis	rs875971	0.862	rs35378740	ENSG00000232559.3	GS1-124K5.12	6.93	1.36e-11	3.72e-09	0.29	0.3	Aortic root size;	chr7:66522725	chr7:66554588~66576923:-
THCA	cis	rs9816784	0.696	rs6778081	ENSG00000226155.1	AC124944.3	6.93	1.36e-11	3.72e-09	0.35	0.3	Mean corpuscular hemoglobin;	chr3:196092334	chr3:195912049~195913986:+
THCA	cis	rs853679	0.599	rs149949	ENSG00000219392.1	RP1-265C24.5	-6.93	1.36e-11	3.73e-09	-0.49	-0.3	Depression;	chr6:28043738	chr6:28115628~28116551:+
THCA	cis	rs12681366	0.734	rs4735288	ENSG00000253704.1	RP11-267M23.4	6.93	1.36e-11	3.73e-09	0.3	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94354316	chr8:94553722~94569745:+
THCA	cis	rs7267979	1	rs10966	ENSG00000274414.1	RP5-965G21.4	-6.93	1.36e-11	3.74e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25239007~25245229:-
THCA	cis	rs9341808	0.718	rs2322631	ENSG00000272129.1	RP11-250B2.6	6.93	1.36e-11	3.74e-09	0.38	0.3	Sitting height ratio;	chr6:80134239	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.718	rs9448899	ENSG00000272129.1	RP11-250B2.6	6.93	1.36e-11	3.74e-09	0.38	0.3	Sitting height ratio;	chr6:80136147	chr6:80355424~80356859:+
THCA	cis	rs5771242	0.769	rs4838865	ENSG00000273253.2	RP3-402G11.26	-6.93	1.36e-11	3.74e-09	-0.35	-0.3	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50226183	chr22:50199090~50200837:-
THCA	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	6.93	1.36e-11	3.74e-09	0.18	0.3	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
THCA	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	6.93	1.36e-11	3.74e-09	0.18	0.3	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
THCA	cis	rs8012947	1	rs2180871	ENSG00000279636.2	LINC00216	-6.93	1.37e-11	3.75e-09	-0.32	-0.3	Alcohol consumption in current drinkers;	chr14:58272819	chr14:58288033~58289158:+
THCA	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	6.93	1.37e-11	3.76e-09	0.36	0.3	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
THCA	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	6.93	1.37e-11	3.76e-09	0.37	0.3	Height;	chr6:109486036	chr6:109382795~109383666:+
THCA	cis	rs4819052	0.788	rs35323494	ENSG00000237664.1	LINC00316	-6.93	1.37e-11	3.76e-09	-0.32	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45338590~45341990:-
THCA	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-6.93	1.37e-11	3.77e-09	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
THCA	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-6.93	1.37e-11	3.77e-09	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
THCA	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-6.93	1.37e-11	3.77e-09	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
THCA	cis	rs9813712	0.595	rs12490957	ENSG00000228252.7	COL6A4P2	6.93	1.37e-11	3.77e-09	0.31	0.3	Response to amphetamines;	chr3:130287851	chr3:130212823~130273806:+
THCA	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	6.93	1.37e-11	3.77e-09	0.46	0.3	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
THCA	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	6.93	1.37e-11	3.77e-09	0.27	0.3	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
THCA	cis	rs7208859	0.623	rs426434	ENSG00000264538.5	SUZ12P1	-6.93	1.37e-11	3.77e-09	-0.29	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30709299~30790908:+
THCA	cis	rs12928939	0.954	rs8057568	ENSG00000260886.1	TAT-AS1	6.93	1.37e-11	3.77e-09	0.41	0.3	Post bronchodilator FEV1;	chr16:71778092	chr16:71565789~71578187:+
THCA	cis	rs7260598	0.792	rs11669251	ENSG00000268442.1	CTD-2027I19.2	6.93	1.38e-11	3.78e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24154192	chr19:24162370~24163425:-
THCA	cis	rs7044106	0.791	rs10984997	ENSG00000238181.2	AHCYP2	-6.93	1.38e-11	3.78e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120720673~120721972:+
THCA	cis	rs11024102	1	rs4141194	ENSG00000184669.7	OR7E14P	6.93	1.38e-11	3.78e-09	0.42	0.3	Glaucoma (primary angle closure);	chr11:16989629	chr11:17013998~17053024:+
THCA	cis	rs11722228	0.521	rs56403947	ENSG00000261490.1	RP11-448G15.3	6.93	1.38e-11	3.78e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10110905	chr4:10068089~10073019:-
THCA	cis	rs71636778	0.509	rs35041418	ENSG00000260063.1	RP5-968P14.2	-6.93	1.38e-11	3.78e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26722492	chr1:26692132~26694131:-
THCA	cis	rs651907	0.557	rs13066768	ENSG00000256628.3	ZBTB11-AS1	-6.93	1.38e-11	3.79e-09	-0.36	-0.3	Colorectal cancer;	chr3:101768076	chr3:101676475~101679217:+
THCA	cis	rs6751744	0.513	rs7563368	ENSG00000226266.5	AC009961.3	6.93	1.38e-11	3.79e-09	0.35	0.3	Dysphagia;	chr2:159600564	chr2:159670708~159712435:-
THCA	cis	rs10208649	1	rs6731217	ENSG00000272156.1	RP11-477N3.1	-6.93	1.38e-11	3.8e-09	-0.54	-0.3	Body mass index;	chr2:53903956	chr2:54082554~54085066:+
THCA	cis	rs7942368	1	rs56228827	ENSG00000254761.1	RP11-672A2.1	6.93	1.38e-11	3.8e-09	0.44	0.3	Endometriosis;	chr11:76756479	chr11:76712396~76719608:-
THCA	cis	rs8012947	1	rs10147580	ENSG00000279636.2	LINC00216	-6.93	1.39e-11	3.8e-09	-0.32	-0.3	Alcohol consumption in current drinkers;	chr14:58247422	chr14:58288033~58289158:+
THCA	cis	rs74233809	1	rs11191515	ENSG00000213277.3	MARCKSL1P1	6.93	1.39e-11	3.8e-09	0.5	0.3	Birth weight;	chr10:103016770	chr10:103175554~103176094:+
THCA	cis	rs72843506	0.586	rs80289275	ENSG00000270091.1	RP11-78O7.2	-6.93	1.39e-11	3.8e-09	-0.35	-0.3	Schizophrenia;	chr17:19914367	chr17:19896590~19897287:-
THCA	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-6.93	1.39e-11	3.8e-09	-0.29	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
THCA	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-6.93	1.39e-11	3.8e-09	-0.29	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
THCA	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-6.93	1.39e-11	3.8e-09	-0.29	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
THCA	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-6.93	1.39e-11	3.8e-09	-0.29	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
THCA	cis	rs7267979	1	rs2482940	ENSG00000274414.1	RP5-965G21.4	6.93	1.39e-11	3.81e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2027003	ENSG00000274414.1	RP5-965G21.4	6.93	1.39e-11	3.81e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2027004	ENSG00000274414.1	RP5-965G21.4	6.93	1.39e-11	3.81e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2500404	ENSG00000274414.1	RP5-965G21.4	6.93	1.39e-11	3.81e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2500405	ENSG00000274414.1	RP5-965G21.4	6.93	1.39e-11	3.81e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2482941	ENSG00000274414.1	RP5-965G21.4	6.93	1.39e-11	3.81e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.903	rs2500423	ENSG00000274414.1	RP5-965G21.4	6.93	1.39e-11	3.81e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25239007~25245229:-
THCA	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-6.93	1.39e-11	3.81e-09	-0.3	-0.3	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
THCA	cis	rs7267979	1	rs453329	ENSG00000274414.1	RP5-965G21.4	-6.93	1.39e-11	3.81e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25239007~25245229:-
THCA	cis	rs7688540	0.8	rs2353599	ENSG00000211553.1	AC253576.2	-6.93	1.39e-11	3.82e-09	-0.41	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:136461~136568:+
THCA	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-6.93	1.39e-11	3.82e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
THCA	cis	rs71636778	0.509	rs35021342	ENSG00000260063.1	RP5-968P14.2	-6.93	1.39e-11	3.82e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759736	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34201939	ENSG00000260063.1	RP5-968P14.2	-6.93	1.39e-11	3.82e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767220	chr1:26692132~26694131:-
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000263603.1	CTD-2349P21.5	-6.93	1.4e-11	3.83e-09	-0.52	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30729469~30731202:+
THCA	cis	rs829883	0.664	rs249833	ENSG00000227825.4	SLC9A7P1	6.93	1.4e-11	3.83e-09	0.26	0.3	Colorectal adenoma (advanced);	chr12:98438411	chr12:98453835~98457145:-
THCA	cis	rs829883	0.616	rs249832	ENSG00000227825.4	SLC9A7P1	6.93	1.4e-11	3.83e-09	0.26	0.3	Colorectal adenoma (advanced);	chr12:98438609	chr12:98453835~98457145:-
THCA	cis	rs9287719	0.649	rs10190774	ENSG00000243819.4	RN7SL832P	6.93	1.4e-11	3.83e-09	0.25	0.3	Prostate cancer;	chr2:10578620	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10188373	ENSG00000243819.4	RN7SL832P	6.93	1.4e-11	3.83e-09	0.25	0.3	Prostate cancer;	chr2:10578676	chr2:10690344~10692099:+
THCA	cis	rs16843372	0.599	rs1807921	ENSG00000251491.2	OR7E28P	6.93	1.4e-11	3.84e-09	0.41	0.3	Obesity-related traits;	chr2:158838237	chr2:158862311~158863285:+
THCA	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-6.93	1.4e-11	3.84e-09	-0.28	-0.3	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
THCA	cis	rs853679	0.545	rs35949109	ENSG00000219392.1	RP1-265C24.5	-6.93	1.4e-11	3.84e-09	-0.49	-0.3	Depression;	chr6:28058148	chr6:28115628~28116551:+
THCA	cis	rs6672530	0.518	rs2018651	ENSG00000227711.2	RP11-275O4.5	6.93	1.4e-11	3.84e-09	0.32	0.3	Hip circumference adjusted for BMI;	chr1:227508409	chr1:227509028~227520477:-
THCA	cis	rs453301	0.682	rs2929308	ENSG00000254153.1	CTA-398F10.2	6.93	1.4e-11	3.84e-09	0.33	0.3	Joint mobility (Beighton score);	chr8:9226611	chr8:8456909~8461337:-
THCA	cis	rs11168351	0.889	rs12817104	ENSG00000258273.1	RP11-370I10.4	-6.93	1.4e-11	3.84e-09	-0.4	-0.3	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48333755~48333901:-
THCA	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-6.93	1.41e-11	3.85e-09	-0.32	-0.3	Height;	chr11:118856460	chr11:118704607~118750263:+
THCA	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-6.93	1.41e-11	3.85e-09	-0.32	-0.3	Height;	chr11:118856623	chr11:118704607~118750263:+
THCA	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-6.93	1.41e-11	3.85e-09	-0.32	-0.3	Height;	chr11:118857611	chr11:118704607~118750263:+
THCA	cis	rs516805	0.667	rs2606600	ENSG00000279453.1	RP3-425C14.4	6.93	1.41e-11	3.85e-09	0.33	0.3	Lymphocyte counts;	chr6:122204398	chr6:122436789~122439223:-
THCA	cis	rs7208859	0.615	rs216462	ENSG00000266490.1	CTD-2349P21.9	-6.93	1.41e-11	3.86e-09	-0.42	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30792372~30792833:+
THCA	cis	rs10799445	0.508	rs10916179	ENSG00000227711.2	RP11-275O4.5	-6.93	1.41e-11	3.86e-09	-0.32	-0.3	Height;	chr1:227630495	chr1:227509028~227520477:-
THCA	cis	rs10799445	0.568	rs10799431	ENSG00000227711.2	RP11-275O4.5	-6.93	1.41e-11	3.86e-09	-0.32	-0.3	Height;	chr1:227631423	chr1:227509028~227520477:-
THCA	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	6.93	1.41e-11	3.86e-09	0.39	0.3	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
THCA	cis	rs3745672	1	rs365323	ENSG00000219665.7	CTD-2006C1.2	-6.93	1.41e-11	3.86e-09	-0.64	-0.3	Multiple sclerosis;	chr19:12002134	chr19:11987617~12046275:+
THCA	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	6.93	1.41e-11	3.87e-09	0.36	0.3	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
THCA	cis	rs875971	0.825	rs4587224	ENSG00000232559.3	GS1-124K5.12	-6.93	1.41e-11	3.87e-09	-0.29	-0.3	Aortic root size;	chr7:66271195	chr7:66554588~66576923:-
THCA	cis	rs875971	0.792	rs6971752	ENSG00000232559.3	GS1-124K5.12	-6.93	1.41e-11	3.87e-09	-0.29	-0.3	Aortic root size;	chr7:66272999	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs10950033	ENSG00000232559.3	GS1-124K5.12	-6.93	1.41e-11	3.87e-09	-0.29	-0.3	Aortic root size;	chr7:66274686	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs11760844	ENSG00000232559.3	GS1-124K5.12	-6.93	1.41e-11	3.87e-09	-0.29	-0.3	Aortic root size;	chr7:66274896	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs4149461	ENSG00000232559.3	GS1-124K5.12	-6.93	1.41e-11	3.87e-09	-0.29	-0.3	Aortic root size;	chr7:66279745	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs10261398	ENSG00000232559.3	GS1-124K5.12	-6.93	1.41e-11	3.87e-09	-0.29	-0.3	Aortic root size;	chr7:66285177	chr7:66554588~66576923:-
THCA	cis	rs227932	0.764	rs4722246	ENSG00000234286.1	AC006026.13	6.93	1.42e-11	3.88e-09	0.57	0.3	Schizophrenia;	chr7:23682359	chr7:23680195~23680786:-
THCA	cis	rs227932	0.614	rs12700458	ENSG00000234286.1	AC006026.13	6.93	1.42e-11	3.88e-09	0.57	0.3	Schizophrenia;	chr7:23682525	chr7:23680195~23680786:-
THCA	cis	rs516805	0.667	rs2606610	ENSG00000279453.1	RP3-425C14.4	-6.93	1.42e-11	3.88e-09	-0.32	-0.3	Lymphocyte counts;	chr6:122189959	chr6:122436789~122439223:-
THCA	cis	rs516805	0.667	rs2606608	ENSG00000279453.1	RP3-425C14.4	-6.93	1.42e-11	3.88e-09	-0.32	-0.3	Lymphocyte counts;	chr6:122195051	chr6:122436789~122439223:-
THCA	cis	rs853679	0.699	rs9468318	ENSG00000280107.1	AL022393.9	-6.93	1.42e-11	3.88e-09	-0.38	-0.3	Depression;	chr6:28241753	chr6:28170845~28172521:+
THCA	cis	rs8067545	0.641	rs860335	ENSG00000270091.1	RP11-78O7.2	-6.93	1.42e-11	3.88e-09	-0.22	-0.3	Schizophrenia;	chr17:19934366	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.616	rs203470	ENSG00000270091.1	RP11-78O7.2	-6.93	1.42e-11	3.88e-09	-0.22	-0.3	Schizophrenia;	chr17:19955313	chr17:19896590~19897287:-
THCA	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	6.93	1.42e-11	3.89e-09	0.6	0.3	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
THCA	cis	rs853679	1	rs1936365	ENSG00000280107.1	AL022393.9	6.93	1.42e-11	3.89e-09	0.41	0.3	Depression;	chr6:28300675	chr6:28170845~28172521:+
THCA	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-6.93	1.42e-11	3.89e-09	-0.23	-0.3	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
THCA	cis	rs9376098	0.763	rs7746481	ENSG00000232876.1	CTA-212D2.2	-6.93	1.42e-11	3.89e-09	-0.36	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135162673	chr6:135055033~135060550:+
THCA	cis	rs79349575	0.783	rs55771415	ENSG00000248278.1	SUMO2P17	6.93	1.42e-11	3.9e-09	0.36	0.3	Type 2 diabetes;	chr17:48922575	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs2088139	ENSG00000248278.1	SUMO2P17	6.93	1.42e-11	3.9e-09	0.36	0.3	Type 2 diabetes;	chr17:48922748	chr17:48874860~48908983:-
THCA	cis	rs9902453	0.904	rs4567782	ENSG00000264007.1	RP11-68I3.10	6.93	1.43e-11	3.91e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29941782	chr17:29621617~29622254:-
THCA	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-6.93	1.43e-11	3.91e-09	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
THCA	cis	rs6479891	1	rs4746149	ENSG00000232075.1	MRPL35P2	-6.93	1.43e-11	3.91e-09	-0.53	-0.3	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63634317~63634827:-
THCA	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	6.93	1.43e-11	3.91e-09	0.31	0.3	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	6.93	1.43e-11	3.91e-09	0.33	0.3	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
THCA	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-6.93	1.43e-11	3.91e-09	-0.3	-0.3	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
THCA	cis	rs453301	0.624	rs7014430	ENSG00000253893.2	FAM85B	-6.93	1.43e-11	3.91e-09	-0.39	-0.3	Joint mobility (Beighton score);	chr8:8970227	chr8:8167819~8226614:-
THCA	cis	rs17695224	0.675	rs56177367	ENSG00000269483.1	AC006272.1	6.93	1.43e-11	3.92e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51835343	chr19:51839924~51843324:-
THCA	cis	rs3806843	0.75	rs2563285	ENSG00000202515.1	VTRNA1-3	6.93	1.43e-11	3.92e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140746552	chr5:140726158~140726246:+
THCA	cis	rs8030379	0.967	rs8028359	ENSG00000230373.7	GOLGA6L5P	-6.93	1.43e-11	3.92e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906593	chr15:84507885~84516814:-
THCA	cis	rs17684571	0.938	rs13192037	ENSG00000231441.1	RP11-472M19.2	6.93	1.43e-11	3.92e-09	0.39	0.3	Schizophrenia;	chr6:56689474	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.938	rs62412528	ENSG00000231441.1	RP11-472M19.2	6.93	1.43e-11	3.92e-09	0.39	0.3	Schizophrenia;	chr6:56693587	chr6:56844002~56864078:+
THCA	cis	rs6723108	0.604	rs2322251	ENSG00000224043.6	CCNT2-AS1	-6.93	1.44e-11	3.93e-09	-0.32	-0.3	Type 2 diabetes;	chr2:134913732	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.603	rs62168891	ENSG00000224043.6	CCNT2-AS1	-6.93	1.44e-11	3.93e-09	-0.32	-0.3	Type 2 diabetes;	chr2:134914617	chr2:134735464~134918710:-
THCA	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-6.93	1.44e-11	3.93e-09	-0.6	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
THCA	cis	rs202072	0.729	rs202038	ENSG00000272379.1	RP1-257A7.5	-6.93	1.44e-11	3.94e-09	-0.49	-0.3	HIV-1 viral setpoint;	chr6:13288416	chr6:13290018~13290490:-
THCA	cis	rs9402743	0.635	rs9373135	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135611101	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs2143681	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135611867	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.564	rs9376113	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135612254	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs6934482	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135612363	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs9402724	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135614046	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.564	rs2327649	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135615097	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs6925684	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135615740	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs6905536	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135615865	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs6905555	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135615894	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.671	rs9402725	ENSG00000231028.7	LINC00271	-6.93	1.44e-11	3.94e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135616509	chr6:135497801~135716055:+
THCA	cis	rs11668609	0.938	rs8110507	ENSG00000268442.1	CTD-2027I19.2	6.93	1.44e-11	3.94e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24099470	chr19:24162370~24163425:-
THCA	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	6.92	1.44e-11	3.94e-09	0.31	0.3	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
THCA	cis	rs748404	0.69	rs2467737	ENSG00000166763.7	STRCP1	6.92	1.44e-11	3.94e-09	0.32	0.3	Lung cancer;	chr15:43444990	chr15:43699488~43718184:-
THCA	cis	rs713477	1	rs4901562	ENSG00000258413.1	RP11-665C16.6	6.92	1.44e-11	3.94e-09	0.4	0.3	Pediatric bone mineral content (femoral neck);	chr14:55434655	chr14:55262767~55272075:-
THCA	cis	rs9816784	0.901	rs12490036	ENSG00000231464.1	AC024937.4	-6.92	1.44e-11	3.94e-09	-0.35	-0.3	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195996738~195998233:+
THCA	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-6.92	1.44e-11	3.94e-09	-0.55	-0.3	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
THCA	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-6.92	1.44e-11	3.95e-09	-0.45	-0.3	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
THCA	cis	rs875971	0.862	rs880166	ENSG00000232559.3	GS1-124K5.12	-6.92	1.44e-11	3.95e-09	-0.29	-0.3	Aortic root size;	chr7:66205775	chr7:66554588~66576923:-
THCA	cis	rs9402743	0.634	rs6570018	ENSG00000231028.7	LINC00271	-6.92	1.44e-11	3.95e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135602218	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.634	rs9494294	ENSG00000231028.7	LINC00271	-6.92	1.44e-11	3.95e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135603460	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.634	rs66513771	ENSG00000231028.7	LINC00271	-6.92	1.44e-11	3.95e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135603885	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.634	rs7774974	ENSG00000231028.7	LINC00271	-6.92	1.44e-11	3.95e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135604248	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.538	rs6570019	ENSG00000231028.7	LINC00271	-6.92	1.44e-11	3.95e-09	-0.24	-0.3	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135604595	chr6:135497801~135716055:+
THCA	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	6.92	1.44e-11	3.95e-09	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
THCA	cis	rs34787248	1	rs34787248	ENSG00000280107.1	AL022393.9	-6.92	1.44e-11	3.95e-09	-0.39	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28170845~28172521:+
THCA	cis	rs6504622	0.875	rs4968250	ENSG00000262879.4	RP11-156P1.3	6.92	1.44e-11	3.95e-09	0.28	0.3	Orofacial clefts;	chr17:46967985	chr17:46984045~47100323:-
THCA	cis	rs7942368	0.941	rs11236936	ENSG00000254632.1	RP11-21L23.4	6.92	1.44e-11	3.95e-09	0.44	0.3	Endometriosis;	chr11:76789786	chr11:76759916~76768223:-
THCA	cis	rs5742933	0.857	rs1437891	ENSG00000273240.1	RP11-455J20.3	-6.92	1.44e-11	3.95e-09	-0.32	-0.3	Ferritin levels;	chr2:189697982	chr2:189763859~189764456:-
THCA	cis	rs7811142	1	rs67471932	ENSG00000078319.8	PMS2P1	-6.92	1.45e-11	3.96e-09	-0.43	-0.3	Platelet count;	chr7:100412362	chr7:100320992~100341908:-
THCA	cis	rs6840258	1	rs10516788	ENSG00000251411.1	RP11-397E7.4	-6.92	1.45e-11	3.96e-09	-0.37	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87039705	chr4:86913266~86914817:-
THCA	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-6.92	1.45e-11	3.97e-09	-0.38	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
THCA	cis	rs2439831	1	rs1814538	ENSG00000249839.1	AC011330.5	6.92	1.45e-11	3.97e-09	0.44	0.3	Lung cancer in ever smokers;	chr15:43467576	chr15:43663654~43684339:-
THCA	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	6.92	1.45e-11	3.97e-09	0.34	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
THCA	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	6.92	1.45e-11	3.97e-09	0.34	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
THCA	cis	rs7267979	1	rs2482930	ENSG00000274414.1	RP5-965G21.4	6.92	1.45e-11	3.98e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2500446	ENSG00000274414.1	RP5-965G21.4	6.92	1.45e-11	3.98e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2482937	ENSG00000274414.1	RP5-965G21.4	6.92	1.45e-11	3.98e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25239007~25245229:-
THCA	cis	rs12348691	0.503	rs894672	ENSG00000236130.1	PTCSC2	-6.92	1.45e-11	3.98e-09	-0.25	-0.3	Alopecia areata;	chr9:97849903	chr9:97805935~97810008:-
THCA	cis	rs12348691	0.503	rs7849497	ENSG00000236130.1	PTCSC2	-6.92	1.45e-11	3.98e-09	-0.25	-0.3	Alopecia areata;	chr9:97853378	chr9:97805935~97810008:-
THCA	cis	rs12348691	0.503	rs1867279	ENSG00000236130.1	PTCSC2	-6.92	1.45e-11	3.98e-09	-0.25	-0.3	Alopecia areata;	chr9:97853759	chr9:97805935~97810008:-
THCA	cis	rs12348691	0.503	rs3021523	ENSG00000236130.1	PTCSC2	-6.92	1.45e-11	3.98e-09	-0.25	-0.3	Alopecia areata;	chr9:97854301	chr9:97805935~97810008:-
THCA	cis	rs12348691	0.503	rs7046645	ENSG00000236130.1	PTCSC2	-6.92	1.45e-11	3.98e-09	-0.25	-0.3	Alopecia areata;	chr9:97855093	chr9:97805935~97810008:-
THCA	cis	rs56804039	0.524	rs11783173	ENSG00000253893.2	FAM85B	6.92	1.46e-11	3.98e-09	0.5	0.3	Cervical cancer;	chr8:8505200	chr8:8167819~8226614:-
THCA	cis	rs9341808	0.718	rs2322630	ENSG00000272129.1	RP11-250B2.6	6.92	1.46e-11	3.99e-09	0.38	0.3	Sitting height ratio;	chr6:80131316	chr6:80355424~80356859:+
THCA	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	6.92	1.46e-11	3.99e-09	0.34	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
THCA	cis	rs944289	0.553	rs1169134	ENSG00000257826.1	RP11-116N8.4	-6.92	1.46e-11	3.99e-09	-0.35	-0.3	Thyroid cancer;	chr14:36155514	chr14:36061026~36067190:-
THCA	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-6.92	1.46e-11	3.99e-09	-0.28	-0.3	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
THCA	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	6.92	1.46e-11	4e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
THCA	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-6.92	1.46e-11	4e-09	-0.35	-0.3	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
THCA	cis	rs2439831	0.717	rs2447198	ENSG00000275601.1	AC011330.13	-6.92	1.46e-11	4.01e-09	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43602920	chr15:43642389~43643023:-
THCA	cis	rs72843506	0.586	rs74433421	ENSG00000270091.1	RP11-78O7.2	-6.92	1.47e-11	4.01e-09	-0.35	-0.3	Schizophrenia;	chr17:19914774	chr17:19896590~19897287:-
THCA	cis	rs9902453	0.904	rs9905638	ENSG00000264007.1	RP11-68I3.10	6.92	1.47e-11	4.01e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29934004	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.874	rs62070271	ENSG00000264007.1	RP11-68I3.10	6.92	1.47e-11	4.01e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29941340	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs9894893	ENSG00000264007.1	RP11-68I3.10	6.92	1.47e-11	4.01e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29943332	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.935	rs9909093	ENSG00000264007.1	RP11-68I3.10	6.92	1.47e-11	4.01e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29944189	chr17:29621617~29622254:-
THCA	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-6.92	1.47e-11	4.01e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-6.92	1.47e-11	4.01e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-6.92	1.47e-11	4.01e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-6.92	1.47e-11	4.01e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
THCA	cis	rs9876781	0.559	rs11130167	ENSG00000229759.1	MRPS18AP1	6.92	1.47e-11	4.02e-09	0.37	0.3	Longevity;	chr3:48358570	chr3:48256350~48256938:-
THCA	cis	rs9876781	0.559	rs13073692	ENSG00000229759.1	MRPS18AP1	6.92	1.47e-11	4.02e-09	0.37	0.3	Longevity;	chr3:48361812	chr3:48256350~48256938:-
THCA	cis	rs9876781	0.559	rs7611415	ENSG00000229759.1	MRPS18AP1	6.92	1.47e-11	4.02e-09	0.37	0.3	Longevity;	chr3:48363659	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs9846818	ENSG00000228638.1	FCF1P2	-6.92	1.47e-11	4.02e-09	-0.29	-0.3	Coronary artery disease;	chr3:48334195	chr3:48290793~48291375:-
THCA	cis	rs875971	0.862	rs10276077	ENSG00000232559.3	GS1-124K5.12	-6.92	1.47e-11	4.03e-09	-0.29	-0.3	Aortic root size;	chr7:66263424	chr7:66554588~66576923:-
THCA	cis	rs875971	0.928	rs2036263	ENSG00000232559.3	GS1-124K5.12	-6.92	1.47e-11	4.03e-09	-0.29	-0.3	Aortic root size;	chr7:66335210	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs10240949	ENSG00000232559.3	GS1-124K5.12	-6.92	1.47e-11	4.03e-09	-0.29	-0.3	Aortic root size;	chr7:66339430	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs7782704	ENSG00000232559.3	GS1-124K5.12	-6.92	1.47e-11	4.03e-09	-0.29	-0.3	Aortic root size;	chr7:66340379	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6959268	ENSG00000232559.3	GS1-124K5.12	-6.92	1.47e-11	4.03e-09	-0.29	-0.3	Aortic root size;	chr7:66347979	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs12537823	ENSG00000232559.3	GS1-124K5.12	6.92	1.47e-11	4.03e-09	0.29	0.3	Aortic root size;	chr7:66255897	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs778686	ENSG00000232559.3	GS1-124K5.12	6.92	1.47e-11	4.03e-09	0.29	0.3	Aortic root size;	chr7:66370923	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.573	rs73267873	ENSG00000264538.5	SUZ12P1	-6.92	1.48e-11	4.04e-09	-0.29	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.561	rs4085382	ENSG00000264538.5	SUZ12P1	-6.92	1.48e-11	4.04e-09	-0.29	-0.3	Body mass index;	chr17:30744184	chr17:30709299~30790908:+
THCA	cis	rs875971	0.798	rs12698522	ENSG00000232559.3	GS1-124K5.12	6.92	1.48e-11	4.04e-09	0.29	0.3	Aortic root size;	chr7:66502354	chr7:66554588~66576923:-
THCA	cis	rs875971	0.83	rs28714531	ENSG00000232559.3	GS1-124K5.12	6.92	1.48e-11	4.04e-09	0.29	0.3	Aortic root size;	chr7:66503250	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs12698526	ENSG00000232559.3	GS1-124K5.12	6.92	1.48e-11	4.04e-09	0.29	0.3	Aortic root size;	chr7:66504118	chr7:66554588~66576923:-
THCA	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-6.92	1.48e-11	4.04e-09	-0.31	-0.3	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
THCA	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	6.92	1.48e-11	4.05e-09	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
THCA	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	6.92	1.48e-11	4.06e-09	0.18	0.3	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
THCA	cis	rs9902453	0.78	rs10445384	ENSG00000264007.1	RP11-68I3.10	6.92	1.49e-11	4.06e-09	0.35	0.3	Coffee consumption (cups per day);	chr17:29855667	chr17:29621617~29622254:-
THCA	cis	rs12435908	1	rs17246035	ENSG00000276116.2	FUT8-AS1	-6.92	1.49e-11	4.06e-09	-0.48	-0.3	Ischemic stroke;	chr14:65407412	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs59685862	ENSG00000276116.2	FUT8-AS1	-6.92	1.49e-11	4.06e-09	-0.49	-0.3	Ischemic stroke;	chr14:65613412	chr14:65411170~65412690:-
THCA	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-6.92	1.49e-11	4.06e-09	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
THCA	cis	rs853679	0.517	rs9283884	ENSG00000220721.1	OR1F12	-6.92	1.49e-11	4.07e-09	-0.42	-0.3	Depression;	chr6:28167882	chr6:28073316~28074233:+
THCA	cis	rs73186030	0.764	rs34408666	ENSG00000272758.4	RP11-299J3.8	6.92	1.49e-11	4.08e-09	0.4	0.3	Serum parathyroid hormone levels;	chr3:122262762	chr3:122416207~122443180:+
THCA	cis	rs8030379	1	rs4842924	ENSG00000230373.7	GOLGA6L5P	6.92	1.5e-11	4.09e-09	0.28	0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84507885~84516814:-
THCA	cis	rs160451	1	rs160448	ENSG00000251136.7	RP11-37B2.1	6.92	1.5e-11	4.1e-09	0.26	0.3	Leprosy;	chr8:89647622	chr8:89609409~89757727:-
THCA	cis	rs2412819	0.571	rs4923965	ENSG00000205771.5	CATSPER2P1	6.92	1.5e-11	4.1e-09	0.39	0.3	Lung cancer;	chr15:43790232	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.571	rs4644832	ENSG00000205771.5	CATSPER2P1	6.92	1.5e-11	4.1e-09	0.39	0.3	Lung cancer;	chr15:43792507	chr15:43726918~43747094:-
THCA	cis	rs732716	0.813	rs760369	ENSG00000267980.1	AC007292.6	6.92	1.5e-11	4.1e-09	0.34	0.3	Mean corpuscular volume;	chr19:4449290	chr19:4363789~4364640:+
THCA	cis	rs17684571	0.938	rs16888124	ENSG00000231441.1	RP11-472M19.2	6.92	1.5e-11	4.1e-09	0.36	0.3	Schizophrenia;	chr6:56700826	chr6:56844002~56864078:+
THCA	cis	rs832187	0.704	rs3774720	ENSG00000280620.1	SCAANT1	6.92	1.5e-11	4.1e-09	0.41	0.3	Schizophrenia;	chr3:63966089	chr3:63911518~63911772:-
THCA	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-6.92	1.5e-11	4.1e-09	-0.31	-0.3	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
THCA	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	6.92	1.5e-11	4.1e-09	0.31	0.3	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
THCA	cis	rs12819124	0.502	rs10875718	ENSG00000258273.1	RP11-370I10.4	-6.92	1.5e-11	4.11e-09	-0.4	-0.3	Glycated hemoglobin levels;	chr12:48017319	chr12:48333755~48333901:-
THCA	cis	rs875971	0.861	rs801215	ENSG00000232559.3	GS1-124K5.12	-6.92	1.5e-11	4.11e-09	-0.29	-0.3	Aortic root size;	chr7:66546951	chr7:66554588~66576923:-
THCA	cis	rs4950322	0.58	rs2014106	ENSG00000237188.3	RP11-337C18.8	6.92	1.5e-11	4.11e-09	0.37	0.3	Protein quantitative trait loci;	chr1:147118499	chr1:147172771~147211568:+
THCA	cis	rs848490	0.928	rs62460675	ENSG00000214293.7	APTR	6.92	1.51e-11	4.11e-09	0.24	0.3	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678027	chr7:77657660~77696265:-
THCA	cis	rs7189233	1	rs62048543	ENSG00000279344.1	RP11-44F14.7	6.92	1.51e-11	4.11e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr16:53500712	chr16:53478957~53481550:-
THCA	cis	rs728616	0.764	rs11201025	ENSG00000225484.5	NUTM2B-AS1	-6.92	1.51e-11	4.12e-09	-0.46	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79663088~79826594:-
THCA	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-6.92	1.51e-11	4.12e-09	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
THCA	cis	rs17695224	0.611	rs10420568	ENSG00000269483.1	AC006272.1	6.92	1.51e-11	4.12e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51835662	chr19:51839924~51843324:-
THCA	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	6.92	1.51e-11	4.13e-09	0.46	0.3	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
THCA	cis	rs7583236	0.5	rs6728352	ENSG00000179818.12	PCBP1-AS1	-6.92	1.51e-11	4.13e-09	-0.37	-0.3	Obesity-related traits;	chr2:70116300	chr2:69962263~70103220:-
THCA	cis	rs8177876	0.658	rs77874075	ENSG00000261061.1	RP11-303E16.2	-6.92	1.51e-11	4.14e-09	-0.44	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81030770~81031485:+
THCA	cis	rs910316	0.789	rs4899552	ENSG00000279594.1	RP11-950C14.10	-6.92	1.52e-11	4.14e-09	-0.28	-0.3	Height;	chr14:75201218	chr14:75011269~75012851:-
THCA	cis	rs12928939	0.862	rs7197104	ENSG00000260886.1	TAT-AS1	6.92	1.52e-11	4.16e-09	0.41	0.3	Post bronchodilator FEV1;	chr16:71760158	chr16:71565789~71578187:+
THCA	cis	rs7727544	0.678	rs7735891	ENSG00000233006.5	AC034220.3	6.92	1.52e-11	4.16e-09	0.24	0.3	Blood metabolite levels;	chr5:132261312	chr5:132311285~132369916:-
THCA	cis	rs6921919	0.673	rs13201681	ENSG00000280107.1	AL022393.9	-6.92	1.53e-11	4.16e-09	-0.6	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.778	rs67381177	ENSG00000280107.1	AL022393.9	-6.92	1.53e-11	4.16e-09	-0.6	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28170845~28172521:+
THCA	cis	rs9926296	0.568	rs1230	ENSG00000260259.1	RP11-368I7.4	6.92	1.53e-11	4.17e-09	0.33	0.3	Vitiligo;	chr16:89738447	chr16:89682620~89686569:-
THCA	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-6.92	1.53e-11	4.18e-09	-0.44	-0.3	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
THCA	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	6.92	1.53e-11	4.18e-09	0.26	0.3	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
THCA	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-6.92	1.53e-11	4.18e-09	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
THCA	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-6.92	1.53e-11	4.18e-09	-0.33	-0.3	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
THCA	cis	rs8067545	0.641	rs1638525	ENSG00000270091.1	RP11-78O7.2	-6.92	1.53e-11	4.18e-09	-0.23	-0.3	Schizophrenia;	chr17:19945281	chr17:19896590~19897287:-
THCA	cis	rs1005277	0.505	rs7069702	ENSG00000263064.2	RP11-291L22.7	-6.92	1.53e-11	4.18e-09	-0.34	-0.3	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38448689~38448949:+
THCA	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-6.91	1.54e-11	4.19e-09	-0.39	-0.3	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
THCA	cis	rs7608910	0.578	rs2698193	ENSG00000271889.1	RP11-493E12.1	6.91	1.54e-11	4.19e-09	0.3	0.3	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:61003879	chr2:61151433~61162105:-
THCA	cis	rs2976388	1	rs2585179	ENSG00000253741.1	CTD-2292P10.4	6.91	1.54e-11	4.19e-09	0.38	0.3	Urinary tract infection frequency;	chr8:142692775	chr8:142702252~142726973:-
THCA	cis	rs7044106	0.762	rs1158554	ENSG00000238181.2	AHCYP2	-6.91	1.54e-11	4.19e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120720673~120721972:+
THCA	cis	rs1501911	0.509	rs34487	ENSG00000246763.5	RGMB-AS1	6.91	1.54e-11	4.2e-09	0.29	0.3	Lung function (FEV1/FVC);	chr5:98872725	chr5:98769618~98773469:-
THCA	cis	rs8067545	0.641	rs203455	ENSG00000270091.1	RP11-78O7.2	-6.91	1.54e-11	4.21e-09	-0.22	-0.3	Schizophrenia;	chr17:19917872	chr17:19896590~19897287:-
THCA	cis	rs860295	0.775	rs729022	ENSG00000225855.5	RUSC1-AS1	-6.91	1.54e-11	4.21e-09	-0.2	-0.3	Body mass index;	chr1:155882332	chr1:155316863~155324176:-
THCA	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-6.91	1.54e-11	4.21e-09	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
THCA	cis	rs667920	0.5	rs34498968	ENSG00000239213.4	NCK1-AS1	-6.91	1.54e-11	4.21e-09	-0.41	-0.3	Coronary artery disease;	chr3:136476288	chr3:136841726~136862054:-
THCA	cis	rs9467773	0.587	rs3208733	ENSG00000124549.13	BTN2A3P	-6.91	1.55e-11	4.22e-09	-0.29	-0.3	Intelligence (multi-trait analysis);	chr6:26414197	chr6:26421391~26432383:+
THCA	cis	rs853679	0.76	rs9393910	ENSG00000280107.1	AL022393.9	-6.91	1.55e-11	4.22e-09	-0.38	-0.3	Depression;	chr6:28240414	chr6:28170845~28172521:+
THCA	cis	rs853679	0.76	rs9368563	ENSG00000280107.1	AL022393.9	-6.91	1.55e-11	4.22e-09	-0.38	-0.3	Depression;	chr6:28240780	chr6:28170845~28172521:+
THCA	cis	rs853679	0.76	rs9295768	ENSG00000280107.1	AL022393.9	-6.91	1.55e-11	4.22e-09	-0.38	-0.3	Depression;	chr6:28241324	chr6:28170845~28172521:+
THCA	cis	rs1005277	0.505	rs13503	ENSG00000263064.2	RP11-291L22.7	-6.91	1.55e-11	4.23e-09	-0.34	-0.3	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38448689~38448949:+
THCA	cis	rs453301	0.571	rs330057	ENSG00000254153.1	CTA-398F10.2	6.91	1.55e-11	4.23e-09	0.32	0.3	Joint mobility (Beighton score);	chr8:9232283	chr8:8456909~8461337:-
THCA	cis	rs1395	0.71	rs1992291	ENSG00000234072.1	AC074117.10	-6.91	1.55e-11	4.24e-09	-0.27	-0.3	Blood metabolite levels;	chr2:27281444	chr2:27356246~27367622:+
THCA	cis	rs7267979	0.932	rs6037125	ENSG00000274414.1	RP5-965G21.4	-6.91	1.55e-11	4.24e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25239007~25245229:-
THCA	cis	rs12701220	0.69	rs10243973	ENSG00000229043.2	AC091729.9	-6.91	1.55e-11	4.24e-09	-0.4	-0.3	Bronchopulmonary dysplasia;	chr7:1025347	chr7:1160374~1165267:+
THCA	cis	rs7727544	0.716	rs72793283	ENSG00000233006.5	AC034220.3	6.91	1.55e-11	4.24e-09	0.24	0.3	Blood metabolite levels;	chr5:132231248	chr5:132311285~132369916:-
THCA	cis	rs9467773	0.649	rs2145318	ENSG00000124549.13	BTN2A3P	6.91	1.56e-11	4.24e-09	0.29	0.3	Intelligence (multi-trait analysis);	chr6:26496375	chr6:26421391~26432383:+
THCA	cis	rs792448	0.717	rs7544225	ENSG00000226251.4	RP11-15I11.3	6.91	1.56e-11	4.25e-09	0.38	0.3	White blood cell count (basophil);	chr1:212235666	chr1:212225278~212238977:-
THCA	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-6.91	1.56e-11	4.25e-09	-0.35	-0.3	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
THCA	cis	rs8081395	0.627	rs12952730	ENSG00000266992.1	DHX40P1	6.91	1.56e-11	4.25e-09	0.36	0.3	White blood cell count;	chr17:59901475	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.627	rs180536	ENSG00000266992.1	DHX40P1	6.91	1.56e-11	4.25e-09	0.36	0.3	White blood cell count;	chr17:59919445	chr17:59976009~60002384:-
THCA	cis	rs875971	0.862	rs10224872	ENSG00000232559.3	GS1-124K5.12	-6.91	1.56e-11	4.26e-09	-0.29	-0.3	Aortic root size;	chr7:66294786	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs949930	ENSG00000232559.3	GS1-124K5.12	-6.91	1.56e-11	4.26e-09	-0.29	-0.3	Aortic root size;	chr7:66301835	chr7:66554588~66576923:-
THCA	cis	rs13113518	0.812	rs12648271	ENSG00000273257.1	RP11-177J6.1	6.91	1.56e-11	4.26e-09	0.43	0.3	Height;	chr4:55501955	chr4:55387949~55388271:+
THCA	cis	rs9287719	0.649	rs6722126	ENSG00000243819.4	RN7SL832P	6.91	1.56e-11	4.26e-09	0.25	0.3	Prostate cancer;	chr2:10581516	chr2:10690344~10692099:+
THCA	cis	rs4950322	0.857	rs72693002	ENSG00000237188.3	RP11-337C18.8	6.91	1.56e-11	4.26e-09	0.38	0.3	Protein quantitative trait loci;	chr1:147357593	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.857	rs72694703	ENSG00000237188.3	RP11-337C18.8	6.91	1.56e-11	4.26e-09	0.38	0.3	Protein quantitative trait loci;	chr1:147358427	chr1:147172771~147211568:+
THCA	cis	rs7044106	0.791	rs4617229	ENSG00000238181.2	AHCYP2	-6.91	1.56e-11	4.26e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120720673~120721972:+
THCA	cis	rs6600671	0.934	rs12060031	ENSG00000275538.1	RNVU1-19	-6.91	1.57e-11	4.27e-09	-0.39	-0.3	Hip geometry;	chr1:121501652	chr1:120850819~120850985:-
THCA	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-6.91	1.57e-11	4.27e-09	-0.3	-0.3	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
THCA	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	6.91	1.57e-11	4.27e-09	0.26	0.3	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
THCA	cis	rs1005277	0.505	rs10827836	ENSG00000263064.2	RP11-291L22.7	-6.91	1.57e-11	4.28e-09	-0.34	-0.3	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38448689~38448949:+
THCA	cis	rs12435908	1	rs884247	ENSG00000276116.2	FUT8-AS1	-6.91	1.57e-11	4.28e-09	-0.48	-0.3	Ischemic stroke;	chr14:65428988	chr14:65411170~65412690:-
THCA	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	6.91	1.57e-11	4.28e-09	0.25	0.3	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
THCA	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	6.91	1.57e-11	4.28e-09	0.24	0.3	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
THCA	cis	rs8067545	0.641	rs203458	ENSG00000270091.1	RP11-78O7.2	-6.91	1.57e-11	4.28e-09	-0.22	-0.3	Schizophrenia;	chr17:19913585	chr17:19896590~19897287:-
THCA	cis	rs748404	0.66	rs2467742	ENSG00000166763.7	STRCP1	6.91	1.57e-11	4.29e-09	0.32	0.3	Lung cancer;	chr15:43458039	chr15:43699488~43718184:-
THCA	cis	rs748404	0.69	rs2244981	ENSG00000166763.7	STRCP1	6.91	1.57e-11	4.29e-09	0.32	0.3	Lung cancer;	chr15:43460553	chr15:43699488~43718184:-
THCA	cis	rs8062405	0.755	rs1074631	ENSG00000278665.1	RP11-666O2.4	-6.91	1.57e-11	4.29e-09	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28599241~28601881:-
THCA	cis	rs4938303	0.671	rs2008915	ENSG00000254851.1	RP11-109L13.1	-6.91	1.58e-11	4.29e-09	-0.48	-0.3	Triglycerides;	chr11:116732418	chr11:117135528~117138582:+
THCA	cis	rs875971	0.767	rs12668005	ENSG00000232559.3	GS1-124K5.12	6.91	1.58e-11	4.3e-09	0.29	0.3	Aortic root size;	chr7:66444034	chr7:66554588~66576923:-
THCA	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	6.91	1.58e-11	4.31e-09	0.38	0.3	Height;	chr6:109469907	chr6:109382795~109383666:+
THCA	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-6.91	1.58e-11	4.31e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-6.91	1.58e-11	4.31e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-6.91	1.58e-11	4.31e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-6.91	1.58e-11	4.31e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
THCA	cis	rs8062405	0.69	rs62034351	ENSG00000278665.1	RP11-666O2.4	6.91	1.58e-11	4.31e-09	0.36	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28599241~28601881:-
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	6.91	1.58e-11	4.32e-09	0.32	0.3	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
THCA	cis	rs4713118	0.588	rs200994	ENSG00000280107.1	AL022393.9	6.91	1.59e-11	4.32e-09	0.36	0.3	Parkinson's disease;	chr6:27846035	chr6:28170845~28172521:+
THCA	cis	rs11722228	0.508	rs3796826	ENSG00000261490.1	RP11-448G15.3	6.91	1.59e-11	4.33e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10091104	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.508	rs3796825	ENSG00000261490.1	RP11-448G15.3	6.91	1.59e-11	4.33e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10091255	chr4:10068089~10073019:-
THCA	cis	rs736801	0.607	rs11739135	ENSG00000233006.5	AC034220.3	6.91	1.59e-11	4.33e-09	0.25	0.3	Mosquito bite size;Breast cancer;	chr5:132397705	chr5:132311285~132369916:-
THCA	cis	rs9902453	0.578	rs8073217	ENSG00000264007.1	RP11-68I3.10	6.91	1.59e-11	4.33e-09	0.35	0.3	Coffee consumption (cups per day);	chr17:29837245	chr17:29621617~29622254:-
THCA	cis	rs7044106	0.791	rs10985000	ENSG00000238181.2	AHCYP2	-6.91	1.59e-11	4.33e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120720673~120721972:+
THCA	cis	rs7044106	0.791	rs10985001	ENSG00000238181.2	AHCYP2	-6.91	1.59e-11	4.33e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120720673~120721972:+
THCA	cis	rs875971	0.862	rs13232191	ENSG00000232559.3	GS1-124K5.12	6.91	1.59e-11	4.33e-09	0.29	0.3	Aortic root size;	chr7:66521661	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs10950043	ENSG00000232559.3	GS1-124K5.12	6.91	1.59e-11	4.33e-09	0.29	0.3	Aortic root size;	chr7:66523623	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs17747530	ENSG00000232559.3	GS1-124K5.12	6.91	1.59e-11	4.33e-09	0.29	0.3	Aortic root size;	chr7:66529742	chr7:66554588~66576923:-
THCA	cis	rs875971	0.767	rs61348003	ENSG00000232559.3	GS1-124K5.12	6.91	1.59e-11	4.33e-09	0.29	0.3	Aortic root size;	chr7:66540947	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs13536	ENSG00000232559.3	GS1-124K5.12	-6.91	1.59e-11	4.33e-09	-0.29	-0.3	Aortic root size;	chr7:66554203	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs801209	ENSG00000232559.3	GS1-124K5.12	-6.91	1.59e-11	4.33e-09	-0.29	-0.3	Aortic root size;	chr7:66554403	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs801206	ENSG00000232559.3	GS1-124K5.12	-6.91	1.59e-11	4.33e-09	-0.29	-0.3	Aortic root size;	chr7:66556979	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs801204	ENSG00000232559.3	GS1-124K5.12	-6.91	1.59e-11	4.33e-09	-0.29	-0.3	Aortic root size;	chr7:66557934	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs801203	ENSG00000232559.3	GS1-124K5.12	-6.91	1.59e-11	4.33e-09	-0.29	-0.3	Aortic root size;	chr7:66558025	chr7:66554588~66576923:-
THCA	cis	rs875971	0.825	rs801202	ENSG00000232559.3	GS1-124K5.12	-6.91	1.59e-11	4.33e-09	-0.29	-0.3	Aortic root size;	chr7:66558942	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs801195	ENSG00000232559.3	GS1-124K5.12	-6.91	1.59e-11	4.33e-09	-0.29	-0.3	Aortic root size;	chr7:66561128	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs801194	ENSG00000232559.3	GS1-124K5.12	-6.91	1.59e-11	4.33e-09	-0.29	-0.3	Aortic root size;	chr7:66563508	chr7:66554588~66576923:-
THCA	cis	rs7119038	0.686	rs55894437	ENSG00000255239.1	AP002954.6	-6.91	1.59e-11	4.33e-09	-0.43	-0.3	Sjögren's syndrome;	chr11:118736708	chr11:118688039~118690600:-
THCA	cis	rs6672530	0.518	rs2018654	ENSG00000227711.2	RP11-275O4.5	6.91	1.59e-11	4.33e-09	0.32	0.3	Hip circumference adjusted for BMI;	chr1:227508332	chr1:227509028~227520477:-
THCA	cis	rs7727544	0.631	rs13357280	ENSG00000233006.5	AC034220.3	6.91	1.59e-11	4.34e-09	0.24	0.3	Blood metabolite levels;	chr5:132264494	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.594	rs10479000	ENSG00000233006.5	AC034220.3	6.91	1.59e-11	4.34e-09	0.24	0.3	Blood metabolite levels;	chr5:132271709	chr5:132311285~132369916:-
THCA	cis	rs6540731	1	rs6540731	ENSG00000226251.4	RP11-15I11.3	6.91	1.6e-11	4.34e-09	0.37	0.3	Intelligence (childhood);	chr1:212218821	chr1:212225278~212238977:-
THCA	cis	rs7923837	0.687	rs1977833	ENSG00000236493.2	EIF2S2P3	6.91	1.6e-11	4.34e-09	0.31	0.3	Multiple sclerosis;Body mass index;	chr10:92704188	chr10:92668745~92669743:-
THCA	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	6.91	1.6e-11	4.34e-09	0.18	0.3	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000206090.4	AP000350.7	-6.91	1.6e-11	4.35e-09	-0.41	-0.3	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23939998~23942798:+
THCA	cis	rs9393777	0.844	rs72839477	ENSG00000280107.1	AL022393.9	-6.91	1.6e-11	4.35e-09	-0.62	-0.3	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28170845~28172521:+
THCA	cis	rs4950322	0.57	rs72691012	ENSG00000237188.3	RP11-337C18.8	6.91	1.6e-11	4.35e-09	0.37	0.3	Protein quantitative trait loci;	chr1:147239751	chr1:147172771~147211568:+
THCA	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	6.91	1.6e-11	4.35e-09	0.35	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
THCA	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	6.91	1.6e-11	4.35e-09	0.18	0.3	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
THCA	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	6.91	1.6e-11	4.35e-09	0.18	0.3	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
THCA	cis	rs7044106	0.648	rs2031369	ENSG00000238181.2	AHCYP2	-6.91	1.6e-11	4.36e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120720673~120721972:+
THCA	cis	rs2976388	0.507	rs2572874	ENSG00000253741.1	CTD-2292P10.4	-6.91	1.6e-11	4.36e-09	-0.39	-0.3	Urinary tract infection frequency;	chr8:142755801	chr8:142702252~142726973:-
THCA	cis	rs9393777	0.777	rs56114371	ENSG00000280107.1	AL022393.9	-6.91	1.6e-11	4.36e-09	-0.6	-0.3	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28170845~28172521:+
THCA	cis	rs2880765	0.743	rs7168345	ENSG00000259295.5	CSPG4P12	-6.91	1.6e-11	4.36e-09	-0.38	-0.3	Coronary artery disease;	chr15:85470370	chr15:85191438~85213905:+
THCA	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-6.91	1.6e-11	4.37e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-6.91	1.6e-11	4.37e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-6.91	1.6e-11	4.37e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-6.91	1.6e-11	4.37e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-6.91	1.6e-11	4.37e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-6.91	1.6e-11	4.37e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-6.91	1.6e-11	4.37e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
THCA	cis	rs2839186	0.596	rs4819217	ENSG00000239415.1	AP001469.9	6.91	1.61e-11	4.37e-09	0.32	0.3	Testicular germ cell tumor;	chr21:46224178	chr21:46251549~46254133:-
THCA	cis	rs6569038	0.557	rs9387629	ENSG00000253194.1	RP11-351A11.1	6.91	1.61e-11	4.37e-09	0.42	0.3	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119035036	chr6:118934785~119031541:+
THCA	cis	rs11168351	0.75	rs11168366	ENSG00000258273.1	RP11-370I10.4	6.91	1.61e-11	4.37e-09	0.42	0.3	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48333755~48333901:-
THCA	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-6.91	1.61e-11	4.37e-09	-0.37	-0.3	Height;	chr6:109405874	chr6:109382795~109383666:+
THCA	cis	rs172166	0.694	rs1631552	ENSG00000280107.1	AL022393.9	-6.91	1.61e-11	4.39e-09	-0.33	-0.3	Cardiac Troponin-T levels;	chr6:28121921	chr6:28170845~28172521:+
THCA	cis	rs7260598	0.685	rs73524177	ENSG00000268442.1	CTD-2027I19.2	6.91	1.61e-11	4.39e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24156376	chr19:24162370~24163425:-
THCA	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	6.91	1.61e-11	4.39e-09	0.37	0.3	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
THCA	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	6.91	1.62e-11	4.39e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
THCA	cis	rs875971	0.862	rs11773628	ENSG00000232559.3	GS1-124K5.12	-6.91	1.62e-11	4.39e-09	-0.29	-0.3	Aortic root size;	chr7:66517644	chr7:66554588~66576923:-
THCA	cis	rs934734	0.699	rs268138	ENSG00000204929.10	AC074391.1	-6.91	1.62e-11	4.39e-09	-0.38	-0.3	Rheumatoid arthritis;	chr2:65380160	chr2:65436711~66084639:+
THCA	cis	rs4950322	0.57	rs79810882	ENSG00000237188.3	RP11-337C18.8	6.91	1.62e-11	4.39e-09	0.37	0.3	Protein quantitative trait loci;	chr1:147235575	chr1:147172771~147211568:+
THCA	cis	rs11096990	0.855	rs2566177	ENSG00000249207.1	RP11-360F5.1	6.91	1.62e-11	4.4e-09	0.4	0.3	Cognitive function;	chr4:39154558	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2711934	ENSG00000249207.1	RP11-360F5.1	6.91	1.62e-11	4.4e-09	0.4	0.3	Cognitive function;	chr4:39156254	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2711935	ENSG00000249207.1	RP11-360F5.1	6.91	1.62e-11	4.4e-09	0.4	0.3	Cognitive function;	chr4:39160837	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2566183	ENSG00000249207.1	RP11-360F5.1	6.91	1.62e-11	4.4e-09	0.4	0.3	Cognitive function;	chr4:39162288	chr4:39112677~39126818:-
THCA	cis	rs11722228	0.508	rs2241472	ENSG00000261490.1	RP11-448G15.3	6.91	1.62e-11	4.4e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10084278	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.508	rs3822246	ENSG00000261490.1	RP11-448G15.3	6.91	1.62e-11	4.4e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10093074	chr4:10068089~10073019:-
THCA	cis	rs4664293	0.867	rs13415025	ENSG00000226266.5	AC009961.3	-6.91	1.62e-11	4.4e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159729799	chr2:159670708~159712435:-
THCA	cis	rs42490	0.528	rs1032516	ENSG00000251136.7	RP11-37B2.1	6.91	1.62e-11	4.41e-09	0.26	0.3	Leprosy;	chr8:89670055	chr8:89609409~89757727:-
THCA	cis	rs1426063	1	rs1426063	ENSG00000260265.1	RP11-44F21.5	-6.91	1.62e-11	4.41e-09	-0.53	-0.3	QT interval;	chr4:75105711	chr4:75081702~75084717:-
THCA	cis	rs6840258	1	rs17012234	ENSG00000251411.1	RP11-397E7.4	6.91	1.63e-11	4.42e-09	0.36	0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86990539	chr4:86913266~86914817:-
THCA	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	6.91	1.63e-11	4.42e-09	0.37	0.3	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
THCA	cis	rs12928939	0.911	rs7202840	ENSG00000260886.1	TAT-AS1	6.91	1.63e-11	4.42e-09	0.41	0.3	Post bronchodilator FEV1;	chr16:71790811	chr16:71565789~71578187:+
THCA	cis	rs9287719	0.649	rs10182589	ENSG00000243819.4	RN7SL832P	6.91	1.63e-11	4.43e-09	0.25	0.3	Prostate cancer;	chr2:10580538	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10208103	ENSG00000243819.4	RN7SL832P	6.91	1.63e-11	4.43e-09	0.25	0.3	Prostate cancer;	chr2:10580741	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs12621977	ENSG00000243819.4	RN7SL832P	6.91	1.63e-11	4.43e-09	0.25	0.3	Prostate cancer;	chr2:10581805	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs12617968	ENSG00000243819.4	RN7SL832P	6.91	1.63e-11	4.43e-09	0.25	0.3	Prostate cancer;	chr2:10581819	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.614	rs12622053	ENSG00000243819.4	RN7SL832P	6.91	1.63e-11	4.43e-09	0.25	0.3	Prostate cancer;	chr2:10582014	chr2:10690344~10692099:+
THCA	cis	rs7044106	0.762	rs966396	ENSG00000238181.2	AHCYP2	-6.91	1.63e-11	4.43e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120720673~120721972:+
THCA	cis	rs5006884	0.515	rs9704071	ENSG00000167355.6	AC104389.28	-6.91	1.63e-11	4.43e-09	-0.39	-0.3	Fetal hemoglobin levels;	chr11:5360025	chr11:5304976~5505652:-
THCA	cis	rs7246657	0.943	rs10424574	ENSG00000226686.6	LINC01535	-6.91	1.63e-11	4.44e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37347491	chr19:37251912~37265535:+
THCA	cis	rs8059260	0.736	rs77920180	ENSG00000274038.1	RP11-66H6.4	-6.91	1.63e-11	4.44e-09	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10949041	chr16:11056556~11057034:+
THCA	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	6.91	1.63e-11	4.44e-09	0.35	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
THCA	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	6.9	1.64e-11	4.45e-09	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
THCA	cis	rs7260598	0.792	rs11671960	ENSG00000268442.1	CTD-2027I19.2	6.9	1.64e-11	4.45e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24135019	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs59756985	ENSG00000268442.1	CTD-2027I19.2	6.9	1.64e-11	4.45e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24141664	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs73021467	ENSG00000268442.1	CTD-2027I19.2	6.9	1.64e-11	4.45e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24142863	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs4019979	ENSG00000268442.1	CTD-2027I19.2	6.9	1.64e-11	4.45e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24143881	chr19:24162370~24163425:-
THCA	cis	rs875971	0.862	rs778724	ENSG00000232559.3	GS1-124K5.12	6.9	1.64e-11	4.45e-09	0.29	0.3	Aortic root size;	chr7:66364304	chr7:66554588~66576923:-
THCA	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-6.9	1.64e-11	4.45e-09	-0.38	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
THCA	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-6.9	1.64e-11	4.46e-09	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
THCA	cis	rs7727544	0.716	rs7701414	ENSG00000233006.5	AC034220.3	6.9	1.65e-11	4.47e-09	0.24	0.3	Blood metabolite levels;	chr5:132250265	chr5:132311285~132369916:-
THCA	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	6.9	1.65e-11	4.47e-09	0.47	0.3	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
THCA	cis	rs1598856	1	rs3774932	ENSG00000246560.2	RP11-10L12.4	6.9	1.65e-11	4.47e-09	0.37	0.3	Primary biliary cholangitis;	chr4:102503036	chr4:102828055~102844075:+
THCA	cis	rs10208649	0.831	rs6724214	ENSG00000272156.1	RP11-477N3.1	6.9	1.65e-11	4.48e-09	0.43	0.3	Body mass index;	chr2:53807744	chr2:54082554~54085066:+
THCA	cis	rs4835473	0.897	rs34425128	ENSG00000251600.4	RP11-673E1.1	-6.9	1.65e-11	4.48e-09	-0.42	-0.3	Immature fraction of reticulocytes;	chr4:143725191	chr4:143912331~143982454:+
THCA	cis	rs728616	0.867	rs2152548	ENSG00000225484.5	NUTM2B-AS1	-6.9	1.65e-11	4.48e-09	-0.58	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:79663088~79826594:-
THCA	cis	rs9287719	0.649	rs10929677	ENSG00000243819.4	RN7SL832P	6.9	1.65e-11	4.49e-09	0.25	0.3	Prostate cancer;	chr2:10577422	chr2:10690344~10692099:+
THCA	cis	rs7189233	1	rs62048520	ENSG00000279722.1	RP11-44F14.6	-6.9	1.65e-11	4.49e-09	-0.32	-0.3	Intelligence (multi-trait analysis);	chr16:53457183	chr16:53487607~53489943:-
THCA	cis	rs12928939	0.911	rs11645704	ENSG00000260886.1	TAT-AS1	6.9	1.65e-11	4.49e-09	0.41	0.3	Post bronchodilator FEV1;	chr16:71792708	chr16:71565789~71578187:+
THCA	cis	rs73186030	0.764	rs17251221	ENSG00000272758.4	RP11-299J3.8	6.9	1.65e-11	4.49e-09	0.39	0.3	Serum parathyroid hormone levels;	chr3:122274400	chr3:122416207~122443180:+
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000229886.1	RP5-1132H15.3	-6.9	1.66e-11	4.49e-09	-0.5	-0.3	Diabetic kidney disease;	chr7:66226660	chr7:66025126~66031544:-
THCA	cis	rs7044106	0.762	rs1158553	ENSG00000238181.2	AHCYP2	-6.9	1.66e-11	4.5e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120720673~120721972:+
THCA	cis	rs10266483	0.739	rs682662	ENSG00000227986.1	TRIM60P18	-6.9	1.66e-11	4.5e-09	-0.25	-0.3	Response to statin therapy;	chr7:64306107	chr7:64355078~64356199:+
THCA	cis	rs9400467	0.528	rs11153280	ENSG00000271789.1	RP5-1112D6.7	-6.9	1.66e-11	4.5e-09	-0.29	-0.3	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111297126~111298510:+
THCA	cis	rs848490	0.889	rs6966257	ENSG00000214293.7	APTR	6.9	1.66e-11	4.5e-09	0.24	0.3	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77656151	chr7:77657660~77696265:-
THCA	cis	rs848490	0.889	rs56198418	ENSG00000214293.7	APTR	6.9	1.66e-11	4.5e-09	0.24	0.3	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659141	chr7:77657660~77696265:-
THCA	cis	rs1862618	0.853	rs9283717	ENSG00000271828.1	CTD-2310F14.1	6.9	1.66e-11	4.5e-09	0.46	0.3	Initial pursuit acceleration;	chr5:56782832	chr5:56927874~56929573:+
THCA	cis	rs728616	0.867	rs57257258	ENSG00000225484.5	NUTM2B-AS1	-6.9	1.66e-11	4.51e-09	-0.58	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80084264	chr10:79663088~79826594:-
THCA	cis	rs728616	1	rs728615	ENSG00000225484.5	NUTM2B-AS1	-6.9	1.66e-11	4.51e-09	-0.58	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088333	chr10:79663088~79826594:-
THCA	cis	rs6723108	0.603	rs1374289	ENSG00000224043.6	CCNT2-AS1	6.9	1.66e-11	4.51e-09	0.33	0.3	Type 2 diabetes;	chr2:134936809	chr2:134735464~134918710:-
THCA	cis	rs72843506	0.527	rs76860197	ENSG00000270091.1	RP11-78O7.2	-6.9	1.66e-11	4.52e-09	-0.35	-0.3	Schizophrenia;	chr17:19933383	chr17:19896590~19897287:-
THCA	cis	rs34375054	0.624	rs4073534	ENSG00000279233.1	RP11-158L12.4	6.9	1.66e-11	4.52e-09	0.33	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125187254	chr12:125138245~125141711:+
THCA	cis	rs7044106	0.762	rs7357638	ENSG00000238181.2	AHCYP2	-6.9	1.66e-11	4.52e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120720673~120721972:+
THCA	cis	rs4908760	0.811	rs301819	ENSG00000232912.4	RP5-1115A15.1	6.9	1.67e-11	4.52e-09	0.3	0.3	Vitiligo;	chr1:8441726	chr1:8424645~8434838:+
THCA	cis	rs227275	0.554	rs223485	ENSG00000251288.2	RP11-10L12.2	-6.9	1.67e-11	4.52e-09	-0.4	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102751401~102752641:+
THCA	cis	rs6570726	0.526	rs4895674	ENSG00000235652.6	RP11-545I5.3	-6.9	1.67e-11	4.53e-09	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145414724	chr6:145799409~145886585:+
THCA	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	6.9	1.67e-11	4.53e-09	0.18	0.3	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
THCA	cis	rs71636778	0.509	rs35583548	ENSG00000260063.1	RP5-968P14.2	-6.9	1.67e-11	4.53e-09	-0.59	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813658	chr1:26692132~26694131:-
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000263603.1	CTD-2349P21.5	-6.9	1.67e-11	4.53e-09	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30729469~30731202:+
THCA	cis	rs7554547	0.871	rs11588551	ENSG00000199347.1	RNU5E-1	-6.9	1.67e-11	4.54e-09	-0.41	-0.3	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr1:11908152~11908271:+
THCA	cis	rs6672530	0.518	rs6683151	ENSG00000227711.2	RP11-275O4.5	-6.9	1.67e-11	4.54e-09	-0.31	-0.3	Hip circumference adjusted for BMI;	chr1:227623813	chr1:227509028~227520477:-
THCA	cis	rs6723108	0.517	rs12473839	ENSG00000224043.6	CCNT2-AS1	-6.9	1.67e-11	4.54e-09	-0.31	-0.3	Type 2 diabetes;	chr2:134880474	chr2:134735464~134918710:-
THCA	cis	rs5742933	0.857	rs893784	ENSG00000273240.1	RP11-455J20.3	-6.9	1.68e-11	4.55e-09	-0.32	-0.3	Ferritin levels;	chr2:189671557	chr2:189763859~189764456:-
THCA	cis	rs1426063	1	rs17000242	ENSG00000260265.1	RP11-44F21.5	6.9	1.68e-11	4.55e-09	0.53	0.3	QT interval;	chr4:75103857	chr4:75081702~75084717:-
THCA	cis	rs1426063	1	rs7666371	ENSG00000260265.1	RP11-44F21.5	6.9	1.68e-11	4.55e-09	0.53	0.3	QT interval;	chr4:75104325	chr4:75081702~75084717:-
THCA	cis	rs1426063	1	rs6829858	ENSG00000260265.1	RP11-44F21.5	6.9	1.68e-11	4.55e-09	0.53	0.3	QT interval;	chr4:75105202	chr4:75081702~75084717:-
THCA	cis	rs11024102	0.962	rs12575487	ENSG00000184669.7	OR7E14P	-6.9	1.68e-11	4.55e-09	-0.41	-0.3	Glaucoma (primary angle closure);	chr11:16997770	chr11:17013998~17053024:+
THCA	cis	rs7746199	0.736	rs10484399	ENSG00000280107.1	AL022393.9	-6.9	1.68e-11	4.56e-09	-0.59	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28170845~28172521:+
THCA	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-6.9	1.68e-11	4.56e-09	-0.3	-0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
THCA	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	6.9	1.68e-11	4.57e-09	0.45	0.3	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
THCA	cis	rs9287719	0.649	rs10207885	ENSG00000243819.4	RN7SL832P	6.9	1.69e-11	4.57e-09	0.25	0.3	Prostate cancer;	chr2:10593062	chr2:10690344~10692099:+
THCA	cis	rs8012947	1	rs8012947	ENSG00000279636.2	LINC00216	-6.9	1.69e-11	4.58e-09	-0.32	-0.3	Alcohol consumption in current drinkers;	chr14:58317737	chr14:58288033~58289158:+
THCA	cis	rs922182	0.554	rs9972387	ENSG00000275785.1	RP11-111E14.2	6.9	1.69e-11	4.58e-09	0.36	0.3	Blood protein levels;	chr15:63899286	chr15:63890030~63890317:+
THCA	cis	rs6504622	0.935	rs62075889	ENSG00000262879.4	RP11-156P1.3	-6.9	1.69e-11	4.58e-09	-0.28	-0.3	Orofacial clefts;	chr17:46950671	chr17:46984045~47100323:-
THCA	cis	rs6504622	1	rs12940071	ENSG00000262879.4	RP11-156P1.3	-6.9	1.69e-11	4.58e-09	-0.28	-0.3	Orofacial clefts;	chr17:46950686	chr17:46984045~47100323:-
THCA	cis	rs34119086	1	rs34119086	ENSG00000280107.1	AL022393.9	-6.9	1.69e-11	4.58e-09	-0.61	-0.3	Breast cancer;	chr6:28594471	chr6:28170845~28172521:+
THCA	cis	rs748404	0.66	rs690446	ENSG00000166763.7	STRCP1	6.9	1.69e-11	4.58e-09	0.32	0.3	Lung cancer;	chr15:43469066	chr15:43699488~43718184:-
THCA	cis	rs748404	0.631	rs560191	ENSG00000166763.7	STRCP1	6.9	1.69e-11	4.58e-09	0.32	0.3	Lung cancer;	chr15:43475576	chr15:43699488~43718184:-
THCA	cis	rs748404	0.69	rs2924369	ENSG00000166763.7	STRCP1	-6.9	1.69e-11	4.58e-09	-0.32	-0.3	Lung cancer;	chr15:43485787	chr15:43699488~43718184:-
THCA	cis	rs748404	0.66	rs2444251	ENSG00000166763.7	STRCP1	6.9	1.69e-11	4.58e-09	0.32	0.3	Lung cancer;	chr15:43496397	chr15:43699488~43718184:-
THCA	cis	rs748404	0.66	rs548704	ENSG00000166763.7	STRCP1	6.9	1.69e-11	4.58e-09	0.32	0.3	Lung cancer;	chr15:43499508	chr15:43699488~43718184:-
THCA	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	6.9	1.69e-11	4.58e-09	0.38	0.3	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
THCA	cis	rs1577330	0.8	rs625630	ENSG00000254396.1	RP11-56F10.3	-6.9	1.69e-11	4.58e-09	-0.43	-0.3	IgG glycosylation;	chr9:27097318	chr9:27102630~27104728:+
THCA	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-6.9	1.69e-11	4.58e-09	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
THCA	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	6.9	1.69e-11	4.59e-09	0.59	0.3	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
THCA	cis	rs2911132	0.66	rs754615	ENSG00000248734.2	CTD-2260A17.1	6.9	1.69e-11	4.59e-09	0.31	0.3	Urate levels (BMI interaction);	chr5:96750630	chr5:96784777~96785999:+
THCA	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-6.9	1.69e-11	4.59e-09	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
THCA	cis	rs7260598	0.792	rs11671489	ENSG00000268442.1	CTD-2027I19.2	6.9	1.69e-11	4.6e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24156070	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs60773823	ENSG00000268442.1	CTD-2027I19.2	6.9	1.69e-11	4.6e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24156730	chr19:24162370~24163425:-
THCA	cis	rs12435908	1	rs17826820	ENSG00000276116.2	FUT8-AS1	-6.9	1.69e-11	4.6e-09	-0.49	-0.3	Ischemic stroke;	chr14:65647119	chr14:65411170~65412690:-
THCA	cis	rs4784934	0.819	rs28627526	ENSG00000260186.4	RP11-481J2.2	6.9	1.7e-11	4.6e-09	0.42	0.3	QT interval;	chr16:58433835	chr16:58421326~58462470:+
THCA	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	6.9	1.7e-11	4.6e-09	0.32	0.3	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
THCA	cis	rs240993	0.812	rs458806	ENSG00000230177.1	RP5-1112D6.4	-6.9	1.7e-11	4.61e-09	-0.31	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111354825	chr6:111277932~111278742:+
THCA	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	6.9	1.7e-11	4.61e-09	0.54	0.3	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
THCA	cis	rs2412819	0.571	rs6493090	ENSG00000205771.5	CATSPER2P1	6.9	1.7e-11	4.62e-09	0.39	0.3	Lung cancer;	chr15:43792084	chr15:43726918~43747094:-
THCA	cis	rs453301	0.624	rs2915251	ENSG00000253893.2	FAM85B	-6.9	1.7e-11	4.62e-09	-0.38	-0.3	Joint mobility (Beighton score);	chr8:9009901	chr8:8167819~8226614:-
THCA	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	6.9	1.71e-11	4.62e-09	0.38	0.3	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
THCA	cis	rs7044106	0.791	rs10985009	ENSG00000238181.2	AHCYP2	6.9	1.71e-11	4.64e-09	0.39	0.3	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120720673~120721972:+
THCA	cis	rs3806843	0.838	rs2563289	ENSG00000202515.1	VTRNA1-3	6.9	1.71e-11	4.64e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140743181	chr5:140726158~140726246:+
THCA	cis	rs41307935	0.818	rs35738294	ENSG00000260063.1	RP5-968P14.2	-6.9	1.71e-11	4.65e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26693642	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs71636769	ENSG00000260063.1	RP5-968P14.2	-6.9	1.71e-11	4.65e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26694100	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs71636770	ENSG00000260063.1	RP5-968P14.2	-6.9	1.71e-11	4.65e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26694624	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34585496	ENSG00000260063.1	RP5-968P14.2	-6.9	1.71e-11	4.65e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26699449	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.57	rs12744003	ENSG00000260063.1	RP5-968P14.2	-6.9	1.71e-11	4.65e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701808	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.908	rs77408691	ENSG00000260063.1	RP5-968P14.2	-6.9	1.71e-11	4.65e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26707898	chr1:26692132~26694131:-
THCA	cis	rs748404	0.66	rs690012	ENSG00000166763.7	STRCP1	6.9	1.71e-11	4.65e-09	0.32	0.3	Lung cancer;	chr15:43427557	chr15:43699488~43718184:-
THCA	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	6.9	1.72e-11	4.65e-09	0.25	0.3	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
THCA	cis	rs7246657	0.943	rs34603719	ENSG00000226686.6	LINC01535	-6.9	1.72e-11	4.65e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37303626	chr19:37251912~37265535:+
THCA	cis	rs9376098	0.698	rs6908307	ENSG00000232876.1	CTA-212D2.2	-6.9	1.72e-11	4.66e-09	-0.36	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135141542	chr6:135055033~135060550:+
THCA	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-6.9	1.72e-11	4.66e-09	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
THCA	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-6.9	1.72e-11	4.66e-09	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
THCA	cis	rs4845875	0.534	rs4846052	ENSG00000242349.4	NPPA-AS1	6.9	1.72e-11	4.67e-09	0.29	0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11797894	chr1:11841017~11848079:+
THCA	cis	rs944289	0.576	rs1169140	ENSG00000257826.1	RP11-116N8.4	-6.9	1.72e-11	4.67e-09	-0.35	-0.3	Thyroid cancer;	chr14:36159160	chr14:36061026~36067190:-
THCA	cis	rs71636778	0.57	rs34026565	ENSG00000260063.1	RP5-968P14.2	-6.9	1.72e-11	4.67e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903485	chr1:26692132~26694131:-
THCA	cis	rs8067545	0.641	rs203481	ENSG00000270091.1	RP11-78O7.2	-6.9	1.72e-11	4.67e-09	-0.22	-0.3	Schizophrenia;	chr17:19925415	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.641	rs203479	ENSG00000270091.1	RP11-78O7.2	-6.9	1.72e-11	4.67e-09	-0.22	-0.3	Schizophrenia;	chr17:19925998	chr17:19896590~19897287:-
THCA	cis	rs9902453	0.791	rs7219163	ENSG00000264007.1	RP11-68I3.10	6.9	1.73e-11	4.68e-09	0.35	0.3	Coffee consumption (cups per day);	chr17:29883685	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs7221516	ENSG00000264007.1	RP11-68I3.10	6.9	1.73e-11	4.68e-09	0.35	0.3	Coffee consumption (cups per day);	chr17:29905488	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.791	rs9904051	ENSG00000264007.1	RP11-68I3.10	6.9	1.73e-11	4.68e-09	0.35	0.3	Coffee consumption (cups per day);	chr17:29917104	chr17:29621617~29622254:-
THCA	cis	rs853679	0.513	rs13437444	ENSG00000272009.1	RP1-313I6.12	-6.9	1.73e-11	4.68e-09	-0.4	-0.3	Depression;	chr6:28103220	chr6:28078792~28081130:-
THCA	cis	rs7267979	1	rs6138572	ENSG00000274414.1	RP5-965G21.4	-6.9	1.73e-11	4.69e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6138575	ENSG00000274414.1	RP5-965G21.4	-6.9	1.73e-11	4.69e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs11087521	ENSG00000274414.1	RP5-965G21.4	-6.9	1.73e-11	4.69e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25239007~25245229:-
THCA	cis	rs875971	0.862	rs11765791	ENSG00000232559.3	GS1-124K5.12	6.9	1.73e-11	4.7e-09	0.29	0.3	Aortic root size;	chr7:66471587	chr7:66554588~66576923:-
THCA	cis	rs4950322	0.57	rs72691004	ENSG00000237188.3	RP11-337C18.8	6.9	1.74e-11	4.7e-09	0.36	0.3	Protein quantitative trait loci;	chr1:147234309	chr1:147172771~147211568:+
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	6.9	1.74e-11	4.7e-09	0.32	0.3	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
THCA	cis	rs172166	0.694	rs203884	ENSG00000280107.1	AL022393.9	-6.9	1.74e-11	4.71e-09	-0.33	-0.3	Cardiac Troponin-T levels;	chr6:28109596	chr6:28170845~28172521:+
THCA	cis	rs7851660	0.809	rs12006522	ENSG00000236130.1	PTCSC2	-6.9	1.74e-11	4.71e-09	-0.24	-0.3	Strep throat;	chr9:97890429	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs12004762	ENSG00000236130.1	PTCSC2	-6.9	1.74e-11	4.71e-09	-0.24	-0.3	Strep throat;	chr9:97890473	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs12550872	ENSG00000236130.1	PTCSC2	-6.9	1.74e-11	4.71e-09	-0.24	-0.3	Strep throat;	chr9:97890846	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs7034249	ENSG00000236130.1	PTCSC2	-6.9	1.74e-11	4.71e-09	-0.24	-0.3	Strep throat;	chr9:97891539	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs7034648	ENSG00000236130.1	PTCSC2	-6.9	1.74e-11	4.71e-09	-0.24	-0.3	Strep throat;	chr9:97891811	chr9:97805935~97810008:-
THCA	cis	rs1501911	0.527	rs109843	ENSG00000246763.5	RGMB-AS1	6.9	1.74e-11	4.71e-09	0.29	0.3	Lung function (FEV1/FVC);	chr5:98985233	chr5:98769618~98773469:-
THCA	cis	rs8067545	0.641	rs175922	ENSG00000270091.1	RP11-78O7.2	-6.9	1.74e-11	4.71e-09	-0.22	-0.3	Schizophrenia;	chr17:19922266	chr17:19896590~19897287:-
THCA	cis	rs73186030	0.844	rs73186015	ENSG00000272758.4	RP11-299J3.8	6.89	1.74e-11	4.72e-09	0.38	0.3	Serum parathyroid hormone levels;	chr3:122272236	chr3:122416207~122443180:+
THCA	cis	rs990871	1	rs1432639	ENSG00000227207.2	RPL31P12	-6.89	1.74e-11	4.72e-09	-0.38	-0.3	Subcutaneous adipose tissue;	chr1:72347535	chr1:72301472~72301829:+
THCA	cis	rs853679	0.607	rs34243448	ENSG00000280107.1	AL022393.9	-6.89	1.75e-11	4.73e-09	-0.6	-0.3	Depression;	chr6:28225324	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs200489	ENSG00000219392.1	RP1-265C24.5	-6.89	1.75e-11	4.73e-09	-0.52	-0.3	Depression;	chr6:27830479	chr6:28115628~28116551:+
THCA	cis	rs72843506	0.586	rs79634508	ENSG00000270091.1	RP11-78O7.2	-6.89	1.75e-11	4.73e-09	-0.35	-0.3	Schizophrenia;	chr17:19933734	chr17:19896590~19897287:-
THCA	cis	rs4713118	0.955	rs9468206	ENSG00000280107.1	AL022393.9	-6.89	1.75e-11	4.73e-09	-0.35	-0.3	Parkinson's disease;	chr6:27722674	chr6:28170845~28172521:+
THCA	cis	rs6696239	0.513	rs2201571	ENSG00000227711.2	RP11-275O4.5	6.89	1.75e-11	4.73e-09	0.32	0.3	Height;	chr1:227532250	chr1:227509028~227520477:-
THCA	cis	rs9902453	0.619	rs1038088	ENSG00000264007.1	RP11-68I3.10	-6.89	1.75e-11	4.74e-09	-0.35	-0.3	Coffee consumption (cups per day);	chr17:29747545	chr17:29621617~29622254:-
THCA	cis	rs5742933	0.557	rs1233276	ENSG00000273240.1	RP11-455J20.3	-6.89	1.75e-11	4.74e-09	-0.34	-0.3	Ferritin levels;	chr2:189820056	chr2:189763859~189764456:-
THCA	cis	rs848490	0.888	rs56100966	ENSG00000214293.7	APTR	6.89	1.75e-11	4.75e-09	0.24	0.3	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77661233	chr7:77657660~77696265:-
THCA	cis	rs875971	0.893	rs62465470	ENSG00000232559.3	GS1-124K5.12	-6.89	1.75e-11	4.75e-09	-0.29	-0.3	Aortic root size;	chr7:66136231	chr7:66554588~66576923:-
THCA	cis	rs7267979	1	rs2500443	ENSG00000274414.1	RP5-965G21.4	6.89	1.76e-11	4.75e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25239007~25245229:-
THCA	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-6.89	1.76e-11	4.75e-09	-0.41	-0.3	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
THCA	cis	rs7267979	0.586	rs6037057	ENSG00000274414.1	RP5-965G21.4	-6.89	1.76e-11	4.75e-09	-0.37	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25239007~25245229:-
THCA	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-6.89	1.76e-11	4.76e-09	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
THCA	cis	rs9568764	1	rs9568764	ENSG00000150276.8	PPIAP26	-6.89	1.76e-11	4.76e-09	-0.38	-0.3	Interleukin-17 levels;	chr13:52814750	chr13:52820497~52821018:+
THCA	cis	rs4664293	0.867	rs1427329	ENSG00000226266.5	AC009961.3	-6.89	1.76e-11	4.77e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159748301	chr2:159670708~159712435:-
THCA	cis	rs7247513	0.897	rs12979146	ENSG00000213290.4	PGK1P2	-6.89	1.77e-11	4.78e-09	-0.36	-0.3	Bipolar disorder;	chr19:12607090	chr19:12559571~12561105:+
THCA	cis	rs7580658	0.521	rs2404535	ENSG00000236682.1	AC068282.3	6.89	1.77e-11	4.79e-09	0.38	0.3	Protein C levels;	chr2:127190133	chr2:127389130~127400580:+
THCA	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	6.89	1.77e-11	4.79e-09	0.25	0.3	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
THCA	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	6.89	1.77e-11	4.79e-09	0.74	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
THCA	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	6.89	1.77e-11	4.79e-09	0.74	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
THCA	cis	rs4789693	0.546	rs7220204	ENSG00000265458.1	RP13-20L14.6	6.89	1.77e-11	4.8e-09	0.3	0.3	Glucocorticoid-induced osteonecrosis;	chr17:82418254	chr17:82454273~82458521:-
THCA	cis	rs12435908	1	rs73284133	ENSG00000276116.2	FUT8-AS1	-6.89	1.77e-11	4.8e-09	-0.48	-0.3	Ischemic stroke;	chr14:65479894	chr14:65411170~65412690:-
THCA	cis	rs12435908	0.748	rs12437427	ENSG00000276116.2	FUT8-AS1	-6.89	1.77e-11	4.8e-09	-0.48	-0.3	Ischemic stroke;	chr14:65520482	chr14:65411170~65412690:-
THCA	cis	rs4908760	0.757	rs301807	ENSG00000232912.4	RP5-1115A15.1	6.89	1.77e-11	4.8e-09	0.3	0.3	Vitiligo;	chr1:8424763	chr1:8424645~8434838:+
THCA	cis	rs713477	1	rs713477	ENSG00000258413.1	RP11-665C16.6	6.89	1.77e-11	4.8e-09	0.4	0.3	Pediatric bone mineral content (femoral neck);	chr14:55437708	chr14:55262767~55272075:-
THCA	cis	rs7120173	0.778	rs548638	ENSG00000254851.1	RP11-109L13.1	-6.89	1.78e-11	4.8e-09	-0.5	-0.3	Visceral adipose tissue adjusted for BMI;	chr11:116866377	chr11:117135528~117138582:+
THCA	cis	rs7120173	0.735	rs518547	ENSG00000254851.1	RP11-109L13.1	-6.89	1.78e-11	4.8e-09	-0.5	-0.3	Visceral adipose tissue adjusted for BMI;	chr11:116867330	chr11:117135528~117138582:+
THCA	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	6.89	1.78e-11	4.8e-09	0.38	0.3	Height;	chr6:109452743	chr6:109382795~109383666:+
THCA	cis	rs6672530	0.518	rs2093610	ENSG00000227711.2	RP11-275O4.5	-6.89	1.78e-11	4.81e-09	-0.31	-0.3	Hip circumference adjusted for BMI;	chr1:227633345	chr1:227509028~227520477:-
THCA	cis	rs9402743	0.962	rs9321521	ENSG00000231028.7	LINC00271	-6.89	1.78e-11	4.81e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135668512	chr6:135497801~135716055:+
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000263603.1	CTD-2349P21.5	-6.89	1.78e-11	4.81e-09	-0.52	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000263603.1	CTD-2349P21.5	-6.89	1.78e-11	4.81e-09	-0.52	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30729469~30731202:+
THCA	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-6.89	1.78e-11	4.82e-09	-0.36	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
THCA	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-6.89	1.78e-11	4.82e-09	-0.26	-0.3	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
THCA	cis	rs496547	0.719	rs1790189	ENSG00000255239.1	AP002954.6	6.89	1.78e-11	4.82e-09	0.39	0.3	Hip minimal joint space width;	chr11:118781617	chr11:118688039~118690600:-
THCA	cis	rs71636778	0.509	rs12756074	ENSG00000260063.1	RP5-968P14.2	-6.89	1.78e-11	4.82e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26721402	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs71636773	ENSG00000260063.1	RP5-968P14.2	-6.89	1.78e-11	4.82e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724828	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.818	rs35145624	ENSG00000260063.1	RP5-968P14.2	-6.89	1.78e-11	4.82e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26726121	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34026879	ENSG00000260063.1	RP5-968P14.2	-6.89	1.78e-11	4.82e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26741747	chr1:26692132~26694131:-
THCA	cis	rs2288884	1	rs80278704	ENSG00000275055.1	CTC-471J1.11	-6.89	1.78e-11	4.82e-09	-0.3	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52045930	chr19:52049007~52049754:+
THCA	cis	rs2288884	1	rs11669540	ENSG00000275055.1	CTC-471J1.11	-6.89	1.78e-11	4.82e-09	-0.3	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52046486	chr19:52049007~52049754:+
THCA	cis	rs2288884	1	rs78543982	ENSG00000275055.1	CTC-471J1.11	-6.89	1.78e-11	4.82e-09	-0.3	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047614	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.943	rs3752120	ENSG00000275055.1	CTC-471J1.11	-6.89	1.78e-11	4.82e-09	-0.3	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048768	chr19:52049007~52049754:+
THCA	cis	rs2288884	1	rs79817140	ENSG00000275055.1	CTC-471J1.11	-6.89	1.78e-11	4.82e-09	-0.3	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068404	chr19:52049007~52049754:+
THCA	cis	rs2288884	1	rs11669385	ENSG00000275055.1	CTC-471J1.11	-6.89	1.78e-11	4.82e-09	-0.3	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068699	chr19:52049007~52049754:+
THCA	cis	rs2288884	1	rs17835749	ENSG00000275055.1	CTC-471J1.11	-6.89	1.78e-11	4.82e-09	-0.3	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075442	chr19:52049007~52049754:+
THCA	cis	rs2288884	1	rs12609219	ENSG00000275055.1	CTC-471J1.11	-6.89	1.78e-11	4.82e-09	-0.3	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077743	chr19:52049007~52049754:+
THCA	cis	rs7847628	0.55	rs12343516	ENSG00000270917.1	RP11-27I1.6	-6.89	1.78e-11	4.83e-09	-0.42	-0.3	Birth weight;	chr9:120841191	chr9:120812475~120812845:-
THCA	cis	rs853679	0.76	rs9357067	ENSG00000280107.1	AL022393.9	-6.89	1.79e-11	4.83e-09	-0.38	-0.3	Depression;	chr6:28242515	chr6:28170845~28172521:+
THCA	cis	rs853679	0.76	rs967005	ENSG00000280107.1	AL022393.9	-6.89	1.79e-11	4.83e-09	-0.38	-0.3	Depression;	chr6:28242910	chr6:28170845~28172521:+
THCA	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-6.89	1.79e-11	4.83e-09	-0.41	-0.3	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-6.89	1.79e-11	4.83e-09	-0.41	-0.3	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
THCA	cis	rs71636778	0.509	rs12753981	ENSG00000260063.1	RP5-968P14.2	-6.89	1.79e-11	4.83e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26675402	chr1:26692132~26694131:-
THCA	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-6.89	1.79e-11	4.83e-09	-0.31	-0.3	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
THCA	cis	rs875971	0.756	rs2901210	ENSG00000232559.3	GS1-124K5.12	-6.89	1.79e-11	4.84e-09	-0.29	-0.3	Aortic root size;	chr7:66552518	chr7:66554588~66576923:-
THCA	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-6.89	1.79e-11	4.84e-09	-0.3	-0.3	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
THCA	cis	rs2439831	1	rs565007	ENSG00000249839.1	AC011330.5	-6.89	1.79e-11	4.84e-09	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43424443	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs550239	ENSG00000249839.1	AC011330.5	-6.89	1.79e-11	4.84e-09	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43427999	chr15:43663654~43684339:-
THCA	cis	rs10916248	0.53	rs72753952	ENSG00000232628.4	RP11-365O16.3	6.89	1.79e-11	4.85e-09	0.47	0.3	QT interval (drug interaction);	chr1:224126348	chr1:224208747~224213279:-
THCA	cis	rs2439831	0.681	rs956391	ENSG00000249839.1	AC011330.5	6.89	1.79e-11	4.85e-09	0.45	0.3	Lung cancer in ever smokers;	chr15:43325295	chr15:43663654~43684339:-
THCA	cis	rs17695224	0.565	rs28800315	ENSG00000269483.1	AC006272.1	6.89	1.8e-11	4.85e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51805837	chr19:51839924~51843324:-
THCA	cis	rs7580658	0.891	rs3768866	ENSG00000236682.1	AC068282.3	-6.89	1.8e-11	4.85e-09	-0.4	-0.3	Protein C levels;	chr2:127287839	chr2:127389130~127400580:+
THCA	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	6.89	1.8e-11	4.85e-09	0.26	0.3	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
THCA	cis	rs6504622	0.905	rs9898981	ENSG00000262879.4	RP11-156P1.3	6.89	1.8e-11	4.87e-09	0.28	0.3	Orofacial clefts;	chr17:46949349	chr17:46984045~47100323:-
THCA	cis	rs7267979	0.932	rs6107052	ENSG00000274414.1	RP5-965G21.4	-6.89	1.8e-11	4.87e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25239007~25245229:-
THCA	cis	rs11722228	0.549	rs73212853	ENSG00000261490.1	RP11-448G15.3	6.89	1.81e-11	4.88e-09	0.23	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10094606	chr4:10068089~10073019:-
THCA	cis	rs16843372	0.599	rs12694970	ENSG00000251491.2	OR7E28P	-6.89	1.81e-11	4.89e-09	-0.41	-0.3	Obesity-related traits;	chr2:158832273	chr2:158862311~158863285:+
THCA	cis	rs41307935	0.908	rs34014719	ENSG00000260063.1	RP5-968P14.2	-6.89	1.81e-11	4.89e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26746275	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34885854	ENSG00000260063.1	RP5-968P14.2	-6.89	1.81e-11	4.9e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759758	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs71636777	ENSG00000260063.1	RP5-968P14.2	-6.89	1.81e-11	4.9e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26761777	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34681611	ENSG00000260063.1	RP5-968P14.2	-6.89	1.81e-11	4.9e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26762955	chr1:26692132~26694131:-
THCA	cis	rs7246657	0.943	rs7248733	ENSG00000226686.6	LINC01535	-6.89	1.81e-11	4.9e-09	-0.43	-0.3	Coronary artery calcification;	chr19:37505459	chr19:37251912~37265535:+
THCA	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-6.89	1.82e-11	4.9e-09	-0.29	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
THCA	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-6.89	1.82e-11	4.9e-09	-0.29	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
THCA	cis	rs7044106	0.791	rs7036766	ENSG00000238181.2	AHCYP2	-6.89	1.82e-11	4.9e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120720673~120721972:+
THCA	cis	rs3806843	0.966	rs6891559	ENSG00000202515.1	VTRNA1-3	-6.89	1.82e-11	4.91e-09	-0.34	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs11741994	ENSG00000202515.1	VTRNA1-3	-6.89	1.82e-11	4.91e-09	-0.34	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr5:140726158~140726246:+
THCA	cis	rs7246657	0.943	rs6508733	ENSG00000226686.6	LINC01535	-6.89	1.82e-11	4.91e-09	-0.43	-0.3	Coronary artery calcification;	chr19:37509646	chr19:37251912~37265535:+
THCA	cis	rs7267979	1	rs2258719	ENSG00000274414.1	RP5-965G21.4	-6.89	1.82e-11	4.91e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25239007~25245229:-
THCA	cis	rs7688540	0.771	rs2353605	ENSG00000275426.1	CH17-262A2.1	6.89	1.82e-11	4.91e-09	0.41	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:149738~150317:+
THCA	cis	rs944289	0.537	rs1169137	ENSG00000257826.1	RP11-116N8.4	-6.89	1.82e-11	4.91e-09	-0.35	-0.3	Thyroid cancer;	chr14:36156548	chr14:36061026~36067190:-
THCA	cis	rs17695224	0.675	rs7252671	ENSG00000269483.1	AC006272.1	6.89	1.82e-11	4.92e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51834830	chr19:51839924~51843324:-
THCA	cis	rs2439831	1	rs689754	ENSG00000249839.1	AC011330.5	-6.89	1.82e-11	4.92e-09	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43483697	chr15:43663654~43684339:-
THCA	cis	rs7208859	0.673	rs999798	ENSG00000264538.5	SUZ12P1	-6.89	1.82e-11	4.93e-09	-0.29	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30709299~30790908:+
THCA	cis	rs9341808	0.718	rs9448893	ENSG00000272129.1	RP11-250B2.6	6.89	1.83e-11	4.93e-09	0.38	0.3	Sitting height ratio;	chr6:80127522	chr6:80355424~80356859:+
THCA	cis	rs11096990	0.656	rs7693837	ENSG00000249685.1	RP11-360F5.3	6.89	1.83e-11	4.94e-09	0.35	0.3	Cognitive function;	chr4:39301481	chr4:39133913~39135608:+
THCA	cis	rs7260598	0.792	rs73021461	ENSG00000268442.1	CTD-2027I19.2	6.89	1.83e-11	4.94e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24140154	chr19:24162370~24163425:-
THCA	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	6.89	1.83e-11	4.94e-09	0.4	0.3	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
THCA	cis	rs7688540	0.8	rs9328738	ENSG00000211553.1	AC253576.2	6.89	1.83e-11	4.94e-09	0.41	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:136461~136568:+
THCA	cis	rs6940116	1	rs6940116	ENSG00000280107.1	AL022393.9	-6.89	1.83e-11	4.95e-09	-0.41	-0.3	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28170845~28172521:+
THCA	cis	rs516805	0.748	rs11154078	ENSG00000279453.1	RP3-425C14.4	6.89	1.83e-11	4.95e-09	0.3	0.3	Lymphocyte counts;	chr6:122387058	chr6:122436789~122439223:-
THCA	cis	rs7267979	0.866	rs2424699	ENSG00000274414.1	RP5-965G21.4	-6.89	1.84e-11	4.96e-09	-0.37	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25239007~25245229:-
THCA	cis	rs7617773	0.78	rs11706277	ENSG00000228638.1	FCF1P2	-6.89	1.84e-11	4.96e-09	-0.3	-0.3	Coronary artery disease;	chr3:48318943	chr3:48290793~48291375:-
THCA	cis	rs848490	0.889	rs17156320	ENSG00000214293.7	APTR	-6.89	1.84e-11	4.96e-09	-0.24	-0.3	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77670793	chr7:77657660~77696265:-
THCA	cis	rs7727544	0.716	rs4594848	ENSG00000233006.5	AC034220.3	6.89	1.84e-11	4.96e-09	0.24	0.3	Blood metabolite levels;	chr5:132250905	chr5:132311285~132369916:-
THCA	cis	rs17772222	0.92	rs61975260	ENSG00000258789.1	RP11-507K2.3	-6.89	1.84e-11	4.96e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88429597	chr14:88551597~88552493:+
THCA	cis	rs4072705	0.967	rs4838210	ENSG00000224020.1	MIR181A2HG	6.89	1.85e-11	4.99e-09	0.27	0.3	Menarche (age at onset);	chr9:124783904	chr9:124658467~124698631:+
THCA	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	6.89	1.85e-11	4.99e-09	0.35	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
THCA	cis	rs7267979	0.932	rs1541061	ENSG00000274414.1	RP5-965G21.4	-6.89	1.85e-11	4.99e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.932	rs6138600	ENSG00000274414.1	RP5-965G21.4	-6.89	1.85e-11	4.99e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.899	rs2104734	ENSG00000274414.1	RP5-965G21.4	-6.89	1.85e-11	4.99e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25239007~25245229:-
THCA	cis	rs71636778	0.509	rs35615194	ENSG00000260063.1	RP5-968P14.2	-6.89	1.85e-11	5e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26791680	chr1:26692132~26694131:-
THCA	cis	rs4819052	0.851	rs11558445	ENSG00000237664.1	LINC00316	-6.89	1.85e-11	5e-09	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45338590~45341990:-
THCA	cis	rs5006884	0.547	rs2736563	ENSG00000167355.6	AC104389.28	-6.89	1.85e-11	5e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5354812	chr11:5304976~5505652:-
THCA	cis	rs4950322	0.57	rs4593887	ENSG00000237188.3	RP11-337C18.8	6.89	1.85e-11	5e-09	0.36	0.3	Protein quantitative trait loci;	chr1:147234246	chr1:147172771~147211568:+
THCA	cis	rs853679	0.607	rs13204012	ENSG00000280107.1	AL022393.9	-6.89	1.86e-11	5.01e-09	-0.6	-0.3	Depression;	chr6:28233753	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13205211	ENSG00000280107.1	AL022393.9	-6.89	1.86e-11	5.01e-09	-0.6	-0.3	Depression;	chr6:28235278	chr6:28170845~28172521:+
THCA	cis	rs9876781	0.53	rs11708617	ENSG00000229759.1	MRPS18AP1	6.89	1.86e-11	5.01e-09	0.38	0.3	Longevity;	chr3:48354819	chr3:48256350~48256938:-
THCA	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-6.88	1.86e-11	5.02e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
THCA	cis	rs7608910	0.578	rs2564113	ENSG00000271889.1	RP11-493E12.1	6.88	1.86e-11	5.03e-09	0.3	0.3	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:61003853	chr2:61151433~61162105:-
THCA	cis	rs7942368	0.878	rs1866843	ENSG00000204529.3	GUCY2EP	6.88	1.86e-11	5.03e-09	0.43	0.3	Endometriosis;	chr11:76778292	chr11:76694043~76707641:-
THCA	cis	rs2880765	0.677	rs7181410	ENSG00000259295.5	CSPG4P12	-6.88	1.86e-11	5.03e-09	-0.38	-0.3	Coronary artery disease;	chr15:85463104	chr15:85191438~85213905:+
THCA	cis	rs3806843	0.676	rs2245640	ENSG00000202515.1	VTRNA1-3	6.88	1.86e-11	5.03e-09	0.35	0.3	Depressive symptoms (multi-trait analysis);	chr5:140650373	chr5:140726158~140726246:+
THCA	cis	rs9902453	0.904	rs4598962	ENSG00000264007.1	RP11-68I3.10	6.88	1.86e-11	5.03e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29966930	chr17:29621617~29622254:-
THCA	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	6.88	1.87e-11	5.04e-09	0.41	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
THCA	cis	rs853679	0.546	rs13195291	ENSG00000280107.1	AL022393.9	-6.88	1.87e-11	5.05e-09	-0.6	-0.3	Depression;	chr6:28201463	chr6:28170845~28172521:+
THCA	cis	rs853679	0.556	rs13197633	ENSG00000280107.1	AL022393.9	-6.88	1.87e-11	5.05e-09	-0.6	-0.3	Depression;	chr6:28206979	chr6:28170845~28172521:+
THCA	cis	rs7712401	0.598	rs446116	ENSG00000249996.1	RP11-359P5.1	6.88	1.87e-11	5.05e-09	0.3	0.3	Mean platelet volume;	chr5:122855435	chr5:123036271~123054667:+
THCA	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	6.88	1.88e-11	5.06e-09	0.47	0.3	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
THCA	cis	rs4073416	0.684	rs7161123	ENSG00000276116.2	FUT8-AS1	6.88	1.88e-11	5.07e-09	0.32	0.3	N-glycan levels;	chr14:65586183	chr14:65411170~65412690:-
THCA	cis	rs1707322	1	rs1613296	ENSG00000234329.1	RP11-767N6.2	-6.88	1.88e-11	5.07e-09	-0.29	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45651039~45651826:-
THCA	cis	rs3806843	0.931	rs13168670	ENSG00000202515.1	VTRNA1-3	-6.88	1.88e-11	5.07e-09	-0.34	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140767314	chr5:140726158~140726246:+
THCA	cis	rs853679	0.607	rs35001169	ENSG00000280107.1	AL022393.9	-6.88	1.88e-11	5.07e-09	-0.6	-0.3	Depression;	chr6:28219854	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs35656932	ENSG00000280107.1	AL022393.9	-6.88	1.88e-11	5.07e-09	-0.6	-0.3	Depression;	chr6:28223510	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13208096	ENSG00000280107.1	AL022393.9	-6.88	1.88e-11	5.07e-09	-0.6	-0.3	Depression;	chr6:28257533	chr6:28170845~28172521:+
THCA	cis	rs5006884	0.507	rs2736564	ENSG00000167355.6	AC104389.28	-6.88	1.88e-11	5.08e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5354808	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.507	rs2736561	ENSG00000167355.6	AC104389.28	-6.88	1.88e-11	5.08e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5355238	chr11:5304976~5505652:-
THCA	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	6.88	1.88e-11	5.08e-09	0.38	0.3	Height;	chr6:109465229	chr6:109382795~109383666:+
THCA	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	6.88	1.89e-11	5.08e-09	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
THCA	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-6.88	1.89e-11	5.08e-09	-0.3	-0.3	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-6.88	1.89e-11	5.08e-09	-0.3	-0.3	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
THCA	cis	rs9287719	0.649	rs10175884	ENSG00000243819.4	RN7SL832P	6.88	1.89e-11	5.09e-09	0.25	0.3	Prostate cancer;	chr2:10578408	chr2:10690344~10692099:+
THCA	cis	rs6600671	0.902	rs2222371	ENSG00000223345.3	HIST2H2BA	-6.88	1.89e-11	5.09e-09	-0.34	-0.3	Hip geometry;	chr1:121547320	chr1:121108210~121117257:-
THCA	cis	rs860295	0.58	rs867548	ENSG00000225855.5	RUSC1-AS1	6.88	1.89e-11	5.1e-09	0.21	0.3	Body mass index;	chr1:155910217	chr1:155316863~155324176:-
THCA	cis	rs860295	0.58	rs867550	ENSG00000225855.5	RUSC1-AS1	6.88	1.89e-11	5.1e-09	0.21	0.3	Body mass index;	chr1:155910600	chr1:155316863~155324176:-
THCA	cis	rs875971	0.862	rs4368860	ENSG00000232559.3	GS1-124K5.12	-6.88	1.89e-11	5.1e-09	-0.29	-0.3	Aortic root size;	chr7:66143495	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs7809814	ENSG00000232559.3	GS1-124K5.12	-6.88	1.89e-11	5.1e-09	-0.29	-0.3	Aortic root size;	chr7:66150410	chr7:66554588~66576923:-
THCA	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	6.88	1.9e-11	5.11e-09	0.24	0.3	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
THCA	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	6.88	1.9e-11	5.11e-09	0.24	0.3	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
THCA	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	6.88	1.9e-11	5.11e-09	0.24	0.3	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
THCA	cis	rs7621025	0.505	rs13063893	ENSG00000239213.4	NCK1-AS1	-6.88	1.9e-11	5.11e-09	-0.41	-0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136668796	chr3:136841726~136862054:-
THCA	cis	rs6745190	0.953	rs7559803	ENSG00000236153.1	AC104076.3	6.88	1.9e-11	5.11e-09	0.36	0.3	White blood cell count;	chr2:180986450	chr2:180979427~180980090:-
THCA	cis	rs7580658	0.509	rs12477653	ENSG00000236682.1	AC068282.3	-6.88	1.9e-11	5.11e-09	-0.38	-0.3	Protein C levels;	chr2:127194505	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.545	rs13001179	ENSG00000236682.1	AC068282.3	-6.88	1.9e-11	5.11e-09	-0.38	-0.3	Protein C levels;	chr2:127194617	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.545	rs13001184	ENSG00000236682.1	AC068282.3	-6.88	1.9e-11	5.11e-09	-0.38	-0.3	Protein C levels;	chr2:127194630	chr2:127389130~127400580:+
THCA	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-6.88	1.9e-11	5.11e-09	-0.37	-0.3	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
THCA	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	6.88	1.9e-11	5.12e-09	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
THCA	cis	rs7267979	0.932	rs424487	ENSG00000274414.1	RP5-965G21.4	-6.88	1.9e-11	5.12e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25239007~25245229:-
THCA	cis	rs4784934	1	rs4784935	ENSG00000260186.4	RP11-481J2.2	6.88	1.9e-11	5.13e-09	0.44	0.3	QT interval;	chr16:58426438	chr16:58421326~58462470:+
THCA	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	6.88	1.9e-11	5.13e-09	0.2	0.3	Breast cancer;	chr11:750849	chr11:781645~782105:+
THCA	cis	rs2439831	1	rs471229	ENSG00000275601.1	AC011330.13	-6.88	1.91e-11	5.13e-09	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43441796	chr15:43642389~43643023:-
THCA	cis	rs7044106	0.791	rs747819	ENSG00000238181.2	AHCYP2	-6.88	1.91e-11	5.13e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120720673~120721972:+
THCA	cis	rs7044106	0.791	rs735110	ENSG00000238181.2	AHCYP2	-6.88	1.91e-11	5.13e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120720673~120721972:+
THCA	cis	rs7267979	0.966	rs7270835	ENSG00000274414.1	RP5-965G21.4	-6.88	1.91e-11	5.13e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6115191	ENSG00000274414.1	RP5-965G21.4	-6.88	1.91e-11	5.13e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6107045	ENSG00000274414.1	RP5-965G21.4	-6.88	1.91e-11	5.13e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6107046	ENSG00000274414.1	RP5-965G21.4	-6.88	1.91e-11	5.13e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6107047	ENSG00000274414.1	RP5-965G21.4	-6.88	1.91e-11	5.13e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25239007~25245229:-
THCA	cis	rs748404	0.66	rs518288	ENSG00000166763.7	STRCP1	6.88	1.91e-11	5.13e-09	0.32	0.3	Lung cancer;	chr15:43471801	chr15:43699488~43718184:-
THCA	cis	rs2361718	0.5	rs12451697	ENSG00000279259.1	RP11-334C17.3	6.88	1.91e-11	5.13e-09	0.3	0.3	Yeast infection;	chr17:80126891	chr17:80147250~80148596:+
THCA	cis	rs7847628	0.587	rs4837796	ENSG00000270917.1	RP11-27I1.6	6.88	1.91e-11	5.13e-09	0.41	0.3	Birth weight;	chr9:120848010	chr9:120812475~120812845:-
THCA	cis	rs41307935	0.908	rs12739212	ENSG00000260063.1	RP5-968P14.2	-6.88	1.91e-11	5.14e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26724087	chr1:26692132~26694131:-
THCA	cis	rs2880765	0.743	rs11630410	ENSG00000259295.5	CSPG4P12	6.88	1.91e-11	5.15e-09	0.38	0.3	Coronary artery disease;	chr15:85461510	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.71	rs11630457	ENSG00000259295.5	CSPG4P12	6.88	1.91e-11	5.15e-09	0.38	0.3	Coronary artery disease;	chr15:85461570	chr15:85191438~85213905:+
THCA	cis	rs4474742	1	rs4474742	ENSG00000264007.1	RP11-68I3.10	-6.88	1.91e-11	5.15e-09	-0.35	-0.3	Monocyte count;	chr17:29738560	chr17:29621617~29622254:-
THCA	cis	rs17695224	0.565	rs7253182	ENSG00000269483.1	AC006272.1	6.88	1.92e-11	5.16e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51808838	chr19:51839924~51843324:-
THCA	cis	rs6570726	0.516	rs10457779	ENSG00000235652.6	RP11-545I5.3	6.88	1.92e-11	5.16e-09	0.28	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145415527	chr6:145799409~145886585:+
THCA	cis	rs1023500	0.505	rs134888	ENSG00000205702.9	CYP2D7	6.88	1.92e-11	5.16e-09	0.23	0.3	Schizophrenia;	chr22:42278275	chr22:42140203~42144577:-
THCA	cis	rs2880765	0.743	rs16940052	ENSG00000259295.5	CSPG4P12	6.88	1.92e-11	5.16e-09	0.38	0.3	Coronary artery disease;	chr15:85463443	chr15:85191438~85213905:+
THCA	cis	rs7044106	0.791	rs10818473	ENSG00000238181.2	AHCYP2	-6.88	1.92e-11	5.16e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120720673~120721972:+
THCA	cis	rs7727544	0.716	rs11955347	ENSG00000233006.5	AC034220.3	6.88	1.92e-11	5.17e-09	0.24	0.3	Blood metabolite levels;	chr5:132232231	chr5:132311285~132369916:-
THCA	cis	rs4713118	0.869	rs4713121	ENSG00000280107.1	AL022393.9	-6.88	1.92e-11	5.17e-09	-0.36	-0.3	Parkinson's disease;	chr6:27754285	chr6:28170845~28172521:+
THCA	cis	rs2880765	0.743	rs4551990	ENSG00000259295.5	CSPG4P12	6.88	1.92e-11	5.18e-09	0.38	0.3	Coronary artery disease;	chr15:85472056	chr15:85191438~85213905:+
THCA	cis	rs728616	0.717	rs17098169	ENSG00000225484.5	NUTM2B-AS1	6.88	1.92e-11	5.18e-09	0.57	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:79663088~79826594:-
THCA	cis	rs3806843	0.9	rs2337984	ENSG00000202515.1	VTRNA1-3	6.88	1.93e-11	5.19e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr5:140726158~140726246:+
THCA	cis	rs8062405	0.723	rs4788077	ENSG00000278665.1	RP11-666O2.4	6.88	1.93e-11	5.19e-09	0.36	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28599241~28601881:-
THCA	cis	rs11668609	1	rs66972560	ENSG00000268442.1	CTD-2027I19.2	6.88	1.93e-11	5.2e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24178138	chr19:24162370~24163425:-
THCA	cis	rs9902453	0.904	rs9900974	ENSG00000264007.1	RP11-68I3.10	-6.88	1.93e-11	5.21e-09	-0.34	-0.3	Coffee consumption (cups per day);	chr17:30037438	chr17:29621617~29622254:-
THCA	cis	rs7260598	0.792	rs11672981	ENSG00000268442.1	CTD-2027I19.2	6.88	1.94e-11	5.21e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24144735	chr19:24162370~24163425:-
THCA	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-6.88	1.94e-11	5.22e-09	-0.31	-0.3	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
THCA	cis	rs10055631	0.518	rs778444	ENSG00000229666.1	MAST4-AS1	6.88	1.94e-11	5.22e-09	0.34	0.3	Coronary artery disease;	chr5:67010118	chr5:67001383~67003953:-
THCA	cis	rs6696239	0.513	rs976959	ENSG00000227711.2	RP11-275O4.5	6.88	1.94e-11	5.22e-09	0.32	0.3	Height;	chr1:227518601	chr1:227509028~227520477:-
THCA	cis	rs1125355	1	rs72943174	ENSG00000251491.2	OR7E28P	-6.88	1.94e-11	5.23e-09	-0.48	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158843688	chr2:158862311~158863285:+
THCA	cis	rs1125355	1	rs72943176	ENSG00000251491.2	OR7E28P	-6.88	1.94e-11	5.23e-09	-0.48	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158843689	chr2:158862311~158863285:+
THCA	cis	rs1125355	0.964	rs72943178	ENSG00000251491.2	OR7E28P	-6.88	1.94e-11	5.23e-09	-0.48	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158843707	chr2:158862311~158863285:+
THCA	cis	rs1125355	1	rs1125354	ENSG00000251491.2	OR7E28P	-6.88	1.94e-11	5.23e-09	-0.48	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158844053	chr2:158862311~158863285:+
THCA	cis	rs17695224	0.675	rs1468641	ENSG00000269483.1	AC006272.1	6.88	1.94e-11	5.23e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51838366	chr19:51839924~51843324:-
THCA	cis	rs12928939	0.768	rs71386932	ENSG00000260886.1	TAT-AS1	6.88	1.95e-11	5.24e-09	0.41	0.3	Post bronchodilator FEV1;	chr16:71782288	chr16:71565789~71578187:+
THCA	cis	rs12928939	0.911	rs8051878	ENSG00000260886.1	TAT-AS1	6.88	1.95e-11	5.24e-09	0.41	0.3	Post bronchodilator FEV1;	chr16:71784528	chr16:71565789~71578187:+
THCA	cis	rs4925386	0.808	rs1741634	ENSG00000273619.1	RP5-908M14.9	6.88	1.95e-11	5.24e-09	0.24	0.3	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350923	chr20:62386303~62386970:-
THCA	cis	rs1075232	1	rs66581165	ENSG00000270055.1	CTD-3092A11.2	-6.88	1.95e-11	5.26e-09	-0.57	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30487963~30490313:+
THCA	cis	rs2880765	0.743	rs8039049	ENSG00000259295.5	CSPG4P12	6.88	1.96e-11	5.26e-09	0.38	0.3	Coronary artery disease;	chr15:85464398	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.743	rs8039631	ENSG00000259295.5	CSPG4P12	6.88	1.96e-11	5.26e-09	0.38	0.3	Coronary artery disease;	chr15:85464700	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.743	rs12906308	ENSG00000259295.5	CSPG4P12	-6.88	1.96e-11	5.26e-09	-0.38	-0.3	Coronary artery disease;	chr15:85464828	chr15:85191438~85213905:+
THCA	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	6.88	1.96e-11	5.26e-09	0.36	0.3	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
THCA	cis	rs7247513	0.701	rs8107642	ENSG00000213290.4	PGK1P2	-6.88	1.96e-11	5.27e-09	-0.35	-0.3	Bipolar disorder;	chr19:12655556	chr19:12559571~12561105:+
THCA	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	6.88	1.96e-11	5.27e-09	0.45	0.3	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
THCA	cis	rs11096990	0.855	rs2566170	ENSG00000249207.1	RP11-360F5.1	6.88	1.96e-11	5.27e-09	0.39	0.3	Cognitive function;	chr4:39150757	chr4:39112677~39126818:-
THCA	cis	rs8012947	1	rs7154212	ENSG00000279636.2	LINC00216	-6.88	1.96e-11	5.28e-09	-0.31	-0.3	Alcohol consumption in current drinkers;	chr14:58295491	chr14:58288033~58289158:+
THCA	cis	rs4713118	0.868	rs10484401	ENSG00000280107.1	AL022393.9	6.88	1.97e-11	5.29e-09	0.37	0.3	Parkinson's disease;	chr6:27778811	chr6:28170845~28172521:+
THCA	cis	rs71636778	0.509	rs34728853	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26674088	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.73	rs12724159	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26709637	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12729444	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26710663	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12726081	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711084	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12730386	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711498	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs79568175	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711725	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12726287	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26712737	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.908	rs12756154	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26714018	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs35407375	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26714727	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.818	rs80036989	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26721033	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs60401377	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26725756	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs35256560	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26727525	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs56932185	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26730152	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34693293	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742480	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs35560426	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742678	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs58421016	ENSG00000260063.1	RP5-968P14.2	-6.88	1.97e-11	5.29e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26744038	chr1:26692132~26694131:-
THCA	cis	rs853679	0.607	rs34788973	ENSG00000280107.1	AL022393.9	-6.88	1.97e-11	5.3e-09	-0.6	-0.3	Depression;	chr6:27911422	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs61742093	ENSG00000280107.1	AL022393.9	-6.88	1.97e-11	5.3e-09	-0.6	-0.3	Depression;	chr6:27912204	chr6:28170845~28172521:+
THCA	cis	rs9402743	0.632	rs9389330	ENSG00000231028.7	LINC00271	6.88	1.97e-11	5.3e-09	0.22	0.3	Systemic lupus erythematosus;	chr6:135787865	chr6:135497801~135716055:+
THCA	cis	rs240993	0.81	rs466765	ENSG00000230177.1	RP5-1112D6.4	-6.88	1.97e-11	5.3e-09	-0.31	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111347291	chr6:111277932~111278742:+
THCA	cis	rs2976388	1	rs2920280	ENSG00000253741.1	CTD-2292P10.4	6.88	1.97e-11	5.31e-09	0.38	0.3	Urinary tract infection frequency;	chr8:142679726	chr8:142702252~142726973:-
THCA	cis	rs4950322	0.802	rs72694705	ENSG00000237188.3	RP11-337C18.8	6.88	1.97e-11	5.31e-09	0.38	0.3	Protein quantitative trait loci;	chr1:147362313	chr1:147172771~147211568:+
THCA	cis	rs7580658	0.545	rs885276	ENSG00000236682.1	AC068282.3	-6.88	1.98e-11	5.31e-09	-0.39	-0.3	Protein C levels;	chr2:127193328	chr2:127389130~127400580:+
THCA	cis	rs10266483	0.739	rs679966	ENSG00000227986.1	TRIM60P18	-6.88	1.98e-11	5.31e-09	-0.25	-0.3	Response to statin therapy;	chr7:64306688	chr7:64355078~64356199:+
THCA	cis	rs7044106	0.718	rs1981021	ENSG00000238181.2	AHCYP2	-6.88	1.98e-11	5.31e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120720673~120721972:+
THCA	cis	rs7044106	0.734	rs1981020	ENSG00000238181.2	AHCYP2	-6.88	1.98e-11	5.31e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120720673~120721972:+
THCA	cis	rs7746199	0.736	rs10484399	ENSG00000219392.1	RP1-265C24.5	-6.88	1.98e-11	5.31e-09	-0.66	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28115628~28116551:+
THCA	cis	rs7246657	0.943	rs10407084	ENSG00000226686.6	LINC01535	-6.88	1.98e-11	5.32e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37416890	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.823	rs4802236	ENSG00000226686.6	LINC01535	-6.88	1.98e-11	5.32e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37428344	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs7252099	ENSG00000226686.6	LINC01535	-6.88	1.98e-11	5.32e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37442878	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs7255972	ENSG00000226686.6	LINC01535	-6.88	1.98e-11	5.32e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37442939	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs1015849	ENSG00000226686.6	LINC01535	-6.88	1.98e-11	5.32e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37455278	chr19:37251912~37265535:+
THCA	cis	rs7267979	0.932	rs928121	ENSG00000274414.1	RP5-965G21.4	-6.88	1.98e-11	5.32e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25239007~25245229:-
THCA	cis	rs12348691	0.503	rs7847259	ENSG00000236130.1	PTCSC2	-6.87	1.98e-11	5.33e-09	-0.25	-0.3	Alopecia areata;	chr9:97838430	chr9:97805935~97810008:-
THCA	cis	rs11723261	0.664	rs4627799	ENSG00000211553.1	AC253576.2	-6.87	1.98e-11	5.33e-09	-0.41	-0.3	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:136461~136568:+
THCA	cis	rs7267979	0.932	rs2260997	ENSG00000274414.1	RP5-965G21.4	6.87	1.98e-11	5.33e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25239007~25245229:-
THCA	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	6.87	1.98e-11	5.33e-09	0.6	0.3	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	6.87	1.98e-11	5.33e-09	0.6	0.3	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	6.87	1.98e-11	5.33e-09	0.6	0.3	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
THCA	cis	rs10844706	1	rs10844706	ENSG00000256594.6	RP11-705C15.2	6.87	1.98e-11	5.33e-09	0.25	0.3	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9757536	chr12:9633419~9658412:+
THCA	cis	rs860295	0.775	rs1749410	ENSG00000225855.5	RUSC1-AS1	-6.87	1.98e-11	5.33e-09	-0.2	-0.3	Body mass index;	chr1:155874274	chr1:155316863~155324176:-
THCA	cis	rs12435908	1	rs17826580	ENSG00000276116.2	FUT8-AS1	-6.87	1.98e-11	5.33e-09	-0.48	-0.3	Ischemic stroke;	chr14:65448544	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs2184602	ENSG00000276116.2	FUT8-AS1	-6.87	1.98e-11	5.33e-09	-0.48	-0.3	Ischemic stroke;	chr14:65448954	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs9635251	ENSG00000276116.2	FUT8-AS1	-6.87	1.98e-11	5.33e-09	-0.48	-0.3	Ischemic stroke;	chr14:65461750	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs73284121	ENSG00000276116.2	FUT8-AS1	-6.87	1.98e-11	5.33e-09	-0.48	-0.3	Ischemic stroke;	chr14:65470218	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs12434585	ENSG00000276116.2	FUT8-AS1	-6.87	1.98e-11	5.33e-09	-0.48	-0.3	Ischemic stroke;	chr14:65471650	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs59676254	ENSG00000276116.2	FUT8-AS1	-6.87	1.98e-11	5.33e-09	-0.48	-0.3	Ischemic stroke;	chr14:65476122	chr14:65411170~65412690:-
THCA	cis	rs12435908	0.881	rs73284143	ENSG00000276116.2	FUT8-AS1	-6.87	1.98e-11	5.33e-09	-0.48	-0.3	Ischemic stroke;	chr14:65492725	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs8018909	ENSG00000276116.2	FUT8-AS1	-6.87	1.98e-11	5.33e-09	-0.48	-0.3	Ischemic stroke;	chr14:65493687	chr14:65411170~65412690:-
THCA	cis	rs71636778	0.509	rs34175245	ENSG00000260063.1	RP5-968P14.2	-6.87	1.99e-11	5.34e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26675220	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12731749	ENSG00000260063.1	RP5-968P14.2	-6.87	1.99e-11	5.35e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759071	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs74825034	ENSG00000260063.1	RP5-968P14.2	-6.87	1.99e-11	5.35e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26768641	chr1:26692132~26694131:-
THCA	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	6.87	1.99e-11	5.35e-09	0.39	0.3	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
THCA	cis	rs9287719	0.649	rs6717431	ENSG00000243819.4	RN7SL832P	6.87	1.99e-11	5.36e-09	0.25	0.3	Prostate cancer;	chr2:10585920	chr2:10690344~10692099:+
THCA	cis	rs7726354	0.546	rs77982563	ENSG00000271828.1	CTD-2310F14.1	6.87	2e-11	5.37e-09	0.74	0.3	Breast cancer (early onset);	chr5:56897840	chr5:56927874~56929573:+
THCA	cis	rs7727544	0.654	rs4705849	ENSG00000233006.5	AC034220.3	6.87	2e-11	5.37e-09	0.24	0.3	Blood metabolite levels;	chr5:132223506	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.716	rs72793278	ENSG00000233006.5	AC034220.3	6.87	2e-11	5.37e-09	0.24	0.3	Blood metabolite levels;	chr5:132225679	chr5:132311285~132369916:-
THCA	cis	rs875971	0.862	rs908915	ENSG00000232559.3	GS1-124K5.12	-6.87	2e-11	5.37e-09	-0.29	-0.3	Aortic root size;	chr7:66149664	chr7:66554588~66576923:-
THCA	cis	rs792448	0.692	rs351407	ENSG00000226251.4	RP11-15I11.3	-6.87	2e-11	5.37e-09	-0.39	-0.3	White blood cell count (basophil);	chr1:212264100	chr1:212225278~212238977:-
THCA	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-6.87	2e-11	5.37e-09	-0.47	-0.3	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
THCA	cis	rs7246657	0.943	rs4801803	ENSG00000226686.6	LINC01535	6.87	2e-11	5.37e-09	0.45	0.3	Coronary artery calcification;	chr19:37476021	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs12981532	ENSG00000226686.6	LINC01535	-6.87	2e-11	5.37e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37398378	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs7246993	ENSG00000226686.6	LINC01535	-6.87	2e-11	5.37e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37399252	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs10413602	ENSG00000226686.6	LINC01535	-6.87	2e-11	5.37e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37400590	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs2303131	ENSG00000226686.6	LINC01535	-6.87	2e-11	5.37e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37445123	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs1015848	ENSG00000226686.6	LINC01535	-6.87	2e-11	5.37e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37454372	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.943	rs4801759	ENSG00000226686.6	LINC01535	-6.87	2e-11	5.37e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37464083	chr19:37251912~37265535:+
THCA	cis	rs2976388	1	rs1045605	ENSG00000253741.1	CTD-2292P10.4	6.87	2e-11	5.38e-09	0.37	0.3	Urinary tract infection frequency;	chr8:142682683	chr8:142702252~142726973:-
THCA	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-6.87	2e-11	5.38e-09	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
THCA	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	6.87	2.01e-11	5.39e-09	0.4	0.3	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
THCA	cis	rs7324557	0.651	rs9510875	ENSG00000205861.10	C1QTNF9B-AS1	-6.87	2.01e-11	5.39e-09	-0.37	-0.3	Visceral adipose tissue adjusted for BMI;	chr13:23820351	chr13:23888889~23897263:+
THCA	cis	rs7324557	0.717	rs729137	ENSG00000205861.10	C1QTNF9B-AS1	-6.87	2.01e-11	5.39e-09	-0.37	-0.3	Visceral adipose tissue adjusted for BMI;	chr13:23821523	chr13:23888889~23897263:+
THCA	cis	rs7324557	0.717	rs9318064	ENSG00000205861.10	C1QTNF9B-AS1	-6.87	2.01e-11	5.39e-09	-0.37	-0.3	Visceral adipose tissue adjusted for BMI;	chr13:23822010	chr13:23888889~23897263:+
THCA	cis	rs7324557	0.717	rs9510876	ENSG00000205861.10	C1QTNF9B-AS1	-6.87	2.01e-11	5.39e-09	-0.37	-0.3	Visceral adipose tissue adjusted for BMI;	chr13:23822149	chr13:23888889~23897263:+
THCA	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	6.87	2.01e-11	5.39e-09	0.45	0.3	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
THCA	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-6.87	2.01e-11	5.4e-09	-0.55	-0.3	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000229886.1	RP5-1132H15.3	6.87	2.01e-11	5.4e-09	0.48	0.3	Diabetic kidney disease;	chr7:65951319	chr7:66025126~66031544:-
THCA	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	6.87	2.01e-11	5.4e-09	0.38	0.3	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
THCA	cis	rs4664293	1	rs6432540	ENSG00000226266.5	AC009961.3	-6.87	2.02e-11	5.41e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159594192	chr2:159670708~159712435:-
THCA	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-6.87	2.02e-11	5.43e-09	-0.32	-0.3	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
THCA	cis	rs7246657	0.943	rs13343471	ENSG00000226686.6	LINC01535	-6.87	2.03e-11	5.44e-09	-0.47	-0.3	Coronary artery calcification;	chr19:37441228	chr19:37251912~37265535:+
THCA	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-6.87	2.03e-11	5.44e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
THCA	cis	rs7267979	0.873	rs6132822	ENSG00000274414.1	RP5-965G21.4	-6.87	2.03e-11	5.44e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25239007~25245229:-
THCA	cis	rs651907	0.535	rs9830943	ENSG00000256628.3	ZBTB11-AS1	6.87	2.03e-11	5.45e-09	0.36	0.3	Colorectal cancer;	chr3:101710055	chr3:101676475~101679217:+
THCA	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-6.87	2.03e-11	5.45e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
THCA	cis	rs2562456	0.516	rs56072098	ENSG00000268119.4	CTD-2561J22.5	-6.87	2.03e-11	5.46e-09	-0.37	-0.3	Pain;	chr19:21469158	chr19:21444241~21463908:-
THCA	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	6.87	2.04e-11	5.46e-09	0.56	0.3	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
THCA	cis	rs8059260	0.673	rs8056854	ENSG00000274038.1	RP11-66H6.4	-6.87	2.04e-11	5.46e-09	-0.56	-0.3	Alcohol consumption over the past year;	chr16:10947858	chr16:11056556~11057034:+
THCA	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-6.87	2.04e-11	5.47e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-6.87	2.04e-11	5.47e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-6.87	2.04e-11	5.47e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-6.87	2.04e-11	5.47e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-6.87	2.04e-11	5.47e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
THCA	cis	rs8067545	0.641	rs203466	ENSG00000270091.1	RP11-78O7.2	6.87	2.04e-11	5.47e-09	0.22	0.3	Schizophrenia;	chr17:19906640	chr17:19896590~19897287:-
THCA	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	6.87	2.04e-11	5.47e-09	0.33	0.3	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
THCA	cis	rs6840258	1	rs6819155	ENSG00000251411.1	RP11-397E7.4	-6.87	2.04e-11	5.48e-09	-0.36	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87055026	chr4:86913266~86914817:-
THCA	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	6.87	2.04e-11	5.48e-09	0.33	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
THCA	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-6.87	2.04e-11	5.49e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-6.87	2.04e-11	5.49e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
THCA	cis	rs7942368	1	rs4309181	ENSG00000254632.1	RP11-21L23.4	6.87	2.05e-11	5.49e-09	0.44	0.3	Endometriosis;	chr11:76790661	chr11:76759916~76768223:-
THCA	cis	rs240993	0.715	rs6920798	ENSG00000230177.1	RP5-1112D6.4	6.87	2.05e-11	5.5e-09	0.29	0.3	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111277932~111278742:+
THCA	cis	rs934734	0.736	rs1396210	ENSG00000204929.10	AC074391.1	6.87	2.05e-11	5.5e-09	0.38	0.3	Rheumatoid arthritis;	chr2:65357140	chr2:65436711~66084639:+
THCA	cis	rs17684571	0.938	rs34724718	ENSG00000231441.1	RP11-472M19.2	6.87	2.05e-11	5.5e-09	0.36	0.3	Schizophrenia;	chr6:56693024	chr6:56844002~56864078:+
THCA	cis	rs7208859	0.524	rs8069400	ENSG00000263603.1	CTD-2349P21.5	-6.87	2.05e-11	5.5e-09	-0.55	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30729469~30731202:+
THCA	cis	rs7267979	1	rs2482943	ENSG00000274414.1	RP5-965G21.4	6.87	2.05e-11	5.5e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2500418	ENSG00000274414.1	RP5-965G21.4	6.87	2.05e-11	5.5e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25239007~25245229:-
THCA	cis	rs6539288	0.933	rs1444581	ENSG00000260329.1	RP11-412D9.4	-6.87	2.05e-11	5.51e-09	-0.27	-0.3	Total body bone mineral density;	chr12:106920473	chr12:106954029~106955497:-
THCA	cis	rs4835473	0.897	rs62337587	ENSG00000251600.4	RP11-673E1.1	-6.87	2.06e-11	5.52e-09	-0.41	-0.3	Immature fraction of reticulocytes;	chr4:143725839	chr4:143912331~143982454:+
THCA	cis	rs6928977	0.675	rs7750586	ENSG00000231028.7	LINC00271	6.87	2.06e-11	5.52e-09	0.25	0.3	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135497801~135716055:+
THCA	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	6.87	2.06e-11	5.53e-09	0.39	0.3	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
THCA	cis	rs853679	0.517	rs9393895	ENSG00000220721.1	OR1F12	6.87	2.06e-11	5.53e-09	0.42	0.3	Depression;	chr6:28159843	chr6:28073316~28074233:+
THCA	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	6.87	2.06e-11	5.53e-09	0.23	0.3	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
THCA	cis	rs8141529	0.732	rs5762784	ENSG00000226471.5	CTA-292E10.6	-6.87	2.06e-11	5.54e-09	-0.25	-0.3	Lymphocyte counts;	chr22:28775310	chr22:28800683~28848559:+
THCA	cis	rs3812049	1	rs3812049	ENSG00000245937.6	LINC01184	6.87	2.06e-11	5.54e-09	0.34	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128083158	chr5:127940426~128083172:-
THCA	cis	rs7942368	0.941	rs10899283	ENSG00000254632.1	RP11-21L23.4	6.87	2.07e-11	5.55e-09	0.44	0.3	Endometriosis;	chr11:76794158	chr11:76759916~76768223:-
THCA	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-6.87	2.07e-11	5.56e-09	-0.29	-0.3	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-6.87	2.07e-11	5.56e-09	-0.29	-0.3	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-6.87	2.07e-11	5.56e-09	-0.29	-0.3	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-6.87	2.07e-11	5.56e-09	-0.29	-0.3	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
THCA	cis	rs9902453	0.619	rs2244585	ENSG00000264007.1	RP11-68I3.10	-6.87	2.07e-11	5.56e-09	-0.35	-0.3	Coffee consumption (cups per day);	chr17:29745158	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.619	rs2617866	ENSG00000264007.1	RP11-68I3.10	-6.87	2.07e-11	5.56e-09	-0.35	-0.3	Coffee consumption (cups per day);	chr17:29749199	chr17:29621617~29622254:-
THCA	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	6.87	2.08e-11	5.58e-09	0.45	0.3	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
THCA	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	6.87	2.08e-11	5.58e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
THCA	cis	rs7246657	0.943	rs10422074	ENSG00000226686.6	LINC01535	-6.87	2.08e-11	5.58e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37403334	chr19:37251912~37265535:+
THCA	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	6.87	2.08e-11	5.59e-09	0.2	0.3	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
THCA	cis	rs7851660	0.844	rs13287360	ENSG00000236130.1	PTCSC2	-6.87	2.09e-11	5.59e-09	-0.25	-0.3	Strep throat;	chr9:97875399	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.844	rs4743139	ENSG00000236130.1	PTCSC2	-6.87	2.09e-11	5.59e-09	-0.25	-0.3	Strep throat;	chr9:97876138	chr9:97805935~97810008:-
THCA	cis	rs11158026	0.826	rs7147286	ENSG00000258413.1	RP11-665C16.6	-6.87	2.09e-11	5.6e-09	-0.41	-0.3	Parkinson's disease;	chr14:54891947	chr14:55262767~55272075:-
THCA	cis	rs11148252	0.514	rs9526843	ENSG00000278238.1	RP11-245D16.4	-6.87	2.09e-11	5.6e-09	-0.34	-0.3	Lewy body disease;	chr13:52155921	chr13:52454775~52455331:-
THCA	cis	rs5006884	0.507	rs4910760	ENSG00000167355.6	AC104389.28	-6.87	2.09e-11	5.6e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5354153	chr11:5304976~5505652:-
THCA	cis	rs728616	1	rs56317427	ENSG00000225484.5	NUTM2B-AS1	-6.87	2.09e-11	5.61e-09	-0.58	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80102178	chr10:79663088~79826594:-
THCA	cis	rs8007846	0.521	rs1003401	ENSG00000276116.2	FUT8-AS1	6.87	2.09e-11	5.61e-09	0.31	0.3	Multiple sclerosis--Brain Glutamate Levels;	chr14:65771002	chr14:65411170~65412690:-
THCA	cis	rs875971	0.862	rs1612452	ENSG00000232559.3	GS1-124K5.12	-6.87	2.1e-11	5.62e-09	-0.29	-0.3	Aortic root size;	chr7:66108909	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs1167390	ENSG00000232559.3	GS1-124K5.12	-6.87	2.1e-11	5.62e-09	-0.29	-0.3	Aortic root size;	chr7:66110906	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs35034167	ENSG00000232559.3	GS1-124K5.12	-6.87	2.1e-11	5.62e-09	-0.29	-0.3	Aortic root size;	chr7:66115179	chr7:66554588~66576923:-
THCA	cis	rs516805	0.561	rs9490497	ENSG00000279453.1	RP3-425C14.4	-6.87	2.1e-11	5.62e-09	-0.35	-0.3	Lymphocyte counts;	chr6:122615904	chr6:122436789~122439223:-
THCA	cis	rs7727544	0.716	rs4705926	ENSG00000233006.5	AC034220.3	6.87	2.1e-11	5.62e-09	0.24	0.3	Blood metabolite levels;	chr5:132226065	chr5:132311285~132369916:-
THCA	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	6.87	2.1e-11	5.63e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
THCA	cis	rs34976449	1	rs34976449	ENSG00000232912.4	RP5-1115A15.1	6.87	2.1e-11	5.63e-09	0.3	0.3	Lymphocyte counts;	chr1:8438266	chr1:8424645~8434838:+
THCA	cis	rs6600671	0.934	rs12060031	ENSG00000223345.3	HIST2H2BA	-6.87	2.1e-11	5.63e-09	-0.34	-0.3	Hip geometry;	chr1:121501652	chr1:121108210~121117257:-
THCA	cis	rs1598856	1	rs11934404	ENSG00000246560.2	RP11-10L12.4	6.87	2.1e-11	5.64e-09	0.36	0.3	Primary biliary cholangitis;	chr4:102516444	chr4:102828055~102844075:+
THCA	cis	rs5006884	0.547	rs79780644	ENSG00000167355.6	AC104389.28	-6.87	2.1e-11	5.64e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5361637	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.526	rs2736554	ENSG00000167355.6	AC104389.28	-6.87	2.1e-11	5.64e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5361860	chr11:5304976~5505652:-
THCA	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	6.87	2.11e-11	5.64e-09	0.28	0.3	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
THCA	cis	rs848490	0.925	rs56215603	ENSG00000214293.7	APTR	6.87	2.11e-11	5.64e-09	0.24	0.3	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77688865	chr7:77657660~77696265:-
THCA	cis	rs8030379	0.967	rs6603001	ENSG00000230373.7	GOLGA6L5P	-6.87	2.11e-11	5.65e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896516	chr15:84507885~84516814:-
THCA	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	6.87	2.11e-11	5.65e-09	0.25	0.3	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000228409.4	CCT6P1	-6.87	2.11e-11	5.65e-09	-0.36	-0.3	Diabetic kidney disease;	chr7:66219914	chr7:65751142~65763354:+
THCA	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	6.86	2.11e-11	5.65e-09	0.24	0.3	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
THCA	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	6.86	2.11e-11	5.66e-09	0.37	0.3	Height;	chr6:109416225	chr6:109382795~109383666:+
THCA	cis	rs7727544	0.545	rs4705915	ENSG00000237714.1	P4HA2-AS1	6.86	2.11e-11	5.66e-09	0.43	0.3	Blood metabolite levels;	chr5:132055765	chr5:132184876~132192808:+
THCA	cis	rs55665837	0.701	rs12787709	ENSG00000251991.1	RNU7-49P	6.86	2.12e-11	5.67e-09	0.35	0.3	Vitamin D levels;	chr11:14617711	chr11:14478892~14478953:+
THCA	cis	rs9902453	0.904	rs7208579	ENSG00000264007.1	RP11-68I3.10	6.86	2.12e-11	5.67e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29936049	chr17:29621617~29622254:-
THCA	cis	rs9341808	0.718	rs9448898	ENSG00000272129.1	RP11-250B2.6	6.86	2.12e-11	5.68e-09	0.38	0.3	Sitting height ratio;	chr6:80135624	chr6:80355424~80356859:+
THCA	cis	rs35260072	1	rs35260072	ENSG00000224431.1	AC063976.7	6.86	2.12e-11	5.68e-09	0.27	0.3	Itch intensity from mosquito bite;	chr5:132295159	chr5:132199456~132203487:+
THCA	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-6.86	2.12e-11	5.68e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
THCA	cis	rs7246657	0.882	rs10422667	ENSG00000226686.6	LINC01535	-6.86	2.12e-11	5.69e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37446974	chr19:37251912~37265535:+
THCA	cis	rs12681366	0.762	rs3019148	ENSG00000253704.1	RP11-267M23.4	6.86	2.13e-11	5.69e-09	0.29	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94417407	chr8:94553722~94569745:+
THCA	cis	rs71636778	0.509	rs12748152	ENSG00000260063.1	RP5-968P14.2	-6.86	2.13e-11	5.69e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26811902	chr1:26692132~26694131:-
THCA	cis	rs7208859	0.673	rs1347360	ENSG00000264538.5	SUZ12P1	-6.86	2.13e-11	5.7e-09	-0.29	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30709299~30790908:+
THCA	cis	rs67340775	0.834	rs13218875	ENSG00000280107.1	AL022393.9	-6.86	2.13e-11	5.7e-09	-0.6	-0.3	Lung cancer in ever smokers;	chr6:27916234	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs67040724	ENSG00000280107.1	AL022393.9	-6.86	2.13e-11	5.7e-09	-0.6	-0.3	Depression;	chr6:27937731	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs67662114	ENSG00000280107.1	AL022393.9	-6.86	2.13e-11	5.7e-09	-0.6	-0.3	Depression;	chr6:27964523	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13216117	ENSG00000280107.1	AL022393.9	-6.86	2.13e-11	5.7e-09	-0.6	-0.3	Depression;	chr6:27970706	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs36101351	ENSG00000280107.1	AL022393.9	-6.86	2.13e-11	5.7e-09	-0.6	-0.3	Depression;	chr6:27975591	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs28360499	ENSG00000280107.1	AL022393.9	-6.86	2.13e-11	5.7e-09	-0.6	-0.3	Depression;	chr6:27977618	chr6:28170845~28172521:+
THCA	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	6.86	2.13e-11	5.7e-09	0.49	0.3	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
THCA	cis	rs5006884	0.526	rs2736557	ENSG00000167355.6	AC104389.28	-6.86	2.14e-11	5.71e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5361361	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.507	rs17355388	ENSG00000167355.6	AC104389.28	-6.86	2.14e-11	5.71e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5361512	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.526	rs12808394	ENSG00000167355.6	AC104389.28	-6.86	2.14e-11	5.71e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5361551	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.526	rs12802814	ENSG00000167355.6	AC104389.28	-6.86	2.14e-11	5.71e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5361574	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.507	rs12802968	ENSG00000167355.6	AC104389.28	-6.86	2.14e-11	5.71e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5361636	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.507	rs4910765	ENSG00000167355.6	AC104389.28	-6.86	2.14e-11	5.71e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5362173	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.507	rs4910770	ENSG00000167355.6	AC104389.28	-6.86	2.14e-11	5.71e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5362568	chr11:5304976~5505652:-
THCA	cis	rs7746199	0.736	rs10484399	ENSG00000226314.6	ZNF192P1	-6.86	2.14e-11	5.72e-09	-0.65	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28161781~28169594:+
THCA	cis	rs6504622	0.905	rs2317997	ENSG00000262879.4	RP11-156P1.3	6.86	2.14e-11	5.73e-09	0.28	0.3	Orofacial clefts;	chr17:46950282	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.905	rs3809854	ENSG00000262879.4	RP11-156P1.3	6.86	2.14e-11	5.73e-09	0.28	0.3	Orofacial clefts;	chr17:46951928	chr17:46984045~47100323:-
THCA	cis	rs11668609	0.872	rs4416149	ENSG00000268442.1	CTD-2027I19.2	6.86	2.14e-11	5.74e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24093551	chr19:24162370~24163425:-
THCA	cis	rs11668609	0.935	rs7257096	ENSG00000268442.1	CTD-2027I19.2	6.86	2.14e-11	5.74e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24098965	chr19:24162370~24163425:-
THCA	cis	rs1385374	0.8	rs12321679	ENSG00000274695.1	RP11-21K12.3	6.86	2.15e-11	5.75e-09	0.53	0.3	Systemic lupus erythematosus;	chr12:128800246	chr12:128826836~128827579:+
THCA	cis	rs3806843	0.676	rs778593	ENSG00000202515.1	VTRNA1-3	6.86	2.15e-11	5.75e-09	0.35	0.3	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.676	rs778594	ENSG00000202515.1	VTRNA1-3	6.86	2.15e-11	5.75e-09	0.35	0.3	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr5:140726158~140726246:+
THCA	cis	rs6723108	0.603	rs6430555	ENSG00000224043.6	CCNT2-AS1	-6.86	2.15e-11	5.75e-09	-0.32	-0.3	Type 2 diabetes;	chr2:134890089	chr2:134735464~134918710:-
THCA	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	6.86	2.15e-11	5.76e-09	0.37	0.3	Height;	chr6:109414295	chr6:109382795~109383666:+
THCA	cis	rs1552244	0.882	rs28366039	ENSG00000232901.1	CYCSP10	6.86	2.15e-11	5.76e-09	0.39	0.3	Alzheimer's disease;	chr3:9987304	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs3755783	ENSG00000232901.1	CYCSP10	6.86	2.15e-11	5.76e-09	0.39	0.3	Alzheimer's disease;	chr3:9987605	chr3:10000647~10000940:-
THCA	cis	rs12435908	1	rs2268957	ENSG00000276116.2	FUT8-AS1	6.86	2.15e-11	5.76e-09	0.47	0.3	Ischemic stroke;	chr14:65646515	chr14:65411170~65412690:-
THCA	cis	rs8030379	1	rs8041056	ENSG00000230373.7	GOLGA6L5P	-6.86	2.16e-11	5.77e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896065	chr15:84507885~84516814:-
THCA	cis	rs6088580	0.505	rs6058106	ENSG00000269202.1	RP4-614O4.12	6.86	2.16e-11	5.77e-09	0.26	0.3	Glomerular filtration rate (creatinine);	chr20:34690451	chr20:35201747~35203288:-
THCA	cis	rs7403037	0.754	rs34443849	ENSG00000259905.4	PWRN1	6.86	2.16e-11	5.77e-09	0.33	0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24257156	chr15:24493137~24652130:+
THCA	cis	rs5006884	0.507	rs2647600	ENSG00000167355.6	AC104389.28	-6.86	2.16e-11	5.78e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5355220	chr11:5304976~5505652:-
THCA	cis	rs28510890	0.75	rs12591381	ENSG00000260337.3	RP11-386M24.6	6.86	2.16e-11	5.78e-09	0.42	0.3	Lung cancer in ever smokers;	chr15:92564955	chr15:92592574~92596462:-
THCA	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	6.86	2.16e-11	5.78e-09	0.45	0.3	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
THCA	cis	rs496547	0.654	rs688161	ENSG00000255239.1	AP002954.6	6.86	2.16e-11	5.79e-09	0.38	0.3	Hip minimal joint space width;	chr11:118807001	chr11:118688039~118690600:-
THCA	cis	rs7324557	0.683	rs7327303	ENSG00000205861.10	C1QTNF9B-AS1	6.86	2.16e-11	5.79e-09	0.37	0.3	Visceral adipose tissue adjusted for BMI;	chr13:23823175	chr13:23888889~23897263:+
THCA	cis	rs6696239	0.531	rs951083	ENSG00000227711.2	RP11-275O4.5	-6.86	2.17e-11	5.8e-09	-0.32	-0.3	Height;	chr1:227512770	chr1:227509028~227520477:-
THCA	cis	rs4664293	1	rs12692554	ENSG00000226266.5	AC009961.3	-6.86	2.17e-11	5.8e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159594777	chr2:159670708~159712435:-
THCA	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	6.86	2.17e-11	5.8e-09	0.21	0.3	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
THCA	cis	rs4835473	0.801	rs999049	ENSG00000251600.4	RP11-673E1.1	-6.86	2.17e-11	5.8e-09	-0.41	-0.3	Immature fraction of reticulocytes;	chr4:143715440	chr4:143912331~143982454:+
THCA	cis	rs5006884	0.547	rs2736553	ENSG00000167355.6	AC104389.28	-6.86	2.17e-11	5.81e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5363199	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.547	rs2647603	ENSG00000167355.6	AC104389.28	-6.86	2.17e-11	5.81e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5363287	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.547	rs2647604	ENSG00000167355.6	AC104389.28	-6.86	2.17e-11	5.81e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5363305	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.568	rs2647605	ENSG00000167355.6	AC104389.28	-6.86	2.17e-11	5.81e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5363331	chr11:5304976~5505652:-
THCA	cis	rs9287719	0.593	rs13009015	ENSG00000243819.4	RN7SL832P	6.86	2.17e-11	5.81e-09	0.25	0.3	Prostate cancer;	chr2:10622992	chr2:10690344~10692099:+
THCA	cis	rs17695224	0.585	rs721890	ENSG00000269483.1	AC006272.1	6.86	2.18e-11	5.83e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51837808	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.701	rs721889	ENSG00000269483.1	AC006272.1	6.86	2.18e-11	5.83e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51837996	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.701	rs1468642	ENSG00000269483.1	AC006272.1	6.86	2.18e-11	5.83e-09	0.33	0.3	HDL cholesterol;HDL cholesterol levels;	chr19:51838504	chr19:51839924~51843324:-
THCA	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	6.86	2.18e-11	5.83e-09	0.39	0.3	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
THCA	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-6.86	2.18e-11	5.83e-09	-0.37	-0.3	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
THCA	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	6.86	2.18e-11	5.84e-09	0.36	0.3	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	6.86	2.18e-11	5.84e-09	0.36	0.3	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
THCA	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-6.86	2.19e-11	5.84e-09	-0.36	-0.3	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
THCA	cis	rs595244	0.831	rs55694948	ENSG00000259705.1	RP11-227D13.1	6.86	2.19e-11	5.85e-09	0.41	0.3	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48465935	chr15:48645951~48652016:+
THCA	cis	rs17826219	0.561	rs562840	ENSG00000264538.5	SUZ12P1	-6.86	2.19e-11	5.85e-09	-0.29	-0.3	Body mass index;	chr17:30622372	chr17:30709299~30790908:+
THCA	cis	rs2439831	1	rs9920763	ENSG00000249839.1	AC011330.5	-6.86	2.19e-11	5.86e-09	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43468310	chr15:43663654~43684339:-
THCA	cis	rs7044106	0.762	rs4837790	ENSG00000238181.2	AHCYP2	-6.86	2.19e-11	5.86e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120720673~120721972:+
THCA	cis	rs2554380	0.628	rs4473150	ENSG00000230373.7	GOLGA6L5P	-6.86	2.2e-11	5.87e-09	-0.33	-0.3	Height;	chr15:83814079	chr15:84507885~84516814:-
THCA	cis	rs12681366	0.762	rs7824722	ENSG00000253704.1	RP11-267M23.4	6.86	2.2e-11	5.87e-09	0.3	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94338623	chr8:94553722~94569745:+
THCA	cis	rs9902453	0.765	rs8079209	ENSG00000264007.1	RP11-68I3.10	6.86	2.2e-11	5.87e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29859755	chr17:29621617~29622254:-
THCA	cis	rs375066	0.762	rs239943	ENSG00000267058.1	RP11-15A1.3	-6.86	2.2e-11	5.88e-09	-0.25	-0.3	Breast cancer;	chr19:43870564	chr19:43891804~43901805:-
THCA	cis	rs12348691	0.503	rs907576	ENSG00000236130.1	PTCSC2	-6.86	2.2e-11	5.88e-09	-0.25	-0.3	Alopecia areata;	chr9:97853077	chr9:97805935~97810008:-
THCA	cis	rs728616	0.867	rs41297151	ENSG00000225484.5	NUTM2B-AS1	-6.86	2.2e-11	5.88e-09	-0.57	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047411	chr10:79663088~79826594:-
THCA	cis	rs2243480	1	rs7778911	ENSG00000229886.1	RP5-1132H15.3	-6.86	2.2e-11	5.88e-09	-0.5	-0.3	Diabetic kidney disease;	chr7:66229519	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1979823	ENSG00000229886.1	RP5-1132H15.3	-6.86	2.2e-11	5.88e-09	-0.5	-0.3	Diabetic kidney disease;	chr7:66239626	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6964245	ENSG00000229886.1	RP5-1132H15.3	-6.86	2.2e-11	5.88e-09	-0.5	-0.3	Diabetic kidney disease;	chr7:66253730	chr7:66025126~66031544:-
THCA	cis	rs7294478	1	rs7294478	ENSG00000205885.6	C1RL-AS1	6.86	2.2e-11	5.89e-09	0.21	0.3	Neuritic plaque;	chr12:7114209	chr12:7108052~7122501:+
THCA	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	6.86	2.2e-11	5.89e-09	0.39	0.3	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
THCA	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-6.86	2.2e-11	5.89e-09	-0.38	-0.3	Height;	chr6:109444615	chr6:109382795~109383666:+
THCA	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-6.86	2.2e-11	5.89e-09	-0.3	-0.3	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
THCA	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-6.86	2.21e-11	5.89e-09	-0.4	-0.3	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
THCA	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	6.86	2.21e-11	5.89e-09	0.31	0.3	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
THCA	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-6.86	2.21e-11	5.89e-09	-0.39	-0.3	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
THCA	cis	rs853679	0.546	rs175597	ENSG00000219392.1	RP1-265C24.5	-6.86	2.21e-11	5.9e-09	-0.51	-0.3	Depression;	chr6:27842848	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs200989	ENSG00000219392.1	RP1-265C24.5	-6.86	2.21e-11	5.9e-09	-0.51	-0.3	Depression;	chr6:27848664	chr6:28115628~28116551:+
THCA	cis	rs8030379	1	rs4842923	ENSG00000230373.7	GOLGA6L5P	-6.86	2.21e-11	5.9e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913152	chr15:84507885~84516814:-
THCA	cis	rs5006884	0.547	rs2647606	ENSG00000167355.6	AC104389.28	-6.86	2.21e-11	5.91e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5363376	chr11:5304976~5505652:-
THCA	cis	rs42490	0.506	rs160429	ENSG00000251136.7	RP11-37B2.1	6.86	2.21e-11	5.91e-09	0.26	0.3	Leprosy;	chr8:89661255	chr8:89609409~89757727:-
THCA	cis	rs7727544	0.545	rs7716474	ENSG00000237714.1	P4HA2-AS1	6.86	2.22e-11	5.92e-09	0.42	0.3	Blood metabolite levels;	chr5:132048290	chr5:132184876~132192808:+
THCA	cis	rs11668609	0.935	rs8113172	ENSG00000268442.1	CTD-2027I19.2	6.86	2.22e-11	5.92e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24121251	chr19:24162370~24163425:-
THCA	cis	rs11668609	1	rs12609544	ENSG00000268442.1	CTD-2027I19.2	6.86	2.22e-11	5.92e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24142763	chr19:24162370~24163425:-
THCA	cis	rs2976388	0.507	rs1036385	ENSG00000253741.1	CTD-2292P10.4	-6.86	2.22e-11	5.92e-09	-0.39	-0.3	Urinary tract infection frequency;	chr8:142761483	chr8:142702252~142726973:-
THCA	cis	rs11096990	0.855	rs2566184	ENSG00000249207.1	RP11-360F5.1	6.86	2.22e-11	5.93e-09	0.39	0.3	Cognitive function;	chr4:39162700	chr4:39112677~39126818:-
THCA	cis	rs7324557	0.717	rs7139473	ENSG00000205861.10	C1QTNF9B-AS1	-6.86	2.22e-11	5.93e-09	-0.37	-0.3	Visceral adipose tissue adjusted for BMI;	chr13:23824083	chr13:23888889~23897263:+
THCA	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-6.86	2.22e-11	5.93e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
THCA	cis	rs4604234	0.614	rs11963923	ENSG00000272129.1	RP11-250B2.6	-6.86	2.22e-11	5.94e-09	-0.76	-0.3	Cancer;	chr6:80355099	chr6:80355424~80356859:+
THCA	cis	rs3806843	0.966	rs2337516	ENSG00000202515.1	VTRNA1-3	6.86	2.22e-11	5.94e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140761268	chr5:140726158~140726246:+
THCA	cis	rs2380205	0.58	rs907687	ENSG00000232807.2	RP11-536K7.3	-6.86	2.22e-11	5.94e-09	-0.28	-0.3	Breast cancer;	chr10:5858799	chr10:5934270~5945900:-
THCA	cis	rs1577330	0.747	rs1161603	ENSG00000254396.1	RP11-56F10.3	-6.86	2.23e-11	5.94e-09	-0.43	-0.3	IgG glycosylation;	chr9:27098942	chr9:27102630~27104728:+
THCA	cis	rs6504622	1	rs2003539	ENSG00000262879.4	RP11-156P1.3	-6.86	2.23e-11	5.94e-09	-0.28	-0.3	Orofacial clefts;	chr17:46947953	chr17:46984045~47100323:-
THCA	cis	rs9318086	0.534	rs17338049	ENSG00000205861.10	C1QTNF9B-AS1	6.86	2.23e-11	5.95e-09	0.36	0.3	Myopia (pathological);	chr13:23808009	chr13:23888889~23897263:+
THCA	cis	rs4713118	0.955	rs9393848	ENSG00000280107.1	AL022393.9	-6.86	2.23e-11	5.95e-09	-0.35	-0.3	Parkinson's disease;	chr6:27720590	chr6:28170845~28172521:+
THCA	cis	rs10875746	0.551	rs2054903	ENSG00000269514.1	RP11-370I10.12	6.86	2.23e-11	5.96e-09	0.31	0.3	Longevity (90 years and older);	chr12:48330710	chr12:48198387~48202031:+
THCA	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-6.86	2.24e-11	5.97e-09	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
THCA	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	6.86	2.24e-11	5.97e-09	0.36	0.3	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	6.86	2.24e-11	5.97e-09	0.36	0.3	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	6.86	2.24e-11	5.97e-09	0.36	0.3	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
THCA	cis	rs829883	0.664	rs829876	ENSG00000227825.4	SLC9A7P1	6.86	2.24e-11	5.97e-09	0.25	0.3	Colorectal adenoma (advanced);	chr12:98448360	chr12:98453835~98457145:-
THCA	cis	rs853679	1	rs6905391	ENSG00000280107.1	AL022393.9	-6.86	2.24e-11	5.97e-09	-0.41	-0.3	Depression;	chr6:28294909	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs1340004	ENSG00000272009.1	RP1-313I6.12	-6.86	2.24e-11	5.97e-09	-0.36	-0.3	Depression;	chr6:28135913	chr6:28078792~28081130:-
THCA	cis	rs7267979	1	rs8125868	ENSG00000274414.1	RP5-965G21.4	6.86	2.24e-11	5.98e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25239007~25245229:-
THCA	cis	rs6539288	0.933	rs10746070	ENSG00000260329.1	RP11-412D9.4	-6.86	2.24e-11	5.98e-09	-0.27	-0.3	Total body bone mineral density;	chr12:106910681	chr12:106954029~106955497:-
THCA	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-6.86	2.24e-11	5.99e-09	-0.39	-0.3	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
THCA	cis	rs1043099	0.571	rs4820844	ENSG00000279699.1	RP1-102K2.9	-6.86	2.24e-11	5.99e-09	-0.36	-0.3	Rheumatoid arthritis;	chr22:30399226	chr22:30275215~30276951:-
THCA	cis	rs8030379	1	rs6603003	ENSG00000230373.7	GOLGA6L5P	-6.86	2.25e-11	5.99e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896850	chr15:84507885~84516814:-
THCA	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	6.86	2.25e-11	5.99e-09	0.32	0.3	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
THCA	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	6.86	2.25e-11	6e-09	0.39	0.3	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	6.86	2.25e-11	6e-09	0.39	0.3	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
THCA	cis	rs910316	0.934	rs8006587	ENSG00000279594.1	RP11-950C14.10	6.85	2.25e-11	6.01e-09	0.28	0.3	Height;	chr14:75198236	chr14:75011269~75012851:-
THCA	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	6.85	2.25e-11	6.01e-09	0.46	0.3	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
THCA	cis	rs7267979	0.966	rs2500417	ENSG00000274414.1	RP5-965G21.4	6.85	2.26e-11	6.02e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25239007~25245229:-
THCA	cis	rs4664293	0.867	rs7566802	ENSG00000226266.5	AC009961.3	-6.85	2.26e-11	6.02e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159728480	chr2:159670708~159712435:-
THCA	cis	rs8081395	0.576	rs1292032	ENSG00000266992.1	DHX40P1	6.85	2.26e-11	6.03e-09	0.34	0.3	White blood cell count;	chr17:59914982	chr17:59976009~60002384:-
THCA	cis	rs12701220	0.803	rs12701432	ENSG00000229043.2	AC091729.9	-6.85	2.26e-11	6.03e-09	-0.4	-0.3	Bronchopulmonary dysplasia;	chr7:1012817	chr7:1160374~1165267:+
THCA	cis	rs8012947	1	rs11158203	ENSG00000279636.2	LINC00216	-6.85	2.26e-11	6.03e-09	-0.32	-0.3	Alcohol consumption in current drinkers;	chr14:58303305	chr14:58288033~58289158:+
THCA	cis	rs8012947	1	rs10145280	ENSG00000279636.2	LINC00216	-6.85	2.26e-11	6.03e-09	-0.32	-0.3	Alcohol consumption in current drinkers;	chr14:58303337	chr14:58288033~58289158:+
THCA	cis	rs73186030	0.925	rs1801725	ENSG00000272758.4	RP11-299J3.8	6.85	2.26e-11	6.03e-09	0.38	0.3	Serum parathyroid hormone levels;	chr3:122284910	chr3:122416207~122443180:+
THCA	cis	rs516805	0.748	rs12212981	ENSG00000279453.1	RP3-425C14.4	6.85	2.26e-11	6.03e-09	0.35	0.3	Lymphocyte counts;	chr6:122580854	chr6:122436789~122439223:-
THCA	cis	rs792448	0.743	rs351408	ENSG00000226251.4	RP11-15I11.3	-6.85	2.26e-11	6.04e-09	-0.39	-0.3	White blood cell count (basophil);	chr1:212267786	chr1:212225278~212238977:-
THCA	cis	rs1993293	0.569	rs62042315	ENSG00000182397.13	DNM1P46	-6.85	2.26e-11	6.04e-09	-0.42	-0.3	Coronary artery calcification;	chr15:99751724	chr15:99790156~99806927:-
THCA	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	6.85	2.26e-11	6.04e-09	0.38	0.3	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
THCA	cis	rs74233809	0.901	rs17878846	ENSG00000213277.3	MARCKSL1P1	6.85	2.27e-11	6.05e-09	0.49	0.3	Birth weight;	chr10:102870655	chr10:103175554~103176094:+
THCA	cis	rs7044106	0.5	rs56725168	ENSG00000270917.1	RP11-27I1.6	-6.85	2.27e-11	6.06e-09	-0.42	-0.3	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120812475~120812845:-
THCA	cis	rs6600671	0.934	rs11249431	ENSG00000223345.3	HIST2H2BA	-6.85	2.27e-11	6.06e-09	-0.34	-0.3	Hip geometry;	chr1:121544405	chr1:121108210~121117257:-
THCA	cis	rs71636778	0.509	rs35108146	ENSG00000260063.1	RP5-968P14.2	-6.85	2.28e-11	6.07e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921949	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12752711	ENSG00000260063.1	RP5-968P14.2	-6.85	2.28e-11	6.07e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26923767	chr1:26692132~26694131:-
THCA	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	6.85	2.28e-11	6.08e-09	0.26	0.3	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
THCA	cis	rs10266483	0.739	rs2692099	ENSG00000227986.1	TRIM60P18	-6.85	2.28e-11	6.08e-09	-0.25	-0.3	Response to statin therapy;	chr7:64307384	chr7:64355078~64356199:+
THCA	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-6.85	2.28e-11	6.08e-09	-0.38	-0.3	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
THCA	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	6.85	2.28e-11	6.08e-09	0.54	0.3	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	6.85	2.28e-11	6.08e-09	0.54	0.3	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
THCA	cis	rs2380205	0.601	rs4293039	ENSG00000232807.2	RP11-536K7.3	6.85	2.28e-11	6.08e-09	0.28	0.3	Breast cancer;	chr10:5856261	chr10:5934270~5945900:-
THCA	cis	rs17684571	1	rs16888128	ENSG00000231441.1	RP11-472M19.2	6.85	2.29e-11	6.1e-09	0.35	0.3	Schizophrenia;	chr6:56704306	chr6:56844002~56864078:+
THCA	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	6.85	2.29e-11	6.1e-09	0.79	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
THCA	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-6.85	2.29e-11	6.1e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-6.85	2.29e-11	6.1e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
THCA	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	6.85	2.29e-11	6.1e-09	0.25	0.3	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
THCA	cis	rs4072705	0.967	rs12339980	ENSG00000224020.1	MIR181A2HG	-6.85	2.29e-11	6.1e-09	-0.27	-0.3	Menarche (age at onset);	chr9:124556424	chr9:124658467~124698631:+
THCA	cis	rs7942368	1	rs7107409	ENSG00000204529.3	GUCY2EP	6.85	2.29e-11	6.11e-09	0.43	0.3	Endometriosis;	chr11:76781151	chr11:76694043~76707641:-
THCA	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-6.85	2.29e-11	6.12e-09	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
THCA	cis	rs453301	0.624	rs330049	ENSG00000254153.1	CTA-398F10.2	-6.85	2.3e-11	6.12e-09	-0.32	-0.3	Joint mobility (Beighton score);	chr8:9229789	chr8:8456909~8461337:-
THCA	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-6.85	2.3e-11	6.12e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
THCA	cis	rs4664293	0.867	rs10194483	ENSG00000226266.5	AC009961.3	-6.85	2.3e-11	6.12e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159739883	chr2:159670708~159712435:-
THCA	cis	rs227932	0.764	rs6461725	ENSG00000234286.1	AC006026.13	-6.85	2.3e-11	6.12e-09	-0.55	-0.3	Schizophrenia;	chr7:23690555	chr7:23680195~23680786:-
THCA	cis	rs1150668	0.796	rs2531825	ENSG00000219392.1	RP1-265C24.5	-6.85	2.3e-11	6.13e-09	-0.32	-0.3	Pubertal anthropometrics;	chr6:28381487	chr6:28115628~28116551:+
THCA	cis	rs72843506	0.586	rs59890010	ENSG00000270091.1	RP11-78O7.2	-6.85	2.3e-11	6.13e-09	-0.34	-0.3	Schizophrenia;	chr17:19960360	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.586	rs73980762	ENSG00000270091.1	RP11-78O7.2	-6.85	2.3e-11	6.13e-09	-0.34	-0.3	Schizophrenia;	chr17:19966113	chr17:19896590~19897287:-
THCA	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-6.85	2.3e-11	6.13e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
THCA	cis	rs10411161	0.752	rs8107388	ENSG00000269483.1	AC006272.1	6.85	2.3e-11	6.13e-09	0.44	0.3	Breast cancer;	chr19:51904033	chr19:51839924~51843324:-
THCA	cis	rs8062405	0.755	rs4788074	ENSG00000278665.1	RP11-666O2.4	-6.85	2.3e-11	6.13e-09	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28599241~28601881:-
THCA	cis	rs1385374	1	rs1385374	ENSG00000274695.1	RP11-21K12.3	6.85	2.3e-11	6.13e-09	0.53	0.3	Systemic lupus erythematosus;	chr12:128816149	chr12:128826836~128827579:+
THCA	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-6.85	2.3e-11	6.13e-09	-0.29	-0.3	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
THCA	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	6.85	2.3e-11	6.13e-09	0.38	0.3	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
THCA	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-6.85	2.3e-11	6.14e-09	-0.33	-0.3	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
THCA	cis	rs8012947	1	rs1984549	ENSG00000279636.2	LINC00216	-6.85	2.3e-11	6.14e-09	-0.31	-0.3	Alcohol consumption in current drinkers;	chr14:58322121	chr14:58288033~58289158:+
THCA	cis	rs4789693	0.544	rs4789770	ENSG00000265458.1	RP13-20L14.6	6.85	2.3e-11	6.14e-09	0.3	0.3	Glucocorticoid-induced osteonecrosis;	chr17:82418779	chr17:82454273~82458521:-
THCA	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	6.85	2.31e-11	6.14e-09	0.38	0.3	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
THCA	cis	rs6540731	1	rs6540733	ENSG00000226251.4	RP11-15I11.3	-6.85	2.31e-11	6.15e-09	-0.38	-0.3	Intelligence (childhood);	chr1:212219611	chr1:212225278~212238977:-
THCA	cis	rs56114371	0.777	rs200483	ENSG00000219392.1	RP1-265C24.5	-6.85	2.31e-11	6.15e-09	-0.51	-0.3	Breast cancer;	chr6:27807046	chr6:28115628~28116551:+
THCA	cis	rs9287719	0.601	rs10177062	ENSG00000243819.4	RN7SL832P	6.85	2.31e-11	6.16e-09	0.25	0.3	Prostate cancer;	chr2:10573572	chr2:10690344~10692099:+
THCA	cis	rs7811142	1	rs68116612	ENSG00000078319.8	PMS2P1	-6.85	2.31e-11	6.16e-09	-0.42	-0.3	Platelet count;	chr7:100408870	chr7:100320992~100341908:-
THCA	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-6.85	2.32e-11	6.17e-09	-0.29	-0.3	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
THCA	cis	rs9506514	0.509	rs9509279	ENSG00000222726.1	RNU2-7P	6.85	2.32e-11	6.17e-09	0.36	0.3	Coronary artery calcification;	chr13:20559580	chr13:20612161~20612338:+
THCA	cis	rs1552244	0.832	rs61056817	ENSG00000232901.1	CYCSP10	6.85	2.32e-11	6.18e-09	0.4	0.3	Alzheimer's disease;	chr3:9985957	chr3:10000647~10000940:-
THCA	cis	rs9902453	1	rs9906340	ENSG00000264007.1	RP11-68I3.10	-6.85	2.32e-11	6.19e-09	-0.34	-0.3	Coffee consumption (cups per day);	chr17:30071959	chr17:29621617~29622254:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000206090.4	AP000350.7	-6.85	2.32e-11	6.19e-09	-0.44	-0.3	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23939998~23942798:+
THCA	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	6.85	2.32e-11	6.19e-09	0.6	0.3	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
THCA	cis	rs11096990	0.821	rs2711991	ENSG00000249207.1	RP11-360F5.1	6.85	2.33e-11	6.2e-09	0.39	0.3	Cognitive function;	chr4:39149733	chr4:39112677~39126818:-
THCA	cis	rs7512898	0.9	rs6427847	ENSG00000260088.1	RP11-92G12.3	-6.85	2.33e-11	6.21e-09	-0.38	-0.3	Electrocardiographic conduction measures;	chr1:200700052	chr1:200669507~200694250:+
THCA	cis	rs2834188	1	rs9982088	ENSG00000272659.1	AP000295.10	-6.85	2.34e-11	6.22e-09	-0.41	-0.3	Narcolepsy;	chr21:33314536	chr21:33309491~33310181:+
THCA	cis	rs4664293	0.867	rs34392518	ENSG00000226266.5	AC009961.3	-6.85	2.34e-11	6.22e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159749367	chr2:159670708~159712435:-
THCA	cis	rs9287719	0.615	rs12613769	ENSG00000243819.4	RN7SL832P	6.85	2.34e-11	6.22e-09	0.25	0.3	Prostate cancer;	chr2:10602164	chr2:10690344~10692099:+
THCA	cis	rs651907	0.535	rs1460097	ENSG00000256628.3	ZBTB11-AS1	6.85	2.34e-11	6.24e-09	0.36	0.3	Colorectal cancer;	chr3:101778725	chr3:101676475~101679217:+
THCA	cis	rs6723226	0.806	rs2710606	ENSG00000276334.1	AL133243.1	6.85	2.34e-11	6.24e-09	0.35	0.3	Intelligence (multi-trait analysis);	chr2:32586842	chr2:32521927~32523547:+
THCA	cis	rs6672530	0.518	rs11484723	ENSG00000227711.2	RP11-275O4.5	-6.85	2.34e-11	6.24e-09	-0.31	-0.3	Hip circumference adjusted for BMI;	chr1:227715357	chr1:227509028~227520477:-
THCA	cis	rs9467773	0.595	rs2237236	ENSG00000124549.13	BTN2A3P	-6.85	2.34e-11	6.24e-09	-0.28	-0.3	Intelligence (multi-trait analysis);	chr6:26451325	chr6:26421391~26432383:+
THCA	cis	rs8030379	1	rs7162129	ENSG00000230373.7	GOLGA6L5P	-6.85	2.34e-11	6.24e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897692	chr15:84507885~84516814:-
THCA	cis	rs79349575	0.783	rs4793991	ENSG00000248278.1	SUMO2P17	6.85	2.35e-11	6.24e-09	0.35	0.3	Type 2 diabetes;	chr17:48924439	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.715	rs62075844	ENSG00000248278.1	SUMO2P17	6.85	2.35e-11	6.24e-09	0.35	0.3	Type 2 diabetes;	chr17:48925027	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.749	rs957557	ENSG00000248278.1	SUMO2P17	6.85	2.35e-11	6.24e-09	0.35	0.3	Type 2 diabetes;	chr17:48925859	chr17:48874860~48908983:-
THCA	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-6.85	2.35e-11	6.25e-09	-0.29	-0.3	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-6.85	2.35e-11	6.25e-09	-0.29	-0.3	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
THCA	cis	rs7942368	0.941	rs10160769	ENSG00000204529.3	GUCY2EP	6.85	2.35e-11	6.26e-09	0.42	0.3	Endometriosis;	chr11:76763783	chr11:76694043~76707641:-
THCA	cis	rs7267979	1	rs2297496	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs7343481	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6115146	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.934	rs6037085	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs6050532	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6083804	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4815405	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050542	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6076336	ENSG00000274414.1	RP5-965G21.4	6.85	2.35e-11	6.26e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2257808	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2257809	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2424700	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs910997	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs1077889	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs3002702	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2257982	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2257985	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2257988	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2257432	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2258066	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2258135	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2258201	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2258563	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2258617	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2258769	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2258879	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2257496	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2258884	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2259837	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2259873	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs11100	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs1046073	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2259926	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2259928	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2259956	ENSG00000274414.1	RP5-965G21.4	-6.85	2.35e-11	6.26e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25239007~25245229:-
THCA	cis	rs13230714	1	rs13230714	ENSG00000204959.4	ARHGEF34P	-6.85	2.37e-11	6.29e-09	-0.33	-0.3	Breast cancer;	chr7:144477198	chr7:144272445~144286966:-
THCA	cis	rs7044106	0.762	rs7849566	ENSG00000238181.2	AHCYP2	-6.85	2.37e-11	6.29e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120720673~120721972:+
THCA	cis	rs3806843	0.966	rs2563267	ENSG00000202515.1	VTRNA1-3	6.85	2.37e-11	6.3e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140757328	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs2563266	ENSG00000202515.1	VTRNA1-3	6.85	2.37e-11	6.3e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140757330	chr5:140726158~140726246:+
THCA	cis	rs7260598	0.792	rs73021416	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24081849	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.685	rs73021422	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24082919	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.685	rs73021424	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24090897	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.685	rs11667970	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24094893	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.581	rs73021432	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24101827	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.685	rs11671000	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24110025	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs11672468	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24119770	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs73021445	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24121306	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs7252836	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24122787	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs61737180	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24127230	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.792	rs73021454	ENSG00000268442.1	CTD-2027I19.2	6.85	2.37e-11	6.3e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24133074	chr19:24162370~24163425:-
THCA	cis	rs228614	0.509	rs223476	ENSG00000251288.2	RP11-10L12.2	-6.85	2.37e-11	6.31e-09	-0.4	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102751401~102752641:+
THCA	cis	rs228614	0.509	rs150896	ENSG00000251288.2	RP11-10L12.2	-6.85	2.37e-11	6.31e-09	-0.4	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102751401~102752641:+
THCA	cis	rs6600671	1	rs2319969	ENSG00000275538.1	RNVU1-19	6.85	2.37e-11	6.31e-09	0.39	0.3	Hip geometry;	chr1:121465481	chr1:120850819~120850985:-
THCA	cis	rs7267979	0.933	rs2261109	ENSG00000274414.1	RP5-965G21.4	-6.85	2.37e-11	6.31e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2261698	ENSG00000274414.1	RP5-965G21.4	-6.85	2.37e-11	6.31e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2261720	ENSG00000274414.1	RP5-965G21.4	-6.85	2.37e-11	6.31e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2227890	ENSG00000274414.1	RP5-965G21.4	-6.85	2.37e-11	6.31e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25239007~25245229:-
THCA	cis	rs728616	0.867	rs7080405	ENSG00000225484.5	NUTM2B-AS1	-6.85	2.37e-11	6.32e-09	-0.58	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142187	chr10:79663088~79826594:-
THCA	cis	rs1005277	0.579	rs2800485	ENSG00000276805.1	RP11-291L22.6	6.85	2.37e-11	6.32e-09	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38451030~38451785:+
THCA	cis	rs12664251	0.598	rs3756939	ENSG00000253194.1	RP11-351A11.1	-6.85	2.38e-11	6.32e-09	-0.42	-0.3	Schizophrenia;	chr6:119019716	chr6:118934785~119031541:+
THCA	cis	rs7851660	0.844	rs10119760	ENSG00000236130.1	PTCSC2	-6.85	2.38e-11	6.32e-09	-0.24	-0.3	Strep throat;	chr9:97862320	chr9:97805935~97810008:-
THCA	cis	rs41307935	0.915	rs57189461	ENSG00000260063.1	RP5-968P14.2	-6.85	2.38e-11	6.32e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26798054	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs71636783	ENSG00000260063.1	RP5-968P14.2	-6.85	2.38e-11	6.32e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813370	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.57	rs12728091	ENSG00000260063.1	RP5-968P14.2	-6.85	2.38e-11	6.32e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26817022	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.73	rs34716450	ENSG00000260063.1	RP5-968P14.2	-6.85	2.38e-11	6.32e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26817084	chr1:26692132~26694131:-
THCA	cis	rs150992	0.507	rs377731	ENSG00000248489.1	CTD-2007H13.3	6.85	2.38e-11	6.33e-09	0.27	0.3	Body mass index;	chr5:98996535	chr5:98929171~98995013:+
THCA	cis	rs7942368	1	rs1837680	ENSG00000254632.1	RP11-21L23.4	6.85	2.38e-11	6.33e-09	0.44	0.3	Endometriosis;	chr11:76790407	chr11:76759916~76768223:-
THCA	cis	rs7044106	0.791	rs735109	ENSG00000270917.1	RP11-27I1.6	-6.85	2.39e-11	6.35e-09	-0.43	-0.3	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120812475~120812845:-
THCA	cis	rs5006884	0.507	rs12801179	ENSG00000167355.6	AC104389.28	-6.85	2.39e-11	6.35e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5361473	chr11:5304976~5505652:-
THCA	cis	rs12347191	0.5	rs973473	ENSG00000236130.1	PTCSC2	-6.85	2.39e-11	6.35e-09	-0.25	-0.3	Orofacial clefts;	chr9:97858448	chr9:97805935~97810008:-
THCA	cis	rs12347191	0.5	rs1912998	ENSG00000236130.1	PTCSC2	-6.85	2.39e-11	6.35e-09	-0.25	-0.3	Orofacial clefts;	chr9:97859104	chr9:97805935~97810008:-
THCA	cis	rs9902453	0.817	rs4294865	ENSG00000264007.1	RP11-68I3.10	6.85	2.39e-11	6.35e-09	0.35	0.3	Coffee consumption (cups per day);	chr17:29878718	chr17:29621617~29622254:-
THCA	cis	rs7189233	0.91	rs3809634	ENSG00000279344.1	RP11-44F14.7	6.85	2.39e-11	6.36e-09	0.31	0.3	Intelligence (multi-trait analysis);	chr16:53504245	chr16:53478957~53481550:-
THCA	cis	rs2348418	0.715	rs1912782	ENSG00000247934.4	RP11-967K21.1	6.85	2.4e-11	6.37e-09	0.26	0.3	Lung function (FEV1);Lung function (FVC);	chr12:28568774	chr12:28163298~28190738:-
THCA	cis	rs6504622	0.905	rs9889741	ENSG00000262879.4	RP11-156P1.3	6.84	2.4e-11	6.38e-09	0.28	0.3	Orofacial clefts;	chr17:46948967	chr17:46984045~47100323:-
THCA	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-6.84	2.4e-11	6.38e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
THCA	cis	rs7044106	0.708	rs10984992	ENSG00000238181.2	AHCYP2	-6.84	2.4e-11	6.38e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120720673~120721972:+
THCA	cis	rs7044106	0.762	rs10760115	ENSG00000238181.2	AHCYP2	-6.84	2.4e-11	6.38e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120720673~120721972:+
THCA	cis	rs41307935	0.915	rs12685	ENSG00000260063.1	RP5-968P14.2	-6.84	2.4e-11	6.39e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781754	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.818	rs71636779	ENSG00000260063.1	RP5-968P14.2	-6.84	2.4e-11	6.39e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26787521	chr1:26692132~26694131:-
THCA	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	6.84	2.41e-11	6.4e-09	0.46	0.3	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
THCA	cis	rs9926296	0.533	rs12102290	ENSG00000260259.1	RP11-368I7.4	-6.84	2.41e-11	6.41e-09	-0.33	-0.3	Vitiligo;	chr16:89746209	chr16:89682620~89686569:-
THCA	cis	rs9926296	0.533	rs12102297	ENSG00000260259.1	RP11-368I7.4	-6.84	2.41e-11	6.41e-09	-0.33	-0.3	Vitiligo;	chr16:89746354	chr16:89682620~89686569:-
THCA	cis	rs667920	0.5	rs34738913	ENSG00000239213.4	NCK1-AS1	-6.84	2.41e-11	6.41e-09	-0.41	-0.3	Coronary artery disease;	chr3:136719042	chr3:136841726~136862054:-
THCA	cis	rs7621025	0.505	rs34613715	ENSG00000239213.4	NCK1-AS1	-6.84	2.41e-11	6.41e-09	-0.41	-0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136736165	chr3:136841726~136862054:-
THCA	cis	rs7621025	0.505	rs34281413	ENSG00000239213.4	NCK1-AS1	-6.84	2.41e-11	6.41e-09	-0.41	-0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136743018	chr3:136841726~136862054:-
THCA	cis	rs7208859	0.725	rs9897673	ENSG00000266490.1	CTD-2349P21.9	6.84	2.41e-11	6.41e-09	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30792372~30792833:+
THCA	cis	rs2976388	1	rs1045574	ENSG00000253741.1	CTD-2292P10.4	6.84	2.41e-11	6.41e-09	0.37	0.3	Urinary tract infection frequency;	chr8:142682540	chr8:142702252~142726973:-
THCA	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-6.84	2.41e-11	6.42e-09	-0.44	-0.3	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
THCA	cis	rs1125355	1	rs114087196	ENSG00000251491.2	OR7E28P	-6.84	2.42e-11	6.42e-09	-0.49	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158849636	chr2:158862311~158863285:+
THCA	cis	rs7811142	0.943	rs111757992	ENSG00000078319.8	PMS2P1	-6.84	2.42e-11	6.42e-09	-0.42	-0.3	Platelet count;	chr7:100418731	chr7:100320992~100341908:-
THCA	cis	rs9287719	0.649	rs9973456	ENSG00000243819.4	RN7SL832P	6.84	2.42e-11	6.42e-09	0.25	0.3	Prostate cancer;	chr2:10578004	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10190673	ENSG00000243819.4	RN7SL832P	6.84	2.42e-11	6.42e-09	0.25	0.3	Prostate cancer;	chr2:10578492	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs10198971	ENSG00000243819.4	RN7SL832P	6.84	2.42e-11	6.42e-09	0.25	0.3	Prostate cancer;	chr2:10578573	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.649	rs2884232	ENSG00000243819.4	RN7SL832P	6.84	2.42e-11	6.42e-09	0.25	0.3	Prostate cancer;	chr2:10579553	chr2:10690344~10692099:+
THCA	cis	rs748404	0.66	rs690472	ENSG00000166763.7	STRCP1	6.84	2.42e-11	6.43e-09	0.32	0.3	Lung cancer;	chr15:43472170	chr15:43699488~43718184:-
THCA	cis	rs748404	0.69	rs1079309	ENSG00000166763.7	STRCP1	6.84	2.42e-11	6.43e-09	0.32	0.3	Lung cancer;	chr15:43490966	chr15:43699488~43718184:-
THCA	cis	rs71636778	0.509	rs12741472	ENSG00000260063.1	RP5-968P14.2	-6.84	2.42e-11	6.44e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26895118	chr1:26692132~26694131:-
THCA	cis	rs228614	0.509	rs223486	ENSG00000251288.2	RP11-10L12.2	-6.84	2.43e-11	6.44e-09	-0.4	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102751401~102752641:+
THCA	cis	rs7120173	0.915	rs12786797	ENSG00000254851.1	RP11-109L13.1	-6.84	2.43e-11	6.45e-09	-0.49	-0.3	Visceral adipose tissue adjusted for BMI;	chr11:117017035	chr11:117135528~117138582:+
THCA	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-6.84	2.43e-11	6.45e-09	-0.29	-0.3	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
THCA	cis	rs736801	0.569	rs12517950	ENSG00000233006.5	AC034220.3	6.84	2.43e-11	6.45e-09	0.24	0.3	Mosquito bite size;Breast cancer;	chr5:132395634	chr5:132311285~132369916:-
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000219392.1	RP1-265C24.5	-6.84	2.43e-11	6.45e-09	-0.32	-0.3	Pubertal anthropometrics;	chr6:28411584	chr6:28115628~28116551:+
THCA	cis	rs4780355	0.776	rs9936459	ENSG00000262703.1	RP11-485G7.6	-6.84	2.43e-11	6.46e-09	-0.36	-0.3	Crohn's disease and psoriasis;	chr16:11343922	chr16:11348143~11349321:-
THCA	cis	rs4947019	0.609	rs4946968	ENSG00000260273.1	RP11-425D10.10	6.84	2.44e-11	6.48e-09	0.65	0.3	Hematological parameters;	chr6:109357907	chr6:109382795~109383666:+
THCA	cis	rs4664293	0.867	rs2357531	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159740907	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs2357532	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159740916	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs16844269	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159742569	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.836	rs4664300	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159743927	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs16822556	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159744392	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs16822558	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159744496	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs1834761	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159745278	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs6432558	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159745397	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.836	rs7567818	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159746186	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs12692563	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159746300	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs12620924	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159746452	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.836	rs13397597	ENSG00000226266.5	AC009961.3	-6.84	2.44e-11	6.48e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159747084	chr2:159670708~159712435:-
THCA	cis	rs7324557	0.621	rs9507166	ENSG00000205861.10	C1QTNF9B-AS1	6.84	2.44e-11	6.48e-09	0.37	0.3	Visceral adipose tissue adjusted for BMI;	chr13:23824844	chr13:23888889~23897263:+
THCA	cis	rs4266144	0.562	rs56357317	ENSG00000241770.1	RP11-555M1.3	-6.84	2.44e-11	6.49e-09	-0.43	-0.3	Coronary artery disease;	chr3:157117385	chr3:157163452~157169133:+
THCA	cis	rs4664293	0.867	rs7606046	ENSG00000226266.5	AC009961.3	-6.84	2.45e-11	6.5e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159719647	chr2:159670708~159712435:-
THCA	cis	rs934734	0.736	rs6738087	ENSG00000204929.10	AC074391.1	6.84	2.45e-11	6.5e-09	0.38	0.3	Rheumatoid arthritis;	chr2:65365191	chr2:65436711~66084639:+
THCA	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-6.84	2.45e-11	6.5e-09	-0.3	-0.3	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
THCA	cis	rs4713118	0.955	rs9380010	ENSG00000280107.1	AL022393.9	-6.84	2.46e-11	6.52e-09	-0.35	-0.3	Parkinson's disease;	chr6:27715793	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.955	rs9368528	ENSG00000280107.1	AL022393.9	-6.84	2.46e-11	6.52e-09	-0.35	-0.3	Parkinson's disease;	chr6:27716019	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.955	rs9380011	ENSG00000280107.1	AL022393.9	-6.84	2.46e-11	6.52e-09	-0.35	-0.3	Parkinson's disease;	chr6:27716145	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.955	rs9368529	ENSG00000280107.1	AL022393.9	-6.84	2.46e-11	6.52e-09	-0.35	-0.3	Parkinson's disease;	chr6:27716852	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.955	rs9380012	ENSG00000280107.1	AL022393.9	-6.84	2.46e-11	6.52e-09	-0.35	-0.3	Parkinson's disease;	chr6:27716875	chr6:28170845~28172521:+
THCA	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-6.84	2.46e-11	6.52e-09	-0.47	-0.3	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
THCA	cis	rs11668609	0.872	rs11668697	ENSG00000268442.1	CTD-2027I19.2	6.84	2.46e-11	6.53e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24108247	chr19:24162370~24163425:-
THCA	cis	rs7635879	0.702	rs4687494	ENSG00000230102.6	RP11-407B7.1	-6.84	2.46e-11	6.53e-09	-0.23	-0.3	Breastfeeding duration;	chr3:194010581	chr3:194005259~194070970:-
THCA	cis	rs8081395	0.741	rs1292053	ENSG00000266992.1	DHX40P1	-6.84	2.46e-11	6.53e-09	-0.34	-0.3	White blood cell count;	chr17:59886176	chr17:59976009~60002384:-
THCA	cis	rs7688540	0.8	rs10023604	ENSG00000211553.1	AC253576.2	-6.84	2.46e-11	6.54e-09	-0.41	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:136461~136568:+
THCA	cis	rs9902453	0.753	rs7226121	ENSG00000264007.1	RP11-68I3.10	6.84	2.46e-11	6.54e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29881107	chr17:29621617~29622254:-
THCA	cis	rs875971	0.862	rs6460282	ENSG00000232559.3	GS1-124K5.12	-6.84	2.47e-11	6.54e-09	-0.29	-0.3	Aortic root size;	chr7:66226259	chr7:66554588~66576923:-
THCA	cis	rs3806843	0.676	rs2245643	ENSG00000202515.1	VTRNA1-3	6.84	2.47e-11	6.55e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140650195	chr5:140726158~140726246:+
THCA	cis	rs7246657	0.941	rs12982333	ENSG00000226686.6	LINC01535	-6.84	2.47e-11	6.55e-09	-0.43	-0.3	Coronary artery calcification;	chr19:37303822	chr19:37251912~37265535:+
THCA	cis	rs7246657	1	rs10426297	ENSG00000226686.6	LINC01535	-6.84	2.47e-11	6.55e-09	-0.43	-0.3	Coronary artery calcification;	chr19:37307471	chr19:37251912~37265535:+
THCA	cis	rs7246657	1	rs1823061	ENSG00000226686.6	LINC01535	-6.84	2.47e-11	6.55e-09	-0.43	-0.3	Coronary artery calcification;	chr19:37309724	chr19:37251912~37265535:+
THCA	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	6.84	2.47e-11	6.56e-09	0.33	0.3	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
THCA	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	6.84	2.47e-11	6.56e-09	0.33	0.3	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
THCA	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	6.84	2.47e-11	6.56e-09	0.33	0.3	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
THCA	cis	rs523522	0.962	rs4767905	ENSG00000278344.1	RP11-18C24.8	6.84	2.47e-11	6.56e-09	0.33	0.3	High light scatter reticulocyte count;	chr12:120493032	chr12:120500735~120501090:-
THCA	cis	rs7267979	0.966	rs2263204	ENSG00000274414.1	RP5-965G21.4	6.84	2.48e-11	6.58e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25239007~25245229:-
THCA	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-6.84	2.48e-11	6.58e-09	-0.31	-0.3	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
THCA	cis	rs10050311	0.79	rs17012132	ENSG00000251411.1	RP11-397E7.4	-6.84	2.48e-11	6.59e-09	-0.39	-0.3	Insulin-related traits;	chr4:86860135	chr4:86913266~86914817:-
THCA	cis	rs853679	1	rs1778508	ENSG00000280107.1	AL022393.9	6.84	2.49e-11	6.6e-09	0.42	0.3	Depression;	chr6:28262103	chr6:28170845~28172521:+
THCA	cis	rs867529	1	rs62157778	ENSG00000234028.3	AC062029.1	6.84	2.49e-11	6.61e-09	0.26	0.3	Height;	chr2:88634572	chr2:88627539~88631821:+
THCA	cis	rs2243480	1	rs427044	ENSG00000229886.1	RP5-1132H15.3	6.84	2.49e-11	6.61e-09	0.49	0.3	Diabetic kidney disease;	chr7:66043558	chr7:66025126~66031544:-
THCA	cis	rs7191700	0.509	rs415595	ENSG00000262636.1	CTD-3088G3.4	6.84	2.5e-11	6.62e-09	0.36	0.3	Multiple sclerosis;	chr16:11269835	chr16:11380859~11381118:-
THCA	cis	rs7191700	0.509	rs416603	ENSG00000262636.1	CTD-3088G3.4	-6.84	2.5e-11	6.62e-09	-0.36	-0.3	Multiple sclerosis;	chr16:11270222	chr16:11380859~11381118:-
THCA	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-6.84	2.5e-11	6.63e-09	-0.38	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
THCA	cis	rs2797160	0.651	rs1269176	ENSG00000237742.5	RP11-624M8.1	-6.84	2.5e-11	6.63e-09	-0.27	-0.3	Endometrial cancer;	chr6:125708536	chr6:125578558~125749190:-
THCA	cis	rs7727544	0.507	rs9791170	ENSG00000233006.5	AC034220.3	6.84	2.5e-11	6.63e-09	0.23	0.3	Blood metabolite levels;	chr5:132233934	chr5:132311285~132369916:-
THCA	cis	rs4713118	0.955	rs9468203	ENSG00000280107.1	AL022393.9	-6.84	2.51e-11	6.65e-09	-0.34	-0.3	Parkinson's disease;	chr6:27720888	chr6:28170845~28172521:+
THCA	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-6.84	2.51e-11	6.66e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-6.84	2.51e-11	6.66e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
THCA	cis	rs7267979	0.933	rs2258728	ENSG00000274414.1	RP5-965G21.4	-6.84	2.51e-11	6.66e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25239007~25245229:-
THCA	cis	rs9326248	0.689	rs236916	ENSG00000280143.1	AP000892.6	-6.84	2.52e-11	6.67e-09	-0.46	-0.3	Blood protein levels;	chr11:117218912	chr11:117204967~117210292:+
THCA	cis	rs2243480	1	rs410128	ENSG00000228409.4	CCT6P1	6.84	2.52e-11	6.68e-09	0.35	0.3	Diabetic kidney disease;	chr7:66138186	chr7:65751142~65763354:+
THCA	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	6.84	2.52e-11	6.69e-09	0.37	0.3	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
THCA	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-6.84	2.53e-11	6.7e-09	-0.39	-0.3	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
THCA	cis	rs9402743	0.634	rs7765113	ENSG00000231028.7	LINC00271	-6.84	2.53e-11	6.71e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135598935	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.597	rs9385729	ENSG00000231028.7	LINC00271	-6.84	2.53e-11	6.71e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135600001	chr6:135497801~135716055:+
THCA	cis	rs6569038	0.557	rs9401118	ENSG00000253194.1	RP11-351A11.1	-6.84	2.53e-11	6.72e-09	-0.41	-0.3	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119053584	chr6:118934785~119031541:+
THCA	cis	rs5006884	0.507	rs2736560	ENSG00000167355.6	AC104389.28	-6.84	2.54e-11	6.73e-09	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5355568	chr11:5304976~5505652:-
THCA	cis	rs7727544	0.669	rs113823725	ENSG00000233006.5	AC034220.3	6.84	2.54e-11	6.73e-09	0.24	0.3	Blood metabolite levels;	chr5:132227808	chr5:132311285~132369916:-
THCA	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	6.84	2.54e-11	6.73e-09	0.38	0.3	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
THCA	cis	rs6840258	1	rs56395939	ENSG00000251411.1	RP11-397E7.4	-6.84	2.55e-11	6.74e-09	-0.36	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87042481	chr4:86913266~86914817:-
THCA	cis	rs593531	0.524	rs634608	ENSG00000212961.4	HNRNPA1P40	6.84	2.55e-11	6.75e-09	0.37	0.3	Neuroticism;	chr11:74373684	chr11:74354443~74355720:+
THCA	cis	rs7302981	0.719	rs836188	ENSG00000272368.2	RP4-605O3.4	6.83	2.56e-11	6.77e-09	0.18	0.3	Systolic blood pressure;	chr12:50067569	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.719	rs836189	ENSG00000272368.2	RP4-605O3.4	6.83	2.56e-11	6.77e-09	0.18	0.3	Systolic blood pressure;	chr12:50067715	chr12:50112197~50165618:+
THCA	cis	rs4908760	0.783	rs301799	ENSG00000232912.4	RP5-1115A15.1	6.83	2.56e-11	6.77e-09	0.29	0.3	Vitiligo;	chr1:8429242	chr1:8424645~8434838:+
THCA	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-6.83	2.56e-11	6.77e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
THCA	cis	rs875971	0.862	rs6460290	ENSG00000232559.3	GS1-124K5.12	-6.83	2.56e-11	6.77e-09	-0.28	-0.3	Aortic root size;	chr7:66344119	chr7:66554588~66576923:-
THCA	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-6.83	2.56e-11	6.77e-09	-0.29	-0.3	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
THCA	cis	rs6696239	0.513	rs12132444	ENSG00000227711.2	RP11-275O4.5	6.83	2.56e-11	6.78e-09	0.32	0.3	Height;	chr1:227521845	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs4653846	ENSG00000227711.2	RP11-275O4.5	6.83	2.56e-11	6.78e-09	0.32	0.3	Hip circumference adjusted for BMI;	chr1:227524770	chr1:227509028~227520477:-
THCA	cis	rs2439831	0.85	rs8032649	ENSG00000275601.1	AC011330.13	6.83	2.56e-11	6.78e-09	0.49	0.3	Lung cancer in ever smokers;	chr15:43842724	chr15:43642389~43643023:-
THCA	cis	rs7811142	1	rs112317829	ENSG00000078319.8	PMS2P1	-6.83	2.56e-11	6.78e-09	-0.42	-0.3	Platelet count;	chr7:100445550	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.943	rs28578163	ENSG00000078319.8	PMS2P1	-6.83	2.56e-11	6.78e-09	-0.42	-0.3	Platelet count;	chr7:100447131	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs67239991	ENSG00000078319.8	PMS2P1	-6.83	2.56e-11	6.78e-09	-0.42	-0.3	Platelet count;	chr7:100448881	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.943	rs111493473	ENSG00000078319.8	PMS2P1	-6.83	2.56e-11	6.78e-09	-0.42	-0.3	Platelet count;	chr7:100452119	chr7:100320992~100341908:-
THCA	cis	rs4934494	0.768	rs11330	ENSG00000232936.4	RP11-80H5.2	-6.83	2.56e-11	6.78e-09	-0.41	-0.3	Red blood cell count;	chr10:89634322	chr10:89645282~89650667:+
THCA	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	6.83	2.56e-11	6.78e-09	0.38	0.3	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
THCA	cis	rs1385374	0.858	rs3765107	ENSG00000274695.1	RP11-21K12.3	6.83	2.56e-11	6.79e-09	0.53	0.3	Systemic lupus erythematosus;	chr12:128793765	chr12:128826836~128827579:+
THCA	cis	rs16843372	0.599	rs2138386	ENSG00000251491.2	OR7E28P	-6.83	2.57e-11	6.79e-09	-0.4	-0.3	Obesity-related traits;	chr2:158827374	chr2:158862311~158863285:+
THCA	cis	rs12594515	0.694	rs2068295	ENSG00000259200.1	RP11-718O11.1	-6.83	2.57e-11	6.8e-09	-0.36	-0.3	Weight;Waist circumference;	chr15:45693348	chr15:45705078~45931069:+
THCA	cis	rs875971	0.965	rs697968	ENSG00000232559.3	GS1-124K5.12	-6.83	2.57e-11	6.8e-09	-0.29	-0.3	Aortic root size;	chr7:66070046	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs1183245	ENSG00000232559.3	GS1-124K5.12	-6.83	2.57e-11	6.8e-09	-0.29	-0.3	Aortic root size;	chr7:66076198	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs1144894	ENSG00000232559.3	GS1-124K5.12	-6.83	2.57e-11	6.8e-09	-0.29	-0.3	Aortic root size;	chr7:66077907	chr7:66554588~66576923:-
THCA	cis	rs748404	0.66	rs694725	ENSG00000166763.7	STRCP1	6.83	2.57e-11	6.8e-09	0.32	0.3	Lung cancer;	chr15:43464012	chr15:43699488~43718184:-
THCA	cis	rs4835473	0.897	rs13144504	ENSG00000251600.4	RP11-673E1.1	-6.83	2.57e-11	6.8e-09	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143707402	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs1817027	ENSG00000251600.4	RP11-673E1.1	-6.83	2.57e-11	6.8e-09	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143713336	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs11735341	ENSG00000251600.4	RP11-673E1.1	-6.83	2.57e-11	6.8e-09	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143716030	chr4:143912331~143982454:+
THCA	cis	rs240993	0.715	rs240995	ENSG00000230177.1	RP5-1112D6.4	-6.83	2.57e-11	6.8e-09	-0.32	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111355310	chr6:111277932~111278742:+
THCA	cis	rs7246657	0.714	rs12972195	ENSG00000226686.6	LINC01535	-6.83	2.57e-11	6.8e-09	-0.43	-0.3	Coronary artery calcification;	chr19:37261603	chr19:37251912~37265535:+
THCA	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	6.83	2.57e-11	6.81e-09	0.18	0.3	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	6.83	2.57e-11	6.81e-09	0.18	0.3	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
THCA	cis	rs4845875	0.559	rs4846047	ENSG00000242349.4	NPPA-AS1	6.83	2.57e-11	6.81e-09	0.31	0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11783575	chr1:11841017~11848079:+
THCA	cis	rs12681366	0.537	rs2919664	ENSG00000253704.1	RP11-267M23.4	6.83	2.58e-11	6.82e-09	0.3	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94456485	chr8:94553722~94569745:+
THCA	cis	rs7688540	0.771	rs11737268	ENSG00000211553.1	AC253576.2	-6.83	2.58e-11	6.83e-09	-0.43	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs11726829	ENSG00000211553.1	AC253576.2	-6.83	2.58e-11	6.83e-09	-0.43	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:136461~136568:+
THCA	cis	rs453301	0.597	rs7001187	ENSG00000253893.2	FAM85B	6.83	2.58e-11	6.83e-09	0.41	0.3	Joint mobility (Beighton score);	chr8:8935272	chr8:8167819~8226614:-
THCA	cis	rs4266144	0.562	rs2086667	ENSG00000241770.1	RP11-555M1.3	-6.83	2.58e-11	6.84e-09	-0.43	-0.3	Coronary artery disease;	chr3:157118728	chr3:157163452~157169133:+
THCA	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	6.83	2.59e-11	6.84e-09	0.34	0.3	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
THCA	cis	rs12681366	0.762	rs7831073	ENSG00000253704.1	RP11-267M23.4	6.83	2.59e-11	6.84e-09	0.29	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94342138	chr8:94553722~94569745:+
THCA	cis	rs1850744	0.826	rs10939504	ENSG00000250942.1	ENPP7P11	-6.83	2.59e-11	6.84e-09	-0.45	-0.3	Economic and political preferences;	chr4:9765746	chr4:9677308~9677934:+
THCA	cis	rs4947019	0.609	rs4946972	ENSG00000260273.1	RP11-425D10.10	6.83	2.59e-11	6.85e-09	0.64	0.3	Hematological parameters;	chr6:109400025	chr6:109382795~109383666:+
THCA	cis	rs2243480	1	rs2462569	ENSG00000229886.1	RP5-1132H15.3	-6.83	2.59e-11	6.85e-09	-0.48	-0.3	Diabetic kidney disease;	chr7:66009859	chr7:66025126~66031544:-
THCA	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	6.83	2.59e-11	6.86e-09	0.37	0.3	Height;	chr6:109482392	chr6:109382795~109383666:+
THCA	cis	rs736801	0.569	rs11748193	ENSG00000233006.5	AC034220.3	6.83	2.59e-11	6.86e-09	0.24	0.3	Mosquito bite size;Breast cancer;	chr5:132389637	chr5:132311285~132369916:-
THCA	cis	rs2976388	0.967	rs2976387	ENSG00000253741.1	CTD-2292P10.4	6.83	2.6e-11	6.86e-09	0.38	0.3	Urinary tract infection frequency;	chr8:142677946	chr8:142702252~142726973:-
THCA	cis	rs7580658	0.521	rs35577992	ENSG00000236682.1	AC068282.3	-6.83	2.6e-11	6.87e-09	-0.38	-0.3	Protein C levels;	chr2:127183748	chr2:127389130~127400580:+
THCA	cis	rs160451	0.934	rs160453	ENSG00000251136.7	RP11-37B2.1	6.83	2.6e-11	6.87e-09	0.26	0.3	Leprosy;	chr8:89652326	chr8:89609409~89757727:-
THCA	cis	rs7267979	0.966	rs2261795	ENSG00000274414.1	RP5-965G21.4	-6.83	2.6e-11	6.87e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25239007~25245229:-
THCA	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	6.83	2.6e-11	6.87e-09	0.72	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
THCA	cis	rs12347191	0.5	rs907582	ENSG00000236130.1	PTCSC2	-6.83	2.6e-11	6.88e-09	-0.25	-0.3	Orofacial clefts;	chr9:97859644	chr9:97805935~97810008:-
THCA	cis	rs6696239	0.513	rs2018828	ENSG00000227711.2	RP11-275O4.5	6.83	2.6e-11	6.88e-09	0.32	0.3	Height;	chr1:227508301	chr1:227509028~227520477:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000280107.1	AL022393.9	-6.83	2.6e-11	6.88e-09	-0.3	-0.3	Cardiac Troponin-T levels;	chr6:28200255	chr6:28170845~28172521:+
THCA	cis	rs10266483	0.921	rs683510	ENSG00000227986.1	TRIM60P18	-6.83	2.6e-11	6.88e-09	-0.25	-0.3	Response to statin therapy;	chr7:64288983	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.881	rs665452	ENSG00000227986.1	TRIM60P18	-6.83	2.6e-11	6.88e-09	-0.25	-0.3	Response to statin therapy;	chr7:64289077	chr7:64355078~64356199:+
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000228409.4	CCT6P1	6.83	2.6e-11	6.89e-09	0.22	0.3	Calcium levels;	chr7:65733651	chr7:65751142~65763354:+
THCA	cis	rs5742933	0.557	rs6756571	ENSG00000273240.1	RP11-455J20.3	6.83	2.61e-11	6.89e-09	0.32	0.3	Ferritin levels;	chr2:189640971	chr2:189763859~189764456:-
THCA	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-6.83	2.61e-11	6.89e-09	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
THCA	cis	rs7688540	0.8	rs1578898	ENSG00000211553.1	AC253576.2	-6.83	2.61e-11	6.9e-09	-0.41	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:136461~136568:+
THCA	cis	rs4819052	0.679	rs28623526	ENSG00000237664.1	LINC00316	-6.83	2.61e-11	6.91e-09	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45338590~45341990:-
THCA	cis	rs11148252	0.514	rs3818422	ENSG00000278238.1	RP11-245D16.4	6.83	2.62e-11	6.92e-09	0.34	0.3	Lewy body disease;	chr13:52145079	chr13:52454775~52455331:-
THCA	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	6.83	2.62e-11	6.92e-09	0.59	0.3	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
THCA	cis	rs944289	0.553	rs1169127	ENSG00000257826.1	RP11-116N8.4	-6.83	2.62e-11	6.93e-09	-0.35	-0.3	Thyroid cancer;	chr14:36151474	chr14:36061026~36067190:-
THCA	cis	rs944289	0.515	rs1169130	ENSG00000257826.1	RP11-116N8.4	-6.83	2.62e-11	6.93e-09	-0.35	-0.3	Thyroid cancer;	chr14:36152701	chr14:36061026~36067190:-
THCA	cis	rs516805	0.561	rs9482260	ENSG00000279453.1	RP3-425C14.4	6.83	2.63e-11	6.95e-09	0.34	0.3	Lymphocyte counts;	chr6:122606981	chr6:122436789~122439223:-
THCA	cis	rs2976388	0.647	rs2585174	ENSG00000253741.1	CTD-2292P10.4	-6.83	2.63e-11	6.95e-09	-0.37	-0.3	Urinary tract infection frequency;	chr8:142700626	chr8:142702252~142726973:-
THCA	cis	rs375066	0.762	rs17656688	ENSG00000267058.1	RP11-15A1.3	6.83	2.63e-11	6.95e-09	0.25	0.3	Breast cancer;	chr19:43920925	chr19:43891804~43901805:-
THCA	cis	rs12701220	0.894	rs2141274	ENSG00000229043.2	AC091729.9	-6.83	2.64e-11	6.97e-09	-0.4	-0.3	Bronchopulmonary dysplasia;	chr7:995081	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.894	rs10263252	ENSG00000229043.2	AC091729.9	-6.83	2.64e-11	6.97e-09	-0.4	-0.3	Bronchopulmonary dysplasia;	chr7:1010313	chr7:1160374~1165267:+
THCA	cis	rs71636778	0.73	rs34951175	ENSG00000260063.1	RP5-968P14.2	-6.83	2.64e-11	6.97e-09	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26778568	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.908	rs60798877	ENSG00000260063.1	RP5-968P14.2	-6.83	2.64e-11	6.97e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781648	chr1:26692132~26694131:-
THCA	cis	rs7403037	0.642	rs61993169	ENSG00000259905.4	PWRN1	6.83	2.64e-11	6.98e-09	0.33	0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24231216	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.794	rs12902460	ENSG00000259905.4	PWRN1	6.83	2.64e-11	6.98e-09	0.33	0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24254531	chr15:24493137~24652130:+
THCA	cis	rs4713118	0.868	rs9468220	ENSG00000280107.1	AL022393.9	6.83	2.64e-11	6.98e-09	0.37	0.3	Parkinson's disease;	chr6:27765197	chr6:28170845~28172521:+
THCA	cis	rs523522	0.962	rs3759394	ENSG00000278344.1	RP11-18C24.8	6.83	2.64e-11	6.98e-09	0.33	0.3	High light scatter reticulocyte count;	chr12:120495370	chr12:120500735~120501090:-
THCA	cis	rs7260598	0.685	rs73021420	ENSG00000268442.1	CTD-2027I19.2	6.83	2.64e-11	6.98e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24082833	chr19:24162370~24163425:-
THCA	cis	rs1552244	0.572	rs7645667	ENSG00000232901.1	CYCSP10	6.83	2.64e-11	6.98e-09	0.48	0.3	Alzheimer's disease;	chr3:10115653	chr3:10000647~10000940:-
THCA	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	6.83	2.64e-11	6.98e-09	0.29	0.3	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
THCA	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	6.83	2.64e-11	6.99e-09	0.28	0.3	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
THCA	cis	rs6723108	0.627	rs2166480	ENSG00000224043.6	CCNT2-AS1	6.83	2.64e-11	6.99e-09	0.32	0.3	Type 2 diabetes;	chr2:134879768	chr2:134735464~134918710:-
THCA	cis	rs55661361	0.532	rs3802902	ENSG00000254941.1	RP11-677M14.5	-6.83	2.64e-11	6.99e-09	-0.24	-0.3	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124765139	chr11:124807822~124808269:-
THCA	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	6.83	2.65e-11	7e-09	0.3	0.3	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
THCA	cis	rs12435908	1	rs59204447	ENSG00000276116.2	FUT8-AS1	-6.83	2.65e-11	7.01e-09	-0.49	-0.3	Ischemic stroke;	chr14:65640009	chr14:65411170~65412690:-
THCA	cis	rs7942368	1	rs3758711	ENSG00000204529.3	GUCY2EP	6.83	2.65e-11	7.01e-09	0.42	0.3	Endometriosis;	chr11:76784516	chr11:76694043~76707641:-
THCA	cis	rs42490	0.51	rs13278061	ENSG00000251136.7	RP11-37B2.1	-6.83	2.65e-11	7.01e-09	-0.26	-0.3	Leprosy;	chr8:89686032	chr8:89609409~89757727:-
THCA	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	6.83	2.65e-11	7.01e-09	0.36	0.3	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
THCA	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	6.83	2.66e-11	7.03e-09	0.38	0.3	Height;	chr6:109479396	chr6:109382795~109383666:+
THCA	cis	rs516805	0.667	rs7752093	ENSG00000279453.1	RP3-425C14.4	6.83	2.66e-11	7.04e-09	0.32	0.3	Lymphocyte counts;	chr6:122301265	chr6:122436789~122439223:-
THCA	cis	rs453301	0.571	rs2929453	ENSG00000254153.1	CTA-398F10.2	6.83	2.66e-11	7.04e-09	0.32	0.3	Joint mobility (Beighton score);	chr8:9226831	chr8:8456909~8461337:-
THCA	cis	rs11158026	0.757	rs8013521	ENSG00000258413.1	RP11-665C16.6	-6.83	2.66e-11	7.04e-09	-0.41	-0.3	Parkinson's disease;	chr14:54947007	chr14:55262767~55272075:-
THCA	cis	rs79349575	0.655	rs62078384	ENSG00000248278.1	SUMO2P17	6.83	2.67e-11	7.04e-09	0.35	0.3	Type 2 diabetes;	chr17:48967101	chr17:48874860~48908983:-
THCA	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-6.83	2.67e-11	7.05e-09	-0.77	-0.3	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
THCA	cis	rs73186030	0.748	rs16832956	ENSG00000272758.4	RP11-299J3.8	6.83	2.67e-11	7.05e-09	0.34	0.3	Serum parathyroid hormone levels;	chr3:122298661	chr3:122416207~122443180:+
THCA	cis	rs2976388	0.904	rs2920281	ENSG00000253741.1	CTD-2292P10.4	6.83	2.67e-11	7.06e-09	0.38	0.3	Urinary tract infection frequency;	chr8:142679026	chr8:142702252~142726973:-
THCA	cis	rs728616	0.867	rs55835350	ENSG00000225484.5	NUTM2B-AS1	-6.83	2.67e-11	7.07e-09	-0.57	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80041972	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs79904324	ENSG00000225484.5	NUTM2B-AS1	-6.83	2.67e-11	7.07e-09	-0.57	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80044932	chr10:79663088~79826594:-
THCA	cis	rs7267979	1	rs2500448	ENSG00000274414.1	RP5-965G21.4	6.83	2.67e-11	7.07e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.873	rs6083853	ENSG00000274414.1	RP5-965G21.4	6.83	2.67e-11	7.07e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.934	rs2482913	ENSG00000274414.1	RP5-965G21.4	6.83	2.67e-11	7.07e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25239007~25245229:-
THCA	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-6.83	2.68e-11	7.07e-09	-0.29	-0.3	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-6.83	2.68e-11	7.07e-09	-0.29	-0.3	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
THCA	cis	rs11089937	0.963	rs5757078	ENSG00000211639.2	IGLV4-60	6.83	2.68e-11	7.08e-09	0.2	0.3	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22162199~22162681:+
THCA	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-6.83	2.68e-11	7.08e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
THCA	cis	rs1005277	0.579	rs1740735	ENSG00000276805.1	RP11-291L22.6	6.83	2.68e-11	7.08e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38451030~38451785:+
THCA	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-6.83	2.68e-11	7.09e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
THCA	cis	rs7586673	0.93	rs7591506	ENSG00000235724.7	AC009299.2	-6.83	2.69e-11	7.09e-09	-0.32	-0.3	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161222785~161308303:-
THCA	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	6.83	2.69e-11	7.1e-09	0.31	0.3	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
THCA	cis	rs9902453	0.765	rs62068653	ENSG00000264007.1	RP11-68I3.10	6.83	2.69e-11	7.1e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29885645	chr17:29621617~29622254:-
THCA	cis	rs2243480	1	rs12698509	ENSG00000229886.1	RP5-1132H15.3	6.83	2.69e-11	7.11e-09	0.48	0.3	Diabetic kidney disease;	chr7:65953889	chr7:66025126~66031544:-
THCA	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	6.83	2.69e-11	7.11e-09	0.47	0.3	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	6.83	2.69e-11	7.11e-09	0.47	0.3	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
THCA	cis	rs10266483	0.921	rs651934	ENSG00000227986.1	TRIM60P18	-6.83	2.7e-11	7.12e-09	-0.26	-0.3	Response to statin therapy;	chr7:64283972	chr7:64355078~64356199:+
THCA	cis	rs2243480	1	rs781156	ENSG00000229886.1	RP5-1132H15.3	6.83	2.7e-11	7.13e-09	0.48	0.3	Diabetic kidney disease;	chr7:66014154	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs451396	ENSG00000229886.1	RP5-1132H15.3	6.83	2.7e-11	7.13e-09	0.48	0.3	Diabetic kidney disease;	chr7:66019087	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1715235	ENSG00000229886.1	RP5-1132H15.3	6.83	2.7e-11	7.13e-09	0.48	0.3	Diabetic kidney disease;	chr7:66023407	chr7:66025126~66031544:-
THCA	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	6.83	2.7e-11	7.13e-09	0.39	0.3	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
THCA	cis	rs9402743	0.671	rs6934889	ENSG00000231028.7	LINC00271	6.83	2.7e-11	7.14e-09	0.24	0.3	Systemic lupus erythematosus;	chr6:135629542	chr6:135497801~135716055:+
THCA	cis	rs2976388	0.507	rs7813604	ENSG00000253741.1	CTD-2292P10.4	-6.83	2.7e-11	7.14e-09	-0.38	-0.3	Urinary tract infection frequency;	chr8:142756644	chr8:142702252~142726973:-
THCA	cis	rs3764021	0.527	rs10844380	ENSG00000256594.6	RP11-705C15.2	6.83	2.7e-11	7.14e-09	0.26	0.3	Type 1 diabetes;	chr12:9670678	chr12:9633419~9658412:+
THCA	cis	rs867529	1	rs1606803	ENSG00000234028.3	AC062029.1	6.83	2.71e-11	7.14e-09	0.25	0.3	Height;	chr2:88633798	chr2:88627539~88631821:+
THCA	cis	rs7119038	0.774	rs7945144	ENSG00000255239.1	AP002954.6	-6.83	2.71e-11	7.16e-09	-0.43	-0.3	Sjögren's syndrome;	chr11:118738007	chr11:118688039~118690600:-
THCA	cis	rs7246657	0.943	rs2126977	ENSG00000226686.6	LINC01535	6.83	2.71e-11	7.16e-09	0.42	0.3	Coronary artery calcification;	chr19:37504845	chr19:37251912~37265535:+
THCA	cis	rs11668609	1	rs3844579	ENSG00000268442.1	CTD-2027I19.2	6.83	2.71e-11	7.16e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24120337	chr19:24162370~24163425:-
THCA	cis	rs8012947	0.92	rs2348071	ENSG00000279636.2	LINC00216	-6.83	2.72e-11	7.17e-09	-0.31	-0.3	Alcohol consumption in current drinkers;	chr14:58263908	chr14:58288033~58289158:+
THCA	cis	rs10899021	0.92	rs11236171	ENSG00000279353.1	RP11-864N7.4	6.83	2.72e-11	7.17e-09	0.59	0.3	Response to metformin (IC50);	chr11:74606473	chr11:74698231~74699658:-
THCA	cis	rs2243480	0.908	rs4718273	ENSG00000229886.1	RP5-1132H15.3	-6.83	2.72e-11	7.17e-09	-0.48	-0.3	Diabetic kidney disease;	chr7:65751112	chr7:66025126~66031544:-
THCA	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-6.83	2.72e-11	7.18e-09	-0.39	-0.3	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
THCA	cis	rs240993	0.812	rs9398272	ENSG00000230177.1	RP5-1112D6.4	6.83	2.72e-11	7.18e-09	0.31	0.3	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:111277932~111278742:+
THCA	cis	rs228614	0.509	rs223482	ENSG00000251288.2	RP11-10L12.2	-6.82	2.72e-11	7.18e-09	-0.4	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102751401~102752641:+
THCA	cis	rs228614	0.536	rs223478	ENSG00000251288.2	RP11-10L12.2	-6.82	2.72e-11	7.18e-09	-0.4	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102751401~102752641:+
THCA	cis	rs228614	0.536	rs150898	ENSG00000251288.2	RP11-10L12.2	-6.82	2.72e-11	7.18e-09	-0.4	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102751401~102752641:+
THCA	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	6.82	2.73e-11	7.2e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-6.82	2.73e-11	7.2e-09	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
THCA	cis	rs4664293	0.669	rs1549387	ENSG00000226266.5	AC009961.3	6.82	2.73e-11	7.2e-09	0.35	0.3	Monocyte percentage of white cells;	chr2:159561029	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.669	rs1863219	ENSG00000226266.5	AC009961.3	6.82	2.73e-11	7.2e-09	0.35	0.3	Monocyte percentage of white cells;	chr2:159561660	chr2:159670708~159712435:-
THCA	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	6.82	2.73e-11	7.21e-09	0.54	0.3	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	6.82	2.73e-11	7.21e-09	0.54	0.3	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	6.82	2.73e-11	7.21e-09	0.54	0.3	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
THCA	cis	rs9287719	0.674	rs12620209	ENSG00000243819.4	RN7SL832P	6.82	2.73e-11	7.21e-09	0.24	0.3	Prostate cancer;	chr2:10580315	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.674	rs12622551	ENSG00000243819.4	RN7SL832P	6.82	2.73e-11	7.21e-09	0.24	0.3	Prostate cancer;	chr2:10580317	chr2:10690344~10692099:+
THCA	cis	rs7267979	0.934	rs2500399	ENSG00000274414.1	RP5-965G21.4	6.82	2.74e-11	7.22e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25239007~25245229:-
THCA	cis	rs3847687	0.546	rs12832254	ENSG00000256810.1	RP11-76C10.2	6.82	2.74e-11	7.22e-09	0.36	0.3	Longevity;	chr12:131034843	chr12:131030570~131035487:-
THCA	cis	rs160451	0.966	rs218886	ENSG00000251136.7	RP11-37B2.1	-6.82	2.74e-11	7.22e-09	-0.26	-0.3	Leprosy;	chr8:89678365	chr8:89609409~89757727:-
THCA	cis	rs4819052	0.851	rs2256000	ENSG00000237664.1	LINC00316	-6.82	2.74e-11	7.22e-09	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45338590~45341990:-
THCA	cis	rs393155	0.517	rs330050	ENSG00000254153.1	CTA-398F10.2	6.82	2.74e-11	7.24e-09	0.32	0.3	Neuroticism;	chr8:9230169	chr8:8456909~8461337:-
THCA	cis	rs453301	0.571	rs330054	ENSG00000254153.1	CTA-398F10.2	6.82	2.74e-11	7.24e-09	0.32	0.3	Joint mobility (Beighton score);	chr8:9230781	chr8:8456909~8461337:-
THCA	cis	rs867529	0.855	rs13001657	ENSG00000234028.3	AC062029.1	6.82	2.75e-11	7.24e-09	0.25	0.3	Height;	chr2:88647093	chr2:88627539~88631821:+
THCA	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	6.82	2.75e-11	7.24e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
THCA	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-6.82	2.75e-11	7.25e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-6.82	2.75e-11	7.25e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
THCA	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-6.82	2.75e-11	7.25e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
THCA	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-6.82	2.75e-11	7.25e-09	-0.24	-0.3	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
THCA	cis	rs6509701	0.813	rs8111139	ENSG00000268225.1	CTD-2331H12.5	6.82	2.75e-11	7.25e-09	0.32	0.3	Psychosis in Alzheimer's disease;	chr19:52871309	chr19:52861807~52862866:-
THCA	cis	rs728616	0.867	rs17096197	ENSG00000225484.5	NUTM2B-AS1	-6.82	2.75e-11	7.26e-09	-0.57	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80048428	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs56123058	ENSG00000225484.5	NUTM2B-AS1	-6.82	2.75e-11	7.26e-09	-0.57	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:79663088~79826594:-
THCA	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-6.82	2.75e-11	7.26e-09	-0.32	-0.3	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
THCA	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-6.82	2.76e-11	7.29e-09	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
THCA	cis	rs228614	0.509	rs223481	ENSG00000251288.2	RP11-10L12.2	-6.82	2.76e-11	7.29e-09	-0.39	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102751401~102752641:+
THCA	cis	rs2179367	1	rs2179367	ENSG00000231760.4	RP11-350J20.5	6.82	2.77e-11	7.29e-09	0.4	0.3	Dupuytren's disease;	chr6:149441401	chr6:149796151~149826294:-
THCA	cis	rs11096990	0.855	rs2566168	ENSG00000249207.1	RP11-360F5.1	6.82	2.77e-11	7.29e-09	0.39	0.3	Cognitive function;	chr4:39150053	chr4:39112677~39126818:-
THCA	cis	rs736801	0.607	rs11746555	ENSG00000233006.5	AC034220.3	6.82	2.77e-11	7.29e-09	0.24	0.3	Mosquito bite size;Breast cancer;	chr5:132391341	chr5:132311285~132369916:-
THCA	cis	rs467650	0.509	rs29768	ENSG00000246763.5	RGMB-AS1	6.82	2.77e-11	7.3e-09	0.29	0.3	Venous thromboembolism (SNP x SNP interaction);	chr5:98645743	chr5:98769618~98773469:-
THCA	cis	rs523522	0.673	rs643372	ENSG00000278344.1	RP11-18C24.8	6.82	2.77e-11	7.3e-09	0.33	0.3	High light scatter reticulocyte count;	chr12:120584837	chr12:120500735~120501090:-
THCA	cis	rs2408955	0.521	rs1476607	ENSG00000240399.1	RP1-228P16.1	-6.82	2.77e-11	7.3e-09	-0.31	-0.3	Glycated hemoglobin levels;	chr12:48131021	chr12:48054813~48055591:-
THCA	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-6.82	2.77e-11	7.3e-09	-0.38	-0.3	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
THCA	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-6.82	2.77e-11	7.3e-09	-0.38	-0.3	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
THCA	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	6.82	2.77e-11	7.31e-09	0.44	0.3	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
THCA	cis	rs35934224	0.891	rs34249993	ENSG00000232926.1	AC000078.5	6.82	2.77e-11	7.31e-09	0.38	0.3	Glaucoma (primary open-angle);	chr22:19884647	chr22:19887289~19887970:+
THCA	cis	rs79349575	0.721	rs2291725	ENSG00000248278.1	SUMO2P17	6.82	2.77e-11	7.31e-09	0.36	0.3	Type 2 diabetes;	chr17:48961770	chr17:48874860~48908983:-
THCA	cis	rs2797160	0.651	rs9491503	ENSG00000237742.5	RP11-624M8.1	6.82	2.78e-11	7.32e-09	0.26	0.3	Endometrial cancer;	chr6:125710536	chr6:125578558~125749190:-
THCA	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-6.82	2.78e-11	7.33e-09	-0.38	-0.3	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
THCA	cis	rs375066	0.762	rs239939	ENSG00000267058.1	RP11-15A1.3	-6.82	2.78e-11	7.33e-09	-0.25	-0.3	Breast cancer;	chr19:43883815	chr19:43891804~43901805:-
THCA	cis	rs375066	0.762	rs239938	ENSG00000267058.1	RP11-15A1.3	-6.82	2.78e-11	7.33e-09	-0.25	-0.3	Breast cancer;	chr19:43886153	chr19:43891804~43901805:-
THCA	cis	rs438465	1	rs407690	ENSG00000226194.4	RP1-137D17.1	6.82	2.78e-11	7.33e-09	0.45	0.3	Corneal astigmatism;	chr6:169426436	chr6:169369998~169388385:-
THCA	cis	rs6569038	0.669	rs7764418	ENSG00000253194.1	RP11-351A11.1	6.82	2.78e-11	7.34e-09	0.41	0.3	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119062817	chr6:118934785~119031541:+
THCA	cis	rs9402743	0.702	rs9399150	ENSG00000231028.7	LINC00271	-6.82	2.79e-11	7.35e-09	-0.25	-0.3	Systemic lupus erythematosus;	chr6:135599752	chr6:135497801~135716055:+
THCA	cis	rs1005277	0.557	rs2983338	ENSG00000276805.1	RP11-291L22.6	6.82	2.79e-11	7.35e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38451030~38451785:+
THCA	cis	rs10266483	0.656	rs670966	ENSG00000227986.1	TRIM60P18	-6.82	2.79e-11	7.35e-09	-0.25	-0.3	Response to statin therapy;	chr7:64302521	chr7:64355078~64356199:+
THCA	cis	rs7044106	0.734	rs12553070	ENSG00000270917.1	RP11-27I1.6	-6.82	2.8e-11	7.37e-09	-0.43	-0.3	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120812475~120812845:-
THCA	cis	rs516805	0.631	rs2606647	ENSG00000279453.1	RP3-425C14.4	-6.82	2.8e-11	7.37e-09	-0.33	-0.3	Lymphocyte counts;	chr6:122118967	chr6:122436789~122439223:-
THCA	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-6.82	2.8e-11	7.38e-09	-0.29	-0.3	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
THCA	cis	rs3806843	0.676	rs778591	ENSG00000202515.1	VTRNA1-3	6.82	2.8e-11	7.39e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140645899	chr5:140726158~140726246:+
THCA	cis	rs4713118	0.513	rs200971	ENSG00000219392.1	RP1-265C24.5	-6.82	2.8e-11	7.39e-09	-0.37	-0.3	Parkinson's disease;	chr6:27891126	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9468201	ENSG00000280107.1	AL022393.9	-6.82	2.81e-11	7.39e-09	-0.35	-0.3	Parkinson's disease;	chr6:27719256	chr6:28170845~28172521:+
THCA	cis	rs9341808	0.69	rs3805926	ENSG00000272129.1	RP11-250B2.6	6.82	2.81e-11	7.4e-09	0.38	0.3	Sitting height ratio;	chr6:80169563	chr6:80355424~80356859:+
THCA	cis	rs7942368	1	rs1440978	ENSG00000204529.3	GUCY2EP	6.82	2.81e-11	7.4e-09	0.42	0.3	Endometriosis;	chr11:76765236	chr11:76694043~76707641:-
THCA	cis	rs7851660	0.844	rs907581	ENSG00000236130.1	PTCSC2	-6.82	2.81e-11	7.41e-09	-0.24	-0.3	Strep throat;	chr9:97859907	chr9:97805935~97810008:-
THCA	cis	rs453301	0.571	rs2929452	ENSG00000254153.1	CTA-398F10.2	6.82	2.82e-11	7.42e-09	0.32	0.3	Joint mobility (Beighton score);	chr8:9226955	chr8:8456909~8461337:-
THCA	cis	rs5751614	0.557	rs5759666	ENSG00000230701.2	FBXW4P1	6.82	2.82e-11	7.44e-09	0.35	0.3	Height;	chr22:23260155	chr22:23262767~23265005:+
THCA	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	6.82	2.82e-11	7.44e-09	0.47	0.3	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	6.82	2.82e-11	7.44e-09	0.47	0.3	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	6.82	2.82e-11	7.44e-09	0.47	0.3	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
THCA	cis	rs1850744	1	rs938556	ENSG00000250942.1	ENPP7P11	6.82	2.82e-11	7.44e-09	0.41	0.3	Economic and political preferences;	chr4:9800742	chr4:9677308~9677934:+
THCA	cis	rs667920	0.512	rs13065626	ENSG00000239213.4	NCK1-AS1	-6.82	2.83e-11	7.44e-09	-0.41	-0.3	Coronary artery disease;	chr3:136575915	chr3:136841726~136862054:-
THCA	cis	rs7617773	0.746	rs7619865	ENSG00000228638.1	FCF1P2	-6.82	2.83e-11	7.46e-09	-0.28	-0.3	Coronary artery disease;	chr3:48329090	chr3:48290793~48291375:-
THCA	cis	rs516805	0.561	rs7772659	ENSG00000279453.1	RP3-425C14.4	6.82	2.83e-11	7.46e-09	0.34	0.3	Lymphocyte counts;	chr6:122608055	chr6:122436789~122439223:-
THCA	cis	rs516805	0.561	rs9490494	ENSG00000279453.1	RP3-425C14.4	6.82	2.83e-11	7.46e-09	0.34	0.3	Lymphocyte counts;	chr6:122612860	chr6:122436789~122439223:-
THCA	cis	rs516805	0.561	rs9490495	ENSG00000279453.1	RP3-425C14.4	6.82	2.83e-11	7.46e-09	0.34	0.3	Lymphocyte counts;	chr6:122613043	chr6:122436789~122439223:-
THCA	cis	rs11148252	0.514	rs2296347	ENSG00000278238.1	RP11-245D16.4	6.82	2.84e-11	7.47e-09	0.34	0.3	Lewy body disease;	chr13:52154288	chr13:52454775~52455331:-
THCA	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	6.82	2.84e-11	7.47e-09	0.44	0.3	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
THCA	cis	rs11668609	1	rs2099360	ENSG00000268442.1	CTD-2027I19.2	6.82	2.84e-11	7.48e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24147361	chr19:24162370~24163425:-
THCA	cis	rs11668609	1	rs2082493	ENSG00000268442.1	CTD-2027I19.2	6.82	2.84e-11	7.48e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24147554	chr19:24162370~24163425:-
THCA	cis	rs16843372	0.576	rs10190307	ENSG00000251491.2	OR7E28P	-6.82	2.84e-11	7.48e-09	-0.4	-0.3	Obesity-related traits;	chr2:158839676	chr2:158862311~158863285:+
THCA	cis	rs16843372	0.576	rs10175732	ENSG00000251491.2	OR7E28P	-6.82	2.84e-11	7.48e-09	-0.4	-0.3	Obesity-related traits;	chr2:158839775	chr2:158862311~158863285:+
THCA	cis	rs853679	0.607	rs67998226	ENSG00000280107.1	AL022393.9	-6.82	2.84e-11	7.48e-09	-0.59	-0.3	Depression;	chr6:28270281	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34878803	ENSG00000280107.1	AL022393.9	-6.82	2.84e-11	7.48e-09	-0.59	-0.3	Depression;	chr6:28282402	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34396849	ENSG00000280107.1	AL022393.9	-6.82	2.84e-11	7.48e-09	-0.59	-0.3	Depression;	chr6:28283178	chr6:28170845~28172521:+
THCA	cis	rs7580658	0.963	rs12991768	ENSG00000236682.1	AC068282.3	-6.82	2.84e-11	7.48e-09	-0.4	-0.3	Protein C levels;	chr2:127388669	chr2:127389130~127400580:+
THCA	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	6.82	2.85e-11	7.49e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	6.82	2.85e-11	7.49e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-6.82	2.85e-11	7.49e-09	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
THCA	cis	rs853679	0.546	rs71537572	ENSG00000280107.1	AL022393.9	-6.82	2.85e-11	7.49e-09	-0.6	-0.3	Depression;	chr6:28002937	chr6:28170845~28172521:+
THCA	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	6.82	2.85e-11	7.51e-09	0.22	0.3	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
THCA	cis	rs11148252	0.514	rs1886539	ENSG00000278238.1	RP11-245D16.4	-6.82	2.85e-11	7.51e-09	-0.34	-0.3	Lewy body disease;	chr13:52151955	chr13:52454775~52455331:-
THCA	cis	rs2243480	1	rs402418	ENSG00000229886.1	RP5-1132H15.3	6.82	2.86e-11	7.52e-09	0.49	0.3	Diabetic kidney disease;	chr7:66044482	chr7:66025126~66031544:-
THCA	cis	rs9928842	0.653	rs8046665	ENSG00000280152.1	RP11-331F4.5	6.82	2.86e-11	7.52e-09	0.49	0.3	Alcoholic chronic pancreatitis;	chr16:75193697	chr16:75245994~75250077:-
THCA	cis	rs72843506	0.586	rs75836592	ENSG00000270091.1	RP11-78O7.2	-6.82	2.86e-11	7.52e-09	-0.35	-0.3	Schizophrenia;	chr17:19935039	chr17:19896590~19897287:-
THCA	cis	rs2915864	0.8	rs17098069	ENSG00000280047.1	CTC-463A16.1	-6.82	2.86e-11	7.53e-09	-0.46	-0.3	Facial morphology (factor 20);	chr5:142119870	chr5:142165767~142168387:+
THCA	cis	rs8030379	1	rs11259931	ENSG00000230373.7	GOLGA6L5P	6.82	2.86e-11	7.53e-09	0.27	0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911270	chr15:84507885~84516814:-
THCA	cis	rs11018904	0.906	rs17227345	ENSG00000280385.1	AP000648.5	6.82	2.86e-11	7.53e-09	0.4	0.3	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90193614~90198120:+
THCA	cis	rs2439831	1	rs565007	ENSG00000275601.1	AC011330.13	-6.82	2.86e-11	7.54e-09	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43424443	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs550239	ENSG00000275601.1	AC011330.13	-6.82	2.86e-11	7.54e-09	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43427999	chr15:43642389~43643023:-
THCA	cis	rs7208859	0.673	rs216440	ENSG00000264538.5	SUZ12P1	-6.82	2.86e-11	7.54e-09	-0.28	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30709299~30790908:+
THCA	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-6.82	2.87e-11	7.54e-09	-0.42	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
THCA	cis	rs853679	0.517	rs4713150	ENSG00000272009.1	RP1-313I6.12	-6.82	2.87e-11	7.55e-09	-0.35	-0.3	Depression;	chr6:28168434	chr6:28078792~28081130:-
THCA	cis	rs8012947	0.959	rs7147470	ENSG00000279636.2	LINC00216	-6.82	2.87e-11	7.55e-09	-0.31	-0.3	Alcohol consumption in current drinkers;	chr14:58292948	chr14:58288033~58289158:+
THCA	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-6.82	2.87e-11	7.56e-09	-0.33	-0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
THCA	cis	rs75422866	0.541	rs61918136	ENSG00000274902.1	RP1-197B17.4	6.82	2.87e-11	7.56e-09	0.65	0.3	Pneumonia;	chr12:47566798	chr12:47731908~47732351:+
THCA	cis	rs13113518	0.513	rs13147861	ENSG00000273257.1	RP11-177J6.1	6.82	2.88e-11	7.57e-09	0.41	0.3	Height;	chr4:55611014	chr4:55387949~55388271:+
THCA	cis	rs7923837	0.687	rs1111875	ENSG00000236493.2	EIF2S2P3	6.82	2.88e-11	7.57e-09	0.3	0.3	Multiple sclerosis;Body mass index;	chr10:92703125	chr10:92668745~92669743:-
THCA	cis	rs2439831	0.867	rs2470134	ENSG00000275601.1	AC011330.13	6.82	2.88e-11	7.57e-09	0.48	0.3	Lung cancer in ever smokers;	chr15:43557688	chr15:43642389~43643023:-
THCA	cis	rs1005277	0.529	rs1780125	ENSG00000276805.1	RP11-291L22.6	6.82	2.88e-11	7.57e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38451030~38451785:+
THCA	cis	rs875971	0.825	rs1129531	ENSG00000232559.3	GS1-124K5.12	-6.82	2.88e-11	7.58e-09	-0.29	-0.3	Aortic root size;	chr7:66154117	chr7:66554588~66576923:-
THCA	cis	rs9309473	0.5	rs12996463	ENSG00000163016.8	ALMS1P	-6.82	2.88e-11	7.58e-09	-0.39	-0.3	Metabolite levels;	chr2:73428368	chr2:73644919~73685576:+
THCA	cis	rs453301	0.571	rs2929456	ENSG00000254153.1	CTA-398F10.2	6.82	2.88e-11	7.58e-09	0.32	0.3	Joint mobility (Beighton score);	chr8:9225906	chr8:8456909~8461337:-
THCA	cis	rs7746199	0.736	rs13202295	ENSG00000280107.1	AL022393.9	-6.82	2.88e-11	7.59e-09	-0.61	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28170845~28172521:+
THCA	cis	rs6840258	1	rs17701999	ENSG00000251411.1	RP11-397E7.4	-6.82	2.89e-11	7.59e-09	-0.35	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87034392	chr4:86913266~86914817:-
THCA	cis	rs8012947	1	rs1885134	ENSG00000279636.2	LINC00216	-6.82	2.89e-11	7.61e-09	-0.31	-0.3	Alcohol consumption in current drinkers;	chr14:58270812	chr14:58288033~58289158:+
THCA	cis	rs8012947	0.727	rs10135729	ENSG00000279636.2	LINC00216	-6.82	2.89e-11	7.61e-09	-0.31	-0.3	Alcohol consumption in current drinkers;	chr14:58277859	chr14:58288033~58289158:+
THCA	cis	rs7554547	0.871	rs6661289	ENSG00000201801.1	RNU5E-4P	6.82	2.89e-11	7.61e-09	0.36	0.3	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr1:11909808~11909927:-
THCA	cis	rs7688540	0.8	rs61794998	ENSG00000211553.1	AC253576.2	-6.82	2.9e-11	7.61e-09	-0.42	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:136461~136568:+
THCA	cis	rs7727544	0.716	rs7720230	ENSG00000233006.5	AC034220.3	6.82	2.9e-11	7.62e-09	0.24	0.3	Blood metabolite levels;	chr5:132256712	chr5:132311285~132369916:-
THCA	cis	rs7119038	0.509	rs11216960	ENSG00000255239.1	AP002954.6	-6.82	2.9e-11	7.62e-09	-0.46	-0.3	Sjögren's syndrome;	chr11:118707164	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.509	rs10892256	ENSG00000255239.1	AP002954.6	-6.82	2.9e-11	7.62e-09	-0.46	-0.3	Sjögren's syndrome;	chr11:118707996	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.509	rs10892257	ENSG00000255239.1	AP002954.6	-6.82	2.9e-11	7.62e-09	-0.46	-0.3	Sjögren's syndrome;	chr11:118708618	chr11:118688039~118690600:-
THCA	cis	rs7267979	0.932	rs431579	ENSG00000274414.1	RP5-965G21.4	-6.81	2.9e-11	7.63e-09	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25239007~25245229:-
THCA	cis	rs42490	0.51	rs7003919	ENSG00000251136.7	RP11-37B2.1	6.81	2.91e-11	7.64e-09	0.26	0.3	Leprosy;	chr8:89688185	chr8:89609409~89757727:-
THCA	cis	rs7851660	0.844	rs10759975	ENSG00000236130.1	PTCSC2	6.81	2.91e-11	7.64e-09	0.24	0.3	Strep throat;	chr9:97862911	chr9:97805935~97810008:-
THCA	cis	rs72843506	0.586	rs113833946	ENSG00000270091.1	RP11-78O7.2	-6.81	2.92e-11	7.67e-09	-0.35	-0.3	Schizophrenia;	chr17:19955593	chr17:19896590~19897287:-
THCA	cis	rs7015630	0.657	rs6984540	ENSG00000251136.7	RP11-37B2.1	-6.81	2.92e-11	7.68e-09	-0.32	-0.3	Inflammatory bowel disease;Crohn's disease;	chr8:89835724	chr8:89609409~89757727:-
THCA	cis	rs875971	0.862	rs28470208	ENSG00000232559.3	GS1-124K5.12	-6.81	2.92e-11	7.68e-09	-0.29	-0.3	Aortic root size;	chr7:66119713	chr7:66554588~66576923:-
THCA	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	6.81	2.93e-11	7.69e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
THCA	cis	rs7942368	1	rs11236924	ENSG00000254761.1	RP11-672A2.1	6.81	2.93e-11	7.7e-09	0.44	0.3	Endometriosis;	chr11:76756303	chr11:76712396~76719608:-
THCA	cis	rs4835473	0.864	rs61427459	ENSG00000251600.4	RP11-673E1.1	-6.81	2.93e-11	7.71e-09	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143699605	chr4:143912331~143982454:+
THCA	cis	rs8012947	0.958	rs7158746	ENSG00000279636.2	LINC00216	-6.81	2.93e-11	7.71e-09	-0.31	-0.3	Alcohol consumption in current drinkers;	chr14:58254081	chr14:58288033~58289158:+
THCA	cis	rs7580658	0.963	rs6732279	ENSG00000236682.1	AC068282.3	-6.81	2.94e-11	7.72e-09	-0.4	-0.3	Protein C levels;	chr2:127331964	chr2:127389130~127400580:+
THCA	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-6.81	2.94e-11	7.73e-09	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
THCA	cis	rs240993	0.812	rs2025269	ENSG00000230177.1	RP5-1112D6.4	-6.81	2.94e-11	7.73e-09	-0.31	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111489237	chr6:111277932~111278742:+
THCA	cis	rs5758659	1	rs5751255	ENSG00000182057.4	OGFRP1	6.81	2.94e-11	7.73e-09	0.34	0.3	Cognitive function;	chr22:42252402	chr22:42269753~42275196:+
THCA	cis	rs7811142	0.943	rs67196635	ENSG00000078319.8	PMS2P1	-6.81	2.94e-11	7.73e-09	-0.42	-0.3	Platelet count;	chr7:100427941	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs6962151	ENSG00000078319.8	PMS2P1	-6.81	2.94e-11	7.73e-09	-0.42	-0.3	Platelet count;	chr7:100430861	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.943	rs67483801	ENSG00000078319.8	PMS2P1	-6.81	2.94e-11	7.73e-09	-0.42	-0.3	Platelet count;	chr7:100434135	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs11761784	ENSG00000078319.8	PMS2P1	-6.81	2.94e-11	7.73e-09	-0.42	-0.3	Platelet count;	chr7:100442347	chr7:100320992~100341908:-
THCA	cis	rs2976388	0.507	rs13259549	ENSG00000253741.1	CTD-2292P10.4	-6.81	2.94e-11	7.73e-09	-0.38	-0.3	Urinary tract infection frequency;	chr8:142757101	chr8:142702252~142726973:-
THCA	cis	rs7247513	0.79	rs17476839	ENSG00000213290.4	PGK1P2	6.81	2.94e-11	7.73e-09	0.36	0.3	Bipolar disorder;	chr19:12651969	chr19:12559571~12561105:+
THCA	cis	rs7811142	1	rs2406255	ENSG00000078319.8	PMS2P1	-6.81	2.94e-11	7.74e-09	-0.44	-0.3	Platelet count;	chr7:100456067	chr7:100320992~100341908:-
THCA	cis	rs7267979	0.586	rs6050445	ENSG00000274414.1	RP5-965G21.4	-6.81	2.95e-11	7.75e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25239007~25245229:-
THCA	cis	rs2243480	1	rs1404147	ENSG00000228409.4	CCT6P1	6.81	2.95e-11	7.76e-09	0.33	0.3	Diabetic kidney disease;	chr7:65799537	chr7:65751142~65763354:+
THCA	cis	rs736801	0.78	rs12521868	ENSG00000224431.1	AC063976.7	-6.81	2.95e-11	7.76e-09	-0.27	-0.3	Mosquito bite size;Breast cancer;	chr5:132448701	chr5:132199456~132203487:+
THCA	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	6.81	2.95e-11	7.76e-09	0.38	0.3	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
THCA	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	6.81	2.95e-11	7.76e-09	0.38	0.3	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
THCA	cis	rs7580658	0.926	rs79789049	ENSG00000236682.1	AC068282.3	-6.81	2.96e-11	7.77e-09	-0.39	-0.3	Protein C levels;	chr2:127387896	chr2:127389130~127400580:+
THCA	cis	rs12701220	0.817	rs1058727	ENSG00000229043.2	AC091729.9	-6.81	2.96e-11	7.77e-09	-0.38	-0.3	Bronchopulmonary dysplasia;	chr7:1047459	chr7:1160374~1165267:+
THCA	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	6.81	2.96e-11	7.78e-09	0.33	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
THCA	cis	rs7247513	0.964	rs4804200	ENSG00000213290.4	PGK1P2	-6.81	2.96e-11	7.78e-09	-0.37	-0.3	Bipolar disorder;	chr19:12599938	chr19:12559571~12561105:+
THCA	cis	rs7247513	0.964	rs4371272	ENSG00000213290.4	PGK1P2	-6.81	2.96e-11	7.78e-09	-0.37	-0.3	Bipolar disorder;	chr19:12600467	chr19:12559571~12561105:+
THCA	cis	rs1075232	0.826	rs12437800	ENSG00000270055.1	CTD-3092A11.2	-6.81	2.96e-11	7.79e-09	-0.59	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30487963~30490313:+
THCA	cis	rs1598856	1	rs1598856	ENSG00000246560.2	RP11-10L12.4	6.81	2.97e-11	7.8e-09	0.36	0.3	Primary biliary cholangitis;	chr4:102524958	chr4:102828055~102844075:+
THCA	cis	rs3806843	0.9	rs2563286	ENSG00000202515.1	VTRNA1-3	6.81	2.97e-11	7.8e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140745614	chr5:140726158~140726246:+
THCA	cis	rs4814920	0.818	rs4813377	ENSG00000233895.1	RP1-122P22.2	-6.81	2.97e-11	7.8e-09	-0.3	-0.3	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19757708~19809675:+
THCA	cis	rs7267979	1	rs2500436	ENSG00000274414.1	RP5-965G21.4	6.81	2.97e-11	7.81e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6083856	ENSG00000274414.1	RP5-965G21.4	6.81	2.97e-11	7.81e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25239007~25245229:-
THCA	cis	rs13230714	0.858	rs714429	ENSG00000204959.4	ARHGEF34P	-6.81	2.97e-11	7.81e-09	-0.33	-0.3	Breast cancer;	chr7:144456641	chr7:144272445~144286966:-
THCA	cis	rs7688540	0.8	rs28531997	ENSG00000211553.1	AC253576.2	-6.81	2.98e-11	7.82e-09	-0.41	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:136461~136568:+
THCA	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-6.81	2.98e-11	7.82e-09	-0.45	-0.3	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
THCA	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	6.81	2.98e-11	7.82e-09	0.23	0.3	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
THCA	cis	rs6723108	0.627	rs4954187	ENSG00000224043.6	CCNT2-AS1	-6.81	2.98e-11	7.82e-09	-0.32	-0.3	Type 2 diabetes;	chr2:134842848	chr2:134735464~134918710:-
THCA	cis	rs2439831	0.867	rs2470134	ENSG00000249839.1	AC011330.5	6.81	2.98e-11	7.82e-09	0.47	0.3	Lung cancer in ever smokers;	chr15:43557688	chr15:43663654~43684339:-
THCA	cis	rs3847687	0.869	rs11061300	ENSG00000256810.1	RP11-76C10.2	6.81	2.98e-11	7.83e-09	0.37	0.3	Longevity;	chr12:131038716	chr12:131030570~131035487:-
THCA	cis	rs1823874	0.653	rs12902823	ENSG00000182397.13	DNM1P46	-6.81	2.98e-11	7.83e-09	-0.33	-0.3	IgG glycosylation;	chr15:99812013	chr15:99790156~99806927:-
THCA	cis	rs853679	0.556	rs13200214	ENSG00000280107.1	AL022393.9	-6.81	2.98e-11	7.83e-09	-0.59	-0.3	Depression;	chr6:28049472	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs71559070	ENSG00000280107.1	AL022393.9	-6.81	2.98e-11	7.83e-09	-0.59	-0.3	Depression;	chr6:28071151	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34166054	ENSG00000280107.1	AL022393.9	-6.81	2.98e-11	7.83e-09	-0.59	-0.3	Depression;	chr6:28098023	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34662244	ENSG00000280107.1	AL022393.9	-6.81	2.98e-11	7.83e-09	-0.59	-0.3	Depression;	chr6:28106103	chr6:28170845~28172521:+
THCA	cis	rs35952432	1	rs35952432	ENSG00000280107.1	AL022393.9	-6.81	2.98e-11	7.83e-09	-0.59	-0.3	Lung cancer;	chr6:28107123	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13203816	ENSG00000280107.1	AL022393.9	-6.81	2.98e-11	7.83e-09	-0.59	-0.3	Depression;	chr6:28111820	chr6:28170845~28172521:+
THCA	cis	rs853679	0.556	rs34588114	ENSG00000280107.1	AL022393.9	-6.81	2.98e-11	7.83e-09	-0.59	-0.3	Depression;	chr6:28112850	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs34371502	ENSG00000280107.1	AL022393.9	-6.81	2.98e-11	7.83e-09	-0.59	-0.3	Depression;	chr6:28113980	chr6:28170845~28172521:+
THCA	cis	rs7260598	0.792	rs10500223	ENSG00000268442.1	CTD-2027I19.2	6.81	2.98e-11	7.84e-09	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:24163222	chr19:24162370~24163425:-
THCA	cis	rs8062405	0.723	rs12445744	ENSG00000278665.1	RP11-666O2.4	6.81	2.98e-11	7.84e-09	0.35	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.755	rs4787455	ENSG00000278665.1	RP11-666O2.4	6.81	2.98e-11	7.84e-09	0.35	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28599241~28601881:-
THCA	cis	rs7131987	0.683	rs7954278	ENSG00000275476.1	RP11-996F15.4	-6.81	2.99e-11	7.84e-09	-0.3	-0.3	QT interval;	chr12:29306357	chr12:29277397~29277882:-
THCA	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	6.81	2.99e-11	7.85e-09	0.43	0.3	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	6.81	2.99e-11	7.85e-09	0.43	0.3	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
THCA	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	6.81	2.99e-11	7.85e-09	0.43	0.3	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
THCA	cis	rs516805	0.667	rs2606609	ENSG00000279453.1	RP3-425C14.4	6.81	2.99e-11	7.86e-09	0.32	0.3	Lymphocyte counts;	chr6:122190346	chr6:122436789~122439223:-
THCA	cis	rs7324557	0.683	rs7325328	ENSG00000205861.10	C1QTNF9B-AS1	6.81	2.99e-11	7.86e-09	0.37	0.3	Visceral adipose tissue adjusted for BMI;	chr13:23822955	chr13:23888889~23897263:+
THCA	cis	rs7851660	0.844	rs6478445	ENSG00000236130.1	PTCSC2	-6.81	2.99e-11	7.86e-09	-0.24	-0.3	Strep throat;	chr9:97862017	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.839	rs10113884	ENSG00000236130.1	PTCSC2	-6.81	2.99e-11	7.86e-09	-0.24	-0.3	Strep throat;	chr9:97862340	chr9:97805935~97810008:-
THCA	cis	rs11603691	0.892	rs668408	ENSG00000254662.1	RP11-872D17.4	6.81	2.99e-11	7.86e-09	0.51	0.3	Low high density lipoprotein cholesterol levels;	chr11:57249260	chr11:57325603~57327958:+
THCA	cis	rs150992	0.53	rs13155749	ENSG00000248489.1	CTD-2007H13.3	-6.81	3e-11	7.87e-09	-0.27	-0.3	Body mass index;	chr5:99003092	chr5:98929171~98995013:+
THCA	cis	rs2688608	0.62	rs11000767	ENSG00000271816.1	BMS1P4	6.81	3e-11	7.88e-09	0.31	0.3	Inflammatory bowel disease;	chr10:73756868	chr10:73699151~73730487:-
THCA	cis	rs1150668	0.796	rs728122	ENSG00000219392.1	RP1-265C24.5	-6.81	3e-11	7.88e-09	-0.32	-0.3	Pubertal anthropometrics;	chr6:28431347	chr6:28115628~28116551:+
THCA	cis	rs6479901	0.846	rs10761761	ENSG00000232075.1	MRPL35P2	-6.81	3e-11	7.88e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63419398	chr10:63634317~63634827:-
THCA	cis	rs11603691	0.515	rs10896603	ENSG00000254662.1	RP11-872D17.4	-6.81	3.01e-11	7.9e-09	-0.5	-0.3	Low high density lipoprotein cholesterol levels;	chr11:57316888	chr11:57325603~57327958:+
THCA	cis	rs699371	0.525	rs7144263	ENSG00000270000.1	RP3-449M8.9	6.81	3.01e-11	7.91e-09	0.29	0.3	Height;	chr14:74438928	chr14:74471930~74472360:-
THCA	cis	rs9287719	0.566	rs34595606	ENSG00000243819.4	RN7SL832P	6.81	3.02e-11	7.92e-09	0.25	0.3	Prostate cancer;	chr2:10582392	chr2:10690344~10692099:+
THCA	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	6.81	3.02e-11	7.93e-09	0.39	0.3	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
THCA	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	6.81	3.02e-11	7.93e-09	0.45	0.3	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
THCA	cis	rs3806843	0.966	rs2563261	ENSG00000202515.1	VTRNA1-3	6.81	3.02e-11	7.94e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140758128	chr5:140726158~140726246:+
THCA	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-6.81	3.02e-11	7.94e-09	-0.29	-0.3	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-6.81	3.02e-11	7.94e-09	-0.29	-0.3	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
THCA	cis	rs7942368	0.941	rs10899279	ENSG00000204529.3	GUCY2EP	6.81	3.02e-11	7.94e-09	0.42	0.3	Endometriosis;	chr11:76766200	chr11:76694043~76707641:-
THCA	cis	rs9902453	0.689	rs7216948	ENSG00000264007.1	RP11-68I3.10	6.81	3.04e-11	7.97e-09	0.34	0.3	Coffee consumption (cups per day);	chr17:29876155	chr17:29621617~29622254:-
THCA	cis	rs2243480	1	rs431318	ENSG00000229886.1	RP5-1132H15.3	6.81	3.04e-11	7.97e-09	0.48	0.3	Diabetic kidney disease;	chr7:66046610	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs313803	ENSG00000229886.1	RP5-1132H15.3	6.81	3.04e-11	7.97e-09	0.48	0.3	Diabetic kidney disease;	chr7:66049744	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs313802	ENSG00000229886.1	RP5-1132H15.3	6.81	3.04e-11	7.97e-09	0.48	0.3	Diabetic kidney disease;	chr7:66051386	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.803	rs403089	ENSG00000229886.1	RP5-1132H15.3	6.81	3.04e-11	7.97e-09	0.48	0.3	Diabetic kidney disease;	chr7:66052736	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs458291	ENSG00000229886.1	RP5-1132H15.3	6.81	3.04e-11	7.97e-09	0.48	0.3	Diabetic kidney disease;	chr7:66055492	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs464895	ENSG00000229886.1	RP5-1132H15.3	6.81	3.04e-11	7.97e-09	0.48	0.3	Diabetic kidney disease;	chr7:66062119	chr7:66025126~66031544:-
THCA	cis	rs4664293	0.867	rs7579206	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159715992	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs7565297	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159716008	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs7594329	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159716207	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs7582124	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159716326	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.802	rs13025347	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159721056	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs6432554	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159722573	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs6760485	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159723179	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs6761145	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159725673	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs6732987	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159725918	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs7589941	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159727589	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs7566584	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159728284	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs3732289	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159728887	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs3821299	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159729229	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs13415100	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159729716	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs13389662	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159729926	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs7562060	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159730618	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs4665110	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159731014	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs34893664	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159732266	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs34795915	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159732420	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs10204867	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159732674	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs35196716	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159733266	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs6432557	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159735699	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs7603274	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159736179	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.836	rs13403371	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159736603	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs13428679	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159736687	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs12623283	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159736959	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs2098976	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159737264	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs2081723	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159737649	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs2081722	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159737697	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs10166694	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159738380	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs2357529	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159738922	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs12692562	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159739199	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs12998291	ENSG00000226266.5	AC009961.3	-6.81	3.04e-11	7.98e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159739392	chr2:159670708~159712435:-
THCA	cis	rs2880765	0.714	rs6497187	ENSG00000259295.5	CSPG4P12	6.81	3.04e-11	7.98e-09	0.38	0.3	Coronary artery disease;	chr15:85468119	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.743	rs6497191	ENSG00000259295.5	CSPG4P12	6.81	3.04e-11	7.98e-09	0.38	0.3	Coronary artery disease;	chr15:85468270	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.743	rs6416598	ENSG00000259295.5	CSPG4P12	6.81	3.04e-11	7.98e-09	0.38	0.3	Coronary artery disease;	chr15:85468617	chr15:85191438~85213905:+
THCA	cis	rs9381040	0.692	rs4714430	ENSG00000161912.16	ADCY10P1	6.81	3.04e-11	7.98e-09	0.19	0.3	Alzheimer's disease (late onset);	chr6:41189316	chr6:41101022~41140835:+
THCA	cis	rs8030379	1	rs8024628	ENSG00000230373.7	GOLGA6L5P	-6.81	3.05e-11	7.99e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917711	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs8029016	ENSG00000230373.7	GOLGA6L5P	-6.81	3.05e-11	7.99e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917712	chr15:84507885~84516814:-
THCA	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	6.81	3.06e-11	8.01e-09	0.3	0.3	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	6.81	3.06e-11	8.01e-09	0.3	0.3	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
THCA	cis	rs11662586	0.517	rs7228070	ENSG00000261126.6	RP11-795F19.1	6.81	3.06e-11	8.02e-09	0.24	0.3	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79938967	chr18:80046900~80095482:+
THCA	cis	rs8062405	0.755	rs56272201	ENSG00000278665.1	RP11-666O2.4	6.81	3.06e-11	8.02e-09	0.35	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.755	rs62034355	ENSG00000278665.1	RP11-666O2.4	6.81	3.06e-11	8.02e-09	0.35	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28599241~28601881:-
THCA	cis	rs270601	0.683	rs81598	ENSG00000233006.5	AC034220.3	6.81	3.06e-11	8.02e-09	0.23	0.3	Acylcarnitine levels;	chr5:132252267	chr5:132311285~132369916:-
THCA	cis	rs2361718	0.501	rs12944619	ENSG00000279259.1	RP11-334C17.3	6.81	3.06e-11	8.03e-09	0.3	0.3	Yeast infection;	chr17:80170310	chr17:80147250~80148596:+
THCA	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-6.81	3.07e-11	8.04e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-6.81	3.07e-11	8.04e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-6.81	3.07e-11	8.04e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
THCA	cis	rs736801	0.78	rs2188962	ENSG00000224431.1	AC063976.7	6.81	3.07e-11	8.04e-09	0.27	0.3	Mosquito bite size;Breast cancer;	chr5:132435113	chr5:132199456~132203487:+
THCA	cis	rs4835473	0.618	rs7685385	ENSG00000251600.4	RP11-673E1.1	-6.81	3.07e-11	8.04e-09	-0.42	-0.3	Immature fraction of reticulocytes;	chr4:144029851	chr4:143912331~143982454:+
THCA	cis	rs4819052	0.632	rs4819050	ENSG00000237664.1	LINC00316	-6.81	3.07e-11	8.06e-09	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45338590~45341990:-
THCA	cis	rs516805	0.561	rs7754101	ENSG00000279453.1	RP3-425C14.4	6.81	3.07e-11	8.06e-09	0.34	0.3	Lymphocyte counts;	chr6:122607828	chr6:122436789~122439223:-
THCA	cis	rs6504622	0.935	rs740617	ENSG00000262879.4	RP11-156P1.3	6.81	3.07e-11	8.06e-09	0.28	0.3	Orofacial clefts;	chr17:46950635	chr17:46984045~47100323:-
THCA	cis	rs867529	0.961	rs11898161	ENSG00000234028.3	AC062029.1	-6.81	3.08e-11	8.07e-09	-0.26	-0.3	Height;	chr2:88582130	chr2:88627539~88631821:+
THCA	cis	rs867529	0.889	rs7571971	ENSG00000234028.3	AC062029.1	-6.81	3.08e-11	8.07e-09	-0.26	-0.3	Height;	chr2:88595833	chr2:88627539~88631821:+
THCA	cis	rs45509595	0.841	rs200485	ENSG00000219392.1	RP1-265C24.5	-6.81	3.08e-11	8.08e-09	-0.51	-0.3	Breast cancer;	chr6:27807919	chr6:28115628~28116551:+
THCA	cis	rs7267979	1	rs2424713	ENSG00000274414.1	RP5-965G21.4	-6.81	3.08e-11	8.08e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2387885	ENSG00000274414.1	RP5-965G21.4	6.81	3.08e-11	8.08e-09	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25239007~25245229:-
THCA	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	6.81	3.09e-11	8.09e-09	0.23	0.3	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
THCA	cis	rs72843506	0.586	rs74429763	ENSG00000270091.1	RP11-78O7.2	-6.8	3.09e-11	8.1e-09	-0.35	-0.3	Schizophrenia;	chr17:19960206	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.586	rs16960554	ENSG00000270091.1	RP11-78O7.2	-6.8	3.09e-11	8.1e-09	-0.35	-0.3	Schizophrenia;	chr17:19966485	chr17:19896590~19897287:-
THCA	cis	rs7267979	1	rs4815424	ENSG00000274414.1	RP5-965G21.4	6.8	3.1e-11	8.12e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25239007~25245229:-
THCA	cis	rs71636778	0.509	rs34217609	ENSG00000260063.1	RP5-968P14.2	-6.8	3.1e-11	8.12e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26681776	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.818	rs35161452	ENSG00000260063.1	RP5-968P14.2	-6.8	3.1e-11	8.12e-09	-0.57	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26691718	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.908	rs4579782	ENSG00000260063.1	RP5-968P14.2	-6.8	3.1e-11	8.12e-09	-0.57	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26700496	chr1:26692132~26694131:-
THCA	cis	rs792448	0.743	rs351377	ENSG00000226251.4	RP11-15I11.3	-6.8	3.1e-11	8.13e-09	-0.38	-0.3	White blood cell count (basophil);	chr1:212252429	chr1:212225278~212238977:-
THCA	cis	rs11668609	1	rs919812	ENSG00000268442.1	CTD-2027I19.2	6.8	3.11e-11	8.15e-09	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24163425	chr19:24162370~24163425:-
THCA	cis	rs6539288	0.63	rs10778520	ENSG00000260329.1	RP11-412D9.4	6.8	3.11e-11	8.15e-09	0.27	0.3	Total body bone mineral density;	chr12:106971095	chr12:106954029~106955497:-
THCA	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-6.8	3.11e-11	8.15e-09	-0.28	-0.3	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
THCA	cis	rs160451	0.933	rs218888	ENSG00000251136.7	RP11-37B2.1	-6.8	3.11e-11	8.15e-09	-0.26	-0.3	Leprosy;	chr8:89679693	chr8:89609409~89757727:-
THCA	cis	rs516805	0.683	rs115988443	ENSG00000279453.1	RP3-425C14.4	6.8	3.11e-11	8.16e-09	0.33	0.3	Lymphocyte counts;	chr6:122383201	chr6:122436789~122439223:-
THCA	cis	rs7208859	0.673	rs423151	ENSG00000264538.5	SUZ12P1	-6.8	3.12e-11	8.17e-09	-0.29	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30709299~30790908:+
THCA	cis	rs7260598	0.642	rs67908565	ENSG00000268442.1	CTD-2027I19.2	6.8	3.12e-11	8.18e-09	0.4	0.3	Response to taxane treatment (placlitaxel);	chr19:23998579	chr19:24162370~24163425:-
THCA	cis	rs9402743	0.634	rs9483853	ENSG00000231028.7	LINC00271	-6.8	3.13e-11	8.19e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135595767	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.634	rs4394233	ENSG00000231028.7	LINC00271	-6.8	3.13e-11	8.19e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135596752	chr6:135497801~135716055:+
THCA	cis	rs1275468	1	rs3858534	ENSG00000257497.2	RP11-585P4.5	-6.8	3.13e-11	8.19e-09	-0.44	-0.3	Polycystic ovary syndrome;	chr12:75553304	chr12:75483454~75489820:-
THCA	cis	rs7131987	0.874	rs10843366	ENSG00000257176.2	RP11-996F15.2	-6.8	3.13e-11	8.19e-09	-0.3	-0.3	QT interval;	chr12:29254970	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.845	rs2042511	ENSG00000257176.2	RP11-996F15.2	-6.8	3.13e-11	8.19e-09	-0.3	-0.3	QT interval;	chr12:29255847	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.903	rs10843371	ENSG00000257176.2	RP11-996F15.2	-6.8	3.13e-11	8.19e-09	-0.3	-0.3	QT interval;	chr12:29261299	chr12:29280418~29317848:-
THCA	cis	rs4713118	0.955	rs9468204	ENSG00000280107.1	AL022393.9	-6.8	3.13e-11	8.19e-09	-0.34	-0.3	Parkinson's disease;	chr6:27721030	chr6:28170845~28172521:+
THCA	cis	rs944289	0.553	rs1169132	ENSG00000257826.1	RP11-116N8.4	-6.8	3.13e-11	8.19e-09	-0.35	-0.3	Thyroid cancer;	chr14:36153446	chr14:36061026~36067190:-
THCA	cis	rs6430585	0.528	rs78274583	ENSG00000231890.6	DARS-AS1	-6.8	3.13e-11	8.19e-09	-0.38	-0.3	Corneal structure;	chr2:135976999	chr2:135985176~136022593:+
THCA	cis	rs4947019	0.609	rs752260	ENSG00000260273.1	RP11-425D10.10	6.8	3.13e-11	8.2e-09	0.65	0.3	Hematological parameters;	chr6:109449605	chr6:109382795~109383666:+
THCA	cis	rs2243480	1	rs4718270	ENSG00000229886.1	RP5-1132H15.3	6.8	3.13e-11	8.2e-09	0.48	0.3	Diabetic kidney disease;	chr7:65737415	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs4718269	ENSG00000229886.1	RP5-1132H15.3	-6.8	3.13e-11	8.2e-09	-0.48	-0.3	Diabetic kidney disease;	chr7:65735810	chr7:66025126~66031544:-
THCA	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	6.8	3.14e-11	8.21e-09	0.25	0.3	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
THCA	cis	rs9341808	0.718	rs2179842	ENSG00000272129.1	RP11-250B2.6	6.8	3.14e-11	8.21e-09	0.39	0.3	Sitting height ratio;	chr6:80269336	chr6:80355424~80356859:+
THCA	cis	rs875971	0.862	rs778734	ENSG00000232559.3	GS1-124K5.12	6.8	3.14e-11	8.23e-09	0.28	0.3	Aortic root size;	chr7:66349862	chr7:66554588~66576923:-
THCA	cis	rs4947019	0.609	rs9480934	ENSG00000260273.1	RP11-425D10.10	6.8	3.15e-11	8.26e-09	0.68	0.3	Hematological parameters;	chr6:109350845	chr6:109382795~109383666:+
THCA	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-6.8	3.15e-11	8.26e-09	-0.29	-0.3	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
THCA	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-6.8	3.15e-11	8.26e-09	-0.24	-0.3	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
THCA	cis	rs3806843	0.932	rs2563269	ENSG00000202515.1	VTRNA1-3	6.8	3.16e-11	8.27e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140756883	chr5:140726158~140726246:+
THCA	cis	rs1552244	0.882	rs9312044	ENSG00000232901.1	CYCSP10	6.8	3.16e-11	8.27e-09	0.38	0.3	Alzheimer's disease;	chr3:9995797	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs6796419	ENSG00000232901.1	CYCSP10	6.8	3.16e-11	8.27e-09	0.38	0.3	Alzheimer's disease;	chr3:9999128	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.752	rs9867091	ENSG00000232901.1	CYCSP10	6.8	3.16e-11	8.27e-09	0.38	0.3	Alzheimer's disease;	chr3:10001745	chr3:10000647~10000940:-
THCA	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-6.8	3.16e-11	8.27e-09	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
THCA	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-6.8	3.16e-11	8.27e-09	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
THCA	cis	rs17684571	0.872	rs6901176	ENSG00000231441.1	RP11-472M19.2	6.8	3.16e-11	8.28e-09	0.36	0.3	Schizophrenia;	chr6:56696759	chr6:56844002~56864078:+
THCA	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
THCA	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
THCA	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
THCA	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
THCA	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
THCA	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-6.8	3.16e-11	8.28e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
THCA	cis	rs7221109	0.682	rs1358173	ENSG00000278834.1	RP11-458J1.1	6.8	3.17e-11	8.29e-09	0.32	0.3	Type 1 diabetes;	chr17:40601477	chr17:40648300~40649718:+
THCA	cis	rs26528	0.584	rs153103	ENSG00000259982.1	CDC37P1	-6.8	3.17e-11	8.29e-09	-0.34	-0.3	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28700294~28701540:-
THCA	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-6.8	3.17e-11	8.29e-09	-0.37	-0.3	Height;	chr3:52819385	chr3:53064283~53065091:-
THCA	cis	rs5769707	0.521	rs5769719	ENSG00000235111.1	RP1-29C18.8	-6.8	3.17e-11	8.3e-09	-0.38	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.521	rs5769720	ENSG00000235111.1	RP1-29C18.8	-6.8	3.17e-11	8.3e-09	-0.38	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.521	rs5770633	ENSG00000235111.1	RP1-29C18.8	-6.8	3.17e-11	8.3e-09	-0.38	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49612657~49615716:-
THCA	cis	rs56114371	0.777	rs200482	ENSG00000219392.1	RP1-265C24.5	-6.8	3.17e-11	8.3e-09	-0.51	-0.3	Breast cancer;	chr6:27806126	chr6:28115628~28116551:+
THCA	cis	rs8030379	1	rs1526080	ENSG00000230373.7	GOLGA6L5P	-6.8	3.17e-11	8.3e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921168	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs1852264	ENSG00000230373.7	GOLGA6L5P	-6.8	3.17e-11	8.3e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921188	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs1526081	ENSG00000230373.7	GOLGA6L5P	-6.8	3.17e-11	8.3e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921314	chr15:84507885~84516814:-
THCA	cis	rs8030379	1	rs8030379	ENSG00000230373.7	GOLGA6L5P	-6.8	3.17e-11	8.3e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922158	chr15:84507885~84516814:-
THCA	cis	rs741668	0.931	rs17350833	ENSG00000235903.6	CPB2-AS1	6.8	3.18e-11	8.31e-09	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:45963622	chr13:46052806~46113332:+
THCA	cis	rs11158026	0.757	rs7146285	ENSG00000258413.1	RP11-665C16.6	-6.8	3.18e-11	8.31e-09	-0.41	-0.3	Parkinson's disease;	chr14:54946151	chr14:55262767~55272075:-
THCA	cis	rs375066	0.762	rs17713001	ENSG00000267058.1	RP11-15A1.3	6.8	3.18e-11	8.32e-09	0.25	0.3	Breast cancer;	chr19:43917073	chr19:43891804~43901805:-
THCA	cis	rs375066	0.762	rs2284245	ENSG00000267058.1	RP11-15A1.3	6.8	3.18e-11	8.32e-09	0.25	0.3	Breast cancer;	chr19:43918437	chr19:43891804~43901805:-
THCA	cis	rs7246657	0.943	rs13343502	ENSG00000226686.6	LINC01535	-6.8	3.18e-11	8.33e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37471390	chr19:37251912~37265535:+
THCA	cis	rs4950322	0.57	rs17160051	ENSG00000237188.3	RP11-337C18.8	6.8	3.18e-11	8.33e-09	0.36	0.3	Protein quantitative trait loci;	chr1:147255733	chr1:147172771~147211568:+
THCA	cis	rs10208649	0.908	rs72906778	ENSG00000272156.1	RP11-477N3.1	6.8	3.19e-11	8.35e-09	0.57	0.3	Body mass index;	chr2:54121865	chr2:54082554~54085066:+
THCA	cis	rs72843506	0.586	rs79246843	ENSG00000270091.1	RP11-78O7.2	-6.8	3.19e-11	8.36e-09	-0.35	-0.3	Schizophrenia;	chr17:19938749	chr17:19896590~19897287:-
THCA	cis	rs9402743	0.634	rs7767072	ENSG00000231028.7	LINC00271	-6.8	3.2e-11	8.37e-09	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135593899	chr6:135497801~135716055:+
THCA	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-6.8	3.2e-11	8.38e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-6.8	3.2e-11	8.38e-09	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
THCA	cis	rs2412819	0.571	rs8030536	ENSG00000249839.1	AC011330.5	-6.8	3.21e-11	8.38e-09	-0.47	-0.3	Lung cancer;	chr15:43627365	chr15:43663654~43684339:-
THCA	cis	rs5758659	0.819	rs134871	ENSG00000182057.4	OGFRP1	6.8	3.21e-11	8.4e-09	0.33	0.3	Cognitive function;	chr22:42256710	chr22:42269753~42275196:+
THCA	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-6.8	3.21e-11	8.4e-09	-0.32	-0.3	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
THCA	cis	rs5742933	0.817	rs7591929	ENSG00000273240.1	RP11-455J20.3	6.8	3.22e-11	8.42e-09	0.31	0.3	Ferritin levels;	chr2:189778531	chr2:189763859~189764456:-
THCA	cis	rs1552244	0.882	rs9812006	ENSG00000232901.1	CYCSP10	6.8	3.22e-11	8.43e-09	0.38	0.3	Alzheimer's disease;	chr3:9980974	chr3:10000647~10000940:-
THCA	cis	rs516805	0.561	rs9320881	ENSG00000279453.1	RP3-425C14.4	6.8	3.22e-11	8.43e-09	0.34	0.3	Lymphocyte counts;	chr6:122613577	chr6:122436789~122439223:-
THCA	cis	rs4591358	0.731	rs13031745	ENSG00000223466.1	AC064834.2	-6.8	3.23e-11	8.44e-09	-0.41	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195440458	chr2:195533035~195538681:+
THCA	cis	rs728616	0.867	rs17098720	ENSG00000225484.5	NUTM2B-AS1	-6.8	3.23e-11	8.44e-09	-0.57	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80080480	chr10:79663088~79826594:-
THCA	cis	rs728616	0.717	rs12414332	ENSG00000225484.5	NUTM2B-AS1	-6.8	3.23e-11	8.44e-09	-0.57	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80081199	chr10:79663088~79826594:-
THCA	cis	rs7474896	0.507	rs2474555	ENSG00000263064.2	RP11-291L22.7	6.8	3.23e-11	8.44e-09	0.42	0.3	Obesity (extreme);	chr10:38176292	chr10:38448689~38448949:+
THCA	cis	rs10875746	0.551	rs3185921	ENSG00000269514.1	RP11-370I10.12	6.8	3.23e-11	8.45e-09	0.31	0.3	Longevity (90 years and older);	chr12:48340948	chr12:48198387~48202031:+
THCA	cis	rs7189233	0.911	rs72801854	ENSG00000279722.1	RP11-44F14.6	-6.8	3.23e-11	8.45e-09	-0.32	-0.3	Intelligence (multi-trait analysis);	chr16:53483330	chr16:53487607~53489943:-
THCA	cis	rs4835473	0.897	rs7657088	ENSG00000251600.4	RP11-673E1.1	-6.8	3.24e-11	8.46e-09	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143701877	chr4:143912331~143982454:+
THCA	cis	rs7615952	0.736	rs13063122	ENSG00000241288.6	RP11-379B18.5	-6.8	3.24e-11	8.47e-09	-0.37	-0.3	Blood pressure (smoking interaction);	chr3:125925017	chr3:125827238~125916384:-
THCA	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	6.8	3.24e-11	8.48e-09	0.38	0.3	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000213640.3	EEF1DP4	-6.8	3.24e-11	8.48e-09	-0.36	-0.3	Calcium levels;	chr7:65829495	chr7:64862999~64864370:+
THCA	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	6.8	3.24e-11	8.48e-09	0.45	0.3	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
THCA	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-6.8	3.25e-11	8.49e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
THCA	cis	rs9376098	0.698	rs2050020	ENSG00000232876.1	CTA-212D2.2	-6.8	3.25e-11	8.49e-09	-0.35	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135142915	chr6:135055033~135060550:+
THCA	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	6.8	3.25e-11	8.5e-09	0.31	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
THCA	cis	rs7923837	0.713	rs10882099	ENSG00000236493.2	EIF2S2P3	6.8	3.25e-11	8.51e-09	0.31	0.3	Multiple sclerosis;Body mass index;	chr10:92700893	chr10:92668745~92669743:-
THCA	cis	rs41307935	0.778	rs78533482	ENSG00000260063.1	RP5-968P14.2	-6.8	3.26e-11	8.51e-09	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26715851	chr1:26692132~26694131:-
THCA	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-6.8	3.26e-11	8.52e-09	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
THCA	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	6.8	3.26e-11	8.52e-09	0.24	0.3	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
THCA	cis	rs3806843	0.801	rs801170	ENSG00000202515.1	VTRNA1-3	6.8	3.26e-11	8.53e-09	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140735758	chr5:140726158~140726246:+
THCA	cis	rs42490	0.51	rs218917	ENSG00000251136.7	RP11-37B2.1	-6.8	3.26e-11	8.53e-09	-0.26	-0.3	Leprosy;	chr8:89688902	chr8:89609409~89757727:-
THCA	cis	rs12347191	0.5	rs907580	ENSG00000236130.1	PTCSC2	-6.8	3.27e-11	8.55e-09	-0.25	-0.3	Orofacial clefts;	chr9:97860315	chr9:97805935~97810008:-
THCA	cis	rs12347191	0.5	rs907579	ENSG00000236130.1	PTCSC2	-6.8	3.27e-11	8.55e-09	-0.25	-0.3	Orofacial clefts;	chr9:97860441	chr9:97805935~97810008:-
THCA	cis	rs7746199	0.736	rs17749927	ENSG00000219392.1	RP1-265C24.5	-6.8	3.27e-11	8.55e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs13192965	ENSG00000219392.1	RP1-265C24.5	-6.8	3.27e-11	8.55e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28115628~28116551:+
THCA	cis	rs9549328	1	rs9549328	ENSG00000267868.1	RP11-120K24.3	6.8	3.27e-11	8.55e-09	0.32	0.3	Systolic blood pressure;	chr13:112981842	chr13:112964835~112966131:-
THCA	cis	rs7267979	0.934	rs4815423	ENSG00000274414.1	RP5-965G21.4	6.8	3.27e-11	8.56e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25239007~25245229:-
THCA	cis	rs7189233	1	rs7189233	ENSG00000279344.1	RP11-44F14.7	6.8	3.28e-11	8.57e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr16:53421471	chr16:53478957~53481550:-
THCA	cis	rs7615952	0.611	rs2971298	ENSG00000241288.6	RP11-379B18.5	-6.8	3.28e-11	8.57e-09	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:125883870	chr3:125827238~125916384:-
THCA	cis	rs367615	0.68	rs253246	ENSG00000249476.1	CTD-2587M2.1	6.8	3.28e-11	8.58e-09	0.34	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109648317	chr5:109237120~109326369:-
THCA	cis	rs7131987	0.834	rs11050167	ENSG00000257176.2	RP11-996F15.2	-6.8	3.29e-11	8.59e-09	-0.31	-0.3	QT interval;	chr12:29273454	chr12:29280418~29317848:-
THCA	cis	rs875971	0.862	rs1983372	ENSG00000232559.3	GS1-124K5.12	-6.8	3.29e-11	8.59e-09	-0.28	-0.3	Aortic root size;	chr7:66146364	chr7:66554588~66576923:-
THCA	cis	rs2412819	0.571	rs66903736	ENSG00000249839.1	AC011330.5	-6.79	3.29e-11	8.6e-09	-0.47	-0.3	Lung cancer;	chr15:43619435	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs66749753	ENSG00000249839.1	AC011330.5	-6.79	3.29e-11	8.6e-09	-0.47	-0.3	Lung cancer;	chr15:43619601	chr15:43663654~43684339:-
THCA	cis	rs6479901	0.947	rs10761755	ENSG00000232075.1	MRPL35P2	-6.79	3.3e-11	8.61e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63412212	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs10761757	ENSG00000232075.1	MRPL35P2	-6.79	3.3e-11	8.61e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63412790	chr10:63634317~63634827:-
THCA	cis	rs6479901	1	rs6479901	ENSG00000232075.1	MRPL35P2	-6.79	3.3e-11	8.61e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63421016	chr10:63634317~63634827:-
THCA	cis	rs2255336	0.938	rs2126888	ENSG00000245648.1	RP11-277P12.20	6.79	3.3e-11	8.61e-09	0.38	0.3	Blood protein levels;	chr12:10393789	chr12:10363769~10398506:+
THCA	cis	rs4835473	0.897	rs2036880	ENSG00000251600.4	RP11-673E1.1	6.79	3.3e-11	8.61e-09	0.38	0.3	Immature fraction of reticulocytes;	chr4:143907834	chr4:143912331~143982454:+
THCA	cis	rs7746199	0.736	rs35037868	ENSG00000280107.1	AL022393.9	-6.79	3.3e-11	8.63e-09	-0.61	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28170845~28172521:+
THCA	cis	rs3806843	0.9	rs2563287	ENSG00000202515.1	VTRNA1-3	-6.79	3.31e-11	8.63e-09	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140745201	chr5:140726158~140726246:+
THCA	cis	rs7811142	1	rs11773661	ENSG00000078319.8	PMS2P1	-6.79	3.31e-11	8.65e-09	-0.43	-0.3	Platelet count;	chr7:100475446	chr7:100320992~100341908:-
THCA	cis	rs16843372	0.563	rs13403565	ENSG00000251491.2	OR7E28P	-6.79	3.31e-11	8.65e-09	-0.4	-0.3	Obesity-related traits;	chr2:158827692	chr2:158862311~158863285:+
THCA	cis	rs6840360	0.642	rs2709838	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2724580	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709834	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs6845648	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2724571	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709833	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.667	rs2709832	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709816	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs10454251	ENSG00000251611.1	RP11-610P16.1	-6.79	3.32e-11	8.66e-09	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151407551~151408835:-
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000228409.4	CCT6P1	-6.79	3.32e-11	8.66e-09	-0.22	-0.3	Calcium levels;	chr7:65829754	chr7:65751142~65763354:+
THCA	cis	rs2915864	0.628	rs6580216	ENSG00000280047.1	CTC-463A16.1	6.79	3.32e-11	8.66e-09	0.43	0.3	Facial morphology (factor 20);	chr5:142053510	chr5:142165767~142168387:+
THCA	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	6.79	3.32e-11	8.66e-09	0.31	0.3	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
THCA	cis	rs12701220	0.817	rs7798459	ENSG00000229043.2	AC091729.9	-6.79	3.32e-11	8.67e-09	-0.38	-0.3	Bronchopulmonary dysplasia;	chr7:1048329	chr7:1160374~1165267:+
THCA	cis	rs3806843	0.9	rs2261651	ENSG00000202515.1	VTRNA1-3	6.79	3.33e-11	8.69e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140757219	chr5:140726158~140726246:+
THCA	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-6.79	3.33e-11	8.69e-09	-0.39	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
THCA	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-6.79	3.33e-11	8.69e-09	-0.39	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
THCA	cis	rs71636778	0.509	rs71640337	ENSG00000260063.1	RP5-968P14.2	-6.79	3.33e-11	8.69e-09	-0.56	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26677897	chr1:26692132~26694131:-
THCA	cis	rs7851660	0.809	rs1561957	ENSG00000236130.1	PTCSC2	-6.79	3.33e-11	8.7e-09	-0.24	-0.3	Strep throat;	chr9:97907990	chr9:97805935~97810008:-
THCA	cis	rs11976180	1	rs1533267	ENSG00000170356.8	OR2A20P	-6.79	3.33e-11	8.7e-09	-0.41	-0.3	Obesity-related traits;	chr7:144069347	chr7:144250045~144252957:-
THCA	cis	rs911555	0.539	rs4374097	ENSG00000269958.1	RP11-73M18.8	6.79	3.34e-11	8.7e-09	0.29	0.3	Intelligence (multi-trait analysis);	chr14:103606429	chr14:103696353~103697163:+
THCA	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	6.79	3.34e-11	8.73e-09	0.53	0.3	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	6.79	3.34e-11	8.73e-09	0.53	0.3	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
THCA	cis	rs1577330	0.796	rs639826	ENSG00000254396.1	RP11-56F10.3	-6.79	3.35e-11	8.73e-09	-0.42	-0.3	IgG glycosylation;	chr9:27096419	chr9:27102630~27104728:+
THCA	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-6.79	3.35e-11	8.73e-09	-0.31	-0.3	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
THCA	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-6.79	3.35e-11	8.74e-09	-0.21	-0.3	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
THCA	cis	rs75422866	0.51	rs73105845	ENSG00000274902.1	RP1-197B17.4	6.79	3.35e-11	8.74e-09	0.64	0.3	Pneumonia;	chr12:47741824	chr12:47731908~47732351:+
THCA	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	6.79	3.35e-11	8.75e-09	0.3	0.3	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	6.79	3.35e-11	8.75e-09	0.3	0.3	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
THCA	cis	rs9467773	0.901	rs1407045	ENSG00000124549.13	BTN2A3P	6.79	3.36e-11	8.76e-09	0.28	0.3	Intelligence (multi-trait analysis);	chr6:26475927	chr6:26421391~26432383:+
THCA	cis	rs6840360	0.642	rs7658169	ENSG00000251611.1	RP11-610P16.1	-6.79	3.36e-11	8.76e-09	-0.22	-0.3	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151407551~151408835:-
THCA	cis	rs7119038	0.509	rs11216961	ENSG00000255239.1	AP002954.6	-6.79	3.36e-11	8.76e-09	-0.45	-0.3	Sjögren's syndrome;	chr11:118709629	chr11:118688039~118690600:-
THCA	cis	rs6696239	0.513	rs2492635	ENSG00000227711.2	RP11-275O4.5	-6.79	3.36e-11	8.77e-09	-0.32	-0.3	Height;	chr1:227517134	chr1:227509028~227520477:-
THCA	cis	rs1005277	0.505	rs1208689	ENSG00000263064.2	RP11-291L22.7	6.79	3.37e-11	8.79e-09	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38448689~38448949:+
THCA	cis	rs6676180	0.555	rs947430	ENSG00000231365.4	RP11-418J17.1	-6.79	3.37e-11	8.79e-09	-0.29	-0.3	Monobrow;	chr1:119236111	chr1:119140396~119275973:+
THCA	cis	rs853679	0.76	rs9468317	ENSG00000280107.1	AL022393.9	-6.79	3.37e-11	8.8e-09	-0.38	-0.3	Depression;	chr6:28230678	chr6:28170845~28172521:+
THCA	cis	rs7267979	0.966	rs2482918	ENSG00000274414.1	RP5-965G21.4	6.79	3.38e-11	8.8e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25239007~25245229:-
THCA	cis	rs45509595	0.841	rs9368531	ENSG00000219392.1	RP1-265C24.5	-6.79	3.38e-11	8.81e-09	-0.51	-0.3	Breast cancer;	chr6:27814094	chr6:28115628~28116551:+
THCA	cis	rs45509595	0.749	rs401763	ENSG00000219392.1	RP1-265C24.5	-6.79	3.38e-11	8.81e-09	-0.51	-0.3	Breast cancer;	chr6:27814750	chr6:28115628~28116551:+
THCA	cis	rs45509595	0.659	rs390764	ENSG00000219392.1	RP1-265C24.5	-6.79	3.38e-11	8.81e-09	-0.51	-0.3	Breast cancer;	chr6:27814757	chr6:28115628~28116551:+
THCA	cis	rs45509595	0.841	rs401754	ENSG00000219392.1	RP1-265C24.5	-6.79	3.38e-11	8.81e-09	-0.51	-0.3	Breast cancer;	chr6:27814760	chr6:28115628~28116551:+
THCA	cis	rs45509595	0.841	rs2747054	ENSG00000219392.1	RP1-265C24.5	-6.79	3.38e-11	8.81e-09	-0.51	-0.3	Breast cancer;	chr6:27815581	chr6:28115628~28116551:+
THCA	cis	rs45509595	0.841	rs200501	ENSG00000219392.1	RP1-265C24.5	-6.79	3.38e-11	8.81e-09	-0.51	-0.3	Breast cancer;	chr6:27821164	chr6:28115628~28116551:+
THCA	cis	rs2439831	1	rs1814538	ENSG00000275601.1	AC011330.13	6.79	3.38e-11	8.82e-09	0.44	0.3	Lung cancer in ever smokers;	chr15:43467576	chr15:43642389~43643023:-
THCA	cis	rs2442825	0.693	rs2258768	ENSG00000206573.7	THUMPD3-AS1	6.79	3.39e-11	8.83e-09	0.18	0.3	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9349689~9398579:-
THCA	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	6.79	3.39e-11	8.83e-09	0.25	0.3	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	6.79	3.39e-11	8.83e-09	0.25	0.3	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
THCA	cis	rs11719291	0.651	rs1134043	ENSG00000270441.1	RP11-694I15.7	6.79	3.39e-11	8.84e-09	0.34	0.3	Cognitive function;	chr3:49162704	chr3:49140086~49160851:-
THCA	cis	rs1009647	0.645	rs117502961	ENSG00000258413.1	RP11-665C16.6	-6.79	3.39e-11	8.84e-09	-0.53	-0.3	Testicular germ cell tumor;	chr14:55133196	chr14:55262767~55272075:-
THCA	cis	rs7811142	1	rs11761725	ENSG00000078319.8	PMS2P1	-6.79	3.39e-11	8.85e-09	-0.44	-0.3	Platelet count;	chr7:100442192	chr7:100320992~100341908:-
THCA	cis	rs7189233	0.955	rs72801817	ENSG00000279344.1	RP11-44F14.7	6.79	3.39e-11	8.85e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr16:53440656	chr16:53478957~53481550:-
THCA	cis	rs1577330	0.848	rs1591356	ENSG00000254396.1	RP11-56F10.3	6.79	3.4e-11	8.85e-09	0.43	0.3	IgG glycosylation;	chr9:27076188	chr9:27102630~27104728:+
THCA	cis	rs1385374	0.858	rs10847692	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128805134	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs10773578	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128805481	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.698	rs2170988	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128806331	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs11059923	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128808512	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs11059927	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128809788	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs34888374	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128811991	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs11059930	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128813315	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs3741615	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128814303	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs10847697	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128814840	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs10847698	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128815677	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs12321643	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128818322	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs11059933	ENSG00000274695.1	RP11-21K12.3	6.79	3.4e-11	8.85e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128819048	chr12:128826836~128827579:+
THCA	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	6.79	3.4e-11	8.88e-09	0.3	0.3	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
THCA	cis	rs8141529	0.732	rs6005872	ENSG00000226471.5	CTA-292E10.6	-6.79	3.41e-11	8.88e-09	-0.25	-0.3	Lymphocyte counts;	chr22:28776910	chr22:28800683~28848559:+
THCA	cis	rs6840360	0.642	rs2709842	ENSG00000251611.1	RP11-610P16.1	6.79	3.41e-11	8.88e-09	0.22	0.3	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151407551~151408835:-
THCA	cis	rs4947019	0.609	rs2177092	ENSG00000260273.1	RP11-425D10.10	6.79	3.41e-11	8.88e-09	0.64	0.3	Hematological parameters;	chr6:109365466	chr6:109382795~109383666:+
THCA	cis	rs4947019	0.609	rs2275649	ENSG00000260273.1	RP11-425D10.10	6.79	3.41e-11	8.88e-09	0.64	0.3	Hematological parameters;	chr6:109370125	chr6:109382795~109383666:+
THCA	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-6.79	3.42e-11	8.91e-09	-0.27	-0.3	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
THCA	cis	rs1385374	0.858	rs12298615	ENSG00000274695.1	RP11-21K12.3	6.79	3.42e-11	8.91e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128802211	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.642	rs10847691	ENSG00000274695.1	RP11-21K12.3	6.79	3.42e-11	8.91e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128802904	chr12:128826836~128827579:+
THCA	cis	rs34375054	0.573	rs12579211	ENSG00000279233.1	RP11-158L12.4	6.79	3.42e-11	8.91e-09	0.34	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125163206	chr12:125138245~125141711:+
THCA	cis	rs1075232	1	rs67634762	ENSG00000270055.1	CTD-3092A11.2	-6.79	3.42e-11	8.91e-09	-0.56	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30487963~30490313:+
THCA	cis	rs55665837	0.701	rs11023265	ENSG00000251991.1	RNU7-49P	6.79	3.42e-11	8.91e-09	0.34	0.3	Vitamin D levels;	chr11:14594492	chr11:14478892~14478953:+
THCA	cis	rs1005277	0.505	rs200910	ENSG00000263064.2	RP11-291L22.7	6.79	3.42e-11	8.91e-09	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38448689~38448949:+
THCA	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	6.79	3.42e-11	8.92e-09	0.31	0.3	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
THCA	cis	rs4908760	0.811	rs301817	ENSG00000232912.4	RP5-1115A15.1	6.79	3.43e-11	8.94e-09	0.3	0.3	Vitiligo;	chr1:8443319	chr1:8424645~8434838:+
THCA	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	6.79	3.43e-11	8.95e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
THCA	cis	rs853679	0.607	rs13199649	ENSG00000280107.1	AL022393.9	-6.79	3.43e-11	8.95e-09	-0.61	-0.3	Depression;	chr6:27901014	chr6:28170845~28172521:+
THCA	cis	rs375066	0.762	rs12610287	ENSG00000267058.1	RP11-15A1.3	6.79	3.43e-11	8.95e-09	0.25	0.3	Breast cancer;	chr19:43896511	chr19:43891804~43901805:-
THCA	cis	rs375066	0.762	rs1073654	ENSG00000267058.1	RP11-15A1.3	6.79	3.43e-11	8.95e-09	0.25	0.3	Breast cancer;	chr19:43907268	chr19:43891804~43901805:-
THCA	cis	rs375066	0.762	rs1073653	ENSG00000267058.1	RP11-15A1.3	6.79	3.43e-11	8.95e-09	0.25	0.3	Breast cancer;	chr19:43907391	chr19:43891804~43901805:-
THCA	cis	rs375066	0.762	rs62114648	ENSG00000267058.1	RP11-15A1.3	6.79	3.43e-11	8.95e-09	0.25	0.3	Breast cancer;	chr19:43910664	chr19:43891804~43901805:-
THCA	cis	rs6723226	0.739	rs2069213	ENSG00000276334.1	AL133243.1	6.79	3.44e-11	8.95e-09	0.34	0.3	Intelligence (multi-trait analysis);	chr2:32518017	chr2:32521927~32523547:+
THCA	cis	rs2976388	1	rs2976388	ENSG00000253741.1	CTD-2292P10.4	6.79	3.44e-11	8.96e-09	0.38	0.3	Urinary tract infection frequency;	chr8:142678838	chr8:142702252~142726973:-
THCA	cis	rs453301	0.571	rs2929305	ENSG00000254153.1	CTA-398F10.2	6.79	3.44e-11	8.96e-09	0.32	0.3	Joint mobility (Beighton score);	chr8:9227707	chr8:8456909~8461337:-
THCA	cis	rs1385374	0.858	rs11059928	ENSG00000274695.1	RP11-21K12.3	6.79	3.44e-11	8.96e-09	0.52	0.3	Systemic lupus erythematosus;	chr12:128811558	chr12:128826836~128827579:+
THCA	cis	rs160451	0.966	rs160427	ENSG00000251136.7	RP11-37B2.1	6.79	3.44e-11	8.97e-09	0.26	0.3	Leprosy;	chr8:89659156	chr8:89609409~89757727:-
THCA	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-6.79	3.45e-11	8.98e-09	-0.22	-0.3	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
THCA	cis	rs2797160	0.651	rs1268066	ENSG00000237742.5	RP11-624M8.1	6.79	3.45e-11	8.98e-09	0.27	0.3	Endometrial cancer;	chr6:125713895	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.651	rs1343121	ENSG00000237742.5	RP11-624M8.1	6.79	3.45e-11	8.98e-09	0.27	0.3	Endometrial cancer;	chr6:125715038	chr6:125578558~125749190:-
THCA	cis	rs13134327	0.513	rs7679687	ENSG00000251600.4	RP11-673E1.1	-6.79	3.46e-11	9e-09	-0.41	-0.3	Glycated hemoglobin levels;	chr4:144024031	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-6.79	3.46e-11	9.01e-09	-0.38	-0.3	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
THCA	cis	rs6600671	1	rs11249351	ENSG00000270392.2	PFN1P2	6.79	3.46e-11	9.01e-09	0.29	0.3	Hip geometry;	chr1:121430082	chr1:120432204~120434052:-
THCA	cis	rs6928977	0.675	rs58761508	ENSG00000231028.7	LINC00271	6.79	3.46e-11	9.02e-09	0.25	0.3	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135514763	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.631	rs9385726	ENSG00000231028.7	LINC00271	6.79	3.46e-11	9.02e-09	0.25	0.3	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135515824	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.637	rs9647635	ENSG00000231028.7	LINC00271	6.79	3.46e-11	9.02e-09	0.25	0.3	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135497801~135716055:+
THCA	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	6.79	3.46e-11	9.02e-09	0.48	0.3	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
THCA	cis	rs728616	0.614	rs10887199	ENSG00000225484.5	NUTM2B-AS1	-6.79	3.46e-11	9.02e-09	-0.44	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79943078	chr10:79663088~79826594:-
THCA	cis	rs2380205	0.546	rs635532	ENSG00000232807.2	RP11-536K7.3	-6.79	3.46e-11	9.02e-09	-0.28	-0.3	Breast cancer;	chr10:5928365	chr10:5934270~5945900:-
THCA	cis	rs741668	0.895	rs61953326	ENSG00000235903.6	CPB2-AS1	6.79	3.47e-11	9.03e-09	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:45994147	chr13:46052806~46113332:+
THCA	cis	rs741668	0.931	rs7317990	ENSG00000235903.6	CPB2-AS1	6.79	3.47e-11	9.03e-09	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:45994362	chr13:46052806~46113332:+
THCA	cis	rs741668	0.897	rs17429573	ENSG00000235903.6	CPB2-AS1	6.79	3.47e-11	9.03e-09	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:45995923	chr13:46052806~46113332:+
THCA	cis	rs741668	0.931	rs4417456	ENSG00000235903.6	CPB2-AS1	6.79	3.47e-11	9.03e-09	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:46014273	chr13:46052806~46113332:+
THCA	cis	rs741668	0.931	rs61953330	ENSG00000235903.6	CPB2-AS1	6.79	3.47e-11	9.03e-09	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:46014741	chr13:46052806~46113332:+
THCA	cis	rs4947019	0.609	rs9487074	ENSG00000260273.1	RP11-425D10.10	6.79	3.47e-11	9.03e-09	0.64	0.3	Hematological parameters;	chr6:109368478	chr6:109382795~109383666:+
THCA	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	6.79	3.47e-11	9.03e-09	0.37	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000229886.1	RP5-1132H15.3	6.79	3.47e-11	9.04e-09	0.48	0.3	Diabetic kidney disease;	chr7:65970805	chr7:66025126~66031544:-
THCA	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	6.79	3.48e-11	9.05e-09	0.44	0.3	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	6.79	3.48e-11	9.05e-09	0.44	0.3	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
THCA	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	6.79	3.48e-11	9.05e-09	0.47	0.3	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
THCA	cis	rs453301	0.624	rs2288671	ENSG00000253893.2	FAM85B	-6.79	3.48e-11	9.06e-09	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9003384	chr8:8167819~8226614:-
THCA	cis	rs4601821	0.635	rs7114433	ENSG00000270179.1	RP11-159N11.4	-6.79	3.48e-11	9.06e-09	-0.3	-0.3	Alcoholic chronic pancreatitis;	chr11:113337376	chr11:113368478~113369117:+
THCA	cis	rs9393777	0.92	rs72839445	ENSG00000280107.1	AL022393.9	-6.79	3.49e-11	9.09e-09	-0.61	-0.3	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28170845~28172521:+
THCA	cis	rs6671200	0.586	rs80118674	ENSG00000235501.4	RP4-639F20.1	-6.79	3.5e-11	9.11e-09	-0.61	-0.3	Stearic acid (18:0) levels;	chr1:94915867	chr1:94927566~94963270:+
THCA	cis	rs2562456	0.793	rs2562428	ENSG00000213976.4	CTD-2561J22.2	6.79	3.5e-11	9.11e-09	0.33	0.3	Pain;	chr19:21442652	chr19:21382865~21387177:+
THCA	cis	rs1501911	0.527	rs161934	ENSG00000246763.5	RGMB-AS1	-6.79	3.5e-11	9.12e-09	-0.29	-0.3	Lung function (FEV1/FVC);	chr5:98981283	chr5:98769618~98773469:-
THCA	cis	rs7733403	1	rs7733403	ENSG00000202515.1	VTRNA1-3	-6.78	3.51e-11	9.14e-09	-0.33	-0.3	Schizophrenia;	chr5:140774630	chr5:140726158~140726246:+
THCA	cis	rs6696239	0.513	rs903690	ENSG00000227711.2	RP11-275O4.5	6.78	3.51e-11	9.14e-09	0.31	0.3	Height;	chr1:227534009	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs7539914	ENSG00000227711.2	RP11-275O4.5	6.78	3.51e-11	9.14e-09	0.31	0.3	Hip circumference adjusted for BMI;	chr1:227536210	chr1:227509028~227520477:-
THCA	cis	rs7746199	0.736	rs58616630	ENSG00000226314.6	ZNF192P1	-6.78	3.51e-11	9.14e-09	-0.64	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs34573979	ENSG00000226314.6	ZNF192P1	-6.78	3.51e-11	9.14e-09	-0.64	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28161781~28169594:+
THCA	cis	rs831571	0.636	rs831565	ENSG00000280620.1	SCAANT1	-6.78	3.52e-11	9.16e-09	-0.46	-0.3	Type 2 diabetes;	chr3:64090682	chr3:63911518~63911772:-
THCA	cis	rs9902453	0.868	rs12944395	ENSG00000264007.1	RP11-68I3.10	-6.78	3.52e-11	9.16e-09	-0.34	-0.3	Coffee consumption (cups per day);	chr17:29996481	chr17:29621617~29622254:-
THCA	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-6.78	3.52e-11	9.16e-09	-0.45	-0.3	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
THCA	cis	rs1552244	0.572	rs67227131	ENSG00000232901.1	CYCSP10	6.78	3.52e-11	9.16e-09	0.47	0.3	Alzheimer's disease;	chr3:10131060	chr3:10000647~10000940:-
THCA	cis	rs1395	0.634	rs72817542	ENSG00000234072.1	AC074117.10	-6.78	3.53e-11	9.18e-09	-0.27	-0.3	Blood metabolite levels;	chr2:27303813	chr2:27356246~27367622:+
THCA	cis	rs1552244	0.882	rs17050672	ENSG00000232901.1	CYCSP10	6.78	3.53e-11	9.18e-09	0.39	0.3	Alzheimer's disease;	chr3:9983779	chr3:10000647~10000940:-
THCA	cis	rs2243480	1	rs781142	ENSG00000229886.1	RP5-1132H15.3	6.78	3.53e-11	9.18e-09	0.48	0.3	Diabetic kidney disease;	chr7:65973791	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs7804223	ENSG00000229886.1	RP5-1132H15.3	-6.78	3.53e-11	9.19e-09	-0.49	-0.3	Diabetic kidney disease;	chr7:66199572	chr7:66025126~66031544:-
THCA	cis	rs6570726	0.526	rs9376934	ENSG00000235652.6	RP11-545I5.3	6.78	3.54e-11	9.21e-09	0.28	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145417566	chr6:145799409~145886585:+
THCA	cis	rs71636778	0.509	rs34576193	ENSG00000260063.1	RP5-968P14.2	-6.78	3.55e-11	9.23e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26728289	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs41303629	ENSG00000260063.1	RP5-968P14.2	-6.78	3.55e-11	9.23e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26731130	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34216334	ENSG00000260063.1	RP5-968P14.2	-6.78	3.55e-11	9.23e-09	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26736928	chr1:26692132~26694131:-
THCA	cis	rs77204473	0.744	rs12420200	ENSG00000254851.1	RP11-109L13.1	-6.78	3.55e-11	9.23e-09	-0.7	-0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117135528~117138582:+
THCA	cis	rs4713118	0.869	rs9461405	ENSG00000280107.1	AL022393.9	-6.78	3.55e-11	9.24e-09	-0.34	-0.3	Parkinson's disease;	chr6:27751596	chr6:28170845~28172521:+
THCA	cis	rs7512898	0.9	rs6427851	ENSG00000260088.1	RP11-92G12.3	-6.78	3.55e-11	9.24e-09	-0.38	-0.3	Electrocardiographic conduction measures;	chr1:200704177	chr1:200669507~200694250:+
THCA	cis	rs8030379	0.967	rs10520573	ENSG00000230373.7	GOLGA6L5P	-6.78	3.56e-11	9.25e-09	-0.28	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922823	chr15:84507885~84516814:-
THCA	cis	rs523522	0.924	rs11065150	ENSG00000278344.1	RP11-18C24.8	6.78	3.56e-11	9.26e-09	0.33	0.3	High light scatter reticulocyte count;	chr12:120521072	chr12:120500735~120501090:-
THCA	cis	rs7246657	0.943	rs10409204	ENSG00000226686.6	LINC01535	-6.78	3.56e-11	9.26e-09	-0.45	-0.3	Coronary artery calcification;	chr19:37426790	chr19:37251912~37265535:+
THCA	cis	rs7247513	0.964	rs35235213	ENSG00000213290.4	PGK1P2	-6.78	3.56e-11	9.27e-09	-0.36	-0.3	Bipolar disorder;	chr19:12602342	chr19:12559571~12561105:+
THCA	cis	rs2412819	0.571	rs4923964	ENSG00000249839.1	AC011330.5	6.78	3.57e-11	9.27e-09	0.43	0.3	Lung cancer;	chr15:43722882	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.655	rs2330103	ENSG00000237664.1	LINC00316	-6.78	3.57e-11	9.28e-09	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45338590~45341990:-
THCA	cis	rs7119038	0.629	rs73001429	ENSG00000255239.1	AP002954.6	-6.78	3.57e-11	9.29e-09	-0.44	-0.3	Sjögren's syndrome;	chr11:118732456	chr11:118688039~118690600:-
THCA	cis	rs7580658	0.929	rs4150496	ENSG00000236682.1	AC068282.3	-6.78	3.58e-11	9.3e-09	-0.39	-0.3	Protein C levels;	chr2:127271927	chr2:127389130~127400580:+
THCA	cis	rs2243480	1	rs1546059	ENSG00000228409.4	CCT6P1	-6.78	3.58e-11	9.3e-09	-0.34	-0.3	Diabetic kidney disease;	chr7:66189722	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs2420170	ENSG00000228409.4	CCT6P1	-6.78	3.58e-11	9.3e-09	-0.34	-0.3	Diabetic kidney disease;	chr7:66191066	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6958289	ENSG00000228409.4	CCT6P1	-6.78	3.58e-11	9.3e-09	-0.34	-0.3	Diabetic kidney disease;	chr7:66192124	chr7:65751142~65763354:+
THCA	cis	rs7923837	0.663	rs5015480	ENSG00000236493.2	EIF2S2P3	6.78	3.58e-11	9.3e-09	0.3	0.3	Multiple sclerosis;Body mass index;	chr10:92705802	chr10:92668745~92669743:-
THCA	cis	rs13113518	0.729	rs12641881	ENSG00000273257.1	RP11-177J6.1	6.78	3.58e-11	9.31e-09	0.42	0.3	Height;	chr4:55401306	chr4:55387949~55388271:+
THCA	cis	rs2243480	1	rs781149	ENSG00000229886.1	RP5-1132H15.3	6.78	3.58e-11	9.31e-09	0.48	0.3	Diabetic kidney disease;	chr7:66016297	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000229886.1	RP5-1132H15.3	6.78	3.58e-11	9.31e-09	0.48	0.3	Diabetic kidney disease;	chr7:66021736	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1167613	ENSG00000229886.1	RP5-1132H15.3	6.78	3.58e-11	9.31e-09	0.48	0.3	Diabetic kidney disease;	chr7:66022452	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs313799	ENSG00000229886.1	RP5-1132H15.3	6.78	3.58e-11	9.31e-09	0.48	0.3	Diabetic kidney disease;	chr7:66029343	chr7:66025126~66031544:-
THCA	cis	rs7474896	0.616	rs2505239	ENSG00000263064.2	RP11-291L22.7	6.78	3.58e-11	9.32e-09	0.42	0.3	Obesity (extreme);	chr10:38151837	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.561	rs2474603	ENSG00000263064.2	RP11-291L22.7	6.78	3.58e-11	9.32e-09	0.42	0.3	Obesity (extreme);	chr10:38156754	chr10:38448689~38448949:+
THCA	cis	rs9376098	0.825	rs6922541	ENSG00000232876.1	CTA-212D2.2	-6.78	3.58e-11	9.32e-09	-0.35	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161681	chr6:135055033~135060550:+
THCA	cis	rs12701220	0.689	rs12701824	ENSG00000229043.2	AC091729.9	-6.78	3.58e-11	9.32e-09	-0.47	-0.3	Bronchopulmonary dysplasia;	chr7:1062728	chr7:1160374~1165267:+
THCA	cis	rs6907340	0.517	rs9465533	ENSG00000237404.1	RP3-471C18.2	-6.78	3.59e-11	9.34e-09	-0.35	-0.3	Endometriosis;	chr6:19801477	chr6:19689825~19753113:-
THCA	cis	rs7688540	0.8	rs11723492	ENSG00000211553.1	AC253576.2	-6.78	3.59e-11	9.34e-09	-0.42	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:136461~136568:+
THCA	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	6.78	3.6e-11	9.35e-09	0.36	0.3	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
THCA	cis	rs2439831	1	rs2253708	ENSG00000249839.1	AC011330.5	-6.78	3.6e-11	9.37e-09	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43505075	chr15:43663654~43684339:-
THCA	cis	rs1552244	0.882	rs6443279	ENSG00000232901.1	CYCSP10	6.78	3.6e-11	9.37e-09	0.38	0.3	Alzheimer's disease;	chr3:10011915	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs36006511	ENSG00000232901.1	CYCSP10	6.78	3.6e-11	9.37e-09	0.38	0.3	Alzheimer's disease;	chr3:10012507	chr3:10000647~10000940:-
THCA	cis	rs12908161	0.96	rs11633450	ENSG00000225151.9	GOLGA2P7	-6.78	3.61e-11	9.38e-09	-0.44	-0.3	Schizophrenia;	chr15:84764056	chr15:84199311~84230136:-
THCA	cis	rs16843372	1	rs16843372	ENSG00000251491.2	OR7E28P	-6.78	3.61e-11	9.38e-09	-0.38	-0.3	Obesity-related traits;	chr2:158813937	chr2:158862311~158863285:+
THCA	cis	rs9595908	0.865	rs2761365	ENSG00000212293.1	SNORA16	-6.78	3.61e-11	9.38e-09	-0.36	-0.3	Body mass index;	chr13:32437687	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.827	rs2761366	ENSG00000212293.1	SNORA16	-6.78	3.61e-11	9.38e-09	-0.36	-0.3	Body mass index;	chr13:32437735	chr13:32420390~32420516:-
THCA	cis	rs12928939	0.954	rs34998650	ENSG00000260886.1	TAT-AS1	6.78	3.62e-11	9.4e-09	0.4	0.3	Post bronchodilator FEV1;	chr16:71795426	chr16:71565789~71578187:+
THCA	cis	rs897984	0.762	rs4889599	ENSG00000279196.1	RP11-1072A3.3	-6.78	3.62e-11	9.4e-09	-0.3	-0.3	Dementia with Lewy bodies;	chr16:30957268	chr16:30984630~30988270:-
THCA	cis	rs897984	0.721	rs2305884	ENSG00000279196.1	RP11-1072A3.3	-6.78	3.62e-11	9.4e-09	-0.3	-0.3	Dementia with Lewy bodies;	chr16:30959420	chr16:30984630~30988270:-
THCA	cis	rs7474896	0.616	rs2474561	ENSG00000263064.2	RP11-291L22.7	6.78	3.62e-11	9.4e-09	0.41	0.3	Obesity (extreme);	chr10:38084616	chr10:38448689~38448949:+
THCA	cis	rs7657257	1	rs4502676	ENSG00000214846.4	RP11-115L11.1	-6.78	3.62e-11	9.4e-09	-0.75	-0.3	Blood protein levels;	chr4:15733919	chr4:15730962~15731627:-
THCA	cis	rs9549328	0.8	rs1317507	ENSG00000267868.1	RP11-120K24.3	6.78	3.62e-11	9.4e-09	0.3	0.3	Systolic blood pressure;	chr13:112977466	chr13:112964835~112966131:-
THCA	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-6.78	3.62e-11	9.41e-09	-0.38	-0.3	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-6.78	3.62e-11	9.41e-09	-0.38	-0.3	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
THCA	cis	rs17772222	0.917	rs61986669	ENSG00000258983.2	RP11-507K2.2	6.78	3.62e-11	9.41e-09	0.37	0.3	Coronary artery calcification;	chr14:88727121	chr14:88499334~88515502:+
THCA	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-6.78	3.63e-11	9.42e-09	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
THCA	cis	rs3806843	0.778	rs2531346	ENSG00000202515.1	VTRNA1-3	6.78	3.63e-11	9.43e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140746554	chr5:140726158~140726246:+
THCA	cis	rs2361701	0.929	rs1561810	ENSG00000279259.1	RP11-334C17.3	6.78	3.63e-11	9.43e-09	0.33	0.3	IgG glycosylation;	chr17:80095525	chr17:80147250~80148596:+
THCA	cis	rs3806843	0.966	rs2563260	ENSG00000202515.1	VTRNA1-3	6.78	3.63e-11	9.44e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140758282	chr5:140726158~140726246:+
THCA	cis	rs8007846	0.524	rs6573625	ENSG00000276116.2	FUT8-AS1	6.78	3.63e-11	9.44e-09	0.31	0.3	Multiple sclerosis--Brain Glutamate Levels;	chr14:65773916	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.777	rs7158556	ENSG00000276116.2	FUT8-AS1	6.78	3.63e-11	9.44e-09	0.31	0.3	N-glycan levels;	chr14:65774011	chr14:65411170~65412690:-
THCA	cis	rs853679	0.882	rs9380069	ENSG00000226314.6	ZNF192P1	-6.78	3.64e-11	9.45e-09	-0.48	-0.3	Depression;	chr6:28235522	chr6:28161781~28169594:+
THCA	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-6.78	3.64e-11	9.46e-09	-0.37	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
THCA	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	6.78	3.64e-11	9.46e-09	0.73	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
THCA	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	6.78	3.64e-11	9.46e-09	0.73	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
THCA	cis	rs2380205	0.546	rs649537	ENSG00000232807.2	RP11-536K7.3	-6.78	3.64e-11	9.46e-09	-0.28	-0.3	Breast cancer;	chr10:5903709	chr10:5934270~5945900:-
THCA	cis	rs11722228	0.522	rs2241468	ENSG00000261490.1	RP11-448G15.3	6.78	3.65e-11	9.47e-09	0.22	0.3	Urate levels;Serum uric acid levels;Gout;	chr4:10112281	chr4:10068089~10073019:-
THCA	cis	rs71636778	0.509	rs35617712	ENSG00000260063.1	RP5-968P14.2	-6.78	3.65e-11	9.47e-09	-0.56	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724732	chr1:26692132~26694131:-
THCA	cis	rs867529	1	rs1805165	ENSG00000234028.3	AC062029.1	-6.78	3.65e-11	9.49e-09	-0.25	-0.3	Height;	chr2:88575373	chr2:88627539~88631821:+
THCA	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	6.78	3.65e-11	9.49e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
THCA	cis	rs1125355	1	rs116204562	ENSG00000251491.2	OR7E28P	-6.78	3.66e-11	9.49e-09	-0.48	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158849713	chr2:158862311~158863285:+
THCA	cis	rs6723226	0.764	rs176403	ENSG00000276334.1	AL133243.1	-6.78	3.66e-11	9.51e-09	-0.35	-0.3	Intelligence (multi-trait analysis);	chr2:32412796	chr2:32521927~32523547:+
THCA	cis	rs6430585	0.528	rs16832417	ENSG00000231890.6	DARS-AS1	-6.78	3.67e-11	9.52e-09	-0.37	-0.3	Corneal structure;	chr2:135987108	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.528	rs721765	ENSG00000231890.6	DARS-AS1	-6.78	3.67e-11	9.52e-09	-0.37	-0.3	Corneal structure;	chr2:135991209	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.528	rs10496738	ENSG00000231890.6	DARS-AS1	-6.78	3.67e-11	9.52e-09	-0.37	-0.3	Corneal structure;	chr2:135993918	chr2:135985176~136022593:+
THCA	cis	rs853679	0.599	rs13193295	ENSG00000280107.1	AL022393.9	-6.78	3.67e-11	9.52e-09	-0.59	-0.3	Depression;	chr6:28035450	chr6:28170845~28172521:+
THCA	cis	rs7260598	0.642	rs66750293	ENSG00000268442.1	CTD-2027I19.2	6.78	3.67e-11	9.54e-09	0.4	0.3	Response to taxane treatment (placlitaxel);	chr19:23997819	chr19:24162370~24163425:-
THCA	cis	rs1005277	0.579	rs1621040	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780136	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780138	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780139	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.602	rs1780141	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.541	rs1740741	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.528	rs2057228	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1740742	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.602	rs1740743	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1740745	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1740747	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1740749	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780115	ENSG00000276805.1	RP11-291L22.6	6.78	3.67e-11	9.54e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38451030~38451785:+
THCA	cis	rs6600671	1	rs6600671	ENSG00000275538.1	RNVU1-19	-6.78	3.68e-11	9.54e-09	-0.39	-0.3	Hip geometry;	chr1:121458637	chr1:120850819~120850985:-
THCA	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	6.78	3.68e-11	9.54e-09	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	6.78	3.68e-11	9.54e-09	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	6.78	3.68e-11	9.54e-09	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
THCA	cis	rs1005277	0.579	rs2103938	ENSG00000276805.1	RP11-291L22.6	6.78	3.68e-11	9.55e-09	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38451030~38451785:+
THCA	cis	rs7948661	1	rs9332819	ENSG00000278376.1	RP11-158I9.8	-6.78	3.68e-11	9.55e-09	-0.48	-0.3	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118494548	chr11:118791254~118793137:+
THCA	cis	rs4780355	0.619	rs918737	ENSG00000262703.1	RP11-485G7.6	-6.78	3.68e-11	9.55e-09	-0.35	-0.3	Crohn's disease and psoriasis;	chr16:11345782	chr16:11348143~11349321:-
THCA	cis	rs6504622	0.875	rs28553405	ENSG00000262879.4	RP11-156P1.3	6.78	3.68e-11	9.56e-09	0.28	0.3	Orofacial clefts;	chr17:46968529	chr17:46984045~47100323:-
THCA	cis	rs8014204	0.604	rs11159109	ENSG00000279594.1	RP11-950C14.10	6.78	3.69e-11	9.58e-09	0.3	0.3	Caffeine consumption;	chr14:74922371	chr14:75011269~75012851:-
THCA	cis	rs853679	1	rs10456362	ENSG00000280107.1	AL022393.9	6.78	3.69e-11	9.58e-09	0.39	0.3	Depression;	chr6:28254038	chr6:28170845~28172521:+
THCA	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-6.78	3.7e-11	9.59e-09	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
THCA	cis	rs2976388	1	rs2920295	ENSG00000253741.1	CTD-2292P10.4	6.78	3.7e-11	9.59e-09	0.37	0.3	Urinary tract infection frequency;	chr8:142683519	chr8:142702252~142726973:-
THCA	cis	rs6696239	0.513	rs4359006	ENSG00000227711.2	RP11-275O4.5	6.78	3.7e-11	9.61e-09	0.31	0.3	Height;	chr1:227533085	chr1:227509028~227520477:-
THCA	cis	rs1198430	0.925	rs2811975	ENSG00000232482.2	RP4-654C18.1	-6.78	3.71e-11	9.61e-09	-0.56	-0.3	Total cholesterol levels;	chr1:23474588	chr1:23410832~23412146:+
THCA	cis	rs4143844	0.867	rs12912477	ENSG00000259251.2	RP11-643M14.1	6.78	3.71e-11	9.62e-09	0.56	0.3	Bipolar disorder and schizophrenia;	chr15:61949909	chr15:62060503~62062434:+
THCA	cis	rs4835473	0.932	rs9997931	ENSG00000251600.4	RP11-673E1.1	6.78	3.71e-11	9.62e-09	0.38	0.3	Immature fraction of reticulocytes;	chr4:143904601	chr4:143912331~143982454:+
THCA	cis	rs7189233	0.955	rs7184800	ENSG00000279344.1	RP11-44F14.7	6.78	3.72e-11	9.64e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr16:53475219	chr16:53478957~53481550:-
THCA	cis	rs7208859	0.623	rs3752019	ENSG00000263603.1	CTD-2349P21.5	-6.78	3.72e-11	9.65e-09	-0.54	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs56146117	ENSG00000263603.1	CTD-2349P21.5	-6.78	3.72e-11	9.65e-09	-0.54	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30729469~30731202:+
THCA	cis	rs7746199	0.736	rs13209332	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs34105070	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.673	rs72845046	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs67652222	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs13212093	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs34038546	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28115628~28116551:+
THCA	cis	rs141342723	1	rs141342723	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs34543938	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs56405707	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs13210634	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs13215275	ENSG00000219392.1	RP1-265C24.5	-6.78	3.72e-11	9.65e-09	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28115628~28116551:+
THCA	cis	rs4964805	0.507	rs4964786	ENSG00000257681.1	RP11-341G23.4	6.78	3.72e-11	9.66e-09	0.32	0.3	Attention deficit hyperactivity disorder;	chr12:103810805	chr12:103746315~103768858:-
THCA	cis	rs3204270	0.516	rs62077189	ENSG00000262049.1	RP13-1032I1.7	6.78	3.72e-11	9.66e-09	0.24	0.3	Dental caries;	chr17:81706058	chr17:81701324~81703300:-
THCA	cis	rs7324557	0.652	rs7332811	ENSG00000205861.10	C1QTNF9B-AS1	6.78	3.72e-11	9.66e-09	0.37	0.3	Visceral adipose tissue adjusted for BMI;	chr13:23823066	chr13:23888889~23897263:+
THCA	cis	rs9926296	0.568	rs4420527	ENSG00000260259.1	RP11-368I7.4	6.78	3.72e-11	9.66e-09	0.32	0.3	Vitiligo;	chr16:89747780	chr16:89682620~89686569:-
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000220721.1	OR1F12	6.78	3.73e-11	9.67e-09	0.4	0.3	Parkinson's disease;	chr6:28066959	chr6:28073316~28074233:+
THCA	cis	rs7044106	0.791	rs12554440	ENSG00000270917.1	RP11-27I1.6	-6.78	3.73e-11	9.67e-09	-0.43	-0.3	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120812475~120812845:-
THCA	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	6.78	3.73e-11	9.68e-09	0.22	0.3	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
THCA	cis	rs3806843	0.868	rs2531345	ENSG00000202515.1	VTRNA1-3	6.77	3.74e-11	9.69e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140747196	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.864	rs2531343	ENSG00000202515.1	VTRNA1-3	6.77	3.74e-11	9.69e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140749761	chr5:140726158~140726246:+
THCA	cis	rs230529	0.51	rs1120986	ENSG00000246560.2	RP11-10L12.4	6.77	3.74e-11	9.69e-09	0.36	0.3	Schizophrenia (treatment resistant);	chr4:102515484	chr4:102828055~102844075:+
THCA	cis	rs116139393	0.54	rs12539942	ENSG00000187953.9	PMS2CL	-6.77	3.74e-11	9.69e-09	-0.37	-0.3	Alzheimer's disease (APOE e4 interaction);	chr7:6736954	chr7:6710128~6753862:+
THCA	cis	rs7811142	1	rs7794485	ENSG00000078319.8	PMS2P1	-6.77	3.74e-11	9.7e-09	-0.44	-0.3	Platelet count;	chr7:100471313	chr7:100320992~100341908:-
THCA	cis	rs453301	0.571	rs2929454	ENSG00000254153.1	CTA-398F10.2	6.77	3.74e-11	9.7e-09	0.32	0.3	Joint mobility (Beighton score);	chr8:9226344	chr8:8456909~8461337:-
THCA	cis	rs10875746	0.551	rs1471997	ENSG00000269514.1	RP11-370I10.12	6.77	3.74e-11	9.71e-09	0.3	0.3	Longevity (90 years and older);	chr12:48329812	chr12:48198387~48202031:+
THCA	cis	rs1134634	0.838	rs2302467	ENSG00000273133.1	RP11-799M12.2	-6.77	3.75e-11	9.71e-09	-0.36	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15703416	chr4:15563698~15564253:-
THCA	cis	rs7615952	0.8	rs12489350	ENSG00000241288.6	RP11-379B18.5	-6.77	3.75e-11	9.71e-09	-0.37	-0.3	Blood pressure (smoking interaction);	chr3:125925273	chr3:125827238~125916384:-
THCA	cis	rs7688540	0.76	rs7687833	ENSG00000211553.1	AC253576.2	-6.77	3.75e-11	9.73e-09	-0.41	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:136461~136568:+
THCA	cis	rs7044106	0.762	rs13291660	ENSG00000238181.2	AHCYP2	-6.77	3.76e-11	9.74e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120720673~120721972:+
THCA	cis	rs6061231	0.518	rs639836	ENSG00000273619.1	RP5-908M14.9	6.77	3.76e-11	9.75e-09	0.24	0.3	Colorectal cancer;	chr20:62351167	chr20:62386303~62386970:-
THCA	cis	rs853679	0.628	rs9368560	ENSG00000272009.1	RP1-313I6.12	-6.77	3.76e-11	9.76e-09	-0.35	-0.3	Depression;	chr6:28192182	chr6:28078792~28081130:-
THCA	cis	rs6600671	0.967	rs12069545	ENSG00000270392.2	PFN1P2	6.77	3.77e-11	9.78e-09	0.29	0.3	Hip geometry;	chr1:121430343	chr1:120432204~120434052:-
THCA	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	6.77	3.77e-11	9.78e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	6.77	3.77e-11	9.78e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	6.77	3.77e-11	9.78e-09	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
THCA	cis	rs3806843	0.808	rs6893708	ENSG00000202515.1	VTRNA1-3	6.77	3.77e-11	9.78e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140746337	chr5:140726158~140726246:+
THCA	cis	rs12347191	0.5	rs925485	ENSG00000236130.1	PTCSC2	-6.77	3.77e-11	9.78e-09	-0.25	-0.3	Orofacial clefts;	chr9:97857279	chr9:97805935~97810008:-
THCA	cis	rs12347191	0.5	rs925486	ENSG00000236130.1	PTCSC2	-6.77	3.77e-11	9.78e-09	-0.25	-0.3	Orofacial clefts;	chr9:97857451	chr9:97805935~97810008:-
THCA	cis	rs12347191	0.5	rs1465965	ENSG00000236130.1	PTCSC2	-6.77	3.77e-11	9.78e-09	-0.25	-0.3	Orofacial clefts;	chr9:97858044	chr9:97805935~97810008:-
THCA	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-6.77	3.78e-11	9.8e-09	-0.58	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
THCA	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-6.77	3.78e-11	9.8e-09	-0.58	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
THCA	cis	rs7267979	1	rs6050544	ENSG00000274414.1	RP5-965G21.4	6.77	3.78e-11	9.8e-09	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25239007~25245229:-
THCA	cis	rs10799445	0.55	rs12023298	ENSG00000227711.2	RP11-275O4.5	6.77	3.78e-11	9.8e-09	0.31	0.3	Height;	chr1:227541713	chr1:227509028~227520477:-
THCA	cis	rs4664293	0.867	rs2114626	ENSG00000226266.5	AC009961.3	6.77	3.79e-11	9.82e-09	0.36	0.3	Monocyte percentage of white cells;	chr2:159783459	chr2:159670708~159712435:-
THCA	cis	rs7267979	0.586	rs6050431	ENSG00000274414.1	RP5-965G21.4	-6.77	3.79e-11	9.82e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.586	rs6050432	ENSG00000274414.1	RP5-965G21.4	-6.77	3.79e-11	9.82e-09	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25239007~25245229:-
THCA	cis	rs9981595	1	rs9981595	ENSG00000255568.3	BRWD1-AS2	6.77	3.79e-11	9.82e-09	0.38	0.3	Venous thromboembolism (SNP x SNP interaction);	chr21:39188752	chr21:39313935~39314962:+
THCA	cis	rs7674212	0.865	rs1481279	ENSG00000246560.2	RP11-10L12.4	-6.77	3.79e-11	9.83e-09	-0.37	-0.3	Type 2 diabetes;	chr4:103056781	chr4:102828055~102844075:+
THCA	cis	rs1598856	0.966	rs28573147	ENSG00000246560.2	RP11-10L12.4	6.77	3.8e-11	9.83e-09	0.36	0.3	Primary biliary cholangitis;	chr4:102497028	chr4:102828055~102844075:+
THCA	cis	rs2735413	0.564	rs8059851	ENSG00000276007.1	RP11-358L22.3	6.77	3.8e-11	9.85e-09	0.31	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78084435	chr16:78123243~78124332:+
THCA	cis	rs4819052	0.679	rs2255761	ENSG00000237664.1	LINC00316	-6.77	3.8e-11	9.85e-09	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45338590~45341990:-
THCA	cis	rs3806843	0.966	rs2563265	ENSG00000202515.1	VTRNA1-3	6.77	3.8e-11	9.85e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.868	rs2531352	ENSG00000202515.1	VTRNA1-3	6.77	3.81e-11	9.86e-09	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140739949	chr5:140726158~140726246:+
THCA	cis	rs4266144	1	rs12487629	ENSG00000241770.1	RP11-555M1.3	-6.77	3.81e-11	9.88e-09	-0.38	-0.3	Coronary artery disease;	chr3:157134416	chr3:157163452~157169133:+
THCA	cis	rs8059260	0.736	rs80079627	ENSG00000274038.1	RP11-66H6.4	-6.77	3.82e-11	9.88e-09	-0.53	-0.3	Alcohol consumption over the past year;	chr16:10948741	chr16:11056556~11057034:+
THCA	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	6.77	3.82e-11	9.88e-09	0.31	0.3	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
THCA	cis	rs4925386	0.808	rs1760073	ENSG00000273619.1	RP5-908M14.9	6.77	3.82e-11	9.9e-09	0.24	0.3	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62351050	chr20:62386303~62386970:-
THCA	cis	rs7044106	0.791	rs10760116	ENSG00000238181.2	AHCYP2	-6.77	3.82e-11	9.9e-09	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120720673~120721972:+
THCA	cis	rs1850744	0.826	rs7685513	ENSG00000250942.1	ENPP7P11	-6.77	3.82e-11	9.9e-09	-0.37	-0.3	Economic and political preferences;	chr4:9726975	chr4:9677308~9677934:+
THCA	cis	rs853679	0.882	rs9393908	ENSG00000226314.6	ZNF192P1	-6.77	3.82e-11	9.91e-09	-0.52	-0.3	Depression;	chr6:28223052	chr6:28161781~28169594:+
THCA	cis	rs853679	0.882	rs9366717	ENSG00000226314.6	ZNF192P1	-6.77	3.82e-11	9.91e-09	-0.52	-0.3	Depression;	chr6:28223279	chr6:28161781~28169594:+
THCA	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-6.77	3.83e-11	9.91e-09	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
THCA	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-6.77	3.83e-11	9.91e-09	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
THCA	cis	rs5742933	0.817	rs6942	ENSG00000273240.1	RP11-455J20.3	6.77	3.83e-11	9.92e-09	0.31	0.3	Ferritin levels;	chr2:189771685	chr2:189763859~189764456:-
THCA	cis	rs55665837	0.701	rs12286408	ENSG00000251991.1	RNU7-49P	6.77	3.83e-11	9.92e-09	0.34	0.3	Vitamin D levels;	chr11:14557830	chr11:14478892~14478953:+
THCA	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	6.77	3.84e-11	9.93e-09	0.38	0.3	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
THCA	cis	rs984222	0.838	rs6428789	ENSG00000231365.4	RP11-418J17.1	-6.77	3.84e-11	9.94e-09	-0.29	-0.3	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119007857	chr1:119140396~119275973:+
THCA	cis	rs13113518	0.783	rs12504300	ENSG00000273257.1	RP11-177J6.1	6.77	3.84e-11	9.94e-09	0.42	0.3	Height;	chr4:55482360	chr4:55387949~55388271:+
THCA	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-6.77	3.84e-11	9.95e-09	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
THCA	cis	rs7044106	0.791	rs10984994	ENSG00000238181.2	AHCYP2	6.77	3.86e-11	1e-08	0.39	0.3	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120720673~120721972:+
THCA	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	6.77	3.87e-11	1e-08	0.37	0.3	Height;	chr6:109694120	chr6:109382795~109383666:+
THCA	cis	rs4266144	0.926	rs4368453	ENSG00000241770.1	RP11-555M1.3	-6.77	3.87e-11	1e-08	-0.38	-0.3	Coronary artery disease;	chr3:157134352	chr3:157163452~157169133:+
THCA	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-6.77	3.87e-11	1e-08	-0.32	-0.3	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
THCA	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-6.77	3.87e-11	1e-08	-0.32	-0.3	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
THCA	cis	rs853679	0.546	rs200948	ENSG00000219392.1	RP1-265C24.5	-6.77	3.87e-11	1e-08	-0.51	-0.3	Depression;	chr6:27867494	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs200950	ENSG00000219392.1	RP1-265C24.5	-6.77	3.87e-11	1e-08	-0.51	-0.3	Depression;	chr6:27867994	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs200952	ENSG00000219392.1	RP1-265C24.5	-6.77	3.87e-11	1e-08	-0.51	-0.3	Depression;	chr6:27869198	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs200954	ENSG00000219392.1	RP1-265C24.5	-6.77	3.87e-11	1e-08	-0.51	-0.3	Depression;	chr6:27870986	chr6:28115628~28116551:+
THCA	cis	rs2562456	0.516	rs56072098	ENSG00000213976.4	CTD-2561J22.2	6.77	3.87e-11	1e-08	0.32	0.3	Pain;	chr19:21469158	chr19:21382865~21387177:+
THCA	cis	rs453301	0.579	rs10096850	ENSG00000253893.2	FAM85B	6.77	3.88e-11	1e-08	0.41	0.3	Joint mobility (Beighton score);	chr8:8940712	chr8:8167819~8226614:-
THCA	cis	rs1395	0.744	rs1122227	ENSG00000234072.1	AC074117.10	-6.77	3.88e-11	1e-08	-0.27	-0.3	Blood metabolite levels;	chr2:27321418	chr2:27356246~27367622:+
THCA	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	6.77	3.88e-11	1e-08	0.31	0.3	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
THCA	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	6.77	3.88e-11	1.01e-08	0.38	0.3	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
THCA	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	6.77	3.89e-11	1.01e-08	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	6.77	3.89e-11	1.01e-08	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	6.77	3.89e-11	1.01e-08	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
THCA	cis	rs875971	0.862	rs10256544	ENSG00000232559.3	GS1-124K5.12	6.77	3.89e-11	1.01e-08	0.29	0.3	Aortic root size;	chr7:66210141	chr7:66554588~66576923:-
THCA	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-6.77	3.89e-11	1.01e-08	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.764	rs12324584	ENSG00000249839.1	AC011330.5	-6.77	3.89e-11	1.01e-08	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43391248	chr15:43663654~43684339:-
THCA	cis	rs897984	0.609	rs17839567	ENSG00000279196.1	RP11-1072A3.3	6.77	3.89e-11	1.01e-08	0.3	0.3	Dementia with Lewy bodies;	chr16:31046624	chr16:30984630~30988270:-
THCA	cis	rs4834770	1	rs878374	ENSG00000245958.5	RP11-33B1.1	-6.77	3.89e-11	1.01e-08	-0.27	-0.3	Blood protein levels;	chr4:119316409	chr4:119454791~119552025:+
THCA	cis	rs853679	0.76	rs2299029	ENSG00000280107.1	AL022393.9	-6.77	3.9e-11	1.01e-08	-0.37	-0.3	Depression;	chr6:28231053	chr6:28170845~28172521:+
THCA	cis	rs7403037	0.754	rs2133276	ENSG00000259905.4	PWRN1	6.77	3.9e-11	1.01e-08	0.33	0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24247137	chr15:24493137~24652130:+
THCA	cis	rs467650	0.509	rs152985	ENSG00000246763.5	RGMB-AS1	6.77	3.9e-11	1.01e-08	0.29	0.3	Venous thromboembolism (SNP x SNP interaction);	chr5:98653103	chr5:98769618~98773469:-
THCA	cis	rs6907340	0.517	rs9465531	ENSG00000237404.1	RP3-471C18.2	-6.77	3.9e-11	1.01e-08	-0.35	-0.3	Endometriosis;	chr6:19798418	chr6:19689825~19753113:-
THCA	cis	rs2243480	1	rs437889	ENSG00000229886.1	RP5-1132H15.3	6.77	3.9e-11	1.01e-08	0.48	0.3	Diabetic kidney disease;	chr7:66044247	chr7:66025126~66031544:-
THCA	cis	rs75422866	0.51	rs73105845	ENSG00000257433.4	RP1-197B17.3	6.77	3.9e-11	1.01e-08	0.45	0.3	Pneumonia;	chr12:47741824	chr12:47706085~47742294:+
THCA	cis	rs7044106	0.791	rs747819	ENSG00000270917.1	RP11-27I1.6	-6.77	3.9e-11	1.01e-08	-0.42	-0.3	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.791	rs735110	ENSG00000270917.1	RP11-27I1.6	-6.77	3.9e-11	1.01e-08	-0.42	-0.3	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120812475~120812845:-
THCA	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-6.77	3.9e-11	1.01e-08	-0.41	-0.3	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
THCA	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-6.77	3.91e-11	1.01e-08	-0.4	-0.3	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
THCA	cis	rs1005277	0.505	rs200939	ENSG00000263064.2	RP11-291L22.7	6.77	3.91e-11	1.01e-08	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38448689~38448949:+
THCA	cis	rs2976388	1	rs10216533	ENSG00000253741.1	CTD-2292P10.4	6.77	3.91e-11	1.01e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142682272	chr8:142702252~142726973:-
THCA	cis	rs4835473	0.832	rs55935372	ENSG00000251600.4	RP11-673E1.1	-6.77	3.91e-11	1.01e-08	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143700626	chr4:143912331~143982454:+
THCA	cis	rs2915864	0.8	rs6886204	ENSG00000280047.1	CTC-463A16.1	6.77	3.92e-11	1.01e-08	0.47	0.3	Facial morphology (factor 20);	chr5:142117198	chr5:142165767~142168387:+
THCA	cis	rs5006884	0.547	rs17356445	ENSG00000167355.6	AC104389.28	-6.77	3.92e-11	1.01e-08	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5368920	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.547	rs12796030	ENSG00000167355.6	AC104389.28	-6.77	3.92e-11	1.01e-08	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5369045	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.547	rs884222	ENSG00000167355.6	AC104389.28	-6.77	3.92e-11	1.01e-08	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5371742	chr11:5304976~5505652:-
THCA	cis	rs748404	0.66	rs509306	ENSG00000166763.7	STRCP1	6.77	3.92e-11	1.02e-08	0.32	0.3	Lung cancer;	chr15:43422973	chr15:43699488~43718184:-
THCA	cis	rs6723226	0.732	rs6747560	ENSG00000276334.1	AL133243.1	6.77	3.93e-11	1.02e-08	0.35	0.3	Intelligence (multi-trait analysis);	chr2:32559699	chr2:32521927~32523547:+
THCA	cis	rs7942368	1	rs1440980	ENSG00000204529.3	GUCY2EP	6.77	3.93e-11	1.02e-08	0.42	0.3	Endometriosis;	chr11:76784032	chr11:76694043~76707641:-
THCA	cis	rs4664293	0.836	rs13016015	ENSG00000226266.5	AC009961.3	-6.77	3.93e-11	1.02e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159790018	chr2:159670708~159712435:-
THCA	cis	rs1552244	0.572	rs12107622	ENSG00000232901.1	CYCSP10	6.77	3.93e-11	1.02e-08	0.46	0.3	Alzheimer's disease;	chr3:10130214	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs2054478	ENSG00000232901.1	CYCSP10	6.77	3.93e-11	1.02e-08	0.46	0.3	Alzheimer's disease;	chr3:10130527	chr3:10000647~10000940:-
THCA	cis	rs7580658	0.545	rs12477559	ENSG00000236682.1	AC068282.3	-6.77	3.93e-11	1.02e-08	-0.38	-0.3	Protein C levels;	chr2:127194221	chr2:127389130~127400580:+
THCA	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-6.77	3.94e-11	1.02e-08	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
THCA	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	6.77	3.94e-11	1.02e-08	0.19	0.3	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
THCA	cis	rs45509595	0.556	rs34409918	ENSG00000219392.1	RP1-265C24.5	-6.77	3.94e-11	1.02e-08	-0.67	-0.3	Breast cancer;	chr6:27717569	chr6:28115628~28116551:+
THCA	cis	rs6504622	1	rs4968285	ENSG00000262879.4	RP11-156P1.3	-6.77	3.94e-11	1.02e-08	-0.27	-0.3	Orofacial clefts;	chr17:46938266	chr17:46984045~47100323:-
THCA	cis	rs867529	1	rs867529	ENSG00000234028.3	AC062029.1	6.77	3.94e-11	1.02e-08	0.25	0.3	Height;	chr2:88613755	chr2:88627539~88631821:+
THCA	cis	rs651907	0.557	rs3094296	ENSG00000256628.3	ZBTB11-AS1	6.77	3.95e-11	1.02e-08	0.35	0.3	Colorectal cancer;	chr3:101681323	chr3:101676475~101679217:+
THCA	cis	rs71636778	0.509	rs17356923	ENSG00000260063.1	RP5-968P14.2	-6.77	3.96e-11	1.02e-08	-0.59	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26956185	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12742376	ENSG00000260063.1	RP5-968P14.2	-6.77	3.96e-11	1.02e-08	-0.59	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26958704	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34514856	ENSG00000260063.1	RP5-968P14.2	-6.77	3.96e-11	1.02e-08	-0.59	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26961069	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs60340200	ENSG00000260063.1	RP5-968P14.2	-6.77	3.96e-11	1.02e-08	-0.59	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26961225	chr1:26692132~26694131:-
THCA	cis	rs7267979	0.966	rs4815425	ENSG00000274414.1	RP5-965G21.4	6.77	3.97e-11	1.03e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25239007~25245229:-
THCA	cis	rs2439831	1	rs690002	ENSG00000249839.1	AC011330.5	-6.77	3.97e-11	1.03e-08	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43437151	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs537115	ENSG00000249839.1	AC011330.5	-6.77	3.97e-11	1.03e-08	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43437750	chr15:43663654~43684339:-
THCA	cis	rs853679	0.546	rs34295134	ENSG00000219392.1	RP1-265C24.5	-6.77	3.97e-11	1.03e-08	-0.51	-0.3	Depression;	chr6:27860373	chr6:28115628~28116551:+
THCA	cis	rs6061231	0.597	rs624313	ENSG00000273619.1	RP5-908M14.9	6.77	3.98e-11	1.03e-08	0.24	0.3	Colorectal cancer;	chr20:62352356	chr20:62386303~62386970:-
THCA	cis	rs6504108	0.541	rs12603115	ENSG00000278765.1	RP5-890E16.5	6.76	3.98e-11	1.03e-08	0.33	0.3	Body mass index;	chr17:48171632	chr17:48066704~48067293:-
THCA	cis	rs1125355	1	rs111609722	ENSG00000251491.2	OR7E28P	-6.76	3.98e-11	1.03e-08	-0.48	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158850333	chr2:158862311~158863285:+
THCA	cis	rs875971	1	rs1144895	ENSG00000232559.3	GS1-124K5.12	-6.76	3.98e-11	1.03e-08	-0.29	-0.3	Aortic root size;	chr7:66076320	chr7:66554588~66576923:-
THCA	cis	rs6696239	0.513	rs4653848	ENSG00000227711.2	RP11-275O4.5	6.76	3.99e-11	1.03e-08	0.31	0.3	Height;	chr1:227541210	chr1:227509028~227520477:-
THCA	cis	rs375066	0.736	rs62114649	ENSG00000267058.1	RP11-15A1.3	6.76	3.99e-11	1.03e-08	0.25	0.3	Breast cancer;	chr19:43912415	chr19:43891804~43901805:-
THCA	cis	rs4601821	0.635	rs11214579	ENSG00000270179.1	RP11-159N11.4	6.76	3.99e-11	1.03e-08	0.3	0.3	Alcoholic chronic pancreatitis;	chr11:113337464	chr11:113368478~113369117:+
THCA	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	6.76	3.99e-11	1.03e-08	0.37	0.3	Height;	chr6:109407148	chr6:109382795~109383666:+
THCA	cis	rs990871	1	rs11209951	ENSG00000227207.2	RPL31P12	-6.76	3.99e-11	1.03e-08	-0.37	-0.3	Subcutaneous adipose tissue;	chr1:72371807	chr1:72301472~72301829:+
THCA	cis	rs1881744	0.588	rs78808618	ENSG00000274902.1	RP1-197B17.4	6.76	4.01e-11	1.04e-08	0.62	0.3	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47731908~47732351:+
THCA	cis	rs7727544	0.836	rs10463892	ENSG00000224431.1	AC063976.7	6.76	4.01e-11	1.04e-08	0.26	0.3	Blood metabolite levels;	chr5:132263012	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.901	rs55633655	ENSG00000224431.1	AC063976.7	6.76	4.01e-11	1.04e-08	0.26	0.3	Blood metabolite levels;	chr5:132263063	chr5:132199456~132203487:+
THCA	cis	rs9287719	0.601	rs62128635	ENSG00000243819.4	RN7SL832P	6.76	4.01e-11	1.04e-08	0.25	0.3	Prostate cancer;	chr2:10585208	chr2:10690344~10692099:+
THCA	cis	rs7580658	0.963	rs9789510	ENSG00000236682.1	AC068282.3	-6.76	4.01e-11	1.04e-08	-0.39	-0.3	Protein C levels;	chr2:127379436	chr2:127389130~127400580:+
THCA	cis	rs2976388	0.967	rs2976395	ENSG00000253741.1	CTD-2292P10.4	6.76	4.02e-11	1.04e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142682332	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs1045547	ENSG00000253741.1	CTD-2292P10.4	6.76	4.02e-11	1.04e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142682339	chr8:142702252~142726973:-
THCA	cis	rs1395	0.744	rs62130714	ENSG00000234072.1	AC074117.10	-6.76	4.02e-11	1.04e-08	-0.27	-0.3	Blood metabolite levels;	chr2:27310002	chr2:27356246~27367622:+
THCA	cis	rs7044106	0.791	rs10985008	ENSG00000270917.1	RP11-27I1.6	-6.76	4.04e-11	1.04e-08	-0.42	-0.3	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120812475~120812845:-
THCA	cis	rs3806843	0.966	rs10053945	ENSG00000202515.1	VTRNA1-3	-6.76	4.04e-11	1.04e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140780542	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs1548700	ENSG00000202515.1	VTRNA1-3	-6.76	4.04e-11	1.04e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140785304	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs1548699	ENSG00000202515.1	VTRNA1-3	-6.76	4.04e-11	1.04e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140785333	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs12055222	ENSG00000202515.1	VTRNA1-3	-6.76	4.04e-11	1.04e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140785983	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs6898939	ENSG00000202515.1	VTRNA1-3	-6.76	4.04e-11	1.04e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140789770	chr5:140726158~140726246:+
THCA	cis	rs7267979	0.586	rs6083776	ENSG00000274414.1	RP5-965G21.4	-6.76	4.05e-11	1.05e-08	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.586	rs1473695	ENSG00000274414.1	RP5-965G21.4	-6.76	4.05e-11	1.05e-08	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25239007~25245229:-
THCA	cis	rs12348691	0.503	rs10739513	ENSG00000236130.1	PTCSC2	-6.76	4.05e-11	1.05e-08	-0.25	-0.3	Alopecia areata;	chr9:97830423	chr9:97805935~97810008:-
THCA	cis	rs4934494	0.871	rs927907	ENSG00000232936.4	RP11-80H5.2	6.76	4.05e-11	1.05e-08	0.39	0.3	Red blood cell count;	chr10:89629981	chr10:89645282~89650667:+
THCA	cis	rs7267979	0.586	rs6050429	ENSG00000274414.1	RP5-965G21.4	-6.76	4.05e-11	1.05e-08	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.586	rs11087505	ENSG00000274414.1	RP5-965G21.4	-6.76	4.06e-11	1.05e-08	-0.36	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:25239007~25245229:-
THCA	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-6.76	4.06e-11	1.05e-08	-0.21	-0.3	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
THCA	cis	rs10208649	0.908	rs10181332	ENSG00000272156.1	RP11-477N3.1	6.76	4.06e-11	1.05e-08	0.56	0.3	Body mass index;	chr2:54118288	chr2:54082554~54085066:+
THCA	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	6.76	4.06e-11	1.05e-08	0.38	0.3	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
THCA	cis	rs2018683	0.834	rs733485	ENSG00000228421.2	AC005013.5	6.76	4.06e-11	1.05e-08	0.33	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28957667~28959345:+
THCA	cis	rs523522	0.923	rs3916065	ENSG00000278344.1	RP11-18C24.8	6.76	4.07e-11	1.05e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120496821	chr12:120500735~120501090:-
THCA	cis	rs11672691	0.519	rs7249258	ENSG00000267107.5	PCAT19	-6.76	4.07e-11	1.05e-08	-0.31	-0.3	Prostate cancer;	chr19:41501959	chr19:41454169~41500649:-
THCA	cis	rs7727544	0.904	rs58835386	ENSG00000224431.1	AC063976.7	6.76	4.07e-11	1.05e-08	0.26	0.3	Blood metabolite levels;	chr5:132264866	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.904	rs7736102	ENSG00000224431.1	AC063976.7	6.76	4.07e-11	1.05e-08	0.26	0.3	Blood metabolite levels;	chr5:132268564	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.904	rs6897575	ENSG00000224431.1	AC063976.7	6.76	4.07e-11	1.05e-08	0.26	0.3	Blood metabolite levels;	chr5:132268842	chr5:132199456~132203487:+
THCA	cis	rs829883	0.763	rs249843	ENSG00000227825.4	SLC9A7P1	6.76	4.07e-11	1.05e-08	0.26	0.3	Colorectal adenoma (advanced);	chr12:98477209	chr12:98453835~98457145:-
THCA	cis	rs3806843	0.9	rs2337983	ENSG00000202515.1	VTRNA1-3	6.76	4.08e-11	1.05e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140757223	chr5:140726158~140726246:+
THCA	cis	rs160451	0.933	rs218889	ENSG00000251136.7	RP11-37B2.1	-6.76	4.08e-11	1.05e-08	-0.26	-0.3	Leprosy;	chr8:89679935	chr8:89609409~89757727:-
THCA	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	6.76	4.09e-11	1.05e-08	0.45	0.3	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
THCA	cis	rs10899021	0.92	rs7112384	ENSG00000279353.1	RP11-864N7.4	6.76	4.09e-11	1.06e-08	0.59	0.3	Response to metformin (IC50);	chr11:74637160	chr11:74698231~74699658:-
THCA	cis	rs10899021	0.92	rs7112664	ENSG00000279353.1	RP11-864N7.4	6.76	4.09e-11	1.06e-08	0.59	0.3	Response to metformin (IC50);	chr11:74637381	chr11:74698231~74699658:-
THCA	cis	rs3806843	0.966	rs2563263	ENSG00000202515.1	VTRNA1-3	-6.76	4.09e-11	1.06e-08	-0.34	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140758059	chr5:140726158~140726246:+
THCA	cis	rs1395	0.626	rs72817537	ENSG00000234072.1	AC074117.10	-6.76	4.09e-11	1.06e-08	-0.27	-0.3	Blood metabolite levels;	chr2:27274681	chr2:27356246~27367622:+
THCA	cis	rs11168351	0.927	rs11168342	ENSG00000258273.1	RP11-370I10.4	-6.76	4.1e-11	1.06e-08	-0.39	-0.3	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48333755~48333901:-
THCA	cis	rs10971721	0.818	rs10971708	ENSG00000281128.1	PTENP1-AS	6.76	4.1e-11	1.06e-08	0.7	0.3	Body mass index;	chr9:33803273	chr9:33677268~33688011:+
THCA	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-6.76	4.1e-11	1.06e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-6.76	4.1e-11	1.06e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-6.76	4.1e-11	1.06e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-6.76	4.1e-11	1.06e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-6.76	4.1e-11	1.06e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-6.76	4.1e-11	1.06e-08	-0.54	-0.3	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
THCA	cis	rs9926296	0.605	rs8046243	ENSG00000260259.1	RP11-368I7.4	-6.76	4.1e-11	1.06e-08	-0.32	-0.3	Vitiligo;	chr16:89785725	chr16:89682620~89686569:-
THCA	cis	rs41307935	0.818	rs34339345	ENSG00000260063.1	RP5-968P14.2	-6.76	4.11e-11	1.06e-08	-0.58	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26899598	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs12739698	ENSG00000260063.1	RP5-968P14.2	-6.76	4.11e-11	1.06e-08	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903542	chr1:26692132~26694131:-
THCA	cis	rs1865760	0.541	rs1436309	ENSG00000272462.2	U91328.19	-6.76	4.12e-11	1.06e-08	-0.24	-0.3	Height;	chr6:25969881	chr6:25992662~26001775:+
THCA	cis	rs523522	0.962	rs2233676	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120495804	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs9788155	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120500605	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs10849754	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120502615	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs7471	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120503412	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs11065145	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120509616	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs4766968	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120509985	chr12:120500735~120501090:-
THCA	cis	rs523522	0.923	rs10774553	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120517181	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs11065149	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120519160	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs10849757	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120526211	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs55848094	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120528856	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs3742052	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120529118	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs10849758	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120533346	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs11065154	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120533614	chr12:120500735~120501090:-
THCA	cis	rs523522	0.926	rs10774555	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120534175	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs7488320	ENSG00000278344.1	RP11-18C24.8	6.76	4.12e-11	1.06e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120543827	chr12:120500735~120501090:-
THCA	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	6.76	4.12e-11	1.06e-08	0.33	0.3	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
THCA	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	6.76	4.12e-11	1.06e-08	0.33	0.3	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
THCA	cis	rs12435908	1	rs2073294	ENSG00000276116.2	FUT8-AS1	-6.76	4.14e-11	1.07e-08	-0.49	-0.3	Ischemic stroke;	chr14:65615775	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.842	rs968540	ENSG00000276116.2	FUT8-AS1	6.76	4.14e-11	1.07e-08	0.31	0.3	N-glycan levels;	chr14:65782346	chr14:65411170~65412690:-
THCA	cis	rs5006884	0.547	rs2467232	ENSG00000167355.6	AC104389.28	-6.76	4.14e-11	1.07e-08	-0.38	-0.3	Fetal hemoglobin levels;	chr11:5363551	chr11:5304976~5505652:-
THCA	cis	rs11838725	1	rs11838725	ENSG00000239827.7	SUGT1P3	-6.76	4.15e-11	1.07e-08	-0.31	-0.3	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40908159~40921774:-
THCA	cis	rs9813712	0.595	rs6439226	ENSG00000228252.7	COL6A4P2	6.76	4.15e-11	1.07e-08	0.3	0.3	Response to amphetamines;	chr3:130283686	chr3:130212823~130273806:+
THCA	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-6.76	4.15e-11	1.07e-08	-0.41	-0.3	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-6.76	4.15e-11	1.07e-08	-0.41	-0.3	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-6.76	4.15e-11	1.07e-08	-0.41	-0.3	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
THCA	cis	rs12348691	0.503	rs7024345	ENSG00000236130.1	PTCSC2	-6.76	4.15e-11	1.07e-08	-0.25	-0.3	Alopecia areata;	chr9:97832956	chr9:97805935~97810008:-
THCA	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	6.76	4.16e-11	1.07e-08	0.38	0.3	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
THCA	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	6.76	4.16e-11	1.07e-08	0.38	0.3	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
THCA	cis	rs11668609	0.81	rs9305015	ENSG00000268442.1	CTD-2027I19.2	-6.76	4.16e-11	1.07e-08	-0.36	-0.3	Response to taxane treatment (docetaxel);	chr19:24157700	chr19:24162370~24163425:-
THCA	cis	rs4713118	0.869	rs9468214	ENSG00000280107.1	AL022393.9	-6.76	4.16e-11	1.07e-08	-0.34	-0.3	Parkinson's disease;	chr6:27745520	chr6:28170845~28172521:+
THCA	cis	rs11168351	0.75	rs11168366	ENSG00000240399.1	RP1-228P16.1	-6.76	4.16e-11	1.07e-08	-0.32	-0.3	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48054813~48055591:-
THCA	cis	rs728616	0.717	rs111403425	ENSG00000225484.5	NUTM2B-AS1	-6.76	4.16e-11	1.07e-08	-0.56	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060786	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs78131725	ENSG00000225484.5	NUTM2B-AS1	-6.76	4.16e-11	1.07e-08	-0.56	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061163	chr10:79663088~79826594:-
THCA	cis	rs2239557	1	rs2358633	ENSG00000259065.1	RP5-1021I20.1	6.76	4.17e-11	1.07e-08	0.36	0.3	Common traits (Other);	chr14:74180715	chr14:73787360~73803270:+
THCA	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	6.76	4.17e-11	1.08e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	6.76	4.17e-11	1.08e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	6.76	4.17e-11	1.08e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	6.76	4.17e-11	1.08e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	6.76	4.17e-11	1.08e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	6.76	4.17e-11	1.08e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	6.76	4.17e-11	1.08e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
THCA	cis	rs1023500	0.505	rs2143139	ENSG00000205702.9	CYP2D7	6.76	4.18e-11	1.08e-08	0.23	0.3	Schizophrenia;	chr22:42218395	chr22:42140203~42144577:-
THCA	cis	rs6565180	1	rs11863150	ENSG00000273724.1	RP11-347C12.12	6.76	4.18e-11	1.08e-08	0.3	0.3	Tonsillectomy;	chr16:30374182	chr16:30336400~30343336:+
THCA	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	6.76	4.18e-11	1.08e-08	0.43	0.3	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	6.76	4.18e-11	1.08e-08	0.43	0.3	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
THCA	cis	rs10483853	0.579	rs58546337	ENSG00000258695.2	RP3-414A15.2	-6.76	4.18e-11	1.08e-08	-0.46	-0.3	Coronary artery calcification;	chr14:73483753	chr14:73522878~73530610:+
THCA	cis	rs6545883	0.894	rs9677047	ENSG00000271889.1	RP11-493E12.1	-6.76	4.18e-11	1.08e-08	-0.29	-0.3	Tuberculosis;	chr2:61358160	chr2:61151433~61162105:-
THCA	cis	rs897984	0.572	rs112906665	ENSG00000279196.1	RP11-1072A3.3	6.76	4.18e-11	1.08e-08	0.3	0.3	Dementia with Lewy bodies;	chr16:31028818	chr16:30984630~30988270:-
THCA	cis	rs897984	0.609	rs12445650	ENSG00000279196.1	RP11-1072A3.3	6.76	4.18e-11	1.08e-08	0.3	0.3	Dementia with Lewy bodies;	chr16:31033576	chr16:30984630~30988270:-
THCA	cis	rs7267979	0.509	rs6115218	ENSG00000274973.1	RP13-401N8.7	-6.76	4.18e-11	1.08e-08	-0.38	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25845497~25845862:+
THCA	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	6.76	4.18e-11	1.08e-08	0.46	0.3	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
THCA	cis	rs9487094	0.614	rs11968978	ENSG00000260273.1	RP11-425D10.10	6.76	4.19e-11	1.08e-08	0.39	0.3	Height;	chr6:109775693	chr6:109382795~109383666:+
THCA	cis	rs4908760	0.811	rs301806	ENSG00000232912.4	RP5-1115A15.1	6.76	4.19e-11	1.08e-08	0.29	0.3	Vitiligo;	chr1:8422018	chr1:8424645~8434838:+
THCA	cis	rs7221109	0.682	rs11656173	ENSG00000278834.1	RP11-458J1.1	-6.76	4.19e-11	1.08e-08	-0.32	-0.3	Type 1 diabetes;	chr17:40599413	chr17:40648300~40649718:+
THCA	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-6.76	4.2e-11	1.08e-08	-0.21	-0.3	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
THCA	cis	rs6723226	0.699	rs376914	ENSG00000276334.1	AL133243.1	6.76	4.2e-11	1.08e-08	0.34	0.3	Intelligence (multi-trait analysis);	chr2:32283324	chr2:32521927~32523547:+
THCA	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-6.76	4.2e-11	1.08e-08	-0.4	-0.3	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
THCA	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-6.76	4.21e-11	1.08e-08	-0.39	-0.3	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
THCA	cis	rs1150668	0.796	rs2247002	ENSG00000219392.1	RP1-265C24.5	-6.76	4.21e-11	1.08e-08	-0.31	-0.3	Pubertal anthropometrics;	chr6:28430174	chr6:28115628~28116551:+
THCA	cis	rs741668	0.931	rs61953335	ENSG00000235903.6	CPB2-AS1	6.76	4.21e-11	1.08e-08	0.4	0.3	Cerebrospinal fluid clusterin levels;	chr13:46024681	chr13:46052806~46113332:+
THCA	cis	rs4664293	0.867	rs6432553	ENSG00000226266.5	AC009961.3	-6.76	4.21e-11	1.09e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159720499	chr2:159670708~159712435:-
THCA	cis	rs240993	0.812	rs6929024	ENSG00000230177.1	RP5-1112D6.4	6.76	4.22e-11	1.09e-08	0.3	0.3	Inflammatory skin disease;Psoriasis;	chr6:111545104	chr6:111277932~111278742:+
THCA	cis	rs62130978	0.509	rs243372	ENSG00000267769.1	CTB-50L17.9	-6.76	4.22e-11	1.09e-08	-0.31	-0.3	Red cell distribution width;	chr19:4432976	chr19:4454014~4455286:+
THCA	cis	rs7746199	0.736	rs13195636	ENSG00000219392.1	RP1-265C24.5	-6.76	4.22e-11	1.09e-08	-0.67	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28115628~28116551:+
THCA	cis	rs79349575	0.756	rs62078385	ENSG00000248278.1	SUMO2P17	6.76	4.22e-11	1.09e-08	0.35	0.3	Type 2 diabetes;	chr17:48967647	chr17:48874860~48908983:-
THCA	cis	rs853679	0.607	rs66868086	ENSG00000280107.1	AL022393.9	-6.76	4.23e-11	1.09e-08	-0.6	-0.3	Depression;	chr6:27898124	chr6:28170845~28172521:+
THCA	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-6.75	4.24e-11	1.09e-08	-0.41	-0.3	Height;	chr6:109625358	chr6:109382795~109383666:+
THCA	cis	rs9287719	0.649	rs12476554	ENSG00000243819.4	RN7SL832P	6.75	4.24e-11	1.09e-08	0.25	0.3	Prostate cancer;	chr2:10587621	chr2:10690344~10692099:+
THCA	cis	rs728616	0.867	rs41298231	ENSG00000242600.5	MBL1P	6.75	4.24e-11	1.09e-08	0.44	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922705	chr10:79904898~79950336:+
THCA	cis	rs7267979	1	rs3761117	ENSG00000274414.1	RP5-965G21.4	6.75	4.24e-11	1.09e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25239007~25245229:-
THCA	cis	rs2243480	1	rs10807701	ENSG00000229886.1	RP5-1132H15.3	-6.75	4.24e-11	1.09e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66259699	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1499613	ENSG00000229886.1	RP5-1132H15.3	-6.75	4.24e-11	1.09e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66265873	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1553174	ENSG00000229886.1	RP5-1132H15.3	-6.75	4.24e-11	1.09e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66266207	chr7:66025126~66031544:-
THCA	cis	rs853679	0.556	rs45509595	ENSG00000280107.1	AL022393.9	-6.75	4.25e-11	1.1e-08	-0.6	-0.3	Depression;	chr6:27873148	chr6:28170845~28172521:+
THCA	cis	rs9813712	0.547	rs6807290	ENSG00000228252.7	COL6A4P2	6.75	4.26e-11	1.1e-08	0.3	0.3	Response to amphetamines;	chr3:130297952	chr3:130212823~130273806:+
THCA	cis	rs9402743	0.634	rs2327646	ENSG00000231028.7	LINC00271	-6.75	4.26e-11	1.1e-08	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135597186	chr6:135497801~135716055:+
THCA	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-6.75	4.26e-11	1.1e-08	-0.29	-0.3	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
THCA	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-6.75	4.26e-11	1.1e-08	-0.48	-0.3	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
THCA	cis	rs516805	0.634	rs2816159	ENSG00000279453.1	RP3-425C14.4	-6.75	4.27e-11	1.1e-08	-0.32	-0.3	Lymphocyte counts;	chr6:122121982	chr6:122436789~122439223:-
THCA	cis	rs227932	0.541	rs78177212	ENSG00000234286.1	AC006026.13	-6.75	4.27e-11	1.1e-08	-0.55	-0.3	Schizophrenia;	chr7:23770500	chr7:23680195~23680786:-
THCA	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	6.75	4.28e-11	1.1e-08	0.39	0.3	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
THCA	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	6.75	4.28e-11	1.1e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
THCA	cis	rs1552244	0.882	rs56332224	ENSG00000232901.1	CYCSP10	6.75	4.28e-11	1.1e-08	0.38	0.3	Alzheimer's disease;	chr3:9995637	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs13066757	ENSG00000232901.1	CYCSP10	6.75	4.28e-11	1.1e-08	0.38	0.3	Alzheimer's disease;	chr3:10003346	chr3:10000647~10000940:-
THCA	cis	rs7189233	0.911	rs8057808	ENSG00000279722.1	RP11-44F14.6	-6.75	4.29e-11	1.1e-08	-0.31	-0.3	Intelligence (multi-trait analysis);	chr16:53486701	chr16:53487607~53489943:-
THCA	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-6.75	4.29e-11	1.1e-08	-0.37	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
THCA	cis	rs1023500	0.596	rs133350	ENSG00000205702.9	CYP2D7	6.75	4.29e-11	1.1e-08	0.25	0.3	Schizophrenia;	chr22:42033045	chr22:42140203~42144577:-
THCA	cis	rs438465	1	rs391468	ENSG00000226194.4	RP1-137D17.1	6.75	4.29e-11	1.11e-08	0.45	0.3	Corneal astigmatism;	chr6:169409004	chr6:169369998~169388385:-
THCA	cis	rs1150668	0.83	rs2859365	ENSG00000219392.1	RP1-265C24.5	6.75	4.3e-11	1.11e-08	0.31	0.3	Pubertal anthropometrics;	chr6:28423688	chr6:28115628~28116551:+
THCA	cis	rs9287719	0.649	rs7589694	ENSG00000243819.4	RN7SL832P	6.75	4.3e-11	1.11e-08	0.25	0.3	Prostate cancer;	chr2:10560748	chr2:10690344~10692099:+
THCA	cis	rs7208859	0.573	rs216443	ENSG00000263603.1	CTD-2349P21.5	-6.75	4.3e-11	1.11e-08	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30729469~30731202:+
THCA	cis	rs6600671	0.899	rs2319971	ENSG00000223345.3	HIST2H2BA	6.75	4.3e-11	1.11e-08	0.34	0.3	Hip geometry;	chr1:121485184	chr1:121108210~121117257:-
THCA	cis	rs950169	0.734	rs67119537	ENSG00000225151.9	GOLGA2P7	-6.75	4.3e-11	1.11e-08	-0.41	-0.3	Schizophrenia;	chr15:84395671	chr15:84199311~84230136:-
THCA	cis	rs6723226	0.552	rs62136336	ENSG00000276334.1	AL133243.1	6.75	4.31e-11	1.11e-08	0.34	0.3	Intelligence (multi-trait analysis);	chr2:32579039	chr2:32521927~32523547:+
THCA	cis	rs944990	0.597	rs11789176	ENSG00000227603.1	RP11-165J3.6	6.75	4.31e-11	1.11e-08	0.3	0.3	Body mass index;	chr9:93433884	chr9:93435332~93437121:-
THCA	cis	rs35934224	0.783	rs7288061	ENSG00000232926.1	AC000078.5	6.75	4.31e-11	1.11e-08	0.37	0.3	Glaucoma (primary open-angle);	chr22:19876716	chr22:19887289~19887970:+
THCA	cis	rs2412819	0.545	rs35822148	ENSG00000249839.1	AC011330.5	-6.75	4.31e-11	1.11e-08	-0.5	-0.3	Lung cancer;	chr15:43808084	chr15:43663654~43684339:-
THCA	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-6.75	4.32e-11	1.11e-08	-0.29	-0.3	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
THCA	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-6.75	4.32e-11	1.11e-08	-0.33	-0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
THCA	cis	rs7267979	0.966	rs8123949	ENSG00000274414.1	RP5-965G21.4	6.75	4.32e-11	1.11e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2184000	ENSG00000274414.1	RP5-965G21.4	6.75	4.32e-11	1.11e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25239007~25245229:-
THCA	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	6.75	4.32e-11	1.11e-08	0.45	0.3	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
THCA	cis	rs2243480	1	rs10950032	ENSG00000229886.1	RP5-1132H15.3	-6.75	4.32e-11	1.11e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66273604	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6958420	ENSG00000229886.1	RP5-1132H15.3	-6.75	4.32e-11	1.11e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66286184	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1392104	ENSG00000229886.1	RP5-1132H15.3	-6.75	4.32e-11	1.11e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66294120	chr7:66025126~66031544:-
THCA	cis	rs853679	0.517	rs9283884	ENSG00000272009.1	RP1-313I6.12	6.75	4.33e-11	1.11e-08	0.35	0.3	Depression;	chr6:28167882	chr6:28078792~28081130:-
THCA	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	6.75	4.33e-11	1.12e-08	0.45	0.3	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
THCA	cis	rs990871	1	rs990871	ENSG00000227207.2	RPL31P12	-6.75	4.34e-11	1.12e-08	-0.37	-0.3	Subcutaneous adipose tissue;	chr1:72358030	chr1:72301472~72301829:+
THCA	cis	rs8012947	0.959	rs4520767	ENSG00000279636.2	LINC00216	-6.75	4.36e-11	1.12e-08	-0.31	-0.3	Alcohol consumption in current drinkers;	chr14:58302220	chr14:58288033~58289158:+
THCA	cis	rs7674212	0.772	rs13113099	ENSG00000246560.2	RP11-10L12.4	6.75	4.36e-11	1.12e-08	0.37	0.3	Type 2 diabetes;	chr4:103052965	chr4:102828055~102844075:+
THCA	cis	rs4835473	0.897	rs1450249	ENSG00000251600.4	RP11-673E1.1	6.75	4.36e-11	1.12e-08	0.4	0.3	Immature fraction of reticulocytes;	chr4:143724425	chr4:143912331~143982454:+
THCA	cis	rs736801	0.74	rs17622378	ENSG00000224431.1	AC063976.7	6.75	4.36e-11	1.12e-08	0.27	0.3	Mosquito bite size;Breast cancer;	chr5:132442760	chr5:132199456~132203487:+
THCA	cis	rs7119038	0.509	rs10892258	ENSG00000255239.1	AP002954.6	6.75	4.37e-11	1.12e-08	0.45	0.3	Sjögren's syndrome;	chr11:118709156	chr11:118688039~118690600:-
THCA	cis	rs6600671	1	rs4844616	ENSG00000270392.2	PFN1P2	6.75	4.38e-11	1.13e-08	0.29	0.3	Hip geometry;	chr1:121429348	chr1:120432204~120434052:-
THCA	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	6.75	4.38e-11	1.13e-08	0.37	0.3	Height;	chr6:109350188	chr6:109382795~109383666:+
THCA	cis	rs6430585	0.528	rs309154	ENSG00000231890.6	DARS-AS1	-6.75	4.38e-11	1.13e-08	-0.36	-0.3	Corneal structure;	chr2:135968997	chr2:135985176~136022593:+
THCA	cis	rs1125355	1	rs1125355	ENSG00000251491.2	OR7E28P	-6.75	4.38e-11	1.13e-08	-0.47	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158844068	chr2:158862311~158863285:+
THCA	cis	rs728616	0.614	rs1998374	ENSG00000225484.5	NUTM2B-AS1	-6.75	4.38e-11	1.13e-08	-0.44	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79942966	chr10:79663088~79826594:-
THCA	cis	rs4664293	0.805	rs6432559	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159750649	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs6432560	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159750758	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs3863924	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159758247	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs11681565	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159760362	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.836	rs11687502	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159760464	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.836	rs13401087	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159760957	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs12692564	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159761326	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs1427328	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159762064	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.613	rs9784044	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159765854	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs4664301	ENSG00000226266.5	AC009961.3	-6.75	4.39e-11	1.13e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159766855	chr2:159670708~159712435:-
THCA	cis	rs7189233	1	rs62048520	ENSG00000279344.1	RP11-44F14.7	6.75	4.39e-11	1.13e-08	0.32	0.3	Intelligence (multi-trait analysis);	chr16:53457183	chr16:53478957~53481550:-
THCA	cis	rs4713118	0.539	rs200967	ENSG00000219392.1	RP1-265C24.5	-6.75	4.39e-11	1.13e-08	-0.37	-0.3	Parkinson's disease;	chr6:27894349	chr6:28115628~28116551:+
THCA	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	6.75	4.39e-11	1.13e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
THCA	cis	rs7580658	0.545	rs885275	ENSG00000236682.1	AC068282.3	-6.75	4.4e-11	1.13e-08	-0.38	-0.3	Protein C levels;	chr2:127193519	chr2:127389130~127400580:+
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000228409.4	CCT6P1	-6.75	4.4e-11	1.13e-08	-0.35	-0.3	Diabetic kidney disease;	chr7:66226660	chr7:65751142~65763354:+
THCA	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	6.75	4.41e-11	1.13e-08	0.4	0.3	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs12505617	ENSG00000251600.4	RP11-673E1.1	6.75	4.41e-11	1.13e-08	0.4	0.3	Immature fraction of reticulocytes;	chr4:143723522	chr4:143912331~143982454:+
THCA	cis	rs7851660	0.839	rs10818213	ENSG00000236130.1	PTCSC2	-6.75	4.41e-11	1.13e-08	-0.24	-0.3	Strep throat;	chr9:97886349	chr9:97805935~97810008:-
THCA	cis	rs2303319	1	rs62194247	ENSG00000227403.1	AC009299.3	6.75	4.41e-11	1.14e-08	0.63	0.3	Cognitive function;	chr2:161256895	chr2:161244739~161249050:+
THCA	cis	rs4591358	0.731	rs13036252	ENSG00000223466.1	AC064834.2	-6.75	4.42e-11	1.14e-08	-0.41	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195425834	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.68	rs7568240	ENSG00000223466.1	AC064834.2	-6.75	4.42e-11	1.14e-08	-0.41	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195428263	chr2:195533035~195538681:+
THCA	cis	rs6676180	0.555	rs871665	ENSG00000231365.4	RP11-418J17.1	-6.75	4.42e-11	1.14e-08	-0.29	-0.3	Monobrow;	chr1:119230040	chr1:119140396~119275973:+
THCA	cis	rs73607972	0.778	rs55662133	ENSG00000275191.1	RP11-36I17.2	-6.75	4.43e-11	1.14e-08	-0.44	-0.3	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612761	chr16:53628256~53628816:-
THCA	cis	rs516805	0.667	rs2606598	ENSG00000279453.1	RP3-425C14.4	6.75	4.43e-11	1.14e-08	0.34	0.3	Lymphocyte counts;	chr6:122206501	chr6:122436789~122439223:-
THCA	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	6.75	4.43e-11	1.14e-08	0.4	0.3	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
THCA	cis	rs523522	0.962	rs4767904	ENSG00000278344.1	RP11-18C24.8	6.75	4.43e-11	1.14e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120492995	chr12:120500735~120501090:-
THCA	cis	rs11096990	0.855	rs2711990	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39150116	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2566173	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39151111	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2711988	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39151128	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2043102	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39151292	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2711986	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39152258	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.75	rs2465242	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39153796	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2465243	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39154036	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2566176	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39154373	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2566178	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39155194	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2711933	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39156090	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2566179	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39156413	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2566180	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39157381	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2566181	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39157987	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.819	rs2381225	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39158915	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.819	rs1367297	ENSG00000249207.1	RP11-360F5.1	6.75	4.43e-11	1.14e-08	0.39	0.3	Cognitive function;	chr4:39159614	chr4:39112677~39126818:-
THCA	cis	rs7580658	0.963	rs10803585	ENSG00000236682.1	AC068282.3	-6.75	4.44e-11	1.14e-08	-0.39	-0.3	Protein C levels;	chr2:127372532	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.963	rs2090574	ENSG00000236682.1	AC068282.3	-6.75	4.44e-11	1.14e-08	-0.39	-0.3	Protein C levels;	chr2:127373815	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.963	rs12052483	ENSG00000236682.1	AC068282.3	-6.75	4.44e-11	1.14e-08	-0.39	-0.3	Protein C levels;	chr2:127379244	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.926	rs4662725	ENSG00000236682.1	AC068282.3	-6.75	4.44e-11	1.14e-08	-0.39	-0.3	Protein C levels;	chr2:127383744	chr2:127389130~127400580:+
THCA	cis	rs12681366	0.623	rs10106494	ENSG00000253704.1	RP11-267M23.4	6.75	4.44e-11	1.14e-08	0.3	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94471226	chr8:94553722~94569745:+
THCA	cis	rs42490	0.546	rs160437	ENSG00000251136.7	RP11-37B2.1	6.75	4.44e-11	1.14e-08	0.26	0.3	Leprosy;	chr8:89669656	chr8:89609409~89757727:-
THCA	cis	rs741668	0.931	rs17428825	ENSG00000235903.6	CPB2-AS1	6.75	4.44e-11	1.14e-08	0.4	0.3	Cerebrospinal fluid clusterin levels;	chr13:45948541	chr13:46052806~46113332:+
THCA	cis	rs741668	0.897	rs56223000	ENSG00000235903.6	CPB2-AS1	6.75	4.44e-11	1.14e-08	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:46028500	chr13:46052806~46113332:+
THCA	cis	rs853679	0.607	rs13211507	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28289600	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34691223	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28290431	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13207345	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28297795	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs72854513	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28298177	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs56189111	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28304196	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34950484	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28310911	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs35072899	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28313764	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34661125	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28314117	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13190888	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28318208	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs56075693	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28322551	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34218844	ENSG00000280107.1	AL022393.9	-6.75	4.45e-11	1.14e-08	-0.58	-0.3	Depression;	chr6:28322870	chr6:28170845~28172521:+
THCA	cis	rs3806843	0.868	rs2262573	ENSG00000202515.1	VTRNA1-3	6.75	4.45e-11	1.14e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr5:140726158~140726246:+
THCA	cis	rs6504622	0.875	rs3851786	ENSG00000262879.4	RP11-156P1.3	6.75	4.45e-11	1.14e-08	0.28	0.3	Orofacial clefts;	chr17:46969566	chr17:46984045~47100323:-
THCA	cis	rs2243480	1	rs35542501	ENSG00000229886.1	RP5-1132H15.3	6.75	4.45e-11	1.14e-08	0.47	0.3	Diabetic kidney disease;	chr7:65966228	chr7:66025126~66031544:-
THCA	cis	rs7851660	0.874	rs7847010	ENSG00000236130.1	PTCSC2	-6.75	4.46e-11	1.15e-08	-0.24	-0.3	Strep throat;	chr9:97868157	chr9:97805935~97810008:-
THCA	cis	rs853679	0.607	rs67340775	ENSG00000280107.1	AL022393.9	-6.75	4.46e-11	1.15e-08	-0.58	-0.3	Depression;	chr6:28336607	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs35030260	ENSG00000280107.1	AL022393.9	-6.75	4.46e-11	1.15e-08	-0.58	-0.3	Depression;	chr6:28337731	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13217619	ENSG00000280107.1	AL022393.9	-6.75	4.46e-11	1.15e-08	-0.58	-0.3	Depression;	chr6:28338894	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs35016036	ENSG00000280107.1	AL022393.9	-6.75	4.46e-11	1.15e-08	-0.58	-0.3	Depression;	chr6:28347103	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs35744819	ENSG00000280107.1	AL022393.9	-6.75	4.46e-11	1.15e-08	-0.58	-0.3	Depression;	chr6:28350554	chr6:28170845~28172521:+
THCA	cis	rs4947019	0.609	rs2146411	ENSG00000260273.1	RP11-425D10.10	6.75	4.46e-11	1.15e-08	0.64	0.3	Hematological parameters;	chr6:109444585	chr6:109382795~109383666:+
THCA	cis	rs3806843	0.766	rs2251860	ENSG00000202515.1	VTRNA1-3	6.75	4.46e-11	1.15e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140668624	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.766	rs702397	ENSG00000202515.1	VTRNA1-3	6.75	4.46e-11	1.15e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140670680	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.766	rs2530239	ENSG00000202515.1	VTRNA1-3	6.75	4.46e-11	1.15e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140682962	chr5:140726158~140726246:+
THCA	cis	rs6723108	0.627	rs55865348	ENSG00000224043.6	CCNT2-AS1	-6.75	4.47e-11	1.15e-08	-0.31	-0.3	Type 2 diabetes;	chr2:134892235	chr2:134735464~134918710:-
THCA	cis	rs2408955	0.521	rs11168437	ENSG00000240399.1	RP1-228P16.1	6.75	4.47e-11	1.15e-08	0.31	0.3	Glycated hemoglobin levels;	chr12:48172373	chr12:48054813~48055591:-
THCA	cis	rs792448	0.743	rs2516331	ENSG00000226251.4	RP11-15I11.3	-6.75	4.47e-11	1.15e-08	-0.37	-0.3	White blood cell count (basophil);	chr1:212243647	chr1:212225278~212238977:-
THCA	cis	rs6840360	0.557	rs1143036	ENSG00000251611.1	RP11-610P16.1	-6.75	4.47e-11	1.15e-08	-0.22	-0.3	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151407551~151408835:-
THCA	cis	rs853679	0.546	rs35017208	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28377505	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs13213152	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28381921	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs36092177	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28390030	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs13213986	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28390232	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs2232429	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28391855	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs2232426	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28392882	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs34546986	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28394532	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs34871267	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28396455	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs2232423	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28398374	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs35883476	ENSG00000280107.1	AL022393.9	-6.75	4.48e-11	1.15e-08	-0.59	-0.3	Depression;	chr6:28400731	chr6:28170845~28172521:+
THCA	cis	rs2408955	0.522	rs4760612	ENSG00000240399.1	RP1-228P16.1	-6.75	4.48e-11	1.15e-08	-0.31	-0.3	Glycated hemoglobin levels;	chr12:48028073	chr12:48054813~48055591:-
THCA	cis	rs6740322	0.748	rs6544636	ENSG00000234936.1	AC010883.5	6.75	4.48e-11	1.15e-08	0.32	0.3	Coronary artery disease;	chr2:43260347	chr2:43229573~43233394:+
THCA	cis	rs438465	0.786	rs430206	ENSG00000226194.4	RP1-137D17.1	6.75	4.49e-11	1.15e-08	0.45	0.3	Corneal astigmatism;	chr6:169426971	chr6:169369998~169388385:-
THCA	cis	rs7267979	1	rs6050547	ENSG00000274414.1	RP5-965G21.4	6.75	4.49e-11	1.15e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25239007~25245229:-
THCA	cis	rs7045881	0.674	rs3429	ENSG00000254396.1	RP11-56F10.3	6.75	4.49e-11	1.15e-08	0.47	0.3	Schizophrenia;	chr9:27062723	chr9:27102630~27104728:+
THCA	cis	rs4073416	0.746	rs79588408	ENSG00000276116.2	FUT8-AS1	6.75	4.5e-11	1.15e-08	0.31	0.3	N-glycan levels;	chr14:65677163	chr14:65411170~65412690:-
THCA	cis	rs2280018	0.609	rs2941253	ENSG00000188599.16	NPIPP1	-6.75	4.5e-11	1.16e-08	-0.23	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15104312~15123498:-
THCA	cis	rs496547	0.52	rs11216963	ENSG00000255239.1	AP002954.6	-6.75	4.5e-11	1.16e-08	-0.45	-0.3	Hip minimal joint space width;	chr11:118710105	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.509	rs11216964	ENSG00000255239.1	AP002954.6	-6.75	4.5e-11	1.16e-08	-0.45	-0.3	Sjögren's syndrome;	chr11:118711186	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.509	rs10892259	ENSG00000255239.1	AP002954.6	-6.75	4.5e-11	1.16e-08	-0.45	-0.3	Sjögren's syndrome;	chr11:118712293	chr11:118688039~118690600:-
THCA	cis	rs9487094	1	rs17070580	ENSG00000260273.1	RP11-425D10.10	-6.74	4.51e-11	1.16e-08	-0.36	-0.3	Height;	chr6:109417511	chr6:109382795~109383666:+
THCA	cis	rs16843372	0.562	rs34525522	ENSG00000251491.2	OR7E28P	-6.74	4.51e-11	1.16e-08	-0.39	-0.3	Obesity-related traits;	chr2:158837311	chr2:158862311~158863285:+
THCA	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-6.74	4.51e-11	1.16e-08	-0.31	-0.3	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
THCA	cis	rs741668	0.894	rs2031633	ENSG00000235903.6	CPB2-AS1	6.74	4.51e-11	1.16e-08	0.4	0.3	Cerebrospinal fluid clusterin levels;	chr13:46022005	chr13:46052806~46113332:+
THCA	cis	rs7208859	0.725	rs9910051	ENSG00000266490.1	CTD-2349P21.9	6.74	4.52e-11	1.16e-08	0.39	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.725	rs7210904	ENSG00000266490.1	CTD-2349P21.9	6.74	4.52e-11	1.16e-08	0.39	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.725	rs9915802	ENSG00000266490.1	CTD-2349P21.9	6.74	4.52e-11	1.16e-08	0.39	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.725	rs7342938	ENSG00000266490.1	CTD-2349P21.9	6.74	4.52e-11	1.16e-08	0.39	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.725	rs6505215	ENSG00000266490.1	CTD-2349P21.9	6.74	4.52e-11	1.16e-08	0.39	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30792372~30792833:+
THCA	cis	rs4927850	0.709	rs6783079	ENSG00000207650.1	MIR570	6.74	4.52e-11	1.16e-08	0.37	0.3	Pancreatic cancer;	chr3:195925837	chr3:195699401~195699497:+
THCA	cis	rs4927850	0.709	rs6765762	ENSG00000207650.1	MIR570	6.74	4.52e-11	1.16e-08	0.37	0.3	Pancreatic cancer;	chr3:195925980	chr3:195699401~195699497:+
THCA	cis	rs9813712	0.595	rs1901787	ENSG00000228252.7	COL6A4P2	6.74	4.53e-11	1.16e-08	0.3	0.3	Response to amphetamines;	chr3:130288678	chr3:130212823~130273806:+
THCA	cis	rs3806843	0.766	rs6848	ENSG00000202515.1	VTRNA1-3	6.74	4.53e-11	1.16e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140706477	chr5:140726158~140726246:+
THCA	cis	rs7580658	0.929	rs2276583	ENSG00000236682.1	AC068282.3	-6.74	4.53e-11	1.16e-08	-0.39	-0.3	Protein C levels;	chr2:127257108	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.929	rs4662575	ENSG00000236682.1	AC068282.3	-6.74	4.53e-11	1.16e-08	-0.39	-0.3	Protein C levels;	chr2:127264639	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.929	rs11886231	ENSG00000236682.1	AC068282.3	-6.74	4.53e-11	1.16e-08	-0.39	-0.3	Protein C levels;	chr2:127270554	chr2:127389130~127400580:+
THCA	cis	rs6600671	0.967	rs4844613	ENSG00000270392.2	PFN1P2	6.74	4.53e-11	1.16e-08	0.29	0.3	Hip geometry;	chr1:121431913	chr1:120432204~120434052:-
THCA	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-6.74	4.54e-11	1.17e-08	-0.38	-0.3	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
THCA	cis	rs6672530	0.518	rs10916156	ENSG00000227711.2	RP11-275O4.5	6.74	4.54e-11	1.17e-08	0.31	0.3	Hip circumference adjusted for BMI;	chr1:227525576	chr1:227509028~227520477:-
THCA	cis	rs2243480	1	rs10807701	ENSG00000228409.4	CCT6P1	-6.74	4.55e-11	1.17e-08	-0.35	-0.3	Diabetic kidney disease;	chr7:66259699	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1499613	ENSG00000228409.4	CCT6P1	-6.74	4.55e-11	1.17e-08	-0.35	-0.3	Diabetic kidney disease;	chr7:66265873	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1553174	ENSG00000228409.4	CCT6P1	-6.74	4.55e-11	1.17e-08	-0.35	-0.3	Diabetic kidney disease;	chr7:66266207	chr7:65751142~65763354:+
THCA	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	6.74	4.57e-11	1.17e-08	0.37	0.3	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
THCA	cis	rs6600671	1	rs7532615	ENSG00000270392.2	PFN1P2	-6.74	4.57e-11	1.17e-08	-0.3	-0.3	Hip geometry;	chr1:121430980	chr1:120432204~120434052:-
THCA	cis	rs10129255	0.826	rs7150693	ENSG00000211974.3	IGHV2-70	6.74	4.57e-11	1.17e-08	0.24	0.3	Kawasaki disease;	chr14:106705382	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.869	rs7150549	ENSG00000211974.3	IGHV2-70	6.74	4.57e-11	1.17e-08	0.24	0.3	Kawasaki disease;	chr14:106705441	chr14:106723574~106724093:-
THCA	cis	rs516805	0.634	rs2816142	ENSG00000279453.1	RP3-425C14.4	6.74	4.6e-11	1.18e-08	0.34	0.3	Lymphocyte counts;	chr6:122177653	chr6:122436789~122439223:-
THCA	cis	rs867529	1	rs11681299	ENSG00000234028.3	AC062029.1	6.74	4.6e-11	1.18e-08	0.25	0.3	Height;	chr2:88602214	chr2:88627539~88631821:+
THCA	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	6.74	4.6e-11	1.18e-08	0.34	0.3	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
THCA	cis	rs4845570	1	rs4845579	ENSG00000203288.3	RP11-98D18.9	-6.74	4.6e-11	1.18e-08	-0.29	-0.3	Coronary artery disease;	chr1:151797662	chr1:151790804~151794402:+
THCA	cis	rs9475752	1	rs71564868	ENSG00000231441.1	RP11-472M19.2	6.74	4.6e-11	1.18e-08	0.38	0.3	Menarche (age at onset);	chr6:56933643	chr6:56844002~56864078:+
THCA	cis	rs35260072	1	rs35260072	ENSG00000233006.5	AC034220.3	6.74	4.61e-11	1.18e-08	0.24	0.3	Itch intensity from mosquito bite;	chr5:132295159	chr5:132311285~132369916:-
THCA	cis	rs11018904	0.906	rs55685917	ENSG00000280385.1	AP000648.5	-6.74	4.61e-11	1.18e-08	-0.39	-0.3	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90193614~90198120:+
THCA	cis	rs11018904	0.906	rs35286339	ENSG00000280385.1	AP000648.5	-6.74	4.61e-11	1.18e-08	-0.39	-0.3	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90193614~90198120:+
THCA	cis	rs853679	0.723	rs9366718	ENSG00000280107.1	AL022393.9	-6.74	4.61e-11	1.18e-08	-0.37	-0.3	Depression;	chr6:28237724	chr6:28170845~28172521:+
THCA	cis	rs55665837	0.701	rs2007361	ENSG00000251991.1	RNU7-49P	6.74	4.61e-11	1.18e-08	0.34	0.3	Vitamin D levels;	chr11:14641176	chr11:14478892~14478953:+
THCA	cis	rs7760535	0.764	rs2343614	ENSG00000230177.1	RP5-1112D6.4	-6.74	4.62e-11	1.18e-08	-0.23	-0.3	Metabolic traits;	chr6:111383955	chr6:111277932~111278742:+
THCA	cis	rs73607972	0.935	rs73605911	ENSG00000275191.1	RP11-36I17.2	-6.74	4.62e-11	1.18e-08	-0.47	-0.3	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53597184	chr16:53628256~53628816:-
THCA	cis	rs73607972	0.866	rs111763946	ENSG00000275191.1	RP11-36I17.2	-6.74	4.62e-11	1.18e-08	-0.47	-0.3	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602740	chr16:53628256~53628816:-
THCA	cis	rs7688540	0.76	rs12506250	ENSG00000211553.1	AC253576.2	-6.74	4.62e-11	1.18e-08	-0.41	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:136461~136568:+
THCA	cis	rs7688540	0.76	rs2883229	ENSG00000211553.1	AC253576.2	-6.74	4.62e-11	1.18e-08	-0.41	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:136461~136568:+
THCA	cis	rs7688540	0.76	rs4510422	ENSG00000211553.1	AC253576.2	-6.74	4.62e-11	1.18e-08	-0.41	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:136461~136568:+
THCA	cis	rs45509595	0.841	rs370155	ENSG00000219392.1	RP1-265C24.5	-6.74	4.62e-11	1.19e-08	-0.51	-0.3	Breast cancer;	chr6:27814253	chr6:28115628~28116551:+
THCA	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	6.74	4.62e-11	1.19e-08	0.38	0.3	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
THCA	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	6.74	4.62e-11	1.19e-08	0.38	0.3	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
THCA	cis	rs2408955	0.715	rs1793957	ENSG00000240399.1	RP1-228P16.1	6.74	4.63e-11	1.19e-08	0.3	0.3	Glycated hemoglobin levels;	chr12:47999041	chr12:48054813~48055591:-
THCA	cis	rs4950322	0.857	rs55790545	ENSG00000237188.3	RP11-337C18.8	6.74	4.63e-11	1.19e-08	0.37	0.3	Protein quantitative trait loci;	chr1:147366649	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.857	rs7522219	ENSG00000237188.3	RP11-337C18.8	6.74	4.63e-11	1.19e-08	0.37	0.3	Protein quantitative trait loci;	chr1:147366904	chr1:147172771~147211568:+
THCA	cis	rs6061231	0.571	rs482010	ENSG00000273619.1	RP5-908M14.9	6.74	4.63e-11	1.19e-08	0.24	0.3	Colorectal cancer;	chr20:62352495	chr20:62386303~62386970:-
THCA	cis	rs748404	0.66	rs690367	ENSG00000166763.7	STRCP1	-6.74	4.64e-11	1.19e-08	-0.32	-0.3	Lung cancer;	chr15:43456106	chr15:43699488~43718184:-
THCA	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-6.74	4.64e-11	1.19e-08	-0.41	-0.3	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
THCA	cis	rs4664293	0.867	rs2303550	ENSG00000226266.5	AC009961.3	-6.74	4.64e-11	1.19e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159781110	chr2:159670708~159712435:-
THCA	cis	rs12928939	0.911	rs77823468	ENSG00000260886.1	TAT-AS1	6.74	4.64e-11	1.19e-08	0.4	0.3	Post bronchodilator FEV1;	chr16:71794713	chr16:71565789~71578187:+
THCA	cis	rs7267979	0.844	rs6107027	ENSG00000274414.1	RP5-965G21.4	-6.74	4.65e-11	1.19e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25239007~25245229:-
THCA	cis	rs7119038	0.629	rs11216994	ENSG00000255239.1	AP002954.6	-6.74	4.65e-11	1.19e-08	-0.43	-0.3	Sjögren's syndrome;	chr11:118732811	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.629	rs11216995	ENSG00000255239.1	AP002954.6	-6.74	4.65e-11	1.19e-08	-0.43	-0.3	Sjögren's syndrome;	chr11:118732817	chr11:118688039~118690600:-
THCA	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	6.74	4.66e-11	1.19e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
THCA	cis	rs925255	0.81	rs2048240	ENSG00000270210.1	RP11-373D23.3	6.74	4.66e-11	1.19e-08	0.3	0.3	Inflammatory bowel disease;Crohn's disease;	chr2:28417460	chr2:28425945~28426719:+
THCA	cis	rs7851660	0.844	rs10119853	ENSG00000236130.1	PTCSC2	-6.74	4.66e-11	1.19e-08	-0.24	-0.3	Strep throat;	chr9:97862699	chr9:97805935~97810008:-
THCA	cis	rs7267979	1	rs6115153	ENSG00000274414.1	RP5-965G21.4	6.74	4.66e-11	1.19e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs7268053	ENSG00000274414.1	RP5-965G21.4	6.74	4.66e-11	1.19e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6083809	ENSG00000274414.1	RP5-965G21.4	6.74	4.66e-11	1.19e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25239007~25245229:-
THCA	cis	rs4819052	0.62	rs421619	ENSG00000223768.1	LINC00205	-6.74	4.67e-11	1.2e-08	-0.31	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45126200	chr21:45293285~45297354:+
THCA	cis	rs2562456	0.72	rs6511250	ENSG00000213976.4	CTD-2561J22.2	6.74	4.67e-11	1.2e-08	0.32	0.3	Pain;	chr19:21473244	chr19:21382865~21387177:+
THCA	cis	rs9847710	0.869	rs2564917	ENSG00000242142.1	SERBP1P3	6.74	4.67e-11	1.2e-08	0.32	0.3	Ulcerative colitis;	chr3:53003679	chr3:53064283~53065091:-
THCA	cis	rs7267979	1	rs2257420	ENSG00000274414.1	RP5-965G21.4	-6.74	4.67e-11	1.2e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25239007~25245229:-
THCA	cis	rs875971	1	rs1167411	ENSG00000232559.3	GS1-124K5.12	-6.74	4.68e-11	1.2e-08	-0.29	-0.3	Aortic root size;	chr7:66074277	chr7:66554588~66576923:-
THCA	cis	rs438465	1	rs2997885	ENSG00000226194.4	RP1-137D17.1	6.74	4.68e-11	1.2e-08	0.46	0.3	Corneal astigmatism;	chr6:169468492	chr6:169369998~169388385:-
THCA	cis	rs7247513	0.93	rs2861408	ENSG00000213290.4	PGK1P2	-6.74	4.68e-11	1.2e-08	-0.36	-0.3	Bipolar disorder;	chr19:12591285	chr19:12559571~12561105:+
THCA	cis	rs2439831	1	rs2253708	ENSG00000275601.1	AC011330.13	-6.74	4.68e-11	1.2e-08	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43505075	chr15:43642389~43643023:-
THCA	cis	rs1499614	0.901	rs3936	ENSG00000229886.1	RP5-1132H15.3	6.74	4.69e-11	1.2e-08	0.49	0.3	Gout;	chr7:66661502	chr7:66025126~66031544:-
THCA	cis	rs1499614	1	rs1638731	ENSG00000229886.1	RP5-1132H15.3	6.74	4.69e-11	1.2e-08	0.49	0.3	Gout;	chr7:66679692	chr7:66025126~66031544:-
THCA	cis	rs1499614	1	rs1882655	ENSG00000229886.1	RP5-1132H15.3	-6.74	4.69e-11	1.2e-08	-0.49	-0.3	Gout;	chr7:66682070	chr7:66025126~66031544:-
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000229886.1	RP5-1132H15.3	-6.74	4.69e-11	1.2e-08	-0.49	-0.3	Gout;	chr7:66682162	chr7:66025126~66031544:-
THCA	cis	rs17684571	0.872	rs13191164	ENSG00000231441.1	RP11-472M19.2	6.74	4.69e-11	1.2e-08	0.35	0.3	Schizophrenia;	chr6:56701832	chr6:56844002~56864078:+
THCA	cis	rs7267979	0.934	rs2261753	ENSG00000274414.1	RP5-965G21.4	-6.74	4.69e-11	1.2e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25239007~25245229:-
THCA	cis	rs2243480	0.708	rs781141	ENSG00000229886.1	RP5-1132H15.3	6.74	4.69e-11	1.2e-08	0.48	0.3	Diabetic kidney disease;	chr7:65973566	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs313820	ENSG00000228409.4	CCT6P1	6.74	4.7e-11	1.2e-08	0.33	0.3	Diabetic kidney disease;	chr7:66109479	chr7:65751142~65763354:+
THCA	cis	rs7267979	0.966	rs2261790	ENSG00000274414.1	RP5-965G21.4	-6.74	4.7e-11	1.21e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2261794	ENSG00000274414.1	RP5-965G21.4	-6.74	4.7e-11	1.21e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2145126	ENSG00000274414.1	RP5-965G21.4	-6.74	4.7e-11	1.21e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2257705	ENSG00000274414.1	RP5-965G21.4	-6.74	4.7e-11	1.21e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2227892	ENSG00000274414.1	RP5-965G21.4	-6.74	4.7e-11	1.21e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2257712	ENSG00000274414.1	RP5-965G21.4	-6.74	4.7e-11	1.21e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2257461	ENSG00000274414.1	RP5-965G21.4	-6.74	4.7e-11	1.21e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25239007~25245229:-
THCA	cis	rs1005277	0.579	rs1740732	ENSG00000276805.1	RP11-291L22.6	6.74	4.7e-11	1.21e-08	0.32	0.3	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38451030~38451785:+
THCA	cis	rs1198430	0.683	rs1198433	ENSG00000232482.2	RP4-654C18.1	-6.74	4.71e-11	1.21e-08	-0.45	-0.3	Total cholesterol levels;	chr1:23430202	chr1:23410832~23412146:+
THCA	cis	rs2834188	0.883	rs16997869	ENSG00000272659.1	AP000295.10	6.74	4.71e-11	1.21e-08	0.4	0.3	Narcolepsy;	chr21:33324562	chr21:33309491~33310181:+
THCA	cis	rs8062405	0.755	rs62034358	ENSG00000278665.1	RP11-666O2.4	6.74	4.71e-11	1.21e-08	0.35	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.755	rs12445823	ENSG00000278665.1	RP11-666O2.4	6.74	4.71e-11	1.21e-08	0.35	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28599241~28601881:-
THCA	cis	rs16843372	0.576	rs10184397	ENSG00000251491.2	OR7E28P	-6.74	4.71e-11	1.21e-08	-0.4	-0.3	Obesity-related traits;	chr2:158838730	chr2:158862311~158863285:+
THCA	cis	rs71403859	0.554	rs12373065	ENSG00000260886.1	TAT-AS1	6.74	4.72e-11	1.21e-08	0.58	0.3	Post bronchodilator FEV1;	chr16:71836129	chr16:71565789~71578187:+
THCA	cis	rs28386778	0.897	rs2665795	ENSG00000240280.5	TCAM1P	6.74	4.73e-11	1.21e-08	0.41	0.3	Prudent dietary pattern;	chr17:63847912	chr17:63849292~63864379:+
THCA	cis	rs7580658	0.963	rs12479003	ENSG00000236682.1	AC068282.3	-6.74	4.74e-11	1.21e-08	-0.39	-0.3	Protein C levels;	chr2:127360977	chr2:127389130~127400580:+
THCA	cis	rs7189233	1	rs62048491	ENSG00000279344.1	RP11-44F14.7	6.74	4.74e-11	1.21e-08	0.32	0.3	Intelligence (multi-trait analysis);	chr16:53422479	chr16:53478957~53481550:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000229886.1	RP5-1132H15.3	-6.74	4.74e-11	1.21e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66253864	chr7:66025126~66031544:-
THCA	cis	rs4835473	0.897	rs13135627	ENSG00000251600.4	RP11-673E1.1	-6.74	4.75e-11	1.22e-08	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143691099	chr4:143912331~143982454:+
THCA	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	6.74	4.76e-11	1.22e-08	0.32	0.3	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
THCA	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-6.74	4.77e-11	1.22e-08	-0.34	-0.3	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
THCA	cis	rs741668	0.894	rs6561282	ENSG00000235903.6	CPB2-AS1	6.74	4.77e-11	1.22e-08	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:46022607	chr13:46052806~46113332:+
THCA	cis	rs7208859	0.623	rs73271869	ENSG00000263603.1	CTD-2349P21.5	-6.74	4.79e-11	1.23e-08	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73271872	ENSG00000263603.1	CTD-2349P21.5	-6.74	4.79e-11	1.23e-08	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.568	rs9907834	ENSG00000263603.1	CTD-2349P21.5	-6.74	4.79e-11	1.23e-08	-0.53	-0.3	Body mass index;	chr17:30826995	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73271887	ENSG00000263603.1	CTD-2349P21.5	-6.74	4.79e-11	1.23e-08	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9898858	ENSG00000263603.1	CTD-2349P21.5	-6.74	4.79e-11	1.23e-08	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs55658077	ENSG00000263603.1	CTD-2349P21.5	-6.74	4.79e-11	1.23e-08	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9899692	ENSG00000263603.1	CTD-2349P21.5	-6.74	4.79e-11	1.23e-08	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9906957	ENSG00000263603.1	CTD-2349P21.5	-6.74	4.79e-11	1.23e-08	-0.53	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30729469~30731202:+
THCA	cis	rs7119038	0.629	rs10892272	ENSG00000255239.1	AP002954.6	-6.74	4.79e-11	1.23e-08	-0.44	-0.3	Sjögren's syndrome;	chr11:118731998	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.629	rs10892273	ENSG00000255239.1	AP002954.6	-6.74	4.79e-11	1.23e-08	-0.44	-0.3	Sjögren's syndrome;	chr11:118732100	chr11:118688039~118690600:-
THCA	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-6.74	4.8e-11	1.23e-08	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
THCA	cis	rs2976388	1	rs2717562	ENSG00000253741.1	CTD-2292P10.4	6.74	4.8e-11	1.23e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142695250	chr8:142702252~142726973:-
THCA	cis	rs160451	0.966	rs160423	ENSG00000251136.7	RP11-37B2.1	6.73	4.81e-11	1.23e-08	0.26	0.3	Leprosy;	chr8:89658395	chr8:89609409~89757727:-
THCA	cis	rs8027521	0.519	rs59714164	ENSG00000280362.1	RP11-643A5.3	6.73	4.82e-11	1.23e-08	0.36	0.3	Circulating chemerin levels;	chr15:53937790	chr15:53910769~53914712:+
THCA	cis	rs7580658	0.963	rs62157555	ENSG00000236682.1	AC068282.3	-6.73	4.82e-11	1.23e-08	-0.39	-0.3	Protein C levels;	chr2:127349600	chr2:127389130~127400580:+
THCA	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-6.73	4.82e-11	1.23e-08	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
THCA	cis	rs792448	0.743	rs351386	ENSG00000226251.4	RP11-15I11.3	-6.73	4.82e-11	1.23e-08	-0.38	-0.3	White blood cell count (basophil);	chr1:212248429	chr1:212225278~212238977:-
THCA	cis	rs792448	0.743	rs351379	ENSG00000226251.4	RP11-15I11.3	-6.73	4.82e-11	1.23e-08	-0.38	-0.3	White blood cell count (basophil);	chr1:212250447	chr1:212225278~212238977:-
THCA	cis	rs9475752	1	rs1460561	ENSG00000231441.1	RP11-472M19.2	6.73	4.83e-11	1.23e-08	0.39	0.3	Menarche (age at onset);	chr6:56932776	chr6:56844002~56864078:+
THCA	cis	rs4713118	0.955	rs9468200	ENSG00000280107.1	AL022393.9	-6.73	4.83e-11	1.24e-08	-0.34	-0.3	Parkinson's disease;	chr6:27715284	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.955	rs34752872	ENSG00000280107.1	AL022393.9	-6.73	4.83e-11	1.24e-08	-0.34	-0.3	Parkinson's disease;	chr6:27715465	chr6:28170845~28172521:+
THCA	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-6.73	4.83e-11	1.24e-08	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-6.73	4.83e-11	1.24e-08	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
THCA	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-6.73	4.83e-11	1.24e-08	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-6.73	4.83e-11	1.24e-08	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-6.73	4.83e-11	1.24e-08	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-6.73	4.83e-11	1.24e-08	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
THCA	cis	rs2243480	1	rs10950032	ENSG00000228409.4	CCT6P1	-6.73	4.83e-11	1.24e-08	-0.35	-0.3	Diabetic kidney disease;	chr7:66273604	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6958420	ENSG00000228409.4	CCT6P1	-6.73	4.83e-11	1.24e-08	-0.35	-0.3	Diabetic kidney disease;	chr7:66286184	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1392104	ENSG00000228409.4	CCT6P1	-6.73	4.83e-11	1.24e-08	-0.35	-0.3	Diabetic kidney disease;	chr7:66294120	chr7:65751142~65763354:+
THCA	cis	rs3806843	0.733	rs801181	ENSG00000202515.1	VTRNA1-3	6.73	4.83e-11	1.24e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140713229	chr5:140726158~140726246:+
THCA	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	6.73	4.83e-11	1.24e-08	0.74	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
THCA	cis	rs7942368	1	rs1440979	ENSG00000204529.3	GUCY2EP	6.73	4.84e-11	1.24e-08	0.42	0.3	Endometriosis;	chr11:76784085	chr11:76694043~76707641:-
THCA	cis	rs7923837	0.687	rs2185756	ENSG00000236493.2	EIF2S2P3	6.73	4.84e-11	1.24e-08	0.3	0.3	Multiple sclerosis;Body mass index;	chr10:92670740	chr10:92668745~92669743:-
THCA	cis	rs797680	0.586	rs2281525	ENSG00000223745.6	RP4-717I23.3	6.73	4.84e-11	1.24e-08	0.18	0.3	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93129749	chr1:93262186~93346025:-
THCA	cis	rs2929278	0.638	rs2016840	ENSG00000166763.7	STRCP1	-6.73	4.84e-11	1.24e-08	-0.32	-0.3	Schizophrenia;	chr15:43919670	chr15:43699488~43718184:-
THCA	cis	rs12435908	1	rs75927128	ENSG00000276116.2	FUT8-AS1	-6.73	4.84e-11	1.24e-08	-0.48	-0.3	Ischemic stroke;	chr14:65428602	chr14:65411170~65412690:-
THCA	cis	rs12435908	0.881	rs77144060	ENSG00000276116.2	FUT8-AS1	-6.73	4.84e-11	1.24e-08	-0.48	-0.3	Ischemic stroke;	chr14:65428605	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs60927973	ENSG00000276116.2	FUT8-AS1	-6.73	4.84e-11	1.24e-08	-0.48	-0.3	Ischemic stroke;	chr14:65430613	chr14:65411170~65412690:-
THCA	cis	rs9318086	0.537	rs7993131	ENSG00000205861.10	C1QTNF9B-AS1	6.73	4.85e-11	1.24e-08	0.33	0.3	Myopia (pathological);	chr13:23723014	chr13:23888889~23897263:+
THCA	cis	rs853679	1	rs10456362	ENSG00000219392.1	RP1-265C24.5	6.73	4.85e-11	1.24e-08	0.44	0.3	Depression;	chr6:28254038	chr6:28115628~28116551:+
THCA	cis	rs6504622	0.905	rs3851787	ENSG00000262879.4	RP11-156P1.3	6.73	4.85e-11	1.24e-08	0.27	0.3	Orofacial clefts;	chr17:46969616	chr17:46984045~47100323:-
THCA	cis	rs2380205	0.546	rs633928	ENSG00000232807.2	RP11-536K7.3	-6.73	4.87e-11	1.24e-08	-0.27	-0.3	Breast cancer;	chr10:5902547	chr10:5934270~5945900:-
THCA	cis	rs3806843	1	rs2098058	ENSG00000202515.1	VTRNA1-3	6.73	4.87e-11	1.25e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140777842	chr5:140726158~140726246:+
THCA	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	6.73	4.87e-11	1.25e-08	0.3	0.3	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	6.73	4.87e-11	1.25e-08	0.3	0.3	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
THCA	cis	rs6539288	0.705	rs1053051	ENSG00000260329.1	RP11-412D9.4	-6.73	4.87e-11	1.25e-08	-0.27	-0.3	Total body bone mineral density;	chr12:106973447	chr12:106954029~106955497:-
THCA	cis	rs4835473	0.897	rs1450246	ENSG00000251600.4	RP11-673E1.1	6.73	4.88e-11	1.25e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143702954	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs7695328	ENSG00000251600.4	RP11-673E1.1	6.73	4.88e-11	1.25e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143703768	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs57137521	ENSG00000251600.4	RP11-673E1.1	-6.73	4.88e-11	1.25e-08	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143704045	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs55945293	ENSG00000251600.4	RP11-673E1.1	-6.73	4.88e-11	1.25e-08	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143704766	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs924234	ENSG00000251600.4	RP11-673E1.1	6.73	4.88e-11	1.25e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143706799	chr4:143912331~143982454:+
THCA	cis	rs3806843	0.868	rs2563281	ENSG00000202515.1	VTRNA1-3	6.73	4.88e-11	1.25e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751634	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.9	rs2563280	ENSG00000202515.1	VTRNA1-3	6.73	4.88e-11	1.25e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751945	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.838	rs2262567	ENSG00000202515.1	VTRNA1-3	6.73	4.88e-11	1.25e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140752549	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.838	rs2337514	ENSG00000202515.1	VTRNA1-3	6.73	4.88e-11	1.25e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140753147	chr5:140726158~140726246:+
THCA	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-6.73	4.88e-11	1.25e-08	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
THCA	cis	rs7586673	0.578	rs6723840	ENSG00000227403.1	AC009299.3	-6.73	4.88e-11	1.25e-08	-0.37	-0.3	Intelligence (multi-trait analysis);	chr2:161023104	chr2:161244739~161249050:+
THCA	cis	rs7586673	0.578	rs6723841	ENSG00000227403.1	AC009299.3	-6.73	4.88e-11	1.25e-08	-0.37	-0.3	Intelligence (multi-trait analysis);	chr2:161023105	chr2:161244739~161249050:+
THCA	cis	rs6928977	0.675	rs7759971	ENSG00000231028.7	LINC00271	-6.73	4.88e-11	1.25e-08	-0.25	-0.3	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135425746	chr6:135497801~135716055:+
THCA	cis	rs4835473	0.897	rs1545437	ENSG00000251600.4	RP11-673E1.1	-6.73	4.89e-11	1.25e-08	-0.39	-0.3	Immature fraction of reticulocytes;	chr4:143696689	chr4:143912331~143982454:+
THCA	cis	rs6504622	0.905	rs736603	ENSG00000262879.4	RP11-156P1.3	6.73	4.9e-11	1.25e-08	0.27	0.3	Orofacial clefts;	chr17:46947379	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.905	rs736604	ENSG00000262879.4	RP11-156P1.3	6.73	4.9e-11	1.25e-08	0.27	0.3	Orofacial clefts;	chr17:46947443	chr17:46984045~47100323:-
THCA	cis	rs34375054	0.573	rs12581367	ENSG00000279233.1	RP11-158L12.4	6.73	4.9e-11	1.25e-08	0.31	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125170095	chr12:125138245~125141711:+
THCA	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	6.73	4.9e-11	1.25e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
THCA	cis	rs2439831	1	rs690436	ENSG00000275601.1	AC011330.13	-6.73	4.91e-11	1.26e-08	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43469007	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2264239	ENSG00000275601.1	AC011330.13	-6.73	4.91e-11	1.26e-08	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43473335	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2439831	ENSG00000275601.1	AC011330.13	-6.73	4.91e-11	1.26e-08	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43492277	chr15:43642389~43643023:-
THCA	cis	rs12347191	0.5	rs907578	ENSG00000236130.1	PTCSC2	-6.73	4.92e-11	1.26e-08	-0.25	-0.3	Orofacial clefts;	chr9:97860601	chr9:97805935~97810008:-
THCA	cis	rs4664293	0.805	rs7593273	ENSG00000226266.5	AC009961.3	-6.73	4.92e-11	1.26e-08	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159749349	chr2:159670708~159712435:-
THCA	cis	rs741668	0.931	rs61953331	ENSG00000235903.6	CPB2-AS1	6.73	4.92e-11	1.26e-08	0.4	0.3	Cerebrospinal fluid clusterin levels;	chr13:46015336	chr13:46052806~46113332:+
THCA	cis	rs748404	0.66	rs493377	ENSG00000166763.7	STRCP1	6.73	4.93e-11	1.26e-08	0.32	0.3	Lung cancer;	chr15:43481269	chr15:43699488~43718184:-
THCA	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	6.73	4.93e-11	1.26e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs1597446	ENSG00000251600.4	RP11-673E1.1	6.73	4.93e-11	1.26e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143708338	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.835	rs1450247	ENSG00000251600.4	RP11-673E1.1	6.73	4.93e-11	1.26e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143708529	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs7687317	ENSG00000251600.4	RP11-673E1.1	6.73	4.93e-11	1.26e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143709010	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs6537171	ENSG00000251600.4	RP11-673E1.1	6.73	4.93e-11	1.26e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143709222	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	6.73	4.93e-11	1.26e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	6.73	4.93e-11	1.26e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs1553070	ENSG00000251600.4	RP11-673E1.1	6.73	4.93e-11	1.26e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143715981	chr4:143912331~143982454:+
THCA	cis	rs12819124	0.502	rs10875718	ENSG00000240399.1	RP1-228P16.1	6.73	4.93e-11	1.26e-08	0.31	0.3	Glycated hemoglobin levels;	chr12:48017319	chr12:48054813~48055591:-
THCA	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	6.73	4.93e-11	1.26e-08	0.4	0.3	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
THCA	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-6.73	4.93e-11	1.26e-08	-0.43	-0.3	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-6.73	4.93e-11	1.26e-08	-0.43	-0.3	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
THCA	cis	rs17345786	0.602	rs11923273	ENSG00000256628.3	ZBTB11-AS1	6.73	4.93e-11	1.26e-08	0.36	0.3	Colonoscopy-negative controls vs population controls;	chr3:101619019	chr3:101676475~101679217:+
THCA	cis	rs7267979	1	rs6037095	ENSG00000274414.1	RP5-965G21.4	6.73	4.94e-11	1.26e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050562	ENSG00000274414.1	RP5-965G21.4	6.73	4.94e-11	1.26e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4815407	ENSG00000274414.1	RP5-965G21.4	6.73	4.94e-11	1.26e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25239007~25245229:-
THCA	cis	rs2018683	0.523	rs886834	ENSG00000228421.2	AC005013.5	6.73	4.94e-11	1.26e-08	0.35	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28981720	chr7:28957667~28959345:+
THCA	cis	rs1501911	0.509	rs692759	ENSG00000246763.5	RGMB-AS1	-6.73	4.94e-11	1.26e-08	-0.29	-0.3	Lung function (FEV1/FVC);	chr5:98856841	chr5:98769618~98773469:-
THCA	cis	rs4266144	1	rs4266144	ENSG00000241770.1	RP11-555M1.3	-6.73	4.95e-11	1.26e-08	-0.37	-0.3	Coronary artery disease;	chr3:157134803	chr3:157163452~157169133:+
THCA	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	6.73	4.95e-11	1.27e-08	0.38	0.3	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
THCA	cis	rs3806843	0.766	rs801399	ENSG00000202515.1	VTRNA1-3	6.73	4.96e-11	1.27e-08	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr5:140726158~140726246:+
THCA	cis	rs741668	0.931	rs2806926	ENSG00000235903.6	CPB2-AS1	6.73	4.96e-11	1.27e-08	0.39	0.3	Cerebrospinal fluid clusterin levels;	chr13:45947532	chr13:46052806~46113332:+
THCA	cis	rs1552244	0.765	rs17050675	ENSG00000232901.1	CYCSP10	6.73	4.97e-11	1.27e-08	0.38	0.3	Alzheimer's disease;	chr3:9986002	chr3:10000647~10000940:-
THCA	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-6.73	4.97e-11	1.27e-08	-0.28	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
THCA	cis	rs897984	0.609	rs35468353	ENSG00000279196.1	RP11-1072A3.3	6.73	4.98e-11	1.27e-08	0.29	0.3	Dementia with Lewy bodies;	chr16:31045112	chr16:30984630~30988270:-
THCA	cis	rs897984	0.609	rs11862744	ENSG00000279196.1	RP11-1072A3.3	6.73	4.98e-11	1.27e-08	0.29	0.3	Dementia with Lewy bodies;	chr16:31046479	chr16:30984630~30988270:-
THCA	cis	rs7189233	0.955	rs11540358	ENSG00000279344.1	RP11-44F14.7	6.73	4.98e-11	1.27e-08	0.31	0.3	Intelligence (multi-trait analysis);	chr16:53470031	chr16:53478957~53481550:-
THCA	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-6.73	4.98e-11	1.27e-08	-0.33	-0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
THCA	cis	rs17684571	0.938	rs16888118	ENSG00000231441.1	RP11-472M19.2	6.73	4.98e-11	1.27e-08	0.36	0.3	Schizophrenia;	chr6:56687838	chr6:56844002~56864078:+
THCA	cis	rs728616	0.867	rs56235549	ENSG00000225484.5	NUTM2B-AS1	-6.73	4.98e-11	1.27e-08	-0.56	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80075192	chr10:79663088~79826594:-
THCA	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	6.73	4.99e-11	1.27e-08	0.37	0.3	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
THCA	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	6.73	4.99e-11	1.27e-08	0.25	0.3	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
THCA	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	6.73	4.99e-11	1.27e-08	0.25	0.3	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
THCA	cis	rs897984	0.645	rs58726213	ENSG00000279196.1	RP11-1072A3.3	6.73	4.99e-11	1.28e-08	0.3	0.3	Dementia with Lewy bodies;	chr16:31033362	chr16:30984630~30988270:-
THCA	cis	rs7430456	0.837	rs7651130	ENSG00000228221.4	LINC00578	6.73	5e-11	1.28e-08	0.38	0.3	Breast cancer;	chr3:177719720	chr3:177441921~177752305:+
THCA	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-6.73	5e-11	1.28e-08	-0.28	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
THCA	cis	rs5742933	0.857	rs13021611	ENSG00000273240.1	RP11-455J20.3	6.73	5.02e-11	1.28e-08	0.31	0.3	Ferritin levels;	chr2:189700038	chr2:189763859~189764456:-
THCA	cis	rs467650	0.517	rs469491	ENSG00000246763.5	RGMB-AS1	6.73	5.02e-11	1.28e-08	0.29	0.3	Venous thromboembolism (SNP x SNP interaction);	chr5:98599799	chr5:98769618~98773469:-
THCA	cis	rs5758659	1	rs134869	ENSG00000182057.4	OGFRP1	6.73	5.03e-11	1.28e-08	0.34	0.3	Cognitive function;	chr22:42256068	chr22:42269753~42275196:+
THCA	cis	rs2239557	1	rs11159067	ENSG00000259065.1	RP5-1021I20.1	-6.73	5.03e-11	1.29e-08	-0.37	-0.3	Common traits (Other);	chr14:74170741	chr14:73787360~73803270:+
THCA	cis	rs4722166	0.599	rs7776857	ENSG00000179428.2	AC073072.5	-6.73	5.03e-11	1.29e-08	-0.4	-0.3	Lung cancer;	chr7:22715149	chr7:22725395~22727620:-
THCA	cis	rs934734	0.563	rs11684155	ENSG00000237979.1	AC007389.1	6.73	5.05e-11	1.29e-08	0.36	0.3	Rheumatoid arthritis;	chr2:65354166	chr2:65500993~65502138:-
THCA	cis	rs3806843	0.9	rs2531341	ENSG00000202515.1	VTRNA1-3	6.73	5.05e-11	1.29e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751309	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.9	rs2531340	ENSG00000202515.1	VTRNA1-3	6.73	5.05e-11	1.29e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751461	chr5:140726158~140726246:+
THCA	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	6.73	5.05e-11	1.29e-08	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
THCA	cis	rs1005277	0.505	rs10827835	ENSG00000263064.2	RP11-291L22.7	-6.73	5.05e-11	1.29e-08	-0.33	-0.3	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38448689~38448949:+
THCA	cis	rs2281636	0.66	rs7072263	ENSG00000233690.1	EBAG9P1	6.73	5.05e-11	1.29e-08	0.33	0.3	Obesity-related traits;	chr10:99607888	chr10:99697407~99697949:-
THCA	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-6.73	5.06e-11	1.29e-08	-0.38	-0.3	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
THCA	cis	rs4713118	0.869	rs9283880	ENSG00000280107.1	AL022393.9	-6.73	5.06e-11	1.29e-08	-0.34	-0.3	Parkinson's disease;	chr6:27747464	chr6:28170845~28172521:+
THCA	cis	rs7189233	0.955	rs7184800	ENSG00000279722.1	RP11-44F14.6	-6.73	5.06e-11	1.29e-08	-0.31	-0.3	Intelligence (multi-trait analysis);	chr16:53475219	chr16:53487607~53489943:-
THCA	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	6.73	5.06e-11	1.29e-08	0.39	0.3	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
THCA	cis	rs9402743	1	rs7739635	ENSG00000231028.7	LINC00271	-6.73	5.06e-11	1.29e-08	-0.23	-0.3	Systemic lupus erythematosus;	chr6:135676640	chr6:135497801~135716055:+
THCA	cis	rs516805	0.63	rs2606606	ENSG00000279453.1	RP3-425C14.4	-6.73	5.06e-11	1.29e-08	-0.32	-0.3	Lymphocyte counts;	chr6:122201126	chr6:122436789~122439223:-
THCA	cis	rs7942368	0.941	rs737185	ENSG00000204529.3	GUCY2EP	6.73	5.08e-11	1.3e-08	0.42	0.3	Endometriosis;	chr11:76774314	chr11:76694043~76707641:-
THCA	cis	rs4073416	0.872	rs7156078	ENSG00000276116.2	FUT8-AS1	6.73	5.09e-11	1.3e-08	0.3	0.3	N-glycan levels;	chr14:65771983	chr14:65411170~65412690:-
THCA	cis	rs467650	0.509	rs27391	ENSG00000246763.5	RGMB-AS1	6.73	5.09e-11	1.3e-08	0.29	0.3	Venous thromboembolism (SNP x SNP interaction);	chr5:98644719	chr5:98769618~98773469:-
THCA	cis	rs71386933	0.543	rs36114735	ENSG00000260886.1	TAT-AS1	6.73	5.09e-11	1.3e-08	0.65	0.3	Post bronchodilator FEV1;	chr16:71983784	chr16:71565789~71578187:+
THCA	cis	rs4835473	0.897	rs6832722	ENSG00000251600.4	RP11-673E1.1	6.73	5.09e-11	1.3e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143709430	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs6832749	ENSG00000251600.4	RP11-673E1.1	6.73	5.09e-11	1.3e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143709473	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs6831477	ENSG00000251600.4	RP11-673E1.1	6.73	5.09e-11	1.3e-08	0.39	0.3	Immature fraction of reticulocytes;	chr4:143709487	chr4:143912331~143982454:+
THCA	cis	rs9402743	0.634	rs9494306	ENSG00000231028.7	LINC00271	-6.73	5.09e-11	1.3e-08	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135622823	chr6:135497801~135716055:+
THCA	cis	rs7569084	0.566	rs7584295	ENSG00000237979.1	AC007389.1	6.73	5.1e-11	1.3e-08	0.36	0.3	Sum eosinophil basophil counts;	chr2:65353940	chr2:65500993~65502138:-
THCA	cis	rs934734	0.563	rs11695373	ENSG00000237979.1	AC007389.1	6.73	5.1e-11	1.3e-08	0.36	0.3	Rheumatoid arthritis;	chr2:65354066	chr2:65500993~65502138:-
THCA	cis	rs5751614	0.517	rs928780	ENSG00000230701.2	FBXW4P1	6.73	5.11e-11	1.3e-08	0.34	0.3	Height;	chr22:23257682	chr22:23262767~23265005:+
THCA	cis	rs9847710	0.869	rs2581793	ENSG00000242142.1	SERBP1P3	6.73	5.11e-11	1.3e-08	0.32	0.3	Ulcerative colitis;	chr3:53001639	chr3:53064283~53065091:-
THCA	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	6.73	5.11e-11	1.3e-08	0.38	0.3	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
THCA	cis	rs7267979	0.789	rs4815400	ENSG00000274414.1	RP5-965G21.4	6.72	5.11e-11	1.3e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.844	rs2424703	ENSG00000274414.1	RP5-965G21.4	-6.72	5.11e-11	1.3e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.74	rs2259961	ENSG00000274414.1	RP5-965G21.4	-6.72	5.11e-11	1.3e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.844	rs2474780	ENSG00000274414.1	RP5-965G21.4	-6.72	5.11e-11	1.3e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25239007~25245229:-
THCA	cis	rs6569038	0.669	rs2884078	ENSG00000253194.1	RP11-351A11.1	-6.72	5.12e-11	1.31e-08	-0.4	-0.3	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065019	chr6:118934785~119031541:+
THCA	cis	rs1865760	0.688	rs1436310	ENSG00000272462.2	U91328.19	-6.72	5.12e-11	1.31e-08	-0.24	-0.3	Height;	chr6:25969730	chr6:25992662~26001775:+
THCA	cis	rs2834188	1	rs2834188	ENSG00000272659.1	AP000295.10	-6.72	5.12e-11	1.31e-08	-0.4	-0.3	Narcolepsy;	chr21:33316948	chr21:33309491~33310181:+
THCA	cis	rs2834188	0.961	rs8130807	ENSG00000272659.1	AP000295.10	-6.72	5.12e-11	1.31e-08	-0.4	-0.3	Narcolepsy;	chr21:33317708	chr21:33309491~33310181:+
THCA	cis	rs79349575	0.783	rs58591767	ENSG00000248278.1	SUMO2P17	6.72	5.13e-11	1.31e-08	0.35	0.3	Type 2 diabetes;	chr17:48948714	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs59270107	ENSG00000248278.1	SUMO2P17	6.72	5.13e-11	1.31e-08	0.35	0.3	Type 2 diabetes;	chr17:48948823	chr17:48874860~48908983:-
THCA	cis	rs55665837	0.701	rs11023272	ENSG00000251991.1	RNU7-49P	6.72	5.14e-11	1.31e-08	0.34	0.3	Vitamin D levels;	chr11:14608824	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.665	rs11023273	ENSG00000251991.1	RNU7-49P	6.72	5.14e-11	1.31e-08	0.34	0.3	Vitamin D levels;	chr11:14609273	chr11:14478892~14478953:+
THCA	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	6.72	5.14e-11	1.31e-08	0.37	0.3	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	6.72	5.14e-11	1.31e-08	0.37	0.3	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
THCA	cis	rs11158026	0.757	rs72715573	ENSG00000258413.1	RP11-665C16.6	-6.72	5.14e-11	1.31e-08	-0.41	-0.3	Parkinson's disease;	chr14:54992853	chr14:55262767~55272075:-
THCA	cis	rs2239547	0.603	rs6805298	ENSG00000242142.1	SERBP1P3	-6.72	5.15e-11	1.31e-08	-0.38	-0.3	Schizophrenia;	chr3:53062536	chr3:53064283~53065091:-
THCA	cis	rs7976269	0.515	rs10743637	ENSG00000257176.2	RP11-996F15.2	6.72	5.15e-11	1.31e-08	0.3	0.3	Male-pattern baldness;	chr12:29025962	chr12:29280418~29317848:-
THCA	cis	rs224090	0.601	rs10761661	ENSG00000238280.1	RP11-436D10.3	-6.72	5.15e-11	1.31e-08	-0.37	-0.3	Crohn's disease;	chr10:62765375	chr10:62793562~62805887:-
THCA	cis	rs7267979	1	rs6050566	ENSG00000274414.1	RP5-965G21.4	6.72	5.16e-11	1.32e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4813563	ENSG00000274414.1	RP5-965G21.4	6.72	5.16e-11	1.32e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs6037103	ENSG00000274414.1	RP5-965G21.4	6.72	5.16e-11	1.32e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25239007~25245229:-
THCA	cis	rs516805	0.667	rs2816139	ENSG00000279453.1	RP3-425C14.4	-6.72	5.16e-11	1.32e-08	-0.34	-0.3	Lymphocyte counts;	chr6:122182267	chr6:122436789~122439223:-
THCA	cis	rs523522	0.962	rs4767912	ENSG00000278344.1	RP11-18C24.8	6.72	5.17e-11	1.32e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120543399	chr12:120500735~120501090:-
THCA	cis	rs7267979	1	rs6050565	ENSG00000274414.1	RP5-965G21.4	6.72	5.17e-11	1.32e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25239007~25245229:-
THCA	cis	rs12701220	0.895	rs12534778	ENSG00000229043.2	AC091729.9	6.72	5.18e-11	1.32e-08	0.41	0.3	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1160374~1165267:+
THCA	cis	rs2841233	0.681	rs2841235	ENSG00000258701.1	LINC00638	6.72	5.18e-11	1.32e-08	0.31	0.3	IgG glycosylation;	chr14:104882396	chr14:104821201~104823718:+
THCA	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	6.72	5.18e-11	1.32e-08	0.37	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
THCA	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-6.72	5.18e-11	1.32e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
THCA	cis	rs3806843	0.9	rs2262576	ENSG00000202515.1	VTRNA1-3	6.72	5.19e-11	1.32e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140755951	chr5:140726158~140726246:+
THCA	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	6.72	5.19e-11	1.32e-08	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
THCA	cis	rs11668609	0.748	rs8112938	ENSG00000268442.1	CTD-2027I19.2	6.72	5.19e-11	1.32e-08	0.35	0.3	Response to taxane treatment (docetaxel);	chr19:24169654	chr19:24162370~24163425:-
THCA	cis	rs4947019	0.609	rs4946977	ENSG00000260273.1	RP11-425D10.10	6.72	5.19e-11	1.32e-08	0.64	0.3	Hematological parameters;	chr6:109454163	chr6:109382795~109383666:+
THCA	cis	rs875971	0.862	rs709609	ENSG00000232559.3	GS1-124K5.12	-6.72	5.2e-11	1.33e-08	-0.29	-0.3	Aortic root size;	chr7:66095574	chr7:66554588~66576923:-
THCA	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	6.72	5.21e-11	1.33e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	6.72	5.21e-11	1.33e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	6.72	5.21e-11	1.33e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	6.72	5.21e-11	1.33e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	6.72	5.21e-11	1.33e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	6.72	5.21e-11	1.33e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	6.72	5.21e-11	1.33e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	6.72	5.21e-11	1.33e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
THCA	cis	rs7246657	0.943	rs4802766	ENSG00000226686.6	LINC01535	-6.72	5.21e-11	1.33e-08	-0.44	-0.3	Coronary artery calcification;	chr19:37491031	chr19:37251912~37265535:+
THCA	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-6.72	5.22e-11	1.33e-08	-0.26	-0.3	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
THCA	cis	rs9402743	0.634	rs9494289	ENSG00000231028.7	LINC00271	-6.72	5.22e-11	1.33e-08	-0.24	-0.3	Systemic lupus erythematosus;	chr6:135594751	chr6:135497801~135716055:+
THCA	cis	rs12435908	1	rs73286169	ENSG00000276116.2	FUT8-AS1	-6.72	5.22e-11	1.33e-08	-0.48	-0.3	Ischemic stroke;	chr14:65611730	chr14:65411170~65412690:-
THCA	cis	rs4950322	0.547	rs61838945	ENSG00000237188.3	RP11-337C18.8	6.72	5.22e-11	1.33e-08	0.36	0.3	Protein quantitative trait loci;	chr1:147111477	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.563	rs6686480	ENSG00000237188.3	RP11-337C18.8	6.72	5.22e-11	1.33e-08	0.36	0.3	Protein quantitative trait loci;	chr1:147111986	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.563	rs6700783	ENSG00000237188.3	RP11-337C18.8	6.72	5.22e-11	1.33e-08	0.36	0.3	Protein quantitative trait loci;	chr1:147111987	chr1:147172771~147211568:+
THCA	cis	rs7247513	0.964	rs4414604	ENSG00000213290.4	PGK1P2	-6.72	5.23e-11	1.33e-08	-0.36	-0.3	Bipolar disorder;	chr19:12591623	chr19:12559571~12561105:+
THCA	cis	rs7746199	0.736	rs58616630	ENSG00000219392.1	RP1-265C24.5	-6.72	5.23e-11	1.33e-08	-0.65	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs34573979	ENSG00000219392.1	RP1-265C24.5	-6.72	5.23e-11	1.33e-08	-0.65	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28115628~28116551:+
THCA	cis	rs516805	0.667	rs2816078	ENSG00000279453.1	RP3-425C14.4	-6.72	5.23e-11	1.33e-08	-0.32	-0.3	Lymphocyte counts;	chr6:122201755	chr6:122436789~122439223:-
THCA	cis	rs516805	0.597	rs666046	ENSG00000279453.1	RP3-425C14.4	-6.72	5.24e-11	1.33e-08	-0.33	-0.3	Lymphocyte counts;	chr6:122290427	chr6:122436789~122439223:-
THCA	cis	rs741668	0.931	rs61953332	ENSG00000235903.6	CPB2-AS1	6.72	5.24e-11	1.33e-08	0.41	0.3	Cerebrospinal fluid clusterin levels;	chr13:46016139	chr13:46052806~46113332:+
THCA	cis	rs6540731	1	rs951623	ENSG00000226251.4	RP11-15I11.3	-6.72	5.24e-11	1.34e-08	-0.37	-0.3	Intelligence (childhood);	chr1:212225720	chr1:212225278~212238977:-
THCA	cis	rs1005277	0.505	rs7917943	ENSG00000263064.2	RP11-291L22.7	-6.72	5.24e-11	1.34e-08	-0.33	-0.3	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38448689~38448949:+
THCA	cis	rs7246657	0.943	rs10420722	ENSG00000226686.6	LINC01535	-6.72	5.24e-11	1.34e-08	-0.44	-0.3	Coronary artery calcification;	chr19:37482872	chr19:37251912~37265535:+
THCA	cis	rs4072705	1	rs3739760	ENSG00000224020.1	MIR181A2HG	-6.72	5.24e-11	1.34e-08	-0.26	-0.3	Menarche (age at onset);	chr9:124690925	chr9:124658467~124698631:+
THCA	cis	rs4664293	0.867	rs12617546	ENSG00000226266.5	AC009961.3	-6.72	5.25e-11	1.34e-08	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159767079	chr2:159670708~159712435:-
THCA	cis	rs8012947	0.527	rs1190981	ENSG00000279636.2	LINC00216	-6.72	5.25e-11	1.34e-08	-0.29	-0.3	Alcohol consumption in current drinkers;	chr14:58348357	chr14:58288033~58289158:+
THCA	cis	rs13113518	0.513	rs13132085	ENSG00000273257.1	RP11-177J6.1	-6.72	5.26e-11	1.34e-08	-0.4	-0.3	Height;	chr4:55593918	chr4:55387949~55388271:+
THCA	cis	rs5742933	0.817	rs3816196	ENSG00000273240.1	RP11-455J20.3	6.72	5.27e-11	1.34e-08	0.3	0.3	Ferritin levels;	chr2:189775749	chr2:189763859~189764456:-
THCA	cis	rs7208859	0.725	rs9891656	ENSG00000264538.5	SUZ12P1	-6.72	5.27e-11	1.34e-08	-0.29	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30709299~30790908:+
THCA	cis	rs367615	0.642	rs439182	ENSG00000249476.1	CTD-2587M2.1	-6.72	5.28e-11	1.35e-08	-0.33	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109616666	chr5:109237120~109326369:-
THCA	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	6.72	5.29e-11	1.35e-08	0.32	0.3	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
THCA	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	6.72	5.29e-11	1.35e-08	0.32	0.3	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
THCA	cis	rs10165862	0.572	rs11674212	ENSG00000163016.8	ALMS1P	6.72	5.29e-11	1.35e-08	0.46	0.3	Intelligence (multi-trait analysis);	chr2:73684053	chr2:73644919~73685576:+
THCA	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	6.72	5.3e-11	1.35e-08	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
THCA	cis	rs7580658	0.963	rs867304	ENSG00000236682.1	AC068282.3	-6.72	5.3e-11	1.35e-08	-0.39	-0.3	Protein C levels;	chr2:127320912	chr2:127389130~127400580:+
THCA	cis	rs7580658	0.963	rs12622436	ENSG00000236682.1	AC068282.3	-6.72	5.3e-11	1.35e-08	-0.39	-0.3	Protein C levels;	chr2:127324106	chr2:127389130~127400580:+
THCA	cis	rs55665837	0.701	rs10160597	ENSG00000251991.1	RNU7-49P	6.72	5.3e-11	1.35e-08	0.34	0.3	Vitamin D levels;	chr11:14582446	chr11:14478892~14478953:+
THCA	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-6.72	5.31e-11	1.35e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
THCA	cis	rs2239557	0.961	rs4903200	ENSG00000259065.1	RP5-1021I20.1	6.72	5.32e-11	1.35e-08	0.36	0.3	Common traits (Other);	chr14:74192934	chr14:73787360~73803270:+
THCA	cis	rs7208859	0.673	rs450585	ENSG00000264538.5	SUZ12P1	-6.72	5.33e-11	1.36e-08	-0.28	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30709299~30790908:+
THCA	cis	rs7811142	0.83	rs118119933	ENSG00000078319.8	PMS2P1	-6.72	5.33e-11	1.36e-08	-0.45	-0.3	Platelet count;	chr7:100341427	chr7:100320992~100341908:-
THCA	cis	rs9400467	0.528	rs10872066	ENSG00000271789.1	RP5-1112D6.7	-6.72	5.33e-11	1.36e-08	-0.28	-0.3	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111297126~111298510:+
THCA	cis	rs593531	0.614	rs655719	ENSG00000212961.4	HNRNPA1P40	6.72	5.33e-11	1.36e-08	0.38	0.3	Neuroticism;	chr11:74331196	chr11:74354443~74355720:+
THCA	cis	rs4664293	0.833	rs3764969	ENSG00000226266.5	AC009961.3	-6.72	5.34e-11	1.36e-08	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159764337	chr2:159670708~159712435:-
THCA	cis	rs4713118	0.869	rs6914924	ENSG00000280107.1	AL022393.9	-6.72	5.35e-11	1.36e-08	-0.34	-0.3	Parkinson's disease;	chr6:27743751	chr6:28170845~28172521:+
THCA	cis	rs4266144	0.821	rs56237906	ENSG00000241770.1	RP11-555M1.3	-6.72	5.35e-11	1.36e-08	-0.39	-0.3	Coronary artery disease;	chr3:157134684	chr3:157163452~157169133:+
THCA	cis	rs7044106	0.762	rs12003646	ENSG00000238181.2	AHCYP2	-6.72	5.36e-11	1.36e-08	-0.38	-0.3	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120720673~120721972:+
THCA	cis	rs1499614	1	rs2707832	ENSG00000228409.4	CCT6P1	6.72	5.37e-11	1.37e-08	0.35	0.3	Gout;	chr7:66671562	chr7:65751142~65763354:+
THCA	cis	rs7617773	0.746	rs4130995	ENSG00000228638.1	FCF1P2	-6.72	5.37e-11	1.37e-08	-0.28	-0.3	Coronary artery disease;	chr3:48316765	chr3:48290793~48291375:-
THCA	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-6.72	5.37e-11	1.37e-08	-0.52	-0.3	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
THCA	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-6.72	5.37e-11	1.37e-08	-0.37	-0.3	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
THCA	cis	rs56804039	0.895	rs11776995	ENSG00000253893.2	FAM85B	6.72	5.37e-11	1.37e-08	0.42	0.3	Cervical cancer;	chr8:8528037	chr8:8167819~8226614:-
THCA	cis	rs2288884	1	rs58817690	ENSG00000275055.1	CTC-471J1.11	-6.72	5.38e-11	1.37e-08	-0.29	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52033439	chr19:52049007~52049754:+
THCA	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-6.72	5.38e-11	1.37e-08	-0.3	-0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
THCA	cis	rs3806843	0.619	rs2569160	ENSG00000202515.1	VTRNA1-3	6.72	5.39e-11	1.37e-08	0.34	0.3	Depressive symptoms (multi-trait analysis);	chr5:140649189	chr5:140726158~140726246:+
THCA	cis	rs7044106	0.791	rs10985009	ENSG00000270917.1	RP11-27I1.6	6.72	5.39e-11	1.37e-08	0.41	0.3	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120812475~120812845:-
THCA	cis	rs7267979	0.714	rs1555329	ENSG00000274414.1	RP5-965G21.4	-6.72	5.4e-11	1.37e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.714	rs3787082	ENSG00000274414.1	RP5-965G21.4	-6.72	5.4e-11	1.37e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.714	rs6115107	ENSG00000274414.1	RP5-965G21.4	-6.72	5.4e-11	1.37e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25239007~25245229:-
THCA	cis	rs4835473	0.864	rs7681559	ENSG00000251600.4	RP11-673E1.1	-6.72	5.4e-11	1.37e-08	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143695248	chr4:143912331~143982454:+
THCA	cis	rs71636778	0.509	rs78581866	ENSG00000260063.1	RP5-968P14.2	-6.72	5.4e-11	1.37e-08	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921075	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs11538549	ENSG00000260063.1	RP5-968P14.2	-6.72	5.4e-11	1.37e-08	-0.57	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921792	chr1:26692132~26694131:-
THCA	cis	rs8007846	0.588	rs11627605	ENSG00000276116.2	FUT8-AS1	6.72	5.4e-11	1.37e-08	0.3	0.3	Multiple sclerosis--Brain Glutamate Levels;	chr14:65767595	chr14:65411170~65412690:-
THCA	cis	rs240993	0.812	rs9374262	ENSG00000230177.1	RP5-1112D6.4	6.72	5.41e-11	1.38e-08	0.31	0.3	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111277932~111278742:+
THCA	cis	rs7267979	0.899	rs442834	ENSG00000274414.1	RP5-965G21.4	-6.72	5.41e-11	1.38e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.932	rs417110	ENSG00000274414.1	RP5-965G21.4	-6.72	5.41e-11	1.38e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.932	rs449703	ENSG00000274414.1	RP5-965G21.4	-6.72	5.41e-11	1.38e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25239007~25245229:-
THCA	cis	rs2243480	1	rs4149468	ENSG00000229886.1	RP5-1132H15.3	6.72	5.41e-11	1.38e-08	0.49	0.3	Diabetic kidney disease;	chr7:66360703	chr7:66025126~66031544:-
THCA	cis	rs2976388	1	rs2920298	ENSG00000253741.1	CTD-2292P10.4	6.72	5.42e-11	1.38e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142681625	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2920297	ENSG00000253741.1	CTD-2292P10.4	6.72	5.42e-11	1.38e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142681665	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2920296	ENSG00000253741.1	CTD-2292P10.4	6.72	5.42e-11	1.38e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142681691	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs1045531	ENSG00000253741.1	CTD-2292P10.4	6.72	5.42e-11	1.38e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142682129	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2976394	ENSG00000253741.1	CTD-2292P10.4	6.72	5.42e-11	1.38e-08	0.37	0.3	Urinary tract infection frequency;	chr8:142682204	chr8:142702252~142726973:-
THCA	cis	rs160451	1	rs160449	ENSG00000251136.7	RP11-37B2.1	6.72	5.42e-11	1.38e-08	0.25	0.3	Leprosy;	chr8:89648287	chr8:89609409~89757727:-
THCA	cis	rs8007846	0.615	rs11627578	ENSG00000276116.2	FUT8-AS1	6.72	5.42e-11	1.38e-08	0.29	0.3	Multiple sclerosis--Brain Glutamate Levels;	chr14:65767730	chr14:65411170~65412690:-
THCA	cis	rs2243480	1	rs781157	ENSG00000229886.1	RP5-1132H15.3	6.72	5.42e-11	1.38e-08	0.47	0.3	Diabetic kidney disease;	chr7:66013324	chr7:66025126~66031544:-
THCA	cis	rs1005277	0.638	rs1005278	ENSG00000263064.2	RP11-291L22.7	-6.72	5.43e-11	1.38e-08	-0.34	-0.3	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:38448689~38448949:+
THCA	cis	rs6723226	0.593	rs176401	ENSG00000276334.1	AL133243.1	-6.72	5.43e-11	1.38e-08	-0.34	-0.3	Intelligence (multi-trait analysis);	chr2:32411443	chr2:32521927~32523547:+
THCA	cis	rs4845875	0.6	rs1889293	ENSG00000242349.4	NPPA-AS1	6.72	5.44e-11	1.38e-08	0.31	0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11780805	chr1:11841017~11848079:+
THCA	cis	rs11158026	0.757	rs8019220	ENSG00000258413.1	RP11-665C16.6	-6.71	5.44e-11	1.38e-08	-0.41	-0.3	Parkinson's disease;	chr14:54986751	chr14:55262767~55272075:-
THCA	cis	rs453301	0.522	rs2929309	ENSG00000254153.1	CTA-398F10.2	6.71	5.45e-11	1.39e-08	0.31	0.3	Joint mobility (Beighton score);	chr8:9226261	chr8:8456909~8461337:-
THCA	cis	rs9376098	0.825	rs6569999	ENSG00000232876.1	CTA-212D2.2	6.71	5.45e-11	1.39e-08	0.35	0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161428	chr6:135055033~135060550:+
THCA	cis	rs10899021	1	rs11236211	ENSG00000279353.1	RP11-864N7.4	6.71	5.47e-11	1.39e-08	0.67	0.3	Response to metformin (IC50);	chr11:74682166	chr11:74698231~74699658:-
THCA	cis	rs71636778	0.509	rs34667713	ENSG00000260063.1	RP5-968P14.2	-6.71	5.47e-11	1.39e-08	-0.58	-0.3	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26966187	chr1:26692132~26694131:-
THCA	cis	rs7189233	0.956	rs62048490	ENSG00000279344.1	RP11-44F14.7	6.71	5.47e-11	1.39e-08	0.31	0.3	Intelligence (multi-trait analysis);	chr16:53422364	chr16:53478957~53481550:-
THCA	cis	rs4784934	1	rs9928581	ENSG00000260186.4	RP11-481J2.2	6.71	5.48e-11	1.39e-08	0.43	0.3	QT interval;	chr16:58427461	chr16:58421326~58462470:+
THCA	cis	rs1005277	0.505	rs200935	ENSG00000263064.2	RP11-291L22.7	6.71	5.48e-11	1.39e-08	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38448689~38448949:+
THCA	cis	rs12701220	0.857	rs1057558	ENSG00000229043.2	AC091729.9	-6.71	5.48e-11	1.39e-08	-0.39	-0.3	Bronchopulmonary dysplasia;	chr7:1022730	chr7:1160374~1165267:+
THCA	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-6.71	5.5e-11	1.4e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
THCA	cis	rs7221109	0.711	rs1358174	ENSG00000278834.1	RP11-458J1.1	6.71	5.51e-11	1.4e-08	0.31	0.3	Type 1 diabetes;	chr17:40601507	chr17:40648300~40649718:+
THCA	cis	rs690037	0.673	rs690573	ENSG00000272529.1	RP11-415F23.4	6.71	5.51e-11	1.4e-08	0.27	0.3	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334933	chr3:16345126~16346440:+
THCA	cis	rs9287719	0.649	rs2160258	ENSG00000243819.4	RN7SL832P	6.71	5.51e-11	1.4e-08	0.24	0.3	Prostate cancer;	chr2:10577095	chr2:10690344~10692099:+
THCA	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-6.71	5.52e-11	1.4e-08	-0.77	-0.3	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
THCA	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	6.71	5.52e-11	1.4e-08	0.38	0.3	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	6.71	5.52e-11	1.4e-08	0.38	0.3	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	6.71	5.52e-11	1.4e-08	0.38	0.3	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
THCA	cis	rs453301	0.522	rs2929455	ENSG00000254153.1	CTA-398F10.2	6.71	5.52e-11	1.4e-08	0.31	0.3	Joint mobility (Beighton score);	chr8:9225923	chr8:8456909~8461337:-
THCA	cis	rs2439831	1	rs690436	ENSG00000249839.1	AC011330.5	-6.71	5.54e-11	1.41e-08	-0.43	-0.3	Lung cancer in ever smokers;	chr15:43469007	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2264239	ENSG00000249839.1	AC011330.5	-6.71	5.54e-11	1.41e-08	-0.43	-0.3	Lung cancer in ever smokers;	chr15:43473335	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2439831	ENSG00000249839.1	AC011330.5	-6.71	5.54e-11	1.41e-08	-0.43	-0.3	Lung cancer in ever smokers;	chr15:43492277	chr15:43663654~43684339:-
THCA	cis	rs2976388	0.525	rs2016749	ENSG00000253741.1	CTD-2292P10.4	6.71	5.54e-11	1.41e-08	0.38	0.3	Urinary tract infection frequency;	chr8:142754700	chr8:142702252~142726973:-
THCA	cis	rs7615952	0.866	rs13063119	ENSG00000241288.6	RP11-379B18.5	-6.71	5.54e-11	1.41e-08	-0.37	-0.3	Blood pressure (smoking interaction);	chr3:125925004	chr3:125827238~125916384:-
THCA	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-6.71	5.55e-11	1.41e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
THCA	cis	rs523522	0.962	rs12814055	ENSG00000278344.1	RP11-18C24.8	6.71	5.55e-11	1.41e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120549588	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs12371550	ENSG00000278344.1	RP11-18C24.8	6.71	5.55e-11	1.41e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120549840	chr12:120500735~120501090:-
THCA	cis	rs367615	0.68	rs114059	ENSG00000249476.1	CTD-2587M2.1	6.71	5.56e-11	1.41e-08	0.34	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109652086	chr5:109237120~109326369:-
THCA	cis	rs523522	0.962	rs2168319	ENSG00000278344.1	RP11-18C24.8	6.71	5.56e-11	1.41e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120495414	chr12:120500735~120501090:-
THCA	cis	rs7403037	1	rs7402778	ENSG00000259905.4	PWRN1	6.71	5.57e-11	1.41e-08	0.33	0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24529801	chr15:24493137~24652130:+
THCA	cis	rs12435908	1	rs1998035	ENSG00000276116.2	FUT8-AS1	-6.71	5.57e-11	1.41e-08	-0.48	-0.3	Ischemic stroke;	chr14:65659512	chr14:65411170~65412690:-
THCA	cis	rs2018683	0.621	rs10261556	ENSG00000228421.2	AC005013.5	6.71	5.57e-11	1.41e-08	0.33	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28937019	chr7:28957667~28959345:+
THCA	cis	rs8014204	0.604	rs2159906	ENSG00000279594.1	RP11-950C14.10	6.71	5.57e-11	1.42e-08	0.29	0.3	Caffeine consumption;	chr14:74924209	chr14:75011269~75012851:-
THCA	cis	rs76935404	0.773	rs72480748	ENSG00000256612.6	CYP2B7P	-6.71	5.57e-11	1.42e-08	-0.39	-0.3	nicotine metabolite ratio in current smokers;	chr19:40908576	chr19:40924219~40950660:+
THCA	cis	rs7044106	0.791	rs10739572	ENSG00000270917.1	RP11-27I1.6	-6.71	5.59e-11	1.42e-08	-0.42	-0.3	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120812475~120812845:-
THCA	cis	rs6496044	0.568	rs4842888	ENSG00000259295.5	CSPG4P12	-6.71	5.59e-11	1.42e-08	-0.37	-0.3	Interstitial lung disease;	chr15:85519902	chr15:85191438~85213905:+
THCA	cis	rs55823223	0.646	rs55868394	ENSG00000267801.1	RP11-552F3.9	6.71	5.59e-11	1.42e-08	0.53	0.3	Psoriasis;	chr17:75855032	chr17:75876372~75879546:+
THCA	cis	rs7324557	0.717	rs6490826	ENSG00000205861.10	C1QTNF9B-AS1	-6.71	5.6e-11	1.42e-08	-0.37	-0.3	Visceral adipose tissue adjusted for BMI;	chr13:23804999	chr13:23888889~23897263:+
THCA	cis	rs651907	0.535	rs13085776	ENSG00000256628.3	ZBTB11-AS1	6.71	5.6e-11	1.42e-08	0.37	0.3	Colorectal cancer;	chr3:101786663	chr3:101676475~101679217:+
THCA	cis	rs7512898	0.9	rs7535122	ENSG00000260088.1	RP11-92G12.3	6.71	5.6e-11	1.42e-08	0.37	0.3	Electrocardiographic conduction measures;	chr1:200703571	chr1:200669507~200694250:+
THCA	cis	rs9287719	0.578	rs7598541	ENSG00000243819.4	RN7SL832P	6.71	5.61e-11	1.42e-08	0.25	0.3	Prostate cancer;	chr2:10560390	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.578	rs10175555	ENSG00000243819.4	RN7SL832P	6.71	5.61e-11	1.42e-08	0.25	0.3	Prostate cancer;	chr2:10563107	chr2:10690344~10692099:+
THCA	cis	rs7580658	0.545	rs67996371	ENSG00000236682.1	AC068282.3	-6.71	5.65e-11	1.43e-08	-0.38	-0.3	Protein C levels;	chr2:127195841	chr2:127389130~127400580:+
THCA	cis	rs2243480	1	rs4718334	ENSG00000229886.1	RP5-1132H15.3	-6.71	5.65e-11	1.43e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66324467	chr7:66025126~66031544:-
THCA	cis	rs2976388	1	rs2976396	ENSG00000253741.1	CTD-2292P10.4	-6.71	5.65e-11	1.43e-08	-0.38	-0.3	Urinary tract infection frequency;	chr8:142682583	chr8:142702252~142726973:-
THCA	cis	rs4819052	0.679	rs2838860	ENSG00000237664.1	LINC00316	-6.71	5.66e-11	1.44e-08	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45338590~45341990:-
THCA	cis	rs6479901	0.841	rs10761721	ENSG00000232075.1	MRPL35P2	-6.71	5.66e-11	1.44e-08	-0.45	-0.3	Intelligence (multi-trait analysis);	chr10:63178644	chr10:63634317~63634827:-
THCA	cis	rs7324557	0.717	rs9510869	ENSG00000205861.10	C1QTNF9B-AS1	-6.71	5.67e-11	1.44e-08	-0.36	-0.3	Visceral adipose tissue adjusted for BMI;	chr13:23809990	chr13:23888889~23897263:+
THCA	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-6.71	5.67e-11	1.44e-08	-0.26	-0.3	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-6.71	5.67e-11	1.44e-08	-0.26	-0.3	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-6.71	5.67e-11	1.44e-08	-0.26	-0.3	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-6.71	5.67e-11	1.44e-08	-0.26	-0.3	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-6.71	5.67e-11	1.44e-08	-0.26	-0.3	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
THCA	cis	rs41307935	0.908	rs34618114	ENSG00000260063.1	RP5-968P14.2	-6.71	5.67e-11	1.44e-08	-0.57	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26771828	chr1:26692132~26694131:-
THCA	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-6.71	5.67e-11	1.44e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-6.71	5.67e-11	1.44e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-6.71	5.67e-11	1.44e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-6.71	5.67e-11	1.44e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-6.71	5.67e-11	1.44e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-6.71	5.67e-11	1.44e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-6.71	5.67e-11	1.44e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
THCA	cis	rs3847687	0.869	rs11061300	ENSG00000279128.1	RP11-76C10.4	6.71	5.67e-11	1.44e-08	0.34	0.3	Longevity;	chr12:131038716	chr12:131022769~131024741:-
THCA	cis	rs8027521	0.56	rs2465196	ENSG00000280362.1	RP11-643A5.3	6.71	5.68e-11	1.44e-08	0.38	0.3	Circulating chemerin levels;	chr15:53954159	chr15:53910769~53914712:+
THCA	cis	rs2243480	1	rs313824	ENSG00000228409.4	CCT6P1	6.71	5.69e-11	1.44e-08	0.33	0.3	Diabetic kidney disease;	chr7:66116220	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs186378	ENSG00000228409.4	CCT6P1	6.71	5.69e-11	1.44e-08	0.33	0.3	Diabetic kidney disease;	chr7:66117071	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs160637	ENSG00000228409.4	CCT6P1	6.71	5.69e-11	1.44e-08	0.33	0.3	Diabetic kidney disease;	chr7:66119331	chr7:65751142~65763354:+
THCA	cis	rs1005277	0.505	rs200936	ENSG00000263064.2	RP11-291L22.7	6.71	5.7e-11	1.45e-08	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.505	rs200937	ENSG00000263064.2	RP11-291L22.7	6.71	5.7e-11	1.45e-08	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38448689~38448949:+
THCA	cis	rs367615	0.591	rs4530812	ENSG00000249476.1	CTD-2587M2.1	-6.71	5.71e-11	1.45e-08	-0.3	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109522886	chr5:109237120~109326369:-
THCA	cis	rs7773456	0.74	rs6917179	ENSG00000237404.1	RP3-471C18.2	6.71	5.71e-11	1.45e-08	0.36	0.3	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19689825~19753113:-
THCA	cis	rs7851660	0.809	rs3824495	ENSG00000236130.1	PTCSC2	6.71	5.71e-11	1.45e-08	0.24	0.3	Strep throat;	chr9:97901418	chr9:97805935~97810008:-
THCA	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-6.71	5.71e-11	1.45e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
THCA	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	6.71	5.72e-11	1.45e-08	0.38	0.3	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
THCA	cis	rs35264875	0.846	rs72930625	ENSG00000259799.1	RP11-554A11.9	6.71	5.72e-11	1.45e-08	0.52	0.3	Blond vs. brown hair color;	chr11:69099652	chr11:69155910~69159752:+
THCA	cis	rs35264875	0.846	rs72930627	ENSG00000259799.1	RP11-554A11.9	6.71	5.72e-11	1.45e-08	0.52	0.3	Blond vs. brown hair color;	chr11:69099653	chr11:69155910~69159752:+
THCA	cis	rs5742933	0.817	rs1055091	ENSG00000273240.1	RP11-455J20.3	6.71	5.73e-11	1.45e-08	0.3	0.3	Ferritin levels;	chr2:189770417	chr2:189763859~189764456:-
THCA	cis	rs10740039	0.516	rs2893840	ENSG00000254271.1	RP11-131N11.4	6.71	5.74e-11	1.45e-08	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60554257	chr10:60734342~60741828:+
THCA	cis	rs7015630	0.648	rs16901016	ENSG00000251136.7	RP11-37B2.1	-6.71	5.74e-11	1.46e-08	-0.31	-0.3	Inflammatory bowel disease;Crohn's disease;	chr8:89839916	chr8:89609409~89757727:-
THCA	cis	rs4713118	0.868	rs7756968	ENSG00000280107.1	AL022393.9	-6.71	5.74e-11	1.46e-08	-0.36	-0.3	Parkinson's disease;	chr6:27767175	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.826	rs2893929	ENSG00000280107.1	AL022393.9	-6.71	5.74e-11	1.46e-08	-0.36	-0.3	Parkinson's disease;	chr6:27770953	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.666	rs4140646	ENSG00000280107.1	AL022393.9	-6.71	5.74e-11	1.46e-08	-0.36	-0.3	Parkinson's disease;	chr6:27771022	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.666	rs2893930	ENSG00000280107.1	AL022393.9	-6.71	5.74e-11	1.46e-08	-0.36	-0.3	Parkinson's disease;	chr6:27771027	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.868	rs742047	ENSG00000280107.1	AL022393.9	-6.71	5.74e-11	1.46e-08	-0.36	-0.3	Parkinson's disease;	chr6:27771601	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.868	rs760587	ENSG00000280107.1	AL022393.9	-6.71	5.74e-11	1.46e-08	-0.36	-0.3	Parkinson's disease;	chr6:27772521	chr6:28170845~28172521:+
THCA	cis	rs9880211	0.898	rs1052620	ENSG00000273486.1	RP11-731C17.2	6.71	5.75e-11	1.46e-08	0.31	0.3	Height;Body mass index;	chr3:136855679	chr3:136837338~136839021:-
THCA	cis	rs847577	0.832	rs1799068	ENSG00000272950.1	RP11-307C18.1	-6.71	5.75e-11	1.46e-08	-0.37	-0.3	Breast cancer;	chr7:98077757	chr7:98322853~98323430:+
THCA	cis	rs7267979	0.934	rs2257464	ENSG00000274414.1	RP5-965G21.4	-6.71	5.76e-11	1.46e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25239007~25245229:-
THCA	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-6.71	5.77e-11	1.46e-08	-0.45	-0.3	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-6.71	5.77e-11	1.46e-08	-0.45	-0.3	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-6.71	5.77e-11	1.46e-08	-0.45	-0.3	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-6.71	5.77e-11	1.46e-08	-0.45	-0.3	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
THCA	cis	rs7189233	0.955	rs8044205	ENSG00000279722.1	RP11-44F14.6	-6.71	5.77e-11	1.46e-08	-0.31	-0.3	Intelligence (multi-trait analysis);	chr16:53481181	chr16:53487607~53489943:-
THCA	cis	rs7189233	0.955	rs8058684	ENSG00000279722.1	RP11-44F14.6	-6.71	5.77e-11	1.46e-08	-0.31	-0.3	Intelligence (multi-trait analysis);	chr16:53481206	chr16:53487607~53489943:-
THCA	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-6.71	5.77e-11	1.46e-08	-0.21	-0.3	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
THCA	cis	rs6840360	0.642	rs1470280	ENSG00000251611.1	RP11-610P16.1	-6.71	5.77e-11	1.46e-08	-0.21	-0.3	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151407551~151408835:-
THCA	cis	rs1667284	0.846	rs1026123	ENSG00000266521.1	RP11-650P15.1	6.71	5.78e-11	1.46e-08	0.36	0.3	Problematic alcohol use in trauma-exposed individuals;	chr18:31627192	chr18:31496645~31497195:-
THCA	cis	rs910316	0.687	rs11627442	ENSG00000279594.1	RP11-950C14.10	-6.71	5.79e-11	1.47e-08	-0.27	-0.3	Height;	chr14:75202946	chr14:75011269~75012851:-
THCA	cis	rs3806843	1	rs3806845	ENSG00000202515.1	VTRNA1-3	-6.7	5.8e-11	1.47e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140801152	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs3733707	ENSG00000202515.1	VTRNA1-3	-6.7	5.8e-11	1.47e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140802307	chr5:140726158~140726246:+
THCA	cis	rs4660456	0.576	rs2780948	ENSG00000237899.1	RP4-739H11.3	-6.7	5.8e-11	1.47e-08	-0.35	-0.3	Platelet count;	chr1:40776205	chr1:40669089~40687588:-
THCA	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	6.7	5.8e-11	1.47e-08	0.26	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
THCA	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-6.7	5.8e-11	1.47e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
THCA	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-6.7	5.81e-11	1.47e-08	-0.41	-0.3	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-6.7	5.81e-11	1.47e-08	-0.41	-0.3	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
THCA	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-6.7	5.81e-11	1.47e-08	-0.49	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
THCA	cis	rs149866169	1	rs149866169	ENSG00000219392.1	RP1-265C24.5	-6.7	5.82e-11	1.47e-08	-0.57	-0.3	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28115628~28116551:+
THCA	cis	rs7267979	0.586	rs1007707	ENSG00000274414.1	RP5-965G21.4	-6.7	5.82e-11	1.48e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25239007~25245229:-
THCA	cis	rs10740039	0.516	rs2393645	ENSG00000254271.1	RP11-131N11.4	6.7	5.82e-11	1.48e-08	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60555269	chr10:60734342~60741828:+
THCA	cis	rs7851660	0.967	rs13288000	ENSG00000214417.4	KRT18P13	-6.7	5.83e-11	1.48e-08	-0.25	-0.3	Strep throat;	chr9:97846698	chr9:97698922~97700734:+
THCA	cis	rs1125355	0.964	rs72939969	ENSG00000251491.2	OR7E28P	-6.7	5.84e-11	1.48e-08	-0.48	-0.3	Alzheimer's disease in APOE e4+ carriers;	chr2:158845256	chr2:158862311~158863285:+
THCA	cis	rs523522	0.962	rs687873	ENSG00000278344.1	RP11-18C24.8	6.7	5.86e-11	1.48e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120581831	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs670568	ENSG00000278344.1	RP11-18C24.8	6.7	5.86e-11	1.48e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120583403	chr12:120500735~120501090:-
THCA	cis	rs523522	0.885	rs524735	ENSG00000278344.1	RP11-18C24.8	6.7	5.86e-11	1.48e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120584296	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs655530	ENSG00000278344.1	RP11-18C24.8	6.7	5.86e-11	1.48e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120584472	chr12:120500735~120501090:-
THCA	cis	rs4689592	0.503	rs56099074	ENSG00000245468.3	RP11-367J11.3	-6.7	5.86e-11	1.48e-08	-0.27	-0.3	Monocyte percentage of white cells;	chr4:7069532	chr4:7094571~7103385:-
THCA	cis	rs6479901	0.512	rs11817169	ENSG00000232075.1	MRPL35P2	6.7	5.86e-11	1.48e-08	0.58	0.3	Intelligence (multi-trait analysis);	chr10:63596549	chr10:63634317~63634827:-
THCA	cis	rs2361718	0.5	rs8064429	ENSG00000279259.1	RP11-334C17.3	6.7	5.87e-11	1.49e-08	0.29	0.3	Yeast infection;	chr17:80122388	chr17:80147250~80148596:+
THCA	cis	rs2439831	0.85	rs7181039	ENSG00000275601.1	AC011330.13	-6.7	5.87e-11	1.49e-08	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43886914	chr15:43642389~43643023:-
THCA	cis	rs7267979	1	rs6050559	ENSG00000274414.1	RP5-965G21.4	-6.7	5.88e-11	1.49e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25239007~25245229:-
THCA	cis	rs853679	0.527	rs853690	ENSG00000219392.1	RP1-265C24.5	-6.7	5.88e-11	1.49e-08	-0.33	-0.3	Depression;	chr6:28317705	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs6930992	ENSG00000280107.1	AL022393.9	-6.7	5.88e-11	1.49e-08	-0.34	-0.3	Parkinson's disease;	chr6:27744341	chr6:28170845~28172521:+
THCA	cis	rs3758785	0.623	rs75164831	ENSG00000255893.1	RP11-685N10.1	-6.7	5.88e-11	1.49e-08	-0.36	-0.3	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94410667	chr11:94472908~94473570:-
THCA	cis	rs3758785	0.562	rs79850307	ENSG00000255893.1	RP11-685N10.1	-6.7	5.88e-11	1.49e-08	-0.36	-0.3	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94411859	chr11:94472908~94473570:-
THCA	cis	rs848490	0.889	rs68153348	ENSG00000214293.7	APTR	6.7	5.88e-11	1.49e-08	0.23	0.3	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77589017	chr7:77657660~77696265:-
THCA	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-6.7	5.88e-11	1.49e-08	-0.4	-0.3	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
THCA	cis	rs453301	0.658	rs9650616	ENSG00000253893.2	FAM85B	6.7	5.89e-11	1.49e-08	0.38	0.3	Joint mobility (Beighton score);	chr8:9011689	chr8:8167819~8226614:-
THCA	cis	rs4835473	0.897	rs7676614	ENSG00000251600.4	RP11-673E1.1	-6.7	5.89e-11	1.49e-08	-0.4	-0.3	Immature fraction of reticulocytes;	chr4:143695213	chr4:143912331~143982454:+
THCA	cis	rs7267979	0.816	rs8115257	ENSG00000274414.1	RP5-965G21.4	-6.7	5.9e-11	1.49e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25239007~25245229:-
THCA	cis	rs10131894	0.611	rs175002	ENSG00000279594.1	RP11-950C14.10	6.7	5.9e-11	1.49e-08	0.27	0.3	Coronary artery disease;	chr14:74969763	chr14:75011269~75012851:-
THCA	cis	rs3822625	1	rs56822906	ENSG00000271828.1	CTD-2310F14.1	6.7	5.91e-11	1.49e-08	0.75	0.3	Breast cancer (early onset);	chr5:56870087	chr5:56927874~56929573:+
THCA	cis	rs438465	1	rs12055542	ENSG00000226194.4	RP1-137D17.1	-6.7	5.91e-11	1.5e-08	-0.45	-0.3	Corneal astigmatism;	chr6:169460886	chr6:169369998~169388385:-
THCA	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-6.7	5.92e-11	1.5e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-6.7	5.92e-11	1.5e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-6.7	5.92e-11	1.5e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-6.7	5.92e-11	1.5e-08	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
THCA	cis	rs7746199	0.736	rs13212318	ENSG00000219392.1	RP1-265C24.5	-6.7	5.93e-11	1.5e-08	-0.66	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs13202291	ENSG00000219392.1	RP1-265C24.5	-6.7	5.93e-11	1.5e-08	-0.66	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs17750424	ENSG00000219392.1	RP1-265C24.5	-6.7	5.93e-11	1.5e-08	-0.66	-0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28115628~28116551:+
THCA	cis	rs2006933	0.625	rs62065057	ENSG00000237575.4	PYY2	6.7	5.93e-11	1.5e-08	0.39	0.3	Amyotrophic lateral sclerosis;	chr17:28114259	chr17:28226563~28228065:+
THCA	cis	rs6600671	0.899	rs2319971	ENSG00000275538.1	RNVU1-19	6.7	5.94e-11	1.5e-08	0.38	0.3	Hip geometry;	chr1:121485184	chr1:120850819~120850985:-
THCA	cis	rs9400467	0.508	rs11153283	ENSG00000271789.1	RP5-1112D6.7	-6.7	5.94e-11	1.5e-08	-0.28	-0.3	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111297126~111298510:+
THCA	cis	rs720475	0.732	rs17195725	ENSG00000204959.4	ARHGEF34P	6.7	5.95e-11	1.5e-08	0.34	0.3	Breast cancer;	chr7:144440044	chr7:144272445~144286966:-
THCA	cis	rs79349575	0.783	rs4793992	ENSG00000248278.1	SUMO2P17	6.7	5.95e-11	1.5e-08	0.34	0.3	Type 2 diabetes;	chr17:48930845	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs56046215	ENSG00000248278.1	SUMO2P17	6.7	5.95e-11	1.5e-08	0.34	0.3	Type 2 diabetes;	chr17:48931395	chr17:48874860~48908983:-
THCA	cis	rs6504622	1	rs1047779	ENSG00000262879.4	RP11-156P1.3	-6.7	5.95e-11	1.5e-08	-0.27	-0.3	Orofacial clefts;	chr17:46941877	chr17:46984045~47100323:-
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000229886.1	RP5-1132H15.3	-6.7	5.96e-11	1.51e-08	-0.49	-0.3	Diabetic kidney disease;	chr7:66219914	chr7:66025126~66031544:-
THCA	cis	rs2834188	1	rs2409488	ENSG00000272659.1	AP000295.10	-6.7	5.96e-11	1.51e-08	-0.4	-0.3	Narcolepsy;	chr21:33316609	chr21:33309491~33310181:+
THCA	cis	rs28386778	0.863	rs6919	ENSG00000240280.5	TCAM1P	6.7	5.97e-11	1.51e-08	0.41	0.3	Prudent dietary pattern;	chr17:63832125	chr17:63849292~63864379:+
THCA	cis	rs8012947	0.565	rs4901852	ENSG00000279636.2	LINC00216	6.7	5.97e-11	1.51e-08	0.28	0.3	Alcohol consumption in current drinkers;	chr14:58355211	chr14:58288033~58289158:+
THCA	cis	rs17270561	0.578	rs76182885	ENSG00000272462.2	U91328.19	-6.7	5.97e-11	1.51e-08	-0.3	-0.3	Iron status biomarkers;	chr6:25903857	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.541	rs12192932	ENSG00000272462.2	U91328.19	-6.7	5.97e-11	1.51e-08	-0.3	-0.3	Iron status biomarkers;	chr6:25911274	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.579	rs10456326	ENSG00000272462.2	U91328.19	-6.7	5.97e-11	1.51e-08	-0.3	-0.3	Iron status biomarkers;	chr6:25919434	chr6:25992662~26001775:+
THCA	cis	rs12216125	0.537	rs12207059	ENSG00000272462.2	U91328.19	-6.7	5.97e-11	1.51e-08	-0.3	-0.3	Iron status biomarkers;	chr6:25922157	chr6:25992662~26001775:+
THCA	cis	rs6545883	0.894	rs2463102	ENSG00000271889.1	RP11-493E12.1	-6.7	5.98e-11	1.51e-08	-0.28	-0.3	Tuberculosis;	chr2:61344160	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.894	rs2593633	ENSG00000271889.1	RP11-493E12.1	-6.7	5.98e-11	1.51e-08	-0.28	-0.3	Tuberculosis;	chr2:61344378	chr2:61151433~61162105:-
THCA	cis	rs11018904	0.906	rs12793836	ENSG00000280385.1	AP000648.5	-6.7	5.99e-11	1.51e-08	-0.39	-0.3	Intelligence (multi-trait analysis);	chr11:90220325	chr11:90193614~90198120:+
THCA	cis	rs4767841	0.552	rs12827937	ENSG00000248636.5	RP11-768F21.1	-6.7	5.99e-11	1.52e-08	-0.31	-0.3	Urgency urinary incontinence;	chr12:119612444	chr12:119387987~119668079:-
THCA	cis	rs7247513	0.964	rs8100964	ENSG00000213290.4	PGK1P2	-6.7	6e-11	1.52e-08	-0.36	-0.3	Bipolar disorder;	chr19:12609817	chr19:12559571~12561105:+
THCA	cis	rs6539288	0.739	rs7302653	ENSG00000260329.1	RP11-412D9.4	-6.7	6e-11	1.52e-08	-0.27	-0.3	Total body bone mineral density;	chr12:106979744	chr12:106954029~106955497:-
THCA	cis	rs28386778	0.897	rs2665833	ENSG00000240280.5	TCAM1P	-6.7	6e-11	1.52e-08	-0.41	-0.3	Prudent dietary pattern;	chr17:63829486	chr17:63849292~63864379:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000228409.4	CCT6P1	-6.7	6e-11	1.52e-08	-0.23	-0.3	Calcium levels;	chr7:65825628	chr7:65751142~65763354:+
THCA	cis	rs7267979	1	rs4815408	ENSG00000274414.1	RP5-965G21.4	6.7	6e-11	1.52e-08	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25239007~25245229:-
THCA	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	6.7	6.01e-11	1.52e-08	0.73	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
THCA	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	6.7	6.01e-11	1.52e-08	0.73	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
THCA	cis	rs7833787	0.832	rs7827258	ENSG00000278886.1	RP11-108A14.1	-6.7	6.01e-11	1.52e-08	-0.38	-0.3	Obesity-related traits;	chr8:18840785	chr8:18864681~18865247:-
THCA	cis	rs7119038	0.509	rs10892260	ENSG00000255239.1	AP002954.6	-6.7	6.02e-11	1.52e-08	-0.45	-0.3	Sjögren's syndrome;	chr11:118712816	chr11:118688039~118690600:-
THCA	cis	rs875971	0.862	rs709596	ENSG00000232559.3	GS1-124K5.12	6.7	6.02e-11	1.52e-08	0.28	0.3	Aortic root size;	chr7:66360926	chr7:66554588~66576923:-
THCA	cis	rs79349575	0.783	rs4399576	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48932473	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.687	rs12602179	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48932672	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs17708633	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48934258	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs9747646	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48939520	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs62075852	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48939814	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs12601858	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48940115	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.715	rs55724082	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48940517	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.749	rs8182364	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48940663	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.681	rs56080003	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48941687	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs4793995	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48942037	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs4793996	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48942235	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.715	rs4793997	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48942310	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs4793998	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48942537	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.749	rs2270574	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48944908	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs4794000	ENSG00000248278.1	SUMO2P17	6.7	6.02e-11	1.52e-08	0.35	0.3	Type 2 diabetes;	chr17:48945393	chr17:48874860~48908983:-
THCA	cis	rs56804039	1	rs59620654	ENSG00000253893.2	FAM85B	6.7	6.02e-11	1.52e-08	0.42	0.3	Cervical cancer;	chr8:8525122	chr8:8167819~8226614:-
THCA	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-6.7	6.03e-11	1.52e-08	-0.32	-0.3	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
THCA	cis	rs2915864	0.8	rs13185299	ENSG00000280047.1	CTC-463A16.1	6.7	6.03e-11	1.52e-08	0.45	0.3	Facial morphology (factor 20);	chr5:142146055	chr5:142165767~142168387:+
THCA	cis	rs2834188	1	rs2834187	ENSG00000272659.1	AP000295.10	-6.7	6.04e-11	1.53e-08	-0.4	-0.3	Narcolepsy;	chr21:33315105	chr21:33309491~33310181:+
THCA	cis	rs28386778	0.562	rs721575	ENSG00000240280.5	TCAM1P	6.7	6.04e-11	1.53e-08	0.41	0.3	Prudent dietary pattern;	chr17:63705560	chr17:63849292~63864379:+
THCA	cis	rs7247513	0.964	rs1007352	ENSG00000213290.4	PGK1P2	-6.7	6.04e-11	1.53e-08	-0.36	-0.3	Bipolar disorder;	chr19:12611731	chr19:12559571~12561105:+
THCA	cis	rs4950322	0.58	rs4950371	ENSG00000237188.3	RP11-337C18.8	6.7	6.05e-11	1.53e-08	0.36	0.3	Protein quantitative trait loci;	chr1:147114243	chr1:147172771~147211568:+
THCA	cis	rs6545883	0.894	rs778144	ENSG00000271889.1	RP11-493E12.1	-6.7	6.05e-11	1.53e-08	-0.28	-0.3	Tuberculosis;	chr2:61355993	chr2:61151433~61162105:-
THCA	cis	rs3806843	1	rs11167600	ENSG00000202515.1	VTRNA1-3	-6.7	6.06e-11	1.53e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140795280	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs3756340	ENSG00000202515.1	VTRNA1-3	-6.7	6.06e-11	1.53e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140800866	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs3756338	ENSG00000202515.1	VTRNA1-3	-6.7	6.06e-11	1.53e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140800976	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs7701755	ENSG00000202515.1	VTRNA1-3	-6.7	6.06e-11	1.53e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140802516	chr5:140726158~140726246:+
THCA	cis	rs797680	0.927	rs797675	ENSG00000223745.6	RP4-717I23.3	6.7	6.07e-11	1.53e-08	0.18	0.3	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93208669	chr1:93262186~93346025:-
THCA	cis	rs9287719	0.625	rs12473787	ENSG00000243819.4	RN7SL832P	6.7	6.07e-11	1.53e-08	0.24	0.3	Prostate cancer;	chr2:10577068	chr2:10690344~10692099:+
THCA	cis	rs7948661	1	rs73615909	ENSG00000278376.1	RP11-158I9.8	6.7	6.07e-11	1.53e-08	0.45	0.3	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118451773	chr11:118791254~118793137:+
THCA	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	6.7	6.08e-11	1.54e-08	0.38	0.3	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
THCA	cis	rs2243480	1	rs1638734	ENSG00000229886.1	RP5-1132H15.3	6.7	6.08e-11	1.54e-08	0.49	0.3	Diabetic kidney disease;	chr7:66632552	chr7:66025126~66031544:-
THCA	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	6.7	6.08e-11	1.54e-08	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
THCA	cis	rs7617773	0.851	rs13068288	ENSG00000228638.1	FCF1P2	-6.7	6.08e-11	1.54e-08	-0.29	-0.3	Coronary artery disease;	chr3:48290261	chr3:48290793~48291375:-
THCA	cis	rs3806843	1	rs10066278	ENSG00000202515.1	VTRNA1-3	-6.7	6.1e-11	1.54e-08	-0.33	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140776733	chr5:140726158~140726246:+
THCA	cis	rs227275	0.524	rs223337	ENSG00000230069.3	LRRC37A15P	-6.7	6.1e-11	1.54e-08	-0.3	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102727274~102730721:-
THCA	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	6.7	6.1e-11	1.54e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
THCA	cis	rs453301	0.507	rs2929306	ENSG00000254153.1	CTA-398F10.2	6.7	6.1e-11	1.54e-08	0.31	0.3	Joint mobility (Beighton score);	chr8:9227399	chr8:8456909~8461337:-
THCA	cis	rs9380516	0.796	rs10947556	ENSG00000228559.1	RP3-340B19.3	-6.7	6.1e-11	1.54e-08	-0.45	-0.3	Hepatitis C induced liver fibrosis;	chr6:35545202	chr6:35544632~35545669:+
THCA	cis	rs9902453	0.834	rs9901694	ENSG00000264007.1	RP11-68I3.10	6.7	6.11e-11	1.54e-08	0.34	0.3	Coffee consumption (cups per day);	chr17:29944627	chr17:29621617~29622254:-
THCA	cis	rs748404	0.66	rs2439846	ENSG00000166763.7	STRCP1	6.7	6.12e-11	1.55e-08	0.31	0.3	Lung cancer;	chr15:43448772	chr15:43699488~43718184:-
THCA	cis	rs748404	0.66	rs2467741	ENSG00000166763.7	STRCP1	6.7	6.12e-11	1.55e-08	0.31	0.3	Lung cancer;	chr15:43450428	chr15:43699488~43718184:-
THCA	cis	rs4713118	0.869	rs6901520	ENSG00000280107.1	AL022393.9	-6.7	6.12e-11	1.55e-08	-0.34	-0.3	Parkinson's disease;	chr6:27746796	chr6:28170845~28172521:+
THCA	cis	rs10266483	1	rs10266483	ENSG00000227986.1	TRIM60P18	-6.7	6.13e-11	1.55e-08	-0.24	-0.3	Response to statin therapy;	chr7:64272953	chr7:64355078~64356199:+
THCA	cis	rs7942368	1	rs10899280	ENSG00000204529.3	GUCY2EP	6.7	6.13e-11	1.55e-08	0.42	0.3	Endometriosis;	chr11:76785693	chr11:76694043~76707641:-
THCA	cis	rs1876905	0.539	rs62420362	ENSG00000255389.1	C6orf3	6.7	6.13e-11	1.55e-08	0.37	0.3	Mean corpuscular hemoglobin;	chr6:111224167	chr6:111599875~111602295:+
THCA	cis	rs10129255	0.912	rs730099	ENSG00000211974.3	IGHV2-70	6.7	6.13e-11	1.55e-08	0.23	0.3	Kawasaki disease;	chr14:106711838	chr14:106723574~106724093:-
THCA	cis	rs6430585	0.528	rs16832440	ENSG00000231890.6	DARS-AS1	-6.7	6.15e-11	1.55e-08	-0.37	-0.3	Corneal structure;	chr2:135996613	chr2:135985176~136022593:+
THCA	cis	rs831571	0.774	rs254858	ENSG00000280620.1	SCAANT1	-6.7	6.15e-11	1.55e-08	-0.42	-0.3	Type 2 diabetes;	chr3:64070579	chr3:63911518~63911772:-
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	6.7	6.15e-11	1.55e-08	0.31	0.3	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
THCA	cis	rs897984	0.806	rs11150600	ENSG00000279196.1	RP11-1072A3.3	-6.7	6.15e-11	1.55e-08	-0.29	-0.3	Dementia with Lewy bodies;	chr16:30929010	chr16:30984630~30988270:-
THCA	cis	rs6928977	0.514	rs2757635	ENSG00000231028.7	LINC00271	6.7	6.15e-11	1.55e-08	0.23	0.3	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135413172	chr6:135497801~135716055:+
THCA	cis	rs2243480	1	rs316307	ENSG00000228409.4	CCT6P1	6.7	6.15e-11	1.55e-08	0.33	0.3	Diabetic kidney disease;	chr7:66105184	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs160646	ENSG00000228409.4	CCT6P1	6.7	6.16e-11	1.55e-08	0.33	0.3	Diabetic kidney disease;	chr7:66091293	chr7:65751142~65763354:+
THCA	cis	rs28386778	0.897	rs2584601	ENSG00000240280.5	TCAM1P	-6.7	6.16e-11	1.56e-08	-0.41	-0.3	Prudent dietary pattern;	chr17:63863617	chr17:63849292~63864379:+
THCA	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	6.69	6.17e-11	1.56e-08	0.29	0.3	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
THCA	cis	rs736801	0.78	rs11951091	ENSG00000224431.1	AC063976.7	6.69	6.17e-11	1.56e-08	0.27	0.3	Mosquito bite size;Breast cancer;	chr5:132450903	chr5:132199456~132203487:+
THCA	cis	rs523522	0.962	rs4767914	ENSG00000278344.1	RP11-18C24.8	6.69	6.18e-11	1.56e-08	0.32	0.3	High light scatter reticulocyte count;	chr12:120556014	chr12:120500735~120501090:-
THCA	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	6.69	6.19e-11	1.56e-08	0.37	0.3	Height;	chr6:109428824	chr6:109382795~109383666:+
THCA	cis	rs944289	0.576	rs1169131	ENSG00000257826.1	RP11-116N8.4	-6.69	6.2e-11	1.56e-08	-0.34	-0.3	Thyroid cancer;	chr14:36153349	chr14:36061026~36067190:-
THCA	cis	rs11976180	1	rs1533268	ENSG00000170356.8	OR2A20P	-6.69	6.2e-11	1.56e-08	-0.4	-0.3	Obesity-related traits;	chr7:144069265	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs1533266	ENSG00000170356.8	OR2A20P	-6.69	6.2e-11	1.56e-08	-0.4	-0.3	Obesity-related traits;	chr7:144069621	chr7:144250045~144252957:-
THCA	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	6.69	6.2e-11	1.56e-08	0.41	0.3	Height;	chr6:109645257	chr6:109382795~109383666:+
THCA	cis	rs28386778	0.863	rs9207	ENSG00000240280.5	TCAM1P	-6.69	6.2e-11	1.56e-08	-0.41	-0.3	Prudent dietary pattern;	chr17:63746539	chr17:63849292~63864379:+
THCA	cis	rs748404	0.66	rs693510	ENSG00000166763.7	STRCP1	6.69	6.2e-11	1.56e-08	0.31	0.3	Lung cancer;	chr15:43422427	chr15:43699488~43718184:-
THCA	cis	rs748404	0.66	rs690512	ENSG00000166763.7	STRCP1	6.69	6.2e-11	1.56e-08	0.31	0.3	Lung cancer;	chr15:43425480	chr15:43699488~43718184:-
THCA	cis	rs748404	0.66	rs542898	ENSG00000166763.7	STRCP1	6.69	6.2e-11	1.56e-08	0.31	0.3	Lung cancer;	chr15:43427194	chr15:43699488~43718184:-
THCA	cis	rs748404	0.66	rs2249952	ENSG00000166763.7	STRCP1	6.69	6.2e-11	1.56e-08	0.31	0.3	Lung cancer;	chr15:43428335	chr15:43699488~43718184:-
THCA	cis	rs748404	0.66	rs689767	ENSG00000166763.7	STRCP1	6.69	6.2e-11	1.56e-08	0.31	0.3	Lung cancer;	chr15:43429879	chr15:43699488~43718184:-
THCA	cis	rs748404	0.66	rs2439845	ENSG00000166763.7	STRCP1	6.69	6.2e-11	1.56e-08	0.31	0.3	Lung cancer;	chr15:43430412	chr15:43699488~43718184:-
THCA	cis	rs748404	0.631	rs2467745	ENSG00000166763.7	STRCP1	6.69	6.2e-11	1.56e-08	0.31	0.3	Lung cancer;	chr15:43430544	chr15:43699488~43718184:-
THCA	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	6.69	6.2e-11	1.56e-08	0.4	0.3	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
THCA	cis	rs3806843	0.832	rs2531360	ENSG00000202515.1	VTRNA1-3	6.69	6.2e-11	1.56e-08	0.33	0.3	Depressive symptoms (multi-trait analysis);	chr5:140737079	chr5:140726158~140726246:+
THCA	cis	rs2243480	1	rs937108	ENSG00000229886.1	RP5-1132H15.3	6.69	6.21e-11	1.57e-08	0.47	0.3	Diabetic kidney disease;	chr7:65963465	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34970380	ENSG00000229886.1	RP5-1132H15.3	6.69	6.21e-11	1.57e-08	0.48	0.3	Diabetic kidney disease;	chr7:65966506	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1723270	ENSG00000229886.1	RP5-1132H15.3	6.69	6.21e-11	1.57e-08	0.48	0.3	Diabetic kidney disease;	chr7:66004843	chr7:66025126~66031544:-
THCA	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-6.69	6.21e-11	1.57e-08	-0.53	-0.3	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
THCA	cis	rs6991838	0.778	rs11779601	ENSG00000200714.1	Y_RNA	6.69	6.21e-11	1.57e-08	0.36	0.3	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65592731~65592820:+
THCA	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-6.69	6.21e-11	1.57e-08	-0.49	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
THCA	cis	rs73252553	0.615	rs1973604	ENSG00000281501.1	SEPSECS-AS1	-6.69	6.23e-11	1.57e-08	-0.4	-0.3	Cannabis dependence symptom count;	chr4:25252741	chr4:25160641~25201440:+
THCA	cis	rs2915864	0.8	rs2043281	ENSG00000280047.1	CTC-463A16.1	6.69	6.23e-11	1.57e-08	0.45	0.29	Facial morphology (factor 20);	chr5:142143290	chr5:142165767~142168387:+
THCA	cis	rs2915864	0.747	rs3850577	ENSG00000280047.1	CTC-463A16.1	6.69	6.23e-11	1.57e-08	0.45	0.29	Facial morphology (factor 20);	chr5:142147398	chr5:142165767~142168387:+
THCA	cis	rs2915864	0.8	rs3911911	ENSG00000280047.1	CTC-463A16.1	6.69	6.23e-11	1.57e-08	0.45	0.29	Facial morphology (factor 20);	chr5:142147632	chr5:142165767~142168387:+
THCA	cis	rs4845875	0.563	rs11121829	ENSG00000242349.4	NPPA-AS1	6.69	6.24e-11	1.57e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11774708	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.6	rs6696752	ENSG00000242349.4	NPPA-AS1	6.69	6.24e-11	1.57e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11775878	chr1:11841017~11848079:+
THCA	cis	rs227275	0.554	rs223334	ENSG00000230069.3	LRRC37A15P	6.69	6.24e-11	1.57e-08	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102727274~102730721:-
THCA	cis	rs11158026	0.79	rs10131633	ENSG00000258413.1	RP11-665C16.6	-6.69	6.24e-11	1.57e-08	-0.4	-0.29	Parkinson's disease;	chr14:54896603	chr14:55262767~55272075:-
THCA	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	6.69	6.24e-11	1.57e-08	0.33	0.29	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	6.69	6.24e-11	1.57e-08	0.33	0.29	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
THCA	cis	rs28386778	0.897	rs2584608	ENSG00000240280.5	TCAM1P	-6.69	6.24e-11	1.57e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63859350	chr17:63849292~63864379:+
THCA	cis	rs2243480	0.908	rs313822	ENSG00000228409.4	CCT6P1	6.69	6.24e-11	1.57e-08	0.33	0.29	Diabetic kidney disease;	chr7:66108952	chr7:65751142~65763354:+
THCA	cis	rs7189233	0.956	rs62048486	ENSG00000279344.1	RP11-44F14.7	6.69	6.25e-11	1.58e-08	0.32	0.29	Intelligence (multi-trait analysis);	chr16:53414427	chr16:53478957~53481550:-
THCA	cis	rs853679	0.607	rs33932084	ENSG00000280107.1	AL022393.9	-6.69	6.25e-11	1.58e-08	-0.56	-0.29	Depression;	chr6:28301047	chr6:28170845~28172521:+
THCA	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	6.69	6.25e-11	1.58e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
THCA	cis	rs4819052	0.679	rs4819053	ENSG00000237664.1	LINC00316	6.69	6.26e-11	1.58e-08	0.29	0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45338590~45341990:-
THCA	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-6.69	6.28e-11	1.58e-08	-0.41	-0.29	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
THCA	cis	rs7851660	0.809	rs35324451	ENSG00000236130.1	PTCSC2	-6.69	6.28e-11	1.58e-08	-0.24	-0.29	Strep throat;	chr9:97897854	chr9:97805935~97810008:-
THCA	cis	rs77204473	1	rs1135663	ENSG00000254851.1	RP11-109L13.1	6.69	6.29e-11	1.58e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116918121	chr11:117135528~117138582:+
THCA	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	6.69	6.29e-11	1.59e-08	0.4	0.29	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
THCA	cis	rs848490	0.962	rs1045463	ENSG00000214293.7	APTR	6.69	6.29e-11	1.59e-08	0.24	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77793835	chr7:77657660~77696265:-
THCA	cis	rs438465	1	rs374076	ENSG00000226194.4	RP1-137D17.1	6.69	6.3e-11	1.59e-08	0.45	0.29	Corneal astigmatism;	chr6:169419680	chr6:169369998~169388385:-
THCA	cis	rs438465	1	rs438465	ENSG00000226194.4	RP1-137D17.1	6.69	6.3e-11	1.59e-08	0.45	0.29	Corneal astigmatism;	chr6:169420286	chr6:169369998~169388385:-
THCA	cis	rs7324557	0.683	rs9510868	ENSG00000205861.10	C1QTNF9B-AS1	-6.69	6.3e-11	1.59e-08	-0.36	-0.29	Visceral adipose tissue adjusted for BMI;	chr13:23809555	chr13:23888889~23897263:+
THCA	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	6.69	6.31e-11	1.59e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
THCA	cis	rs797680	0.789	rs531514	ENSG00000223745.6	RP4-717I23.3	-6.69	6.33e-11	1.6e-08	-0.18	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93234655	chr1:93262186~93346025:-
THCA	cis	rs797680	0.789	rs797671	ENSG00000223745.6	RP4-717I23.3	-6.69	6.33e-11	1.6e-08	-0.18	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93234806	chr1:93262186~93346025:-
THCA	cis	rs2243480	1	rs34702770	ENSG00000229886.1	RP5-1132H15.3	6.69	6.34e-11	1.6e-08	0.47	0.29	Diabetic kidney disease;	chr7:65879836	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34637256	ENSG00000229886.1	RP5-1132H15.3	6.69	6.34e-11	1.6e-08	0.47	0.29	Diabetic kidney disease;	chr7:65895144	chr7:66025126~66031544:-
THCA	cis	rs7302981	0.741	rs10783342	ENSG00000272368.2	RP4-605O3.4	6.69	6.34e-11	1.6e-08	0.18	0.29	Systolic blood pressure;	chr12:50234683	chr12:50112197~50165618:+
THCA	cis	rs1275468	1	rs1148000	ENSG00000257497.2	RP11-585P4.5	-6.69	6.35e-11	1.6e-08	-0.43	-0.29	Polycystic ovary syndrome;	chr12:75542521	chr12:75483454~75489820:-
THCA	cis	rs12928939	0.723	rs34053338	ENSG00000260886.1	TAT-AS1	6.69	6.35e-11	1.6e-08	0.4	0.29	Post bronchodilator FEV1;	chr16:71816071	chr16:71565789~71578187:+
THCA	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-6.69	6.35e-11	1.6e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
THCA	cis	rs4950322	0.58	rs972368	ENSG00000237188.3	RP11-337C18.8	6.69	6.36e-11	1.6e-08	0.36	0.29	Protein quantitative trait loci;	chr1:147111142	chr1:147172771~147211568:+
THCA	cis	rs593531	0.571	rs7934621	ENSG00000212961.4	HNRNPA1P40	6.69	6.37e-11	1.61e-08	0.38	0.29	Neuroticism;	chr11:74379883	chr11:74354443~74355720:+
THCA	cis	rs7267979	1	rs6050598	ENSG00000274414.1	RP5-965G21.4	-6.69	6.38e-11	1.61e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25239007~25245229:-
THCA	cis	rs7260598	0.681	rs62114776	ENSG00000268442.1	CTD-2027I19.2	6.69	6.38e-11	1.61e-08	0.39	0.29	Response to taxane treatment (placlitaxel);	chr19:24054513	chr19:24162370~24163425:-
THCA	cis	rs748404	0.587	rs690276	ENSG00000166763.7	STRCP1	6.69	6.38e-11	1.61e-08	0.32	0.29	Lung cancer;	chr15:43412360	chr15:43699488~43718184:-
THCA	cis	rs4845875	0.53	rs6667720	ENSG00000242349.4	NPPA-AS1	-6.69	6.39e-11	1.61e-08	-0.31	-0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11771558	chr1:11841017~11848079:+
THCA	cis	rs7208859	0.673	rs7211776	ENSG00000263603.1	CTD-2349P21.5	-6.69	6.39e-11	1.61e-08	-0.49	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30729469~30731202:+
THCA	cis	rs12435908	1	rs1953417	ENSG00000276116.2	FUT8-AS1	-6.69	6.39e-11	1.61e-08	-0.46	-0.29	Ischemic stroke;	chr14:65412191	chr14:65411170~65412690:-
THCA	cis	rs16846053	0.71	rs11901817	ENSG00000227403.1	AC009299.3	6.69	6.4e-11	1.61e-08	0.48	0.29	Blood osmolality (transformed sodium);	chr2:161732331	chr2:161244739~161249050:+
THCA	cis	rs7267979	1	rs11087520	ENSG00000274414.1	RP5-965G21.4	-6.69	6.4e-11	1.61e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs398036	ENSG00000274414.1	RP5-965G21.4	-6.69	6.4e-11	1.61e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs397119	ENSG00000274414.1	RP5-965G21.4	-6.69	6.4e-11	1.61e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25239007~25245229:-
THCA	cis	rs17684571	0.938	rs62412526	ENSG00000231441.1	RP11-472M19.2	6.69	6.4e-11	1.61e-08	0.36	0.29	Schizophrenia;	chr6:56689171	chr6:56844002~56864078:+
THCA	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-6.69	6.41e-11	1.61e-08	-0.32	-0.29	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
THCA	cis	rs12681366	0.762	rs6997115	ENSG00000253704.1	RP11-267M23.4	6.69	6.41e-11	1.61e-08	0.29	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94353657	chr8:94553722~94569745:+
THCA	cis	rs4650994	0.525	rs10913567	ENSG00000273384.1	RP5-1098D14.1	6.69	6.42e-11	1.62e-08	0.37	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178542806	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.507	rs12405456	ENSG00000273384.1	RP5-1098D14.1	6.69	6.42e-11	1.62e-08	0.37	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178543196	chr1:178651706~178652282:+
THCA	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	6.69	6.43e-11	1.62e-08	0.36	0.29	Height;	chr6:109355573	chr6:109382795~109383666:+
THCA	cis	rs1609391	0.543	rs2117009	ENSG00000273486.1	RP11-731C17.2	-6.69	6.43e-11	1.62e-08	-0.26	-0.29	Neuroticism;	chr3:136914729	chr3:136837338~136839021:-
THCA	cis	rs6921919	0.562	rs13198809	ENSG00000280107.1	AL022393.9	-6.69	6.43e-11	1.62e-08	-0.58	-0.29	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs35353359	ENSG00000280107.1	AL022393.9	-6.69	6.43e-11	1.62e-08	-0.58	-0.29	Depression;	chr6:28356601	chr6:28170845~28172521:+
THCA	cis	rs7942368	1	rs7933092	ENSG00000204529.3	GUCY2EP	6.69	6.43e-11	1.62e-08	0.41	0.29	Endometriosis;	chr11:76764444	chr11:76694043~76707641:-
THCA	cis	rs1125355	0.964	rs72939960	ENSG00000251491.2	OR7E28P	-6.69	6.44e-11	1.62e-08	-0.47	-0.29	Alzheimer's disease in APOE e4+ carriers;	chr2:158844648	chr2:158862311~158863285:+
THCA	cis	rs848490	0.851	rs62473663	ENSG00000214293.7	APTR	6.69	6.44e-11	1.62e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77587098	chr7:77657660~77696265:-
THCA	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-6.69	6.45e-11	1.62e-08	-0.53	-0.29	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
THCA	cis	rs6903823	0.527	rs4713158	ENSG00000219392.1	RP1-265C24.5	-6.69	6.46e-11	1.63e-08	-0.33	-0.29	Pulmonary function;	chr6:28309994	chr6:28115628~28116551:+
THCA	cis	rs728616	1	rs728616	ENSG00000225484.5	NUTM2B-AS1	-6.69	6.46e-11	1.63e-08	-0.56	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088158	chr10:79663088~79826594:-
THCA	cis	rs5742933	0.857	rs10931430	ENSG00000273240.1	RP11-455J20.3	6.69	6.46e-11	1.63e-08	0.31	0.29	Ferritin levels;	chr2:189677460	chr2:189763859~189764456:-
THCA	cis	rs7247513	0.93	rs1864082	ENSG00000213290.4	PGK1P2	-6.69	6.47e-11	1.63e-08	-0.36	-0.29	Bipolar disorder;	chr19:12597090	chr19:12559571~12561105:+
THCA	cis	rs28386778	0.897	rs2727287	ENSG00000240280.5	TCAM1P	-6.69	6.47e-11	1.63e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63827368	chr17:63849292~63864379:+
THCA	cis	rs7044106	0.512	rs7873848	ENSG00000238181.2	AHCYP2	-6.69	6.47e-11	1.63e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120720673~120721972:+
THCA	cis	rs28510890	0.75	rs17522931	ENSG00000260337.3	RP11-386M24.6	-6.69	6.47e-11	1.63e-08	-0.39	-0.29	Lung cancer in ever smokers;	chr15:92563187	chr15:92592574~92596462:-
THCA	cis	rs2834188	1	rs2843994	ENSG00000272659.1	AP000295.10	-6.69	6.47e-11	1.63e-08	-0.4	-0.29	Narcolepsy;	chr21:33334564	chr21:33309491~33310181:+
THCA	cis	rs6479891	0.818	rs9415700	ENSG00000232075.1	MRPL35P2	6.69	6.48e-11	1.63e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs9415701	ENSG00000232075.1	MRPL35P2	6.69	6.48e-11	1.63e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63634317~63634827:-
THCA	cis	rs7247513	0.866	rs7247171	ENSG00000213290.4	PGK1P2	-6.69	6.48e-11	1.63e-08	-0.36	-0.29	Bipolar disorder;	chr19:12595186	chr19:12559571~12561105:+
THCA	cis	rs7267979	0.866	rs437635	ENSG00000274414.1	RP5-965G21.4	-6.69	6.48e-11	1.63e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25239007~25245229:-
THCA	cis	rs11722228	0.522	rs1109472	ENSG00000261490.1	RP11-448G15.3	6.69	6.48e-11	1.63e-08	0.21	0.29	Urate levels;Serum uric acid levels;Gout;	chr4:10132824	chr4:10068089~10073019:-
THCA	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	6.69	6.49e-11	1.63e-08	0.38	0.29	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
THCA	cis	rs2361701	0.636	rs1982244	ENSG00000279259.1	RP11-334C17.3	6.69	6.49e-11	1.63e-08	0.31	0.29	IgG glycosylation;	chr17:80095149	chr17:80147250~80148596:+
THCA	cis	rs780096	0.778	rs780094	ENSG00000234072.1	AC074117.10	6.69	6.5e-11	1.63e-08	0.23	0.29	Total body bone mineral density;	chr2:27518370	chr2:27356246~27367622:+
THCA	cis	rs7247513	0.797	rs3815914	ENSG00000213290.4	PGK1P2	-6.69	6.51e-11	1.64e-08	-0.35	-0.29	Bipolar disorder;	chr19:12649850	chr19:12559571~12561105:+
THCA	cis	rs8113308	0.515	rs73066981	ENSG00000269235.1	ZNF350-AS1	6.69	6.51e-11	1.64e-08	0.57	0.29	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51959146	chr19:51949134~51981367:+
THCA	cis	rs375066	0.71	rs11881193	ENSG00000267058.1	RP11-15A1.3	6.69	6.51e-11	1.64e-08	0.25	0.29	Breast cancer;	chr19:43917364	chr19:43891804~43901805:-
THCA	cis	rs7727544	0.647	rs72793280	ENSG00000233006.5	AC034220.3	6.69	6.51e-11	1.64e-08	0.24	0.29	Blood metabolite levels;	chr5:132227207	chr5:132311285~132369916:-
THCA	cis	rs6802315	0.74	rs9822005	ENSG00000272247.1	RP11-379F4.9	-6.69	6.52e-11	1.64e-08	-0.28	-0.29	Periodontitis (CDC/AAP);	chr3:158794592	chr3:158801257~158801935:-
THCA	cis	rs523522	0.962	rs10849759	ENSG00000278344.1	RP11-18C24.8	6.69	6.52e-11	1.64e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120556685	chr12:120500735~120501090:-
THCA	cis	rs585510	1	rs585510	ENSG00000278344.1	RP11-18C24.8	6.69	6.52e-11	1.64e-08	0.32	0.29	Reticulocyte fraction of red cells;	chr12:120562330	chr12:120500735~120501090:-
THCA	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	6.69	6.52e-11	1.64e-08	0.32	0.29	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
THCA	cis	rs71636778	0.509	rs71640338	ENSG00000260063.1	RP5-968P14.2	-6.69	6.52e-11	1.64e-08	-0.56	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26684958	chr1:26692132~26694131:-
THCA	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-6.69	6.53e-11	1.64e-08	-0.37	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
THCA	cis	rs12348691	0.503	rs1348386	ENSG00000236130.1	PTCSC2	-6.69	6.54e-11	1.64e-08	-0.26	-0.29	Alopecia areata;	chr9:97850525	chr9:97805935~97810008:-
THCA	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-6.69	6.54e-11	1.65e-08	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
THCA	cis	rs4713118	0.869	rs9366700	ENSG00000280107.1	AL022393.9	-6.69	6.54e-11	1.65e-08	-0.34	-0.29	Parkinson's disease;	chr6:27729172	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs6456802	ENSG00000280107.1	AL022393.9	-6.69	6.54e-11	1.65e-08	-0.34	-0.29	Parkinson's disease;	chr6:27730576	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs9393851	ENSG00000280107.1	AL022393.9	-6.69	6.54e-11	1.65e-08	-0.34	-0.29	Parkinson's disease;	chr6:27731802	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs9461400	ENSG00000280107.1	AL022393.9	-6.69	6.54e-11	1.65e-08	-0.34	-0.29	Parkinson's disease;	chr6:27732780	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs9295742	ENSG00000280107.1	AL022393.9	-6.69	6.54e-11	1.65e-08	-0.34	-0.29	Parkinson's disease;	chr6:27735053	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs9461401	ENSG00000280107.1	AL022393.9	-6.69	6.54e-11	1.65e-08	-0.34	-0.29	Parkinson's disease;	chr6:27735512	chr6:28170845~28172521:+
THCA	cis	rs6539288	0.63	rs3759316	ENSG00000260329.1	RP11-412D9.4	-6.69	6.54e-11	1.65e-08	-0.27	-0.29	Total body bone mineral density;	chr12:106976432	chr12:106954029~106955497:-
THCA	cis	rs523522	0.962	rs509445	ENSG00000278344.1	RP11-18C24.8	6.69	6.56e-11	1.65e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120579440	chr12:120500735~120501090:-
THCA	cis	rs6902257	1	rs6927397	ENSG00000272129.1	RP11-250B2.6	-6.69	6.56e-11	1.65e-08	-0.78	-0.29	Obesity-related traits;	chr6:80610148	chr6:80355424~80356859:+
THCA	cis	rs1275468	0.954	rs1148002	ENSG00000257497.2	RP11-585P4.5	6.69	6.56e-11	1.65e-08	0.43	0.29	Polycystic ovary syndrome;	chr12:75539244	chr12:75483454~75489820:-
THCA	cis	rs45509595	0.841	rs17751184	ENSG00000219392.1	RP1-265C24.5	-6.68	6.56e-11	1.65e-08	-0.66	-0.29	Breast cancer;	chr6:27807250	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs67101035	ENSG00000219392.1	RP1-265C24.5	-6.68	6.56e-11	1.65e-08	-0.66	-0.29	Depression;	chr6:27831109	chr6:28115628~28116551:+
THCA	cis	rs853679	0.556	rs34706883	ENSG00000219392.1	RP1-265C24.5	-6.68	6.56e-11	1.65e-08	-0.66	-0.29	Depression;	chr6:27837477	chr6:28115628~28116551:+
THCA	cis	rs67340775	0.748	rs13212651	ENSG00000219392.1	RP1-265C24.5	-6.68	6.56e-11	1.65e-08	-0.66	-0.29	Lung cancer in ever smokers;	chr6:27839207	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs35819751	ENSG00000219392.1	RP1-265C24.5	-6.68	6.56e-11	1.65e-08	-0.66	-0.29	Depression;	chr6:27842791	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9295743	ENSG00000280107.1	AL022393.9	-6.68	6.57e-11	1.65e-08	-0.34	-0.29	Parkinson's disease;	chr6:27747323	chr6:28170845~28172521:+
THCA	cis	rs2439831	0.867	rs45585139	ENSG00000249839.1	AC011330.5	-6.68	6.57e-11	1.65e-08	-0.51	-0.29	Lung cancer in ever smokers;	chr15:43408229	chr15:43663654~43684339:-
THCA	cis	rs1499614	1	rs1267817	ENSG00000229886.1	RP5-1132H15.3	6.68	6.58e-11	1.65e-08	0.49	0.29	Gout;	chr7:66645053	chr7:66025126~66031544:-
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000229886.1	RP5-1132H15.3	6.68	6.58e-11	1.65e-08	0.49	0.29	Gout;	chr7:66654674	chr7:66025126~66031544:-
THCA	cis	rs4835473	0.868	rs7683365	ENSG00000251600.4	RP11-673E1.1	-6.68	6.59e-11	1.66e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143999443	chr4:143912331~143982454:+
THCA	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	6.68	6.59e-11	1.66e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	6.68	6.59e-11	1.66e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	6.68	6.59e-11	1.66e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
THCA	cis	rs2562456	0.72	rs6511250	ENSG00000268119.4	CTD-2561J22.5	-6.68	6.6e-11	1.66e-08	-0.36	-0.29	Pain;	chr19:21473244	chr19:21444241~21463908:-
THCA	cis	rs55665837	0.701	rs10766188	ENSG00000251991.1	RNU7-49P	6.68	6.61e-11	1.66e-08	0.34	0.29	Vitamin D levels;	chr11:14639280	chr11:14478892~14478953:+
THCA	cis	rs9380516	0.891	rs9394305	ENSG00000228559.1	RP3-340B19.3	-6.68	6.63e-11	1.67e-08	-0.45	-0.29	Hepatitis C induced liver fibrosis;	chr6:35550801	chr6:35544632~35545669:+
THCA	cis	rs2439831	1	rs689596	ENSG00000275601.1	AC011330.13	-6.68	6.63e-11	1.67e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43469519	chr15:43642389~43643023:-
THCA	cis	rs7208859	0.673	rs9912122	ENSG00000263603.1	CTD-2349P21.5	-6.68	6.63e-11	1.67e-08	-0.49	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30729469~30731202:+
THCA	cis	rs28386778	0.897	rs8066754	ENSG00000240280.5	TCAM1P	-6.68	6.64e-11	1.67e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63739230	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs3826341	ENSG00000240280.5	TCAM1P	-6.68	6.64e-11	1.67e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63741862	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs3760256	ENSG00000240280.5	TCAM1P	-6.68	6.64e-11	1.67e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63743801	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs8069969	ENSG00000240280.5	TCAM1P	-6.68	6.64e-11	1.67e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63744863	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs3785572	ENSG00000240280.5	TCAM1P	-6.68	6.64e-11	1.67e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63752629	chr17:63849292~63864379:+
THCA	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-6.68	6.64e-11	1.67e-08	-0.36	-0.29	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
THCA	cis	rs6479901	0.947	rs10822167	ENSG00000232075.1	MRPL35P2	-6.68	6.64e-11	1.67e-08	-0.46	-0.29	Intelligence (multi-trait analysis);	chr10:63398991	chr10:63634317~63634827:-
THCA	cis	rs34375054	0.573	rs34579346	ENSG00000279233.1	RP11-158L12.4	6.68	6.64e-11	1.67e-08	0.32	0.29	Post bronchodilator FEV1/FVC ratio;	chr12:125173628	chr12:125138245~125141711:+
THCA	cis	rs4835473	0.863	rs13146607	ENSG00000251600.4	RP11-673E1.1	-6.68	6.64e-11	1.67e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143687283	chr4:143912331~143982454:+
THCA	cis	rs780096	0.814	rs780093	ENSG00000234072.1	AC074117.10	-6.68	6.65e-11	1.67e-08	-0.23	-0.29	Total body bone mineral density;	chr2:27519736	chr2:27356246~27367622:+
THCA	cis	rs7267979	0.816	rs3746337	ENSG00000274414.1	RP5-965G21.4	-6.68	6.65e-11	1.67e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25239007~25245229:-
THCA	cis	rs7119038	0.629	rs10892271	ENSG00000255239.1	AP002954.6	-6.68	6.66e-11	1.67e-08	-0.45	-0.29	Sjögren's syndrome;	chr11:118727835	chr11:118688039~118690600:-
THCA	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-6.68	6.66e-11	1.67e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-6.68	6.66e-11	1.67e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
THCA	cis	rs2243480	1	rs7778911	ENSG00000228409.4	CCT6P1	-6.68	6.66e-11	1.67e-08	-0.35	-0.29	Diabetic kidney disease;	chr7:66229519	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1979823	ENSG00000228409.4	CCT6P1	-6.68	6.66e-11	1.67e-08	-0.35	-0.29	Diabetic kidney disease;	chr7:66239626	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6964245	ENSG00000228409.4	CCT6P1	-6.68	6.66e-11	1.67e-08	-0.35	-0.29	Diabetic kidney disease;	chr7:66253730	chr7:65751142~65763354:+
THCA	cis	rs4713118	0.911	rs2394000	ENSG00000280107.1	AL022393.9	-6.68	6.66e-11	1.67e-08	-0.34	-0.29	Parkinson's disease;	chr6:27719212	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.955	rs9393847	ENSG00000280107.1	AL022393.9	-6.68	6.66e-11	1.67e-08	-0.34	-0.29	Parkinson's disease;	chr6:27720194	chr6:28170845~28172521:+
THCA	cis	rs944990	0.576	rs10992731	ENSG00000227603.1	RP11-165J3.6	6.68	6.66e-11	1.67e-08	0.3	0.29	Body mass index;	chr9:93436816	chr9:93435332~93437121:-
THCA	cis	rs3204270	0.5	rs62077175	ENSG00000262049.1	RP13-1032I1.7	6.68	6.66e-11	1.67e-08	0.26	0.29	Dental caries;	chr17:81682538	chr17:81701324~81703300:-
THCA	cis	rs3204270	0.714	rs8074828	ENSG00000262049.1	RP13-1032I1.7	6.68	6.66e-11	1.67e-08	0.26	0.29	Dental caries;	chr17:81690106	chr17:81701324~81703300:-
THCA	cis	rs28386778	0.863	rs3760252	ENSG00000240280.5	TCAM1P	-6.68	6.67e-11	1.68e-08	-0.42	-0.29	Prudent dietary pattern;	chr17:63774826	chr17:63849292~63864379:+
THCA	cis	rs4780355	0.843	rs243325	ENSG00000262703.1	RP11-485G7.6	6.68	6.68e-11	1.68e-08	0.34	0.29	Crohn's disease and psoriasis;	chr16:11260640	chr16:11348143~11349321:-
THCA	cis	rs2834188	1	rs2026254	ENSG00000272659.1	AP000295.10	-6.68	6.68e-11	1.68e-08	-0.4	-0.29	Narcolepsy;	chr21:33315727	chr21:33309491~33310181:+
THCA	cis	rs2834188	1	rs13050445	ENSG00000272659.1	AP000295.10	6.68	6.68e-11	1.68e-08	0.4	0.29	Narcolepsy;	chr21:33331291	chr21:33309491~33310181:+
THCA	cis	rs2834188	1	rs2252930	ENSG00000272659.1	AP000295.10	6.68	6.68e-11	1.68e-08	0.4	0.29	Narcolepsy;	chr21:33331895	chr21:33309491~33310181:+
THCA	cis	rs9399135	0.517	rs1041478	ENSG00000232876.1	CTA-212D2.2	-6.68	6.7e-11	1.68e-08	-0.36	-0.29	Red blood cell count;	chr6:135130059	chr6:135055033~135060550:+
THCA	cis	rs9677476	0.731	rs1477470	ENSG00000224376.1	AC017104.6	6.68	6.7e-11	1.68e-08	0.33	0.29	Food antigen IgG levels;	chr2:231212011	chr2:231388976~231394991:+
THCA	cis	rs9677476	0.863	rs10187005	ENSG00000224376.1	AC017104.6	6.68	6.7e-11	1.68e-08	0.33	0.29	Food antigen IgG levels;	chr2:231213235	chr2:231388976~231394991:+
THCA	cis	rs944289	0.553	rs1169128	ENSG00000257826.1	RP11-116N8.4	-6.68	6.7e-11	1.68e-08	-0.34	-0.29	Thyroid cancer;	chr14:36151659	chr14:36061026~36067190:-
THCA	cis	rs8062405	0.755	rs7193402	ENSG00000278665.1	RP11-666O2.4	6.68	6.71e-11	1.69e-08	0.34	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28599241~28601881:-
THCA	cis	rs7189233	0.956	rs62048478	ENSG00000279344.1	RP11-44F14.7	6.68	6.71e-11	1.69e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53395268	chr16:53478957~53481550:-
THCA	cis	rs8027521	0.54	rs12185070	ENSG00000280362.1	RP11-643A5.3	6.68	6.71e-11	1.69e-08	0.36	0.29	Circulating chemerin levels;	chr15:53936494	chr15:53910769~53914712:+
THCA	cis	rs28386778	0.897	rs2727290	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63817368	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs1062788	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63818767	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs1062790	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63819095	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs894408	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63819454	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs2727288	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63823837	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs894407	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63824281	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs894406	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63824297	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs716880	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63825462	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2584626	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63825819	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs2665834	ENSG00000240280.5	TCAM1P	-6.68	6.71e-11	1.69e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63827364	chr17:63849292~63864379:+
THCA	cis	rs7746199	0.673	rs72847313	ENSG00000219392.1	RP1-265C24.5	-6.68	6.72e-11	1.69e-08	-0.66	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.611	rs17750747	ENSG00000219392.1	RP1-265C24.5	-6.68	6.72e-11	1.69e-08	-0.66	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9283883	ENSG00000280107.1	AL022393.9	-6.68	6.72e-11	1.69e-08	-0.34	-0.29	Parkinson's disease;	chr6:27747691	chr6:28170845~28172521:+
THCA	cis	rs2243480	1	rs316331	ENSG00000228409.4	CCT6P1	-6.68	6.73e-11	1.69e-08	-0.34	-0.29	Diabetic kidney disease;	chr7:66139635	chr7:65751142~65763354:+
THCA	cis	rs2288884	0.775	rs7508491	ENSG00000275055.1	CTC-471J1.11	-6.68	6.74e-11	1.69e-08	-0.29	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52001631	chr19:52049007~52049754:+
THCA	cis	rs944990	0.597	rs4607675	ENSG00000227603.1	RP11-165J3.6	6.68	6.75e-11	1.7e-08	0.3	0.29	Body mass index;	chr9:93454127	chr9:93435332~93437121:-
THCA	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-6.68	6.75e-11	1.7e-08	-0.37	-0.29	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
THCA	cis	rs6671200	0.667	rs76032537	ENSG00000235501.4	RP4-639F20.1	-6.68	6.76e-11	1.7e-08	-0.61	-0.29	Stearic acid (18:0) levels;	chr1:94926014	chr1:94927566~94963270:+
THCA	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	6.68	6.77e-11	1.7e-08	0.34	0.29	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
THCA	cis	rs4273100	1	rs16960158	ENSG00000265185.4	SNORD3B-1	6.68	6.77e-11	1.7e-08	0.44	0.29	Schizophrenia;	chr17:19259739	chr17:19061912~19062669:+
THCA	cis	rs6569038	0.669	rs17513308	ENSG00000253194.1	RP11-351A11.1	6.68	6.77e-11	1.7e-08	0.4	0.29	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119061186	chr6:118934785~119031541:+
THCA	cis	rs16843372	0.599	rs10196949	ENSG00000251491.2	OR7E28P	-6.68	6.78e-11	1.7e-08	-0.39	-0.29	Obesity-related traits;	chr2:158823718	chr2:158862311~158863285:+
THCA	cis	rs35934224	0.783	rs7287073	ENSG00000232926.1	AC000078.5	6.68	6.78e-11	1.7e-08	0.37	0.29	Glaucoma (primary open-angle);	chr22:19876812	chr22:19887289~19887970:+
THCA	cis	rs11603023	1	rs11603023	ENSG00000255422.1	AP002954.4	-6.68	6.79e-11	1.7e-08	-0.32	-0.29	Cholesterol, total;	chr11:118615352	chr11:118704607~118750263:+
THCA	cis	rs10875746	0.551	rs3751273	ENSG00000269514.1	RP11-370I10.12	6.68	6.79e-11	1.7e-08	0.3	0.29	Longevity (90 years and older);	chr12:48345655	chr12:48198387~48202031:+
THCA	cis	rs5758659	1	rs5758677	ENSG00000182057.4	OGFRP1	6.68	6.8e-11	1.71e-08	0.34	0.29	Cognitive function;	chr22:42247033	chr22:42269753~42275196:+
THCA	cis	rs7267979	0.966	rs6037097	ENSG00000274414.1	RP5-965G21.4	-6.68	6.8e-11	1.71e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25239007~25245229:-
THCA	cis	rs453301	0.686	rs28665409	ENSG00000253893.2	FAM85B	6.68	6.82e-11	1.71e-08	0.38	0.29	Joint mobility (Beighton score);	chr8:9011767	chr8:8167819~8226614:-
THCA	cis	rs7302981	0.667	rs1362984	ENSG00000272368.2	RP4-605O3.4	-6.68	6.82e-11	1.71e-08	-0.18	-0.29	Systolic blood pressure;	chr12:50206201	chr12:50112197~50165618:+
THCA	cis	rs4835473	0.897	rs6537170	ENSG00000251600.4	RP11-673E1.1	6.68	6.83e-11	1.71e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143691747	chr4:143912331~143982454:+
THCA	cis	rs2564921	0.513	rs12638195	ENSG00000242142.1	SERBP1P3	-6.68	6.83e-11	1.71e-08	-0.38	-0.29	Height;	chr3:52842623	chr3:53064283~53065091:-
THCA	cis	rs2439831	1	rs2584726	ENSG00000249839.1	AC011330.5	-6.68	6.83e-11	1.71e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43423184	chr15:43663654~43684339:-
THCA	cis	rs1005277	0.502	rs2800484	ENSG00000276805.1	RP11-291L22.6	6.68	6.84e-11	1.72e-08	0.32	0.29	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38451030~38451785:+
THCA	cis	rs1124609	0.527	rs11632154	ENSG00000244879.4	GABPB1-AS1	6.68	6.84e-11	1.72e-08	0.39	0.29	Subjective well-being;	chr15:50204321	chr15:50354959~50372202:+
THCA	cis	rs4934494	0.727	rs12764076	ENSG00000232936.4	RP11-80H5.2	6.68	6.85e-11	1.72e-08	0.41	0.29	Red blood cell count;	chr10:89630443	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.634	rs12762448	ENSG00000232936.4	RP11-80H5.2	6.68	6.85e-11	1.72e-08	0.41	0.29	Red blood cell count;	chr10:89630483	chr10:89645282~89650667:+
THCA	cis	rs2439831	1	rs689754	ENSG00000275601.1	AC011330.13	-6.68	6.85e-11	1.72e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43483697	chr15:43642389~43643023:-
THCA	cis	rs1005277	0.579	rs1780133	ENSG00000276805.1	RP11-291L22.6	6.68	6.85e-11	1.72e-08	0.32	0.29	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38451030~38451785:+
THCA	cis	rs853679	0.607	rs35902873	ENSG00000280107.1	AL022393.9	-6.68	6.86e-11	1.72e-08	-0.59	-0.29	Depression;	chr6:28091171	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13197574	ENSG00000280107.1	AL022393.9	-6.68	6.86e-11	1.72e-08	-0.59	-0.29	Depression;	chr6:28092461	chr6:28170845~28172521:+
THCA	cis	rs4835473	0.932	rs6849896	ENSG00000251600.4	RP11-673E1.1	-6.68	6.87e-11	1.72e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143794927	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs35998817	ENSG00000251600.4	RP11-673E1.1	-6.68	6.87e-11	1.72e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143795355	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13134808	ENSG00000251600.4	RP11-673E1.1	-6.68	6.87e-11	1.72e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143798339	chr4:143912331~143982454:+
THCA	cis	rs720475	0.732	rs17172978	ENSG00000204959.4	ARHGEF34P	-6.68	6.88e-11	1.73e-08	-0.34	-0.29	Breast cancer;	chr7:144429551	chr7:144272445~144286966:-
THCA	cis	rs6504622	1	rs4968286	ENSG00000262879.4	RP11-156P1.3	-6.68	6.88e-11	1.73e-08	-0.27	-0.29	Orofacial clefts;	chr17:46940279	chr17:46984045~47100323:-
THCA	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-6.68	6.9e-11	1.73e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-6.68	6.9e-11	1.73e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
THCA	cis	rs28386778	0.897	rs2584624	ENSG00000240280.5	TCAM1P	-6.68	6.9e-11	1.73e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63827186	chr17:63849292~63864379:+
THCA	cis	rs4689592	0.503	rs11945642	ENSG00000245468.3	RP11-367J11.3	-6.68	6.9e-11	1.73e-08	-0.25	-0.29	Monocyte percentage of white cells;	chr4:7049338	chr4:7094571~7103385:-
THCA	cis	rs13113518	0.729	rs11133377	ENSG00000273257.1	RP11-177J6.1	6.68	6.91e-11	1.73e-08	0.41	0.29	Height;	chr4:55413708	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.729	rs13120134	ENSG00000273257.1	RP11-177J6.1	6.68	6.91e-11	1.73e-08	0.41	0.29	Height;	chr4:55415153	chr4:55387949~55388271:+
THCA	cis	rs797680	0.856	rs797672	ENSG00000223745.6	RP4-717I23.3	-6.68	6.91e-11	1.73e-08	-0.18	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93236562	chr1:93262186~93346025:-
THCA	cis	rs2243480	1	rs383402	ENSG00000228409.4	CCT6P1	-6.68	6.92e-11	1.74e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66121666	chr7:65751142~65763354:+
THCA	cis	rs523522	0.962	rs4766969	ENSG00000278344.1	RP11-18C24.8	6.68	6.93e-11	1.74e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120550435	chr12:120500735~120501090:-
THCA	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-6.68	6.93e-11	1.74e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
THCA	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	6.68	6.94e-11	1.74e-08	0.36	0.29	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	6.68	6.94e-11	1.74e-08	0.36	0.29	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
THCA	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-6.68	6.94e-11	1.74e-08	-0.35	-0.29	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.565	rs35776291	ENSG00000237664.1	LINC00316	-6.68	6.94e-11	1.74e-08	-0.29	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45338590~45341990:-
THCA	cis	rs28386778	0.897	rs11079510	ENSG00000240280.5	TCAM1P	-6.68	6.94e-11	1.74e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63743542	chr17:63849292~63864379:+
THCA	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	6.68	6.95e-11	1.74e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	6.68	6.95e-11	1.74e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
THCA	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	6.68	6.95e-11	1.74e-08	0.25	0.29	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
THCA	cis	rs3806843	0.712	rs2530244	ENSG00000202515.1	VTRNA1-3	6.68	6.95e-11	1.74e-08	0.34	0.29	Depressive symptoms (multi-trait analysis);	chr5:140729570	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.897	rs2531338	ENSG00000202515.1	VTRNA1-3	6.68	6.95e-11	1.74e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140757372	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.868	rs2262574	ENSG00000202515.1	VTRNA1-3	6.68	6.96e-11	1.74e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr5:140726158~140726246:+
THCA	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-6.68	6.96e-11	1.74e-08	-0.38	-0.29	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-6.68	6.96e-11	1.74e-08	-0.38	-0.29	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-6.68	6.96e-11	1.74e-08	-0.38	-0.29	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-6.68	6.96e-11	1.74e-08	-0.38	-0.29	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
THCA	cis	rs3806843	0.966	rs2563264	ENSG00000202515.1	VTRNA1-3	6.68	6.97e-11	1.75e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140757918	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.932	rs2563257	ENSG00000202515.1	VTRNA1-3	6.68	6.97e-11	1.75e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140760944	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.932	rs2563256	ENSG00000202515.1	VTRNA1-3	6.68	6.97e-11	1.75e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140762194	chr5:140726158~140726246:+
THCA	cis	rs853679	0.527	rs9468333	ENSG00000219392.1	RP1-265C24.5	-6.68	6.97e-11	1.75e-08	-0.33	-0.29	Depression;	chr6:28303421	chr6:28115628~28116551:+
THCA	cis	rs6928977	0.66	rs9373131	ENSG00000231028.7	LINC00271	6.68	6.98e-11	1.75e-08	0.23	0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135478786	chr6:135497801~135716055:+
THCA	cis	rs4591358	0.68	rs12693771	ENSG00000223466.1	AC064834.2	-6.67	7e-11	1.76e-08	-0.4	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195461651	chr2:195533035~195538681:+
THCA	cis	rs2562456	0.833	rs2562487	ENSG00000268119.4	CTD-2561J22.5	6.67	7e-11	1.76e-08	0.36	0.29	Pain;	chr19:21468580	chr19:21444241~21463908:-
THCA	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-6.67	7e-11	1.76e-08	-0.37	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
THCA	cis	rs7267979	0.586	rs1007708	ENSG00000274414.1	RP5-965G21.4	-6.67	7.01e-11	1.76e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25239007~25245229:-
THCA	cis	rs2439831	0.702	rs495175	ENSG00000249839.1	AC011330.5	-6.67	7.02e-11	1.76e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43506486	chr15:43663654~43684339:-
THCA	cis	rs797680	0.856	rs2031225	ENSG00000223745.6	RP4-717I23.3	-6.67	7.02e-11	1.76e-08	-0.18	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93321157	chr1:93262186~93346025:-
THCA	cis	rs2976388	0.762	rs34635647	ENSG00000253741.1	CTD-2292P10.4	6.67	7.03e-11	1.76e-08	0.37	0.29	Urinary tract infection frequency;	chr8:142675472	chr8:142702252~142726973:-
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	6.67	7.03e-11	1.76e-08	0.31	0.29	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
THCA	cis	rs2243480	1	rs1964692	ENSG00000229886.1	RP5-1132H15.3	6.67	7.04e-11	1.76e-08	0.48	0.29	Diabetic kidney disease;	chr7:65989196	chr7:66025126~66031544:-
THCA	cis	rs523522	0.892	rs4767916	ENSG00000278344.1	RP11-18C24.8	6.67	7.04e-11	1.76e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120586229	chr12:120500735~120501090:-
THCA	cis	rs523522	0.926	rs10849766	ENSG00000278344.1	RP11-18C24.8	6.67	7.04e-11	1.76e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120588091	chr12:120500735~120501090:-
THCA	cis	rs3806843	0.966	rs2563255	ENSG00000202515.1	VTRNA1-3	6.67	7.05e-11	1.77e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140762962	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.9	rs2563254	ENSG00000202515.1	VTRNA1-3	6.67	7.05e-11	1.77e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140763116	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs7737424	ENSG00000202515.1	VTRNA1-3	-6.67	7.05e-11	1.77e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140766760	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs12659129	ENSG00000202515.1	VTRNA1-3	-6.67	7.05e-11	1.77e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140767663	chr5:140726158~140726246:+
THCA	cis	rs74233809	0.901	rs11191425	ENSG00000213277.3	MARCKSL1P1	6.67	7.06e-11	1.77e-08	0.47	0.29	Birth weight;	chr10:102866213	chr10:103175554~103176094:+
THCA	cis	rs5758659	0.967	rs5751250	ENSG00000182057.4	OGFRP1	6.67	7.06e-11	1.77e-08	0.34	0.29	Cognitive function;	chr22:42243639	chr22:42269753~42275196:+
THCA	cis	rs7131987	0.65	rs11050208	ENSG00000275476.1	RP11-996F15.4	-6.67	7.06e-11	1.77e-08	-0.3	-0.29	QT interval;	chr12:29357436	chr12:29277397~29277882:-
THCA	cis	rs28386778	0.897	rs2665823	ENSG00000240280.5	TCAM1P	-6.67	7.07e-11	1.77e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63808557	chr17:63849292~63864379:+
THCA	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	6.67	7.08e-11	1.77e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
THCA	cis	rs2657294	0.603	rs11543	ENSG00000226051.5	ZNF503-AS1	-6.67	7.08e-11	1.77e-08	-0.43	-0.29	Pneumonia;	chr10:75210855	chr10:75269819~75373500:+
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000229886.1	RP5-1132H15.3	6.67	7.1e-11	1.78e-08	0.47	0.29	Diabetic kidney disease;	chr7:65947955	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs59794892	ENSG00000229886.1	RP5-1132H15.3	6.67	7.1e-11	1.78e-08	0.47	0.29	Diabetic kidney disease;	chr7:65950886	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000229886.1	RP5-1132H15.3	6.67	7.1e-11	1.78e-08	0.47	0.29	Diabetic kidney disease;	chr7:65951525	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000229886.1	RP5-1132H15.3	6.67	7.1e-11	1.78e-08	0.47	0.29	Diabetic kidney disease;	chr7:65951549	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs11538349	ENSG00000229886.1	RP5-1132H15.3	6.67	7.1e-11	1.78e-08	0.47	0.29	Diabetic kidney disease;	chr7:65956884	chr7:66025126~66031544:-
THCA	cis	rs7267979	0.586	rs6050439	ENSG00000274414.1	RP5-965G21.4	-6.67	7.11e-11	1.78e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25239007~25245229:-
THCA	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	6.67	7.11e-11	1.78e-08	0.37	0.29	Height;	chr6:109423238	chr6:109382795~109383666:+
THCA	cis	rs17594362	0.697	rs9562319	ENSG00000264190.1	MIR5006	6.67	7.12e-11	1.78e-08	0.39	0.29	Multiple sclerosis;	chr13:41563311	chr13:41568286~41568395:-
THCA	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	6.67	7.13e-11	1.79e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
THCA	cis	rs7267979	0.844	rs2257649	ENSG00000274414.1	RP5-965G21.4	-6.67	7.14e-11	1.79e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25239007~25245229:-
THCA	cis	rs4845875	0.6	rs4846039	ENSG00000242349.4	NPPA-AS1	6.67	7.14e-11	1.79e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11776811	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.6	rs4846040	ENSG00000242349.4	NPPA-AS1	6.67	7.14e-11	1.79e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11776991	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.6	rs4846041	ENSG00000242349.4	NPPA-AS1	6.67	7.14e-11	1.79e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11776994	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.6	rs10779765	ENSG00000242349.4	NPPA-AS1	6.67	7.14e-11	1.79e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11777954	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.563	rs10864540	ENSG00000242349.4	NPPA-AS1	6.67	7.14e-11	1.79e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11778042	chr1:11841017~11848079:+
THCA	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	6.67	7.15e-11	1.79e-08	0.51	0.29	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
THCA	cis	rs4143844	0.609	rs62007453	ENSG00000259251.2	RP11-643M14.1	6.67	7.16e-11	1.79e-08	0.57	0.29	Bipolar disorder and schizophrenia;	chr15:62062061	chr15:62060503~62062434:+
THCA	cis	rs7712401	0.592	rs154515	ENSG00000249996.1	RP11-359P5.1	6.67	7.16e-11	1.79e-08	0.29	0.29	Mean platelet volume;	chr5:122855450	chr5:123036271~123054667:+
THCA	cis	rs712022	1	rs10833825	ENSG00000246225.5	RP11-17A1.3	-6.67	7.16e-11	1.79e-08	-0.38	-0.29	Dialysis-related mortality;	chr11:22829207	chr11:22829380~22945393:+
THCA	cis	rs516805	0.667	rs225074	ENSG00000279453.1	RP3-425C14.4	-6.67	7.16e-11	1.79e-08	-0.31	-0.29	Lymphocyte counts;	chr6:122265102	chr6:122436789~122439223:-
THCA	cis	rs516805	0.665	rs225077	ENSG00000279453.1	RP3-425C14.4	-6.67	7.16e-11	1.79e-08	-0.31	-0.29	Lymphocyte counts;	chr6:122269794	chr6:122436789~122439223:-
THCA	cis	rs79349575	0.749	rs12601672	ENSG00000248278.1	SUMO2P17	6.67	7.16e-11	1.79e-08	0.34	0.29	Type 2 diabetes;	chr17:48929131	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs17635252	ENSG00000248278.1	SUMO2P17	6.67	7.16e-11	1.79e-08	0.34	0.29	Type 2 diabetes;	chr17:48929588	chr17:48874860~48908983:-
THCA	cis	rs12435908	1	rs74611500	ENSG00000276116.2	FUT8-AS1	-6.67	7.17e-11	1.8e-08	-0.47	-0.29	Ischemic stroke;	chr14:65543071	chr14:65411170~65412690:-
THCA	cis	rs10208649	0.536	rs10191950	ENSG00000272156.1	RP11-477N3.1	6.67	7.18e-11	1.8e-08	0.4	0.29	Body mass index;	chr2:53732432	chr2:54082554~54085066:+
THCA	cis	rs1385374	0.858	rs12305142	ENSG00000274695.1	RP11-21K12.3	6.67	7.19e-11	1.8e-08	0.51	0.29	Systemic lupus erythematosus;	chr12:128792945	chr12:128826836~128827579:+
THCA	cis	rs7403037	0.794	rs66500833	ENSG00000259905.4	PWRN1	6.67	7.19e-11	1.8e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24218264	chr15:24493137~24652130:+
THCA	cis	rs6928977	0.66	rs2614267	ENSG00000231028.7	LINC00271	6.67	7.19e-11	1.8e-08	0.23	0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135455340	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.66	rs2614263	ENSG00000231028.7	LINC00271	6.67	7.19e-11	1.8e-08	0.23	0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135459579	chr6:135497801~135716055:+
THCA	cis	rs28386778	0.83	rs67905415	ENSG00000240280.5	TCAM1P	-6.67	7.2e-11	1.8e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63763876	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.797	rs4968664	ENSG00000240280.5	TCAM1P	-6.67	7.2e-11	1.8e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63774006	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs9913323	ENSG00000240280.5	TCAM1P	-6.67	7.2e-11	1.8e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63774125	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs3760254	ENSG00000240280.5	TCAM1P	-6.67	7.2e-11	1.8e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63774391	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs7221573	ENSG00000240280.5	TCAM1P	-6.67	7.2e-11	1.8e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63782030	chr17:63849292~63864379:+
THCA	cis	rs7829975	0.742	rs7832968	ENSG00000254153.1	CTA-398F10.2	-6.67	7.2e-11	1.8e-08	-0.31	-0.29	Mood instability;	chr8:8795379	chr8:8456909~8461337:-
THCA	cis	rs7403037	0.794	rs35985747	ENSG00000259905.4	PWRN1	6.67	7.2e-11	1.8e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24513803	chr15:24493137~24652130:+
THCA	cis	rs6504108	0.56	rs2072441	ENSG00000278765.1	RP5-890E16.5	-6.67	7.2e-11	1.8e-08	-0.33	-0.29	Body mass index;	chr17:48107652	chr17:48066704~48067293:-
THCA	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	6.67	7.21e-11	1.8e-08	0.34	0.29	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
THCA	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	6.67	7.21e-11	1.8e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	6.67	7.21e-11	1.8e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
THCA	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-6.67	7.21e-11	1.8e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
THCA	cis	rs801193	0.548	rs6975044	ENSG00000232559.3	GS1-124K5.12	6.67	7.21e-11	1.8e-08	0.29	0.29	Aortic root size;	chr7:66762495	chr7:66554588~66576923:-
THCA	cis	rs4273100	0.834	rs59415593	ENSG00000265185.4	SNORD3B-1	6.67	7.22e-11	1.81e-08	0.44	0.29	Schizophrenia;	chr17:19319911	chr17:19061912~19062669:+
THCA	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	6.67	7.22e-11	1.81e-08	0.34	0.29	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
THCA	cis	rs593531	0.614	rs10793080	ENSG00000212961.4	HNRNPA1P40	6.67	7.22e-11	1.81e-08	0.37	0.29	Neuroticism;	chr11:74377698	chr11:74354443~74355720:+
THCA	cis	rs17270561	0.562	rs74293932	ENSG00000272462.2	U91328.19	-6.67	7.22e-11	1.81e-08	-0.31	-0.29	Iron status biomarkers;	chr6:26014583	chr6:25992662~26001775:+
THCA	cis	rs7811142	0.943	rs66958101	ENSG00000078319.8	PMS2P1	-6.67	7.23e-11	1.81e-08	-0.42	-0.29	Platelet count;	chr7:100476397	chr7:100320992~100341908:-
THCA	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	6.67	7.23e-11	1.81e-08	0.35	0.29	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
THCA	cis	rs71636778	0.509	rs12754468	ENSG00000260063.1	RP5-968P14.2	-6.67	7.24e-11	1.81e-08	-0.56	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26688257	chr1:26692132~26694131:-
THCA	cis	rs7120173	1	rs7120173	ENSG00000254851.1	RP11-109L13.1	6.67	7.24e-11	1.81e-08	0.46	0.29	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117135528~117138582:+
THCA	cis	rs523522	1	rs1563333	ENSG00000278344.1	RP11-18C24.8	6.67	7.25e-11	1.81e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120496604	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs7136951	ENSG00000278344.1	RP11-18C24.8	6.67	7.25e-11	1.81e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120504124	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs4766966	ENSG00000278344.1	RP11-18C24.8	6.67	7.25e-11	1.81e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120505108	chr12:120500735~120501090:-
THCA	cis	rs10875746	0.551	rs10875799	ENSG00000269514.1	RP11-370I10.12	6.67	7.25e-11	1.81e-08	0.3	0.29	Longevity (90 years and older);	chr12:48347096	chr12:48198387~48202031:+
THCA	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-6.67	7.26e-11	1.82e-08	-0.38	-0.29	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
THCA	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-6.67	7.26e-11	1.82e-08	-0.44	-0.29	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
THCA	cis	rs17027633	0.5	rs1764808	ENSG00000260948.1	RP11-552M11.8	-6.67	7.26e-11	1.82e-08	-0.47	-0.29	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111413696	chr1:111431046~111433068:-
THCA	cis	rs227932	0.571	rs3801898	ENSG00000234286.1	AC006026.13	-6.67	7.26e-11	1.82e-08	-0.56	-0.29	Schizophrenia;	chr7:23762526	chr7:23680195~23680786:-
THCA	cis	rs11976180	0.953	rs2951355	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144063469	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2951354	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144063908	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2951353	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144064023	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2961125	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144064677	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2961126	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144065643	chr7:144250045~144252957:-
THCA	cis	rs11976180	0.953	rs2961127	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144065644	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs1919948	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144065750	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2961128	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144066390	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2371247	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144067086	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2371248	ENSG00000170356.8	OR2A20P	-6.67	7.26e-11	1.82e-08	-0.4	-0.29	Obesity-related traits;	chr7:144067096	chr7:144250045~144252957:-
THCA	cis	rs2439831	0.85	rs524417	ENSG00000249839.1	AC011330.5	-6.67	7.26e-11	1.82e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43480176	chr15:43663654~43684339:-
THCA	cis	rs6696239	0.513	rs4653849	ENSG00000227711.2	RP11-275O4.5	-6.67	7.27e-11	1.82e-08	-0.31	-0.29	Height;	chr1:227541299	chr1:227509028~227520477:-
THCA	cis	rs9287719	0.649	rs9973374	ENSG00000243819.4	RN7SL832P	6.67	7.27e-11	1.82e-08	0.24	0.29	Prostate cancer;	chr2:10576258	chr2:10690344~10692099:+
THCA	cis	rs7267979	1	rs6050555	ENSG00000274414.1	RP5-965G21.4	6.67	7.28e-11	1.82e-08	0.35	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25239007~25245229:-
THCA	cis	rs7044106	0.791	rs7043969	ENSG00000238181.2	AHCYP2	-6.67	7.28e-11	1.82e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120720673~120721972:+
THCA	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	6.67	7.28e-11	1.82e-08	0.43	0.29	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
THCA	cis	rs11672691	0.519	rs10407939	ENSG00000267107.5	PCAT19	6.67	7.28e-11	1.82e-08	0.31	0.29	Prostate cancer;	chr19:41502561	chr19:41454169~41500649:-
THCA	cis	rs16843372	0.562	rs28523325	ENSG00000251491.2	OR7E28P	-6.67	7.29e-11	1.82e-08	-0.39	-0.29	Obesity-related traits;	chr2:158820839	chr2:158862311~158863285:+
THCA	cis	rs6570726	0.516	rs9376932	ENSG00000235652.6	RP11-545I5.3	6.67	7.29e-11	1.82e-08	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145408354	chr6:145799409~145886585:+
THCA	cis	rs10129255	0.834	rs10139893	ENSG00000211974.3	IGHV2-70	6.67	7.3e-11	1.83e-08	0.23	0.29	Kawasaki disease;	chr14:106711377	chr14:106723574~106724093:-
THCA	cis	rs6539288	0.803	rs7307895	ENSG00000260329.1	RP11-412D9.4	-6.67	7.3e-11	1.83e-08	-0.26	-0.29	Total body bone mineral density;	chr12:106938348	chr12:106954029~106955497:-
THCA	cis	rs11096990	0.855	rs2711989	ENSG00000249207.1	RP11-360F5.1	6.67	7.3e-11	1.83e-08	0.38	0.29	Cognitive function;	chr4:39150416	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.855	rs2566169	ENSG00000249207.1	RP11-360F5.1	6.67	7.3e-11	1.83e-08	0.38	0.29	Cognitive function;	chr4:39150420	chr4:39112677~39126818:-
THCA	cis	rs7849973	0.595	rs1349151	ENSG00000224549.1	RP11-370B11.3	-6.67	7.31e-11	1.83e-08	-0.38	-0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22767237	chr9:22767175~22768316:+
THCA	cis	rs62158211	0.691	rs1964463	ENSG00000272563.1	RP11-480C16.1	6.67	7.31e-11	1.83e-08	0.37	0.29	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113311444	chr2:113432600~113436042:+
THCA	cis	rs12928939	0.911	rs12917983	ENSG00000260886.1	TAT-AS1	6.67	7.32e-11	1.83e-08	0.39	0.29	Post bronchodilator FEV1;	chr16:71801340	chr16:71565789~71578187:+
THCA	cis	rs28386778	0.897	rs11654841	ENSG00000240280.5	TCAM1P	-6.67	7.32e-11	1.83e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63760899	chr17:63849292~63864379:+
THCA	cis	rs11976180	1	rs11976037	ENSG00000170356.8	OR2A20P	-6.67	7.33e-11	1.83e-08	-0.41	-0.29	Obesity-related traits;	chr7:144043931	chr7:144250045~144252957:-
THCA	cis	rs2717559	0.542	rs34147336	ENSG00000253741.1	CTD-2292P10.4	6.67	7.34e-11	1.83e-08	0.38	0.29	Urinary tract infection frequency;	chr8:142803453	chr8:142702252~142726973:-
THCA	cis	rs2717559	0.522	rs35816096	ENSG00000253741.1	CTD-2292P10.4	6.67	7.34e-11	1.83e-08	0.38	0.29	Urinary tract infection frequency;	chr8:142803522	chr8:142702252~142726973:-
THCA	cis	rs916888	0.61	rs199530	ENSG00000232300.1	FAM215B	-6.67	7.34e-11	1.84e-08	-0.41	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46558830~46562795:-
THCA	cis	rs2439831	0.85	rs544122	ENSG00000275601.1	AC011330.13	-6.67	7.35e-11	1.84e-08	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43483534	chr15:43642389~43643023:-
THCA	cis	rs8014252	0.803	rs74062743	ENSG00000259158.2	ADAM20P1	-6.67	7.36e-11	1.84e-08	-0.38	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70556694	chr14:70468881~70483756:-
THCA	cis	rs934734	0.789	rs10188563	ENSG00000204929.10	AC074391.1	6.67	7.36e-11	1.84e-08	0.37	0.29	Rheumatoid arthritis;	chr2:65342805	chr2:65436711~66084639:+
THCA	cis	rs16846053	0.71	rs13022437	ENSG00000227403.1	AC009299.3	-6.67	7.37e-11	1.84e-08	-0.46	-0.29	Blood osmolality (transformed sodium);	chr2:161765775	chr2:161244739~161249050:+
THCA	cis	rs8014252	0.803	rs74062746	ENSG00000259158.2	ADAM20P1	-6.67	7.37e-11	1.84e-08	-0.38	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70558227	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.708	rs74062750	ENSG00000259158.2	ADAM20P1	-6.67	7.37e-11	1.84e-08	-0.38	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70559335	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs58092588	ENSG00000259158.2	ADAM20P1	-6.67	7.37e-11	1.84e-08	-0.38	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70561961	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs74938470	ENSG00000259158.2	ADAM20P1	-6.67	7.37e-11	1.84e-08	-0.38	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70573305	chr14:70468881~70483756:-
THCA	cis	rs10844706	0.699	rs2401390	ENSG00000256594.6	RP11-705C15.2	6.67	7.38e-11	1.85e-08	0.25	0.29	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9719218	chr12:9633419~9658412:+
THCA	cis	rs7746199	0.736	rs13193542	ENSG00000226314.6	ZNF192P1	-6.67	7.38e-11	1.85e-08	-0.65	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs13193480	ENSG00000226314.6	ZNF192P1	-6.67	7.38e-11	1.85e-08	-0.65	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28161781~28169594:+
THCA	cis	rs7202877	0.706	rs247434	ENSG00000261783.1	RP11-252K23.2	6.67	7.39e-11	1.85e-08	0.51	0.29	Type 1 diabetes;Type 2 diabetes;	chr16:75411406	chr16:75379818~75381260:-
THCA	cis	rs6504108	0.522	rs12603380	ENSG00000278765.1	RP5-890E16.5	-6.67	7.39e-11	1.85e-08	-0.32	-0.29	Body mass index;	chr17:48127046	chr17:48066704~48067293:-
THCA	cis	rs7260598	0.901	rs7251567	ENSG00000268442.1	CTD-2027I19.2	6.67	7.4e-11	1.85e-08	0.39	0.29	Response to taxane treatment (placlitaxel);	chr19:24034489	chr19:24162370~24163425:-
THCA	cis	rs228614	0.536	rs223325	ENSG00000230069.3	LRRC37A15P	-6.67	7.4e-11	1.85e-08	-0.3	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102727274~102730721:-
THCA	cis	rs4072705	1	rs4838197	ENSG00000224020.1	MIR181A2HG	-6.67	7.4e-11	1.85e-08	-0.26	-0.29	Menarche (age at onset);	chr9:124602236	chr9:124658467~124698631:+
THCA	cis	rs896854	0.654	rs1453377	ENSG00000253528.2	RP11-347C18.4	6.67	7.41e-11	1.85e-08	0.34	0.29	Type 2 diabetes;	chr8:94957719	chr8:94974573~94974853:-
THCA	cis	rs6672530	0.518	rs12079123	ENSG00000227711.2	RP11-275O4.5	-6.67	7.42e-11	1.85e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr1:227625240	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs2132367	ENSG00000227711.2	RP11-275O4.5	-6.67	7.42e-11	1.85e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr1:227626689	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs12080321	ENSG00000227711.2	RP11-275O4.5	-6.67	7.42e-11	1.85e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr1:227631668	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs12070002	ENSG00000227711.2	RP11-275O4.5	-6.67	7.42e-11	1.85e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr1:227631789	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs12070036	ENSG00000227711.2	RP11-275O4.5	-6.67	7.42e-11	1.85e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr1:227631813	chr1:227509028~227520477:-
THCA	cis	rs28386778	0.897	rs2036911	ENSG00000240280.5	TCAM1P	-6.67	7.42e-11	1.85e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63717479	chr17:63849292~63864379:+
THCA	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	6.67	7.42e-11	1.85e-08	0.38	0.29	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
THCA	cis	rs11024102	0.925	rs7123383	ENSG00000184669.7	OR7E14P	-6.67	7.42e-11	1.85e-08	-0.4	-0.29	Glaucoma (primary angle closure);	chr11:16981438	chr11:17013998~17053024:+
THCA	cis	rs11024102	0.925	rs7127818	ENSG00000184669.7	OR7E14P	-6.67	7.42e-11	1.85e-08	-0.4	-0.29	Glaucoma (primary angle closure);	chr11:16982543	chr11:17013998~17053024:+
THCA	cis	rs11024102	1	rs11024101	ENSG00000184669.7	OR7E14P	-6.67	7.42e-11	1.85e-08	-0.4	-0.29	Glaucoma (primary angle closure);	chr11:16983997	chr11:17013998~17053024:+
THCA	cis	rs10131894	0.575	rs1860935	ENSG00000279594.1	RP11-950C14.10	6.67	7.43e-11	1.86e-08	0.27	0.29	Coronary artery disease;	chr14:74965761	chr14:75011269~75012851:-
THCA	cis	rs7851660	0.809	rs10512255	ENSG00000236130.1	PTCSC2	-6.66	7.44e-11	1.86e-08	-0.24	-0.29	Strep throat;	chr9:97890300	chr9:97805935~97810008:-
THCA	cis	rs4706831	0.647	rs9350847	ENSG00000272129.1	RP11-250B2.6	6.66	7.44e-11	1.86e-08	0.37	0.29	Joint mobility (Beighton score);	chr6:80179300	chr6:80355424~80356859:+
THCA	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	6.66	7.46e-11	1.86e-08	0.43	0.29	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
THCA	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-6.66	7.47e-11	1.87e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-6.66	7.47e-11	1.87e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
THCA	cis	rs2439831	1	rs2467743	ENSG00000249839.1	AC011330.5	-6.66	7.47e-11	1.87e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43458148	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2245176	ENSG00000249839.1	AC011330.5	-6.66	7.47e-11	1.87e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43458564	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2245054	ENSG00000249839.1	AC011330.5	-6.66	7.47e-11	1.87e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43459711	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2264876	ENSG00000249839.1	AC011330.5	-6.66	7.47e-11	1.87e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43465221	chr15:43663654~43684339:-
THCA	cis	rs1005277	0.579	rs2008449	ENSG00000276805.1	RP11-291L22.6	-6.66	7.47e-11	1.87e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38451030~38451785:+
THCA	cis	rs17270561	0.562	rs12199626	ENSG00000272462.2	U91328.19	-6.66	7.48e-11	1.87e-08	-0.31	-0.29	Iron status biomarkers;	chr6:26013376	chr6:25992662~26001775:+
THCA	cis	rs7247513	0.866	rs2861405	ENSG00000213290.4	PGK1P2	-6.66	7.48e-11	1.87e-08	-0.35	-0.29	Bipolar disorder;	chr19:12611518	chr19:12559571~12561105:+
THCA	cis	rs28386778	0.897	rs2584615	ENSG00000240280.5	TCAM1P	-6.66	7.48e-11	1.87e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63850414	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.865	rs2727276	ENSG00000240280.5	TCAM1P	-6.66	7.48e-11	1.87e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63852349	chr17:63849292~63864379:+
THCA	cis	rs467650	0.534	rs468562	ENSG00000246763.5	RGMB-AS1	6.66	7.48e-11	1.87e-08	0.29	0.29	Venous thromboembolism (SNP x SNP interaction);	chr5:98601492	chr5:98769618~98773469:-
THCA	cis	rs2303319	1	rs75552514	ENSG00000227403.1	AC009299.3	6.66	7.5e-11	1.87e-08	0.63	0.29	Cognitive function;	chr2:161259812	chr2:161244739~161249050:+
THCA	cis	rs7189233	0.911	rs72801854	ENSG00000279344.1	RP11-44F14.7	6.66	7.5e-11	1.87e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53483330	chr16:53478957~53481550:-
THCA	cis	rs4845875	0.6	rs11805138	ENSG00000242349.4	NPPA-AS1	6.66	7.51e-11	1.87e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11773102	chr1:11841017~11848079:+
THCA	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-6.66	7.51e-11	1.88e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
THCA	cis	rs28386778	0.897	rs2156903	ENSG00000240280.5	TCAM1P	-6.66	7.52e-11	1.88e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63859819	chr17:63849292~63864379:+
THCA	cis	rs4835473	0.618	rs12499907	ENSG00000251600.4	RP11-673E1.1	-6.66	7.53e-11	1.88e-08	-0.41	-0.29	Immature fraction of reticulocytes;	chr4:143999748	chr4:143912331~143982454:+
THCA	cis	rs2439831	1	rs2444029	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43445286	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2467740	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43454594	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs561863	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43469154	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs689616	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43469703	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs689647	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43469998	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2251538	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43475011	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs2439832	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43487488	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2439850	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43492656	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2467736	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43492719	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2444250	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43492853	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs101094	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43495124	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs689781	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43499899	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2584725	ENSG00000275601.1	AC011330.13	-6.66	7.53e-11	1.88e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43500937	chr15:43642389~43643023:-
THCA	cis	rs1499614	1	rs1267818	ENSG00000229886.1	RP5-1132H15.3	6.66	7.53e-11	1.88e-08	0.49	0.29	Gout;	chr7:66642037	chr7:66025126~66031544:-
THCA	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-6.66	7.53e-11	1.88e-08	-0.26	-0.29	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
THCA	cis	rs3764021	0.506	rs10844468	ENSG00000256594.6	RP11-705C15.2	6.66	7.53e-11	1.88e-08	0.25	0.29	Type 1 diabetes;	chr12:9690799	chr12:9633419~9658412:+
THCA	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	6.66	7.53e-11	1.88e-08	0.28	0.29	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
THCA	cis	rs7208859	0.673	rs2470251	ENSG00000263603.1	CTD-2349P21.5	-6.66	7.54e-11	1.88e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30729469~30731202:+
THCA	cis	rs28386778	0.897	rs2236737	ENSG00000240280.5	TCAM1P	-6.66	7.55e-11	1.89e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63860740	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2236736	ENSG00000240280.5	TCAM1P	-6.66	7.55e-11	1.89e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63860888	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2854221	ENSG00000240280.5	TCAM1P	-6.66	7.55e-11	1.89e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63864085	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2584642	ENSG00000240280.5	TCAM1P	-6.66	7.55e-11	1.89e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63865067	chr17:63849292~63864379:+
THCA	cis	rs4950322	0.518	rs56151278	ENSG00000237188.3	RP11-337C18.8	6.66	7.55e-11	1.89e-08	0.36	0.29	Protein quantitative trait loci;	chr1:147117421	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.518	rs4950306	ENSG00000237188.3	RP11-337C18.8	6.66	7.55e-11	1.89e-08	0.36	0.29	Protein quantitative trait loci;	chr1:147117838	chr1:147172771~147211568:+
THCA	cis	rs4664293	0.867	rs1126842	ENSG00000226266.5	AC009961.3	-6.66	7.56e-11	1.89e-08	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159770806	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs3771721	ENSG00000226266.5	AC009961.3	-6.66	7.56e-11	1.89e-08	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159771644	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs11681245	ENSG00000226266.5	AC009961.3	-6.66	7.56e-11	1.89e-08	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159772882	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.867	rs3771718	ENSG00000226266.5	AC009961.3	-6.66	7.56e-11	1.89e-08	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159780397	chr2:159670708~159712435:-
THCA	cis	rs227275	0.554	rs223333	ENSG00000230069.3	LRRC37A15P	-6.66	7.56e-11	1.89e-08	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223328	ENSG00000230069.3	LRRC37A15P	-6.66	7.56e-11	1.89e-08	-0.3	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102727274~102730721:-
THCA	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-6.66	7.56e-11	1.89e-08	-0.43	-0.29	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
THCA	cis	rs4934494	0.768	rs34663515	ENSG00000232936.4	RP11-80H5.2	6.66	7.56e-11	1.89e-08	0.4	0.29	Red blood cell count;	chr10:89632786	chr10:89645282~89650667:+
THCA	cis	rs7688540	0.76	rs28460123	ENSG00000211553.1	AC253576.2	-6.66	7.57e-11	1.89e-08	-0.4	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:136461~136568:+
THCA	cis	rs7267979	1	rs2856	ENSG00000274414.1	RP5-965G21.4	-6.66	7.57e-11	1.89e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25239007~25245229:-
THCA	cis	rs172166	0.694	rs536704	ENSG00000280107.1	AL022393.9	-6.66	7.57e-11	1.89e-08	-0.32	-0.29	Cardiac Troponin-T levels;	chr6:28124825	chr6:28170845~28172521:+
THCA	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-6.66	7.58e-11	1.89e-08	-0.52	-0.29	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
THCA	cis	rs8014252	0.803	rs61388426	ENSG00000259158.2	ADAM20P1	-6.66	7.59e-11	1.89e-08	-0.38	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70578285	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs56328037	ENSG00000259158.2	ADAM20P1	-6.66	7.59e-11	1.89e-08	-0.38	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70578624	chr14:70468881~70483756:-
THCA	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-6.66	7.59e-11	1.89e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
THCA	cis	rs6672530	0.518	rs4653850	ENSG00000227711.2	RP11-275O4.5	6.66	7.6e-11	1.9e-08	0.31	0.29	Hip circumference adjusted for BMI;	chr1:227550187	chr1:227509028~227520477:-
THCA	cis	rs7208859	0.673	rs216424	ENSG00000264538.5	SUZ12P1	-6.66	7.6e-11	1.9e-08	-0.28	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30709299~30790908:+
THCA	cis	rs934734	0.563	rs11673956	ENSG00000237979.1	AC007389.1	6.66	7.6e-11	1.9e-08	0.36	0.29	Rheumatoid arthritis;	chr2:65370523	chr2:65500993~65502138:-
THCA	cis	rs934734	0.563	rs11673987	ENSG00000237979.1	AC007389.1	6.66	7.6e-11	1.9e-08	0.36	0.29	Rheumatoid arthritis;	chr2:65370537	chr2:65500993~65502138:-
THCA	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-6.66	7.61e-11	1.9e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
THCA	cis	rs2408955	0.561	rs11168365	ENSG00000240399.1	RP1-228P16.1	-6.66	7.61e-11	1.9e-08	-0.31	-0.29	Glycated hemoglobin levels;	chr12:48027989	chr12:48054813~48055591:-
THCA	cis	rs4664293	0.669	rs35299907	ENSG00000226266.5	AC009961.3	6.66	7.61e-11	1.9e-08	0.34	0.29	Monocyte percentage of white cells;	chr2:159562142	chr2:159670708~159712435:-
THCA	cis	rs797680	0.856	rs10874759	ENSG00000223745.6	RP4-717I23.3	6.66	7.61e-11	1.9e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93164615	chr1:93262186~93346025:-
THCA	cis	rs9959145	0.543	rs11664013	ENSG00000267108.1	RP11-861E21.1	-6.66	7.62e-11	1.9e-08	-0.29	-0.29	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12432897~12437635:+
THCA	cis	rs7851660	0.809	rs1561961	ENSG00000236130.1	PTCSC2	-6.66	7.63e-11	1.9e-08	-0.23	-0.29	Strep throat;	chr9:97905317	chr9:97805935~97810008:-
THCA	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	6.66	7.63e-11	1.9e-08	0.36	0.29	Height;	chr6:109429207	chr6:109382795~109383666:+
THCA	cis	rs28386778	0.897	rs2665797	ENSG00000240280.5	TCAM1P	6.66	7.63e-11	1.9e-08	0.41	0.29	Prudent dietary pattern;	chr17:63845125	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs894413	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63838987	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs894414	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63839024	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs8076760	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63843137	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.83	rs2665798	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63844037	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.799	rs2727322	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63844346	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2727323	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63844639	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2727326	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63845656	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2727328	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63846204	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2665796	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63846356	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2584617	ENSG00000240280.5	TCAM1P	-6.66	7.63e-11	1.9e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63847938	chr17:63849292~63864379:+
THCA	cis	rs860295	0.775	rs822505	ENSG00000225855.5	RUSC1-AS1	-6.66	7.64e-11	1.91e-08	-0.19	-0.29	Body mass index;	chr1:155876737	chr1:155316863~155324176:-
THCA	cis	rs11715604	1	rs11715604	ENSG00000273486.1	RP11-731C17.2	-6.66	7.64e-11	1.91e-08	-0.34	-0.29	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);	chr3:136870707	chr3:136837338~136839021:-
THCA	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	6.66	7.64e-11	1.91e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
THCA	cis	rs11668609	0.81	rs8105851	ENSG00000268442.1	CTD-2027I19.2	6.66	7.64e-11	1.91e-08	0.34	0.29	Response to taxane treatment (docetaxel);	chr19:24080533	chr19:24162370~24163425:-
THCA	cis	rs7208859	0.623	rs55724095	ENSG00000263603.1	CTD-2349P21.5	-6.66	7.65e-11	1.91e-08	-0.52	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.568	rs9903854	ENSG00000263603.1	CTD-2349P21.5	-6.66	7.65e-11	1.91e-08	-0.52	-0.29	Body mass index;	chr17:30826980	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs80355557	ENSG00000263603.1	CTD-2349P21.5	-6.66	7.65e-11	1.91e-08	-0.52	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9911173	ENSG00000263603.1	CTD-2349P21.5	-6.66	7.65e-11	1.91e-08	-0.52	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30729469~30731202:+
THCA	cis	rs16976116	0.901	rs3759861	ENSG00000279145.1	RP11-547D13.1	6.66	7.65e-11	1.91e-08	0.29	0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55180994	chr15:55171972~55178175:-
THCA	cis	rs6840360	0.642	rs6535803	ENSG00000251611.1	RP11-610P16.1	-6.66	7.65e-11	1.91e-08	-0.22	-0.29	Intelligence (multi-trait analysis);	chr4:151520762	chr4:151407551~151408835:-
THCA	cis	rs897984	0.762	rs897986	ENSG00000279196.1	RP11-1072A3.3	-6.66	7.65e-11	1.91e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30969581	chr16:30984630~30988270:-
THCA	cis	rs897984	0.721	rs28360557	ENSG00000279196.1	RP11-1072A3.3	-6.66	7.65e-11	1.91e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30971939	chr16:30984630~30988270:-
THCA	cis	rs897984	0.684	rs6950	ENSG00000279196.1	RP11-1072A3.3	-6.66	7.65e-11	1.91e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30984348	chr16:30984630~30988270:-
THCA	cis	rs897984	0.762	rs2305880	ENSG00000279196.1	RP11-1072A3.3	-6.66	7.65e-11	1.91e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30988141	chr16:30984630~30988270:-
THCA	cis	rs2439831	1	rs2444032	ENSG00000249839.1	AC011330.5	-6.66	7.66e-11	1.91e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43463148	chr15:43663654~43684339:-
THCA	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-6.66	7.66e-11	1.91e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
THCA	cis	rs934734	0.563	rs955903	ENSG00000237979.1	AC007389.1	6.66	7.66e-11	1.91e-08	0.36	0.29	Rheumatoid arthritis;	chr2:65348419	chr2:65500993~65502138:-
THCA	cis	rs7580658	0.68	rs12468304	ENSG00000236682.1	AC068282.3	6.66	7.67e-11	1.91e-08	0.38	0.29	Protein C levels;	chr2:127436236	chr2:127389130~127400580:+
THCA	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	6.66	7.67e-11	1.91e-08	0.32	0.29	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
THCA	cis	rs10875746	0.551	rs12322347	ENSG00000269514.1	RP11-370I10.12	6.66	7.67e-11	1.91e-08	0.3	0.29	Longevity (90 years and older);	chr12:48313915	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.551	rs12322348	ENSG00000269514.1	RP11-370I10.12	6.66	7.67e-11	1.91e-08	0.3	0.29	Longevity (90 years and older);	chr12:48313916	chr12:48198387~48202031:+
THCA	cis	rs4835473	0.897	rs11723113	ENSG00000251600.4	RP11-673E1.1	6.66	7.68e-11	1.91e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143707283	chr4:143912331~143982454:+
THCA	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-6.66	7.68e-11	1.92e-08	-0.37	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-6.66	7.68e-11	1.92e-08	-0.37	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
THCA	cis	rs1395	0.778	rs60631624	ENSG00000234072.1	AC074117.10	-6.66	7.68e-11	1.92e-08	-0.27	-0.29	Blood metabolite levels;	chr2:27274947	chr2:27356246~27367622:+
THCA	cis	rs10208649	0.908	rs72906786	ENSG00000272156.1	RP11-477N3.1	6.66	7.69e-11	1.92e-08	0.56	0.29	Body mass index;	chr2:54128523	chr2:54082554~54085066:+
THCA	cis	rs28386778	0.863	rs2727355	ENSG00000240280.5	TCAM1P	-6.66	7.69e-11	1.92e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63854430	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.799	rs2584612	ENSG00000240280.5	TCAM1P	-6.66	7.69e-11	1.92e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63854844	chr17:63849292~63864379:+
THCA	cis	rs4835473	0.897	rs12508285	ENSG00000251600.4	RP11-673E1.1	-6.66	7.69e-11	1.92e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143792642	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs7667544	ENSG00000251600.4	RP11-673E1.1	-6.66	7.69e-11	1.92e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143793802	chr4:143912331~143982454:+
THCA	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-6.66	7.7e-11	1.92e-08	-0.4	-0.29	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-6.66	7.7e-11	1.92e-08	-0.4	-0.29	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-6.66	7.7e-11	1.92e-08	-0.4	-0.29	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-6.66	7.7e-11	1.92e-08	-0.4	-0.29	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-6.66	7.7e-11	1.92e-08	-0.4	-0.29	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-6.66	7.7e-11	1.92e-08	-0.4	-0.29	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
THCA	cis	rs9400467	0.528	rs465796	ENSG00000271789.1	RP5-1112D6.7	-6.66	7.7e-11	1.92e-08	-0.28	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111297126~111298510:+
THCA	cis	rs934734	0.563	rs11126035	ENSG00000237979.1	AC007389.1	6.66	7.7e-11	1.92e-08	0.36	0.29	Rheumatoid arthritis;	chr2:65369932	chr2:65500993~65502138:-
THCA	cis	rs2439831	1	rs690316	ENSG00000275601.1	AC011330.13	-6.66	7.71e-11	1.92e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43445682	chr15:43642389~43643023:-
THCA	cis	rs240993	0.812	rs9481160	ENSG00000230177.1	RP5-1112D6.4	6.66	7.71e-11	1.92e-08	0.3	0.29	Inflammatory skin disease;Psoriasis;	chr6:111517317	chr6:111277932~111278742:+
THCA	cis	rs4835473	0.863	rs7696828	ENSG00000251600.4	RP11-673E1.1	6.66	7.72e-11	1.92e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143700846	chr4:143912331~143982454:+
THCA	cis	rs10129255	0.917	rs7142373	ENSG00000211974.3	IGHV2-70	6.66	7.72e-11	1.93e-08	0.23	0.29	Kawasaki disease;	chr14:106708947	chr14:106723574~106724093:-
THCA	cis	rs13113518	0.678	rs13149568	ENSG00000249700.7	SRD5A3-AS1	6.66	7.72e-11	1.93e-08	0.37	0.29	Height;	chr4:55370412	chr4:55363971~55395847:-
THCA	cis	rs4072705	1	rs4836988	ENSG00000224020.1	MIR181A2HG	-6.66	7.72e-11	1.93e-08	-0.26	-0.29	Menarche (age at onset);	chr9:124735294	chr9:124658467~124698631:+
THCA	cis	rs12435908	1	rs58115860	ENSG00000276116.2	FUT8-AS1	-6.66	7.72e-11	1.93e-08	-0.48	-0.29	Ischemic stroke;	chr14:65590908	chr14:65411170~65412690:-
THCA	cis	rs17270561	0.525	rs10484432	ENSG00000272462.2	U91328.19	-6.66	7.73e-11	1.93e-08	-0.3	-0.29	Iron status biomarkers;	chr6:26008648	chr6:25992662~26001775:+
THCA	cis	rs1198430	0.925	rs1767148	ENSG00000232482.2	RP4-654C18.1	-6.66	7.74e-11	1.93e-08	-0.51	-0.29	Total cholesterol levels;	chr1:23438979	chr1:23410832~23412146:+
THCA	cis	rs7208859	0.673	rs56846352	ENSG00000263603.1	CTD-2349P21.5	-6.66	7.74e-11	1.93e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30729469~30731202:+
THCA	cis	rs4072705	0.967	rs10818984	ENSG00000224020.1	MIR181A2HG	-6.66	7.75e-11	1.93e-08	-0.26	-0.29	Menarche (age at onset);	chr9:124651272	chr9:124658467~124698631:+
THCA	cis	rs748404	0.631	rs7163288	ENSG00000166763.7	STRCP1	6.66	7.75e-11	1.93e-08	0.32	0.29	Lung cancer;	chr15:43379157	chr15:43699488~43718184:-
THCA	cis	rs11668609	0.81	rs17000162	ENSG00000268442.1	CTD-2027I19.2	6.66	7.75e-11	1.93e-08	0.39	0.29	Response to taxane treatment (docetaxel);	chr19:24185347	chr19:24162370~24163425:-
THCA	cis	rs7324557	0.717	rs9510870	ENSG00000205861.10	C1QTNF9B-AS1	-6.66	7.75e-11	1.93e-08	-0.36	-0.29	Visceral adipose tissue adjusted for BMI;	chr13:23810346	chr13:23888889~23897263:+
THCA	cis	rs4072705	1	rs2067791	ENSG00000224020.1	MIR181A2HG	-6.66	7.75e-11	1.93e-08	-0.26	-0.29	Menarche (age at onset);	chr9:124676015	chr9:124658467~124698631:+
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000228409.4	CCT6P1	6.66	7.76e-11	1.93e-08	0.34	0.29	Diabetic kidney disease;	chr7:66136229	chr7:65751142~65763354:+
THCA	cis	rs4835473	0.897	rs4835333	ENSG00000251600.4	RP11-673E1.1	-6.66	7.76e-11	1.93e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143703174	chr4:143912331~143982454:+
THCA	cis	rs10266483	1	rs1960321	ENSG00000227986.1	TRIM60P18	-6.66	7.76e-11	1.93e-08	-0.24	-0.29	Response to statin therapy;	chr7:64270906	chr7:64355078~64356199:+
THCA	cis	rs4835473	0.897	rs7681914	ENSG00000251600.4	RP11-673E1.1	6.66	7.77e-11	1.94e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143708838	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs7682096	ENSG00000251600.4	RP11-673E1.1	6.66	7.77e-11	1.94e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143708892	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs7682128	ENSG00000251600.4	RP11-673E1.1	6.66	7.77e-11	1.94e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143708950	chr4:143912331~143982454:+
THCA	cis	rs2361718	0.564	rs2304844	ENSG00000279259.1	RP11-334C17.3	6.66	7.77e-11	1.94e-08	0.29	0.29	Yeast infection;	chr17:80110708	chr17:80147250~80148596:+
THCA	cis	rs853679	0.527	rs1997660	ENSG00000219392.1	RP1-265C24.5	-6.66	7.77e-11	1.94e-08	-0.33	-0.29	Depression;	chr6:28301886	chr6:28115628~28116551:+
THCA	cis	rs2243480	1	rs1499614	ENSG00000228409.4	CCT6P1	6.66	7.79e-11	1.94e-08	0.34	0.29	Diabetic kidney disease;	chr7:66265811	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs10247526	ENSG00000228409.4	CCT6P1	-6.66	7.79e-11	1.94e-08	-0.35	-0.29	Diabetic kidney disease;	chr7:66315709	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000228409.4	CCT6P1	-6.66	7.79e-11	1.94e-08	-0.35	-0.29	Diabetic kidney disease;	chr7:66333815	chr7:65751142~65763354:+
THCA	cis	rs2439831	1	rs690002	ENSG00000275601.1	AC011330.13	-6.66	7.79e-11	1.94e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43437151	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs537115	ENSG00000275601.1	AC011330.13	-6.66	7.79e-11	1.94e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43437750	chr15:43642389~43643023:-
THCA	cis	rs8030379	0.967	rs8036748	ENSG00000230373.7	GOLGA6L5P	-6.66	7.8e-11	1.94e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903084	chr15:84507885~84516814:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000228409.4	CCT6P1	-6.66	7.81e-11	1.95e-08	-0.34	-0.29	Diabetic kidney disease;	chr7:66172773	chr7:65751142~65763354:+
THCA	cis	rs2562456	0.833	rs2928211	ENSG00000213976.4	CTD-2561J22.2	6.66	7.81e-11	1.95e-08	0.32	0.29	Pain;	chr19:21358495	chr19:21382865~21387177:+
THCA	cis	rs1043099	0.571	rs2299830	ENSG00000279699.1	RP1-102K2.9	-6.66	7.82e-11	1.95e-08	-0.35	-0.29	Rheumatoid arthritis;	chr22:30421642	chr22:30275215~30276951:-
THCA	cis	rs9813712	0.595	rs1453238	ENSG00000228252.7	COL6A4P2	6.66	7.82e-11	1.95e-08	0.29	0.29	Response to amphetamines;	chr3:130290494	chr3:130212823~130273806:+
THCA	cis	rs860295	0.775	rs822508	ENSG00000225855.5	RUSC1-AS1	6.66	7.82e-11	1.95e-08	0.19	0.29	Body mass index;	chr1:155880767	chr1:155316863~155324176:-
THCA	cis	rs728616	0.867	rs12411407	ENSG00000225484.5	NUTM2B-AS1	-6.66	7.83e-11	1.95e-08	-0.55	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80068475	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61859008	ENSG00000225484.5	NUTM2B-AS1	-6.66	7.83e-11	1.95e-08	-0.55	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80071955	chr10:79663088~79826594:-
THCA	cis	rs28386778	0.897	rs2584640	ENSG00000240280.5	TCAM1P	-6.66	7.84e-11	1.95e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63786128	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2584639	ENSG00000240280.5	TCAM1P	-6.66	7.84e-11	1.95e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63786372	chr17:63849292~63864379:+
THCA	cis	rs6545883	0.894	rs2177962	ENSG00000271889.1	RP11-493E12.1	-6.66	7.86e-11	1.96e-08	-0.28	-0.29	Tuberculosis;	chr2:61360935	chr2:61151433~61162105:-
THCA	cis	rs9318086	0.534	rs12428855	ENSG00000205861.10	C1QTNF9B-AS1	6.66	7.86e-11	1.96e-08	0.35	0.29	Myopia (pathological);	chr13:23808822	chr13:23888889~23897263:+
THCA	cis	rs9719620	0.74	rs4731793	ENSG00000236753.4	MKLN1-AS	-6.66	7.86e-11	1.96e-08	-0.29	-0.29	Male-pattern baldness;	chr7:131310104	chr7:131309744~131328222:-
THCA	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-6.66	7.86e-11	1.96e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-6.66	7.86e-11	1.96e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-6.66	7.86e-11	1.96e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-6.66	7.86e-11	1.96e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
THCA	cis	rs72843506	0.722	rs74255387	ENSG00000270091.1	RP11-78O7.2	-6.66	7.87e-11	1.96e-08	-0.34	-0.29	Schizophrenia;	chr17:20198070	chr17:19896590~19897287:-
THCA	cis	rs28386778	0.897	rs2727333	ENSG00000240280.5	TCAM1P	-6.66	7.88e-11	1.96e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63798663	chr17:63849292~63864379:+
THCA	cis	rs2976388	0.868	rs2585176	ENSG00000253741.1	CTD-2292P10.4	6.66	7.88e-11	1.96e-08	0.38	0.29	Urinary tract infection frequency;	chr8:142696963	chr8:142702252~142726973:-
THCA	cis	rs2726040	0.902	rs33957528	ENSG00000251417.2	RP11-1348G14.4	6.66	7.88e-11	1.96e-08	0.26	0.29	Hip circumference;	chr16:28296619	chr16:28802743~28817828:+
THCA	cis	rs11976180	1	rs11975942	ENSG00000170356.8	OR2A20P	-6.66	7.88e-11	1.96e-08	-0.41	-0.29	Obesity-related traits;	chr7:144043487	chr7:144250045~144252957:-
THCA	cis	rs6672530	0.518	rs1323022	ENSG00000227711.2	RP11-275O4.5	6.66	7.89e-11	1.96e-08	0.3	0.29	Hip circumference adjusted for BMI;	chr1:227688435	chr1:227509028~227520477:-
THCA	cis	rs4835473	0.863	rs11735239	ENSG00000251600.4	RP11-673E1.1	-6.66	7.89e-11	1.96e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143689372	chr4:143912331~143982454:+
THCA	cis	rs9487094	0.553	rs11968891	ENSG00000260273.1	RP11-425D10.10	6.66	7.89e-11	1.96e-08	0.41	0.29	Height;	chr6:109548647	chr6:109382795~109383666:+
THCA	cis	rs11668609	1	rs4452076	ENSG00000268442.1	CTD-2027I19.2	6.66	7.9e-11	1.97e-08	0.34	0.29	Response to taxane treatment (docetaxel);	chr19:24143981	chr19:24162370~24163425:-
THCA	cis	rs10131894	0.635	rs174997	ENSG00000279594.1	RP11-950C14.10	-6.65	7.91e-11	1.97e-08	-0.27	-0.29	Coronary artery disease;	chr14:74968103	chr14:75011269~75012851:-
THCA	cis	rs11668609	1	rs7260280	ENSG00000268442.1	CTD-2027I19.2	6.65	7.92e-11	1.97e-08	0.34	0.29	Response to taxane treatment (docetaxel);	chr19:24140020	chr19:24162370~24163425:-
THCA	cis	rs438465	1	rs9371135	ENSG00000226194.4	RP1-137D17.1	-6.65	7.93e-11	1.97e-08	-0.45	-0.29	Corneal astigmatism;	chr6:169450169	chr6:169369998~169388385:-
THCA	cis	rs2439831	0.85	rs12442297	ENSG00000275601.1	AC011330.13	-6.65	7.93e-11	1.97e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43876272	chr15:43642389~43643023:-
THCA	cis	rs797680	0.964	rs1932314	ENSG00000223745.6	RP4-717I23.3	6.65	7.94e-11	1.97e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93172843	chr1:93262186~93346025:-
THCA	cis	rs16958440	1	rs62096476	ENSG00000267800.1	RP11-49K24.5	-6.65	7.94e-11	1.98e-08	-0.6	-0.29	Sitting height ratio;	chr18:47132250	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs62096478	ENSG00000267800.1	RP11-49K24.5	-6.65	7.94e-11	1.98e-08	-0.6	-0.29	Sitting height ratio;	chr18:47136038	chr18:47137018~47137290:+
THCA	cis	rs1005277	0.505	rs719569	ENSG00000263064.2	RP11-291L22.7	-6.65	7.95e-11	1.98e-08	-0.33	-0.29	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.505	rs7099777	ENSG00000263064.2	RP11-291L22.7	-6.65	7.95e-11	1.98e-08	-0.33	-0.29	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.522	rs200943	ENSG00000263064.2	RP11-291L22.7	6.65	7.95e-11	1.98e-08	0.33	0.29	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38448689~38448949:+
THCA	cis	rs6570726	0.516	rs9322025	ENSG00000235652.6	RP11-545I5.3	6.65	7.96e-11	1.98e-08	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145408060	chr6:145799409~145886585:+
THCA	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	6.65	7.96e-11	1.98e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
THCA	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	6.65	7.96e-11	1.98e-08	0.39	0.29	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
THCA	cis	rs853679	0.607	rs13194781	ENSG00000219392.1	RP1-265C24.5	-6.65	7.96e-11	1.98e-08	-0.66	-0.29	Depression;	chr6:27847861	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs36116761	ENSG00000219392.1	RP1-265C24.5	-6.65	7.96e-11	1.98e-08	-0.66	-0.29	Depression;	chr6:27850704	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs34194357	ENSG00000219392.1	RP1-265C24.5	-6.65	7.96e-11	1.98e-08	-0.66	-0.29	Depression;	chr6:27850757	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13199772	ENSG00000219392.1	RP1-265C24.5	-6.65	7.96e-11	1.98e-08	-0.66	-0.29	Depression;	chr6:27866307	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13199906	ENSG00000219392.1	RP1-265C24.5	-6.65	7.96e-11	1.98e-08	-0.66	-0.29	Depression;	chr6:27866361	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs17763089	ENSG00000219392.1	RP1-265C24.5	-6.65	7.96e-11	1.98e-08	-0.66	-0.29	Depression;	chr6:27867440	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs17695758	ENSG00000219392.1	RP1-265C24.5	-6.65	7.96e-11	1.98e-08	-0.66	-0.29	Depression;	chr6:27869405	chr6:28115628~28116551:+
THCA	cis	rs2834188	0.814	rs2843996	ENSG00000272659.1	AP000295.10	-6.65	7.97e-11	1.98e-08	-0.4	-0.29	Narcolepsy;	chr21:33339142	chr21:33309491~33310181:+
THCA	cis	rs793571	0.505	rs2305421	ENSG00000259250.1	RP11-50C13.1	-6.65	7.97e-11	1.98e-08	-0.32	-0.29	Schizophrenia;	chr15:58610884	chr15:58587507~58591676:+
THCA	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-6.65	7.98e-11	1.98e-08	-0.37	-0.29	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
THCA	cis	rs4950322	0.748	rs17360812	ENSG00000237188.3	RP11-337C18.8	-6.65	7.98e-11	1.98e-08	-0.37	-0.29	Protein quantitative trait loci;	chr1:147355010	chr1:147172771~147211568:+
THCA	cis	rs7260598	1	rs62114762	ENSG00000268442.1	CTD-2027I19.2	6.65	7.98e-11	1.98e-08	0.39	0.29	Response to taxane treatment (placlitaxel);	chr19:24051066	chr19:24162370~24163425:-
THCA	cis	rs2915864	0.8	rs3850576	ENSG00000280047.1	CTC-463A16.1	6.65	7.98e-11	1.98e-08	0.45	0.29	Facial morphology (factor 20);	chr5:142144467	chr5:142165767~142168387:+
THCA	cis	rs2348418	0.647	rs10843210	ENSG00000247934.4	RP11-967K21.1	6.65	8.02e-11	1.99e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28575800	chr12:28163298~28190738:-
THCA	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-6.65	8.03e-11	2e-08	-0.27	-0.29	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
THCA	cis	rs74233809	0.901	rs7098825	ENSG00000213277.3	MARCKSL1P1	6.65	8.03e-11	2e-08	0.46	0.29	Birth weight;	chr10:102868477	chr10:103175554~103176094:+
THCA	cis	rs1552244	0.882	rs7633769	ENSG00000232901.1	CYCSP10	6.65	8.04e-11	2e-08	0.37	0.29	Alzheimer's disease;	chr3:9978938	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.751	rs12715665	ENSG00000232901.1	CYCSP10	6.65	8.04e-11	2e-08	0.37	0.29	Alzheimer's disease;	chr3:9979917	chr3:10000647~10000940:-
THCA	cis	rs9816784	0.901	rs56253832	ENSG00000242086.7	LINC00969	6.65	8.04e-11	2e-08	0.28	0.29	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195658062~195739964:+
THCA	cis	rs848490	0.889	rs11763798	ENSG00000214293.7	APTR	6.65	8.05e-11	2e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77605323	chr7:77657660~77696265:-
THCA	cis	rs7085104	0.552	rs11191414	ENSG00000236937.2	PTGES3P4	6.65	8.05e-11	2e-08	0.37	0.29	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102845595~102845950:+
THCA	cis	rs3806843	1	rs4451093	ENSG00000202515.1	VTRNA1-3	6.65	8.06e-11	2e-08	0.32	0.29	Depressive symptoms (multi-trait analysis);	chr5:140778957	chr5:140726158~140726246:+
THCA	cis	rs17772222	0.655	rs7160717	ENSG00000258983.2	RP11-507K2.2	6.65	8.06e-11	2e-08	0.33	0.29	Coronary artery calcification;	chr14:88498232	chr14:88499334~88515502:+
THCA	cis	rs7746199	0.736	rs34965299	ENSG00000219392.1	RP1-265C24.5	-6.65	8.08e-11	2.01e-08	-0.65	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28115628~28116551:+
THCA	cis	rs35491132	1	rs35491132	ENSG00000219392.1	RP1-265C24.5	-6.65	8.08e-11	2.01e-08	-0.65	-0.29	Urinary tract infection frequency;	chr6:27559449	chr6:28115628~28116551:+
THCA	cis	rs867529	0.695	rs62157805	ENSG00000234028.3	AC062029.1	6.65	8.09e-11	2.01e-08	0.24	0.29	Height;	chr2:88715210	chr2:88627539~88631821:+
THCA	cis	rs523522	0.962	rs603574	ENSG00000278344.1	RP11-18C24.8	6.65	8.09e-11	2.01e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120560640	chr12:120500735~120501090:-
THCA	cis	rs2439831	0.85	rs524417	ENSG00000275601.1	AC011330.13	-6.65	8.09e-11	2.01e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43480176	chr15:43642389~43643023:-
THCA	cis	rs7617773	0.817	rs11130163	ENSG00000228638.1	FCF1P2	-6.65	8.1e-11	2.01e-08	-0.27	-0.29	Coronary artery disease;	chr3:48271168	chr3:48290793~48291375:-
THCA	cis	rs11168351	0.889	rs12817104	ENSG00000240399.1	RP1-228P16.1	6.65	8.11e-11	2.01e-08	0.31	0.29	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48054813~48055591:-
THCA	cis	rs7208859	0.673	rs999796	ENSG00000264538.5	SUZ12P1	-6.65	8.11e-11	2.02e-08	-0.29	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30709299~30790908:+
THCA	cis	rs7811142	1	rs4472444	ENSG00000078319.8	PMS2P1	-6.65	8.13e-11	2.02e-08	-0.42	-0.29	Platelet count;	chr7:100473135	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs7809801	ENSG00000078319.8	PMS2P1	-6.65	8.13e-11	2.02e-08	-0.42	-0.29	Platelet count;	chr7:100474408	chr7:100320992~100341908:-
THCA	cis	rs6539288	0.803	rs7305715	ENSG00000260329.1	RP11-412D9.4	-6.65	8.14e-11	2.02e-08	-0.26	-0.29	Total body bone mineral density;	chr12:106932774	chr12:106954029~106955497:-
THCA	cis	rs6539288	0.803	rs2374651	ENSG00000260329.1	RP11-412D9.4	-6.65	8.14e-11	2.02e-08	-0.26	-0.29	Total body bone mineral density;	chr12:106934346	chr12:106954029~106955497:-
THCA	cis	rs6672530	0.518	rs10799433	ENSG00000227711.2	RP11-275O4.5	-6.65	8.14e-11	2.02e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr1:227632371	chr1:227509028~227520477:-
THCA	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	6.65	8.16e-11	2.03e-08	0.38	0.29	Depression;	chr6:28407125	chr6:28176188~28176674:+
THCA	cis	rs6696239	0.513	rs28407112	ENSG00000227711.2	RP11-275O4.5	6.65	8.17e-11	2.03e-08	0.31	0.29	Height;	chr1:227549051	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.531	rs10799423	ENSG00000227711.2	RP11-275O4.5	6.65	8.17e-11	2.03e-08	0.31	0.29	Height;	chr1:227549683	chr1:227509028~227520477:-
THCA	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-6.65	8.17e-11	2.03e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-6.65	8.17e-11	2.03e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-6.65	8.17e-11	2.03e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-6.65	8.17e-11	2.03e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-6.65	8.17e-11	2.03e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-6.65	8.17e-11	2.03e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-6.65	8.17e-11	2.03e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
THCA	cis	rs8113308	0.515	rs56343029	ENSG00000269235.1	ZNF350-AS1	6.65	8.17e-11	2.03e-08	0.56	0.29	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960184	chr19:51949134~51981367:+
THCA	cis	rs28386778	0.897	rs1062787	ENSG00000240280.5	TCAM1P	-6.65	8.17e-11	2.03e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63818644	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.799	rs2665836	ENSG00000240280.5	TCAM1P	-6.65	8.17e-11	2.03e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63820775	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2584627	ENSG00000240280.5	TCAM1P	-6.65	8.17e-11	2.03e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63824079	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.83	rs2584625	ENSG00000240280.5	TCAM1P	-6.65	8.17e-11	2.03e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63826085	chr17:63849292~63864379:+
THCA	cis	rs11168351	0.927	rs7971880	ENSG00000240399.1	RP1-228P16.1	6.65	8.18e-11	2.03e-08	0.31	0.29	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48054813~48055591:-
THCA	cis	rs4689592	0.554	rs66925245	ENSG00000245468.3	RP11-367J11.3	-6.65	8.19e-11	2.03e-08	-0.27	-0.29	Monocyte percentage of white cells;	chr4:7070272	chr4:7094571~7103385:-
THCA	cis	rs2243480	1	rs465359	ENSG00000228409.4	CCT6P1	6.65	8.19e-11	2.03e-08	0.33	0.29	Diabetic kidney disease;	chr7:66093177	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs462853	ENSG00000228409.4	CCT6P1	6.65	8.19e-11	2.03e-08	0.33	0.29	Diabetic kidney disease;	chr7:66093180	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs160642	ENSG00000228409.4	CCT6P1	6.65	8.19e-11	2.03e-08	0.33	0.29	Diabetic kidney disease;	chr7:66093386	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000228409.4	CCT6P1	6.65	8.19e-11	2.03e-08	0.33	0.29	Diabetic kidney disease;	chr7:66100154	chr7:65751142~65763354:+
THCA	cis	rs7811142	1	rs7783159	ENSG00000078319.8	PMS2P1	-6.65	8.2e-11	2.04e-08	-0.43	-0.29	Platelet count;	chr7:100419831	chr7:100320992~100341908:-
THCA	cis	rs1552244	0.882	rs34706481	ENSG00000232901.1	CYCSP10	6.65	8.2e-11	2.04e-08	0.38	0.29	Alzheimer's disease;	chr3:9962439	chr3:10000647~10000940:-
THCA	cis	rs748404	0.66	rs2602141	ENSG00000166763.7	STRCP1	6.65	8.2e-11	2.04e-08	0.31	0.29	Lung cancer;	chr15:43432448	chr15:43699488~43718184:-
THCA	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-6.65	8.2e-11	2.04e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-6.65	8.2e-11	2.04e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-6.65	8.2e-11	2.04e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-6.65	8.2e-11	2.04e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-6.65	8.2e-11	2.04e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-6.65	8.2e-11	2.04e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
THCA	cis	rs8141529	0.732	rs5762788	ENSG00000226471.5	CTA-292E10.6	-6.65	8.21e-11	2.04e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28778782	chr22:28800683~28848559:+
THCA	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	6.65	8.22e-11	2.04e-08	0.38	0.29	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
THCA	cis	rs16958440	1	rs62096468	ENSG00000267800.1	RP11-49K24.5	-6.65	8.22e-11	2.04e-08	-0.61	-0.29	Sitting height ratio;	chr18:47111195	chr18:47137018~47137290:+
THCA	cis	rs1023500	0.551	rs2301521	ENSG00000205702.9	CYP2D7	6.65	8.23e-11	2.04e-08	0.24	0.29	Schizophrenia;	chr22:42027106	chr22:42140203~42144577:-
THCA	cis	rs55665837	0.701	rs11023278	ENSG00000251991.1	RNU7-49P	6.65	8.25e-11	2.05e-08	0.33	0.29	Vitamin D levels;	chr11:14619638	chr11:14478892~14478953:+
THCA	cis	rs35934224	0.771	rs34820460	ENSG00000232926.1	AC000078.5	6.65	8.25e-11	2.05e-08	0.33	0.29	Glaucoma (primary open-angle);	chr22:19881687	chr22:19887289~19887970:+
THCA	cis	rs853679	0.55	rs1233704	ENSG00000272009.1	RP1-313I6.12	6.65	8.26e-11	2.05e-08	0.34	0.29	Depression;	chr6:28199145	chr6:28078792~28081130:-
THCA	cis	rs853679	0.55	rs1237875	ENSG00000272009.1	RP1-313I6.12	6.65	8.26e-11	2.05e-08	0.34	0.29	Depression;	chr6:28205232	chr6:28078792~28081130:-
THCA	cis	rs853679	0.55	rs1225598	ENSG00000272009.1	RP1-313I6.12	-6.65	8.26e-11	2.05e-08	-0.34	-0.29	Depression;	chr6:28193021	chr6:28078792~28081130:-
THCA	cis	rs853679	0.55	rs1150689	ENSG00000272009.1	RP1-313I6.12	-6.65	8.26e-11	2.05e-08	-0.34	-0.29	Depression;	chr6:28197321	chr6:28078792~28081130:-
THCA	cis	rs853679	0.55	rs1225599	ENSG00000272009.1	RP1-313I6.12	-6.65	8.26e-11	2.05e-08	-0.34	-0.29	Depression;	chr6:28197412	chr6:28078792~28081130:-
THCA	cis	rs853679	0.574	rs1233705	ENSG00000272009.1	RP1-313I6.12	-6.65	8.26e-11	2.05e-08	-0.34	-0.29	Depression;	chr6:28198669	chr6:28078792~28081130:-
THCA	cis	rs853679	0.55	rs1233707	ENSG00000272009.1	RP1-313I6.12	-6.65	8.26e-11	2.05e-08	-0.34	-0.29	Depression;	chr6:28205175	chr6:28078792~28081130:-
THCA	cis	rs45509595	0.556	rs34409918	ENSG00000226314.6	ZNF192P1	-6.65	8.26e-11	2.05e-08	-0.65	-0.29	Breast cancer;	chr6:27717569	chr6:28161781~28169594:+
THCA	cis	rs6504622	0.905	rs197926	ENSG00000262879.4	RP11-156P1.3	6.65	8.27e-11	2.05e-08	0.27	0.29	Orofacial clefts;	chr17:46934721	chr17:46984045~47100323:-
THCA	cis	rs10899021	1	rs10899021	ENSG00000279353.1	RP11-864N7.4	-6.65	8.27e-11	2.05e-08	-0.56	-0.29	Response to metformin (IC50);	chr11:74627009	chr11:74698231~74699658:-
THCA	cis	rs55665837	0.524	rs61884009	ENSG00000251991.1	RNU7-49P	6.65	8.27e-11	2.05e-08	0.35	0.29	Vitamin D levels;	chr11:14404916	chr11:14478892~14478953:+
THCA	cis	rs1552244	0.572	rs58862481	ENSG00000232901.1	CYCSP10	6.65	8.29e-11	2.06e-08	0.46	0.29	Alzheimer's disease;	chr3:10122624	chr3:10000647~10000940:-
THCA	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
THCA	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	6.65	8.3e-11	2.06e-08	0.35	0.29	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
THCA	cis	rs6696239	0.513	rs3010191	ENSG00000227711.2	RP11-275O4.5	6.65	8.3e-11	2.06e-08	0.3	0.29	Height;	chr1:227615460	chr1:227509028~227520477:-
THCA	cis	rs4835473	0.897	rs11100802	ENSG00000251600.4	RP11-673E1.1	-6.65	8.3e-11	2.06e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143700046	chr4:143912331~143982454:+
THCA	cis	rs797680	0.93	rs12124771	ENSG00000223745.6	RP4-717I23.3	6.65	8.31e-11	2.06e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93333682	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs1535701	ENSG00000223745.6	RP4-717I23.3	6.65	8.31e-11	2.06e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93339644	chr1:93262186~93346025:-
THCA	cis	rs797680	0.964	rs2152358	ENSG00000223745.6	RP4-717I23.3	6.65	8.31e-11	2.06e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93168452	chr1:93262186~93346025:-
THCA	cis	rs10266483	0.739	rs2692104	ENSG00000227986.1	TRIM60P18	-6.65	8.31e-11	2.06e-08	-0.24	-0.29	Response to statin therapy;	chr7:64300577	chr7:64355078~64356199:+
THCA	cis	rs897984	0.762	rs11150601	ENSG00000279196.1	RP11-1072A3.3	-6.65	8.32e-11	2.06e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30966478	chr16:30984630~30988270:-
THCA	cis	rs897984	0.721	rs4889525	ENSG00000279196.1	RP11-1072A3.3	-6.65	8.32e-11	2.06e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30978537	chr16:30984630~30988270:-
THCA	cis	rs9393777	0.92	rs35768595	ENSG00000280107.1	AL022393.9	-6.65	8.32e-11	2.06e-08	-0.6	-0.29	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28170845~28172521:+
THCA	cis	rs4072705	1	rs4838207	ENSG00000224020.1	MIR181A2HG	-6.65	8.32e-11	2.06e-08	-0.26	-0.29	Menarche (age at onset);	chr9:124756855	chr9:124658467~124698631:+
THCA	cis	rs6545883	0.894	rs2121661	ENSG00000271889.1	RP11-493E12.1	-6.65	8.32e-11	2.06e-08	-0.28	-0.29	Tuberculosis;	chr2:61334523	chr2:61151433~61162105:-
THCA	cis	rs3764021	0.527	rs11052423	ENSG00000256594.6	RP11-705C15.2	-6.65	8.34e-11	2.07e-08	-0.25	-0.29	Type 1 diabetes;	chr12:9687442	chr12:9633419~9658412:+
THCA	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-6.65	8.36e-11	2.07e-08	-0.35	-0.29	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
THCA	cis	rs3204270	0.639	rs62077183	ENSG00000262049.1	RP13-1032I1.7	6.65	8.37e-11	2.08e-08	0.26	0.29	Dental caries;	chr17:81691910	chr17:81701324~81703300:-
THCA	cis	rs17772222	1	rs17124700	ENSG00000258789.1	RP11-507K2.3	-6.65	8.38e-11	2.08e-08	-0.31	-0.29	Coronary artery calcification;	chr14:88439285	chr14:88551597~88552493:+
THCA	cis	rs4934494	0.768	rs12570813	ENSG00000232936.4	RP11-80H5.2	6.65	8.38e-11	2.08e-08	0.4	0.29	Red blood cell count;	chr10:89630974	chr10:89645282~89650667:+
THCA	cis	rs2243480	1	rs316322	ENSG00000228409.4	CCT6P1	6.65	8.38e-11	2.08e-08	0.34	0.29	Diabetic kidney disease;	chr7:66146246	chr7:65751142~65763354:+
THCA	cis	rs2439831	1	rs2245908	ENSG00000249839.1	AC011330.5	-6.65	8.39e-11	2.08e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43439256	chr15:43663654~43684339:-
THCA	cis	rs7202877	0.706	rs247438	ENSG00000261783.1	RP11-252K23.2	6.65	8.41e-11	2.08e-08	0.51	0.29	Type 1 diabetes;Type 2 diabetes;	chr16:75398751	chr16:75379818~75381260:-
THCA	cis	rs523522	0.962	rs12309824	ENSG00000278344.1	RP11-18C24.8	6.65	8.41e-11	2.08e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120552779	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs3213565	ENSG00000278344.1	RP11-18C24.8	6.65	8.41e-11	2.08e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120554598	chr12:120500735~120501090:-
THCA	cis	rs17711722	0.523	rs313812	ENSG00000228409.4	CCT6P1	6.64	8.42e-11	2.09e-08	0.22	0.29	Calcium levels;	chr7:66040056	chr7:65751142~65763354:+
THCA	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	6.64	8.43e-11	2.09e-08	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000229886.1	RP5-1132H15.3	6.64	8.43e-11	2.09e-08	0.47	0.29	Diabetic kidney disease;	chr7:65892097	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs35391607	ENSG00000229886.1	RP5-1132H15.3	6.64	8.43e-11	2.09e-08	0.47	0.29	Diabetic kidney disease;	chr7:65895842	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs13220979	ENSG00000229886.1	RP5-1132H15.3	6.64	8.43e-11	2.09e-08	0.47	0.29	Diabetic kidney disease;	chr7:65898217	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34974928	ENSG00000229886.1	RP5-1132H15.3	6.64	8.43e-11	2.09e-08	0.47	0.29	Diabetic kidney disease;	chr7:65899019	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000228409.4	CCT6P1	-6.64	8.43e-11	2.09e-08	-0.35	-0.29	Diabetic kidney disease;	chr7:66253864	chr7:65751142~65763354:+
THCA	cis	rs944990	0.576	rs10821126	ENSG00000227603.1	RP11-165J3.6	6.64	8.44e-11	2.09e-08	0.3	0.29	Body mass index;	chr9:93436451	chr9:93435332~93437121:-
THCA	cis	rs2439831	0.85	rs68079546	ENSG00000275601.1	AC011330.13	-6.64	8.44e-11	2.09e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43844759	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs56909447	ENSG00000275601.1	AC011330.13	-6.64	8.44e-11	2.09e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43845420	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28476182	ENSG00000275601.1	AC011330.13	-6.64	8.44e-11	2.09e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43847445	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28696802	ENSG00000275601.1	AC011330.13	-6.64	8.44e-11	2.09e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43848197	chr15:43642389~43643023:-
THCA	cis	rs5758659	0.967	rs5758670	ENSG00000182057.4	OGFRP1	6.64	8.44e-11	2.09e-08	0.34	0.29	Cognitive function;	chr22:42240681	chr22:42269753~42275196:+
THCA	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	6.64	8.44e-11	2.09e-08	0.43	0.29	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
THCA	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	6.64	8.44e-11	2.09e-08	0.43	0.29	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	6.64	8.44e-11	2.09e-08	0.43	0.29	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	6.64	8.44e-11	2.09e-08	0.43	0.29	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
THCA	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-6.64	8.45e-11	2.09e-08	-0.31	-0.29	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
THCA	cis	rs10129255	0.784	rs7147210	ENSG00000211974.3	IGHV2-70	6.64	8.48e-11	2.1e-08	0.23	0.29	Kawasaki disease;	chr14:106705271	chr14:106723574~106724093:-
THCA	cis	rs28386778	0.897	rs7222189	ENSG00000240280.5	TCAM1P	-6.64	8.49e-11	2.1e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63759012	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs2597633	ENSG00000240280.5	TCAM1P	-6.64	8.49e-11	2.1e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63795511	chr17:63849292~63864379:+
THCA	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	6.64	8.49e-11	2.1e-08	0.37	0.29	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
THCA	cis	rs516805	0.564	rs2679658	ENSG00000279453.1	RP3-425C14.4	-6.64	8.5e-11	2.1e-08	-0.32	-0.29	Lymphocyte counts;	chr6:122109293	chr6:122436789~122439223:-
THCA	cis	rs4072705	0.935	rs2184219	ENSG00000224020.1	MIR181A2HG	-6.64	8.51e-11	2.11e-08	-0.28	-0.29	Menarche (age at onset);	chr9:124770625	chr9:124658467~124698631:+
THCA	cis	rs10875746	0.551	rs2054904	ENSG00000269514.1	RP11-370I10.12	6.64	8.51e-11	2.11e-08	0.29	0.29	Longevity (90 years and older);	chr12:48330571	chr12:48198387~48202031:+
THCA	cis	rs6545883	0.894	rs2694649	ENSG00000271889.1	RP11-493E12.1	-6.64	8.51e-11	2.11e-08	-0.28	-0.29	Tuberculosis;	chr2:61346691	chr2:61151433~61162105:-
THCA	cis	rs10131894	0.611	rs175000	ENSG00000279594.1	RP11-950C14.10	-6.64	8.51e-11	2.11e-08	-0.27	-0.29	Coronary artery disease;	chr14:74969664	chr14:75011269~75012851:-
THCA	cis	rs28386778	0.897	rs7221853	ENSG00000240280.5	TCAM1P	-6.64	8.52e-11	2.11e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63782476	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs7207005	ENSG00000240280.5	TCAM1P	-6.64	8.52e-11	2.11e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63782995	chr17:63849292~63864379:+
THCA	cis	rs77972916	0.519	rs13411327	ENSG00000234936.1	AC010883.5	6.64	8.52e-11	2.11e-08	0.37	0.29	Granulocyte percentage of myeloid white cells;	chr2:43288344	chr2:43229573~43233394:+
THCA	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	6.64	8.52e-11	2.11e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	6.64	8.52e-11	2.11e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
THCA	cis	rs10491083	0.661	rs2072150	ENSG00000256806.3	C17orf100	-6.64	8.53e-11	2.11e-08	-0.49	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6661308	chr17:6651718~6653473:+
THCA	cis	rs853679	0.76	rs11967137	ENSG00000280107.1	AL022393.9	-6.64	8.53e-11	2.11e-08	-0.36	-0.29	Depression;	chr6:28231986	chr6:28170845~28172521:+
THCA	cis	rs28386778	0.863	rs2251164	ENSG00000240280.5	TCAM1P	-6.64	8.54e-11	2.11e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63806760	chr17:63849292~63864379:+
THCA	cis	rs6696239	0.513	rs3010194	ENSG00000227711.2	RP11-275O4.5	-6.64	8.55e-11	2.12e-08	-0.31	-0.29	Height;	chr1:227608220	chr1:227509028~227520477:-
THCA	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-6.64	8.56e-11	2.12e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-6.64	8.56e-11	2.12e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-6.64	8.56e-11	2.12e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-6.64	8.56e-11	2.12e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
THCA	cis	rs11096990	0.892	rs2381349	ENSG00000249207.1	RP11-360F5.1	6.64	8.56e-11	2.12e-08	0.36	0.29	Cognitive function;	chr4:39210390	chr4:39112677~39126818:-
THCA	cis	rs4713118	0.869	rs10214440	ENSG00000280107.1	AL022393.9	-6.64	8.57e-11	2.12e-08	-0.34	-0.29	Parkinson's disease;	chr6:27734661	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs6902689	ENSG00000280107.1	AL022393.9	-6.64	8.57e-11	2.12e-08	-0.34	-0.29	Parkinson's disease;	chr6:27741662	chr6:28170845~28172521:+
THCA	cis	rs2239557	0.961	rs10133356	ENSG00000259065.1	RP5-1021I20.1	6.64	8.58e-11	2.12e-08	0.36	0.29	Common traits (Other);	chr14:74181056	chr14:73787360~73803270:+
THCA	cis	rs2239557	1	rs10144220	ENSG00000259065.1	RP5-1021I20.1	6.64	8.58e-11	2.12e-08	0.36	0.29	Common traits (Other);	chr14:74181201	chr14:73787360~73803270:+
THCA	cis	rs2239557	0.961	rs10135858	ENSG00000259065.1	RP5-1021I20.1	6.64	8.58e-11	2.12e-08	0.36	0.29	Common traits (Other);	chr14:74181259	chr14:73787360~73803270:+
THCA	cis	rs2239557	1	rs10140433	ENSG00000259065.1	RP5-1021I20.1	6.64	8.59e-11	2.12e-08	0.36	0.29	Common traits (Other);	chr14:74193286	chr14:73787360~73803270:+
THCA	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-6.64	8.59e-11	2.13e-08	-0.28	-0.29	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
THCA	cis	rs7208859	0.673	rs1347360	ENSG00000263603.1	CTD-2349P21.5	-6.64	8.59e-11	2.13e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30729469~30731202:+
THCA	cis	rs28386778	0.897	rs2665831	ENSG00000240280.5	TCAM1P	-6.64	8.6e-11	2.13e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63835032	chr17:63849292~63864379:+
THCA	cis	rs7189233	1	rs16952251	ENSG00000279344.1	RP11-44F14.7	6.64	8.61e-11	2.13e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53449226	chr16:53478957~53481550:-
THCA	cis	rs4819052	0.679	rs2838859	ENSG00000237664.1	LINC00316	-6.64	8.61e-11	2.13e-08	-0.29	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45338590~45341990:-
THCA	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-6.64	8.62e-11	2.13e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-6.64	8.62e-11	2.13e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
THCA	cis	rs1020064	0.583	rs2576775	ENSG00000235319.1	AC012360.4	-6.64	8.62e-11	2.13e-08	-0.37	-0.29	AIDS;	chr2:105356755	chr2:105324210~105330529:+
THCA	cis	rs5742933	0.711	rs12693551	ENSG00000273240.1	RP11-455J20.3	6.64	8.63e-11	2.13e-08	0.31	0.29	Ferritin levels;	chr2:189664505	chr2:189763859~189764456:-
THCA	cis	rs7208859	0.673	rs216418	ENSG00000264538.5	SUZ12P1	-6.64	8.63e-11	2.13e-08	-0.28	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs216423	ENSG00000264538.5	SUZ12P1	-6.64	8.63e-11	2.13e-08	-0.28	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30709299~30790908:+
THCA	cis	rs2976388	1	rs2294008	ENSG00000253741.1	CTD-2292P10.4	6.64	8.63e-11	2.14e-08	0.37	0.29	Urinary tract infection frequency;	chr8:142680513	chr8:142702252~142726973:-
THCA	cis	rs7586673	0.725	rs6715870	ENSG00000227403.1	AC009299.3	-6.64	8.64e-11	2.14e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr2:161038275	chr2:161244739~161249050:+
THCA	cis	rs2562456	0.876	rs7252585	ENSG00000213976.4	CTD-2561J22.2	6.64	8.64e-11	2.14e-08	0.31	0.29	Pain;	chr19:21475141	chr19:21382865~21387177:+
THCA	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	6.64	8.64e-11	2.14e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	6.64	8.64e-11	2.14e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
THCA	cis	rs4835473	0.897	rs28825455	ENSG00000251600.4	RP11-673E1.1	6.64	8.64e-11	2.14e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143707593	chr4:143912331~143982454:+
THCA	cis	rs8014204	0.604	rs11625594	ENSG00000279594.1	RP11-950C14.10	6.64	8.65e-11	2.14e-08	0.29	0.29	Caffeine consumption;	chr14:74923130	chr14:75011269~75012851:-
THCA	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	6.64	8.65e-11	2.14e-08	0.24	0.29	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000229886.1	RP5-1132H15.3	6.64	8.66e-11	2.14e-08	0.47	0.29	Diabetic kidney disease;	chr7:65999249	chr7:66025126~66031544:-
THCA	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-6.64	8.66e-11	2.14e-08	-0.47	-0.29	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
THCA	cis	rs2243480	1	rs313809	ENSG00000229886.1	RP5-1132H15.3	6.64	8.66e-11	2.14e-08	0.48	0.29	Diabetic kidney disease;	chr7:66034996	chr7:66025126~66031544:-
THCA	cis	rs7208859	0.673	rs11652370	ENSG00000263603.1	CTD-2349P21.5	-6.64	8.68e-11	2.15e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30729469~30731202:+
THCA	cis	rs593531	0.531	rs662393	ENSG00000212961.4	HNRNPA1P40	6.64	8.69e-11	2.15e-08	0.37	0.29	Neuroticism;	chr11:74375263	chr11:74354443~74355720:+
THCA	cis	rs10740039	0.516	rs10761526	ENSG00000254271.1	RP11-131N11.4	6.64	8.7e-11	2.15e-08	0.38	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60594661	chr10:60734342~60741828:+
THCA	cis	rs7851660	0.805	rs7038998	ENSG00000236130.1	PTCSC2	-6.64	8.7e-11	2.15e-08	-0.24	-0.29	Strep throat;	chr9:97900114	chr9:97805935~97810008:-
THCA	cis	rs1577330	0.747	rs2991949	ENSG00000254396.1	RP11-56F10.3	6.64	8.71e-11	2.15e-08	0.41	0.29	IgG glycosylation;	chr9:27100893	chr9:27102630~27104728:+
THCA	cis	rs7267979	1	rs6050573	ENSG00000274414.1	RP5-965G21.4	-6.64	8.71e-11	2.15e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25239007~25245229:-
THCA	cis	rs720475	0.732	rs73159066	ENSG00000204959.4	ARHGEF34P	-6.64	8.72e-11	2.16e-08	-0.34	-0.29	Breast cancer;	chr7:144426495	chr7:144272445~144286966:-
THCA	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-6.64	8.73e-11	2.16e-08	-0.34	-0.29	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
THCA	cis	rs897984	0.762	rs12931046	ENSG00000279196.1	RP11-1072A3.3	-6.64	8.73e-11	2.16e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30975823	chr16:30984630~30988270:-
THCA	cis	rs804292	0.6	rs3729851	ENSG00000255046.1	RP11-297N6.4	6.64	8.73e-11	2.16e-08	0.46	0.29	Nicotine use;Alcohol dependence;	chr8:11755333	chr8:11797928~11802568:-
THCA	cis	rs3806843	0.966	rs10036519	ENSG00000202515.1	VTRNA1-3	6.64	8.73e-11	2.16e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140772116	chr5:140726158~140726246:+
THCA	cis	rs4835473	0.864	rs57648439	ENSG00000251600.4	RP11-673E1.1	-6.64	8.74e-11	2.16e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143691519	chr4:143912331~143982454:+
THCA	cis	rs7085104	0.632	rs6162	ENSG00000236937.2	PTGES3P4	6.64	8.74e-11	2.16e-08	0.37	0.29	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102845595~102845950:+
THCA	cis	rs11096990	0.819	rs2711992	ENSG00000249207.1	RP11-360F5.1	6.64	8.74e-11	2.16e-08	0.38	0.29	Cognitive function;	chr4:39148651	chr4:39112677~39126818:-
THCA	cis	rs2288884	0.943	rs11671792	ENSG00000275055.1	CTC-471J1.11	-6.64	8.75e-11	2.16e-08	-0.3	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52078430	chr19:52049007~52049754:+
THCA	cis	rs12348691	0.503	rs6478423	ENSG00000236130.1	PTCSC2	-6.64	8.76e-11	2.16e-08	-0.25	-0.29	Alopecia areata;	chr9:97829748	chr9:97805935~97810008:-
THCA	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-6.64	8.77e-11	2.17e-08	-0.27	-0.29	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
THCA	cis	rs10740039	0.516	rs7072678	ENSG00000254271.1	RP11-131N11.4	-6.64	8.77e-11	2.17e-08	-0.38	-0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60585011	chr10:60734342~60741828:+
THCA	cis	rs71636778	0.509	rs12746810	ENSG00000260063.1	RP5-968P14.2	-6.64	8.77e-11	2.17e-08	-0.57	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26686642	chr1:26692132~26694131:-
THCA	cis	rs9400467	0.528	rs6933627	ENSG00000271789.1	RP5-1112D6.7	-6.64	8.78e-11	2.17e-08	-0.28	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111297126~111298510:+
THCA	cis	rs3204270	0.714	rs79243595	ENSG00000262049.1	RP13-1032I1.7	6.64	8.8e-11	2.17e-08	0.26	0.29	Dental caries;	chr17:81714190	chr17:81701324~81703300:-
THCA	cis	rs2243480	1	rs160644	ENSG00000228409.4	CCT6P1	6.64	8.8e-11	2.18e-08	0.33	0.29	Diabetic kidney disease;	chr7:66093199	chr7:65751142~65763354:+
THCA	cis	rs2836950	1	rs2836950	ENSG00000255568.3	BRWD1-AS2	-6.64	8.83e-11	2.18e-08	-0.25	-0.29	Menarche (age at onset);	chr21:39232503	chr21:39313935~39314962:+
THCA	cis	rs3764021	0.527	rs10772062	ENSG00000256594.6	RP11-705C15.2	6.64	8.83e-11	2.18e-08	0.25	0.29	Type 1 diabetes;	chr12:9712561	chr12:9633419~9658412:+
THCA	cis	rs2439831	1	rs2444029	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43445286	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2467740	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43454594	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs561863	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43469154	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs689616	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43469703	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs689647	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43469998	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2251538	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43475011	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs2439832	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43487488	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2439850	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43492656	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2467736	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43492719	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2444250	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43492853	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs101094	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43495124	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs689781	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43499899	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2584725	ENSG00000249839.1	AC011330.5	-6.64	8.84e-11	2.18e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43500937	chr15:43663654~43684339:-
THCA	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	6.64	8.84e-11	2.18e-08	0.37	0.29	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
THCA	cis	rs6696239	0.513	rs2999741	ENSG00000227711.2	RP11-275O4.5	-6.64	8.86e-11	2.19e-08	-0.31	-0.29	Height;	chr1:227597504	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs2999743	ENSG00000227711.2	RP11-275O4.5	-6.64	8.86e-11	2.19e-08	-0.31	-0.29	Height;	chr1:227598205	chr1:227509028~227520477:-
THCA	cis	rs10799445	0.568	rs2935147	ENSG00000227711.2	RP11-275O4.5	-6.64	8.86e-11	2.19e-08	-0.31	-0.29	Height;	chr1:227600286	chr1:227509028~227520477:-
THCA	cis	rs605783	0.564	rs9295574	ENSG00000237685.1	RP11-360O19.4	6.64	8.86e-11	2.19e-08	0.36	0.29	Monocyte percentage of white cells;Monocyte count;	chr6:10531011	chr6:10511036~10514546:-
THCA	cis	rs7247513	0.964	rs8105902	ENSG00000213290.4	PGK1P2	-6.64	8.89e-11	2.2e-08	-0.35	-0.29	Bipolar disorder;	chr19:12607537	chr19:12559571~12561105:+
THCA	cis	rs9400467	0.528	rs456865	ENSG00000271789.1	RP5-1112D6.7	-6.64	8.89e-11	2.2e-08	-0.28	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.508	rs1676863	ENSG00000271789.1	RP5-1112D6.7	-6.64	8.89e-11	2.2e-08	-0.28	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111297126~111298510:+
THCA	cis	rs6991838	0.778	rs13261559	ENSG00000272010.1	CTD-3025N20.3	6.64	8.9e-11	2.2e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.778	rs7843697	ENSG00000272010.1	CTD-3025N20.3	6.64	8.9e-11	2.2e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.778	rs7843724	ENSG00000272010.1	CTD-3025N20.3	6.64	8.9e-11	2.2e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.806	rs35284121	ENSG00000272010.1	CTD-3025N20.3	6.64	8.9e-11	2.2e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65591850~65592472:-
THCA	cis	rs7403037	0.92	rs11161097	ENSG00000259905.4	PWRN1	6.64	8.9e-11	2.2e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24486725	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.959	rs12914724	ENSG00000259905.4	PWRN1	6.64	8.9e-11	2.2e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24500623	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.959	rs12910800	ENSG00000259905.4	PWRN1	6.64	8.9e-11	2.2e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24500787	chr15:24493137~24652130:+
THCA	cis	rs79349575	0.783	rs62078370	ENSG00000248278.1	SUMO2P17	6.64	8.93e-11	2.2e-08	0.34	0.29	Type 2 diabetes;	chr17:48949474	chr17:48874860~48908983:-
THCA	cis	rs28386778	0.863	rs2584637	ENSG00000240280.5	TCAM1P	-6.64	8.94e-11	2.21e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63865592	chr17:63849292~63864379:+
THCA	cis	rs2243480	1	rs422164	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66121618	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316313	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66128561	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316312	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66131504	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs419603	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66132354	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs387676	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66133233	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66133553	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs431076	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66135333	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66136518	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316334	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66137139	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316330	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66140385	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316326	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66144466	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316325	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66144531	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316321	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66146626	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316318	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66147917	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316317	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66148650	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316304	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66151907	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs2465120	ENSG00000228409.4	CCT6P1	6.64	8.94e-11	2.21e-08	0.33	0.29	Diabetic kidney disease;	chr7:66155987	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66157859	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs4718309	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66162777	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6460274	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66163497	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs7787230	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66164112	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66170354	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6974723	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66172952	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs9769882	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66177938	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6966322	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66181767	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs4145008	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66182524	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs4718315	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66183554	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs4718316	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66183744	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1873494	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66184912	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6959002	ENSG00000228409.4	CCT6P1	-6.64	8.94e-11	2.21e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66185509	chr7:65751142~65763354:+
THCA	cis	rs728616	0.867	rs61858980	ENSG00000225484.5	NUTM2B-AS1	-6.64	8.94e-11	2.21e-08	-0.55	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056862	chr10:79663088~79826594:-
THCA	cis	rs2243480	1	rs10247526	ENSG00000229886.1	RP5-1132H15.3	-6.64	8.95e-11	2.21e-08	-0.48	-0.29	Diabetic kidney disease;	chr7:66315709	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000229886.1	RP5-1132H15.3	-6.64	8.95e-11	2.21e-08	-0.48	-0.29	Diabetic kidney disease;	chr7:66333815	chr7:66025126~66031544:-
THCA	cis	rs3204270	0.639	rs7215738	ENSG00000262049.1	RP13-1032I1.7	6.64	8.95e-11	2.21e-08	0.26	0.29	Dental caries;	chr17:81692817	chr17:81701324~81703300:-
THCA	cis	rs7586673	1	rs16845584	ENSG00000235724.7	AC009299.2	6.64	8.95e-11	2.21e-08	0.32	0.29	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161222785~161308303:-
THCA	cis	rs7119038	0.509	rs10790261	ENSG00000255239.1	AP002954.6	6.64	8.95e-11	2.21e-08	0.45	0.29	Sjögren's syndrome;	chr11:118709038	chr11:118688039~118690600:-
THCA	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-6.63	8.96e-11	2.21e-08	-0.43	-0.29	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
THCA	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-6.63	8.97e-11	2.21e-08	-0.27	-0.29	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
THCA	cis	rs6671200	0.667	rs76833598	ENSG00000235501.4	RP4-639F20.1	-6.63	8.97e-11	2.21e-08	-0.6	-0.29	Stearic acid (18:0) levels;	chr1:94928425	chr1:94927566~94963270:+
THCA	cis	rs1577330	0.898	rs627339	ENSG00000254396.1	RP11-56F10.3	-6.63	8.98e-11	2.22e-08	-0.41	-0.29	IgG glycosylation;	chr9:27096924	chr9:27102630~27104728:+
THCA	cis	rs56804039	1	rs17616779	ENSG00000253893.2	FAM85B	-6.63	8.99e-11	2.22e-08	-0.42	-0.29	Cervical cancer;	chr8:8524864	chr8:8167819~8226614:-
THCA	cis	rs10899021	0.92	rs10899014	ENSG00000279353.1	RP11-864N7.4	6.63	9e-11	2.22e-08	0.57	0.29	Response to metformin (IC50);	chr11:74614064	chr11:74698231~74699658:-
THCA	cis	rs10899021	0.92	rs11236172	ENSG00000279353.1	RP11-864N7.4	6.63	9e-11	2.22e-08	0.57	0.29	Response to metformin (IC50);	chr11:74619843	chr11:74698231~74699658:-
THCA	cis	rs10899021	0.92	rs12287097	ENSG00000279353.1	RP11-864N7.4	6.63	9e-11	2.22e-08	0.57	0.29	Response to metformin (IC50);	chr11:74621619	chr11:74698231~74699658:-
THCA	cis	rs6696239	0.513	rs7542685	ENSG00000227711.2	RP11-275O4.5	6.63	9e-11	2.22e-08	0.31	0.29	Height;	chr1:227542752	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs1495847	ENSG00000227711.2	RP11-275O4.5	6.63	9e-11	2.22e-08	0.31	0.29	Hip circumference adjusted for BMI;	chr1:227546608	chr1:227509028~227520477:-
THCA	cis	rs853679	0.76	rs11962305	ENSG00000280107.1	AL022393.9	-6.63	9e-11	2.22e-08	-0.37	-0.29	Depression;	chr6:28232159	chr6:28170845~28172521:+
THCA	cis	rs7208859	0.673	rs216420	ENSG00000264538.5	SUZ12P1	-6.63	9.02e-11	2.22e-08	-0.28	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30709299~30790908:+
THCA	cis	rs7189233	0.955	rs72801821	ENSG00000279344.1	RP11-44F14.7	6.63	9.03e-11	2.23e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53445740	chr16:53478957~53481550:-
THCA	cis	rs2243480	0.803	rs423187	ENSG00000229886.1	RP5-1132H15.3	6.63	9.04e-11	2.23e-08	0.48	0.29	Diabetic kidney disease;	chr7:66044512	chr7:66025126~66031544:-
THCA	cis	rs28386778	0.897	rs2665832	ENSG00000240280.5	TCAM1P	-6.63	9.04e-11	2.23e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63834901	chr17:63849292~63864379:+
THCA	cis	rs529866	0.5	rs918739	ENSG00000262703.1	RP11-485G7.6	-6.63	9.06e-11	2.23e-08	-0.34	-0.29	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11348143~11349321:-
THCA	cis	rs9867325	0.895	rs9879531	ENSG00000273486.1	RP11-731C17.2	6.63	9.07e-11	2.24e-08	0.31	0.29	Body mass index;	chr3:136920133	chr3:136837338~136839021:-
THCA	cis	rs10208649	1	rs72904915	ENSG00000233266.1	HMGB1P31	6.63	9.07e-11	2.24e-08	0.68	0.29	Body mass index;	chr2:54000213	chr2:54051334~54051760:+
THCA	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-6.63	9.07e-11	2.24e-08	-0.52	-0.29	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-6.63	9.07e-11	2.24e-08	-0.52	-0.29	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-6.63	9.08e-11	2.24e-08	-0.52	-0.29	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
THCA	cis	rs4143844	0.867	rs34997975	ENSG00000259251.2	RP11-643M14.1	6.63	9.09e-11	2.24e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:61929987	chr15:62060503~62062434:+
THCA	cis	rs9402743	0.678	rs965191	ENSG00000231028.7	LINC00271	-6.63	9.09e-11	2.24e-08	-0.24	-0.29	Systemic lupus erythematosus;	chr6:135618363	chr6:135497801~135716055:+
THCA	cis	rs6479901	0.841	rs10995453	ENSG00000232075.1	MRPL35P2	-6.63	9.09e-11	2.24e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63174571	chr10:63634317~63634827:-
THCA	cis	rs3806843	0.966	rs11953833	ENSG00000202515.1	VTRNA1-3	-6.63	9.09e-11	2.24e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140775538	chr5:140726158~140726246:+
THCA	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-6.63	9.1e-11	2.24e-08	-0.38	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
THCA	cis	rs12435908	1	rs61315421	ENSG00000276116.2	FUT8-AS1	-6.63	9.1e-11	2.24e-08	-0.49	-0.29	Ischemic stroke;	chr14:65609885	chr14:65411170~65412690:-
THCA	cis	rs4835473	0.897	rs6835827	ENSG00000251600.4	RP11-673E1.1	6.63	9.11e-11	2.24e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143712803	chr4:143912331~143982454:+
THCA	cis	rs6061231	0.834	rs2427307	ENSG00000275437.1	RP5-908M14.10	6.63	9.11e-11	2.25e-08	0.27	0.29	Colorectal cancer;	chr20:62391630	chr20:62402236~62405935:-
THCA	cis	rs28386778	0.897	rs2584610	ENSG00000240280.5	TCAM1P	-6.63	9.11e-11	2.25e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63857423	chr17:63849292~63864379:+
THCA	cis	rs2562456	0.55	rs4809143	ENSG00000268555.1	RP11-678G14.3	6.63	9.12e-11	2.25e-08	0.44	0.29	Pain;	chr19:21589926	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.583	rs4809144	ENSG00000268555.1	RP11-678G14.3	6.63	9.12e-11	2.25e-08	0.44	0.29	Pain;	chr19:21589928	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.652	rs62110214	ENSG00000268555.1	RP11-678G14.3	6.63	9.12e-11	2.25e-08	0.44	0.29	Pain;	chr19:21592406	chr19:21570822~21587322:-
THCA	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-6.63	9.12e-11	2.25e-08	-0.32	-0.29	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs2130813	ENSG00000232901.1	CYCSP10	6.63	9.12e-11	2.25e-08	0.37	0.29	Alzheimer's disease;	chr3:9997022	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs17081288	ENSG00000232901.1	CYCSP10	6.63	9.12e-11	2.25e-08	0.37	0.29	Alzheimer's disease;	chr3:10000429	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.816	rs56271597	ENSG00000232901.1	CYCSP10	6.63	9.12e-11	2.25e-08	0.37	0.29	Alzheimer's disease;	chr3:10001106	chr3:10000647~10000940:-
THCA	cis	rs7208859	0.673	rs216440	ENSG00000263603.1	CTD-2349P21.5	-6.63	9.12e-11	2.25e-08	-0.47	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30729469~30731202:+
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000220721.1	OR1F12	6.63	9.13e-11	2.25e-08	0.39	0.29	Parkinson's disease;	chr6:28055973	chr6:28073316~28074233:+
THCA	cis	rs17594362	0.697	rs9562318	ENSG00000264190.1	MIR5006	6.63	9.14e-11	2.25e-08	0.39	0.29	Multiple sclerosis;	chr13:41563187	chr13:41568286~41568395:-
THCA	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	6.63	9.15e-11	2.25e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
THCA	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-6.63	9.15e-11	2.26e-08	-0.31	-0.29	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
THCA	cis	rs8059260	0.673	rs77240340	ENSG00000274038.1	RP11-66H6.4	-6.63	9.16e-11	2.26e-08	-0.54	-0.29	Alcohol consumption over the past year;	chr16:10945778	chr16:11056556~11057034:+
THCA	cis	rs3758785	0.623	rs77241189	ENSG00000255893.1	RP11-685N10.1	-6.63	9.16e-11	2.26e-08	-0.35	-0.29	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94410151	chr11:94472908~94473570:-
THCA	cis	rs74233809	0.901	rs4409766	ENSG00000213277.3	MARCKSL1P1	6.63	9.16e-11	2.26e-08	0.45	0.29	Birth weight;	chr10:102856906	chr10:103175554~103176094:+
THCA	cis	rs10129255	0.956	rs10137268	ENSG00000211974.3	IGHV2-70	6.63	9.17e-11	2.26e-08	0.23	0.29	Kawasaki disease;	chr14:106697402	chr14:106723574~106724093:-
THCA	cis	rs7746199	0.668	rs7749305	ENSG00000219392.1	RP1-265C24.5	-6.63	9.17e-11	2.26e-08	-0.57	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28115628~28116551:+
THCA	cis	rs4143844	0.867	rs34486946	ENSG00000259251.2	RP11-643M14.1	6.63	9.18e-11	2.26e-08	0.56	0.29	Bipolar disorder and schizophrenia;	chr15:61929355	chr15:62060503~62062434:+
THCA	cis	rs28386778	0.897	rs7212196	ENSG00000240280.5	TCAM1P	-6.63	9.19e-11	2.26e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63757621	chr17:63849292~63864379:+
THCA	cis	rs438465	1	rs9371114	ENSG00000226194.4	RP1-137D17.1	-6.63	9.21e-11	2.27e-08	-0.45	-0.29	Corneal astigmatism;	chr6:169449792	chr6:169369998~169388385:-
THCA	cis	rs12435908	1	rs8005309	ENSG00000276116.2	FUT8-AS1	-6.63	9.21e-11	2.27e-08	-0.47	-0.29	Ischemic stroke;	chr14:65589790	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs73268521	ENSG00000276116.2	FUT8-AS1	-6.63	9.21e-11	2.27e-08	-0.47	-0.29	Ischemic stroke;	chr14:65626525	chr14:65411170~65412690:-
THCA	cis	rs4845570	0.85	rs4504897	ENSG00000203288.3	RP11-98D18.9	6.63	9.24e-11	2.28e-08	0.29	0.29	Coronary artery disease;	chr1:151794375	chr1:151790804~151794402:+
THCA	cis	rs2562456	0.917	rs2650804	ENSG00000213976.4	CTD-2561J22.2	-6.63	9.25e-11	2.28e-08	-0.31	-0.29	Pain;	chr19:21497382	chr19:21382865~21387177:+
THCA	cis	rs7829975	0.626	rs332040	ENSG00000254153.1	CTA-398F10.2	-6.63	9.25e-11	2.28e-08	-0.32	-0.29	Mood instability;	chr8:8872978	chr8:8456909~8461337:-
THCA	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	6.63	9.25e-11	2.28e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	6.63	9.25e-11	2.28e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
THCA	cis	rs28386778	0.897	rs896064	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63783572	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.83	rs2665841	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63783859	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2584635	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63788574	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs9915552	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63791735	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2665844	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63797095	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.83	rs2597637	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63797706	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2028567	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63837966	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs6504187	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63839739	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2859619	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63840326	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs2727327	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63846062	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.831	rs2584618	ENSG00000240280.5	TCAM1P	-6.63	9.28e-11	2.29e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63846251	chr17:63849292~63864379:+
THCA	cis	rs6496044	0.568	rs12899946	ENSG00000259295.5	CSPG4P12	6.63	9.28e-11	2.29e-08	0.37	0.29	Interstitial lung disease;	chr15:85522851	chr15:85191438~85213905:+
THCA	cis	rs6496044	0.568	rs12898783	ENSG00000259295.5	CSPG4P12	6.63	9.28e-11	2.29e-08	0.37	0.29	Interstitial lung disease;	chr15:85522869	chr15:85191438~85213905:+
THCA	cis	rs11722228	0.522	rs73212817	ENSG00000261490.1	RP11-448G15.3	6.63	9.29e-11	2.29e-08	0.22	0.29	Urate levels;Serum uric acid levels;Gout;	chr4:10062387	chr4:10068089~10073019:-
THCA	cis	rs523522	0.962	rs651627	ENSG00000278344.1	RP11-18C24.8	6.63	9.29e-11	2.29e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120571395	chr12:120500735~120501090:-
THCA	cis	rs9926296	0.548	rs6500439	ENSG00000260259.1	RP11-368I7.4	-6.63	9.3e-11	2.29e-08	-0.32	-0.29	Vitiligo;	chr16:89741867	chr16:89682620~89686569:-
THCA	cis	rs6696239	0.513	rs2088211	ENSG00000227711.2	RP11-275O4.5	6.63	9.3e-11	2.29e-08	0.31	0.29	Height;	chr1:227575956	chr1:227509028~227520477:-
THCA	cis	rs7085104	0.632	rs7097872	ENSG00000236937.2	PTGES3P4	6.63	9.3e-11	2.29e-08	0.37	0.29	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102845595~102845950:+
THCA	cis	rs9902453	0.709	rs6505162	ENSG00000264007.1	RP11-68I3.10	6.63	9.3e-11	2.29e-08	0.33	0.29	Coffee consumption (cups per day);	chr17:30117165	chr17:29621617~29622254:-
THCA	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-6.63	9.32e-11	2.29e-08	-0.26	-0.29	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
THCA	cis	rs9878978	0.722	rs17194427	ENSG00000237990.3	CNTN4-AS1	6.63	9.32e-11	2.3e-08	0.36	0.29	Blood pressure (smoking interaction);	chr3:2453518	chr3:3039033~3069242:-
THCA	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	6.63	9.33e-11	2.3e-08	0.43	0.29	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
THCA	cis	rs853679	0.546	rs200490	ENSG00000219392.1	RP1-265C24.5	-6.63	9.33e-11	2.3e-08	-0.5	-0.29	Depression;	chr6:27829157	chr6:28115628~28116551:+
THCA	cis	rs16949788	1	rs9806474	ENSG00000261351.2	CTD-3185P2.1	-6.63	9.33e-11	2.3e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66354175	chr15:66488658~66492109:-
THCA	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-6.63	9.35e-11	2.3e-08	-0.27	-0.29	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
THCA	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-6.63	9.35e-11	2.3e-08	-0.27	-0.29	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
THCA	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-6.63	9.35e-11	2.3e-08	-0.27	-0.29	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
THCA	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-6.63	9.35e-11	2.3e-08	-0.27	-0.29	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
THCA	cis	rs2243480	1	rs1723267	ENSG00000229886.1	RP5-1132H15.3	6.63	9.35e-11	2.3e-08	0.47	0.29	Diabetic kidney disease;	chr7:66008327	chr7:66025126~66031544:-
THCA	cis	rs11096990	0.819	rs2435528	ENSG00000249207.1	RP11-360F5.1	6.63	9.36e-11	2.3e-08	0.38	0.29	Cognitive function;	chr4:39155916	chr4:39112677~39126818:-
THCA	cis	rs16843372	0.562	rs10194836	ENSG00000251491.2	OR7E28P	-6.63	9.36e-11	2.3e-08	-0.39	-0.29	Obesity-related traits;	chr2:158838428	chr2:158862311~158863285:+
THCA	cis	rs4143844	0.867	rs11071640	ENSG00000259251.2	RP11-643M14.1	6.63	9.36e-11	2.3e-08	0.56	0.29	Bipolar disorder and schizophrenia;	chr15:61918305	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs12907567	ENSG00000259251.2	RP11-643M14.1	6.63	9.36e-11	2.3e-08	0.56	0.29	Bipolar disorder and schizophrenia;	chr15:61922408	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs34853395	ENSG00000259251.2	RP11-643M14.1	6.63	9.36e-11	2.3e-08	0.56	0.29	Bipolar disorder and schizophrenia;	chr15:61923024	chr15:62060503~62062434:+
THCA	cis	rs8141529	0.778	rs7287806	ENSG00000226471.5	CTA-292E10.6	-6.63	9.37e-11	2.31e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28817023	chr22:28800683~28848559:+
THCA	cis	rs467650	0.534	rs251532	ENSG00000246763.5	RGMB-AS1	6.63	9.37e-11	2.31e-08	0.29	0.29	Venous thromboembolism (SNP x SNP interaction);	chr5:98603579	chr5:98769618~98773469:-
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000213640.3	EEF1DP4	-6.63	9.37e-11	2.31e-08	-0.35	-0.29	Calcium levels;	chr7:65825628	chr7:64862999~64864370:+
THCA	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	6.63	9.38e-11	2.31e-08	0.25	0.29	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000229886.1	RP5-1132H15.3	6.63	9.39e-11	2.31e-08	0.47	0.29	Diabetic kidney disease;	chr7:65996588	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1701750	ENSG00000229886.1	RP5-1132H15.3	6.63	9.39e-11	2.31e-08	0.47	0.29	Diabetic kidney disease;	chr7:66002158	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1701758	ENSG00000229886.1	RP5-1132H15.3	6.63	9.39e-11	2.31e-08	0.47	0.29	Diabetic kidney disease;	chr7:66005214	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000229886.1	RP5-1132H15.3	6.63	9.39e-11	2.31e-08	0.47	0.29	Diabetic kidney disease;	chr7:66005945	chr7:66025126~66031544:-
THCA	cis	rs7260598	1	rs11666415	ENSG00000268442.1	CTD-2027I19.2	6.63	9.39e-11	2.31e-08	0.39	0.29	Response to taxane treatment (placlitaxel);	chr19:24045710	chr19:24162370~24163425:-
THCA	cis	rs7260598	1	rs7254349	ENSG00000268442.1	CTD-2027I19.2	6.63	9.39e-11	2.31e-08	0.39	0.29	Response to taxane treatment (placlitaxel);	chr19:24047541	chr19:24162370~24163425:-
THCA	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-6.63	9.39e-11	2.31e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-6.63	9.39e-11	2.31e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-6.63	9.39e-11	2.31e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-6.63	9.39e-11	2.31e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-6.63	9.39e-11	2.31e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
THCA	cis	rs9311474	0.967	rs610060	ENSG00000243224.1	RP5-1157M23.2	6.63	9.4e-11	2.31e-08	0.29	0.29	Electroencephalogram traits;	chr3:52239405	chr3:52239258~52241097:+
THCA	cis	rs5758659	0.935	rs134879	ENSG00000182057.4	OGFRP1	6.63	9.4e-11	2.31e-08	0.33	0.29	Cognitive function;	chr22:42268195	chr22:42269753~42275196:+
THCA	cis	rs9902453	0.817	rs67206808	ENSG00000264007.1	RP11-68I3.10	6.63	9.4e-11	2.31e-08	0.34	0.29	Coffee consumption (cups per day);	chr17:29863078	chr17:29621617~29622254:-
THCA	cis	rs853679	0.55	rs1233701	ENSG00000272009.1	RP1-313I6.12	6.63	9.41e-11	2.32e-08	0.34	0.29	Depression;	chr6:28200948	chr6:28078792~28081130:-
THCA	cis	rs77972916	0.517	rs17406126	ENSG00000234936.1	AC010883.5	6.63	9.42e-11	2.32e-08	0.38	0.29	Granulocyte percentage of myeloid white cells;	chr2:43319493	chr2:43229573~43233394:+
THCA	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	6.63	9.43e-11	2.32e-08	0.38	0.29	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
THCA	cis	rs6840360	0.582	rs2709823	ENSG00000251611.1	RP11-610P16.1	-6.63	9.44e-11	2.32e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151407551~151408835:-
THCA	cis	rs2439831	1	rs2467743	ENSG00000275601.1	AC011330.13	-6.63	9.44e-11	2.32e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43458148	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2245176	ENSG00000275601.1	AC011330.13	-6.63	9.44e-11	2.32e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43458564	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2245054	ENSG00000275601.1	AC011330.13	-6.63	9.44e-11	2.32e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43459711	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2264876	ENSG00000275601.1	AC011330.13	-6.63	9.44e-11	2.32e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43465221	chr15:43642389~43643023:-
THCA	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-6.63	9.44e-11	2.32e-08	-0.27	-0.29	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
THCA	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	6.63	9.44e-11	2.32e-08	0.43	0.29	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	6.63	9.44e-11	2.32e-08	0.43	0.29	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	6.63	9.44e-11	2.32e-08	0.43	0.29	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
THCA	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	6.63	9.46e-11	2.33e-08	0.35	0.29	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
THCA	cis	rs5742933	0.75	rs10197331	ENSG00000273240.1	RP11-455J20.3	6.63	9.47e-11	2.33e-08	0.3	0.29	Ferritin levels;	chr2:189768112	chr2:189763859~189764456:-
THCA	cis	rs848490	0.962	rs11764879	ENSG00000214293.7	APTR	6.63	9.47e-11	2.33e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77703950	chr7:77657660~77696265:-
THCA	cis	rs28386778	0.897	rs3744293	ENSG00000240280.5	TCAM1P	-6.63	9.47e-11	2.33e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63764428	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs6504184	ENSG00000240280.5	TCAM1P	-6.63	9.47e-11	2.33e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63765048	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs8081454	ENSG00000240280.5	TCAM1P	-6.63	9.47e-11	2.33e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63765286	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs58269663	ENSG00000240280.5	TCAM1P	-6.63	9.47e-11	2.33e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63765770	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs8067102	ENSG00000240280.5	TCAM1P	-6.63	9.47e-11	2.33e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63771419	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs6504185	ENSG00000240280.5	TCAM1P	-6.63	9.47e-11	2.33e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63771432	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs8077013	ENSG00000240280.5	TCAM1P	-6.63	9.47e-11	2.33e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63773032	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs9906247	ENSG00000240280.5	TCAM1P	-6.63	9.47e-11	2.33e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63779954	chr17:63849292~63864379:+
THCA	cis	rs17684571	0.938	rs13205013	ENSG00000231441.1	RP11-472M19.2	6.63	9.48e-11	2.33e-08	0.35	0.29	Schizophrenia;	chr6:56692546	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.938	rs35637749	ENSG00000231441.1	RP11-472M19.2	6.63	9.48e-11	2.33e-08	0.35	0.29	Schizophrenia;	chr6:56692613	chr6:56844002~56864078:+
THCA	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-6.63	9.48e-11	2.33e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-6.63	9.48e-11	2.33e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-6.63	9.48e-11	2.33e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-6.63	9.48e-11	2.33e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-6.63	9.48e-11	2.33e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-6.63	9.48e-11	2.33e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-6.63	9.48e-11	2.33e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
THCA	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-6.63	9.49e-11	2.33e-08	-0.4	-0.29	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-6.63	9.49e-11	2.33e-08	-0.4	-0.29	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
THCA	cis	rs4834770	1	rs4336213	ENSG00000245958.5	RP11-33B1.1	-6.63	9.49e-11	2.33e-08	-0.27	-0.29	Blood protein levels;	chr4:119315314	chr4:119454791~119552025:+
THCA	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	6.63	9.5e-11	2.34e-08	0.36	0.29	Height;	chr6:109416903	chr6:109382795~109383666:+
THCA	cis	rs875971	0.862	rs1167408	ENSG00000232559.3	GS1-124K5.12	-6.63	9.5e-11	2.34e-08	-0.29	-0.29	Aortic root size;	chr7:66091121	chr7:66554588~66576923:-
THCA	cis	rs875971	0.83	rs1167406	ENSG00000232559.3	GS1-124K5.12	-6.63	9.5e-11	2.34e-08	-0.29	-0.29	Aortic root size;	chr7:66091949	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs1167399	ENSG00000232559.3	GS1-124K5.12	-6.63	9.5e-11	2.34e-08	-0.29	-0.29	Aortic root size;	chr7:66096890	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs57866200	ENSG00000232559.3	GS1-124K5.12	-6.63	9.5e-11	2.34e-08	-0.29	-0.29	Aortic root size;	chr7:66100405	chr7:66554588~66576923:-
THCA	cis	rs797680	0.821	rs2391254	ENSG00000223745.6	RP4-717I23.3	6.63	9.51e-11	2.34e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93329609	chr1:93262186~93346025:-
THCA	cis	rs797680	0.82	rs10874773	ENSG00000223745.6	RP4-717I23.3	6.63	9.51e-11	2.34e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93332939	chr1:93262186~93346025:-
THCA	cis	rs6504663	0.586	rs60117965	ENSG00000275897.1	RP11-94C24.13	6.63	9.51e-11	2.34e-08	0.28	0.29	Visceral fat;	chr17:50492394	chr17:50475819~50478391:+
THCA	cis	rs897984	0.762	rs7204459	ENSG00000279196.1	RP11-1072A3.3	-6.62	9.53e-11	2.34e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30972891	chr16:30984630~30988270:-
THCA	cis	rs897984	0.762	rs4889604	ENSG00000279196.1	RP11-1072A3.3	-6.62	9.53e-11	2.34e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30974673	chr16:30984630~30988270:-
THCA	cis	rs17772222	0.917	rs61984736	ENSG00000258789.1	RP11-507K2.3	-6.62	9.54e-11	2.34e-08	-0.31	-0.29	Coronary artery calcification;	chr14:88626359	chr14:88551597~88552493:+
THCA	cis	rs6539288	0.745	rs2041895	ENSG00000260329.1	RP11-412D9.4	-6.62	9.55e-11	2.35e-08	-0.26	-0.29	Total body bone mineral density;	chr12:106956310	chr12:106954029~106955497:-
THCA	cis	rs2274273	0.542	rs3783642	ENSG00000258413.1	RP11-665C16.6	-6.62	9.56e-11	2.35e-08	-0.39	-0.29	Protein biomarker;	chr14:54893485	chr14:55262767~55272075:-
THCA	cis	rs28386778	0.897	rs1062791	ENSG00000240280.5	TCAM1P	-6.62	9.58e-11	2.35e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63819127	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.83	rs2597636	ENSG00000240280.5	TCAM1P	-6.62	9.58e-11	2.35e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63798650	chr17:63849292~63864379:+
THCA	cis	rs2243480	1	rs466983	ENSG00000229886.1	RP5-1132H15.3	6.62	9.58e-11	2.36e-08	0.48	0.29	Diabetic kidney disease;	chr7:66055509	chr7:66025126~66031544:-
THCA	cis	rs3806843	0.735	rs2563333	ENSG00000202515.1	VTRNA1-3	6.62	9.59e-11	2.36e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140672686	chr5:140726158~140726246:+
THCA	cis	rs35264875	0.796	rs72930637	ENSG00000259799.1	RP11-554A11.9	6.62	9.59e-11	2.36e-08	0.51	0.29	Blond vs. brown hair color;	chr11:69102499	chr11:69155910~69159752:+
THCA	cis	rs9926296	0.565	rs8055825	ENSG00000260259.1	RP11-368I7.4	-6.62	9.59e-11	2.36e-08	-0.32	-0.29	Vitiligo;	chr16:89766440	chr16:89682620~89686569:-
THCA	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-6.62	9.6e-11	2.36e-08	-0.27	-0.29	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
THCA	cis	rs7567389	0.504	rs2069898	ENSG00000236682.1	AC068282.3	-6.62	9.6e-11	2.36e-08	-0.44	-0.29	Self-rated health;	chr2:127416651	chr2:127389130~127400580:+
THCA	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	6.62	9.61e-11	2.36e-08	0.34	0.29	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-6.62	9.61e-11	2.36e-08	-0.34	-0.29	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
THCA	cis	rs11668609	1	rs10412517	ENSG00000268442.1	CTD-2027I19.2	6.62	9.61e-11	2.36e-08	0.34	0.29	Response to taxane treatment (docetaxel);	chr19:24119111	chr19:24162370~24163425:-
THCA	cis	rs5742933	0.744	rs12693557	ENSG00000273240.1	RP11-455J20.3	6.62	9.61e-11	2.36e-08	0.3	0.29	Ferritin levels;	chr2:189726211	chr2:189763859~189764456:-
THCA	cis	rs11024102	0.962	rs34927905	ENSG00000184669.7	OR7E14P	-6.62	9.62e-11	2.36e-08	-0.4	-0.29	Glaucoma (primary angle closure);	chr11:16979880	chr11:17013998~17053024:+
THCA	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-6.62	9.62e-11	2.36e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-6.62	9.62e-11	2.36e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	6.62	9.62e-11	2.36e-08	0.37	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	6.62	9.62e-11	2.36e-08	0.37	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
THCA	cis	rs7044106	0.708	rs2416760	ENSG00000270917.1	RP11-27I1.6	-6.62	9.63e-11	2.37e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120812475~120812845:-
THCA	cis	rs741668	1	rs2806923	ENSG00000235903.6	CPB2-AS1	-6.62	9.64e-11	2.37e-08	-0.38	-0.29	Cerebrospinal fluid clusterin levels;	chr13:45944435	chr13:46052806~46113332:+
THCA	cis	rs1499614	1	rs2707840	ENSG00000229886.1	RP5-1132H15.3	6.62	9.64e-11	2.37e-08	0.49	0.29	Gout;	chr7:66693028	chr7:66025126~66031544:-
THCA	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-6.62	9.67e-11	2.38e-08	-0.43	-0.29	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
THCA	cis	rs11722228	0.522	rs12504600	ENSG00000261490.1	RP11-448G15.3	6.62	9.67e-11	2.38e-08	0.22	0.29	Urate levels;Serum uric acid levels;Gout;	chr4:10065514	chr4:10068089~10073019:-
THCA	cis	rs897984	0.762	rs2054213	ENSG00000279196.1	RP11-1072A3.3	-6.62	9.68e-11	2.38e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30960489	chr16:30984630~30988270:-
THCA	cis	rs7727544	0.642	rs7705189	ENSG00000233006.5	AC034220.3	-6.62	9.69e-11	2.38e-08	-0.23	-0.29	Blood metabolite levels;	chr5:132287665	chr5:132311285~132369916:-
THCA	cis	rs950169	0.734	rs67119537	ENSG00000259728.4	LINC00933	6.62	9.69e-11	2.38e-08	0.38	0.29	Schizophrenia;	chr15:84395671	chr15:84570649~84580175:+
THCA	cis	rs16843372	0.563	rs13398569	ENSG00000251491.2	OR7E28P	-6.62	9.69e-11	2.38e-08	-0.39	-0.29	Obesity-related traits;	chr2:158830764	chr2:158862311~158863285:+
THCA	cis	rs16843372	0.563	rs13398901	ENSG00000251491.2	OR7E28P	-6.62	9.69e-11	2.38e-08	-0.39	-0.29	Obesity-related traits;	chr2:158831058	chr2:158862311~158863285:+
THCA	cis	rs1005277	0.579	rs932538	ENSG00000276805.1	RP11-291L22.6	6.62	9.7e-11	2.38e-08	0.31	0.29	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.541	rs2472177	ENSG00000276805.1	RP11-291L22.6	6.62	9.7e-11	2.38e-08	0.31	0.29	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2472178	ENSG00000276805.1	RP11-291L22.6	6.62	9.7e-11	2.38e-08	0.31	0.29	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474572	ENSG00000276805.1	RP11-291L22.6	6.62	9.7e-11	2.38e-08	0.31	0.29	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2505198	ENSG00000276805.1	RP11-291L22.6	6.62	9.7e-11	2.38e-08	0.31	0.29	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38451030~38451785:+
THCA	cis	rs4591358	0.68	rs12995102	ENSG00000223466.1	AC064834.2	-6.62	9.7e-11	2.38e-08	-0.41	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195447752	chr2:195533035~195538681:+
THCA	cis	rs7267979	0.844	rs6083845	ENSG00000274414.1	RP5-965G21.4	6.62	9.71e-11	2.38e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25239007~25245229:-
THCA	cis	rs9926296	0.585	rs8045232	ENSG00000260259.1	RP11-368I7.4	-6.62	9.71e-11	2.38e-08	-0.31	-0.29	Vitiligo;	chr16:89791140	chr16:89682620~89686569:-
THCA	cis	rs2439831	0.702	rs495175	ENSG00000275601.1	AC011330.13	-6.62	9.71e-11	2.38e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43506486	chr15:43642389~43643023:-
THCA	cis	rs7202877	0.706	rs247436	ENSG00000261783.1	RP11-252K23.2	6.62	9.71e-11	2.39e-08	0.51	0.29	Type 1 diabetes;Type 2 diabetes;	chr16:75412073	chr16:75379818~75381260:-
THCA	cis	rs4845875	0.6	rs6699881	ENSG00000242349.4	NPPA-AS1	6.62	9.72e-11	2.39e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11776571	chr1:11841017~11848079:+
THCA	cis	rs6545883	0.929	rs2694625	ENSG00000271889.1	RP11-493E12.1	-6.62	9.74e-11	2.39e-08	-0.28	-0.29	Tuberculosis;	chr2:61388920	chr2:61151433~61162105:-
THCA	cis	rs1499614	1	rs2659913	ENSG00000229886.1	RP5-1132H15.3	6.62	9.75e-11	2.39e-08	0.49	0.29	Gout;	chr7:66692349	chr7:66025126~66031544:-
THCA	cis	rs1499614	1	rs2659911	ENSG00000229886.1	RP5-1132H15.3	6.62	9.75e-11	2.39e-08	0.49	0.29	Gout;	chr7:66693433	chr7:66025126~66031544:-
THCA	cis	rs1499614	1	rs2707838	ENSG00000229886.1	RP5-1132H15.3	6.62	9.75e-11	2.39e-08	0.49	0.29	Gout;	chr7:66694214	chr7:66025126~66031544:-
THCA	cis	rs1499614	1	rs60326618	ENSG00000229886.1	RP5-1132H15.3	6.62	9.75e-11	2.39e-08	0.49	0.29	Gout;	chr7:66701371	chr7:66025126~66031544:-
THCA	cis	rs1499614	1	rs2707830	ENSG00000229886.1	RP5-1132H15.3	6.62	9.75e-11	2.39e-08	0.49	0.29	Gout;	chr7:66702658	chr7:66025126~66031544:-
THCA	cis	rs1499614	1	rs2707828	ENSG00000229886.1	RP5-1132H15.3	6.62	9.75e-11	2.39e-08	0.49	0.29	Gout;	chr7:66706390	chr7:66025126~66031544:-
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000229886.1	RP5-1132H15.3	6.62	9.75e-11	2.39e-08	0.49	0.29	Gout;	chr7:66710076	chr7:66025126~66031544:-
THCA	cis	rs1499614	1	rs2659903	ENSG00000229886.1	RP5-1132H15.3	6.62	9.75e-11	2.39e-08	0.49	0.29	Gout;	chr7:66715944	chr7:66025126~66031544:-
THCA	cis	rs6545883	0.894	rs2694642	ENSG00000271889.1	RP11-493E12.1	-6.62	9.76e-11	2.4e-08	-0.28	-0.29	Tuberculosis;	chr2:61369045	chr2:61151433~61162105:-
THCA	cis	rs944990	0.557	rs10761237	ENSG00000227603.1	RP11-165J3.6	6.62	9.77e-11	2.4e-08	0.3	0.29	Body mass index;	chr9:93578535	chr9:93435332~93437121:-
THCA	cis	rs1667284	0.846	rs1667280	ENSG00000266521.1	RP11-650P15.1	6.62	9.79e-11	2.4e-08	0.36	0.29	Problematic alcohol use in trauma-exposed individuals;	chr18:31639209	chr18:31496645~31497195:-
THCA	cis	rs7942368	1	rs12282785	ENSG00000204529.3	GUCY2EP	6.62	9.79e-11	2.4e-08	0.41	0.29	Endometriosis;	chr11:76764986	chr11:76694043~76707641:-
THCA	cis	rs2976388	0.935	rs2976386	ENSG00000253741.1	CTD-2292P10.4	6.62	9.8e-11	2.41e-08	0.37	0.29	Urinary tract infection frequency;	chr8:142675991	chr8:142702252~142726973:-
THCA	cis	rs7247513	0.964	rs2042946	ENSG00000213290.4	PGK1P2	-6.62	9.8e-11	2.41e-08	-0.36	-0.29	Bipolar disorder;	chr19:12594540	chr19:12559571~12561105:+
THCA	cis	rs728616	0.867	rs2152550	ENSG00000225484.5	NUTM2B-AS1	-6.62	9.8e-11	2.41e-08	-0.55	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80058753	chr10:79663088~79826594:-
THCA	cis	rs5742933	0.817	rs11679767	ENSG00000273240.1	RP11-455J20.3	6.62	9.82e-11	2.41e-08	0.31	0.29	Ferritin levels;	chr2:189681574	chr2:189763859~189764456:-
THCA	cis	rs28386778	0.897	rs2854213	ENSG00000240280.5	TCAM1P	-6.62	9.82e-11	2.41e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63868271	chr17:63849292~63864379:+
THCA	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	6.62	9.83e-11	2.41e-08	0.22	0.29	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
THCA	cis	rs2243480	1	rs7456042	ENSG00000229886.1	RP5-1132H15.3	6.62	9.83e-11	2.41e-08	0.47	0.29	Diabetic kidney disease;	chr7:65834791	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs73142121	ENSG00000229886.1	RP5-1132H15.3	6.62	9.83e-11	2.41e-08	0.47	0.29	Diabetic kidney disease;	chr7:65846219	chr7:66025126~66031544:-
THCA	cis	rs1552244	0.832	rs3732968	ENSG00000232901.1	CYCSP10	6.62	9.83e-11	2.41e-08	0.37	0.29	Alzheimer's disease;	chr3:9971589	chr3:10000647~10000940:-
THCA	cis	rs7646881	0.504	rs7617304	ENSG00000240207.5	RP11-379F4.4	-6.62	9.85e-11	2.42e-08	-0.36	-0.29	Tetralogy of Fallot;	chr3:158745312	chr3:158732263~158784070:+
THCA	cis	rs3806843	0.766	rs801176	ENSG00000202515.1	VTRNA1-3	-6.62	9.87e-11	2.42e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140707425	chr5:140726158~140726246:+
THCA	cis	rs16958440	1	rs62096471	ENSG00000267800.1	RP11-49K24.5	-6.62	9.88e-11	2.42e-08	-0.6	-0.29	Sitting height ratio;	chr18:47117443	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs4609941	ENSG00000267800.1	RP11-49K24.5	-6.62	9.88e-11	2.42e-08	-0.6	-0.29	Sitting height ratio;	chr18:47119120	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs57928699	ENSG00000267800.1	RP11-49K24.5	-6.62	9.88e-11	2.42e-08	-0.6	-0.29	Sitting height ratio;	chr18:47119222	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs60854219	ENSG00000267800.1	RP11-49K24.5	-6.62	9.88e-11	2.42e-08	-0.6	-0.29	Sitting height ratio;	chr18:47120293	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs62096474	ENSG00000267800.1	RP11-49K24.5	-6.62	9.88e-11	2.42e-08	-0.6	-0.29	Sitting height ratio;	chr18:47121133	chr18:47137018~47137290:+
THCA	cis	rs10131894	0.611	rs174995	ENSG00000279594.1	RP11-950C14.10	-6.62	9.88e-11	2.43e-08	-0.27	-0.29	Coronary artery disease;	chr14:74967480	chr14:75011269~75012851:-
THCA	cis	rs4072705	0.904	rs721863	ENSG00000224020.1	MIR181A2HG	-6.62	9.89e-11	2.43e-08	-0.27	-0.29	Menarche (age at onset);	chr9:124773988	chr9:124658467~124698631:+
THCA	cis	rs467650	0.509	rs183628	ENSG00000246763.5	RGMB-AS1	6.62	9.9e-11	2.43e-08	0.28	0.29	Venous thromboembolism (SNP x SNP interaction);	chr5:98643787	chr5:98769618~98773469:-
THCA	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	6.62	9.9e-11	2.43e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
THCA	cis	rs2975734	0.68	rs1052453	ENSG00000261451.1	RP11-981G7.1	-6.62	9.92e-11	2.43e-08	-0.39	-0.29	Chronotype;Morning vs. evening chronotype;	chr8:10250815	chr8:10433672~10438312:+
THCA	cis	rs71636778	0.57	rs12737407	ENSG00000260063.1	RP5-968P14.2	-6.62	9.92e-11	2.43e-08	-0.56	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26709671	chr1:26692132~26694131:-
THCA	cis	rs4143844	0.867	rs36004142	ENSG00000259251.2	RP11-643M14.1	6.62	9.92e-11	2.43e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:61940042	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs12905403	ENSG00000259251.2	RP11-643M14.1	6.62	9.92e-11	2.43e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:61940109	chr15:62060503~62062434:+
THCA	cis	rs4767841	0.562	rs10849683	ENSG00000248636.5	RP11-768F21.1	-6.62	9.92e-11	2.43e-08	-0.3	-0.29	Urgency urinary incontinence;	chr12:119624203	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.552	rs11064855	ENSG00000248636.5	RP11-768F21.1	-6.62	9.92e-11	2.43e-08	-0.3	-0.29	Urgency urinary incontinence;	chr12:119626986	chr12:119387987~119668079:-
THCA	cis	rs4950322	0.58	rs17355419	ENSG00000237188.3	RP11-337C18.8	6.62	9.93e-11	2.44e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147110094	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.58	rs72706428	ENSG00000237188.3	RP11-337C18.8	6.62	9.93e-11	2.44e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147110219	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.563	rs61838944	ENSG00000237188.3	RP11-337C18.8	6.62	9.93e-11	2.44e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147110275	chr1:147172771~147211568:+
THCA	cis	rs11672691	0.519	rs12973063	ENSG00000267107.5	PCAT19	6.62	9.94e-11	2.44e-08	0.31	0.29	Prostate cancer;	chr19:41503757	chr19:41454169~41500649:-
THCA	cis	rs4591358	0.731	rs12693772	ENSG00000223466.1	AC064834.2	-6.62	9.94e-11	2.44e-08	-0.4	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195473636	chr2:195533035~195538681:+
THCA	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-6.62	9.95e-11	2.44e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
THCA	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-6.62	9.96e-11	2.44e-08	-0.44	-0.29	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
THCA	cis	rs3806843	0.868	rs2563291	ENSG00000202515.1	VTRNA1-3	6.62	9.96e-11	2.44e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140740014	chr5:140726158~140726246:+
THCA	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	6.62	9.96e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
THCA	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-6.62	9.97e-11	2.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-6.62	9.97e-11	2.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-6.62	9.97e-11	2.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-6.62	9.97e-11	2.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-6.62	9.97e-11	2.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-6.62	9.97e-11	2.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
THCA	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	6.62	9.97e-11	2.44e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
THCA	cis	rs7208859	0.623	rs8082537	ENSG00000263603.1	CTD-2349P21.5	-6.62	9.98e-11	2.45e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30729469~30731202:+
THCA	cis	rs3806843	0.9	rs2563279	ENSG00000202515.1	VTRNA1-3	6.62	9.98e-11	2.45e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140751950	chr5:140726158~140726246:+
THCA	cis	rs10491083	1	rs10491083	ENSG00000256806.3	C17orf100	-6.62	1e-10	2.45e-08	-0.49	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6655238	chr17:6651718~6653473:+
THCA	cis	rs7569084	0.522	rs906577	ENSG00000237979.1	AC007389.1	6.62	1e-10	2.45e-08	0.36	0.29	Sum eosinophil basophil counts;	chr2:65369523	chr2:65500993~65502138:-
THCA	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	6.62	1e-10	2.45e-08	0.44	0.29	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
THCA	cis	rs5758659	1	rs5758660	ENSG00000182057.4	OGFRP1	6.62	1e-10	2.45e-08	0.34	0.29	Cognitive function;	chr22:42227712	chr22:42269753~42275196:+
THCA	cis	rs950169	0.881	rs150965	ENSG00000259295.5	CSPG4P12	6.62	1e-10	2.46e-08	0.45	0.29	Schizophrenia;	chr15:84537296	chr15:85191438~85213905:+
THCA	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-6.62	1e-10	2.46e-08	-0.31	-0.29	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
THCA	cis	rs947583	0.573	rs12191817	ENSG00000231028.7	LINC00271	-6.62	1e-10	2.46e-08	-0.24	-0.29	Phosphorus levels;	chr6:135702608	chr6:135497801~135716055:+
THCA	cis	rs748404	0.587	rs9920879	ENSG00000166763.7	STRCP1	6.62	1e-10	2.46e-08	0.32	0.29	Lung cancer;	chr15:43347572	chr15:43699488~43718184:-
THCA	cis	rs748404	0.631	rs7166812	ENSG00000166763.7	STRCP1	6.62	1e-10	2.46e-08	0.32	0.29	Lung cancer;	chr15:43352562	chr15:43699488~43718184:-
THCA	cis	rs11603691	1	rs117497302	ENSG00000254662.1	RP11-872D17.4	-6.62	1.01e-10	2.46e-08	-0.61	-0.29	Low high density lipoprotein cholesterol levels;	chr11:57242333	chr11:57325603~57327958:+
THCA	cis	rs9381040	0.692	rs3088370	ENSG00000161912.16	ADCY10P1	6.62	1.01e-10	2.47e-08	0.19	0.29	Alzheimer's disease (late onset);	chr6:41189932	chr6:41101022~41140835:+
THCA	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	6.62	1.01e-10	2.47e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	6.62	1.01e-10	2.47e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
THCA	cis	rs2439831	1	rs690316	ENSG00000249839.1	AC011330.5	-6.62	1.01e-10	2.47e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43445682	chr15:43663654~43684339:-
THCA	cis	rs1552244	0.882	rs7636817	ENSG00000180385.7	EMC3-AS1	6.62	1.01e-10	2.47e-08	0.31	0.29	Alzheimer's disease;	chr3:9973192	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs73117481	ENSG00000232901.1	CYCSP10	6.62	1.01e-10	2.48e-08	0.45	0.29	Alzheimer's disease;	chr3:10118448	chr3:10000647~10000940:-
THCA	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	6.62	1.01e-10	2.48e-08	0.35	0.29	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
THCA	cis	rs9402743	0.634	rs6923032	ENSG00000231028.7	LINC00271	-6.62	1.01e-10	2.48e-08	-0.24	-0.29	Systemic lupus erythematosus;	chr6:135597708	chr6:135497801~135716055:+
THCA	cis	rs7208859	0.673	rs450585	ENSG00000263603.1	CTD-2349P21.5	-6.62	1.01e-10	2.48e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30729469~30731202:+
THCA	cis	rs10131894	0.611	rs174994	ENSG00000279594.1	RP11-950C14.10	-6.62	1.01e-10	2.48e-08	-0.27	-0.29	Coronary artery disease;	chr14:74967399	chr14:75011269~75012851:-
THCA	cis	rs797680	0.822	rs942196	ENSG00000223745.6	RP4-717I23.3	6.61	1.01e-10	2.49e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93336707	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs4847410	ENSG00000223745.6	RP4-717I23.3	6.61	1.01e-10	2.49e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93337224	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs1535699	ENSG00000223745.6	RP4-717I23.3	6.61	1.01e-10	2.49e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93339395	chr1:93262186~93346025:-
THCA	cis	rs7727544	0.506	rs10040809	ENSG00000224431.1	AC063976.7	6.61	1.02e-10	2.49e-08	0.26	0.29	Blood metabolite levels;	chr5:132007324	chr5:132199456~132203487:+
THCA	cis	rs990871	1	rs11209943	ENSG00000227207.2	RPL31P12	-6.61	1.02e-10	2.49e-08	-0.36	-0.29	Subcutaneous adipose tissue;	chr1:72284817	chr1:72301472~72301829:+
THCA	cis	rs10208649	1	rs13387291	ENSG00000272156.1	RP11-477N3.1	6.61	1.02e-10	2.49e-08	0.54	0.29	Body mass index;	chr2:53808114	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.71	rs10190353	ENSG00000233266.1	HMGB1P31	6.61	1.02e-10	2.49e-08	0.68	0.29	Body mass index;	chr2:54015688	chr2:54051334~54051760:+
THCA	cis	rs2006933	0.625	rs56692730	ENSG00000237575.4	PYY2	6.61	1.02e-10	2.49e-08	0.39	0.29	Amyotrophic lateral sclerosis;	chr17:28111201	chr17:28226563~28228065:+
THCA	cis	rs28386778	0.897	rs2044125	ENSG00000240280.5	TCAM1P	6.61	1.02e-10	2.49e-08	0.41	0.29	Prudent dietary pattern;	chr17:63785824	chr17:63849292~63864379:+
THCA	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	6.61	1.02e-10	2.5e-08	0.27	0.29	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
THCA	cis	rs7267979	1	rs6076345	ENSG00000274414.1	RP5-965G21.4	6.61	1.02e-10	2.5e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4815418	ENSG00000274414.1	RP5-965G21.4	6.61	1.02e-10	2.5e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4813566	ENSG00000274414.1	RP5-965G21.4	6.61	1.02e-10	2.5e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4815421	ENSG00000274414.1	RP5-965G21.4	6.61	1.02e-10	2.5e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25239007~25245229:-
THCA	cis	rs28386778	0.897	rs4968662	ENSG00000240280.5	TCAM1P	-6.61	1.02e-10	2.5e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63757177	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs4968598	ENSG00000240280.5	TCAM1P	-6.61	1.02e-10	2.5e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63758219	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs4968663	ENSG00000240280.5	TCAM1P	-6.61	1.02e-10	2.5e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63758243	chr17:63849292~63864379:+
THCA	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	6.61	1.02e-10	2.5e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
THCA	cis	rs944289	0.553	rs1169135	ENSG00000257826.1	RP11-116N8.4	-6.61	1.02e-10	2.5e-08	-0.34	-0.29	Thyroid cancer;	chr14:36155696	chr14:36061026~36067190:-
THCA	cis	rs2439831	1	rs2444032	ENSG00000275601.1	AC011330.13	-6.61	1.02e-10	2.5e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43463148	chr15:43642389~43643023:-
THCA	cis	rs897984	0.806	rs8050588	ENSG00000279196.1	RP11-1072A3.3	6.61	1.02e-10	2.5e-08	0.29	0.29	Dementia with Lewy bodies;	chr16:30926478	chr16:30984630~30988270:-
THCA	cis	rs16958440	1	rs62096469	ENSG00000267800.1	RP11-49K24.5	-6.61	1.02e-10	2.5e-08	-0.6	-0.29	Sitting height ratio;	chr18:47111927	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs60228288	ENSG00000267800.1	RP11-49K24.5	-6.61	1.02e-10	2.5e-08	-0.6	-0.29	Sitting height ratio;	chr18:47114041	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs62096470	ENSG00000267800.1	RP11-49K24.5	-6.61	1.02e-10	2.5e-08	-0.6	-0.29	Sitting height ratio;	chr18:47115095	chr18:47137018~47137290:+
THCA	cis	rs4934494	0.689	rs11185895	ENSG00000232936.4	RP11-80H5.2	-6.61	1.02e-10	2.5e-08	-0.38	-0.29	Red blood cell count;	chr10:89817482	chr10:89645282~89650667:+
THCA	cis	rs6504108	0.522	rs2924257	ENSG00000278765.1	RP5-890E16.5	-6.61	1.02e-10	2.51e-08	-0.33	-0.29	Body mass index;	chr17:48240193	chr17:48066704~48067293:-
THCA	cis	rs7131987	0.834	rs1989478	ENSG00000257176.2	RP11-996F15.2	-6.61	1.02e-10	2.51e-08	-0.29	-0.29	QT interval;	chr12:29289296	chr12:29280418~29317848:-
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000273142.1	RP11-458F8.4	-6.61	1.02e-10	2.51e-08	-0.43	-0.29	Diabetic kidney disease;	chr7:66009932	chr7:66902857~66906297:+
THCA	cis	rs728616	0.702	rs78734698	ENSG00000242600.5	MBL1P	6.61	1.03e-10	2.51e-08	0.42	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:79904898~79950336:+
THCA	cis	rs12928939	0.768	rs11861296	ENSG00000260886.1	TAT-AS1	6.61	1.03e-10	2.51e-08	0.4	0.29	Post bronchodilator FEV1;	chr16:71816729	chr16:71565789~71578187:+
THCA	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	6.61	1.03e-10	2.51e-08	0.3	0.29	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
THCA	cis	rs12554020	0.786	rs78547192	ENSG00000227603.1	RP11-165J3.6	6.61	1.03e-10	2.51e-08	0.53	0.29	Schizophrenia;	chr9:93597221	chr9:93435332~93437121:-
THCA	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-6.61	1.03e-10	2.51e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
THCA	cis	rs7567389	0.504	rs2069895	ENSG00000236682.1	AC068282.3	-6.61	1.03e-10	2.51e-08	-0.44	-0.29	Self-rated health;	chr2:127416492	chr2:127389130~127400580:+
THCA	cis	rs2239557	1	rs4903201	ENSG00000259065.1	RP5-1021I20.1	6.61	1.03e-10	2.52e-08	0.36	0.29	Common traits (Other);	chr14:74192987	chr14:73787360~73803270:+
THCA	cis	rs2239557	1	rs4903202	ENSG00000259065.1	RP5-1021I20.1	6.61	1.03e-10	2.52e-08	0.36	0.29	Common traits (Other);	chr14:74193599	chr14:73787360~73803270:+
THCA	cis	rs2239557	1	rs4903203	ENSG00000259065.1	RP5-1021I20.1	6.61	1.03e-10	2.52e-08	0.36	0.29	Common traits (Other);	chr14:74193805	chr14:73787360~73803270:+
THCA	cis	rs28386778	0.897	rs4968599	ENSG00000240280.5	TCAM1P	-6.61	1.03e-10	2.53e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63758632	chr17:63849292~63864379:+
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000263603.1	CTD-2349P21.5	-6.61	1.03e-10	2.53e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000263603.1	CTD-2349P21.5	-6.61	1.03e-10	2.53e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30729469~30731202:+
THCA	cis	rs3806843	0.868	rs2531342	ENSG00000202515.1	VTRNA1-3	6.61	1.03e-10	2.53e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140751027	chr5:140726158~140726246:+
THCA	cis	rs2282300	0.956	rs2685286	ENSG00000242353.1	RP4-710M3.1	-6.61	1.03e-10	2.53e-08	-0.27	-0.29	Morning vs. evening chronotype;	chr11:30360041	chr11:30368148~30368646:+
THCA	cis	rs7621025	0.542	rs71336078	ENSG00000239213.4	NCK1-AS1	-6.61	1.03e-10	2.53e-08	-0.39	-0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136770760	chr3:136841726~136862054:-
THCA	cis	rs72843506	0.722	rs16942325	ENSG00000270091.1	RP11-78O7.2	-6.61	1.04e-10	2.53e-08	-0.34	-0.29	Schizophrenia;	chr17:20123750	chr17:19896590~19897287:-
THCA	cis	rs2562456	0.833	rs11666447	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21416270	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs11666525	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21416503	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs62110424	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21416835	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs3853837	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21419172	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs3853838	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21419192	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62110426	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21420124	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.755	rs11670868	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21373613	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs55961038	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21375205	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs2358993	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21375367	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs11672583	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21379363	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs17680605	ENSG00000268555.1	RP11-678G14.3	6.61	1.04e-10	2.54e-08	0.48	0.29	Pain;	chr19:21379646	chr19:21570822~21587322:-
THCA	cis	rs712022	0.872	rs12419860	ENSG00000246225.5	RP11-17A1.3	6.61	1.04e-10	2.54e-08	0.37	0.29	Dialysis-related mortality;	chr11:22824515	chr11:22829380~22945393:+
THCA	cis	rs741668	0.897	rs2274381	ENSG00000235903.6	CPB2-AS1	6.61	1.04e-10	2.54e-08	0.4	0.29	Cerebrospinal fluid clusterin levels;	chr13:46052326	chr13:46052806~46113332:+
THCA	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	6.61	1.04e-10	2.54e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
THCA	cis	rs28386778	0.897	rs2597634	ENSG00000240280.5	TCAM1P	-6.61	1.04e-10	2.54e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63800784	chr17:63849292~63864379:+
THCA	cis	rs8141529	0.778	rs5762795	ENSG00000226471.5	CTA-292E10.6	-6.61	1.04e-10	2.54e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28786512	chr22:28800683~28848559:+
THCA	cis	rs642803	0.527	rs1647570	ENSG00000214659.4	KRT8P26	-6.61	1.04e-10	2.54e-08	-0.27	-0.29	Urate levels;	chr11:65800785	chr11:65726939~65728214:+
THCA	cis	rs10740039	0.516	rs10740034	ENSG00000254271.1	RP11-131N11.4	6.61	1.04e-10	2.54e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60592624	chr10:60734342~60741828:+
THCA	cis	rs16846053	0.792	rs6714082	ENSG00000227403.1	AC009299.3	6.61	1.04e-10	2.55e-08	0.46	0.29	Blood osmolality (transformed sodium);	chr2:161743646	chr2:161244739~161249050:+
THCA	cis	rs9543976	0.614	rs73223948	ENSG00000261553.4	RP11-29G8.3	-6.61	1.04e-10	2.55e-08	-0.45	-0.29	Diabetic retinopathy;	chr13:75523889	chr13:75549773~75807120:+
THCA	cis	rs10208649	0.831	rs2287347	ENSG00000272156.1	RP11-477N3.1	-6.61	1.04e-10	2.55e-08	-0.42	-0.29	Body mass index;	chr2:53812428	chr2:54082554~54085066:+
THCA	cis	rs7267979	1	rs6050590	ENSG00000274414.1	RP5-965G21.4	6.61	1.04e-10	2.55e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25239007~25245229:-
THCA	cis	rs7688540	0.8	rs6837796	ENSG00000211553.1	AC253576.2	-6.61	1.04e-10	2.55e-08	-0.4	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:136461~136568:+
THCA	cis	rs16843372	0.563	rs13397887	ENSG00000251491.2	OR7E28P	-6.61	1.04e-10	2.55e-08	-0.39	-0.29	Obesity-related traits;	chr2:158830147	chr2:158862311~158863285:+
THCA	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	6.61	1.04e-10	2.55e-08	0.44	0.29	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	6.61	1.04e-10	2.55e-08	0.44	0.29	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
THCA	cis	rs897984	0.806	rs4889571	ENSG00000279196.1	RP11-1072A3.3	-6.61	1.04e-10	2.55e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30937726	chr16:30984630~30988270:-
THCA	cis	rs897984	0.806	rs11640534	ENSG00000279196.1	RP11-1072A3.3	-6.61	1.04e-10	2.55e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30938194	chr16:30984630~30988270:-
THCA	cis	rs897984	0.762	rs7206511	ENSG00000279196.1	RP11-1072A3.3	-6.61	1.04e-10	2.55e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30939031	chr16:30984630~30988270:-
THCA	cis	rs9601248	0.711	rs9530937	ENSG00000227354.5	RBM26-AS1	-6.61	1.04e-10	2.55e-08	-0.28	-0.29	Major depressive disorder;	chr13:79603701	chr13:79406309~79424328:+
THCA	cis	rs7746199	0.668	rs34864796	ENSG00000219392.1	RP1-265C24.5	-6.61	1.04e-10	2.55e-08	-0.56	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28115628~28116551:+
THCA	cis	rs7267979	1	rs6050561	ENSG00000274414.1	RP5-965G21.4	6.61	1.04e-10	2.55e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6083813	ENSG00000274414.1	RP5-965G21.4	6.61	1.04e-10	2.55e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4815406	ENSG00000274414.1	RP5-965G21.4	6.61	1.04e-10	2.55e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs6083817	ENSG00000274414.1	RP5-965G21.4	6.61	1.04e-10	2.55e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050564	ENSG00000274414.1	RP5-965G21.4	6.61	1.04e-10	2.55e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25239007~25245229:-
THCA	cis	rs6504622	0.818	rs9910899	ENSG00000262879.4	RP11-156P1.3	6.61	1.04e-10	2.55e-08	0.27	0.29	Orofacial clefts;	chr17:46956976	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.818	rs9912794	ENSG00000262879.4	RP11-156P1.3	6.61	1.04e-10	2.55e-08	0.27	0.29	Orofacial clefts;	chr17:46957075	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.818	rs9898527	ENSG00000262879.4	RP11-156P1.3	6.61	1.04e-10	2.55e-08	0.27	0.29	Orofacial clefts;	chr17:46958844	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.791	rs61671555	ENSG00000262879.4	RP11-156P1.3	6.61	1.04e-10	2.55e-08	0.27	0.29	Orofacial clefts;	chr17:46960491	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.818	rs9303532	ENSG00000262879.4	RP11-156P1.3	-6.61	1.04e-10	2.55e-08	-0.27	-0.29	Orofacial clefts;	chr17:46956636	chr17:46984045~47100323:-
THCA	cis	rs7403037	0.837	rs2133278	ENSG00000259905.4	PWRN1	6.61	1.04e-10	2.56e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24227131	chr15:24493137~24652130:+
THCA	cis	rs2239547	0.603	rs9870898	ENSG00000242142.1	SERBP1P3	6.61	1.05e-10	2.56e-08	0.38	0.29	Schizophrenia;	chr3:53058359	chr3:53064283~53065091:-
THCA	cis	rs741668	0.931	rs2806924	ENSG00000235903.6	CPB2-AS1	-6.61	1.05e-10	2.56e-08	-0.38	-0.29	Cerebrospinal fluid clusterin levels;	chr13:45944831	chr13:46052806~46113332:+
THCA	cis	rs7403037	0.753	rs12899368	ENSG00000259905.4	PWRN1	6.61	1.05e-10	2.56e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24248877	chr15:24493137~24652130:+
THCA	cis	rs7267979	0.966	rs2261784	ENSG00000274414.1	RP5-965G21.4	-6.61	1.05e-10	2.56e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2261785	ENSG00000274414.1	RP5-965G21.4	-6.61	1.05e-10	2.56e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25239007~25245229:-
THCA	cis	rs7260598	1	rs8110727	ENSG00000268442.1	CTD-2027I19.2	6.61	1.05e-10	2.56e-08	0.39	0.29	Response to taxane treatment (placlitaxel);	chr19:24048114	chr19:24162370~24163425:-
THCA	cis	rs6840360	0.642	rs2709822	ENSG00000251611.1	RP11-610P16.1	-6.61	1.05e-10	2.57e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151407551~151408835:-
THCA	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	6.61	1.05e-10	2.57e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	6.61	1.05e-10	2.57e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	6.61	1.05e-10	2.57e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
THCA	cis	rs55665837	0.701	rs1522633	ENSG00000251991.1	RNU7-49P	6.61	1.05e-10	2.57e-08	0.34	0.29	Vitamin D levels;	chr11:14623692	chr11:14478892~14478953:+
THCA	cis	rs5742933	0.857	rs7571089	ENSG00000273240.1	RP11-455J20.3	6.61	1.05e-10	2.57e-08	0.3	0.29	Ferritin levels;	chr2:189697067	chr2:189763859~189764456:-
THCA	cis	rs17684571	0.938	rs6924375	ENSG00000231441.1	RP11-472M19.2	6.61	1.05e-10	2.57e-08	0.34	0.29	Schizophrenia;	chr6:56696993	chr6:56844002~56864078:+
THCA	cis	rs736801	0.74	rs12515180	ENSG00000224431.1	AC063976.7	6.61	1.05e-10	2.57e-08	0.27	0.29	Mosquito bite size;Breast cancer;	chr5:132449992	chr5:132199456~132203487:+
THCA	cis	rs5752326	1	rs134144	ENSG00000261188.1	CTA-445C9.14	-6.61	1.05e-10	2.57e-08	-0.41	-0.29	Ischemic stroke;	chr22:26513004	chr22:26512537~26514568:+
THCA	cis	rs848490	0.889	rs55708205	ENSG00000214293.7	APTR	6.61	1.05e-10	2.57e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77560753	chr7:77657660~77696265:-
THCA	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	6.61	1.05e-10	2.58e-08	0.25	0.29	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
THCA	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	6.61	1.06e-10	2.58e-08	0.4	0.29	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
THCA	cis	rs6545883	0.894	rs778143	ENSG00000271889.1	RP11-493E12.1	6.61	1.06e-10	2.58e-08	0.28	0.29	Tuberculosis;	chr2:61354755	chr2:61151433~61162105:-
THCA	cis	rs7927592	0.701	rs12226585	ENSG00000212093.1	AP000807.1	-6.61	1.06e-10	2.58e-08	-0.3	-0.29	Total body bone mineral density;	chr11:68490393	chr11:68506083~68506166:-
THCA	cis	rs1552244	0.882	rs68080705	ENSG00000232901.1	CYCSP10	6.61	1.06e-10	2.58e-08	0.37	0.29	Alzheimer's disease;	chr3:9984059	chr3:10000647~10000940:-
THCA	cis	rs848490	1	rs11770446	ENSG00000214293.7	APTR	6.61	1.06e-10	2.58e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77728755	chr7:77657660~77696265:-
THCA	cis	rs4819052	0.679	rs2236450	ENSG00000237664.1	LINC00316	-6.61	1.06e-10	2.59e-08	-0.28	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45338590~45341990:-
THCA	cis	rs797680	0.861	rs612037	ENSG00000223745.6	RP4-717I23.3	-6.61	1.06e-10	2.59e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93217321	chr1:93262186~93346025:-
THCA	cis	rs797680	0.964	rs624131	ENSG00000223745.6	RP4-717I23.3	-6.61	1.06e-10	2.59e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93217653	chr1:93262186~93346025:-
THCA	cis	rs797680	0.964	rs797668	ENSG00000223745.6	RP4-717I23.3	-6.61	1.06e-10	2.59e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93229232	chr1:93262186~93346025:-
THCA	cis	rs11723261	0.582	rs4582104	ENSG00000211553.1	AC253576.2	-6.61	1.06e-10	2.59e-08	-0.4	-0.29	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:136461~136568:+
THCA	cis	rs1667284	0.846	rs1667279	ENSG00000266521.1	RP11-650P15.1	6.61	1.06e-10	2.59e-08	0.36	0.29	Problematic alcohol use in trauma-exposed individuals;	chr18:31638910	chr18:31496645~31497195:-
THCA	cis	rs7208859	0.673	rs216420	ENSG00000263603.1	CTD-2349P21.5	-6.61	1.06e-10	2.59e-08	-0.47	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30729469~30731202:+
THCA	cis	rs16958440	0.737	rs16958699	ENSG00000267800.1	RP11-49K24.5	-6.61	1.06e-10	2.59e-08	-0.59	-0.29	Sitting height ratio;	chr18:47128475	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs16958701	ENSG00000267800.1	RP11-49K24.5	-6.61	1.06e-10	2.59e-08	-0.59	-0.29	Sitting height ratio;	chr18:47128870	chr18:47137018~47137290:+
THCA	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	6.61	1.06e-10	2.6e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	6.61	1.06e-10	2.6e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	6.61	1.06e-10	2.6e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	6.61	1.06e-10	2.6e-08	0.52	0.29	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
THCA	cis	rs797680	0.93	rs11164870	ENSG00000223745.6	RP4-717I23.3	6.61	1.06e-10	2.6e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93086630	chr1:93262186~93346025:-
THCA	cis	rs7324557	0.717	rs9507164	ENSG00000205861.10	C1QTNF9B-AS1	-6.61	1.07e-10	2.6e-08	-0.36	-0.29	Visceral adipose tissue adjusted for BMI;	chr13:23806400	chr13:23888889~23897263:+
THCA	cis	rs2734839	0.537	rs6277	ENSG00000270179.1	RP11-159N11.4	-6.61	1.07e-10	2.6e-08	-0.32	-0.29	Information processing speed;	chr11:113412737	chr11:113368478~113369117:+
THCA	cis	rs7554547	0.871	rs11588551	ENSG00000201801.1	RNU5E-4P	-6.61	1.07e-10	2.61e-08	-0.34	-0.29	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr1:11909808~11909927:-
THCA	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-6.61	1.07e-10	2.61e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
THCA	cis	rs438465	1	rs368028	ENSG00000226194.4	RP1-137D17.1	-6.61	1.07e-10	2.61e-08	-0.44	-0.29	Corneal astigmatism;	chr6:169411199	chr6:169369998~169388385:-
THCA	cis	rs7267979	0.966	rs6083818	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4815409	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs6107031	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6115159	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4813562	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6037099	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs4815414	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6083825	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs34645895	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6115168	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6037105	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2387880	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2387882	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2387884	ENSG00000274414.1	RP5-965G21.4	6.61	1.07e-10	2.62e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25239007~25245229:-
THCA	cis	rs2439831	0.85	rs7183809	ENSG00000275601.1	AC011330.13	-6.61	1.07e-10	2.62e-08	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43828670	chr15:43642389~43643023:-
THCA	cis	rs7189233	0.955	rs7189726	ENSG00000279344.1	RP11-44F14.7	6.61	1.07e-10	2.62e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53463862	chr16:53478957~53481550:-
THCA	cis	rs7267979	1	rs6050631	ENSG00000274414.1	RP5-965G21.4	-6.61	1.07e-10	2.62e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25239007~25245229:-
THCA	cis	rs6928977	0.66	rs2757647	ENSG00000231028.7	LINC00271	6.61	1.07e-10	2.62e-08	0.23	0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135446416	chr6:135497801~135716055:+
THCA	cis	rs2243480	1	rs13247184	ENSG00000229886.1	RP5-1132H15.3	6.61	1.08e-10	2.63e-08	0.47	0.29	Diabetic kidney disease;	chr7:65893941	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs35283677	ENSG00000229886.1	RP5-1132H15.3	6.61	1.08e-10	2.63e-08	0.47	0.29	Diabetic kidney disease;	chr7:65894246	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs35421653	ENSG00000229886.1	RP5-1132H15.3	6.61	1.08e-10	2.63e-08	0.47	0.29	Diabetic kidney disease;	chr7:65898442	chr7:66025126~66031544:-
THCA	cis	rs28386778	0.805	rs9911714	ENSG00000240280.5	TCAM1P	-6.61	1.08e-10	2.63e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63751592	chr17:63849292~63864379:+
THCA	cis	rs6840360	0.617	rs2724563	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.617	rs2724564	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.607	rs2724565	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2724567	ENSG00000251611.1	RP11-610P16.1	6.61	1.08e-10	2.63e-08	0.21	0.29	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2724568	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7677131	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7657670	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709828	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2724551	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.667	rs2709829	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.606	rs2709813	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.606	rs2724550	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709815	ENSG00000251611.1	RP11-610P16.1	-6.61	1.08e-10	2.63e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151407551~151408835:-
THCA	cis	rs2976388	0.967	rs2978981	ENSG00000253741.1	CTD-2292P10.4	6.61	1.08e-10	2.63e-08	0.37	0.29	Urinary tract infection frequency;	chr8:142677719	chr8:142702252~142726973:-
THCA	cis	rs516805	0.667	rs2045354	ENSG00000279453.1	RP3-425C14.4	-6.61	1.08e-10	2.63e-08	-0.32	-0.29	Lymphocyte counts;	chr6:122209244	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs2606596	ENSG00000279453.1	RP3-425C14.4	-6.61	1.08e-10	2.63e-08	-0.32	-0.29	Lymphocyte counts;	chr6:122211597	chr6:122436789~122439223:-
THCA	cis	rs748404	0.631	rs1133395	ENSG00000166763.7	STRCP1	6.61	1.08e-10	2.63e-08	0.31	0.29	Lung cancer;	chr15:43358186	chr15:43699488~43718184:-
THCA	cis	rs7267979	0.844	rs8184820	ENSG00000274414.1	RP5-965G21.4	6.6	1.08e-10	2.63e-08	0.35	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25239007~25245229:-
THCA	cis	rs8030379	0.967	rs2401171	ENSG00000230373.7	GOLGA6L5P	-6.6	1.08e-10	2.63e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83888924	chr15:84507885~84516814:-
THCA	cis	rs3204270	0.714	rs7503307	ENSG00000262049.1	RP13-1032I1.7	6.6	1.08e-10	2.64e-08	0.26	0.29	Dental caries;	chr17:81707899	chr17:81701324~81703300:-
THCA	cis	rs4601821	0.635	rs12282356	ENSG00000270179.1	RP11-159N11.4	-6.6	1.08e-10	2.64e-08	-0.3	-0.29	Alcoholic chronic pancreatitis;	chr11:113337660	chr11:113368478~113369117:+
THCA	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-6.6	1.08e-10	2.64e-08	-0.26	-0.29	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-6.6	1.08e-10	2.64e-08	-0.26	-0.29	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
THCA	cis	rs10740039	0.516	rs2393675	ENSG00000254271.1	RP11-131N11.4	6.6	1.08e-10	2.64e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60590990	chr10:60734342~60741828:+
THCA	cis	rs79464052	0.826	rs76686252	ENSG00000228737.2	AC008781.7	-6.6	1.08e-10	2.64e-08	-0.71	-0.29	Diffuse large B cell lymphoma;	chr5:141632446	chr5:141618414~141626481:+
THCA	cis	rs2975734	0.709	rs6988826	ENSG00000261451.1	RP11-981G7.1	-6.6	1.08e-10	2.64e-08	-0.39	-0.29	Chronotype;Morning vs. evening chronotype;	chr8:10252115	chr8:10433672~10438312:+
THCA	cis	rs875971	0.825	rs59466412	ENSG00000232559.3	GS1-124K5.12	-6.6	1.08e-10	2.64e-08	-0.29	-0.29	Aortic root size;	chr7:66100371	chr7:66554588~66576923:-
THCA	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-6.6	1.08e-10	2.64e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
THCA	cis	rs4834770	1	rs878375	ENSG00000245958.5	RP11-33B1.1	-6.6	1.08e-10	2.64e-08	-0.27	-0.29	Blood protein levels;	chr4:119316419	chr4:119454791~119552025:+
THCA	cis	rs438465	0.947	rs400607	ENSG00000226194.4	RP1-137D17.1	6.6	1.08e-10	2.64e-08	0.44	0.29	Corneal astigmatism;	chr6:169408314	chr6:169369998~169388385:-
THCA	cis	rs7851660	0.809	rs3808893	ENSG00000236130.1	PTCSC2	-6.6	1.08e-10	2.64e-08	-0.23	-0.29	Strep throat;	chr9:97901463	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs10984253	ENSG00000236130.1	PTCSC2	-6.6	1.08e-10	2.64e-08	-0.23	-0.29	Strep throat;	chr9:97902192	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs7044799	ENSG00000236130.1	PTCSC2	-6.6	1.08e-10	2.64e-08	-0.23	-0.29	Strep throat;	chr9:97903111	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs7031386	ENSG00000236130.1	PTCSC2	-6.6	1.08e-10	2.64e-08	-0.23	-0.29	Strep throat;	chr9:97903387	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs7048255	ENSG00000236130.1	PTCSC2	-6.6	1.08e-10	2.64e-08	-0.23	-0.29	Strep throat;	chr9:97903416	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs9299258	ENSG00000236130.1	PTCSC2	-6.6	1.08e-10	2.64e-08	-0.23	-0.29	Strep throat;	chr9:97904261	chr9:97805935~97810008:-
THCA	cis	rs6540731	0.967	rs2884512	ENSG00000226251.4	RP11-15I11.3	-6.6	1.08e-10	2.64e-08	-0.36	-0.29	Intelligence (childhood);	chr1:212229848	chr1:212225278~212238977:-
THCA	cis	rs4845875	0.529	rs6680385	ENSG00000242349.4	NPPA-AS1	6.6	1.08e-10	2.64e-08	0.31	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11771699	chr1:11841017~11848079:+
THCA	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-6.6	1.08e-10	2.65e-08	-0.3	-0.29	Height;	chr11:118860890	chr11:118704607~118750263:+
THCA	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-6.6	1.08e-10	2.65e-08	-0.3	-0.29	Height;	chr11:118861053	chr11:118704607~118750263:+
THCA	cis	rs11018904	0.906	rs10501713	ENSG00000280385.1	AP000648.5	-6.6	1.08e-10	2.65e-08	-0.39	-0.29	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90193614~90198120:+
THCA	cis	rs7324557	0.684	rs9510871	ENSG00000205861.10	C1QTNF9B-AS1	-6.6	1.08e-10	2.65e-08	-0.36	-0.29	Visceral adipose tissue adjusted for BMI;	chr13:23810713	chr13:23888889~23897263:+
THCA	cis	rs934734	0.563	rs1858036	ENSG00000237979.1	AC007389.1	6.6	1.09e-10	2.65e-08	0.36	0.29	Rheumatoid arthritis;	chr2:65371107	chr2:65500993~65502138:-
THCA	cis	rs1552244	0.882	rs13063098	ENSG00000232901.1	CYCSP10	6.6	1.09e-10	2.65e-08	0.37	0.29	Alzheimer's disease;	chr3:9968235	chr3:10000647~10000940:-
THCA	cis	rs9475752	0.947	rs748996	ENSG00000231441.1	RP11-472M19.2	6.6	1.09e-10	2.65e-08	0.36	0.29	Menarche (age at onset);	chr6:56933223	chr6:56844002~56864078:+
THCA	cis	rs7189233	0.955	rs8044205	ENSG00000279344.1	RP11-44F14.7	6.6	1.09e-10	2.65e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53481181	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.955	rs8058684	ENSG00000279344.1	RP11-44F14.7	6.6	1.09e-10	2.65e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53481206	chr16:53478957~53481550:-
THCA	cis	rs79464052	0.677	rs77605361	ENSG00000228737.2	AC008781.7	-6.6	1.09e-10	2.65e-08	-0.69	-0.29	Diffuse large B cell lymphoma;	chr5:141574459	chr5:141618414~141626481:+
THCA	cis	rs4819052	0.58	rs419322	ENSG00000223768.1	LINC00205	-6.6	1.09e-10	2.65e-08	-0.32	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45131787	chr21:45293285~45297354:+
THCA	cis	rs3213758	0.588	rs12931642	ENSG00000275191.1	RP11-36I17.2	-6.6	1.09e-10	2.65e-08	-0.52	-0.29	Vitiligo (non-segmental);	chr16:53565725	chr16:53628256~53628816:-
THCA	cis	rs7727544	1	rs7727038	ENSG00000224431.1	AC063976.7	6.6	1.09e-10	2.66e-08	0.25	0.29	Blood metabolite levels;	chr5:132254564	chr5:132199456~132203487:+
THCA	cis	rs7727544	1	rs7727544	ENSG00000224431.1	AC063976.7	6.6	1.09e-10	2.66e-08	0.25	0.29	Blood metabolite levels;	chr5:132254841	chr5:132199456~132203487:+
THCA	cis	rs3764021	0.509	rs10772070	ENSG00000256594.6	RP11-705C15.2	6.6	1.09e-10	2.66e-08	0.25	0.29	Type 1 diabetes;	chr12:9717320	chr12:9633419~9658412:+
THCA	cis	rs11976180	1	rs2371244	ENSG00000170356.8	OR2A20P	-6.6	1.09e-10	2.66e-08	-0.4	-0.29	Obesity-related traits;	chr7:144060518	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs4726669	ENSG00000170356.8	OR2A20P	-6.6	1.09e-10	2.66e-08	-0.4	-0.29	Obesity-related traits;	chr7:144061098	chr7:144250045~144252957:-
THCA	cis	rs3750082	0.582	rs3750079	ENSG00000231952.3	DPY19L1P2	6.6	1.09e-10	2.66e-08	0.39	0.29	Glomerular filtration rate (creatinine);	chr7:32929807	chr7:32812757~32838570:+
THCA	cis	rs6840360	0.642	rs4235219	ENSG00000251611.1	RP11-610P16.1	-6.6	1.09e-10	2.66e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs6851814	ENSG00000251611.1	RP11-610P16.1	-6.6	1.09e-10	2.66e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.606	rs10028035	ENSG00000251611.1	RP11-610P16.1	-6.6	1.09e-10	2.66e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.667	rs4266275	ENSG00000251611.1	RP11-610P16.1	-6.6	1.09e-10	2.66e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7684462	ENSG00000251611.1	RP11-610P16.1	-6.6	1.09e-10	2.66e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151407551~151408835:-
THCA	cis	rs4713118	0.869	rs9283881	ENSG00000280107.1	AL022393.9	-6.6	1.09e-10	2.67e-08	-0.34	-0.29	Parkinson's disease;	chr6:27747476	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs9283882	ENSG00000280107.1	AL022393.9	-6.6	1.09e-10	2.67e-08	-0.34	-0.29	Parkinson's disease;	chr6:27747479	chr6:28170845~28172521:+
THCA	cis	rs2439831	1	rs2245908	ENSG00000275601.1	AC011330.13	-6.6	1.09e-10	2.67e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43439256	chr15:43642389~43643023:-
THCA	cis	rs9926296	0.605	rs6500449	ENSG00000260259.1	RP11-368I7.4	-6.6	1.09e-10	2.67e-08	-0.31	-0.29	Vitiligo;	chr16:89789985	chr16:89682620~89686569:-
THCA	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	6.6	1.1e-10	2.67e-08	0.27	0.29	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
THCA	cis	rs7267979	0.966	rs6037083	ENSG00000274414.1	RP5-965G21.4	6.6	1.1e-10	2.67e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25239007~25245229:-
THCA	cis	rs1395	0.744	rs62130709	ENSG00000234072.1	AC074117.10	-6.6	1.1e-10	2.67e-08	-0.26	-0.29	Blood metabolite levels;	chr2:27282914	chr2:27356246~27367622:+
THCA	cis	rs1395	0.744	rs11686131	ENSG00000234072.1	AC074117.10	-6.6	1.1e-10	2.67e-08	-0.26	-0.29	Blood metabolite levels;	chr2:27285842	chr2:27356246~27367622:+
THCA	cis	rs2439831	0.85	rs28590651	ENSG00000275601.1	AC011330.13	-6.6	1.1e-10	2.68e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43820818	chr15:43642389~43643023:-
THCA	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-6.6	1.1e-10	2.68e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
THCA	cis	rs11158026	0.757	rs56206440	ENSG00000258413.1	RP11-665C16.6	-6.6	1.1e-10	2.68e-08	-0.4	-0.29	Parkinson's disease;	chr14:54984168	chr14:55262767~55272075:-
THCA	cis	rs11668609	1	rs919813	ENSG00000268442.1	CTD-2027I19.2	6.6	1.1e-10	2.68e-08	0.34	0.29	Response to taxane treatment (docetaxel);	chr19:24163431	chr19:24162370~24163425:-
THCA	cis	rs7246657	0.943	rs2291004	ENSG00000226686.6	LINC01535	-6.6	1.1e-10	2.68e-08	-0.43	-0.29	Coronary artery calcification;	chr19:37507050	chr19:37251912~37265535:+
THCA	cis	rs7617773	0.817	rs11720622	ENSG00000228638.1	FCF1P2	-6.6	1.1e-10	2.68e-08	-0.27	-0.29	Coronary artery disease;	chr3:48205189	chr3:48290793~48291375:-
THCA	cis	rs6840360	0.642	rs1470281	ENSG00000251611.1	RP11-610P16.1	-6.6	1.1e-10	2.68e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151407551~151408835:-
THCA	cis	rs7267979	0.739	rs6138555	ENSG00000274414.1	RP5-965G21.4	-6.6	1.1e-10	2.69e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25239007~25245229:-
THCA	cis	rs7851660	0.809	rs10984235	ENSG00000236130.1	PTCSC2	-6.6	1.1e-10	2.69e-08	-0.23	-0.29	Strep throat;	chr9:97898614	chr9:97805935~97810008:-
THCA	cis	rs934734	0.563	rs1858037	ENSG00000237979.1	AC007389.1	6.6	1.1e-10	2.69e-08	0.35	0.29	Rheumatoid arthritis;	chr2:65371166	chr2:65500993~65502138:-
THCA	cis	rs748404	0.631	rs6493083	ENSG00000166763.7	STRCP1	6.6	1.1e-10	2.69e-08	0.32	0.29	Lung cancer;	chr15:43345787	chr15:43699488~43718184:-
THCA	cis	rs1075232	0.677	rs72714666	ENSG00000270055.1	CTD-3092A11.2	-6.6	1.1e-10	2.69e-08	-0.51	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31200023	chr15:30487963~30490313:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000224205.1	AP000351.4	6.6	1.1e-10	2.69e-08	0.37	0.29	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23987320~23991421:-
THCA	cis	rs7727544	1	rs10076701	ENSG00000224431.1	AC063976.7	6.6	1.11e-10	2.69e-08	0.25	0.29	Blood metabolite levels;	chr5:132260726	chr5:132199456~132203487:+
THCA	cis	rs925255	0.682	rs7590263	ENSG00000270210.1	RP11-373D23.3	6.6	1.11e-10	2.69e-08	0.29	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28422935	chr2:28425945~28426719:+
THCA	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-6.6	1.11e-10	2.7e-08	-0.27	-0.29	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
THCA	cis	rs7811142	1	rs11559117	ENSG00000078319.8	PMS2P1	-6.6	1.11e-10	2.7e-08	-0.42	-0.29	Platelet count;	chr7:100478991	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs2406253	ENSG00000078319.8	PMS2P1	-6.6	1.11e-10	2.7e-08	-0.42	-0.29	Platelet count;	chr7:100479650	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs4463351	ENSG00000078319.8	PMS2P1	-6.6	1.11e-10	2.7e-08	-0.42	-0.29	Platelet count;	chr7:100480603	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs11769700	ENSG00000078319.8	PMS2P1	-6.6	1.11e-10	2.7e-08	-0.42	-0.29	Platelet count;	chr7:100492426	chr7:100320992~100341908:-
THCA	cis	rs17826219	0.561	rs562840	ENSG00000263603.1	CTD-2349P21.5	-6.6	1.11e-10	2.7e-08	-0.47	-0.29	Body mass index;	chr17:30622372	chr17:30729469~30731202:+
THCA	cis	rs3806843	1	rs10477033	ENSG00000202515.1	VTRNA1-3	-6.6	1.11e-10	2.7e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140790018	chr5:140726158~140726246:+
THCA	cis	rs7189233	0.955	rs16952242	ENSG00000279344.1	RP11-44F14.7	6.6	1.11e-10	2.71e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53440338	chr16:53478957~53481550:-
THCA	cis	rs1552244	0.882	rs17050699	ENSG00000232901.1	CYCSP10	6.6	1.11e-10	2.71e-08	0.37	0.29	Alzheimer's disease;	chr3:9995483	chr3:10000647~10000940:-
THCA	cis	rs7851660	0.772	rs6478471	ENSG00000236130.1	PTCSC2	-6.6	1.11e-10	2.71e-08	-0.23	-0.29	Strep throat;	chr9:97902100	chr9:97805935~97810008:-
THCA	cis	rs6671200	0.667	rs113926595	ENSG00000235501.4	RP4-639F20.1	-6.6	1.11e-10	2.71e-08	-0.59	-0.29	Stearic acid (18:0) levels;	chr1:94930060	chr1:94927566~94963270:+
THCA	cis	rs831571	0.55	rs153734	ENSG00000280620.1	SCAANT1	6.6	1.12e-10	2.72e-08	0.41	0.29	Type 2 diabetes;	chr3:64092333	chr3:63911518~63911772:-
THCA	cis	rs10899021	0.704	rs11236177	ENSG00000279353.1	RP11-864N7.4	6.6	1.12e-10	2.72e-08	0.56	0.29	Response to metformin (IC50);	chr11:74628022	chr11:74698231~74699658:-
THCA	cis	rs10899021	0.79	rs10899022	ENSG00000279353.1	RP11-864N7.4	6.6	1.12e-10	2.72e-08	0.56	0.29	Response to metformin (IC50);	chr11:74628341	chr11:74698231~74699658:-
THCA	cis	rs10899021	0.79	rs11236180	ENSG00000279353.1	RP11-864N7.4	6.6	1.12e-10	2.72e-08	0.56	0.29	Response to metformin (IC50);	chr11:74631883	chr11:74698231~74699658:-
THCA	cis	rs7267979	1	rs6515651	ENSG00000274414.1	RP5-965G21.4	6.6	1.12e-10	2.72e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2424716	ENSG00000274414.1	RP5-965G21.4	-6.6	1.12e-10	2.72e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs761025	ENSG00000274414.1	RP5-965G21.4	-6.6	1.12e-10	2.72e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25239007~25245229:-
THCA	cis	rs4604234	1	rs112881252	ENSG00000272129.1	RP11-250B2.6	-6.6	1.12e-10	2.73e-08	-0.8	-0.29	Cancer;	chr6:80397655	chr6:80355424~80356859:+
THCA	cis	rs330048	0.561	rs4840401	ENSG00000254153.1	CTA-398F10.2	6.6	1.12e-10	2.73e-08	0.33	0.29	Systemic lupus erythematosus;	chr8:9290615	chr8:8456909~8461337:-
THCA	cis	rs2303319	1	rs62188139	ENSG00000227403.1	AC009299.3	6.6	1.12e-10	2.73e-08	0.62	0.29	Cognitive function;	chr2:161413264	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs62188140	ENSG00000227403.1	AC009299.3	6.6	1.12e-10	2.73e-08	0.62	0.29	Cognitive function;	chr2:161413355	chr2:161244739~161249050:+
THCA	cis	rs6545883	0.894	rs12997538	ENSG00000271889.1	RP11-493E12.1	-6.6	1.12e-10	2.73e-08	-0.28	-0.29	Tuberculosis;	chr2:61337114	chr2:61151433~61162105:-
THCA	cis	rs7976269	0.537	rs2117992	ENSG00000257176.2	RP11-996F15.2	-6.6	1.12e-10	2.73e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29070611	chr12:29280418~29317848:-
THCA	cis	rs1043099	0.536	rs9620979	ENSG00000279699.1	RP1-102K2.9	-6.6	1.12e-10	2.73e-08	-0.35	-0.29	Rheumatoid arthritis;	chr22:30412763	chr22:30275215~30276951:-
THCA	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-6.6	1.12e-10	2.74e-08	-0.17	-0.29	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
THCA	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-6.6	1.13e-10	2.74e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-6.6	1.13e-10	2.74e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
THCA	cis	rs11096990	0.855	rs4974986	ENSG00000249207.1	RP11-360F5.1	6.6	1.13e-10	2.74e-08	0.38	0.29	Cognitive function;	chr4:39165308	chr4:39112677~39126818:-
THCA	cis	rs7851660	0.809	rs7022148	ENSG00000236130.1	PTCSC2	-6.6	1.13e-10	2.74e-08	-0.23	-0.29	Strep throat;	chr9:97898542	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.775	rs7034336	ENSG00000236130.1	PTCSC2	-6.6	1.13e-10	2.74e-08	-0.23	-0.29	Strep throat;	chr9:97898818	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs10818241	ENSG00000236130.1	PTCSC2	-6.6	1.13e-10	2.74e-08	-0.23	-0.29	Strep throat;	chr9:97899690	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.839	rs7027221	ENSG00000236130.1	PTCSC2	-6.6	1.13e-10	2.74e-08	-0.23	-0.29	Strep throat;	chr9:97900097	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.809	rs10739526	ENSG00000236130.1	PTCSC2	-6.6	1.13e-10	2.74e-08	-0.23	-0.29	Strep throat;	chr9:97900389	chr9:97805935~97810008:-
THCA	cis	rs5742933	0.817	rs13035966	ENSG00000273240.1	RP11-455J20.3	6.6	1.13e-10	2.74e-08	0.3	0.29	Ferritin levels;	chr2:189726507	chr2:189763859~189764456:-
THCA	cis	rs4950322	0.58	rs7541393	ENSG00000237188.3	RP11-337C18.8	6.6	1.13e-10	2.74e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147117186	chr1:147172771~147211568:+
THCA	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-6.6	1.13e-10	2.75e-08	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
THCA	cis	rs11779988	0.501	rs3760	ENSG00000253671.1	RP11-806O11.1	-6.6	1.13e-10	2.75e-08	-0.35	-0.29	Breast cancer;	chr8:18028836	chr8:17808941~17820868:+
THCA	cis	rs1552244	0.572	rs3843008	ENSG00000232901.1	CYCSP10	6.6	1.13e-10	2.75e-08	0.46	0.29	Alzheimer's disease;	chr3:10132058	chr3:10000647~10000940:-
THCA	cis	rs9876781	0.559	rs1841178	ENSG00000229759.1	MRPS18AP1	6.6	1.13e-10	2.75e-08	0.36	0.29	Longevity;	chr3:48355556	chr3:48256350~48256938:-
THCA	cis	rs10208649	0.908	rs2161083	ENSG00000233266.1	HMGB1P31	6.6	1.13e-10	2.75e-08	0.68	0.29	Body mass index;	chr2:54024661	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs2112120	ENSG00000233266.1	HMGB1P31	6.6	1.13e-10	2.75e-08	0.68	0.29	Body mass index;	chr2:54024957	chr2:54051334~54051760:+
THCA	cis	rs12435908	1	rs2300867	ENSG00000276116.2	FUT8-AS1	-6.6	1.13e-10	2.75e-08	-0.46	-0.29	Ischemic stroke;	chr14:65662436	chr14:65411170~65412690:-
THCA	cis	rs12928939	1	rs12928939	ENSG00000260886.1	TAT-AS1	6.6	1.13e-10	2.75e-08	0.39	0.29	Post bronchodilator FEV1;	chr16:71766142	chr16:71565789~71578187:+
THCA	cis	rs4713118	0.869	rs7773070	ENSG00000280107.1	AL022393.9	-6.6	1.13e-10	2.75e-08	-0.34	-0.29	Parkinson's disease;	chr6:27761048	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs7776351	ENSG00000280107.1	AL022393.9	6.6	1.13e-10	2.75e-08	0.34	0.29	Parkinson's disease;	chr6:27758952	chr6:28170845~28172521:+
THCA	cis	rs4143844	0.867	rs11631273	ENSG00000259251.2	RP11-643M14.1	6.6	1.13e-10	2.75e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:61985871	chr15:62060503~62062434:+
THCA	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	6.6	1.13e-10	2.76e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	6.6	1.13e-10	2.76e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	6.6	1.13e-10	2.76e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	6.6	1.13e-10	2.76e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
THCA	cis	rs17270561	0.525	rs12201678	ENSG00000272462.2	U91328.19	-6.6	1.13e-10	2.76e-08	-0.31	-0.29	Iron status biomarkers;	chr6:25978765	chr6:25992662~26001775:+
THCA	cis	rs9926296	0.529	rs7195906	ENSG00000260259.1	RP11-368I7.4	-6.6	1.13e-10	2.76e-08	-0.32	-0.29	Vitiligo;	chr16:89739939	chr16:89682620~89686569:-
THCA	cis	rs950169	0.922	rs11630507	ENSG00000259295.5	CSPG4P12	6.6	1.14e-10	2.76e-08	0.44	0.29	Schizophrenia;	chr15:84552494	chr15:85191438~85213905:+
THCA	cis	rs10799445	0.568	rs3010190	ENSG00000227711.2	RP11-275O4.5	-6.6	1.14e-10	2.76e-08	-0.31	-0.29	Height;	chr1:227616609	chr1:227509028~227520477:-
THCA	cis	rs10740039	0.516	rs1938546	ENSG00000254271.1	RP11-131N11.4	6.6	1.14e-10	2.77e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60556228	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs2154392	ENSG00000254271.1	RP11-131N11.4	6.6	1.14e-10	2.77e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60557728	chr10:60734342~60741828:+
THCA	cis	rs9543976	0.544	rs73223950	ENSG00000261553.4	RP11-29G8.3	-6.6	1.14e-10	2.77e-08	-0.46	-0.29	Diabetic retinopathy;	chr13:75524901	chr13:75549773~75807120:+
THCA	cis	rs7851660	0.809	rs7037324	ENSG00000236130.1	PTCSC2	-6.6	1.14e-10	2.77e-08	-0.23	-0.29	Strep throat;	chr9:97896036	chr9:97805935~97810008:-
THCA	cis	rs7746199	0.736	rs17749927	ENSG00000226314.6	ZNF192P1	-6.6	1.14e-10	2.78e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs13192965	ENSG00000226314.6	ZNF192P1	-6.6	1.14e-10	2.78e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28161781~28169594:+
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000228409.4	CCT6P1	-6.6	1.14e-10	2.78e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66158142	chr7:65751142~65763354:+
THCA	cis	rs853679	0.546	rs200996	ENSG00000219392.1	RP1-265C24.5	-6.6	1.14e-10	2.78e-08	-0.49	-0.29	Depression;	chr6:27844050	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs200990	ENSG00000219392.1	RP1-265C24.5	-6.6	1.14e-10	2.78e-08	-0.49	-0.29	Depression;	chr6:27848045	chr6:28115628~28116551:+
THCA	cis	rs8072100	0.713	rs4968318	ENSG00000228782.6	CTD-2026D20.3	6.6	1.14e-10	2.78e-08	0.26	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47374528	chr17:47450568~47492492:-
THCA	cis	rs7849973	0.595	rs7469568	ENSG00000224549.1	RP11-370B11.3	-6.6	1.14e-10	2.78e-08	-0.37	-0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22767768	chr9:22767175~22768316:+
THCA	cis	rs848490	0.894	rs848476	ENSG00000214293.7	APTR	-6.6	1.14e-10	2.79e-08	-0.23	-0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77912356	chr7:77657660~77696265:-
THCA	cis	rs58785573	0.624	rs337605	ENSG00000231160.8	KLF3-AS1	-6.6	1.15e-10	2.79e-08	-0.16	-0.29	Lymphocyte percentage of white cells;	chr4:38646132	chr4:38612701~38664883:-
THCA	cis	rs1552244	0.882	rs9812006	ENSG00000180385.7	EMC3-AS1	6.6	1.15e-10	2.79e-08	0.31	0.29	Alzheimer's disease;	chr3:9980974	chr3:9986893~10006990:+
THCA	cis	rs1395	0.744	rs4665962	ENSG00000234072.1	AC074117.10	-6.59	1.15e-10	2.79e-08	-0.26	-0.29	Blood metabolite levels;	chr2:27292237	chr2:27356246~27367622:+
THCA	cis	rs2348418	0.966	rs7316351	ENSG00000247934.4	RP11-967K21.1	6.59	1.15e-10	2.8e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28545595	chr12:28163298~28190738:-
THCA	cis	rs4947019	0.534	rs10080925	ENSG00000260273.1	RP11-425D10.10	6.59	1.15e-10	2.8e-08	0.65	0.29	Hematological parameters;	chr6:109339389	chr6:109382795~109383666:+
THCA	cis	rs1275468	1	rs1679381	ENSG00000257497.2	RP11-585P4.5	-6.59	1.15e-10	2.8e-08	-0.43	-0.29	Polycystic ovary syndrome;	chr12:75552344	chr12:75483454~75489820:-
THCA	cis	rs728616	0.867	rs726289	ENSG00000242600.5	MBL1P	6.59	1.15e-10	2.8e-08	0.4	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79904898~79950336:+
THCA	cis	rs9800506	0.584	rs6936583	ENSG00000228559.1	RP3-340B19.3	6.59	1.15e-10	2.8e-08	0.41	0.29	Neutrophil percentage of granulocytes;	chr6:35558148	chr6:35544632~35545669:+
THCA	cis	rs2562456	0.833	rs55875743	ENSG00000268555.1	RP11-678G14.3	6.59	1.15e-10	2.81e-08	0.47	0.29	Pain;	chr19:21383393	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62110416	ENSG00000268555.1	RP11-678G14.3	6.59	1.15e-10	2.81e-08	0.47	0.29	Pain;	chr19:21401924	chr19:21570822~21587322:-
THCA	cis	rs11976180	1	rs11976180	ENSG00000170356.8	OR2A20P	-6.59	1.15e-10	2.81e-08	-0.41	-0.29	Obesity-related traits;	chr7:144044487	chr7:144250045~144252957:-
THCA	cis	rs1385374	0.841	rs11059929	ENSG00000274695.1	RP11-21K12.3	6.59	1.15e-10	2.81e-08	0.52	0.29	Systemic lupus erythematosus;	chr12:128812348	chr12:128826836~128827579:+
THCA	cis	rs853679	0.607	rs201002	ENSG00000219392.1	RP1-265C24.5	-6.59	1.16e-10	2.81e-08	-0.49	-0.29	Depression;	chr6:27840414	chr6:28115628~28116551:+
THCA	cis	rs4835473	0.932	rs6826665	ENSG00000251600.4	RP11-673E1.1	-6.59	1.16e-10	2.81e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:143795140	chr4:143912331~143982454:+
THCA	cis	rs2243480	1	rs4718317	ENSG00000228409.4	CCT6P1	-6.59	1.16e-10	2.82e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66183914	chr7:65751142~65763354:+
THCA	cis	rs7208859	0.673	rs216424	ENSG00000263603.1	CTD-2349P21.5	-6.59	1.16e-10	2.82e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30729469~30731202:+
THCA	cis	rs728616	0.867	rs56235549	ENSG00000242600.5	MBL1P	6.59	1.16e-10	2.82e-08	0.4	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80075192	chr10:79904898~79950336:+
THCA	cis	rs4835473	0.897	rs36083752	ENSG00000251600.4	RP11-673E1.1	-6.59	1.16e-10	2.82e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143693377	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs35162238	ENSG00000251600.4	RP11-673E1.1	-6.59	1.16e-10	2.82e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143693518	chr4:143912331~143982454:+
THCA	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-6.59	1.16e-10	2.82e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
THCA	cis	rs7189233	0.911	rs8057808	ENSG00000279344.1	RP11-44F14.7	6.59	1.16e-10	2.83e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53486701	chr16:53478957~53481550:-
THCA	cis	rs4767841	0.552	rs11064861	ENSG00000248636.5	RP11-768F21.1	-6.59	1.16e-10	2.83e-08	-0.3	-0.29	Urgency urinary incontinence;	chr12:119633855	chr12:119387987~119668079:-
THCA	cis	rs12534093	0.602	rs11765452	ENSG00000234286.1	AC006026.13	-6.59	1.16e-10	2.83e-08	-0.38	-0.29	Infant length;Height;	chr7:23542936	chr7:23680195~23680786:-
THCA	cis	rs797680	0.856	rs627779	ENSG00000223745.6	RP4-717I23.3	-6.59	1.16e-10	2.83e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93218532	chr1:93262186~93346025:-
THCA	cis	rs797680	0.796	rs797661	ENSG00000223745.6	RP4-717I23.3	-6.59	1.16e-10	2.83e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93221534	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs12030549	ENSG00000223745.6	RP4-717I23.3	6.59	1.16e-10	2.83e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93203661	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs531358	ENSG00000223745.6	RP4-717I23.3	6.59	1.16e-10	2.83e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93210454	chr1:93262186~93346025:-
THCA	cis	rs797680	0.786	rs555161	ENSG00000223745.6	RP4-717I23.3	6.59	1.16e-10	2.83e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93210757	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs2765545	ENSG00000223745.6	RP4-717I23.3	6.59	1.16e-10	2.83e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93211712	chr1:93262186~93346025:-
THCA	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	6.59	1.17e-10	2.83e-08	0.25	0.29	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
THCA	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	6.59	1.17e-10	2.83e-08	0.25	0.29	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
THCA	cis	rs8141529	0.732	rs5997408	ENSG00000226471.5	CTA-292E10.6	-6.59	1.17e-10	2.84e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28811927	chr22:28800683~28848559:+
THCA	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	6.59	1.17e-10	2.84e-08	0.35	0.29	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
THCA	cis	rs2282300	0.956	rs1717773	ENSG00000242353.1	RP4-710M3.1	-6.59	1.17e-10	2.84e-08	-0.27	-0.29	Morning vs. evening chronotype;	chr11:30361607	chr11:30368148~30368646:+
THCA	cis	rs7829975	0.681	rs2271342	ENSG00000254153.1	CTA-398F10.2	-6.59	1.17e-10	2.84e-08	-0.31	-0.29	Mood instability;	chr8:8786428	chr8:8456909~8461337:-
THCA	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-6.59	1.17e-10	2.85e-08	-0.26	-0.29	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
THCA	cis	rs4845875	0.564	rs2151655	ENSG00000242349.4	NPPA-AS1	6.59	1.17e-10	2.85e-08	0.3	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11785461	chr1:11841017~11848079:+
THCA	cis	rs2303319	1	rs76063526	ENSG00000227403.1	AC009299.3	6.59	1.17e-10	2.85e-08	0.62	0.29	Cognitive function;	chr2:161374323	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs62188121	ENSG00000227403.1	AC009299.3	6.59	1.17e-10	2.85e-08	0.62	0.29	Cognitive function;	chr2:161375574	chr2:161244739~161249050:+
THCA	cis	rs116139393	0.611	rs7792579	ENSG00000187953.9	PMS2CL	-6.59	1.17e-10	2.85e-08	-0.38	-0.29	Alzheimer's disease (APOE e4 interaction);	chr7:6725962	chr7:6710128~6753862:+
THCA	cis	rs4819052	0.766	rs4819035	ENSG00000237664.1	LINC00316	-6.59	1.18e-10	2.86e-08	-0.33	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45338590~45341990:-
THCA	cis	rs6907340	0.517	rs6939160	ENSG00000237404.1	RP3-471C18.2	-6.59	1.18e-10	2.86e-08	-0.34	-0.29	Endometriosis;	chr6:19802086	chr6:19689825~19753113:-
THCA	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-6.59	1.18e-10	2.86e-08	-0.35	-0.29	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
THCA	cis	rs10875746	0.551	rs11168536	ENSG00000269514.1	RP11-370I10.12	6.59	1.18e-10	2.86e-08	0.3	0.29	Longevity (90 years and older);	chr12:48351268	chr12:48198387~48202031:+
THCA	cis	rs523522	1	rs523522	ENSG00000278344.1	RP11-18C24.8	6.59	1.18e-10	2.86e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120582447	chr12:120500735~120501090:-
THCA	cis	rs438465	1	rs452888	ENSG00000226194.4	RP1-137D17.1	6.59	1.18e-10	2.86e-08	0.44	0.29	Corneal astigmatism;	chr6:169416321	chr6:169369998~169388385:-
THCA	cis	rs12701220	0.59	rs1881124	ENSG00000229043.2	AC091729.9	-6.59	1.18e-10	2.86e-08	-0.46	-0.29	Bronchopulmonary dysplasia;	chr7:1057130	chr7:1160374~1165267:+
THCA	cis	rs7044106	0.791	rs10760116	ENSG00000270917.1	RP11-27I1.6	-6.59	1.18e-10	2.86e-08	-0.41	-0.29	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120812475~120812845:-
THCA	cis	rs9926296	0.605	rs8047486	ENSG00000260259.1	RP11-368I7.4	-6.59	1.18e-10	2.86e-08	-0.31	-0.29	Vitiligo;	chr16:89787617	chr16:89682620~89686569:-
THCA	cis	rs62184315	0.536	rs5743047	ENSG00000273240.1	RP11-455J20.3	6.59	1.18e-10	2.86e-08	0.37	0.29	Alcohol dependence (age at onset);	chr2:189819942	chr2:189763859~189764456:-
THCA	cis	rs17826219	0.568	rs59858012	ENSG00000263603.1	CTD-2349P21.5	-6.59	1.18e-10	2.87e-08	-0.57	-0.29	Body mass index;	chr17:30751564	chr17:30729469~30731202:+
THCA	cis	rs11096990	0.855	rs11737290	ENSG00000249207.1	RP11-360F5.1	6.59	1.18e-10	2.87e-08	0.38	0.29	Cognitive function;	chr4:39192318	chr4:39112677~39126818:-
THCA	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	6.59	1.18e-10	2.87e-08	0.35	0.29	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
THCA	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	6.59	1.18e-10	2.87e-08	0.38	0.29	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
THCA	cis	rs2834188	1	rs1018741	ENSG00000272659.1	AP000295.10	-6.59	1.18e-10	2.87e-08	-0.4	-0.29	Narcolepsy;	chr21:33314040	chr21:33309491~33310181:+
THCA	cis	rs2834188	1	rs1018742	ENSG00000272659.1	AP000295.10	-6.59	1.18e-10	2.87e-08	-0.4	-0.29	Narcolepsy;	chr21:33314076	chr21:33309491~33310181:+
THCA	cis	rs116139393	0.54	rs13224907	ENSG00000187953.9	PMS2CL	-6.59	1.18e-10	2.87e-08	-0.37	-0.29	Alzheimer's disease (APOE e4 interaction);	chr7:6734261	chr7:6710128~6753862:+
THCA	cis	rs2239557	1	rs10150201	ENSG00000259065.1	RP5-1021I20.1	6.59	1.18e-10	2.87e-08	0.35	0.29	Common traits (Other);	chr14:74182454	chr14:73787360~73803270:+
THCA	cis	rs3806843	0.966	rs2563262	ENSG00000202515.1	VTRNA1-3	6.59	1.18e-10	2.87e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140758127	chr5:140726158~140726246:+
THCA	cis	rs7403037	0.958	rs61994700	ENSG00000259905.4	PWRN1	6.59	1.18e-10	2.87e-08	0.34	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24335185	chr15:24493137~24652130:+
THCA	cis	rs2282300	0.91	rs528292	ENSG00000242353.1	RP4-710M3.1	6.59	1.18e-10	2.87e-08	0.27	0.29	Morning vs. evening chronotype;	chr11:30368163	chr11:30368148~30368646:+
THCA	cis	rs2239547	0.603	rs4687698	ENSG00000242142.1	SERBP1P3	6.59	1.18e-10	2.87e-08	0.37	0.29	Schizophrenia;	chr3:53063092	chr3:53064283~53065091:-
THCA	cis	rs4950322	0.57	rs11800580	ENSG00000237188.3	RP11-337C18.8	-6.59	1.18e-10	2.87e-08	-0.36	-0.29	Protein quantitative trait loci;	chr1:147261053	chr1:147172771~147211568:+
THCA	cis	rs1552244	0.572	rs6797536	ENSG00000232901.1	CYCSP10	-6.59	1.18e-10	2.88e-08	-0.45	-0.29	Alzheimer's disease;	chr3:10127118	chr3:10000647~10000940:-
THCA	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	6.59	1.18e-10	2.88e-08	0.38	0.29	Depression;	chr6:28428413	chr6:28176188~28176674:+
THCA	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	6.59	1.18e-10	2.88e-08	0.38	0.29	Depression;	chr6:28430971	chr6:28176188~28176674:+
THCA	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	6.59	1.18e-10	2.88e-08	0.38	0.29	Depression;	chr6:28431469	chr6:28176188~28176674:+
THCA	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	6.59	1.18e-10	2.88e-08	0.38	0.29	Depression;	chr6:28432562	chr6:28176188~28176674:+
THCA	cis	rs1552244	0.882	rs6443276	ENSG00000180385.7	EMC3-AS1	6.59	1.19e-10	2.88e-08	0.3	0.29	Alzheimer's disease;	chr3:9967221	chr3:9986893~10006990:+
THCA	cis	rs853679	0.546	rs200995	ENSG00000219392.1	RP1-265C24.5	6.59	1.19e-10	2.88e-08	0.5	0.29	Depression;	chr6:27845916	chr6:28115628~28116551:+
THCA	cis	rs9388451	0.559	rs1777210	ENSG00000237742.5	RP11-624M8.1	-6.59	1.19e-10	2.88e-08	-0.26	-0.29	Brugada syndrome;	chr6:125777770	chr6:125578558~125749190:-
THCA	cis	rs6496044	0.568	rs6496040	ENSG00000259295.5	CSPG4P12	6.59	1.19e-10	2.88e-08	0.37	0.29	Interstitial lung disease;	chr15:85520898	chr15:85191438~85213905:+
THCA	cis	rs6496044	0.568	rs11855789	ENSG00000259295.5	CSPG4P12	6.59	1.19e-10	2.88e-08	0.37	0.29	Interstitial lung disease;	chr15:85523172	chr15:85191438~85213905:+
THCA	cis	rs8141529	0.732	rs6005881	ENSG00000226471.5	CTA-292E10.6	-6.59	1.19e-10	2.88e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28787145	chr22:28800683~28848559:+
THCA	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-6.59	1.19e-10	2.89e-08	-0.31	-0.29	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
THCA	cis	rs990871	1	rs11209952	ENSG00000227207.2	RPL31P12	-6.59	1.19e-10	2.89e-08	-0.37	-0.29	Subcutaneous adipose tissue;	chr1:72371817	chr1:72301472~72301829:+
THCA	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	6.59	1.19e-10	2.89e-08	0.35	0.29	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
THCA	cis	rs2976388	1	rs2294010	ENSG00000253741.1	CTD-2292P10.4	6.59	1.19e-10	2.89e-08	0.36	0.29	Urinary tract infection frequency;	chr8:142681012	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2976392	ENSG00000253741.1	CTD-2292P10.4	6.59	1.19e-10	2.89e-08	0.36	0.29	Urinary tract infection frequency;	chr8:142681514	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2978982	ENSG00000253741.1	CTD-2292P10.4	6.59	1.19e-10	2.89e-08	0.36	0.29	Urinary tract infection frequency;	chr8:142682072	chr8:142702252~142726973:-
THCA	cis	rs728616	0.867	rs723191	ENSG00000242600.5	MBL1P	6.59	1.19e-10	2.89e-08	0.4	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs723193	ENSG00000242600.5	MBL1P	6.59	1.19e-10	2.89e-08	0.4	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:79904898~79950336:+
THCA	cis	rs867529	0.695	rs335115	ENSG00000234028.3	AC062029.1	-6.59	1.19e-10	2.9e-08	-0.24	-0.29	Height;	chr2:88728129	chr2:88627539~88631821:+
THCA	cis	rs438465	0.853	rs394053	ENSG00000226194.4	RP1-137D17.1	6.59	1.19e-10	2.9e-08	0.43	0.29	Corneal astigmatism;	chr6:169408609	chr6:169369998~169388385:-
THCA	cis	rs7267979	1	rs4815411	ENSG00000274414.1	RP5-965G21.4	6.59	1.19e-10	2.9e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25239007~25245229:-
THCA	cis	rs7976269	0.537	rs10843303	ENSG00000257176.2	RP11-996F15.2	-6.59	1.19e-10	2.9e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29069435	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.559	rs10843304	ENSG00000257176.2	RP11-996F15.2	-6.59	1.19e-10	2.9e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29071226	chr12:29280418~29317848:-
THCA	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-6.59	1.19e-10	2.9e-08	-0.43	-0.29	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
THCA	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	6.59	1.2e-10	2.9e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
THCA	cis	rs516805	0.63	rs225087	ENSG00000279453.1	RP3-425C14.4	-6.59	1.2e-10	2.91e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122277884	chr6:122436789~122439223:-
THCA	cis	rs797680	0.856	rs4847408	ENSG00000223745.6	RP4-717I23.3	-6.59	1.2e-10	2.91e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93325880	chr1:93262186~93346025:-
THCA	cis	rs7202877	0.656	rs247427	ENSG00000261783.1	RP11-252K23.2	6.59	1.2e-10	2.91e-08	0.51	0.29	Type 1 diabetes;Type 2 diabetes;	chr16:75405234	chr16:75379818~75381260:-
THCA	cis	rs2117029	1	rs11168839	ENSG00000258017.1	RP11-386G11.10	6.59	1.2e-10	2.91e-08	0.38	0.29	Intelligence (multi-trait analysis);	chr12:49063852	chr12:49127782~49147869:+
THCA	cis	rs4073416	0.872	rs1984855	ENSG00000276116.2	FUT8-AS1	6.59	1.2e-10	2.92e-08	0.3	0.29	N-glycan levels;	chr14:65772539	chr14:65411170~65412690:-
THCA	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	6.59	1.2e-10	2.92e-08	0.36	0.29	Height;	chr6:109415123	chr6:109382795~109383666:+
THCA	cis	rs6840360	0.642	rs1596290	ENSG00000251611.1	RP11-610P16.1	-6.59	1.2e-10	2.92e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151407551~151408835:-
THCA	cis	rs4713118	0.869	rs2056925	ENSG00000280107.1	AL022393.9	-6.59	1.2e-10	2.92e-08	-0.33	-0.29	Parkinson's disease;	chr6:27723126	chr6:28170845~28172521:+
THCA	cis	rs3764021	0.527	rs2114870	ENSG00000256594.6	RP11-705C15.2	6.59	1.2e-10	2.92e-08	0.25	0.29	Type 1 diabetes;	chr12:9670544	chr12:9633419~9658412:+
THCA	cis	rs7829975	0.688	rs13270194	ENSG00000254153.1	CTA-398F10.2	-6.59	1.2e-10	2.92e-08	-0.32	-0.29	Mood instability;	chr8:8520592	chr8:8456909~8461337:-
THCA	cis	rs1275468	1	rs3847669	ENSG00000257497.2	RP11-585P4.5	-6.59	1.2e-10	2.92e-08	-0.42	-0.29	Polycystic ovary syndrome;	chr12:75555378	chr12:75483454~75489820:-
THCA	cis	rs2834188	0.924	rs2007849	ENSG00000272659.1	AP000295.10	-6.59	1.2e-10	2.92e-08	-0.39	-0.29	Narcolepsy;	chr21:33308811	chr21:33309491~33310181:+
THCA	cis	rs10129255	0.642	rs11624918	ENSG00000223648.3	IGHV3-64	6.59	1.21e-10	2.92e-08	0.19	0.29	Kawasaki disease;	chr14:106664672	chr14:106643132~106658258:-
THCA	cis	rs2348418	0.765	rs11049381	ENSG00000247934.4	RP11-967K21.1	-6.59	1.21e-10	2.93e-08	-0.25	-0.29	Lung function (FEV1);Lung function (FVC);	chr12:28162107	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.765	rs10843117	ENSG00000247934.4	RP11-967K21.1	-6.59	1.21e-10	2.93e-08	-0.25	-0.29	Lung function (FEV1);Lung function (FVC);	chr12:28162457	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.765	rs7954851	ENSG00000247934.4	RP11-967K21.1	-6.59	1.21e-10	2.93e-08	-0.25	-0.29	Lung function (FEV1);Lung function (FVC);	chr12:28162909	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.765	rs7954877	ENSG00000247934.4	RP11-967K21.1	-6.59	1.21e-10	2.93e-08	-0.25	-0.29	Lung function (FEV1);Lung function (FVC);	chr12:28163008	chr12:28163298~28190738:-
THCA	cis	rs6496044	0.568	rs7166642	ENSG00000259295.5	CSPG4P12	6.59	1.21e-10	2.93e-08	0.37	0.29	Interstitial lung disease;	chr15:85518040	chr15:85191438~85213905:+
THCA	cis	rs4073416	0.872	rs2236067	ENSG00000276116.2	FUT8-AS1	6.59	1.21e-10	2.94e-08	0.3	0.29	N-glycan levels;	chr14:65781294	chr14:65411170~65412690:-
THCA	cis	rs4820539	0.641	rs5759602	ENSG00000221069.1	AC000029.1	6.59	1.21e-10	2.94e-08	0.38	0.29	Bone mineral density;	chr22:23147175	chr22:23136620~23136710:+
THCA	cis	rs2562456	0.834	rs2173727	ENSG00000213976.4	CTD-2561J22.2	6.59	1.21e-10	2.94e-08	0.31	0.29	Pain;	chr19:21491155	chr19:21382865~21387177:+
THCA	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	6.59	1.22e-10	2.95e-08	0.24	0.29	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
THCA	cis	rs17772222	0.958	rs1816372	ENSG00000258789.1	RP11-507K2.3	-6.59	1.22e-10	2.95e-08	-0.3	-0.29	Coronary artery calcification;	chr14:88507033	chr14:88551597~88552493:+
THCA	cis	rs2408955	0.715	rs1793957	ENSG00000258273.1	RP11-370I10.4	-6.59	1.22e-10	2.95e-08	-0.38	-0.29	Glycated hemoglobin levels;	chr12:47999041	chr12:48333755~48333901:-
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000263603.1	CTD-2349P21.5	-6.59	1.22e-10	2.95e-08	-0.47	-0.29	Body mass index;	chr17:30690132	chr17:30729469~30731202:+
THCA	cis	rs7403037	0.793	rs4597275	ENSG00000259905.4	PWRN1	6.58	1.22e-10	2.96e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24217564	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.794	rs35626304	ENSG00000259905.4	PWRN1	6.58	1.22e-10	2.96e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24220160	chr15:24493137~24652130:+
THCA	cis	rs6840360	0.642	rs10857260	ENSG00000251611.1	RP11-610P16.1	-6.58	1.22e-10	2.96e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7676493	ENSG00000251611.1	RP11-610P16.1	-6.58	1.22e-10	2.96e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs11735957	ENSG00000251611.1	RP11-610P16.1	-6.58	1.22e-10	2.96e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.607	rs6815320	ENSG00000251611.1	RP11-610P16.1	-6.58	1.22e-10	2.96e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs11726254	ENSG00000251611.1	RP11-610P16.1	-6.58	1.22e-10	2.96e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2053566	ENSG00000251611.1	RP11-610P16.1	-6.58	1.22e-10	2.96e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.607	rs1561918	ENSG00000251611.1	RP11-610P16.1	-6.58	1.22e-10	2.96e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs1443089	ENSG00000251611.1	RP11-610P16.1	-6.58	1.22e-10	2.96e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151407551~151408835:-
THCA	cis	rs853679	0.55	rs1233699	ENSG00000272009.1	RP1-313I6.12	-6.58	1.22e-10	2.96e-08	-0.33	-0.29	Depression;	chr6:28201380	chr6:28078792~28081130:-
THCA	cis	rs1499614	1	rs2707832	ENSG00000229886.1	RP5-1132H15.3	6.58	1.22e-10	2.96e-08	0.48	0.29	Gout;	chr7:66671562	chr7:66025126~66031544:-
THCA	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-6.58	1.22e-10	2.96e-08	-0.24	-0.29	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
THCA	cis	rs2303319	1	rs1559629	ENSG00000227403.1	AC009299.3	6.58	1.22e-10	2.97e-08	0.61	0.29	Cognitive function;	chr2:161414217	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs62194493	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161362103	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs12467117	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161369804	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs62188122	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161383896	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs2194726	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161389321	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs2194727	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161389360	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs16845807	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161390888	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs74733151	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161395345	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs12463483	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161396108	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs12463535	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161396388	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs62188137	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161401037	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs16845830	ENSG00000227403.1	AC009299.3	6.58	1.23e-10	2.97e-08	0.62	0.29	Cognitive function;	chr2:161401684	chr2:161244739~161249050:+
THCA	cis	rs227275	0.525	rs223461	ENSG00000251288.2	RP11-10L12.2	-6.58	1.23e-10	2.97e-08	-0.38	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102751401~102752641:+
THCA	cis	rs6840360	0.642	rs7698816	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.98e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151407551~151408835:-
THCA	cis	rs4950322	0.634	rs4950415	ENSG00000237188.3	RP11-337C18.8	6.58	1.23e-10	2.98e-08	0.36	0.29	Protein quantitative trait loci;	chr1:147350951	chr1:147172771~147211568:+
THCA	cis	rs529866	0.555	rs367569	ENSG00000262636.1	CTD-3088G3.4	6.58	1.23e-10	2.99e-08	0.39	0.29	Inflammatory bowel disease;Crohn's disease;	chr16:11271643	chr16:11380859~11381118:-
THCA	cis	rs6840360	0.642	rs2724578	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.574	rs2709844	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.693	rs28622593	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709831	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2724574	ENSG00000251611.1	RP11-610P16.1	6.58	1.23e-10	2.99e-08	0.21	0.29	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709817	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709818	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs2709819	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7682770	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7676059	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7657747	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs4696089	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs11932398	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs4263379	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs12647555	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs1899550	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7680013	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7680236	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs4696092	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs6843639	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs28666858	ENSG00000251611.1	RP11-610P16.1	-6.58	1.23e-10	2.99e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151407551~151408835:-
THCA	cis	rs10740039	0.516	rs1009410	ENSG00000254271.1	RP11-131N11.4	6.58	1.23e-10	2.99e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60595039	chr10:60734342~60741828:+
THCA	cis	rs690037	0.551	rs690522	ENSG00000272529.1	RP11-415F23.4	6.58	1.23e-10	2.99e-08	0.27	0.29	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16335560	chr3:16345126~16346440:+
THCA	cis	rs2243480	1	rs2707844	ENSG00000229886.1	RP5-1132H15.3	6.58	1.23e-10	2.99e-08	0.48	0.29	Diabetic kidney disease;	chr7:66594522	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1796220	ENSG00000229886.1	RP5-1132H15.3	6.58	1.23e-10	2.99e-08	0.48	0.29	Diabetic kidney disease;	chr7:66597113	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs2707831	ENSG00000229886.1	RP5-1132H15.3	6.58	1.23e-10	2.99e-08	0.48	0.29	Diabetic kidney disease;	chr7:66597524	chr7:66025126~66031544:-
THCA	cis	rs7267979	1	rs6107033	ENSG00000274414.1	RP5-965G21.4	6.58	1.24e-10	2.99e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25239007~25245229:-
THCA	cis	rs2834188	1	rs2096464	ENSG00000272659.1	AP000295.10	6.58	1.24e-10	2.99e-08	0.4	0.29	Narcolepsy;	chr21:33313744	chr21:33309491~33310181:+
THCA	cis	rs9400467	0.528	rs56827	ENSG00000271789.1	RP5-1112D6.7	-6.58	1.24e-10	3e-08	-0.27	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111297126~111298510:+
THCA	cis	rs6860806	0.631	rs6863548	ENSG00000237714.1	P4HA2-AS1	6.58	1.24e-10	3e-08	0.37	0.29	Breast cancer;	chr5:132240227	chr5:132184876~132192808:+
THCA	cis	rs4948275	0.53	rs2393853	ENSG00000237233.2	TMEM26-AS1	6.58	1.24e-10	3e-08	0.39	0.29	Night sleep phenotypes;	chr10:61407930	chr10:61452639~61481956:+
THCA	cis	rs28386778	0.897	rs1877318	ENSG00000240280.5	TCAM1P	-6.58	1.24e-10	3e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63742600	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs8079818	ENSG00000240280.5	TCAM1P	-6.58	1.24e-10	3e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63747307	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs4638645	ENSG00000240280.5	TCAM1P	-6.58	1.24e-10	3e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63750989	chr17:63849292~63864379:+
THCA	cis	rs16843372	0.599	rs10172746	ENSG00000251491.2	OR7E28P	-6.58	1.24e-10	3.01e-08	-0.38	-0.29	Obesity-related traits;	chr2:158819586	chr2:158862311~158863285:+
THCA	cis	rs3806843	0.9	rs3756334	ENSG00000202515.1	VTRNA1-3	-6.58	1.24e-10	3.01e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140834211	chr5:140726158~140726246:+
THCA	cis	rs1385374	0.858	rs959989	ENSG00000274695.1	RP11-21K12.3	6.58	1.24e-10	3.01e-08	0.51	0.29	Systemic lupus erythematosus;	chr12:128808163	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.858	rs11059926	ENSG00000274695.1	RP11-21K12.3	6.58	1.24e-10	3.01e-08	0.51	0.29	Systemic lupus erythematosus;	chr12:128809699	chr12:128826836~128827579:+
THCA	cis	rs7688540	0.8	rs9328737	ENSG00000211553.1	AC253576.2	-6.58	1.25e-10	3.01e-08	-0.4	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:136461~136568:+
THCA	cis	rs4273100	0.79	rs60606605	ENSG00000265185.4	SNORD3B-1	6.58	1.25e-10	3.02e-08	0.42	0.29	Schizophrenia;	chr17:19373831	chr17:19061912~19062669:+
THCA	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-6.58	1.25e-10	3.02e-08	-0.27	-0.29	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
THCA	cis	rs6840360	0.642	rs2709820	ENSG00000251611.1	RP11-610P16.1	-6.58	1.25e-10	3.02e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151407551~151408835:-
THCA	cis	rs73607972	0.935	rs4783818	ENSG00000275191.1	RP11-36I17.2	-6.58	1.25e-10	3.03e-08	-0.47	-0.29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53704371	chr16:53628256~53628816:-
THCA	cis	rs516805	0.667	rs2816165	ENSG00000279453.1	RP3-425C14.4	-6.58	1.25e-10	3.03e-08	-0.32	-0.29	Lymphocyte counts;	chr6:122114717	chr6:122436789~122439223:-
THCA	cis	rs2834188	1	rs2834190	ENSG00000272659.1	AP000295.10	6.58	1.25e-10	3.03e-08	0.4	0.29	Narcolepsy;	chr21:33320706	chr21:33309491~33310181:+
THCA	cis	rs1499614	1	rs2141924	ENSG00000229886.1	RP5-1132H15.3	6.58	1.25e-10	3.03e-08	0.49	0.29	Gout;	chr7:66721259	chr7:66025126~66031544:-
THCA	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-6.58	1.25e-10	3.03e-08	-0.17	-0.29	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
THCA	cis	rs7208859	0.673	rs999796	ENSG00000266490.1	CTD-2349P21.9	6.58	1.25e-10	3.04e-08	0.38	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30792372~30792833:+
THCA	cis	rs71636778	0.509	rs35969145	ENSG00000260063.1	RP5-968P14.2	-6.58	1.25e-10	3.04e-08	-0.58	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26932901	chr1:26692132~26694131:-
THCA	cis	rs41307935	0.818	rs35576939	ENSG00000260063.1	RP5-968P14.2	-6.58	1.25e-10	3.04e-08	-0.58	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26947604	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs17340509	ENSG00000260063.1	RP5-968P14.2	-6.58	1.25e-10	3.04e-08	-0.58	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26948209	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs17360994	ENSG00000260063.1	RP5-968P14.2	-6.58	1.25e-10	3.04e-08	-0.58	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26952082	chr1:26692132~26694131:-
THCA	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	6.58	1.25e-10	3.04e-08	0.39	0.29	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
THCA	cis	rs848490	1	rs848490	ENSG00000214293.7	APTR	-6.58	1.26e-10	3.04e-08	-0.23	-0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77925688	chr7:77657660~77696265:-
THCA	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	6.58	1.26e-10	3.04e-08	0.53	0.29	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
THCA	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-6.58	1.26e-10	3.04e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
THCA	cis	rs4835473	0.932	rs17750042	ENSG00000251600.4	RP11-673E1.1	-6.58	1.26e-10	3.05e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143726691	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1375989	ENSG00000251600.4	RP11-673E1.1	-6.58	1.26e-10	3.05e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143726893	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35598827	ENSG00000251600.4	RP11-673E1.1	-6.58	1.26e-10	3.05e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143729605	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34570929	ENSG00000251600.4	RP11-673E1.1	-6.58	1.26e-10	3.05e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143730766	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs17750172	ENSG00000251600.4	RP11-673E1.1	-6.58	1.26e-10	3.05e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143731094	chr4:143912331~143982454:+
THCA	cis	rs202072	0.729	rs202040	ENSG00000272379.1	RP1-257A7.5	6.58	1.26e-10	3.05e-08	0.48	0.29	HIV-1 viral setpoint;	chr6:13288303	chr6:13290018~13290490:-
THCA	cis	rs7746199	0.736	rs34064842	ENSG00000219392.1	RP1-265C24.5	-6.58	1.26e-10	3.06e-08	-0.65	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28115628~28116551:+
THCA	cis	rs10875746	0.551	rs1471998	ENSG00000269514.1	RP11-370I10.12	6.58	1.26e-10	3.06e-08	0.29	0.29	Longevity (90 years and older);	chr12:48318219	chr12:48198387~48202031:+
THCA	cis	rs7811142	1	rs60844404	ENSG00000078319.8	PMS2P1	-6.58	1.26e-10	3.06e-08	-0.41	-0.29	Platelet count;	chr7:100482851	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs113738841	ENSG00000078319.8	PMS2P1	-6.58	1.26e-10	3.06e-08	-0.41	-0.29	Platelet count;	chr7:100483683	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs11763511	ENSG00000078319.8	PMS2P1	-6.58	1.26e-10	3.06e-08	-0.41	-0.29	Platelet count;	chr7:100484321	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs2897358	ENSG00000078319.8	PMS2P1	-6.58	1.26e-10	3.06e-08	-0.41	-0.29	Platelet count;	chr7:100491017	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs7787620	ENSG00000078319.8	PMS2P1	-6.58	1.26e-10	3.06e-08	-0.41	-0.29	Platelet count;	chr7:100491611	chr7:100320992~100341908:-
THCA	cis	rs3822625	1	rs16886448	ENSG00000271828.1	CTD-2310F14.1	6.58	1.27e-10	3.06e-08	0.74	0.29	Breast cancer (early onset);	chr5:56874986	chr5:56927874~56929573:+
THCA	cis	rs6696239	0.513	rs7528094	ENSG00000227711.2	RP11-275O4.5	-6.58	1.27e-10	3.07e-08	-0.3	-0.29	Height;	chr1:227548538	chr1:227509028~227520477:-
THCA	cis	rs6840360	0.642	rs11729923	ENSG00000251611.1	RP11-610P16.1	-6.58	1.27e-10	3.07e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151407551~151408835:-
THCA	cis	rs720475	0.732	rs62483106	ENSG00000204959.4	ARHGEF34P	-6.58	1.27e-10	3.08e-08	-0.33	-0.29	Breast cancer;	chr7:144439533	chr7:144272445~144286966:-
THCA	cis	rs2915864	0.8	rs7733001	ENSG00000280047.1	CTC-463A16.1	6.58	1.27e-10	3.08e-08	0.44	0.29	Facial morphology (factor 20);	chr5:142136203	chr5:142165767~142168387:+
THCA	cis	rs4835473	0.9	rs71612420	ENSG00000251600.4	RP11-673E1.1	-6.58	1.27e-10	3.08e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143779107	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13134869	ENSG00000251600.4	RP11-673E1.1	-6.58	1.27e-10	3.08e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143782301	chr4:143912331~143982454:+
THCA	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-6.58	1.27e-10	3.08e-08	-0.45	-0.29	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
THCA	cis	rs28386778	0.724	rs35092235	ENSG00000240280.5	TCAM1P	-6.58	1.28e-10	3.09e-08	-0.41	-0.29	Prudent dietary pattern;	chr17:63867261	chr17:63849292~63864379:+
THCA	cis	rs202072	0.676	rs202048	ENSG00000272379.1	RP1-257A7.5	6.58	1.28e-10	3.09e-08	0.48	0.29	HIV-1 viral setpoint;	chr6:13274269	chr6:13290018~13290490:-
THCA	cis	rs7267979	1	rs6050599	ENSG00000274414.1	RP5-965G21.4	6.58	1.28e-10	3.09e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050602	ENSG00000274414.1	RP5-965G21.4	6.58	1.28e-10	3.09e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs6083855	ENSG00000274414.1	RP5-965G21.4	6.58	1.28e-10	3.09e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs4815426	ENSG00000274414.1	RP5-965G21.4	6.58	1.28e-10	3.09e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25239007~25245229:-
THCA	cis	rs16958440	0.867	rs12326457	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47152054	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs12326465	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47152274	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs75934126	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47153410	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs12326221	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47156522	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs12326412	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47157223	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs77615793	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47158093	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs75287977	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47160452	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs28578518	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47161177	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs28587821	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47161535	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs77599321	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47163271	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs75901436	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47163273	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs74845165	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47164481	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs114475395	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47164639	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs16949157	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47164953	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs75808931	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47166671	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs59217333	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47168473	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs10083937	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47169231	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs79395141	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47169309	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs80006910	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47170011	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs77149690	ENSG00000267800.1	RP11-49K24.5	-6.58	1.28e-10	3.09e-08	-0.64	-0.29	Sitting height ratio;	chr18:47170772	chr18:47137018~47137290:+
THCA	cis	rs10740039	0.516	rs6479717	ENSG00000254271.1	RP11-131N11.4	6.58	1.28e-10	3.09e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559530	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs2068044	ENSG00000254271.1	RP11-131N11.4	6.58	1.28e-10	3.09e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60560679	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs1975443	ENSG00000254271.1	RP11-131N11.4	6.58	1.28e-10	3.09e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60561584	chr10:60734342~60741828:+
THCA	cis	rs11976180	1	rs7777389	ENSG00000170356.8	OR2A20P	-6.58	1.28e-10	3.09e-08	-0.4	-0.29	Obesity-related traits;	chr7:144047709	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs67239267	ENSG00000170356.8	OR2A20P	-6.58	1.28e-10	3.09e-08	-0.4	-0.29	Obesity-related traits;	chr7:144048023	chr7:144250045~144252957:-
THCA	cis	rs7746199	0.736	rs34965299	ENSG00000226314.6	ZNF192P1	-6.58	1.28e-10	3.09e-08	-0.63	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28161781~28169594:+
THCA	cis	rs35491132	1	rs35491132	ENSG00000226314.6	ZNF192P1	-6.58	1.28e-10	3.09e-08	-0.63	-0.29	Urinary tract infection frequency;	chr6:27559449	chr6:28161781~28169594:+
THCA	cis	rs793571	0.505	rs16940587	ENSG00000259250.1	RP11-50C13.1	-6.58	1.28e-10	3.1e-08	-0.31	-0.29	Schizophrenia;	chr15:58606464	chr15:58587507~58591676:+
THCA	cis	rs7746199	0.736	rs13193542	ENSG00000219392.1	RP1-265C24.5	-6.58	1.28e-10	3.1e-08	-0.66	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28115628~28116551:+
THCA	cis	rs7746199	0.736	rs13193480	ENSG00000219392.1	RP1-265C24.5	-6.58	1.28e-10	3.1e-08	-0.66	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28115628~28116551:+
THCA	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	6.58	1.28e-10	3.1e-08	0.35	0.29	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
THCA	cis	rs1609391	0.561	rs9289523	ENSG00000273486.1	RP11-731C17.2	6.58	1.28e-10	3.1e-08	0.25	0.29	Neuroticism;	chr3:136916747	chr3:136837338~136839021:-
THCA	cis	rs2562456	0.652	rs4809145	ENSG00000268555.1	RP11-678G14.3	6.58	1.28e-10	3.1e-08	0.44	0.29	Pain;	chr19:21597907	chr19:21570822~21587322:-
THCA	cis	rs73607972	0.74	rs66961852	ENSG00000275191.1	RP11-36I17.2	-6.58	1.28e-10	3.1e-08	-0.43	-0.29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53587476	chr16:53628256~53628816:-
THCA	cis	rs1865760	0.663	rs9379815	ENSG00000272462.2	U91328.19	-6.58	1.28e-10	3.1e-08	-0.24	-0.29	Height;	chr6:25979888	chr6:25992662~26001775:+
THCA	cis	rs7267979	1	rs4815420	ENSG00000274414.1	RP5-965G21.4	6.58	1.28e-10	3.1e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25239007~25245229:-
THCA	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-6.58	1.28e-10	3.1e-08	-0.17	-0.29	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
THCA	cis	rs2439831	1	rs689596	ENSG00000249839.1	AC011330.5	-6.58	1.29e-10	3.11e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43469519	chr15:43663654~43684339:-
THCA	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-6.58	1.29e-10	3.11e-08	-0.29	-0.29	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
THCA	cis	rs4072705	1	rs10818987	ENSG00000224020.1	MIR181A2HG	-6.58	1.29e-10	3.11e-08	-0.26	-0.29	Menarche (age at onset);	chr9:124758450	chr9:124658467~124698631:+
THCA	cis	rs7191700	0.712	rs7187741	ENSG00000263080.1	RP11-485G7.5	-6.58	1.29e-10	3.11e-08	-0.34	-0.29	Multiple sclerosis;	chr16:11339246	chr16:11341809~11345211:-
THCA	cis	rs71403859	0.554	rs12920245	ENSG00000260886.1	TAT-AS1	6.58	1.29e-10	3.11e-08	0.65	0.29	Post bronchodilator FEV1;	chr16:71995170	chr16:71565789~71578187:+
THCA	cis	rs2562456	0.833	rs2359145	ENSG00000268555.1	RP11-678G14.3	6.58	1.29e-10	3.11e-08	0.47	0.29	Pain;	chr19:21409791	chr19:21570822~21587322:-
THCA	cis	rs10208649	1	rs6545369	ENSG00000272156.1	RP11-477N3.1	6.58	1.29e-10	3.12e-08	0.54	0.29	Body mass index;	chr2:53828006	chr2:54082554~54085066:+
THCA	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-6.58	1.29e-10	3.12e-08	-0.22	-0.29	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
THCA	cis	rs4835473	0.591	rs6822129	ENSG00000251600.4	RP11-673E1.1	-6.58	1.29e-10	3.12e-08	-0.4	-0.29	Immature fraction of reticulocytes;	chr4:144058755	chr4:143912331~143982454:+
THCA	cis	rs2243480	1	rs316327	ENSG00000228409.4	CCT6P1	-6.58	1.29e-10	3.12e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:66144214	chr7:65751142~65763354:+
THCA	cis	rs526231	0.853	rs1991797	ENSG00000175749.11	EIF3KP1	6.58	1.29e-10	3.13e-08	0.4	0.29	Primary biliary cholangitis;	chr5:103286752	chr5:103032376~103033031:+
THCA	cis	rs6696239	0.513	rs10495276	ENSG00000227711.2	RP11-275O4.5	6.58	1.3e-10	3.13e-08	0.3	0.29	Height;	chr1:227549245	chr1:227509028~227520477:-
THCA	cis	rs860295	0.678	rs1749405	ENSG00000225855.5	RUSC1-AS1	-6.58	1.3e-10	3.13e-08	-0.19	-0.29	Body mass index;	chr1:155890300	chr1:155316863~155324176:-
THCA	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-6.58	1.3e-10	3.13e-08	-0.37	-0.29	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
THCA	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-6.58	1.3e-10	3.13e-08	-0.37	-0.29	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
THCA	cis	rs2243480	1	rs34815098	ENSG00000229886.1	RP5-1132H15.3	6.57	1.3e-10	3.13e-08	0.47	0.29	Diabetic kidney disease;	chr7:65827267	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs35735127	ENSG00000229886.1	RP5-1132H15.3	6.57	1.3e-10	3.13e-08	0.47	0.29	Diabetic kidney disease;	chr7:65835436	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.901	rs35256305	ENSG00000229886.1	RP5-1132H15.3	6.57	1.3e-10	3.13e-08	0.47	0.29	Diabetic kidney disease;	chr7:65841418	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.803	rs34004500	ENSG00000229886.1	RP5-1132H15.3	6.57	1.3e-10	3.13e-08	0.47	0.29	Diabetic kidney disease;	chr7:65847191	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs35825738	ENSG00000229886.1	RP5-1132H15.3	6.57	1.3e-10	3.13e-08	0.47	0.29	Diabetic kidney disease;	chr7:65853040	chr7:66025126~66031544:-
THCA	cis	rs7567389	0.576	rs2069902	ENSG00000236682.1	AC068282.3	-6.57	1.3e-10	3.14e-08	-0.44	-0.29	Self-rated health;	chr2:127417287	chr2:127389130~127400580:+
THCA	cis	rs9928842	0.664	rs9921632	ENSG00000280152.1	RP11-331F4.5	6.57	1.3e-10	3.14e-08	0.33	0.29	Alcoholic chronic pancreatitis;	chr16:75186365	chr16:75245994~75250077:-
THCA	cis	rs7246657	0.525	rs1667351	ENSG00000226686.6	LINC01535	-6.57	1.3e-10	3.15e-08	-0.39	-0.29	Coronary artery calcification;	chr19:36987125	chr19:37251912~37265535:+
THCA	cis	rs6840360	0.642	rs2709825	ENSG00000251611.1	RP11-610P16.1	-6.57	1.3e-10	3.15e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.607	rs2724547	ENSG00000251611.1	RP11-610P16.1	-6.57	1.3e-10	3.15e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151407551~151408835:-
THCA	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	6.57	1.3e-10	3.15e-08	0.22	0.29	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000219392.1	RP1-265C24.5	-6.57	1.3e-10	3.15e-08	-0.31	-0.29	Pubertal anthropometrics;	chr6:28420988	chr6:28115628~28116551:+
THCA	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-6.57	1.31e-10	3.15e-08	-0.3	-0.29	Height;	chr11:118855938	chr11:118704607~118750263:+
THCA	cis	rs367615	0.68	rs31592	ENSG00000249476.1	CTD-2587M2.1	6.57	1.31e-10	3.16e-08	0.34	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109651135	chr5:109237120~109326369:-
THCA	cis	rs9813712	0.596	rs2587988	ENSG00000253540.4	FAM86HP	-6.57	1.31e-10	3.16e-08	-0.32	-0.29	Response to amphetamines;	chr3:130201415	chr3:130099092~130111472:-
THCA	cis	rs853679	0.55	rs6901017	ENSG00000220721.1	OR1F12	6.57	1.31e-10	3.16e-08	0.39	0.29	Depression;	chr6:28184805	chr6:28073316~28074233:+
THCA	cis	rs10208649	0.908	rs11889527	ENSG00000233266.1	HMGB1P31	6.57	1.31e-10	3.16e-08	0.68	0.29	Body mass index;	chr2:53999178	chr2:54051334~54051760:+
THCA	cis	rs8030379	0.967	rs7182563	ENSG00000230373.7	GOLGA6L5P	-6.57	1.31e-10	3.16e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83879994	chr15:84507885~84516814:-
THCA	cis	rs8030379	0.967	rs11629657	ENSG00000230373.7	GOLGA6L5P	-6.57	1.31e-10	3.16e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880228	chr15:84507885~84516814:-
THCA	cis	rs8030379	0.967	rs7181926	ENSG00000230373.7	GOLGA6L5P	-6.57	1.31e-10	3.16e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880676	chr15:84507885~84516814:-
THCA	cis	rs8030379	0.967	rs12916223	ENSG00000230373.7	GOLGA6L5P	-6.57	1.31e-10	3.16e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883742	chr15:84507885~84516814:-
THCA	cis	rs8030379	0.875	rs28801104	ENSG00000230373.7	GOLGA6L5P	-6.57	1.31e-10	3.16e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884091	chr15:84507885~84516814:-
THCA	cis	rs8030379	0.967	rs12900412	ENSG00000230373.7	GOLGA6L5P	-6.57	1.31e-10	3.16e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884314	chr15:84507885~84516814:-
THCA	cis	rs897984	0.762	rs12930545	ENSG00000279196.1	RP11-1072A3.3	-6.57	1.31e-10	3.17e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30927490	chr16:30984630~30988270:-
THCA	cis	rs897984	0.806	rs10782001	ENSG00000279196.1	RP11-1072A3.3	-6.57	1.31e-10	3.17e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30931304	chr16:30984630~30988270:-
THCA	cis	rs897984	0.806	rs12928852	ENSG00000279196.1	RP11-1072A3.3	-6.57	1.31e-10	3.17e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30932667	chr16:30984630~30988270:-
THCA	cis	rs4845570	0.92	rs1521185	ENSG00000203288.3	RP11-98D18.9	6.57	1.31e-10	3.17e-08	0.28	0.29	Coronary artery disease;	chr1:151791573	chr1:151790804~151794402:+
THCA	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	6.57	1.31e-10	3.17e-08	0.35	0.29	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
THCA	cis	rs7615952	0.688	rs4422259	ENSG00000241288.6	RP11-379B18.5	-6.57	1.31e-10	3.17e-08	-0.34	-0.29	Blood pressure (smoking interaction);	chr3:125826988	chr3:125827238~125916384:-
THCA	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	6.57	1.31e-10	3.17e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
THCA	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	6.57	1.31e-10	3.17e-08	0.38	0.29	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	6.57	1.31e-10	3.17e-08	0.38	0.29	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
THCA	cis	rs227275	0.554	rs223466	ENSG00000251288.2	RP11-10L12.2	-6.57	1.31e-10	3.17e-08	-0.38	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102751401~102752641:+
THCA	cis	rs467650	0.534	rs466366	ENSG00000246763.5	RGMB-AS1	6.57	1.31e-10	3.17e-08	0.28	0.29	Venous thromboembolism (SNP x SNP interaction);	chr5:98600506	chr5:98769618~98773469:-
THCA	cis	rs71636778	0.509	rs35989952	ENSG00000260063.1	RP5-968P14.2	-6.57	1.31e-10	3.17e-08	-0.56	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26678663	chr1:26692132~26694131:-
THCA	cis	rs7208859	0.623	rs426434	ENSG00000263603.1	CTD-2349P21.5	-6.57	1.32e-10	3.18e-08	-0.48	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30729469~30731202:+
THCA	cis	rs9800506	0.522	rs6907931	ENSG00000228559.1	RP3-340B19.3	6.57	1.32e-10	3.18e-08	0.41	0.29	Neutrophil percentage of granulocytes;	chr6:35548358	chr6:35544632~35545669:+
THCA	cis	rs453301	0.538	rs7830804	ENSG00000253893.2	FAM85B	6.57	1.32e-10	3.18e-08	0.36	0.29	Joint mobility (Beighton score);	chr8:9113252	chr8:8167819~8226614:-
THCA	cis	rs9380516	0.891	rs7747190	ENSG00000228559.1	RP3-340B19.3	-6.57	1.32e-10	3.18e-08	-0.44	-0.29	Hepatitis C induced liver fibrosis;	chr6:35548985	chr6:35544632~35545669:+
THCA	cis	rs9380516	0.945	rs4713891	ENSG00000228559.1	RP3-340B19.3	-6.57	1.32e-10	3.18e-08	-0.44	-0.29	Hepatitis C induced liver fibrosis;	chr6:35549919	chr6:35544632~35545669:+
THCA	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-6.57	1.32e-10	3.19e-08	-0.22	-0.29	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
THCA	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-6.57	1.32e-10	3.19e-08	-0.22	-0.29	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
THCA	cis	rs6540731	1	rs3816912	ENSG00000226251.4	RP11-15I11.3	6.57	1.32e-10	3.19e-08	0.36	0.29	Intelligence (childhood);	chr1:212226507	chr1:212225278~212238977:-
THCA	cis	rs28386778	0.863	rs11649912	ENSG00000240280.5	TCAM1P	-6.57	1.32e-10	3.19e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63720155	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs4968597	ENSG00000240280.5	TCAM1P	-6.57	1.32e-10	3.19e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63728387	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.83	rs6504180	ENSG00000240280.5	TCAM1P	-6.57	1.32e-10	3.19e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63735809	chr17:63849292~63864379:+
THCA	cis	rs7746199	0.673	rs35501037	ENSG00000219392.1	RP1-265C24.5	-6.57	1.32e-10	3.19e-08	-0.65	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28115628~28116551:+
THCA	cis	rs7267979	1	rs6076339	ENSG00000274414.1	RP5-965G21.4	6.57	1.32e-10	3.19e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25239007~25245229:-
THCA	cis	rs2915864	0.8	rs7725919	ENSG00000280047.1	CTC-463A16.1	6.57	1.32e-10	3.19e-08	0.44	0.29	Facial morphology (factor 20);	chr5:142146608	chr5:142165767~142168387:+
THCA	cis	rs11168351	0.927	rs11168342	ENSG00000240399.1	RP1-228P16.1	6.57	1.33e-10	3.2e-08	0.3	0.29	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48054813~48055591:-
THCA	cis	rs797680	0.964	rs12139009	ENSG00000223745.6	RP4-717I23.3	6.57	1.33e-10	3.2e-08	0.18	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93107936	chr1:93262186~93346025:-
THCA	cis	rs6545883	0.894	rs12622458	ENSG00000271889.1	RP11-493E12.1	-6.57	1.33e-10	3.21e-08	-0.28	-0.29	Tuberculosis;	chr2:61296419	chr2:61151433~61162105:-
THCA	cis	rs7267979	1	rs2297497	ENSG00000274414.1	RP5-965G21.4	6.57	1.33e-10	3.21e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25239007~25245229:-
THCA	cis	rs1707322	0.717	rs3014246	ENSG00000281133.1	AL355480.3	6.57	1.33e-10	3.21e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45580892~45580996:-
THCA	cis	rs6504622	0.967	rs11869840	ENSG00000262879.4	RP11-156P1.3	-6.57	1.33e-10	3.22e-08	-0.26	-0.29	Orofacial clefts;	chr17:46918734	chr17:46984045~47100323:-
THCA	cis	rs9467773	0.933	rs2024970	ENSG00000124549.13	BTN2A3P	6.57	1.33e-10	3.22e-08	0.28	0.29	Intelligence (multi-trait analysis);	chr6:26497292	chr6:26421391~26432383:+
THCA	cis	rs17684571	0.938	rs4073960	ENSG00000231441.1	RP11-472M19.2	6.57	1.33e-10	3.22e-08	0.35	0.29	Schizophrenia;	chr6:56683561	chr6:56844002~56864078:+
THCA	cis	rs7760535	0.826	rs3777905	ENSG00000230177.1	RP5-1112D6.4	-6.57	1.34e-10	3.22e-08	-0.23	-0.29	Metabolic traits;	chr6:111549385	chr6:111277932~111278742:+
THCA	cis	rs853679	0.527	rs707907	ENSG00000219392.1	RP1-265C24.5	-6.57	1.34e-10	3.22e-08	-0.32	-0.29	Depression;	chr6:28323463	chr6:28115628~28116551:+
THCA	cis	rs5742933	0.652	rs10210345	ENSG00000273240.1	RP11-455J20.3	6.57	1.34e-10	3.23e-08	0.3	0.29	Ferritin levels;	chr2:189754760	chr2:189763859~189764456:-
THCA	cis	rs6479901	0.557	rs4746125	ENSG00000232075.1	MRPL35P2	6.57	1.34e-10	3.23e-08	0.49	0.29	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63634317~63634827:-
THCA	cis	rs797680	0.93	rs2295423	ENSG00000223745.6	RP4-717I23.3	6.57	1.34e-10	3.23e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93115467	chr1:93262186~93346025:-
THCA	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-6.57	1.34e-10	3.23e-08	-0.26	-0.29	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-6.57	1.34e-10	3.23e-08	-0.26	-0.29	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
THCA	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-6.57	1.34e-10	3.23e-08	-0.26	-0.29	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
THCA	cis	rs9381040	0.701	rs722442	ENSG00000161912.16	ADCY10P1	6.57	1.34e-10	3.24e-08	0.19	0.29	Alzheimer's disease (late onset);	chr6:41121942	chr6:41101022~41140835:+
THCA	cis	rs3204270	0.684	rs62080212	ENSG00000262049.1	RP13-1032I1.7	6.57	1.35e-10	3.24e-08	0.26	0.29	Dental caries;	chr17:81675470	chr17:81701324~81703300:-
THCA	cis	rs6545883	0.602	rs11125871	ENSG00000271889.1	RP11-493E12.1	-6.57	1.35e-10	3.24e-08	-0.27	-0.29	Tuberculosis;	chr2:61242991	chr2:61151433~61162105:-
THCA	cis	rs112029703	1	rs112029703	ENSG00000214293.7	APTR	6.57	1.35e-10	3.24e-08	0.23	0.29	Glomerular filtration rate (creatinine);	chr7:77609361	chr7:77657660~77696265:-
THCA	cis	rs2243480	1	rs2533288	ENSG00000228409.4	CCT6P1	6.57	1.35e-10	3.25e-08	0.35	0.29	Diabetic kidney disease;	chr7:66591724	chr7:65751142~65763354:+
THCA	cis	rs7646881	0.767	rs73015629	ENSG00000240207.5	RP11-379F4.4	-6.57	1.35e-10	3.25e-08	-0.41	-0.29	Tetralogy of Fallot;	chr3:158716051	chr3:158732263~158784070:+
THCA	cis	rs848490	0.962	rs62460738	ENSG00000214293.7	APTR	6.57	1.35e-10	3.25e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77774943	chr7:77657660~77696265:-
THCA	cis	rs7948661	1	rs9332871	ENSG00000278376.1	RP11-158I9.8	6.57	1.35e-10	3.25e-08	0.48	0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118523141	chr11:118791254~118793137:+
THCA	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	6.57	1.35e-10	3.25e-08	0.43	0.29	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	6.57	1.35e-10	3.25e-08	0.43	0.29	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
THCA	cis	rs6061231	0.958	rs2427305	ENSG00000275437.1	RP5-908M14.10	6.57	1.35e-10	3.25e-08	0.27	0.29	Colorectal cancer;	chr20:62378693	chr20:62402236~62405935:-
THCA	cis	rs6545883	0.894	rs10177303	ENSG00000271889.1	RP11-493E12.1	-6.57	1.35e-10	3.25e-08	-0.28	-0.29	Tuberculosis;	chr2:61367324	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.894	rs2694639	ENSG00000271889.1	RP11-493E12.1	-6.57	1.35e-10	3.25e-08	-0.28	-0.29	Tuberculosis;	chr2:61368156	chr2:61151433~61162105:-
THCA	cis	rs8007846	0.588	rs7142165	ENSG00000276116.2	FUT8-AS1	-6.57	1.35e-10	3.25e-08	-0.3	-0.29	Multiple sclerosis--Brain Glutamate Levels;	chr14:65783514	chr14:65411170~65412690:-
THCA	cis	rs11158026	0.757	rs8012152	ENSG00000258413.1	RP11-665C16.6	-6.57	1.35e-10	3.25e-08	-0.4	-0.29	Parkinson's disease;	chr14:54958849	chr14:55262767~55272075:-
THCA	cis	rs16949788	1	rs7183477	ENSG00000261351.2	CTD-3185P2.1	-6.57	1.35e-10	3.26e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66455874	chr15:66488658~66492109:-
THCA	cis	rs16949788	1	rs7182169	ENSG00000261351.2	CTD-3185P2.1	-6.57	1.35e-10	3.26e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66455875	chr15:66488658~66492109:-
THCA	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-6.57	1.35e-10	3.26e-08	-0.49	-0.29	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
THCA	cis	rs2120243	0.539	rs988587	ENSG00000244515.1	KRT18P34	-6.57	1.35e-10	3.26e-08	-0.34	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157336482	chr3:157162663~157163932:-
THCA	cis	rs16843372	0.599	rs13390359	ENSG00000251491.2	OR7E28P	6.57	1.35e-10	3.26e-08	0.38	0.29	Obesity-related traits;	chr2:158818795	chr2:158862311~158863285:+
THCA	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-6.57	1.36e-10	3.27e-08	-0.4	-0.29	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
THCA	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-6.57	1.36e-10	3.27e-08	-0.4	-0.29	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
THCA	cis	rs4819052	0.655	rs2330102	ENSG00000237664.1	LINC00316	-6.57	1.36e-10	3.28e-08	-0.28	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.679	rs8132135	ENSG00000237664.1	LINC00316	-6.57	1.36e-10	3.28e-08	-0.28	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45338590~45341990:-
THCA	cis	rs6504622	1	rs6504622	ENSG00000262879.4	RP11-156P1.3	6.57	1.36e-10	3.28e-08	0.27	0.29	Orofacial clefts;	chr17:46942365	chr17:46984045~47100323:-
THCA	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-6.57	1.37e-10	3.29e-08	-0.3	-0.29	Height;	chr11:118859432	chr11:118704607~118750263:+
THCA	cis	rs4950322	0.518	rs61838951	ENSG00000237188.3	RP11-337C18.8	6.57	1.37e-10	3.29e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147116081	chr1:147172771~147211568:+
THCA	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	6.57	1.37e-10	3.29e-08	0.33	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
THCA	cis	rs9388451	0.626	rs1268074	ENSG00000237742.5	RP11-624M8.1	-6.57	1.37e-10	3.3e-08	-0.26	-0.29	Brugada syndrome;	chr6:125786645	chr6:125578558~125749190:-
THCA	cis	rs6928977	0.66	rs2757643	ENSG00000231028.7	LINC00271	-6.57	1.37e-10	3.3e-08	-0.23	-0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135440095	chr6:135497801~135716055:+
THCA	cis	rs7976269	0.609	rs10771475	ENSG00000257176.2	RP11-996F15.2	-6.57	1.37e-10	3.3e-08	-0.3	-0.29	Male-pattern baldness;	chr12:29071077	chr12:29280418~29317848:-
THCA	cis	rs7267979	1	rs6115182	ENSG00000274414.1	RP5-965G21.4	6.57	1.37e-10	3.3e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25239007~25245229:-
THCA	cis	rs28386778	0.897	rs2727295	ENSG00000240280.5	TCAM1P	-6.57	1.37e-10	3.3e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63810333	chr17:63849292~63864379:+
THCA	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-6.57	1.37e-10	3.3e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-6.57	1.37e-10	3.3e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-6.57	1.37e-10	3.3e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-6.57	1.37e-10	3.3e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-6.57	1.37e-10	3.3e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-6.57	1.37e-10	3.3e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
THCA	cis	rs7851660	0.594	rs28703314	ENSG00000236130.1	PTCSC2	-6.57	1.37e-10	3.31e-08	-0.24	-0.29	Strep throat;	chr9:97897863	chr9:97805935~97810008:-
THCA	cis	rs4845570	0.85	rs11204892	ENSG00000203288.3	RP11-98D18.9	6.57	1.37e-10	3.31e-08	0.29	0.29	Coronary artery disease;	chr1:151795572	chr1:151790804~151794402:+
THCA	cis	rs2836950	0.959	rs4818008	ENSG00000255568.3	BRWD1-AS2	-6.57	1.37e-10	3.31e-08	-0.25	-0.29	Menarche (age at onset);	chr21:39239516	chr21:39313935~39314962:+
THCA	cis	rs2243480	1	rs316329	ENSG00000228409.4	CCT6P1	6.57	1.37e-10	3.31e-08	0.33	0.29	Diabetic kidney disease;	chr7:66143429	chr7:65751142~65763354:+
THCA	cis	rs6539288	0.803	rs4479083	ENSG00000260329.1	RP11-412D9.4	-6.57	1.38e-10	3.31e-08	-0.26	-0.29	Total body bone mineral density;	chr12:106927467	chr12:106954029~106955497:-
THCA	cis	rs11603691	1	rs11606862	ENSG00000254662.1	RP11-872D17.4	6.57	1.38e-10	3.31e-08	0.59	0.29	Low high density lipoprotein cholesterol levels;	chr11:57245268	chr11:57325603~57327958:+
THCA	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	6.57	1.38e-10	3.31e-08	0.39	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
THCA	cis	rs16958440	0.867	rs76922914	ENSG00000267800.1	RP11-49K24.5	-6.57	1.38e-10	3.32e-08	-0.64	-0.29	Sitting height ratio;	chr18:47162083	chr18:47137018~47137290:+
THCA	cis	rs853679	0.607	rs68188794	ENSG00000280107.1	AL022393.9	-6.57	1.38e-10	3.32e-08	-0.58	-0.29	Depression;	chr6:28112999	chr6:28170845~28172521:+
THCA	cis	rs10512488	1	rs10512488	ENSG00000108785.7	HSD17B1P1	-6.57	1.38e-10	3.32e-08	-0.34	-0.29	Type 2 diabetes (age of onset);	chr17:42811886	chr17:42546764~42548706:+
THCA	cis	rs2120243	0.539	rs2047649	ENSG00000244515.1	KRT18P34	-6.56	1.38e-10	3.32e-08	-0.34	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157367816	chr3:157162663~157163932:-
THCA	cis	rs897984	0.542	rs73530203	ENSG00000260911.2	RP11-196G11.2	6.56	1.38e-10	3.32e-08	0.25	0.29	Dementia with Lewy bodies;	chr16:31088538	chr16:31043150~31049868:+
THCA	cis	rs1876905	0.597	rs191631	ENSG00000255389.1	C6orf3	6.56	1.38e-10	3.33e-08	0.36	0.29	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111599875~111602295:+
THCA	cis	rs848490	0.962	rs17807736	ENSG00000214293.7	APTR	6.56	1.39e-10	3.34e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77838142	chr7:77657660~77696265:-
THCA	cis	rs6504108	0.624	rs2123341	ENSG00000278765.1	RP5-890E16.5	-6.56	1.39e-10	3.34e-08	-0.33	-0.29	Body mass index;	chr17:48187264	chr17:48066704~48067293:-
THCA	cis	rs3806843	1	rs991918	ENSG00000202515.1	VTRNA1-3	-6.56	1.39e-10	3.34e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140815273	chr5:140726158~140726246:+
THCA	cis	rs748404	0.631	rs7167882	ENSG00000166763.7	STRCP1	6.56	1.39e-10	3.34e-08	0.31	0.29	Lung cancer;	chr15:43386465	chr15:43699488~43718184:-
THCA	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-6.56	1.39e-10	3.34e-08	-0.76	-0.29	Gout;	chr7:66723871	chr7:66654538~66669855:+
THCA	cis	rs6496044	0.568	rs2880764	ENSG00000259295.5	CSPG4P12	6.56	1.39e-10	3.34e-08	0.37	0.29	Interstitial lung disease;	chr15:85513177	chr15:85191438~85213905:+
THCA	cis	rs7560272	0.695	rs10190002	ENSG00000163016.8	ALMS1P	6.56	1.39e-10	3.34e-08	0.37	0.29	Schizophrenia;	chr2:73566927	chr2:73644919~73685576:+
THCA	cis	rs6545883	0.826	rs2694651	ENSG00000271889.1	RP11-493E12.1	-6.56	1.39e-10	3.34e-08	-0.28	-0.29	Tuberculosis;	chr2:61361507	chr2:61151433~61162105:-
THCA	cis	rs797680	0.856	rs12124011	ENSG00000223745.6	RP4-717I23.3	6.56	1.39e-10	3.34e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93186987	chr1:93262186~93346025:-
THCA	cis	rs797680	0.82	rs11164879	ENSG00000223745.6	RP4-717I23.3	6.56	1.39e-10	3.34e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93189965	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs7541687	ENSG00000223745.6	RP4-717I23.3	6.56	1.39e-10	3.34e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93191031	chr1:93262186~93346025:-
THCA	cis	rs797680	0.753	rs11164881	ENSG00000223745.6	RP4-717I23.3	6.56	1.39e-10	3.34e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93193432	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs10874764	ENSG00000223745.6	RP4-717I23.3	6.56	1.39e-10	3.34e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93195785	chr1:93262186~93346025:-
THCA	cis	rs7208859	0.725	rs9910051	ENSG00000264538.5	SUZ12P1	-6.56	1.39e-10	3.34e-08	-0.29	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.725	rs7210904	ENSG00000264538.5	SUZ12P1	-6.56	1.39e-10	3.34e-08	-0.29	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.725	rs9915802	ENSG00000264538.5	SUZ12P1	-6.56	1.39e-10	3.34e-08	-0.29	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.725	rs7342938	ENSG00000264538.5	SUZ12P1	-6.56	1.39e-10	3.34e-08	-0.29	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.725	rs6505215	ENSG00000264538.5	SUZ12P1	-6.56	1.39e-10	3.34e-08	-0.29	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30709299~30790908:+
THCA	cis	rs1707322	0.717	rs1135850	ENSG00000281133.1	AL355480.3	-6.56	1.39e-10	3.34e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.655	rs3014240	ENSG00000281133.1	AL355480.3	6.56	1.39e-10	3.34e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.686	rs3014235	ENSG00000281133.1	AL355480.3	6.56	1.39e-10	3.34e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45580892~45580996:-
THCA	cis	rs7746199	0.736	rs13209332	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs34105070	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.673	rs72845046	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs67652222	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs13212093	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs34038546	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28161781~28169594:+
THCA	cis	rs141342723	1	rs141342723	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs34543938	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs56405707	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs13210634	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs13215275	ENSG00000226314.6	ZNF192P1	-6.56	1.39e-10	3.35e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28161781~28169594:+
THCA	cis	rs17772222	0.958	rs17798341	ENSG00000258789.1	RP11-507K2.3	-6.56	1.39e-10	3.35e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88548201	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.958	rs10134008	ENSG00000258789.1	RP11-507K2.3	-6.56	1.39e-10	3.35e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88549183	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.958	rs891750	ENSG00000258789.1	RP11-507K2.3	-6.56	1.39e-10	3.35e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88550856	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.958	rs891749	ENSG00000258789.1	RP11-507K2.3	-6.56	1.39e-10	3.35e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88550893	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs61984683	ENSG00000258789.1	RP11-507K2.3	-6.56	1.39e-10	3.35e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88553162	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs61984684	ENSG00000258789.1	RP11-507K2.3	-6.56	1.39e-10	3.35e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88559104	chr14:88551597~88552493:+
THCA	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-6.56	1.39e-10	3.35e-08	-0.44	-0.29	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-6.56	1.39e-10	3.35e-08	-0.44	-0.29	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
THCA	cis	rs56114371	0.53	rs9348774	ENSG00000219392.1	RP1-265C24.5	-6.56	1.39e-10	3.35e-08	-0.39	-0.29	Breast cancer;	chr6:27721151	chr6:28115628~28116551:+
THCA	cis	rs79349575	0.783	rs11079844	ENSG00000248278.1	SUMO2P17	6.56	1.39e-10	3.35e-08	0.34	0.29	Type 2 diabetes;	chr17:48950972	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs62078372	ENSG00000248278.1	SUMO2P17	6.56	1.39e-10	3.35e-08	0.34	0.29	Type 2 diabetes;	chr17:48951627	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs12602933	ENSG00000248278.1	SUMO2P17	6.56	1.39e-10	3.35e-08	0.34	0.29	Type 2 diabetes;	chr17:48951918	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs4794003	ENSG00000248278.1	SUMO2P17	6.56	1.39e-10	3.35e-08	0.34	0.29	Type 2 diabetes;	chr17:48952542	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs12602746	ENSG00000248278.1	SUMO2P17	6.56	1.39e-10	3.35e-08	0.34	0.29	Type 2 diabetes;	chr17:48954379	chr17:48874860~48908983:-
THCA	cis	rs5769707	0.521	rs6009810	ENSG00000235111.1	RP1-29C18.8	-6.56	1.39e-10	3.35e-08	-0.37	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49612657~49615716:-
THCA	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-6.56	1.39e-10	3.35e-08	-0.27	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
THCA	cis	rs9926296	0.605	rs12709094	ENSG00000260259.1	RP11-368I7.4	-6.56	1.39e-10	3.35e-08	-0.31	-0.29	Vitiligo;	chr16:89786609	chr16:89682620~89686569:-
THCA	cis	rs4835473	0.868	rs35809032	ENSG00000251600.4	RP11-673E1.1	-6.56	1.39e-10	3.36e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143824797	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs17763107	ENSG00000251600.4	RP11-673E1.1	-6.56	1.39e-10	3.36e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143828512	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs17695782	ENSG00000251600.4	RP11-673E1.1	-6.56	1.39e-10	3.36e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143830311	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34917094	ENSG00000251600.4	RP11-673E1.1	-6.56	1.39e-10	3.36e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143832003	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11736609	ENSG00000251600.4	RP11-673E1.1	-6.56	1.39e-10	3.36e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143832876	chr4:143912331~143982454:+
THCA	cis	rs10799445	0.547	rs10799432	ENSG00000227711.2	RP11-275O4.5	-6.56	1.4e-10	3.36e-08	-0.3	-0.29	Height;	chr1:227632059	chr1:227509028~227520477:-
THCA	cis	rs3806843	0.966	rs7710380	ENSG00000202515.1	VTRNA1-3	-6.56	1.4e-10	3.36e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140776679	chr5:140726158~140726246:+
THCA	cis	rs2348418	0.765	rs10843118	ENSG00000247934.4	RP11-967K21.1	-6.56	1.4e-10	3.36e-08	-0.25	-0.29	Lung function (FEV1);Lung function (FVC);	chr12:28164396	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.966	rs11049699	ENSG00000247934.4	RP11-967K21.1	6.56	1.4e-10	3.36e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28535487	chr12:28163298~28190738:-
THCA	cis	rs72772090	0.634	rs17401901	ENSG00000248734.2	CTD-2260A17.1	-6.56	1.4e-10	3.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.634	rs72773906	ENSG00000248734.2	CTD-2260A17.1	-6.56	1.4e-10	3.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96784777~96785999:+
THCA	cis	rs7688540	0.8	rs12510827	ENSG00000211553.1	AC253576.2	-6.56	1.4e-10	3.36e-08	-0.4	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:136461~136568:+
THCA	cis	rs3806843	0.898	rs3756335	ENSG00000202515.1	VTRNA1-3	-6.56	1.4e-10	3.37e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140833925	chr5:140726158~140726246:+
THCA	cis	rs12554020	0.579	rs76025942	ENSG00000227603.1	RP11-165J3.6	6.56	1.4e-10	3.37e-08	0.53	0.29	Schizophrenia;	chr9:93605618	chr9:93435332~93437121:-
THCA	cis	rs10429558	0.609	rs76290025	ENSG00000227603.1	RP11-165J3.6	6.56	1.4e-10	3.37e-08	0.53	0.29	Neuroticism;	chr9:93608100	chr9:93435332~93437121:-
THCA	cis	rs7225151	0.808	rs77493189	ENSG00000234327.6	AC012146.7	-6.56	1.4e-10	3.37e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr17:5215656	chr17:5111468~5115004:+
THCA	cis	rs12554020	0.786	rs78619366	ENSG00000227603.1	RP11-165J3.6	6.56	1.4e-10	3.38e-08	0.53	0.29	Schizophrenia;	chr9:93590541	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.579	rs78814851	ENSG00000227603.1	RP11-165J3.6	6.56	1.4e-10	3.38e-08	0.53	0.29	Schizophrenia;	chr9:93590652	chr9:93435332~93437121:-
THCA	cis	rs7119038	0.818	rs10892279	ENSG00000255239.1	AP002954.6	-6.56	1.4e-10	3.38e-08	-0.41	-0.29	Sjögren's syndrome;	chr11:118741072	chr11:118688039~118690600:-
THCA	cis	rs17684571	0.938	rs7767128	ENSG00000231441.1	RP11-472M19.2	6.56	1.4e-10	3.38e-08	0.34	0.29	Schizophrenia;	chr6:56694489	chr6:56844002~56864078:+
THCA	cis	rs1876905	0.68	rs9384787	ENSG00000255389.1	C6orf3	-6.56	1.4e-10	3.38e-08	-0.34	-0.29	Mean corpuscular hemoglobin;	chr6:111113707	chr6:111599875~111602295:+
THCA	cis	rs77972916	0.561	rs72788900	ENSG00000234936.1	AC010883.5	6.56	1.41e-10	3.39e-08	0.38	0.29	Granulocyte percentage of myeloid white cells;	chr2:43331948	chr2:43229573~43233394:+
THCA	cis	rs3020264	0.669	rs7005662	ENSG00000271743.1	CTD-2541M15.3	6.56	1.41e-10	3.39e-08	0.4	0.29	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6619105	chr8:6615604~6617198:-
THCA	cis	rs2439831	1	rs2584726	ENSG00000275601.1	AC011330.13	-6.56	1.41e-10	3.4e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43423184	chr15:43642389~43643023:-
THCA	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-6.56	1.41e-10	3.4e-08	-0.43	-0.29	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-6.56	1.41e-10	3.4e-08	-0.43	-0.29	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
THCA	cis	rs2348418	0.966	rs7136139	ENSG00000247934.4	RP11-967K21.1	6.56	1.42e-10	3.4e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28531087	chr12:28163298~28190738:-
THCA	cis	rs848490	0.889	rs55689723	ENSG00000214293.7	APTR	6.56	1.42e-10	3.4e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77616939	chr7:77657660~77696265:-
THCA	cis	rs7811142	1	rs6972167	ENSG00000078319.8	PMS2P1	-6.56	1.42e-10	3.4e-08	-0.42	-0.29	Platelet count;	chr7:100482390	chr7:100320992~100341908:-
THCA	cis	rs7044106	0.791	rs10985004	ENSG00000270917.1	RP11-27I1.6	-6.56	1.42e-10	3.41e-08	-0.42	-0.29	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120812475~120812845:-
THCA	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-6.56	1.42e-10	3.41e-08	-0.26	-0.29	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
THCA	cis	rs11148252	0.595	rs4885325	ENSG00000278238.1	RP11-245D16.4	-6.56	1.42e-10	3.42e-08	-0.33	-0.29	Lewy body disease;	chr13:52597182	chr13:52454775~52455331:-
THCA	cis	rs4835473	0.868	rs4350958	ENSG00000251600.4	RP11-673E1.1	6.56	1.42e-10	3.42e-08	0.4	0.29	Immature fraction of reticulocytes;	chr4:143744656	chr4:143912331~143982454:+
THCA	cis	rs6430585	0.528	rs75524146	ENSG00000231890.6	DARS-AS1	-6.56	1.42e-10	3.42e-08	-0.36	-0.29	Corneal structure;	chr2:135967889	chr2:135985176~136022593:+
THCA	cis	rs4604234	0.708	rs73467544	ENSG00000272129.1	RP11-250B2.6	-6.56	1.42e-10	3.42e-08	-0.73	-0.29	Cancer;	chr6:80346789	chr6:80355424~80356859:+
THCA	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	6.56	1.43e-10	3.42e-08	0.32	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
THCA	cis	rs7727544	0.625	rs3091338	ENSG00000224431.1	AC063976.7	6.56	1.43e-10	3.43e-08	0.26	0.29	Blood metabolite levels;	chr5:132067045	chr5:132199456~132203487:+
THCA	cis	rs7267979	0.932	rs1985737	ENSG00000274414.1	RP5-965G21.4	-6.56	1.43e-10	3.43e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25239007~25245229:-
THCA	cis	rs748404	0.586	rs2584700	ENSG00000166763.7	STRCP1	6.56	1.43e-10	3.44e-08	0.32	0.29	Lung cancer;	chr15:43393134	chr15:43699488~43718184:-
THCA	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-6.56	1.43e-10	3.44e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
THCA	cis	rs11976180	1	rs2961118	ENSG00000170356.8	OR2A20P	-6.56	1.43e-10	3.44e-08	-0.39	-0.29	Obesity-related traits;	chr7:144058350	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2961119	ENSG00000170356.8	OR2A20P	-6.56	1.43e-10	3.44e-08	-0.39	-0.29	Obesity-related traits;	chr7:144058759	chr7:144250045~144252957:-
THCA	cis	rs7044106	0.762	rs10739570	ENSG00000270917.1	RP11-27I1.6	-6.56	1.43e-10	3.44e-08	-0.41	-0.29	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120812475~120812845:-
THCA	cis	rs16843372	0.599	rs10182297	ENSG00000251491.2	OR7E28P	-6.56	1.43e-10	3.45e-08	-0.38	-0.29	Obesity-related traits;	chr2:158822240	chr2:158862311~158863285:+
THCA	cis	rs16843372	0.599	rs10184861	ENSG00000251491.2	OR7E28P	-6.56	1.43e-10	3.45e-08	-0.38	-0.29	Obesity-related traits;	chr2:158822249	chr2:158862311~158863285:+
THCA	cis	rs2303319	0.901	rs62188141	ENSG00000227403.1	AC009299.3	6.56	1.43e-10	3.45e-08	0.63	0.29	Cognitive function;	chr2:161417380	chr2:161244739~161249050:+
THCA	cis	rs1865760	0.588	rs9467658	ENSG00000272462.2	U91328.19	-6.56	1.44e-10	3.45e-08	-0.23	-0.29	Height;	chr6:26010653	chr6:25992662~26001775:+
THCA	cis	rs1979679	0.842	rs4931727	ENSG00000278733.1	RP11-425D17.1	6.56	1.44e-10	3.45e-08	0.29	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146186	chr12:28185625~28186190:-
THCA	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-6.56	1.44e-10	3.45e-08	-0.3	-0.29	Height;	chr11:118855233	chr11:118704607~118750263:+
THCA	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	6.56	1.44e-10	3.46e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
THCA	cis	rs7811142	1	rs11766752	ENSG00000078319.8	PMS2P1	-6.56	1.44e-10	3.46e-08	-0.41	-0.29	Platelet count;	chr7:100475669	chr7:100320992~100341908:-
THCA	cis	rs748404	0.631	rs8042688	ENSG00000166763.7	STRCP1	6.56	1.44e-10	3.46e-08	0.31	0.29	Lung cancer;	chr15:43346327	chr15:43699488~43718184:-
THCA	cis	rs748404	0.631	rs4296223	ENSG00000166763.7	STRCP1	6.56	1.44e-10	3.46e-08	0.31	0.29	Lung cancer;	chr15:43353048	chr15:43699488~43718184:-
THCA	cis	rs2562456	0.833	rs62107539	ENSG00000268555.1	RP11-678G14.3	6.56	1.44e-10	3.46e-08	0.48	0.29	Pain;	chr19:21334910	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs76646508	ENSG00000268555.1	RP11-678G14.3	6.56	1.44e-10	3.46e-08	0.48	0.29	Pain;	chr19:21335247	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs77576302	ENSG00000268555.1	RP11-678G14.3	6.56	1.44e-10	3.46e-08	0.48	0.29	Pain;	chr19:21335385	chr19:21570822~21587322:-
THCA	cis	rs1594829	0.553	rs17055108	ENSG00000228451.3	SDAD1P1	6.56	1.44e-10	3.46e-08	0.29	0.29	Height;	chr8:26303223	chr8:26379259~26382953:-
THCA	cis	rs1594829	0.553	rs1564577	ENSG00000228451.3	SDAD1P1	6.56	1.44e-10	3.46e-08	0.29	0.29	Height;	chr8:26307207	chr8:26379259~26382953:-
THCA	cis	rs848490	0.925	rs56111978	ENSG00000214293.7	APTR	6.56	1.44e-10	3.47e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77755031	chr7:77657660~77696265:-
THCA	cis	rs273909	0.686	rs77335401	ENSG00000233006.5	AC034220.3	-6.56	1.44e-10	3.47e-08	-0.39	-0.29	Coronary artery disease;	chr5:132424133	chr5:132311285~132369916:-
THCA	cis	rs77972916	0.518	rs55877805	ENSG00000234936.1	AC010883.5	6.56	1.44e-10	3.47e-08	0.38	0.29	Granulocyte percentage of myeloid white cells;	chr2:43330458	chr2:43229573~43233394:+
THCA	cis	rs4143844	0.867	rs957348	ENSG00000259251.2	RP11-643M14.1	6.56	1.45e-10	3.47e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:61935700	chr15:62060503~62062434:+
THCA	cis	rs7267979	0.966	rs2424715	ENSG00000274414.1	RP5-965G21.4	-6.56	1.45e-10	3.47e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25239007~25245229:-
THCA	cis	rs11603691	0.551	rs34135716	ENSG00000254662.1	RP11-872D17.4	-6.56	1.45e-10	3.47e-08	-0.48	-0.29	Low high density lipoprotein cholesterol levels;	chr11:57339055	chr11:57325603~57327958:+
THCA	cis	rs6696239	0.513	rs1021554	ENSG00000227711.2	RP11-275O4.5	6.56	1.45e-10	3.48e-08	0.3	0.29	Height;	chr1:227556250	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs1021553	ENSG00000227711.2	RP11-275O4.5	6.56	1.45e-10	3.48e-08	0.3	0.29	Height;	chr1:227556286	chr1:227509028~227520477:-
THCA	cis	rs6545883	0.894	rs778158	ENSG00000271889.1	RP11-493E12.1	-6.56	1.45e-10	3.48e-08	-0.27	-0.29	Tuberculosis;	chr2:61328286	chr2:61151433~61162105:-
THCA	cis	rs7833787	0.832	rs12546229	ENSG00000278886.1	RP11-108A14.1	-6.56	1.45e-10	3.48e-08	-0.37	-0.29	Obesity-related traits;	chr8:18844369	chr8:18864681~18865247:-
THCA	cis	rs35264875	0.851	rs72930621	ENSG00000259799.1	RP11-554A11.9	6.56	1.45e-10	3.48e-08	0.5	0.29	Blond vs. brown hair color;	chr11:69099277	chr11:69155910~69159752:+
THCA	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-6.56	1.45e-10	3.48e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
THCA	cis	rs2348418	0.966	rs11049694	ENSG00000247934.4	RP11-967K21.1	6.56	1.45e-10	3.49e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28527925	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.966	rs11049695	ENSG00000247934.4	RP11-967K21.1	6.56	1.45e-10	3.49e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28527934	chr12:28163298~28190738:-
THCA	cis	rs1552244	0.882	rs2030564	ENSG00000180385.7	EMC3-AS1	6.56	1.45e-10	3.49e-08	0.3	0.29	Alzheimer's disease;	chr3:9997360	chr3:9986893~10006990:+
THCA	cis	rs2348418	0.864	rs7295120	ENSG00000247934.4	RP11-967K21.1	6.56	1.45e-10	3.49e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28565175	chr12:28163298~28190738:-
THCA	cis	rs6723108	0.627	rs766271	ENSG00000224043.6	CCNT2-AS1	-6.56	1.45e-10	3.49e-08	-0.3	-0.29	Type 2 diabetes;	chr2:134909561	chr2:134735464~134918710:-
THCA	cis	rs7474896	0.616	rs1985260	ENSG00000120555.12	SEPT7P9	6.56	1.45e-10	3.49e-08	0.4	0.29	Obesity (extreme);	chr10:38145162	chr10:38383069~38402916:-
THCA	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	6.56	1.45e-10	3.49e-08	0.32	0.29	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
THCA	cis	rs6479891	1	rs12416113	ENSG00000232075.1	MRPL35P2	6.56	1.46e-10	3.49e-08	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63634317~63634827:-
THCA	cis	rs797680	0.93	rs622608	ENSG00000223745.6	RP4-717I23.3	-6.56	1.46e-10	3.5e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93249662	chr1:93262186~93346025:-
THCA	cis	rs712022	1	rs10766969	ENSG00000246225.5	RP11-17A1.3	-6.56	1.46e-10	3.5e-08	-0.37	-0.29	Dialysis-related mortality;	chr11:22828406	chr11:22829380~22945393:+
THCA	cis	rs2243480	0.803	rs160649	ENSG00000232546.1	RP11-458F8.1	-6.56	1.46e-10	3.5e-08	-0.37	-0.29	Diabetic kidney disease;	chr7:66078212	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs160648	ENSG00000232546.1	RP11-458F8.1	-6.56	1.46e-10	3.5e-08	-0.37	-0.29	Diabetic kidney disease;	chr7:66078397	chr7:66848496~66858136:+
THCA	cis	rs2562456	0.833	rs62107540	ENSG00000268555.1	RP11-678G14.3	6.56	1.46e-10	3.5e-08	0.48	0.29	Pain;	chr19:21335693	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62107541	ENSG00000268555.1	RP11-678G14.3	6.56	1.46e-10	3.5e-08	0.48	0.29	Pain;	chr19:21335733	chr19:21570822~21587322:-
THCA	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	6.56	1.46e-10	3.51e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	6.56	1.46e-10	3.51e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	6.56	1.46e-10	3.51e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	6.56	1.46e-10	3.51e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	6.56	1.46e-10	3.51e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
THCA	cis	rs9307551	0.817	rs13127970	ENSG00000250334.4	LINC00989	-6.56	1.46e-10	3.51e-08	-0.34	-0.29	Refractive error;	chr4:79581236	chr4:79492416~79576460:+
THCA	cis	rs10208649	0.908	rs13395751	ENSG00000233266.1	HMGB1P31	6.55	1.47e-10	3.52e-08	0.68	0.29	Body mass index;	chr2:54011657	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.908	rs6715161	ENSG00000233266.1	HMGB1P31	6.55	1.47e-10	3.52e-08	0.68	0.29	Body mass index;	chr2:54012968	chr2:54051334~54051760:+
THCA	cis	rs12594515	0.548	rs55932467	ENSG00000273972.1	CTD-2306A12.1	-6.55	1.47e-10	3.52e-08	-0.38	-0.29	Weight;Waist circumference;	chr15:45704926	chr15:45702640~45703183:+
THCA	cis	rs6545883	0.894	rs2694632	ENSG00000271889.1	RP11-493E12.1	-6.55	1.47e-10	3.52e-08	-0.27	-0.29	Tuberculosis;	chr2:61331547	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.825	rs7578139	ENSG00000271889.1	RP11-493E12.1	-6.55	1.47e-10	3.52e-08	-0.27	-0.29	Tuberculosis;	chr2:61336986	chr2:61151433~61162105:-
THCA	cis	rs2243480	1	rs1638734	ENSG00000228409.4	CCT6P1	6.55	1.47e-10	3.53e-08	0.34	0.29	Diabetic kidney disease;	chr7:66632552	chr7:65751142~65763354:+
THCA	cis	rs7131987	0.903	rs1035604	ENSG00000257176.2	RP11-996F15.2	-6.55	1.47e-10	3.53e-08	-0.29	-0.29	QT interval;	chr12:29240169	chr12:29280418~29317848:-
THCA	cis	rs66823261	0.778	rs2906332	ENSG00000272240.1	RP5-855D21.1	6.55	1.47e-10	3.53e-08	0.33	0.29	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:234347~234887:-
THCA	cis	rs227275	0.554	rs223467	ENSG00000230069.3	LRRC37A15P	-6.55	1.47e-10	3.53e-08	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102727274~102730721:-
THCA	cis	rs1348850	0.831	rs1345139	ENSG00000280374.1	RP11-337N6.3	-6.55	1.47e-10	3.53e-08	-0.56	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177585063	chr2:177317715~177318471:-
THCA	cis	rs11168351	0.927	rs10875716	ENSG00000240399.1	RP1-228P16.1	6.55	1.47e-10	3.53e-08	0.3	0.29	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48054813~48055591:-
THCA	cis	rs10129255	1	rs10137758	ENSG00000211974.3	IGHV2-70	6.55	1.47e-10	3.53e-08	0.23	0.29	Kawasaki disease;	chr14:106697673	chr14:106723574~106724093:-
THCA	cis	rs7851660	0.844	rs993501	ENSG00000236130.1	PTCSC2	6.55	1.48e-10	3.54e-08	0.24	0.29	Strep throat;	chr9:97861095	chr9:97805935~97810008:-
THCA	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	6.55	1.48e-10	3.54e-08	0.42	0.29	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
THCA	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	6.55	1.48e-10	3.54e-08	0.44	0.29	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
THCA	cis	rs7221109	0.682	rs7216890	ENSG00000278834.1	RP11-458J1.1	-6.55	1.48e-10	3.55e-08	-0.3	-0.29	Type 1 diabetes;	chr17:40600717	chr17:40648300~40649718:+
THCA	cis	rs2243480	1	rs4718333	ENSG00000228409.4	CCT6P1	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Diabetic kidney disease;	chr7:66307771	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs7792391	ENSG00000228409.4	CCT6P1	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Diabetic kidney disease;	chr7:66308442	chr7:65751142~65763354:+
THCA	cis	rs6860806	0.661	rs334902	ENSG00000237714.1	P4HA2-AS1	6.55	1.48e-10	3.55e-08	0.37	0.29	Breast cancer;	chr5:132250866	chr5:132184876~132192808:+
THCA	cis	rs7267979	1	rs6050609	ENSG00000274414.1	RP5-965G21.4	6.55	1.48e-10	3.55e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs2424712	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs2424714	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050617	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.933	rs2387887	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050626	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6037121	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs1047171	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050629	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050630	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs6050632	ENSG00000274414.1	RP5-965G21.4	-6.55	1.48e-10	3.55e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25239007~25245229:-
THCA	cis	rs12701220	0.689	rs12533004	ENSG00000229043.2	AC091729.9	-6.55	1.48e-10	3.56e-08	-0.45	-0.29	Bronchopulmonary dysplasia;	chr7:1055774	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.689	rs12530960	ENSG00000229043.2	AC091729.9	-6.55	1.48e-10	3.56e-08	-0.45	-0.29	Bronchopulmonary dysplasia;	chr7:1055835	chr7:1160374~1165267:+
THCA	cis	rs4835473	0.9	rs10025455	ENSG00000251600.4	RP11-673E1.1	-6.55	1.49e-10	3.56e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143998417	chr4:143912331~143982454:+
THCA	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	6.55	1.49e-10	3.56e-08	0.4	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
THCA	cis	rs853679	0.517	rs6932109	ENSG00000261839.1	RP1-265C24.8	-6.55	1.49e-10	3.56e-08	-0.34	-0.29	Depression;	chr6:28110525	chr6:28136849~28139678:+
THCA	cis	rs8012947	1	rs61450169	ENSG00000279636.2	LINC00216	6.55	1.49e-10	3.57e-08	0.31	0.29	Alcohol consumption in current drinkers;	chr14:58246142	chr14:58288033~58289158:+
THCA	cis	rs4845570	0.92	rs3811414	ENSG00000203288.3	RP11-98D18.9	-6.55	1.49e-10	3.57e-08	-0.28	-0.29	Coronary artery disease;	chr1:151790770	chr1:151790804~151794402:+
THCA	cis	rs6545883	0.929	rs2593627	ENSG00000271889.1	RP11-493E12.1	-6.55	1.49e-10	3.57e-08	-0.28	-0.29	Tuberculosis;	chr2:61391439	chr2:61151433~61162105:-
THCA	cis	rs9329221	0.657	rs17694485	ENSG00000261451.1	RP11-981G7.1	6.55	1.49e-10	3.57e-08	0.38	0.29	Neuroticism;	chr8:10256948	chr8:10433672~10438312:+
THCA	cis	rs227275	0.554	rs223467	ENSG00000251288.2	RP11-10L12.2	-6.55	1.49e-10	3.57e-08	-0.38	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102751401~102752641:+
THCA	cis	rs7302981	0.667	rs7308692	ENSG00000272368.2	RP4-605O3.4	-6.55	1.49e-10	3.57e-08	-0.17	-0.29	Systolic blood pressure;	chr12:50233871	chr12:50112197~50165618:+
THCA	cis	rs1499614	1	rs1882655	ENSG00000228409.4	CCT6P1	-6.55	1.49e-10	3.57e-08	-0.35	-0.29	Gout;	chr7:66682070	chr7:65751142~65763354:+
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000228409.4	CCT6P1	-6.55	1.49e-10	3.57e-08	-0.35	-0.29	Gout;	chr7:66682162	chr7:65751142~65763354:+
THCA	cis	rs1499614	0.901	rs3936	ENSG00000228409.4	CCT6P1	6.55	1.49e-10	3.57e-08	0.35	0.29	Gout;	chr7:66661502	chr7:65751142~65763354:+
THCA	cis	rs1499614	1	rs1638731	ENSG00000228409.4	CCT6P1	6.55	1.49e-10	3.57e-08	0.35	0.29	Gout;	chr7:66679692	chr7:65751142~65763354:+
THCA	cis	rs6866614	0.639	rs1858074	ENSG00000237714.1	P4HA2-AS1	6.55	1.49e-10	3.58e-08	0.42	0.29	Perceived unattractiveness to mosquitoes;	chr5:132036306	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.508	rs11739935	ENSG00000237714.1	P4HA2-AS1	6.55	1.49e-10	3.58e-08	0.42	0.29	Blood metabolite levels;	chr5:132044965	chr5:132184876~132192808:+
THCA	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-6.55	1.49e-10	3.58e-08	-0.36	-0.29	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
THCA	cis	rs6696239	0.513	rs1495845	ENSG00000227711.2	RP11-275O4.5	6.55	1.5e-10	3.58e-08	0.31	0.29	Height;	chr1:227538346	chr1:227509028~227520477:-
THCA	cis	rs11148252	0.595	rs4884522	ENSG00000278238.1	RP11-245D16.4	-6.55	1.5e-10	3.58e-08	-0.33	-0.29	Lewy body disease;	chr13:52479633	chr13:52454775~52455331:-
THCA	cis	rs4950322	0.58	rs1813002	ENSG00000237188.3	RP11-337C18.8	6.55	1.5e-10	3.59e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147112579	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.518	rs4950304	ENSG00000237188.3	RP11-337C18.8	6.55	1.5e-10	3.59e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147116685	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.518	rs4950305	ENSG00000237188.3	RP11-337C18.8	6.55	1.5e-10	3.59e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147117711	chr1:147172771~147211568:+
THCA	cis	rs1876905	0.62	rs354525	ENSG00000255389.1	C6orf3	6.55	1.5e-10	3.59e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111186193	chr6:111599875~111602295:+
THCA	cis	rs8113308	0.515	rs113082012	ENSG00000269235.1	ZNF350-AS1	6.55	1.5e-10	3.6e-08	0.56	0.29	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960980	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.515	rs73066986	ENSG00000269235.1	ZNF350-AS1	6.55	1.5e-10	3.6e-08	0.56	0.29	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51962805	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.515	rs4986770	ENSG00000269235.1	ZNF350-AS1	6.55	1.5e-10	3.6e-08	0.56	0.29	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51964781	chr19:51949134~51981367:+
THCA	cis	rs4143844	1	rs11629645	ENSG00000259251.2	RP11-643M14.1	6.55	1.5e-10	3.6e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:62014275	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs35324423	ENSG00000259251.2	RP11-643M14.1	6.55	1.5e-10	3.6e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:62019946	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs4143845	ENSG00000259251.2	RP11-643M14.1	6.55	1.5e-10	3.6e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:62020894	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs36126734	ENSG00000259251.2	RP11-643M14.1	6.55	1.5e-10	3.6e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:62022710	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs34088392	ENSG00000259251.2	RP11-643M14.1	6.55	1.5e-10	3.6e-08	0.55	0.29	Bipolar disorder and schizophrenia;	chr15:62022843	chr15:62060503~62062434:+
THCA	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-6.55	1.5e-10	3.6e-08	-0.17	-0.29	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
THCA	cis	rs1552244	0.882	rs17050660	ENSG00000232901.1	CYCSP10	-6.55	1.5e-10	3.6e-08	-0.37	-0.29	Alzheimer's disease;	chr3:9960088	chr3:10000647~10000940:-
THCA	cis	rs4273100	0.85	rs11204306	ENSG00000265185.4	SNORD3B-1	6.55	1.5e-10	3.6e-08	0.42	0.29	Schizophrenia;	chr17:19364058	chr17:19061912~19062669:+
THCA	cis	rs4273100	0.79	rs2048230	ENSG00000265185.4	SNORD3B-1	6.55	1.5e-10	3.6e-08	0.42	0.29	Schizophrenia;	chr17:19372886	chr17:19061912~19062669:+
THCA	cis	rs35264875	0.851	rs72930611	ENSG00000259799.1	RP11-554A11.9	6.55	1.5e-10	3.6e-08	0.5	0.29	Blond vs. brown hair color;	chr11:69096191	chr11:69155910~69159752:+
THCA	cis	rs16846053	0.71	rs6755071	ENSG00000227403.1	AC009299.3	6.55	1.51e-10	3.6e-08	0.45	0.29	Blood osmolality (transformed sodium);	chr2:161748720	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.71	rs973940	ENSG00000227403.1	AC009299.3	6.55	1.51e-10	3.6e-08	0.45	0.29	Blood osmolality (transformed sodium);	chr2:161750890	chr2:161244739~161249050:+
THCA	cis	rs1949733	0.523	rs16842560	ENSG00000205959.3	RP11-689P11.2	6.55	1.51e-10	3.61e-08	0.26	0.29	Response to antineoplastic agents;	chr4:8542511	chr4:8482270~8512610:+
THCA	cis	rs28386778	0.897	rs8073515	ENSG00000240280.5	TCAM1P	-6.55	1.51e-10	3.61e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63717968	chr17:63849292~63864379:+
THCA	cis	rs7746199	0.736	rs13195636	ENSG00000226314.6	ZNF192P1	-6.55	1.51e-10	3.61e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28161781~28169594:+
THCA	cis	rs8141529	0.732	rs2347447	ENSG00000226471.5	CTA-292E10.6	-6.55	1.51e-10	3.61e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28783751	chr22:28800683~28848559:+
THCA	cis	rs4947019	0.534	rs13437492	ENSG00000260273.1	RP11-425D10.10	-6.55	1.51e-10	3.61e-08	-0.6	-0.29	Hematological parameters;	chr6:109365424	chr6:109382795~109383666:+
THCA	cis	rs807029	0.533	rs67692077	ENSG00000272572.1	RP11-179B2.2	-6.55	1.51e-10	3.62e-08	-0.26	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100911103~100912739:-
THCA	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-6.55	1.51e-10	3.62e-08	-0.38	-0.29	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
THCA	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	6.55	1.52e-10	3.63e-08	0.36	0.29	Height;	chr6:109350642	chr6:109382795~109383666:+
THCA	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	6.55	1.52e-10	3.63e-08	0.35	0.29	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	6.55	1.52e-10	3.63e-08	0.35	0.29	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
THCA	cis	rs6565180	0.962	rs6565183	ENSG00000273724.1	RP11-347C12.12	-6.55	1.52e-10	3.64e-08	-0.29	-0.29	Tonsillectomy;	chr16:30371434	chr16:30336400~30343336:+
THCA	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	6.55	1.52e-10	3.65e-08	0.35	0.29	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	6.55	1.52e-10	3.65e-08	0.35	0.29	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
THCA	cis	rs1275468	1	rs1148004	ENSG00000257497.2	RP11-585P4.5	-6.55	1.52e-10	3.65e-08	-0.43	-0.29	Polycystic ovary syndrome;	chr12:75584897	chr12:75483454~75489820:-
THCA	cis	rs7015630	0.697	rs34699769	ENSG00000251136.7	RP11-37B2.1	-6.55	1.52e-10	3.65e-08	-0.31	-0.29	Inflammatory bowel disease;Crohn's disease;	chr8:89841119	chr8:89609409~89757727:-
THCA	cis	rs6860806	0.631	rs4705931	ENSG00000237714.1	P4HA2-AS1	6.55	1.53e-10	3.65e-08	0.37	0.29	Breast cancer;	chr5:132252652	chr5:132184876~132192808:+
THCA	cis	rs227275	0.525	rs4596243	ENSG00000251288.2	RP11-10L12.2	-6.55	1.53e-10	3.65e-08	-0.39	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102751401~102752641:+
THCA	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	6.55	1.53e-10	3.66e-08	0.35	0.29	Height;	chr6:109417941	chr6:109382795~109383666:+
THCA	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	6.55	1.53e-10	3.66e-08	0.35	0.29	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	6.55	1.53e-10	3.66e-08	0.35	0.29	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	6.55	1.53e-10	3.66e-08	0.35	0.29	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	6.55	1.53e-10	3.66e-08	0.35	0.29	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	6.55	1.53e-10	3.66e-08	0.35	0.29	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
THCA	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	6.55	1.53e-10	3.66e-08	0.21	0.29	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
THCA	cis	rs853679	1	rs1679732	ENSG00000226314.6	ZNF192P1	6.55	1.53e-10	3.66e-08	0.45	0.29	Depression;	chr6:28253486	chr6:28161781~28169594:+
THCA	cis	rs9878978	0.722	rs34160306	ENSG00000237990.3	CNTN4-AS1	6.55	1.53e-10	3.66e-08	0.35	0.29	Blood pressure (smoking interaction);	chr3:2456443	chr3:3039033~3069242:-
THCA	cis	rs7226408	0.857	rs3747896	ENSG00000267707.2	RP11-95O2.5	-6.55	1.53e-10	3.67e-08	-0.38	-0.29	Obesity-related traits;	chr18:37067360	chr18:37243776~37247506:+
THCA	cis	rs7044106	0.791	rs7043969	ENSG00000270917.1	RP11-27I1.6	-6.55	1.54e-10	3.67e-08	-0.41	-0.29	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120812475~120812845:-
THCA	cis	rs2282300	0.956	rs594937	ENSG00000242353.1	RP4-710M3.1	6.55	1.54e-10	3.67e-08	0.26	0.29	Morning vs. evening chronotype;	chr11:30368585	chr11:30368148~30368646:+
THCA	cis	rs748404	0.631	rs6493084	ENSG00000166763.7	STRCP1	6.55	1.54e-10	3.68e-08	0.31	0.29	Lung cancer;	chr15:43355429	chr15:43699488~43718184:-
THCA	cis	rs748404	0.631	rs12905772	ENSG00000166763.7	STRCP1	6.55	1.54e-10	3.68e-08	0.31	0.29	Lung cancer;	chr15:43356246	chr15:43699488~43718184:-
THCA	cis	rs748404	0.676	rs4401024	ENSG00000166763.7	STRCP1	6.55	1.54e-10	3.68e-08	0.31	0.29	Lung cancer;	chr15:43358137	chr15:43699488~43718184:-
THCA	cis	rs853679	0.517	rs4713135	ENSG00000220721.1	OR1F12	6.55	1.54e-10	3.68e-08	0.4	0.29	Depression;	chr6:28071808	chr6:28073316~28074233:+
THCA	cis	rs2243480	1	rs160655	ENSG00000232546.1	RP11-458F8.1	-6.55	1.54e-10	3.69e-08	-0.37	-0.29	Diabetic kidney disease;	chr7:66068227	chr7:66848496~66858136:+
THCA	cis	rs2018683	0.711	rs2158788	ENSG00000228421.2	AC005013.5	6.55	1.54e-10	3.69e-08	0.32	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932341	chr7:28957667~28959345:+
THCA	cis	rs8012947	0.877	rs12879675	ENSG00000279636.2	LINC00216	-6.55	1.54e-10	3.69e-08	-0.31	-0.29	Alcohol consumption in current drinkers;	chr14:58240535	chr14:58288033~58289158:+
THCA	cis	rs10799445	0.55	rs7512348	ENSG00000227711.2	RP11-275O4.5	6.55	1.54e-10	3.69e-08	0.3	0.29	Height;	chr1:227552571	chr1:227509028~227520477:-
THCA	cis	rs77972916	0.561	rs17406174	ENSG00000234936.1	AC010883.5	6.55	1.54e-10	3.69e-08	0.38	0.29	Granulocyte percentage of myeloid white cells;	chr2:43330345	chr2:43229573~43233394:+
THCA	cis	rs7567389	0.719	rs11890243	ENSG00000236682.1	AC068282.3	6.55	1.55e-10	3.69e-08	0.43	0.29	Self-rated health;	chr2:127200465	chr2:127389130~127400580:+
THCA	cis	rs72843506	0.722	rs117096120	ENSG00000270091.1	RP11-78O7.2	-6.55	1.55e-10	3.7e-08	-0.33	-0.29	Schizophrenia;	chr17:20264380	chr17:19896590~19897287:-
THCA	cis	rs1609391	0.561	rs6439675	ENSG00000273486.1	RP11-731C17.2	6.55	1.55e-10	3.7e-08	0.25	0.29	Neuroticism;	chr3:136906594	chr3:136837338~136839021:-
THCA	cis	rs9677476	0.818	rs7598728	ENSG00000224376.1	AC017104.6	6.55	1.55e-10	3.7e-08	0.33	0.29	Food antigen IgG levels;	chr2:231221342	chr2:231388976~231394991:+
THCA	cis	rs9640161	0.83	rs1051760	ENSG00000261305.1	RP4-584D14.7	6.55	1.55e-10	3.7e-08	0.33	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150373541	chr7:150341771~150342607:+
THCA	cis	rs9926296	0.605	rs1800287	ENSG00000260259.1	RP11-368I7.4	-6.55	1.55e-10	3.7e-08	-0.31	-0.29	Vitiligo;	chr16:89792117	chr16:89682620~89686569:-
THCA	cis	rs9926296	0.605	rs6500453	ENSG00000260259.1	RP11-368I7.4	-6.55	1.55e-10	3.7e-08	-0.31	-0.29	Vitiligo;	chr16:89792249	chr16:89682620~89686569:-
THCA	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	6.55	1.55e-10	3.71e-08	0.25	0.29	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
THCA	cis	rs5742933	0.744	rs13009889	ENSG00000273240.1	RP11-455J20.3	6.55	1.55e-10	3.71e-08	0.29	0.29	Ferritin levels;	chr2:189763842	chr2:189763859~189764456:-
THCA	cis	rs9393777	0.764	rs35565446	ENSG00000280107.1	AL022393.9	-6.55	1.55e-10	3.71e-08	-0.58	-0.29	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28170845~28172521:+
THCA	cis	rs7267979	0.966	rs2257233	ENSG00000274414.1	RP5-965G21.4	6.55	1.55e-10	3.71e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25239007~25245229:-
THCA	cis	rs11148252	0.532	rs9536190	ENSG00000273784.3	RP11-78J21.7	-6.55	1.55e-10	3.71e-08	-0.32	-0.29	Lewy body disease;	chr13:52606909	chr13:52600042~52642542:+
THCA	cis	rs34779708	0.766	rs7913451	ENSG00000271335.4	RP11-324I22.4	6.55	1.55e-10	3.72e-08	0.29	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35314552~35336401:-
THCA	cis	rs17772222	0.958	rs60878614	ENSG00000258789.1	RP11-507K2.3	-6.55	1.55e-10	3.72e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88513871	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.958	rs76559451	ENSG00000258789.1	RP11-507K2.3	-6.55	1.55e-10	3.72e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88523193	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.958	rs12436326	ENSG00000258789.1	RP11-507K2.3	-6.55	1.55e-10	3.72e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88533632	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.958	rs17203789	ENSG00000258789.1	RP11-507K2.3	-6.55	1.55e-10	3.72e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88541362	chr14:88551597~88552493:+
THCA	cis	rs6496044	0.611	rs6496055	ENSG00000259295.5	CSPG4P12	6.55	1.56e-10	3.72e-08	0.36	0.29	Interstitial lung disease;	chr15:85527457	chr15:85191438~85213905:+
THCA	cis	rs7247513	0.93	rs28368916	ENSG00000213290.4	PGK1P2	-6.55	1.56e-10	3.72e-08	-0.35	-0.29	Bipolar disorder;	chr19:12590763	chr19:12559571~12561105:+
THCA	cis	rs797680	0.856	rs6688230	ENSG00000223745.6	RP4-717I23.3	6.55	1.56e-10	3.73e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93175567	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs7553465	ENSG00000223745.6	RP4-717I23.3	6.55	1.56e-10	3.73e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93178853	chr1:93262186~93346025:-
THCA	cis	rs797680	0.822	rs2297707	ENSG00000223745.6	RP4-717I23.3	6.55	1.56e-10	3.73e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93180650	chr1:93262186~93346025:-
THCA	cis	rs2348418	0.932	rs7136429	ENSG00000247934.4	RP11-967K21.1	6.55	1.56e-10	3.73e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28460306	chr12:28163298~28190738:-
THCA	cis	rs8007846	0.563	rs7149301	ENSG00000276116.2	FUT8-AS1	6.54	1.56e-10	3.73e-08	0.29	0.29	Multiple sclerosis--Brain Glutamate Levels;	chr14:65763696	chr14:65411170~65412690:-
THCA	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-6.54	1.56e-10	3.73e-08	-0.44	-0.29	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
THCA	cis	rs7267979	0.932	rs446649	ENSG00000274414.1	RP5-965G21.4	-6.54	1.56e-10	3.73e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.727	rs4815431	ENSG00000274414.1	RP5-965G21.4	6.54	1.56e-10	3.73e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25239007~25245229:-
THCA	cis	rs227275	0.554	rs223339	ENSG00000230069.3	LRRC37A15P	-6.54	1.56e-10	3.73e-08	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102727274~102730721:-
THCA	cis	rs7015630	0.738	rs34642426	ENSG00000251136.7	RP11-37B2.1	-6.54	1.56e-10	3.74e-08	-0.3	-0.29	Inflammatory bowel disease;Crohn's disease;	chr8:89842618	chr8:89609409~89757727:-
THCA	cis	rs4938573	0.526	rs11216973	ENSG00000255239.1	AP002954.6	-6.54	1.56e-10	3.74e-08	-0.45	-0.29	Follicular lymphoma;	chr11:118716292	chr11:118688039~118690600:-
THCA	cis	rs6540731	1	rs6540732	ENSG00000226251.4	RP11-15I11.3	6.54	1.56e-10	3.74e-08	0.37	0.29	Intelligence (childhood);	chr1:212219144	chr1:212225278~212238977:-
THCA	cis	rs1552244	0.882	rs55808392	ENSG00000232901.1	CYCSP10	6.54	1.56e-10	3.74e-08	0.36	0.29	Alzheimer's disease;	chr3:10012997	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs13075842	ENSG00000232901.1	CYCSP10	6.54	1.56e-10	3.74e-08	0.36	0.29	Alzheimer's disease;	chr3:10014129	chr3:10000647~10000940:-
THCA	cis	rs9640161	0.83	rs1051764	ENSG00000261305.1	RP4-584D14.7	6.54	1.57e-10	3.74e-08	0.33	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150373574	chr7:150341771~150342607:+
THCA	cis	rs6860806	0.661	rs2136188	ENSG00000237714.1	P4HA2-AS1	-6.54	1.57e-10	3.74e-08	-0.37	-0.29	Breast cancer;	chr5:132241821	chr5:132184876~132192808:+
THCA	cis	rs10740039	0.516	rs7477771	ENSG00000254271.1	RP11-131N11.4	6.54	1.57e-10	3.75e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60595970	chr10:60734342~60741828:+
THCA	cis	rs11749327	0.688	rs72700688	ENSG00000225138.6	CTD-2228K2.7	-6.54	1.57e-10	3.75e-08	-0.37	-0.29	Hemoglobin concentration;Hypospadias;	chr5:473976	chr5:473236~480884:+
THCA	cis	rs523522	0.847	rs11065132	ENSG00000278344.1	RP11-18C24.8	6.54	1.57e-10	3.76e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120470656	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs4767902	ENSG00000278344.1	RP11-18C24.8	6.54	1.57e-10	3.76e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120472201	chr12:120500735~120501090:-
THCA	cis	rs523522	0.962	rs10849753	ENSG00000278344.1	RP11-18C24.8	6.54	1.57e-10	3.76e-08	0.32	0.29	High light scatter reticulocyte count;	chr12:120473010	chr12:120500735~120501090:-
THCA	cis	rs367615	0.501	rs447849	ENSG00000249476.1	CTD-2587M2.1	-6.54	1.58e-10	3.76e-08	-0.29	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109615489	chr5:109237120~109326369:-
THCA	cis	rs5742933	0.681	rs4525728	ENSG00000273240.1	RP11-455J20.3	6.54	1.58e-10	3.77e-08	0.3	0.29	Ferritin levels;	chr2:189780324	chr2:189763859~189764456:-
THCA	cis	rs797680	0.856	rs6682670	ENSG00000223745.6	RP4-717I23.3	6.54	1.58e-10	3.77e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93184175	chr1:93262186~93346025:-
THCA	cis	rs797680	0.754	rs12118230	ENSG00000223745.6	RP4-717I23.3	6.54	1.58e-10	3.77e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93185904	chr1:93262186~93346025:-
THCA	cis	rs6430553	0.894	rs6730306	ENSG00000224043.6	CCNT2-AS1	-6.54	1.58e-10	3.77e-08	-0.29	-0.29	Blood metabolite levels;	chr2:134851597	chr2:134735464~134918710:-
THCA	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	6.54	1.58e-10	3.77e-08	0.37	0.29	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
THCA	cis	rs1552244	0.882	rs13099136	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:9989747	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.51	rs13075308	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:9993241	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.808	rs7615088	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:9994212	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs61429272	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:9995636	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.626	rs2886396	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:9995986	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs9757159	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:9997482	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.816	rs17050701	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:9999870	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs55840655	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:10001006	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.816	rs56387520	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:10001098	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs56224841	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:10002330	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs13088350	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	3.77e-08	0.3	0.29	Alzheimer's disease;	chr3:10002942	chr3:9986893~10006990:+
THCA	cis	rs5758659	1	rs5758659	ENSG00000182057.4	OGFRP1	6.54	1.58e-10	3.77e-08	0.33	0.29	Cognitive function;	chr22:42225997	chr22:42269753~42275196:+
THCA	cis	rs4947019	0.688	rs1476386	ENSG00000260273.1	RP11-425D10.10	6.54	1.58e-10	3.77e-08	0.74	0.29	Hematological parameters;	chr6:109443201	chr6:109382795~109383666:+
THCA	cis	rs75920871	0.528	rs4388921	ENSG00000254851.1	RP11-109L13.1	6.54	1.58e-10	3.77e-08	0.43	0.29	Subjective well-being;	chr11:117106062	chr11:117135528~117138582:+
THCA	cis	rs17772222	1	rs61977058	ENSG00000258789.1	RP11-507K2.3	-6.54	1.58e-10	3.78e-08	-0.3	-0.29	Coronary artery calcification;	chr14:88415571	chr14:88551597~88552493:+
THCA	cis	rs7746199	0.736	rs34064842	ENSG00000226314.6	ZNF192P1	-6.54	1.58e-10	3.78e-08	-0.63	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28161781~28169594:+
THCA	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-6.54	1.58e-10	3.78e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
THCA	cis	rs16958440	0.867	rs80106524	ENSG00000267800.1	RP11-49K24.5	-6.54	1.58e-10	3.78e-08	-0.63	-0.29	Sitting height ratio;	chr18:47150268	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs79712753	ENSG00000267800.1	RP11-49K24.5	-6.54	1.58e-10	3.78e-08	-0.63	-0.29	Sitting height ratio;	chr18:47150356	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs3809966	ENSG00000267800.1	RP11-49K24.5	-6.54	1.58e-10	3.78e-08	-0.63	-0.29	Sitting height ratio;	chr18:47151256	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs78585258	ENSG00000267800.1	RP11-49K24.5	-6.54	1.58e-10	3.78e-08	-0.63	-0.29	Sitting height ratio;	chr18:47151358	chr18:47137018~47137290:+
THCA	cis	rs6545883	0.929	rs6707830	ENSG00000271889.1	RP11-493E12.1	6.54	1.58e-10	3.78e-08	0.28	0.29	Tuberculosis;	chr2:61522337	chr2:61151433~61162105:-
THCA	cis	rs516805	0.63	rs2606638	ENSG00000279453.1	RP3-425C14.4	-6.54	1.58e-10	3.78e-08	-0.32	-0.29	Lymphocyte counts;	chr6:122102107	chr6:122436789~122439223:-
THCA	cis	rs683257	0.636	rs55942214	ENSG00000234147.1	RP3-460G2.2	-6.54	1.58e-10	3.78e-08	-0.44	-0.29	Facial emotion recognition (angry faces);	chr6:140827313	chr6:140845958~140852924:-
THCA	cis	rs683257	0.636	rs56266921	ENSG00000234147.1	RP3-460G2.2	-6.54	1.58e-10	3.78e-08	-0.44	-0.29	Facial emotion recognition (angry faces);	chr6:140827339	chr6:140845958~140852924:-
THCA	cis	rs683257	0.636	rs72988142	ENSG00000234147.1	RP3-460G2.2	-6.54	1.58e-10	3.78e-08	-0.44	-0.29	Facial emotion recognition (angry faces);	chr6:140827387	chr6:140845958~140852924:-
THCA	cis	rs683257	0.563	rs9495842	ENSG00000234147.1	RP3-460G2.2	-6.54	1.58e-10	3.78e-08	-0.44	-0.29	Facial emotion recognition (angry faces);	chr6:140828411	chr6:140845958~140852924:-
THCA	cis	rs683257	0.636	rs9495843	ENSG00000234147.1	RP3-460G2.2	-6.54	1.58e-10	3.78e-08	-0.44	-0.29	Facial emotion recognition (angry faces);	chr6:140829354	chr6:140845958~140852924:-
THCA	cis	rs683257	0.636	rs72988149	ENSG00000234147.1	RP3-460G2.2	-6.54	1.58e-10	3.78e-08	-0.44	-0.29	Facial emotion recognition (angry faces);	chr6:140829500	chr6:140845958~140852924:-
THCA	cis	rs3750082	0.632	rs7811630	ENSG00000231952.3	DPY19L1P2	6.54	1.59e-10	3.78e-08	0.41	0.29	Glomerular filtration rate (creatinine);	chr7:32921106	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.603	rs2278818	ENSG00000231952.3	DPY19L1P2	6.54	1.59e-10	3.78e-08	0.41	0.29	Glomerular filtration rate (creatinine);	chr7:32921568	chr7:32812757~32838570:+
THCA	cis	rs848490	0.889	rs6955503	ENSG00000214293.7	APTR	6.54	1.59e-10	3.79e-08	0.22	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77597924	chr7:77657660~77696265:-
THCA	cis	rs17767294	1	rs17767294	ENSG00000219392.1	RP1-265C24.5	-6.54	1.59e-10	3.79e-08	-0.62	-0.29	Parkinson's disease;	chr6:28086420	chr6:28115628~28116551:+
THCA	cis	rs7324557	0.684	rs9507165	ENSG00000205861.10	C1QTNF9B-AS1	-6.54	1.59e-10	3.79e-08	-0.35	-0.29	Visceral adipose tissue adjusted for BMI;	chr13:23810291	chr13:23888889~23897263:+
THCA	cis	rs944289	0.517	rs1766125	ENSG00000257826.1	RP11-116N8.4	-6.54	1.59e-10	3.79e-08	-0.3	-0.29	Thyroid cancer;	chr14:36197511	chr14:36061026~36067190:-
THCA	cis	rs467650	0.509	rs152989	ENSG00000246763.5	RGMB-AS1	6.54	1.59e-10	3.79e-08	0.28	0.29	Venous thromboembolism (SNP x SNP interaction);	chr5:98654131	chr5:98769618~98773469:-
THCA	cis	rs2439831	0.85	rs16965120	ENSG00000275601.1	AC011330.13	-6.54	1.59e-10	3.79e-08	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43808144	chr15:43642389~43643023:-
THCA	cis	rs5742933	0.803	rs1233262	ENSG00000273240.1	RP11-455J20.3	-6.54	1.59e-10	3.79e-08	-0.3	-0.29	Ferritin levels;	chr2:189793107	chr2:189763859~189764456:-
THCA	cis	rs6545883	0.929	rs10190332	ENSG00000271889.1	RP11-493E12.1	-6.54	1.59e-10	3.8e-08	-0.27	-0.29	Tuberculosis;	chr2:61392132	chr2:61151433~61162105:-
THCA	cis	rs11096990	0.855	rs2167494	ENSG00000249207.1	RP11-360F5.1	6.54	1.59e-10	3.8e-08	0.38	0.29	Cognitive function;	chr4:39214601	chr4:39112677~39126818:-
THCA	cis	rs1594829	0.553	rs11135933	ENSG00000228451.3	SDAD1P1	6.54	1.59e-10	3.8e-08	0.29	0.29	Height;	chr8:26304848	chr8:26379259~26382953:-
THCA	cis	rs12681366	0.614	rs3099401	ENSG00000253704.1	RP11-267M23.4	6.54	1.59e-10	3.8e-08	0.28	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94473303	chr8:94553722~94569745:+
THCA	cis	rs6840360	0.582	rs2724555	ENSG00000251611.1	RP11-610P16.1	-6.54	1.59e-10	3.8e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151407551~151408835:-
THCA	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-6.54	1.59e-10	3.8e-08	-0.42	-0.29	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
THCA	cis	rs6496044	0.568	rs1351196	ENSG00000259295.5	CSPG4P12	6.54	1.59e-10	3.8e-08	0.37	0.29	Interstitial lung disease;	chr15:85534173	chr15:85191438~85213905:+
THCA	cis	rs4072705	0.904	rs4593661	ENSG00000224020.1	MIR181A2HG	6.54	1.6e-10	3.81e-08	0.27	0.29	Menarche (age at onset);	chr9:124648236	chr9:124658467~124698631:+
THCA	cis	rs10899021	0.92	rs76121309	ENSG00000279353.1	RP11-864N7.4	6.54	1.6e-10	3.81e-08	0.59	0.29	Response to metformin (IC50);	chr11:74632876	chr11:74698231~74699658:-
THCA	cis	rs1499614	1	rs1267817	ENSG00000228409.4	CCT6P1	6.54	1.6e-10	3.82e-08	0.35	0.29	Gout;	chr7:66645053	chr7:65751142~65763354:+
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000228409.4	CCT6P1	6.54	1.6e-10	3.82e-08	0.35	0.29	Gout;	chr7:66654674	chr7:65751142~65763354:+
THCA	cis	rs6540731	0.967	rs1472226	ENSG00000226251.4	RP11-15I11.3	-6.54	1.6e-10	3.82e-08	-0.36	-0.29	Intelligence (childhood);	chr1:212229238	chr1:212225278~212238977:-
THCA	cis	rs71636778	0.509	rs35917448	ENSG00000260063.1	RP5-968P14.2	-6.54	1.6e-10	3.83e-08	-0.56	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26690834	chr1:26692132~26694131:-
THCA	cis	rs6061231	0.544	rs2427314	ENSG00000275437.1	RP5-908M14.10	6.54	1.6e-10	3.83e-08	0.26	0.29	Colorectal cancer;	chr20:62398610	chr20:62402236~62405935:-
THCA	cis	rs9402743	0.709	rs9373136	ENSG00000231028.7	LINC00271	-6.54	1.61e-10	3.83e-08	-0.24	-0.29	Systemic lupus erythematosus;	chr6:135617531	chr6:135497801~135716055:+
THCA	cis	rs741668	0.897	rs12429980	ENSG00000235903.6	CPB2-AS1	6.54	1.61e-10	3.84e-08	0.39	0.29	Cerebrospinal fluid clusterin levels;	chr13:45976003	chr13:46052806~46113332:+
THCA	cis	rs338389	0.609	rs338382	ENSG00000260657.2	RP11-315D16.4	-6.54	1.61e-10	3.84e-08	-0.39	-0.29	Survival in rectal cancer;	chr15:67952045	chr15:68267792~68277994:-
THCA	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	6.54	1.61e-10	3.84e-08	0.35	0.29	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
THCA	cis	rs16843372	0.599	rs11688793	ENSG00000251491.2	OR7E28P	-6.54	1.61e-10	3.85e-08	-0.38	-0.29	Obesity-related traits;	chr2:158823354	chr2:158862311~158863285:+
THCA	cis	rs6840360	0.642	rs11099819	ENSG00000251611.1	RP11-610P16.1	-6.54	1.61e-10	3.85e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151407551~151408835:-
THCA	cis	rs6696239	0.513	rs2935152	ENSG00000227711.2	RP11-275O4.5	6.54	1.61e-10	3.85e-08	0.3	0.29	Height;	chr1:227616000	chr1:227509028~227520477:-
THCA	cis	rs7851660	0.809	rs7032114	ENSG00000236130.1	PTCSC2	-6.54	1.62e-10	3.86e-08	-0.23	-0.29	Strep throat;	chr9:97894177	chr9:97805935~97810008:-
THCA	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	6.54	1.62e-10	3.86e-08	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	6.54	1.62e-10	3.86e-08	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	6.54	1.62e-10	3.86e-08	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
THCA	cis	rs3847687	0.869	rs11061300	ENSG00000279993.1	RP11-76C10.3	6.54	1.62e-10	3.87e-08	0.33	0.29	Longevity;	chr12:131038716	chr12:131025561~131028060:-
THCA	cis	rs848490	0.889	rs55641721	ENSG00000214293.7	APTR	6.54	1.63e-10	3.88e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77559584	chr7:77657660~77696265:-
THCA	cis	rs7044106	0.718	rs1981021	ENSG00000270917.1	RP11-27I1.6	-6.54	1.63e-10	3.88e-08	-0.41	-0.29	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.734	rs1981020	ENSG00000270917.1	RP11-27I1.6	-6.54	1.63e-10	3.88e-08	-0.41	-0.29	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120812475~120812845:-
THCA	cis	rs5742933	0.597	rs7568449	ENSG00000273240.1	RP11-455J20.3	6.54	1.63e-10	3.88e-08	0.31	0.29	Ferritin levels;	chr2:189656328	chr2:189763859~189764456:-
THCA	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	6.54	1.63e-10	3.88e-08	0.27	0.29	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
THCA	cis	rs7617773	0.638	rs7644414	ENSG00000228638.1	FCF1P2	-6.54	1.63e-10	3.88e-08	-0.28	-0.29	Coronary artery disease;	chr3:48257589	chr3:48290793~48291375:-
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000229886.1	RP5-1132H15.3	6.54	1.63e-10	3.89e-08	0.46	0.29	Diabetic kidney disease;	chr7:66136229	chr7:66025126~66031544:-
THCA	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	6.54	1.63e-10	3.89e-08	0.42	0.29	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
THCA	cis	rs2243480	1	rs34703416	ENSG00000229886.1	RP5-1132H15.3	6.54	1.63e-10	3.9e-08	0.46	0.29	Diabetic kidney disease;	chr7:65835655	chr7:66025126~66031544:-
THCA	cis	rs227275	0.525	rs7660298	ENSG00000251288.2	RP11-10L12.2	-6.54	1.64e-10	3.9e-08	-0.39	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102751401~102752641:+
THCA	cis	rs2303319	1	rs2303319	ENSG00000227403.1	AC009299.3	6.54	1.64e-10	3.91e-08	0.62	0.29	Cognitive function;	chr2:161368153	chr2:161244739~161249050:+
THCA	cis	rs9400467	0.528	rs457492	ENSG00000271789.1	RP5-1112D6.7	-6.54	1.64e-10	3.91e-08	-0.28	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111297126~111298510:+
THCA	cis	rs720475	0.732	rs7784282	ENSG00000204959.4	ARHGEF34P	-6.54	1.64e-10	3.91e-08	-0.33	-0.29	Breast cancer;	chr7:144431561	chr7:144272445~144286966:-
THCA	cis	rs860295	0.54	rs11264426	ENSG00000225855.5	RUSC1-AS1	-6.54	1.64e-10	3.91e-08	-0.2	-0.29	Body mass index;	chr1:155971157	chr1:155316863~155324176:-
THCA	cis	rs2562456	0.876	rs7252585	ENSG00000268119.4	CTD-2561J22.5	-6.54	1.64e-10	3.92e-08	-0.35	-0.29	Pain;	chr19:21475141	chr19:21444241~21463908:-
THCA	cis	rs6991838	0.778	rs11782837	ENSG00000200714.1	Y_RNA	6.54	1.64e-10	3.92e-08	0.35	0.29	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65592731~65592820:+
THCA	cis	rs5742933	0.817	rs2033870	ENSG00000273240.1	RP11-455J20.3	-6.54	1.64e-10	3.92e-08	-0.3	-0.29	Ferritin levels;	chr2:189739104	chr2:189763859~189764456:-
THCA	cis	rs2243480	1	rs160639	ENSG00000228409.4	CCT6P1	6.54	1.65e-10	3.93e-08	0.33	0.29	Diabetic kidney disease;	chr7:66115000	chr7:65751142~65763354:+
THCA	cis	rs2717559	0.542	rs11777634	ENSG00000253741.1	CTD-2292P10.4	6.54	1.65e-10	3.93e-08	0.37	0.29	Urinary tract infection frequency;	chr8:142806541	chr8:142702252~142726973:-
THCA	cis	rs12701220	0.739	rs2293523	ENSG00000229043.2	AC091729.9	-6.54	1.65e-10	3.93e-08	-0.45	-0.29	Bronchopulmonary dysplasia;	chr7:1058882	chr7:1160374~1165267:+
THCA	cis	rs2439831	0.85	rs3097773	ENSG00000275601.1	AC011330.13	6.54	1.65e-10	3.93e-08	0.44	0.29	Lung cancer in ever smokers;	chr15:43600874	chr15:43642389~43643023:-
THCA	cis	rs7267979	0.966	rs6050567	ENSG00000274414.1	RP5-965G21.4	6.54	1.65e-10	3.94e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25239007~25245229:-
THCA	cis	rs138249	0.505	rs138218	ENSG00000273253.2	RP3-402G11.26	-6.54	1.65e-10	3.94e-08	-0.32	-0.29	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50109129	chr22:50199090~50200837:-
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000220721.1	OR1F12	6.54	1.65e-10	3.94e-08	0.39	0.29	Parkinson's disease;	chr6:28065745	chr6:28073316~28074233:+
THCA	cis	rs1707322	0.717	rs2253862	ENSG00000281133.1	AL355480.3	6.54	1.65e-10	3.94e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.717	rs2991988	ENSG00000281133.1	AL355480.3	6.54	1.65e-10	3.94e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.717	rs2991989	ENSG00000281133.1	AL355480.3	6.54	1.65e-10	3.94e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45580892~45580996:-
THCA	cis	rs11148252	0.553	rs2147692	ENSG00000278238.1	RP11-245D16.4	-6.54	1.65e-10	3.94e-08	-0.32	-0.29	Lewy body disease;	chr13:52712888	chr13:52454775~52455331:-
THCA	cis	rs950169	0.922	rs11635505	ENSG00000259295.5	CSPG4P12	-6.54	1.66e-10	3.94e-08	-0.44	-0.29	Schizophrenia;	chr15:84553803	chr15:85191438~85213905:+
THCA	cis	rs56804039	1	rs11777086	ENSG00000253893.2	FAM85B	6.54	1.66e-10	3.95e-08	0.42	0.29	Cervical cancer;	chr8:8526969	chr8:8167819~8226614:-
THCA	cis	rs2735413	0.564	rs8051817	ENSG00000276007.1	RP11-358L22.3	6.54	1.66e-10	3.95e-08	0.31	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78087357	chr16:78123243~78124332:+
THCA	cis	rs62292953	0.535	rs11923081	ENSG00000248724.5	NPHP3-AS1	-6.54	1.66e-10	3.95e-08	-0.54	-0.29	Red cell distribution width;	chr3:132720559	chr3:132721750~132874223:+
THCA	cis	rs10208649	1	rs17045242	ENSG00000272156.1	RP11-477N3.1	6.54	1.66e-10	3.95e-08	0.53	0.29	Body mass index;	chr2:53806326	chr2:54082554~54085066:+
THCA	cis	rs9329221	0.572	rs4841295	ENSG00000261451.1	RP11-981G7.1	6.53	1.66e-10	3.95e-08	0.36	0.29	Neuroticism;	chr8:10247605	chr8:10433672~10438312:+
THCA	cis	rs227275	0.525	rs2086499	ENSG00000251288.2	RP11-10L12.2	-6.53	1.66e-10	3.95e-08	-0.39	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102751401~102752641:+
THCA	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	6.53	1.66e-10	3.96e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
THCA	cis	rs62292953	0.535	rs62292475	ENSG00000248724.5	NPHP3-AS1	-6.53	1.66e-10	3.96e-08	-0.53	-0.29	Red cell distribution width;	chr3:132718190	chr3:132721750~132874223:+
THCA	cis	rs2348418	0.932	rs16932850	ENSG00000247934.4	RP11-967K21.1	6.53	1.66e-10	3.96e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28457941	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.932	rs11049623	ENSG00000247934.4	RP11-967K21.1	6.53	1.66e-10	3.96e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28458374	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.932	rs7136886	ENSG00000247934.4	RP11-967K21.1	6.53	1.66e-10	3.96e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28460684	chr12:28163298~28190738:-
THCA	cis	rs2243480	0.522	rs431168	ENSG00000273142.1	RP11-458F8.4	-6.53	1.67e-10	3.97e-08	-0.43	-0.29	Diabetic kidney disease;	chr7:66046617	chr7:66902857~66906297:+
THCA	cis	rs149866169	1	rs149866169	ENSG00000280107.1	AL022393.9	-6.53	1.67e-10	3.97e-08	-0.5	-0.29	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28170845~28172521:+
THCA	cis	rs9287719	0.601	rs12996735	ENSG00000243819.4	RN7SL832P	6.53	1.67e-10	3.97e-08	0.24	0.29	Prostate cancer;	chr2:10576590	chr2:10690344~10692099:+
THCA	cis	rs9625935	0.748	rs12537	ENSG00000279159.1	RP3-394A18.1	-6.53	1.67e-10	3.97e-08	-0.2	-0.29	Tonsillectomy;	chr22:30027471	chr22:29978950~30028236:-
THCA	cis	rs741668	0.931	rs12431359	ENSG00000235903.6	CPB2-AS1	6.53	1.67e-10	3.98e-08	0.4	0.29	Cerebrospinal fluid clusterin levels;	chr13:45972048	chr13:46052806~46113332:+
THCA	cis	rs5769707	0.542	rs739242	ENSG00000235111.1	RP1-29C18.8	-6.53	1.67e-10	3.98e-08	-0.37	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49612657~49615716:-
THCA	cis	rs2243480	1	rs4718333	ENSG00000229886.1	RP5-1132H15.3	-6.53	1.67e-10	3.98e-08	-0.48	-0.29	Diabetic kidney disease;	chr7:66307771	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs7792391	ENSG00000229886.1	RP5-1132H15.3	-6.53	1.67e-10	3.98e-08	-0.48	-0.29	Diabetic kidney disease;	chr7:66308442	chr7:66025126~66031544:-
THCA	cis	rs2348418	0.966	rs4144964	ENSG00000247934.4	RP11-967K21.1	6.53	1.67e-10	3.99e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28531249	chr12:28163298~28190738:-
THCA	cis	rs897984	0.806	rs9319588	ENSG00000279196.1	RP11-1072A3.3	-6.53	1.68e-10	3.99e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30919662	chr16:30984630~30988270:-
THCA	cis	rs897984	0.77	rs12930657	ENSG00000279196.1	RP11-1072A3.3	-6.53	1.68e-10	3.99e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30920647	chr16:30984630~30988270:-
THCA	cis	rs897984	0.77	rs3813020	ENSG00000279196.1	RP11-1072A3.3	-6.53	1.68e-10	3.99e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30922754	chr16:30984630~30988270:-
THCA	cis	rs9677476	0.909	rs10181602	ENSG00000224376.1	AC017104.6	6.53	1.68e-10	3.99e-08	0.33	0.29	Food antigen IgG levels;	chr2:231256929	chr2:231388976~231394991:+
THCA	cis	rs12701220	0.901	rs12701710	ENSG00000229043.2	AC091729.9	6.53	1.68e-10	3.99e-08	0.38	0.29	Bronchopulmonary dysplasia;	chr7:1050760	chr7:1160374~1165267:+
THCA	cis	rs6504108	0.512	rs12950225	ENSG00000278765.1	RP5-890E16.5	6.53	1.68e-10	3.99e-08	0.33	0.29	Body mass index;	chr17:48067838	chr17:48066704~48067293:-
THCA	cis	rs2243480	1	rs3885839	ENSG00000229886.1	RP5-1132H15.3	6.53	1.68e-10	3.99e-08	0.47	0.29	Diabetic kidney disease;	chr7:65825416	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs73142122	ENSG00000229886.1	RP5-1132H15.3	6.53	1.68e-10	3.99e-08	0.47	0.29	Diabetic kidney disease;	chr7:65846311	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.901	rs73142137	ENSG00000229886.1	RP5-1132H15.3	6.53	1.68e-10	3.99e-08	0.47	0.29	Diabetic kidney disease;	chr7:65878455	chr7:66025126~66031544:-
THCA	cis	rs17711722	0.523	rs365896	ENSG00000228409.4	CCT6P1	6.53	1.68e-10	3.99e-08	0.21	0.29	Calcium levels;	chr7:66045710	chr7:65751142~65763354:+
THCA	cis	rs7851660	0.809	rs10984230	ENSG00000236130.1	PTCSC2	-6.53	1.68e-10	4e-08	-0.23	-0.29	Strep throat;	chr9:97898002	chr9:97805935~97810008:-
THCA	cis	rs12435908	1	rs2268958	ENSG00000276116.2	FUT8-AS1	-6.53	1.68e-10	4e-08	-0.48	-0.29	Ischemic stroke;	chr14:65661520	chr14:65411170~65412690:-
THCA	cis	rs6496044	0.568	rs6496039	ENSG00000259295.5	CSPG4P12	6.53	1.68e-10	4.01e-08	0.37	0.29	Interstitial lung disease;	chr15:85518732	chr15:85191438~85213905:+
THCA	cis	rs7829975	0.626	rs907183	ENSG00000254153.1	CTA-398F10.2	6.53	1.68e-10	4.01e-08	0.32	0.29	Mood instability;	chr8:8872251	chr8:8456909~8461337:-
THCA	cis	rs3806843	1	rs7710794	ENSG00000202515.1	VTRNA1-3	-6.53	1.69e-10	4.01e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140829882	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs10038174	ENSG00000202515.1	VTRNA1-3	-6.53	1.69e-10	4.01e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140831031	chr5:140726158~140726246:+
THCA	cis	rs9800506	0.584	rs2011361	ENSG00000228559.1	RP3-340B19.3	6.53	1.69e-10	4.02e-08	0.4	0.29	Neutrophil percentage of granulocytes;	chr6:35556617	chr6:35544632~35545669:+
THCA	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	6.53	1.69e-10	4.02e-08	0.35	0.29	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
THCA	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	6.53	1.69e-10	4.02e-08	0.37	0.29	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
THCA	cis	rs28386778	0.863	rs4968661	ENSG00000240280.5	TCAM1P	-6.53	1.69e-10	4.02e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63718946	chr17:63849292~63864379:+
THCA	cis	rs2735413	0.564	rs11859770	ENSG00000276007.1	RP11-358L22.3	6.53	1.69e-10	4.02e-08	0.31	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78092837	chr16:78123243~78124332:+
THCA	cis	rs897984	0.572	rs4889526	ENSG00000279196.1	RP11-1072A3.3	6.53	1.69e-10	4.02e-08	0.29	0.29	Dementia with Lewy bodies;	chr16:31019023	chr16:30984630~30988270:-
THCA	cis	rs7044106	0.762	rs1470307	ENSG00000270917.1	RP11-27I1.6	-6.53	1.69e-10	4.02e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120812475~120812845:-
THCA	cis	rs5769707	0.521	rs7285764	ENSG00000235111.1	RP1-29C18.8	-6.53	1.69e-10	4.03e-08	-0.37	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.521	rs9616715	ENSG00000235111.1	RP1-29C18.8	-6.53	1.69e-10	4.03e-08	-0.37	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.521	rs6009805	ENSG00000235111.1	RP1-29C18.8	-6.53	1.69e-10	4.03e-08	-0.37	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49612657~49615716:-
THCA	cis	rs8141529	0.732	rs5752798	ENSG00000226471.5	CTA-292E10.6	-6.53	1.69e-10	4.03e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28785880	chr22:28800683~28848559:+
THCA	cis	rs71636778	0.509	rs6659176	ENSG00000260063.1	RP5-968P14.2	-6.53	1.69e-10	4.03e-08	-0.56	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26913429	chr1:26692132~26694131:-
THCA	cis	rs4835473	0.932	rs1813908	ENSG00000251600.4	RP11-673E1.1	6.53	1.69e-10	4.03e-08	0.38	0.29	Immature fraction of reticulocytes;	chr4:143728174	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs4835454	ENSG00000251600.4	RP11-673E1.1	6.53	1.69e-10	4.03e-08	0.38	0.29	Immature fraction of reticulocytes;	chr4:143730081	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1839449	ENSG00000251600.4	RP11-673E1.1	6.53	1.69e-10	4.03e-08	0.38	0.29	Immature fraction of reticulocytes;	chr4:143730222	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1450250	ENSG00000251600.4	RP11-673E1.1	6.53	1.69e-10	4.03e-08	0.38	0.29	Immature fraction of reticulocytes;	chr4:143731873	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	6.53	1.69e-10	4.03e-08	0.38	0.29	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
THCA	cis	rs1594829	0.553	rs2046225	ENSG00000228451.3	SDAD1P1	-6.53	1.69e-10	4.03e-08	-0.29	-0.29	Height;	chr8:26294286	chr8:26379259~26382953:-
THCA	cis	rs10899021	0.79	rs12280434	ENSG00000279353.1	RP11-864N7.4	6.53	1.7e-10	4.03e-08	0.56	0.29	Response to metformin (IC50);	chr11:74621782	chr11:74698231~74699658:-
THCA	cis	rs848490	0.963	rs73136294	ENSG00000214293.7	APTR	6.53	1.7e-10	4.04e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777171	chr7:77657660~77696265:-
THCA	cis	rs848490	1	rs62460739	ENSG00000214293.7	APTR	6.53	1.7e-10	4.04e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777430	chr7:77657660~77696265:-
THCA	cis	rs9467773	0.595	rs3799379	ENSG00000124549.13	BTN2A3P	-6.53	1.7e-10	4.04e-08	-0.27	-0.29	Intelligence (multi-trait analysis);	chr6:26404466	chr6:26421391~26432383:+
THCA	cis	rs922182	0.617	rs4776264	ENSG00000275785.1	RP11-111E14.2	6.53	1.7e-10	4.04e-08	0.33	0.29	Blood protein levels;	chr15:63934925	chr15:63890030~63890317:+
THCA	cis	rs5742933	0.817	rs6738042	ENSG00000273240.1	RP11-455J20.3	6.53	1.7e-10	4.04e-08	0.3	0.29	Ferritin levels;	chr2:189776958	chr2:189763859~189764456:-
THCA	cis	rs797680	0.897	rs2295424	ENSG00000223745.6	RP4-717I23.3	6.53	1.7e-10	4.04e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93115322	chr1:93262186~93346025:-
THCA	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-6.53	1.7e-10	4.04e-08	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-6.53	1.7e-10	4.04e-08	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
THCA	cis	rs6496044	0.527	rs7163068	ENSG00000259295.5	CSPG4P12	6.53	1.7e-10	4.05e-08	0.36	0.29	Interstitial lung disease;	chr15:85529235	chr15:85191438~85213905:+
THCA	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	6.53	1.7e-10	4.05e-08	0.4	0.29	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
THCA	cis	rs6061231	0.958	rs2379126	ENSG00000275437.1	RP5-908M14.10	6.53	1.7e-10	4.06e-08	0.27	0.29	Colorectal cancer;	chr20:62377949	chr20:62402236~62405935:-
THCA	cis	rs6061231	0.958	rs2427304	ENSG00000275437.1	RP5-908M14.10	6.53	1.7e-10	4.06e-08	0.27	0.29	Colorectal cancer;	chr20:62378528	chr20:62402236~62405935:-
THCA	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	6.53	1.71e-10	4.06e-08	0.37	0.29	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
THCA	cis	rs3806843	0.966	rs2240693	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140803740	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs2240692	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140804000	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs6579987	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140804074	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs1030163	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140805547	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs1030164	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140805687	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs1030165	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140805863	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs1030166	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140805888	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs4151680	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140807072	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs3822346	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140807737	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.933	rs2337987	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140808798	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.933	rs2879087	ENSG00000202515.1	VTRNA1-3	-6.53	1.71e-10	4.06e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140808990	chr5:140726158~140726246:+
THCA	cis	rs2239557	0.961	rs8003212	ENSG00000259065.1	RP5-1021I20.1	6.53	1.71e-10	4.06e-08	0.35	0.29	Common traits (Other);	chr14:74158260	chr14:73787360~73803270:+
THCA	cis	rs7586673	1	rs7586673	ENSG00000235724.7	AC009299.2	-6.53	1.71e-10	4.06e-08	-0.31	-0.29	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161222785~161308303:-
THCA	cis	rs1552244	0.882	rs2030564	ENSG00000232901.1	CYCSP10	6.53	1.71e-10	4.06e-08	0.36	0.29	Alzheimer's disease;	chr3:9997360	chr3:10000647~10000940:-
THCA	cis	rs10844706	0.699	rs741199	ENSG00000256594.6	RP11-705C15.2	6.53	1.71e-10	4.06e-08	0.24	0.29	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9720769	chr12:9633419~9658412:+
THCA	cis	rs2303319	0.892	rs58627659	ENSG00000227403.1	AC009299.3	6.53	1.71e-10	4.07e-08	0.62	0.29	Cognitive function;	chr2:161394399	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs62188133	ENSG00000227403.1	AC009299.3	6.53	1.71e-10	4.07e-08	0.62	0.29	Cognitive function;	chr2:161396924	chr2:161244739~161249050:+
THCA	cis	rs2243480	0.901	rs778730	ENSG00000228409.4	CCT6P1	6.53	1.71e-10	4.07e-08	0.34	0.29	Diabetic kidney disease;	chr7:66358338	chr7:65751142~65763354:+
THCA	cis	rs1552244	0.882	rs13064570	ENSG00000232901.1	CYCSP10	6.53	1.71e-10	4.07e-08	0.37	0.29	Alzheimer's disease;	chr3:9955861	chr3:10000647~10000940:-
THCA	cis	rs9926296	0.605	rs7205053	ENSG00000260259.1	RP11-368I7.4	-6.53	1.71e-10	4.07e-08	-0.31	-0.29	Vitiligo;	chr16:89790355	chr16:89682620~89686569:-
THCA	cis	rs2018683	0.87	rs13232487	ENSG00000228421.2	AC005013.5	6.53	1.71e-10	4.07e-08	0.32	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945502	chr7:28957667~28959345:+
THCA	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-6.53	1.71e-10	4.07e-08	-0.17	-0.29	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-6.53	1.71e-10	4.07e-08	-0.17	-0.29	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
THCA	cis	rs847577	0.609	rs17435590	ENSG00000272950.1	RP11-307C18.1	6.53	1.71e-10	4.07e-08	0.36	0.29	Breast cancer;	chr7:98154749	chr7:98322853~98323430:+
THCA	cis	rs847577	0.609	rs34320230	ENSG00000272950.1	RP11-307C18.1	6.53	1.71e-10	4.07e-08	0.36	0.29	Breast cancer;	chr7:98156188	chr7:98322853~98323430:+
THCA	cis	rs847577	0.588	rs12666406	ENSG00000272950.1	RP11-307C18.1	6.53	1.71e-10	4.07e-08	0.36	0.29	Breast cancer;	chr7:98161679	chr7:98322853~98323430:+
THCA	cis	rs3764021	0.527	rs12227655	ENSG00000256594.6	RP11-705C15.2	6.53	1.71e-10	4.08e-08	0.24	0.29	Type 1 diabetes;	chr12:9715652	chr12:9633419~9658412:+
THCA	cis	rs3764021	0.506	rs12228641	ENSG00000256594.6	RP11-705C15.2	6.53	1.71e-10	4.08e-08	0.24	0.29	Type 1 diabetes;	chr12:9715680	chr12:9633419~9658412:+
THCA	cis	rs5742933	0.75	rs10197331	ENSG00000253559.1	OSGEPL1-AS1	6.53	1.72e-10	4.08e-08	0.32	0.29	Ferritin levels;	chr2:189768112	chr2:189762704~189765556:+
THCA	cis	rs6545883	0.894	rs4672436	ENSG00000271889.1	RP11-493E12.1	-6.53	1.72e-10	4.08e-08	-0.28	-0.29	Tuberculosis;	chr2:61376222	chr2:61151433~61162105:-
THCA	cis	rs62292953	0.535	rs17414558	ENSG00000248724.5	NPHP3-AS1	-6.53	1.72e-10	4.08e-08	-0.52	-0.29	Red cell distribution width;	chr3:132715312	chr3:132721750~132874223:+
THCA	cis	rs4143844	0.609	rs11632560	ENSG00000259251.2	RP11-643M14.1	6.53	1.72e-10	4.08e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:62009299	chr15:62060503~62062434:+
THCA	cis	rs4143844	1	rs34173668	ENSG00000259251.2	RP11-643M14.1	6.53	1.72e-10	4.08e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:62013385	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs11639286	ENSG00000259251.2	RP11-643M14.1	6.53	1.72e-10	4.08e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:62024397	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs34958705	ENSG00000259251.2	RP11-643M14.1	6.53	1.72e-10	4.08e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:62024558	chr15:62060503~62062434:+
THCA	cis	rs2439831	0.85	rs28413881	ENSG00000275601.1	AC011330.13	-6.53	1.72e-10	4.09e-08	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43881901	chr15:43642389~43643023:-
THCA	cis	rs17594362	0.697	rs9562317	ENSG00000264190.1	MIR5006	6.53	1.72e-10	4.09e-08	0.39	0.29	Multiple sclerosis;	chr13:41562923	chr13:41568286~41568395:-
THCA	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	6.53	1.72e-10	4.09e-08	0.39	0.29	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
THCA	cis	rs7208859	0.673	rs216435	ENSG00000264538.5	SUZ12P1	-6.53	1.72e-10	4.1e-08	-0.28	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30709299~30790908:+
THCA	cis	rs3806843	1	rs4404730	ENSG00000202515.1	VTRNA1-3	-6.53	1.72e-10	4.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140783025	chr5:140726158~140726246:+
THCA	cis	rs6860806	0.603	rs112300250	ENSG00000237714.1	P4HA2-AS1	6.53	1.73e-10	4.1e-08	0.37	0.29	Breast cancer;	chr5:132247599	chr5:132184876~132192808:+
THCA	cis	rs934734	0.563	rs11126034	ENSG00000237979.1	AC007389.1	-6.53	1.73e-10	4.1e-08	-0.35	-0.29	Rheumatoid arthritis;	chr2:65353087	chr2:65500993~65502138:-
THCA	cis	rs2239547	0.562	rs6794389	ENSG00000242142.1	SERBP1P3	6.53	1.73e-10	4.1e-08	0.37	0.29	Schizophrenia;	chr3:53062378	chr3:53064283~53065091:-
THCA	cis	rs16949788	1	rs10468036	ENSG00000261351.2	CTD-3185P2.1	-6.53	1.73e-10	4.1e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66417938	chr15:66488658~66492109:-
THCA	cis	rs1979679	0.842	rs7138497	ENSG00000278733.1	RP11-425D17.1	6.53	1.73e-10	4.11e-08	0.28	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28242918	chr12:28185625~28186190:-
THCA	cis	rs7267979	0.966	rs3827014	ENSG00000274414.1	RP5-965G21.4	6.53	1.73e-10	4.11e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25239007~25245229:-
THCA	cis	rs853679	0.527	rs853683	ENSG00000219392.1	RP1-265C24.5	-6.53	1.73e-10	4.11e-08	-0.32	-0.29	Depression;	chr6:28327262	chr6:28115628~28116551:+
THCA	cis	rs4143844	1	rs4143844	ENSG00000259251.2	RP11-643M14.1	-6.53	1.73e-10	4.11e-08	-0.55	-0.29	Bipolar disorder and schizophrenia;	chr15:62020641	chr15:62060503~62062434:+
THCA	cis	rs72843506	0.656	rs77314146	ENSG00000270091.1	RP11-78O7.2	-6.53	1.73e-10	4.11e-08	-0.34	-0.29	Schizophrenia;	chr17:20003827	chr17:19896590~19897287:-
THCA	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	6.53	1.73e-10	4.11e-08	0.35	0.29	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	6.53	1.73e-10	4.11e-08	0.35	0.29	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	6.53	1.73e-10	4.11e-08	0.35	0.29	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	6.53	1.73e-10	4.11e-08	0.35	0.29	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
THCA	cis	rs7267979	1	rs2474777	ENSG00000274414.1	RP5-965G21.4	-6.53	1.73e-10	4.11e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25239007~25245229:-
THCA	cis	rs7260598	0.792	rs4635459	ENSG00000268442.1	CTD-2027I19.2	6.53	1.73e-10	4.12e-08	0.39	0.29	Response to taxane treatment (placlitaxel);	chr19:23999020	chr19:24162370~24163425:-
THCA	cis	rs1865760	0.713	rs7766342	ENSG00000272462.2	U91328.19	-6.53	1.73e-10	4.12e-08	-0.23	-0.29	Height;	chr6:25990446	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.713	rs9461229	ENSG00000272462.2	U91328.19	-6.53	1.73e-10	4.12e-08	-0.23	-0.29	Height;	chr6:25992051	chr6:25992662~26001775:+
THCA	cis	rs897984	0.609	rs72800847	ENSG00000260911.2	RP11-196G11.2	6.53	1.73e-10	4.12e-08	0.25	0.29	Dementia with Lewy bodies;	chr16:31011318	chr16:31043150~31049868:+
THCA	cis	rs7208859	0.673	rs216409	ENSG00000264538.5	SUZ12P1	6.53	1.73e-10	4.12e-08	0.27	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30709299~30790908:+
THCA	cis	rs1552244	0.882	rs17050699	ENSG00000180385.7	EMC3-AS1	6.53	1.74e-10	4.12e-08	0.3	0.29	Alzheimer's disease;	chr3:9995483	chr3:9986893~10006990:+
THCA	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	6.53	1.74e-10	4.12e-08	0.35	0.29	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
THCA	cis	rs7746199	0.736	rs13212318	ENSG00000226314.6	ZNF192P1	-6.53	1.74e-10	4.12e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs13202291	ENSG00000226314.6	ZNF192P1	-6.53	1.74e-10	4.12e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.736	rs17750424	ENSG00000226314.6	ZNF192P1	-6.53	1.74e-10	4.12e-08	-0.64	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28161781~28169594:+
THCA	cis	rs10129255	0.5	rs988132	ENSG00000280411.1	IGHV1-69-2	-6.53	1.74e-10	4.13e-08	-0.17	-0.29	Kawasaki disease;	chr14:106776758	chr14:106762092~106762588:-
THCA	cis	rs2439831	0.867	rs2260160	ENSG00000249839.1	AC011330.5	-6.53	1.74e-10	4.13e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43603445	chr15:43663654~43684339:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000272009.1	RP1-313I6.12	-6.53	1.74e-10	4.13e-08	-0.33	-0.29	Depression;	chr6:28206179	chr6:28078792~28081130:-
THCA	cis	rs1552244	0.572	rs7645759	ENSG00000232901.1	CYCSP10	6.53	1.74e-10	4.13e-08	0.44	0.29	Alzheimer's disease;	chr3:10115684	chr3:10000647~10000940:-
THCA	cis	rs7508	0.511	rs208025	ENSG00000253671.1	RP11-806O11.1	-6.53	1.74e-10	4.13e-08	-0.36	-0.29	Atrial fibrillation;	chr8:18020661	chr8:17808941~17820868:+
THCA	cis	rs9800506	0.6	rs10456080	ENSG00000228559.1	RP3-340B19.3	6.53	1.74e-10	4.14e-08	0.4	0.29	Neutrophil percentage of granulocytes;	chr6:35547416	chr6:35544632~35545669:+
THCA	cis	rs9800506	0.624	rs12194405	ENSG00000228559.1	RP3-340B19.3	6.53	1.74e-10	4.14e-08	0.4	0.29	Neutrophil percentage of granulocytes;	chr6:35549681	chr6:35544632~35545669:+
THCA	cis	rs748404	0.631	rs3809482	ENSG00000166763.7	STRCP1	6.53	1.74e-10	4.14e-08	0.31	0.29	Lung cancer;	chr15:43369604	chr15:43699488~43718184:-
THCA	cis	rs1552244	0.744	rs6763366	ENSG00000232901.1	CYCSP10	6.53	1.74e-10	4.14e-08	0.36	0.29	Alzheimer's disease;	chr3:9991860	chr3:10000647~10000940:-
THCA	cis	rs4950322	0.515	rs72691016	ENSG00000237188.3	RP11-337C18.8	6.53	1.74e-10	4.14e-08	0.35	0.29	Protein quantitative trait loci;	chr1:147245375	chr1:147172771~147211568:+
THCA	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	6.53	1.74e-10	4.14e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	6.53	1.74e-10	4.14e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	6.53	1.74e-10	4.14e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	6.53	1.74e-10	4.14e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	6.53	1.74e-10	4.14e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	6.53	1.74e-10	4.14e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	6.53	1.74e-10	4.14e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	6.53	1.74e-10	4.14e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
THCA	cis	rs5742933	0.817	rs1233265	ENSG00000273240.1	RP11-455J20.3	-6.53	1.74e-10	4.14e-08	-0.3	-0.29	Ferritin levels;	chr2:189796390	chr2:189763859~189764456:-
THCA	cis	rs2735413	0.599	rs73562710	ENSG00000276007.1	RP11-358L22.3	6.53	1.75e-10	4.14e-08	0.31	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78090709	chr16:78123243~78124332:+
THCA	cis	rs2735413	0.564	rs79006334	ENSG00000276007.1	RP11-358L22.3	6.53	1.75e-10	4.14e-08	0.31	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78091057	chr16:78123243~78124332:+
THCA	cis	rs6840360	0.642	rs7678823	ENSG00000251611.1	RP11-610P16.1	-6.53	1.75e-10	4.15e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151407551~151408835:-
THCA	cis	rs848490	0.814	rs11770844	ENSG00000214293.7	APTR	6.53	1.75e-10	4.15e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77598997	chr7:77657660~77696265:-
THCA	cis	rs10208649	0.803	rs6739630	ENSG00000272156.1	RP11-477N3.1	6.53	1.75e-10	4.15e-08	0.55	0.29	Body mass index;	chr2:53753668	chr2:54082554~54085066:+
THCA	cis	rs75422866	0.764	rs67408202	ENSG00000274902.1	RP1-197B17.4	6.53	1.75e-10	4.15e-08	0.62	0.29	Pneumonia;	chr12:47713564	chr12:47731908~47732351:+
THCA	cis	rs6545883	0.929	rs1838978	ENSG00000271889.1	RP11-493E12.1	-6.53	1.75e-10	4.16e-08	-0.27	-0.29	Tuberculosis;	chr2:61313788	chr2:61151433~61162105:-
THCA	cis	rs4143844	0.867	rs2303405	ENSG00000259251.2	RP11-643M14.1	-6.53	1.75e-10	4.16e-08	-0.53	-0.29	Bipolar disorder and schizophrenia;	chr15:61961592	chr15:62060503~62062434:+
THCA	cis	rs728616	0.867	rs56271768	ENSG00000225484.5	NUTM2B-AS1	-6.53	1.75e-10	4.16e-08	-0.54	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80077295	chr10:79663088~79826594:-
THCA	cis	rs748404	1	rs748404	ENSG00000249839.1	AC011330.5	-6.53	1.75e-10	4.16e-08	-0.38	-0.29	Lung cancer;	chr15:43267033	chr15:43663654~43684339:-
THCA	cis	rs11722779	0.873	rs223346	ENSG00000230069.3	LRRC37A15P	-6.53	1.76e-10	4.17e-08	-0.3	-0.29	Schizophrenia;	chr4:102859339	chr4:102727274~102730721:-
THCA	cis	rs438465	1	rs433756	ENSG00000226194.4	RP1-137D17.1	6.53	1.76e-10	4.17e-08	0.44	0.29	Corneal astigmatism;	chr6:169413214	chr6:169369998~169388385:-
THCA	cis	rs438465	1	rs425239	ENSG00000226194.4	RP1-137D17.1	6.53	1.76e-10	4.17e-08	0.44	0.29	Corneal astigmatism;	chr6:169413663	chr6:169369998~169388385:-
THCA	cis	rs1552244	0.882	rs3755782	ENSG00000180385.7	EMC3-AS1	6.53	1.76e-10	4.17e-08	0.3	0.29	Alzheimer's disease;	chr3:9987621	chr3:9986893~10006990:+
THCA	cis	rs4934494	0.768	rs12771413	ENSG00000232936.4	RP11-80H5.2	-6.53	1.76e-10	4.18e-08	-0.4	-0.29	Red blood cell count;	chr10:89633010	chr10:89645282~89650667:+
THCA	cis	rs848490	0.851	rs62473661	ENSG00000214293.7	APTR	6.53	1.76e-10	4.18e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77576197	chr7:77657660~77696265:-
THCA	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	6.52	1.76e-10	4.19e-08	0.41	0.29	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
THCA	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	6.52	1.76e-10	4.19e-08	0.32	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
THCA	cis	rs6802315	0.712	rs7615751	ENSG00000272247.1	RP11-379F4.9	-6.52	1.76e-10	4.19e-08	-0.27	-0.29	Periodontitis (CDC/AAP);	chr3:158792041	chr3:158801257~158801935:-
THCA	cis	rs2348418	0.864	rs6487688	ENSG00000247934.4	RP11-967K21.1	-6.52	1.76e-10	4.19e-08	-0.25	-0.29	Lung function (FEV1);Lung function (FVC);	chr12:28558278	chr12:28163298~28190738:-
THCA	cis	rs16843372	0.599	rs10016	ENSG00000251491.2	OR7E28P	-6.52	1.77e-10	4.19e-08	-0.38	-0.29	Obesity-related traits;	chr2:158815930	chr2:158862311~158863285:+
THCA	cis	rs6802315	1	rs6802315	ENSG00000272247.1	RP11-379F4.9	-6.52	1.77e-10	4.19e-08	-0.27	-0.29	Periodontitis (CDC/AAP);	chr3:158796571	chr3:158801257~158801935:-
THCA	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-6.52	1.77e-10	4.2e-08	-0.35	-0.29	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
THCA	cis	rs7942368	0.941	rs10793195	ENSG00000204529.3	GUCY2EP	6.52	1.77e-10	4.2e-08	0.41	0.29	Endometriosis;	chr11:76793688	chr11:76694043~76707641:-
THCA	cis	rs7302981	0.719	rs835592	ENSG00000272368.2	RP4-605O3.4	6.52	1.77e-10	4.2e-08	0.17	0.29	Systolic blood pressure;	chr12:50067048	chr12:50112197~50165618:+
THCA	cis	rs922182	0.579	rs4620909	ENSG00000275785.1	RP11-111E14.2	-6.52	1.77e-10	4.2e-08	-0.33	-0.29	Blood protein levels;	chr15:63900540	chr15:63890030~63890317:+
THCA	cis	rs4950322	0.547	rs56864370	ENSG00000237188.3	RP11-337C18.8	6.52	1.77e-10	4.2e-08	0.34	0.29	Protein quantitative trait loci;	chr1:147111847	chr1:147172771~147211568:+
THCA	cis	rs4650994	0.507	rs12141152	ENSG00000273384.1	RP5-1098D14.1	6.52	1.77e-10	4.2e-08	0.36	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178545030	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.525	rs4076563	ENSG00000273384.1	RP5-1098D14.1	6.52	1.77e-10	4.2e-08	0.36	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178547766	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.525	rs4650996	ENSG00000273384.1	RP5-1098D14.1	6.52	1.77e-10	4.2e-08	0.36	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178548230	chr1:178651706~178652282:+
THCA	cis	rs10740039	0.516	rs7088259	ENSG00000254271.1	RP11-131N11.4	6.52	1.77e-10	4.21e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559094	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs2393646	ENSG00000254271.1	RP11-131N11.4	6.52	1.77e-10	4.21e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559676	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs2068042	ENSG00000254271.1	RP11-131N11.4	6.52	1.77e-10	4.21e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60560535	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs10740032	ENSG00000254271.1	RP11-131N11.4	6.52	1.77e-10	4.21e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60562627	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs958852	ENSG00000254271.1	RP11-131N11.4	6.52	1.77e-10	4.21e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60562860	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs1442551	ENSG00000254271.1	RP11-131N11.4	6.52	1.77e-10	4.21e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60564733	chr10:60734342~60741828:+
THCA	cis	rs11723261	0.527	rs11731581	ENSG00000211553.1	AC253576.2	-6.52	1.78e-10	4.21e-08	-0.4	-0.29	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:136461~136568:+
THCA	cis	rs9677476	0.909	rs13408391	ENSG00000224376.1	AC017104.6	6.52	1.78e-10	4.22e-08	0.33	0.29	Food antigen IgG levels;	chr2:231259414	chr2:231388976~231394991:+
THCA	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-6.52	1.78e-10	4.22e-08	-0.5	-0.29	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
THCA	cis	rs4835473	0.808	rs6831401	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143801038	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.778	rs6853798	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143801153	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs12502940	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143812117	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.778	rs2622380	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143814571	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35792820	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143814806	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs62337300	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143815897	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7697498	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143816854	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7656455	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143817005	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13133239	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143818894	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13106488	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143818969	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13105102	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143819046	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs13105118	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143819077	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35271123	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143819629	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1383443	ENSG00000251600.4	RP11-673E1.1	-6.52	1.78e-10	4.22e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143819940	chr4:143912331~143982454:+
THCA	cis	rs34779708	0.766	rs7897088	ENSG00000271335.4	RP11-324I22.4	6.52	1.78e-10	4.22e-08	0.29	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35314552~35336401:-
THCA	cis	rs7189233	0.955	rs72801853	ENSG00000279344.1	RP11-44F14.7	6.52	1.78e-10	4.22e-08	0.31	0.29	Intelligence (multi-trait analysis);	chr16:53482912	chr16:53478957~53481550:-
THCA	cis	rs4950322	0.744	rs2353987	ENSG00000237188.3	RP11-337C18.8	6.52	1.78e-10	4.22e-08	0.36	0.29	Protein quantitative trait loci;	chr1:147355845	chr1:147172771~147211568:+
THCA	cis	rs9800506	0.624	rs12195290	ENSG00000228559.1	RP3-340B19.3	6.52	1.78e-10	4.23e-08	0.4	0.29	Neutrophil percentage of granulocytes;	chr6:35545072	chr6:35544632~35545669:+
THCA	cis	rs6540731	1	rs11119884	ENSG00000226251.4	RP11-15I11.3	-6.52	1.78e-10	4.23e-08	-0.35	-0.29	Intelligence (childhood);	chr1:212226804	chr1:212225278~212238977:-
THCA	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	6.52	1.78e-10	4.23e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
THCA	cis	rs6479891	1	rs10761730	ENSG00000232075.1	MRPL35P2	-6.52	1.78e-10	4.23e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs7916282	ENSG00000232075.1	MRPL35P2	-6.52	1.78e-10	4.23e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.915	rs9415682	ENSG00000232075.1	MRPL35P2	-6.52	1.78e-10	4.23e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.778	rs10761735	ENSG00000232075.1	MRPL35P2	-6.52	1.78e-10	4.23e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs9414786	ENSG00000232075.1	MRPL35P2	-6.52	1.78e-10	4.23e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.822	rs6479892	ENSG00000232075.1	MRPL35P2	-6.52	1.78e-10	4.23e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63634317~63634827:-
THCA	cis	rs984222	0.838	rs10923724	ENSG00000231365.4	RP11-418J17.1	-6.52	1.78e-10	4.23e-08	-0.28	-0.29	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119004219	chr1:119140396~119275973:+
THCA	cis	rs3806843	1	rs4151682	ENSG00000202515.1	VTRNA1-3	-6.52	1.78e-10	4.23e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140821679	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs11958868	ENSG00000202515.1	VTRNA1-3	-6.52	1.78e-10	4.23e-08	-0.33	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140821835	chr5:140726158~140726246:+
THCA	cis	rs1552244	0.882	rs13099136	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:9989747	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.51	rs13075308	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:9993241	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.808	rs7615088	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:9994212	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs61429272	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:9995636	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.626	rs2886396	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:9995986	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs9757159	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:9997482	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.816	rs17050701	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:9999870	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs55840655	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:10001006	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.816	rs56387520	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:10001098	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs56224841	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:10002330	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs13088350	ENSG00000232901.1	CYCSP10	6.52	1.78e-10	4.23e-08	0.36	0.29	Alzheimer's disease;	chr3:10002942	chr3:10000647~10000940:-
THCA	cis	rs2243480	1	rs160643	ENSG00000228409.4	CCT6P1	6.52	1.78e-10	4.23e-08	0.33	0.29	Diabetic kidney disease;	chr7:66093235	chr7:65751142~65763354:+
THCA	cis	rs28386778	0.897	rs6504177	ENSG00000240280.5	TCAM1P	-6.52	1.79e-10	4.24e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63735295	chr17:63849292~63864379:+
THCA	cis	rs7131987	0.903	rs11050152	ENSG00000257176.2	RP11-996F15.2	-6.52	1.79e-10	4.24e-08	-0.29	-0.29	QT interval;	chr12:29251491	chr12:29280418~29317848:-
THCA	cis	rs2348418	0.932	rs11049661	ENSG00000247934.4	RP11-967K21.1	6.52	1.79e-10	4.24e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28486215	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.932	rs7306581	ENSG00000247934.4	RP11-967K21.1	6.52	1.79e-10	4.24e-08	0.26	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28488641	chr12:28163298~28190738:-
THCA	cis	rs4143844	1	rs17271291	ENSG00000259251.2	RP11-643M14.1	6.52	1.79e-10	4.24e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:61982818	chr15:62060503~62062434:+
THCA	cis	rs7773456	0.74	rs4140625	ENSG00000237404.1	RP3-471C18.2	6.52	1.79e-10	4.25e-08	0.35	0.29	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19689825~19753113:-
THCA	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	6.52	1.79e-10	4.26e-08	0.37	0.29	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
THCA	cis	rs7267979	0.816	rs6076358	ENSG00000274414.1	RP5-965G21.4	6.52	1.8e-10	4.26e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25239007~25245229:-
THCA	cis	rs5742933	0.762	rs2033746	ENSG00000273240.1	RP11-455J20.3	6.52	1.8e-10	4.26e-08	0.29	0.29	Ferritin levels;	chr2:189734726	chr2:189763859~189764456:-
THCA	cis	rs3204270	0.639	rs7216239	ENSG00000262049.1	RP13-1032I1.7	6.52	1.8e-10	4.27e-08	0.26	0.29	Dental caries;	chr17:81693157	chr17:81701324~81703300:-
THCA	cis	rs595244	1	rs595244	ENSG00000259705.1	RP11-227D13.1	6.52	1.8e-10	4.27e-08	0.52	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48548638	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs1561207	ENSG00000259705.1	RP11-227D13.1	6.52	1.8e-10	4.27e-08	0.52	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48566774	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs2437947	ENSG00000259705.1	RP11-227D13.1	6.52	1.8e-10	4.27e-08	0.52	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48584684	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs627634	ENSG00000259705.1	RP11-227D13.1	6.52	1.8e-10	4.27e-08	0.52	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48587094	chr15:48645951~48652016:+
THCA	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	6.52	1.8e-10	4.27e-08	0.38	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
THCA	cis	rs1198872	0.558	rs10929699	ENSG00000272275.1	RP11-791G15.2	-6.52	1.8e-10	4.27e-08	-0.35	-0.29	Cardiac Troponin-T levels;	chr2:10778083	chr2:10767875~10770058:-
THCA	cis	rs4835473	0.9	rs6834494	ENSG00000251600.4	RP11-673E1.1	-6.52	1.8e-10	4.27e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143822257	chr4:143912331~143982454:+
THCA	cis	rs853679	0.607	rs35749575	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28147040	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs72846780	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28151277	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13205911	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28156336	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13197176	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28161454	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs13201308	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28162311	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34765154	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28162672	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs34505829	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28165461	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs35098436	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28166443	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs72846794	ENSG00000280107.1	AL022393.9	-6.52	1.8e-10	4.27e-08	-0.58	-0.29	Depression;	chr6:28169721	chr6:28170845~28172521:+
THCA	cis	rs801193	0.569	rs35070132	ENSG00000232559.3	GS1-124K5.12	6.52	1.8e-10	4.27e-08	0.28	0.29	Aortic root size;	chr7:66773096	chr7:66554588~66576923:-
THCA	cis	rs438465	1	rs454974	ENSG00000226194.4	RP1-137D17.1	6.52	1.8e-10	4.28e-08	0.43	0.29	Corneal astigmatism;	chr6:169412263	chr6:169369998~169388385:-
THCA	cis	rs4266144	1	rs4561781	ENSG00000241770.1	RP11-555M1.3	6.52	1.81e-10	4.28e-08	0.36	0.29	Coronary artery disease;	chr3:157135154	chr3:157163452~157169133:+
THCA	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	6.52	1.81e-10	4.28e-08	0.32	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
THCA	cis	rs11668609	1	rs11668609	ENSG00000268442.1	CTD-2027I19.2	6.52	1.81e-10	4.28e-08	0.34	0.29	Response to taxane treatment (docetaxel);	chr19:24172691	chr19:24162370~24163425:-
THCA	cis	rs2243480	1	rs4548056	ENSG00000229886.1	RP5-1132H15.3	6.52	1.81e-10	4.29e-08	0.46	0.29	Diabetic kidney disease;	chr7:65833886	chr7:66025126~66031544:-
THCA	cis	rs7267979	0.816	rs390123	ENSG00000274414.1	RP5-965G21.4	-6.52	1.81e-10	4.29e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.816	rs404775	ENSG00000274414.1	RP5-965G21.4	-6.52	1.81e-10	4.29e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25239007~25245229:-
THCA	cis	rs7247513	0.658	rs4804728	ENSG00000213290.4	PGK1P2	-6.52	1.81e-10	4.29e-08	-0.34	-0.29	Bipolar disorder;	chr19:12642114	chr19:12559571~12561105:+
THCA	cis	rs9800506	0.624	rs77137655	ENSG00000228559.1	RP3-340B19.3	6.52	1.81e-10	4.29e-08	0.41	0.29	Neutrophil percentage of granulocytes;	chr6:35542482	chr6:35544632~35545669:+
THCA	cis	rs9475752	1	rs17752459	ENSG00000231441.1	RP11-472M19.2	6.52	1.81e-10	4.3e-08	0.36	0.29	Menarche (age at onset);	chr6:56933957	chr6:56844002~56864078:+
THCA	cis	rs526231	0.853	rs187579	ENSG00000175749.11	EIF3KP1	6.52	1.82e-10	4.3e-08	0.39	0.29	Primary biliary cholangitis;	chr5:103269232	chr5:103032376~103033031:+
THCA	cis	rs2120243	0.539	rs9990136	ENSG00000244515.1	KRT18P34	-6.52	1.82e-10	4.3e-08	-0.34	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157358045	chr3:157162663~157163932:-
THCA	cis	rs4767841	0.552	rs10849682	ENSG00000248636.5	RP11-768F21.1	-6.52	1.82e-10	4.3e-08	-0.3	-0.29	Urgency urinary incontinence;	chr12:119622325	chr12:119387987~119668079:-
THCA	cis	rs9388451	0.537	rs1739383	ENSG00000237742.5	RP11-624M8.1	-6.52	1.82e-10	4.3e-08	-0.25	-0.29	Brugada syndrome;	chr6:125777769	chr6:125578558~125749190:-
THCA	cis	rs7045881	0.558	rs17694631	ENSG00000254396.1	RP11-56F10.3	-6.52	1.82e-10	4.31e-08	-0.44	-0.29	Schizophrenia;	chr9:27066072	chr9:27102630~27104728:+
THCA	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	6.52	1.82e-10	4.31e-08	0.37	0.29	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
THCA	cis	rs1876905	0.68	rs187130	ENSG00000255389.1	C6orf3	6.52	1.82e-10	4.31e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111599875~111602295:+
THCA	cis	rs71636778	0.509	rs71514277	ENSG00000260063.1	RP5-968P14.2	-6.52	1.82e-10	4.31e-08	-0.56	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26707937	chr1:26692132~26694131:-
THCA	cis	rs2243480	1	rs13247184	ENSG00000228409.4	CCT6P1	6.52	1.82e-10	4.32e-08	0.33	0.29	Diabetic kidney disease;	chr7:65893941	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs35283677	ENSG00000228409.4	CCT6P1	6.52	1.82e-10	4.32e-08	0.33	0.29	Diabetic kidney disease;	chr7:65894246	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs35421653	ENSG00000228409.4	CCT6P1	6.52	1.82e-10	4.32e-08	0.33	0.29	Diabetic kidney disease;	chr7:65898442	chr7:65751142~65763354:+
THCA	cis	rs6565180	1	rs8049108	ENSG00000273724.1	RP11-347C12.12	-6.52	1.82e-10	4.32e-08	-0.29	-0.29	Tonsillectomy;	chr16:30365165	chr16:30336400~30343336:+
THCA	cis	rs2120243	0.592	rs7618502	ENSG00000244515.1	KRT18P34	-6.52	1.82e-10	4.32e-08	-0.33	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157377755	chr3:157162663~157163932:-
THCA	cis	rs10799445	0.531	rs6697867	ENSG00000227711.2	RP11-275O4.5	6.52	1.83e-10	4.32e-08	0.3	0.29	Height;	chr1:227557973	chr1:227509028~227520477:-
THCA	cis	rs2562456	0.833	rs1626404	ENSG00000268555.1	RP11-678G14.3	6.52	1.83e-10	4.33e-08	0.47	0.29	Pain;	chr19:21300986	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs1781867	ENSG00000268555.1	RP11-678G14.3	6.52	1.83e-10	4.33e-08	0.47	0.29	Pain;	chr19:21304368	chr19:21570822~21587322:-
THCA	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-6.52	1.83e-10	4.33e-08	-0.3	-0.29	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
THCA	cis	rs2282300	0.956	rs1222212	ENSG00000242353.1	RP4-710M3.1	-6.52	1.83e-10	4.34e-08	-0.26	-0.29	Morning vs. evening chronotype;	chr11:30353096	chr11:30368148~30368646:+
THCA	cis	rs6840258	0.76	rs340650	ENSG00000251411.1	RP11-397E7.4	6.52	1.83e-10	4.34e-08	0.31	0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87017533	chr4:86913266~86914817:-
THCA	cis	rs7746199	0.673	rs35501037	ENSG00000226314.6	ZNF192P1	-6.52	1.83e-10	4.34e-08	-0.63	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28161781~28169594:+
THCA	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	6.52	1.84e-10	4.35e-08	0.33	0.29	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
THCA	cis	rs4650994	0.525	rs4993304	ENSG00000273384.1	RP5-1098D14.1	6.52	1.84e-10	4.36e-08	0.36	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178566009	chr1:178651706~178652282:+
THCA	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-6.52	1.84e-10	4.36e-08	-0.26	-0.29	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
THCA	cis	rs6603134	0.502	rs10405588	ENSG00000269139.2	CTD-3193O13.8	6.52	1.84e-10	4.36e-08	0.27	0.29	Blood protein levels;	chr19:8038663	chr19:7926001~7926810:+
THCA	cis	rs2243480	1	rs3885839	ENSG00000228409.4	CCT6P1	6.52	1.84e-10	4.36e-08	0.34	0.29	Diabetic kidney disease;	chr7:65825416	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs73142122	ENSG00000228409.4	CCT6P1	6.52	1.84e-10	4.36e-08	0.34	0.29	Diabetic kidney disease;	chr7:65846311	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs73142137	ENSG00000228409.4	CCT6P1	6.52	1.84e-10	4.36e-08	0.34	0.29	Diabetic kidney disease;	chr7:65878455	chr7:65751142~65763354:+
THCA	cis	rs11096990	0.793	rs9997050	ENSG00000249207.1	RP11-360F5.1	6.52	1.84e-10	4.36e-08	0.38	0.29	Cognitive function;	chr4:39301045	chr4:39112677~39126818:-
THCA	cis	rs72843506	0.656	rs78325601	ENSG00000270091.1	RP11-78O7.2	-6.52	1.84e-10	4.36e-08	-0.34	-0.29	Schizophrenia;	chr17:20018486	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs74648067	ENSG00000270091.1	RP11-78O7.2	-6.52	1.84e-10	4.36e-08	-0.34	-0.29	Schizophrenia;	chr17:20022938	chr17:19896590~19897287:-
THCA	cis	rs5742933	0.817	rs4667297	ENSG00000273240.1	RP11-455J20.3	6.52	1.84e-10	4.36e-08	0.3	0.29	Ferritin levels;	chr2:189664270	chr2:189763859~189764456:-
THCA	cis	rs7826238	0.543	rs2976908	ENSG00000254153.1	CTA-398F10.2	-6.52	1.85e-10	4.37e-08	-0.33	-0.29	Systolic blood pressure;	chr8:8488264	chr8:8456909~8461337:-
THCA	cis	rs1865760	1	rs2071301	ENSG00000272462.2	U91328.19	-6.52	1.85e-10	4.38e-08	-0.24	-0.29	Height;	chr6:25914035	chr6:25992662~26001775:+
THCA	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-6.52	1.85e-10	4.38e-08	-0.4	-0.29	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
THCA	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-6.52	1.85e-10	4.38e-08	-0.4	-0.29	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
THCA	cis	rs2303319	1	rs3769959	ENSG00000227403.1	AC009299.3	-6.52	1.85e-10	4.38e-08	-0.61	-0.29	Cognitive function;	chr2:161392695	chr2:161244739~161249050:+
THCA	cis	rs797680	0.789	rs35940311	ENSG00000223745.6	RP4-717I23.3	6.52	1.85e-10	4.38e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93198047	chr1:93262186~93346025:-
THCA	cis	rs10208649	1	rs13417051	ENSG00000272156.1	RP11-477N3.1	-6.52	1.85e-10	4.39e-08	-0.5	-0.29	Body mass index;	chr2:53874635	chr2:54082554~54085066:+
THCA	cis	rs748404	0.631	rs6493086	ENSG00000166763.7	STRCP1	6.52	1.86e-10	4.39e-08	0.31	0.29	Lung cancer;	chr15:43363196	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs6493090	ENSG00000249839.1	AC011330.5	6.52	1.86e-10	4.39e-08	0.42	0.29	Lung cancer;	chr15:43792084	chr15:43663654~43684339:-
THCA	cis	rs7403037	1	rs9788767	ENSG00000259905.4	PWRN1	6.52	1.86e-10	4.4e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24516306	chr15:24493137~24652130:+
THCA	cis	rs7267979	0.816	rs422148	ENSG00000274414.1	RP5-965G21.4	-6.52	1.86e-10	4.4e-08	-0.33	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25239007~25245229:-
THCA	cis	rs13113518	0.812	rs12500686	ENSG00000273257.1	RP11-177J6.1	6.52	1.86e-10	4.4e-08	0.4	0.29	Height;	chr4:55457922	chr4:55387949~55388271:+
THCA	cis	rs3806843	1	rs2879089	ENSG00000202515.1	VTRNA1-3	-6.52	1.86e-10	4.41e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140812308	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs11167609	ENSG00000202515.1	VTRNA1-3	-6.52	1.86e-10	4.41e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140820841	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs6885319	ENSG00000202515.1	VTRNA1-3	-6.52	1.86e-10	4.41e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140821026	chr5:140726158~140726246:+
THCA	cis	rs75422866	0.867	rs57848393	ENSG00000274902.1	RP1-197B17.4	6.52	1.86e-10	4.41e-08	0.62	0.29	Pneumonia;	chr12:47714734	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.764	rs67201012	ENSG00000274902.1	RP1-197B17.4	6.52	1.86e-10	4.41e-08	0.62	0.29	Pneumonia;	chr12:47715881	chr12:47731908~47732351:+
THCA	cis	rs2348418	0.831	rs1581074	ENSG00000247934.4	RP11-967K21.1	6.52	1.86e-10	4.41e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28571031	chr12:28163298~28190738:-
THCA	cis	rs12435908	1	rs12433827	ENSG00000276116.2	FUT8-AS1	-6.52	1.86e-10	4.41e-08	-0.48	-0.29	Ischemic stroke;	chr14:65588892	chr14:65411170~65412690:-
THCA	cis	rs227275	0.525	rs223461	ENSG00000230069.3	LRRC37A15P	-6.52	1.87e-10	4.41e-08	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102727274~102730721:-
THCA	cis	rs683257	0.636	rs58922657	ENSG00000234147.1	RP3-460G2.2	-6.52	1.87e-10	4.41e-08	-0.44	-0.29	Facial emotion recognition (angry faces);	chr6:140831739	chr6:140845958~140852924:-
THCA	cis	rs1594829	0.553	rs2046226	ENSG00000228451.3	SDAD1P1	6.52	1.87e-10	4.41e-08	0.29	0.29	Height;	chr8:26294534	chr8:26379259~26382953:-
THCA	cis	rs1594829	0.535	rs1434022	ENSG00000228451.3	SDAD1P1	6.52	1.87e-10	4.41e-08	0.29	0.29	Height;	chr8:26295706	chr8:26379259~26382953:-
THCA	cis	rs1594829	0.553	rs6996531	ENSG00000228451.3	SDAD1P1	6.52	1.87e-10	4.41e-08	0.29	0.29	Height;	chr8:26295939	chr8:26379259~26382953:-
THCA	cis	rs944990	0.557	rs10821155	ENSG00000227603.1	RP11-165J3.6	6.52	1.87e-10	4.42e-08	0.3	0.29	Body mass index;	chr9:93541996	chr9:93435332~93437121:-
THCA	cis	rs6545883	0.929	rs13413337	ENSG00000271889.1	RP11-493E12.1	6.52	1.87e-10	4.42e-08	0.27	0.29	Tuberculosis;	chr2:61519988	chr2:61151433~61162105:-
THCA	cis	rs4266144	0.592	rs1545854	ENSG00000241770.1	RP11-555M1.3	6.52	1.87e-10	4.42e-08	0.41	0.29	Coronary artery disease;	chr3:157122349	chr3:157163452~157169133:+
THCA	cis	rs4143844	0.867	rs11629900	ENSG00000259251.2	RP11-643M14.1	6.52	1.87e-10	4.42e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:61954938	chr15:62060503~62062434:+
THCA	cis	rs4143844	1	rs34556569	ENSG00000259251.2	RP11-643M14.1	6.52	1.87e-10	4.42e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:61989619	chr15:62060503~62062434:+
THCA	cis	rs4143844	1	rs62007791	ENSG00000259251.2	RP11-643M14.1	6.52	1.87e-10	4.42e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:61992487	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs35259011	ENSG00000259251.2	RP11-643M14.1	6.52	1.87e-10	4.42e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:61993260	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs34257602	ENSG00000259251.2	RP11-643M14.1	6.52	1.87e-10	4.42e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:61993548	chr15:62060503~62062434:+
THCA	cis	rs4143844	1	rs34424197	ENSG00000259251.2	RP11-643M14.1	6.52	1.87e-10	4.42e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:61996620	chr15:62060503~62062434:+
THCA	cis	rs56046484	0.75	rs7173332	ENSG00000259295.5	CSPG4P12	6.52	1.87e-10	4.42e-08	0.52	0.29	Testicular germ cell tumor;	chr15:84978503	chr15:85191438~85213905:+
THCA	cis	rs4835473	0.722	rs7666296	ENSG00000251600.4	RP11-673E1.1	-6.52	1.87e-10	4.42e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143999004	chr4:143912331~143982454:+
THCA	cis	rs848490	0.962	rs55759218	ENSG00000214293.7	APTR	6.52	1.87e-10	4.42e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77824040	chr7:77657660~77696265:-
THCA	cis	rs848490	0.962	rs11765656	ENSG00000214293.7	APTR	6.52	1.87e-10	4.42e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77827673	chr7:77657660~77696265:-
THCA	cis	rs4819052	0.788	rs9978857	ENSG00000237664.1	LINC00316	-6.52	1.87e-10	4.42e-08	-0.3	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45338590~45341990:-
THCA	cis	rs6840360	0.642	rs11099815	ENSG00000251611.1	RP11-610P16.1	-6.52	1.87e-10	4.42e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151407551~151408835:-
THCA	cis	rs1552244	0.882	rs55808392	ENSG00000180385.7	EMC3-AS1	6.52	1.87e-10	4.43e-08	0.3	0.29	Alzheimer's disease;	chr3:10012997	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs13075842	ENSG00000180385.7	EMC3-AS1	6.52	1.87e-10	4.43e-08	0.3	0.29	Alzheimer's disease;	chr3:10014129	chr3:9986893~10006990:+
THCA	cis	rs494459	0.536	rs7103067	ENSG00000255422.1	AP002954.4	-6.52	1.87e-10	4.43e-08	-0.3	-0.29	Height;	chr11:118852670	chr11:118704607~118750263:+
THCA	cis	rs6840360	0.642	rs7666571	ENSG00000251611.1	RP11-610P16.1	-6.51	1.88e-10	4.44e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151407551~151408835:-
THCA	cis	rs4819052	0.634	rs8128636	ENSG00000237664.1	LINC00316	-6.51	1.88e-10	4.44e-08	-0.28	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45338590~45341990:-
THCA	cis	rs7688540	0.8	rs10028482	ENSG00000211553.1	AC253576.2	-6.51	1.88e-10	4.44e-08	-0.39	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:136461~136568:+
THCA	cis	rs202072	0.729	rs8541	ENSG00000272379.1	RP1-257A7.5	6.51	1.88e-10	4.44e-08	0.47	0.29	HIV-1 viral setpoint;	chr6:13290006	chr6:13290018~13290490:-
THCA	cis	rs6840360	0.667	rs9994482	ENSG00000251611.1	RP11-610P16.1	-6.51	1.88e-10	4.44e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151407551~151408835:-
THCA	cis	rs11672691	0.67	rs4802119	ENSG00000267107.5	PCAT19	6.51	1.88e-10	4.45e-08	0.32	0.29	Prostate cancer;	chr19:41484417	chr19:41454169~41500649:-
THCA	cis	rs797680	0.856	rs12118262	ENSG00000223745.6	RP4-717I23.3	-6.51	1.88e-10	4.45e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93185990	chr1:93262186~93346025:-
THCA	cis	rs6977955	1	rs740122	ENSG00000234336.5	JAZF1-AS1	-6.51	1.88e-10	4.45e-08	-0.33	-0.29	Allergic disease (asthma, hay fever or eczema);	chr7:28126823	chr7:28180322~28243917:+
THCA	cis	rs2243480	1	rs778729	ENSG00000228409.4	CCT6P1	6.51	1.88e-10	4.45e-08	0.34	0.29	Diabetic kidney disease;	chr7:66359432	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs778687	ENSG00000228409.4	CCT6P1	6.51	1.88e-10	4.45e-08	0.34	0.29	Diabetic kidney disease;	chr7:66370832	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs778679	ENSG00000228409.4	CCT6P1	6.51	1.88e-10	4.45e-08	0.34	0.29	Diabetic kidney disease;	chr7:66375924	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs778704	ENSG00000228409.4	CCT6P1	6.51	1.88e-10	4.45e-08	0.34	0.29	Diabetic kidney disease;	chr7:66398480	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs778693	ENSG00000228409.4	CCT6P1	6.51	1.88e-10	4.45e-08	0.34	0.29	Diabetic kidney disease;	chr7:66407358	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs778691	ENSG00000228409.4	CCT6P1	6.51	1.88e-10	4.45e-08	0.34	0.29	Diabetic kidney disease;	chr7:66408105	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs13235972	ENSG00000228409.4	CCT6P1	6.51	1.88e-10	4.45e-08	0.34	0.29	Diabetic kidney disease;	chr7:66418618	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs34192067	ENSG00000228409.4	CCT6P1	6.51	1.88e-10	4.45e-08	0.34	0.29	Diabetic kidney disease;	chr7:66422670	chr7:65751142~65763354:+
THCA	cis	rs10491083	0.661	rs55748285	ENSG00000256806.3	C17orf100	-6.51	1.88e-10	4.45e-08	-0.49	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6654010	chr17:6651718~6653473:+
THCA	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	6.51	1.88e-10	4.45e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
THCA	cis	rs5769707	0.521	rs6009807	ENSG00000235111.1	RP1-29C18.8	-6.51	1.88e-10	4.45e-08	-0.36	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49612657~49615716:-
THCA	cis	rs3750082	0.582	rs7800883	ENSG00000231952.3	DPY19L1P2	6.51	1.88e-10	4.46e-08	0.38	0.29	Glomerular filtration rate (creatinine);	chr7:32931670	chr7:32812757~32838570:+
THCA	cis	rs7948661	1	rs9332816	ENSG00000278376.1	RP11-158I9.8	6.51	1.89e-10	4.46e-08	0.45	0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118493689	chr11:118791254~118793137:+
THCA	cis	rs793571	0.505	rs9635351	ENSG00000259250.1	RP11-50C13.1	-6.51	1.89e-10	4.47e-08	-0.31	-0.29	Schizophrenia;	chr15:58625762	chr15:58587507~58591676:+
THCA	cis	rs6866614	0.605	rs5029422	ENSG00000237714.1	P4HA2-AS1	6.51	1.89e-10	4.47e-08	0.42	0.29	Perceived unattractiveness to mosquitoes;	chr5:132054921	chr5:132184876~132192808:+
THCA	cis	rs847577	0.609	rs6965016	ENSG00000272950.1	RP11-307C18.1	6.51	1.89e-10	4.47e-08	0.36	0.29	Breast cancer;	chr7:98178570	chr7:98322853~98323430:+
THCA	cis	rs847577	0.609	rs6465657	ENSG00000272950.1	RP11-307C18.1	6.51	1.89e-10	4.47e-08	0.36	0.29	Breast cancer;	chr7:98187015	chr7:98322853~98323430:+
THCA	cis	rs860295	0.775	rs822509	ENSG00000225855.5	RUSC1-AS1	-6.51	1.89e-10	4.48e-08	-0.19	-0.29	Body mass index;	chr1:155881020	chr1:155316863~155324176:-
THCA	cis	rs7617773	0.746	rs11713476	ENSG00000228638.1	FCF1P2	-6.51	1.89e-10	4.48e-08	-0.27	-0.29	Coronary artery disease;	chr3:48333944	chr3:48290793~48291375:-
THCA	cis	rs8141529	0.732	rs5762815	ENSG00000226471.5	CTA-292E10.6	-6.51	1.9e-10	4.48e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28809088	chr22:28800683~28848559:+
THCA	cis	rs2243480	1	rs2707844	ENSG00000228409.4	CCT6P1	6.51	1.9e-10	4.48e-08	0.34	0.29	Diabetic kidney disease;	chr7:66594522	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1796220	ENSG00000228409.4	CCT6P1	6.51	1.9e-10	4.48e-08	0.34	0.29	Diabetic kidney disease;	chr7:66597113	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs2707831	ENSG00000228409.4	CCT6P1	6.51	1.9e-10	4.48e-08	0.34	0.29	Diabetic kidney disease;	chr7:66597524	chr7:65751142~65763354:+
THCA	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	6.51	1.9e-10	4.48e-08	0.35	0.29	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
THCA	cis	rs2412819	0.571	rs514255	ENSG00000205771.5	CATSPER2P1	-6.51	1.9e-10	4.48e-08	-0.38	-0.29	Lung cancer;	chr15:43893134	chr15:43726918~43747094:-
THCA	cis	rs7044106	0.708	rs959558	ENSG00000270917.1	RP11-27I1.6	-6.51	1.9e-10	4.49e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120812475~120812845:-
THCA	cis	rs11148252	0.574	rs61958118	ENSG00000278238.1	RP11-245D16.4	-6.51	1.9e-10	4.49e-08	-0.32	-0.29	Lewy body disease;	chr13:52596091	chr13:52454775~52455331:-
THCA	cis	rs6496044	0.548	rs7163032	ENSG00000259295.5	CSPG4P12	6.51	1.9e-10	4.49e-08	0.36	0.29	Interstitial lung disease;	chr15:85529188	chr15:85191438~85213905:+
THCA	cis	rs2006933	0.612	rs9894461	ENSG00000237575.4	PYY2	6.51	1.9e-10	4.49e-08	0.37	0.29	Amyotrophic lateral sclerosis;	chr17:28158043	chr17:28226563~28228065:+
THCA	cis	rs16843372	0.599	rs7603880	ENSG00000251491.2	OR7E28P	-6.51	1.9e-10	4.5e-08	-0.38	-0.29	Obesity-related traits;	chr2:158818293	chr2:158862311~158863285:+
THCA	cis	rs8113308	0.515	rs60581730	ENSG00000269235.1	ZNF350-AS1	6.51	1.91e-10	4.5e-08	0.54	0.29	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51937883	chr19:51949134~51981367:+
THCA	cis	rs7403037	0.959	rs35600665	ENSG00000259905.4	PWRN1	6.51	1.91e-10	4.5e-08	0.32	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24496144	chr15:24493137~24652130:+
THCA	cis	rs4908760	0.773	rs301805	ENSG00000232912.4	RP5-1115A15.1	6.51	1.91e-10	4.51e-08	0.29	0.29	Vitiligo;	chr1:8420956	chr1:8424645~8434838:+
THCA	cis	rs16846053	0.71	rs11891026	ENSG00000227403.1	AC009299.3	6.51	1.91e-10	4.51e-08	0.46	0.29	Blood osmolality (transformed sodium);	chr2:161735366	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs1551052	ENSG00000227403.1	AC009299.3	6.51	1.91e-10	4.51e-08	0.46	0.29	Cognitive function;	chr2:161736144	chr2:161244739~161249050:+
THCA	cis	rs9677476	0.909	rs60240472	ENSG00000224376.1	AC017104.6	6.51	1.91e-10	4.51e-08	0.33	0.29	Food antigen IgG levels;	chr2:231266504	chr2:231388976~231394991:+
THCA	cis	rs9843304	0.967	rs12633863	ENSG00000244503.1	RP11-278L15.6	-6.51	1.91e-10	4.51e-08	-0.36	-0.29	Gallstone disease;	chr3:149493725	chr3:149494660~149495995:+
THCA	cis	rs6545883	0.931	rs12713438	ENSG00000271889.1	RP11-493E12.1	6.51	1.91e-10	4.52e-08	0.28	0.29	Tuberculosis;	chr2:61498366	chr2:61151433~61162105:-
THCA	cis	rs9287719	0.649	rs12617968	ENSG00000243819.4	RN7SL832P	-6.51	1.91e-10	4.52e-08	-0.4	-0.29	Prostate cancer;	chr2:10581819	chr2:10690344~10692099:+
THCA	cis	rs1005277	1	rs1005277	ENSG00000263064.2	RP11-291L22.7	-6.51	1.91e-10	4.52e-08	-0.35	-0.29	Extrinsic epigenetic age acceleration;	chr10:37929331	chr10:38448689~38448949:+
THCA	cis	rs9402743	0.634	rs2327647	ENSG00000231028.7	LINC00271	6.51	1.91e-10	4.52e-08	0.23	0.29	Systemic lupus erythematosus;	chr6:135597296	chr6:135497801~135716055:+
THCA	cis	rs728616	0.867	rs28365998	ENSG00000242600.5	MBL1P	6.51	1.91e-10	4.52e-08	0.42	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:79904898~79950336:+
THCA	cis	rs10510102	0.507	rs12244092	ENSG00000276742.1	RP11-500G22.4	6.51	1.91e-10	4.52e-08	0.43	0.29	Breast cancer;	chr10:122005769	chr10:121956782~121957098:+
THCA	cis	rs7851660	0.809	rs10115216	ENSG00000236130.1	PTCSC2	6.51	1.91e-10	4.52e-08	0.23	0.29	Strep throat;	chr9:97894837	chr9:97805935~97810008:-
THCA	cis	rs9867325	1	rs9867325	ENSG00000273486.1	RP11-731C17.2	6.51	1.92e-10	4.52e-08	0.3	0.29	Body mass index;	chr3:136900067	chr3:136837338~136839021:-
THCA	cis	rs9867325	1	rs9840500	ENSG00000273486.1	RP11-731C17.2	6.51	1.92e-10	4.52e-08	0.3	0.29	Body mass index;	chr3:136902496	chr3:136837338~136839021:-
THCA	cis	rs7044106	0.762	rs13291660	ENSG00000270917.1	RP11-27I1.6	-6.51	1.92e-10	4.53e-08	-0.41	-0.29	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120812475~120812845:-
THCA	cis	rs58785573	1	rs58785573	ENSG00000231160.8	KLF3-AS1	-6.51	1.92e-10	4.53e-08	-0.16	-0.29	Lymphocyte percentage of white cells;	chr4:38652152	chr4:38612701~38664883:-
THCA	cis	rs9926296	0.508	rs1558184	ENSG00000260259.1	RP11-368I7.4	-6.51	1.92e-10	4.53e-08	-0.31	-0.29	Vitiligo;	chr16:89775966	chr16:89682620~89686569:-
THCA	cis	rs6479891	1	rs9415680	ENSG00000232075.1	MRPL35P2	-6.51	1.92e-10	4.54e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63634317~63634827:-
THCA	cis	rs11096990	0.855	rs75746161	ENSG00000249207.1	RP11-360F5.1	6.51	1.92e-10	4.54e-08	0.38	0.29	Cognitive function;	chr4:39167481	chr4:39112677~39126818:-
THCA	cis	rs7045881	0.825	rs10967625	ENSG00000254396.1	RP11-56F10.3	6.51	1.92e-10	4.54e-08	0.42	0.29	Schizophrenia;	chr9:26962490	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.799	rs12352441	ENSG00000254396.1	RP11-56F10.3	6.51	1.92e-10	4.54e-08	0.42	0.29	Schizophrenia;	chr9:26962771	chr9:27102630~27104728:+
THCA	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-6.51	1.92e-10	4.54e-08	-0.37	-0.29	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
THCA	cis	rs7015630	0.657	rs34970073	ENSG00000251136.7	RP11-37B2.1	-6.51	1.92e-10	4.54e-08	-0.33	-0.29	Inflammatory bowel disease;Crohn's disease;	chr8:89825134	chr8:89609409~89757727:-
THCA	cis	rs6928977	0.538	rs9494290	ENSG00000231028.7	LINC00271	-6.51	1.92e-10	4.54e-08	-0.24	-0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135596407	chr6:135497801~135716055:+
THCA	cis	rs12701220	0.541	rs12535516	ENSG00000229043.2	AC091729.9	-6.51	1.92e-10	4.54e-08	-0.44	-0.29	Bronchopulmonary dysplasia;	chr7:1074804	chr7:1160374~1165267:+
THCA	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	6.51	1.93e-10	4.55e-08	0.34	0.29	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
THCA	cis	rs16949788	0.793	rs78198355	ENSG00000261351.2	CTD-3185P2.1	-6.51	1.93e-10	4.55e-08	-0.34	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66393470	chr15:66488658~66492109:-
THCA	cis	rs453301	0.522	rs1964356	ENSG00000253893.2	FAM85B	-6.51	1.93e-10	4.55e-08	-0.36	-0.29	Joint mobility (Beighton score);	chr8:8995760	chr8:8167819~8226614:-
THCA	cis	rs3764021	0.527	rs3764022	ENSG00000256594.6	RP11-705C15.2	6.51	1.93e-10	4.56e-08	0.24	0.29	Type 1 diabetes;	chr12:9680928	chr12:9633419~9658412:+
THCA	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	6.51	1.93e-10	4.56e-08	0.4	0.29	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
THCA	cis	rs1707322	0.686	rs1250	ENSG00000281133.1	AL355480.3	-6.51	1.93e-10	4.56e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45580892~45580996:-
THCA	cis	rs3764021	0.509	rs10844569	ENSG00000256594.6	RP11-705C15.2	6.51	1.93e-10	4.56e-08	0.25	0.29	Type 1 diabetes;	chr12:9717756	chr12:9633419~9658412:+
THCA	cis	rs7267979	0.753	rs400357	ENSG00000274414.1	RP5-965G21.4	-6.51	1.93e-10	4.57e-08	-0.33	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25239007~25245229:-
THCA	cis	rs6545883	0.759	rs777585	ENSG00000271889.1	RP11-493E12.1	-6.51	1.93e-10	4.57e-08	-0.27	-0.29	Tuberculosis;	chr2:61185424	chr2:61151433~61162105:-
THCA	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-6.51	1.93e-10	4.57e-08	-0.17	-0.29	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
THCA	cis	rs6545883	0.894	rs2694643	ENSG00000271889.1	RP11-493E12.1	6.51	1.94e-10	4.57e-08	0.28	0.29	Tuberculosis;	chr2:61377248	chr2:61151433~61162105:-
THCA	cis	rs797680	0.856	rs10874762	ENSG00000223745.6	RP4-717I23.3	6.51	1.94e-10	4.57e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93173544	chr1:93262186~93346025:-
THCA	cis	rs1876905	0.68	rs402940	ENSG00000255389.1	C6orf3	6.51	1.94e-10	4.58e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111599875~111602295:+
THCA	cis	rs1234598	1	rs1234598	ENSG00000255389.1	C6orf3	6.51	1.94e-10	4.58e-08	0.34	0.29	Mean corpuscular volume;	chr6:111208250	chr6:111599875~111602295:+
THCA	cis	rs1876905	0.68	rs354543	ENSG00000255389.1	C6orf3	6.51	1.94e-10	4.58e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111599875~111602295:+
THCA	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	6.51	1.94e-10	4.58e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
THCA	cis	rs9329221	0.513	rs4841296	ENSG00000261451.1	RP11-981G7.1	-6.51	1.94e-10	4.58e-08	-0.36	-0.29	Neuroticism;	chr8:10247937	chr8:10433672~10438312:+
THCA	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-6.51	1.94e-10	4.59e-08	-0.17	-0.29	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
THCA	cis	rs4664293	0.764	rs10195287	ENSG00000226266.5	AC009961.3	-6.51	1.95e-10	4.59e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159604967	chr2:159670708~159712435:-
THCA	cis	rs2243480	0.901	rs3813708	ENSG00000228409.4	CCT6P1	6.51	1.95e-10	4.59e-08	0.34	0.29	Diabetic kidney disease;	chr7:65840645	chr7:65751142~65763354:+
THCA	cis	rs8141529	0.644	rs5752795	ENSG00000226471.5	CTA-292E10.6	-6.51	1.95e-10	4.59e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28782832	chr22:28800683~28848559:+
THCA	cis	rs1552244	0.882	rs28366039	ENSG00000180385.7	EMC3-AS1	6.51	1.95e-10	4.6e-08	0.31	0.29	Alzheimer's disease;	chr3:9987304	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs3755783	ENSG00000180385.7	EMC3-AS1	6.51	1.95e-10	4.6e-08	0.31	0.29	Alzheimer's disease;	chr3:9987605	chr3:9986893~10006990:+
THCA	cis	rs9843304	1	rs9843304	ENSG00000244503.1	RP11-278L15.6	-6.51	1.95e-10	4.6e-08	-0.36	-0.29	Gallstone disease;	chr3:149493600	chr3:149494660~149495995:+
THCA	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	6.51	1.95e-10	4.6e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
THCA	cis	rs438465	0.947	rs438217	ENSG00000226194.4	RP1-137D17.1	6.51	1.95e-10	4.6e-08	0.44	0.29	Corneal astigmatism;	chr6:169415854	chr6:169369998~169388385:-
THCA	cis	rs3806843	0.966	rs3756341	ENSG00000202515.1	VTRNA1-3	-6.51	1.95e-10	4.6e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140791609	chr5:140726158~140726246:+
THCA	cis	rs853679	0.546	rs200981	ENSG00000219392.1	RP1-265C24.5	-6.51	1.95e-10	4.6e-08	-0.49	-0.29	Depression;	chr6:27865396	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs200953	ENSG00000219392.1	RP1-265C24.5	-6.51	1.95e-10	4.6e-08	-0.49	-0.29	Depression;	chr6:27869489	chr6:28115628~28116551:+
THCA	cis	rs2439831	0.717	rs2447198	ENSG00000249839.1	AC011330.5	-6.51	1.95e-10	4.6e-08	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43602920	chr15:43663654~43684339:-
THCA	cis	rs832187	0.64	rs56293138	ENSG00000280620.1	SCAANT1	6.51	1.95e-10	4.61e-08	0.39	0.29	Schizophrenia;	chr3:63903259	chr3:63911518~63911772:-
THCA	cis	rs7829975	0.774	rs11249893	ENSG00000254153.1	CTA-398F10.2	-6.51	1.95e-10	4.61e-08	-0.32	-0.29	Mood instability;	chr8:8843341	chr8:8456909~8461337:-
THCA	cis	rs35264875	0.898	rs72928701	ENSG00000259799.1	RP11-554A11.9	6.51	1.95e-10	4.61e-08	0.5	0.29	Blond vs. brown hair color;	chr11:69094096	chr11:69155910~69159752:+
THCA	cis	rs35264875	0.898	rs55648928	ENSG00000259799.1	RP11-554A11.9	6.51	1.95e-10	4.61e-08	0.5	0.29	Blond vs. brown hair color;	chr11:69094123	chr11:69155910~69159752:+
THCA	cis	rs35264875	0.898	rs56140802	ENSG00000259799.1	RP11-554A11.9	6.51	1.95e-10	4.61e-08	0.5	0.29	Blond vs. brown hair color;	chr11:69094163	chr11:69155910~69159752:+
THCA	cis	rs4650994	0.525	rs10913574	ENSG00000273384.1	RP5-1098D14.1	6.51	1.96e-10	4.61e-08	0.35	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178567347	chr1:178651706~178652282:+
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000264538.5	SUZ12P1	-6.51	1.96e-10	4.61e-08	-0.27	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs216433	ENSG00000264538.5	SUZ12P1	-6.51	1.96e-10	4.61e-08	-0.27	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30709299~30790908:+
THCA	cis	rs2243480	1	rs73142162	ENSG00000228409.4	CCT6P1	6.51	1.96e-10	4.62e-08	0.34	0.29	Diabetic kidney disease;	chr7:65909309	chr7:65751142~65763354:+
THCA	cis	rs4591358	0.731	rs12693769	ENSG00000223466.1	AC064834.2	-6.51	1.96e-10	4.62e-08	-0.4	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195453722	chr2:195533035~195538681:+
THCA	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-6.51	1.96e-10	4.62e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
THCA	cis	rs35797862	1	rs35797862	ENSG00000223745.6	RP4-717I23.3	-6.51	1.96e-10	4.63e-08	-0.17	-0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;	chr1:93272958	chr1:93262186~93346025:-
THCA	cis	rs2412819	0.597	rs7181912	ENSG00000249839.1	AC011330.5	6.51	1.96e-10	4.63e-08	0.41	0.29	Lung cancer;	chr15:43770676	chr15:43663654~43684339:-
THCA	cis	rs797680	0.964	rs4847398	ENSG00000223745.6	RP4-717I23.3	6.51	1.96e-10	4.63e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93112845	chr1:93262186~93346025:-
THCA	cis	rs11722228	0.522	rs73212880	ENSG00000261490.1	RP11-448G15.3	6.51	1.97e-10	4.64e-08	0.21	0.29	Urate levels;Serum uric acid levels;Gout;	chr4:10114068	chr4:10068089~10073019:-
THCA	cis	rs16843372	0.599	rs2356510	ENSG00000251491.2	OR7E28P	-6.51	1.97e-10	4.64e-08	-0.38	-0.29	Obesity-related traits;	chr2:158833318	chr2:158862311~158863285:+
THCA	cis	rs7851660	0.809	rs7036589	ENSG00000236130.1	PTCSC2	6.51	1.97e-10	4.65e-08	0.23	0.29	Strep throat;	chr9:97895438	chr9:97805935~97810008:-
THCA	cis	rs944289	0.553	rs1305576	ENSG00000257826.1	RP11-116N8.4	-6.51	1.97e-10	4.65e-08	-0.33	-0.29	Thyroid cancer;	chr14:36161528	chr14:36061026~36067190:-
THCA	cis	rs897984	0.647	rs8060857	ENSG00000279196.1	RP11-1072A3.3	-6.51	1.97e-10	4.66e-08	-0.29	-0.29	Dementia with Lewy bodies;	chr16:30991399	chr16:30984630~30988270:-
THCA	cis	rs7044106	0.762	rs10760112	ENSG00000270917.1	RP11-27I1.6	-6.51	1.97e-10	4.66e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120812475~120812845:-
THCA	cis	rs728616	0.867	rs1054054	ENSG00000242600.5	MBL1P	6.51	1.98e-10	4.66e-08	0.42	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61859766	ENSG00000242600.5	MBL1P	6.51	1.98e-10	4.66e-08	0.42	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:79904898~79950336:+
THCA	cis	rs6840360	0.582	rs11732918	ENSG00000251611.1	RP11-610P16.1	-6.51	1.98e-10	4.66e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.557	rs4696261	ENSG00000251611.1	RP11-610P16.1	-6.51	1.98e-10	4.66e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151407551~151408835:-
THCA	cis	rs4852324	0.536	rs71418714	ENSG00000217702.2	RP11-287D1.4	6.51	1.98e-10	4.66e-08	0.8	0.29	Systemic lupus erythematosus;	chr2:73992759	chr2:74130583~74135395:+
THCA	cis	rs4852324	0.536	rs17009553	ENSG00000217702.2	RP11-287D1.4	-6.51	1.98e-10	4.66e-08	-0.8	-0.29	Systemic lupus erythematosus;	chr2:73992908	chr2:74130583~74135395:+
THCA	cis	rs1876905	0.68	rs1150082	ENSG00000255389.1	C6orf3	6.51	1.98e-10	4.67e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111599875~111602295:+
THCA	cis	rs529866	0.519	rs4451969	ENSG00000262703.1	RP11-485G7.6	-6.51	1.98e-10	4.67e-08	-0.33	-0.29	Inflammatory bowel disease;Crohn's disease;	chr16:11289662	chr16:11348143~11349321:-
THCA	cis	rs1594829	0.553	rs2046224	ENSG00000228451.3	SDAD1P1	6.51	1.99e-10	4.68e-08	0.29	0.29	Height;	chr8:26294088	chr8:26379259~26382953:-
THCA	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-6.51	1.99e-10	4.68e-08	-0.3	-0.29	Height;	chr11:118854014	chr11:118704607~118750263:+
THCA	cis	rs28386778	0.933	rs2665804	ENSG00000240280.5	TCAM1P	-6.51	1.99e-10	4.68e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63874476	chr17:63849292~63864379:+
THCA	cis	rs1552244	0.882	rs56125067	ENSG00000232901.1	CYCSP10	6.51	1.99e-10	4.69e-08	0.38	0.29	Alzheimer's disease;	chr3:9942446	chr3:10000647~10000940:-
THCA	cis	rs240993	0.595	rs4947127	ENSG00000230177.1	RP5-1112D6.4	6.51	1.99e-10	4.69e-08	0.25	0.29	Inflammatory skin disease;Psoriasis;	chr6:111581595	chr6:111277932~111278742:+
THCA	cis	rs11158026	0.662	rs28481699	ENSG00000258413.1	RP11-665C16.6	-6.51	1.99e-10	4.69e-08	-0.39	-0.29	Parkinson's disease;	chr14:54939831	chr14:55262767~55272075:-
THCA	cis	rs7209700	0.777	rs8073827	ENSG00000228782.6	CTD-2026D20.3	-6.5	1.99e-10	4.7e-08	-0.29	-0.29	IgG glycosylation;	chr17:47267296	chr17:47450568~47492492:-
THCA	cis	rs17772222	0.917	rs61986669	ENSG00000258789.1	RP11-507K2.3	-6.5	1.99e-10	4.7e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88727121	chr14:88551597~88552493:+
THCA	cis	rs7189233	0.956	rs62048478	ENSG00000279722.1	RP11-44F14.6	-6.5	2e-10	4.7e-08	-0.3	-0.29	Intelligence (multi-trait analysis);	chr16:53395268	chr16:53487607~53489943:-
THCA	cis	rs8014252	0.803	rs17108264	ENSG00000259158.2	ADAM20P1	-6.5	2e-10	4.71e-08	-0.37	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70599767	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs57598551	ENSG00000259158.2	ADAM20P1	-6.5	2e-10	4.71e-08	-0.37	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70601684	chr14:70468881~70483756:-
THCA	cis	rs10899021	0.92	rs11236174	ENSG00000279353.1	RP11-864N7.4	6.5	2e-10	4.71e-08	0.56	0.29	Response to metformin (IC50);	chr11:74623156	chr11:74698231~74699658:-
THCA	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	6.5	2e-10	4.72e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
THCA	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	6.5	2e-10	4.72e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
THCA	cis	rs2239547	0.603	rs59989280	ENSG00000242142.1	SERBP1P3	6.5	2e-10	4.72e-08	0.37	0.29	Schizophrenia;	chr3:53064859	chr3:53064283~53065091:-
THCA	cis	rs2239547	0.603	rs6789219	ENSG00000242142.1	SERBP1P3	6.5	2e-10	4.72e-08	0.37	0.29	Schizophrenia;	chr3:53064922	chr3:53064283~53065091:-
THCA	cis	rs3204270	0.759	rs8071492	ENSG00000262049.1	RP13-1032I1.7	6.5	2e-10	4.72e-08	0.26	0.29	Dental caries;	chr17:81715620	chr17:81701324~81703300:-
THCA	cis	rs11018904	0.906	rs61903722	ENSG00000280385.1	AP000648.5	-6.5	2e-10	4.72e-08	-0.38	-0.29	Intelligence (multi-trait analysis);	chr11:90233874	chr11:90193614~90198120:+
THCA	cis	rs79349575	0.783	rs12603969	ENSG00000248278.1	SUMO2P17	6.5	2.01e-10	4.72e-08	0.34	0.29	Type 2 diabetes;	chr17:48957057	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.783	rs12601955	ENSG00000248278.1	SUMO2P17	6.5	2.01e-10	4.72e-08	0.34	0.29	Type 2 diabetes;	chr17:48957058	chr17:48874860~48908983:-
THCA	cis	rs860295	0.65	rs11264422	ENSG00000225855.5	RUSC1-AS1	-6.5	2.01e-10	4.73e-08	-0.19	-0.29	Body mass index;	chr1:155938032	chr1:155316863~155324176:-
THCA	cis	rs7302981	0.719	rs844347	ENSG00000272368.2	RP4-605O3.4	6.5	2.01e-10	4.73e-08	0.17	0.29	Systolic blood pressure;	chr12:50067893	chr12:50112197~50165618:+
THCA	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	6.5	2.01e-10	4.73e-08	0.36	0.29	Height;	chr4:55387515	chr4:55363971~55395847:-
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000229886.1	RP5-1132H15.3	-6.5	2.01e-10	4.73e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:65928187	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34136756	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65916269	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34933526	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65918212	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6949812	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65922114	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6970243	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65923503	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65925372	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs35058610	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65925938	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65940221	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs35046236	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65943626	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs36068983	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65944004	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs68189316	ENSG00000229886.1	RP5-1132H15.3	6.5	2.01e-10	4.73e-08	0.46	0.29	Diabetic kidney disease;	chr7:65944182	chr7:66025126~66031544:-
THCA	cis	rs2797160	0.651	rs6569437	ENSG00000237742.5	RP11-624M8.1	6.5	2.01e-10	4.74e-08	0.26	0.29	Endometrial cancer;	chr6:125713394	chr6:125578558~125749190:-
THCA	cis	rs10208649	0.505	rs17045116	ENSG00000272156.1	RP11-477N3.1	6.5	2.01e-10	4.74e-08	0.42	0.29	Body mass index;	chr2:53694754	chr2:54082554~54085066:+
THCA	cis	rs4713118	0.662	rs149969	ENSG00000220721.1	OR1F12	6.5	2.01e-10	4.74e-08	0.37	0.29	Parkinson's disease;	chr6:28009959	chr6:28073316~28074233:+
THCA	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-6.5	2.02e-10	4.75e-08	-0.33	-0.29	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	6.5	2.02e-10	4.75e-08	0.33	0.29	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
THCA	cis	rs897984	0.609	rs57576577	ENSG00000279196.1	RP11-1072A3.3	6.5	2.02e-10	4.75e-08	0.29	0.29	Dementia with Lewy bodies;	chr16:31025046	chr16:30984630~30988270:-
THCA	cis	rs2439831	0.85	rs3759790	ENSG00000275601.1	AC011330.13	-6.5	2.02e-10	4.75e-08	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43828832	chr15:43642389~43643023:-
THCA	cis	rs897984	0.806	rs1458202	ENSG00000279196.1	RP11-1072A3.3	6.5	2.02e-10	4.76e-08	0.28	0.29	Dementia with Lewy bodies;	chr16:30941881	chr16:30984630~30988270:-
THCA	cis	rs3745672	1	rs279150	ENSG00000219665.7	CTD-2006C1.2	-6.5	2.02e-10	4.76e-08	-0.63	-0.29	Multiple sclerosis;	chr19:11984815	chr19:11987617~12046275:+
THCA	cis	rs11096990	0.855	rs6855008	ENSG00000249207.1	RP11-360F5.1	6.5	2.02e-10	4.76e-08	0.37	0.29	Cognitive function;	chr4:39172006	chr4:39112677~39126818:-
THCA	cis	rs934734	0.967	rs17534670	ENSG00000281920.1	RP11-418H16.1	-6.5	2.02e-10	4.76e-08	-0.36	-0.29	Rheumatoid arthritis;	chr2:65388294	chr2:65623272~65628424:+
THCA	cis	rs9926296	0.605	rs12448860	ENSG00000260259.1	RP11-368I7.4	-6.5	2.02e-10	4.76e-08	-0.31	-0.29	Vitiligo;	chr16:89783221	chr16:89682620~89686569:-
THCA	cis	rs9800506	0.624	rs12213536	ENSG00000228559.1	RP3-340B19.3	6.5	2.02e-10	4.76e-08	0.41	0.29	Neutrophil percentage of granulocytes;	chr6:35545216	chr6:35544632~35545669:+
THCA	cis	rs79349575	0.594	rs62078375	ENSG00000248278.1	SUMO2P17	6.5	2.03e-10	4.77e-08	0.34	0.29	Type 2 diabetes;	chr17:48957612	chr17:48874860~48908983:-
THCA	cis	rs4767841	0.552	rs2893796	ENSG00000248636.5	RP11-768F21.1	-6.5	2.03e-10	4.77e-08	-0.31	-0.29	Urgency urinary incontinence;	chr12:119613464	chr12:119387987~119668079:-
THCA	cis	rs79349575	0.756	rs4793605	ENSG00000248278.1	SUMO2P17	6.5	2.03e-10	4.78e-08	0.34	0.29	Type 2 diabetes;	chr17:48958507	chr17:48874860~48908983:-
THCA	cis	rs17772222	0.958	rs17798341	ENSG00000222990.1	RNU4-22P	6.5	2.03e-10	4.78e-08	0.37	0.29	Coronary artery calcification;	chr14:88548201	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.958	rs10134008	ENSG00000222990.1	RNU4-22P	6.5	2.03e-10	4.78e-08	0.37	0.29	Coronary artery calcification;	chr14:88549183	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.958	rs891750	ENSG00000222990.1	RNU4-22P	6.5	2.03e-10	4.78e-08	0.37	0.29	Coronary artery calcification;	chr14:88550856	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.958	rs891749	ENSG00000222990.1	RNU4-22P	6.5	2.03e-10	4.78e-08	0.37	0.29	Coronary artery calcification;	chr14:88550893	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs61984683	ENSG00000222990.1	RNU4-22P	6.5	2.03e-10	4.78e-08	0.37	0.29	Coronary artery calcification;	chr14:88553162	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs61984684	ENSG00000222990.1	RNU4-22P	6.5	2.03e-10	4.78e-08	0.37	0.29	Coronary artery calcification;	chr14:88559104	chr14:88513498~88513663:+
THCA	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	6.5	2.03e-10	4.78e-08	0.34	0.29	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	6.5	2.03e-10	4.78e-08	0.34	0.29	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
THCA	cis	rs9800506	0.624	rs3807050	ENSG00000228559.1	RP3-340B19.3	6.5	2.03e-10	4.79e-08	0.4	0.29	Neutrophil percentage of granulocytes;	chr6:35545149	chr6:35544632~35545669:+
THCA	cis	rs8012947	0.545	rs1190980	ENSG00000279636.2	LINC00216	-6.5	2.03e-10	4.79e-08	-0.28	-0.29	Alcohol consumption in current drinkers;	chr14:58348088	chr14:58288033~58289158:+
THCA	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-6.5	2.03e-10	4.79e-08	-0.17	-0.29	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-6.5	2.03e-10	4.79e-08	-0.17	-0.29	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
THCA	cis	rs28386778	0.897	rs2854208	ENSG00000240280.5	TCAM1P	-6.5	2.04e-10	4.79e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63869525	chr17:63849292~63864379:+
THCA	cis	rs10740039	0.516	rs10740035	ENSG00000254271.1	RP11-131N11.4	-6.5	2.04e-10	4.8e-08	-0.37	-0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60592848	chr10:60734342~60741828:+
THCA	cis	rs8062405	0.755	rs17707300	ENSG00000278665.1	RP11-666O2.4	6.5	2.04e-10	4.8e-08	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28599241~28601881:-
THCA	cis	rs17826219	0.706	rs609472	ENSG00000263603.1	CTD-2349P21.5	-6.5	2.04e-10	4.8e-08	-0.46	-0.29	Body mass index;	chr17:30624409	chr17:30729469~30731202:+
THCA	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	-6.5	2.04e-10	4.8e-08	-0.48	-0.29	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
THCA	cis	rs7267979	0.816	rs374701	ENSG00000274414.1	RP5-965G21.4	-6.5	2.04e-10	4.81e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25239007~25245229:-
THCA	cis	rs526231	0.853	rs2561477	ENSG00000175749.11	EIF3KP1	6.5	2.05e-10	4.81e-08	0.4	0.29	Primary biliary cholangitis;	chr5:103273223	chr5:103032376~103033031:+
THCA	cis	rs11148252	0.557	rs9536223	ENSG00000278238.1	RP11-245D16.4	-6.5	2.05e-10	4.81e-08	-0.32	-0.29	Lewy body disease;	chr13:52659059	chr13:52454775~52455331:-
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000263603.1	CTD-2349P21.5	-6.5	2.05e-10	4.82e-08	-0.47	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs216433	ENSG00000263603.1	CTD-2349P21.5	-6.5	2.05e-10	4.82e-08	-0.47	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30729469~30731202:+
THCA	cis	rs6840360	0.582	rs2709827	ENSG00000251611.1	RP11-610P16.1	-6.5	2.05e-10	4.82e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151407551~151408835:-
THCA	cis	rs17772222	0.917	rs10143767	ENSG00000258789.1	RP11-507K2.3	-6.5	2.05e-10	4.82e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88514867	chr14:88551597~88552493:+
THCA	cis	rs2243480	1	rs160634	ENSG00000229886.1	RP5-1132H15.3	-6.5	2.05e-10	4.82e-08	-0.45	-0.29	Diabetic kidney disease;	chr7:66063677	chr7:66025126~66031544:-
THCA	cis	rs7942368	1	rs1837679	ENSG00000204529.3	GUCY2EP	6.5	2.05e-10	4.83e-08	0.42	0.29	Endometriosis;	chr11:76790513	chr11:76694043~76707641:-
THCA	cis	rs7129556	0.69	rs648601	ENSG00000254691.1	RP11-91P24.5	6.5	2.05e-10	4.83e-08	0.39	0.29	Weight loss (gastric bypass surgery);	chr11:77875864	chr11:77850604~77851511:+
THCA	cis	rs1949733	0.523	rs4619877	ENSG00000205959.3	RP11-689P11.2	6.5	2.05e-10	4.83e-08	0.25	0.29	Response to antineoplastic agents;	chr4:8541508	chr4:8482270~8512610:+
THCA	cis	rs595244	1	rs77360718	ENSG00000259705.1	RP11-227D13.1	6.5	2.05e-10	4.83e-08	0.52	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48501418	chr15:48645951~48652016:+
THCA	cis	rs1876905	0.68	rs354547	ENSG00000255389.1	C6orf3	-6.5	2.05e-10	4.83e-08	-0.34	-0.29	Mean corpuscular hemoglobin;	chr6:111213919	chr6:111599875~111602295:+
THCA	cis	rs507080	0.922	rs654792	ENSG00000278376.1	RP11-158I9.8	6.5	2.06e-10	4.84e-08	0.22	0.29	Serum metabolite levels;	chr11:118682287	chr11:118791254~118793137:+
THCA	cis	rs6671200	0.667	rs76468062	ENSG00000235501.4	RP4-639F20.1	-6.5	2.06e-10	4.84e-08	-0.59	-0.29	Stearic acid (18:0) levels;	chr1:94932483	chr1:94927566~94963270:+
THCA	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-6.5	2.06e-10	4.84e-08	-0.25	-0.29	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
THCA	cis	rs2754412	1	rs2754412	ENSG00000276805.1	RP11-291L22.6	6.5	2.06e-10	4.84e-08	0.32	0.29	Breast cancer;	chr10:38338906	chr10:38451030~38451785:+
THCA	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-6.5	2.06e-10	4.85e-08	-0.31	-0.29	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
THCA	cis	rs10208649	1	rs41536750	ENSG00000272156.1	RP11-477N3.1	-6.5	2.06e-10	4.85e-08	-0.49	-0.29	Body mass index;	chr2:53894823	chr2:54082554~54085066:+
THCA	cis	rs7044106	0.708	rs991121	ENSG00000270917.1	RP11-27I1.6	-6.5	2.06e-10	4.85e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120812475~120812845:-
THCA	cis	rs807029	0.533	rs12571302	ENSG00000272572.1	RP11-179B2.2	-6.5	2.06e-10	4.85e-08	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100911103~100912739:-
THCA	cis	rs807029	0.533	rs2863095	ENSG00000272572.1	RP11-179B2.2	-6.5	2.06e-10	4.85e-08	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100911103~100912739:-
THCA	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	6.5	2.06e-10	4.85e-08	0.35	0.29	Height;	chr6:109421257	chr6:109382795~109383666:+
THCA	cis	rs2120243	0.539	rs9857875	ENSG00000244515.1	KRT18P34	-6.5	2.07e-10	4.86e-08	-0.34	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157361108	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.565	rs1500919	ENSG00000244515.1	KRT18P34	-6.5	2.07e-10	4.86e-08	-0.34	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157361259	chr3:157162663~157163932:-
THCA	cis	rs2976388	0.967	rs2976393	ENSG00000253741.1	CTD-2292P10.4	6.5	2.07e-10	4.86e-08	0.36	0.29	Urinary tract infection frequency;	chr8:142682200	chr8:142702252~142726973:-
THCA	cis	rs9649213	0.593	rs6967576	ENSG00000272950.1	RP11-307C18.1	-6.5	2.07e-10	4.86e-08	-0.34	-0.29	Prostate cancer (SNP x SNP interaction);	chr7:98387061	chr7:98322853~98323430:+
THCA	cis	rs7621025	0.542	rs13075615	ENSG00000239213.4	NCK1-AS1	-6.5	2.07e-10	4.87e-08	-0.38	-0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136786990	chr3:136841726~136862054:-
THCA	cis	rs1949733	0.598	rs55765509	ENSG00000205959.3	RP11-689P11.2	6.5	2.07e-10	4.87e-08	0.26	0.29	Response to antineoplastic agents;	chr4:8531005	chr4:8482270~8512610:+
THCA	cis	rs10208649	0.908	rs10193846	ENSG00000272156.1	RP11-477N3.1	6.5	2.07e-10	4.87e-08	0.55	0.29	Body mass index;	chr2:54127605	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.808	rs72906787	ENSG00000272156.1	RP11-477N3.1	6.5	2.07e-10	4.87e-08	0.55	0.29	Body mass index;	chr2:54128804	chr2:54082554~54085066:+
THCA	cis	rs2735413	0.564	rs7192226	ENSG00000276007.1	RP11-358L22.3	6.5	2.07e-10	4.87e-08	0.31	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78086363	chr16:78123243~78124332:+
THCA	cis	rs17772222	0.958	rs60213984	ENSG00000258789.1	RP11-507K2.3	-6.5	2.07e-10	4.87e-08	-0.3	-0.29	Coronary artery calcification;	chr14:88401473	chr14:88551597~88552493:+
THCA	cis	rs9393777	0.92	rs13196692	ENSG00000219392.1	RP1-265C24.5	-6.5	2.08e-10	4.89e-08	-0.63	-0.29	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28115628~28116551:+
THCA	cis	rs9393777	0.92	rs34150729	ENSG00000219392.1	RP1-265C24.5	-6.5	2.08e-10	4.89e-08	-0.63	-0.29	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28115628~28116551:+
THCA	cis	rs9393777	0.92	rs13191227	ENSG00000219392.1	RP1-265C24.5	-6.5	2.08e-10	4.89e-08	-0.63	-0.29	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28115628~28116551:+
THCA	cis	rs2243480	1	rs4149468	ENSG00000228409.4	CCT6P1	6.5	2.08e-10	4.9e-08	0.34	0.29	Diabetic kidney disease;	chr7:66360703	chr7:65751142~65763354:+
THCA	cis	rs10208649	0.908	rs11884857	ENSG00000233266.1	HMGB1P31	6.5	2.08e-10	4.9e-08	0.67	0.29	Body mass index;	chr2:54033185	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.901	rs6748686	ENSG00000233266.1	HMGB1P31	6.5	2.08e-10	4.9e-08	0.67	0.29	Body mass index;	chr2:54037481	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.808	rs77805752	ENSG00000233266.1	HMGB1P31	6.5	2.08e-10	4.9e-08	0.67	0.29	Body mass index;	chr2:54037506	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.908	rs6719990	ENSG00000233266.1	HMGB1P31	6.5	2.08e-10	4.9e-08	0.67	0.29	Body mass index;	chr2:54037515	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.908	rs72906714	ENSG00000233266.1	HMGB1P31	6.5	2.08e-10	4.9e-08	0.67	0.29	Body mass index;	chr2:54038423	chr2:54051334~54051760:+
THCA	cis	rs2239557	1	rs2358628	ENSG00000259065.1	RP5-1021I20.1	6.5	2.08e-10	4.9e-08	0.35	0.29	Common traits (Other);	chr14:74165054	chr14:73787360~73803270:+
THCA	cis	rs2243480	1	rs316322	ENSG00000229886.1	RP5-1132H15.3	6.5	2.09e-10	4.9e-08	0.46	0.29	Diabetic kidney disease;	chr7:66146246	chr7:66025126~66031544:-
THCA	cis	rs3204270	0.639	rs11867543	ENSG00000262049.1	RP13-1032I1.7	6.5	2.09e-10	4.91e-08	0.26	0.29	Dental caries;	chr17:81688016	chr17:81701324~81703300:-
THCA	cis	rs193541	0.501	rs3943379	ENSG00000263432.2	RN7SL689P	6.5	2.09e-10	4.91e-08	0.36	0.29	Glucose homeostasis traits;	chr5:122720442	chr5:123022487~123022783:-
THCA	cis	rs193541	0.502	rs2061511	ENSG00000263432.2	RN7SL689P	6.5	2.09e-10	4.91e-08	0.36	0.29	Glucose homeostasis traits;	chr5:122721032	chr5:123022487~123022783:-
THCA	cis	rs6496044	0.568	rs11632326	ENSG00000259295.5	CSPG4P12	6.5	2.09e-10	4.91e-08	0.37	0.29	Interstitial lung disease;	chr15:85536603	chr15:85191438~85213905:+
THCA	cis	rs7015630	0.657	rs13278954	ENSG00000251136.7	RP11-37B2.1	-6.5	2.09e-10	4.91e-08	-0.31	-0.29	Inflammatory bowel disease;Crohn's disease;	chr8:89839830	chr8:89609409~89757727:-
THCA	cis	rs5742933	0.857	rs11685425	ENSG00000273240.1	RP11-455J20.3	6.5	2.09e-10	4.91e-08	0.29	0.29	Ferritin levels;	chr2:189747977	chr2:189763859~189764456:-
THCA	cis	rs10899021	0.92	rs61901541	ENSG00000279353.1	RP11-864N7.4	6.5	2.09e-10	4.92e-08	0.56	0.29	Response to metformin (IC50);	chr11:74606940	chr11:74698231~74699658:-
THCA	cis	rs10899021	0.92	rs7122710	ENSG00000279353.1	RP11-864N7.4	6.5	2.09e-10	4.92e-08	0.56	0.29	Response to metformin (IC50);	chr11:74612130	chr11:74698231~74699658:-
THCA	cis	rs595244	1	rs1036476	ENSG00000259705.1	RP11-227D13.1	6.5	2.09e-10	4.92e-08	0.52	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48622578	chr15:48645951~48652016:+
THCA	cis	rs17711722	0.503	rs453835	ENSG00000228409.4	CCT6P1	6.5	2.09e-10	4.92e-08	0.22	0.29	Calcium levels;	chr7:66046172	chr7:65751142~65763354:+
THCA	cis	rs7131987	0.903	rs10843367	ENSG00000257176.2	RP11-996F15.2	-6.5	2.1e-10	4.93e-08	-0.29	-0.29	QT interval;	chr12:29255447	chr12:29280418~29317848:-
THCA	cis	rs4845875	0.626	rs4845882	ENSG00000242349.4	NPPA-AS1	6.5	2.1e-10	4.93e-08	0.28	0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11783110	chr1:11841017~11848079:+
THCA	cis	rs848490	0.889	rs62462688	ENSG00000214293.7	APTR	6.5	2.1e-10	4.93e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77886105	chr7:77657660~77696265:-
THCA	cis	rs1009647	0.645	rs73271727	ENSG00000258413.1	RP11-665C16.6	-6.5	2.1e-10	4.93e-08	-0.53	-0.29	Testicular germ cell tumor;	chr14:55133712	chr14:55262767~55272075:-
THCA	cis	rs7044106	0.708	rs920745	ENSG00000270917.1	RP11-27I1.6	-6.5	2.1e-10	4.93e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120812475~120812845:-
THCA	cis	rs1552244	0.744	rs6763366	ENSG00000180385.7	EMC3-AS1	6.5	2.1e-10	4.94e-08	0.3	0.29	Alzheimer's disease;	chr3:9991860	chr3:9986893~10006990:+
THCA	cis	rs13113518	0.812	rs12649507	ENSG00000273257.1	RP11-177J6.1	-6.5	2.1e-10	4.94e-08	-0.39	-0.29	Height;	chr4:55514317	chr4:55387949~55388271:+
THCA	cis	rs10740039	0.516	rs9731224	ENSG00000254271.1	RP11-131N11.4	6.5	2.1e-10	4.94e-08	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60583390	chr10:60734342~60741828:+
THCA	cis	rs897984	0.571	rs7184567	ENSG00000279196.1	RP11-1072A3.3	6.5	2.1e-10	4.94e-08	0.29	0.29	Dementia with Lewy bodies;	chr16:31009757	chr16:30984630~30988270:-
THCA	cis	rs7829975	0.711	rs4481596	ENSG00000254153.1	CTA-398F10.2	-6.5	2.1e-10	4.94e-08	-0.31	-0.29	Mood instability;	chr8:8846820	chr8:8456909~8461337:-
THCA	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-6.5	2.1e-10	4.94e-08	-0.46	-0.29	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
THCA	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	6.5	2.1e-10	4.94e-08	0.34	0.29	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
THCA	cis	rs848490	0.894	rs6465773	ENSG00000214293.7	APTR	6.5	2.11e-10	4.94e-08	0.22	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77677384	chr7:77657660~77696265:-
THCA	cis	rs4713118	0.699	rs573179	ENSG00000226314.6	ZNF192P1	-6.5	2.11e-10	4.95e-08	-0.38	-0.29	Parkinson's disease;	chr6:27881898	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.699	rs200978	ENSG00000226314.6	ZNF192P1	-6.5	2.11e-10	4.95e-08	-0.38	-0.29	Parkinson's disease;	chr6:27885390	chr6:28161781~28169594:+
THCA	cis	rs797680	0.822	rs1057257	ENSG00000223745.6	RP4-717I23.3	6.5	2.11e-10	4.95e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93155926	chr1:93262186~93346025:-
THCA	cis	rs847577	0.569	rs7804318	ENSG00000272950.1	RP11-307C18.1	-6.5	2.11e-10	4.95e-08	-0.36	-0.29	Breast cancer;	chr7:98167323	chr7:98322853~98323430:+
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000220721.1	OR1F12	6.5	2.11e-10	4.95e-08	0.38	0.29	Parkinson's disease;	chr6:28066257	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000220721.1	OR1F12	6.5	2.11e-10	4.95e-08	0.38	0.29	Parkinson's disease;	chr6:28066263	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000220721.1	OR1F12	6.5	2.11e-10	4.95e-08	0.38	0.29	Parkinson's disease;	chr6:28066343	chr6:28073316~28074233:+
THCA	cis	rs4689592	0.503	rs10516184	ENSG00000245468.3	RP11-367J11.3	6.5	2.11e-10	4.95e-08	0.25	0.29	Monocyte percentage of white cells;	chr4:7059232	chr4:7094571~7103385:-
THCA	cis	rs35264875	0.796	rs72928657	ENSG00000259799.1	RP11-554A11.9	6.5	2.11e-10	4.95e-08	0.49	0.29	Blond vs. brown hair color;	chr11:69084868	chr11:69155910~69159752:+
THCA	cis	rs35264875	0.95	rs72928659	ENSG00000259799.1	RP11-554A11.9	6.5	2.11e-10	4.95e-08	0.49	0.29	Blond vs. brown hair color;	chr11:69084890	chr11:69155910~69159752:+
THCA	cis	rs6840360	0.642	rs56301462	ENSG00000251611.1	RP11-610P16.1	-6.5	2.11e-10	4.95e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151407551~151408835:-
THCA	cis	rs1707322	0.717	rs1547925	ENSG00000281133.1	AL355480.3	6.5	2.11e-10	4.96e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45580892~45580996:-
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000228409.4	CCT6P1	6.5	2.11e-10	4.96e-08	0.34	0.29	Diabetic kidney disease;	chr7:66474549	chr7:65751142~65763354:+
THCA	cis	rs7746199	0.673	rs72847313	ENSG00000226314.6	ZNF192P1	-6.5	2.11e-10	4.96e-08	-0.63	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28161781~28169594:+
THCA	cis	rs7746199	0.611	rs17750747	ENSG00000226314.6	ZNF192P1	-6.5	2.11e-10	4.96e-08	-0.63	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28161781~28169594:+
THCA	cis	rs9307551	0.857	rs7662551	ENSG00000250334.4	LINC00989	-6.5	2.11e-10	4.96e-08	-0.34	-0.29	Refractive error;	chr4:79616484	chr4:79492416~79576460:+
THCA	cis	rs7246657	0.943	rs35540940	ENSG00000226686.6	LINC01535	-6.5	2.12e-10	4.97e-08	-0.43	-0.29	Coronary artery calcification;	chr19:37517333	chr19:37251912~37265535:+
THCA	cis	rs12999373	0.501	rs2867134	ENSG00000272342.1	RP13-539J13.1	-6.5	2.12e-10	4.97e-08	-0.34	-0.29	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:739588~740164:-
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000263603.1	CTD-2349P21.5	-6.5	2.12e-10	4.97e-08	-0.47	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30729469~30731202:+
THCA	cis	rs947583	0.617	rs56048607	ENSG00000231028.7	LINC00271	-6.5	2.12e-10	4.97e-08	-0.23	-0.29	Phosphorus levels;	chr6:135699171	chr6:135497801~135716055:+
THCA	cis	rs2243480	1	rs422164	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66121618	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316313	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66128561	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316312	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66131504	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs419603	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66132354	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs387676	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66133233	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs13310597	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66133553	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs431076	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66135333	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs2460422	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66136518	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316334	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66137139	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316330	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66140385	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316326	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66144466	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316325	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66144531	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316321	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66146626	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316318	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66147917	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316317	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66148650	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316304	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66151907	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs2465120	ENSG00000229886.1	RP5-1132H15.3	6.49	2.12e-10	4.97e-08	0.46	0.29	Diabetic kidney disease;	chr7:66155987	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66157859	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs4718309	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66162777	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6460274	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66163497	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs7787230	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66164112	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66170354	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6974723	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66172952	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs9769882	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66177938	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6966322	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66181767	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs4145008	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66182524	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs4718315	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66183554	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs4718316	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66183744	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1873494	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66184912	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6959002	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.12e-10	4.97e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66185509	chr7:66025126~66031544:-
THCA	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-6.49	2.12e-10	4.97e-08	-0.39	-0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
THCA	cis	rs847577	0.609	rs11768309	ENSG00000272950.1	RP11-307C18.1	6.49	2.12e-10	4.97e-08	0.36	0.29	Breast cancer;	chr7:98144500	chr7:98322853~98323430:+
THCA	cis	rs836788	0.535	rs6151840	ENSG00000249655.1	CTC-325J23.2	-6.49	2.12e-10	4.98e-08	-0.29	-0.29	Glomerular filtration rate (creatinine);	chr5:80791435	chr5:80630313~80631590:-
THCA	cis	rs6545883	0.894	rs2694634	ENSG00000271889.1	RP11-493E12.1	-6.49	2.12e-10	4.98e-08	-0.27	-0.29	Tuberculosis;	chr2:61324300	chr2:61151433~61162105:-
THCA	cis	rs7567389	0.534	rs2069904	ENSG00000236682.1	AC068282.3	-6.49	2.12e-10	4.98e-08	-0.43	-0.29	Self-rated health;	chr2:127418203	chr2:127389130~127400580:+
THCA	cis	rs3822625	1	rs16886364	ENSG00000271828.1	CTD-2310F14.1	-6.49	2.13e-10	4.99e-08	-0.74	-0.29	Breast cancer (early onset);	chr5:56826517	chr5:56927874~56929573:+
THCA	cis	rs6860806	0.661	rs1588263	ENSG00000237714.1	P4HA2-AS1	6.49	2.13e-10	4.99e-08	0.37	0.29	Breast cancer;	chr5:132241465	chr5:132184876~132192808:+
THCA	cis	rs860295	0.65	rs670523	ENSG00000225855.5	RUSC1-AS1	-6.49	2.13e-10	5e-08	-0.19	-0.29	Body mass index;	chr1:155908941	chr1:155316863~155324176:-
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000228409.4	CCT6P1	6.49	2.13e-10	5e-08	0.34	0.29	Diabetic kidney disease;	chr7:66433290	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs58669269	ENSG00000228409.4	CCT6P1	6.49	2.13e-10	5e-08	0.34	0.29	Diabetic kidney disease;	chr7:66486966	chr7:65751142~65763354:+
THCA	cis	rs5742933	0.857	rs12471217	ENSG00000273240.1	RP11-455J20.3	6.49	2.13e-10	5e-08	0.3	0.29	Ferritin levels;	chr2:189707337	chr2:189763859~189764456:-
THCA	cis	rs1499614	1	rs1267818	ENSG00000228409.4	CCT6P1	6.49	2.13e-10	5.01e-08	0.34	0.29	Gout;	chr7:66642037	chr7:65751142~65763354:+
THCA	cis	rs7976269	0.559	rs10771473	ENSG00000257176.2	RP11-996F15.2	-6.49	2.14e-10	5.01e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29068729	chr12:29280418~29317848:-
THCA	cis	rs17772222	0.876	rs12587598	ENSG00000258789.1	RP11-507K2.3	-6.49	2.14e-10	5.02e-08	-0.28	-0.29	Coronary artery calcification;	chr14:88729474	chr14:88551597~88552493:+
THCA	cis	rs797680	0.856	rs2031226	ENSG00000223745.6	RP4-717I23.3	6.49	2.14e-10	5.02e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93321207	chr1:93262186~93346025:-
THCA	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-6.49	2.14e-10	5.02e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
THCA	cis	rs848490	0.963	rs848494	ENSG00000214293.7	APTR	-6.49	2.14e-10	5.03e-08	-0.23	-0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77908647	chr7:77657660~77696265:-
THCA	cis	rs10208649	1	rs6759437	ENSG00000272156.1	RP11-477N3.1	6.49	2.14e-10	5.03e-08	0.55	0.29	Body mass index;	chr2:53821907	chr2:54082554~54085066:+
THCA	cis	rs7044106	0.762	rs10491783	ENSG00000270917.1	RP11-27I1.6	-6.49	2.15e-10	5.03e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.762	rs966397	ENSG00000270917.1	RP11-27I1.6	-6.49	2.15e-10	5.03e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120812475~120812845:-
THCA	cis	rs7712401	0.598	rs367768	ENSG00000249996.1	RP11-359P5.1	6.49	2.15e-10	5.04e-08	0.28	0.29	Mean platelet volume;	chr5:122855431	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.567	rs154516	ENSG00000249996.1	RP11-359P5.1	6.49	2.15e-10	5.04e-08	0.28	0.29	Mean platelet volume;	chr5:122855444	chr5:123036271~123054667:+
THCA	cis	rs848490	0.681	rs12537271	ENSG00000214293.7	APTR	6.49	2.15e-10	5.04e-08	0.22	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77671409	chr7:77657660~77696265:-
THCA	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	6.49	2.15e-10	5.05e-08	0.35	0.29	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	6.49	2.15e-10	5.05e-08	0.35	0.29	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
THCA	cis	rs516805	0.63	rs696651	ENSG00000279453.1	RP3-425C14.4	-6.49	2.15e-10	5.05e-08	-0.3	-0.29	Lymphocyte counts;	chr6:122280069	chr6:122436789~122439223:-
THCA	cis	rs4835473	0.9	rs12503074	ENSG00000251600.4	RP11-673E1.1	-6.49	2.15e-10	5.05e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143812560	chr4:143912331~143982454:+
THCA	cis	rs10129255	1	rs10134517	ENSG00000211974.3	IGHV2-70	6.49	2.15e-10	5.05e-08	0.22	0.29	Kawasaki disease;	chr14:106718498	chr14:106723574~106724093:-
THCA	cis	rs202072	0.729	rs202030	ENSG00000272379.1	RP1-257A7.5	6.49	2.15e-10	5.05e-08	0.47	0.29	HIV-1 viral setpoint;	chr6:13291920	chr6:13290018~13290490:-
THCA	cis	rs8014252	0.614	rs60251828	ENSG00000259158.2	ADAM20P1	-6.49	2.16e-10	5.06e-08	-0.37	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70594734	chr14:70468881~70483756:-
THCA	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	6.49	2.16e-10	5.06e-08	0.34	0.29	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	6.49	2.16e-10	5.06e-08	0.34	0.29	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
THCA	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	6.49	2.16e-10	5.06e-08	0.54	0.29	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	6.49	2.16e-10	5.06e-08	0.54	0.29	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	6.49	2.16e-10	5.06e-08	0.54	0.29	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	6.49	2.16e-10	5.06e-08	0.54	0.29	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
THCA	cis	rs12701220	0.689	rs12536282	ENSG00000229043.2	AC091729.9	-6.49	2.16e-10	5.06e-08	-0.44	-0.29	Bronchopulmonary dysplasia;	chr7:1076014	chr7:1160374~1165267:+
THCA	cis	rs6840360	0.582	rs6535796	ENSG00000251611.1	RP11-610P16.1	-6.49	2.16e-10	5.06e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151407551~151408835:-
THCA	cis	rs4713118	0.869	rs6922574	ENSG00000280107.1	AL022393.9	-6.49	2.16e-10	5.06e-08	-0.33	-0.29	Parkinson's disease;	chr6:27725224	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.869	rs9348775	ENSG00000280107.1	AL022393.9	-6.49	2.16e-10	5.06e-08	-0.33	-0.29	Parkinson's disease;	chr6:27727550	chr6:28170845~28172521:+
THCA	cis	rs9543976	0.614	rs73223955	ENSG00000261553.4	RP11-29G8.3	-6.49	2.16e-10	5.06e-08	-0.44	-0.29	Diabetic retinopathy;	chr13:75529075	chr13:75549773~75807120:+
THCA	cis	rs228614	0.509	rs223486	ENSG00000230069.3	LRRC37A15P	-6.49	2.16e-10	5.06e-08	-0.3	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102727274~102730721:-
THCA	cis	rs1707322	0.717	rs3014237	ENSG00000281133.1	AL355480.3	6.49	2.16e-10	5.07e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45580892~45580996:-
THCA	cis	rs9487094	0.645	rs34292461	ENSG00000260273.1	RP11-425D10.10	6.49	2.16e-10	5.07e-08	0.4	0.29	Height;	chr6:109352277	chr6:109382795~109383666:+
THCA	cis	rs6570726	0.516	rs10484700	ENSG00000235652.6	RP11-545I5.3	6.49	2.16e-10	5.07e-08	0.26	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145407797	chr6:145799409~145886585:+
THCA	cis	rs12681366	0.663	rs2919665	ENSG00000253704.1	RP11-267M23.4	6.49	2.16e-10	5.08e-08	0.28	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94453147	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.571	rs2930959	ENSG00000253704.1	RP11-267M23.4	6.49	2.16e-10	5.08e-08	0.28	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94461930	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.553	rs2930967	ENSG00000253704.1	RP11-267M23.4	-6.49	2.16e-10	5.08e-08	-0.28	-0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94450371	chr8:94553722~94569745:+
THCA	cis	rs8141529	0.778	rs763073	ENSG00000226471.5	CTA-292E10.6	-6.49	2.17e-10	5.08e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28819554	chr22:28800683~28848559:+
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000229886.1	RP5-1132H15.3	-6.49	2.17e-10	5.08e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66158142	chr7:66025126~66031544:-
THCA	cis	rs6860806	0.507	rs2631362	ENSG00000263597.1	MIR3936	-6.49	2.17e-10	5.08e-08	-0.29	-0.29	Breast cancer;	chr5:132371601	chr5:132365490~132365599:-
THCA	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	6.49	2.17e-10	5.09e-08	0.34	0.29	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	6.49	2.17e-10	5.09e-08	0.34	0.29	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	6.49	2.17e-10	5.09e-08	0.34	0.29	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	6.49	2.17e-10	5.09e-08	0.34	0.29	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	6.49	2.17e-10	5.09e-08	0.34	0.29	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	6.49	2.17e-10	5.09e-08	0.34	0.29	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	6.49	2.17e-10	5.09e-08	0.34	0.29	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
THCA	cis	rs4073416	0.902	rs7143026	ENSG00000276116.2	FUT8-AS1	-6.49	2.17e-10	5.09e-08	-0.31	-0.29	N-glycan levels;	chr14:65784238	chr14:65411170~65412690:-
THCA	cis	rs60678552	0.642	rs73548947	ENSG00000233558.1	RP3-486I3.4	6.49	2.18e-10	5.1e-08	0.43	0.29	Heschl's gyrus morphology;	chr6:116318148	chr6:116258493~116259115:-
THCA	cis	rs1552244	0.572	rs59132826	ENSG00000232901.1	CYCSP10	6.49	2.18e-10	5.1e-08	0.43	0.29	Alzheimer's disease;	chr3:10128041	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs58223482	ENSG00000232901.1	CYCSP10	6.49	2.18e-10	5.1e-08	0.43	0.29	Alzheimer's disease;	chr3:10128062	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs113406084	ENSG00000232901.1	CYCSP10	6.49	2.18e-10	5.1e-08	0.43	0.29	Alzheimer's disease;	chr3:10128506	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs17032440	ENSG00000232901.1	CYCSP10	-6.49	2.18e-10	5.1e-08	-0.43	-0.29	Alzheimer's disease;	chr3:10128135	chr3:10000647~10000940:-
THCA	cis	rs4835473	0.932	rs9685306	ENSG00000251600.4	RP11-673E1.1	-6.49	2.18e-10	5.1e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143748843	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13107719	ENSG00000251600.4	RP11-673E1.1	-6.49	2.18e-10	5.1e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143752034	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs2323194	ENSG00000251600.4	RP11-673E1.1	-6.49	2.18e-10	5.1e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143752879	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35055653	ENSG00000251600.4	RP11-673E1.1	-6.49	2.18e-10	5.1e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143754836	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs35017645	ENSG00000251600.4	RP11-673E1.1	-6.49	2.18e-10	5.1e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143760196	chr4:143912331~143982454:+
THCA	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	6.49	2.18e-10	5.11e-08	0.22	0.29	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
THCA	cis	rs28386778	0.897	rs2854214	ENSG00000240280.5	TCAM1P	6.49	2.18e-10	5.11e-08	0.4	0.29	Prudent dietary pattern;	chr17:63868089	chr17:63849292~63864379:+
THCA	cis	rs7267979	1	rs12428	ENSG00000274414.1	RP5-965G21.4	6.49	2.18e-10	5.12e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25239007~25245229:-
THCA	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	6.49	2.18e-10	5.12e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	6.49	2.18e-10	5.12e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	6.49	2.18e-10	5.12e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	6.49	2.18e-10	5.12e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	6.49	2.18e-10	5.12e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	6.49	2.18e-10	5.12e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	6.49	2.18e-10	5.12e-08	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
THCA	cis	rs10078	0.559	rs2672725	ENSG00000221990.4	EXOC3-AS1	6.49	2.18e-10	5.12e-08	0.3	0.29	Fat distribution (HIV);	chr5:434866	chr5:441498~443160:-
THCA	cis	rs4143844	1	rs34391931	ENSG00000259251.2	RP11-643M14.1	6.49	2.18e-10	5.12e-08	0.57	0.29	Bipolar disorder and schizophrenia;	chr15:62065419	chr15:62060503~62062434:+
THCA	cis	rs5742933	0.779	rs7595020	ENSG00000273240.1	RP11-455J20.3	6.49	2.19e-10	5.13e-08	0.3	0.29	Ferritin levels;	chr2:189778950	chr2:189763859~189764456:-
THCA	cis	rs17594362	0.731	rs8181810	ENSG00000264190.1	MIR5006	6.49	2.19e-10	5.13e-08	0.39	0.29	Multiple sclerosis;	chr13:41566822	chr13:41568286~41568395:-
THCA	cis	rs2018683	0.745	rs917217	ENSG00000228421.2	AC005013.5	-6.49	2.19e-10	5.13e-08	-0.32	-0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935408	chr7:28957667~28959345:+
THCA	cis	rs6545883	0.895	rs2177961	ENSG00000271889.1	RP11-493E12.1	-6.49	2.19e-10	5.14e-08	-0.27	-0.29	Tuberculosis;	chr2:61333129	chr2:61151433~61162105:-
THCA	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	6.49	2.2e-10	5.14e-08	0.34	0.29	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs1998670	ENSG00000258789.1	RP11-507K2.3	-6.49	2.2e-10	5.14e-08	-0.3	-0.29	Coronary artery calcification;	chr14:88504581	chr14:88551597~88552493:+
THCA	cis	rs7208859	0.673	rs216435	ENSG00000263603.1	CTD-2349P21.5	-6.49	2.2e-10	5.15e-08	-0.47	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30729469~30731202:+
THCA	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-6.49	2.2e-10	5.15e-08	-0.5	-0.29	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-6.49	2.2e-10	5.15e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-6.49	2.2e-10	5.15e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-6.49	2.2e-10	5.15e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-6.49	2.2e-10	5.15e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-6.49	2.2e-10	5.15e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-6.49	2.2e-10	5.15e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-6.49	2.2e-10	5.15e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
THCA	cis	rs28386778	0.734	rs7210724	ENSG00000240280.5	TCAM1P	-6.49	2.2e-10	5.15e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63721838	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs1470697	ENSG00000240280.5	TCAM1P	-6.49	2.2e-10	5.15e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63722480	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs10221279	ENSG00000240280.5	TCAM1P	-6.49	2.2e-10	5.15e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63728778	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.687	rs59596917	ENSG00000240280.5	TCAM1P	-6.49	2.2e-10	5.15e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63728904	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.897	rs6504176	ENSG00000240280.5	TCAM1P	-6.49	2.2e-10	5.15e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63734560	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.863	rs6504178	ENSG00000240280.5	TCAM1P	6.49	2.2e-10	5.15e-08	0.4	0.29	Prudent dietary pattern;	chr17:63735373	chr17:63849292~63864379:+
THCA	cis	rs8141529	0.732	rs2269577	ENSG00000226471.5	CTA-292E10.6	-6.49	2.2e-10	5.15e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28800769	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.732	rs3788409	ENSG00000226471.5	CTA-292E10.6	-6.49	2.2e-10	5.15e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28802163	chr22:28800683~28848559:+
THCA	cis	rs6496044	0.634	rs4843066	ENSG00000259295.5	CSPG4P12	6.49	2.2e-10	5.15e-08	0.36	0.29	Interstitial lung disease;	chr15:85519680	chr15:85191438~85213905:+
THCA	cis	rs2018683	0.711	rs917213	ENSG00000228421.2	AC005013.5	6.49	2.2e-10	5.16e-08	0.32	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928587	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.711	rs917214	ENSG00000228421.2	AC005013.5	6.49	2.2e-10	5.16e-08	0.32	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928676	chr7:28957667~28959345:+
THCA	cis	rs7225151	0.901	rs61481506	ENSG00000234327.6	AC012146.7	-6.49	2.2e-10	5.16e-08	-0.33	-0.29	Alzheimer's disease (late onset);	chr17:5255419	chr17:5111468~5115004:+
THCA	cis	rs8012947	1	rs11628909	ENSG00000279636.2	LINC00216	6.49	2.21e-10	5.16e-08	0.3	0.29	Alcohol consumption in current drinkers;	chr14:58352508	chr14:58288033~58289158:+
THCA	cis	rs11722779	0.844	rs223345	ENSG00000230069.3	LRRC37A15P	-6.49	2.21e-10	5.17e-08	-0.3	-0.29	Schizophrenia;	chr4:102859366	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.873	rs223344	ENSG00000230069.3	LRRC37A15P	-6.49	2.21e-10	5.17e-08	-0.3	-0.29	Schizophrenia;	chr4:102859765	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.775	rs223341	ENSG00000230069.3	LRRC37A15P	-6.49	2.21e-10	5.17e-08	-0.3	-0.29	Schizophrenia;	chr4:102862343	chr4:102727274~102730721:-
THCA	cis	rs7586673	0.725	rs6757645	ENSG00000227403.1	AC009299.3	-6.49	2.21e-10	5.17e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr2:161034871	chr2:161244739~161249050:+
THCA	cis	rs227275	0.554	rs223466	ENSG00000230069.3	LRRC37A15P	-6.49	2.21e-10	5.17e-08	-0.29	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102727274~102730721:-
THCA	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	6.49	2.21e-10	5.17e-08	0.26	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
THCA	cis	rs45509595	0.841	rs17751184	ENSG00000226314.6	ZNF192P1	-6.49	2.21e-10	5.17e-08	-0.63	-0.29	Breast cancer;	chr6:27807250	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs67101035	ENSG00000226314.6	ZNF192P1	-6.49	2.21e-10	5.17e-08	-0.63	-0.29	Depression;	chr6:27831109	chr6:28161781~28169594:+
THCA	cis	rs853679	0.556	rs34706883	ENSG00000226314.6	ZNF192P1	-6.49	2.21e-10	5.17e-08	-0.63	-0.29	Depression;	chr6:27837477	chr6:28161781~28169594:+
THCA	cis	rs67340775	0.748	rs13212651	ENSG00000226314.6	ZNF192P1	-6.49	2.21e-10	5.17e-08	-0.63	-0.29	Lung cancer in ever smokers;	chr6:27839207	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs35819751	ENSG00000226314.6	ZNF192P1	-6.49	2.21e-10	5.17e-08	-0.63	-0.29	Depression;	chr6:27842791	chr6:28161781~28169594:+
THCA	cis	rs4835473	0.932	rs1473055	ENSG00000251600.4	RP11-673E1.1	6.49	2.21e-10	5.18e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143997714	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4835126	ENSG00000251600.4	RP11-673E1.1	6.49	2.21e-10	5.18e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143997740	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.699	rs4835127	ENSG00000251600.4	RP11-673E1.1	6.49	2.21e-10	5.18e-08	0.39	0.29	Immature fraction of reticulocytes;	chr4:143997972	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4092718	ENSG00000251600.4	RP11-673E1.1	-6.49	2.21e-10	5.18e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143799637	chr4:143912331~143982454:+
THCA	cis	rs9402743	1	rs6570026	ENSG00000231028.7	LINC00271	-6.49	2.21e-10	5.18e-08	-0.23	-0.29	Systemic lupus erythematosus;	chr6:135670039	chr6:135497801~135716055:+
THCA	cis	rs6496044	0.568	rs2344436	ENSG00000259295.5	CSPG4P12	6.49	2.21e-10	5.18e-08	0.36	0.29	Interstitial lung disease;	chr15:85531675	chr15:85191438~85213905:+
THCA	cis	rs6496044	0.568	rs6496065	ENSG00000259295.5	CSPG4P12	6.49	2.21e-10	5.18e-08	0.36	0.29	Interstitial lung disease;	chr15:85532141	chr15:85191438~85213905:+
THCA	cis	rs6496044	0.568	rs6496066	ENSG00000259295.5	CSPG4P12	6.49	2.21e-10	5.18e-08	0.36	0.29	Interstitial lung disease;	chr15:85532231	chr15:85191438~85213905:+
THCA	cis	rs11603691	0.551	rs11602265	ENSG00000254662.1	RP11-872D17.4	-6.49	2.22e-10	5.19e-08	-0.48	-0.29	Low high density lipoprotein cholesterol levels;	chr11:57327032	chr11:57325603~57327958:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-6.49	2.22e-10	5.19e-08	-0.31	-0.29	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
THCA	cis	rs2303319	1	rs16845734	ENSG00000227403.1	AC009299.3	6.49	2.23e-10	5.21e-08	0.61	0.29	Cognitive function;	chr2:161268079	chr2:161244739~161249050:+
THCA	cis	rs7267979	0.744	rs6050464	ENSG00000274414.1	RP5-965G21.4	-6.49	2.23e-10	5.21e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25239007~25245229:-
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000228409.4	CCT6P1	6.49	2.23e-10	5.21e-08	0.34	0.29	Diabetic kidney disease;	chr7:65946971	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs2961102	ENSG00000228409.4	CCT6P1	6.49	2.23e-10	5.21e-08	0.34	0.29	Diabetic kidney disease;	chr7:65959671	chr7:65751142~65763354:+
THCA	cis	rs60678552	0.642	rs9488903	ENSG00000233558.1	RP3-486I3.4	6.49	2.23e-10	5.22e-08	0.42	0.29	Heschl's gyrus morphology;	chr6:116321749	chr6:116258493~116259115:-
THCA	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-6.49	2.23e-10	5.22e-08	-0.25	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
THCA	cis	rs1552244	0.816	rs13059144	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9968513	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs66559400	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9970867	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs68153882	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9971426	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs35056669	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9972487	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs3732967	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9973753	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs3732966	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9974056	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs13062917	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9975348	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.816	rs13076197	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9978089	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs34779351	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9980117	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs13077641	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9981251	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs13074282	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9983015	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs67895180	ENSG00000180385.7	EMC3-AS1	6.49	2.23e-10	5.22e-08	0.3	0.29	Alzheimer's disease;	chr3:9984395	chr3:9986893~10006990:+
THCA	cis	rs10208649	0.908	rs60776154	ENSG00000233266.1	HMGB1P31	6.49	2.23e-10	5.22e-08	0.66	0.29	Body mass index;	chr2:54026676	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.831	rs72906704	ENSG00000233266.1	HMGB1P31	6.49	2.23e-10	5.22e-08	0.66	0.29	Body mass index;	chr2:54028088	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.908	rs7556936	ENSG00000233266.1	HMGB1P31	6.49	2.23e-10	5.22e-08	0.66	0.29	Body mass index;	chr2:54028594	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.908	rs7583508	ENSG00000233266.1	HMGB1P31	6.49	2.23e-10	5.22e-08	0.66	0.29	Body mass index;	chr2:54028648	chr2:54051334~54051760:+
THCA	cis	rs375066	0.762	rs10424336	ENSG00000267058.1	RP11-15A1.3	-6.49	2.23e-10	5.22e-08	-0.25	-0.29	Breast cancer;	chr19:43887948	chr19:43891804~43901805:-
THCA	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-6.49	2.23e-10	5.23e-08	-0.27	-0.29	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
THCA	cis	rs1707322	0.682	rs3014241	ENSG00000281133.1	AL355480.3	6.49	2.24e-10	5.23e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45580892~45580996:-
THCA	cis	rs2976388	0.934	rs2920279	ENSG00000253741.1	CTD-2292P10.4	6.49	2.24e-10	5.23e-08	0.36	0.29	Urinary tract infection frequency;	chr8:142680717	chr8:142702252~142726973:-
THCA	cis	rs699371	0.525	rs7140692	ENSG00000270000.1	RP3-449M8.9	6.49	2.24e-10	5.23e-08	0.28	0.29	Height;	chr14:74434484	chr14:74471930~74472360:-
THCA	cis	rs4604234	0.901	rs73471414	ENSG00000272129.1	RP11-250B2.6	-6.49	2.24e-10	5.23e-08	-0.77	-0.29	Cancer;	chr6:80394685	chr6:80355424~80356859:+
THCA	cis	rs2562456	0.833	rs1781872	ENSG00000268555.1	RP11-678G14.3	6.49	2.24e-10	5.23e-08	0.47	0.29	Pain;	chr19:21294601	chr19:21570822~21587322:-
THCA	cis	rs797680	0.856	rs6703310	ENSG00000223745.6	RP4-717I23.3	6.49	2.24e-10	5.24e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93323183	chr1:93262186~93346025:-
THCA	cis	rs7976269	0.609	rs10843305	ENSG00000257176.2	RP11-996F15.2	-6.49	2.24e-10	5.25e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29073147	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs10843306	ENSG00000257176.2	RP11-996F15.2	-6.49	2.24e-10	5.25e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29073417	chr12:29280418~29317848:-
THCA	cis	rs4835473	0.932	rs13129993	ENSG00000251600.4	RP11-673E1.1	-6.49	2.25e-10	5.26e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143763076	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1580002	ENSG00000251600.4	RP11-673E1.1	-6.49	2.25e-10	5.26e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143766507	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs34521499	ENSG00000251600.4	RP11-673E1.1	-6.49	2.25e-10	5.26e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143777628	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs34264936	ENSG00000251600.4	RP11-673E1.1	-6.49	2.25e-10	5.26e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143780294	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13140028	ENSG00000251600.4	RP11-673E1.1	-6.49	2.25e-10	5.26e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143782195	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34324222	ENSG00000251600.4	RP11-673E1.1	-6.49	2.25e-10	5.26e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143784572	chr4:143912331~143982454:+
THCA	cis	rs17772222	0.917	rs8021690	ENSG00000258789.1	RP11-507K2.3	-6.49	2.25e-10	5.26e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88717806	chr14:88551597~88552493:+
THCA	cis	rs9393777	0.92	rs13207689	ENSG00000219392.1	RP1-265C24.5	-6.48	2.25e-10	5.26e-08	-0.63	-0.29	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28115628~28116551:+
THCA	cis	rs16958440	0.867	rs58061761	ENSG00000267800.1	RP11-49K24.5	-6.48	2.25e-10	5.27e-08	-0.63	-0.29	Sitting height ratio;	chr18:47159794	chr18:47137018~47137290:+
THCA	cis	rs1799810	0.523	rs11683986	ENSG00000236682.1	AC068282.3	6.48	2.26e-10	5.27e-08	0.41	0.29	Self-rated health;	chr2:127438822	chr2:127389130~127400580:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000228409.4	CCT6P1	-6.48	2.26e-10	5.28e-08	-0.22	-0.29	Calcium levels;	chr7:65829495	chr7:65751142~65763354:+
THCA	cis	rs7976269	0.609	rs2196482	ENSG00000257176.2	RP11-996F15.2	-6.48	2.26e-10	5.28e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29052559	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs2217906	ENSG00000257176.2	RP11-996F15.2	-6.48	2.26e-10	5.28e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29052626	chr12:29280418~29317848:-
THCA	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-6.48	2.26e-10	5.29e-08	-0.31	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
THCA	cis	rs7267979	1	rs6132835	ENSG00000274414.1	RP5-965G21.4	-6.48	2.26e-10	5.29e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25239007~25245229:-
THCA	cis	rs8042680	0.614	rs7171333	ENSG00000214432.8	AC068831.10	-6.48	2.26e-10	5.29e-08	-0.31	-0.29	Type 2 diabetes;	chr15:90963972	chr15:91022619~91036611:+
THCA	cis	rs11148252	0.846	rs7333451	ENSG00000235660.1	LINC00345	-6.48	2.26e-10	5.29e-08	-0.36	-0.29	Lewy body disease;	chr13:52473574	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.846	rs9379	ENSG00000235660.1	LINC00345	-6.48	2.26e-10	5.29e-08	-0.36	-0.29	Lewy body disease;	chr13:52476344	chr13:52484161~52484680:-
THCA	cis	rs848490	1	rs11765986	ENSG00000214293.7	APTR	6.48	2.26e-10	5.29e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77727957	chr7:77657660~77696265:-
THCA	cis	rs831571	1	rs17069791	ENSG00000280620.1	SCAANT1	6.48	2.26e-10	5.29e-08	0.5	0.29	Type 2 diabetes;	chr3:64066603	chr3:63911518~63911772:-
THCA	cis	rs4835473	0.932	rs13117421	ENSG00000251600.4	RP11-673E1.1	-6.48	2.27e-10	5.3e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143769405	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-6.48	2.27e-10	5.3e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
THCA	cis	rs950169	0.922	rs12910334	ENSG00000259295.5	CSPG4P12	6.48	2.27e-10	5.3e-08	0.44	0.29	Schizophrenia;	chr15:84403620	chr15:85191438~85213905:+
THCA	cis	rs7811142	1	rs60478351	ENSG00000078319.8	PMS2P1	-6.48	2.27e-10	5.3e-08	-0.41	-0.29	Platelet count;	chr7:100491394	chr7:100320992~100341908:-
THCA	cis	rs897984	0.609	rs4889609	ENSG00000279196.1	RP11-1072A3.3	6.48	2.27e-10	5.3e-08	0.29	0.29	Dementia with Lewy bodies;	chr16:31015106	chr16:30984630~30988270:-
THCA	cis	rs10844706	0.699	rs2058560	ENSG00000256594.6	RP11-705C15.2	6.48	2.27e-10	5.3e-08	0.24	0.29	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721093	chr12:9633419~9658412:+
THCA	cis	rs10899021	0.92	rs61901540	ENSG00000279353.1	RP11-864N7.4	6.48	2.27e-10	5.31e-08	0.56	0.29	Response to metformin (IC50);	chr11:74603820	chr11:74698231~74699658:-
THCA	cis	rs853679	1	rs735765	ENSG00000219392.1	RP1-265C24.5	-6.48	2.27e-10	5.31e-08	-0.48	-0.29	Depression;	chr6:28202519	chr6:28115628~28116551:+
THCA	cis	rs3806843	0.966	rs3806842	ENSG00000202515.1	VTRNA1-3	-6.48	2.27e-10	5.32e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140833091	chr5:140726158~140726246:+
THCA	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-6.48	2.28e-10	5.32e-08	-0.55	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
THCA	cis	rs8014252	0.614	rs28612538	ENSG00000259158.2	ADAM20P1	-6.48	2.28e-10	5.32e-08	-0.35	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70558489	chr14:70468881~70483756:-
THCA	cis	rs1552244	0.882	rs3846168	ENSG00000232901.1	CYCSP10	6.48	2.28e-10	5.32e-08	0.36	0.29	Alzheimer's disease;	chr3:9955241	chr3:10000647~10000940:-
THCA	cis	rs227275	0.554	rs223485	ENSG00000230069.3	LRRC37A15P	-6.48	2.28e-10	5.32e-08	-0.29	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102727274~102730721:-
THCA	cis	rs748404	0.631	rs28702649	ENSG00000166763.7	STRCP1	6.48	2.28e-10	5.32e-08	0.31	0.29	Lung cancer;	chr15:43356431	chr15:43699488~43718184:-
THCA	cis	rs17772222	0.917	rs61986671	ENSG00000258789.1	RP11-507K2.3	-6.48	2.28e-10	5.32e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88732917	chr14:88551597~88552493:+
THCA	cis	rs79349575	0.749	rs1057902	ENSG00000248278.1	SUMO2P17	6.48	2.28e-10	5.33e-08	0.33	0.29	Type 2 diabetes;	chr17:48928226	chr17:48874860~48908983:-
THCA	cis	rs7942368	0.941	rs1465900	ENSG00000204529.3	GUCY2EP	6.48	2.28e-10	5.33e-08	0.4	0.29	Endometriosis;	chr11:76762094	chr11:76694043~76707641:-
THCA	cis	rs7942368	1	rs10160660	ENSG00000204529.3	GUCY2EP	6.48	2.28e-10	5.33e-08	0.4	0.29	Endometriosis;	chr11:76763493	chr11:76694043~76707641:-
THCA	cis	rs5758659	0.904	rs134877	ENSG00000182057.4	OGFRP1	6.48	2.28e-10	5.33e-08	0.32	0.29	Cognitive function;	chr22:42266365	chr22:42269753~42275196:+
THCA	cis	rs6860806	0.507	rs183898	ENSG00000263597.1	MIR3936	-6.48	2.28e-10	5.33e-08	-0.29	-0.29	Breast cancer;	chr5:132381210	chr5:132365490~132365599:-
THCA	cis	rs4835473	0.932	rs3872	ENSG00000251600.4	RP11-673E1.1	6.48	2.28e-10	5.33e-08	0.38	0.29	Immature fraction of reticulocytes;	chr4:143968788	chr4:143912331~143982454:+
THCA	cis	rs853679	0.55	rs9295762	ENSG00000220721.1	OR1F12	-6.48	2.28e-10	5.34e-08	-0.38	-0.29	Depression;	chr6:28187640	chr6:28073316~28074233:+
THCA	cis	rs1876905	0.68	rs557028	ENSG00000255389.1	C6orf3	6.48	2.28e-10	5.34e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111599875~111602295:+
THCA	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-6.48	2.28e-10	5.34e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
THCA	cis	rs16843372	0.599	rs13393279	ENSG00000251491.2	OR7E28P	-6.48	2.28e-10	5.34e-08	-0.37	-0.29	Obesity-related traits;	chr2:158819216	chr2:158862311~158863285:+
THCA	cis	rs16843372	0.599	rs10207728	ENSG00000251491.2	OR7E28P	-6.48	2.28e-10	5.34e-08	-0.37	-0.29	Obesity-related traits;	chr2:158819604	chr2:158862311~158863285:+
THCA	cis	rs1552244	0.882	rs3755782	ENSG00000232901.1	CYCSP10	6.48	2.29e-10	5.34e-08	0.36	0.29	Alzheimer's disease;	chr3:9987621	chr3:10000647~10000940:-
THCA	cis	rs1979679	0.842	rs36097532	ENSG00000278733.1	RP11-425D17.1	6.48	2.29e-10	5.35e-08	0.28	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28228557	chr12:28185625~28186190:-
THCA	cis	rs4835473	0.932	rs11734290	ENSG00000251600.4	RP11-673E1.1	-6.48	2.29e-10	5.35e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143823636	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs11734383	ENSG00000251600.4	RP11-673E1.1	-6.48	2.29e-10	5.35e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143824093	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs11735295	ENSG00000251600.4	RP11-673E1.1	-6.48	2.29e-10	5.35e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143824150	chr4:143912331~143982454:+
THCA	cis	rs2120243	0.592	rs1456110	ENSG00000244515.1	KRT18P34	-6.48	2.29e-10	5.36e-08	-0.32	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157388283	chr3:157162663~157163932:-
THCA	cis	rs11148252	0.574	rs2038826	ENSG00000278238.1	RP11-245D16.4	-6.48	2.29e-10	5.36e-08	-0.33	-0.29	Lewy body disease;	chr13:52705878	chr13:52454775~52455331:-
THCA	cis	rs6672530	0.518	rs1407718	ENSG00000227711.2	RP11-275O4.5	-6.48	2.29e-10	5.36e-08	-0.3	-0.29	Hip circumference adjusted for BMI;	chr1:227691562	chr1:227509028~227520477:-
THCA	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-6.48	2.3e-10	5.37e-08	-0.35	-0.29	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
THCA	cis	rs7923837	0.65	rs10882098	ENSG00000236493.2	EIF2S2P3	6.48	2.3e-10	5.37e-08	0.3	0.29	Multiple sclerosis;Body mass index;	chr10:92685036	chr10:92668745~92669743:-
THCA	cis	rs7567389	0.583	rs11683427	ENSG00000236682.1	AC068282.3	-6.48	2.3e-10	5.37e-08	-0.41	-0.29	Self-rated health;	chr2:127198967	chr2:127389130~127400580:+
THCA	cis	rs17772222	1	rs2295135	ENSG00000258789.1	RP11-507K2.3	-6.48	2.3e-10	5.38e-08	-0.3	-0.29	Coronary artery calcification;	chr14:88427866	chr14:88551597~88552493:+
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000228409.4	CCT6P1	6.48	2.31e-10	5.39e-08	0.32	0.29	Diabetic kidney disease;	chr7:66100518	chr7:65751142~65763354:+
THCA	cis	rs4835473	0.868	rs1828503	ENSG00000251600.4	RP11-673E1.1	-6.48	2.31e-10	5.39e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143993354	chr4:143912331~143982454:+
THCA	cis	rs6065	0.529	rs113183521	ENSG00000234203.1	RP5-1050D4.2	6.48	2.31e-10	5.4e-08	0.59	0.29	Platelet count;	chr17:5026820	chr17:4972851~4974681:+
THCA	cis	rs2282300	0.956	rs654710	ENSG00000242353.1	RP4-710M3.1	6.48	2.31e-10	5.4e-08	0.26	0.29	Morning vs. evening chronotype;	chr11:30372756	chr11:30368148~30368646:+
THCA	cis	rs1707322	0.717	rs1972410	ENSG00000281133.1	AL355480.3	-6.48	2.31e-10	5.4e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45580892~45580996:-
THCA	cis	rs28386778	0.897	rs9912557	ENSG00000240280.5	TCAM1P	-6.48	2.32e-10	5.41e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63707603	chr17:63849292~63864379:+
THCA	cis	rs35264875	1	rs72928636	ENSG00000259799.1	RP11-554A11.9	6.48	2.32e-10	5.42e-08	0.49	0.29	Blond vs. brown hair color;	chr11:69080918	chr11:69155910~69159752:+
THCA	cis	rs35264875	1	rs72928644	ENSG00000259799.1	RP11-554A11.9	6.48	2.32e-10	5.42e-08	0.49	0.29	Blond vs. brown hair color;	chr11:69082377	chr11:69155910~69159752:+
THCA	cis	rs35264875	1	rs1542334	ENSG00000259799.1	RP11-554A11.9	6.48	2.32e-10	5.42e-08	0.49	0.29	Blond vs. brown hair color;	chr11:69083305	chr11:69155910~69159752:+
THCA	cis	rs35264875	1	rs72928652	ENSG00000259799.1	RP11-554A11.9	6.48	2.32e-10	5.42e-08	0.49	0.29	Blond vs. brown hair color;	chr11:69084079	chr11:69155910~69159752:+
THCA	cis	rs7015630	0.657	rs10094579	ENSG00000251136.7	RP11-37B2.1	-6.48	2.32e-10	5.43e-08	-0.32	-0.29	Inflammatory bowel disease;Crohn's disease;	chr8:89837077	chr8:89609409~89757727:-
THCA	cis	rs143626010	1	rs143626010	ENSG00000278665.1	RP11-666O2.4	6.48	2.33e-10	5.43e-08	0.33	0.29	Mosquito bite size;	chr16:28528081	chr16:28599241~28601881:-
THCA	cis	rs3806843	1	rs12717860	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140791857	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs6870764	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140792205	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs6891995	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140792423	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs13184940	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140793333	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs1476768	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140794012	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs9686540	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140795037	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs3756339	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140800952	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs3733708	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140802149	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs2240694	ENSG00000202515.1	VTRNA1-3	-6.48	2.33e-10	5.43e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140803473	chr5:140726158~140726246:+
THCA	cis	rs2243480	1	rs1546059	ENSG00000229886.1	RP5-1132H15.3	-6.48	2.33e-10	5.44e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66189722	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs2420170	ENSG00000229886.1	RP5-1132H15.3	-6.48	2.33e-10	5.44e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66191066	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6958289	ENSG00000229886.1	RP5-1132H15.3	-6.48	2.33e-10	5.44e-08	-0.46	-0.29	Diabetic kidney disease;	chr7:66192124	chr7:66025126~66031544:-
THCA	cis	rs897984	0.76	rs11076	ENSG00000279196.1	RP11-1072A3.3	-6.48	2.34e-10	5.45e-08	-0.28	-0.29	Dementia with Lewy bodies;	chr16:30984207	chr16:30984630~30988270:-
THCA	cis	rs7208859	0.673	rs423151	ENSG00000263603.1	CTD-2349P21.5	-6.48	2.34e-10	5.45e-08	-0.47	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30729469~30731202:+
THCA	cis	rs6840360	0.642	rs2034061	ENSG00000251611.1	RP11-610P16.1	-6.48	2.34e-10	5.45e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs7682837	ENSG00000251611.1	RP11-610P16.1	-6.48	2.34e-10	5.45e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151407551~151408835:-
THCA	cis	rs7267979	1	rs6083844	ENSG00000274414.1	RP5-965G21.4	6.48	2.34e-10	5.46e-08	0.33	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25239007~25245229:-
THCA	cis	rs1552244	0.882	rs67762674	ENSG00000232901.1	CYCSP10	6.48	2.34e-10	5.46e-08	0.37	0.29	Alzheimer's disease;	chr3:9972801	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.688	rs7645137	ENSG00000232901.1	CYCSP10	6.48	2.34e-10	5.46e-08	0.37	0.29	Alzheimer's disease;	chr3:9978865	chr3:10000647~10000940:-
THCA	cis	rs5758659	0.714	rs133373	ENSG00000270083.1	RP1-257I20.14	6.48	2.34e-10	5.47e-08	0.3	0.29	Cognitive function;	chr22:42069784	chr22:42089630~42090028:-
THCA	cis	rs17772222	0.917	rs8006652	ENSG00000258789.1	RP11-507K2.3	-6.48	2.34e-10	5.47e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88631290	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs12587200	ENSG00000258789.1	RP11-507K2.3	-6.48	2.34e-10	5.47e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88632060	chr14:88551597~88552493:+
THCA	cis	rs4273100	1	rs16960499	ENSG00000265185.4	SNORD3B-1	6.48	2.34e-10	5.47e-08	0.44	0.29	Schizophrenia;	chr17:19299719	chr17:19061912~19062669:+
THCA	cis	rs6840360	0.642	rs6855845	ENSG00000251611.1	RP11-610P16.1	-6.48	2.35e-10	5.48e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151407551~151408835:-
THCA	cis	rs7267979	0.933	rs11699203	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.933	rs6138571	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.966	rs416745	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs448396	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs447722	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs422424	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs422844	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs401166	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25239007~25245229:-
THCA	cis	rs7267979	1	rs404394	ENSG00000274414.1	RP5-965G21.4	-6.48	2.35e-10	5.48e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25239007~25245229:-
THCA	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-6.48	2.35e-10	5.48e-08	-0.33	-0.29	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
THCA	cis	rs17772222	0.917	rs61986664	ENSG00000258789.1	RP11-507K2.3	-6.48	2.35e-10	5.48e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88711251	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.876	rs61986665	ENSG00000258789.1	RP11-507K2.3	-6.48	2.35e-10	5.48e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88711354	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs8018755	ENSG00000258789.1	RP11-507K2.3	-6.48	2.35e-10	5.48e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88714249	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs8018630	ENSG00000258789.1	RP11-507K2.3	-6.48	2.35e-10	5.48e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88714250	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs8020072	ENSG00000258789.1	RP11-507K2.3	-6.48	2.35e-10	5.48e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88714332	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs17260408	ENSG00000258789.1	RP11-507K2.3	-6.48	2.35e-10	5.48e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88715464	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs12589982	ENSG00000258789.1	RP11-507K2.3	-6.48	2.35e-10	5.48e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88716861	chr14:88551597~88552493:+
THCA	cis	rs17684571	0.938	rs17751695	ENSG00000231441.1	RP11-472M19.2	6.48	2.35e-10	5.48e-08	0.38	0.29	Schizophrenia;	chr6:56695966	chr6:56844002~56864078:+
THCA	cis	rs2280018	0.538	rs7404526	ENSG00000188599.16	NPIPP1	-6.48	2.35e-10	5.48e-08	-0.22	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15104312~15123498:-
THCA	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-6.48	2.35e-10	5.48e-08	-0.35	-0.29	AIDS;	chr2:105333211	chr2:105324210~105330529:+
THCA	cis	rs72843506	0.722	rs78041331	ENSG00000270091.1	RP11-78O7.2	-6.48	2.35e-10	5.49e-08	-0.33	-0.29	Schizophrenia;	chr17:20305533	chr17:19896590~19897287:-
THCA	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-6.48	2.35e-10	5.49e-08	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
THCA	cis	rs8062405	0.755	rs17640009	ENSG00000278665.1	RP11-666O2.4	6.48	2.35e-10	5.49e-08	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28599241~28601881:-
THCA	cis	rs4835473	0.808	rs6836630	ENSG00000251600.4	RP11-673E1.1	-6.48	2.35e-10	5.49e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143801068	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13101541	ENSG00000251600.4	RP11-673E1.1	-6.48	2.35e-10	5.49e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143806590	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs17695238	ENSG00000251600.4	RP11-673E1.1	-6.48	2.35e-10	5.49e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143820720	chr4:143912331~143982454:+
THCA	cis	rs9388451	0.626	rs1739384	ENSG00000237742.5	RP11-624M8.1	-6.48	2.36e-10	5.49e-08	-0.25	-0.29	Brugada syndrome;	chr6:125778100	chr6:125578558~125749190:-
THCA	cis	rs17772222	0.876	rs12436982	ENSG00000258789.1	RP11-507K2.3	-6.48	2.36e-10	5.49e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88689862	chr14:88551597~88552493:+
THCA	cis	rs4604234	0.901	rs59779073	ENSG00000272129.1	RP11-250B2.6	-6.48	2.36e-10	5.5e-08	-0.78	-0.29	Cancer;	chr6:80394880	chr6:80355424~80356859:+
THCA	cis	rs848490	0.851	rs57394986	ENSG00000214293.7	APTR	6.48	2.36e-10	5.5e-08	0.22	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77587686	chr7:77657660~77696265:-
THCA	cis	rs4650994	0.525	rs4651000	ENSG00000273384.1	RP5-1098D14.1	6.48	2.36e-10	5.5e-08	0.35	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178563088	chr1:178651706~178652282:+
THCA	cis	rs17772222	0.917	rs10143767	ENSG00000222990.1	RNU4-22P	6.48	2.36e-10	5.51e-08	0.37	0.29	Coronary artery calcification;	chr14:88514867	chr14:88513498~88513663:+
THCA	cis	rs9329221	0.597	rs17751178	ENSG00000261451.1	RP11-981G7.1	6.48	2.36e-10	5.51e-08	0.37	0.29	Neuroticism;	chr8:10259220	chr8:10433672~10438312:+
THCA	cis	rs4713118	0.628	rs9295740	ENSG00000219392.1	RP1-265C24.5	-6.48	2.36e-10	5.51e-08	-0.39	-0.29	Parkinson's disease;	chr6:27721723	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	6.48	2.37e-10	5.52e-08	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
THCA	cis	rs1707322	0.656	rs9429172	ENSG00000281133.1	AL355480.3	6.48	2.37e-10	5.52e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45580892~45580996:-
THCA	cis	rs6840360	0.539	rs1443087	ENSG00000251611.1	RP11-610P16.1	-6.48	2.37e-10	5.52e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.642	rs1443088	ENSG00000251611.1	RP11-610P16.1	-6.48	2.37e-10	5.52e-08	-0.21	-0.29	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151407551~151408835:-
THCA	cis	rs4072705	1	rs4838203	ENSG00000224020.1	MIR181A2HG	-6.48	2.37e-10	5.52e-08	-0.25	-0.29	Menarche (age at onset);	chr9:124736095	chr9:124658467~124698631:+
THCA	cis	rs2834188	0.924	rs6517160	ENSG00000272659.1	AP000295.10	-6.48	2.37e-10	5.52e-08	-0.39	-0.29	Narcolepsy;	chr21:33311207	chr21:33309491~33310181:+
THCA	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-6.48	2.37e-10	5.52e-08	-0.43	-0.29	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	6.48	2.37e-10	5.53e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
THCA	cis	rs4713118	0.513	rs9368547	ENSG00000280107.1	AL022393.9	-6.48	2.37e-10	5.53e-08	-0.3	-0.29	Parkinson's disease;	chr6:28060289	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.513	rs183244	ENSG00000280107.1	AL022393.9	-6.48	2.37e-10	5.53e-08	-0.3	-0.29	Parkinson's disease;	chr6:28064060	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.513	rs149950	ENSG00000280107.1	AL022393.9	-6.48	2.37e-10	5.53e-08	-0.3	-0.29	Parkinson's disease;	chr6:28065261	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.513	rs149951	ENSG00000280107.1	AL022393.9	-6.48	2.37e-10	5.53e-08	-0.3	-0.29	Parkinson's disease;	chr6:28065309	chr6:28170845~28172521:+
THCA	cis	rs916888	0.61	rs199444	ENSG00000232300.1	FAM215B	6.48	2.37e-10	5.53e-08	0.4	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46558830~46562795:-
THCA	cis	rs916888	0.61	rs199442	ENSG00000232300.1	FAM215B	6.48	2.37e-10	5.53e-08	0.4	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46558830~46562795:-
THCA	cis	rs8007846	0.588	rs11158611	ENSG00000276116.2	FUT8-AS1	6.48	2.38e-10	5.54e-08	0.28	0.29	Multiple sclerosis--Brain Glutamate Levels;	chr14:65768356	chr14:65411170~65412690:-
THCA	cis	rs8007846	0.588	rs11628840	ENSG00000276116.2	FUT8-AS1	6.48	2.38e-10	5.54e-08	0.28	0.29	Multiple sclerosis--Brain Glutamate Levels;	chr14:65768924	chr14:65411170~65412690:-
THCA	cis	rs8007846	0.588	rs4902415	ENSG00000276116.2	FUT8-AS1	6.48	2.38e-10	5.54e-08	0.28	0.29	Multiple sclerosis--Brain Glutamate Levels;	chr14:65768972	chr14:65411170~65412690:-
THCA	cis	rs1005277	0.683	rs7923868	ENSG00000263064.2	RP11-291L22.7	6.48	2.38e-10	5.54e-08	0.32	0.29	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38448689~38448949:+
THCA	cis	rs748404	0.578	rs510108	ENSG00000166763.7	STRCP1	6.48	2.38e-10	5.54e-08	0.3	0.29	Lung cancer;	chr15:43313241	chr15:43699488~43718184:-
THCA	cis	rs523522	0.962	rs1050187	ENSG00000278344.1	RP11-18C24.8	-6.48	2.38e-10	5.54e-08	-0.31	-0.29	High light scatter reticulocyte count;	chr12:120464308	chr12:120500735~120501090:-
THCA	cis	rs227275	0.554	rs223319	ENSG00000230069.3	LRRC37A15P	-6.48	2.38e-10	5.55e-08	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102727274~102730721:-
THCA	cis	rs228614	0.509	rs223318	ENSG00000230069.3	LRRC37A15P	-6.48	2.38e-10	5.55e-08	-0.3	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223315	ENSG00000230069.3	LRRC37A15P	-6.48	2.38e-10	5.55e-08	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102727274~102730721:-
THCA	cis	rs1499614	1	rs2659913	ENSG00000228409.4	CCT6P1	6.48	2.38e-10	5.55e-08	0.34	0.29	Gout;	chr7:66692349	chr7:65751142~65763354:+
THCA	cis	rs1499614	1	rs2659911	ENSG00000228409.4	CCT6P1	6.48	2.38e-10	5.55e-08	0.34	0.29	Gout;	chr7:66693433	chr7:65751142~65763354:+
THCA	cis	rs1499614	1	rs2707838	ENSG00000228409.4	CCT6P1	6.48	2.38e-10	5.55e-08	0.34	0.29	Gout;	chr7:66694214	chr7:65751142~65763354:+
THCA	cis	rs1499614	1	rs60326618	ENSG00000228409.4	CCT6P1	6.48	2.38e-10	5.55e-08	0.34	0.29	Gout;	chr7:66701371	chr7:65751142~65763354:+
THCA	cis	rs1499614	1	rs2707830	ENSG00000228409.4	CCT6P1	6.48	2.38e-10	5.55e-08	0.34	0.29	Gout;	chr7:66702658	chr7:65751142~65763354:+
THCA	cis	rs1499614	1	rs2707828	ENSG00000228409.4	CCT6P1	6.48	2.38e-10	5.55e-08	0.34	0.29	Gout;	chr7:66706390	chr7:65751142~65763354:+
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000228409.4	CCT6P1	6.48	2.38e-10	5.55e-08	0.34	0.29	Gout;	chr7:66710076	chr7:65751142~65763354:+
THCA	cis	rs1499614	1	rs2659903	ENSG00000228409.4	CCT6P1	6.48	2.38e-10	5.55e-08	0.34	0.29	Gout;	chr7:66715944	chr7:65751142~65763354:+
THCA	cis	rs1865760	0.713	rs1130000	ENSG00000272462.2	U91328.19	-6.48	2.38e-10	5.55e-08	-0.23	-0.29	Height;	chr6:25985168	chr6:25992662~26001775:+
THCA	cis	rs8007846	0.588	rs12050182	ENSG00000276116.2	FUT8-AS1	6.48	2.38e-10	5.56e-08	0.29	0.29	Multiple sclerosis--Brain Glutamate Levels;	chr14:65776362	chr14:65411170~65412690:-
THCA	cis	rs9402743	1	rs6926161	ENSG00000231028.7	LINC00271	-6.48	2.39e-10	5.56e-08	-0.23	-0.29	Systemic lupus erythematosus;	chr6:135653341	chr6:135497801~135716055:+
THCA	cis	rs9388451	0.657	rs4895799	ENSG00000237742.5	RP11-624M8.1	-6.48	2.39e-10	5.56e-08	-0.25	-0.29	Brugada syndrome;	chr6:125731583	chr6:125578558~125749190:-
THCA	cis	rs2562456	0.833	rs2650801	ENSG00000268119.4	CTD-2561J22.5	6.48	2.39e-10	5.57e-08	0.38	0.29	Pain;	chr19:21452553	chr19:21444241~21463908:-
THCA	cis	rs728616	0.867	rs41302709	ENSG00000225484.5	NUTM2B-AS1	-6.47	2.39e-10	5.57e-08	-0.53	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047522	chr10:79663088~79826594:-
THCA	cis	rs11158026	0.757	rs6572994	ENSG00000258413.1	RP11-665C16.6	-6.47	2.39e-10	5.58e-08	-0.39	-0.29	Parkinson's disease;	chr14:54960385	chr14:55262767~55272075:-
THCA	cis	rs7260598	0.642	rs73023276	ENSG00000268442.1	CTD-2027I19.2	6.47	2.39e-10	5.58e-08	0.38	0.29	Response to taxane treatment (placlitaxel);	chr19:23976045	chr19:24162370~24163425:-
THCA	cis	rs11749327	0.719	rs72698512	ENSG00000225138.6	CTD-2228K2.7	-6.47	2.4e-10	5.58e-08	-0.37	-0.29	Hemoglobin concentration;Hypospadias;	chr5:467028	chr5:473236~480884:+
THCA	cis	rs11749327	0.688	rs72698513	ENSG00000225138.6	CTD-2228K2.7	-6.47	2.4e-10	5.58e-08	-0.37	-0.29	Hemoglobin concentration;Hypospadias;	chr5:467029	chr5:473236~480884:+
THCA	cis	rs11749327	0.678	rs72698514	ENSG00000225138.6	CTD-2228K2.7	-6.47	2.4e-10	5.58e-08	-0.37	-0.29	Hemoglobin concentration;Hypospadias;	chr5:468629	chr5:473236~480884:+
THCA	cis	rs12188164	0.507	rs115438441	ENSG00000225138.6	CTD-2228K2.7	-6.47	2.4e-10	5.58e-08	-0.37	-0.29	Cystic fibrosis severity;	chr5:469537	chr5:473236~480884:+
THCA	cis	rs11749327	0.719	rs11169	ENSG00000225138.6	CTD-2228K2.7	-6.47	2.4e-10	5.58e-08	-0.37	-0.29	Hemoglobin concentration;Hypospadias;	chr5:470548	chr5:473236~480884:+
THCA	cis	rs11749327	0.719	rs3315	ENSG00000225138.6	CTD-2228K2.7	-6.47	2.4e-10	5.58e-08	-0.37	-0.29	Hemoglobin concentration;Hypospadias;	chr5:470580	chr5:473236~480884:+
THCA	cis	rs11749327	0.719	rs72698516	ENSG00000225138.6	CTD-2228K2.7	-6.47	2.4e-10	5.58e-08	-0.37	-0.29	Hemoglobin concentration;Hypospadias;	chr5:472106	chr5:473236~480884:+
THCA	cis	rs7208859	0.562	rs216408	ENSG00000264538.5	SUZ12P1	6.47	2.4e-10	5.58e-08	0.27	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30709299~30790908:+
THCA	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-6.47	2.4e-10	5.58e-08	-0.17	-0.29	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
THCA	cis	rs7403037	0.652	rs4778457	ENSG00000259905.4	PWRN1	6.47	2.4e-10	5.58e-08	0.31	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24318136	chr15:24493137~24652130:+
THCA	cis	rs16958440	0.867	rs78854354	ENSG00000267800.1	RP11-49K24.5	-6.47	2.4e-10	5.59e-08	-0.61	-0.29	Sitting height ratio;	chr18:47140553	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs79078752	ENSG00000267800.1	RP11-49K24.5	-6.47	2.4e-10	5.59e-08	-0.61	-0.29	Sitting height ratio;	chr18:47141091	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs61689863	ENSG00000267800.1	RP11-49K24.5	-6.47	2.4e-10	5.59e-08	-0.61	-0.29	Sitting height ratio;	chr18:47142786	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs80064497	ENSG00000267800.1	RP11-49K24.5	-6.47	2.4e-10	5.59e-08	-0.61	-0.29	Sitting height ratio;	chr18:47143282	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs78547658	ENSG00000267800.1	RP11-49K24.5	-6.47	2.4e-10	5.59e-08	-0.61	-0.29	Sitting height ratio;	chr18:47143481	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs12386092	ENSG00000267800.1	RP11-49K24.5	-6.47	2.4e-10	5.59e-08	-0.61	-0.29	Sitting height ratio;	chr18:47145687	chr18:47137018~47137290:+
THCA	cis	rs9926296	0.568	rs7203907	ENSG00000260259.1	RP11-368I7.4	-6.47	2.4e-10	5.59e-08	-0.31	-0.29	Vitiligo;	chr16:89767366	chr16:89682620~89686569:-
THCA	cis	rs3750082	0.632	rs35165932	ENSG00000231952.3	DPY19L1P2	6.47	2.4e-10	5.59e-08	0.39	0.29	Glomerular filtration rate (creatinine);	chr7:32886648	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.692	rs10248993	ENSG00000231952.3	DPY19L1P2	6.47	2.4e-10	5.59e-08	0.39	0.29	Glomerular filtration rate (creatinine);	chr7:32887535	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.692	rs34737146	ENSG00000231952.3	DPY19L1P2	6.47	2.4e-10	5.59e-08	0.39	0.29	Glomerular filtration rate (creatinine);	chr7:32896314	chr7:32812757~32838570:+
THCA	cis	rs848490	0.926	rs17807580	ENSG00000214293.7	APTR	6.47	2.4e-10	5.6e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77829461	chr7:77657660~77696265:-
THCA	cis	rs1395	0.571	rs114507490	ENSG00000234072.1	AC074117.10	-6.47	2.4e-10	5.6e-08	-0.26	-0.29	Blood metabolite levels;	chr2:27304378	chr2:27356246~27367622:+
THCA	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-6.47	2.41e-10	5.6e-08	-0.3	-0.29	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
THCA	cis	rs2243480	1	rs778729	ENSG00000229886.1	RP5-1132H15.3	6.47	2.41e-10	5.6e-08	0.48	0.29	Diabetic kidney disease;	chr7:66359432	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.901	rs778687	ENSG00000229886.1	RP5-1132H15.3	6.47	2.41e-10	5.6e-08	0.48	0.29	Diabetic kidney disease;	chr7:66370832	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs778679	ENSG00000229886.1	RP5-1132H15.3	6.47	2.41e-10	5.6e-08	0.48	0.29	Diabetic kidney disease;	chr7:66375924	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs778704	ENSG00000229886.1	RP5-1132H15.3	6.47	2.41e-10	5.6e-08	0.48	0.29	Diabetic kidney disease;	chr7:66398480	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.901	rs778693	ENSG00000229886.1	RP5-1132H15.3	6.47	2.41e-10	5.6e-08	0.48	0.29	Diabetic kidney disease;	chr7:66407358	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs778691	ENSG00000229886.1	RP5-1132H15.3	6.47	2.41e-10	5.6e-08	0.48	0.29	Diabetic kidney disease;	chr7:66408105	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs13235972	ENSG00000229886.1	RP5-1132H15.3	6.47	2.41e-10	5.6e-08	0.48	0.29	Diabetic kidney disease;	chr7:66418618	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34192067	ENSG00000229886.1	RP5-1132H15.3	6.47	2.41e-10	5.6e-08	0.48	0.29	Diabetic kidney disease;	chr7:66422670	chr7:66025126~66031544:-
THCA	cis	rs848490	0.855	rs55860308	ENSG00000214293.7	APTR	6.47	2.41e-10	5.61e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77616657	chr7:77657660~77696265:-
THCA	cis	rs7260598	1	rs7260598	ENSG00000268442.1	CTD-2027I19.2	-6.47	2.41e-10	5.61e-08	-0.38	-0.29	Response to taxane treatment (placlitaxel);	chr19:24039984	chr19:24162370~24163425:-
THCA	cis	rs848490	0.925	rs848488	ENSG00000214293.7	APTR	-6.47	2.41e-10	5.62e-08	-0.23	-0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77925160	chr7:77657660~77696265:-
THCA	cis	rs35264875	1	rs72919432	ENSG00000259799.1	RP11-554A11.9	6.47	2.41e-10	5.62e-08	0.5	0.29	Blond vs. brown hair color;	chr11:69062486	chr11:69155910~69159752:+
THCA	cis	rs916888	0.647	rs199524	ENSG00000232300.1	FAM215B	-6.47	2.41e-10	5.62e-08	-0.4	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46558830~46562795:-
THCA	cis	rs7615952	0.611	rs35321002	ENSG00000241288.6	RP11-379B18.5	-6.47	2.41e-10	5.62e-08	-0.4	-0.29	Blood pressure (smoking interaction);	chr3:125893222	chr3:125827238~125916384:-
THCA	cis	rs6504622	0.967	rs9889762	ENSG00000262879.4	RP11-156P1.3	6.47	2.41e-10	5.62e-08	0.26	0.29	Orofacial clefts;	chr17:46949000	chr17:46984045~47100323:-
THCA	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-6.47	2.42e-10	5.63e-08	-0.44	-0.29	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
THCA	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-6.47	2.42e-10	5.64e-08	-0.33	-0.29	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
THCA	cis	rs2120243	0.539	rs12629552	ENSG00000244515.1	KRT18P34	-6.47	2.42e-10	5.64e-08	-0.34	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157368841	chr3:157162663~157163932:-
THCA	cis	rs748404	0.631	rs11070399	ENSG00000166763.7	STRCP1	6.47	2.43e-10	5.65e-08	0.31	0.29	Lung cancer;	chr15:43354149	chr15:43699488~43718184:-
THCA	cis	rs10208649	0.908	rs11904365	ENSG00000233266.1	HMGB1P31	-6.47	2.43e-10	5.65e-08	-0.66	-0.29	Body mass index;	chr2:53998444	chr2:54051334~54051760:+
THCA	cis	rs6496044	0.568	rs11636764	ENSG00000259295.5	CSPG4P12	6.47	2.43e-10	5.65e-08	0.37	0.29	Interstitial lung disease;	chr15:85536520	chr15:85191438~85213905:+
THCA	cis	rs6496044	0.591	rs979825	ENSG00000259295.5	CSPG4P12	6.47	2.43e-10	5.65e-08	0.37	0.29	Interstitial lung disease;	chr15:85537394	chr15:85191438~85213905:+
THCA	cis	rs6496044	0.547	rs8039929	ENSG00000259295.5	CSPG4P12	6.47	2.43e-10	5.65e-08	0.37	0.29	Interstitial lung disease;	chr15:85537731	chr15:85191438~85213905:+
THCA	cis	rs116139393	0.561	rs62439737	ENSG00000187953.9	PMS2CL	-6.47	2.43e-10	5.66e-08	-0.37	-0.29	Alzheimer's disease (APOE e4 interaction);	chr7:6740179	chr7:6710128~6753862:+
THCA	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-6.47	2.43e-10	5.66e-08	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
THCA	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-6.47	2.43e-10	5.66e-08	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
THCA	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-6.47	2.43e-10	5.66e-08	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
THCA	cis	rs2236295	0.503	rs10822064	ENSG00000238280.1	RP11-436D10.3	6.47	2.43e-10	5.66e-08	0.35	0.29	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62849964	chr10:62793562~62805887:-
THCA	cis	rs28386778	0.966	rs2854206	ENSG00000240280.5	TCAM1P	-6.47	2.43e-10	5.66e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63869843	chr17:63849292~63864379:+
THCA	cis	rs2439831	0.85	rs67541383	ENSG00000275601.1	AC011330.13	-6.47	2.43e-10	5.66e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43880350	chr15:43642389~43643023:-
THCA	cis	rs2976388	1	rs2920282	ENSG00000253741.1	CTD-2292P10.4	6.47	2.43e-10	5.66e-08	0.36	0.29	Urinary tract infection frequency;	chr8:142676345	chr8:142702252~142726973:-
THCA	cis	rs8014252	0.803	rs11158863	ENSG00000259158.2	ADAM20P1	6.47	2.44e-10	5.67e-08	0.37	0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70514449	chr14:70468881~70483756:-
THCA	cis	rs72843506	0.656	rs111249650	ENSG00000270091.1	RP11-78O7.2	-6.47	2.44e-10	5.67e-08	-0.33	-0.29	Schizophrenia;	chr17:20008517	chr17:19896590~19897287:-
THCA	cis	rs10992756	0.551	rs883784	ENSG00000227603.1	RP11-165J3.6	6.47	2.44e-10	5.67e-08	0.29	0.29	Intelligence (multi-trait analysis);	chr9:93519954	chr9:93435332~93437121:-
THCA	cis	rs2412819	0.571	rs4923965	ENSG00000249839.1	AC011330.5	6.47	2.44e-10	5.67e-08	0.41	0.29	Lung cancer;	chr15:43790232	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs4644832	ENSG00000249839.1	AC011330.5	6.47	2.44e-10	5.67e-08	0.41	0.29	Lung cancer;	chr15:43792507	chr15:43663654~43684339:-
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000263603.1	CTD-2349P21.5	-6.47	2.44e-10	5.68e-08	-0.46	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30729469~30731202:+
THCA	cis	rs6545883	0.894	rs6734628	ENSG00000271889.1	RP11-493E12.1	-6.47	2.44e-10	5.68e-08	-0.27	-0.29	Tuberculosis;	chr2:61224125	chr2:61151433~61162105:-
THCA	cis	rs17826219	0.706	rs609472	ENSG00000264538.5	SUZ12P1	-6.47	2.44e-10	5.68e-08	-0.27	-0.29	Body mass index;	chr17:30624409	chr17:30709299~30790908:+
THCA	cis	rs11148252	0.595	rs4885117	ENSG00000278238.1	RP11-245D16.4	-6.47	2.44e-10	5.68e-08	-0.32	-0.29	Lewy body disease;	chr13:52578892	chr13:52454775~52455331:-
THCA	cis	rs2348418	0.966	rs7315631	ENSG00000247934.4	RP11-967K21.1	6.47	2.45e-10	5.69e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28545311	chr12:28163298~28190738:-
THCA	cis	rs2282300	0.956	rs1717779	ENSG00000242353.1	RP4-710M3.1	-6.47	2.45e-10	5.7e-08	-0.26	-0.29	Morning vs. evening chronotype;	chr11:30355151	chr11:30368148~30368646:+
THCA	cis	rs860295	0.65	rs2993207	ENSG00000225855.5	RUSC1-AS1	-6.47	2.45e-10	5.7e-08	-0.19	-0.29	Body mass index;	chr1:155903523	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs781150	ENSG00000229886.1	RP5-1132H15.3	6.47	2.45e-10	5.7e-08	0.47	0.29	Diabetic kidney disease;	chr7:66015986	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs313798	ENSG00000229886.1	RP5-1132H15.3	6.47	2.45e-10	5.7e-08	0.47	0.29	Diabetic kidney disease;	chr7:66028044	chr7:66025126~66031544:-
THCA	cis	rs7044106	0.734	rs10491784	ENSG00000270917.1	RP11-27I1.6	-6.47	2.45e-10	5.71e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120812475~120812845:-
THCA	cis	rs797680	0.964	rs4000699	ENSG00000223745.6	RP4-717I23.3	6.47	2.46e-10	5.72e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93314248	chr1:93262186~93346025:-
THCA	cis	rs6860806	0.695	rs6867282	ENSG00000237714.1	P4HA2-AS1	6.47	2.46e-10	5.72e-08	0.36	0.29	Breast cancer;	chr5:132247427	chr5:132184876~132192808:+
THCA	cis	rs2976388	0.935	rs2976384	ENSG00000253741.1	CTD-2292P10.4	6.47	2.46e-10	5.72e-08	0.36	0.29	Urinary tract infection frequency;	chr8:142671576	chr8:142702252~142726973:-
THCA	cis	rs7044106	0.762	rs4837790	ENSG00000270917.1	RP11-27I1.6	-6.47	2.46e-10	5.72e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120812475~120812845:-
THCA	cis	rs4934494	0.834	rs3740033	ENSG00000232936.4	RP11-80H5.2	-6.47	2.46e-10	5.73e-08	-0.35	-0.29	Red blood cell count;	chr10:89634639	chr10:89645282~89650667:+
THCA	cis	rs1499614	1	rs2707840	ENSG00000228409.4	CCT6P1	6.47	2.47e-10	5.73e-08	0.34	0.29	Gout;	chr7:66693028	chr7:65751142~65763354:+
THCA	cis	rs6840258	0.76	rs10032244	ENSG00000251411.1	RP11-397E7.4	-6.47	2.47e-10	5.73e-08	-0.31	-0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86996779	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.689	rs6811587	ENSG00000251411.1	RP11-397E7.4	6.47	2.47e-10	5.73e-08	0.31	0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000653	chr4:86913266~86914817:-
THCA	cis	rs2717559	0.542	rs11774823	ENSG00000253741.1	CTD-2292P10.4	6.47	2.47e-10	5.74e-08	0.37	0.29	Urinary tract infection frequency;	chr8:142806152	chr8:142702252~142726973:-
THCA	cis	rs1707322	0.506	rs2991983	ENSG00000281133.1	AL355480.3	6.47	2.47e-10	5.74e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.717	rs3014249	ENSG00000281133.1	AL355480.3	6.47	2.47e-10	5.74e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45580892~45580996:-
THCA	cis	rs3847687	0.565	rs11061293	ENSG00000256810.1	RP11-76C10.2	6.47	2.47e-10	5.75e-08	0.34	0.29	Longevity;	chr12:131035034	chr12:131030570~131035487:-
THCA	cis	rs7131987	0.834	rs12228468	ENSG00000257176.2	RP11-996F15.2	6.47	2.47e-10	5.75e-08	0.29	0.29	QT interval;	chr12:29300677	chr12:29280418~29317848:-
THCA	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-6.47	2.47e-10	5.75e-08	-0.17	-0.29	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
THCA	cis	rs2006933	0.625	rs2125846	ENSG00000237575.4	PYY2	6.47	2.48e-10	5.76e-08	0.38	0.29	Amyotrophic lateral sclerosis;	chr17:28171022	chr17:28226563~28228065:+
THCA	cis	rs11148252	0.51	rs7337430	ENSG00000278238.1	RP11-245D16.4	-6.47	2.48e-10	5.76e-08	-0.31	-0.29	Lewy body disease;	chr13:52010108	chr13:52454775~52455331:-
THCA	cis	rs2120243	0.539	rs988588	ENSG00000244515.1	KRT18P34	-6.47	2.48e-10	5.76e-08	-0.33	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157336227	chr3:157162663~157163932:-
THCA	cis	rs890448	0.694	rs2583392	ENSG00000254531.1	FLJ20021	-6.47	2.48e-10	5.76e-08	-0.25	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101338208	chr4:101347780~101348883:+
THCA	cis	rs890448	0.726	rs2850326	ENSG00000254531.1	FLJ20021	-6.47	2.48e-10	5.76e-08	-0.25	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101343418	chr4:101347780~101348883:+
THCA	cis	rs11096990	0.892	rs28639548	ENSG00000249207.1	RP11-360F5.1	6.47	2.48e-10	5.77e-08	0.37	0.29	Cognitive function;	chr4:39185530	chr4:39112677~39126818:-
THCA	cis	rs7580658	0.613	rs12478656	ENSG00000236682.1	AC068282.3	-6.47	2.48e-10	5.77e-08	-0.38	-0.29	Protein C levels;	chr2:127438944	chr2:127389130~127400580:+
THCA	cis	rs7302981	0.667	rs7136648	ENSG00000272368.2	RP4-605O3.4	6.47	2.48e-10	5.77e-08	0.17	0.29	Systolic blood pressure;	chr12:50231039	chr12:50112197~50165618:+
THCA	cis	rs7976269	0.609	rs6487744	ENSG00000257176.2	RP11-996F15.2	-6.47	2.48e-10	5.77e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29030756	chr12:29280418~29317848:-
THCA	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-6.47	2.48e-10	5.78e-08	-0.31	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
THCA	cis	rs7267979	0.816	rs376742	ENSG00000274414.1	RP5-965G21.4	-6.47	2.49e-10	5.78e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25239007~25245229:-
THCA	cis	rs7851660	0.809	rs7032086	ENSG00000236130.1	PTCSC2	-6.47	2.49e-10	5.78e-08	-0.23	-0.29	Strep throat;	chr9:97894120	chr9:97805935~97810008:-
THCA	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	6.47	2.49e-10	5.8e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-6.47	2.49e-10	5.8e-08	-0.42	-0.29	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
THCA	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	6.47	2.5e-10	5.8e-08	0.34	0.29	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	6.47	2.5e-10	5.8e-08	0.34	0.29	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	6.47	2.5e-10	5.8e-08	0.34	0.29	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
THCA	cis	rs4835473	0.932	rs7669198	ENSG00000251600.4	RP11-673E1.1	-6.47	2.5e-10	5.8e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143821229	chr4:143912331~143982454:+
THCA	cis	rs17772222	0.917	rs12431548	ENSG00000258789.1	RP11-507K2.3	-6.47	2.5e-10	5.81e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88635826	chr14:88551597~88552493:+
THCA	cis	rs2243480	1	rs1499614	ENSG00000229886.1	RP5-1132H15.3	6.47	2.5e-10	5.81e-08	0.47	0.29	Diabetic kidney disease;	chr7:66265811	chr7:66025126~66031544:-
THCA	cis	rs2221433	1	rs1110269	ENSG00000260310.1	RP11-27M24.2	-6.47	2.5e-10	5.81e-08	-0.35	-0.29	Eating disorders;	chr16:10578731	chr16:10576499~10578183:-
THCA	cis	rs7727544	0.548	rs2069614	ENSG00000224431.1	AC063976.7	6.47	2.5e-10	5.81e-08	0.25	0.29	Blood metabolite levels;	chr5:132071908	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.548	rs2069616	ENSG00000224431.1	AC063976.7	6.47	2.5e-10	5.81e-08	0.25	0.29	Blood metabolite levels;	chr5:132072384	chr5:132199456~132203487:+
THCA	cis	rs1964356	0.967	rs17701675	ENSG00000253893.2	FAM85B	6.47	2.5e-10	5.81e-08	0.36	0.29	Mean corpuscular volume;	chr8:8993123	chr8:8167819~8226614:-
THCA	cis	rs2562456	0.754	rs112195516	ENSG00000268555.1	RP11-678G14.3	6.47	2.5e-10	5.81e-08	0.46	0.29	Pain;	chr19:21410849	chr19:21570822~21587322:-
THCA	cis	rs8030379	0.967	rs6603000	ENSG00000230373.7	GOLGA6L5P	-6.47	2.5e-10	5.82e-08	-0.27	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883142	chr15:84507885~84516814:-
THCA	cis	rs9388451	0.587	rs1739385	ENSG00000237742.5	RP11-624M8.1	-6.47	2.51e-10	5.83e-08	-0.25	-0.29	Brugada syndrome;	chr6:125778793	chr6:125578558~125749190:-
THCA	cis	rs35264875	1	rs72919412	ENSG00000259799.1	RP11-554A11.9	6.47	2.51e-10	5.83e-08	0.5	0.29	Blond vs. brown hair color;	chr11:69059387	chr11:69155910~69159752:+
THCA	cis	rs35264875	1	rs72919415	ENSG00000259799.1	RP11-554A11.9	6.47	2.51e-10	5.83e-08	0.5	0.29	Blond vs. brown hair color;	chr11:69059614	chr11:69155910~69159752:+
THCA	cis	rs2239547	0.523	rs6803486	ENSG00000242142.1	SERBP1P3	6.47	2.51e-10	5.83e-08	0.37	0.29	Schizophrenia;	chr3:53064193	chr3:53064283~53065091:-
THCA	cis	rs7302981	0.702	rs2358538	ENSG00000272368.2	RP4-605O3.4	-6.47	2.51e-10	5.83e-08	-0.17	-0.29	Systolic blood pressure;	chr12:50192844	chr12:50112197~50165618:+
THCA	cis	rs56804039	1	rs34154295	ENSG00000253893.2	FAM85B	6.47	2.51e-10	5.84e-08	0.41	0.29	Cervical cancer;	chr8:8525967	chr8:8167819~8226614:-
THCA	cis	rs853679	1	rs2799077	ENSG00000226314.6	ZNF192P1	-6.47	2.51e-10	5.84e-08	-0.44	-0.29	Depression;	chr6:28266819	chr6:28161781~28169594:+
THCA	cis	rs7225151	0.522	rs78534596	ENSG00000234327.6	AC012146.7	-6.47	2.51e-10	5.84e-08	-0.35	-0.29	Alzheimer's disease (late onset);	chr17:5232065	chr17:5111468~5115004:+
THCA	cis	rs6545883	0.894	rs778148	ENSG00000271889.1	RP11-493E12.1	-6.47	2.51e-10	5.84e-08	-0.28	-0.29	Tuberculosis;	chr2:61379731	chr2:61151433~61162105:-
THCA	cis	rs4683346	0.616	rs6779561	ENSG00000173811.9	CCDC13-AS1	6.47	2.51e-10	5.84e-08	0.29	0.29	Granulocyte percentage of myeloid white cells;	chr3:42808326	chr3:42732575~42746768:+
THCA	cis	rs7829975	0.564	rs2921060	ENSG00000254153.1	CTA-398F10.2	6.47	2.52e-10	5.85e-08	0.31	0.29	Mood instability;	chr8:8460307	chr8:8456909~8461337:-
THCA	cis	rs11096990	0.892	rs11937540	ENSG00000249207.1	RP11-360F5.1	6.47	2.52e-10	5.85e-08	0.37	0.29	Cognitive function;	chr4:39179897	chr4:39112677~39126818:-
THCA	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-6.47	2.52e-10	5.85e-08	-0.17	-0.29	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
THCA	cis	rs7044106	0.762	rs1411158	ENSG00000270917.1	RP11-27I1.6	-6.47	2.52e-10	5.85e-08	-0.4	-0.29	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120812475~120812845:-
THCA	cis	rs8014252	0.803	rs74712571	ENSG00000259158.2	ADAM20P1	-6.47	2.52e-10	5.86e-08	-0.37	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70520034	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs17108201	ENSG00000259158.2	ADAM20P1	-6.47	2.52e-10	5.86e-08	-0.37	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70522214	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.708	rs74062730	ENSG00000259158.2	ADAM20P1	-6.47	2.52e-10	5.86e-08	-0.37	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70524933	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs74062733	ENSG00000259158.2	ADAM20P1	-6.47	2.52e-10	5.86e-08	-0.37	-0.29	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70528677	chr14:70468881~70483756:-
THCA	cis	rs2243480	1	rs313831	ENSG00000228409.4	CCT6P1	6.47	2.52e-10	5.86e-08	0.32	0.29	Diabetic kidney disease;	chr7:66086239	chr7:65751142~65763354:+
THCA	cis	rs4713118	0.513	rs149962	ENSG00000280107.1	AL022393.9	-6.47	2.53e-10	5.87e-08	-0.3	-0.29	Parkinson's disease;	chr6:28048140	chr6:28170845~28172521:+
THCA	cis	rs7727544	0.709	rs441969	ENSG00000237714.1	P4HA2-AS1	6.47	2.53e-10	5.87e-08	0.37	0.29	Blood metabolite levels;	chr5:132366428	chr5:132184876~132192808:+
THCA	cis	rs3204270	0.81	rs8077959	ENSG00000262049.1	RP13-1032I1.7	6.47	2.53e-10	5.87e-08	0.26	0.29	Dental caries;	chr17:81703092	chr17:81701324~81703300:-
THCA	cis	rs3204270	0.759	rs8066217	ENSG00000262049.1	RP13-1032I1.7	6.47	2.53e-10	5.87e-08	0.26	0.29	Dental caries;	chr17:81705585	chr17:81701324~81703300:-
THCA	cis	rs7131987	0.801	rs6487804	ENSG00000257176.2	RP11-996F15.2	-6.47	2.53e-10	5.87e-08	-0.29	-0.29	QT interval;	chr12:29302001	chr12:29280418~29317848:-
THCA	cis	rs11722779	0.844	rs7694724	ENSG00000251288.2	RP11-10L12.2	-6.47	2.53e-10	5.87e-08	-0.39	-0.29	Schizophrenia;	chr4:103041375	chr4:102751401~102752641:+
THCA	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-6.47	2.53e-10	5.87e-08	-0.35	-0.29	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
THCA	cis	rs4950322	0.515	rs17160050	ENSG00000237188.3	RP11-337C18.8	6.47	2.53e-10	5.87e-08	0.34	0.29	Protein quantitative trait loci;	chr1:147255558	chr1:147172771~147211568:+
THCA	cis	rs28472312	0.667	rs9937676	ENSG00000251417.2	RP11-1348G14.4	6.47	2.53e-10	5.88e-08	0.25	0.29	Intelligence (multi-trait analysis);	chr16:28958159	chr16:28802743~28817828:+
THCA	cis	rs9402743	0.962	rs6935033	ENSG00000231028.7	LINC00271	-6.47	2.53e-10	5.88e-08	-0.22	-0.29	Systemic lupus erythematosus;	chr6:135659499	chr6:135497801~135716055:+
THCA	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	6.47	2.53e-10	5.88e-08	0.43	0.29	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
THCA	cis	rs227275	0.554	rs223357	ENSG00000230069.3	LRRC37A15P	-6.47	2.53e-10	5.89e-08	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102727274~102730721:-
THCA	cis	rs6545883	0.794	rs778152	ENSG00000271889.1	RP11-493E12.1	-6.47	2.53e-10	5.89e-08	-0.27	-0.29	Tuberculosis;	chr2:61381405	chr2:61151433~61162105:-
THCA	cis	rs7976269	0.559	rs4930848	ENSG00000257176.2	RP11-996F15.2	-6.47	2.53e-10	5.89e-08	-0.29	-0.29	Male-pattern baldness;	chr12:29068441	chr12:29280418~29317848:-
THCA	cis	rs797680	0.856	rs7540025	ENSG00000223745.6	RP4-717I23.3	-6.47	2.54e-10	5.89e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93293671	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs9432681	ENSG00000223745.6	RP4-717I23.3	-6.47	2.54e-10	5.89e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93296339	chr1:93262186~93346025:-
THCA	cis	rs934734	0.935	rs6711791	ENSG00000204929.10	AC074391.1	6.47	2.54e-10	5.89e-08	0.35	0.29	Rheumatoid arthritis;	chr2:65352094	chr2:65436711~66084639:+
THCA	cis	rs10483853	0.579	rs10134243	ENSG00000258695.2	RP3-414A15.2	-6.47	2.54e-10	5.89e-08	-0.43	-0.29	Coronary artery calcification;	chr14:73478444	chr14:73522878~73530610:+
THCA	cis	rs1964356	0.967	rs2953802	ENSG00000253893.2	FAM85B	-6.46	2.54e-10	5.91e-08	-0.36	-0.29	Mean corpuscular volume;	chr8:8994371	chr8:8167819~8226614:-
THCA	cis	rs516805	0.63	rs2606641	ENSG00000279453.1	RP3-425C14.4	-6.46	2.55e-10	5.91e-08	-0.3	-0.29	Lymphocyte counts;	chr6:122103704	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs2606643	ENSG00000279453.1	RP3-425C14.4	-6.46	2.55e-10	5.91e-08	-0.3	-0.29	Lymphocyte counts;	chr6:122104352	chr6:122436789~122439223:-
THCA	cis	rs516805	0.596	rs2606644	ENSG00000279453.1	RP3-425C14.4	-6.46	2.55e-10	5.91e-08	-0.3	-0.29	Lymphocyte counts;	chr6:122104734	chr6:122436789~122439223:-
THCA	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-6.46	2.55e-10	5.91e-08	-0.17	-0.29	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
THCA	cis	rs890448	0.726	rs2850367	ENSG00000254531.1	FLJ20021	-6.46	2.55e-10	5.92e-08	-0.25	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101310306	chr4:101347780~101348883:+
THCA	cis	rs2554380	0.628	rs6602993	ENSG00000230373.7	GOLGA6L5P	-6.46	2.55e-10	5.92e-08	-0.31	-0.29	Height;	chr15:83813610	chr15:84507885~84516814:-
THCA	cis	rs853679	0.527	rs9461443	ENSG00000226314.6	ZNF192P1	-6.46	2.55e-10	5.93e-08	-0.38	-0.29	Depression;	chr6:28226851	chr6:28161781~28169594:+
THCA	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-6.46	2.55e-10	5.93e-08	-0.17	-0.29	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
THCA	cis	rs6545883	1	rs6545883	ENSG00000271889.1	RP11-493E12.1	6.46	2.55e-10	5.93e-08	0.27	0.29	Tuberculosis;	chr2:61545122	chr2:61151433~61162105:-
THCA	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-6.46	2.56e-10	5.94e-08	-0.17	-0.29	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-6.46	2.56e-10	5.94e-08	-0.17	-0.29	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-6.46	2.56e-10	5.94e-08	-0.17	-0.29	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-6.46	2.56e-10	5.94e-08	-0.17	-0.29	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
THCA	cis	rs2243480	0.908	rs4718273	ENSG00000228409.4	CCT6P1	-6.46	2.56e-10	5.94e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:65751112	chr7:65751142~65763354:+
THCA	cis	rs2834188	0.924	rs2409487	ENSG00000272659.1	AP000295.10	-6.46	2.56e-10	5.95e-08	-0.38	-0.29	Narcolepsy;	chr21:33312653	chr21:33309491~33310181:+
THCA	cis	rs9859260	0.744	rs539816	ENSG00000226155.1	AC124944.3	6.46	2.57e-10	5.96e-08	0.34	0.29	Mean corpuscular volume;	chr3:196057205	chr3:195912049~195913986:+
THCA	cis	rs9859260	0.744	rs492349	ENSG00000226155.1	AC124944.3	6.46	2.57e-10	5.96e-08	0.34	0.29	Mean corpuscular volume;	chr3:196057321	chr3:195912049~195913986:+
THCA	cis	rs9859260	0.744	rs492288	ENSG00000226155.1	AC124944.3	6.46	2.57e-10	5.96e-08	0.34	0.29	Mean corpuscular volume;	chr3:196057339	chr3:195912049~195913986:+
THCA	cis	rs1707322	0.627	rs3014213	ENSG00000281133.1	AL355480.3	6.46	2.57e-10	5.96e-08	0.35	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.686	rs2152078	ENSG00000281133.1	AL355480.3	6.46	2.57e-10	5.96e-08	0.35	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.686	rs2991979	ENSG00000281133.1	AL355480.3	6.46	2.57e-10	5.96e-08	0.35	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	6.46	2.57e-10	5.96e-08	0.37	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
THCA	cis	rs8059260	0.604	rs2160042	ENSG00000274038.1	RP11-66H6.4	-6.46	2.57e-10	5.96e-08	-0.51	-0.29	Alcohol consumption over the past year;	chr16:11064375	chr16:11056556~11057034:+
THCA	cis	rs1707322	0.717	rs3014245	ENSG00000281133.1	AL355480.3	6.46	2.57e-10	5.97e-08	0.36	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45580892~45580996:-
THCA	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	6.46	2.58e-10	5.98e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	6.46	2.58e-10	5.98e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
THCA	cis	rs2915864	0.8	rs6580231	ENSG00000280047.1	CTC-463A16.1	6.46	2.58e-10	5.99e-08	0.43	0.29	Facial morphology (factor 20);	chr5:142150581	chr5:142165767~142168387:+
THCA	cis	rs12594515	0.6	rs12903858	ENSG00000259200.1	RP11-718O11.1	-6.46	2.58e-10	5.99e-08	-0.34	-0.29	Weight;Waist circumference;	chr15:45679968	chr15:45705078~45931069:+
THCA	cis	rs1552244	0.882	rs7633769	ENSG00000180385.7	EMC3-AS1	6.46	2.58e-10	5.99e-08	0.3	0.29	Alzheimer's disease;	chr3:9978938	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.751	rs12715665	ENSG00000180385.7	EMC3-AS1	6.46	2.58e-10	5.99e-08	0.3	0.29	Alzheimer's disease;	chr3:9979917	chr3:9986893~10006990:+
THCA	cis	rs699371	0.525	rs10138386	ENSG00000270000.1	RP3-449M8.9	6.46	2.58e-10	5.99e-08	0.28	0.29	Height;	chr14:74434183	chr14:74471930~74472360:-
THCA	cis	rs2834188	0.889	rs2040108	ENSG00000272659.1	AP000295.10	-6.46	2.58e-10	5.99e-08	-0.38	-0.29	Narcolepsy;	chr21:33303853	chr21:33309491~33310181:+
THCA	cis	rs7247513	0.856	rs6511828	ENSG00000213290.4	PGK1P2	-6.46	2.59e-10	6e-08	-0.35	-0.29	Bipolar disorder;	chr19:12634985	chr19:12559571~12561105:+
THCA	cis	rs7267979	0.816	rs6037158	ENSG00000274414.1	RP5-965G21.4	-6.46	2.59e-10	6e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25239007~25245229:-
THCA	cis	rs12681366	0.659	rs2450558	ENSG00000253704.1	RP11-267M23.4	-6.46	2.59e-10	6e-08	-0.27	-0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94398279	chr8:94553722~94569745:+
THCA	cis	rs11018904	0.906	rs36177012	ENSG00000280385.1	AP000648.5	-6.46	2.59e-10	6.01e-08	-0.38	-0.29	Intelligence (multi-trait analysis);	chr11:90200151	chr11:90193614~90198120:+
THCA	cis	rs11018904	0.906	rs7925507	ENSG00000280385.1	AP000648.5	-6.46	2.59e-10	6.01e-08	-0.38	-0.29	Intelligence (multi-trait analysis);	chr11:90206978	chr11:90193614~90198120:+
THCA	cis	rs35934224	0.831	rs8141610	ENSG00000232926.1	AC000078.5	-6.46	2.59e-10	6.01e-08	-0.34	-0.29	Glaucoma (primary open-angle);	chr22:19882624	chr22:19887289~19887970:+
THCA	cis	rs7260598	0.642	rs10425299	ENSG00000268442.1	CTD-2027I19.2	6.46	2.59e-10	6.02e-08	0.38	0.29	Response to taxane treatment (placlitaxel);	chr19:23995757	chr19:24162370~24163425:-
THCA	cis	rs6026584	0.823	rs6026574	ENSG00000270951.1	RP1-309F20.4	-6.46	2.59e-10	6.02e-08	-0.3	-0.29	Renal function-related traits (BUN);	chr20:58881440	chr20:58876592~58876981:-
THCA	cis	rs8062405	0.755	rs62034325	ENSG00000278665.1	RP11-666O2.4	6.46	2.6e-10	6.03e-08	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28599241~28601881:-
THCA	cis	rs516805	0.563	rs2816083	ENSG00000279453.1	RP3-425C14.4	-6.46	2.6e-10	6.03e-08	-0.32	-0.29	Lymphocyte counts;	chr6:122101611	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2606637	ENSG00000279453.1	RP3-425C14.4	-6.46	2.6e-10	6.03e-08	-0.32	-0.29	Lymphocyte counts;	chr6:122101832	chr6:122436789~122439223:-
THCA	cis	rs2439831	0.867	rs2243434	ENSG00000249839.1	AC011330.5	-6.46	2.6e-10	6.03e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43397669	chr15:43663654~43684339:-
THCA	cis	rs2239557	1	rs2239557	ENSG00000259065.1	RP5-1021I20.1	-6.46	2.6e-10	6.03e-08	-0.34	-0.29	Common traits (Other);	chr14:74085267	chr14:73787360~73803270:+
THCA	cis	rs2243480	1	rs2257790	ENSG00000228409.4	CCT6P1	6.46	2.6e-10	6.03e-08	0.33	0.29	Diabetic kidney disease;	chr7:66135463	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs316332	ENSG00000228409.4	CCT6P1	6.46	2.6e-10	6.03e-08	0.33	0.29	Diabetic kidney disease;	chr7:66139312	chr7:65751142~65763354:+
THCA	cis	rs17270561	0.541	rs2009610	ENSG00000272462.2	U91328.19	-6.46	2.61e-10	6.05e-08	-0.3	-0.29	Iron status biomarkers;	chr6:25966840	chr6:25992662~26001775:+
THCA	cis	rs848490	1	rs56400413	ENSG00000214293.7	APTR	6.46	2.61e-10	6.06e-08	0.22	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77711504	chr7:77657660~77696265:-
THCA	cis	rs848490	0.962	rs11768148	ENSG00000214293.7	APTR	6.46	2.61e-10	6.06e-08	0.22	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77715977	chr7:77657660~77696265:-
THCA	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-6.46	2.61e-10	6.06e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
THCA	cis	rs7267979	0.966	rs2151144	ENSG00000274414.1	RP5-965G21.4	6.46	2.61e-10	6.06e-08	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25239007~25245229:-
THCA	cis	rs7208859	0.573	rs73267873	ENSG00000263603.1	CTD-2349P21.5	-6.46	2.62e-10	6.07e-08	-0.46	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.561	rs4085382	ENSG00000263603.1	CTD-2349P21.5	-6.46	2.62e-10	6.07e-08	-0.46	-0.29	Body mass index;	chr17:30744184	chr17:30729469~30731202:+
THCA	cis	rs797680	0.894	rs7418101	ENSG00000223745.6	RP4-717I23.3	-6.46	2.62e-10	6.07e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93290635	chr1:93262186~93346025:-
THCA	cis	rs1707322	0.686	rs2991977	ENSG00000281133.1	AL355480.3	6.46	2.62e-10	6.07e-08	0.35	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.656	rs2991981	ENSG00000281133.1	AL355480.3	6.46	2.62e-10	6.07e-08	0.35	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.656	rs3014210	ENSG00000281133.1	AL355480.3	6.46	2.62e-10	6.07e-08	0.35	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45580892~45580996:-
THCA	cis	rs6860806	0.695	rs11952099	ENSG00000237714.1	P4HA2-AS1	6.46	2.62e-10	6.07e-08	0.37	0.29	Breast cancer;	chr5:132241079	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.661	rs2136187	ENSG00000237714.1	P4HA2-AS1	6.46	2.62e-10	6.07e-08	0.37	0.29	Breast cancer;	chr5:132242201	chr5:132184876~132192808:+
THCA	cis	rs595244	1	rs57829342	ENSG00000259705.1	RP11-227D13.1	6.46	2.62e-10	6.07e-08	0.48	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48516633	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs11634611	ENSG00000259705.1	RP11-227D13.1	6.46	2.62e-10	6.07e-08	0.48	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48522100	chr15:48645951~48652016:+
THCA	cis	rs2348418	0.932	rs6487685	ENSG00000247934.4	RP11-967K21.1	6.46	2.62e-10	6.07e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28505417	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.932	rs10843190	ENSG00000247934.4	RP11-967K21.1	6.46	2.62e-10	6.07e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28507412	chr12:28163298~28190738:-
THCA	cis	rs2243480	1	rs78803505	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65917585	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34577383	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65920739	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs55895244	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65922691	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs7795242	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65925107	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs2177703	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65926730	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs35432774	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65928032	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs56985706	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65929575	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs60683927	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65929781	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs58062456	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65929865	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34529418	ENSG00000229886.1	RP5-1132H15.3	6.46	2.62e-10	6.07e-08	0.46	0.29	Diabetic kidney disease;	chr7:65938222	chr7:66025126~66031544:-
THCA	cis	rs3806843	0.801	rs801171	ENSG00000202515.1	VTRNA1-3	6.46	2.62e-10	6.07e-08	0.33	0.29	Depressive symptoms (multi-trait analysis);	chr5:140735718	chr5:140726158~140726246:+
THCA	cis	rs34779708	0.832	rs12764283	ENSG00000230534.5	RP11-297A16.2	6.46	2.62e-10	6.08e-08	0.34	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35241532	chr10:35098006~35127020:-
THCA	cis	rs1949733	0.523	rs16842557	ENSG00000205959.3	RP11-689P11.2	6.46	2.62e-10	6.08e-08	0.25	0.29	Response to antineoplastic agents;	chr4:8542258	chr4:8482270~8512610:+
THCA	cis	rs832187	0.629	rs13272	ENSG00000280620.1	SCAANT1	6.46	2.63e-10	6.09e-08	0.38	0.29	Schizophrenia;	chr3:64000494	chr3:63911518~63911772:-
THCA	cis	rs910316	0.503	rs12894709	ENSG00000279594.1	RP11-950C14.10	6.46	2.63e-10	6.09e-08	0.26	0.29	Height;	chr14:74975031	chr14:75011269~75012851:-
THCA	cis	rs797680	0.786	rs10874772	ENSG00000223745.6	RP4-717I23.3	6.46	2.63e-10	6.09e-08	0.17	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93322213	chr1:93262186~93346025:-
THCA	cis	rs5758659	1	rs134900	ENSG00000182057.4	OGFRP1	6.46	2.63e-10	6.09e-08	0.32	0.29	Cognitive function;	chr22:42287337	chr22:42269753~42275196:+
THCA	cis	rs7580658	0.613	rs12463538	ENSG00000236682.1	AC068282.3	-6.46	2.63e-10	6.1e-08	-0.38	-0.29	Protein C levels;	chr2:127439278	chr2:127389130~127400580:+
THCA	cis	rs3806843	1	rs10057161	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140777246	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs2337985	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140778276	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs2337986	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140781037	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs1548701	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140784972	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs10073974	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140785646	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs3756342	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140786039	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.933	rs2240696	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140788485	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs2240695	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140788566	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.966	rs6579965	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140789226	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs6898906	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140789714	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs10477034	ENSG00000202515.1	VTRNA1-3	-6.46	2.63e-10	6.1e-08	-0.32	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140790145	chr5:140726158~140726246:+
THCA	cis	rs228614	0.509	rs223482	ENSG00000230069.3	LRRC37A15P	-6.46	2.63e-10	6.1e-08	-0.29	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102727274~102730721:-
THCA	cis	rs228614	0.536	rs223478	ENSG00000230069.3	LRRC37A15P	-6.46	2.63e-10	6.1e-08	-0.29	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102727274~102730721:-
THCA	cis	rs228614	0.536	rs150898	ENSG00000230069.3	LRRC37A15P	-6.46	2.63e-10	6.1e-08	-0.29	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102727274~102730721:-
THCA	cis	rs5742933	0.762	rs12992061	ENSG00000273240.1	RP11-455J20.3	6.46	2.63e-10	6.1e-08	0.29	0.29	Ferritin levels;	chr2:189736026	chr2:189763859~189764456:-
THCA	cis	rs62292953	0.589	rs62292471	ENSG00000248724.5	NPHP3-AS1	-6.46	2.63e-10	6.1e-08	-0.52	-0.29	Red cell distribution width;	chr3:132710603	chr3:132721750~132874223:+
THCA	cis	rs7119038	0.818	rs6589685	ENSG00000255239.1	AP002954.6	-6.46	2.64e-10	6.11e-08	-0.41	-0.29	Sjögren's syndrome;	chr11:118741488	chr11:118688039~118690600:-
THCA	cis	rs853679	1	rs7740487	ENSG00000226314.6	ZNF192P1	-6.46	2.64e-10	6.11e-08	-0.45	-0.29	Depression;	chr6:28248708	chr6:28161781~28169594:+
THCA	cis	rs853679	1	rs68141011	ENSG00000226314.6	ZNF192P1	-6.46	2.64e-10	6.11e-08	-0.45	-0.29	Depression;	chr6:28250019	chr6:28161781~28169594:+
THCA	cis	rs853679	1	rs13200462	ENSG00000226314.6	ZNF192P1	-6.46	2.64e-10	6.11e-08	-0.45	-0.29	Depression;	chr6:28250421	chr6:28161781~28169594:+
THCA	cis	rs8141529	0.719	rs2097461	ENSG00000226471.5	CTA-292E10.6	-6.46	2.64e-10	6.11e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28795891	chr22:28800683~28848559:+
THCA	cis	rs11018904	0.861	rs4589254	ENSG00000280385.1	AP000648.5	6.46	2.64e-10	6.11e-08	0.37	0.29	Intelligence (multi-trait analysis);	chr11:90230187	chr11:90193614~90198120:+
THCA	cis	rs2115630	0.967	rs7171167	ENSG00000225151.9	GOLGA2P7	6.46	2.64e-10	6.12e-08	0.37	0.29	P wave terminal force;	chr15:84695892	chr15:84199311~84230136:-
THCA	cis	rs228614	0.509	rs223481	ENSG00000230069.3	LRRC37A15P	-6.46	2.64e-10	6.13e-08	-0.29	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102727274~102730721:-
THCA	cis	rs6545883	0.894	rs12615783	ENSG00000271889.1	RP11-493E12.1	-6.46	2.65e-10	6.13e-08	-0.27	-0.29	Tuberculosis;	chr2:61213812	chr2:61151433~61162105:-
THCA	cis	rs4835473	0.669	rs56112476	ENSG00000251600.4	RP11-673E1.1	-6.46	2.65e-10	6.14e-08	-0.39	-0.29	Immature fraction of reticulocytes;	chr4:143948716	chr4:143912331~143982454:+
THCA	cis	rs595244	1	rs8034829	ENSG00000259705.1	RP11-227D13.1	6.46	2.65e-10	6.14e-08	0.48	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48513830	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs16961065	ENSG00000259705.1	RP11-227D13.1	6.46	2.65e-10	6.14e-08	0.48	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48514342	chr15:48645951~48652016:+
THCA	cis	rs7202877	0.706	rs8046184	ENSG00000261783.1	RP11-252K23.2	-6.46	2.65e-10	6.14e-08	-0.5	-0.29	Type 1 diabetes;Type 2 diabetes;	chr16:75377827	chr16:75379818~75381260:-
THCA	cis	rs7044106	0.791	rs12554440	ENSG00000238181.2	AHCYP2	-6.46	2.65e-10	6.14e-08	-0.37	-0.29	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120720673~120721972:+
THCA	cis	rs227275	0.554	rs223334	ENSG00000251288.2	RP11-10L12.2	6.46	2.65e-10	6.15e-08	0.37	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102751401~102752641:+
THCA	cis	rs6496044	0.568	rs10468112	ENSG00000259295.5	CSPG4P12	6.46	2.66e-10	6.16e-08	0.36	0.29	Interstitial lung disease;	chr15:85530193	chr15:85191438~85213905:+
THCA	cis	rs7746199	0.668	rs7749305	ENSG00000280107.1	AL022393.9	-6.46	2.66e-10	6.17e-08	-0.49	-0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28170845~28172521:+
THCA	cis	rs7208859	0.673	rs216409	ENSG00000263603.1	CTD-2349P21.5	6.46	2.67e-10	6.17e-08	0.46	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30729469~30731202:+
THCA	cis	rs848490	1	rs62460740	ENSG00000214293.7	APTR	6.46	2.67e-10	6.17e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77780122	chr7:77657660~77696265:-
THCA	cis	rs595244	1	rs1018148	ENSG00000259705.1	RP11-227D13.1	-6.46	2.67e-10	6.18e-08	-0.52	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48610929	chr15:48645951~48652016:+
THCA	cis	rs6840258	0.76	rs340637	ENSG00000251411.1	RP11-397E7.4	6.46	2.67e-10	6.18e-08	0.31	0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87008040	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.723	rs340633	ENSG00000251411.1	RP11-397E7.4	6.46	2.67e-10	6.18e-08	0.31	0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87010746	chr4:86913266~86914817:-
THCA	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	6.46	2.67e-10	6.19e-08	0.26	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
THCA	cis	rs2243480	1	rs2533288	ENSG00000229886.1	RP5-1132H15.3	6.46	2.67e-10	6.19e-08	0.48	0.29	Diabetic kidney disease;	chr7:66591724	chr7:66025126~66031544:-
THCA	cis	rs934734	0.789	rs906579	ENSG00000234255.7	AC012370.3	-6.46	2.67e-10	6.19e-08	-0.33	-0.29	Rheumatoid arthritis;	chr2:65374464	chr2:65439888~65456571:-
THCA	cis	rs934734	0.789	rs906578	ENSG00000234255.7	AC012370.3	-6.46	2.67e-10	6.19e-08	-0.33	-0.29	Rheumatoid arthritis;	chr2:65374466	chr2:65439888~65456571:-
THCA	cis	rs853679	1	rs2799079	ENSG00000226314.6	ZNF192P1	-6.46	2.67e-10	6.19e-08	-0.44	-0.29	Depression;	chr6:28267398	chr6:28161781~28169594:+
THCA	cis	rs848490	0.926	rs62460744	ENSG00000214293.7	APTR	6.46	2.68e-10	6.2e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77819363	chr7:77657660~77696265:-
THCA	cis	rs848490	0.962	rs11772392	ENSG00000214293.7	APTR	6.46	2.68e-10	6.2e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77834526	chr7:77657660~77696265:-
THCA	cis	rs847577	0.609	rs17435847	ENSG00000272950.1	RP11-307C18.1	6.46	2.68e-10	6.2e-08	0.36	0.29	Breast cancer;	chr7:98163508	chr7:98322853~98323430:+
THCA	cis	rs8141529	0.753	rs5752813	ENSG00000226471.5	CTA-292E10.6	-6.46	2.68e-10	6.2e-08	-0.24	-0.29	Lymphocyte counts;	chr22:28830582	chr22:28800683~28848559:+
THCA	cis	rs7942368	1	rs4309181	ENSG00000204529.3	GUCY2EP	6.46	2.68e-10	6.21e-08	0.41	0.29	Endometriosis;	chr11:76790661	chr11:76694043~76707641:-
THCA	cis	rs2735413	0.564	rs11863846	ENSG00000276007.1	RP11-358L22.3	6.46	2.68e-10	6.21e-08	0.31	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78085660	chr16:78123243~78124332:+
THCA	cis	rs6840258	0.76	rs340638	ENSG00000251411.1	RP11-397E7.4	6.46	2.68e-10	6.21e-08	0.31	0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87007052	chr4:86913266~86914817:-
THCA	cis	rs2562456	0.754	rs11666213	ENSG00000268555.1	RP11-678G14.3	6.46	2.68e-10	6.21e-08	0.46	0.29	Pain;	chr19:21422843	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62110429	ENSG00000268555.1	RP11-678G14.3	6.46	2.68e-10	6.21e-08	0.46	0.29	Pain;	chr19:21430984	chr19:21570822~21587322:-
THCA	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	6.46	2.68e-10	6.21e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
THCA	cis	rs916888	0.61	rs142167	ENSG00000232300.1	FAM215B	-6.46	2.68e-10	6.21e-08	-0.4	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46558830~46562795:-
THCA	cis	rs7267979	0.745	rs6132845	ENSG00000274414.1	RP5-965G21.4	-6.46	2.69e-10	6.22e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25239007~25245229:-
THCA	cis	rs12435908	1	rs59921977	ENSG00000276116.2	FUT8-AS1	-6.46	2.69e-10	6.22e-08	-0.47	-0.29	Ischemic stroke;	chr14:65551941	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs11851772	ENSG00000276116.2	FUT8-AS1	-6.46	2.69e-10	6.22e-08	-0.47	-0.29	Ischemic stroke;	chr14:65555329	chr14:65411170~65412690:-
THCA	cis	rs7688540	0.74	rs28784663	ENSG00000211553.1	AC253576.2	-6.46	2.69e-10	6.22e-08	-0.41	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:136461~136568:+
THCA	cis	rs11148252	0.512	rs9526950	ENSG00000273784.3	RP11-78J21.7	-6.46	2.69e-10	6.22e-08	-0.31	-0.29	Lewy body disease;	chr13:52600328	chr13:52600042~52642542:+
THCA	cis	rs987724	0.519	rs9818684	ENSG00000240875.4	LINC00886	6.46	2.69e-10	6.23e-08	0.23	0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156806431	chr3:156747346~156817062:-
THCA	cis	rs6565180	0.889	rs8051096	ENSG00000273724.1	RP11-347C12.12	-6.46	2.69e-10	6.23e-08	-0.29	-0.29	Tonsillectomy;	chr16:30336410	chr16:30336400~30343336:+
THCA	cis	rs4143844	0.867	rs11637599	ENSG00000259251.2	RP11-643M14.1	6.46	2.69e-10	6.23e-08	0.54	0.29	Bipolar disorder and schizophrenia;	chr15:62058866	chr15:62060503~62062434:+
THCA	cis	rs10844706	0.666	rs10844609	ENSG00000256594.6	RP11-705C15.2	6.46	2.69e-10	6.23e-08	0.24	0.29	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9723909	chr12:9633419~9658412:+
THCA	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-6.46	2.69e-10	6.23e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-6.46	2.69e-10	6.23e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-6.46	2.69e-10	6.23e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-6.46	2.69e-10	6.23e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
THCA	cis	rs2303319	1	rs10490568	ENSG00000227403.1	AC009299.3	-6.46	2.7e-10	6.24e-08	-0.61	-0.29	Cognitive function;	chr2:161395910	chr2:161244739~161249050:+
THCA	cis	rs2562456	0.833	rs11669790	ENSG00000268555.1	RP11-678G14.3	6.46	2.7e-10	6.24e-08	0.47	0.29	Pain;	chr19:21328980	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62107534	ENSG00000268555.1	RP11-678G14.3	6.46	2.7e-10	6.24e-08	0.47	0.29	Pain;	chr19:21329389	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs7258473	ENSG00000268555.1	RP11-678G14.3	6.46	2.7e-10	6.24e-08	0.47	0.29	Pain;	chr19:21331795	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs2219839	ENSG00000268555.1	RP11-678G14.3	6.46	2.7e-10	6.24e-08	0.47	0.29	Pain;	chr19:21333520	chr19:21570822~21587322:-
THCA	cis	rs838147	0.505	rs1688264	ENSG00000232871.7	SEC1P	6.45	2.7e-10	6.25e-08	0.33	0.29	Dietary macronutrient intake;	chr19:48706303	chr19:48638071~48682245:+
THCA	cis	rs838147	0.507	rs1704773	ENSG00000232871.7	SEC1P	6.45	2.7e-10	6.25e-08	0.33	0.29	Dietary macronutrient intake;	chr19:48706309	chr19:48638071~48682245:+
THCA	cis	rs6903823	0.508	rs1150718	ENSG00000219392.1	RP1-265C24.5	-6.45	2.7e-10	6.26e-08	-0.32	-0.29	Pulmonary function;	chr6:28289170	chr6:28115628~28116551:+
THCA	cis	rs728616	0.571	rs113030473	ENSG00000242600.5	MBL1P	6.45	2.7e-10	6.26e-08	0.42	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79889275	chr10:79904898~79950336:+
THCA	cis	rs2243480	1	rs4718270	ENSG00000228409.4	CCT6P1	6.45	2.71e-10	6.26e-08	0.33	0.29	Diabetic kidney disease;	chr7:65737415	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs4718269	ENSG00000228409.4	CCT6P1	-6.45	2.71e-10	6.26e-08	-0.33	-0.29	Diabetic kidney disease;	chr7:65735810	chr7:65751142~65763354:+
THCA	cis	rs7044106	0.734	rs12553070	ENSG00000238181.2	AHCYP2	-6.45	2.71e-10	6.26e-08	-0.37	-0.29	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120720673~120721972:+
THCA	cis	rs2976388	0.524	rs7012804	ENSG00000253741.1	CTD-2292P10.4	-6.45	2.71e-10	6.26e-08	-0.37	-0.29	Urinary tract infection frequency;	chr8:142763232	chr8:142702252~142726973:-
THCA	cis	rs17772222	1	rs55722539	ENSG00000258789.1	RP11-507K2.3	-6.45	2.71e-10	6.26e-08	-0.3	-0.29	Coronary artery calcification;	chr14:88411691	chr14:88551597~88552493:+
THCA	cis	rs35264875	0.846	rs2924534	ENSG00000259799.1	RP11-554A11.9	-6.45	2.71e-10	6.27e-08	-0.5	-0.29	Blond vs. brown hair color;	chr11:69103048	chr11:69155910~69159752:+
THCA	cis	rs7044106	0.791	rs735109	ENSG00000238181.2	AHCYP2	-6.45	2.71e-10	6.27e-08	-0.37	-0.29	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120720673~120721972:+
THCA	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-6.45	2.72e-10	6.29e-08	-0.33	-0.29	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
THCA	cis	rs2243480	1	rs316329	ENSG00000229886.1	RP5-1132H15.3	6.45	2.72e-10	6.3e-08	0.45	0.29	Diabetic kidney disease;	chr7:66143429	chr7:66025126~66031544:-
THCA	cis	rs8012947	1	rs941752	ENSG00000279636.2	LINC00216	-6.45	2.73e-10	6.3e-08	-0.3	-0.29	Alcohol consumption in current drinkers;	chr14:58332643	chr14:58288033~58289158:+
THCA	cis	rs2120243	0.539	rs4680358	ENSG00000244515.1	KRT18P34	-6.45	2.73e-10	6.31e-08	-0.34	-0.29	Hepatocellular carcinoma in hepatitis B infection;	chr3:157351486	chr3:157162663~157163932:-
THCA	cis	rs7583236	0.5	rs7565597	ENSG00000179818.12	PCBP1-AS1	-6.45	2.73e-10	6.31e-08	-0.33	-0.29	Obesity-related traits;	chr2:70108938	chr2:69962263~70103220:-
THCA	cis	rs944289	0.553	rs1169147	ENSG00000257826.1	RP11-116N8.4	-6.45	2.73e-10	6.32e-08	-0.33	-0.29	Thyroid cancer;	chr14:36163697	chr14:36061026~36067190:-
THCA	cis	rs1318937	0.831	rs9851648	ENSG00000224660.1	SH3BP5-AS1	6.45	2.73e-10	6.32e-08	0.18	0.29	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15259292	chr3:15254184~15264493:+
THCA	cis	rs16949788	1	rs79097157	ENSG00000261351.2	CTD-3185P2.1	-6.45	2.73e-10	6.32e-08	-0.34	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66472476	chr15:66488658~66492109:-
THCA	cis	rs16949788	1	rs76623374	ENSG00000261351.2	CTD-3185P2.1	-6.45	2.73e-10	6.32e-08	-0.34	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66475530	chr15:66488658~66492109:-
THCA	cis	rs848490	0.928	rs848487	ENSG00000214293.7	APTR	-6.45	2.73e-10	6.32e-08	-0.23	-0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77925097	chr7:77657660~77696265:-
THCA	cis	rs797680	0.856	rs687394	ENSG00000223745.6	RP4-717I23.3	-6.45	2.74e-10	6.33e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93248360	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs7512911	ENSG00000223745.6	RP4-717I23.3	-6.45	2.74e-10	6.33e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93250261	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs637646	ENSG00000223745.6	RP4-717I23.3	-6.45	2.74e-10	6.33e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93250826	chr1:93262186~93346025:-
THCA	cis	rs7580658	0.929	rs13029237	ENSG00000236682.1	AC068282.3	-6.45	2.74e-10	6.33e-08	-0.38	-0.29	Protein C levels;	chr2:127390278	chr2:127389130~127400580:+
THCA	cis	rs17772222	0.793	rs7143853	ENSG00000258789.1	RP11-507K2.3	-6.45	2.74e-10	6.33e-08	-0.29	-0.29	Coronary artery calcification;	chr14:88578477	chr14:88551597~88552493:+
THCA	cis	rs6061231	0.624	rs8668	ENSG00000275437.1	RP5-908M14.10	-6.45	2.74e-10	6.33e-08	-0.25	-0.29	Colorectal cancer;	chr20:62389008	chr20:62402236~62405935:-
THCA	cis	rs6671200	0.667	rs79658099	ENSG00000235501.4	RP4-639F20.1	-6.45	2.74e-10	6.33e-08	-0.57	-0.29	Stearic acid (18:0) levels;	chr1:94951833	chr1:94927566~94963270:+
THCA	cis	rs2797160	0.651	rs1268092	ENSG00000237742.5	RP11-624M8.1	-6.45	2.74e-10	6.33e-08	-0.25	-0.29	Endometrial cancer;	chr6:125707897	chr6:125578558~125749190:-
THCA	cis	rs9601248	0.627	rs2146593	ENSG00000227354.5	RBM26-AS1	6.45	2.74e-10	6.33e-08	0.28	0.29	Major depressive disorder;	chr13:79605977	chr13:79406309~79424328:+
THCA	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	6.45	2.74e-10	6.34e-08	0.31	0.29	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
THCA	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-6.45	2.75e-10	6.35e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-6.45	2.75e-10	6.35e-08	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
THCA	cis	rs35934224	0.891	rs12158214	ENSG00000232926.1	AC000078.5	6.45	2.75e-10	6.36e-08	0.33	0.29	Glaucoma (primary open-angle);	chr22:19884168	chr22:19887289~19887970:+
THCA	cis	rs2717559	0.542	rs2585156	ENSG00000253741.1	CTD-2292P10.4	6.45	2.75e-10	6.36e-08	0.37	0.29	Urinary tract infection frequency;	chr8:142798379	chr8:142702252~142726973:-
THCA	cis	rs2562456	0.833	rs62110428	ENSG00000268555.1	RP11-678G14.3	6.45	2.76e-10	6.37e-08	0.46	0.29	Pain;	chr19:21430854	chr19:21570822~21587322:-
THCA	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	6.45	2.76e-10	6.37e-08	0.37	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
THCA	cis	rs7131987	0.903	rs7302129	ENSG00000257176.2	RP11-996F15.2	-6.45	2.76e-10	6.38e-08	-0.29	-0.29	QT interval;	chr12:29262347	chr12:29280418~29317848:-
THCA	cis	rs2562456	0.833	rs1932087	ENSG00000268555.1	RP11-678G14.3	6.45	2.76e-10	6.38e-08	0.47	0.29	Pain;	chr19:21338625	chr19:21570822~21587322:-
THCA	cis	rs6928977	0.897	rs2746431	ENSG00000231028.7	LINC00271	6.45	2.76e-10	6.38e-08	0.24	0.29	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366063	chr6:135497801~135716055:+
THCA	cis	rs1876905	0.569	rs354542	ENSG00000255389.1	C6orf3	6.45	2.76e-10	6.38e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111599875~111602295:+
THCA	cis	rs1876905	0.68	rs1216020	ENSG00000255389.1	C6orf3	6.45	2.76e-10	6.38e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111599875~111602295:+
THCA	cis	rs1876905	0.569	rs354541	ENSG00000255389.1	C6orf3	6.45	2.76e-10	6.38e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111599875~111602295:+
THCA	cis	rs1876905	0.68	rs354537	ENSG00000255389.1	C6orf3	6.45	2.76e-10	6.38e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111599875~111602295:+
THCA	cis	rs1876905	0.68	rs354536	ENSG00000255389.1	C6orf3	6.45	2.76e-10	6.38e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111599875~111602295:+
THCA	cis	rs1876905	0.68	rs1215848	ENSG00000255389.1	C6orf3	6.45	2.76e-10	6.38e-08	0.34	0.29	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111599875~111602295:+
THCA	cis	rs2302464	1	rs6828144	ENSG00000214846.4	RP11-115L11.1	6.45	2.76e-10	6.39e-08	0.64	0.29	Cerebrospinal fluid biomarker levels;	chr4:15725766	chr4:15730962~15731627:-
THCA	cis	rs9902453	0.704	rs1972305	ENSG00000264007.1	RP11-68I3.10	6.45	2.76e-10	6.39e-08	0.34	0.29	Coffee consumption (cups per day);	chr17:30206862	chr17:29621617~29622254:-
THCA	cis	rs6907340	0.513	rs6938418	ENSG00000227116.1	RP3-471C18.1	6.45	2.77e-10	6.4e-08	0.32	0.29	Endometriosis;	chr6:19808802	chr6:19730427~19734567:-
THCA	cis	rs73607972	0.935	rs73609950	ENSG00000275191.1	RP11-36I17.2	-6.45	2.77e-10	6.4e-08	-0.46	-0.29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53688838	chr16:53628256~53628816:-
THCA	cis	rs2562456	0.793	rs61445561	ENSG00000268555.1	RP11-678G14.3	6.45	2.77e-10	6.4e-08	0.47	0.29	Pain;	chr19:21321230	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs57299552	ENSG00000268555.1	RP11-678G14.3	6.45	2.77e-10	6.4e-08	0.47	0.29	Pain;	chr19:21321326	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.754	rs76688173	ENSG00000268555.1	RP11-678G14.3	6.45	2.77e-10	6.4e-08	0.47	0.29	Pain;	chr19:21321856	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs74711277	ENSG00000268555.1	RP11-678G14.3	6.45	2.77e-10	6.4e-08	0.47	0.29	Pain;	chr19:21322641	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62107479	ENSG00000268555.1	RP11-678G14.3	6.45	2.77e-10	6.4e-08	0.47	0.29	Pain;	chr19:21323962	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62107531	ENSG00000268555.1	RP11-678G14.3	6.45	2.77e-10	6.4e-08	0.47	0.29	Pain;	chr19:21326263	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs55756795	ENSG00000268555.1	RP11-678G14.3	6.45	2.77e-10	6.4e-08	0.47	0.29	Pain;	chr19:21327257	chr19:21570822~21587322:-
THCA	cis	rs12935418	1	rs62054589	ENSG00000261061.1	RP11-303E16.2	-6.45	2.77e-10	6.4e-08	-0.35	-0.29	Mean corpuscular volume;	chr16:81035143	chr16:81030770~81031485:+
THCA	cis	rs944289	0.503	rs4999746	ENSG00000257826.1	RP11-116N8.4	-6.45	2.77e-10	6.4e-08	-0.31	-0.29	Thyroid cancer;	chr14:36190730	chr14:36061026~36067190:-
THCA	cis	rs6866614	0.608	rs17132288	ENSG00000224431.1	AC063976.7	6.45	2.77e-10	6.41e-08	0.25	0.29	Perceived unattractiveness to mosquitoes;	chr5:132000412	chr5:132199456~132203487:+
THCA	cis	rs7712401	1	rs7712401	ENSG00000249996.1	RP11-359P5.1	6.45	2.77e-10	6.41e-08	0.28	0.29	Mean platelet volume;	chr5:123038764	chr5:123036271~123054667:+
THCA	cis	rs6860806	0.631	rs7736284	ENSG00000237714.1	P4HA2-AS1	6.45	2.77e-10	6.41e-08	0.36	0.29	Breast cancer;	chr5:132252458	chr5:132184876~132192808:+
THCA	cis	rs2239557	1	rs2072293	ENSG00000259065.1	RP5-1021I20.1	-6.45	2.77e-10	6.41e-08	-0.35	-0.29	Common traits (Other);	chr14:74071182	chr14:73787360~73803270:+
THCA	cis	rs728616	0.867	rs12413715	ENSG00000242600.5	MBL1P	6.45	2.78e-10	6.41e-08	0.41	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:79904898~79950336:+
THCA	cis	rs748404	0.631	rs2412781	ENSG00000166763.7	STRCP1	-6.45	2.78e-10	6.41e-08	-0.31	-0.29	Lung cancer;	chr15:43375702	chr15:43699488~43718184:-
THCA	cis	rs2303319	0.901	rs62194249	ENSG00000227403.1	AC009299.3	6.45	2.78e-10	6.42e-08	0.62	0.29	Cognitive function;	chr2:161266450	chr2:161244739~161249050:+
THCA	cis	rs6421571	0.564	rs11216972	ENSG00000255239.1	AP002954.6	-6.45	2.78e-10	6.42e-08	-0.45	-0.29	Primary biliary cholangitis;	chr11:118715117	chr11:118688039~118690600:-
THCA	cis	rs7942368	0.941	rs12290350	ENSG00000204529.3	GUCY2EP	-6.45	2.78e-10	6.43e-08	-0.41	-0.29	Endometriosis;	chr11:76769211	chr11:76694043~76707641:-
THCA	cis	rs6088580	0.524	rs6088570	ENSG00000269202.1	RP4-614O4.12	6.45	2.79e-10	6.44e-08	0.24	0.29	Glomerular filtration rate (creatinine);	chr20:34680491	chr20:35201747~35203288:-
THCA	cis	rs9475752	1	rs1599280	ENSG00000231441.1	RP11-472M19.2	6.45	2.79e-10	6.45e-08	0.36	0.29	Menarche (age at onset);	chr6:56927778	chr6:56844002~56864078:+
THCA	cis	rs7942368	0.941	rs10899283	ENSG00000204529.3	GUCY2EP	6.45	2.79e-10	6.45e-08	0.4	0.29	Endometriosis;	chr11:76794158	chr11:76694043~76707641:-
THCA	cis	rs807029	0.577	rs11190787	ENSG00000272572.1	RP11-179B2.2	-6.45	2.8e-10	6.46e-08	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100911103~100912739:-
THCA	cis	rs12435908	1	rs59117465	ENSG00000276116.2	FUT8-AS1	-6.45	2.8e-10	6.46e-08	-0.47	-0.29	Ischemic stroke;	chr14:65585754	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs57201867	ENSG00000276116.2	FUT8-AS1	-6.45	2.8e-10	6.46e-08	-0.47	-0.29	Ischemic stroke;	chr14:65627154	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs60942639	ENSG00000276116.2	FUT8-AS1	-6.45	2.8e-10	6.46e-08	-0.47	-0.29	Ischemic stroke;	chr14:65640918	chr14:65411170~65412690:-
THCA	cis	rs9926296	0.533	rs9938865	ENSG00000260259.1	RP11-368I7.4	-6.45	2.8e-10	6.47e-08	-0.31	-0.29	Vitiligo;	chr16:89801389	chr16:89682620~89686569:-
THCA	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-6.45	2.81e-10	6.48e-08	-0.21	-0.29	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
THCA	cis	rs848490	0.926	rs73138439	ENSG00000214293.7	APTR	6.45	2.81e-10	6.48e-08	0.23	0.29	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77887027	chr7:77657660~77696265:-
THCA	cis	rs2348418	0.932	rs61922464	ENSG00000247934.4	RP11-967K21.1	6.45	2.81e-10	6.48e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28485665	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.932	rs11049662	ENSG00000247934.4	RP11-967K21.1	6.45	2.81e-10	6.48e-08	0.25	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28487344	chr12:28163298~28190738:-
THCA	cis	rs4650994	0.525	rs2493858	ENSG00000273384.1	RP5-1098D14.1	6.45	2.81e-10	6.48e-08	0.36	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178572075	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.525	rs2493860	ENSG00000273384.1	RP5-1098D14.1	6.45	2.81e-10	6.48e-08	0.36	0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178572357	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.525	rs2224811	ENSG00000273384.1	RP5-1098D14.1	-6.45	2.81e-10	6.48e-08	-0.36	-0.29	HDL cholesterol;HDL cholesterol levels;	chr1:178575188	chr1:178651706~178652282:+
THCA	cis	rs6479891	1	rs9414800	ENSG00000232075.1	MRPL35P2	6.45	2.81e-10	6.48e-08	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63634317~63634827:-
THCA	cis	rs797680	0.821	rs7551485	ENSG00000223745.6	RP4-717I23.3	-6.45	2.81e-10	6.49e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93285723	chr1:93262186~93346025:-
THCA	cis	rs797680	0.822	rs7541304	ENSG00000223745.6	RP4-717I23.3	-6.45	2.81e-10	6.49e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93292281	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs7526112	ENSG00000223745.6	RP4-717I23.3	-6.45	2.81e-10	6.49e-08	-0.17	-0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93282126	chr1:93262186~93346025:-
THCA	cis	rs28386778	0.897	rs1043127	ENSG00000240280.5	TCAM1P	-6.45	2.81e-10	6.49e-08	-0.4	-0.29	Prudent dietary pattern;	chr17:63713850	chr17:63849292~63864379:+
THCA	cis	rs2562456	0.793	rs73537884	ENSG00000268555.1	RP11-678G14.3	6.45	2.81e-10	6.5e-08	0.46	0.29	Pain;	chr19:21321908	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs78467454	ENSG00000268555.1	RP11-678G14.3	6.45	2.81e-10	6.5e-08	0.46	0.29	Pain;	chr19:21321930	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs55790393	ENSG00000268555.1	RP11-678G14.3	6.45	2.81e-10	6.5e-08	0.46	0.29	Pain;	chr19:21323382	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs11672341	ENSG00000268555.1	RP11-678G14.3	6.45	2.81e-10	6.5e-08	0.46	0.29	Pain;	chr19:21324502	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.754	rs11673234	ENSG00000268555.1	RP11-678G14.3	6.45	2.81e-10	6.5e-08	0.46	0.29	Pain;	chr19:21324800	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.754	rs11673320	ENSG00000268555.1	RP11-678G14.3	6.45	2.81e-10	6.5e-08	0.46	0.29	Pain;	chr19:21324801	chr19:21570822~21587322:-
THCA	cis	rs916888	0.647	rs199449	ENSG00000232300.1	FAM215B	6.45	2.82e-10	6.5e-08	0.4	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46558830~46562795:-
THCA	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	6.45	2.82e-10	6.5e-08	0.4	0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
THCA	cis	rs6545883	0.562	rs777588	ENSG00000271889.1	RP11-493E12.1	6.45	2.82e-10	6.5e-08	0.26	0.29	Tuberculosis;	chr2:61199685	chr2:61151433~61162105:-
THCA	cis	rs5742933	0.744	rs13002216	ENSG00000273240.1	RP11-455J20.3	6.45	2.82e-10	6.5e-08	0.29	0.29	Ferritin levels;	chr2:189746358	chr2:189763859~189764456:-
THCA	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	6.45	2.82e-10	6.51e-08	0.25	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
THCA	cis	rs2243480	1	rs2257790	ENSG00000229886.1	RP5-1132H15.3	6.45	2.82e-10	6.52e-08	0.45	0.29	Diabetic kidney disease;	chr7:66135463	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs316332	ENSG00000229886.1	RP5-1132H15.3	6.45	2.82e-10	6.52e-08	0.45	0.29	Diabetic kidney disease;	chr7:66139312	chr7:66025126~66031544:-
THCA	cis	rs4835473	0.897	rs35140014	ENSG00000251600.4	RP11-673E1.1	6.45	2.83e-10	6.52e-08	0.38	0.29	Immature fraction of reticulocytes;	chr4:143964292	chr4:143912331~143982454:+
THCA	cis	rs7129556	0.69	rs947841	ENSG00000254691.1	RP11-91P24.5	6.45	2.83e-10	6.52e-08	0.39	0.29	Weight loss (gastric bypass surgery);	chr11:77881863	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.69	rs695046	ENSG00000254691.1	RP11-91P24.5	6.45	2.83e-10	6.52e-08	0.39	0.29	Weight loss (gastric bypass surgery);	chr11:77883308	chr11:77850604~77851511:+
THCA	cis	rs7324557	0.717	rs9553071	ENSG00000205861.10	C1QTNF9B-AS1	-6.45	2.83e-10	6.53e-08	-0.35	-0.29	Visceral adipose tissue adjusted for BMI;	chr13:23807240	chr13:23888889~23897263:+
THCA	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	6.45	2.83e-10	6.53e-08	0.43	0.29	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
THCA	cis	rs73607972	0.935	rs4617860	ENSG00000275191.1	RP11-36I17.2	-6.45	2.83e-10	6.53e-08	-0.45	-0.29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53690608	chr16:53628256~53628816:-
THCA	cis	rs73607972	0.935	rs35089292	ENSG00000275191.1	RP11-36I17.2	-6.45	2.83e-10	6.53e-08	-0.45	-0.29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53692910	chr16:53628256~53628816:-
THCA	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	6.45	2.83e-10	6.54e-08	0.38	0.29	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
THCA	cis	rs6545883	0.929	rs10200055	ENSG00000271889.1	RP11-493E12.1	-6.45	2.83e-10	6.54e-08	-0.27	-0.29	Tuberculosis;	chr2:61400882	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.929	rs10193666	ENSG00000271889.1	RP11-493E12.1	-6.45	2.83e-10	6.54e-08	-0.27	-0.29	Tuberculosis;	chr2:61402273	chr2:61151433~61162105:-
THCA	cis	rs73607972	0.935	rs4591140	ENSG00000275191.1	RP11-36I17.2	-6.45	2.83e-10	6.54e-08	-0.45	-0.29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53699775	chr16:53628256~53628816:-
THCA	cis	rs17772222	0.958	rs59136503	ENSG00000258789.1	RP11-507K2.3	-6.45	2.84e-10	6.54e-08	-0.3	-0.29	Coronary artery calcification;	chr14:88501921	chr14:88551597~88552493:+
THCA	cis	rs3847687	0.901	rs12370258	ENSG00000279993.1	RP11-76C10.3	6.45	2.84e-10	6.55e-08	0.32	0.29	Longevity;	chr12:131042756	chr12:131025561~131028060:-
THCA	cis	rs2439831	0.867	rs12323999	ENSG00000249839.1	AC011330.5	-6.45	2.84e-10	6.55e-08	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43390917	chr15:43663654~43684339:-
THCA	cis	rs853679	0.55	rs34477097	ENSG00000226314.6	ZNF192P1	-6.45	2.84e-10	6.55e-08	-0.37	-0.29	Depression;	chr6:28229408	chr6:28161781~28169594:+
THCA	cis	rs11722779	0.869	rs223350	ENSG00000230069.3	LRRC37A15P	-6.45	2.84e-10	6.55e-08	-0.3	-0.29	Schizophrenia;	chr4:102856899	chr4:102727274~102730721:-
THCA	cis	rs934734	0.725	rs2271198	ENSG00000204929.10	AC074391.1	6.45	2.84e-10	6.55e-08	0.36	0.29	Rheumatoid arthritis;	chr2:65331893	chr2:65436711~66084639:+
THCA	cis	rs1499614	1	rs2141924	ENSG00000228409.4	CCT6P1	6.45	2.84e-10	6.56e-08	0.34	0.29	Gout;	chr7:66721259	chr7:65751142~65763354:+
THCA	cis	rs451417	1	rs236115	ENSG00000275632.1	RP5-967N21.11	6.45	2.84e-10	6.56e-08	0.33	0.29	Menopause (age at onset);	chr20:5954803	chr20:6000418~6000941:+
THCA	cis	rs3755397	1	rs3755397	ENSG00000223374.1	AC005104.3	6.45	2.85e-10	6.56e-08	0.33	0.29	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Chronic lymphocytic leukemia;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr2:241355498	chr2:241351340~241353104:-
THCA	cis	rs467650	0.553	rs29771	ENSG00000246763.5	RGMB-AS1	6.45	2.85e-10	6.57e-08	0.28	0.29	Venous thromboembolism (SNP x SNP interaction);	chr5:98640442	chr5:98769618~98773469:-
THCA	cis	rs1979679	0.842	rs4931730	ENSG00000278733.1	RP11-425D17.1	6.45	2.85e-10	6.57e-08	0.28	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146343	chr12:28185625~28186190:-
THCA	cis	rs728616	0.867	rs17884637	ENSG00000242600.5	MBL1P	6.45	2.85e-10	6.57e-08	0.41	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928166	chr10:79904898~79950336:+
THCA	cis	rs227275	0.554	rs223421	ENSG00000251288.2	RP11-10L12.2	-6.45	2.85e-10	6.58e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102751401~102752641:+
THCA	cis	rs4845570	0.85	rs4504897	ENSG00000249602.1	RP11-98D18.3	6.45	2.85e-10	6.58e-08	0.36	0.28	Coronary artery disease;	chr1:151794375	chr1:151763384~151769501:-
THCA	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-6.45	2.86e-10	6.59e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
THCA	cis	rs7260598	1	rs62117633	ENSG00000268442.1	CTD-2027I19.2	6.45	2.86e-10	6.59e-08	0.38	0.28	Response to taxane treatment (placlitaxel);	chr19:24036672	chr19:24162370~24163425:-
THCA	cis	rs28386778	0.933	rs2665801	ENSG00000240280.5	TCAM1P	-6.45	2.86e-10	6.59e-08	-0.4	-0.28	Prudent dietary pattern;	chr17:63874740	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.901	rs2854194	ENSG00000240280.5	TCAM1P	-6.45	2.86e-10	6.59e-08	-0.4	-0.28	Prudent dietary pattern;	chr17:63874750	chr17:63849292~63864379:+
THCA	cis	rs28386778	1	rs2665849	ENSG00000240280.5	TCAM1P	-6.45	2.86e-10	6.59e-08	-0.4	-0.28	Prudent dietary pattern;	chr17:63876310	chr17:63849292~63864379:+
THCA	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-6.45	2.86e-10	6.6e-08	-0.35	-0.28	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
THCA	cis	rs11722779	0.873	rs223346	ENSG00000251288.2	RP11-10L12.2	-6.45	2.86e-10	6.6e-08	-0.38	-0.28	Schizophrenia;	chr4:102859339	chr4:102751401~102752641:+
THCA	cis	rs2255336	0.938	rs2617151	ENSG00000245648.1	RP11-277P12.20	6.45	2.86e-10	6.6e-08	0.35	0.28	Blood protein levels;	chr12:10379835	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs1478309	ENSG00000245648.1	RP11-277P12.20	6.45	2.86e-10	6.6e-08	0.35	0.28	Blood protein levels;	chr12:10389146	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs2045876	ENSG00000245648.1	RP11-277P12.20	6.45	2.86e-10	6.6e-08	0.35	0.28	Blood protein levels;	chr12:10389233	chr12:10363769~10398506:+
THCA	cis	rs330048	0.561	rs330088	ENSG00000254153.1	CTA-398F10.2	-6.45	2.87e-10	6.61e-08	-0.31	-0.28	Systemic lupus erythematosus;	chr8:9292236	chr8:8456909~8461337:-
THCA	cis	rs35934224	0.783	rs7290770	ENSG00000232926.1	AC000078.5	6.45	2.87e-10	6.61e-08	0.36	0.28	Glaucoma (primary open-angle);	chr22:19873638	chr22:19887289~19887970:+
THCA	cis	rs2976388	0.935	rs2920285	ENSG00000253741.1	CTD-2292P10.4	6.44	2.87e-10	6.62e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142674800	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.935	rs2978978	ENSG00000253741.1	CTD-2292P10.4	6.44	2.87e-10	6.62e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142675112	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.935	rs2920284	ENSG00000253741.1	CTD-2292P10.4	6.44	2.87e-10	6.62e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142675501	chr8:142702252~142726973:-
THCA	cis	rs2976388	1	rs2920283	ENSG00000253741.1	CTD-2292P10.4	6.44	2.87e-10	6.62e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142675619	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.935	rs2978979	ENSG00000253741.1	CTD-2292P10.4	6.44	2.87e-10	6.62e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142675868	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.935	rs2978980	ENSG00000253741.1	CTD-2292P10.4	6.44	2.87e-10	6.62e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142676290	chr8:142702252~142726973:-
THCA	cis	rs9800506	0.504	rs10456079	ENSG00000228559.1	RP3-340B19.3	6.44	2.87e-10	6.62e-08	0.4	0.28	Neutrophil percentage of granulocytes;	chr6:35547220	chr6:35544632~35545669:+
THCA	cis	rs797680	0.856	rs6680107	ENSG00000223745.6	RP4-717I23.3	6.44	2.87e-10	6.62e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93305323	chr1:93262186~93346025:-
THCA	cis	rs797680	0.891	rs9432453	ENSG00000223745.6	RP4-717I23.3	6.44	2.87e-10	6.62e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93306072	chr1:93262186~93346025:-
THCA	cis	rs797680	0.927	rs1000607	ENSG00000223745.6	RP4-717I23.3	6.44	2.87e-10	6.62e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93306444	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs4240966	ENSG00000223745.6	RP4-717I23.3	6.44	2.87e-10	6.62e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93309255	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs7537403	ENSG00000223745.6	RP4-717I23.3	6.44	2.87e-10	6.62e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93312167	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs11164902	ENSG00000223745.6	RP4-717I23.3	6.44	2.87e-10	6.62e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93313237	chr1:93262186~93346025:-
THCA	cis	rs797680	0.786	rs9432465	ENSG00000223745.6	RP4-717I23.3	6.44	2.87e-10	6.62e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93315034	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs7547244	ENSG00000223745.6	RP4-717I23.3	6.44	2.87e-10	6.62e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93316211	chr1:93262186~93346025:-
THCA	cis	rs3764021	0.527	rs10844537	ENSG00000256594.6	RP11-705C15.2	6.44	2.88e-10	6.63e-08	0.24	0.28	Type 1 diabetes;	chr12:9709528	chr12:9633419~9658412:+
THCA	cis	rs7131987	0.903	rs1991114	ENSG00000257176.2	RP11-996F15.2	-6.44	2.88e-10	6.63e-08	-0.29	-0.28	QT interval;	chr12:29239149	chr12:29280418~29317848:-
THCA	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-6.44	2.88e-10	6.64e-08	-0.5	-0.28	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs9415696	ENSG00000232075.1	MRPL35P2	6.44	2.88e-10	6.64e-08	0.5	0.28	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs9415697	ENSG00000232075.1	MRPL35P2	6.44	2.88e-10	6.64e-08	0.5	0.28	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs724553	ENSG00000232075.1	MRPL35P2	6.44	2.88e-10	6.64e-08	0.5	0.28	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs4745706	ENSG00000232075.1	MRPL35P2	6.44	2.88e-10	6.64e-08	0.5	0.28	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12415038	ENSG00000232075.1	MRPL35P2	6.44	2.88e-10	6.64e-08	0.5	0.28	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63634317~63634827:-
THCA	cis	rs9813712	0.526	rs62281641	ENSG00000249846.5	RP11-77P16.4	-6.44	2.88e-10	6.64e-08	-0.29	-0.28	Response to amphetamines;	chr3:130235668	chr3:130112550~130120579:+
THCA	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-6.44	2.88e-10	6.64e-08	-0.36	-0.28	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
THCA	cis	rs7568498	0.564	rs10490563	ENSG00000235724.7	AC009299.2	6.44	2.88e-10	6.64e-08	0.33	0.28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161222785~161308303:-
THCA	cis	rs11749327	0.719	rs36111336	ENSG00000225138.6	CTD-2228K2.7	-6.44	2.88e-10	6.65e-08	-0.37	-0.28	Hemoglobin concentration;Hypospadias;	chr5:463501	chr5:473236~480884:+
THCA	cis	rs11749327	0.719	rs72698510	ENSG00000225138.6	CTD-2228K2.7	-6.44	2.88e-10	6.65e-08	-0.37	-0.28	Hemoglobin concentration;Hypospadias;	chr5:464224	chr5:473236~480884:+
THCA	cis	rs13113518	0.812	rs12505880	ENSG00000249700.7	SRD5A3-AS1	6.44	2.89e-10	6.65e-08	0.36	0.28	Height;	chr4:55440988	chr4:55363971~55395847:-
THCA	cis	rs6479891	1	rs9414799	ENSG00000232075.1	MRPL35P2	6.44	2.89e-10	6.65e-08	0.5	0.28	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs4746119	ENSG00000232075.1	MRPL35P2	6.44	2.89e-10	6.65e-08	0.5	0.28	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63634317~63634827:-
THCA	cis	rs847577	0.677	rs4729403	ENSG00000272950.1	RP11-307C18.1	-6.44	2.89e-10	6.65e-08	-0.36	-0.28	Breast cancer;	chr7:98078529	chr7:98322853~98323430:+
THCA	cis	rs10740039	0.516	rs1442549	ENSG00000254271.1	RP11-131N11.4	6.44	2.89e-10	6.66e-08	0.37	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60574542	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs7072017	ENSG00000254271.1	RP11-131N11.4	6.44	2.89e-10	6.66e-08	0.37	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60584568	chr10:60734342~60741828:+
THCA	cis	rs1552244	0.832	rs17050674	ENSG00000232901.1	CYCSP10	6.44	2.89e-10	6.66e-08	0.36	0.28	Alzheimer's disease;	chr3:9985574	chr3:10000647~10000940:-
THCA	cis	rs6672530	0.518	rs6671825	ENSG00000227711.2	RP11-275O4.5	-6.44	2.89e-10	6.66e-08	-0.3	-0.28	Hip circumference adjusted for BMI;	chr1:227677737	chr1:227509028~227520477:-
THCA	cis	rs2717559	0.561	rs7841267	ENSG00000253741.1	CTD-2292P10.4	6.44	2.89e-10	6.67e-08	0.37	0.28	Urinary tract infection frequency;	chr8:142800267	chr8:142702252~142726973:-
THCA	cis	rs6496044	0.568	rs7176291	ENSG00000259295.5	CSPG4P12	6.44	2.89e-10	6.67e-08	0.36	0.28	Interstitial lung disease;	chr15:85524167	chr15:85191438~85213905:+
THCA	cis	rs4950322	0.518	rs61838936	ENSG00000278811.3	LINC00624	6.44	2.9e-10	6.67e-08	0.35	0.28	Protein quantitative trait loci;	chr1:147098422	chr1:147258885~147517875:-
THCA	cis	rs797680	0.822	rs6541401	ENSG00000223745.6	RP4-717I23.3	-6.44	2.9e-10	6.68e-08	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93273391	chr1:93262186~93346025:-
THCA	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-6.44	2.9e-10	6.68e-08	-0.34	-0.28	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
THCA	cis	rs3764021	0.527	rs11052604	ENSG00000256594.6	RP11-705C15.2	6.44	2.9e-10	6.68e-08	0.24	0.28	Type 1 diabetes;	chr12:9709952	chr12:9633419~9658412:+
THCA	cis	rs11148252	0.595	rs9526974	ENSG00000278238.1	RP11-245D16.4	-6.44	2.9e-10	6.68e-08	-0.32	-0.28	Lewy body disease;	chr13:52676905	chr13:52454775~52455331:-
THCA	cis	rs28386778	0.897	rs2727330	ENSG00000240280.5	TCAM1P	6.44	2.9e-10	6.68e-08	0.39	0.28	Prudent dietary pattern;	chr17:63848138	chr17:63849292~63864379:+
THCA	cis	rs2562456	0.833	rs62110367	ENSG00000268555.1	RP11-678G14.3	6.44	2.9e-10	6.68e-08	0.47	0.28	Pain;	chr19:21365829	chr19:21570822~21587322:-
THCA	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	6.44	2.9e-10	6.69e-08	0.39	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
THCA	cis	rs7044106	0.762	rs1158554	ENSG00000270917.1	RP11-27I1.6	-6.44	2.91e-10	6.69e-08	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.791	rs10739572	ENSG00000238181.2	AHCYP2	-6.44	2.91e-10	6.7e-08	-0.37	-0.28	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120720673~120721972:+
THCA	cis	rs9487094	0.645	rs1322818	ENSG00000260273.1	RP11-425D10.10	6.44	2.91e-10	6.7e-08	0.39	0.28	Height;	chr6:109369898	chr6:109382795~109383666:+
THCA	cis	rs4650994	0.525	rs2493848	ENSG00000273384.1	RP5-1098D14.1	-6.44	2.91e-10	6.7e-08	-0.35	-0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178578703	chr1:178651706~178652282:+
THCA	cis	rs9402743	0.811	rs6570024	ENSG00000231028.7	LINC00271	-6.44	2.91e-10	6.7e-08	-0.23	-0.28	Systemic lupus erythematosus;	chr6:135649186	chr6:135497801~135716055:+
THCA	cis	rs9640161	0.83	rs1051823	ENSG00000261305.1	RP4-584D14.7	6.44	2.91e-10	6.7e-08	0.33	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150373725	chr7:150341771~150342607:+
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	6.44	2.91e-10	6.71e-08	0.33	0.28	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
THCA	cis	rs896854	0.654	rs16893776	ENSG00000253528.2	RP11-347C18.4	6.44	2.91e-10	6.71e-08	0.32	0.28	Type 2 diabetes;	chr8:94961376	chr8:94974573~94974853:-
THCA	cis	rs2243480	0.901	rs2900904	ENSG00000228409.4	CCT6P1	6.44	2.91e-10	6.71e-08	0.33	0.28	Diabetic kidney disease;	chr7:65739282	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6460260	ENSG00000228409.4	CCT6P1	-6.44	2.91e-10	6.71e-08	-0.33	-0.28	Diabetic kidney disease;	chr7:65750468	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6460261	ENSG00000228409.4	CCT6P1	-6.44	2.91e-10	6.71e-08	-0.33	-0.28	Diabetic kidney disease;	chr7:65750593	chr7:65751142~65763354:+
THCA	cis	rs9926296	0.546	rs6500442	ENSG00000260259.1	RP11-368I7.4	-6.44	2.91e-10	6.71e-08	-0.31	-0.28	Vitiligo;	chr16:89762454	chr16:89682620~89686569:-
THCA	cis	rs2880765	0.546	rs11637726	ENSG00000259295.5	CSPG4P12	-6.44	2.92e-10	6.71e-08	-0.44	-0.28	Coronary artery disease;	chr15:85516040	chr15:85191438~85213905:+
THCA	cis	rs7260598	0.579	rs9676579	ENSG00000268442.1	CTD-2027I19.2	6.44	2.92e-10	6.72e-08	0.38	0.28	Response to taxane treatment (placlitaxel);	chr19:24029180	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.818	rs11666653	ENSG00000268442.1	CTD-2027I19.2	6.44	2.92e-10	6.72e-08	0.38	0.28	Response to taxane treatment (placlitaxel);	chr19:24037440	chr19:24162370~24163425:-
THCA	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-6.44	2.92e-10	6.72e-08	-0.3	-0.28	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
THCA	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-6.44	2.92e-10	6.72e-08	-0.4	-0.28	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
THCA	cis	rs451417	0.722	rs236189	ENSG00000275632.1	RP5-967N21.11	6.44	2.92e-10	6.72e-08	0.3	0.28	Menopause (age at onset);	chr20:5951544	chr20:6000418~6000941:+
THCA	cis	rs897984	0.759	rs13708	ENSG00000279196.1	RP11-1072A3.3	-6.44	2.92e-10	6.72e-08	-0.28	-0.28	Dementia with Lewy bodies;	chr16:30989488	chr16:30984630~30988270:-
THCA	cis	rs2657294	0.62	rs9783273	ENSG00000233313.2	HMGA1P5	-6.44	2.92e-10	6.73e-08	-0.39	-0.28	Pneumonia;	chr10:75081982	chr10:75276376~75276646:-
THCA	cis	rs9677476	0.863	rs10202295	ENSG00000224376.1	AC017104.6	6.44	2.93e-10	6.74e-08	0.32	0.28	Food antigen IgG levels;	chr2:231219698	chr2:231388976~231394991:+
THCA	cis	rs1005277	0.54	rs1987431	ENSG00000263064.2	RP11-291L22.7	6.44	2.93e-10	6.75e-08	0.32	0.28	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38448689~38448949:+
THCA	cis	rs2562456	0.833	rs61035285	ENSG00000268555.1	RP11-678G14.3	6.44	2.93e-10	6.75e-08	0.46	0.28	Pain;	chr19:21329475	chr19:21570822~21587322:-
THCA	cis	rs4934494	0.588	rs10881683	ENSG00000232936.4	RP11-80H5.2	6.44	2.93e-10	6.75e-08	0.37	0.28	Red blood cell count;	chr10:89827231	chr10:89645282~89650667:+
THCA	cis	rs4072705	0.9	rs4836992	ENSG00000224020.1	MIR181A2HG	-6.44	2.94e-10	6.76e-08	-0.26	-0.28	Menarche (age at onset);	chr9:124796011	chr9:124658467~124698631:+
THCA	cis	rs9311474	0.841	rs352139	ENSG00000243224.1	RP5-1157M23.2	-6.44	2.94e-10	6.76e-08	-0.29	-0.28	Electroencephalogram traits;	chr3:52224356	chr3:52239258~52241097:+
THCA	cis	rs3806843	1	rs10053586	ENSG00000202515.1	VTRNA1-3	-6.44	2.94e-10	6.76e-08	-0.32	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140831175	chr5:140726158~140726246:+
THCA	cis	rs797680	0.964	rs7517363	ENSG00000223745.6	RP4-717I23.3	6.44	2.94e-10	6.77e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93187228	chr1:93262186~93346025:-
THCA	cis	rs17772222	0.958	rs60878614	ENSG00000222990.1	RNU4-22P	6.44	2.94e-10	6.77e-08	0.37	0.28	Coronary artery calcification;	chr14:88513871	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.958	rs76559451	ENSG00000222990.1	RNU4-22P	6.44	2.94e-10	6.77e-08	0.37	0.28	Coronary artery calcification;	chr14:88523193	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.958	rs12436326	ENSG00000222990.1	RNU4-22P	6.44	2.94e-10	6.77e-08	0.37	0.28	Coronary artery calcification;	chr14:88533632	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.958	rs17203789	ENSG00000222990.1	RNU4-22P	6.44	2.94e-10	6.77e-08	0.37	0.28	Coronary artery calcification;	chr14:88541362	chr14:88513498~88513663:+
THCA	cis	rs10208649	0.505	rs17045114	ENSG00000272156.1	RP11-477N3.1	6.44	2.95e-10	6.78e-08	0.42	0.28	Body mass index;	chr2:53694646	chr2:54082554~54085066:+
THCA	cis	rs11089937	1	rs11089937	ENSG00000211639.2	IGLV4-60	6.44	2.95e-10	6.78e-08	0.2	0.28	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22162199~22162681:+
THCA	cis	rs6840360	0.582	rs2709826	ENSG00000251611.1	RP11-610P16.1	-6.44	2.95e-10	6.79e-08	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151407551~151408835:-
THCA	cis	rs848490	0.962	rs62462680	ENSG00000214293.7	APTR	6.44	2.95e-10	6.79e-08	0.23	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77859117	chr7:77657660~77696265:-
THCA	cis	rs9813712	0.548	rs9880123	ENSG00000253540.4	FAM86HP	-6.44	2.95e-10	6.79e-08	-0.31	-0.28	Response to amphetamines;	chr3:130215275	chr3:130099092~130111472:-
THCA	cis	rs17772222	1	rs11159856	ENSG00000258789.1	RP11-507K2.3	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88417585	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs17124652	ENSG00000258789.1	RP11-507K2.3	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88424384	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.876	rs4375590	ENSG00000258789.1	RP11-507K2.3	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88451334	chr14:88551597~88552493:+
THCA	cis	rs227275	0.554	rs223395	ENSG00000230069.3	LRRC37A15P	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102727274~102730721:-
THCA	cis	rs4143844	0.867	rs12915585	ENSG00000259251.2	RP11-643M14.1	6.44	2.95e-10	6.79e-08	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61962693	chr15:62060503~62062434:+
THCA	cis	rs5758659	0.904	rs5758653	ENSG00000182057.4	OGFRP1	6.44	2.95e-10	6.79e-08	0.33	0.28	Cognitive function;	chr22:42217479	chr22:42269753~42275196:+
THCA	cis	rs7208859	0.673	rs9889755	ENSG00000264538.5	SUZ12P1	6.44	2.95e-10	6.79e-08	0.28	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30709299~30790908:+
THCA	cis	rs227275	0.554	rs223399	ENSG00000230069.3	LRRC37A15P	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223386	ENSG00000230069.3	LRRC37A15P	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223385	ENSG00000230069.3	LRRC37A15P	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.873	rs223384	ENSG00000230069.3	LRRC37A15P	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Schizophrenia;	chr4:102829976	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223383	ENSG00000230069.3	LRRC37A15P	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223382	ENSG00000230069.3	LRRC37A15P	-6.44	2.95e-10	6.79e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102727274~102730721:-
THCA	cis	rs3764021	0.527	rs11052426	ENSG00000256594.6	RP11-705C15.2	6.44	2.95e-10	6.8e-08	0.24	0.28	Type 1 diabetes;	chr12:9688330	chr12:9633419~9658412:+
THCA	cis	rs3764021	0.527	rs17806710	ENSG00000256594.6	RP11-705C15.2	6.44	2.95e-10	6.8e-08	0.24	0.28	Type 1 diabetes;	chr12:9688368	chr12:9633419~9658412:+
THCA	cis	rs11148252	0.574	rs3742297	ENSG00000278238.1	RP11-245D16.4	-6.44	2.95e-10	6.8e-08	-0.32	-0.28	Lewy body disease;	chr13:52703932	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.574	rs9536247	ENSG00000278238.1	RP11-245D16.4	-6.44	2.95e-10	6.8e-08	-0.32	-0.28	Lewy body disease;	chr13:52705407	chr13:52454775~52455331:-
THCA	cis	rs1865760	0.663	rs9348704	ENSG00000272462.2	U91328.19	-6.44	2.96e-10	6.8e-08	-0.23	-0.28	Height;	chr6:26000165	chr6:25992662~26001775:+
THCA	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-6.44	2.96e-10	6.8e-08	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
THCA	cis	rs17772222	0.917	rs2004329	ENSG00000258789.1	RP11-507K2.3	-6.44	2.96e-10	6.8e-08	-0.29	-0.28	Coronary artery calcification;	chr14:88532965	chr14:88551597~88552493:+
THCA	cis	rs7688540	0.8	rs73793597	ENSG00000211553.1	AC253576.2	-6.44	2.96e-10	6.8e-08	-0.39	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:136461~136568:+
THCA	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-6.44	2.96e-10	6.8e-08	-0.44	-0.28	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
THCA	cis	rs72843506	0.656	rs79773274	ENSG00000270091.1	RP11-78O7.2	-6.44	2.96e-10	6.81e-08	-0.33	-0.28	Schizophrenia;	chr17:20002618	chr17:19896590~19897287:-
THCA	cis	rs7567389	0.502	rs2069919	ENSG00000236682.1	AC068282.3	-6.44	2.96e-10	6.81e-08	-0.43	-0.28	Self-rated health;	chr2:127421977	chr2:127389130~127400580:+
THCA	cis	rs847577	0.609	rs7791463	ENSG00000272950.1	RP11-307C18.1	6.44	2.96e-10	6.81e-08	0.36	0.28	Breast cancer;	chr7:98189735	chr7:98322853~98323430:+
THCA	cis	rs6545883	0.862	rs1880866	ENSG00000271889.1	RP11-493E12.1	6.44	2.96e-10	6.82e-08	0.27	0.28	Tuberculosis;	chr2:61471837	chr2:61151433~61162105:-
THCA	cis	rs4835473	0.932	rs7697916	ENSG00000251600.4	RP11-673E1.1	-6.44	2.97e-10	6.82e-08	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143765628	chr4:143912331~143982454:+
THCA	cis	rs4143844	0.867	rs12907534	ENSG00000259251.2	RP11-643M14.1	6.44	2.97e-10	6.82e-08	0.55	0.28	Bipolar disorder and schizophrenia;	chr15:61908396	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs35607089	ENSG00000259251.2	RP11-643M14.1	6.44	2.97e-10	6.82e-08	0.55	0.28	Bipolar disorder and schizophrenia;	chr15:61909573	chr15:62060503~62062434:+
THCA	cis	rs46522	0.585	rs79049364	ENSG00000248278.1	SUMO2P17	6.44	2.97e-10	6.82e-08	0.34	0.28	Coronary heart disease;	chr17:48937629	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.811	rs80032154	ENSG00000248278.1	SUMO2P17	6.44	2.97e-10	6.82e-08	0.34	0.28	Type 2 diabetes;	chr17:48937630	chr17:48874860~48908983:-
THCA	cis	rs7727544	0.636	rs2631365	ENSG00000237714.1	P4HA2-AS1	-6.44	2.97e-10	6.83e-08	-0.37	-0.28	Blood metabolite levels;	chr5:132370257	chr5:132184876~132192808:+
THCA	cis	rs35264875	1	rs72917389	ENSG00000259799.1	RP11-554A11.9	6.44	2.97e-10	6.83e-08	0.5	0.28	Blond vs. brown hair color;	chr11:69055363	chr11:69155910~69159752:+
THCA	cis	rs10208649	1	rs72906711	ENSG00000233266.1	HMGB1P31	6.44	2.97e-10	6.83e-08	0.66	0.28	Body mass index;	chr2:54036465	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.908	rs13387890	ENSG00000233266.1	HMGB1P31	6.44	2.97e-10	6.83e-08	0.66	0.28	Body mass index;	chr2:54039249	chr2:54051334~54051760:+
THCA	cis	rs6860806	0.661	rs4705929	ENSG00000237714.1	P4HA2-AS1	6.44	2.97e-10	6.83e-08	0.36	0.28	Breast cancer;	chr5:132248485	chr5:132184876~132192808:+
THCA	cis	rs1552244	0.882	rs9312044	ENSG00000180385.7	EMC3-AS1	6.44	2.97e-10	6.84e-08	0.3	0.28	Alzheimer's disease;	chr3:9995797	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs6796419	ENSG00000180385.7	EMC3-AS1	6.44	2.97e-10	6.84e-08	0.3	0.28	Alzheimer's disease;	chr3:9999128	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.752	rs9867091	ENSG00000180385.7	EMC3-AS1	6.44	2.97e-10	6.84e-08	0.3	0.28	Alzheimer's disease;	chr3:10001745	chr3:9986893~10006990:+
THCA	cis	rs1979679	0.842	rs4931729	ENSG00000278733.1	RP11-425D17.1	6.44	2.97e-10	6.84e-08	0.28	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146306	chr12:28185625~28186190:-
THCA	cis	rs9926296	0.548	rs12447465	ENSG00000260259.1	RP11-368I7.4	-6.44	2.98e-10	6.84e-08	-0.31	-0.28	Vitiligo;	chr16:89763487	chr16:89682620~89686569:-
THCA	cis	rs228614	0.51	rs223377	ENSG00000230069.3	LRRC37A15P	-6.44	2.98e-10	6.84e-08	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102727274~102730721:-
THCA	cis	rs11158026	0.79	rs1107960	ENSG00000258413.1	RP11-665C16.6	-6.44	2.98e-10	6.86e-08	-0.39	-0.28	Parkinson's disease;	chr14:54917622	chr14:55262767~55272075:-
THCA	cis	rs7044106	0.762	rs10984972	ENSG00000270917.1	RP11-27I1.6	-6.44	2.99e-10	6.86e-08	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120812475~120812845:-
THCA	cis	rs73607972	0.935	rs73609954	ENSG00000275191.1	RP11-36I17.2	-6.44	2.99e-10	6.87e-08	-0.45	-0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53693937	chr16:53628256~53628816:-
THCA	cis	rs16949788	1	rs12323975	ENSG00000261351.2	CTD-3185P2.1	-6.44	2.99e-10	6.88e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66382296	chr15:66488658~66492109:-
THCA	cis	rs16949788	1	rs16949849	ENSG00000261351.2	CTD-3185P2.1	-6.44	2.99e-10	6.88e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66390371	chr15:66488658~66492109:-
THCA	cis	rs16949788	1	rs80298548	ENSG00000261351.2	CTD-3185P2.1	-6.44	2.99e-10	6.88e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66398110	chr15:66488658~66492109:-
THCA	cis	rs12681366	0.571	rs2919654	ENSG00000253704.1	RP11-267M23.4	6.44	2.99e-10	6.88e-08	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94464045	chr8:94553722~94569745:+
THCA	cis	rs6928977	0.5	rs9494308	ENSG00000231028.7	LINC00271	6.44	2.99e-10	6.88e-08	0.24	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627666	chr6:135497801~135716055:+
THCA	cis	rs797680	0.856	rs797681	ENSG00000223745.6	RP4-717I23.3	-6.44	2.99e-10	6.88e-08	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93252189	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs682514	ENSG00000223745.6	RP4-717I23.3	-6.44	2.99e-10	6.88e-08	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93253873	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs693737	ENSG00000223745.6	RP4-717I23.3	-6.44	2.99e-10	6.88e-08	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93259367	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs535760	ENSG00000223745.6	RP4-717I23.3	-6.44	2.99e-10	6.88e-08	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93263201	chr1:93262186~93346025:-
THCA	cis	rs227275	0.554	rs223457	ENSG00000230069.3	LRRC37A15P	-6.44	3e-10	6.88e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102727274~102730721:-
THCA	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-6.44	3e-10	6.89e-08	-0.26	-0.28	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
THCA	cis	rs526231	0.819	rs35803	ENSG00000175749.11	EIF3KP1	6.44	3e-10	6.89e-08	0.39	0.28	Primary biliary cholangitis;	chr5:103271241	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.755	rs55792032	ENSG00000278665.1	RP11-666O2.4	6.44	3e-10	6.89e-08	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28599241~28601881:-
THCA	cis	rs4143844	0.867	rs34646089	ENSG00000259251.2	RP11-643M14.1	6.44	3e-10	6.9e-08	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61978298	chr15:62060503~62062434:+
THCA	cis	rs3806843	1	rs10037757	ENSG00000202515.1	VTRNA1-3	-6.44	3e-10	6.9e-08	-0.32	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140817637	chr5:140726158~140726246:+
THCA	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-6.44	3.01e-10	6.92e-08	-0.37	-0.28	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
THCA	cis	rs4819052	0.788	rs2236449	ENSG00000237664.1	LINC00316	-6.44	3.01e-10	6.92e-08	-0.3	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45338590~45341990:-
THCA	cis	rs6545883	0.862	rs11691734	ENSG00000271889.1	RP11-493E12.1	6.44	3.02e-10	6.94e-08	0.27	0.28	Tuberculosis;	chr2:61475331	chr2:61151433~61162105:-
THCA	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	6.44	3.02e-10	6.94e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
THCA	cis	rs807029	0.577	rs11190786	ENSG00000272572.1	RP11-179B2.2	-6.44	3.02e-10	6.94e-08	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100997685	chr10:100911103~100912739:-
THCA	cis	rs807029	0.577	rs7902510	ENSG00000272572.1	RP11-179B2.2	-6.44	3.02e-10	6.94e-08	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998177	chr10:100911103~100912739:-
THCA	cis	rs807029	0.577	rs7903239	ENSG00000272572.1	RP11-179B2.2	-6.44	3.02e-10	6.94e-08	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998580	chr10:100911103~100912739:-
THCA	cis	rs797680	0.964	rs2296558	ENSG00000223745.6	RP4-717I23.3	-6.44	3.02e-10	6.95e-08	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93270998	chr1:93262186~93346025:-
THCA	cis	rs7208859	0.673	rs216418	ENSG00000263603.1	CTD-2349P21.5	-6.44	3.03e-10	6.95e-08	-0.46	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs216423	ENSG00000263603.1	CTD-2349P21.5	-6.44	3.03e-10	6.95e-08	-0.46	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30729469~30731202:+
THCA	cis	rs438465	0.945	rs9371133	ENSG00000226194.4	RP1-137D17.1	-6.44	3.03e-10	6.95e-08	-0.43	-0.28	Corneal astigmatism;	chr6:169446169	chr6:169369998~169388385:-
THCA	cis	rs17594362	0.697	rs7322968	ENSG00000264190.1	MIR5006	-6.44	3.03e-10	6.95e-08	-0.39	-0.28	Multiple sclerosis;	chr13:41576362	chr13:41568286~41568395:-
THCA	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-6.44	3.03e-10	6.95e-08	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
THCA	cis	rs1580019	0.563	rs13225132	ENSG00000231952.3	DPY19L1P2	-6.44	3.03e-10	6.96e-08	-0.35	-0.28	Cognitive ability;	chr7:32761363	chr7:32812757~32838570:+
THCA	cis	rs2439831	0.85	rs558656	ENSG00000249839.1	AC011330.5	-6.44	3.03e-10	6.96e-08	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43431316	chr15:43663654~43684339:-
THCA	cis	rs7746199	0.668	rs34864796	ENSG00000280107.1	AL022393.9	-6.44	3.03e-10	6.96e-08	-0.49	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28170845~28172521:+
THCA	cis	rs7044106	0.762	rs1886337	ENSG00000270917.1	RP11-27I1.6	-6.44	3.03e-10	6.97e-08	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120812475~120812845:-
THCA	cis	rs681343	0.746	rs633372	ENSG00000232871.7	SEC1P	6.44	3.04e-10	6.97e-08	0.33	0.28	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48705969	chr19:48638071~48682245:+
THCA	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	6.44	3.04e-10	6.98e-08	0.49	0.28	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
THCA	cis	rs2243480	1	rs73150014	ENSG00000228409.4	CCT6P1	6.44	3.04e-10	6.98e-08	0.32	0.28	Diabetic kidney disease;	chr7:65985932	chr7:65751142~65763354:+
THCA	cis	rs848490	0.734	rs12531933	ENSG00000214293.7	APTR	6.44	3.04e-10	6.98e-08	0.21	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77671171	chr7:77657660~77696265:-
THCA	cis	rs897984	0.645	rs9938550	ENSG00000279196.1	RP11-1072A3.3	-6.44	3.04e-10	6.98e-08	-0.28	-0.28	Dementia with Lewy bodies;	chr16:30987821	chr16:30984630~30988270:-
THCA	cis	rs6496044	0.568	rs6496049	ENSG00000259295.5	CSPG4P12	6.44	3.04e-10	6.99e-08	0.36	0.28	Interstitial lung disease;	chr15:85525974	chr15:85191438~85213905:+
THCA	cis	rs595244	1	rs636178	ENSG00000259705.1	RP11-227D13.1	6.44	3.05e-10	6.99e-08	0.51	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48605085	chr15:48645951~48652016:+
THCA	cis	rs595244	0.901	rs2466790	ENSG00000259705.1	RP11-227D13.1	6.44	3.05e-10	6.99e-08	0.51	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48607202	chr15:48645951~48652016:+
THCA	cis	rs2348418	0.966	rs1527578	ENSG00000247934.4	RP11-967K21.1	6.44	3.05e-10	7e-08	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28536903	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.966	rs16932891	ENSG00000247934.4	RP11-967K21.1	6.44	3.05e-10	7e-08	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28537055	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.932	rs7968515	ENSG00000247934.4	RP11-967K21.1	6.44	3.05e-10	7e-08	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28542914	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.966	rs2881910	ENSG00000247934.4	RP11-967K21.1	6.44	3.05e-10	7e-08	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28544459	chr12:28163298~28190738:-
THCA	cis	rs12554020	0.681	rs78792144	ENSG00000227603.1	RP11-165J3.6	6.43	3.05e-10	7e-08	0.52	0.28	Schizophrenia;	chr9:93583725	chr9:93435332~93437121:-
THCA	cis	rs3847687	0.546	rs12815872	ENSG00000256810.1	RP11-76C10.2	6.43	3.05e-10	7e-08	0.34	0.28	Longevity;	chr12:131036293	chr12:131030570~131035487:-
THCA	cis	rs1609391	0.543	rs9859810	ENSG00000273486.1	RP11-731C17.2	6.43	3.05e-10	7e-08	0.25	0.28	Neuroticism;	chr3:136911144	chr3:136837338~136839021:-
THCA	cis	rs797680	0.964	rs1060622	ENSG00000223745.6	RP4-717I23.3	6.43	3.05e-10	7.01e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93154836	chr1:93262186~93346025:-
THCA	cis	rs1005277	0.522	rs9417256	ENSG00000263064.2	RP11-291L22.7	6.43	3.05e-10	7.01e-08	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38448689~38448949:+
THCA	cis	rs227275	0.554	rs223388	ENSG00000230069.3	LRRC37A15P	-6.43	3.06e-10	7.01e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102727274~102730721:-
THCA	cis	rs9341808	0.617	rs9294170	ENSG00000272129.1	RP11-250B2.6	6.43	3.06e-10	7.02e-08	0.36	0.28	Sitting height ratio;	chr6:80104363	chr6:80355424~80356859:+
THCA	cis	rs17594362	0.697	rs2875448	ENSG00000264190.1	MIR5006	6.43	3.06e-10	7.03e-08	0.38	0.28	Multiple sclerosis;	chr13:41569686	chr13:41568286~41568395:-
THCA	cis	rs17594362	0.697	rs9562321	ENSG00000264190.1	MIR5006	6.43	3.06e-10	7.03e-08	0.38	0.28	Multiple sclerosis;	chr13:41570717	chr13:41568286~41568395:-
THCA	cis	rs2243480	1	rs313813	ENSG00000232546.1	RP11-458F8.1	-6.43	3.06e-10	7.03e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66038513	chr7:66848496~66858136:+
THCA	cis	rs11148252	0.574	rs7139495	ENSG00000278238.1	RP11-245D16.4	-6.43	3.06e-10	7.03e-08	-0.32	-0.28	Lewy body disease;	chr13:52709183	chr13:52454775~52455331:-
THCA	cis	rs10761482	0.5	rs1892547	ENSG00000254271.1	RP11-131N11.4	6.43	3.06e-10	7.03e-08	0.36	0.28	Schizophrenia;	chr10:60533200	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.516	rs1348281	ENSG00000254271.1	RP11-131N11.4	-6.43	3.07e-10	7.04e-08	-0.36	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60596475	chr10:60734342~60741828:+
THCA	cis	rs2834188	1	rs2252931	ENSG00000272659.1	AP000295.10	-6.43	3.07e-10	7.05e-08	-0.39	-0.28	Narcolepsy;	chr21:33332014	chr21:33309491~33310181:+
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000264538.5	SUZ12P1	-6.43	3.07e-10	7.05e-08	-0.27	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30709299~30790908:+
THCA	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	6.43	3.07e-10	7.05e-08	0.32	0.28	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
THCA	cis	rs7294478	0.839	rs6487849	ENSG00000205885.6	C1RL-AS1	6.43	3.07e-10	7.05e-08	0.21	0.28	Neuritic plaque;	chr12:7111103	chr12:7108052~7122501:+
THCA	cis	rs2562456	0.833	rs4429400	ENSG00000268555.1	RP11-678G14.3	6.43	3.07e-10	7.05e-08	0.47	0.28	Pain;	chr19:21338163	chr19:21570822~21587322:-
THCA	cis	rs2243480	1	rs1039664	ENSG00000229886.1	RP5-1132H15.3	6.43	3.07e-10	7.05e-08	0.45	0.28	Diabetic kidney disease;	chr7:65984729	chr7:66025126~66031544:-
THCA	cis	rs2280018	0.581	rs7404524	ENSG00000188599.16	NPIPP1	-6.43	3.07e-10	7.06e-08	-0.22	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15104312~15123498:-
THCA	cis	rs853679	1	rs9986596	ENSG00000226314.6	ZNF192P1	-6.43	3.08e-10	7.06e-08	-0.45	-0.28	Depression;	chr6:28251883	chr6:28161781~28169594:+
THCA	cis	rs848490	0.962	rs55869229	ENSG00000214293.7	APTR	6.43	3.08e-10	7.07e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77721148	chr7:77657660~77696265:-
THCA	cis	rs62103177	0.561	rs891489	ENSG00000261126.6	RP11-795F19.1	-6.43	3.09e-10	7.09e-08	-0.28	-0.28	Opioid sensitivity;	chr18:79877493	chr18:80046900~80095482:+
THCA	cis	rs1789	0.558	rs10021522	ENSG00000273133.1	RP11-799M12.2	-6.43	3.09e-10	7.09e-08	-0.37	-0.28	Blood protein levels;	chr4:15522985	chr4:15563698~15564253:-
THCA	cis	rs7927592	0.83	rs7120635	ENSG00000212093.1	AP000807.1	6.43	3.09e-10	7.1e-08	0.31	0.28	Total body bone mineral density;	chr11:68493825	chr11:68506083~68506166:-
THCA	cis	rs807029	0.577	rs3740488	ENSG00000272572.1	RP11-179B2.2	-6.43	3.1e-10	7.1e-08	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100911103~100912739:-
THCA	cis	rs916888	0.779	rs199498	ENSG00000232300.1	FAM215B	6.43	3.1e-10	7.1e-08	0.41	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46558830~46562795:-
THCA	cis	rs12681366	0.659	rs2470742	ENSG00000253704.1	RP11-267M23.4	-6.43	3.1e-10	7.11e-08	-0.27	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94385929	chr8:94553722~94569745:+
THCA	cis	rs4650994	0.507	rs56229230	ENSG00000273384.1	RP5-1098D14.1	6.43	3.1e-10	7.11e-08	0.36	0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178557428	chr1:178651706~178652282:+
THCA	cis	rs890448	0.662	rs2850372	ENSG00000254531.1	FLJ20021	-6.43	3.1e-10	7.11e-08	-0.25	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101326034	chr4:101347780~101348883:+
THCA	cis	rs860295	0.65	rs625658	ENSG00000225855.5	RUSC1-AS1	-6.43	3.1e-10	7.11e-08	-0.18	-0.28	Body mass index;	chr1:155921254	chr1:155316863~155324176:-
THCA	cis	rs831571	0.703	rs55714137	ENSG00000280620.1	SCAANT1	6.43	3.1e-10	7.11e-08	0.47	0.28	Type 2 diabetes;	chr3:64091103	chr3:63911518~63911772:-
THCA	cis	rs934734	0.967	rs702875	ENSG00000281920.1	RP11-418H16.1	6.43	3.1e-10	7.12e-08	0.35	0.28	Rheumatoid arthritis;	chr2:65387063	chr2:65623272~65628424:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000228409.4	CCT6P1	-6.43	3.1e-10	7.12e-08	-0.22	-0.28	Calcium levels;	chr7:65977808	chr7:65751142~65763354:+
THCA	cis	rs7580658	0.55	rs62160290	ENSG00000236682.1	AC068282.3	-6.43	3.11e-10	7.13e-08	-0.38	-0.28	Protein C levels;	chr2:127443119	chr2:127389130~127400580:+
THCA	cis	rs848490	0.855	rs17155183	ENSG00000214293.7	APTR	6.43	3.11e-10	7.13e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77571075	chr7:77657660~77696265:-
THCA	cis	rs7615952	0.551	rs6438945	ENSG00000241288.6	RP11-379B18.5	-6.43	3.11e-10	7.13e-08	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125915630	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.673	rs7632557	ENSG00000241288.6	RP11-379B18.5	-6.43	3.11e-10	7.13e-08	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125916038	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.932	rs9841157	ENSG00000241288.6	RP11-379B18.5	-6.43	3.11e-10	7.13e-08	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125916812	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.551	rs12695470	ENSG00000241288.6	RP11-379B18.5	-6.43	3.11e-10	7.13e-08	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125916875	chr3:125827238~125916384:-
THCA	cis	rs17772222	0.958	rs1123421	ENSG00000258789.1	RP11-507K2.3	-6.43	3.11e-10	7.13e-08	-0.29	-0.28	Coronary artery calcification;	chr14:88524651	chr14:88551597~88552493:+
THCA	cis	rs748404	0.578	rs2584701	ENSG00000166763.7	STRCP1	6.43	3.11e-10	7.13e-08	0.31	0.28	Lung cancer;	chr15:43392741	chr15:43699488~43718184:-
THCA	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	6.43	3.11e-10	7.14e-08	0.33	0.28	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
THCA	cis	rs35264875	0.808	rs921675	ENSG00000259799.1	RP11-554A11.9	-6.43	3.11e-10	7.14e-08	-0.38	-0.28	Blond vs. brown hair color;	chr11:69101566	chr11:69155910~69159752:+
THCA	cis	rs7568498	0.564	rs9287807	ENSG00000235724.7	AC009299.2	6.43	3.11e-10	7.14e-08	0.33	0.28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161222785~161308303:-
THCA	cis	rs3764021	0.527	rs10844503	ENSG00000256594.6	RP11-705C15.2	6.43	3.12e-10	7.14e-08	0.24	0.28	Type 1 diabetes;	chr12:9701660	chr12:9633419~9658412:+
THCA	cis	rs17158807	0.639	rs72760366	ENSG00000274128.1	RP11-342A23.2	6.43	3.12e-10	7.15e-08	0.48	0.28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr15:83562446	chr15:83962176~83962583:+
THCA	cis	rs8027521	0.54	rs17793649	ENSG00000280362.1	RP11-643A5.3	6.43	3.12e-10	7.15e-08	0.35	0.28	Circulating chemerin levels;	chr15:53947572	chr15:53910769~53914712:+
THCA	cis	rs2243480	1	rs67728539	ENSG00000229886.1	RP5-1132H15.3	6.43	3.12e-10	7.15e-08	0.46	0.28	Diabetic kidney disease;	chr7:65913137	chr7:66025126~66031544:-
THCA	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-6.43	3.12e-10	7.16e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
THCA	cis	rs16843372	0.562	rs10174267	ENSG00000251491.2	OR7E28P	-6.43	3.12e-10	7.16e-08	-0.37	-0.28	Obesity-related traits;	chr2:158824629	chr2:158862311~158863285:+
THCA	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	6.43	3.12e-10	7.16e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
THCA	cis	rs1979679	0.808	rs71452082	ENSG00000278733.1	RP11-425D17.1	6.43	3.12e-10	7.16e-08	0.28	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28221647	chr12:28185625~28186190:-
THCA	cis	rs4835473	0.897	rs1391189	ENSG00000251600.4	RP11-673E1.1	-6.43	3.12e-10	7.17e-08	-0.37	-0.28	Immature fraction of reticulocytes;	chr4:143690951	chr4:143912331~143982454:+
THCA	cis	rs1865760	0.568	rs2032450	ENSG00000272462.2	U91328.19	-6.43	3.13e-10	7.17e-08	-0.23	-0.28	Height;	chr6:25992886	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.713	rs2013063	ENSG00000272462.2	U91328.19	-6.43	3.13e-10	7.17e-08	-0.23	-0.28	Height;	chr6:25993870	chr6:25992662~26001775:+
THCA	cis	rs2976388	0.935	rs13249440	ENSG00000253741.1	CTD-2292P10.4	6.43	3.13e-10	7.17e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142675474	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.904	rs13256647	ENSG00000253741.1	CTD-2292P10.4	6.43	3.13e-10	7.17e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142675477	chr8:142702252~142726973:-
THCA	cis	rs1707322	0.717	rs2275086	ENSG00000281133.1	AL355480.3	6.43	3.13e-10	7.17e-08	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45580892~45580996:-
THCA	cis	rs2243480	0.901	rs2900904	ENSG00000229886.1	RP5-1132H15.3	6.43	3.13e-10	7.18e-08	0.46	0.28	Diabetic kidney disease;	chr7:65739282	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6460260	ENSG00000229886.1	RP5-1132H15.3	-6.43	3.13e-10	7.18e-08	-0.46	-0.28	Diabetic kidney disease;	chr7:65750468	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs6460261	ENSG00000229886.1	RP5-1132H15.3	-6.43	3.13e-10	7.18e-08	-0.46	-0.28	Diabetic kidney disease;	chr7:65750593	chr7:66025126~66031544:-
THCA	cis	rs12681366	0.659	rs2046666	ENSG00000253704.1	RP11-267M23.4	-6.43	3.13e-10	7.18e-08	-0.27	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94375920	chr8:94553722~94569745:+
THCA	cis	rs6903823	0.508	rs1778484	ENSG00000219392.1	RP1-265C24.5	-6.43	3.13e-10	7.19e-08	-0.32	-0.28	Pulmonary function;	chr6:28273021	chr6:28115628~28116551:+
THCA	cis	rs2243480	1	rs313832	ENSG00000228409.4	CCT6P1	6.43	3.14e-10	7.19e-08	0.32	0.28	Diabetic kidney disease;	chr7:66085904	chr7:65751142~65763354:+
THCA	cis	rs1005277	0.579	rs1780116	ENSG00000276805.1	RP11-291L22.6	6.43	3.14e-10	7.2e-08	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780121	ENSG00000276805.1	RP11-291L22.6	6.43	3.14e-10	7.2e-08	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780122	ENSG00000276805.1	RP11-291L22.6	6.43	3.14e-10	7.2e-08	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780145	ENSG00000276805.1	RP11-291L22.6	6.43	3.14e-10	7.2e-08	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38451030~38451785:+
THCA	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-6.43	3.14e-10	7.2e-08	-0.5	-0.28	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
THCA	cis	rs2243480	1	rs781150	ENSG00000228409.4	CCT6P1	6.43	3.15e-10	7.21e-08	0.33	0.28	Diabetic kidney disease;	chr7:66015986	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs313798	ENSG00000228409.4	CCT6P1	6.43	3.15e-10	7.21e-08	0.33	0.28	Diabetic kidney disease;	chr7:66028044	chr7:65751142~65763354:+
THCA	cis	rs728616	0.867	rs61859022	ENSG00000242600.5	MBL1P	6.43	3.15e-10	7.21e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:79904898~79950336:+
THCA	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-6.43	3.15e-10	7.22e-08	-0.17	-0.28	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
THCA	cis	rs896854	0.654	rs10429443	ENSG00000253528.2	RP11-347C18.4	6.43	3.15e-10	7.22e-08	0.32	0.28	Type 2 diabetes;	chr8:94958936	chr8:94974573~94974853:-
THCA	cis	rs896854	0.654	rs896846	ENSG00000253528.2	RP11-347C18.4	6.43	3.15e-10	7.22e-08	0.32	0.28	Type 2 diabetes;	chr8:94960225	chr8:94974573~94974853:-
THCA	cis	rs896854	0.654	rs896847	ENSG00000253528.2	RP11-347C18.4	6.43	3.15e-10	7.22e-08	0.32	0.28	Type 2 diabetes;	chr8:94960323	chr8:94974573~94974853:-
THCA	cis	rs896854	0.654	rs13281625	ENSG00000253528.2	RP11-347C18.4	6.43	3.15e-10	7.22e-08	0.32	0.28	Type 2 diabetes;	chr8:94960510	chr8:94974573~94974853:-
THCA	cis	rs896854	0.625	rs13281709	ENSG00000253528.2	RP11-347C18.4	6.43	3.15e-10	7.22e-08	0.32	0.28	Type 2 diabetes;	chr8:94960591	chr8:94974573~94974853:-
THCA	cis	rs896854	0.625	rs4735335	ENSG00000253528.2	RP11-347C18.4	6.43	3.15e-10	7.22e-08	0.32	0.28	Type 2 diabetes;	chr8:94961099	chr8:94974573~94974853:-
THCA	cis	rs896854	0.654	rs4735337	ENSG00000253528.2	RP11-347C18.4	6.43	3.15e-10	7.22e-08	0.32	0.28	Type 2 diabetes;	chr8:94961237	chr8:94974573~94974853:-
THCA	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	6.43	3.15e-10	7.22e-08	0.32	0.28	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
THCA	cis	rs2439831	1	rs2467739	ENSG00000249839.1	AC011330.5	-6.43	3.15e-10	7.22e-08	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43447998	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs28666488	ENSG00000249839.1	AC011330.5	-6.43	3.15e-10	7.22e-08	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43448892	chr15:43663654~43684339:-
THCA	cis	rs2439831	1	rs2245790	ENSG00000249839.1	AC011330.5	-6.43	3.15e-10	7.22e-08	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43452259	chr15:43663654~43684339:-
THCA	cis	rs28386778	0.897	rs2727320	ENSG00000240280.5	TCAM1P	-6.43	3.15e-10	7.22e-08	-0.4	-0.28	Prudent dietary pattern;	chr17:63787965	chr17:63849292~63864379:+
THCA	cis	rs728616	0.764	rs79529820	ENSG00000225484.5	NUTM2B-AS1	-6.43	3.15e-10	7.23e-08	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060773	chr10:79663088~79826594:-
THCA	cis	rs516805	0.63	rs2606642	ENSG00000279453.1	RP3-425C14.4	6.43	3.15e-10	7.23e-08	0.3	0.28	Lymphocyte counts;	chr6:122103758	chr6:122436789~122439223:-
THCA	cis	rs2303319	1	rs62197078	ENSG00000227403.1	AC009299.3	6.43	3.15e-10	7.23e-08	0.6	0.28	Cognitive function;	chr2:161326443	chr2:161244739~161249050:+
THCA	cis	rs748404	0.578	rs576557	ENSG00000166763.7	STRCP1	6.43	3.16e-10	7.24e-08	0.3	0.28	Lung cancer;	chr15:43305539	chr15:43699488~43718184:-
THCA	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	6.43	3.16e-10	7.24e-08	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-6.43	3.16e-10	7.24e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-6.43	3.16e-10	7.24e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-6.43	3.16e-10	7.24e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
THCA	cis	rs2292342	0.85	rs11878449	ENSG00000232871.7	SEC1P	-6.43	3.16e-10	7.25e-08	-0.53	-0.28	Elevated serum carcinoembryonic antigen levels;	chr19:48641677	chr19:48638071~48682245:+
THCA	cis	rs516805	0.63	rs2816077	ENSG00000279453.1	RP3-425C14.4	-6.43	3.17e-10	7.25e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122105669	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs2816075	ENSG00000279453.1	RP3-425C14.4	-6.43	3.17e-10	7.25e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122106110	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs2816073	ENSG00000279453.1	RP3-425C14.4	-6.43	3.17e-10	7.25e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122106794	chr6:122436789~122439223:-
THCA	cis	rs516805	0.666	rs2816071	ENSG00000279453.1	RP3-425C14.4	-6.43	3.17e-10	7.25e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122106995	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs720205	ENSG00000279453.1	RP3-425C14.4	-6.43	3.17e-10	7.25e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122107329	chr6:122436789~122439223:-
THCA	cis	rs853679	0.506	rs1150693	ENSG00000272009.1	RP1-313I6.12	-6.43	3.17e-10	7.25e-08	-0.33	-0.28	Depression;	chr6:28206812	chr6:28078792~28081130:-
THCA	cis	rs9677476	0.863	rs11558174	ENSG00000224376.1	AC017104.6	6.43	3.17e-10	7.25e-08	0.32	0.28	Food antigen IgG levels;	chr2:231208199	chr2:231388976~231394991:+
THCA	cis	rs9677476	0.863	rs12465438	ENSG00000224376.1	AC017104.6	6.43	3.17e-10	7.25e-08	0.32	0.28	Food antigen IgG levels;	chr2:231208393	chr2:231388976~231394991:+
THCA	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	6.43	3.17e-10	7.26e-08	0.33	0.28	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
THCA	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-6.43	3.17e-10	7.26e-08	-0.23	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
THCA	cis	rs7202877	0.656	rs3851736	ENSG00000261783.1	RP11-252K23.2	-6.43	3.17e-10	7.27e-08	-0.5	-0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75353434	chr16:75379818~75381260:-
THCA	cis	rs7202877	0.572	rs8051611	ENSG00000261783.1	RP11-252K23.2	-6.43	3.17e-10	7.27e-08	-0.5	-0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75355035	chr16:75379818~75381260:-
THCA	cis	rs1865760	0.713	rs6928951	ENSG00000272462.2	U91328.19	-6.43	3.18e-10	7.27e-08	-0.23	-0.28	Height;	chr6:25995326	chr6:25992662~26001775:+
THCA	cis	rs7976269	0.609	rs7135891	ENSG00000257176.2	RP11-996F15.2	-6.43	3.18e-10	7.28e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29053944	chr12:29280418~29317848:-
THCA	cis	rs10916248	0.511	rs10916512	ENSG00000232628.4	RP11-365O16.3	6.43	3.18e-10	7.28e-08	0.41	0.28	QT interval (drug interaction);	chr1:224220968	chr1:224208747~224213279:-
THCA	cis	rs2562456	0.833	rs56179986	ENSG00000268555.1	RP11-678G14.3	6.43	3.18e-10	7.29e-08	0.47	0.28	Pain;	chr19:21337882	chr19:21570822~21587322:-
THCA	cis	rs28386778	0.897	rs7501614	ENSG00000240280.5	TCAM1P	-6.43	3.18e-10	7.29e-08	-0.4	-0.28	Prudent dietary pattern;	chr17:63725252	chr17:63849292~63864379:+
THCA	cis	rs2163813	1	rs247771	ENSG00000275540.1	CTC-559E9.12	-6.43	3.18e-10	7.29e-08	-0.34	-0.28	Toenail selenium levels;	chr19:19737073	chr19:19740884~19750127:+
THCA	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-6.43	3.18e-10	7.29e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
THCA	cis	rs4650994	0.525	rs17361286	ENSG00000273384.1	RP5-1098D14.1	6.43	3.18e-10	7.29e-08	0.36	0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178552781	chr1:178651706~178652282:+
THCA	cis	rs593531	0.614	rs10736795	ENSG00000212961.4	HNRNPA1P40	6.43	3.18e-10	7.29e-08	0.36	0.28	Neuroticism;	chr11:74328501	chr11:74354443~74355720:+
THCA	cis	rs1707322	0.682	rs12037459	ENSG00000281133.1	AL355480.3	-6.43	3.19e-10	7.3e-08	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45580892~45580996:-
THCA	cis	rs7948661	1	rs7113994	ENSG00000278376.1	RP11-158I9.8	6.43	3.19e-10	7.3e-08	0.46	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118511612	chr11:118791254~118793137:+
THCA	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-6.43	3.19e-10	7.3e-08	-0.37	-0.28	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
THCA	cis	rs7403037	0.793	rs12917411	ENSG00000259905.4	PWRN1	6.43	3.19e-10	7.3e-08	0.3	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24386786	chr15:24493137~24652130:+
THCA	cis	rs8014252	0.803	rs17108246	ENSG00000259158.2	ADAM20P1	-6.43	3.19e-10	7.3e-08	-0.37	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70588275	chr14:70468881~70483756:-
THCA	cis	rs12681366	0.683	rs2470746	ENSG00000253704.1	RP11-267M23.4	-6.43	3.19e-10	7.31e-08	-0.27	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94383580	chr8:94553722~94569745:+
THCA	cis	rs227275	0.554	rs223457	ENSG00000251288.2	RP11-10L12.2	-6.43	3.2e-10	7.33e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102751401~102752641:+
THCA	cis	rs2163813	0.959	rs247773	ENSG00000275540.1	CTC-559E9.12	-6.43	3.21e-10	7.34e-08	-0.34	-0.28	Toenail selenium levels;	chr19:19735277	chr19:19740884~19750127:+
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000228409.4	CCT6P1	6.43	3.21e-10	7.34e-08	0.33	0.28	Diabetic kidney disease;	chr7:65914813	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs427044	ENSG00000232546.1	RP11-458F8.1	-6.43	3.21e-10	7.34e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66043558	chr7:66848496~66858136:+
THCA	cis	rs4143844	0.867	rs12901036	ENSG00000259251.2	RP11-643M14.1	6.43	3.21e-10	7.34e-08	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61977797	chr15:62060503~62062434:+
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000264538.5	SUZ12P1	-6.43	3.21e-10	7.34e-08	-0.27	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30709299~30790908:+
THCA	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	6.43	3.21e-10	7.35e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	6.43	3.21e-10	7.35e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
THCA	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-6.43	3.21e-10	7.35e-08	-0.25	-0.28	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
THCA	cis	rs6421571	0.565	rs10892263	ENSG00000255239.1	AP002954.6	-6.43	3.22e-10	7.36e-08	-0.44	-0.28	Primary biliary cholangitis;	chr11:118716610	chr11:118688039~118690600:-
THCA	cis	rs11783469	0.522	rs4872125	ENSG00000253390.1	CTC-756D1.2	-6.43	3.22e-10	7.37e-08	-0.47	-0.28	Reticulocyte count;	chr8:23410757	chr8:23458601~23484971:+
THCA	cis	rs4835473	0.9	rs13101531	ENSG00000251600.4	RP11-673E1.1	-6.43	3.22e-10	7.37e-08	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143982197	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs28668841	ENSG00000251600.4	RP11-673E1.1	-6.43	3.22e-10	7.37e-08	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143982530	chr4:143912331~143982454:+
THCA	cis	rs6740322	0.895	rs11684601	ENSG00000234936.1	AC010883.5	6.43	3.22e-10	7.38e-08	0.31	0.28	Coronary artery disease;	chr2:43347103	chr2:43229573~43233394:+
THCA	cis	rs9890032	0.509	rs11656986	ENSG00000263531.1	RP13-753N3.1	6.43	3.22e-10	7.38e-08	0.39	0.28	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30863921~30864940:-
THCA	cis	rs736801	0.808	rs6866614	ENSG00000224431.1	AC063976.7	-6.43	3.23e-10	7.38e-08	-0.26	-0.28	Mosquito bite size;Breast cancer;	chr5:132451445	chr5:132199456~132203487:+
THCA	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	6.43	3.23e-10	7.39e-08	0.29	0.28	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
THCA	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	6.43	3.23e-10	7.39e-08	0.23	0.28	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
THCA	cis	rs228614	0.536	rs223477	ENSG00000251288.2	RP11-10L12.2	-6.43	3.23e-10	7.39e-08	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102751401~102752641:+
THCA	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	6.43	3.23e-10	7.39e-08	0.32	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
THCA	cis	rs228614	0.543	rs223330	ENSG00000230069.3	LRRC37A15P	-6.43	3.23e-10	7.39e-08	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223329	ENSG00000230069.3	LRRC37A15P	-6.43	3.23e-10	7.39e-08	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102727274~102730721:-
THCA	cis	rs228614	0.536	rs223327	ENSG00000230069.3	LRRC37A15P	-6.43	3.23e-10	7.39e-08	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223326	ENSG00000230069.3	LRRC37A15P	-6.43	3.23e-10	7.39e-08	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223324	ENSG00000230069.3	LRRC37A15P	-6.43	3.23e-10	7.39e-08	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102727274~102730721:-
THCA	cis	rs9990333	0.544	rs11915082	ENSG00000226155.1	AC124944.3	-6.43	3.23e-10	7.39e-08	-0.35	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195912049~195913986:+
THCA	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	6.43	3.23e-10	7.39e-08	0.38	0.28	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
THCA	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	6.43	3.24e-10	7.4e-08	0.31	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
THCA	cis	rs2562456	0.833	rs62110071	ENSG00000268555.1	RP11-678G14.3	6.43	3.24e-10	7.4e-08	0.47	0.28	Pain;	chr19:21288101	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs11667392	ENSG00000268555.1	RP11-678G14.3	6.43	3.24e-10	7.4e-08	0.47	0.28	Pain;	chr19:21289806	chr19:21570822~21587322:-
THCA	cis	rs1005277	0.522	rs1208684	ENSG00000263064.2	RP11-291L22.7	6.43	3.24e-10	7.4e-08	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38448689~38448949:+
THCA	cis	rs1198430	0.925	rs1207124	ENSG00000232482.2	RP4-654C18.1	-6.43	3.24e-10	7.41e-08	-0.51	-0.28	Total cholesterol levels;	chr1:23433915	chr1:23410832~23412146:+
THCA	cis	rs60678552	0.642	rs11754913	ENSG00000233558.1	RP3-486I3.4	6.43	3.24e-10	7.41e-08	0.43	0.28	Heschl's gyrus morphology;	chr6:116321517	chr6:116258493~116259115:-
THCA	cis	rs2243480	1	rs67536397	ENSG00000228409.4	CCT6P1	6.42	3.24e-10	7.41e-08	0.34	0.28	Diabetic kidney disease;	chr7:66482930	chr7:65751142~65763354:+
THCA	cis	rs2834188	0.889	rs1467849	ENSG00000272659.1	AP000295.10	-6.42	3.24e-10	7.41e-08	-0.38	-0.28	Narcolepsy;	chr21:33309764	chr21:33309491~33310181:+
THCA	cis	rs2562456	0.833	rs7260065	ENSG00000268555.1	RP11-678G14.3	6.42	3.24e-10	7.41e-08	0.46	0.28	Pain;	chr19:21334175	chr19:21570822~21587322:-
THCA	cis	rs4835473	0.831	rs4323050	ENSG00000251600.4	RP11-673E1.1	6.42	3.24e-10	7.41e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143992106	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs4423826	ENSG00000251600.4	RP11-673E1.1	6.42	3.24e-10	7.41e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143992165	chr4:143912331~143982454:+
THCA	cis	rs2361701	0.543	rs59252872	ENSG00000279259.1	RP11-334C17.3	6.42	3.24e-10	7.42e-08	0.3	0.28	IgG glycosylation;	chr17:80097448	chr17:80147250~80148596:+
THCA	cis	rs227275	0.525	rs4596243	ENSG00000230069.3	LRRC37A15P	-6.42	3.24e-10	7.42e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102727274~102730721:-
THCA	cis	rs227275	0.524	rs223337	ENSG00000251288.2	RP11-10L12.2	-6.42	3.25e-10	7.42e-08	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102751401~102752641:+
THCA	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-6.42	3.25e-10	7.42e-08	-0.17	-0.28	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-6.42	3.25e-10	7.42e-08	-0.17	-0.28	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	6.42	3.25e-10	7.42e-08	0.17	0.28	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-6.42	3.25e-10	7.42e-08	-0.17	-0.28	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-6.42	3.25e-10	7.42e-08	-0.17	-0.28	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-6.42	3.25e-10	7.42e-08	-0.17	-0.28	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-6.42	3.25e-10	7.42e-08	-0.17	-0.28	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-6.42	3.25e-10	7.42e-08	-0.17	-0.28	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
THCA	cis	rs6840360	0.516	rs6535794	ENSG00000251611.1	RP11-610P16.1	-6.42	3.25e-10	7.42e-08	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151381631	chr4:151407551~151408835:-
THCA	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-6.42	3.25e-10	7.43e-08	-0.44	-0.28	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
THCA	cis	rs11158026	0.757	rs56164809	ENSG00000258413.1	RP11-665C16.6	-6.42	3.25e-10	7.43e-08	-0.39	-0.28	Parkinson's disease;	chr14:54933494	chr14:55262767~55272075:-
THCA	cis	rs7260598	0.636	rs62114769	ENSG00000268442.1	CTD-2027I19.2	6.42	3.25e-10	7.43e-08	0.36	0.28	Response to taxane treatment (placlitaxel);	chr19:24052658	chr19:24162370~24163425:-
THCA	cis	rs1707322	0.686	rs3014239	ENSG00000281133.1	AL355480.3	6.42	3.25e-10	7.43e-08	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45580892~45580996:-
THCA	cis	rs17695224	0.675	rs2109658	ENSG00000269483.1	AC006272.1	-6.42	3.25e-10	7.43e-08	-0.32	-0.28	HDL cholesterol;HDL cholesterol levels;	chr19:51838871	chr19:51839924~51843324:-
THCA	cis	rs7829975	0.564	rs2921057	ENSG00000254153.1	CTA-398F10.2	-6.42	3.25e-10	7.44e-08	-0.31	-0.28	Mood instability;	chr8:8461157	chr8:8456909~8461337:-
THCA	cis	rs7567389	0.504	rs41280570	ENSG00000236682.1	AC068282.3	-6.42	3.26e-10	7.44e-08	-0.43	-0.28	Self-rated health;	chr2:127418654	chr2:127389130~127400580:+
THCA	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-6.42	3.26e-10	7.45e-08	-0.35	-0.28	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
THCA	cis	rs35934224	0.783	rs13056219	ENSG00000232926.1	AC000078.5	6.42	3.26e-10	7.45e-08	0.36	0.28	Glaucoma (primary open-angle);	chr22:19873323	chr22:19887289~19887970:+
THCA	cis	rs16958440	0.867	rs57744138	ENSG00000267800.1	RP11-49K24.5	-6.42	3.26e-10	7.45e-08	-0.63	-0.28	Sitting height ratio;	chr18:47174111	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs16949275	ENSG00000267800.1	RP11-49K24.5	-6.42	3.26e-10	7.45e-08	-0.63	-0.28	Sitting height ratio;	chr18:47174332	chr18:47137018~47137290:+
THCA	cis	rs9813712	0.571	rs9836814	ENSG00000253540.4	FAM86HP	6.42	3.26e-10	7.45e-08	0.31	0.28	Response to amphetamines;	chr3:130216054	chr3:130099092~130111472:-
THCA	cis	rs2239557	1	rs7153587	ENSG00000259065.1	RP5-1021I20.1	-6.42	3.26e-10	7.45e-08	-0.34	-0.28	Common traits (Other);	chr14:74042957	chr14:73787360~73803270:+
THCA	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-6.42	3.26e-10	7.45e-08	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
THCA	cis	rs7267979	0.808	rs84816	ENSG00000274414.1	RP5-965G21.4	-6.42	3.26e-10	7.46e-08	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25239007~25245229:-
THCA	cis	rs728616	0.867	rs1923534	ENSG00000242600.5	MBL1P	6.42	3.26e-10	7.46e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs12414096	ENSG00000242600.5	MBL1P	6.42	3.26e-10	7.46e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:79904898~79950336:+
THCA	cis	rs728616	0.557	rs17107449	ENSG00000242600.5	MBL1P	6.42	3.26e-10	7.46e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:79904898~79950336:+
THCA	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	6.42	3.27e-10	7.46e-08	0.36	0.28	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
THCA	cis	rs77972916	0.561	rs13411485	ENSG00000234936.1	AC010883.5	-6.42	3.27e-10	7.47e-08	-0.36	-0.28	Granulocyte percentage of myeloid white cells;	chr2:43348845	chr2:43229573~43233394:+
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000228409.4	CCT6P1	6.42	3.27e-10	7.47e-08	0.34	0.28	Diabetic kidney disease;	chr7:66500146	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000228409.4	CCT6P1	6.42	3.27e-10	7.47e-08	0.34	0.28	Diabetic kidney disease;	chr7:66500834	chr7:65751142~65763354:+
THCA	cis	rs2562456	0.833	rs2650776	ENSG00000268555.1	RP11-678G14.3	6.42	3.27e-10	7.47e-08	0.46	0.28	Pain;	chr19:21430595	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs2562416	ENSG00000268555.1	RP11-678G14.3	6.42	3.27e-10	7.47e-08	0.46	0.28	Pain;	chr19:21430609	chr19:21570822~21587322:-
THCA	cis	rs4591358	0.731	rs10208012	ENSG00000223466.1	AC064834.2	6.42	3.27e-10	7.47e-08	0.4	0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195452137	chr2:195533035~195538681:+
THCA	cis	rs7267979	0.844	rs6115188	ENSG00000274414.1	RP5-965G21.4	-6.42	3.27e-10	7.48e-08	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25239007~25245229:-
THCA	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	6.42	3.27e-10	7.48e-08	0.32	0.28	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
THCA	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	6.42	3.27e-10	7.48e-08	0.32	0.28	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
THCA	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	6.42	3.27e-10	7.48e-08	0.32	0.28	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
THCA	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	6.42	3.27e-10	7.48e-08	0.32	0.28	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
THCA	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	6.42	3.27e-10	7.48e-08	0.32	0.28	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
THCA	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	6.42	3.27e-10	7.48e-08	0.39	0.28	Height;	chr6:109409645	chr6:109382795~109383666:+
THCA	cis	rs9543976	0.614	rs9573577	ENSG00000261553.4	RP11-29G8.3	-6.42	3.28e-10	7.49e-08	-0.43	-0.28	Diabetic retinopathy;	chr13:75529653	chr13:75549773~75807120:+
THCA	cis	rs11148252	0.574	rs73186430	ENSG00000278238.1	RP11-245D16.4	-6.42	3.28e-10	7.49e-08	-0.32	-0.28	Lewy body disease;	chr13:52658756	chr13:52454775~52455331:-
THCA	cis	rs7763441	0.545	rs9378700	ENSG00000272465.1	RP1-136B1.1	6.42	3.28e-10	7.49e-08	0.37	0.28	Monobrow;	chr6:2452320	chr6:2437549~2438249:+
THCA	cis	rs713477	0.967	rs34652660	ENSG00000258413.1	RP11-665C16.6	6.42	3.28e-10	7.5e-08	0.39	0.28	Pediatric bone mineral content (femoral neck);	chr14:55452762	chr14:55262767~55272075:-
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000229886.1	RP5-1132H15.3	6.42	3.28e-10	7.5e-08	0.47	0.28	Diabetic kidney disease;	chr7:66500146	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000229886.1	RP5-1132H15.3	6.42	3.28e-10	7.5e-08	0.47	0.28	Diabetic kidney disease;	chr7:66500834	chr7:66025126~66031544:-
THCA	cis	rs2735413	0.564	rs7201557	ENSG00000276007.1	RP11-358L22.3	6.42	3.29e-10	7.51e-08	0.31	0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78076162	chr16:78123243~78124332:+
THCA	cis	rs4835473	0.932	rs1849128	ENSG00000251600.4	RP11-673E1.1	6.42	3.29e-10	7.51e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143992582	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.771	rs2175452	ENSG00000251600.4	RP11-673E1.1	6.42	3.29e-10	7.51e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143992887	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.8	rs2175451	ENSG00000251600.4	RP11-673E1.1	6.42	3.29e-10	7.51e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143992964	chr4:143912331~143982454:+
THCA	cis	rs4323050	0.51	rs4254715	ENSG00000251600.4	RP11-673E1.1	6.42	3.29e-10	7.51e-08	0.38	0.28	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143912331~143982454:+
THCA	cis	rs4323050	0.51	rs4273414	ENSG00000251600.4	RP11-673E1.1	6.42	3.29e-10	7.51e-08	0.38	0.28	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.831	rs1912743	ENSG00000251600.4	RP11-673E1.1	6.42	3.29e-10	7.51e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143993705	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.614	rs4487293	ENSG00000251600.4	RP11-673E1.1	6.42	3.29e-10	7.51e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143993880	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.742	rs6537238	ENSG00000251600.4	RP11-673E1.1	6.42	3.29e-10	7.51e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143996463	chr4:143912331~143982454:+
THCA	cis	rs1275468	0.954	rs6582292	ENSG00000257497.2	RP11-585P4.5	6.42	3.29e-10	7.52e-08	0.41	0.28	Polycystic ovary syndrome;	chr12:75539175	chr12:75483454~75489820:-
THCA	cis	rs7829975	0.688	rs6601703	ENSG00000254153.1	CTA-398F10.2	-6.42	3.29e-10	7.52e-08	-0.31	-0.28	Mood instability;	chr8:8522714	chr8:8456909~8461337:-
THCA	cis	rs9800506	0.624	rs9470054	ENSG00000228559.1	RP3-340B19.3	6.42	3.29e-10	7.53e-08	0.4	0.28	Neutrophil percentage of granulocytes;	chr6:35543424	chr6:35544632~35545669:+
THCA	cis	rs12025262	0.546	rs10754539	ENSG00000227671.4	RP11-488L18.4	-6.42	3.3e-10	7.53e-08	-0.16	-0.28	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247189851~247210856:-
THCA	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	6.42	3.3e-10	7.53e-08	0.29	0.28	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
THCA	cis	rs9677476	0.863	rs13423632	ENSG00000224376.1	AC017104.6	6.42	3.3e-10	7.53e-08	0.32	0.28	Food antigen IgG levels;	chr2:231214403	chr2:231388976~231394991:+
THCA	cis	rs2554380	0.628	rs7177929	ENSG00000230373.7	GOLGA6L5P	-6.42	3.3e-10	7.53e-08	-0.31	-0.28	Height;	chr15:83809927	chr15:84507885~84516814:-
THCA	cis	rs4835473	0.932	rs10025527	ENSG00000251600.4	RP11-673E1.1	6.42	3.3e-10	7.53e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143968391	chr4:143912331~143982454:+
THCA	cis	rs6600671	0.899	rs11249432	ENSG00000275538.1	RNVU1-19	6.42	3.3e-10	7.54e-08	0.36	0.28	Hip geometry;	chr1:121541678	chr1:120850819~120850985:-
THCA	cis	rs6545883	0.929	rs7563678	ENSG00000271889.1	RP11-493E12.1	-6.42	3.31e-10	7.55e-08	-0.27	-0.28	Tuberculosis;	chr2:61514676	chr2:61151433~61162105:-
THCA	cis	rs28386778	0.897	rs57108948	ENSG00000240280.5	TCAM1P	-6.42	3.31e-10	7.55e-08	-0.39	-0.28	Prudent dietary pattern;	chr17:63725018	chr17:63849292~63864379:+
THCA	cis	rs12681366	0.636	rs2921388	ENSG00000253704.1	RP11-267M23.4	6.42	3.31e-10	7.56e-08	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94440531	chr8:94553722~94569745:+
THCA	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-6.42	3.31e-10	7.56e-08	-0.27	-0.28	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
THCA	cis	rs7225151	1	rs7225151	ENSG00000234327.6	AC012146.7	-6.42	3.31e-10	7.56e-08	-0.33	-0.28	Alzheimer's disease (late onset);	chr17:5233752	chr17:5111468~5115004:+
THCA	cis	rs4689592	0.503	rs2292461	ENSG00000245468.3	RP11-367J11.3	6.42	3.31e-10	7.56e-08	0.25	0.28	Monocyte percentage of white cells;	chr4:7056746	chr4:7094571~7103385:-
THCA	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	6.42	3.31e-10	7.56e-08	0.41	0.28	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
THCA	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-6.42	3.32e-10	7.57e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
THCA	cis	rs4820539	0.708	rs5751591	ENSG00000221069.1	AC000029.1	-6.42	3.32e-10	7.57e-08	-0.37	-0.28	Bone mineral density;	chr22:23146855	chr22:23136620~23136710:+
THCA	cis	rs1043099	0.556	rs4820847	ENSG00000279699.1	RP1-102K2.9	-6.42	3.32e-10	7.57e-08	-0.33	-0.28	Rheumatoid arthritis;	chr22:30414956	chr22:30275215~30276951:-
THCA	cis	rs438465	1	rs745398	ENSG00000226194.4	RP1-137D17.1	6.42	3.32e-10	7.58e-08	0.43	0.28	Corneal astigmatism;	chr6:169454658	chr6:169369998~169388385:-
THCA	cis	rs224278	0.584	rs752602	ENSG00000238280.1	RP11-436D10.3	-6.42	3.32e-10	7.58e-08	-0.34	-0.28	Ewing sarcoma;	chr10:62831797	chr10:62793562~62805887:-
THCA	cis	rs848490	0.889	rs55688853	ENSG00000214293.7	APTR	6.42	3.33e-10	7.59e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77594304	chr7:77657660~77696265:-
THCA	cis	rs6740322	0.696	rs10188539	ENSG00000234936.1	AC010883.5	6.42	3.33e-10	7.59e-08	0.31	0.28	Coronary artery disease;	chr2:43257536	chr2:43229573~43233394:+
THCA	cis	rs28386778	0.897	rs7210443	ENSG00000240280.5	TCAM1P	-6.42	3.33e-10	7.6e-08	-0.4	-0.28	Prudent dietary pattern;	chr17:63708014	chr17:63849292~63864379:+
THCA	cis	rs755249	1	rs76841360	ENSG00000228060.1	RP11-69E11.8	-6.42	3.33e-10	7.6e-08	-0.31	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594353	chr1:39565160~39573203:+
THCA	cis	rs9380516	0.74	rs873942	ENSG00000228559.1	RP3-340B19.3	-6.42	3.33e-10	7.6e-08	-0.41	-0.28	Hepatitis C induced liver fibrosis;	chr6:35557097	chr6:35544632~35545669:+
THCA	cis	rs944990	0.576	rs10821135	ENSG00000227603.1	RP11-165J3.6	6.42	3.33e-10	7.6e-08	0.29	0.28	Body mass index;	chr9:93476296	chr9:93435332~93437121:-
THCA	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	6.42	3.33e-10	7.61e-08	0.31	0.28	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	6.42	3.33e-10	7.61e-08	0.31	0.28	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	6.42	3.33e-10	7.61e-08	0.31	0.28	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
THCA	cis	rs10129255	0.744	rs28517388	ENSG00000211974.3	IGHV2-70	6.42	3.33e-10	7.61e-08	0.23	0.28	Kawasaki disease;	chr14:106704323	chr14:106723574~106724093:-
THCA	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-6.42	3.34e-10	7.62e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
THCA	cis	rs875971	0.895	rs4145009	ENSG00000232559.3	GS1-124K5.12	-6.42	3.34e-10	7.62e-08	-0.27	-0.28	Aortic root size;	chr7:66261628	chr7:66554588~66576923:-
THCA	cis	rs2239547	0.563	rs4687699	ENSG00000242142.1	SERBP1P3	6.42	3.34e-10	7.63e-08	0.35	0.28	Schizophrenia;	chr3:53067208	chr3:53064283~53065091:-
THCA	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	6.42	3.34e-10	7.63e-08	0.5	0.28	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-6.42	3.34e-10	7.63e-08	-0.5	-0.28	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-6.42	3.34e-10	7.63e-08	-0.5	-0.28	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-6.42	3.34e-10	7.63e-08	-0.5	-0.28	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
THCA	cis	rs7560272	0.723	rs2421548	ENSG00000163016.8	ALMS1P	-6.42	3.34e-10	7.63e-08	-0.37	-0.28	Schizophrenia;	chr2:73414112	chr2:73644919~73685576:+
THCA	cis	rs227275	0.527	rs223338	ENSG00000230069.3	LRRC37A15P	-6.42	3.34e-10	7.63e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102727274~102730721:-
THCA	cis	rs2562456	0.833	rs4321312	ENSG00000268555.1	RP11-678G14.3	6.42	3.35e-10	7.64e-08	0.45	0.28	Pain;	chr19:21336614	chr19:21570822~21587322:-
THCA	cis	rs11722228	0.521	rs12501336	ENSG00000261490.1	RP11-448G15.3	6.42	3.35e-10	7.64e-08	0.21	0.28	Urate levels;Serum uric acid levels;Gout;	chr4:10135727	chr4:10068089~10073019:-
THCA	cis	rs1552244	0.882	rs13063929	ENSG00000232901.1	CYCSP10	6.42	3.35e-10	7.64e-08	0.36	0.28	Alzheimer's disease;	chr3:9968624	chr3:10000647~10000940:-
THCA	cis	rs71636778	0.509	rs57217461	ENSG00000260063.1	RP5-968P14.2	-6.42	3.35e-10	7.64e-08	-0.56	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701425	chr1:26692132~26694131:-
THCA	cis	rs2976388	0.507	rs13279795	ENSG00000253741.1	CTD-2292P10.4	-6.42	3.35e-10	7.65e-08	-0.37	-0.28	Urinary tract infection frequency;	chr8:142757251	chr8:142702252~142726973:-
THCA	cis	rs1005277	0.579	rs2474595	ENSG00000276805.1	RP11-291L22.6	-6.42	3.35e-10	7.65e-08	-0.31	-0.28	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38451030~38451785:+
THCA	cis	rs7267979	0.789	rs6050472	ENSG00000274973.1	RP13-401N8.7	-6.42	3.35e-10	7.65e-08	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:25845497~25845862:+
THCA	cis	rs8027521	0.54	rs17551448	ENSG00000280362.1	RP11-643A5.3	6.42	3.35e-10	7.65e-08	0.35	0.28	Circulating chemerin levels;	chr15:53948729	chr15:53910769~53914712:+
THCA	cis	rs3764021	0.509	rs10772071	ENSG00000256594.6	RP11-705C15.2	6.42	3.35e-10	7.65e-08	0.24	0.28	Type 1 diabetes;	chr12:9717324	chr12:9633419~9658412:+
THCA	cis	rs3764021	0.509	rs10772072	ENSG00000256594.6	RP11-705C15.2	6.42	3.35e-10	7.65e-08	0.24	0.28	Type 1 diabetes;	chr12:9717335	chr12:9633419~9658412:+
THCA	cis	rs1707322	0.686	rs1547924	ENSG00000281133.1	AL355480.3	-6.42	3.35e-10	7.66e-08	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.686	rs3014236	ENSG00000281133.1	AL355480.3	6.42	3.35e-10	7.66e-08	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45580892~45580996:-
THCA	cis	rs9990333	0.562	rs56038600	ENSG00000226155.1	AC124944.3	-6.42	3.36e-10	7.66e-08	-0.35	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195912049~195913986:+
THCA	cis	rs60678552	0.642	rs58437684	ENSG00000233558.1	RP3-486I3.4	6.42	3.36e-10	7.66e-08	0.41	0.28	Heschl's gyrus morphology;	chr6:116311709	chr6:116258493~116259115:-
THCA	cis	rs7560272	0.723	rs4852927	ENSG00000163016.8	ALMS1P	-6.42	3.36e-10	7.67e-08	-0.37	-0.28	Schizophrenia;	chr2:73414429	chr2:73644919~73685576:+
THCA	cis	rs2439831	1	rs689826	ENSG00000249839.1	AC011330.5	-6.42	3.36e-10	7.67e-08	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43457718	chr15:43663654~43684339:-
THCA	cis	rs4950322	0.542	rs3766519	ENSG00000278811.3	LINC00624	6.42	3.36e-10	7.68e-08	0.36	0.28	Protein quantitative trait loci;	chr1:147214802	chr1:147258885~147517875:-
THCA	cis	rs7260598	1	rs17304569	ENSG00000268442.1	CTD-2027I19.2	6.42	3.37e-10	7.68e-08	0.37	0.28	Response to taxane treatment (placlitaxel);	chr19:24058103	chr19:24162370~24163425:-
THCA	cis	rs227932	0.764	rs73084758	ENSG00000234286.1	AC006026.13	-6.42	3.37e-10	7.68e-08	-0.51	-0.28	Schizophrenia;	chr7:23804816	chr7:23680195~23680786:-
THCA	cis	rs9380516	0.891	rs6457830	ENSG00000228559.1	RP3-340B19.3	-6.42	3.37e-10	7.69e-08	-0.45	-0.28	Hepatitis C induced liver fibrosis;	chr6:35538838	chr6:35544632~35545669:+
THCA	cis	rs853679	0.55	rs1225598	ENSG00000220721.1	OR1F12	6.42	3.37e-10	7.69e-08	0.38	0.28	Depression;	chr6:28193021	chr6:28073316~28074233:+
THCA	cis	rs853679	0.55	rs1150689	ENSG00000220721.1	OR1F12	6.42	3.37e-10	7.69e-08	0.38	0.28	Depression;	chr6:28197321	chr6:28073316~28074233:+
THCA	cis	rs853679	0.55	rs1225599	ENSG00000220721.1	OR1F12	6.42	3.37e-10	7.69e-08	0.38	0.28	Depression;	chr6:28197412	chr6:28073316~28074233:+
THCA	cis	rs853679	0.574	rs1233705	ENSG00000220721.1	OR1F12	6.42	3.37e-10	7.69e-08	0.38	0.28	Depression;	chr6:28198669	chr6:28073316~28074233:+
THCA	cis	rs853679	0.55	rs1233704	ENSG00000220721.1	OR1F12	-6.42	3.37e-10	7.69e-08	-0.38	-0.28	Depression;	chr6:28199145	chr6:28073316~28074233:+
THCA	cis	rs853679	0.55	rs1233707	ENSG00000220721.1	OR1F12	6.42	3.37e-10	7.69e-08	0.38	0.28	Depression;	chr6:28205175	chr6:28073316~28074233:+
THCA	cis	rs853679	0.55	rs1237875	ENSG00000220721.1	OR1F12	-6.42	3.37e-10	7.69e-08	-0.38	-0.28	Depression;	chr6:28205232	chr6:28073316~28074233:+
THCA	cis	rs801193	0.742	rs9969300	ENSG00000237310.1	GS1-124K5.4	-6.42	3.37e-10	7.7e-08	-0.21	-0.28	Aortic root size;	chr7:66316659	chr7:66493706~66495474:+
THCA	cis	rs16958440	0.867	rs79275306	ENSG00000267800.1	RP11-49K24.5	-6.42	3.38e-10	7.7e-08	-0.63	-0.28	Sitting height ratio;	chr18:47185249	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.609	rs75911383	ENSG00000267800.1	RP11-49K24.5	-6.42	3.38e-10	7.7e-08	-0.63	-0.28	Sitting height ratio;	chr18:47189640	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs75481537	ENSG00000267800.1	RP11-49K24.5	-6.42	3.38e-10	7.7e-08	-0.63	-0.28	Sitting height ratio;	chr18:47193575	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs9304342	ENSG00000267800.1	RP11-49K24.5	-6.42	3.38e-10	7.7e-08	-0.63	-0.28	Sitting height ratio;	chr18:47193828	chr18:47137018~47137290:+
THCA	cis	rs944289	0.6	rs2899846	ENSG00000257826.1	RP11-116N8.4	-6.42	3.38e-10	7.71e-08	-0.32	-0.28	Thyroid cancer;	chr14:36140737	chr14:36061026~36067190:-
THCA	cis	rs10971721	0.543	rs72731230	ENSG00000281128.1	PTENP1-AS	6.42	3.38e-10	7.71e-08	0.6	0.28	Body mass index;	chr9:34133733	chr9:33677268~33688011:+
THCA	cis	rs8012947	0.651	rs8008129	ENSG00000279636.2	LINC00216	6.42	3.39e-10	7.72e-08	0.28	0.28	Alcohol consumption in current drinkers;	chr14:58362314	chr14:58288033~58289158:+
THCA	cis	rs3806843	1	rs3733710	ENSG00000202515.1	VTRNA1-3	-6.42	3.39e-10	7.73e-08	-0.32	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140787878	chr5:140726158~140726246:+
THCA	cis	rs11722779	0.815	rs223347	ENSG00000230069.3	LRRC37A15P	-6.42	3.39e-10	7.73e-08	-0.3	-0.28	Schizophrenia;	chr4:102858815	chr4:102727274~102730721:-
THCA	cis	rs728616	0.867	rs55690691	ENSG00000242600.5	MBL1P	6.42	3.39e-10	7.73e-08	0.42	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79899186	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs1983775	ENSG00000242600.5	MBL1P	6.42	3.39e-10	7.73e-08	0.42	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903819	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs1983776	ENSG00000242600.5	MBL1P	6.42	3.39e-10	7.73e-08	0.42	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903939	chr10:79904898~79950336:+
THCA	cis	rs6504622	0.818	rs758391	ENSG00000262879.4	RP11-156P1.3	6.42	3.39e-10	7.73e-08	0.26	0.28	Orofacial clefts;	chr17:46939875	chr17:46984045~47100323:-
THCA	cis	rs6496044	0.568	rs12708554	ENSG00000259295.5	CSPG4P12	6.42	3.39e-10	7.74e-08	0.36	0.28	Interstitial lung disease;	chr15:85531066	chr15:85191438~85213905:+
THCA	cis	rs12435908	1	rs11850847	ENSG00000276116.2	FUT8-AS1	-6.42	3.39e-10	7.74e-08	-0.47	-0.28	Ischemic stroke;	chr14:65467080	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs7140261	ENSG00000276116.2	FUT8-AS1	-6.42	3.39e-10	7.74e-08	-0.47	-0.28	Ischemic stroke;	chr14:65507238	chr14:65411170~65412690:-
THCA	cis	rs6860806	0.507	rs635620	ENSG00000263597.1	MIR3936	-6.42	3.39e-10	7.74e-08	-0.28	-0.28	Breast cancer;	chr5:132384571	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.507	rs635619	ENSG00000263597.1	MIR3936	-6.42	3.39e-10	7.74e-08	-0.28	-0.28	Breast cancer;	chr5:132384573	chr5:132365490~132365599:-
THCA	cis	rs11672691	0.67	rs758643	ENSG00000267107.5	PCAT19	-6.42	3.4e-10	7.74e-08	-0.33	-0.28	Prostate cancer;	chr19:41485616	chr19:41454169~41500649:-
THCA	cis	rs17772222	0.727	rs3179969	ENSG00000258983.2	RP11-507K2.2	6.42	3.4e-10	7.75e-08	0.33	0.28	Coronary artery calcification;	chr14:88396185	chr14:88499334~88515502:+
THCA	cis	rs7302981	0.741	rs8181679	ENSG00000272368.2	RP4-605O3.4	-6.42	3.41e-10	7.77e-08	-0.17	-0.28	Systolic blood pressure;	chr12:50217237	chr12:50112197~50165618:+
THCA	cis	rs807029	0.577	rs3740489	ENSG00000272572.1	RP11-179B2.2	-6.42	3.41e-10	7.77e-08	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100911103~100912739:-
THCA	cis	rs807029	0.577	rs3740490	ENSG00000272572.1	RP11-179B2.2	-6.42	3.41e-10	7.77e-08	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100996986	chr10:100911103~100912739:-
THCA	cis	rs35264875	1	rs72919428	ENSG00000259799.1	RP11-554A11.9	6.42	3.41e-10	7.77e-08	0.49	0.28	Blond vs. brown hair color;	chr11:69061481	chr11:69155910~69159752:+
THCA	cis	rs35264875	1	rs72919430	ENSG00000259799.1	RP11-554A11.9	6.42	3.41e-10	7.77e-08	0.49	0.28	Blond vs. brown hair color;	chr11:69062349	chr11:69155910~69159752:+
THCA	cis	rs9990333	0.521	rs3862281	ENSG00000226155.1	AC124944.3	-6.42	3.41e-10	7.78e-08	-0.35	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195912049~195913986:+
THCA	cis	rs16958440	1	rs11082563	ENSG00000267800.1	RP11-49K24.5	-6.42	3.41e-10	7.78e-08	-0.56	-0.28	Sitting height ratio;	chr18:47132630	chr18:47137018~47137290:+
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000228409.4	CCT6P1	6.42	3.41e-10	7.78e-08	0.34	0.28	Diabetic kidney disease;	chr7:66521515	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs13237037	ENSG00000228409.4	CCT6P1	6.42	3.41e-10	7.78e-08	0.34	0.28	Diabetic kidney disease;	chr7:66532895	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1796228	ENSG00000228409.4	CCT6P1	6.42	3.41e-10	7.78e-08	0.34	0.28	Diabetic kidney disease;	chr7:66568097	chr7:65751142~65763354:+
THCA	cis	rs7809950	0.954	rs2894466	ENSG00000238832.1	snoU109	6.42	3.41e-10	7.78e-08	0.31	0.28	Coronary artery disease;	chr7:107602464	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.834	rs3801946	ENSG00000238832.1	snoU109	6.42	3.41e-10	7.78e-08	0.31	0.28	Coronary artery disease;	chr7:107602550	chr7:107603363~107603507:+
THCA	cis	rs8007846	0.588	rs4902416	ENSG00000276116.2	FUT8-AS1	6.42	3.41e-10	7.78e-08	0.28	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65771372	chr14:65411170~65412690:-
THCA	cis	rs728616	0.867	rs56198874	ENSG00000242600.5	MBL1P	6.42	3.42e-10	7.79e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:79904898~79950336:+
THCA	cis	rs728616	1	rs12414891	ENSG00000242600.5	MBL1P	6.42	3.42e-10	7.79e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79930629	chr10:79904898~79950336:+
THCA	cis	rs728616	0.717	rs12415523	ENSG00000242600.5	MBL1P	6.42	3.42e-10	7.79e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79932220	chr10:79904898~79950336:+
THCA	cis	rs728616	0.764	rs75385771	ENSG00000242600.5	MBL1P	6.42	3.42e-10	7.79e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79933023	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs17883671	ENSG00000242600.5	MBL1P	6.42	3.42e-10	7.79e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs17885031	ENSG00000242600.5	MBL1P	6.42	3.42e-10	7.79e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs3088308	ENSG00000242600.5	MBL1P	6.42	3.42e-10	7.79e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs17879726	ENSG00000242600.5	MBL1P	6.42	3.42e-10	7.79e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:79904898~79950336:+
THCA	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-6.42	3.42e-10	7.79e-08	-0.17	-0.28	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-6.42	3.42e-10	7.79e-08	-0.17	-0.28	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
THCA	cis	rs7267979	0.789	rs1983974	ENSG00000274414.1	RP5-965G21.4	6.42	3.42e-10	7.79e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25239007~25245229:-
THCA	cis	rs526231	0.819	rs366437	ENSG00000175749.11	EIF3KP1	6.42	3.42e-10	7.79e-08	0.39	0.28	Primary biliary cholangitis;	chr5:103269900	chr5:103032376~103033031:+
THCA	cis	rs848490	1	rs11767651	ENSG00000214293.7	APTR	6.42	3.42e-10	7.8e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77761063	chr7:77657660~77696265:-
THCA	cis	rs7976269	0.609	rs7979788	ENSG00000257176.2	RP11-996F15.2	-6.42	3.42e-10	7.8e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29064827	chr12:29280418~29317848:-
THCA	cis	rs8027521	0.54	rs8029307	ENSG00000280362.1	RP11-643A5.3	6.42	3.42e-10	7.8e-08	0.35	0.28	Circulating chemerin levels;	chr15:53939315	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.54	rs11509350	ENSG00000280362.1	RP11-643A5.3	6.42	3.42e-10	7.8e-08	0.35	0.28	Circulating chemerin levels;	chr15:53939698	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.54	rs11071010	ENSG00000280362.1	RP11-643A5.3	6.42	3.42e-10	7.8e-08	0.35	0.28	Circulating chemerin levels;	chr15:53939747	chr15:53910769~53914712:+
THCA	cis	rs7829975	0.508	rs4841006	ENSG00000254153.1	CTA-398F10.2	6.42	3.42e-10	7.8e-08	0.29	0.28	Mood instability;	chr8:8643964	chr8:8456909~8461337:-
THCA	cis	rs4835473	0.932	rs36018946	ENSG00000251600.4	RP11-673E1.1	-6.42	3.42e-10	7.8e-08	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143980942	chr4:143912331~143982454:+
THCA	cis	rs7044106	0.648	rs2031369	ENSG00000270917.1	RP11-27I1.6	-6.42	3.42e-10	7.8e-08	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120812475~120812845:-
THCA	cis	rs2412819	0.571	rs2930530	ENSG00000249839.1	AC011330.5	6.42	3.43e-10	7.81e-08	0.41	0.28	Lung cancer;	chr15:43823268	chr15:43663654~43684339:-
THCA	cis	rs8062405	0.755	rs2077031	ENSG00000278665.1	RP11-666O2.4	6.42	3.43e-10	7.81e-08	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28599241~28601881:-
THCA	cis	rs6545883	0.63	rs12998475	ENSG00000271889.1	RP11-493E12.1	-6.42	3.43e-10	7.81e-08	-0.27	-0.28	Tuberculosis;	chr2:61210352	chr2:61151433~61162105:-
THCA	cis	rs7829975	0.688	rs7837587	ENSG00000254153.1	CTA-398F10.2	-6.42	3.43e-10	7.82e-08	-0.31	-0.28	Mood instability;	chr8:8521482	chr8:8456909~8461337:-
THCA	cis	rs853679	0.517	rs9380058	ENSG00000261839.1	RP1-265C24.8	6.42	3.43e-10	7.82e-08	0.34	0.28	Depression;	chr6:28159666	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000261839.1	RP1-265C24.8	6.42	3.43e-10	7.82e-08	0.34	0.28	Depression;	chr6:28162598	chr6:28136849~28139678:+
THCA	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-6.42	3.43e-10	7.82e-08	-0.23	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
THCA	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-6.42	3.43e-10	7.82e-08	-0.23	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
THCA	cis	rs8012947	0.651	rs74055634	ENSG00000279636.2	LINC00216	6.42	3.43e-10	7.82e-08	0.28	0.28	Alcohol consumption in current drinkers;	chr14:58361359	chr14:58288033~58289158:+
THCA	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	6.42	3.44e-10	7.83e-08	0.42	0.28	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	6.42	3.44e-10	7.83e-08	0.42	0.28	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	6.42	3.44e-10	7.83e-08	0.42	0.28	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	6.42	3.44e-10	7.83e-08	0.42	0.28	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	6.42	3.44e-10	7.83e-08	0.42	0.28	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
THCA	cis	rs11148252	0.553	rs7999849	ENSG00000278238.1	RP11-245D16.4	-6.41	3.44e-10	7.84e-08	-0.32	-0.28	Lewy body disease;	chr13:52675279	chr13:52454775~52455331:-
THCA	cis	rs17772222	0.958	rs2274737	ENSG00000258789.1	RP11-507K2.3	-6.41	3.44e-10	7.84e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88469307	chr14:88551597~88552493:+
THCA	cis	rs2243480	1	rs2243480	ENSG00000228409.4	CCT6P1	6.41	3.45e-10	7.85e-08	0.32	0.28	Diabetic kidney disease;	chr7:66134209	chr7:65751142~65763354:+
THCA	cis	rs2239557	0.961	rs11159061	ENSG00000259065.1	RP5-1021I20.1	-6.41	3.45e-10	7.85e-08	-0.34	-0.28	Common traits (Other);	chr14:74089560	chr14:73787360~73803270:+
THCA	cis	rs2239557	1	rs17096228	ENSG00000259065.1	RP5-1021I20.1	-6.41	3.45e-10	7.85e-08	-0.34	-0.28	Common traits (Other);	chr14:74091966	chr14:73787360~73803270:+
THCA	cis	rs172166	0.769	rs149965	ENSG00000280107.1	AL022393.9	-6.41	3.45e-10	7.85e-08	-0.3	-0.28	Cardiac Troponin-T levels;	chr6:28050911	chr6:28170845~28172521:+
THCA	cis	rs2303319	1	rs62197073	ENSG00000227403.1	AC009299.3	6.41	3.45e-10	7.85e-08	0.6	0.28	Cognitive function;	chr2:161304877	chr2:161244739~161249050:+
THCA	cis	rs1275468	1	rs17115231	ENSG00000257497.2	RP11-585P4.5	-6.41	3.45e-10	7.86e-08	-0.41	-0.28	Polycystic ovary syndrome;	chr12:75539895	chr12:75483454~75489820:-
THCA	cis	rs853679	1	rs11965538	ENSG00000226314.6	ZNF192P1	-6.41	3.46e-10	7.87e-08	-0.44	-0.28	Depression;	chr6:28272137	chr6:28161781~28169594:+
THCA	cis	rs853679	0.882	rs2743555	ENSG00000226314.6	ZNF192P1	-6.41	3.46e-10	7.87e-08	-0.44	-0.28	Depression;	chr6:28273304	chr6:28161781~28169594:+
THCA	cis	rs853679	1	rs1419183	ENSG00000226314.6	ZNF192P1	-6.41	3.46e-10	7.87e-08	-0.44	-0.28	Depression;	chr6:28275017	chr6:28161781~28169594:+
THCA	cis	rs853679	1	rs6901575	ENSG00000226314.6	ZNF192P1	-6.41	3.46e-10	7.87e-08	-0.44	-0.28	Depression;	chr6:28283207	chr6:28161781~28169594:+
THCA	cis	rs853679	1	rs1679709	ENSG00000226314.6	ZNF192P1	6.41	3.46e-10	7.87e-08	0.44	0.28	Depression;	chr6:28260564	chr6:28161781~28169594:+
THCA	cis	rs853679	1	rs1778511	ENSG00000226314.6	ZNF192P1	6.41	3.46e-10	7.87e-08	0.44	0.28	Depression;	chr6:28261633	chr6:28161781~28169594:+
THCA	cis	rs516805	0.63	rs2816082	ENSG00000279453.1	RP3-425C14.4	-6.41	3.46e-10	7.87e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122102489	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs2315814	ENSG00000279453.1	RP3-425C14.4	-6.41	3.46e-10	7.87e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122102712	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs2315816	ENSG00000279453.1	RP3-425C14.4	-6.41	3.46e-10	7.87e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122102793	chr6:122436789~122439223:-
THCA	cis	rs516805	0.596	rs2606640	ENSG00000279453.1	RP3-425C14.4	-6.41	3.46e-10	7.87e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122102901	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs2262318	ENSG00000279453.1	RP3-425C14.4	-6.41	3.46e-10	7.87e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122102980	chr6:122436789~122439223:-
THCA	cis	rs8042680	0.688	rs4244883	ENSG00000214432.8	AC068831.10	-6.41	3.46e-10	7.87e-08	-0.31	-0.28	Type 2 diabetes;	chr15:91003267	chr15:91022619~91036611:+
THCA	cis	rs2839186	1	rs2839181	ENSG00000239415.1	AP001469.9	6.41	3.46e-10	7.88e-08	0.29	0.28	Testicular germ cell tumor;	chr21:46266025	chr21:46251549~46254133:-
THCA	cis	rs12168402	0.524	rs6001251	ENSG00000235209.1	CTA-150C2.13	6.41	3.46e-10	7.88e-08	0.36	0.28	Subjective well-being;	chr22:38836758	chr22:38921227~38924708:+
THCA	cis	rs56804039	1	rs11780966	ENSG00000253893.2	FAM85B	6.41	3.46e-10	7.88e-08	0.4	0.28	Cervical cancer;	chr8:8525886	chr8:8167819~8226614:-
THCA	cis	rs16958440	0.867	rs79285649	ENSG00000267800.1	RP11-49K24.5	-6.41	3.46e-10	7.88e-08	-0.63	-0.28	Sitting height ratio;	chr18:47172648	chr18:47137018~47137290:+
THCA	cis	rs2018683	0.523	rs1499227	ENSG00000228421.2	AC005013.5	6.41	3.46e-10	7.88e-08	0.34	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985999	chr7:28957667~28959345:+
THCA	cis	rs4713118	0.662	rs156744	ENSG00000220721.1	OR1F12	6.41	3.47e-10	7.89e-08	0.37	0.28	Parkinson's disease;	chr6:27999496	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000220721.1	OR1F12	-6.41	3.47e-10	7.89e-08	-0.37	-0.28	Parkinson's disease;	chr6:28002253	chr6:28073316~28074233:+
THCA	cis	rs79349575	0.721	rs4794004	ENSG00000248278.1	SUMO2P17	6.41	3.47e-10	7.9e-08	0.33	0.28	Type 2 diabetes;	chr17:48961109	chr17:48874860~48908983:-
THCA	cis	rs2442825	0.691	rs2600182	ENSG00000206573.7	THUMPD3-AS1	6.41	3.47e-10	7.9e-08	0.18	0.28	Cerebrospinal fluid clusterin levels;	chr3:9396376	chr3:9349689~9398579:-
THCA	cis	rs1865760	0.663	rs9467656	ENSG00000272462.2	U91328.19	-6.41	3.47e-10	7.9e-08	-0.23	-0.28	Height;	chr6:25993331	chr6:25992662~26001775:+
THCA	cis	rs2243480	1	rs73142166	ENSG00000228409.4	CCT6P1	6.41	3.48e-10	7.91e-08	0.33	0.28	Diabetic kidney disease;	chr7:65910845	chr7:65751142~65763354:+
THCA	cis	rs847577	0.715	rs4729402	ENSG00000272950.1	RP11-307C18.1	6.41	3.48e-10	7.92e-08	0.36	0.28	Breast cancer;	chr7:98078419	chr7:98322853~98323430:+
THCA	cis	rs4835473	0.932	rs1877235	ENSG00000251600.4	RP11-673E1.1	-6.41	3.48e-10	7.92e-08	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143986961	chr4:143912331~143982454:+
THCA	cis	rs2834188	0.924	rs2850015	ENSG00000272659.1	AP000295.10	-6.41	3.48e-10	7.92e-08	-0.39	-0.28	Narcolepsy;	chr21:33324959	chr21:33309491~33310181:+
THCA	cis	rs2243480	1	rs56016656	ENSG00000229886.1	RP5-1132H15.3	6.41	3.49e-10	7.93e-08	0.46	0.28	Diabetic kidney disease;	chr7:65918494	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs56291018	ENSG00000229886.1	RP5-1132H15.3	6.41	3.49e-10	7.93e-08	0.46	0.28	Diabetic kidney disease;	chr7:65925352	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs36033484	ENSG00000229886.1	RP5-1132H15.3	6.41	3.49e-10	7.93e-08	0.46	0.28	Diabetic kidney disease;	chr7:65925571	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs34560516	ENSG00000229886.1	RP5-1132H15.3	6.41	3.49e-10	7.93e-08	0.46	0.28	Diabetic kidney disease;	chr7:65939105	chr7:66025126~66031544:-
THCA	cis	rs227275	0.525	rs1383733	ENSG00000251288.2	RP11-10L12.2	-6.41	3.49e-10	7.93e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102751401~102752641:+
THCA	cis	rs11051970	0.659	rs1809913	ENSG00000274964.1	RP11-817I4.1	-6.41	3.49e-10	7.93e-08	-0.34	-0.28	Response to tocilizumab in rheumatoid arthritis;	chr12:32438692	chr12:32339368~32340724:+
THCA	cis	rs1594829	0.553	rs7003030	ENSG00000228451.3	SDAD1P1	6.41	3.49e-10	7.94e-08	0.28	0.28	Height;	chr8:26315183	chr8:26379259~26382953:-
THCA	cis	rs848490	0.963	rs17385959	ENSG00000214293.7	APTR	6.41	3.49e-10	7.95e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77750439	chr7:77657660~77696265:-
THCA	cis	rs6545883	0.894	rs778157	ENSG00000271889.1	RP11-493E12.1	6.41	3.49e-10	7.95e-08	0.27	0.28	Tuberculosis;	chr2:61327154	chr2:61151433~61162105:-
THCA	cis	rs7267979	0.78	rs6050679	ENSG00000274414.1	RP5-965G21.4	-6.41	3.49e-10	7.95e-08	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25239007~25245229:-
THCA	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-6.41	3.5e-10	7.96e-08	-0.36	-0.28	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
THCA	cis	rs227275	0.554	rs223339	ENSG00000251288.2	RP11-10L12.2	-6.41	3.5e-10	7.96e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102751401~102752641:+
THCA	cis	rs6545883	0.894	rs7572603	ENSG00000271889.1	RP11-493E12.1	-6.41	3.5e-10	7.97e-08	-0.27	-0.28	Tuberculosis;	chr2:61325010	chr2:61151433~61162105:-
THCA	cis	rs7727544	0.661	rs273900	ENSG00000237714.1	P4HA2-AS1	6.41	3.5e-10	7.97e-08	0.37	0.28	Blood metabolite levels;	chr5:132358913	chr5:132184876~132192808:+
THCA	cis	rs8030379	1	rs1564472	ENSG00000230373.7	GOLGA6L5P	-6.41	3.5e-10	7.97e-08	-0.27	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901041	chr15:84507885~84516814:-
THCA	cis	rs4950322	0.518	rs56151278	ENSG00000278811.3	LINC00624	6.41	3.51e-10	7.97e-08	0.35	0.28	Protein quantitative trait loci;	chr1:147117421	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.518	rs4950306	ENSG00000278811.3	LINC00624	6.41	3.51e-10	7.97e-08	0.35	0.28	Protein quantitative trait loci;	chr1:147117838	chr1:147258885~147517875:-
THCA	cis	rs7727544	0.526	rs4705908	ENSG00000224431.1	AC063976.7	6.41	3.51e-10	7.98e-08	0.25	0.28	Blood metabolite levels;	chr5:132011827	chr5:132199456~132203487:+
THCA	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	6.41	3.51e-10	7.98e-08	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	6.41	3.51e-10	7.98e-08	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
THCA	cis	rs728616	0.867	rs12414877	ENSG00000242600.5	MBL1P	6.41	3.51e-10	7.99e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80020952	chr10:79904898~79950336:+
THCA	cis	rs848490	0.817	rs17467232	ENSG00000214293.7	APTR	6.41	3.51e-10	7.99e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77626624	chr7:77657660~77696265:-
THCA	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	6.41	3.51e-10	7.99e-08	0.36	0.28	Height;	chr4:55363436	chr4:55363971~55395847:-
THCA	cis	rs16843372	0.576	rs13393248	ENSG00000251491.2	OR7E28P	-6.41	3.52e-10	7.99e-08	-0.38	-0.28	Obesity-related traits;	chr2:158844883	chr2:158862311~158863285:+
THCA	cis	rs16843372	0.576	rs1403289	ENSG00000251491.2	OR7E28P	-6.41	3.52e-10	7.99e-08	-0.38	-0.28	Obesity-related traits;	chr2:158845060	chr2:158862311~158863285:+
THCA	cis	rs7044106	0.69	rs10739569	ENSG00000270917.1	RP11-27I1.6	-6.41	3.52e-10	8e-08	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120812475~120812845:-
THCA	cis	rs2243480	1	rs160633	ENSG00000228409.4	CCT6P1	6.41	3.52e-10	8e-08	0.33	0.28	Diabetic kidney disease;	chr7:66063241	chr7:65751142~65763354:+
THCA	cis	rs6479891	1	rs4746974	ENSG00000232075.1	MRPL35P2	6.41	3.52e-10	8.01e-08	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63634317~63634827:-
THCA	cis	rs1167827	1	rs1167827	ENSG00000223705.8	NSUN5P1	6.41	3.53e-10	8.02e-08	0.2	0.28	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75410322~75416787:+
THCA	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-6.41	3.53e-10	8.03e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
THCA	cis	rs6696239	0.513	rs3010186	ENSG00000227711.2	RP11-275O4.5	-6.41	3.53e-10	8.03e-08	-0.29	-0.28	Height;	chr1:227587125	chr1:227509028~227520477:-
THCA	cis	rs4650994	0.525	rs2493865	ENSG00000273384.1	RP5-1098D14.1	-6.41	3.53e-10	8.03e-08	-0.35	-0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178575881	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.525	rs2811295	ENSG00000273384.1	RP5-1098D14.1	-6.41	3.53e-10	8.03e-08	-0.35	-0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178582132	chr1:178651706~178652282:+
THCA	cis	rs4792901	0.543	rs9894814	ENSG00000267151.3	RP11-100E5.2	6.41	3.53e-10	8.03e-08	0.31	0.28	Dupuytren's disease;	chr17:43453618	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.507	rs9910371	ENSG00000267151.3	RP11-100E5.2	6.41	3.53e-10	8.03e-08	0.31	0.28	Dupuytren's disease;	chr17:43453619	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.543	rs56124217	ENSG00000267151.3	RP11-100E5.2	6.41	3.53e-10	8.03e-08	0.31	0.28	Dupuytren's disease;	chr17:43453630	chr17:43444707~43451200:+
THCA	cis	rs2717559	0.542	rs10956986	ENSG00000253741.1	CTD-2292P10.4	6.41	3.54e-10	8.04e-08	0.36	0.28	Urinary tract infection frequency;	chr8:142805185	chr8:142702252~142726973:-
THCA	cis	rs28386778	0.897	rs968719	ENSG00000240280.5	TCAM1P	-6.41	3.54e-10	8.04e-08	-0.4	-0.28	Prudent dietary pattern;	chr17:63830911	chr17:63849292~63864379:+
THCA	cis	rs228614	0.536	rs223484	ENSG00000251288.2	RP11-10L12.2	-6.41	3.54e-10	8.05e-08	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102751401~102752641:+
THCA	cis	rs3806843	0.648	rs702399	ENSG00000202515.1	VTRNA1-3	6.41	3.55e-10	8.07e-08	0.32	0.28	Depressive symptoms (multi-trait analysis);	chr5:140644847	chr5:140726158~140726246:+
THCA	cis	rs847577	0.609	rs11765552	ENSG00000272950.1	RP11-307C18.1	6.41	3.55e-10	8.07e-08	0.36	0.28	Breast cancer;	chr7:98192803	chr7:98322853~98323430:+
THCA	cis	rs847577	0.63	rs3801294	ENSG00000272950.1	RP11-307C18.1	6.41	3.55e-10	8.07e-08	0.36	0.28	Breast cancer;	chr7:98192898	chr7:98322853~98323430:+
THCA	cis	rs847577	0.63	rs2132276	ENSG00000272950.1	RP11-307C18.1	6.41	3.55e-10	8.07e-08	0.36	0.28	Breast cancer;	chr7:98197028	chr7:98322853~98323430:+
THCA	cis	rs836788	0.535	rs6151850	ENSG00000249655.1	CTC-325J23.2	6.41	3.55e-10	8.07e-08	0.29	0.28	Glomerular filtration rate (creatinine);	chr5:80793241	chr5:80630313~80631590:-
THCA	cis	rs2439831	1	rs2467739	ENSG00000275601.1	AC011330.13	-6.41	3.55e-10	8.07e-08	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43447998	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs28666488	ENSG00000275601.1	AC011330.13	-6.41	3.55e-10	8.07e-08	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43448892	chr15:43642389~43643023:-
THCA	cis	rs2439831	1	rs2245790	ENSG00000275601.1	AC011330.13	-6.41	3.55e-10	8.07e-08	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43452259	chr15:43642389~43643023:-
THCA	cis	rs3764021	0.527	rs10844427	ENSG00000256594.6	RP11-705C15.2	6.41	3.55e-10	8.08e-08	0.24	0.28	Type 1 diabetes;	chr12:9681798	chr12:9633419~9658412:+
THCA	cis	rs2303319	1	rs34731727	ENSG00000227403.1	AC009299.3	6.41	3.56e-10	8.09e-08	0.6	0.28	Cognitive function;	chr2:161300769	chr2:161244739~161249050:+
THCA	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	6.41	3.56e-10	8.09e-08	0.52	0.28	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
THCA	cis	rs7976269	0.609	rs4931137	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29049701	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs2082943	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29050251	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs10743641	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29050819	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs4930846	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29051306	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs4402335	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29052836	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs2117994	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29054666	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.583	rs6487753	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29056103	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.583	rs6487754	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29056104	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs6487755	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29056156	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs4931142	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29057877	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs2117993	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29060041	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs10843300	ENSG00000257176.2	RP11-996F15.2	-6.41	3.56e-10	8.09e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29060934	chr12:29280418~29317848:-
THCA	cis	rs7085104	0.632	rs3781287	ENSG00000236937.2	PTGES3P4	6.41	3.56e-10	8.09e-08	0.36	0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102845595~102845950:+
THCA	cis	rs72627509	1	rs72627509	ENSG00000269949.1	RP11-738E22.3	6.41	3.56e-10	8.09e-08	0.4	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972885	chr4:56960927~56961373:-
THCA	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	6.41	3.56e-10	8.1e-08	0.39	0.28	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000229886.1	RP5-1132H15.3	-6.41	3.57e-10	8.1e-08	-0.45	-0.28	Diabetic kidney disease;	chr7:66172773	chr7:66025126~66031544:-
THCA	cis	rs467650	0.517	rs28078	ENSG00000246763.5	RGMB-AS1	6.41	3.57e-10	8.11e-08	0.28	0.28	Venous thromboembolism (SNP x SNP interaction);	chr5:98610999	chr5:98769618~98773469:-
THCA	cis	rs848490	0.851	rs62462686	ENSG00000214293.7	APTR	6.41	3.57e-10	8.11e-08	0.23	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77879330	chr7:77657660~77696265:-
THCA	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-6.41	3.57e-10	8.11e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-6.41	3.57e-10	8.11e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-6.41	3.57e-10	8.11e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-6.41	3.57e-10	8.11e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-6.41	3.57e-10	8.11e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-6.41	3.57e-10	8.11e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-6.41	3.57e-10	8.11e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-6.41	3.57e-10	8.11e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
THCA	cis	rs227275	0.525	rs7685399	ENSG00000251288.2	RP11-10L12.2	-6.41	3.57e-10	8.12e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs7688940	ENSG00000251288.2	RP11-10L12.2	-6.41	3.57e-10	8.12e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102751401~102752641:+
THCA	cis	rs848490	0.928	rs2471604	ENSG00000214293.7	APTR	6.41	3.58e-10	8.13e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77896070	chr7:77657660~77696265:-
THCA	cis	rs1876905	0.597	rs354526	ENSG00000255389.1	C6orf3	6.41	3.58e-10	8.13e-08	0.35	0.28	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111599875~111602295:+
THCA	cis	rs227275	0.525	rs28845922	ENSG00000251288.2	RP11-10L12.2	-6.41	3.58e-10	8.14e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102751401~102752641:+
THCA	cis	rs2412819	0.571	rs2930529	ENSG00000249839.1	AC011330.5	6.41	3.58e-10	8.14e-08	0.41	0.28	Lung cancer;	chr15:43819467	chr15:43663654~43684339:-
THCA	cis	rs6545883	0.894	rs7566035	ENSG00000271889.1	RP11-493E12.1	-6.41	3.59e-10	8.14e-08	-0.27	-0.28	Tuberculosis;	chr2:61293680	chr2:61151433~61162105:-
THCA	cis	rs897984	0.542	rs7294	ENSG00000260911.2	RP11-196G11.2	-6.41	3.59e-10	8.16e-08	-0.24	-0.28	Dementia with Lewy bodies;	chr16:31091000	chr16:31043150~31049868:+
THCA	cis	rs4835473	0.831	rs7689328	ENSG00000251600.4	RP11-673E1.1	6.41	3.59e-10	8.16e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143973768	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.831	rs7694353	ENSG00000251600.4	RP11-673E1.1	6.41	3.59e-10	8.16e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143973787	chr4:143912331~143982454:+
THCA	cis	rs944990	0.576	rs3901421	ENSG00000227603.1	RP11-165J3.6	6.41	3.59e-10	8.16e-08	0.29	0.28	Body mass index;	chr9:93442256	chr9:93435332~93437121:-
THCA	cis	rs11148252	0.595	rs9526968	ENSG00000278238.1	RP11-245D16.4	-6.41	3.59e-10	8.16e-08	-0.32	-0.28	Lewy body disease;	chr13:52666048	chr13:52454775~52455331:-
THCA	cis	rs1609391	0.543	rs9881139	ENSG00000273486.1	RP11-731C17.2	6.41	3.6e-10	8.17e-08	0.24	0.28	Neuroticism;	chr3:136915198	chr3:136837338~136839021:-
THCA	cis	rs35264875	1	rs6591370	ENSG00000259799.1	RP11-554A11.9	6.41	3.6e-10	8.18e-08	0.49	0.28	Blond vs. brown hair color;	chr11:69075535	chr11:69155910~69159752:+
THCA	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	6.41	3.6e-10	8.18e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	6.41	3.6e-10	8.18e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	6.41	3.6e-10	8.18e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	6.41	3.6e-10	8.18e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
THCA	cis	rs4835473	0.618	rs7666297	ENSG00000251600.4	RP11-673E1.1	-6.41	3.6e-10	8.18e-08	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143999005	chr4:143912331~143982454:+
THCA	cis	rs227275	0.554	rs223363	ENSG00000230069.3	LRRC37A15P	-6.41	3.61e-10	8.19e-08	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102727274~102730721:-
THCA	cis	rs6430585	0.528	rs12474975	ENSG00000231890.6	DARS-AS1	-6.41	3.61e-10	8.19e-08	-0.35	-0.28	Corneal structure;	chr2:135944548	chr2:135985176~136022593:+
THCA	cis	rs12681366	0.663	rs3099398	ENSG00000253704.1	RP11-267M23.4	6.41	3.61e-10	8.2e-08	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94467651	chr8:94553722~94569745:+
THCA	cis	rs8007846	0.588	rs8022764	ENSG00000276116.2	FUT8-AS1	6.41	3.61e-10	8.2e-08	0.29	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65777937	chr14:65411170~65412690:-
THCA	cis	rs8007846	0.588	rs11625882	ENSG00000276116.2	FUT8-AS1	6.41	3.61e-10	8.2e-08	0.29	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65778481	chr14:65411170~65412690:-
THCA	cis	rs8007846	0.588	rs12887957	ENSG00000276116.2	FUT8-AS1	6.41	3.61e-10	8.2e-08	0.29	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65779874	chr14:65411170~65412690:-
THCA	cis	rs848490	0.889	rs4291201	ENSG00000214293.7	APTR	-6.41	3.61e-10	8.2e-08	-0.22	-0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77867238	chr7:77657660~77696265:-
THCA	cis	rs7829975	0.508	rs1594437	ENSG00000253893.2	FAM85B	-6.41	3.61e-10	8.2e-08	-0.35	-0.28	Mood instability;	chr8:8968365	chr8:8167819~8226614:-
THCA	cis	rs944289	0.6	rs2415320	ENSG00000257826.1	RP11-116N8.4	-6.41	3.62e-10	8.21e-08	-0.32	-0.28	Thyroid cancer;	chr14:36148733	chr14:36061026~36067190:-
THCA	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-6.41	3.62e-10	8.21e-08	-0.23	-0.28	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
THCA	cis	rs944990	0.576	rs7040832	ENSG00000227603.1	RP11-165J3.6	6.41	3.62e-10	8.21e-08	0.29	0.28	Body mass index;	chr9:93436508	chr9:93435332~93437121:-
THCA	cis	rs71636778	0.509	rs12738345	ENSG00000260063.1	RP5-968P14.2	-6.41	3.62e-10	8.23e-08	-0.55	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26693253	chr1:26692132~26694131:-
THCA	cis	rs12435908	0.867	rs11849862	ENSG00000276116.2	FUT8-AS1	-6.41	3.62e-10	8.23e-08	-0.46	-0.28	Ischemic stroke;	chr14:65631307	chr14:65411170~65412690:-
THCA	cis	rs2797160	0.651	rs6939969	ENSG00000237742.5	RP11-624M8.1	6.41	3.63e-10	8.24e-08	0.26	0.28	Endometrial cancer;	chr6:125713417	chr6:125578558~125749190:-
THCA	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	6.41	3.63e-10	8.24e-08	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	6.41	3.63e-10	8.24e-08	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	6.41	3.63e-10	8.24e-08	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	6.41	3.63e-10	8.24e-08	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-6.41	3.63e-10	8.24e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
THCA	cis	rs795484	0.683	rs514826	ENSG00000275409.1	RP11-131L12.4	6.41	3.63e-10	8.24e-08	0.24	0.28	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118371498	chr12:118430147~118430699:+
THCA	cis	rs890448	0.726	rs2850329	ENSG00000254531.1	FLJ20021	6.41	3.63e-10	8.25e-08	0.25	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101354107	chr4:101347780~101348883:+
THCA	cis	rs737008	0.821	rs28671554	ENSG00000262636.1	CTD-3088G3.4	6.41	3.64e-10	8.25e-08	0.36	0.28	Obesity-related traits;	chr16:11309896	chr16:11380859~11381118:-
THCA	cis	rs890448	0.726	rs2850328	ENSG00000254531.1	FLJ20021	-6.41	3.64e-10	8.26e-08	-0.25	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101347783	chr4:101347780~101348883:+
THCA	cis	rs35264875	0.95	rs35337391	ENSG00000259799.1	RP11-554A11.9	6.41	3.64e-10	8.27e-08	0.48	0.28	Blond vs. brown hair color;	chr11:69086544	chr11:69155910~69159752:+
THCA	cis	rs7976269	0.559	rs10771477	ENSG00000257176.2	RP11-996F15.2	-6.41	3.64e-10	8.27e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29074137	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.559	rs10843307	ENSG00000257176.2	RP11-996F15.2	-6.41	3.64e-10	8.27e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29074710	chr12:29280418~29317848:-
THCA	cis	rs7085104	0.7	rs10786712	ENSG00000236937.2	PTGES3P4	-6.41	3.65e-10	8.28e-08	-0.36	-0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102845595~102845950:+
THCA	cis	rs11096990	0.855	rs1597722	ENSG00000249207.1	RP11-360F5.1	-6.41	3.65e-10	8.28e-08	-0.37	-0.28	Cognitive function;	chr4:39173255	chr4:39112677~39126818:-
THCA	cis	rs11158026	0.757	rs9285583	ENSG00000258413.1	RP11-665C16.6	-6.41	3.65e-10	8.28e-08	-0.39	-0.28	Parkinson's disease;	chr14:54964717	chr14:55262767~55272075:-
THCA	cis	rs3764021	0.527	rs10844456	ENSG00000256594.6	RP11-705C15.2	6.41	3.65e-10	8.29e-08	0.24	0.28	Type 1 diabetes;	chr12:9689319	chr12:9633419~9658412:+
THCA	cis	rs7580658	0.68	rs2069931	ENSG00000236682.1	AC068282.3	-6.4	3.65e-10	8.29e-08	-0.37	-0.28	Protein C levels;	chr2:127427993	chr2:127389130~127400580:+
THCA	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	6.4	3.66e-10	8.29e-08	0.17	0.28	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
THCA	cis	rs11018904	0.906	rs11603498	ENSG00000280385.1	AP000648.5	-6.4	3.66e-10	8.29e-08	-0.38	-0.28	Intelligence (multi-trait analysis);	chr11:90195615	chr11:90193614~90198120:+
THCA	cis	rs2243480	1	rs56016656	ENSG00000228409.4	CCT6P1	6.4	3.66e-10	8.29e-08	0.33	0.28	Diabetic kidney disease;	chr7:65918494	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs56291018	ENSG00000228409.4	CCT6P1	6.4	3.66e-10	8.29e-08	0.33	0.28	Diabetic kidney disease;	chr7:65925352	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs36033484	ENSG00000228409.4	CCT6P1	6.4	3.66e-10	8.29e-08	0.33	0.28	Diabetic kidney disease;	chr7:65925571	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs34560516	ENSG00000228409.4	CCT6P1	6.4	3.66e-10	8.29e-08	0.33	0.28	Diabetic kidney disease;	chr7:65939105	chr7:65751142~65763354:+
THCA	cis	rs2562456	0.833	rs2650801	ENSG00000213976.4	CTD-2561J22.2	-6.4	3.66e-10	8.29e-08	-0.32	-0.28	Pain;	chr19:21452553	chr19:21382865~21387177:+
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000229886.1	RP5-1132H15.3	6.4	3.66e-10	8.3e-08	0.47	0.28	Diabetic kidney disease;	chr7:66474549	chr7:66025126~66031544:-
THCA	cis	rs2439831	0.541	rs12440854	ENSG00000249839.1	AC011330.5	-6.4	3.66e-10	8.3e-08	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43318474	chr15:43663654~43684339:-
THCA	cis	rs6088580	0.524	rs6088569	ENSG00000269202.1	RP4-614O4.12	6.4	3.66e-10	8.3e-08	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34680395	chr20:35201747~35203288:-
THCA	cis	rs2735413	0.564	rs17776122	ENSG00000276007.1	RP11-358L22.3	6.4	3.67e-10	8.32e-08	0.3	0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78072389	chr16:78123243~78124332:+
THCA	cis	rs755249	1	rs4660303	ENSG00000228060.1	RP11-69E11.8	-6.4	3.67e-10	8.33e-08	-0.31	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594801	chr1:39565160~39573203:+
THCA	cis	rs5742933	0.857	rs1233282	ENSG00000273240.1	RP11-455J20.3	-6.4	3.68e-10	8.34e-08	-0.29	-0.28	Ferritin levels;	chr2:189823518	chr2:189763859~189764456:-
THCA	cis	rs6600671	0.934	rs12131379	ENSG00000275538.1	RNVU1-19	6.4	3.68e-10	8.34e-08	0.36	0.28	Hip geometry;	chr1:121551639	chr1:120850819~120850985:-
THCA	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	6.4	3.68e-10	8.34e-08	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000228409.4	CCT6P1	6.4	3.68e-10	8.35e-08	0.34	0.28	Gout;	chr7:66732812	chr7:65751142~65763354:+
THCA	cis	rs7727544	0.709	rs272852	ENSG00000237714.1	P4HA2-AS1	6.4	3.69e-10	8.36e-08	0.36	0.28	Blood metabolite levels;	chr5:132353074	chr5:132184876~132192808:+
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	6.4	3.69e-10	8.36e-08	0.32	0.28	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
THCA	cis	rs7568498	0.517	rs197261	ENSG00000235724.7	AC009299.2	6.4	3.69e-10	8.37e-08	0.33	0.28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161048312	chr2:161222785~161308303:-
THCA	cis	rs9816784	0.525	rs3326	ENSG00000226155.1	AC124944.3	-6.4	3.69e-10	8.37e-08	-0.35	-0.28	Mean corpuscular hemoglobin;	chr3:196054635	chr3:195912049~195913986:+
THCA	cis	rs10899021	0.79	rs10899019	ENSG00000279353.1	RP11-864N7.4	6.4	3.69e-10	8.37e-08	0.55	0.28	Response to metformin (IC50);	chr11:74624117	chr11:74698231~74699658:-
THCA	cis	rs7267979	0.816	rs405822	ENSG00000274414.1	RP5-965G21.4	-6.4	3.69e-10	8.37e-08	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.816	rs6138593	ENSG00000274414.1	RP5-965G21.4	-6.4	3.69e-10	8.37e-08	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.816	rs409853	ENSG00000274414.1	RP5-965G21.4	-6.4	3.69e-10	8.37e-08	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25239007~25245229:-
THCA	cis	rs950169	0.887	rs35986397	ENSG00000259295.5	CSPG4P12	6.4	3.69e-10	8.37e-08	0.44	0.28	Schizophrenia;	chr15:84400409	chr15:85191438~85213905:+
THCA	cis	rs2239557	1	rs75824542	ENSG00000259065.1	RP5-1021I20.1	-6.4	3.69e-10	8.37e-08	-0.34	-0.28	Common traits (Other);	chr14:74056344	chr14:73787360~73803270:+
THCA	cis	rs17772222	0.917	rs61986670	ENSG00000258789.1	RP11-507K2.3	-6.4	3.7e-10	8.38e-08	-0.28	-0.28	Coronary artery calcification;	chr14:88730875	chr14:88551597~88552493:+
THCA	cis	rs2018683	0.523	rs4513881	ENSG00000228421.2	AC005013.5	-6.4	3.7e-10	8.38e-08	-0.34	-0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985794	chr7:28957667~28959345:+
THCA	cis	rs728616	0.867	rs76239460	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61860400	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61860412	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs12412257	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs117139504	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs12412226	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs4387301	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79904898~79950336:+
THCA	cis	rs728616	0.764	rs117833443	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs116994688	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61860420	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs75447386	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs4520539	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61860421	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs118134654	ENSG00000242600.5	MBL1P	6.4	3.7e-10	8.38e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79904898~79950336:+
THCA	cis	rs6545883	0.826	rs2694617	ENSG00000271889.1	RP11-493E12.1	-6.4	3.7e-10	8.38e-08	-0.27	-0.28	Tuberculosis;	chr2:61310079	chr2:61151433~61162105:-
THCA	cis	rs7851660	0.901	rs7873389	ENSG00000214417.4	KRT18P13	-6.4	3.7e-10	8.39e-08	-0.24	-0.28	Strep throat;	chr9:97846948	chr9:97698922~97700734:+
THCA	cis	rs10844706	0.699	rs10844610	ENSG00000256594.6	RP11-705C15.2	6.4	3.7e-10	8.39e-08	0.24	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9724016	chr12:9633419~9658412:+
THCA	cis	rs72843506	0.722	rs3764436	ENSG00000270091.1	RP11-78O7.2	-6.4	3.7e-10	8.39e-08	-0.31	-0.28	Schizophrenia;	chr17:20110489	chr17:19896590~19897287:-
THCA	cis	rs6840258	0.76	rs340643	ENSG00000251411.1	RP11-397E7.4	-6.4	3.71e-10	8.41e-08	-0.31	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87026006	chr4:86913266~86914817:-
THCA	cis	rs6088580	0.524	rs6088567	ENSG00000269202.1	RP4-614O4.12	6.4	3.71e-10	8.41e-08	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34676068	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.524	rs6088568	ENSG00000269202.1	RP4-614O4.12	6.4	3.71e-10	8.41e-08	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34678167	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.524	rs1321306	ENSG00000269202.1	RP4-614O4.12	6.4	3.71e-10	8.41e-08	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34678575	chr20:35201747~35203288:-
THCA	cis	rs642803	1	rs557675	ENSG00000214659.4	KRT8P26	6.4	3.71e-10	8.41e-08	0.24	0.28	Urate levels;	chr11:65799248	chr11:65726939~65728214:+
THCA	cis	rs7568498	0.564	rs10490563	ENSG00000227403.1	AC009299.3	6.4	3.71e-10	8.41e-08	0.36	0.28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161244739~161249050:+
THCA	cis	rs1609391	0.543	rs6800690	ENSG00000273486.1	RP11-731C17.2	6.4	3.71e-10	8.41e-08	0.24	0.28	Neuroticism;	chr3:136904184	chr3:136837338~136839021:-
THCA	cis	rs1609391	0.543	rs7651085	ENSG00000273486.1	RP11-731C17.2	6.4	3.71e-10	8.41e-08	0.24	0.28	Neuroticism;	chr3:136906497	chr3:136837338~136839021:-
THCA	cis	rs1609391	0.543	rs6761993	ENSG00000273486.1	RP11-731C17.2	6.4	3.71e-10	8.41e-08	0.24	0.28	Neuroticism;	chr3:136907060	chr3:136837338~136839021:-
THCA	cis	rs797680	0.856	rs1335679	ENSG00000223745.6	RP4-717I23.3	6.4	3.72e-10	8.43e-08	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93179625	chr1:93262186~93346025:-
THCA	cis	rs4143844	0.867	rs35168171	ENSG00000259251.2	RP11-643M14.1	6.4	3.72e-10	8.43e-08	0.54	0.28	Bipolar disorder and schizophrenia;	chr15:62060759	chr15:62060503~62062434:+
THCA	cis	rs7976269	0.583	rs7955393	ENSG00000257176.2	RP11-996F15.2	-6.4	3.72e-10	8.43e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29065773	chr12:29280418~29317848:-
THCA	cis	rs11148252	0.846	rs7323666	ENSG00000235660.1	LINC00345	-6.4	3.72e-10	8.43e-08	-0.35	-0.28	Lewy body disease;	chr13:52431923	chr13:52484161~52484680:-
THCA	cis	rs1020064	0.636	rs1529975	ENSG00000235319.1	AC012360.4	-6.4	3.72e-10	8.43e-08	-0.35	-0.28	AIDS;	chr2:105313444	chr2:105324210~105330529:+
THCA	cis	rs9649465	1	rs7776792	ENSG00000272686.1	RP11-390E23.6	-6.4	3.72e-10	8.43e-08	-0.19	-0.28	Migraine;	chr7:123695296	chr7:123749068~123751166:+
THCA	cis	rs748404	0.578	rs507178	ENSG00000166763.7	STRCP1	6.4	3.72e-10	8.44e-08	0.3	0.28	Lung cancer;	chr15:43317937	chr15:43699488~43718184:-
THCA	cis	rs4713118	0.662	rs149947	ENSG00000220721.1	OR1F12	6.4	3.72e-10	8.44e-08	0.37	0.28	Parkinson's disease;	chr6:28004655	chr6:28073316~28074233:+
THCA	cis	rs9813712	0.571	rs9289368	ENSG00000253540.4	FAM86HP	-6.4	3.73e-10	8.45e-08	-0.31	-0.28	Response to amphetamines;	chr3:130225562	chr3:130099092~130111472:-
THCA	cis	rs9813712	0.571	rs6774141	ENSG00000253540.4	FAM86HP	-6.4	3.73e-10	8.45e-08	-0.31	-0.28	Response to amphetamines;	chr3:130225599	chr3:130099092~130111472:-
THCA	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	6.4	3.73e-10	8.45e-08	0.27	0.28	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
THCA	cis	rs848490	0.851	rs56052251	ENSG00000214293.7	APTR	6.4	3.74e-10	8.46e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77626547	chr7:77657660~77696265:-
THCA	cis	rs9813712	0.571	rs9855777	ENSG00000253540.4	FAM86HP	6.4	3.74e-10	8.47e-08	0.31	0.28	Response to amphetamines;	chr3:130214805	chr3:130099092~130111472:-
THCA	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	6.4	3.74e-10	8.47e-08	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
THCA	cis	rs867529	0.62	rs335121	ENSG00000234028.3	AC062029.1	-6.4	3.74e-10	8.47e-08	-0.24	-0.28	Height;	chr2:88784810	chr2:88627539~88631821:+
THCA	cis	rs526231	0.853	rs35802	ENSG00000175749.11	EIF3KP1	6.4	3.74e-10	8.47e-08	0.39	0.28	Primary biliary cholangitis;	chr5:103271884	chr5:103032376~103033031:+
THCA	cis	rs526231	0.819	rs35801	ENSG00000175749.11	EIF3KP1	6.4	3.74e-10	8.47e-08	0.39	0.28	Primary biliary cholangitis;	chr5:103272512	chr5:103032376~103033031:+
THCA	cis	rs526231	0.819	rs2561476	ENSG00000175749.11	EIF3KP1	6.4	3.74e-10	8.47e-08	0.39	0.28	Primary biliary cholangitis;	chr5:103273133	chr5:103032376~103033031:+
THCA	cis	rs526231	0.781	rs2569015	ENSG00000175749.11	EIF3KP1	6.4	3.74e-10	8.47e-08	0.39	0.28	Primary biliary cholangitis;	chr5:103273146	chr5:103032376~103033031:+
THCA	cis	rs10771431	0.782	rs10771415	ENSG00000111788.10	RP11-22B23.1	6.4	3.74e-10	8.48e-08	0.27	0.28	Breast size;	chr12:9205627	chr12:9277235~9313241:+
THCA	cis	rs812925	0.659	rs2167565	ENSG00000271889.1	RP11-493E12.1	-6.4	3.74e-10	8.48e-08	-0.29	-0.28	Immature fraction of reticulocytes;	chr2:61249323	chr2:61151433~61162105:-
THCA	cis	rs28386778	0.863	rs1376110	ENSG00000240280.5	TCAM1P	-6.4	3.74e-10	8.48e-08	-0.4	-0.28	Prudent dietary pattern;	chr17:63702567	chr17:63849292~63864379:+
THCA	cis	rs4604234	0.901	rs112709609	ENSG00000272129.1	RP11-250B2.6	-6.4	3.74e-10	8.48e-08	-0.77	-0.28	Cancer;	chr6:80388244	chr6:80355424~80356859:+
THCA	cis	rs8027521	0.936	rs1478175	ENSG00000280362.1	RP11-643A5.3	6.4	3.74e-10	8.48e-08	0.34	0.28	Circulating chemerin levels;	chr15:53964529	chr15:53910769~53914712:+
THCA	cis	rs2348418	0.868	rs12302861	ENSG00000247934.4	RP11-967K21.1	6.4	3.74e-10	8.49e-08	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28516269	chr12:28163298~28190738:-
THCA	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-6.4	3.75e-10	8.49e-08	-0.35	-0.28	AIDS;	chr2:105300178	chr2:105324210~105330529:+
THCA	cis	rs9309473	0.519	rs2421545	ENSG00000163016.8	ALMS1P	-6.4	3.75e-10	8.5e-08	-0.37	-0.28	Metabolite levels;	chr2:73412348	chr2:73644919~73685576:+
THCA	cis	rs7560272	0.723	rs12995433	ENSG00000163016.8	ALMS1P	-6.4	3.75e-10	8.5e-08	-0.37	-0.28	Schizophrenia;	chr2:73414198	chr2:73644919~73685576:+
THCA	cis	rs35264875	1	rs7110274	ENSG00000259799.1	RP11-554A11.9	6.4	3.76e-10	8.51e-08	0.49	0.28	Blond vs. brown hair color;	chr11:69075236	chr11:69155910~69159752:+
THCA	cis	rs12435908	1	rs2152375	ENSG00000276116.2	FUT8-AS1	-6.4	3.76e-10	8.52e-08	-0.47	-0.28	Ischemic stroke;	chr14:65449060	chr14:65411170~65412690:-
THCA	cis	rs1876905	0.597	rs1150076	ENSG00000255389.1	C6orf3	6.4	3.76e-10	8.52e-08	0.35	0.28	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111599875~111602295:+
THCA	cis	rs10844706	0.699	rs10844615	ENSG00000256594.6	RP11-705C15.2	6.4	3.76e-10	8.52e-08	0.24	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725646	chr12:9633419~9658412:+
THCA	cis	rs10844706	0.699	rs11052717	ENSG00000256594.6	RP11-705C15.2	6.4	3.76e-10	8.52e-08	0.24	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9726217	chr12:9633419~9658412:+
THCA	cis	rs7208859	0.524	rs8069400	ENSG00000264538.5	SUZ12P1	-6.4	3.77e-10	8.53e-08	-0.3	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30709299~30790908:+
THCA	cis	rs1876905	0.68	rs354540	ENSG00000255389.1	C6orf3	6.4	3.77e-10	8.53e-08	0.33	0.28	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111599875~111602295:+
THCA	cis	rs4835473	0.897	rs28701142	ENSG00000251600.4	RP11-673E1.1	6.4	3.77e-10	8.53e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143945730	chr4:143912331~143982454:+
THCA	cis	rs6545883	0.894	rs7602859	ENSG00000271889.1	RP11-493E12.1	-6.4	3.77e-10	8.53e-08	-0.27	-0.28	Tuberculosis;	chr2:61231071	chr2:61151433~61162105:-
THCA	cis	rs7727544	0.735	rs272875	ENSG00000237714.1	P4HA2-AS1	6.4	3.77e-10	8.53e-08	0.36	0.28	Blood metabolite levels;	chr5:132339195	chr5:132184876~132192808:+
THCA	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-6.4	3.77e-10	8.54e-08	-0.28	-0.28	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
THCA	cis	rs453301	0.652	rs2043129	ENSG00000253893.2	FAM85B	-6.4	3.77e-10	8.54e-08	-0.35	-0.28	Joint mobility (Beighton score);	chr8:8967994	chr8:8167819~8226614:-
THCA	cis	rs6565180	1	rs68051857	ENSG00000273724.1	RP11-347C12.12	-6.4	3.77e-10	8.54e-08	-0.29	-0.28	Tonsillectomy;	chr16:30348690	chr16:30336400~30343336:+
THCA	cis	rs6565180	1	rs6565180	ENSG00000273724.1	RP11-347C12.12	-6.4	3.77e-10	8.54e-08	-0.29	-0.28	Tonsillectomy;	chr16:30350020	chr16:30336400~30343336:+
THCA	cis	rs4950322	0.518	rs61838938	ENSG00000237188.3	RP11-337C18.8	6.4	3.77e-10	8.54e-08	0.34	0.28	Protein quantitative trait loci;	chr1:147105943	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.529	rs11809327	ENSG00000237188.3	RP11-337C18.8	6.4	3.77e-10	8.54e-08	0.34	0.28	Protein quantitative trait loci;	chr1:147106679	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.563	rs11809328	ENSG00000237188.3	RP11-337C18.8	6.4	3.77e-10	8.54e-08	0.34	0.28	Protein quantitative trait loci;	chr1:147106681	chr1:147172771~147211568:+
THCA	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	6.4	3.78e-10	8.56e-08	0.27	0.28	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
THCA	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-6.4	3.78e-10	8.57e-08	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-6.4	3.78e-10	8.57e-08	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
THCA	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-6.4	3.78e-10	8.57e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
THCA	cis	rs9329221	0.521	rs4841294	ENSG00000261451.1	RP11-981G7.1	-6.4	3.79e-10	8.58e-08	-0.36	-0.28	Neuroticism;	chr8:10247558	chr8:10433672~10438312:+
THCA	cis	rs7267979	0.844	rs6050477	ENSG00000274973.1	RP13-401N8.7	6.4	3.8e-10	8.6e-08	0.31	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:25845497~25845862:+
THCA	cis	rs11018904	0.817	rs11606060	ENSG00000280385.1	AP000648.5	-6.4	3.8e-10	8.6e-08	-0.38	-0.28	Intelligence (multi-trait analysis);	chr11:90195429	chr11:90193614~90198120:+
THCA	cis	rs16976116	0.951	rs3809540	ENSG00000279145.1	RP11-547D13.1	6.4	3.8e-10	8.61e-08	0.28	0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55197214	chr15:55171972~55178175:-
THCA	cis	rs7267979	0.844	rs6083851	ENSG00000274414.1	RP5-965G21.4	6.4	3.81e-10	8.62e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.844	rs4423675	ENSG00000274414.1	RP5-965G21.4	6.4	3.81e-10	8.62e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25239007~25245229:-
THCA	cis	rs7976269	0.609	rs11050010	ENSG00000257176.2	RP11-996F15.2	-6.4	3.81e-10	8.63e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29061952	chr12:29280418~29317848:-
THCA	cis	rs8141529	0.764	rs5762824	ENSG00000226471.5	CTA-292E10.6	-6.4	3.81e-10	8.63e-08	-0.24	-0.28	Lymphocyte counts;	chr22:28826942	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.764	rs5752807	ENSG00000226471.5	CTA-292E10.6	-6.4	3.81e-10	8.63e-08	-0.24	-0.28	Lymphocyte counts;	chr22:28827181	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.719	rs5762825	ENSG00000226471.5	CTA-292E10.6	-6.4	3.81e-10	8.63e-08	-0.24	-0.28	Lymphocyte counts;	chr22:28827654	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.764	rs5752809	ENSG00000226471.5	CTA-292E10.6	-6.4	3.81e-10	8.63e-08	-0.24	-0.28	Lymphocyte counts;	chr22:28829512	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.764	rs5752812	ENSG00000226471.5	CTA-292E10.6	-6.4	3.81e-10	8.63e-08	-0.24	-0.28	Lymphocyte counts;	chr22:28829615	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.764	rs8137969	ENSG00000226471.5	CTA-292E10.6	-6.4	3.81e-10	8.63e-08	-0.24	-0.28	Lymphocyte counts;	chr22:28832496	chr22:28800683~28848559:+
THCA	cis	rs2243480	1	rs4718317	ENSG00000229886.1	RP5-1132H15.3	-6.4	3.82e-10	8.64e-08	-0.45	-0.28	Diabetic kidney disease;	chr7:66183914	chr7:66025126~66031544:-
THCA	cis	rs860295	0.595	rs490498	ENSG00000225855.5	RUSC1-AS1	-6.4	3.82e-10	8.64e-08	-0.19	-0.28	Body mass index;	chr1:155911161	chr1:155316863~155324176:-
THCA	cis	rs807029	0.533	rs3824783	ENSG00000272572.1	RP11-179B2.2	-6.4	3.82e-10	8.64e-08	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100911103~100912739:-
THCA	cis	rs5758659	0.714	rs5758578	ENSG00000270083.1	RP1-257I20.14	-6.4	3.82e-10	8.64e-08	-0.3	-0.28	Cognitive function;	chr22:42094288	chr22:42089630~42090028:-
THCA	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	6.4	3.82e-10	8.65e-08	0.23	0.28	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
THCA	cis	rs6088580	0.524	rs2889855	ENSG00000269202.1	RP4-614O4.12	6.4	3.82e-10	8.65e-08	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34689049	chr20:35201747~35203288:-
THCA	cis	rs7044106	0.762	rs1324473	ENSG00000270917.1	RP11-27I1.6	6.4	3.82e-10	8.65e-08	0.4	0.28	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120812475~120812845:-
THCA	cis	rs72843506	0.656	rs10459970	ENSG00000270091.1	RP11-78O7.2	-6.4	3.83e-10	8.66e-08	-0.33	-0.28	Schizophrenia;	chr17:20034028	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs2385960	ENSG00000270091.1	RP11-78O7.2	-6.4	3.83e-10	8.66e-08	-0.33	-0.28	Schizophrenia;	chr17:20034904	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs8073875	ENSG00000270091.1	RP11-78O7.2	-6.4	3.83e-10	8.66e-08	-0.33	-0.28	Schizophrenia;	chr17:20035746	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs57040439	ENSG00000270091.1	RP11-78O7.2	-6.4	3.83e-10	8.66e-08	-0.33	-0.28	Schizophrenia;	chr17:20036522	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs58313980	ENSG00000270091.1	RP11-78O7.2	-6.4	3.83e-10	8.66e-08	-0.33	-0.28	Schizophrenia;	chr17:20036737	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs73984559	ENSG00000270091.1	RP11-78O7.2	-6.4	3.83e-10	8.66e-08	-0.33	-0.28	Schizophrenia;	chr17:20043203	chr17:19896590~19897287:-
THCA	cis	rs6860806	0.507	rs582490	ENSG00000263597.1	MIR3936	-6.4	3.83e-10	8.66e-08	-0.28	-0.28	Breast cancer;	chr5:132374403	chr5:132365490~132365599:-
THCA	cis	rs274567	0.501	rs581968	ENSG00000263597.1	MIR3936	-6.4	3.83e-10	8.66e-08	-0.28	-0.28	Blood metabolite levels;	chr5:132374510	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.507	rs274572	ENSG00000263597.1	MIR3936	-6.4	3.83e-10	8.66e-08	-0.28	-0.28	Breast cancer;	chr5:132375225	chr5:132365490~132365599:-
THCA	cis	rs274567	0.501	rs274571	ENSG00000263597.1	MIR3936	-6.4	3.83e-10	8.66e-08	-0.28	-0.28	Blood metabolite levels;	chr5:132376433	chr5:132365490~132365599:-
THCA	cis	rs7712401	0.72	rs10075963	ENSG00000249996.1	RP11-359P5.1	6.4	3.83e-10	8.67e-08	0.27	0.28	Mean platelet volume;	chr5:122849726	chr5:123036271~123054667:+
THCA	cis	rs10208649	0.572	rs7582542	ENSG00000272156.1	RP11-477N3.1	6.4	3.83e-10	8.67e-08	0.39	0.28	Body mass index;	chr2:53709116	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.572	rs7609067	ENSG00000272156.1	RP11-477N3.1	6.4	3.83e-10	8.67e-08	0.39	0.28	Body mass index;	chr2:53709416	chr2:54082554~54085066:+
THCA	cis	rs1594829	0.535	rs11784209	ENSG00000228451.3	SDAD1P1	6.4	3.83e-10	8.67e-08	0.28	0.28	Height;	chr8:26312730	chr8:26379259~26382953:-
THCA	cis	rs526231	0.819	rs403214	ENSG00000175749.11	EIF3KP1	6.4	3.83e-10	8.67e-08	0.39	0.28	Primary biliary cholangitis;	chr5:103268000	chr5:103032376~103033031:+
THCA	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	6.4	3.84e-10	8.68e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
THCA	cis	rs2303319	0.892	rs16845742	ENSG00000227403.1	AC009299.3	6.4	3.84e-10	8.69e-08	0.6	0.28	Cognitive function;	chr2:161270523	chr2:161244739~161249050:+
THCA	cis	rs2303319	1	rs16845747	ENSG00000227403.1	AC009299.3	6.4	3.84e-10	8.69e-08	0.6	0.28	Cognitive function;	chr2:161277014	chr2:161244739~161249050:+
THCA	cis	rs240993	0.595	rs3777912	ENSG00000230177.1	RP5-1112D6.4	6.4	3.84e-10	8.69e-08	0.25	0.28	Inflammatory skin disease;Psoriasis;	chr6:111581473	chr6:111277932~111278742:+
THCA	cis	rs11096990	0.855	rs1820939	ENSG00000249207.1	RP11-360F5.1	6.4	3.85e-10	8.71e-08	0.37	0.28	Cognitive function;	chr4:39170115	chr4:39112677~39126818:-
THCA	cis	rs7176527	0.796	rs72630464	ENSG00000188388.10	GOLGA6L3	6.4	3.85e-10	8.71e-08	0.49	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84754895	chr15:85240472~85247170:+
THCA	cis	rs848490	1	rs56364559	ENSG00000214293.7	APTR	6.4	3.85e-10	8.71e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77851244	chr7:77657660~77696265:-
THCA	cis	rs6496044	0.568	rs1982742	ENSG00000259295.5	CSPG4P12	6.4	3.85e-10	8.71e-08	0.36	0.28	Interstitial lung disease;	chr15:85525519	chr15:85191438~85213905:+
THCA	cis	rs6496044	0.568	rs1982743	ENSG00000259295.5	CSPG4P12	6.4	3.85e-10	8.71e-08	0.36	0.28	Interstitial lung disease;	chr15:85525528	chr15:85191438~85213905:+
THCA	cis	rs853679	0.517	rs17711344	ENSG00000261839.1	RP1-265C24.8	-6.4	3.85e-10	8.71e-08	-0.34	-0.28	Depression;	chr6:28109824	chr6:28136849~28139678:+
THCA	cis	rs7267979	0.932	rs367666	ENSG00000274414.1	RP5-965G21.4	-6.4	3.85e-10	8.72e-08	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25239007~25245229:-
THCA	cis	rs16958440	1	rs76594057	ENSG00000267800.1	RP11-49K24.5	-6.4	3.86e-10	8.73e-08	-0.59	-0.28	Sitting height ratio;	chr18:47110901	chr18:47137018~47137290:+
THCA	cis	rs4835473	0.715	rs4538428	ENSG00000251600.4	RP11-673E1.1	6.4	3.86e-10	8.73e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143992751	chr4:143912331~143982454:+
THCA	cis	rs3806843	1	rs7732179	ENSG00000202515.1	VTRNA1-3	-6.4	3.86e-10	8.73e-08	-0.32	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140819454	chr5:140726158~140726246:+
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000228409.4	CCT6P1	6.4	3.86e-10	8.73e-08	0.34	0.28	Diabetic kidney disease;	chr7:66528779	chr7:65751142~65763354:+
THCA	cis	rs9311474	0.967	rs11717383	ENSG00000243224.1	RP5-1157M23.2	-6.4	3.86e-10	8.73e-08	-0.29	-0.28	Electroencephalogram traits;	chr3:52253452	chr3:52239258~52241097:+
THCA	cis	rs7208859	0.673	rs999797	ENSG00000263603.1	CTD-2349P21.5	-6.4	3.86e-10	8.73e-08	-0.52	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30729469~30731202:+
THCA	cis	rs7267979	0.844	rs4815413	ENSG00000274414.1	RP5-965G21.4	6.4	3.86e-10	8.74e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.844	rs6083824	ENSG00000274414.1	RP5-965G21.4	6.4	3.86e-10	8.74e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.844	rs6076343	ENSG00000274414.1	RP5-965G21.4	6.4	3.86e-10	8.74e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25239007~25245229:-
THCA	cis	rs1865760	0.625	rs9393681	ENSG00000272462.2	U91328.19	-6.4	3.87e-10	8.74e-08	-0.23	-0.28	Height;	chr6:26008032	chr6:25992662~26001775:+
THCA	cis	rs1552244	0.882	rs13063929	ENSG00000180385.7	EMC3-AS1	6.4	3.87e-10	8.75e-08	0.3	0.28	Alzheimer's disease;	chr3:9968624	chr3:9986893~10006990:+
THCA	cis	rs7202877	0.706	rs42472	ENSG00000261783.1	RP11-252K23.2	6.4	3.87e-10	8.75e-08	0.5	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75439422	chr16:75379818~75381260:-
THCA	cis	rs7829975	0.535	rs4841005	ENSG00000254153.1	CTA-398F10.2	6.4	3.88e-10	8.76e-08	0.29	0.28	Mood instability;	chr8:8643720	chr8:8456909~8461337:-
THCA	cis	rs950169	0.84	rs62029595	ENSG00000259295.5	CSPG4P12	6.4	3.88e-10	8.77e-08	0.44	0.28	Schizophrenia;	chr15:84400603	chr15:85191438~85213905:+
THCA	cis	rs9800506	0.584	rs9470056	ENSG00000228559.1	RP3-340B19.3	-6.4	3.88e-10	8.77e-08	-0.39	-0.28	Neutrophil percentage of granulocytes;	chr6:35554368	chr6:35544632~35545669:+
THCA	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	6.39	3.88e-10	8.78e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
THCA	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	6.39	3.88e-10	8.78e-08	0.42	0.28	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
THCA	cis	rs9926296	0.744	rs164746	ENSG00000274627.1	RP11-104N10.2	6.39	3.89e-10	8.78e-08	0.29	0.28	Vitiligo;	chr16:89642611	chr16:89516797~89522217:+
THCA	cis	rs847577	0.609	rs6977321	ENSG00000272950.1	RP11-307C18.1	6.39	3.89e-10	8.79e-08	0.35	0.28	Breast cancer;	chr7:98145547	chr7:98322853~98323430:+
THCA	cis	rs9813712	0.953	rs9847910	ENSG00000249846.5	RP11-77P16.4	6.39	3.89e-10	8.79e-08	0.33	0.28	Response to amphetamines;	chr3:130248174	chr3:130112550~130120579:+
THCA	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-6.39	3.89e-10	8.79e-08	-0.25	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
THCA	cis	rs922182	0.569	rs6494457	ENSG00000275785.1	RP11-111E14.2	6.39	3.89e-10	8.8e-08	0.32	0.28	Blood protein levels;	chr15:63971333	chr15:63890030~63890317:+
THCA	cis	rs9649465	1	rs3807635	ENSG00000272686.1	RP11-390E23.6	6.39	3.9e-10	8.8e-08	0.19	0.28	Migraine;	chr7:123742098	chr7:123749068~123751166:+
THCA	cis	rs9813712	0.571	rs6795143	ENSG00000253540.4	FAM86HP	-6.39	3.9e-10	8.81e-08	-0.31	-0.28	Response to amphetamines;	chr3:130224355	chr3:130099092~130111472:-
THCA	cis	rs9813712	0.571	rs9289366	ENSG00000253540.4	FAM86HP	-6.39	3.9e-10	8.81e-08	-0.31	-0.28	Response to amphetamines;	chr3:130225267	chr3:130099092~130111472:-
THCA	cis	rs9813712	0.571	rs9289367	ENSG00000253540.4	FAM86HP	-6.39	3.9e-10	8.81e-08	-0.31	-0.28	Response to amphetamines;	chr3:130225286	chr3:130099092~130111472:-
THCA	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	6.39	3.9e-10	8.81e-08	0.36	0.28	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
THCA	cis	rs2562456	0.752	rs7258562	ENSG00000268555.1	RP11-678G14.3	6.39	3.9e-10	8.82e-08	0.45	0.28	Pain;	chr19:21331762	chr19:21570822~21587322:-
THCA	cis	rs227275	0.554	rs223399	ENSG00000251288.2	RP11-10L12.2	-6.39	3.9e-10	8.82e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223386	ENSG00000251288.2	RP11-10L12.2	-6.39	3.9e-10	8.82e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223385	ENSG00000251288.2	RP11-10L12.2	-6.39	3.9e-10	8.82e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.873	rs223384	ENSG00000251288.2	RP11-10L12.2	-6.39	3.9e-10	8.82e-08	-0.38	-0.28	Schizophrenia;	chr4:102829976	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223383	ENSG00000251288.2	RP11-10L12.2	-6.39	3.9e-10	8.82e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223382	ENSG00000251288.2	RP11-10L12.2	-6.39	3.9e-10	8.82e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102751401~102752641:+
THCA	cis	rs4713118	0.615	rs9295747	ENSG00000219392.1	RP1-265C24.5	6.39	3.9e-10	8.82e-08	0.34	0.28	Parkinson's disease;	chr6:27769214	chr6:28115628~28116551:+
THCA	cis	rs7976269	0.609	rs10771474	ENSG00000257176.2	RP11-996F15.2	6.39	3.9e-10	8.82e-08	0.29	0.28	Male-pattern baldness;	chr12:29068776	chr12:29280418~29317848:-
THCA	cis	rs807029	0.533	rs67813203	ENSG00000272572.1	RP11-179B2.2	-6.39	3.9e-10	8.82e-08	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100911103~100912739:-
THCA	cis	rs1005277	0.579	rs1740737	ENSG00000276805.1	RP11-291L22.6	6.39	3.91e-10	8.83e-08	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38451030~38451785:+
THCA	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	6.39	3.91e-10	8.83e-08	0.29	0.28	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
THCA	cis	rs1876905	0.569	rs354523	ENSG00000255389.1	C6orf3	6.39	3.91e-10	8.84e-08	0.33	0.28	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111599875~111602295:+
THCA	cis	rs9381040	1	rs2093396	ENSG00000161912.16	ADCY10P1	6.39	3.91e-10	8.84e-08	0.19	0.28	Alzheimer's disease (late onset);	chr6:41187262	chr6:41101022~41140835:+
THCA	cis	rs9880211	0.898	rs73230099	ENSG00000273486.1	RP11-731C17.2	6.39	3.92e-10	8.85e-08	0.3	0.28	Height;Body mass index;	chr3:136833785	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.898	rs73231903	ENSG00000273486.1	RP11-731C17.2	6.39	3.92e-10	8.85e-08	0.3	0.28	Height;Body mass index;	chr3:136842783	chr3:136837338~136839021:-
THCA	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-6.39	3.92e-10	8.85e-08	-0.55	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
THCA	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-6.39	3.92e-10	8.85e-08	-0.55	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
THCA	cis	rs10078	0.515	rs2672739	ENSG00000221990.4	EXOC3-AS1	6.39	3.92e-10	8.85e-08	0.29	0.28	Fat distribution (HIV);	chr5:443332	chr5:441498~443160:-
THCA	cis	rs8027521	0.54	rs1904111	ENSG00000280362.1	RP11-643A5.3	6.39	3.92e-10	8.86e-08	0.35	0.28	Circulating chemerin levels;	chr15:53949181	chr15:53910769~53914712:+
THCA	cis	rs2853333	0.739	rs34805185	ENSG00000269553.1	U62631.5	-6.39	3.92e-10	8.86e-08	-0.3	-0.28	Red blood cell count;	chr19:35279881	chr19:35330843~35331920:+
THCA	cis	rs2853333	0.818	rs35478572	ENSG00000269553.1	U62631.5	-6.39	3.92e-10	8.86e-08	-0.3	-0.28	Red blood cell count;	chr19:35280029	chr19:35330843~35331920:+
THCA	cis	rs950169	0.887	rs12903946	ENSG00000259295.5	CSPG4P12	6.39	3.92e-10	8.86e-08	0.44	0.28	Schizophrenia;	chr15:84399732	chr15:85191438~85213905:+
THCA	cis	rs950169	0.887	rs62029593	ENSG00000259295.5	CSPG4P12	6.39	3.92e-10	8.86e-08	0.44	0.28	Schizophrenia;	chr15:84400482	chr15:85191438~85213905:+
THCA	cis	rs950169	0.81	rs62029594	ENSG00000259295.5	CSPG4P12	6.39	3.92e-10	8.86e-08	0.44	0.28	Schizophrenia;	chr15:84400554	chr15:85191438~85213905:+
THCA	cis	rs950169	0.881	rs62029596	ENSG00000259295.5	CSPG4P12	6.39	3.92e-10	8.86e-08	0.44	0.28	Schizophrenia;	chr15:84400736	chr15:85191438~85213905:+
THCA	cis	rs950169	0.881	rs4081123	ENSG00000259295.5	CSPG4P12	6.39	3.92e-10	8.86e-08	0.44	0.28	Schizophrenia;	chr15:84401537	chr15:85191438~85213905:+
THCA	cis	rs950169	0.881	rs62029599	ENSG00000259295.5	CSPG4P12	6.39	3.92e-10	8.86e-08	0.44	0.28	Schizophrenia;	chr15:84401867	chr15:85191438~85213905:+
THCA	cis	rs950169	0.8	rs4099846	ENSG00000259295.5	CSPG4P12	6.39	3.92e-10	8.86e-08	0.44	0.28	Schizophrenia;	chr15:84402196	chr15:85191438~85213905:+
THCA	cis	rs17772222	0.917	rs58984912	ENSG00000258789.1	RP11-507K2.3	-6.39	3.93e-10	8.87e-08	-0.28	-0.28	Coronary artery calcification;	chr14:88698172	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs17188207	ENSG00000258789.1	RP11-507K2.3	-6.39	3.93e-10	8.87e-08	-0.28	-0.28	Coronary artery calcification;	chr14:88699579	chr14:88551597~88552493:+
THCA	cis	rs227275	0.525	rs1080081	ENSG00000251288.2	RP11-10L12.2	-6.39	3.93e-10	8.87e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs4699049	ENSG00000251288.2	RP11-10L12.2	-6.39	3.93e-10	8.87e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102751401~102752641:+
THCA	cis	rs6600671	1	rs1856572	ENSG00000270392.2	PFN1P2	6.39	3.93e-10	8.87e-08	0.28	0.28	Hip geometry;	chr1:121427719	chr1:120432204~120434052:-
THCA	cis	rs7942368	0.941	rs11236936	ENSG00000204529.3	GUCY2EP	6.39	3.93e-10	8.88e-08	0.4	0.28	Endometriosis;	chr11:76789786	chr11:76694043~76707641:-
THCA	cis	rs227275	0.554	rs223395	ENSG00000251288.2	RP11-10L12.2	-6.39	3.93e-10	8.88e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102751401~102752641:+
THCA	cis	rs10208649	0.572	rs12621547	ENSG00000272156.1	RP11-477N3.1	6.39	3.94e-10	8.89e-08	0.42	0.28	Body mass index;	chr2:53696078	chr2:54082554~54085066:+
THCA	cis	rs11722779	0.81	rs223417	ENSG00000251288.2	RP11-10L12.2	-6.39	3.94e-10	8.9e-08	-0.38	-0.28	Schizophrenia;	chr4:102810568	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.805	rs223416	ENSG00000251288.2	RP11-10L12.2	-6.39	3.94e-10	8.9e-08	-0.38	-0.28	Schizophrenia;	chr4:102810580	chr4:102751401~102752641:+
THCA	cis	rs2243480	1	rs34970380	ENSG00000228409.4	CCT6P1	6.39	3.94e-10	8.9e-08	0.33	0.28	Diabetic kidney disease;	chr7:65966506	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000228409.4	CCT6P1	6.39	3.94e-10	8.9e-08	0.33	0.28	Diabetic kidney disease;	chr7:66004843	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs34193460	ENSG00000228409.4	CCT6P1	6.39	3.94e-10	8.91e-08	0.33	0.28	Diabetic kidney disease;	chr7:65928123	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs57057549	ENSG00000228409.4	CCT6P1	6.39	3.94e-10	8.91e-08	0.33	0.28	Diabetic kidney disease;	chr7:65940751	chr7:65751142~65763354:+
THCA	cis	rs7044106	0.762	rs3903886	ENSG00000270917.1	RP11-27I1.6	6.39	3.95e-10	8.91e-08	0.4	0.28	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120812475~120812845:-
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000228409.4	CCT6P1	6.39	3.95e-10	8.91e-08	0.33	0.28	Diabetic kidney disease;	chr7:65924813	chr7:65751142~65763354:+
THCA	cis	rs3806843	0.933	rs10069930	ENSG00000202515.1	VTRNA1-3	-6.39	3.95e-10	8.93e-08	-0.32	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140783743	chr5:140726158~140726246:+
THCA	cis	rs17772222	0.958	rs2297128	ENSG00000258789.1	RP11-507K2.3	-6.39	3.95e-10	8.93e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88469910	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.837	rs1864748	ENSG00000258789.1	RP11-507K2.3	-6.39	3.95e-10	8.93e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88488847	chr14:88551597~88552493:+
THCA	cis	rs79349575	0.783	rs2112617	ENSG00000248278.1	SUMO2P17	6.39	3.95e-10	8.93e-08	0.34	0.28	Type 2 diabetes;	chr17:48899763	chr17:48874860~48908983:-
THCA	cis	rs17158807	0.752	rs72760369	ENSG00000274128.1	RP11-342A23.2	6.39	3.96e-10	8.93e-08	0.48	0.28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr15:83562745	chr15:83962176~83962583:+
THCA	cis	rs7267979	0.714	rs6132825	ENSG00000274414.1	RP5-965G21.4	-6.39	3.96e-10	8.94e-08	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:25239007~25245229:-
THCA	cis	rs890448	0.726	rs2583395	ENSG00000254531.1	FLJ20021	-6.39	3.96e-10	8.94e-08	-0.25	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101320584	chr4:101347780~101348883:+
THCA	cis	rs6088580	0.524	rs2378251	ENSG00000269202.1	RP4-614O4.12	6.39	3.97e-10	8.95e-08	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34688946	chr20:35201747~35203288:-
THCA	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-6.39	3.97e-10	8.96e-08	-0.34	-0.28	AIDS;	chr2:105311539	chr2:105324210~105330529:+
THCA	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-6.39	3.97e-10	8.96e-08	-0.34	-0.28	AIDS;	chr2:105321650	chr2:105324210~105330529:+
THCA	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	6.39	3.97e-10	8.96e-08	0.46	0.28	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
THCA	cis	rs7267979	0.844	rs35735333	ENSG00000274414.1	RP5-965G21.4	6.39	3.97e-10	8.97e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25239007~25245229:-
THCA	cis	rs2243480	1	rs1723267	ENSG00000232546.1	RP11-458F8.1	-6.39	3.98e-10	8.97e-08	-0.36	-0.28	Diabetic kidney disease;	chr7:66008327	chr7:66848496~66858136:+
THCA	cis	rs7267979	0.966	rs6050611	ENSG00000274414.1	RP5-965G21.4	-6.39	3.98e-10	8.97e-08	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25239007~25245229:-
THCA	cis	rs5742933	0.779	rs7595020	ENSG00000253559.1	OSGEPL1-AS1	6.39	3.98e-10	8.99e-08	0.32	0.28	Ferritin levels;	chr2:189778950	chr2:189762704~189765556:+
THCA	cis	rs712022	1	rs11026804	ENSG00000246225.5	RP11-17A1.3	6.39	3.98e-10	8.99e-08	0.36	0.28	Dialysis-related mortality;	chr11:22820036	chr11:22829380~22945393:+
THCA	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-6.39	3.98e-10	8.99e-08	-0.5	-0.28	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
THCA	cis	rs897984	0.806	rs10782002	ENSG00000279196.1	RP11-1072A3.3	-6.39	3.99e-10	9e-08	-0.28	-0.28	Dementia with Lewy bodies;	chr16:30935185	chr16:30984630~30988270:-
THCA	cis	rs6545883	0.859	rs2694644	ENSG00000271889.1	RP11-493E12.1	-6.39	3.99e-10	9.01e-08	-0.27	-0.28	Tuberculosis;	chr2:61377721	chr2:61151433~61162105:-
THCA	cis	rs2765539	0.701	rs4659148	ENSG00000231365.4	RP11-418J17.1	-6.39	4e-10	9.02e-08	-0.31	-0.28	Waist-hip ratio;	chr1:119104071	chr1:119140396~119275973:+
THCA	cis	rs451417	1	rs236110	ENSG00000275632.1	RP5-967N21.11	6.39	4e-10	9.02e-08	0.32	0.28	Menopause (age at onset);	chr20:5952462	chr20:6000418~6000941:+
THCA	cis	rs228614	0.51	rs223377	ENSG00000251288.2	RP11-10L12.2	-6.39	4e-10	9.02e-08	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102751401~102752641:+
THCA	cis	rs728616	0.867	rs17606361	ENSG00000242600.5	MBL1P	6.39	4e-10	9.02e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80085655	chr10:79904898~79950336:+
THCA	cis	rs728616	0.764	rs61859016	ENSG00000242600.5	MBL1P	6.39	4e-10	9.02e-08	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80092744	chr10:79904898~79950336:+
THCA	cis	rs1707322	0.686	rs1084086	ENSG00000281133.1	AL355480.3	6.39	4e-10	9.03e-08	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45580892~45580996:-
THCA	cis	rs2253762	0.527	rs11200323	ENSG00000276742.1	RP11-500G22.4	-6.39	4.01e-10	9.05e-08	-0.38	-0.28	Breast cancer;	chr10:122008869	chr10:121956782~121957098:+
THCA	cis	rs7189233	0.956	rs62048486	ENSG00000279722.1	RP11-44F14.6	-6.39	4.01e-10	9.05e-08	-0.3	-0.28	Intelligence (multi-trait analysis);	chr16:53414427	chr16:53487607~53489943:-
THCA	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	6.39	4.01e-10	9.05e-08	0.31	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
THCA	cis	rs1707322	0.686	rs1541131	ENSG00000281133.1	AL355480.3	6.39	4.02e-10	9.07e-08	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45580892~45580996:-
THCA	cis	rs8027521	0.54	rs57288942	ENSG00000280362.1	RP11-643A5.3	6.39	4.02e-10	9.07e-08	0.35	0.28	Circulating chemerin levels;	chr15:53931874	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.54	rs7174598	ENSG00000280362.1	RP11-643A5.3	6.39	4.02e-10	9.07e-08	0.35	0.28	Circulating chemerin levels;	chr15:53931877	chr15:53910769~53914712:+
THCA	cis	rs2915864	0.747	rs79549403	ENSG00000280047.1	CTC-463A16.1	6.39	4.02e-10	9.07e-08	0.46	0.28	Facial morphology (factor 20);	chr5:142055839	chr5:142165767~142168387:+
THCA	cis	rs9381040	1	rs9381040	ENSG00000161912.16	ADCY10P1	6.39	4.03e-10	9.08e-08	0.19	0.28	Alzheimer's disease (late onset);	chr6:41186912	chr6:41101022~41140835:+
THCA	cis	rs1552244	0.515	rs67626468	ENSG00000232901.1	CYCSP10	6.39	4.03e-10	9.08e-08	0.43	0.28	Alzheimer's disease;	chr3:10119834	chr3:10000647~10000940:-
THCA	cis	rs12554020	0.579	rs79056932	ENSG00000227603.1	RP11-165J3.6	6.39	4.03e-10	9.09e-08	0.51	0.28	Schizophrenia;	chr9:93585431	chr9:93435332~93437121:-
THCA	cis	rs17158807	0.752	rs72760376	ENSG00000274128.1	RP11-342A23.2	6.39	4.03e-10	9.09e-08	0.48	0.28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr15:83566647	chr15:83962176~83962583:+
THCA	cis	rs1876905	1	rs1876905	ENSG00000230177.1	RP5-1112D6.4	-6.39	4.03e-10	9.09e-08	-0.29	-0.28	Mean corpuscular hemoglobin;	chr6:111096756	chr6:111277932~111278742:+
THCA	cis	rs1949733	0.848	rs2255501	ENSG00000205959.3	RP11-689P11.2	6.39	4.04e-10	9.1e-08	0.24	0.28	Response to antineoplastic agents;	chr4:8473287	chr4:8482270~8512610:+
THCA	cis	rs4072705	0.869	rs2416951	ENSG00000224020.1	MIR181A2HG	-6.39	4.04e-10	9.1e-08	-0.26	-0.28	Menarche (age at onset);	chr9:124788324	chr9:124658467~124698631:+
THCA	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	6.39	4.04e-10	9.11e-08	0.32	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
THCA	cis	rs227275	0.525	rs17215211	ENSG00000251288.2	RP11-10L12.2	-6.39	4.04e-10	9.12e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102751401~102752641:+
THCA	cis	rs4845570	0.92	rs11810571	ENSG00000203288.3	RP11-98D18.9	6.39	4.05e-10	9.13e-08	0.28	0.28	Coronary artery disease;	chr1:151789832	chr1:151790804~151794402:+
THCA	cis	rs4143844	0.867	rs77585482	ENSG00000259251.2	RP11-643M14.1	6.39	4.05e-10	9.14e-08	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61925442	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs62009109	ENSG00000259251.2	RP11-643M14.1	6.39	4.05e-10	9.14e-08	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61927032	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.609	rs34234705	ENSG00000259251.2	RP11-643M14.1	6.39	4.05e-10	9.14e-08	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61938475	chr15:62060503~62062434:+
THCA	cis	rs11672691	0.627	rs6508981	ENSG00000267107.5	PCAT19	6.39	4.05e-10	9.14e-08	0.32	0.28	Prostate cancer;	chr19:41483668	chr19:41454169~41500649:-
THCA	cis	rs2243480	1	rs4149468	ENSG00000232546.1	RP11-458F8.1	-6.39	4.05e-10	9.14e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66360703	chr7:66848496~66858136:+
THCA	cis	rs853679	0.55	rs1233701	ENSG00000220721.1	OR1F12	-6.39	4.06e-10	9.15e-08	-0.38	-0.28	Depression;	chr6:28200948	chr6:28073316~28074233:+
THCA	cis	rs7727544	0.735	rs274558	ENSG00000237714.1	P4HA2-AS1	-6.39	4.06e-10	9.15e-08	-0.36	-0.28	Blood metabolite levels;	chr5:132385482	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.735	rs274557	ENSG00000237714.1	P4HA2-AS1	-6.39	4.06e-10	9.15e-08	-0.36	-0.28	Blood metabolite levels;	chr5:132385512	chr5:132184876~132192808:+
THCA	cis	rs2120243	0.592	rs1869857	ENSG00000244515.1	KRT18P34	6.39	4.06e-10	9.15e-08	0.32	0.28	Hepatocellular carcinoma in hepatitis B infection;	chr3:157405568	chr3:157162663~157163932:-
THCA	cis	rs7727544	0.735	rs2631370	ENSG00000237714.1	P4HA2-AS1	-6.39	4.06e-10	9.15e-08	-0.36	-0.28	Blood metabolite levels;	chr5:132368084	chr5:132184876~132192808:+
THCA	cis	rs438465	1	rs2860563	ENSG00000226194.4	RP1-137D17.1	6.39	4.06e-10	9.15e-08	0.43	0.28	Corneal astigmatism;	chr6:169488146	chr6:169369998~169388385:-
THCA	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	6.39	4.06e-10	9.16e-08	0.36	0.28	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
THCA	cis	rs6840360	0.582	rs59714108	ENSG00000251611.1	RP11-610P16.1	-6.39	4.07e-10	9.17e-08	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151404787	chr4:151407551~151408835:-
THCA	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	6.39	4.07e-10	9.18e-08	0.41	0.28	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
THCA	cis	rs2348418	0.966	rs11049698	ENSG00000247934.4	RP11-967K21.1	6.39	4.07e-10	9.18e-08	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28535354	chr12:28163298~28190738:-
THCA	cis	rs890448	0.726	rs2850369	ENSG00000254531.1	FLJ20021	-6.39	4.08e-10	9.2e-08	-0.25	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101311828	chr4:101347780~101348883:+
THCA	cis	rs890448	0.726	rs2044043	ENSG00000254531.1	FLJ20021	-6.39	4.08e-10	9.2e-08	-0.25	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101314983	chr4:101347780~101348883:+
THCA	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	6.39	4.08e-10	9.2e-08	0.37	0.28	Depression;	chr6:28364057	chr6:28176188~28176674:+
THCA	cis	rs7267979	0.549	rs11698185	ENSG00000274414.1	RP5-965G21.4	-6.39	4.08e-10	9.21e-08	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:25239007~25245229:-
THCA	cis	rs17772222	0.958	rs1123421	ENSG00000222990.1	RNU4-22P	6.39	4.09e-10	9.21e-08	0.36	0.28	Coronary artery calcification;	chr14:88524651	chr14:88513498~88513663:+
THCA	cis	rs712022	1	rs712022	ENSG00000246225.5	RP11-17A1.3	-6.39	4.09e-10	9.21e-08	-0.37	-0.28	Dialysis-related mortality;	chr11:22821609	chr11:22829380~22945393:+
THCA	cis	rs5742933	0.857	rs2289226	ENSG00000273240.1	RP11-455J20.3	-6.39	4.09e-10	9.22e-08	-0.29	-0.28	Ferritin levels;	chr2:189661479	chr2:189763859~189764456:-
THCA	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	6.39	4.09e-10	9.22e-08	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
THCA	cis	rs2717559	0.542	rs2717560	ENSG00000253741.1	CTD-2292P10.4	6.39	4.1e-10	9.24e-08	0.37	0.28	Urinary tract infection frequency;	chr8:142800254	chr8:142702252~142726973:-
THCA	cis	rs6840360	0.582	rs11733820	ENSG00000251611.1	RP11-610P16.1	-6.39	4.11e-10	9.25e-08	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.582	rs4473638	ENSG00000251611.1	RP11-610P16.1	-6.39	4.11e-10	9.25e-08	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151407551~151408835:-
THCA	cis	rs2239557	1	rs11628710	ENSG00000259065.1	RP5-1021I20.1	-6.39	4.11e-10	9.25e-08	-0.34	-0.28	Common traits (Other);	chr14:74182577	chr14:73787360~73803270:+
THCA	cis	rs12435908	1	rs11851013	ENSG00000276116.2	FUT8-AS1	-6.39	4.11e-10	9.26e-08	-0.47	-0.28	Ischemic stroke;	chr14:65549494	chr14:65411170~65412690:-
THCA	cis	rs10895275	0.625	rs7107909	ENSG00000277459.1	RP11-732A21.3	6.39	4.11e-10	9.26e-08	0.22	0.28	Migraine;	chr11:102209255	chr11:102109827~102110457:-
THCA	cis	rs9649465	1	rs3807634	ENSG00000272686.1	RP11-390E23.6	6.39	4.11e-10	9.26e-08	0.19	0.28	Migraine;	chr7:123742236	chr7:123749068~123751166:+
THCA	cis	rs8062405	0.755	rs12447461	ENSG00000278665.1	RP11-666O2.4	6.39	4.12e-10	9.28e-08	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28599241~28601881:-
THCA	cis	rs6928977	0.896	rs2614285	ENSG00000231028.7	LINC00271	6.38	4.12e-10	9.29e-08	0.23	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371480	chr6:135497801~135716055:+
THCA	cis	rs712022	1	rs10833824	ENSG00000246225.5	RP11-17A1.3	-6.38	4.13e-10	9.3e-08	-0.36	-0.28	Dialysis-related mortality;	chr11:22825939	chr11:22829380~22945393:+
THCA	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-6.38	4.13e-10	9.31e-08	-0.44	-0.28	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
THCA	cis	rs6545883	0.86	rs6545848	ENSG00000271889.1	RP11-493E12.1	-6.38	4.14e-10	9.33e-08	-0.27	-0.28	Tuberculosis;	chr2:61234048	chr2:61151433~61162105:-
THCA	cis	rs2243480	1	rs67536397	ENSG00000229886.1	RP5-1132H15.3	6.38	4.15e-10	9.34e-08	0.47	0.28	Diabetic kidney disease;	chr7:66482930	chr7:66025126~66031544:-
THCA	cis	rs6504622	0.728	rs7222781	ENSG00000262879.4	RP11-156P1.3	-6.38	4.15e-10	9.34e-08	-0.26	-0.28	Orofacial clefts;	chr17:47100059	chr17:46984045~47100323:-
THCA	cis	rs2657294	0.62	rs4746259	ENSG00000233313.2	HMGA1P5	-6.38	4.15e-10	9.35e-08	-0.39	-0.28	Pneumonia;	chr10:75082310	chr10:75276376~75276646:-
THCA	cis	rs6545883	0.655	rs11893880	ENSG00000271889.1	RP11-493E12.1	6.38	4.15e-10	9.36e-08	0.26	0.28	Tuberculosis;	chr2:61194884	chr2:61151433~61162105:-
THCA	cis	rs7191700	0.674	rs12597893	ENSG00000263080.1	RP11-485G7.5	6.38	4.16e-10	9.36e-08	0.33	0.28	Multiple sclerosis;	chr16:11332474	chr16:11341809~11345211:-
THCA	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	6.38	4.16e-10	9.37e-08	0.29	0.28	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
THCA	cis	rs2348418	0.831	rs2348416	ENSG00000247934.4	RP11-967K21.1	6.38	4.16e-10	9.37e-08	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28556283	chr12:28163298~28190738:-
THCA	cis	rs6545883	0.825	rs4672426	ENSG00000271889.1	RP11-493E12.1	-6.38	4.16e-10	9.37e-08	-0.27	-0.28	Tuberculosis;	chr2:61230013	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.86	rs4671399	ENSG00000271889.1	RP11-493E12.1	-6.38	4.16e-10	9.37e-08	-0.27	-0.28	Tuberculosis;	chr2:61231383	chr2:61151433~61162105:-
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000229886.1	RP5-1132H15.3	6.38	4.16e-10	9.37e-08	0.46	0.28	Diabetic kidney disease;	chr7:65914813	chr7:66025126~66031544:-
THCA	cis	rs7727544	0.735	rs272879	ENSG00000237714.1	P4HA2-AS1	6.38	4.16e-10	9.38e-08	0.36	0.28	Blood metabolite levels;	chr5:132334853	chr5:132184876~132192808:+
THCA	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	6.38	4.17e-10	9.38e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
THCA	cis	rs4143844	1	rs62007454	ENSG00000259251.2	RP11-643M14.1	6.38	4.17e-10	9.38e-08	0.54	0.28	Bipolar disorder and schizophrenia;	chr15:62062496	chr15:62060503~62062434:+
THCA	cis	rs227275	0.554	rs223367	ENSG00000230069.3	LRRC37A15P	-6.38	4.17e-10	9.39e-08	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102727274~102730721:-
THCA	cis	rs28386778	0.897	rs1982400	ENSG00000240280.5	TCAM1P	-6.38	4.17e-10	9.4e-08	-0.39	-0.28	Prudent dietary pattern;	chr17:63716458	chr17:63849292~63864379:+
THCA	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	6.38	4.17e-10	9.4e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
THCA	cis	rs9649465	1	rs13230338	ENSG00000272686.1	RP11-390E23.6	6.38	4.17e-10	9.4e-08	0.19	0.28	Migraine;	chr7:123733568	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs6963231	ENSG00000272686.1	RP11-390E23.6	6.38	4.17e-10	9.4e-08	0.19	0.28	Migraine;	chr7:123734712	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs9649465	ENSG00000272686.1	RP11-390E23.6	6.38	4.17e-10	9.4e-08	0.19	0.28	Migraine;	chr7:123736506	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs12537072	ENSG00000272686.1	RP11-390E23.6	6.38	4.17e-10	9.4e-08	0.19	0.28	Migraine;	chr7:123737159	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs13230294	ENSG00000272686.1	RP11-390E23.6	6.38	4.17e-10	9.4e-08	0.19	0.28	Migraine;	chr7:123740767	chr7:123749068~123751166:+
THCA	cis	rs7942368	1	rs1837680	ENSG00000204529.3	GUCY2EP	6.38	4.18e-10	9.41e-08	0.4	0.28	Endometriosis;	chr11:76790407	chr11:76694043~76707641:-
THCA	cis	rs683257	0.673	rs72990126	ENSG00000234147.1	RP3-460G2.2	-6.38	4.18e-10	9.41e-08	-0.43	-0.28	Facial emotion recognition (angry faces);	chr6:140850534	chr6:140845958~140852924:-
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000226155.1	AC124944.3	-6.38	4.18e-10	9.41e-08	-0.38	-0.28	Pancreatic cancer;	chr3:196025182	chr3:195912049~195913986:+
THCA	cis	rs728616	0.867	rs61860039	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61860041	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61860042	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61860043	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61860044	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs12415870	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs12414521	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs55666905	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs56008106	ENSG00000242600.5	MBL1P	6.38	4.18e-10	9.41e-08	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:79904898~79950336:+
THCA	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	6.38	4.18e-10	9.42e-08	0.39	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
THCA	cis	rs847577	0.609	rs6465658	ENSG00000272950.1	RP11-307C18.1	6.38	4.19e-10	9.42e-08	0.36	0.28	Breast cancer;	chr7:98187326	chr7:98322853~98323430:+
THCA	cis	rs4835473	0.808	rs11725413	ENSG00000251600.4	RP11-673E1.1	-6.38	4.19e-10	9.43e-08	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143943366	chr4:143912331~143982454:+
THCA	cis	rs2243480	1	rs160652	ENSG00000228409.4	CCT6P1	6.38	4.19e-10	9.43e-08	0.33	0.28	Diabetic kidney disease;	chr7:66073444	chr7:65751142~65763354:+
THCA	cis	rs9677476	0.644	rs12470661	ENSG00000224376.1	AC017104.6	6.38	4.19e-10	9.43e-08	0.33	0.28	Food antigen IgG levels;	chr2:231195336	chr2:231388976~231394991:+
THCA	cis	rs9677476	0.818	rs13431424	ENSG00000224376.1	AC017104.6	6.38	4.19e-10	9.43e-08	0.33	0.28	Food antigen IgG levels;	chr2:231195839	chr2:231388976~231394991:+
THCA	cis	rs2439831	0.867	rs2584702	ENSG00000249839.1	AC011330.5	-6.38	4.19e-10	9.44e-08	-0.43	-0.28	Lung cancer in ever smokers;	chr15:43392716	chr15:43663654~43684339:-
THCA	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	6.38	4.19e-10	9.44e-08	0.37	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
THCA	cis	rs11096990	0.821	rs76235093	ENSG00000249207.1	RP11-360F5.1	6.38	4.19e-10	9.44e-08	0.36	0.28	Cognitive function;	chr4:39281157	chr4:39112677~39126818:-
THCA	cis	rs5742933	0.779	rs1899025	ENSG00000273240.1	RP11-455J20.3	6.38	4.19e-10	9.44e-08	0.29	0.28	Ferritin levels;	chr2:189784856	chr2:189763859~189764456:-
THCA	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-6.38	4.2e-10	9.44e-08	-0.17	-0.28	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-6.38	4.2e-10	9.44e-08	-0.17	-0.28	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
THCA	cis	rs8014252	0.803	rs12586441	ENSG00000259158.2	ADAM20P1	-6.38	4.2e-10	9.45e-08	-0.37	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70521345	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs77359887	ENSG00000259158.2	ADAM20P1	-6.38	4.2e-10	9.45e-08	-0.37	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70532521	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs12588723	ENSG00000259158.2	ADAM20P1	6.38	4.2e-10	9.45e-08	0.37	0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70518234	chr14:70468881~70483756:-
THCA	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	6.38	4.2e-10	9.45e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	6.38	4.2e-10	9.45e-08	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
THCA	cis	rs1707322	0.686	rs3014242	ENSG00000281133.1	AL355480.3	6.38	4.21e-10	9.46e-08	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45580892~45580996:-
THCA	cis	rs6603134	0.502	rs6603133	ENSG00000269139.2	CTD-3193O13.8	6.38	4.21e-10	9.48e-08	0.26	0.28	Blood protein levels;	chr19:8038352	chr19:7926001~7926810:+
THCA	cis	rs467650	0.517	rs27022	ENSG00000246763.5	RGMB-AS1	6.38	4.21e-10	9.48e-08	0.28	0.28	Venous thromboembolism (SNP x SNP interaction);	chr5:98605336	chr5:98769618~98773469:-
THCA	cis	rs7044106	0.537	rs10739573	ENSG00000238181.2	AHCYP2	-6.38	4.21e-10	9.48e-08	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120720673~120721972:+
THCA	cis	rs16976116	0.951	rs8043029	ENSG00000279145.1	RP11-547D13.1	6.38	4.21e-10	9.48e-08	0.28	0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55193813	chr15:55171972~55178175:-
THCA	cis	rs9843304	0.9	rs6774253	ENSG00000244503.1	RP11-278L15.6	-6.38	4.22e-10	9.49e-08	-0.35	-0.28	Gallstone disease;	chr3:149494110	chr3:149494660~149495995:+
THCA	cis	rs516805	0.63	rs2816072	ENSG00000279453.1	RP3-425C14.4	-6.38	4.22e-10	9.49e-08	-0.3	-0.28	Lymphocyte counts;	chr6:122106871	chr6:122436789~122439223:-
THCA	cis	rs526231	0.784	rs28157	ENSG00000175749.11	EIF3KP1	6.38	4.22e-10	9.49e-08	0.4	0.28	Primary biliary cholangitis;	chr5:103260136	chr5:103032376~103033031:+
THCA	cis	rs7976269	0.609	rs10771470	ENSG00000257176.2	RP11-996F15.2	-6.38	4.22e-10	9.49e-08	-0.29	-0.28	Male-pattern baldness;	chr12:29050620	chr12:29280418~29317848:-
THCA	cis	rs1876905	0.68	rs373526	ENSG00000255389.1	C6orf3	-6.38	4.22e-10	9.5e-08	-0.33	-0.28	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111599875~111602295:+
THCA	cis	rs2255336	0.938	rs2733840	ENSG00000245648.1	RP11-277P12.20	6.38	4.23e-10	9.51e-08	0.36	0.28	Blood protein levels;	chr12:10393326	chr12:10363769~10398506:+
THCA	cis	rs9990333	0.544	rs73208092	ENSG00000226155.1	AC124944.3	-6.38	4.23e-10	9.51e-08	-0.35	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195912049~195913986:+
THCA	cis	rs712022	1	rs1019217	ENSG00000246225.5	RP11-17A1.3	6.38	4.24e-10	9.53e-08	0.36	0.28	Dialysis-related mortality;	chr11:22821076	chr11:22829380~22945393:+
THCA	cis	rs7727544	0.735	rs270605	ENSG00000237714.1	P4HA2-AS1	6.38	4.24e-10	9.53e-08	0.36	0.28	Blood metabolite levels;	chr5:132316118	chr5:132184876~132192808:+
THCA	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-6.38	4.24e-10	9.54e-08	-0.17	-0.28	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
THCA	cis	rs1043099	0.556	rs737723	ENSG00000279699.1	RP1-102K2.9	-6.38	4.25e-10	9.55e-08	-0.33	-0.28	Rheumatoid arthritis;	chr22:30406040	chr22:30275215~30276951:-
THCA	cis	rs6860806	0.661	rs2171247	ENSG00000237714.1	P4HA2-AS1	6.38	4.25e-10	9.56e-08	0.36	0.28	Breast cancer;	chr5:132244541	chr5:132184876~132192808:+
THCA	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	6.38	4.25e-10	9.56e-08	0.27	0.28	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
THCA	cis	rs10276381	0.786	rs73300665	ENSG00000234336.5	JAZF1-AS1	-6.38	4.25e-10	9.57e-08	-0.4	-0.28	Crohn's disease;	chr7:28187405	chr7:28180322~28243917:+
THCA	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	6.38	4.25e-10	9.57e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
THCA	cis	rs2243480	0.522	rs1638736	ENSG00000273142.1	RP11-458F8.4	-6.38	4.26e-10	9.57e-08	-0.45	-0.28	Diabetic kidney disease;	chr7:66627321	chr7:66902857~66906297:+
THCA	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	6.38	4.26e-10	9.58e-08	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
THCA	cis	rs9649465	0.967	rs12531955	ENSG00000272686.1	RP11-390E23.6	6.38	4.26e-10	9.58e-08	0.19	0.28	Migraine;	chr7:123737012	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.935	rs7780086	ENSG00000272686.1	RP11-390E23.6	6.38	4.26e-10	9.58e-08	0.19	0.28	Migraine;	chr7:123738417	chr7:123749068~123751166:+
THCA	cis	rs16958440	0.867	rs3809965	ENSG00000267800.1	RP11-49K24.5	-6.38	4.26e-10	9.58e-08	-0.62	-0.28	Sitting height ratio;	chr18:47150501	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs74411203	ENSG00000267800.1	RP11-49K24.5	-6.38	4.26e-10	9.58e-08	-0.62	-0.28	Sitting height ratio;	chr18:47151095	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs74346439	ENSG00000267800.1	RP11-49K24.5	-6.38	4.26e-10	9.58e-08	-0.62	-0.28	Sitting height ratio;	chr18:47151096	chr18:47137018~47137290:+
THCA	cis	rs9467773	0.525	rs1535274	ENSG00000124549.13	BTN2A3P	6.38	4.26e-10	9.58e-08	0.27	0.28	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.565	rs6925047	ENSG00000124549.13	BTN2A3P	6.38	4.26e-10	9.58e-08	0.27	0.28	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.565	rs4343916	ENSG00000124549.13	BTN2A3P	6.38	4.26e-10	9.58e-08	0.27	0.28	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26421391~26432383:+
THCA	cis	rs6565180	1	rs11862806	ENSG00000273724.1	RP11-347C12.12	-6.38	4.26e-10	9.58e-08	-0.29	-0.28	Tonsillectomy;	chr16:30352750	chr16:30336400~30343336:+
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000228409.4	CCT6P1	6.38	4.27e-10	9.59e-08	0.33	0.28	Diabetic kidney disease;	chr7:65966800	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs906134	ENSG00000228409.4	CCT6P1	6.38	4.27e-10	9.59e-08	0.33	0.28	Diabetic kidney disease;	chr7:65979301	chr7:65751142~65763354:+
THCA	cis	rs6088580	0.524	rs4911437	ENSG00000269202.1	RP4-614O4.12	6.38	4.27e-10	9.59e-08	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34678345	chr20:35201747~35203288:-
THCA	cis	rs944990	0.538	rs10992788	ENSG00000227603.1	RP11-165J3.6	6.38	4.27e-10	9.6e-08	0.29	0.28	Body mass index;	chr9:93571377	chr9:93435332~93437121:-
THCA	cis	rs2945232	1	rs2945232	ENSG00000253981.4	ALG1L13P	6.38	4.27e-10	9.6e-08	0.26	0.28	Schizophrenia;	chr8:8240516	chr8:8236003~8244667:-
THCA	cis	rs11976180	1	rs1919949	ENSG00000170356.8	OR2A20P	-6.38	4.27e-10	9.61e-08	-0.39	-0.28	Obesity-related traits;	chr7:144070630	chr7:144250045~144252957:-
THCA	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-6.38	4.27e-10	9.61e-08	-0.44	-0.28	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
THCA	cis	rs7615952	0.611	rs2947646	ENSG00000241288.6	RP11-379B18.5	6.38	4.28e-10	9.62e-08	0.4	0.28	Blood pressure (smoking interaction);	chr3:125874759	chr3:125827238~125916384:-
THCA	cis	rs10761482	0.5	rs1574466	ENSG00000254271.1	RP11-131N11.4	6.38	4.29e-10	9.63e-08	0.36	0.28	Schizophrenia;	chr10:60534634	chr10:60734342~60741828:+
THCA	cis	rs7015630	0.648	rs35183880	ENSG00000251136.7	RP11-37B2.1	-6.38	4.29e-10	9.64e-08	-0.29	-0.28	Inflammatory bowel disease;Crohn's disease;	chr8:89840843	chr8:89609409~89757727:-
THCA	cis	rs7225151	0.71	rs112809920	ENSG00000234327.6	AC012146.7	-6.38	4.29e-10	9.64e-08	-0.34	-0.28	Alzheimer's disease (late onset);	chr17:5293315	chr17:5111468~5115004:+
THCA	cis	rs848490	0.962	rs11761324	ENSG00000214293.7	APTR	6.38	4.29e-10	9.64e-08	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77803597	chr7:77657660~77696265:-
THCA	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	6.38	4.29e-10	9.65e-08	0.37	0.28	Depression;	chr6:28379133	chr6:28176188~28176674:+
THCA	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	6.38	4.29e-10	9.65e-08	0.37	0.28	Depression;	chr6:28379168	chr6:28176188~28176674:+
THCA	cis	rs4835473	0.715	rs1849124	ENSG00000251600.4	RP11-673E1.1	6.38	4.29e-10	9.65e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143978494	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.689	rs1849123	ENSG00000251600.4	RP11-673E1.1	6.38	4.29e-10	9.65e-08	0.38	0.28	Immature fraction of reticulocytes;	chr4:143978495	chr4:143912331~143982454:+
THCA	cis	rs712022	0.967	rs11026800	ENSG00000246225.5	RP11-17A1.3	-6.38	4.3e-10	9.66e-08	-0.36	-0.28	Dialysis-related mortality;	chr11:22810859	chr11:22829380~22945393:+
THCA	cis	rs944990	0.618	rs7023577	ENSG00000227603.1	RP11-165J3.6	6.38	4.3e-10	9.66e-08	0.29	0.28	Body mass index;	chr9:93574711	chr9:93435332~93437121:-
THCA	cis	rs712022	0.837	rs2159668	ENSG00000246225.5	RP11-17A1.3	6.38	4.3e-10	9.67e-08	0.36	0.28	Dialysis-related mortality;	chr11:22817914	chr11:22829380~22945393:+
THCA	cis	rs28386778	0.897	rs2137144	ENSG00000240280.5	TCAM1P	-6.38	4.3e-10	9.67e-08	-0.39	-0.28	Prudent dietary pattern;	chr17:63728247	chr17:63849292~63864379:+
THCA	cis	rs4835473	0.838	rs10024263	ENSG00000251600.4	RP11-673E1.1	6.38	4.3e-10	9.67e-08	0.39	0.28	Immature fraction of reticulocytes;	chr4:144038174	chr4:143912331~143982454:+
THCA	cis	rs5742933	0.817	rs1055091	ENSG00000253559.1	OSGEPL1-AS1	6.38	4.3e-10	9.67e-08	0.32	0.28	Ferritin levels;	chr2:189770417	chr2:189762704~189765556:+
THCA	cis	rs7085104	0.66	rs3781286	ENSG00000236937.2	PTGES3P4	6.38	4.3e-10	9.67e-08	0.36	0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102845595~102845950:+
THCA	cis	rs4835473	0.932	rs12503900	ENSG00000251600.4	RP11-673E1.1	-6.38	4.31e-10	9.67e-08	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143812459	chr4:143912331~143982454:+
THCA	cis	rs853679	0.607	rs13194781	ENSG00000226314.6	ZNF192P1	-6.38	4.31e-10	9.68e-08	-0.62	-0.28	Depression;	chr6:27847861	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs36116761	ENSG00000226314.6	ZNF192P1	-6.38	4.31e-10	9.68e-08	-0.62	-0.28	Depression;	chr6:27850704	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs34194357	ENSG00000226314.6	ZNF192P1	-6.38	4.31e-10	9.68e-08	-0.62	-0.28	Depression;	chr6:27850757	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13199772	ENSG00000226314.6	ZNF192P1	-6.38	4.31e-10	9.68e-08	-0.62	-0.28	Depression;	chr6:27866307	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13199906	ENSG00000226314.6	ZNF192P1	-6.38	4.31e-10	9.68e-08	-0.62	-0.28	Depression;	chr6:27866361	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs17763089	ENSG00000226314.6	ZNF192P1	-6.38	4.31e-10	9.68e-08	-0.62	-0.28	Depression;	chr6:27867440	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs17695758	ENSG00000226314.6	ZNF192P1	-6.38	4.31e-10	9.68e-08	-0.62	-0.28	Depression;	chr6:27869405	chr6:28161781~28169594:+
THCA	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-6.38	4.31e-10	9.68e-08	-0.34	-0.28	AIDS;	chr2:105319955	chr2:105324210~105330529:+
THCA	cis	rs2554380	0.628	rs7179507	ENSG00000230373.7	GOLGA6L5P	-6.38	4.31e-10	9.68e-08	-0.3	-0.28	Height;	chr15:83804779	chr15:84507885~84516814:-
THCA	cis	rs9859260	0.744	rs406271	ENSG00000226155.1	AC124944.3	6.38	4.32e-10	9.7e-08	0.34	0.28	Mean corpuscular volume;	chr3:196050105	chr3:195912049~195913986:+
THCA	cis	rs438465	1	rs2997878	ENSG00000226194.4	RP1-137D17.1	6.38	4.32e-10	9.7e-08	0.42	0.28	Corneal astigmatism;	chr6:169483334	chr6:169369998~169388385:-
THCA	cis	rs227275	0.554	rs223367	ENSG00000251288.2	RP11-10L12.2	-6.38	4.32e-10	9.7e-08	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102751401~102752641:+
THCA	cis	rs2163813	1	rs247772	ENSG00000275540.1	CTC-559E9.12	-6.38	4.32e-10	9.7e-08	-0.34	-0.28	Toenail selenium levels;	chr19:19735649	chr19:19740884~19750127:+
THCA	cis	rs7617773	0.539	rs12486944	ENSG00000228638.1	FCF1P2	-6.38	4.32e-10	9.71e-08	-0.27	-0.28	Coronary artery disease;	chr3:48348526	chr3:48290793~48291375:-
THCA	cis	rs5751614	0.577	rs11090227	ENSG00000230701.2	FBXW4P1	6.38	4.33e-10	9.73e-08	0.3	0.28	Height;	chr22:23285436	chr22:23262767~23265005:+
THCA	cis	rs2243480	1	rs35396113	ENSG00000228409.4	CCT6P1	6.38	4.33e-10	9.73e-08	0.32	0.28	Diabetic kidney disease;	chr7:66030474	chr7:65751142~65763354:+
THCA	cis	rs28386778	1	rs2665851	ENSG00000240280.5	TCAM1P	-6.38	4.33e-10	9.73e-08	-0.39	-0.28	Prudent dietary pattern;	chr17:63879663	chr17:63849292~63864379:+
THCA	cis	rs990871	1	rs10889947	ENSG00000227207.2	RPL31P12	-6.38	4.33e-10	9.74e-08	-0.35	-0.28	Subcutaneous adipose tissue;	chr1:72362538	chr1:72301472~72301829:+
THCA	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-6.38	4.34e-10	9.74e-08	-0.36	-0.28	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
THCA	cis	rs934734	0.789	rs268122	ENSG00000234255.7	AC012370.3	-6.38	4.34e-10	9.74e-08	-0.32	-0.28	Rheumatoid arthritis;	chr2:65374975	chr2:65439888~65456571:-
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000229886.1	RP5-1132H15.3	6.38	4.34e-10	9.74e-08	0.47	0.28	Diabetic kidney disease;	chr7:66433290	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs58669269	ENSG00000229886.1	RP5-1132H15.3	6.38	4.34e-10	9.74e-08	0.47	0.28	Diabetic kidney disease;	chr7:66486966	chr7:66025126~66031544:-
THCA	cis	rs7225151	1	rs4456560	ENSG00000234327.6	AC012146.7	-6.38	4.34e-10	9.74e-08	-0.33	-0.28	Alzheimer's disease (late onset);	chr17:5237104	chr17:5111468~5115004:+
THCA	cis	rs17772222	0.958	rs74074098	ENSG00000258789.1	RP11-507K2.3	-6.38	4.34e-10	9.75e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88484213	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.876	rs12587528	ENSG00000258789.1	RP11-507K2.3	-6.38	4.34e-10	9.75e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88487652	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.916	rs77306894	ENSG00000258789.1	RP11-507K2.3	-6.38	4.34e-10	9.75e-08	-0.3	-0.28	Coronary artery calcification;	chr14:88494507	chr14:88551597~88552493:+
THCA	cis	rs2562456	0.833	rs516519	ENSG00000213976.4	CTD-2561J22.2	6.38	4.34e-10	9.75e-08	0.31	0.28	Pain;	chr19:21298730	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs552800	ENSG00000213976.4	CTD-2561J22.2	6.38	4.34e-10	9.75e-08	0.31	0.28	Pain;	chr19:21301840	chr19:21382865~21387177:+
THCA	cis	rs7586673	0.964	rs34444368	ENSG00000235724.7	AC009299.2	-6.38	4.34e-10	9.75e-08	-0.31	-0.28	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161222785~161308303:-
THCA	cis	rs1552244	0.572	rs6785976	ENSG00000232901.1	CYCSP10	6.38	4.34e-10	9.76e-08	0.42	0.28	Alzheimer's disease;	chr3:10126963	chr3:10000647~10000940:-
THCA	cis	rs6142102	0.812	rs4911375	ENSG00000275784.1	RP5-1125A11.6	-6.38	4.35e-10	9.77e-08	-0.29	-0.28	Skin pigmentation;	chr20:33928216	chr20:33989480~33991818:-
THCA	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-6.38	4.35e-10	9.77e-08	-0.32	-0.28	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
THCA	cis	rs2439831	0.867	rs6493085	ENSG00000249839.1	AC011330.5	-6.38	4.35e-10	9.78e-08	-0.43	-0.28	Lung cancer in ever smokers;	chr15:43361984	chr15:43663654~43684339:-
THCA	cis	rs8027521	0.54	rs61693599	ENSG00000280362.1	RP11-643A5.3	6.38	4.35e-10	9.78e-08	0.35	0.28	Circulating chemerin levels;	chr15:53944045	chr15:53910769~53914712:+
THCA	cis	rs934734	0.752	rs1876518	ENSG00000234255.7	AC012370.3	-6.38	4.35e-10	9.78e-08	-0.32	-0.28	Rheumatoid arthritis;	chr2:65381775	chr2:65439888~65456571:-
THCA	cis	rs224278	0.604	rs1040875	ENSG00000238280.1	RP11-436D10.3	-6.38	4.36e-10	9.79e-08	-0.34	-0.28	Ewing sarcoma;	chr10:62828449	chr10:62793562~62805887:-
THCA	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-6.38	4.36e-10	9.79e-08	-0.28	-0.28	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
THCA	cis	rs11148252	0.532	rs9536185	ENSG00000273784.3	RP11-78J21.7	-6.38	4.36e-10	9.79e-08	-0.31	-0.28	Lewy body disease;	chr13:52605666	chr13:52600042~52642542:+
THCA	cis	rs2562456	0.793	rs279807	ENSG00000268555.1	RP11-678G14.3	6.38	4.36e-10	9.8e-08	0.46	0.28	Pain;	chr19:21283020	chr19:21570822~21587322:-
THCA	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-6.38	4.37e-10	9.8e-08	-0.26	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
THCA	cis	rs4835473	0.932	rs13103072	ENSG00000251600.4	RP11-673E1.1	-6.38	4.37e-10	9.8e-08	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143952116	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs28609839	ENSG00000251600.4	RP11-673E1.1	-6.38	4.37e-10	9.8e-08	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143954160	chr4:143912331~143982454:+
THCA	cis	rs72843506	0.656	rs79406817	ENSG00000270091.1	RP11-78O7.2	-6.38	4.37e-10	9.81e-08	-0.33	-0.28	Schizophrenia;	chr17:20011814	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs77090106	ENSG00000270091.1	RP11-78O7.2	-6.38	4.37e-10	9.81e-08	-0.33	-0.28	Schizophrenia;	chr17:20044832	chr17:19896590~19897287:-
THCA	cis	rs4835473	0.797	rs34585546	ENSG00000251600.4	RP11-673E1.1	-6.38	4.37e-10	9.82e-08	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143680693	chr4:143912331~143982454:+
THCA	cis	rs7267979	0.816	rs443009	ENSG00000274414.1	RP5-965G21.4	6.37	4.38e-10	9.83e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25239007~25245229:-
THCA	cis	rs79349575	0.756	rs2291726	ENSG00000248278.1	SUMO2P17	-6.37	4.38e-10	9.83e-08	-0.33	-0.28	Type 2 diabetes;	chr17:48961892	chr17:48874860~48908983:-
THCA	cis	rs934734	0.752	rs1039764	ENSG00000234255.7	AC012370.3	-6.37	4.38e-10	9.84e-08	-0.32	-0.28	Rheumatoid arthritis;	chr2:65387479	chr2:65439888~65456571:-
THCA	cis	rs831571	0.876	rs56363381	ENSG00000280620.1	SCAANT1	6.37	4.38e-10	9.84e-08	0.48	0.28	Type 2 diabetes;	chr3:64071001	chr3:63911518~63911772:-
THCA	cis	rs9834975	0.935	rs10045	ENSG00000272758.4	RP11-299J3.8	-6.37	4.38e-10	9.84e-08	-0.26	-0.28	Diastolic blood pressure;	chr3:122426105	chr3:122416207~122443180:+
THCA	cis	rs17594362	0.697	rs1887743	ENSG00000264190.1	MIR5006	6.37	4.39e-10	9.86e-08	0.38	0.28	Multiple sclerosis;	chr13:41564073	chr13:41568286~41568395:-
THCA	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-6.37	4.39e-10	9.86e-08	-0.26	-0.28	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-6.37	4.39e-10	9.86e-08	-0.26	-0.28	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
THCA	cis	rs2018683	0.711	rs1874977	ENSG00000228421.2	AC005013.5	6.37	4.39e-10	9.86e-08	0.32	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928466	chr7:28957667~28959345:+
THCA	cis	rs2243480	1	rs313820	ENSG00000229886.1	RP5-1132H15.3	6.37	4.39e-10	9.86e-08	0.44	0.28	Diabetic kidney disease;	chr7:66109479	chr7:66025126~66031544:-
THCA	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-6.37	4.39e-10	9.86e-08	-0.26	-0.28	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
THCA	cis	rs2274273	0.516	rs3759665	ENSG00000258413.1	RP11-665C16.6	-6.37	4.4e-10	9.87e-08	-0.38	-0.28	Protein biomarker;	chr14:54904887	chr14:55262767~55272075:-
THCA	cis	rs7811142	1	rs6979335	ENSG00000078319.8	PMS2P1	-6.37	4.4e-10	9.87e-08	-0.41	-0.28	Platelet count;	chr7:100492237	chr7:100320992~100341908:-
THCA	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-6.37	4.4e-10	9.87e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
THCA	cis	rs2975734	0.676	rs4841299	ENSG00000261451.1	RP11-981G7.1	-6.37	4.4e-10	9.87e-08	-0.38	-0.28	Chronotype;Morning vs. evening chronotype;	chr8:10255083	chr8:10433672~10438312:+
THCA	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-6.37	4.4e-10	9.87e-08	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
THCA	cis	rs5758659	1	rs134873	ENSG00000182057.4	OGFRP1	6.37	4.4e-10	9.88e-08	0.32	0.28	Cognitive function;	chr22:42261560	chr22:42269753~42275196:+
THCA	cis	rs7267979	1	rs4815417	ENSG00000274414.1	RP5-965G21.4	6.37	4.4e-10	9.88e-08	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25239007~25245229:-
THCA	cis	rs9287719	0.649	rs10186984	ENSG00000243819.4	RN7SL832P	-6.37	4.4e-10	9.88e-08	-0.23	-0.28	Prostate cancer;	chr2:10594066	chr2:10690344~10692099:+
THCA	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	6.37	4.41e-10	9.89e-08	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
THCA	cis	rs6840360	0.681	rs4519779	ENSG00000251611.1	RP11-610P16.1	-6.37	4.41e-10	9.89e-08	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151407551~151408835:-
THCA	cis	rs35264875	1	rs35264875	ENSG00000259799.1	RP11-554A11.9	6.37	4.41e-10	9.9e-08	0.48	0.28	Blond vs. brown hair color;	chr11:69078931	chr11:69155910~69159752:+
THCA	cis	rs7568498	0.564	rs9287807	ENSG00000227403.1	AC009299.3	6.37	4.42e-10	9.91e-08	0.36	0.28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161244739~161249050:+
THCA	cis	rs7246657	1	rs34544865	ENSG00000276846.1	CTD-3220F14.3	6.37	4.42e-10	9.91e-08	0.3	0.28	Coronary artery calcification;	chr19:37310340	chr19:37314868~37315620:-
THCA	cis	rs11051970	0.659	rs904917	ENSG00000274964.1	RP11-817I4.1	-6.37	4.42e-10	9.92e-08	-0.34	-0.28	Response to tocilizumab in rheumatoid arthritis;	chr12:32438368	chr12:32339368~32340724:+
THCA	cis	rs10899021	0.79	rs7932194	ENSG00000279353.1	RP11-864N7.4	6.37	4.42e-10	9.93e-08	0.55	0.28	Response to metformin (IC50);	chr11:74616333	chr11:74698231~74699658:-
THCA	cis	rs7617773	0.925	rs7374376	ENSG00000228638.1	FCF1P2	6.37	4.43e-10	9.93e-08	0.27	0.28	Coronary artery disease;	chr3:48131197	chr3:48290793~48291375:-
THCA	cis	rs4689592	0.503	rs3857180	ENSG00000245468.3	RP11-367J11.3	-6.37	4.43e-10	9.93e-08	-0.26	-0.28	Monocyte percentage of white cells;	chr4:7072172	chr4:7094571~7103385:-
THCA	cis	rs16949788	0.826	rs74245473	ENSG00000261351.2	CTD-3185P2.1	-6.37	4.43e-10	9.94e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66416437	chr15:66488658~66492109:-
THCA	cis	rs4143844	0.867	rs12905103	ENSG00000259251.2	RP11-643M14.1	6.37	4.44e-10	9.95e-08	0.54	0.28	Bipolar disorder and schizophrenia;	chr15:61940083	chr15:62060503~62062434:+
THCA	cis	rs7615952	0.932	rs13065725	ENSG00000241288.6	RP11-379B18.5	-6.37	4.44e-10	9.96e-08	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125913446	chr3:125827238~125916384:-
THCA	cis	rs12681366	0.614	rs2919663	ENSG00000253704.1	RP11-267M23.4	6.37	4.45e-10	9.97e-08	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94457918	chr8:94553722~94569745:+
THCA	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	6.37	4.45e-10	9.98e-08	0.43	0.28	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
THCA	cis	rs73607972	0.935	rs6499628	ENSG00000275191.1	RP11-36I17.2	-6.37	4.46e-10	1e-07	-0.42	-0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53570265	chr16:53628256~53628816:-
THCA	cis	rs2243480	1	rs781156	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	1e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs451396	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	1e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1715235	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	1e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66848496~66858136:+
THCA	cis	rs5758659	0.714	rs5758574	ENSG00000270083.1	RP1-257I20.14	-6.37	4.46e-10	1e-07	-0.3	-0.28	Cognitive function;	chr22:42085396	chr22:42089630~42090028:-
THCA	cis	rs922182	0.569	rs7180050	ENSG00000275785.1	RP11-111E14.2	6.37	4.47e-10	1e-07	0.32	0.28	Blood protein levels;	chr15:63971585	chr15:63890030~63890317:+
THCA	cis	rs922182	0.542	rs7179912	ENSG00000275785.1	RP11-111E14.2	6.37	4.47e-10	1e-07	0.32	0.28	Blood protein levels;	chr15:63971655	chr15:63890030~63890317:+
THCA	cis	rs60180747	0.544	rs11633808	ENSG00000261318.1	RP11-653J6.1	6.37	4.47e-10	1e-07	0.38	0.28	Testicular germ cell tumor;	chr15:66275773	chr15:66278498~66293357:-
THCA	cis	rs9487094	1	rs9480955	ENSG00000260273.1	RP11-425D10.10	6.37	4.47e-10	1e-07	0.35	0.28	Height;	chr6:109423330	chr6:109382795~109383666:+
THCA	cis	rs9487094	1	rs9320287	ENSG00000260273.1	RP11-425D10.10	6.37	4.47e-10	1e-07	0.35	0.28	Height;	chr6:109423487	chr6:109382795~109383666:+
THCA	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	6.37	4.48e-10	1e-07	0.34	0.28	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
THCA	cis	rs9926296	0.533	rs7190823	ENSG00000260259.1	RP11-368I7.4	-6.37	4.48e-10	1e-07	-0.3	-0.28	Vitiligo;	chr16:89799635	chr16:89682620~89686569:-
THCA	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	6.37	4.48e-10	1.01e-07	0.25	0.28	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
THCA	cis	rs7221109	0.711	rs9889953	ENSG00000278834.1	RP11-458J1.1	6.37	4.5e-10	1.01e-07	0.3	0.28	Type 1 diabetes;	chr17:40598548	chr17:40648300~40649718:+
THCA	cis	rs2797160	0.651	rs6569436	ENSG00000237742.5	RP11-624M8.1	6.37	4.5e-10	1.01e-07	0.25	0.28	Endometrial cancer;	chr6:125710958	chr6:125578558~125749190:-
THCA	cis	rs4835473	0.932	rs11730929	ENSG00000251600.4	RP11-673E1.1	-6.37	4.5e-10	1.01e-07	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143834795	chr4:143912331~143982454:+
THCA	cis	rs944990	0.557	rs7019001	ENSG00000227603.1	RP11-165J3.6	6.37	4.5e-10	1.01e-07	0.29	0.28	Body mass index;	chr9:93528942	chr9:93435332~93437121:-
THCA	cis	rs944990	0.557	rs13292712	ENSG00000227603.1	RP11-165J3.6	6.37	4.5e-10	1.01e-07	0.29	0.28	Body mass index;	chr9:93534438	chr9:93435332~93437121:-
THCA	cis	rs28386778	0.863	rs9897229	ENSG00000240280.5	TCAM1P	-6.37	4.5e-10	1.01e-07	-0.39	-0.28	Prudent dietary pattern;	chr17:63704965	chr17:63849292~63864379:+
THCA	cis	rs16846053	0.534	rs1227926	ENSG00000227403.1	AC009299.3	6.37	4.51e-10	1.01e-07	0.47	0.28	Blood osmolality (transformed sodium);	chr2:161827383	chr2:161244739~161249050:+
THCA	cis	rs17772222	0.839	rs2274735	ENSG00000258983.2	RP11-507K2.2	6.37	4.51e-10	1.01e-07	0.32	0.28	Coronary artery calcification;	chr14:88505414	chr14:88499334~88515502:+
THCA	cis	rs7942368	0.887	rs10899282	ENSG00000204529.3	GUCY2EP	6.37	4.51e-10	1.01e-07	0.4	0.28	Endometriosis;	chr11:76793654	chr11:76694043~76707641:-
THCA	cis	rs10266483	0.545	rs1812912	ENSG00000271550.1	BNIP3P11	-6.37	4.53e-10	1.01e-07	-0.43	-0.28	Response to statin therapy;	chr7:64282891	chr7:64678954~64687393:-
THCA	cis	rs34779708	0.733	rs7083266	ENSG00000271335.4	RP11-324I22.4	6.37	4.53e-10	1.01e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35314552~35336401:-
THCA	cis	rs6903823	0.508	rs1150726	ENSG00000219392.1	RP1-265C24.5	-6.37	4.53e-10	1.01e-07	-0.31	-0.28	Pulmonary function;	chr6:28275265	chr6:28115628~28116551:+
THCA	cis	rs2243480	0.901	rs778732	ENSG00000232546.1	RP11-458F8.1	-6.37	4.53e-10	1.02e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66357373	chr7:66848496~66858136:+
THCA	cis	rs1552244	0.572	rs57268864	ENSG00000232901.1	CYCSP10	6.37	4.53e-10	1.02e-07	0.43	0.28	Alzheimer's disease;	chr3:10122549	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs59074548	ENSG00000232901.1	CYCSP10	6.37	4.53e-10	1.02e-07	0.43	0.28	Alzheimer's disease;	chr3:10122663	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs3774208	ENSG00000232901.1	CYCSP10	6.37	4.53e-10	1.02e-07	0.43	0.28	Alzheimer's disease;	chr3:10123038	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs6783705	ENSG00000232901.1	CYCSP10	6.37	4.53e-10	1.02e-07	0.43	0.28	Alzheimer's disease;	chr3:10123099	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs68013239	ENSG00000232901.1	CYCSP10	6.37	4.53e-10	1.02e-07	0.43	0.28	Alzheimer's disease;	chr3:10124027	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs68121641	ENSG00000232901.1	CYCSP10	6.37	4.53e-10	1.02e-07	0.43	0.28	Alzheimer's disease;	chr3:10124161	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.515	rs67342818	ENSG00000232901.1	CYCSP10	6.37	4.53e-10	1.02e-07	0.43	0.28	Alzheimer's disease;	chr3:10124722	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs66514627	ENSG00000232901.1	CYCSP10	6.37	4.53e-10	1.02e-07	0.43	0.28	Alzheimer's disease;	chr3:10124948	chr3:10000647~10000940:-
THCA	cis	rs7927592	0.763	rs7129248	ENSG00000212093.1	AP000807.1	6.37	4.54e-10	1.02e-07	0.29	0.28	Total body bone mineral density;	chr11:68495808	chr11:68506083~68506166:-
THCA	cis	rs9859260	0.71	rs41298097	ENSG00000226155.1	AC124944.3	6.37	4.54e-10	1.02e-07	0.34	0.28	Mean corpuscular volume;	chr3:196052284	chr3:195912049~195913986:+
THCA	cis	rs9859260	0.744	rs557527	ENSG00000226155.1	AC124944.3	6.37	4.54e-10	1.02e-07	0.34	0.28	Mean corpuscular volume;	chr3:196053838	chr3:195912049~195913986:+
THCA	cis	rs10875746	0.669	rs11168516	ENSG00000269514.1	RP11-370I10.12	6.37	4.54e-10	1.02e-07	0.28	0.28	Longevity (90 years and older);	chr12:48308282	chr12:48198387~48202031:+
THCA	cis	rs11154801	0.732	rs13202115	ENSG00000231028.7	LINC00271	-6.37	4.54e-10	1.02e-07	-0.23	-0.28	Multiple sclerosis;	chr6:135604386	chr6:135497801~135716055:+
THCA	cis	rs4143844	1	rs12911422	ENSG00000259251.2	RP11-643M14.1	6.37	4.54e-10	1.02e-07	0.54	0.28	Bipolar disorder and schizophrenia;	chr15:62035935	chr15:62060503~62062434:+
THCA	cis	rs10844706	0.699	rs10844627	ENSG00000256594.6	RP11-705C15.2	6.37	4.54e-10	1.02e-07	0.24	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733781	chr12:9633419~9658412:+
THCA	cis	rs10844706	0.699	rs10844632	ENSG00000256594.6	RP11-705C15.2	6.37	4.54e-10	1.02e-07	0.24	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734309	chr12:9633419~9658412:+
THCA	cis	rs890448	0.726	rs2583396	ENSG00000254531.1	FLJ20021	-6.37	4.55e-10	1.02e-07	-0.25	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101308621	chr4:101347780~101348883:+
THCA	cis	rs7617773	0.539	rs12486935	ENSG00000228638.1	FCF1P2	-6.37	4.55e-10	1.02e-07	-0.27	-0.28	Coronary artery disease;	chr3:48348674	chr3:48290793~48291375:-
THCA	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-6.37	4.55e-10	1.02e-07	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
THCA	cis	rs35264875	1	rs72919409	ENSG00000259799.1	RP11-554A11.9	6.37	4.55e-10	1.02e-07	0.49	0.28	Blond vs. brown hair color;	chr11:69059085	chr11:69155910~69159752:+
THCA	cis	rs728616	0.867	rs61860034	ENSG00000242600.5	MBL1P	6.37	4.55e-10	1.02e-07	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79904898~79950336:+
THCA	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	6.37	4.55e-10	1.02e-07	0.33	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
THCA	cis	rs7267979	0.789	rs4815429	ENSG00000274414.1	RP5-965G21.4	6.37	4.56e-10	1.02e-07	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25239007~25245229:-
THCA	cis	rs11154801	0.589	rs6924066	ENSG00000231028.7	LINC00271	-6.37	4.57e-10	1.02e-07	-0.23	-0.28	Multiple sclerosis;	chr6:135598006	chr6:135497801~135716055:+
THCA	cis	rs4713118	0.699	rs200969	ENSG00000226314.6	ZNF192P1	-6.37	4.57e-10	1.02e-07	-0.37	-0.28	Parkinson's disease;	chr6:27891675	chr6:28161781~28169594:+
THCA	cis	rs12908161	0.959	rs11637728	ENSG00000259295.5	CSPG4P12	6.37	4.57e-10	1.02e-07	0.43	0.28	Schizophrenia;	chr15:84660161	chr15:85191438~85213905:+
THCA	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	6.37	4.57e-10	1.02e-07	0.29	0.28	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
THCA	cis	rs2292342	1	rs11880333	ENSG00000232871.7	SEC1P	-6.37	4.57e-10	1.02e-07	-0.52	-0.28	Elevated serum carcinoembryonic antigen levels;	chr19:48641533	chr19:48638071~48682245:+
THCA	cis	rs10129255	0.957	rs6576233	ENSG00000211974.3	IGHV2-70	6.37	4.58e-10	1.02e-07	0.22	0.28	Kawasaki disease;	chr14:106787239	chr14:106723574~106724093:-
THCA	cis	rs1552244	0.816	rs13059144	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9968513	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs66559400	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9970867	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs68153882	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9971426	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs35056669	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9972487	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs3732967	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9973753	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs3732966	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9974056	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs13062917	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9975348	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.816	rs13076197	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9978089	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs34779351	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9980117	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs13077641	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9981251	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs13074282	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9983015	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.882	rs67895180	ENSG00000232901.1	CYCSP10	6.37	4.58e-10	1.02e-07	0.36	0.28	Alzheimer's disease;	chr3:9984395	chr3:10000647~10000940:-
THCA	cis	rs6545883	0.868	rs2441381	ENSG00000271889.1	RP11-493E12.1	6.37	4.58e-10	1.03e-07	0.27	0.28	Tuberculosis;	chr2:61571694	chr2:61151433~61162105:-
THCA	cis	rs7267979	0.844	rs869358	ENSG00000274414.1	RP5-965G21.4	6.37	4.58e-10	1.03e-07	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25239007~25245229:-
THCA	cis	rs9311474	1	rs6445358	ENSG00000243224.1	RP5-1157M23.2	-6.37	4.58e-10	1.03e-07	-0.29	-0.28	Electroencephalogram traits;	chr3:52274829	chr3:52239258~52241097:+
THCA	cis	rs860295	0.65	rs12024880	ENSG00000225855.5	RUSC1-AS1	-6.37	4.58e-10	1.03e-07	-0.18	-0.28	Body mass index;	chr1:155939119	chr1:155316863~155324176:-
THCA	cis	rs7746199	0.736	rs72845070	ENSG00000219392.1	RP1-265C24.5	-6.37	4.58e-10	1.03e-07	-0.68	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28115628~28116551:+
THCA	cis	rs12534093	0.562	rs66797912	ENSG00000234286.1	AC006026.13	-6.37	4.59e-10	1.03e-07	-0.37	-0.28	Infant length;Height;	chr7:23537569	chr7:23680195~23680786:-
THCA	cis	rs10875746	0.669	rs4760701	ENSG00000269514.1	RP11-370I10.12	6.37	4.59e-10	1.03e-07	0.28	0.28	Longevity (90 years and older);	chr12:48304735	chr12:48198387~48202031:+
THCA	cis	rs1552244	0.515	rs111560858	ENSG00000232901.1	CYCSP10	6.37	4.59e-10	1.03e-07	0.43	0.28	Alzheimer's disease;	chr3:10125161	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs17032426	ENSG00000232901.1	CYCSP10	6.37	4.59e-10	1.03e-07	0.43	0.28	Alzheimer's disease;	chr3:10125428	chr3:10000647~10000940:-
THCA	cis	rs2348418	0.832	rs1552761	ENSG00000247934.4	RP11-967K21.1	6.37	4.59e-10	1.03e-07	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28383406	chr12:28163298~28190738:-
THCA	cis	rs6840258	0.723	rs340642	ENSG00000251411.1	RP11-397E7.4	6.37	4.6e-10	1.03e-07	0.31	0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87028261	chr4:86913266~86914817:-
THCA	cis	rs28386778	0.787	rs2665827	ENSG00000240280.5	TCAM1P	-6.37	4.6e-10	1.03e-07	-0.4	-0.28	Prudent dietary pattern;	chr17:63883990	chr17:63849292~63864379:+
THCA	cis	rs11158026	0.757	rs10150110	ENSG00000258413.1	RP11-665C16.6	-6.37	4.6e-10	1.03e-07	-0.39	-0.28	Parkinson's disease;	chr14:54995292	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.757	rs7153937	ENSG00000258413.1	RP11-665C16.6	-6.37	4.6e-10	1.03e-07	-0.39	-0.28	Parkinson's disease;	chr14:55004157	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.722	rs2840268	ENSG00000258413.1	RP11-665C16.6	-6.37	4.6e-10	1.03e-07	-0.39	-0.28	Parkinson's disease;	chr14:55005265	chr14:55262767~55272075:-
THCA	cis	rs5742933	0.817	rs1233297	ENSG00000273240.1	RP11-455J20.3	-6.37	4.61e-10	1.03e-07	-0.29	-0.28	Ferritin levels;	chr2:189829449	chr2:189763859~189764456:-
THCA	cis	rs2915864	0.704	rs2906084	ENSG00000280047.1	CTC-463A16.1	-6.37	4.61e-10	1.03e-07	-0.43	-0.28	Facial morphology (factor 20);	chr5:142161591	chr5:142165767~142168387:+
THCA	cis	rs73607972	0.736	rs73614566	ENSG00000275191.1	RP11-36I17.2	-6.37	4.61e-10	1.03e-07	-0.49	-0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53529415	chr16:53628256~53628816:-
THCA	cis	rs6928977	0.897	rs2246852	ENSG00000231028.7	LINC00271	6.37	4.62e-10	1.03e-07	0.24	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370654	chr6:135497801~135716055:+
THCA	cis	rs897984	0.542	rs7197717	ENSG00000279196.1	RP11-1072A3.3	6.37	4.62e-10	1.03e-07	0.28	0.28	Dementia with Lewy bodies;	chr16:31071754	chr16:30984630~30988270:-
THCA	cis	rs11915082	0.686	rs7349507	ENSG00000226155.1	AC124944.3	-6.37	4.62e-10	1.03e-07	-0.35	-0.28	Mean corpuscular hemoglobin;	chr3:196059617	chr3:195912049~195913986:+
THCA	cis	rs6545883	0.894	rs2600660	ENSG00000271889.1	RP11-493E12.1	-6.37	4.64e-10	1.04e-07	-0.27	-0.28	Tuberculosis;	chr2:61322465	chr2:61151433~61162105:-
THCA	cis	rs34779708	0.733	rs16935948	ENSG00000271335.4	RP11-324I22.4	6.37	4.64e-10	1.04e-07	0.28	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35314552~35336401:-
THCA	cis	rs6088580	0.543	rs4911158	ENSG00000269202.1	RP4-614O4.12	6.37	4.64e-10	1.04e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34651708	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.524	rs1853056	ENSG00000269202.1	RP4-614O4.12	6.37	4.64e-10	1.04e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34674254	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.524	rs6087616	ENSG00000269202.1	RP4-614O4.12	6.37	4.64e-10	1.04e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34675229	chr20:35201747~35203288:-
THCA	cis	rs71403859	0.504	rs35203704	ENSG00000260886.1	TAT-AS1	6.37	4.65e-10	1.04e-07	0.55	0.28	Post bronchodilator FEV1;	chr16:71925758	chr16:71565789~71578187:+
THCA	cis	rs71403859	0.504	rs12926413	ENSG00000260886.1	TAT-AS1	6.37	4.65e-10	1.04e-07	0.55	0.28	Post bronchodilator FEV1;	chr16:71938422	chr16:71565789~71578187:+
THCA	cis	rs2243480	0.908	rs313822	ENSG00000229886.1	RP5-1132H15.3	6.36	4.65e-10	1.04e-07	0.44	0.28	Diabetic kidney disease;	chr7:66108952	chr7:66025126~66031544:-
THCA	cis	rs2915864	1	rs2915864	ENSG00000280047.1	CTC-463A16.1	-6.36	4.65e-10	1.04e-07	-0.43	-0.28	Facial morphology (factor 20);	chr5:142173642	chr5:142165767~142168387:+
THCA	cis	rs9595908	0.965	rs7335710	ENSG00000212293.1	SNORA16	6.36	4.65e-10	1.04e-07	0.33	0.28	Body mass index;	chr13:32561287	chr13:32420390~32420516:-
THCA	cis	rs9990333	0.622	rs57783901	ENSG00000231464.1	AC024937.4	6.36	4.66e-10	1.04e-07	0.35	0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195996738~195998233:+
THCA	cis	rs7927592	0.731	rs488381	ENSG00000212093.1	AP000807.1	-6.36	4.66e-10	1.04e-07	-0.29	-0.28	Total body bone mineral density;	chr11:68524225	chr11:68506083~68506166:-
THCA	cis	rs467650	0.517	rs27021	ENSG00000246763.5	RGMB-AS1	6.36	4.67e-10	1.04e-07	0.28	0.28	Venous thromboembolism (SNP x SNP interaction);	chr5:98610412	chr5:98769618~98773469:-
THCA	cis	rs6860806	0.661	rs6890009	ENSG00000237714.1	P4HA2-AS1	6.36	4.67e-10	1.04e-07	0.36	0.28	Breast cancer;	chr5:132244340	chr5:132184876~132192808:+
THCA	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	6.36	4.67e-10	1.04e-07	0.34	0.28	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
THCA	cis	rs860295	0.615	rs656737	ENSG00000225855.5	RUSC1-AS1	-6.36	4.67e-10	1.05e-07	-0.18	-0.28	Body mass index;	chr1:155908104	chr1:155316863~155324176:-
THCA	cis	rs8027521	0.519	rs4776190	ENSG00000280362.1	RP11-643A5.3	6.36	4.67e-10	1.05e-07	0.35	0.28	Circulating chemerin levels;	chr15:53930831	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.54	rs4776191	ENSG00000280362.1	RP11-643A5.3	6.36	4.67e-10	1.05e-07	0.35	0.28	Circulating chemerin levels;	chr15:53931050	chr15:53910769~53914712:+
THCA	cis	rs1005277	0.522	rs289649	ENSG00000263064.2	RP11-291L22.7	6.36	4.68e-10	1.05e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38448689~38448949:+
THCA	cis	rs16976116	0.951	rs11857087	ENSG00000279145.1	RP11-547D13.1	6.36	4.68e-10	1.05e-07	0.28	0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55194983	chr15:55171972~55178175:-
THCA	cis	rs2276314	0.6	rs28729782	ENSG00000278986.1	RP11-723J4.3	-6.36	4.68e-10	1.05e-07	-0.29	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36010566	chr18:35972151~35973916:+
THCA	cis	rs3806843	1	rs10072015	ENSG00000202515.1	VTRNA1-3	6.36	4.68e-10	1.05e-07	0.32	0.28	Depressive symptoms (multi-trait analysis);	chr5:140791070	chr5:140726158~140726246:+
THCA	cis	rs7976269	0.609	rs7310276	ENSG00000257176.2	RP11-996F15.2	6.36	4.68e-10	1.05e-07	0.29	0.28	Male-pattern baldness;	chr12:29054128	chr12:29280418~29317848:-
THCA	cis	rs11148252	0.777	rs9535889	ENSG00000235660.1	LINC00345	-6.36	4.69e-10	1.05e-07	-0.36	-0.28	Lewy body disease;	chr13:52159499	chr13:52484161~52484680:-
THCA	cis	rs227275	0.554	rs223363	ENSG00000251288.2	RP11-10L12.2	-6.36	4.69e-10	1.05e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102751401~102752641:+
THCA	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	6.36	4.69e-10	1.05e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
THCA	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-6.36	4.7e-10	1.05e-07	-0.31	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
THCA	cis	rs9677476	0.909	rs7562116	ENSG00000224376.1	AC017104.6	6.36	4.7e-10	1.05e-07	0.33	0.28	Food antigen IgG levels;	chr2:231243533	chr2:231388976~231394991:+
THCA	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	6.36	4.7e-10	1.05e-07	0.44	0.28	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
THCA	cis	rs2243480	1	rs313824	ENSG00000229886.1	RP5-1132H15.3	6.36	4.7e-10	1.05e-07	0.44	0.28	Diabetic kidney disease;	chr7:66116220	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs186378	ENSG00000229886.1	RP5-1132H15.3	6.36	4.7e-10	1.05e-07	0.44	0.28	Diabetic kidney disease;	chr7:66117071	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs160637	ENSG00000229886.1	RP5-1132H15.3	6.36	4.7e-10	1.05e-07	0.44	0.28	Diabetic kidney disease;	chr7:66119331	chr7:66025126~66031544:-
THCA	cis	rs227275	0.554	rs223454	ENSG00000251288.2	RP11-10L12.2	-6.36	4.7e-10	1.05e-07	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102751401~102752641:+
THCA	cis	rs2243480	1	rs316327	ENSG00000229886.1	RP5-1132H15.3	-6.36	4.71e-10	1.05e-07	-0.45	-0.28	Diabetic kidney disease;	chr7:66144214	chr7:66025126~66031544:-
THCA	cis	rs10266483	0.661	rs608769	ENSG00000227986.1	TRIM60P18	-6.36	4.71e-10	1.05e-07	-0.24	-0.28	Response to statin therapy;	chr7:64292783	chr7:64355078~64356199:+
THCA	cis	rs5758511	0.68	rs5758698	ENSG00000281538.1	RP4-669P10.20	-6.36	4.71e-10	1.05e-07	-0.31	-0.28	Birth weight;	chr22:42288812	chr22:42138060~42139726:+
THCA	cis	rs4780355	0.877	rs243317	ENSG00000262703.1	RP11-485G7.6	-6.36	4.71e-10	1.05e-07	-0.33	-0.28	Crohn's disease and psoriasis;	chr16:11263474	chr16:11348143~11349321:-
THCA	cis	rs7202877	0.706	rs4993971	ENSG00000261783.1	RP11-252K23.2	6.36	4.72e-10	1.05e-07	0.49	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75377736	chr16:75379818~75381260:-
THCA	cis	rs7085104	0.7	rs10883785	ENSG00000236937.2	PTGES3P4	6.36	4.72e-10	1.05e-07	0.36	0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102845595~102845950:+
THCA	cis	rs1552244	0.882	rs67631672	ENSG00000232901.1	CYCSP10	6.36	4.72e-10	1.06e-07	0.35	0.28	Alzheimer's disease;	chr3:9963084	chr3:10000647~10000940:-
THCA	cis	rs797680	0.856	rs602204	ENSG00000223745.6	RP4-717I23.3	-6.36	4.72e-10	1.06e-07	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93262022	chr1:93262186~93346025:-
THCA	cis	rs9475752	0.947	rs17685185	ENSG00000231441.1	RP11-472M19.2	6.36	4.72e-10	1.06e-07	0.34	0.28	Menarche (age at onset);	chr6:56926807	chr6:56844002~56864078:+
THCA	cis	rs6486730	1	rs7953661	ENSG00000274695.1	RP11-21K12.3	-6.36	4.72e-10	1.06e-07	-0.34	-0.28	Systemic lupus erythematosus;	chr12:128791278	chr12:128826836~128827579:+
THCA	cis	rs6860806	0.507	rs156322	ENSG00000263597.1	MIR3936	6.36	4.73e-10	1.06e-07	0.28	0.28	Breast cancer;	chr5:132318232	chr5:132365490~132365599:-
THCA	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-6.36	4.73e-10	1.06e-07	-0.41	-0.28	Pain;	chr19:21513185	chr19:21554640~21569237:-
THCA	cis	rs4934494	0.588	rs2026554	ENSG00000232936.4	RP11-80H5.2	6.36	4.73e-10	1.06e-07	0.37	0.28	Red blood cell count;	chr10:89829699	chr10:89645282~89650667:+
THCA	cis	rs227275	0.527	rs223308	ENSG00000230069.3	LRRC37A15P	-6.36	4.73e-10	1.06e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102727274~102730721:-
THCA	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	6.36	4.73e-10	1.06e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
THCA	cis	rs728616	0.717	rs17098169	ENSG00000242600.5	MBL1P	-6.36	4.73e-10	1.06e-07	-0.38	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:79904898~79950336:+
THCA	cis	rs12908161	1	rs12908161	ENSG00000259295.5	CSPG4P12	6.36	4.74e-10	1.06e-07	0.43	0.28	Schizophrenia;	chr15:84664594	chr15:85191438~85213905:+
THCA	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	6.36	4.74e-10	1.06e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	6.36	4.74e-10	1.06e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	6.36	4.74e-10	1.06e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	6.36	4.74e-10	1.06e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	6.36	4.74e-10	1.06e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	6.36	4.74e-10	1.06e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000273009.1	RP11-352G9.1	-6.36	4.74e-10	1.06e-07	-0.35	-0.28	Pancreatic cancer;	chr3:196025182	chr3:195913078~195913683:-
THCA	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-6.36	4.75e-10	1.06e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
THCA	cis	rs4713118	0.662	rs175954	ENSG00000220721.1	OR1F12	6.36	4.76e-10	1.06e-07	0.37	0.28	Parkinson's disease;	chr6:28043807	chr6:28073316~28074233:+
THCA	cis	rs1005277	0.563	rs2505215	ENSG00000276805.1	RP11-291L22.6	6.36	4.76e-10	1.06e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.563	rs2505216	ENSG00000276805.1	RP11-291L22.6	6.36	4.76e-10	1.06e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2749612	ENSG00000276805.1	RP11-291L22.6	6.36	4.76e-10	1.06e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38451030~38451785:+
THCA	cis	rs34779708	0.832	rs6481946	ENSG00000230534.5	RP11-297A16.2	6.36	4.76e-10	1.06e-07	0.33	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35098006~35127020:-
THCA	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	6.36	4.76e-10	1.06e-07	0.29	0.28	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
THCA	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-6.36	4.76e-10	1.06e-07	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
THCA	cis	rs8062405	0.755	rs4788073	ENSG00000278665.1	RP11-666O2.4	6.36	4.77e-10	1.06e-07	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28599241~28601881:-
THCA	cis	rs8113308	0.515	rs55866828	ENSG00000269235.1	ZNF350-AS1	6.36	4.77e-10	1.06e-07	0.53	0.28	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938332	chr19:51949134~51981367:+
THCA	cis	rs5758659	0.819	rs134871	ENSG00000281538.1	RP4-669P10.20	6.36	4.77e-10	1.07e-07	0.25	0.28	Cognitive function;	chr22:42256710	chr22:42138060~42139726:+
THCA	cis	rs2243480	1	rs1964692	ENSG00000232546.1	RP11-458F8.1	-6.36	4.77e-10	1.07e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65989196	chr7:66848496~66858136:+
THCA	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	6.36	4.78e-10	1.07e-07	0.41	0.28	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
THCA	cis	rs7044106	0.718	rs10616	ENSG00000270917.1	RP11-27I1.6	-6.36	4.78e-10	1.07e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120812475~120812845:-
THCA	cis	rs56114371	0.53	rs2056923	ENSG00000280107.1	AL022393.9	-6.36	4.78e-10	1.07e-07	-0.39	-0.28	Breast cancer;	chr6:27722160	chr6:28170845~28172521:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000206090.4	AP000350.7	6.36	4.78e-10	1.07e-07	0.36	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23939998~23942798:+
THCA	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-6.36	4.78e-10	1.07e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-6.36	4.78e-10	1.07e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
THCA	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-6.36	4.79e-10	1.07e-07	-0.47	-0.28	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
THCA	cis	rs7829975	0.591	rs12677543	ENSG00000254153.1	CTA-398F10.2	-6.36	4.79e-10	1.07e-07	-0.3	-0.28	Mood instability;	chr8:8786764	chr8:8456909~8461337:-
THCA	cis	rs5758659	0.714	rs2284087	ENSG00000270083.1	RP1-257I20.14	-6.36	4.79e-10	1.07e-07	-0.3	-0.28	Cognitive function;	chr22:42089667	chr22:42089630~42090028:-
THCA	cis	rs1043099	0.556	rs5997642	ENSG00000279699.1	RP1-102K2.9	-6.36	4.81e-10	1.07e-07	-0.33	-0.28	Rheumatoid arthritis;	chr22:30416560	chr22:30275215~30276951:-
THCA	cis	rs950169	0.84	rs62019457	ENSG00000259295.5	CSPG4P12	6.36	4.81e-10	1.07e-07	0.43	0.28	Schizophrenia;	chr15:84558911	chr15:85191438~85213905:+
THCA	cis	rs950169	0.922	rs67804993	ENSG00000259295.5	CSPG4P12	6.36	4.81e-10	1.07e-07	0.43	0.28	Schizophrenia;	chr15:84560799	chr15:85191438~85213905:+
THCA	cis	rs4805272	0.759	rs1030099	ENSG00000267799.1	MAN1A2P1	-6.36	4.81e-10	1.07e-07	-0.3	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28852709	chr19:28790812~28792871:-
THCA	cis	rs10208649	0.908	rs7559651	ENSG00000233266.1	HMGB1P31	6.36	4.81e-10	1.07e-07	0.66	0.28	Body mass index;	chr2:53981801	chr2:54051334~54051760:+
THCA	cis	rs728616	0.867	rs4633405	ENSG00000242600.5	MBL1P	6.36	4.83e-10	1.08e-07	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79904898~79950336:+
THCA	cis	rs6840360	0.582	rs4696260	ENSG00000251611.1	RP11-610P16.1	-6.36	4.84e-10	1.08e-07	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151397772	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.515	rs11099811	ENSG00000251611.1	RP11-610P16.1	-6.36	4.84e-10	1.08e-07	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151399380	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.582	rs7691601	ENSG00000251611.1	RP11-610P16.1	-6.36	4.84e-10	1.08e-07	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151400479	chr4:151407551~151408835:-
THCA	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	6.36	4.84e-10	1.08e-07	0.35	0.28	Height;	chr6:109420812	chr6:109382795~109383666:+
THCA	cis	rs1005277	0.505	rs200931	ENSG00000263064.2	RP11-291L22.7	6.36	4.84e-10	1.08e-07	0.32	0.28	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:38448689~38448949:+
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000229886.1	RP5-1132H15.3	6.36	4.85e-10	1.08e-07	0.46	0.28	Diabetic kidney disease;	chr7:65924813	chr7:66025126~66031544:-
THCA	cis	rs11722779	0.903	rs13130741	ENSG00000251288.2	RP11-10L12.2	-6.36	4.85e-10	1.08e-07	-0.38	-0.28	Schizophrenia;	chr4:103035799	chr4:102751401~102752641:+
THCA	cis	rs6545883	0.895	rs2421192	ENSG00000271889.1	RP11-493E12.1	-6.36	4.85e-10	1.08e-07	-0.27	-0.28	Tuberculosis;	chr2:61416496	chr2:61151433~61162105:-
THCA	cis	rs7727544	0.584	rs7714191	ENSG00000224431.1	AC063976.7	6.36	4.85e-10	1.08e-07	0.25	0.28	Blood metabolite levels;	chr5:132005848	chr5:132199456~132203487:+
THCA	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-6.36	4.85e-10	1.08e-07	-0.21	-0.28	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
THCA	cis	rs8012947	0.917	rs57044214	ENSG00000279636.2	LINC00216	6.36	4.86e-10	1.08e-07	0.3	0.28	Alcohol consumption in current drinkers;	chr14:58367191	chr14:58288033~58289158:+
THCA	cis	rs736801	0.808	rs2706396	ENSG00000233006.5	AC034220.3	-6.36	4.86e-10	1.08e-07	-0.22	-0.28	Mosquito bite size;Breast cancer;	chr5:132461117	chr5:132311285~132369916:-
THCA	cis	rs736801	0.836	rs2522052	ENSG00000233006.5	AC034220.3	-6.36	4.86e-10	1.08e-07	-0.22	-0.28	Mosquito bite size;Breast cancer;	chr5:132462795	chr5:132311285~132369916:-
THCA	cis	rs736801	0.808	rs2706403	ENSG00000233006.5	AC034220.3	-6.36	4.86e-10	1.08e-07	-0.22	-0.28	Mosquito bite size;Breast cancer;	chr5:132463320	chr5:132311285~132369916:-
THCA	cis	rs736801	0.754	rs2706336	ENSG00000233006.5	AC034220.3	-6.36	4.86e-10	1.08e-07	-0.22	-0.28	Mosquito bite size;Breast cancer;	chr5:132464269	chr5:132311285~132369916:-
THCA	cis	rs944990	0.557	rs952288	ENSG00000227603.1	RP11-165J3.6	6.36	4.86e-10	1.08e-07	0.29	0.28	Body mass index;	chr9:93502629	chr9:93435332~93437121:-
THCA	cis	rs2303319	1	rs12471336	ENSG00000227403.1	AC009299.3	-6.36	4.86e-10	1.08e-07	-0.58	-0.28	Cognitive function;	chr2:161408678	chr2:161244739~161249050:+
THCA	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-6.36	4.86e-10	1.09e-07	-0.17	-0.28	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
THCA	cis	rs7976269	0.515	rs11049999	ENSG00000257176.2	RP11-996F15.2	-6.36	4.87e-10	1.09e-07	-0.28	-0.28	Male-pattern baldness;	chr12:29042854	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.559	rs10771471	ENSG00000257176.2	RP11-996F15.2	-6.36	4.87e-10	1.09e-07	-0.28	-0.28	Male-pattern baldness;	chr12:29050894	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.559	rs1344853	ENSG00000257176.2	RP11-996F15.2	-6.36	4.87e-10	1.09e-07	-0.28	-0.28	Male-pattern baldness;	chr12:29058623	chr12:29280418~29317848:-
THCA	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	6.36	4.88e-10	1.09e-07	0.41	0.28	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
THCA	cis	rs922182	0.569	rs72752984	ENSG00000275785.1	RP11-111E14.2	6.36	4.88e-10	1.09e-07	0.32	0.28	Blood protein levels;	chr15:63971883	chr15:63890030~63890317:+
THCA	cis	rs947583	0.573	rs9494336	ENSG00000231028.7	LINC00271	-6.36	4.88e-10	1.09e-07	-0.24	-0.28	Phosphorus levels;	chr6:135694749	chr6:135497801~135716055:+
THCA	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-6.36	4.88e-10	1.09e-07	-0.17	-0.28	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
THCA	cis	rs28386778	0.966	rs2008053	ENSG00000240280.5	TCAM1P	-6.36	4.88e-10	1.09e-07	-0.39	-0.28	Prudent dietary pattern;	chr17:63877558	chr17:63849292~63864379:+
THCA	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-6.36	4.88e-10	1.09e-07	-0.43	-0.28	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
THCA	cis	rs7976269	0.515	rs9300183	ENSG00000257176.2	RP11-996F15.2	-6.36	4.89e-10	1.09e-07	-0.29	-0.28	Male-pattern baldness;	chr12:29002316	chr12:29280418~29317848:-
THCA	cis	rs7615952	0.673	rs34209763	ENSG00000241288.6	RP11-379B18.5	-6.36	4.89e-10	1.09e-07	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:125880752	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.8	rs35390120	ENSG00000241288.6	RP11-379B18.5	-6.36	4.89e-10	1.09e-07	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:125880966	chr3:125827238~125916384:-
THCA	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	6.36	4.9e-10	1.09e-07	0.34	0.28	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
THCA	cis	rs60180747	0.544	rs11635253	ENSG00000261318.1	RP11-653J6.1	6.36	4.9e-10	1.09e-07	0.38	0.28	Testicular germ cell tumor;	chr15:66276869	chr15:66278498~66293357:-
THCA	cis	rs807029	0.577	rs750866	ENSG00000272572.1	RP11-179B2.2	-6.36	4.91e-10	1.09e-07	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100911103~100912739:-
THCA	cis	rs11158026	0.757	rs7159933	ENSG00000258413.1	RP11-665C16.6	-6.36	4.91e-10	1.09e-07	-0.39	-0.28	Parkinson's disease;	chr14:54974923	chr14:55262767~55272075:-
THCA	cis	rs4835473	0.9	rs10027246	ENSG00000251600.4	RP11-673E1.1	-6.36	4.92e-10	1.1e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143935069	chr4:143912331~143982454:+
THCA	cis	rs7267979	0.78	rs2500413	ENSG00000274414.1	RP5-965G21.4	-6.36	4.92e-10	1.1e-07	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.714	rs2474763	ENSG00000274414.1	RP5-965G21.4	-6.36	4.92e-10	1.1e-07	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25239007~25245229:-
THCA	cis	rs6545883	0.929	rs778155	ENSG00000271889.1	RP11-493E12.1	-6.36	4.92e-10	1.1e-07	-0.28	-0.28	Tuberculosis;	chr2:61420766	chr2:61151433~61162105:-
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000228409.4	CCT6P1	6.36	4.92e-10	1.1e-07	0.34	0.28	Diabetic kidney disease;	chr7:66557269	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1267820	ENSG00000228409.4	CCT6P1	6.36	4.92e-10	1.1e-07	0.34	0.28	Diabetic kidney disease;	chr7:66585308	chr7:65751142~65763354:+
THCA	cis	rs7968440	0.715	rs7967954	ENSG00000272368.2	RP4-605O3.4	-6.36	4.92e-10	1.1e-07	-0.17	-0.28	Fibrinogen;	chr12:50279701	chr12:50112197~50165618:+
THCA	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-6.36	4.93e-10	1.1e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
THCA	cis	rs838147	0.508	rs507766	ENSG00000232871.7	SEC1P	6.36	4.93e-10	1.1e-07	0.33	0.28	Dietary macronutrient intake;	chr19:48705286	chr19:48638071~48682245:+
THCA	cis	rs6088580	0.524	rs6142210	ENSG00000269202.1	RP4-614O4.12	6.36	4.93e-10	1.1e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34635208	chr20:35201747~35203288:-
THCA	cis	rs748404	0.578	rs478028	ENSG00000166763.7	STRCP1	6.35	4.94e-10	1.1e-07	0.3	0.28	Lung cancer;	chr15:43318574	chr15:43699488~43718184:-
THCA	cis	rs748404	0.578	rs552701	ENSG00000166763.7	STRCP1	6.35	4.94e-10	1.1e-07	0.3	0.28	Lung cancer;	chr15:43321612	chr15:43699488~43718184:-
THCA	cis	rs748404	0.578	rs573615	ENSG00000166763.7	STRCP1	6.35	4.94e-10	1.1e-07	0.3	0.28	Lung cancer;	chr15:43322083	chr15:43699488~43718184:-
THCA	cis	rs728616	0.867	rs2152548	ENSG00000242600.5	MBL1P	6.35	4.94e-10	1.1e-07	0.39	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:79904898~79950336:+
THCA	cis	rs2657294	0.62	rs9783273	ENSG00000226051.5	ZNF503-AS1	-6.35	4.94e-10	1.1e-07	-0.4	-0.28	Pneumonia;	chr10:75081982	chr10:75269819~75373500:+
THCA	cis	rs3204270	0.639	rs11871678	ENSG00000262049.1	RP13-1032I1.7	6.35	4.94e-10	1.1e-07	0.26	0.28	Dental caries;	chr17:81687255	chr17:81701324~81703300:-
THCA	cis	rs7617773	0.925	rs35942721	ENSG00000228638.1	FCF1P2	-6.35	4.94e-10	1.1e-07	-0.28	-0.28	Coronary artery disease;	chr3:48131579	chr3:48290793~48291375:-
THCA	cis	rs847577	0.609	rs11763970	ENSG00000272950.1	RP11-307C18.1	6.35	4.95e-10	1.1e-07	0.35	0.28	Breast cancer;	chr7:98188009	chr7:98322853~98323430:+
THCA	cis	rs1865760	0.963	rs9356991	ENSG00000272462.2	U91328.19	-6.35	4.95e-10	1.1e-07	-0.23	-0.28	Height;	chr6:25901530	chr6:25992662~26001775:+
THCA	cis	rs10266483	0.545	rs7777148	ENSG00000271550.1	BNIP3P11	-6.35	4.95e-10	1.1e-07	-0.43	-0.28	Response to statin therapy;	chr7:64285795	chr7:64678954~64687393:-
THCA	cis	rs7208859	0.725	rs9897673	ENSG00000264538.5	SUZ12P1	-6.35	4.95e-10	1.1e-07	-0.28	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30709299~30790908:+
THCA	cis	rs2975734	0.68	rs10503406	ENSG00000261451.1	RP11-981G7.1	-6.35	4.95e-10	1.1e-07	-0.37	-0.28	Chronotype;Morning vs. evening chronotype;	chr8:10251462	chr8:10433672~10438312:+
THCA	cis	rs1275468	1	rs1275469	ENSG00000257497.2	RP11-585P4.5	-6.35	4.95e-10	1.1e-07	-0.41	-0.28	Polycystic ovary syndrome;	chr12:75541450	chr12:75483454~75489820:-
THCA	cis	rs853679	0.55	rs1233699	ENSG00000220721.1	OR1F12	6.35	4.95e-10	1.1e-07	0.38	0.28	Depression;	chr6:28201380	chr6:28073316~28074233:+
THCA	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-6.35	4.96e-10	1.11e-07	-0.3	-0.28	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
THCA	cis	rs10761482	0.5	rs1938524	ENSG00000254271.1	RP11-131N11.4	6.35	4.96e-10	1.11e-07	0.36	0.28	Schizophrenia;	chr10:60543815	chr10:60734342~60741828:+
THCA	cis	rs4713118	0.513	rs202908	ENSG00000280107.1	AL022393.9	-6.35	4.96e-10	1.11e-07	-0.3	-0.28	Parkinson's disease;	chr6:28043773	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.513	rs156739	ENSG00000280107.1	AL022393.9	-6.35	4.96e-10	1.11e-07	-0.3	-0.28	Parkinson's disease;	chr6:28045632	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.513	rs149958	ENSG00000280107.1	AL022393.9	-6.35	4.96e-10	1.11e-07	-0.3	-0.28	Parkinson's disease;	chr6:28045839	chr6:28170845~28172521:+
THCA	cis	rs438465	1	rs2865089	ENSG00000226194.4	RP1-137D17.1	6.35	4.97e-10	1.11e-07	0.43	0.28	Corneal astigmatism;	chr6:169482887	chr6:169369998~169388385:-
THCA	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-6.35	4.98e-10	1.11e-07	-0.36	-0.28	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
THCA	cis	rs7267979	0.903	rs2500400	ENSG00000274414.1	RP5-965G21.4	6.35	4.98e-10	1.11e-07	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25239007~25245229:-
THCA	cis	rs9475752	0.564	rs9464401	ENSG00000231441.1	RP11-472M19.2	6.35	4.98e-10	1.11e-07	0.32	0.28	Menarche (age at onset);	chr6:56871857	chr6:56844002~56864078:+
THCA	cis	rs9859260	0.71	rs419068	ENSG00000226155.1	AC124944.3	6.35	4.99e-10	1.11e-07	0.34	0.28	Mean corpuscular volume;	chr3:196055305	chr3:195912049~195913986:+
THCA	cis	rs9859260	0.71	rs366268	ENSG00000226155.1	AC124944.3	6.35	4.99e-10	1.11e-07	0.34	0.28	Mean corpuscular volume;	chr3:196055306	chr3:195912049~195913986:+
THCA	cis	rs9859260	0.744	rs419059	ENSG00000226155.1	AC124944.3	6.35	4.99e-10	1.11e-07	0.34	0.28	Mean corpuscular volume;	chr3:196055313	chr3:195912049~195913986:+
THCA	cis	rs595244	1	rs11635605	ENSG00000259705.1	RP11-227D13.1	6.35	4.99e-10	1.11e-07	0.5	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48494720	chr15:48645951~48652016:+
THCA	cis	rs1850744	1	rs10939507	ENSG00000250942.1	ENPP7P11	6.35	4.99e-10	1.11e-07	0.41	0.28	Economic and political preferences;	chr4:9767199	chr4:9677308~9677934:+
THCA	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-6.35	4.99e-10	1.11e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	6.35	5e-10	1.11e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
THCA	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	6.35	5e-10	1.11e-07	0.26	0.28	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
THCA	cis	rs7811142	1	rs73405353	ENSG00000078319.8	PMS2P1	-6.35	5.01e-10	1.12e-07	-0.41	-0.28	Platelet count;	chr7:100493592	chr7:100320992~100341908:-
THCA	cis	rs2243480	1	rs35820085	ENSG00000228409.4	CCT6P1	6.35	5.01e-10	1.12e-07	0.33	0.28	Diabetic kidney disease;	chr7:65977771	chr7:65751142~65763354:+
THCA	cis	rs55951657	1	rs55951657	ENSG00000279026.1	RP3-414A15.12	-6.35	5.03e-10	1.12e-07	-0.35	-0.28	Hippocampal volume;	chr14:73608028	chr14:73580694~73582918:+
THCA	cis	rs6840360	0.642	rs1372977	ENSG00000251611.1	RP11-610P16.1	-6.35	5.03e-10	1.12e-07	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151531246	chr4:151407551~151408835:-
THCA	cis	rs10129255	0.957	rs10136817	ENSG00000211974.3	IGHV2-70	6.35	5.03e-10	1.12e-07	0.22	0.28	Kawasaki disease;	chr14:106787730	chr14:106723574~106724093:-
THCA	cis	rs6088580	0.505	rs6141503	ENSG00000269202.1	RP4-614O4.12	6.35	5.03e-10	1.12e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34686665	chr20:35201747~35203288:-
THCA	cis	rs58785573	0.624	rs2126526	ENSG00000231160.8	KLF3-AS1	-6.35	5.03e-10	1.12e-07	-0.15	-0.28	Lymphocyte percentage of white cells;	chr4:38617068	chr4:38612701~38664883:-
THCA	cis	rs7260598	0.892	rs58931976	ENSG00000268442.1	CTD-2027I19.2	6.35	5.04e-10	1.12e-07	0.4	0.28	Response to taxane treatment (placlitaxel);	chr19:24008247	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.892	rs59831281	ENSG00000268442.1	CTD-2027I19.2	6.35	5.04e-10	1.12e-07	0.4	0.28	Response to taxane treatment (placlitaxel);	chr19:24008258	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.786	rs59387271	ENSG00000268442.1	CTD-2027I19.2	6.35	5.04e-10	1.12e-07	0.4	0.28	Response to taxane treatment (placlitaxel);	chr19:24009130	chr19:24162370~24163425:-
THCA	cis	rs4835473	0.897	rs2590034	ENSG00000251600.4	RP11-673E1.1	6.35	5.05e-10	1.12e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143926778	chr4:143912331~143982454:+
THCA	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	6.35	5.05e-10	1.12e-07	0.34	0.28	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
THCA	cis	rs10078	0.559	rs2037077	ENSG00000221990.4	EXOC3-AS1	6.35	5.05e-10	1.12e-07	0.29	0.28	Fat distribution (HIV);	chr5:447111	chr5:441498~443160:-
THCA	cis	rs2562456	0.92	rs2650784	ENSG00000213976.4	CTD-2561J22.2	6.35	5.05e-10	1.13e-07	0.29	0.28	Pain;	chr19:21483795	chr19:21382865~21387177:+
THCA	cis	rs755249	1	rs12037222	ENSG00000228060.1	RP11-69E11.8	-6.35	5.06e-10	1.13e-07	-0.31	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39599289	chr1:39565160~39573203:+
THCA	cis	rs848490	0.889	rs12113982	ENSG00000214293.7	APTR	6.35	5.06e-10	1.13e-07	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77547073	chr7:77657660~77696265:-
THCA	cis	rs6840258	0.76	rs340626	ENSG00000251411.1	RP11-397E7.4	6.35	5.06e-10	1.13e-07	0.3	0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87035287	chr4:86913266~86914817:-
THCA	cis	rs9649465	0.967	rs1506642	ENSG00000272686.1	RP11-390E23.6	6.35	5.07e-10	1.13e-07	0.18	0.28	Migraine;	chr7:123750004	chr7:123749068~123751166:+
THCA	cis	rs2292342	1	rs3745734	ENSG00000232871.7	SEC1P	-6.35	5.07e-10	1.13e-07	-0.53	-0.28	Elevated serum carcinoembryonic antigen levels;	chr19:48631131	chr19:48638071~48682245:+
THCA	cis	rs2292342	1	rs28540190	ENSG00000232871.7	SEC1P	-6.35	5.07e-10	1.13e-07	-0.53	-0.28	Elevated serum carcinoembryonic antigen levels;	chr19:48631786	chr19:48638071~48682245:+
THCA	cis	rs7809950	1	rs10258385	ENSG00000238832.1	snoU109	6.35	5.07e-10	1.13e-07	0.31	0.28	Coronary artery disease;	chr7:107602905	chr7:107603363~107603507:+
THCA	cis	rs9677476	0.863	rs5018532	ENSG00000224376.1	AC017104.6	6.35	5.07e-10	1.13e-07	0.31	0.28	Food antigen IgG levels;	chr2:231212362	chr2:231388976~231394991:+
THCA	cis	rs2348418	0.831	rs7299042	ENSG00000247934.4	RP11-967K21.1	6.35	5.07e-10	1.13e-07	0.24	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28571750	chr12:28163298~28190738:-
THCA	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-6.35	5.08e-10	1.13e-07	-0.39	-0.28	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
THCA	cis	rs950169	0.922	rs11638445	ENSG00000259295.5	CSPG4P12	6.35	5.08e-10	1.13e-07	0.44	0.28	Schizophrenia;	chr15:84594463	chr15:85191438~85213905:+
THCA	cis	rs4950322	0.542	rs3766520	ENSG00000278811.3	LINC00624	6.35	5.08e-10	1.13e-07	0.35	0.28	Protein quantitative trait loci;	chr1:147214658	chr1:147258885~147517875:-
THCA	cis	rs2765539	0.701	rs6671822	ENSG00000231365.4	RP11-418J17.1	-6.35	5.08e-10	1.13e-07	-0.31	-0.28	Waist-hip ratio;	chr1:119118898	chr1:119140396~119275973:+
THCA	cis	rs28386778	0.83	rs7209321	ENSG00000240280.5	TCAM1P	-6.35	5.08e-10	1.13e-07	-0.4	-0.28	Prudent dietary pattern;	chr17:63778308	chr17:63849292~63864379:+
THCA	cis	rs12908161	0.96	rs34452033	ENSG00000259295.5	CSPG4P12	6.35	5.08e-10	1.13e-07	0.43	0.28	Schizophrenia;	chr15:84678762	chr15:85191438~85213905:+
THCA	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-6.35	5.08e-10	1.13e-07	-0.41	-0.28	Pain;	chr19:21509773	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-6.35	5.08e-10	1.13e-07	-0.41	-0.28	Pain;	chr19:21510513	chr19:21554640~21569237:-
THCA	cis	rs4950322	0.542	rs56080828	ENSG00000278811.3	LINC00624	6.35	5.09e-10	1.13e-07	0.35	0.28	Protein quantitative trait loci;	chr1:147183447	chr1:147258885~147517875:-
THCA	cis	rs7044106	0.537	rs10818474	ENSG00000238181.2	AHCYP2	-6.35	5.09e-10	1.13e-07	-0.38	-0.28	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120720673~120721972:+
THCA	cis	rs4143844	0.737	rs11634818	ENSG00000259251.2	RP11-643M14.1	6.35	5.09e-10	1.13e-07	0.55	0.28	Bipolar disorder and schizophrenia;	chr15:62064187	chr15:62060503~62062434:+
THCA	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	1.13e-07	0.29	0.28	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	1.13e-07	0.29	0.28	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	1.13e-07	0.29	0.28	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	1.13e-07	0.29	0.28	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	1.13e-07	0.29	0.28	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	1.13e-07	0.29	0.28	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	1.13e-07	0.29	0.28	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
THCA	cis	rs6723108	0.627	rs3814358	ENSG00000224043.6	CCNT2-AS1	-6.35	5.09e-10	1.13e-07	-0.29	-0.28	Type 2 diabetes;	chr2:134866438	chr2:134735464~134918710:-
THCA	cis	rs11148252	0.668	rs6561658	ENSG00000278238.1	RP11-245D16.4	-6.35	5.1e-10	1.13e-07	-0.33	-0.28	Lewy body disease;	chr13:52160016	chr13:52454775~52455331:-
THCA	cis	rs7015630	0.738	rs7013987	ENSG00000251136.7	RP11-37B2.1	-6.35	5.1e-10	1.13e-07	-0.29	-0.28	Inflammatory bowel disease;Crohn's disease;	chr8:89860755	chr8:89609409~89757727:-
THCA	cis	rs16846053	0.71	rs1449629	ENSG00000227403.1	AC009299.3	6.35	5.1e-10	1.14e-07	0.44	0.28	Blood osmolality (transformed sodium);	chr2:161738314	chr2:161244739~161249050:+
THCA	cis	rs7260598	0.892	rs60186040	ENSG00000268442.1	CTD-2027I19.2	6.35	5.1e-10	1.14e-07	0.38	0.28	Response to taxane treatment (placlitaxel);	chr19:24024068	chr19:24162370~24163425:-
THCA	cis	rs240993	0.812	rs4945881	ENSG00000230177.1	RP5-1112D6.4	6.35	5.11e-10	1.14e-07	0.28	0.28	Inflammatory skin disease;Psoriasis;	chr6:111470260	chr6:111277932~111278742:+
THCA	cis	rs11722779	0.815	rs223347	ENSG00000251288.2	RP11-10L12.2	-6.35	5.11e-10	1.14e-07	-0.37	-0.28	Schizophrenia;	chr4:102858815	chr4:102751401~102752641:+
THCA	cis	rs792448	0.743	rs3767863	ENSG00000226251.4	RP11-15I11.3	-6.35	5.11e-10	1.14e-07	-0.33	-0.28	White blood cell count (basophil);	chr1:212364365	chr1:212225278~212238977:-
THCA	cis	rs2915864	0.747	rs34143804	ENSG00000280047.1	CTC-463A16.1	6.35	5.12e-10	1.14e-07	0.47	0.28	Facial morphology (factor 20);	chr5:142057091	chr5:142165767~142168387:+
THCA	cis	rs7948661	1	rs2071702	ENSG00000278376.1	RP11-158I9.8	6.35	5.12e-10	1.14e-07	0.46	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118503146	chr11:118791254~118793137:+
THCA	cis	rs4950322	0.518	rs11811023	ENSG00000237188.3	RP11-337C18.8	-6.35	5.12e-10	1.14e-07	-0.34	-0.28	Protein quantitative trait loci;	chr1:147109536	chr1:147172771~147211568:+
THCA	cis	rs11722779	0.935	rs7676736	ENSG00000251288.2	RP11-10L12.2	-6.35	5.12e-10	1.14e-07	-0.37	-0.28	Schizophrenia;	chr4:103016729	chr4:102751401~102752641:+
THCA	cis	rs5742933	0.597	rs6756913	ENSG00000273240.1	RP11-455J20.3	6.35	5.12e-10	1.14e-07	0.3	0.28	Ferritin levels;	chr2:189641040	chr2:189763859~189764456:-
THCA	cis	rs6088580	0.524	rs7274854	ENSG00000269202.1	RP4-614O4.12	-6.35	5.12e-10	1.14e-07	-0.24	-0.28	Glomerular filtration rate (creatinine);	chr20:34640868	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.524	rs6088564	ENSG00000269202.1	RP4-614O4.12	6.35	5.13e-10	1.14e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34661640	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.524	rs11167241	ENSG00000269202.1	RP4-614O4.12	6.35	5.13e-10	1.14e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34663031	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.505	rs6142219	ENSG00000269202.1	RP4-614O4.12	6.35	5.13e-10	1.14e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34668541	chr20:35201747~35203288:-
THCA	cis	rs4143844	0.867	rs62007764	ENSG00000259251.2	RP11-643M14.1	6.35	5.14e-10	1.14e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:61948855	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs12901735	ENSG00000259251.2	RP11-643M14.1	6.35	5.14e-10	1.14e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:61951360	chr15:62060503~62062434:+
THCA	cis	rs6860806	0.661	rs4705927	ENSG00000237714.1	P4HA2-AS1	6.35	5.14e-10	1.14e-07	0.36	0.28	Breast cancer;	chr5:132242915	chr5:132184876~132192808:+
THCA	cis	rs10208649	0.536	rs13414472	ENSG00000272156.1	RP11-477N3.1	6.35	5.14e-10	1.14e-07	0.39	0.28	Body mass index;	chr2:53738470	chr2:54082554~54085066:+
THCA	cis	rs2562456	0.754	rs62107469	ENSG00000268555.1	RP11-678G14.3	6.35	5.14e-10	1.14e-07	0.46	0.28	Pain;	chr19:21312699	chr19:21570822~21587322:-
THCA	cis	rs6065	0.618	rs4790719	ENSG00000234203.1	RP5-1050D4.2	-6.35	5.14e-10	1.14e-07	-0.55	-0.28	Platelet count;	chr17:4978139	chr17:4972851~4974681:+
THCA	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	6.35	5.14e-10	1.14e-07	0.22	0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
THCA	cis	rs3204270	0.639	rs79193599	ENSG00000262049.1	RP13-1032I1.7	6.35	5.14e-10	1.14e-07	0.26	0.28	Dental caries;	chr17:81684460	chr17:81701324~81703300:-
THCA	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-6.35	5.15e-10	1.14e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-6.35	5.15e-10	1.14e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-6.35	5.15e-10	1.14e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-6.35	5.15e-10	1.14e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-6.35	5.15e-10	1.14e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-6.35	5.15e-10	1.14e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-6.35	5.15e-10	1.14e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-6.35	5.15e-10	1.14e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
THCA	cis	rs12435908	1	rs12431420	ENSG00000276116.2	FUT8-AS1	-6.35	5.15e-10	1.14e-07	-0.45	-0.28	Ischemic stroke;	chr14:65534358	chr14:65411170~65412690:-
THCA	cis	rs11668609	0.505	rs60605343	ENSG00000268442.1	CTD-2027I19.2	6.35	5.15e-10	1.14e-07	0.38	0.28	Response to taxane treatment (docetaxel);	chr19:23968486	chr19:24162370~24163425:-
THCA	cis	rs7044106	0.708	rs1324472	ENSG00000270917.1	RP11-27I1.6	-6.35	5.16e-10	1.15e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120812475~120812845:-
THCA	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-6.35	5.16e-10	1.15e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
THCA	cis	rs16976116	0.951	rs6493768	ENSG00000279145.1	RP11-547D13.1	6.35	5.16e-10	1.15e-07	0.28	0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55192096	chr15:55171972~55178175:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000220721.1	OR1F12	6.35	5.16e-10	1.15e-07	0.38	0.28	Depression;	chr6:28206179	chr6:28073316~28074233:+
THCA	cis	rs5751614	0.557	rs928781	ENSG00000230701.2	FBXW4P1	-6.35	5.16e-10	1.15e-07	-0.32	-0.28	Height;	chr22:23257826	chr22:23262767~23265005:+
THCA	cis	rs2439831	0.717	rs690170	ENSG00000249839.1	AC011330.5	-6.35	5.16e-10	1.15e-07	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43518224	chr15:43663654~43684339:-
THCA	cis	rs7209700	0.742	rs7217710	ENSG00000228782.6	CTD-2026D20.3	6.35	5.16e-10	1.15e-07	0.28	0.28	IgG glycosylation;	chr17:47293216	chr17:47450568~47492492:-
THCA	cis	rs7688540	0.8	rs6857106	ENSG00000211553.1	AC253576.2	6.35	5.17e-10	1.15e-07	0.37	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:136461~136568:+
THCA	cis	rs1005277	0.579	rs2504143	ENSG00000276805.1	RP11-291L22.6	6.35	5.17e-10	1.15e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38451030~38451785:+
THCA	cis	rs2342371	0.539	rs35959625	ENSG00000273013.1	CTD-2002J20.1	-6.35	5.17e-10	1.15e-07	-0.25	-0.28	Fat distribution (HIV);	chr3:196405070	chr3:196474801~196475394:+
THCA	cis	rs2243480	1	rs781156	ENSG00000228409.4	CCT6P1	6.35	5.17e-10	1.15e-07	0.32	0.28	Diabetic kidney disease;	chr7:66014154	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs451396	ENSG00000228409.4	CCT6P1	6.35	5.17e-10	1.15e-07	0.32	0.28	Diabetic kidney disease;	chr7:66019087	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1715235	ENSG00000228409.4	CCT6P1	6.35	5.17e-10	1.15e-07	0.32	0.28	Diabetic kidney disease;	chr7:66023407	chr7:65751142~65763354:+
THCA	cis	rs6860806	0.507	rs2631364	ENSG00000263597.1	MIR3936	-6.35	5.18e-10	1.15e-07	-0.28	-0.28	Breast cancer;	chr5:132371222	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.531	rs2631359	ENSG00000263597.1	MIR3936	-6.35	5.18e-10	1.15e-07	-0.28	-0.28	Breast cancer;	chr5:132372200	chr5:132365490~132365599:-
THCA	cis	rs17772222	0.917	rs61984708	ENSG00000222990.1	RNU4-22P	6.35	5.18e-10	1.15e-07	0.36	0.28	Coronary artery calcification;	chr14:88565523	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs17260380	ENSG00000258789.1	RP11-507K2.3	-6.35	5.18e-10	1.15e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88682142	chr14:88551597~88552493:+
THCA	cis	rs6479891	0.915	rs10740110	ENSG00000232075.1	MRPL35P2	-6.35	5.18e-10	1.15e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63634317~63634827:-
THCA	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-6.35	5.18e-10	1.15e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-6.35	5.18e-10	1.15e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-6.35	5.18e-10	1.15e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
THCA	cis	rs79349575	0.811	rs1057897	ENSG00000248278.1	SUMO2P17	6.35	5.18e-10	1.15e-07	0.33	0.28	Type 2 diabetes;	chr17:48928147	chr17:48874860~48908983:-
THCA	cis	rs228614	0.509	rs223476	ENSG00000230069.3	LRRC37A15P	-6.35	5.18e-10	1.15e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102727274~102730721:-
THCA	cis	rs228614	0.509	rs150896	ENSG00000230069.3	LRRC37A15P	-6.35	5.18e-10	1.15e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.844	rs223345	ENSG00000251288.2	RP11-10L12.2	-6.35	5.19e-10	1.15e-07	-0.37	-0.28	Schizophrenia;	chr4:102859366	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.873	rs223344	ENSG00000251288.2	RP11-10L12.2	-6.35	5.19e-10	1.15e-07	-0.37	-0.28	Schizophrenia;	chr4:102859765	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.775	rs223341	ENSG00000251288.2	RP11-10L12.2	-6.35	5.19e-10	1.15e-07	-0.37	-0.28	Schizophrenia;	chr4:102862343	chr4:102751401~102752641:+
THCA	cis	rs12435908	1	rs2300872	ENSG00000276116.2	FUT8-AS1	-6.35	5.19e-10	1.15e-07	-0.47	-0.28	Ischemic stroke;	chr14:65681043	chr14:65411170~65412690:-
THCA	cis	rs17772222	0.876	rs12586348	ENSG00000258789.1	RP11-507K2.3	-6.35	5.19e-10	1.15e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88643523	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs12434935	ENSG00000258789.1	RP11-507K2.3	-6.35	5.19e-10	1.15e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88645449	chr14:88551597~88552493:+
THCA	cis	rs77972916	0.609	rs72790907	ENSG00000234936.1	AC010883.5	6.35	5.2e-10	1.15e-07	0.37	0.28	Granulocyte percentage of myeloid white cells;	chr2:43348056	chr2:43229573~43233394:+
THCA	cis	rs228614	0.536	rs223475	ENSG00000251288.2	RP11-10L12.2	-6.35	5.2e-10	1.16e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102751401~102752641:+
THCA	cis	rs228614	0.536	rs223474	ENSG00000251288.2	RP11-10L12.2	-6.35	5.2e-10	1.16e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102751401~102752641:+
THCA	cis	rs9287719	0.774	rs4997811	ENSG00000234818.1	AC092687.5	6.35	5.2e-10	1.16e-07	0.34	0.28	Prostate cancer;	chr2:10615412	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.745	rs4997810	ENSG00000234818.1	AC092687.5	6.35	5.2e-10	1.16e-07	0.34	0.28	Prostate cancer;	chr2:10615414	chr2:10589166~10604830:+
THCA	cis	rs9287719	0.745	rs4997809	ENSG00000234818.1	AC092687.5	6.35	5.2e-10	1.16e-07	0.34	0.28	Prostate cancer;	chr2:10615416	chr2:10589166~10604830:+
THCA	cis	rs7851660	0.967	rs7847126	ENSG00000214417.4	KRT18P13	-6.35	5.2e-10	1.16e-07	-0.24	-0.28	Strep throat;	chr9:97838353	chr9:97698922~97700734:+
THCA	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-6.35	5.21e-10	1.16e-07	-0.17	-0.28	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
THCA	cis	rs7746199	0.736	rs35848276	ENSG00000226314.6	ZNF192P1	-6.35	5.21e-10	1.16e-07	-0.62	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28161781~28169594:+
THCA	cis	rs4689592	0.503	rs66885632	ENSG00000245468.3	RP11-367J11.3	-6.35	5.21e-10	1.16e-07	-0.25	-0.28	Monocyte percentage of white cells;	chr4:7052011	chr4:7094571~7103385:-
THCA	cis	rs1707322	0.686	rs3014251	ENSG00000281133.1	AL355480.3	6.35	5.22e-10	1.16e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45580892~45580996:-
THCA	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	6.35	5.22e-10	1.16e-07	0.28	0.28	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
THCA	cis	rs984222	1	rs984222	ENSG00000231365.4	RP11-418J17.1	-6.35	5.22e-10	1.16e-07	-0.27	-0.28	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961220	chr1:119140396~119275973:+
THCA	cis	rs984222	0.967	rs984225	ENSG00000231365.4	RP11-418J17.1	-6.35	5.22e-10	1.16e-07	-0.27	-0.28	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961661	chr1:119140396~119275973:+
THCA	cis	rs984222	0.967	rs1409157	ENSG00000231365.4	RP11-418J17.1	-6.35	5.22e-10	1.16e-07	-0.27	-0.28	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961864	chr1:119140396~119275973:+
THCA	cis	rs984222	0.967	rs10923712	ENSG00000231365.4	RP11-418J17.1	-6.35	5.22e-10	1.16e-07	-0.27	-0.28	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118962811	chr1:119140396~119275973:+
THCA	cis	rs984222	0.967	rs10923713	ENSG00000231365.4	RP11-418J17.1	-6.35	5.22e-10	1.16e-07	-0.27	-0.28	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118967864	chr1:119140396~119275973:+
THCA	cis	rs944990	0.538	rs966789	ENSG00000227603.1	RP11-165J3.6	6.35	5.23e-10	1.16e-07	0.29	0.28	Body mass index;	chr9:93556861	chr9:93435332~93437121:-
THCA	cis	rs11158026	0.757	rs8018800	ENSG00000258413.1	RP11-665C16.6	6.35	5.23e-10	1.16e-07	0.38	0.28	Parkinson's disease;	chr14:54986588	chr14:55262767~55272075:-
THCA	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	6.34	5.24e-10	1.16e-07	0.37	0.28	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
THCA	cis	rs2562456	0.752	rs279809	ENSG00000268555.1	RP11-678G14.3	6.34	5.24e-10	1.16e-07	0.46	0.28	Pain;	chr19:21284729	chr19:21570822~21587322:-
THCA	cis	rs3204270	0.714	rs7189	ENSG00000262049.1	RP13-1032I1.7	6.34	5.24e-10	1.17e-07	0.26	0.28	Dental caries;	chr17:81701867	chr17:81701324~81703300:-
THCA	cis	rs3204270	0.759	rs8065104	ENSG00000262049.1	RP13-1032I1.7	6.34	5.24e-10	1.17e-07	0.26	0.28	Dental caries;	chr17:81705575	chr17:81701324~81703300:-
THCA	cis	rs6860806	0.531	rs274556	ENSG00000263597.1	MIR3936	-6.34	5.25e-10	1.17e-07	-0.29	-0.28	Breast cancer;	chr5:132386383	chr5:132365490~132365599:-
THCA	cis	rs934734	0.544	rs4671127	ENSG00000237979.1	AC007389.1	6.34	5.25e-10	1.17e-07	0.35	0.28	Rheumatoid arthritis;	chr2:65335836	chr2:65500993~65502138:-
THCA	cis	rs7085104	0.7	rs6163	ENSG00000236937.2	PTGES3P4	6.34	5.25e-10	1.17e-07	0.36	0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102845595~102845950:+
THCA	cis	rs7085104	0.7	rs743572	ENSG00000236937.2	PTGES3P4	6.34	5.25e-10	1.17e-07	0.36	0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102845595~102845950:+
THCA	cis	rs9475752	0.564	rs1870638	ENSG00000231441.1	RP11-472M19.2	6.34	5.25e-10	1.17e-07	0.31	0.28	Menarche (age at onset);	chr6:56876978	chr6:56844002~56864078:+
THCA	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-6.34	5.25e-10	1.17e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-6.34	5.25e-10	1.17e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
THCA	cis	rs7727544	0.735	rs273914	ENSG00000237714.1	P4HA2-AS1	6.34	5.25e-10	1.17e-07	0.36	0.28	Blood metabolite levels;	chr5:132324738	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.735	rs272894	ENSG00000237714.1	P4HA2-AS1	6.34	5.25e-10	1.17e-07	0.36	0.28	Blood metabolite levels;	chr5:132326767	chr5:132184876~132192808:+
THCA	cis	rs7474896	0.507	rs2474555	ENSG00000120555.12	SEPT7P9	6.34	5.25e-10	1.17e-07	0.39	0.28	Obesity (extreme);	chr10:38176292	chr10:38383069~38402916:-
THCA	cis	rs2975734	0.736	rs4841300	ENSG00000261451.1	RP11-981G7.1	-6.34	5.26e-10	1.17e-07	-0.38	-0.28	Chronotype;Morning vs. evening chronotype;	chr8:10255085	chr8:10433672~10438312:+
THCA	cis	rs2303319	1	rs62197070	ENSG00000227403.1	AC009299.3	6.34	5.26e-10	1.17e-07	0.6	0.28	Cognitive function;	chr2:161292656	chr2:161244739~161249050:+
THCA	cis	rs9677476	0.863	rs58067379	ENSG00000224376.1	AC017104.6	6.34	5.26e-10	1.17e-07	0.31	0.28	Food antigen IgG levels;	chr2:231223582	chr2:231388976~231394991:+
THCA	cis	rs7829975	0.711	rs12682352	ENSG00000254153.1	CTA-398F10.2	-6.34	5.26e-10	1.17e-07	-0.3	-0.28	Mood instability;	chr8:8788736	chr8:8456909~8461337:-
THCA	cis	rs896854	0.624	rs9297949	ENSG00000253528.2	RP11-347C18.4	6.34	5.26e-10	1.17e-07	0.32	0.28	Type 2 diabetes;	chr8:94957217	chr8:94974573~94974853:-
THCA	cis	rs9880211	1	rs4038586	ENSG00000273486.1	RP11-731C17.2	6.34	5.27e-10	1.17e-07	0.29	0.28	Height;Body mass index;	chr3:136644449	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs6767889	ENSG00000273486.1	RP11-731C17.2	6.34	5.27e-10	1.17e-07	0.29	0.28	Height;Body mass index;	chr3:136646613	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.898	rs35304385	ENSG00000273486.1	RP11-731C17.2	6.34	5.27e-10	1.17e-07	0.29	0.28	Height;Body mass index;	chr3:136667411	chr3:136837338~136839021:-
THCA	cis	rs9475752	0.947	rs17752435	ENSG00000231441.1	RP11-472M19.2	6.34	5.27e-10	1.17e-07	0.34	0.28	Menarche (age at onset);	chr6:56926697	chr6:56844002~56864078:+
THCA	cis	rs2243480	0.901	rs778732	ENSG00000229886.1	RP5-1132H15.3	6.34	5.27e-10	1.17e-07	0.46	0.28	Diabetic kidney disease;	chr7:66357373	chr7:66025126~66031544:-
THCA	cis	rs2380205	0.546	rs626344	ENSG00000232807.2	RP11-536K7.3	-6.34	5.27e-10	1.17e-07	-0.26	-0.28	Breast cancer;	chr10:5908272	chr10:5934270~5945900:-
THCA	cis	rs12908161	1	rs11638290	ENSG00000259295.5	CSPG4P12	6.34	5.28e-10	1.17e-07	0.43	0.28	Schizophrenia;	chr15:84684405	chr15:85191438~85213905:+
THCA	cis	rs12908161	0.959	rs34028043	ENSG00000259295.5	CSPG4P12	6.34	5.28e-10	1.17e-07	0.43	0.28	Schizophrenia;	chr15:84688354	chr15:85191438~85213905:+
THCA	cis	rs12908161	0.959	rs34784022	ENSG00000259295.5	CSPG4P12	6.34	5.28e-10	1.17e-07	0.43	0.28	Schizophrenia;	chr15:84688675	chr15:85191438~85213905:+
THCA	cis	rs8062405	0.755	rs56209193	ENSG00000278665.1	RP11-666O2.4	6.34	5.28e-10	1.17e-07	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28599241~28601881:-
THCA	cis	rs807029	0.533	rs2295716	ENSG00000272572.1	RP11-179B2.2	-6.34	5.29e-10	1.17e-07	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100911103~100912739:-
THCA	cis	rs807029	0.533	rs722435	ENSG00000272572.1	RP11-179B2.2	-6.34	5.29e-10	1.17e-07	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100911103~100912739:-
THCA	cis	rs748404	0.589	rs62020616	ENSG00000249839.1	AC011330.5	-6.34	5.29e-10	1.17e-07	-0.4	-0.28	Lung cancer;	chr15:43558554	chr15:43663654~43684339:-
THCA	cis	rs748404	0.626	rs60367691	ENSG00000249839.1	AC011330.5	-6.34	5.29e-10	1.17e-07	-0.4	-0.28	Lung cancer;	chr15:43559201	chr15:43663654~43684339:-
THCA	cis	rs7044106	0.537	rs4434680	ENSG00000238181.2	AHCYP2	-6.34	5.29e-10	1.17e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120720673~120721972:+
THCA	cis	rs2439831	0.867	rs3213990	ENSG00000249839.1	AC011330.5	-6.34	5.29e-10	1.17e-07	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43378028	chr15:43663654~43684339:-
THCA	cis	rs9813712	0.548	rs9880123	ENSG00000249846.5	RP11-77P16.4	-6.34	5.29e-10	1.17e-07	-0.3	-0.28	Response to amphetamines;	chr3:130215275	chr3:130112550~130120579:+
THCA	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	6.34	5.29e-10	1.18e-07	0.36	0.28	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
THCA	cis	rs4835473	0.708	rs7655939	ENSG00000251600.4	RP11-673E1.1	6.34	5.3e-10	1.18e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143956889	chr4:143912331~143982454:+
THCA	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-6.34	5.3e-10	1.18e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
THCA	cis	rs8177876	0.749	rs58144189	ENSG00000261061.1	RP11-303E16.2	-6.34	5.31e-10	1.18e-07	-0.41	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.749	rs1035541	ENSG00000261061.1	RP11-303E16.2	-6.34	5.31e-10	1.18e-07	-0.41	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81030770~81031485:+
THCA	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-6.34	5.31e-10	1.18e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
THCA	cis	rs736801	0.808	rs6866614	ENSG00000233006.5	AC034220.3	-6.34	5.32e-10	1.18e-07	-0.23	-0.28	Mosquito bite size;Breast cancer;	chr5:132451445	chr5:132311285~132369916:-
THCA	cis	rs934734	0.752	rs2661795	ENSG00000281920.1	RP11-418H16.1	-6.34	5.32e-10	1.18e-07	-0.35	-0.28	Rheumatoid arthritis;	chr2:65399672	chr2:65623272~65628424:+
THCA	cis	rs950169	0.887	rs3860265	ENSG00000259295.5	CSPG4P12	6.34	5.33e-10	1.18e-07	0.43	0.28	Schizophrenia;	chr15:84390487	chr15:85191438~85213905:+
THCA	cis	rs950169	0.724	rs11632668	ENSG00000259295.5	CSPG4P12	6.34	5.33e-10	1.18e-07	0.43	0.28	Schizophrenia;	chr15:84393989	chr15:85191438~85213905:+
THCA	cis	rs950169	0.881	rs34591918	ENSG00000259295.5	CSPG4P12	6.34	5.33e-10	1.18e-07	0.43	0.28	Schizophrenia;	chr15:84396135	chr15:85191438~85213905:+
THCA	cis	rs116139393	0.505	rs3801033	ENSG00000187953.9	PMS2CL	6.34	5.33e-10	1.18e-07	0.32	0.28	Alzheimer's disease (APOE e4 interaction);	chr7:6694472	chr7:6710128~6753862:+
THCA	cis	rs9816784	0.576	rs12631246	ENSG00000226155.1	AC124944.3	-6.34	5.33e-10	1.18e-07	-0.35	-0.28	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195912049~195913986:+
THCA	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	6.34	5.34e-10	1.18e-07	0.29	0.28	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
THCA	cis	rs9487094	0.922	rs9487098	ENSG00000260273.1	RP11-425D10.10	6.34	5.34e-10	1.18e-07	0.35	0.28	Height;	chr6:109422189	chr6:109382795~109383666:+
THCA	cis	rs17772222	0.917	rs1950806	ENSG00000258789.1	RP11-507K2.3	-6.34	5.34e-10	1.18e-07	-0.3	-0.28	Coronary artery calcification;	chr14:88774412	chr14:88551597~88552493:+
THCA	cis	rs3764021	0.509	rs10772073	ENSG00000256594.6	RP11-705C15.2	6.34	5.34e-10	1.19e-07	0.24	0.28	Type 1 diabetes;	chr12:9717428	chr12:9633419~9658412:+
THCA	cis	rs4143844	1	rs34338090	ENSG00000259251.2	RP11-643M14.1	6.34	5.35e-10	1.19e-07	0.56	0.28	Bipolar disorder and schizophrenia;	chr15:62062776	chr15:62060503~62062434:+
THCA	cis	rs7044106	0.708	rs10760113	ENSG00000270917.1	RP11-27I1.6	-6.34	5.35e-10	1.19e-07	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120812475~120812845:-
THCA	cis	rs1552244	0.7	rs9833566	ENSG00000232901.1	CYCSP10	6.34	5.35e-10	1.19e-07	0.37	0.28	Alzheimer's disease;	chr3:9939987	chr3:10000647~10000940:-
THCA	cis	rs16949788	1	rs11071885	ENSG00000261351.2	CTD-3185P2.1	-6.34	5.35e-10	1.19e-07	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66332823	chr15:66488658~66492109:-
THCA	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-6.34	5.35e-10	1.19e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-6.34	5.35e-10	1.19e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
THCA	cis	rs832187	0.603	rs7615475	ENSG00000280620.1	SCAANT1	6.34	5.35e-10	1.19e-07	0.37	0.28	Schizophrenia;	chr3:63940985	chr3:63911518~63911772:-
THCA	cis	rs55665837	0.559	rs11023210	ENSG00000251991.1	RNU7-49P	-6.34	5.35e-10	1.19e-07	-0.33	-0.28	Vitamin D levels;	chr11:14401216	chr11:14478892~14478953:+
THCA	cis	rs12534093	0.562	rs6461716	ENSG00000234286.1	AC006026.13	-6.34	5.35e-10	1.19e-07	-0.38	-0.28	Infant length;Height;	chr7:23540935	chr7:23680195~23680786:-
THCA	cis	rs2915864	0.8	rs58625131	ENSG00000280047.1	CTC-463A16.1	6.34	5.36e-10	1.19e-07	0.43	0.28	Facial morphology (factor 20);	chr5:142158500	chr5:142165767~142168387:+
THCA	cis	rs7608910	0.556	rs10181042	ENSG00000271889.1	RP11-493E12.1	-6.34	5.36e-10	1.19e-07	-0.28	-0.28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60997124	chr2:61151433~61162105:-
THCA	cis	rs11018904	0.861	rs12786959	ENSG00000280385.1	AP000648.5	-6.34	5.36e-10	1.19e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr11:90210508	chr11:90193614~90198120:+
THCA	cis	rs11018904	0.861	rs12787117	ENSG00000280385.1	AP000648.5	-6.34	5.36e-10	1.19e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr11:90210513	chr11:90193614~90198120:+
THCA	cis	rs11018904	0.906	rs35129016	ENSG00000280385.1	AP000648.5	-6.34	5.36e-10	1.19e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr11:90215521	chr11:90193614~90198120:+
THCA	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	6.34	5.36e-10	1.19e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
THCA	cis	rs7976269	0.609	rs2196480	ENSG00000257176.2	RP11-996F15.2	-6.34	5.36e-10	1.19e-07	-0.29	-0.28	Male-pattern baldness;	chr12:29062850	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.537	rs10743642	ENSG00000257176.2	RP11-996F15.2	-6.34	5.36e-10	1.19e-07	-0.29	-0.28	Male-pattern baldness;	chr12:29063557	chr12:29280418~29317848:-
THCA	cis	rs7976269	0.609	rs10771472	ENSG00000257176.2	RP11-996F15.2	-6.34	5.36e-10	1.19e-07	-0.29	-0.28	Male-pattern baldness;	chr12:29063930	chr12:29280418~29317848:-
THCA	cis	rs2562456	0.874	rs9304986	ENSG00000268081.1	RP11-678G14.2	-6.34	5.36e-10	1.19e-07	-0.41	-0.28	Pain;	chr19:21499260	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.917	rs2650805	ENSG00000268081.1	RP11-678G14.2	-6.34	5.36e-10	1.19e-07	-0.41	-0.28	Pain;	chr19:21505137	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.917	rs10420016	ENSG00000268081.1	RP11-678G14.2	-6.34	5.36e-10	1.19e-07	-0.41	-0.28	Pain;	chr19:21505800	chr19:21554640~21569237:-
THCA	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-6.34	5.37e-10	1.19e-07	-0.26	-0.28	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
THCA	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-6.34	5.37e-10	1.19e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
THCA	cis	rs73607972	0.935	rs17214955	ENSG00000275191.1	RP11-36I17.2	-6.34	5.37e-10	1.19e-07	-0.44	-0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612064	chr16:53628256~53628816:-
THCA	cis	rs12435908	0.609	rs73268524	ENSG00000276116.2	FUT8-AS1	-6.34	5.37e-10	1.19e-07	-0.45	-0.28	Ischemic stroke;	chr14:65629815	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs17826790	ENSG00000276116.2	FUT8-AS1	-6.34	5.37e-10	1.19e-07	-0.45	-0.28	Ischemic stroke;	chr14:65636709	chr14:65411170~65412690:-
THCA	cis	rs916888	0.61	rs199446	ENSG00000232300.1	FAM215B	-6.34	5.37e-10	1.19e-07	-0.4	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46558830~46562795:-
THCA	cis	rs73110464	0.609	rs11170348	ENSG00000278185.1	RP11-153F5.7	6.34	5.37e-10	1.19e-07	0.29	0.28	Cancer (pleiotropy);	chr12:52961804	chr12:52946614~52947125:-
THCA	cis	rs2163813	0.959	rs247770	ENSG00000275540.1	CTC-559E9.12	6.34	5.37e-10	1.19e-07	0.33	0.28	Toenail selenium levels;	chr19:19737995	chr19:19740884~19750127:+
THCA	cis	rs34375054	0.573	rs35698828	ENSG00000279233.1	RP11-158L12.4	6.34	5.38e-10	1.19e-07	0.32	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125174057	chr12:125138245~125141711:+
THCA	cis	rs4143844	0.867	rs34589937	ENSG00000259251.2	RP11-643M14.1	6.34	5.38e-10	1.19e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61876196	chr15:62060503~62062434:+
THCA	cis	rs6860806	0.661	rs28472559	ENSG00000237714.1	P4HA2-AS1	6.34	5.38e-10	1.19e-07	0.36	0.28	Breast cancer;	chr5:132245918	chr5:132184876~132192808:+
THCA	cis	rs7208859	0.673	rs2433	ENSG00000263603.1	CTD-2349P21.5	-6.34	5.38e-10	1.19e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30729469~30731202:+
THCA	cis	rs6840360	0.642	rs1443090	ENSG00000251611.1	RP11-610P16.1	-6.34	5.39e-10	1.19e-07	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151530667	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.582	rs1372976	ENSG00000251611.1	RP11-610P16.1	-6.34	5.39e-10	1.2e-07	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151407551~151408835:-
THCA	cis	rs860295	0.65	rs488079	ENSG00000225855.5	RUSC1-AS1	-6.34	5.39e-10	1.2e-07	-0.18	-0.28	Body mass index;	chr1:155920790	chr1:155316863~155324176:-
THCA	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-6.34	5.4e-10	1.2e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-6.34	5.4e-10	1.2e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-6.34	5.4e-10	1.2e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
THCA	cis	rs34779708	0.733	rs12240638	ENSG00000271335.4	RP11-324I22.4	6.34	5.4e-10	1.2e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35314552~35336401:-
THCA	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-6.34	5.4e-10	1.2e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
THCA	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-6.34	5.4e-10	1.2e-07	-0.3	-0.28	Height;	chr5:36861889	chr5:36666214~36725195:-
THCA	cis	rs6545883	0.894	rs6739427	ENSG00000271889.1	RP11-493E12.1	-6.34	5.41e-10	1.2e-07	-0.27	-0.28	Tuberculosis;	chr2:61225744	chr2:61151433~61162105:-
THCA	cis	rs713477	0.967	rs10483642	ENSG00000258413.1	RP11-665C16.6	-6.34	5.41e-10	1.2e-07	-0.37	-0.28	Pediatric bone mineral content (femoral neck);	chr14:55453742	chr14:55262767~55272075:-
THCA	cis	rs6545883	0.894	rs6545845	ENSG00000271889.1	RP11-493E12.1	-6.34	5.41e-10	1.2e-07	-0.26	-0.28	Tuberculosis;	chr2:61209909	chr2:61151433~61162105:-
THCA	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-6.34	5.41e-10	1.2e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-6.34	5.41e-10	1.2e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
THCA	cis	rs7829975	0.688	rs7826654	ENSG00000254153.1	CTA-398F10.2	-6.34	5.42e-10	1.2e-07	-0.31	-0.28	Mood instability;	chr8:8521596	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.688	rs7826660	ENSG00000254153.1	CTA-398F10.2	-6.34	5.42e-10	1.2e-07	-0.31	-0.28	Mood instability;	chr8:8521597	chr8:8456909~8461337:-
THCA	cis	rs2765539	0.7	rs4659147	ENSG00000231365.4	RP11-418J17.1	-6.34	5.42e-10	1.2e-07	-0.31	-0.28	Waist-hip ratio;	chr1:119103412	chr1:119140396~119275973:+
THCA	cis	rs10799445	0.569	rs2999745	ENSG00000227711.2	RP11-275O4.5	-6.34	5.42e-10	1.2e-07	-0.29	-0.28	Height;	chr1:227604838	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs2999746	ENSG00000227711.2	RP11-275O4.5	-6.34	5.42e-10	1.2e-07	-0.29	-0.28	Height;	chr1:227605784	chr1:227509028~227520477:-
THCA	cis	rs797680	0.891	rs4847399	ENSG00000223745.6	RP4-717I23.3	6.34	5.43e-10	1.2e-07	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93119049	chr1:93262186~93346025:-
THCA	cis	rs5758659	0.692	rs5751251	ENSG00000281538.1	RP4-669P10.20	6.34	5.43e-10	1.2e-07	0.25	0.28	Cognitive function;	chr22:42244600	chr22:42138060~42139726:+
THCA	cis	rs593531	0.571	rs35170680	ENSG00000212961.4	HNRNPA1P40	6.34	5.44e-10	1.2e-07	0.36	0.28	Neuroticism;	chr11:74374375	chr11:74354443~74355720:+
THCA	cis	rs593531	0.571	rs6592557	ENSG00000212961.4	HNRNPA1P40	6.34	5.44e-10	1.2e-07	0.36	0.28	Neuroticism;	chr11:74375597	chr11:74354443~74355720:+
THCA	cis	rs17772222	0.917	rs2004329	ENSG00000222990.1	RNU4-22P	6.34	5.44e-10	1.21e-07	0.36	0.28	Coronary artery calcification;	chr14:88532965	chr14:88513498~88513663:+
THCA	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	6.34	5.44e-10	1.21e-07	0.56	0.28	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
THCA	cis	rs7119038	0.629	rs11217000	ENSG00000255239.1	AP002954.6	-6.34	5.44e-10	1.21e-07	-0.43	-0.28	Sjögren's syndrome;	chr11:118734275	chr11:118688039~118690600:-
THCA	cis	rs2274273	0.516	rs2149482	ENSG00000258413.1	RP11-665C16.6	-6.34	5.45e-10	1.21e-07	-0.38	-0.28	Protein biomarker;	chr14:54901909	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.516	rs10136972	ENSG00000258413.1	RP11-665C16.6	-6.34	5.45e-10	1.21e-07	-0.38	-0.28	Protein biomarker;	chr14:54903567	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.516	rs10137071	ENSG00000258413.1	RP11-665C16.6	-6.34	5.45e-10	1.21e-07	-0.38	-0.28	Protein biomarker;	chr14:54903622	chr14:55262767~55272075:-
THCA	cis	rs6603134	0.502	rs10411185	ENSG00000269139.2	CTD-3193O13.8	6.34	5.45e-10	1.21e-07	0.26	0.28	Blood protein levels;	chr19:8038997	chr19:7926001~7926810:+
THCA	cis	rs79349575	0.783	rs1994970	ENSG00000248278.1	SUMO2P17	-6.34	5.45e-10	1.21e-07	-0.33	-0.28	Type 2 diabetes;	chr17:48936765	chr17:48874860~48908983:-
THCA	cis	rs2442825	0.691	rs2596912	ENSG00000206573.7	THUMPD3-AS1	6.34	5.46e-10	1.21e-07	0.17	0.28	Cerebrospinal fluid clusterin levels;	chr3:9397062	chr3:9349689~9398579:-
THCA	cis	rs11668609	0.505	rs60888272	ENSG00000268442.1	CTD-2027I19.2	6.34	5.46e-10	1.21e-07	0.38	0.28	Response to taxane treatment (docetaxel);	chr19:23968491	chr19:24162370~24163425:-
THCA	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-6.34	5.46e-10	1.21e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
THCA	cis	rs2179367	0.509	rs9485390	ENSG00000231760.4	RP11-350J20.5	6.34	5.46e-10	1.21e-07	0.4	0.28	Dupuytren's disease;	chr6:149421004	chr6:149796151~149826294:-
THCA	cis	rs2554380	0.628	rs7175491	ENSG00000230373.7	GOLGA6L5P	-6.34	5.46e-10	1.21e-07	-0.3	-0.28	Height;	chr15:83806187	chr15:84507885~84516814:-
THCA	cis	rs2243480	1	rs1723269	ENSG00000228409.4	CCT6P1	6.34	5.46e-10	1.21e-07	0.33	0.28	Diabetic kidney disease;	chr7:66007799	chr7:65751142~65763354:+
THCA	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	6.34	5.47e-10	1.21e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
THCA	cis	rs867371	1	rs867370	ENSG00000259429.4	UBE2Q2P2	6.34	5.47e-10	1.21e-07	0.23	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82355142~82420075:+
THCA	cis	rs867371	1	rs867371	ENSG00000259429.4	UBE2Q2P2	6.34	5.47e-10	1.21e-07	0.23	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82355142~82420075:+
THCA	cis	rs7712401	0.686	rs246305	ENSG00000249996.1	RP11-359P5.1	6.34	5.47e-10	1.21e-07	0.27	0.28	Mean platelet volume;	chr5:122863911	chr5:123036271~123054667:+
THCA	cis	rs7727544	0.735	rs274566	ENSG00000237714.1	P4HA2-AS1	-6.34	5.47e-10	1.21e-07	-0.36	-0.28	Blood metabolite levels;	chr5:132379319	chr5:132184876~132192808:+
THCA	cis	rs7202877	0.61	rs468079	ENSG00000261783.1	RP11-252K23.2	6.34	5.47e-10	1.21e-07	0.48	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75394576	chr16:75379818~75381260:-
THCA	cis	rs860295	0.614	rs639398	ENSG00000225855.5	RUSC1-AS1	-6.34	5.47e-10	1.21e-07	-0.18	-0.28	Body mass index;	chr1:155920447	chr1:155316863~155324176:-
THCA	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	6.34	5.48e-10	1.21e-07	0.4	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
THCA	cis	rs8027521	0.54	rs8024684	ENSG00000280362.1	RP11-643A5.3	6.34	5.48e-10	1.21e-07	0.34	0.28	Circulating chemerin levels;	chr15:53945584	chr15:53910769~53914712:+
THCA	cis	rs317689	0.581	rs160829	ENSG00000274979.1	RP11-1143G9.5	-6.34	5.48e-10	1.21e-07	-0.32	-0.28	Response to diuretic therapy;	chr12:69375758	chr12:69326574~69331882:-
THCA	cis	rs1979679	0.842	rs34043014	ENSG00000278733.1	RP11-425D17.1	6.34	5.49e-10	1.22e-07	0.27	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171359	chr12:28185625~28186190:-
THCA	cis	rs1979679	0.842	rs10492370	ENSG00000278733.1	RP11-425D17.1	6.34	5.49e-10	1.22e-07	0.27	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171900	chr12:28185625~28186190:-
THCA	cis	rs2179367	0.887	rs6570965	ENSG00000231760.4	RP11-350J20.5	6.34	5.49e-10	1.22e-07	0.36	0.28	Dupuytren's disease;	chr6:149396340	chr6:149796151~149826294:-
THCA	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	6.34	5.49e-10	1.22e-07	0.36	0.28	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
THCA	cis	rs9677476	0.863	rs12465477	ENSG00000224376.1	AC017104.6	6.34	5.49e-10	1.22e-07	0.31	0.28	Food antigen IgG levels;	chr2:231208569	chr2:231388976~231394991:+
THCA	cis	rs1594829	0.535	rs17055121	ENSG00000228451.3	SDAD1P1	6.34	5.49e-10	1.22e-07	0.28	0.28	Height;	chr8:26313459	chr8:26379259~26382953:-
THCA	cis	rs2797160	0.651	rs1268067	ENSG00000237742.5	RP11-624M8.1	6.34	5.5e-10	1.22e-07	0.25	0.28	Endometrial cancer;	chr6:125715475	chr6:125578558~125749190:-
THCA	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	6.34	5.5e-10	1.22e-07	0.39	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
THCA	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-6.34	5.5e-10	1.22e-07	-0.25	-0.28	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
THCA	cis	rs7809950	1	rs7809950	ENSG00000238832.1	snoU109	6.34	5.51e-10	1.22e-07	0.31	0.28	Coronary artery disease;	chr7:107597362	chr7:107603363~107603507:+
THCA	cis	rs7617773	0.963	rs12493256	ENSG00000228638.1	FCF1P2	6.34	5.51e-10	1.22e-07	0.27	0.28	Coronary artery disease;	chr3:48135257	chr3:48290793~48291375:-
THCA	cis	rs4971059	0.654	rs7364524	ENSG00000160766.13	GBAP1	-6.34	5.52e-10	1.22e-07	-0.3	-0.28	Breast cancer;	chr1:155149446	chr1:155213821~155227422:-
THCA	cis	rs10266483	0.515	rs17689514	ENSG00000271550.1	BNIP3P11	-6.34	5.52e-10	1.22e-07	-0.43	-0.28	Response to statin therapy;	chr7:64279269	chr7:64678954~64687393:-
THCA	cis	rs10208649	1	rs7594327	ENSG00000272156.1	RP11-477N3.1	6.34	5.52e-10	1.22e-07	0.52	0.28	Body mass index;	chr2:53830766	chr2:54082554~54085066:+
THCA	cis	rs6061231	1	rs67941642	ENSG00000275437.1	RP5-908M14.10	6.34	5.52e-10	1.22e-07	0.26	0.28	Colorectal cancer;	chr20:62383052	chr20:62402236~62405935:-
THCA	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-6.34	5.53e-10	1.22e-07	-0.25	-0.28	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-6.34	5.53e-10	1.22e-07	-0.25	-0.28	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-6.34	5.53e-10	1.22e-07	-0.25	-0.28	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
THCA	cis	rs12534093	0.562	rs6461715	ENSG00000234286.1	AC006026.13	-6.34	5.53e-10	1.22e-07	-0.38	-0.28	Infant length;Height;	chr7:23539496	chr7:23680195~23680786:-
THCA	cis	rs7201929	1	rs11644151	ENSG00000251417.2	RP11-1348G14.4	6.34	5.53e-10	1.23e-07	0.3	0.28	QT interval;	chr16:28884339	chr16:28802743~28817828:+
THCA	cis	rs1318937	0.915	rs3773472	ENSG00000224660.1	SH3BP5-AS1	6.34	5.53e-10	1.23e-07	0.19	0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15261246	chr3:15254184~15264493:+
THCA	cis	rs1865760	0.929	rs2876693	ENSG00000272462.2	U91328.19	-6.34	5.54e-10	1.23e-07	-0.23	-0.28	Height;	chr6:25954206	chr6:25992662~26001775:+
THCA	cis	rs9309711	0.961	rs11686236	ENSG00000225234.1	TRAPPC12-AS1	-6.34	5.54e-10	1.23e-07	-0.3	-0.28	Neurofibrillary tangles;	chr2:3467778	chr2:3481242~3482409:-
THCA	cis	rs593531	0.571	rs10793081	ENSG00000212961.4	HNRNPA1P40	6.34	5.54e-10	1.23e-07	0.35	0.28	Neuroticism;	chr11:74381358	chr11:74354443~74355720:+
THCA	cis	rs7829975	0.688	rs7817376	ENSG00000254153.1	CTA-398F10.2	6.34	5.54e-10	1.23e-07	0.31	0.28	Mood instability;	chr8:8523020	chr8:8456909~8461337:-
THCA	cis	rs7948661	1	rs7113959	ENSG00000278376.1	RP11-158I9.8	6.34	5.54e-10	1.23e-07	0.46	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118508381	chr11:118791254~118793137:+
THCA	cis	rs60180747	0.544	rs12908529	ENSG00000261318.1	RP11-653J6.1	6.34	5.55e-10	1.23e-07	0.38	0.28	Testicular germ cell tumor;	chr15:66279630	chr15:66278498~66293357:-
THCA	cis	rs10129255	0.912	rs61997792	ENSG00000211974.3	IGHV2-70	6.34	5.55e-10	1.23e-07	0.22	0.28	Kawasaki disease;	chr14:106799304	chr14:106723574~106724093:-
THCA	cis	rs2255336	0.938	rs1382264	ENSG00000245648.1	RP11-277P12.20	-6.34	5.55e-10	1.23e-07	-0.34	-0.28	Blood protein levels;	chr12:10390740	chr12:10363769~10398506:+
THCA	cis	rs7727544	0.735	rs274559	ENSG00000237714.1	P4HA2-AS1	-6.34	5.55e-10	1.23e-07	-0.36	-0.28	Blood metabolite levels;	chr5:132384378	chr5:132184876~132192808:+
THCA	cis	rs7044106	0.512	rs7873848	ENSG00000270917.1	RP11-27I1.6	-6.34	5.55e-10	1.23e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120812475~120812845:-
THCA	cis	rs17594362	0.731	rs1034204	ENSG00000264190.1	MIR5006	6.33	5.56e-10	1.23e-07	0.38	0.28	Multiple sclerosis;	chr13:41564452	chr13:41568286~41568395:-
THCA	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	6.33	5.57e-10	1.23e-07	0.26	0.28	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
THCA	cis	rs6545883	0.965	rs6718887	ENSG00000271889.1	RP11-493E12.1	6.33	5.57e-10	1.23e-07	0.27	0.28	Tuberculosis;	chr2:61500080	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.965	rs6734830	ENSG00000271889.1	RP11-493E12.1	6.33	5.57e-10	1.23e-07	0.27	0.28	Tuberculosis;	chr2:61503977	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.931	rs9807965	ENSG00000271889.1	RP11-493E12.1	6.33	5.57e-10	1.23e-07	0.27	0.28	Tuberculosis;	chr2:61505024	chr2:61151433~61162105:-
THCA	cis	rs595244	1	rs59343375	ENSG00000259705.1	RP11-227D13.1	6.33	5.57e-10	1.23e-07	0.46	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48526928	chr15:48645951~48652016:+
THCA	cis	rs12893668	0.572	rs2273175	ENSG00000269910.1	RP11-73M18.10	6.33	5.58e-10	1.23e-07	0.26	0.28	Reticulocyte count;	chr14:103693804	chr14:103694516~103695050:-
THCA	cis	rs7712401	0.686	rs154511	ENSG00000249996.1	RP11-359P5.1	6.33	5.58e-10	1.23e-07	0.27	0.28	Mean platelet volume;	chr5:122859859	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.686	rs154509	ENSG00000249996.1	RP11-359P5.1	6.33	5.58e-10	1.23e-07	0.27	0.28	Mean platelet volume;	chr5:122862645	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.686	rs185007	ENSG00000249996.1	RP11-359P5.1	6.33	5.58e-10	1.23e-07	0.27	0.28	Mean platelet volume;	chr5:122863623	chr5:123036271~123054667:+
THCA	cis	rs6600671	0.899	rs6674392	ENSG00000275538.1	RNVU1-19	6.33	5.59e-10	1.24e-07	0.35	0.28	Hip geometry;	chr1:121518864	chr1:120850819~120850985:-
THCA	cis	rs5742933	0.948	rs7592066	ENSG00000273240.1	RP11-455J20.3	6.33	5.6e-10	1.24e-07	0.29	0.28	Ferritin levels;	chr2:189778792	chr2:189763859~189764456:-
THCA	cis	rs6696239	0.513	rs2999744	ENSG00000227711.2	RP11-275O4.5	-6.33	5.6e-10	1.24e-07	-0.29	-0.28	Height;	chr1:227599667	chr1:227509028~227520477:-
THCA	cis	rs34779708	0.733	rs61449529	ENSG00000271335.4	RP11-324I22.4	6.33	5.6e-10	1.24e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs59287215	ENSG00000271335.4	RP11-324I22.4	6.33	5.6e-10	1.24e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.702	rs35969476	ENSG00000271335.4	RP11-324I22.4	6.33	5.6e-10	1.24e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35314552~35336401:-
THCA	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-6.33	5.6e-10	1.24e-07	-0.26	-0.28	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-6.33	5.6e-10	1.24e-07	-0.26	-0.28	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
THCA	cis	rs944990	0.686	rs6479485	ENSG00000227603.1	RP11-165J3.6	6.33	5.61e-10	1.24e-07	0.29	0.28	Body mass index;	chr9:93456969	chr9:93435332~93437121:-
THCA	cis	rs10761482	0.5	rs1890926	ENSG00000254271.1	RP11-131N11.4	6.33	5.61e-10	1.24e-07	0.36	0.28	Schizophrenia;	chr10:60530347	chr10:60734342~60741828:+
THCA	cis	rs2439831	1	rs689826	ENSG00000275601.1	AC011330.13	-6.33	5.61e-10	1.24e-07	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43457718	chr15:43642389~43643023:-
THCA	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-6.33	5.61e-10	1.24e-07	-0.31	-0.28	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
THCA	cis	rs17767294	0.612	rs9461425	ENSG00000219392.1	RP1-265C24.5	-6.33	5.61e-10	1.24e-07	-0.51	-0.28	Parkinson's disease;	chr6:27951910	chr6:28115628~28116551:+
THCA	cis	rs934734	0.725	rs7581149	ENSG00000204929.10	AC074391.1	6.33	5.62e-10	1.24e-07	0.36	0.28	Rheumatoid arthritis;	chr2:65332507	chr2:65436711~66084639:+
THCA	cis	rs6545883	0.929	rs2121660	ENSG00000271889.1	RP11-493E12.1	-6.33	5.62e-10	1.24e-07	-0.27	-0.28	Tuberculosis;	chr2:61425923	chr2:61151433~61162105:-
THCA	cis	rs11158026	0.859	rs8019824	ENSG00000258413.1	RP11-665C16.6	-6.33	5.63e-10	1.24e-07	-0.38	-0.28	Parkinson's disease;	chr14:54898613	chr14:55262767~55272075:-
THCA	cis	rs848490	0.889	rs56265941	ENSG00000214293.7	APTR	6.33	5.63e-10	1.25e-07	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77593621	chr7:77657660~77696265:-
THCA	cis	rs6603134	0.502	rs10406511	ENSG00000269139.2	CTD-3193O13.8	6.33	5.63e-10	1.25e-07	0.26	0.28	Blood protein levels;	chr19:8039061	chr19:7926001~7926810:+
THCA	cis	rs6968419	0.585	rs9692117	ENSG00000237870.5	AC073130.1	6.33	5.63e-10	1.25e-07	0.29	0.28	Intraocular pressure;	chr7:116287905	chr7:116275606~116286734:-
THCA	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-6.33	5.63e-10	1.25e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
THCA	cis	rs7976269	0.537	rs4471475	ENSG00000257176.2	RP11-996F15.2	-6.33	5.64e-10	1.25e-07	-0.29	-0.28	Male-pattern baldness;	chr12:29022461	chr12:29280418~29317848:-
THCA	cis	rs9813712	0.904	rs6439223	ENSG00000249846.5	RP11-77P16.4	6.33	5.64e-10	1.25e-07	0.33	0.28	Response to amphetamines;	chr3:130256697	chr3:130112550~130120579:+
THCA	cis	rs10276381	0.786	rs10255700	ENSG00000234336.5	JAZF1-AS1	-6.33	5.65e-10	1.25e-07	-0.39	-0.28	Crohn's disease;	chr7:28180609	chr7:28180322~28243917:+
THCA	cis	rs1005277	0.602	rs1831315	ENSG00000276805.1	RP11-291L22.6	6.33	5.65e-10	1.25e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780130	ENSG00000276805.1	RP11-291L22.6	6.33	5.65e-10	1.25e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38451030~38451785:+
THCA	cis	rs73110464	0.609	rs6580923	ENSG00000278185.1	RP11-153F5.7	6.33	5.65e-10	1.25e-07	0.29	0.28	Cancer (pleiotropy);	chr12:52964568	chr12:52946614~52947125:-
THCA	cis	rs4650994	0.525	rs2761463	ENSG00000273384.1	RP5-1098D14.1	-6.33	5.66e-10	1.25e-07	-0.35	-0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178588002	chr1:178651706~178652282:+
THCA	cis	rs8027521	0.54	rs8036751	ENSG00000280362.1	RP11-643A5.3	6.33	5.66e-10	1.25e-07	0.34	0.28	Circulating chemerin levels;	chr15:53941093	chr15:53910769~53914712:+
THCA	cis	rs8012947	0.848	rs1190982	ENSG00000279636.2	LINC00216	-6.33	5.66e-10	1.25e-07	-0.29	-0.28	Alcohol consumption in current drinkers;	chr14:58349121	chr14:58288033~58289158:+
THCA	cis	rs7976269	0.609	rs10771478	ENSG00000257176.2	RP11-996F15.2	6.33	5.67e-10	1.25e-07	0.28	0.28	Male-pattern baldness;	chr12:29075351	chr12:29280418~29317848:-
THCA	cis	rs17772222	0.837	rs57118463	ENSG00000258789.1	RP11-507K2.3	-6.33	5.67e-10	1.25e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88665822	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.874	rs61984746	ENSG00000258789.1	RP11-507K2.3	-6.33	5.67e-10	1.25e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88668136	chr14:88551597~88552493:+
THCA	cis	rs6603134	0.502	rs10405582	ENSG00000269139.2	CTD-3193O13.8	6.33	5.67e-10	1.25e-07	0.26	0.28	Blood protein levels;	chr19:8038654	chr19:7926001~7926810:+
THCA	cis	rs7403037	1	rs9920830	ENSG00000259905.4	PWRN1	6.33	5.67e-10	1.25e-07	0.31	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24550769	chr15:24493137~24652130:+
THCA	cis	rs7403037	1	rs9920079	ENSG00000259905.4	PWRN1	6.33	5.67e-10	1.25e-07	0.31	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24550772	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.958	rs9920094	ENSG00000259905.4	PWRN1	6.33	5.67e-10	1.25e-07	0.31	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24550982	chr15:24493137~24652130:+
THCA	cis	rs595244	1	rs75225368	ENSG00000259705.1	RP11-227D13.1	6.33	5.68e-10	1.26e-07	0.5	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48493009	chr15:48645951~48652016:+
THCA	cis	rs8062405	0.755	rs111693583	ENSG00000278665.1	RP11-666O2.4	6.33	5.68e-10	1.26e-07	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28599241~28601881:-
THCA	cis	rs6504663	1	rs6504661	ENSG00000275897.1	RP11-94C24.13	-6.33	5.69e-10	1.26e-07	-0.26	-0.28	Visceral fat;	chr17:50502765	chr17:50475819~50478391:+
THCA	cis	rs595244	1	rs11638586	ENSG00000259705.1	RP11-227D13.1	6.33	5.69e-10	1.26e-07	0.5	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48480646	chr15:48645951~48652016:+
THCA	cis	rs11976180	1	rs2951308	ENSG00000170356.8	OR2A20P	6.33	5.69e-10	1.26e-07	0.38	0.28	Obesity-related traits;	chr7:144070056	chr7:144250045~144252957:-
THCA	cis	rs8062405	0.755	rs7186573	ENSG00000278665.1	RP11-666O2.4	6.33	5.69e-10	1.26e-07	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28599241~28601881:-
THCA	cis	rs3950186	1	rs7739256	ENSG00000215124.2	RP3-420J14.1	-6.33	5.69e-10	1.26e-07	-0.31	-0.28	Anxiety and major depressive disorder;	chr6:11815815	chr6:11861626~11862970:-
THCA	cis	rs11696845	0.712	rs6130685	ENSG00000276223.1	RP4-781B1.5	-6.33	5.7e-10	1.26e-07	-0.34	-0.28	Obesity-related traits;	chr20:44738089	chr20:44746642~44747201:+
THCA	cis	rs10208649	1	rs41536750	ENSG00000233266.1	HMGB1P31	-6.33	5.71e-10	1.26e-07	-0.6	-0.28	Body mass index;	chr2:53894823	chr2:54051334~54051760:+
THCA	cis	rs1005277	0.54	rs2474598	ENSG00000276805.1	RP11-291L22.6	-6.33	5.72e-10	1.26e-07	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38451030~38451785:+
THCA	cis	rs831571	0.649	rs831556	ENSG00000280620.1	SCAANT1	-6.33	5.72e-10	1.26e-07	-0.43	-0.28	Type 2 diabetes;	chr3:64036017	chr3:63911518~63911772:-
THCA	cis	rs9813712	0.571	rs11715351	ENSG00000249846.5	RP11-77P16.4	-6.33	5.72e-10	1.27e-07	-0.29	-0.28	Response to amphetamines;	chr3:130214704	chr3:130112550~130120579:+
THCA	cis	rs10510102	0.608	rs4486560	ENSG00000226864.1	ATE1-AS1	6.33	5.73e-10	1.27e-07	0.36	0.28	Breast cancer;	chr10:121844840	chr10:121928312~121951965:+
THCA	cis	rs11603691	1	rs113309829	ENSG00000254662.1	RP11-872D17.4	-6.33	5.73e-10	1.27e-07	-0.6	-0.28	Low high density lipoprotein cholesterol levels;	chr11:57239098	chr11:57325603~57327958:+
THCA	cis	rs5758659	0.714	rs6002607	ENSG00000227370.1	RP4-669P10.19	6.33	5.74e-10	1.27e-07	0.26	0.28	Cognitive function;	chr22:42100502	chr22:42132543~42132998:+
THCA	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-6.33	5.74e-10	1.27e-07	-0.25	-0.28	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-6.33	5.74e-10	1.27e-07	-0.25	-0.28	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
THCA	cis	rs6903823	0.508	rs1150721	ENSG00000219392.1	RP1-265C24.5	-6.33	5.74e-10	1.27e-07	-0.31	-0.28	Pulmonary function;	chr6:28287263	chr6:28115628~28116551:+
THCA	cis	rs6903823	0.508	rs1233660	ENSG00000219392.1	RP1-265C24.5	-6.33	5.74e-10	1.27e-07	-0.31	-0.28	Pulmonary function;	chr6:28292472	chr6:28115628~28116551:+
THCA	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-6.33	5.74e-10	1.27e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-6.33	5.74e-10	1.27e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000229886.1	RP5-1132H15.3	6.33	5.75e-10	1.27e-07	0.47	0.28	Gout;	chr7:66732812	chr7:66025126~66031544:-
THCA	cis	rs4650994	0.525	rs4650997	ENSG00000273384.1	RP5-1098D14.1	6.33	5.75e-10	1.27e-07	0.35	0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178561609	chr1:178651706~178652282:+
THCA	cis	rs7617773	0.539	rs6779517	ENSG00000228638.1	FCF1P2	-6.33	5.75e-10	1.27e-07	-0.27	-0.28	Coronary artery disease;	chr3:48342898	chr3:48290793~48291375:-
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000220721.1	OR1F12	6.33	5.76e-10	1.27e-07	0.37	0.28	Parkinson's disease;	chr6:28065618	chr6:28073316~28074233:+
THCA	cis	rs1005277	0.603	rs1998062	ENSG00000276805.1	RP11-291L22.6	6.33	5.76e-10	1.27e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38451030~38451785:+
THCA	cis	rs9677476	0.863	rs16827863	ENSG00000224376.1	AC017104.6	-6.33	5.76e-10	1.27e-07	-0.31	-0.28	Food antigen IgG levels;	chr2:231212957	chr2:231388976~231394991:+
THCA	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	6.33	5.76e-10	1.27e-07	0.32	0.28	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
THCA	cis	rs4713118	0.614	rs9380007	ENSG00000219392.1	RP1-265C24.5	-6.33	5.77e-10	1.27e-07	-0.31	-0.28	Parkinson's disease;	chr6:27692729	chr6:28115628~28116551:+
THCA	cis	rs728616	0.717	rs61860016	ENSG00000242600.5	MBL1P	6.33	5.77e-10	1.27e-07	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:79904898~79950336:+
THCA	cis	rs916888	0.61	rs199453	ENSG00000232300.1	FAM215B	6.33	5.77e-10	1.27e-07	0.39	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46558830~46562795:-
THCA	cis	rs838147	0.537	rs632111	ENSG00000232871.7	SEC1P	6.33	5.77e-10	1.27e-07	0.33	0.28	Dietary macronutrient intake;	chr19:48705721	chr19:48638071~48682245:+
THCA	cis	rs2439831	0.867	rs7170489	ENSG00000249839.1	AC011330.5	-6.33	5.77e-10	1.27e-07	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43344453	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs16957630	ENSG00000249839.1	AC011330.5	-6.33	5.77e-10	1.27e-07	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43350582	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs16957632	ENSG00000249839.1	AC011330.5	-6.33	5.77e-10	1.27e-07	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43350699	chr15:43663654~43684339:-
THCA	cis	rs1949733	0.523	rs62287455	ENSG00000205959.3	RP11-689P11.2	6.33	5.78e-10	1.28e-07	0.25	0.28	Response to antineoplastic agents;	chr4:8543267	chr4:8482270~8512610:+
THCA	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-6.33	5.78e-10	1.28e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
THCA	cis	rs4713118	0.629	rs203887	ENSG00000220721.1	OR1F12	6.33	5.78e-10	1.28e-07	0.4	0.28	Parkinson's disease;	chr6:28053491	chr6:28073316~28074233:+
THCA	cis	rs2243480	0.901	rs73142137	ENSG00000232546.1	RP11-458F8.1	-6.33	5.79e-10	1.28e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65878455	chr7:66848496~66858136:+
THCA	cis	rs6903823	0.508	rs1150724	ENSG00000219392.1	RP1-265C24.5	-6.33	5.79e-10	1.28e-07	-0.31	-0.28	Pulmonary function;	chr6:28282459	chr6:28115628~28116551:+
THCA	cis	rs17594362	0.697	rs9566789	ENSG00000264190.1	MIR5006	6.33	5.79e-10	1.28e-07	0.38	0.28	Multiple sclerosis;	chr13:41562164	chr13:41568286~41568395:-
THCA	cis	rs4835473	0.932	rs4835120	ENSG00000251600.4	RP11-673E1.1	6.33	5.79e-10	1.28e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143982370	chr4:143912331~143982454:+
THCA	cis	rs4713118	0.513	rs156738	ENSG00000280107.1	AL022393.9	-6.33	5.8e-10	1.28e-07	-0.3	-0.28	Parkinson's disease;	chr6:28046247	chr6:28170845~28172521:+
THCA	cis	rs227275	0.525	rs3974485	ENSG00000251288.2	RP11-10L12.2	-6.33	5.8e-10	1.28e-07	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs2866417	ENSG00000251288.2	RP11-10L12.2	-6.33	5.8e-10	1.28e-07	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102751401~102752641:+
THCA	cis	rs1005277	0.579	rs2474571	ENSG00000276805.1	RP11-291L22.6	6.33	5.8e-10	1.28e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38451030~38451785:+
THCA	cis	rs801193	0.742	rs9969300	ENSG00000273142.1	RP11-458F8.4	6.33	5.8e-10	1.28e-07	0.22	0.28	Aortic root size;	chr7:66316659	chr7:66902857~66906297:+
THCA	cis	rs8027521	0.504	rs62010932	ENSG00000280362.1	RP11-643A5.3	6.33	5.8e-10	1.28e-07	0.35	0.28	Circulating chemerin levels;	chr15:53933892	chr15:53910769~53914712:+
THCA	cis	rs890448	0.726	rs2583394	ENSG00000254531.1	FLJ20021	6.33	5.8e-10	1.28e-07	0.25	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101330625	chr4:101347780~101348883:+
THCA	cis	rs56114371	0.53	rs9357045	ENSG00000219392.1	RP1-265C24.5	-6.33	5.81e-10	1.28e-07	-0.39	-0.28	Breast cancer;	chr6:27721148	chr6:28115628~28116551:+
THCA	cis	rs11051970	0.614	rs2728684	ENSG00000274964.1	RP11-817I4.1	-6.33	5.81e-10	1.28e-07	-0.34	-0.28	Response to tocilizumab in rheumatoid arthritis;	chr12:32422731	chr12:32339368~32340724:+
THCA	cis	rs748404	1	rs17779494	ENSG00000249839.1	AC011330.5	6.33	5.81e-10	1.28e-07	0.37	0.28	Lung cancer;	chr15:43287025	chr15:43663654~43684339:-
THCA	cis	rs227275	0.525	rs10032234	ENSG00000251288.2	RP11-10L12.2	-6.33	5.81e-10	1.28e-07	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs3886723	ENSG00000251288.2	RP11-10L12.2	-6.33	5.81e-10	1.28e-07	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102751401~102752641:+
THCA	cis	rs228614	0.517	rs3886722	ENSG00000251288.2	RP11-10L12.2	-6.33	5.81e-10	1.28e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs11737544	ENSG00000251288.2	RP11-10L12.2	-6.33	5.81e-10	1.28e-07	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102751401~102752641:+
THCA	cis	rs10971721	0.584	rs72731218	ENSG00000281128.1	PTENP1-AS	6.33	5.81e-10	1.28e-07	0.59	0.28	Body mass index;	chr9:34119678	chr9:33677268~33688011:+
THCA	cis	rs9402743	0.926	rs7762826	ENSG00000231028.7	LINC00271	-6.33	5.82e-10	1.28e-07	-0.22	-0.28	Systemic lupus erythematosus;	chr6:135654485	chr6:135497801~135716055:+
THCA	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-6.33	5.82e-10	1.29e-07	-0.17	-0.28	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
THCA	cis	rs9677476	0.774	rs1973016	ENSG00000224376.1	AC017104.6	6.33	5.82e-10	1.29e-07	0.33	0.28	Food antigen IgG levels;	chr2:231252800	chr2:231388976~231394991:+
THCA	cis	rs1707322	0.686	rs2230658	ENSG00000281133.1	AL355480.3	6.33	5.83e-10	1.29e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.686	rs2991986	ENSG00000281133.1	AL355480.3	6.33	5.83e-10	1.29e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.686	rs2991987	ENSG00000281133.1	AL355480.3	6.33	5.83e-10	1.29e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45580892~45580996:-
THCA	cis	rs4073416	0.647	rs11158592	ENSG00000276116.2	FUT8-AS1	6.33	5.83e-10	1.29e-07	0.28	0.28	N-glycan levels;	chr14:65393250	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.647	rs11158593	ENSG00000276116.2	FUT8-AS1	6.33	5.83e-10	1.29e-07	0.28	0.28	N-glycan levels;	chr14:65393266	chr14:65411170~65412690:-
THCA	cis	rs9677476	0.863	rs3731775	ENSG00000224376.1	AC017104.6	6.33	5.84e-10	1.29e-07	0.32	0.28	Food antigen IgG levels;	chr2:231198864	chr2:231388976~231394991:+
THCA	cis	rs7015630	0.779	rs13260987	ENSG00000251136.7	RP11-37B2.1	-6.33	5.84e-10	1.29e-07	-0.29	-0.28	Inflammatory bowel disease;Crohn's disease;	chr8:89854126	chr8:89609409~89757727:-
THCA	cis	rs848490	0.928	rs62462681	ENSG00000214293.7	APTR	6.33	5.84e-10	1.29e-07	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77863702	chr7:77657660~77696265:-
THCA	cis	rs911555	0.511	rs8007489	ENSG00000269940.1	RP11-73M18.7	-6.33	5.85e-10	1.29e-07	-0.28	-0.28	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103694560~103695170:+
THCA	cis	rs4143844	1	rs35932993	ENSG00000259251.2	RP11-643M14.1	6.33	5.85e-10	1.29e-07	0.54	0.28	Bipolar disorder and schizophrenia;	chr15:62069557	chr15:62060503~62062434:+
THCA	cis	rs853679	0.546	rs200949	ENSG00000226314.6	ZNF192P1	-6.33	5.85e-10	1.29e-07	-0.44	-0.28	Depression;	chr6:27867657	chr6:28161781~28169594:+
THCA	cis	rs4835473	0.831	rs4452380	ENSG00000251600.4	RP11-673E1.1	6.33	5.85e-10	1.29e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143972856	chr4:143912331~143982454:+
THCA	cis	rs227275	0.554	rs223333	ENSG00000251288.2	RP11-10L12.2	-6.33	5.86e-10	1.29e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223328	ENSG00000251288.2	RP11-10L12.2	-6.33	5.86e-10	1.29e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102751401~102752641:+
THCA	cis	rs6908034	0.607	rs73376650	ENSG00000237404.1	RP3-471C18.2	-6.33	5.86e-10	1.29e-07	-0.55	-0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805275	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs112599867	ENSG00000237404.1	RP3-471C18.2	-6.33	5.86e-10	1.29e-07	-0.55	-0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805301	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs73376651	ENSG00000237404.1	RP3-471C18.2	-6.33	5.86e-10	1.29e-07	-0.55	-0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805328	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs73376655	ENSG00000237404.1	RP3-471C18.2	-6.33	5.86e-10	1.29e-07	-0.55	-0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805433	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs113592672	ENSG00000237404.1	RP3-471C18.2	-6.33	5.86e-10	1.29e-07	-0.55	-0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805832	chr6:19689825~19753113:-
THCA	cis	rs6545883	0.929	rs2463100	ENSG00000271889.1	RP11-493E12.1	6.33	5.86e-10	1.29e-07	0.27	0.28	Tuberculosis;	chr2:61432064	chr2:61151433~61162105:-
THCA	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-6.33	5.87e-10	1.29e-07	-0.25	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000099984.9	GSTT2	6.33	5.87e-10	1.29e-07	0.39	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23980123~23983911:+
THCA	cis	rs11668609	0.766	rs10414075	ENSG00000268442.1	CTD-2027I19.2	6.33	5.87e-10	1.3e-07	0.32	0.28	Response to taxane treatment (docetaxel);	chr19:24055649	chr19:24162370~24163425:-
THCA	cis	rs2120243	0.592	rs4640513	ENSG00000244515.1	KRT18P34	-6.33	5.87e-10	1.3e-07	-0.31	-0.28	Hepatocellular carcinoma in hepatitis B infection;	chr3:157398161	chr3:157162663~157163932:-
THCA	cis	rs3764021	0.509	rs10772074	ENSG00000256594.6	RP11-705C15.2	6.33	5.87e-10	1.3e-07	0.24	0.28	Type 1 diabetes;	chr12:9717686	chr12:9633419~9658412:+
THCA	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-6.33	5.87e-10	1.3e-07	-0.36	-0.28	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
THCA	cis	rs228614	0.536	rs150897	ENSG00000251288.2	RP11-10L12.2	-6.33	5.87e-10	1.3e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223472	ENSG00000251288.2	RP11-10L12.2	-6.33	5.87e-10	1.3e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102751401~102752641:+
THCA	cis	rs228614	0.536	rs223325	ENSG00000251288.2	RP11-10L12.2	-6.33	5.87e-10	1.3e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102751401~102752641:+
THCA	cis	rs7202877	0.706	rs247437	ENSG00000261783.1	RP11-252K23.2	6.33	5.88e-10	1.3e-07	0.48	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75397377	chr16:75379818~75381260:-
THCA	cis	rs3743772	1	rs3743772	ENSG00000279722.1	RP11-44F14.6	6.33	5.88e-10	1.3e-07	0.47	0.28	Depressive symptoms (SSRI exposure interaction);	chr16:53503511	chr16:53487607~53489943:-
THCA	cis	rs1707322	0.686	rs2275085	ENSG00000281133.1	AL355480.3	6.33	5.88e-10	1.3e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45580892~45580996:-
THCA	cis	rs74233809	0.901	rs1004467	ENSG00000213277.3	MARCKSL1P1	6.33	5.88e-10	1.3e-07	0.43	0.28	Birth weight;	chr10:102834750	chr10:103175554~103176094:+
THCA	cis	rs10208649	0.505	rs3770412	ENSG00000272156.1	RP11-477N3.1	6.33	5.89e-10	1.3e-07	0.41	0.28	Body mass index;	chr2:53685202	chr2:54082554~54085066:+
THCA	cis	rs56804039	1	rs67180327	ENSG00000253893.2	FAM85B	6.33	5.89e-10	1.3e-07	0.4	0.28	Cervical cancer;	chr8:8523244	chr8:8167819~8226614:-
THCA	cis	rs56804039	1	rs67611618	ENSG00000253893.2	FAM85B	6.33	5.89e-10	1.3e-07	0.4	0.28	Cervical cancer;	chr8:8523429	chr8:8167819~8226614:-
THCA	cis	rs56804039	1	rs58361948	ENSG00000253893.2	FAM85B	6.33	5.89e-10	1.3e-07	0.4	0.28	Cervical cancer;	chr8:8523485	chr8:8167819~8226614:-
THCA	cis	rs56804039	1	rs56804039	ENSG00000253893.2	FAM85B	6.33	5.89e-10	1.3e-07	0.4	0.28	Cervical cancer;	chr8:8523519	chr8:8167819~8226614:-
THCA	cis	rs56804039	1	rs6986470	ENSG00000253893.2	FAM85B	6.33	5.89e-10	1.3e-07	0.4	0.28	Cervical cancer;	chr8:8523920	chr8:8167819~8226614:-
THCA	cis	rs2797160	0.651	rs1268093	ENSG00000237742.5	RP11-624M8.1	6.33	5.89e-10	1.3e-07	0.25	0.28	Endometrial cancer;	chr6:125708089	chr6:125578558~125749190:-
THCA	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	6.33	5.9e-10	1.3e-07	0.36	0.28	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
THCA	cis	rs6674176	0.569	rs34830883	ENSG00000237950.1	RP11-7O11.3	6.32	5.91e-10	1.3e-07	0.25	0.28	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43939667	chr1:43944370~43946551:-
THCA	cis	rs8141529	0.732	rs11556025	ENSG00000226471.5	CTA-292E10.6	-6.32	5.91e-10	1.3e-07	-0.24	-0.28	Lymphocyte counts;	chr22:28772767	chr22:28800683~28848559:+
THCA	cis	rs7829975	0.593	rs2921061	ENSG00000254153.1	CTA-398F10.2	-6.32	5.92e-10	1.31e-07	-0.31	-0.28	Mood instability;	chr8:8460105	chr8:8456909~8461337:-
THCA	cis	rs4835473	0.932	rs1988206	ENSG00000251600.4	RP11-673E1.1	6.32	5.92e-10	1.31e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143991344	chr4:143912331~143982454:+
THCA	cis	rs3758785	0.737	rs3758786	ENSG00000255893.1	RP11-685N10.1	-6.32	5.92e-10	1.31e-07	-0.35	-0.28	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94399118	chr11:94472908~94473570:-
THCA	cis	rs11018904	0.861	rs61903723	ENSG00000280385.1	AP000648.5	-6.32	5.92e-10	1.31e-07	-0.38	-0.28	Intelligence (multi-trait analysis);	chr11:90235078	chr11:90193614~90198120:+
THCA	cis	rs12701220	0.542	rs6957866	ENSG00000229043.2	AC091729.9	-6.32	5.92e-10	1.31e-07	-0.43	-0.28	Bronchopulmonary dysplasia;	chr7:1072038	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.689	rs6973645	ENSG00000229043.2	AC091729.9	-6.32	5.92e-10	1.31e-07	-0.43	-0.28	Bronchopulmonary dysplasia;	chr7:1072610	chr7:1160374~1165267:+
THCA	cis	rs227275	0.554	rs223439	ENSG00000251288.2	RP11-10L12.2	-6.32	5.93e-10	1.31e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102751401~102752641:+
THCA	cis	rs11722228	0.522	rs881641	ENSG00000261490.1	RP11-448G15.3	6.32	5.94e-10	1.31e-07	0.2	0.28	Urate levels;Serum uric acid levels;Gout;	chr4:10132123	chr4:10068089~10073019:-
THCA	cis	rs77972916	0.505	rs6736400	ENSG00000234936.1	AC010883.5	6.32	5.96e-10	1.31e-07	0.31	0.28	Granulocyte percentage of myeloid white cells;	chr2:43273665	chr2:43229573~43233394:+
THCA	cis	rs8012947	0.916	rs8004077	ENSG00000279636.2	LINC00216	6.32	5.96e-10	1.32e-07	0.31	0.28	Alcohol consumption in current drinkers;	chr14:58380013	chr14:58288033~58289158:+
THCA	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-6.32	5.97e-10	1.32e-07	-0.46	-0.28	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
THCA	cis	rs172166	0.637	rs1233708	ENSG00000280107.1	AL022393.9	-6.32	5.97e-10	1.32e-07	-0.3	-0.28	Cardiac Troponin-T levels;	chr6:28205441	chr6:28170845~28172521:+
THCA	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-6.32	5.98e-10	1.32e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
THCA	cis	rs16976116	0.951	rs12385963	ENSG00000279145.1	RP11-547D13.1	6.32	5.98e-10	1.32e-07	0.28	0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55190653	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.951	rs3759862	ENSG00000279145.1	RP11-547D13.1	6.32	5.98e-10	1.32e-07	0.28	0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55190906	chr15:55171972~55178175:-
THCA	cis	rs807029	0.544	rs55646950	ENSG00000272572.1	RP11-179B2.2	-6.32	5.98e-10	1.32e-07	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100911103~100912739:-
THCA	cis	rs228614	0.509	rs223480	ENSG00000251288.2	RP11-10L12.2	-6.32	6e-10	1.32e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102751401~102752641:+
THCA	cis	rs7727544	0.735	rs272842	ENSG00000237714.1	P4HA2-AS1	6.32	6e-10	1.32e-07	0.36	0.28	Blood metabolite levels;	chr5:132320824	chr5:132184876~132192808:+
THCA	cis	rs2115630	0.846	rs8024538	ENSG00000275120.1	RP11-182J1.17	-6.32	6e-10	1.32e-07	-0.3	-0.28	P wave terminal force;	chr15:84825188	chr15:84599434~84606463:-
THCA	cis	rs1865760	0.929	rs9467646	ENSG00000272462.2	U91328.19	-6.32	6e-10	1.32e-07	-0.23	-0.28	Height;	chr6:25957180	chr6:25992662~26001775:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-6.32	6e-10	1.32e-07	-0.32	-0.28	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
THCA	cis	rs2562456	0.833	rs7246339	ENSG00000268555.1	RP11-678G14.3	6.32	6.01e-10	1.33e-07	0.46	0.28	Pain;	chr19:21292495	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs55899865	ENSG00000268555.1	RP11-678G14.3	6.32	6.01e-10	1.33e-07	0.46	0.28	Pain;	chr19:21298933	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs11667103	ENSG00000268555.1	RP11-678G14.3	6.32	6.01e-10	1.33e-07	0.46	0.28	Pain;	chr19:21303839	chr19:21570822~21587322:-
THCA	cis	rs6600671	0.934	rs11249429	ENSG00000275538.1	RNVU1-19	-6.32	6.02e-10	1.33e-07	-0.35	-0.28	Hip geometry;	chr1:121549282	chr1:120850819~120850985:-
THCA	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	6.32	6.02e-10	1.33e-07	0.36	0.28	Depression;	chr6:28402301	chr6:28176188~28176674:+
THCA	cis	rs847577	0.63	rs11764933	ENSG00000272950.1	RP11-307C18.1	6.32	6.02e-10	1.33e-07	0.35	0.28	Breast cancer;	chr7:98195876	chr7:98322853~98323430:+
THCA	cis	rs11089937	0.963	rs2073454	ENSG00000211639.2	IGLV4-60	6.32	6.02e-10	1.33e-07	0.19	0.28	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22162199~22162681:+
THCA	cis	rs60180747	0.544	rs11635867	ENSG00000261318.1	RP11-653J6.1	6.32	6.02e-10	1.33e-07	0.38	0.28	Testicular germ cell tumor;	chr15:66278908	chr15:66278498~66293357:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	6.32	6.03e-10	1.33e-07	0.32	0.28	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
THCA	cis	rs28386778	1	rs3020613	ENSG00000240280.5	TCAM1P	-6.32	6.03e-10	1.33e-07	-0.39	-0.28	Prudent dietary pattern;	chr17:63878623	chr17:63849292~63864379:+
THCA	cis	rs4971059	0.654	rs4971076	ENSG00000160766.13	GBAP1	-6.32	6.03e-10	1.33e-07	-0.3	-0.28	Breast cancer;	chr1:155152296	chr1:155213821~155227422:-
THCA	cis	rs4971059	0.654	rs4971052	ENSG00000160766.13	GBAP1	-6.32	6.03e-10	1.33e-07	-0.3	-0.28	Breast cancer;	chr1:155153542	chr1:155213821~155227422:-
THCA	cis	rs228614	0.51	rs223405	ENSG00000251288.2	RP11-10L12.2	-6.32	6.04e-10	1.33e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102751401~102752641:+
THCA	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-6.32	6.04e-10	1.33e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-6.32	6.04e-10	1.33e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-6.32	6.04e-10	1.33e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-6.32	6.04e-10	1.33e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	6.32	6.04e-10	1.33e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
THCA	cis	rs451417	1	rs379418	ENSG00000275632.1	RP5-967N21.11	6.32	6.04e-10	1.33e-07	0.32	0.28	Menopause (age at onset);	chr20:5961561	chr20:6000418~6000941:+
THCA	cis	rs451417	0.841	rs12106220	ENSG00000275632.1	RP5-967N21.11	6.32	6.04e-10	1.33e-07	0.32	0.28	Menopause (age at onset);	chr20:5963609	chr20:6000418~6000941:+
THCA	cis	rs2243480	0.901	rs778730	ENSG00000229886.1	RP5-1132H15.3	6.32	6.06e-10	1.33e-07	0.46	0.28	Diabetic kidney disease;	chr7:66358338	chr7:66025126~66031544:-
THCA	cis	rs12893668	0.628	rs57072546	ENSG00000269910.1	RP11-73M18.10	6.32	6.06e-10	1.34e-07	0.26	0.28	Reticulocyte count;	chr14:103597386	chr14:103694516~103695050:-
THCA	cis	rs6840360	0.582	rs6813735	ENSG00000251611.1	RP11-610P16.1	-6.32	6.07e-10	1.34e-07	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151405838	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.582	rs57585665	ENSG00000251611.1	RP11-610P16.1	-6.32	6.07e-10	1.34e-07	-0.21	-0.28	Intelligence (multi-trait analysis);	chr4:151405865	chr4:151407551~151408835:-
THCA	cis	rs853679	0.517	rs1904841	ENSG00000261839.1	RP1-265C24.8	6.32	6.07e-10	1.34e-07	0.34	0.28	Depression;	chr6:28140307	chr6:28136849~28139678:+
THCA	cis	rs1979679	0.842	rs10459091	ENSG00000278733.1	RP11-425D17.1	6.32	6.07e-10	1.34e-07	0.28	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28185625~28186190:-
THCA	cis	rs1979679	0.842	rs35098487	ENSG00000278733.1	RP11-425D17.1	6.32	6.07e-10	1.34e-07	0.28	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28185625~28186190:-
THCA	cis	rs2717559	0.522	rs10956987	ENSG00000253741.1	CTD-2292P10.4	6.32	6.08e-10	1.34e-07	0.35	0.28	Urinary tract infection frequency;	chr8:142805197	chr8:142702252~142726973:-
THCA	cis	rs240993	0.595	rs1040383	ENSG00000230177.1	RP5-1112D6.4	6.32	6.08e-10	1.34e-07	0.24	0.28	Inflammatory skin disease;Psoriasis;	chr6:111580985	chr6:111277932~111278742:+
THCA	cis	rs227275	0.554	rs223436	ENSG00000251288.2	RP11-10L12.2	-6.32	6.08e-10	1.34e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223424	ENSG00000251288.2	RP11-10L12.2	-6.32	6.08e-10	1.34e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102751401~102752641:+
THCA	cis	rs227275	0.524	rs223423	ENSG00000251288.2	RP11-10L12.2	-6.32	6.08e-10	1.34e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223422	ENSG00000251288.2	RP11-10L12.2	-6.32	6.08e-10	1.34e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102751401~102752641:+
THCA	cis	rs9649465	0.967	rs12538876	ENSG00000272686.1	RP11-390E23.6	6.32	6.1e-10	1.34e-07	0.18	0.28	Migraine;	chr7:123656266	chr7:123749068~123751166:+
THCA	cis	rs6545883	0.894	rs10496092	ENSG00000271889.1	RP11-493E12.1	-6.32	6.1e-10	1.34e-07	-0.27	-0.28	Tuberculosis;	chr2:61297544	chr2:61151433~61162105:-
THCA	cis	rs6540731	0.54	rs7548606	ENSG00000226251.4	RP11-15I11.3	-6.32	6.1e-10	1.34e-07	-0.34	-0.28	Intelligence (childhood);	chr1:212215265	chr1:212225278~212238977:-
THCA	cis	rs9649465	0.967	rs12539091	ENSG00000272686.1	RP11-390E23.6	6.32	6.1e-10	1.34e-07	0.18	0.28	Migraine;	chr7:123651260	chr7:123749068~123751166:+
THCA	cis	rs7617773	0.963	rs12494304	ENSG00000228638.1	FCF1P2	6.32	6.11e-10	1.34e-07	0.26	0.28	Coronary artery disease;	chr3:48136539	chr3:48290793~48291375:-
THCA	cis	rs6545883	0.894	rs6545867	ENSG00000271889.1	RP11-493E12.1	-6.32	6.11e-10	1.34e-07	-0.27	-0.28	Tuberculosis;	chr2:61423892	chr2:61151433~61162105:-
THCA	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	6.32	6.11e-10	1.34e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-6.32	6.11e-10	1.34e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	6.32	6.11e-10	1.34e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
THCA	cis	rs17772222	0.917	rs61984737	ENSG00000258789.1	RP11-507K2.3	-6.32	6.11e-10	1.34e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88637028	chr14:88551597~88552493:+
THCA	cis	rs12893668	0.667	rs71417869	ENSG00000269910.1	RP11-73M18.10	6.32	6.11e-10	1.34e-07	0.26	0.28	Reticulocyte count;	chr14:103611097	chr14:103694516~103695050:-
THCA	cis	rs1005277	0.579	rs2474608	ENSG00000276805.1	RP11-291L22.6	6.32	6.11e-10	1.35e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38451030~38451785:+
THCA	cis	rs10761482	0.5	rs2393644	ENSG00000254271.1	RP11-131N11.4	6.32	6.11e-10	1.35e-07	0.36	0.28	Schizophrenia;	chr10:60551516	chr10:60734342~60741828:+
THCA	cis	rs227275	0.554	rs223409	ENSG00000251288.2	RP11-10L12.2	-6.32	6.11e-10	1.35e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223404	ENSG00000251288.2	RP11-10L12.2	-6.32	6.11e-10	1.35e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102751401~102752641:+
THCA	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	6.32	6.12e-10	1.35e-07	0.3	0.28	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
THCA	cis	rs6840360	0.548	rs4254751	ENSG00000251611.1	RP11-610P16.1	-6.32	6.12e-10	1.35e-07	-0.2	-0.28	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151407551~151408835:-
THCA	cis	rs6545883	0.929	rs2600663	ENSG00000271889.1	RP11-493E12.1	-6.32	6.12e-10	1.35e-07	-0.26	-0.28	Tuberculosis;	chr2:61313552	chr2:61151433~61162105:-
THCA	cis	rs4143844	0.867	rs11634077	ENSG00000259251.2	RP11-643M14.1	6.32	6.12e-10	1.35e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:62001376	chr15:62060503~62062434:+
THCA	cis	rs12435908	1	rs59561356	ENSG00000276116.2	FUT8-AS1	-6.32	6.12e-10	1.35e-07	-0.46	-0.28	Ischemic stroke;	chr14:65553304	chr14:65411170~65412690:-
THCA	cis	rs4143844	0.867	rs12916410	ENSG00000259251.2	RP11-643M14.1	6.32	6.12e-10	1.35e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:62010687	chr15:62060503~62062434:+
THCA	cis	rs73110464	0.609	rs4919752	ENSG00000278185.1	RP11-153F5.7	6.32	6.13e-10	1.35e-07	0.29	0.28	Cancer (pleiotropy);	chr12:52965445	chr12:52946614~52947125:-
THCA	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-6.32	6.13e-10	1.35e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
THCA	cis	rs6600671	1	rs10794671	ENSG00000270392.2	PFN1P2	6.32	6.13e-10	1.35e-07	0.28	0.28	Hip geometry;	chr1:121426382	chr1:120432204~120434052:-
THCA	cis	rs11018904	0.817	rs11601793	ENSG00000280385.1	AP000648.5	-6.32	6.13e-10	1.35e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr11:90213186	chr11:90193614~90198120:+
THCA	cis	rs56804039	1	rs7017341	ENSG00000253893.2	FAM85B	6.32	6.14e-10	1.35e-07	0.4	0.28	Cervical cancer;	chr8:8524154	chr8:8167819~8226614:-
THCA	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	6.32	6.14e-10	1.35e-07	0.32	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
THCA	cis	rs2562456	0.833	rs2562507	ENSG00000213976.4	CTD-2561J22.2	6.32	6.15e-10	1.35e-07	0.3	0.28	Pain;	chr19:21543535	chr19:21382865~21387177:+
THCA	cis	rs12681366	0.636	rs1580498	ENSG00000253704.1	RP11-267M23.4	-6.32	6.15e-10	1.35e-07	-0.27	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94413326	chr8:94553722~94569745:+
THCA	cis	rs4273100	1	rs4924986	ENSG00000265185.4	SNORD3B-1	-6.32	6.15e-10	1.35e-07	-0.42	-0.28	Schizophrenia;	chr17:19339154	chr17:19061912~19062669:+
THCA	cis	rs227275	0.554	rs223442	ENSG00000251288.2	RP11-10L12.2	-6.32	6.15e-10	1.35e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223441	ENSG00000251288.2	RP11-10L12.2	-6.32	6.15e-10	1.35e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102751401~102752641:+
THCA	cis	rs12653396	1	rs12653396	ENSG00000247828.6	TMEM161B-AS1	-6.32	6.15e-10	1.35e-07	-0.21	-0.28	Educational attainment (years of education);	chr5:88551455	chr5:88268895~88436685:+
THCA	cis	rs3806843	0.966	rs10060640	ENSG00000202515.1	VTRNA1-3	-6.32	6.16e-10	1.36e-07	-0.32	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140831641	chr5:140726158~140726246:+
THCA	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	6.32	6.16e-10	1.36e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	6.32	6.16e-10	1.36e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
THCA	cis	rs9677476	0.818	rs6753393	ENSG00000224376.1	AC017104.6	6.32	6.17e-10	1.36e-07	0.32	0.28	Food antigen IgG levels;	chr2:231197253	chr2:231388976~231394991:+
THCA	cis	rs1005277	0.579	rs2505248	ENSG00000276805.1	RP11-291L22.6	6.32	6.17e-10	1.36e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38451030~38451785:+
THCA	cis	rs6504622	0.818	rs3851784	ENSG00000262879.4	RP11-156P1.3	6.32	6.17e-10	1.36e-07	0.26	0.28	Orofacial clefts;	chr17:46962751	chr17:46984045~47100323:-
THCA	cis	rs7727544	0.735	rs274568	ENSG00000237714.1	P4HA2-AS1	-6.32	6.18e-10	1.36e-07	-0.36	-0.28	Blood metabolite levels;	chr5:132377886	chr5:132184876~132192808:+
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000229886.1	RP5-1132H15.3	6.32	6.18e-10	1.36e-07	0.46	0.28	Diabetic kidney disease;	chr7:65966800	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs906134	ENSG00000229886.1	RP5-1132H15.3	6.32	6.18e-10	1.36e-07	0.46	0.28	Diabetic kidney disease;	chr7:65979301	chr7:66025126~66031544:-
THCA	cis	rs10208649	0.908	rs11887593	ENSG00000233266.1	HMGB1P31	6.32	6.18e-10	1.36e-07	0.65	0.28	Body mass index;	chr2:54040638	chr2:54051334~54051760:+
THCA	cis	rs7851660	0.967	rs12348691	ENSG00000214417.4	KRT18P13	-6.32	6.18e-10	1.36e-07	-0.24	-0.28	Strep throat;	chr9:97846400	chr9:97698922~97700734:+
THCA	cis	rs712022	0.534	rs4567455	ENSG00000246225.5	RP11-17A1.3	-6.32	6.18e-10	1.36e-07	-0.37	-0.28	Dialysis-related mortality;	chr11:22841980	chr11:22829380~22945393:+
THCA	cis	rs17772222	0.917	rs61984708	ENSG00000258789.1	RP11-507K2.3	-6.32	6.19e-10	1.36e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88565523	chr14:88551597~88552493:+
THCA	cis	rs10844706	0.699	rs1008610	ENSG00000256594.6	RP11-705C15.2	6.32	6.19e-10	1.36e-07	0.23	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9731264	chr12:9633419~9658412:+
THCA	cis	rs2562456	0.958	rs2562508	ENSG00000213976.4	CTD-2561J22.2	6.32	6.19e-10	1.36e-07	0.29	0.28	Pain;	chr19:21543479	chr19:21382865~21387177:+
THCA	cis	rs2243480	1	rs160639	ENSG00000229886.1	RP5-1132H15.3	6.32	6.19e-10	1.36e-07	0.44	0.28	Diabetic kidney disease;	chr7:66115000	chr7:66025126~66031544:-
THCA	cis	rs6545883	0.894	rs2600672	ENSG00000271889.1	RP11-493E12.1	6.32	6.19e-10	1.36e-07	0.26	0.28	Tuberculosis;	chr2:61309605	chr2:61151433~61162105:-
THCA	cis	rs9649465	1	rs3807640	ENSG00000272686.1	RP11-390E23.6	6.32	6.19e-10	1.36e-07	0.18	0.28	Migraine;	chr7:123698659	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs13225110	ENSG00000272686.1	RP11-390E23.6	6.32	6.19e-10	1.36e-07	0.18	0.28	Migraine;	chr7:123700795	chr7:123749068~123751166:+
THCA	cis	rs4143844	0.867	rs11637967	ENSG00000259251.2	RP11-643M14.1	6.32	6.19e-10	1.36e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61928417	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs35523559	ENSG00000259251.2	RP11-643M14.1	6.32	6.19e-10	1.36e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61936571	chr15:62060503~62062434:+
THCA	cis	rs7576126	0.515	rs1866050	ENSG00000281920.1	RP11-418H16.1	6.32	6.2e-10	1.36e-07	0.38	0.28	Severe influenza A (H1N1) infection;	chr2:65450595	chr2:65623272~65628424:+
THCA	cis	rs2562456	0.754	rs58338799	ENSG00000268555.1	RP11-678G14.3	6.32	6.2e-10	1.36e-07	0.45	0.28	Pain;	chr19:21339009	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs7259396	ENSG00000268555.1	RP11-678G14.3	6.32	6.2e-10	1.36e-07	0.45	0.28	Pain;	chr19:21340661	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.678	rs7260140	ENSG00000268555.1	RP11-678G14.3	6.32	6.2e-10	1.36e-07	0.45	0.28	Pain;	chr19:21340723	chr19:21570822~21587322:-
THCA	cis	rs6740322	0.748	rs6544634	ENSG00000234936.1	AC010883.5	6.32	6.21e-10	1.37e-07	0.3	0.28	Coronary artery disease;	chr2:43244389	chr2:43229573~43233394:+
THCA	cis	rs12030196	0.788	rs10889125	ENSG00000230812.4	LINC01358	6.32	6.21e-10	1.37e-07	0.32	0.28	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58951444	chr1:59020387~59044614:+
THCA	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-6.32	6.21e-10	1.37e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
THCA	cis	rs8014252	0.803	rs45523543	ENSG00000259158.2	ADAM20P1	-6.32	6.21e-10	1.37e-07	-0.36	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70584371	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs56922268	ENSG00000259158.2	ADAM20P1	-6.32	6.21e-10	1.37e-07	-0.36	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70585454	chr14:70468881~70483756:-
THCA	cis	rs9649465	0.688	rs34967330	ENSG00000272686.1	RP11-390E23.6	6.32	6.21e-10	1.37e-07	0.18	0.28	Migraine;	chr7:123678506	chr7:123749068~123751166:+
THCA	cis	rs227275	0.524	rs150894	ENSG00000251288.2	RP11-10L12.2	-6.32	6.21e-10	1.37e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102751401~102752641:+
THCA	cis	rs5742933	0.817	rs5742938	ENSG00000273240.1	RP11-455J20.3	6.32	6.21e-10	1.37e-07	0.29	0.28	Ferritin levels;	chr2:189785232	chr2:189763859~189764456:-
THCA	cis	rs6545883	0.794	rs12053388	ENSG00000271889.1	RP11-493E12.1	-6.32	6.22e-10	1.37e-07	-0.27	-0.28	Tuberculosis;	chr2:61305185	chr2:61151433~61162105:-
THCA	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-6.32	6.22e-10	1.37e-07	-0.29	-0.28	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
THCA	cis	rs4971059	0.617	rs10908458	ENSG00000160766.13	GBAP1	-6.32	6.22e-10	1.37e-07	-0.3	-0.28	Breast cancer;	chr1:155154472	chr1:155213821~155227422:-
THCA	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-6.32	6.22e-10	1.37e-07	-0.29	-0.28	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
THCA	cis	rs11051970	0.659	rs2728674	ENSG00000274964.1	RP11-817I4.1	-6.32	6.22e-10	1.37e-07	-0.34	-0.28	Response to tocilizumab in rheumatoid arthritis;	chr12:32434531	chr12:32339368~32340724:+
THCA	cis	rs6600671	1	rs4844607	ENSG00000275538.1	RNVU1-19	-6.32	6.23e-10	1.37e-07	-0.34	-0.28	Hip geometry;	chr1:121442201	chr1:120850819~120850985:-
THCA	cis	rs4971059	0.654	rs4971078	ENSG00000160766.13	GBAP1	-6.32	6.23e-10	1.37e-07	-0.3	-0.28	Breast cancer;	chr1:155156547	chr1:155213821~155227422:-
THCA	cis	rs2562456	0.917	rs2650793	ENSG00000213976.4	CTD-2561J22.2	6.32	6.24e-10	1.37e-07	0.29	0.28	Pain;	chr19:21493313	chr19:21382865~21387177:+
THCA	cis	rs728616	0.85	rs3889823	ENSG00000242600.5	MBL1P	6.32	6.24e-10	1.37e-07	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79904898~79950336:+
THCA	cis	rs7474896	0.616	rs2505239	ENSG00000120555.12	SEPT7P9	6.32	6.24e-10	1.37e-07	0.38	0.28	Obesity (extreme);	chr10:38151837	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.561	rs2474603	ENSG00000120555.12	SEPT7P9	6.32	6.24e-10	1.37e-07	0.38	0.28	Obesity (extreme);	chr10:38156754	chr10:38383069~38402916:-
THCA	cis	rs7617773	0.539	rs13087050	ENSG00000228638.1	FCF1P2	-6.32	6.24e-10	1.37e-07	-0.27	-0.28	Coronary artery disease;	chr3:48351310	chr3:48290793~48291375:-
THCA	cis	rs227275	0.586	rs223448	ENSG00000251288.2	RP11-10L12.2	-6.32	6.24e-10	1.37e-07	-0.38	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102751401~102752641:+
THCA	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-6.32	6.24e-10	1.37e-07	-0.35	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
THCA	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-6.32	6.24e-10	1.37e-07	-0.38	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
THCA	cis	rs8027521	0.54	rs2199613	ENSG00000280362.1	RP11-643A5.3	6.32	6.25e-10	1.37e-07	0.34	0.28	Circulating chemerin levels;	chr15:53941446	chr15:53910769~53914712:+
THCA	cis	rs9329221	0.592	rs7832708	ENSG00000261451.1	RP11-981G7.1	6.32	6.25e-10	1.37e-07	0.35	0.28	Neuroticism;	chr8:10332530	chr8:10433672~10438312:+
THCA	cis	rs6545883	0.895	rs796597	ENSG00000271889.1	RP11-493E12.1	6.32	6.25e-10	1.37e-07	0.27	0.28	Tuberculosis;	chr2:61453925	chr2:61151433~61162105:-
THCA	cis	rs1865760	0.929	rs12195653	ENSG00000272462.2	U91328.19	-6.32	6.25e-10	1.38e-07	-0.23	-0.28	Height;	chr6:25958393	chr6:25992662~26001775:+
THCA	cis	rs5758659	0.714	rs5751216	ENSG00000270083.1	RP1-257I20.14	-6.32	6.26e-10	1.38e-07	-0.29	-0.28	Cognitive function;	chr22:42112933	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.714	rs5758589	ENSG00000270083.1	RP1-257I20.14	-6.32	6.26e-10	1.38e-07	-0.29	-0.28	Cognitive function;	chr22:42122378	chr22:42089630~42090028:-
THCA	cis	rs227275	0.554	rs223388	ENSG00000251288.2	RP11-10L12.2	-6.32	6.26e-10	1.38e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102751401~102752641:+
THCA	cis	rs6928977	0.896	rs2614287	ENSG00000231028.7	LINC00271	6.32	6.26e-10	1.38e-07	0.23	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135497801~135716055:+
THCA	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	6.32	6.27e-10	1.38e-07	0.37	0.28	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
THCA	cis	rs7727544	0.66	rs272886	ENSG00000237714.1	P4HA2-AS1	6.31	6.27e-10	1.38e-07	0.36	0.28	Blood metabolite levels;	chr5:132330147	chr5:132184876~132192808:+
THCA	cis	rs1552244	0.572	rs3894321	ENSG00000232901.1	CYCSP10	6.31	6.27e-10	1.38e-07	0.42	0.28	Alzheimer's disease;	chr3:10127208	chr3:10000647~10000940:-
THCA	cis	rs4948102	0.686	rs11771788	ENSG00000273720.1	RP11-613E4.4	-6.31	6.27e-10	1.38e-07	-0.38	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56090347	chr7:55743073~55743457:+
THCA	cis	rs4950322	0.58	rs4950371	ENSG00000278811.3	LINC00624	6.31	6.27e-10	1.38e-07	0.34	0.28	Protein quantitative trait loci;	chr1:147114243	chr1:147258885~147517875:-
THCA	cis	rs9649465	1	rs12537287	ENSG00000272686.1	RP11-390E23.6	6.31	6.27e-10	1.38e-07	0.18	0.28	Migraine;	chr7:123724693	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs11770041	ENSG00000272686.1	RP11-390E23.6	6.31	6.27e-10	1.38e-07	0.18	0.28	Migraine;	chr7:123725734	chr7:123749068~123751166:+
THCA	cis	rs8062405	0.69	rs4787458	ENSG00000278665.1	RP11-666O2.4	6.31	6.28e-10	1.38e-07	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28599241~28601881:-
THCA	cis	rs7976269	0.609	rs1344854	ENSG00000257176.2	RP11-996F15.2	6.31	6.28e-10	1.38e-07	0.29	0.28	Male-pattern baldness;	chr12:29065440	chr12:29280418~29317848:-
THCA	cis	rs12664251	0.66	rs7738420	ENSG00000253194.1	RP11-351A11.1	-6.31	6.28e-10	1.38e-07	-0.39	-0.28	Schizophrenia;	chr6:119028371	chr6:118934785~119031541:+
THCA	cis	rs516805	0.63	rs170422	ENSG00000279453.1	RP3-425C14.4	-6.31	6.28e-10	1.38e-07	-0.29	-0.28	Lymphocyte counts;	chr6:122261422	chr6:122436789~122439223:-
THCA	cis	rs227275	0.554	rs150895	ENSG00000251288.2	RP11-10L12.2	-6.31	6.28e-10	1.38e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102751401~102752641:+
THCA	cis	rs5758659	0.714	rs7245	ENSG00000227370.1	RP4-669P10.19	6.31	6.29e-10	1.38e-07	0.26	0.28	Cognitive function;	chr22:42085845	chr22:42132543~42132998:+
THCA	cis	rs7247513	0.964	rs12979795	ENSG00000213290.4	PGK1P2	6.31	6.29e-10	1.38e-07	0.33	0.28	Bipolar disorder;	chr19:12607033	chr19:12559571~12561105:+
THCA	cis	rs1979679	0.842	rs981494	ENSG00000278733.1	RP11-425D17.1	-6.31	6.29e-10	1.38e-07	-0.27	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28172916	chr12:28185625~28186190:-
THCA	cis	rs240993	0.595	rs3777911	ENSG00000230177.1	RP5-1112D6.4	6.31	6.29e-10	1.38e-07	0.24	0.28	Inflammatory skin disease;Psoriasis;	chr6:111581277	chr6:111277932~111278742:+
THCA	cis	rs3096299	0.781	rs2170839	ENSG00000274627.1	RP11-104N10.2	6.31	6.3e-10	1.39e-07	0.26	0.28	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89516797~89522217:+
THCA	cis	rs6723226	0.881	rs10181198	ENSG00000276334.1	AL133243.1	6.31	6.3e-10	1.39e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr2:32461514	chr2:32521927~32523547:+
THCA	cis	rs9311474	1	rs7614727	ENSG00000243224.1	RP5-1157M23.2	-6.31	6.3e-10	1.39e-07	-0.28	-0.28	Electroencephalogram traits;	chr3:52261879	chr3:52239258~52241097:+
THCA	cis	rs147858478	1	rs147858478	ENSG00000237714.1	P4HA2-AS1	6.31	6.3e-10	1.39e-07	0.36	0.28	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132184876~132192808:+
THCA	cis	rs4143844	0.867	rs11637606	ENSG00000259251.2	RP11-643M14.1	-6.31	6.31e-10	1.39e-07	-0.53	-0.28	Bipolar disorder and schizophrenia;	chr15:61912515	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.737	rs35984535	ENSG00000259251.2	RP11-643M14.1	6.31	6.31e-10	1.39e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61912747	chr15:62060503~62062434:+
THCA	cis	rs6545883	0.86	rs6545847	ENSG00000271889.1	RP11-493E12.1	-6.31	6.31e-10	1.39e-07	-0.26	-0.28	Tuberculosis;	chr2:61218198	chr2:61151433~61162105:-
THCA	cis	rs4713118	0.513	rs149959	ENSG00000280107.1	AL022393.9	-6.31	6.32e-10	1.39e-07	-0.3	-0.28	Parkinson's disease;	chr6:28046076	chr6:28170845~28172521:+
THCA	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-6.31	6.32e-10	1.39e-07	-0.31	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
THCA	cis	rs2303319	0.786	rs62194491	ENSG00000227403.1	AC009299.3	6.31	6.33e-10	1.39e-07	0.59	0.28	Cognitive function;	chr2:161348550	chr2:161244739~161249050:+
THCA	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	6.31	6.33e-10	1.39e-07	0.23	0.28	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
THCA	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	6.31	6.33e-10	1.39e-07	0.23	0.28	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
THCA	cis	rs451417	1	rs236120	ENSG00000275632.1	RP5-967N21.11	6.31	6.33e-10	1.39e-07	0.32	0.28	Menopause (age at onset);	chr20:5959003	chr20:6000418~6000941:+
THCA	cis	rs7617773	0.539	rs17593974	ENSG00000228638.1	FCF1P2	-6.31	6.34e-10	1.39e-07	-0.27	-0.28	Coronary artery disease;	chr3:48345844	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.514	rs11130166	ENSG00000228638.1	FCF1P2	-6.31	6.34e-10	1.39e-07	-0.27	-0.28	Coronary artery disease;	chr3:48346566	chr3:48290793~48291375:-
THCA	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	6.31	6.34e-10	1.39e-07	0.34	0.28	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
THCA	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-6.31	6.34e-10	1.39e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
THCA	cis	rs228614	0.51	rs223452	ENSG00000251288.2	RP11-10L12.2	-6.31	6.34e-10	1.39e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102751401~102752641:+
THCA	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	6.31	6.35e-10	1.4e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
THCA	cis	rs7260598	0.892	rs67180860	ENSG00000268442.1	CTD-2027I19.2	6.31	6.36e-10	1.4e-07	0.4	0.28	Response to taxane treatment (placlitaxel);	chr19:24023433	chr19:24162370~24163425:-
THCA	cis	rs3758785	0.737	rs79512686	ENSG00000255893.1	RP11-685N10.1	-6.31	6.37e-10	1.4e-07	-0.34	-0.28	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94398331	chr11:94472908~94473570:-
THCA	cis	rs6142102	1	rs6142102	ENSG00000275784.1	RP5-1125A11.6	-6.31	6.37e-10	1.4e-07	-0.29	-0.28	Skin pigmentation;	chr20:34116821	chr20:33989480~33991818:-
THCA	cis	rs681343	1	rs492602	ENSG00000232871.7	SEC1P	6.31	6.38e-10	1.4e-07	0.33	0.28	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48703160	chr19:48638071~48682245:+
THCA	cis	rs7829975	0.688	rs7827182	ENSG00000254153.1	CTA-398F10.2	-6.31	6.38e-10	1.4e-07	-0.31	-0.28	Mood instability;	chr8:8522961	chr8:8456909~8461337:-
THCA	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-6.31	6.39e-10	1.4e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
THCA	cis	rs1005277	0.522	rs7090858	ENSG00000263064.2	RP11-291L22.7	-6.31	6.39e-10	1.4e-07	-0.31	-0.28	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38448689~38448949:+
THCA	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-6.31	6.39e-10	1.4e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-6.31	6.39e-10	1.4e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
THCA	cis	rs950169	0.65	rs12902052	ENSG00000259295.5	CSPG4P12	6.31	6.39e-10	1.4e-07	0.43	0.28	Schizophrenia;	chr15:84582607	chr15:85191438~85213905:+
THCA	cis	rs12435908	1	rs17246007	ENSG00000276116.2	FUT8-AS1	6.31	6.4e-10	1.4e-07	0.44	0.28	Ischemic stroke;	chr14:65398953	chr14:65411170~65412690:-
THCA	cis	rs9834975	0.903	rs56131302	ENSG00000272758.4	RP11-299J3.8	-6.31	6.4e-10	1.41e-07	-0.26	-0.28	Diastolic blood pressure;	chr3:122499141	chr3:122416207~122443180:+
THCA	cis	rs9834975	0.935	rs6438735	ENSG00000272758.4	RP11-299J3.8	-6.31	6.4e-10	1.41e-07	-0.26	-0.28	Diastolic blood pressure;	chr3:122500539	chr3:122416207~122443180:+
THCA	cis	rs9834975	0.967	rs6438737	ENSG00000272758.4	RP11-299J3.8	6.31	6.4e-10	1.41e-07	0.26	0.28	Diastolic blood pressure;	chr3:122510127	chr3:122416207~122443180:+
THCA	cis	rs2348418	0.832	rs4244844	ENSG00000247934.4	RP11-967K21.1	6.31	6.4e-10	1.41e-07	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28434062	chr12:28163298~28190738:-
THCA	cis	rs9311474	1	rs1060330	ENSG00000243224.1	RP5-1157M23.2	-6.31	6.41e-10	1.41e-07	-0.28	-0.28	Electroencephalogram traits;	chr3:52254929	chr3:52239258~52241097:+
THCA	cis	rs728616	0.867	rs56000427	ENSG00000242600.5	MBL1P	6.31	6.41e-10	1.41e-07	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80227190	chr10:79904898~79950336:+
THCA	cis	rs1949733	0.636	rs16842498	ENSG00000205959.3	RP11-689P11.2	6.31	6.41e-10	1.41e-07	0.25	0.28	Response to antineoplastic agents;	chr4:8537802	chr4:8482270~8512610:+
THCA	cis	rs944990	0.576	rs6479484	ENSG00000227603.1	RP11-165J3.6	6.31	6.41e-10	1.41e-07	0.28	0.28	Body mass index;	chr9:93454288	chr9:93435332~93437121:-
THCA	cis	rs4073416	0.647	rs10138570	ENSG00000276116.2	FUT8-AS1	6.31	6.42e-10	1.41e-07	0.28	0.28	N-glycan levels;	chr14:65393320	chr14:65411170~65412690:-
THCA	cis	rs7202877	0.706	rs467780	ENSG00000261783.1	RP11-252K23.2	6.31	6.42e-10	1.41e-07	0.48	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75403240	chr16:75379818~75381260:-
THCA	cis	rs1005277	0.54	rs2145487	ENSG00000263064.2	RP11-291L22.7	6.31	6.43e-10	1.41e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38448689~38448949:+
THCA	cis	rs7727544	0.625	rs4705916	ENSG00000224431.1	AC063976.7	6.31	6.43e-10	1.41e-07	0.25	0.28	Blood metabolite levels;	chr5:132071800	chr5:132199456~132203487:+
THCA	cis	rs62103177	0.714	rs28691615	ENSG00000261126.6	RP11-795F19.1	6.31	6.44e-10	1.41e-07	0.27	0.28	Opioid sensitivity;	chr18:79852254	chr18:80046900~80095482:+
THCA	cis	rs2243480	1	rs1039664	ENSG00000232546.1	RP11-458F8.1	-6.31	6.44e-10	1.41e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65984729	chr7:66848496~66858136:+
THCA	cis	rs838147	0.508	rs507711	ENSG00000232871.7	SEC1P	6.31	6.45e-10	1.42e-07	0.33	0.28	Dietary macronutrient intake;	chr19:48705307	chr19:48638071~48682245:+
THCA	cis	rs11148252	0.553	rs9536219	ENSG00000278238.1	RP11-245D16.4	-6.31	6.45e-10	1.42e-07	-0.32	-0.28	Lewy body disease;	chr13:52653166	chr13:52454775~52455331:-
THCA	cis	rs2274273	0.622	rs11846809	ENSG00000258413.1	RP11-665C16.6	-6.31	6.45e-10	1.42e-07	-0.37	-0.28	Protein biomarker;	chr14:54935064	chr14:55262767~55272075:-
THCA	cis	rs848490	0.816	rs1636665	ENSG00000214293.7	APTR	-6.31	6.45e-10	1.42e-07	-0.22	-0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77934500	chr7:77657660~77696265:-
THCA	cis	rs2554380	0.628	rs4843158	ENSG00000230373.7	GOLGA6L5P	-6.31	6.45e-10	1.42e-07	-0.3	-0.28	Height;	chr15:83802884	chr15:84507885~84516814:-
THCA	cis	rs8007846	0.588	rs761831	ENSG00000276116.2	FUT8-AS1	6.31	6.46e-10	1.42e-07	0.28	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65772652	chr14:65411170~65412690:-
THCA	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	6.31	6.46e-10	1.42e-07	0.55	0.28	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
THCA	cis	rs17772222	0.917	rs4635267	ENSG00000222990.1	RNU4-22P	6.31	6.46e-10	1.42e-07	0.36	0.28	Coronary artery calcification;	chr14:88621922	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.876	rs56144430	ENSG00000222990.1	RNU4-22P	6.31	6.46e-10	1.42e-07	0.36	0.28	Coronary artery calcification;	chr14:88622013	chr14:88513498~88513663:+
THCA	cis	rs6465657	0.903	rs11767962	ENSG00000272950.1	RP11-307C18.1	6.31	6.47e-10	1.42e-07	0.35	0.28	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr7:98149264	chr7:98322853~98323430:+
THCA	cis	rs8007846	0.588	rs11625362	ENSG00000276116.2	FUT8-AS1	-6.31	6.47e-10	1.42e-07	-0.28	-0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65766151	chr14:65411170~65412690:-
THCA	cis	rs228614	0.51	rs223349	ENSG00000230069.3	LRRC37A15P	-6.31	6.49e-10	1.42e-07	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102727274~102730721:-
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000220721.1	OR1F12	-6.31	6.49e-10	1.42e-07	-0.37	-0.28	Parkinson's disease;	chr6:28065396	chr6:28073316~28074233:+
THCA	cis	rs227275	0.525	rs3974608	ENSG00000251288.2	RP11-10L12.2	-6.31	6.49e-10	1.42e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102751401~102752641:+
THCA	cis	rs4835473	0.808	rs62334580	ENSG00000251600.4	RP11-673E1.1	-6.31	6.5e-10	1.43e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144084916	chr4:143912331~143982454:+
THCA	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-6.31	6.5e-10	1.43e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
THCA	cis	rs4784934	1	rs4784934	ENSG00000260186.4	RP11-481J2.2	6.31	6.51e-10	1.43e-07	0.38	0.28	QT interval;	chr16:58426022	chr16:58421326~58462470:+
THCA	cis	rs4835473	0.932	rs7667092	ENSG00000251600.4	RP11-673E1.1	6.31	6.51e-10	1.43e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143968604	chr4:143912331~143982454:+
THCA	cis	rs2243480	0.803	rs160649	ENSG00000228409.4	CCT6P1	6.31	6.51e-10	1.43e-07	0.32	0.28	Diabetic kidney disease;	chr7:66078212	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs160648	ENSG00000228409.4	CCT6P1	6.31	6.51e-10	1.43e-07	0.32	0.28	Diabetic kidney disease;	chr7:66078397	chr7:65751142~65763354:+
THCA	cis	rs6928977	0.86	rs2746432	ENSG00000231028.7	LINC00271	6.31	6.52e-10	1.43e-07	0.23	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135375459	chr6:135497801~135716055:+
THCA	cis	rs4143844	0.867	rs12902859	ENSG00000259251.2	RP11-643M14.1	6.31	6.52e-10	1.43e-07	0.54	0.28	Bipolar disorder and schizophrenia;	chr15:61884966	chr15:62060503~62062434:+
THCA	cis	rs848490	0.928	rs73138424	ENSG00000214293.7	APTR	6.31	6.52e-10	1.43e-07	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77858999	chr7:77657660~77696265:-
THCA	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	6.31	6.52e-10	1.43e-07	0.34	0.28	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
THCA	cis	rs7044106	0.791	rs4837792	ENSG00000270917.1	RP11-27I1.6	-6.31	6.52e-10	1.43e-07	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.791	rs4837793	ENSG00000270917.1	RP11-27I1.6	-6.31	6.53e-10	1.43e-07	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120812475~120812845:-
THCA	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	6.31	6.53e-10	1.43e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	6.31	6.53e-10	1.43e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
THCA	cis	rs838147	0.537	rs504963	ENSG00000232871.7	SEC1P	6.31	6.53e-10	1.43e-07	0.33	0.28	Dietary macronutrient intake;	chr19:48705608	chr19:48638071~48682245:+
THCA	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-6.31	6.54e-10	1.43e-07	-0.38	-0.28	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
THCA	cis	rs113835537	0.735	rs519380	ENSG00000255517.5	CTD-3074O7.5	-6.31	6.54e-10	1.43e-07	-0.26	-0.28	Airway imaging phenotypes;	chr11:66641938	chr11:66473490~66480233:-
THCA	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-6.31	6.54e-10	1.44e-07	-0.33	-0.28	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
THCA	cis	rs7208859	0.673	rs11651802	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs17826219	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs61223749	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs3764421	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11651858	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs36056619	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9909497	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11080135	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9894876	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73277967	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs60020217	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs73277974	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73277978	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30729469~30731202:+
THCA	cis	rs17826219	0.706	rs9905827	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Body mass index;	chr17:30865150	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11657391	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs58089675	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73263755	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9899349	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11652358	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11656845	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9891179	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9891413	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73263776	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11650271	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11657270	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73263785	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs55904046	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9889968	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs61348930	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.614	rs28758251	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9899943	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11080138	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73265612	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11658435	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73265624	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs2269915	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs2269916	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11649765	ENSG00000263603.1	CTD-2349P21.5	-6.31	6.54e-10	1.44e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30729469~30731202:+
THCA	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	6.31	6.55e-10	1.44e-07	0.23	0.28	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
THCA	cis	rs595244	1	rs111297611	ENSG00000259705.1	RP11-227D13.1	6.31	6.55e-10	1.44e-07	0.5	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48518744	chr15:48645951~48652016:+
THCA	cis	rs832187	0.629	rs7624403	ENSG00000280620.1	SCAANT1	6.31	6.55e-10	1.44e-07	0.37	0.28	Schizophrenia;	chr3:63984401	chr3:63911518~63911772:-
THCA	cis	rs9649465	0.967	rs12706546	ENSG00000272686.1	RP11-390E23.6	6.31	6.55e-10	1.44e-07	0.18	0.28	Migraine;	chr7:123713360	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs7803287	ENSG00000272686.1	RP11-390E23.6	6.31	6.55e-10	1.44e-07	0.18	0.28	Migraine;	chr7:123714753	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs2299982	ENSG00000272686.1	RP11-390E23.6	6.31	6.55e-10	1.44e-07	0.18	0.28	Migraine;	chr7:123716457	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs2299983	ENSG00000272686.1	RP11-390E23.6	6.31	6.55e-10	1.44e-07	0.18	0.28	Migraine;	chr7:123716588	chr7:123749068~123751166:+
THCA	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	6.31	6.56e-10	1.44e-07	0.27	0.28	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
THCA	cis	rs11722779	0.81	rs223417	ENSG00000230069.3	LRRC37A15P	-6.31	6.56e-10	1.44e-07	-0.29	-0.28	Schizophrenia;	chr4:102810568	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.805	rs223416	ENSG00000230069.3	LRRC37A15P	-6.31	6.56e-10	1.44e-07	-0.29	-0.28	Schizophrenia;	chr4:102810580	chr4:102727274~102730721:-
THCA	cis	rs1005277	0.54	rs4934907	ENSG00000263064.2	RP11-291L22.7	6.31	6.57e-10	1.44e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.54	rs11011351	ENSG00000263064.2	RP11-291L22.7	6.31	6.57e-10	1.44e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38448689~38448949:+
THCA	cis	rs6860806	0.661	rs6871350	ENSG00000237714.1	P4HA2-AS1	6.31	6.57e-10	1.44e-07	0.36	0.28	Breast cancer;	chr5:132244527	chr5:132184876~132192808:+
THCA	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	6.31	6.57e-10	1.44e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
THCA	cis	rs7120173	0.779	rs7103842	ENSG00000254851.1	RP11-109L13.1	-6.31	6.58e-10	1.44e-07	-0.46	-0.28	Visceral adipose tissue adjusted for BMI;	chr11:117087312	chr11:117135528~117138582:+
THCA	cis	rs7119038	0.818	rs73003215	ENSG00000255239.1	AP002954.6	-6.31	6.58e-10	1.44e-07	-0.4	-0.28	Sjögren's syndrome;	chr11:118778803	chr11:118688039~118690600:-
THCA	cis	rs2243480	1	rs1404147	ENSG00000229886.1	RP5-1132H15.3	6.31	6.58e-10	1.44e-07	0.43	0.28	Diabetic kidney disease;	chr7:65799537	chr7:66025126~66031544:-
THCA	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-6.31	6.59e-10	1.44e-07	-0.4	-0.28	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
THCA	cis	rs11722228	0.522	rs73212808	ENSG00000261490.1	RP11-448G15.3	6.31	6.59e-10	1.44e-07	0.21	0.28	Urate levels;Serum uric acid levels;Gout;	chr4:10053815	chr4:10068089~10073019:-
THCA	cis	rs9326248	0.731	rs90192	ENSG00000280143.1	AP000892.6	6.31	6.6e-10	1.45e-07	0.42	0.28	Blood protein levels;	chr11:117188631	chr11:117204967~117210292:+
THCA	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-6.31	6.6e-10	1.45e-07	-0.25	-0.28	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
THCA	cis	rs8062405	0.69	rs762634	ENSG00000278665.1	RP11-666O2.4	6.31	6.6e-10	1.45e-07	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28599241~28601881:-
THCA	cis	rs62034325	0.697	rs710410	ENSG00000278665.1	RP11-666O2.4	6.31	6.6e-10	1.45e-07	0.33	0.28	Body mass index;	chr16:28592021	chr16:28599241~28601881:-
THCA	cis	rs2303319	1	rs3769964	ENSG00000227403.1	AC009299.3	6.31	6.6e-10	1.45e-07	0.59	0.28	Cognitive function;	chr2:161350835	chr2:161244739~161249050:+
THCA	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-6.31	6.61e-10	1.45e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
THCA	cis	rs17102884	0.506	rs4899541	ENSG00000279594.1	RP11-950C14.10	-6.31	6.61e-10	1.45e-07	-0.27	-0.28	Neuroticism;	chr14:74936734	chr14:75011269~75012851:-
THCA	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	6.31	6.61e-10	1.45e-07	0.26	0.28	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
THCA	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	6.31	6.61e-10	1.45e-07	0.26	0.28	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
THCA	cis	rs7129556	0.954	rs11823651	ENSG00000254691.1	RP11-91P24.5	6.31	6.61e-10	1.45e-07	0.38	0.28	Weight loss (gastric bypass surgery);	chr11:77542834	chr11:77850604~77851511:+
THCA	cis	rs10875746	0.903	rs11168414	ENSG00000269514.1	RP11-370I10.12	6.31	6.63e-10	1.45e-07	0.28	0.28	Longevity (90 years and older);	chr12:48118548	chr12:48198387~48202031:+
THCA	cis	rs74233809	0.748	rs10786736	ENSG00000213277.3	MARCKSL1P1	6.31	6.63e-10	1.45e-07	0.41	0.28	Birth weight;	chr10:103089359	chr10:103175554~103176094:+
THCA	cis	rs227275	0.554	rs223359	ENSG00000230069.3	LRRC37A15P	-6.31	6.63e-10	1.45e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102727274~102730721:-
THCA	cis	rs831571	0.668	rs34723451	ENSG00000280620.1	SCAANT1	6.31	6.63e-10	1.45e-07	0.46	0.28	Type 2 diabetes;	chr3:64096160	chr3:63911518~63911772:-
THCA	cis	rs1005277	0.577	rs4934906	ENSG00000263064.2	RP11-291L22.7	6.31	6.64e-10	1.45e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38448689~38448949:+
THCA	cis	rs7208859	0.562	rs216408	ENSG00000263603.1	CTD-2349P21.5	6.31	6.64e-10	1.45e-07	0.45	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30729469~30731202:+
THCA	cis	rs7727544	0.684	rs274546	ENSG00000237714.1	P4HA2-AS1	6.31	6.65e-10	1.46e-07	0.36	0.28	Blood metabolite levels;	chr5:132364175	chr5:132184876~132192808:+
THCA	cis	rs8027521	0.561	rs62010936	ENSG00000280362.1	RP11-643A5.3	6.31	6.65e-10	1.46e-07	0.34	0.28	Circulating chemerin levels;	chr15:53946766	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.54	rs58197485	ENSG00000280362.1	RP11-643A5.3	6.31	6.65e-10	1.46e-07	0.34	0.28	Circulating chemerin levels;	chr15:53948546	chr15:53910769~53914712:+
THCA	cis	rs1005277	0.563	rs2800550	ENSG00000276805.1	RP11-291L22.6	6.31	6.65e-10	1.46e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38451030~38451785:+
THCA	cis	rs60678552	0.642	rs6926908	ENSG00000233558.1	RP3-486I3.4	-6.3	6.65e-10	1.46e-07	-0.4	-0.28	Heschl's gyrus morphology;	chr6:116310770	chr6:116258493~116259115:-
THCA	cis	rs7267979	0.549	rs6138536	ENSG00000274414.1	RP5-965G21.4	-6.3	6.65e-10	1.46e-07	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:25239007~25245229:-
THCA	cis	rs6928977	0.538	rs17064702	ENSG00000231028.7	LINC00271	-6.3	6.66e-10	1.46e-07	-0.24	-0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135607114	chr6:135497801~135716055:+
THCA	cis	rs13113518	0.841	rs7699867	ENSG00000273257.1	RP11-177J6.1	6.3	6.66e-10	1.46e-07	0.38	0.28	Height;	chr4:55483718	chr4:55387949~55388271:+
THCA	cis	rs2439831	0.85	rs2957637	ENSG00000166763.7	STRCP1	6.3	6.66e-10	1.46e-07	0.4	0.28	Lung cancer in ever smokers;	chr15:43658920	chr15:43699488~43718184:-
THCA	cis	rs4845570	0.92	rs3811414	ENSG00000268288.1	RP11-98D18.16	-6.3	6.66e-10	1.46e-07	-0.35	-0.28	Coronary artery disease;	chr1:151790770	chr1:151766486~151767000:-
THCA	cis	rs9649465	0.967	rs6950373	ENSG00000272686.1	RP11-390E23.6	6.3	6.66e-10	1.46e-07	0.18	0.28	Migraine;	chr7:123721719	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs6951138	ENSG00000272686.1	RP11-390E23.6	6.3	6.66e-10	1.46e-07	0.18	0.28	Migraine;	chr7:123722016	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.935	rs3807636	ENSG00000272686.1	RP11-390E23.6	6.3	6.66e-10	1.46e-07	0.18	0.28	Migraine;	chr7:123728434	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs13224762	ENSG00000272686.1	RP11-390E23.6	6.3	6.66e-10	1.46e-07	0.18	0.28	Migraine;	chr7:123730656	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs13225220	ENSG00000272686.1	RP11-390E23.6	6.3	6.66e-10	1.46e-07	0.18	0.28	Migraine;	chr7:123730972	chr7:123749068~123751166:+
THCA	cis	rs741668	1	rs741668	ENSG00000235903.6	CPB2-AS1	-6.3	6.66e-10	1.46e-07	-0.36	-0.28	Cerebrospinal fluid clusterin levels;	chr13:45942333	chr13:46052806~46113332:+
THCA	cis	rs2163813	1	rs17699333	ENSG00000275540.1	CTC-559E9.12	-6.3	6.67e-10	1.46e-07	-0.33	-0.28	Toenail selenium levels;	chr19:19720735	chr19:19740884~19750127:+
THCA	cis	rs2243480	1	rs1039664	ENSG00000228409.4	CCT6P1	6.3	6.67e-10	1.46e-07	0.32	0.28	Diabetic kidney disease;	chr7:65984729	chr7:65751142~65763354:+
THCA	cis	rs950169	0.922	rs17531523	ENSG00000259295.5	CSPG4P12	6.3	6.68e-10	1.46e-07	0.43	0.28	Schizophrenia;	chr15:84589218	chr15:85191438~85213905:+
THCA	cis	rs16846053	0.642	rs1979112	ENSG00000227403.1	AC009299.3	6.3	6.68e-10	1.46e-07	0.45	0.28	Blood osmolality (transformed sodium);	chr2:161801445	chr2:161244739~161249050:+
THCA	cis	rs11722779	0.838	rs4533776	ENSG00000251288.2	RP11-10L12.2	-6.3	6.69e-10	1.47e-07	-0.37	-0.28	Schizophrenia;	chr4:102912732	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.838	rs6821247	ENSG00000251288.2	RP11-10L12.2	-6.3	6.69e-10	1.47e-07	-0.37	-0.28	Schizophrenia;	chr4:102913483	chr4:102751401~102752641:+
THCA	cis	rs6603134	0.502	rs10406540	ENSG00000269139.2	CTD-3193O13.8	6.3	6.69e-10	1.47e-07	0.26	0.28	Blood protein levels;	chr19:8039113	chr19:7926001~7926810:+
THCA	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	6.3	6.7e-10	1.47e-07	0.51	0.28	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
THCA	cis	rs9926296	0.585	rs6500441	ENSG00000260259.1	RP11-368I7.4	-6.3	6.7e-10	1.47e-07	-0.3	-0.28	Vitiligo;	chr16:89762261	chr16:89682620~89686569:-
THCA	cis	rs10844706	0.699	rs10772079	ENSG00000256594.6	RP11-705C15.2	6.3	6.71e-10	1.47e-07	0.23	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721798	chr12:9633419~9658412:+
THCA	cis	rs516805	0.667	rs9490411	ENSG00000279453.1	RP3-425C14.4	6.3	6.71e-10	1.47e-07	0.32	0.28	Lymphocyte counts;	chr6:122217270	chr6:122436789~122439223:-
THCA	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-6.3	6.71e-10	1.47e-07	-0.32	-0.28	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-6.3	6.71e-10	1.47e-07	-0.32	-0.28	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
THCA	cis	rs10829156	0.898	rs7095666	ENSG00000240291.1	RP11-499P20.2	-6.3	6.71e-10	1.47e-07	-0.23	-0.28	Sudden cardiac arrest;	chr10:18650538	chr10:18513115~18545651:-
THCA	cis	rs934734	0.752	rs2661795	ENSG00000234255.7	AC012370.3	-6.3	6.72e-10	1.47e-07	-0.31	-0.28	Rheumatoid arthritis;	chr2:65399672	chr2:65439888~65456571:-
THCA	cis	rs934734	1	rs934734	ENSG00000281920.1	RP11-418H16.1	-6.3	6.73e-10	1.47e-07	-0.34	-0.28	Rheumatoid arthritis;	chr2:65368452	chr2:65623272~65628424:+
THCA	cis	rs1005277	0.579	rs2472173	ENSG00000276805.1	RP11-291L22.6	6.3	6.74e-10	1.47e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2472174	ENSG00000276805.1	RP11-291L22.6	6.3	6.74e-10	1.47e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474563	ENSG00000276805.1	RP11-291L22.6	6.3	6.74e-10	1.47e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs9418322	ENSG00000276805.1	RP11-291L22.6	6.3	6.74e-10	1.47e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs9299760	ENSG00000276805.1	RP11-291L22.6	6.3	6.74e-10	1.47e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2023351	ENSG00000276805.1	RP11-291L22.6	6.3	6.74e-10	1.47e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38451030~38451785:+
THCA	cis	rs2439831	1	rs2601014	ENSG00000275601.1	AC011330.13	-6.3	6.74e-10	1.48e-07	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43463815	chr15:43642389~43643023:-
THCA	cis	rs12534093	0.562	rs6461714	ENSG00000234286.1	AC006026.13	-6.3	6.74e-10	1.48e-07	-0.37	-0.28	Infant length;Height;	chr7:23536633	chr7:23680195~23680786:-
THCA	cis	rs3806843	1	rs10223116	ENSG00000202515.1	VTRNA1-3	-6.3	6.75e-10	1.48e-07	-0.31	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140813058	chr5:140726158~140726246:+
THCA	cis	rs7569084	0.566	rs7584295	ENSG00000234255.7	AC012370.3	6.3	6.75e-10	1.48e-07	0.33	0.28	Sum eosinophil basophil counts;	chr2:65353940	chr2:65439888~65456571:-
THCA	cis	rs934734	0.563	rs11695373	ENSG00000234255.7	AC012370.3	6.3	6.75e-10	1.48e-07	0.33	0.28	Rheumatoid arthritis;	chr2:65354066	chr2:65439888~65456571:-
THCA	cis	rs9381040	0.626	rs2272986	ENSG00000161912.16	ADCY10P1	6.3	6.75e-10	1.48e-07	0.19	0.28	Alzheimer's disease (late onset);	chr6:41070039	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.655	rs7738684	ENSG00000161912.16	ADCY10P1	6.3	6.75e-10	1.48e-07	0.19	0.28	Alzheimer's disease (late onset);	chr6:41070813	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.655	rs4140578	ENSG00000161912.16	ADCY10P1	6.3	6.75e-10	1.48e-07	0.19	0.28	Alzheimer's disease (late onset);	chr6:41074090	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.655	rs9381032	ENSG00000161912.16	ADCY10P1	6.3	6.75e-10	1.48e-07	0.19	0.28	Alzheimer's disease (late onset);	chr6:41077247	chr6:41101022~41140835:+
THCA	cis	rs2975734	0.709	rs4841298	ENSG00000261451.1	RP11-981G7.1	-6.3	6.75e-10	1.48e-07	-0.38	-0.28	Chronotype;Morning vs. evening chronotype;	chr8:10254127	chr8:10433672~10438312:+
THCA	cis	rs2657294	0.62	rs2395132	ENSG00000226051.5	ZNF503-AS1	-6.3	6.75e-10	1.48e-07	-0.4	-0.28	Pneumonia;	chr10:75080840	chr10:75269819~75373500:+
THCA	cis	rs2348418	0.832	rs2100924	ENSG00000247934.4	RP11-967K21.1	-6.3	6.76e-10	1.48e-07	-0.25	-0.28	Lung function (FEV1);Lung function (FVC);	chr12:28340798	chr12:28163298~28190738:-
THCA	cis	rs7833787	0.965	rs7833694	ENSG00000278886.1	RP11-108A14.1	-6.3	6.76e-10	1.48e-07	-0.36	-0.28	Obesity-related traits;	chr8:18842836	chr8:18864681~18865247:-
THCA	cis	rs6545883	0.859	rs35760550	ENSG00000271889.1	RP11-493E12.1	-6.3	6.77e-10	1.48e-07	-0.27	-0.28	Tuberculosis;	chr2:61376730	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.859	rs62149714	ENSG00000271889.1	RP11-493E12.1	-6.3	6.77e-10	1.48e-07	-0.27	-0.28	Tuberculosis;	chr2:61376734	chr2:61151433~61162105:-
THCA	cis	rs6504622	0.791	rs758392	ENSG00000262879.4	RP11-156P1.3	-6.3	6.77e-10	1.48e-07	-0.25	-0.28	Orofacial clefts;	chr17:46940493	chr17:46984045~47100323:-
THCA	cis	rs9898641	1	rs9898641	ENSG00000267302.4	RP11-178C3.2	6.3	6.78e-10	1.48e-07	0.33	0.28	Interleukin-1-beta levels;	chr17:59493672	chr17:59964832~59996972:+
THCA	cis	rs227275	0.554	rs223409	ENSG00000230069.3	LRRC37A15P	-6.3	6.78e-10	1.48e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223404	ENSG00000230069.3	LRRC37A15P	-6.3	6.78e-10	1.48e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102727274~102730721:-
THCA	cis	rs7608910	0.668	rs6754585	ENSG00000271889.1	RP11-493E12.1	6.3	6.79e-10	1.49e-07	0.28	0.28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60995008	chr2:61151433~61162105:-
THCA	cis	rs728616	0.681	rs35420115	ENSG00000242600.5	MBL1P	6.3	6.79e-10	1.49e-07	0.35	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148432	chr10:79904898~79950336:+
THCA	cis	rs4664293	0.625	rs3821300	ENSG00000226266.5	AC009961.3	6.3	6.79e-10	1.49e-07	0.32	0.28	Monocyte percentage of white cells;	chr2:159710719	chr2:159670708~159712435:-
THCA	cis	rs16846053	0.71	rs13006199	ENSG00000227403.1	AC009299.3	6.3	6.79e-10	1.49e-07	0.44	0.28	Blood osmolality (transformed sodium);	chr2:161770258	chr2:161244739~161249050:+
THCA	cis	rs6432852	0.516	rs2304002	ENSG00000232411.1	AC009495.3	6.3	6.79e-10	1.49e-07	0.3	0.28	Diabetic kidney disease;	chr2:165857585	chr2:165833048~165839098:-
THCA	cis	rs12908161	0.959	rs2175567	ENSG00000259295.5	CSPG4P12	6.3	6.79e-10	1.49e-07	0.43	0.28	Schizophrenia;	chr15:84657715	chr15:85191438~85213905:+
THCA	cis	rs728616	0.867	rs1537835	ENSG00000225484.5	NUTM2B-AS1	-6.3	6.79e-10	1.49e-07	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80070396	chr10:79663088~79826594:-
THCA	cis	rs7976269	0.537	rs10843308	ENSG00000257176.2	RP11-996F15.2	-6.3	6.8e-10	1.49e-07	-0.28	-0.28	Male-pattern baldness;	chr12:29075172	chr12:29280418~29317848:-
THCA	cis	rs9816784	0.901	rs56253832	ENSG00000226155.1	AC124944.3	-6.3	6.8e-10	1.49e-07	-0.32	-0.28	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195912049~195913986:+
THCA	cis	rs1979679	0.842	rs11049411	ENSG00000278733.1	RP11-425D17.1	6.3	6.8e-10	1.49e-07	0.27	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28184723	chr12:28185625~28186190:-
THCA	cis	rs9859260	0.71	rs34906439	ENSG00000226155.1	AC124944.3	6.3	6.81e-10	1.49e-07	0.34	0.28	Mean corpuscular volume;	chr3:196052835	chr3:195912049~195913986:+
THCA	cis	rs13113518	0.812	rs12649507	ENSG00000249700.7	SRD5A3-AS1	-6.3	6.81e-10	1.49e-07	-0.36	-0.28	Height;	chr4:55514317	chr4:55363971~55395847:-
THCA	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	6.3	6.81e-10	1.49e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
THCA	cis	rs3213758	0.541	rs5005161	ENSG00000275191.1	RP11-36I17.2	-6.3	6.81e-10	1.49e-07	-0.4	-0.28	Vitiligo (non-segmental);	chr16:53664764	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.541	rs10852520	ENSG00000275191.1	RP11-36I17.2	-6.3	6.81e-10	1.49e-07	-0.4	-0.28	Vitiligo (non-segmental);	chr16:53676961	chr16:53628256~53628816:-
THCA	cis	rs11148252	0.51	rs35895576	ENSG00000278238.1	RP11-245D16.4	-6.3	6.81e-10	1.49e-07	-0.31	-0.28	Lewy body disease;	chr13:52010764	chr13:52454775~52455331:-
THCA	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-6.3	6.82e-10	1.49e-07	-0.37	-0.28	Depression;	chr6:28422360	chr6:28176188~28176674:+
THCA	cis	rs516805	0.563	rs2606635	ENSG00000279453.1	RP3-425C14.4	-6.3	6.82e-10	1.49e-07	-0.31	-0.28	Lymphocyte counts;	chr6:122101222	chr6:122436789~122439223:-
THCA	cis	rs1318937	0.516	rs73023424	ENSG00000224660.1	SH3BP5-AS1	6.3	6.82e-10	1.49e-07	0.19	0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15201995	chr3:15254184~15264493:+
THCA	cis	rs3806843	0.966	rs3806844	ENSG00000202515.1	VTRNA1-3	-6.3	6.83e-10	1.49e-07	-0.31	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140826678	chr5:140726158~140726246:+
THCA	cis	rs6479891	1	rs9415692	ENSG00000232075.1	MRPL35P2	6.3	6.83e-10	1.49e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs7081275	ENSG00000232075.1	MRPL35P2	-6.3	6.83e-10	1.49e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs7895348	ENSG00000232075.1	MRPL35P2	-6.3	6.83e-10	1.49e-07	-0.49	-0.28	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63634317~63634827:-
THCA	cis	rs1707322	0.686	rs2050376	ENSG00000281133.1	AL355480.3	-6.3	6.83e-10	1.49e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45580892~45580996:-
THCA	cis	rs9402743	0.962	rs11967412	ENSG00000231028.7	LINC00271	-6.3	6.84e-10	1.5e-07	-0.22	-0.28	Systemic lupus erythematosus;	chr6:135648288	chr6:135497801~135716055:+
THCA	cis	rs2243480	1	rs313814	ENSG00000232546.1	RP11-458F8.1	-6.3	6.84e-10	1.5e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66038306	chr7:66848496~66858136:+
THCA	cis	rs2562456	0.641	rs62107468	ENSG00000268555.1	RP11-678G14.3	6.3	6.85e-10	1.5e-07	0.44	0.28	Pain;	chr19:21307177	chr19:21570822~21587322:-
THCA	cis	rs1609391	0.543	rs1347209	ENSG00000273486.1	RP11-731C17.2	6.3	6.85e-10	1.5e-07	0.24	0.28	Neuroticism;	chr3:136907855	chr3:136837338~136839021:-
THCA	cis	rs2243480	1	rs431318	ENSG00000232546.1	RP11-458F8.1	-6.3	6.86e-10	1.5e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66046610	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs313803	ENSG00000232546.1	RP11-458F8.1	-6.3	6.86e-10	1.5e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66049744	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs313802	ENSG00000232546.1	RP11-458F8.1	-6.3	6.86e-10	1.5e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66051386	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000232546.1	RP11-458F8.1	-6.3	6.86e-10	1.5e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66052736	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs458291	ENSG00000232546.1	RP11-458F8.1	-6.3	6.86e-10	1.5e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66055492	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs464895	ENSG00000232546.1	RP11-458F8.1	-6.3	6.86e-10	1.5e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66062119	chr7:66848496~66858136:+
THCA	cis	rs3847687	0.565	rs11061294	ENSG00000256810.1	RP11-76C10.2	6.3	6.86e-10	1.5e-07	0.33	0.28	Longevity;	chr12:131035116	chr12:131030570~131035487:-
THCA	cis	rs3847687	0.565	rs10848270	ENSG00000256810.1	RP11-76C10.2	6.3	6.86e-10	1.5e-07	0.33	0.28	Longevity;	chr12:131035119	chr12:131030570~131035487:-
THCA	cis	rs3847687	0.565	rs10848271	ENSG00000256810.1	RP11-76C10.2	6.3	6.86e-10	1.5e-07	0.33	0.28	Longevity;	chr12:131035158	chr12:131030570~131035487:-
THCA	cis	rs9926296	0.744	rs164749	ENSG00000274627.1	RP11-104N10.2	6.3	6.87e-10	1.5e-07	0.27	0.28	Vitiligo;	chr16:89641816	chr16:89516797~89522217:+
THCA	cis	rs2562456	0.793	rs627522	ENSG00000213976.4	CTD-2561J22.2	-6.3	6.87e-10	1.5e-07	-0.29	-0.28	Pain;	chr19:21313002	chr19:21382865~21387177:+
THCA	cis	rs17772222	1	rs17772222	ENSG00000258789.1	RP11-507K2.3	6.3	6.87e-10	1.5e-07	0.29	0.28	Coronary artery calcification;	chr14:88360138	chr14:88551597~88552493:+
THCA	cis	rs10208649	0.505	rs2287512	ENSG00000272156.1	RP11-477N3.1	6.3	6.87e-10	1.5e-07	0.4	0.28	Body mass index;	chr2:53670895	chr2:54082554~54085066:+
THCA	cis	rs4835473	0.8	rs1849122	ENSG00000251600.4	RP11-673E1.1	6.3	6.87e-10	1.5e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143978699	chr4:143912331~143982454:+
THCA	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	6.3	6.89e-10	1.51e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	6.3	6.89e-10	1.51e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	6.3	6.89e-10	1.51e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
THCA	cis	rs916888	0.647	rs199523	ENSG00000232300.1	FAM215B	-6.3	6.89e-10	1.51e-07	-0.39	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46558830~46562795:-
THCA	cis	rs7851660	0.967	rs4743134	ENSG00000214417.4	KRT18P13	-6.3	6.89e-10	1.51e-07	-0.23	-0.28	Strep throat;	chr9:97836286	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs4743135	ENSG00000214417.4	KRT18P13	-6.3	6.89e-10	1.51e-07	-0.23	-0.28	Strep throat;	chr9:97837211	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs7049054	ENSG00000214417.4	KRT18P13	-6.3	6.89e-10	1.51e-07	-0.23	-0.28	Strep throat;	chr9:97837687	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs7860598	ENSG00000214417.4	KRT18P13	-6.3	6.89e-10	1.51e-07	-0.23	-0.28	Strep throat;	chr9:97838420	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.935	rs10818124	ENSG00000214417.4	KRT18P13	-6.3	6.89e-10	1.51e-07	-0.23	-0.28	Strep throat;	chr9:97840726	chr9:97698922~97700734:+
THCA	cis	rs1005277	0.522	rs1208767	ENSG00000263064.2	RP11-291L22.7	6.3	6.89e-10	1.51e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38448689~38448949:+
THCA	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-6.3	6.89e-10	1.51e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
THCA	cis	rs1062177	0.502	rs10463321	ENSG00000253921.1	CTB-113P19.3	-6.3	6.89e-10	1.51e-07	-0.36	-0.28	Preschool internalizing problems;	chr5:151944344	chr5:151753992~151767247:+
THCA	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	6.3	6.9e-10	1.51e-07	0.17	0.28	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
THCA	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	6.3	6.9e-10	1.51e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
THCA	cis	rs2562456	0.833	rs4334427	ENSG00000268555.1	RP11-678G14.3	6.3	6.91e-10	1.51e-07	0.45	0.28	Pain;	chr19:21338090	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs4644962	ENSG00000268555.1	RP11-678G14.3	6.3	6.91e-10	1.51e-07	0.45	0.28	Pain;	chr19:21338125	chr19:21570822~21587322:-
THCA	cis	rs228614	0.514	rs59550147	ENSG00000251288.2	RP11-10L12.2	-6.3	6.91e-10	1.51e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102751401~102752641:+
THCA	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	6.3	6.91e-10	1.51e-07	0.23	0.28	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
THCA	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	6.3	6.91e-10	1.51e-07	0.23	0.28	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
THCA	cis	rs28386778	0.591	rs2584619	ENSG00000240280.5	TCAM1P	-6.3	6.92e-10	1.51e-07	-0.39	-0.28	Prudent dietary pattern;	chr17:63835855	chr17:63849292~63864379:+
THCA	cis	rs3020264	0.55	rs2515557	ENSG00000271743.1	CTD-2541M15.3	-6.3	6.92e-10	1.51e-07	-0.39	-0.28	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6617592	chr8:6615604~6617198:-
THCA	cis	rs950169	0.845	rs4502182	ENSG00000259295.5	CSPG4P12	6.3	6.92e-10	1.51e-07	0.43	0.28	Schizophrenia;	chr15:84254768	chr15:85191438~85213905:+
THCA	cis	rs9595908	0.897	rs10083285	ENSG00000212293.1	SNORA16	6.3	6.92e-10	1.51e-07	0.32	0.28	Body mass index;	chr13:32557205	chr13:32420390~32420516:-
THCA	cis	rs10129255	1	rs8010605	ENSG00000211974.3	IGHV2-70	6.3	6.92e-10	1.51e-07	0.22	0.28	Kawasaki disease;	chr14:106678742	chr14:106723574~106724093:-
THCA	cis	rs4835473	0.932	rs1450235	ENSG00000251600.4	RP11-673E1.1	6.3	6.93e-10	1.51e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143782927	chr4:143912331~143982454:+
THCA	cis	rs4143844	0.655	rs35633657	ENSG00000259251.2	RP11-643M14.1	6.3	6.93e-10	1.52e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61977739	chr15:62060503~62062434:+
THCA	cis	rs838147	0.507	rs692854	ENSG00000232871.7	SEC1P	6.3	6.93e-10	1.52e-07	0.32	0.28	Dietary macronutrient intake;	chr19:48706207	chr19:48638071~48682245:+
THCA	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	6.3	6.93e-10	1.52e-07	0.64	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
THCA	cis	rs13113518	0.783	rs11133389	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55486718	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs4865001	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55490176	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs4864543	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55490228	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs6825774	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55491150	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs3805153	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55493557	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.756	rs7658446	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55495262	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.776	rs13124436	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55502504	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.783	rs6843997	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55508982	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.783	rs12508367	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55509442	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs2272073	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55510177	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs4865003	ENSG00000273257.1	RP11-177J6.1	6.3	6.93e-10	1.52e-07	0.38	0.28	Height;	chr4:55514802	chr4:55387949~55388271:+
THCA	cis	rs2348418	0.832	rs1405811	ENSG00000247934.4	RP11-967K21.1	6.3	6.94e-10	1.52e-07	0.25	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28428169	chr12:28163298~28190738:-
THCA	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	6.3	6.94e-10	1.52e-07	0.36	0.28	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
THCA	cis	rs3847687	0.546	rs11061295	ENSG00000256810.1	RP11-76C10.2	6.3	6.94e-10	1.52e-07	0.33	0.28	Longevity;	chr12:131035139	chr12:131030570~131035487:-
THCA	cis	rs683257	0.636	rs6934165	ENSG00000234147.1	RP3-460G2.2	-6.3	6.94e-10	1.52e-07	-0.43	-0.28	Facial emotion recognition (angry faces);	chr6:140851191	chr6:140845958~140852924:-
THCA	cis	rs683257	0.636	rs56295525	ENSG00000234147.1	RP3-460G2.2	-6.3	6.94e-10	1.52e-07	-0.43	-0.28	Facial emotion recognition (angry faces);	chr6:140853380	chr6:140845958~140852924:-
THCA	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-6.3	6.95e-10	1.52e-07	-0.29	-0.28	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
THCA	cis	rs2243480	1	rs160652	ENSG00000229886.1	RP5-1132H15.3	6.3	6.96e-10	1.52e-07	0.45	0.28	Diabetic kidney disease;	chr7:66073444	chr7:66025126~66031544:-
THCA	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	6.3	6.96e-10	1.52e-07	0.45	0.28	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
THCA	cis	rs6672530	0.518	rs3010196	ENSG00000227711.2	RP11-275O4.5	-6.3	6.96e-10	1.52e-07	-0.29	-0.28	Hip circumference adjusted for BMI;	chr1:227606207	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.531	rs3010195	ENSG00000227711.2	RP11-275O4.5	-6.3	6.96e-10	1.52e-07	-0.29	-0.28	Height;	chr1:227607008	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs3010193	ENSG00000227711.2	RP11-275O4.5	-6.3	6.96e-10	1.52e-07	-0.29	-0.28	Height;	chr1:227610621	chr1:227509028~227520477:-
THCA	cis	rs227275	0.556	rs4235407	ENSG00000230069.3	LRRC37A15P	-6.3	6.97e-10	1.52e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223436	ENSG00000230069.3	LRRC37A15P	-6.3	6.98e-10	1.52e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223424	ENSG00000230069.3	LRRC37A15P	-6.3	6.98e-10	1.52e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102727274~102730721:-
THCA	cis	rs227275	0.524	rs223423	ENSG00000230069.3	LRRC37A15P	-6.3	6.98e-10	1.52e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223422	ENSG00000230069.3	LRRC37A15P	-6.3	6.98e-10	1.52e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102727274~102730721:-
THCA	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	6.3	6.98e-10	1.52e-07	0.22	0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
THCA	cis	rs6740322	0.748	rs6732337	ENSG00000234936.1	AC010883.5	-6.3	6.98e-10	1.52e-07	-0.3	-0.28	Coronary artery disease;	chr2:43235683	chr2:43229573~43233394:+
THCA	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-6.3	6.99e-10	1.53e-07	-0.21	-0.28	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
THCA	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-6.3	6.99e-10	1.53e-07	-0.21	-0.28	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
THCA	cis	rs3758785	0.697	rs3758789	ENSG00000255893.1	RP11-685N10.1	-6.3	6.99e-10	1.53e-07	-0.34	-0.28	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94399958	chr11:94472908~94473570:-
THCA	cis	rs227275	0.554	rs223442	ENSG00000230069.3	LRRC37A15P	-6.3	6.99e-10	1.53e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223441	ENSG00000230069.3	LRRC37A15P	-6.3	6.99e-10	1.53e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102727274~102730721:-
THCA	cis	rs3750082	0.574	rs9639668	ENSG00000231952.3	DPY19L1P2	6.3	7e-10	1.53e-07	0.4	0.28	Glomerular filtration rate (creatinine);	chr7:32873023	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.574	rs10262714	ENSG00000231952.3	DPY19L1P2	6.3	7e-10	1.53e-07	0.4	0.28	Glomerular filtration rate (creatinine);	chr7:32878214	chr7:32812757~32838570:+
THCA	cis	rs7851660	0.933	rs894673	ENSG00000214417.4	KRT18P13	-6.3	7e-10	1.53e-07	-0.24	-0.28	Strep throat;	chr9:97849988	chr9:97698922~97700734:+
THCA	cis	rs9309473	0.519	rs2178154	ENSG00000163016.8	ALMS1P	-6.3	7e-10	1.53e-07	-0.36	-0.28	Metabolite levels;	chr2:73434610	chr2:73644919~73685576:+
THCA	cis	rs60180747	0.544	rs12913465	ENSG00000261318.1	RP11-653J6.1	6.3	7e-10	1.53e-07	0.38	0.28	Testicular germ cell tumor;	chr15:66280896	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.544	rs9920422	ENSG00000261318.1	RP11-653J6.1	6.3	7e-10	1.53e-07	0.38	0.28	Testicular germ cell tumor;	chr15:66283212	chr15:66278498~66293357:-
THCA	cis	rs12908161	1	rs12911736	ENSG00000259295.5	CSPG4P12	6.3	7e-10	1.53e-07	0.43	0.28	Schizophrenia;	chr15:84696777	chr15:85191438~85213905:+
THCA	cis	rs12908161	0.959	rs12908699	ENSG00000259295.5	CSPG4P12	6.3	7e-10	1.53e-07	0.43	0.28	Schizophrenia;	chr15:84697172	chr15:85191438~85213905:+
THCA	cis	rs848490	1	rs10215453	ENSG00000214293.7	APTR	6.3	7.01e-10	1.53e-07	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77859361	chr7:77657660~77696265:-
THCA	cis	rs4835473	0.932	rs28377887	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143977075	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6826862	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143978180	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.663	rs4835115	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143979308	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs4257604	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143980261	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs35599924	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143980602	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4516663	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143980791	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.8	rs2089839	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143980955	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4835118	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143981994	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4835471	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143982153	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs4835119	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143982210	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4835472	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143982398	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs4835474	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143982444	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6847869	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143982881	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs6846984	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143983098	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs34617134	ENSG00000251600.4	RP11-673E1.1	6.3	7.01e-10	1.53e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143983606	chr4:143912331~143982454:+
THCA	cis	rs4683346	0.652	rs339671	ENSG00000173811.9	CCDC13-AS1	-6.3	7.02e-10	1.53e-07	-0.28	-0.28	Granulocyte percentage of myeloid white cells;	chr3:42760420	chr3:42732575~42746768:+
THCA	cis	rs7727544	0.684	rs272849	ENSG00000237714.1	P4HA2-AS1	6.3	7.02e-10	1.53e-07	0.36	0.28	Blood metabolite levels;	chr5:132354548	chr5:132184876~132192808:+
THCA	cis	rs7044106	0.762	rs10984974	ENSG00000270917.1	RP11-27I1.6	-6.3	7.02e-10	1.53e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120812475~120812845:-
THCA	cis	rs6065	0.529	rs1056626	ENSG00000234203.1	RP5-1050D4.2	6.3	7.04e-10	1.54e-07	0.55	0.28	Platelet count;	chr17:5028258	chr17:4972851~4974681:+
THCA	cis	rs62103177	0.714	rs12607447	ENSG00000261126.6	RP11-795F19.1	6.3	7.04e-10	1.54e-07	0.27	0.28	Opioid sensitivity;	chr18:79845212	chr18:80046900~80095482:+
THCA	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	6.3	7.04e-10	1.54e-07	0.26	0.28	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
THCA	cis	rs6142102	0.659	rs6057945	ENSG00000275784.1	RP5-1125A11.6	-6.3	7.04e-10	1.54e-07	-0.28	-0.28	Skin pigmentation;	chr20:33929374	chr20:33989480~33991818:-
THCA	cis	rs73607972	0.935	rs16952396	ENSG00000275191.1	RP11-36I17.2	-6.3	7.04e-10	1.54e-07	-0.42	-0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53616751	chr16:53628256~53628816:-
THCA	cis	rs227275	0.554	rs223439	ENSG00000230069.3	LRRC37A15P	-6.3	7.04e-10	1.54e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102727274~102730721:-
THCA	cis	rs7267979	0.816	rs1044573	ENSG00000274414.1	RP5-965G21.4	-6.3	7.05e-10	1.54e-07	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25239007~25245229:-
THCA	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	6.3	7.05e-10	1.54e-07	0.3	0.28	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000229886.1	RP5-1132H15.3	6.3	7.05e-10	1.54e-07	0.47	0.28	Diabetic kidney disease;	chr7:66521515	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs13237037	ENSG00000229886.1	RP5-1132H15.3	6.3	7.05e-10	1.54e-07	0.47	0.28	Diabetic kidney disease;	chr7:66532895	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1796228	ENSG00000229886.1	RP5-1132H15.3	6.3	7.05e-10	1.54e-07	0.47	0.28	Diabetic kidney disease;	chr7:66568097	chr7:66025126~66031544:-
THCA	cis	rs848490	1	rs17385641	ENSG00000214293.7	APTR	-6.3	7.05e-10	1.54e-07	-0.22	-0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77733172	chr7:77657660~77696265:-
THCA	cis	rs2834188	0.924	rs2834177	ENSG00000272659.1	AP000295.10	-6.3	7.05e-10	1.54e-07	-0.37	-0.28	Narcolepsy;	chr21:33304501	chr21:33309491~33310181:+
THCA	cis	rs2765539	0.701	rs12068932	ENSG00000231365.4	RP11-418J17.1	-6.3	7.05e-10	1.54e-07	-0.31	-0.28	Waist-hip ratio;	chr1:119113057	chr1:119140396~119275973:+
THCA	cis	rs2243480	1	rs1964692	ENSG00000228409.4	CCT6P1	6.3	7.05e-10	1.54e-07	0.32	0.28	Diabetic kidney disease;	chr7:65989196	chr7:65751142~65763354:+
THCA	cis	rs10875746	0.537	rs4760625	ENSG00000269514.1	RP11-370I10.12	6.29	7.06e-10	1.54e-07	0.28	0.28	Longevity (90 years and older);	chr12:48279960	chr12:48198387~48202031:+
THCA	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-6.29	7.06e-10	1.54e-07	-0.37	-0.28	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
THCA	cis	rs7617773	0.563	rs62263035	ENSG00000228638.1	FCF1P2	-6.29	7.06e-10	1.54e-07	-0.27	-0.28	Coronary artery disease;	chr3:48350079	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.563	rs13082269	ENSG00000228638.1	FCF1P2	-6.29	7.06e-10	1.54e-07	-0.27	-0.28	Coronary artery disease;	chr3:48350784	chr3:48290793~48291375:-
THCA	cis	rs227275	0.525	rs10028116	ENSG00000230069.3	LRRC37A15P	-6.29	7.06e-10	1.54e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs9307281	ENSG00000230069.3	LRRC37A15P	-6.29	7.06e-10	1.54e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.903	rs6533037	ENSG00000230069.3	LRRC37A15P	-6.29	7.06e-10	1.54e-07	-0.29	-0.28	Schizophrenia;	chr4:102935865	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.903	rs4530634	ENSG00000230069.3	LRRC37A15P	-6.29	7.06e-10	1.54e-07	-0.29	-0.28	Schizophrenia;	chr4:102937924	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs7676943	ENSG00000230069.3	LRRC37A15P	-6.29	7.06e-10	1.54e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs6419160	ENSG00000230069.3	LRRC37A15P	-6.29	7.06e-10	1.54e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.901	rs28674656	ENSG00000230069.3	LRRC37A15P	-6.29	7.06e-10	1.54e-07	-0.29	-0.28	Schizophrenia;	chr4:102944396	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.838	rs3974494	ENSG00000230069.3	LRRC37A15P	-6.29	7.06e-10	1.54e-07	-0.29	-0.28	Schizophrenia;	chr4:102945323	chr4:102727274~102730721:-
THCA	cis	rs16846053	0.642	rs16846107	ENSG00000227403.1	AC009299.3	6.29	7.06e-10	1.54e-07	0.48	0.28	Blood osmolality (transformed sodium);	chr2:161775746	chr2:161244739~161249050:+
THCA	cis	rs7727544	0.735	rs4705933	ENSG00000237714.1	P4HA2-AS1	6.29	7.07e-10	1.54e-07	0.36	0.28	Blood metabolite levels;	chr5:132342719	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.735	rs272867	ENSG00000237714.1	P4HA2-AS1	6.29	7.07e-10	1.54e-07	0.36	0.28	Blood metabolite levels;	chr5:132345364	chr5:132184876~132192808:+
THCA	cis	rs4835473	0.615	rs6857432	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.54e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143971912	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.742	rs1838519	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.54e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143972242	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.798	rs34353812	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.54e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143973949	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.831	rs10428468	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.54e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143974104	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.75	rs57610804	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.54e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143974341	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13148097	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.54e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143976238	chr4:143912331~143982454:+
THCA	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	6.29	7.08e-10	1.54e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
THCA	cis	rs7727544	0.735	rs272884	ENSG00000237714.1	P4HA2-AS1	6.29	7.08e-10	1.55e-07	0.36	0.28	Blood metabolite levels;	chr5:132332961	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.735	rs272881	ENSG00000237714.1	P4HA2-AS1	6.29	7.08e-10	1.55e-07	0.36	0.28	Blood metabolite levels;	chr5:132333571	chr5:132184876~132192808:+
THCA	cis	rs4835473	0.736	rs11724009	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.55e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143984291	chr4:143912331~143982454:+
THCA	cis	rs4323050	0.514	rs28647406	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.55e-07	0.37	0.28	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.604	rs11938387	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.55e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143984476	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.798	rs11100829	ENSG00000251600.4	RP11-673E1.1	6.29	7.08e-10	1.55e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143984761	chr4:143912331~143982454:+
THCA	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-6.29	7.09e-10	1.55e-07	-0.17	-0.28	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
THCA	cis	rs227275	0.524	rs150894	ENSG00000230069.3	LRRC37A15P	-6.29	7.09e-10	1.55e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102727274~102730721:-
THCA	cis	rs4835473	0.663	rs1511423	ENSG00000251600.4	RP11-673E1.1	6.29	7.09e-10	1.55e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143990136	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.639	rs5029916	ENSG00000251600.4	RP11-673E1.1	6.29	7.09e-10	1.55e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143990684	chr4:143912331~143982454:+
THCA	cis	rs2243480	1	rs35820085	ENSG00000229886.1	RP5-1132H15.3	6.29	7.09e-10	1.55e-07	0.46	0.28	Diabetic kidney disease;	chr7:65977771	chr7:66025126~66031544:-
THCA	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	6.29	7.09e-10	1.55e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	6.29	7.09e-10	1.55e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	6.29	7.09e-10	1.55e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
THCA	cis	rs3204270	0.639	rs62080213	ENSG00000262049.1	RP13-1032I1.7	6.29	7.09e-10	1.55e-07	0.26	0.28	Dental caries;	chr17:81675501	chr17:81701324~81703300:-
THCA	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-6.29	7.1e-10	1.55e-07	-0.17	-0.28	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
THCA	cis	rs2562456	0.833	rs55920089	ENSG00000268555.1	RP11-678G14.3	6.29	7.1e-10	1.55e-07	0.45	0.28	Pain;	chr19:21337891	chr19:21570822~21587322:-
THCA	cis	rs7560272	0.723	rs7566315	ENSG00000163016.8	ALMS1P	6.29	7.1e-10	1.55e-07	0.36	0.28	Schizophrenia;	chr2:73564681	chr2:73644919~73685576:+
THCA	cis	rs17772222	0.793	rs7143853	ENSG00000222990.1	RNU4-22P	6.29	7.1e-10	1.55e-07	0.36	0.28	Coronary artery calcification;	chr14:88578477	chr14:88513498~88513663:+
THCA	cis	rs227275	0.554	rs150895	ENSG00000230069.3	LRRC37A15P	-6.29	7.1e-10	1.55e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102727274~102730721:-
THCA	cis	rs317689	0.702	rs544696	ENSG00000274979.1	RP11-1143G9.5	-6.29	7.11e-10	1.55e-07	-0.32	-0.28	Response to diuretic therapy;	chr12:69356159	chr12:69326574~69331882:-
THCA	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	6.29	7.11e-10	1.55e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	6.29	7.11e-10	1.55e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	6.29	7.11e-10	1.55e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
THCA	cis	rs7927592	0.913	rs10047412	ENSG00000212093.1	AP000807.1	6.29	7.11e-10	1.55e-07	0.31	0.28	Total body bone mineral density;	chr11:68465444	chr11:68506083~68506166:-
THCA	cis	rs367615	0.68	rs385728	ENSG00000249476.1	CTD-2587M2.1	-6.29	7.11e-10	1.55e-07	-0.31	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109630308	chr5:109237120~109326369:-
THCA	cis	rs2243480	1	rs781149	ENSG00000232546.1	RP11-458F8.1	-6.29	7.11e-10	1.55e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000232546.1	RP11-458F8.1	-6.29	7.11e-10	1.55e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1167613	ENSG00000232546.1	RP11-458F8.1	-6.29	7.11e-10	1.55e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs313799	ENSG00000232546.1	RP11-458F8.1	-6.29	7.11e-10	1.55e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66029343	chr7:66848496~66858136:+
THCA	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	6.29	7.11e-10	1.55e-07	0.56	0.28	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
THCA	cis	rs11603691	1	rs73470506	ENSG00000254662.1	RP11-872D17.4	-6.29	7.12e-10	1.55e-07	-0.58	-0.28	Low high density lipoprotein cholesterol levels;	chr11:57240772	chr11:57325603~57327958:+
THCA	cis	rs516805	0.63	rs699405	ENSG00000279453.1	RP3-425C14.4	-6.29	7.13e-10	1.55e-07	-0.29	-0.28	Lymphocyte counts;	chr6:122274145	chr6:122436789~122439223:-
THCA	cis	rs516805	0.596	rs225088	ENSG00000279453.1	RP3-425C14.4	-6.29	7.13e-10	1.55e-07	-0.29	-0.28	Lymphocyte counts;	chr6:122277898	chr6:122436789~122439223:-
THCA	cis	rs228614	0.536	rs223420	ENSG00000251288.2	RP11-10L12.2	-6.29	7.13e-10	1.55e-07	-0.38	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102751401~102752641:+
THCA	cis	rs1005277	0.541	rs2505193	ENSG00000276805.1	RP11-291L22.6	6.29	7.14e-10	1.56e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474580	ENSG00000276805.1	RP11-291L22.6	6.29	7.14e-10	1.56e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38451030~38451785:+
THCA	cis	rs728616	0.867	rs12411407	ENSG00000242600.5	MBL1P	6.29	7.14e-10	1.56e-07	0.38	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80068475	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs61859008	ENSG00000242600.5	MBL1P	6.29	7.14e-10	1.56e-07	0.38	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80071955	chr10:79904898~79950336:+
THCA	cis	rs2562456	0.792	rs2562398	ENSG00000268081.1	RP11-678G14.2	-6.29	7.14e-10	1.56e-07	-0.4	-0.28	Pain;	chr19:21540147	chr19:21554640~21569237:-
THCA	cis	rs4591358	0.731	rs12693768	ENSG00000223466.1	AC064834.2	-6.29	7.15e-10	1.56e-07	-0.39	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195451897	chr2:195533035~195538681:+
THCA	cis	rs3950186	1	rs1014972	ENSG00000215124.2	RP3-420J14.1	6.29	7.15e-10	1.56e-07	0.31	0.28	Anxiety and major depressive disorder;	chr6:11815357	chr6:11861626~11862970:-
THCA	cis	rs728616	0.764	rs56122289	ENSG00000242600.5	MBL1P	6.29	7.16e-10	1.56e-07	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79986271	chr10:79904898~79950336:+
THCA	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	6.29	7.17e-10	1.56e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
THCA	cis	rs7403037	1	rs17831583	ENSG00000259905.4	PWRN1	6.29	7.17e-10	1.56e-07	0.29	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24352075	chr15:24493137~24652130:+
THCA	cis	rs853679	0.542	rs9393892	ENSG00000261839.1	RP1-265C24.8	6.29	7.17e-10	1.56e-07	0.33	0.28	Depression;	chr6:28113616	chr6:28136849~28139678:+
THCA	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	6.29	7.17e-10	1.56e-07	0.31	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
THCA	cis	rs6696239	0.513	rs2935155	ENSG00000227711.2	RP11-275O4.5	6.29	7.18e-10	1.57e-07	0.29	0.28	Height;	chr1:227585305	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs2935146	ENSG00000227711.2	RP11-275O4.5	-6.29	7.18e-10	1.57e-07	-0.29	-0.28	Height;	chr1:227598332	chr1:227509028~227520477:-
THCA	cis	rs55665837	0.559	rs11023209	ENSG00000251991.1	RNU7-49P	6.29	7.18e-10	1.57e-07	0.33	0.28	Vitamin D levels;	chr11:14401054	chr11:14478892~14478953:+
THCA	cis	rs6061231	1	rs11696991	ENSG00000275437.1	RP5-908M14.10	6.29	7.18e-10	1.57e-07	0.26	0.28	Colorectal cancer;	chr20:62384638	chr20:62402236~62405935:-
THCA	cis	rs1005277	0.579	rs2474567	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2472175	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2472176	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474568	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2983343	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474569	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.602	rs2504142	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2472181	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474574	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2504140	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474575	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2472182	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.541	rs2263163	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2021649	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2472183	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2505197	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2505196	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.557	rs1854563	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2505237	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474599	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2505240	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.54	rs2224248	ENSG00000276805.1	RP11-291L22.6	6.29	7.19e-10	1.57e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38451030~38451785:+
THCA	cis	rs944289	0.561	rs1169122	ENSG00000257826.1	RP11-116N8.4	-6.29	7.2e-10	1.57e-07	-0.31	-0.28	Thyroid cancer;	chr14:36148896	chr14:36061026~36067190:-
THCA	cis	rs11722779	0.873	rs6533041	ENSG00000230069.3	LRRC37A15P	-6.29	7.2e-10	1.57e-07	-0.29	-0.28	Schizophrenia;	chr4:102951615	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs4699037	ENSG00000230069.3	LRRC37A15P	-6.29	7.2e-10	1.57e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs3857198	ENSG00000230069.3	LRRC37A15P	-6.29	7.2e-10	1.57e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.935	rs3857199	ENSG00000230069.3	LRRC37A15P	-6.29	7.2e-10	1.57e-07	-0.29	-0.28	Schizophrenia;	chr4:102957991	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs4699039	ENSG00000230069.3	LRRC37A15P	-6.29	7.2e-10	1.57e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102727274~102730721:-
THCA	cis	rs12908161	1	rs58416181	ENSG00000259295.5	CSPG4P12	6.29	7.2e-10	1.57e-07	0.43	0.28	Schizophrenia;	chr15:84721230	chr15:85191438~85213905:+
THCA	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-6.29	7.2e-10	1.57e-07	-0.26	-0.28	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
THCA	cis	rs4601821	0.583	rs1893696	ENSG00000270179.1	RP11-159N11.4	-6.29	7.21e-10	1.57e-07	-0.29	-0.28	Alcoholic chronic pancreatitis;	chr11:113335553	chr11:113368478~113369117:+
THCA	cis	rs2243480	1	rs316307	ENSG00000229886.1	RP5-1132H15.3	6.29	7.21e-10	1.57e-07	0.44	0.28	Diabetic kidney disease;	chr7:66105184	chr7:66025126~66031544:-
THCA	cis	rs12435908	1	rs7153679	ENSG00000276116.2	FUT8-AS1	-6.29	7.21e-10	1.57e-07	-0.44	-0.28	Ischemic stroke;	chr14:65546236	chr14:65411170~65412690:-
THCA	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-6.29	7.21e-10	1.57e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-6.29	7.21e-10	1.57e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-6.29	7.21e-10	1.57e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-6.29	7.21e-10	1.57e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
THCA	cis	rs2915864	0.706	rs55872445	ENSG00000280047.1	CTC-463A16.1	6.29	7.22e-10	1.57e-07	0.42	0.28	Facial morphology (factor 20);	chr5:142158691	chr5:142165767~142168387:+
THCA	cis	rs2915864	0.706	rs57393241	ENSG00000280047.1	CTC-463A16.1	6.29	7.22e-10	1.57e-07	0.42	0.28	Facial morphology (factor 20);	chr5:142158692	chr5:142165767~142168387:+
THCA	cis	rs595244	1	rs685091	ENSG00000259705.1	RP11-227D13.1	6.29	7.22e-10	1.57e-07	0.46	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48555933	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs10744953	ENSG00000259705.1	RP11-227D13.1	-6.29	7.22e-10	1.57e-07	-0.46	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48567769	chr15:48645951~48652016:+
THCA	cis	rs5742933	0.597	rs12471663	ENSG00000273240.1	RP11-455J20.3	6.29	7.22e-10	1.57e-07	0.29	0.28	Ferritin levels;	chr2:189642372	chr2:189763859~189764456:-
THCA	cis	rs5742933	0.597	rs6761923	ENSG00000273240.1	RP11-455J20.3	6.29	7.22e-10	1.57e-07	0.29	0.28	Ferritin levels;	chr2:189642873	chr2:189763859~189764456:-
THCA	cis	rs2117029	0.767	rs11168838	ENSG00000258017.1	RP11-386G11.10	-6.29	7.23e-10	1.58e-07	-0.38	-0.28	Intelligence (multi-trait analysis);	chr12:49061223	chr12:49127782~49147869:+
THCA	cis	rs7727544	0.645	rs272857	ENSG00000237714.1	P4HA2-AS1	6.29	7.23e-10	1.58e-07	0.36	0.28	Blood metabolite levels;	chr5:132349604	chr5:132184876~132192808:+
THCA	cis	rs853679	0.607	rs66886492	ENSG00000280107.1	AL022393.9	-6.29	7.24e-10	1.58e-07	-0.57	-0.28	Depression;	chr6:28121953	chr6:28170845~28172521:+
THCA	cis	rs853679	0.607	rs35345226	ENSG00000280107.1	AL022393.9	-6.29	7.24e-10	1.58e-07	-0.57	-0.28	Depression;	chr6:28123802	chr6:28170845~28172521:+
THCA	cis	rs28386778	0.83	rs2854210	ENSG00000240280.5	TCAM1P	-6.29	7.24e-10	1.58e-07	-0.39	-0.28	Prudent dietary pattern;	chr17:63868978	chr17:63849292~63864379:+
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000232546.1	RP11-458F8.1	-6.29	7.25e-10	1.58e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65999249	chr7:66848496~66858136:+
THCA	cis	rs16958440	0.867	rs12386076	ENSG00000267800.1	RP11-49K24.5	-6.29	7.25e-10	1.58e-07	-0.6	-0.28	Sitting height ratio;	chr18:47146969	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs77348110	ENSG00000267800.1	RP11-49K24.5	-6.29	7.25e-10	1.58e-07	-0.6	-0.28	Sitting height ratio;	chr18:47147796	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs16948928	ENSG00000267800.1	RP11-49K24.5	-6.29	7.25e-10	1.58e-07	-0.6	-0.28	Sitting height ratio;	chr18:47149450	chr18:47137018~47137290:+
THCA	cis	rs5742933	0.948	rs7592066	ENSG00000253559.1	OSGEPL1-AS1	6.29	7.25e-10	1.58e-07	0.32	0.28	Ferritin levels;	chr2:189778792	chr2:189762704~189765556:+
THCA	cis	rs8014252	0.803	rs74062769	ENSG00000259158.2	ADAM20P1	-6.29	7.26e-10	1.58e-07	-0.34	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70603859	chr14:70468881~70483756:-
THCA	cis	rs642803	0.569	rs44205	ENSG00000214659.4	KRT8P26	-6.29	7.26e-10	1.58e-07	-0.26	-0.28	Urate levels;	chr11:65797315	chr11:65726939~65728214:+
THCA	cis	rs1005277	0.579	rs1985707	ENSG00000276805.1	RP11-291L22.6	6.29	7.27e-10	1.58e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38451030~38451785:+
THCA	cis	rs8141529	0.687	rs6005867	ENSG00000226471.5	CTA-292E10.6	-6.29	7.28e-10	1.58e-07	-0.24	-0.28	Lymphocyte counts;	chr22:28769132	chr22:28800683~28848559:+
THCA	cis	rs4143844	1	rs62006969	ENSG00000259251.2	RP11-643M14.1	6.29	7.28e-10	1.59e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:62001213	chr15:62060503~62062434:+
THCA	cis	rs7617773	0.925	rs34513961	ENSG00000228638.1	FCF1P2	-6.29	7.28e-10	1.59e-07	-0.28	-0.28	Coronary artery disease;	chr3:48132163	chr3:48290793~48291375:-
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000229886.1	RP5-1132H15.3	6.29	7.29e-10	1.59e-07	0.47	0.28	Diabetic kidney disease;	chr7:66528779	chr7:66025126~66031544:-
THCA	cis	rs748404	0.578	rs512628	ENSG00000166763.7	STRCP1	6.29	7.29e-10	1.59e-07	0.3	0.28	Lung cancer;	chr15:43326536	chr15:43699488~43718184:-
THCA	cis	rs7851660	0.935	rs4460498	ENSG00000214417.4	KRT18P13	-6.29	7.29e-10	1.59e-07	-0.24	-0.28	Strep throat;	chr9:97858130	chr9:97698922~97700734:+
THCA	cis	rs793571	0.518	rs12912327	ENSG00000259250.1	RP11-50C13.1	-6.29	7.29e-10	1.59e-07	-0.3	-0.28	Schizophrenia;	chr15:58693935	chr15:58587507~58591676:+
THCA	cis	rs17772222	0.917	rs17260415	ENSG00000222990.1	RNU4-22P	6.29	7.29e-10	1.59e-07	0.36	0.28	Coronary artery calcification;	chr14:88745629	chr14:88513498~88513663:+
THCA	cis	rs2834188	0.889	rs8134026	ENSG00000272659.1	AP000295.10	-6.29	7.3e-10	1.59e-07	-0.38	-0.28	Narcolepsy;	chr21:33298793	chr21:33309491~33310181:+
THCA	cis	rs11722228	0.522	rs62286604	ENSG00000261490.1	RP11-448G15.3	6.29	7.3e-10	1.59e-07	0.2	0.28	Urate levels;Serum uric acid levels;Gout;	chr4:10129537	chr4:10068089~10073019:-
THCA	cis	rs950169	0.84	rs2896002	ENSG00000259295.5	CSPG4P12	6.29	7.31e-10	1.59e-07	0.43	0.28	Schizophrenia;	chr15:84390423	chr15:85191438~85213905:+
THCA	cis	rs240993	0.595	rs3777910	ENSG00000230177.1	RP5-1112D6.4	6.29	7.31e-10	1.59e-07	0.24	0.28	Inflammatory skin disease;Psoriasis;	chr6:111581248	chr6:111277932~111278742:+
THCA	cis	rs2243480	1	rs10807702	ENSG00000228409.4	CCT6P1	6.29	7.31e-10	1.59e-07	0.32	0.28	Diabetic kidney disease;	chr7:66302856	chr7:65751142~65763354:+
THCA	cis	rs792448	0.743	rs351398	ENSG00000226251.4	RP11-15I11.3	-6.29	7.32e-10	1.59e-07	-0.34	-0.28	White blood cell count (basophil);	chr1:212292897	chr1:212225278~212238977:-
THCA	cis	rs1005277	0.579	rs2505241	ENSG00000276805.1	RP11-291L22.6	6.29	7.32e-10	1.59e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38451030~38451785:+
THCA	cis	rs1552244	0.882	rs13100734	ENSG00000180385.7	EMC3-AS1	6.29	7.32e-10	1.59e-07	0.29	0.28	Alzheimer's disease;	chr3:9981194	chr3:9986893~10006990:+
THCA	cis	rs9926296	0.568	rs886950	ENSG00000260259.1	RP11-368I7.4	-6.29	7.32e-10	1.59e-07	-0.3	-0.28	Vitiligo;	chr16:89770464	chr16:89682620~89686569:-
THCA	cis	rs4143844	1	rs11071644	ENSG00000259251.2	RP11-643M14.1	6.29	7.32e-10	1.59e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:61969565	chr15:62060503~62062434:+
THCA	cis	rs950169	0.881	rs4842852	ENSG00000259295.5	CSPG4P12	6.29	7.33e-10	1.59e-07	0.43	0.28	Schizophrenia;	chr15:84387263	chr15:85191438~85213905:+
THCA	cis	rs950169	0.84	rs4842853	ENSG00000259295.5	CSPG4P12	6.29	7.33e-10	1.59e-07	0.43	0.28	Schizophrenia;	chr15:84387606	chr15:85191438~85213905:+
THCA	cis	rs950169	0.922	rs4842946	ENSG00000259295.5	CSPG4P12	6.29	7.33e-10	1.59e-07	0.43	0.28	Schizophrenia;	chr15:84387633	chr15:85191438~85213905:+
THCA	cis	rs950169	0.84	rs4842854	ENSG00000259295.5	CSPG4P12	6.29	7.33e-10	1.59e-07	0.43	0.28	Schizophrenia;	chr15:84387641	chr15:85191438~85213905:+
THCA	cis	rs1005277	0.522	rs9418276	ENSG00000263064.2	RP11-291L22.7	6.29	7.33e-10	1.6e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.522	rs7072977	ENSG00000263064.2	RP11-291L22.7	6.29	7.33e-10	1.6e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38448689~38448949:+
THCA	cis	rs2348418	0.798	rs7309905	ENSG00000247934.4	RP11-967K21.1	6.29	7.33e-10	1.6e-07	0.24	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28373473	chr12:28163298~28190738:-
THCA	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-6.29	7.34e-10	1.6e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
THCA	cis	rs8100891	0.614	rs6510243	ENSG00000267213.4	AC007773.2	-6.29	7.34e-10	1.6e-07	-0.25	-0.28	Neuroticism;	chr19:32342765	chr19:32390050~32405560:-
THCA	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-6.29	7.34e-10	1.6e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
THCA	cis	rs2243480	1	rs781142	ENSG00000232546.1	RP11-458F8.1	-6.29	7.34e-10	1.6e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65973791	chr7:66848496~66858136:+
THCA	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-6.29	7.35e-10	1.6e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
THCA	cis	rs3745672	0.661	rs279151	ENSG00000219665.7	CTD-2006C1.2	6.29	7.35e-10	1.6e-07	0.57	0.28	Multiple sclerosis;	chr19:11985647	chr19:11987617~12046275:+
THCA	cis	rs4835473	0.742	rs7654409	ENSG00000251600.4	RP11-673E1.1	6.29	7.35e-10	1.6e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143956842	chr4:143912331~143982454:+
THCA	cis	rs7809950	1	rs4727684	ENSG00000238832.1	snoU109	-6.29	7.35e-10	1.6e-07	-0.3	-0.28	Coronary artery disease;	chr7:107586025	chr7:107603363~107603507:+
THCA	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	6.29	7.35e-10	1.6e-07	0.39	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
THCA	cis	rs1005277	0.579	rs2504148	ENSG00000276805.1	RP11-291L22.6	6.29	7.36e-10	1.6e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs176886	ENSG00000276805.1	RP11-291L22.6	6.29	7.36e-10	1.6e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.557	rs176887	ENSG00000276805.1	RP11-291L22.6	6.29	7.36e-10	1.6e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474594	ENSG00000276805.1	RP11-291L22.6	6.29	7.36e-10	1.6e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs11011461	ENSG00000276805.1	RP11-291L22.6	6.29	7.36e-10	1.6e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38451030~38451785:+
THCA	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-6.29	7.36e-10	1.6e-07	-0.34	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
THCA	cis	rs72843506	0.656	rs9901357	ENSG00000270091.1	RP11-78O7.2	-6.29	7.36e-10	1.6e-07	-0.31	-0.28	Schizophrenia;	chr17:20105729	chr17:19896590~19897287:-
THCA	cis	rs4950322	0.58	rs2014106	ENSG00000278811.3	LINC00624	6.29	7.36e-10	1.6e-07	0.34	0.28	Protein quantitative trait loci;	chr1:147118499	chr1:147258885~147517875:-
THCA	cis	rs9859260	0.744	rs3933	ENSG00000226155.1	AC124944.3	6.29	7.37e-10	1.6e-07	0.34	0.28	Mean corpuscular volume;	chr3:196058126	chr3:195912049~195913986:+
THCA	cis	rs7085104	0.632	rs7096475	ENSG00000236937.2	PTGES3P4	6.29	7.37e-10	1.6e-07	0.36	0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102845595~102845950:+
THCA	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	6.29	7.37e-10	1.6e-07	0.39	0.28	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
THCA	cis	rs2657294	0.62	rs4746259	ENSG00000226051.5	ZNF503-AS1	-6.29	7.38e-10	1.6e-07	-0.4	-0.28	Pneumonia;	chr10:75082310	chr10:75269819~75373500:+
THCA	cis	rs1865760	1	rs9393675	ENSG00000272462.2	U91328.19	-6.29	7.38e-10	1.61e-07	-0.23	-0.28	Height;	chr6:25929888	chr6:25992662~26001775:+
THCA	cis	rs4835473	0.83	rs75309663	ENSG00000251600.4	RP11-673E1.1	-6.29	7.38e-10	1.61e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:143675647	chr4:143912331~143982454:+
THCA	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	6.29	7.39e-10	1.61e-07	0.31	0.28	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
THCA	cis	rs593531	0.571	rs11236088	ENSG00000212961.4	HNRNPA1P40	6.29	7.39e-10	1.61e-07	0.35	0.28	Neuroticism;	chr11:74383298	chr11:74354443~74355720:+
THCA	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-6.29	7.4e-10	1.61e-07	-0.22	-0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
THCA	cis	rs1949733	0.523	rs16842563	ENSG00000205959.3	RP11-689P11.2	6.29	7.4e-10	1.61e-07	0.24	0.28	Response to antineoplastic agents;	chr4:8543419	chr4:8482270~8512610:+
THCA	cis	rs4835473	0.549	rs11940719	ENSG00000251600.4	RP11-673E1.1	6.29	7.4e-10	1.61e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143970855	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.83	rs7692672	ENSG00000251600.4	RP11-673E1.1	6.29	7.4e-10	1.61e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143971048	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.766	rs6537222	ENSG00000251600.4	RP11-673E1.1	6.29	7.4e-10	1.61e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143971459	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs6537223	ENSG00000251600.4	RP11-673E1.1	6.29	7.4e-10	1.61e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143971541	chr4:143912331~143982454:+
THCA	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	6.29	7.4e-10	1.61e-07	0.37	0.28	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
THCA	cis	rs10761482	0.5	rs6479716	ENSG00000254271.1	RP11-131N11.4	6.29	7.41e-10	1.61e-07	0.36	0.28	Schizophrenia;	chr10:60542800	chr10:60734342~60741828:+
THCA	cis	rs73607972	0.935	rs7186069	ENSG00000275191.1	RP11-36I17.2	-6.29	7.41e-10	1.61e-07	-0.45	-0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53563693	chr16:53628256~53628816:-
THCA	cis	rs73607972	0.935	rs7193194	ENSG00000275191.1	RP11-36I17.2	-6.29	7.41e-10	1.61e-07	-0.45	-0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53563802	chr16:53628256~53628816:-
THCA	cis	rs7809950	0.862	rs62482502	ENSG00000238832.1	snoU109	-6.29	7.43e-10	1.62e-07	-0.3	-0.28	Coronary artery disease;	chr7:107347365	chr7:107603363~107603507:+
THCA	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	6.29	7.43e-10	1.62e-07	0.38	0.28	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
THCA	cis	rs9381040	0.655	rs7775972	ENSG00000161912.16	ADCY10P1	6.29	7.44e-10	1.62e-07	0.18	0.28	Alzheimer's disease (late onset);	chr6:41070377	chr6:41101022~41140835:+
THCA	cis	rs4835473	0.932	rs1511425	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143985122	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1849120	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143985337	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs4835476	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143985517	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1828502	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143985797	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs7668698	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143986333	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6537231	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143986489	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1877234	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143986774	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs6852502	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143987174	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	6.29	7.44e-10	1.62e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
THCA	cis	rs4664293	0.836	rs10190704	ENSG00000226266.5	AC009961.3	-6.29	7.45e-10	1.62e-07	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159738451	chr2:159670708~159712435:-
THCA	cis	rs6928977	0.802	rs2614276	ENSG00000231028.7	LINC00271	6.29	7.45e-10	1.62e-07	0.24	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135360566	chr6:135497801~135716055:+
THCA	cis	rs7727544	0.564	rs3852206	ENSG00000224431.1	AC063976.7	6.29	7.45e-10	1.62e-07	0.25	0.28	Blood metabolite levels;	chr5:132079743	chr5:132199456~132203487:+
THCA	cis	rs9902453	0.691	rs140701	ENSG00000264007.1	RP11-68I3.10	6.29	7.45e-10	1.62e-07	0.31	0.28	Coffee consumption (cups per day);	chr17:30211514	chr17:29621617~29622254:-
THCA	cis	rs8027521	0.54	rs899140	ENSG00000280362.1	RP11-643A5.3	6.29	7.45e-10	1.62e-07	0.34	0.28	Circulating chemerin levels;	chr15:53950899	chr15:53910769~53914712:+
THCA	cis	rs11976180	1	rs2961132	ENSG00000170356.8	OR2A20P	-6.29	7.46e-10	1.62e-07	-0.38	-0.28	Obesity-related traits;	chr7:144071035	chr7:144250045~144252957:-
THCA	cis	rs10208649	1	rs6545372	ENSG00000272156.1	RP11-477N3.1	6.29	7.47e-10	1.62e-07	0.5	0.28	Body mass index;	chr2:53855124	chr2:54082554~54085066:+
THCA	cis	rs6672530	0.518	rs12025815	ENSG00000227711.2	RP11-275O4.5	6.29	7.47e-10	1.62e-07	0.29	0.28	Hip circumference adjusted for BMI;	chr1:227570371	chr1:227509028~227520477:-
THCA	cis	rs6672530	0.518	rs10916169	ENSG00000227711.2	RP11-275O4.5	6.29	7.47e-10	1.62e-07	0.29	0.28	Hip circumference adjusted for BMI;	chr1:227577156	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.513	rs903697	ENSG00000227711.2	RP11-275O4.5	6.29	7.47e-10	1.62e-07	0.29	0.28	Height;	chr1:227579144	chr1:227509028~227520477:-
THCA	cis	rs7267979	1	rs6083862	ENSG00000274414.1	RP5-965G21.4	6.29	7.47e-10	1.62e-07	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25239007~25245229:-
THCA	cis	rs797680	0.93	rs1474927	ENSG00000223745.6	RP4-717I23.3	6.29	7.47e-10	1.62e-07	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93104811	chr1:93262186~93346025:-
THCA	cis	rs6142102	1	rs6059672	ENSG00000275784.1	RP5-1125A11.6	-6.29	7.47e-10	1.62e-07	-0.29	-0.28	Skin pigmentation;	chr20:34117662	chr20:33989480~33991818:-
THCA	cis	rs755249	1	rs61779359	ENSG00000228060.1	RP11-69E11.8	-6.29	7.48e-10	1.62e-07	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39565160~39573203:+
THCA	cis	rs755249	0.959	rs61781363	ENSG00000228060.1	RP11-69E11.8	-6.29	7.48e-10	1.62e-07	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39565160~39573203:+
THCA	cis	rs755249	1	rs4660808	ENSG00000228060.1	RP11-69E11.8	-6.29	7.48e-10	1.62e-07	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39565160~39573203:+
THCA	cis	rs755249	1	rs61781364	ENSG00000228060.1	RP11-69E11.8	-6.29	7.48e-10	1.62e-07	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39565160~39573203:+
THCA	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-6.29	7.48e-10	1.62e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-6.29	7.48e-10	1.62e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-6.29	7.48e-10	1.62e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-6.29	7.48e-10	1.62e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
THCA	cis	rs1552244	0.882	rs2130813	ENSG00000180385.7	EMC3-AS1	6.29	7.48e-10	1.63e-07	0.3	0.28	Alzheimer's disease;	chr3:9997022	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs17081288	ENSG00000180385.7	EMC3-AS1	6.29	7.48e-10	1.63e-07	0.3	0.28	Alzheimer's disease;	chr3:10000429	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.816	rs56271597	ENSG00000180385.7	EMC3-AS1	6.29	7.48e-10	1.63e-07	0.3	0.28	Alzheimer's disease;	chr3:10001106	chr3:9986893~10006990:+
THCA	cis	rs797680	0.856	rs569414	ENSG00000223745.6	RP4-717I23.3	6.29	7.49e-10	1.63e-07	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93319344	chr1:93262186~93346025:-
THCA	cis	rs2562456	1	rs2562456	ENSG00000213976.4	CTD-2561J22.2	-6.29	7.49e-10	1.63e-07	-0.29	-0.28	Pain;	chr19:21483408	chr19:21382865~21387177:+
THCA	cis	rs7615952	0.512	rs2979336	ENSG00000241278.1	ENPP7P4	6.28	7.5e-10	1.63e-07	0.35	0.28	Blood pressure (smoking interaction);	chr3:125638626	chr3:125848223~125909372:+
THCA	cis	rs9649465	0.967	rs6944031	ENSG00000272686.1	RP11-390E23.6	6.28	7.53e-10	1.64e-07	0.18	0.28	Migraine;	chr7:123659250	chr7:123749068~123751166:+
THCA	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-6.28	7.53e-10	1.64e-07	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
THCA	cis	rs2562456	0.917	rs6511253	ENSG00000213976.4	CTD-2561J22.2	6.28	7.53e-10	1.64e-07	0.3	0.28	Pain;	chr19:21495996	chr19:21382865~21387177:+
THCA	cis	rs11096990	0.892	rs11729098	ENSG00000249207.1	RP11-360F5.1	6.28	7.54e-10	1.64e-07	0.36	0.28	Cognitive function;	chr4:39232357	chr4:39112677~39126818:-
THCA	cis	rs30380	0.69	rs2216752	ENSG00000248734.2	CTD-2260A17.1	-6.28	7.54e-10	1.64e-07	-0.31	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96784777~96785999:+
THCA	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	6.28	7.55e-10	1.64e-07	0.26	0.28	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
THCA	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	6.28	7.55e-10	1.64e-07	0.3	0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
THCA	cis	rs227275	0.525	rs4623004	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs11097796	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs11097797	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs4699046	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs4699047	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs28778380	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs10029073	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs4698874	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs724446	ENSG00000251288.2	RP11-10L12.2	-6.28	7.55e-10	1.64e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102751401~102752641:+
THCA	cis	rs72843506	0.586	rs75721433	ENSG00000270091.1	RP11-78O7.2	-6.28	7.56e-10	1.64e-07	-0.34	-0.28	Schizophrenia;	chr17:19978747	chr17:19896590~19897287:-
THCA	cis	rs2439831	0.85	rs558656	ENSG00000275601.1	AC011330.13	-6.28	7.57e-10	1.64e-07	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43431316	chr15:43642389~43643023:-
THCA	cis	rs8027521	0.54	rs1026695	ENSG00000280362.1	RP11-643A5.3	6.28	7.59e-10	1.65e-07	0.34	0.28	Circulating chemerin levels;	chr15:53927252	chr15:53910769~53914712:+
THCA	cis	rs2243480	1	rs781157	ENSG00000232546.1	RP11-458F8.1	-6.28	7.59e-10	1.65e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66013324	chr7:66848496~66858136:+
THCA	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	6.28	7.6e-10	1.65e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
THCA	cis	rs5758511	0.68	rs1107554	ENSG00000281538.1	RP4-669P10.20	-6.28	7.6e-10	1.65e-07	-0.3	-0.28	Birth weight;	chr22:42271588	chr22:42138060~42139726:+
THCA	cis	rs16949788	0.793	rs78483581	ENSG00000261351.2	CTD-3185P2.1	-6.28	7.6e-10	1.65e-07	-0.33	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477027	chr15:66488658~66492109:-
THCA	cis	rs16949788	1	rs76847935	ENSG00000261351.2	CTD-3185P2.1	-6.28	7.6e-10	1.65e-07	-0.33	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477275	chr15:66488658~66492109:-
THCA	cis	rs453301	0.509	rs7000323	ENSG00000253893.2	FAM85B	6.28	7.6e-10	1.65e-07	0.39	0.28	Joint mobility (Beighton score);	chr8:8934763	chr8:8167819~8226614:-
THCA	cis	rs7615952	0.932	rs13325495	ENSG00000241288.6	RP11-379B18.5	-6.28	7.6e-10	1.65e-07	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125918573	chr3:125827238~125916384:-
THCA	cis	rs9926296	0.512	rs11076626	ENSG00000260259.1	RP11-368I7.4	-6.28	7.61e-10	1.65e-07	-0.3	-0.28	Vitiligo;	chr16:89798695	chr16:89682620~89686569:-
THCA	cis	rs9926296	0.533	rs10852623	ENSG00000260259.1	RP11-368I7.4	-6.28	7.61e-10	1.65e-07	-0.3	-0.28	Vitiligo;	chr16:89798834	chr16:89682620~89686569:-
THCA	cis	rs35398779	1	rs35398779	ENSG00000270091.1	RP11-78O7.2	-6.28	7.61e-10	1.65e-07	-0.21	-0.28	Platelet count;	chr17:19949782	chr17:19896590~19897287:-
THCA	cis	rs736801	0.964	rs17622656	ENSG00000237714.1	P4HA2-AS1	-6.28	7.61e-10	1.65e-07	-0.38	-0.28	Mosquito bite size;Breast cancer;	chr5:132485305	chr5:132184876~132192808:+
THCA	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-6.28	7.62e-10	1.65e-07	-0.5	-0.28	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
THCA	cis	rs12681366	0.663	rs2919666	ENSG00000253704.1	RP11-267M23.4	6.28	7.63e-10	1.66e-07	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94453059	chr8:94553722~94569745:+
THCA	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-6.28	7.64e-10	1.66e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-6.28	7.64e-10	1.66e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
THCA	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-6.28	7.64e-10	1.66e-07	-0.25	-0.28	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
THCA	cis	rs2243480	1	rs402418	ENSG00000232546.1	RP11-458F8.1	-6.28	7.65e-10	1.66e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66044482	chr7:66848496~66858136:+
THCA	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	6.28	7.65e-10	1.66e-07	0.51	0.28	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	6.28	7.65e-10	1.66e-07	0.51	0.28	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
THCA	cis	rs1005277	0.579	rs2474584	ENSG00000276805.1	RP11-291L22.6	6.28	7.65e-10	1.66e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474586	ENSG00000276805.1	RP11-291L22.6	6.28	7.65e-10	1.66e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38451030~38451785:+
THCA	cis	rs12893668	0.697	rs67899457	ENSG00000269910.1	RP11-73M18.10	6.28	7.65e-10	1.66e-07	0.26	0.28	Reticulocyte count;	chr14:103593729	chr14:103694516~103695050:-
THCA	cis	rs7044106	0.708	rs10984992	ENSG00000270917.1	RP11-27I1.6	-6.28	7.66e-10	1.66e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.762	rs10760115	ENSG00000270917.1	RP11-27I1.6	-6.28	7.66e-10	1.66e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120812475~120812845:-
THCA	cis	rs712022	0.967	rs10766971	ENSG00000246225.5	RP11-17A1.3	-6.28	7.66e-10	1.66e-07	-0.36	-0.28	Dialysis-related mortality;	chr11:22832005	chr11:22829380~22945393:+
THCA	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	6.28	7.66e-10	1.66e-07	0.4	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
THCA	cis	rs7567389	0.504	rs1568278	ENSG00000236682.1	AC068282.3	-6.28	7.67e-10	1.66e-07	-0.4	-0.28	Self-rated health;	chr2:127432619	chr2:127389130~127400580:+
THCA	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-6.28	7.67e-10	1.66e-07	-0.36	-0.28	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
THCA	cis	rs4143844	0.867	rs17303915	ENSG00000259251.2	RP11-643M14.1	6.28	7.67e-10	1.66e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61882695	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs12185103	ENSG00000259251.2	RP11-643M14.1	6.28	7.67e-10	1.66e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61889092	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs35559361	ENSG00000259251.2	RP11-643M14.1	6.28	7.67e-10	1.66e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61891318	chr15:62060503~62062434:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000224316.1	RP11-479O9.2	-6.28	7.67e-10	1.66e-07	-0.31	-0.28	Aortic root size;	chr7:66120784	chr7:65773620~65802067:+
THCA	cis	rs6686643	0.868	rs9333461	ENSG00000236206.1	RP11-306I1.2	6.28	7.67e-10	1.66e-07	0.37	0.28	Total ventricular volume;	chr1:165649083	chr1:165598463~165623331:+
THCA	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	6.28	7.67e-10	1.66e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000232546.1	RP11-458F8.1	-6.28	7.68e-10	1.67e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65996588	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1701750	ENSG00000232546.1	RP11-458F8.1	-6.28	7.68e-10	1.67e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66002158	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1701758	ENSG00000232546.1	RP11-458F8.1	-6.28	7.68e-10	1.67e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66005214	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000232546.1	RP11-458F8.1	-6.28	7.68e-10	1.67e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66005945	chr7:66848496~66858136:+
THCA	cis	rs10844706	0.73	rs12317499	ENSG00000256594.6	RP11-705C15.2	6.28	7.69e-10	1.67e-07	0.23	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9732764	chr12:9633419~9658412:+
THCA	cis	rs9816784	0.525	rs714602	ENSG00000226155.1	AC124944.3	-6.28	7.69e-10	1.67e-07	-0.35	-0.28	Mean corpuscular hemoglobin;	chr3:196067108	chr3:195912049~195913986:+
THCA	cis	rs736801	0.808	rs2522057	ENSG00000224431.1	AC063976.7	6.28	7.69e-10	1.67e-07	0.25	0.28	Mosquito bite size;Breast cancer;	chr5:132466255	chr5:132199456~132203487:+
THCA	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-6.28	7.7e-10	1.67e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
THCA	cis	rs4835473	0.639	rs28674022	ENSG00000251600.4	RP11-673E1.1	6.28	7.7e-10	1.67e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143966409	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs28423022	ENSG00000251600.4	RP11-673E1.1	6.28	7.7e-10	1.67e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143966416	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs35888177	ENSG00000251600.4	RP11-673E1.1	6.28	7.7e-10	1.67e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143966863	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs10033382	ENSG00000251600.4	RP11-673E1.1	6.28	7.7e-10	1.67e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143967103	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs3874	ENSG00000251600.4	RP11-673E1.1	6.28	7.7e-10	1.67e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143968795	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs2323417	ENSG00000251600.4	RP11-673E1.1	6.28	7.7e-10	1.67e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143969108	chr4:143912331~143982454:+
THCA	cis	rs4835473	1	rs4835473	ENSG00000251600.4	RP11-673E1.1	6.28	7.7e-10	1.67e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143982419	chr4:143912331~143982454:+
THCA	cis	rs944289	0.576	rs10150608	ENSG00000257826.1	RP11-116N8.4	-6.28	7.72e-10	1.67e-07	-0.31	-0.28	Thyroid cancer;	chr14:36142221	chr14:36061026~36067190:-
THCA	cis	rs853679	0.506	rs1150693	ENSG00000220721.1	OR1F12	6.28	7.72e-10	1.67e-07	0.38	0.28	Depression;	chr6:28206812	chr6:28073316~28074233:+
THCA	cis	rs8007846	0.536	rs743084	ENSG00000276116.2	FUT8-AS1	6.28	7.72e-10	1.67e-07	0.28	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65765884	chr14:65411170~65412690:-
THCA	cis	rs17695224	0.74	rs10407041	ENSG00000269483.1	AC006272.1	6.28	7.72e-10	1.67e-07	0.32	0.28	HDL cholesterol;HDL cholesterol levels;	chr19:51839416	chr19:51839924~51843324:-
THCA	cis	rs4925386	1	rs2151512	ENSG00000273619.1	RP5-908M14.9	6.28	7.73e-10	1.68e-07	0.22	0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338439	chr20:62386303~62386970:-
THCA	cis	rs728616	0.717	rs116884206	ENSG00000242600.5	MBL1P	6.28	7.74e-10	1.68e-07	0.4	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80230790	chr10:79904898~79950336:+
THCA	cis	rs7833787	1	rs7833787	ENSG00000278886.1	RP11-108A14.1	-6.28	7.74e-10	1.68e-07	-0.36	-0.28	Obesity-related traits;	chr8:18850361	chr8:18864681~18865247:-
THCA	cis	rs797680	0.822	rs1572343	ENSG00000223745.6	RP4-717I23.3	6.28	7.75e-10	1.68e-07	0.17	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93150645	chr1:93262186~93346025:-
THCA	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-6.28	7.75e-10	1.68e-07	-0.48	-0.28	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
THCA	cis	rs227275	0.525	rs13150426	ENSG00000251288.2	RP11-10L12.2	-6.28	7.75e-10	1.68e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs28445579	ENSG00000251288.2	RP11-10L12.2	-6.28	7.75e-10	1.68e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102751401~102752641:+
THCA	cis	rs17594362	0.697	rs34398605	ENSG00000264190.1	MIR5006	6.28	7.75e-10	1.68e-07	0.38	0.28	Multiple sclerosis;	chr13:41575316	chr13:41568286~41568395:-
THCA	cis	rs9311474	0.713	rs352168	ENSG00000243224.1	RP5-1157M23.2	-6.28	7.76e-10	1.68e-07	-0.28	-0.28	Electroencephalogram traits;	chr3:52203954	chr3:52239258~52241097:+
THCA	cis	rs897984	0.683	rs729482	ENSG00000260911.2	RP11-196G11.2	6.28	7.76e-10	1.68e-07	0.24	0.28	Dementia with Lewy bodies;	chr16:31005649	chr16:31043150~31049868:+
THCA	cis	rs934734	0.752	rs2661795	ENSG00000237979.1	AC007389.1	-6.28	7.77e-10	1.68e-07	-0.32	-0.28	Rheumatoid arthritis;	chr2:65399672	chr2:65500993~65502138:-
THCA	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-6.28	7.77e-10	1.68e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
THCA	cis	rs4835473	0.932	rs62337619	ENSG00000251600.4	RP11-673E1.1	-6.28	7.77e-10	1.69e-07	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143742083	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13152443	ENSG00000251600.4	RP11-673E1.1	-6.28	7.77e-10	1.69e-07	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143742492	chr4:143912331~143982454:+
THCA	cis	rs4927850	0.709	rs6783079	ENSG00000226155.1	AC124944.3	-6.28	7.78e-10	1.69e-07	-0.38	-0.28	Pancreatic cancer;	chr3:195925837	chr3:195912049~195913986:+
THCA	cis	rs4927850	0.709	rs6765762	ENSG00000226155.1	AC124944.3	-6.28	7.78e-10	1.69e-07	-0.38	-0.28	Pancreatic cancer;	chr3:195925980	chr3:195912049~195913986:+
THCA	cis	rs6088580	0.543	rs13042351	ENSG00000269202.1	RP4-614O4.12	6.28	7.78e-10	1.69e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34650769	chr20:35201747~35203288:-
THCA	cis	rs227275	0.554	rs149576	ENSG00000251288.2	RP11-10L12.2	-6.28	7.78e-10	1.69e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102751401~102752641:+
THCA	cis	rs2735413	0.564	rs73580867	ENSG00000276007.1	RP11-358L22.3	6.28	7.79e-10	1.69e-07	0.3	0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78087056	chr16:78123243~78124332:+
THCA	cis	rs9880211	1	rs9828976	ENSG00000273486.1	RP11-731C17.2	6.28	7.79e-10	1.69e-07	0.29	0.28	Height;Body mass index;	chr3:136817993	chr3:136837338~136839021:-
THCA	cis	rs227275	0.554	rs149576	ENSG00000230069.3	LRRC37A15P	-6.28	7.79e-10	1.69e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102727274~102730721:-
THCA	cis	rs2921073	0.51	rs2976945	ENSG00000254153.1	CTA-398F10.2	-6.28	7.79e-10	1.69e-07	-0.29	-0.28	Parkinson's disease;	chr8:8413361	chr8:8456909~8461337:-
THCA	cis	rs7809950	0.784	rs7803102	ENSG00000238832.1	snoU109	6.28	7.8e-10	1.69e-07	0.3	0.28	Coronary artery disease;	chr7:107608484	chr7:107603363~107603507:+
THCA	cis	rs7129556	0.911	rs10899394	ENSG00000254691.1	RP11-91P24.5	6.28	7.8e-10	1.69e-07	0.37	0.28	Weight loss (gastric bypass surgery);	chr11:77613216	chr11:77850604~77851511:+
THCA	cis	rs367615	0.68	rs1103198	ENSG00000249476.1	CTD-2587M2.1	6.28	7.81e-10	1.69e-07	0.31	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109637882	chr5:109237120~109326369:-
THCA	cis	rs896854	0.654	rs13278601	ENSG00000253528.2	RP11-347C18.4	6.28	7.81e-10	1.69e-07	0.31	0.28	Type 2 diabetes;	chr8:94960746	chr8:94974573~94974853:-
THCA	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	6.28	7.81e-10	1.69e-07	0.27	0.28	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
THCA	cis	rs7829975	0.659	rs4382480	ENSG00000254153.1	CTA-398F10.2	-6.28	7.81e-10	1.69e-07	-0.31	-0.28	Mood instability;	chr8:8863963	chr8:8456909~8461337:-
THCA	cis	rs8014252	0.803	rs60120955	ENSG00000259158.2	ADAM20P1	-6.28	7.82e-10	1.69e-07	-0.34	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595016	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs17113651	ENSG00000259158.2	ADAM20P1	-6.28	7.82e-10	1.69e-07	-0.34	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595119	chr14:70468881~70483756:-
THCA	cis	rs7829975	0.514	rs2920983	ENSG00000254153.1	CTA-398F10.2	-6.28	7.82e-10	1.69e-07	-0.29	-0.28	Mood instability;	chr8:8410553	chr8:8456909~8461337:-
THCA	cis	rs2243480	1	rs4718334	ENSG00000228409.4	CCT6P1	-6.28	7.83e-10	1.7e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66324467	chr7:65751142~65763354:+
THCA	cis	rs9813712	0.953	rs1453258	ENSG00000249846.5	RP11-77P16.4	6.28	7.83e-10	1.7e-07	0.33	0.28	Response to amphetamines;	chr3:130256454	chr3:130112550~130120579:+
THCA	cis	rs7129556	0.69	rs588217	ENSG00000254691.1	RP11-91P24.5	-6.28	7.83e-10	1.7e-07	-0.37	-0.28	Weight loss (gastric bypass surgery);	chr11:77872330	chr11:77850604~77851511:+
THCA	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	6.28	7.83e-10	1.7e-07	0.23	0.28	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
THCA	cis	rs7044106	0.791	rs10818473	ENSG00000270917.1	RP11-27I1.6	-6.28	7.84e-10	1.7e-07	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120812475~120812845:-
THCA	cis	rs6479891	1	rs868798	ENSG00000232075.1	MRPL35P2	6.28	7.85e-10	1.7e-07	0.48	0.28	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63634317~63634827:-
THCA	cis	rs2281636	0.824	rs2160620	ENSG00000260475.1	RP11-85A1.3	6.28	7.86e-10	1.7e-07	0.25	0.28	Obesity-related traits;	chr10:99627261	chr10:99621055~99621918:+
THCA	cis	rs7809950	1	rs10276604	ENSG00000238832.1	snoU109	6.28	7.86e-10	1.7e-07	0.31	0.28	Coronary artery disease;	chr7:107576293	chr7:107603363~107603507:+
THCA	cis	rs34779708	0.733	rs16935945	ENSG00000271335.4	RP11-324I22.4	6.28	7.87e-10	1.7e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs12777960	ENSG00000271335.4	RP11-324I22.4	6.28	7.87e-10	1.7e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35314552~35336401:-
THCA	cis	rs7727544	0.735	rs272860	ENSG00000237714.1	P4HA2-AS1	6.28	7.87e-10	1.71e-07	0.36	0.28	Blood metabolite levels;	chr5:132348482	chr5:132184876~132192808:+
THCA	cis	rs7746199	0.736	rs6904596	ENSG00000219392.1	RP1-265C24.5	-6.28	7.87e-10	1.71e-07	-0.53	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28115628~28116551:+
THCA	cis	rs4689592	0.523	rs4256224	ENSG00000245468.3	RP11-367J11.3	6.28	7.88e-10	1.71e-07	0.23	0.28	Monocyte percentage of white cells;	chr4:7072856	chr4:7094571~7103385:-
THCA	cis	rs6545883	0.929	rs12612982	ENSG00000271889.1	RP11-493E12.1	6.28	7.88e-10	1.71e-07	0.27	0.28	Tuberculosis;	chr2:61520220	chr2:61151433~61162105:-
THCA	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	6.28	7.88e-10	1.71e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
THCA	cis	rs1979679	0.801	rs1463571	ENSG00000278733.1	RP11-425D17.1	6.28	7.88e-10	1.71e-07	0.28	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28144514	chr12:28185625~28186190:-
THCA	cis	rs10208649	0.808	rs6730494	ENSG00000233266.1	HMGB1P31	6.28	7.88e-10	1.71e-07	0.66	0.28	Body mass index;	chr2:53992049	chr2:54051334~54051760:+
THCA	cis	rs860295	0.65	rs4661151	ENSG00000225855.5	RUSC1-AS1	-6.28	7.88e-10	1.71e-07	-0.18	-0.28	Body mass index;	chr1:155933617	chr1:155316863~155324176:-
THCA	cis	rs7225151	0.901	rs75511804	ENSG00000234327.6	AC012146.7	-6.28	7.89e-10	1.71e-07	-0.34	-0.28	Alzheimer's disease (late onset);	chr17:5235009	chr17:5111468~5115004:+
THCA	cis	rs7044106	0.791	rs10985000	ENSG00000270917.1	RP11-27I1.6	-6.28	7.9e-10	1.71e-07	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.791	rs10985001	ENSG00000270917.1	RP11-27I1.6	-6.28	7.9e-10	1.71e-07	-0.4	-0.28	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120812475~120812845:-
THCA	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	6.28	7.9e-10	1.71e-07	0.32	0.28	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
THCA	cis	rs4143844	0.867	rs978141	ENSG00000259251.2	RP11-643M14.1	6.28	7.9e-10	1.71e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:61974584	chr15:62060503~62062434:+
THCA	cis	rs4143844	1	rs34042779	ENSG00000259251.2	RP11-643M14.1	6.28	7.9e-10	1.71e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:61990899	chr15:62060503~62062434:+
THCA	cis	rs4143844	1	rs12905264	ENSG00000259251.2	RP11-643M14.1	6.28	7.9e-10	1.71e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:61994464	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs62006964	ENSG00000259251.2	RP11-643M14.1	6.28	7.9e-10	1.71e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:61995424	chr15:62060503~62062434:+
THCA	cis	rs1979679	0.842	rs7139154	ENSG00000278733.1	RP11-425D17.1	6.28	7.9e-10	1.71e-07	0.27	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28181603	chr12:28185625~28186190:-
THCA	cis	rs2976388	0.874	rs2976389	ENSG00000253741.1	CTD-2292P10.4	6.28	7.91e-10	1.71e-07	0.35	0.28	Urinary tract infection frequency;	chr8:142679003	chr8:142702252~142726973:-
THCA	cis	rs17270561	0.541	rs17586946	ENSG00000272462.2	U91328.19	-6.28	7.91e-10	1.71e-07	-0.29	-0.28	Iron status biomarkers;	chr6:25938825	chr6:25992662~26001775:+
THCA	cis	rs2562456	0.755	rs1879234	ENSG00000268081.1	RP11-678G14.2	-6.28	7.91e-10	1.71e-07	-0.4	-0.28	Pain;	chr19:21521677	chr19:21554640~21569237:-
THCA	cis	rs2243480	1	rs1723269	ENSG00000229886.1	RP5-1132H15.3	6.28	7.92e-10	1.71e-07	0.45	0.28	Diabetic kidney disease;	chr7:66007799	chr7:66025126~66031544:-
THCA	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	6.28	7.93e-10	1.72e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	6.28	7.93e-10	1.72e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
THCA	cis	rs2554380	0.628	rs2401130	ENSG00000230373.7	GOLGA6L5P	-6.28	7.93e-10	1.72e-07	-0.3	-0.28	Height;	chr15:83801983	chr15:84507885~84516814:-
THCA	cis	rs2554380	0.628	rs2401131	ENSG00000230373.7	GOLGA6L5P	-6.28	7.93e-10	1.72e-07	-0.3	-0.28	Height;	chr15:83802144	chr15:84507885~84516814:-
THCA	cis	rs853679	0.517	rs9393884	ENSG00000261839.1	RP1-265C24.8	6.28	7.93e-10	1.72e-07	0.33	0.28	Depression;	chr6:28079011	chr6:28136849~28139678:+
THCA	cis	rs113835537	0.569	rs17496586	ENSG00000255517.5	CTD-3074O7.5	-6.28	7.93e-10	1.72e-07	-0.26	-0.28	Airway imaging phenotypes;	chr11:66548041	chr11:66473490~66480233:-
THCA	cis	rs9311474	0.713	rs352169	ENSG00000243224.1	RP5-1157M23.2	-6.28	7.93e-10	1.72e-07	-0.28	-0.28	Electroencephalogram traits;	chr3:52202746	chr3:52239258~52241097:+
THCA	cis	rs6504622	0.875	rs3785888	ENSG00000262879.4	RP11-156P1.3	-6.28	7.94e-10	1.72e-07	-0.25	-0.28	Orofacial clefts;	chr17:46928337	chr17:46984045~47100323:-
THCA	cis	rs72843506	0.586	rs76886618	ENSG00000270091.1	RP11-78O7.2	-6.28	7.94e-10	1.72e-07	-0.34	-0.28	Schizophrenia;	chr17:19975483	chr17:19896590~19897287:-
THCA	cis	rs7044106	0.762	rs10818471	ENSG00000270917.1	RP11-27I1.6	-6.28	7.94e-10	1.72e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.718	rs1960421	ENSG00000270917.1	RP11-27I1.6	-6.28	7.94e-10	1.72e-07	-0.39	-0.28	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120812475~120812845:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	6.28	7.94e-10	1.72e-07	0.32	0.28	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	6.28	7.94e-10	1.72e-07	0.32	0.28	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
THCA	cis	rs17102884	0.506	rs4899540	ENSG00000279594.1	RP11-950C14.10	-6.28	7.94e-10	1.72e-07	-0.27	-0.28	Neuroticism;	chr14:74936705	chr14:75011269~75012851:-
THCA	cis	rs6545883	0.894	rs4672431	ENSG00000271889.1	RP11-493E12.1	-6.28	7.94e-10	1.72e-07	-0.26	-0.28	Tuberculosis;	chr2:61292787	chr2:61151433~61162105:-
THCA	cis	rs950169	0.8	rs4842847	ENSG00000259295.5	CSPG4P12	6.28	7.95e-10	1.72e-07	0.43	0.28	Schizophrenia;	chr15:84262447	chr15:85191438~85213905:+
THCA	cis	rs526231	0.963	rs12187443	ENSG00000175749.11	EIF3KP1	6.27	7.95e-10	1.72e-07	0.39	0.28	Primary biliary cholangitis;	chr5:103324699	chr5:103032376~103033031:+
THCA	cis	rs2657294	0.62	rs2395132	ENSG00000233313.2	HMGA1P5	-6.27	7.95e-10	1.72e-07	-0.38	-0.28	Pneumonia;	chr10:75080840	chr10:75276376~75276646:-
THCA	cis	rs853679	0.517	rs9380047	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28070115	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28071237	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28074687	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28076559	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28076704	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28078391	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28080757	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28080760	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28082231	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28082261	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Parkinson's disease;	chr6:28082269	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28082984	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28083994	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28084025	chr6:28136849~28139678:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28085319	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28096855	chr6:28136849~28139678:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28099759	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Parkinson's disease;	chr6:28100173	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28100648	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28104824	chr6:28136849~28139678:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28107222	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28108492	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000261839.1	RP1-265C24.8	6.27	7.95e-10	1.72e-07	0.33	0.28	Depression;	chr6:28110254	chr6:28136849~28139678:+
THCA	cis	rs7176527	0.848	rs72630463	ENSG00000188388.10	GOLGA6L3	6.27	7.96e-10	1.72e-07	0.48	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84750699	chr15:85240472~85247170:+
THCA	cis	rs11722779	0.935	rs7676736	ENSG00000230069.3	LRRC37A15P	-6.27	7.96e-10	1.72e-07	-0.29	-0.28	Schizophrenia;	chr4:103016729	chr4:102727274~102730721:-
THCA	cis	rs10844706	0.699	rs10772087	ENSG00000256594.6	RP11-705C15.2	6.27	7.97e-10	1.73e-07	0.23	0.28	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9730515	chr12:9633419~9658412:+
THCA	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-6.27	7.98e-10	1.73e-07	-0.34	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
THCA	cis	rs79349575	0.756	rs937301	ENSG00000248278.1	SUMO2P17	-6.27	7.98e-10	1.73e-07	-0.33	-0.28	Type 2 diabetes;	chr17:48968914	chr17:48874860~48908983:-
THCA	cis	rs6860806	0.661	rs3763112	ENSG00000237714.1	P4HA2-AS1	6.27	7.98e-10	1.73e-07	0.36	0.28	Breast cancer;	chr5:132250787	chr5:132184876~132192808:+
THCA	cis	rs6968419	0.585	rs10953816	ENSG00000237870.5	AC073130.1	6.27	7.98e-10	1.73e-07	0.29	0.28	Intraocular pressure;	chr7:116278473	chr7:116275606~116286734:-
THCA	cis	rs6908034	0.556	rs7750703	ENSG00000237404.1	RP3-471C18.2	-6.27	7.98e-10	1.73e-07	-0.49	-0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19689825~19753113:-
THCA	cis	rs1823913	0.927	rs34765012	ENSG00000227542.1	AC092614.2	6.27	7.99e-10	1.73e-07	0.34	0.28	Obesity-related traits;	chr2:191247926	chr2:191229165~191246172:-
THCA	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-6.27	8.01e-10	1.73e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
THCA	cis	rs2243480	1	rs160655	ENSG00000228409.4	CCT6P1	6.27	8.01e-10	1.73e-07	0.32	0.28	Diabetic kidney disease;	chr7:66068227	chr7:65751142~65763354:+
THCA	cis	rs10266483	0.576	rs2863327	ENSG00000271550.1	BNIP3P11	-6.27	8.03e-10	1.74e-07	-0.43	-0.28	Response to statin therapy;	chr7:64268698	chr7:64678954~64687393:-
THCA	cis	rs7927592	0.731	rs643609	ENSG00000212093.1	AP000807.1	6.27	8.03e-10	1.74e-07	0.28	0.28	Total body bone mineral density;	chr11:68474365	chr11:68506083~68506166:-
THCA	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	6.27	8.03e-10	1.74e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
THCA	cis	rs6860806	0.507	rs2631369	ENSG00000263597.1	MIR3936	-6.27	8.03e-10	1.74e-07	-0.27	-0.28	Breast cancer;	chr5:132369574	chr5:132365490~132365599:-
THCA	cis	rs274567	0.501	rs2631368	ENSG00000263597.1	MIR3936	-6.27	8.03e-10	1.74e-07	-0.27	-0.28	Blood metabolite levels;	chr5:132369605	chr5:132365490~132365599:-
THCA	cis	rs736801	0.808	rs2248116	ENSG00000233006.5	AC034220.3	-6.27	8.04e-10	1.74e-07	-0.22	-0.28	Mosquito bite size;Breast cancer;	chr5:132468655	chr5:132311285~132369916:-
THCA	cis	rs9813712	0.571	rs9836814	ENSG00000249846.5	RP11-77P16.4	6.27	8.04e-10	1.74e-07	0.29	0.28	Response to amphetamines;	chr3:130216054	chr3:130112550~130120579:+
THCA	cis	rs1865760	1	rs7770139	ENSG00000272462.2	U91328.19	-6.27	8.04e-10	1.74e-07	-0.23	-0.28	Height;	chr6:25925595	chr6:25992662~26001775:+
THCA	cis	rs5742933	0.803	rs1233302	ENSG00000273240.1	RP11-455J20.3	-6.27	8.04e-10	1.74e-07	-0.29	-0.28	Ferritin levels;	chr2:189804154	chr2:189763859~189764456:-
THCA	cis	rs6142102	0.812	rs6059558	ENSG00000275784.1	RP5-1125A11.6	-6.27	8.05e-10	1.74e-07	-0.28	-0.28	Skin pigmentation;	chr20:33929024	chr20:33989480~33991818:-
THCA	cis	rs227275	0.525	rs7698608	ENSG00000251288.2	RP11-10L12.2	-6.27	8.05e-10	1.74e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102751401~102752641:+
THCA	cis	rs72772090	0.634	rs17402639	ENSG00000248734.2	CTD-2260A17.1	-6.27	8.06e-10	1.74e-07	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96771301	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.634	rs72773912	ENSG00000248734.2	CTD-2260A17.1	-6.27	8.06e-10	1.74e-07	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96772097	chr5:96784777~96785999:+
THCA	cis	rs17772222	0.917	rs4635267	ENSG00000258789.1	RP11-507K2.3	-6.27	8.06e-10	1.74e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88621922	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.876	rs56144430	ENSG00000258789.1	RP11-507K2.3	-6.27	8.06e-10	1.74e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88622013	chr14:88551597~88552493:+
THCA	cis	rs34779708	0.766	rs35308730	ENSG00000271335.4	RP11-324I22.4	6.27	8.07e-10	1.74e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.736	rs34195979	ENSG00000271335.4	RP11-324I22.4	6.27	8.07e-10	1.74e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.649	rs34421369	ENSG00000271335.4	RP11-324I22.4	6.27	8.07e-10	1.74e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.677	rs112355105	ENSG00000271335.4	RP11-324I22.4	6.27	8.07e-10	1.74e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35314552~35336401:-
THCA	cis	rs1395	0.744	rs11126931	ENSG00000234072.1	AC074117.10	-6.27	8.07e-10	1.74e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27251438	chr2:27356246~27367622:+
THCA	cis	rs1395	0.744	rs7600932	ENSG00000234072.1	AC074117.10	-6.27	8.07e-10	1.74e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27252001	chr2:27356246~27367622:+
THCA	cis	rs890448	0.76	rs293210	ENSG00000254531.1	FLJ20021	6.27	8.07e-10	1.74e-07	0.25	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395248	chr4:101347780~101348883:+
THCA	cis	rs12908161	1	rs4643294	ENSG00000259295.5	CSPG4P12	6.27	8.07e-10	1.74e-07	0.43	0.28	Schizophrenia;	chr15:84707022	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs62021219	ENSG00000259295.5	CSPG4P12	6.27	8.07e-10	1.74e-07	0.43	0.28	Schizophrenia;	chr15:84712928	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs34900908	ENSG00000259295.5	CSPG4P12	6.27	8.07e-10	1.74e-07	0.43	0.28	Schizophrenia;	chr15:84714368	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs35524990	ENSG00000259295.5	CSPG4P12	6.27	8.07e-10	1.74e-07	0.43	0.28	Schizophrenia;	chr15:84714972	chr15:85191438~85213905:+
THCA	cis	rs1005277	0.579	rs1614236	ENSG00000276805.1	RP11-291L22.6	6.27	8.07e-10	1.74e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2749616	ENSG00000276805.1	RP11-291L22.6	6.27	8.07e-10	1.74e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs1780146	ENSG00000276805.1	RP11-291L22.6	6.27	8.07e-10	1.74e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38451030~38451785:+
THCA	cis	rs712022	0.534	rs7940885	ENSG00000246225.5	RP11-17A1.3	-6.27	8.07e-10	1.75e-07	-0.37	-0.28	Dialysis-related mortality;	chr11:22839479	chr11:22829380~22945393:+
THCA	cis	rs11722779	0.838	rs4533776	ENSG00000230069.3	LRRC37A15P	-6.27	8.09e-10	1.75e-07	-0.29	-0.28	Schizophrenia;	chr4:102912732	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.838	rs6821247	ENSG00000230069.3	LRRC37A15P	-6.27	8.09e-10	1.75e-07	-0.29	-0.28	Schizophrenia;	chr4:102913483	chr4:102727274~102730721:-
THCA	cis	rs793571	0.554	rs12442451	ENSG00000259250.1	RP11-50C13.1	-6.27	8.09e-10	1.75e-07	-0.29	-0.28	Schizophrenia;	chr15:58630196	chr15:58587507~58591676:+
THCA	cis	rs6840360	0.582	rs4696259	ENSG00000251611.1	RP11-610P16.1	-6.27	8.1e-10	1.75e-07	-0.2	-0.28	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151407551~151408835:-
THCA	cis	rs4971059	0.654	rs12028043	ENSG00000160766.13	GBAP1	-6.27	8.1e-10	1.75e-07	-0.3	-0.28	Breast cancer;	chr1:155160360	chr1:155213821~155227422:-
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	6.27	8.12e-10	1.76e-07	0.32	0.28	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
THCA	cis	rs11158026	0.757	rs2183085	ENSG00000258413.1	RP11-665C16.6	-6.27	8.12e-10	1.76e-07	-0.38	-0.28	Parkinson's disease;	chr14:55005673	chr14:55262767~55272075:-
THCA	cis	rs7811142	0.945	rs6978739	ENSG00000078319.8	PMS2P1	-6.27	8.13e-10	1.76e-07	-0.41	-0.28	Platelet count;	chr7:100501057	chr7:100320992~100341908:-
THCA	cis	rs228614	0.514	rs59550147	ENSG00000230069.3	LRRC37A15P	-6.27	8.13e-10	1.76e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102727274~102730721:-
THCA	cis	rs2243480	1	rs160634	ENSG00000228409.4	CCT6P1	-6.27	8.14e-10	1.76e-07	-0.31	-0.28	Diabetic kidney disease;	chr7:66063677	chr7:65751142~65763354:+
THCA	cis	rs2348418	0.832	rs12301674	ENSG00000247934.4	RP11-967K21.1	6.27	8.14e-10	1.76e-07	0.24	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28357543	chr12:28163298~28190738:-
THCA	cis	rs13113518	0.783	rs11943206	ENSG00000273257.1	RP11-177J6.1	6.27	8.15e-10	1.76e-07	0.38	0.28	Height;	chr4:55570843	chr4:55387949~55388271:+
THCA	cis	rs12653396	0.609	rs6452792	ENSG00000247828.6	TMEM161B-AS1	6.27	8.15e-10	1.76e-07	0.21	0.28	Educational attainment (years of education);	chr5:88497027	chr5:88268895~88436685:+
THCA	cis	rs748404	1	rs12911132	ENSG00000249839.1	AC011330.5	-6.27	8.15e-10	1.76e-07	-0.37	-0.28	Lung cancer;	chr15:43268238	chr15:43663654~43684339:-
THCA	cis	rs7246657	0.765	rs10402455	ENSG00000276846.1	CTD-3220F14.3	6.27	8.16e-10	1.76e-07	0.31	0.28	Coronary artery calcification;	chr19:37237805	chr19:37314868~37315620:-
THCA	cis	rs10129255	0.576	rs2157616	ENSG00000280411.1	IGHV1-69-2	-6.27	8.16e-10	1.76e-07	-0.17	-0.28	Kawasaki disease;	chr14:106767802	chr14:106762092~106762588:-
THCA	cis	rs911555	0.57	rs11625397	ENSG00000269958.1	RP11-73M18.8	-6.27	8.17e-10	1.77e-07	-0.26	-0.28	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103696353~103697163:+
THCA	cis	rs62103177	0.673	rs55852342	ENSG00000261126.6	RP11-795F19.1	6.27	8.18e-10	1.77e-07	0.27	0.28	Opioid sensitivity;	chr18:79834109	chr18:80046900~80095482:+
THCA	cis	rs72843506	0.722	rs79590067	ENSG00000270091.1	RP11-78O7.2	-6.27	8.18e-10	1.77e-07	-0.3	-0.28	Schizophrenia;	chr17:20204101	chr17:19896590~19897287:-
THCA	cis	rs2439831	0.867	rs11856184	ENSG00000166763.7	STRCP1	6.27	8.19e-10	1.77e-07	0.39	0.28	Lung cancer in ever smokers;	chr15:43626964	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2927072	ENSG00000166763.7	STRCP1	6.27	8.19e-10	1.77e-07	0.39	0.28	Lung cancer in ever smokers;	chr15:43630200	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2920781	ENSG00000166763.7	STRCP1	6.27	8.19e-10	1.77e-07	0.39	0.28	Lung cancer in ever smokers;	chr15:43632484	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.764	rs2447193	ENSG00000166763.7	STRCP1	6.27	8.19e-10	1.77e-07	0.39	0.28	Lung cancer in ever smokers;	chr15:43637535	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2447211	ENSG00000166763.7	STRCP1	6.27	8.19e-10	1.77e-07	0.39	0.28	Lung cancer in ever smokers;	chr15:43644153	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.571	rs2470121	ENSG00000166763.7	STRCP1	6.27	8.19e-10	1.77e-07	0.39	0.28	Lung cancer in ever smokers;	chr15:43645420	chr15:43699488~43718184:-
THCA	cis	rs6142102	1	rs6059681	ENSG00000275784.1	RP5-1125A11.6	-6.27	8.19e-10	1.77e-07	-0.29	-0.28	Skin pigmentation;	chr20:34135535	chr20:33989480~33991818:-
THCA	cis	rs9649465	0.967	rs11765790	ENSG00000272686.1	RP11-390E23.6	6.27	8.2e-10	1.77e-07	0.18	0.28	Migraine;	chr7:123653098	chr7:123749068~123751166:+
THCA	cis	rs3020264	0.59	rs2515561	ENSG00000271743.1	CTD-2541M15.3	-6.27	8.2e-10	1.77e-07	-0.36	-0.28	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6633454	chr8:6615604~6617198:-
THCA	cis	rs7129556	0.859	rs11237236	ENSG00000254691.1	RP11-91P24.5	6.27	8.2e-10	1.77e-07	0.41	0.28	Weight loss (gastric bypass surgery);	chr11:77601745	chr11:77850604~77851511:+
THCA	cis	rs890448	0.726	rs2850371	ENSG00000254531.1	FLJ20021	-6.27	8.21e-10	1.77e-07	-0.25	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101319590	chr4:101347780~101348883:+
THCA	cis	rs227275	0.525	rs9917919	ENSG00000251288.2	RP11-10L12.2	-6.27	8.21e-10	1.77e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223356	ENSG00000230069.3	LRRC37A15P	-6.27	8.22e-10	1.78e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102727274~102730721:-
THCA	cis	rs7085104	0.684	rs7092690	ENSG00000236937.2	PTGES3P4	6.27	8.24e-10	1.78e-07	0.36	0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102845595~102845950:+
THCA	cis	rs7403037	1	rs4992989	ENSG00000259905.4	PWRN1	6.27	8.24e-10	1.78e-07	0.31	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24576334	chr15:24493137~24652130:+
THCA	cis	rs6545883	0.895	rs2442029	ENSG00000271889.1	RP11-493E12.1	6.27	8.25e-10	1.78e-07	0.27	0.28	Tuberculosis;	chr2:61452417	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.929	rs2256615	ENSG00000271889.1	RP11-493E12.1	6.27	8.25e-10	1.78e-07	0.27	0.28	Tuberculosis;	chr2:61452759	chr2:61151433~61162105:-
THCA	cis	rs8027521	0.54	rs11855997	ENSG00000280362.1	RP11-643A5.3	6.27	8.25e-10	1.78e-07	0.34	0.28	Circulating chemerin levels;	chr15:53921205	chr15:53910769~53914712:+
THCA	cis	rs17772222	0.917	rs17188228	ENSG00000258789.1	RP11-507K2.3	-6.27	8.26e-10	1.78e-07	-0.28	-0.28	Coronary artery calcification;	chr14:88738921	chr14:88551597~88552493:+
THCA	cis	rs3824488	0.599	rs16909859	ENSG00000237857.2	RP11-435O5.2	-6.27	8.27e-10	1.78e-07	-0.45	-0.28	Neuroticism;	chr9:95442510	chr9:95414834~95426796:-
THCA	cis	rs9381040	0.655	rs2268187	ENSG00000161912.16	ADCY10P1	6.27	8.27e-10	1.79e-07	0.18	0.28	Alzheimer's disease (late onset);	chr6:41075254	chr6:41101022~41140835:+
THCA	cis	rs7202877	0.656	rs8048677	ENSG00000261783.1	RP11-252K23.2	-6.27	8.27e-10	1.79e-07	-0.48	-0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75358130	chr16:75379818~75381260:-
THCA	cis	rs7202877	0.706	rs8055609	ENSG00000261783.1	RP11-252K23.2	-6.27	8.27e-10	1.79e-07	-0.48	-0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75368190	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.539	rs35460860	ENSG00000228638.1	FCF1P2	-6.27	8.28e-10	1.79e-07	-0.27	-0.28	Coronary artery disease;	chr3:48350595	chr3:48290793~48291375:-
THCA	cis	rs6928977	0.896	rs2246943	ENSG00000231028.7	LINC00271	6.27	8.28e-10	1.79e-07	0.22	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370378	chr6:135497801~135716055:+
THCA	cis	rs227275	0.554	rs223454	ENSG00000230069.3	LRRC37A15P	-6.27	8.29e-10	1.79e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102727274~102730721:-
THCA	cis	rs8072100	0.72	rs4794057	ENSG00000228782.6	CTD-2026D20.3	6.27	8.3e-10	1.79e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47709086	chr17:47450568~47492492:-
THCA	cis	rs1005277	0.579	rs1548255	ENSG00000276805.1	RP11-291L22.6	6.27	8.3e-10	1.79e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38451030~38451785:+
THCA	cis	rs4650994	0.525	rs2493864	ENSG00000273384.1	RP5-1098D14.1	6.27	8.31e-10	1.79e-07	0.35	0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178575868	chr1:178651706~178652282:+
THCA	cis	rs227275	0.525	rs3974608	ENSG00000230069.3	LRRC37A15P	-6.27	8.32e-10	1.8e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102727274~102730721:-
THCA	cis	rs4776997	0.559	rs12902904	ENSG00000270964.1	RP11-502I4.3	6.27	8.32e-10	1.8e-07	0.25	0.28	Verbal declarative memory;	chr15:67784195	chr15:67541072~67542604:-
THCA	cis	rs1993293	0.636	rs2168067	ENSG00000259363.4	CTD-2054N24.2	6.27	8.33e-10	1.8e-07	0.37	0.28	Coronary artery calcification;	chr15:99758972	chr15:99807023~99877148:+
THCA	cis	rs2439831	0.867	rs2412778	ENSG00000249839.1	AC011330.5	-6.27	8.33e-10	1.8e-07	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43368784	chr15:43663654~43684339:-
THCA	cis	rs9467773	0.55	rs4712987	ENSG00000124549.13	BTN2A3P	-6.27	8.33e-10	1.8e-07	-0.26	-0.28	Intelligence (multi-trait analysis);	chr6:26399387	chr6:26421391~26432383:+
THCA	cis	rs4835473	0.722	rs3901420	ENSG00000251600.4	RP11-673E1.1	-6.27	8.34e-10	1.8e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144092039	chr4:143912331~143982454:+
THCA	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-6.27	8.34e-10	1.8e-07	-0.36	-0.28	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
THCA	cis	rs860295	0.65	rs539602	ENSG00000225855.5	RUSC1-AS1	-6.27	8.35e-10	1.8e-07	-0.18	-0.28	Body mass index;	chr1:155929229	chr1:155316863~155324176:-
THCA	cis	rs1949733	0.523	rs56053534	ENSG00000205959.3	RP11-689P11.2	6.27	8.35e-10	1.8e-07	0.25	0.28	Response to antineoplastic agents;	chr4:8541149	chr4:8482270~8512610:+
THCA	cis	rs1707322	1	rs1707303	ENSG00000280836.1	AL355480.1	6.27	8.37e-10	1.81e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45581219~45581321:-
THCA	cis	rs4934494	0.768	rs3740034	ENSG00000232936.4	RP11-80H5.2	6.27	8.38e-10	1.81e-07	0.37	0.28	Red blood cell count;	chr10:89634902	chr10:89645282~89650667:+
THCA	cis	rs16958440	0.867	rs79420880	ENSG00000267800.1	RP11-49K24.5	-6.27	8.38e-10	1.81e-07	-0.6	-0.28	Sitting height ratio;	chr18:47137316	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs78720782	ENSG00000267800.1	RP11-49K24.5	-6.27	8.38e-10	1.81e-07	-0.6	-0.28	Sitting height ratio;	chr18:47137644	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs79231363	ENSG00000267800.1	RP11-49K24.5	-6.27	8.38e-10	1.81e-07	-0.6	-0.28	Sitting height ratio;	chr18:47138716	chr18:47137018~47137290:+
THCA	cis	rs76297747	1	rs76297747	ENSG00000267800.1	RP11-49K24.5	-6.27	8.38e-10	1.81e-07	-0.6	-0.28	Response to paliperidone in schizophrenia (Multivariate);	chr18:47139286	chr18:47137018~47137290:+
THCA	cis	rs7225151	0.71	rs8077567	ENSG00000234327.6	AC012146.7	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Alzheimer's disease (late onset);	chr17:5286121	chr17:5111468~5115004:+
THCA	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-6.27	8.38e-10	1.81e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
THCA	cis	rs7727544	0.684	rs274561	ENSG00000237714.1	P4HA2-AS1	6.27	8.4e-10	1.81e-07	0.36	0.28	Blood metabolite levels;	chr5:132383536	chr5:132184876~132192808:+
THCA	cis	rs5752326	0.717	rs5761545	ENSG00000261188.1	CTA-445C9.14	6.27	8.41e-10	1.81e-07	0.37	0.28	Ischemic stroke;	chr22:26466806	chr22:26512537~26514568:+
THCA	cis	rs16846053	0.642	rs971284	ENSG00000227403.1	AC009299.3	6.27	8.42e-10	1.82e-07	0.42	0.28	Blood osmolality (transformed sodium);	chr2:161751944	chr2:161244739~161249050:+
THCA	cis	rs9381040	0.61	rs2294694	ENSG00000161912.16	ADCY10P1	6.27	8.43e-10	1.82e-07	0.19	0.28	Alzheimer's disease (late onset);	chr6:41078438	chr6:41101022~41140835:+
THCA	cis	rs7129556	0.954	rs2032395	ENSG00000254691.1	RP11-91P24.5	6.27	8.43e-10	1.82e-07	0.38	0.28	Weight loss (gastric bypass surgery);	chr11:77603458	chr11:77850604~77851511:+
THCA	cis	rs7851660	0.967	rs6478437	ENSG00000214417.4	KRT18P13	-6.27	8.43e-10	1.82e-07	-0.23	-0.28	Strep throat;	chr9:97845215	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.901	rs2401639	ENSG00000214417.4	KRT18P13	-6.27	8.43e-10	1.82e-07	-0.23	-0.28	Strep throat;	chr9:97845555	chr9:97698922~97700734:+
THCA	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	6.27	8.43e-10	1.82e-07	0.3	0.28	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
THCA	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	6.26	8.43e-10	1.82e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	6.26	8.43e-10	1.82e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	6.26	8.43e-10	1.82e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	6.26	8.43e-10	1.82e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
THCA	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	6.26	8.44e-10	1.82e-07	0.39	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
THCA	cis	rs72843506	0.656	rs9913018	ENSG00000270091.1	RP11-78O7.2	-6.26	8.44e-10	1.82e-07	-0.3	-0.28	Schizophrenia;	chr17:20160759	chr17:19896590~19897287:-
THCA	cis	rs7809950	0.862	rs2299421	ENSG00000238832.1	snoU109	-6.26	8.45e-10	1.82e-07	-0.3	-0.28	Coronary artery disease;	chr7:107305750	chr7:107603363~107603507:+
THCA	cis	rs7727544	0.684	rs272889	ENSG00000237714.1	P4HA2-AS1	6.26	8.45e-10	1.82e-07	0.36	0.28	Blood metabolite levels;	chr5:132329685	chr5:132184876~132192808:+
THCA	cis	rs2243480	1	rs313807	ENSG00000232546.1	RP11-458F8.1	-6.26	8.46e-10	1.82e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66034494	chr7:66848496~66858136:+
THCA	cis	rs71007656	1	rs71007656	ENSG00000263064.2	RP11-291L22.7	6.26	8.46e-10	1.82e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.522	rs289648	ENSG00000263064.2	RP11-291L22.7	6.26	8.46e-10	1.82e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38448689~38448949:+
THCA	cis	rs748404	0.578	rs2278856	ENSG00000166763.7	STRCP1	6.26	8.47e-10	1.83e-07	0.29	0.28	Lung cancer;	chr15:43339158	chr15:43699488~43718184:-
THCA	cis	rs925255	0.591	rs7559046	ENSG00000270210.1	RP11-373D23.3	6.26	8.47e-10	1.83e-07	0.28	0.28	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28425945~28426719:+
THCA	cis	rs6088580	0.524	rs6088560	ENSG00000269202.1	RP4-614O4.12	6.26	8.47e-10	1.83e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34640745	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.524	rs7269596	ENSG00000269202.1	RP4-614O4.12	6.26	8.47e-10	1.83e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34641259	chr20:35201747~35203288:-
THCA	cis	rs6088580	0.524	rs6087612	ENSG00000269202.1	RP4-614O4.12	6.26	8.47e-10	1.83e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34643018	chr20:35201747~35203288:-
THCA	cis	rs699371	0.525	rs1156021	ENSG00000270000.1	RP3-449M8.9	6.26	8.48e-10	1.83e-07	0.26	0.28	Height;	chr14:74432889	chr14:74471930~74472360:-
THCA	cis	rs8027521	0.54	rs58048222	ENSG00000280362.1	RP11-643A5.3	6.26	8.49e-10	1.83e-07	0.34	0.28	Circulating chemerin levels;	chr15:53940861	chr15:53910769~53914712:+
THCA	cis	rs2243480	1	rs316331	ENSG00000229886.1	RP5-1132H15.3	-6.26	8.5e-10	1.83e-07	-0.44	-0.28	Diabetic kidney disease;	chr7:66139635	chr7:66025126~66031544:-
THCA	cis	rs28386778	0.742	rs3020617	ENSG00000240280.5	TCAM1P	-6.26	8.51e-10	1.83e-07	-0.39	-0.28	Prudent dietary pattern;	chr17:63869943	chr17:63849292~63864379:+
THCA	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	6.26	8.51e-10	1.83e-07	0.22	0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
THCA	cis	rs6696239	0.513	rs4653514	ENSG00000227711.2	RP11-275O4.5	6.26	8.51e-10	1.83e-07	0.29	0.28	Height;	chr1:227565381	chr1:227509028~227520477:-
THCA	cis	rs10799445	0.508	rs10916165	ENSG00000227711.2	RP11-275O4.5	6.26	8.51e-10	1.83e-07	0.29	0.28	Height;	chr1:227567234	chr1:227509028~227520477:-
THCA	cis	rs10875746	0.669	rs11168510	ENSG00000269514.1	RP11-370I10.12	6.26	8.51e-10	1.83e-07	0.28	0.28	Longevity (90 years and older);	chr12:48291772	chr12:48198387~48202031:+
THCA	cis	rs4662750	0.527	rs10164978	ENSG00000236682.1	AC068282.3	6.26	8.51e-10	1.83e-07	0.36	0.28	Renal cell carcinoma;	chr2:127627649	chr2:127389130~127400580:+
THCA	cis	rs74233809	0.901	rs3824754	ENSG00000213277.3	MARCKSL1P1	6.26	8.52e-10	1.83e-07	0.44	0.28	Birth weight;	chr10:102854593	chr10:103175554~103176094:+
THCA	cis	rs686320	1	rs72643572	ENSG00000245532.5	NEAT1	6.26	8.52e-10	1.84e-07	0.26	0.28	Hip circumference adjusted for BMI;	chr11:65483496	chr11:65422774~65445540:+
THCA	cis	rs4950322	0.58	rs17355474	ENSG00000278811.3	LINC00624	6.26	8.52e-10	1.84e-07	0.34	0.28	Protein quantitative trait loci;	chr1:147120541	chr1:147258885~147517875:-
THCA	cis	rs9926296	0.605	rs886951	ENSG00000260259.1	RP11-368I7.4	-6.26	8.52e-10	1.84e-07	-0.3	-0.28	Vitiligo;	chr16:89770457	chr16:89682620~89686569:-
THCA	cis	rs7015630	0.603	rs2189025	ENSG00000251136.7	RP11-37B2.1	-6.26	8.53e-10	1.84e-07	-0.27	-0.28	Inflammatory bowel disease;Crohn's disease;	chr8:89836956	chr8:89609409~89757727:-
THCA	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-6.26	8.53e-10	1.84e-07	-0.25	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
THCA	cis	rs227275	0.525	rs4623004	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs11097796	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs11097797	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs4699046	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs4699047	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs28778380	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs10029073	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs4698874	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs724446	ENSG00000230069.3	LRRC37A15P	-6.26	8.53e-10	1.84e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102727274~102730721:-
THCA	cis	rs2243480	1	rs35825738	ENSG00000232546.1	RP11-458F8.1	-6.26	8.54e-10	1.84e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65853040	chr7:66848496~66858136:+
THCA	cis	rs4664293	0.647	rs7580539	ENSG00000226266.5	AC009961.3	-6.26	8.55e-10	1.84e-07	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159589238	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.539	rs7580661	ENSG00000226266.5	AC009961.3	-6.26	8.55e-10	1.84e-07	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159589326	chr2:159670708~159712435:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000261839.1	RP1-265C24.8	6.26	8.56e-10	1.84e-07	0.33	0.28	Depression;	chr6:28151096	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000261839.1	RP1-265C24.8	6.26	8.56e-10	1.84e-07	0.33	0.28	Depression;	chr6:28152885	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000261839.1	RP1-265C24.8	6.26	8.56e-10	1.84e-07	0.33	0.28	Depression;	chr6:28153120	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000261839.1	RP1-265C24.8	6.26	8.56e-10	1.84e-07	0.33	0.28	Depression;	chr6:28161802	chr6:28136849~28139678:+
THCA	cis	rs7202877	0.706	rs247423	ENSG00000261783.1	RP11-252K23.2	6.26	8.56e-10	1.84e-07	0.48	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75422733	chr16:75379818~75381260:-
THCA	cis	rs5742933	0.817	rs1233299	ENSG00000273240.1	RP11-455J20.3	-6.26	8.56e-10	1.84e-07	-0.29	-0.28	Ferritin levels;	chr2:189799912	chr2:189763859~189764456:-
THCA	cis	rs12534093	0.522	rs11768826	ENSG00000234286.1	AC006026.13	-6.26	8.56e-10	1.84e-07	-0.37	-0.28	Infant length;Height;	chr7:23534595	chr7:23680195~23680786:-
THCA	cis	rs9990333	0.562	rs55970879	ENSG00000226155.1	AC124944.3	-6.26	8.57e-10	1.85e-07	-0.34	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195912049~195913986:+
THCA	cis	rs9990333	0.562	rs75681503	ENSG00000226155.1	AC124944.3	-6.26	8.57e-10	1.85e-07	-0.34	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195912049~195913986:+
THCA	cis	rs17102884	0.506	rs11845397	ENSG00000279594.1	RP11-950C14.10	-6.26	8.57e-10	1.85e-07	-0.26	-0.28	Neuroticism;	chr14:74937884	chr14:75011269~75012851:-
THCA	cis	rs6696239	0.513	rs2088214	ENSG00000227711.2	RP11-275O4.5	-6.26	8.57e-10	1.85e-07	-0.29	-0.28	Height;	chr1:227590490	chr1:227509028~227520477:-
THCA	cis	rs12681366	0.614	rs3099397	ENSG00000253704.1	RP11-267M23.4	6.26	8.58e-10	1.85e-07	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94467091	chr8:94553722~94569745:+
THCA	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-6.26	8.58e-10	1.85e-07	-0.3	-0.28	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
THCA	cis	rs6723108	0.581	rs10176573	ENSG00000224043.6	CCNT2-AS1	-6.26	8.59e-10	1.85e-07	-0.29	-0.28	Type 2 diabetes;	chr2:134899901	chr2:134735464~134918710:-
THCA	cis	rs728616	0.681	rs34816332	ENSG00000242600.5	MBL1P	6.26	8.59e-10	1.85e-07	0.35	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148211	chr10:79904898~79950336:+
THCA	cis	rs4971059	0.629	rs4246529	ENSG00000160766.13	GBAP1	-6.26	8.6e-10	1.85e-07	-0.29	-0.28	Breast cancer;	chr1:155142784	chr1:155213821~155227422:-
THCA	cis	rs2348418	0.832	rs10506031	ENSG00000247934.4	RP11-967K21.1	-6.26	8.6e-10	1.85e-07	-0.24	-0.28	Lung function (FEV1);Lung function (FVC);	chr12:28379061	chr12:28163298~28190738:-
THCA	cis	rs227275	0.525	rs13150426	ENSG00000230069.3	LRRC37A15P	-6.26	8.6e-10	1.85e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs28445579	ENSG00000230069.3	LRRC37A15P	-6.26	8.6e-10	1.85e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102727274~102730721:-
THCA	cis	rs7615952	0.512	rs4679430	ENSG00000241278.1	ENPP7P4	6.26	8.6e-10	1.85e-07	0.35	0.28	Blood pressure (smoking interaction);	chr3:125639049	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.512	rs34651730	ENSG00000241278.1	ENPP7P4	6.26	8.6e-10	1.85e-07	0.35	0.28	Blood pressure (smoking interaction);	chr3:125639796	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.512	rs2979334	ENSG00000241278.1	ENPP7P4	6.26	8.6e-10	1.85e-07	0.35	0.28	Blood pressure (smoking interaction);	chr3:125639980	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.512	rs11929125	ENSG00000241278.1	ENPP7P4	6.26	8.6e-10	1.85e-07	0.35	0.28	Blood pressure (smoking interaction);	chr3:125640599	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.512	rs11921452	ENSG00000241278.1	ENPP7P4	6.26	8.6e-10	1.85e-07	0.35	0.28	Blood pressure (smoking interaction);	chr3:125640906	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.512	rs2922175	ENSG00000241278.1	ENPP7P4	6.26	8.6e-10	1.85e-07	0.35	0.28	Blood pressure (smoking interaction);	chr3:125642516	chr3:125848223~125909372:+
THCA	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	6.26	8.61e-10	1.85e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
THCA	cis	rs2562456	0.833	rs11666828	ENSG00000268555.1	RP11-678G14.3	6.26	8.62e-10	1.85e-07	0.45	0.28	Pain;	chr19:21342218	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs11671609	ENSG00000268555.1	RP11-678G14.3	6.26	8.62e-10	1.85e-07	0.45	0.28	Pain;	chr19:21342769	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs62109212	ENSG00000268555.1	RP11-678G14.3	6.26	8.62e-10	1.85e-07	0.45	0.28	Pain;	chr19:21343716	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs57250002	ENSG00000268555.1	RP11-678G14.3	6.26	8.62e-10	1.85e-07	0.45	0.28	Pain;	chr19:21344048	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62109218	ENSG00000268555.1	RP11-678G14.3	6.26	8.62e-10	1.85e-07	0.45	0.28	Pain;	chr19:21346059	chr19:21570822~21587322:-
THCA	cis	rs1876905	0.597	rs1215964	ENSG00000255389.1	C6orf3	6.26	8.62e-10	1.86e-07	0.34	0.28	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111599875~111602295:+
THCA	cis	rs848490	0.723	rs62462685	ENSG00000214293.7	APTR	6.26	8.62e-10	1.86e-07	0.21	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77879316	chr7:77657660~77696265:-
THCA	cis	rs9921338	0.961	rs9302459	ENSG00000262703.1	RP11-485G7.6	6.26	8.62e-10	1.86e-07	0.36	0.28	Vein graft stenosis in coronary artery bypass grafting;	chr16:11326482	chr16:11348143~11349321:-
THCA	cis	rs9326248	0.53	rs11216316	ENSG00000280143.1	AP000892.6	-6.26	8.62e-10	1.86e-07	-0.46	-0.28	Blood protein levels;	chr11:117210784	chr11:117204967~117210292:+
THCA	cis	rs10208649	1	rs11125517	ENSG00000272156.1	RP11-477N3.1	6.26	8.63e-10	1.86e-07	0.5	0.28	Body mass index;	chr2:53864611	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs1049894	ENSG00000272156.1	RP11-477N3.1	6.26	8.63e-10	1.86e-07	0.5	0.28	Body mass index;	chr2:53866819	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs7608085	ENSG00000272156.1	RP11-477N3.1	6.26	8.63e-10	1.86e-07	0.5	0.28	Body mass index;	chr2:53867147	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.803	rs28699646	ENSG00000272156.1	RP11-477N3.1	6.26	8.63e-10	1.86e-07	0.5	0.28	Body mass index;	chr2:53868313	chr2:54082554~54085066:+
THCA	cis	rs4845570	1	rs4845579	ENSG00000249602.1	RP11-98D18.3	-6.26	8.64e-10	1.86e-07	-0.35	-0.28	Coronary artery disease;	chr1:151797662	chr1:151763384~151769501:-
THCA	cis	rs6545883	0.859	rs2600661	ENSG00000271889.1	RP11-493E12.1	-6.26	8.65e-10	1.86e-07	-0.26	-0.28	Tuberculosis;	chr2:61315946	chr2:61151433~61162105:-
THCA	cis	rs4664293	0.715	rs13002625	ENSG00000226266.5	AC009961.3	6.26	8.65e-10	1.86e-07	0.31	0.28	Monocyte percentage of white cells;	chr2:159648114	chr2:159670708~159712435:-
THCA	cis	rs12908161	1	rs35316992	ENSG00000259295.5	CSPG4P12	6.26	8.65e-10	1.86e-07	0.43	0.28	Schizophrenia;	chr15:84704902	chr15:85191438~85213905:+
THCA	cis	rs1614887	1	rs1614887	ENSG00000124549.13	BTN2A3P	6.26	8.65e-10	1.86e-07	0.26	0.28	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr6:26421391~26432383:+
THCA	cis	rs317689	0.613	rs315112	ENSG00000274979.1	RP11-1143G9.5	-6.26	8.65e-10	1.86e-07	-0.31	-0.28	Response to diuretic therapy;	chr12:69392146	chr12:69326574~69331882:-
THCA	cis	rs944990	0.538	rs10992789	ENSG00000227603.1	RP11-165J3.6	6.26	8.66e-10	1.86e-07	0.29	0.28	Body mass index;	chr9:93578914	chr9:93435332~93437121:-
THCA	cis	rs4835473	0.9	rs28617357	ENSG00000251600.4	RP11-673E1.1	-6.26	8.66e-10	1.86e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144096343	chr4:143912331~143982454:+
THCA	cis	rs6740322	0.748	rs1549723	ENSG00000234936.1	AC010883.5	6.26	8.67e-10	1.87e-07	0.3	0.28	Coronary artery disease;	chr2:43233375	chr2:43229573~43233394:+
THCA	cis	rs12435908	1	rs10138765	ENSG00000276116.2	FUT8-AS1	-6.26	8.68e-10	1.87e-07	-0.44	-0.28	Ischemic stroke;	chr14:65393521	chr14:65411170~65412690:-
THCA	cis	rs2562456	0.833	rs2154302	ENSG00000268555.1	RP11-678G14.3	6.26	8.68e-10	1.87e-07	0.44	0.28	Pain;	chr19:21307609	chr19:21570822~21587322:-
THCA	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-6.26	8.68e-10	1.87e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
THCA	cis	rs1609391	0.561	rs9817967	ENSG00000273486.1	RP11-731C17.2	6.26	8.69e-10	1.87e-07	0.24	0.28	Neuroticism;	chr3:136910648	chr3:136837338~136839021:-
THCA	cis	rs1609391	0.543	rs9828009	ENSG00000273486.1	RP11-731C17.2	6.26	8.69e-10	1.87e-07	0.24	0.28	Neuroticism;	chr3:136912433	chr3:136837338~136839021:-
THCA	cis	rs4950322	0.57	rs72691054	ENSG00000278811.3	LINC00624	6.26	8.69e-10	1.87e-07	0.35	0.28	Protein quantitative trait loci;	chr1:147277942	chr1:147258885~147517875:-
THCA	cis	rs9926296	0.744	rs460984	ENSG00000274627.1	RP11-104N10.2	6.26	8.7e-10	1.87e-07	0.29	0.28	Vitiligo;	chr16:89646766	chr16:89516797~89522217:+
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000229886.1	RP5-1132H15.3	6.26	8.71e-10	1.87e-07	0.45	0.28	Diabetic kidney disease;	chr7:65946971	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs2961102	ENSG00000229886.1	RP5-1132H15.3	6.26	8.71e-10	1.87e-07	0.45	0.28	Diabetic kidney disease;	chr7:65959671	chr7:66025126~66031544:-
THCA	cis	rs853679	0.517	rs4713141	ENSG00000261839.1	RP1-265C24.8	6.26	8.71e-10	1.87e-07	0.33	0.28	Depression;	chr6:28133900	chr6:28136849~28139678:+
THCA	cis	rs4950322	0.542	rs17159924	ENSG00000278811.3	LINC00624	6.26	8.72e-10	1.87e-07	0.34	0.28	Protein quantitative trait loci;	chr1:147199463	chr1:147258885~147517875:-
THCA	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	6.26	8.72e-10	1.88e-07	0.27	0.28	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
THCA	cis	rs62103177	0.673	rs4438371	ENSG00000261126.6	RP11-795F19.1	6.26	8.73e-10	1.88e-07	0.27	0.28	Opioid sensitivity;	chr18:79855988	chr18:80046900~80095482:+
THCA	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	6.26	8.73e-10	1.88e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	6.26	8.73e-10	1.88e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
THCA	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	6.26	8.73e-10	1.88e-07	0.32	0.28	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
THCA	cis	rs934734	0.967	rs1866051	ENSG00000281920.1	RP11-418H16.1	6.26	8.73e-10	1.88e-07	0.34	0.28	Rheumatoid arthritis;	chr2:65375015	chr2:65623272~65628424:+
THCA	cis	rs12681366	0.614	rs2921387	ENSG00000253704.1	RP11-267M23.4	6.26	8.73e-10	1.88e-07	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94446109	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.614	rs935052	ENSG00000253704.1	RP11-267M23.4	6.26	8.73e-10	1.88e-07	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94449718	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.614	rs2930969	ENSG00000253704.1	RP11-267M23.4	6.26	8.73e-10	1.88e-07	0.27	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94451857	chr8:94553722~94569745:+
THCA	cis	rs760794	0.577	rs17483277	ENSG00000227116.1	RP3-471C18.1	-6.26	8.74e-10	1.88e-07	-0.28	-0.28	Endometriosis;	chr6:19790340	chr6:19730427~19734567:-
THCA	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	6.26	8.75e-10	1.88e-07	0.42	0.28	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
THCA	cis	rs9307551	0.857	rs2165387	ENSG00000250334.4	LINC00989	-6.26	8.76e-10	1.88e-07	-0.33	-0.28	Refractive error;	chr4:79570666	chr4:79492416~79576460:+
THCA	cis	rs10875746	0.951	rs8804	ENSG00000269514.1	RP11-370I10.12	6.26	8.76e-10	1.88e-07	0.28	0.28	Longevity (90 years and older);	chr12:48147974	chr12:48198387~48202031:+
THCA	cis	rs2303319	1	rs62194492	ENSG00000227403.1	AC009299.3	6.26	8.76e-10	1.88e-07	0.59	0.28	Cognitive function;	chr2:161359052	chr2:161244739~161249050:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-6.26	8.77e-10	1.89e-07	-0.32	-0.28	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
THCA	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	6.26	8.77e-10	1.89e-07	0.45	0.28	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
THCA	cis	rs8027521	0.54	rs11853921	ENSG00000280362.1	RP11-643A5.3	6.26	8.77e-10	1.89e-07	0.34	0.28	Circulating chemerin levels;	chr15:53925822	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.54	rs1026698	ENSG00000280362.1	RP11-643A5.3	6.26	8.77e-10	1.89e-07	0.34	0.28	Circulating chemerin levels;	chr15:53926365	chr15:53910769~53914712:+
THCA	cis	rs12664251	0.638	rs2782573	ENSG00000253194.1	RP11-351A11.1	-6.26	8.77e-10	1.89e-07	-0.38	-0.28	Schizophrenia;	chr6:119031549	chr6:118934785~119031541:+
THCA	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	6.26	8.78e-10	1.89e-07	0.28	0.28	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
THCA	cis	rs7809950	1	rs6976607	ENSG00000238832.1	snoU109	6.26	8.78e-10	1.89e-07	0.3	0.28	Coronary artery disease;	chr7:107582956	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.911	rs7778250	ENSG00000238832.1	snoU109	6.26	8.78e-10	1.89e-07	0.3	0.28	Coronary artery disease;	chr7:107584120	chr7:107603363~107603507:+
THCA	cis	rs838147	0.537	rs503279	ENSG00000232871.7	SEC1P	-6.26	8.79e-10	1.89e-07	-0.32	-0.28	Dietary macronutrient intake;	chr19:48705753	chr19:48638071~48682245:+
THCA	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-6.26	8.79e-10	1.89e-07	-0.29	-0.28	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
THCA	cis	rs4950322	0.518	rs61838951	ENSG00000278811.3	LINC00624	6.26	8.79e-10	1.89e-07	0.33	0.28	Protein quantitative trait loci;	chr1:147116081	chr1:147258885~147517875:-
THCA	cis	rs9677476	0.821	rs6708809	ENSG00000224376.1	AC017104.6	6.26	8.8e-10	1.89e-07	0.32	0.28	Food antigen IgG levels;	chr2:231248017	chr2:231388976~231394991:+
THCA	cis	rs1552244	0.882	rs7636817	ENSG00000232901.1	CYCSP10	6.26	8.8e-10	1.89e-07	0.35	0.28	Alzheimer's disease;	chr3:9973192	chr3:10000647~10000940:-
THCA	cis	rs9921338	0.961	rs4390613	ENSG00000262703.1	RP11-485G7.6	6.26	8.81e-10	1.89e-07	0.36	0.28	Vein graft stenosis in coronary artery bypass grafting;	chr16:11328979	chr16:11348143~11349321:-
THCA	cis	rs755249	0.958	rs61781370	ENSG00000228060.1	RP11-69E11.8	-6.26	8.81e-10	1.89e-07	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39565160~39573203:+
THCA	cis	rs3764021	0.506	rs11052372	ENSG00000256594.6	RP11-705C15.2	6.26	8.81e-10	1.89e-07	0.25	0.28	Type 1 diabetes;	chr12:9679363	chr12:9633419~9658412:+
THCA	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-6.26	8.82e-10	1.9e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
THCA	cis	rs2243480	1	rs466983	ENSG00000228409.4	CCT6P1	6.26	8.82e-10	1.9e-07	0.32	0.28	Diabetic kidney disease;	chr7:66055509	chr7:65751142~65763354:+
THCA	cis	rs6142102	0.961	rs4911407	ENSG00000275784.1	RP5-1125A11.6	-6.26	8.83e-10	1.9e-07	-0.29	-0.28	Skin pigmentation;	chr20:34095759	chr20:33989480~33991818:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	6.26	8.83e-10	1.9e-07	0.31	0.28	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
THCA	cis	rs1876905	0.68	rs354528	ENSG00000255389.1	C6orf3	6.26	8.83e-10	1.9e-07	0.33	0.28	Mean corpuscular hemoglobin;	chr6:111184068	chr6:111599875~111602295:+
THCA	cis	rs2880765	0.835	rs4281668	ENSG00000259295.5	CSPG4P12	6.26	8.84e-10	1.9e-07	0.35	0.28	Coronary artery disease;	chr15:85504055	chr15:85191438~85213905:+
THCA	cis	rs690037	0.641	rs538525	ENSG00000272529.1	RP11-415F23.4	-6.26	8.84e-10	1.9e-07	-0.25	-0.28	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334772	chr3:16345126~16346440:+
THCA	cis	rs755249	0.958	rs2068663	ENSG00000228060.1	RP11-69E11.8	-6.26	8.85e-10	1.9e-07	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39565160~39573203:+
THCA	cis	rs741668	1	rs17067467	ENSG00000235903.6	CPB2-AS1	6.26	8.85e-10	1.9e-07	0.36	0.28	Cerebrospinal fluid clusterin levels;	chr13:45943774	chr13:46052806~46113332:+
THCA	cis	rs944990	0.557	rs4743927	ENSG00000227603.1	RP11-165J3.6	6.26	8.86e-10	1.9e-07	0.28	0.28	Body mass index;	chr9:93510364	chr9:93435332~93437121:-
THCA	cis	rs944990	0.576	rs6479492	ENSG00000227603.1	RP11-165J3.6	6.26	8.86e-10	1.9e-07	0.28	0.28	Body mass index;	chr9:93513684	chr9:93435332~93437121:-
THCA	cis	rs6142102	1	rs4911412	ENSG00000275784.1	RP5-1125A11.6	-6.26	8.87e-10	1.91e-07	-0.29	-0.28	Skin pigmentation;	chr20:34128629	chr20:33989480~33991818:-
THCA	cis	rs1318937	1	rs8225	ENSG00000224660.1	SH3BP5-AS1	6.26	8.88e-10	1.91e-07	0.18	0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15264363	chr3:15254184~15264493:+
THCA	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	6.26	8.88e-10	1.91e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	6.26	8.88e-10	1.91e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	6.26	8.88e-10	1.91e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	6.26	8.88e-10	1.91e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	6.26	8.88e-10	1.91e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	6.26	8.88e-10	1.91e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
THCA	cis	rs4835473	0.771	rs4261935	ENSG00000251600.4	RP11-673E1.1	6.26	8.88e-10	1.91e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143979751	chr4:143912331~143982454:+
THCA	cis	rs3806843	1	rs13157397	ENSG00000202515.1	VTRNA1-3	-6.26	8.89e-10	1.91e-07	-0.31	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140804857	chr5:140726158~140726246:+
THCA	cis	rs2562456	0.833	rs62109223	ENSG00000268555.1	RP11-678G14.3	6.26	8.89e-10	1.91e-07	0.45	0.28	Pain;	chr19:21349591	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62109225	ENSG00000268555.1	RP11-678G14.3	6.26	8.89e-10	1.91e-07	0.45	0.28	Pain;	chr19:21353861	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.754	rs62109226	ENSG00000268555.1	RP11-678G14.3	6.26	8.89e-10	1.91e-07	0.45	0.28	Pain;	chr19:21354111	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.754	rs62109227	ENSG00000268555.1	RP11-678G14.3	6.26	8.89e-10	1.91e-07	0.45	0.28	Pain;	chr19:21354128	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.754	rs62109228	ENSG00000268555.1	RP11-678G14.3	6.26	8.89e-10	1.91e-07	0.45	0.28	Pain;	chr19:21354129	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs8102783	ENSG00000268555.1	RP11-678G14.3	6.26	8.89e-10	1.91e-07	0.45	0.28	Pain;	chr19:21355751	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs2061916	ENSG00000268555.1	RP11-678G14.3	6.26	8.89e-10	1.91e-07	0.45	0.28	Pain;	chr19:21358906	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs4359573	ENSG00000268555.1	RP11-678G14.3	6.26	8.89e-10	1.91e-07	0.45	0.28	Pain;	chr19:21359494	chr19:21570822~21587322:-
THCA	cis	rs6088580	0.524	rs6088552	ENSG00000269202.1	RP4-614O4.12	6.26	8.9e-10	1.91e-07	0.24	0.28	Glomerular filtration rate (creatinine);	chr20:34638687	chr20:35201747~35203288:-
THCA	cis	rs7829975	0.774	rs1703982	ENSG00000254153.1	CTA-398F10.2	6.26	8.9e-10	1.91e-07	0.3	0.28	Mood instability;	chr8:8740878	chr8:8456909~8461337:-
THCA	cis	rs7246657	0.943	rs8109038	ENSG00000226686.6	LINC01535	6.26	8.91e-10	1.91e-07	0.42	0.28	Coronary artery calcification;	chr19:37524807	chr19:37251912~37265535:+
THCA	cis	rs227275	0.525	rs9917919	ENSG00000230069.3	LRRC37A15P	-6.26	8.91e-10	1.91e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.873	rs6533041	ENSG00000251288.2	RP11-10L12.2	-6.26	8.91e-10	1.91e-07	-0.37	-0.28	Schizophrenia;	chr4:102951615	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs4699037	ENSG00000251288.2	RP11-10L12.2	-6.26	8.91e-10	1.91e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs3857198	ENSG00000251288.2	RP11-10L12.2	-6.26	8.91e-10	1.91e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.935	rs3857199	ENSG00000251288.2	RP11-10L12.2	-6.26	8.91e-10	1.91e-07	-0.37	-0.28	Schizophrenia;	chr4:102957991	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs4699039	ENSG00000251288.2	RP11-10L12.2	-6.26	8.91e-10	1.91e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.869	rs223323	ENSG00000230069.3	LRRC37A15P	-6.26	8.91e-10	1.91e-07	-0.3	-0.28	Schizophrenia;	chr4:102878412	chr4:102727274~102730721:-
THCA	cis	rs10131894	0.575	rs6574203	ENSG00000279594.1	RP11-950C14.10	6.26	8.93e-10	1.92e-07	0.26	0.28	Coronary artery disease;	chr14:74963143	chr14:75011269~75012851:-
THCA	cis	rs6142102	0.961	rs6087557	ENSG00000275784.1	RP5-1125A11.6	-6.26	8.93e-10	1.92e-07	-0.28	-0.28	Skin pigmentation;	chr20:34110469	chr20:33989480~33991818:-
THCA	cis	rs227275	0.525	rs7672319	ENSG00000230069.3	LRRC37A15P	-6.26	8.93e-10	1.92e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs6533051	ENSG00000230069.3	LRRC37A15P	-6.26	8.93e-10	1.92e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102727274~102730721:-
THCA	cis	rs853679	0.513	rs9468296	ENSG00000261839.1	RP1-265C24.8	6.26	8.93e-10	1.92e-07	0.33	0.28	Depression;	chr6:28145952	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000261839.1	RP1-265C24.8	6.26	8.93e-10	1.92e-07	0.33	0.28	Depression;	chr6:28147378	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000261839.1	RP1-265C24.8	6.26	8.93e-10	1.92e-07	0.33	0.28	Depression;	chr6:28147406	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000261839.1	RP1-265C24.8	6.26	8.93e-10	1.92e-07	0.33	0.28	Depression;	chr6:28148143	chr6:28136849~28139678:+
THCA	cis	rs9926296	0.712	rs258332	ENSG00000274627.1	RP11-104N10.2	6.26	8.94e-10	1.92e-07	0.29	0.28	Vitiligo;	chr16:89661275	chr16:89516797~89522217:+
THCA	cis	rs686320	0.748	rs580933	ENSG00000245532.5	NEAT1	-6.26	8.94e-10	1.92e-07	-0.28	-0.28	Hip circumference adjusted for BMI;	chr11:65429413	chr11:65422774~65445540:+
THCA	cis	rs748404	0.723	rs512431	ENSG00000166763.7	STRCP1	-6.26	8.94e-10	1.92e-07	-0.3	-0.28	Lung cancer;	chr15:43249741	chr15:43699488~43718184:-
THCA	cis	rs3822625	0.867	rs76418981	ENSG00000271828.1	CTD-2310F14.1	6.26	8.94e-10	1.92e-07	0.71	0.28	Breast cancer (early onset);	chr5:56834707	chr5:56927874~56929573:+
THCA	cis	rs3822625	1	rs16886397	ENSG00000271828.1	CTD-2310F14.1	6.26	8.94e-10	1.92e-07	0.71	0.28	Breast cancer (early onset);	chr5:56838449	chr5:56927874~56929573:+
THCA	cis	rs3822625	1	rs16886420	ENSG00000271828.1	CTD-2310F14.1	6.26	8.94e-10	1.92e-07	0.71	0.28	Breast cancer (early onset);	chr5:56847172	chr5:56927874~56929573:+
THCA	cis	rs3822625	1	rs9686160	ENSG00000271828.1	CTD-2310F14.1	6.26	8.94e-10	1.92e-07	0.71	0.28	Breast cancer (early onset);	chr5:56876174	chr5:56927874~56929573:+
THCA	cis	rs3822625	1	rs9687226	ENSG00000271828.1	CTD-2310F14.1	6.26	8.94e-10	1.92e-07	0.71	0.28	Breast cancer (early onset);	chr5:56880619	chr5:56927874~56929573:+
THCA	cis	rs10208649	0.505	rs10200897	ENSG00000272156.1	RP11-477N3.1	6.25	8.95e-10	1.92e-07	0.38	0.28	Body mass index;	chr2:53731345	chr2:54082554~54085066:+
THCA	cis	rs9926296	0.546	rs7187436	ENSG00000260259.1	RP11-368I7.4	-6.25	8.95e-10	1.92e-07	-0.3	-0.28	Vitiligo;	chr16:89778702	chr16:89682620~89686569:-
THCA	cis	rs7809950	0.953	rs1468336	ENSG00000238832.1	snoU109	6.25	8.95e-10	1.92e-07	0.3	0.28	Coronary artery disease;	chr7:107567805	chr7:107603363~107603507:+
THCA	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-6.25	8.95e-10	1.92e-07	-0.28	-0.28	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
THCA	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-6.25	8.96e-10	1.92e-07	-0.36	-0.28	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
THCA	cis	rs2976388	0.566	rs4736301	ENSG00000253741.1	CTD-2292P10.4	6.25	8.97e-10	1.93e-07	0.36	0.28	Urinary tract infection frequency;	chr8:142748081	chr8:142702252~142726973:-
THCA	cis	rs11096990	0.964	rs6831700	ENSG00000249207.1	RP11-360F5.1	-6.25	8.97e-10	1.93e-07	-0.36	-0.28	Cognitive function;	chr4:39255344	chr4:39112677~39126818:-
THCA	cis	rs9309473	0.519	rs6746971	ENSG00000163016.8	ALMS1P	6.25	8.97e-10	1.93e-07	0.36	0.28	Metabolite levels;	chr2:73442334	chr2:73644919~73685576:+
THCA	cis	rs7927592	0.731	rs11228275	ENSG00000212093.1	AP000807.1	-6.25	8.98e-10	1.93e-07	-0.29	-0.28	Total body bone mineral density;	chr11:68536512	chr11:68506083~68506166:-
THCA	cis	rs1865760	1	rs6905887	ENSG00000272462.2	U91328.19	-6.25	8.98e-10	1.93e-07	-0.23	-0.28	Height;	chr6:25911875	chr6:25992662~26001775:+
THCA	cis	rs6142102	0.923	rs4911379	ENSG00000275784.1	RP5-1125A11.6	-6.25	8.98e-10	1.93e-07	-0.28	-0.28	Skin pigmentation;	chr20:33947499	chr20:33989480~33991818:-
THCA	cis	rs227275	0.525	rs6853193	ENSG00000251288.2	RP11-10L12.2	-6.25	8.99e-10	1.93e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102751401~102752641:+
THCA	cis	rs2243480	1	rs1723267	ENSG00000228409.4	CCT6P1	6.25	8.99e-10	1.93e-07	0.32	0.28	Diabetic kidney disease;	chr7:66008327	chr7:65751142~65763354:+
THCA	cis	rs72843506	0.722	rs9908032	ENSG00000270091.1	RP11-78O7.2	-6.25	8.99e-10	1.93e-07	-0.3	-0.28	Schizophrenia;	chr17:20204871	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.722	rs12051550	ENSG00000270091.1	RP11-78O7.2	-6.25	8.99e-10	1.93e-07	-0.3	-0.28	Schizophrenia;	chr17:20226233	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.722	rs75226250	ENSG00000270091.1	RP11-78O7.2	-6.25	8.99e-10	1.93e-07	-0.3	-0.28	Schizophrenia;	chr17:20229004	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.722	rs9901484	ENSG00000270091.1	RP11-78O7.2	-6.25	8.99e-10	1.93e-07	-0.3	-0.28	Schizophrenia;	chr17:20229581	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.722	rs78477504	ENSG00000270091.1	RP11-78O7.2	-6.25	8.99e-10	1.93e-07	-0.3	-0.28	Schizophrenia;	chr17:20235034	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs16959946	ENSG00000270091.1	RP11-78O7.2	-6.25	8.99e-10	1.93e-07	-0.3	-0.28	Schizophrenia;	chr17:20269134	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.722	rs76309839	ENSG00000270091.1	RP11-78O7.2	-6.25	8.99e-10	1.93e-07	-0.3	-0.28	Schizophrenia;	chr17:20272147	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.652	rs28550747	ENSG00000270091.1	RP11-78O7.2	-6.25	8.99e-10	1.93e-07	-0.3	-0.28	Schizophrenia;	chr17:20274999	chr17:19896590~19897287:-
THCA	cis	rs7849973	0.579	rs10965453	ENSG00000224549.1	RP11-370B11.3	6.25	9.01e-10	1.94e-07	0.34	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22778493	chr9:22767175~22768316:+
THCA	cis	rs6951245	0.554	rs2070118	ENSG00000229043.2	AC091729.9	-6.25	9.02e-10	1.94e-07	-0.37	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092869	chr7:1160374~1165267:+
THCA	cis	rs1395	0.848	rs6716850	ENSG00000234072.1	AC074117.10	-6.25	9.03e-10	1.94e-07	-0.23	-0.28	Blood metabolite levels;	chr2:27302482	chr2:27356246~27367622:+
THCA	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	6.25	9.03e-10	1.94e-07	0.41	0.28	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
THCA	cis	rs853679	0.505	rs200992	ENSG00000219392.1	RP1-265C24.5	-6.25	9.03e-10	1.94e-07	-0.48	-0.28	Depression;	chr6:27846899	chr6:28115628~28116551:+
THCA	cis	rs9649465	0.806	rs6971297	ENSG00000272686.1	RP11-390E23.6	6.25	9.03e-10	1.94e-07	0.18	0.28	Migraine;	chr7:123653288	chr7:123749068~123751166:+
THCA	cis	rs2243480	1	rs437889	ENSG00000232546.1	RP11-458F8.1	-6.25	9.03e-10	1.94e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66044247	chr7:66848496~66858136:+
THCA	cis	rs848490	0.851	rs11761228	ENSG00000214293.7	APTR	6.25	9.04e-10	1.94e-07	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77833181	chr7:77657660~77696265:-
THCA	cis	rs853679	0.713	rs200991	ENSG00000280107.1	AL022393.9	6.25	9.04e-10	1.94e-07	0.36	0.28	Depression;	chr6:27847716	chr6:28170845~28172521:+
THCA	cis	rs12681366	0.683	rs2450572	ENSG00000253704.1	RP11-267M23.4	-6.25	9.04e-10	1.94e-07	-0.27	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94412107	chr8:94553722~94569745:+
THCA	cis	rs516805	0.63	rs696650	ENSG00000279453.1	RP3-425C14.4	-6.25	9.06e-10	1.94e-07	-0.29	-0.28	Lymphocyte counts;	chr6:122261316	chr6:122436789~122439223:-
THCA	cis	rs11148252	0.846	rs13431	ENSG00000235660.1	LINC00345	-6.25	9.06e-10	1.95e-07	-0.34	-0.28	Lewy body disease;	chr13:52413342	chr13:52484161~52484680:-
THCA	cis	rs10129255	1	rs10129255	ENSG00000211974.3	IGHV2-70	-6.25	9.07e-10	1.95e-07	-0.21	-0.28	Kawasaki disease;	chr14:106767970	chr14:106723574~106724093:-
THCA	cis	rs62103177	0.673	rs7242867	ENSG00000261126.6	RP11-795F19.1	6.25	9.07e-10	1.95e-07	0.27	0.28	Opioid sensitivity;	chr18:79843270	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.714	rs7227962	ENSG00000261126.6	RP11-795F19.1	6.25	9.07e-10	1.95e-07	0.27	0.28	Opioid sensitivity;	chr18:79843283	chr18:80046900~80095482:+
THCA	cis	rs72949976	0.584	rs12471471	ENSG00000270659.1	RP11-105N14.1	6.25	9.07e-10	1.95e-07	0.22	0.28	Squamous cell lung carcinoma;Lung cancer;	chr2:213158328	chr2:213152970~213153659:+
THCA	cis	rs2243480	0.901	rs778732	ENSG00000228409.4	CCT6P1	6.25	9.07e-10	1.95e-07	0.32	0.28	Diabetic kidney disease;	chr7:66357373	chr7:65751142~65763354:+
THCA	cis	rs736801	0.808	rs72797303	ENSG00000233006.5	AC034220.3	6.25	9.07e-10	1.95e-07	0.22	0.28	Mosquito bite size;Breast cancer;	chr5:132460471	chr5:132311285~132369916:-
THCA	cis	rs736801	0.808	rs72797306	ENSG00000233006.5	AC034220.3	6.25	9.07e-10	1.95e-07	0.22	0.28	Mosquito bite size;Breast cancer;	chr5:132465058	chr5:132311285~132369916:-
THCA	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	6.25	9.07e-10	1.95e-07	0.4	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
THCA	cis	rs227275	0.554	rs223319	ENSG00000251288.2	RP11-10L12.2	-6.25	9.08e-10	1.95e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102751401~102752641:+
THCA	cis	rs228614	0.509	rs223318	ENSG00000251288.2	RP11-10L12.2	-6.25	9.08e-10	1.95e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223315	ENSG00000251288.2	RP11-10L12.2	-6.25	9.08e-10	1.95e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102751401~102752641:+
THCA	cis	rs2243480	1	rs313809	ENSG00000228409.4	CCT6P1	6.25	9.09e-10	1.95e-07	0.32	0.28	Diabetic kidney disease;	chr7:66034996	chr7:65751142~65763354:+
THCA	cis	rs3822625	1	rs79953845	ENSG00000271828.1	CTD-2310F14.1	6.25	9.09e-10	1.95e-07	0.71	0.28	Breast cancer (early onset);	chr5:56828967	chr5:56927874~56929573:+
THCA	cis	rs7976269	0.609	rs2349574	ENSG00000257176.2	RP11-996F15.2	-6.25	9.1e-10	1.95e-07	-0.28	-0.28	Male-pattern baldness;	chr12:29053805	chr12:29280418~29317848:-
THCA	cis	rs34779708	0.733	rs11010146	ENSG00000271335.4	RP11-324I22.4	6.25	9.1e-10	1.95e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs7086715	ENSG00000271335.4	RP11-324I22.4	6.25	9.1e-10	1.95e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.702	rs7087150	ENSG00000271335.4	RP11-324I22.4	6.25	9.1e-10	1.95e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs60553075	ENSG00000271335.4	RP11-324I22.4	6.25	9.1e-10	1.95e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs12249814	ENSG00000271335.4	RP11-324I22.4	6.25	9.1e-10	1.95e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35314552~35336401:-
THCA	cis	rs9649465	0.967	rs10487806	ENSG00000272686.1	RP11-390E23.6	-6.25	9.11e-10	1.95e-07	-0.18	-0.28	Migraine;	chr7:123674392	chr7:123749068~123751166:+
THCA	cis	rs6600671	1	rs4844616	ENSG00000275538.1	RNVU1-19	6.25	9.11e-10	1.95e-07	0.35	0.28	Hip geometry;	chr1:121429348	chr1:120850819~120850985:-
THCA	cis	rs2880765	0.546	rs11639291	ENSG00000259295.5	CSPG4P12	6.25	9.12e-10	1.96e-07	0.42	0.28	Coronary artery disease;	chr15:85520899	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.546	rs35316253	ENSG00000259295.5	CSPG4P12	6.25	9.12e-10	1.96e-07	0.42	0.28	Coronary artery disease;	chr15:85522329	chr15:85191438~85213905:+
THCA	cis	rs11603023	0.874	rs613243	ENSG00000278376.1	RP11-158I9.8	-6.25	9.12e-10	1.96e-07	-0.21	-0.28	Cholesterol, total;	chr11:118643304	chr11:118791254~118793137:+
THCA	cis	rs7247513	0.897	rs12972944	ENSG00000213290.4	PGK1P2	-6.25	9.12e-10	1.96e-07	-0.34	-0.28	Bipolar disorder;	chr19:12602994	chr19:12559571~12561105:+
THCA	cis	rs442309	0.551	rs10995305	ENSG00000238280.1	RP11-436D10.3	-6.25	9.13e-10	1.96e-07	-0.33	-0.28	Vogt-Koyanagi-Harada syndrome;	chr10:62781150	chr10:62793562~62805887:-
THCA	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	6.25	9.13e-10	1.96e-07	0.45	0.28	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
THCA	cis	rs3204270	0.673	rs62077190	ENSG00000262049.1	RP13-1032I1.7	6.25	9.13e-10	1.96e-07	0.26	0.28	Dental caries;	chr17:81709079	chr17:81701324~81703300:-
THCA	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	6.25	9.13e-10	1.96e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	6.25	9.13e-10	1.96e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	6.25	9.13e-10	1.96e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
THCA	cis	rs12908161	0.92	rs35738019	ENSG00000259295.5	CSPG4P12	6.25	9.14e-10	1.96e-07	0.42	0.28	Schizophrenia;	chr15:84736979	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs34570071	ENSG00000259295.5	CSPG4P12	6.25	9.14e-10	1.96e-07	0.42	0.28	Schizophrenia;	chr15:84736981	chr15:85191438~85213905:+
THCA	cis	rs7208859	0.614	rs216412	ENSG00000263603.1	CTD-2349P21.5	6.25	9.15e-10	1.96e-07	0.44	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30729469~30731202:+
THCA	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-6.25	9.16e-10	1.96e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
THCA	cis	rs72843506	0.586	rs56153261	ENSG00000270091.1	RP11-78O7.2	-6.25	9.17e-10	1.97e-07	-0.3	-0.28	Schizophrenia;	chr17:19904200	chr17:19896590~19897287:-
THCA	cis	rs227275	0.525	rs5028609	ENSG00000230069.3	LRRC37A15P	-6.25	9.18e-10	1.97e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs6815540	ENSG00000230069.3	LRRC37A15P	-6.25	9.18e-10	1.97e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs4698867	ENSG00000230069.3	LRRC37A15P	-6.25	9.18e-10	1.97e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs7663876	ENSG00000230069.3	LRRC37A15P	-6.25	9.18e-10	1.97e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs6821173	ENSG00000230069.3	LRRC37A15P	-6.25	9.18e-10	1.97e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102727274~102730721:-
THCA	cis	rs10875746	0.951	rs2286021	ENSG00000269514.1	RP11-370I10.12	6.25	9.18e-10	1.97e-07	0.28	0.28	Longevity (90 years and older);	chr12:48134437	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs11168427	ENSG00000269514.1	RP11-370I10.12	6.25	9.18e-10	1.97e-07	0.28	0.28	Longevity (90 years and older);	chr12:48145196	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.951	rs61918826	ENSG00000269514.1	RP11-370I10.12	6.25	9.18e-10	1.97e-07	0.28	0.28	Longevity (90 years and older);	chr12:48150195	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.904	rs10875750	ENSG00000269514.1	RP11-370I10.12	6.25	9.18e-10	1.97e-07	0.28	0.28	Longevity (90 years and older);	chr12:48151847	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.951	rs7485355	ENSG00000269514.1	RP11-370I10.12	6.25	9.18e-10	1.97e-07	0.28	0.28	Longevity (90 years and older);	chr12:48154559	chr12:48198387~48202031:+
THCA	cis	rs593531	0.571	rs10898983	ENSG00000212961.4	HNRNPA1P40	6.25	9.18e-10	1.97e-07	0.35	0.28	Neuroticism;	chr11:74382947	chr11:74354443~74355720:+
THCA	cis	rs4948102	0.642	rs4948104	ENSG00000273720.1	RP11-613E4.4	-6.25	9.18e-10	1.97e-07	-0.37	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55743073~55743457:+
THCA	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-6.25	9.18e-10	1.97e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-6.25	9.18e-10	1.97e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
THCA	cis	rs8042680	0.522	rs10775251	ENSG00000214432.8	AC068831.10	-6.25	9.19e-10	1.97e-07	-0.3	-0.28	Type 2 diabetes;	chr15:91011195	chr15:91022619~91036611:+
THCA	cis	rs2765539	0.572	rs2361274	ENSG00000231365.4	RP11-418J17.1	-6.25	9.19e-10	1.97e-07	-0.31	-0.28	Waist-hip ratio;	chr1:119062604	chr1:119140396~119275973:+
THCA	cis	rs2562456	0.917	rs2562466	ENSG00000268081.1	RP11-678G14.2	-6.25	9.19e-10	1.97e-07	-0.4	-0.28	Pain;	chr19:21531402	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.917	rs2562468	ENSG00000268081.1	RP11-678G14.2	-6.25	9.19e-10	1.97e-07	-0.4	-0.28	Pain;	chr19:21532048	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.917	rs2562471	ENSG00000268081.1	RP11-678G14.2	-6.25	9.19e-10	1.97e-07	-0.4	-0.28	Pain;	chr19:21533017	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.917	rs2681377	ENSG00000268081.1	RP11-678G14.2	-6.25	9.19e-10	1.97e-07	-0.4	-0.28	Pain;	chr19:21533718	chr19:21554640~21569237:-
THCA	cis	rs10875746	0.669	rs10875792	ENSG00000269514.1	RP11-370I10.12	6.25	9.19e-10	1.97e-07	0.28	0.28	Longevity (90 years and older);	chr12:48303640	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.623	rs10875793	ENSG00000269514.1	RP11-370I10.12	6.25	9.19e-10	1.97e-07	0.28	0.28	Longevity (90 years and older);	chr12:48303647	chr12:48198387~48202031:+
THCA	cis	rs227275	0.525	rs6533050	ENSG00000230069.3	LRRC37A15P	-6.25	9.2e-10	1.97e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102727274~102730721:-
THCA	cis	rs7727544	0.544	rs55722650	ENSG00000233006.5	AC034220.3	6.25	9.2e-10	1.97e-07	0.23	0.28	Blood metabolite levels;	chr5:132271607	chr5:132311285~132369916:-
THCA	cis	rs6928977	0.896	rs2614284	ENSG00000231028.7	LINC00271	6.25	9.21e-10	1.97e-07	0.22	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135368697	chr6:135497801~135716055:+
THCA	cis	rs853679	0.517	rs3734573	ENSG00000261839.1	RP1-265C24.8	6.25	9.21e-10	1.97e-07	0.33	0.28	Depression;	chr6:28091659	chr6:28136849~28139678:+
THCA	cis	rs6991838	0.806	rs4285523	ENSG00000200714.1	Y_RNA	6.25	9.21e-10	1.97e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65592731~65592820:+
THCA	cis	rs4950322	0.542	rs4950384	ENSG00000278811.3	LINC00624	6.25	9.21e-10	1.97e-07	0.34	0.28	Protein quantitative trait loci;	chr1:147177310	chr1:147258885~147517875:-
THCA	cis	rs516805	0.528	rs2679703	ENSG00000279453.1	RP3-425C14.4	-6.25	9.22e-10	1.98e-07	-0.3	-0.28	Lymphocyte counts;	chr6:122099490	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2606632	ENSG00000279453.1	RP3-425C14.4	-6.25	9.22e-10	1.98e-07	-0.3	-0.28	Lymphocyte counts;	chr6:122099728	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2606634	ENSG00000279453.1	RP3-425C14.4	-6.25	9.22e-10	1.98e-07	-0.3	-0.28	Lymphocyte counts;	chr6:122100337	chr6:122436789~122439223:-
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000232546.1	RP11-458F8.1	-6.25	9.22e-10	1.98e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65951319	chr7:66848496~66858136:+
THCA	cis	rs17772222	0.917	rs8006652	ENSG00000222990.1	RNU4-22P	6.25	9.22e-10	1.98e-07	0.35	0.28	Coronary artery calcification;	chr14:88631290	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs12587200	ENSG00000222990.1	RNU4-22P	6.25	9.22e-10	1.98e-07	0.35	0.28	Coronary artery calcification;	chr14:88632060	chr14:88513498~88513663:+
THCA	cis	rs699371	0.525	rs7156302	ENSG00000270000.1	RP3-449M8.9	6.25	9.22e-10	1.98e-07	0.26	0.28	Height;	chr14:74428260	chr14:74471930~74472360:-
THCA	cis	rs7712401	0.755	rs13172043	ENSG00000249996.1	RP11-359P5.1	6.25	9.22e-10	1.98e-07	0.27	0.28	Mean platelet volume;	chr5:122849064	chr5:123036271~123054667:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000261839.1	RP1-265C24.8	6.25	9.22e-10	1.98e-07	0.33	0.28	Depression;	chr6:28149979	chr6:28136849~28139678:+
THCA	cis	rs5758659	0.714	rs5758574	ENSG00000227370.1	RP4-669P10.19	6.25	9.24e-10	1.98e-07	0.25	0.28	Cognitive function;	chr22:42085396	chr22:42132543~42132998:+
THCA	cis	rs7202877	0.706	rs40217	ENSG00000261783.1	RP11-252K23.2	6.25	9.24e-10	1.98e-07	0.49	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75446168	chr16:75379818~75381260:-
THCA	cis	rs4143844	0.867	rs11629741	ENSG00000259251.2	RP11-643M14.1	6.25	9.25e-10	1.98e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61892783	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs34796280	ENSG00000259251.2	RP11-643M14.1	6.25	9.25e-10	1.98e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61893680	chr15:62060503~62062434:+
THCA	cis	rs656319	0.607	rs55836143	ENSG00000261451.1	RP11-981G7.1	-6.25	9.25e-10	1.98e-07	-0.36	-0.28	Myopia (pathological);	chr8:10242560	chr8:10433672~10438312:+
THCA	cis	rs7727544	0.684	rs272869	ENSG00000237714.1	P4HA2-AS1	6.25	9.26e-10	1.98e-07	0.36	0.28	Blood metabolite levels;	chr5:132342304	chr5:132184876~132192808:+
THCA	cis	rs1789	0.526	rs4698393	ENSG00000273133.1	RP11-799M12.2	-6.25	9.27e-10	1.99e-07	-0.36	-0.28	Blood protein levels;	chr4:15525474	chr4:15563698~15564253:-
THCA	cis	rs1789	0.558	rs4698394	ENSG00000273133.1	RP11-799M12.2	-6.25	9.27e-10	1.99e-07	-0.36	-0.28	Blood protein levels;	chr4:15525475	chr4:15563698~15564253:-
THCA	cis	rs867529	0.6	rs335120	ENSG00000234028.3	AC062029.1	-6.25	9.27e-10	1.99e-07	-0.23	-0.28	Height;	chr2:88773214	chr2:88627539~88631821:+
THCA	cis	rs10875746	0.669	rs2279464	ENSG00000269514.1	RP11-370I10.12	6.25	9.27e-10	1.99e-07	0.28	0.28	Longevity (90 years and older);	chr12:48296626	chr12:48198387~48202031:+
THCA	cis	rs12908161	0.853	rs12912342	ENSG00000259728.4	LINC00933	6.25	9.27e-10	1.99e-07	0.36	0.28	Schizophrenia;	chr15:84704985	chr15:84570649~84580175:+
THCA	cis	rs7617773	0.963	rs9822496	ENSG00000228638.1	FCF1P2	-6.25	9.27e-10	1.99e-07	-0.26	-0.28	Coronary artery disease;	chr3:48139843	chr3:48290793~48291375:-
THCA	cis	rs728616	0.764	rs12413678	ENSG00000225484.5	NUTM2B-AS1	-6.25	9.28e-10	1.99e-07	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927343	chr10:79663088~79826594:-
THCA	cis	rs853679	0.517	rs4713152	ENSG00000261839.1	RP1-265C24.8	6.25	9.28e-10	1.99e-07	0.33	0.28	Depression;	chr6:28169676	chr6:28136849~28139678:+
THCA	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-6.25	9.29e-10	1.99e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-6.25	9.29e-10	1.99e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-6.25	9.29e-10	1.99e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-6.25	9.29e-10	1.99e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
THCA	cis	rs11158026	0.575	rs8008150	ENSG00000258413.1	RP11-665C16.6	-6.25	9.3e-10	1.99e-07	-0.39	-0.28	Parkinson's disease;	chr14:54954718	chr14:55262767~55272075:-
THCA	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	6.25	9.31e-10	1.99e-07	0.3	0.28	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
THCA	cis	rs9926296	0.527	rs1800335	ENSG00000260259.1	RP11-368I7.4	-6.25	9.31e-10	1.99e-07	-0.3	-0.28	Vitiligo;	chr16:89779787	chr16:89682620~89686569:-
THCA	cis	rs11971779	0.651	rs74368518	ENSG00000273391.1	RP11-634H22.1	6.25	9.31e-10	1.99e-07	0.3	0.28	Diisocyanate-induced asthma;	chr7:139319581	chr7:139359032~139359566:-
THCA	cis	rs4273100	0.79	rs60166680	ENSG00000265185.4	SNORD3B-1	6.25	9.32e-10	2e-07	0.41	0.28	Schizophrenia;	chr17:19374231	chr17:19061912~19062669:+
THCA	cis	rs897984	0.806	rs8052245	ENSG00000279196.1	RP11-1072A3.3	-6.25	9.32e-10	2e-07	-0.28	-0.28	Dementia with Lewy bodies;	chr16:30905109	chr16:30984630~30988270:-
THCA	cis	rs7727544	0.508	rs10900804	ENSG00000224431.1	AC063976.7	6.25	9.32e-10	2e-07	0.25	0.28	Blood metabolite levels;	chr5:132066152	chr5:132199456~132203487:+
THCA	cis	rs2765539	0.851	rs1409158	ENSG00000231365.4	RP11-418J17.1	6.25	9.33e-10	2e-07	0.3	0.28	Waist-hip ratio;	chr1:118996267	chr1:119140396~119275973:+
THCA	cis	rs2765539	0.851	rs1409159	ENSG00000231365.4	RP11-418J17.1	-6.25	9.33e-10	2e-07	-0.3	-0.28	Waist-hip ratio;	chr1:118995810	chr1:119140396~119275973:+
THCA	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-6.25	9.35e-10	2e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
THCA	cis	rs227275	0.525	rs6533052	ENSG00000230069.3	LRRC37A15P	-6.25	9.36e-10	2e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs13117110	ENSG00000230069.3	LRRC37A15P	-6.25	9.36e-10	2e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs13144033	ENSG00000230069.3	LRRC37A15P	-6.25	9.36e-10	2e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102727274~102730721:-
THCA	cis	rs7811142	0.945	rs6974282	ENSG00000078319.8	PMS2P1	-6.25	9.36e-10	2e-07	-0.4	-0.28	Platelet count;	chr7:100500672	chr7:100320992~100341908:-
THCA	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-6.25	9.37e-10	2e-07	-0.31	-0.28	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
THCA	cis	rs10129255	0.957	rs4387509	ENSG00000211974.3	IGHV2-70	6.25	9.37e-10	2.01e-07	0.22	0.28	Kawasaki disease;	chr14:106704386	chr14:106723574~106724093:-
THCA	cis	rs6479891	1	rs9414788	ENSG00000232075.1	MRPL35P2	-6.25	9.38e-10	2.01e-07	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63634317~63634827:-
THCA	cis	rs8007846	0.588	rs2411405	ENSG00000276116.2	FUT8-AS1	6.25	9.38e-10	2.01e-07	0.28	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65765368	chr14:65411170~65412690:-
THCA	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	6.25	9.39e-10	2.01e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	6.25	9.39e-10	2.01e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	6.25	9.39e-10	2.01e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	6.25	9.39e-10	2.01e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
THCA	cis	rs4650994	0.525	rs11806608	ENSG00000273384.1	RP5-1098D14.1	6.25	9.39e-10	2.01e-07	0.35	0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178542240	chr1:178651706~178652282:+
THCA	cis	rs227275	0.525	rs7698608	ENSG00000230069.3	LRRC37A15P	-6.25	9.4e-10	2.01e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102727274~102730721:-
THCA	cis	rs11158026	0.757	rs7157085	ENSG00000258413.1	RP11-665C16.6	-6.25	9.4e-10	2.01e-07	-0.38	-0.28	Parkinson's disease;	chr14:54978028	chr14:55262767~55272075:-
THCA	cis	rs712022	0.933	rs7129430	ENSG00000246225.5	RP11-17A1.3	-6.25	9.4e-10	2.01e-07	-0.35	-0.28	Dialysis-related mortality;	chr11:22806924	chr11:22829380~22945393:+
THCA	cis	rs8027521	0.54	rs2199612	ENSG00000280362.1	RP11-643A5.3	6.25	9.4e-10	2.01e-07	0.34	0.28	Circulating chemerin levels;	chr15:53941530	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.54	rs11071011	ENSG00000280362.1	RP11-643A5.3	6.25	9.4e-10	2.01e-07	0.34	0.28	Circulating chemerin levels;	chr15:53941861	chr15:53910769~53914712:+
THCA	cis	rs6600671	1	rs2319969	ENSG00000223345.3	HIST2H2BA	6.25	9.41e-10	2.01e-07	0.31	0.28	Hip geometry;	chr1:121465481	chr1:121108210~121117257:-
THCA	cis	rs7851660	0.967	rs10818133	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97848066	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.933	rs12341377	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97848100	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs7851552	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97848370	chr9:97698922~97700734:+
THCA	cis	rs7851660	1	rs7851660	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97848477	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs12348304	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97848951	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs3758251	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97851418	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs10046805	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97851674	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs3758249	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97851858	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs3758248	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97852319	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs907577	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97852835	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.933	rs13302470	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97853271	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.933	rs1867277	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97853632	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.87	rs1867278	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97853667	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs1867280	ENSG00000214417.4	KRT18P13	-6.25	9.41e-10	2.01e-07	-0.23	-0.28	Strep throat;	chr9:97853784	chr9:97698922~97700734:+
THCA	cis	rs7615952	0.641	rs6438951	ENSG00000250012.1	RP11-124N2.1	-6.25	9.41e-10	2.01e-07	-0.27	-0.28	Blood pressure (smoking interaction);	chr3:125978156	chr3:126084220~126095349:+
THCA	cis	rs72843506	0.722	rs9897161	ENSG00000270091.1	RP11-78O7.2	-6.25	9.41e-10	2.01e-07	-0.3	-0.28	Schizophrenia;	chr17:20130957	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.722	rs9897168	ENSG00000270091.1	RP11-78O7.2	-6.25	9.41e-10	2.01e-07	-0.3	-0.28	Schizophrenia;	chr17:20130961	chr17:19896590~19897287:-
THCA	cis	rs6600671	1	rs7532615	ENSG00000275538.1	RNVU1-19	-6.25	9.42e-10	2.01e-07	-0.35	-0.28	Hip geometry;	chr1:121430980	chr1:120850819~120850985:-
THCA	cis	rs11148252	0.819	rs7336679	ENSG00000235660.1	LINC00345	-6.25	9.42e-10	2.01e-07	-0.35	-0.28	Lewy body disease;	chr13:52469198	chr13:52484161~52484680:-
THCA	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	6.25	9.42e-10	2.02e-07	0.32	0.28	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
THCA	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-6.25	9.44e-10	2.02e-07	-0.21	-0.28	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
THCA	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-6.25	9.44e-10	2.02e-07	-0.21	-0.28	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
THCA	cis	rs9402743	0.923	rs4896159	ENSG00000231028.7	LINC00271	-6.25	9.44e-10	2.02e-07	-0.22	-0.28	Systemic lupus erythematosus;	chr6:135650304	chr6:135497801~135716055:+
THCA	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	6.25	9.45e-10	2.02e-07	0.26	0.28	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
THCA	cis	rs6840360	0.606	rs2709814	ENSG00000251611.1	RP11-610P16.1	-6.25	9.45e-10	2.02e-07	-0.2	-0.28	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151407551~151408835:-
THCA	cis	rs9677476	0.818	rs9973675	ENSG00000224376.1	AC017104.6	6.25	9.46e-10	2.02e-07	0.32	0.28	Food antigen IgG levels;	chr2:231230771	chr2:231388976~231394991:+
THCA	cis	rs1859596	1	rs1017039	ENSG00000234456.6	MAGI2-AS3	6.25	9.46e-10	2.02e-07	0.27	0.28	Reading or mathematical ability;	chr7:79481476	chr7:79452877~79471208:+
THCA	cis	rs1859596	1	rs1017040	ENSG00000234456.6	MAGI2-AS3	6.25	9.46e-10	2.02e-07	0.27	0.28	Reading or mathematical ability;	chr7:79481522	chr7:79452877~79471208:+
THCA	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	6.25	9.48e-10	2.03e-07	0.34	0.28	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
THCA	cis	rs10875746	0.669	rs11168499	ENSG00000269514.1	RP11-370I10.12	6.25	9.48e-10	2.03e-07	0.28	0.28	Longevity (90 years and older);	chr12:48268887	chr12:48198387~48202031:+
THCA	cis	rs755249	1	rs2293476	ENSG00000228060.1	RP11-69E11.8	6.25	9.48e-10	2.03e-07	0.3	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39565160~39573203:+
THCA	cis	rs73607972	0.877	rs4290466	ENSG00000275191.1	RP11-36I17.2	6.25	9.48e-10	2.03e-07	0.45	0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53658122	chr16:53628256~53628816:-
THCA	cis	rs6545883	0.929	rs3732171	ENSG00000271889.1	RP11-493E12.1	6.25	9.48e-10	2.03e-07	0.27	0.28	Tuberculosis;	chr2:61522555	chr2:61151433~61162105:-
THCA	cis	rs17122278	0.613	rs572126	ENSG00000278376.1	RP11-158I9.8	-6.25	9.48e-10	2.03e-07	-0.25	-0.28	Total cholesterol levels;	chr11:118488446	chr11:118791254~118793137:+
THCA	cis	rs853679	0.599	rs13193295	ENSG00000219392.1	RP1-265C24.5	-6.25	9.48e-10	2.03e-07	-0.61	-0.28	Depression;	chr6:28035450	chr6:28115628~28116551:+
THCA	cis	rs8177876	0.749	rs754429	ENSG00000261061.1	RP11-303E16.2	-6.25	9.48e-10	2.03e-07	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81030770~81031485:+
THCA	cis	rs944990	0.576	rs883782	ENSG00000227603.1	RP11-165J3.6	6.25	9.48e-10	2.03e-07	0.29	0.28	Body mass index;	chr9:93520003	chr9:93435332~93437121:-
THCA	cis	rs2348418	0.798	rs10843161	ENSG00000247934.4	RP11-967K21.1	6.25	9.49e-10	2.03e-07	0.24	0.28	Lung function (FEV1);Lung function (FVC);	chr12:28367688	chr12:28163298~28190738:-
THCA	cis	rs2562456	0.917	rs9304987	ENSG00000268081.1	RP11-678G14.2	-6.25	9.49e-10	2.03e-07	-0.4	-0.28	Pain;	chr19:21499472	chr19:21554640~21569237:-
THCA	cis	rs2243480	1	rs35396113	ENSG00000232546.1	RP11-458F8.1	-6.24	9.49e-10	2.03e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66030474	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316315	ENSG00000229886.1	RP5-1132H15.3	-6.24	9.5e-10	2.03e-07	-0.39	-0.28	Diabetic kidney disease;	chr7:66126218	chr7:66025126~66031544:-
THCA	cis	rs79349575	0.691	rs28528789	ENSG00000248278.1	SUMO2P17	-6.24	9.5e-10	2.03e-07	-0.32	-0.28	Type 2 diabetes;	chr17:48909254	chr17:48874860~48908983:-
THCA	cis	rs9834975	0.967	rs7638180	ENSG00000272758.4	RP11-299J3.8	-6.24	9.5e-10	2.03e-07	-0.26	-0.28	Diastolic blood pressure;	chr3:122431449	chr3:122416207~122443180:+
THCA	cis	rs7976269	0.583	rs4931131	ENSG00000257176.2	RP11-996F15.2	-6.24	9.51e-10	2.03e-07	-0.29	-0.28	Male-pattern baldness;	chr12:29015898	chr12:29280418~29317848:-
THCA	cis	rs965513	0.524	rs1443432	ENSG00000236130.1	PTCSC2	-6.24	9.51e-10	2.03e-07	-0.23	-0.28	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97820913	chr9:97805935~97810008:-
THCA	cis	rs7727544	0.505	rs721121	ENSG00000224431.1	AC063976.7	6.24	9.53e-10	2.04e-07	0.24	0.28	Blood metabolite levels;	chr5:132070740	chr5:132199456~132203487:+
THCA	cis	rs7829975	0.777	rs560544	ENSG00000254153.1	CTA-398F10.2	6.24	9.53e-10	2.04e-07	0.3	0.28	Mood instability;	chr8:8779919	chr8:8456909~8461337:-
THCA	cis	rs442309	0.783	rs224111	ENSG00000238280.1	RP11-436D10.3	6.24	9.53e-10	2.04e-07	0.33	0.28	Vogt-Koyanagi-Harada syndrome;	chr10:62792250	chr10:62793562~62805887:-
THCA	cis	rs9813712	0.953	rs6782280	ENSG00000249846.5	RP11-77P16.4	6.24	9.53e-10	2.04e-07	0.33	0.28	Response to amphetamines;	chr3:130245370	chr3:130112550~130120579:+
THCA	cis	rs526231	0.819	rs568999	ENSG00000175749.11	EIF3KP1	6.24	9.54e-10	2.04e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103265657	chr5:103032376~103033031:+
THCA	cis	rs526231	0.819	rs411648	ENSG00000175749.11	EIF3KP1	6.24	9.54e-10	2.04e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103267201	chr5:103032376~103033031:+
THCA	cis	rs526231	0.819	rs2569016	ENSG00000175749.11	EIF3KP1	6.24	9.54e-10	2.04e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103267431	chr5:103032376~103033031:+
THCA	cis	rs526231	0.853	rs377192	ENSG00000175749.11	EIF3KP1	6.24	9.54e-10	2.04e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103267853	chr5:103032376~103033031:+
THCA	cis	rs9475752	0.564	rs6911654	ENSG00000231441.1	RP11-472M19.2	6.24	9.54e-10	2.04e-07	0.31	0.28	Menarche (age at onset);	chr6:56877566	chr6:56844002~56864078:+
THCA	cis	rs8141529	1	rs8141529	ENSG00000226471.5	CTA-292E10.6	-6.24	9.54e-10	2.04e-07	-0.23	-0.28	Lymphocyte counts;	chr22:28873704	chr22:28800683~28848559:+
THCA	cis	rs736801	0.78	rs2188962	ENSG00000233006.5	AC034220.3	6.24	9.55e-10	2.04e-07	0.23	0.28	Mosquito bite size;Breast cancer;	chr5:132435113	chr5:132311285~132369916:-
THCA	cis	rs4950322	0.57	rs3737855	ENSG00000278811.3	LINC00624	6.24	9.56e-10	2.04e-07	0.35	0.28	Protein quantitative trait loci;	chr1:147271257	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs4950316	ENSG00000278811.3	LINC00624	6.24	9.56e-10	2.04e-07	0.35	0.28	Protein quantitative trait loci;	chr1:147273712	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs2354428	ENSG00000278811.3	LINC00624	6.24	9.56e-10	2.04e-07	0.35	0.28	Protein quantitative trait loci;	chr1:147277512	chr1:147258885~147517875:-
THCA	cis	rs55665837	0.559	rs9667144	ENSG00000251991.1	RNU7-49P	-6.24	9.56e-10	2.04e-07	-0.33	-0.28	Vitamin D levels;	chr11:14399555	chr11:14478892~14478953:+
THCA	cis	rs2243480	1	rs160633	ENSG00000229886.1	RP5-1132H15.3	6.24	9.56e-10	2.04e-07	0.45	0.28	Diabetic kidney disease;	chr7:66063241	chr7:66025126~66031544:-
THCA	cis	rs8042680	1	rs12593261	ENSG00000214432.8	AC068831.10	-6.24	9.57e-10	2.05e-07	-0.3	-0.28	Type 2 diabetes;	chr15:90977089	chr15:91022619~91036611:+
THCA	cis	rs7746199	0.668	rs34864796	ENSG00000226314.6	ZNF192P1	-6.24	9.57e-10	2.05e-07	-0.52	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28161781~28169594:+
THCA	cis	rs7129556	0.954	rs11237220	ENSG00000254691.1	RP11-91P24.5	6.24	9.57e-10	2.05e-07	0.39	0.28	Weight loss (gastric bypass surgery);	chr11:77557415	chr11:77850604~77851511:+
THCA	cis	rs2299587	0.585	rs208751	ENSG00000253671.1	RP11-806O11.1	-6.24	9.57e-10	2.05e-07	-0.34	-0.28	Economic and political preferences;	chr8:17918581	chr8:17808941~17820868:+
THCA	cis	rs1005277	0.522	rs1208681	ENSG00000263064.2	RP11-291L22.7	6.24	9.57e-10	2.05e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38448689~38448949:+
THCA	cis	rs7851660	0.967	rs7043885	ENSG00000214417.4	KRT18P13	-6.24	9.57e-10	2.05e-07	-0.23	-0.28	Strep throat;	chr9:97834157	chr9:97698922~97700734:+
THCA	cis	rs8027521	0.56	rs1478189	ENSG00000280362.1	RP11-643A5.3	-6.24	9.57e-10	2.05e-07	-0.36	-0.28	Circulating chemerin levels;	chr15:53953744	chr15:53910769~53914712:+
THCA	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	6.24	9.58e-10	2.05e-07	0.36	0.28	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
THCA	cis	rs227275	0.525	rs10028116	ENSG00000251288.2	RP11-10L12.2	-6.24	9.58e-10	2.05e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs9307281	ENSG00000251288.2	RP11-10L12.2	-6.24	9.58e-10	2.05e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.903	rs6533037	ENSG00000251288.2	RP11-10L12.2	-6.24	9.58e-10	2.05e-07	-0.37	-0.28	Schizophrenia;	chr4:102935865	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.903	rs4530634	ENSG00000251288.2	RP11-10L12.2	-6.24	9.58e-10	2.05e-07	-0.37	-0.28	Schizophrenia;	chr4:102937924	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs7676943	ENSG00000251288.2	RP11-10L12.2	-6.24	9.58e-10	2.05e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs6419160	ENSG00000251288.2	RP11-10L12.2	-6.24	9.58e-10	2.05e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.901	rs28674656	ENSG00000251288.2	RP11-10L12.2	-6.24	9.58e-10	2.05e-07	-0.37	-0.28	Schizophrenia;	chr4:102944396	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.838	rs3974494	ENSG00000251288.2	RP11-10L12.2	-6.24	9.58e-10	2.05e-07	-0.37	-0.28	Schizophrenia;	chr4:102945323	chr4:102751401~102752641:+
THCA	cis	rs1005277	0.579	rs176880	ENSG00000276805.1	RP11-291L22.6	-6.24	9.58e-10	2.05e-07	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38451030~38451785:+
THCA	cis	rs6479891	1	rs11814792	ENSG00000232075.1	MRPL35P2	6.24	9.58e-10	2.05e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	6.24	9.58e-10	2.05e-07	0.49	0.28	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
THCA	cis	rs227275	0.556	rs223398	ENSG00000251288.2	RP11-10L12.2	-6.24	9.59e-10	2.05e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102751401~102752641:+
THCA	cis	rs7927592	0.956	rs55816191	ENSG00000212093.1	AP000807.1	6.24	9.6e-10	2.05e-07	0.3	0.28	Total body bone mineral density;	chr11:68495511	chr11:68506083~68506166:-
THCA	cis	rs6740322	0.696	rs11685054	ENSG00000234936.1	AC010883.5	6.24	9.6e-10	2.05e-07	0.3	0.28	Coronary artery disease;	chr2:43247156	chr2:43229573~43233394:+
THCA	cis	rs2120243	0.598	rs1500916	ENSG00000244515.1	KRT18P34	-6.24	9.6e-10	2.05e-07	-0.33	-0.28	Hepatocellular carcinoma in hepatitis B infection;	chr3:157370253	chr3:157162663~157163932:-
THCA	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-6.24	9.61e-10	2.05e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
THCA	cis	rs3806843	0.966	rs4141841	ENSG00000202515.1	VTRNA1-3	-6.24	9.61e-10	2.05e-07	-0.31	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140823847	chr5:140726158~140726246:+
THCA	cis	rs3806843	1	rs10050455	ENSG00000202515.1	VTRNA1-3	-6.24	9.61e-10	2.05e-07	-0.31	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140825065	chr5:140726158~140726246:+
THCA	cis	rs6860806	0.507	rs270601	ENSG00000263597.1	MIR3936	6.24	9.62e-10	2.05e-07	0.27	0.28	Breast cancer;	chr5:132321304	chr5:132365490~132365599:-
THCA	cis	rs228614	0.51	rs223455	ENSG00000251288.2	RP11-10L12.2	-6.24	9.62e-10	2.06e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102751401~102752641:+
THCA	cis	rs7208859	0.673	rs78799101	ENSG00000263603.1	CTD-2349P21.5	-6.24	9.62e-10	2.06e-07	-0.5	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30729469~30731202:+
THCA	cis	rs9880211	0.898	rs13434116	ENSG00000273486.1	RP11-731C17.2	6.24	9.63e-10	2.06e-07	0.29	0.28	Height;Body mass index;	chr3:136634232	chr3:136837338~136839021:-
THCA	cis	rs228614	0.51	rs223464	ENSG00000230069.3	LRRC37A15P	-6.24	9.64e-10	2.06e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223463	ENSG00000230069.3	LRRC37A15P	-6.24	9.64e-10	2.06e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs223462	ENSG00000230069.3	LRRC37A15P	-6.24	9.64e-10	2.06e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102727274~102730721:-
THCA	cis	rs227275	0.531	rs223460	ENSG00000230069.3	LRRC37A15P	-6.24	9.64e-10	2.06e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223464	ENSG00000251288.2	RP11-10L12.2	-6.24	9.64e-10	2.06e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223463	ENSG00000251288.2	RP11-10L12.2	-6.24	9.64e-10	2.06e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs223462	ENSG00000251288.2	RP11-10L12.2	-6.24	9.64e-10	2.06e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102751401~102752641:+
THCA	cis	rs227275	0.531	rs223460	ENSG00000251288.2	RP11-10L12.2	-6.24	9.64e-10	2.06e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102751401~102752641:+
THCA	cis	rs2562456	0.876	rs11085468	ENSG00000268081.1	RP11-678G14.2	6.24	9.65e-10	2.06e-07	0.4	0.28	Pain;	chr19:21569087	chr19:21554640~21569237:-
THCA	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	6.24	9.65e-10	2.06e-07	0.3	0.28	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
THCA	cis	rs797680	1	rs797680	ENSG00000223745.6	RP4-717I23.3	-6.24	9.65e-10	2.06e-07	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93251417	chr1:93262186~93346025:-
THCA	cis	rs7302981	0.775	rs7301566	ENSG00000272368.2	RP4-605O3.4	-6.24	9.65e-10	2.06e-07	-0.17	-0.28	Systolic blood pressure;	chr12:50187864	chr12:50112197~50165618:+
THCA	cis	rs10266483	0.545	rs12540100	ENSG00000271550.1	BNIP3P11	6.24	9.66e-10	2.06e-07	0.42	0.28	Response to statin therapy;	chr7:64289924	chr7:64678954~64687393:-
THCA	cis	rs6696239	0.513	rs3010192	ENSG00000227711.2	RP11-275O4.5	-6.24	9.66e-10	2.06e-07	-0.29	-0.28	Height;	chr1:227615350	chr1:227509028~227520477:-
THCA	cis	rs593531	0.571	rs10898981	ENSG00000212961.4	HNRNPA1P40	6.24	9.66e-10	2.06e-07	0.36	0.28	Neuroticism;	chr11:74381420	chr11:74354443~74355720:+
THCA	cis	rs9834975	0.967	rs12487598	ENSG00000272758.4	RP11-299J3.8	-6.24	9.67e-10	2.06e-07	-0.25	-0.28	Diastolic blood pressure;	chr3:122459755	chr3:122416207~122443180:+
THCA	cis	rs9834975	0.967	rs6771095	ENSG00000272758.4	RP11-299J3.8	-6.24	9.67e-10	2.06e-07	-0.25	-0.28	Diastolic blood pressure;	chr3:122472888	chr3:122416207~122443180:+
THCA	cis	rs9834975	0.901	rs10934600	ENSG00000272758.4	RP11-299J3.8	-6.24	9.67e-10	2.06e-07	-0.25	-0.28	Diastolic blood pressure;	chr3:122477270	chr3:122416207~122443180:+
THCA	cis	rs9834975	0.967	rs7642161	ENSG00000272758.4	RP11-299J3.8	-6.24	9.67e-10	2.06e-07	-0.25	-0.28	Diastolic blood pressure;	chr3:122480385	chr3:122416207~122443180:+
THCA	cis	rs728616	0.867	rs17098720	ENSG00000242600.5	MBL1P	6.24	9.67e-10	2.07e-07	0.38	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80080480	chr10:79904898~79950336:+
THCA	cis	rs728616	0.717	rs12414332	ENSG00000242600.5	MBL1P	6.24	9.67e-10	2.07e-07	0.38	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80081199	chr10:79904898~79950336:+
THCA	cis	rs4971059	0.617	rs12127609	ENSG00000160766.13	GBAP1	-6.24	9.67e-10	2.07e-07	-0.3	-0.28	Breast cancer;	chr1:155161015	chr1:155213821~155227422:-
THCA	cis	rs1005277	0.565	rs2474565	ENSG00000276805.1	RP11-291L22.6	6.24	9.67e-10	2.07e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38451030~38451785:+
THCA	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-6.24	9.68e-10	2.07e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
THCA	cis	rs227275	0.588	rs223458	ENSG00000230069.3	LRRC37A15P	-6.24	9.68e-10	2.07e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102727274~102730721:-
THCA	cis	rs6547741	0.935	rs2384626	ENSG00000234072.1	AC074117.10	6.24	9.68e-10	2.07e-07	0.21	0.28	Oral cavity cancer;	chr2:27550781	chr2:27356246~27367622:+
THCA	cis	rs6547741	0.935	rs6761095	ENSG00000234072.1	AC074117.10	6.24	9.68e-10	2.07e-07	0.21	0.28	Oral cavity cancer;	chr2:27555143	chr2:27356246~27367622:+
THCA	cis	rs7746199	0.668	rs7749305	ENSG00000226314.6	ZNF192P1	-6.24	9.68e-10	2.07e-07	-0.52	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28161781~28169594:+
THCA	cis	rs6545883	0.801	rs778142	ENSG00000271889.1	RP11-493E12.1	6.24	9.68e-10	2.07e-07	0.27	0.28	Tuberculosis;	chr2:61454293	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.862	rs778141	ENSG00000271889.1	RP11-493E12.1	6.24	9.68e-10	2.07e-07	0.27	0.28	Tuberculosis;	chr2:61455043	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.929	rs778140	ENSG00000271889.1	RP11-493E12.1	6.24	9.69e-10	2.07e-07	0.27	0.28	Tuberculosis;	chr2:61455841	chr2:61151433~61162105:-
THCA	cis	rs9649465	0.967	rs598115	ENSG00000272686.1	RP11-390E23.6	-6.24	9.69e-10	2.07e-07	-0.18	-0.28	Migraine;	chr7:123762549	chr7:123749068~123751166:+
THCA	cis	rs6061231	1	rs6061231	ENSG00000275437.1	RP5-908M14.10	6.24	9.69e-10	2.07e-07	0.26	0.28	Colorectal cancer;	chr20:62381861	chr20:62402236~62405935:-
THCA	cis	rs7176527	0.848	rs17600128	ENSG00000188388.10	GOLGA6L3	6.24	9.71e-10	2.07e-07	0.47	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:85240472~85247170:+
THCA	cis	rs227275	0.556	rs223398	ENSG00000230069.3	LRRC37A15P	-6.24	9.71e-10	2.07e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102727274~102730721:-
THCA	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-6.24	9.71e-10	2.07e-07	-0.22	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
THCA	cis	rs853679	0.517	rs9393887	ENSG00000261839.1	RP1-265C24.8	6.24	9.72e-10	2.07e-07	0.33	0.28	Depression;	chr6:28091242	chr6:28136849~28139678:+
THCA	cis	rs10208649	0.536	rs10211650	ENSG00000272156.1	RP11-477N3.1	6.24	9.72e-10	2.08e-07	0.38	0.28	Body mass index;	chr2:53731121	chr2:54082554~54085066:+
THCA	cis	rs6928977	0.897	rs2614258	ENSG00000231028.7	LINC00271	6.24	9.72e-10	2.08e-07	0.24	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356064	chr6:135497801~135716055:+
THCA	cis	rs7615952	0.673	rs16834637	ENSG00000241288.6	RP11-379B18.5	-6.24	9.72e-10	2.08e-07	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:125886628	chr3:125827238~125916384:-
THCA	cis	rs10971721	0.631	rs10971945	ENSG00000281128.1	PTENP1-AS	6.24	9.73e-10	2.08e-07	0.57	0.28	Body mass index;	chr9:34129397	chr9:33677268~33688011:+
THCA	cis	rs228614	0.51	rs223455	ENSG00000230069.3	LRRC37A15P	-6.24	9.73e-10	2.08e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102727274~102730721:-
THCA	cis	rs2562456	0.874	rs2562408	ENSG00000268081.1	RP11-678G14.2	-6.24	9.74e-10	2.08e-07	-0.4	-0.28	Pain;	chr19:21527079	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.874	rs2562417	ENSG00000268081.1	RP11-678G14.2	-6.24	9.74e-10	2.08e-07	-0.4	-0.28	Pain;	chr19:21528400	chr19:21554640~21569237:-
THCA	cis	rs4925386	0.559	rs2427291	ENSG00000273619.1	RP5-908M14.9	-6.24	9.74e-10	2.08e-07	-0.27	-0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346268	chr20:62386303~62386970:-
THCA	cis	rs4835473	0.897	rs7682204	ENSG00000251600.4	RP11-673E1.1	6.24	9.74e-10	2.08e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143966306	chr4:143912331~143982454:+
THCA	cis	rs2243480	1	rs431318	ENSG00000228409.4	CCT6P1	6.24	9.74e-10	2.08e-07	0.32	0.28	Diabetic kidney disease;	chr7:66046610	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs313803	ENSG00000228409.4	CCT6P1	6.24	9.74e-10	2.08e-07	0.32	0.28	Diabetic kidney disease;	chr7:66049744	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs313802	ENSG00000228409.4	CCT6P1	6.24	9.74e-10	2.08e-07	0.32	0.28	Diabetic kidney disease;	chr7:66051386	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000228409.4	CCT6P1	6.24	9.74e-10	2.08e-07	0.32	0.28	Diabetic kidney disease;	chr7:66052736	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs458291	ENSG00000228409.4	CCT6P1	6.24	9.74e-10	2.08e-07	0.32	0.28	Diabetic kidney disease;	chr7:66055492	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs464895	ENSG00000228409.4	CCT6P1	6.24	9.74e-10	2.08e-07	0.32	0.28	Diabetic kidney disease;	chr7:66062119	chr7:65751142~65763354:+
THCA	cis	rs7727544	0.735	rs2569266	ENSG00000237714.1	P4HA2-AS1	-6.24	9.74e-10	2.08e-07	-0.35	-0.28	Blood metabolite levels;	chr5:132371099	chr5:132184876~132192808:+
THCA	cis	rs6866614	0.639	rs1858074	ENSG00000224431.1	AC063976.7	6.24	9.75e-10	2.08e-07	0.27	0.28	Perceived unattractiveness to mosquitoes;	chr5:132036306	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.508	rs11739935	ENSG00000224431.1	AC063976.7	6.24	9.75e-10	2.08e-07	0.27	0.28	Blood metabolite levels;	chr5:132044965	chr5:132199456~132203487:+
THCA	cis	rs270601	0.909	rs2569265	ENSG00000263597.1	MIR3936	-6.24	9.75e-10	2.08e-07	-0.28	-0.28	Acylcarnitine levels;	chr5:132368827	chr5:132365490~132365599:-
THCA	cis	rs9926296	0.712	rs258330	ENSG00000274627.1	RP11-104N10.2	6.24	9.76e-10	2.08e-07	0.29	0.28	Vitiligo;	chr16:89663166	chr16:89516797~89522217:+
THCA	cis	rs10129255	0.957	rs1024349	ENSG00000211974.3	IGHV2-70	6.24	9.76e-10	2.08e-07	0.22	0.28	Kawasaki disease;	chr14:106689997	chr14:106723574~106724093:-
THCA	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-6.24	9.77e-10	2.08e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
THCA	cis	rs853679	0.517	rs2273564	ENSG00000261839.1	RP1-265C24.8	6.24	9.78e-10	2.09e-07	0.33	0.28	Depression;	chr6:28089816	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000261839.1	RP1-265C24.8	6.24	9.78e-10	2.09e-07	0.33	0.28	Depression;	chr6:28090857	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000261839.1	RP1-265C24.8	6.24	9.78e-10	2.09e-07	0.33	0.28	Depression;	chr6:28091439	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000261839.1	RP1-265C24.8	6.24	9.78e-10	2.09e-07	0.33	0.28	Depression;	chr6:28092227	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000261839.1	RP1-265C24.8	6.24	9.78e-10	2.09e-07	0.33	0.28	Depression;	chr6:28093966	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000261839.1	RP1-265C24.8	6.24	9.78e-10	2.09e-07	0.33	0.28	Depression;	chr6:28094014	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000261839.1	RP1-265C24.8	6.24	9.78e-10	2.09e-07	0.33	0.28	Depression;	chr6:28096077	chr6:28136849~28139678:+
THCA	cis	rs934734	0.752	rs198478	ENSG00000237979.1	AC007389.1	-6.24	9.78e-10	2.09e-07	-0.32	-0.28	Rheumatoid arthritis;	chr2:65379877	chr2:65500993~65502138:-
THCA	cis	rs17594362	0.697	rs1023031	ENSG00000264190.1	MIR5006	6.24	9.78e-10	2.09e-07	0.38	0.28	Multiple sclerosis;	chr13:41578269	chr13:41568286~41568395:-
THCA	cis	rs8062405	0.723	rs762633	ENSG00000278665.1	RP11-666O2.4	6.24	9.78e-10	2.09e-07	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28599241~28601881:-
THCA	cis	rs763121	0.962	rs1980455	ENSG00000235209.1	CTA-150C2.13	6.24	9.78e-10	2.09e-07	0.35	0.28	Menopause (age at onset);	chr22:38529714	chr22:38921227~38924708:+
THCA	cis	rs227275	0.525	rs223332	ENSG00000230069.3	LRRC37A15P	-6.24	9.78e-10	2.09e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102727274~102730721:-
THCA	cis	rs1865760	1	rs3799371	ENSG00000272462.2	U91328.19	6.24	9.79e-10	2.09e-07	0.23	0.28	Height;	chr6:25912588	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs2071297	ENSG00000272462.2	U91328.19	6.24	9.79e-10	2.09e-07	0.23	0.28	Height;	chr6:25924285	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs7757666	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25902398	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs6910138	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25904124	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs7739966	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25905812	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs56118523	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25908747	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs12209482	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25909001	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.963	rs3846838	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25911547	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.964	rs6932113	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25912870	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs6938233	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25913849	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs2071299	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25914573	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs2071298	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25914673	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.964	rs1324084	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25914906	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs1865760	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25916751	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs3830057	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25918282	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs3752421	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25918460	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs9467636	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25919321	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs9358893	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25921533	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs3799372	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25922083	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.963	rs1540273	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25923930	chr6:25992662~26001775:+
THCA	cis	rs1865760	1	rs9358895	ENSG00000272462.2	U91328.19	-6.24	9.79e-10	2.09e-07	-0.23	-0.28	Height;	chr6:25924427	chr6:25992662~26001775:+
THCA	cis	rs890448	0.726	rs1348161	ENSG00000254531.1	FLJ20021	6.24	9.81e-10	2.09e-07	0.25	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101331539	chr4:101347780~101348883:+
THCA	cis	rs3750082	0.582	rs6462436	ENSG00000231952.3	DPY19L1P2	6.24	9.81e-10	2.09e-07	0.37	0.28	Glomerular filtration rate (creatinine);	chr7:32931288	chr7:32812757~32838570:+
THCA	cis	rs7267979	0.565	rs6107060	ENSG00000125804.12	FAM182A	-6.24	9.81e-10	2.09e-07	-0.37	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26054655~26086917:+
THCA	cis	rs7208859	0.673	rs3764420	ENSG00000263603.1	CTD-2349P21.5	-6.24	9.82e-10	2.09e-07	-0.5	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30729469~30731202:+
THCA	cis	rs853679	0.517	rs9468298	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28154567	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28156691	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28158424	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28159056	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28159925	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28159932	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28162053	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28163375	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28163759	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28164580	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28164825	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28164948	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28165025	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28165528	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Parkinson's disease;	chr6:28165750	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Parkinson's disease;	chr6:28168578	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28169019	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28169249	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28169755	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28169791	chr6:28136849~28139678:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000261839.1	RP1-265C24.8	6.24	9.82e-10	2.09e-07	0.33	0.28	Depression;	chr6:28170075	chr6:28136849~28139678:+
THCA	cis	rs7085104	0.591	rs4919683	ENSG00000236937.2	PTGES3P4	6.24	9.82e-10	2.09e-07	0.35	0.28	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102845595~102845950:+
THCA	cis	rs890448	0.694	rs13108283	ENSG00000254531.1	FLJ20021	6.24	9.82e-10	2.09e-07	0.25	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371711	chr4:101347780~101348883:+
THCA	cis	rs8012947	1	rs10142973	ENSG00000279636.2	LINC00216	-6.24	9.82e-10	2.09e-07	-0.29	-0.28	Alcohol consumption in current drinkers;	chr14:58332400	chr14:58288033~58289158:+
THCA	cis	rs4835473	0.9	rs10003922	ENSG00000251600.4	RP11-673E1.1	-6.24	9.82e-10	2.09e-07	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143921235	chr4:143912331~143982454:+
THCA	cis	rs4819052	0.788	rs13049700	ENSG00000237664.1	LINC00316	-6.24	9.82e-10	2.09e-07	-0.29	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45338590~45341990:-
THCA	cis	rs227275	0.554	rs223316	ENSG00000230069.3	LRRC37A15P	-6.24	9.83e-10	2.1e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223314	ENSG00000230069.3	LRRC37A15P	-6.24	9.83e-10	2.1e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs7254	ENSG00000230069.3	LRRC37A15P	-6.24	9.83e-10	2.1e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.566	rs6822658	ENSG00000230069.3	LRRC37A15P	-6.24	9.83e-10	2.1e-07	-0.29	-0.28	Schizophrenia;	chr4:102891964	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs6823625	ENSG00000230069.3	LRRC37A15P	-6.24	9.83e-10	2.1e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs6846762	ENSG00000230069.3	LRRC37A15P	-6.24	9.83e-10	2.1e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs4699032	ENSG00000230069.3	LRRC37A15P	-6.24	9.83e-10	2.1e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223313	ENSG00000230069.3	LRRC37A15P	-6.24	9.83e-10	2.1e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223459	ENSG00000230069.3	LRRC37A15P	-6.24	9.84e-10	2.1e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102727274~102730721:-
THCA	cis	rs227275	0.588	rs223458	ENSG00000251288.2	RP11-10L12.2	-6.24	9.84e-10	2.1e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102751401~102752641:+
THCA	cis	rs11051970	0.885	rs7309692	ENSG00000274964.1	RP11-817I4.1	-6.24	9.85e-10	2.1e-07	-0.3	-0.28	Response to tocilizumab in rheumatoid arthritis;	chr12:32385246	chr12:32339368~32340724:+
THCA	cis	rs4073416	0.902	rs56379231	ENSG00000276116.2	FUT8-AS1	-6.24	9.85e-10	2.1e-07	-0.29	-0.28	N-glycan levels;	chr14:65788679	chr14:65411170~65412690:-
THCA	cis	rs4143844	0.867	rs17271312	ENSG00000259251.2	RP11-643M14.1	6.24	9.85e-10	2.1e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:62044080	chr15:62060503~62062434:+
THCA	cis	rs10875746	1	rs10875746	ENSG00000269514.1	RP11-370I10.12	6.24	9.86e-10	2.1e-07	0.26	0.28	Longevity (90 years and older);	chr12:48124481	chr12:48198387~48202031:+
THCA	cis	rs6844153	0.823	rs12642922	ENSG00000240005.4	RP11-293A21.1	-6.24	9.86e-10	2.1e-07	-0.38	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:27025996	chr4:26859806~26860599:-
THCA	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	6.24	9.86e-10	2.1e-07	0.4	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
THCA	cis	rs4143844	0.867	rs11629598	ENSG00000259251.2	RP11-643M14.1	6.24	9.86e-10	2.1e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:61950998	chr15:62060503~62062434:+
THCA	cis	rs7176527	0.796	rs1057946	ENSG00000188388.10	GOLGA6L3	6.24	9.87e-10	2.1e-07	0.45	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85240472~85247170:+
THCA	cis	rs16958440	1	rs62096466	ENSG00000267800.1	RP11-49K24.5	-6.24	9.87e-10	2.1e-07	-0.58	-0.28	Sitting height ratio;	chr18:47109800	chr18:47137018~47137290:+
THCA	cis	rs699371	0.548	rs2058126	ENSG00000270000.1	RP3-449M8.9	6.24	9.88e-10	2.11e-07	0.26	0.28	Height;	chr14:74432576	chr14:74471930~74472360:-
THCA	cis	rs9326246	0.643	rs651821	ENSG00000254851.1	RP11-109L13.1	-6.24	9.88e-10	2.11e-07	-0.54	-0.28	Coronary artery disease;	chr11:116791863	chr11:117135528~117138582:+
THCA	cis	rs4835473	0.897	rs4054616	ENSG00000251600.4	RP11-673E1.1	6.24	9.88e-10	2.11e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143837472	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs2323325	ENSG00000251600.4	RP11-673E1.1	6.24	9.88e-10	2.11e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143837561	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.8	rs4835330	ENSG00000251600.4	RP11-673E1.1	6.24	9.88e-10	2.11e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143846303	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.736	rs6851661	ENSG00000251600.4	RP11-673E1.1	6.24	9.88e-10	2.11e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143850587	chr4:143912331~143982454:+
THCA	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	6.24	9.89e-10	2.11e-07	0.39	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
THCA	cis	rs34779708	0.733	rs4102764	ENSG00000271335.4	RP11-324I22.4	6.24	9.89e-10	2.11e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35314552~35336401:-
THCA	cis	rs526231	0.853	rs2288786	ENSG00000175749.11	EIF3KP1	6.24	9.9e-10	2.11e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103265053	chr5:103032376~103033031:+
THCA	cis	rs11722779	0.692	rs223414	ENSG00000251288.2	RP11-10L12.2	-6.24	9.9e-10	2.11e-07	-0.37	-0.28	Schizophrenia;	chr4:102811688	chr4:102751401~102752641:+
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	6.24	9.9e-10	2.11e-07	0.32	0.28	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
THCA	cis	rs13113518	0.756	rs12510275	ENSG00000273257.1	RP11-177J6.1	6.24	9.9e-10	2.11e-07	0.37	0.28	Height;	chr4:55516548	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs12510327	ENSG00000273257.1	RP11-177J6.1	6.24	9.9e-10	2.11e-07	0.37	0.28	Height;	chr4:55516744	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs11939580	ENSG00000273257.1	RP11-177J6.1	6.24	9.9e-10	2.11e-07	0.37	0.28	Height;	chr4:55517185	chr4:55387949~55388271:+
THCA	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	6.24	9.9e-10	2.11e-07	0.32	0.28	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
THCA	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	6.24	9.91e-10	2.11e-07	0.38	0.28	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
THCA	cis	rs1552244	0.882	rs67762674	ENSG00000180385.7	EMC3-AS1	6.24	9.92e-10	2.11e-07	0.29	0.28	Alzheimer's disease;	chr3:9972801	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.688	rs7645137	ENSG00000180385.7	EMC3-AS1	6.24	9.92e-10	2.11e-07	0.29	0.28	Alzheimer's disease;	chr3:9978865	chr3:9986893~10006990:+
THCA	cis	rs4689592	0.554	rs3951346	ENSG00000245468.3	RP11-367J11.3	6.24	9.92e-10	2.11e-07	0.22	0.28	Monocyte percentage of white cells;	chr4:7071594	chr4:7094571~7103385:-
THCA	cis	rs1395	0.71	rs11674947	ENSG00000234072.1	AC074117.10	-6.24	9.92e-10	2.11e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27249128	chr2:27356246~27367622:+
THCA	cis	rs1395	0.744	rs9653564	ENSG00000234072.1	AC074117.10	-6.24	9.92e-10	2.11e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27249750	chr2:27356246~27367622:+
THCA	cis	rs1395	0.744	rs57881048	ENSG00000234072.1	AC074117.10	-6.24	9.92e-10	2.11e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27251297	chr2:27356246~27367622:+
THCA	cis	rs1395	0.71	rs2083363	ENSG00000234072.1	AC074117.10	-6.24	9.92e-10	2.11e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27252450	chr2:27356246~27367622:+
THCA	cis	rs1395	0.744	rs11126932	ENSG00000234072.1	AC074117.10	-6.24	9.92e-10	2.11e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27253414	chr2:27356246~27367622:+
THCA	cis	rs1395	0.744	rs11126934	ENSG00000234072.1	AC074117.10	-6.24	9.92e-10	2.11e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27253745	chr2:27356246~27367622:+
THCA	cis	rs1395	0.744	rs11126935	ENSG00000234072.1	AC074117.10	-6.24	9.92e-10	2.11e-07	-0.24	-0.28	Blood metabolite levels;	chr2:27253872	chr2:27356246~27367622:+
THCA	cis	rs79349575	0.756	rs3848460	ENSG00000248278.1	SUMO2P17	-6.24	9.92e-10	2.11e-07	-0.32	-0.28	Type 2 diabetes;	chr17:48969752	chr17:48874860~48908983:-
THCA	cis	rs516805	0.528	rs2606631	ENSG00000279453.1	RP3-425C14.4	-6.24	9.92e-10	2.11e-07	-0.3	-0.28	Lymphocyte counts;	chr6:122099510	chr6:122436789~122439223:-
THCA	cis	rs1005277	0.579	rs2474587	ENSG00000276805.1	RP11-291L22.6	6.24	9.93e-10	2.12e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.579	rs2474588	ENSG00000276805.1	RP11-291L22.6	6.24	9.93e-10	2.12e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38451030~38451785:+
THCA	cis	rs9859260	0.614	rs493661	ENSG00000226155.1	AC124944.3	6.24	9.93e-10	2.12e-07	0.33	0.28	Mean corpuscular volume;	chr3:196059618	chr3:195912049~195913986:+
THCA	cis	rs890448	0.796	rs293212	ENSG00000254531.1	FLJ20021	6.24	9.94e-10	2.12e-07	0.24	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395077	chr4:101347780~101348883:+
THCA	cis	rs7809950	0.678	rs2395869	ENSG00000238832.1	snoU109	-6.24	9.95e-10	2.12e-07	-0.32	-0.28	Coronary artery disease;	chr7:107299653	chr7:107603363~107603507:+
THCA	cis	rs8027521	0.58	rs2466794	ENSG00000280362.1	RP11-643A5.3	6.24	9.95e-10	2.12e-07	0.35	0.28	Circulating chemerin levels;	chr15:53956943	chr15:53910769~53914712:+
THCA	cis	rs2243480	1	rs73150014	ENSG00000232546.1	RP11-458F8.1	-6.24	9.96e-10	2.12e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65985932	chr7:66848496~66858136:+
THCA	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-6.24	9.97e-10	2.12e-07	-0.36	-0.28	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
THCA	cis	rs7809950	1	rs2057837	ENSG00000238832.1	snoU109	6.24	9.97e-10	2.12e-07	0.3	0.28	Coronary artery disease;	chr7:107582280	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs7778270	ENSG00000238832.1	snoU109	6.24	9.97e-10	2.12e-07	0.3	0.28	Coronary artery disease;	chr7:107584222	chr7:107603363~107603507:+
THCA	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	6.24	9.98e-10	2.12e-07	0.51	0.28	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
THCA	cis	rs6545883	0.868	rs2518932	ENSG00000271889.1	RP11-493E12.1	6.24	9.98e-10	2.13e-07	0.26	0.28	Tuberculosis;	chr2:61574142	chr2:61151433~61162105:-
THCA	cis	rs4950322	0.518	rs61838936	ENSG00000237188.3	RP11-337C18.8	6.24	9.99e-10	2.13e-07	0.34	0.28	Protein quantitative trait loci;	chr1:147098422	chr1:147172771~147211568:+
THCA	cis	rs7202877	0.706	rs247443	ENSG00000261783.1	RP11-252K23.2	6.24	1e-09	2.13e-07	0.48	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75431175	chr16:75379818~75381260:-
THCA	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	6.24	1e-09	2.13e-07	0.3	0.28	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
THCA	cis	rs6723226	0.732	rs390480	ENSG00000276334.1	AL133243.1	-6.24	1e-09	2.13e-07	-0.32	-0.28	Intelligence (multi-trait analysis);	chr2:32285003	chr2:32521927~32523547:+
THCA	cis	rs1005277	0.579	rs1780137	ENSG00000276805.1	RP11-291L22.6	6.24	1e-09	2.13e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38451030~38451785:+
THCA	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	6.24	1e-09	2.13e-07	0.3	0.28	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
THCA	cis	rs1865760	1	rs6910174	ENSG00000272462.2	U91328.19	-6.24	1e-09	2.14e-07	-0.23	-0.28	Height;	chr6:25904186	chr6:25992662~26001775:+
THCA	cis	rs911555	0.57	rs11625397	ENSG00000269940.1	RP11-73M18.7	-6.24	1e-09	2.14e-07	-0.28	-0.28	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103694560~103695170:+
THCA	cis	rs944289	0.531	rs1169149	ENSG00000257826.1	RP11-116N8.4	-6.24	1e-09	2.14e-07	-0.32	-0.28	Thyroid cancer;	chr14:36165019	chr14:36061026~36067190:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	6.24	1e-09	2.14e-07	0.31	0.28	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
THCA	cis	rs4835473	0.932	rs7670010	ENSG00000251600.4	RP11-673E1.1	6.24	1e-09	2.14e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143821679	chr4:143912331~143982454:+
THCA	cis	rs934734	0.752	rs198478	ENSG00000234255.7	AC012370.3	-6.24	1e-09	2.14e-07	-0.31	-0.28	Rheumatoid arthritis;	chr2:65379877	chr2:65439888~65456571:-
THCA	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-6.24	1e-09	2.14e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
THCA	cis	rs763121	1	rs1946990	ENSG00000273076.1	RP3-508I15.22	-6.24	1e-09	2.14e-07	-0.26	-0.28	Menopause (age at onset);	chr22:38516766	chr22:38743495~38743910:+
THCA	cis	rs1865760	0.964	rs3799373	ENSG00000272462.2	U91328.19	-6.24	1.01e-09	2.14e-07	-0.23	-0.28	Height;	chr6:25928945	chr6:25992662~26001775:+
THCA	cis	rs797680	0.964	rs547866	ENSG00000223745.6	RP4-717I23.3	-6.24	1.01e-09	2.14e-07	-0.17	-0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93259496	chr1:93262186~93346025:-
THCA	cis	rs2243480	0.901	rs313808	ENSG00000232546.1	RP11-458F8.1	-6.24	1.01e-09	2.14e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66034886	chr7:66848496~66858136:+
THCA	cis	rs6479891	1	rs10437345	ENSG00000232075.1	MRPL35P2	-6.24	1.01e-09	2.14e-07	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63634317~63634827:-
THCA	cis	rs7267979	0.966	rs454723	ENSG00000274414.1	RP5-965G21.4	-6.23	1.01e-09	2.15e-07	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25239007~25245229:-
THCA	cis	rs10129255	0.957	rs2013423	ENSG00000211974.3	IGHV2-70	6.23	1.01e-09	2.15e-07	0.22	0.28	Kawasaki disease;	chr14:106690675	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs56134540	ENSG00000211974.3	IGHV2-70	6.23	1.01e-09	2.15e-07	0.22	0.28	Kawasaki disease;	chr14:106691290	chr14:106723574~106724093:-
THCA	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	6.23	1.01e-09	2.15e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-6.23	1.01e-09	2.15e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-6.23	1.01e-09	2.15e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-6.23	1.01e-09	2.15e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
THCA	cis	rs2243480	1	rs34702770	ENSG00000232546.1	RP11-458F8.1	-6.23	1.01e-09	2.15e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65879836	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs34637256	ENSG00000232546.1	RP11-458F8.1	-6.23	1.01e-09	2.15e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65895144	chr7:66848496~66858136:+
THCA	cis	rs5758659	0.716	rs2143138	ENSG00000281538.1	RP4-669P10.20	6.23	1.01e-09	2.15e-07	0.25	0.28	Cognitive function;	chr22:42222334	chr22:42138060~42139726:+
THCA	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-6.23	1.01e-09	2.15e-07	-0.37	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
THCA	cis	rs7746199	0.736	rs35848276	ENSG00000219392.1	RP1-265C24.5	-6.23	1.01e-09	2.15e-07	-0.63	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28115628~28116551:+
THCA	cis	rs228614	0.51	rs223311	ENSG00000230069.3	LRRC37A15P	-6.23	1.02e-09	2.16e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102727274~102730721:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	6.23	1.02e-09	2.16e-07	0.32	0.28	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
THCA	cis	rs228614	0.51	rs223459	ENSG00000251288.2	RP11-10L12.2	-6.23	1.02e-09	2.16e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102751401~102752641:+
THCA	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-6.23	1.02e-09	2.16e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
THCA	cis	rs6142102	0.812	rs6059554	ENSG00000275784.1	RP5-1125A11.6	-6.23	1.02e-09	2.16e-07	-0.28	-0.28	Skin pigmentation;	chr20:33926286	chr20:33989480~33991818:-
THCA	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-6.23	1.02e-09	2.17e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
THCA	cis	rs228614	0.51	rs223353	ENSG00000230069.3	LRRC37A15P	-6.23	1.02e-09	2.17e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223352	ENSG00000230069.3	LRRC37A15P	-6.23	1.02e-09	2.17e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102727274~102730721:-
THCA	cis	rs8007846	0.588	rs12894466	ENSG00000276116.2	FUT8-AS1	6.23	1.02e-09	2.17e-07	0.28	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65774049	chr14:65411170~65412690:-
THCA	cis	rs10875746	0.951	rs11168433	ENSG00000269514.1	RP11-370I10.12	6.23	1.02e-09	2.17e-07	0.28	0.28	Longevity (90 years and older);	chr12:48164281	chr12:48198387~48202031:+
THCA	cis	rs451417	1	rs236122	ENSG00000275632.1	RP5-967N21.11	6.23	1.02e-09	2.17e-07	0.31	0.28	Menopause (age at onset);	chr20:5992882	chr20:6000418~6000941:+
THCA	cis	rs9926296	0.682	rs645019	ENSG00000274627.1	RP11-104N10.2	6.23	1.02e-09	2.17e-07	0.29	0.28	Vitiligo;	chr16:89650475	chr16:89516797~89522217:+
THCA	cis	rs4664293	0.647	rs6756502	ENSG00000226266.5	AC009961.3	6.23	1.02e-09	2.17e-07	0.32	0.28	Monocyte percentage of white cells;	chr2:159698072	chr2:159670708~159712435:-
THCA	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	6.23	1.02e-09	2.17e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
THCA	cis	rs9926296	0.585	rs6500450	ENSG00000260259.1	RP11-368I7.4	-6.23	1.02e-09	2.17e-07	-0.3	-0.28	Vitiligo;	chr16:89791616	chr16:89682620~89686569:-
THCA	cis	rs4950322	0.57	rs6703892	ENSG00000278811.3	LINC00624	6.23	1.02e-09	2.17e-07	0.34	0.28	Protein quantitative trait loci;	chr1:147287627	chr1:147258885~147517875:-
THCA	cis	rs6545883	0.929	rs2252662	ENSG00000271889.1	RP11-493E12.1	6.23	1.02e-09	2.18e-07	0.27	0.28	Tuberculosis;	chr2:61443596	chr2:61151433~61162105:-
THCA	cis	rs748404	0.578	rs4547312	ENSG00000166763.7	STRCP1	6.23	1.02e-09	2.18e-07	0.29	0.28	Lung cancer;	chr15:43339940	chr15:43699488~43718184:-
THCA	cis	rs8072100	0.688	rs8079142	ENSG00000228782.6	CTD-2026D20.3	6.23	1.02e-09	2.18e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364683	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.688	rs8075843	ENSG00000228782.6	CTD-2026D20.3	6.23	1.02e-09	2.18e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364997	chr17:47450568~47492492:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	6.23	1.02e-09	2.18e-07	0.32	0.28	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
THCA	cis	rs1865760	0.928	rs9295673	ENSG00000272462.2	U91328.19	-6.23	1.02e-09	2.18e-07	-0.23	-0.28	Height;	chr6:25911866	chr6:25992662~26001775:+
THCA	cis	rs9381040	0.61	rs4140580	ENSG00000161912.16	ADCY10P1	6.23	1.02e-09	2.18e-07	0.18	0.28	Alzheimer's disease (late onset);	chr6:41074003	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs4140579	ENSG00000161912.16	ADCY10P1	6.23	1.02e-09	2.18e-07	0.18	0.28	Alzheimer's disease (late onset);	chr6:41074013	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.655	rs2268188	ENSG00000161912.16	ADCY10P1	6.23	1.02e-09	2.18e-07	0.18	0.28	Alzheimer's disease (late onset);	chr6:41074851	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs6941090	ENSG00000161912.16	ADCY10P1	6.23	1.02e-09	2.18e-07	0.18	0.28	Alzheimer's disease (late onset);	chr6:41075726	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.655	rs9381031	ENSG00000161912.16	ADCY10P1	6.23	1.02e-09	2.18e-07	0.18	0.28	Alzheimer's disease (late onset);	chr6:41077218	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs717883	ENSG00000161912.16	ADCY10P1	6.23	1.02e-09	2.18e-07	0.18	0.28	Alzheimer's disease (late onset);	chr6:41077531	chr6:41101022~41140835:+
THCA	cis	rs6928977	0.897	rs6570001	ENSG00000231028.7	LINC00271	6.23	1.03e-09	2.18e-07	0.24	0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135330583	chr6:135497801~135716055:+
THCA	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-6.23	1.03e-09	2.18e-07	-0.25	-0.28	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
THCA	cis	rs6928977	0.5	rs6941629	ENSG00000231028.7	LINC00271	-6.23	1.03e-09	2.18e-07	-0.23	-0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135621634	chr6:135497801~135716055:+
THCA	cis	rs916888	0.61	rs199452	ENSG00000232300.1	FAM215B	6.23	1.03e-09	2.18e-07	0.38	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46558830~46562795:-
THCA	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-6.23	1.03e-09	2.18e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
THCA	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	6.23	1.03e-09	2.18e-07	0.38	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
THCA	cis	rs944990	0.597	rs10821162	ENSG00000227603.1	RP11-165J3.6	6.23	1.03e-09	2.19e-07	0.29	0.28	Body mass index;	chr9:93579042	chr9:93435332~93437121:-
THCA	cis	rs853679	0.517	rs9393891	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Depression;	chr6:28111382	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Depression;	chr6:28111650	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Parkinson's disease;	chr6:28112168	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Depression;	chr6:28112175	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Depression;	chr6:28113851	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Depression;	chr6:28114487	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Depression;	chr6:28114933	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Depression;	chr6:28115743	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Depression;	chr6:28116411	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Parkinson's disease;	chr6:28118700	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Parkinson's disease;	chr6:28118701	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000261839.1	RP1-265C24.8	6.23	1.03e-09	2.19e-07	0.33	0.28	Parkinson's disease;	chr6:28119896	chr6:28136849~28139678:+
THCA	cis	rs10208649	0.803	rs2177791	ENSG00000272156.1	RP11-477N3.1	6.23	1.03e-09	2.19e-07	0.51	0.28	Body mass index;	chr2:53832771	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.803	rs2177792	ENSG00000272156.1	RP11-477N3.1	6.23	1.03e-09	2.19e-07	0.51	0.28	Body mass index;	chr2:53832776	chr2:54082554~54085066:+
THCA	cis	rs16949788	1	rs78288367	ENSG00000261351.2	CTD-3185P2.1	-6.23	1.03e-09	2.19e-07	-0.35	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66480383	chr15:66488658~66492109:-
THCA	cis	rs890448	0.796	rs10009249	ENSG00000254531.1	FLJ20021	6.23	1.03e-09	2.19e-07	0.25	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369460	chr4:101347780~101348883:+
THCA	cis	rs1876905	0.68	rs193281	ENSG00000255389.1	C6orf3	-6.23	1.03e-09	2.19e-07	-0.33	-0.28	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111599875~111602295:+
THCA	cis	rs228614	0.51	rs223468	ENSG00000251288.2	RP11-10L12.2	-6.23	1.03e-09	2.19e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223465	ENSG00000251288.2	RP11-10L12.2	-6.23	1.03e-09	2.19e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102751401~102752641:+
THCA	cis	rs2243480	1	rs437889	ENSG00000228409.4	CCT6P1	6.23	1.03e-09	2.19e-07	0.32	0.28	Diabetic kidney disease;	chr7:66044247	chr7:65751142~65763354:+
THCA	cis	rs7851660	0.87	rs55960649	ENSG00000214417.4	KRT18P13	-6.23	1.03e-09	2.19e-07	-0.23	-0.28	Strep throat;	chr9:97836413	chr9:97698922~97700734:+
THCA	cis	rs7129556	0.954	rs10899386	ENSG00000254691.1	RP11-91P24.5	6.23	1.03e-09	2.19e-07	0.37	0.28	Weight loss (gastric bypass surgery);	chr11:77535381	chr11:77850604~77851511:+
THCA	cis	rs240993	0.548	rs1040382	ENSG00000230177.1	RP5-1112D6.4	6.23	1.03e-09	2.19e-07	0.24	0.28	Inflammatory skin disease;Psoriasis;	chr6:111580876	chr6:111277932~111278742:+
THCA	cis	rs728616	0.867	rs7893241	ENSG00000242600.5	MBL1P	6.23	1.03e-09	2.19e-07	0.38	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194582	chr10:79904898~79950336:+
THCA	cis	rs838147	0.534	rs2638280	ENSG00000232871.7	SEC1P	6.23	1.03e-09	2.19e-07	0.33	0.28	Dietary macronutrient intake;	chr19:48706061	chr19:48638071~48682245:+
THCA	cis	rs1865760	1	rs9348698	ENSG00000272462.2	U91328.19	-6.23	1.03e-09	2.19e-07	-0.23	-0.28	Height;	chr6:25929461	chr6:25992662~26001775:+
THCA	cis	rs6928977	0.5	rs12211833	ENSG00000231028.7	LINC00271	-6.23	1.03e-09	2.2e-07	-0.23	-0.28	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629066	chr6:135497801~135716055:+
THCA	cis	rs6479891	1	rs10733790	ENSG00000232075.1	MRPL35P2	-6.23	1.03e-09	2.2e-07	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-6.23	1.03e-09	2.2e-07	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
THCA	cis	rs6479891	0.915	rs7091664	ENSG00000232075.1	MRPL35P2	-6.23	1.03e-09	2.2e-07	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63634317~63634827:-
THCA	cis	rs9467773	0.572	rs2076029	ENSG00000124549.13	BTN2A3P	-6.23	1.03e-09	2.2e-07	-0.26	-0.28	Intelligence (multi-trait analysis);	chr6:26390602	chr6:26421391~26432383:+
THCA	cis	rs2274273	0.564	rs10140164	ENSG00000258413.1	RP11-665C16.6	-6.23	1.04e-09	2.2e-07	-0.37	-0.28	Protein biomarker;	chr14:54939405	chr14:55262767~55272075:-
THCA	cis	rs55823223	0.564	rs936396	ENSG00000267801.1	RP11-552F3.9	6.23	1.04e-09	2.2e-07	0.35	0.28	Psoriasis;	chr17:75850748	chr17:75876372~75879546:+
THCA	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	6.23	1.04e-09	2.2e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
THCA	cis	rs9816784	0.901	rs56253832	ENSG00000231464.1	AC024937.4	6.23	1.04e-09	2.2e-07	0.33	0.28	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195996738~195998233:+
THCA	cis	rs227275	0.554	rs6810668	ENSG00000230069.3	LRRC37A15P	-6.23	1.04e-09	2.21e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102727274~102730721:-
THCA	cis	rs6600671	1	rs6600671	ENSG00000223345.3	HIST2H2BA	-6.23	1.04e-09	2.21e-07	-0.31	-0.28	Hip geometry;	chr1:121458637	chr1:121108210~121117257:-
THCA	cis	rs1395	0.744	rs11126929	ENSG00000234072.1	AC074117.10	6.23	1.04e-09	2.21e-07	0.24	0.28	Blood metabolite levels;	chr2:27249159	chr2:27356246~27367622:+
THCA	cis	rs3213958	0.574	rs16846347	ENSG00000249274.1	PDLIM1P4	-6.23	1.04e-09	2.21e-07	-0.34	-0.28	Blood protein levels;	chr3:98777624	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs73136045	ENSG00000249274.1	PDLIM1P4	-6.23	1.04e-09	2.21e-07	-0.34	-0.28	Blood protein levels;	chr3:98785149	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs73136048	ENSG00000249274.1	PDLIM1P4	-6.23	1.04e-09	2.21e-07	-0.34	-0.28	Blood protein levels;	chr3:98785923	chr3:98782188~98783193:+
THCA	cis	rs1823874	0.72	rs7162911	ENSG00000182397.13	DNM1P46	-6.23	1.04e-09	2.21e-07	-0.3	-0.28	IgG glycosylation;	chr15:99814845	chr15:99790156~99806927:-
THCA	cis	rs1823913	0.963	rs4146105	ENSG00000227542.1	AC092614.2	6.23	1.04e-09	2.21e-07	0.34	0.28	Obesity-related traits;	chr2:191245240	chr2:191229165~191246172:-
THCA	cis	rs1823913	1	rs13019004	ENSG00000227542.1	AC092614.2	6.23	1.04e-09	2.21e-07	0.34	0.28	Obesity-related traits;	chr2:191245493	chr2:191229165~191246172:-
THCA	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-6.23	1.04e-09	2.21e-07	-0.34	-0.28	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
THCA	cis	rs728616	0.867	rs7906286	ENSG00000225484.5	NUTM2B-AS1	-6.23	1.04e-09	2.21e-07	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80074279	chr10:79663088~79826594:-
THCA	cis	rs7189233	0.955	rs11540358	ENSG00000279722.1	RP11-44F14.6	-6.23	1.04e-09	2.21e-07	-0.29	-0.28	Intelligence (multi-trait analysis);	chr16:53470031	chr16:53487607~53489943:-
THCA	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-6.23	1.04e-09	2.21e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
THCA	cis	rs950169	0.922	rs4338765	ENSG00000259295.5	CSPG4P12	6.23	1.04e-09	2.21e-07	0.42	0.28	Schizophrenia;	chr15:84248084	chr15:85191438~85213905:+
THCA	cis	rs10276381	0.786	rs10281102	ENSG00000234336.5	JAZF1-AS1	-6.23	1.04e-09	2.22e-07	-0.39	-0.28	Crohn's disease;	chr7:28203854	chr7:28180322~28243917:+
THCA	cis	rs7568498	0.517	rs197261	ENSG00000227403.1	AC009299.3	6.23	1.04e-09	2.22e-07	0.35	0.28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161048312	chr2:161244739~161249050:+
THCA	cis	rs6142102	0.961	rs973409	ENSG00000275784.1	RP5-1125A11.6	-6.23	1.04e-09	2.22e-07	-0.28	-0.28	Skin pigmentation;	chr20:33948558	chr20:33989480~33991818:-
THCA	cis	rs7927592	0.763	rs624003	ENSG00000212093.1	AP000807.1	6.23	1.04e-09	2.22e-07	0.29	0.28	Total body bone mineral density;	chr11:68463772	chr11:68506083~68506166:-
THCA	cis	rs13113518	0.812	rs11133385	ENSG00000273257.1	RP11-177J6.1	6.23	1.04e-09	2.22e-07	0.37	0.28	Height;	chr4:55460485	chr4:55387949~55388271:+
THCA	cis	rs11603023	0.805	rs687190	ENSG00000278376.1	RP11-158I9.8	-6.23	1.04e-09	2.22e-07	-0.21	-0.28	Cholesterol, total;	chr11:118671674	chr11:118791254~118793137:+
THCA	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	6.23	1.04e-09	2.22e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
THCA	cis	rs11722779	0.933	rs7695096	ENSG00000230069.3	LRRC37A15P	-6.23	1.05e-09	2.22e-07	-0.29	-0.28	Schizophrenia;	chr4:103011399	chr4:102727274~102730721:-
THCA	cis	rs523522	0.962	rs9040	ENSG00000278344.1	RP11-18C24.8	6.23	1.05e-09	2.22e-07	0.31	0.28	High light scatter reticulocyte count;	chr12:120462471	chr12:120500735~120501090:-
THCA	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	6.23	1.05e-09	2.22e-07	0.39	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
THCA	cis	rs9475752	1	rs1903330	ENSG00000231441.1	RP11-472M19.2	-6.23	1.05e-09	2.22e-07	-0.35	-0.28	Menarche (age at onset);	chr6:56912187	chr6:56844002~56864078:+
THCA	cis	rs2243480	1	rs410128	ENSG00000229886.1	RP5-1132H15.3	6.23	1.05e-09	2.22e-07	0.46	0.28	Diabetic kidney disease;	chr7:66138186	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs73142162	ENSG00000229886.1	RP5-1132H15.3	6.23	1.05e-09	2.22e-07	0.45	0.28	Diabetic kidney disease;	chr7:65909309	chr7:66025126~66031544:-
THCA	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-6.23	1.05e-09	2.23e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
THCA	cis	rs7927592	0.673	rs498782	ENSG00000212093.1	AP000807.1	6.23	1.05e-09	2.23e-07	0.28	0.28	Total body bone mineral density;	chr11:68508383	chr11:68506083~68506166:-
THCA	cis	rs4713118	0.696	rs2394002	ENSG00000280107.1	AL022393.9	-6.23	1.05e-09	2.23e-07	-0.33	-0.28	Parkinson's disease;	chr6:27780236	chr6:28170845~28172521:+
THCA	cis	rs848490	0.928	rs62462679	ENSG00000214293.7	APTR	6.23	1.05e-09	2.23e-07	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77856423	chr7:77657660~77696265:-
THCA	cis	rs2281636	0.792	rs10883385	ENSG00000260475.1	RP11-85A1.3	6.23	1.05e-09	2.23e-07	0.25	0.28	Obesity-related traits;	chr10:99621956	chr10:99621055~99621918:+
THCA	cis	rs227275	0.527	rs223308	ENSG00000251288.2	RP11-10L12.2	-6.23	1.05e-09	2.23e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102751401~102752641:+
THCA	cis	rs10208649	0.536	rs3770400	ENSG00000272156.1	RP11-477N3.1	6.23	1.05e-09	2.23e-07	0.38	0.28	Body mass index;	chr2:53734438	chr2:54082554~54085066:+
THCA	cis	rs2239547	0.603	rs17304995	ENSG00000242142.1	SERBP1P3	6.23	1.05e-09	2.24e-07	0.35	0.28	Schizophrenia;	chr3:53036739	chr3:53064283~53065091:-
THCA	cis	rs712022	0.868	rs10833819	ENSG00000246225.5	RP11-17A1.3	-6.23	1.05e-09	2.24e-07	-0.35	-0.28	Dialysis-related mortality;	chr11:22801736	chr11:22829380~22945393:+
THCA	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-6.23	1.05e-09	2.24e-07	-0.21	-0.28	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
THCA	cis	rs950169	0.922	rs62028133	ENSG00000259295.5	CSPG4P12	6.23	1.05e-09	2.24e-07	0.42	0.28	Schizophrenia;	chr15:84250623	chr15:85191438~85213905:+
THCA	cis	rs950169	0.723	rs17589320	ENSG00000259295.5	CSPG4P12	6.23	1.05e-09	2.24e-07	0.42	0.28	Schizophrenia;	chr15:84251244	chr15:85191438~85213905:+
THCA	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	6.23	1.05e-09	2.24e-07	0.33	0.28	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	6.23	1.05e-09	2.24e-07	0.33	0.28	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
THCA	cis	rs6545883	0.929	rs6705235	ENSG00000271889.1	RP11-493E12.1	6.23	1.05e-09	2.24e-07	0.27	0.28	Tuberculosis;	chr2:61486445	chr2:61151433~61162105:-
THCA	cis	rs6142102	0.886	rs6142098	ENSG00000275784.1	RP5-1125A11.6	-6.23	1.06e-09	2.24e-07	-0.28	-0.28	Skin pigmentation;	chr20:34100488	chr20:33989480~33991818:-
THCA	cis	rs2439831	0.717	rs9806227	ENSG00000249839.1	AC011330.5	-6.23	1.06e-09	2.24e-07	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43387917	chr15:43663654~43684339:-
THCA	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	6.23	1.06e-09	2.24e-07	0.44	0.28	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
THCA	cis	rs728616	0.681	rs35014047	ENSG00000242600.5	MBL1P	6.23	1.06e-09	2.24e-07	0.34	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80152641	chr10:79904898~79950336:+
THCA	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	6.23	1.06e-09	2.24e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
THCA	cis	rs699371	0.507	rs10149538	ENSG00000259005.1	RP3-449M8.6	6.23	1.06e-09	2.25e-07	0.25	0.28	Height;	chr14:74458694	chr14:74474007~74474864:-
THCA	cis	rs62103177	0.673	rs62096717	ENSG00000261126.6	RP11-795F19.1	6.23	1.06e-09	2.25e-07	0.27	0.28	Opioid sensitivity;	chr18:79856819	chr18:80046900~80095482:+
THCA	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	6.23	1.06e-09	2.25e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	6.23	1.06e-09	2.25e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
THCA	cis	rs12681366	0.659	rs2470735	ENSG00000253704.1	RP11-267M23.4	-6.23	1.06e-09	2.25e-07	-0.26	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94403670	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.636	rs2246066	ENSG00000253704.1	RP11-267M23.4	-6.23	1.06e-09	2.25e-07	-0.26	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94406927	chr8:94553722~94569745:+
THCA	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	6.23	1.06e-09	2.25e-07	0.28	0.28	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
THCA	cis	rs728616	0.681	rs12412762	ENSG00000242600.5	MBL1P	-6.23	1.06e-09	2.25e-07	-0.35	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147714	chr10:79904898~79950336:+
THCA	cis	rs2412819	0.597	rs2412821	ENSG00000249839.1	AC011330.5	-6.23	1.06e-09	2.25e-07	-0.4	-0.28	Lung cancer;	chr15:43864966	chr15:43663654~43684339:-
THCA	cis	rs11722779	0.935	rs3974481	ENSG00000251288.2	RP11-10L12.2	-6.23	1.06e-09	2.25e-07	-0.37	-0.28	Schizophrenia;	chr4:102956834	chr4:102751401~102752641:+
THCA	cis	rs274567	0.599	rs11242110	ENSG00000237714.1	P4HA2-AS1	-6.23	1.06e-09	2.25e-07	-0.34	-0.28	Blood metabolite levels;	chr5:132408085	chr5:132184876~132192808:+
THCA	cis	rs6545883	0.894	rs6760075	ENSG00000271889.1	RP11-493E12.1	-6.23	1.06e-09	2.25e-07	-0.27	-0.28	Tuberculosis;	chr2:61385746	chr2:61151433~61162105:-
THCA	cis	rs1385374	0.502	rs923077	ENSG00000274695.1	RP11-21K12.3	-6.23	1.06e-09	2.26e-07	-0.47	-0.28	Systemic lupus erythematosus;	chr12:128792163	chr12:128826836~128827579:+
THCA	cis	rs6026584	1	rs15754	ENSG00000270951.1	RP1-309F20.4	-6.23	1.06e-09	2.26e-07	-0.3	-0.28	Renal function-related traits (BUN);	chr20:58894172	chr20:58876592~58876981:-
THCA	cis	rs16949788	1	rs9672789	ENSG00000261351.2	CTD-3185P2.1	-6.23	1.06e-09	2.26e-07	-0.33	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66421295	chr15:66488658~66492109:-
THCA	cis	rs2117029	0.965	rs2241726	ENSG00000258017.1	RP11-386G11.10	-6.23	1.06e-09	2.26e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr12:49050762	chr12:49127782~49147869:+
THCA	cis	rs2115536	0.692	rs8036559	ENSG00000278600.1	RP11-81A1.6	-6.23	1.07e-09	2.26e-07	-0.17	-0.28	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79878221	chr15:79920195~79922455:-
THCA	cis	rs2243480	1	rs34970380	ENSG00000232546.1	RP11-458F8.1	-6.23	1.07e-09	2.26e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65966506	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000232546.1	RP11-458F8.1	-6.23	1.07e-09	2.26e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66004843	chr7:66848496~66858136:+
THCA	cis	rs7267979	1	rs2387881	ENSG00000274414.1	RP5-965G21.4	6.23	1.07e-09	2.26e-07	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25239007~25245229:-
THCA	cis	rs451417	1	rs236102	ENSG00000275632.1	RP5-967N21.11	6.23	1.07e-09	2.26e-07	0.31	0.28	Menopause (age at onset);	chr20:5971320	chr20:6000418~6000941:+
THCA	cis	rs17772222	0.917	rs12431548	ENSG00000222990.1	RNU4-22P	6.23	1.07e-09	2.26e-07	0.35	0.28	Coronary artery calcification;	chr14:88635826	chr14:88513498~88513663:+
THCA	cis	rs934734	0.752	rs1876518	ENSG00000237979.1	AC007389.1	-6.23	1.07e-09	2.27e-07	-0.32	-0.28	Rheumatoid arthritis;	chr2:65381775	chr2:65500993~65502138:-
THCA	cis	rs9880211	0.898	rs28877020	ENSG00000273486.1	RP11-731C17.2	6.23	1.07e-09	2.27e-07	0.29	0.28	Height;Body mass index;	chr3:136676874	chr3:136837338~136839021:-
THCA	cis	rs11671005	0.695	rs8106061	ENSG00000232098.3	CTD-2619J13.14	6.23	1.07e-09	2.27e-07	0.27	0.28	Mean platelet volume;	chr19:58406623	chr19:58404238~58408484:-
THCA	cis	rs797680	0.789	rs7539307	ENSG00000223745.6	RP4-717I23.3	6.22	1.07e-09	2.27e-07	0.16	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93187146	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs11164880	ENSG00000223745.6	RP4-717I23.3	6.22	1.07e-09	2.27e-07	0.16	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93192539	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs7513705	ENSG00000223745.6	RP4-717I23.3	6.22	1.07e-09	2.27e-07	0.16	0.28	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93200792	chr1:93262186~93346025:-
THCA	cis	rs12935418	0.83	rs12928638	ENSG00000261061.1	RP11-303E16.2	-6.22	1.07e-09	2.27e-07	-0.33	-0.28	Mean corpuscular volume;	chr16:81016195	chr16:81030770~81031485:+
THCA	cis	rs947583	0.573	rs12202212	ENSG00000231028.7	LINC00271	-6.22	1.07e-09	2.27e-07	-0.23	-0.28	Phosphorus levels;	chr6:135698009	chr6:135497801~135716055:+
THCA	cis	rs17684571	0.938	rs4072271	ENSG00000231441.1	RP11-472M19.2	-6.22	1.07e-09	2.27e-07	-0.32	-0.28	Schizophrenia;	chr6:56707679	chr6:56844002~56864078:+
THCA	cis	rs10899021	0.79	rs12288525	ENSG00000279353.1	RP11-864N7.4	6.22	1.07e-09	2.27e-07	0.54	0.28	Response to metformin (IC50);	chr11:74621544	chr11:74698231~74699658:-
THCA	cis	rs6479891	1	rs6479899	ENSG00000232075.1	MRPL35P2	-6.22	1.07e-09	2.27e-07	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63634317~63634827:-
THCA	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	6.22	1.07e-09	2.27e-07	0.54	0.28	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
THCA	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	6.22	1.07e-09	2.27e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
THCA	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	6.22	1.07e-09	2.27e-07	0.28	0.28	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
THCA	cis	rs7260598	0.642	rs11667910	ENSG00000268442.1	CTD-2027I19.2	6.22	1.07e-09	2.27e-07	0.37	0.28	Response to taxane treatment (placlitaxel);	chr19:23976911	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.642	rs10424894	ENSG00000268442.1	CTD-2027I19.2	6.22	1.07e-09	2.27e-07	0.37	0.28	Response to taxane treatment (placlitaxel);	chr19:23978053	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.642	rs10423626	ENSG00000268442.1	CTD-2027I19.2	6.22	1.07e-09	2.27e-07	0.37	0.28	Response to taxane treatment (placlitaxel);	chr19:23978229	chr19:24162370~24163425:-
THCA	cis	rs6142102	0.812	rs2377955	ENSG00000275784.1	RP5-1125A11.6	-6.22	1.07e-09	2.28e-07	-0.28	-0.28	Skin pigmentation;	chr20:33937564	chr20:33989480~33991818:-
THCA	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	6.22	1.07e-09	2.28e-07	0.43	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
THCA	cis	rs2562456	0.876	rs2650844	ENSG00000268555.1	RP11-678G14.3	6.22	1.07e-09	2.28e-07	0.44	0.28	Pain;	chr19:21419288	chr19:21570822~21587322:-
THCA	cis	rs6545883	0.895	rs2256617	ENSG00000271889.1	RP11-493E12.1	6.22	1.07e-09	2.28e-07	0.27	0.28	Tuberculosis;	chr2:61452789	chr2:61151433~61162105:-
THCA	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-6.22	1.07e-09	2.28e-07	-0.21	-0.28	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
THCA	cis	rs6545883	0.894	rs4672423	ENSG00000271889.1	RP11-493E12.1	-6.22	1.07e-09	2.28e-07	-0.26	-0.28	Tuberculosis;	chr2:61208140	chr2:61151433~61162105:-
THCA	cis	rs10971721	0.584	rs72731212	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34109710	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs12376939	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34110139	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs72731214	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34113019	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs117997985	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34113176	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs72731216	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34115066	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs10971933	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34117073	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs10971935	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34118147	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs10971936	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34118988	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs72731217	ENSG00000281128.1	PTENP1-AS	6.22	1.08e-09	2.28e-07	0.58	0.28	Body mass index;	chr9:34119555	chr9:33677268~33688011:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000228039.3	KB-1125A3.10	6.22	1.08e-09	2.28e-07	0.37	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23963780~23964374:+
THCA	cis	rs7015630	0.657	rs34126178	ENSG00000251136.7	RP11-37B2.1	-6.22	1.08e-09	2.28e-07	-0.32	-0.28	Inflammatory bowel disease;Crohn's disease;	chr8:89807953	chr8:89609409~89757727:-
THCA	cis	rs4713118	0.739	rs2893931	ENSG00000280107.1	AL022393.9	-6.22	1.08e-09	2.28e-07	-0.33	-0.28	Parkinson's disease;	chr6:27780231	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.824	rs2092075	ENSG00000280107.1	AL022393.9	-6.22	1.08e-09	2.28e-07	-0.33	-0.28	Parkinson's disease;	chr6:27781551	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.824	rs13211701	ENSG00000280107.1	AL022393.9	-6.22	1.08e-09	2.28e-07	-0.33	-0.28	Parkinson's disease;	chr6:27782300	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.824	rs9468229	ENSG00000280107.1	AL022393.9	-6.22	1.08e-09	2.28e-07	-0.33	-0.28	Parkinson's disease;	chr6:27782307	chr6:28170845~28172521:+
THCA	cis	rs944990	0.513	rs10821144	ENSG00000227603.1	RP11-165J3.6	6.22	1.08e-09	2.28e-07	0.28	0.28	Body mass index;	chr9:93502976	chr9:93435332~93437121:-
THCA	cis	rs72843506	0.586	rs73296067	ENSG00000270091.1	RP11-78O7.2	-6.22	1.08e-09	2.29e-07	-0.32	-0.28	Schizophrenia;	chr17:19976988	chr17:19896590~19897287:-
THCA	cis	rs8012947	0.916	rs28411823	ENSG00000279636.2	LINC00216	-6.22	1.08e-09	2.29e-07	-0.3	-0.28	Alcohol consumption in current drinkers;	chr14:58239891	chr14:58288033~58289158:+
THCA	cis	rs950169	0.541	rs10795	ENSG00000259295.5	CSPG4P12	6.22	1.08e-09	2.29e-07	0.43	0.28	Schizophrenia;	chr15:84634066	chr15:85191438~85213905:+
THCA	cis	rs950169	0.58	rs36126054	ENSG00000259295.5	CSPG4P12	6.22	1.08e-09	2.29e-07	0.43	0.28	Schizophrenia;	chr15:84634492	chr15:85191438~85213905:+
THCA	cis	rs7727544	0.684	rs270602	ENSG00000237714.1	P4HA2-AS1	6.22	1.08e-09	2.29e-07	0.35	0.28	Blood metabolite levels;	chr5:132321007	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.684	rs272893	ENSG00000237714.1	P4HA2-AS1	6.22	1.08e-09	2.29e-07	0.35	0.28	Blood metabolite levels;	chr5:132327369	chr5:132184876~132192808:+
THCA	cis	rs79349575	0.716	rs46522	ENSG00000248278.1	SUMO2P17	6.22	1.08e-09	2.29e-07	0.34	0.28	Type 2 diabetes;	chr17:48911235	chr17:48874860~48908983:-
THCA	cis	rs5742933	0.681	rs4525728	ENSG00000253559.1	OSGEPL1-AS1	6.22	1.08e-09	2.29e-07	0.32	0.28	Ferritin levels;	chr2:189780324	chr2:189762704~189765556:+
THCA	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	6.22	1.08e-09	2.29e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
THCA	cis	rs2562456	0.682	rs11085464	ENSG00000268081.1	RP11-678G14.2	6.22	1.08e-09	2.29e-07	0.4	0.28	Pain;	chr19:21568976	chr19:21554640~21569237:-
THCA	cis	rs7976269	0.559	rs10843313	ENSG00000257176.2	RP11-996F15.2	-6.22	1.08e-09	2.3e-07	-0.28	-0.28	Male-pattern baldness;	chr12:29078317	chr12:29280418~29317848:-
THCA	cis	rs683257	0.636	rs17070386	ENSG00000234147.1	RP3-460G2.2	6.22	1.08e-09	2.3e-07	0.42	0.28	Facial emotion recognition (angry faces);	chr6:140850424	chr6:140845958~140852924:-
THCA	cis	rs4459386	0.509	rs10876020	ENSG00000272368.2	RP4-605O3.4	6.22	1.08e-09	2.3e-07	0.16	0.28	Schizophrenia;	chr12:50342482	chr12:50112197~50165618:+
THCA	cis	rs6142102	0.778	rs6059555	ENSG00000275784.1	RP5-1125A11.6	-6.22	1.08e-09	2.3e-07	-0.28	-0.28	Skin pigmentation;	chr20:33926518	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.778	rs4911374	ENSG00000275784.1	RP5-1125A11.6	-6.22	1.08e-09	2.3e-07	-0.28	-0.28	Skin pigmentation;	chr20:33928195	chr20:33989480~33991818:-
THCA	cis	rs28386778	0.901	rs2665855	ENSG00000240280.5	TCAM1P	-6.22	1.08e-09	2.3e-07	-0.39	-0.28	Prudent dietary pattern;	chr17:63887783	chr17:63849292~63864379:+
THCA	cis	rs12681366	0.683	rs2470739	ENSG00000253704.1	RP11-267M23.4	-6.22	1.08e-09	2.3e-07	-0.26	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94389694	chr8:94553722~94569745:+
THCA	cis	rs4950322	0.542	rs2883434	ENSG00000278811.3	LINC00624	6.22	1.08e-09	2.3e-07	0.31	0.28	Protein quantitative trait loci;	chr1:147177505	chr1:147258885~147517875:-
THCA	cis	rs7712401	0.755	rs27740	ENSG00000249996.1	RP11-359P5.1	-6.22	1.09e-09	2.3e-07	-0.26	-0.28	Mean platelet volume;	chr5:122869077	chr5:123036271~123054667:+
THCA	cis	rs950169	0.509	rs71395455	ENSG00000259295.5	CSPG4P12	6.22	1.09e-09	2.3e-07	0.43	0.28	Schizophrenia;	chr15:84610573	chr15:85191438~85213905:+
THCA	cis	rs8027521	1	rs8027521	ENSG00000280362.1	RP11-643A5.3	6.22	1.09e-09	2.3e-07	0.33	0.28	Circulating chemerin levels;	chr15:53964061	chr15:53910769~53914712:+
THCA	cis	rs10129255	0.5	rs1974468	ENSG00000280411.1	IGHV1-69-2	-6.22	1.09e-09	2.3e-07	-0.17	-0.28	Kawasaki disease;	chr14:106686149	chr14:106762092~106762588:-
THCA	cis	rs72843506	0.656	rs73984573	ENSG00000270091.1	RP11-78O7.2	-6.22	1.09e-09	2.3e-07	-0.3	-0.28	Schizophrenia;	chr17:20082027	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs78408002	ENSG00000270091.1	RP11-78O7.2	-6.22	1.09e-09	2.3e-07	-0.3	-0.28	Schizophrenia;	chr17:20082601	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs7210439	ENSG00000270091.1	RP11-78O7.2	-6.22	1.09e-09	2.3e-07	-0.3	-0.28	Schizophrenia;	chr17:20082728	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs7225605	ENSG00000270091.1	RP11-78O7.2	-6.22	1.09e-09	2.3e-07	-0.3	-0.28	Schizophrenia;	chr17:20083136	chr17:19896590~19897287:-
THCA	cis	rs5760092	0.572	rs738806	ENSG00000206090.4	AP000350.7	6.22	1.09e-09	2.3e-07	0.37	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23939998~23942798:+
THCA	cis	rs13113518	0.812	rs12505880	ENSG00000273257.1	RP11-177J6.1	6.22	1.09e-09	2.3e-07	0.37	0.28	Height;	chr4:55440988	chr4:55387949~55388271:+
THCA	cis	rs34779708	0.733	rs12254018	ENSG00000271335.4	RP11-324I22.4	6.22	1.09e-09	2.3e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35314552~35336401:-
THCA	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	6.22	1.09e-09	2.3e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	6.22	1.09e-09	2.3e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	6.22	1.09e-09	2.3e-07	0.25	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
THCA	cis	rs2253762	0.54	rs11200324	ENSG00000276742.1	RP11-500G22.4	-6.22	1.09e-09	2.3e-07	-0.4	-0.28	Breast cancer;	chr10:122009999	chr10:121956782~121957098:+
THCA	cis	rs4143844	0.867	rs71411468	ENSG00000259251.2	RP11-643M14.1	6.22	1.09e-09	2.3e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61894514	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs36056548	ENSG00000259251.2	RP11-643M14.1	6.22	1.09e-09	2.3e-07	0.53	0.28	Bipolar disorder and schizophrenia;	chr15:61904187	chr15:62060503~62062434:+
THCA	cis	rs748404	1	rs66651343	ENSG00000249839.1	AC011330.5	-6.22	1.09e-09	2.3e-07	-0.36	-0.28	Lung cancer;	chr15:43265806	chr15:43663654~43684339:-
THCA	cis	rs2657294	0.62	rs7475340	ENSG00000226051.5	ZNF503-AS1	-6.22	1.09e-09	2.31e-07	-0.39	-0.28	Pneumonia;	chr10:75079597	chr10:75269819~75373500:+
THCA	cis	rs12681366	0.683	rs2046665	ENSG00000253704.1	RP11-267M23.4	-6.22	1.09e-09	2.31e-07	-0.26	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94375731	chr8:94553722~94569745:+
THCA	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	6.22	1.09e-09	2.31e-07	0.43	0.28	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
THCA	cis	rs2562456	0.876	rs62110163	ENSG00000213976.4	CTD-2561J22.2	-6.22	1.09e-09	2.31e-07	-0.29	-0.28	Pain;	chr19:21546020	chr19:21382865~21387177:+
THCA	cis	rs2115630	0.936	rs8033459	ENSG00000225151.9	GOLGA2P7	6.22	1.09e-09	2.31e-07	0.36	0.28	P wave terminal force;	chr15:84710027	chr15:84199311~84230136:-
THCA	cis	rs9311474	1	rs7629072	ENSG00000243224.1	RP5-1157M23.2	-6.22	1.09e-09	2.31e-07	-0.28	-0.28	Electroencephalogram traits;	chr3:52271617	chr3:52239258~52241097:+
THCA	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-6.22	1.09e-09	2.31e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-6.22	1.09e-09	2.32e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
THCA	cis	rs11976180	1	rs1540894	ENSG00000170356.8	OR2A20P	-6.22	1.09e-09	2.32e-07	-0.38	-0.28	Obesity-related traits;	chr7:144070583	chr7:144250045~144252957:-
THCA	cis	rs10276381	0.786	rs740261	ENSG00000234336.5	JAZF1-AS1	-6.22	1.09e-09	2.32e-07	-0.4	-0.28	Crohn's disease;	chr7:28201657	chr7:28180322~28243917:+
THCA	cis	rs848490	1	rs10279537	ENSG00000214293.7	APTR	6.22	1.09e-09	2.32e-07	0.22	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77845644	chr7:77657660~77696265:-
THCA	cis	rs28472312	0.862	rs11150623	ENSG00000251417.2	RP11-1348G14.4	-6.22	1.09e-09	2.32e-07	-0.27	-0.28	Intelligence (multi-trait analysis);	chr16:28869680	chr16:28802743~28817828:+
THCA	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	6.22	1.09e-09	2.32e-07	0.31	0.28	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	6.22	1.09e-09	2.32e-07	0.31	0.28	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	6.22	1.09e-09	2.32e-07	0.31	0.28	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
THCA	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	6.22	1.1e-09	2.32e-07	0.35	0.28	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
THCA	cis	rs4650994	0.544	rs6664493	ENSG00000273384.1	RP5-1098D14.1	6.22	1.1e-09	2.32e-07	0.35	0.28	HDL cholesterol;HDL cholesterol levels;	chr1:178525293	chr1:178651706~178652282:+
THCA	cis	rs4713118	0.513	rs149975	ENSG00000280107.1	AL022393.9	-6.22	1.1e-09	2.33e-07	-0.29	-0.28	Parkinson's disease;	chr6:28018562	chr6:28170845~28172521:+
THCA	cis	rs9926296	0.585	rs1800337	ENSG00000260259.1	RP11-368I7.4	-6.22	1.1e-09	2.33e-07	-0.3	-0.28	Vitiligo;	chr16:89778786	chr16:89682620~89686569:-
THCA	cis	rs10875746	0.951	rs58865997	ENSG00000269514.1	RP11-370I10.12	6.22	1.1e-09	2.33e-07	0.28	0.28	Longevity (90 years and older);	chr12:48173090	chr12:48198387~48202031:+
THCA	cis	rs890448	0.726	rs293214	ENSG00000254531.1	FLJ20021	6.22	1.1e-09	2.33e-07	0.24	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101393116	chr4:101347780~101348883:+
THCA	cis	rs228614	0.51	rs223470	ENSG00000251288.2	RP11-10L12.2	-6.22	1.1e-09	2.33e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102751401~102752641:+
THCA	cis	rs2412819	0.597	rs541871	ENSG00000249839.1	AC011330.5	-6.22	1.1e-09	2.33e-07	-0.4	-0.28	Lung cancer;	chr15:43868656	chr15:43663654~43684339:-
THCA	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	6.22	1.1e-09	2.33e-07	0.3	0.28	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	6.22	1.1e-09	2.33e-07	0.3	0.28	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
THCA	cis	rs1005277	0.522	rs289643	ENSG00000263064.2	RP11-291L22.7	6.22	1.1e-09	2.33e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38448689~38448949:+
THCA	cis	rs2834188	0.924	rs6517159	ENSG00000272659.1	AP000295.10	-6.22	1.1e-09	2.33e-07	-0.37	-0.28	Narcolepsy;	chr21:33301095	chr21:33309491~33310181:+
THCA	cis	rs7202877	0.706	rs247425	ENSG00000261783.1	RP11-252K23.2	6.22	1.1e-09	2.33e-07	0.48	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75426504	chr16:75379818~75381260:-
THCA	cis	rs7119038	0.818	rs76704408	ENSG00000255239.1	AP002954.6	-6.22	1.1e-09	2.33e-07	-0.4	-0.28	Sjögren's syndrome;	chr11:118812618	chr11:118688039~118690600:-
THCA	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	6.22	1.1e-09	2.33e-07	0.35	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
THCA	cis	rs16949788	0.793	rs12439705	ENSG00000261351.2	CTD-3185P2.1	-6.22	1.1e-09	2.33e-07	-0.33	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66375665	chr15:66488658~66492109:-
THCA	cis	rs16949788	0.793	rs12439706	ENSG00000261351.2	CTD-3185P2.1	-6.22	1.1e-09	2.33e-07	-0.33	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66375666	chr15:66488658~66492109:-
THCA	cis	rs2243480	0.803	rs423187	ENSG00000228409.4	CCT6P1	6.22	1.1e-09	2.33e-07	0.32	0.28	Diabetic kidney disease;	chr7:66044512	chr7:65751142~65763354:+
THCA	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	6.22	1.1e-09	2.34e-07	0.36	0.28	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
THCA	cis	rs2657294	0.62	rs7475340	ENSG00000233313.2	HMGA1P5	-6.22	1.1e-09	2.34e-07	-0.38	-0.28	Pneumonia;	chr10:75079597	chr10:75276376~75276646:-
THCA	cis	rs368187	0.517	rs17836290	ENSG00000257826.1	RP11-116N8.4	-6.22	1.11e-09	2.34e-07	-0.29	-0.28	Thyroid cancer;	chr14:36021066	chr14:36061026~36067190:-
THCA	cis	rs2243480	1	rs12698509	ENSG00000232546.1	RP11-458F8.1	-6.22	1.11e-09	2.34e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65953889	chr7:66848496~66858136:+
THCA	cis	rs7246657	0.765	rs10402455	ENSG00000226686.6	LINC01535	-6.22	1.11e-09	2.34e-07	-0.44	-0.28	Coronary artery calcification;	chr19:37237805	chr19:37251912~37265535:+
THCA	cis	rs4835473	0.932	rs4240334	ENSG00000251600.4	RP11-673E1.1	6.22	1.11e-09	2.34e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143871352	chr4:143912331~143982454:+
THCA	cis	rs1005277	0.522	rs289645	ENSG00000263064.2	RP11-291L22.7	6.22	1.11e-09	2.35e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:38448689~38448949:+
THCA	cis	rs4950322	0.515	rs11239954	ENSG00000237188.3	RP11-337C18.8	6.22	1.11e-09	2.35e-07	0.33	0.28	Protein quantitative trait loci;	chr1:147246045	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.515	rs76327075	ENSG00000237188.3	RP11-337C18.8	6.22	1.11e-09	2.35e-07	0.33	0.28	Protein quantitative trait loci;	chr1:147246319	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.515	rs11239958	ENSG00000237188.3	RP11-337C18.8	6.22	1.11e-09	2.35e-07	0.33	0.28	Protein quantitative trait loci;	chr1:147247454	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.515	rs12060046	ENSG00000237188.3	RP11-337C18.8	6.22	1.11e-09	2.35e-07	0.33	0.28	Protein quantitative trait loci;	chr1:147249278	chr1:147172771~147211568:+
THCA	cis	rs7727544	0.684	rs274567	ENSG00000237714.1	P4HA2-AS1	-6.22	1.11e-09	2.35e-07	-0.35	-0.28	Blood metabolite levels;	chr5:132378717	chr5:132184876~132192808:+
THCA	cis	rs10829156	0.898	rs6482565	ENSG00000240291.1	RP11-499P20.2	6.22	1.11e-09	2.35e-07	0.23	0.28	Sudden cardiac arrest;	chr10:18611664	chr10:18513115~18545651:-
THCA	cis	rs11976180	1	rs1919950	ENSG00000170356.8	OR2A20P	-6.22	1.11e-09	2.35e-07	-0.38	-0.28	Obesity-related traits;	chr7:144070805	chr7:144250045~144252957:-
THCA	cis	rs1318937	0.764	rs60977744	ENSG00000224660.1	SH3BP5-AS1	6.22	1.11e-09	2.36e-07	0.19	0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15198464	chr3:15254184~15264493:+
THCA	cis	rs1318937	0.764	rs58837640	ENSG00000224660.1	SH3BP5-AS1	6.22	1.11e-09	2.36e-07	0.19	0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15199139	chr3:15254184~15264493:+
THCA	cis	rs10875746	0.624	rs11168498	ENSG00000269514.1	RP11-370I10.12	6.22	1.11e-09	2.36e-07	0.28	0.28	Longevity (90 years and older);	chr12:48261305	chr12:48198387~48202031:+
THCA	cis	rs2243480	1	rs13247184	ENSG00000232546.1	RP11-458F8.1	-6.22	1.11e-09	2.36e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65893941	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs35283677	ENSG00000232546.1	RP11-458F8.1	-6.22	1.11e-09	2.36e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65894246	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs35421653	ENSG00000232546.1	RP11-458F8.1	-6.22	1.11e-09	2.36e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65898442	chr7:66848496~66858136:+
THCA	cis	rs1876905	0.597	rs354551	ENSG00000255389.1	C6orf3	6.22	1.11e-09	2.36e-07	0.33	0.28	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111599875~111602295:+
THCA	cis	rs4950322	0.542	rs115179956	ENSG00000278811.3	LINC00624	6.22	1.11e-09	2.36e-07	0.31	0.28	Protein quantitative trait loci;	chr1:147172620	chr1:147258885~147517875:-
THCA	cis	rs934734	0.789	rs11689314	ENSG00000234255.7	AC012370.3	-6.22	1.12e-09	2.36e-07	-0.31	-0.28	Rheumatoid arthritis;	chr2:65378274	chr2:65439888~65456571:-
THCA	cis	rs12435908	0.867	rs73268557	ENSG00000276116.2	FUT8-AS1	-6.22	1.12e-09	2.36e-07	-0.44	-0.28	Ischemic stroke;	chr14:65654835	chr14:65411170~65412690:-
THCA	cis	rs1005277	0.579	rs2505194	ENSG00000276805.1	RP11-291L22.6	6.22	1.12e-09	2.36e-07	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38451030~38451785:+
THCA	cis	rs11158026	0.603	rs3783646	ENSG00000258413.1	RP11-665C16.6	-6.22	1.12e-09	2.36e-07	-0.39	-0.28	Parkinson's disease;	chr14:55005169	chr14:55262767~55272075:-
THCA	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-6.22	1.12e-09	2.36e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
THCA	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-6.22	1.12e-09	2.36e-07	-0.5	-0.28	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
THCA	cis	rs2562456	0.761	rs35008138	ENSG00000268081.1	RP11-678G14.2	6.22	1.12e-09	2.37e-07	0.4	0.28	Pain;	chr19:21548822	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs2681388	ENSG00000268081.1	RP11-678G14.2	6.22	1.12e-09	2.37e-07	0.4	0.28	Pain;	chr19:21549451	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.876	rs2681370	ENSG00000268081.1	RP11-678G14.2	6.22	1.12e-09	2.37e-07	0.4	0.28	Pain;	chr19:21554036	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.876	rs11668606	ENSG00000268081.1	RP11-678G14.2	6.22	1.12e-09	2.37e-07	0.4	0.28	Pain;	chr19:21554618	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.876	rs2681395	ENSG00000268081.1	RP11-678G14.2	6.22	1.12e-09	2.37e-07	0.4	0.28	Pain;	chr19:21555338	chr19:21554640~21569237:-
THCA	cis	rs16949788	1	rs16949788	ENSG00000261351.2	CTD-3185P2.1	-6.22	1.12e-09	2.37e-07	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66297699	chr15:66488658~66492109:-
THCA	cis	rs35343117	1	rs35343117	ENSG00000259295.5	CSPG4P12	6.22	1.12e-09	2.37e-07	0.42	0.28	Psoriasis;	chr15:85535884	chr15:85191438~85213905:+
THCA	cis	rs9487094	0.645	rs34533653	ENSG00000260273.1	RP11-425D10.10	6.22	1.12e-09	2.37e-07	0.38	0.28	Height;	chr6:109479488	chr6:109382795~109383666:+
THCA	cis	rs9902453	0.679	rs2054847	ENSG00000264007.1	RP11-68I3.10	6.22	1.12e-09	2.37e-07	0.32	0.28	Coffee consumption (cups per day);	chr17:30204995	chr17:29621617~29622254:-
THCA	cis	rs1552244	0.882	rs6443276	ENSG00000232901.1	CYCSP10	6.22	1.12e-09	2.37e-07	0.34	0.28	Alzheimer's disease;	chr3:9967221	chr3:10000647~10000940:-
THCA	cis	rs6545883	0.929	rs6545873	ENSG00000271889.1	RP11-493E12.1	6.22	1.12e-09	2.37e-07	0.27	0.28	Tuberculosis;	chr2:61505877	chr2:61151433~61162105:-
THCA	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-6.22	1.12e-09	2.37e-07	-0.29	-0.28	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
THCA	cis	rs728616	0.681	rs17100316	ENSG00000242600.5	MBL1P	6.22	1.12e-09	2.37e-07	0.34	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80153581	chr10:79904898~79950336:+
THCA	cis	rs728616	0.681	rs36073865	ENSG00000242600.5	MBL1P	6.22	1.12e-09	2.37e-07	0.34	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156299	chr10:79904898~79950336:+
THCA	cis	rs8007846	0.588	rs12894034	ENSG00000276116.2	FUT8-AS1	6.22	1.12e-09	2.37e-07	0.28	0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65772045	chr14:65411170~65412690:-
THCA	cis	rs1823913	1	rs68014803	ENSG00000227542.1	AC092614.2	6.22	1.12e-09	2.37e-07	0.34	0.28	Obesity-related traits;	chr2:191241877	chr2:191229165~191246172:-
THCA	cis	rs8027521	0.519	rs1993865	ENSG00000280362.1	RP11-643A5.3	6.22	1.12e-09	2.37e-07	0.34	0.28	Circulating chemerin levels;	chr15:53922523	chr15:53910769~53914712:+
THCA	cis	rs227275	0.554	rs223421	ENSG00000230069.3	LRRC37A15P	-6.22	1.12e-09	2.37e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102727274~102730721:-
THCA	cis	rs934734	0.752	rs1039764	ENSG00000281920.1	RP11-418H16.1	-6.22	1.12e-09	2.37e-07	-0.34	-0.28	Rheumatoid arthritis;	chr2:65387479	chr2:65623272~65628424:+
THCA	cis	rs72627509	0.556	rs4412049	ENSG00000269949.1	RP11-738E22.3	6.22	1.12e-09	2.37e-07	0.41	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56861796	chr4:56960927~56961373:-
THCA	cis	rs6600671	0.934	rs7528274	ENSG00000275538.1	RNVU1-19	6.22	1.12e-09	2.38e-07	0.35	0.28	Hip geometry;	chr1:121545103	chr1:120850819~120850985:-
THCA	cis	rs451417	1	rs236105	ENSG00000275632.1	RP5-967N21.11	-6.22	1.12e-09	2.38e-07	-0.31	-0.28	Menopause (age at onset);	chr20:5979186	chr20:6000418~6000941:+
THCA	cis	rs5742933	0.817	rs13035966	ENSG00000253559.1	OSGEPL1-AS1	6.22	1.12e-09	2.38e-07	0.31	0.28	Ferritin levels;	chr2:189726507	chr2:189762704~189765556:+
THCA	cis	rs4841097	0.876	rs6601288	ENSG00000253893.2	FAM85B	-6.22	1.12e-09	2.38e-07	-0.38	-0.28	Platelet distribution width;	chr8:9085920	chr8:8167819~8226614:-
THCA	cis	rs9990333	0.622	rs57783901	ENSG00000226155.1	AC124944.3	-6.22	1.13e-09	2.38e-07	-0.33	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195912049~195913986:+
THCA	cis	rs2439831	0.867	rs6493082	ENSG00000249839.1	AC011330.5	-6.22	1.13e-09	2.38e-07	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43342610	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs8041132	ENSG00000249839.1	AC011330.5	-6.22	1.13e-09	2.38e-07	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43342938	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs16957627	ENSG00000249839.1	AC011330.5	-6.22	1.13e-09	2.38e-07	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43350459	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.717	rs7165471	ENSG00000249839.1	AC011330.5	-6.22	1.13e-09	2.38e-07	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43352590	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs4075674	ENSG00000249839.1	AC011330.5	-6.22	1.13e-09	2.38e-07	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43358032	chr15:43663654~43684339:-
THCA	cis	rs934734	0.563	rs1858037	ENSG00000234255.7	AC012370.3	6.22	1.13e-09	2.38e-07	0.33	0.28	Rheumatoid arthritis;	chr2:65371166	chr2:65439888~65456571:-
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000235689.1	AP000351.13	6.22	1.13e-09	2.38e-07	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:24006305~24008258:-
THCA	cis	rs7615952	0.599	rs67566088	ENSG00000250012.1	RP11-124N2.1	-6.22	1.13e-09	2.38e-07	-0.26	-0.28	Blood pressure (smoking interaction);	chr3:126050130	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs12495947	ENSG00000250012.1	RP11-124N2.1	-6.22	1.13e-09	2.38e-07	-0.26	-0.28	Blood pressure (smoking interaction);	chr3:126052855	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs6805074	ENSG00000250012.1	RP11-124N2.1	-6.22	1.13e-09	2.38e-07	-0.26	-0.28	Blood pressure (smoking interaction);	chr3:126053431	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs4422257	ENSG00000250012.1	RP11-124N2.1	-6.22	1.13e-09	2.38e-07	-0.26	-0.28	Blood pressure (smoking interaction);	chr3:126055520	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs66520539	ENSG00000250012.1	RP11-124N2.1	-6.22	1.13e-09	2.38e-07	-0.26	-0.28	Blood pressure (smoking interaction);	chr3:126061531	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs7632497	ENSG00000250012.1	RP11-124N2.1	-6.22	1.13e-09	2.38e-07	-0.26	-0.28	Blood pressure (smoking interaction);	chr3:126064243	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs12487875	ENSG00000250012.1	RP11-124N2.1	-6.22	1.13e-09	2.38e-07	-0.26	-0.28	Blood pressure (smoking interaction);	chr3:126068381	chr3:126084220~126095349:+
THCA	cis	rs72843506	0.656	rs16960678	ENSG00000270091.1	RP11-78O7.2	-6.22	1.13e-09	2.39e-07	-0.3	-0.28	Schizophrenia;	chr17:20080378	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs73984571	ENSG00000270091.1	RP11-78O7.2	-6.22	1.13e-09	2.39e-07	-0.3	-0.28	Schizophrenia;	chr17:20080746	chr17:19896590~19897287:-
THCA	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	6.22	1.13e-09	2.39e-07	0.27	0.28	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
THCA	cis	rs3096299	0.838	rs3102376	ENSG00000274627.1	RP11-104N10.2	6.22	1.13e-09	2.39e-07	0.26	0.28	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89516797~89522217:+
THCA	cis	rs4835473	0.9	rs12506168	ENSG00000251600.4	RP11-673E1.1	-6.22	1.13e-09	2.39e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144085653	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs62334608	ENSG00000251600.4	RP11-673E1.1	-6.22	1.13e-09	2.39e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144093427	chr4:143912331~143982454:+
THCA	cis	rs6545883	0.86	rs13023037	ENSG00000271889.1	RP11-493E12.1	-6.22	1.13e-09	2.39e-07	-0.27	-0.28	Tuberculosis;	chr2:61393854	chr2:61151433~61162105:-
THCA	cis	rs1949733	0.523	rs55977448	ENSG00000205959.3	RP11-689P11.2	6.21	1.13e-09	2.4e-07	0.25	0.28	Response to antineoplastic agents;	chr4:8541191	chr4:8482270~8512610:+
THCA	cis	rs1865760	0.865	rs2164485	ENSG00000272462.2	U91328.19	-6.21	1.13e-09	2.4e-07	-0.23	-0.28	Height;	chr6:25951878	chr6:25992662~26001775:+
THCA	cis	rs11722779	0.658	rs6533044	ENSG00000251288.2	RP11-10L12.2	-6.21	1.13e-09	2.4e-07	-0.37	-0.28	Schizophrenia;	chr4:102965261	chr4:102751401~102752641:+
THCA	cis	rs317689	0.581	rs315132	ENSG00000274979.1	RP11-1143G9.5	-6.21	1.13e-09	2.4e-07	-0.32	-0.28	Response to diuretic therapy;	chr12:69368216	chr12:69326574~69331882:-
THCA	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	6.21	1.14e-09	2.4e-07	0.38	0.28	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
THCA	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-6.21	1.14e-09	2.4e-07	-0.45	-0.28	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
THCA	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-6.21	1.14e-09	2.4e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
THCA	cis	rs3213958	0.621	rs73138053	ENSG00000249274.1	PDLIM1P4	-6.21	1.14e-09	2.4e-07	-0.35	-0.28	Blood protein levels;	chr3:98876058	chr3:98782188~98783193:+
THCA	cis	rs853679	0.517	rs1947863	ENSG00000261839.1	RP1-265C24.8	6.21	1.14e-09	2.4e-07	0.33	0.28	Depression;	chr6:28131566	chr6:28136849~28139678:+
THCA	cis	rs8014252	0.803	rs60860517	ENSG00000259158.2	ADAM20P1	-6.21	1.14e-09	2.4e-07	-0.34	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70563202	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs10135356	ENSG00000259158.2	ADAM20P1	-6.21	1.14e-09	2.4e-07	-0.34	-0.28	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70563638	chr14:70468881~70483756:-
THCA	cis	rs4950322	0.517	rs114823926	ENSG00000278811.3	LINC00624	6.21	1.14e-09	2.4e-07	0.34	0.28	Protein quantitative trait loci;	chr1:147281805	chr1:147258885~147517875:-
THCA	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-6.21	1.14e-09	2.4e-07	-0.3	-0.28	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-6.21	1.14e-09	2.4e-07	-0.3	-0.28	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-6.21	1.14e-09	2.4e-07	-0.3	-0.28	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
THCA	cis	rs3742264	0.961	rs11620308	ENSG00000235903.6	CPB2-AS1	-6.21	1.14e-09	2.41e-07	-0.37	-0.28	Blood protein levels;	chr13:46075588	chr13:46052806~46113332:+
THCA	cis	rs7202877	0.706	rs1540	ENSG00000261783.1	RP11-252K23.2	6.21	1.14e-09	2.41e-07	0.49	0.28	Type 1 diabetes;Type 2 diabetes;	chr16:75447287	chr16:75379818~75381260:-
THCA	cis	rs9813712	0.571	rs11715351	ENSG00000253540.4	FAM86HP	-6.21	1.14e-09	2.41e-07	-0.3	-0.28	Response to amphetamines;	chr3:130214704	chr3:130099092~130111472:-
THCA	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-6.21	1.14e-09	2.41e-07	-0.3	-0.28	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-6.21	1.14e-09	2.41e-07	-0.3	-0.28	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
THCA	cis	rs681343	1	rs681343	ENSG00000232871.7	SEC1P	6.21	1.14e-09	2.41e-07	0.33	0.28	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48703205	chr19:48638071~48682245:+
THCA	cis	rs9813712	0.953	rs12635811	ENSG00000249846.5	RP11-77P16.4	-6.21	1.14e-09	2.41e-07	-0.32	-0.28	Response to amphetamines;	chr3:130262534	chr3:130112550~130120579:+
THCA	cis	rs12435908	1	rs17826796	ENSG00000276116.2	FUT8-AS1	-6.21	1.14e-09	2.41e-07	-0.44	-0.28	Ischemic stroke;	chr14:65637469	chr14:65411170~65412690:-
THCA	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	6.21	1.14e-09	2.42e-07	0.43	0.28	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65916269	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65918212	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65922114	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65923503	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65925372	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65925938	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000232546.1	RP11-458F8.1	6.21	1.14e-09	2.42e-07	0.35	0.28	Diabetic kidney disease;	chr7:65928187	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65940221	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65943626	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65944004	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	2.42e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65944182	chr7:66848496~66858136:+
THCA	cis	rs1031391	0.716	rs10772416	ENSG00000247157.5	LINC01252	-6.21	1.14e-09	2.42e-07	-0.41	-0.28	Bitter taste perception;	chr12:11017488	chr12:11548030~11590369:+
THCA	cis	rs1552244	0.882	rs68080705	ENSG00000180385.7	EMC3-AS1	6.21	1.14e-09	2.42e-07	0.29	0.28	Alzheimer's disease;	chr3:9984059	chr3:9986893~10006990:+
THCA	cis	rs9393777	0.841	rs13207082	ENSG00000226314.6	ZNF192P1	-6.21	1.14e-09	2.42e-07	-0.53	-0.28	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28161781~28169594:+
THCA	cis	rs847577	0.55	rs6465654	ENSG00000272950.1	RP11-307C18.1	6.21	1.14e-09	2.42e-07	0.35	0.28	Breast cancer;	chr7:98156970	chr7:98322853~98323430:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	6.21	1.14e-09	2.42e-07	0.31	0.28	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
THCA	cis	rs7208859	0.614	rs4794874	ENSG00000264538.5	SUZ12P1	6.21	1.15e-09	2.42e-07	0.27	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30709299~30790908:+
THCA	cis	rs8007846	0.569	rs6573627	ENSG00000276116.2	FUT8-AS1	-6.21	1.15e-09	2.42e-07	-0.28	-0.28	Multiple sclerosis--Brain Glutamate Levels;	chr14:65785608	chr14:65411170~65412690:-
THCA	cis	rs728616	1	rs56317427	ENSG00000242600.5	MBL1P	6.21	1.15e-09	2.42e-07	0.38	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80102178	chr10:79904898~79950336:+
THCA	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	6.21	1.15e-09	2.42e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174230438	chr1:174115300~174160004:-
THCA	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-6.21	1.15e-09	2.43e-07	-0.43	-0.28	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
THCA	cis	rs4805272	0.82	rs10408080	ENSG00000267799.1	MAN1A2P1	-6.21	1.15e-09	2.43e-07	-0.3	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28850745	chr19:28790812~28792871:-
THCA	cis	rs8067545	0.72	rs9916675	ENSG00000270091.1	RP11-78O7.2	-6.21	1.15e-09	2.43e-07	-0.2	-0.28	Schizophrenia;	chr17:19996855	chr17:19896590~19897287:-
THCA	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-6.21	1.15e-09	2.43e-07	-0.35	-0.28	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
THCA	cis	rs440932	0.565	rs19334	ENSG00000254340.1	RP11-10A14.3	6.21	1.15e-09	2.43e-07	0.31	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:9141424~9145435:+
THCA	cis	rs7176527	0.8	rs56747535	ENSG00000188388.10	GOLGA6L3	6.21	1.15e-09	2.43e-07	0.44	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85240472~85247170:+
THCA	cis	rs7851660	0.967	rs3021526	ENSG00000214417.4	KRT18P13	-6.21	1.15e-09	2.43e-07	-0.23	-0.28	Strep throat;	chr9:97854739	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs1443434	ENSG00000214417.4	KRT18P13	-6.21	1.15e-09	2.43e-07	-0.23	-0.28	Strep throat;	chr9:97855197	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.967	rs1443435	ENSG00000214417.4	KRT18P13	-6.21	1.15e-09	2.43e-07	-0.23	-0.28	Strep throat;	chr9:97855301	chr9:97698922~97700734:+
THCA	cis	rs73110464	0.609	rs727266	ENSG00000278185.1	RP11-153F5.7	6.21	1.15e-09	2.44e-07	0.29	0.28	Cancer (pleiotropy);	chr12:52962627	chr12:52946614~52947125:-
THCA	cis	rs10208649	0.536	rs3821080	ENSG00000272156.1	RP11-477N3.1	6.21	1.15e-09	2.44e-07	0.38	0.28	Body mass index;	chr2:53740109	chr2:54082554~54085066:+
THCA	cis	rs9902453	0.654	rs3794809	ENSG00000264007.1	RP11-68I3.10	6.21	1.15e-09	2.44e-07	0.31	0.28	Coffee consumption (cups per day);	chr17:30204240	chr17:29621617~29622254:-
THCA	cis	rs11672691	0.756	rs8107333	ENSG00000267107.5	PCAT19	6.21	1.16e-09	2.44e-07	0.31	0.28	Prostate cancer;	chr19:41481965	chr19:41454169~41500649:-
THCA	cis	rs944990	0.538	rs10761234	ENSG00000227603.1	RP11-165J3.6	6.21	1.16e-09	2.44e-07	0.28	0.28	Body mass index;	chr9:93545230	chr9:93435332~93437121:-
THCA	cis	rs965513	0.627	rs7848973	ENSG00000236130.1	PTCSC2	-6.21	1.16e-09	2.44e-07	-0.23	-0.28	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97826557	chr9:97805935~97810008:-
THCA	cis	rs10276381	0.786	rs10272155	ENSG00000234336.5	JAZF1-AS1	-6.21	1.16e-09	2.44e-07	-0.39	-0.28	Crohn's disease;	chr7:28207370	chr7:28180322~28243917:+
THCA	cis	rs2562456	0.561	rs12610883	ENSG00000268081.1	RP11-678G14.2	6.21	1.16e-09	2.44e-07	0.4	0.28	Pain;	chr19:21567257	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	6.21	1.16e-09	2.44e-07	0.4	0.28	Pain;	chr19:21567846	chr19:21554640~21569237:-
THCA	cis	rs7727544	0.684	rs274560	ENSG00000237714.1	P4HA2-AS1	-6.21	1.16e-09	2.44e-07	-0.35	-0.28	Blood metabolite levels;	chr5:132383758	chr5:132184876~132192808:+
THCA	cis	rs6504622	0.755	rs12939753	ENSG00000262879.4	RP11-156P1.3	-6.21	1.16e-09	2.44e-07	-0.25	-0.28	Orofacial clefts;	chr17:47104133	chr17:46984045~47100323:-
THCA	cis	rs6840360	0.582	rs2709812	ENSG00000251611.1	RP11-610P16.1	6.21	1.16e-09	2.44e-07	0.21	0.28	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151407551~151408835:-
THCA	cis	rs9800506	0.584	rs6924087	ENSG00000228559.1	RP3-340B19.3	6.21	1.16e-09	2.44e-07	0.39	0.28	Neutrophil percentage of granulocytes;	chr6:35563428	chr6:35544632~35545669:+
THCA	cis	rs34779708	0.733	rs3853672	ENSG00000271335.4	RP11-324I22.4	6.21	1.16e-09	2.44e-07	0.27	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35314552~35336401:-
THCA	cis	rs2915864	0.747	rs61250178	ENSG00000280047.1	CTC-463A16.1	6.21	1.16e-09	2.45e-07	0.45	0.28	Facial morphology (factor 20);	chr5:142111058	chr5:142165767~142168387:+
THCA	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	6.21	1.16e-09	2.45e-07	0.23	0.28	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
THCA	cis	rs240993	0.809	rs11153277	ENSG00000272356.1	RP5-1112D6.8	-6.21	1.16e-09	2.45e-07	-0.24	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111309203~111313517:+
THCA	cis	rs11096990	0.892	rs3733288	ENSG00000249207.1	RP11-360F5.1	6.21	1.16e-09	2.45e-07	0.36	0.28	Cognitive function;	chr4:39216949	chr4:39112677~39126818:-
THCA	cis	rs2243480	1	rs2462569	ENSG00000232546.1	RP11-458F8.1	6.21	1.16e-09	2.45e-07	0.35	0.28	Diabetic kidney disease;	chr7:66009859	chr7:66848496~66858136:+
THCA	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-6.21	1.16e-09	2.45e-07	-0.26	-0.28	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-6.21	1.16e-09	2.45e-07	-0.26	-0.28	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
THCA	cis	rs950169	0.922	rs12906983	ENSG00000259295.5	CSPG4P12	6.21	1.16e-09	2.45e-07	0.43	0.28	Schizophrenia;	chr15:84262270	chr15:85191438~85213905:+
THCA	cis	rs2439831	0.681	rs2278859	ENSG00000249839.1	AC011330.5	-6.21	1.16e-09	2.45e-07	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43340762	chr15:43663654~43684339:-
THCA	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-6.21	1.16e-09	2.45e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-6.21	1.16e-09	2.45e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-6.21	1.16e-09	2.45e-07	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
THCA	cis	rs922182	0.845	rs17777742	ENSG00000275785.1	RP11-111E14.2	6.21	1.16e-09	2.46e-07	0.33	0.28	Blood protein levels;	chr15:63982160	chr15:63890030~63890317:+
THCA	cis	rs6088590	0.61	rs6120663	ENSG00000276073.1	RP5-1125A11.7	6.21	1.16e-09	2.46e-07	0.25	0.28	Coronary artery disease;	chr20:34494101	chr20:33985617~33988989:-
THCA	cis	rs2243480	0.708	rs781141	ENSG00000232546.1	RP11-458F8.1	-6.21	1.16e-09	2.46e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65973566	chr7:66848496~66858136:+
THCA	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-6.21	1.17e-09	2.46e-07	-0.34	-0.28	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
THCA	cis	rs9677476	0.909	rs7573577	ENSG00000224376.1	AC017104.6	6.21	1.17e-09	2.46e-07	0.32	0.28	Food antigen IgG levels;	chr2:231239366	chr2:231388976~231394991:+
THCA	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	6.21	1.17e-09	2.46e-07	0.4	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
THCA	cis	rs7201929	1	rs7499878	ENSG00000251417.2	RP11-1348G14.4	6.21	1.17e-09	2.46e-07	0.29	0.28	QT interval;	chr16:28857143	chr16:28802743~28817828:+
THCA	cis	rs5758659	0.714	rs7245	ENSG00000270083.1	RP1-257I20.14	-6.21	1.17e-09	2.46e-07	-0.29	-0.28	Cognitive function;	chr22:42085845	chr22:42089630~42090028:-
THCA	cis	rs17772222	0.682	rs7142053	ENSG00000258983.2	RP11-507K2.2	6.21	1.17e-09	2.46e-07	0.31	0.28	Coronary artery calcification;	chr14:88511594	chr14:88499334~88515502:+
THCA	cis	rs5742933	0.857	rs1437891	ENSG00000253559.1	OSGEPL1-AS1	-6.21	1.17e-09	2.46e-07	-0.31	-0.28	Ferritin levels;	chr2:189697982	chr2:189762704~189765556:+
THCA	cis	rs10027350	0.765	rs6838393	ENSG00000281501.1	SEPSECS-AS1	6.21	1.17e-09	2.46e-07	0.31	0.28	Childhood ear infection;	chr4:25172629	chr4:25160641~25201440:+
THCA	cis	rs13113518	0.812	rs6830409	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55522229	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs2035692	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55528801	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs4507426	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55529387	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs2035691	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55529786	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.756	rs11939652	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55532542	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs13107810	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55542243	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs7667741	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55544621	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs13140590	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55548666	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs13116035	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55561218	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.783	rs2171618	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55564241	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.783	rs7690837	ENSG00000273257.1	RP11-177J6.1	6.21	1.17e-09	2.47e-07	0.37	0.28	Height;	chr4:55575856	chr4:55387949~55388271:+
THCA	cis	rs10875746	0.951	rs4760689	ENSG00000269514.1	RP11-370I10.12	6.21	1.17e-09	2.47e-07	0.28	0.28	Longevity (90 years and older);	chr12:48169861	chr12:48198387~48202031:+
THCA	cis	rs4663866	1	rs71426508	ENSG00000186235.9	AC016757.3	6.21	1.17e-09	2.47e-07	0.62	0.28	Irritable bowel syndrome;	chr2:238229126	chr2:238224552~238231677:-
THCA	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	6.21	1.17e-09	2.47e-07	0.21	0.28	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
THCA	cis	rs4835473	0.808	rs62334569	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144081617	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs62334572	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144082688	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.838	rs7675833	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144083315	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13131176	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144086655	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13118488	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144087490	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs34113094	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144087840	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs3901418	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144089427	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs34343851	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144091704	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs62334609	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144093452	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.868	rs6834756	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144093813	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.778	rs6818017	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144093868	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.9	rs13112465	ENSG00000251600.4	RP11-673E1.1	-6.21	1.17e-09	2.47e-07	-0.39	-0.28	Immature fraction of reticulocytes;	chr4:144096711	chr4:143912331~143982454:+
THCA	cis	rs4845875	0.626	rs11121827	ENSG00000242349.4	NPPA-AS1	6.21	1.17e-09	2.47e-07	0.27	0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11772043	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.626	rs10779764	ENSG00000242349.4	NPPA-AS1	6.21	1.17e-09	2.47e-07	0.27	0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11772254	chr1:11841017~11848079:+
THCA	cis	rs7403037	0.876	rs61993152	ENSG00000259905.4	PWRN1	6.21	1.17e-09	2.47e-07	0.3	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24553782	chr15:24493137~24652130:+
THCA	cis	rs8012947	0.565	rs7151036	ENSG00000279636.2	LINC00216	6.21	1.17e-09	2.48e-07	0.25	0.28	Alcohol consumption in current drinkers;	chr14:58356315	chr14:58288033~58289158:+
THCA	cis	rs9921338	0.961	rs4390613	ENSG00000262636.1	CTD-3088G3.4	6.21	1.17e-09	2.48e-07	0.4	0.28	Vein graft stenosis in coronary artery bypass grafting;	chr16:11328979	chr16:11380859~11381118:-
THCA	cis	rs10266483	0.774	rs10949901	ENSG00000227986.1	TRIM60P18	6.21	1.18e-09	2.48e-07	0.24	0.28	Response to statin therapy;	chr7:64352396	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.774	rs10239221	ENSG00000227986.1	TRIM60P18	6.21	1.18e-09	2.48e-07	0.24	0.28	Response to statin therapy;	chr7:64352852	chr7:64355078~64356199:+
THCA	cis	rs728616	0.764	rs12413678	ENSG00000242600.5	MBL1P	6.21	1.18e-09	2.48e-07	0.38	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927343	chr10:79904898~79950336:+
THCA	cis	rs1552244	0.7	rs9833566	ENSG00000180385.7	EMC3-AS1	6.21	1.18e-09	2.48e-07	0.3	0.28	Alzheimer's disease;	chr3:9939987	chr3:9986893~10006990:+
THCA	cis	rs5743077	1	rs5743077	ENSG00000273240.1	RP11-455J20.3	-6.21	1.18e-09	2.48e-07	-0.37	-0.28	Iron status biomarkers (ferritin levels);	chr2:189832613	chr2:189763859~189764456:-
THCA	cis	rs4835473	0.864	rs4835343	ENSG00000251600.4	RP11-673E1.1	6.21	1.18e-09	2.48e-07	0.38	0.28	Immature fraction of reticulocytes;	chr4:143866038	chr4:143912331~143982454:+
THCA	cis	rs4950322	0.542	rs12046706	ENSG00000278811.3	LINC00624	6.21	1.18e-09	2.49e-07	0.31	0.28	Protein quantitative trait loci;	chr1:147189758	chr1:147258885~147517875:-
THCA	cis	rs61677309	0.638	rs7940554	ENSG00000280032.1	RP11-832A4.7	6.21	1.18e-09	2.49e-07	0.28	0.28	Lung cancer in ever smokers;	chr11:118272215	chr11:118264593~118266817:+
THCA	cis	rs748404	0.604	rs2278857	ENSG00000166763.7	STRCP1	6.21	1.18e-09	2.49e-07	0.29	0.28	Lung cancer;	chr15:43340351	chr15:43699488~43718184:-
THCA	cis	rs11668609	0.935	rs10412575	ENSG00000268442.1	CTD-2027I19.2	6.21	1.18e-09	2.49e-07	0.34	0.28	Response to taxane treatment (docetaxel);	chr19:24186084	chr19:24162370~24163425:-
THCA	cis	rs4664293	0.764	rs1425044	ENSG00000226266.5	AC009961.3	-6.21	1.18e-09	2.49e-07	-0.31	-0.28	Monocyte percentage of white cells;	chr2:159618426	chr2:159670708~159712435:-
THCA	cis	rs4713118	0.513	rs149972	ENSG00000280107.1	AL022393.9	-6.21	1.18e-09	2.5e-07	-0.29	-0.28	Parkinson's disease;	chr6:28015449	chr6:28170845~28172521:+
THCA	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	6.21	1.18e-09	2.5e-07	0.21	0.28	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
THCA	cis	rs9880211	0.848	rs71336069	ENSG00000273486.1	RP11-731C17.2	6.21	1.18e-09	2.5e-07	0.29	0.28	Height;Body mass index;	chr3:136633024	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs28750366	ENSG00000273486.1	RP11-731C17.2	6.21	1.18e-09	2.5e-07	0.29	0.28	Height;Body mass index;	chr3:136642213	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.846	rs73230043	ENSG00000273486.1	RP11-731C17.2	6.21	1.18e-09	2.5e-07	0.29	0.28	Height;Body mass index;	chr3:136688317	chr3:136837338~136839021:-
THCA	cis	rs16958440	1	rs60422392	ENSG00000267800.1	RP11-49K24.5	-6.21	1.18e-09	2.5e-07	-0.58	-0.28	Sitting height ratio;	chr18:47095102	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs2289130	ENSG00000267800.1	RP11-49K24.5	-6.21	1.18e-09	2.5e-07	-0.58	-0.28	Sitting height ratio;	chr18:47100259	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs62096463	ENSG00000267800.1	RP11-49K24.5	-6.21	1.18e-09	2.5e-07	-0.58	-0.28	Sitting height ratio;	chr18:47102557	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs62096464	ENSG00000267800.1	RP11-49K24.5	-6.21	1.18e-09	2.5e-07	-0.58	-0.28	Sitting height ratio;	chr18:47102836	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs16958432	ENSG00000267800.1	RP11-49K24.5	-6.21	1.18e-09	2.5e-07	-0.58	-0.28	Sitting height ratio;	chr18:47105402	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs16958440	ENSG00000267800.1	RP11-49K24.5	-6.21	1.18e-09	2.5e-07	-0.58	-0.28	Sitting height ratio;	chr18:47106513	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs75800624	ENSG00000267800.1	RP11-49K24.5	-6.21	1.18e-09	2.5e-07	-0.58	-0.28	Sitting height ratio;	chr18:47107234	chr18:47137018~47137290:+
THCA	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	6.21	1.18e-09	2.5e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	6.21	1.18e-09	2.5e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	6.21	1.18e-09	2.5e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	6.21	1.18e-09	2.5e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	6.21	1.18e-09	2.5e-07	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
THCA	cis	rs4835473	0.932	rs4305468	ENSG00000251600.4	RP11-673E1.1	-6.21	1.19e-09	2.5e-07	-0.36	-0.28	Immature fraction of reticulocytes;	chr4:143987315	chr4:143912331~143982454:+
THCA	cis	rs1552244	0.832	rs3732968	ENSG00000180385.7	EMC3-AS1	6.21	1.19e-09	2.5e-07	0.29	0.28	Alzheimer's disease;	chr3:9971589	chr3:9986893~10006990:+
THCA	cis	rs950169	0.656	rs748455	ENSG00000259295.5	CSPG4P12	6.21	1.19e-09	2.5e-07	0.43	0.28	Schizophrenia;	chr15:84606344	chr15:85191438~85213905:+
THCA	cis	rs12681366	0.663	rs10216902	ENSG00000253704.1	RP11-267M23.4	6.21	1.19e-09	2.5e-07	0.26	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94467750	chr8:94553722~94569745:+
THCA	cis	rs9380516	0.891	rs4713892	ENSG00000228559.1	RP3-340B19.3	-6.21	1.19e-09	2.5e-07	-0.4	-0.28	Hepatitis C induced liver fibrosis;	chr6:35550178	chr6:35544632~35545669:+
THCA	cis	rs116139393	0.611	rs62439722	ENSG00000187953.9	PMS2CL	-6.21	1.19e-09	2.5e-07	-0.37	-0.28	Alzheimer's disease (APOE e4 interaction);	chr7:6725309	chr7:6710128~6753862:+
THCA	cis	rs860295	0.678	rs12563627	ENSG00000225855.5	RUSC1-AS1	-6.21	1.19e-09	2.51e-07	-0.18	-0.28	Body mass index;	chr1:155893175	chr1:155316863~155324176:-
THCA	cis	rs4835473	0.868	rs5025156	ENSG00000251600.4	RP11-673E1.1	-6.21	1.19e-09	2.51e-07	-0.37	-0.28	Immature fraction of reticulocytes;	chr4:143738025	chr4:143912331~143982454:+
THCA	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	6.21	1.19e-09	2.51e-07	0.46	0.28	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
THCA	cis	rs516805	0.596	rs2606625	ENSG00000279453.1	RP3-425C14.4	-6.21	1.19e-09	2.51e-07	-0.31	-0.28	Lymphocyte counts;	chr6:122165363	chr6:122436789~122439223:-
THCA	cis	rs12550612	1	rs12550612	ENSG00000253616.4	RP11-875O11.3	6.21	1.19e-09	2.51e-07	0.38	0.28	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109256	chr8:23071377~23074488:-
THCA	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	6.21	1.19e-09	2.51e-07	0.42	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
THCA	cis	rs10129255	1	rs9324091	ENSG00000211974.3	IGHV2-70	6.21	1.19e-09	2.51e-07	0.21	0.28	Kawasaki disease;	chr14:106676625	chr14:106723574~106724093:-
THCA	cis	rs10129255	1	rs61997605	ENSG00000211974.3	IGHV2-70	6.21	1.19e-09	2.51e-07	0.21	0.28	Kawasaki disease;	chr14:106678368	chr14:106723574~106724093:-
THCA	cis	rs10129255	1	rs8012033	ENSG00000211974.3	IGHV2-70	6.21	1.19e-09	2.51e-07	0.21	0.28	Kawasaki disease;	chr14:106678854	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.912	rs8011090	ENSG00000211974.3	IGHV2-70	6.21	1.19e-09	2.51e-07	0.21	0.28	Kawasaki disease;	chr14:106678896	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.912	rs67410411	ENSG00000211974.3	IGHV2-70	6.21	1.19e-09	2.51e-07	0.21	0.28	Kawasaki disease;	chr14:106680324	chr14:106723574~106724093:-
THCA	cis	rs6951245	0.554	rs10246354	ENSG00000229043.2	AC091729.9	-6.21	1.19e-09	2.51e-07	-0.38	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1160374~1165267:+
THCA	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	6.21	1.19e-09	2.51e-07	0.25	0.28	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
THCA	cis	rs4143844	1	rs34311301	ENSG00000259251.2	RP11-643M14.1	6.21	1.19e-09	2.51e-07	0.52	0.28	Bipolar disorder and schizophrenia;	chr15:62050356	chr15:62060503~62062434:+
THCA	cis	rs6026584	0.931	rs6026580	ENSG00000270951.1	RP1-309F20.4	-6.21	1.19e-09	2.52e-07	-0.3	-0.28	Renal function-related traits (BUN);	chr20:58893095	chr20:58876592~58876981:-
THCA	cis	rs7176527	0.706	rs35641144	ENSG00000188388.10	GOLGA6L3	6.21	1.19e-09	2.52e-07	0.48	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84723543	chr15:85240472~85247170:+
THCA	cis	rs6545883	0.826	rs777590	ENSG00000271889.1	RP11-493E12.1	6.21	1.2e-09	2.52e-07	0.26	0.28	Tuberculosis;	chr2:61190010	chr2:61151433~61162105:-
THCA	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-6.21	1.2e-09	2.52e-07	-0.35	-0.28	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
THCA	cis	rs987724	0.519	rs12492968	ENSG00000240875.4	LINC00886	-6.21	1.2e-09	2.52e-07	-0.22	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824048	chr3:156747346~156817062:-
THCA	cis	rs2562456	0.917	rs9304987	ENSG00000213976.4	CTD-2561J22.2	6.21	1.2e-09	2.52e-07	0.29	0.28	Pain;	chr19:21499472	chr19:21382865~21387177:+
THCA	cis	rs4845875	0.626	rs12735869	ENSG00000242349.4	NPPA-AS1	6.21	1.2e-09	2.52e-07	0.27	0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11774106	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.626	rs12734761	ENSG00000242349.4	NPPA-AS1	6.21	1.2e-09	2.52e-07	0.27	0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11774125	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.626	rs11121828	ENSG00000242349.4	NPPA-AS1	6.21	1.2e-09	2.52e-07	0.27	0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11774397	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.557	rs6659541	ENSG00000242349.4	NPPA-AS1	6.21	1.2e-09	2.52e-07	0.27	0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11776385	chr1:11841017~11848079:+
THCA	cis	rs699371	0.507	rs10149787	ENSG00000259005.1	RP3-449M8.6	-6.21	1.2e-09	2.52e-07	-0.24	-0.28	Height;	chr14:74458749	chr14:74474007~74474864:-
THCA	cis	rs227275	0.554	rs223357	ENSG00000251288.2	RP11-10L12.2	-6.21	1.2e-09	2.52e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102751401~102752641:+
THCA	cis	rs965513	0.524	rs6478413	ENSG00000236130.1	PTCSC2	-6.21	1.2e-09	2.52e-07	-0.23	-0.28	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97819742	chr9:97805935~97810008:-
THCA	cis	rs17158807	0.543	rs1896807	ENSG00000274128.1	RP11-342A23.2	6.21	1.2e-09	2.52e-07	0.44	0.28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr15:83549563	chr15:83962176~83962583:+
THCA	cis	rs6142102	0.812	rs761238	ENSG00000275784.1	RP5-1125A11.6	6.21	1.2e-09	2.52e-07	0.28	0.28	Skin pigmentation;	chr20:33932182	chr20:33989480~33991818:-
THCA	cis	rs728616	0.867	rs61859763	ENSG00000242600.5	MBL1P	6.21	1.2e-09	2.52e-07	0.41	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:79904898~79950336:+
THCA	cis	rs4835473	0.618	rs12499429	ENSG00000251600.4	RP11-673E1.1	-6.21	1.2e-09	2.52e-07	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143889914	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.801	rs28715976	ENSG00000251600.4	RP11-673E1.1	-6.21	1.2e-09	2.52e-07	-0.38	-0.28	Immature fraction of reticulocytes;	chr4:143891603	chr4:143912331~143982454:+
THCA	cis	rs227275	0.525	rs7672319	ENSG00000251288.2	RP11-10L12.2	-6.21	1.2e-09	2.52e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs6533051	ENSG00000251288.2	RP11-10L12.2	-6.21	1.2e-09	2.52e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102751401~102752641:+
THCA	cis	rs35934224	0.831	rs1044732	ENSG00000232926.1	AC000078.5	6.21	1.2e-09	2.52e-07	0.34	0.28	Glaucoma (primary open-angle);	chr22:19875619	chr22:19887289~19887970:+
THCA	cis	rs9475752	0.895	rs36112505	ENSG00000231441.1	RP11-472M19.2	6.21	1.2e-09	2.52e-07	0.36	0.28	Menarche (age at onset);	chr6:56903733	chr6:56844002~56864078:+
THCA	cis	rs4689592	0.523	rs6446565	ENSG00000245468.3	RP11-367J11.3	6.21	1.2e-09	2.53e-07	0.22	0.28	Monocyte percentage of white cells;	chr4:7072300	chr4:7094571~7103385:-
THCA	cis	rs13113518	0.812	rs11932712	ENSG00000273257.1	RP11-177J6.1	6.21	1.2e-09	2.53e-07	0.37	0.28	Height;	chr4:55436423	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs12501746	ENSG00000273257.1	RP11-177J6.1	6.21	1.2e-09	2.53e-07	0.37	0.28	Height;	chr4:55437438	chr4:55387949~55388271:+
THCA	cis	rs1005277	0.54	rs1814077	ENSG00000263064.2	RP11-291L22.7	6.21	1.2e-09	2.53e-07	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38448689~38448949:+
THCA	cis	rs8049040	0.609	rs9940485	ENSG00000260886.1	TAT-AS1	6.21	1.2e-09	2.53e-07	0.38	0.28	Blood protein levels;	chr16:71452202	chr16:71565789~71578187:+
THCA	cis	rs10771431	0.817	rs10843149	ENSG00000111788.10	RP11-22B23.1	6.21	1.2e-09	2.53e-07	0.27	0.28	Breast size;	chr12:9209471	chr12:9277235~9313241:+
THCA	cis	rs228614	0.51	rs223468	ENSG00000230069.3	LRRC37A15P	-6.21	1.2e-09	2.53e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223465	ENSG00000230069.3	LRRC37A15P	-6.21	1.2e-09	2.53e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102727274~102730721:-
THCA	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.2e-09	2.53e-07	-0.24	-0.28	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
THCA	cis	rs6545883	0.929	rs1186707	ENSG00000271889.1	RP11-493E12.1	6.2	1.2e-09	2.53e-07	0.27	0.28	Tuberculosis;	chr2:61446385	chr2:61151433~61162105:-
THCA	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-6.2	1.2e-09	2.53e-07	-0.31	-0.28	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
THCA	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	6.2	1.2e-09	2.53e-07	0.36	0.28	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
THCA	cis	rs7403037	0.794	rs72703490	ENSG00000259905.4	PWRN1	6.2	1.2e-09	2.53e-07	0.3	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24250413	chr15:24493137~24652130:+
THCA	cis	rs899997	0.814	rs28661610	ENSG00000261143.1	ADAMTS7P3	-6.2	1.2e-09	2.54e-07	-0.39	-0.28	Coronary artery disease or large artery stroke;	chr15:78692975	chr15:77976042~77993057:+
THCA	cis	rs934734	0.752	rs268136	ENSG00000237979.1	AC007389.1	-6.2	1.2e-09	2.54e-07	-0.32	-0.28	Rheumatoid arthritis;	chr2:65380409	chr2:65500993~65502138:-
THCA	cis	rs7260598	0.642	rs10407805	ENSG00000268442.1	CTD-2027I19.2	6.2	1.21e-09	2.54e-07	0.37	0.28	Response to taxane treatment (placlitaxel);	chr19:23982903	chr19:24162370~24163425:-
THCA	cis	rs7247513	0.964	rs4804202	ENSG00000213290.4	PGK1P2	-6.2	1.21e-09	2.54e-07	-0.33	-0.28	Bipolar disorder;	chr19:12607805	chr19:12559571~12561105:+
THCA	cis	rs890448	0.796	rs833945	ENSG00000254531.1	FLJ20021	6.2	1.21e-09	2.54e-07	0.24	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101396936	chr4:101347780~101348883:+
THCA	cis	rs12908161	1	rs12905057	ENSG00000259295.5	CSPG4P12	6.2	1.21e-09	2.54e-07	0.42	0.28	Schizophrenia;	chr15:84667534	chr15:85191438~85213905:+
THCA	cis	rs6545883	0.826	rs1186697	ENSG00000271889.1	RP11-493E12.1	6.2	1.21e-09	2.54e-07	0.27	0.28	Tuberculosis;	chr2:61434282	chr2:61151433~61162105:-
THCA	cis	rs934734	0.752	rs2661797	ENSG00000234255.7	AC012370.3	-6.2	1.21e-09	2.54e-07	-0.31	-0.28	Rheumatoid arthritis;	chr2:65406056	chr2:65439888~65456571:-
THCA	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-6.2	1.21e-09	2.55e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-6.2	1.21e-09	2.55e-07	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
THCA	cis	rs7580658	0.613	rs6754999	ENSG00000236682.1	AC068282.3	-6.2	1.21e-09	2.55e-07	-0.37	-0.28	Protein C levels;	chr2:127437811	chr2:127389130~127400580:+
THCA	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	6.2	1.21e-09	2.55e-07	0.3	0.28	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	6.2	1.21e-09	2.55e-07	0.3	0.28	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
THCA	cis	rs2915864	0.747	rs78046051	ENSG00000280047.1	CTC-463A16.1	6.2	1.21e-09	2.55e-07	0.46	0.28	Facial morphology (factor 20);	chr5:142071007	chr5:142165767~142168387:+
THCA	cis	rs228614	0.51	rs223397	ENSG00000251288.2	RP11-10L12.2	-6.2	1.21e-09	2.55e-07	-0.37	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102751401~102752641:+
THCA	cis	rs4950322	1	rs1806618	ENSG00000237188.3	RP11-337C18.8	6.2	1.21e-09	2.55e-07	0.36	0.28	Protein quantitative trait loci;	chr1:147377075	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.895	rs17356735	ENSG00000237188.3	RP11-337C18.8	6.2	1.21e-09	2.55e-07	0.36	0.28	Protein quantitative trait loci;	chr1:147378328	chr1:147172771~147211568:+
THCA	cis	rs7201929	1	rs7201929	ENSG00000251417.2	RP11-1348G14.4	-6.2	1.21e-09	2.55e-07	-0.28	-0.28	QT interval;	chr16:28860645	chr16:28802743~28817828:+
THCA	cis	rs6545883	0.895	rs7588814	ENSG00000271889.1	RP11-493E12.1	6.2	1.21e-09	2.55e-07	0.27	0.28	Tuberculosis;	chr2:61468454	chr2:61151433~61162105:-
THCA	cis	rs13113518	0.783	rs34534635	ENSG00000273257.1	RP11-177J6.1	6.2	1.21e-09	2.55e-07	0.37	0.28	Height;	chr4:55573424	chr4:55387949~55388271:+
THCA	cis	rs73607972	0.877	rs66646415	ENSG00000275191.1	RP11-36I17.2	-6.2	1.21e-09	2.55e-07	-0.4	-0.28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572317	chr16:53628256~53628816:-
THCA	cis	rs9880211	0.898	rs9866840	ENSG00000273486.1	RP11-731C17.2	6.2	1.21e-09	2.55e-07	0.29	0.28	Height;Body mass index;	chr3:136310416	chr3:136837338~136839021:-
THCA	cis	rs8062405	0.723	rs62031562	ENSG00000278665.1	RP11-666O2.4	6.2	1.21e-09	2.56e-07	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28599241~28601881:-
THCA	cis	rs4948102	0.599	rs2230197	ENSG00000273720.1	RP11-613E4.4	-6.2	1.21e-09	2.56e-07	-0.36	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55743073~55743457:+
THCA	cis	rs4948102	0.642	rs6593297	ENSG00000273720.1	RP11-613E4.4	6.2	1.21e-09	2.56e-07	0.36	0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55743073~55743457:+
THCA	cis	rs2243480	1	rs937108	ENSG00000232546.1	RP11-458F8.1	-6.2	1.21e-09	2.56e-07	-0.35	-0.28	Diabetic kidney disease;	chr7:65963465	chr7:66848496~66858136:+
THCA	cis	rs853679	0.546	rs200977	ENSG00000219392.1	RP1-265C24.5	-6.2	1.21e-09	2.56e-07	-0.48	-0.28	Depression;	chr6:27886523	chr6:28115628~28116551:+
THCA	cis	rs2562456	0.516	rs56072098	ENSG00000268081.1	RP11-678G14.2	-6.2	1.22e-09	2.56e-07	-0.4	-0.28	Pain;	chr19:21469158	chr19:21554640~21569237:-
THCA	cis	rs4664293	0.836	rs4665118	ENSG00000226266.5	AC009961.3	-6.2	1.22e-09	2.56e-07	-0.35	-0.28	Monocyte percentage of white cells;	chr2:159802938	chr2:159670708~159712435:-
THCA	cis	rs2562456	0.876	rs11085467	ENSG00000268081.1	RP11-678G14.2	6.2	1.22e-09	2.56e-07	0.4	0.28	Pain;	chr19:21569041	chr19:21554640~21569237:-
THCA	cis	rs2243480	1	rs402418	ENSG00000228409.4	CCT6P1	6.2	1.22e-09	2.56e-07	0.32	0.28	Diabetic kidney disease;	chr7:66044482	chr7:65751142~65763354:+
THCA	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-6.2	1.22e-09	2.56e-07	-0.25	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
THCA	cis	rs2915864	0.747	rs116814914	ENSG00000280047.1	CTC-463A16.1	6.2	1.22e-09	2.56e-07	0.45	0.28	Facial morphology (factor 20);	chr5:142062313	chr5:142165767~142168387:+
THCA	cis	rs1865760	0.865	rs4478388	ENSG00000272462.2	U91328.19	-6.2	1.22e-09	2.56e-07	-0.23	-0.28	Height;	chr6:25953405	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs1115920	ENSG00000272462.2	U91328.19	-6.2	1.22e-09	2.56e-07	-0.23	-0.28	Height;	chr6:25953799	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs9467645	ENSG00000272462.2	U91328.19	-6.2	1.22e-09	2.56e-07	-0.23	-0.28	Height;	chr6:25954948	chr6:25992662~26001775:+
THCA	cis	rs1552244	0.882	rs13064570	ENSG00000180385.7	EMC3-AS1	6.2	1.22e-09	2.56e-07	0.29	0.28	Alzheimer's disease;	chr3:9955861	chr3:9986893~10006990:+
THCA	cis	rs227275	0.525	rs6533052	ENSG00000251288.2	RP11-10L12.2	-6.2	1.22e-09	2.56e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs13117110	ENSG00000251288.2	RP11-10L12.2	-6.2	1.22e-09	2.56e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs13144033	ENSG00000251288.2	RP11-10L12.2	-6.2	1.22e-09	2.56e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102751401~102752641:+
THCA	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-6.2	1.22e-09	2.56e-07	-0.17	-0.28	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
THCA	cis	rs2145598	0.835	rs2147609	ENSG00000279636.2	LINC00216	-6.2	1.22e-09	2.56e-07	-0.27	-0.28	Coronary artery disease;	chr14:58380261	chr14:58288033~58289158:+
THCA	cis	rs748404	0.697	rs513970	ENSG00000166763.7	STRCP1	6.2	1.22e-09	2.56e-07	0.3	0.28	Lung cancer;	chr15:43287368	chr15:43699488~43718184:-
THCA	cis	rs7129556	0.863	rs11237225	ENSG00000254691.1	RP11-91P24.5	6.2	1.22e-09	2.56e-07	0.38	0.28	Weight loss (gastric bypass surgery);	chr11:77572516	chr11:77850604~77851511:+
THCA	cis	rs1993293	0.636	rs2924778	ENSG00000259363.4	CTD-2054N24.2	6.2	1.22e-09	2.57e-07	0.36	0.28	Coronary artery calcification;	chr15:99758621	chr15:99807023~99877148:+
THCA	cis	rs17301013	0.507	rs6689327	ENSG00000227373.4	RP11-160H22.5	6.2	1.22e-09	2.57e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174464274	chr1:174115300~174160004:-
THCA	cis	rs7615952	0.599	rs16834938	ENSG00000250012.1	RP11-124N2.1	-6.2	1.22e-09	2.57e-07	-0.26	-0.28	Blood pressure (smoking interaction);	chr3:125987203	chr3:126084220~126095349:+
THCA	cis	rs227275	0.525	rs6533050	ENSG00000251288.2	RP11-10L12.2	-6.2	1.22e-09	2.57e-07	-0.37	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102751401~102752641:+
THCA	cis	rs28530618	0.87	rs6057612	ENSG00000175730.8	BAK1P1	6.2	1.22e-09	2.57e-07	0.3	0.28	Birth weight;	chr20:32660723	chr20:32690180~32690815:-
THCA	cis	rs2179367	0.887	rs2143076	ENSG00000231760.4	RP11-350J20.5	6.2	1.22e-09	2.57e-07	0.35	0.28	Dupuytren's disease;	chr6:149425315	chr6:149796151~149826294:-
THCA	cis	rs7208859	0.614	rs73265646	ENSG00000263603.1	CTD-2349P21.5	-6.2	1.22e-09	2.57e-07	-0.51	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30729469~30731202:+
THCA	cis	rs4323050	0.546	rs13124157	ENSG00000251600.4	RP11-673E1.1	6.2	1.22e-09	2.57e-07	0.37	0.28	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13147170	ENSG00000251600.4	RP11-673E1.1	6.2	1.22e-09	2.57e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143975848	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs13147184	ENSG00000251600.4	RP11-673E1.1	6.2	1.22e-09	2.57e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143975873	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.8	rs13124170	ENSG00000251600.4	RP11-673E1.1	6.2	1.22e-09	2.57e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143975951	chr4:143912331~143982454:+
THCA	cis	rs10872587	0.598	rs10457057	ENSG00000235652.6	RP11-545I5.3	6.2	1.22e-09	2.57e-07	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146221184	chr6:145799409~145886585:+
THCA	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	6.2	1.23e-09	2.58e-07	0.26	0.28	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
THCA	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-6.2	1.23e-09	2.58e-07	-0.37	-0.28	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
THCA	cis	rs12681366	0.734	rs2515153	ENSG00000253704.1	RP11-267M23.4	-6.2	1.23e-09	2.58e-07	-0.26	-0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94411696	chr8:94553722~94569745:+
THCA	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	6.2	1.23e-09	2.58e-07	0.4	0.28	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
THCA	cis	rs228614	0.51	rs223392	ENSG00000230069.3	LRRC37A15P	-6.2	1.23e-09	2.58e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223390	ENSG00000230069.3	LRRC37A15P	-6.2	1.23e-09	2.58e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs50034	ENSG00000230069.3	LRRC37A15P	-6.2	1.23e-09	2.58e-07	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs223380	ENSG00000230069.3	LRRC37A15P	-6.2	1.23e-09	2.58e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs223379	ENSG00000230069.3	LRRC37A15P	-6.2	1.23e-09	2.58e-07	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102727274~102730721:-
THCA	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	6.2	1.23e-09	2.58e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	6.2	1.23e-09	2.58e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	6.2	1.23e-09	2.58e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	6.2	1.23e-09	2.58e-07	0.37	0.28	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
THCA	cis	rs8062405	0.723	rs113208333	ENSG00000278665.1	RP11-666O2.4	6.2	1.23e-09	2.59e-07	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28599241~28601881:-
THCA	cis	rs6545883	0.965	rs766447	ENSG00000271889.1	RP11-493E12.1	6.2	1.23e-09	2.59e-07	0.26	0.28	Tuberculosis;	chr2:61508434	chr2:61151433~61162105:-
THCA	cis	rs6479891	1	rs4746994	ENSG00000232075.1	MRPL35P2	6.2	1.23e-09	2.59e-07	0.48	0.27	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63634317~63634827:-
THCA	cis	rs6479891	1	rs12415984	ENSG00000232075.1	MRPL35P2	6.2	1.23e-09	2.59e-07	0.48	0.27	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63634317~63634827:-
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000232546.1	RP11-458F8.1	-6.2	1.23e-09	2.59e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65947955	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000232546.1	RP11-458F8.1	-6.2	1.23e-09	2.59e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65950886	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000232546.1	RP11-458F8.1	-6.2	1.23e-09	2.59e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65951525	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000232546.1	RP11-458F8.1	-6.2	1.23e-09	2.59e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65951549	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000232546.1	RP11-458F8.1	-6.2	1.23e-09	2.59e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65956884	chr7:66848496~66858136:+
THCA	cis	rs5742933	0.744	rs12693557	ENSG00000253559.1	OSGEPL1-AS1	6.2	1.23e-09	2.59e-07	0.31	0.27	Ferritin levels;	chr2:189726211	chr2:189762704~189765556:+
THCA	cis	rs2145598	0.967	rs7147757	ENSG00000279636.2	LINC00216	-6.2	1.23e-09	2.59e-07	-0.27	-0.27	Coronary artery disease;	chr14:58285869	chr14:58288033~58289158:+
THCA	cis	rs4925386	1	rs4925382	ENSG00000273619.1	RP5-908M14.9	6.2	1.23e-09	2.59e-07	0.22	0.27	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62386303~62386970:-
THCA	cis	rs10266483	0.739	rs12671185	ENSG00000227986.1	TRIM60P18	6.2	1.23e-09	2.59e-07	0.24	0.27	Response to statin therapy;	chr7:64333329	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.774	rs10949894	ENSG00000227986.1	TRIM60P18	6.2	1.23e-09	2.59e-07	0.24	0.27	Response to statin therapy;	chr7:64340143	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.774	rs28580000	ENSG00000227986.1	TRIM60P18	6.2	1.23e-09	2.59e-07	0.24	0.27	Response to statin therapy;	chr7:64341531	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.774	rs1404678	ENSG00000227986.1	TRIM60P18	6.2	1.23e-09	2.59e-07	0.24	0.27	Response to statin therapy;	chr7:64342138	chr7:64355078~64356199:+
THCA	cis	rs17772222	1	rs17698817	ENSG00000258789.1	RP11-507K2.3	-6.2	1.23e-09	2.59e-07	-0.29	-0.27	Coronary artery calcification;	chr14:88356632	chr14:88551597~88552493:+
THCA	cis	rs897984	0.647	rs7203999	ENSG00000279196.1	RP11-1072A3.3	-6.2	1.23e-09	2.59e-07	-0.27	-0.27	Dementia with Lewy bodies;	chr16:31006233	chr16:30984630~30988270:-
THCA	cis	rs9902453	0.967	rs12150261	ENSG00000264007.1	RP11-68I3.10	-6.2	1.23e-09	2.59e-07	-0.31	-0.27	Coffee consumption (cups per day);	chr17:29993455	chr17:29621617~29622254:-
THCA	cis	rs683257	0.636	rs6918856	ENSG00000234147.1	RP3-460G2.2	-6.2	1.23e-09	2.59e-07	-0.42	-0.27	Facial emotion recognition (angry faces);	chr6:140851609	chr6:140845958~140852924:-
THCA	cis	rs797680	0.856	rs7535628	ENSG00000223745.6	RP4-717I23.3	6.2	1.23e-09	2.59e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93183171	chr1:93262186~93346025:-
THCA	cis	rs853679	0.546	rs493161	ENSG00000219392.1	RP1-265C24.5	-6.2	1.23e-09	2.59e-07	-0.48	-0.27	Depression;	chr6:27882936	chr6:28115628~28116551:+
THCA	cis	rs934734	0.789	rs2661798	ENSG00000234255.7	AC012370.3	-6.2	1.23e-09	2.6e-07	-0.32	-0.27	Rheumatoid arthritis;	chr2:65408554	chr2:65439888~65456571:-
THCA	cis	rs10129255	1	rs11627342	ENSG00000211974.3	IGHV2-70	6.2	1.24e-09	2.6e-07	0.21	0.27	Kawasaki disease;	chr14:106675823	chr14:106723574~106724093:-
THCA	cis	rs1823913	1	rs4853568	ENSG00000280083.1	RP11-317J9.1	6.2	1.24e-09	2.6e-07	0.34	0.27	Obesity-related traits;	chr2:191261464	chr2:191154118~191156070:-
THCA	cis	rs9393777	0.777	rs35984974	ENSG00000280107.1	AL022393.9	-6.2	1.24e-09	2.6e-07	-0.46	-0.27	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28170845~28172521:+
THCA	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	6.2	1.24e-09	2.6e-07	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	6.2	1.24e-09	2.6e-07	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
THCA	cis	rs9549328	0.527	rs9549622	ENSG00000267868.1	RP11-120K24.3	6.2	1.24e-09	2.6e-07	0.35	0.27	Systolic blood pressure;	chr13:112985750	chr13:112964835~112966131:-
THCA	cis	rs2562456	0.724	rs58001930	ENSG00000268081.1	RP11-678G14.2	6.2	1.24e-09	2.61e-07	0.4	0.27	Pain;	chr19:21560061	chr19:21554640~21569237:-
THCA	cis	rs228614	0.536	rs223375	ENSG00000230069.3	LRRC37A15P	-6.2	1.24e-09	2.61e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102727274~102730721:-
THCA	cis	rs922182	1	rs4436737	ENSG00000275785.1	RP11-111E14.2	6.2	1.24e-09	2.61e-07	0.32	0.27	Blood protein levels;	chr15:63990877	chr15:63890030~63890317:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	6.2	1.24e-09	2.61e-07	0.31	0.27	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
THCA	cis	rs6908034	0.607	rs34109983	ENSG00000237404.1	RP3-471C18.2	-6.2	1.24e-09	2.61e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807811	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs73376680	ENSG00000237404.1	RP3-471C18.2	-6.2	1.24e-09	2.61e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807868	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs73376681	ENSG00000237404.1	RP3-471C18.2	-6.2	1.24e-09	2.61e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807944	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs80355837	ENSG00000237404.1	RP3-471C18.2	-6.2	1.24e-09	2.61e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808112	chr6:19689825~19753113:-
THCA	cis	rs228614	0.51	rs223358	ENSG00000230069.3	LRRC37A15P	-6.2	1.24e-09	2.61e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102727274~102730721:-
THCA	cis	rs2439831	0.681	rs2278858	ENSG00000249839.1	AC011330.5	-6.2	1.24e-09	2.61e-07	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43340557	chr15:43663654~43684339:-
THCA	cis	rs4925386	1	rs6121990	ENSG00000273619.1	RP5-908M14.9	6.2	1.24e-09	2.61e-07	0.22	0.27	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62386303~62386970:-
THCA	cis	rs6600671	1	rs4844380	ENSG00000275538.1	RNVU1-19	6.2	1.25e-09	2.62e-07	0.34	0.27	Hip geometry;	chr1:121451764	chr1:120850819~120850985:-
THCA	cis	rs934734	0.752	rs268139	ENSG00000234255.7	AC012370.3	-6.2	1.25e-09	2.62e-07	-0.31	-0.27	Rheumatoid arthritis;	chr2:65379857	chr2:65439888~65456571:-
THCA	cis	rs72627509	0.857	rs55762216	ENSG00000269949.1	RP11-738E22.3	6.2	1.25e-09	2.62e-07	0.38	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899565	chr4:56960927~56961373:-
THCA	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	6.2	1.25e-09	2.62e-07	0.36	0.27	Depression;	chr6:28399846	chr6:28176188~28176674:+
THCA	cis	rs13113518	0.783	rs6843722	ENSG00000273257.1	RP11-177J6.1	6.2	1.25e-09	2.62e-07	0.37	0.27	Height;	chr4:55465165	chr4:55387949~55388271:+
THCA	cis	rs10844706	0.699	rs10844620	ENSG00000256594.6	RP11-705C15.2	6.2	1.25e-09	2.62e-07	0.23	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9729910	chr12:9633419~9658412:+
THCA	cis	rs934734	0.752	rs1039764	ENSG00000237979.1	AC007389.1	-6.2	1.25e-09	2.62e-07	-0.32	-0.27	Rheumatoid arthritis;	chr2:65387479	chr2:65500993~65502138:-
THCA	cis	rs916888	0.61	rs199536	ENSG00000232300.1	FAM215B	-6.2	1.25e-09	2.62e-07	-0.39	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46558830~46562795:-
THCA	cis	rs5758659	0.714	rs6002626	ENSG00000227370.1	RP4-669P10.19	6.2	1.25e-09	2.62e-07	0.25	0.27	Cognitive function;	chr22:42121985	chr22:42132543~42132998:+
THCA	cis	rs17772222	0.917	rs17188046	ENSG00000222990.1	RNU4-22P	6.2	1.25e-09	2.62e-07	0.35	0.27	Coronary artery calcification;	chr14:88624417	chr14:88513498~88513663:+
THCA	cis	rs1318937	0.764	rs66813829	ENSG00000224660.1	SH3BP5-AS1	6.2	1.25e-09	2.63e-07	0.19	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15202214	chr3:15254184~15264493:+
THCA	cis	rs227275	0.525	rs5028609	ENSG00000251288.2	RP11-10L12.2	-6.2	1.25e-09	2.63e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs6815540	ENSG00000251288.2	RP11-10L12.2	-6.2	1.25e-09	2.63e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs4698867	ENSG00000251288.2	RP11-10L12.2	-6.2	1.25e-09	2.63e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102751401~102752641:+
THCA	cis	rs227275	0.525	rs7663876	ENSG00000251288.2	RP11-10L12.2	-6.2	1.25e-09	2.63e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs6821173	ENSG00000251288.2	RP11-10L12.2	-6.2	1.25e-09	2.63e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102751401~102752641:+
THCA	cis	rs6545883	0.929	rs12617911	ENSG00000271889.1	RP11-493E12.1	6.2	1.25e-09	2.63e-07	0.26	0.27	Tuberculosis;	chr2:61513690	chr2:61151433~61162105:-
THCA	cis	rs8042680	0.784	rs6496747	ENSG00000214432.8	AC068831.10	-6.2	1.25e-09	2.63e-07	-0.31	-0.27	Type 2 diabetes;	chr15:90993397	chr15:91022619~91036611:+
THCA	cis	rs60180747	0.575	rs17198181	ENSG00000261318.1	RP11-653J6.1	6.2	1.25e-09	2.63e-07	0.38	0.27	Testicular germ cell tumor;	chr15:66284705	chr15:66278498~66293357:-
THCA	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.25e-09	2.63e-07	-0.25	-0.27	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.25e-09	2.63e-07	-0.25	-0.27	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.25e-09	2.63e-07	-0.25	-0.27	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.25e-09	2.63e-07	-0.25	-0.27	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
THCA	cis	rs10078	0.559	rs2671891	ENSG00000221990.4	EXOC3-AS1	6.2	1.25e-09	2.63e-07	0.29	0.27	Fat distribution (HIV);	chr5:456271	chr5:441498~443160:-
THCA	cis	rs10078	0.571	rs2671890	ENSG00000221990.4	EXOC3-AS1	6.2	1.25e-09	2.63e-07	0.29	0.27	Fat distribution (HIV);	chr5:456342	chr5:441498~443160:-
THCA	cis	rs10078	0.571	rs2561664	ENSG00000221990.4	EXOC3-AS1	6.2	1.25e-09	2.63e-07	0.29	0.27	Fat distribution (HIV);	chr5:459678	chr5:441498~443160:-
THCA	cis	rs10078	0.571	rs2721014	ENSG00000221990.4	EXOC3-AS1	6.2	1.25e-09	2.63e-07	0.29	0.27	Fat distribution (HIV);	chr5:463424	chr5:441498~443160:-
THCA	cis	rs6545883	0.965	rs6545872	ENSG00000271889.1	RP11-493E12.1	6.2	1.25e-09	2.63e-07	0.27	0.27	Tuberculosis;	chr2:61497433	chr2:61151433~61162105:-
THCA	cis	rs7617773	0.539	rs13094496	ENSG00000228638.1	FCF1P2	-6.2	1.25e-09	2.63e-07	-0.27	-0.27	Coronary artery disease;	chr3:48345560	chr3:48290793~48291375:-
THCA	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-6.2	1.25e-09	2.63e-07	-0.21	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
THCA	cis	rs7044106	0.791	rs4836829	ENSG00000270917.1	RP11-27I1.6	-6.2	1.26e-09	2.64e-07	-0.39	-0.27	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120812475~120812845:-
THCA	cis	rs950169	0.922	rs11633534	ENSG00000259295.5	CSPG4P12	6.2	1.26e-09	2.64e-07	0.43	0.27	Schizophrenia;	chr15:84581411	chr15:85191438~85213905:+
THCA	cis	rs5742933	0.817	rs6738042	ENSG00000253559.1	OSGEPL1-AS1	6.2	1.26e-09	2.64e-07	0.31	0.27	Ferritin levels;	chr2:189776958	chr2:189762704~189765556:+
THCA	cis	rs11976180	1	rs1919951	ENSG00000273234.1	OR2A13P	-6.2	1.26e-09	2.64e-07	-0.31	-0.27	Obesity-related traits;	chr7:144071798	chr7:144142009~144142938:+
THCA	cis	rs6545883	0.894	rs6709441	ENSG00000271889.1	RP11-493E12.1	-6.2	1.26e-09	2.64e-07	-0.26	-0.27	Tuberculosis;	chr2:61209795	chr2:61151433~61162105:-
THCA	cis	rs853679	0.607	rs33932084	ENSG00000219392.1	RP1-265C24.5	-6.2	1.26e-09	2.64e-07	-0.58	-0.27	Depression;	chr6:28301047	chr6:28115628~28116551:+
THCA	cis	rs55823223	0.68	rs57287238	ENSG00000267801.1	RP11-552F3.9	6.2	1.26e-09	2.64e-07	0.37	0.27	Psoriasis;	chr17:75854859	chr17:75876372~75879546:+
THCA	cis	rs55823223	0.648	rs936394	ENSG00000267801.1	RP11-552F3.9	6.2	1.26e-09	2.64e-07	0.37	0.27	Psoriasis;	chr17:75855927	chr17:75876372~75879546:+
THCA	cis	rs5758659	0.653	rs133383	ENSG00000270083.1	RP1-257I20.14	6.2	1.26e-09	2.64e-07	0.29	0.27	Cognitive function;	chr22:42077599	chr22:42089630~42090028:-
THCA	cis	rs3204270	0.81	rs62077191	ENSG00000262049.1	RP13-1032I1.7	6.2	1.26e-09	2.64e-07	0.26	0.27	Dental caries;	chr17:81711033	chr17:81701324~81703300:-
THCA	cis	rs6142102	0.812	rs761236	ENSG00000275784.1	RP5-1125A11.6	-6.2	1.26e-09	2.64e-07	-0.28	-0.27	Skin pigmentation;	chr20:33932245	chr20:33989480~33991818:-
THCA	cis	rs467650	0.534	rs27024	ENSG00000246763.5	RGMB-AS1	6.2	1.26e-09	2.64e-07	0.27	0.27	Venous thromboembolism (SNP x SNP interaction);	chr5:98623657	chr5:98769618~98773469:-
THCA	cis	rs11096990	0.927	rs6845858	ENSG00000249207.1	RP11-360F5.1	6.2	1.26e-09	2.65e-07	0.36	0.27	Cognitive function;	chr4:39237099	chr4:39112677~39126818:-
THCA	cis	rs6928977	0.5	rs3734213	ENSG00000231028.7	LINC00271	-6.2	1.26e-09	2.65e-07	-0.23	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135620170	chr6:135497801~135716055:+
THCA	cis	rs6545883	0.929	rs7561229	ENSG00000271889.1	RP11-493E12.1	6.2	1.26e-09	2.65e-07	0.26	0.27	Tuberculosis;	chr2:61510855	chr2:61151433~61162105:-
THCA	cis	rs853679	0.517	rs9295761	ENSG00000261839.1	RP1-265C24.8	6.2	1.26e-09	2.65e-07	0.33	0.27	Depression;	chr6:28180209	chr6:28136849~28139678:+
THCA	cis	rs526231	0.819	rs2288787	ENSG00000175749.11	EIF3KP1	6.2	1.26e-09	2.65e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103265005	chr5:103032376~103033031:+
THCA	cis	rs6142102	0.812	rs725478	ENSG00000275784.1	RP5-1125A11.6	6.2	1.26e-09	2.65e-07	0.28	0.27	Skin pigmentation;	chr20:33930548	chr20:33989480~33991818:-
THCA	cis	rs13113518	0.812	rs1522114	ENSG00000273257.1	RP11-177J6.1	6.2	1.26e-09	2.65e-07	0.37	0.27	Height;	chr4:55489895	chr4:55387949~55388271:+
THCA	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-6.2	1.27e-09	2.66e-07	-0.21	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
THCA	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-6.2	1.27e-09	2.66e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
THCA	cis	rs7208859	0.673	rs216411	ENSG00000264538.5	SUZ12P1	6.2	1.27e-09	2.66e-07	0.26	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30709299~30790908:+
THCA	cis	rs897984	0.542	rs11864839	ENSG00000279196.1	RP11-1072A3.3	6.2	1.27e-09	2.66e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31083930	chr16:30984630~30988270:-
THCA	cis	rs34779708	0.733	rs7070778	ENSG00000271335.4	RP11-324I22.4	6.2	1.27e-09	2.66e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35314552~35336401:-
THCA	cis	rs2915864	0.699	rs75299873	ENSG00000280047.1	CTC-463A16.1	6.2	1.27e-09	2.66e-07	0.46	0.27	Facial morphology (factor 20);	chr5:142072878	chr5:142165767~142168387:+
THCA	cis	rs5758659	0.633	rs762995	ENSG00000281538.1	RP4-669P10.20	6.2	1.27e-09	2.67e-07	0.24	0.27	Cognitive function;	chr22:42276118	chr22:42138060~42139726:+
THCA	cis	rs10875746	0.669	rs11168508	ENSG00000269514.1	RP11-370I10.12	6.2	1.27e-09	2.67e-07	0.27	0.27	Longevity (90 years and older);	chr12:48289728	chr12:48198387~48202031:+
THCA	cis	rs2243480	1	rs56016656	ENSG00000232546.1	RP11-458F8.1	-6.2	1.27e-09	2.67e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65918494	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs56291018	ENSG00000232546.1	RP11-458F8.1	-6.2	1.27e-09	2.67e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65925352	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs36033484	ENSG00000232546.1	RP11-458F8.1	-6.2	1.27e-09	2.67e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65925571	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs34560516	ENSG00000232546.1	RP11-458F8.1	-6.2	1.27e-09	2.67e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65939105	chr7:66848496~66858136:+
THCA	cis	rs8014252	0.518	rs58919501	ENSG00000259158.2	ADAM20P1	-6.2	1.27e-09	2.67e-07	-0.3	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70602305	chr14:70468881~70483756:-
THCA	cis	rs11168936	1	rs11168936	ENSG00000258017.1	RP11-386G11.10	-6.2	1.27e-09	2.67e-07	-0.36	-0.27	Cancer (pleiotropy);	chr12:49251457	chr12:49127782~49147869:+
THCA	cis	rs6430585	0.528	rs309133	ENSG00000231890.6	DARS-AS1	-6.2	1.27e-09	2.67e-07	-0.32	-0.27	Corneal structure;	chr2:135994272	chr2:135985176~136022593:+
THCA	cis	rs8014252	0.803	rs17108274	ENSG00000259158.2	ADAM20P1	-6.2	1.27e-09	2.67e-07	-0.35	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70603684	chr14:70468881~70483756:-
THCA	cis	rs4835473	0.524	rs4404495	ENSG00000251600.4	RP11-673E1.1	6.2	1.27e-09	2.67e-07	0.37	0.27	Immature fraction of reticulocytes;	chr4:143979791	chr4:143912331~143982454:+
THCA	cis	rs9475752	0.514	rs4443500	ENSG00000231441.1	RP11-472M19.2	6.19	1.28e-09	2.68e-07	0.3	0.27	Menarche (age at onset);	chr6:56873878	chr6:56844002~56864078:+
THCA	cis	rs6061231	1	rs11908473	ENSG00000275437.1	RP5-908M14.10	6.19	1.28e-09	2.68e-07	0.25	0.27	Colorectal cancer;	chr20:62382714	chr20:62402236~62405935:-
THCA	cis	rs6061231	1	rs13043313	ENSG00000275437.1	RP5-908M14.10	6.19	1.28e-09	2.68e-07	0.25	0.27	Colorectal cancer;	chr20:62383213	chr20:62402236~62405935:-
THCA	cis	rs11783469	0.522	rs13281304	ENSG00000253390.1	CTC-756D1.2	-6.19	1.28e-09	2.68e-07	-0.44	-0.27	Reticulocyte count;	chr8:23409409	chr8:23458601~23484971:+
THCA	cis	rs9926296	0.605	rs3743859	ENSG00000260259.1	RP11-368I7.4	6.19	1.28e-09	2.68e-07	0.3	0.27	Vitiligo;	chr16:89779642	chr16:89682620~89686569:-
THCA	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-6.19	1.28e-09	2.68e-07	-0.26	-0.27	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
THCA	cis	rs3950186	1	rs9470184	ENSG00000215124.2	RP3-420J14.1	6.19	1.28e-09	2.68e-07	0.3	0.27	Anxiety and major depressive disorder;	chr6:11814742	chr6:11861626~11862970:-
THCA	cis	rs1015362	0.54	rs2050209	ENSG00000276073.1	RP5-1125A11.7	6.19	1.28e-09	2.68e-07	0.28	0.27	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33985617~33988989:-
THCA	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	6.19	1.28e-09	2.68e-07	0.2	0.27	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
THCA	cis	rs17508449	0.865	rs4838993	ENSG00000232450.1	RP4-730K3.3	-6.19	1.28e-09	2.69e-07	-0.43	-0.27	Leprosy;	chr1:113592511	chr1:113698884~113699631:-
THCA	cis	rs6723226	0.765	rs12612824	ENSG00000276334.1	AL133243.1	-6.19	1.28e-09	2.69e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr2:32354691	chr2:32521927~32523547:+
THCA	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	6.19	1.28e-09	2.69e-07	0.3	0.27	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	6.19	1.28e-09	2.69e-07	0.3	0.27	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
THCA	cis	rs10208649	1	rs72902931	ENSG00000272156.1	RP11-477N3.1	6.19	1.28e-09	2.69e-07	0.5	0.27	Body mass index;	chr2:53845566	chr2:54082554~54085066:+
THCA	cis	rs12681287	0.605	rs2976181	ENSG00000254231.1	CTD-2284J15.1	6.19	1.28e-09	2.69e-07	0.29	0.27	Caudate activity during reward;	chr8:86332241	chr8:86333274~86343314:-
THCA	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	6.19	1.28e-09	2.69e-07	0.3	0.27	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
THCA	cis	rs9677476	0.738	rs72985811	ENSG00000224376.1	AC017104.6	6.19	1.28e-09	2.69e-07	0.33	0.27	Food antigen IgG levels;	chr2:231272433	chr2:231388976~231394991:+
THCA	cis	rs6860806	0.631	rs4705931	ENSG00000224431.1	AC063976.7	6.19	1.28e-09	2.69e-07	0.23	0.27	Breast cancer;	chr5:132252652	chr5:132199456~132203487:+
THCA	cis	rs6545883	0.791	rs2600665	ENSG00000271889.1	RP11-493E12.1	6.19	1.28e-09	2.69e-07	0.26	0.27	Tuberculosis;	chr2:61178660	chr2:61151433~61162105:-
THCA	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-6.19	1.28e-09	2.69e-07	-0.5	-0.27	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
THCA	cis	rs8062405	0.723	rs35175818	ENSG00000278665.1	RP11-666O2.4	6.19	1.28e-09	2.69e-07	0.32	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28599241~28601881:-
THCA	cis	rs7617773	0.539	rs13069884	ENSG00000228638.1	FCF1P2	-6.19	1.28e-09	2.69e-07	-0.27	-0.27	Coronary artery disease;	chr3:48339658	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.539	rs2017859	ENSG00000228638.1	FCF1P2	-6.19	1.28e-09	2.69e-07	-0.27	-0.27	Coronary artery disease;	chr3:48340771	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.501	rs12185901	ENSG00000228638.1	FCF1P2	-6.19	1.28e-09	2.69e-07	-0.27	-0.27	Coronary artery disease;	chr3:48341429	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.539	rs13082217	ENSG00000228638.1	FCF1P2	-6.19	1.28e-09	2.69e-07	-0.27	-0.27	Coronary artery disease;	chr3:48341774	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.539	rs11706939	ENSG00000228638.1	FCF1P2	-6.19	1.28e-09	2.69e-07	-0.27	-0.27	Coronary artery disease;	chr3:48342502	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.539	rs11130165	ENSG00000228638.1	FCF1P2	-6.19	1.28e-09	2.69e-07	-0.27	-0.27	Coronary artery disease;	chr3:48343231	chr3:48290793~48291375:-
THCA	cis	rs9475752	1	rs13220510	ENSG00000231441.1	RP11-472M19.2	6.19	1.28e-09	2.69e-07	0.35	0.27	Menarche (age at onset);	chr6:56914343	chr6:56844002~56864078:+
THCA	cis	rs9475752	1	rs71550519	ENSG00000231441.1	RP11-472M19.2	6.19	1.28e-09	2.69e-07	0.35	0.27	Menarche (age at onset);	chr6:56915474	chr6:56844002~56864078:+
THCA	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-6.19	1.28e-09	2.69e-07	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
THCA	cis	rs9926296	0.712	rs2434872	ENSG00000274627.1	RP11-104N10.2	6.19	1.29e-09	2.7e-07	0.29	0.27	Vitiligo;	chr16:89650507	chr16:89516797~89522217:+
THCA	cis	rs9926296	0.682	rs467357	ENSG00000274627.1	RP11-104N10.2	6.19	1.29e-09	2.7e-07	0.29	0.27	Vitiligo;	chr16:89650989	chr16:89516797~89522217:+
THCA	cis	rs9595908	0.9	rs9595850	ENSG00000212293.1	SNORA16	6.19	1.29e-09	2.7e-07	0.32	0.27	Body mass index;	chr13:32579773	chr13:32420390~32420516:-
THCA	cis	rs9926296	0.744	rs154657	ENSG00000274627.1	RP11-104N10.2	-6.19	1.29e-09	2.7e-07	-0.28	-0.27	Vitiligo;	chr16:89641688	chr16:89516797~89522217:+
THCA	cis	rs2562456	0.761	rs35008138	ENSG00000213976.4	CTD-2561J22.2	-6.19	1.29e-09	2.7e-07	-0.29	-0.27	Pain;	chr19:21548822	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs2681388	ENSG00000213976.4	CTD-2561J22.2	-6.19	1.29e-09	2.7e-07	-0.29	-0.27	Pain;	chr19:21549451	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.876	rs2681370	ENSG00000213976.4	CTD-2561J22.2	-6.19	1.29e-09	2.7e-07	-0.29	-0.27	Pain;	chr19:21554036	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.876	rs11668606	ENSG00000213976.4	CTD-2561J22.2	-6.19	1.29e-09	2.7e-07	-0.29	-0.27	Pain;	chr19:21554618	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.876	rs2681395	ENSG00000213976.4	CTD-2561J22.2	-6.19	1.29e-09	2.7e-07	-0.29	-0.27	Pain;	chr19:21555338	chr19:21382865~21387177:+
THCA	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	6.19	1.29e-09	2.71e-07	0.38	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
THCA	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	6.19	1.29e-09	2.71e-07	0.38	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
THCA	cis	rs8007846	0.588	rs6573626	ENSG00000276116.2	FUT8-AS1	6.19	1.29e-09	2.71e-07	0.28	0.27	Multiple sclerosis--Brain Glutamate Levels;	chr14:65773977	chr14:65411170~65412690:-
THCA	cis	rs16949788	1	rs7169463	ENSG00000261351.2	CTD-3185P2.1	-6.19	1.29e-09	2.71e-07	-0.33	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66453591	chr15:66488658~66492109:-
THCA	cis	rs7615952	0.599	rs2279821	ENSG00000250012.1	RP11-124N2.1	-6.19	1.29e-09	2.71e-07	-0.27	-0.27	Blood pressure (smoking interaction);	chr3:126015465	chr3:126084220~126095349:+
THCA	cis	rs5758659	0.714	rs5751220	ENSG00000227370.1	RP4-669P10.19	6.19	1.29e-09	2.71e-07	0.25	0.27	Cognitive function;	chr22:42120201	chr22:42132543~42132998:+
THCA	cis	rs797680	0.856	rs12044657	ENSG00000223745.6	RP4-717I23.3	6.19	1.29e-09	2.71e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93174039	chr1:93262186~93346025:-
THCA	cis	rs149866169	1	rs149866169	ENSG00000226314.6	ZNF192P1	-6.19	1.29e-09	2.71e-07	-0.52	-0.27	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28161781~28169594:+
THCA	cis	rs74233809	0.901	rs3824755	ENSG00000213277.3	MARCKSL1P1	6.19	1.3e-09	2.72e-07	0.42	0.27	Birth weight;	chr10:102836092	chr10:103175554~103176094:+
THCA	cis	rs11051970	0.659	rs950082	ENSG00000274964.1	RP11-817I4.1	-6.19	1.3e-09	2.72e-07	-0.33	-0.27	Response to tocilizumab in rheumatoid arthritis;	chr12:32435480	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.659	rs950081	ENSG00000274964.1	RP11-817I4.1	-6.19	1.3e-09	2.72e-07	-0.33	-0.27	Response to tocilizumab in rheumatoid arthritis;	chr12:32435554	chr12:32339368~32340724:+
THCA	cis	rs2299587	0.585	rs208750	ENSG00000253671.1	RP11-806O11.1	-6.19	1.3e-09	2.72e-07	-0.34	-0.27	Economic and political preferences;	chr8:17918710	chr8:17808941~17820868:+
THCA	cis	rs17772222	0.874	rs78077739	ENSG00000258789.1	RP11-507K2.3	-6.19	1.3e-09	2.72e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88741176	chr14:88551597~88552493:+
THCA	cis	rs10829156	0.773	rs7909552	ENSG00000240291.1	RP11-499P20.2	6.19	1.3e-09	2.72e-07	0.23	0.27	Sudden cardiac arrest;	chr10:18620407	chr10:18513115~18545651:-
THCA	cis	rs763121	0.962	rs5757130	ENSG00000273076.1	RP3-508I15.22	6.19	1.3e-09	2.72e-07	0.27	0.27	Menopause (age at onset);	chr22:38541789	chr22:38743495~38743910:+
THCA	cis	rs1329650	1	rs1329650	ENSG00000228701.1	TNKS2-AS1	6.19	1.3e-09	2.73e-07	0.33	0.27	Smoking behavior;	chr10:91588363	chr10:91782839~91798291:-
THCA	cis	rs7968440	0.651	rs7309519	ENSG00000272368.2	RP4-605O3.4	-6.19	1.3e-09	2.73e-07	-0.17	-0.27	Fibrinogen;	chr12:50258497	chr12:50112197~50165618:+
THCA	cis	rs6088580	0.524	rs6088565	ENSG00000269202.1	RP4-614O4.12	6.19	1.3e-09	2.73e-07	0.24	0.27	Glomerular filtration rate (creatinine);	chr20:34667182	chr20:35201747~35203288:-
THCA	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	6.19	1.3e-09	2.73e-07	0.31	0.27	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
THCA	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	6.19	1.3e-09	2.73e-07	0.32	0.27	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
THCA	cis	rs2120243	0.539	rs6801110	ENSG00000244515.1	KRT18P34	-6.19	1.3e-09	2.73e-07	-0.33	-0.27	Hepatocellular carcinoma in hepatitis B infection;	chr3:157366942	chr3:157162663~157163932:-
THCA	cis	rs10936632	0.536	rs9811071	ENSG00000242578.1	RP11-469J4.3	-6.19	1.3e-09	2.73e-07	-0.31	-0.27	Prostate cancer;	chr3:170439044	chr3:170410512~170418615:+
THCA	cis	rs6600671	0.764	rs6600673	ENSG00000270392.2	PFN1P2	6.19	1.31e-09	2.74e-07	0.28	0.27	Hip geometry;	chr1:121426988	chr1:120432204~120434052:-
THCA	cis	rs1552244	0.882	rs13063098	ENSG00000180385.7	EMC3-AS1	6.19	1.31e-09	2.74e-07	0.29	0.27	Alzheimer's disease;	chr3:9968235	chr3:9986893~10006990:+
THCA	cis	rs763121	0.925	rs9835	ENSG00000235209.1	CTA-150C2.13	6.19	1.31e-09	2.74e-07	0.35	0.27	Menopause (age at onset);	chr22:38734966	chr22:38921227~38924708:+
THCA	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-6.19	1.31e-09	2.74e-07	-0.46	-0.27	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
THCA	cis	rs228614	0.51	rs223470	ENSG00000230069.3	LRRC37A15P	-6.19	1.31e-09	2.74e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102727274~102730721:-
THCA	cis	rs10761482	0.5	rs4540900	ENSG00000254271.1	RP11-131N11.4	6.19	1.31e-09	2.74e-07	0.36	0.27	Schizophrenia;	chr10:60548976	chr10:60734342~60741828:+
THCA	cis	rs7833787	0.929	rs7844317	ENSG00000278886.1	RP11-108A14.1	-6.19	1.31e-09	2.74e-07	-0.35	-0.27	Obesity-related traits;	chr8:18839536	chr8:18864681~18865247:-
THCA	cis	rs28386778	0.829	rs1877317	ENSG00000240280.5	TCAM1P	-6.19	1.31e-09	2.74e-07	-0.39	-0.27	Prudent dietary pattern;	chr17:63699119	chr17:63849292~63864379:+
THCA	cis	rs8177876	0.749	rs10459872	ENSG00000261061.1	RP11-303E16.2	6.19	1.31e-09	2.75e-07	0.4	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81030770~81031485:+
THCA	cis	rs6545883	0.929	rs10173974	ENSG00000271889.1	RP11-493E12.1	6.19	1.31e-09	2.75e-07	0.27	0.27	Tuberculosis;	chr2:61521765	chr2:61151433~61162105:-
THCA	cis	rs6479891	1	rs61853336	ENSG00000232075.1	MRPL35P2	6.19	1.31e-09	2.75e-07	0.48	0.27	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63634317~63634827:-
THCA	cis	rs7247513	0.856	rs2162863	ENSG00000213290.4	PGK1P2	-6.19	1.31e-09	2.75e-07	-0.34	-0.27	Bipolar disorder;	chr19:12588963	chr19:12559571~12561105:+
THCA	cis	rs7247513	1	rs8104385	ENSG00000213290.4	PGK1P2	-6.19	1.31e-09	2.75e-07	-0.34	-0.27	Bipolar disorder;	chr19:12589470	chr19:12559571~12561105:+
THCA	cis	rs9926296	0.744	rs164748	ENSG00000274627.1	RP11-104N10.2	6.19	1.31e-09	2.75e-07	0.28	0.27	Vitiligo;	chr16:89641884	chr16:89516797~89522217:+
THCA	cis	rs7208859	0.673	rs73277964	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11652409	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9896095	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs58920731	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73277984	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73277986	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs12103588	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.614	rs9914534	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs4131618	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11658344	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs9900144	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.573	rs11656121	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs11650973	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs56085216	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11650305	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs11654914	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9914271	ENSG00000263603.1	CTD-2349P21.5	-6.19	1.32e-09	2.76e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30729469~30731202:+
THCA	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-6.19	1.32e-09	2.76e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
THCA	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-6.19	1.32e-09	2.76e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
THCA	cis	rs853679	0.517	rs12332979	ENSG00000261839.1	RP1-265C24.8	6.19	1.32e-09	2.76e-07	0.33	0.27	Depression;	chr6:28173770	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000261839.1	RP1-265C24.8	6.19	1.32e-09	2.76e-07	0.33	0.27	Depression;	chr6:28174809	chr6:28136849~28139678:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000261839.1	RP1-265C24.8	6.19	1.32e-09	2.76e-07	0.33	0.27	Depression;	chr6:28175233	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000261839.1	RP1-265C24.8	6.19	1.32e-09	2.76e-07	0.33	0.27	Depression;	chr6:28176973	chr6:28136849~28139678:+
THCA	cis	rs526231	0.926	rs35805	ENSG00000175749.11	EIF3KP1	6.19	1.32e-09	2.76e-07	0.39	0.27	Primary biliary cholangitis;	chr5:103337432	chr5:103032376~103033031:+
THCA	cis	rs1859596	1	rs4560732	ENSG00000234456.6	MAGI2-AS3	6.19	1.32e-09	2.76e-07	0.27	0.27	Reading or mathematical ability;	chr7:79486307	chr7:79452877~79471208:+
THCA	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-6.19	1.32e-09	2.76e-07	-0.21	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	6.19	1.32e-09	2.76e-07	0.31	0.27	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
THCA	cis	rs8049040	0.609	rs7188858	ENSG00000260886.1	TAT-AS1	6.19	1.32e-09	2.77e-07	0.38	0.27	Blood protein levels;	chr16:71434992	chr16:71565789~71578187:+
THCA	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	6.19	1.32e-09	2.77e-07	0.5	0.27	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
THCA	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	6.19	1.32e-09	2.77e-07	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
THCA	cis	rs17301013	0.507	rs1622802	ENSG00000227373.4	RP11-160H22.5	-6.19	1.32e-09	2.77e-07	-0.41	-0.27	Systemic lupus erythematosus;	chr1:174766066	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs1329281	ENSG00000227373.4	RP11-160H22.5	-6.19	1.32e-09	2.77e-07	-0.41	-0.27	Systemic lupus erythematosus;	chr1:174766432	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs6696465	ENSG00000227373.4	RP11-160H22.5	-6.19	1.32e-09	2.77e-07	-0.41	-0.27	Systemic lupus erythematosus;	chr1:174769700	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.531	rs1653634	ENSG00000227373.4	RP11-160H22.5	-6.19	1.32e-09	2.77e-07	-0.41	-0.27	Systemic lupus erythematosus;	chr1:174783348	chr1:174115300~174160004:-
THCA	cis	rs4948102	0.597	rs12669623	ENSG00000273720.1	RP11-613E4.4	-6.19	1.32e-09	2.77e-07	-0.37	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55743073~55743457:+
THCA	cis	rs7809950	0.954	rs3779494	ENSG00000238832.1	snoU109	6.19	1.32e-09	2.77e-07	0.3	0.27	Coronary artery disease;	chr7:107609910	chr7:107603363~107603507:+
THCA	cis	rs2179367	0.887	rs2789492	ENSG00000231760.4	RP11-350J20.5	-6.19	1.32e-09	2.77e-07	-0.35	-0.27	Dupuytren's disease;	chr6:149426243	chr6:149796151~149826294:-
THCA	cis	rs11096990	0.964	rs3733280	ENSG00000249207.1	RP11-360F5.1	6.19	1.33e-09	2.78e-07	0.35	0.27	Cognitive function;	chr4:39269921	chr4:39112677~39126818:-
THCA	cis	rs934734	0.752	rs2661796	ENSG00000237979.1	AC007389.1	-6.19	1.33e-09	2.78e-07	-0.32	-0.27	Rheumatoid arthritis;	chr2:65400272	chr2:65500993~65502138:-
THCA	cis	rs2243480	1	rs160655	ENSG00000229886.1	RP5-1132H15.3	6.19	1.33e-09	2.78e-07	0.44	0.27	Diabetic kidney disease;	chr7:66068227	chr7:66025126~66031544:-
THCA	cis	rs916888	0.61	rs199454	ENSG00000232300.1	FAM215B	-6.19	1.33e-09	2.78e-07	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46558830~46562795:-
THCA	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	6.19	1.33e-09	2.78e-07	0.38	0.27	Height;	chr6:109455700	chr6:109382795~109383666:+
THCA	cis	rs9402743	0.851	rs4896167	ENSG00000231028.7	LINC00271	-6.19	1.33e-09	2.78e-07	-0.22	-0.27	Systemic lupus erythematosus;	chr6:135693164	chr6:135497801~135716055:+
THCA	cis	rs10808739	0.534	rs13277887	ENSG00000254006.4	RP11-1D12.2	6.19	1.33e-09	2.78e-07	0.42	0.27	HIV-1 susceptibility;	chr8:64695683	chr8:64801236~64817573:-
THCA	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	6.19	1.33e-09	2.78e-07	0.38	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
THCA	cis	rs62292953	0.86	rs10935018	ENSG00000248724.5	NPHP3-AS1	-6.19	1.33e-09	2.79e-07	-0.44	-0.27	Red cell distribution width;	chr3:132549625	chr3:132721750~132874223:+
THCA	cis	rs7727544	0.526	rs17516457	ENSG00000233006.5	AC034220.3	6.19	1.33e-09	2.79e-07	0.22	0.27	Blood metabolite levels;	chr5:132254694	chr5:132311285~132369916:-
THCA	cis	rs860295	0.65	rs12027412	ENSG00000225855.5	RUSC1-AS1	-6.19	1.33e-09	2.79e-07	-0.18	-0.27	Body mass index;	chr1:155939139	chr1:155316863~155324176:-
THCA	cis	rs4664293	0.836	rs73967923	ENSG00000226266.5	AC009961.3	-6.19	1.33e-09	2.79e-07	-0.35	-0.27	Monocyte percentage of white cells;	chr2:159801754	chr2:159670708~159712435:-
THCA	cis	rs227275	0.554	rs223359	ENSG00000251288.2	RP11-10L12.2	-6.19	1.34e-09	2.79e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102751401~102752641:+
THCA	cis	rs853679	0.517	rs4713150	ENSG00000261839.1	RP1-265C24.8	6.19	1.34e-09	2.8e-07	0.33	0.27	Depression;	chr6:28168434	chr6:28136849~28139678:+
THCA	cis	rs17772222	1	rs17772288	ENSG00000258789.1	RP11-507K2.3	-6.19	1.34e-09	2.8e-07	-0.29	-0.27	Coronary artery calcification;	chr14:88361022	chr14:88551597~88552493:+
THCA	cis	rs9816784	0.525	rs555412	ENSG00000226155.1	AC124944.3	-6.19	1.34e-09	2.8e-07	-0.34	-0.27	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195912049~195913986:+
THCA	cis	rs9816784	0.525	rs422772	ENSG00000226155.1	AC124944.3	-6.19	1.34e-09	2.8e-07	-0.34	-0.27	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195912049~195913986:+
THCA	cis	rs736801	0.808	rs2522057	ENSG00000233006.5	AC034220.3	6.19	1.34e-09	2.8e-07	0.22	0.27	Mosquito bite size;Breast cancer;	chr5:132466255	chr5:132311285~132369916:-
THCA	cis	rs9921338	0.961	rs9302459	ENSG00000262636.1	CTD-3088G3.4	6.19	1.34e-09	2.8e-07	0.4	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11326482	chr16:11380859~11381118:-
THCA	cis	rs10844706	0.699	rs10844626	ENSG00000256594.6	RP11-705C15.2	6.19	1.34e-09	2.8e-07	0.23	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733757	chr12:9633419~9658412:+
THCA	cis	rs10844706	0.699	rs10844630	ENSG00000256594.6	RP11-705C15.2	6.19	1.34e-09	2.8e-07	0.23	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734268	chr12:9633419~9658412:+
THCA	cis	rs728616	0.717	rs111403425	ENSG00000242600.5	MBL1P	6.19	1.34e-09	2.8e-07	0.38	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060786	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs78131725	ENSG00000242600.5	MBL1P	6.19	1.34e-09	2.8e-07	0.38	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061163	chr10:79904898~79950336:+
THCA	cis	rs10875746	0.951	rs2269935	ENSG00000269514.1	RP11-370I10.12	6.19	1.34e-09	2.8e-07	0.28	0.27	Longevity (90 years and older);	chr12:48122681	chr12:48198387~48202031:+
THCA	cis	rs228614	0.51	rs223392	ENSG00000251288.2	RP11-10L12.2	-6.19	1.34e-09	2.8e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223390	ENSG00000251288.2	RP11-10L12.2	-6.19	1.34e-09	2.8e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs50034	ENSG00000251288.2	RP11-10L12.2	-6.19	1.34e-09	2.8e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs223380	ENSG00000251288.2	RP11-10L12.2	-6.19	1.34e-09	2.8e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs223379	ENSG00000251288.2	RP11-10L12.2	-6.19	1.34e-09	2.8e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102751401~102752641:+
THCA	cis	rs34779708	0.733	rs7081597	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs4007271	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.702	rs4007272	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs4934740	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.702	rs4244995	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs4244997	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs4298846	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs4391768	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs7914468	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs7914560	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs4444023	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs12243593	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.733	rs3936502	ENSG00000271335.4	RP11-324I22.4	6.19	1.34e-09	2.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35314552~35336401:-
THCA	cis	rs1552244	0.688	rs113940455	ENSG00000232901.1	CYCSP10	6.19	1.34e-09	2.81e-07	0.36	0.27	Alzheimer's disease;	chr3:9972481	chr3:10000647~10000940:-
THCA	cis	rs9326248	0.53	rs236918	ENSG00000280143.1	AP000892.6	-6.19	1.34e-09	2.81e-07	-0.45	-0.27	Blood protein levels;	chr11:117220893	chr11:117204967~117210292:+
THCA	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-6.19	1.34e-09	2.81e-07	-0.36	-0.27	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
THCA	cis	rs2562456	0.874	rs9304986	ENSG00000213976.4	CTD-2561J22.2	6.19	1.34e-09	2.81e-07	0.29	0.27	Pain;	chr19:21499260	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.917	rs2650805	ENSG00000213976.4	CTD-2561J22.2	6.19	1.34e-09	2.81e-07	0.29	0.27	Pain;	chr19:21505137	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.917	rs10420016	ENSG00000213976.4	CTD-2561J22.2	6.19	1.34e-09	2.81e-07	0.29	0.27	Pain;	chr19:21505800	chr19:21382865~21387177:+
THCA	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-6.19	1.34e-09	2.81e-07	-0.35	-0.27	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
THCA	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-6.19	1.34e-09	2.81e-07	-0.35	-0.27	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
THCA	cis	rs10266483	0.739	rs10949900	ENSG00000227986.1	TRIM60P18	6.19	1.34e-09	2.81e-07	0.24	0.27	Response to statin therapy;	chr7:64351751	chr7:64355078~64356199:+
THCA	cis	rs60180747	0.544	rs11632542	ENSG00000261318.1	RP11-653J6.1	-6.19	1.34e-09	2.81e-07	-0.36	-0.27	Testicular germ cell tumor;	chr15:66267733	chr15:66278498~66293357:-
THCA	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-6.19	1.35e-09	2.81e-07	-0.38	-0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
THCA	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-6.19	1.35e-09	2.81e-07	-0.35	-0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
THCA	cis	rs228614	0.51	rs223451	ENSG00000251288.2	RP11-10L12.2	-6.19	1.35e-09	2.81e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223450	ENSG00000251288.2	RP11-10L12.2	-6.19	1.35e-09	2.81e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102751401~102752641:+
THCA	cis	rs4805272	0.853	rs8109100	ENSG00000267799.1	MAN1A2P1	-6.19	1.35e-09	2.81e-07	-0.29	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28848233	chr19:28790812~28792871:-
THCA	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-6.19	1.35e-09	2.82e-07	-0.16	-0.27	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-6.19	1.35e-09	2.82e-07	-0.16	-0.27	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
THCA	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-6.19	1.35e-09	2.82e-07	-0.26	-0.27	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
THCA	cis	rs7202877	0.706	rs4888393	ENSG00000261783.1	RP11-252K23.2	-6.19	1.35e-09	2.82e-07	-0.48	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75379775	chr16:75379818~75381260:-
THCA	cis	rs7202877	0.656	rs4888394	ENSG00000261783.1	RP11-252K23.2	-6.19	1.35e-09	2.82e-07	-0.48	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75379811	chr16:75379818~75381260:-
THCA	cis	rs7202877	0.611	rs4888395	ENSG00000261783.1	RP11-252K23.2	-6.19	1.35e-09	2.82e-07	-0.48	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75379817	chr16:75379818~75381260:-
THCA	cis	rs1552244	0.882	rs17050672	ENSG00000180385.7	EMC3-AS1	6.19	1.35e-09	2.82e-07	0.3	0.27	Alzheimer's disease;	chr3:9983779	chr3:9986893~10006990:+
THCA	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	6.19	1.35e-09	2.82e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	6.19	1.35e-09	2.82e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	6.19	1.35e-09	2.82e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	6.19	1.35e-09	2.82e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	6.19	1.35e-09	2.82e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	6.19	1.35e-09	2.82e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	6.19	1.35e-09	2.82e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
THCA	cis	rs2348418	0.832	rs7136426	ENSG00000247934.4	RP11-967K21.1	6.19	1.35e-09	2.82e-07	0.24	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28400129	chr12:28163298~28190738:-
THCA	cis	rs11722228	0.508	rs61335146	ENSG00000261490.1	RP11-448G15.3	6.19	1.35e-09	2.82e-07	0.2	0.27	Urate levels;Serum uric acid levels;Gout;	chr4:10129169	chr4:10068089~10073019:-
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000232546.1	RP11-458F8.1	6.19	1.35e-09	2.82e-07	0.36	0.27	Diabetic kidney disease;	chr7:66226660	chr7:66848496~66858136:+
THCA	cis	rs4143844	1	rs35119291	ENSG00000259251.2	RP11-643M14.1	6.19	1.35e-09	2.82e-07	0.52	0.27	Bipolar disorder and schizophrenia;	chr15:62042007	chr15:62060503~62062434:+
THCA	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	6.19	1.35e-09	2.82e-07	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	6.19	1.35e-09	2.82e-07	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	6.18	1.35e-09	2.82e-07	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
THCA	cis	rs72843506	0.591	rs75925580	ENSG00000270091.1	RP11-78O7.2	-6.18	1.35e-09	2.83e-07	-0.3	-0.27	Schizophrenia;	chr17:20211700	chr17:19896590~19897287:-
THCA	cis	rs11971779	0.7	rs11763942	ENSG00000273391.1	RP11-634H22.1	6.18	1.35e-09	2.83e-07	0.3	0.27	Diisocyanate-induced asthma;	chr7:139321049	chr7:139359032~139359566:-
THCA	cis	rs2348418	0.832	rs11049587	ENSG00000247934.4	RP11-967K21.1	6.18	1.35e-09	2.83e-07	0.24	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28418090	chr12:28163298~28190738:-
THCA	cis	rs8062405	0.755	rs4149398	ENSG00000278665.1	RP11-666O2.4	6.18	1.35e-09	2.83e-07	0.32	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28599241~28601881:-
THCA	cis	rs12435908	0.881	rs58227678	ENSG00000276116.2	FUT8-AS1	-6.18	1.35e-09	2.83e-07	-0.44	-0.27	Ischemic stroke;	chr14:65666890	chr14:65411170~65412690:-
THCA	cis	rs228614	0.51	rs6830407	ENSG00000230069.3	LRRC37A15P	-6.18	1.35e-09	2.83e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102727274~102730721:-
THCA	cis	rs3820443	0.957	rs10158004	ENSG00000234020.1	CHIAP3	-6.18	1.36e-09	2.83e-07	-0.37	-0.27	Late-onset Alzheimer's disease;	chr1:111351086	chr1:111353275~111367409:-
THCA	cis	rs227275	0.525	rs28845922	ENSG00000230069.3	LRRC37A15P	-6.18	1.36e-09	2.83e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102727274~102730721:-
THCA	cis	rs6723226	0.699	rs805830	ENSG00000276334.1	AL133243.1	6.18	1.36e-09	2.83e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr2:32276406	chr2:32521927~32523547:+
THCA	cis	rs5751614	0.537	rs9608093	ENSG00000230701.2	FBXW4P1	6.18	1.36e-09	2.83e-07	0.32	0.27	Height;	chr22:23271352	chr22:23262767~23265005:+
THCA	cis	rs807029	0.577	rs701835	ENSG00000272572.1	RP11-179B2.2	-6.18	1.36e-09	2.84e-07	-0.24	-0.27	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100911103~100912739:-
THCA	cis	rs2221433	1	rs2354423	ENSG00000260310.1	RP11-27M24.2	6.18	1.36e-09	2.84e-07	0.33	0.27	Eating disorders;	chr16:10578271	chr16:10576499~10578183:-
THCA	cis	rs6430585	0.528	rs12476127	ENSG00000231890.6	DARS-AS1	-6.18	1.36e-09	2.84e-07	-0.33	-0.27	Corneal structure;	chr2:136005672	chr2:135985176~136022593:+
THCA	cis	rs1865760	0.865	rs9467647	ENSG00000272462.2	U91328.19	-6.18	1.36e-09	2.84e-07	-0.23	-0.27	Height;	chr6:25957414	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs10946800	ENSG00000272462.2	U91328.19	-6.18	1.36e-09	2.84e-07	-0.23	-0.27	Height;	chr6:25957545	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs9467648	ENSG00000272462.2	U91328.19	-6.18	1.36e-09	2.84e-07	-0.23	-0.27	Height;	chr6:25957705	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs9467650	ENSG00000272462.2	U91328.19	-6.18	1.36e-09	2.84e-07	-0.23	-0.27	Height;	chr6:25958007	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs9467651	ENSG00000272462.2	U91328.19	-6.18	1.36e-09	2.84e-07	-0.23	-0.27	Height;	chr6:25958029	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs9467652	ENSG00000272462.2	U91328.19	-6.18	1.36e-09	2.84e-07	-0.23	-0.27	Height;	chr6:25958899	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.827	rs9461227	ENSG00000272462.2	U91328.19	-6.18	1.36e-09	2.84e-07	-0.23	-0.27	Height;	chr6:25960587	chr6:25992662~26001775:+
THCA	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	6.18	1.36e-09	2.84e-07	0.31	0.27	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
THCA	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-6.18	1.36e-09	2.84e-07	-0.28	-0.27	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
THCA	cis	rs2858942	0.575	rs2858011	ENSG00000268836.1	LA16c-OS12.2	6.18	1.36e-09	2.85e-07	0.25	0.27	Mean corpuscular hemoglobin;	chr16:197939	chr16:185748~186294:-
THCA	cis	rs934734	0.752	rs1194849	ENSG00000234255.7	AC012370.3	-6.18	1.36e-09	2.85e-07	-0.31	-0.27	Rheumatoid arthritis;	chr2:65379519	chr2:65439888~65456571:-
THCA	cis	rs1395	0.885	rs7575245	ENSG00000234072.1	AC074117.10	-6.18	1.36e-09	2.85e-07	-0.23	-0.27	Blood metabolite levels;	chr2:27304453	chr2:27356246~27367622:+
THCA	cis	rs1395	0.961	rs4665963	ENSG00000234072.1	AC074117.10	-6.18	1.36e-09	2.85e-07	-0.23	-0.27	Blood metabolite levels;	chr2:27305824	chr2:27356246~27367622:+
THCA	cis	rs55823223	0.564	rs936391	ENSG00000267801.1	RP11-552F3.9	-6.18	1.36e-09	2.85e-07	-0.34	-0.27	Psoriasis;	chr17:75851718	chr17:75876372~75879546:+
THCA	cis	rs2243480	1	rs781157	ENSG00000228409.4	CCT6P1	6.18	1.36e-09	2.85e-07	0.32	0.27	Diabetic kidney disease;	chr7:66013324	chr7:65751142~65763354:+
THCA	cis	rs9649465	0.967	rs3779261	ENSG00000272686.1	RP11-390E23.6	6.18	1.36e-09	2.85e-07	0.18	0.27	Migraine;	chr7:123675120	chr7:123749068~123751166:+
THCA	cis	rs60180747	0.544	rs11635096	ENSG00000261318.1	RP11-653J6.1	6.18	1.36e-09	2.85e-07	0.37	0.27	Testicular germ cell tumor;	chr15:66276362	chr15:66278498~66293357:-
THCA	cis	rs9816784	0.525	rs41301371	ENSG00000226155.1	AC124944.3	-6.18	1.37e-09	2.85e-07	-0.34	-0.27	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195912049~195913986:+
THCA	cis	rs228614	0.51	rs4699033	ENSG00000230069.3	LRRC37A15P	-6.18	1.37e-09	2.85e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102727274~102730721:-
THCA	cis	rs228614	0.536	rs223375	ENSG00000251288.2	RP11-10L12.2	-6.18	1.37e-09	2.86e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102751401~102752641:+
THCA	cis	rs934734	0.752	rs2661796	ENSG00000234255.7	AC012370.3	-6.18	1.37e-09	2.86e-07	-0.31	-0.27	Rheumatoid arthritis;	chr2:65400272	chr2:65439888~65456571:-
THCA	cis	rs950169	0.58	rs4603535	ENSG00000259295.5	CSPG4P12	6.18	1.37e-09	2.86e-07	0.42	0.27	Schizophrenia;	chr15:84630641	chr15:85191438~85213905:+
THCA	cis	rs2255336	0.702	rs7964772	ENSG00000245648.1	RP11-277P12.20	6.18	1.37e-09	2.87e-07	0.36	0.27	Blood protein levels;	chr12:10367498	chr12:10363769~10398506:+
THCA	cis	rs934734	0.752	rs1194849	ENSG00000237979.1	AC007389.1	-6.18	1.37e-09	2.87e-07	-0.32	-0.27	Rheumatoid arthritis;	chr2:65379519	chr2:65500993~65502138:-
THCA	cis	rs9595908	0.9	rs7994229	ENSG00000212293.1	SNORA16	6.18	1.37e-09	2.87e-07	0.31	0.27	Body mass index;	chr13:32586568	chr13:32420390~32420516:-
THCA	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	6.18	1.37e-09	2.87e-07	0.36	0.27	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
THCA	cis	rs16976116	0.951	rs9300	ENSG00000279145.1	RP11-547D13.1	6.18	1.37e-09	2.87e-07	0.27	0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55196867	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.951	rs13733	ENSG00000279145.1	RP11-547D13.1	6.18	1.37e-09	2.87e-07	0.27	0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55196906	chr15:55171972~55178175:-
THCA	cis	rs890448	0.726	rs2583391	ENSG00000254531.1	FLJ20021	-6.18	1.37e-09	2.87e-07	-0.25	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101346296	chr4:101347780~101348883:+
THCA	cis	rs797680	0.856	rs4847235	ENSG00000223745.6	RP4-717I23.3	6.18	1.37e-09	2.87e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93162170	chr1:93262186~93346025:-
THCA	cis	rs797680	0.856	rs11164876	ENSG00000223745.6	RP4-717I23.3	6.18	1.37e-09	2.87e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93164953	chr1:93262186~93346025:-
THCA	cis	rs4835473	0.932	rs1849113	ENSG00000251600.4	RP11-673E1.1	-6.18	1.38e-09	2.87e-07	-0.37	-0.27	Immature fraction of reticulocytes;	chr4:143962512	chr4:143912331~143982454:+
THCA	cis	rs9990333	0.562	rs12632706	ENSG00000226155.1	AC124944.3	-6.18	1.38e-09	2.87e-07	-0.33	-0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195912049~195913986:+
THCA	cis	rs28472312	0.832	rs28433345	ENSG00000251417.2	RP11-1348G14.4	-6.18	1.38e-09	2.88e-07	-0.26	-0.27	Intelligence (multi-trait analysis);	chr16:28872006	chr16:28802743~28817828:+
THCA	cis	rs6674176	0.561	rs4660263	ENSG00000237950.1	RP11-7O11.3	6.18	1.38e-09	2.88e-07	0.25	0.27	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43955761	chr1:43944370~43946551:-
THCA	cis	rs227275	0.525	rs7685399	ENSG00000230069.3	LRRC37A15P	-6.18	1.38e-09	2.88e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs7688940	ENSG00000230069.3	LRRC37A15P	-6.18	1.38e-09	2.88e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102727274~102730721:-
THCA	cis	rs6545883	0.929	rs1186700	ENSG00000271889.1	RP11-493E12.1	6.18	1.38e-09	2.89e-07	0.27	0.27	Tuberculosis;	chr2:61436237	chr2:61151433~61162105:-
THCA	cis	rs8014252	0.803	rs59233924	ENSG00000259158.2	ADAM20P1	-6.18	1.38e-09	2.89e-07	-0.35	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70583943	chr14:70468881~70483756:-
THCA	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	6.18	1.38e-09	2.89e-07	0.28	0.27	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
THCA	cis	rs728616	0.867	rs57257258	ENSG00000242600.5	MBL1P	6.18	1.38e-09	2.89e-07	0.38	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80084264	chr10:79904898~79950336:+
THCA	cis	rs728616	1	rs728615	ENSG00000242600.5	MBL1P	6.18	1.38e-09	2.89e-07	0.38	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088333	chr10:79904898~79950336:+
THCA	cis	rs227275	0.525	rs1383733	ENSG00000230069.3	LRRC37A15P	-6.18	1.39e-09	2.89e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102727274~102730721:-
THCA	cis	rs1993293	0.636	rs1993294	ENSG00000259363.4	CTD-2054N24.2	-6.18	1.39e-09	2.89e-07	-0.37	-0.27	Coronary artery calcification;	chr15:99757486	chr15:99807023~99877148:+
THCA	cis	rs8177876	0.749	rs75923695	ENSG00000261061.1	RP11-303E16.2	-6.18	1.39e-09	2.9e-07	-0.4	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81030770~81031485:+
THCA	cis	rs17767294	0.612	rs9461424	ENSG00000219392.1	RP1-265C24.5	-6.18	1.39e-09	2.9e-07	-0.5	-0.27	Parkinson's disease;	chr6:27951623	chr6:28115628~28116551:+
THCA	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-6.18	1.39e-09	2.9e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-6.18	1.39e-09	2.9e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
THCA	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	6.18	1.39e-09	2.9e-07	0.25	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
THCA	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	6.18	1.39e-09	2.9e-07	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
THCA	cis	rs2880765	0.546	rs36098649	ENSG00000259295.5	CSPG4P12	6.18	1.39e-09	2.9e-07	0.42	0.27	Coronary artery disease;	chr15:85513576	chr15:85191438~85213905:+
THCA	cis	rs7615952	0.512	rs4679430	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	2.91e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:125639049	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.512	rs34651730	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	2.91e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:125639796	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.512	rs2979334	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	2.91e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:125639980	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.512	rs11929125	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	2.91e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:125640599	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.512	rs11921452	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	2.91e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:125640906	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.512	rs2922175	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	2.91e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:125642516	chr3:125916620~125930024:+
THCA	cis	rs34779708	0.643	rs4275563	ENSG00000271335.4	RP11-324I22.4	6.18	1.39e-09	2.91e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35314552~35336401:-
THCA	cis	rs10844706	0.699	rs7296241	ENSG00000256594.6	RP11-705C15.2	6.18	1.4e-09	2.91e-07	0.23	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725044	chr12:9633419~9658412:+
THCA	cis	rs7202877	0.561	rs8050662	ENSG00000261783.1	RP11-252K23.2	6.18	1.4e-09	2.92e-07	0.47	0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75326836	chr16:75379818~75381260:-
THCA	cis	rs9921338	1	rs8049173	ENSG00000262636.1	CTD-3088G3.4	-6.18	1.4e-09	2.92e-07	-0.4	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343025	chr16:11380859~11381118:-
THCA	cis	rs9921338	1	rs8055427	ENSG00000262636.1	CTD-3088G3.4	-6.18	1.4e-09	2.92e-07	-0.4	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343026	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.887	rs9926136	ENSG00000262636.1	CTD-3088G3.4	-6.18	1.4e-09	2.92e-07	-0.4	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343418	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs9936093	ENSG00000262636.1	CTD-3088G3.4	-6.18	1.4e-09	2.92e-07	-0.4	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343459	chr16:11380859~11381118:-
THCA	cis	rs5758659	0.714	rs133376	ENSG00000270083.1	RP1-257I20.14	6.18	1.4e-09	2.93e-07	0.29	0.27	Cognitive function;	chr22:42070901	chr22:42089630~42090028:-
THCA	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-6.18	1.4e-09	2.93e-07	-0.26	-0.27	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
THCA	cis	rs9475752	0.564	rs7744799	ENSG00000231441.1	RP11-472M19.2	6.18	1.4e-09	2.93e-07	0.31	0.27	Menarche (age at onset);	chr6:56879045	chr6:56844002~56864078:+
THCA	cis	rs2280018	0.963	rs12928424	ENSG00000188599.16	NPIPP1	-6.18	1.41e-09	2.93e-07	-0.2	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15104312~15123498:-
THCA	cis	rs4934494	0.768	rs34993776	ENSG00000232936.4	RP11-80H5.2	6.18	1.41e-09	2.93e-07	0.4	0.27	Red blood cell count;	chr10:89681932	chr10:89645282~89650667:+
THCA	cis	rs9393777	0.92	rs13196692	ENSG00000226314.6	ZNF192P1	-6.18	1.41e-09	2.93e-07	-0.59	-0.27	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28161781~28169594:+
THCA	cis	rs9393777	0.92	rs34150729	ENSG00000226314.6	ZNF192P1	-6.18	1.41e-09	2.93e-07	-0.59	-0.27	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28161781~28169594:+
THCA	cis	rs9393777	0.92	rs13191227	ENSG00000226314.6	ZNF192P1	-6.18	1.41e-09	2.93e-07	-0.59	-0.27	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28161781~28169594:+
THCA	cis	rs950169	0.544	rs12913702	ENSG00000259295.5	CSPG4P12	6.18	1.41e-09	2.94e-07	0.43	0.27	Schizophrenia;	chr15:84609953	chr15:85191438~85213905:+
THCA	cis	rs853679	0.517	rs6922063	ENSG00000261839.1	RP1-265C24.8	6.18	1.41e-09	2.94e-07	0.33	0.27	Depression;	chr6:28126588	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000261839.1	RP1-265C24.8	6.18	1.41e-09	2.94e-07	0.33	0.27	Depression;	chr6:28126953	chr6:28136849~28139678:+
THCA	cis	rs911555	0.546	rs28798508	ENSG00000269940.1	RP11-73M18.7	6.18	1.41e-09	2.94e-07	0.28	0.27	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103694560~103695170:+
THCA	cis	rs6671200	0.518	rs77369148	ENSG00000235501.4	RP4-639F20.1	-6.18	1.41e-09	2.94e-07	-0.5	-0.27	Stearic acid (18:0) levels;	chr1:94912122	chr1:94927566~94963270:+
THCA	cis	rs2915864	0.628	rs78749116	ENSG00000280047.1	CTC-463A16.1	6.18	1.41e-09	2.94e-07	0.4	0.27	Facial morphology (factor 20);	chr5:142052102	chr5:142165767~142168387:+
THCA	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-6.18	1.41e-09	2.95e-07	-0.29	-0.27	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
THCA	cis	rs2243480	1	rs781149	ENSG00000228409.4	CCT6P1	6.18	1.41e-09	2.95e-07	0.31	0.27	Diabetic kidney disease;	chr7:66016297	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000228409.4	CCT6P1	6.18	1.41e-09	2.95e-07	0.31	0.27	Diabetic kidney disease;	chr7:66021736	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1167613	ENSG00000228409.4	CCT6P1	6.18	1.41e-09	2.95e-07	0.31	0.27	Diabetic kidney disease;	chr7:66022452	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs313799	ENSG00000228409.4	CCT6P1	6.18	1.41e-09	2.95e-07	0.31	0.27	Diabetic kidney disease;	chr7:66029343	chr7:65751142~65763354:+
THCA	cis	rs61677309	0.558	rs7940047	ENSG00000280032.1	RP11-832A4.7	6.18	1.42e-09	2.95e-07	0.28	0.27	Lung cancer in ever smokers;	chr11:118271904	chr11:118264593~118266817:+
THCA	cis	rs6545883	0.894	rs35292974	ENSG00000271889.1	RP11-493E12.1	-6.18	1.42e-09	2.95e-07	-0.26	-0.27	Tuberculosis;	chr2:61294912	chr2:61151433~61162105:-
THCA	cis	rs8012947	0.916	rs4901853	ENSG00000279636.2	LINC00216	6.18	1.42e-09	2.96e-07	0.31	0.27	Alcohol consumption in current drinkers;	chr14:58382581	chr14:58288033~58289158:+
THCA	cis	rs9595908	1	rs9595905	ENSG00000212293.1	SNORA16	6.18	1.42e-09	2.96e-07	0.31	0.27	Body mass index;	chr13:32609266	chr13:32420390~32420516:-
THCA	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	6.18	1.42e-09	2.96e-07	0.43	0.27	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
THCA	cis	rs529866	0.555	rs367569	ENSG00000262703.1	RP11-485G7.6	6.18	1.42e-09	2.96e-07	0.33	0.27	Inflammatory bowel disease;Crohn's disease;	chr16:11271643	chr16:11348143~11349321:-
THCA	cis	rs7617773	0.817	rs17647717	ENSG00000228638.1	FCF1P2	-6.18	1.42e-09	2.96e-07	-0.28	-0.27	Coronary artery disease;	chr3:48263966	chr3:48290793~48291375:-
THCA	cis	rs4948102	0.667	rs7811270	ENSG00000273720.1	RP11-613E4.4	-6.18	1.42e-09	2.96e-07	-0.37	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55743073~55743457:+
THCA	cis	rs7617773	0.539	rs1471217	ENSG00000228638.1	FCF1P2	-6.18	1.42e-09	2.96e-07	-0.27	-0.27	Coronary artery disease;	chr3:48343405	chr3:48290793~48291375:-
THCA	cis	rs1979679	0.842	rs1118097	ENSG00000278733.1	RP11-425D17.1	6.18	1.42e-09	2.96e-07	0.27	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28177156	chr12:28185625~28186190:-
THCA	cis	rs6908034	0.607	rs73376650	ENSG00000227116.1	RP3-471C18.1	-6.18	1.42e-09	2.96e-07	-0.49	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805275	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs112599867	ENSG00000227116.1	RP3-471C18.1	-6.18	1.42e-09	2.96e-07	-0.49	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805301	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs73376651	ENSG00000227116.1	RP3-471C18.1	-6.18	1.42e-09	2.96e-07	-0.49	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805328	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs73376655	ENSG00000227116.1	RP3-471C18.1	-6.18	1.42e-09	2.96e-07	-0.49	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805433	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs113592672	ENSG00000227116.1	RP3-471C18.1	-6.18	1.42e-09	2.96e-07	-0.49	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805832	chr6:19730427~19734567:-
THCA	cis	rs1005277	0.579	rs2505257	ENSG00000276805.1	RP11-291L22.6	6.18	1.43e-09	2.97e-07	0.3	0.27	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38451030~38451785:+
THCA	cis	rs6545883	0.965	rs7591345	ENSG00000271889.1	RP11-493E12.1	6.18	1.43e-09	2.97e-07	0.26	0.27	Tuberculosis;	chr2:61502506	chr2:61151433~61162105:-
THCA	cis	rs10129255	0.517	rs11625572	ENSG00000211970.3	IGHV4-61	-6.18	1.43e-09	2.97e-07	-0.16	-0.27	Kawasaki disease;	chr14:106656426	chr14:106639119~106639657:-
THCA	cis	rs853679	0.607	rs34788973	ENSG00000219392.1	RP1-265C24.5	-6.18	1.43e-09	2.98e-07	-0.61	-0.27	Depression;	chr6:27911422	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs61742093	ENSG00000219392.1	RP1-265C24.5	-6.18	1.43e-09	2.98e-07	-0.61	-0.27	Depression;	chr6:27912204	chr6:28115628~28116551:+
THCA	cis	rs35264875	0.851	rs7933746	ENSG00000259799.1	RP11-554A11.9	6.18	1.43e-09	2.98e-07	0.37	0.27	Blond vs. brown hair color;	chr11:69100254	chr11:69155910~69159752:+
THCA	cis	rs2562456	0.833	rs2650801	ENSG00000268555.1	RP11-678G14.3	6.17	1.43e-09	2.98e-07	0.41	0.27	Pain;	chr19:21452553	chr19:21570822~21587322:-
THCA	cis	rs9649465	1	rs10228367	ENSG00000272686.1	RP11-390E23.6	6.17	1.43e-09	2.99e-07	0.18	0.27	Migraine;	chr7:123730849	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs1468656	ENSG00000272686.1	RP11-390E23.6	6.17	1.43e-09	2.99e-07	0.18	0.27	Migraine;	chr7:123735451	chr7:123749068~123751166:+
THCA	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	6.17	1.43e-09	2.99e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
THCA	cis	rs6545883	0.965	rs1992765	ENSG00000271889.1	RP11-493E12.1	6.17	1.43e-09	2.99e-07	0.26	0.27	Tuberculosis;	chr2:61524198	chr2:61151433~61162105:-
THCA	cis	rs9926296	0.744	rs460879	ENSG00000274627.1	RP11-104N10.2	6.17	1.44e-09	2.99e-07	0.28	0.27	Vitiligo;	chr16:89646481	chr16:89516797~89522217:+
THCA	cis	rs867186	0.535	rs6058220	ENSG00000126005.14	MMP24-AS1	-6.17	1.44e-09	2.99e-07	-0.47	-0.27	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35271461	chr20:35216462~35278131:-
THCA	cis	rs7615952	0.543	rs4645102	ENSG00000241278.1	ENPP7P4	6.17	1.44e-09	2.99e-07	0.34	0.27	Blood pressure (smoking interaction);	chr3:125705597	chr3:125848223~125909372:+
THCA	cis	rs11089937	0.626	rs5757051	ENSG00000211639.2	IGLV4-60	-6.17	1.44e-09	3e-07	-0.19	-0.27	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22162199~22162681:+
THCA	cis	rs6430585	0.528	rs895285	ENSG00000231890.6	DARS-AS1	-6.17	1.44e-09	3e-07	-0.35	-0.27	Corneal structure;	chr2:135952984	chr2:135985176~136022593:+
THCA	cis	rs2562456	0.917	rs2562466	ENSG00000213976.4	CTD-2561J22.2	6.17	1.44e-09	3e-07	0.29	0.27	Pain;	chr19:21531402	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.917	rs2562468	ENSG00000213976.4	CTD-2561J22.2	6.17	1.44e-09	3e-07	0.29	0.27	Pain;	chr19:21532048	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.917	rs2562471	ENSG00000213976.4	CTD-2561J22.2	6.17	1.44e-09	3e-07	0.29	0.27	Pain;	chr19:21533017	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.917	rs2681377	ENSG00000213976.4	CTD-2561J22.2	6.17	1.44e-09	3e-07	0.29	0.27	Pain;	chr19:21533718	chr19:21382865~21387177:+
THCA	cis	rs367615	0.68	rs31595	ENSG00000249476.1	CTD-2587M2.1	6.17	1.44e-09	3e-07	0.31	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109643617	chr5:109237120~109326369:-
THCA	cis	rs1865760	0.786	rs2164487	ENSG00000272462.2	U91328.19	-6.17	1.44e-09	3e-07	-0.23	-0.27	Height;	chr6:25950572	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs6929805	ENSG00000272462.2	U91328.19	-6.17	1.44e-09	3e-07	-0.23	-0.27	Height;	chr6:25950606	chr6:25992662~26001775:+
THCA	cis	rs7044106	0.762	rs7357638	ENSG00000270917.1	RP11-27I1.6	-6.17	1.44e-09	3e-07	-0.39	-0.27	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120812475~120812845:-
THCA	cis	rs9393777	0.92	rs13207689	ENSG00000226314.6	ZNF192P1	-6.17	1.44e-09	3e-07	-0.59	-0.27	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28161781~28169594:+
THCA	cis	rs7615952	0.641	rs12488180	ENSG00000250012.1	RP11-124N2.1	-6.17	1.44e-09	3e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126063393	chr3:126084220~126095349:+
THCA	cis	rs61677309	0.638	rs57506367	ENSG00000280032.1	RP11-832A4.7	6.17	1.44e-09	3e-07	0.28	0.27	Lung cancer in ever smokers;	chr11:118271278	chr11:118264593~118266817:+
THCA	cis	rs10971721	0.584	rs10971940	ENSG00000281128.1	PTENP1-AS	6.17	1.44e-09	3.01e-07	0.57	0.27	Body mass index;	chr9:34127213	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs72731226	ENSG00000281128.1	PTENP1-AS	6.17	1.44e-09	3.01e-07	0.57	0.27	Body mass index;	chr9:34128832	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs10971944	ENSG00000281128.1	PTENP1-AS	6.17	1.44e-09	3.01e-07	0.57	0.27	Body mass index;	chr9:34129008	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.631	rs74450404	ENSG00000281128.1	PTENP1-AS	6.17	1.44e-09	3.01e-07	0.57	0.27	Body mass index;	chr9:34134666	chr9:33677268~33688011:+
THCA	cis	rs7260598	0.606	rs72483177	ENSG00000268442.1	CTD-2027I19.2	6.17	1.44e-09	3.01e-07	0.37	0.27	Response to taxane treatment (placlitaxel);	chr19:23970913	chr19:24162370~24163425:-
THCA	cis	rs7560272	0.695	rs780393	ENSG00000163016.8	ALMS1P	-6.17	1.44e-09	3.01e-07	-0.36	-0.27	Schizophrenia;	chr2:73474542	chr2:73644919~73685576:+
THCA	cis	rs338389	0.542	rs7182139	ENSG00000260657.2	RP11-315D16.4	-6.17	1.44e-09	3.01e-07	-0.38	-0.27	Survival in rectal cancer;	chr15:67993116	chr15:68267792~68277994:-
THCA	cis	rs72843506	0.656	rs28567541	ENSG00000270091.1	RP11-78O7.2	-6.17	1.44e-09	3.01e-07	-0.3	-0.27	Schizophrenia;	chr17:20051789	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs80250684	ENSG00000270091.1	RP11-78O7.2	-6.17	1.44e-09	3.01e-07	-0.3	-0.27	Schizophrenia;	chr17:20054983	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs28622601	ENSG00000270091.1	RP11-78O7.2	-6.17	1.44e-09	3.01e-07	-0.3	-0.27	Schizophrenia;	chr17:20055341	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.586	rs75048432	ENSG00000270091.1	RP11-78O7.2	-6.17	1.44e-09	3.01e-07	-0.3	-0.27	Schizophrenia;	chr17:20057571	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs16960660	ENSG00000270091.1	RP11-78O7.2	-6.17	1.44e-09	3.01e-07	-0.3	-0.27	Schizophrenia;	chr17:20062274	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs73984564	ENSG00000270091.1	RP11-78O7.2	-6.17	1.44e-09	3.01e-07	-0.3	-0.27	Schizophrenia;	chr17:20068535	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs13339684	ENSG00000270091.1	RP11-78O7.2	-6.17	1.44e-09	3.01e-07	-0.3	-0.27	Schizophrenia;	chr17:20073898	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.656	rs73984568	ENSG00000270091.1	RP11-78O7.2	-6.17	1.44e-09	3.01e-07	-0.3	-0.27	Schizophrenia;	chr17:20074301	chr17:19896590~19897287:-
THCA	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	6.17	1.44e-09	3.01e-07	0.32	0.27	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
THCA	cis	rs713477	0.901	rs7146306	ENSG00000258413.1	RP11-665C16.6	6.17	1.45e-09	3.01e-07	0.37	0.27	Pediatric bone mineral content (femoral neck);	chr14:55439135	chr14:55262767~55272075:-
THCA	cis	rs713477	0.935	rs12888181	ENSG00000258413.1	RP11-665C16.6	6.17	1.45e-09	3.01e-07	0.37	0.27	Pediatric bone mineral content (femoral neck);	chr14:55439364	chr14:55262767~55272075:-
THCA	cis	rs713477	1	rs12888361	ENSG00000258413.1	RP11-665C16.6	6.17	1.45e-09	3.01e-07	0.37	0.27	Pediatric bone mineral content (femoral neck);	chr14:55439469	chr14:55262767~55272075:-
THCA	cis	rs848490	0.889	rs10953356	ENSG00000214293.7	APTR	6.17	1.45e-09	3.01e-07	0.22	0.27	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77820281	chr7:77657660~77696265:-
THCA	cis	rs3213958	0.574	rs11914715	ENSG00000249274.1	PDLIM1P4	-6.17	1.45e-09	3.02e-07	-0.34	-0.27	Blood protein levels;	chr3:98780118	chr3:98782188~98783193:+
THCA	cis	rs853679	0.517	rs16893666	ENSG00000261839.1	RP1-265C24.8	-6.17	1.45e-09	3.02e-07	-0.33	-0.27	Depression;	chr6:28086929	chr6:28136849~28139678:+
THCA	cis	rs4835473	0.9	rs3856989	ENSG00000251600.4	RP11-673E1.1	6.17	1.45e-09	3.02e-07	0.38	0.27	Immature fraction of reticulocytes;	chr4:143921752	chr4:143912331~143982454:+
THCA	cis	rs11722779	0.935	rs7681629	ENSG00000251288.2	RP11-10L12.2	-6.17	1.45e-09	3.02e-07	-0.37	-0.27	Schizophrenia;	chr4:102974407	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.844	rs17033381	ENSG00000251288.2	RP11-10L12.2	-6.17	1.45e-09	3.02e-07	-0.37	-0.27	Schizophrenia;	chr4:102974952	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs4699044	ENSG00000251288.2	RP11-10L12.2	-6.17	1.45e-09	3.02e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs4699045	ENSG00000251288.2	RP11-10L12.2	-6.17	1.45e-09	3.02e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs10015289	ENSG00000251288.2	RP11-10L12.2	-6.17	1.45e-09	3.02e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs6852141	ENSG00000251288.2	RP11-10L12.2	-6.17	1.45e-09	3.02e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102751401~102752641:+
THCA	cis	rs228614	0.509	rs4455415	ENSG00000251288.2	RP11-10L12.2	-6.17	1.45e-09	3.02e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102751401~102752641:+
THCA	cis	rs9990333	0.562	rs58079878	ENSG00000226155.1	AC124944.3	-6.17	1.45e-09	3.02e-07	-0.34	-0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195912049~195913986:+
THCA	cis	rs28386778	0.966	rs2854161	ENSG00000240280.5	TCAM1P	6.17	1.45e-09	3.02e-07	0.38	0.27	Prudent dietary pattern;	chr17:63898733	chr17:63849292~63864379:+
THCA	cis	rs3822625	1	rs3822625	ENSG00000271828.1	CTD-2310F14.1	6.17	1.45e-09	3.02e-07	0.68	0.27	Breast cancer (early onset);	chr5:56882284	chr5:56927874~56929573:+
THCA	cis	rs944990	0.576	rs3933795	ENSG00000227603.1	RP11-165J3.6	6.17	1.45e-09	3.03e-07	0.28	0.27	Body mass index;	chr9:93423391	chr9:93435332~93437121:-
THCA	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-6.17	1.46e-09	3.03e-07	-0.39	-0.27	Pain;	chr19:21491155	chr19:21554640~21569237:-
THCA	cis	rs2239547	0.603	rs34230854	ENSG00000242142.1	SERBP1P3	6.17	1.46e-09	3.03e-07	0.35	0.27	Schizophrenia;	chr3:53044574	chr3:53064283~53065091:-
THCA	cis	rs6600671	1	rs12047116	ENSG00000275538.1	RNVU1-19	6.17	1.46e-09	3.03e-07	0.34	0.27	Hip geometry;	chr1:121443912	chr1:120850819~120850985:-
THCA	cis	rs6600671	0.967	rs11249347	ENSG00000275538.1	RNVU1-19	6.17	1.46e-09	3.03e-07	0.34	0.27	Hip geometry;	chr1:121446489	chr1:120850819~120850985:-
THCA	cis	rs8002861	0.87	rs4942255	ENSG00000274001.1	RP11-5G9.5	-6.17	1.46e-09	3.03e-07	-0.31	-0.27	Leprosy;	chr13:43877708	chr13:43877715~43878163:-
THCA	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-6.17	1.46e-09	3.03e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
THCA	cis	rs934734	0.752	rs268136	ENSG00000234255.7	AC012370.3	-6.17	1.46e-09	3.03e-07	-0.31	-0.27	Rheumatoid arthritis;	chr2:65380409	chr2:65439888~65456571:-
THCA	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-6.17	1.46e-09	3.04e-07	-0.25	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
THCA	cis	rs227275	0.556	rs223449	ENSG00000251288.2	RP11-10L12.2	-6.17	1.46e-09	3.04e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102751401~102752641:+
THCA	cis	rs7044106	0.791	rs4617229	ENSG00000270917.1	RP11-27I1.6	-6.17	1.46e-09	3.04e-07	-0.39	-0.27	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120812475~120812845:-
THCA	cis	rs2562456	0.874	rs2562408	ENSG00000213976.4	CTD-2561J22.2	6.17	1.46e-09	3.04e-07	0.29	0.27	Pain;	chr19:21527079	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.874	rs2562417	ENSG00000213976.4	CTD-2561J22.2	6.17	1.46e-09	3.04e-07	0.29	0.27	Pain;	chr19:21528400	chr19:21382865~21387177:+
THCA	cis	rs10129255	0.957	rs10132367	ENSG00000211974.3	IGHV2-70	6.17	1.46e-09	3.04e-07	0.22	0.27	Kawasaki disease;	chr14:106690981	chr14:106723574~106724093:-
THCA	cis	rs10844706	0.669	rs10844682	ENSG00000256594.6	RP11-705C15.2	-6.17	1.46e-09	3.04e-07	-0.22	-0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9747028	chr12:9633419~9658412:+
THCA	cis	rs4664293	0.605	rs6741498	ENSG00000226266.5	AC009961.3	6.17	1.46e-09	3.04e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159698111	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs6760931	ENSG00000226266.5	AC009961.3	6.17	1.46e-09	3.04e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159702600	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs6713600	ENSG00000226266.5	AC009961.3	6.17	1.46e-09	3.04e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159706559	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs7607394	ENSG00000226266.5	AC009961.3	6.17	1.46e-09	3.04e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159707286	chr2:159670708~159712435:-
THCA	cis	rs6142102	0.961	rs2235596	ENSG00000275784.1	RP5-1125A11.6	6.17	1.46e-09	3.04e-07	0.28	0.27	Skin pigmentation;	chr20:34096503	chr20:33989480~33991818:-
THCA	cis	rs2915864	0.747	rs79490407	ENSG00000280047.1	CTC-463A16.1	6.17	1.46e-09	3.05e-07	0.45	0.27	Facial morphology (factor 20);	chr5:142086559	chr5:142165767~142168387:+
THCA	cis	rs227275	0.556	rs12508069	ENSG00000251288.2	RP11-10L12.2	-6.17	1.47e-09	3.05e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102751401~102752641:+
THCA	cis	rs748404	0.666	rs72709871	ENSG00000249839.1	AC011330.5	-6.17	1.47e-09	3.05e-07	-0.39	-0.27	Lung cancer;	chr15:43499025	chr15:43663654~43684339:-
THCA	cis	rs9921338	0.961	rs8043692	ENSG00000262636.1	CTD-3088G3.4	-6.17	1.47e-09	3.05e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333100	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.923	rs6498181	ENSG00000262636.1	CTD-3088G3.4	-6.17	1.47e-09	3.05e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333336	chr16:11380859~11381118:-
THCA	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	6.17	1.47e-09	3.06e-07	0.26	0.27	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
THCA	cis	rs11018904	0.552	rs12806034	ENSG00000280385.1	AP000648.5	-6.17	1.47e-09	3.06e-07	-0.31	-0.27	Intelligence (multi-trait analysis);	chr11:90236771	chr11:90193614~90198120:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	6.17	1.47e-09	3.06e-07	0.31	0.27	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
THCA	cis	rs11722779	0.935	rs3974481	ENSG00000230069.3	LRRC37A15P	-6.17	1.47e-09	3.06e-07	-0.29	-0.27	Schizophrenia;	chr4:102956834	chr4:102727274~102730721:-
THCA	cis	rs1005277	0.691	rs2474558	ENSG00000276805.1	RP11-291L22.6	-6.17	1.47e-09	3.06e-07	-0.3	-0.27	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38451030~38451785:+
THCA	cis	rs10129255	0.913	rs28861466	ENSG00000211974.3	IGHV2-70	6.17	1.47e-09	3.06e-07	0.21	0.27	Kawasaki disease;	chr14:106718572	chr14:106723574~106724093:-
THCA	cis	rs12681366	0.708	rs2515100	ENSG00000253704.1	RP11-267M23.4	6.17	1.47e-09	3.06e-07	0.26	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94368728	chr8:94553722~94569745:+
THCA	cis	rs9926296	0.715	rs2115401	ENSG00000274627.1	RP11-104N10.2	-6.17	1.47e-09	3.06e-07	-0.27	-0.27	Vitiligo;	chr16:89674201	chr16:89516797~89522217:+
THCA	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	6.17	1.47e-09	3.06e-07	0.37	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
THCA	cis	rs9601248	0.627	rs9545151	ENSG00000227354.5	RBM26-AS1	-6.17	1.48e-09	3.07e-07	-0.27	-0.27	Major depressive disorder;	chr13:79608400	chr13:79406309~79424328:+
THCA	cis	rs7615952	0.512	rs2979336	ENSG00000171084.14	FAM86JP	6.17	1.48e-09	3.07e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:125638626	chr3:125916620~125930024:+
THCA	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	6.17	1.48e-09	3.07e-07	0.42	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
THCA	cis	rs812925	0.559	rs2600667	ENSG00000271889.1	RP11-493E12.1	6.17	1.48e-09	3.07e-07	0.29	0.27	Immature fraction of reticulocytes;	chr2:61177796	chr2:61151433~61162105:-
THCA	cis	rs6545883	1	rs6545883	ENSG00000270820.4	RP11-355B11.2	6.17	1.48e-09	3.07e-07	0.22	0.27	Tuberculosis;	chr2:61545122	chr2:61471188~61484130:+
THCA	cis	rs681343	1	rs679574	ENSG00000232871.7	SEC1P	6.17	1.48e-09	3.08e-07	0.32	0.27	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702851	chr19:48638071~48682245:+
THCA	cis	rs228614	0.51	rs223410	ENSG00000251288.2	RP11-10L12.2	-6.17	1.48e-09	3.08e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223400	ENSG00000251288.2	RP11-10L12.2	-6.17	1.48e-09	3.08e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102751401~102752641:+
THCA	cis	rs1005277	0.522	rs11011343	ENSG00000263064.2	RP11-291L22.7	6.17	1.48e-09	3.08e-07	0.3	0.27	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38448689~38448949:+
THCA	cis	rs4835473	0.831	rs1579816	ENSG00000251600.4	RP11-673E1.1	6.17	1.48e-09	3.08e-07	0.37	0.27	Immature fraction of reticulocytes;	chr4:143866772	chr4:143912331~143982454:+
THCA	cis	rs4664293	0.605	rs6745815	ENSG00000226266.5	AC009961.3	6.17	1.48e-09	3.08e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159693558	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.551	rs11898293	ENSG00000226266.5	AC009961.3	6.17	1.48e-09	3.08e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159696082	chr2:159670708~159712435:-
THCA	cis	rs736801	0.808	rs72797303	ENSG00000224431.1	AC063976.7	6.17	1.48e-09	3.08e-07	0.24	0.27	Mosquito bite size;Breast cancer;	chr5:132460471	chr5:132199456~132203487:+
THCA	cis	rs736801	0.808	rs72797306	ENSG00000224431.1	AC063976.7	6.17	1.48e-09	3.08e-07	0.24	0.27	Mosquito bite size;Breast cancer;	chr5:132465058	chr5:132199456~132203487:+
THCA	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	6.17	1.48e-09	3.08e-07	0.33	0.27	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
THCA	cis	rs4713118	0.662	rs149900	ENSG00000220721.1	OR1F12	6.17	1.48e-09	3.08e-07	0.36	0.27	Parkinson's disease;	chr6:28046819	chr6:28073316~28074233:+
THCA	cis	rs4664293	0.625	rs62171654	ENSG00000226266.5	AC009961.3	6.17	1.48e-09	3.08e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159675107	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs11903816	ENSG00000226266.5	AC009961.3	6.17	1.48e-09	3.08e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159675347	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs6738523	ENSG00000226266.5	AC009961.3	6.17	1.48e-09	3.08e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159681203	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.585	rs11893106	ENSG00000226266.5	AC009961.3	6.17	1.48e-09	3.08e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159684294	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs11899419	ENSG00000226266.5	AC009961.3	6.17	1.48e-09	3.08e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159688858	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs2114625	ENSG00000226266.5	AC009961.3	-6.17	1.48e-09	3.08e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159687297	chr2:159670708~159712435:-
THCA	cis	rs17345786	0.511	rs12639028	ENSG00000256628.3	ZBTB11-AS1	6.17	1.48e-09	3.08e-07	0.33	0.27	Colonoscopy-negative controls vs population controls;	chr3:101627189	chr3:101676475~101679217:+
THCA	cis	rs2562456	0.792	rs2562398	ENSG00000213976.4	CTD-2561J22.2	6.17	1.48e-09	3.08e-07	0.29	0.27	Pain;	chr19:21540147	chr19:21382865~21387177:+
THCA	cis	rs1866631	0.692	rs34658268	ENSG00000238133.5	MLK7-AS1	6.17	1.48e-09	3.08e-07	0.34	0.27	Lung cancer in ever smokers;	chr2:173177254	chr2:173166446~173282036:-
THCA	cis	rs2033711	0.654	rs734380	ENSG00000269473.1	CTD-2619J13.19	6.17	1.48e-09	3.08e-07	0.26	0.27	Uric acid clearance;	chr19:58387596	chr19:58440448~58445849:+
THCA	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-6.17	1.49e-09	3.09e-07	-0.39	-0.27	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
THCA	cis	rs9926296	0.605	rs886952	ENSG00000260259.1	RP11-368I7.4	-6.17	1.49e-09	3.09e-07	-0.3	-0.27	Vitiligo;	chr16:89770373	chr16:89682620~89686569:-
THCA	cis	rs227275	0.525	rs10032234	ENSG00000230069.3	LRRC37A15P	-6.17	1.49e-09	3.09e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs3886723	ENSG00000230069.3	LRRC37A15P	-6.17	1.49e-09	3.09e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102727274~102730721:-
THCA	cis	rs228614	0.517	rs3886722	ENSG00000230069.3	LRRC37A15P	-6.17	1.49e-09	3.09e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs11737544	ENSG00000230069.3	LRRC37A15P	-6.17	1.49e-09	3.09e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102727274~102730721:-
THCA	cis	rs17772222	0.917	rs7157149	ENSG00000258789.1	RP11-507K2.3	-6.17	1.49e-09	3.09e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88765501	chr14:88551597~88552493:+
THCA	cis	rs7712401	0.791	rs154507	ENSG00000249996.1	RP11-359P5.1	-6.17	1.49e-09	3.1e-07	-0.26	-0.27	Mean platelet volume;	chr5:122865212	chr5:123036271~123054667:+
THCA	cis	rs797680	0.786	rs7532195	ENSG00000223745.6	RP4-717I23.3	6.17	1.49e-09	3.1e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93151846	chr1:93262186~93346025:-
THCA	cis	rs1979679	0.842	rs60025108	ENSG00000278733.1	RP11-425D17.1	6.17	1.49e-09	3.1e-07	0.27	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168238	chr12:28185625~28186190:-
THCA	cis	rs1979679	0.842	rs7487773	ENSG00000278733.1	RP11-425D17.1	6.17	1.49e-09	3.1e-07	0.27	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168418	chr12:28185625~28186190:-
THCA	cis	rs6487679	0.614	rs6487668	ENSG00000111788.10	RP11-22B23.1	6.17	1.49e-09	3.1e-07	0.32	0.27	Non-alcoholic fatty liver disease histology (AST);	chr12:9200312	chr12:9277235~9313241:+
THCA	cis	rs12681366	0.614	rs2921385	ENSG00000253704.1	RP11-267M23.4	-6.17	1.49e-09	3.1e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94447120	chr8:94553722~94569745:+
THCA	cis	rs11089937	0.597	rs2213156	ENSG00000211639.2	IGLV4-60	6.17	1.49e-09	3.1e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.626	rs2213157	ENSG00000211639.2	IGLV4-60	6.17	1.49e-09	3.1e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.626	rs9622955	ENSG00000211639.2	IGLV4-60	6.17	1.49e-09	3.1e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22162199~22162681:+
THCA	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	6.17	1.49e-09	3.1e-07	0.3	0.27	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	6.17	1.49e-09	3.1e-07	0.3	0.27	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	6.17	1.49e-09	3.1e-07	0.3	0.27	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
THCA	cis	rs1538970	0.504	rs3790585	ENSG00000234329.1	RP11-767N6.2	6.17	1.5e-09	3.11e-07	0.3	0.27	Platelet count;	chr1:45557684	chr1:45651039~45651826:-
THCA	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	6.17	1.5e-09	3.12e-07	0.34	0.27	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
THCA	cis	rs6545883	0.929	rs3732170	ENSG00000271889.1	RP11-493E12.1	6.17	1.5e-09	3.12e-07	0.26	0.27	Tuberculosis;	chr2:61522581	chr2:61151433~61162105:-
THCA	cis	rs748404	1	rs12909095	ENSG00000249839.1	AC011330.5	-6.17	1.5e-09	3.12e-07	-0.35	-0.27	Lung cancer;	chr15:43265944	chr15:43663654~43684339:-
THCA	cis	rs228614	0.51	rs223446	ENSG00000251288.2	RP11-10L12.2	-6.17	1.5e-09	3.12e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102751401~102752641:+
THCA	cis	rs228614	0.536	rs223437	ENSG00000251288.2	RP11-10L12.2	-6.17	1.5e-09	3.12e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102751401~102752641:+
THCA	cis	rs228614	0.536	rs223419	ENSG00000251288.2	RP11-10L12.2	-6.17	1.5e-09	3.12e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102751401~102752641:+
THCA	cis	rs6740322	0.895	rs13384080	ENSG00000234936.1	AC010883.5	6.17	1.5e-09	3.12e-07	0.29	0.27	Coronary artery disease;	chr2:43330224	chr2:43229573~43233394:+
THCA	cis	rs7246657	0.722	rs12974225	ENSG00000267422.1	CTD-2554C21.1	6.17	1.5e-09	3.12e-07	0.31	0.27	Coronary artery calcification;	chr19:37749458	chr19:37779686~37792865:+
THCA	cis	rs7833787	0.77	rs4921966	ENSG00000278886.1	RP11-108A14.1	-6.17	1.5e-09	3.12e-07	-0.36	-0.27	Obesity-related traits;	chr8:18840908	chr8:18864681~18865247:-
THCA	cis	rs4604234	0.901	rs6907326	ENSG00000272129.1	RP11-250B2.6	-6.17	1.5e-09	3.12e-07	-0.71	-0.27	Cancer;	chr6:80395748	chr6:80355424~80356859:+
THCA	cis	rs10895275	0.625	rs10895271	ENSG00000277459.1	RP11-732A21.3	6.17	1.51e-09	3.13e-07	0.21	0.27	Migraine;	chr11:102199014	chr11:102109827~102110457:-
THCA	cis	rs763121	0.813	rs2179143	ENSG00000235209.1	CTA-150C2.13	6.17	1.51e-09	3.13e-07	0.35	0.27	Menopause (age at onset);	chr22:38641979	chr22:38921227~38924708:+
THCA	cis	rs34779708	0.801	rs12246600	ENSG00000271335.4	RP11-324I22.4	6.17	1.51e-09	3.13e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.801	rs12098720	ENSG00000271335.4	RP11-324I22.4	6.17	1.51e-09	3.13e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.801	rs34592588	ENSG00000271335.4	RP11-324I22.4	6.17	1.51e-09	3.13e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35314552~35336401:-
THCA	cis	rs10266483	0.515	rs6949304	ENSG00000271550.1	BNIP3P11	-6.17	1.51e-09	3.14e-07	-0.42	-0.27	Response to statin therapy;	chr7:64257903	chr7:64678954~64687393:-
THCA	cis	rs10266483	0.545	rs73132069	ENSG00000271550.1	BNIP3P11	-6.17	1.51e-09	3.14e-07	-0.42	-0.27	Response to statin therapy;	chr7:64258440	chr7:64678954~64687393:-
THCA	cis	rs2438150	1	rs2438150	ENSG00000249996.1	RP11-359P5.1	6.17	1.51e-09	3.14e-07	0.26	0.27	Plateletcrit;	chr5:122863501	chr5:123036271~123054667:+
THCA	cis	rs72843506	0.722	rs9902683	ENSG00000270091.1	RP11-78O7.2	-6.17	1.51e-09	3.14e-07	-0.3	-0.27	Schizophrenia;	chr17:20112115	chr17:19896590~19897287:-
THCA	cis	rs9309473	0.5	rs6757996	ENSG00000163016.8	ALMS1P	6.17	1.51e-09	3.14e-07	0.36	0.27	Metabolite levels;	chr2:73545124	chr2:73644919~73685576:+
THCA	cis	rs934734	0.789	rs4303705	ENSG00000281920.1	RP11-418H16.1	-6.17	1.51e-09	3.14e-07	-0.34	-0.27	Rheumatoid arthritis;	chr2:65392576	chr2:65623272~65628424:+
THCA	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-6.17	1.51e-09	3.15e-07	-0.27	-0.27	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
THCA	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	6.17	1.52e-09	3.15e-07	0.31	0.27	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
THCA	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-6.17	1.52e-09	3.15e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
THCA	cis	rs3213958	0.533	rs3772100	ENSG00000249274.1	PDLIM1P4	-6.17	1.52e-09	3.15e-07	-0.34	-0.27	Blood protein levels;	chr3:98782236	chr3:98782188~98783193:+
THCA	cis	rs28530618	0.87	rs6057610	ENSG00000175730.8	BAK1P1	6.17	1.52e-09	3.15e-07	0.3	0.27	Birth weight;	chr20:32653587	chr20:32690180~32690815:-
THCA	cis	rs12681366	0.636	rs2515155	ENSG00000253704.1	RP11-267M23.4	-6.17	1.52e-09	3.15e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94376469	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.593	rs2515154	ENSG00000253704.1	RP11-267M23.4	-6.17	1.52e-09	3.15e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94376675	chr8:94553722~94569745:+
THCA	cis	rs11154801	0.696	rs4432992	ENSG00000231028.7	LINC00271	-6.17	1.52e-09	3.15e-07	-0.23	-0.27	Multiple sclerosis;	chr6:135612356	chr6:135497801~135716055:+
THCA	cis	rs227275	0.525	rs3974485	ENSG00000230069.3	LRRC37A15P	-6.17	1.52e-09	3.15e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs2866417	ENSG00000230069.3	LRRC37A15P	-6.17	1.52e-09	3.15e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223447	ENSG00000251288.2	RP11-10L12.2	-6.17	1.52e-09	3.15e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102751401~102752641:+
THCA	cis	rs6545883	0.929	rs9679557	ENSG00000271889.1	RP11-493E12.1	6.17	1.52e-09	3.15e-07	0.27	0.27	Tuberculosis;	chr2:61482214	chr2:61151433~61162105:-
THCA	cis	rs2657294	0.62	rs2395136	ENSG00000233313.2	HMGA1P5	-6.16	1.52e-09	3.15e-07	-0.38	-0.27	Pneumonia;	chr10:75088213	chr10:75276376~75276646:-
THCA	cis	rs6545883	0.965	rs12713439	ENSG00000271889.1	RP11-493E12.1	6.16	1.52e-09	3.15e-07	0.26	0.27	Tuberculosis;	chr2:61525019	chr2:61151433~61162105:-
THCA	cis	rs7115242	0.8	rs7131536	ENSG00000280143.1	AP000892.6	6.16	1.52e-09	3.15e-07	0.45	0.27	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117204967~117210292:+
THCA	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-6.16	1.52e-09	3.16e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
THCA	cis	rs9393777	0.777	rs56114371	ENSG00000219392.1	RP1-265C24.5	-6.16	1.52e-09	3.16e-07	-0.61	-0.27	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28115628~28116551:+
THCA	cis	rs6674176	0.628	rs2240447	ENSG00000237950.1	RP11-7O11.3	6.16	1.52e-09	3.16e-07	0.25	0.27	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43949743	chr1:43944370~43946551:-
THCA	cis	rs6674176	0.628	rs7556565	ENSG00000237950.1	RP11-7O11.3	6.16	1.52e-09	3.16e-07	0.25	0.27	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43950418	chr1:43944370~43946551:-
THCA	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-6.16	1.52e-09	3.16e-07	-0.29	-0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
THCA	cis	rs3758785	0.737	rs12270338	ENSG00000255893.1	RP11-685N10.1	6.16	1.52e-09	3.16e-07	0.32	0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94414298	chr11:94472908~94473570:-
THCA	cis	rs6860806	0.632	rs4330455	ENSG00000237714.1	P4HA2-AS1	6.16	1.52e-09	3.16e-07	0.35	0.27	Breast cancer;	chr5:132250656	chr5:132184876~132192808:+
THCA	cis	rs712022	0.534	rs10833839	ENSG00000246225.5	RP11-17A1.3	-6.16	1.53e-09	3.17e-07	-0.36	-0.27	Dialysis-related mortality;	chr11:22846282	chr11:22829380~22945393:+
THCA	cis	rs6674176	0.628	rs12145999	ENSG00000237950.1	RP11-7O11.3	6.16	1.53e-09	3.17e-07	0.25	0.27	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43962960	chr1:43944370~43946551:-
THCA	cis	rs890448	0.796	rs6845368	ENSG00000254531.1	FLJ20021	-6.16	1.53e-09	3.17e-07	-0.24	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101364742	chr4:101347780~101348883:+
THCA	cis	rs228614	0.51	rs223362	ENSG00000230069.3	LRRC37A15P	-6.16	1.53e-09	3.18e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102727274~102730721:-
THCA	cis	rs2834188	0.924	rs2040107	ENSG00000272659.1	AP000295.10	6.16	1.53e-09	3.18e-07	0.37	0.27	Narcolepsy;	chr21:33303657	chr21:33309491~33310181:+
THCA	cis	rs4845875	0.626	rs6540999	ENSG00000242349.4	NPPA-AS1	6.16	1.53e-09	3.18e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11773309	chr1:11841017~11848079:+
THCA	cis	rs228614	0.51	rs223445	ENSG00000251288.2	RP11-10L12.2	-6.16	1.53e-09	3.18e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223443	ENSG00000251288.2	RP11-10L12.2	-6.16	1.53e-09	3.18e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102751401~102752641:+
THCA	cis	rs13113518	0.812	rs12500456	ENSG00000273257.1	RP11-177J6.1	6.16	1.53e-09	3.18e-07	0.37	0.27	Height;	chr4:55561053	chr4:55387949~55388271:+
THCA	cis	rs6545883	0.929	rs6545877	ENSG00000271889.1	RP11-493E12.1	6.16	1.54e-09	3.19e-07	0.26	0.27	Tuberculosis;	chr2:61514812	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.929	rs7606167	ENSG00000271889.1	RP11-493E12.1	6.16	1.54e-09	3.19e-07	0.26	0.27	Tuberculosis;	chr2:61515519	chr2:61151433~61162105:-
THCA	cis	rs10078	0.515	rs1053299	ENSG00000221990.4	EXOC3-AS1	6.16	1.54e-09	3.19e-07	0.29	0.27	Fat distribution (HIV);	chr5:470645	chr5:441498~443160:-
THCA	cis	rs10078	0.571	rs890973	ENSG00000221990.4	EXOC3-AS1	6.16	1.54e-09	3.19e-07	0.29	0.27	Fat distribution (HIV);	chr5:471379	chr5:441498~443160:-
THCA	cis	rs10129255	0.957	rs10138532	ENSG00000211974.3	IGHV2-70	6.16	1.54e-09	3.19e-07	0.22	0.27	Kawasaki disease;	chr14:106803901	chr14:106723574~106724093:-
THCA	cis	rs7044106	0.791	rs10984998	ENSG00000270917.1	RP11-27I1.6	-6.16	1.54e-09	3.19e-07	-0.39	-0.27	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120812475~120812845:-
THCA	cis	rs72843506	0.722	rs74255392	ENSG00000270091.1	RP11-78O7.2	-6.16	1.54e-09	3.19e-07	-0.29	-0.27	Schizophrenia;	chr17:20425739	chr17:19896590~19897287:-
THCA	cis	rs5758659	1	rs134882	ENSG00000182057.4	OGFRP1	6.16	1.54e-09	3.19e-07	0.3	0.27	Cognitive function;	chr22:42274959	chr22:42269753~42275196:+
THCA	cis	rs4971059	0.617	rs12025371	ENSG00000160766.13	GBAP1	-6.16	1.54e-09	3.2e-07	-0.29	-0.27	Breast cancer;	chr1:155146851	chr1:155213821~155227422:-
THCA	cis	rs728616	0.717	rs12412999	ENSG00000242600.5	MBL1P	6.16	1.54e-09	3.2e-07	0.39	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:79904898~79950336:+
THCA	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-6.16	1.54e-09	3.2e-07	-0.21	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
THCA	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-6.16	1.54e-09	3.2e-07	-0.21	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
THCA	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-6.16	1.54e-09	3.2e-07	-0.21	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
THCA	cis	rs2439831	0.85	rs544122	ENSG00000249839.1	AC011330.5	-6.16	1.54e-09	3.2e-07	-0.42	-0.27	Lung cancer in ever smokers;	chr15:43483534	chr15:43663654~43684339:-
THCA	cis	rs12681287	0.605	rs6471296	ENSG00000254231.1	CTD-2284J15.1	-6.16	1.54e-09	3.21e-07	-0.29	-0.27	Caudate activity during reward;	chr8:86362425	chr8:86333274~86343314:-
THCA	cis	rs7617773	0.963	rs12495221	ENSG00000228638.1	FCF1P2	6.16	1.55e-09	3.21e-07	0.26	0.27	Coronary artery disease;	chr3:48137688	chr3:48290793~48291375:-
THCA	cis	rs853679	0.517	rs4713146	ENSG00000261839.1	RP1-265C24.8	6.16	1.55e-09	3.21e-07	0.33	0.27	Depression;	chr6:28143758	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000261839.1	RP1-265C24.8	6.16	1.55e-09	3.21e-07	0.33	0.27	Depression;	chr6:28144784	chr6:28136849~28139678:+
THCA	cis	rs950169	0.84	rs72748702	ENSG00000259295.5	CSPG4P12	6.16	1.55e-09	3.21e-07	0.42	0.27	Schizophrenia;	chr15:84246494	chr15:85191438~85213905:+
THCA	cis	rs7129556	0.69	rs687037	ENSG00000254691.1	RP11-91P24.5	6.16	1.55e-09	3.21e-07	0.39	0.27	Weight loss (gastric bypass surgery);	chr11:77885058	chr11:77850604~77851511:+
THCA	cis	rs4650994	0.525	rs4650991	ENSG00000273384.1	RP5-1098D14.1	6.16	1.55e-09	3.21e-07	0.35	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178542030	chr1:178651706~178652282:+
THCA	cis	rs7615952	0.546	rs2979307	ENSG00000243429.1	OR7E29P	-6.16	1.55e-09	3.21e-07	-0.39	-0.27	Blood pressure (smoking interaction);	chr3:125590730	chr3:125712139~125713045:+
THCA	cis	rs7260598	0.642	rs56977104	ENSG00000268442.1	CTD-2027I19.2	6.16	1.55e-09	3.21e-07	0.37	0.27	Response to taxane treatment (placlitaxel);	chr19:23956560	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.585	rs8112076	ENSG00000268442.1	CTD-2027I19.2	6.16	1.55e-09	3.21e-07	0.37	0.27	Response to taxane treatment (placlitaxel);	chr19:23956561	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.642	rs8112289	ENSG00000268442.1	CTD-2027I19.2	6.16	1.55e-09	3.21e-07	0.37	0.27	Response to taxane treatment (placlitaxel);	chr19:23956571	chr19:24162370~24163425:-
THCA	cis	rs2120243	0.625	rs4482625	ENSG00000244515.1	KRT18P34	-6.16	1.55e-09	3.21e-07	-0.31	-0.27	Hepatocellular carcinoma in hepatitis B infection;	chr3:157378220	chr3:157162663~157163932:-
THCA	cis	rs6860806	0.631	rs6863548	ENSG00000224431.1	AC063976.7	6.16	1.55e-09	3.21e-07	0.23	0.27	Breast cancer;	chr5:132240227	chr5:132199456~132203487:+
THCA	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	6.16	1.55e-09	3.21e-07	0.22	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
THCA	cis	rs9880211	0.948	rs9844666	ENSG00000273486.1	RP11-731C17.2	6.16	1.55e-09	3.21e-07	0.29	0.27	Height;Body mass index;	chr3:136255374	chr3:136837338~136839021:-
THCA	cis	rs712022	0.507	rs11026815	ENSG00000246225.5	RP11-17A1.3	-6.16	1.55e-09	3.21e-07	-0.36	-0.27	Dialysis-related mortality;	chr11:22854432	chr11:22829380~22945393:+
THCA	cis	rs712022	0.505	rs11026816	ENSG00000246225.5	RP11-17A1.3	-6.16	1.55e-09	3.21e-07	-0.36	-0.27	Dialysis-related mortality;	chr11:22855277	chr11:22829380~22945393:+
THCA	cis	rs712022	0.534	rs7395098	ENSG00000246225.5	RP11-17A1.3	-6.16	1.55e-09	3.21e-07	-0.36	-0.27	Dialysis-related mortality;	chr11:22856901	chr11:22829380~22945393:+
THCA	cis	rs7829975	0.623	rs10092965	ENSG00000254153.1	CTA-398F10.2	-6.16	1.55e-09	3.22e-07	-0.3	-0.27	Mood instability;	chr8:8515975	chr8:8456909~8461337:-
THCA	cis	rs7615952	0.546	rs2976733	ENSG00000171084.14	FAM86JP	6.16	1.55e-09	3.22e-07	0.32	0.27	Blood pressure (smoking interaction);	chr3:125695294	chr3:125916620~125930024:+
THCA	cis	rs10129255	0.83	rs61997609	ENSG00000211974.3	IGHV2-70	6.16	1.55e-09	3.22e-07	0.22	0.27	Kawasaki disease;	chr14:106692376	chr14:106723574~106724093:-
THCA	cis	rs7567389	0.504	rs5937	ENSG00000236682.1	AC068282.3	-6.16	1.55e-09	3.22e-07	-0.4	-0.27	Self-rated health;	chr2:127427194	chr2:127389130~127400580:+
THCA	cis	rs890448	0.796	rs2583387	ENSG00000254531.1	FLJ20021	6.16	1.55e-09	3.22e-07	0.25	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101359241	chr4:101347780~101348883:+
THCA	cis	rs4713118	0.738	rs200465	ENSG00000280107.1	AL022393.9	-6.16	1.55e-09	3.22e-07	-0.32	-0.27	Parkinson's disease;	chr6:27789875	chr6:28170845~28172521:+
THCA	cis	rs6600671	1	rs11249351	ENSG00000275538.1	RNVU1-19	6.16	1.55e-09	3.22e-07	0.34	0.27	Hip geometry;	chr1:121430082	chr1:120850819~120850985:-
THCA	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-6.16	1.55e-09	3.22e-07	-0.35	-0.27	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
THCA	cis	rs77972916	0.505	rs11899984	ENSG00000234936.1	AC010883.5	6.16	1.55e-09	3.22e-07	0.3	0.27	Granulocyte percentage of myeloid white cells;	chr2:43351107	chr2:43229573~43233394:+
THCA	cis	rs5742933	0.69	rs62183657	ENSG00000273240.1	RP11-455J20.3	-6.16	1.56e-09	3.22e-07	-0.34	-0.27	Ferritin levels;	chr2:189669448	chr2:189763859~189764456:-
THCA	cis	rs9926296	0.712	rs2437957	ENSG00000274627.1	RP11-104N10.2	6.16	1.56e-09	3.23e-07	0.29	0.27	Vitiligo;	chr16:89649240	chr16:89516797~89522217:+
THCA	cis	rs7615952	0.599	rs12486459	ENSG00000250012.1	RP11-124N2.1	-6.16	1.56e-09	3.23e-07	-0.27	-0.27	Blood pressure (smoking interaction);	chr3:126022622	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.599	rs67575510	ENSG00000250012.1	RP11-124N2.1	-6.16	1.56e-09	3.23e-07	-0.27	-0.27	Blood pressure (smoking interaction);	chr3:126023512	chr3:126084220~126095349:+
THCA	cis	rs2337406	0.5	rs57619050	ENSG00000274576.2	IGHV2-70	-6.16	1.56e-09	3.23e-07	-0.24	-0.27	Alzheimer's disease (late onset);	chr14:106820074	chr14:106770577~106771020:-
THCA	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-6.16	1.56e-09	3.23e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
THCA	cis	rs728616	0.867	rs77376252	ENSG00000242600.5	MBL1P	6.16	1.56e-09	3.23e-07	0.39	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80049626	chr10:79904898~79950336:+
THCA	cis	rs6671200	0.607	rs2296308	ENSG00000228852.5	RP11-57H12.5	6.16	1.56e-09	3.23e-07	0.32	0.27	Stearic acid (18:0) levels;	chr1:95244383	chr1:95243167~95278940:-
THCA	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	6.16	1.56e-09	3.23e-07	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
THCA	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	6.16	1.56e-09	3.23e-07	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
THCA	cis	rs6600671	0.967	rs12069545	ENSG00000275538.1	RNVU1-19	6.16	1.56e-09	3.23e-07	0.34	0.27	Hip geometry;	chr1:121430343	chr1:120850819~120850985:-
THCA	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-6.16	1.56e-09	3.24e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
THCA	cis	rs3950186	0.874	rs2179742	ENSG00000215124.2	RP3-420J14.1	6.16	1.56e-09	3.24e-07	0.3	0.27	Anxiety and major depressive disorder;	chr6:11826138	chr6:11861626~11862970:-
THCA	cis	rs4664293	0.585	rs34385495	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159656372	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.605	rs12474082	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159657403	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.585	rs1991372	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159659556	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.546	rs1991373	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159659714	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs6707985	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159659877	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs62171641	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159659994	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.585	rs35293435	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159662396	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs62171646	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159662563	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs4664295	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159663807	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs6722715	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159668515	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.669	rs2042778	ENSG00000226266.5	AC009961.3	6.16	1.57e-09	3.24e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159672119	chr2:159670708~159712435:-
THCA	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	6.16	1.57e-09	3.24e-07	0.31	0.27	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
THCA	cis	rs7829975	0.742	rs12547493	ENSG00000254153.1	CTA-398F10.2	6.16	1.57e-09	3.25e-07	0.3	0.27	Mood instability;	chr8:8804024	chr8:8456909~8461337:-
THCA	cis	rs7727544	0.684	rs2516788	ENSG00000237714.1	P4HA2-AS1	-6.16	1.57e-09	3.25e-07	-0.35	-0.27	Blood metabolite levels;	chr5:132379873	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.66	rs274563	ENSG00000237714.1	P4HA2-AS1	-6.16	1.57e-09	3.25e-07	-0.35	-0.27	Blood metabolite levels;	chr5:132382167	chr5:132184876~132192808:+
THCA	cis	rs7829975	0.628	rs1109618	ENSG00000253893.2	FAM85B	6.16	1.57e-09	3.25e-07	0.37	0.27	Mood instability;	chr8:8713854	chr8:8167819~8226614:-
THCA	cis	rs7968440	0.715	rs7957659	ENSG00000272368.2	RP4-605O3.4	-6.16	1.57e-09	3.25e-07	-0.16	-0.27	Fibrinogen;	chr12:50245027	chr12:50112197~50165618:+
THCA	cis	rs7615952	0.512	rs4234285	ENSG00000241278.1	ENPP7P4	6.16	1.57e-09	3.25e-07	0.34	0.27	Blood pressure (smoking interaction);	chr3:125685633	chr3:125848223~125909372:+
THCA	cis	rs9402743	1	rs9402743	ENSG00000231028.7	LINC00271	-6.16	1.57e-09	3.25e-07	-0.22	-0.27	Systemic lupus erythematosus;	chr6:135679896	chr6:135497801~135716055:+
THCA	cis	rs9921338	0.923	rs7186455	ENSG00000262636.1	CTD-3088G3.4	-6.16	1.57e-09	3.25e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333891	chr16:11380859~11381118:-
THCA	cis	rs2439831	0.867	rs2447208	ENSG00000166763.7	STRCP1	6.16	1.57e-09	3.26e-07	0.38	0.27	Lung cancer in ever smokers;	chr15:43641697	chr15:43699488~43718184:-
THCA	cis	rs1552244	0.882	rs56332224	ENSG00000180385.7	EMC3-AS1	6.16	1.57e-09	3.26e-07	0.29	0.27	Alzheimer's disease;	chr3:9995637	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs13066757	ENSG00000180385.7	EMC3-AS1	6.16	1.57e-09	3.26e-07	0.29	0.27	Alzheimer's disease;	chr3:10003346	chr3:9986893~10006990:+
THCA	cis	rs1023500	0.505	rs134901	ENSG00000205702.9	CYP2D7	6.16	1.57e-09	3.26e-07	0.21	0.27	Schizophrenia;	chr22:42287514	chr22:42140203~42144577:-
THCA	cis	rs451417	1	rs384578	ENSG00000275632.1	RP5-967N21.11	-6.16	1.57e-09	3.26e-07	-0.31	-0.27	Menopause (age at onset);	chr20:6000830	chr20:6000418~6000941:+
THCA	cis	rs11018904	0.53	rs12789669	ENSG00000280385.1	AP000648.5	-6.16	1.58e-09	3.26e-07	-0.31	-0.27	Intelligence (multi-trait analysis);	chr11:90237435	chr11:90193614~90198120:+
THCA	cis	rs72949976	0.584	rs12471432	ENSG00000270659.1	RP11-105N14.1	-6.16	1.58e-09	3.27e-07	-0.22	-0.27	Squamous cell lung carcinoma;Lung cancer;	chr2:213158169	chr2:213152970~213153659:+
THCA	cis	rs4073582	0.595	rs9326370	ENSG00000255320.1	RP11-755F10.1	-6.16	1.58e-09	3.27e-07	-0.33	-0.27	Gout;	chr11:66224537	chr11:66244840~66246239:-
THCA	cis	rs9843304	0.868	rs4681516	ENSG00000244503.1	RP11-278L15.6	-6.16	1.58e-09	3.27e-07	-0.34	-0.27	Gallstone disease;	chr3:149494338	chr3:149494660~149495995:+
THCA	cis	rs516805	0.528	rs2606628	ENSG00000279453.1	RP3-425C14.4	-6.16	1.58e-09	3.27e-07	-0.29	-0.27	Lymphocyte counts;	chr6:122097460	chr6:122436789~122439223:-
THCA	cis	rs10829156	0.755	rs10732437	ENSG00000240291.1	RP11-499P20.2	6.16	1.58e-09	3.27e-07	0.23	0.27	Sudden cardiac arrest;	chr10:18626973	chr10:18513115~18545651:-
THCA	cis	rs7560272	0.723	rs780391	ENSG00000163016.8	ALMS1P	-6.16	1.58e-09	3.27e-07	-0.36	-0.27	Schizophrenia;	chr2:73476777	chr2:73644919~73685576:+
THCA	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-6.16	1.58e-09	3.27e-07	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
THCA	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	6.16	1.58e-09	3.28e-07	0.43	0.27	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
THCA	cis	rs60678552	1	rs60678552	ENSG00000233558.1	RP3-486I3.4	6.16	1.58e-09	3.28e-07	0.43	0.27	Heschl's gyrus morphology;	chr6:116289038	chr6:116258493~116259115:-
THCA	cis	rs1979679	0.842	rs2035271	ENSG00000278733.1	RP11-425D17.1	6.16	1.59e-09	3.28e-07	0.27	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28165638	chr12:28185625~28186190:-
THCA	cis	rs7615952	0.599	rs7652883	ENSG00000250012.1	RP11-124N2.1	-6.16	1.59e-09	3.29e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:125989134	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.599	rs6803160	ENSG00000250012.1	RP11-124N2.1	-6.16	1.59e-09	3.29e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:125990711	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.688	rs12485622	ENSG00000250012.1	RP11-124N2.1	-6.16	1.59e-09	3.29e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:125991896	chr3:126084220~126095349:+
THCA	cis	rs4948102	0.642	rs766333	ENSG00000273720.1	RP11-613E4.4	-6.16	1.59e-09	3.29e-07	-0.36	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55743073~55743457:+
THCA	cis	rs2243480	0.901	rs3813708	ENSG00000229886.1	RP5-1132H15.3	6.16	1.59e-09	3.29e-07	0.45	0.27	Diabetic kidney disease;	chr7:65840645	chr7:66025126~66031544:-
THCA	cis	rs4845570	0.92	rs3811414	ENSG00000249602.1	RP11-98D18.3	-6.16	1.59e-09	3.29e-07	-0.35	-0.27	Coronary artery disease;	chr1:151790770	chr1:151763384~151769501:-
THCA	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	6.16	1.59e-09	3.3e-07	0.29	0.27	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
THCA	cis	rs287982	0.611	rs111493633	ENSG00000269973.1	RP11-95D17.1	-6.16	1.6e-09	3.3e-07	-0.25	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9840033	chr2:9936360~9939590:+
THCA	cis	rs4143844	1	rs34017665	ENSG00000259251.2	RP11-643M14.1	6.16	1.6e-09	3.31e-07	0.52	0.27	Bipolar disorder and schizophrenia;	chr15:62027008	chr15:62060503~62062434:+
THCA	cis	rs11722779	0.658	rs6533044	ENSG00000230069.3	LRRC37A15P	-6.16	1.6e-09	3.31e-07	-0.29	-0.27	Schizophrenia;	chr4:102965261	chr4:102727274~102730721:-
THCA	cis	rs9843304	0.772	rs4681515	ENSG00000244503.1	RP11-278L15.6	-6.16	1.6e-09	3.31e-07	-0.34	-0.27	Gallstone disease;	chr3:149494289	chr3:149494660~149495995:+
THCA	cis	rs6545883	0.965	rs7421663	ENSG00000271889.1	RP11-493E12.1	6.16	1.6e-09	3.31e-07	0.26	0.27	Tuberculosis;	chr2:61526651	chr2:61151433~61162105:-
THCA	cis	rs2562456	0.917	rs2650804	ENSG00000268081.1	RP11-678G14.2	6.16	1.6e-09	3.31e-07	0.39	0.27	Pain;	chr19:21497382	chr19:21554640~21569237:-
THCA	cis	rs7403037	0.92	rs34804878	ENSG00000259905.4	PWRN1	6.16	1.6e-09	3.31e-07	0.29	0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24579295	chr15:24493137~24652130:+
THCA	cis	rs6991838	0.778	rs11779602	ENSG00000200714.1	Y_RNA	6.16	1.6e-09	3.31e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65592731~65592820:+
THCA	cis	rs853679	0.517	rs1340004	ENSG00000261839.1	RP1-265C24.8	6.16	1.6e-09	3.31e-07	0.33	0.27	Depression;	chr6:28135913	chr6:28136849~28139678:+
THCA	cis	rs11148252	0.74	rs9536046	ENSG00000235660.1	LINC00345	-6.16	1.6e-09	3.31e-07	-0.35	-0.27	Lewy body disease;	chr13:52381764	chr13:52484161~52484680:-
THCA	cis	rs944990	0.557	rs7035504	ENSG00000227603.1	RP11-165J3.6	6.16	1.6e-09	3.31e-07	0.28	0.27	Body mass index;	chr9:93528639	chr9:93435332~93437121:-
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000232546.1	RP11-458F8.1	-6.16	1.6e-09	3.31e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65892097	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs35391607	ENSG00000232546.1	RP11-458F8.1	-6.16	1.6e-09	3.31e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65895842	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs13220979	ENSG00000232546.1	RP11-458F8.1	-6.16	1.6e-09	3.31e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65898217	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs34974928	ENSG00000232546.1	RP11-458F8.1	-6.16	1.6e-09	3.31e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65899019	chr7:66848496~66858136:+
THCA	cis	rs853679	0.517	rs3757187	ENSG00000261839.1	RP1-265C24.8	6.16	1.6e-09	3.31e-07	0.33	0.27	Depression;	chr6:28139876	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000261839.1	RP1-265C24.8	6.16	1.6e-09	3.31e-07	0.33	0.27	Depression;	chr6:28139998	chr6:28136849~28139678:+
THCA	cis	rs7208859	0.673	rs11655623	ENSG00000263603.1	CTD-2349P21.5	-6.16	1.6e-09	3.31e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30729469~30731202:+
THCA	cis	rs934734	0.752	rs268139	ENSG00000237979.1	AC007389.1	-6.16	1.6e-09	3.31e-07	-0.32	-0.27	Rheumatoid arthritis;	chr2:65379857	chr2:65500993~65502138:-
THCA	cis	rs10875746	0.859	rs4760695	ENSG00000269514.1	RP11-370I10.12	6.16	1.6e-09	3.31e-07	0.28	0.27	Longevity (90 years and older);	chr12:48198065	chr12:48198387~48202031:+
THCA	cis	rs12681366	0.708	rs2515099	ENSG00000253704.1	RP11-267M23.4	-6.16	1.6e-09	3.32e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94367430	chr8:94553722~94569745:+
THCA	cis	rs1949733	0.598	rs4696838	ENSG00000205959.3	RP11-689P11.2	6.16	1.61e-09	3.32e-07	0.24	0.27	Response to antineoplastic agents;	chr4:8538622	chr4:8482270~8512610:+
THCA	cis	rs797680	0.856	rs6685271	ENSG00000223745.6	RP4-717I23.3	6.16	1.61e-09	3.32e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93169033	chr1:93262186~93346025:-
THCA	cis	rs17214007	0.518	rs8047940	ENSG00000263335.1	AF001548.5	-6.16	1.61e-09	3.32e-07	-0.36	-0.27	Cognitive function;	chr16:15691787	chr16:15726674~15732993:+
THCA	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	6.16	1.61e-09	3.33e-07	0.35	0.27	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
THCA	cis	rs9595908	1	rs9591165	ENSG00000212293.1	SNORA16	6.16	1.61e-09	3.33e-07	0.31	0.27	Body mass index;	chr13:32611016	chr13:32420390~32420516:-
THCA	cis	rs916888	0.61	rs199438	ENSG00000232300.1	FAM215B	6.16	1.61e-09	3.33e-07	0.38	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46558830~46562795:-
THCA	cis	rs4950322	0.57	rs79810882	ENSG00000278811.3	LINC00624	6.16	1.61e-09	3.33e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147235575	chr1:147258885~147517875:-
THCA	cis	rs7202877	0.706	rs1074961	ENSG00000261783.1	RP11-252K23.2	-6.15	1.61e-09	3.33e-07	-0.47	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75355586	chr16:75379818~75381260:-
THCA	cis	rs1859596	0.966	rs726655	ENSG00000234456.6	MAGI2-AS3	6.15	1.61e-09	3.34e-07	0.27	0.27	Reading or mathematical ability;	chr7:79467259	chr7:79452877~79471208:+
THCA	cis	rs7615952	0.576	rs66671308	ENSG00000250012.1	RP11-124N2.1	-6.15	1.62e-09	3.34e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126074683	chr3:126084220~126095349:+
THCA	cis	rs2562456	0.917	rs2681389	ENSG00000213976.4	CTD-2561J22.2	6.15	1.62e-09	3.34e-07	0.29	0.27	Pain;	chr19:21509773	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.917	rs6511256	ENSG00000213976.4	CTD-2561J22.2	6.15	1.62e-09	3.34e-07	0.29	0.27	Pain;	chr19:21510513	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.72	rs6511250	ENSG00000268081.1	RP11-678G14.2	-6.15	1.62e-09	3.34e-07	-0.4	-0.27	Pain;	chr19:21473244	chr19:21554640~21569237:-
THCA	cis	rs3794924	1	rs7236589	ENSG00000266521.1	RP11-650P15.1	6.15	1.62e-09	3.34e-07	0.51	0.27	Survival in colon cancer;	chr18:31475207	chr18:31496645~31497195:-
THCA	cis	rs11668609	1	rs10414556	ENSG00000268442.1	CTD-2027I19.2	6.15	1.62e-09	3.35e-07	0.33	0.27	Response to taxane treatment (docetaxel);	chr19:24186167	chr19:24162370~24163425:-
THCA	cis	rs4845875	0.626	rs7538516	ENSG00000242349.4	NPPA-AS1	6.15	1.62e-09	3.35e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11776625	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.626	rs6697244	ENSG00000242349.4	NPPA-AS1	6.15	1.62e-09	3.35e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11778791	chr1:11841017~11848079:+
THCA	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	6.15	1.62e-09	3.36e-07	0.3	0.27	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
THCA	cis	rs13113518	0.812	rs2048564	ENSG00000273257.1	RP11-177J6.1	6.15	1.62e-09	3.36e-07	0.37	0.27	Height;	chr4:55407965	chr4:55387949~55388271:+
THCA	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	6.15	1.62e-09	3.36e-07	0.28	0.27	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
THCA	cis	rs7182621	0.639	rs34701806	ENSG00000182397.13	DNM1P46	6.15	1.63e-09	3.36e-07	0.37	0.27	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99790156~99806927:-
THCA	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	6.15	1.63e-09	3.36e-07	0.27	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
THCA	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	6.15	1.63e-09	3.36e-07	0.38	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
THCA	cis	rs911555	0.504	rs4444269	ENSG00000269940.1	RP11-73M18.7	6.15	1.63e-09	3.36e-07	0.28	0.27	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103694560~103695170:+
THCA	cis	rs3213958	0.574	rs55730510	ENSG00000249274.1	PDLIM1P4	-6.15	1.63e-09	3.36e-07	-0.34	-0.27	Blood protein levels;	chr3:98900191	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs1827158	ENSG00000249274.1	PDLIM1P4	6.15	1.63e-09	3.36e-07	0.34	0.27	Blood protein levels;	chr3:98902821	chr3:98782188~98783193:+
THCA	cis	rs5758511	0.68	rs5758699	ENSG00000281538.1	RP4-669P10.20	-6.15	1.63e-09	3.37e-07	-0.29	-0.27	Birth weight;	chr22:42292028	chr22:42138060~42139726:+
THCA	cis	rs934734	0.563	rs11684155	ENSG00000234255.7	AC012370.3	6.15	1.63e-09	3.37e-07	0.32	0.27	Rheumatoid arthritis;	chr2:65354166	chr2:65439888~65456571:-
THCA	cis	rs1979679	0.766	rs11049365	ENSG00000278733.1	RP11-425D17.1	6.15	1.63e-09	3.37e-07	0.28	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28138401	chr12:28185625~28186190:-
THCA	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	6.15	1.63e-09	3.37e-07	0.25	0.27	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
THCA	cis	rs7260598	0.642	rs67799720	ENSG00000268442.1	CTD-2027I19.2	6.15	1.63e-09	3.37e-07	0.37	0.27	Response to taxane treatment (placlitaxel);	chr19:23981347	chr19:24162370~24163425:-
THCA	cis	rs2439831	0.681	rs28594657	ENSG00000249839.1	AC011330.5	-6.15	1.63e-09	3.37e-07	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43296690	chr15:43663654~43684339:-
THCA	cis	rs9813712	0.571	rs9855777	ENSG00000249846.5	RP11-77P16.4	6.15	1.63e-09	3.37e-07	0.29	0.27	Response to amphetamines;	chr3:130214805	chr3:130112550~130120579:+
THCA	cis	rs11148252	0.74	rs9536052	ENSG00000235660.1	LINC00345	6.15	1.63e-09	3.37e-07	0.35	0.27	Lewy body disease;	chr13:52386574	chr13:52484161~52484680:-
THCA	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	6.15	1.63e-09	3.38e-07	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
THCA	cis	rs9880211	1	rs9823373	ENSG00000273486.1	RP11-731C17.2	6.15	1.63e-09	3.38e-07	0.28	0.27	Height;Body mass index;	chr3:136448185	chr3:136837338~136839021:-
THCA	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	6.15	1.63e-09	3.38e-07	0.3	0.27	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	6.15	1.63e-09	3.38e-07	0.3	0.27	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	6.15	1.63e-09	3.38e-07	0.3	0.27	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	6.15	1.63e-09	3.38e-07	0.3	0.27	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
THCA	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	6.15	1.63e-09	3.38e-07	0.28	0.27	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
THCA	cis	rs7129556	0.906	rs72945508	ENSG00000254691.1	RP11-91P24.5	6.15	1.64e-09	3.38e-07	0.37	0.27	Weight loss (gastric bypass surgery);	chr11:77556492	chr11:77850604~77851511:+
THCA	cis	rs1552244	0.572	rs3894322	ENSG00000232901.1	CYCSP10	6.15	1.64e-09	3.38e-07	0.41	0.27	Alzheimer's disease;	chr3:10127281	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs3894323	ENSG00000232901.1	CYCSP10	6.15	1.64e-09	3.38e-07	0.41	0.27	Alzheimer's disease;	chr3:10127283	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.572	rs67439440	ENSG00000232901.1	CYCSP10	6.15	1.64e-09	3.38e-07	0.41	0.27	Alzheimer's disease;	chr3:10127819	chr3:10000647~10000940:-
THCA	cis	rs792448	0.701	rs1774247	ENSG00000226251.4	RP11-15I11.3	-6.15	1.64e-09	3.39e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212376015	chr1:212225278~212238977:-
THCA	cis	rs9649465	0.967	rs10269196	ENSG00000272686.1	RP11-390E23.6	6.15	1.64e-09	3.39e-07	0.18	0.27	Migraine;	chr7:123681019	chr7:123749068~123751166:+
THCA	cis	rs10829156	0.898	rs7923072	ENSG00000240291.1	RP11-499P20.2	6.15	1.64e-09	3.39e-07	0.23	0.27	Sudden cardiac arrest;	chr10:18649305	chr10:18513115~18545651:-
THCA	cis	rs7809950	0.678	rs7803151	ENSG00000238832.1	snoU109	-6.15	1.64e-09	3.39e-07	-0.32	-0.27	Coronary artery disease;	chr7:107293801	chr7:107603363~107603507:+
THCA	cis	rs4835473	0.897	rs11931330	ENSG00000251600.4	RP11-673E1.1	6.15	1.64e-09	3.39e-07	0.36	0.27	Immature fraction of reticulocytes;	chr4:143970808	chr4:143912331~143982454:+
THCA	cis	rs1979679	0.842	rs10459090	ENSG00000278733.1	RP11-425D17.1	6.15	1.64e-09	3.39e-07	0.27	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188207	chr12:28185625~28186190:-
THCA	cis	rs890448	0.796	rs7434301	ENSG00000254531.1	FLJ20021	-6.15	1.64e-09	3.4e-07	-0.24	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101445370	chr4:101347780~101348883:+
THCA	cis	rs17214007	0.518	rs35694612	ENSG00000263335.1	AF001548.5	-6.15	1.65e-09	3.4e-07	-0.36	-0.27	Cognitive function;	chr16:15674392	chr16:15726674~15732993:+
THCA	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	6.15	1.65e-09	3.41e-07	0.3	0.27	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	6.15	1.65e-09	3.41e-07	0.3	0.27	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
THCA	cis	rs7208859	0.573	rs73277960	ENSG00000263603.1	CTD-2349P21.5	-6.15	1.65e-09	3.41e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs73263788	ENSG00000263603.1	CTD-2349P21.5	-6.15	1.65e-09	3.41e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs12949860	ENSG00000263603.1	CTD-2349P21.5	-6.15	1.65e-09	3.41e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30729469~30731202:+
THCA	cis	rs9595908	0.931	rs7998440	ENSG00000212293.1	SNORA16	6.15	1.65e-09	3.41e-07	0.33	0.27	Body mass index;	chr13:32551069	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.965	rs7991314	ENSG00000212293.1	SNORA16	6.15	1.65e-09	3.41e-07	0.33	0.27	Body mass index;	chr13:32551937	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.965	rs7328733	ENSG00000212293.1	SNORA16	6.15	1.65e-09	3.41e-07	0.33	0.27	Body mass index;	chr13:32552600	chr13:32420390~32420516:-
THCA	cis	rs2439831	0.681	rs825740	ENSG00000249839.1	AC011330.5	-6.15	1.65e-09	3.41e-07	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43300210	chr15:43663654~43684339:-
THCA	cis	rs10208649	1	rs6751340	ENSG00000272156.1	RP11-477N3.1	6.15	1.65e-09	3.42e-07	0.48	0.27	Body mass index;	chr2:53960480	chr2:54082554~54085066:+
THCA	cis	rs7044106	0.762	rs3904197	ENSG00000270917.1	RP11-27I1.6	-6.15	1.65e-09	3.42e-07	-0.39	-0.27	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120812475~120812845:-
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000232546.1	RP11-458F8.1	-6.15	1.65e-09	3.42e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65924813	chr7:66848496~66858136:+
THCA	cis	rs4845875	0.602	rs4846043	ENSG00000242349.4	NPPA-AS1	6.15	1.66e-09	3.42e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11779909	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.626	rs1889292	ENSG00000242349.4	NPPA-AS1	6.15	1.66e-09	3.42e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11780886	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.626	rs2004445	ENSG00000242349.4	NPPA-AS1	6.15	1.66e-09	3.42e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11781309	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.626	rs10864542	ENSG00000242349.4	NPPA-AS1	6.15	1.66e-09	3.42e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11782087	chr1:11841017~11848079:+
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000229886.1	RP5-1132H15.3	6.15	1.66e-09	3.42e-07	0.46	0.27	Diabetic kidney disease;	chr7:66557269	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs1267820	ENSG00000229886.1	RP5-1132H15.3	6.15	1.66e-09	3.42e-07	0.46	0.27	Diabetic kidney disease;	chr7:66585308	chr7:66025126~66031544:-
THCA	cis	rs1859596	1	rs4727869	ENSG00000234456.6	MAGI2-AS3	6.15	1.66e-09	3.42e-07	0.27	0.27	Reading or mathematical ability;	chr7:79461824	chr7:79452877~79471208:+
THCA	cis	rs934734	0.752	rs2661796	ENSG00000281920.1	RP11-418H16.1	-6.15	1.66e-09	3.42e-07	-0.34	-0.27	Rheumatoid arthritis;	chr2:65400272	chr2:65623272~65628424:+
THCA	cis	rs7773987	1	rs7773987	ENSG00000231028.7	LINC00271	6.15	1.66e-09	3.42e-07	0.22	0.27	Selective IgA deficiency;	chr6:135386348	chr6:135497801~135716055:+
THCA	cis	rs7208859	0.614	rs7216394	ENSG00000264538.5	SUZ12P1	6.15	1.66e-09	3.43e-07	0.27	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30709299~30790908:+
THCA	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	6.15	1.66e-09	3.43e-07	0.2	0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
THCA	cis	rs7727544	0.684	rs611084	ENSG00000237714.1	P4HA2-AS1	-6.15	1.66e-09	3.43e-07	-0.35	-0.27	Blood metabolite levels;	chr5:132374047	chr5:132184876~132192808:+
THCA	cis	rs9813712	0.953	rs7619208	ENSG00000249846.5	RP11-77P16.4	-6.15	1.66e-09	3.44e-07	-0.32	-0.27	Response to amphetamines;	chr3:130258163	chr3:130112550~130120579:+
THCA	cis	rs7129556	0.954	rs10899387	ENSG00000254691.1	RP11-91P24.5	6.15	1.66e-09	3.44e-07	0.37	0.27	Weight loss (gastric bypass surgery);	chr11:77565143	chr11:77850604~77851511:+
THCA	cis	rs4767841	0.552	rs4767833	ENSG00000248636.5	RP11-768F21.1	-6.15	1.67e-09	3.44e-07	-0.28	-0.27	Urgency urinary incontinence;	chr12:119613165	chr12:119387987~119668079:-
THCA	cis	rs9595908	0.929	rs7328939	ENSG00000212293.1	SNORA16	6.15	1.67e-09	3.44e-07	0.33	0.27	Body mass index;	chr13:32552711	chr13:32420390~32420516:-
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000232546.1	RP11-458F8.1	-6.15	1.67e-09	3.44e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65914813	chr7:66848496~66858136:+
THCA	cis	rs523522	0.962	rs3893104	ENSG00000278344.1	RP11-18C24.8	6.15	1.67e-09	3.44e-07	0.3	0.27	High light scatter reticulocyte count;	chr12:120466133	chr12:120500735~120501090:-
THCA	cis	rs180730	0.66	rs1114026	ENSG00000251609.2	SETP12	-6.15	1.67e-09	3.44e-07	-0.46	-0.27	Fasting plasma glucose;	chr4:120934416	chr4:120895494~120897083:-
THCA	cis	rs28472312	0.667	rs3922668	ENSG00000251417.2	RP11-1348G14.4	6.15	1.67e-09	3.44e-07	0.24	0.27	Intelligence (multi-trait analysis);	chr16:28981325	chr16:28802743~28817828:+
THCA	cis	rs6951245	0.554	rs11544331	ENSG00000229043.2	AC091729.9	-6.15	1.67e-09	3.45e-07	-0.37	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1160374~1165267:+
THCA	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-6.15	1.67e-09	3.45e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
THCA	cis	rs7811142	1	rs67040465	ENSG00000078319.8	PMS2P1	-6.15	1.67e-09	3.45e-07	-0.4	-0.27	Platelet count;	chr7:100485455	chr7:100320992~100341908:-
THCA	cis	rs6569038	0.557	rs9374777	ENSG00000253194.1	RP11-351A11.1	-6.15	1.67e-09	3.45e-07	-0.37	-0.27	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119056334	chr6:118934785~119031541:+
THCA	cis	rs6740322	1	rs6756736	ENSG00000234936.1	AC010883.5	6.15	1.67e-09	3.45e-07	0.28	0.27	Coronary artery disease;	chr2:43331604	chr2:43229573~43233394:+
THCA	cis	rs4845875	0.602	rs2001584	ENSG00000242349.4	NPPA-AS1	6.15	1.67e-09	3.45e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11781294	chr1:11841017~11848079:+
THCA	cis	rs797680	0.897	rs3767962	ENSG00000223745.6	RP4-717I23.3	6.15	1.67e-09	3.45e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93348854	chr1:93262186~93346025:-
THCA	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	6.15	1.67e-09	3.45e-07	0.3	0.27	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
THCA	cis	rs7260598	0.892	rs2116956	ENSG00000268442.1	CTD-2027I19.2	6.15	1.67e-09	3.45e-07	0.39	0.27	Response to taxane treatment (placlitaxel);	chr19:24005987	chr19:24162370~24163425:-
THCA	cis	rs2303319	1	rs57090160	ENSG00000227403.1	AC009299.3	6.15	1.67e-09	3.45e-07	0.57	0.27	Cognitive function;	chr2:161322686	chr2:161244739~161249050:+
THCA	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	6.15	1.67e-09	3.46e-07	0.38	0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
THCA	cis	rs5758659	0.714	rs6002607	ENSG00000270083.1	RP1-257I20.14	-6.15	1.67e-09	3.46e-07	-0.29	-0.27	Cognitive function;	chr22:42100502	chr22:42089630~42090028:-
THCA	cis	rs3950186	0.874	rs6936286	ENSG00000215124.2	RP3-420J14.1	6.15	1.67e-09	3.46e-07	0.31	0.27	Anxiety and major depressive disorder;	chr6:11827364	chr6:11861626~11862970:-
THCA	cis	rs10875746	0.669	rs10783244	ENSG00000269514.1	RP11-370I10.12	6.15	1.67e-09	3.46e-07	0.26	0.27	Longevity (90 years and older);	chr12:48271206	chr12:48198387~48202031:+
THCA	cis	rs10971721	0.584	rs72731221	ENSG00000281128.1	PTENP1-AS	6.15	1.68e-09	3.46e-07	0.57	0.27	Body mass index;	chr9:34122376	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs72731222	ENSG00000281128.1	PTENP1-AS	6.15	1.68e-09	3.46e-07	0.57	0.27	Body mass index;	chr9:34122864	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs10971939	ENSG00000281128.1	PTENP1-AS	6.15	1.68e-09	3.46e-07	0.57	0.27	Body mass index;	chr9:34123437	chr9:33677268~33688011:+
THCA	cis	rs11148252	0.744	rs4884354	ENSG00000235660.1	LINC00345	-6.15	1.68e-09	3.46e-07	-0.34	-0.27	Lewy body disease;	chr13:52443339	chr13:52484161~52484680:-
THCA	cis	rs6600671	1	rs1986111	ENSG00000275538.1	RNVU1-19	6.15	1.68e-09	3.46e-07	0.34	0.27	Hip geometry;	chr1:121462934	chr1:120850819~120850985:-
THCA	cis	rs897984	0.762	rs1870293	ENSG00000260911.2	RP11-196G11.2	-6.15	1.68e-09	3.46e-07	-0.23	-0.27	Dementia with Lewy bodies;	chr16:30959620	chr16:31043150~31049868:+
THCA	cis	rs9813712	0.672	rs73210789	ENSG00000249846.5	RP11-77P16.4	6.15	1.68e-09	3.47e-07	0.32	0.27	Response to amphetamines;	chr3:130243418	chr3:130112550~130120579:+
THCA	cis	rs6545883	0.929	rs2593635	ENSG00000271889.1	RP11-493E12.1	-6.15	1.68e-09	3.47e-07	-0.27	-0.27	Tuberculosis;	chr2:61407571	chr2:61151433~61162105:-
THCA	cis	rs1707322	0.686	rs2230659	ENSG00000281133.1	AL355480.3	6.15	1.68e-09	3.47e-07	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45580892~45580996:-
THCA	cis	rs6840360	0.558	rs2709821	ENSG00000251611.1	RP11-610P16.1	-6.15	1.68e-09	3.47e-07	-0.2	-0.27	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151407551~151408835:-
THCA	cis	rs7044106	0.791	rs10985004	ENSG00000238181.2	AHCYP2	-6.15	1.68e-09	3.47e-07	-0.36	-0.27	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120720673~120721972:+
THCA	cis	rs7202877	0.61	rs10871307	ENSG00000261783.1	RP11-252K23.2	-6.15	1.68e-09	3.48e-07	-0.48	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75301216	chr16:75379818~75381260:-
THCA	cis	rs7202877	0.519	rs3743606	ENSG00000261783.1	RP11-252K23.2	-6.15	1.68e-09	3.48e-07	-0.48	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75301576	chr16:75379818~75381260:-
THCA	cis	rs6142102	1	rs6059673	ENSG00000275784.1	RP5-1125A11.6	-6.15	1.69e-09	3.48e-07	-0.29	-0.27	Skin pigmentation;	chr20:34117755	chr20:33989480~33991818:-
THCA	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	6.15	1.69e-09	3.48e-07	0.35	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
THCA	cis	rs2439831	0.867	rs2278860	ENSG00000249839.1	AC011330.5	6.15	1.69e-09	3.48e-07	0.4	0.27	Lung cancer in ever smokers;	chr15:43366848	chr15:43663654~43684339:-
THCA	cis	rs1979679	0.842	rs1841964	ENSG00000278733.1	RP11-425D17.1	-6.15	1.69e-09	3.48e-07	-0.27	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28190100	chr12:28185625~28186190:-
THCA	cis	rs6908034	0.607	rs12525152	ENSG00000227116.1	RP3-471C18.1	-6.15	1.69e-09	3.48e-07	-0.49	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19809193	chr6:19730427~19734567:-
THCA	cis	rs4835473	0.932	rs1849115	ENSG00000251600.4	RP11-673E1.1	6.15	1.69e-09	3.48e-07	0.36	0.27	Immature fraction of reticulocytes;	chr4:143989687	chr4:143912331~143982454:+
THCA	cis	rs2554380	0.6	rs6602986	ENSG00000230373.7	GOLGA6L5P	-6.15	1.69e-09	3.48e-07	-0.3	-0.27	Height;	chr15:83778347	chr15:84507885~84516814:-
THCA	cis	rs11089937	0.626	rs4821781	ENSG00000211639.2	IGLV4-60	6.15	1.69e-09	3.49e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.626	rs5750589	ENSG00000211639.2	IGLV4-60	6.15	1.69e-09	3.49e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.626	rs5757038	ENSG00000211639.2	IGLV4-60	6.15	1.69e-09	3.49e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22162199~22162681:+
THCA	cis	rs6545883	0.929	rs55806663	ENSG00000271889.1	RP11-493E12.1	6.15	1.69e-09	3.49e-07	0.26	0.27	Tuberculosis;	chr2:61513352	chr2:61151433~61162105:-
THCA	cis	rs10844706	0.669	rs10772108	ENSG00000256594.6	RP11-705C15.2	6.15	1.69e-09	3.49e-07	0.22	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9746454	chr12:9633419~9658412:+
THCA	cis	rs853679	0.517	rs9380056	ENSG00000261839.1	RP1-265C24.8	6.15	1.69e-09	3.49e-07	0.33	0.27	Depression;	chr6:28136698	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000261839.1	RP1-265C24.8	6.15	1.69e-09	3.49e-07	0.33	0.27	Depression;	chr6:28136856	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000261839.1	RP1-265C24.8	6.15	1.69e-09	3.49e-07	0.33	0.27	Depression;	chr6:28137418	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000261839.1	RP1-265C24.8	6.15	1.69e-09	3.49e-07	0.33	0.27	Depression;	chr6:28138363	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000261839.1	RP1-265C24.8	6.15	1.69e-09	3.49e-07	0.33	0.27	Parkinson's disease;	chr6:28138569	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000261839.1	RP1-265C24.8	6.15	1.69e-09	3.49e-07	0.33	0.27	Depression;	chr6:28138981	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000261839.1	RP1-265C24.8	6.15	1.69e-09	3.49e-07	0.33	0.27	Depression;	chr6:28139012	chr6:28136849~28139678:+
THCA	cis	rs5758659	0.714	rs2413668	ENSG00000270083.1	RP1-257I20.14	-6.15	1.69e-09	3.49e-07	-0.29	-0.27	Cognitive function;	chr22:42109837	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.657	rs5758587	ENSG00000270083.1	RP1-257I20.14	-6.15	1.69e-09	3.49e-07	-0.29	-0.27	Cognitive function;	chr22:42121632	chr22:42089630~42090028:-
THCA	cis	rs7608910	0.668	rs10207958	ENSG00000271889.1	RP11-493E12.1	6.15	1.69e-09	3.49e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60998195	chr2:61151433~61162105:-
THCA	cis	rs6539288	0.677	rs4964509	ENSG00000260329.1	RP11-412D9.4	-6.15	1.69e-09	3.49e-07	-0.24	-0.27	Total body bone mineral density;	chr12:106963280	chr12:106954029~106955497:-
THCA	cis	rs9813712	0.855	rs6806152	ENSG00000249846.5	RP11-77P16.4	-6.15	1.69e-09	3.49e-07	-0.33	-0.27	Response to amphetamines;	chr3:130245358	chr3:130112550~130120579:+
THCA	cis	rs12908161	1	rs35630683	ENSG00000259295.5	CSPG4P12	6.15	1.69e-09	3.5e-07	0.42	0.27	Schizophrenia;	chr15:84806000	chr15:85191438~85213905:+
THCA	cis	rs35828350	1	rs35828350	ENSG00000259295.5	CSPG4P12	6.15	1.69e-09	3.5e-07	0.42	0.27	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs56864281	ENSG00000259295.5	CSPG4P12	6.15	1.69e-09	3.5e-07	0.42	0.27	Schizophrenia;	chr15:84814418	chr15:85191438~85213905:+
THCA	cis	rs1552244	0.882	rs13084194	ENSG00000180385.7	EMC3-AS1	6.15	1.69e-09	3.5e-07	0.3	0.27	Alzheimer's disease;	chr3:9989808	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs13099507	ENSG00000180385.7	EMC3-AS1	6.15	1.69e-09	3.5e-07	0.3	0.27	Alzheimer's disease;	chr3:9989919	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs55962400	ENSG00000180385.7	EMC3-AS1	6.15	1.69e-09	3.5e-07	0.3	0.27	Alzheimer's disease;	chr3:10002773	chr3:9986893~10006990:+
THCA	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-6.15	1.7e-09	3.5e-07	-0.34	-0.27	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
THCA	cis	rs7208859	0.673	rs11654331	ENSG00000263603.1	CTD-2349P21.5	-6.15	1.7e-09	3.5e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30729469~30731202:+
THCA	cis	rs4845875	0.535	rs4846045	ENSG00000242349.4	NPPA-AS1	6.15	1.7e-09	3.5e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11780323	chr1:11841017~11848079:+
THCA	cis	rs797680	0.897	rs12752223	ENSG00000223745.6	RP4-717I23.3	6.15	1.7e-09	3.5e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93371576	chr1:93262186~93346025:-
THCA	cis	rs6928977	0.863	rs2223803	ENSG00000231028.7	LINC00271	6.15	1.7e-09	3.5e-07	0.22	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135366924	chr6:135497801~135716055:+
THCA	cis	rs867186	0.535	rs2275274	ENSG00000126005.14	MMP24-AS1	-6.15	1.7e-09	3.5e-07	-0.47	-0.27	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35269741	chr20:35216462~35278131:-
THCA	cis	rs7927592	0.763	rs7119422	ENSG00000212093.1	AP000807.1	-6.15	1.7e-09	3.5e-07	-0.28	-0.27	Total body bone mineral density;	chr11:68563686	chr11:68506083~68506166:-
THCA	cis	rs2915864	0.8	rs78403069	ENSG00000280047.1	CTC-463A16.1	6.15	1.7e-09	3.51e-07	0.44	0.27	Facial morphology (factor 20);	chr5:142135301	chr5:142165767~142168387:+
THCA	cis	rs4950322	1	rs4950322	ENSG00000237188.3	RP11-337C18.8	-6.15	1.7e-09	3.51e-07	-0.36	-0.27	Protein quantitative trait loci;	chr1:147383114	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.547	rs17355509	ENSG00000278811.3	LINC00624	6.15	1.7e-09	3.51e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147123139	chr1:147258885~147517875:-
THCA	cis	rs7015630	0.657	rs34525502	ENSG00000251136.7	RP11-37B2.1	-6.15	1.71e-09	3.52e-07	-0.31	-0.27	Inflammatory bowel disease;Crohn's disease;	chr8:89840352	chr8:89609409~89757727:-
THCA	cis	rs6860806	0.507	rs270606	ENSG00000263597.1	MIR3936	6.15	1.71e-09	3.52e-07	0.27	0.27	Breast cancer;	chr5:132315174	chr5:132365490~132365599:-
THCA	cis	rs17772222	0.958	rs61579615	ENSG00000258789.1	RP11-507K2.3	-6.15	1.71e-09	3.52e-07	-0.29	-0.27	Coronary artery calcification;	chr14:88400054	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs1956406	ENSG00000222990.1	RNU4-22P	6.15	1.71e-09	3.52e-07	0.35	0.27	Coronary artery calcification;	chr14:88749711	chr14:88513498~88513663:+
THCA	cis	rs6142102	0.962	rs2206448	ENSG00000275784.1	RP5-1125A11.6	-6.15	1.71e-09	3.52e-07	-0.28	-0.27	Skin pigmentation;	chr20:34121719	chr20:33989480~33991818:-
THCA	cis	rs10266483	0.545	rs114664455	ENSG00000271550.1	BNIP3P11	-6.15	1.71e-09	3.52e-07	-0.42	-0.27	Response to statin therapy;	chr7:64263634	chr7:64678954~64687393:-
THCA	cis	rs7201929	0.801	rs9933198	ENSG00000251417.2	RP11-1348G14.4	6.15	1.71e-09	3.52e-07	0.29	0.27	QT interval;	chr16:28877088	chr16:28802743~28817828:+
THCA	cis	rs11148252	0.846	rs1056335	ENSG00000235660.1	LINC00345	-6.15	1.71e-09	3.52e-07	-0.34	-0.27	Lewy body disease;	chr13:52415728	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.846	rs7985262	ENSG00000235660.1	LINC00345	-6.15	1.71e-09	3.52e-07	-0.34	-0.27	Lewy body disease;	chr13:52423026	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.846	rs4886077	ENSG00000235660.1	LINC00345	-6.15	1.71e-09	3.52e-07	-0.34	-0.27	Lewy body disease;	chr13:52424562	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.846	rs8001624	ENSG00000235660.1	LINC00345	-6.15	1.71e-09	3.52e-07	-0.34	-0.27	Lewy body disease;	chr13:52428860	chr13:52484161~52484680:-
THCA	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-6.14	1.71e-09	3.52e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
THCA	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-6.14	1.71e-09	3.52e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
THCA	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-6.14	1.71e-09	3.52e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
THCA	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-6.14	1.71e-09	3.52e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
THCA	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-6.14	1.71e-09	3.52e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
THCA	cis	rs17772222	0.874	rs78077739	ENSG00000222990.1	RNU4-22P	6.14	1.71e-09	3.52e-07	0.35	0.27	Coronary artery calcification;	chr14:88741176	chr14:88513498~88513663:+
THCA	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	6.14	1.71e-09	3.52e-07	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
THCA	cis	rs79349575	0.715	rs999474	ENSG00000248278.1	SUMO2P17	-6.14	1.71e-09	3.52e-07	-0.32	-0.27	Type 2 diabetes;	chr17:48910303	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.715	rs9894220	ENSG00000248278.1	SUMO2P17	6.14	1.71e-09	3.52e-07	0.32	0.27	Type 2 diabetes;	chr17:48911792	chr17:48874860~48908983:-
THCA	cis	rs79349575	0.679	rs9894239	ENSG00000248278.1	SUMO2P17	-6.14	1.71e-09	3.52e-07	-0.32	-0.27	Type 2 diabetes;	chr17:48920597	chr17:48874860~48908983:-
THCA	cis	rs17772222	1	rs1955600	ENSG00000258789.1	RP11-507K2.3	-6.14	1.71e-09	3.52e-07	-0.29	-0.27	Coronary artery calcification;	chr14:88359040	chr14:88551597~88552493:+
THCA	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	6.14	1.71e-09	3.53e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	6.14	1.71e-09	3.53e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	6.14	1.71e-09	3.53e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	6.14	1.71e-09	3.53e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
THCA	cis	rs287982	0.611	rs111636862	ENSG00000269973.1	RP11-95D17.1	-6.14	1.71e-09	3.53e-07	-0.25	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9840128	chr2:9936360~9939590:+
THCA	cis	rs451417	1	rs236108	ENSG00000275632.1	RP5-967N21.11	6.14	1.71e-09	3.53e-07	0.31	0.27	Menopause (age at onset);	chr20:5987913	chr20:6000418~6000941:+
THCA	cis	rs7044106	0.791	rs3904196	ENSG00000270917.1	RP11-27I1.6	-6.14	1.71e-09	3.53e-07	-0.39	-0.27	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120812475~120812845:-
THCA	cis	rs897984	0.511	rs7196726	ENSG00000279196.1	RP11-1072A3.3	6.14	1.71e-09	3.53e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31080754	chr16:30984630~30988270:-
THCA	cis	rs11722779	0.692	rs223414	ENSG00000230069.3	LRRC37A15P	-6.14	1.71e-09	3.53e-07	-0.29	-0.27	Schizophrenia;	chr4:102811688	chr4:102727274~102730721:-
THCA	cis	rs934734	0.563	rs1858036	ENSG00000234255.7	AC012370.3	6.14	1.71e-09	3.53e-07	0.32	0.27	Rheumatoid arthritis;	chr2:65371107	chr2:65439888~65456571:-
THCA	cis	rs934734	0.789	rs4303705	ENSG00000237979.1	AC007389.1	-6.14	1.71e-09	3.53e-07	-0.31	-0.27	Rheumatoid arthritis;	chr2:65392576	chr2:65500993~65502138:-
THCA	cis	rs6840258	0.8	rs6839933	ENSG00000251411.1	RP11-397E7.4	-6.14	1.72e-09	3.54e-07	-0.29	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87043211	chr4:86913266~86914817:-
THCA	cis	rs6860806	0.507	rs274570	ENSG00000263597.1	MIR3936	-6.14	1.72e-09	3.54e-07	-0.27	-0.27	Breast cancer;	chr5:132377534	chr5:132365490~132365599:-
THCA	cis	rs595244	0.803	rs2028109	ENSG00000259705.1	RP11-227D13.1	6.14	1.72e-09	3.54e-07	0.51	0.27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48626906	chr15:48645951~48652016:+
THCA	cis	rs11795343	0.509	rs7044989	ENSG00000232303.2	DFFBP1	-6.14	1.72e-09	3.54e-07	-0.32	-0.27	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32522131	chr9:32566148~32567126:-
THCA	cis	rs853679	0.517	rs9393895	ENSG00000261839.1	RP1-265C24.8	6.14	1.72e-09	3.54e-07	0.33	0.27	Depression;	chr6:28159843	chr6:28136849~28139678:+
THCA	cis	rs848490	0.928	rs848492	ENSG00000214293.7	APTR	-6.14	1.72e-09	3.55e-07	-0.22	-0.27	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77928401	chr7:77657660~77696265:-
THCA	cis	rs2562456	0.876	rs62110163	ENSG00000268081.1	RP11-678G14.2	6.14	1.72e-09	3.55e-07	0.39	0.27	Pain;	chr19:21546020	chr19:21554640~21569237:-
THCA	cis	rs897984	0.542	rs3751855	ENSG00000279196.1	RP11-1072A3.3	6.14	1.72e-09	3.55e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31079888	chr16:30984630~30988270:-
THCA	cis	rs897984	0.542	rs11865038	ENSG00000279196.1	RP11-1072A3.3	6.14	1.72e-09	3.55e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31083850	chr16:30984630~30988270:-
THCA	cis	rs897984	0.542	rs11864806	ENSG00000279196.1	RP11-1072A3.3	6.14	1.72e-09	3.55e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31083883	chr16:30984630~30988270:-
THCA	cis	rs897984	0.542	rs7199949	ENSG00000279196.1	RP11-1072A3.3	6.14	1.72e-09	3.55e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31084843	chr16:30984630~30988270:-
THCA	cis	rs897984	0.513	rs17839568	ENSG00000279196.1	RP11-1072A3.3	6.14	1.72e-09	3.55e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31088462	chr16:30984630~30988270:-
THCA	cis	rs832187	0.776	rs854622	ENSG00000280620.1	SCAANT1	6.14	1.72e-09	3.55e-07	0.37	0.27	Schizophrenia;	chr3:63877166	chr3:63911518~63911772:-
THCA	cis	rs5742933	0.857	rs13021611	ENSG00000253559.1	OSGEPL1-AS1	6.14	1.72e-09	3.55e-07	0.31	0.27	Ferritin levels;	chr2:189700038	chr2:189762704~189765556:+
THCA	cis	rs2562456	0.755	rs1879234	ENSG00000213976.4	CTD-2561J22.2	6.14	1.72e-09	3.55e-07	0.29	0.27	Pain;	chr19:21521677	chr19:21382865~21387177:+
THCA	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-6.14	1.72e-09	3.55e-07	-0.36	-0.27	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
THCA	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-6.14	1.72e-09	3.55e-07	-0.32	-0.27	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
THCA	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-6.14	1.72e-09	3.55e-07	-0.32	-0.27	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
THCA	cis	rs2735413	0.564	rs73578755	ENSG00000276007.1	RP11-358L22.3	6.14	1.72e-09	3.55e-07	0.29	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78074912	chr16:78123243~78124332:+
THCA	cis	rs2735413	0.564	rs73580814	ENSG00000276007.1	RP11-358L22.3	6.14	1.72e-09	3.55e-07	0.29	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78075002	chr16:78123243~78124332:+
THCA	cis	rs72843506	0.656	rs77540008	ENSG00000270091.1	RP11-78O7.2	-6.14	1.72e-09	3.55e-07	-0.3	-0.27	Schizophrenia;	chr17:20069886	chr17:19896590~19897287:-
THCA	cis	rs4664293	0.625	rs6745448	ENSG00000226266.5	AC009961.3	-6.14	1.72e-09	3.55e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159699087	chr2:159670708~159712435:-
THCA	cis	rs2562456	0.917	rs2681376	ENSG00000268081.1	RP11-678G14.2	-6.14	1.73e-09	3.56e-07	-0.4	-0.27	Pain;	chr19:21532723	chr19:21554640~21569237:-
THCA	cis	rs1043099	0.556	rs4820846	ENSG00000279699.1	RP1-102K2.9	-6.14	1.73e-09	3.56e-07	-0.32	-0.27	Rheumatoid arthritis;	chr22:30404379	chr22:30275215~30276951:-
THCA	cis	rs16976116	0.951	rs28706531	ENSG00000279145.1	RP11-547D13.1	6.14	1.73e-09	3.56e-07	0.27	0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55184874	chr15:55171972~55178175:-
THCA	cis	rs853679	0.517	rs1904840	ENSG00000261839.1	RP1-265C24.8	6.14	1.73e-09	3.57e-07	0.33	0.27	Depression;	chr6:28140454	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000261839.1	RP1-265C24.8	6.14	1.73e-09	3.57e-07	0.33	0.27	Depression;	chr6:28141189	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000261839.1	RP1-265C24.8	6.14	1.73e-09	3.57e-07	0.33	0.27	Depression;	chr6:28141484	chr6:28136849~28139678:+
THCA	cis	rs9649465	0.935	rs1506641	ENSG00000272686.1	RP11-390E23.6	6.14	1.73e-09	3.57e-07	0.18	0.27	Migraine;	chr7:123750089	chr7:123749068~123751166:+
THCA	cis	rs12681366	0.683	rs2445721	ENSG00000253704.1	RP11-267M23.4	-6.14	1.74e-09	3.58e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94377083	chr8:94553722~94569745:+
THCA	cis	rs28386778	1	rs28386778	ENSG00000240280.5	TCAM1P	-6.14	1.74e-09	3.58e-07	-0.39	-0.27	Prudent dietary pattern;	chr17:63887455	chr17:63849292~63864379:+
THCA	cis	rs3742264	0.922	rs4942473	ENSG00000235903.6	CPB2-AS1	-6.14	1.74e-09	3.58e-07	-0.37	-0.27	Blood protein levels;	chr13:46077173	chr13:46052806~46113332:+
THCA	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	6.14	1.74e-09	3.58e-07	0.34	0.27	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
THCA	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	6.14	1.74e-09	3.59e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
THCA	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	6.14	1.74e-09	3.59e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
THCA	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	6.14	1.74e-09	3.59e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
THCA	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	6.14	1.74e-09	3.59e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
THCA	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	6.14	1.74e-09	3.59e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
THCA	cis	rs2915864	0.747	rs78012725	ENSG00000280047.1	CTC-463A16.1	6.14	1.74e-09	3.59e-07	0.45	0.27	Facial morphology (factor 20);	chr5:142061401	chr5:142165767~142168387:+
THCA	cis	rs792448	0.743	rs3767861	ENSG00000226251.4	RP11-15I11.3	-6.14	1.74e-09	3.59e-07	-0.34	-0.27	White blood cell count (basophil);	chr1:212364211	chr1:212225278~212238977:-
THCA	cis	rs792448	0.743	rs3767862	ENSG00000226251.4	RP11-15I11.3	-6.14	1.74e-09	3.59e-07	-0.34	-0.27	White blood cell count (basophil);	chr1:212364360	chr1:212225278~212238977:-
THCA	cis	rs253959	0.672	rs4921056	ENSG00000272265.1	CTD-2287O16.4	6.14	1.74e-09	3.59e-07	0.29	0.27	Bipolar disorder and schizophrenia;	chr5:116087237	chr5:116078110~116078570:-
THCA	cis	rs11722228	0.522	rs7681250	ENSG00000261490.1	RP11-448G15.3	6.14	1.74e-09	3.59e-07	0.2	0.27	Urate levels;Serum uric acid levels;Gout;	chr4:10131389	chr4:10068089~10073019:-
THCA	cis	rs11722228	0.522	rs7662229	ENSG00000261490.1	RP11-448G15.3	6.14	1.74e-09	3.59e-07	0.2	0.27	Urate levels;Serum uric acid levels;Gout;	chr4:10131390	chr4:10068089~10073019:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	6.14	1.74e-09	3.59e-07	0.31	0.27	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
THCA	cis	rs12435908	1	rs73286173	ENSG00000276116.2	FUT8-AS1	-6.14	1.75e-09	3.59e-07	-0.43	-0.27	Ischemic stroke;	chr14:65612822	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs73268512	ENSG00000276116.2	FUT8-AS1	-6.14	1.75e-09	3.59e-07	-0.43	-0.27	Ischemic stroke;	chr14:65622187	chr14:65411170~65412690:-
THCA	cis	rs9880211	1	rs17200216	ENSG00000273486.1	RP11-731C17.2	6.14	1.75e-09	3.6e-07	0.28	0.27	Height;Body mass index;	chr3:136348390	chr3:136837338~136839021:-
THCA	cis	rs5758659	0.729	rs134866	ENSG00000281538.1	RP4-669P10.20	6.14	1.75e-09	3.6e-07	0.24	0.27	Cognitive function;	chr22:42254657	chr22:42138060~42139726:+
THCA	cis	rs7129556	0.954	rs4509797	ENSG00000254691.1	RP11-91P24.5	-6.14	1.75e-09	3.6e-07	-0.37	-0.27	Weight loss (gastric bypass surgery);	chr11:77552158	chr11:77850604~77851511:+
THCA	cis	rs6600671	1	rs4844381	ENSG00000275538.1	RNVU1-19	6.14	1.75e-09	3.61e-07	0.34	0.27	Hip geometry;	chr1:121443040	chr1:120850819~120850985:-
THCA	cis	rs9649465	0.967	rs3757505	ENSG00000272686.1	RP11-390E23.6	6.14	1.76e-09	3.61e-07	0.18	0.27	Migraine;	chr7:123751587	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.905	rs3757504	ENSG00000272686.1	RP11-390E23.6	6.14	1.76e-09	3.61e-07	0.18	0.27	Migraine;	chr7:123751696	chr7:123749068~123751166:+
THCA	cis	rs1993293	0.543	rs11636039	ENSG00000259363.4	CTD-2054N24.2	6.14	1.76e-09	3.62e-07	0.36	0.27	Coronary artery calcification;	chr15:99751886	chr15:99807023~99877148:+
THCA	cis	rs17772222	0.917	rs61986670	ENSG00000222990.1	RNU4-22P	6.14	1.76e-09	3.62e-07	0.35	0.27	Coronary artery calcification;	chr14:88730875	chr14:88513498~88513663:+
THCA	cis	rs5742933	0.817	rs3816196	ENSG00000253559.1	OSGEPL1-AS1	6.14	1.76e-09	3.62e-07	0.31	0.27	Ferritin levels;	chr2:189775749	chr2:189762704~189765556:+
THCA	cis	rs2243480	1	rs2462569	ENSG00000228409.4	CCT6P1	-6.14	1.76e-09	3.62e-07	-0.31	-0.27	Diabetic kidney disease;	chr7:66009859	chr7:65751142~65763354:+
THCA	cis	rs5742933	0.817	rs2033870	ENSG00000253559.1	OSGEPL1-AS1	-6.14	1.76e-09	3.62e-07	-0.31	-0.27	Ferritin levels;	chr2:189739104	chr2:189762704~189765556:+
THCA	cis	rs228614	0.534	rs223387	ENSG00000230069.3	LRRC37A15P	-6.14	1.76e-09	3.62e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223381	ENSG00000230069.3	LRRC37A15P	-6.14	1.76e-09	3.62e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102727274~102730721:-
THCA	cis	rs7044106	0.664	rs7861679	ENSG00000270917.1	RP11-27I1.6	6.14	1.76e-09	3.62e-07	0.38	0.27	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120812475~120812845:-
THCA	cis	rs9649465	1	rs3779260	ENSG00000272686.1	RP11-390E23.6	-6.14	1.76e-09	3.63e-07	-0.18	-0.27	Migraine;	chr7:123708261	chr7:123749068~123751166:+
THCA	cis	rs4950322	0.58	rs2083720	ENSG00000278811.3	LINC00624	6.14	1.76e-09	3.63e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147122296	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.58	rs72706441	ENSG00000278811.3	LINC00624	6.14	1.76e-09	3.63e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147122601	chr1:147258885~147517875:-
THCA	cis	rs9813712	0.526	rs13065659	ENSG00000253540.4	FAM86HP	-6.14	1.76e-09	3.63e-07	-0.3	-0.27	Response to amphetamines;	chr3:130231945	chr3:130099092~130111472:-
THCA	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	6.14	1.77e-09	3.63e-07	0.31	0.27	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
THCA	cis	rs7260598	0.642	rs11667315	ENSG00000268442.1	CTD-2027I19.2	6.14	1.77e-09	3.63e-07	0.37	0.27	Response to taxane treatment (placlitaxel);	chr19:23932336	chr19:24162370~24163425:-
THCA	cis	rs11795343	0.509	rs10738891	ENSG00000232303.2	DFFBP1	-6.14	1.77e-09	3.64e-07	-0.32	-0.27	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32519156	chr9:32566148~32567126:-
THCA	cis	rs11976180	0.517	rs6949375	ENSG00000244198.4	RP4-545C24.1	-6.14	1.77e-09	3.64e-07	-0.35	-0.27	Obesity-related traits;	chr7:144076758	chr7:144194858~144280547:+
THCA	cis	rs6928977	0.832	rs2614286	ENSG00000231028.7	LINC00271	-6.14	1.77e-09	3.64e-07	-0.22	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371533	chr6:135497801~135716055:+
THCA	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	6.14	1.77e-09	3.64e-07	0.35	0.27	Height;	chr4:55407965	chr4:55363971~55395847:-
THCA	cis	rs12608544	1	rs12608544	ENSG00000232871.7	SEC1P	-6.14	1.77e-09	3.64e-07	-0.55	-0.27	Elevated serum carcinoembryonic antigen levels;	chr19:48633394	chr19:48638071~48682245:+
THCA	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-6.14	1.77e-09	3.65e-07	-0.47	-0.27	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
THCA	cis	rs7617773	0.963	rs6766754	ENSG00000228638.1	FCF1P2	6.14	1.77e-09	3.65e-07	0.25	0.27	Coronary artery disease;	chr3:48141099	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.832	rs6775114	ENSG00000228638.1	FCF1P2	6.14	1.77e-09	3.65e-07	0.25	0.27	Coronary artery disease;	chr3:48141130	chr3:48290793~48291375:-
THCA	cis	rs16949788	0.826	rs28723485	ENSG00000261351.2	CTD-3185P2.1	-6.14	1.77e-09	3.65e-07	-0.33	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66331828	chr15:66488658~66492109:-
THCA	cis	rs227275	0.554	rs223371	ENSG00000230069.3	LRRC37A15P	-6.14	1.78e-09	3.65e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102727274~102730721:-
THCA	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	6.14	1.78e-09	3.66e-07	0.32	0.27	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
THCA	cis	rs11603691	0.551	rs7106462	ENSG00000254662.1	RP11-872D17.4	6.14	1.78e-09	3.66e-07	0.42	0.27	Low high density lipoprotein cholesterol levels;	chr11:57332877	chr11:57325603~57327958:+
THCA	cis	rs4950322	0.542	rs28381210	ENSG00000278811.3	LINC00624	6.14	1.78e-09	3.66e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147201925	chr1:147258885~147517875:-
THCA	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-6.14	1.78e-09	3.66e-07	-0.25	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
THCA	cis	rs2412819	0.545	rs35822148	ENSG00000205771.5	CATSPER2P1	-6.14	1.78e-09	3.66e-07	-0.41	-0.27	Lung cancer;	chr15:43808084	chr15:43726918~43747094:-
THCA	cis	rs516805	0.528	rs2684243	ENSG00000279453.1	RP3-425C14.4	-6.14	1.78e-09	3.66e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122092700	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2684244	ENSG00000279453.1	RP3-425C14.4	-6.14	1.78e-09	3.66e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122092734	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2606604	ENSG00000279453.1	RP3-425C14.4	-6.14	1.78e-09	3.66e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122093150	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2606611	ENSG00000279453.1	RP3-425C14.4	-6.14	1.78e-09	3.66e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122094502	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs1402537	ENSG00000279453.1	RP3-425C14.4	-6.14	1.78e-09	3.66e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122094962	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2606622	ENSG00000279453.1	RP3-425C14.4	-6.14	1.78e-09	3.66e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122096367	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2606627	ENSG00000279453.1	RP3-425C14.4	-6.14	1.78e-09	3.66e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122097129	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2816085	ENSG00000279453.1	RP3-425C14.4	-6.14	1.78e-09	3.66e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122097324	chr6:122436789~122439223:-
THCA	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-6.14	1.78e-09	3.66e-07	-0.39	-0.27	Pain;	chr19:21475141	chr19:21554640~21569237:-
THCA	cis	rs7267979	1	rs4815412	ENSG00000274414.1	RP5-965G21.4	-6.14	1.78e-09	3.66e-07	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25239007~25245229:-
THCA	cis	rs6696239	0.513	rs4653853	ENSG00000227711.2	RP11-275O4.5	6.14	1.78e-09	3.66e-07	0.28	0.27	Height;	chr1:227563901	chr1:227509028~227520477:-
THCA	cis	rs9813712	0.83	rs9755184	ENSG00000249846.5	RP11-77P16.4	-6.14	1.78e-09	3.66e-07	-0.32	-0.27	Response to amphetamines;	chr3:130262278	chr3:130112550~130120579:+
THCA	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	6.14	1.78e-09	3.66e-07	0.35	0.27	Height;	chr4:55436423	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	6.14	1.78e-09	3.66e-07	0.35	0.27	Height;	chr4:55437438	chr4:55363971~55395847:-
THCA	cis	rs7208859	0.673	rs79541516	ENSG00000263603.1	CTD-2349P21.5	-6.14	1.78e-09	3.67e-07	-0.5	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30729469~30731202:+
THCA	cis	rs2243480	1	rs35542501	ENSG00000232546.1	RP11-458F8.1	-6.14	1.78e-09	3.67e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65966228	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.803	rs160649	ENSG00000229886.1	RP5-1132H15.3	6.14	1.78e-09	3.67e-07	0.43	0.27	Diabetic kidney disease;	chr7:66078212	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs160648	ENSG00000229886.1	RP5-1132H15.3	6.14	1.78e-09	3.67e-07	0.43	0.27	Diabetic kidney disease;	chr7:66078397	chr7:66025126~66031544:-
THCA	cis	rs2337406	0.714	rs7152055	ENSG00000274576.2	IGHV2-70	-6.14	1.78e-09	3.67e-07	-0.24	-0.27	Alzheimer's disease (late onset);	chr14:106818996	chr14:106770577~106771020:-
THCA	cis	rs12908161	0.959	rs17598603	ENSG00000259295.5	CSPG4P12	-6.14	1.79e-09	3.67e-07	-0.42	-0.27	Schizophrenia;	chr15:84656980	chr15:85191438~85213905:+
THCA	cis	rs9677476	0.863	rs58383275	ENSG00000224376.1	AC017104.6	6.14	1.79e-09	3.67e-07	0.31	0.27	Food antigen IgG levels;	chr2:231199232	chr2:231388976~231394991:+
THCA	cis	rs9677476	0.818	rs28678038	ENSG00000224376.1	AC017104.6	6.14	1.79e-09	3.67e-07	0.31	0.27	Food antigen IgG levels;	chr2:231199283	chr2:231388976~231394991:+
THCA	cis	rs9677476	0.863	rs12478335	ENSG00000224376.1	AC017104.6	6.14	1.79e-09	3.67e-07	0.31	0.27	Food antigen IgG levels;	chr2:231200253	chr2:231388976~231394991:+
THCA	cis	rs6142102	0.961	rs761235	ENSG00000275784.1	RP5-1125A11.6	-6.14	1.79e-09	3.67e-07	-0.28	-0.27	Skin pigmentation;	chr20:33946602	chr20:33989480~33991818:-
THCA	cis	rs3794924	1	rs7233484	ENSG00000266521.1	RP11-650P15.1	6.14	1.79e-09	3.68e-07	0.51	0.27	Survival in colon cancer;	chr18:31474869	chr18:31496645~31497195:-
THCA	cis	rs836788	0.608	rs26784	ENSG00000249655.1	CTC-325J23.2	-6.14	1.79e-09	3.68e-07	-0.28	-0.27	Glomerular filtration rate (creatinine);	chr5:80754073	chr5:80630313~80631590:-
THCA	cis	rs836788	0.57	rs26783	ENSG00000249655.1	CTC-325J23.2	-6.14	1.79e-09	3.68e-07	-0.28	-0.27	Glomerular filtration rate (creatinine);	chr5:80754284	chr5:80630313~80631590:-
THCA	cis	rs8012947	0.565	rs12891852	ENSG00000279636.2	LINC00216	-6.14	1.79e-09	3.68e-07	-0.27	-0.27	Alcohol consumption in current drinkers;	chr14:58330922	chr14:58288033~58289158:+
THCA	cis	rs2562456	0.833	rs11667361	ENSG00000268555.1	RP11-678G14.3	6.14	1.79e-09	3.68e-07	0.43	0.27	Pain;	chr19:21356580	chr19:21570822~21587322:-
THCA	cis	rs12681366	0.573	rs2470740	ENSG00000253704.1	RP11-267M23.4	-6.14	1.79e-09	3.68e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94387323	chr8:94553722~94569745:+
THCA	cis	rs9309473	0.519	rs2421667	ENSG00000163016.8	ALMS1P	-6.14	1.79e-09	3.68e-07	-0.35	-0.27	Metabolite levels;	chr2:73605332	chr2:73644919~73685576:+
THCA	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-6.14	1.79e-09	3.68e-07	-0.25	-0.27	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
THCA	cis	rs896854	0.625	rs4735336	ENSG00000253528.2	RP11-347C18.4	-6.14	1.79e-09	3.69e-07	-0.31	-0.27	Type 2 diabetes;	chr8:94961182	chr8:94974573~94974853:-
THCA	cis	rs8002861	0.935	rs7319725	ENSG00000274001.1	RP11-5G9.5	6.14	1.79e-09	3.69e-07	0.31	0.27	Leprosy;	chr13:43871285	chr13:43877715~43878163:-
THCA	cis	rs2562456	0.724	rs58001930	ENSG00000213976.4	CTD-2561J22.2	-6.14	1.79e-09	3.69e-07	-0.29	-0.27	Pain;	chr19:21560061	chr19:21382865~21387177:+
THCA	cis	rs2179367	0.6	rs58747890	ENSG00000231760.4	RP11-350J20.5	6.14	1.8e-09	3.69e-07	0.44	0.27	Dupuytren's disease;	chr6:149459369	chr6:149796151~149826294:-
THCA	cis	rs7246657	0.606	rs2972439	ENSG00000267422.1	CTD-2554C21.1	6.14	1.8e-09	3.69e-07	0.31	0.27	Coronary artery calcification;	chr19:37721680	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs2909100	ENSG00000267422.1	CTD-2554C21.1	6.14	1.8e-09	3.69e-07	0.31	0.27	Coronary artery calcification;	chr19:37721779	chr19:37779686~37792865:+
THCA	cis	rs227275	0.556	rs7676765	ENSG00000230069.3	LRRC37A15P	6.14	1.8e-09	3.69e-07	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102727274~102730721:-
THCA	cis	rs2243480	1	rs78803505	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65917585	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65920739	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65922691	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65925107	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65926730	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65928032	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65929575	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65929781	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65929865	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000232546.1	RP11-458F8.1	-6.14	1.8e-09	3.69e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65938222	chr7:66848496~66858136:+
THCA	cis	rs6860806	0.507	rs272878	ENSG00000263597.1	MIR3936	-6.14	1.8e-09	3.7e-07	-0.27	-0.27	Breast cancer;	chr5:132336076	chr5:132365490~132365599:-
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-6.14	1.8e-09	3.7e-07	-0.31	-0.27	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
THCA	cis	rs681343	1	rs516246	ENSG00000232871.7	SEC1P	6.14	1.8e-09	3.7e-07	0.32	0.27	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702915	chr19:48638071~48682245:+
THCA	cis	rs4950322	0.542	rs17159914	ENSG00000278811.3	LINC00624	-6.14	1.8e-09	3.7e-07	-0.31	-0.27	Protein quantitative trait loci;	chr1:147183226	chr1:147258885~147517875:-
THCA	cis	rs2735413	0.564	rs73580826	ENSG00000276007.1	RP11-358L22.3	6.14	1.8e-09	3.7e-07	0.29	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78076992	chr16:78123243~78124332:+
THCA	cis	rs793571	0.505	rs12901989	ENSG00000259250.1	RP11-50C13.1	-6.14	1.8e-09	3.7e-07	-0.3	-0.27	Schizophrenia;	chr15:58603861	chr15:58587507~58591676:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000275400.1	RP4-756H11.5	-6.14	1.8e-09	3.71e-07	-0.27	-0.27	Calcium levels;	chr7:65977808	chr7:66553805~66554199:-
THCA	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	6.14	1.8e-09	3.71e-07	0.63	0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
THCA	cis	rs10266483	0.774	rs4718067	ENSG00000227986.1	TRIM60P18	-6.14	1.8e-09	3.71e-07	-0.24	-0.27	Response to statin therapy;	chr7:64356018	chr7:64355078~64356199:+
THCA	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	6.14	1.8e-09	3.71e-07	0.22	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
THCA	cis	rs7712401	0.755	rs1870560	ENSG00000249996.1	RP11-359P5.1	6.14	1.8e-09	3.71e-07	0.26	0.27	Mean platelet volume;	chr5:122775515	chr5:123036271~123054667:+
THCA	cis	rs2562456	0.833	rs11880624	ENSG00000268555.1	RP11-678G14.3	6.14	1.8e-09	3.71e-07	0.43	0.27	Pain;	chr19:21341028	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62107547	ENSG00000268555.1	RP11-678G14.3	6.14	1.8e-09	3.71e-07	0.43	0.27	Pain;	chr19:21341245	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs56187954	ENSG00000268555.1	RP11-678G14.3	6.14	1.8e-09	3.71e-07	0.43	0.27	Pain;	chr19:21345258	chr19:21570822~21587322:-
THCA	cis	rs13113518	0.783	rs13111128	ENSG00000273257.1	RP11-177J6.1	6.14	1.81e-09	3.71e-07	0.37	0.27	Height;	chr4:55578154	chr4:55387949~55388271:+
THCA	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	6.14	1.81e-09	3.71e-07	0.34	0.27	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
THCA	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	6.14	1.81e-09	3.71e-07	0.22	0.27	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
THCA	cis	rs12935418	1	rs12935418	ENSG00000261061.1	RP11-303E16.2	-6.14	1.81e-09	3.71e-07	-0.34	-0.27	Mean corpuscular volume;	chr16:81036403	chr16:81030770~81031485:+
THCA	cis	rs8067545	0.693	rs8066150	ENSG00000270091.1	RP11-78O7.2	-6.14	1.81e-09	3.71e-07	-0.2	-0.27	Schizophrenia;	chr17:19983635	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.72	rs11204419	ENSG00000270091.1	RP11-78O7.2	-6.14	1.81e-09	3.71e-07	-0.2	-0.27	Schizophrenia;	chr17:19985684	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.72	rs11204420	ENSG00000270091.1	RP11-78O7.2	-6.14	1.81e-09	3.71e-07	-0.2	-0.27	Schizophrenia;	chr17:19985707	chr17:19896590~19897287:-
THCA	cis	rs4950322	0.58	rs7514970	ENSG00000278811.3	LINC00624	6.14	1.81e-09	3.71e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147120516	chr1:147258885~147517875:-
THCA	cis	rs7976269	0.609	rs1344855	ENSG00000257176.2	RP11-996F15.2	6.14	1.81e-09	3.72e-07	0.28	0.27	Male-pattern baldness;	chr12:29065605	chr12:29280418~29317848:-
THCA	cis	rs16846053	0.642	rs13399126	ENSG00000227403.1	AC009299.3	6.14	1.81e-09	3.72e-07	0.44	0.27	Blood osmolality (transformed sodium);	chr2:161777799	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.642	rs10469686	ENSG00000227403.1	AC009299.3	6.14	1.81e-09	3.72e-07	0.44	0.27	Blood osmolality (transformed sodium);	chr2:161779321	chr2:161244739~161249050:+
THCA	cis	rs72627509	0.723	rs62308104	ENSG00000269949.1	RP11-738E22.3	6.13	1.81e-09	3.72e-07	0.41	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56859814	chr4:56960927~56961373:-
THCA	cis	rs12908161	1	rs60957376	ENSG00000259295.5	CSPG4P12	6.13	1.81e-09	3.72e-07	0.41	0.27	Schizophrenia;	chr15:84737561	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs11632465	ENSG00000259295.5	CSPG4P12	6.13	1.81e-09	3.72e-07	0.41	0.27	Schizophrenia;	chr15:84738814	chr15:85191438~85213905:+
THCA	cis	rs526231	0.783	rs28158	ENSG00000175749.11	EIF3KP1	6.13	1.81e-09	3.73e-07	0.38	0.27	Primary biliary cholangitis;	chr5:103260191	chr5:103032376~103033031:+
THCA	cis	rs527616	0.793	rs675150	ENSG00000265369.3	PCAT18	6.13	1.81e-09	3.73e-07	0.33	0.27	Breast cancer;	chr18:26759755	chr18:26687621~26703638:-
THCA	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-6.13	1.81e-09	3.73e-07	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
THCA	cis	rs17772222	0.917	rs61977053	ENSG00000258789.1	RP11-507K2.3	-6.13	1.82e-09	3.73e-07	-0.29	-0.27	Coronary artery calcification;	chr14:88380876	chr14:88551597~88552493:+
THCA	cis	rs792448	0.701	rs3099112	ENSG00000226251.4	RP11-15I11.3	-6.13	1.82e-09	3.73e-07	-0.34	-0.27	White blood cell count (basophil);	chr1:212369068	chr1:212225278~212238977:-
THCA	cis	rs10771431	0.81	rs10771418	ENSG00000111788.10	RP11-22B23.1	6.13	1.82e-09	3.73e-07	0.26	0.27	Breast size;	chr12:9206399	chr12:9277235~9313241:+
THCA	cis	rs9402743	0.816	rs7757431	ENSG00000231028.7	LINC00271	-6.13	1.82e-09	3.73e-07	-0.21	-0.27	Systemic lupus erythematosus;	chr6:135680422	chr6:135497801~135716055:+
THCA	cis	rs2281636	0.894	rs11190196	ENSG00000260475.1	RP11-85A1.3	6.13	1.82e-09	3.73e-07	0.25	0.27	Obesity-related traits;	chr10:99626757	chr10:99621055~99621918:+
THCA	cis	rs1552244	0.882	rs6443279	ENSG00000180385.7	EMC3-AS1	6.13	1.82e-09	3.74e-07	0.29	0.27	Alzheimer's disease;	chr3:10011915	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.882	rs36006511	ENSG00000180385.7	EMC3-AS1	6.13	1.82e-09	3.74e-07	0.29	0.27	Alzheimer's disease;	chr3:10012507	chr3:9986893~10006990:+
THCA	cis	rs7927592	0.83	rs11228240	ENSG00000212093.1	AP000807.1	6.13	1.82e-09	3.74e-07	0.31	0.27	Total body bone mineral density;	chr11:68450822	chr11:68506083~68506166:-
THCA	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-6.13	1.82e-09	3.74e-07	-0.28	-0.27	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000228409.4	CCT6P1	6.13	1.82e-09	3.74e-07	0.31	0.27	Diabetic kidney disease;	chr7:65970805	chr7:65751142~65763354:+
THCA	cis	rs3758785	0.679	rs11819857	ENSG00000255893.1	RP11-685N10.1	-6.13	1.82e-09	3.74e-07	-0.33	-0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94495070	chr11:94472908~94473570:-
THCA	cis	rs2243480	1	rs1618893	ENSG00000228409.4	CCT6P1	6.13	1.82e-09	3.74e-07	0.3	0.27	Diabetic kidney disease;	chr7:66631132	chr7:65751142~65763354:+
THCA	cis	rs4845875	0.54	rs10864543	ENSG00000242349.4	NPPA-AS1	6.13	1.82e-09	3.74e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11784273	chr1:11841017~11848079:+
THCA	cis	rs737008	0.5	rs7189239	ENSG00000263080.1	RP11-485G7.5	6.13	1.82e-09	3.74e-07	0.32	0.27	Obesity-related traits;	chr16:11308658	chr16:11341809~11345211:-
THCA	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	6.13	1.82e-09	3.74e-07	0.28	0.27	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
THCA	cis	rs4950322	0.57	rs17356184	ENSG00000278811.3	LINC00624	6.13	1.82e-09	3.74e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147262943	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs80270233	ENSG00000278811.3	LINC00624	6.13	1.82e-09	3.74e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147263320	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs4950392	ENSG00000278811.3	LINC00624	6.13	1.82e-09	3.74e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147264889	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs17356219	ENSG00000278811.3	LINC00624	6.13	1.82e-09	3.74e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147265684	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72691041	ENSG00000278811.3	LINC00624	6.13	1.82e-09	3.74e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147267084	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs17356233	ENSG00000278811.3	LINC00624	6.13	1.82e-09	3.74e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147268843	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs17356240	ENSG00000278811.3	LINC00624	6.13	1.82e-09	3.74e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147269877	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs1999820	ENSG00000278811.3	LINC00624	6.13	1.82e-09	3.74e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147270329	chr1:147258885~147517875:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	6.13	1.82e-09	3.74e-07	0.31	0.27	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
THCA	cis	rs3822625	1	rs16877026	ENSG00000271828.1	CTD-2310F14.1	6.13	1.82e-09	3.74e-07	0.71	0.27	Breast cancer (early onset);	chr5:56889099	chr5:56927874~56929573:+
THCA	cis	rs3822625	1	rs76058858	ENSG00000271828.1	CTD-2310F14.1	6.13	1.82e-09	3.74e-07	0.71	0.27	Breast cancer (early onset);	chr5:56890612	chr5:56927874~56929573:+
THCA	cis	rs1552244	0.688	rs113940455	ENSG00000180385.7	EMC3-AS1	6.13	1.82e-09	3.74e-07	0.3	0.27	Alzheimer's disease;	chr3:9972481	chr3:9986893~10006990:+
THCA	cis	rs2911132	0.967	rs2042380	ENSG00000248734.2	CTD-2260A17.1	6.13	1.82e-09	3.75e-07	0.28	0.27	Urate levels (BMI interaction);	chr5:96851563	chr5:96784777~96785999:+
THCA	cis	rs2115630	0.936	rs11073663	ENSG00000225151.9	GOLGA2P7	6.13	1.82e-09	3.75e-07	0.35	0.27	P wave terminal force;	chr15:84717037	chr15:84199311~84230136:-
THCA	cis	rs1499614	0.522	rs13247442	ENSG00000273142.1	RP11-458F8.4	-6.13	1.83e-09	3.75e-07	-0.45	-0.27	Gout;	chr7:66723871	chr7:66902857~66906297:+
THCA	cis	rs2880765	0.631	rs55767890	ENSG00000259630.2	CTD-2262B20.1	-6.13	1.83e-09	3.75e-07	-0.32	-0.27	Coronary artery disease;	chr15:85460911	chr15:85415228~85415633:+
THCA	cis	rs2337406	1	rs78631692	ENSG00000274576.2	IGHV2-70	-6.13	1.83e-09	3.75e-07	-0.25	-0.27	Alzheimer's disease (late onset);	chr14:106709371	chr14:106770577~106771020:-
THCA	cis	rs9990333	0.544	rs112577972	ENSG00000226155.1	AC124944.3	-6.13	1.83e-09	3.75e-07	-0.34	-0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195912049~195913986:+
THCA	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	6.13	1.83e-09	3.75e-07	0.28	0.27	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	6.13	1.83e-09	3.75e-07	0.28	0.27	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
THCA	cis	rs9816784	0.525	rs3326	ENSG00000231464.1	AC024937.4	6.13	1.83e-09	3.75e-07	0.35	0.27	Mean corpuscular hemoglobin;	chr3:196054635	chr3:195996738~195998233:+
THCA	cis	rs984222	0.967	rs10802069	ENSG00000231365.4	RP11-418J17.1	-6.13	1.83e-09	3.76e-07	-0.26	-0.27	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118974734	chr1:119140396~119275973:+
THCA	cis	rs228614	0.536	rs223484	ENSG00000230069.3	LRRC37A15P	-6.13	1.83e-09	3.76e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102727274~102730721:-
THCA	cis	rs17772222	0.682	rs4904452	ENSG00000258983.2	RP11-507K2.2	-6.13	1.83e-09	3.76e-07	-0.32	-0.27	Coronary artery calcification;	chr14:88517329	chr14:88499334~88515502:+
THCA	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	6.13	1.83e-09	3.76e-07	0.36	0.27	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
THCA	cis	rs9813712	0.909	rs1453257	ENSG00000249846.5	RP11-77P16.4	-6.13	1.83e-09	3.76e-07	-0.32	-0.27	Response to amphetamines;	chr3:130258730	chr3:130112550~130120579:+
THCA	cis	rs9813712	0.953	rs1453256	ENSG00000249846.5	RP11-77P16.4	-6.13	1.83e-09	3.76e-07	-0.32	-0.27	Response to amphetamines;	chr3:130258787	chr3:130112550~130120579:+
THCA	cis	rs9813712	0.953	rs935916	ENSG00000249846.5	RP11-77P16.4	-6.13	1.83e-09	3.76e-07	-0.32	-0.27	Response to amphetamines;	chr3:130258931	chr3:130112550~130120579:+
THCA	cis	rs9921338	0.923	rs4563054	ENSG00000262636.1	CTD-3088G3.4	-6.13	1.83e-09	3.76e-07	-0.41	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353689	chr16:11380859~11381118:-
THCA	cis	rs10208649	0.536	rs13423576	ENSG00000272156.1	RP11-477N3.1	6.13	1.84e-09	3.77e-07	0.38	0.27	Body mass index;	chr2:53737028	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.536	rs13414183	ENSG00000272156.1	RP11-477N3.1	6.13	1.84e-09	3.77e-07	0.38	0.27	Body mass index;	chr2:53738387	chr2:54082554~54085066:+
THCA	cis	rs228614	0.51	rs3774987	ENSG00000251288.2	RP11-10L12.2	-6.13	1.84e-09	3.77e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102751401~102752641:+
THCA	cis	rs16846053	0.642	rs13420505	ENSG00000227403.1	AC009299.3	6.13	1.84e-09	3.77e-07	0.44	0.27	Blood osmolality (transformed sodium);	chr2:161776433	chr2:161244739~161249050:+
THCA	cis	rs836788	0.633	rs245013	ENSG00000249655.1	CTC-325J23.2	-6.13	1.84e-09	3.77e-07	-0.27	-0.27	Glomerular filtration rate (creatinine);	chr5:80751257	chr5:80630313~80631590:-
THCA	cis	rs7833787	0.965	rs7830045	ENSG00000278886.1	RP11-108A14.1	-6.13	1.84e-09	3.78e-07	-0.35	-0.27	Obesity-related traits;	chr8:18842772	chr8:18864681~18865247:-
THCA	cis	rs2274273	0.592	rs2878174	ENSG00000258413.1	RP11-665C16.6	-6.13	1.84e-09	3.78e-07	-0.36	-0.27	Protein biomarker;	chr14:55003906	chr14:55262767~55272075:-
THCA	cis	rs5742933	0.762	rs12992061	ENSG00000253559.1	OSGEPL1-AS1	6.13	1.84e-09	3.78e-07	0.31	0.27	Ferritin levels;	chr2:189736026	chr2:189762704~189765556:+
THCA	cis	rs72802342	0.541	rs185052	ENSG00000261783.1	RP11-252K23.2	6.13	1.85e-09	3.79e-07	0.49	0.27	Advanced age-related macular degeneration;	chr16:75433165	chr16:75379818~75381260:-
THCA	cis	rs2562456	0.55	rs4809143	ENSG00000213976.4	CTD-2561J22.2	-6.13	1.85e-09	3.79e-07	-0.31	-0.27	Pain;	chr19:21589926	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.583	rs4809144	ENSG00000213976.4	CTD-2561J22.2	-6.13	1.85e-09	3.79e-07	-0.31	-0.27	Pain;	chr19:21589928	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.652	rs62110214	ENSG00000213976.4	CTD-2561J22.2	-6.13	1.85e-09	3.79e-07	-0.31	-0.27	Pain;	chr19:21592406	chr19:21382865~21387177:+
THCA	cis	rs8113308	1	rs6509600	ENSG00000269235.1	ZNF350-AS1	6.13	1.85e-09	3.79e-07	0.37	0.27	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939336	chr19:51949134~51981367:+
THCA	cis	rs10129255	0.957	rs11846893	ENSG00000211974.3	IGHV2-70	6.13	1.85e-09	3.79e-07	0.21	0.27	Kawasaki disease;	chr14:106779068	chr14:106723574~106724093:-
THCA	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	6.13	1.85e-09	3.8e-07	0.3	0.27	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
THCA	cis	rs4072705	0.835	rs10122154	ENSG00000224020.1	MIR181A2HG	-6.13	1.85e-09	3.8e-07	-0.26	-0.27	Menarche (age at onset);	chr9:124796759	chr9:124658467~124698631:+
THCA	cis	rs4713118	0.513	rs149945	ENSG00000280107.1	AL022393.9	-6.13	1.85e-09	3.8e-07	-0.29	-0.27	Parkinson's disease;	chr6:28035075	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs853676	ENSG00000226314.6	ZNF192P1	-6.13	1.85e-09	3.8e-07	-0.42	-0.27	Depression;	chr6:28331910	chr6:28161781~28169594:+
THCA	cis	rs17301013	0.507	rs72713537	ENSG00000227373.4	RP11-160H22.5	6.13	1.85e-09	3.8e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174354189	chr1:174115300~174160004:-
THCA	cis	rs9880211	1	rs9818056	ENSG00000273486.1	RP11-731C17.2	6.13	1.85e-09	3.8e-07	0.28	0.27	Height;Body mass index;	chr3:136491232	chr3:136837338~136839021:-
THCA	cis	rs944990	0.557	rs4237221	ENSG00000227603.1	RP11-165J3.6	6.13	1.86e-09	3.81e-07	0.28	0.27	Body mass index;	chr9:93533821	chr9:93435332~93437121:-
THCA	cis	rs34779708	0.733	rs7087099	ENSG00000271335.4	RP11-324I22.4	6.13	1.86e-09	3.81e-07	0.27	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35314552~35336401:-
THCA	cis	rs950169	0.686	rs12906474	ENSG00000259295.5	CSPG4P12	6.13	1.86e-09	3.81e-07	0.41	0.27	Schizophrenia;	chr15:84566006	chr15:85191438~85213905:+
THCA	cis	rs950169	0.81	rs2879976	ENSG00000259295.5	CSPG4P12	6.13	1.86e-09	3.81e-07	0.41	0.27	Schizophrenia;	chr15:84566347	chr15:85191438~85213905:+
THCA	cis	rs10971721	0.584	rs10971938	ENSG00000281128.1	PTENP1-AS	-6.13	1.86e-09	3.82e-07	-0.57	-0.27	Body mass index;	chr9:34120722	chr9:33677268~33688011:+
THCA	cis	rs7617773	0.539	rs2017858	ENSG00000228638.1	FCF1P2	-6.13	1.86e-09	3.82e-07	-0.27	-0.27	Coronary artery disease;	chr3:48340792	chr3:48290793~48291375:-
THCA	cis	rs11722779	0.869	rs223350	ENSG00000251288.2	RP11-10L12.2	-6.13	1.86e-09	3.82e-07	-0.36	-0.27	Schizophrenia;	chr4:102856899	chr4:102751401~102752641:+
THCA	cis	rs2562456	0.833	rs7258099	ENSG00000268555.1	RP11-678G14.3	6.13	1.86e-09	3.82e-07	0.43	0.27	Pain;	chr19:21352941	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs62109229	ENSG00000268555.1	RP11-678G14.3	6.13	1.86e-09	3.82e-07	0.43	0.27	Pain;	chr19:21354380	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs11670815	ENSG00000268555.1	RP11-678G14.3	6.13	1.86e-09	3.82e-07	0.43	0.27	Pain;	chr19:21356515	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs11666540	ENSG00000268555.1	RP11-678G14.3	6.13	1.86e-09	3.82e-07	0.43	0.27	Pain;	chr19:21356550	chr19:21570822~21587322:-
THCA	cis	rs7615952	0.512	rs2979351	ENSG00000171084.14	FAM86JP	6.13	1.87e-09	3.83e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:125644755	chr3:125916620~125930024:+
THCA	cis	rs13113518	0.783	rs12510400	ENSG00000273257.1	RP11-177J6.1	6.13	1.87e-09	3.83e-07	0.37	0.27	Height;	chr4:55577294	chr4:55387949~55388271:+
THCA	cis	rs10971721	0.584	rs55857848	ENSG00000281128.1	PTENP1-AS	6.13	1.87e-09	3.83e-07	0.57	0.27	Body mass index;	chr9:34121512	chr9:33677268~33688011:+
THCA	cis	rs4143844	1	rs12909386	ENSG00000259251.2	RP11-643M14.1	6.13	1.87e-09	3.83e-07	0.52	0.27	Bipolar disorder and schizophrenia;	chr15:62040700	chr15:62060503~62062434:+
THCA	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-6.13	1.87e-09	3.84e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-6.13	1.87e-09	3.84e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
THCA	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	6.13	1.87e-09	3.84e-07	0.3	0.27	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
THCA	cis	rs890448	0.796	rs10433980	ENSG00000254531.1	FLJ20021	6.13	1.87e-09	3.84e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362429	chr4:101347780~101348883:+
THCA	cis	rs853679	0.527	rs853693	ENSG00000219392.1	RP1-265C24.5	-6.13	1.87e-09	3.84e-07	-0.31	-0.27	Depression;	chr6:28314871	chr6:28115628~28116551:+
THCA	cis	rs7927592	0.645	rs7936582	ENSG00000212093.1	AP000807.1	6.13	1.87e-09	3.84e-07	0.28	0.27	Total body bone mineral density;	chr11:68525462	chr11:68506083~68506166:-
THCA	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	6.13	1.88e-09	3.84e-07	0.35	0.27	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
THCA	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-6.13	1.88e-09	3.84e-07	-0.35	-0.27	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
THCA	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-6.13	1.88e-09	3.84e-07	-0.35	-0.27	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
THCA	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-6.13	1.88e-09	3.84e-07	-0.35	-0.27	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
THCA	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-6.13	1.88e-09	3.84e-07	-0.35	-0.27	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
THCA	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-6.13	1.88e-09	3.84e-07	-0.35	-0.27	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
THCA	cis	rs9813712	0.953	rs896822	ENSG00000249846.5	RP11-77P16.4	-6.13	1.88e-09	3.85e-07	-0.32	-0.27	Response to amphetamines;	chr3:130259987	chr3:130112550~130120579:+
THCA	cis	rs7674212	0.541	rs2720460	ENSG00000246560.2	RP11-10L12.4	-6.13	1.88e-09	3.85e-07	-0.33	-0.27	Type 2 diabetes;	chr4:103133529	chr4:102828055~102844075:+
THCA	cis	rs1876905	0.62	rs354530	ENSG00000255389.1	C6orf3	6.13	1.88e-09	3.85e-07	0.32	0.27	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111599875~111602295:+
THCA	cis	rs9990333	0.562	rs73210005	ENSG00000226155.1	AC124944.3	-6.13	1.88e-09	3.85e-07	-0.34	-0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195912049~195913986:+
THCA	cis	rs890448	0.796	rs2471682	ENSG00000254531.1	FLJ20021	6.13	1.88e-09	3.85e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101428822	chr4:101347780~101348883:+
THCA	cis	rs8067545	0.667	rs7222403	ENSG00000270091.1	RP11-78O7.2	-6.13	1.88e-09	3.86e-07	-0.2	-0.27	Schizophrenia;	chr17:19975851	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.72	rs6587206	ENSG00000270091.1	RP11-78O7.2	-6.13	1.88e-09	3.86e-07	-0.2	-0.27	Schizophrenia;	chr17:19978274	chr17:19896590~19897287:-
THCA	cis	rs11148252	0.74	rs9526914	ENSG00000235660.1	LINC00345	-6.13	1.88e-09	3.86e-07	-0.35	-0.27	Lewy body disease;	chr13:52402165	chr13:52484161~52484680:-
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000228409.4	CCT6P1	6.13	1.88e-09	3.86e-07	0.31	0.27	Diabetic kidney disease;	chr7:65999249	chr7:65751142~65763354:+
THCA	cis	rs10208649	0.901	rs10180492	ENSG00000272156.1	RP11-477N3.1	6.13	1.88e-09	3.86e-07	0.51	0.27	Body mass index;	chr2:53829003	chr2:54082554~54085066:+
THCA	cis	rs8042680	0.688	rs2386584	ENSG00000214432.8	AC068831.10	-6.13	1.88e-09	3.86e-07	-0.3	-0.27	Type 2 diabetes;	chr15:90996342	chr15:91022619~91036611:+
THCA	cis	rs17772222	1	rs12589480	ENSG00000258789.1	RP11-507K2.3	-6.13	1.88e-09	3.86e-07	-0.29	-0.27	Coronary artery calcification;	chr14:88414926	chr14:88551597~88552493:+
THCA	cis	rs72949976	0.584	rs12467619	ENSG00000270659.1	RP11-105N14.1	-6.13	1.88e-09	3.86e-07	-0.22	-0.27	Squamous cell lung carcinoma;Lung cancer;	chr2:213158209	chr2:213152970~213153659:+
THCA	cis	rs13256369	0.774	rs13260303	ENSG00000253893.2	FAM85B	-6.13	1.89e-09	3.86e-07	-0.36	-0.27	Obesity-related traits;	chr8:8729832	chr8:8167819~8226614:-
THCA	cis	rs7833787	1	rs7007413	ENSG00000278886.1	RP11-108A14.1	6.13	1.89e-09	3.86e-07	0.35	0.27	Obesity-related traits;	chr8:18847922	chr8:18864681~18865247:-
THCA	cis	rs2364403	1	rs2364403	ENSG00000225855.5	RUSC1-AS1	6.13	1.89e-09	3.86e-07	0.2	0.27	Amyotrophic lateral sclerosis (age of onset);	chr1:155957961	chr1:155316863~155324176:-
THCA	cis	rs7727544	0.545	rs10074490	ENSG00000224431.1	AC063976.7	6.13	1.89e-09	3.87e-07	0.24	0.27	Blood metabolite levels;	chr5:132004339	chr5:132199456~132203487:+
THCA	cis	rs7615952	0.599	rs60847438	ENSG00000250012.1	RP11-124N2.1	-6.13	1.89e-09	3.87e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126027162	chr3:126084220~126095349:+
THCA	cis	rs9800506	0.609	rs3798346	ENSG00000228559.1	RP3-340B19.3	6.13	1.89e-09	3.87e-07	0.4	0.27	Neutrophil percentage of granulocytes;	chr6:35594863	chr6:35544632~35545669:+
THCA	cis	rs7044106	0.791	rs7036766	ENSG00000270917.1	RP11-27I1.6	-6.13	1.89e-09	3.87e-07	-0.39	-0.27	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120812475~120812845:-
THCA	cis	rs6860806	0.531	rs272887	ENSG00000263597.1	MIR3936	6.13	1.89e-09	3.88e-07	0.27	0.27	Breast cancer;	chr5:132330020	chr5:132365490~132365599:-
THCA	cis	rs62184315	0.629	rs5743072	ENSG00000273240.1	RP11-455J20.3	-6.13	1.89e-09	3.88e-07	-0.33	-0.27	Alcohol dependence (age at onset);	chr2:189832198	chr2:189763859~189764456:-
THCA	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	6.13	1.89e-09	3.88e-07	0.28	0.27	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	6.13	1.89e-09	3.88e-07	0.28	0.27	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	6.13	1.89e-09	3.88e-07	0.28	0.27	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	6.13	1.89e-09	3.88e-07	0.28	0.27	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	6.13	1.89e-09	3.88e-07	0.28	0.27	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
THCA	cis	rs11722779	0.935	rs3857200	ENSG00000251288.2	RP11-10L12.2	-6.13	1.89e-09	3.88e-07	-0.37	-0.27	Schizophrenia;	chr4:103001864	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs11731885	ENSG00000251288.2	RP11-10L12.2	-6.13	1.89e-09	3.88e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102751401~102752641:+
THCA	cis	rs72949976	0.584	rs4673729	ENSG00000270659.1	RP11-105N14.1	-6.13	1.89e-09	3.88e-07	-0.22	-0.27	Squamous cell lung carcinoma;Lung cancer;	chr2:213159086	chr2:213152970~213153659:+
THCA	cis	rs6751744	0.855	rs7585513	ENSG00000226266.5	AC009961.3	-6.13	1.9e-09	3.89e-07	-0.34	-0.27	Dysphagia;	chr2:159550379	chr2:159670708~159712435:-
THCA	cis	rs10129255	0.872	rs10133674	ENSG00000223648.3	IGHV3-64	6.13	1.9e-09	3.89e-07	0.17	0.27	Kawasaki disease;	chr14:106692788	chr14:106643132~106658258:-
THCA	cis	rs2281636	0.66	rs61871318	ENSG00000233690.1	EBAG9P1	6.13	1.9e-09	3.89e-07	0.3	0.27	Obesity-related traits;	chr10:99606784	chr10:99697407~99697949:-
THCA	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	6.13	1.9e-09	3.89e-07	0.35	0.27	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
THCA	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	6.13	1.9e-09	3.89e-07	0.22	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
THCA	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	6.13	1.9e-09	3.9e-07	0.28	0.27	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	6.13	1.9e-09	3.9e-07	0.28	0.27	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
THCA	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	6.13	1.9e-09	3.9e-07	0.43	0.27	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
THCA	cis	rs7246657	0.722	rs2909093	ENSG00000267422.1	CTD-2554C21.1	6.13	1.9e-09	3.9e-07	0.31	0.27	Coronary artery calcification;	chr19:37708561	chr19:37779686~37792865:+
THCA	cis	rs10266483	0.705	rs1111649	ENSG00000227986.1	TRIM60P18	-6.13	1.9e-09	3.9e-07	-0.23	-0.27	Response to statin therapy;	chr7:64296435	chr7:64355078~64356199:+
THCA	cis	rs7260598	0.642	rs8101310	ENSG00000268442.1	CTD-2027I19.2	6.13	1.91e-09	3.9e-07	0.36	0.27	Response to taxane treatment (placlitaxel);	chr19:23961137	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.642	rs8104784	ENSG00000268442.1	CTD-2027I19.2	6.13	1.91e-09	3.9e-07	0.36	0.27	Response to taxane treatment (placlitaxel);	chr19:23961732	chr19:24162370~24163425:-
THCA	cis	rs12435908	1	rs17246259	ENSG00000276116.2	FUT8-AS1	-6.13	1.91e-09	3.9e-07	-0.43	-0.27	Ischemic stroke;	chr14:65608609	chr14:65411170~65412690:-
THCA	cis	rs2735413	0.564	rs73580821	ENSG00000276007.1	RP11-358L22.3	6.13	1.91e-09	3.9e-07	0.29	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78076407	chr16:78123243~78124332:+
THCA	cis	rs4650994	0.524	rs2209170	ENSG00000273384.1	RP5-1098D14.1	-6.13	1.91e-09	3.9e-07	-0.34	-0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178638253	chr1:178651706~178652282:+
THCA	cis	rs728616	0.867	rs12781912	ENSG00000242600.5	MBL1P	6.13	1.91e-09	3.91e-07	0.34	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158372	chr10:79904898~79950336:+
THCA	cis	rs451417	1	rs236107	ENSG00000275632.1	RP5-967N21.11	6.13	1.91e-09	3.91e-07	0.31	0.27	Menopause (age at onset);	chr20:5985085	chr20:6000418~6000941:+
THCA	cis	rs3002142	0.658	rs1053316	ENSG00000272750.1	RP11-378J18.8	6.13	1.91e-09	3.91e-07	0.41	0.27	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:222658867~222661512:-
THCA	cis	rs965513	0.627	rs10124220	ENSG00000236130.1	PTCSC2	-6.13	1.91e-09	3.91e-07	-0.23	-0.27	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97820792	chr9:97805935~97810008:-
THCA	cis	rs8002861	0.935	rs7320988	ENSG00000274001.1	RP11-5G9.5	6.13	1.91e-09	3.92e-07	0.3	0.27	Leprosy;	chr13:43839387	chr13:43877715~43878163:-
THCA	cis	rs7809950	0.834	rs2712199	ENSG00000238832.1	snoU109	-6.13	1.91e-09	3.92e-07	-0.29	-0.27	Coronary artery disease;	chr7:107499794	chr7:107603363~107603507:+
THCA	cis	rs4664293	0.667	rs6432562	ENSG00000226266.5	AC009961.3	-6.13	1.91e-09	3.92e-07	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159791495	chr2:159670708~159712435:-
THCA	cis	rs4947019	0.614	rs117663805	ENSG00000260273.1	RP11-425D10.10	6.13	1.91e-09	3.92e-07	0.69	0.27	Hematological parameters;	chr6:109455712	chr6:109382795~109383666:+
THCA	cis	rs2243480	1	rs313814	ENSG00000228409.4	CCT6P1	6.13	1.91e-09	3.92e-07	0.31	0.27	Diabetic kidney disease;	chr7:66038306	chr7:65751142~65763354:+
THCA	cis	rs853679	1	rs1778508	ENSG00000226314.6	ZNF192P1	6.13	1.91e-09	3.92e-07	0.42	0.27	Depression;	chr6:28262103	chr6:28161781~28169594:+
THCA	cis	rs6908034	0.66	rs7746588	ENSG00000237404.1	RP3-471C18.2	-6.13	1.92e-09	3.92e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.66	rs7750716	ENSG00000237404.1	RP3-471C18.2	-6.13	1.92e-09	3.92e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19689825~19753113:-
THCA	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	6.13	1.92e-09	3.92e-07	0.33	0.27	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
THCA	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	6.13	1.92e-09	3.92e-07	0.33	0.27	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
THCA	cis	rs1949733	0.917	rs10461079	ENSG00000205959.3	RP11-689P11.2	6.13	1.92e-09	3.92e-07	0.23	0.27	Response to antineoplastic agents;	chr4:8390997	chr4:8482270~8512610:+
THCA	cis	rs7615952	0.599	rs6779141	ENSG00000250012.1	RP11-124N2.1	-6.12	1.92e-09	3.93e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:125991152	chr3:126084220~126095349:+
THCA	cis	rs11096990	0.892	rs11932351	ENSG00000249207.1	RP11-360F5.1	6.12	1.92e-09	3.93e-07	0.35	0.27	Cognitive function;	chr4:39229837	chr4:39112677~39126818:-
THCA	cis	rs792448	0.743	rs351401	ENSG00000226251.4	RP11-15I11.3	-6.12	1.92e-09	3.93e-07	-0.34	-0.27	White blood cell count (basophil);	chr1:212290450	chr1:212225278~212238977:-
THCA	cis	rs4713118	0.662	rs149961	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28047791	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28056708	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28056792	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28057501	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28057708	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28058299	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28058358	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28059910	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28060612	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28060704	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.35	0.27	Parkinson's disease;	chr6:28062059	chr6:28073316~28074233:+
THCA	cis	rs6866614	0.605	rs5029422	ENSG00000224431.1	AC063976.7	6.12	1.92e-09	3.93e-07	0.26	0.27	Perceived unattractiveness to mosquitoes;	chr5:132054921	chr5:132199456~132203487:+
THCA	cis	rs172166	0.694	rs536704	ENSG00000220721.1	OR1F12	6.12	1.92e-09	3.93e-07	0.34	0.27	Cardiac Troponin-T levels;	chr6:28124825	chr6:28073316~28074233:+
THCA	cis	rs11148252	0.967	rs11618716	ENSG00000235660.1	LINC00345	6.12	1.92e-09	3.93e-07	0.34	0.27	Lewy body disease;	chr13:52472701	chr13:52484161~52484680:-
THCA	cis	rs16958440	0.867	rs76558586	ENSG00000267800.1	RP11-49K24.5	-6.12	1.92e-09	3.93e-07	-0.62	-0.27	Sitting height ratio;	chr18:47211242	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.867	rs75228657	ENSG00000267800.1	RP11-49K24.5	-6.12	1.92e-09	3.93e-07	-0.62	-0.27	Sitting height ratio;	chr18:47214692	chr18:47137018~47137290:+
THCA	cis	rs4934494	0.813	rs34928397	ENSG00000232936.4	RP11-80H5.2	6.12	1.92e-09	3.93e-07	0.38	0.27	Red blood cell count;	chr10:89766842	chr10:89645282~89650667:+
THCA	cis	rs2243480	1	rs7794661	ENSG00000229886.1	RP5-1132H15.3	6.12	1.92e-09	3.94e-07	0.44	0.27	Diabetic kidney disease;	chr7:65924743	chr7:66025126~66031544:-
THCA	cis	rs270601	0.913	rs273916	ENSG00000263597.1	MIR3936	6.12	1.92e-09	3.94e-07	0.27	0.27	Acylcarnitine levels;	chr5:132324137	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.507	rs273915	ENSG00000263597.1	MIR3936	6.12	1.92e-09	3.94e-07	0.27	0.27	Breast cancer;	chr5:132324426	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.507	rs272892	ENSG00000263597.1	MIR3936	6.12	1.92e-09	3.94e-07	0.27	0.27	Breast cancer;	chr5:132328656	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.531	rs272888	ENSG00000263597.1	MIR3936	6.12	1.92e-09	3.94e-07	0.27	0.27	Breast cancer;	chr5:132329730	chr5:132365490~132365599:-
THCA	cis	rs728616	1	rs12768613	ENSG00000242600.5	MBL1P	6.12	1.93e-09	3.94e-07	0.33	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156810	chr10:79904898~79950336:+
THCA	cis	rs228614	0.51	rs223378	ENSG00000251288.2	RP11-10L12.2	-6.12	1.93e-09	3.94e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102751401~102752641:+
THCA	cis	rs17767294	0.612	rs12332927	ENSG00000280107.1	AL022393.9	-6.12	1.93e-09	3.94e-07	-0.42	-0.27	Parkinson's disease;	chr6:27987337	chr6:28170845~28172521:+
THCA	cis	rs17772222	1	rs60310240	ENSG00000258789.1	RP11-507K2.3	-6.12	1.93e-09	3.95e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88356365	chr14:88551597~88552493:+
THCA	cis	rs2735413	0.564	rs78898310	ENSG00000276007.1	RP11-358L22.3	6.12	1.93e-09	3.95e-07	0.29	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78081613	chr16:78123243~78124332:+
THCA	cis	rs6860806	0.603	rs112300250	ENSG00000224431.1	AC063976.7	6.12	1.93e-09	3.95e-07	0.23	0.27	Breast cancer;	chr5:132247599	chr5:132199456~132203487:+
THCA	cis	rs713477	1	rs12887846	ENSG00000258413.1	RP11-665C16.6	6.12	1.93e-09	3.95e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55444421	chr14:55262767~55272075:-
THCA	cis	rs713477	1	rs12886860	ENSG00000258413.1	RP11-665C16.6	6.12	1.93e-09	3.95e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55444432	chr14:55262767~55272075:-
THCA	cis	rs713477	1	rs28478984	ENSG00000258413.1	RP11-665C16.6	6.12	1.93e-09	3.95e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55444608	chr14:55262767~55272075:-
THCA	cis	rs713477	1	rs12888234	ENSG00000258413.1	RP11-665C16.6	6.12	1.93e-09	3.95e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55444634	chr14:55262767~55272075:-
THCA	cis	rs4925386	0.959	rs6121989	ENSG00000273619.1	RP5-908M14.9	6.12	1.93e-09	3.95e-07	0.22	0.27	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62386303~62386970:-
THCA	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-6.12	1.93e-09	3.96e-07	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
THCA	cis	rs7727544	0.684	rs2631363	ENSG00000237714.1	P4HA2-AS1	-6.12	1.93e-09	3.96e-07	-0.35	-0.27	Blood metabolite levels;	chr5:132371403	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.66	rs2631361	ENSG00000237714.1	P4HA2-AS1	-6.12	1.93e-09	3.96e-07	-0.35	-0.27	Blood metabolite levels;	chr5:132371688	chr5:132184876~132192808:+
THCA	cis	rs10875746	0.951	rs2228500	ENSG00000269514.1	RP11-370I10.12	-6.12	1.94e-09	3.96e-07	-0.27	-0.27	Longevity (90 years and older);	chr12:48132929	chr12:48198387~48202031:+
THCA	cis	rs1552244	0.882	rs67631672	ENSG00000180385.7	EMC3-AS1	6.12	1.94e-09	3.96e-07	0.28	0.27	Alzheimer's disease;	chr3:9963084	chr3:9986893~10006990:+
THCA	cis	rs6545883	0.965	rs3771261	ENSG00000271889.1	RP11-493E12.1	6.12	1.94e-09	3.97e-07	0.26	0.27	Tuberculosis;	chr2:61535026	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.718	rs3771260	ENSG00000271889.1	RP11-493E12.1	6.12	1.94e-09	3.97e-07	0.26	0.27	Tuberculosis;	chr2:61535249	chr2:61151433~61162105:-
THCA	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-6.12	1.94e-09	3.97e-07	-0.25	-0.27	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
THCA	cis	rs55823223	0.564	rs4572466	ENSG00000267801.1	RP11-552F3.9	6.12	1.94e-09	3.97e-07	0.35	0.27	Psoriasis;	chr17:75850233	chr17:75876372~75879546:+
THCA	cis	rs2029362	0.935	rs7949590	ENSG00000245573.6	BDNF-AS	6.12	1.94e-09	3.97e-07	0.22	0.27	Total body bone mineral density;	chr11:27602064	chr11:27506838~27698174:+
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000228409.4	CCT6P1	6.12	1.94e-09	3.97e-07	0.31	0.27	Diabetic kidney disease;	chr7:65996588	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1701750	ENSG00000228409.4	CCT6P1	6.12	1.94e-09	3.97e-07	0.31	0.27	Diabetic kidney disease;	chr7:66002158	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs1701758	ENSG00000228409.4	CCT6P1	6.12	1.94e-09	3.97e-07	0.31	0.27	Diabetic kidney disease;	chr7:66005214	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000228409.4	CCT6P1	6.12	1.94e-09	3.97e-07	0.31	0.27	Diabetic kidney disease;	chr7:66005945	chr7:65751142~65763354:+
THCA	cis	rs6142102	0.961	rs6120519	ENSG00000275784.1	RP5-1125A11.6	-6.12	1.94e-09	3.97e-07	-0.28	-0.27	Skin pigmentation;	chr20:34100307	chr20:33989480~33991818:-
THCA	cis	rs172166	0.694	rs2791332	ENSG00000220721.1	OR1F12	6.12	1.94e-09	3.97e-07	0.34	0.27	Cardiac Troponin-T levels;	chr6:28141010	chr6:28073316~28074233:+
THCA	cis	rs10875746	0.904	rs11168422	ENSG00000269514.1	RP11-370I10.12	6.12	1.94e-09	3.97e-07	0.28	0.27	Longevity (90 years and older);	chr12:48125722	chr12:48198387~48202031:+
THCA	cis	rs2018683	0.707	rs917219	ENSG00000228421.2	AC005013.5	6.12	1.94e-09	3.97e-07	0.31	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935726	chr7:28957667~28959345:+
THCA	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	6.12	1.94e-09	3.98e-07	0.37	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
THCA	cis	rs7015630	0.657	rs16900888	ENSG00000251136.7	RP11-37B2.1	6.12	1.94e-09	3.98e-07	0.31	0.27	Inflammatory bowel disease;Crohn's disease;	chr8:89825519	chr8:89609409~89757727:-
THCA	cis	rs7044106	0.791	rs10984995	ENSG00000270917.1	RP11-27I1.6	-6.12	1.95e-09	3.98e-07	-0.39	-0.27	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120812475~120812845:-
THCA	cis	rs950169	0.58	rs17598114	ENSG00000259295.5	CSPG4P12	6.12	1.95e-09	3.98e-07	0.42	0.27	Schizophrenia;	chr15:84628086	chr15:85191438~85213905:+
THCA	cis	rs950169	0.58	rs11634322	ENSG00000259295.5	CSPG4P12	6.12	1.95e-09	3.98e-07	0.42	0.27	Schizophrenia;	chr15:84628978	chr15:85191438~85213905:+
THCA	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	6.12	1.95e-09	3.98e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
THCA	cis	rs5742933	0.817	rs6942	ENSG00000253559.1	OSGEPL1-AS1	6.12	1.95e-09	3.98e-07	0.3	0.27	Ferritin levels;	chr2:189771685	chr2:189762704~189765556:+
THCA	cis	rs73607972	0.935	rs73603987	ENSG00000275191.1	RP11-36I17.2	-6.12	1.95e-09	3.99e-07	-0.41	-0.27	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577714	chr16:53628256~53628816:-
THCA	cis	rs4713118	0.513	rs149989	ENSG00000280107.1	AL022393.9	-6.12	1.95e-09	3.99e-07	-0.29	-0.27	Parkinson's disease;	chr6:28030406	chr6:28170845~28172521:+
THCA	cis	rs9494145	0.68	rs9402686	ENSG00000232876.1	CTA-212D2.2	-6.12	1.95e-09	3.99e-07	-0.38	-0.27	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106679	chr6:135055033~135060550:+
THCA	cis	rs8062405	0.755	rs62031607	ENSG00000278665.1	RP11-666O2.4	6.12	1.96e-09	4e-07	0.31	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28599241~28601881:-
THCA	cis	rs10411161	0.63	rs76234335	ENSG00000269483.1	AC006272.1	6.12	1.96e-09	4e-07	0.56	0.27	Breast cancer;	chr19:51954215	chr19:51839924~51843324:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-6.12	1.96e-09	4e-07	-0.31	-0.27	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
THCA	cis	rs60678552	0.642	rs6568928	ENSG00000233558.1	RP3-486I3.4	6.12	1.96e-09	4e-07	0.4	0.27	Heschl's gyrus morphology;	chr6:116306096	chr6:116258493~116259115:-
THCA	cis	rs228614	0.51	rs223397	ENSG00000230069.3	LRRC37A15P	-6.12	1.96e-09	4.01e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102727274~102730721:-
THCA	cis	rs9813712	0.953	rs9871734	ENSG00000249846.5	RP11-77P16.4	6.12	1.96e-09	4.01e-07	0.32	0.27	Response to amphetamines;	chr3:130240756	chr3:130112550~130120579:+
THCA	cis	rs228614	0.536	rs223477	ENSG00000230069.3	LRRC37A15P	-6.12	1.96e-09	4.01e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102727274~102730721:-
THCA	cis	rs7615952	1	rs7616044	ENSG00000241288.6	RP11-379B18.5	-6.12	1.96e-09	4.01e-07	-0.34	-0.27	Blood pressure (smoking interaction);	chr3:125930511	chr3:125827238~125916384:-
THCA	cis	rs1859596	1	rs7791832	ENSG00000234456.6	MAGI2-AS3	6.12	1.96e-09	4.01e-07	0.26	0.27	Reading or mathematical ability;	chr7:79459270	chr7:79452877~79471208:+
THCA	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	6.12	1.96e-09	4.01e-07	0.3	0.27	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
THCA	cis	rs1125355	0.655	rs1515924	ENSG00000251491.2	OR7E28P	6.12	1.96e-09	4.02e-07	0.43	0.27	Alzheimer's disease in APOE e4+ carriers;	chr2:158792828	chr2:158862311~158863285:+
THCA	cis	rs897984	0.542	rs4468641	ENSG00000279196.1	RP11-1072A3.3	6.12	1.96e-09	4.02e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31085555	chr16:30984630~30988270:-
THCA	cis	rs9813712	1	rs57804141	ENSG00000249846.5	RP11-77P16.4	6.12	1.96e-09	4.02e-07	0.32	0.27	Response to amphetamines;	chr3:130243669	chr3:130112550~130120579:+
THCA	cis	rs3213958	0.574	rs73138030	ENSG00000249274.1	PDLIM1P4	-6.12	1.96e-09	4.02e-07	-0.36	-0.27	Blood protein levels;	chr3:98855209	chr3:98782188~98783193:+
THCA	cis	rs467650	0.5	rs13160853	ENSG00000246763.5	RGMB-AS1	-6.12	1.97e-09	4.02e-07	-0.26	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr5:98585193	chr5:98769618~98773469:-
THCA	cis	rs2243480	1	rs7778911	ENSG00000232546.1	RP11-458F8.1	6.12	1.97e-09	4.02e-07	0.36	0.27	Diabetic kidney disease;	chr7:66229519	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1979823	ENSG00000232546.1	RP11-458F8.1	6.12	1.97e-09	4.02e-07	0.36	0.27	Diabetic kidney disease;	chr7:66239626	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6964245	ENSG00000232546.1	RP11-458F8.1	6.12	1.97e-09	4.02e-07	0.36	0.27	Diabetic kidney disease;	chr7:66253730	chr7:66848496~66858136:+
THCA	cis	rs6908034	0.607	rs73376657	ENSG00000237404.1	RP3-471C18.2	-6.12	1.97e-09	4.02e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805729	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs74573060	ENSG00000237404.1	RP3-471C18.2	-6.12	1.97e-09	4.02e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805801	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs113894708	ENSG00000237404.1	RP3-471C18.2	-6.12	1.97e-09	4.02e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805835	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs62404179	ENSG00000237404.1	RP3-471C18.2	-6.12	1.97e-09	4.02e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806041	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.546	rs73376662	ENSG00000237404.1	RP3-471C18.2	-6.12	1.97e-09	4.02e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806109	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs12529148	ENSG00000237404.1	RP3-471C18.2	-6.12	1.97e-09	4.02e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806566	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs112659166	ENSG00000237404.1	RP3-471C18.2	-6.12	1.97e-09	4.02e-07	-0.54	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807178	chr6:19689825~19753113:-
THCA	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	6.12	1.97e-09	4.02e-07	0.39	0.27	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	6.12	1.97e-09	4.02e-07	0.39	0.27	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs495880	ENSG00000249839.1	AC011330.5	6.12	1.97e-09	4.02e-07	0.39	0.27	Lung cancer;	chr15:43855067	chr15:43663654~43684339:-
THCA	cis	rs74233809	0.901	rs11191416	ENSG00000213277.3	MARCKSL1P1	-6.12	1.97e-09	4.02e-07	-0.43	-0.27	Birth weight;	chr10:102845159	chr10:103175554~103176094:+
THCA	cis	rs9380516	0.74	rs10947558	ENSG00000228559.1	RP3-340B19.3	-6.12	1.97e-09	4.02e-07	-0.39	-0.27	Hepatitis C induced liver fibrosis;	chr6:35559660	chr6:35544632~35545669:+
THCA	cis	rs11696845	0.649	rs6031782	ENSG00000276223.1	RP4-781B1.5	6.12	1.97e-09	4.03e-07	0.32	0.27	Obesity-related traits;	chr20:44755191	chr20:44746642~44747201:+
THCA	cis	rs227275	0.586	rs223448	ENSG00000230069.3	LRRC37A15P	-6.12	1.97e-09	4.03e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102727274~102730721:-
THCA	cis	rs2243480	1	rs313832	ENSG00000229886.1	RP5-1132H15.3	6.12	1.97e-09	4.03e-07	0.43	0.27	Diabetic kidney disease;	chr7:66085904	chr7:66025126~66031544:-
THCA	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	6.12	1.97e-09	4.03e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
THCA	cis	rs5758659	0.714	rs5751220	ENSG00000270083.1	RP1-257I20.14	-6.12	1.97e-09	4.03e-07	-0.29	-0.27	Cognitive function;	chr22:42120201	chr22:42089630~42090028:-
THCA	cis	rs9402743	0.717	rs6930773	ENSG00000231028.7	LINC00271	-6.12	1.98e-09	4.04e-07	-0.21	-0.27	Systemic lupus erythematosus;	chr6:135694363	chr6:135497801~135716055:+
THCA	cis	rs736801	0.78	rs12521868	ENSG00000233006.5	AC034220.3	-6.12	1.98e-09	4.04e-07	-0.22	-0.27	Mosquito bite size;Breast cancer;	chr5:132448701	chr5:132311285~132369916:-
THCA	cis	rs12908161	0.959	rs1051168	ENSG00000259295.5	CSPG4P12	6.12	1.98e-09	4.04e-07	0.42	0.27	Schizophrenia;	chr15:84657289	chr15:85191438~85213905:+
THCA	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-6.12	1.98e-09	4.04e-07	-0.31	-0.27	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
THCA	cis	rs228614	0.543	rs223330	ENSG00000251288.2	RP11-10L12.2	-6.12	1.98e-09	4.04e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223329	ENSG00000251288.2	RP11-10L12.2	-6.12	1.98e-09	4.04e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102751401~102752641:+
THCA	cis	rs228614	0.536	rs223327	ENSG00000251288.2	RP11-10L12.2	-6.12	1.98e-09	4.04e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223326	ENSG00000251288.2	RP11-10L12.2	-6.12	1.98e-09	4.04e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223324	ENSG00000251288.2	RP11-10L12.2	-6.12	1.98e-09	4.04e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102751401~102752641:+
THCA	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	6.12	1.98e-09	4.04e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	6.12	1.98e-09	4.04e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
THCA	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-6.12	1.98e-09	4.04e-07	-0.31	-0.27	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-6.12	1.98e-09	4.04e-07	-0.31	-0.27	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
THCA	cis	rs17772222	0.917	rs12588535	ENSG00000258789.1	RP11-507K2.3	-6.12	1.98e-09	4.05e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88781900	chr14:88551597~88552493:+
THCA	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	6.12	1.98e-09	4.05e-07	0.5	0.27	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	6.12	1.98e-09	4.05e-07	0.5	0.27	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	6.12	1.98e-09	4.05e-07	0.5	0.27	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
THCA	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	6.12	1.98e-09	4.05e-07	0.5	0.27	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
THCA	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	6.12	1.98e-09	4.05e-07	0.44	0.27	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
THCA	cis	rs6740322	0.895	rs10166994	ENSG00000234936.1	AC010883.5	6.12	1.98e-09	4.05e-07	0.29	0.27	Coronary artery disease;	chr2:43330838	chr2:43229573~43233394:+
THCA	cis	rs7809950	0.954	rs62482543	ENSG00000238832.1	snoU109	-6.12	1.98e-09	4.05e-07	-0.29	-0.27	Coronary artery disease;	chr7:107440211	chr7:107603363~107603507:+
THCA	cis	rs7829975	0.514	rs2979139	ENSG00000254153.1	CTA-398F10.2	-6.12	1.98e-09	4.05e-07	-0.28	-0.27	Mood instability;	chr8:8410803	chr8:8456909~8461337:-
THCA	cis	rs950169	0.58	rs11635597	ENSG00000259295.5	CSPG4P12	6.12	1.98e-09	4.05e-07	0.42	0.27	Schizophrenia;	chr15:84622468	chr15:85191438~85213905:+
THCA	cis	rs9475752	1	rs71564866	ENSG00000231441.1	RP11-472M19.2	6.12	1.99e-09	4.06e-07	0.35	0.27	Menarche (age at onset);	chr6:56906409	chr6:56844002~56864078:+
THCA	cis	rs9475752	1	rs17685143	ENSG00000231441.1	RP11-472M19.2	6.12	1.99e-09	4.06e-07	0.35	0.27	Menarche (age at onset);	chr6:56909990	chr6:56844002~56864078:+
THCA	cis	rs7615952	0.641	rs7618515	ENSG00000250012.1	RP11-124N2.1	-6.12	1.99e-09	4.06e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126071735	chr3:126084220~126095349:+
THCA	cis	rs253959	0.672	rs4920903	ENSG00000272265.1	CTD-2287O16.4	6.12	1.99e-09	4.06e-07	0.29	0.27	Bipolar disorder and schizophrenia;	chr5:116085892	chr5:116078110~116078570:-
THCA	cis	rs2364403	1	rs12080846	ENSG00000225855.5	RUSC1-AS1	6.12	1.99e-09	4.07e-07	0.2	0.27	Amyotrophic lateral sclerosis (age of onset);	chr1:155959910	chr1:155316863~155324176:-
THCA	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	6.12	1.99e-09	4.07e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
THCA	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	6.12	1.99e-09	4.07e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
THCA	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	6.12	1.99e-09	4.07e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
THCA	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	6.12	1.99e-09	4.07e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
THCA	cis	rs2880765	0.566	rs17553249	ENSG00000259630.2	CTD-2262B20.1	-6.12	1.99e-09	4.07e-07	-0.32	-0.27	Coronary artery disease;	chr15:85463463	chr15:85415228~85415633:+
THCA	cis	rs6928977	0.86	rs3827780	ENSG00000231028.7	LINC00271	6.12	1.99e-09	4.07e-07	0.22	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135388622	chr6:135497801~135716055:+
THCA	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-6.12	2e-09	4.08e-07	-0.16	-0.27	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
THCA	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-6.12	2e-09	4.08e-07	-0.29	-0.27	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
THCA	cis	rs13113518	0.812	rs2412648	ENSG00000273257.1	RP11-177J6.1	6.12	2e-09	4.08e-07	0.37	0.27	Height;	chr4:55454900	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs12512737	ENSG00000273257.1	RP11-177J6.1	6.12	2e-09	4.08e-07	0.37	0.27	Height;	chr4:55454938	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.812	rs13125984	ENSG00000273257.1	RP11-177J6.1	6.12	2e-09	4.08e-07	0.37	0.27	Height;	chr4:55455102	chr4:55387949~55388271:+
THCA	cis	rs2018683	0.523	rs1499224	ENSG00000228421.2	AC005013.5	6.12	2e-09	4.08e-07	0.33	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28989852	chr7:28957667~28959345:+
THCA	cis	rs6142102	0.961	rs4911408	ENSG00000275784.1	RP5-1125A11.6	-6.12	2e-09	4.08e-07	-0.29	-0.27	Skin pigmentation;	chr20:34112760	chr20:33989480~33991818:-
THCA	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	6.12	2e-09	4.08e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
THCA	cis	rs287982	0.611	rs80268780	ENSG00000269973.1	RP11-95D17.1	-6.12	2e-09	4.08e-07	-0.24	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9840948	chr2:9936360~9939590:+
THCA	cis	rs4713118	0.513	rs149944	ENSG00000280107.1	AL022393.9	-6.12	2e-09	4.08e-07	-0.29	-0.27	Parkinson's disease;	chr6:28035040	chr6:28170845~28172521:+
THCA	cis	rs831571	0.695	rs73120926	ENSG00000280620.1	SCAANT1	6.12	2e-09	4.08e-07	0.44	0.27	Type 2 diabetes;	chr3:64051274	chr3:63911518~63911772:-
THCA	cis	rs9649465	0.934	rs718781	ENSG00000272686.1	RP11-390E23.6	6.12	2e-09	4.08e-07	0.18	0.27	Migraine;	chr7:123673519	chr7:123749068~123751166:+
THCA	cis	rs227275	0.527	rs223338	ENSG00000251288.2	RP11-10L12.2	-6.12	2e-09	4.08e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102751401~102752641:+
THCA	cis	rs17772222	0.71	rs1028455	ENSG00000258983.2	RP11-507K2.2	6.12	2e-09	4.08e-07	0.31	0.27	Coronary artery calcification;	chr14:88363631	chr14:88499334~88515502:+
THCA	cis	rs9880211	1	rs13071220	ENSG00000273486.1	RP11-731C17.2	6.12	2e-09	4.09e-07	0.28	0.27	Height;Body mass index;	chr3:136595277	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.904	rs9857833	ENSG00000273486.1	RP11-731C17.2	6.12	2e-09	4.09e-07	0.28	0.27	Height;Body mass index;	chr3:136685625	chr3:136837338~136839021:-
THCA	cis	rs10916248	0.511	rs10916489	ENSG00000232628.4	RP11-365O16.3	-6.12	2e-09	4.09e-07	-0.39	-0.27	QT interval (drug interaction);	chr1:224215164	chr1:224208747~224213279:-
THCA	cis	rs228614	0.51	rs223435	ENSG00000230069.3	LRRC37A15P	-6.12	2e-09	4.09e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223434	ENSG00000230069.3	LRRC37A15P	-6.12	2e-09	4.09e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102727274~102730721:-
THCA	cis	rs853679	0.517	rs4713145	ENSG00000261839.1	RP1-265C24.8	6.12	2.01e-09	4.09e-07	0.33	0.27	Depression;	chr6:28139049	chr6:28136849~28139678:+
THCA	cis	rs712022	1	rs2286809	ENSG00000246225.5	RP11-17A1.3	6.12	2.01e-09	4.1e-07	0.35	0.27	Dialysis-related mortality;	chr11:22829909	chr11:22829380~22945393:+
THCA	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-6.12	2.01e-09	4.1e-07	-0.16	-0.27	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
THCA	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	6.12	2.01e-09	4.1e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000232546.1	RP11-458F8.1	-6.12	2.01e-09	4.11e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65988305	chr7:66848496~66858136:+
THCA	cis	rs2412819	0.571	rs678084	ENSG00000249839.1	AC011330.5	6.12	2.01e-09	4.11e-07	0.39	0.27	Lung cancer;	chr15:43828361	chr15:43663654~43684339:-
THCA	cis	rs8014252	0.803	rs10483830	ENSG00000259158.2	ADAM20P1	-6.12	2.01e-09	4.11e-07	-0.35	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70587761	chr14:70468881~70483756:-
THCA	cis	rs9649465	0.967	rs13239184	ENSG00000272686.1	RP11-390E23.6	6.12	2.02e-09	4.11e-07	0.18	0.27	Migraine;	chr7:123674564	chr7:123749068~123751166:+
THCA	cis	rs6430553	0.929	rs6430547	ENSG00000224043.6	CCNT2-AS1	6.12	2.02e-09	4.11e-07	0.27	0.27	Blood metabolite levels;	chr2:134854852	chr2:134735464~134918710:-
THCA	cis	rs2253762	0.54	rs12249581	ENSG00000276742.1	RP11-500G22.4	6.12	2.02e-09	4.11e-07	0.4	0.27	Breast cancer;	chr10:122013486	chr10:121956782~121957098:+
THCA	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	6.12	2.02e-09	4.11e-07	0.38	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
THCA	cis	rs6496044	0.568	rs3743321	ENSG00000259295.5	CSPG4P12	6.12	2.02e-09	4.12e-07	0.34	0.27	Interstitial lung disease;	chr15:85521737	chr15:85191438~85213905:+
THCA	cis	rs2439831	0.867	rs12443102	ENSG00000166763.7	STRCP1	6.12	2.02e-09	4.12e-07	0.38	0.27	Lung cancer in ever smokers;	chr15:43639905	chr15:43699488~43718184:-
THCA	cis	rs7044106	0.791	rs7036196	ENSG00000270917.1	RP11-27I1.6	-6.12	2.02e-09	4.12e-07	-0.38	-0.27	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120812475~120812845:-
THCA	cis	rs11089937	0.626	rs5757056	ENSG00000211639.2	IGLV4-60	6.12	2.02e-09	4.13e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22162199~22162681:+
THCA	cis	rs2412819	0.545	rs654276	ENSG00000205771.5	CATSPER2P1	6.12	2.02e-09	4.13e-07	0.38	0.27	Lung cancer;	chr15:43798656	chr15:43726918~43747094:-
THCA	cis	rs763567	0.933	rs531007	ENSG00000271811.1	RP1-79C4.4	6.12	2.03e-09	4.13e-07	0.31	0.27	Tonsillectomy;	chr1:170649241	chr1:170667381~170669425:+
THCA	cis	rs847577	0.588	rs6946915	ENSG00000272950.1	RP11-307C18.1	6.12	2.03e-09	4.13e-07	0.33	0.27	Breast cancer;	chr7:98082028	chr7:98322853~98323430:+
THCA	cis	rs17772222	0.917	rs61982733	ENSG00000258789.1	RP11-507K2.3	-6.12	2.03e-09	4.14e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88776244	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs2145120	ENSG00000258789.1	RP11-507K2.3	-6.12	2.03e-09	4.14e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88777699	chr14:88551597~88552493:+
THCA	cis	rs801193	0.742	rs9969300	ENSG00000232546.1	RP11-458F8.1	6.12	2.03e-09	4.14e-07	0.22	0.27	Aortic root size;	chr7:66316659	chr7:66848496~66858136:+
THCA	cis	rs227275	0.556	rs223426	ENSG00000251288.2	RP11-10L12.2	-6.12	2.03e-09	4.14e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223425	ENSG00000251288.2	RP11-10L12.2	-6.12	2.03e-09	4.14e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102751401~102752641:+
THCA	cis	rs228614	0.536	rs223418	ENSG00000251288.2	RP11-10L12.2	-6.12	2.03e-09	4.14e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102751401~102752641:+
THCA	cis	rs9926296	0.682	rs258328	ENSG00000274627.1	RP11-104N10.2	6.12	2.03e-09	4.14e-07	0.28	0.27	Vitiligo;	chr16:89663906	chr16:89516797~89522217:+
THCA	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-6.12	2.03e-09	4.14e-07	-0.35	-0.27	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
THCA	cis	rs17158807	0.555	rs11636742	ENSG00000274128.1	RP11-342A23.2	6.11	2.03e-09	4.15e-07	0.65	0.27	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr15:83811484	chr15:83962176~83962583:+
THCA	cis	rs274567	0.55	rs272885	ENSG00000263597.1	MIR3936	6.11	2.03e-09	4.15e-07	0.27	0.27	Blood metabolite levels;	chr5:132332043	chr5:132365490~132365599:-
THCA	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-6.11	2.03e-09	4.15e-07	-0.3	-0.27	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
THCA	cis	rs253959	0.629	rs10054121	ENSG00000272265.1	CTD-2287O16.4	6.11	2.03e-09	4.15e-07	0.29	0.27	Bipolar disorder and schizophrenia;	chr5:116084271	chr5:116078110~116078570:-
THCA	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	6.11	2.04e-09	4.15e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
THCA	cis	rs642803	1	rs642803	ENSG00000214659.4	KRT8P26	-6.11	2.04e-09	4.15e-07	-0.23	-0.27	Urate levels;	chr11:65793149	chr11:65726939~65728214:+
THCA	cis	rs2439831	0.867	rs2260160	ENSG00000166763.7	STRCP1	6.11	2.04e-09	4.15e-07	0.37	0.27	Lung cancer in ever smokers;	chr15:43603445	chr15:43699488~43718184:-
THCA	cis	rs7208859	0.673	rs12103759	ENSG00000263603.1	CTD-2349P21.5	-6.11	2.04e-09	4.15e-07	-0.5	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.623	rs59029591	ENSG00000263603.1	CTD-2349P21.5	-6.11	2.04e-09	4.15e-07	-0.5	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs73265633	ENSG00000263603.1	CTD-2349P21.5	-6.11	2.04e-09	4.15e-07	-0.5	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9913782	ENSG00000263603.1	CTD-2349P21.5	-6.11	2.04e-09	4.15e-07	-0.5	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.673	rs9911989	ENSG00000263603.1	CTD-2349P21.5	6.11	2.04e-09	4.15e-07	0.5	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30729469~30731202:+
THCA	cis	rs2243480	1	rs383402	ENSG00000229886.1	RP5-1132H15.3	-6.11	2.04e-09	4.16e-07	-0.43	-0.27	Diabetic kidney disease;	chr7:66121666	chr7:66025126~66031544:-
THCA	cis	rs131777	0.577	rs131748	ENSG00000272940.1	CTA-384D8.33	-6.11	2.04e-09	4.16e-07	-0.39	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50597152~50597599:+
THCA	cis	rs5742933	0.744	rs13002216	ENSG00000253559.1	OSGEPL1-AS1	6.11	2.04e-09	4.16e-07	0.3	0.27	Ferritin levels;	chr2:189746358	chr2:189762704~189765556:+
THCA	cis	rs6860806	0.507	rs2631371	ENSG00000263597.1	MIR3936	-6.11	2.04e-09	4.16e-07	-0.27	-0.27	Breast cancer;	chr5:132367999	chr5:132365490~132365599:-
THCA	cis	rs2562456	0.917	rs6511253	ENSG00000268081.1	RP11-678G14.2	-6.11	2.04e-09	4.16e-07	-0.39	-0.27	Pain;	chr19:21495996	chr19:21554640~21569237:-
THCA	cis	rs10875746	0.903	rs4760681	ENSG00000269514.1	RP11-370I10.12	6.11	2.04e-09	4.17e-07	0.27	0.27	Longevity (90 years and older);	chr12:48111447	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs11168418	ENSG00000269514.1	RP11-370I10.12	6.11	2.04e-09	4.17e-07	0.27	0.27	Longevity (90 years and older);	chr12:48121971	chr12:48198387~48202031:+
THCA	cis	rs7044106	0.762	rs10760107	ENSG00000270917.1	RP11-27I1.6	-6.11	2.05e-09	4.17e-07	-0.38	-0.27	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120812475~120812845:-
THCA	cis	rs5742933	0.762	rs2033746	ENSG00000253559.1	OSGEPL1-AS1	6.11	2.05e-09	4.17e-07	0.3	0.27	Ferritin levels;	chr2:189734726	chr2:189762704~189765556:+
THCA	cis	rs9649465	0.967	rs7809453	ENSG00000272686.1	RP11-390E23.6	6.11	2.05e-09	4.17e-07	0.18	0.27	Migraine;	chr7:123661886	chr7:123749068~123751166:+
THCA	cis	rs227275	0.555	rs223403	ENSG00000251288.2	RP11-10L12.2	-6.11	2.05e-09	4.17e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102751401~102752641:+
THCA	cis	rs227275	0.555	rs223402	ENSG00000251288.2	RP11-10L12.2	-6.11	2.05e-09	4.17e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102751401~102752641:+
THCA	cis	rs4950322	0.542	rs1932977	ENSG00000278811.3	LINC00624	6.11	2.05e-09	4.17e-07	0.31	0.27	Protein quantitative trait loci;	chr1:147217371	chr1:147258885~147517875:-
THCA	cis	rs9649465	0.967	rs2286831	ENSG00000272686.1	RP11-390E23.6	6.11	2.05e-09	4.17e-07	0.18	0.27	Migraine;	chr7:123663423	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.935	rs3815458	ENSG00000272686.1	RP11-390E23.6	6.11	2.05e-09	4.17e-07	0.18	0.27	Migraine;	chr7:123664269	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs10224062	ENSG00000272686.1	RP11-390E23.6	6.11	2.05e-09	4.17e-07	0.18	0.27	Migraine;	chr7:123664555	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs1008539	ENSG00000272686.1	RP11-390E23.6	6.11	2.05e-09	4.17e-07	0.18	0.27	Migraine;	chr7:123665464	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs1005568	ENSG00000272686.1	RP11-390E23.6	6.11	2.05e-09	4.17e-07	0.18	0.27	Migraine;	chr7:123666416	chr7:123749068~123751166:+
THCA	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	6.11	2.05e-09	4.18e-07	0.35	0.27	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
THCA	cis	rs6545883	0.965	rs2305156	ENSG00000271889.1	RP11-493E12.1	6.11	2.05e-09	4.18e-07	0.26	0.27	Tuberculosis;	chr2:61502133	chr2:61151433~61162105:-
THCA	cis	rs10129255	0.957	rs1056705	ENSG00000211974.3	IGHV2-70	6.11	2.05e-09	4.18e-07	0.21	0.27	Kawasaki disease;	chr14:106714323	chr14:106723574~106724093:-
THCA	cis	rs7833787	1	rs6586778	ENSG00000278886.1	RP11-108A14.1	-6.11	2.06e-09	4.19e-07	-0.35	-0.27	Obesity-related traits;	chr8:18848660	chr8:18864681~18865247:-
THCA	cis	rs4664293	0.625	rs4665102	ENSG00000226266.5	AC009961.3	6.11	2.06e-09	4.19e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159666076	chr2:159670708~159712435:-
THCA	cis	rs763121	0.962	rs909564	ENSG00000235209.1	CTA-150C2.13	6.11	2.06e-09	4.19e-07	0.35	0.27	Menopause (age at onset);	chr22:38730503	chr22:38921227~38924708:+
THCA	cis	rs792448	0.743	rs11119904	ENSG00000226251.4	RP11-15I11.3	-6.11	2.06e-09	4.2e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212293262	chr1:212225278~212238977:-
THCA	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	6.11	2.06e-09	4.2e-07	0.33	0.27	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
THCA	cis	rs17772222	0.917	rs57889459	ENSG00000258789.1	RP11-507K2.3	-6.11	2.06e-09	4.2e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88770820	chr14:88551597~88552493:+
THCA	cis	rs17301013	0.507	rs116545832	ENSG00000227373.4	RP11-160H22.5	6.11	2.06e-09	4.2e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174438725	chr1:174115300~174160004:-
THCA	cis	rs9813712	1	rs9864582	ENSG00000249846.5	RP11-77P16.4	6.11	2.06e-09	4.2e-07	0.32	0.27	Response to amphetamines;	chr3:130251619	chr3:130112550~130120579:+
THCA	cis	rs2299587	0.56	rs391299	ENSG00000253671.1	RP11-806O11.1	-6.11	2.06e-09	4.21e-07	-0.33	-0.27	Economic and political preferences;	chr8:17921413	chr8:17808941~17820868:+
THCA	cis	rs6545883	0.965	rs2305155	ENSG00000271889.1	RP11-493E12.1	6.11	2.06e-09	4.21e-07	0.26	0.27	Tuberculosis;	chr2:61502123	chr2:61151433~61162105:-
THCA	cis	rs7085104	0.7	rs7096183	ENSG00000236937.2	PTGES3P4	6.11	2.06e-09	4.21e-07	0.35	0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102845595~102845950:+
THCA	cis	rs2145598	0.802	rs2147610	ENSG00000279636.2	LINC00216	-6.11	2.07e-09	4.21e-07	-0.27	-0.27	Coronary artery disease;	chr14:58380269	chr14:58288033~58289158:+
THCA	cis	rs77972916	0.609	rs72790903	ENSG00000234936.1	AC010883.5	6.11	2.07e-09	4.21e-07	0.35	0.27	Granulocyte percentage of myeloid white cells;	chr2:43334846	chr2:43229573~43233394:+
THCA	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	6.11	2.07e-09	4.21e-07	0.3	0.27	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
THCA	cis	rs10208649	0.536	rs6717642	ENSG00000272156.1	RP11-477N3.1	6.11	2.07e-09	4.21e-07	0.38	0.27	Body mass index;	chr2:53729961	chr2:54082554~54085066:+
THCA	cis	rs7202877	0.61	rs11646418	ENSG00000261783.1	RP11-252K23.2	-6.11	2.07e-09	4.22e-07	-0.5	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75333687	chr16:75379818~75381260:-
THCA	cis	rs6928977	0.86	rs2746433	ENSG00000231028.7	LINC00271	6.11	2.07e-09	4.22e-07	0.22	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135379567	chr6:135497801~135716055:+
THCA	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-6.11	2.07e-09	4.22e-07	-0.29	-0.27	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
THCA	cis	rs7746199	0.736	rs72845070	ENSG00000280107.1	AL022393.9	-6.11	2.07e-09	4.23e-07	-0.58	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28170845~28172521:+
THCA	cis	rs1552244	0.572	rs41464050	ENSG00000232901.1	CYCSP10	6.11	2.08e-09	4.23e-07	0.41	0.27	Alzheimer's disease;	chr3:10116709	chr3:10000647~10000940:-
THCA	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	6.11	2.08e-09	4.23e-07	0.28	0.27	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
THCA	cis	rs2179367	0.568	rs9498358	ENSG00000231760.4	RP11-350J20.5	6.11	2.08e-09	4.23e-07	0.43	0.27	Dupuytren's disease;	chr6:149458529	chr6:149796151~149826294:-
THCA	cis	rs9649465	1	rs4588795	ENSG00000272686.1	RP11-390E23.6	-6.11	2.08e-09	4.23e-07	-0.18	-0.27	Migraine;	chr7:123709870	chr7:123749068~123751166:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	6.11	2.08e-09	4.23e-07	0.32	0.27	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
THCA	cis	rs7246657	0.722	rs2909098	ENSG00000267422.1	CTD-2554C21.1	6.11	2.08e-09	4.23e-07	0.31	0.27	Coronary artery calcification;	chr19:37713347	chr19:37779686~37792865:+
THCA	cis	rs451417	1	rs236124	ENSG00000275632.1	RP5-967N21.11	6.11	2.08e-09	4.24e-07	0.31	0.27	Menopause (age at onset);	chr20:5995333	chr20:6000418~6000941:+
THCA	cis	rs9287719	0.649	rs12617968	ENSG00000234818.1	AC092687.5	6.11	2.09e-09	4.25e-07	0.58	0.27	Prostate cancer;	chr2:10581819	chr2:10589166~10604830:+
THCA	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-6.11	2.09e-09	4.25e-07	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
THCA	cis	rs6430553	0.929	rs3819121	ENSG00000224043.6	CCNT2-AS1	-6.11	2.09e-09	4.25e-07	-0.27	-0.27	Blood metabolite levels;	chr2:134865290	chr2:134735464~134918710:-
THCA	cis	rs7129556	0.859	rs11237215	ENSG00000254691.1	RP11-91P24.5	6.11	2.09e-09	4.25e-07	0.36	0.27	Weight loss (gastric bypass surgery);	chr11:77536470	chr11:77850604~77851511:+
THCA	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	6.11	2.09e-09	4.25e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
THCA	cis	rs1859596	1	rs7802883	ENSG00000234456.6	MAGI2-AS3	6.11	2.09e-09	4.25e-07	0.27	0.27	Reading or mathematical ability;	chr7:79455947	chr7:79452877~79471208:+
THCA	cis	rs2018683	0.509	rs221192	ENSG00000228421.2	AC005013.5	-6.11	2.09e-09	4.26e-07	-0.36	-0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28975293	chr7:28957667~28959345:+
THCA	cis	rs961831	0.539	rs2671622	ENSG00000234840.1	LINC01239	6.11	2.09e-09	4.26e-07	0.5	0.27	Personality dimensions;	chr9:22446752	chr9:22646200~22824213:+
THCA	cis	rs4713118	0.824	rs2179095	ENSG00000280107.1	AL022393.9	6.11	2.09e-09	4.26e-07	0.32	0.27	Parkinson's disease;	chr6:27783079	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.866	rs2179094	ENSG00000280107.1	AL022393.9	-6.11	2.09e-09	4.26e-07	-0.32	-0.27	Parkinson's disease;	chr6:27774046	chr6:28170845~28172521:+
THCA	cis	rs11096990	0.892	rs7680520	ENSG00000249207.1	RP11-360F5.1	6.11	2.09e-09	4.26e-07	0.35	0.27	Cognitive function;	chr4:39219013	chr4:39112677~39126818:-
THCA	cis	rs28530618	0.87	rs6058790	ENSG00000175730.8	BAK1P1	6.11	2.09e-09	4.26e-07	0.3	0.27	Birth weight;	chr20:32659515	chr20:32690180~32690815:-
THCA	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	6.11	2.09e-09	4.26e-07	0.35	0.27	Depression;	chr6:28386473	chr6:28176188~28176674:+
THCA	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	6.11	2.09e-09	4.26e-07	0.35	0.27	Depression;	chr6:28391932	chr6:28176188~28176674:+
THCA	cis	rs3764400	0.567	rs12936369	ENSG00000278765.1	RP5-890E16.5	6.11	2.09e-09	4.26e-07	0.48	0.27	Body mass index;	chr17:48193334	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs36071506	ENSG00000278765.1	RP5-890E16.5	6.11	2.09e-09	4.26e-07	0.48	0.27	Body mass index;	chr17:48202410	chr17:48066704~48067293:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	6.11	2.1e-09	4.27e-07	0.31	0.27	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
THCA	cis	rs7554547	0.818	rs4993566	ENSG00000201801.1	RNU5E-4P	6.11	2.1e-09	4.27e-07	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr1:11909937	chr1:11909808~11909927:-
THCA	cis	rs7615952	0.546	rs16836896	ENSG00000243429.1	OR7E29P	6.11	2.1e-09	4.27e-07	0.4	0.27	Blood pressure (smoking interaction);	chr3:125592418	chr3:125712139~125713045:+
THCA	cis	rs2115536	0.73	rs4238512	ENSG00000278600.1	RP11-81A1.6	6.11	2.1e-09	4.27e-07	0.17	0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79891556	chr15:79920195~79922455:-
THCA	cis	rs16846053	0.642	rs10193728	ENSG00000227403.1	AC009299.3	6.11	2.1e-09	4.27e-07	0.44	0.27	Blood osmolality (transformed sodium);	chr2:161772833	chr2:161244739~161249050:+
THCA	cis	rs228614	0.51	rs223415	ENSG00000251288.2	RP11-10L12.2	-6.11	2.1e-09	4.27e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102751401~102752641:+
THCA	cis	rs72802342	0.51	rs12932952	ENSG00000261783.1	RP11-252K23.2	-6.11	2.1e-09	4.27e-07	-0.47	-0.27	Advanced age-related macular degeneration;	chr16:75331588	chr16:75379818~75381260:-
THCA	cis	rs6671200	0.607	rs6671408	ENSG00000228852.5	RP11-57H12.5	-6.11	2.1e-09	4.28e-07	-0.32	-0.27	Stearic acid (18:0) levels;	chr1:95231535	chr1:95243167~95278940:-
THCA	cis	rs6671200	0.573	rs6666528	ENSG00000228852.5	RP11-57H12.5	-6.11	2.1e-09	4.28e-07	-0.32	-0.27	Stearic acid (18:0) levels;	chr1:95231934	chr1:95243167~95278940:-
THCA	cis	rs6671200	0.541	rs3738170	ENSG00000228852.5	RP11-57H12.5	-6.11	2.1e-09	4.28e-07	-0.32	-0.27	Stearic acid (18:0) levels;	chr1:95234048	chr1:95243167~95278940:-
THCA	cis	rs934734	0.789	rs4303705	ENSG00000234255.7	AC012370.3	-6.11	2.1e-09	4.28e-07	-0.3	-0.27	Rheumatoid arthritis;	chr2:65392576	chr2:65439888~65456571:-
THCA	cis	rs12435908	1	rs73286118	ENSG00000276116.2	FUT8-AS1	-6.11	2.1e-09	4.28e-07	-0.46	-0.27	Ischemic stroke;	chr14:65568103	chr14:65411170~65412690:-
THCA	cis	rs5758659	0.714	rs2284087	ENSG00000227370.1	RP4-669P10.19	6.11	2.1e-09	4.28e-07	0.25	0.27	Cognitive function;	chr22:42089667	chr22:42132543~42132998:+
THCA	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-6.11	2.11e-09	4.28e-07	-0.45	-0.27	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
THCA	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	6.11	2.11e-09	4.28e-07	0.43	0.27	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
THCA	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-6.11	2.11e-09	4.29e-07	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
THCA	cis	rs589448	0.538	rs622656	ENSG00000274979.1	RP11-1143G9.5	-6.11	2.11e-09	4.29e-07	-0.31	-0.27	Cerebrospinal fluid biomarker levels;	chr12:69359815	chr12:69326574~69331882:-
THCA	cis	rs7560272	0.723	rs1052161	ENSG00000163016.8	ALMS1P	6.11	2.11e-09	4.29e-07	0.35	0.27	Schizophrenia;	chr2:73601411	chr2:73644919~73685576:+
THCA	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	6.11	2.11e-09	4.29e-07	0.43	0.27	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
THCA	cis	rs3213958	0.533	rs73140009	ENSG00000249274.1	PDLIM1P4	-6.11	2.11e-09	4.3e-07	-0.34	-0.27	Blood protein levels;	chr3:98907890	chr3:98782188~98783193:+
THCA	cis	rs227275	0.525	rs223332	ENSG00000251288.2	RP11-10L12.2	-6.11	2.11e-09	4.3e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102751401~102752641:+
THCA	cis	rs227932	0.618	rs2109348	ENSG00000234286.1	AC006026.13	6.11	2.11e-09	4.3e-07	0.52	0.27	Schizophrenia;	chr7:23644160	chr7:23680195~23680786:-
THCA	cis	rs1876905	0.597	rs354546	ENSG00000255389.1	C6orf3	6.11	2.11e-09	4.3e-07	0.34	0.27	Mean corpuscular hemoglobin;	chr6:111211927	chr6:111599875~111602295:+
THCA	cis	rs3213758	0.541	rs7187504	ENSG00000275191.1	RP11-36I17.2	-6.11	2.11e-09	4.3e-07	-0.4	-0.27	Vitiligo (non-segmental);	chr16:53696788	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.541	rs7204936	ENSG00000275191.1	RP11-36I17.2	-6.11	2.11e-09	4.3e-07	-0.4	-0.27	Vitiligo (non-segmental);	chr16:53696879	chr16:53628256~53628816:-
THCA	cis	rs6479891	1	rs7070052	ENSG00000232075.1	MRPL35P2	-6.11	2.11e-09	4.3e-07	-0.47	-0.27	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63634317~63634827:-
THCA	cis	rs7560272	0.695	rs13022149	ENSG00000163016.8	ALMS1P	-6.11	2.12e-09	4.3e-07	-0.35	-0.27	Schizophrenia;	chr2:73414387	chr2:73644919~73685576:+
THCA	cis	rs10208649	0.536	rs12613353	ENSG00000272156.1	RP11-477N3.1	6.11	2.12e-09	4.3e-07	0.32	0.27	Body mass index;	chr2:53747086	chr2:54082554~54085066:+
THCA	cis	rs12440869	0.649	rs4776929	ENSG00000270964.1	RP11-502I4.3	6.11	2.12e-09	4.31e-07	0.26	0.27	Peak velocity of the mitral A-wave;	chr15:67414796	chr15:67541072~67542604:-
THCA	cis	rs6951245	0.744	rs1133122	ENSG00000229043.2	AC091729.9	-6.11	2.12e-09	4.31e-07	-0.45	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1160374~1165267:+
THCA	cis	rs4713118	0.55	rs9368527	ENSG00000219392.1	RP1-265C24.5	-6.11	2.12e-09	4.31e-07	-0.31	-0.27	Parkinson's disease;	chr6:27711666	chr6:28115628~28116551:+
THCA	cis	rs72627509	0.68	rs73165962	ENSG00000269949.1	RP11-738E22.3	6.11	2.12e-09	4.31e-07	0.41	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56874367	chr4:56960927~56961373:-
THCA	cis	rs72627509	0.638	rs73165963	ENSG00000269949.1	RP11-738E22.3	6.11	2.12e-09	4.31e-07	0.41	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56874370	chr4:56960927~56961373:-
THCA	cis	rs7615952	0.932	rs11922218	ENSG00000241288.6	RP11-379B18.5	-6.11	2.12e-09	4.31e-07	-0.34	-0.27	Blood pressure (smoking interaction);	chr3:125912446	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.866	rs11922276	ENSG00000241288.6	RP11-379B18.5	-6.11	2.12e-09	4.31e-07	-0.34	-0.27	Blood pressure (smoking interaction);	chr3:125912483	chr3:125827238~125916384:-
THCA	cis	rs9467773	0.935	rs1056668	ENSG00000124549.13	BTN2A3P	6.11	2.12e-09	4.31e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26510377	chr6:26421391~26432383:+
THCA	cis	rs2117029	0.782	rs11168850	ENSG00000258017.1	RP11-386G11.10	-6.11	2.12e-09	4.32e-07	-0.34	-0.27	Intelligence (multi-trait analysis);	chr12:49079182	chr12:49127782~49147869:+
THCA	cis	rs7948661	1	rs7941217	ENSG00000278376.1	RP11-158I9.8	-6.11	2.13e-09	4.32e-07	-0.42	-0.27	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118478532	chr11:118791254~118793137:+
THCA	cis	rs6430585	0.528	rs2278682	ENSG00000231890.6	DARS-AS1	-6.11	2.13e-09	4.32e-07	-0.32	-0.27	Corneal structure;	chr2:135985573	chr2:135985176~136022593:+
THCA	cis	rs7267979	0.738	rs2892409	ENSG00000274973.1	RP13-401N8.7	-6.11	2.13e-09	4.32e-07	-0.3	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:25845497~25845862:+
THCA	cis	rs7560272	0.723	rs7585119	ENSG00000163016.8	ALMS1P	6.11	2.13e-09	4.33e-07	0.36	0.27	Schizophrenia;	chr2:73497552	chr2:73644919~73685576:+
THCA	cis	rs7923837	0.616	rs12219514	ENSG00000236493.2	EIF2S2P3	6.11	2.13e-09	4.33e-07	0.28	0.27	Multiple sclerosis;Body mass index;	chr10:92706682	chr10:92668745~92669743:-
THCA	cis	rs5758659	0.714	rs6002626	ENSG00000270083.1	RP1-257I20.14	-6.11	2.13e-09	4.33e-07	-0.29	-0.27	Cognitive function;	chr22:42121985	chr22:42089630~42090028:-
THCA	cis	rs7044106	0.791	rs2416799	ENSG00000270917.1	RP11-27I1.6	-6.11	2.14e-09	4.34e-07	-0.38	-0.27	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120812475~120812845:-
THCA	cis	rs1865760	0.865	rs1541987	ENSG00000272462.2	U91328.19	6.11	2.14e-09	4.35e-07	0.22	0.27	Height;	chr6:25950169	chr6:25992662~26001775:+
THCA	cis	rs17772222	0.917	rs17260415	ENSG00000258789.1	RP11-507K2.3	-6.11	2.14e-09	4.35e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88745629	chr14:88551597~88552493:+
THCA	cis	rs72949976	0.564	rs4673730	ENSG00000270659.1	RP11-105N14.1	-6.11	2.14e-09	4.35e-07	-0.22	-0.27	Squamous cell lung carcinoma;Lung cancer;	chr2:213160112	chr2:213152970~213153659:+
THCA	cis	rs72949976	0.584	rs13001511	ENSG00000270659.1	RP11-105N14.1	-6.11	2.14e-09	4.35e-07	-0.22	-0.27	Squamous cell lung carcinoma;Lung cancer;	chr2:213160538	chr2:213152970~213153659:+
THCA	cis	rs11148252	0.74	rs9596648	ENSG00000235660.1	LINC00345	6.11	2.14e-09	4.35e-07	0.35	0.27	Lewy body disease;	chr13:52360434	chr13:52484161~52484680:-
THCA	cis	rs6600671	0.966	rs6600664	ENSG00000275538.1	RNVU1-19	6.11	2.14e-09	4.36e-07	0.34	0.27	Hip geometry;	chr1:121480638	chr1:120850819~120850985:-
THCA	cis	rs6600671	0.932	rs6600663	ENSG00000275538.1	RNVU1-19	6.11	2.14e-09	4.36e-07	0.34	0.27	Hip geometry;	chr1:121480639	chr1:120850819~120850985:-
THCA	cis	rs4591358	0.608	rs12693770	ENSG00000223466.1	AC064834.2	6.11	2.15e-09	4.36e-07	0.38	0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195461422	chr2:195533035~195538681:+
THCA	cis	rs853679	0.607	rs13217984	ENSG00000280107.1	AL022393.9	-6.11	2.15e-09	4.37e-07	-0.56	-0.27	Depression;	chr6:28171932	chr6:28170845~28172521:+
THCA	cis	rs853679	0.556	rs67297533	ENSG00000280107.1	AL022393.9	-6.11	2.15e-09	4.37e-07	-0.56	-0.27	Depression;	chr6:28173475	chr6:28170845~28172521:+
THCA	cis	rs853679	0.505	rs35781323	ENSG00000280107.1	AL022393.9	-6.11	2.15e-09	4.37e-07	-0.56	-0.27	Depression;	chr6:28177054	chr6:28170845~28172521:+
THCA	cis	rs736801	0.78	rs11951091	ENSG00000233006.5	AC034220.3	6.11	2.15e-09	4.37e-07	0.22	0.27	Mosquito bite size;Breast cancer;	chr5:132450903	chr5:132311285~132369916:-
THCA	cis	rs11148252	0.633	rs9535888	ENSG00000278238.1	RP11-245D16.4	-6.11	2.15e-09	4.37e-07	-0.31	-0.27	Lewy body disease;	chr13:52159071	chr13:52454775~52455331:-
THCA	cis	rs9878978	0.722	rs11717960	ENSG00000237990.3	CNTN4-AS1	6.11	2.15e-09	4.37e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:2472183	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.722	rs11717961	ENSG00000237990.3	CNTN4-AS1	6.11	2.15e-09	4.37e-07	0.33	0.27	Blood pressure (smoking interaction);	chr3:2472185	chr3:3039033~3069242:-
THCA	cis	rs4143844	0.867	rs12901055	ENSG00000259251.2	RP11-643M14.1	6.11	2.15e-09	4.37e-07	0.52	0.27	Bipolar disorder and schizophrenia;	chr15:61880708	chr15:62060503~62062434:+
THCA	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-6.11	2.15e-09	4.38e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
THCA	cis	rs4664293	0.747	rs7600347	ENSG00000226266.5	AC009961.3	-6.1	2.15e-09	4.38e-07	-0.35	-0.27	Monocyte percentage of white cells;	chr2:159800981	chr2:159670708~159712435:-
THCA	cis	rs7119038	0.818	rs11217042	ENSG00000255239.1	AP002954.6	-6.1	2.16e-09	4.38e-07	-0.39	-0.27	Sjögren's syndrome;	chr11:118811819	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.818	rs17122453	ENSG00000255239.1	AP002954.6	-6.1	2.16e-09	4.38e-07	-0.39	-0.27	Sjögren's syndrome;	chr11:118812855	chr11:118688039~118690600:-
THCA	cis	rs2915864	0.747	rs80195149	ENSG00000280047.1	CTC-463A16.1	6.1	2.16e-09	4.39e-07	0.45	0.27	Facial morphology (factor 20);	chr5:142069142	chr5:142165767~142168387:+
THCA	cis	rs7246657	0.722	rs2972437	ENSG00000267422.1	CTD-2554C21.1	-6.1	2.16e-09	4.4e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37719610	chr19:37779686~37792865:+
THCA	cis	rs390966	0.585	rs13420242	ENSG00000205847.5	OR7E91P	-6.1	2.16e-09	4.4e-07	-0.31	-0.27	Erythema nodosum in inflammatory bowel disease;	chr2:71036638	chr2:71029028~71029893:+
THCA	cis	rs10029851	0.58	rs6854331	ENSG00000234492.4	RPL34-AS1	6.1	2.17e-09	4.4e-07	0.31	0.27	Amyotrophic lateral sclerosis (sporadic);	chr4:108589529	chr4:108538190~108620460:-
THCA	cis	rs7202877	0.706	rs2059257	ENSG00000261783.1	RP11-252K23.2	-6.1	2.17e-09	4.4e-07	-0.47	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75362478	chr16:75379818~75381260:-
THCA	cis	rs7829975	0.514	rs2976926	ENSG00000254153.1	CTA-398F10.2	-6.1	2.17e-09	4.4e-07	-0.28	-0.27	Mood instability;	chr8:8404114	chr8:8456909~8461337:-
THCA	cis	rs934734	0.563	rs11673956	ENSG00000234255.7	AC012370.3	6.1	2.17e-09	4.4e-07	0.32	0.27	Rheumatoid arthritis;	chr2:65370523	chr2:65439888~65456571:-
THCA	cis	rs934734	0.563	rs11673987	ENSG00000234255.7	AC012370.3	6.1	2.17e-09	4.4e-07	0.32	0.27	Rheumatoid arthritis;	chr2:65370537	chr2:65439888~65456571:-
THCA	cis	rs6600671	1	rs1856572	ENSG00000275538.1	RNVU1-19	6.1	2.17e-09	4.41e-07	0.34	0.27	Hip geometry;	chr1:121427719	chr1:120850819~120850985:-
THCA	cis	rs228614	0.51	rs223435	ENSG00000251288.2	RP11-10L12.2	-6.1	2.18e-09	4.42e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223434	ENSG00000251288.2	RP11-10L12.2	-6.1	2.18e-09	4.42e-07	-0.37	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102751401~102752641:+
THCA	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	6.1	2.18e-09	4.42e-07	0.29	0.27	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
THCA	cis	rs7324557	0.93	rs7324545	ENSG00000205861.10	C1QTNF9B-AS1	6.1	2.18e-09	4.42e-07	0.33	0.27	Visceral adipose tissue adjusted for BMI;	chr13:23722702	chr13:23888889~23897263:+
THCA	cis	rs4650994	0.505	rs2811291	ENSG00000273384.1	RP5-1098D14.1	-6.1	2.18e-09	4.42e-07	-0.34	-0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178605082	chr1:178651706~178652282:+
THCA	cis	rs4950322	1	rs4448568	ENSG00000237188.3	RP11-337C18.8	6.1	2.18e-09	4.42e-07	0.36	0.27	Protein quantitative trait loci;	chr1:147377296	chr1:147172771~147211568:+
THCA	cis	rs9287719	0.649	rs58633964	ENSG00000234818.1	AC092687.5	6.1	2.18e-09	4.43e-07	0.33	0.27	Prostate cancer;	chr2:10596256	chr2:10589166~10604830:+
THCA	cis	rs228614	0.536	rs150897	ENSG00000230069.3	LRRC37A15P	-6.1	2.18e-09	4.43e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223472	ENSG00000230069.3	LRRC37A15P	-6.1	2.18e-09	4.43e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102727274~102730721:-
THCA	cis	rs875971	0.651	rs313829	ENSG00000164669.11	INTS4P1	6.1	2.18e-09	4.43e-07	0.37	0.27	Aortic root size;	chr7:66087510	chr7:65141225~65234216:+
THCA	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	6.1	2.18e-09	4.43e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
THCA	cis	rs5758659	0.714	rs5758578	ENSG00000227370.1	RP4-669P10.19	6.1	2.18e-09	4.43e-07	0.25	0.27	Cognitive function;	chr22:42094288	chr22:42132543~42132998:+
THCA	cis	rs228614	0.51	rs223410	ENSG00000230069.3	LRRC37A15P	-6.1	2.19e-09	4.44e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223400	ENSG00000230069.3	LRRC37A15P	-6.1	2.19e-09	4.44e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102727274~102730721:-
THCA	cis	rs836788	0.633	rs35548549	ENSG00000249655.1	CTC-325J23.2	6.1	2.19e-09	4.44e-07	0.27	0.27	Glomerular filtration rate (creatinine);	chr5:80686115	chr5:80630313~80631590:-
THCA	cis	rs7176527	0.848	rs1374463	ENSG00000188388.10	GOLGA6L3	6.1	2.19e-09	4.44e-07	0.48	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:85240472~85247170:+
THCA	cis	rs13113518	0.812	rs13140173	ENSG00000273257.1	RP11-177J6.1	6.1	2.19e-09	4.44e-07	0.37	0.27	Height;	chr4:55527164	chr4:55387949~55388271:+
THCA	cis	rs10043228	0.702	rs7711510	ENSG00000248445.4	SEMA6A-AS1	-6.1	2.19e-09	4.44e-07	-0.3	-0.27	Asthma or chronic obstructive pulmonary disease;	chr5:116296556	chr5:116447547~116508276:+
THCA	cis	rs950169	0.544	rs2036949	ENSG00000259295.5	CSPG4P12	6.1	2.19e-09	4.45e-07	0.42	0.27	Schizophrenia;	chr15:84620374	chr15:85191438~85213905:+
THCA	cis	rs8141529	0.719	rs6005916	ENSG00000226471.5	CTA-292E10.6	-6.1	2.19e-09	4.45e-07	-0.22	-0.27	Lymphocyte counts;	chr22:28837354	chr22:28800683~28848559:+
THCA	cis	rs7512898	0.51	rs10920054	ENSG00000260088.1	RP11-92G12.3	-6.1	2.19e-09	4.45e-07	-0.36	-0.27	Electrocardiographic conduction measures;	chr1:200861312	chr1:200669507~200694250:+
THCA	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-6.1	2.19e-09	4.45e-07	-0.35	-0.27	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
THCA	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-6.1	2.19e-09	4.45e-07	-0.35	-0.27	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
THCA	cis	rs10208649	0.536	rs6714424	ENSG00000272156.1	RP11-477N3.1	6.1	2.19e-09	4.45e-07	0.38	0.27	Body mass index;	chr2:53729843	chr2:54082554~54085066:+
THCA	cis	rs526231	0.819	rs2569018	ENSG00000175749.11	EIF3KP1	6.1	2.19e-09	4.45e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103262042	chr5:103032376~103033031:+
THCA	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	6.1	2.19e-09	4.45e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
THCA	cis	rs526231	0.782	rs434816	ENSG00000175749.11	EIF3KP1	6.1	2.19e-09	4.45e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103263627	chr5:103032376~103033031:+
THCA	cis	rs526231	0.747	rs375637	ENSG00000175749.11	EIF3KP1	6.1	2.19e-09	4.45e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103263877	chr5:103032376~103033031:+
THCA	cis	rs526231	0.747	rs434294	ENSG00000175749.11	EIF3KP1	6.1	2.19e-09	4.45e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103263925	chr5:103032376~103033031:+
THCA	cis	rs9649465	0.935	rs1605285	ENSG00000272686.1	RP11-390E23.6	6.1	2.2e-09	4.45e-07	0.18	0.27	Migraine;	chr7:123734358	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs2052128	ENSG00000272686.1	RP11-390E23.6	6.1	2.2e-09	4.45e-07	0.18	0.27	Migraine;	chr7:123740351	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs10215473	ENSG00000272686.1	RP11-390E23.6	6.1	2.2e-09	4.45e-07	0.18	0.27	Migraine;	chr7:123740627	chr7:123749068~123751166:+
THCA	cis	rs228614	0.509	rs223480	ENSG00000230069.3	LRRC37A15P	-6.1	2.2e-09	4.46e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102727274~102730721:-
THCA	cis	rs1859596	0.932	rs2269990	ENSG00000234456.6	MAGI2-AS3	6.1	2.2e-09	4.46e-07	0.26	0.27	Reading or mathematical ability;	chr7:79460720	chr7:79452877~79471208:+
THCA	cis	rs9880211	1	rs9809988	ENSG00000273486.1	RP11-731C17.2	6.1	2.2e-09	4.46e-07	0.28	0.27	Height;Body mass index;	chr3:136803379	chr3:136837338~136839021:-
THCA	cis	rs12478296	0.681	rs55802421	ENSG00000261186.2	RP11-341N2.1	-6.1	2.2e-09	4.46e-07	-0.43	-0.27	Obesity-related traits;	chr2:242091811	chr2:242087351~242088457:-
THCA	cis	rs12478296	0.681	rs56357900	ENSG00000261186.2	RP11-341N2.1	-6.1	2.2e-09	4.46e-07	-0.43	-0.27	Obesity-related traits;	chr2:242091815	chr2:242087351~242088457:-
THCA	cis	rs2115630	0.967	rs12595786	ENSG00000225151.9	GOLGA2P7	6.1	2.2e-09	4.47e-07	0.34	0.27	P wave terminal force;	chr15:84793439	chr15:84199311~84230136:-
THCA	cis	rs9402743	0.715	rs9389315	ENSG00000231028.7	LINC00271	-6.1	2.2e-09	4.47e-07	-0.22	-0.27	Systemic lupus erythematosus;	chr6:135679277	chr6:135497801~135716055:+
THCA	cis	rs13113518	0.812	rs2412648	ENSG00000249700.7	SRD5A3-AS1	6.1	2.2e-09	4.47e-07	0.35	0.27	Height;	chr4:55454900	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs12512737	ENSG00000249700.7	SRD5A3-AS1	6.1	2.2e-09	4.47e-07	0.35	0.27	Height;	chr4:55454938	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs13125984	ENSG00000249700.7	SRD5A3-AS1	6.1	2.2e-09	4.47e-07	0.35	0.27	Height;	chr4:55455102	chr4:55363971~55395847:-
THCA	cis	rs4664293	0.647	rs6711049	ENSG00000226266.5	AC009961.3	-6.1	2.2e-09	4.47e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159584634	chr2:159670708~159712435:-
THCA	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	6.1	2.21e-09	4.47e-07	0.3	0.27	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
THCA	cis	rs934734	0.752	rs268131	ENSG00000237979.1	AC007389.1	-6.1	2.21e-09	4.47e-07	-0.31	-0.27	Rheumatoid arthritis;	chr2:65383337	chr2:65500993~65502138:-
THCA	cis	rs4664293	0.647	rs7587700	ENSG00000226266.5	AC009961.3	-6.1	2.21e-09	4.48e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159587809	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.609	rs10209829	ENSG00000226266.5	AC009961.3	-6.1	2.21e-09	4.48e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159591113	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs6432539	ENSG00000226266.5	AC009961.3	-6.1	2.21e-09	4.48e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159592209	chr2:159670708~159712435:-
THCA	cis	rs12435908	1	rs11849252	ENSG00000276116.2	FUT8-AS1	-6.1	2.21e-09	4.48e-07	-0.42	-0.27	Ischemic stroke;	chr14:65603051	chr14:65411170~65412690:-
THCA	cis	rs793571	0.505	rs12591290	ENSG00000259250.1	RP11-50C13.1	-6.1	2.21e-09	4.48e-07	-0.3	-0.27	Schizophrenia;	chr15:58603305	chr15:58587507~58591676:+
THCA	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	6.1	2.21e-09	4.48e-07	0.3	0.27	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
THCA	cis	rs2439831	0.867	rs3101443	ENSG00000166763.7	STRCP1	6.1	2.21e-09	4.48e-07	0.38	0.27	Lung cancer in ever smokers;	chr15:43620174	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2614811	ENSG00000166763.7	STRCP1	6.1	2.21e-09	4.48e-07	0.38	0.27	Lung cancer in ever smokers;	chr15:43621289	chr15:43699488~43718184:-
THCA	cis	rs1979679	0.842	rs7316299	ENSG00000278733.1	RP11-425D17.1	6.1	2.21e-09	4.48e-07	0.27	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28179757	chr12:28185625~28186190:-
THCA	cis	rs4713118	0.615	rs9348772	ENSG00000219392.1	RP1-265C24.5	-6.1	2.21e-09	4.49e-07	-0.31	-0.27	Parkinson's disease;	chr6:27688311	chr6:28115628~28116551:+
THCA	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	6.1	2.21e-09	4.49e-07	0.39	0.27	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
THCA	cis	rs763121	0.962	rs1980455	ENSG00000273076.1	RP3-508I15.22	6.1	2.21e-09	4.49e-07	0.26	0.27	Menopause (age at onset);	chr22:38529714	chr22:38743495~38743910:+
THCA	cis	rs3758785	0.679	rs13447595	ENSG00000255893.1	RP11-685N10.1	-6.1	2.21e-09	4.49e-07	-0.32	-0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94489524	chr11:94472908~94473570:-
THCA	cis	rs9813712	0.953	rs6439222	ENSG00000249846.5	RP11-77P16.4	6.1	2.22e-09	4.49e-07	0.32	0.27	Response to amphetamines;	chr3:130256298	chr3:130112550~130120579:+
THCA	cis	rs593531	0.571	rs11236087	ENSG00000212961.4	HNRNPA1P40	-6.1	2.22e-09	4.5e-07	-0.34	-0.27	Neuroticism;	chr11:74383093	chr11:74354443~74355720:+
THCA	cis	rs10276381	1	rs10276381	ENSG00000234336.5	JAZF1-AS1	6.1	2.22e-09	4.5e-07	0.38	0.27	Crohn's disease;	chr7:28150502	chr7:28180322~28243917:+
THCA	cis	rs9813712	1	rs9813712	ENSG00000249846.5	RP11-77P16.4	6.1	2.22e-09	4.5e-07	0.32	0.27	Response to amphetamines;	chr3:130252258	chr3:130112550~130120579:+
THCA	cis	rs853679	0.546	rs71537572	ENSG00000219392.1	RP1-265C24.5	-6.1	2.22e-09	4.51e-07	-0.61	-0.27	Depression;	chr6:28002937	chr6:28115628~28116551:+
THCA	cis	rs6723226	0.803	rs387780	ENSG00000276334.1	AL133243.1	6.1	2.22e-09	4.51e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr2:32277426	chr2:32521927~32523547:+
THCA	cis	rs72843506	0.591	rs74319100	ENSG00000270091.1	RP11-78O7.2	-6.1	2.22e-09	4.51e-07	-0.29	-0.27	Schizophrenia;	chr17:20318079	chr17:19896590~19897287:-
THCA	cis	rs853679	0.517	rs868987	ENSG00000261839.1	RP1-265C24.8	-6.1	2.22e-09	4.51e-07	-0.32	-0.27	Depression;	chr6:28142370	chr6:28136849~28139678:+
THCA	cis	rs853679	0.607	rs13211507	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28289600	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34691223	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28290431	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13207345	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28297795	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs72854513	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28298177	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs56189111	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28304196	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34950484	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28310911	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs35072899	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28313764	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34661125	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28314117	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13190888	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28318208	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs56075693	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28322551	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34218844	ENSG00000219392.1	RP1-265C24.5	-6.1	2.23e-09	4.51e-07	-0.6	-0.27	Depression;	chr6:28322870	chr6:28115628~28116551:+
THCA	cis	rs9625935	0.748	rs1468177	ENSG00000279159.1	RP3-394A18.1	6.1	2.23e-09	4.52e-07	0.18	0.27	Tonsillectomy;	chr22:30148570	chr22:29978950~30028236:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	6.1	2.23e-09	4.52e-07	0.3	0.27	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
THCA	cis	rs7942368	1	rs56228827	ENSG00000204529.3	GUCY2EP	6.1	2.23e-09	4.52e-07	0.39	0.27	Endometriosis;	chr11:76756479	chr11:76694043~76707641:-
THCA	cis	rs9921338	0.886	rs3931015	ENSG00000262703.1	RP11-485G7.6	6.1	2.23e-09	4.52e-07	0.35	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321782	chr16:11348143~11349321:-
THCA	cis	rs6545883	0.859	rs7561672	ENSG00000271889.1	RP11-493E12.1	-6.1	2.23e-09	4.52e-07	-0.26	-0.27	Tuberculosis;	chr2:61291959	chr2:61151433~61162105:-
THCA	cis	rs8042680	0.868	rs12595029	ENSG00000214432.8	AC068831.10	-6.1	2.23e-09	4.53e-07	-0.3	-0.27	Type 2 diabetes;	chr15:90976929	chr15:91022619~91036611:+
THCA	cis	rs56114371	0.777	rs200481	ENSG00000219392.1	RP1-265C24.5	-6.1	2.24e-09	4.53e-07	-0.43	-0.27	Breast cancer;	chr6:27806054	chr6:28115628~28116551:+
THCA	cis	rs6600671	1	rs2185281	ENSG00000275538.1	RNVU1-19	6.1	2.24e-09	4.53e-07	0.34	0.27	Hip geometry;	chr1:121438132	chr1:120850819~120850985:-
THCA	cis	rs6142102	0.961	rs4911405	ENSG00000275784.1	RP5-1125A11.6	-6.1	2.24e-09	4.53e-07	-0.29	-0.27	Skin pigmentation;	chr20:34087161	chr20:33989480~33991818:-
THCA	cis	rs17772222	0.876	rs12586348	ENSG00000222990.1	RNU4-22P	6.1	2.24e-09	4.53e-07	0.35	0.27	Coronary artery calcification;	chr14:88643523	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs12434935	ENSG00000222990.1	RNU4-22P	6.1	2.24e-09	4.53e-07	0.35	0.27	Coronary artery calcification;	chr14:88645449	chr14:88513498~88513663:+
THCA	cis	rs9388451	0.868	rs10457467	ENSG00000226409.1	RP11-735G4.1	-6.1	2.24e-09	4.54e-07	-0.32	-0.27	Brugada syndrome;	chr6:125724002	chr6:125370211~125374324:-
THCA	cis	rs8002861	0.935	rs9533672	ENSG00000274001.1	RP11-5G9.5	6.1	2.24e-09	4.54e-07	0.3	0.27	Leprosy;	chr13:43877044	chr13:43877715~43878163:-
THCA	cis	rs7809950	0.817	rs58052742	ENSG00000238832.1	snoU109	6.1	2.24e-09	4.54e-07	0.31	0.27	Coronary artery disease;	chr7:107569558	chr7:107603363~107603507:+
THCA	cis	rs2243480	0.522	rs73150635	ENSG00000273142.1	RP11-458F8.4	-6.1	2.24e-09	4.54e-07	-0.45	-0.27	Diabetic kidney disease;	chr7:66507503	chr7:66902857~66906297:+
THCA	cis	rs763121	0.815	rs4821799	ENSG00000235209.1	CTA-150C2.13	6.1	2.24e-09	4.54e-07	0.34	0.27	Menopause (age at onset);	chr22:38625321	chr22:38921227~38924708:+
THCA	cis	rs7976269	0.559	rs9651838	ENSG00000257176.2	RP11-996F15.2	6.1	2.24e-09	4.54e-07	0.28	0.27	Male-pattern baldness;	chr12:28999700	chr12:29280418~29317848:-
THCA	cis	rs3213958	0.574	rs73138027	ENSG00000249274.1	PDLIM1P4	-6.1	2.25e-09	4.55e-07	-0.34	-0.27	Blood protein levels;	chr3:98848889	chr3:98782188~98783193:+
THCA	cis	rs11158026	0.603	rs8009997	ENSG00000258413.1	RP11-665C16.6	-6.1	2.25e-09	4.55e-07	-0.39	-0.27	Parkinson's disease;	chr14:54955193	chr14:55262767~55272075:-
THCA	cis	rs62103177	0.673	rs36087369	ENSG00000261126.6	RP11-795F19.1	6.1	2.25e-09	4.55e-07	0.27	0.27	Opioid sensitivity;	chr18:79829596	chr18:80046900~80095482:+
THCA	cis	rs9813712	0.526	rs62281641	ENSG00000253540.4	FAM86HP	-6.1	2.25e-09	4.56e-07	-0.28	-0.27	Response to amphetamines;	chr3:130235668	chr3:130099092~130111472:-
THCA	cis	rs16958440	0.867	rs117060920	ENSG00000267800.1	RP11-49K24.5	-6.1	2.25e-09	4.56e-07	-0.6	-0.27	Sitting height ratio;	chr18:47182664	chr18:47137018~47137290:+
THCA	cis	rs6860806	0.631	rs7736284	ENSG00000224431.1	AC063976.7	6.1	2.25e-09	4.56e-07	0.23	0.27	Breast cancer;	chr5:132252458	chr5:132199456~132203487:+
THCA	cis	rs62292953	0.719	rs10935027	ENSG00000248724.5	NPHP3-AS1	-6.1	2.25e-09	4.56e-07	-0.51	-0.27	Red cell distribution width;	chr3:132661908	chr3:132721750~132874223:+
THCA	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-6.1	2.25e-09	4.57e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
THCA	cis	rs72843506	0.722	rs74658636	ENSG00000270091.1	RP11-78O7.2	-6.1	2.26e-09	4.57e-07	-0.3	-0.27	Schizophrenia;	chr17:20294669	chr17:19896590~19897287:-
THCA	cis	rs16976116	1	rs16976116	ENSG00000279145.1	RP11-547D13.1	6.1	2.26e-09	4.57e-07	0.27	0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55188269	chr15:55171972~55178175:-
THCA	cis	rs8042680	1	rs8031915	ENSG00000214432.8	AC068831.10	-6.1	2.26e-09	4.57e-07	-0.3	-0.27	Type 2 diabetes;	chr15:90976061	chr15:91022619~91036611:+
THCA	cis	rs516805	0.596	rs1531186	ENSG00000279453.1	RP3-425C14.4	-6.1	2.26e-09	4.57e-07	-0.31	-0.27	Lymphocyte counts;	chr6:122208219	chr6:122436789~122439223:-
THCA	cis	rs4948275	0.773	rs2256597	ENSG00000237233.2	TMEM26-AS1	-6.1	2.26e-09	4.57e-07	-0.35	-0.27	Night sleep phenotypes;	chr10:61503536	chr10:61452639~61481956:+
THCA	cis	rs172166	0.694	rs1150666	ENSG00000226314.6	ZNF192P1	-6.1	2.26e-09	4.58e-07	-0.33	-0.27	Cardiac Troponin-T levels;	chr6:28156150	chr6:28161781~28169594:+
THCA	cis	rs7942368	0.793	rs12273016	ENSG00000204529.3	GUCY2EP	-6.1	2.26e-09	4.58e-07	-0.37	-0.27	Endometriosis;	chr11:76779672	chr11:76694043~76707641:-
THCA	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	6.1	2.26e-09	4.58e-07	0.3	0.27	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
THCA	cis	rs72843506	0.52	rs78178505	ENSG00000270091.1	RP11-78O7.2	-6.1	2.26e-09	4.58e-07	-0.33	-0.27	Schizophrenia;	chr17:19984410	chr17:19896590~19897287:-
THCA	cis	rs17772222	0.917	rs61983300	ENSG00000222990.1	RNU4-22P	6.1	2.26e-09	4.58e-07	0.34	0.27	Coronary artery calcification;	chr14:88754047	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.876	rs78068036	ENSG00000222990.1	RNU4-22P	6.1	2.26e-09	4.58e-07	0.34	0.27	Coronary artery calcification;	chr14:88754817	chr14:88513498~88513663:+
THCA	cis	rs4908760	0.965	rs301814	ENSG00000232912.4	RP5-1115A15.1	6.1	2.26e-09	4.59e-07	0.27	0.27	Vitiligo;	chr1:8450517	chr1:8424645~8434838:+
THCA	cis	rs7615952	0.546	rs2976733	ENSG00000241278.1	ENPP7P4	6.1	2.26e-09	4.59e-07	0.34	0.27	Blood pressure (smoking interaction);	chr3:125695294	chr3:125848223~125909372:+
THCA	cis	rs10266483	0.774	rs7796802	ENSG00000227986.1	TRIM60P18	6.1	2.27e-09	4.59e-07	0.24	0.27	Response to statin therapy;	chr7:64323744	chr7:64355078~64356199:+
THCA	cis	rs6860806	0.695	rs6867282	ENSG00000224431.1	AC063976.7	6.1	2.27e-09	4.59e-07	0.23	0.27	Breast cancer;	chr5:132247427	chr5:132199456~132203487:+
THCA	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	6.1	2.27e-09	4.59e-07	0.34	0.27	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
THCA	cis	rs4950322	0.57	rs4950400	ENSG00000278811.3	LINC00624	-6.1	2.27e-09	4.59e-07	-0.33	-0.27	Protein quantitative trait loci;	chr1:147319383	chr1:147258885~147517875:-
THCA	cis	rs2299587	0.585	rs379167	ENSG00000253671.1	RP11-806O11.1	-6.1	2.27e-09	4.59e-07	-0.34	-0.27	Economic and political preferences;	chr8:17921415	chr8:17808941~17820868:+
THCA	cis	rs9307551	0.711	rs11098774	ENSG00000250334.4	LINC00989	6.1	2.27e-09	4.59e-07	0.33	0.27	Refractive error;	chr4:79615697	chr4:79492416~79576460:+
THCA	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	6.1	2.27e-09	4.6e-07	0.28	0.27	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
THCA	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	6.1	2.27e-09	4.6e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
THCA	cis	rs4713118	0.513	rs149941	ENSG00000280107.1	AL022393.9	-6.1	2.27e-09	4.6e-07	-0.29	-0.27	Parkinson's disease;	chr6:28033255	chr6:28170845~28172521:+
THCA	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-6.1	2.27e-09	4.6e-07	-0.34	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
THCA	cis	rs10875746	0.951	rs10875747	ENSG00000269514.1	RP11-370I10.12	6.1	2.28e-09	4.61e-07	0.27	0.27	Longevity (90 years and older);	chr12:48132078	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.951	rs10875748	ENSG00000269514.1	RP11-370I10.12	6.1	2.28e-09	4.61e-07	0.27	0.27	Longevity (90 years and older);	chr12:48132577	chr12:48198387~48202031:+
THCA	cis	rs755249	1	rs4660293	ENSG00000228060.1	RP11-69E11.8	6.1	2.28e-09	4.61e-07	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39565160~39573203:+
THCA	cis	rs4664293	0.647	rs2162023	ENSG00000226266.5	AC009961.3	-6.1	2.28e-09	4.61e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159569719	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs10199805	ENSG00000226266.5	AC009961.3	-6.1	2.28e-09	4.61e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159570880	chr2:159670708~159712435:-
THCA	cis	rs228614	0.51	rs223446	ENSG00000230069.3	LRRC37A15P	-6.1	2.28e-09	4.61e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102727274~102730721:-
THCA	cis	rs228614	0.536	rs223437	ENSG00000230069.3	LRRC37A15P	-6.1	2.28e-09	4.61e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102727274~102730721:-
THCA	cis	rs228614	0.536	rs223419	ENSG00000230069.3	LRRC37A15P	-6.1	2.28e-09	4.61e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102727274~102730721:-
THCA	cis	rs2243480	1	rs427044	ENSG00000228409.4	CCT6P1	6.1	2.28e-09	4.61e-07	0.31	0.27	Diabetic kidney disease;	chr7:66043558	chr7:65751142~65763354:+
THCA	cis	rs755249	0.959	rs72663520	ENSG00000228060.1	RP11-69E11.8	-6.1	2.28e-09	4.62e-07	-0.29	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39565160~39573203:+
THCA	cis	rs9625935	0.957	rs737909	ENSG00000279159.1	RP3-394A18.1	6.09	2.29e-09	4.63e-07	0.22	0.27	Tonsillectomy;	chr22:29992769	chr22:29978950~30028236:-
THCA	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	6.09	2.29e-09	4.63e-07	0.43	0.27	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
THCA	cis	rs3020264	0.579	rs1256	ENSG00000271743.1	CTD-2541M15.3	-6.09	2.29e-09	4.63e-07	-0.38	-0.27	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6615835	chr8:6615604~6617198:-
THCA	cis	rs7191700	0.673	rs12325495	ENSG00000263080.1	RP11-485G7.5	6.09	2.29e-09	4.63e-07	0.31	0.27	Multiple sclerosis;	chr16:11324471	chr16:11341809~11345211:-
THCA	cis	rs228614	0.51	rs223445	ENSG00000230069.3	LRRC37A15P	-6.09	2.29e-09	4.63e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223443	ENSG00000230069.3	LRRC37A15P	-6.09	2.29e-09	4.63e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102727274~102730721:-
THCA	cis	rs1876905	0.597	rs354538	ENSG00000255389.1	C6orf3	6.09	2.29e-09	4.63e-07	0.32	0.27	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111599875~111602295:+
THCA	cis	rs1876905	0.68	rs434034	ENSG00000255389.1	C6orf3	6.09	2.29e-09	4.63e-07	0.32	0.27	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111599875~111602295:+
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000232546.1	RP11-458F8.1	6.09	2.29e-09	4.64e-07	0.36	0.27	Diabetic kidney disease;	chr7:66219914	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs313831	ENSG00000229886.1	RP5-1132H15.3	6.09	2.29e-09	4.64e-07	0.43	0.27	Diabetic kidney disease;	chr7:66086239	chr7:66025126~66031544:-
THCA	cis	rs4664293	0.836	rs4516379	ENSG00000226266.5	AC009961.3	-6.09	2.3e-09	4.64e-07	-0.35	-0.27	Monocyte percentage of white cells;	chr2:159808892	chr2:159670708~159712435:-
THCA	cis	rs6600671	1	rs11249350	ENSG00000275538.1	RNVU1-19	6.09	2.3e-09	4.64e-07	0.34	0.27	Hip geometry;	chr1:121436587	chr1:120850819~120850985:-
THCA	cis	rs7615952	0.599	rs1875683	ENSG00000250012.1	RP11-124N2.1	-6.09	2.3e-09	4.65e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126013638	chr3:126084220~126095349:+
THCA	cis	rs763121	1	rs138457	ENSG00000273076.1	RP3-508I15.22	-6.09	2.3e-09	4.66e-07	-0.26	-0.27	Menopause (age at onset);	chr22:38502046	chr22:38743495~38743910:+
THCA	cis	rs10411161	0.58	rs12151288	ENSG00000269483.1	AC006272.1	6.09	2.3e-09	4.66e-07	0.32	0.27	Breast cancer;	chr19:51878299	chr19:51839924~51843324:-
THCA	cis	rs72843506	0.722	rs5025290	ENSG00000270091.1	RP11-78O7.2	-6.09	2.3e-09	4.66e-07	-0.29	-0.27	Schizophrenia;	chr17:20302504	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.722	rs9895177	ENSG00000270091.1	RP11-78O7.2	-6.09	2.3e-09	4.66e-07	-0.29	-0.27	Schizophrenia;	chr17:20304281	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.722	rs9908418	ENSG00000270091.1	RP11-78O7.2	-6.09	2.3e-09	4.66e-07	-0.29	-0.27	Schizophrenia;	chr17:20311252	chr17:19896590~19897287:-
THCA	cis	rs72843506	0.591	rs75334890	ENSG00000270091.1	RP11-78O7.2	-6.09	2.3e-09	4.66e-07	-0.29	-0.27	Schizophrenia;	chr17:20318087	chr17:19896590~19897287:-
THCA	cis	rs4950322	0.57	rs72691032	ENSG00000278811.3	LINC00624	6.09	2.3e-09	4.66e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147261120	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72691033	ENSG00000278811.3	LINC00624	6.09	2.3e-09	4.66e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147261267	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs111370771	ENSG00000278811.3	LINC00624	6.09	2.3e-09	4.66e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147261420	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs4301678	ENSG00000278811.3	LINC00624	6.09	2.3e-09	4.66e-07	0.34	0.27	Protein quantitative trait loci;	chr1:147261907	chr1:147258885~147517875:-
THCA	cis	rs7119038	0.774	rs73005426	ENSG00000255239.1	AP002954.6	-6.09	2.3e-09	4.66e-07	-0.39	-0.27	Sjögren's syndrome;	chr11:118810374	chr11:118688039~118690600:-
THCA	cis	rs7302981	0.741	rs4459386	ENSG00000272368.2	RP4-605O3.4	-6.09	2.3e-09	4.66e-07	-0.16	-0.27	Systolic blood pressure;	chr12:50201164	chr12:50112197~50165618:+
THCA	cis	rs6860806	0.661	rs334902	ENSG00000224431.1	AC063976.7	6.09	2.3e-09	4.66e-07	0.23	0.27	Breast cancer;	chr5:132250866	chr5:132199456~132203487:+
THCA	cis	rs728616	0.867	rs56271768	ENSG00000242600.5	MBL1P	6.09	2.31e-09	4.66e-07	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80077295	chr10:79904898~79950336:+
THCA	cis	rs7809950	1	rs10267907	ENSG00000238832.1	snoU109	-6.09	2.31e-09	4.66e-07	-0.29	-0.27	Coronary artery disease;	chr7:107544021	chr7:107603363~107603507:+
THCA	cis	rs28472312	0.894	rs7498491	ENSG00000251417.2	RP11-1348G14.4	-6.09	2.31e-09	4.67e-07	-0.27	-0.27	Intelligence (multi-trait analysis);	chr16:28832747	chr16:28802743~28817828:+
THCA	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	6.09	2.31e-09	4.67e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000228409.4	CCT6P1	6.09	2.31e-09	4.68e-07	0.31	0.27	Diabetic kidney disease;	chr7:65951319	chr7:65751142~65763354:+
THCA	cis	rs13113518	0.812	rs11945371	ENSG00000273257.1	RP11-177J6.1	6.09	2.31e-09	4.68e-07	0.36	0.27	Height;	chr4:55409063	chr4:55387949~55388271:+
THCA	cis	rs227275	0.556	rs223449	ENSG00000230069.3	LRRC37A15P	-6.09	2.31e-09	4.68e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102727274~102730721:-
THCA	cis	rs4664293	0.647	rs1425042	ENSG00000226266.5	AC009961.3	-6.09	2.31e-09	4.68e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159584004	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs7576644	ENSG00000226266.5	AC009961.3	-6.09	2.31e-09	4.68e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159584947	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs7562850	ENSG00000226266.5	AC009961.3	-6.09	2.31e-09	4.68e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159585023	chr2:159670708~159712435:-
THCA	cis	rs4689592	0.503	rs4689064	ENSG00000245468.3	RP11-367J11.3	-6.09	2.32e-09	4.68e-07	-0.24	-0.27	Monocyte percentage of white cells;	chr4:7053876	chr4:7094571~7103385:-
THCA	cis	rs6545883	0.895	rs4430924	ENSG00000271889.1	RP11-493E12.1	6.09	2.32e-09	4.68e-07	0.27	0.27	Tuberculosis;	chr2:61476721	chr2:61151433~61162105:-
THCA	cis	rs1979679	0.842	rs11049380	ENSG00000278733.1	RP11-425D17.1	6.09	2.32e-09	4.68e-07	0.27	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28160904	chr12:28185625~28186190:-
THCA	cis	rs4852324	0.536	rs13387174	ENSG00000217702.2	RP11-287D1.4	6.09	2.32e-09	4.69e-07	0.76	0.27	Systemic lupus erythematosus;	chr2:73979558	chr2:74130583~74135395:+
THCA	cis	rs4664293	0.647	rs7595044	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	4.69e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159589694	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs12623149	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	4.69e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159590835	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.631	rs6714899	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	4.69e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159592895	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs6714917	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	4.69e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159592942	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs6734085	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	4.69e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159595711	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs4665090	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	4.69e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159597396	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs4635484	ENSG00000226266.5	AC009961.3	-6.09	2.32e-09	4.69e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159597619	chr2:159670708~159712435:-
THCA	cis	rs7727544	0.545	rs17674015	ENSG00000224431.1	AC063976.7	6.09	2.32e-09	4.69e-07	0.25	0.27	Blood metabolite levels;	chr5:132026085	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.545	rs3916443	ENSG00000224431.1	AC063976.7	6.09	2.32e-09	4.69e-07	0.25	0.27	Blood metabolite levels;	chr5:132033386	chr5:132199456~132203487:+
THCA	cis	rs853679	0.527	rs9461443	ENSG00000220721.1	OR1F12	6.09	2.32e-09	4.69e-07	0.37	0.27	Depression;	chr6:28226851	chr6:28073316~28074233:+
THCA	cis	rs227275	0.525	rs2086499	ENSG00000230069.3	LRRC37A15P	-6.09	2.32e-09	4.7e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102727274~102730721:-
THCA	cis	rs7512898	0.51	rs7522087	ENSG00000260088.1	RP11-92G12.3	-6.09	2.32e-09	4.7e-07	-0.36	-0.27	Electrocardiographic conduction measures;	chr1:200868190	chr1:200669507~200694250:+
THCA	cis	rs10875746	0.951	rs10875756	ENSG00000269514.1	RP11-370I10.12	6.09	2.32e-09	4.7e-07	0.27	0.27	Longevity (90 years and older);	chr12:48168521	chr12:48198387~48202031:+
THCA	cis	rs4713118	0.513	rs149942	ENSG00000280107.1	AL022393.9	-6.09	2.33e-09	4.7e-07	-0.29	-0.27	Parkinson's disease;	chr6:28033832	chr6:28170845~28172521:+
THCA	cis	rs228614	0.51	rs223452	ENSG00000230069.3	LRRC37A15P	-6.09	2.33e-09	4.71e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102727274~102730721:-
THCA	cis	rs55823223	0.648	rs936393	ENSG00000267801.1	RP11-552F3.9	6.09	2.33e-09	4.71e-07	0.36	0.27	Psoriasis;	chr17:75851532	chr17:75876372~75879546:+
THCA	cis	rs7044106	0.615	rs10818470	ENSG00000270917.1	RP11-27I1.6	-6.09	2.33e-09	4.71e-07	-0.38	-0.27	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120812475~120812845:-
THCA	cis	rs4950322	0.518	rs55697094	ENSG00000278811.3	LINC00624	6.09	2.33e-09	4.71e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147121205	chr1:147258885~147517875:-
THCA	cis	rs16949788	1	rs11071894	ENSG00000261351.2	CTD-3185P2.1	6.09	2.33e-09	4.71e-07	0.32	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66481395	chr15:66488658~66492109:-
THCA	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	6.09	2.33e-09	4.71e-07	0.3	0.27	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
THCA	cis	rs848490	0.889	rs11767942	ENSG00000214293.7	APTR	6.09	2.33e-09	4.72e-07	0.21	0.27	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77589922	chr7:77657660~77696265:-
THCA	cis	rs11783469	0.524	rs17089281	ENSG00000253390.1	CTC-756D1.2	-6.09	2.33e-09	4.72e-07	-0.46	-0.27	Reticulocyte count;	chr8:23477638	chr8:23458601~23484971:+
THCA	cis	rs712022	0.534	rs4494299	ENSG00000246225.5	RP11-17A1.3	-6.09	2.34e-09	4.72e-07	-0.36	-0.27	Dialysis-related mortality;	chr11:22850686	chr11:22829380~22945393:+
THCA	cis	rs748404	0.697	rs546722	ENSG00000166763.7	STRCP1	6.09	2.34e-09	4.72e-07	0.29	0.27	Lung cancer;	chr15:43288621	chr15:43699488~43718184:-
THCA	cis	rs7044106	0.762	rs1547267	ENSG00000270917.1	RP11-27I1.6	-6.09	2.34e-09	4.73e-07	-0.38	-0.27	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.762	rs4142158	ENSG00000270917.1	RP11-27I1.6	-6.09	2.34e-09	4.73e-07	-0.38	-0.27	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120812475~120812845:-
THCA	cis	rs2243480	1	rs67728539	ENSG00000232546.1	RP11-458F8.1	-6.09	2.34e-09	4.73e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66848496~66858136:+
THCA	cis	rs227275	0.525	rs13113923	ENSG00000251288.2	RP11-10L12.2	-6.09	2.34e-09	4.73e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102751401~102752641:+
THCA	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-6.09	2.34e-09	4.73e-07	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
THCA	cis	rs7809950	1	rs2712214	ENSG00000238832.1	snoU109	-6.09	2.34e-09	4.73e-07	-0.29	-0.27	Coronary artery disease;	chr7:107547586	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs2712215	ENSG00000238832.1	snoU109	-6.09	2.34e-09	4.73e-07	-0.29	-0.27	Coronary artery disease;	chr7:107547762	chr7:107603363~107603507:+
THCA	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	6.09	2.34e-09	4.73e-07	0.55	0.27	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
THCA	cis	rs712022	0.935	rs2286810	ENSG00000246225.5	RP11-17A1.3	6.09	2.34e-09	4.73e-07	0.35	0.27	Dialysis-related mortality;	chr11:22829863	chr11:22829380~22945393:+
THCA	cis	rs258324	0.79	rs460319	ENSG00000260259.1	RP11-368I7.4	6.09	2.34e-09	4.74e-07	0.38	0.27	Height;	chr16:89667685	chr16:89682620~89686569:-
THCA	cis	rs7615952	0.932	rs13314869	ENSG00000241288.6	RP11-379B18.5	-6.09	2.35e-09	4.74e-07	-0.34	-0.27	Blood pressure (smoking interaction);	chr3:125925826	chr3:125827238~125916384:-
THCA	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	6.09	2.35e-09	4.74e-07	0.31	0.27	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
THCA	cis	rs10129255	0.957	rs8009073	ENSG00000211974.3	IGHV2-70	6.09	2.35e-09	4.75e-07	0.21	0.27	Kawasaki disease;	chr14:106777278	chr14:106723574~106724093:-
THCA	cis	rs2439831	0.867	rs28729853	ENSG00000249839.1	AC011330.5	-6.09	2.35e-09	4.75e-07	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43381482	chr15:43663654~43684339:-
THCA	cis	rs7202877	0.61	rs3784936	ENSG00000261783.1	RP11-252K23.2	-6.09	2.35e-09	4.76e-07	-0.48	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75303685	chr16:75379818~75381260:-
THCA	cis	rs6570726	0.533	rs1832374	ENSG00000235652.6	RP11-545I5.3	6.09	2.35e-09	4.76e-07	0.25	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145396616	chr6:145799409~145886585:+
THCA	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	6.09	2.35e-09	4.76e-07	0.29	0.27	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
THCA	cis	rs7044106	0.762	rs1158553	ENSG00000270917.1	RP11-27I1.6	-6.09	2.36e-09	4.76e-07	-0.38	-0.27	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120812475~120812845:-
THCA	cis	rs9677476	0.863	rs4637098	ENSG00000224376.1	AC017104.6	6.09	2.36e-09	4.76e-07	0.31	0.27	Food antigen IgG levels;	chr2:231210815	chr2:231388976~231394991:+
THCA	cis	rs5742933	0.817	rs7591929	ENSG00000253559.1	OSGEPL1-AS1	6.09	2.36e-09	4.76e-07	0.3	0.27	Ferritin levels;	chr2:189778531	chr2:189762704~189765556:+
THCA	cis	rs1275468	0.731	rs1795380	ENSG00000257497.2	RP11-585P4.5	-6.09	2.36e-09	4.77e-07	-0.41	-0.27	Polycystic ovary syndrome;	chr12:75559432	chr12:75483454~75489820:-
THCA	cis	rs1275468	0.678	rs2620687	ENSG00000257497.2	RP11-585P4.5	-6.09	2.36e-09	4.77e-07	-0.41	-0.27	Polycystic ovary syndrome;	chr12:75560395	chr12:75483454~75489820:-
THCA	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	6.09	2.36e-09	4.77e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
THCA	cis	rs1859596	1	rs1859596	ENSG00000234456.6	MAGI2-AS3	-6.09	2.36e-09	4.77e-07	-0.26	-0.27	Reading or mathematical ability;	chr7:79480326	chr7:79452877~79471208:+
THCA	cis	rs9381040	1	rs2093395	ENSG00000161912.16	ADCY10P1	-6.09	2.36e-09	4.77e-07	-0.18	-0.27	Alzheimer's disease (late onset);	chr6:41187288	chr6:41101022~41140835:+
THCA	cis	rs3096299	0.589	rs3114898	ENSG00000274627.1	RP11-104N10.2	6.09	2.36e-09	4.77e-07	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89325907	chr16:89516797~89522217:+
THCA	cis	rs7968440	0.591	rs6580732	ENSG00000272368.2	RP4-605O3.4	-6.09	2.37e-09	4.78e-07	-0.16	-0.27	Fibrinogen;	chr12:50252496	chr12:50112197~50165618:+
THCA	cis	rs9880211	0.898	rs9870825	ENSG00000273486.1	RP11-731C17.2	6.09	2.37e-09	4.78e-07	0.28	0.27	Height;Body mass index;	chr3:136346878	chr3:136837338~136839021:-
THCA	cis	rs853679	0.607	rs67340775	ENSG00000219392.1	RP1-265C24.5	-6.09	2.37e-09	4.78e-07	-0.6	-0.27	Depression;	chr6:28336607	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs35030260	ENSG00000219392.1	RP1-265C24.5	-6.09	2.37e-09	4.78e-07	-0.6	-0.27	Depression;	chr6:28337731	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13217619	ENSG00000219392.1	RP1-265C24.5	-6.09	2.37e-09	4.78e-07	-0.6	-0.27	Depression;	chr6:28338894	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs35016036	ENSG00000219392.1	RP1-265C24.5	-6.09	2.37e-09	4.78e-07	-0.6	-0.27	Depression;	chr6:28347103	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs35744819	ENSG00000219392.1	RP1-265C24.5	-6.09	2.37e-09	4.78e-07	-0.6	-0.27	Depression;	chr6:28350554	chr6:28115628~28116551:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-6.09	2.37e-09	4.79e-07	-0.3	-0.27	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
THCA	cis	rs2562456	0.917	rs2650793	ENSG00000268081.1	RP11-678G14.2	-6.09	2.37e-09	4.79e-07	-0.38	-0.27	Pain;	chr19:21493313	chr19:21554640~21569237:-
THCA	cis	rs7529073	0.545	rs1431985	ENSG00000274895.1	RP11-478J18.2	-6.09	2.37e-09	4.79e-07	-0.22	-0.27	Schizophrenia;	chr1:213974903	chr1:213983793~213986419:-
THCA	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	6.09	2.37e-09	4.79e-07	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
THCA	cis	rs7615952	0.512	rs2979351	ENSG00000241278.1	ENPP7P4	6.09	2.37e-09	4.79e-07	0.34	0.27	Blood pressure (smoking interaction);	chr3:125644755	chr3:125848223~125909372:+
THCA	cis	rs7833787	0.965	rs6991832	ENSG00000278886.1	RP11-108A14.1	6.09	2.37e-09	4.79e-07	0.35	0.27	Obesity-related traits;	chr8:18853431	chr8:18864681~18865247:-
THCA	cis	rs9494145	0.68	rs9389269	ENSG00000232876.1	CTA-212D2.2	-6.09	2.37e-09	4.79e-07	-0.38	-0.27	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106021	chr6:135055033~135060550:+
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	6.09	2.38e-09	4.8e-07	0.3	0.27	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
THCA	cis	rs6740322	0.895	rs6760797	ENSG00000234936.1	AC010883.5	6.09	2.38e-09	4.8e-07	0.29	0.27	Coronary artery disease;	chr2:43332473	chr2:43229573~43233394:+
THCA	cis	rs7809950	1	rs2808	ENSG00000238832.1	snoU109	6.09	2.38e-09	4.8e-07	0.29	0.27	Coronary artery disease;	chr7:107620411	chr7:107603363~107603507:+
THCA	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-6.09	2.38e-09	4.8e-07	-0.32	-0.27	Height;	chr2:231516587	chr2:231501990~231502201:-
THCA	cis	rs9649465	1	rs55633050	ENSG00000272686.1	RP11-390E23.6	6.09	2.38e-09	4.8e-07	0.18	0.27	Migraine;	chr7:123748420	chr7:123749068~123751166:+
THCA	cis	rs1552244	1	rs6804473	ENSG00000232901.1	CYCSP10	6.09	2.38e-09	4.8e-07	0.36	0.27	Alzheimer's disease;	chr3:10018741	chr3:10000647~10000940:-
THCA	cis	rs526231	0.819	rs2561482	ENSG00000175749.11	EIF3KP1	6.09	2.38e-09	4.8e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103262097	chr5:103032376~103033031:+
THCA	cis	rs4143844	1	rs62007448	ENSG00000259251.2	RP11-643M14.1	6.09	2.38e-09	4.8e-07	0.51	0.27	Bipolar disorder and schizophrenia;	chr15:62036971	chr15:62060503~62062434:+
THCA	cis	rs4143844	1	rs11634312	ENSG00000259251.2	RP11-643M14.1	6.09	2.38e-09	4.8e-07	0.51	0.27	Bipolar disorder and schizophrenia;	chr15:62038868	chr15:62060503~62062434:+
THCA	cis	rs73198271	0.722	rs488566	ENSG00000253893.2	FAM85B	6.09	2.38e-09	4.81e-07	0.37	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8782065	chr8:8167819~8226614:-
THCA	cis	rs728616	0.867	rs17096197	ENSG00000242600.5	MBL1P	6.09	2.38e-09	4.81e-07	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80048428	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs56123058	ENSG00000242600.5	MBL1P	6.09	2.38e-09	4.81e-07	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:79904898~79950336:+
THCA	cis	rs1865760	0.602	rs2157050	ENSG00000272462.2	U91328.19	-6.09	2.38e-09	4.81e-07	-0.22	-0.27	Height;	chr6:26020203	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.602	rs9467662	ENSG00000272462.2	U91328.19	-6.09	2.38e-09	4.81e-07	-0.22	-0.27	Height;	chr6:26021099	chr6:25992662~26001775:+
THCA	cis	rs7119038	0.818	rs6589686	ENSG00000255239.1	AP002954.6	-6.09	2.38e-09	4.81e-07	-0.4	-0.27	Sjögren's syndrome;	chr11:118741856	chr11:118688039~118690600:-
THCA	cis	rs792448	0.743	rs10019	ENSG00000226251.4	RP11-15I11.3	-6.09	2.38e-09	4.81e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212361035	chr1:212225278~212238977:-
THCA	cis	rs7809950	1	rs10251808	ENSG00000238832.1	snoU109	-6.09	2.39e-09	4.82e-07	-0.29	-0.27	Coronary artery disease;	chr7:107480008	chr7:107603363~107603507:+
THCA	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-6.09	2.39e-09	4.82e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
THCA	cis	rs72843506	0.656	rs74333705	ENSG00000270091.1	RP11-78O7.2	-6.09	2.39e-09	4.82e-07	-0.3	-0.27	Schizophrenia;	chr17:20097448	chr17:19896590~19897287:-
THCA	cis	rs7403037	1	rs7403037	ENSG00000259905.4	PWRN1	-6.09	2.39e-09	4.82e-07	-0.3	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24573350	chr15:24493137~24652130:+
THCA	cis	rs4664293	0.647	rs10196064	ENSG00000226266.5	AC009961.3	-6.09	2.39e-09	4.82e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159569454	chr2:159670708~159712435:-
THCA	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	6.09	2.39e-09	4.83e-07	0.24	0.27	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
THCA	cis	rs6674176	0.597	rs6671164	ENSG00000237950.1	RP11-7O11.3	6.09	2.39e-09	4.83e-07	0.25	0.27	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43937817	chr1:43944370~43946551:-
THCA	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-6.09	2.39e-09	4.83e-07	-0.28	-0.27	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
THCA	cis	rs7493	0.806	rs17876090	ENSG00000233942.1	AC004012.1	6.09	2.4e-09	4.84e-07	0.41	0.27	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424092	chr7:95471835~95473998:+
THCA	cis	rs2018683	0.707	rs2057957	ENSG00000228421.2	AC005013.5	-6.09	2.4e-09	4.84e-07	-0.3	-0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935009	chr7:28957667~28959345:+
THCA	cis	rs9859260	0.614	rs493661	ENSG00000242086.7	LINC00969	-6.09	2.4e-09	4.84e-07	-0.27	-0.27	Mean corpuscular volume;	chr3:196059618	chr3:195658062~195739964:+
THCA	cis	rs934734	0.752	rs268131	ENSG00000234255.7	AC012370.3	-6.09	2.4e-09	4.85e-07	-0.3	-0.27	Rheumatoid arthritis;	chr2:65383337	chr2:65439888~65456571:-
THCA	cis	rs34779708	0.733	rs3936503	ENSG00000271335.4	RP11-324I22.4	-6.09	2.4e-09	4.85e-07	-0.26	-0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35314552~35336401:-
THCA	cis	rs8002861	0.87	rs4942254	ENSG00000274001.1	RP11-5G9.5	6.09	2.4e-09	4.85e-07	0.3	0.27	Leprosy;	chr13:43877684	chr13:43877715~43878163:-
THCA	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-6.09	2.4e-09	4.85e-07	-0.3	-0.27	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
THCA	cis	rs6545883	0.826	rs777591	ENSG00000271889.1	RP11-493E12.1	6.09	2.4e-09	4.85e-07	0.25	0.27	Tuberculosis;	chr2:61190482	chr2:61151433~61162105:-
THCA	cis	rs4713118	0.615	rs57252182	ENSG00000219392.1	RP1-265C24.5	-6.09	2.41e-09	4.85e-07	-0.32	-0.27	Parkinson's disease;	chr6:27752470	chr6:28115628~28116551:+
THCA	cis	rs34034915	1	rs34034915	ENSG00000219392.1	RP1-265C24.5	-6.09	2.41e-09	4.85e-07	-0.32	-0.27	Hepatitis A;	chr6:27752924	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.527	rs36042294	ENSG00000219392.1	RP1-265C24.5	-6.09	2.41e-09	4.85e-07	-0.32	-0.27	Parkinson's disease;	chr6:27752933	chr6:28115628~28116551:+
THCA	cis	rs4143844	1	rs12913358	ENSG00000259251.2	RP11-643M14.1	6.09	2.41e-09	4.85e-07	0.51	0.27	Bipolar disorder and schizophrenia;	chr15:62032293	chr15:62060503~62062434:+
THCA	cis	rs3794924	1	rs35585743	ENSG00000266521.1	RP11-650P15.1	6.09	2.41e-09	4.85e-07	0.52	0.27	Survival in colon cancer;	chr18:31470398	chr18:31496645~31497195:-
THCA	cis	rs11020821	0.828	rs16924603	ENSG00000255893.1	RP11-685N10.1	-6.09	2.41e-09	4.86e-07	-0.32	-0.27	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94522093	chr11:94472908~94473570:-
THCA	cis	rs6669008	1	rs1891969	ENSG00000232450.1	RP4-730K3.3	-6.09	2.41e-09	4.86e-07	-0.3	-0.27	Bacteremia;	chr1:113643233	chr1:113698884~113699631:-
THCA	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	6.09	2.41e-09	4.86e-07	0.46	0.27	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
THCA	cis	rs10276381	0.901	rs73300638	ENSG00000234336.5	JAZF1-AS1	-6.09	2.41e-09	4.87e-07	-0.4	-0.27	Crohn's disease;	chr7:28147725	chr7:28180322~28243917:+
THCA	cis	rs2281636	0.823	rs4917877	ENSG00000260475.1	RP11-85A1.3	6.09	2.41e-09	4.87e-07	0.24	0.27	Obesity-related traits;	chr10:99670281	chr10:99621055~99621918:+
THCA	cis	rs9880211	0.948	rs9872178	ENSG00000273486.1	RP11-731C17.2	6.09	2.42e-09	4.87e-07	0.28	0.27	Height;Body mass index;	chr3:136267596	chr3:136837338~136839021:-
THCA	cis	rs7044106	0.762	rs7044226	ENSG00000270917.1	RP11-27I1.6	-6.09	2.42e-09	4.87e-07	-0.38	-0.27	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120812475~120812845:-
THCA	cis	rs5742933	0.652	rs10210345	ENSG00000253559.1	OSGEPL1-AS1	6.09	2.42e-09	4.87e-07	0.3	0.27	Ferritin levels;	chr2:189754760	chr2:189762704~189765556:+
THCA	cis	rs11976180	1	rs2961134	ENSG00000170356.8	OR2A20P	-6.09	2.42e-09	4.88e-07	-0.37	-0.27	Obesity-related traits;	chr7:144073969	chr7:144250045~144252957:-
THCA	cis	rs916888	0.61	rs199436	ENSG00000232300.1	FAM215B	-6.09	2.42e-09	4.88e-07	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46558830~46562795:-
THCA	cis	rs2303319	1	rs60767767	ENSG00000227403.1	AC009299.3	6.08	2.42e-09	4.88e-07	0.57	0.27	Cognitive function;	chr2:161329047	chr2:161244739~161249050:+
THCA	cis	rs7260598	0.581	rs17311328	ENSG00000268442.1	CTD-2027I19.2	6.08	2.42e-09	4.88e-07	0.4	0.27	Response to taxane treatment (placlitaxel);	chr19:24186640	chr19:24162370~24163425:-
THCA	cis	rs10078	0.528	rs2434697	ENSG00000221990.4	EXOC3-AS1	6.08	2.42e-09	4.88e-07	0.28	0.27	Fat distribution (HIV);	chr5:466696	chr5:441498~443160:-
THCA	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-6.08	2.42e-09	4.89e-07	-0.37	-0.27	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
THCA	cis	rs4803480	0.578	rs7252454	ENSG00000270164.1	LINC01480	-6.08	2.43e-09	4.89e-07	-0.26	-0.27	Schizophrenia;	chr19:41527343	chr19:41535183~41536904:+
THCA	cis	rs9475752	0.564	rs13191084	ENSG00000231441.1	RP11-472M19.2	-6.08	2.43e-09	4.89e-07	-0.3	-0.27	Menarche (age at onset);	chr6:56875706	chr6:56844002~56864078:+
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	6.08	2.43e-09	4.9e-07	0.3	0.27	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	6.08	2.43e-09	4.9e-07	0.3	0.27	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
THCA	cis	rs2439831	0.681	rs524527	ENSG00000249839.1	AC011330.5	6.08	2.43e-09	4.9e-07	0.4	0.27	Lung cancer in ever smokers;	chr15:43306918	chr15:43663654~43684339:-
THCA	cis	rs17772222	1	rs7145588	ENSG00000258789.1	RP11-507K2.3	-6.08	2.43e-09	4.9e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88360452	chr14:88551597~88552493:+
THCA	cis	rs17772222	1	rs61977049	ENSG00000258789.1	RP11-507K2.3	-6.08	2.43e-09	4.9e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88360656	chr14:88551597~88552493:+
THCA	cis	rs17772222	1	rs12587386	ENSG00000258789.1	RP11-507K2.3	-6.08	2.43e-09	4.9e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88361420	chr14:88551597~88552493:+
THCA	cis	rs2364403	1	rs12091273	ENSG00000225855.5	RUSC1-AS1	6.08	2.43e-09	4.9e-07	0.2	0.27	Amyotrophic lateral sclerosis (age of onset);	chr1:155959771	chr1:155316863~155324176:-
THCA	cis	rs2281636	0.625	rs7075305	ENSG00000233690.1	EBAG9P1	-6.08	2.43e-09	4.91e-07	-0.29	-0.27	Obesity-related traits;	chr10:99604767	chr10:99697407~99697949:-
THCA	cis	rs7615952	0.534	rs1503072	ENSG00000250012.1	RP11-124N2.1	-6.08	2.43e-09	4.91e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126035848	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.599	rs7631268	ENSG00000250012.1	RP11-124N2.1	-6.08	2.43e-09	4.91e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126036821	chr3:126084220~126095349:+
THCA	cis	rs2562456	0.917	rs2681392	ENSG00000213976.4	CTD-2561J22.2	6.08	2.44e-09	4.91e-07	0.29	0.27	Pain;	chr19:21513185	chr19:21382865~21387177:+
THCA	cis	rs2765539	0.701	rs10754391	ENSG00000231365.4	RP11-418J17.1	-6.08	2.44e-09	4.92e-07	-0.3	-0.27	Waist-hip ratio;	chr1:119087081	chr1:119140396~119275973:+
THCA	cis	rs60180747	0.543	rs1871006	ENSG00000261318.1	RP11-653J6.1	6.08	2.44e-09	4.92e-07	0.36	0.27	Testicular germ cell tumor;	chr15:66255303	chr15:66278498~66293357:-
THCA	cis	rs890448	0.796	rs1125180	ENSG00000254531.1	FLJ20021	6.08	2.44e-09	4.92e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101400473	chr4:101347780~101348883:+
THCA	cis	rs11976180	1	rs13243677	ENSG00000273234.1	OR2A13P	-6.08	2.44e-09	4.92e-07	-0.3	-0.27	Obesity-related traits;	chr7:144049479	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs13226728	ENSG00000273234.1	OR2A13P	-6.08	2.44e-09	4.92e-07	-0.3	-0.27	Obesity-related traits;	chr7:144049485	chr7:144142009~144142938:+
THCA	cis	rs950169	0.58	rs11633762	ENSG00000259295.5	CSPG4P12	6.08	2.44e-09	4.93e-07	0.41	0.27	Schizophrenia;	chr15:84643921	chr15:85191438~85213905:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-6.08	2.44e-09	4.93e-07	-0.31	-0.27	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
THCA	cis	rs6860806	0.507	rs272883	ENSG00000263597.1	MIR3936	6.08	2.44e-09	4.93e-07	0.27	0.27	Breast cancer;	chr5:132333005	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.507	rs272882	ENSG00000263597.1	MIR3936	6.08	2.44e-09	4.93e-07	0.27	0.27	Breast cancer;	chr5:132333468	chr5:132365490~132365599:-
THCA	cis	rs6671200	0.607	rs3767313	ENSG00000228852.5	RP11-57H12.5	-6.08	2.44e-09	4.93e-07	-0.32	-0.27	Stearic acid (18:0) levels;	chr1:95247241	chr1:95243167~95278940:-
THCA	cis	rs6671200	0.573	rs3820345	ENSG00000228852.5	RP11-57H12.5	-6.08	2.44e-09	4.93e-07	-0.32	-0.27	Stearic acid (18:0) levels;	chr1:95247619	chr1:95243167~95278940:-
THCA	cis	rs6671200	0.688	rs4950024	ENSG00000228852.5	RP11-57H12.5	-6.08	2.44e-09	4.93e-07	-0.32	-0.27	Stearic acid (18:0) levels;	chr1:95247943	chr1:95243167~95278940:-
THCA	cis	rs2408955	0.561	rs11168365	ENSG00000258273.1	RP11-370I10.4	6.08	2.44e-09	4.93e-07	0.36	0.27	Glycated hemoglobin levels;	chr12:48027989	chr12:48333755~48333901:-
THCA	cis	rs4713118	0.513	rs156734	ENSG00000280107.1	AL022393.9	-6.08	2.45e-09	4.93e-07	-0.29	-0.27	Parkinson's disease;	chr6:28039579	chr6:28170845~28172521:+
THCA	cis	rs6545883	0.826	rs777593	ENSG00000271889.1	RP11-493E12.1	6.08	2.45e-09	4.93e-07	0.26	0.27	Tuberculosis;	chr2:61191968	chr2:61151433~61162105:-
THCA	cis	rs17301013	0.507	rs1613634	ENSG00000227373.4	RP11-160H22.5	-6.08	2.45e-09	4.93e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174803184	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	6.08	2.45e-09	4.93e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
THCA	cis	rs4650994	0.544	rs2476560	ENSG00000273384.1	RP5-1098D14.1	-6.08	2.45e-09	4.94e-07	-0.34	-0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178625784	chr1:178651706~178652282:+
THCA	cis	rs713477	1	rs7148481	ENSG00000258413.1	RP11-665C16.6	6.08	2.45e-09	4.94e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55442549	chr14:55262767~55272075:-
THCA	cis	rs228614	0.51	rs223438	ENSG00000230069.3	LRRC37A15P	6.08	2.45e-09	4.94e-07	0.28	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102727274~102730721:-
THCA	cis	rs72627509	0.904	rs12645070	ENSG00000269949.1	RP11-738E22.3	6.08	2.45e-09	4.94e-07	0.38	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903940	chr4:56960927~56961373:-
THCA	cis	rs934734	0.563	rs11126035	ENSG00000234255.7	AC012370.3	6.08	2.45e-09	4.94e-07	0.32	0.27	Rheumatoid arthritis;	chr2:65369932	chr2:65439888~65456571:-
THCA	cis	rs5758659	0.653	rs133383	ENSG00000227370.1	RP4-669P10.19	-6.08	2.45e-09	4.95e-07	-0.25	-0.27	Cognitive function;	chr22:42077599	chr22:42132543~42132998:+
THCA	cis	rs4713118	0.824	rs9366702	ENSG00000280107.1	AL022393.9	-6.08	2.45e-09	4.95e-07	-0.32	-0.27	Parkinson's disease;	chr6:27766691	chr6:28170845~28172521:+
THCA	cis	rs7176527	0.848	rs72630462	ENSG00000188388.10	GOLGA6L3	6.08	2.46e-09	4.95e-07	0.48	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:85240472~85247170:+
THCA	cis	rs1552244	0.572	rs6442154	ENSG00000232901.1	CYCSP10	6.08	2.46e-09	4.95e-07	0.41	0.27	Alzheimer's disease;	chr3:10127101	chr3:10000647~10000940:-
THCA	cis	rs9859260	0.744	rs406271	ENSG00000242086.7	LINC00969	-6.08	2.46e-09	4.96e-07	-0.27	-0.27	Mean corpuscular volume;	chr3:196050105	chr3:195658062~195739964:+
THCA	cis	rs12908161	0.96	rs11633450	ENSG00000259295.5	CSPG4P12	6.08	2.47e-09	4.97e-07	0.41	0.27	Schizophrenia;	chr15:84764056	chr15:85191438~85213905:+
THCA	cis	rs228614	0.51	rs223451	ENSG00000230069.3	LRRC37A15P	-6.08	2.47e-09	4.97e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223450	ENSG00000230069.3	LRRC37A15P	-6.08	2.47e-09	4.97e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102727274~102730721:-
THCA	cis	rs3213958	0.574	rs12203	ENSG00000249274.1	PDLIM1P4	6.08	2.47e-09	4.97e-07	0.34	0.27	Blood protein levels;	chr3:98795197	chr3:98782188~98783193:+
THCA	cis	rs8007846	0.588	rs730807	ENSG00000276116.2	FUT8-AS1	-6.08	2.47e-09	4.97e-07	-0.27	-0.27	Multiple sclerosis--Brain Glutamate Levels;	chr14:65772572	chr14:65411170~65412690:-
THCA	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	6.08	2.47e-09	4.97e-07	0.31	0.27	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	6.08	2.47e-09	4.97e-07	0.31	0.27	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
THCA	cis	rs1866631	0.572	rs3769157	ENSG00000238133.5	MLK7-AS1	-6.08	2.47e-09	4.98e-07	-0.34	-0.27	Lung cancer in ever smokers;	chr2:173214674	chr2:173166446~173282036:-
THCA	cis	rs1823913	0.927	rs56209234	ENSG00000280083.1	RP11-317J9.1	-6.08	2.47e-09	4.98e-07	-0.33	-0.27	Obesity-related traits;	chr2:191261748	chr2:191154118~191156070:-
THCA	cis	rs7809950	0.862	rs12112877	ENSG00000238832.1	snoU109	-6.08	2.47e-09	4.98e-07	-0.29	-0.27	Coronary artery disease;	chr7:107300879	chr7:107603363~107603507:+
THCA	cis	rs739525	0.518	rs178268	ENSG00000272829.1	XXbac-B135H6.18	6.08	2.47e-09	4.98e-07	0.24	0.27	Testicular germ cell tumor;	chr22:20975977	chr22:20981361~20981755:-
THCA	cis	rs1275468	0.731	rs1627431	ENSG00000257497.2	RP11-585P4.5	-6.08	2.47e-09	4.98e-07	-0.41	-0.27	Polycystic ovary syndrome;	chr12:75569132	chr12:75483454~75489820:-
THCA	cis	rs516805	0.528	rs2606633	ENSG00000279453.1	RP3-425C14.4	-6.08	2.47e-09	4.98e-07	-0.31	-0.27	Lymphocyte counts;	chr6:122100131	chr6:122436789~122439223:-
THCA	cis	rs5758659	0.716	rs5758661	ENSG00000281538.1	RP4-669P10.20	6.08	2.47e-09	4.99e-07	0.24	0.27	Cognitive function;	chr22:42228439	chr22:42138060~42139726:+
THCA	cis	rs12612619	0.732	rs2304681	ENSG00000229122.1	AGBL5-IT1	-6.08	2.48e-09	4.99e-07	-0.2	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092384	chr2:27061038~27061815:+
THCA	cis	rs686320	0.748	rs673753	ENSG00000245532.5	NEAT1	-6.08	2.48e-09	4.99e-07	-0.26	-0.27	Hip circumference adjusted for BMI;	chr11:65438546	chr11:65422774~65445540:+
THCA	cis	rs6600671	1	rs6600669	ENSG00000275538.1	RNVU1-19	6.08	2.48e-09	4.99e-07	0.34	0.27	Hip geometry;	chr1:121471785	chr1:120850819~120850985:-
THCA	cis	rs720475	0.695	rs62483108	ENSG00000204959.4	ARHGEF34P	-6.08	2.48e-09	4.99e-07	-0.31	-0.27	Breast cancer;	chr7:144442326	chr7:144272445~144286966:-
THCA	cis	rs11148252	0.716	rs3803262	ENSG00000235660.1	LINC00345	-6.08	2.48e-09	5e-07	-0.34	-0.27	Lewy body disease;	chr13:52462263	chr13:52484161~52484680:-
THCA	cis	rs17772222	1	rs56987357	ENSG00000258789.1	RP11-507K2.3	-6.08	2.48e-09	5e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88358019	chr14:88551597~88552493:+
THCA	cis	rs7260598	0.642	rs10403746	ENSG00000268442.1	CTD-2027I19.2	6.08	2.48e-09	5e-07	0.36	0.27	Response to taxane treatment (placlitaxel);	chr19:23924452	chr19:24162370~24163425:-
THCA	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-6.08	2.48e-09	5e-07	-0.31	-0.27	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
THCA	cis	rs2243480	1	rs958550	ENSG00000229886.1	RP5-1132H15.3	-6.08	2.48e-09	5e-07	-0.43	-0.27	Diabetic kidney disease;	chr7:66170692	chr7:66025126~66031544:-
THCA	cis	rs4948102	0.551	rs4275190	ENSG00000273720.1	RP11-613E4.4	-6.08	2.48e-09	5e-07	-0.36	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55743073~55743457:+
THCA	cis	rs12935418	0.83	rs7188549	ENSG00000261061.1	RP11-303E16.2	-6.08	2.49e-09	5.01e-07	-0.32	-0.27	Mean corpuscular volume;	chr16:81016371	chr16:81030770~81031485:+
THCA	cis	rs2364403	1	rs12091361	ENSG00000225855.5	RUSC1-AS1	6.08	2.49e-09	5.02e-07	0.2	0.27	Amyotrophic lateral sclerosis (age of onset);	chr1:155959882	chr1:155316863~155324176:-
THCA	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	6.08	2.49e-09	5.02e-07	0.31	0.27	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	6.08	2.49e-09	5.02e-07	0.31	0.27	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
THCA	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-6.08	2.49e-09	5.02e-07	-0.31	-0.27	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-6.08	2.49e-09	5.02e-07	-0.31	-0.27	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
THCA	cis	rs10208649	1	rs6712561	ENSG00000272156.1	RP11-477N3.1	6.08	2.49e-09	5.02e-07	0.49	0.27	Body mass index;	chr2:53836808	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs6740063	ENSG00000272156.1	RP11-477N3.1	6.08	2.49e-09	5.02e-07	0.49	0.27	Body mass index;	chr2:53841732	chr2:54082554~54085066:+
THCA	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	6.08	2.49e-09	5.02e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
THCA	cis	rs7829975	0.774	rs13259216	ENSG00000254153.1	CTA-398F10.2	-6.08	2.49e-09	5.02e-07	-0.29	-0.27	Mood instability;	chr8:8816091	chr8:8456909~8461337:-
THCA	cis	rs9467773	0.529	rs7356988	ENSG00000124549.13	BTN2A3P	-6.08	2.49e-09	5.02e-07	-0.26	-0.27	Intelligence (multi-trait analysis);	chr6:26396499	chr6:26421391~26432383:+
THCA	cis	rs6908034	0.66	rs12525506	ENSG00000227116.1	RP3-471C18.1	-6.08	2.49e-09	5.02e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19794003	chr6:19730427~19734567:-
THCA	cis	rs7615952	0.599	rs12485717	ENSG00000250012.1	RP11-124N2.1	6.08	2.49e-09	5.02e-07	0.26	0.27	Blood pressure (smoking interaction);	chr3:125988232	chr3:126084220~126095349:+
THCA	cis	rs9311474	0.713	rs352167	ENSG00000243224.1	RP5-1157M23.2	6.08	2.49e-09	5.02e-07	0.27	0.27	Electroencephalogram traits;	chr3:52204640	chr3:52239258~52241097:+
THCA	cis	rs7688540	0.8	rs11731285	ENSG00000275426.1	CH17-262A2.1	6.08	2.5e-09	5.02e-07	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:149738~150317:+
THCA	cis	rs2562456	0.682	rs11085464	ENSG00000213976.4	CTD-2561J22.2	-6.08	2.5e-09	5.03e-07	-0.29	-0.27	Pain;	chr19:21568976	chr19:21382865~21387177:+
THCA	cis	rs17102884	0.506	rs887746	ENSG00000279594.1	RP11-950C14.10	-6.08	2.5e-09	5.03e-07	-0.26	-0.27	Neuroticism;	chr14:74937114	chr14:75011269~75012851:-
THCA	cis	rs10875746	0.859	rs4760622	ENSG00000269514.1	RP11-370I10.12	6.08	2.5e-09	5.03e-07	0.27	0.27	Longevity (90 years and older);	chr12:48198177	chr12:48198387~48202031:+
THCA	cis	rs228614	0.51	rs3774987	ENSG00000230069.3	LRRC37A15P	-6.08	2.5e-09	5.03e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102727274~102730721:-
THCA	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	6.08	2.5e-09	5.04e-07	0.28	0.27	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
THCA	cis	rs9880211	0.948	rs13321721	ENSG00000273486.1	RP11-731C17.2	6.08	2.51e-09	5.05e-07	0.28	0.27	Height;Body mass index;	chr3:136490708	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs67949818	ENSG00000273486.1	RP11-731C17.2	6.08	2.51e-09	5.05e-07	0.28	0.27	Height;Body mass index;	chr3:136494136	chr3:136837338~136839021:-
THCA	cis	rs736801	0.74	rs17622378	ENSG00000233006.5	AC034220.3	6.08	2.51e-09	5.05e-07	0.22	0.27	Mosquito bite size;Breast cancer;	chr5:132442760	chr5:132311285~132369916:-
THCA	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-6.08	2.51e-09	5.05e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
THCA	cis	rs2274273	0.567	rs2878172	ENSG00000258413.1	RP11-665C16.6	-6.08	2.51e-09	5.06e-07	-0.36	-0.27	Protein biomarker;	chr14:54906952	chr14:55262767~55272075:-
THCA	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	6.08	2.51e-09	5.06e-07	0.29	0.27	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
THCA	cis	rs8042680	1	rs12898311	ENSG00000214432.8	AC068831.10	-6.08	2.51e-09	5.06e-07	-0.3	-0.27	Type 2 diabetes;	chr15:90974550	chr15:91022619~91036611:+
THCA	cis	rs17772222	1	rs17772064	ENSG00000258789.1	RP11-507K2.3	-6.08	2.52e-09	5.06e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88356527	chr14:88551597~88552493:+
THCA	cis	rs4950322	0.542	rs4950382	ENSG00000278811.3	LINC00624	6.08	2.52e-09	5.07e-07	0.31	0.27	Protein quantitative trait loci;	chr1:147176645	chr1:147258885~147517875:-
THCA	cis	rs2562456	0.561	rs12610883	ENSG00000213976.4	CTD-2561J22.2	-6.08	2.52e-09	5.07e-07	-0.29	-0.27	Pain;	chr19:21567257	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.793	rs7259708	ENSG00000213976.4	CTD-2561J22.2	-6.08	2.52e-09	5.07e-07	-0.29	-0.27	Pain;	chr19:21567846	chr19:21382865~21387177:+
THCA	cis	rs4664293	0.647	rs4665082	ENSG00000226266.5	AC009961.3	-6.08	2.52e-09	5.08e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159573455	chr2:159670708~159712435:-
THCA	cis	rs10844706	0.676	rs10844657	ENSG00000256594.6	RP11-705C15.2	6.08	2.52e-09	5.08e-07	0.23	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9740617	chr12:9633419~9658412:+
THCA	cis	rs12681366	0.708	rs2470718	ENSG00000253704.1	RP11-267M23.4	-6.08	2.53e-09	5.08e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94346849	chr8:94553722~94569745:+
THCA	cis	rs9880211	1	rs6768743	ENSG00000273486.1	RP11-731C17.2	-6.08	2.53e-09	5.08e-07	-0.28	-0.27	Height;Body mass index;	chr3:136486165	chr3:136837338~136839021:-
THCA	cis	rs8114671	0.545	rs2378335	ENSG00000269202.1	RP4-614O4.12	-6.08	2.53e-09	5.09e-07	-0.28	-0.27	Height;	chr20:35169027	chr20:35201747~35203288:-
THCA	cis	rs890448	0.726	rs2583399	ENSG00000254531.1	FLJ20021	-6.08	2.53e-09	5.09e-07	-0.24	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101315757	chr4:101347780~101348883:+
THCA	cis	rs7851660	0.935	rs12347191	ENSG00000214417.4	KRT18P13	-6.08	2.53e-09	5.09e-07	-0.23	-0.27	Strep throat;	chr9:97857437	chr9:97698922~97700734:+
THCA	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-6.08	2.53e-09	5.09e-07	-0.34	-0.27	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
THCA	cis	rs9467773	0.609	rs12663780	ENSG00000124549.13	BTN2A3P	-6.08	2.53e-09	5.1e-07	-0.26	-0.27	Intelligence (multi-trait analysis);	chr6:26397345	chr6:26421391~26432383:+
THCA	cis	rs287982	0.611	rs79276033	ENSG00000269973.1	RP11-95D17.1	-6.08	2.53e-09	5.1e-07	-0.24	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9835868	chr2:9936360~9939590:+
THCA	cis	rs897984	0.542	rs6565217	ENSG00000279196.1	RP11-1072A3.3	6.08	2.53e-09	5.1e-07	0.26	0.27	Dementia with Lewy bodies;	chr16:31072003	chr16:30984630~30988270:-
THCA	cis	rs896854	0.54	rs2011567	ENSG00000253528.2	RP11-347C18.4	6.08	2.54e-09	5.1e-07	0.3	0.27	Type 2 diabetes;	chr8:94959692	chr8:94974573~94974853:-
THCA	cis	rs11089937	0.626	rs9622968	ENSG00000211639.2	IGLV4-60	6.08	2.54e-09	5.1e-07	0.2	0.27	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22162199~22162681:+
THCA	cis	rs11158026	0.757	rs17128120	ENSG00000258413.1	RP11-665C16.6	-6.08	2.54e-09	5.11e-07	-0.37	-0.27	Parkinson's disease;	chr14:55007880	chr14:55262767~55272075:-
THCA	cis	rs10771431	0.817	rs17202253	ENSG00000111788.10	RP11-22B23.1	6.08	2.54e-09	5.11e-07	0.26	0.27	Breast size;	chr12:9209254	chr12:9277235~9313241:+
THCA	cis	rs7829975	0.777	rs486781	ENSG00000254153.1	CTA-398F10.2	6.08	2.54e-09	5.11e-07	0.29	0.27	Mood instability;	chr8:8782230	chr8:8456909~8461337:-
THCA	cis	rs9926296	0.744	rs164747	ENSG00000274627.1	RP11-104N10.2	6.08	2.54e-09	5.11e-07	0.28	0.27	Vitiligo;	chr16:89642272	chr16:89516797~89522217:+
THCA	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-6.08	2.54e-09	5.12e-07	-0.25	-0.27	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
THCA	cis	rs9880211	1	rs12695645	ENSG00000273486.1	RP11-731C17.2	6.08	2.54e-09	5.12e-07	0.28	0.27	Height;Body mass index;	chr3:136272039	chr3:136837338~136839021:-
THCA	cis	rs728616	0.867	rs41297151	ENSG00000242600.5	MBL1P	6.08	2.54e-09	5.12e-07	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047411	chr10:79904898~79950336:+
THCA	cis	rs4803480	0.543	rs7257282	ENSG00000270164.1	LINC01480	-6.08	2.55e-09	5.12e-07	-0.27	-0.27	Schizophrenia;	chr19:41536585	chr19:41535183~41536904:+
THCA	cis	rs2439831	0.681	rs7168940	ENSG00000249839.1	AC011330.5	-6.08	2.55e-09	5.12e-07	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43341136	chr15:43663654~43684339:-
THCA	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-6.08	2.55e-09	5.12e-07	-0.3	-0.27	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
THCA	cis	rs11722779	0.844	rs3974602	ENSG00000251288.2	RP11-10L12.2	-6.08	2.55e-09	5.12e-07	-0.36	-0.27	Schizophrenia;	chr4:102928840	chr4:102751401~102752641:+
THCA	cis	rs12612619	0.704	rs10185736	ENSG00000229122.1	AGBL5-IT1	-6.08	2.55e-09	5.12e-07	-0.2	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27098356	chr2:27061038~27061815:+
THCA	cis	rs7202877	0.61	rs3844219	ENSG00000261783.1	RP11-252K23.2	-6.08	2.55e-09	5.12e-07	-0.47	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75336332	chr16:75379818~75381260:-
THCA	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	6.08	2.55e-09	5.13e-07	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
THCA	cis	rs8012947	0.607	rs8004532	ENSG00000279636.2	LINC00216	6.08	2.55e-09	5.13e-07	0.27	0.27	Alcohol consumption in current drinkers;	chr14:58363791	chr14:58288033~58289158:+
THCA	cis	rs8012947	0.607	rs1051858	ENSG00000279636.2	LINC00216	6.08	2.55e-09	5.13e-07	0.27	0.27	Alcohol consumption in current drinkers;	chr14:58364424	chr14:58288033~58289158:+
THCA	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	6.08	2.55e-09	5.13e-07	0.34	0.27	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
THCA	cis	rs6430585	0.528	rs115553816	ENSG00000231890.6	DARS-AS1	-6.08	2.55e-09	5.13e-07	-0.34	-0.27	Corneal structure;	chr2:135935323	chr2:135985176~136022593:+
THCA	cis	rs3742264	1	rs8181800	ENSG00000235903.6	CPB2-AS1	-6.08	2.55e-09	5.13e-07	-0.36	-0.27	Blood protein levels;	chr13:46076559	chr13:46052806~46113332:+
THCA	cis	rs10129255	1	rs10129319	ENSG00000211974.3	IGHV2-70	6.08	2.56e-09	5.14e-07	0.21	0.27	Kawasaki disease;	chr14:106767996	chr14:106723574~106724093:-
THCA	cis	rs7927592	0.717	rs7126451	ENSG00000212093.1	AP000807.1	-6.08	2.56e-09	5.14e-07	-0.28	-0.27	Total body bone mineral density;	chr11:68489918	chr11:68506083~68506166:-
THCA	cis	rs11158026	0.603	rs943914	ENSG00000258413.1	RP11-665C16.6	-6.08	2.56e-09	5.15e-07	-0.38	-0.27	Parkinson's disease;	chr14:54973350	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.603	rs11846514	ENSG00000258413.1	RP11-665C16.6	-6.08	2.56e-09	5.15e-07	-0.38	-0.27	Parkinson's disease;	chr14:54973622	chr14:55262767~55272075:-
THCA	cis	rs9813712	0.571	rs9824426	ENSG00000253540.4	FAM86HP	-6.08	2.56e-09	5.15e-07	-0.29	-0.27	Response to amphetamines;	chr3:130226115	chr3:130099092~130111472:-
THCA	cis	rs527616	0.965	rs1667550	ENSG00000275805.1	RP11-349H17.2	6.07	2.56e-09	5.15e-07	0.34	0.27	Breast cancer;	chr18:26752512	chr18:26565723~26575626:-
THCA	cis	rs3950186	1	rs7766152	ENSG00000215124.2	RP3-420J14.1	6.07	2.56e-09	5.15e-07	0.3	0.27	Anxiety and major depressive disorder;	chr6:11820713	chr6:11861626~11862970:-
THCA	cis	rs4845875	0.603	rs10864539	ENSG00000242349.4	NPPA-AS1	6.07	2.57e-09	5.16e-07	0.26	0.27	Midregional pro atrial natriuretic peptide levels;	chr1:11773853	chr1:11841017~11848079:+
THCA	cis	rs10266483	0.774	rs1404679	ENSG00000227986.1	TRIM60P18	6.07	2.57e-09	5.16e-07	0.24	0.27	Response to statin therapy;	chr7:64358254	chr7:64355078~64356199:+
THCA	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	6.07	2.57e-09	5.17e-07	0.35	0.27	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
THCA	cis	rs7833787	0.965	rs6586777	ENSG00000278886.1	RP11-108A14.1	6.07	2.57e-09	5.17e-07	0.34	0.27	Obesity-related traits;	chr8:18844961	chr8:18864681~18865247:-
THCA	cis	rs10761482	0.5	rs1892546	ENSG00000254271.1	RP11-131N11.4	6.07	2.57e-09	5.17e-07	0.35	0.27	Schizophrenia;	chr10:60534258	chr10:60734342~60741828:+
THCA	cis	rs7202877	0.706	rs247450	ENSG00000261783.1	RP11-252K23.2	6.07	2.57e-09	5.17e-07	0.48	0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75456119	chr16:75379818~75381260:-
THCA	cis	rs75920871	0.588	rs6589580	ENSG00000254851.1	RP11-109L13.1	6.07	2.57e-09	5.17e-07	0.4	0.27	Subjective well-being;	chr11:116949157	chr11:117135528~117138582:+
THCA	cis	rs3764400	0.517	rs7224461	ENSG00000278765.1	RP5-890E16.5	-6.07	2.57e-09	5.17e-07	-0.48	-0.27	Body mass index;	chr17:48126068	chr17:48066704~48067293:-
THCA	cis	rs9926296	0.528	rs4785721	ENSG00000260259.1	RP11-368I7.4	-6.07	2.57e-09	5.17e-07	-0.29	-0.27	Vitiligo;	chr16:89773589	chr16:89682620~89686569:-
THCA	cis	rs11671005	0.737	rs11671033	ENSG00000269473.1	CTD-2619J13.19	6.07	2.57e-09	5.17e-07	0.32	0.27	Mean platelet volume;	chr19:58452302	chr19:58440448~58445849:+
THCA	cis	rs3020264	0.579	rs2454517	ENSG00000271743.1	CTD-2541M15.3	-6.07	2.58e-09	5.18e-07	-0.37	-0.27	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6616237	chr8:6615604~6617198:-
THCA	cis	rs2239547	0.603	rs12489490	ENSG00000242142.1	SERBP1P3	6.07	2.58e-09	5.18e-07	0.35	0.27	Schizophrenia;	chr3:53030006	chr3:53064283~53065091:-
THCA	cis	rs7829975	0.539	rs35571782	ENSG00000254153.1	CTA-398F10.2	-6.07	2.58e-09	5.18e-07	-0.29	-0.27	Mood instability;	chr8:8284301	chr8:8456909~8461337:-
THCA	cis	rs17772222	0.917	rs61986664	ENSG00000222990.1	RNU4-22P	6.07	2.58e-09	5.18e-07	0.34	0.27	Coronary artery calcification;	chr14:88711251	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.876	rs61986665	ENSG00000222990.1	RNU4-22P	6.07	2.58e-09	5.18e-07	0.34	0.27	Coronary artery calcification;	chr14:88711354	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs8018755	ENSG00000222990.1	RNU4-22P	6.07	2.58e-09	5.18e-07	0.34	0.27	Coronary artery calcification;	chr14:88714249	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs8018630	ENSG00000222990.1	RNU4-22P	6.07	2.58e-09	5.18e-07	0.34	0.27	Coronary artery calcification;	chr14:88714250	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs8020072	ENSG00000222990.1	RNU4-22P	6.07	2.58e-09	5.18e-07	0.34	0.27	Coronary artery calcification;	chr14:88714332	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs17260408	ENSG00000222990.1	RNU4-22P	6.07	2.58e-09	5.18e-07	0.34	0.27	Coronary artery calcification;	chr14:88715464	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs12589982	ENSG00000222990.1	RNU4-22P	6.07	2.58e-09	5.18e-07	0.34	0.27	Coronary artery calcification;	chr14:88716861	chr14:88513498~88513663:+
THCA	cis	rs792448	0.743	rs351380	ENSG00000226251.4	RP11-15I11.3	-6.07	2.58e-09	5.18e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212309510	chr1:212225278~212238977:-
THCA	cis	rs9880211	0.898	rs34031772	ENSG00000273486.1	RP11-731C17.2	6.07	2.58e-09	5.19e-07	0.28	0.27	Height;Body mass index;	chr3:136299299	chr3:136837338~136839021:-
THCA	cis	rs2562456	0.876	rs11085465	ENSG00000268081.1	RP11-678G14.2	-6.07	2.58e-09	5.19e-07	-0.39	-0.27	Pain;	chr19:21568988	chr19:21554640~21569237:-
THCA	cis	rs9649465	1	rs6466881	ENSG00000272686.1	RP11-390E23.6	6.07	2.58e-09	5.19e-07	0.18	0.27	Migraine;	chr7:123697680	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs1073670	ENSG00000272686.1	RP11-390E23.6	6.07	2.58e-09	5.19e-07	0.18	0.27	Migraine;	chr7:123704975	chr7:123749068~123751166:+
THCA	cis	rs897984	0.542	rs4468641	ENSG00000260911.2	RP11-196G11.2	6.07	2.58e-09	5.19e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31085555	chr16:31043150~31049868:+
THCA	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	6.07	2.58e-09	5.19e-07	0.3	0.27	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	6.07	2.58e-09	5.19e-07	0.3	0.27	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	6.07	2.58e-09	5.19e-07	0.3	0.27	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
THCA	cis	rs9649465	1	rs7805759	ENSG00000272686.1	RP11-390E23.6	6.07	2.59e-09	5.2e-07	0.18	0.27	Migraine;	chr7:123678642	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs2109723	ENSG00000272686.1	RP11-390E23.6	6.07	2.59e-09	5.2e-07	0.18	0.27	Migraine;	chr7:123685285	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs10270877	ENSG00000272686.1	RP11-390E23.6	6.07	2.59e-09	5.2e-07	0.18	0.27	Migraine;	chr7:123687806	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs13230230	ENSG00000272686.1	RP11-390E23.6	6.07	2.59e-09	5.2e-07	0.18	0.27	Migraine;	chr7:123689549	chr7:123749068~123751166:+
THCA	cis	rs748404	0.666	rs72709879	ENSG00000249839.1	AC011330.5	-6.07	2.59e-09	5.2e-07	-0.39	-0.27	Lung cancer;	chr15:43507777	chr15:43663654~43684339:-
THCA	cis	rs6545883	0.929	rs1186710	ENSG00000271889.1	RP11-493E12.1	6.07	2.59e-09	5.2e-07	0.26	0.27	Tuberculosis;	chr2:61461592	chr2:61151433~61162105:-
THCA	cis	rs2145598	0.967	rs12892257	ENSG00000279636.2	LINC00216	-6.07	2.59e-09	5.21e-07	-0.26	-0.27	Coronary artery disease;	chr14:58266030	chr14:58288033~58289158:+
THCA	cis	rs6142102	0.961	rs6059587	ENSG00000275784.1	RP5-1125A11.6	-6.07	2.59e-09	5.21e-07	-0.28	-0.27	Skin pigmentation;	chr20:33955120	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs6088355	ENSG00000275784.1	RP5-1125A11.6	-6.07	2.59e-09	5.21e-07	-0.28	-0.27	Skin pigmentation;	chr20:33958081	chr20:33989480~33991818:-
THCA	cis	rs2976388	0.59	rs3736011	ENSG00000253741.1	CTD-2292P10.4	6.07	2.59e-09	5.21e-07	0.35	0.27	Urinary tract infection frequency;	chr8:142736371	chr8:142702252~142726973:-
THCA	cis	rs11976180	1	rs2961117	ENSG00000273234.1	OR2A13P	-6.07	2.59e-09	5.21e-07	-0.3	-0.27	Obesity-related traits;	chr7:144058160	chr7:144142009~144142938:+
THCA	cis	rs922182	1	rs55986634	ENSG00000275785.1	RP11-111E14.2	6.07	2.59e-09	5.21e-07	0.32	0.27	Blood protein levels;	chr15:63983446	chr15:63890030~63890317:+
THCA	cis	rs848490	0.962	rs17807802	ENSG00000214293.7	APTR	-6.07	2.59e-09	5.21e-07	-0.21	-0.27	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77840169	chr7:77657660~77696265:-
THCA	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	6.07	2.6e-09	5.21e-07	0.63	0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
THCA	cis	rs763121	0.925	rs1043312	ENSG00000235209.1	CTA-150C2.13	6.07	2.6e-09	5.22e-07	0.34	0.27	Menopause (age at onset);	chr22:38735722	chr22:38921227~38924708:+
THCA	cis	rs17772222	0.917	rs61984737	ENSG00000222990.1	RNU4-22P	6.07	2.6e-09	5.22e-07	0.35	0.27	Coronary artery calcification;	chr14:88637028	chr14:88513498~88513663:+
THCA	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	6.07	2.6e-09	5.22e-07	0.25	0.27	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
THCA	cis	rs2927438	0.571	rs2965106	ENSG00000266903.1	CTB-171A8.1	-6.07	2.6e-09	5.22e-07	-0.32	-0.27	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr19:44729108	chr19:44632199~44718759:-
THCA	cis	rs180730	0.752	rs343168	ENSG00000251609.2	SETP12	-6.07	2.6e-09	5.22e-07	-0.51	-0.27	Fasting plasma glucose;	chr4:120895346	chr4:120895494~120897083:-
THCA	cis	rs516805	0.528	rs2198863	ENSG00000279453.1	RP3-425C14.4	-6.07	2.6e-09	5.22e-07	-0.29	-0.27	Lymphocyte counts;	chr6:122091576	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs1379094	ENSG00000279453.1	RP3-425C14.4	6.07	2.6e-09	5.22e-07	0.29	0.27	Lymphocyte counts;	chr6:122098054	chr6:122436789~122439223:-
THCA	cis	rs228614	0.51	rs223405	ENSG00000230069.3	LRRC37A15P	-6.07	2.6e-09	5.22e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102727274~102730721:-
THCA	cis	rs7619708	1	rs7619708	ENSG00000242086.7	LINC00969	-6.07	2.6e-09	5.22e-07	-0.31	-0.27	Red cell distribution width;	chr3:196083316	chr3:195658062~195739964:+
THCA	cis	rs16949788	1	rs41315964	ENSG00000261351.2	CTD-3185P2.1	-6.07	2.6e-09	5.22e-07	-0.32	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66487360	chr15:66488658~66492109:-
THCA	cis	rs16949788	1	rs41306345	ENSG00000261351.2	CTD-3185P2.1	-6.07	2.6e-09	5.22e-07	-0.32	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66489710	chr15:66488658~66492109:-
THCA	cis	rs7713065	0.531	rs2522051	ENSG00000237714.1	P4HA2-AS1	6.07	2.6e-09	5.23e-07	0.33	0.27	Lung function (FEV1/FVC);	chr5:132461886	chr5:132184876~132192808:+
THCA	cis	rs7809950	0.678	rs17153981	ENSG00000238832.1	snoU109	-6.07	2.6e-09	5.23e-07	-0.32	-0.27	Coronary artery disease;	chr7:107281661	chr7:107603363~107603507:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-6.07	2.61e-09	5.24e-07	-0.31	-0.27	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
THCA	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-6.07	2.61e-09	5.24e-07	-0.39	-0.27	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
THCA	cis	rs10875746	0.951	rs4760690	ENSG00000269514.1	RP11-370I10.12	6.07	2.61e-09	5.24e-07	0.27	0.27	Longevity (90 years and older);	chr12:48169870	chr12:48198387~48202031:+
THCA	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	6.07	2.61e-09	5.24e-07	0.28	0.27	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
THCA	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-6.07	2.61e-09	5.24e-07	-0.39	-0.27	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
THCA	cis	rs7208859	0.673	rs216410	ENSG00000263603.1	CTD-2349P21.5	6.07	2.61e-09	5.24e-07	0.45	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30729469~30731202:+
THCA	cis	rs896854	0.812	rs4582532	ENSG00000253528.2	RP11-347C18.4	6.07	2.61e-09	5.24e-07	0.31	0.27	Type 2 diabetes;	chr8:94957029	chr8:94974573~94974853:-
THCA	cis	rs896854	0.812	rs2340586	ENSG00000253528.2	RP11-347C18.4	6.07	2.61e-09	5.24e-07	0.31	0.27	Type 2 diabetes;	chr8:94957033	chr8:94974573~94974853:-
THCA	cis	rs2439831	1	rs2256764	ENSG00000275601.1	AC011330.13	-6.07	2.61e-09	5.24e-07	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43443565	chr15:43642389~43643023:-
THCA	cis	rs4845570	0.92	rs1521185	ENSG00000249602.1	RP11-98D18.3	6.07	2.61e-09	5.25e-07	0.34	0.27	Coronary artery disease;	chr1:151791573	chr1:151763384~151769501:-
THCA	cis	rs60678552	0.748	rs73548928	ENSG00000233558.1	RP3-486I3.4	6.07	2.61e-09	5.25e-07	0.4	0.27	Heschl's gyrus morphology;	chr6:116281923	chr6:116258493~116259115:-
THCA	cis	rs10875746	0.624	rs7297298	ENSG00000269514.1	RP11-370I10.12	6.07	2.62e-09	5.25e-07	0.27	0.27	Longevity (90 years and older);	chr12:48278523	chr12:48198387~48202031:+
THCA	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-6.07	2.62e-09	5.25e-07	-0.34	-0.27	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
THCA	cis	rs3742264	0.961	rs11620307	ENSG00000235903.6	CPB2-AS1	-6.07	2.62e-09	5.25e-07	-0.36	-0.27	Blood protein levels;	chr13:46075586	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs9534311	ENSG00000235903.6	CPB2-AS1	-6.07	2.62e-09	5.25e-07	-0.36	-0.27	Blood protein levels;	chr13:46075986	chr13:46052806~46113332:+
THCA	cis	rs5742933	0.857	rs10931430	ENSG00000253559.1	OSGEPL1-AS1	6.07	2.62e-09	5.26e-07	0.31	0.27	Ferritin levels;	chr2:189677460	chr2:189762704~189765556:+
THCA	cis	rs2041895	0.565	rs10861679	ENSG00000260329.1	RP11-412D9.4	-6.07	2.62e-09	5.26e-07	-0.27	-0.27	Glaucoma (low intraocular pressure);	chr12:106929137	chr12:106954029~106955497:-
THCA	cis	rs890448	0.726	rs293211	ENSG00000254531.1	FLJ20021	6.07	2.62e-09	5.26e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395224	chr4:101347780~101348883:+
THCA	cis	rs595244	1	rs2456475	ENSG00000259705.1	RP11-227D13.1	6.07	2.62e-09	5.26e-07	0.48	0.27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48593680	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs682737	ENSG00000259705.1	RP11-227D13.1	6.07	2.62e-09	5.26e-07	0.48	0.27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48599574	chr15:48645951~48652016:+
THCA	cis	rs2280018	0.609	rs2941253	ENSG00000260735.1	RP11-72I8.1	-6.07	2.62e-09	5.27e-07	-0.32	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15094411~15109197:+
THCA	cis	rs4713118	0.513	rs149897	ENSG00000280107.1	AL022393.9	-6.07	2.62e-09	5.27e-07	-0.29	-0.27	Parkinson's disease;	chr6:28038872	chr6:28170845~28172521:+
THCA	cis	rs9393777	0.92	rs72839445	ENSG00000219392.1	RP1-265C24.5	-6.07	2.63e-09	5.27e-07	-0.62	-0.27	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28115628~28116551:+
THCA	cis	rs17772222	0.917	rs17260380	ENSG00000222990.1	RNU4-22P	6.07	2.63e-09	5.27e-07	0.35	0.27	Coronary artery calcification;	chr14:88682142	chr14:88513498~88513663:+
THCA	cis	rs8177876	0.749	rs2287995	ENSG00000261061.1	RP11-303E16.2	-6.07	2.63e-09	5.27e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81030770~81031485:+
THCA	cis	rs13113518	0.812	rs4864996	ENSG00000273257.1	RP11-177J6.1	6.07	2.63e-09	5.27e-07	0.36	0.27	Height;	chr4:55452921	chr4:55387949~55388271:+
THCA	cis	rs2657294	0.62	rs7903537	ENSG00000226051.5	ZNF503-AS1	-6.07	2.63e-09	5.28e-07	-0.39	-0.27	Pneumonia;	chr10:75087732	chr10:75269819~75373500:+
THCA	cis	rs9921338	0.961	rs17605444	ENSG00000262636.1	CTD-3088G3.4	-6.07	2.63e-09	5.28e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319732	chr16:11380859~11381118:-
THCA	cis	rs2657294	0.62	rs7903537	ENSG00000233313.2	HMGA1P5	-6.07	2.63e-09	5.28e-07	-0.37	-0.27	Pneumonia;	chr10:75087732	chr10:75276376~75276646:-
THCA	cis	rs10971721	0.822	rs72725392	ENSG00000281128.1	PTENP1-AS	6.07	2.63e-09	5.28e-07	0.61	0.27	Body mass index;	chr9:33867780	chr9:33677268~33688011:+
THCA	cis	rs7829975	0.511	rs2980512	ENSG00000254153.1	CTA-398F10.2	-6.07	2.63e-09	5.28e-07	-0.29	-0.27	Mood instability;	chr8:8283379	chr8:8456909~8461337:-
THCA	cis	rs9859260	0.71	rs419068	ENSG00000242086.7	LINC00969	-6.07	2.63e-09	5.29e-07	-0.27	-0.27	Mean corpuscular volume;	chr3:196055305	chr3:195658062~195739964:+
THCA	cis	rs9859260	0.71	rs366268	ENSG00000242086.7	LINC00969	-6.07	2.63e-09	5.29e-07	-0.27	-0.27	Mean corpuscular volume;	chr3:196055306	chr3:195658062~195739964:+
THCA	cis	rs9859260	0.744	rs419059	ENSG00000242086.7	LINC00969	-6.07	2.63e-09	5.29e-07	-0.27	-0.27	Mean corpuscular volume;	chr3:196055313	chr3:195658062~195739964:+
THCA	cis	rs11603023	0.874	rs577396	ENSG00000278376.1	RP11-158I9.8	-6.07	2.63e-09	5.29e-07	-0.2	-0.27	Cholesterol, total;	chr11:118628753	chr11:118791254~118793137:+
THCA	cis	rs11603023	0.874	rs11216934	ENSG00000278376.1	RP11-158I9.8	-6.07	2.63e-09	5.29e-07	-0.2	-0.27	Cholesterol, total;	chr11:118630742	chr11:118791254~118793137:+
THCA	cis	rs12497850	0.931	rs9840050	ENSG00000229759.1	MRPS18AP1	6.07	2.64e-09	5.29e-07	0.36	0.27	Parkinson's disease;	chr3:49095877	chr3:48256350~48256938:-
THCA	cis	rs9921338	0.961	rs4315353	ENSG00000262703.1	RP11-485G7.6	6.07	2.64e-09	5.29e-07	0.35	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320303	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs4356497	ENSG00000262703.1	RP11-485G7.6	6.07	2.64e-09	5.29e-07	0.35	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320339	chr16:11348143~11349321:-
THCA	cis	rs12908161	0.96	rs62019463	ENSG00000259295.5	CSPG4P12	6.07	2.64e-09	5.29e-07	0.41	0.27	Schizophrenia;	chr15:84744856	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs62019464	ENSG00000259295.5	CSPG4P12	6.07	2.64e-09	5.29e-07	0.41	0.27	Schizophrenia;	chr15:84751238	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs11637142	ENSG00000259295.5	CSPG4P12	6.07	2.64e-09	5.29e-07	0.41	0.27	Schizophrenia;	chr15:84752696	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs12910012	ENSG00000259295.5	CSPG4P12	6.07	2.64e-09	5.29e-07	0.41	0.27	Schizophrenia;	chr15:84755431	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs12899981	ENSG00000259295.5	CSPG4P12	6.07	2.64e-09	5.29e-07	0.41	0.27	Schizophrenia;	chr15:84759142	chr15:85191438~85213905:+
THCA	cis	rs8012947	0.916	rs12433823	ENSG00000279636.2	LINC00216	6.07	2.64e-09	5.29e-07	0.3	0.27	Alcohol consumption in current drinkers;	chr14:58378959	chr14:58288033~58289158:+
THCA	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-6.07	2.64e-09	5.29e-07	-0.39	-0.27	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
THCA	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-6.07	2.64e-09	5.29e-07	-0.31	-0.27	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
THCA	cis	rs12664251	0.66	rs794257	ENSG00000253194.1	RP11-351A11.1	-6.07	2.64e-09	5.29e-07	-0.37	-0.27	Schizophrenia;	chr6:119032047	chr6:118934785~119031541:+
THCA	cis	rs1949733	0.816	rs2631746	ENSG00000205959.3	RP11-689P11.2	6.07	2.64e-09	5.29e-07	0.22	0.27	Response to antineoplastic agents;	chr4:8489207	chr4:8482270~8512610:+
THCA	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-6.07	2.64e-09	5.29e-07	-0.2	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
THCA	cis	rs10208649	0.831	rs2287347	ENSG00000233266.1	HMGB1P31	-6.07	2.64e-09	5.3e-07	-0.49	-0.27	Body mass index;	chr2:53812428	chr2:54051334~54051760:+
THCA	cis	rs4664293	0.647	rs10192408	ENSG00000226266.5	AC009961.3	-6.07	2.64e-09	5.3e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159568083	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs10202352	ENSG00000226266.5	AC009961.3	-6.07	2.64e-09	5.3e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159571097	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs1425040	ENSG00000226266.5	AC009961.3	-6.07	2.64e-09	5.3e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159571912	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs11693108	ENSG00000226266.5	AC009961.3	-6.07	2.64e-09	5.3e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159572076	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs7575924	ENSG00000226266.5	AC009961.3	-6.07	2.64e-09	5.3e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159573049	chr2:159670708~159712435:-
THCA	cis	rs2033711	0.503	rs6510141	ENSG00000268049.1	CTD-2619J13.9	6.07	2.64e-09	5.3e-07	0.32	0.27	Uric acid clearance;	chr19:58374419	chr19:58357999~58359603:+
THCA	cis	rs10971721	0.822	rs117703548	ENSG00000281128.1	PTENP1-AS	6.07	2.64e-09	5.3e-07	0.61	0.27	Body mass index;	chr9:34041199	chr9:33677268~33688011:+
THCA	cis	rs2120243	0.539	rs4679793	ENSG00000244515.1	KRT18P34	6.07	2.64e-09	5.3e-07	0.32	0.27	Hepatocellular carcinoma in hepatitis B infection;	chr3:157404872	chr3:157162663~157163932:-
THCA	cis	rs4664293	0.647	rs1425039	ENSG00000226266.5	AC009961.3	-6.07	2.64e-09	5.3e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159571612	chr2:159670708~159712435:-
THCA	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-6.07	2.64e-09	5.3e-07	-0.43	-0.27	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
THCA	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	6.07	2.65e-09	5.31e-07	0.35	0.27	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
THCA	cis	rs5742933	0.857	rs11685425	ENSG00000253559.1	OSGEPL1-AS1	6.07	2.65e-09	5.31e-07	0.3	0.27	Ferritin levels;	chr2:189747977	chr2:189762704~189765556:+
THCA	cis	rs17772222	0.876	rs58655091	ENSG00000222990.1	RNU4-22P	6.07	2.65e-09	5.31e-07	0.34	0.27	Coronary artery calcification;	chr14:88748567	chr14:88513498~88513663:+
THCA	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	6.07	2.65e-09	5.31e-07	0.33	0.27	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
THCA	cis	rs12681366	0.683	rs1379246	ENSG00000253704.1	RP11-267M23.4	-6.07	2.65e-09	5.31e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94361073	chr8:94553722~94569745:+
THCA	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	6.07	2.65e-09	5.32e-07	0.41	0.27	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	6.07	2.65e-09	5.32e-07	0.31	0.27	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
THCA	cis	rs1318937	1	rs3773471	ENSG00000224660.1	SH3BP5-AS1	-6.07	2.65e-09	5.32e-07	-0.17	-0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15261540	chr3:15254184~15264493:+
THCA	cis	rs2239547	0.603	rs7644973	ENSG00000242142.1	SERBP1P3	6.07	2.65e-09	5.32e-07	0.34	0.27	Schizophrenia;	chr3:53048921	chr3:53064283~53065091:-
THCA	cis	rs3213958	0.574	rs73138004	ENSG00000249274.1	PDLIM1P4	-6.07	2.66e-09	5.33e-07	-0.35	-0.27	Blood protein levels;	chr3:98825460	chr3:98782188~98783193:+
THCA	cis	rs2243480	1	rs73150014	ENSG00000229886.1	RP5-1132H15.3	6.07	2.66e-09	5.33e-07	0.43	0.27	Diabetic kidney disease;	chr7:65985932	chr7:66025126~66031544:-
THCA	cis	rs17772222	0.917	rs17188228	ENSG00000222990.1	RNU4-22P	6.07	2.66e-09	5.33e-07	0.34	0.27	Coronary artery calcification;	chr14:88738921	chr14:88513498~88513663:+
THCA	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	6.07	2.66e-09	5.34e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
THCA	cis	rs7324557	1	rs7324557	ENSG00000205861.10	C1QTNF9B-AS1	6.07	2.66e-09	5.34e-07	0.32	0.27	Visceral adipose tissue adjusted for BMI;	chr13:23722723	chr13:23888889~23897263:+
THCA	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	6.07	2.66e-09	5.34e-07	0.33	0.27	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
THCA	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	6.07	2.66e-09	5.34e-07	0.33	0.27	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
THCA	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	6.07	2.66e-09	5.34e-07	0.33	0.27	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
THCA	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	6.07	2.66e-09	5.34e-07	0.33	0.27	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
THCA	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	6.07	2.66e-09	5.34e-07	0.33	0.27	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
THCA	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	6.07	2.66e-09	5.34e-07	0.33	0.27	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
THCA	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	6.07	2.66e-09	5.34e-07	0.33	0.27	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
THCA	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	6.07	2.66e-09	5.34e-07	0.33	0.27	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
THCA	cis	rs984222	0.538	rs1106529	ENSG00000231365.4	RP11-418J17.1	-6.07	2.66e-09	5.34e-07	-0.29	-0.27	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118988874	chr1:119140396~119275973:+
THCA	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
THCA	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
THCA	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
THCA	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
THCA	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
THCA	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	6.07	2.67e-09	5.35e-07	0.49	0.27	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
THCA	cis	rs527616	0.93	rs604702	ENSG00000275805.1	RP11-349H17.2	6.07	2.67e-09	5.35e-07	0.34	0.27	Breast cancer;	chr18:26751502	chr18:26565723~26575626:-
THCA	cis	rs944990	0.64	rs10821131	ENSG00000227603.1	RP11-165J3.6	6.07	2.67e-09	5.35e-07	0.27	0.27	Body mass index;	chr9:93466540	chr9:93435332~93437121:-
THCA	cis	rs4664293	0.647	rs1549385	ENSG00000226266.5	AC009961.3	-6.07	2.67e-09	5.35e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159582540	chr2:159670708~159712435:-
THCA	cis	rs7015630	0.738	rs11785163	ENSG00000251136.7	RP11-37B2.1	-6.07	2.67e-09	5.35e-07	-0.28	-0.27	Inflammatory bowel disease;Crohn's disease;	chr8:89857181	chr8:89609409~89757727:-
THCA	cis	rs17301013	0.507	rs10798324	ENSG00000227373.4	RP11-160H22.5	-6.07	2.67e-09	5.35e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174787485	chr1:174115300~174160004:-
THCA	cis	rs4950322	0.57	rs72692980	ENSG00000278811.3	LINC00624	6.07	2.67e-09	5.36e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147337830	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.634	rs7542951	ENSG00000278811.3	LINC00624	6.07	2.67e-09	5.36e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147340308	chr1:147258885~147517875:-
THCA	cis	rs6671200	0.607	rs7528790	ENSG00000228852.5	RP11-57H12.5	-6.07	2.67e-09	5.36e-07	-0.32	-0.27	Stearic acid (18:0) levels;	chr1:95243518	chr1:95243167~95278940:-
THCA	cis	rs9880211	1	rs9837158	ENSG00000273486.1	RP11-731C17.2	6.07	2.67e-09	5.36e-07	0.28	0.27	Height;Body mass index;	chr3:136354321	chr3:136837338~136839021:-
THCA	cis	rs6951245	0.58	rs77101766	ENSG00000229043.2	AC091729.9	-6.07	2.68e-09	5.36e-07	-0.36	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1160374~1165267:+
THCA	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	6.07	2.68e-09	5.37e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
THCA	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	6.07	2.68e-09	5.37e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
THCA	cis	rs3794924	1	rs35242229	ENSG00000266521.1	RP11-650P15.1	6.07	2.68e-09	5.37e-07	0.52	0.27	Survival in colon cancer;	chr18:31472920	chr18:31496645~31497195:-
THCA	cis	rs3794924	1	rs71372018	ENSG00000266521.1	RP11-650P15.1	6.07	2.68e-09	5.37e-07	0.52	0.27	Survival in colon cancer;	chr18:31473571	chr18:31496645~31497195:-
THCA	cis	rs3794924	1	rs3810005	ENSG00000266521.1	RP11-650P15.1	6.07	2.68e-09	5.37e-07	0.52	0.27	Survival in colon cancer;	chr18:31473913	chr18:31496645~31497195:-
THCA	cis	rs227275	0.527	rs12500379	ENSG00000251288.2	RP11-10L12.2	-6.07	2.68e-09	5.37e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102751401~102752641:+
THCA	cis	rs2115630	0.967	rs8027779	ENSG00000225151.9	GOLGA2P7	6.07	2.68e-09	5.37e-07	0.35	0.27	P wave terminal force;	chr15:84712154	chr15:84199311~84230136:-
THCA	cis	rs2562456	0.876	rs11085465	ENSG00000213976.4	CTD-2561J22.2	6.07	2.68e-09	5.37e-07	0.28	0.27	Pain;	chr19:21568988	chr19:21382865~21387177:+
THCA	cis	rs8042680	1	rs6496743	ENSG00000214432.8	AC068831.10	-6.07	2.68e-09	5.38e-07	-0.3	-0.27	Type 2 diabetes;	chr15:90985128	chr15:91022619~91036611:+
THCA	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	6.07	2.68e-09	5.38e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	6.07	2.68e-09	5.38e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	6.07	2.68e-09	5.38e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	6.07	2.68e-09	5.38e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
THCA	cis	rs227275	0.555	rs223403	ENSG00000230069.3	LRRC37A15P	-6.07	2.68e-09	5.38e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102727274~102730721:-
THCA	cis	rs227275	0.555	rs223402	ENSG00000230069.3	LRRC37A15P	-6.07	2.68e-09	5.38e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223349	ENSG00000251288.2	RP11-10L12.2	-6.07	2.68e-09	5.38e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102751401~102752641:+
THCA	cis	rs9649465	0.967	rs12534834	ENSG00000272686.1	RP11-390E23.6	6.07	2.68e-09	5.38e-07	0.18	0.27	Migraine;	chr7:123667025	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs12537989	ENSG00000272686.1	RP11-390E23.6	6.07	2.68e-09	5.38e-07	0.18	0.27	Migraine;	chr7:123668141	chr7:123749068~123751166:+
THCA	cis	rs7615952	0.641	rs12491577	ENSG00000250012.1	RP11-124N2.1	-6.07	2.69e-09	5.38e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126012288	chr3:126084220~126095349:+
THCA	cis	rs7202877	0.61	rs8053632	ENSG00000261783.1	RP11-252K23.2	-6.07	2.69e-09	5.39e-07	-0.46	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75331042	chr16:75379818~75381260:-
THCA	cis	rs17772222	0.876	rs61983303	ENSG00000222990.1	RNU4-22P	6.07	2.69e-09	5.4e-07	0.34	0.27	Coronary artery calcification;	chr14:88764459	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs2224333	ENSG00000222990.1	RNU4-22P	6.07	2.69e-09	5.4e-07	0.34	0.27	Coronary artery calcification;	chr14:88768748	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs12590826	ENSG00000222990.1	RNU4-22P	6.07	2.69e-09	5.4e-07	0.34	0.27	Coronary artery calcification;	chr14:88769357	chr14:88513498~88513663:+
THCA	cis	rs7833787	1	rs34270955	ENSG00000278886.1	RP11-108A14.1	-6.07	2.69e-09	5.4e-07	-0.35	-0.27	Obesity-related traits;	chr8:18847740	chr8:18864681~18865247:-
THCA	cis	rs8042680	0.522	rs1867225	ENSG00000214432.8	AC068831.10	-6.07	2.69e-09	5.4e-07	-0.29	-0.27	Type 2 diabetes;	chr15:91020599	chr15:91022619~91036611:+
THCA	cis	rs1823913	0.927	rs1454761	ENSG00000227542.1	AC092614.2	6.07	2.69e-09	5.4e-07	0.33	0.27	Obesity-related traits;	chr2:191237092	chr2:191229165~191246172:-
THCA	cis	rs7833787	0.929	rs11995692	ENSG00000278886.1	RP11-108A14.1	6.07	2.69e-09	5.4e-07	0.35	0.27	Obesity-related traits;	chr8:18853359	chr8:18864681~18865247:-
THCA	cis	rs728616	0.681	rs3862518	ENSG00000225484.5	NUTM2B-AS1	-6.07	2.7e-09	5.4e-07	-0.45	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158201	chr10:79663088~79826594:-
THCA	cis	rs13113518	0.812	rs6849474	ENSG00000273257.1	RP11-177J6.1	6.07	2.7e-09	5.4e-07	0.36	0.27	Height;	chr4:55452295	chr4:55387949~55388271:+
THCA	cis	rs6142102	0.961	rs2377957	ENSG00000275784.1	RP5-1125A11.6	-6.07	2.7e-09	5.4e-07	-0.27	-0.27	Skin pigmentation;	chr20:33966667	chr20:33989480~33991818:-
THCA	cis	rs11722779	0.933	rs7695096	ENSG00000251288.2	RP11-10L12.2	-6.07	2.7e-09	5.4e-07	-0.36	-0.27	Schizophrenia;	chr4:103011399	chr4:102751401~102752641:+
THCA	cis	rs8007846	0.588	rs2411404	ENSG00000276116.2	FUT8-AS1	6.07	2.7e-09	5.41e-07	0.27	0.27	Multiple sclerosis--Brain Glutamate Levels;	chr14:65772683	chr14:65411170~65412690:-
THCA	cis	rs911555	0.504	rs4906340	ENSG00000269940.1	RP11-73M18.7	-6.07	2.7e-09	5.41e-07	-0.29	-0.27	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103694560~103695170:+
THCA	cis	rs9880211	1	rs28634226	ENSG00000273486.1	RP11-731C17.2	6.07	2.7e-09	5.42e-07	0.28	0.27	Height;Body mass index;	chr3:136411040	chr3:136837338~136839021:-
THCA	cis	rs3742264	0.885	rs4942476	ENSG00000235903.6	CPB2-AS1	-6.07	2.71e-09	5.42e-07	-0.36	-0.27	Blood protein levels;	chr13:46077491	chr13:46052806~46113332:+
THCA	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	6.07	2.71e-09	5.42e-07	0.4	0.27	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
THCA	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-6.07	2.71e-09	5.42e-07	-0.34	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
THCA	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-6.07	2.71e-09	5.42e-07	-0.34	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
THCA	cis	rs9649465	1	rs2896334	ENSG00000272686.1	RP11-390E23.6	6.07	2.71e-09	5.42e-07	0.18	0.27	Migraine;	chr7:123727651	chr7:123749068~123751166:+
THCA	cis	rs412050	1	rs412050	ENSG00000224086.5	LL22NC03-86G7.1	-6.07	2.71e-09	5.43e-07	-0.43	-0.27	Attention deficit hyperactivity disorder;	chr22:21953147	chr22:21938293~21977632:+
THCA	cis	rs7246657	0.722	rs1531549	ENSG00000267422.1	CTD-2554C21.1	-6.07	2.71e-09	5.44e-07	-0.31	-0.27	Coronary artery calcification;	chr19:37597108	chr19:37779686~37792865:+
THCA	cis	rs7208859	0.673	rs3816780	ENSG00000263603.1	CTD-2349P21.5	-6.06	2.72e-09	5.44e-07	-0.48	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30729469~30731202:+
THCA	cis	rs72627509	0.68	rs59708338	ENSG00000269949.1	RP11-738E22.3	6.06	2.72e-09	5.44e-07	0.41	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56859155	chr4:56960927~56961373:-
THCA	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-6.06	2.72e-09	5.44e-07	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
THCA	cis	rs11783469	0.524	rs13250995	ENSG00000253390.1	CTC-756D1.2	-6.06	2.72e-09	5.45e-07	-0.47	-0.27	Reticulocyte count;	chr8:23472472	chr8:23458601~23484971:+
THCA	cis	rs7129556	0.645	rs598071	ENSG00000254691.1	RP11-91P24.5	6.06	2.72e-09	5.45e-07	0.36	0.27	Weight loss (gastric bypass surgery);	chr11:77849606	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.69	rs12285765	ENSG00000254691.1	RP11-91P24.5	6.06	2.72e-09	5.45e-07	0.36	0.27	Weight loss (gastric bypass surgery);	chr11:77857989	chr11:77850604~77851511:+
THCA	cis	rs8027521	0.905	rs2711595	ENSG00000280362.1	RP11-643A5.3	-6.06	2.72e-09	5.45e-07	-0.33	-0.27	Circulating chemerin levels;	chr15:53974382	chr15:53910769~53914712:+
THCA	cis	rs7833787	1	rs17468166	ENSG00000278886.1	RP11-108A14.1	-6.06	2.72e-09	5.45e-07	-0.35	-0.27	Obesity-related traits;	chr8:18847537	chr8:18864681~18865247:-
THCA	cis	rs712022	1	rs6483880	ENSG00000246225.5	RP11-17A1.3	6.06	2.72e-09	5.45e-07	0.35	0.27	Dialysis-related mortality;	chr11:22831194	chr11:22829380~22945393:+
THCA	cis	rs6142102	0.961	rs6057957	ENSG00000275784.1	RP5-1125A11.6	-6.06	2.72e-09	5.46e-07	-0.28	-0.27	Skin pigmentation;	chr20:33962052	chr20:33989480~33991818:-
THCA	cis	rs11096990	0.964	rs9998591	ENSG00000249207.1	RP11-360F5.1	-6.06	2.73e-09	5.46e-07	-0.35	-0.27	Cognitive function;	chr4:39240491	chr4:39112677~39126818:-
THCA	cis	rs7560272	0.723	rs7562047	ENSG00000163016.8	ALMS1P	6.06	2.73e-09	5.46e-07	0.35	0.27	Schizophrenia;	chr2:73498041	chr2:73644919~73685576:+
THCA	cis	rs9649465	1	rs11765478	ENSG00000272686.1	RP11-390E23.6	6.06	2.73e-09	5.46e-07	0.18	0.27	Migraine;	chr7:123722818	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs2299985	ENSG00000272686.1	RP11-390E23.6	6.06	2.73e-09	5.46e-07	0.18	0.27	Migraine;	chr7:123728990	chr7:123749068~123751166:+
THCA	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-6.06	2.73e-09	5.46e-07	-0.39	-0.27	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
THCA	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	6.06	2.73e-09	5.46e-07	0.38	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
THCA	cis	rs2980439	0.729	rs2955586	ENSG00000253981.4	ALG1L13P	6.06	2.73e-09	5.46e-07	0.25	0.27	Neuroticism;	chr8:8236445	chr8:8236003~8244667:-
THCA	cis	rs7005380	0.58	rs11781657	ENSG00000245330.4	KB-1471A8.1	6.06	2.73e-09	5.47e-07	0.26	0.27	Interstitial lung disease;	chr8:119877002	chr8:119867419~119874488:-
THCA	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	6.06	2.73e-09	5.47e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	6.06	2.73e-09	5.47e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	6.06	2.73e-09	5.47e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	6.06	2.73e-09	5.47e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	6.06	2.73e-09	5.47e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	6.06	2.73e-09	5.47e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
THCA	cis	rs17772222	0.837	rs57118463	ENSG00000222990.1	RNU4-22P	6.06	2.73e-09	5.47e-07	0.34	0.27	Coronary artery calcification;	chr14:88665822	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.874	rs61984746	ENSG00000222990.1	RNU4-22P	6.06	2.73e-09	5.47e-07	0.34	0.27	Coronary artery calcification;	chr14:88668136	chr14:88513498~88513663:+
THCA	cis	rs2439831	0.618	rs8023508	ENSG00000275601.1	AC011330.13	6.06	2.74e-09	5.47e-07	0.39	0.27	Lung cancer in ever smokers;	chr15:43883905	chr15:43642389~43643023:-
THCA	cis	rs4925386	1	rs6089351	ENSG00000273619.1	RP5-908M14.9	6.06	2.74e-09	5.48e-07	0.22	0.27	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62386303~62386970:-
THCA	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-6.06	2.74e-09	5.48e-07	-0.25	-0.27	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
THCA	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	6.06	2.74e-09	5.48e-07	0.15	0.27	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
THCA	cis	rs7246657	0.678	rs2927740	ENSG00000267422.1	CTD-2554C21.1	6.06	2.74e-09	5.48e-07	0.31	0.27	Coronary artery calcification;	chr19:37650065	chr19:37779686~37792865:+
THCA	cis	rs17772222	0.917	rs61986671	ENSG00000222990.1	RNU4-22P	6.06	2.74e-09	5.48e-07	0.34	0.27	Coronary artery calcification;	chr14:88732917	chr14:88513498~88513663:+
THCA	cis	rs2439831	0.867	rs2412780	ENSG00000249839.1	AC011330.5	-6.06	2.74e-09	5.48e-07	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43363596	chr15:43663654~43684339:-
THCA	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-6.06	2.74e-09	5.49e-07	-0.29	-0.27	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-6.06	2.74e-09	5.49e-07	-0.29	-0.27	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
THCA	cis	rs8042680	0.522	rs12595616	ENSG00000214432.8	AC068831.10	6.06	2.74e-09	5.49e-07	0.29	0.27	Type 2 diabetes;	chr15:91020283	chr15:91022619~91036611:+
THCA	cis	rs7746199	0.736	rs13202295	ENSG00000219392.1	RP1-265C24.5	-6.06	2.74e-09	5.49e-07	-0.62	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28115628~28116551:+
THCA	cis	rs9326248	0.53	rs2471884	ENSG00000280143.1	AP000892.6	6.06	2.75e-09	5.49e-07	0.44	0.27	Blood protein levels;	chr11:117139604	chr11:117204967~117210292:+
THCA	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	6.06	2.75e-09	5.5e-07	0.41	0.27	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
THCA	cis	rs7727544	0.647	rs7721882	ENSG00000224431.1	AC063976.7	6.06	2.75e-09	5.5e-07	0.24	0.27	Blood metabolite levels;	chr5:132083255	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.625	rs3864277	ENSG00000224431.1	AC063976.7	6.06	2.75e-09	5.5e-07	0.24	0.27	Blood metabolite levels;	chr5:132084556	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.647	rs6898270	ENSG00000224431.1	AC063976.7	6.06	2.75e-09	5.5e-07	0.24	0.27	Blood metabolite levels;	chr5:132085497	chr5:132199456~132203487:+
THCA	cis	rs28472312	0.823	rs62037373	ENSG00000251417.2	RP11-1348G14.4	-6.06	2.75e-09	5.51e-07	-0.26	-0.27	Intelligence (multi-trait analysis);	chr16:28881974	chr16:28802743~28817828:+
THCA	cis	rs11148252	0.74	rs3803264	ENSG00000235660.1	LINC00345	6.06	2.75e-09	5.51e-07	0.34	0.27	Lewy body disease;	chr13:52397758	chr13:52484161~52484680:-
THCA	cis	rs6860806	0.661	rs1588263	ENSG00000224431.1	AC063976.7	6.06	2.75e-09	5.51e-07	0.23	0.27	Breast cancer;	chr5:132241465	chr5:132199456~132203487:+
THCA	cis	rs12939005	1	rs12939005	ENSG00000275710.1	RP11-257O5.4	-6.06	2.75e-09	5.51e-07	-0.4	-0.27	Large artery stroke;	chr17:54909123	chr17:54964474~54964679:+
THCA	cis	rs7220401	0.512	rs71371126	ENSG00000264007.1	RP11-68I3.10	-6.06	2.75e-09	5.51e-07	-0.34	-0.27	Coronary artery disease;	chr17:29675624	chr17:29621617~29622254:-
THCA	cis	rs4650994	0.524	rs1998544	ENSG00000273384.1	RP5-1098D14.1	-6.06	2.75e-09	5.51e-07	-0.34	-0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178636141	chr1:178651706~178652282:+
THCA	cis	rs8027521	0.846	rs1841945	ENSG00000280362.1	RP11-643A5.3	-6.06	2.75e-09	5.51e-07	-0.33	-0.27	Circulating chemerin levels;	chr15:53978200	chr15:53910769~53914712:+
THCA	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	6.06	2.76e-09	5.51e-07	0.15	0.27	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
THCA	cis	rs9990333	0.562	rs56038600	ENSG00000231464.1	AC024937.4	6.06	2.76e-09	5.52e-07	0.35	0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195996738~195998233:+
THCA	cis	rs3213958	0.574	rs10935518	ENSG00000249274.1	PDLIM1P4	-6.06	2.76e-09	5.52e-07	-0.34	-0.27	Blood protein levels;	chr3:98896767	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs17852693	ENSG00000249274.1	PDLIM1P4	-6.06	2.76e-09	5.52e-07	-0.34	-0.27	Blood protein levels;	chr3:98901153	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs55988144	ENSG00000249274.1	PDLIM1P4	-6.06	2.76e-09	5.52e-07	-0.34	-0.27	Blood protein levels;	chr3:98902108	chr3:98782188~98783193:+
THCA	cis	rs4934494	0.834	rs1359624	ENSG00000240996.1	RP11-80H5.7	-6.06	2.76e-09	5.52e-07	-0.28	-0.27	Red blood cell count;	chr10:89635671	chr10:89694295~89697928:-
THCA	cis	rs7727544	0.604	rs2069803	ENSG00000224431.1	AC063976.7	6.06	2.76e-09	5.52e-07	0.24	0.27	Blood metabolite levels;	chr5:132064740	chr5:132199456~132203487:+
THCA	cis	rs2303319	0.504	rs62188729	ENSG00000227403.1	AC009299.3	6.06	2.76e-09	5.52e-07	0.56	0.27	Cognitive function;	chr2:161480541	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188731	ENSG00000227403.1	AC009299.3	6.06	2.76e-09	5.52e-07	0.56	0.27	Cognitive function;	chr2:161488265	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56384808	ENSG00000227403.1	AC009299.3	6.06	2.76e-09	5.52e-07	0.56	0.27	Cognitive function;	chr2:161491244	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12463509	ENSG00000227403.1	AC009299.3	6.06	2.76e-09	5.52e-07	0.56	0.27	Cognitive function;	chr2:161491437	chr2:161244739~161249050:+
THCA	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	6.06	2.76e-09	5.53e-07	0.42	0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000232546.1	RP11-458F8.1	-6.06	2.76e-09	5.53e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65970805	chr7:66848496~66858136:+
THCA	cis	rs890448	0.796	rs2433307	ENSG00000254531.1	FLJ20021	6.06	2.76e-09	5.53e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426059	chr4:101347780~101348883:+
THCA	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-6.06	2.76e-09	5.53e-07	-0.34	-0.27	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
THCA	cis	rs9990333	0.562	rs56224853	ENSG00000226155.1	AC124944.3	-6.06	2.76e-09	5.53e-07	-0.33	-0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195912049~195913986:+
THCA	cis	rs9990333	0.544	rs73210008	ENSG00000226155.1	AC124944.3	-6.06	2.76e-09	5.53e-07	-0.33	-0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195912049~195913986:+
THCA	cis	rs9649465	0.967	rs9641717	ENSG00000272686.1	RP11-390E23.6	6.06	2.77e-09	5.53e-07	0.18	0.27	Migraine;	chr7:123710006	chr7:123749068~123751166:+
THCA	cis	rs7129556	0.859	rs11605638	ENSG00000254691.1	RP11-91P24.5	6.06	2.77e-09	5.53e-07	0.37	0.27	Weight loss (gastric bypass surgery);	chr11:77528289	chr11:77850604~77851511:+
THCA	cis	rs10129255	0.957	rs61997760	ENSG00000211974.3	IGHV2-70	6.06	2.77e-09	5.53e-07	0.21	0.27	Kawasaki disease;	chr14:106716993	chr14:106723574~106724093:-
THCA	cis	rs11722779	0.903	rs13130741	ENSG00000230069.3	LRRC37A15P	-6.06	2.77e-09	5.54e-07	-0.28	-0.27	Schizophrenia;	chr4:103035799	chr4:102727274~102730721:-
THCA	cis	rs13113518	0.812	rs12500601	ENSG00000273257.1	RP11-177J6.1	6.06	2.77e-09	5.54e-07	0.35	0.27	Height;	chr4:55451489	chr4:55387949~55388271:+
THCA	cis	rs10129255	1	rs4612959	ENSG00000211974.3	IGHV2-70	6.06	2.77e-09	5.54e-07	0.21	0.27	Kawasaki disease;	chr14:106767055	chr14:106723574~106724093:-
THCA	cis	rs10129255	1	rs10129407	ENSG00000211974.3	IGHV2-70	6.06	2.77e-09	5.54e-07	0.21	0.27	Kawasaki disease;	chr14:106767956	chr14:106723574~106724093:-
THCA	cis	rs713477	1	rs7142204	ENSG00000258413.1	RP11-665C16.6	-6.06	2.77e-09	5.54e-07	-0.36	-0.27	Pediatric bone mineral content (femoral neck);	chr14:55441718	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs61976571	ENSG00000258413.1	RP11-665C16.6	6.06	2.77e-09	5.54e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55442056	chr14:55262767~55272075:-
THCA	cis	rs713477	0.935	rs7147968	ENSG00000258413.1	RP11-665C16.6	6.06	2.77e-09	5.54e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55442322	chr14:55262767~55272075:-
THCA	cis	rs713477	1	rs7149622	ENSG00000258413.1	RP11-665C16.6	6.06	2.77e-09	5.54e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55442684	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs1572613	ENSG00000258413.1	RP11-665C16.6	6.06	2.77e-09	5.54e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55443179	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs4243600	ENSG00000258413.1	RP11-665C16.6	6.06	2.77e-09	5.54e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55443961	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs4898865	ENSG00000258413.1	RP11-665C16.6	6.06	2.77e-09	5.54e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55444280	chr14:55262767~55272075:-
THCA	cis	rs73607972	0.799	rs112105499	ENSG00000275191.1	RP11-36I17.2	-6.06	2.77e-09	5.54e-07	-0.41	-0.27	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577948	chr16:53628256~53628816:-
THCA	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	6.06	2.77e-09	5.54e-07	0.29	0.27	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
THCA	cis	rs17772222	0.917	rs58550317	ENSG00000258789.1	RP11-507K2.3	-6.06	2.77e-09	5.55e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88775243	chr14:88551597~88552493:+
THCA	cis	rs4713118	0.824	rs9468223	ENSG00000280107.1	AL022393.9	-6.06	2.77e-09	5.55e-07	-0.32	-0.27	Parkinson's disease;	chr6:27772887	chr6:28170845~28172521:+
THCA	cis	rs6740322	0.748	rs6755601	ENSG00000234936.1	AC010883.5	6.06	2.77e-09	5.55e-07	0.29	0.27	Coronary artery disease;	chr2:43255905	chr2:43229573~43233394:+
THCA	cis	rs17772222	1	rs12589467	ENSG00000258789.1	RP11-507K2.3	-6.06	2.77e-09	5.55e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88357239	chr14:88551597~88552493:+
THCA	cis	rs10411161	0.58	rs10409620	ENSG00000269483.1	AC006272.1	6.06	2.78e-09	5.55e-07	0.33	0.27	Breast cancer;	chr19:51867923	chr19:51839924~51843324:-
THCA	cis	rs7833787	0.868	rs34629387	ENSG00000278886.1	RP11-108A14.1	-6.06	2.78e-09	5.55e-07	-0.35	-0.27	Obesity-related traits;	chr8:18847407	chr8:18864681~18865247:-
THCA	cis	rs9487605	1	rs9487605	ENSG00000272356.1	RP5-1112D6.8	-6.06	2.78e-09	5.55e-07	-0.23	-0.27	Inflammatory skin disease;	chr6:111261682	chr6:111309203~111313517:+
THCA	cis	rs713477	0.967	rs8020152	ENSG00000258413.1	RP11-665C16.6	6.06	2.78e-09	5.56e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55440307	chr14:55262767~55272075:-
THCA	cis	rs6545883	0.931	rs7557230	ENSG00000271889.1	RP11-493E12.1	6.06	2.78e-09	5.56e-07	0.26	0.27	Tuberculosis;	chr2:61509517	chr2:61151433~61162105:-
THCA	cis	rs17772222	0.876	rs12436982	ENSG00000222990.1	RNU4-22P	6.06	2.78e-09	5.56e-07	0.35	0.27	Coronary artery calcification;	chr14:88689862	chr14:88513498~88513663:+
THCA	cis	rs8014252	0.803	rs7157618	ENSG00000259158.2	ADAM20P1	-6.06	2.78e-09	5.56e-07	-0.33	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70543449	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs8006487	ENSG00000259158.2	ADAM20P1	-6.06	2.78e-09	5.56e-07	-0.33	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70545217	chr14:70468881~70483756:-
THCA	cis	rs728616	0.614	rs35395602	ENSG00000242600.5	MBL1P	6.06	2.79e-09	5.57e-07	0.34	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147014	chr10:79904898~79950336:+
THCA	cis	rs728616	0.681	rs36023925	ENSG00000242600.5	MBL1P	6.06	2.79e-09	5.57e-07	0.34	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147090	chr10:79904898~79950336:+
THCA	cis	rs10844706	0.699	rs11052752	ENSG00000256594.6	RP11-705C15.2	6.06	2.79e-09	5.57e-07	0.22	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735222	chr12:9633419~9658412:+
THCA	cis	rs12701220	0.842	rs10236293	ENSG00000229043.2	AC091729.9	-6.06	2.79e-09	5.57e-07	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:993001	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.5	rs6463224	ENSG00000229043.2	AC091729.9	-6.06	2.79e-09	5.57e-07	-0.36	-0.27	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1160374~1165267:+
THCA	cis	rs4072705	0.835	rs7855360	ENSG00000224020.1	MIR181A2HG	-6.06	2.79e-09	5.57e-07	-0.25	-0.27	Menarche (age at onset);	chr9:124794425	chr9:124658467~124698631:+
THCA	cis	rs227275	0.556	rs4455413	ENSG00000251288.2	RP11-10L12.2	-6.06	2.79e-09	5.57e-07	-0.37	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102751401~102752641:+
THCA	cis	rs7617773	1	rs12496784	ENSG00000228638.1	FCF1P2	6.06	2.79e-09	5.58e-07	0.25	0.27	Coronary artery disease;	chr3:48144777	chr3:48290793~48291375:-
THCA	cis	rs797680	0.754	rs3767964	ENSG00000223745.6	RP4-717I23.3	6.06	2.79e-09	5.58e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93349933	chr1:93262186~93346025:-
THCA	cis	rs28386778	1	rs2955241	ENSG00000240280.5	TCAM1P	-6.06	2.79e-09	5.58e-07	-0.38	-0.27	Prudent dietary pattern;	chr17:63890753	chr17:63849292~63864379:+
THCA	cis	rs12612619	0.732	rs11126857	ENSG00000229122.1	AGBL5-IT1	-6.06	2.79e-09	5.58e-07	-0.2	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27074889	chr2:27061038~27061815:+
THCA	cis	rs11722779	0.935	rs3857200	ENSG00000230069.3	LRRC37A15P	-6.06	2.79e-09	5.58e-07	-0.28	-0.27	Schizophrenia;	chr4:103001864	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs11731885	ENSG00000230069.3	LRRC37A15P	-6.06	2.79e-09	5.58e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102727274~102730721:-
THCA	cis	rs523522	0.962	rs10774549	ENSG00000278344.1	RP11-18C24.8	6.06	2.8e-09	5.59e-07	0.3	0.27	High light scatter reticulocyte count;	chr12:120453369	chr12:120500735~120501090:-
THCA	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	6.06	2.8e-09	5.59e-07	0.27	0.27	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
THCA	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	6.06	2.8e-09	5.6e-07	0.35	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
THCA	cis	rs595244	1	rs1678982	ENSG00000259705.1	RP11-227D13.1	-6.06	2.8e-09	5.6e-07	-0.47	-0.27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48609223	chr15:48645951~48652016:+
THCA	cis	rs67340775	0.834	rs13218875	ENSG00000219392.1	RP1-265C24.5	-6.06	2.8e-09	5.6e-07	-0.6	-0.27	Lung cancer in ever smokers;	chr6:27916234	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs67040724	ENSG00000219392.1	RP1-265C24.5	-6.06	2.8e-09	5.6e-07	-0.6	-0.27	Depression;	chr6:27937731	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs67662114	ENSG00000219392.1	RP1-265C24.5	-6.06	2.8e-09	5.6e-07	-0.6	-0.27	Depression;	chr6:27964523	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13216117	ENSG00000219392.1	RP1-265C24.5	-6.06	2.8e-09	5.6e-07	-0.6	-0.27	Depression;	chr6:27970706	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs36101351	ENSG00000219392.1	RP1-265C24.5	-6.06	2.8e-09	5.6e-07	-0.6	-0.27	Depression;	chr6:27975591	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs28360499	ENSG00000219392.1	RP1-265C24.5	-6.06	2.8e-09	5.6e-07	-0.6	-0.27	Depression;	chr6:27977618	chr6:28115628~28116551:+
THCA	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	6.06	2.8e-09	5.6e-07	0.25	0.27	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
THCA	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-6.06	2.81e-09	5.6e-07	-0.3	-0.27	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
THCA	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	6.06	2.81e-09	5.61e-07	0.39	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
THCA	cis	rs78487399	0.614	rs77061610	ENSG00000234936.1	AC010883.5	6.06	2.81e-09	5.61e-07	0.39	0.27	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43432831	chr2:43229573~43233394:+
THCA	cis	rs227275	0.556	rs223426	ENSG00000230069.3	LRRC37A15P	-6.06	2.81e-09	5.61e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102727274~102730721:-
THCA	cis	rs227275	0.554	rs223425	ENSG00000230069.3	LRRC37A15P	-6.06	2.81e-09	5.61e-07	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102727274~102730721:-
THCA	cis	rs228614	0.536	rs223418	ENSG00000230069.3	LRRC37A15P	-6.06	2.81e-09	5.61e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102727274~102730721:-
THCA	cis	rs6545883	0.931	rs12713437	ENSG00000271889.1	RP11-493E12.1	6.06	2.81e-09	5.61e-07	0.26	0.27	Tuberculosis;	chr2:61495769	chr2:61151433~61162105:-
THCA	cis	rs6860806	0.661	rs2136188	ENSG00000224431.1	AC063976.7	-6.06	2.81e-09	5.61e-07	-0.23	-0.27	Breast cancer;	chr5:132241821	chr5:132199456~132203487:+
THCA	cis	rs6545883	0.86	rs777589	ENSG00000271889.1	RP11-493E12.1	6.06	2.81e-09	5.61e-07	0.25	0.27	Tuberculosis;	chr2:61198486	chr2:61151433~61162105:-
THCA	cis	rs7202877	0.61	rs4888381	ENSG00000261783.1	RP11-252K23.2	-6.06	2.81e-09	5.61e-07	-0.47	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75322949	chr16:75379818~75381260:-
THCA	cis	rs2145598	0.967	rs10151752	ENSG00000279636.2	LINC00216	-6.06	2.81e-09	5.62e-07	-0.26	-0.27	Coronary artery disease;	chr14:58282708	chr14:58288033~58289158:+
THCA	cis	rs944990	0.538	rs10115234	ENSG00000227603.1	RP11-165J3.6	-6.06	2.81e-09	5.62e-07	-0.28	-0.27	Body mass index;	chr9:93538990	chr9:93435332~93437121:-
THCA	cis	rs2145598	0.967	rs6573194	ENSG00000279636.2	LINC00216	-6.06	2.81e-09	5.62e-07	-0.26	-0.27	Coronary artery disease;	chr14:58246196	chr14:58288033~58289158:+
THCA	cis	rs228614	0.534	rs223387	ENSG00000251288.2	RP11-10L12.2	-6.06	2.82e-09	5.63e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223381	ENSG00000251288.2	RP11-10L12.2	-6.06	2.82e-09	5.63e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102751401~102752641:+
THCA	cis	rs853679	0.607	rs35902873	ENSG00000219392.1	RP1-265C24.5	-6.06	2.82e-09	5.63e-07	-0.6	-0.27	Depression;	chr6:28091171	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13197574	ENSG00000219392.1	RP1-265C24.5	-6.06	2.82e-09	5.63e-07	-0.6	-0.27	Depression;	chr6:28092461	chr6:28115628~28116551:+
THCA	cis	rs712039	0.652	rs853196	ENSG00000276054.1	RP11-378E13.3	6.06	2.82e-09	5.63e-07	0.41	0.27	Tuberculosis;	chr17:37488553	chr17:37386886~37387926:+
THCA	cis	rs17772222	0.958	rs1816372	ENSG00000222990.1	RNU4-22P	6.06	2.82e-09	5.63e-07	0.35	0.27	Coronary artery calcification;	chr14:88507033	chr14:88513498~88513663:+
THCA	cis	rs6908034	0.607	rs76413455	ENSG00000237404.1	RP3-471C18.2	-6.06	2.82e-09	5.64e-07	-0.53	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808733	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs76525593	ENSG00000237404.1	RP3-471C18.2	-6.06	2.82e-09	5.64e-07	-0.53	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808939	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.546	rs74514942	ENSG00000237404.1	RP3-471C18.2	-6.06	2.82e-09	5.64e-07	-0.53	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810289	chr6:19689825~19753113:-
THCA	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	6.06	2.83e-09	5.65e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
THCA	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	6.06	2.83e-09	5.65e-07	0.25	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
THCA	cis	rs7809950	0.678	rs6949634	ENSG00000238832.1	snoU109	-6.06	2.83e-09	5.65e-07	-0.32	-0.27	Coronary artery disease;	chr7:107344239	chr7:107603363~107603507:+
THCA	cis	rs4776997	0.559	rs11071960	ENSG00000270964.1	RP11-502I4.3	6.06	2.83e-09	5.65e-07	0.25	0.27	Verbal declarative memory;	chr15:67784784	chr15:67541072~67542604:-
THCA	cis	rs62292953	1	rs56705566	ENSG00000248724.5	NPHP3-AS1	-6.06	2.83e-09	5.65e-07	-0.43	-0.27	Red cell distribution width;	chr3:132548460	chr3:132721750~132874223:+
THCA	cis	rs2303759	0.918	rs8107548	ENSG00000268686.1	AC010524.2	-6.06	2.83e-09	5.65e-07	-0.39	-0.27	Multiple sclerosis;	chr19:49367386	chr19:49368705~49388081:-
THCA	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	6.06	2.83e-09	5.65e-07	0.41	0.27	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
THCA	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-6.06	2.83e-09	5.65e-07	-0.34	-0.27	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
THCA	cis	rs11096990	0.892	rs11930865	ENSG00000249207.1	RP11-360F5.1	6.06	2.83e-09	5.66e-07	0.35	0.27	Cognitive function;	chr4:39218711	chr4:39112677~39126818:-
THCA	cis	rs10761482	0.5	rs10740030	ENSG00000254271.1	RP11-131N11.4	6.06	2.83e-09	5.66e-07	0.35	0.27	Schizophrenia;	chr10:60532054	chr10:60734342~60741828:+
THCA	cis	rs792448	0.717	rs17042034	ENSG00000226251.4	RP11-15I11.3	-6.06	2.83e-09	5.66e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212285673	chr1:212225278~212238977:-
THCA	cis	rs9467773	0.844	rs2393669	ENSG00000124549.13	BTN2A3P	6.06	2.84e-09	5.67e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26503645	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs9461259	ENSG00000124549.13	BTN2A3P	6.06	2.84e-09	5.67e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26504607	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs9467774	ENSG00000124549.13	BTN2A3P	6.06	2.84e-09	5.67e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26504808	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs3736781	ENSG00000124549.13	BTN2A3P	6.06	2.84e-09	5.67e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26505134	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs3736782	ENSG00000124549.13	BTN2A3P	6.06	2.84e-09	5.67e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26505175	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs2208331	ENSG00000124549.13	BTN2A3P	6.06	2.84e-09	5.67e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26507091	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs9393728	ENSG00000124549.13	BTN2A3P	6.06	2.84e-09	5.67e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26509102	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs1056667	ENSG00000124549.13	BTN2A3P	6.06	2.84e-09	5.67e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26510336	chr6:26421391~26432383:+
THCA	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-6.06	2.84e-09	5.67e-07	-0.28	-0.27	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
THCA	cis	rs7267979	0.932	rs449370	ENSG00000274414.1	RP5-965G21.4	6.06	2.84e-09	5.67e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25239007~25245229:-
THCA	cis	rs950169	0.58	rs11630887	ENSG00000259295.5	CSPG4P12	6.06	2.84e-09	5.67e-07	0.41	0.27	Schizophrenia;	chr15:84649784	chr15:85191438~85213905:+
THCA	cis	rs11158026	1	rs11158026	ENSG00000258413.1	RP11-665C16.6	-6.06	2.84e-09	5.67e-07	-0.36	-0.27	Parkinson's disease;	chr14:54882151	chr14:55262767~55272075:-
THCA	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	6.06	2.84e-09	5.67e-07	0.33	0.27	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
THCA	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	6.06	2.84e-09	5.67e-07	0.23	0.27	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
THCA	cis	rs6951245	0.706	rs28522260	ENSG00000229043.2	AC091729.9	-6.06	2.84e-09	5.67e-07	-0.44	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1144328	chr7:1160374~1165267:+
THCA	cis	rs589448	0.538	rs683790	ENSG00000274979.1	RP11-1143G9.5	-6.06	2.84e-09	5.67e-07	-0.31	-0.27	Cerebrospinal fluid biomarker levels;	chr12:69357654	chr12:69326574~69331882:-
THCA	cis	rs1859596	0.966	rs1034796	ENSG00000234456.6	MAGI2-AS3	6.06	2.84e-09	5.67e-07	0.26	0.27	Reading or mathematical ability;	chr7:79474220	chr7:79452877~79471208:+
THCA	cis	rs4934494	0.862	rs12246250	ENSG00000240996.1	RP11-80H5.7	-6.06	2.84e-09	5.67e-07	-0.29	-0.27	Red blood cell count;	chr10:89629540	chr10:89694295~89697928:-
THCA	cis	rs2976388	0.59	rs4736322	ENSG00000253741.1	CTD-2292P10.4	6.06	2.84e-09	5.68e-07	0.36	0.27	Urinary tract infection frequency;	chr8:142740790	chr8:142702252~142726973:-
THCA	cis	rs9921338	0.924	rs72773831	ENSG00000262636.1	CTD-3088G3.4	-6.06	2.84e-09	5.68e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319070	chr16:11380859~11381118:-
THCA	cis	rs6860806	0.632	rs4330455	ENSG00000224431.1	AC063976.7	6.06	2.84e-09	5.68e-07	0.23	0.27	Breast cancer;	chr5:132250656	chr5:132199456~132203487:+
THCA	cis	rs7809950	0.817	rs2222845	ENSG00000238832.1	snoU109	6.06	2.85e-09	5.68e-07	0.31	0.27	Coronary artery disease;	chr7:107641384	chr7:107603363~107603507:+
THCA	cis	rs1552244	0.882	rs34706481	ENSG00000180385.7	EMC3-AS1	6.06	2.85e-09	5.68e-07	0.29	0.27	Alzheimer's disease;	chr3:9962439	chr3:9986893~10006990:+
THCA	cis	rs5006884	0.951	rs4910764	ENSG00000167355.6	AC104389.28	-6.06	2.85e-09	5.68e-07	-0.55	-0.27	Fetal hemoglobin levels;	chr11:5362157	chr11:5304976~5505652:-
THCA	cis	rs797680	0.754	rs4847419	ENSG00000223745.6	RP4-717I23.3	6.06	2.85e-09	5.68e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93380098	chr1:93262186~93346025:-
THCA	cis	rs797680	0.664	rs4847420	ENSG00000223745.6	RP4-717I23.3	6.06	2.85e-09	5.68e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93380117	chr1:93262186~93346025:-
THCA	cis	rs2562456	0.876	rs11085467	ENSG00000213976.4	CTD-2561J22.2	-6.06	2.85e-09	5.69e-07	-0.29	-0.27	Pain;	chr19:21569041	chr19:21382865~21387177:+
THCA	cis	rs934734	0.563	rs11126034	ENSG00000234255.7	AC012370.3	-6.06	2.85e-09	5.69e-07	-0.32	-0.27	Rheumatoid arthritis;	chr2:65353087	chr2:65439888~65456571:-
THCA	cis	rs783540	0.872	rs2678445	ENSG00000278603.1	RP13-608F4.5	-6.06	2.85e-09	5.69e-07	-0.35	-0.27	Schizophrenia;	chr15:82577391	chr15:82472203~82472426:+
THCA	cis	rs12435908	1	rs73282260	ENSG00000276116.2	FUT8-AS1	-6.06	2.85e-09	5.69e-07	-0.44	-0.27	Ischemic stroke;	chr14:65392246	chr14:65411170~65412690:-
THCA	cis	rs6840360	0.681	rs9968292	ENSG00000251611.1	RP11-610P16.1	-6.06	2.85e-09	5.69e-07	-0.2	-0.27	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151407551~151408835:-
THCA	cis	rs453301	0.571	rs330048	ENSG00000254153.1	CTA-398F10.2	6.06	2.85e-09	5.7e-07	0.29	0.27	Joint mobility (Beighton score);	chr8:9229768	chr8:8456909~8461337:-
THCA	cis	rs4950322	0.512	rs2353974	ENSG00000237188.3	RP11-337C18.8	-6.06	2.86e-09	5.7e-07	-0.29	-0.27	Protein quantitative trait loci;	chr1:147384534	chr1:147172771~147211568:+
THCA	cis	rs7225151	0.71	rs12602528	ENSG00000234327.6	AC012146.7	-6.06	2.86e-09	5.7e-07	-0.3	-0.27	Alzheimer's disease (late onset);	chr17:5342142	chr17:5111468~5115004:+
THCA	cis	rs9921338	0.961	rs72773829	ENSG00000262636.1	CTD-3088G3.4	-6.06	2.86e-09	5.7e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318766	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs72773830	ENSG00000262636.1	CTD-3088G3.4	-6.06	2.86e-09	5.7e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318966	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs72773832	ENSG00000262636.1	CTD-3088G3.4	-6.06	2.86e-09	5.7e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319266	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs72773833	ENSG00000262636.1	CTD-3088G3.4	-6.06	2.86e-09	5.7e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319417	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs72773834	ENSG00000262636.1	CTD-3088G3.4	-6.06	2.86e-09	5.7e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319436	chr16:11380859~11381118:-
THCA	cis	rs934734	0.789	rs11689314	ENSG00000281920.1	RP11-418H16.1	-6.06	2.86e-09	5.7e-07	-0.34	-0.27	Rheumatoid arthritis;	chr2:65378274	chr2:65623272~65628424:+
THCA	cis	rs7615952	0.599	rs2270986	ENSG00000250012.1	RP11-124N2.1	-6.06	2.86e-09	5.71e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:125982256	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.599	rs12496921	ENSG00000250012.1	RP11-124N2.1	-6.06	2.86e-09	5.71e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:125983105	chr3:126084220~126095349:+
THCA	cis	rs6545883	1	rs6742276	ENSG00000271889.1	RP11-493E12.1	6.06	2.86e-09	5.71e-07	0.26	0.27	Tuberculosis;	chr2:61541610	chr2:61151433~61162105:-
THCA	cis	rs228614	0.51	rs223313	ENSG00000251288.2	RP11-10L12.2	-6.06	2.86e-09	5.71e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102751401~102752641:+
THCA	cis	rs11971779	0.729	rs10464730	ENSG00000273391.1	RP11-634H22.1	6.06	2.86e-09	5.71e-07	0.28	0.27	Diisocyanate-induced asthma;	chr7:139317481	chr7:139359032~139359566:-
THCA	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	6.06	2.86e-09	5.71e-07	0.49	0.27	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	6.06	2.86e-09	5.71e-07	0.49	0.27	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	6.06	2.86e-09	5.71e-07	0.49	0.27	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
THCA	cis	rs690037	0.528	rs568833	ENSG00000272529.1	RP11-415F23.4	6.06	2.86e-09	5.71e-07	0.24	0.27	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16326329	chr3:16345126~16346440:+
THCA	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-6.06	2.86e-09	5.71e-07	-0.3	-0.27	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
THCA	cis	rs526231	0.819	rs26232	ENSG00000175749.11	EIF3KP1	6.06	2.86e-09	5.71e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103261019	chr5:103032376~103033031:+
THCA	cis	rs526231	0.819	rs26234	ENSG00000175749.11	EIF3KP1	6.06	2.86e-09	5.71e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103261455	chr5:103032376~103033031:+
THCA	cis	rs526231	0.747	rs39984	ENSG00000175749.11	EIF3KP1	6.06	2.86e-09	5.71e-07	0.37	0.27	Primary biliary cholangitis;	chr5:103261591	chr5:103032376~103033031:+
THCA	cis	rs227275	0.554	rs223371	ENSG00000251288.2	RP11-10L12.2	-6.06	2.86e-09	5.71e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102751401~102752641:+
THCA	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-6.06	2.86e-09	5.71e-07	-0.39	-0.27	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
THCA	cis	rs13129838	1	rs13129838	ENSG00000250334.4	LINC00989	-6.06	2.86e-09	5.72e-07	-0.31	-0.27	Myopia;	chr4:79587634	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.817	rs12643976	ENSG00000250334.4	LINC00989	-6.06	2.86e-09	5.72e-07	-0.31	-0.27	Refractive error;	chr4:79589616	chr4:79492416~79576460:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000261839.1	RP1-265C24.8	6.06	2.87e-09	5.72e-07	0.32	0.27	Depression;	chr6:28096845	chr6:28136849~28139678:+
THCA	cis	rs713477	1	rs2185036	ENSG00000258413.1	RP11-665C16.6	6.06	2.87e-09	5.72e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55440992	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs2152975	ENSG00000258413.1	RP11-665C16.6	6.06	2.87e-09	5.72e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55441201	chr14:55262767~55272075:-
THCA	cis	rs7428	0.527	rs6547612	ENSG00000246575.2	AC093162.5	6.06	2.87e-09	5.72e-07	0.24	0.27	Ear protrusion;	chr2:85324061	chr2:85315041~85316529:+
THCA	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	6.06	2.87e-09	5.73e-07	0.49	0.27	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
THCA	cis	rs60180747	0.544	rs1020927	ENSG00000261318.1	RP11-653J6.1	6.06	2.87e-09	5.73e-07	0.36	0.27	Testicular germ cell tumor;	chr15:66258920	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.544	rs11630157	ENSG00000261318.1	RP11-653J6.1	6.06	2.87e-09	5.73e-07	0.36	0.27	Testicular germ cell tumor;	chr15:66261087	chr15:66278498~66293357:-
THCA	cis	rs713477	0.967	rs11158039	ENSG00000258413.1	RP11-665C16.6	6.05	2.88e-09	5.74e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55439978	chr14:55262767~55272075:-
THCA	cis	rs228614	0.51	rs223415	ENSG00000230069.3	LRRC37A15P	-6.05	2.88e-09	5.74e-07	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102727274~102730721:-
THCA	cis	rs9880211	0.948	rs13316214	ENSG00000273486.1	RP11-731C17.2	6.05	2.88e-09	5.74e-07	0.28	0.27	Height;Body mass index;	chr3:136439379	chr3:136837338~136839021:-
THCA	cis	rs12908161	0.92	rs12904605	ENSG00000259295.5	CSPG4P12	6.05	2.88e-09	5.74e-07	0.41	0.27	Schizophrenia;	chr15:84658188	chr15:85191438~85213905:+
THCA	cis	rs2041895	0.527	rs10861681	ENSG00000260329.1	RP11-412D9.4	-6.05	2.88e-09	5.74e-07	-0.27	-0.27	Glaucoma (low intraocular pressure);	chr12:106940484	chr12:106954029~106955497:-
THCA	cis	rs61677309	0.597	rs112590920	ENSG00000280032.1	RP11-832A4.7	6.05	2.88e-09	5.74e-07	0.27	0.27	Lung cancer in ever smokers;	chr11:118272871	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.558	rs4245179	ENSG00000280032.1	RP11-832A4.7	6.05	2.88e-09	5.74e-07	0.27	0.27	Lung cancer in ever smokers;	chr11:118273730	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.638	rs4245180	ENSG00000280032.1	RP11-832A4.7	6.05	2.88e-09	5.74e-07	0.27	0.27	Lung cancer in ever smokers;	chr11:118273797	chr11:118264593~118266817:+
THCA	cis	rs728616	0.867	rs55835350	ENSG00000242600.5	MBL1P	6.05	2.88e-09	5.75e-07	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80041972	chr10:79904898~79950336:+
THCA	cis	rs728616	0.867	rs79904324	ENSG00000242600.5	MBL1P	6.05	2.88e-09	5.75e-07	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80044932	chr10:79904898~79950336:+
THCA	cis	rs7712401	0.72	rs12109791	ENSG00000249996.1	RP11-359P5.1	6.05	2.89e-09	5.75e-07	0.26	0.27	Mean platelet volume;	chr5:122811136	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.818	rs13166350	ENSG00000249996.1	RP11-359P5.1	6.05	2.89e-09	5.75e-07	0.26	0.27	Mean platelet volume;	chr5:122817874	chr5:123036271~123054667:+
THCA	cis	rs10129255	0.957	rs10136560	ENSG00000211974.3	IGHV2-70	6.05	2.89e-09	5.75e-07	0.21	0.27	Kawasaki disease;	chr14:106787630	chr14:106723574~106724093:-
THCA	cis	rs8177876	0.749	rs2278024	ENSG00000261061.1	RP11-303E16.2	-6.05	2.89e-09	5.75e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81030770~81031485:+
THCA	cis	rs944289	0.6	rs1169123	ENSG00000257826.1	RP11-116N8.4	-6.05	2.89e-09	5.75e-07	-0.3	-0.27	Thyroid cancer;	chr14:36149287	chr14:36061026~36067190:-
THCA	cis	rs338389	0.542	rs7494835	ENSG00000260657.2	RP11-315D16.4	-6.05	2.89e-09	5.76e-07	-0.37	-0.27	Survival in rectal cancer;	chr15:68001993	chr15:68267792~68277994:-
THCA	cis	rs7246657	0.722	rs2972438	ENSG00000267422.1	CTD-2554C21.1	-6.05	2.89e-09	5.76e-07	-0.31	-0.27	Coronary artery calcification;	chr19:37719946	chr19:37779686~37792865:+
THCA	cis	rs4713118	0.628	rs9295740	ENSG00000280107.1	AL022393.9	-6.05	2.89e-09	5.76e-07	-0.32	-0.27	Parkinson's disease;	chr6:27721723	chr6:28170845~28172521:+
THCA	cis	rs72627509	0.68	rs56162812	ENSG00000269949.1	RP11-738E22.3	6.05	2.89e-09	5.76e-07	0.4	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56874501	chr4:56960927~56961373:-
THCA	cis	rs6545883	0.868	rs2518933	ENSG00000271889.1	RP11-493E12.1	6.05	2.89e-09	5.76e-07	0.26	0.27	Tuberculosis;	chr2:61569895	chr2:61151433~61162105:-
THCA	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	6.05	2.89e-09	5.77e-07	0.29	0.27	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	6.05	2.89e-09	5.77e-07	0.29	0.27	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
THCA	cis	rs55665837	0.502	rs12795794	ENSG00000251991.1	RNU7-49P	6.05	2.89e-09	5.77e-07	0.3	0.27	Vitamin D levels;	chr11:14825327	chr11:14478892~14478953:+
THCA	cis	rs2145598	0.933	rs12590259	ENSG00000279636.2	LINC00216	-6.05	2.89e-09	5.77e-07	-0.26	-0.27	Coronary artery disease;	chr14:58274407	chr14:58288033~58289158:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-6.05	2.89e-09	5.77e-07	-0.3	-0.27	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
THCA	cis	rs9921338	0.887	rs6498183	ENSG00000262636.1	CTD-3088G3.4	-6.05	2.89e-09	5.77e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11337051	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs7187870	ENSG00000262636.1	CTD-3088G3.4	-6.05	2.89e-09	5.77e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11338062	chr16:11380859~11381118:-
THCA	cis	rs6674176	0.66	rs6680421	ENSG00000237950.1	RP11-7O11.3	-6.05	2.89e-09	5.77e-07	-0.24	-0.27	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43943297	chr1:43944370~43946551:-
THCA	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-6.05	2.9e-09	5.77e-07	-0.41	-0.27	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912789	ENSG00000227373.4	RP11-160H22.5	6.05	2.9e-09	5.77e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174465616	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs6684141	ENSG00000227373.4	RP11-160H22.5	6.05	2.9e-09	5.77e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174467305	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12058377	ENSG00000227373.4	RP11-160H22.5	6.05	2.9e-09	5.77e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174470971	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs6656925	ENSG00000227373.4	RP11-160H22.5	6.05	2.9e-09	5.77e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174474161	chr1:174115300~174160004:-
THCA	cis	rs9921338	0.961	rs9936328	ENSG00000262636.1	CTD-3088G3.4	-6.05	2.9e-09	5.77e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11344364	chr16:11380859~11381118:-
THCA	cis	rs713477	0.901	rs1572612	ENSG00000258413.1	RP11-665C16.6	6.05	2.9e-09	5.77e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55443221	chr14:55262767~55272075:-
THCA	cis	rs4886920	0.672	rs12437900	ENSG00000260776.4	RP11-114H24.2	6.05	2.9e-09	5.78e-07	0.33	0.27	Neuroticism;	chr15:77841796	chr15:77914217~77926846:-
THCA	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	6.05	2.9e-09	5.78e-07	0.3	0.27	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
THCA	cis	rs728616	0.764	rs56196124	ENSG00000242600.5	MBL1P	6.05	2.9e-09	5.79e-07	0.34	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142899	chr10:79904898~79950336:+
THCA	cis	rs9903692	0.505	rs208008	ENSG00000278765.1	RP5-890E16.5	-6.05	2.9e-09	5.79e-07	-0.47	-0.27	Pulse pressure;	chr17:48153476	chr17:48066704~48067293:-
THCA	cis	rs748404	0.534	rs489509	ENSG00000166763.7	STRCP1	6.05	2.91e-09	5.81e-07	0.29	0.27	Lung cancer;	chr15:43294709	chr15:43699488~43718184:-
THCA	cis	rs681343	1	rs516316	ENSG00000232871.7	SEC1P	6.05	2.92e-09	5.81e-07	0.32	0.27	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702888	chr19:48638071~48682245:+
THCA	cis	rs2765539	0.851	rs1891141	ENSG00000231365.4	RP11-418J17.1	-6.05	2.92e-09	5.81e-07	-0.29	-0.27	Waist-hip ratio;	chr1:119034787	chr1:119140396~119275973:+
THCA	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	6.05	2.92e-09	5.81e-07	0.34	0.27	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
THCA	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-6.05	2.92e-09	5.81e-07	-0.34	-0.27	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
THCA	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-6.05	2.92e-09	5.81e-07	-0.32	-0.27	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
THCA	cis	rs7560272	0.723	rs4346412	ENSG00000163016.8	ALMS1P	6.05	2.92e-09	5.82e-07	0.34	0.27	Schizophrenia;	chr2:73616444	chr2:73644919~73685576:+
THCA	cis	rs71520386	0.632	rs2286509	ENSG00000228649.7	AC005682.5	-6.05	2.92e-09	5.82e-07	-0.34	-0.27	Fibrinogen levels;	chr7:22814832	chr7:22854178~22861579:+
THCA	cis	rs9921338	0.961	rs77552156	ENSG00000262636.1	CTD-3088G3.4	-6.05	2.92e-09	5.82e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11332542	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs4781069	ENSG00000262636.1	CTD-3088G3.4	-6.05	2.92e-09	5.82e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334905	chr16:11380859~11381118:-
THCA	cis	rs11148252	0.716	rs2760772	ENSG00000235660.1	LINC00345	-6.05	2.92e-09	5.82e-07	-0.35	-0.27	Lewy body disease;	chr13:52206238	chr13:52484161~52484680:-
THCA	cis	rs7809950	0.678	rs62482499	ENSG00000238832.1	snoU109	-6.05	2.92e-09	5.82e-07	-0.31	-0.27	Coronary artery disease;	chr7:107334614	chr7:107603363~107603507:+
THCA	cis	rs2288884	0.806	rs12460587	ENSG00000275055.1	CTC-471J1.11	-6.05	2.92e-09	5.83e-07	-0.26	-0.27	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52083666	chr19:52049007~52049754:+
THCA	cis	rs227275	0.556	rs28367331	ENSG00000230069.3	LRRC37A15P	-6.05	2.93e-09	5.83e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102727274~102730721:-
THCA	cis	rs9880211	0.699	rs34804893	ENSG00000273486.1	RP11-731C17.2	6.05	2.93e-09	5.83e-07	0.28	0.27	Height;Body mass index;	chr3:136621128	chr3:136837338~136839021:-
THCA	cis	rs55665837	0.54	rs3206554	ENSG00000251991.1	RNU7-49P	6.05	2.93e-09	5.84e-07	0.29	0.27	Vitamin D levels;	chr11:14776399	chr11:14478892~14478953:+
THCA	cis	rs17301013	0.507	rs969472	ENSG00000227373.4	RP11-160H22.5	6.05	2.93e-09	5.84e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174458562	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10798314	ENSG00000227373.4	RP11-160H22.5	6.05	2.93e-09	5.84e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174458958	chr1:174115300~174160004:-
THCA	cis	rs2243480	1	rs778729	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	5.84e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66359432	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.901	rs778687	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	5.84e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66370832	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs778679	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	5.84e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66375924	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs778704	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	5.84e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66398480	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.901	rs778693	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	5.84e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66407358	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs778691	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	5.84e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66408105	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs13235972	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	5.84e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66418618	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs34192067	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	5.84e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66422670	chr7:66848496~66858136:+
THCA	cis	rs17301013	0.507	rs10912791	ENSG00000227373.4	RP11-160H22.5	6.05	2.93e-09	5.84e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174479298	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12079334	ENSG00000227373.4	RP11-160H22.5	6.05	2.93e-09	5.84e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174480815	chr1:174115300~174160004:-
THCA	cis	rs7129556	0.954	rs6592738	ENSG00000254691.1	RP11-91P24.5	6.05	2.93e-09	5.84e-07	0.36	0.27	Weight loss (gastric bypass surgery);	chr11:77612081	chr11:77850604~77851511:+
THCA	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-6.05	2.94e-09	5.85e-07	-0.45	-0.27	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
THCA	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	6.05	2.94e-09	5.86e-07	0.41	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
THCA	cis	rs17301013	0.531	rs332806	ENSG00000227373.4	RP11-160H22.5	6.05	2.94e-09	5.86e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174653645	chr1:174115300~174160004:-
THCA	cis	rs2657294	0.62	rs2395136	ENSG00000226051.5	ZNF503-AS1	-6.05	2.94e-09	5.86e-07	-0.39	-0.27	Pneumonia;	chr10:75088213	chr10:75269819~75373500:+
THCA	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	6.05	2.95e-09	5.86e-07	0.32	0.27	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
THCA	cis	rs9311474	1	rs2276834	ENSG00000243224.1	RP5-1157M23.2	-6.05	2.95e-09	5.87e-07	-0.28	-0.27	Electroencephalogram traits;	chr3:52291743	chr3:52239258~52241097:+
THCA	cis	rs556990	0.76	rs3024739	ENSG00000269125.1	RP11-98F14.11	-6.05	2.95e-09	5.87e-07	-0.34	-0.27	Blood protein levels;	chr13:113165634	chr13:113165002~113165183:-
THCA	cis	rs6430553	0.929	rs74265413	ENSG00000224043.6	CCNT2-AS1	-6.05	2.95e-09	5.87e-07	-0.27	-0.27	Blood metabolite levels;	chr2:134892083	chr2:134735464~134918710:-
THCA	cis	rs4927850	0.709	rs6783079	ENSG00000273009.1	RP11-352G9.1	-6.05	2.95e-09	5.87e-07	-0.34	-0.27	Pancreatic cancer;	chr3:195925837	chr3:195913078~195913683:-
THCA	cis	rs4927850	0.709	rs6765762	ENSG00000273009.1	RP11-352G9.1	-6.05	2.95e-09	5.87e-07	-0.34	-0.27	Pancreatic cancer;	chr3:195925980	chr3:195913078~195913683:-
THCA	cis	rs3213958	0.509	rs73136060	ENSG00000249274.1	PDLIM1P4	-6.05	2.95e-09	5.87e-07	-0.33	-0.27	Blood protein levels;	chr3:98792641	chr3:98782188~98783193:+
THCA	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	6.05	2.95e-09	5.87e-07	0.28	0.27	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	6.05	2.95e-09	5.87e-07	0.28	0.27	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	6.05	2.95e-09	5.87e-07	0.28	0.27	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	6.05	2.95e-09	5.87e-07	0.28	0.27	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	6.05	2.95e-09	5.87e-07	0.28	0.27	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	6.05	2.95e-09	5.87e-07	0.28	0.27	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-6.05	2.95e-09	5.87e-07	-0.28	-0.27	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
THCA	cis	rs4950322	1	rs72694715	ENSG00000237188.3	RP11-337C18.8	6.05	2.95e-09	5.87e-07	0.36	0.27	Protein quantitative trait loci;	chr1:147368468	chr1:147172771~147211568:+
THCA	cis	rs7760535	0.826	rs3851229	ENSG00000230177.1	RP5-1112D6.4	-6.05	2.95e-09	5.88e-07	-0.22	-0.27	Metabolic traits;	chr6:111533457	chr6:111277932~111278742:+
THCA	cis	rs2765539	0.851	rs8928	ENSG00000231365.4	RP11-418J17.1	-6.05	2.95e-09	5.88e-07	-0.29	-0.27	Waist-hip ratio;	chr1:119031451	chr1:119140396~119275973:+
THCA	cis	rs2029362	0.612	rs1519479	ENSG00000245573.6	BDNF-AS	6.05	2.96e-09	5.88e-07	0.21	0.27	Total body bone mineral density;	chr11:27645984	chr11:27506838~27698174:+
THCA	cis	rs11603691	0.551	rs10792086	ENSG00000254662.1	RP11-872D17.4	6.05	2.96e-09	5.89e-07	0.42	0.27	Low high density lipoprotein cholesterol levels;	chr11:57315422	chr11:57325603~57327958:+
THCA	cis	rs897984	0.609	rs55979739	ENSG00000279196.1	RP11-1072A3.3	6.05	2.96e-09	5.89e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31037834	chr16:30984630~30988270:-
THCA	cis	rs897984	0.609	rs732172	ENSG00000279196.1	RP11-1072A3.3	6.05	2.96e-09	5.89e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31038712	chr16:30984630~30988270:-
THCA	cis	rs16976116	0.803	rs28530662	ENSG00000279145.1	RP11-547D13.1	6.05	2.96e-09	5.89e-07	0.27	0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55206638	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs8030981	ENSG00000279145.1	RP11-547D13.1	6.05	2.96e-09	5.89e-07	0.27	0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55207244	chr15:55171972~55178175:-
THCA	cis	rs6902257	0.59	rs2168107	ENSG00000272129.1	RP11-250B2.6	6.05	2.96e-09	5.89e-07	0.72	0.27	Obesity-related traits;	chr6:80600723	chr6:80355424~80356859:+
THCA	cis	rs6844153	0.877	rs10939146	ENSG00000240005.4	RP11-293A21.1	-6.05	2.96e-09	5.9e-07	-0.37	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26978399	chr4:26859806~26860599:-
THCA	cis	rs7246657	0.722	rs3101746	ENSG00000267422.1	CTD-2554C21.1	6.05	2.96e-09	5.9e-07	0.31	0.27	Coronary artery calcification;	chr19:37655499	chr19:37779686~37792865:+
THCA	cis	rs736801	0.808	rs4705950	ENSG00000233006.5	AC034220.3	6.05	2.96e-09	5.9e-07	0.22	0.27	Mosquito bite size;Breast cancer;	chr5:132457594	chr5:132311285~132369916:-
THCA	cis	rs12908161	1	rs62019469	ENSG00000259295.5	CSPG4P12	6.05	2.96e-09	5.9e-07	0.41	0.27	Schizophrenia;	chr15:84777989	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs12908549	ENSG00000259295.5	CSPG4P12	6.05	2.96e-09	5.9e-07	0.41	0.27	Schizophrenia;	chr15:84779120	chr15:85191438~85213905:+
THCA	cis	rs2735413	0.564	rs73578752	ENSG00000276007.1	RP11-358L22.3	6.05	2.96e-09	5.9e-07	0.29	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78073657	chr16:78123243~78124332:+
THCA	cis	rs9921338	0.961	rs9937269	ENSG00000262636.1	CTD-3088G3.4	6.05	2.97e-09	5.9e-07	0.39	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322822	chr16:11380859~11381118:-
THCA	cis	rs9921338	1	rs9921338	ENSG00000262636.1	CTD-3088G3.4	6.05	2.97e-09	5.9e-07	0.39	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322982	chr16:11380859~11381118:-
THCA	cis	rs6545883	0.899	rs12473030	ENSG00000271889.1	RP11-493E12.1	6.05	2.97e-09	5.9e-07	0.26	0.27	Tuberculosis;	chr2:61493362	chr2:61151433~61162105:-
THCA	cis	rs4699052	0.537	rs1580278	ENSG00000246560.2	RP11-10L12.4	-6.05	2.97e-09	5.91e-07	-0.33	-0.27	Testicular germ cell tumor;	chr4:103219691	chr4:102828055~102844075:+
THCA	cis	rs9880211	1	rs35899944	ENSG00000273486.1	RP11-731C17.2	6.05	2.98e-09	5.92e-07	0.28	0.27	Height;Body mass index;	chr3:136510215	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs9878078	ENSG00000273486.1	RP11-731C17.2	6.05	2.98e-09	5.92e-07	0.28	0.27	Height;Body mass index;	chr3:136518731	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs28811905	ENSG00000273486.1	RP11-731C17.2	6.05	2.98e-09	5.92e-07	0.28	0.27	Height;Body mass index;	chr3:136533210	chr3:136837338~136839021:-
THCA	cis	rs3213958	0.574	rs7614892	ENSG00000249274.1	PDLIM1P4	-6.05	2.98e-09	5.93e-07	-0.34	-0.27	Blood protein levels;	chr3:98859053	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs73138048	ENSG00000249274.1	PDLIM1P4	-6.05	2.98e-09	5.93e-07	-0.34	-0.27	Blood protein levels;	chr3:98871788	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.621	rs73138055	ENSG00000249274.1	PDLIM1P4	-6.05	2.98e-09	5.93e-07	-0.34	-0.27	Blood protein levels;	chr3:98877161	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.621	rs73138058	ENSG00000249274.1	PDLIM1P4	-6.05	2.98e-09	5.93e-07	-0.34	-0.27	Blood protein levels;	chr3:98880597	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs73138063	ENSG00000249274.1	PDLIM1P4	-6.05	2.98e-09	5.93e-07	-0.34	-0.27	Blood protein levels;	chr3:98885058	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs16840260	ENSG00000249274.1	PDLIM1P4	-6.05	2.98e-09	5.93e-07	-0.34	-0.27	Blood protein levels;	chr3:98885752	chr3:98782188~98783193:+
THCA	cis	rs9381040	0.61	rs2268196	ENSG00000161912.16	ADCY10P1	-6.05	2.98e-09	5.94e-07	-0.18	-0.27	Alzheimer's disease (late onset);	chr6:41054211	chr6:41101022~41140835:+
THCA	cis	rs5742933	0.744	rs13009889	ENSG00000253559.1	OSGEPL1-AS1	6.05	2.98e-09	5.94e-07	0.3	0.27	Ferritin levels;	chr2:189763842	chr2:189762704~189765556:+
THCA	cis	rs950169	0.544	rs62021193	ENSG00000259295.5	CSPG4P12	6.05	2.99e-09	5.94e-07	0.41	0.27	Schizophrenia;	chr15:84627352	chr15:85191438~85213905:+
THCA	cis	rs6840258	0.76	rs58633957	ENSG00000251411.1	RP11-397E7.4	-6.05	2.99e-09	5.94e-07	-0.29	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87047827	chr4:86913266~86914817:-
THCA	cis	rs7202877	0.706	rs8054586	ENSG00000261783.1	RP11-252K23.2	-6.05	2.99e-09	5.95e-07	-0.46	-0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75376807	chr16:75379818~75381260:-
THCA	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	6.05	2.99e-09	5.95e-07	0.41	0.27	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
THCA	cis	rs950169	0.922	rs62021167	ENSG00000259295.5	CSPG4P12	6.05	2.99e-09	5.95e-07	0.41	0.27	Schizophrenia;	chr15:84574820	chr15:85191438~85213905:+
THCA	cis	rs2439831	0.867	rs28461955	ENSG00000249839.1	AC011330.5	-6.05	2.99e-09	5.95e-07	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43369261	chr15:43663654~43684339:-
THCA	cis	rs227275	0.556	rs724447	ENSG00000251288.2	RP11-10L12.2	6.05	2.99e-09	5.95e-07	0.36	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102751401~102752641:+
THCA	cis	rs28530618	0.84	rs6058783	ENSG00000175730.8	BAK1P1	6.05	3e-09	5.96e-07	0.3	0.27	Birth weight;	chr20:32647980	chr20:32690180~32690815:-
THCA	cis	rs1395	0.922	rs11898114	ENSG00000234072.1	AC074117.10	-6.05	3e-09	5.97e-07	-0.22	-0.27	Blood metabolite levels;	chr2:27292659	chr2:27356246~27367622:+
THCA	cis	rs1395	0.922	rs13404327	ENSG00000234072.1	AC074117.10	-6.05	3e-09	5.97e-07	-0.22	-0.27	Blood metabolite levels;	chr2:27296285	chr2:27356246~27367622:+
THCA	cis	rs890448	0.796	rs1365381	ENSG00000254531.1	FLJ20021	-6.05	3e-09	5.97e-07	-0.24	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422718	chr4:101347780~101348883:+
THCA	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-6.05	3e-09	5.97e-07	-0.33	-0.27	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
THCA	cis	rs836788	0.608	rs863221	ENSG00000249655.1	CTC-325J23.2	-6.05	3e-09	5.97e-07	-0.27	-0.27	Glomerular filtration rate (creatinine);	chr5:80746456	chr5:80630313~80631590:-
THCA	cis	rs712022	0.534	rs7927085	ENSG00000246225.5	RP11-17A1.3	-6.05	3e-09	5.98e-07	-0.36	-0.27	Dialysis-related mortality;	chr11:22852337	chr11:22829380~22945393:+
THCA	cis	rs2803122	0.501	rs10811140	ENSG00000273226.1	RP11-513M16.8	-6.05	3.01e-09	5.98e-07	-0.3	-0.27	Pulse pressure;	chr9:19230401	chr9:19375451~19375996:+
THCA	cis	rs227275	0.525	rs3974604	ENSG00000230069.3	LRRC37A15P	-6.05	3.01e-09	5.98e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102727274~102730721:-
THCA	cis	rs367615	0.68	rs77013	ENSG00000249476.1	CTD-2587M2.1	6.05	3.01e-09	5.98e-07	0.3	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109627385	chr5:109237120~109326369:-
THCA	cis	rs1552244	0.882	rs3846168	ENSG00000180385.7	EMC3-AS1	6.05	3.01e-09	5.98e-07	0.28	0.27	Alzheimer's disease;	chr3:9955241	chr3:9986893~10006990:+
THCA	cis	rs7044106	0.762	rs1547268	ENSG00000270917.1	RP11-27I1.6	-6.05	3.01e-09	5.99e-07	-0.37	-0.27	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120812475~120812845:-
THCA	cis	rs72843506	0.591	rs117720402	ENSG00000270091.1	RP11-78O7.2	-6.05	3.01e-09	5.99e-07	-0.31	-0.27	Schizophrenia;	chr17:20444298	chr17:19896590~19897287:-
THCA	cis	rs853679	1	rs10456362	ENSG00000226314.6	ZNF192P1	6.05	3.01e-09	5.99e-07	0.39	0.27	Depression;	chr6:28254038	chr6:28161781~28169594:+
THCA	cis	rs1859596	1	rs1859598	ENSG00000234456.6	MAGI2-AS3	6.05	3.01e-09	5.99e-07	0.26	0.27	Reading or mathematical ability;	chr7:79484678	chr7:79452877~79471208:+
THCA	cis	rs1859596	0.934	rs2365423	ENSG00000234456.6	MAGI2-AS3	6.05	3.01e-09	5.99e-07	0.26	0.27	Reading or mathematical ability;	chr7:79485440	chr7:79452877~79471208:+
THCA	cis	rs1859596	0.903	rs2365424	ENSG00000234456.6	MAGI2-AS3	6.05	3.01e-09	5.99e-07	0.26	0.27	Reading or mathematical ability;	chr7:79485459	chr7:79452877~79471208:+
THCA	cis	rs1859596	1	rs4727886	ENSG00000234456.6	MAGI2-AS3	6.05	3.01e-09	5.99e-07	0.26	0.27	Reading or mathematical ability;	chr7:79485656	chr7:79452877~79471208:+
THCA	cis	rs4845570	0.85	rs4504897	ENSG00000268288.1	RP11-98D18.16	6.05	3.02e-09	6e-07	0.34	0.27	Coronary artery disease;	chr1:151794375	chr1:151766486~151767000:-
THCA	cis	rs16846053	0.71	rs7581747	ENSG00000227403.1	AC009299.3	-6.05	3.02e-09	6e-07	-0.41	-0.27	Blood osmolality (transformed sodium);	chr2:161758605	chr2:161244739~161249050:+
THCA	cis	rs4841097	0.876	rs6601288	ENSG00000254153.1	CTA-398F10.2	-6.05	3.02e-09	6e-07	-0.31	-0.27	Platelet distribution width;	chr8:9085920	chr8:8456909~8461337:-
THCA	cis	rs6445975	0.666	rs4681856	ENSG00000272360.1	RP11-359I18.5	-6.05	3.02e-09	6e-07	-0.32	-0.27	Systemic lupus erythematosus;	chr3:58475489	chr3:58490830~58491291:-
THCA	cis	rs11089937	0.626	rs5757011	ENSG00000211638.2	IGLV8-61	-6.05	3.02e-09	6e-07	-0.21	-0.27	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22098700~22099212:+
THCA	cis	rs6430585	0.583	rs12472293	ENSG00000231890.6	DARS-AS1	-6.05	3.02e-09	6.01e-07	-0.32	-0.27	Corneal structure;	chr2:135890507	chr2:135985176~136022593:+
THCA	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-6.05	3.02e-09	6.01e-07	-0.24	-0.27	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
THCA	cis	rs9921338	0.961	rs12934968	ENSG00000262703.1	RP11-485G7.6	6.05	3.02e-09	6.01e-07	0.34	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320209	chr16:11348143~11349321:-
THCA	cis	rs227275	0.556	rs6815526	ENSG00000230069.3	LRRC37A15P	-6.05	3.02e-09	6.01e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs6824070	ENSG00000230069.3	LRRC37A15P	-6.05	3.02e-09	6.01e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.935	rs6856176	ENSG00000230069.3	LRRC37A15P	-6.05	3.02e-09	6.01e-07	-0.28	-0.27	Schizophrenia;	chr4:102902574	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs11722779	ENSG00000230069.3	LRRC37A15P	-6.05	3.02e-09	6.01e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102727274~102730721:-
THCA	cis	rs2562456	0.958	rs2562508	ENSG00000268081.1	RP11-678G14.2	-6.05	3.03e-09	6.02e-07	-0.38	-0.27	Pain;	chr19:21543479	chr19:21554640~21569237:-
THCA	cis	rs7045881	0.808	rs7039400	ENSG00000254396.1	RP11-56F10.3	6.05	3.03e-09	6.02e-07	0.39	0.27	Schizophrenia;	chr9:26946251	chr9:27102630~27104728:+
THCA	cis	rs860295	0.65	rs4661175	ENSG00000225855.5	RUSC1-AS1	-6.05	3.03e-09	6.02e-07	-0.17	-0.27	Body mass index;	chr1:155961577	chr1:155316863~155324176:-
THCA	cis	rs4713118	0.512	rs2622319	ENSG00000226314.6	ZNF192P1	-6.05	3.03e-09	6.02e-07	-0.32	-0.27	Parkinson's disease;	chr6:28152623	chr6:28161781~28169594:+
THCA	cis	rs7615952	0.599	rs6766327	ENSG00000250012.1	RP11-124N2.1	-6.05	3.03e-09	6.03e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126004834	chr3:126084220~126095349:+
THCA	cis	rs7085104	0.632	rs4290163	ENSG00000236937.2	PTGES3P4	6.05	3.03e-09	6.03e-07	0.34	0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102845595~102845950:+
THCA	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-6.05	3.03e-09	6.03e-07	-0.3	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
THCA	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-6.05	3.03e-09	6.03e-07	-0.3	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
THCA	cis	rs12664251	0.66	rs794249	ENSG00000253194.1	RP11-351A11.1	-6.05	3.04e-09	6.03e-07	-0.37	-0.27	Schizophrenia;	chr6:119027102	chr6:118934785~119031541:+
THCA	cis	rs227275	0.556	rs9999303	ENSG00000251288.2	RP11-10L12.2	-6.05	3.04e-09	6.04e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102751401~102752641:+
THCA	cis	rs516805	0.528	rs2606626	ENSG00000279453.1	RP3-425C14.4	-6.05	3.04e-09	6.05e-07	-0.3	-0.27	Lymphocyte counts;	chr6:122096882	chr6:122436789~122439223:-
THCA	cis	rs9393777	0.92	rs67859638	ENSG00000226314.6	ZNF192P1	-6.05	3.05e-09	6.05e-07	-0.61	-0.27	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28161781~28169594:+
THCA	cis	rs1861628	0.927	rs6724363	ENSG00000237930.1	AC007563.4	6.04	3.05e-09	6.05e-07	0.31	0.27	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216761868	chr2:216785774~216786144:-
THCA	cis	rs12549025	0.516	rs13257250	ENSG00000253390.1	CTC-756D1.2	-6.04	3.05e-09	6.06e-07	-0.46	-0.27	Reticulocyte fraction of red cells;	chr8:23485446	chr8:23458601~23484971:+
THCA	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	6.04	3.05e-09	6.06e-07	0.39	0.27	Pain;	chr19:21567449	chr19:21554640~21569237:-
THCA	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-6.04	3.05e-09	6.06e-07	-0.16	-0.27	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
THCA	cis	rs17772222	0.876	rs58655091	ENSG00000258789.1	RP11-507K2.3	-6.04	3.05e-09	6.07e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88748567	chr14:88551597~88552493:+
THCA	cis	rs4650994	0.544	rs2811306	ENSG00000273384.1	RP5-1098D14.1	-6.04	3.05e-09	6.07e-07	-0.34	-0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178630113	chr1:178651706~178652282:+
THCA	cis	rs451417	1	rs236125	ENSG00000275632.1	RP5-967N21.11	6.04	3.06e-09	6.07e-07	0.31	0.27	Menopause (age at onset);	chr20:5996328	chr20:6000418~6000941:+
THCA	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-6.04	3.06e-09	6.08e-07	-0.16	-0.27	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-6.04	3.06e-09	6.08e-07	-0.16	-0.27	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-6.04	3.06e-09	6.08e-07	-0.16	-0.27	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
THCA	cis	rs847577	0.609	rs705308	ENSG00000272950.1	RP11-307C18.1	-6.04	3.06e-09	6.08e-07	-0.34	-0.27	Breast cancer;	chr7:98066051	chr7:98322853~98323430:+
THCA	cis	rs16958440	1	rs2289132	ENSG00000267800.1	RP11-49K24.5	-6.04	3.06e-09	6.08e-07	-0.59	-0.27	Sitting height ratio;	chr18:47075921	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs2289131	ENSG00000267800.1	RP11-49K24.5	-6.04	3.06e-09	6.08e-07	-0.59	-0.27	Sitting height ratio;	chr18:47076493	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs61316646	ENSG00000267800.1	RP11-49K24.5	-6.04	3.06e-09	6.08e-07	-0.59	-0.27	Sitting height ratio;	chr18:47084299	chr18:47137018~47137290:+
THCA	cis	rs12908161	0.683	rs12903256	ENSG00000259728.4	LINC00933	6.04	3.06e-09	6.08e-07	0.34	0.27	Schizophrenia;	chr15:84764910	chr15:84570649~84580175:+
THCA	cis	rs11722779	0.935	rs6533046	ENSG00000230069.3	LRRC37A15P	-6.04	3.06e-09	6.08e-07	-0.28	-0.27	Schizophrenia;	chr4:102965917	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223356	ENSG00000251288.2	RP11-10L12.2	-6.04	3.06e-09	6.09e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102751401~102752641:+
THCA	cis	rs9719620	0.606	rs7807337	ENSG00000236753.4	MKLN1-AS	-6.04	3.07e-09	6.09e-07	-0.26	-0.27	Male-pattern baldness;	chr7:131299059	chr7:131309744~131328222:-
THCA	cis	rs172166	0.694	rs1225716	ENSG00000226314.6	ZNF192P1	-6.04	3.07e-09	6.09e-07	-0.32	-0.27	Cardiac Troponin-T levels;	chr6:28145968	chr6:28161781~28169594:+
THCA	cis	rs2255336	0.616	rs6488285	ENSG00000245648.1	RP11-277P12.20	6.04	3.07e-09	6.09e-07	0.35	0.27	Blood protein levels;	chr12:10366107	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.608	rs7957681	ENSG00000245648.1	RP11-277P12.20	6.04	3.07e-09	6.09e-07	0.35	0.27	Blood protein levels;	chr12:10366223	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.608	rs7958658	ENSG00000245648.1	RP11-277P12.20	6.04	3.07e-09	6.09e-07	0.35	0.27	Blood protein levels;	chr12:10366229	chr12:10363769~10398506:+
THCA	cis	rs227275	0.556	rs9999303	ENSG00000230069.3	LRRC37A15P	-6.04	3.07e-09	6.1e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102727274~102730721:-
THCA	cis	rs13256369	0.774	rs13248423	ENSG00000253893.2	FAM85B	-6.04	3.07e-09	6.1e-07	-0.35	-0.27	Obesity-related traits;	chr8:8720092	chr8:8167819~8226614:-
THCA	cis	rs3822625	1	rs16886272	ENSG00000271828.1	CTD-2310F14.1	6.04	3.07e-09	6.1e-07	0.71	0.27	Breast cancer (early onset);	chr5:56771607	chr5:56927874~56929573:+
THCA	cis	rs1552244	0.882	rs17050660	ENSG00000180385.7	EMC3-AS1	-6.04	3.07e-09	6.1e-07	-0.28	-0.27	Alzheimer's disease;	chr3:9960088	chr3:9986893~10006990:+
THCA	cis	rs875971	0.964	rs160635	ENSG00000232559.3	GS1-124K5.12	6.04	3.07e-09	6.1e-07	0.26	0.27	Aortic root size;	chr7:66063931	chr7:66554588~66576923:-
THCA	cis	rs8062405	0.691	rs743590	ENSG00000278665.1	RP11-666O2.4	6.04	3.07e-09	6.11e-07	0.31	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28599241~28601881:-
THCA	cis	rs11089937	0.568	rs59356111	ENSG00000211639.2	IGLV4-60	6.04	3.07e-09	6.11e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.626	rs5757019	ENSG00000211639.2	IGLV4-60	6.04	3.07e-09	6.11e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22162199~22162681:+
THCA	cis	rs10129255	0.957	rs12590667	ENSG00000211974.3	IGHV2-70	-6.04	3.08e-09	6.11e-07	-0.2	-0.27	Kawasaki disease;	chr14:106779223	chr14:106723574~106724093:-
THCA	cis	rs11158026	0.603	rs12147796	ENSG00000258413.1	RP11-665C16.6	-6.04	3.08e-09	6.11e-07	-0.38	-0.27	Parkinson's disease;	chr14:54941978	chr14:55262767~55272075:-
THCA	cis	rs11976180	1	rs2961120	ENSG00000273234.1	OR2A13P	-6.04	3.08e-09	6.11e-07	-0.3	-0.27	Obesity-related traits;	chr7:144059492	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2951360	ENSG00000273234.1	OR2A13P	-6.04	3.08e-09	6.11e-07	-0.3	-0.27	Obesity-related traits;	chr7:144060256	chr7:144142009~144142938:+
THCA	cis	rs792448	0.717	rs1992643	ENSG00000226251.4	RP11-15I11.3	-6.04	3.08e-09	6.11e-07	-0.34	-0.27	White blood cell count (basophil);	chr1:212281682	chr1:212225278~212238977:-
THCA	cis	rs6600671	1	rs10903161	ENSG00000275538.1	RNVU1-19	6.04	3.08e-09	6.11e-07	0.34	0.27	Hip geometry;	chr1:121436882	chr1:120850819~120850985:-
THCA	cis	rs4845570	0.85	rs11204892	ENSG00000249602.1	RP11-98D18.3	6.04	3.08e-09	6.12e-07	0.34	0.27	Coronary artery disease;	chr1:151795572	chr1:151763384~151769501:-
THCA	cis	rs516805	0.561	rs2684239	ENSG00000279453.1	RP3-425C14.4	-6.04	3.08e-09	6.12e-07	-0.29	-0.27	Lymphocyte counts;	chr6:122086976	chr6:122436789~122439223:-
THCA	cis	rs516805	0.561	rs2679640	ENSG00000279453.1	RP3-425C14.4	-6.04	3.08e-09	6.12e-07	-0.29	-0.27	Lymphocyte counts;	chr6:122087013	chr6:122436789~122439223:-
THCA	cis	rs755249	1	rs17513135	ENSG00000228060.1	RP11-69E11.8	-6.04	3.08e-09	6.12e-07	-0.29	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39565160~39573203:+
THCA	cis	rs792448	0.534	rs6702346	ENSG00000226251.4	RP11-15I11.3	-6.04	3.08e-09	6.12e-07	-0.37	-0.27	White blood cell count (basophil);	chr1:212439565	chr1:212225278~212238977:-
THCA	cis	rs28530618	0.754	rs8120730	ENSG00000175730.8	BAK1P1	6.04	3.08e-09	6.12e-07	0.29	0.27	Birth weight;	chr20:32652127	chr20:32690180~32690815:-
THCA	cis	rs9311474	0.713	rs352171	ENSG00000243224.1	RP5-1157M23.2	-6.04	3.08e-09	6.12e-07	-0.28	-0.27	Electroencephalogram traits;	chr3:52200187	chr3:52239258~52241097:+
THCA	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-6.04	3.08e-09	6.12e-07	-0.2	-0.27	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	6.04	3.08e-09	6.12e-07	0.3	0.27	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
THCA	cis	rs10829156	0.679	rs4748476	ENSG00000240291.1	RP11-499P20.2	6.04	3.09e-09	6.13e-07	0.23	0.27	Sudden cardiac arrest;	chr10:18503946	chr10:18513115~18545651:-
THCA	cis	rs11089937	0.597	rs5750579	ENSG00000211639.2	IGLV4-60	6.04	3.09e-09	6.13e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs11089925	ENSG00000211639.2	IGLV4-60	6.04	3.09e-09	6.13e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22162199~22162681:+
THCA	cis	rs8067545	0.641	rs119672	ENSG00000270091.1	RP11-78O7.2	-6.04	3.09e-09	6.14e-07	-0.2	-0.27	Schizophrenia;	chr17:19915288	chr17:19896590~19897287:-
THCA	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	6.04	3.09e-09	6.14e-07	0.29	0.27	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
THCA	cis	rs801193	0.591	rs9986881	ENSG00000228409.4	CCT6P1	-6.04	3.09e-09	6.14e-07	-0.2	-0.27	Aortic root size;	chr7:66708053	chr7:65751142~65763354:+
THCA	cis	rs13113518	0.812	rs56055342	ENSG00000273257.1	RP11-177J6.1	6.04	3.09e-09	6.14e-07	0.36	0.27	Height;	chr4:55540928	chr4:55387949~55388271:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	6.04	3.09e-09	6.14e-07	0.3	0.27	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
THCA	cis	rs17772222	1	rs74071851	ENSG00000258789.1	RP11-507K2.3	-6.04	3.1e-09	6.14e-07	-0.29	-0.27	Coronary artery calcification;	chr14:88415858	chr14:88551597~88552493:+
THCA	cis	rs6600671	0.967	rs4844613	ENSG00000275538.1	RNVU1-19	6.04	3.1e-09	6.15e-07	0.34	0.27	Hip geometry;	chr1:121431913	chr1:120850819~120850985:-
THCA	cis	rs60180747	0.544	rs11637318	ENSG00000261318.1	RP11-653J6.1	6.04	3.1e-09	6.15e-07	0.36	0.27	Testicular germ cell tumor;	chr15:66266317	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.544	rs11638535	ENSG00000261318.1	RP11-653J6.1	6.04	3.1e-09	6.15e-07	0.36	0.27	Testicular germ cell tumor;	chr15:66266923	chr15:66278498~66293357:-
THCA	cis	rs7182621	0.639	rs12906050	ENSG00000182397.13	DNM1P46	6.04	3.1e-09	6.15e-07	0.37	0.27	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99790156~99806927:-
THCA	cis	rs7182621	0.639	rs35248328	ENSG00000182397.13	DNM1P46	6.04	3.1e-09	6.15e-07	0.37	0.27	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99790156~99806927:-
THCA	cis	rs2735413	0.564	rs7193020	ENSG00000276007.1	RP11-358L22.3	6.04	3.1e-09	6.15e-07	0.29	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78072543	chr16:78123243~78124332:+
THCA	cis	rs11722779	0.903	rs6830193	ENSG00000251288.2	RP11-10L12.2	-6.04	3.1e-09	6.15e-07	-0.36	-0.27	Schizophrenia;	chr4:102955457	chr4:102751401~102752641:+
THCA	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	6.04	3.1e-09	6.15e-07	0.28	0.27	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
THCA	cis	rs6671200	0.607	rs2147587	ENSG00000228852.5	RP11-57H12.5	-6.04	3.1e-09	6.15e-07	-0.32	-0.27	Stearic acid (18:0) levels;	chr1:95249328	chr1:95243167~95278940:-
THCA	cis	rs8007846	0.537	rs7157449	ENSG00000276116.2	FUT8-AS1	6.04	3.1e-09	6.15e-07	0.27	0.27	Multiple sclerosis--Brain Glutamate Levels;	chr14:65773419	chr14:65411170~65412690:-
THCA	cis	rs55823223	0.503	rs9906971	ENSG00000267801.1	RP11-552F3.9	6.04	3.1e-09	6.16e-07	0.34	0.27	Psoriasis;	chr17:75852396	chr17:75876372~75879546:+
THCA	cis	rs55823223	0.564	rs9894009	ENSG00000267801.1	RP11-552F3.9	6.04	3.1e-09	6.16e-07	0.34	0.27	Psoriasis;	chr17:75854333	chr17:75876372~75879546:+
THCA	cis	rs227275	0.554	rs223316	ENSG00000251288.2	RP11-10L12.2	-6.04	3.1e-09	6.16e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102751401~102752641:+
THCA	cis	rs227275	0.554	rs223314	ENSG00000251288.2	RP11-10L12.2	-6.04	3.1e-09	6.16e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs7254	ENSG00000251288.2	RP11-10L12.2	-6.04	3.1e-09	6.16e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.566	rs6822658	ENSG00000251288.2	RP11-10L12.2	-6.04	3.1e-09	6.16e-07	-0.36	-0.27	Schizophrenia;	chr4:102891964	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs6823625	ENSG00000251288.2	RP11-10L12.2	-6.04	3.1e-09	6.16e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs6846762	ENSG00000251288.2	RP11-10L12.2	-6.04	3.1e-09	6.16e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs4699032	ENSG00000251288.2	RP11-10L12.2	-6.04	3.1e-09	6.16e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102751401~102752641:+
THCA	cis	rs4601821	0.635	rs2303380	ENSG00000270179.1	RP11-159N11.4	-6.04	3.1e-09	6.16e-07	-0.27	-0.27	Alcoholic chronic pancreatitis;	chr11:113329987	chr11:113368478~113369117:+
THCA	cis	rs6860806	0.661	rs28472559	ENSG00000224431.1	AC063976.7	6.04	3.11e-09	6.16e-07	0.23	0.27	Breast cancer;	chr5:132245918	chr5:132199456~132203487:+
THCA	cis	rs17301013	0.507	rs7537823	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174502222	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2281011	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174509890	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2072759	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174510189	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4652511	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174515500	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4652513	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174515794	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12084948	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174525776	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs11809482	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174530269	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs909533	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174531428	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12093966	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174535120	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	6.04	3.11e-09	6.16e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
THCA	cis	rs7712401	0.791	rs6872932	ENSG00000249996.1	RP11-359P5.1	6.04	3.11e-09	6.17e-07	0.26	0.27	Mean platelet volume;	chr5:122809941	chr5:123036271~123054667:+
THCA	cis	rs934734	0.752	rs2661797	ENSG00000237979.1	AC007389.1	-6.04	3.11e-09	6.17e-07	-0.31	-0.27	Rheumatoid arthritis;	chr2:65406056	chr2:65500993~65502138:-
THCA	cis	rs3764400	0.567	rs741058	ENSG00000278765.1	RP5-890E16.5	-6.04	3.11e-09	6.17e-07	-0.47	-0.27	Body mass index;	chr17:48127991	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs2109983	ENSG00000278765.1	RP5-890E16.5	-6.04	3.11e-09	6.17e-07	-0.47	-0.27	Body mass index;	chr17:48129786	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.517	rs7209042	ENSG00000278765.1	RP5-890E16.5	-6.04	3.11e-09	6.17e-07	-0.47	-0.27	Body mass index;	chr17:48130430	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs8071879	ENSG00000278765.1	RP5-890E16.5	-6.04	3.11e-09	6.17e-07	-0.47	-0.27	Body mass index;	chr17:48140095	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs2325804	ENSG00000278765.1	RP5-890E16.5	-6.04	3.11e-09	6.17e-07	-0.47	-0.27	Body mass index;	chr17:48141183	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.505	rs208009	ENSG00000278765.1	RP5-890E16.5	-6.04	3.11e-09	6.17e-07	-0.47	-0.27	Pulse pressure;	chr17:48152329	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.505	rs208005	ENSG00000278765.1	RP5-890E16.5	-6.04	3.11e-09	6.17e-07	-0.47	-0.27	Pulse pressure;	chr17:48162623	chr17:48066704~48067293:-
THCA	cis	rs2337406	0.714	rs2337463	ENSG00000274576.2	IGHV2-70	-6.04	3.11e-09	6.17e-07	-0.24	-0.27	Alzheimer's disease (late onset);	chr14:106816066	chr14:106770577~106771020:-
THCA	cis	rs836788	0.571	rs6151766	ENSG00000249655.1	CTC-325J23.2	-6.04	3.11e-09	6.17e-07	-0.27	-0.27	Glomerular filtration rate (creatinine);	chr5:80756429	chr5:80630313~80631590:-
THCA	cis	rs240993	0.909	rs240991	ENSG00000271789.1	RP5-1112D6.7	-6.04	3.11e-09	6.18e-07	-0.29	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111297126~111298510:+
THCA	cis	rs240993	1	rs240993	ENSG00000271789.1	RP5-1112D6.7	-6.04	3.11e-09	6.18e-07	-0.29	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111297126~111298510:+
THCA	cis	rs934734	0.752	rs1876518	ENSG00000281920.1	RP11-418H16.1	-6.04	3.11e-09	6.18e-07	-0.33	-0.27	Rheumatoid arthritis;	chr2:65381775	chr2:65623272~65628424:+
THCA	cis	rs9990333	0.521	rs3862281	ENSG00000231464.1	AC024937.4	6.04	3.12e-09	6.18e-07	0.35	0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195996738~195998233:+
THCA	cis	rs6908034	0.607	rs78402429	ENSG00000227116.1	RP3-471C18.1	-6.04	3.12e-09	6.18e-07	-0.5	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19811459	chr6:19730427~19734567:-
THCA	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-6.04	3.12e-09	6.18e-07	-0.33	-0.27	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
THCA	cis	rs890448	0.76	rs293215	ENSG00000254531.1	FLJ20021	6.04	3.12e-09	6.18e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101392717	chr4:101347780~101348883:+
THCA	cis	rs2243480	1	rs7804223	ENSG00000232546.1	RP11-458F8.1	6.04	3.12e-09	6.19e-07	0.36	0.27	Diabetic kidney disease;	chr7:66199572	chr7:66848496~66858136:+
THCA	cis	rs4683346	0.549	rs6442067	ENSG00000173811.9	CCDC13-AS1	6.04	3.12e-09	6.19e-07	0.27	0.27	Granulocyte percentage of myeloid white cells;	chr3:42783623	chr3:42732575~42746768:+
THCA	cis	rs1275468	0.68	rs1697753	ENSG00000257497.2	RP11-585P4.5	-6.04	3.12e-09	6.2e-07	-0.41	-0.27	Polycystic ovary syndrome;	chr12:75562074	chr12:75483454~75489820:-
THCA	cis	rs656319	0.607	rs12156030	ENSG00000261451.1	RP11-981G7.1	-6.04	3.13e-09	6.2e-07	-0.36	-0.27	Myopia (pathological);	chr8:10240012	chr8:10433672~10438312:+
THCA	cis	rs9677476	0.648	rs7565313	ENSG00000224376.1	AC017104.6	6.04	3.13e-09	6.2e-07	0.32	0.27	Food antigen IgG levels;	chr2:231189800	chr2:231388976~231394991:+
THCA	cis	rs9677476	0.689	rs55748426	ENSG00000224376.1	AC017104.6	6.04	3.13e-09	6.2e-07	0.32	0.27	Food antigen IgG levels;	chr2:231190183	chr2:231388976~231394991:+
THCA	cis	rs9677476	0.689	rs6761645	ENSG00000224376.1	AC017104.6	6.04	3.13e-09	6.2e-07	0.32	0.27	Food antigen IgG levels;	chr2:231190439	chr2:231388976~231394991:+
THCA	cis	rs9677476	0.818	rs6749936	ENSG00000224376.1	AC017104.6	6.04	3.13e-09	6.2e-07	0.32	0.27	Food antigen IgG levels;	chr2:231190970	chr2:231388976~231394991:+
THCA	cis	rs11976180	1	rs2961118	ENSG00000273234.1	OR2A13P	-6.04	3.13e-09	6.2e-07	-0.3	-0.27	Obesity-related traits;	chr7:144058350	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2961119	ENSG00000273234.1	OR2A13P	-6.04	3.13e-09	6.2e-07	-0.3	-0.27	Obesity-related traits;	chr7:144058759	chr7:144142009~144142938:+
THCA	cis	rs10129255	0.957	rs2007467	ENSG00000211974.3	IGHV2-70	-6.04	3.13e-09	6.2e-07	-0.21	-0.27	Kawasaki disease;	chr14:106771605	chr14:106723574~106724093:-
THCA	cis	rs11722779	0.903	rs6830193	ENSG00000230069.3	LRRC37A15P	-6.04	3.13e-09	6.21e-07	-0.28	-0.27	Schizophrenia;	chr4:102955457	chr4:102727274~102730721:-
THCA	cis	rs8025790	0.508	rs4776370	ENSG00000270964.1	RP11-502I4.3	-6.04	3.13e-09	6.21e-07	-0.23	-0.27	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67612173	chr15:67541072~67542604:-
THCA	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	6.04	3.13e-09	6.21e-07	0.32	0.27	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
THCA	cis	rs6669008	1	rs55912359	ENSG00000232450.1	RP4-730K3.3	-6.04	3.13e-09	6.21e-07	-0.3	-0.27	Bacteremia;	chr1:113624477	chr1:113698884~113699631:-
THCA	cis	rs916888	0.531	rs183211	ENSG00000232300.1	FAM215B	6.04	3.13e-09	6.21e-07	0.37	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46558830~46562795:-
THCA	cis	rs12681366	0.708	rs2470728	ENSG00000253704.1	RP11-267M23.4	-6.04	3.13e-09	6.21e-07	-0.26	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94354142	chr8:94553722~94569745:+
THCA	cis	rs4143844	0.867	rs17303894	ENSG00000259251.2	RP11-643M14.1	6.04	3.13e-09	6.21e-07	0.52	0.27	Bipolar disorder and schizophrenia;	chr15:61873378	chr15:62060503~62062434:+
THCA	cis	rs228614	0.51	rs223311	ENSG00000251288.2	RP11-10L12.2	-6.04	3.14e-09	6.22e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102751401~102752641:+
THCA	cis	rs12893668	0.703	rs55751606	ENSG00000269940.1	RP11-73M18.7	6.04	3.14e-09	6.22e-07	0.29	0.27	Reticulocyte count;	chr14:103562469	chr14:103694560~103695170:+
THCA	cis	rs7809950	1	rs3801954	ENSG00000238832.1	snoU109	-6.04	3.14e-09	6.22e-07	-0.29	-0.27	Coronary artery disease;	chr7:107476603	chr7:107603363~107603507:+
THCA	cis	rs9921338	0.961	rs7199821	ENSG00000262636.1	CTD-3088G3.4	-6.04	3.14e-09	6.22e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11331154	chr16:11380859~11381118:-
THCA	cis	rs227932	0.558	rs55941756	ENSG00000234286.1	AC006026.13	6.04	3.14e-09	6.22e-07	0.52	0.27	Schizophrenia;	chr7:23654887	chr7:23680195~23680786:-
THCA	cis	rs6745190	0.953	rs12989967	ENSG00000236153.1	AC104076.3	-6.04	3.14e-09	6.22e-07	-0.36	-0.27	White blood cell count;	chr2:181040627	chr2:180979427~180980090:-
THCA	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	6.04	3.14e-09	6.22e-07	0.29	0.27	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
THCA	cis	rs11089937	0.626	rs5757017	ENSG00000211639.2	IGLV4-60	6.04	3.14e-09	6.23e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22162199~22162681:+
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000237310.1	GS1-124K5.4	6.04	3.14e-09	6.23e-07	0.2	0.27	Calcium levels;	chr7:65800652	chr7:66493706~66495474:+
THCA	cis	rs3213958	0.574	rs2278599	ENSG00000249274.1	PDLIM1P4	-6.04	3.14e-09	6.23e-07	-0.33	-0.27	Blood protein levels;	chr3:98793344	chr3:98782188~98783193:+
THCA	cis	rs853679	0.546	rs200949	ENSG00000219392.1	RP1-265C24.5	-6.04	3.15e-09	6.23e-07	-0.43	-0.27	Depression;	chr6:27867657	chr6:28115628~28116551:+
THCA	cis	rs9309473	0.5	rs11688718	ENSG00000163016.8	ALMS1P	6.04	3.15e-09	6.24e-07	0.35	0.27	Metabolite levels;	chr2:73533812	chr2:73644919~73685576:+
THCA	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	6.04	3.15e-09	6.24e-07	0.25	0.27	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
THCA	cis	rs17301013	0.507	rs4652494	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174495861	chr1:174115300~174160004:-
THCA	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	6.04	3.15e-09	6.24e-07	0.29	0.27	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	6.04	3.15e-09	6.24e-07	0.29	0.27	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
THCA	cis	rs17772222	0.917	rs8021690	ENSG00000222990.1	RNU4-22P	6.04	3.15e-09	6.24e-07	0.34	0.27	Coronary artery calcification;	chr14:88717806	chr14:88513498~88513663:+
THCA	cis	rs17301013	0.507	rs6684688	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174357180	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs28628056	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174369545	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912772	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174370832	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12073751	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174373177	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4652422	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174419501	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4233181	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174419697	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10489258	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174420447	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10798313	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.24e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174420995	chr1:174115300~174160004:-
THCA	cis	rs3213958	0.574	rs8179927	ENSG00000249274.1	PDLIM1P4	-6.04	3.15e-09	6.24e-07	-0.33	-0.27	Blood protein levels;	chr3:98830307	chr3:98782188~98783193:+
THCA	cis	rs35160687	0.712	rs12052607	ENSG00000273080.1	RP11-301O19.1	-6.04	3.15e-09	6.25e-07	-0.29	-0.27	Night sleep phenotypes;	chr2:86279394	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs1863059	ENSG00000273080.1	RP11-301O19.1	-6.04	3.15e-09	6.25e-07	-0.29	-0.27	Night sleep phenotypes;	chr2:86282265	chr2:86195590~86196049:+
THCA	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	6.04	3.15e-09	6.25e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
THCA	cis	rs11722779	0.935	rs6533046	ENSG00000251288.2	RP11-10L12.2	-6.04	3.16e-09	6.25e-07	-0.36	-0.27	Schizophrenia;	chr4:102965917	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223358	ENSG00000251288.2	RP11-10L12.2	-6.04	3.16e-09	6.25e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102751401~102752641:+
THCA	cis	rs2243480	1	rs160646	ENSG00000229886.1	RP5-1132H15.3	6.04	3.16e-09	6.26e-07	0.42	0.27	Diabetic kidney disease;	chr7:66091293	chr7:66025126~66031544:-
THCA	cis	rs11722779	0.844	rs10003326	ENSG00000230069.3	LRRC37A15P	-6.04	3.16e-09	6.26e-07	-0.28	-0.27	Schizophrenia;	chr4:102948193	chr4:102727274~102730721:-
THCA	cis	rs7809950	0.815	rs62482495	ENSG00000238832.1	snoU109	-6.04	3.16e-09	6.26e-07	-0.32	-0.27	Coronary artery disease;	chr7:107324564	chr7:107603363~107603507:+
THCA	cis	rs8177876	0.658	rs2278022	ENSG00000261061.1	RP11-303E16.2	-6.04	3.16e-09	6.26e-07	-0.4	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81030770~81031485:+
THCA	cis	rs10129255	0.879	rs7160512	ENSG00000223648.3	IGHV3-64	6.04	3.16e-09	6.27e-07	0.16	0.27	Kawasaki disease;	chr14:106694574	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.879	rs7159157	ENSG00000223648.3	IGHV3-64	6.04	3.16e-09	6.27e-07	0.16	0.27	Kawasaki disease;	chr14:106694578	chr14:106643132~106658258:-
THCA	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	6.04	3.16e-09	6.27e-07	0.36	0.27	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
THCA	cis	rs9326248	0.53	rs7112513	ENSG00000280143.1	AP000892.6	6.04	3.16e-09	6.27e-07	0.44	0.27	Blood protein levels;	chr11:117166645	chr11:117204967~117210292:+
THCA	cis	rs11603023	0.874	rs483598	ENSG00000278376.1	RP11-158I9.8	-6.04	3.17e-09	6.27e-07	-0.2	-0.27	Cholesterol, total;	chr11:118638950	chr11:118791254~118793137:+
THCA	cis	rs367615	0.68	rs2256556	ENSG00000249476.1	CTD-2587M2.1	-6.04	3.17e-09	6.28e-07	-0.29	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109629206	chr5:109237120~109326369:-
THCA	cis	rs12612619	0.704	rs6714547	ENSG00000229122.1	AGBL5-IT1	6.04	3.17e-09	6.28e-07	0.19	0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27098338	chr2:27061038~27061815:+
THCA	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-6.04	3.17e-09	6.28e-07	-0.27	-0.27	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-6.04	3.17e-09	6.28e-07	-0.27	-0.27	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
THCA	cis	rs9649465	0.967	rs2402666	ENSG00000272686.1	RP11-390E23.6	6.04	3.17e-09	6.28e-07	0.18	0.27	Migraine;	chr7:123645424	chr7:123749068~123751166:+
THCA	cis	rs4950322	0.57	rs4950409	ENSG00000278811.3	LINC00624	6.04	3.18e-09	6.29e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147335879	chr1:147258885~147517875:-
THCA	cis	rs11096990	0.892	rs11931354	ENSG00000249207.1	RP11-360F5.1	6.04	3.18e-09	6.29e-07	0.34	0.27	Cognitive function;	chr4:39229856	chr4:39112677~39126818:-
THCA	cis	rs6860806	0.507	rs273917	ENSG00000263597.1	MIR3936	6.04	3.18e-09	6.3e-07	0.27	0.27	Breast cancer;	chr5:132323925	chr5:132365490~132365599:-
THCA	cis	rs270601	0.955	rs273911	ENSG00000263597.1	MIR3936	6.04	3.18e-09	6.3e-07	0.27	0.27	Acylcarnitine levels;	chr5:132325833	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.507	rs272891	ENSG00000263597.1	MIR3936	6.04	3.18e-09	6.3e-07	0.27	0.27	Breast cancer;	chr5:132328701	chr5:132365490~132365599:-
THCA	cis	rs3750082	0.621	rs7778110	ENSG00000231952.3	DPY19L1P2	6.04	3.18e-09	6.3e-07	0.35	0.27	Glomerular filtration rate (creatinine);	chr7:32909389	chr7:32812757~32838570:+
THCA	cis	rs890448	0.76	rs293209	ENSG00000254531.1	FLJ20021	6.04	3.18e-09	6.3e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395285	chr4:101347780~101348883:+
THCA	cis	rs35934224	0.831	rs13057374	ENSG00000232926.1	AC000078.5	6.04	3.19e-09	6.31e-07	0.29	0.27	Glaucoma (primary open-angle);	chr22:19883574	chr22:19887289~19887970:+
THCA	cis	rs3213958	0.509	rs56322058	ENSG00000249274.1	PDLIM1P4	-6.04	3.19e-09	6.31e-07	-0.36	-0.27	Blood protein levels;	chr3:98900445	chr3:98782188~98783193:+
THCA	cis	rs1912483	0.545	rs35161461	ENSG00000228782.6	CTD-2026D20.3	6.04	3.19e-09	6.31e-07	0.27	0.27	Coronary artery disease;	chr17:47324391	chr17:47450568~47492492:-
THCA	cis	rs11722779	0.844	rs10003326	ENSG00000251288.2	RP11-10L12.2	-6.04	3.19e-09	6.31e-07	-0.36	-0.27	Schizophrenia;	chr4:102948193	chr4:102751401~102752641:+
THCA	cis	rs17772222	0.876	rs61983303	ENSG00000258789.1	RP11-507K2.3	-6.04	3.19e-09	6.32e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88764459	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs2224333	ENSG00000258789.1	RP11-507K2.3	-6.04	3.19e-09	6.32e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88768748	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.917	rs12590826	ENSG00000258789.1	RP11-507K2.3	-6.04	3.19e-09	6.32e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88769357	chr14:88551597~88552493:+
THCA	cis	rs2033711	0.622	rs975947	ENSG00000269473.1	CTD-2619J13.19	6.04	3.19e-09	6.32e-07	0.25	0.27	Uric acid clearance;	chr19:58386826	chr19:58440448~58445849:+
THCA	cis	rs2337406	0.714	rs7150993	ENSG00000274576.2	IGHV2-70	-6.04	3.19e-09	6.32e-07	-0.24	-0.27	Alzheimer's disease (late onset);	chr14:106818515	chr14:106770577~106771020:-
THCA	cis	rs17772222	0.674	rs112788894	ENSG00000258789.1	RP11-507K2.3	-6.04	3.19e-09	6.32e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88442850	chr14:88551597~88552493:+
THCA	cis	rs3204270	0.543	rs34034499	ENSG00000262049.1	RP13-1032I1.7	6.04	3.19e-09	6.32e-07	0.22	0.27	Dental caries;	chr17:81671538	chr17:81701324~81703300:-
THCA	cis	rs66823261	0.741	rs7841786	ENSG00000272240.1	RP5-855D21.1	6.04	3.19e-09	6.32e-07	0.3	0.27	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:234347~234887:-
THCA	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	6.04	3.2e-09	6.33e-07	0.27	0.27	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
THCA	cis	rs4664293	0.625	rs10460300	ENSG00000226266.5	AC009961.3	6.04	3.2e-09	6.33e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159778210	chr2:159670708~159712435:-
THCA	cis	rs17301013	0.507	rs10912786	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174427609	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12074416	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174430109	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12069134	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174434287	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs6677262	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174434539	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs60409344	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174438724	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs72713584	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174439129	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12077381	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174439566	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs74126805	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174440226	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12078960	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174440891	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12079011	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174441055	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12080407	ENSG00000227373.4	RP11-160H22.5	6.04	3.2e-09	6.33e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174441964	chr1:174115300~174160004:-
THCA	cis	rs5742933	0.725	rs1132360	ENSG00000253559.1	OSGEPL1-AS1	6.04	3.2e-09	6.33e-07	0.31	0.27	Ferritin levels;	chr2:189661498	chr2:189762704~189765556:+
THCA	cis	rs5742933	0.857	rs12471217	ENSG00000253559.1	OSGEPL1-AS1	6.04	3.2e-09	6.33e-07	0.31	0.27	Ferritin levels;	chr2:189707337	chr2:189762704~189765556:+
THCA	cis	rs11976180	1	rs1320893	ENSG00000273234.1	OR2A13P	-6.04	3.2e-09	6.34e-07	-0.3	-0.27	Obesity-related traits;	chr7:144055019	chr7:144142009~144142938:+
THCA	cis	rs728616	0.867	rs34870056	ENSG00000242600.5	MBL1P	6.04	3.21e-09	6.34e-07	0.38	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79904898~79950336:+
THCA	cis	rs10895275	0.606	rs2846837	ENSG00000277459.1	RP11-732A21.3	6.04	3.21e-09	6.34e-07	0.2	0.27	Migraine;	chr11:102234874	chr11:102109827~102110457:-
THCA	cis	rs7615952	0.741	rs13314845	ENSG00000241288.6	RP11-379B18.5	-6.04	3.21e-09	6.35e-07	-0.34	-0.27	Blood pressure (smoking interaction);	chr3:125925939	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.733	rs13314847	ENSG00000241288.6	RP11-379B18.5	-6.04	3.21e-09	6.35e-07	-0.34	-0.27	Blood pressure (smoking interaction);	chr3:125925945	chr3:125827238~125916384:-
THCA	cis	rs1993293	0.569	rs62042315	ENSG00000259363.4	CTD-2054N24.2	6.04	3.21e-09	6.35e-07	0.36	0.27	Coronary artery calcification;	chr15:99751724	chr15:99807023~99877148:+
THCA	cis	rs7617773	0.502	rs6804828	ENSG00000228638.1	FCF1P2	-6.04	3.21e-09	6.35e-07	-0.26	-0.27	Coronary artery disease;	chr3:48352066	chr3:48290793~48291375:-
THCA	cis	rs2243480	1	rs34193460	ENSG00000229886.1	RP5-1132H15.3	6.04	3.21e-09	6.35e-07	0.44	0.27	Diabetic kidney disease;	chr7:65928123	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs57057549	ENSG00000229886.1	RP5-1132H15.3	6.04	3.21e-09	6.35e-07	0.44	0.27	Diabetic kidney disease;	chr7:65940751	chr7:66025126~66031544:-
THCA	cis	rs792448	0.743	rs351393	ENSG00000226251.4	RP11-15I11.3	6.04	3.22e-09	6.37e-07	0.33	0.27	White blood cell count (basophil);	chr1:212303177	chr1:212225278~212238977:-
THCA	cis	rs613391	0.522	rs555828	ENSG00000224549.1	RP11-370B11.3	6.04	3.22e-09	6.37e-07	0.31	0.27	Quantitative traits;	chr9:22733239	chr9:22767175~22768316:+
THCA	cis	rs17301013	0.507	rs6665535	ENSG00000227373.4	RP11-160H22.5	6.04	3.22e-09	6.37e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174522480	chr1:174115300~174160004:-
THCA	cis	rs17594362	0.697	rs4325448	ENSG00000264190.1	MIR5006	6.04	3.22e-09	6.37e-07	0.38	0.27	Multiple sclerosis;	chr13:41580661	chr13:41568286~41568395:-
THCA	cis	rs17772222	0.636	rs77528165	ENSG00000258983.2	RP11-507K2.2	6.04	3.22e-09	6.37e-07	0.35	0.27	Coronary artery calcification;	chr14:88794249	chr14:88499334~88515502:+
THCA	cis	rs3213958	0.574	rs56075614	ENSG00000249274.1	PDLIM1P4	-6.04	3.22e-09	6.37e-07	-0.34	-0.27	Blood protein levels;	chr3:98819973	chr3:98782188~98783193:+
THCA	cis	rs9494145	0.68	rs4895441	ENSG00000232876.1	CTA-212D2.2	6.04	3.22e-09	6.37e-07	0.38	0.27	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135055033~135060550:+
THCA	cis	rs3213958	0.574	rs1440154	ENSG00000249274.1	PDLIM1P4	-6.04	3.22e-09	6.38e-07	-0.33	-0.27	Blood protein levels;	chr3:98826022	chr3:98782188~98783193:+
THCA	cis	rs11148252	0.967	rs11620062	ENSG00000235660.1	LINC00345	-6.04	3.22e-09	6.38e-07	-0.33	-0.27	Lewy body disease;	chr13:52419891	chr13:52484161~52484680:-
THCA	cis	rs935334	1	rs2543383	ENSG00000258454.1	RP11-361H10.3	6.04	3.22e-09	6.38e-07	0.38	0.27	Blood pressure;	chr14:76160360	chr14:76235817~76263474:+
THCA	cis	rs79349575	0.715	rs11657238	ENSG00000248278.1	SUMO2P17	6.04	3.23e-09	6.38e-07	0.31	0.27	Type 2 diabetes;	chr17:48908272	chr17:48874860~48908983:-
THCA	cis	rs12893668	0.638	rs11851616	ENSG00000269910.1	RP11-73M18.10	6.04	3.23e-09	6.38e-07	0.25	0.27	Reticulocyte count;	chr14:103599263	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.667	rs11844466	ENSG00000269910.1	RP11-73M18.10	6.04	3.23e-09	6.38e-07	0.25	0.27	Reticulocyte count;	chr14:103600085	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.637	rs12892038	ENSG00000269910.1	RP11-73M18.10	6.04	3.23e-09	6.38e-07	0.25	0.27	Reticulocyte count;	chr14:103602292	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.637	rs4525427	ENSG00000269910.1	RP11-73M18.10	6.04	3.23e-09	6.38e-07	0.25	0.27	Reticulocyte count;	chr14:103606456	chr14:103694516~103695050:-
THCA	cis	rs9813712	0.818	rs16845853	ENSG00000249846.5	RP11-77P16.4	6.03	3.23e-09	6.39e-07	0.32	0.27	Response to amphetamines;	chr3:130229587	chr3:130112550~130120579:+
THCA	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	6.03	3.23e-09	6.39e-07	0.51	0.27	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
THCA	cis	rs934734	0.752	rs268139	ENSG00000281920.1	RP11-418H16.1	-6.03	3.24e-09	6.4e-07	-0.33	-0.27	Rheumatoid arthritis;	chr2:65379857	chr2:65623272~65628424:+
THCA	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	6.03	3.24e-09	6.41e-07	0.34	0.27	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
THCA	cis	rs12550612	0.83	rs9918919	ENSG00000253616.4	RP11-875O11.3	6.03	3.25e-09	6.42e-07	0.37	0.27	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109777	chr8:23071377~23074488:-
THCA	cis	rs6802315	0.575	rs57932243	ENSG00000272247.1	RP11-379F4.9	-6.03	3.25e-09	6.43e-07	-0.25	-0.27	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158801257~158801935:-
THCA	cis	rs6802315	0.604	rs2364927	ENSG00000272247.1	RP11-379F4.9	-6.03	3.25e-09	6.43e-07	-0.25	-0.27	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158801257~158801935:-
THCA	cis	rs227275	0.525	rs3974604	ENSG00000251288.2	RP11-10L12.2	-6.03	3.25e-09	6.43e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102751401~102752641:+
THCA	cis	rs9813712	0.571	rs9855426	ENSG00000253540.4	FAM86HP	6.03	3.25e-09	6.43e-07	0.29	0.27	Response to amphetamines;	chr3:130214475	chr3:130099092~130111472:-
THCA	cis	rs4664293	0.647	rs10198053	ENSG00000226266.5	AC009961.3	-6.03	3.26e-09	6.44e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159605169	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.669	rs10174515	ENSG00000226266.5	AC009961.3	-6.03	3.26e-09	6.44e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159605524	chr2:159670708~159712435:-
THCA	cis	rs2288884	0.806	rs17779439	ENSG00000275055.1	CTC-471J1.11	-6.03	3.26e-09	6.44e-07	-0.26	-0.27	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080738	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.806	rs60193983	ENSG00000275055.1	CTC-471J1.11	-6.03	3.26e-09	6.44e-07	-0.26	-0.27	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082659	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.806	rs59667666	ENSG00000275055.1	CTC-471J1.11	-6.03	3.26e-09	6.44e-07	-0.26	-0.27	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082941	chr19:52049007~52049754:+
THCA	cis	rs72843506	0.656	rs73981807	ENSG00000270091.1	RP11-78O7.2	-6.03	3.26e-09	6.44e-07	-0.29	-0.27	Schizophrenia;	chr17:20092917	chr17:19896590~19897287:-
THCA	cis	rs73607972	0.877	rs8055188	ENSG00000275191.1	RP11-36I17.2	6.03	3.26e-09	6.44e-07	0.43	0.27	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53655975	chr16:53628256~53628816:-
THCA	cis	rs2439831	0.867	rs3213991	ENSG00000249839.1	AC011330.5	-6.03	3.26e-09	6.44e-07	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43378082	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs7163245	ENSG00000249839.1	AC011330.5	-6.03	3.26e-09	6.44e-07	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43379096	chr15:43663654~43684339:-
THCA	cis	rs17594362	0.697	rs9283075	ENSG00000264190.1	MIR5006	6.03	3.26e-09	6.45e-07	0.37	0.27	Multiple sclerosis;	chr13:41579400	chr13:41568286~41568395:-
THCA	cis	rs2562456	0.754	rs55771551	ENSG00000268081.1	RP11-678G14.2	6.03	3.26e-09	6.45e-07	0.39	0.27	Pain;	chr19:21563578	chr19:21554640~21569237:-
THCA	cis	rs10971721	0.822	rs10971793	ENSG00000281128.1	PTENP1-AS	6.03	3.27e-09	6.46e-07	0.61	0.27	Body mass index;	chr9:33922628	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971794	ENSG00000281128.1	PTENP1-AS	6.03	3.27e-09	6.46e-07	0.61	0.27	Body mass index;	chr9:33924314	chr9:33677268~33688011:+
THCA	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	6.03	3.27e-09	6.46e-07	0.29	0.27	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-6.03	3.27e-09	6.46e-07	-0.29	-0.27	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
THCA	cis	rs9880211	0.948	rs1604793	ENSG00000273486.1	RP11-731C17.2	6.03	3.27e-09	6.47e-07	0.28	0.27	Height;Body mass index;	chr3:136462228	chr3:136837338~136839021:-
THCA	cis	rs4664293	0.609	rs12470879	ENSG00000226266.5	AC009961.3	-6.03	3.27e-09	6.47e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159612116	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs357022	ENSG00000226266.5	AC009961.3	-6.03	3.27e-09	6.47e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159632933	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs35241460	ENSG00000226266.5	AC009961.3	6.03	3.27e-09	6.47e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159651689	chr2:159670708~159712435:-
THCA	cis	rs7809950	0.678	rs7788271	ENSG00000238832.1	snoU109	-6.03	3.27e-09	6.47e-07	-0.32	-0.27	Coronary artery disease;	chr7:107345428	chr7:107603363~107603507:+
THCA	cis	rs8062405	0.789	rs1968752	ENSG00000278665.1	RP11-666O2.4	6.03	3.27e-09	6.47e-07	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28599241~28601881:-
THCA	cis	rs9921338	0.961	rs56136462	ENSG00000262636.1	CTD-3088G3.4	-6.03	3.28e-09	6.47e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321738	chr16:11380859~11381118:-
THCA	cis	rs6547741	0.935	rs4260197	ENSG00000234072.1	AC074117.10	-6.03	3.28e-09	6.47e-07	-0.2	-0.27	Oral cavity cancer;	chr2:27571283	chr2:27356246~27367622:+
THCA	cis	rs6430553	0.929	rs6758113	ENSG00000224043.6	CCNT2-AS1	-6.03	3.28e-09	6.47e-07	-0.27	-0.27	Blood metabolite levels;	chr2:134851677	chr2:134735464~134918710:-
THCA	cis	rs7324557	0.719	rs7325364	ENSG00000205861.10	C1QTNF9B-AS1	-6.03	3.28e-09	6.48e-07	-0.33	-0.27	Visceral adipose tissue adjusted for BMI;	chr13:23805008	chr13:23888889~23897263:+
THCA	cis	rs595244	1	rs56286136	ENSG00000259705.1	RP11-227D13.1	6.03	3.28e-09	6.48e-07	0.44	0.27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48463617	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs55999498	ENSG00000259705.1	RP11-227D13.1	6.03	3.28e-09	6.48e-07	0.44	0.27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48466330	chr15:48645951~48652016:+
THCA	cis	rs3742264	1	rs9534313	ENSG00000235903.6	CPB2-AS1	-6.03	3.28e-09	6.48e-07	-0.36	-0.27	Blood protein levels;	chr13:46076411	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs17844052	ENSG00000235903.6	CPB2-AS1	-6.03	3.28e-09	6.48e-07	-0.36	-0.27	Blood protein levels;	chr13:46076653	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.961	rs4942474	ENSG00000235903.6	CPB2-AS1	-6.03	3.28e-09	6.48e-07	-0.36	-0.27	Blood protein levels;	chr13:46077209	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.922	rs4942475	ENSG00000235903.6	CPB2-AS1	-6.03	3.28e-09	6.48e-07	-0.36	-0.27	Blood protein levels;	chr13:46077386	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.922	rs4942477	ENSG00000235903.6	CPB2-AS1	-6.03	3.28e-09	6.48e-07	-0.36	-0.27	Blood protein levels;	chr13:46077628	chr13:46052806~46113332:+
THCA	cis	rs797680	0.897	rs6658257	ENSG00000223745.6	RP4-717I23.3	6.03	3.28e-09	6.49e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93355127	chr1:93262186~93346025:-
THCA	cis	rs763121	0.962	rs6001193	ENSG00000235209.1	CTA-150C2.13	6.03	3.28e-09	6.49e-07	0.34	0.27	Menopause (age at onset);	chr22:38678732	chr22:38921227~38924708:+
THCA	cis	rs113835537	0.597	rs3737525	ENSG00000255517.5	CTD-3074O7.5	-6.03	3.28e-09	6.49e-07	-0.25	-0.27	Airway imaging phenotypes;	chr11:66538884	chr11:66473490~66480233:-
THCA	cis	rs9649465	0.807	rs11770249	ENSG00000272686.1	RP11-390E23.6	6.03	3.28e-09	6.49e-07	0.18	0.27	Migraine;	chr7:123646358	chr7:123749068~123751166:+
THCA	cis	rs17772222	0.917	rs11159868	ENSG00000258789.1	RP11-507K2.3	-6.03	3.29e-09	6.49e-07	-0.27	-0.27	Coronary artery calcification;	chr14:88760528	chr14:88551597~88552493:+
THCA	cis	rs8014252	0.803	rs73282126	ENSG00000259158.2	ADAM20P1	-6.03	3.29e-09	6.49e-07	-0.33	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519324	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs74062726	ENSG00000259158.2	ADAM20P1	-6.03	3.29e-09	6.49e-07	-0.33	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519462	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs73282127	ENSG00000259158.2	ADAM20P1	-6.03	3.29e-09	6.49e-07	-0.33	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519696	chr14:70468881~70483756:-
THCA	cis	rs10043228	0.702	rs62384474	ENSG00000248445.4	SEMA6A-AS1	-6.03	3.29e-09	6.5e-07	-0.29	-0.27	Asthma or chronic obstructive pulmonary disease;	chr5:116298321	chr5:116447547~116508276:+
THCA	cis	rs9311474	0.713	rs181274	ENSG00000243224.1	RP5-1157M23.2	-6.03	3.29e-09	6.5e-07	-0.27	-0.27	Electroencephalogram traits;	chr3:52199845	chr3:52239258~52241097:+
THCA	cis	rs7119038	0.818	rs7942535	ENSG00000255239.1	AP002954.6	6.03	3.29e-09	6.5e-07	0.39	0.27	Sjögren's syndrome;	chr11:118810755	chr11:118688039~118690600:-
THCA	cis	rs61677309	0.638	rs57461652	ENSG00000280032.1	RP11-832A4.7	6.03	3.29e-09	6.5e-07	0.27	0.27	Lung cancer in ever smokers;	chr11:118275482	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.638	rs58162302	ENSG00000280032.1	RP11-832A4.7	6.03	3.29e-09	6.5e-07	0.27	0.27	Lung cancer in ever smokers;	chr11:118275484	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.638	rs58507982	ENSG00000280032.1	RP11-832A4.7	6.03	3.29e-09	6.5e-07	0.27	0.27	Lung cancer in ever smokers;	chr11:118275795	chr11:118264593~118266817:+
THCA	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	6.03	3.29e-09	6.5e-07	0.29	0.27	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	6.03	3.29e-09	6.5e-07	0.29	0.27	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
THCA	cis	rs9921338	0.961	rs72773825	ENSG00000262636.1	CTD-3088G3.4	-6.03	3.3e-09	6.51e-07	-0.39	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318591	chr16:11380859~11381118:-
THCA	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	6.03	3.3e-09	6.51e-07	0.33	0.27	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
THCA	cis	rs10129255	0.872	rs8015406	ENSG00000211974.3	IGHV2-70	6.03	3.3e-09	6.52e-07	0.21	0.27	Kawasaki disease;	chr14:106670611	chr14:106723574~106724093:-
THCA	cis	rs72843506	0.586	rs75128113	ENSG00000270091.1	RP11-78O7.2	-6.03	3.3e-09	6.52e-07	-0.32	-0.27	Schizophrenia;	chr17:20000172	chr17:19896590~19897287:-
THCA	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	6.03	3.31e-09	6.53e-07	0.25	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
THCA	cis	rs6908034	0.556	rs113071446	ENSG00000237404.1	RP3-471C18.2	-6.03	3.31e-09	6.53e-07	-0.53	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810604	chr6:19689825~19753113:-
THCA	cis	rs9843304	0.565	rs9857136	ENSG00000244503.1	RP11-278L15.6	-6.03	3.31e-09	6.54e-07	-0.34	-0.27	Gallstone disease;	chr3:149492066	chr3:149494660~149495995:+
THCA	cis	rs73198271	0.813	rs17697237	ENSG00000253893.2	FAM85B	-6.03	3.31e-09	6.54e-07	-0.39	-0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8167819~8226614:-
THCA	cis	rs6902257	1	rs2496676	ENSG00000272129.1	RP11-250B2.6	6.03	3.31e-09	6.54e-07	0.72	0.27	Obesity-related traits;	chr6:80595953	chr6:80355424~80356859:+
THCA	cis	rs227275	0.556	rs4235407	ENSG00000251288.2	RP11-10L12.2	-6.03	3.31e-09	6.54e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102751401~102752641:+
THCA	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	6.03	3.31e-09	6.54e-07	0.32	0.27	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
THCA	cis	rs2765539	1	rs7525637	ENSG00000231365.4	RP11-418J17.1	-6.03	3.32e-09	6.55e-07	-0.29	-0.27	Waist-hip ratio;	chr1:119000848	chr1:119140396~119275973:+
THCA	cis	rs11158026	0.603	rs8020545	ENSG00000258413.1	RP11-665C16.6	-6.03	3.32e-09	6.55e-07	-0.38	-0.27	Parkinson's disease;	chr14:54942352	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.574	rs8019390	ENSG00000258413.1	RP11-665C16.6	-6.03	3.32e-09	6.55e-07	-0.38	-0.27	Parkinson's disease;	chr14:54942366	chr14:55262767~55272075:-
THCA	cis	rs4683346	0.581	rs339684	ENSG00000173811.9	CCDC13-AS1	-6.03	3.32e-09	6.55e-07	-0.27	-0.27	Granulocyte percentage of myeloid white cells;	chr3:42742143	chr3:42732575~42746768:+
THCA	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	6.03	3.32e-09	6.55e-07	0.28	0.27	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
THCA	cis	rs16846053	0.642	rs2389533	ENSG00000227403.1	AC009299.3	6.03	3.32e-09	6.56e-07	0.43	0.27	Blood osmolality (transformed sodium);	chr2:161783216	chr2:161244739~161249050:+
THCA	cis	rs12612619	0.704	rs6754356	ENSG00000229122.1	AGBL5-IT1	6.03	3.32e-09	6.56e-07	0.19	0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092153	chr2:27061038~27061815:+
THCA	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	6.03	3.32e-09	6.56e-07	0.28	0.27	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
THCA	cis	rs7809950	1	rs2237673	ENSG00000238832.1	snoU109	-6.03	3.32e-09	6.56e-07	-0.28	-0.27	Coronary artery disease;	chr7:107491135	chr7:107603363~107603507:+
THCA	cis	rs4650994	0.525	rs4457535	ENSG00000273384.1	RP5-1098D14.1	-6.03	3.32e-09	6.56e-07	-0.34	-0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178528051	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.544	rs11579513	ENSG00000273384.1	RP5-1098D14.1	6.03	3.32e-09	6.56e-07	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178526957	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.544	rs6675811	ENSG00000273384.1	RP5-1098D14.1	6.03	3.32e-09	6.56e-07	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178529933	chr1:178651706~178652282:+
THCA	cis	rs4805272	0.962	rs4805277	ENSG00000267799.1	MAN1A2P1	6.03	3.33e-09	6.57e-07	0.29	0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840036	chr19:28790812~28792871:-
THCA	cis	rs9878978	0.722	rs35763288	ENSG00000237990.3	CNTN4-AS1	6.03	3.33e-09	6.57e-07	0.32	0.27	Blood pressure (smoking interaction);	chr3:2471979	chr3:3039033~3069242:-
THCA	cis	rs7942368	0.715	rs12788118	ENSG00000204529.3	GUCY2EP	6.03	3.33e-09	6.57e-07	0.37	0.27	Endometriosis;	chr11:76783176	chr11:76694043~76707641:-
THCA	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	6.03	3.33e-09	6.57e-07	0.29	0.27	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
THCA	cis	rs10875746	0.903	rs17122666	ENSG00000269514.1	RP11-370I10.12	6.03	3.33e-09	6.58e-07	0.27	0.27	Longevity (90 years and older);	chr12:48108791	chr12:48198387~48202031:+
THCA	cis	rs2243480	1	rs313813	ENSG00000228409.4	CCT6P1	6.03	3.34e-09	6.59e-07	0.31	0.27	Diabetic kidney disease;	chr7:66038513	chr7:65751142~65763354:+
THCA	cis	rs3096299	0.838	rs3102384	ENSG00000274627.1	RP11-104N10.2	6.03	3.34e-09	6.59e-07	0.25	0.27	Multiple myeloma (IgH translocation);	chr16:89345253	chr16:89516797~89522217:+
THCA	cis	rs6908034	0.607	rs76413455	ENSG00000227116.1	RP3-471C18.1	-6.03	3.34e-09	6.59e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808733	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs76525593	ENSG00000227116.1	RP3-471C18.1	-6.03	3.34e-09	6.59e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808939	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.546	rs74514942	ENSG00000227116.1	RP3-471C18.1	-6.03	3.34e-09	6.59e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810289	chr6:19730427~19734567:-
THCA	cis	rs11976180	1	rs7777389	ENSG00000273234.1	OR2A13P	-6.03	3.34e-09	6.59e-07	-0.3	-0.27	Obesity-related traits;	chr7:144047709	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs67239267	ENSG00000273234.1	OR2A13P	-6.03	3.34e-09	6.59e-07	-0.3	-0.27	Obesity-related traits;	chr7:144048023	chr7:144142009~144142938:+
THCA	cis	rs17301013	0.507	rs12084291	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174395721	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2901815	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174397404	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs1883262	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174401104	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2860959	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174403704	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912779	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174404311	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12090860	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174405166	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12064126	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174405312	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10798310	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174408581	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs11799704	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174413640	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2901817	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174414479	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs6701534	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174418612	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10798312	ENSG00000227373.4	RP11-160H22.5	6.03	3.34e-09	6.59e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174419089	chr1:174115300~174160004:-
THCA	cis	rs853679	0.546	rs483143	ENSG00000219392.1	RP1-265C24.5	-6.03	3.34e-09	6.59e-07	-0.46	-0.27	Depression;	chr6:27878966	chr6:28115628~28116551:+
THCA	cis	rs6840360	0.557	rs1143036	ENSG00000270265.1	RP11-731D1.4	-6.03	3.34e-09	6.59e-07	-0.25	-0.27	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151333775~151353224:-
THCA	cis	rs1859596	1	rs4388396	ENSG00000234456.6	MAGI2-AS3	6.03	3.34e-09	6.59e-07	0.26	0.27	Reading or mathematical ability;	chr7:79486399	chr7:79452877~79471208:+
THCA	cis	rs1859596	0.966	rs2214806	ENSG00000234456.6	MAGI2-AS3	6.03	3.34e-09	6.59e-07	0.26	0.27	Reading or mathematical ability;	chr7:79487151	chr7:79452877~79471208:+
THCA	cis	rs934734	0.967	rs1866051	ENSG00000234255.7	AC012370.3	6.03	3.34e-09	6.59e-07	0.3	0.27	Rheumatoid arthritis;	chr2:65375015	chr2:65439888~65456571:-
THCA	cis	rs454422	0.812	rs236118	ENSG00000275632.1	RP5-967N21.11	6.03	3.34e-09	6.59e-07	0.26	0.27	HIV-1 viral setpoint;	chr20:5957561	chr20:6000418~6000941:+
THCA	cis	rs12101261	0.744	rs2284727	ENSG00000259167.2	NMNAT1P1	6.03	3.34e-09	6.6e-07	0.39	0.27	Graves' disease;	chr14:80988340	chr14:81032529~81033404:+
THCA	cis	rs2115536	0.64	rs934134	ENSG00000278600.1	RP11-81A1.6	-6.03	3.35e-09	6.6e-07	-0.17	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79875876	chr15:79920195~79922455:-
THCA	cis	rs28510890	0.508	rs6496962	ENSG00000260337.3	RP11-386M24.6	6.03	3.35e-09	6.61e-07	0.28	0.27	Lung cancer in ever smokers;	chr15:92614992	chr15:92592574~92596462:-
THCA	cis	rs7763441	0.545	rs9501844	ENSG00000272465.1	RP1-136B1.1	-6.03	3.35e-09	6.61e-07	-0.35	-0.27	Monobrow;	chr6:2452706	chr6:2437549~2438249:+
THCA	cis	rs9475752	1	rs35527216	ENSG00000231441.1	RP11-472M19.2	6.03	3.35e-09	6.61e-07	0.33	0.27	Menarche (age at onset);	chr6:56926480	chr6:56844002~56864078:+
THCA	cis	rs2018683	0.707	rs10279610	ENSG00000228421.2	AC005013.5	-6.03	3.35e-09	6.62e-07	-0.3	-0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936079	chr7:28957667~28959345:+
THCA	cis	rs10461617	0.592	rs6450403	ENSG00000271828.1	CTD-2310F14.1	6.03	3.35e-09	6.62e-07	0.37	0.27	Type 2 diabetes;	chr5:56766910	chr5:56927874~56929573:+
THCA	cis	rs797680	0.897	rs12133907	ENSG00000223745.6	RP4-717I23.3	6.03	3.35e-09	6.62e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93384726	chr1:93262186~93346025:-
THCA	cis	rs6908034	0.556	rs113071446	ENSG00000227116.1	RP3-471C18.1	-6.03	3.36e-09	6.62e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810604	chr6:19730427~19734567:-
THCA	cis	rs935334	1	rs8006048	ENSG00000258454.1	RP11-361H10.3	6.03	3.36e-09	6.63e-07	0.39	0.27	Blood pressure;	chr14:76217165	chr14:76235817~76263474:+
THCA	cis	rs899997	0.862	rs8043123	ENSG00000261143.1	ADAMTS7P3	-6.03	3.36e-09	6.63e-07	-0.37	-0.27	Coronary artery disease or large artery stroke;	chr15:78681051	chr15:77976042~77993057:+
THCA	cis	rs9311474	0.713	rs352170	ENSG00000243224.1	RP5-1157M23.2	-6.03	3.36e-09	6.63e-07	-0.27	-0.27	Electroencephalogram traits;	chr3:52202061	chr3:52239258~52241097:+
THCA	cis	rs34779708	0.706	rs36027395	ENSG00000271335.4	RP11-324I22.4	6.03	3.36e-09	6.64e-07	0.26	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35314552~35336401:-
THCA	cis	rs7208859	0.673	rs11656462	ENSG00000263603.1	CTD-2349P21.5	-6.03	3.37e-09	6.64e-07	-0.48	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30729469~30731202:+
THCA	cis	rs2554380	0.628	rs6602990	ENSG00000230373.7	GOLGA6L5P	-6.03	3.37e-09	6.65e-07	-0.29	-0.27	Height;	chr15:83783470	chr15:84507885~84516814:-
THCA	cis	rs713477	1	rs28604440	ENSG00000258413.1	RP11-665C16.6	6.03	3.37e-09	6.65e-07	0.35	0.27	Pediatric bone mineral content (femoral neck);	chr14:55444606	chr14:55262767~55272075:-
THCA	cis	rs11148252	0.967	rs4286007	ENSG00000235660.1	LINC00345	-6.03	3.37e-09	6.65e-07	-0.33	-0.27	Lewy body disease;	chr13:52448383	chr13:52484161~52484680:-
THCA	cis	rs7512898	0.51	rs7552536	ENSG00000260088.1	RP11-92G12.3	-6.03	3.38e-09	6.66e-07	-0.36	-0.27	Electrocardiographic conduction measures;	chr1:200867738	chr1:200669507~200694250:+
THCA	cis	rs72843506	0.586	rs74811834	ENSG00000270091.1	RP11-78O7.2	-6.03	3.38e-09	6.66e-07	-0.32	-0.27	Schizophrenia;	chr17:19982271	chr17:19896590~19897287:-
THCA	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-6.03	3.38e-09	6.66e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-6.03	3.38e-09	6.66e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
THCA	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-6.03	3.38e-09	6.66e-07	-0.34	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
THCA	cis	rs11722228	0.508	rs3756227	ENSG00000261490.1	RP11-448G15.3	6.03	3.38e-09	6.66e-07	0.19	0.27	Urate levels;Serum uric acid levels;Gout;	chr4:10086371	chr4:10068089~10073019:-
THCA	cis	rs3764400	0.567	rs208012	ENSG00000278765.1	RP5-890E16.5	-6.03	3.38e-09	6.67e-07	-0.47	-0.27	Body mass index;	chr17:48180655	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs208011	ENSG00000278765.1	RP5-890E16.5	-6.03	3.38e-09	6.67e-07	-0.47	-0.27	Body mass index;	chr17:48180983	chr17:48066704~48067293:-
THCA	cis	rs11976180	1	rs1919950	ENSG00000273234.1	OR2A13P	-6.03	3.39e-09	6.68e-07	-0.3	-0.27	Obesity-related traits;	chr7:144070805	chr7:144142009~144142938:+
THCA	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	6.03	3.39e-09	6.69e-07	0.35	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	6.03	3.39e-09	6.69e-07	0.35	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
THCA	cis	rs7927592	0.645	rs7950900	ENSG00000212093.1	AP000807.1	6.03	3.4e-09	6.69e-07	0.27	0.27	Total body bone mineral density;	chr11:68526077	chr11:68506083~68506166:-
THCA	cis	rs11722779	0.787	rs6533040	ENSG00000230069.3	LRRC37A15P	-6.03	3.4e-09	6.7e-07	-0.28	-0.27	Schizophrenia;	chr4:102951421	chr4:102727274~102730721:-
THCA	cis	rs7119038	0.818	rs6589684	ENSG00000255239.1	AP002954.6	6.03	3.4e-09	6.7e-07	0.4	0.27	Sjögren's syndrome;	chr11:118740248	chr11:118688039~118690600:-
THCA	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	6.03	3.4e-09	6.7e-07	0.33	0.27	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
THCA	cis	rs4780355	0.918	rs243323	ENSG00000262703.1	RP11-485G7.6	6.03	3.4e-09	6.71e-07	0.32	0.27	Crohn's disease and psoriasis;	chr16:11267345	chr16:11348143~11349321:-
THCA	cis	rs807029	0.577	rs701834	ENSG00000272572.1	RP11-179B2.2	-6.03	3.4e-09	6.71e-07	-0.24	-0.27	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100911103~100912739:-
THCA	cis	rs227275	0.525	rs13113923	ENSG00000230069.3	LRRC37A15P	-6.03	3.41e-09	6.71e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102727274~102730721:-
THCA	cis	rs7617773	0.925	rs6442105	ENSG00000228638.1	FCF1P2	6.03	3.41e-09	6.71e-07	0.25	0.27	Coronary artery disease;	chr3:48140836	chr3:48290793~48291375:-
THCA	cis	rs7569084	0.522	rs906577	ENSG00000234255.7	AC012370.3	6.03	3.41e-09	6.71e-07	0.32	0.27	Sum eosinophil basophil counts;	chr2:65369523	chr2:65439888~65456571:-
THCA	cis	rs227275	0.554	rs6810668	ENSG00000251288.2	RP11-10L12.2	-6.03	3.41e-09	6.72e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102751401~102752641:+
THCA	cis	rs5758659	0.679	rs134870	ENSG00000281538.1	RP4-669P10.20	6.03	3.41e-09	6.72e-07	0.24	0.27	Cognitive function;	chr22:42256311	chr22:42138060~42139726:+
THCA	cis	rs9467773	0.935	rs1884947	ENSG00000124549.13	BTN2A3P	6.03	3.41e-09	6.72e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26421391~26432383:+
THCA	cis	rs9859260	0.71	rs34906439	ENSG00000242086.7	LINC00969	-6.03	3.41e-09	6.72e-07	-0.27	-0.27	Mean corpuscular volume;	chr3:196052835	chr3:195658062~195739964:+
THCA	cis	rs4664293	0.647	rs357028	ENSG00000226266.5	AC009961.3	-6.03	3.41e-09	6.73e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159635331	chr2:159670708~159712435:-
THCA	cis	rs72843506	0.528	rs73981803	ENSG00000270091.1	RP11-78O7.2	-6.03	3.41e-09	6.73e-07	-0.29	-0.27	Schizophrenia;	chr17:20088952	chr17:19896590~19897287:-
THCA	cis	rs6142102	0.923	rs6057961	ENSG00000275784.1	RP5-1125A11.6	-6.03	3.42e-09	6.73e-07	-0.28	-0.27	Skin pigmentation;	chr20:33986005	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.923	rs4911394	ENSG00000275784.1	RP5-1125A11.6	-6.03	3.42e-09	6.73e-07	-0.28	-0.27	Skin pigmentation;	chr20:33989521	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs1007090	ENSG00000275784.1	RP5-1125A11.6	-6.03	3.42e-09	6.73e-07	-0.28	-0.27	Skin pigmentation;	chr20:33995065	chr20:33989480~33991818:-
THCA	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	6.02	3.42e-09	6.74e-07	0.34	0.27	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
THCA	cis	rs7829975	0.623	rs7010753	ENSG00000254153.1	CTA-398F10.2	-6.02	3.42e-09	6.74e-07	-0.29	-0.27	Mood instability;	chr8:8516446	chr8:8456909~8461337:-
THCA	cis	rs7809950	1	rs10274041	ENSG00000238832.1	snoU109	6.02	3.42e-09	6.74e-07	0.29	0.27	Coronary artery disease;	chr7:107621111	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.911	rs1015411	ENSG00000238832.1	snoU109	-6.02	3.42e-09	6.74e-07	-0.28	-0.27	Coronary artery disease;	chr7:107495167	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.954	rs2520245	ENSG00000238832.1	snoU109	-6.02	3.42e-09	6.74e-07	-0.28	-0.27	Coronary artery disease;	chr7:107496983	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.953	rs2520263	ENSG00000238832.1	snoU109	-6.02	3.42e-09	6.74e-07	-0.28	-0.27	Coronary artery disease;	chr7:107538674	chr7:107603363~107603507:+
THCA	cis	rs6860806	0.507	rs273912	ENSG00000263597.1	MIR3936	-6.02	3.43e-09	6.75e-07	-0.27	-0.27	Breast cancer;	chr5:132325656	chr5:132365490~132365599:-
THCA	cis	rs7246657	0.722	rs2287229	ENSG00000267422.1	CTD-2554C21.1	6.02	3.43e-09	6.75e-07	0.31	0.27	Coronary artery calcification;	chr19:37697751	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs2075284	ENSG00000267422.1	CTD-2554C21.1	6.02	3.43e-09	6.75e-07	0.31	0.27	Coronary artery calcification;	chr19:37698715	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs968073	ENSG00000267422.1	CTD-2554C21.1	6.02	3.43e-09	6.75e-07	0.31	0.27	Coronary artery calcification;	chr19:37701120	chr19:37779686~37792865:+
THCA	cis	rs77972916	0.614	rs80323638	ENSG00000234936.1	AC010883.5	6.02	3.43e-09	6.75e-07	0.42	0.27	Granulocyte percentage of myeloid white cells;	chr2:43242476	chr2:43229573~43233394:+
THCA	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	6.02	3.43e-09	6.75e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
THCA	cis	rs7809950	0.678	rs62483641	ENSG00000238832.1	snoU109	-6.02	3.43e-09	6.76e-07	-0.31	-0.27	Coronary artery disease;	chr7:107261296	chr7:107603363~107603507:+
THCA	cis	rs848490	0.962	rs848450	ENSG00000214293.7	APTR	-6.02	3.43e-09	6.76e-07	-0.21	-0.27	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77900567	chr7:77657660~77696265:-
THCA	cis	rs11148252	0.633	rs9535888	ENSG00000235660.1	LINC00345	-6.02	3.43e-09	6.77e-07	-0.34	-0.27	Lewy body disease;	chr13:52159071	chr13:52484161~52484680:-
THCA	cis	rs4650994	0.544	rs6682815	ENSG00000273384.1	RP5-1098D14.1	6.02	3.44e-09	6.77e-07	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178531974	chr1:178651706~178652282:+
THCA	cis	rs4664293	0.609	rs10167143	ENSG00000226266.5	AC009961.3	-6.02	3.44e-09	6.78e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159606885	chr2:159670708~159712435:-
THCA	cis	rs7727544	0.617	rs3843503	ENSG00000224431.1	AC063976.7	6.02	3.44e-09	6.78e-07	0.24	0.27	Blood metabolite levels;	chr5:132130936	chr5:132199456~132203487:+
THCA	cis	rs61542988	1	rs61542988	ENSG00000228649.7	AC005682.5	6.02	3.44e-09	6.78e-07	0.32	0.27	Fibrinogen levels;	chr7:22842672	chr7:22854178~22861579:+
THCA	cis	rs11089937	0.626	rs5757013	ENSG00000211638.2	IGLV8-61	-6.02	3.44e-09	6.78e-07	-0.21	-0.27	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22098700~22099212:+
THCA	cis	rs10129255	0.957	rs12590799	ENSG00000211974.3	IGHV2-70	6.02	3.44e-09	6.79e-07	0.2	0.27	Kawasaki disease;	chr14:106779713	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs10136781	ENSG00000211974.3	IGHV2-70	6.02	3.44e-09	6.79e-07	0.2	0.27	Kawasaki disease;	chr14:106780451	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs8022165	ENSG00000211974.3	IGHV2-70	6.02	3.44e-09	6.79e-07	0.2	0.27	Kawasaki disease;	chr14:106781682	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.917	rs8022493	ENSG00000211974.3	IGHV2-70	6.02	3.44e-09	6.79e-07	0.2	0.27	Kawasaki disease;	chr14:106781820	chr14:106723574~106724093:-
THCA	cis	rs2243480	1	rs12698509	ENSG00000228409.4	CCT6P1	6.02	3.45e-09	6.79e-07	0.3	0.27	Diabetic kidney disease;	chr7:65953889	chr7:65751142~65763354:+
THCA	cis	rs7809950	0.678	rs62483640	ENSG00000238832.1	snoU109	-6.02	3.45e-09	6.79e-07	-0.32	-0.27	Coronary artery disease;	chr7:107259769	chr7:107603363~107603507:+
THCA	cis	rs9649465	0.846	rs13044	ENSG00000272686.1	RP11-390E23.6	6.02	3.45e-09	6.79e-07	0.18	0.27	Migraine;	chr7:123682662	chr7:123749068~123751166:+
THCA	cis	rs5742933	0.857	rs1233291	ENSG00000273240.1	RP11-455J20.3	-6.02	3.45e-09	6.79e-07	-0.28	-0.27	Ferritin levels;	chr2:189826225	chr2:189763859~189764456:-
THCA	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	6.02	3.45e-09	6.79e-07	0.25	0.27	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
THCA	cis	rs11722779	0.844	rs3974602	ENSG00000230069.3	LRRC37A15P	-6.02	3.45e-09	6.79e-07	-0.28	-0.27	Schizophrenia;	chr4:102928840	chr4:102727274~102730721:-
THCA	cis	rs9329221	0.905	rs6601451	ENSG00000261451.1	RP11-981G7.1	-6.02	3.45e-09	6.8e-07	-0.33	-0.27	Neuroticism;	chr8:10386171	chr8:10433672~10438312:+
THCA	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55486718	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55490176	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55490228	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55491150	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55493557	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.756	rs7658446	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55495262	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55502504	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55508982	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55509442	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55510177	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	6.02	3.45e-09	6.8e-07	0.34	0.27	Height;	chr4:55514802	chr4:55363971~55395847:-
THCA	cis	rs1322639	0.531	rs11751421	ENSG00000261039.2	RP11-417E7.2	6.02	3.45e-09	6.8e-07	0.3	0.27	Pulse pressure;	chr6:169174898	chr6:169175304~169182740:-
THCA	cis	rs13113518	0.812	rs6849474	ENSG00000249700.7	SRD5A3-AS1	6.02	3.46e-09	6.8e-07	0.34	0.27	Height;	chr4:55452295	chr4:55363971~55395847:-
THCA	cis	rs4664293	0.669	rs13389096	ENSG00000226266.5	AC009961.3	-6.02	3.46e-09	6.8e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159611246	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.55	rs13388082	ENSG00000226266.5	AC009961.3	-6.02	3.46e-09	6.8e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159616439	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.582	rs1046496	ENSG00000226266.5	AC009961.3	-6.02	3.46e-09	6.8e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159616888	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.669	rs357021	ENSG00000226266.5	AC009961.3	-6.02	3.46e-09	6.8e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159632572	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs357030	ENSG00000226266.5	AC009961.3	-6.02	3.46e-09	6.8e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159636515	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.609	rs357033	ENSG00000226266.5	AC009961.3	-6.02	3.46e-09	6.8e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159637962	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs1863686	ENSG00000226266.5	AC009961.3	-6.02	3.46e-09	6.8e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159647538	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs6432543	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159638820	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs4665099	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159639027	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs6724151	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159642788	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs34573069	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159643561	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.567	rs6711125	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159645040	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs4144512	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159651008	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs13006088	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159652915	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.605	rs2042774	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159653496	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.647	rs2042775	ENSG00000226266.5	AC009961.3	6.02	3.46e-09	6.8e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159653581	chr2:159670708~159712435:-
THCA	cis	rs9649465	1	rs1006764	ENSG00000272686.1	RP11-390E23.6	6.02	3.46e-09	6.81e-07	0.18	0.27	Migraine;	chr7:123697819	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs7791183	ENSG00000272686.1	RP11-390E23.6	6.02	3.46e-09	6.81e-07	0.18	0.27	Migraine;	chr7:123703665	chr7:123749068~123751166:+
THCA	cis	rs1185460	0.967	rs11217133	ENSG00000272186.1	RP11-110I1.13	-6.02	3.46e-09	6.81e-07	-0.26	-0.27	Coronary artery disease;	chr11:119057538	chr11:119067374~119067698:-
THCA	cis	rs7809950	1	rs4727681	ENSG00000238832.1	snoU109	-6.02	3.46e-09	6.81e-07	-0.29	-0.27	Coronary artery disease;	chr7:107455699	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs7782057	ENSG00000238832.1	snoU109	-6.02	3.46e-09	6.81e-07	-0.29	-0.27	Coronary artery disease;	chr7:107458432	chr7:107603363~107603507:+
THCA	cis	rs9649465	1	rs1506635	ENSG00000272686.1	RP11-390E23.6	6.02	3.46e-09	6.81e-07	0.18	0.27	Migraine;	chr7:123677130	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs2109724	ENSG00000272686.1	RP11-390E23.6	6.02	3.46e-09	6.81e-07	0.18	0.27	Migraine;	chr7:123685337	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs2109725	ENSG00000272686.1	RP11-390E23.6	6.02	3.46e-09	6.81e-07	0.18	0.27	Migraine;	chr7:123685405	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs10215466	ENSG00000272686.1	RP11-390E23.6	6.02	3.46e-09	6.81e-07	0.18	0.27	Migraine;	chr7:123685990	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs3958047	ENSG00000272686.1	RP11-390E23.6	6.02	3.46e-09	6.81e-07	0.18	0.27	Migraine;	chr7:123687882	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs13244694	ENSG00000272686.1	RP11-390E23.6	6.02	3.46e-09	6.81e-07	0.18	0.27	Migraine;	chr7:123689825	chr7:123749068~123751166:+
THCA	cis	rs2348418	0.966	rs7316797	ENSG00000247934.4	RP11-967K21.1	6.02	3.46e-09	6.82e-07	0.24	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28529776	chr12:28163298~28190738:-
THCA	cis	rs16846053	0.681	rs62187563	ENSG00000227403.1	AC009299.3	6.02	3.46e-09	6.82e-07	0.56	0.27	Blood osmolality (transformed sodium);	chr2:161498142	chr2:161244739~161249050:+
THCA	cis	rs11722779	0.935	rs11938650	ENSG00000230069.3	LRRC37A15P	-6.02	3.47e-09	6.82e-07	-0.28	-0.27	Schizophrenia;	chr4:103021639	chr4:102727274~102730721:-
THCA	cis	rs4143844	0.867	rs11638455	ENSG00000259251.2	RP11-643M14.1	6.02	3.47e-09	6.83e-07	0.53	0.27	Bipolar disorder and schizophrenia;	chr15:61870969	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs11629559	ENSG00000259251.2	RP11-643M14.1	6.02	3.47e-09	6.83e-07	0.53	0.27	Bipolar disorder and schizophrenia;	chr15:61871348	chr15:62060503~62062434:+
THCA	cis	rs4143844	0.867	rs17303887	ENSG00000259251.2	RP11-643M14.1	6.02	3.47e-09	6.83e-07	0.53	0.27	Bipolar disorder and schizophrenia;	chr15:61873354	chr15:62060503~62062434:+
THCA	cis	rs9677476	0.863	rs57199832	ENSG00000224376.1	AC017104.6	6.02	3.47e-09	6.83e-07	0.3	0.27	Food antigen IgG levels;	chr2:231204370	chr2:231388976~231394991:+
THCA	cis	rs72843506	0.656	rs9911879	ENSG00000270091.1	RP11-78O7.2	-6.02	3.47e-09	6.83e-07	-0.29	-0.27	Schizophrenia;	chr17:20086829	chr17:19896590~19897287:-
THCA	cis	rs914615	0.552	rs11264337	ENSG00000225855.5	RUSC1-AS1	6.02	3.48e-09	6.84e-07	0.17	0.27	Urinary albumin-to-creatinine ratio;	chr1:155165974	chr1:155316863~155324176:-
THCA	cis	rs9649465	1	rs9641715	ENSG00000272686.1	RP11-390E23.6	6.02	3.48e-09	6.84e-07	0.18	0.27	Migraine;	chr7:123708569	chr7:123749068~123751166:+
THCA	cis	rs6600671	1	rs10903159	ENSG00000275538.1	RNVU1-19	6.02	3.48e-09	6.84e-07	0.33	0.27	Hip geometry;	chr1:121440138	chr1:120850819~120850985:-
THCA	cis	rs11266744	0.756	rs916091	ENSG00000223552.1	RP11-24F11.2	6.02	3.48e-09	6.85e-07	0.24	0.27	Monocyte percentage of white cells;	chr3:46382516	chr3:46364955~46407059:-
THCA	cis	rs13113518	0.595	rs13120635	ENSG00000273257.1	RP11-177J6.1	6.02	3.48e-09	6.85e-07	0.37	0.27	Height;	chr4:55361200	chr4:55387949~55388271:+
THCA	cis	rs4664293	0.647	rs7580816	ENSG00000226266.5	AC009961.3	-6.02	3.48e-09	6.85e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159619370	chr2:159670708~159712435:-
THCA	cis	rs3742264	0.848	rs9567615	ENSG00000235903.6	CPB2-AS1	-6.02	3.48e-09	6.85e-07	-0.36	-0.27	Blood protein levels;	chr13:46076945	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.848	rs9567616	ENSG00000235903.6	CPB2-AS1	-6.02	3.48e-09	6.85e-07	-0.36	-0.27	Blood protein levels;	chr13:46076956	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.848	rs9567617	ENSG00000235903.6	CPB2-AS1	-6.02	3.48e-09	6.85e-07	-0.36	-0.27	Blood protein levels;	chr13:46076973	chr13:46052806~46113332:+
THCA	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	6.02	3.48e-09	6.85e-07	0.22	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
THCA	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-6.02	3.48e-09	6.85e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
THCA	cis	rs2136613	0.533	rs1412554	ENSG00000238280.1	RP11-436D10.3	6.02	3.49e-09	6.86e-07	0.31	0.27	Selective IgA deficiency;	chr10:62850180	chr10:62793562~62805887:-
THCA	cis	rs4664293	0.647	rs1966530	ENSG00000226266.5	AC009961.3	-6.02	3.49e-09	6.86e-07	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159620897	chr2:159670708~159712435:-
THCA	cis	rs7208859	0.673	rs9895684	ENSG00000263603.1	CTD-2349P21.5	-6.02	3.49e-09	6.86e-07	-0.49	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30729469~30731202:+
THCA	cis	rs2018683	0.707	rs4722877	ENSG00000228421.2	AC005013.5	6.02	3.49e-09	6.86e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933289	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.707	rs4722878	ENSG00000228421.2	AC005013.5	6.02	3.49e-09	6.86e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933414	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.677	rs2057956	ENSG00000228421.2	AC005013.5	6.02	3.49e-09	6.86e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933843	chr7:28957667~28959345:+
THCA	cis	rs890448	0.726	rs1549515	ENSG00000254531.1	FLJ20021	6.02	3.49e-09	6.87e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417750	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs1549514	ENSG00000254531.1	FLJ20021	6.02	3.49e-09	6.87e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417870	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs10433984	ENSG00000254531.1	FLJ20021	6.02	3.49e-09	6.87e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101419152	chr4:101347780~101348883:+
THCA	cis	rs2348418	0.932	rs12305750	ENSG00000247934.4	RP11-967K21.1	-6.02	3.49e-09	6.87e-07	-0.23	-0.27	Lung function (FEV1);Lung function (FVC);	chr12:28535758	chr12:28163298~28190738:-
THCA	cis	rs4713118	0.786	rs200503	ENSG00000280107.1	AL022393.9	-6.02	3.49e-09	6.87e-07	-0.32	-0.27	Parkinson's disease;	chr6:27818104	chr6:28170845~28172521:+
THCA	cis	rs4591358	0.569	rs6718998	ENSG00000223466.1	AC064834.2	-6.02	3.49e-09	6.87e-07	-0.43	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195578245	chr2:195533035~195538681:+
THCA	cis	rs8014252	0.803	rs12587714	ENSG00000259158.2	ADAM20P1	-6.02	3.49e-09	6.87e-07	-0.33	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70537659	chr14:70468881~70483756:-
THCA	cis	rs934734	0.752	rs268132	ENSG00000281920.1	RP11-418H16.1	6.02	3.49e-09	6.87e-07	0.34	0.27	Rheumatoid arthritis;	chr2:65382543	chr2:65623272~65628424:+
THCA	cis	rs17772222	0.917	rs11159868	ENSG00000222990.1	RNU4-22P	6.02	3.5e-09	6.88e-07	0.34	0.27	Coronary artery calcification;	chr14:88760528	chr14:88513498~88513663:+
THCA	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-6.02	3.5e-09	6.88e-07	-0.25	-0.27	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
THCA	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	6.02	3.5e-09	6.89e-07	0.34	0.27	Height;	chr4:55465165	chr4:55363971~55395847:-
THCA	cis	rs2018683	0.835	rs7782264	ENSG00000228421.2	AC005013.5	-6.02	3.5e-09	6.89e-07	-0.3	-0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28939369	chr7:28957667~28959345:+
THCA	cis	rs4072705	0.967	rs10120039	ENSG00000224020.1	MIR181A2HG	-6.02	3.5e-09	6.89e-07	-0.24	-0.27	Menarche (age at onset);	chr9:124644682	chr9:124658467~124698631:+
THCA	cis	rs9649465	1	rs627689	ENSG00000272686.1	RP11-390E23.6	6.02	3.51e-09	6.9e-07	0.18	0.27	Migraine;	chr7:123760489	chr7:123749068~123751166:+
THCA	cis	rs12935418	0.83	rs7195459	ENSG00000261061.1	RP11-303E16.2	-6.02	3.51e-09	6.9e-07	-0.32	-0.27	Mean corpuscular volume;	chr16:81016376	chr16:81030770~81031485:+
THCA	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	6.02	3.51e-09	6.91e-07	0.29	0.27	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	6.02	3.51e-09	6.91e-07	0.29	0.27	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
THCA	cis	rs1823913	0.927	rs35339956	ENSG00000280083.1	RP11-317J9.1	-6.02	3.51e-09	6.91e-07	-0.33	-0.27	Obesity-related traits;	chr2:191261668	chr2:191154118~191156070:-
THCA	cis	rs8042680	1	rs4508401	ENSG00000214432.8	AC068831.10	-6.02	3.51e-09	6.91e-07	-0.29	-0.27	Type 2 diabetes;	chr15:90971491	chr15:91022619~91036611:+
THCA	cis	rs6142102	1	rs4911414	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.52e-09	6.91e-07	-0.29	-0.27	Skin pigmentation;	chr20:34141638	chr20:33989480~33991818:-
THCA	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-6.02	3.52e-09	6.92e-07	-0.33	-0.27	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
THCA	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	6.02	3.52e-09	6.92e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs3117838	ENSG00000227373.4	RP11-160H22.5	6.02	3.52e-09	6.92e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174749205	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs332801	ENSG00000227373.4	RP11-160H22.5	6.02	3.52e-09	6.92e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174753192	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs1793292	ENSG00000227373.4	RP11-160H22.5	-6.02	3.52e-09	6.92e-07	-0.41	-0.27	Systemic lupus erythematosus;	chr1:174778185	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs1793298	ENSG00000227373.4	RP11-160H22.5	-6.02	3.52e-09	6.92e-07	-0.41	-0.27	Systemic lupus erythematosus;	chr1:174784601	chr1:174115300~174160004:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-6.02	3.52e-09	6.92e-07	-0.3	-0.27	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-6.02	3.52e-09	6.92e-07	-0.3	-0.27	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
THCA	cis	rs10208649	0.908	rs10199995	ENSG00000233266.1	HMGB1P31	6.02	3.52e-09	6.92e-07	0.64	0.27	Body mass index;	chr2:53981138	chr2:54051334~54051760:+
THCA	cis	rs10129255	0.957	rs8009464	ENSG00000211974.3	IGHV2-70	6.02	3.52e-09	6.93e-07	0.2	0.27	Kawasaki disease;	chr14:106777611	chr14:106723574~106724093:-
THCA	cis	rs7688540	0.771	rs61792114	ENSG00000211553.1	AC253576.2	-6.02	3.53e-09	6.93e-07	-0.39	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:136461~136568:+
THCA	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-6.02	3.53e-09	6.94e-07	-0.37	-0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
THCA	cis	rs10875746	0.669	rs9634261	ENSG00000269514.1	RP11-370I10.12	6.02	3.53e-09	6.94e-07	0.26	0.27	Longevity (90 years and older);	chr12:48293088	chr12:48198387~48202031:+
THCA	cis	rs2018683	0.707	rs2391718	ENSG00000228421.2	AC005013.5	6.02	3.53e-09	6.94e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935371	chr7:28957667~28959345:+
THCA	cis	rs875971	0.658	rs432667	ENSG00000232559.3	GS1-124K5.12	6.02	3.53e-09	6.94e-07	0.26	0.27	Aortic root size;	chr7:66049646	chr7:66554588~66576923:-
THCA	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-6.02	3.53e-09	6.94e-07	-0.3	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
THCA	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	6.02	3.53e-09	6.94e-07	0.25	0.27	Height;	chr2:46624894	chr2:46668870~46670778:+
THCA	cis	rs6600671	1	rs1591882	ENSG00000275538.1	RNVU1-19	6.02	3.53e-09	6.95e-07	0.33	0.27	Hip geometry;	chr1:121441455	chr1:120850819~120850985:-
THCA	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-6.02	3.54e-09	6.95e-07	-0.3	-0.27	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
THCA	cis	rs10761482	0.5	rs7906760	ENSG00000254271.1	RP11-131N11.4	6.02	3.54e-09	6.95e-07	0.34	0.27	Schizophrenia;	chr10:60526895	chr10:60734342~60741828:+
THCA	cis	rs7208859	0.673	rs75142521	ENSG00000263603.1	CTD-2349P21.5	-6.02	3.54e-09	6.95e-07	-0.48	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30729469~30731202:+
THCA	cis	rs523522	0.923	rs1048830	ENSG00000278344.1	RP11-18C24.8	6.02	3.54e-09	6.95e-07	0.29	0.27	High light scatter reticulocyte count;	chr12:120444414	chr12:120500735~120501090:-
THCA	cis	rs12497850	0.931	rs62262517	ENSG00000229759.1	MRPS18AP1	6.02	3.54e-09	6.96e-07	0.36	0.27	Parkinson's disease;	chr3:49097481	chr3:48256350~48256938:-
THCA	cis	rs7811142	1	rs6953107	ENSG00000078319.8	PMS2P1	-6.02	3.54e-09	6.96e-07	-0.39	-0.27	Platelet count;	chr7:100498041	chr7:100320992~100341908:-
THCA	cis	rs2562456	0.839	rs2562411	ENSG00000268555.1	RP11-678G14.3	6.02	3.54e-09	6.96e-07	0.42	0.27	Pain;	chr19:21419181	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.876	rs2562413	ENSG00000268555.1	RP11-678G14.3	6.02	3.54e-09	6.96e-07	0.42	0.27	Pain;	chr19:21420084	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.916	rs1967182	ENSG00000268555.1	RP11-678G14.3	6.02	3.54e-09	6.96e-07	0.42	0.27	Pain;	chr19:21420337	chr19:21570822~21587322:-
THCA	cis	rs7005380	0.62	rs7387694	ENSG00000245330.4	KB-1471A8.1	6.02	3.55e-09	6.98e-07	0.26	0.27	Interstitial lung disease;	chr8:119885261	chr8:119867419~119874488:-
THCA	cis	rs17772222	1	rs1955599	ENSG00000258789.1	RP11-507K2.3	-6.02	3.55e-09	6.98e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88358788	chr14:88551597~88552493:+
THCA	cis	rs2018683	0.707	rs1021689	ENSG00000228421.2	AC005013.5	6.02	3.56e-09	6.99e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934606	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.707	rs1021690	ENSG00000228421.2	AC005013.5	6.02	3.56e-09	6.99e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934871	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.707	rs1021691	ENSG00000228421.2	AC005013.5	6.02	3.56e-09	6.99e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934879	chr7:28957667~28959345:+
THCA	cis	rs61677309	0.638	rs4938493	ENSG00000280032.1	RP11-832A4.7	6.02	3.56e-09	6.99e-07	0.27	0.27	Lung cancer in ever smokers;	chr11:118274089	chr11:118264593~118266817:+
THCA	cis	rs9990333	0.544	rs73208092	ENSG00000231464.1	AC024937.4	6.02	3.56e-09	6.99e-07	0.34	0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195996738~195998233:+
THCA	cis	rs2439831	1	rs2601014	ENSG00000249839.1	AC011330.5	-6.02	3.56e-09	6.99e-07	-0.43	-0.27	Lung cancer in ever smokers;	chr15:43463815	chr15:43663654~43684339:-
THCA	cis	rs10276381	0.786	rs28430601	ENSG00000234336.5	JAZF1-AS1	-6.02	3.56e-09	7e-07	-0.39	-0.27	Crohn's disease;	chr7:28199192	chr7:28180322~28243917:+
THCA	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-6.02	3.56e-09	7e-07	-0.23	-0.27	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
THCA	cis	rs11096990	0.964	rs11096987	ENSG00000249207.1	RP11-360F5.1	6.02	3.56e-09	7e-07	0.34	0.27	Cognitive function;	chr4:39257570	chr4:39112677~39126818:-
THCA	cis	rs6430585	0.583	rs2839740	ENSG00000231890.6	DARS-AS1	-6.02	3.56e-09	7e-07	-0.33	-0.27	Corneal structure;	chr2:135891313	chr2:135985176~136022593:+
THCA	cis	rs3213958	0.574	rs17210963	ENSG00000249274.1	PDLIM1P4	-6.02	3.56e-09	7e-07	-0.35	-0.27	Blood protein levels;	chr3:98778815	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs73136038	ENSG00000249274.1	PDLIM1P4	-6.02	3.56e-09	7e-07	-0.35	-0.27	Blood protein levels;	chr3:98782993	chr3:98782188~98783193:+
THCA	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-6.02	3.57e-09	7.01e-07	-0.33	-0.27	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
THCA	cis	rs5758659	0.714	rs133376	ENSG00000227370.1	RP4-669P10.19	-6.02	3.57e-09	7.01e-07	-0.24	-0.27	Cognitive function;	chr22:42070901	chr22:42132543~42132998:+
THCA	cis	rs935334	1	rs4304957	ENSG00000258454.1	RP11-361H10.3	6.02	3.57e-09	7.01e-07	0.37	0.27	Blood pressure;	chr14:76181229	chr14:76235817~76263474:+
THCA	cis	rs935334	0.825	rs4389088	ENSG00000258454.1	RP11-361H10.3	6.02	3.57e-09	7.01e-07	0.37	0.27	Blood pressure;	chr14:76181254	chr14:76235817~76263474:+
THCA	cis	rs6545883	0.831	rs9309336	ENSG00000271889.1	RP11-493E12.1	6.02	3.57e-09	7.01e-07	0.26	0.27	Tuberculosis;	chr2:61536030	chr2:61151433~61162105:-
THCA	cis	rs10029851	0.627	rs72893189	ENSG00000234492.4	RPL34-AS1	6.02	3.57e-09	7.01e-07	0.32	0.27	Amyotrophic lateral sclerosis (sporadic);	chr4:108635577	chr4:108538190~108620460:-
THCA	cis	rs5758659	0.714	rs5751216	ENSG00000227370.1	RP4-669P10.19	6.02	3.57e-09	7.01e-07	0.24	0.27	Cognitive function;	chr22:42112933	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.714	rs5758589	ENSG00000227370.1	RP4-669P10.19	6.02	3.57e-09	7.01e-07	0.24	0.27	Cognitive function;	chr22:42122378	chr22:42132543~42132998:+
THCA	cis	rs2239547	0.603	rs71301807	ENSG00000242142.1	SERBP1P3	6.02	3.57e-09	7.01e-07	0.34	0.27	Schizophrenia;	chr3:53051459	chr3:53064283~53065091:-
THCA	cis	rs10129255	0.957	rs17113284	ENSG00000211974.3	IGHV2-70	-6.02	3.58e-09	7.03e-07	-0.21	-0.27	Kawasaki disease;	chr14:106684476	chr14:106723574~106724093:-
THCA	cis	rs6802315	0.575	rs1864508	ENSG00000272247.1	RP11-379F4.9	-6.02	3.58e-09	7.03e-07	-0.25	-0.27	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158801257~158801935:-
THCA	cis	rs890448	0.796	rs2433306	ENSG00000254531.1	FLJ20021	6.02	3.58e-09	7.03e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425843	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2471679	ENSG00000254531.1	FLJ20021	6.02	3.58e-09	7.03e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426354	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2433308	ENSG00000254531.1	FLJ20021	6.02	3.58e-09	7.03e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426421	chr4:101347780~101348883:+
THCA	cis	rs890448	0.828	rs2471680	ENSG00000254531.1	FLJ20021	6.02	3.58e-09	7.03e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426586	chr4:101347780~101348883:+
THCA	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-6.02	3.58e-09	7.03e-07	-0.45	-0.27	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-6.02	3.58e-09	7.03e-07	-0.45	-0.27	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
THCA	cis	rs5742933	0.857	rs893784	ENSG00000253559.1	OSGEPL1-AS1	-6.02	3.58e-09	7.03e-07	-0.3	-0.27	Ferritin levels;	chr2:189671557	chr2:189762704~189765556:+
THCA	cis	rs2243480	1	rs316315	ENSG00000228409.4	CCT6P1	-6.02	3.58e-09	7.03e-07	-0.27	-0.27	Diabetic kidney disease;	chr7:66126218	chr7:65751142~65763354:+
THCA	cis	rs1859596	1	rs2158706	ENSG00000234456.6	MAGI2-AS3	6.02	3.58e-09	7.04e-07	0.26	0.27	Reading or mathematical ability;	chr7:79469955	chr7:79452877~79471208:+
THCA	cis	rs6430553	0.929	rs1348792	ENSG00000224043.6	CCNT2-AS1	-6.02	3.59e-09	7.05e-07	-0.27	-0.27	Blood metabolite levels;	chr2:134903288	chr2:134735464~134918710:-
THCA	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	6.02	3.59e-09	7.05e-07	0.34	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
THCA	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-6.02	3.59e-09	7.05e-07	-0.29	-0.27	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
THCA	cis	rs17301013	0.507	rs332800	ENSG00000227373.4	RP11-160H22.5	6.02	3.59e-09	7.05e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174753467	chr1:174115300~174160004:-
THCA	cis	rs367615	0.68	rs166181	ENSG00000249476.1	CTD-2587M2.1	6.02	3.59e-09	7.06e-07	0.3	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109648392	chr5:109237120~109326369:-
THCA	cis	rs10829156	0.786	rs7077786	ENSG00000240291.1	RP11-499P20.2	6.02	3.6e-09	7.07e-07	0.23	0.27	Sudden cardiac arrest;	chr10:18603453	chr10:18513115~18545651:-
THCA	cis	rs12478296	0.786	rs55876934	ENSG00000261186.2	RP11-341N2.1	-6.02	3.6e-09	7.07e-07	-0.42	-0.27	Obesity-related traits;	chr2:242091665	chr2:242087351~242088457:-
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000224205.1	AP000351.4	6.02	3.6e-09	7.07e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23987320~23991421:-
THCA	cis	rs1211375	0.628	rs3859141	ENSG00000268836.1	LA16c-OS12.2	6.02	3.6e-09	7.07e-07	0.23	0.27	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:195080	chr16:185748~186294:-
THCA	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	6.02	3.6e-09	7.07e-07	0.29	0.27	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
THCA	cis	rs6860806	0.661	rs6871350	ENSG00000224431.1	AC063976.7	6.02	3.6e-09	7.07e-07	0.23	0.27	Breast cancer;	chr5:132244527	chr5:132199456~132203487:+
THCA	cis	rs9649465	1	rs56396297	ENSG00000272686.1	RP11-390E23.6	6.02	3.61e-09	7.09e-07	0.18	0.27	Migraine;	chr7:123710481	chr7:123749068~123751166:+
THCA	cis	rs9649465	1	rs10238422	ENSG00000272686.1	RP11-390E23.6	6.02	3.61e-09	7.09e-07	0.18	0.27	Migraine;	chr7:123713654	chr7:123749068~123751166:+
THCA	cis	rs4886920	0.536	rs11857840	ENSG00000260776.4	RP11-114H24.2	-6.02	3.61e-09	7.09e-07	-0.34	-0.27	Neuroticism;	chr15:77864411	chr15:77914217~77926846:-
THCA	cis	rs934734	0.699	rs268138	ENSG00000237979.1	AC007389.1	-6.01	3.62e-09	7.11e-07	-0.31	-0.27	Rheumatoid arthritis;	chr2:65380160	chr2:65500993~65502138:-
THCA	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	6.01	3.62e-09	7.11e-07	0.34	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	6.01	3.62e-09	7.11e-07	0.34	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
THCA	cis	rs60180747	0.544	rs11633568	ENSG00000261318.1	RP11-653J6.1	6.01	3.62e-09	7.11e-07	0.36	0.27	Testicular germ cell tumor;	chr15:66272068	chr15:66278498~66293357:-
THCA	cis	rs9677476	0.863	rs7601741	ENSG00000224376.1	AC017104.6	6.01	3.62e-09	7.11e-07	0.31	0.27	Food antigen IgG levels;	chr2:231197637	chr2:231388976~231394991:+
THCA	cis	rs2439831	0.867	rs3809481	ENSG00000275601.1	AC011330.13	-6.01	3.63e-09	7.13e-07	-0.42	-0.27	Lung cancer in ever smokers;	chr15:43370631	chr15:43642389~43643023:-
THCA	cis	rs9649465	1	rs6950659	ENSG00000272686.1	RP11-390E23.6	6.01	3.63e-09	7.13e-07	0.18	0.27	Migraine;	chr7:123721856	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs2299986	ENSG00000272686.1	RP11-390E23.6	6.01	3.63e-09	7.13e-07	0.18	0.27	Migraine;	chr7:123729485	chr7:123749068~123751166:+
THCA	cis	rs9649465	0.967	rs768680	ENSG00000272686.1	RP11-390E23.6	6.01	3.64e-09	7.13e-07	0.18	0.27	Migraine;	chr7:123724073	chr7:123749068~123751166:+
THCA	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	6.01	3.64e-09	7.14e-07	0.29	0.27	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
THCA	cis	rs1395	0.961	rs4665965	ENSG00000234072.1	AC074117.10	6.01	3.64e-09	7.14e-07	0.23	0.27	Blood metabolite levels;	chr2:27313513	chr2:27356246~27367622:+
THCA	cis	rs5742933	0.817	rs11679767	ENSG00000253559.1	OSGEPL1-AS1	6.01	3.64e-09	7.14e-07	0.31	0.27	Ferritin levels;	chr2:189681574	chr2:189762704~189765556:+
THCA	cis	rs3794924	1	rs8091481	ENSG00000266521.1	RP11-650P15.1	6.01	3.64e-09	7.15e-07	0.5	0.27	Survival in colon cancer;	chr18:31471714	chr18:31496645~31497195:-
THCA	cis	rs4780355	0.918	rs243318	ENSG00000262703.1	RP11-485G7.6	6.01	3.64e-09	7.15e-07	0.31	0.27	Crohn's disease and psoriasis;	chr16:11264161	chr16:11348143~11349321:-
THCA	cis	rs763121	0.815	rs9306328	ENSG00000235209.1	CTA-150C2.13	6.01	3.64e-09	7.15e-07	0.33	0.27	Menopause (age at onset);	chr22:38632908	chr22:38921227~38924708:+
THCA	cis	rs11603023	1	rs11603023	ENSG00000278376.1	RP11-158I9.8	-6.01	3.64e-09	7.15e-07	-0.21	-0.27	Cholesterol, total;	chr11:118615352	chr11:118791254~118793137:+
THCA	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	6.01	3.64e-09	7.15e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
THCA	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	6.01	3.64e-09	7.15e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
THCA	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-6.01	3.64e-09	7.15e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
THCA	cis	rs2839186	0.967	rs9637172	ENSG00000239415.1	AP001469.9	6.01	3.64e-09	7.15e-07	0.28	0.27	Testicular germ cell tumor;	chr21:46265873	chr21:46251549~46254133:-
THCA	cis	rs2839186	1	rs2839186	ENSG00000239415.1	AP001469.9	6.01	3.64e-09	7.15e-07	0.28	0.27	Testicular germ cell tumor;	chr21:46270154	chr21:46251549~46254133:-
THCA	cis	rs2018683	0.677	rs55718000	ENSG00000228421.2	AC005013.5	6.01	3.64e-09	7.15e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936008	chr7:28957667~28959345:+
THCA	cis	rs736801	0.74	rs12515180	ENSG00000233006.5	AC034220.3	6.01	3.65e-09	7.15e-07	0.22	0.27	Mosquito bite size;Breast cancer;	chr5:132449992	chr5:132311285~132369916:-
THCA	cis	rs9816784	0.525	rs41301371	ENSG00000231464.1	AC024937.4	6.01	3.65e-09	7.15e-07	0.35	0.27	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195996738~195998233:+
THCA	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	6.01	3.65e-09	7.16e-07	0.29	0.27	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	6.01	3.65e-09	7.16e-07	0.29	0.27	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	6.01	3.65e-09	7.16e-07	0.29	0.27	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
THCA	cis	rs793571	0.554	rs12441313	ENSG00000259250.1	RP11-50C13.1	-6.01	3.65e-09	7.16e-07	-0.29	-0.27	Schizophrenia;	chr15:58723289	chr15:58587507~58591676:+
THCA	cis	rs7307902	0.518	rs739856	ENSG00000280054.1	RP1-197B17.7	-6.01	3.65e-09	7.16e-07	-0.3	-0.27	Obesity-related traits;	chr12:47574240	chr12:47728151~47730598:-
THCA	cis	rs8014252	0.803	rs7145530	ENSG00000259158.2	ADAM20P1	-6.01	3.65e-09	7.16e-07	-0.34	-0.27	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70569793	chr14:70468881~70483756:-
THCA	cis	rs11722228	0.539	rs62287552	ENSG00000261490.1	RP11-448G15.3	6.01	3.65e-09	7.17e-07	0.19	0.27	Urate levels;Serum uric acid levels;Gout;	chr4:10151573	chr4:10068089~10073019:-
THCA	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	6.01	3.66e-09	7.18e-07	0.2	0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
THCA	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	6.01	3.66e-09	7.18e-07	0.2	0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
THCA	cis	rs890448	0.726	rs1530259	ENSG00000254531.1	FLJ20021	-6.01	3.66e-09	7.18e-07	-0.24	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101303753	chr4:101347780~101348883:+
THCA	cis	rs12497850	0.931	rs13064784	ENSG00000229759.1	MRPS18AP1	6.01	3.66e-09	7.18e-07	0.36	0.27	Parkinson's disease;	chr3:49098528	chr3:48256350~48256938:-
THCA	cis	rs713477	1	rs10134905	ENSG00000258413.1	RP11-665C16.6	6.01	3.66e-09	7.18e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55445074	chr14:55262767~55272075:-
THCA	cis	rs713477	0.935	rs4901564	ENSG00000258413.1	RP11-665C16.6	6.01	3.66e-09	7.18e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55445691	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs4901565	ENSG00000258413.1	RP11-665C16.6	6.01	3.66e-09	7.18e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55445790	chr14:55262767~55272075:-
THCA	cis	rs847577	0.63	rs13221758	ENSG00000272950.1	RP11-307C18.1	6.01	3.66e-09	7.18e-07	0.33	0.27	Breast cancer;	chr7:98090494	chr7:98322853~98323430:+
THCA	cis	rs9813712	0.595	rs1901787	ENSG00000253540.4	FAM86HP	6.01	3.66e-09	7.19e-07	0.29	0.27	Response to amphetamines;	chr3:130288678	chr3:130099092~130111472:-
THCA	cis	rs10129255	0.957	rs11847726	ENSG00000211974.3	IGHV2-70	6.01	3.66e-09	7.19e-07	0.21	0.27	Kawasaki disease;	chr14:106779116	chr14:106723574~106724093:-
THCA	cis	rs9910055	0.762	rs2526020	ENSG00000267080.4	ASB16-AS1	-6.01	3.67e-09	7.19e-07	-0.24	-0.27	Total body bone mineral density;	chr17:44139220	chr17:44175973~44186717:-
THCA	cis	rs9380516	0.74	rs4713897	ENSG00000228559.1	RP3-340B19.3	6.01	3.67e-09	7.2e-07	0.39	0.27	Hepatitis C induced liver fibrosis;	chr6:35560793	chr6:35544632~35545669:+
THCA	cis	rs1318937	0.764	rs58768954	ENSG00000224660.1	SH3BP5-AS1	6.01	3.67e-09	7.2e-07	0.18	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15198798	chr3:15254184~15264493:+
THCA	cis	rs10844706	0.699	rs10844633	ENSG00000256594.6	RP11-705C15.2	6.01	3.68e-09	7.21e-07	0.22	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734790	chr12:9633419~9658412:+
THCA	cis	rs9921338	1	rs8049173	ENSG00000262703.1	RP11-485G7.6	-6.01	3.68e-09	7.21e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343025	chr16:11348143~11349321:-
THCA	cis	rs9921338	1	rs8055427	ENSG00000262703.1	RP11-485G7.6	-6.01	3.68e-09	7.21e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343026	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.887	rs9926136	ENSG00000262703.1	RP11-485G7.6	-6.01	3.68e-09	7.21e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343418	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs9936093	ENSG00000262703.1	RP11-485G7.6	-6.01	3.68e-09	7.21e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343459	chr16:11348143~11349321:-
THCA	cis	rs9677476	0.818	rs62197333	ENSG00000224376.1	AC017104.6	6.01	3.68e-09	7.22e-07	0.3	0.27	Food antigen IgG levels;	chr2:231220336	chr2:231388976~231394991:+
THCA	cis	rs792448	0.743	rs12033246	ENSG00000226251.4	RP11-15I11.3	-6.01	3.68e-09	7.22e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212339906	chr1:212225278~212238977:-
THCA	cis	rs9649465	1	rs608447	ENSG00000272686.1	RP11-390E23.6	-6.01	3.68e-09	7.22e-07	-0.18	-0.27	Migraine;	chr7:123755929	chr7:123749068~123751166:+
THCA	cis	rs4266144	0.569	rs729257	ENSG00000241770.1	RP11-555M1.3	-6.01	3.69e-09	7.23e-07	-0.32	-0.27	Coronary artery disease;	chr3:157111034	chr3:157163452~157169133:+
THCA	cis	rs10875746	0.669	rs11168496	ENSG00000269514.1	RP11-370I10.12	6.01	3.69e-09	7.23e-07	0.26	0.27	Longevity (90 years and older);	chr12:48257072	chr12:48198387~48202031:+
THCA	cis	rs11158026	1	rs2183081	ENSG00000258413.1	RP11-665C16.6	-6.01	3.69e-09	7.23e-07	-0.36	-0.27	Parkinson's disease;	chr14:54870033	chr14:55262767~55272075:-
THCA	cis	rs741668	0.929	rs9595404	ENSG00000235903.6	CPB2-AS1	6.01	3.69e-09	7.23e-07	0.35	0.27	Cerebrospinal fluid clusterin levels;	chr13:45940621	chr13:46052806~46113332:+
THCA	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	6.01	3.69e-09	7.24e-07	0.29	0.27	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	6.01	3.69e-09	7.24e-07	0.29	0.27	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	6.01	3.69e-09	7.24e-07	0.29	0.27	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
THCA	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-6.01	3.69e-09	7.24e-07	-0.49	-0.27	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
THCA	cis	rs2033711	0.654	rs734380	ENSG00000268912.1	CTD-2619J13.17	-6.01	3.69e-09	7.24e-07	-0.21	-0.27	Uric acid clearance;	chr19:58387596	chr19:58428632~58431148:-
THCA	cis	rs10875746	0.669	rs10875770	ENSG00000269514.1	RP11-370I10.12	6.01	3.69e-09	7.24e-07	0.26	0.27	Longevity (90 years and older);	chr12:48206737	chr12:48198387~48202031:+
THCA	cis	rs6545883	0.859	rs13004855	ENSG00000271889.1	RP11-493E12.1	-6.01	3.69e-09	7.24e-07	-0.26	-0.27	Tuberculosis;	chr2:61277937	chr2:61151433~61162105:-
THCA	cis	rs853679	0.513	rs13437444	ENSG00000220721.1	OR1F12	6.01	3.69e-09	7.24e-07	0.41	0.27	Depression;	chr6:28103220	chr6:28073316~28074233:+
THCA	cis	rs6545883	0.894	rs12620105	ENSG00000271889.1	RP11-493E12.1	-6.01	3.7e-09	7.24e-07	-0.26	-0.27	Tuberculosis;	chr2:61285186	chr2:61151433~61162105:-
THCA	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	6.01	3.7e-09	7.25e-07	0.28	0.27	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
THCA	cis	rs12497850	0.931	rs13064911	ENSG00000229759.1	MRPS18AP1	6.01	3.7e-09	7.25e-07	0.36	0.27	Parkinson's disease;	chr3:48914952	chr3:48256350~48256938:-
THCA	cis	rs7523875	0.72	rs17017431	ENSG00000153363.11	LINC00467	-6.01	3.7e-09	7.25e-07	-0.28	-0.27	Mean corpuscular volume;	chr1:211370352	chr1:211382803~211435333:+
THCA	cis	rs7085104	0.66	rs7902804	ENSG00000236937.2	PTGES3P4	6.01	3.7e-09	7.26e-07	0.34	0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102845595~102845950:+
THCA	cis	rs9307551	0.817	rs12500146	ENSG00000250334.4	LINC00989	-6.01	3.7e-09	7.26e-07	-0.31	-0.27	Refractive error;	chr4:79580002	chr4:79492416~79576460:+
THCA	cis	rs7809950	1	rs17154077	ENSG00000238832.1	snoU109	6.01	3.7e-09	7.26e-07	0.28	0.27	Coronary artery disease;	chr7:107437496	chr7:107603363~107603507:+
THCA	cis	rs523522	0.923	rs2235217	ENSG00000278344.1	RP11-18C24.8	6.01	3.71e-09	7.27e-07	0.3	0.27	High light scatter reticulocyte count;	chr12:120446525	chr12:120500735~120501090:-
THCA	cis	rs1275468	1	rs1148005	ENSG00000257497.2	RP11-585P4.5	-6.01	3.71e-09	7.27e-07	-0.4	-0.27	Polycystic ovary syndrome;	chr12:75584733	chr12:75483454~75489820:-
THCA	cis	rs1707322	0.752	rs7541962	ENSG00000281133.1	AL355480.3	-6.01	3.71e-09	7.28e-07	-0.33	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45580892~45580996:-
THCA	cis	rs2562456	0.834	rs2650848	ENSG00000268555.1	RP11-678G14.3	6.01	3.72e-09	7.28e-07	0.43	0.27	Pain;	chr19:21403835	chr19:21570822~21587322:-
THCA	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-6.01	3.72e-09	7.28e-07	-0.38	-0.27	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
THCA	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-6.01	3.72e-09	7.28e-07	-0.2	-0.27	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
THCA	cis	rs11976180	1	rs1540894	ENSG00000273234.1	OR2A13P	-6.01	3.72e-09	7.29e-07	-0.3	-0.27	Obesity-related traits;	chr7:144070583	chr7:144142009~144142938:+
THCA	cis	rs2243480	0.522	rs778717	ENSG00000273142.1	RP11-458F8.4	-6.01	3.72e-09	7.29e-07	-0.43	-0.27	Diabetic kidney disease;	chr7:66383164	chr7:66902857~66906297:+
THCA	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-6.01	3.72e-09	7.3e-07	-0.22	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
THCA	cis	rs5752326	0.681	rs4822721	ENSG00000261188.1	CTA-445C9.14	6.01	3.72e-09	7.3e-07	0.29	0.27	Ischemic stroke;	chr22:26456191	chr22:26512537~26514568:+
THCA	cis	rs5752326	0.867	rs1894706	ENSG00000261188.1	CTA-445C9.14	6.01	3.72e-09	7.3e-07	0.29	0.27	Ischemic stroke;	chr22:26458475	chr22:26512537~26514568:+
THCA	cis	rs9880211	0.948	rs34913797	ENSG00000273486.1	RP11-731C17.2	6.01	3.73e-09	7.3e-07	0.28	0.27	Height;Body mass index;	chr3:136408728	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs9812579	ENSG00000273486.1	RP11-731C17.2	6.01	3.73e-09	7.3e-07	0.28	0.27	Height;Body mass index;	chr3:136432408	chr3:136837338~136839021:-
THCA	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	6.01	3.73e-09	7.31e-07	0.4	0.27	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
THCA	cis	rs1865760	0.551	rs9461230	ENSG00000272462.2	U91328.19	-6.01	3.73e-09	7.31e-07	-0.22	-0.27	Height;	chr6:26019012	chr6:25992662~26001775:+
THCA	cis	rs11158026	0.603	rs59323730	ENSG00000258413.1	RP11-665C16.6	-6.01	3.73e-09	7.31e-07	-0.38	-0.27	Parkinson's disease;	chr14:54972357	chr14:55262767~55272075:-
THCA	cis	rs55823223	0.648	rs72860389	ENSG00000267801.1	RP11-552F3.9	6.01	3.73e-09	7.32e-07	0.37	0.27	Psoriasis;	chr17:75869990	chr17:75876372~75879546:+
THCA	cis	rs10129255	0.957	rs10141052	ENSG00000211974.3	IGHV2-70	6.01	3.73e-09	7.32e-07	0.2	0.27	Kawasaki disease;	chr14:106776528	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs10141009	ENSG00000211974.3	IGHV2-70	6.01	3.73e-09	7.32e-07	0.2	0.27	Kawasaki disease;	chr14:106776695	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.912	rs6576227	ENSG00000211974.3	IGHV2-70	6.01	3.73e-09	7.32e-07	0.2	0.27	Kawasaki disease;	chr14:106778202	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs6576228	ENSG00000211974.3	IGHV2-70	6.01	3.73e-09	7.32e-07	0.2	0.27	Kawasaki disease;	chr14:106778401	chr14:106723574~106724093:-
THCA	cis	rs2243480	1	rs313807	ENSG00000228409.4	CCT6P1	6.01	3.73e-09	7.32e-07	0.31	0.27	Diabetic kidney disease;	chr7:66034494	chr7:65751142~65763354:+
THCA	cis	rs7015630	0.647	rs12679902	ENSG00000251136.7	RP11-37B2.1	-6.01	3.74e-09	7.32e-07	-0.25	-0.27	Inflammatory bowel disease;Crohn's disease;	chr8:89845761	chr8:89609409~89757727:-
THCA	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-6.01	3.74e-09	7.32e-07	-0.43	-0.27	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
THCA	cis	rs9859260	0.71	rs41298097	ENSG00000242086.7	LINC00969	-6.01	3.74e-09	7.33e-07	-0.26	-0.27	Mean corpuscular volume;	chr3:196052284	chr3:195658062~195739964:+
THCA	cis	rs9859260	0.744	rs557527	ENSG00000242086.7	LINC00969	-6.01	3.74e-09	7.33e-07	-0.26	-0.27	Mean corpuscular volume;	chr3:196053838	chr3:195658062~195739964:+
THCA	cis	rs853679	1	rs853679	ENSG00000226314.6	ZNF192P1	-6.01	3.74e-09	7.33e-07	-0.4	-0.27	Depression;	chr6:28329086	chr6:28161781~28169594:+
THCA	cis	rs853679	1	rs853678	ENSG00000226314.6	ZNF192P1	-6.01	3.74e-09	7.33e-07	-0.4	-0.27	Depression;	chr6:28329536	chr6:28161781~28169594:+
THCA	cis	rs890448	0.796	rs293201	ENSG00000254531.1	FLJ20021	6.01	3.75e-09	7.34e-07	0.23	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101402425	chr4:101347780~101348883:+
THCA	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	6.01	3.75e-09	7.34e-07	0.41	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
THCA	cis	rs847577	0.63	rs6969384	ENSG00000272950.1	RP11-307C18.1	6.01	3.75e-09	7.34e-07	0.33	0.27	Breast cancer;	chr7:98103530	chr7:98322853~98323430:+
THCA	cis	rs853679	0.607	rs68188794	ENSG00000219392.1	RP1-265C24.5	-6.01	3.75e-09	7.35e-07	-0.6	-0.27	Depression;	chr6:28112999	chr6:28115628~28116551:+
THCA	cis	rs7809950	0.678	rs7788330	ENSG00000238832.1	snoU109	-6.01	3.75e-09	7.35e-07	-0.32	-0.27	Coronary artery disease;	chr7:107345203	chr7:107603363~107603507:+
THCA	cis	rs3742264	1	rs9526140	ENSG00000235903.6	CPB2-AS1	-6.01	3.76e-09	7.36e-07	-0.36	-0.27	Blood protein levels;	chr13:46070017	chr13:46052806~46113332:+
THCA	cis	rs10129255	0.912	rs61996059	ENSG00000211974.3	IGHV2-70	6.01	3.76e-09	7.36e-07	0.21	0.27	Kawasaki disease;	chr14:106716897	chr14:106723574~106724093:-
THCA	cis	rs9402743	0.781	rs9494331	ENSG00000231028.7	LINC00271	6.01	3.76e-09	7.37e-07	0.23	0.27	Systemic lupus erythematosus;	chr6:135685163	chr6:135497801~135716055:+
THCA	cis	rs9649465	0.967	rs6966470	ENSG00000272686.1	RP11-390E23.6	-6.01	3.76e-09	7.37e-07	-0.18	-0.27	Migraine;	chr7:123659801	chr7:123749068~123751166:+
THCA	cis	rs6860806	0.661	rs6890009	ENSG00000224431.1	AC063976.7	6.01	3.76e-09	7.37e-07	0.23	0.27	Breast cancer;	chr5:132244340	chr5:132199456~132203487:+
THCA	cis	rs950169	0.763	rs35372971	ENSG00000259295.5	CSPG4P12	6.01	3.76e-09	7.37e-07	0.41	0.27	Schizophrenia;	chr15:84387097	chr15:85191438~85213905:+
THCA	cis	rs6142102	0.961	rs4911389	ENSG00000275784.1	RP5-1125A11.6	-6.01	3.77e-09	7.38e-07	-0.28	-0.27	Skin pigmentation;	chr20:33977235	chr20:33989480~33991818:-
THCA	cis	rs797680	0.786	rs12133576	ENSG00000223745.6	RP4-717I23.3	-6.01	3.77e-09	7.38e-07	-0.16	-0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93350843	chr1:93262186~93346025:-
THCA	cis	rs2243480	1	rs34702770	ENSG00000228409.4	CCT6P1	6.01	3.77e-09	7.38e-07	0.31	0.27	Diabetic kidney disease;	chr7:65879836	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs34637256	ENSG00000228409.4	CCT6P1	6.01	3.77e-09	7.38e-07	0.31	0.27	Diabetic kidney disease;	chr7:65895144	chr7:65751142~65763354:+
THCA	cis	rs7208859	0.573	rs8078182	ENSG00000263603.1	CTD-2349P21.5	-6.01	3.77e-09	7.38e-07	-0.44	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30729469~30731202:+
THCA	cis	rs5758511	0.634	rs1001587	ENSG00000281538.1	RP4-669P10.20	-6.01	3.77e-09	7.38e-07	-0.3	-0.27	Birth weight;	chr22:42274105	chr22:42138060~42139726:+
THCA	cis	rs516805	0.596	rs4326267	ENSG00000279453.1	RP3-425C14.4	-6.01	3.77e-09	7.39e-07	-0.29	-0.27	Lymphocyte counts;	chr6:122106476	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs4245520	ENSG00000279453.1	RP3-425C14.4	-6.01	3.77e-09	7.39e-07	-0.29	-0.27	Lymphocyte counts;	chr6:122106477	chr6:122436789~122439223:-
THCA	cis	rs2303319	0.504	rs57419108	ENSG00000227403.1	AC009299.3	6.01	3.78e-09	7.39e-07	0.57	0.27	Cognitive function;	chr2:161454846	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12469052	ENSG00000227403.1	AC009299.3	6.01	3.78e-09	7.39e-07	0.57	0.27	Cognitive function;	chr2:161462842	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62190168	ENSG00000227403.1	AC009299.3	6.01	3.78e-09	7.39e-07	0.57	0.27	Cognitive function;	chr2:161465501	chr2:161244739~161249050:+
THCA	cis	rs934734	0.752	rs2661797	ENSG00000281920.1	RP11-418H16.1	-6.01	3.78e-09	7.4e-07	-0.33	-0.27	Rheumatoid arthritis;	chr2:65406056	chr2:65623272~65628424:+
THCA	cis	rs4713118	0.786	rs200502	ENSG00000280107.1	AL022393.9	-6.01	3.78e-09	7.4e-07	-0.31	-0.27	Parkinson's disease;	chr6:27820284	chr6:28170845~28172521:+
THCA	cis	rs7260598	0.605	rs67492250	ENSG00000268442.1	CTD-2027I19.2	6.01	3.78e-09	7.4e-07	0.36	0.27	Response to taxane treatment (placlitaxel);	chr19:23924293	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.685	rs67534545	ENSG00000268442.1	CTD-2027I19.2	6.01	3.78e-09	7.4e-07	0.36	0.27	Response to taxane treatment (placlitaxel);	chr19:23927339	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.642	rs28537609	ENSG00000268442.1	CTD-2027I19.2	6.01	3.78e-09	7.4e-07	0.36	0.27	Response to taxane treatment (placlitaxel);	chr19:23928662	chr19:24162370~24163425:-
THCA	cis	rs55665837	0.54	rs4757261	ENSG00000251991.1	RNU7-49P	6.01	3.78e-09	7.4e-07	0.29	0.27	Vitamin D levels;	chr11:14648256	chr11:14478892~14478953:+
THCA	cis	rs6860806	0.507	rs270608	ENSG00000263597.1	MIR3936	6.01	3.78e-09	7.41e-07	0.27	0.27	Breast cancer;	chr5:132312713	chr5:132365490~132365599:-
THCA	cis	rs12681287	0.752	rs4641037	ENSG00000254231.1	CTD-2284J15.1	6.01	3.79e-09	7.41e-07	0.3	0.27	Caudate activity during reward;	chr8:86256150	chr8:86333274~86343314:-
THCA	cis	rs847577	0.587	rs34307903	ENSG00000272950.1	RP11-307C18.1	6.01	3.79e-09	7.42e-07	0.33	0.27	Breast cancer;	chr7:98099137	chr7:98322853~98323430:+
THCA	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	6.01	3.79e-09	7.42e-07	0.32	0.27	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
THCA	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	6.01	3.79e-09	7.42e-07	0.32	0.27	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
THCA	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	6.01	3.79e-09	7.42e-07	0.32	0.27	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
THCA	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	6.01	3.79e-09	7.42e-07	0.32	0.27	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
THCA	cis	rs7809950	1	rs2712201	ENSG00000238832.1	snoU109	-6.01	3.79e-09	7.42e-07	-0.28	-0.27	Coronary artery disease;	chr7:107505119	chr7:107603363~107603507:+
THCA	cis	rs748404	0.629	rs34657657	ENSG00000249839.1	AC011330.5	-6.01	3.8e-09	7.43e-07	-0.38	-0.27	Lung cancer;	chr15:43315763	chr15:43663654~43684339:-
THCA	cis	rs16846053	0.642	rs13390292	ENSG00000227403.1	AC009299.3	6.01	3.8e-09	7.43e-07	0.43	0.27	Blood osmolality (transformed sodium);	chr2:161787585	chr2:161244739~161249050:+
THCA	cis	rs11915082	0.686	rs7349507	ENSG00000231464.1	AC024937.4	6.01	3.8e-09	7.44e-07	0.34	0.27	Mean corpuscular hemoglobin;	chr3:196059617	chr3:195996738~195998233:+
THCA	cis	rs934734	0.789	rs906579	ENSG00000281920.1	RP11-418H16.1	-6.01	3.81e-09	7.45e-07	-0.34	-0.27	Rheumatoid arthritis;	chr2:65374464	chr2:65623272~65628424:+
THCA	cis	rs934734	0.789	rs906578	ENSG00000281920.1	RP11-418H16.1	-6.01	3.81e-09	7.45e-07	-0.34	-0.27	Rheumatoid arthritis;	chr2:65374466	chr2:65623272~65628424:+
THCA	cis	rs2975734	0.674	rs6983870	ENSG00000261451.1	RP11-981G7.1	-6.01	3.81e-09	7.45e-07	-0.35	-0.27	Chronotype;Morning vs. evening chronotype;	chr8:10253784	chr8:10433672~10438312:+
THCA	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	6.01	3.81e-09	7.45e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
THCA	cis	rs2243480	0.901	rs313808	ENSG00000228409.4	CCT6P1	6.01	3.81e-09	7.45e-07	0.31	0.27	Diabetic kidney disease;	chr7:66034886	chr7:65751142~65763354:+
THCA	cis	rs847577	0.506	rs7808528	ENSG00000272950.1	RP11-307C18.1	6.01	3.81e-09	7.45e-07	0.33	0.27	Breast cancer;	chr7:98092113	chr7:98322853~98323430:+
THCA	cis	rs2243480	1	rs466983	ENSG00000232546.1	RP11-458F8.1	-6.01	3.81e-09	7.46e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66055509	chr7:66848496~66858136:+
THCA	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	6.01	3.81e-09	7.46e-07	0.3	0.27	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
THCA	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-6.01	3.82e-09	7.46e-07	-0.34	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
THCA	cis	rs9880211	1	rs28718456	ENSG00000273486.1	RP11-731C17.2	6.01	3.83e-09	7.49e-07	0.28	0.27	Height;Body mass index;	chr3:136485164	chr3:136837338~136839021:-
THCA	cis	rs925255	0.81	rs1396733	ENSG00000270210.1	RP11-373D23.3	-6.01	3.83e-09	7.49e-07	-0.26	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28419880	chr2:28425945~28426719:+
THCA	cis	rs7809950	0.773	rs62483722	ENSG00000238832.1	snoU109	-6	3.84e-09	7.5e-07	-0.28	-0.27	Coronary artery disease;	chr7:107545904	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.906	rs62483723	ENSG00000238832.1	snoU109	-6	3.84e-09	7.5e-07	-0.28	-0.27	Coronary artery disease;	chr7:107545913	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.953	rs2520267	ENSG00000238832.1	snoU109	-6	3.84e-09	7.5e-07	-0.28	-0.27	Coronary artery disease;	chr7:107547052	chr7:107603363~107603507:+
THCA	cis	rs2243480	1	rs7456042	ENSG00000228409.4	CCT6P1	6	3.84e-09	7.5e-07	0.31	0.27	Diabetic kidney disease;	chr7:65834791	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs73142121	ENSG00000228409.4	CCT6P1	6	3.84e-09	7.5e-07	0.31	0.27	Diabetic kidney disease;	chr7:65846219	chr7:65751142~65763354:+
THCA	cis	rs4835473	0.932	rs1849135	ENSG00000251600.4	RP11-673E1.1	-6	3.84e-09	7.5e-07	-0.37	-0.27	Immature fraction of reticulocytes;	chr4:143912279	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.932	rs1849136	ENSG00000251600.4	RP11-673E1.1	-6	3.84e-09	7.5e-07	-0.37	-0.27	Immature fraction of reticulocytes;	chr4:143912380	chr4:143912331~143982454:+
THCA	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	6	3.84e-09	7.5e-07	0.39	0.27	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
THCA	cis	rs2243480	1	rs160644	ENSG00000229886.1	RP5-1132H15.3	6	3.84e-09	7.51e-07	0.42	0.27	Diabetic kidney disease;	chr7:66093199	chr7:66025126~66031544:-
THCA	cis	rs3213758	0.541	rs9935278	ENSG00000275191.1	RP11-36I17.2	-6	3.84e-09	7.51e-07	-0.38	-0.27	Vitiligo (non-segmental);	chr16:53627670	chr16:53628256~53628816:-
THCA	cis	rs2117029	0.782	rs6580699	ENSG00000258017.1	RP11-386G11.10	6	3.84e-09	7.51e-07	0.33	0.27	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49127782~49147869:+
THCA	cis	rs442309	0.812	rs224092	ENSG00000238280.1	RP11-436D10.3	-6	3.84e-09	7.51e-07	-0.32	-0.27	Vogt-Koyanagi-Harada syndrome;	chr10:62781644	chr10:62793562~62805887:-
THCA	cis	rs228614	0.536	rs223420	ENSG00000230069.3	LRRC37A15P	-6	3.85e-09	7.52e-07	-0.28	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102727274~102730721:-
THCA	cis	rs228614	0.51	rs223453	ENSG00000230069.3	LRRC37A15P	-6	3.85e-09	7.53e-07	-0.28	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102727274~102730721:-
THCA	cis	rs10971721	0.584	rs1378	ENSG00000281128.1	PTENP1-AS	6	3.85e-09	7.53e-07	0.56	0.27	Body mass index;	chr9:34107506	chr9:33677268~33688011:+
THCA	cis	rs10078	0.515	rs890984	ENSG00000221990.4	EXOC3-AS1	6	3.85e-09	7.53e-07	0.28	0.27	Fat distribution (HIV);	chr5:479425	chr5:441498~443160:-
THCA	cis	rs2348418	1	rs2348418	ENSG00000247934.4	RP11-967K21.1	6	3.86e-09	7.54e-07	0.23	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28536581	chr12:28163298~28190738:-
THCA	cis	rs17772222	1	rs3814855	ENSG00000258789.1	RP11-507K2.3	-6	3.86e-09	7.54e-07	-0.28	-0.27	Coronary artery calcification;	chr14:88467016	chr14:88551597~88552493:+
THCA	cis	rs7202877	0.706	rs247447	ENSG00000261783.1	RP11-252K23.2	6	3.86e-09	7.54e-07	0.47	0.27	Type 1 diabetes;Type 2 diabetes;	chr16:75452750	chr16:75379818~75381260:-
THCA	cis	rs2337406	0.714	rs8022729	ENSG00000274576.2	IGHV2-70	6	3.86e-09	7.55e-07	0.23	0.27	Alzheimer's disease (late onset);	chr14:106816928	chr14:106770577~106771020:-
THCA	cis	rs2243480	1	rs73142166	ENSG00000229886.1	RP5-1132H15.3	6	3.87e-09	7.55e-07	0.44	0.27	Diabetic kidney disease;	chr7:65910845	chr7:66025126~66031544:-
THCA	cis	rs10078	0.571	rs2721028	ENSG00000221990.4	EXOC3-AS1	6	3.87e-09	7.55e-07	0.29	0.27	Fat distribution (HIV);	chr5:443734	chr5:441498~443160:-
THCA	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	6	3.87e-09	7.56e-07	0.28	0.27	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
THCA	cis	rs11089937	0.597	rs5757024	ENSG00000211638.2	IGLV8-61	-6	3.87e-09	7.56e-07	-0.21	-0.27	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs5757026	ENSG00000211638.2	IGLV8-61	-6	3.87e-09	7.56e-07	-0.21	-0.27	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs5750582	ENSG00000211638.2	IGLV8-61	-6	3.87e-09	7.56e-07	-0.21	-0.27	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.626	rs5757028	ENSG00000211638.2	IGLV8-61	-6	3.87e-09	7.56e-07	-0.21	-0.27	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22098700~22099212:+
THCA	cis	rs4819052	0.59	rs414743	ENSG00000237664.1	LINC00316	-6	3.87e-09	7.56e-07	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45092160	chr21:45338590~45341990:-
THCA	cis	rs7119038	0.818	rs2155433	ENSG00000255239.1	AP002954.6	-6	3.87e-09	7.57e-07	-0.38	-0.27	Sjögren's syndrome;	chr11:118742212	chr11:118688039~118690600:-
THCA	cis	rs1865760	0.892	rs6456705	ENSG00000272462.2	U91328.19	-6	3.87e-09	7.57e-07	-0.22	-0.27	Height;	chr6:25935828	chr6:25992662~26001775:+
THCA	cis	rs7247513	1	rs7247513	ENSG00000213290.4	PGK1P2	-6	3.87e-09	7.57e-07	-0.33	-0.27	Bipolar disorder;	chr19:12580371	chr19:12559571~12561105:+
THCA	cis	rs7809950	0.817	rs10224503	ENSG00000238832.1	snoU109	-6	3.87e-09	7.57e-07	-0.31	-0.27	Coronary artery disease;	chr7:107435124	chr7:107603363~107603507:+
THCA	cis	rs17301013	0.507	rs3118990	ENSG00000227373.4	RP11-160H22.5	-6	3.87e-09	7.57e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174818586	chr1:174115300~174160004:-
THCA	cis	rs2281636	0.894	rs7077070	ENSG00000260475.1	RP11-85A1.3	6	3.88e-09	7.58e-07	0.24	0.27	Obesity-related traits;	chr10:99692220	chr10:99621055~99621918:+
THCA	cis	rs899997	0.862	rs57260218	ENSG00000261143.1	ADAMTS7P3	-6	3.88e-09	7.58e-07	-0.37	-0.27	Coronary artery disease or large artery stroke;	chr15:78681430	chr15:77976042~77993057:+
THCA	cis	rs6545883	0.931	rs11125885	ENSG00000271889.1	RP11-493E12.1	6	3.88e-09	7.58e-07	0.26	0.27	Tuberculosis;	chr2:61528593	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.965	rs9989775	ENSG00000271889.1	RP11-493E12.1	6	3.88e-09	7.58e-07	0.26	0.27	Tuberculosis;	chr2:61534639	chr2:61151433~61162105:-
THCA	cis	rs2029362	0.935	rs7935700	ENSG00000245573.6	BDNF-AS	6	3.88e-09	7.59e-07	0.21	0.27	Total body bone mineral density;	chr11:27601714	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.868	rs7949542	ENSG00000245573.6	BDNF-AS	6	3.88e-09	7.59e-07	0.21	0.27	Total body bone mineral density;	chr11:27601874	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.775	rs10835204	ENSG00000245573.6	BDNF-AS	6	3.88e-09	7.59e-07	0.21	0.27	Total body bone mineral density;	chr11:27602237	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.935	rs11030073	ENSG00000245573.6	BDNF-AS	6	3.88e-09	7.59e-07	0.21	0.27	Total body bone mineral density;	chr11:27604395	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.836	rs11030074	ENSG00000245573.6	BDNF-AS	6	3.88e-09	7.59e-07	0.21	0.27	Total body bone mineral density;	chr11:27604720	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.868	rs7936850	ENSG00000245573.6	BDNF-AS	6	3.88e-09	7.59e-07	0.21	0.27	Total body bone mineral density;	chr11:27605855	chr11:27506838~27698174:+
THCA	cis	rs7176527	0.848	rs3748374	ENSG00000188388.10	GOLGA6L3	6	3.88e-09	7.59e-07	0.43	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85240472~85247170:+
THCA	cis	rs7809950	0.53	rs34021916	ENSG00000238832.1	snoU109	-6	3.89e-09	7.59e-07	-0.32	-0.27	Coronary artery disease;	chr7:107177456	chr7:107603363~107603507:+
THCA	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	6	3.89e-09	7.59e-07	0.38	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
THCA	cis	rs4650994	0.544	rs4652301	ENSG00000273384.1	RP5-1098D14.1	6	3.89e-09	7.59e-07	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178530664	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.544	rs10798613	ENSG00000273384.1	RP5-1098D14.1	6	3.89e-09	7.59e-07	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178530887	chr1:178651706~178652282:+
THCA	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-6	3.89e-09	7.6e-07	-0.33	-0.27	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-6	3.89e-09	7.6e-07	-0.33	-0.27	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
THCA	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	6	3.89e-09	7.6e-07	0.29	0.27	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	6	3.89e-09	7.6e-07	0.29	0.27	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	6	3.89e-09	7.6e-07	0.29	0.27	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
THCA	cis	rs797680	0.786	rs7525248	ENSG00000223745.6	RP4-717I23.3	6	3.89e-09	7.6e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93362966	chr1:93262186~93346025:-
THCA	cis	rs797680	0.786	rs4847412	ENSG00000223745.6	RP4-717I23.3	6	3.89e-09	7.6e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93363691	chr1:93262186~93346025:-
THCA	cis	rs1859596	0.932	rs2269989	ENSG00000234456.6	MAGI2-AS3	6	3.89e-09	7.6e-07	0.26	0.27	Reading or mathematical ability;	chr7:79460715	chr7:79452877~79471208:+
THCA	cis	rs17301013	0.507	rs1793320	ENSG00000227373.4	RP11-160H22.5	6	3.89e-09	7.6e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174796308	chr1:174115300~174160004:-
THCA	cis	rs10971721	0.596	rs9650704	ENSG00000281128.1	PTENP1-AS	6	3.9e-09	7.61e-07	0.56	0.27	Body mass index;	chr9:34141956	chr9:33677268~33688011:+
THCA	cis	rs12893668	0.608	rs12889721	ENSG00000269910.1	RP11-73M18.10	6	3.9e-09	7.62e-07	0.25	0.27	Reticulocyte count;	chr14:103568526	chr14:103694516~103695050:-
THCA	cis	rs10875746	0.859	rs12305647	ENSG00000269514.1	RP11-370I10.12	6	3.9e-09	7.62e-07	0.26	0.27	Longevity (90 years and older);	chr12:48189178	chr12:48198387~48202031:+
THCA	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	6	3.91e-09	7.63e-07	0.34	0.27	Height;	chr4:55460485	chr4:55363971~55395847:-
THCA	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	6	3.91e-09	7.63e-07	0.41	0.27	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
THCA	cis	rs11722779	0.935	rs11938650	ENSG00000251288.2	RP11-10L12.2	-6	3.91e-09	7.63e-07	-0.36	-0.27	Schizophrenia;	chr4:103021639	chr4:102751401~102752641:+
THCA	cis	rs2303319	0.504	rs62188728	ENSG00000227403.1	AC009299.3	6	3.91e-09	7.63e-07	0.56	0.27	Cognitive function;	chr2:161479190	chr2:161244739~161249050:+
THCA	cis	rs6671200	0.607	rs3753872	ENSG00000228852.5	RP11-57H12.5	-6	3.91e-09	7.63e-07	-0.31	-0.27	Stearic acid (18:0) levels;	chr1:95233628	chr1:95243167~95278940:-
THCA	cis	rs6671200	0.607	rs10874908	ENSG00000228852.5	RP11-57H12.5	-6	3.91e-09	7.63e-07	-0.31	-0.27	Stearic acid (18:0) levels;	chr1:95238595	chr1:95243167~95278940:-
THCA	cis	rs6671200	0.607	rs3767315	ENSG00000228852.5	RP11-57H12.5	-6	3.91e-09	7.63e-07	-0.31	-0.27	Stearic acid (18:0) levels;	chr1:95240416	chr1:95243167~95278940:-
THCA	cis	rs4950322	0.57	rs113498894	ENSG00000278811.3	LINC00624	6	3.91e-09	7.64e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147318880	chr1:147258885~147517875:-
THCA	cis	rs317865	0.867	rs73234637	ENSG00000263327.5	TAPT1-AS1	-6	3.91e-09	7.64e-07	-0.43	-0.27	Kidney disease (early stage) in type 1 diabetes;	chr4:16177243	chr4:16226685~16320140:+
THCA	cis	rs6142102	0.961	rs2235597	ENSG00000275784.1	RP5-1125A11.6	-6	3.91e-09	7.64e-07	-0.28	-0.27	Skin pigmentation;	chr20:34077808	chr20:33989480~33991818:-
THCA	cis	rs853679	0.517	rs4713135	ENSG00000261839.1	RP1-265C24.8	6	3.91e-09	7.64e-07	0.32	0.27	Depression;	chr6:28071808	chr6:28136849~28139678:+
THCA	cis	rs853679	0.542	rs6934769	ENSG00000261839.1	RP1-265C24.8	6	3.92e-09	7.65e-07	0.32	0.27	Depression;	chr6:28123153	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs17711801	ENSG00000261839.1	RP1-265C24.8	6	3.92e-09	7.65e-07	0.32	0.27	Depression;	chr6:28124529	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000261839.1	RP1-265C24.8	6	3.92e-09	7.65e-07	0.32	0.27	Parkinson's disease;	chr6:28127394	chr6:28136849~28139678:+
THCA	cis	rs853679	0.517	rs9468292	ENSG00000261839.1	RP1-265C24.8	6	3.92e-09	7.65e-07	0.32	0.27	Depression;	chr6:28127577	chr6:28136849~28139678:+
THCA	cis	rs2243480	1	rs10247526	ENSG00000232546.1	RP11-458F8.1	6	3.92e-09	7.65e-07	0.35	0.27	Diabetic kidney disease;	chr7:66315709	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000232546.1	RP11-458F8.1	6	3.92e-09	7.65e-07	0.35	0.27	Diabetic kidney disease;	chr7:66333815	chr7:66848496~66858136:+
THCA	cis	rs2033711	0.622	rs975947	ENSG00000268912.1	CTD-2619J13.17	-6	3.92e-09	7.65e-07	-0.21	-0.27	Uric acid clearance;	chr19:58386826	chr19:58428632~58431148:-
THCA	cis	rs2255336	0.817	rs12318583	ENSG00000245648.1	RP11-277P12.20	-6	3.92e-09	7.66e-07	-0.34	-0.27	Blood protein levels;	chr12:10426485	chr12:10363769~10398506:+
THCA	cis	rs2243480	1	rs465359	ENSG00000229886.1	RP5-1132H15.3	6	3.92e-09	7.66e-07	0.42	0.27	Diabetic kidney disease;	chr7:66093177	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs462853	ENSG00000229886.1	RP5-1132H15.3	6	3.92e-09	7.66e-07	0.42	0.27	Diabetic kidney disease;	chr7:66093180	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs160642	ENSG00000229886.1	RP5-1132H15.3	6	3.92e-09	7.66e-07	0.42	0.27	Diabetic kidney disease;	chr7:66093386	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000229886.1	RP5-1132H15.3	6	3.92e-09	7.66e-07	0.42	0.27	Diabetic kidney disease;	chr7:66100154	chr7:66025126~66031544:-
THCA	cis	rs2018683	0.739	rs10233884	ENSG00000228421.2	AC005013.5	6	3.92e-09	7.66e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932690	chr7:28957667~28959345:+
THCA	cis	rs1501911	0.566	rs709387	ENSG00000248489.1	CTD-2007H13.3	6	3.92e-09	7.66e-07	0.28	0.27	Lung function (FEV1/FVC);	chr5:98994337	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.588	rs709386	ENSG00000248489.1	CTD-2007H13.3	6	3.92e-09	7.66e-07	0.28	0.27	Lung function (FEV1/FVC);	chr5:98994346	chr5:98929171~98995013:+
THCA	cis	rs755249	0.917	rs61781392	ENSG00000228060.1	RP11-69E11.8	-6	3.93e-09	7.67e-07	-0.3	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39565160~39573203:+
THCA	cis	rs755249	0.917	rs61232586	ENSG00000228060.1	RP11-69E11.8	-6	3.93e-09	7.67e-07	-0.3	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39565160~39573203:+
THCA	cis	rs755249	0.917	rs61781393	ENSG00000228060.1	RP11-69E11.8	-6	3.93e-09	7.67e-07	-0.3	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39565160~39573203:+
THCA	cis	rs10895275	0.649	rs1895916	ENSG00000277459.1	RP11-732A21.3	6	3.93e-09	7.67e-07	0.2	0.27	Migraine;	chr11:102221938	chr11:102109827~102110457:-
THCA	cis	rs4713118	0.568	rs9468213	ENSG00000219392.1	RP1-265C24.5	-6	3.93e-09	7.67e-07	-0.31	-0.27	Parkinson's disease;	chr6:27738401	chr6:28115628~28116551:+
THCA	cis	rs12216125	0.801	rs56107510	ENSG00000272462.2	U91328.19	-6	3.93e-09	7.67e-07	-0.24	-0.27	Iron status biomarkers;	chr6:25987208	chr6:25992662~26001775:+
THCA	cis	rs12497850	0.897	rs9681717	ENSG00000229759.1	MRPS18AP1	6	3.93e-09	7.67e-07	0.35	0.27	Parkinson's disease;	chr3:48835565	chr3:48256350~48256938:-
THCA	cis	rs2915864	0.655	rs35044637	ENSG00000280047.1	CTC-463A16.1	6	3.93e-09	7.67e-07	0.4	0.27	Facial morphology (factor 20);	chr5:142096408	chr5:142165767~142168387:+
THCA	cis	rs728616	0.867	rs2152550	ENSG00000242600.5	MBL1P	6	3.93e-09	7.68e-07	0.36	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80058753	chr10:79904898~79950336:+
THCA	cis	rs6142102	0.961	rs2284379	ENSG00000275784.1	RP5-1125A11.6	-6	3.93e-09	7.68e-07	-0.28	-0.27	Skin pigmentation;	chr20:34006836	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs2268080	ENSG00000275784.1	RP5-1125A11.6	-6	3.93e-09	7.68e-07	-0.28	-0.27	Skin pigmentation;	chr20:34009910	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs1555075	ENSG00000275784.1	RP5-1125A11.6	-6	3.93e-09	7.68e-07	-0.28	-0.27	Skin pigmentation;	chr20:34022595	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs4911144	ENSG00000275784.1	RP5-1125A11.6	-6	3.93e-09	7.68e-07	-0.28	-0.27	Skin pigmentation;	chr20:34026565	chr20:33989480~33991818:-
THCA	cis	rs763567	0.509	rs10919449	ENSG00000271811.1	RP1-79C4.4	6	3.94e-09	7.68e-07	0.31	0.27	Tonsillectomy;	chr1:170669517	chr1:170667381~170669425:+
THCA	cis	rs12899811	0.512	rs7164916	ENSG00000214432.8	AC068831.10	-6	3.94e-09	7.68e-07	-0.29	-0.27	Type 2 diabetes;	chr15:91018216	chr15:91022619~91036611:+
THCA	cis	rs9813712	0.953	rs896822	ENSG00000228252.7	COL6A4P2	-6	3.94e-09	7.68e-07	-0.3	-0.27	Response to amphetamines;	chr3:130259987	chr3:130212823~130273806:+
THCA	cis	rs2692947	0.702	rs4907291	ENSG00000232931.4	LINC00342	6	3.94e-09	7.68e-07	0.21	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95988857	chr2:95807118~95816215:-
THCA	cis	rs6951245	0.706	rs28685743	ENSG00000229043.2	AC091729.9	-6	3.94e-09	7.68e-07	-0.44	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1160374~1165267:+
THCA	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	6	3.94e-09	7.69e-07	0.3	0.27	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
THCA	cis	rs12893668	0.572	rs2273175	ENSG00000269940.1	RP11-73M18.7	6	3.94e-09	7.69e-07	0.27	0.27	Reticulocyte count;	chr14:103693804	chr14:103694560~103695170:+
THCA	cis	rs11976180	1	rs11975942	ENSG00000273234.1	OR2A13P	-6	3.94e-09	7.69e-07	-0.31	-0.27	Obesity-related traits;	chr7:144043487	chr7:144142009~144142938:+
THCA	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-6	3.95e-09	7.7e-07	-0.54	-0.27	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
THCA	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-6	3.95e-09	7.7e-07	-0.29	-0.27	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
THCA	cis	rs3822625	1	rs78209889	ENSG00000271828.1	CTD-2310F14.1	6	3.95e-09	7.71e-07	0.7	0.27	Breast cancer (early onset);	chr5:56769745	chr5:56927874~56929573:+
THCA	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-6	3.95e-09	7.71e-07	-0.28	-0.27	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
THCA	cis	rs2348418	0.832	rs7294553	ENSG00000247934.4	RP11-967K21.1	6	3.95e-09	7.71e-07	0.23	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28334832	chr12:28163298~28190738:-
THCA	cis	rs9813712	0.547	rs6807290	ENSG00000253540.4	FAM86HP	6	3.95e-09	7.71e-07	0.28	0.27	Response to amphetamines;	chr3:130297952	chr3:130099092~130111472:-
THCA	cis	rs9926296	0.744	rs154656	ENSG00000274627.1	RP11-104N10.2	6	3.95e-09	7.71e-07	0.27	0.27	Vitiligo;	chr16:89641595	chr16:89516797~89522217:+
THCA	cis	rs77972916	0.505	rs6756575	ENSG00000234936.1	AC010883.5	6	3.96e-09	7.72e-07	0.3	0.27	Granulocyte percentage of myeloid white cells;	chr2:43301380	chr2:43229573~43233394:+
THCA	cis	rs11148252	0.74	rs7983971	ENSG00000235660.1	LINC00345	-6	3.96e-09	7.72e-07	-0.35	-0.27	Lewy body disease;	chr13:52216565	chr13:52484161~52484680:-
THCA	cis	rs3782123	1	rs3782123	ENSG00000277290.1	RP11-326C3.16	6	3.96e-09	7.72e-07	0.27	0.27	Red cell distribution width;Glycated hemoglobin levels;	chr11:205198	chr11:243099~243483:-
THCA	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	6	3.96e-09	7.72e-07	0.31	0.27	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	6	3.96e-09	7.72e-07	0.31	0.27	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	6	3.96e-09	7.72e-07	0.31	0.27	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
THCA	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	6	3.96e-09	7.73e-07	0.28	0.27	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
THCA	cis	rs5758511	0.689	rs17002947	ENSG00000281538.1	RP4-669P10.20	6	3.97e-09	7.73e-07	0.31	0.27	Birth weight;	chr22:42292526	chr22:42138060~42139726:+
THCA	cis	rs9307551	0.817	rs1975399	ENSG00000250334.4	LINC00989	-6	3.97e-09	7.74e-07	-0.31	-0.27	Refractive error;	chr4:79582612	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.779	rs1440854	ENSG00000250334.4	LINC00989	-6	3.97e-09	7.74e-07	-0.31	-0.27	Refractive error;	chr4:79585580	chr4:79492416~79576460:+
THCA	cis	rs9880211	0.948	rs17298525	ENSG00000273486.1	RP11-731C17.2	6	3.97e-09	7.74e-07	0.28	0.27	Height;Body mass index;	chr3:136474183	chr3:136837338~136839021:-
THCA	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-6	3.97e-09	7.75e-07	-0.21	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
THCA	cis	rs9880211	0.948	rs9857966	ENSG00000273486.1	RP11-731C17.2	6	3.98e-09	7.76e-07	0.28	0.27	Height;Body mass index;	chr3:136560548	chr3:136837338~136839021:-
THCA	cis	rs7246657	0.639	rs12459015	ENSG00000267422.1	CTD-2554C21.1	-6	3.98e-09	7.76e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37592288	chr19:37779686~37792865:+
THCA	cis	rs2880765	0.527	rs35184622	ENSG00000259295.5	CSPG4P12	6	3.98e-09	7.76e-07	0.4	0.27	Coronary artery disease;	chr15:85529804	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.527	rs1483578	ENSG00000259295.5	CSPG4P12	6	3.98e-09	7.76e-07	0.4	0.27	Coronary artery disease;	chr15:85532186	chr15:85191438~85213905:+
THCA	cis	rs2562456	0.837	rs62110205	ENSG00000268081.1	RP11-678G14.2	6	3.98e-09	7.76e-07	0.39	0.27	Pain;	chr19:21577269	chr19:21554640~21569237:-
THCA	cis	rs964184	0.63	rs6589566	ENSG00000254851.1	RP11-109L13.1	-6	3.99e-09	7.77e-07	-0.54	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116781707	chr11:117135528~117138582:+
THCA	cis	rs914615	0.552	rs11264339	ENSG00000225855.5	RUSC1-AS1	-6	3.99e-09	7.77e-07	-0.17	-0.27	Urinary albumin-to-creatinine ratio;	chr1:155168172	chr1:155316863~155324176:-
THCA	cis	rs2439831	1	rs527921	ENSG00000249839.1	AC011330.5	6	3.99e-09	7.78e-07	0.4	0.27	Lung cancer in ever smokers;	chr15:43478218	chr15:43663654~43684339:-
THCA	cis	rs2136613	0.533	rs7088601	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62846627	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs7089121	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62846850	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10740087	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62847511	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs7093716	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62847717	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs7097383	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62848279	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10740088	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62849651	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10740089	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62849674	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10761668	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62849983	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10740090	ENSG00000238280.1	RP11-436D10.3	-6	3.99e-09	7.78e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62850027	chr10:62793562~62805887:-
THCA	cis	rs2348418	0.832	rs1552760	ENSG00000247934.4	RP11-967K21.1	6	3.99e-09	7.79e-07	0.23	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28383884	chr12:28163298~28190738:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000220721.1	OR1F12	6	4e-09	7.79e-07	0.35	0.27	Parkinson's disease;	chr6:28062721	chr6:28073316~28074233:+
THCA	cis	rs712039	0.652	rs736424	ENSG00000276054.1	RP11-378E13.3	6	4e-09	7.8e-07	0.4	0.27	Tuberculosis;	chr17:37429263	chr17:37386886~37387926:+
THCA	cis	rs9307551	0.817	rs12511646	ENSG00000250334.4	LINC00989	-6	4e-09	7.8e-07	-0.31	-0.27	Refractive error;	chr4:79578700	chr4:79492416~79576460:+
THCA	cis	rs2303319	0.582	rs62188151	ENSG00000227403.1	AC009299.3	6	4e-09	7.8e-07	0.57	0.27	Cognitive function;	chr2:161453338	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188153	ENSG00000227403.1	AC009299.3	6	4e-09	7.8e-07	0.57	0.27	Cognitive function;	chr2:161456525	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs79046651	ENSG00000227403.1	AC009299.3	6	4e-09	7.8e-07	0.57	0.27	Cognitive function;	chr2:161469906	chr2:161244739~161249050:+
THCA	cis	rs4950322	0.57	rs17356492	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147296089	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72691093	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147297977	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs76236344	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147297989	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72691095	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147298305	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72691097	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147299711	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72691098	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147300142	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72691102	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147301189	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692904	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147301437	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692905	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147301560	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692907	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147301921	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692914	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147302946	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692917	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147304389	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692920	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147308501	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs66580541	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147308828	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs945742	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147313437	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.543	rs4950318	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147316240	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.543	rs4950319	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147316250	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.543	rs4453096	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147316574	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.571	rs4373796	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147316747	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.543	rs4568882	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147316885	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.543	rs2883323	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147316995	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.543	rs2883324	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147317157	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.542	rs72692942	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147318467	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs4950399	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147319302	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs4950403	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147319723	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.517	rs116479391	ENSG00000278811.3	LINC00624	6	4e-09	7.81e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147320940	chr1:147258885~147517875:-
THCA	cis	rs16846053	0.792	rs62189015	ENSG00000227403.1	AC009299.3	6	4.01e-09	7.81e-07	0.58	0.27	Blood osmolality (transformed sodium);	chr2:161726994	chr2:161244739~161249050:+
THCA	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	6	4.01e-09	7.81e-07	0.2	0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
THCA	cis	rs228614	0.51	rs65671	ENSG00000230069.3	LRRC37A15P	-6	4.01e-09	7.81e-07	-0.28	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102727274~102730721:-
THCA	cis	rs2136613	0.533	rs10761665	ENSG00000238280.1	RP11-436D10.3	-6	4.01e-09	7.82e-07	-0.31	-0.27	Selective IgA deficiency;	chr10:62848538	chr10:62793562~62805887:-
THCA	cis	rs10129255	0.872	rs1858683	ENSG00000211974.3	IGHV2-70	6	4.01e-09	7.82e-07	0.21	0.27	Kawasaki disease;	chr14:106670217	chr14:106723574~106724093:-
THCA	cis	rs2303319	0.504	rs72877969	ENSG00000227403.1	AC009299.3	6	4.02e-09	7.83e-07	0.57	0.27	Cognitive function;	chr2:161434668	chr2:161244739~161249050:+
THCA	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-6	4.02e-09	7.83e-07	-0.25	-0.27	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-6	4.02e-09	7.83e-07	-0.25	-0.27	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
THCA	cis	rs1125355	0.893	rs114932236	ENSG00000251491.2	OR7E28P	-6	4.02e-09	7.84e-07	-0.43	-0.27	Alzheimer's disease in APOE e4+ carriers;	chr2:158827375	chr2:158862311~158863285:+
THCA	cis	rs2117029	0.782	rs10459232	ENSG00000258017.1	RP11-386G11.10	-6	4.02e-09	7.84e-07	-0.34	-0.27	Intelligence (multi-trait analysis);	chr12:49073293	chr12:49127782~49147869:+
THCA	cis	rs7829975	0.627	rs876954	ENSG00000254153.1	CTA-398F10.2	-6	4.02e-09	7.84e-07	-0.3	-0.27	Mood instability;	chr8:8453413	chr8:8456909~8461337:-
THCA	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	6	4.03e-09	7.84e-07	0.31	0.27	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
THCA	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-6	4.03e-09	7.85e-07	-0.41	-0.27	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
THCA	cis	rs4664293	0.647	rs918969	ENSG00000226266.5	AC009961.3	6	4.03e-09	7.85e-07	0.3	0.27	Monocyte percentage of white cells;	chr2:159610145	chr2:159670708~159712435:-
THCA	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	6	4.03e-09	7.85e-07	0.49	0.27	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	6	4.03e-09	7.85e-07	0.49	0.27	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	6	4.03e-09	7.85e-07	0.49	0.27	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
THCA	cis	rs934734	0.967	rs17534670	ENSG00000234255.7	AC012370.3	-6	4.03e-09	7.85e-07	-0.3	-0.27	Rheumatoid arthritis;	chr2:65388294	chr2:65439888~65456571:-
THCA	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	6	4.03e-09	7.85e-07	0.2	0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
THCA	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-6	4.03e-09	7.85e-07	-0.36	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
THCA	cis	rs71520386	0.632	rs10269414	ENSG00000228649.7	AC005682.5	-6	4.03e-09	7.86e-07	-0.34	-0.27	Fibrinogen levels;	chr7:22816674	chr7:22854178~22861579:+
THCA	cis	rs71520386	0.632	rs2286500	ENSG00000228649.7	AC005682.5	-6	4.03e-09	7.86e-07	-0.34	-0.27	Fibrinogen levels;	chr7:22817185	chr7:22854178~22861579:+
THCA	cis	rs793571	0.554	rs2414608	ENSG00000259250.1	RP11-50C13.1	-6	4.03e-09	7.86e-07	-0.29	-0.27	Schizophrenia;	chr15:58731413	chr15:58587507~58591676:+
THCA	cis	rs12681963	0.688	rs73242322	ENSG00000248159.1	HSPA8P11	6	4.04e-09	7.86e-07	0.47	0.27	Migraine;	chr8:30177573	chr8:30237382~30240997:+
THCA	cis	rs7005380	0.58	rs10110216	ENSG00000245330.4	KB-1471A8.1	6	4.04e-09	7.87e-07	0.26	0.27	Interstitial lung disease;	chr8:119875307	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.58	rs10110223	ENSG00000245330.4	KB-1471A8.1	6	4.04e-09	7.87e-07	0.26	0.27	Interstitial lung disease;	chr8:119875326	chr8:119867419~119874488:-
THCA	cis	rs10129255	0.912	rs8009135	ENSG00000211974.3	IGHV2-70	6	4.04e-09	7.87e-07	0.21	0.27	Kawasaki disease;	chr14:106777528	chr14:106723574~106724093:-
THCA	cis	rs73607972	0.877	rs67786703	ENSG00000275191.1	RP11-36I17.2	-6	4.04e-09	7.87e-07	-0.39	-0.27	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572427	chr16:53628256~53628816:-
THCA	cis	rs4689592	0.503	rs59640165	ENSG00000245468.3	RP11-367J11.3	-6	4.04e-09	7.88e-07	-0.25	-0.27	Monocyte percentage of white cells;	chr4:7049934	chr4:7094571~7103385:-
THCA	cis	rs11089937	0.597	rs5757024	ENSG00000211639.2	IGLV4-60	6	4.04e-09	7.88e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs5757026	ENSG00000211639.2	IGLV4-60	6	4.04e-09	7.88e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs5750582	ENSG00000211639.2	IGLV4-60	6	4.04e-09	7.88e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.626	rs5757028	ENSG00000211639.2	IGLV4-60	6	4.04e-09	7.88e-07	0.19	0.27	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22162199~22162681:+
THCA	cis	rs6600671	1	rs12145080	ENSG00000275538.1	RNVU1-19	-6	4.05e-09	7.89e-07	-0.33	-0.27	Hip geometry;	chr1:121443673	chr1:120850819~120850985:-
THCA	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	6	4.05e-09	7.9e-07	0.38	0.27	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
THCA	cis	rs2018683	0.707	rs4722875	ENSG00000228421.2	AC005013.5	6	4.05e-09	7.9e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930015	chr7:28957667~28959345:+
THCA	cis	rs10129255	0.957	rs12590735	ENSG00000211974.3	IGHV2-70	6	4.05e-09	7.9e-07	0.21	0.27	Kawasaki disease;	chr14:106779660	chr14:106723574~106724093:-
THCA	cis	rs2255336	0.938	rs4548707	ENSG00000245648.1	RP11-277P12.20	-6	4.05e-09	7.9e-07	-0.33	-0.27	Blood protein levels;	chr12:10467634	chr12:10363769~10398506:+
THCA	cis	rs34119086	1	rs34119086	ENSG00000226314.6	ZNF192P1	-6	4.05e-09	7.9e-07	-0.59	-0.27	Breast cancer;	chr6:28594471	chr6:28161781~28169594:+
THCA	cis	rs763121	0.925	rs1056661	ENSG00000235209.1	CTA-150C2.13	6	4.06e-09	7.9e-07	0.34	0.27	Menopause (age at onset);	chr22:38684240	chr22:38921227~38924708:+
THCA	cis	rs17772222	0.917	rs61986669	ENSG00000222990.1	RNU4-22P	6	4.06e-09	7.9e-07	0.35	0.27	Coronary artery calcification;	chr14:88727121	chr14:88513498~88513663:+
THCA	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-5.99	4.06e-09	7.91e-07	-0.34	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
THCA	cis	rs6142102	0.812	rs6059578	ENSG00000275784.1	RP5-1125A11.6	-5.99	4.06e-09	7.91e-07	-0.27	-0.27	Skin pigmentation;	chr20:33939900	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.886	rs6059583	ENSG00000275784.1	RP5-1125A11.6	-5.99	4.06e-09	7.91e-07	-0.27	-0.27	Skin pigmentation;	chr20:33944308	chr20:33989480~33991818:-
THCA	cis	rs228614	0.536	rs223475	ENSG00000230069.3	LRRC37A15P	-5.99	4.06e-09	7.91e-07	-0.28	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102727274~102730721:-
THCA	cis	rs228614	0.536	rs223474	ENSG00000230069.3	LRRC37A15P	-5.99	4.06e-09	7.91e-07	-0.28	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102727274~102730721:-
THCA	cis	rs1865760	0.927	rs6915834	ENSG00000272462.2	U91328.19	-5.99	4.07e-09	7.92e-07	-0.22	-0.27	Height;	chr6:25935199	chr6:25992662~26001775:+
THCA	cis	rs9287719	0.625	rs7567304	ENSG00000234818.1	AC092687.5	-5.99	4.07e-09	7.93e-07	-0.32	-0.27	Prostate cancer;	chr2:10649903	chr2:10589166~10604830:+
THCA	cis	rs935334	0.877	rs2197480	ENSG00000258454.1	RP11-361H10.3	5.99	4.07e-09	7.93e-07	0.37	0.27	Blood pressure;	chr14:76159099	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs8005686	ENSG00000258454.1	RP11-361H10.3	5.99	4.07e-09	7.93e-07	0.37	0.27	Blood pressure;	chr14:76167624	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs12437310	ENSG00000258454.1	RP11-361H10.3	5.99	4.07e-09	7.93e-07	0.37	0.27	Blood pressure;	chr14:76176414	chr14:76235817~76263474:+
THCA	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-5.99	4.07e-09	7.93e-07	-0.46	-0.27	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
THCA	cis	rs2018683	0.683	rs12538606	ENSG00000228421.2	AC005013.5	5.99	4.07e-09	7.93e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929791	chr7:28957667~28959345:+
THCA	cis	rs10971721	0.822	rs10971739	ENSG00000260947.1	RP11-384P7.7	5.99	4.07e-09	7.93e-07	0.62	0.27	Body mass index;	chr9:33855467	chr9:33697459~33700986:+
THCA	cis	rs2834188	0.669	rs1467845	ENSG00000272659.1	AP000295.10	-5.99	4.08e-09	7.94e-07	-0.36	-0.27	Narcolepsy;	chr21:33294071	chr21:33309491~33310181:+
THCA	cis	rs4950322	0.58	rs17355419	ENSG00000278811.3	LINC00624	5.99	4.08e-09	7.94e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147110094	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.58	rs72706428	ENSG00000278811.3	LINC00624	5.99	4.08e-09	7.94e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147110219	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.563	rs61838944	ENSG00000278811.3	LINC00624	5.99	4.08e-09	7.94e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147110275	chr1:147258885~147517875:-
THCA	cis	rs6860806	0.507	rs272880	ENSG00000263597.1	MIR3936	5.99	4.08e-09	7.94e-07	0.27	0.27	Breast cancer;	chr5:132334485	chr5:132365490~132365599:-
THCA	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-5.99	4.08e-09	7.94e-07	-0.44	-0.27	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
THCA	cis	rs9878978	0.722	rs62233832	ENSG00000237990.3	CNTN4-AS1	5.99	4.08e-09	7.95e-07	0.32	0.27	Blood pressure (smoking interaction);	chr3:2470415	chr3:3039033~3069242:-
THCA	cis	rs7225151	0.71	rs16954548	ENSG00000234327.6	AC012146.7	-5.99	4.08e-09	7.95e-07	-0.29	-0.27	Alzheimer's disease (late onset);	chr17:5348376	chr17:5111468~5115004:+
THCA	cis	rs6142102	0.847	rs4911413	ENSG00000275784.1	RP5-1125A11.6	-5.99	4.08e-09	7.95e-07	-0.27	-0.27	Skin pigmentation;	chr20:34133969	chr20:33989480~33991818:-
THCA	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	5.99	4.08e-09	7.95e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
THCA	cis	rs7809950	1	rs12667527	ENSG00000238832.1	snoU109	-5.99	4.08e-09	7.95e-07	-0.28	-0.27	Coronary artery disease;	chr7:107446524	chr7:107603363~107603507:+
THCA	cis	rs6545883	0.86	rs6749226	ENSG00000271889.1	RP11-493E12.1	-5.99	4.08e-09	7.95e-07	-0.26	-0.27	Tuberculosis;	chr2:61282648	chr2:61151433~61162105:-
THCA	cis	rs2841277	0.836	rs2841268	ENSG00000258701.1	LINC00638	-5.99	4.09e-09	7.96e-07	-0.27	-0.27	Rheumatoid arthritis;	chr14:104919702	chr14:104821201~104823718:+
THCA	cis	rs831571	0.703	rs831566	ENSG00000280620.1	SCAANT1	-5.99	4.09e-09	7.96e-07	-0.4	-0.27	Type 2 diabetes;	chr3:64090262	chr3:63911518~63911772:-
THCA	cis	rs17301013	0.507	rs926349	ENSG00000227373.4	RP11-160H22.5	5.99	4.09e-09	7.96e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174368408	chr1:174115300~174160004:-
THCA	cis	rs7829975	0.711	rs1039916	ENSG00000254153.1	CTA-398F10.2	-5.99	4.1e-09	7.97e-07	-0.29	-0.27	Mood instability;	chr8:8828344	chr8:8456909~8461337:-
THCA	cis	rs2361718	0.501	rs8065486	ENSG00000279259.1	RP11-334C17.3	-5.99	4.1e-09	7.97e-07	-0.26	-0.27	Yeast infection;	chr17:80164397	chr17:80147250~80148596:+
THCA	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-5.99	4.1e-09	7.97e-07	-0.27	-0.27	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
THCA	cis	rs838147	0.534	rs676388	ENSG00000232871.7	SEC1P	5.99	4.1e-09	7.99e-07	0.32	0.27	Dietary macronutrient intake;	chr19:48708712	chr19:48638071~48682245:+
THCA	cis	rs935334	1	rs1900120	ENSG00000258454.1	RP11-361H10.3	5.99	4.1e-09	7.99e-07	0.37	0.27	Blood pressure;	chr14:76160173	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs2543384	ENSG00000258454.1	RP11-361H10.3	5.99	4.1e-09	7.99e-07	0.37	0.27	Blood pressure;	chr14:76160958	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs1900122	ENSG00000258454.1	RP11-361H10.3	5.99	4.1e-09	7.99e-07	0.37	0.27	Blood pressure;	chr14:76163174	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs2591092	ENSG00000258454.1	RP11-361H10.3	5.99	4.1e-09	7.99e-07	0.37	0.27	Blood pressure;	chr14:76163790	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs2591094	ENSG00000258454.1	RP11-361H10.3	5.99	4.1e-09	7.99e-07	0.37	0.27	Blood pressure;	chr14:76165992	chr14:76235817~76263474:+
THCA	cis	rs71520386	0.632	rs10279864	ENSG00000228649.7	AC005682.5	-5.99	4.11e-09	7.99e-07	-0.34	-0.27	Fibrinogen levels;	chr7:22824205	chr7:22854178~22861579:+
THCA	cis	rs853679	0.607	rs34243448	ENSG00000219392.1	RP1-265C24.5	-5.99	4.11e-09	7.99e-07	-0.59	-0.27	Depression;	chr6:28225324	chr6:28115628~28116551:+
THCA	cis	rs9921338	0.924	rs7204628	ENSG00000262703.1	RP11-485G7.6	-5.99	4.11e-09	7.99e-07	-0.35	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350715	chr16:11348143~11349321:-
THCA	cis	rs9813712	0.818	rs11718381	ENSG00000249846.5	RP11-77P16.4	5.99	4.11e-09	8e-07	0.32	0.27	Response to amphetamines;	chr3:130222660	chr3:130112550~130120579:+
THCA	cis	rs17158807	0.543	rs56026818	ENSG00000274128.1	RP11-342A23.2	5.99	4.11e-09	8e-07	0.43	0.27	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr15:83555604	chr15:83962176~83962583:+
THCA	cis	rs228614	0.51	rs223412	ENSG00000230069.3	LRRC37A15P	-5.99	4.11e-09	8e-07	-0.28	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102727274~102730721:-
THCA	cis	rs720475	0.732	rs62483107	ENSG00000204959.4	ARHGEF34P	-5.99	4.11e-09	8.01e-07	-0.31	-0.27	Breast cancer;	chr7:144442144	chr7:144272445~144286966:-
THCA	cis	rs12681366	0.708	rs2450554	ENSG00000253704.1	RP11-267M23.4	5.99	4.12e-09	8.01e-07	0.25	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94331552	chr8:94553722~94569745:+
THCA	cis	rs228614	0.51	rs223353	ENSG00000251288.2	RP11-10L12.2	-5.99	4.12e-09	8.01e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102751401~102752641:+
THCA	cis	rs228614	0.51	rs223352	ENSG00000251288.2	RP11-10L12.2	-5.99	4.12e-09	8.01e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102751401~102752641:+
THCA	cis	rs1859596	0.966	rs2269992	ENSG00000234456.6	MAGI2-AS3	5.99	4.12e-09	8.02e-07	0.26	0.27	Reading or mathematical ability;	chr7:79461284	chr7:79452877~79471208:+
THCA	cis	rs934734	0.544	rs4671127	ENSG00000234255.7	AC012370.3	5.99	4.12e-09	8.02e-07	0.32	0.27	Rheumatoid arthritis;	chr2:65335836	chr2:65439888~65456571:-
THCA	cis	rs180730	0.752	rs3115316	ENSG00000251609.2	SETP12	-5.99	4.12e-09	8.02e-07	-0.52	-0.27	Fasting plasma glucose;	chr4:120891306	chr4:120895494~120897083:-
THCA	cis	rs180730	0.752	rs343167	ENSG00000251609.2	SETP12	-5.99	4.12e-09	8.02e-07	-0.52	-0.27	Fasting plasma glucose;	chr4:120897351	chr4:120895494~120897083:-
THCA	cis	rs6908034	0.607	rs73376657	ENSG00000227116.1	RP3-471C18.1	-5.99	4.13e-09	8.03e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805729	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs74573060	ENSG00000227116.1	RP3-471C18.1	-5.99	4.13e-09	8.03e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805801	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs113894708	ENSG00000227116.1	RP3-471C18.1	-5.99	4.13e-09	8.03e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805835	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs62404179	ENSG00000227116.1	RP3-471C18.1	-5.99	4.13e-09	8.03e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806041	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.546	rs73376662	ENSG00000227116.1	RP3-471C18.1	-5.99	4.13e-09	8.03e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806109	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs12529148	ENSG00000227116.1	RP3-471C18.1	-5.99	4.13e-09	8.03e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806566	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs112659166	ENSG00000227116.1	RP3-471C18.1	-5.99	4.13e-09	8.03e-07	-0.48	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807178	chr6:19730427~19734567:-
THCA	cis	rs79040073	0.53	rs73396206	ENSG00000259531.2	RP11-295H24.3	5.99	4.13e-09	8.03e-07	0.36	0.27	Lung cancer in ever smokers;	chr15:49323632	chr15:49365124~49366685:-
THCA	cis	rs2029362	0.611	rs10219241	ENSG00000245573.6	BDNF-AS	-5.99	4.13e-09	8.03e-07	-0.21	-0.27	Total body bone mineral density;	chr11:27715576	chr11:27506838~27698174:+
THCA	cis	rs3760982	1	rs3760983	ENSG00000267058.1	RP11-15A1.3	5.99	4.13e-09	8.04e-07	0.23	0.27	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782508	chr19:43891804~43901805:-
THCA	cis	rs6600671	1	rs10794671	ENSG00000275538.1	RNVU1-19	5.99	4.13e-09	8.04e-07	0.34	0.27	Hip geometry;	chr1:121426382	chr1:120850819~120850985:-
THCA	cis	rs1552244	0.882	rs13100734	ENSG00000232901.1	CYCSP10	5.99	4.14e-09	8.05e-07	0.34	0.27	Alzheimer's disease;	chr3:9981194	chr3:10000647~10000940:-
THCA	cis	rs1865760	0.566	rs9467663	ENSG00000272462.2	U91328.19	-5.99	4.14e-09	8.05e-07	-0.22	-0.27	Height;	chr6:26021228	chr6:25992662~26001775:+
THCA	cis	rs7809950	1	rs2520265	ENSG00000238832.1	snoU109	-5.99	4.14e-09	8.05e-07	-0.28	-0.27	Coronary artery disease;	chr7:107540786	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs2712191	ENSG00000238832.1	snoU109	-5.99	4.14e-09	8.05e-07	-0.28	-0.27	Coronary artery disease;	chr7:107542279	chr7:107603363~107603507:+
THCA	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-5.99	4.14e-09	8.05e-07	-0.2	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
THCA	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-5.99	4.14e-09	8.05e-07	-0.2	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
THCA	cis	rs3020264	0.638	rs2980655	ENSG00000271743.1	CTD-2541M15.3	-5.99	4.14e-09	8.06e-07	-0.34	-0.27	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6634870	chr8:6615604~6617198:-
THCA	cis	rs6928977	0.86	rs2757649	ENSG00000231028.7	LINC00271	-5.99	4.14e-09	8.06e-07	-0.22	-0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135405475	chr6:135497801~135716055:+
THCA	cis	rs9677476	0.779	rs60596955	ENSG00000224376.1	AC017104.6	5.99	4.15e-09	8.07e-07	0.31	0.27	Food antigen IgG levels;	chr2:231273528	chr2:231388976~231394991:+
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	5.99	4.16e-09	8.09e-07	0.3	0.27	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
THCA	cis	rs2562456	0.652	rs4809145	ENSG00000213976.4	CTD-2561J22.2	-5.99	4.16e-09	8.09e-07	-0.31	-0.27	Pain;	chr19:21597907	chr19:21382865~21387177:+
THCA	cis	rs950173	1	rs13000153	ENSG00000228389.1	AC068039.4	5.99	4.16e-09	8.09e-07	0.46	0.27	Hippocampal volume;	chr2:171729557	chr2:171773482~171775844:+
THCA	cis	rs17772222	0.917	rs61982733	ENSG00000222990.1	RNU4-22P	5.99	4.16e-09	8.09e-07	0.34	0.27	Coronary artery calcification;	chr14:88776244	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs2145120	ENSG00000222990.1	RNU4-22P	5.99	4.16e-09	8.09e-07	0.34	0.27	Coronary artery calcification;	chr14:88777699	chr14:88513498~88513663:+
THCA	cis	rs748404	0.626	rs62019432	ENSG00000249839.1	AC011330.5	-5.99	4.16e-09	8.09e-07	-0.38	-0.27	Lung cancer;	chr15:43316482	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs7181545	ENSG00000249839.1	AC011330.5	-5.99	4.16e-09	8.09e-07	-0.38	-0.27	Lung cancer;	chr15:43321363	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs17723479	ENSG00000249839.1	AC011330.5	-5.99	4.16e-09	8.09e-07	-0.38	-0.27	Lung cancer;	chr15:43322114	chr15:43663654~43684339:-
THCA	cis	rs77972916	0.505	rs34247383	ENSG00000234936.1	AC010883.5	5.99	4.16e-09	8.1e-07	0.3	0.27	Granulocyte percentage of myeloid white cells;	chr2:43305641	chr2:43229573~43233394:+
THCA	cis	rs1707322	0.752	rs12062535	ENSG00000281133.1	AL355480.3	-5.99	4.17e-09	8.1e-07	-0.33	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45580892~45580996:-
THCA	cis	rs62292953	1	rs10512861	ENSG00000248724.5	NPHP3-AS1	-5.99	4.17e-09	8.1e-07	-0.41	-0.27	Red cell distribution width;	chr3:132539117	chr3:132721750~132874223:+
THCA	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-5.99	4.17e-09	8.11e-07	-0.27	-0.27	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs1055857	ENSG00000275784.1	RP5-1125A11.6	-5.99	4.17e-09	8.11e-07	-0.27	-0.27	Skin pigmentation;	chr20:34026067	chr20:33989480~33991818:-
THCA	cis	rs1993293	0.636	rs2924776	ENSG00000259363.4	CTD-2054N24.2	5.99	4.17e-09	8.11e-07	0.35	0.27	Coronary artery calcification;	chr15:99755973	chr15:99807023~99877148:+
THCA	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	5.99	4.17e-09	8.11e-07	0.29	0.27	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	5.99	4.17e-09	8.11e-07	0.29	0.27	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	5.99	4.17e-09	8.11e-07	0.29	0.27	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	5.99	4.17e-09	8.11e-07	0.29	0.27	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	5.99	4.17e-09	8.11e-07	0.29	0.27	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	5.99	4.17e-09	8.11e-07	0.29	0.27	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	5.99	4.17e-09	8.11e-07	0.29	0.27	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	5.99	4.17e-09	8.11e-07	0.29	0.27	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
THCA	cis	rs2120243	0.647	rs60676003	ENSG00000244515.1	KRT18P34	-5.99	4.18e-09	8.12e-07	-0.3	-0.27	Hepatocellular carcinoma in hepatitis B infection;	chr3:157430150	chr3:157162663~157163932:-
THCA	cis	rs7688540	0.8	rs7694325	ENSG00000275426.1	CH17-262A2.1	5.99	4.18e-09	8.13e-07	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:149738~150317:+
THCA	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	5.99	4.18e-09	8.13e-07	0.34	0.27	Height;	chr4:55409063	chr4:55363971~55395847:-
THCA	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	5.99	4.18e-09	8.13e-07	0.38	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
THCA	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	5.99	4.18e-09	8.13e-07	0.38	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
THCA	cis	rs2299587	0.585	rs394343	ENSG00000253671.1	RP11-806O11.1	-5.99	4.19e-09	8.14e-07	-0.33	-0.27	Economic and political preferences;	chr8:17915657	chr8:17808941~17820868:+
THCA	cis	rs712039	0.652	rs34711199	ENSG00000276054.1	RP11-378E13.3	5.99	4.19e-09	8.14e-07	0.41	0.27	Tuberculosis;	chr17:37497933	chr17:37386886~37387926:+
THCA	cis	rs11976180	1	rs2961132	ENSG00000273234.1	OR2A13P	-5.99	4.19e-09	8.14e-07	-0.3	-0.27	Obesity-related traits;	chr7:144071035	chr7:144142009~144142938:+
THCA	cis	rs10829156	0.57	rs7904365	ENSG00000240291.1	RP11-499P20.2	5.99	4.19e-09	8.15e-07	0.22	0.27	Sudden cardiac arrest;	chr10:18542375	chr10:18513115~18545651:-
THCA	cis	rs1275468	0.731	rs1630753	ENSG00000257497.2	RP11-585P4.5	-5.99	4.2e-09	8.16e-07	-0.41	-0.27	Polycystic ovary syndrome;	chr12:75569518	chr12:75483454~75489820:-
THCA	cis	rs713477	0.845	rs4898863	ENSG00000258413.1	RP11-665C16.6	5.99	4.2e-09	8.16e-07	0.35	0.27	Pediatric bone mineral content (femoral neck);	chr14:55443566	chr14:55262767~55272075:-
THCA	cis	rs17772222	0.682	rs8017689	ENSG00000258983.2	RP11-507K2.2	5.99	4.2e-09	8.17e-07	0.31	0.27	Coronary artery calcification;	chr14:88483442	chr14:88499334~88515502:+
THCA	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	5.99	4.2e-09	8.17e-07	0.38	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
THCA	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	5.99	4.2e-09	8.17e-07	0.38	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
THCA	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-5.99	4.2e-09	8.17e-07	-0.16	-0.27	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
THCA	cis	rs9341808	0.621	rs2322627	ENSG00000272129.1	RP11-250B2.6	5.99	4.21e-09	8.17e-07	0.34	0.27	Sitting height ratio;	chr6:80096624	chr6:80355424~80356859:+
THCA	cis	rs10129255	0.785	rs10150044	ENSG00000211974.3	IGHV2-70	5.99	4.21e-09	8.18e-07	0.2	0.27	Kawasaki disease;	chr14:106775695	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs10137980	ENSG00000211974.3	IGHV2-70	5.99	4.21e-09	8.18e-07	0.2	0.27	Kawasaki disease;	chr14:106775735	chr14:106723574~106724093:-
THCA	cis	rs792448	0.66	rs12035647	ENSG00000226251.4	RP11-15I11.3	-5.99	4.21e-09	8.18e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212313969	chr1:212225278~212238977:-
THCA	cis	rs792448	0.743	rs7519959	ENSG00000226251.4	RP11-15I11.3	-5.99	4.21e-09	8.18e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212325310	chr1:212225278~212238977:-
THCA	cis	rs792448	0.743	rs4951589	ENSG00000226251.4	RP11-15I11.3	-5.99	4.21e-09	8.18e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212327351	chr1:212225278~212238977:-
THCA	cis	rs792448	0.798	rs7521853	ENSG00000226251.4	RP11-15I11.3	-5.99	4.21e-09	8.18e-07	-0.33	-0.27	White blood cell count (basophil);	chr1:212330862	chr1:212225278~212238977:-
THCA	cis	rs6968419	0.674	rs4730723	ENSG00000237870.5	AC073130.1	5.99	4.21e-09	8.18e-07	0.29	0.27	Intraocular pressure;	chr7:116263998	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.674	rs4730724	ENSG00000237870.5	AC073130.1	5.99	4.21e-09	8.18e-07	0.29	0.27	Intraocular pressure;	chr7:116265285	chr7:116275606~116286734:-
THCA	cis	rs2115536	0.73	rs12898642	ENSG00000278600.1	RP11-81A1.6	-5.99	4.21e-09	8.18e-07	-0.17	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79889708	chr15:79920195~79922455:-
THCA	cis	rs4713118	0.662	rs4713120	ENSG00000219392.1	RP1-265C24.5	-5.99	4.22e-09	8.19e-07	-0.3	-0.27	Parkinson's disease;	chr6:27754056	chr6:28115628~28116551:+
THCA	cis	rs13287066	0.692	rs2184255	ENSG00000227603.1	RP11-165J3.6	-5.99	4.22e-09	8.19e-07	-0.28	-0.27	Intelligence (multi-trait analysis);	chr9:93413921	chr9:93435332~93437121:-
THCA	cis	rs6026584	1	rs6026584	ENSG00000270951.1	RP1-309F20.4	5.99	4.22e-09	8.2e-07	0.28	0.27	Renal function-related traits (BUN);	chr20:58894018	chr20:58876592~58876981:-
THCA	cis	rs728616	1	rs728616	ENSG00000242600.5	MBL1P	5.99	4.23e-09	8.21e-07	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088158	chr10:79904898~79950336:+
THCA	cis	rs3758785	0.512	rs7950328	ENSG00000255893.1	RP11-685N10.1	-5.99	4.23e-09	8.21e-07	-0.32	-0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94366449	chr11:94472908~94473570:-
THCA	cis	rs17772222	0.511	rs3850392	ENSG00000258789.1	RP11-507K2.3	-5.99	4.23e-09	8.21e-07	-0.24	-0.27	Coronary artery calcification;	chr14:88833286	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.511	rs7155535	ENSG00000258789.1	RP11-507K2.3	-5.99	4.23e-09	8.21e-07	-0.24	-0.27	Coronary artery calcification;	chr14:88844002	chr14:88551597~88552493:+
THCA	cis	rs12908161	0.92	rs35758837	ENSG00000259295.5	CSPG4P12	5.99	4.23e-09	8.21e-07	0.41	0.27	Schizophrenia;	chr15:84768151	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs17600551	ENSG00000259295.5	CSPG4P12	5.99	4.23e-09	8.21e-07	0.41	0.27	Schizophrenia;	chr15:84776027	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs36033486	ENSG00000259295.5	CSPG4P12	5.99	4.23e-09	8.21e-07	0.41	0.27	Schizophrenia;	chr15:84776461	chr15:85191438~85213905:+
THCA	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	5.99	4.23e-09	8.22e-07	0.3	0.27	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
THCA	cis	rs9652601	0.959	rs741172	ENSG00000274038.1	RP11-66H6.4	-5.99	4.23e-09	8.22e-07	-0.36	-0.27	Systemic lupus erythematosus;	chr16:11106941	chr16:11056556~11057034:+
THCA	cis	rs9816784	0.525	rs555412	ENSG00000231464.1	AC024937.4	5.99	4.23e-09	8.22e-07	0.34	0.27	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195996738~195998233:+
THCA	cis	rs9816784	0.525	rs422772	ENSG00000231464.1	AC024937.4	5.99	4.23e-09	8.22e-07	0.34	0.27	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195996738~195998233:+
THCA	cis	rs2243480	0.803	rs423187	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	8.22e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66044512	chr7:66848496~66858136:+
THCA	cis	rs6496932	0.563	rs2344083	ENSG00000218052.5	ADAMTS7P4	-5.99	4.23e-09	8.22e-07	-0.34	-0.27	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85255369~85330334:-
THCA	cis	rs748404	0.666	rs12900259	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43427369	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs34921640	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43429187	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs62020574	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43429380	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs16957730	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43438288	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs12913977	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43438913	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs12914122	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43438956	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs34697113	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43442041	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs12907870	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43453971	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs72709850	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43462486	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs36078097	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43466209	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs7181783	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43469723	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs35903301	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43472332	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs34002293	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43472401	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs34181131	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43478527	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs7173383	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43480838	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs55801120	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43495042	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs12911740	ENSG00000249839.1	AC011330.5	-5.99	4.24e-09	8.23e-07	-0.38	-0.27	Lung cancer;	chr15:43498254	chr15:43663654~43684339:-
THCA	cis	rs17301013	0.507	rs6677243	ENSG00000227373.4	RP11-160H22.5	5.99	4.24e-09	8.23e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174339471	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912766	ENSG00000227373.4	RP11-160H22.5	5.99	4.24e-09	8.23e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174341129	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12059307	ENSG00000227373.4	RP11-160H22.5	5.99	4.24e-09	8.23e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174342105	chr1:174115300~174160004:-
THCA	cis	rs13256369	0.511	rs7012395	ENSG00000253893.2	FAM85B	5.99	4.24e-09	8.23e-07	0.35	0.27	Obesity-related traits;	chr8:8680499	chr8:8167819~8226614:-
THCA	cis	rs67478160	0.643	rs6575999	ENSG00000258735.1	LINC00637	-5.99	4.24e-09	8.23e-07	-0.32	-0.27	Schizophrenia;	chr14:103784272	chr14:103847721~103858049:+
THCA	cis	rs10899021	0.512	rs2186955	ENSG00000279353.1	RP11-864N7.4	-5.99	4.24e-09	8.23e-07	-0.4	-0.27	Response to metformin (IC50);	chr11:74664430	chr11:74698231~74699658:-
THCA	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	5.99	4.24e-09	8.23e-07	0.29	0.27	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
THCA	cis	rs6951245	0.744	rs10275401	ENSG00000229043.2	AC091729.9	-5.99	4.24e-09	8.24e-07	-0.43	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1160374~1165267:+
THCA	cis	rs1005277	0.54	rs7903942	ENSG00000263064.2	RP11-291L22.7	-5.99	4.24e-09	8.24e-07	-0.29	-0.27	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38448689~38448949:+
THCA	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-5.99	4.24e-09	8.24e-07	-0.26	-0.27	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
THCA	cis	rs713477	1	rs12893000	ENSG00000258413.1	RP11-665C16.6	5.99	4.25e-09	8.24e-07	0.36	0.27	Pediatric bone mineral content (femoral neck);	chr14:55445562	chr14:55262767~55272075:-
THCA	cis	rs253959	0.672	rs1133186	ENSG00000272265.1	CTD-2287O16.4	5.99	4.25e-09	8.25e-07	0.29	0.27	Bipolar disorder and schizophrenia;	chr5:116084718	chr5:116078110~116078570:-
THCA	cis	rs950169	0.58	rs17532346	ENSG00000259295.5	CSPG4P12	5.99	4.25e-09	8.26e-07	0.41	0.27	Schizophrenia;	chr15:84628264	chr15:85191438~85213905:+
THCA	cis	rs11976180	0.953	rs2951355	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144063469	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2951354	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144063908	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2951353	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144064023	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2961125	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144064677	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2961126	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144065643	chr7:144142009~144142938:+
THCA	cis	rs11976180	0.953	rs2961127	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144065644	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs1919948	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144065750	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2961128	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144066390	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2371247	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144067086	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2371248	ENSG00000273234.1	OR2A13P	-5.99	4.25e-09	8.26e-07	-0.3	-0.27	Obesity-related traits;	chr7:144067096	chr7:144142009~144142938:+
THCA	cis	rs797680	0.754	rs12044883	ENSG00000223745.6	RP4-717I23.3	5.99	4.25e-09	8.26e-07	0.16	0.27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93355018	chr1:93262186~93346025:-
THCA	cis	rs228614	0.51	rs65671	ENSG00000251288.2	RP11-10L12.2	-5.99	4.25e-09	8.26e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102751401~102752641:+
THCA	cis	rs6968419	0.674	rs1918911	ENSG00000237870.5	AC073130.1	5.99	4.26e-09	8.26e-07	0.3	0.27	Intraocular pressure;	chr7:116266694	chr7:116275606~116286734:-
THCA	cis	rs2018683	0.707	rs4719961	ENSG00000228421.2	AC005013.5	5.99	4.26e-09	8.26e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929896	chr7:28957667~28959345:+
THCA	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	5.99	4.26e-09	8.26e-07	0.38	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
THCA	cis	rs9921338	0.961	rs7199821	ENSG00000262703.1	RP11-485G7.6	-5.99	4.26e-09	8.27e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11331154	chr16:11348143~11349321:-
THCA	cis	rs7246657	0.722	rs3095726	ENSG00000267422.1	CTD-2554C21.1	5.99	4.26e-09	8.27e-07	0.31	0.27	Coronary artery calcification;	chr19:37738923	chr19:37779686~37792865:+
THCA	cis	rs5742933	0.857	rs7571089	ENSG00000253559.1	OSGEPL1-AS1	5.99	4.26e-09	8.27e-07	0.3	0.27	Ferritin levels;	chr2:189697067	chr2:189762704~189765556:+
THCA	cis	rs12681366	0.708	rs2515157	ENSG00000253704.1	RP11-267M23.4	-5.99	4.26e-09	8.27e-07	-0.25	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94366302	chr8:94553722~94569745:+
THCA	cis	rs7246657	0.722	rs2972430	ENSG00000267422.1	CTD-2554C21.1	5.99	4.26e-09	8.28e-07	0.31	0.27	Coronary artery calcification;	chr19:37691210	chr19:37779686~37792865:+
THCA	cis	rs9880211	1	rs9869630	ENSG00000273486.1	RP11-731C17.2	5.99	4.26e-09	8.28e-07	0.28	0.27	Height;Body mass index;	chr3:136529177	chr3:136837338~136839021:-
THCA	cis	rs934734	0.563	rs955903	ENSG00000234255.7	AC012370.3	5.99	4.27e-09	8.29e-07	0.32	0.27	Rheumatoid arthritis;	chr2:65348419	chr2:65439888~65456571:-
THCA	cis	rs1552244	0.882	rs56125067	ENSG00000180385.7	EMC3-AS1	5.99	4.27e-09	8.29e-07	0.29	0.27	Alzheimer's disease;	chr3:9942446	chr3:9986893~10006990:+
THCA	cis	rs9926296	0.687	rs258317	ENSG00000274627.1	RP11-104N10.2	5.99	4.27e-09	8.3e-07	0.28	0.27	Vitiligo;	chr16:89665830	chr16:89516797~89522217:+
THCA	cis	rs11671005	0.693	rs11668757	ENSG00000269473.1	CTD-2619J13.19	5.99	4.28e-09	8.3e-07	0.31	0.27	Mean platelet volume;	chr19:58416932	chr19:58440448~58445849:+
THCA	cis	rs1859596	0.966	rs4730881	ENSG00000234456.6	MAGI2-AS3	5.99	4.28e-09	8.3e-07	0.26	0.27	Reading or mathematical ability;	chr7:79482675	chr7:79452877~79471208:+
THCA	cis	rs62184315	0.536	rs56324258	ENSG00000273240.1	RP11-455J20.3	-5.99	4.28e-09	8.3e-07	-0.34	-0.27	Alcohol dependence (age at onset);	chr2:189811589	chr2:189763859~189764456:-
THCA	cis	rs17301013	0.507	rs12065454	ENSG00000227373.4	RP11-160H22.5	5.99	4.28e-09	8.3e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174492226	chr1:174115300~174160004:-
THCA	cis	rs227275	0.556	rs6842179	ENSG00000230069.3	LRRC37A15P	-5.99	4.28e-09	8.3e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102727274~102730721:-
THCA	cis	rs4713118	0.662	rs175954	ENSG00000272009.1	RP1-313I6.12	-5.99	4.28e-09	8.3e-07	-0.3	-0.27	Parkinson's disease;	chr6:28043807	chr6:28078792~28081130:-
THCA	cis	rs10761482	0.5	rs1938538	ENSG00000254271.1	RP11-131N11.4	5.99	4.28e-09	8.31e-07	0.34	0.27	Schizophrenia;	chr10:60538475	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.5	rs7080540	ENSG00000254271.1	RP11-131N11.4	5.99	4.28e-09	8.31e-07	0.34	0.27	Schizophrenia;	chr10:60538828	chr10:60734342~60741828:+
THCA	cis	rs832187	0.813	rs704370	ENSG00000280620.1	SCAANT1	-5.99	4.28e-09	8.31e-07	-0.36	-0.27	Schizophrenia;	chr3:63882574	chr3:63911518~63911772:-
THCA	cis	rs832187	0.813	rs704369	ENSG00000280620.1	SCAANT1	-5.99	4.28e-09	8.31e-07	-0.36	-0.27	Schizophrenia;	chr3:63882595	chr3:63911518~63911772:-
THCA	cis	rs832187	0.813	rs704368	ENSG00000280620.1	SCAANT1	-5.99	4.28e-09	8.31e-07	-0.36	-0.27	Schizophrenia;	chr3:63882661	chr3:63911518~63911772:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-5.99	4.29e-09	8.32e-07	-0.3	-0.27	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
THCA	cis	rs228614	0.51	rs223453	ENSG00000251288.2	RP11-10L12.2	-5.99	4.29e-09	8.32e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102751401~102752641:+
THCA	cis	rs10916248	0.511	rs10916515	ENSG00000232628.4	RP11-365O16.3	5.99	4.29e-09	8.32e-07	0.37	0.27	QT interval (drug interaction);	chr1:224222121	chr1:224208747~224213279:-
THCA	cis	rs897984	0.609	rs732173	ENSG00000279196.1	RP11-1072A3.3	5.99	4.29e-09	8.33e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31038702	chr16:30984630~30988270:-
THCA	cis	rs9843304	0.585	rs9837351	ENSG00000244503.1	RP11-278L15.6	-5.99	4.3e-09	8.34e-07	-0.33	-0.27	Gallstone disease;	chr3:149492312	chr3:149494660~149495995:+
THCA	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	5.98	4.3e-09	8.34e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
THCA	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-5.98	4.3e-09	8.34e-07	-0.25	-0.27	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-5.98	4.3e-09	8.34e-07	-0.25	-0.27	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
THCA	cis	rs516805	0.561	rs2684238	ENSG00000279453.1	RP3-425C14.4	-5.98	4.3e-09	8.34e-07	-0.29	-0.27	Lymphocyte counts;	chr6:122085799	chr6:122436789~122439223:-
THCA	cis	rs11266744	0.531	rs2734648	ENSG00000223552.1	RP11-24F11.2	5.98	4.3e-09	8.34e-07	0.24	0.27	Monocyte percentage of white cells;	chr3:46370349	chr3:46364955~46407059:-
THCA	cis	rs2303759	0.676	rs10426452	ENSG00000268686.1	AC010524.2	-5.98	4.3e-09	8.35e-07	-0.38	-0.27	Multiple sclerosis;	chr19:49404433	chr19:49368705~49388081:-
THCA	cis	rs7615952	0.512	rs1077621	ENSG00000250012.1	RP11-124N2.1	-5.98	4.3e-09	8.35e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126100956	chr3:126084220~126095349:+
THCA	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	5.98	4.31e-09	8.36e-07	0.35	0.27	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
THCA	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	5.98	4.31e-09	8.36e-07	0.27	0.27	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
THCA	cis	rs11158026	0.603	rs66820631	ENSG00000258413.1	RP11-665C16.6	-5.98	4.31e-09	8.36e-07	-0.38	-0.27	Parkinson's disease;	chr14:54998835	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.603	rs4335711	ENSG00000258413.1	RP11-665C16.6	-5.98	4.31e-09	8.36e-07	-0.38	-0.27	Parkinson's disease;	chr14:55004145	chr14:55262767~55272075:-
THCA	cis	rs6545883	0.929	rs3821222	ENSG00000271889.1	RP11-493E12.1	5.98	4.31e-09	8.36e-07	0.26	0.27	Tuberculosis;	chr2:61486391	chr2:61151433~61162105:-
THCA	cis	rs7246657	0.722	rs2927746	ENSG00000267422.1	CTD-2554C21.1	5.98	4.31e-09	8.36e-07	0.3	0.27	Coronary artery calcification;	chr19:37665669	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs2927747	ENSG00000267422.1	CTD-2554C21.1	5.98	4.31e-09	8.36e-07	0.3	0.27	Coronary artery calcification;	chr19:37668629	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs2909102	ENSG00000267422.1	CTD-2554C21.1	5.98	4.31e-09	8.36e-07	0.3	0.27	Coronary artery calcification;	chr19:37676463	chr19:37779686~37792865:+
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000237310.1	GS1-124K5.4	5.98	4.31e-09	8.37e-07	0.2	0.27	Calcium levels;	chr7:65751755	chr7:66493706~66495474:+
THCA	cis	rs7833787	1	rs7002237	ENSG00000278886.1	RP11-108A14.1	5.98	4.32e-09	8.37e-07	0.34	0.27	Obesity-related traits;	chr8:18847004	chr8:18864681~18865247:-
THCA	cis	rs9878978	0.722	rs62233819	ENSG00000237990.3	CNTN4-AS1	5.98	4.32e-09	8.37e-07	0.32	0.27	Blood pressure (smoking interaction);	chr3:2462545	chr3:3039033~3069242:-
THCA	cis	rs6860806	0.507	rs272868	ENSG00000263597.1	MIR3936	5.98	4.32e-09	8.37e-07	0.27	0.27	Breast cancer;	chr5:132345058	chr5:132365490~132365599:-
THCA	cis	rs712039	0.652	rs17137970	ENSG00000276054.1	RP11-378E13.3	5.98	4.32e-09	8.38e-07	0.4	0.27	Tuberculosis;	chr17:37411739	chr17:37386886~37387926:+
THCA	cis	rs67517081	1	rs67517081	ENSG00000260911.2	RP11-196G11.2	-5.98	4.32e-09	8.38e-07	-0.23	-0.27	Mean corpuscular hemoglobin;	chr16:30976060	chr16:31043150~31049868:+
THCA	cis	rs2120243	0.565	rs4680363	ENSG00000244515.1	KRT18P34	-5.98	4.32e-09	8.38e-07	-0.31	-0.27	Hepatocellular carcinoma in hepatitis B infection;	chr3:157432293	chr3:157162663~157163932:-
THCA	cis	rs763512	0.504	rs853216	ENSG00000276054.1	RP11-378E13.3	5.98	4.32e-09	8.38e-07	0.42	0.27	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37502902	chr17:37386886~37387926:+
THCA	cis	rs7833787	1	rs12546946	ENSG00000278886.1	RP11-108A14.1	-5.98	4.32e-09	8.39e-07	-0.34	-0.27	Obesity-related traits;	chr8:18845568	chr8:18864681~18865247:-
THCA	cis	rs7833787	1	rs7844375	ENSG00000278886.1	RP11-108A14.1	-5.98	4.32e-09	8.39e-07	-0.34	-0.27	Obesity-related traits;	chr8:18845748	chr8:18864681~18865247:-
THCA	cis	rs7833787	1	rs7844500	ENSG00000278886.1	RP11-108A14.1	-5.98	4.32e-09	8.39e-07	-0.34	-0.27	Obesity-related traits;	chr8:18845833	chr8:18864681~18865247:-
THCA	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	5.98	4.33e-09	8.39e-07	0.35	0.27	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
THCA	cis	rs6061231	0.837	rs6121558	ENSG00000275437.1	RP5-908M14.10	5.98	4.33e-09	8.39e-07	0.25	0.27	Colorectal cancer;	chr20:62386309	chr20:62402236~62405935:-
THCA	cis	rs1125355	0.69	rs1356173	ENSG00000251491.2	OR7E28P	-5.98	4.33e-09	8.4e-07	-0.42	-0.27	Alzheimer's disease in APOE e4+ carriers;	chr2:158795461	chr2:158862311~158863285:+
THCA	cis	rs7246657	0.722	rs2972458	ENSG00000267422.1	CTD-2554C21.1	5.98	4.34e-09	8.41e-07	0.3	0.27	Coronary artery calcification;	chr19:37644502	chr19:37779686~37792865:+
THCA	cis	rs8007846	0.569	rs61378474	ENSG00000276116.2	FUT8-AS1	-5.98	4.34e-09	8.41e-07	-0.28	-0.27	Multiple sclerosis--Brain Glutamate Levels;	chr14:65786719	chr14:65411170~65412690:-
THCA	cis	rs10971721	0.584	rs72731224	ENSG00000281128.1	PTENP1-AS	5.98	4.34e-09	8.41e-07	0.55	0.27	Body mass index;	chr9:34122888	chr9:33677268~33688011:+
THCA	cis	rs228614	0.51	rs6830407	ENSG00000251288.2	RP11-10L12.2	-5.98	4.34e-09	8.42e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102751401~102752641:+
THCA	cis	rs17695224	0.74	rs3752125	ENSG00000269483.1	AC006272.1	5.98	4.35e-09	8.43e-07	0.3	0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51824531	chr19:51839924~51843324:-
THCA	cis	rs713477	0.967	rs12887653	ENSG00000258413.1	RP11-665C16.6	5.98	4.35e-09	8.43e-07	0.35	0.27	Pediatric bone mineral content (femoral neck);	chr14:55444312	chr14:55262767~55272075:-
THCA	cis	rs9652601	0.959	rs9746695	ENSG00000274038.1	RP11-66H6.4	5.98	4.35e-09	8.43e-07	0.35	0.27	Systemic lupus erythematosus;	chr16:11114037	chr16:11056556~11057034:+
THCA	cis	rs12497850	0.931	rs11924597	ENSG00000229759.1	MRPS18AP1	5.98	4.35e-09	8.43e-07	0.35	0.27	Parkinson's disease;	chr3:48900357	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.897	rs9850134	ENSG00000229759.1	MRPS18AP1	5.98	4.35e-09	8.43e-07	0.35	0.27	Parkinson's disease;	chr3:48919714	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9867373	ENSG00000229759.1	MRPS18AP1	5.98	4.35e-09	8.43e-07	0.35	0.27	Parkinson's disease;	chr3:48923505	chr3:48256350~48256938:-
THCA	cis	rs8141529	0.584	rs58004020	ENSG00000226471.5	CTA-292E10.6	-5.98	4.35e-09	8.44e-07	-0.22	-0.27	Lymphocyte counts;	chr22:28861062	chr22:28800683~28848559:+
THCA	cis	rs7191700	0.644	rs12149160	ENSG00000263080.1	RP11-485G7.5	-5.98	4.35e-09	8.44e-07	-0.31	-0.27	Multiple sclerosis;	chr16:11345446	chr16:11341809~11345211:-
THCA	cis	rs10129255	0.957	rs8009638	ENSG00000211974.3	IGHV2-70	5.98	4.35e-09	8.44e-07	0.21	0.27	Kawasaki disease;	chr14:106777570	chr14:106723574~106724093:-
THCA	cis	rs4950322	0.512	rs2883318	ENSG00000237188.3	RP11-337C18.8	5.98	4.36e-09	8.44e-07	0.29	0.27	Protein quantitative trait loci;	chr1:147377422	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.512	rs12409455	ENSG00000237188.3	RP11-337C18.8	5.98	4.36e-09	8.44e-07	0.29	0.27	Protein quantitative trait loci;	chr1:147378563	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.6	rs11240014	ENSG00000237188.3	RP11-337C18.8	5.98	4.36e-09	8.44e-07	0.29	0.27	Protein quantitative trait loci;	chr1:147380674	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.576	rs11240015	ENSG00000237188.3	RP11-337C18.8	5.98	4.36e-09	8.44e-07	0.29	0.27	Protein quantitative trait loci;	chr1:147380813	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.553	rs12093870	ENSG00000237188.3	RP11-337C18.8	5.98	4.36e-09	8.44e-07	0.29	0.27	Protein quantitative trait loci;	chr1:147380815	chr1:147172771~147211568:+
THCA	cis	rs7809950	0.593	rs62482503	ENSG00000238832.1	snoU109	-5.98	4.36e-09	8.44e-07	-0.31	-0.27	Coronary artery disease;	chr7:107347543	chr7:107603363~107603507:+
THCA	cis	rs4971059	0.654	rs10157801	ENSG00000160766.13	GBAP1	-5.98	4.36e-09	8.44e-07	-0.28	-0.27	Breast cancer;	chr1:155147536	chr1:155213821~155227422:-
THCA	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	5.98	4.36e-09	8.45e-07	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
THCA	cis	rs1865760	0.892	rs2328903	ENSG00000272462.2	U91328.19	-5.98	4.36e-09	8.45e-07	-0.22	-0.27	Height;	chr6:25935537	chr6:25992662~26001775:+
THCA	cis	rs11096990	0.891	rs61691409	ENSG00000249207.1	RP11-360F5.1	5.98	4.36e-09	8.45e-07	0.34	0.27	Cognitive function;	chr4:39243801	chr4:39112677~39126818:-
THCA	cis	rs2018683	0.649	rs12536605	ENSG00000228421.2	AC005013.5	5.98	4.37e-09	8.46e-07	0.3	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930883	chr7:28957667~28959345:+
THCA	cis	rs11907546	1	rs11907546	ENSG00000275784.1	RP5-1125A11.6	-5.98	4.37e-09	8.47e-07	-0.27	-0.27	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33989480~33991818:-
THCA	cis	rs6496044	0.568	rs2880765	ENSG00000259295.5	CSPG4P12	-5.98	4.37e-09	8.47e-07	-0.34	-0.27	Interstitial lung disease;	chr15:85513231	chr15:85191438~85213905:+
THCA	cis	rs3213958	0.574	rs1822017	ENSG00000249274.1	PDLIM1P4	-5.98	4.37e-09	8.47e-07	-0.33	-0.27	Blood protein levels;	chr3:98800637	chr3:98782188~98783193:+
THCA	cis	rs4073416	0.902	rs55845504	ENSG00000276116.2	FUT8-AS1	-5.98	4.38e-09	8.48e-07	-0.29	-0.27	N-glycan levels;	chr14:65790250	chr14:65411170~65412690:-
THCA	cis	rs6142102	0.778	rs6059581	ENSG00000275784.1	RP5-1125A11.6	-5.98	4.38e-09	8.48e-07	-0.27	-0.27	Skin pigmentation;	chr20:33940582	chr20:33989480~33991818:-
THCA	cis	rs412050	0.895	rs240065	ENSG00000224086.5	LL22NC03-86G7.1	-5.98	4.38e-09	8.48e-07	-0.43	-0.27	Attention deficit hyperactivity disorder;	chr22:21941747	chr22:21938293~21977632:+
THCA	cis	rs412050	0.895	rs6000236	ENSG00000224086.5	LL22NC03-86G7.1	-5.98	4.38e-09	8.48e-07	-0.43	-0.27	Attention deficit hyperactivity disorder;	chr22:21942087	chr22:21938293~21977632:+
THCA	cis	rs227275	0.556	rs6842179	ENSG00000251288.2	RP11-10L12.2	-5.98	4.38e-09	8.48e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102751401~102752641:+
THCA	cis	rs10266483	0.705	rs599522	ENSG00000227986.1	TRIM60P18	-5.98	4.38e-09	8.49e-07	-0.22	-0.27	Response to statin therapy;	chr7:64298104	chr7:64355078~64356199:+
THCA	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	5.98	4.39e-09	8.5e-07	0.26	0.27	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
THCA	cis	rs2439831	0.702	rs8033995	ENSG00000166763.7	STRCP1	5.98	4.39e-09	8.5e-07	0.39	0.27	Lung cancer in ever smokers;	chr15:43721311	chr15:43699488~43718184:-
THCA	cis	rs4650994	1	rs4076205	ENSG00000273384.1	RP5-1098D14.1	5.98	4.39e-09	8.5e-07	0.33	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178565022	chr1:178651706~178652282:+
THCA	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	5.98	4.39e-09	8.5e-07	0.32	0.27	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
THCA	cis	rs4950322	1	rs72694720	ENSG00000237188.3	RP11-337C18.8	5.98	4.39e-09	8.5e-07	0.35	0.27	Protein quantitative trait loci;	chr1:147371939	chr1:147172771~147211568:+
THCA	cis	rs10029851	0.627	rs2880787	ENSG00000234492.4	RPL34-AS1	5.98	4.39e-09	8.51e-07	0.31	0.27	Amyotrophic lateral sclerosis (sporadic);	chr4:108632175	chr4:108538190~108620460:-
THCA	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	5.98	4.39e-09	8.51e-07	0.28	0.27	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
THCA	cis	rs11671005	0.651	rs11878203	ENSG00000269473.1	CTD-2619J13.19	5.98	4.4e-09	8.53e-07	0.31	0.27	Mean platelet volume;	chr19:58408683	chr19:58440448~58445849:+
THCA	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	5.98	4.4e-09	8.53e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	5.98	4.4e-09	8.53e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	5.98	4.4e-09	8.53e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	5.98	4.4e-09	8.53e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	5.98	4.4e-09	8.53e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	5.98	4.4e-09	8.53e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
THCA	cis	rs812925	0.784	rs6735081	ENSG00000271889.1	RP11-493E12.1	-5.98	4.41e-09	8.54e-07	-0.27	-0.27	Immature fraction of reticulocytes;	chr2:61233582	chr2:61151433~61162105:-
THCA	cis	rs1005277	0.54	rs289638	ENSG00000263064.2	RP11-291L22.7	5.98	4.41e-09	8.54e-07	0.29	0.27	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38448689~38448949:+
THCA	cis	rs9813712	0.585	rs9855392	ENSG00000228252.7	COL6A4P2	-5.98	4.41e-09	8.54e-07	-0.33	-0.27	Response to amphetamines;	chr3:130214403	chr3:130212823~130273806:+
THCA	cis	rs9843304	0.685	rs35815132	ENSG00000244503.1	RP11-278L15.6	-5.98	4.41e-09	8.55e-07	-0.33	-0.27	Gallstone disease;	chr3:149501673	chr3:149494660~149495995:+
THCA	cis	rs17772222	0.63	rs7146241	ENSG00000258983.2	RP11-507K2.2	-5.98	4.42e-09	8.55e-07	-0.31	-0.27	Coronary artery calcification;	chr14:88551622	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.63	rs930181	ENSG00000258983.2	RP11-507K2.2	-5.98	4.42e-09	8.55e-07	-0.31	-0.27	Coronary artery calcification;	chr14:88552364	chr14:88499334~88515502:+
THCA	cis	rs9307551	0.779	rs13124357	ENSG00000250334.4	LINC00989	-5.98	4.42e-09	8.55e-07	-0.31	-0.27	Refractive error;	chr4:79591148	chr4:79492416~79576460:+
THCA	cis	rs8027521	0.66	rs991264	ENSG00000280362.1	RP11-643A5.3	-5.98	4.42e-09	8.55e-07	-0.33	-0.27	Circulating chemerin levels;	chr15:53984354	chr15:53910769~53914712:+
THCA	cis	rs2303759	0.914	rs2288481	ENSG00000268686.1	AC010524.2	-5.98	4.42e-09	8.56e-07	-0.41	-0.27	Multiple sclerosis;	chr19:49374939	chr19:49368705~49388081:-
THCA	cis	rs7809950	0.678	rs2107317	ENSG00000238832.1	snoU109	-5.98	4.42e-09	8.56e-07	-0.31	-0.27	Coronary artery disease;	chr7:107259240	chr7:107603363~107603507:+
THCA	cis	rs56114371	0.53	rs9348774	ENSG00000280107.1	AL022393.9	-5.98	4.42e-09	8.56e-07	-0.32	-0.27	Breast cancer;	chr6:27721151	chr6:28170845~28172521:+
THCA	cis	rs853679	0.556	rs13200214	ENSG00000219392.1	RP1-265C24.5	-5.98	4.42e-09	8.56e-07	-0.59	-0.27	Depression;	chr6:28049472	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs71559070	ENSG00000219392.1	RP1-265C24.5	-5.98	4.42e-09	8.56e-07	-0.59	-0.27	Depression;	chr6:28071151	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34166054	ENSG00000219392.1	RP1-265C24.5	-5.98	4.42e-09	8.56e-07	-0.59	-0.27	Depression;	chr6:28098023	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34662244	ENSG00000219392.1	RP1-265C24.5	-5.98	4.42e-09	8.56e-07	-0.59	-0.27	Depression;	chr6:28106103	chr6:28115628~28116551:+
THCA	cis	rs35952432	1	rs35952432	ENSG00000219392.1	RP1-265C24.5	-5.98	4.42e-09	8.56e-07	-0.59	-0.27	Lung cancer;	chr6:28107123	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13203816	ENSG00000219392.1	RP1-265C24.5	-5.98	4.42e-09	8.56e-07	-0.59	-0.27	Depression;	chr6:28111820	chr6:28115628~28116551:+
THCA	cis	rs853679	0.556	rs34588114	ENSG00000219392.1	RP1-265C24.5	-5.98	4.42e-09	8.56e-07	-0.59	-0.27	Depression;	chr6:28112850	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs34371502	ENSG00000219392.1	RP1-265C24.5	-5.98	4.42e-09	8.56e-07	-0.59	-0.27	Depression;	chr6:28113980	chr6:28115628~28116551:+
THCA	cis	rs732716	0.504	rs9352	ENSG00000267769.1	CTB-50L17.9	-5.98	4.42e-09	8.56e-07	-0.28	-0.27	Mean corpuscular volume;	chr19:4442339	chr19:4454014~4455286:+
THCA	cis	rs2439831	1	rs2256764	ENSG00000249839.1	AC011330.5	-5.98	4.43e-09	8.57e-07	-0.43	-0.27	Lung cancer in ever smokers;	chr15:43443565	chr15:43663654~43684339:-
THCA	cis	rs2765539	1	rs2765539	ENSG00000231365.4	RP11-418J17.1	-5.98	4.43e-09	8.57e-07	-0.29	-0.27	Waist-hip ratio;	chr1:119006795	chr1:119140396~119275973:+
THCA	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	5.98	4.43e-09	8.57e-07	0.33	0.27	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
THCA	cis	rs7809950	1	rs1544336	ENSG00000238832.1	snoU109	-5.98	4.43e-09	8.57e-07	-0.28	-0.27	Coronary artery disease;	chr7:107441970	chr7:107603363~107603507:+
THCA	cis	rs7246657	0.722	rs2291002	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.43e-09	8.58e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37543024	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs10404031	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.43e-09	8.58e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37545052	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs10406379	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.43e-09	8.58e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37545823	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs1564206	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.43e-09	8.58e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37549174	chr19:37779686~37792865:+
THCA	cis	rs897984	0.609	rs1108431	ENSG00000279196.1	RP11-1072A3.3	5.98	4.43e-09	8.58e-07	0.27	0.27	Dementia with Lewy bodies;	chr16:31043286	chr16:30984630~30988270:-
THCA	cis	rs8141529	0.764	rs5762854	ENSG00000226471.5	CTA-292E10.6	-5.98	4.43e-09	8.59e-07	-0.22	-0.27	Lymphocyte counts;	chr22:28850290	chr22:28800683~28848559:+
THCA	cis	rs6902257	0.59	rs2503727	ENSG00000272129.1	RP11-250B2.6	5.98	4.44e-09	8.59e-07	0.72	0.27	Obesity-related traits;	chr6:80601100	chr6:80355424~80356859:+
THCA	cis	rs748404	0.65	rs556851	ENSG00000166763.7	STRCP1	5.98	4.44e-09	8.59e-07	0.29	0.27	Lung cancer;	chr15:43279021	chr15:43699488~43718184:-
THCA	cis	rs9311474	0.652	rs411457	ENSG00000243224.1	RP5-1157M23.2	5.98	4.45e-09	8.62e-07	0.27	0.27	Electroencephalogram traits;	chr3:52194134	chr3:52239258~52241097:+
THCA	cis	rs228614	0.51	rs223412	ENSG00000251288.2	RP11-10L12.2	-5.98	4.45e-09	8.62e-07	-0.36	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102751401~102752641:+
THCA	cis	rs9921338	0.961	rs77552156	ENSG00000262703.1	RP11-485G7.6	-5.98	4.46e-09	8.63e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11332542	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs4781069	ENSG00000262703.1	RP11-485G7.6	-5.98	4.46e-09	8.63e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334905	chr16:11348143~11349321:-
THCA	cis	rs7702057	0.53	rs6890263	ENSG00000271918.1	CTD-2287O16.5	5.98	4.46e-09	8.63e-07	0.29	0.27	Amyotrophic lateral sclerosis;	chr5:116079739	chr5:116083807~116085416:-
THCA	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	5.98	4.46e-09	8.63e-07	0.33	0.27	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
THCA	cis	rs7617773	0.963	rs6771787	ENSG00000228638.1	FCF1P2	5.98	4.46e-09	8.63e-07	0.25	0.27	Coronary artery disease;	chr3:48152752	chr3:48290793~48291375:-
THCA	cis	rs7617773	1	rs6771889	ENSG00000228638.1	FCF1P2	5.98	4.46e-09	8.63e-07	0.25	0.27	Coronary artery disease;	chr3:48152836	chr3:48290793~48291375:-
THCA	cis	rs7307902	0.518	rs739857	ENSG00000280054.1	RP1-197B17.7	-5.98	4.46e-09	8.64e-07	-0.3	-0.27	Obesity-related traits;	chr12:47574503	chr12:47728151~47730598:-
THCA	cis	rs12101261	0.744	rs72693090	ENSG00000259167.2	NMNAT1P1	5.98	4.46e-09	8.64e-07	0.39	0.27	Graves' disease;	chr14:80993409	chr14:81032529~81033404:+
THCA	cis	rs7005380	0.58	rs13263296	ENSG00000245330.4	KB-1471A8.1	5.98	4.47e-09	8.64e-07	0.26	0.27	Interstitial lung disease;	chr8:119874305	chr8:119867419~119874488:-
THCA	cis	rs890448	0.796	rs10012024	ENSG00000254531.1	FLJ20021	5.98	4.47e-09	8.64e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101431868	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs990960	ENSG00000254531.1	FLJ20021	5.98	4.47e-09	8.64e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101432777	chr4:101347780~101348883:+
THCA	cis	rs5742933	0.779	rs1899025	ENSG00000253559.1	OSGEPL1-AS1	5.98	4.47e-09	8.64e-07	0.3	0.27	Ferritin levels;	chr2:189784856	chr2:189762704~189765556:+
THCA	cis	rs4664293	0.625	rs7590617	ENSG00000226266.5	AC009961.3	5.98	4.47e-09	8.65e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159775437	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs7564585	ENSG00000226266.5	AC009961.3	5.98	4.47e-09	8.65e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159775582	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.546	rs7564399	ENSG00000226266.5	AC009961.3	5.98	4.47e-09	8.65e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159775608	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.625	rs35481084	ENSG00000226266.5	AC009961.3	5.98	4.47e-09	8.65e-07	0.31	0.27	Monocyte percentage of white cells;	chr2:159777729	chr2:159670708~159712435:-
THCA	cis	rs595244	0.706	rs9806323	ENSG00000259705.1	RP11-227D13.1	5.98	4.47e-09	8.65e-07	0.33	0.27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48473818	chr15:48645951~48652016:+
THCA	cis	rs763121	0.813	rs2179143	ENSG00000273076.1	RP3-508I15.22	5.98	4.47e-09	8.65e-07	0.26	0.27	Menopause (age at onset);	chr22:38641979	chr22:38743495~38743910:+
THCA	cis	rs6545883	0.929	rs1209434	ENSG00000271889.1	RP11-493E12.1	5.98	4.47e-09	8.66e-07	0.26	0.27	Tuberculosis;	chr2:61445823	chr2:61151433~61162105:-
THCA	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	5.98	4.48e-09	8.66e-07	0.15	0.27	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	5.98	4.48e-09	8.66e-07	0.15	0.27	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
THCA	cis	rs3213958	0.574	rs6440159	ENSG00000249274.1	PDLIM1P4	-5.98	4.48e-09	8.66e-07	-0.34	-0.27	Blood protein levels;	chr3:98823350	chr3:98782188~98783193:+
THCA	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	5.98	4.48e-09	8.67e-07	0.29	0.27	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
THCA	cis	rs9880211	1	rs9841529	ENSG00000273486.1	RP11-731C17.2	5.98	4.48e-09	8.67e-07	0.27	0.27	Height;Body mass index;	chr3:136418441	chr3:136837338~136839021:-
THCA	cis	rs793571	0.554	rs12900343	ENSG00000259250.1	RP11-50C13.1	-5.98	4.48e-09	8.67e-07	-0.29	-0.27	Schizophrenia;	chr15:58731507	chr15:58587507~58591676:+
THCA	cis	rs17301013	0.507	rs333438	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174672782	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2771401	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174678302	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs464540	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174679250	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs467437	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174679861	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs332767	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174686386	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	5.98	4.48e-09	8.67e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
THCA	cis	rs55823223	0.564	rs58363746	ENSG00000267801.1	RP11-552F3.9	5.98	4.48e-09	8.67e-07	0.34	0.27	Psoriasis;	chr17:75854738	chr17:75876372~75879546:+
THCA	cis	rs62184315	0.536	rs2289405	ENSG00000273240.1	RP11-455J20.3	-5.98	4.48e-09	8.67e-07	-0.35	-0.27	Alcohol dependence (age at onset);	chr2:189771313	chr2:189763859~189764456:-
THCA	cis	rs4950322	0.58	rs4950308	ENSG00000278811.3	LINC00624	5.98	4.48e-09	8.67e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147120092	chr1:147258885~147517875:-
THCA	cis	rs17772222	0.917	rs7157149	ENSG00000222990.1	RNU4-22P	5.98	4.49e-09	8.68e-07	0.35	0.27	Coronary artery calcification;	chr14:88765501	chr14:88513498~88513663:+
THCA	cis	rs795484	0.683	rs572869	ENSG00000275409.1	RP11-131L12.4	-5.98	4.49e-09	8.68e-07	-0.23	-0.27	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118370362	chr12:118430147~118430699:+
THCA	cis	rs7746199	0.736	rs13202295	ENSG00000226314.6	ZNF192P1	-5.98	4.49e-09	8.68e-07	-0.6	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28161781~28169594:+
THCA	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	5.98	4.49e-09	8.69e-07	0.34	0.27	Height;	chr4:55452921	chr4:55363971~55395847:-
THCA	cis	rs7246657	0.722	rs954504	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37554492	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs8110865	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37556485	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.678	rs4802024	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37561291	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs4802029	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37564710	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs28512414	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37565672	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs6508736	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37570855	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.765	rs4803262	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37575858	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.712	rs4803263	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37575880	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs10412510	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37585043	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs3829688	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37586199	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs13744	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37587011	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs10403173	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37587779	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.679	rs12461113	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.5e-09	8.7e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37592287	chr19:37779686~37792865:+
THCA	cis	rs2880765	0.546	rs8042776	ENSG00000259295.5	CSPG4P12	5.98	4.5e-09	8.7e-07	0.35	0.27	Coronary artery disease;	chr15:85512398	chr15:85191438~85213905:+
THCA	cis	rs6142102	0.923	rs4911383	ENSG00000275784.1	RP5-1125A11.6	-5.98	4.5e-09	8.7e-07	-0.28	-0.27	Skin pigmentation;	chr20:33967973	chr20:33989480~33991818:-
THCA	cis	rs748404	0.626	rs62021176	ENSG00000249839.1	AC011330.5	-5.98	4.5e-09	8.71e-07	-0.38	-0.27	Lung cancer;	chr15:43388014	chr15:43663654~43684339:-
THCA	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-5.98	4.5e-09	8.71e-07	-0.24	-0.27	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-5.98	4.5e-09	8.71e-07	-0.24	-0.27	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
THCA	cis	rs1823913	1	rs6704784	ENSG00000280083.1	RP11-317J9.1	5.98	4.5e-09	8.71e-07	0.33	0.27	Obesity-related traits;	chr2:191244832	chr2:191154118~191156070:-
THCA	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	5.98	4.51e-09	8.72e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
THCA	cis	rs7246657	0.722	rs4802051	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.51e-09	8.72e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37581427	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.663	rs4803276	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.51e-09	8.72e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37581429	chr19:37779686~37792865:+
THCA	cis	rs4713118	0.523	rs2179096	ENSG00000219392.1	RP1-265C24.5	-5.98	4.52e-09	8.73e-07	-0.3	-0.27	Parkinson's disease;	chr6:27698141	chr6:28115628~28116551:+
THCA	cis	rs11096990	0.964	rs35494908	ENSG00000249207.1	RP11-360F5.1	5.98	4.52e-09	8.73e-07	0.34	0.27	Cognitive function;	chr4:39252574	chr4:39112677~39126818:-
THCA	cis	rs890448	0.796	rs182393	ENSG00000254531.1	FLJ20021	5.98	4.52e-09	8.74e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101403811	chr4:101347780~101348883:+
THCA	cis	rs7246657	0.722	rs1564208	ENSG00000267422.1	CTD-2554C21.1	-5.98	4.52e-09	8.74e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37550319	chr19:37779686~37792865:+
THCA	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	5.98	4.53e-09	8.75e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
THCA	cis	rs1865760	0.865	rs9393677	ENSG00000272462.2	U91328.19	-5.98	4.53e-09	8.75e-07	-0.22	-0.27	Height;	chr6:25945587	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs9393678	ENSG00000272462.2	U91328.19	-5.98	4.53e-09	8.75e-07	-0.22	-0.27	Height;	chr6:25945591	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.865	rs9467641	ENSG00000272462.2	U91328.19	-5.98	4.53e-09	8.75e-07	-0.22	-0.27	Height;	chr6:25947008	chr6:25992662~26001775:+
THCA	cis	rs7554547	0.838	rs885770	ENSG00000199347.1	RNU5E-1	5.98	4.53e-09	8.75e-07	0.36	0.27	Nonsyndromic cleft lip with cleft palate;	chr1:11878699	chr1:11908152~11908271:+
THCA	cis	rs6479901	0.557	rs1009984	ENSG00000232075.1	MRPL35P2	-5.98	4.53e-09	8.75e-07	-0.43	-0.27	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63634317~63634827:-
THCA	cis	rs4934494	0.736	rs10881613	ENSG00000240996.1	RP11-80H5.7	-5.98	4.53e-09	8.75e-07	-0.29	-0.27	Red blood cell count;	chr10:89629468	chr10:89694295~89697928:-
THCA	cis	rs12893668	0.572	rs11846404	ENSG00000269910.1	RP11-73M18.10	5.98	4.53e-09	8.76e-07	0.25	0.27	Reticulocyte count;	chr14:103689771	chr14:103694516~103695050:-
THCA	cis	rs5742933	0.803	rs1233262	ENSG00000253559.1	OSGEPL1-AS1	-5.98	4.53e-09	8.76e-07	-0.3	-0.27	Ferritin levels;	chr2:189793107	chr2:189762704~189765556:+
THCA	cis	rs4950322	0.58	rs1813002	ENSG00000278811.3	LINC00624	5.98	4.54e-09	8.77e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147112579	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.518	rs4950304	ENSG00000278811.3	LINC00624	5.98	4.54e-09	8.77e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147116685	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.518	rs4950305	ENSG00000278811.3	LINC00624	5.98	4.54e-09	8.77e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147117711	chr1:147258885~147517875:-
THCA	cis	rs7267979	0.789	rs6076347	ENSG00000274973.1	RP13-401N8.7	5.98	4.54e-09	8.77e-07	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:25845497~25845862:+
THCA	cis	rs55661361	0.532	rs3802902	ENSG00000245498.5	RP11-677M14.7	-5.98	4.54e-09	8.77e-07	-0.18	-0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124765139	chr11:124800450~124834487:+
THCA	cis	rs2348418	0.864	rs11049578	ENSG00000247934.4	RP11-967K21.1	5.98	4.54e-09	8.77e-07	0.23	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28414520	chr12:28163298~28190738:-
THCA	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-5.98	4.54e-09	8.78e-07	-0.3	-0.27	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
THCA	cis	rs11089937	0.626	rs5757014	ENSG00000211638.2	IGLV8-61	-5.98	4.54e-09	8.78e-07	-0.21	-0.27	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22098700~22099212:+
THCA	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	5.98	4.54e-09	8.78e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	5.98	4.54e-09	8.78e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
THCA	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-5.97	4.55e-09	8.79e-07	-0.29	-0.27	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
THCA	cis	rs4950322	0.518	rs61838938	ENSG00000278811.3	LINC00624	5.97	4.55e-09	8.79e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147105943	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.529	rs11809327	ENSG00000278811.3	LINC00624	5.97	4.55e-09	8.79e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147106679	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.563	rs11809328	ENSG00000278811.3	LINC00624	5.97	4.55e-09	8.79e-07	0.32	0.27	Protein quantitative trait loci;	chr1:147106681	chr1:147258885~147517875:-
THCA	cis	rs853679	0.607	rs67998226	ENSG00000219392.1	RP1-265C24.5	-5.97	4.55e-09	8.79e-07	-0.59	-0.27	Depression;	chr6:28270281	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34878803	ENSG00000219392.1	RP1-265C24.5	-5.97	4.55e-09	8.79e-07	-0.59	-0.27	Depression;	chr6:28282402	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34396849	ENSG00000219392.1	RP1-265C24.5	-5.97	4.55e-09	8.79e-07	-0.59	-0.27	Depression;	chr6:28283178	chr6:28115628~28116551:+
THCA	cis	rs4650994	1	rs10913568	ENSG00000273384.1	RP5-1098D14.1	5.97	4.55e-09	8.8e-07	0.33	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178544276	chr1:178651706~178652282:+
THCA	cis	rs9595908	0.965	rs8000071	ENSG00000212293.1	SNORA16	5.97	4.56e-09	8.8e-07	0.32	0.27	Body mass index;	chr13:32551236	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.965	rs7984903	ENSG00000212293.1	SNORA16	5.97	4.56e-09	8.8e-07	0.32	0.27	Body mass index;	chr13:32552002	chr13:32420390~32420516:-
THCA	cis	rs9921338	0.887	rs6498183	ENSG00000262703.1	RP11-485G7.6	-5.97	4.56e-09	8.8e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11337051	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs7187870	ENSG00000262703.1	RP11-485G7.6	-5.97	4.56e-09	8.8e-07	-0.34	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11338062	chr16:11348143~11349321:-
THCA	cis	rs11976180	0.569	rs12703565	ENSG00000244198.4	RP4-545C24.1	-5.97	4.56e-09	8.81e-07	-0.34	-0.27	Obesity-related traits;	chr7:144057308	chr7:144194858~144280547:+
THCA	cis	rs890448	0.693	rs2433309	ENSG00000254531.1	FLJ20021	5.97	4.56e-09	8.82e-07	0.24	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436381	chr4:101347780~101348883:+
THCA	cis	rs763121	0.815	rs4821799	ENSG00000273076.1	RP3-508I15.22	5.97	4.57e-09	8.83e-07	0.25	0.27	Menopause (age at onset);	chr22:38625321	chr22:38743495~38743910:+
THCA	cis	rs10761482	0.5	rs7072229	ENSG00000254271.1	RP11-131N11.4	5.97	4.57e-09	8.83e-07	0.35	0.27	Schizophrenia;	chr10:60524462	chr10:60734342~60741828:+
THCA	cis	rs71520386	0.632	rs12532938	ENSG00000228649.7	AC005682.5	-5.97	4.57e-09	8.83e-07	-0.34	-0.27	Fibrinogen levels;	chr7:22820876	chr7:22854178~22861579:+
THCA	cis	rs227275	0.556	rs7676765	ENSG00000251288.2	RP11-10L12.2	5.97	4.57e-09	8.83e-07	0.36	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102751401~102752641:+
THCA	cis	rs6802315	0.604	rs9881462	ENSG00000272247.1	RP11-379F4.9	-5.97	4.57e-09	8.83e-07	-0.25	-0.27	Periodontitis (CDC/AAP);	chr3:158763333	chr3:158801257~158801935:-
THCA	cis	rs12497850	0.897	rs6781790	ENSG00000229759.1	MRPS18AP1	5.97	4.58e-09	8.84e-07	0.35	0.27	Parkinson's disease;	chr3:49007334	chr3:48256350~48256938:-
THCA	cis	rs6142102	0.923	rs2284377	ENSG00000275784.1	RP5-1125A11.6	-5.97	4.58e-09	8.85e-07	-0.28	-0.27	Skin pigmentation;	chr20:33998876	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs2284378	ENSG00000275784.1	RP5-1125A11.6	-5.97	4.58e-09	8.85e-07	-0.28	-0.27	Skin pigmentation;	chr20:34000289	chr20:33989480~33991818:-
THCA	cis	rs793571	0.554	rs28818840	ENSG00000259250.1	RP11-50C13.1	-5.97	4.59e-09	8.86e-07	-0.29	-0.27	Schizophrenia;	chr15:58727115	chr15:58587507~58591676:+
THCA	cis	rs793571	0.554	rs28536555	ENSG00000259250.1	RP11-50C13.1	-5.97	4.59e-09	8.86e-07	-0.29	-0.27	Schizophrenia;	chr15:58730403	chr15:58587507~58591676:+
THCA	cis	rs227275	0.525	rs6853193	ENSG00000230069.3	LRRC37A15P	-5.97	4.59e-09	8.87e-07	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102727274~102730721:-
THCA	cis	rs1546924	0.692	rs197379	ENSG00000227811.2	FAM212B-AS1	-5.97	4.59e-09	8.87e-07	-0.32	-0.27	Body mass index;	chr1:111749681	chr1:111739841~111747798:+
THCA	cis	rs1865760	0.865	rs1436306	ENSG00000272462.2	U91328.19	-5.97	4.59e-09	8.87e-07	-0.22	-0.27	Height;	chr6:25948193	chr6:25992662~26001775:+
THCA	cis	rs7005380	0.62	rs13282901	ENSG00000245330.4	KB-1471A8.1	5.97	4.59e-09	8.87e-07	0.26	0.27	Interstitial lung disease;	chr8:119881561	chr8:119867419~119874488:-
THCA	cis	rs6674176	0.597	rs12127737	ENSG00000237950.1	RP11-7O11.3	5.97	4.6e-09	8.87e-07	0.24	0.27	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43936893	chr1:43944370~43946551:-
THCA	cis	rs10875746	0.625	rs2898065	ENSG00000269514.1	RP11-370I10.12	5.97	4.6e-09	8.88e-07	0.26	0.27	Longevity (90 years and older);	chr12:48250836	chr12:48198387~48202031:+
THCA	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	5.97	4.6e-09	8.88e-07	0.27	0.27	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
THCA	cis	rs12681963	0.688	rs55810013	ENSG00000248159.1	HSPA8P11	5.97	4.6e-09	8.88e-07	0.47	0.27	Migraine;	chr8:30181507	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs61621868	ENSG00000248159.1	HSPA8P11	5.97	4.6e-09	8.88e-07	0.47	0.27	Migraine;	chr8:30182621	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.541	rs56302321	ENSG00000248159.1	HSPA8P11	5.97	4.6e-09	8.88e-07	0.47	0.27	Migraine;	chr8:30183018	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs12548744	ENSG00000248159.1	HSPA8P11	5.97	4.6e-09	8.88e-07	0.47	0.27	Migraine;	chr8:30184400	chr8:30237382~30240997:+
THCA	cis	rs7615952	0.576	rs12497295	ENSG00000250012.1	RP11-124N2.1	-5.97	4.6e-09	8.89e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126099807	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.512	rs4646765	ENSG00000250012.1	RP11-124N2.1	-5.97	4.6e-09	8.89e-07	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:126101864	chr3:126084220~126095349:+
THCA	cis	rs6908034	0.607	rs12525152	ENSG00000237404.1	RP3-471C18.2	-5.97	4.61e-09	8.9e-07	-0.52	-0.27	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19809193	chr6:19689825~19753113:-
THCA	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	5.97	4.61e-09	8.9e-07	0.38	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
THCA	cis	rs6430553	0.861	rs12463645	ENSG00000224043.6	CCNT2-AS1	-5.97	4.62e-09	8.91e-07	-0.27	-0.27	Blood metabolite levels;	chr2:134916800	chr2:134735464~134918710:-
THCA	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	5.97	4.62e-09	8.91e-07	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
THCA	cis	rs2243480	1	rs10807701	ENSG00000232546.1	RP11-458F8.1	5.97	4.62e-09	8.92e-07	0.35	0.27	Diabetic kidney disease;	chr7:66259699	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1499613	ENSG00000232546.1	RP11-458F8.1	5.97	4.62e-09	8.92e-07	0.35	0.27	Diabetic kidney disease;	chr7:66265873	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1553174	ENSG00000232546.1	RP11-458F8.1	5.97	4.62e-09	8.92e-07	0.35	0.27	Diabetic kidney disease;	chr7:66266207	chr7:66848496~66858136:+
THCA	cis	rs728616	0.867	rs61858980	ENSG00000242600.5	MBL1P	5.97	4.62e-09	8.92e-07	0.36	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056862	chr10:79904898~79950336:+
THCA	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	5.97	4.62e-09	8.92e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
THCA	cis	rs4950322	0.57	rs80070044	ENSG00000278811.3	LINC00624	5.97	4.62e-09	8.92e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147330238	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692963	ENSG00000278811.3	LINC00624	5.97	4.62e-09	8.92e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147331090	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.518	rs72692965	ENSG00000278811.3	LINC00624	5.97	4.62e-09	8.92e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147332085	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.518	rs72692968	ENSG00000278811.3	LINC00624	5.97	4.62e-09	8.92e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147332884	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.518	rs72692970	ENSG00000278811.3	LINC00624	5.97	4.62e-09	8.92e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147332887	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692971	ENSG00000278811.3	LINC00624	5.97	4.62e-09	8.92e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147333088	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692973	ENSG00000278811.3	LINC00624	5.97	4.62e-09	8.92e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147333281	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692975	ENSG00000278811.3	LINC00624	5.97	4.62e-09	8.92e-07	0.33	0.27	Protein quantitative trait loci;	chr1:147333506	chr1:147258885~147517875:-
THCA	cis	rs2243480	1	rs10950032	ENSG00000232546.1	RP11-458F8.1	5.97	4.63e-09	8.93e-07	0.35	0.27	Diabetic kidney disease;	chr7:66273604	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6958420	ENSG00000232546.1	RP11-458F8.1	5.97	4.63e-09	8.93e-07	0.35	0.27	Diabetic kidney disease;	chr7:66286184	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1392104	ENSG00000232546.1	RP11-458F8.1	5.97	4.63e-09	8.93e-07	0.35	0.27	Diabetic kidney disease;	chr7:66294120	chr7:66848496~66858136:+
THCA	cis	rs2348418	0.864	rs1949978	ENSG00000247934.4	RP11-967K21.1	5.97	4.63e-09	8.93e-07	0.23	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28443951	chr12:28163298~28190738:-
THCA	cis	rs9402743	0.781	rs2273069	ENSG00000231028.7	LINC00271	-5.97	4.63e-09	8.94e-07	-0.23	-0.27	Systemic lupus erythematosus;	chr6:135689660	chr6:135497801~135716055:+
THCA	cis	rs7246657	0.663	rs10408619	ENSG00000267422.1	CTD-2554C21.1	-5.97	4.63e-09	8.94e-07	-0.3	-0.27	Coronary artery calcification;	chr19:37579573	chr19:37779686~37792865:+
THCA	cis	rs7044106	0.762	rs1867254	ENSG00000270917.1	RP11-27I1.6	-5.97	4.64e-09	8.94e-07	-0.37	-0.27	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120812475~120812845:-
THCA	cis	rs4713118	0.513	rs149972	ENSG00000220721.1	OR1F12	5.97	4.64e-09	8.95e-07	0.32	0.27	Parkinson's disease;	chr6:28015449	chr6:28073316~28074233:+
THCA	cis	rs7246657	0.722	rs2927742	ENSG00000267422.1	CTD-2554C21.1	5.97	4.64e-09	8.95e-07	0.3	0.27	Coronary artery calcification;	chr19:37642717	chr19:37779686~37792865:+
THCA	cis	rs4143844	1	rs12148573	ENSG00000259251.2	RP11-643M14.1	5.97	4.65e-09	8.96e-07	0.5	0.27	Bipolar disorder and schizophrenia;	chr15:62051994	chr15:62060503~62062434:+
THCA	cis	rs4143844	1	rs75520981	ENSG00000259251.2	RP11-643M14.1	5.97	4.65e-09	8.96e-07	0.5	0.27	Bipolar disorder and schizophrenia;	chr15:62052478	chr15:62060503~62062434:+
THCA	cis	rs4948275	0.804	rs2650754	ENSG00000237233.2	TMEM26-AS1	-5.97	4.65e-09	8.97e-07	-0.34	-0.27	Night sleep phenotypes;	chr10:61502195	chr10:61452639~61481956:+
THCA	cis	rs12478296	0.892	rs60545379	ENSG00000261186.2	RP11-341N2.1	-5.97	4.65e-09	8.97e-07	-0.42	-0.27	Obesity-related traits;	chr2:242092239	chr2:242087351~242088457:-
THCA	cis	rs9813712	0.597	rs11711883	ENSG00000249846.5	RP11-77P16.4	-5.97	4.65e-09	8.97e-07	-0.27	-0.27	Response to amphetamines;	chr3:130241367	chr3:130112550~130120579:+
THCA	cis	rs9813712	0.574	rs62281647	ENSG00000249846.5	RP11-77P16.4	-5.97	4.65e-09	8.97e-07	-0.27	-0.27	Response to amphetamines;	chr3:130242670	chr3:130112550~130120579:+
THCA	cis	rs6585424	1	rs10466228	ENSG00000225484.5	NUTM2B-AS1	-5.97	4.65e-09	8.97e-07	-0.43	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164617	chr10:79663088~79826594:-
THCA	cis	rs9902453	0.73	rs4583306	ENSG00000264007.1	RP11-68I3.10	-5.97	4.65e-09	8.97e-07	-0.31	-0.27	Coffee consumption (cups per day);	chr17:30211697	chr17:29621617~29622254:-
THCA	cis	rs10971721	0.822	rs56160720	ENSG00000281128.1	PTENP1-AS	5.97	4.66e-09	8.99e-07	0.6	0.27	Body mass index;	chr9:33899827	chr9:33677268~33688011:+
THCA	cis	rs17772222	1	rs11159856	ENSG00000222990.1	RNU4-22P	5.97	4.67e-09	9e-07	0.35	0.27	Coronary artery calcification;	chr14:88417585	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs17124652	ENSG00000222990.1	RNU4-22P	5.97	4.67e-09	9e-07	0.35	0.27	Coronary artery calcification;	chr14:88424384	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.876	rs4375590	ENSG00000222990.1	RNU4-22P	5.97	4.67e-09	9e-07	0.35	0.27	Coronary artery calcification;	chr14:88451334	chr14:88513498~88513663:+
THCA	cis	rs172166	0.694	rs9295760	ENSG00000220721.1	OR1F12	5.97	4.67e-09	9.01e-07	0.33	0.27	Cardiac Troponin-T levels;	chr6:28179607	chr6:28073316~28074233:+
THCA	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	5.97	4.68e-09	9.02e-07	0.22	0.27	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
THCA	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	5.97	4.68e-09	9.02e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	5.97	4.68e-09	9.02e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	5.97	4.68e-09	9.02e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs333454	ENSG00000227373.4	RP11-160H22.5	5.97	4.68e-09	9.02e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174653939	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs333452	ENSG00000227373.4	RP11-160H22.5	5.97	4.68e-09	9.02e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174654718	chr1:174115300~174160004:-
THCA	cis	rs6802315	0.573	rs7635993	ENSG00000272247.1	RP11-379F4.9	-5.97	4.68e-09	9.02e-07	-0.25	-0.27	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158801257~158801935:-
THCA	cis	rs712022	0.534	rs4281481	ENSG00000246225.5	RP11-17A1.3	-5.97	4.68e-09	9.02e-07	-0.36	-0.27	Dialysis-related mortality;	chr11:22859013	chr11:22829380~22945393:+
THCA	cis	rs736801	0.808	rs4705950	ENSG00000224431.1	AC063976.7	5.97	4.68e-09	9.03e-07	0.24	0.27	Mosquito bite size;Breast cancer;	chr5:132457594	chr5:132199456~132203487:+
THCA	cis	rs6545883	0.831	rs2592356	ENSG00000271889.1	RP11-493E12.1	5.97	4.68e-09	9.03e-07	0.25	0.27	Tuberculosis;	chr2:61583293	chr2:61151433~61162105:-
THCA	cis	rs748404	0.666	rs35326382	ENSG00000249839.1	AC011330.5	-5.97	4.69e-09	9.04e-07	-0.38	-0.27	Lung cancer;	chr15:43338686	chr15:43663654~43684339:-
THCA	cis	rs72843506	0.656	rs56138907	ENSG00000270091.1	RP11-78O7.2	-5.97	4.69e-09	9.04e-07	-0.29	-0.27	Schizophrenia;	chr17:20085732	chr17:19896590~19897287:-
THCA	cis	rs2281558	0.833	rs6115202	ENSG00000274414.1	RP5-965G21.4	5.97	4.69e-09	9.04e-07	0.33	0.27	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:25239007~25245229:-
THCA	cis	rs9677476	0.821	rs6731682	ENSG00000224376.1	AC017104.6	5.97	4.69e-09	9.04e-07	0.3	0.27	Food antigen IgG levels;	chr2:231241532	chr2:231388976~231394991:+
THCA	cis	rs1030877	0.515	rs17030766	ENSG00000235319.1	AC012360.4	5.97	4.7e-09	9.05e-07	0.35	0.27	Obesity-related traits;	chr2:105295448	chr2:105324210~105330529:+
THCA	cis	rs2243480	1	rs4718333	ENSG00000232546.1	RP11-458F8.1	5.97	4.7e-09	9.06e-07	0.35	0.27	Diabetic kidney disease;	chr7:66307771	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs7792391	ENSG00000232546.1	RP11-458F8.1	5.97	4.7e-09	9.06e-07	0.35	0.27	Diabetic kidney disease;	chr7:66308442	chr7:66848496~66858136:+
THCA	cis	rs11158026	0.603	rs68065548	ENSG00000258413.1	RP11-665C16.6	-5.97	4.7e-09	9.06e-07	-0.38	-0.27	Parkinson's disease;	chr14:54979835	chr14:55262767~55272075:-
THCA	cis	rs67478160	0.643	rs11160762	ENSG00000258735.1	LINC00637	5.97	4.7e-09	9.06e-07	0.32	0.27	Schizophrenia;	chr14:103788746	chr14:103847721~103858049:+
THCA	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	5.97	4.7e-09	9.07e-07	0.42	0.27	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
THCA	cis	rs4950322	0.57	rs4950315	ENSG00000278811.3	LINC00624	-5.97	4.7e-09	9.07e-07	-0.33	-0.27	Protein quantitative trait loci;	chr1:147264433	chr1:147258885~147517875:-
THCA	cis	rs1707322	0.721	rs10430124	ENSG00000281133.1	AL355480.3	-5.97	4.71e-09	9.07e-07	-0.33	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45580892~45580996:-
THCA	cis	rs10895275	0.625	rs10791566	ENSG00000277459.1	RP11-732A21.3	5.97	4.71e-09	9.07e-07	0.2	0.27	Migraine;	chr11:102170530	chr11:102109827~102110457:-
THCA	cis	rs2348418	0.798	rs10771423	ENSG00000247934.4	RP11-967K21.1	5.97	4.71e-09	9.07e-07	0.23	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28396205	chr12:28163298~28190738:-
THCA	cis	rs7324557	0.717	rs9510866	ENSG00000205861.10	C1QTNF9B-AS1	-5.97	4.71e-09	9.08e-07	-0.33	-0.27	Visceral adipose tissue adjusted for BMI;	chr13:23806708	chr13:23888889~23897263:+
THCA	cis	rs8012947	0.916	rs11851552	ENSG00000279636.2	LINC00216	5.97	4.71e-09	9.08e-07	0.29	0.27	Alcohol consumption in current drinkers;	chr14:58240032	chr14:58288033~58289158:+
THCA	cis	rs2765539	0.772	rs2148150	ENSG00000231365.4	RP11-418J17.1	-5.97	4.71e-09	9.08e-07	-0.26	-0.27	Waist-hip ratio;	chr1:119029434	chr1:119140396~119275973:+
THCA	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-5.97	4.72e-09	9.1e-07	-0.3	-0.27	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
THCA	cis	rs748404	0.697	rs1814323	ENSG00000166763.7	STRCP1	-5.97	4.73e-09	9.11e-07	-0.28	-0.27	Lung cancer;	chr15:43271039	chr15:43699488~43718184:-
THCA	cis	rs11976180	1	rs2371244	ENSG00000273234.1	OR2A13P	-5.97	4.73e-09	9.11e-07	-0.29	-0.27	Obesity-related traits;	chr7:144060518	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs4726669	ENSG00000273234.1	OR2A13P	-5.97	4.73e-09	9.11e-07	-0.29	-0.27	Obesity-related traits;	chr7:144061098	chr7:144142009~144142938:+
THCA	cis	rs9921338	0.961	rs7191093	ENSG00000262703.1	RP11-485G7.6	-5.97	4.73e-09	9.11e-07	-0.35	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348422	chr16:11348143~11349321:-
THCA	cis	rs1823913	1	rs1454749	ENSG00000280083.1	RP11-317J9.1	-5.97	4.73e-09	9.11e-07	-0.33	-0.27	Obesity-related traits;	chr2:191240909	chr2:191154118~191156070:-
THCA	cis	rs1823913	1	rs4853561	ENSG00000280083.1	RP11-317J9.1	5.97	4.73e-09	9.11e-07	0.33	0.27	Obesity-related traits;	chr2:191242980	chr2:191154118~191156070:-
THCA	cis	rs4908768	0.501	rs4908760	ENSG00000232912.4	RP5-1115A15.1	5.97	4.73e-09	9.11e-07	0.26	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8466082	chr1:8424645~8434838:+
THCA	cis	rs9813712	0.597	rs62281648	ENSG00000249846.5	RP11-77P16.4	-5.97	4.73e-09	9.12e-07	-0.27	-0.27	Response to amphetamines;	chr3:130244794	chr3:130112550~130120579:+
THCA	cis	rs62359376	1	rs62359376	ENSG00000247796.2	CTD-2366F13.1	5.97	4.74e-09	9.12e-07	0.38	0.27	Systemic juvenile idiopathic arthritis;	chr5:53115498	chr5:53109842~53115126:+
THCA	cis	rs17772222	0.917	rs1956406	ENSG00000258789.1	RP11-507K2.3	-5.97	4.74e-09	9.13e-07	-0.26	-0.27	Coronary artery calcification;	chr14:88749711	chr14:88551597~88552493:+
THCA	cis	rs3950186	0.834	rs66805427	ENSG00000215124.2	RP3-420J14.1	5.97	4.74e-09	9.13e-07	0.32	0.27	Anxiety and major depressive disorder;	chr6:11826729	chr6:11861626~11862970:-
THCA	cis	rs8012947	0.916	rs11627199	ENSG00000279636.2	LINC00216	5.97	4.75e-09	9.15e-07	0.29	0.27	Alcohol consumption in current drinkers;	chr14:58386288	chr14:58288033~58289158:+
THCA	cis	rs17772222	0.917	rs58984912	ENSG00000222990.1	RNU4-22P	5.97	4.75e-09	9.15e-07	0.34	0.27	Coronary artery calcification;	chr14:88698172	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.917	rs17188207	ENSG00000222990.1	RNU4-22P	5.97	4.75e-09	9.15e-07	0.34	0.27	Coronary artery calcification;	chr14:88699579	chr14:88513498~88513663:+
THCA	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	5.97	4.75e-09	9.15e-07	0.2	0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
THCA	cis	rs9467773	1	rs9393731	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs11756120	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs9393732	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs9358954	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs28558133	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs10946834	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs10946835	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs9467778	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs2393670	ENSG00000124549.13	BTN2A3P	5.97	4.75e-09	9.15e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26421391~26432383:+
THCA	cis	rs7809950	1	rs7793613	ENSG00000238832.1	snoU109	-5.97	4.75e-09	9.16e-07	-0.29	-0.27	Coronary artery disease;	chr7:107610039	chr7:107603363~107603507:+
THCA	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	5.97	4.76e-09	9.16e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
THCA	cis	rs9921338	0.886	rs3931015	ENSG00000262636.1	CTD-3088G3.4	5.97	4.76e-09	9.16e-07	0.38	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321782	chr16:11380859~11381118:-
THCA	cis	rs149313	1	rs149313	ENSG00000248734.2	CTD-2260A17.1	-5.97	4.76e-09	9.16e-07	-0.26	-0.27	Blood protein levels;	chr5:96734501	chr5:96784777~96785999:+
THCA	cis	rs6674176	0.561	rs12127226	ENSG00000237950.1	RP11-7O11.3	5.97	4.76e-09	9.16e-07	0.24	0.27	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43929637	chr1:43944370~43946551:-
THCA	cis	rs6902257	1	rs2503730	ENSG00000272129.1	RP11-250B2.6	-5.97	4.76e-09	9.17e-07	-0.7	-0.27	Obesity-related traits;	chr6:80610884	chr6:80355424~80356859:+
THCA	cis	rs7809950	1	rs2066735	ENSG00000238832.1	snoU109	-5.97	4.76e-09	9.17e-07	-0.29	-0.27	Coronary artery disease;	chr7:107548274	chr7:107603363~107603507:+
THCA	cis	rs12701220	0.947	rs1007765	ENSG00000229043.2	AC091729.9	-5.97	4.76e-09	9.17e-07	-0.37	-0.27	Bronchopulmonary dysplasia;	chr7:993169	chr7:1160374~1165267:+
THCA	cis	rs17345786	1	rs3762729	ENSG00000256628.3	ZBTB11-AS1	5.97	4.76e-09	9.17e-07	0.33	0.27	Colonoscopy-negative controls vs population controls;	chr3:101590030	chr3:101676475~101679217:+
THCA	cis	rs2439831	0.867	rs2447196	ENSG00000166763.7	STRCP1	-5.97	4.77e-09	9.18e-07	-0.36	-0.27	Lung cancer in ever smokers;	chr15:43601620	chr15:43699488~43718184:-
THCA	cis	rs6026584	1	rs2057291	ENSG00000270951.1	RP1-309F20.4	-5.97	4.77e-09	9.18e-07	-0.29	-0.27	Renal function-related traits (BUN);	chr20:58896988	chr20:58876592~58876981:-
THCA	cis	rs6026584	1	rs1407040	ENSG00000270951.1	RP1-309F20.4	-5.97	4.77e-09	9.18e-07	-0.29	-0.27	Renal function-related traits (BUN);	chr20:58897119	chr20:58876592~58876981:-
THCA	cis	rs2036707	1	rs2036707	ENSG00000276740.1	RP11-381O6.1	5.97	4.77e-09	9.18e-07	0.48	0.27	Obesity-related traits;	chr13:107832106	chr13:107465984~107466674:-
THCA	cis	rs12908161	1	rs35960805	ENSG00000259295.5	CSPG4P12	5.97	4.77e-09	9.18e-07	0.4	0.27	Schizophrenia;	chr15:84800749	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs12912388	ENSG00000259295.5	CSPG4P12	5.97	4.77e-09	9.18e-07	0.4	0.27	Schizophrenia;	chr15:84801319	chr15:85191438~85213905:+
THCA	cis	rs4784934	0.589	rs12932284	ENSG00000260186.4	RP11-481J2.2	5.97	4.77e-09	9.18e-07	0.37	0.27	QT interval;	chr16:58434675	chr16:58421326~58462470:+
THCA	cis	rs9329221	0.538	rs2272598	ENSG00000261451.1	RP11-981G7.1	-5.97	4.77e-09	9.18e-07	-0.34	-0.27	Neuroticism;	chr8:10243259	chr8:10433672~10438312:+
THCA	cis	rs2692947	0.55	rs12623771	ENSG00000232931.4	LINC00342	5.97	4.77e-09	9.18e-07	0.21	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95967756	chr2:95807118~95816215:-
THCA	cis	rs2692947	0.826	rs7423942	ENSG00000232931.4	LINC00342	5.97	4.77e-09	9.18e-07	0.21	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979509	chr2:95807118~95816215:-
THCA	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-5.97	4.77e-09	9.18e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
THCA	cis	rs9467773	1	rs1321480	ENSG00000124549.13	BTN2A3P	5.97	4.77e-09	9.19e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26421391~26432383:+
THCA	cis	rs6921919	0.562	rs13198809	ENSG00000219392.1	RP1-265C24.5	-5.97	4.77e-09	9.19e-07	-0.58	-0.27	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs35353359	ENSG00000219392.1	RP1-265C24.5	-5.97	4.77e-09	9.19e-07	-0.58	-0.27	Depression;	chr6:28356601	chr6:28115628~28116551:+
THCA	cis	rs9494145	0.652	rs9399137	ENSG00000232876.1	CTA-212D2.2	-5.97	4.77e-09	9.19e-07	-0.39	-0.27	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135097880	chr6:135055033~135060550:+
THCA	cis	rs9494145	0.567	rs35786788	ENSG00000232876.1	CTA-212D2.2	-5.97	4.77e-09	9.19e-07	-0.39	-0.27	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135097904	chr6:135055033~135060550:+
THCA	cis	rs853679	0.546	rs200949	ENSG00000280107.1	AL022393.9	-5.97	4.77e-09	9.19e-07	-0.38	-0.27	Depression;	chr6:27867657	chr6:28170845~28172521:+
THCA	cis	rs6600671	0.967	rs11249349	ENSG00000275538.1	RNVU1-19	5.97	4.77e-09	9.19e-07	0.33	0.27	Hip geometry;	chr1:121437310	chr1:120850819~120850985:-
THCA	cis	rs6142102	0.961	rs8123521	ENSG00000275784.1	RP5-1125A11.6	-5.97	4.78e-09	9.2e-07	-0.28	-0.27	Skin pigmentation;	chr20:34081079	chr20:33989480~33991818:-
THCA	cis	rs2243480	1	rs1499614	ENSG00000232546.1	RP11-458F8.1	-5.97	4.78e-09	9.2e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66265811	chr7:66848496~66858136:+
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000237310.1	GS1-124K5.4	5.97	4.78e-09	9.2e-07	0.19	0.27	Calcium levels;	chr7:65806798	chr7:66493706~66495474:+
THCA	cis	rs3213758	0.541	rs7192060	ENSG00000275191.1	RP11-36I17.2	5.97	4.78e-09	9.21e-07	0.38	0.27	Vitiligo (non-segmental);	chr16:53658287	chr16:53628256~53628816:-
THCA	cis	rs12701220	0.894	rs12701348	ENSG00000229043.2	AC091729.9	-5.97	4.78e-09	9.21e-07	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:999821	chr7:1160374~1165267:+
THCA	cis	rs9859260	0.744	rs539816	ENSG00000242086.7	LINC00969	-5.97	4.79e-09	9.21e-07	-0.26	-0.27	Mean corpuscular volume;	chr3:196057205	chr3:195658062~195739964:+
THCA	cis	rs9859260	0.744	rs492349	ENSG00000242086.7	LINC00969	-5.97	4.79e-09	9.21e-07	-0.26	-0.27	Mean corpuscular volume;	chr3:196057321	chr3:195658062~195739964:+
THCA	cis	rs9859260	0.744	rs492288	ENSG00000242086.7	LINC00969	-5.97	4.79e-09	9.21e-07	-0.26	-0.27	Mean corpuscular volume;	chr3:196057339	chr3:195658062~195739964:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-5.97	4.79e-09	9.22e-07	-0.3	-0.27	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
THCA	cis	rs7246657	0.722	rs2927739	ENSG00000267422.1	CTD-2554C21.1	5.97	4.79e-09	9.22e-07	0.3	0.27	Coronary artery calcification;	chr19:37658429	chr19:37779686~37792865:+
THCA	cis	rs763567	0.9	rs525489	ENSG00000271811.1	RP1-79C4.4	5.97	4.79e-09	9.23e-07	0.31	0.27	Tonsillectomy;	chr1:170665861	chr1:170667381~170669425:+
THCA	cis	rs763567	0.835	rs503706	ENSG00000271811.1	RP1-79C4.4	5.97	4.79e-09	9.23e-07	0.31	0.27	Tonsillectomy;	chr1:170665943	chr1:170667381~170669425:+
THCA	cis	rs7809950	1	rs2520268	ENSG00000238832.1	snoU109	-5.97	4.79e-09	9.23e-07	-0.28	-0.27	Coronary artery disease;	chr7:107550716	chr7:107603363~107603507:+
THCA	cis	rs7260598	0.642	rs10405341	ENSG00000268442.1	CTD-2027I19.2	5.97	4.8e-09	9.24e-07	0.36	0.27	Response to taxane treatment (placlitaxel);	chr19:23924450	chr19:24162370~24163425:-
THCA	cis	rs10829156	0.679	rs4747352	ENSG00000240291.1	RP11-499P20.2	5.97	4.8e-09	9.24e-07	0.22	0.27	Sudden cardiac arrest;	chr10:18539734	chr10:18513115~18545651:-
THCA	cis	rs12188164	0.84	rs67665078	ENSG00000225138.6	CTD-2228K2.7	5.97	4.81e-09	9.25e-07	0.26	0.27	Cystic fibrosis severity;	chr5:428639	chr5:473236~480884:+
THCA	cis	rs12680842	0.576	rs35593078	ENSG00000253704.1	RP11-267M23.4	5.97	4.81e-09	9.25e-07	0.26	0.27	Body mass index;	chr8:94614917	chr8:94553722~94569745:+
THCA	cis	rs6991838	0.806	rs13262793	ENSG00000200714.1	Y_RNA	5.97	4.81e-09	9.26e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65592731~65592820:+
THCA	cis	rs4650994	0.524	rs2761465	ENSG00000273384.1	RP5-1098D14.1	-5.97	4.81e-09	9.26e-07	-0.34	-0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178610269	chr1:178651706~178652282:+
THCA	cis	rs2559856	0.935	rs2559864	ENSG00000274560.1	RP11-285E23.2	5.96	4.82e-09	9.27e-07	0.16	0.27	Blood protein levels;	chr12:101690932	chr12:101696002~101696450:-
THCA	cis	rs10029851	0.54	rs7682499	ENSG00000234492.4	RPL34-AS1	5.96	4.82e-09	9.27e-07	0.31	0.27	Amyotrophic lateral sclerosis (sporadic);	chr4:108596565	chr4:108538190~108620460:-
THCA	cis	rs17772222	0.917	rs57889459	ENSG00000222990.1	RNU4-22P	5.96	4.82e-09	9.28e-07	0.34	0.27	Coronary artery calcification;	chr14:88770820	chr14:88513498~88513663:+
THCA	cis	rs9467773	0.935	rs11752946	ENSG00000124549.13	BTN2A3P	5.96	4.82e-09	9.28e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26421391~26432383:+
THCA	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	5.96	4.83e-09	9.28e-07	0.35	0.27	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
THCA	cis	rs9467773	0.967	rs1535276	ENSG00000124549.13	BTN2A3P	5.96	4.83e-09	9.29e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26520713	chr6:26421391~26432383:+
THCA	cis	rs2562456	1	rs2359155	ENSG00000213976.4	CTD-2561J22.2	5.96	4.83e-09	9.29e-07	0.28	0.27	Pain;	chr19:21489067	chr19:21382865~21387177:+
THCA	cis	rs4819052	0.704	rs2297283	ENSG00000237664.1	LINC00316	-5.96	4.83e-09	9.29e-07	-0.27	-0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45338590~45341990:-
THCA	cis	rs3204270	0.53	rs57707013	ENSG00000262049.1	RP13-1032I1.7	5.96	4.83e-09	9.29e-07	0.23	0.27	Dental caries;	chr17:81668251	chr17:81701324~81703300:-
THCA	cis	rs2281636	0.898	rs7903514	ENSG00000260475.1	RP11-85A1.3	5.96	4.83e-09	9.29e-07	0.24	0.27	Obesity-related traits;	chr10:99705951	chr10:99621055~99621918:+
THCA	cis	rs6951245	0.638	rs4720486	ENSG00000229043.2	AC091729.9	-5.96	4.83e-09	9.29e-07	-0.35	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1160374~1165267:+
THCA	cis	rs274567	0.501	rs272856	ENSG00000263597.1	MIR3936	5.96	4.83e-09	9.3e-07	0.27	0.27	Blood metabolite levels;	chr5:132351388	chr5:132365490~132365599:-
THCA	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	5.96	4.83e-09	9.3e-07	0.26	0.27	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
THCA	cis	rs2559856	1	rs2695296	ENSG00000274560.1	RP11-285E23.2	5.96	4.83e-09	9.3e-07	0.16	0.27	Blood protein levels;	chr12:101691709	chr12:101696002~101696450:-
THCA	cis	rs17345786	1	rs3804775	ENSG00000256628.3	ZBTB11-AS1	5.96	4.83e-09	9.3e-07	0.33	0.27	Colonoscopy-negative controls vs population controls;	chr3:101587663	chr3:101676475~101679217:+
THCA	cis	rs9921338	0.961	rs4315353	ENSG00000262636.1	CTD-3088G3.4	5.96	4.84e-09	9.3e-07	0.38	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320303	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs4356497	ENSG00000262636.1	CTD-3088G3.4	5.96	4.84e-09	9.3e-07	0.38	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320339	chr16:11380859~11381118:-
THCA	cis	rs9467773	1	rs9295695	ENSG00000124549.13	BTN2A3P	-5.96	4.84e-09	9.3e-07	-0.25	-0.27	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs9295694	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs9467775	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs9393729	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs6456732	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs4713006	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs6924865	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6925703	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6910899	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs9461267	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs1056347	ENSG00000124549.13	BTN2A3P	5.96	4.84e-09	9.3e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26421391~26432383:+
THCA	cis	rs3764400	0.508	rs2240121	ENSG00000278765.1	RP5-890E16.5	5.96	4.84e-09	9.3e-07	0.48	0.27	Body mass index;	chr17:48074960	chr17:48066704~48067293:-
THCA	cis	rs11976180	1	rs6464574	ENSG00000273234.1	OR2A13P	-5.96	4.84e-09	9.31e-07	-0.31	-0.27	Obesity-related traits;	chr7:144051164	chr7:144142009~144142938:+
THCA	cis	rs12908161	0.853	rs12912342	ENSG00000225151.9	GOLGA2P7	-5.96	4.84e-09	9.31e-07	-0.37	-0.27	Schizophrenia;	chr15:84704985	chr15:84199311~84230136:-
THCA	cis	rs338389	0.542	rs8036189	ENSG00000260657.2	RP11-315D16.4	-5.96	4.84e-09	9.32e-07	-0.36	-0.27	Survival in rectal cancer;	chr15:68000614	chr15:68267792~68277994:-
THCA	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	5.96	4.85e-09	9.32e-07	0.34	0.27	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
THCA	cis	rs10896609	0.55	rs2003065	ENSG00000254662.1	RP11-872D17.4	-5.96	4.85e-09	9.32e-07	-0.45	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:57349233	chr11:57325603~57327958:+
THCA	cis	rs4950322	0.576	rs4950427	ENSG00000237188.3	RP11-337C18.8	-5.96	4.85e-09	9.32e-07	-0.29	-0.27	Protein quantitative trait loci;	chr1:147391175	chr1:147172771~147211568:+
THCA	cis	rs7580658	0.68	rs6710535	ENSG00000236682.1	AC068282.3	5.96	4.85e-09	9.32e-07	0.35	0.27	Protein C levels;	chr2:127433384	chr2:127389130~127400580:+
THCA	cis	rs950169	0.58	rs1061737	ENSG00000259295.5	CSPG4P12	5.96	4.85e-09	9.32e-07	0.41	0.27	Schizophrenia;	chr15:84640559	chr15:85191438~85213905:+
THCA	cis	rs6600671	0.934	rs11249348	ENSG00000275538.1	RNVU1-19	5.96	4.85e-09	9.32e-07	0.33	0.27	Hip geometry;	chr1:121446444	chr1:120850819~120850985:-
THCA	cis	rs12681366	0.708	rs2470732	ENSG00000253704.1	RP11-267M23.4	-5.96	4.85e-09	9.32e-07	-0.25	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94364719	chr8:94553722~94569745:+
THCA	cis	rs227275	0.556	rs6815526	ENSG00000251288.2	RP11-10L12.2	-5.96	4.85e-09	9.33e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs6824070	ENSG00000251288.2	RP11-10L12.2	-5.96	4.85e-09	9.33e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102751401~102752641:+
THCA	cis	rs11722779	0.935	rs6856176	ENSG00000251288.2	RP11-10L12.2	-5.96	4.85e-09	9.33e-07	-0.36	-0.27	Schizophrenia;	chr4:102902574	chr4:102751401~102752641:+
THCA	cis	rs227275	0.556	rs11722779	ENSG00000251288.2	RP11-10L12.2	-5.96	4.85e-09	9.33e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102751401~102752641:+
THCA	cis	rs755249	0.876	rs61781391	ENSG00000228060.1	RP11-69E11.8	-5.96	4.86e-09	9.34e-07	-0.3	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39565160~39573203:+
THCA	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-5.96	4.86e-09	9.34e-07	-0.31	-0.27	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
THCA	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	5.96	4.86e-09	9.34e-07	0.15	0.27	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
THCA	cis	rs7976269	0.515	rs10743637	ENSG00000275476.1	RP11-996F15.4	5.96	4.86e-09	9.34e-07	0.27	0.27	Male-pattern baldness;	chr12:29025962	chr12:29277397~29277882:-
THCA	cis	rs1876905	0.597	rs354538	ENSG00000230177.1	RP5-1112D6.4	-5.96	4.86e-09	9.34e-07	-0.27	-0.27	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.68	rs434034	ENSG00000230177.1	RP5-1112D6.4	-5.96	4.86e-09	9.34e-07	-0.27	-0.27	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111277932~111278742:+
THCA	cis	rs6840360	0.582	rs2709823	ENSG00000270265.1	RP11-731D1.4	-5.96	4.86e-09	9.35e-07	-0.25	-0.27	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151333775~151353224:-
THCA	cis	rs9926296	0.568	rs417323	ENSG00000274627.1	RP11-104N10.2	5.96	4.86e-09	9.35e-07	0.27	0.27	Vitiligo;	chr16:89679869	chr16:89516797~89522217:+
THCA	cis	rs6545883	0.929	rs6707830	ENSG00000270820.4	RP11-355B11.2	5.96	4.87e-09	9.35e-07	0.22	0.27	Tuberculosis;	chr2:61522337	chr2:61471188~61484130:+
THCA	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	5.96	4.87e-09	9.35e-07	0.32	0.27	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
THCA	cis	rs6860806	0.661	rs4705927	ENSG00000224431.1	AC063976.7	5.96	4.87e-09	9.36e-07	0.23	0.27	Breast cancer;	chr5:132242915	chr5:132199456~132203487:+
THCA	cis	rs7560272	0.723	rs7609249	ENSG00000163016.8	ALMS1P	5.96	4.87e-09	9.36e-07	0.34	0.27	Schizophrenia;	chr2:73586693	chr2:73644919~73685576:+
THCA	cis	rs7560272	0.723	rs6743576	ENSG00000163016.8	ALMS1P	5.96	4.87e-09	9.36e-07	0.34	0.27	Schizophrenia;	chr2:73587206	chr2:73644919~73685576:+
THCA	cis	rs712022	0.537	rs4420266	ENSG00000246225.5	RP11-17A1.3	-5.96	4.87e-09	9.36e-07	-0.35	-0.27	Dialysis-related mortality;	chr11:22852637	chr11:22829380~22945393:+
THCA	cis	rs6860806	0.695	rs11952099	ENSG00000224431.1	AC063976.7	5.96	4.87e-09	9.37e-07	0.23	0.27	Breast cancer;	chr5:132241079	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.661	rs2136187	ENSG00000224431.1	AC063976.7	5.96	4.87e-09	9.37e-07	0.23	0.27	Breast cancer;	chr5:132242201	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.661	rs2171247	ENSG00000224431.1	AC063976.7	5.96	4.88e-09	9.37e-07	0.23	0.27	Breast cancer;	chr5:132244541	chr5:132199456~132203487:+
THCA	cis	rs34779708	0.733	rs60616028	ENSG00000271335.4	RP11-324I22.4	5.96	4.88e-09	9.38e-07	0.26	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35254874	chr10:35314552~35336401:-
THCA	cis	rs728616	0.867	rs61860417	ENSG00000242600.5	MBL1P	5.96	4.88e-09	9.38e-07	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79904898~79950336:+
THCA	cis	rs4713118	0.824	rs742046	ENSG00000280107.1	AL022393.9	-5.96	4.89e-09	9.39e-07	-0.32	-0.27	Parkinson's disease;	chr6:27771475	chr6:28170845~28172521:+
THCA	cis	rs1861628	1	rs737310	ENSG00000237930.1	AC007563.4	5.96	4.89e-09	9.4e-07	0.3	0.27	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216758503	chr2:216785774~216786144:-
THCA	cis	rs1861628	0.927	rs737308	ENSG00000237930.1	AC007563.4	5.96	4.89e-09	9.4e-07	0.3	0.27	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216758526	chr2:216785774~216786144:-
THCA	cis	rs9402743	0.816	rs9402738	ENSG00000231028.7	LINC00271	-5.96	4.89e-09	9.4e-07	-0.21	-0.27	Systemic lupus erythematosus;	chr6:135652112	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.74	rs9494318	ENSG00000231028.7	LINC00271	-5.96	4.89e-09	9.4e-07	-0.21	-0.27	Systemic lupus erythematosus;	chr6:135653519	chr6:135497801~135716055:+
THCA	cis	rs17772222	0.958	rs59136503	ENSG00000222990.1	RNU4-22P	5.96	4.89e-09	9.4e-07	0.35	0.27	Coronary artery calcification;	chr14:88501921	chr14:88513498~88513663:+
THCA	cis	rs934734	0.752	rs198478	ENSG00000281920.1	RP11-418H16.1	-5.96	4.9e-09	9.41e-07	-0.33	-0.27	Rheumatoid arthritis;	chr2:65379877	chr2:65623272~65628424:+
THCA	cis	rs6545883	0.868	rs6748003	ENSG00000271889.1	RP11-493E12.1	5.96	4.9e-09	9.41e-07	0.25	0.27	Tuberculosis;	chr2:61579565	chr2:61151433~61162105:-
THCA	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	5.96	4.9e-09	9.41e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
THCA	cis	rs287982	0.611	rs112561492	ENSG00000269973.1	RP11-95D17.1	-5.96	4.9e-09	9.41e-07	-0.23	-0.27	Nonsyndromic cleft lip with cleft palate;	chr2:9838991	chr2:9936360~9939590:+
THCA	cis	rs6545883	0.899	rs1562309	ENSG00000271889.1	RP11-493E12.1	5.96	4.9e-09	9.42e-07	0.26	0.27	Tuberculosis;	chr2:61542991	chr2:61151433~61162105:-
THCA	cis	rs987724	0.778	rs2321295	ENSG00000240875.4	LINC00886	-5.96	4.9e-09	9.42e-07	-0.21	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156944556	chr3:156747346~156817062:-
THCA	cis	rs2281636	0.755	rs2111324	ENSG00000260475.1	RP11-85A1.3	5.96	4.91e-09	9.43e-07	0.24	0.27	Obesity-related traits;	chr10:99636807	chr10:99621055~99621918:+
THCA	cis	rs17345786	1	rs73863360	ENSG00000256628.3	ZBTB11-AS1	5.96	4.92e-09	9.44e-07	0.33	0.27	Colonoscopy-negative controls vs population controls;	chr3:101597993	chr3:101676475~101679217:+
THCA	cis	rs17345786	0.911	rs10936707	ENSG00000256628.3	ZBTB11-AS1	5.96	4.92e-09	9.44e-07	0.33	0.27	Colonoscopy-negative controls vs population controls;	chr3:101605219	chr3:101676475~101679217:+
THCA	cis	rs10875746	0.669	rs10467101	ENSG00000269514.1	RP11-370I10.12	5.96	4.92e-09	9.44e-07	0.26	0.27	Longevity (90 years and older);	chr12:48213954	chr12:48198387~48202031:+
THCA	cis	rs4908760	0.965	rs10864354	ENSG00000232912.4	RP5-1115A15.1	5.96	4.92e-09	9.45e-07	0.26	0.27	Vitiligo;	chr1:8489681	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs7530745	ENSG00000232912.4	RP5-1115A15.1	5.96	4.92e-09	9.45e-07	0.26	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497631	chr1:8424645~8434838:+
THCA	cis	rs7688540	0.771	rs2353605	ENSG00000211553.1	AC253576.2	-5.96	4.92e-09	9.45e-07	-0.39	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:136461~136568:+
THCA	cis	rs227917	1	rs227917	ENSG00000234286.1	AC006026.13	5.96	4.92e-09	9.45e-07	0.39	0.27	Common carotid intima-media thickness in HIV negative individuals;	chr7:23606698	chr7:23680195~23680786:-
THCA	cis	rs228614	0.51	rs223438	ENSG00000251288.2	RP11-10L12.2	5.96	4.92e-09	9.45e-07	0.35	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102751401~102752641:+
THCA	cis	rs9309473	0.5	rs10189578	ENSG00000163016.8	ALMS1P	5.96	4.92e-09	9.46e-07	0.34	0.27	Metabolite levels;	chr2:73501482	chr2:73644919~73685576:+
THCA	cis	rs6142102	1	rs2143230	ENSG00000275784.1	RP5-1125A11.6	-5.96	4.93e-09	9.47e-07	-0.27	-0.27	Skin pigmentation;	chr20:34136539	chr20:33989480~33991818:-
THCA	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	5.96	4.93e-09	9.47e-07	0.34	0.27	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
THCA	cis	rs11671005	0.735	rs56292587	ENSG00000269473.1	CTD-2619J13.19	5.96	4.93e-09	9.47e-07	0.3	0.27	Mean platelet volume;	chr19:58407699	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs56290606	ENSG00000269473.1	CTD-2619J13.19	5.96	4.93e-09	9.47e-07	0.3	0.27	Mean platelet volume;	chr19:58407953	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs11878198	ENSG00000269473.1	CTD-2619J13.19	5.96	4.93e-09	9.47e-07	0.3	0.27	Mean platelet volume;	chr19:58408935	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs11666716	ENSG00000269473.1	CTD-2619J13.19	5.96	4.93e-09	9.47e-07	0.3	0.27	Mean platelet volume;	chr19:58409585	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs34511020	ENSG00000269473.1	CTD-2619J13.19	5.96	4.93e-09	9.47e-07	0.3	0.27	Mean platelet volume;	chr19:58409929	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs11666303	ENSG00000269473.1	CTD-2619J13.19	5.96	4.93e-09	9.47e-07	0.3	0.27	Mean platelet volume;	chr19:58411135	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs34152946	ENSG00000269473.1	CTD-2619J13.19	5.96	4.93e-09	9.47e-07	0.3	0.27	Mean platelet volume;	chr19:58411896	chr19:58440448~58445849:+
THCA	cis	rs1979679	0.808	rs10843115	ENSG00000278733.1	RP11-425D17.1	5.96	4.93e-09	9.47e-07	0.26	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28154784	chr12:28185625~28186190:-
THCA	cis	rs2439831	0.867	rs4583210	ENSG00000249839.1	AC011330.5	-5.96	4.93e-09	9.48e-07	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43368727	chr15:43663654~43684339:-
THCA	cis	rs7712401	0.791	rs6595409	ENSG00000249996.1	RP11-359P5.1	5.96	4.94e-09	9.48e-07	0.25	0.27	Mean platelet volume;	chr5:122778061	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.791	rs1870559	ENSG00000249996.1	RP11-359P5.1	5.96	4.94e-09	9.48e-07	0.25	0.27	Mean platelet volume;	chr5:122781011	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.791	rs10059964	ENSG00000249996.1	RP11-359P5.1	5.96	4.94e-09	9.48e-07	0.25	0.27	Mean platelet volume;	chr5:122782598	chr5:123036271~123054667:+
THCA	cis	rs12030196	0.788	rs2716122	ENSG00000230812.4	LINC01358	5.96	4.94e-09	9.49e-07	0.32	0.27	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58964673	chr1:59020387~59044614:+
THCA	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	5.96	4.94e-09	9.49e-07	0.29	0.27	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
THCA	cis	rs12497850	0.931	rs6446205	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48997778	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.897	rs6795025	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:49043814	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.897	rs7432989	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:49067703	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.897	rs7373778	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48798959	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9876848	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48806626	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.805	rs11130176	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48806644	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9311430	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48807818	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9311432	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48813010	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9682444	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48815206	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9835307	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48820372	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9311433	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48826402	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9755490	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48834231	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs7430501	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48852686	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs10780033	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48853842	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs9840684	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48856347	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.864	rs7431857	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48862914	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs4974079	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48869036	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.897	rs6446252	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48873692	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs4974087	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48881799	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs4974085	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48887467	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs28642807	ENSG00000229759.1	MRPS18AP1	5.96	4.94e-09	9.49e-07	0.35	0.27	Parkinson's disease;	chr3:48889383	chr3:48256350~48256938:-
THCA	cis	rs6142102	0.961	rs4911390	ENSG00000275784.1	RP5-1125A11.6	-5.96	4.95e-09	9.49e-07	-0.28	-0.27	Skin pigmentation;	chr20:33977401	chr20:33989480~33991818:-
THCA	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-5.96	4.95e-09	9.5e-07	-0.24	-0.27	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
THCA	cis	rs1395	0.922	rs4665376	ENSG00000234072.1	AC074117.10	-5.96	4.95e-09	9.5e-07	-0.22	-0.27	Blood metabolite levels;	chr2:27286164	chr2:27356246~27367622:+
THCA	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-5.96	4.95e-09	9.5e-07	-0.34	-0.27	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
THCA	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	5.96	4.95e-09	9.5e-07	0.29	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
THCA	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	5.96	4.95e-09	9.51e-07	0.33	0.27	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
THCA	cis	rs9926296	0.744	rs352939	ENSG00000274627.1	RP11-104N10.2	5.96	4.95e-09	9.51e-07	0.27	0.27	Vitiligo;	chr16:89643970	chr16:89516797~89522217:+
THCA	cis	rs12893668	0.581	rs34843146	ENSG00000269910.1	RP11-73M18.10	5.96	4.95e-09	9.51e-07	0.25	0.27	Reticulocyte count;	chr14:103613527	chr14:103694516~103695050:-
THCA	cis	rs2348418	0.832	rs1907692	ENSG00000247934.4	RP11-967K21.1	5.96	4.95e-09	9.51e-07	0.23	0.27	Lung function (FEV1);Lung function (FVC);	chr12:28385178	chr12:28163298~28190738:-
THCA	cis	rs227275	0.556	rs28367331	ENSG00000251288.2	RP11-10L12.2	-5.96	4.95e-09	9.51e-07	-0.36	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102751401~102752641:+
THCA	cis	rs467650	0.553	rs149508	ENSG00000246763.5	RGMB-AS1	5.96	4.95e-09	9.51e-07	0.31	0.27	Venous thromboembolism (SNP x SNP interaction);	chr5:98642741	chr5:98769618~98773469:-
THCA	cis	rs467650	0.553	rs40807	ENSG00000246763.5	RGMB-AS1	5.96	4.95e-09	9.51e-07	0.31	0.27	Venous thromboembolism (SNP x SNP interaction);	chr5:98646095	chr5:98769618~98773469:-
THCA	cis	rs467650	0.553	rs27706	ENSG00000246763.5	RGMB-AS1	5.96	4.95e-09	9.51e-07	0.31	0.27	Venous thromboembolism (SNP x SNP interaction);	chr5:98646475	chr5:98769618~98773469:-
THCA	cis	rs467650	0.553	rs40173	ENSG00000246763.5	RGMB-AS1	5.96	4.95e-09	9.51e-07	0.31	0.27	Venous thromboembolism (SNP x SNP interaction);	chr5:98647713	chr5:98769618~98773469:-
THCA	cis	rs467650	0.553	rs27020	ENSG00000246763.5	RGMB-AS1	5.96	4.95e-09	9.51e-07	0.31	0.27	Venous thromboembolism (SNP x SNP interaction);	chr5:98647962	chr5:98769618~98773469:-
THCA	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	5.96	4.96e-09	9.51e-07	0.26	0.27	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
THCA	cis	rs9921338	0.887	rs7189044	ENSG00000262636.1	CTD-3088G3.4	-5.96	4.96e-09	9.52e-07	-0.38	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348339	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs57579443	ENSG00000262636.1	CTD-3088G3.4	-5.96	4.96e-09	9.52e-07	-0.38	-0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11349140	chr16:11380859~11381118:-
THCA	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	5.96	4.96e-09	9.52e-07	0.35	0.27	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
THCA	cis	rs16846053	0.786	rs62187567	ENSG00000227403.1	AC009299.3	5.96	4.96e-09	9.52e-07	0.56	0.27	Blood osmolality (transformed sodium);	chr2:161506555	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs60824222	ENSG00000227403.1	AC009299.3	5.96	4.96e-09	9.52e-07	0.56	0.27	Cognitive function;	chr2:161512209	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.681	rs62187569	ENSG00000227403.1	AC009299.3	5.96	4.96e-09	9.52e-07	0.56	0.27	Blood osmolality (transformed sodium);	chr2:161517007	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187570	ENSG00000227403.1	AC009299.3	5.96	4.96e-09	9.52e-07	0.56	0.27	Cognitive function;	chr2:161517389	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187571	ENSG00000227403.1	AC009299.3	5.96	4.96e-09	9.52e-07	0.56	0.27	Cognitive function;	chr2:161517809	chr2:161244739~161249050:+
THCA	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	5.96	4.96e-09	9.52e-07	0.29	0.27	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
THCA	cis	rs11266744	0.566	rs2734225	ENSG00000223552.1	RP11-24F11.2	5.96	4.96e-09	9.52e-07	0.24	0.27	Monocyte percentage of white cells;	chr3:46369445	chr3:46364955~46407059:-
THCA	cis	rs9677476	0.863	rs62197323	ENSG00000224376.1	AC017104.6	5.96	4.96e-09	9.52e-07	0.3	0.27	Food antigen IgG levels;	chr2:231199000	chr2:231388976~231394991:+
THCA	cis	rs9926296	0.712	rs447735	ENSG00000274627.1	RP11-104N10.2	5.96	4.96e-09	9.52e-07	0.27	0.27	Vitiligo;	chr16:89667941	chr16:89516797~89522217:+
THCA	cis	rs793571	0.554	rs12439231	ENSG00000259250.1	RP11-50C13.1	-5.96	4.96e-09	9.53e-07	-0.29	-0.27	Schizophrenia;	chr15:58733396	chr15:58587507~58591676:+
THCA	cis	rs7809950	1	rs17154104	ENSG00000238832.1	snoU109	-5.96	4.97e-09	9.53e-07	-0.28	-0.27	Coronary artery disease;	chr7:107450253	chr7:107603363~107603507:+
THCA	cis	rs763567	0.933	rs623752	ENSG00000271811.1	RP1-79C4.4	5.96	4.97e-09	9.53e-07	0.3	0.27	Tonsillectomy;	chr1:170649150	chr1:170667381~170669425:+
THCA	cis	rs11976180	1	rs2961134	ENSG00000273234.1	OR2A13P	-5.96	4.97e-09	9.53e-07	-0.3	-0.27	Obesity-related traits;	chr7:144073969	chr7:144142009~144142938:+
THCA	cis	rs3758785	0.512	rs4753597	ENSG00000255893.1	RP11-685N10.1	5.96	4.97e-09	9.54e-07	0.32	0.27	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94367092	chr11:94472908~94473570:-
THCA	cis	rs7811142	0.945	rs34989573	ENSG00000078319.8	PMS2P1	-5.96	4.97e-09	9.54e-07	-0.39	-0.27	Platelet count;	chr7:100500272	chr7:100320992~100341908:-
THCA	cis	rs10844706	0.699	rs11052750	ENSG00000256594.6	RP11-705C15.2	5.96	4.97e-09	9.54e-07	0.22	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735090	chr12:9633419~9658412:+
THCA	cis	rs10844706	0.699	rs11052751	ENSG00000256594.6	RP11-705C15.2	5.96	4.97e-09	9.54e-07	0.22	0.27	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735136	chr12:9633419~9658412:+
THCA	cis	rs10875746	0.903	rs725454	ENSG00000269514.1	RP11-370I10.12	5.96	4.97e-09	9.55e-07	0.27	0.27	Longevity (90 years and older);	chr12:48108317	chr12:48198387~48202031:+
THCA	cis	rs28386778	1	rs2665810	ENSG00000240280.5	TCAM1P	-5.96	4.98e-09	9.56e-07	-0.37	-0.27	Prudent dietary pattern;	chr17:63892850	chr17:63849292~63864379:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	5.96	4.98e-09	9.56e-07	0.3	0.27	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	5.96	4.98e-09	9.56e-07	0.3	0.27	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
THCA	cis	rs7260598	0.642	rs4313914	ENSG00000268442.1	CTD-2027I19.2	5.96	4.99e-09	9.57e-07	0.36	0.27	Response to taxane treatment (placlitaxel);	chr19:23994194	chr19:24162370~24163425:-
THCA	cis	rs6696239	0.513	rs3010183	ENSG00000227711.2	RP11-275O4.5	5.96	4.99e-09	9.57e-07	0.28	0.27	Height;	chr1:227590321	chr1:227509028~227520477:-
THCA	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-5.96	4.99e-09	9.57e-07	-0.33	-0.27	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
THCA	cis	rs6740322	0.843	rs6727237	ENSG00000234936.1	AC010883.5	5.96	4.99e-09	9.58e-07	0.27	0.27	Coronary artery disease;	chr2:43334861	chr2:43229573~43233394:+
THCA	cis	rs6907340	0.513	rs6938418	ENSG00000237404.1	RP3-471C18.2	5.96	4.99e-09	9.58e-07	0.32	0.27	Endometriosis;	chr6:19808802	chr6:19689825~19753113:-
THCA	cis	rs7617773	0.823	rs9839446	ENSG00000228638.1	FCF1P2	5.96	4.99e-09	9.58e-07	0.25	0.27	Coronary artery disease;	chr3:48153176	chr3:48290793~48291375:-
THCA	cis	rs7617773	0.823	rs9839447	ENSG00000228638.1	FCF1P2	5.96	4.99e-09	9.58e-07	0.25	0.27	Coronary artery disease;	chr3:48153177	chr3:48290793~48291375:-
THCA	cis	rs9467773	1	rs9467773	ENSG00000124549.13	BTN2A3P	5.96	5e-09	9.58e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26498198	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6926629	ENSG00000124549.13	BTN2A3P	5.96	5e-09	9.58e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26499675	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6903973	ENSG00000124549.13	BTN2A3P	5.96	5e-09	9.58e-07	0.25	0.27	Intelligence (multi-trait analysis);	chr6:26499714	chr6:26421391~26432383:+
THCA	cis	rs595244	0.908	rs625034	ENSG00000259705.1	RP11-227D13.1	5.96	5e-09	9.58e-07	0.5	0.27	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48634005	chr15:48645951~48652016:+
THCA	cis	rs7746199	0.736	rs35037868	ENSG00000219392.1	RP1-265C24.5	-5.96	5e-09	9.59e-07	-0.61	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28115628~28116551:+
THCA	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	5.96	5e-09	9.59e-07	0.3	0.27	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
THCA	cis	rs11051970	0.569	rs7298319	ENSG00000274964.1	RP11-817I4.1	5.96	5e-09	9.59e-07	0.27	0.27	Response to tocilizumab in rheumatoid arthritis;	chr12:32377451	chr12:32339368~32340724:+
THCA	cis	rs853679	1	rs6905391	ENSG00000226314.6	ZNF192P1	-5.96	5e-09	9.59e-07	-0.4	-0.27	Depression;	chr6:28294909	chr6:28161781~28169594:+
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000229886.1	RP5-1132H15.3	5.96	5e-09	9.59e-07	0.42	0.27	Diabetic kidney disease;	chr7:66100518	chr7:66025126~66031544:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	5.96	5.01e-09	9.6e-07	0.3	0.27	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
THCA	cis	rs11096990	0.964	rs6842390	ENSG00000249685.1	RP11-360F5.3	-5.96	5.01e-09	9.6e-07	-0.34	-0.27	Cognitive function;	chr4:39261862	chr4:39133913~39135608:+
THCA	cis	rs13201294	1	rs13201294	ENSG00000219392.1	RP1-265C24.5	-5.96	5.01e-09	9.6e-07	-0.47	-0.27	Squamous cell lung carcinoma;	chr6:27588362	chr6:28115628~28116551:+
THCA	cis	rs11266744	0.559	rs3087252	ENSG00000223552.1	RP11-24F11.2	5.96	5.01e-09	9.61e-07	0.24	0.27	Monocyte percentage of white cells;	chr3:46376926	chr3:46364955~46407059:-
THCA	cis	rs516805	0.528	rs2606658	ENSG00000279453.1	RP3-425C14.4	-5.96	5.01e-09	9.61e-07	-0.29	-0.27	Lymphocyte counts;	chr6:122082742	chr6:122436789~122439223:-
THCA	cis	rs748404	0.697	rs530188	ENSG00000166763.7	STRCP1	5.96	5.01e-09	9.61e-07	0.28	0.27	Lung cancer;	chr15:43253116	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs475227	ENSG00000166763.7	STRCP1	5.96	5.01e-09	9.61e-07	0.28	0.27	Lung cancer;	chr15:43254248	chr15:43699488~43718184:-
THCA	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	5.96	5.01e-09	9.62e-07	0.32	0.26	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
THCA	cis	rs728616	0.681	rs12412762	ENSG00000225484.5	NUTM2B-AS1	5.96	5.02e-09	9.62e-07	0.46	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147714	chr10:79663088~79826594:-
THCA	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-5.96	5.02e-09	9.62e-07	-0.33	-0.26	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
THCA	cis	rs6908034	0.66	rs111509549	ENSG00000227116.1	RP3-471C18.1	-5.96	5.02e-09	9.63e-07	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19798139	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.6	rs79733895	ENSG00000227116.1	RP3-471C18.1	-5.96	5.02e-09	9.63e-07	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19799310	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.66	rs111231540	ENSG00000227116.1	RP3-471C18.1	-5.96	5.02e-09	9.63e-07	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801995	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.556	rs77486465	ENSG00000227116.1	RP3-471C18.1	-5.96	5.02e-09	9.63e-07	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803631	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs112824001	ENSG00000227116.1	RP3-471C18.1	-5.96	5.02e-09	9.63e-07	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804460	chr6:19730427~19734567:-
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000237310.1	GS1-124K5.4	5.96	5.02e-09	9.63e-07	0.19	0.26	Calcium levels;	chr7:65829754	chr7:66493706~66495474:+
THCA	cis	rs6671200	0.541	rs7555339	ENSG00000228852.5	RP11-57H12.5	-5.96	5.02e-09	9.63e-07	-0.31	-0.26	Stearic acid (18:0) levels;	chr1:95226023	chr1:95243167~95278940:-
THCA	cis	rs1707322	0.752	rs28550303	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.716	rs28375469	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs28545085	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs28719889	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs28812624	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs28507722	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs28568986	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.717	rs28396194	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.717	rs28752166	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.717	rs10890345	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs10789471	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs11211173	ENSG00000281133.1	AL355480.3	-5.96	5.02e-09	9.63e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45580892~45580996:-
THCA	cis	rs6496044	0.611	rs8026938	ENSG00000259295.5	CSPG4P12	-5.96	5.02e-09	9.63e-07	-0.34	-0.26	Interstitial lung disease;	chr15:85525887	chr15:85191438~85213905:+
THCA	cis	rs2562456	0.834	rs2173727	ENSG00000268119.4	CTD-2561J22.5	-5.96	5.02e-09	9.63e-07	-0.32	-0.26	Pain;	chr19:21491155	chr19:21444241~21463908:-
THCA	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	5.96	5.02e-09	9.63e-07	0.27	0.26	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
THCA	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	5.96	5.02e-09	9.63e-07	0.3	0.26	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	5.96	5.02e-09	9.63e-07	0.3	0.26	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
THCA	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	5.96	5.03e-09	9.64e-07	0.48	0.26	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	5.96	5.03e-09	9.64e-07	0.48	0.26	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	5.96	5.03e-09	9.64e-07	0.48	0.26	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	5.96	5.03e-09	9.64e-07	0.48	0.26	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	5.96	5.03e-09	9.64e-07	0.48	0.26	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	5.96	5.03e-09	9.64e-07	0.48	0.26	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
THCA	cis	rs613391	0.555	rs497100	ENSG00000224549.1	RP11-370B11.3	-5.96	5.03e-09	9.64e-07	-0.3	-0.26	Quantitative traits;	chr9:22747409	chr9:22767175~22768316:+
THCA	cis	rs853679	1	rs1936365	ENSG00000226314.6	ZNF192P1	5.96	5.03e-09	9.65e-07	0.4	0.26	Depression;	chr6:28300675	chr6:28161781~28169594:+
THCA	cis	rs2145598	0.868	rs2348075	ENSG00000279636.2	LINC00216	-5.96	5.03e-09	9.65e-07	-0.26	-0.26	Coronary artery disease;	chr14:58386422	chr14:58288033~58289158:+
THCA	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	5.96	5.04e-09	9.66e-07	0.3	0.26	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	5.96	5.04e-09	9.66e-07	0.3	0.26	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	5.96	5.04e-09	9.66e-07	0.3	0.26	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
THCA	cis	rs2029362	0.611	rs2030324	ENSG00000245573.6	BDNF-AS	5.96	5.04e-09	9.66e-07	0.21	0.26	Total body bone mineral density;	chr11:27705368	chr11:27506838~27698174:+
THCA	cis	rs3824488	0.667	rs112191650	ENSG00000237857.2	RP11-435O5.2	-5.96	5.05e-09	9.68e-07	-0.55	-0.26	Neuroticism;	chr9:95442321	chr9:95414834~95426796:-
THCA	cis	rs713477	1	rs8014621	ENSG00000258413.1	RP11-665C16.6	5.96	5.05e-09	9.68e-07	0.34	0.26	Pediatric bone mineral content (femoral neck);	chr14:55440131	chr14:55262767~55272075:-
THCA	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-5.96	5.05e-09	9.68e-07	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
THCA	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	5.96	5.05e-09	9.68e-07	0.34	0.26	Height;	chr4:55516548	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	5.96	5.05e-09	9.68e-07	0.34	0.26	Height;	chr4:55516744	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	5.96	5.05e-09	9.68e-07	0.34	0.26	Height;	chr4:55517185	chr4:55363971~55395847:-
THCA	cis	rs1859596	1	rs4727868	ENSG00000234456.6	MAGI2-AS3	5.96	5.05e-09	9.68e-07	0.26	0.26	Reading or mathematical ability;	chr7:79461511	chr7:79452877~79471208:+
THCA	cis	rs11722779	0.935	rs7681629	ENSG00000230069.3	LRRC37A15P	-5.96	5.05e-09	9.68e-07	-0.28	-0.26	Schizophrenia;	chr4:102974407	chr4:102727274~102730721:-
THCA	cis	rs11722779	0.844	rs17033381	ENSG00000230069.3	LRRC37A15P	-5.96	5.05e-09	9.68e-07	-0.28	-0.26	Schizophrenia;	chr4:102974952	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs4699044	ENSG00000230069.3	LRRC37A15P	-5.96	5.05e-09	9.68e-07	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs4699045	ENSG00000230069.3	LRRC37A15P	-5.96	5.05e-09	9.68e-07	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs10015289	ENSG00000230069.3	LRRC37A15P	-5.96	5.05e-09	9.68e-07	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102727274~102730721:-
THCA	cis	rs227275	0.556	rs6852141	ENSG00000230069.3	LRRC37A15P	-5.96	5.05e-09	9.68e-07	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102727274~102730721:-
THCA	cis	rs228614	0.509	rs4455415	ENSG00000230069.3	LRRC37A15P	-5.96	5.05e-09	9.68e-07	-0.28	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102727274~102730721:-
THCA	cis	rs911555	0.504	rs8021368	ENSG00000269940.1	RP11-73M18.7	5.96	5.06e-09	9.69e-07	0.27	0.26	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103694560~103695170:+
THCA	cis	rs9921338	0.961	rs7200667	ENSG00000262703.1	RP11-485G7.6	-5.96	5.06e-09	9.69e-07	-0.35	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346547	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.924	rs7202024	ENSG00000262703.1	RP11-485G7.6	-5.96	5.06e-09	9.69e-07	-0.35	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346901	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs7206017	ENSG00000262703.1	RP11-485G7.6	-5.96	5.06e-09	9.69e-07	-0.35	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11347004	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs7195536	ENSG00000262703.1	RP11-485G7.6	-5.96	5.06e-09	9.69e-07	-0.35	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348171	chr16:11348143~11349321:-
THCA	cis	rs12681366	0.708	rs2515156	ENSG00000253704.1	RP11-267M23.4	-5.96	5.06e-09	9.7e-07	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94366958	chr8:94553722~94569745:+
THCA	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	5.96	5.06e-09	9.7e-07	0.27	0.26	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
THCA	cis	rs748404	0.666	rs7177892	ENSG00000249839.1	AC011330.5	-5.96	5.06e-09	9.7e-07	-0.38	-0.26	Lung cancer;	chr15:43321171	chr15:43663654~43684339:-
THCA	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-5.96	5.07e-09	9.71e-07	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
THCA	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	5.96	5.07e-09	9.72e-07	0.4	0.26	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
THCA	cis	rs9307551	0.817	rs11098764	ENSG00000250334.4	LINC00989	-5.96	5.07e-09	9.72e-07	-0.31	-0.26	Refractive error;	chr4:79578860	chr4:79492416~79576460:+
THCA	cis	rs9475752	1	rs4490669	ENSG00000231441.1	RP11-472M19.2	5.96	5.08e-09	9.73e-07	0.32	0.26	Menarche (age at onset);	chr6:56924667	chr6:56844002~56864078:+
THCA	cis	rs10895275	0.649	rs2846836	ENSG00000277459.1	RP11-732A21.3	-5.96	5.08e-09	9.74e-07	-0.2	-0.26	Migraine;	chr11:102234942	chr11:102109827~102110457:-
THCA	cis	rs3020264	0.638	rs3020266	ENSG00000271743.1	CTD-2541M15.3	-5.96	5.08e-09	9.74e-07	-0.34	-0.26	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6634977	chr8:6615604~6617198:-
THCA	cis	rs11971779	0.625	rs10260850	ENSG00000273391.1	RP11-634H22.1	5.96	5.09e-09	9.74e-07	0.25	0.26	Diisocyanate-induced asthma;	chr7:139318856	chr7:139359032~139359566:-
THCA	cis	rs1005277	0.522	rs289650	ENSG00000263064.2	RP11-291L22.7	5.96	5.09e-09	9.75e-07	0.29	0.26	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38448689~38448949:+
THCA	cis	rs9329221	0.538	rs2272597	ENSG00000261451.1	RP11-981G7.1	-5.96	5.09e-09	9.75e-07	-0.34	-0.26	Neuroticism;	chr8:10243014	chr8:10433672~10438312:+
THCA	cis	rs6674176	0.66	rs3791112	ENSG00000237950.1	RP11-7O11.3	5.96	5.09e-09	9.76e-07	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43913576	chr1:43944370~43946551:-
THCA	cis	rs9921338	0.886	rs4780363	ENSG00000262636.1	CTD-3088G3.4	5.96	5.09e-09	9.76e-07	0.39	0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322034	chr16:11380859~11381118:-
THCA	cis	rs6674176	0.628	rs2301993	ENSG00000237950.1	RP11-7O11.3	5.96	5.1e-09	9.76e-07	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43960353	chr1:43944370~43946551:-
THCA	cis	rs6674176	0.628	rs3791119	ENSG00000237950.1	RP11-7O11.3	5.96	5.1e-09	9.76e-07	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43965690	chr1:43944370~43946551:-
THCA	cis	rs6674176	0.593	rs3791120	ENSG00000237950.1	RP11-7O11.3	5.96	5.1e-09	9.76e-07	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43966043	chr1:43944370~43946551:-
THCA	cis	rs6674176	0.628	rs4660759	ENSG00000237950.1	RP11-7O11.3	5.96	5.1e-09	9.76e-07	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43966828	chr1:43944370~43946551:-
THCA	cis	rs2281636	0.931	rs2300984	ENSG00000260475.1	RP11-85A1.3	5.96	5.1e-09	9.77e-07	0.24	0.26	Obesity-related traits;	chr10:99717100	chr10:99621055~99621918:+
THCA	cis	rs2281636	0.894	rs2300985	ENSG00000260475.1	RP11-85A1.3	5.96	5.1e-09	9.77e-07	0.24	0.26	Obesity-related traits;	chr10:99717148	chr10:99621055~99621918:+
THCA	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-5.95	5.1e-09	9.77e-07	-0.29	-0.26	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
THCA	cis	rs3760982	0.845	rs62116962	ENSG00000267058.1	RP11-15A1.3	5.95	5.1e-09	9.77e-07	0.23	0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43783082	chr19:43891804~43901805:-
THCA	cis	rs6142102	1	rs4911410	ENSG00000275784.1	RP5-1125A11.6	-5.95	5.1e-09	9.77e-07	-0.27	-0.26	Skin pigmentation;	chr20:34123168	chr20:33989480~33991818:-
THCA	cis	rs11096990	0.929	rs55976583	ENSG00000249207.1	RP11-360F5.1	5.95	5.1e-09	9.77e-07	0.34	0.26	Cognitive function;	chr4:39222871	chr4:39112677~39126818:-
THCA	cis	rs12101261	0.744	rs17544968	ENSG00000259167.2	NMNAT1P1	5.95	5.1e-09	9.77e-07	0.38	0.26	Graves' disease;	chr14:80990959	chr14:81032529~81033404:+
THCA	cis	rs9400467	0.508	rs11153293	ENSG00000271789.1	RP5-1112D6.7	-5.95	5.1e-09	9.77e-07	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.508	rs11756643	ENSG00000271789.1	RP5-1112D6.7	-5.95	5.1e-09	9.77e-07	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111297126~111298510:+
THCA	cis	rs10266483	0.639	rs6952592	ENSG00000227986.1	TRIM60P18	-5.95	5.1e-09	9.77e-07	-0.22	-0.26	Response to statin therapy;	chr7:64293667	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.705	rs660228	ENSG00000227986.1	TRIM60P18	-5.95	5.1e-09	9.77e-07	-0.22	-0.26	Response to statin therapy;	chr7:64295867	chr7:64355078~64356199:+
THCA	cis	rs17772222	0.917	rs61983300	ENSG00000258789.1	RP11-507K2.3	-5.95	5.11e-09	9.79e-07	-0.26	-0.26	Coronary artery calcification;	chr14:88754047	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.876	rs78068036	ENSG00000258789.1	RP11-507K2.3	-5.95	5.11e-09	9.79e-07	-0.26	-0.26	Coronary artery calcification;	chr14:88754817	chr14:88551597~88552493:+
THCA	cis	rs10971721	0.584	rs12375716	ENSG00000281128.1	PTENP1-AS	5.95	5.11e-09	9.79e-07	0.56	0.26	Body mass index;	chr9:34100034	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs12379730	ENSG00000281128.1	PTENP1-AS	5.95	5.11e-09	9.79e-07	0.56	0.26	Body mass index;	chr9:34100072	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.584	rs55672700	ENSG00000281128.1	PTENP1-AS	5.95	5.11e-09	9.79e-07	0.56	0.26	Body mass index;	chr9:34102723	chr9:33677268~33688011:+
THCA	cis	rs853679	0.607	rs34243448	ENSG00000226314.6	ZNF192P1	-5.95	5.11e-09	9.79e-07	-0.58	-0.26	Depression;	chr6:28225324	chr6:28161781~28169594:+
THCA	cis	rs7404843	0.704	rs112251447	ENSG00000263335.1	AF001548.5	5.95	5.11e-09	9.79e-07	0.44	0.26	Testicular germ cell tumor;	chr16:15428015	chr16:15726674~15732993:+
THCA	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-5.95	5.12e-09	9.81e-07	-0.28	-0.26	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
THCA	cis	rs4950322	0.547	rs61838945	ENSG00000278811.3	LINC00624	5.95	5.12e-09	9.81e-07	0.32	0.26	Protein quantitative trait loci;	chr1:147111477	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.563	rs6686480	ENSG00000278811.3	LINC00624	5.95	5.12e-09	9.81e-07	0.32	0.26	Protein quantitative trait loci;	chr1:147111986	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.563	rs6700783	ENSG00000278811.3	LINC00624	5.95	5.12e-09	9.81e-07	0.32	0.26	Protein quantitative trait loci;	chr1:147111987	chr1:147258885~147517875:-
THCA	cis	rs6674176	0.66	rs6801	ENSG00000237950.1	RP11-7O11.3	-5.95	5.13e-09	9.82e-07	-0.24	-0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43930974	chr1:43944370~43946551:-
THCA	cis	rs6545883	0.783	rs7579651	ENSG00000271889.1	RP11-493E12.1	5.95	5.13e-09	9.82e-07	0.25	0.26	Tuberculosis;	chr2:61573144	chr2:61151433~61162105:-
THCA	cis	rs7129556	0.954	rs10793255	ENSG00000254691.1	RP11-91P24.5	5.95	5.13e-09	9.82e-07	0.36	0.26	Weight loss (gastric bypass surgery);	chr11:77556566	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.954	rs11512896	ENSG00000254691.1	RP11-91P24.5	5.95	5.13e-09	9.82e-07	0.36	0.26	Weight loss (gastric bypass surgery);	chr11:77564673	chr11:77850604~77851511:+
THCA	cis	rs9467773	1	rs10484442	ENSG00000124549.13	BTN2A3P	5.95	5.14e-09	9.84e-07	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26421391~26432383:+
THCA	cis	rs7119038	0.774	rs11217001	ENSG00000255239.1	AP002954.6	-5.95	5.14e-09	9.84e-07	-0.41	-0.26	Sjögren's syndrome;	chr11:118736337	chr11:118688039~118690600:-
THCA	cis	rs67478160	0.643	rs11628332	ENSG00000258735.1	LINC00637	-5.95	5.14e-09	9.84e-07	-0.32	-0.26	Schizophrenia;	chr14:103774804	chr14:103847721~103858049:+
THCA	cis	rs10276381	0.786	rs73089302	ENSG00000234336.5	JAZF1-AS1	-5.95	5.14e-09	9.84e-07	-0.38	-0.26	Crohn's disease;	chr7:28147515	chr7:28180322~28243917:+
THCA	cis	rs10276381	1	rs10263857	ENSG00000234336.5	JAZF1-AS1	-5.95	5.14e-09	9.84e-07	-0.38	-0.26	Crohn's disease;	chr7:28147665	chr7:28180322~28243917:+
THCA	cis	rs934734	0.752	rs268136	ENSG00000281920.1	RP11-418H16.1	-5.95	5.14e-09	9.85e-07	-0.33	-0.26	Rheumatoid arthritis;	chr2:65380409	chr2:65623272~65628424:+
THCA	cis	rs7809950	0.954	rs2712193	ENSG00000238832.1	snoU109	-5.95	5.14e-09	9.85e-07	-0.28	-0.26	Coronary artery disease;	chr7:107485440	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs2520277	ENSG00000238832.1	snoU109	-5.95	5.14e-09	9.85e-07	-0.28	-0.26	Coronary artery disease;	chr7:107489789	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.953	rs2237670	ENSG00000238832.1	snoU109	-5.95	5.14e-09	9.85e-07	-0.28	-0.26	Coronary artery disease;	chr7:107491040	chr7:107603363~107603507:+
THCA	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-5.95	5.15e-09	9.85e-07	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
THCA	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	5.95	5.15e-09	9.86e-07	0.4	0.26	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
THCA	cis	rs1707322	0.717	rs1135812	ENSG00000281133.1	AL355480.3	-5.95	5.15e-09	9.86e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs6703748	ENSG00000281133.1	AL355480.3	-5.95	5.15e-09	9.86e-07	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45580892~45580996:-
THCA	cis	rs2136613	0.728	rs10822065	ENSG00000238280.1	RP11-436D10.3	-5.95	5.15e-09	9.86e-07	-0.31	-0.26	Selective IgA deficiency;	chr10:62851172	chr10:62793562~62805887:-
THCA	cis	rs2179367	0.613	rs62426122	ENSG00000268592.3	RAET1E-AS1	5.95	5.15e-09	9.87e-07	0.37	0.26	Dupuytren's disease;	chr6:149427449	chr6:149863494~149919507:+
THCA	cis	rs12435908	1	rs60554055	ENSG00000276116.2	FUT8-AS1	-5.95	5.16e-09	9.87e-07	-0.42	-0.26	Ischemic stroke;	chr14:65601567	chr14:65411170~65412690:-
THCA	cis	rs7202877	0.561	rs2865532	ENSG00000261783.1	RP11-252K23.2	-5.95	5.16e-09	9.87e-07	-0.47	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75317077	chr16:75379818~75381260:-
THCA	cis	rs2562456	0.754	rs55771551	ENSG00000213976.4	CTD-2561J22.2	-5.95	5.16e-09	9.87e-07	-0.28	-0.26	Pain;	chr19:21563578	chr19:21382865~21387177:+
THCA	cis	rs5752326	0.867	rs1894704	ENSG00000261188.1	CTA-445C9.14	5.95	5.16e-09	9.88e-07	0.29	0.26	Ischemic stroke;	chr22:26457939	chr22:26512537~26514568:+
THCA	cis	rs9402743	0.775	rs2179724	ENSG00000231028.7	LINC00271	-5.95	5.16e-09	9.88e-07	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135647928	chr6:135497801~135716055:+
THCA	cis	rs2554380	0.628	rs963690	ENSG00000230373.7	GOLGA6L5P	-5.95	5.16e-09	9.89e-07	-0.29	-0.26	Height;	chr15:83771068	chr15:84507885~84516814:-
THCA	cis	rs28510890	0.53	rs8032683	ENSG00000260337.3	RP11-386M24.6	5.95	5.17e-09	9.89e-07	0.28	0.26	Lung cancer in ever smokers;	chr15:92614826	chr15:92592574~92596462:-
THCA	cis	rs2120243	0.501	rs1456107	ENSG00000244515.1	KRT18P34	-5.95	5.17e-09	9.9e-07	-0.32	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157401731	chr3:157162663~157163932:-
THCA	cis	rs2732480	0.538	rs1387259	ENSG00000240399.1	RP1-228P16.1	-5.95	5.17e-09	9.9e-07	-0.27	-0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48054813~48055591:-
THCA	cis	rs1185460	0.967	rs2509121	ENSG00000272186.1	RP11-110I1.13	-5.95	5.17e-09	9.9e-07	-0.25	-0.26	Coronary artery disease;	chr11:119057542	chr11:119067374~119067698:-
THCA	cis	rs797680	0.897	rs2114273	ENSG00000223745.6	RP4-717I23.3	5.95	5.18e-09	9.91e-07	0.16	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93388960	chr1:93262186~93346025:-
THCA	cis	rs7267979	0.702	rs449801	ENSG00000274973.1	RP13-401N8.7	-5.95	5.18e-09	9.91e-07	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:25845497~25845862:+
THCA	cis	rs2252790	0.64	rs1128261	ENSG00000233558.1	RP3-486I3.4	-5.95	5.18e-09	9.91e-07	-0.3	-0.26	Fast beta electroencephalogram;	chr6:116277690	chr6:116258493~116259115:-
THCA	cis	rs4950322	0.947	rs72694723	ENSG00000237188.3	RP11-337C18.8	5.95	5.18e-09	9.91e-07	0.35	0.26	Protein quantitative trait loci;	chr1:147373174	chr1:147172771~147211568:+
THCA	cis	rs11671005	0.735	rs12986387	ENSG00000269473.1	CTD-2619J13.19	5.95	5.18e-09	9.91e-07	0.3	0.26	Mean platelet volume;	chr19:58415848	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs11667723	ENSG00000269473.1	CTD-2619J13.19	5.95	5.18e-09	9.91e-07	0.3	0.26	Mean platelet volume;	chr19:58416122	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs11668789	ENSG00000269473.1	CTD-2619J13.19	5.95	5.18e-09	9.91e-07	0.3	0.26	Mean platelet volume;	chr19:58416942	chr19:58440448~58445849:+
THCA	cis	rs10875746	0.669	rs17122812	ENSG00000269514.1	RP11-370I10.12	5.95	5.18e-09	9.91e-07	0.27	0.26	Longevity (90 years and older);	chr12:48203270	chr12:48198387~48202031:+
THCA	cis	rs6432852	0.516	rs12477613	ENSG00000232411.1	AC009495.3	5.95	5.18e-09	9.91e-07	0.29	0.26	Diabetic kidney disease;	chr2:165860674	chr2:165833048~165839098:-
THCA	cis	rs12549025	0.729	rs11784090	ENSG00000253390.1	CTC-756D1.2	-5.95	5.18e-09	9.92e-07	-0.51	-0.26	Reticulocyte fraction of red cells;	chr8:23519648	chr8:23458601~23484971:+
THCA	cis	rs2880765	0.566	rs55899824	ENSG00000259630.2	CTD-2262B20.1	-5.95	5.19e-09	9.92e-07	-0.31	-0.26	Coronary artery disease;	chr15:85460860	chr15:85415228~85415633:+
THCA	cis	rs6600671	1	rs1832558	ENSG00000275538.1	RNVU1-19	5.95	5.19e-09	9.93e-07	0.33	0.26	Hip geometry;	chr1:121435521	chr1:120850819~120850985:-
THCA	cis	rs10875746	0.669	rs10431526	ENSG00000269514.1	RP11-370I10.12	5.95	5.19e-09	9.93e-07	0.26	0.26	Longevity (90 years and older);	chr12:48296360	chr12:48198387~48202031:+
THCA	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	5.95	5.19e-09	9.93e-07	0.24	0.26	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	5.95	5.19e-09	9.93e-07	0.24	0.26	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	5.95	5.19e-09	9.93e-07	0.24	0.26	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
THCA	cis	rs17772222	0.674	rs112788894	ENSG00000222990.1	RNU4-22P	5.95	5.19e-09	9.94e-07	0.36	0.26	Coronary artery calcification;	chr14:88442850	chr14:88513498~88513663:+
THCA	cis	rs228614	0.51	rs150893	ENSG00000230069.3	LRRC37A15P	5.95	5.2e-09	9.95e-07	0.28	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102727274~102730721:-
THCA	cis	rs7615952	0.932	rs7629977	ENSG00000241288.6	RP11-379B18.5	-5.95	5.2e-09	9.95e-07	-0.34	-0.26	Blood pressure (smoking interaction);	chr3:125930730	chr3:125827238~125916384:-
THCA	cis	rs1876905	0.539	rs240980	ENSG00000255389.1	C6orf3	-5.95	5.21e-09	9.96e-07	-0.34	-0.26	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111599875~111602295:+
THCA	cis	rs2129782	1	rs1817684	ENSG00000253553.4	RP11-586K2.1	5.95	5.21e-09	9.96e-07	0.45	0.26	Electrodermal activity;	chr8:88452549	chr8:88326836~88737134:+
THCA	cis	rs2735413	0.564	rs6564508	ENSG00000276007.1	RP11-358L22.3	5.95	5.21e-09	9.96e-07	0.28	0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78082678	chr16:78123243~78124332:+
THCA	cis	rs7005380	0.58	rs1467044	ENSG00000245330.4	KB-1471A8.1	5.95	5.21e-09	9.97e-07	0.26	0.26	Interstitial lung disease;	chr8:119874801	chr8:119867419~119874488:-
THCA	cis	rs5742933	0.69	rs6726636	ENSG00000273240.1	RP11-455J20.3	-5.95	5.22e-09	9.98e-07	-0.33	-0.26	Ferritin levels;	chr2:189653095	chr2:189763859~189764456:-
THCA	cis	rs227275	0.556	rs12508069	ENSG00000230069.3	LRRC37A15P	-5.95	5.22e-09	9.98e-07	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102727274~102730721:-
THCA	cis	rs2439831	0.85	rs28509275	ENSG00000275601.1	AC011330.13	-5.95	5.22e-09	9.99e-07	-0.48	-0.26	Lung cancer in ever smokers;	chr15:43805907	chr15:43642389~43643023:-
THCA	cis	rs712039	0.652	rs7226252	ENSG00000276054.1	RP11-378E13.3	5.95	5.22e-09	9.99e-07	0.4	0.26	Tuberculosis;	chr17:37434812	chr17:37386886~37387926:+
THCA	cis	rs712039	0.652	rs67879888	ENSG00000276054.1	RP11-378E13.3	5.95	5.22e-09	9.99e-07	0.4	0.26	Tuberculosis;	chr17:37435211	chr17:37386886~37387926:+
THCA	cis	rs1823913	1	rs10445782	ENSG00000280083.1	RP11-317J9.1	5.95	5.23e-09	1e-06	0.33	0.26	Obesity-related traits;	chr2:191236639	chr2:191154118~191156070:-
THCA	cis	rs9921338	0.923	rs4563054	ENSG00000262703.1	RP11-485G7.6	-5.95	5.23e-09	1e-06	-0.35	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353689	chr16:11348143~11349321:-
THCA	cis	rs6928977	0.86	rs2614264	ENSG00000231028.7	LINC00271	-5.95	5.24e-09	1e-06	-0.21	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135389556	chr6:135497801~135716055:+
THCA	cis	rs17301013	0.507	rs1653630	ENSG00000227373.4	RP11-160H22.5	-5.95	5.24e-09	1e-06	-0.4	-0.26	Systemic lupus erythematosus;	chr1:174791810	chr1:174115300~174160004:-
THCA	cis	rs2129782	1	rs56324438	ENSG00000253553.4	RP11-586K2.1	5.95	5.24e-09	1e-06	0.45	0.26	Electrodermal activity;	chr8:88428227	chr8:88326836~88737134:+
THCA	cis	rs9402743	0.775	rs2876312	ENSG00000231028.7	LINC00271	-5.95	5.24e-09	1e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135648714	chr6:135497801~135716055:+
THCA	cis	rs890448	0.792	rs1372242	ENSG00000254531.1	FLJ20021	5.95	5.24e-09	1e-06	0.24	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369371	chr4:101347780~101348883:+
THCA	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	5.95	5.25e-09	1e-06	0.26	0.26	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
THCA	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	5.95	5.25e-09	1e-06	0.26	0.26	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
THCA	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	5.95	5.25e-09	1e-06	0.26	0.26	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
THCA	cis	rs6802315	0.604	rs9861938	ENSG00000272247.1	RP11-379F4.9	-5.95	5.25e-09	1e-06	-0.25	-0.26	Periodontitis (CDC/AAP);	chr3:158745257	chr3:158801257~158801935:-
THCA	cis	rs4950322	0.57	rs72692979	ENSG00000278811.3	LINC00624	5.95	5.25e-09	1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147336094	chr1:147258885~147517875:-
THCA	cis	rs1876905	0.524	rs1084639	ENSG00000255389.1	C6orf3	5.95	5.25e-09	1e-06	0.31	0.26	Mean corpuscular hemoglobin;	chr6:111165240	chr6:111599875~111602295:+
THCA	cis	rs7809950	1	rs3801944	ENSG00000238832.1	snoU109	5.95	5.26e-09	1.01e-06	0.28	0.26	Coronary artery disease;	chr7:107615103	chr7:107603363~107603507:+
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	5.95	5.26e-09	1.01e-06	0.33	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
THCA	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-5.95	5.26e-09	1.01e-06	-0.45	-0.26	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
THCA	cis	rs6991838	0.806	rs11777025	ENSG00000200714.1	Y_RNA	-5.95	5.26e-09	1.01e-06	-0.31	-0.26	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65592731~65592820:+
THCA	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	5.95	5.26e-09	1.01e-06	0.21	0.26	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
THCA	cis	rs4650994	1	rs10798615	ENSG00000273384.1	RP5-1098D14.1	5.95	5.26e-09	1.01e-06	0.33	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178544760	chr1:178651706~178652282:+
THCA	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	5.95	5.27e-09	1.01e-06	0.37	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
THCA	cis	rs2554380	0.628	rs2081541	ENSG00000230373.7	GOLGA6L5P	-5.95	5.27e-09	1.01e-06	-0.29	-0.26	Height;	chr15:83774934	chr15:84507885~84516814:-
THCA	cis	rs9326248	0.569	rs10892082	ENSG00000280143.1	AP000892.6	5.95	5.27e-09	1.01e-06	0.44	0.26	Blood protein levels;	chr11:117168609	chr11:117204967~117210292:+
THCA	cis	rs9649465	0.967	rs1005567	ENSG00000272686.1	RP11-390E23.6	-5.95	5.27e-09	1.01e-06	-0.17	-0.26	Migraine;	chr7:123665782	chr7:123749068~123751166:+
THCA	cis	rs12497850	0.931	rs6442130	ENSG00000229759.1	MRPS18AP1	5.95	5.27e-09	1.01e-06	0.35	0.26	Parkinson's disease;	chr3:48740594	chr3:48256350~48256938:-
THCA	cis	rs2348418	0.765	rs12368743	ENSG00000247934.4	RP11-967K21.1	-5.95	5.27e-09	1.01e-06	-0.23	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28192409	chr12:28163298~28190738:-
THCA	cis	rs1061377	0.585	rs12648581	ENSG00000249685.1	RP11-360F5.3	5.95	5.27e-09	1.01e-06	0.32	0.26	Uric acid levels;	chr4:39054024	chr4:39133913~39135608:+
THCA	cis	rs9880211	0.948	rs9813691	ENSG00000273486.1	RP11-731C17.2	5.95	5.28e-09	1.01e-06	0.28	0.26	Height;Body mass index;	chr3:136541880	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs9883189	ENSG00000273486.1	RP11-731C17.2	5.95	5.28e-09	1.01e-06	0.28	0.26	Height;Body mass index;	chr3:136570624	chr3:136837338~136839021:-
THCA	cis	rs7809950	0.817	rs17154091	ENSG00000238832.1	snoU109	-5.95	5.28e-09	1.01e-06	-0.31	-0.26	Coronary artery disease;	chr7:107444345	chr7:107603363~107603507:+
THCA	cis	rs2439831	0.681	rs825739	ENSG00000249839.1	AC011330.5	-5.95	5.28e-09	1.01e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43300230	chr15:43663654~43684339:-
THCA	cis	rs6740322	1	rs4128209	ENSG00000234936.1	AC010883.5	5.95	5.28e-09	1.01e-06	0.27	0.26	Coronary artery disease;	chr2:43327590	chr2:43229573~43233394:+
THCA	cis	rs4950322	0.547	rs6660507	ENSG00000278811.3	LINC00624	5.95	5.28e-09	1.01e-06	0.3	0.26	Protein quantitative trait loci;	chr1:147148574	chr1:147258885~147517875:-
THCA	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-5.95	5.28e-09	1.01e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
THCA	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-5.95	5.28e-09	1.01e-06	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
THCA	cis	rs10875746	0.859	rs12305511	ENSG00000269514.1	RP11-370I10.12	-5.95	5.28e-09	1.01e-06	-0.26	-0.26	Longevity (90 years and older);	chr12:48188933	chr12:48198387~48202031:+
THCA	cis	rs11668609	1	rs10413344	ENSG00000268442.1	CTD-2027I19.2	5.95	5.29e-09	1.01e-06	0.32	0.26	Response to taxane treatment (docetaxel);	chr19:24186158	chr19:24162370~24163425:-
THCA	cis	rs10936632	0.536	rs10936633	ENSG00000242578.1	RP11-469J4.3	5.95	5.29e-09	1.01e-06	0.29	0.26	Prostate cancer;	chr3:170440340	chr3:170410512~170418615:+
THCA	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	5.95	5.29e-09	1.01e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
THCA	cis	rs6860806	0.661	rs4705929	ENSG00000224431.1	AC063976.7	5.95	5.3e-09	1.01e-06	0.23	0.26	Breast cancer;	chr5:132248485	chr5:132199456~132203487:+
THCA	cis	rs6142102	0.886	rs4911147	ENSG00000275784.1	RP5-1125A11.6	-5.95	5.3e-09	1.01e-06	-0.28	-0.26	Skin pigmentation;	chr20:34079801	chr20:33989480~33991818:-
THCA	cis	rs853679	0.607	rs66868086	ENSG00000219392.1	RP1-265C24.5	-5.95	5.3e-09	1.01e-06	-0.6	-0.26	Depression;	chr6:27898124	chr6:28115628~28116551:+
THCA	cis	rs4073582	0.595	rs555360	ENSG00000255320.1	RP11-755F10.1	5.95	5.3e-09	1.01e-06	0.33	0.26	Gout;	chr11:66192590	chr11:66244840~66246239:-
THCA	cis	rs523522	0.962	rs10744752	ENSG00000278344.1	RP11-18C24.8	5.95	5.3e-09	1.01e-06	0.29	0.26	High light scatter reticulocyte count;	chr12:120462751	chr12:120500735~120501090:-
THCA	cis	rs17772222	0.917	rs12588535	ENSG00000222990.1	RNU4-22P	5.95	5.31e-09	1.01e-06	0.34	0.26	Coronary artery calcification;	chr14:88781900	chr14:88513498~88513663:+
THCA	cis	rs896854	0.654	rs10104909	ENSG00000253528.2	RP11-347C18.4	5.95	5.31e-09	1.01e-06	0.3	0.26	Type 2 diabetes;	chr8:94965745	chr8:94974573~94974853:-
THCA	cis	rs10971721	1	rs10971721	ENSG00000281128.1	PTENP1-AS	5.95	5.31e-09	1.01e-06	0.58	0.26	Body mass index;	chr9:33827696	chr9:33677268~33688011:+
THCA	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-5.95	5.31e-09	1.01e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
THCA	cis	rs6565180	0.963	rs4787642	ENSG00000273724.1	RP11-347C12.12	-5.95	5.31e-09	1.01e-06	-0.28	-0.26	Tonsillectomy;	chr16:30348087	chr16:30336400~30343336:+
THCA	cis	rs287982	0.611	rs77095920	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9833092	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs7580521	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9835555	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs80336909	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9835645	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs76624418	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9836389	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs76011221	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9837504	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs75809337	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9837684	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs78100109	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9838280	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs77359699	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9839170	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs75277217	ENSG00000269973.1	RP11-95D17.1	-5.95	5.31e-09	1.01e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9839275	chr2:9936360~9939590:+
THCA	cis	rs4713118	0.591	rs2056924	ENSG00000219392.1	RP1-265C24.5	-5.95	5.31e-09	1.01e-06	-0.31	-0.26	Parkinson's disease;	chr6:27722395	chr6:28115628~28116551:+
THCA	cis	rs1979679	0.842	rs11049373	ENSG00000278733.1	RP11-425D17.1	5.95	5.31e-09	1.02e-06	0.27	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28185625~28186190:-
THCA	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	5.95	5.32e-09	1.02e-06	0.35	0.26	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
THCA	cis	rs1125355	0.69	rs17810428	ENSG00000251491.2	OR7E28P	-5.95	5.32e-09	1.02e-06	-0.43	-0.26	Alzheimer's disease in APOE e4+ carriers;	chr2:158804939	chr2:158862311~158863285:+
THCA	cis	rs2348418	0.832	rs4931080	ENSG00000247934.4	RP11-967K21.1	5.95	5.33e-09	1.02e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28433843	chr12:28163298~28190738:-
THCA	cis	rs1707322	0.662	rs11211160	ENSG00000281133.1	AL355480.3	-5.95	5.33e-09	1.02e-06	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45580892~45580996:-
THCA	cis	rs4908768	0.501	rs910581	ENSG00000232912.4	RP5-1115A15.1	5.95	5.33e-09	1.02e-06	0.26	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469464	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs1024197	ENSG00000232912.4	RP5-1115A15.1	5.95	5.33e-09	1.02e-06	0.26	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8476998	chr1:8424645~8434838:+
THCA	cis	rs2136613	0.728	rs4141618	ENSG00000238280.1	RP11-436D10.3	-5.95	5.34e-09	1.02e-06	-0.31	-0.26	Selective IgA deficiency;	chr10:62854449	chr10:62793562~62805887:-
THCA	cis	rs11051970	0.879	rs10844201	ENSG00000274964.1	RP11-817I4.1	-5.95	5.34e-09	1.02e-06	-0.29	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32422095	chr12:32339368~32340724:+
THCA	cis	rs6928977	0.896	rs2614259	ENSG00000231028.7	LINC00271	5.95	5.34e-09	1.02e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135356114	chr6:135497801~135716055:+
THCA	cis	rs2243480	1	rs160652	ENSG00000232546.1	RP11-458F8.1	-5.95	5.35e-09	1.02e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66073444	chr7:66848496~66858136:+
THCA	cis	rs228614	0.51	rs223378	ENSG00000230069.3	LRRC37A15P	-5.95	5.35e-09	1.02e-06	-0.28	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102727274~102730721:-
THCA	cis	rs6993270	0.779	rs7814126	ENSG00000245330.4	KB-1471A8.1	-5.95	5.35e-09	1.02e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119896996	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.725	rs7814482	ENSG00000245330.4	KB-1471A8.1	-5.95	5.35e-09	1.02e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119897263	chr8:119867419~119874488:-
THCA	cis	rs9921338	0.961	rs17605444	ENSG00000262703.1	RP11-485G7.6	-5.95	5.36e-09	1.02e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319732	chr16:11348143~11349321:-
THCA	cis	rs9652601	0.959	rs12928537	ENSG00000274038.1	RP11-66H6.4	-5.95	5.36e-09	1.02e-06	-0.35	-0.26	Systemic lupus erythematosus;	chr16:11097543	chr16:11056556~11057034:+
THCA	cis	rs792448	0.743	rs7415843	ENSG00000226251.4	RP11-15I11.3	-5.95	5.36e-09	1.02e-06	-0.33	-0.26	White blood cell count (basophil);	chr1:212336420	chr1:212225278~212238977:-
THCA	cis	rs287982	0.611	rs7568330	ENSG00000269973.1	RP11-95D17.1	-5.95	5.37e-09	1.02e-06	-0.24	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9835428	chr2:9936360~9939590:+
THCA	cis	rs6740322	1	rs11693666	ENSG00000234936.1	AC010883.5	-5.95	5.37e-09	1.02e-06	-0.27	-0.26	Coronary artery disease;	chr2:43335340	chr2:43229573~43233394:+
THCA	cis	rs2439831	0.85	rs28509275	ENSG00000166763.7	STRCP1	5.95	5.37e-09	1.03e-06	0.43	0.26	Lung cancer in ever smokers;	chr15:43805907	chr15:43699488~43718184:-
THCA	cis	rs67478160	0.704	rs12894254	ENSG00000258735.1	LINC00637	-5.95	5.37e-09	1.03e-06	-0.32	-0.26	Schizophrenia;	chr14:103824612	chr14:103847721~103858049:+
THCA	cis	rs6908034	0.556	rs79028848	ENSG00000237404.1	RP3-471C18.2	-5.95	5.37e-09	1.03e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782922	chr6:19689825~19753113:-
THCA	cis	rs853679	0.607	rs13199649	ENSG00000219392.1	RP1-265C24.5	-5.95	5.37e-09	1.03e-06	-0.6	-0.26	Depression;	chr6:27901014	chr6:28115628~28116551:+
THCA	cis	rs7927592	0.673	rs2510392	ENSG00000212093.1	AP000807.1	5.95	5.37e-09	1.03e-06	0.28	0.26	Total body bone mineral density;	chr11:68626989	chr11:68506083~68506166:-
THCA	cis	rs11671005	0.695	rs8106061	ENSG00000269473.1	CTD-2619J13.19	5.95	5.38e-09	1.03e-06	0.3	0.26	Mean platelet volume;	chr19:58406623	chr19:58440448~58445849:+
THCA	cis	rs10971721	0.584	rs56145814	ENSG00000281128.1	PTENP1-AS	5.95	5.38e-09	1.03e-06	0.56	0.26	Body mass index;	chr9:34088953	chr9:33677268~33688011:+
THCA	cis	rs11603691	0.551	rs7951793	ENSG00000254662.1	RP11-872D17.4	-5.95	5.38e-09	1.03e-06	-0.41	-0.26	Low high density lipoprotein cholesterol levels;	chr11:57333966	chr11:57325603~57327958:+
THCA	cis	rs950169	0.8	rs34302901	ENSG00000259295.5	CSPG4P12	5.95	5.39e-09	1.03e-06	0.4	0.26	Schizophrenia;	chr15:84567712	chr15:85191438~85213905:+
THCA	cis	rs4650994	0.544	rs2761469	ENSG00000273384.1	RP5-1098D14.1	-5.95	5.39e-09	1.03e-06	-0.33	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178621503	chr1:178651706~178652282:+
THCA	cis	rs2439831	0.717	rs690170	ENSG00000275601.1	AC011330.13	-5.94	5.4e-09	1.03e-06	-0.45	-0.26	Lung cancer in ever smokers;	chr15:43518224	chr15:43642389~43643023:-
THCA	cis	rs7044106	0.791	rs4836830	ENSG00000270917.1	RP11-27I1.6	-5.94	5.4e-09	1.03e-06	-0.38	-0.26	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120812475~120812845:-
THCA	cis	rs9402743	0.775	rs4504492	ENSG00000231028.7	LINC00271	-5.94	5.4e-09	1.03e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135648536	chr6:135497801~135716055:+
THCA	cis	rs10129255	0.957	rs10150241	ENSG00000211974.3	IGHV2-70	-5.94	5.4e-09	1.03e-06	-0.2	-0.26	Kawasaki disease;	chr14:106775945	chr14:106723574~106724093:-
THCA	cis	rs7246657	0.722	rs1975937	ENSG00000267422.1	CTD-2554C21.1	-5.94	5.4e-09	1.03e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37601031	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs8103647	ENSG00000267422.1	CTD-2554C21.1	-5.94	5.4e-09	1.03e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37609551	chr19:37779686~37792865:+
THCA	cis	rs9652601	0.677	rs35732840	ENSG00000274038.1	RP11-66H6.4	-5.94	5.41e-09	1.03e-06	-0.33	-0.26	Systemic lupus erythematosus;	chr16:11134498	chr16:11056556~11057034:+
THCA	cis	rs12681366	0.708	rs2470731	ENSG00000253704.1	RP11-267M23.4	-5.94	5.41e-09	1.03e-06	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94363146	chr8:94553722~94569745:+
THCA	cis	rs78773383	0.505	rs13123782	ENSG00000249685.1	RP11-360F5.3	-5.94	5.41e-09	1.03e-06	-0.33	-0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39133913~39135608:+
THCA	cis	rs17772222	0.638	rs11629164	ENSG00000258983.2	RP11-507K2.2	-5.94	5.41e-09	1.03e-06	-0.32	-0.26	Coronary artery calcification;	chr14:88564740	chr14:88499334~88515502:+
THCA	cis	rs2243480	1	rs34703416	ENSG00000228409.4	CCT6P1	5.94	5.42e-09	1.03e-06	0.3	0.26	Diabetic kidney disease;	chr7:65835655	chr7:65751142~65763354:+
THCA	cis	rs10078	0.571	rs890977	ENSG00000221990.4	EXOC3-AS1	5.94	5.42e-09	1.03e-06	0.28	0.26	Fat distribution (HIV);	chr5:476795	chr5:441498~443160:-
THCA	cis	rs6908034	0.66	rs111509549	ENSG00000237404.1	RP3-471C18.2	-5.94	5.42e-09	1.03e-06	-0.52	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19798139	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.6	rs79733895	ENSG00000237404.1	RP3-471C18.2	-5.94	5.42e-09	1.03e-06	-0.52	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19799310	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.66	rs111231540	ENSG00000237404.1	RP3-471C18.2	-5.94	5.42e-09	1.03e-06	-0.52	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801995	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.556	rs77486465	ENSG00000237404.1	RP3-471C18.2	-5.94	5.42e-09	1.03e-06	-0.52	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803631	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs112824001	ENSG00000237404.1	RP3-471C18.2	-5.94	5.42e-09	1.03e-06	-0.52	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804460	chr6:19689825~19753113:-
THCA	cis	rs6545883	0.791	rs4672445	ENSG00000271889.1	RP11-493E12.1	-5.94	5.42e-09	1.03e-06	-0.26	-0.26	Tuberculosis;	chr2:61427873	chr2:61151433~61162105:-
THCA	cis	rs12908161	0.96	rs17599989	ENSG00000259295.5	CSPG4P12	5.94	5.42e-09	1.03e-06	0.4	0.26	Schizophrenia;	chr15:84742305	chr15:85191438~85213905:+
THCA	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-5.94	5.43e-09	1.04e-06	-0.26	-0.26	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
THCA	cis	rs11671005	0.693	rs11669665	ENSG00000269473.1	CTD-2619J13.19	5.94	5.43e-09	1.04e-06	0.31	0.26	Mean platelet volume;	chr19:58420518	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.693	rs11084542	ENSG00000269473.1	CTD-2619J13.19	5.94	5.43e-09	1.04e-06	0.31	0.26	Mean platelet volume;	chr19:58420732	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs11084543	ENSG00000269473.1	CTD-2619J13.19	5.94	5.43e-09	1.04e-06	0.31	0.26	Mean platelet volume;	chr19:58421334	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs11881000	ENSG00000269473.1	CTD-2619J13.19	5.94	5.43e-09	1.04e-06	0.31	0.26	Mean platelet volume;	chr19:58421421	chr19:58440448~58445849:+
THCA	cis	rs6674176	0.66	rs12726706	ENSG00000237950.1	RP11-7O11.3	5.94	5.44e-09	1.04e-06	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934270	chr1:43944370~43946551:-
THCA	cis	rs1318937	1	rs3773469	ENSG00000224660.1	SH3BP5-AS1	5.94	5.44e-09	1.04e-06	0.17	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15266733	chr3:15254184~15264493:+
THCA	cis	rs6674176	0.561	rs7161	ENSG00000237950.1	RP11-7O11.3	-5.94	5.44e-09	1.04e-06	-0.24	-0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43973302	chr1:43944370~43946551:-
THCA	cis	rs8014252	0.803	rs73283917	ENSG00000259158.2	ADAM20P1	-5.94	5.44e-09	1.04e-06	-0.33	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70566439	chr14:70468881~70483756:-
THCA	cis	rs6973609	0.564	rs10226256	ENSG00000271122.1	RP11-379H18.1	-5.94	5.44e-09	1.04e-06	-0.17	-0.26	Obesity-related traits;	chr7:35573650	chr7:35695214~35699413:+
THCA	cis	rs9400467	0.528	rs445349	ENSG00000271789.1	RP5-1112D6.7	5.94	5.45e-09	1.04e-06	0.25	0.26	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111297126~111298510:+
THCA	cis	rs9326246	0.643	rs2072560	ENSG00000254851.1	RP11-109L13.1	-5.94	5.45e-09	1.04e-06	-0.56	-0.26	Coronary artery disease;	chr11:116791110	chr11:117135528~117138582:+
THCA	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	5.94	5.45e-09	1.04e-06	0.34	0.26	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
THCA	cis	rs890448	0.519	rs10027194	ENSG00000254531.1	FLJ20021	5.94	5.47e-09	1.04e-06	0.24	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371280	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs12642424	ENSG00000254531.1	FLJ20021	5.94	5.47e-09	1.04e-06	0.24	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382629	chr4:101347780~101348883:+
THCA	cis	rs17826219	0.568	rs59858012	ENSG00000264538.5	SUZ12P1	-5.94	5.47e-09	1.04e-06	-0.3	-0.26	Body mass index;	chr17:30751564	chr17:30709299~30790908:+
THCA	cis	rs149313	0.901	rs697976	ENSG00000248734.2	CTD-2260A17.1	5.94	5.47e-09	1.04e-06	0.26	0.26	Blood protein levels;	chr5:96733063	chr5:96784777~96785999:+
THCA	cis	rs12681366	0.683	rs2515161	ENSG00000253704.1	RP11-267M23.4	-5.94	5.47e-09	1.04e-06	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94358690	chr8:94553722~94569745:+
THCA	cis	rs16846053	0.786	rs72877999	ENSG00000227403.1	AC009299.3	5.94	5.47e-09	1.04e-06	0.57	0.26	Blood osmolality (transformed sodium);	chr2:161463877	chr2:161244739~161249050:+
THCA	cis	rs7005380	0.6	rs13267652	ENSG00000245330.4	KB-1471A8.1	5.94	5.47e-09	1.04e-06	0.26	0.26	Interstitial lung disease;	chr8:119878346	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs13275528	ENSG00000245330.4	KB-1471A8.1	5.94	5.47e-09	1.04e-06	0.26	0.26	Interstitial lung disease;	chr8:119878617	chr8:119867419~119874488:-
THCA	cis	rs6058796	0.892	rs34894833	ENSG00000175730.8	BAK1P1	5.94	5.48e-09	1.04e-06	0.39	0.26	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32659352	chr20:32690180~32690815:-
THCA	cis	rs3742264	1	rs9567614	ENSG00000235903.6	CPB2-AS1	-5.94	5.48e-09	1.04e-06	-0.35	-0.26	Blood protein levels;	chr13:46075318	chr13:46052806~46113332:+
THCA	cis	rs3760982	1	rs10421887	ENSG00000267058.1	RP11-15A1.3	5.94	5.48e-09	1.05e-06	0.23	0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790697	chr19:43891804~43901805:-
THCA	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-5.94	5.48e-09	1.05e-06	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-5.94	5.48e-09	1.05e-06	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
THCA	cis	rs8009147	1	rs8009147	ENSG00000258735.1	LINC00637	-5.94	5.48e-09	1.05e-06	-0.32	-0.26	Autism spectrum disorder or schizophrenia;	chr14:103798325	chr14:103847721~103858049:+
THCA	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-5.94	5.48e-09	1.05e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
THCA	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-5.94	5.48e-09	1.05e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
THCA	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-5.94	5.48e-09	1.05e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
THCA	cis	rs11266744	0.688	rs4683220	ENSG00000223552.1	RP11-24F11.2	5.94	5.49e-09	1.05e-06	0.23	0.26	Monocyte percentage of white cells;	chr3:46381632	chr3:46364955~46407059:-
THCA	cis	rs2749592	0.588	rs2504144	ENSG00000263064.2	RP11-291L22.7	5.94	5.49e-09	1.05e-06	0.32	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr10:38094597	chr10:38448689~38448949:+
THCA	cis	rs897984	0.881	rs12920259	ENSG00000279196.1	RP11-1072A3.3	-5.94	5.49e-09	1.05e-06	-0.27	-0.26	Dementia with Lewy bodies;	chr16:30869978	chr16:30984630~30988270:-
THCA	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-5.94	5.49e-09	1.05e-06	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
THCA	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-5.94	5.49e-09	1.05e-06	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
THCA	cis	rs11148252	0.811	rs9535895	ENSG00000235660.1	LINC00345	-5.94	5.49e-09	1.05e-06	-0.33	-0.26	Lewy body disease;	chr13:52191712	chr13:52484161~52484680:-
THCA	cis	rs10129255	0.957	rs28887506	ENSG00000211974.3	IGHV2-70	5.94	5.49e-09	1.05e-06	0.2	0.26	Kawasaki disease;	chr14:106785589	chr14:106723574~106724093:-
THCA	cis	rs9921338	0.961	rs12934968	ENSG00000262636.1	CTD-3088G3.4	5.94	5.5e-09	1.05e-06	0.38	0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320209	chr16:11380859~11381118:-
THCA	cis	rs3760982	1	rs11665924	ENSG00000267058.1	RP11-15A1.3	-5.94	5.5e-09	1.05e-06	-0.23	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782830	chr19:43891804~43901805:-
THCA	cis	rs7523875	0.816	rs61848978	ENSG00000153363.11	LINC00467	-5.94	5.5e-09	1.05e-06	-0.27	-0.26	Mean corpuscular volume;	chr1:211349426	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.72	rs6666324	ENSG00000153363.11	LINC00467	-5.94	5.5e-09	1.05e-06	-0.27	-0.26	Mean corpuscular volume;	chr1:211351467	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.72	rs61848980	ENSG00000153363.11	LINC00467	-5.94	5.5e-09	1.05e-06	-0.27	-0.26	Mean corpuscular volume;	chr1:211354663	chr1:211382803~211435333:+
THCA	cis	rs11158026	0.603	rs17832269	ENSG00000258413.1	RP11-665C16.6	-5.94	5.5e-09	1.05e-06	-0.38	-0.26	Parkinson's disease;	chr14:54965373	chr14:55262767~55272075:-
THCA	cis	rs17772222	1	rs55722539	ENSG00000222990.1	RNU4-22P	5.94	5.5e-09	1.05e-06	0.35	0.26	Coronary artery calcification;	chr14:88411691	chr14:88513498~88513663:+
THCA	cis	rs6142102	0.961	rs6059596	ENSG00000275784.1	RP5-1125A11.6	-5.94	5.51e-09	1.05e-06	-0.27	-0.26	Skin pigmentation;	chr20:33969313	chr20:33989480~33991818:-
THCA	cis	rs7688540	0.771	rs4549329	ENSG00000211553.1	AC253576.2	-5.94	5.51e-09	1.05e-06	-0.39	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:136461~136568:+
THCA	cis	rs7246657	0.722	rs10410588	ENSG00000267422.1	CTD-2554C21.1	-5.94	5.52e-09	1.05e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37551508	chr19:37779686~37792865:+
THCA	cis	rs6740322	0.748	rs13420649	ENSG00000234936.1	AC010883.5	5.94	5.52e-09	1.05e-06	0.28	0.26	Coronary artery disease;	chr2:43236498	chr2:43229573~43233394:+
THCA	cis	rs1876905	0.68	rs187130	ENSG00000230177.1	RP5-1112D6.4	-5.94	5.52e-09	1.05e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111277932~111278742:+
THCA	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	5.94	5.52e-09	1.05e-06	0.2	0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
THCA	cis	rs9307551	0.857	rs2196978	ENSG00000250334.4	LINC00989	5.94	5.52e-09	1.05e-06	0.32	0.26	Refractive error;	chr4:79614815	chr4:79492416~79576460:+
THCA	cis	rs4852324	0.536	rs13390332	ENSG00000217702.2	RP11-287D1.4	5.94	5.52e-09	1.05e-06	0.73	0.26	Systemic lupus erythematosus;	chr2:73980230	chr2:74130583~74135395:+
THCA	cis	rs10971721	0.731	rs12377117	ENSG00000281128.1	PTENP1-AS	5.94	5.53e-09	1.05e-06	0.6	0.26	Body mass index;	chr9:33806586	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.73	rs72725361	ENSG00000281128.1	PTENP1-AS	5.94	5.53e-09	1.05e-06	0.6	0.26	Body mass index;	chr9:33806615	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs12376664	ENSG00000281128.1	PTENP1-AS	5.94	5.53e-09	1.05e-06	0.6	0.26	Body mass index;	chr9:33808705	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72725368	ENSG00000281128.1	PTENP1-AS	5.94	5.53e-09	1.05e-06	0.6	0.26	Body mass index;	chr9:33815457	chr9:33677268~33688011:+
THCA	cis	rs7208859	0.673	rs216411	ENSG00000263603.1	CTD-2349P21.5	5.94	5.53e-09	1.05e-06	0.42	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30729469~30731202:+
THCA	cis	rs9990333	0.526	rs11719682	ENSG00000226155.1	AC124944.3	-5.94	5.53e-09	1.05e-06	-0.33	-0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196107331	chr3:195912049~195913986:+
THCA	cis	rs712039	0.652	rs866465	ENSG00000276054.1	RP11-378E13.3	5.94	5.53e-09	1.05e-06	0.41	0.26	Tuberculosis;	chr17:37499298	chr17:37386886~37387926:+
THCA	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-5.94	5.53e-09	1.05e-06	-0.36	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
THCA	cis	rs2976388	0.578	rs4736324	ENSG00000253741.1	CTD-2292P10.4	5.94	5.53e-09	1.05e-06	0.35	0.26	Urinary tract infection frequency;	chr8:142749044	chr8:142702252~142726973:-
THCA	cis	rs10411161	0.58	rs12151287	ENSG00000269483.1	AC006272.1	5.94	5.53e-09	1.05e-06	0.32	0.26	Breast cancer;	chr19:51878242	chr19:51839924~51843324:-
THCA	cis	rs1865760	0.929	rs9358896	ENSG00000272462.2	U91328.19	-5.94	5.53e-09	1.05e-06	-0.22	-0.26	Height;	chr6:25942969	chr6:25992662~26001775:+
THCA	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-5.94	5.54e-09	1.06e-06	-0.3	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
THCA	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-5.94	5.54e-09	1.06e-06	-0.3	-0.26	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
THCA	cis	rs7202877	0.611	rs56092808	ENSG00000261783.1	RP11-252K23.2	-5.94	5.54e-09	1.06e-06	-0.48	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75278818	chr16:75379818~75381260:-
THCA	cis	rs1876905	0.539	rs240956	ENSG00000272356.1	RP5-1112D6.8	5.94	5.55e-09	1.06e-06	0.28	0.26	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111309203~111313517:+
THCA	cis	rs7403037	0.761	rs36096018	ENSG00000259905.4	PWRN1	5.94	5.55e-09	1.06e-06	0.3	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24375474	chr15:24493137~24652130:+
THCA	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-5.94	5.56e-09	1.06e-06	-0.45	-0.26	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
THCA	cis	rs896854	0.684	rs10099059	ENSG00000253528.2	RP11-347C18.4	5.94	5.56e-09	1.06e-06	0.3	0.26	Type 2 diabetes;	chr8:94974744	chr8:94974573~94974853:-
THCA	cis	rs896854	0.684	rs10099941	ENSG00000253528.2	RP11-347C18.4	5.94	5.56e-09	1.06e-06	0.3	0.26	Type 2 diabetes;	chr8:94974780	chr8:94974573~94974853:-
THCA	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	5.94	5.56e-09	1.06e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
THCA	cis	rs11148252	0.74	rs9596643	ENSG00000235660.1	LINC00345	5.94	5.56e-09	1.06e-06	0.34	0.26	Lewy body disease;	chr13:52338245	chr13:52484161~52484680:-
THCA	cis	rs2439831	0.867	rs933941	ENSG00000249839.1	AC011330.5	-5.94	5.56e-09	1.06e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43340028	chr15:43663654~43684339:-
THCA	cis	rs9876781	0.874	rs56298324	ENSG00000229759.1	MRPS18AP1	-5.94	5.56e-09	1.06e-06	-0.3	-0.26	Longevity;	chr3:48393626	chr3:48256350~48256938:-
THCA	cis	rs1707322	0.752	rs28890893	ENSG00000281133.1	AL355480.3	-5.94	5.56e-09	1.06e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45580892~45580996:-
THCA	cis	rs2243480	1	rs2533288	ENSG00000232546.1	RP11-458F8.1	-5.94	5.56e-09	1.06e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66591724	chr7:66848496~66858136:+
THCA	cis	rs4650994	0.524	rs2476558	ENSG00000273384.1	RP5-1098D14.1	-5.94	5.56e-09	1.06e-06	-0.34	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178611818	chr1:178651706~178652282:+
THCA	cis	rs7493	0.76	rs17876092	ENSG00000233942.1	AC004012.1	5.94	5.56e-09	1.06e-06	0.41	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424001	chr7:95471835~95473998:+
THCA	cis	rs9816784	0.566	rs11720913	ENSG00000226155.1	AC124944.3	-5.94	5.56e-09	1.06e-06	-0.33	-0.26	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195912049~195913986:+
THCA	cis	rs10208649	0.611	rs12616774	ENSG00000272156.1	RP11-477N3.1	5.94	5.57e-09	1.06e-06	0.36	0.26	Body mass index;	chr2:53742789	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.611	rs10211188	ENSG00000272156.1	RP11-477N3.1	5.94	5.57e-09	1.06e-06	0.36	0.26	Body mass index;	chr2:53743800	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.611	rs10187718	ENSG00000272156.1	RP11-477N3.1	5.94	5.57e-09	1.06e-06	0.36	0.26	Body mass index;	chr2:53743882	chr2:54082554~54085066:+
THCA	cis	rs12435908	1	rs2268960	ENSG00000276116.2	FUT8-AS1	-5.94	5.57e-09	1.06e-06	-0.42	-0.26	Ischemic stroke;	chr14:65678782	chr14:65411170~65412690:-
THCA	cis	rs890448	0.693	rs4312760	ENSG00000254531.1	FLJ20021	5.94	5.57e-09	1.06e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417443	chr4:101347780~101348883:+
THCA	cis	rs613391	0.603	rs628225	ENSG00000224549.1	RP11-370B11.3	-5.94	5.57e-09	1.06e-06	-0.3	-0.26	Quantitative traits;	chr9:22741676	chr9:22767175~22768316:+
THCA	cis	rs13191038	1	rs13191038	ENSG00000226314.6	ZNF192P1	-5.94	5.57e-09	1.06e-06	-0.58	-0.26	Urinary tract infection frequency;	chr6:28515140	chr6:28161781~28169594:+
THCA	cis	rs9921338	0.961	rs11545336	ENSG00000262703.1	RP11-485G7.6	-5.94	5.58e-09	1.06e-06	-0.35	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11348143~11349321:-
THCA	cis	rs950169	0.881	rs72750843	ENSG00000259295.5	CSPG4P12	5.94	5.58e-09	1.06e-06	0.41	0.26	Schizophrenia;	chr15:84592552	chr15:85191438~85213905:+
THCA	cis	rs748404	0.666	rs34633582	ENSG00000249839.1	AC011330.5	-5.94	5.58e-09	1.06e-06	-0.37	-0.26	Lung cancer;	chr15:43462683	chr15:43663654~43684339:-
THCA	cis	rs9921338	0.961	rs9937269	ENSG00000262703.1	RP11-485G7.6	5.94	5.58e-09	1.06e-06	0.34	0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322822	chr16:11348143~11349321:-
THCA	cis	rs9921338	1	rs9921338	ENSG00000262703.1	RP11-485G7.6	5.94	5.58e-09	1.06e-06	0.34	0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322982	chr16:11348143~11349321:-
THCA	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-5.94	5.59e-09	1.06e-06	-0.3	-0.26	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
THCA	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-5.94	5.59e-09	1.06e-06	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
THCA	cis	rs7202877	0.706	rs37605	ENSG00000261783.1	RP11-252K23.2	5.94	5.59e-09	1.06e-06	0.47	0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75472674	chr16:75379818~75381260:-
THCA	cis	rs934734	0.752	rs268131	ENSG00000281920.1	RP11-418H16.1	-5.94	5.59e-09	1.07e-06	-0.32	-0.26	Rheumatoid arthritis;	chr2:65383337	chr2:65623272~65628424:+
THCA	cis	rs4948275	0.773	rs2787739	ENSG00000237233.2	TMEM26-AS1	-5.94	5.59e-09	1.07e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61503040	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.806	rs2256377	ENSG00000237233.2	TMEM26-AS1	-5.94	5.59e-09	1.07e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61504725	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2256370	ENSG00000237233.2	TMEM26-AS1	-5.94	5.59e-09	1.07e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61504853	chr10:61452639~61481956:+
THCA	cis	rs4713118	0.824	rs9468225	ENSG00000280107.1	AL022393.9	-5.94	5.6e-09	1.07e-06	-0.31	-0.26	Parkinson's disease;	chr6:27777940	chr6:28170845~28172521:+
THCA	cis	rs9467773	1	rs12526680	ENSG00000124549.13	BTN2A3P	5.94	5.6e-09	1.07e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26421391~26432383:+
THCA	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	5.94	5.6e-09	1.07e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
THCA	cis	rs6908034	0.66	rs76322282	ENSG00000227116.1	RP3-471C18.1	-5.94	5.6e-09	1.07e-06	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801429	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs111533721	ENSG00000227116.1	RP3-471C18.1	-5.94	5.6e-09	1.07e-06	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803514	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.505	rs76709285	ENSG00000227116.1	RP3-471C18.1	-5.94	5.6e-09	1.07e-06	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804099	chr6:19730427~19734567:-
THCA	cis	rs10971721	0.822	rs10971773	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33898781	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971774	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33900111	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727318	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33901802	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs10971782	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33909466	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.908	rs10971787	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33914414	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727327	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33918818	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971791	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33920912	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971792	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33920955	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727329	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33921666	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs11848	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33921921	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727332	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33929479	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727335	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33931720	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727336	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33931795	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971802	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33933284	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971803	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33933289	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs41314578	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33933943	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs56274755	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33934273	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs118115128	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33935451	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727340	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33936736	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727341	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33936878	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727342	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33938084	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs117733169	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33938101	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727344	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33939122	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971807	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33939557	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727345	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33940200	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727346	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33940420	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727350	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33944732	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727351	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33950434	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727353	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33950824	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971817	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33951886	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs10971819	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33954149	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727362	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33957324	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727367	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33965180	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727369	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33965777	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971826	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33972035	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971827	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33972469	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971828	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33973417	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727378	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33975792	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727389	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33987030	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs72727392	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33988921	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72727399	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33997271	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971838	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33997948	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.686	rs10971839	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:33998410	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72729305	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34000293	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72729316	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34008175	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971845	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34009879	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971847	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34011460	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971848	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34012504	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971850	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34013910	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs10814061	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34014032	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs12380173	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34018500	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs12377970	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34021269	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs10971857	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34021621	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.908	rs72729329	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34022884	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.908	rs10971858	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34023693	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72729341	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34031693	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72729344	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34034032	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971866	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34043163	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971867	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34046758	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72729361	ENSG00000281128.1	PTENP1-AS	5.94	5.6e-09	1.07e-06	0.6	0.26	Body mass index;	chr9:34047525	chr9:33677268~33688011:+
THCA	cis	rs7225151	0.71	rs16954552	ENSG00000234327.6	AC012146.7	5.94	5.6e-09	1.07e-06	0.29	0.26	Alzheimer's disease (late onset);	chr17:5349219	chr17:5111468~5115004:+
THCA	cis	rs17594362	0.945	rs9566791	ENSG00000264190.1	MIR5006	5.94	5.6e-09	1.07e-06	0.38	0.26	Multiple sclerosis;	chr13:41570344	chr13:41568286~41568395:-
THCA	cis	rs227275	0.525	rs1080081	ENSG00000230069.3	LRRC37A15P	-5.94	5.6e-09	1.07e-06	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102727274~102730721:-
THCA	cis	rs227275	0.525	rs4699049	ENSG00000230069.3	LRRC37A15P	-5.94	5.6e-09	1.07e-06	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102727274~102730721:-
THCA	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	5.94	5.6e-09	1.07e-06	0.33	0.26	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
THCA	cis	rs227275	0.525	rs17215211	ENSG00000230069.3	LRRC37A15P	-5.94	5.61e-09	1.07e-06	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102727274~102730721:-
THCA	cis	rs9467773	0.804	rs2073526	ENSG00000124549.13	BTN2A3P	-5.94	5.61e-09	1.07e-06	-0.23	-0.26	Intelligence (multi-trait analysis);	chr6:26374430	chr6:26421391~26432383:+
THCA	cis	rs227275	0.556	rs4455413	ENSG00000230069.3	LRRC37A15P	-5.94	5.61e-09	1.07e-06	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102727274~102730721:-
THCA	cis	rs2018683	0.677	rs12531456	ENSG00000228421.2	AC005013.5	5.94	5.61e-09	1.07e-06	0.3	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930994	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.707	rs2391717	ENSG00000228421.2	AC005013.5	5.94	5.61e-09	1.07e-06	0.3	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931545	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.707	rs917215	ENSG00000228421.2	AC005013.5	5.94	5.61e-09	1.07e-06	0.3	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931750	chr7:28957667~28959345:+
THCA	cis	rs2281636	0.894	rs10883396	ENSG00000260475.1	RP11-85A1.3	5.94	5.61e-09	1.07e-06	0.24	0.26	Obesity-related traits;	chr10:99647135	chr10:99621055~99621918:+
THCA	cis	rs2281636	0.894	rs12771048	ENSG00000260475.1	RP11-85A1.3	5.94	5.61e-09	1.07e-06	0.24	0.26	Obesity-related traits;	chr10:99649691	chr10:99621055~99621918:+
THCA	cis	rs9921338	0.961	rs72773829	ENSG00000262703.1	RP11-485G7.6	-5.94	5.61e-09	1.07e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318766	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs72773830	ENSG00000262703.1	RP11-485G7.6	-5.94	5.61e-09	1.07e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318966	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs72773832	ENSG00000262703.1	RP11-485G7.6	-5.94	5.61e-09	1.07e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319266	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs72773833	ENSG00000262703.1	RP11-485G7.6	-5.94	5.61e-09	1.07e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319417	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs72773834	ENSG00000262703.1	RP11-485G7.6	-5.94	5.61e-09	1.07e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319436	chr16:11348143~11349321:-
THCA	cis	rs2018683	0.707	rs7799357	ENSG00000228421.2	AC005013.5	5.94	5.62e-09	1.07e-06	0.3	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930501	chr7:28957667~28959345:+
THCA	cis	rs4950322	1	rs72694750	ENSG00000237188.3	RP11-337C18.8	5.94	5.62e-09	1.07e-06	0.35	0.26	Protein quantitative trait loci;	chr1:147396856	chr1:147172771~147211568:+
THCA	cis	rs4950322	1	rs1986987	ENSG00000237188.3	RP11-337C18.8	5.94	5.62e-09	1.07e-06	0.35	0.26	Protein quantitative trait loci;	chr1:147397553	chr1:147172771~147211568:+
THCA	cis	rs4950322	1	rs61230354	ENSG00000237188.3	RP11-337C18.8	5.94	5.62e-09	1.07e-06	0.35	0.26	Protein quantitative trait loci;	chr1:147398161	chr1:147172771~147211568:+
THCA	cis	rs4950322	1	rs4950429	ENSG00000237188.3	RP11-337C18.8	5.94	5.62e-09	1.07e-06	0.35	0.26	Protein quantitative trait loci;	chr1:147400227	chr1:147172771~147211568:+
THCA	cis	rs4950322	1	rs59498179	ENSG00000237188.3	RP11-337C18.8	5.94	5.62e-09	1.07e-06	0.35	0.26	Protein quantitative trait loci;	chr1:147400417	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.947	rs58671552	ENSG00000237188.3	RP11-337C18.8	5.94	5.62e-09	1.07e-06	0.35	0.26	Protein quantitative trait loci;	chr1:147409534	chr1:147172771~147211568:+
THCA	cis	rs9307551	0.817	rs6852514	ENSG00000250334.4	LINC00989	-5.94	5.62e-09	1.07e-06	-0.31	-0.26	Refractive error;	chr4:79580759	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.744	rs968176	ENSG00000250334.4	LINC00989	-5.94	5.62e-09	1.07e-06	-0.31	-0.26	Refractive error;	chr4:79585080	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.817	rs1440852	ENSG00000250334.4	LINC00989	-5.94	5.62e-09	1.07e-06	-0.31	-0.26	Refractive error;	chr4:79585435	chr4:79492416~79576460:+
THCA	cis	rs227275	0.527	rs12500379	ENSG00000230069.3	LRRC37A15P	-5.94	5.63e-09	1.07e-06	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102727274~102730721:-
THCA	cis	rs317865	0.609	rs73234660	ENSG00000263327.5	TAPT1-AS1	-5.94	5.63e-09	1.07e-06	-0.46	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16219424	chr4:16226685~16320140:+
THCA	cis	rs4835473	0.838	rs12507468	ENSG00000251600.4	RP11-673E1.1	-5.94	5.63e-09	1.07e-06	-0.36	-0.26	Immature fraction of reticulocytes;	chr4:143908061	chr4:143912331~143982454:+
THCA	cis	rs7201929	1	rs12920514	ENSG00000251417.2	RP11-1348G14.4	5.94	5.64e-09	1.07e-06	0.28	0.26	QT interval;	chr16:28824579	chr16:28802743~28817828:+
THCA	cis	rs7976269	0.609	rs4931141	ENSG00000257176.2	RP11-996F15.2	-5.94	5.64e-09	1.07e-06	-0.27	-0.26	Male-pattern baldness;	chr12:29057763	chr12:29280418~29317848:-
THCA	cis	rs9816784	0.525	rs714602	ENSG00000231464.1	AC024937.4	5.94	5.65e-09	1.07e-06	0.34	0.26	Mean corpuscular hemoglobin;	chr3:196067108	chr3:195996738~195998233:+
THCA	cis	rs863750	0.687	rs825461	ENSG00000275389.1	RP11-214K3.24	-5.94	5.65e-09	1.07e-06	-0.34	-0.26	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124077256	chr12:124085761~124088598:+
THCA	cis	rs6430585	0.591	rs3098103	ENSG00000231890.6	DARS-AS1	-5.94	5.65e-09	1.08e-06	-0.32	-0.26	Corneal structure;	chr2:135898524	chr2:135985176~136022593:+
THCA	cis	rs9880211	0.752	rs9847427	ENSG00000273486.1	RP11-731C17.2	5.94	5.66e-09	1.08e-06	0.28	0.26	Height;Body mass index;	chr3:136632708	chr3:136837338~136839021:-
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000261839.1	RP1-265C24.8	5.94	5.66e-09	1.08e-06	0.31	0.26	Parkinson's disease;	chr6:28069254	chr6:28136849~28139678:+
THCA	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-5.94	5.67e-09	1.08e-06	-0.33	-0.26	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-5.94	5.67e-09	1.08e-06	-0.33	-0.26	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
THCA	cis	rs9921338	0.961	rs56136462	ENSG00000262703.1	RP11-485G7.6	-5.94	5.67e-09	1.08e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321738	chr16:11348143~11349321:-
THCA	cis	rs6545883	0.965	rs1562308	ENSG00000271889.1	RP11-493E12.1	5.94	5.67e-09	1.08e-06	0.25	0.26	Tuberculosis;	chr2:61541286	chr2:61151433~61162105:-
THCA	cis	rs10971721	0.822	rs72725370	ENSG00000281128.1	PTENP1-AS	5.94	5.68e-09	1.08e-06	0.6	0.26	Body mass index;	chr9:33818459	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.554	rs10971712	ENSG00000281128.1	PTENP1-AS	5.94	5.68e-09	1.08e-06	0.6	0.26	Body mass index;	chr9:33820940	chr9:33677268~33688011:+
THCA	cis	rs4713118	0.629	rs203890	ENSG00000272009.1	RP1-313I6.12	-5.94	5.68e-09	1.08e-06	-0.3	-0.26	Parkinson's disease;	chr6:28054470	chr6:28078792~28081130:-
THCA	cis	rs13191038	1	rs13191038	ENSG00000219392.1	RP1-265C24.5	-5.94	5.69e-09	1.08e-06	-0.59	-0.26	Urinary tract infection frequency;	chr6:28515140	chr6:28115628~28116551:+
THCA	cis	rs3760982	1	rs3760982	ENSG00000267058.1	RP11-15A1.3	-5.94	5.69e-09	1.08e-06	-0.23	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782361	chr19:43891804~43901805:-
THCA	cis	rs12497850	0.897	rs9884022	ENSG00000229759.1	MRPS18AP1	5.94	5.69e-09	1.08e-06	0.35	0.26	Parkinson's disease;	chr3:48919429	chr3:48256350~48256938:-
THCA	cis	rs12101261	0.744	rs17545038	ENSG00000259167.2	NMNAT1P1	5.94	5.69e-09	1.08e-06	0.38	0.26	Graves' disease;	chr14:80991228	chr14:81032529~81033404:+
THCA	cis	rs7809950	0.723	rs62483634	ENSG00000238832.1	snoU109	-5.94	5.69e-09	1.08e-06	-0.31	-0.26	Coronary artery disease;	chr7:107238071	chr7:107603363~107603507:+
THCA	cis	rs2179367	0.509	rs9485390	ENSG00000268592.3	RAET1E-AS1	5.94	5.69e-09	1.08e-06	0.37	0.26	Dupuytren's disease;	chr6:149421004	chr6:149863494~149919507:+
THCA	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-5.94	5.69e-09	1.08e-06	-0.19	-0.26	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
THCA	cis	rs7829975	0.711	rs4841051	ENSG00000254153.1	CTA-398F10.2	5.94	5.69e-09	1.08e-06	0.28	0.26	Mood instability;	chr8:8828136	chr8:8456909~8461337:-
THCA	cis	rs11603691	0.515	rs10792088	ENSG00000254662.1	RP11-872D17.4	-5.94	5.69e-09	1.08e-06	-0.44	-0.26	Low high density lipoprotein cholesterol levels;	chr11:57329181	chr11:57325603~57327958:+
THCA	cis	rs11603691	0.515	rs10792089	ENSG00000254662.1	RP11-872D17.4	-5.94	5.69e-09	1.08e-06	-0.44	-0.26	Low high density lipoprotein cholesterol levels;	chr11:57329379	chr11:57325603~57327958:+
THCA	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	5.94	5.7e-09	1.08e-06	0.29	0.26	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
THCA	cis	rs6860806	0.507	rs273901	ENSG00000263597.1	MIR3936	5.94	5.7e-09	1.08e-06	0.26	0.26	Breast cancer;	chr5:132358667	chr5:132365490~132365599:-
THCA	cis	rs270601	0.913	rs273899	ENSG00000263597.1	MIR3936	5.94	5.7e-09	1.08e-06	0.26	0.26	Acylcarnitine levels;	chr5:132359485	chr5:132365490~132365599:-
THCA	cis	rs442309	0.812	rs224089	ENSG00000238280.1	RP11-436D10.3	-5.94	5.7e-09	1.08e-06	-0.32	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62780161	chr10:62793562~62805887:-
THCA	cis	rs11089937	0.626	rs5757017	ENSG00000211638.2	IGLV8-61	-5.94	5.71e-09	1.08e-06	-0.21	-0.26	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22098700~22099212:+
THCA	cis	rs1061377	0.621	rs11096974	ENSG00000249685.1	RP11-360F5.3	5.93	5.72e-09	1.09e-06	0.32	0.26	Uric acid levels;	chr4:39062039	chr4:39133913~39135608:+
THCA	cis	rs10808739	0.614	rs9650211	ENSG00000254006.4	RP11-1D12.2	-5.93	5.72e-09	1.09e-06	-0.42	-0.26	HIV-1 susceptibility;	chr8:64723582	chr8:64801236~64817573:-
THCA	cis	rs10808739	0.614	rs36053206	ENSG00000254006.4	RP11-1D12.2	-5.93	5.72e-09	1.09e-06	-0.42	-0.26	HIV-1 susceptibility;	chr8:64724752	chr8:64801236~64817573:-
THCA	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	5.93	5.72e-09	1.09e-06	0.29	0.26	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
THCA	cis	rs2579519	0.547	rs2463560	ENSG00000232931.4	LINC00342	5.93	5.73e-09	1.09e-06	0.21	0.26	Diastolic blood pressure;	chr2:95929841	chr2:95807118~95816215:-
THCA	cis	rs2692947	0.695	rs12464148	ENSG00000232931.4	LINC00342	5.93	5.73e-09	1.09e-06	0.21	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95930962	chr2:95807118~95816215:-
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000237310.1	GS1-124K5.4	-5.93	5.73e-09	1.09e-06	-0.19	-0.26	Calcium levels;	chr7:65733651	chr7:66493706~66495474:+
THCA	cis	rs6674176	0.66	rs2108202	ENSG00000237950.1	RP11-7O11.3	-5.93	5.73e-09	1.09e-06	-0.24	-0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43930114	chr1:43944370~43946551:-
THCA	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-5.93	5.73e-09	1.09e-06	-0.41	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
THCA	cis	rs934734	0.789	rs268122	ENSG00000237979.1	AC007389.1	-5.93	5.74e-09	1.09e-06	-0.31	-0.26	Rheumatoid arthritis;	chr2:65374975	chr2:65500993~65502138:-
THCA	cis	rs4713118	0.629	rs203890	ENSG00000220721.1	OR1F12	5.93	5.74e-09	1.09e-06	0.35	0.26	Parkinson's disease;	chr6:28054470	chr6:28073316~28074233:+
THCA	cis	rs9311474	1	rs9311474	ENSG00000243224.1	RP5-1157M23.2	-5.93	5.74e-09	1.09e-06	-0.27	-0.26	Electroencephalogram traits;	chr3:52304836	chr3:52239258~52241097:+
THCA	cis	rs2562456	0.917	rs2681376	ENSG00000213976.4	CTD-2561J22.2	5.93	5.75e-09	1.09e-06	0.28	0.26	Pain;	chr19:21532723	chr19:21382865~21387177:+
THCA	cis	rs7713065	0.531	rs2522051	ENSG00000233006.5	AC034220.3	5.93	5.75e-09	1.09e-06	0.2	0.26	Lung function (FEV1/FVC);	chr5:132461886	chr5:132311285~132369916:-
THCA	cis	rs10875746	0.669	rs61940962	ENSG00000269514.1	RP11-370I10.12	5.93	5.75e-09	1.09e-06	0.27	0.26	Longevity (90 years and older);	chr12:48201694	chr12:48198387~48202031:+
THCA	cis	rs55704346	0.654	rs11937742	ENSG00000281501.1	SEPSECS-AS1	5.93	5.76e-09	1.09e-06	0.3	0.26	Tonsillectomy;	chr4:25162050	chr4:25160641~25201440:+
THCA	cis	rs55704346	0.654	rs12498160	ENSG00000281501.1	SEPSECS-AS1	5.93	5.76e-09	1.09e-06	0.3	0.26	Tonsillectomy;	chr4:25168324	chr4:25160641~25201440:+
THCA	cis	rs1979679	0.801	rs7977538	ENSG00000278733.1	RP11-425D17.1	5.93	5.76e-09	1.09e-06	0.27	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143503	chr12:28185625~28186190:-
THCA	cis	rs6142102	0.961	rs909884	ENSG00000275784.1	RP5-1125A11.6	-5.93	5.76e-09	1.09e-06	-0.28	-0.26	Skin pigmentation;	chr20:34058257	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs2268088	ENSG00000275784.1	RP5-1125A11.6	-5.93	5.76e-09	1.09e-06	-0.28	-0.26	Skin pigmentation;	chr20:34061258	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs4911401	ENSG00000275784.1	RP5-1125A11.6	-5.93	5.76e-09	1.09e-06	-0.28	-0.26	Skin pigmentation;	chr20:34066756	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.961	rs2284388	ENSG00000275784.1	RP5-1125A11.6	-5.93	5.76e-09	1.09e-06	-0.28	-0.26	Skin pigmentation;	chr20:34067935	chr20:33989480~33991818:-
THCA	cis	rs11722779	0.787	rs6533040	ENSG00000251288.2	RP11-10L12.2	-5.93	5.76e-09	1.09e-06	-0.36	-0.26	Schizophrenia;	chr4:102951421	chr4:102751401~102752641:+
THCA	cis	rs935334	1	rs2121077	ENSG00000258454.1	RP11-361H10.3	-5.93	5.77e-09	1.1e-06	-0.39	-0.26	Blood pressure;	chr14:76210012	chr14:76235817~76263474:+
THCA	cis	rs442309	0.551	rs7083045	ENSG00000238280.1	RP11-436D10.3	-5.93	5.77e-09	1.1e-06	-0.31	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62780204	chr10:62793562~62805887:-
THCA	cis	rs2765539	0.515	rs2788183	ENSG00000231365.4	RP11-418J17.1	-5.93	5.77e-09	1.1e-06	-0.3	-0.26	Waist-hip ratio;	chr1:118929322	chr1:119140396~119275973:+
THCA	cis	rs442309	0.749	rs224109	ENSG00000238280.1	RP11-436D10.3	-5.93	5.77e-09	1.1e-06	-0.32	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62790311	chr10:62793562~62805887:-
THCA	cis	rs4784934	0.55	rs4784939	ENSG00000260186.4	RP11-481J2.2	5.93	5.77e-09	1.1e-06	0.37	0.26	QT interval;	chr16:58434307	chr16:58421326~58462470:+
THCA	cis	rs9311474	0.713	rs352165	ENSG00000243224.1	RP5-1157M23.2	-5.93	5.78e-09	1.1e-06	-0.27	-0.26	Electroencephalogram traits;	chr3:52208886	chr3:52239258~52241097:+
THCA	cis	rs2303319	1	rs78555127	ENSG00000227403.1	AC009299.3	5.93	5.78e-09	1.1e-06	0.58	0.26	Cognitive function;	chr2:161414749	chr2:161244739~161249050:+
THCA	cis	rs7554547	0.838	rs885770	ENSG00000201801.1	RNU5E-4P	5.93	5.79e-09	1.1e-06	0.32	0.26	Nonsyndromic cleft lip with cleft palate;	chr1:11878699	chr1:11909808~11909927:-
THCA	cis	rs2300206	1	rs2300206	ENSG00000275784.1	RP5-1125A11.6	-5.93	5.79e-09	1.1e-06	-0.28	-0.26	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33989480~33991818:-
THCA	cis	rs11158026	0.574	rs7152033	ENSG00000258413.1	RP11-665C16.6	-5.93	5.79e-09	1.1e-06	-0.37	-0.26	Parkinson's disease;	chr14:54926036	chr14:55262767~55272075:-
THCA	cis	rs7727544	0.582	rs3805681	ENSG00000233006.5	AC034220.3	5.93	5.8e-09	1.1e-06	0.2	0.26	Blood metabolite levels;	chr5:132202167	chr5:132311285~132369916:-
THCA	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-5.93	5.8e-09	1.1e-06	-0.3	-0.26	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
THCA	cis	rs4835473	0.932	rs10857415	ENSG00000251600.4	RP11-673E1.1	5.93	5.8e-09	1.1e-06	0.35	0.26	Immature fraction of reticulocytes;	chr4:143908753	chr4:143912331~143982454:+
THCA	cis	rs7615952	0.576	rs4646763	ENSG00000250012.1	RP11-124N2.1	-5.93	5.8e-09	1.1e-06	-0.26	-0.26	Blood pressure (smoking interaction);	chr3:126103286	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.576	rs4646759	ENSG00000250012.1	RP11-124N2.1	-5.93	5.8e-09	1.1e-06	-0.26	-0.26	Blood pressure (smoking interaction);	chr3:126104103	chr3:126084220~126095349:+
THCA	cis	rs1979679	0.842	rs2127315	ENSG00000278733.1	RP11-425D17.1	5.93	5.8e-09	1.1e-06	0.27	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28156247	chr12:28185625~28186190:-
THCA	cis	rs11795343	0.509	rs668559	ENSG00000232303.2	DFFBP1	-5.93	5.81e-09	1.1e-06	-0.31	-0.26	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32520612	chr9:32566148~32567126:-
THCA	cis	rs935334	1	rs2543382	ENSG00000258454.1	RP11-361H10.3	5.93	5.81e-09	1.1e-06	0.37	0.26	Blood pressure;	chr14:76158544	chr14:76235817~76263474:+
THCA	cis	rs12612619	0.732	rs1078809	ENSG00000229122.1	AGBL5-IT1	5.93	5.81e-09	1.1e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27066047	chr2:27061038~27061815:+
THCA	cis	rs12612619	0.732	rs10865461	ENSG00000229122.1	AGBL5-IT1	5.93	5.81e-09	1.1e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27069783	chr2:27061038~27061815:+
THCA	cis	rs12612619	0.732	rs1053609	ENSG00000229122.1	AGBL5-IT1	5.93	5.81e-09	1.1e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27070282	chr2:27061038~27061815:+
THCA	cis	rs4950322	0.57	rs4950401	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147319571	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs4950402	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147319684	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs4950404	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147319834	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692946	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147319966	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692948	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147320298	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692951	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147320551	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs77118461	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147320718	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs78681047	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147321013	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.57	rs72692953	ENSG00000278811.3	LINC00624	5.93	5.81e-09	1.1e-06	0.33	0.26	Protein quantitative trait loci;	chr1:147321416	chr1:147258885~147517875:-
THCA	cis	rs8002861	0.935	rs1819595	ENSG00000274001.1	RP11-5G9.5	5.93	5.81e-09	1.1e-06	0.29	0.26	Leprosy;	chr13:43855580	chr13:43877715~43878163:-
THCA	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	5.93	5.82e-09	1.1e-06	0.26	0.26	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
THCA	cis	rs793571	0.554	rs28489732	ENSG00000259250.1	RP11-50C13.1	-5.93	5.82e-09	1.1e-06	-0.29	-0.26	Schizophrenia;	chr15:58721154	chr15:58587507~58591676:+
THCA	cis	rs10971721	0.908	rs10971722	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33828166	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971723	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33829604	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.908	rs12376055	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33831957	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.908	rs55684780	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33833210	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.908	rs10971728	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33834635	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.642	rs114466241	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33835731	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs12378261	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33837174	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72725374	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33840651	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.749	rs72725375	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33840706	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72725376	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33841931	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72725377	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33842228	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72725378	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33842896	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs12380143	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33847588	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72725381	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33851167	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971735	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33851801	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.642	rs10971736	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33854376	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.749	rs10971741	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33856869	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs56253239	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33860068	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs115554740	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33860888	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72725387	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33863673	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs72725388	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33864624	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs117687546	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33864931	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs56172788	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33865752	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs10971750	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33869783	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971753	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33870438	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971754	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33871714	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971755	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33872007	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs72725398	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33875920	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971758	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33876071	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs72725402	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33878358	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.731	rs72727303	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33878378	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971763	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33879779	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.822	rs10971764	ENSG00000281128.1	PTENP1-AS	5.93	5.82e-09	1.1e-06	0.59	0.26	Body mass index;	chr9:33880102	chr9:33677268~33688011:+
THCA	cis	rs9376098	0.698	rs7774081	ENSG00000232876.1	CTA-212D2.2	-5.93	5.82e-09	1.1e-06	-0.32	-0.26	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135139861	chr6:135055033~135060550:+
THCA	cis	rs2839186	0.903	rs61182475	ENSG00000239415.1	AP001469.9	5.93	5.83e-09	1.11e-06	0.28	0.26	Testicular germ cell tumor;	chr21:46287136	chr21:46251549~46254133:-
THCA	cis	rs12893668	0.644	rs12890820	ENSG00000269910.1	RP11-73M18.10	5.93	5.83e-09	1.11e-06	0.25	0.26	Reticulocyte count;	chr14:103568512	chr14:103694516~103695050:-
THCA	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	5.93	5.83e-09	1.11e-06	0.32	0.26	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
THCA	cis	rs736801	0.808	rs2706396	ENSG00000224431.1	AC063976.7	-5.93	5.83e-09	1.11e-06	-0.23	-0.26	Mosquito bite size;Breast cancer;	chr5:132461117	chr5:132199456~132203487:+
THCA	cis	rs736801	0.836	rs2522052	ENSG00000224431.1	AC063976.7	-5.93	5.83e-09	1.11e-06	-0.23	-0.26	Mosquito bite size;Breast cancer;	chr5:132462795	chr5:132199456~132203487:+
THCA	cis	rs736801	0.808	rs2706403	ENSG00000224431.1	AC063976.7	-5.93	5.83e-09	1.11e-06	-0.23	-0.26	Mosquito bite size;Breast cancer;	chr5:132463320	chr5:132199456~132203487:+
THCA	cis	rs736801	0.754	rs2706336	ENSG00000224431.1	AC063976.7	-5.93	5.83e-09	1.11e-06	-0.23	-0.26	Mosquito bite size;Breast cancer;	chr5:132464269	chr5:132199456~132203487:+
THCA	cis	rs6674176	0.597	rs3762422	ENSG00000237950.1	RP11-7O11.3	5.93	5.84e-09	1.11e-06	0.23	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934860	chr1:43944370~43946551:-
THCA	cis	rs4227	0.565	rs1641550	ENSG00000233223.2	AC113189.5	5.93	5.84e-09	1.11e-06	0.21	0.26	IgA nephropathy;	chr17:7600470	chr17:7581964~7584072:-
THCA	cis	rs6142102	0.961	rs4911385	ENSG00000275784.1	RP5-1125A11.6	-5.93	5.85e-09	1.11e-06	-0.27	-0.26	Skin pigmentation;	chr20:33970787	chr20:33989480~33991818:-
THCA	cis	rs8002861	0.935	rs1822969	ENSG00000274001.1	RP11-5G9.5	5.93	5.85e-09	1.11e-06	0.29	0.26	Leprosy;	chr13:43844028	chr13:43877715~43878163:-
THCA	cis	rs67478160	0.619	rs11160759	ENSG00000258735.1	LINC00637	-5.93	5.86e-09	1.11e-06	-0.32	-0.26	Schizophrenia;	chr14:103765205	chr14:103847721~103858049:+
THCA	cis	rs2018683	0.707	rs10279870	ENSG00000228421.2	AC005013.5	5.93	5.86e-09	1.11e-06	0.3	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929318	chr7:28957667~28959345:+
THCA	cis	rs6585424	1	rs11202031	ENSG00000225484.5	NUTM2B-AS1	-5.93	5.86e-09	1.11e-06	-0.43	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184287	chr10:79663088~79826594:-
THCA	cis	rs9402743	0.775	rs9483862	ENSG00000231028.7	LINC00271	-5.93	5.87e-09	1.11e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135649541	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs9494315	ENSG00000231028.7	LINC00271	-5.93	5.87e-09	1.11e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135649778	chr6:135497801~135716055:+
THCA	cis	rs1577330	0.561	rs10967707	ENSG00000254396.1	RP11-56F10.3	5.93	5.87e-09	1.11e-06	0.44	0.26	IgG glycosylation;	chr9:27090625	chr9:27102630~27104728:+
THCA	cis	rs67478160	0.643	rs34813623	ENSG00000258735.1	LINC00637	-5.93	5.87e-09	1.11e-06	-0.32	-0.26	Schizophrenia;	chr14:103796957	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.608	rs34066659	ENSG00000258735.1	LINC00637	-5.93	5.87e-09	1.11e-06	-0.32	-0.26	Schizophrenia;	chr14:103797090	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs7147171	ENSG00000258735.1	LINC00637	-5.93	5.87e-09	1.11e-06	-0.32	-0.26	Schizophrenia;	chr14:103798520	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.619	rs11623546	ENSG00000258735.1	LINC00637	-5.93	5.87e-09	1.11e-06	-0.32	-0.26	Schizophrenia;	chr14:103802761	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.619	rs55824307	ENSG00000258735.1	LINC00637	-5.93	5.87e-09	1.11e-06	-0.32	-0.26	Schizophrenia;	chr14:103804870	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.595	rs12879501	ENSG00000258735.1	LINC00637	-5.93	5.87e-09	1.11e-06	-0.32	-0.26	Schizophrenia;	chr14:103806297	chr14:103847721~103858049:+
THCA	cis	rs4950322	0.576	rs2353979	ENSG00000237188.3	RP11-337C18.8	-5.93	5.88e-09	1.12e-06	-0.29	-0.26	Protein quantitative trait loci;	chr1:147368185	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.576	rs2353980	ENSG00000237188.3	RP11-337C18.8	-5.93	5.88e-09	1.12e-06	-0.29	-0.26	Protein quantitative trait loci;	chr1:147368274	chr1:147172771~147211568:+
THCA	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	5.93	5.88e-09	1.12e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	5.93	5.88e-09	1.12e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	5.93	5.88e-09	1.12e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
THCA	cis	rs2562456	0.833	rs2928211	ENSG00000268081.1	RP11-678G14.2	-5.93	5.89e-09	1.12e-06	-0.39	-0.26	Pain;	chr19:21358495	chr19:21554640~21569237:-
THCA	cis	rs757978	0.929	rs115271170	ENSG00000223374.1	AC005104.3	5.93	5.9e-09	1.12e-06	0.3	0.26	Chronic lymphocytic leukemia;	chr2:241408199	chr2:241351340~241353104:-
THCA	cis	rs1861628	1	rs13015993	ENSG00000237930.1	AC007563.4	-5.93	5.9e-09	1.12e-06	-0.3	-0.26	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216760800	chr2:216785774~216786144:-
THCA	cis	rs8007846	0.569	rs4400971	ENSG00000276116.2	FUT8-AS1	-5.93	5.9e-09	1.12e-06	-0.27	-0.26	Multiple sclerosis--Brain Glutamate Levels;	chr14:65787860	chr14:65411170~65412690:-
THCA	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-5.93	5.91e-09	1.12e-06	-0.28	-0.26	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
THCA	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-5.93	5.91e-09	1.12e-06	-0.4	-0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
THCA	cis	rs890448	0.694	rs2583398	ENSG00000254531.1	FLJ20021	-5.93	5.91e-09	1.12e-06	-0.24	-0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101307539	chr4:101347780~101348883:+
THCA	cis	rs7727544	0.545	rs7716474	ENSG00000224431.1	AC063976.7	5.93	5.91e-09	1.12e-06	0.25	0.26	Blood metabolite levels;	chr5:132048290	chr5:132199456~132203487:+
THCA	cis	rs12439619	0.705	rs4778665	ENSG00000255769.6	GOLGA2P10	-5.93	5.92e-09	1.12e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472993~82513950:-
THCA	cis	rs11783469	0.522	rs11781808	ENSG00000253390.1	CTC-756D1.2	-5.93	5.92e-09	1.12e-06	-0.43	-0.26	Reticulocyte count;	chr8:23399392	chr8:23458601~23484971:+
THCA	cis	rs11976180	1	rs11976037	ENSG00000273234.1	OR2A13P	-5.93	5.93e-09	1.12e-06	-0.3	-0.26	Obesity-related traits;	chr7:144043931	chr7:144142009~144142938:+
THCA	cis	rs7809950	0.678	rs77395658	ENSG00000238832.1	snoU109	-5.93	5.93e-09	1.12e-06	-0.31	-0.26	Coronary artery disease;	chr7:107360206	chr7:107603363~107603507:+
THCA	cis	rs1876905	0.68	rs402940	ENSG00000230177.1	RP5-1112D6.4	-5.93	5.93e-09	1.12e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111277932~111278742:+
THCA	cis	rs1234598	1	rs1234598	ENSG00000230177.1	RP5-1112D6.4	-5.93	5.93e-09	1.12e-06	-0.27	-0.26	Mean corpuscular volume;	chr6:111208250	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.68	rs354543	ENSG00000230177.1	RP5-1112D6.4	-5.93	5.93e-09	1.12e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111277932~111278742:+
THCA	cis	rs3794924	1	rs35777565	ENSG00000266521.1	RP11-650P15.1	5.93	5.93e-09	1.12e-06	0.5	0.26	Survival in colon cancer;	chr18:31469409	chr18:31496645~31497195:-
THCA	cis	rs6860806	0.507	rs272854	ENSG00000263597.1	MIR3936	5.93	5.93e-09	1.12e-06	0.27	0.26	Breast cancer;	chr5:132352324	chr5:132365490~132365599:-
THCA	cis	rs7493	0.901	rs2237586	ENSG00000233942.1	AC004012.1	5.93	5.94e-09	1.12e-06	0.4	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95421740	chr7:95471835~95473998:+
THCA	cis	rs7493	0.853	rs35686517	ENSG00000233942.1	AC004012.1	5.93	5.94e-09	1.12e-06	0.4	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95423299	chr7:95471835~95473998:+
THCA	cis	rs2243480	1	rs4718334	ENSG00000232546.1	RP11-458F8.1	5.93	5.94e-09	1.13e-06	0.35	0.26	Diabetic kidney disease;	chr7:66324467	chr7:66848496~66858136:+
THCA	cis	rs8030379	0.811	rs7162542	ENSG00000230373.7	GOLGA6L5P	-5.93	5.94e-09	1.13e-06	-0.26	-0.26	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83845538	chr15:84507885~84516814:-
THCA	cis	rs11976180	1	rs6464573	ENSG00000273234.1	OR2A13P	5.93	5.95e-09	1.13e-06	0.29	0.26	Obesity-related traits;	chr7:144051005	chr7:144142009~144142938:+
THCA	cis	rs7267979	0.789	rs6083820	ENSG00000274973.1	RP13-401N8.7	5.93	5.95e-09	1.13e-06	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:25845497~25845862:+
THCA	cis	rs10829156	0.732	rs7075678	ENSG00000240291.1	RP11-499P20.2	5.93	5.95e-09	1.13e-06	0.22	0.26	Sudden cardiac arrest;	chr10:18585174	chr10:18513115~18545651:-
THCA	cis	rs9402743	0.775	rs9494322	ENSG00000231028.7	LINC00271	5.93	5.95e-09	1.13e-06	0.21	0.26	Systemic lupus erythematosus;	chr6:135660922	chr6:135497801~135716055:+
THCA	cis	rs748404	0.697	rs493444	ENSG00000166763.7	STRCP1	5.93	5.95e-09	1.13e-06	0.28	0.26	Lung cancer;	chr15:43274272	chr15:43699488~43718184:-
THCA	cis	rs7829975	0.714	rs6994038	ENSG00000254153.1	CTA-398F10.2	-5.93	5.95e-09	1.13e-06	-0.28	-0.26	Mood instability;	chr8:8803028	chr8:8456909~8461337:-
THCA	cis	rs6908034	0.66	rs76322282	ENSG00000237404.1	RP3-471C18.2	-5.93	5.96e-09	1.13e-06	-0.52	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801429	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs111533721	ENSG00000237404.1	RP3-471C18.2	-5.93	5.96e-09	1.13e-06	-0.52	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803514	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.505	rs76709285	ENSG00000237404.1	RP3-471C18.2	-5.93	5.96e-09	1.13e-06	-0.52	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804099	chr6:19689825~19753113:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	5.93	5.96e-09	1.13e-06	0.3	0.26	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
THCA	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	5.93	5.96e-09	1.13e-06	0.34	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	5.93	5.96e-09	1.13e-06	0.34	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	5.93	5.96e-09	1.13e-06	0.34	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	5.93	5.96e-09	1.13e-06	0.34	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	5.93	5.96e-09	1.13e-06	0.34	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
THCA	cis	rs7809950	0.599	rs2237658	ENSG00000238832.1	snoU109	-5.93	5.96e-09	1.13e-06	-0.32	-0.26	Coronary artery disease;	chr7:107197421	chr7:107603363~107603507:+
THCA	cis	rs792448	0.534	rs66912346	ENSG00000226251.4	RP11-15I11.3	-5.93	5.97e-09	1.13e-06	-0.35	-0.26	White blood cell count (basophil);	chr1:212444178	chr1:212225278~212238977:-
THCA	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-5.93	5.97e-09	1.13e-06	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
THCA	cis	rs10971721	0.749	rs72725371	ENSG00000281128.1	PTENP1-AS	5.93	5.97e-09	1.13e-06	0.6	0.26	Body mass index;	chr9:33825013	chr9:33677268~33688011:+
THCA	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-5.93	5.98e-09	1.13e-06	-0.32	-0.26	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
THCA	cis	rs1861628	1	rs13020935	ENSG00000237930.1	AC007563.4	5.93	5.98e-09	1.13e-06	0.3	0.26	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216760956	chr2:216785774~216786144:-
THCA	cis	rs2120243	0.528	rs62278647	ENSG00000244515.1	KRT18P34	-5.93	5.98e-09	1.13e-06	-0.3	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157431344	chr3:157162663~157163932:-
THCA	cis	rs202072	0.722	rs202068	ENSG00000272379.1	RP1-257A7.5	5.93	5.98e-09	1.13e-06	0.43	0.26	HIV-1 viral setpoint;	chr6:13266818	chr6:13290018~13290490:-
THCA	cis	rs3782123	0.604	rs11245998	ENSG00000277290.1	RP11-326C3.16	5.93	5.99e-09	1.13e-06	0.26	0.26	Red cell distribution width;Glycated hemoglobin levels;	chr11:207462	chr11:243099~243483:-
THCA	cis	rs11603691	0.551	rs10896605	ENSG00000254662.1	RP11-872D17.4	-5.93	5.99e-09	1.13e-06	-0.44	-0.26	Low high density lipoprotein cholesterol levels;	chr11:57330450	chr11:57325603~57327958:+
THCA	cis	rs11089937	0.626	rs11704092	ENSG00000211638.2	IGLV8-61	-5.93	5.99e-09	1.13e-06	-0.22	-0.26	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22098700~22099212:+
THCA	cis	rs7702057	0.53	rs3946989	ENSG00000271918.1	CTD-2287O16.5	5.93	5.99e-09	1.14e-06	0.29	0.26	Amyotrophic lateral sclerosis;	chr5:116078431	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.53	rs1567331	ENSG00000271918.1	CTD-2287O16.5	5.93	5.99e-09	1.14e-06	0.29	0.26	Amyotrophic lateral sclerosis;	chr5:116078627	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.53	rs1567332	ENSG00000271918.1	CTD-2287O16.5	5.93	5.99e-09	1.14e-06	0.29	0.26	Amyotrophic lateral sclerosis;	chr5:116078690	chr5:116083807~116085416:-
THCA	cis	rs6674176	0.66	rs11210936	ENSG00000237950.1	RP11-7O11.3	5.93	5.99e-09	1.14e-06	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43925766	chr1:43944370~43946551:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	5.93	6e-09	1.14e-06	0.3	0.26	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
THCA	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	5.93	6e-09	1.14e-06	0.29	0.26	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
THCA	cis	rs853679	0.607	rs34788973	ENSG00000226314.6	ZNF192P1	-5.93	6e-09	1.14e-06	-0.57	-0.26	Depression;	chr6:27911422	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs61742093	ENSG00000226314.6	ZNF192P1	-5.93	6e-09	1.14e-06	-0.57	-0.26	Depression;	chr6:27912204	chr6:28161781~28169594:+
THCA	cis	rs2280018	0.963	rs4985147	ENSG00000188599.16	NPIPP1	-5.93	6e-09	1.14e-06	-0.19	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15104312~15123498:-
THCA	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55522229	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs2035692	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55528801	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs4507426	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55529387	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55529786	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55532542	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55542243	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55544621	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55548666	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55561218	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55564241	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.783	rs7690837	ENSG00000249700.7	SRD5A3-AS1	5.93	6e-09	1.14e-06	0.34	0.26	Height;	chr4:55575856	chr4:55363971~55395847:-
THCA	cis	rs8062405	0.789	rs240704	ENSG00000278665.1	RP11-666O2.4	5.93	6e-09	1.14e-06	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28599241~28601881:-
THCA	cis	rs17301013	0.507	rs1923818	ENSG00000227373.4	RP11-160H22.5	5.93	6e-09	1.14e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174749737	chr1:174115300~174160004:-
THCA	cis	rs2749592	0.611	rs2505199	ENSG00000263064.2	RP11-291L22.7	5.93	6.01e-09	1.14e-06	0.32	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr10:38103529	chr10:38448689~38448949:+
THCA	cis	rs2749592	0.588	rs2505192	ENSG00000263064.2	RP11-291L22.7	5.93	6.01e-09	1.14e-06	0.32	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr10:38106095	chr10:38448689~38448949:+
THCA	cis	rs2749592	0.611	rs176888	ENSG00000263064.2	RP11-291L22.7	5.93	6.01e-09	1.14e-06	0.32	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr10:38117233	chr10:38448689~38448949:+
THCA	cis	rs9880211	0.948	rs34135127	ENSG00000273486.1	RP11-731C17.2	5.93	6.01e-09	1.14e-06	0.28	0.26	Height;Body mass index;	chr3:136507656	chr3:136837338~136839021:-
THCA	cis	rs9921338	0.961	rs66555362	ENSG00000262636.1	CTD-3088G3.4	-5.93	6.02e-09	1.14e-06	-0.38	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11294976	chr16:11380859~11381118:-
THCA	cis	rs11148252	0.87	rs11148246	ENSG00000235660.1	LINC00345	-5.93	6.02e-09	1.14e-06	-0.33	-0.26	Lewy body disease;	chr13:52223402	chr13:52484161~52484680:-
THCA	cis	rs227275	0.526	rs223497	ENSG00000251288.2	RP11-10L12.2	-5.93	6.02e-09	1.14e-06	-0.36	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102751401~102752641:+
THCA	cis	rs11158026	0.574	rs58055971	ENSG00000258413.1	RP11-665C16.6	-5.93	6.02e-09	1.14e-06	-0.38	-0.26	Parkinson's disease;	chr14:54969606	chr14:55262767~55272075:-
THCA	cis	rs2252790	0.64	rs10484838	ENSG00000233558.1	RP3-486I3.4	-5.93	6.03e-09	1.14e-06	-0.3	-0.26	Fast beta electroencephalogram;	chr6:116276561	chr6:116258493~116259115:-
THCA	cis	rs12435908	1	rs8019491	ENSG00000276116.2	FUT8-AS1	-5.93	6.03e-09	1.14e-06	-0.43	-0.26	Ischemic stroke;	chr14:65701392	chr14:65411170~65412690:-
THCA	cis	rs75422866	0.51	rs73105819	ENSG00000276691.1	RP5-1057I20.5	5.93	6.03e-09	1.14e-06	0.45	0.26	Pneumonia;	chr12:47727190	chr12:47788426~47788971:+
THCA	cis	rs6908034	0.607	rs78402429	ENSG00000237404.1	RP3-471C18.2	-5.93	6.03e-09	1.14e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19811459	chr6:19689825~19753113:-
THCA	cis	rs801193	0.967	rs34356500	ENSG00000273142.1	RP11-458F8.4	-5.93	6.03e-09	1.14e-06	-0.21	-0.26	Aortic root size;	chr7:66771620	chr7:66902857~66906297:+
THCA	cis	rs7702057	0.53	rs74583480	ENSG00000271918.1	CTD-2287O16.5	5.93	6.04e-09	1.14e-06	0.29	0.26	Amyotrophic lateral sclerosis;	chr5:116085200	chr5:116083807~116085416:-
THCA	cis	rs2281636	0.894	rs12782208	ENSG00000260475.1	RP11-85A1.3	5.93	6.04e-09	1.14e-06	0.24	0.26	Obesity-related traits;	chr10:99617219	chr10:99621055~99621918:+
THCA	cis	rs7948661	1	rs78020509	ENSG00000278376.1	RP11-158I9.8	5.92	6.05e-09	1.14e-06	0.4	0.26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118514096	chr11:118791254~118793137:+
THCA	cis	rs7948661	1	rs111405302	ENSG00000278376.1	RP11-158I9.8	5.92	6.05e-09	1.14e-06	0.4	0.26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118514976	chr11:118791254~118793137:+
THCA	cis	rs7948661	1	rs9332858	ENSG00000278376.1	RP11-158I9.8	5.92	6.05e-09	1.14e-06	0.4	0.26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118519367	chr11:118791254~118793137:+
THCA	cis	rs11976180	1	rs1533268	ENSG00000273234.1	OR2A13P	-5.92	6.05e-09	1.14e-06	-0.29	-0.26	Obesity-related traits;	chr7:144069265	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs1533266	ENSG00000273234.1	OR2A13P	-5.92	6.05e-09	1.14e-06	-0.29	-0.26	Obesity-related traits;	chr7:144069621	chr7:144142009~144142938:+
THCA	cis	rs2439831	0.764	rs12324584	ENSG00000275601.1	AC011330.13	-5.92	6.05e-09	1.15e-06	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43391248	chr15:43642389~43643023:-
THCA	cis	rs10971721	0.822	rs12376279	ENSG00000281128.1	PTENP1-AS	5.92	6.06e-09	1.15e-06	0.59	0.26	Body mass index;	chr9:33804256	chr9:33677268~33688011:+
THCA	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	5.92	6.06e-09	1.15e-06	0.26	0.26	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
THCA	cis	rs10411161	0.58	rs3848561	ENSG00000269483.1	AC006272.1	5.92	6.06e-09	1.15e-06	0.31	0.26	Breast cancer;	chr19:51876370	chr19:51839924~51843324:-
THCA	cis	rs7202877	0.656	rs9923834	ENSG00000261783.1	RP11-252K23.2	-5.92	6.06e-09	1.15e-06	-0.47	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75473355	chr16:75379818~75381260:-
THCA	cis	rs2554380	0.628	rs919069	ENSG00000230373.7	GOLGA6L5P	-5.92	6.07e-09	1.15e-06	-0.29	-0.26	Height;	chr15:83775776	chr15:84507885~84516814:-
THCA	cis	rs10875746	0.669	rs61941003	ENSG00000269514.1	RP11-370I10.12	5.92	6.07e-09	1.15e-06	0.26	0.26	Longevity (90 years and older);	chr12:48225842	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.579	rs10875778	ENSG00000269514.1	RP11-370I10.12	5.92	6.07e-09	1.15e-06	0.26	0.26	Longevity (90 years and older);	chr12:48230872	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.669	rs10875779	ENSG00000269514.1	RP11-370I10.12	5.92	6.07e-09	1.15e-06	0.26	0.26	Longevity (90 years and older);	chr12:48236086	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.669	rs11168487	ENSG00000269514.1	RP11-370I10.12	5.92	6.07e-09	1.15e-06	0.26	0.26	Longevity (90 years and older);	chr12:48246926	chr12:48198387~48202031:+
THCA	cis	rs7809950	0.954	rs11977187	ENSG00000238832.1	snoU109	5.92	6.07e-09	1.15e-06	0.29	0.26	Coronary artery disease;	chr7:107569938	chr7:107603363~107603507:+
THCA	cis	rs10078	0.571	rs2241597	ENSG00000221990.4	EXOC3-AS1	5.92	6.08e-09	1.15e-06	0.27	0.26	Fat distribution (HIV);	chr5:480394	chr5:441498~443160:-
THCA	cis	rs10208649	1	rs6745729	ENSG00000233266.1	HMGB1P31	5.92	6.08e-09	1.15e-06	0.6	0.26	Body mass index;	chr2:53888676	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs13432387	ENSG00000233266.1	HMGB1P31	5.92	6.08e-09	1.15e-06	0.6	0.26	Body mass index;	chr2:53889150	chr2:54051334~54051760:+
THCA	cis	rs7809950	0.678	rs2237665	ENSG00000238832.1	snoU109	-5.92	6.08e-09	1.15e-06	-0.31	-0.26	Coronary artery disease;	chr7:107266553	chr7:107603363~107603507:+
THCA	cis	rs755249	0.761	rs3768321	ENSG00000228060.1	RP11-69E11.8	-5.92	6.08e-09	1.15e-06	-0.3	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39565160~39573203:+
THCA	cis	rs4650994	0.967	rs4650998	ENSG00000273384.1	RP5-1098D14.1	5.92	6.08e-09	1.15e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178562715	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs4650999	ENSG00000273384.1	RP5-1098D14.1	-5.92	6.08e-09	1.15e-06	-0.32	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178563053	chr1:178651706~178652282:+
THCA	cis	rs11671005	0.735	rs35652377	ENSG00000269473.1	CTD-2619J13.19	5.92	6.09e-09	1.15e-06	0.3	0.26	Mean platelet volume;	chr19:58417833	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs3764532	ENSG00000269473.1	CTD-2619J13.19	5.92	6.09e-09	1.15e-06	0.3	0.26	Mean platelet volume;	chr19:58417855	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs3088284	ENSG00000269473.1	CTD-2619J13.19	5.92	6.09e-09	1.15e-06	0.3	0.26	Mean platelet volume;	chr19:58418060	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs12981649	ENSG00000269473.1	CTD-2619J13.19	5.92	6.09e-09	1.15e-06	0.3	0.26	Mean platelet volume;	chr19:58418676	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs3826682	ENSG00000269473.1	CTD-2619J13.19	5.92	6.09e-09	1.15e-06	0.3	0.26	Mean platelet volume;	chr19:58407381	chr19:58440448~58445849:+
THCA	cis	rs7948661	1	rs9332846	ENSG00000278376.1	RP11-158I9.8	5.92	6.1e-09	1.15e-06	0.42	0.26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118506808	chr11:118791254~118793137:+
THCA	cis	rs8025790	0.508	rs35930676	ENSG00000270964.1	RP11-502I4.3	-5.92	6.1e-09	1.15e-06	-0.23	-0.26	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67535367	chr15:67541072~67542604:-
THCA	cis	rs950169	0.58	rs11636189	ENSG00000259295.5	CSPG4P12	5.92	6.1e-09	1.15e-06	0.4	0.26	Schizophrenia;	chr15:84650323	chr15:85191438~85213905:+
THCA	cis	rs950169	0.58	rs35516100	ENSG00000259295.5	CSPG4P12	5.92	6.1e-09	1.15e-06	0.4	0.26	Schizophrenia;	chr15:84652199	chr15:85191438~85213905:+
THCA	cis	rs950169	0.58	rs62021208	ENSG00000259295.5	CSPG4P12	5.92	6.1e-09	1.15e-06	0.4	0.26	Schizophrenia;	chr15:84653013	chr15:85191438~85213905:+
THCA	cis	rs2303319	0.504	rs56371522	ENSG00000227403.1	AC009299.3	5.92	6.1e-09	1.15e-06	0.55	0.26	Cognitive function;	chr2:161634599	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188960	ENSG00000227403.1	AC009299.3	5.92	6.1e-09	1.15e-06	0.55	0.26	Cognitive function;	chr2:161636068	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12470590	ENSG00000227403.1	AC009299.3	5.92	6.1e-09	1.15e-06	0.55	0.26	Cognitive function;	chr2:161636592	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.786	rs115562071	ENSG00000227403.1	AC009299.3	5.92	6.1e-09	1.15e-06	0.55	0.26	Blood osmolality (transformed sodium);	chr2:161636731	chr2:161244739~161249050:+
THCA	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-5.92	6.1e-09	1.15e-06	-0.27	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
THCA	cis	rs3760982	0.967	rs3760984	ENSG00000267058.1	RP11-15A1.3	-5.92	6.11e-09	1.16e-06	-0.22	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782610	chr19:43891804~43901805:-
THCA	cis	rs6142102	0.961	rs6088360	ENSG00000275784.1	RP5-1125A11.6	-5.92	6.11e-09	1.16e-06	-0.27	-0.26	Skin pigmentation;	chr20:33969383	chr20:33989480~33991818:-
THCA	cis	rs4950322	0.58	rs972368	ENSG00000278811.3	LINC00624	5.92	6.11e-09	1.16e-06	0.32	0.26	Protein quantitative trait loci;	chr1:147111142	chr1:147258885~147517875:-
THCA	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	5.92	6.11e-09	1.16e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
THCA	cis	rs914615	0.552	rs4276914	ENSG00000225855.5	RUSC1-AS1	5.92	6.11e-09	1.16e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155169753	chr1:155316863~155324176:-
THCA	cis	rs914615	0.552	rs4971088	ENSG00000225855.5	RUSC1-AS1	5.92	6.11e-09	1.16e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155170407	chr1:155316863~155324176:-
THCA	cis	rs914615	0.552	rs4971089	ENSG00000225855.5	RUSC1-AS1	5.92	6.11e-09	1.16e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155170451	chr1:155316863~155324176:-
THCA	cis	rs77972916	0.505	rs6727824	ENSG00000234936.1	AC010883.5	5.92	6.12e-09	1.16e-06	0.29	0.26	Granulocyte percentage of myeloid white cells;	chr2:43301238	chr2:43229573~43233394:+
THCA	cis	rs67478160	0.643	rs12878868	ENSG00000258735.1	LINC00637	-5.92	6.12e-09	1.16e-06	-0.32	-0.26	Schizophrenia;	chr14:103767388	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs11626377	ENSG00000258735.1	LINC00637	-5.92	6.12e-09	1.16e-06	-0.32	-0.26	Schizophrenia;	chr14:103768020	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs876002	ENSG00000258735.1	LINC00637	-5.92	6.12e-09	1.16e-06	-0.32	-0.26	Schizophrenia;	chr14:103773360	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.619	rs11628481	ENSG00000258735.1	LINC00637	-5.92	6.12e-09	1.16e-06	-0.32	-0.26	Schizophrenia;	chr14:103775162	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.595	rs8022783	ENSG00000258735.1	LINC00637	-5.92	6.12e-09	1.16e-06	-0.32	-0.26	Schizophrenia;	chr14:103779236	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.608	rs11160760	ENSG00000258735.1	LINC00637	-5.92	6.12e-09	1.16e-06	-0.32	-0.26	Schizophrenia;	chr14:103782601	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.619	rs11160761	ENSG00000258735.1	LINC00637	-5.92	6.12e-09	1.16e-06	-0.32	-0.26	Schizophrenia;	chr14:103788519	chr14:103847721~103858049:+
THCA	cis	rs7615952	0.576	rs6780025	ENSG00000250012.1	RP11-124N2.1	-5.92	6.12e-09	1.16e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126096781	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.576	rs6804482	ENSG00000250012.1	RP11-124N2.1	-5.92	6.12e-09	1.16e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126096919	chr3:126084220~126095349:+
THCA	cis	rs17122278	0.577	rs537975	ENSG00000278376.1	RP11-158I9.8	-5.92	6.13e-09	1.16e-06	-0.24	-0.26	Total cholesterol levels;	chr11:118492154	chr11:118791254~118793137:+
THCA	cis	rs2255336	0.817	rs4764430	ENSG00000245648.1	RP11-277P12.20	5.92	6.13e-09	1.16e-06	0.34	0.26	Blood protein levels;	chr12:10365209	chr12:10363769~10398506:+
THCA	cis	rs12908161	1	rs12903134	ENSG00000259295.5	CSPG4P12	5.92	6.13e-09	1.16e-06	0.4	0.26	Schizophrenia;	chr15:84794468	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs35726233	ENSG00000259295.5	CSPG4P12	5.92	6.13e-09	1.16e-06	0.4	0.26	Schizophrenia;	chr15:84794569	chr15:85191438~85213905:+
THCA	cis	rs6142102	0.961	rs2268089	ENSG00000275784.1	RP5-1125A11.6	-5.92	6.14e-09	1.16e-06	-0.27	-0.26	Skin pigmentation;	chr20:34079492	chr20:33989480~33991818:-
THCA	cis	rs10875746	0.551	rs12322347	ENSG00000258234.1	RP11-370I10.2	5.92	6.14e-09	1.16e-06	0.32	0.26	Longevity (90 years and older);	chr12:48313915	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.551	rs12322348	ENSG00000258234.1	RP11-370I10.2	5.92	6.14e-09	1.16e-06	0.32	0.26	Longevity (90 years and older);	chr12:48313916	chr12:48231098~48284210:-
THCA	cis	rs7208859	0.623	rs58908911	ENSG00000263603.1	CTD-2349P21.5	-5.92	6.14e-09	1.16e-06	-0.49	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30729469~30731202:+
THCA	cis	rs8042680	0.955	rs2034084	ENSG00000214432.8	AC068831.10	-5.92	6.14e-09	1.16e-06	-0.29	-0.26	Type 2 diabetes;	chr15:90963509	chr15:91022619~91036611:+
THCA	cis	rs35160687	0.688	rs12466728	ENSG00000273080.1	RP11-301O19.1	-5.92	6.14e-09	1.16e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86256976	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.666	rs36104799	ENSG00000273080.1	RP11-301O19.1	-5.92	6.14e-09	1.16e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86257000	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.666	rs7583074	ENSG00000273080.1	RP11-301O19.1	-5.92	6.14e-09	1.16e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86257069	chr2:86195590~86196049:+
THCA	cis	rs2243480	1	rs160644	ENSG00000232546.1	RP11-458F8.1	-5.92	6.14e-09	1.16e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66093199	chr7:66848496~66858136:+
THCA	cis	rs875971	0.793	rs460678	ENSG00000232559.3	GS1-124K5.12	5.92	6.14e-09	1.16e-06	0.26	0.26	Aortic root size;	chr7:66062213	chr7:66554588~66576923:-
THCA	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	5.92	6.14e-09	1.16e-06	0.33	0.26	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
THCA	cis	rs67478160	0.529	rs12880413	ENSG00000258735.1	LINC00637	-5.92	6.14e-09	1.16e-06	-0.32	-0.26	Schizophrenia;	chr14:103801070	chr14:103847721~103858049:+
THCA	cis	rs2348418	0.831	rs10843173	ENSG00000247934.4	RP11-967K21.1	5.92	6.14e-09	1.16e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28453092	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs10843174	ENSG00000247934.4	RP11-967K21.1	5.92	6.14e-09	1.16e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28453135	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7299039	ENSG00000247934.4	RP11-967K21.1	5.92	6.14e-09	1.16e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28454083	chr12:28163298~28190738:-
THCA	cis	rs4908768	0.501	rs4908761	ENSG00000232912.4	RP5-1115A15.1	5.92	6.14e-09	1.16e-06	0.26	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8424645~8434838:+
THCA	cis	rs1707322	0.752	rs4660313	ENSG00000281133.1	AL355480.3	5.92	6.15e-09	1.16e-06	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45580892~45580996:-
THCA	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	5.92	6.15e-09	1.16e-06	0.32	0.26	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
THCA	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	5.92	6.15e-09	1.16e-06	0.32	0.26	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
THCA	cis	rs7829975	0.514	rs2945873	ENSG00000254153.1	CTA-398F10.2	-5.92	6.16e-09	1.16e-06	-0.27	-0.26	Mood instability;	chr8:8402935	chr8:8456909~8461337:-
THCA	cis	rs6545883	1	rs778758	ENSG00000271889.1	RP11-493E12.1	5.92	6.16e-09	1.16e-06	0.25	0.26	Tuberculosis;	chr2:61555026	chr2:61151433~61162105:-
THCA	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	5.92	6.17e-09	1.17e-06	0.27	0.26	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
THCA	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	5.92	6.17e-09	1.17e-06	0.27	0.26	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
THCA	cis	rs12893668	0.703	rs35498576	ENSG00000269940.1	RP11-73M18.7	5.92	6.17e-09	1.17e-06	0.28	0.26	Reticulocyte count;	chr14:103559556	chr14:103694560~103695170:+
THCA	cis	rs1125355	0.69	rs11691004	ENSG00000251491.2	OR7E28P	5.92	6.18e-09	1.17e-06	0.41	0.26	Alzheimer's disease in APOE e4+ carriers;	chr2:158787663	chr2:158862311~158863285:+
THCA	cis	rs11089937	0.597	rs5757027	ENSG00000211639.2	IGLV4-60	5.92	6.18e-09	1.17e-06	0.19	0.26	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22162199~22162681:+
THCA	cis	rs7809950	0.906	rs2395907	ENSG00000238832.1	snoU109	5.92	6.18e-09	1.17e-06	0.28	0.26	Coronary artery disease;	chr7:107612859	chr7:107603363~107603507:+
THCA	cis	rs934734	0.752	rs1194849	ENSG00000281920.1	RP11-418H16.1	-5.92	6.18e-09	1.17e-06	-0.33	-0.26	Rheumatoid arthritis;	chr2:65379519	chr2:65623272~65628424:+
THCA	cis	rs911555	0.511	rs8007489	ENSG00000269958.1	RP11-73M18.8	-5.92	6.19e-09	1.17e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103696353~103697163:+
THCA	cis	rs6908034	0.769	rs6916589	ENSG00000237404.1	RP3-471C18.2	-5.92	6.19e-09	1.17e-06	-0.48	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761132	chr6:19689825~19753113:-
THCA	cis	rs934734	0.789	rs268122	ENSG00000281920.1	RP11-418H16.1	-5.92	6.19e-09	1.17e-06	-0.33	-0.26	Rheumatoid arthritis;	chr2:65374975	chr2:65623272~65628424:+
THCA	cis	rs5758659	0.652	rs133358	ENSG00000227370.1	RP4-669P10.19	-5.92	6.19e-09	1.17e-06	-0.24	-0.26	Cognitive function;	chr22:42046535	chr22:42132543~42132998:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	5.92	6.2e-09	1.17e-06	0.31	0.26	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
THCA	cis	rs7809950	0.953	rs3094383	ENSG00000238832.1	snoU109	-5.92	6.2e-09	1.17e-06	-0.28	-0.26	Coronary artery disease;	chr7:107502719	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs2520264	ENSG00000238832.1	snoU109	-5.92	6.2e-09	1.17e-06	-0.28	-0.26	Coronary artery disease;	chr7:107538899	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.817	rs11535285	ENSG00000238832.1	snoU109	-5.92	6.2e-09	1.17e-06	-0.3	-0.26	Coronary artery disease;	chr7:107503421	chr7:107603363~107603507:+
THCA	cis	rs11051970	0.918	rs325417	ENSG00000274964.1	RP11-817I4.1	-5.92	6.2e-09	1.17e-06	-0.29	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32421283	chr12:32339368~32340724:+
THCA	cis	rs2253762	0.54	rs79586669	ENSG00000276742.1	RP11-500G22.4	5.92	6.2e-09	1.17e-06	0.39	0.26	Breast cancer;	chr10:122015153	chr10:121956782~121957098:+
THCA	cis	rs9990343	0.543	rs3181039	ENSG00000223552.1	RP11-24F11.2	5.92	6.2e-09	1.17e-06	0.23	0.26	Brain structure;	chr3:46380347	chr3:46364955~46407059:-
THCA	cis	rs9813712	0.953	rs9883455	ENSG00000249846.5	RP11-77P16.4	-5.92	6.21e-09	1.17e-06	-0.31	-0.26	Response to amphetamines;	chr3:130260088	chr3:130112550~130120579:+
THCA	cis	rs1881744	0.588	rs78808618	ENSG00000257433.4	RP1-197B17.3	5.92	6.21e-09	1.17e-06	0.39	0.26	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47706085~47742294:+
THCA	cis	rs2243480	1	rs2243480	ENSG00000232546.1	RP11-458F8.1	-5.92	6.21e-09	1.17e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66134209	chr7:66848496~66858136:+
THCA	cis	rs1546924	0.692	rs197374	ENSG00000227811.2	FAM212B-AS1	-5.92	6.21e-09	1.17e-06	-0.32	-0.26	Body mass index;	chr1:111747361	chr1:111739841~111747798:+
THCA	cis	rs12497850	0.931	rs7621015	ENSG00000229759.1	MRPS18AP1	5.92	6.21e-09	1.17e-06	0.35	0.26	Parkinson's disease;	chr3:48978623	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs4072859	ENSG00000229759.1	MRPS18AP1	5.92	6.21e-09	1.17e-06	0.35	0.26	Parkinson's disease;	chr3:48994772	chr3:48256350~48256938:-
THCA	cis	rs287982	0.611	rs79083459	ENSG00000269973.1	RP11-95D17.1	-5.92	6.22e-09	1.17e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9838286	chr2:9936360~9939590:+
THCA	cis	rs287982	0.611	rs78401890	ENSG00000269973.1	RP11-95D17.1	-5.92	6.22e-09	1.17e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9838332	chr2:9936360~9939590:+
THCA	cis	rs11158026	0.895	rs2183084	ENSG00000258413.1	RP11-665C16.6	-5.92	6.22e-09	1.17e-06	-0.35	-0.26	Parkinson's disease;	chr14:54868344	chr14:55262767~55272075:-
THCA	cis	rs797680	0.786	rs6694508	ENSG00000223745.6	RP4-717I23.3	5.92	6.22e-09	1.18e-06	0.15	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93376466	chr1:93262186~93346025:-
THCA	cis	rs5742933	0.817	rs4667297	ENSG00000253559.1	OSGEPL1-AS1	5.92	6.23e-09	1.18e-06	0.3	0.26	Ferritin levels;	chr2:189664270	chr2:189762704~189765556:+
THCA	cis	rs227275	0.525	rs7660298	ENSG00000230069.3	LRRC37A15P	-5.92	6.23e-09	1.18e-06	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102727274~102730721:-
THCA	cis	rs11976180	1	rs1533267	ENSG00000273234.1	OR2A13P	-5.92	6.23e-09	1.18e-06	-0.29	-0.26	Obesity-related traits;	chr7:144069347	chr7:144142009~144142938:+
THCA	cis	rs2129782	1	rs61109805	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88422872	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882464	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88423435	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs61177731	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88423479	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59645827	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88423772	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs78704524	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88424155	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73692571	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88424648	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73289254	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88424673	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73289257	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88424877	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59580800	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88425144	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs58399951	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88425261	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs60779425	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88425382	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs58164144	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88425541	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73289267	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88425798	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs58994609	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88425965	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs58453379	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88426014	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs60245117	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88426176	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs61088422	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88426646	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1394510	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88426723	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs113792528	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88427221	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs114433731	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88427225	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs58720276	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88428585	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs58754325	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88429211	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs57047577	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88429764	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291151	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88429945	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs73291153	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88430585	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs73694046	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88430617	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291154	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88430714	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291157	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88431042	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73694050	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88431139	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291160	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88431756	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs60953371	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88431948	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs55848977	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88431971	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59043278	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88432363	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291164	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88432776	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291166	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88432996	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs113738158	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88433483	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs61234864	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88433628	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7004757	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88433949	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7000891	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88434030	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7001241	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88434230	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs6980734	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88434451	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7001875	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88434583	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291175	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88434701	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73694056	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88434911	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291177	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88435037	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291179	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88435143	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs7814792	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88437099	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs7814799	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88437111	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7845586	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88437206	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7828596	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88437589	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.867	rs6469419	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88437591	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs114897909	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88437729	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs6988021	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88437855	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.764	rs73291190	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88438347	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291191	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88438400	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73291192	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88438603	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs60894020	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88438735	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs58059872	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88438905	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7008219	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88439741	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs60469280	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88440021	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59495340	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88440082	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73292857	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88440287	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59745808	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88440347	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs7838772	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88440799	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs7842479	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88440826	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7820191	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88440941	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs61671299	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88441202	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73694066	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88441264	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882905	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88441730	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882914	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442002	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73292867	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442076	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73694076	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442681	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs61667532	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442768	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs61533446	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442788	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs61683331	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442817	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs57807215	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442839	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs73292871	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442866	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs61498756	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88442963	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882925	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88443178	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs58079230	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88443697	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882945	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88443916	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882947	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88444018	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs73292876	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88444457	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882948	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88444622	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73694079	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88444724	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs61548111	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88444937	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882949	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88445058	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882951	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88445169	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882953	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88445251	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs16882955	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88445456	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882960	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88445655	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882980	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88446423	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73275307	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88446666	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs2171481	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88447385	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1844056	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88447876	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16883006	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88448196	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs60350282	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88448688	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73275324	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88449532	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73275325	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88449547	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs61079180	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88449767	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7840103	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88450492	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1604921	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88450755	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs112279857	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88451709	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs61226117	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88451817	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs58803556	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88451910	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1580509	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88452340	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7463933	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88452639	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs75247012	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88453120	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73275354	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88453213	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73275371	ENSG00000253553.4	RP11-586K2.1	5.92	6.24e-09	1.18e-06	0.45	0.26	Electrodermal activity;	chr8:88455323	chr8:88326836~88737134:+
THCA	cis	rs10800713	0.56	rs10919965	ENSG00000260088.1	RP11-92G12.3	-5.92	6.24e-09	1.18e-06	-0.42	-0.26	Tandem gait;	chr1:200532134	chr1:200669507~200694250:+
THCA	cis	rs17826219	0.562	rs719600	ENSG00000264538.5	SUZ12P1	5.92	6.24e-09	1.18e-06	0.26	0.26	Body mass index;	chr17:30404244	chr17:30709299~30790908:+
THCA	cis	rs71520386	0.632	rs1474349	ENSG00000228649.7	AC005682.5	-5.92	6.24e-09	1.18e-06	-0.34	-0.26	Fibrinogen levels;	chr7:22814146	chr7:22854178~22861579:+
THCA	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-5.92	6.24e-09	1.18e-06	-0.49	-0.26	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
THCA	cis	rs853679	0.546	rs13195291	ENSG00000226314.6	ZNF192P1	-5.92	6.24e-09	1.18e-06	-0.58	-0.26	Depression;	chr6:28201463	chr6:28161781~28169594:+
THCA	cis	rs853679	0.556	rs13197633	ENSG00000226314.6	ZNF192P1	-5.92	6.24e-09	1.18e-06	-0.58	-0.26	Depression;	chr6:28206979	chr6:28161781~28169594:+
THCA	cis	rs3806843	0.676	rs753280	ENSG00000202515.1	VTRNA1-3	-5.92	6.25e-09	1.18e-06	-0.29	-0.26	Depressive symptoms (multi-trait analysis);	chr5:140644457	chr5:140726158~140726246:+
THCA	cis	rs9652601	0.919	rs12924729	ENSG00000274038.1	RP11-66H6.4	-5.92	6.26e-09	1.18e-06	-0.35	-0.26	Systemic lupus erythematosus;	chr16:11093926	chr16:11056556~11057034:+
THCA	cis	rs11089937	0.667	rs78549985	ENSG00000211638.2	IGLV8-61	-5.92	6.27e-09	1.18e-06	-0.22	-0.26	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22098700~22099212:+
THCA	cis	rs1876905	0.68	rs557028	ENSG00000230177.1	RP5-1112D6.4	-5.92	6.27e-09	1.18e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111277932~111278742:+
THCA	cis	rs6740322	0.895	rs6711966	ENSG00000234936.1	AC010883.5	5.92	6.27e-09	1.18e-06	0.27	0.26	Coronary artery disease;	chr2:43334850	chr2:43229573~43233394:+
THCA	cis	rs6740322	0.948	rs6715072	ENSG00000234936.1	AC010883.5	5.92	6.27e-09	1.18e-06	0.27	0.26	Coronary artery disease;	chr2:43335091	chr2:43229573~43233394:+
THCA	cis	rs9380516	0.645	rs5017617	ENSG00000228559.1	RP3-340B19.3	-5.92	6.27e-09	1.18e-06	-0.37	-0.26	Hepatitis C induced liver fibrosis;	chr6:35557898	chr6:35544632~35545669:+
THCA	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	5.92	6.28e-09	1.18e-06	0.24	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
THCA	cis	rs2018683	0.677	rs12540529	ENSG00000228421.2	AC005013.5	5.92	6.28e-09	1.18e-06	0.3	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929767	chr7:28957667~28959345:+
THCA	cis	rs11089937	0.626	rs5757056	ENSG00000211638.2	IGLV8-61	-5.92	6.28e-09	1.18e-06	-0.21	-0.26	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22098700~22099212:+
THCA	cis	rs8042680	1	rs8037254	ENSG00000214432.8	AC068831.10	-5.92	6.28e-09	1.18e-06	-0.29	-0.26	Type 2 diabetes;	chr15:90976869	chr15:91022619~91036611:+
THCA	cis	rs7202877	0.61	rs7202284	ENSG00000261783.1	RP11-252K23.2	-5.92	6.28e-09	1.19e-06	-0.46	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75340448	chr16:75379818~75381260:-
THCA	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	5.92	6.29e-09	1.19e-06	0.32	0.26	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
THCA	cis	rs1823913	0.926	rs12615901	ENSG00000280083.1	RP11-317J9.1	5.92	6.29e-09	1.19e-06	0.32	0.26	Obesity-related traits;	chr2:191233381	chr2:191154118~191156070:-
THCA	cis	rs10761482	0.5	rs10994411	ENSG00000254271.1	RP11-131N11.4	5.92	6.29e-09	1.19e-06	0.34	0.26	Schizophrenia;	chr10:60545050	chr10:60734342~60741828:+
THCA	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-5.92	6.29e-09	1.19e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
THCA	cis	rs7246657	0.722	rs2909105	ENSG00000267422.1	CTD-2554C21.1	5.92	6.29e-09	1.19e-06	0.3	0.26	Coronary artery calcification;	chr19:37677005	chr19:37779686~37792865:+
THCA	cis	rs831571	0.695	rs73120922	ENSG00000280620.1	SCAANT1	5.92	6.29e-09	1.19e-06	0.43	0.26	Type 2 diabetes;	chr3:64049508	chr3:63911518~63911772:-
THCA	cis	rs7809950	0.723	rs62483633	ENSG00000238832.1	snoU109	-5.92	6.3e-09	1.19e-06	-0.31	-0.26	Coronary artery disease;	chr7:107236199	chr7:107603363~107603507:+
THCA	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-5.92	6.3e-09	1.19e-06	-0.24	-0.26	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-5.92	6.3e-09	1.19e-06	-0.24	-0.26	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
THCA	cis	rs9859260	0.744	rs539816	ENSG00000273009.1	RP11-352G9.1	5.92	6.3e-09	1.19e-06	0.29	0.26	Mean corpuscular volume;	chr3:196057205	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.744	rs492349	ENSG00000273009.1	RP11-352G9.1	5.92	6.3e-09	1.19e-06	0.29	0.26	Mean corpuscular volume;	chr3:196057321	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.744	rs492288	ENSG00000273009.1	RP11-352G9.1	5.92	6.3e-09	1.19e-06	0.29	0.26	Mean corpuscular volume;	chr3:196057339	chr3:195913078~195913683:-
THCA	cis	rs853679	0.607	rs13204012	ENSG00000226314.6	ZNF192P1	-5.92	6.31e-09	1.19e-06	-0.58	-0.26	Depression;	chr6:28233753	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13205211	ENSG00000226314.6	ZNF192P1	-5.92	6.31e-09	1.19e-06	-0.58	-0.26	Depression;	chr6:28235278	chr6:28161781~28169594:+
THCA	cis	rs712039	0.583	rs853223	ENSG00000276054.1	RP11-378E13.3	5.92	6.31e-09	1.19e-06	0.4	0.26	Tuberculosis;	chr17:37431050	chr17:37386886~37387926:+
THCA	cis	rs712039	0.617	rs60118041	ENSG00000276054.1	RP11-378E13.3	5.92	6.31e-09	1.19e-06	0.4	0.26	Tuberculosis;	chr17:37443151	chr17:37386886~37387926:+
THCA	cis	rs2129782	1	rs7018226	ENSG00000253553.4	RP11-586K2.1	5.92	6.32e-09	1.19e-06	0.45	0.26	Electrodermal activity;	chr8:88434106	chr8:88326836~88737134:+
THCA	cis	rs12435908	1	rs57012661	ENSG00000276116.2	FUT8-AS1	-5.92	6.32e-09	1.19e-06	-0.42	-0.26	Ischemic stroke;	chr14:65706032	chr14:65411170~65412690:-
THCA	cis	rs1876905	0.68	rs1150082	ENSG00000230177.1	RP5-1112D6.4	-5.92	6.32e-09	1.19e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111277932~111278742:+
THCA	cis	rs4748857	0.685	rs11013316	ENSG00000224215.1	RP11-371A19.2	-5.92	6.32e-09	1.19e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr10:23200823	chr10:23343957~23345181:+
THCA	cis	rs8042680	0.621	rs12899811	ENSG00000214432.8	AC068831.10	-5.92	6.32e-09	1.19e-06	-0.28	-0.26	Type 2 diabetes;	chr15:91000846	chr15:91022619~91036611:+
THCA	cis	rs1322639	1	rs1322639	ENSG00000261039.2	RP11-417E7.2	5.92	6.33e-09	1.19e-06	0.32	0.26	Pulse pressure;	chr6:169187008	chr6:169175304~169182740:-
THCA	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-5.92	6.33e-09	1.19e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
THCA	cis	rs9467773	1	rs6930120	ENSG00000124549.13	BTN2A3P	5.92	6.34e-09	1.2e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26421391~26432383:+
THCA	cis	rs7712401	0.791	rs3822367	ENSG00000249996.1	RP11-359P5.1	-5.92	6.34e-09	1.2e-06	-0.25	-0.26	Mean platelet volume;	chr5:122810577	chr5:123036271~123054667:+
THCA	cis	rs11148252	0.84	rs4369550	ENSG00000235660.1	LINC00345	-5.92	6.34e-09	1.2e-06	-0.33	-0.26	Lewy body disease;	chr13:52170775	chr13:52484161~52484680:-
THCA	cis	rs3213958	0.574	rs11916285	ENSG00000249274.1	PDLIM1P4	-5.92	6.34e-09	1.2e-06	-0.33	-0.26	Blood protein levels;	chr3:98818497	chr3:98782188~98783193:+
THCA	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	5.92	6.34e-09	1.2e-06	0.29	0.26	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	5.92	6.34e-09	1.2e-06	0.29	0.26	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	5.92	6.34e-09	1.2e-06	0.29	0.26	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	5.92	6.34e-09	1.2e-06	0.29	0.26	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
THCA	cis	rs7119038	0.818	rs77209083	ENSG00000255239.1	AP002954.6	-5.92	6.35e-09	1.2e-06	-0.41	-0.26	Sjögren's syndrome;	chr11:118736860	chr11:118688039~118690600:-
THCA	cis	rs9926296	0.712	rs258319	ENSG00000274627.1	RP11-104N10.2	5.92	6.35e-09	1.2e-06	0.27	0.26	Vitiligo;	chr16:89665616	chr16:89516797~89522217:+
THCA	cis	rs9910055	0.762	rs6503489	ENSG00000267080.4	ASB16-AS1	-5.92	6.35e-09	1.2e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44168921	chr17:44175973~44186717:-
THCA	cis	rs11096990	0.927	rs56009503	ENSG00000249207.1	RP11-360F5.1	5.92	6.35e-09	1.2e-06	0.34	0.26	Cognitive function;	chr4:39242642	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.964	rs7687651	ENSG00000249207.1	RP11-360F5.1	5.92	6.35e-09	1.2e-06	0.34	0.26	Cognitive function;	chr4:39243072	chr4:39112677~39126818:-
THCA	cis	rs12291225	0.535	rs10832248	ENSG00000251991.1	RNU7-49P	5.92	6.36e-09	1.2e-06	0.31	0.26	Sense of smell;	chr11:14391541	chr11:14478892~14478953:+
THCA	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-5.92	6.36e-09	1.2e-06	-0.27	-0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
THCA	cis	rs7202877	0.561	rs9933956	ENSG00000261783.1	RP11-252K23.2	-5.92	6.36e-09	1.2e-06	-0.46	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75328915	chr16:75379818~75381260:-
THCA	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	5.92	6.37e-09	1.2e-06	0.21	0.26	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
THCA	cis	rs2554380	0.628	rs4843156	ENSG00000230373.7	GOLGA6L5P	-5.92	6.37e-09	1.2e-06	-0.29	-0.26	Height;	chr15:83788593	chr15:84507885~84516814:-
THCA	cis	rs7942368	1	rs11236924	ENSG00000204529.3	GUCY2EP	5.92	6.37e-09	1.2e-06	0.38	0.26	Endometriosis;	chr11:76756303	chr11:76694043~76707641:-
THCA	cis	rs1555322	0.556	rs7272884	ENSG00000126005.14	MMP24-AS1	-5.92	6.37e-09	1.2e-06	-0.33	-0.26	Attention deficit hyperactivity disorder;	chr20:35295212	chr20:35216462~35278131:-
THCA	cis	rs2281636	0.894	rs1332103	ENSG00000260475.1	RP11-85A1.3	5.92	6.37e-09	1.2e-06	0.24	0.26	Obesity-related traits;	chr10:99616139	chr10:99621055~99621918:+
THCA	cis	rs922182	0.967	rs9972509	ENSG00000275785.1	RP11-111E14.2	5.92	6.39e-09	1.2e-06	0.31	0.26	Blood protein levels;	chr15:63992015	chr15:63890030~63890317:+
THCA	cis	rs1979679	1	rs6487672	ENSG00000278733.1	RP11-425D17.1	5.92	6.39e-09	1.2e-06	0.26	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28270413	chr12:28185625~28186190:-
THCA	cis	rs2129782	1	rs73289264	ENSG00000253553.4	RP11-586K2.1	5.92	6.39e-09	1.2e-06	0.45	0.26	Electrodermal activity;	chr8:88425455	chr8:88326836~88737134:+
THCA	cis	rs9880211	1	rs9828088	ENSG00000273486.1	RP11-731C17.2	5.92	6.39e-09	1.2e-06	0.27	0.26	Height;Body mass index;	chr3:136528948	chr3:136837338~136839021:-
THCA	cis	rs3758785	0.512	rs11020758	ENSG00000255893.1	RP11-685N10.1	-5.92	6.39e-09	1.21e-06	-0.33	-0.26	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94377118	chr11:94472908~94473570:-
THCA	cis	rs338389	0.542	rs6494709	ENSG00000260657.2	RP11-315D16.4	-5.91	6.4e-09	1.21e-06	-0.36	-0.26	Survival in rectal cancer;	chr15:68001672	chr15:68267792~68277994:-
THCA	cis	rs4227	0.565	rs1642772	ENSG00000233223.2	AC113189.5	5.91	6.4e-09	1.21e-06	0.21	0.26	IgA nephropathy;	chr17:7600841	chr17:7581964~7584072:-
THCA	cis	rs12893668	0.572	rs4900590	ENSG00000269910.1	RP11-73M18.10	5.91	6.4e-09	1.21e-06	0.25	0.26	Reticulocyte count;	chr14:103680084	chr14:103694516~103695050:-
THCA	cis	rs897984	0.647	rs7203999	ENSG00000260911.2	RP11-196G11.2	-5.91	6.4e-09	1.21e-06	-0.22	-0.26	Dementia with Lewy bodies;	chr16:31006233	chr16:31043150~31049868:+
THCA	cis	rs62292953	0.719	rs62292461	ENSG00000248724.5	NPHP3-AS1	-5.91	6.41e-09	1.21e-06	-0.49	-0.26	Red cell distribution width;	chr3:132651270	chr3:132721750~132874223:+
THCA	cis	rs853679	0.556	rs45509595	ENSG00000219392.1	RP1-265C24.5	-5.91	6.41e-09	1.21e-06	-0.6	-0.26	Depression;	chr6:27873148	chr6:28115628~28116551:+
THCA	cis	rs227275	0.556	rs724447	ENSG00000230069.3	LRRC37A15P	5.91	6.41e-09	1.21e-06	0.28	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102727274~102730721:-
THCA	cis	rs270601	0.837	rs367805	ENSG00000263597.1	MIR3936	5.91	6.41e-09	1.21e-06	0.26	0.26	Acylcarnitine levels;	chr5:132365587	chr5:132365490~132365599:-
THCA	cis	rs2361701	1	rs2361701	ENSG00000279259.1	RP11-334C17.3	5.91	6.41e-09	1.21e-06	0.3	0.26	IgG glycosylation;	chr17:80092818	chr17:80147250~80148596:+
THCA	cis	rs1859596	1	rs7783388	ENSG00000234456.6	MAGI2-AS3	-5.91	6.41e-09	1.21e-06	-0.26	-0.26	Reading or mathematical ability;	chr7:79456027	chr7:79452877~79471208:+
THCA	cis	rs4971059	0.654	rs4276913	ENSG00000160766.13	GBAP1	-5.91	6.42e-09	1.21e-06	-0.29	-0.26	Breast cancer;	chr1:155159197	chr1:155213821~155227422:-
THCA	cis	rs17772222	0.63	rs12437422	ENSG00000258983.2	RP11-507K2.2	-5.91	6.42e-09	1.21e-06	-0.31	-0.26	Coronary artery calcification;	chr14:88529621	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.605	rs4899955	ENSG00000258983.2	RP11-507K2.2	-5.91	6.42e-09	1.21e-06	-0.31	-0.26	Coronary artery calcification;	chr14:88530381	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.63	rs4904454	ENSG00000258983.2	RP11-507K2.2	-5.91	6.42e-09	1.21e-06	-0.31	-0.26	Coronary artery calcification;	chr14:88537777	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.63	rs2033418	ENSG00000258983.2	RP11-507K2.2	-5.91	6.42e-09	1.21e-06	-0.31	-0.26	Coronary artery calcification;	chr14:88539331	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.63	rs10873392	ENSG00000258983.2	RP11-507K2.2	-5.91	6.42e-09	1.21e-06	-0.31	-0.26	Coronary artery calcification;	chr14:88545124	chr14:88499334~88515502:+
THCA	cis	rs9910055	0.718	rs7212854	ENSG00000267080.4	ASB16-AS1	-5.91	6.43e-09	1.21e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44177049	chr17:44175973~44186717:-
THCA	cis	rs6840360	0.642	rs2709822	ENSG00000270265.1	RP11-731D1.4	-5.91	6.43e-09	1.21e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151333775~151353224:-
THCA	cis	rs9880211	0.948	rs9820621	ENSG00000273486.1	RP11-731C17.2	5.91	6.43e-09	1.21e-06	0.28	0.26	Height;Body mass index;	chr3:136391671	chr3:136837338~136839021:-
THCA	cis	rs75422866	0.51	rs73105818	ENSG00000276691.1	RP5-1057I20.5	5.91	6.43e-09	1.21e-06	0.45	0.26	Pneumonia;	chr12:47726538	chr12:47788426~47788971:+
THCA	cis	rs9307551	0.817	rs13146986	ENSG00000250334.4	LINC00989	-5.91	6.44e-09	1.21e-06	-0.31	-0.26	Refractive error;	chr4:79591074	chr4:79492416~79576460:+
THCA	cis	rs9921338	0.924	rs7193645	ENSG00000262636.1	CTD-3088G3.4	-5.91	6.44e-09	1.21e-06	-0.39	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11287179	chr16:11380859~11381118:-
THCA	cis	rs7809950	1	rs10243340	ENSG00000238832.1	snoU109	-5.91	6.44e-09	1.21e-06	-0.28	-0.26	Coronary artery disease;	chr7:107450510	chr7:107603363~107603507:+
THCA	cis	rs9859260	0.744	rs3933	ENSG00000242086.7	LINC00969	-5.91	6.44e-09	1.21e-06	-0.26	-0.26	Mean corpuscular volume;	chr3:196058126	chr3:195658062~195739964:+
THCA	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-5.91	6.45e-09	1.21e-06	-0.4	-0.26	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-5.91	6.45e-09	1.21e-06	-0.4	-0.26	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
THCA	cis	rs228614	0.51	rs4699033	ENSG00000251288.2	RP11-10L12.2	-5.91	6.45e-09	1.21e-06	-0.35	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102751401~102752641:+
THCA	cis	rs4950322	0.518	rs11811023	ENSG00000278811.3	LINC00624	-5.91	6.45e-09	1.21e-06	-0.32	-0.26	Protein quantitative trait loci;	chr1:147109536	chr1:147258885~147517875:-
THCA	cis	rs6860806	0.507	rs200837	ENSG00000263597.1	MIR3936	5.91	6.45e-09	1.21e-06	0.26	0.26	Breast cancer;	chr5:132364266	chr5:132365490~132365599:-
THCA	cis	rs13113518	0.678	rs7663650	ENSG00000249700.7	SRD5A3-AS1	-5.91	6.45e-09	1.22e-06	-0.33	-0.26	Height;	chr4:55364952	chr4:55363971~55395847:-
THCA	cis	rs1979679	0.801	rs1965280	ENSG00000278733.1	RP11-425D17.1	5.91	6.45e-09	1.22e-06	0.27	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143639	chr12:28185625~28186190:-
THCA	cis	rs2439831	0.681	rs484846	ENSG00000249839.1	AC011330.5	-5.91	6.46e-09	1.22e-06	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43308605	chr15:43663654~43684339:-
THCA	cis	rs3204270	0.684	rs57405099	ENSG00000262049.1	RP13-1032I1.7	5.91	6.47e-09	1.22e-06	0.24	0.26	Dental caries;	chr17:81670035	chr17:81701324~81703300:-
THCA	cis	rs2243480	1	rs465359	ENSG00000232546.1	RP11-458F8.1	-5.91	6.48e-09	1.22e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66093177	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs462853	ENSG00000232546.1	RP11-458F8.1	-5.91	6.48e-09	1.22e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66093180	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs160642	ENSG00000232546.1	RP11-458F8.1	-5.91	6.48e-09	1.22e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66093386	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000232546.1	RP11-458F8.1	-5.91	6.48e-09	1.22e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66100154	chr7:66848496~66858136:+
THCA	cis	rs853679	0.599	rs149949	ENSG00000280107.1	AL022393.9	-5.91	6.48e-09	1.22e-06	-0.37	-0.26	Depression;	chr6:28043738	chr6:28170845~28172521:+
THCA	cis	rs922182	0.967	rs34772505	ENSG00000275785.1	RP11-111E14.2	5.91	6.48e-09	1.22e-06	0.31	0.26	Blood protein levels;	chr15:63984573	chr15:63890030~63890317:+
THCA	cis	rs72799341	0.706	rs889555	ENSG00000260911.2	RP11-196G11.2	5.91	6.48e-09	1.22e-06	0.23	0.26	Diastolic blood pressure;	chr16:31111250	chr16:31043150~31049868:+
THCA	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	5.91	6.48e-09	1.22e-06	0.26	0.26	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
THCA	cis	rs228614	0.51	rs223447	ENSG00000230069.3	LRRC37A15P	-5.91	6.49e-09	1.22e-06	-0.28	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102727274~102730721:-
THCA	cis	rs7404843	0.925	rs7404803	ENSG00000263335.1	AF001548.5	-5.91	6.49e-09	1.22e-06	-0.44	-0.26	Testicular germ cell tumor;	chr16:15436597	chr16:15726674~15732993:+
THCA	cis	rs10971721	0.822	rs56370320	ENSG00000281128.1	PTENP1-AS	5.91	6.49e-09	1.22e-06	0.59	0.26	Body mass index;	chr9:33865630	chr9:33677268~33688011:+
THCA	cis	rs853679	0.666	rs200956	ENSG00000226314.6	ZNF192P1	-5.91	6.49e-09	1.22e-06	-0.36	-0.26	Depression;	chr6:27871968	chr6:28161781~28169594:+
THCA	cis	rs4780355	0.918	rs1646019	ENSG00000262703.1	RP11-485G7.6	5.91	6.49e-09	1.22e-06	0.31	0.26	Crohn's disease and psoriasis;	chr16:11265823	chr16:11348143~11349321:-
THCA	cis	rs9880211	0.752	rs67145204	ENSG00000273486.1	RP11-731C17.2	5.91	6.5e-09	1.22e-06	0.28	0.26	Height;Body mass index;	chr3:136609823	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.752	rs9820717	ENSG00000273486.1	RP11-731C17.2	5.91	6.5e-09	1.22e-06	0.28	0.26	Height;Body mass index;	chr3:136627771	chr3:136837338~136839021:-
THCA	cis	rs9921338	0.961	rs72773825	ENSG00000262703.1	RP11-485G7.6	-5.91	6.5e-09	1.22e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318591	chr16:11348143~11349321:-
THCA	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-5.91	6.51e-09	1.22e-06	-0.24	-0.26	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
THCA	cis	rs10971721	0.822	rs12376145	ENSG00000281128.1	PTENP1-AS	5.91	6.51e-09	1.23e-06	0.59	0.26	Body mass index;	chr9:34050408	chr9:33677268~33688011:+
THCA	cis	rs2348418	0.798	rs11049546	ENSG00000247934.4	RP11-967K21.1	5.91	6.51e-09	1.23e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28346942	chr12:28163298~28190738:-
THCA	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	5.91	6.51e-09	1.23e-06	0.33	0.26	Height;	chr4:55451489	chr4:55363971~55395847:-
THCA	cis	rs875971	0.83	rs587360	ENSG00000232559.3	GS1-124K5.12	5.91	6.52e-09	1.23e-06	0.26	0.26	Aortic root size;	chr7:66057711	chr7:66554588~66576923:-
THCA	cis	rs4713118	0.513	rs149975	ENSG00000220721.1	OR1F12	5.91	6.52e-09	1.23e-06	0.32	0.26	Parkinson's disease;	chr6:28018562	chr6:28073316~28074233:+
THCA	cis	rs17772222	0.958	rs2274737	ENSG00000222990.1	RNU4-22P	5.91	6.52e-09	1.23e-06	0.35	0.26	Coronary artery calcification;	chr14:88469307	chr14:88513498~88513663:+
THCA	cis	rs1823874	0.72	rs2003037	ENSG00000182397.13	DNM1P46	-5.91	6.52e-09	1.23e-06	-0.28	-0.26	IgG glycosylation;	chr15:99821757	chr15:99790156~99806927:-
THCA	cis	rs9813712	0.953	rs6804874	ENSG00000249846.5	RP11-77P16.4	5.91	6.52e-09	1.23e-06	0.31	0.26	Response to amphetamines;	chr3:130257205	chr3:130112550~130120579:+
THCA	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-5.91	6.53e-09	1.23e-06	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
THCA	cis	rs914615	0.552	rs4421576	ENSG00000225855.5	RUSC1-AS1	5.91	6.53e-09	1.23e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155169734	chr1:155316863~155324176:-
THCA	cis	rs9309473	0.519	rs1881246	ENSG00000163016.8	ALMS1P	-5.91	6.54e-09	1.23e-06	-0.34	-0.26	Metabolite levels;	chr2:73422994	chr2:73644919~73685576:+
THCA	cis	rs7493	0.755	rs17166859	ENSG00000233942.1	AC004012.1	5.91	6.55e-09	1.23e-06	0.39	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95366207	chr7:95471835~95473998:+
THCA	cis	rs6928977	0.5	rs6570022	ENSG00000231028.7	LINC00271	-5.91	6.55e-09	1.23e-06	-0.21	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627683	chr6:135497801~135716055:+
THCA	cis	rs9902453	0.542	rs3809789	ENSG00000263370.1	RP11-68I3.5	5.91	6.55e-09	1.23e-06	0.34	0.26	Coffee consumption (cups per day);	chr17:29628743	chr17:29639627~29640825:+
THCA	cis	rs911555	0.504	rs745079	ENSG00000269940.1	RP11-73M18.7	5.91	6.55e-09	1.23e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103694560~103695170:+
THCA	cis	rs911555	0.504	rs61995761	ENSG00000269940.1	RP11-73M18.7	5.91	6.55e-09	1.23e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103694560~103695170:+
THCA	cis	rs2337406	0.714	rs7145254	ENSG00000274576.2	IGHV2-70	-5.91	6.55e-09	1.23e-06	-0.23	-0.26	Alzheimer's disease (late onset);	chr14:106817783	chr14:106770577~106771020:-
THCA	cis	rs935334	1	rs2121070	ENSG00000258454.1	RP11-361H10.3	5.91	6.56e-09	1.23e-06	0.37	0.26	Blood pressure;	chr14:76184421	chr14:76235817~76263474:+
THCA	cis	rs7829975	0.714	rs4841040	ENSG00000254153.1	CTA-398F10.2	-5.91	6.57e-09	1.24e-06	-0.28	-0.26	Mood instability;	chr8:8797017	chr8:8456909~8461337:-
THCA	cis	rs516805	0.528	rs2684241	ENSG00000279453.1	RP3-425C14.4	-5.91	6.57e-09	1.24e-06	-0.29	-0.26	Lymphocyte counts;	chr6:122089903	chr6:122436789~122439223:-
THCA	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-5.91	6.57e-09	1.24e-06	-0.32	-0.26	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
THCA	cis	rs12478296	1	rs66612947	ENSG00000261186.2	RP11-341N2.1	-5.91	6.57e-09	1.24e-06	-0.42	-0.26	Obesity-related traits;	chr2:242093811	chr2:242087351~242088457:-
THCA	cis	rs11089937	0.597	rs5750579	ENSG00000211638.2	IGLV8-61	-5.91	6.57e-09	1.24e-06	-0.21	-0.26	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs11089925	ENSG00000211638.2	IGLV8-61	-5.91	6.57e-09	1.24e-06	-0.21	-0.26	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22098700~22099212:+
THCA	cis	rs62292953	0.719	rs62291488	ENSG00000248724.5	NPHP3-AS1	-5.91	6.57e-09	1.24e-06	-0.49	-0.26	Red cell distribution width;	chr3:132592304	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.651	rs3804636	ENSG00000248724.5	NPHP3-AS1	-5.91	6.57e-09	1.24e-06	-0.49	-0.26	Red cell distribution width;	chr3:132600053	chr3:132721750~132874223:+
THCA	cis	rs8014252	0.803	rs2018131	ENSG00000259158.2	ADAM20P1	-5.91	6.57e-09	1.24e-06	-0.31	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595715	chr14:70468881~70483756:-
THCA	cis	rs7809950	0.954	rs2520243	ENSG00000238832.1	snoU109	-5.91	6.57e-09	1.24e-06	-0.28	-0.26	Coronary artery disease;	chr7:107496528	chr7:107603363~107603507:+
THCA	cis	rs2439831	0.867	rs8039638	ENSG00000249839.1	AC011330.5	-5.91	6.57e-09	1.24e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43342207	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs28415933	ENSG00000249839.1	AC011330.5	-5.91	6.57e-09	1.24e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43343602	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs12324572	ENSG00000249839.1	AC011330.5	-5.91	6.57e-09	1.24e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43344002	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2412779	ENSG00000249839.1	AC011330.5	-5.91	6.57e-09	1.24e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43363729	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2899082	ENSG00000249839.1	AC011330.5	-5.91	6.57e-09	1.24e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43363845	chr15:43663654~43684339:-
THCA	cis	rs1318937	0.764	rs2129947	ENSG00000224660.1	SH3BP5-AS1	5.91	6.58e-09	1.24e-06	0.18	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15180755	chr3:15254184~15264493:+
THCA	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	5.91	6.58e-09	1.24e-06	0.21	0.26	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
THCA	cis	rs713477	1	rs12893964	ENSG00000258413.1	RP11-665C16.6	5.91	6.58e-09	1.24e-06	0.35	0.26	Pediatric bone mineral content (femoral neck);	chr14:55445550	chr14:55262767~55272075:-
THCA	cis	rs10899021	0.79	rs12296094	ENSG00000279353.1	RP11-864N7.4	5.91	6.58e-09	1.24e-06	0.52	0.26	Response to metformin (IC50);	chr11:74610655	chr11:74698231~74699658:-
THCA	cis	rs7809950	0.954	rs2520241	ENSG00000238832.1	snoU109	-5.91	6.58e-09	1.24e-06	-0.28	-0.26	Coronary artery disease;	chr7:107494998	chr7:107603363~107603507:+
THCA	cis	rs2243480	1	rs781142	ENSG00000228409.4	CCT6P1	5.91	6.58e-09	1.24e-06	0.3	0.26	Diabetic kidney disease;	chr7:65973791	chr7:65751142~65763354:+
THCA	cis	rs10129255	1	rs11621409	ENSG00000211974.3	IGHV2-70	5.91	6.58e-09	1.24e-06	0.21	0.26	Kawasaki disease;	chr14:106695603	chr14:106723574~106724093:-
THCA	cis	rs2129782	1	rs1847575	ENSG00000253553.4	RP11-586K2.1	5.91	6.59e-09	1.24e-06	0.45	0.26	Electrodermal activity;	chr8:88450696	chr8:88326836~88737134:+
THCA	cis	rs7586673	0.857	rs16845580	ENSG00000235724.7	AC009299.2	-5.91	6.59e-09	1.24e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161222785~161308303:-
THCA	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-5.91	6.59e-09	1.24e-06	-0.35	-0.26	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
THCA	cis	rs5742933	0.69	rs62183658	ENSG00000273240.1	RP11-455J20.3	-5.91	6.6e-09	1.24e-06	-0.34	-0.26	Ferritin levels;	chr2:189669491	chr2:189763859~189764456:-
THCA	cis	rs62184315	0.536	rs62183659	ENSG00000273240.1	RP11-455J20.3	-5.91	6.6e-09	1.24e-06	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189672131	chr2:189763859~189764456:-
THCA	cis	rs62184315	0.536	rs62185869	ENSG00000273240.1	RP11-455J20.3	-5.91	6.6e-09	1.24e-06	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189672330	chr2:189763859~189764456:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000232546.1	RP11-458F8.1	5.91	6.6e-09	1.24e-06	0.35	0.26	Diabetic kidney disease;	chr7:66253864	chr7:66848496~66858136:+
THCA	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	5.91	6.6e-09	1.24e-06	0.33	0.26	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
THCA	cis	rs172166	0.694	rs1631552	ENSG00000220721.1	OR1F12	5.91	6.6e-09	1.24e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28121921	chr6:28073316~28074233:+
THCA	cis	rs10129255	0.646	rs55995061	ENSG00000211974.3	IGHV2-70	5.91	6.61e-09	1.24e-06	0.2	0.26	Kawasaki disease;	chr14:106799309	chr14:106723574~106724093:-
THCA	cis	rs748404	0.65	rs518234	ENSG00000166763.7	STRCP1	5.91	6.61e-09	1.24e-06	0.28	0.26	Lung cancer;	chr15:43281223	chr15:43699488~43718184:-
THCA	cis	rs748404	0.65	rs518261	ENSG00000166763.7	STRCP1	5.91	6.61e-09	1.24e-06	0.28	0.26	Lung cancer;	chr15:43281231	chr15:43699488~43718184:-
THCA	cis	rs7809950	0.954	rs2520247	ENSG00000238832.1	snoU109	-5.91	6.61e-09	1.24e-06	-0.28	-0.26	Coronary artery disease;	chr7:107503501	chr7:107603363~107603507:+
THCA	cis	rs6142102	0.961	rs4911146	ENSG00000275784.1	RP5-1125A11.6	-5.91	6.61e-09	1.24e-06	-0.28	-0.26	Skin pigmentation;	chr20:34052241	chr20:33989480~33991818:-
THCA	cis	rs7760535	0.794	rs12529158	ENSG00000271789.1	RP5-1112D6.7	5.91	6.61e-09	1.24e-06	0.25	0.26	Metabolic traits;	chr6:111501244	chr6:111297126~111298510:+
THCA	cis	rs12497850	0.931	rs7626445	ENSG00000229759.1	MRPS18AP1	5.91	6.61e-09	1.24e-06	0.35	0.26	Parkinson's disease;	chr3:49077111	chr3:48256350~48256938:-
THCA	cis	rs6545883	0.929	rs778154	ENSG00000271889.1	RP11-493E12.1	-5.91	6.62e-09	1.24e-06	-0.26	-0.26	Tuberculosis;	chr2:61419496	chr2:61151433~61162105:-
THCA	cis	rs7260598	0.642	rs7259787	ENSG00000268442.1	CTD-2027I19.2	5.91	6.62e-09	1.24e-06	0.35	0.26	Response to taxane treatment (placlitaxel);	chr19:23935633	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.71	rs10402319	ENSG00000268442.1	CTD-2027I19.2	5.91	6.62e-09	1.24e-06	0.35	0.26	Response to taxane treatment (placlitaxel);	chr19:23945263	chr19:24162370~24163425:-
THCA	cis	rs7809950	0.678	rs13230144	ENSG00000238832.1	snoU109	-5.91	6.62e-09	1.24e-06	-0.31	-0.26	Coronary artery disease;	chr7:107268727	chr7:107603363~107603507:+
THCA	cis	rs890448	0.796	rs4452435	ENSG00000254531.1	FLJ20021	-5.91	6.62e-09	1.25e-06	-0.23	-0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101416549	chr4:101347780~101348883:+
THCA	cis	rs380904	0.519	rs12541790	ENSG00000254859.1	RP11-661A12.5	-5.91	6.63e-09	1.25e-06	-0.41	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr8:143541973~143549729:-
THCA	cis	rs7615952	0.673	rs9289270	ENSG00000241288.6	RP11-379B18.5	-5.91	6.63e-09	1.25e-06	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:125918136	chr3:125827238~125916384:-
THCA	cis	rs812925	0.855	rs777592	ENSG00000271889.1	RP11-493E12.1	5.91	6.63e-09	1.25e-06	0.26	0.26	Immature fraction of reticulocytes;	chr2:61191208	chr2:61151433~61162105:-
THCA	cis	rs1395	0.922	rs13404446	ENSG00000234072.1	AC074117.10	-5.91	6.63e-09	1.25e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27296386	chr2:27356246~27367622:+
THCA	cis	rs7044106	0.762	rs1530370	ENSG00000270917.1	RP11-27I1.6	-5.91	6.63e-09	1.25e-06	-0.37	-0.26	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120812475~120812845:-
THCA	cis	rs11671005	0.693	rs11668821	ENSG00000269473.1	CTD-2619J13.19	5.91	6.64e-09	1.25e-06	0.3	0.26	Mean platelet volume;	chr19:58444446	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.616	rs12980907	ENSG00000269473.1	CTD-2619J13.19	5.91	6.64e-09	1.25e-06	0.3	0.26	Mean platelet volume;	chr19:58444959	chr19:58440448~58445849:+
THCA	cis	rs9880211	0.948	rs13326151	ENSG00000273486.1	RP11-731C17.2	5.91	6.64e-09	1.25e-06	0.28	0.26	Height;Body mass index;	chr3:136542902	chr3:136837338~136839021:-
THCA	cis	rs3760982	1	rs60184524	ENSG00000267058.1	RP11-15A1.3	-5.91	6.64e-09	1.25e-06	-0.23	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790063	chr19:43891804~43901805:-
THCA	cis	rs1865760	0.827	rs9295680	ENSG00000272462.2	U91328.19	-5.91	6.64e-09	1.25e-06	-0.22	-0.26	Height;	chr6:25943875	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.827	rs9295681	ENSG00000272462.2	U91328.19	-5.91	6.64e-09	1.25e-06	-0.22	-0.26	Height;	chr6:25943889	chr6:25992662~26001775:+
THCA	cis	rs763121	0.962	rs5757130	ENSG00000235209.1	CTA-150C2.13	5.91	6.65e-09	1.25e-06	0.33	0.26	Menopause (age at onset);	chr22:38541789	chr22:38921227~38924708:+
THCA	cis	rs2915864	0.699	rs74520739	ENSG00000280047.1	CTC-463A16.1	5.91	6.65e-09	1.25e-06	0.44	0.26	Facial morphology (factor 20);	chr5:142081085	chr5:142165767~142168387:+
THCA	cis	rs2915864	0.699	rs75295275	ENSG00000280047.1	CTC-463A16.1	5.91	6.65e-09	1.25e-06	0.44	0.26	Facial morphology (factor 20);	chr5:142081964	chr5:142165767~142168387:+
THCA	cis	rs12549025	0.536	rs9644075	ENSG00000253390.1	CTC-756D1.2	-5.91	6.65e-09	1.25e-06	-0.45	-0.26	Reticulocyte fraction of red cells;	chr8:23502448	chr8:23458601~23484971:+
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	5.91	6.65e-09	1.25e-06	0.36	0.26	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
THCA	cis	rs763567	0.9	rs473133	ENSG00000271811.1	RP1-79C4.4	5.91	6.65e-09	1.25e-06	0.31	0.26	Tonsillectomy;	chr1:170666938	chr1:170667381~170669425:+
THCA	cis	rs2303319	0.504	rs62187655	ENSG00000227403.1	AC009299.3	5.91	6.66e-09	1.25e-06	0.55	0.26	Cognitive function;	chr2:161630930	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187656	ENSG00000227403.1	AC009299.3	5.91	6.66e-09	1.25e-06	0.55	0.26	Cognitive function;	chr2:161631189	chr2:161244739~161249050:+
THCA	cis	rs7267979	0.789	rs6083810	ENSG00000274973.1	RP13-401N8.7	5.91	6.67e-09	1.25e-06	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:25845497~25845862:+
THCA	cis	rs7225151	0.71	rs12601720	ENSG00000234327.6	AC012146.7	-5.91	6.67e-09	1.25e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5345387	chr17:5111468~5115004:+
THCA	cis	rs890448	0.796	rs4478190	ENSG00000254531.1	FLJ20021	5.91	6.67e-09	1.25e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417304	chr4:101347780~101348883:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000272009.1	RP1-313I6.12	5.91	6.68e-09	1.25e-06	0.29	0.26	Parkinson's disease;	chr6:28002253	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs156744	ENSG00000272009.1	RP1-313I6.12	-5.91	6.68e-09	1.25e-06	-0.29	-0.26	Parkinson's disease;	chr6:27999496	chr6:28078792~28081130:-
THCA	cis	rs67478160	0.643	rs12880167	ENSG00000258735.1	LINC00637	-5.91	6.68e-09	1.26e-06	-0.32	-0.26	Schizophrenia;	chr14:103834492	chr14:103847721~103858049:+
THCA	cis	rs7209700	0.862	rs2015729	ENSG00000228782.6	CTD-2026D20.3	-5.91	6.68e-09	1.26e-06	-0.25	-0.26	IgG glycosylation;	chr17:47277127	chr17:47450568~47492492:-
THCA	cis	rs367615	0.68	rs816542	ENSG00000249476.1	CTD-2587M2.1	5.91	6.68e-09	1.26e-06	0.29	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109646923	chr5:109237120~109326369:-
THCA	cis	rs3950186	1	rs978565	ENSG00000215124.2	RP3-420J14.1	5.91	6.69e-09	1.26e-06	0.29	0.26	Anxiety and major depressive disorder;	chr6:11809850	chr6:11861626~11862970:-
THCA	cis	rs172166	0.694	rs9295760	ENSG00000226314.6	ZNF192P1	-5.91	6.69e-09	1.26e-06	-0.32	-0.26	Cardiac Troponin-T levels;	chr6:28179607	chr6:28161781~28169594:+
THCA	cis	rs748404	0.55	rs12912505	ENSG00000249839.1	AC011330.5	-5.91	6.69e-09	1.26e-06	-0.39	-0.26	Lung cancer;	chr15:43525206	chr15:43663654~43684339:-
THCA	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	5.91	6.69e-09	1.26e-06	0.22	0.26	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
THCA	cis	rs7619708	1	rs7619708	ENSG00000231464.1	AC024937.4	-5.91	6.69e-09	1.26e-06	-0.39	-0.26	Red cell distribution width;	chr3:196083316	chr3:195996738~195998233:+
THCA	cis	rs7129556	0.737	rs10899404	ENSG00000254691.1	RP11-91P24.5	5.91	6.71e-09	1.26e-06	0.35	0.26	Weight loss (gastric bypass surgery);	chr11:77751747	chr11:77850604~77851511:+
THCA	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	5.91	6.72e-09	1.26e-06	0.27	0.26	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
THCA	cis	rs6671200	0.573	rs3738171	ENSG00000228852.5	RP11-57H12.5	-5.91	6.72e-09	1.26e-06	-0.31	-0.26	Stearic acid (18:0) levels;	chr1:95234038	chr1:95243167~95278940:-
THCA	cis	rs853679	0.607	rs35001169	ENSG00000226314.6	ZNF192P1	-5.91	6.72e-09	1.26e-06	-0.58	-0.26	Depression;	chr6:28219854	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs35656932	ENSG00000226314.6	ZNF192P1	-5.91	6.72e-09	1.26e-06	-0.58	-0.26	Depression;	chr6:28223510	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13208096	ENSG00000226314.6	ZNF192P1	-5.91	6.72e-09	1.26e-06	-0.58	-0.26	Depression;	chr6:28257533	chr6:28161781~28169594:+
THCA	cis	rs7202877	0.61	rs1010631	ENSG00000261783.1	RP11-252K23.2	-5.91	6.72e-09	1.26e-06	-0.46	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75294692	chr16:75379818~75381260:-
THCA	cis	rs12612619	0.704	rs3769139	ENSG00000229122.1	AGBL5-IT1	5.91	6.73e-09	1.26e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092846	chr2:27061038~27061815:+
THCA	cis	rs1876905	0.62	rs377716	ENSG00000255389.1	C6orf3	5.91	6.73e-09	1.26e-06	0.31	0.26	Mean corpuscular hemoglobin;	chr6:111181705	chr6:111599875~111602295:+
THCA	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-5.91	6.73e-09	1.26e-06	-0.19	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
THCA	cis	rs62292953	0.719	rs62291558	ENSG00000248724.5	NPHP3-AS1	-5.91	6.74e-09	1.27e-06	-0.49	-0.26	Red cell distribution width;	chr3:132639992	chr3:132721750~132874223:+
THCA	cis	rs9880211	1	rs34757183	ENSG00000273486.1	RP11-731C17.2	5.91	6.74e-09	1.27e-06	0.27	0.26	Height;Body mass index;	chr3:136424826	chr3:136837338~136839021:-
THCA	cis	rs1275468	1	rs1148003	ENSG00000257497.2	RP11-585P4.5	-5.91	6.74e-09	1.27e-06	-0.39	-0.26	Polycystic ovary syndrome;	chr12:75585216	chr12:75483454~75489820:-
THCA	cis	rs797680	0.786	rs4847240	ENSG00000223745.6	RP4-717I23.3	5.91	6.74e-09	1.27e-06	0.15	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93352389	chr1:93262186~93346025:-
THCA	cis	rs6928977	0.896	rs1012645	ENSG00000231028.7	LINC00271	5.91	6.75e-09	1.27e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324309	chr6:135497801~135716055:+
THCA	cis	rs7809950	1	rs7786801	ENSG00000238832.1	snoU109	-5.91	6.75e-09	1.27e-06	-0.28	-0.26	Coronary artery disease;	chr7:107445444	chr7:107603363~107603507:+
THCA	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	5.91	6.76e-09	1.27e-06	0.24	0.26	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
THCA	cis	rs79040073	0.53	rs8029506	ENSG00000259531.2	RP11-295H24.3	5.91	6.76e-09	1.27e-06	0.36	0.26	Lung cancer in ever smokers;	chr15:49274543	chr15:49365124~49366685:-
THCA	cis	rs9813712	0.595	rs6439226	ENSG00000253540.4	FAM86HP	5.91	6.76e-09	1.27e-06	0.28	0.26	Response to amphetamines;	chr3:130283686	chr3:130099092~130111472:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000232546.1	RP11-458F8.1	5.91	6.76e-09	1.27e-06	0.34	0.26	Diabetic kidney disease;	chr7:66172773	chr7:66848496~66858136:+
THCA	cis	rs7829975	0.624	rs7823056	ENSG00000254153.1	CTA-398F10.2	-5.91	6.77e-09	1.27e-06	-0.29	-0.26	Mood instability;	chr8:8525195	chr8:8456909~8461337:-
THCA	cis	rs9543976	0.614	rs60497706	ENSG00000261553.4	RP11-29G8.3	-5.9	6.77e-09	1.27e-06	-0.41	-0.26	Diabetic retinopathy;	chr13:75509549	chr13:75549773~75807120:+
THCA	cis	rs875971	0.83	rs427575	ENSG00000232559.3	GS1-124K5.12	5.9	6.78e-09	1.27e-06	0.26	0.26	Aortic root size;	chr7:66054232	chr7:66554588~66576923:-
THCA	cis	rs3785574	0.962	rs35448669	ENSG00000240280.5	TCAM1P	-5.9	6.79e-09	1.27e-06	-0.36	-0.26	Height;	chr17:63861563	chr17:63849292~63864379:+
THCA	cis	rs35160687	0.712	rs6705366	ENSG00000273080.1	RP11-301O19.1	-5.9	6.8e-09	1.28e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86257659	chr2:86195590~86196049:+
THCA	cis	rs7615952	0.599	rs66532274	ENSG00000250012.1	RP11-124N2.1	-5.9	6.8e-09	1.28e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126013002	chr3:126084220~126095349:+
THCA	cis	rs16846053	0.786	rs72873645	ENSG00000227403.1	AC009299.3	5.9	6.8e-09	1.28e-06	0.54	0.26	Blood osmolality (transformed sodium);	chr2:161638537	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs55925603	ENSG00000227403.1	AC009299.3	5.9	6.8e-09	1.28e-06	0.54	0.26	Cognitive function;	chr2:161640700	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56260047	ENSG00000227403.1	AC009299.3	5.9	6.8e-09	1.28e-06	0.54	0.26	Cognitive function;	chr2:161640715	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62188983	ENSG00000227403.1	AC009299.3	5.9	6.8e-09	1.28e-06	0.54	0.26	Blood osmolality (transformed sodium);	chr2:161657449	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188987	ENSG00000227403.1	AC009299.3	5.9	6.8e-09	1.28e-06	0.54	0.26	Cognitive function;	chr2:161669176	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12467042	ENSG00000227403.1	AC009299.3	5.9	6.8e-09	1.28e-06	0.54	0.26	Cognitive function;	chr2:161670461	chr2:161244739~161249050:+
THCA	cis	rs9921338	0.961	rs8043692	ENSG00000262703.1	RP11-485G7.6	-5.9	6.81e-09	1.28e-06	-0.33	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333100	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.923	rs6498181	ENSG00000262703.1	RP11-485G7.6	-5.9	6.81e-09	1.28e-06	-0.33	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333336	chr16:11348143~11349321:-
THCA	cis	rs13113518	0.783	rs1586555	ENSG00000273257.1	RP11-177J6.1	5.9	6.81e-09	1.28e-06	0.35	0.26	Height;	chr4:55587104	chr4:55387949~55388271:+
THCA	cis	rs6142102	0.961	rs2284389	ENSG00000275784.1	RP5-1125A11.6	-5.9	6.81e-09	1.28e-06	-0.27	-0.26	Skin pigmentation;	chr20:34069035	chr20:33989480~33991818:-
THCA	cis	rs11671005	0.735	rs3826684	ENSG00000269473.1	CTD-2619J13.19	5.9	6.82e-09	1.28e-06	0.3	0.26	Mean platelet volume;	chr19:58407338	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs3826683	ENSG00000269473.1	CTD-2619J13.19	5.9	6.82e-09	1.28e-06	0.3	0.26	Mean platelet volume;	chr19:58407366	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs3826681	ENSG00000269473.1	CTD-2619J13.19	5.9	6.82e-09	1.28e-06	0.3	0.26	Mean platelet volume;	chr19:58407397	chr19:58440448~58445849:+
THCA	cis	rs7746199	0.736	rs35037868	ENSG00000226314.6	ZNF192P1	-5.9	6.82e-09	1.28e-06	-0.59	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28161781~28169594:+
THCA	cis	rs2136613	0.703	rs10761675	ENSG00000238280.1	RP11-436D10.3	-5.9	6.82e-09	1.28e-06	-0.31	-0.26	Selective IgA deficiency;	chr10:62863436	chr10:62793562~62805887:-
THCA	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	5.9	6.82e-09	1.28e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	5.9	6.82e-09	1.28e-06	0.3	0.26	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
THCA	cis	rs3204270	0.759	rs62075725	ENSG00000262049.1	RP13-1032I1.7	5.9	6.82e-09	1.28e-06	0.25	0.26	Dental caries;	chr17:81644484	chr17:81701324~81703300:-
THCA	cis	rs62184315	0.832	rs12466395	ENSG00000273240.1	RP11-455J20.3	-5.9	6.83e-09	1.28e-06	-0.29	-0.26	Alcohol dependence (age at onset);	chr2:189915972	chr2:189763859~189764456:-
THCA	cis	rs2439831	0.85	rs12441127	ENSG00000166763.7	STRCP1	5.9	6.84e-09	1.28e-06	0.39	0.26	Lung cancer in ever smokers;	chr15:43728977	chr15:43699488~43718184:-
THCA	cis	rs7824557	0.628	rs11250129	ENSG00000154316.13	TDH	-5.9	6.84e-09	1.28e-06	-0.2	-0.26	Retinal vascular caliber;	chr8:11344645	chr8:11339637~11368452:+
THCA	cis	rs934734	0.967	rs17534670	ENSG00000237979.1	AC007389.1	-5.9	6.84e-09	1.28e-06	-0.3	-0.26	Rheumatoid arthritis;	chr2:65388294	chr2:65500993~65502138:-
THCA	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	5.9	6.84e-09	1.28e-06	0.32	0.26	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
THCA	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-5.9	6.84e-09	1.28e-06	-0.25	-0.26	Height;	chr2:46627569	chr2:46668870~46670778:+
THCA	cis	rs9400467	0.528	rs1989574	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.85e-09	1.28e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111297126~111298510:+
THCA	cis	rs2006933	0.592	rs59828704	ENSG00000237575.4	PYY2	5.9	6.85e-09	1.29e-06	0.36	0.26	Amyotrophic lateral sclerosis;	chr17:27993270	chr17:28226563~28228065:+
THCA	cis	rs867529	0.924	rs6547787	ENSG00000234028.3	AC062029.1	5.9	6.85e-09	1.29e-06	0.21	0.26	Height;	chr2:88630218	chr2:88627539~88631821:+
THCA	cis	rs3742264	1	rs9534312	ENSG00000235903.6	CPB2-AS1	-5.9	6.86e-09	1.29e-06	-0.35	-0.26	Blood protein levels;	chr13:46076084	chr13:46052806~46113332:+
THCA	cis	rs7809950	1	rs2520249	ENSG00000238832.1	snoU109	-5.9	6.87e-09	1.29e-06	-0.28	-0.26	Coronary artery disease;	chr7:107506303	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs2520260	ENSG00000238832.1	snoU109	-5.9	6.87e-09	1.29e-06	-0.28	-0.26	Coronary artery disease;	chr7:107532349	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs12668402	ENSG00000238832.1	snoU109	-5.9	6.87e-09	1.29e-06	-0.28	-0.26	Coronary artery disease;	chr7:107532575	chr7:107603363~107603507:+
THCA	cis	rs9816784	0.576	rs12631246	ENSG00000231464.1	AC024937.4	5.9	6.87e-09	1.29e-06	0.34	0.26	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195996738~195998233:+
THCA	cis	rs763121	0.819	rs5757161	ENSG00000273076.1	RP3-508I15.22	5.9	6.87e-09	1.29e-06	0.25	0.26	Menopause (age at onset);	chr22:38594657	chr22:38743495~38743910:+
THCA	cis	rs7760535	0.811	rs1002475	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Metabolic traits;	chr6:111388386	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs11153288	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs11153290	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs11153291	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs11153292	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs12190634	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.508	rs11153294	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111297126~111298510:+
THCA	cis	rs3742597	0.959	rs35206478	ENSG00000276116.2	FUT8-AS1	-5.9	6.87e-09	1.29e-06	-0.32	-0.26	N-glycan levels;	chr14:65756495	chr14:65411170~65412690:-
THCA	cis	rs442309	0.871	rs224043	ENSG00000238280.1	RP11-436D10.3	-5.9	6.87e-09	1.29e-06	-0.31	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62765232	chr10:62793562~62805887:-
THCA	cis	rs34779708	0.801	rs12242110	ENSG00000230534.5	RP11-297A16.2	5.9	6.87e-09	1.29e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35098006~35127020:-
THCA	cis	rs9400467	0.528	rs7451051	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs6913769	ENSG00000271789.1	RP5-1112D6.7	-5.9	6.87e-09	1.29e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111297126~111298510:+
THCA	cis	rs7586673	0.93	rs6432667	ENSG00000235724.7	AC009299.2	-5.9	6.88e-09	1.29e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161222785~161308303:-
THCA	cis	rs12681366	0.592	rs2450556	ENSG00000253704.1	RP11-267M23.4	-5.9	6.88e-09	1.29e-06	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94318104	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.592	rs2445728	ENSG00000253704.1	RP11-267M23.4	-5.9	6.88e-09	1.29e-06	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94318458	chr8:94553722~94569745:+
THCA	cis	rs11154801	0.634	rs6941396	ENSG00000231028.7	LINC00271	-5.9	6.88e-09	1.29e-06	-0.23	-0.26	Multiple sclerosis;	chr6:135606388	chr6:135497801~135716055:+
THCA	cis	rs6991838	0.778	rs13261559	ENSG00000200714.1	Y_RNA	5.9	6.88e-09	1.29e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.778	rs7843697	ENSG00000200714.1	Y_RNA	5.9	6.88e-09	1.29e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.778	rs7843724	ENSG00000200714.1	Y_RNA	5.9	6.88e-09	1.29e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.806	rs35284121	ENSG00000200714.1	Y_RNA	5.9	6.88e-09	1.29e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65592731~65592820:+
THCA	cis	rs6957923	0.655	rs13241000	ENSG00000234286.1	AC006026.13	-5.9	6.89e-09	1.29e-06	-0.32	-0.26	Height;	chr7:23548516	chr7:23680195~23680786:-
THCA	cis	rs914615	0.507	rs4971085	ENSG00000225855.5	RUSC1-AS1	5.9	6.89e-09	1.29e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155165746	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs313832	ENSG00000232546.1	RP11-458F8.1	-5.9	6.89e-09	1.29e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66085904	chr7:66848496~66858136:+
THCA	cis	rs748404	0.666	rs12906017	ENSG00000249839.1	AC011330.5	-5.9	6.9e-09	1.29e-06	-0.39	-0.26	Lung cancer;	chr15:43504710	chr15:43663654~43684339:-
THCA	cis	rs6977955	0.877	rs9648346	ENSG00000234336.5	JAZF1-AS1	-5.9	6.91e-09	1.3e-06	-0.3	-0.26	Allergic disease (asthma, hay fever or eczema);	chr7:28120494	chr7:28180322~28243917:+
THCA	cis	rs523522	0.962	rs2235218	ENSG00000278344.1	RP11-18C24.8	5.9	6.91e-09	1.3e-06	0.29	0.26	High light scatter reticulocyte count;	chr12:120450816	chr12:120500735~120501090:-
THCA	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-5.9	6.91e-09	1.3e-06	-0.33	-0.26	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
THCA	cis	rs9880211	0.948	rs34282798	ENSG00000273486.1	RP11-731C17.2	5.9	6.92e-09	1.3e-06	0.27	0.26	Height;Body mass index;	chr3:136424515	chr3:136837338~136839021:-
THCA	cis	rs17772222	0.958	rs2297128	ENSG00000222990.1	RNU4-22P	5.9	6.92e-09	1.3e-06	0.35	0.26	Coronary artery calcification;	chr14:88469910	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.837	rs1864748	ENSG00000222990.1	RNU4-22P	5.9	6.92e-09	1.3e-06	0.35	0.26	Coronary artery calcification;	chr14:88488847	chr14:88513498~88513663:+
THCA	cis	rs4908760	0.965	rs12080583	ENSG00000232912.4	RP5-1115A15.1	5.9	6.92e-09	1.3e-06	0.26	0.26	Vitiligo;	chr1:8464817	chr1:8424645~8434838:+
THCA	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	5.9	6.92e-09	1.3e-06	0.36	0.26	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
THCA	cis	rs2692947	0.76	rs2438924	ENSG00000232931.4	LINC00342	5.9	6.92e-09	1.3e-06	0.2	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979321	chr2:95807118~95816215:-
THCA	cis	rs2915864	0.747	rs76643044	ENSG00000280047.1	CTC-463A16.1	5.9	6.93e-09	1.3e-06	0.43	0.26	Facial morphology (factor 20);	chr5:142049389	chr5:142165767~142168387:+
THCA	cis	rs79464052	0.571	rs122752	ENSG00000228737.2	AC008781.7	-5.9	6.93e-09	1.3e-06	-0.6	-0.26	Diffuse large B cell lymphoma;	chr5:141527139	chr5:141618414~141626481:+
THCA	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-5.9	6.93e-09	1.3e-06	-0.28	-0.26	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
THCA	cis	rs2033711	0.503	rs7254299	ENSG00000268049.1	CTD-2619J13.9	-5.9	6.93e-09	1.3e-06	-0.32	-0.26	Uric acid clearance;	chr19:58373598	chr19:58357999~58359603:+
THCA	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-5.9	6.93e-09	1.3e-06	-0.28	-0.26	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
THCA	cis	rs6928977	0.796	rs2179781	ENSG00000231028.7	LINC00271	5.9	6.94e-09	1.3e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135398362	chr6:135497801~135716055:+
THCA	cis	rs6908034	0.607	rs34109983	ENSG00000227116.1	RP3-471C18.1	-5.9	6.94e-09	1.3e-06	-0.47	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807811	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs73376680	ENSG00000227116.1	RP3-471C18.1	-5.9	6.94e-09	1.3e-06	-0.47	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807868	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs73376681	ENSG00000227116.1	RP3-471C18.1	-5.9	6.94e-09	1.3e-06	-0.47	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807944	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs80355837	ENSG00000227116.1	RP3-471C18.1	-5.9	6.94e-09	1.3e-06	-0.47	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808112	chr6:19730427~19734567:-
THCA	cis	rs11783469	0.524	rs17089283	ENSG00000253390.1	CTC-756D1.2	-5.9	6.94e-09	1.3e-06	-0.43	-0.26	Reticulocyte count;	chr8:23478249	chr8:23458601~23484971:+
THCA	cis	rs13113518	0.783	rs11943206	ENSG00000249700.7	SRD5A3-AS1	5.9	6.94e-09	1.3e-06	0.34	0.26	Height;	chr4:55570843	chr4:55363971~55395847:-
THCA	cis	rs9990333	0.562	rs55970879	ENSG00000231464.1	AC024937.4	5.9	6.95e-09	1.3e-06	0.34	0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195996738~195998233:+
THCA	cis	rs9990333	0.562	rs75681503	ENSG00000231464.1	AC024937.4	5.9	6.95e-09	1.3e-06	0.34	0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195996738~195998233:+
THCA	cis	rs748404	0.666	rs12906481	ENSG00000249839.1	AC011330.5	-5.9	6.95e-09	1.3e-06	-0.38	-0.26	Lung cancer;	chr15:43467356	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs35958032	ENSG00000249839.1	AC011330.5	-5.9	6.95e-09	1.3e-06	-0.38	-0.26	Lung cancer;	chr15:43494397	chr15:43663654~43684339:-
THCA	cis	rs9813712	0.526	rs13065659	ENSG00000249846.5	RP11-77P16.4	-5.9	6.95e-09	1.3e-06	-0.27	-0.26	Response to amphetamines;	chr3:130231945	chr3:130112550~130120579:+
THCA	cis	rs4947019	0.544	rs3757237	ENSG00000260273.1	RP11-425D10.10	5.9	6.95e-09	1.3e-06	0.48	0.26	Hematological parameters;	chr6:109437475	chr6:109382795~109383666:+
THCA	cis	rs1061377	0.585	rs3733271	ENSG00000249685.1	RP11-360F5.3	5.9	6.96e-09	1.3e-06	0.32	0.26	Uric acid levels;	chr4:39047948	chr4:39133913~39135608:+
THCA	cis	rs240993	0.516	rs414763	ENSG00000230177.1	RP5-1112D6.4	-5.9	6.96e-09	1.3e-06	-0.31	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111324561	chr6:111277932~111278742:+
THCA	cis	rs7824557	0.628	rs11991153	ENSG00000154316.13	TDH	-5.9	6.97e-09	1.31e-06	-0.2	-0.26	Retinal vascular caliber;	chr8:11345598	chr8:11339637~11368452:+
THCA	cis	rs3785574	0.962	rs2584621	ENSG00000240280.5	TCAM1P	-5.9	6.97e-09	1.31e-06	-0.36	-0.26	Height;	chr17:63835076	chr17:63849292~63864379:+
THCA	cis	rs728616	0.681	rs3862518	ENSG00000242600.5	MBL1P	5.9	6.97e-09	1.31e-06	0.32	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158201	chr10:79904898~79950336:+
THCA	cis	rs9329221	0.905	rs10283145	ENSG00000261451.1	RP11-981G7.1	-5.9	6.98e-09	1.31e-06	-0.33	-0.26	Neuroticism;	chr8:10383901	chr8:10433672~10438312:+
THCA	cis	rs7617773	1	rs11711766	ENSG00000228638.1	FCF1P2	5.9	6.98e-09	1.31e-06	0.25	0.26	Coronary artery disease;	chr3:48151680	chr3:48290793~48291375:-
THCA	cis	rs8042680	0.911	rs1443256	ENSG00000214432.8	AC068831.10	-5.9	6.98e-09	1.31e-06	-0.29	-0.26	Type 2 diabetes;	chr15:90972785	chr15:91022619~91036611:+
THCA	cis	rs7809950	1	rs987391	ENSG00000238832.1	snoU109	-5.9	6.98e-09	1.31e-06	-0.28	-0.26	Coronary artery disease;	chr7:107460349	chr7:107603363~107603507:+
THCA	cis	rs2136613	0.533	rs1571922	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62851189	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10822066	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62851432	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10740091	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62851628	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10822067	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62851949	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10761669	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62852050	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10509173	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62852129	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10822068	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62852505	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10822069	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62853482	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10995331	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62853948	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10822070	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62854149	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs4141617	ENSG00000238280.1	RP11-436D10.3	-5.9	6.99e-09	1.31e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62854308	chr10:62793562~62805887:-
THCA	cis	rs3760982	0.626	rs12463370	ENSG00000267058.1	RP11-15A1.3	-5.9	6.99e-09	1.31e-06	-0.23	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788014	chr19:43891804~43901805:-
THCA	cis	rs7702057	0.53	rs3087831	ENSG00000271918.1	CTD-2287O16.5	5.9	7e-09	1.31e-06	0.29	0.26	Amyotrophic lateral sclerosis;	chr5:116084901	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.53	rs3087832	ENSG00000271918.1	CTD-2287O16.5	5.9	7e-09	1.31e-06	0.29	0.26	Amyotrophic lateral sclerosis;	chr5:116084931	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.53	rs73780832	ENSG00000271918.1	CTD-2287O16.5	5.9	7e-09	1.31e-06	0.29	0.26	Amyotrophic lateral sclerosis;	chr5:116085208	chr5:116083807~116085416:-
THCA	cis	rs2243480	1	rs34136756	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65916269	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65918212	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65922114	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65923503	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65925372	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65925938	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000228409.4	CCT6P1	-5.9	7e-09	1.31e-06	-0.3	-0.26	Diabetic kidney disease;	chr7:65928187	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65940221	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65943626	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65944004	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000228409.4	CCT6P1	5.9	7e-09	1.31e-06	0.3	0.26	Diabetic kidney disease;	chr7:65944182	chr7:65751142~65763354:+
THCA	cis	rs17345786	1	rs58907984	ENSG00000256628.3	ZBTB11-AS1	5.9	7e-09	1.31e-06	0.33	0.26	Colonoscopy-negative controls vs population controls;	chr3:101586326	chr3:101676475~101679217:+
THCA	cis	rs4689592	0.503	rs11937667	ENSG00000245468.3	RP11-367J11.3	-5.9	7.01e-09	1.31e-06	-0.24	-0.26	Monocyte percentage of white cells;	chr4:7055310	chr4:7094571~7103385:-
THCA	cis	rs227917	1	rs227923	ENSG00000234286.1	AC006026.13	5.9	7.01e-09	1.31e-06	0.4	0.26	Common carotid intima-media thickness in HIV negative individuals;	chr7:23615929	chr7:23680195~23680786:-
THCA	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	5.9	7.02e-09	1.31e-06	0.29	0.26	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
THCA	cis	rs1318937	0.764	rs9853971	ENSG00000224660.1	SH3BP5-AS1	5.9	7.02e-09	1.31e-06	0.18	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15183840	chr3:15254184~15264493:+
THCA	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-5.9	7.02e-09	1.31e-06	-0.23	-0.26	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
THCA	cis	rs4713118	0.629	rs203889	ENSG00000272009.1	RP1-313I6.12	-5.9	7.02e-09	1.32e-06	-0.29	-0.26	Parkinson's disease;	chr6:28053997	chr6:28078792~28081130:-
THCA	cis	rs9921338	0.924	rs72773831	ENSG00000262703.1	RP11-485G7.6	-5.9	7.03e-09	1.32e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319070	chr16:11348143~11349321:-
THCA	cis	rs4950322	0.57	rs72691090	ENSG00000278811.3	LINC00624	5.9	7.03e-09	1.32e-06	0.32	0.26	Protein quantitative trait loci;	chr1:147297884	chr1:147258885~147517875:-
THCA	cis	rs9880211	1	rs13092193	ENSG00000273486.1	RP11-731C17.2	5.9	7.03e-09	1.32e-06	0.27	0.26	Height;Body mass index;	chr3:136521524	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs6771002	ENSG00000273486.1	RP11-731C17.2	5.9	7.03e-09	1.32e-06	0.27	0.26	Height;Body mass index;	chr3:136522186	chr3:136837338~136839021:-
THCA	cis	rs9381040	0.674	rs3747742	ENSG00000161912.16	ADCY10P1	-5.9	7.04e-09	1.32e-06	-0.18	-0.26	Alzheimer's disease (late onset);	chr6:41194780	chr6:41101022~41140835:+
THCA	cis	rs9467773	1	rs2255070	ENSG00000124549.13	BTN2A3P	5.9	7.04e-09	1.32e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26501549	chr6:26421391~26432383:+
THCA	cis	rs6993270	0.725	rs7823167	ENSG00000245330.4	KB-1471A8.1	-5.9	7.04e-09	1.32e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119898806	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs7461618	ENSG00000245330.4	KB-1471A8.1	-5.9	7.04e-09	1.32e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119899415	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs11995595	ENSG00000245330.4	KB-1471A8.1	-5.9	7.04e-09	1.32e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119903122	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs59865322	ENSG00000245330.4	KB-1471A8.1	-5.9	7.04e-09	1.32e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119903649	chr8:119867419~119874488:-
THCA	cis	rs3764400	0.567	rs4995899	ENSG00000278765.1	RP5-890E16.5	5.9	7.05e-09	1.32e-06	0.47	0.26	Body mass index;	chr17:48073368	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs16951519	ENSG00000278765.1	RP5-890E16.5	5.9	7.05e-09	1.32e-06	0.47	0.26	Body mass index;	chr17:48074929	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs12946143	ENSG00000278765.1	RP5-890E16.5	5.9	7.05e-09	1.32e-06	0.47	0.26	Body mass index;	chr17:48077581	chr17:48066704~48067293:-
THCA	cis	rs9921338	0.961	rs7626	ENSG00000262703.1	RP11-485G7.6	-5.9	7.05e-09	1.32e-06	-0.35	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs7193278	ENSG00000262703.1	RP11-485G7.6	-5.9	7.05e-09	1.32e-06	-0.35	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11348143~11349321:-
THCA	cis	rs7829975	0.508	rs4841006	ENSG00000253893.2	FAM85B	5.9	7.05e-09	1.32e-06	0.32	0.26	Mood instability;	chr8:8643964	chr8:8167819~8226614:-
THCA	cis	rs72843506	0.722	rs16964352	ENSG00000270091.1	RP11-78O7.2	-5.9	7.05e-09	1.32e-06	-0.28	-0.26	Schizophrenia;	chr17:20245095	chr17:19896590~19897287:-
THCA	cis	rs10043228	0.702	rs10519455	ENSG00000248445.4	SEMA6A-AS1	-5.9	7.06e-09	1.32e-06	-0.29	-0.26	Asthma or chronic obstructive pulmonary disease;	chr5:116304281	chr5:116447547~116508276:+
THCA	cis	rs6991838	0.725	rs6995134	ENSG00000200714.1	Y_RNA	5.9	7.07e-09	1.32e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65592731~65592820:+
THCA	cis	rs2303319	0.504	rs12467662	ENSG00000227403.1	AC009299.3	5.9	7.07e-09	1.32e-06	0.55	0.26	Cognitive function;	chr2:161530274	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs55650699	ENSG00000227403.1	AC009299.3	5.9	7.07e-09	1.32e-06	0.55	0.26	Cognitive function;	chr2:161532421	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187597	ENSG00000227403.1	AC009299.3	5.9	7.07e-09	1.32e-06	0.55	0.26	Cognitive function;	chr2:161541753	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56145818	ENSG00000227403.1	AC009299.3	5.9	7.07e-09	1.32e-06	0.55	0.26	Cognitive function;	chr2:161547268	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs60495163	ENSG00000227403.1	AC009299.3	5.9	7.07e-09	1.32e-06	0.55	0.26	Cognitive function;	chr2:161552297	chr2:161244739~161249050:+
THCA	cis	rs3785574	0.962	rs2247435	ENSG00000240280.5	TCAM1P	-5.9	7.07e-09	1.32e-06	-0.36	-0.26	Height;	chr17:63815502	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.924	rs2727292	ENSG00000240280.5	TCAM1P	-5.9	7.07e-09	1.32e-06	-0.36	-0.26	Height;	chr17:63816387	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs2597632	ENSG00000240280.5	TCAM1P	-5.9	7.07e-09	1.32e-06	-0.36	-0.26	Height;	chr17:63817379	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs2665835	ENSG00000240280.5	TCAM1P	-5.9	7.07e-09	1.32e-06	-0.36	-0.26	Height;	chr17:63825898	chr17:63849292~63864379:+
THCA	cis	rs9467773	1	rs6456733	ENSG00000124549.13	BTN2A3P	5.9	7.07e-09	1.32e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6456734	ENSG00000124549.13	BTN2A3P	5.9	7.07e-09	1.32e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs1535277	ENSG00000124549.13	BTN2A3P	5.9	7.07e-09	1.32e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs1884948	ENSG00000124549.13	BTN2A3P	5.9	7.07e-09	1.32e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26421391~26432383:+
THCA	cis	rs9309473	0.539	rs6732440	ENSG00000163016.8	ALMS1P	-5.9	7.08e-09	1.32e-06	-0.34	-0.26	Metabolite levels;	chr2:73599972	chr2:73644919~73685576:+
THCA	cis	rs71520386	0.634	rs13240023	ENSG00000228649.7	AC005682.5	-5.9	7.08e-09	1.33e-06	-0.34	-0.26	Fibrinogen levels;	chr7:22827874	chr7:22854178~22861579:+
THCA	cis	rs1876905	0.68	rs9400468	ENSG00000255389.1	C6orf3	5.9	7.08e-09	1.33e-06	0.32	0.26	Mean corpuscular hemoglobin;	chr6:111138766	chr6:111599875~111602295:+
THCA	cis	rs35160687	0.712	rs6745235	ENSG00000273080.1	RP11-301O19.1	-5.9	7.08e-09	1.33e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86259960	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs7568971	ENSG00000273080.1	RP11-301O19.1	-5.9	7.08e-09	1.33e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86260917	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs12476826	ENSG00000273080.1	RP11-301O19.1	-5.9	7.08e-09	1.33e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86262397	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs4832270	ENSG00000273080.1	RP11-301O19.1	-5.9	7.08e-09	1.33e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86263065	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs6547668	ENSG00000273080.1	RP11-301O19.1	-5.9	7.08e-09	1.33e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86263538	chr2:86195590~86196049:+
THCA	cis	rs728616	0.867	rs1537835	ENSG00000242600.5	MBL1P	5.9	7.09e-09	1.33e-06	0.35	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80070396	chr10:79904898~79950336:+
THCA	cis	rs9926296	0.605	rs12599180	ENSG00000260259.1	RP11-368I7.4	5.9	7.09e-09	1.33e-06	0.28	0.26	Vitiligo;	chr16:89772898	chr16:89682620~89686569:-
THCA	cis	rs7129556	0.69	rs668701	ENSG00000254691.1	RP11-91P24.5	5.9	7.09e-09	1.33e-06	0.37	0.26	Weight loss (gastric bypass surgery);	chr11:77872430	chr11:77850604~77851511:+
THCA	cis	rs12893668	0.703	rs7148456	ENSG00000269910.1	RP11-73M18.10	-5.9	7.1e-09	1.33e-06	-0.25	-0.26	Reticulocyte count;	chr14:103561933	chr14:103694516~103695050:-
THCA	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	5.9	7.1e-09	1.33e-06	0.31	0.26	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
THCA	cis	rs6545883	0.965	rs10186325	ENSG00000270820.4	RP11-355B11.2	5.9	7.1e-09	1.33e-06	0.22	0.26	Tuberculosis;	chr2:61530586	chr2:61471188~61484130:+
THCA	cis	rs4650994	1	rs10798619	ENSG00000273384.1	RP5-1098D14.1	5.9	7.11e-09	1.33e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178563382	chr1:178651706~178652282:+
THCA	cis	rs10829156	0.732	rs1917823	ENSG00000240291.1	RP11-499P20.2	5.9	7.12e-09	1.33e-06	0.23	0.26	Sudden cardiac arrest;	chr10:18528184	chr10:18513115~18545651:-
THCA	cis	rs7247513	1	rs2042947	ENSG00000213290.4	PGK1P2	-5.9	7.12e-09	1.33e-06	-0.32	-0.26	Bipolar disorder;	chr19:12582289	chr19:12559571~12561105:+
THCA	cis	rs6840360	0.642	rs2709842	ENSG00000270265.1	RP11-731D1.4	5.9	7.12e-09	1.33e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151333775~151353224:-
THCA	cis	rs17345786	1	rs997739	ENSG00000256628.3	ZBTB11-AS1	5.9	7.12e-09	1.33e-06	0.33	0.26	Colonoscopy-negative controls vs population controls;	chr3:101595096	chr3:101676475~101679217:+
THCA	cis	rs17345786	0.954	rs17508319	ENSG00000256628.3	ZBTB11-AS1	5.9	7.12e-09	1.33e-06	0.33	0.26	Colonoscopy-negative controls vs population controls;	chr3:101600059	chr3:101676475~101679217:+
THCA	cis	rs17345786	1	rs17345786	ENSG00000256628.3	ZBTB11-AS1	-5.9	7.12e-09	1.33e-06	-0.33	-0.26	Colonoscopy-negative controls vs population controls;	chr3:101599474	chr3:101676475~101679217:+
THCA	cis	rs11158026	0.894	rs10133650	ENSG00000258413.1	RP11-665C16.6	-5.9	7.13e-09	1.33e-06	-0.35	-0.26	Parkinson's disease;	chr14:54879555	chr14:55262767~55272075:-
THCA	cis	rs1876905	0.68	rs354547	ENSG00000230177.1	RP5-1112D6.4	5.9	7.13e-09	1.33e-06	0.27	0.26	Mean corpuscular hemoglobin;	chr6:111213919	chr6:111277932~111278742:+
THCA	cis	rs7267979	0.789	rs6083841	ENSG00000274973.1	RP13-401N8.7	5.9	7.13e-09	1.33e-06	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:25845497~25845862:+
THCA	cis	rs760794	0.577	rs7752808	ENSG00000227116.1	RP3-471C18.1	-5.9	7.14e-09	1.33e-06	-0.27	-0.26	Endometriosis;	chr6:19792665	chr6:19730427~19734567:-
THCA	cis	rs1552244	0.832	rs17050674	ENSG00000180385.7	EMC3-AS1	5.9	7.14e-09	1.34e-06	0.28	0.26	Alzheimer's disease;	chr3:9985574	chr3:9986893~10006990:+
THCA	cis	rs273909	0.514	rs77450473	ENSG00000233006.5	AC034220.3	-5.9	7.14e-09	1.34e-06	-0.36	-0.26	Coronary artery disease;	chr5:132449844	chr5:132311285~132369916:-
THCA	cis	rs748404	0.666	rs12911569	ENSG00000249839.1	AC011330.5	-5.9	7.14e-09	1.34e-06	-0.38	-0.26	Lung cancer;	chr15:43305099	chr15:43663654~43684339:-
THCA	cis	rs11089937	0.597	rs5757027	ENSG00000211638.2	IGLV8-61	-5.9	7.14e-09	1.34e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22098700~22099212:+
THCA	cis	rs2562456	0.837	rs11085462	ENSG00000213976.4	CTD-2561J22.2	-5.9	7.15e-09	1.34e-06	-0.28	-0.26	Pain;	chr19:21567449	chr19:21382865~21387177:+
THCA	cis	rs712039	0.687	rs11656455	ENSG00000276054.1	RP11-378E13.3	5.9	7.15e-09	1.34e-06	0.4	0.26	Tuberculosis;	chr17:37411798	chr17:37386886~37387926:+
THCA	cis	rs793571	0.505	rs16940589	ENSG00000259250.1	RP11-50C13.1	-5.9	7.16e-09	1.34e-06	-0.28	-0.26	Schizophrenia;	chr15:58606485	chr15:58587507~58591676:+
THCA	cis	rs6840360	0.642	rs7658169	ENSG00000270265.1	RP11-731D1.4	-5.9	7.16e-09	1.34e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151333775~151353224:-
THCA	cis	rs13256369	0.826	rs7846050	ENSG00000253893.2	FAM85B	-5.9	7.16e-09	1.34e-06	-0.34	-0.26	Obesity-related traits;	chr8:8718159	chr8:8167819~8226614:-
THCA	cis	rs911555	0.539	rs4374097	ENSG00000269940.1	RP11-73M18.7	5.9	7.16e-09	1.34e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr14:103606429	chr14:103694560~103695170:+
THCA	cis	rs748404	0.697	rs546170	ENSG00000166763.7	STRCP1	5.89	7.16e-09	1.34e-06	0.28	0.26	Lung cancer;	chr15:43272651	chr15:43699488~43718184:-
THCA	cis	rs2732480	0.538	rs2468943	ENSG00000240399.1	RP1-228P16.1	-5.89	7.17e-09	1.34e-06	-0.26	-0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48054813~48055591:-
THCA	cis	rs1552244	0.765	rs17050675	ENSG00000180385.7	EMC3-AS1	5.89	7.17e-09	1.34e-06	0.28	0.26	Alzheimer's disease;	chr3:9986002	chr3:9986893~10006990:+
THCA	cis	rs875971	0.662	rs448725	ENSG00000232559.3	GS1-124K5.12	5.89	7.17e-09	1.34e-06	0.26	0.26	Aortic root size;	chr7:66049641	chr7:66554588~66576923:-
THCA	cis	rs9467773	0.935	rs4573	ENSG00000124549.13	BTN2A3P	5.89	7.18e-09	1.34e-06	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26421391~26432383:+
THCA	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	5.89	7.18e-09	1.34e-06	0.34	0.26	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
THCA	cis	rs61041384	0.661	rs74954864	ENSG00000256092.2	RP13-942N8.1	-5.89	7.18e-09	1.34e-06	-0.41	-0.26	Schizophrenia;	chr12:122995776	chr12:123363868~123366113:+
THCA	cis	rs9381040	0.61	rs6940356	ENSG00000161912.16	ADCY10P1	5.89	7.18e-09	1.34e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41052621	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs2235678	ENSG00000161912.16	ADCY10P1	5.89	7.18e-09	1.34e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41052771	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs2268195	ENSG00000161912.16	ADCY10P1	5.89	7.18e-09	1.34e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41056601	chr6:41101022~41140835:+
THCA	cis	rs3785574	0.962	rs2584614	ENSG00000240280.5	TCAM1P	-5.89	7.18e-09	1.34e-06	-0.36	-0.26	Height;	chr17:63852085	chr17:63849292~63864379:+
THCA	cis	rs11976180	1	rs2951363	ENSG00000273234.1	OR2A13P	-5.89	7.18e-09	1.34e-06	-0.29	-0.26	Obesity-related traits;	chr7:144057631	chr7:144142009~144142938:+
THCA	cis	rs896854	0.654	rs13248607	ENSG00000253528.2	RP11-347C18.4	5.89	7.18e-09	1.34e-06	0.29	0.26	Type 2 diabetes;	chr8:94974409	chr8:94974573~94974853:-
THCA	cis	rs934734	0.736	rs10186240	ENSG00000237979.1	AC007389.1	5.89	7.19e-09	1.34e-06	0.31	0.26	Rheumatoid arthritis;	chr2:65350517	chr2:65500993~65502138:-
THCA	cis	rs7615952	1	rs7615952	ENSG00000241288.6	RP11-379B18.5	5.89	7.19e-09	1.34e-06	0.33	0.26	Blood pressure (smoking interaction);	chr3:125930560	chr3:125827238~125916384:-
THCA	cis	rs4713118	0.824	rs7759217	ENSG00000280107.1	AL022393.9	-5.89	7.19e-09	1.34e-06	-0.31	-0.26	Parkinson's disease;	chr6:27762684	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.784	rs9468219	ENSG00000280107.1	AL022393.9	-5.89	7.19e-09	1.34e-06	-0.31	-0.26	Parkinson's disease;	chr6:27763976	chr6:28170845~28172521:+
THCA	cis	rs16976116	0.901	rs28714578	ENSG00000279145.1	RP11-547D13.1	5.89	7.2e-09	1.35e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55198923	chr15:55171972~55178175:-
THCA	cis	rs896854	0.654	rs13274945	ENSG00000253528.2	RP11-347C18.4	5.89	7.2e-09	1.35e-06	0.29	0.26	Type 2 diabetes;	chr8:94974398	chr8:94974573~94974853:-
THCA	cis	rs76935404	0.811	rs8100418	ENSG00000256612.6	CYP2B7P	-5.89	7.21e-09	1.35e-06	-0.33	-0.26	nicotine metabolite ratio in current smokers;	chr19:40908458	chr19:40924219~40950660:+
THCA	cis	rs5742933	0.817	rs5742938	ENSG00000253559.1	OSGEPL1-AS1	5.89	7.21e-09	1.35e-06	0.3	0.26	Ferritin levels;	chr2:189785232	chr2:189762704~189765556:+
THCA	cis	rs9311474	0.713	rs104903	ENSG00000243224.1	RP5-1157M23.2	-5.89	7.21e-09	1.35e-06	-0.27	-0.26	Electroencephalogram traits;	chr3:52196459	chr3:52239258~52241097:+
THCA	cis	rs6740322	0.895	rs6710656	ENSG00000234936.1	AC010883.5	5.89	7.21e-09	1.35e-06	0.28	0.26	Coronary artery disease;	chr2:43339802	chr2:43229573~43233394:+
THCA	cis	rs9467773	0.587	rs12214031	ENSG00000124549.13	BTN2A3P	-5.89	7.22e-09	1.35e-06	-0.26	-0.26	Intelligence (multi-trait analysis);	chr6:26376400	chr6:26421391~26432383:+
THCA	cis	rs797680	0.786	rs1426318	ENSG00000223745.6	RP4-717I23.3	5.89	7.22e-09	1.35e-06	0.15	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93381863	chr1:93262186~93346025:-
THCA	cis	rs797680	0.786	rs59417472	ENSG00000223745.6	RP4-717I23.3	5.89	7.22e-09	1.35e-06	0.15	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93382956	chr1:93262186~93346025:-
THCA	cis	rs797680	0.786	rs12406245	ENSG00000223745.6	RP4-717I23.3	5.89	7.22e-09	1.35e-06	0.15	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93395068	chr1:93262186~93346025:-
THCA	cis	rs17826219	0.789	rs4794873	ENSG00000264538.5	SUZ12P1	-5.89	7.22e-09	1.35e-06	-0.26	-0.26	Body mass index;	chr17:30421334	chr17:30709299~30790908:+
THCA	cis	rs4852324	0.536	rs6721042	ENSG00000217702.2	RP11-287D1.4	5.89	7.23e-09	1.35e-06	0.71	0.26	Systemic lupus erythematosus;	chr2:73990156	chr2:74130583~74135395:+
THCA	cis	rs748404	0.697	rs567357	ENSG00000166763.7	STRCP1	5.89	7.23e-09	1.35e-06	0.28	0.26	Lung cancer;	chr15:43279192	chr15:43699488~43718184:-
THCA	cis	rs10129255	0.957	rs12589190	ENSG00000211974.3	IGHV2-70	5.89	7.23e-09	1.35e-06	0.2	0.26	Kawasaki disease;	chr14:106783079	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs7493713	ENSG00000211974.3	IGHV2-70	5.89	7.23e-09	1.35e-06	0.2	0.26	Kawasaki disease;	chr14:106783685	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.912	rs35468694	ENSG00000211974.3	IGHV2-70	5.89	7.23e-09	1.35e-06	0.2	0.26	Kawasaki disease;	chr14:106784199	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs8019272	ENSG00000211974.3	IGHV2-70	5.89	7.23e-09	1.35e-06	0.2	0.26	Kawasaki disease;	chr14:106784709	chr14:106723574~106724093:-
THCA	cis	rs11148252	0.634	rs66849828	ENSG00000278238.1	RP11-245D16.4	-5.89	7.24e-09	1.35e-06	-0.3	-0.26	Lewy body disease;	chr13:52140701	chr13:52454775~52455331:-
THCA	cis	rs9475752	0.948	rs61340009	ENSG00000231441.1	RP11-472M19.2	5.89	7.24e-09	1.35e-06	0.32	0.26	Menarche (age at onset);	chr6:56922916	chr6:56844002~56864078:+
THCA	cis	rs9475752	1	rs17450853	ENSG00000231441.1	RP11-472M19.2	5.89	7.24e-09	1.35e-06	0.32	0.26	Menarche (age at onset);	chr6:56923206	chr6:56844002~56864078:+
THCA	cis	rs2976388	0.59	rs13254346	ENSG00000253741.1	CTD-2292P10.4	5.89	7.24e-09	1.35e-06	0.34	0.26	Urinary tract infection frequency;	chr8:142742445	chr8:142702252~142726973:-
THCA	cis	rs202072	0.652	rs1223393	ENSG00000272379.1	RP1-257A7.5	-5.89	7.24e-09	1.35e-06	-0.41	-0.26	HIV-1 viral setpoint;	chr6:13265102	chr6:13290018~13290490:-
THCA	cis	rs11089937	0.626	rs4821781	ENSG00000211638.2	IGLV8-61	-5.89	7.25e-09	1.35e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.626	rs5750589	ENSG00000211638.2	IGLV8-61	-5.89	7.25e-09	1.35e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.626	rs5757038	ENSG00000211638.2	IGLV8-61	-5.89	7.25e-09	1.35e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22098700~22099212:+
THCA	cis	rs2281636	0.823	rs11190225	ENSG00000260475.1	RP11-85A1.3	5.89	7.25e-09	1.35e-06	0.24	0.26	Obesity-related traits;	chr10:99657156	chr10:99621055~99621918:+
THCA	cis	rs12681963	0.688	rs67240919	ENSG00000248159.1	HSPA8P11	5.89	7.26e-09	1.36e-06	0.47	0.26	Migraine;	chr8:30171039	chr8:30237382~30240997:+
THCA	cis	rs713477	0.967	rs12431542	ENSG00000258413.1	RP11-665C16.6	5.89	7.26e-09	1.36e-06	0.35	0.26	Pediatric bone mineral content (femoral neck);	chr14:55446360	chr14:55262767~55272075:-
THCA	cis	rs748404	0.666	rs16957680	ENSG00000249839.1	AC011330.5	-5.89	7.26e-09	1.36e-06	-0.37	-0.26	Lung cancer;	chr15:43396207	chr15:43663654~43684339:-
THCA	cis	rs792448	0.501	rs2307128	ENSG00000226251.4	RP11-15I11.3	-5.89	7.27e-09	1.36e-06	-0.33	-0.26	White blood cell count (basophil);	chr1:212226474	chr1:212225278~212238977:-
THCA	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-5.89	7.27e-09	1.36e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
THCA	cis	rs9473147	0.747	rs9395288	ENSG00000270761.1	RP11-385F7.1	-5.89	7.28e-09	1.36e-06	-0.22	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47630389	chr6:47477243~47477572:-
THCA	cis	rs7809950	1	rs2237672	ENSG00000238832.1	snoU109	-5.89	7.28e-09	1.36e-06	-0.28	-0.26	Coronary artery disease;	chr7:107491118	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs2250414	ENSG00000238832.1	snoU109	-5.89	7.28e-09	1.36e-06	-0.28	-0.26	Coronary artery disease;	chr7:107500542	chr7:107603363~107603507:+
THCA	cis	rs6430585	0.583	rs59213715	ENSG00000231890.6	DARS-AS1	-5.89	7.28e-09	1.36e-06	-0.32	-0.26	Corneal structure;	chr2:135889012	chr2:135985176~136022593:+
THCA	cis	rs17301013	0.507	rs333422	ENSG00000227373.4	RP11-160H22.5	-5.89	7.29e-09	1.36e-06	-0.4	-0.26	Systemic lupus erythematosus;	chr1:174664167	chr1:174115300~174160004:-
THCA	cis	rs6991838	0.751	rs35553155	ENSG00000200714.1	Y_RNA	5.89	7.29e-09	1.36e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.806	rs35024820	ENSG00000200714.1	Y_RNA	5.89	7.29e-09	1.36e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65592731~65592820:+
THCA	cis	rs6840360	0.642	rs1596290	ENSG00000270265.1	RP11-731D1.4	-5.89	7.3e-09	1.36e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151333775~151353224:-
THCA	cis	rs728616	0.614	rs35193855	ENSG00000225484.5	NUTM2B-AS1	-5.89	7.3e-09	1.36e-06	-0.45	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028739	chr10:79663088~79826594:-
THCA	cis	rs11096990	0.964	rs6831700	ENSG00000249685.1	RP11-360F5.3	5.89	7.3e-09	1.36e-06	0.33	0.26	Cognitive function;	chr4:39255344	chr4:39133913~39135608:+
THCA	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-5.89	7.31e-09	1.36e-06	-0.24	-0.26	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
THCA	cis	rs2562456	0.833	rs2562507	ENSG00000268081.1	RP11-678G14.2	-5.89	7.31e-09	1.37e-06	-0.38	-0.26	Pain;	chr19:21543535	chr19:21554640~21569237:-
THCA	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	5.89	7.31e-09	1.37e-06	0.26	0.26	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	5.89	7.31e-09	1.37e-06	0.26	0.26	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
THCA	cis	rs853679	0.546	rs35017208	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28377505	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs13213152	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28381921	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs36092177	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28390030	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs13213986	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28390232	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs2232429	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28391855	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs2232426	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28392882	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs34546986	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28394532	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs34871267	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28396455	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs2232423	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28398374	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs35883476	ENSG00000219392.1	RP1-265C24.5	-5.89	7.31e-09	1.37e-06	-0.59	-0.26	Depression;	chr6:28400731	chr6:28115628~28116551:+
THCA	cis	rs7824557	0.602	rs7834139	ENSG00000154316.13	TDH	-5.89	7.32e-09	1.37e-06	-0.2	-0.26	Retinal vascular caliber;	chr8:11348854	chr8:11339637~11368452:+
THCA	cis	rs2163813	1	rs247776	ENSG00000275540.1	CTC-559E9.12	-5.89	7.33e-09	1.37e-06	-0.32	-0.26	Toenail selenium levels;	chr19:19731806	chr19:19740884~19750127:+
THCA	cis	rs4143844	1	rs12917339	ENSG00000259251.2	RP11-643M14.1	5.89	7.33e-09	1.37e-06	0.5	0.26	Bipolar disorder and schizophrenia;	chr15:62054591	chr15:62060503~62062434:+
THCA	cis	rs9595908	0.931	rs9595617	ENSG00000212293.1	SNORA16	5.89	7.34e-09	1.37e-06	0.31	0.26	Body mass index;	chr13:32483208	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.895	rs9591012	ENSG00000212293.1	SNORA16	5.89	7.34e-09	1.37e-06	0.31	0.26	Body mass index;	chr13:32484196	chr13:32420390~32420516:-
THCA	cis	rs12612619	0.591	rs12714092	ENSG00000229122.1	AGBL5-IT1	-5.89	7.34e-09	1.37e-06	-0.2	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092014	chr2:27061038~27061815:+
THCA	cis	rs11722228	0.508	rs2241473	ENSG00000261490.1	RP11-448G15.3	5.89	7.34e-09	1.37e-06	0.19	0.26	Urate levels;Serum uric acid levels;Gout;	chr4:10084325	chr4:10068089~10073019:-
THCA	cis	rs7927592	0.789	rs2291467	ENSG00000212093.1	AP000807.1	5.89	7.34e-09	1.37e-06	0.3	0.26	Total body bone mineral density;	chr11:68449288	chr11:68506083~68506166:-
THCA	cis	rs2562456	0.917	rs9304987	ENSG00000268119.4	CTD-2561J22.5	-5.89	7.34e-09	1.37e-06	-0.32	-0.26	Pain;	chr19:21499472	chr19:21444241~21463908:-
THCA	cis	rs5758659	0.714	rs2413668	ENSG00000227370.1	RP4-669P10.19	5.89	7.34e-09	1.37e-06	0.24	0.26	Cognitive function;	chr22:42109837	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.657	rs5758587	ENSG00000227370.1	RP4-669P10.19	5.89	7.34e-09	1.37e-06	0.24	0.26	Cognitive function;	chr22:42121632	chr22:42132543~42132998:+
THCA	cis	rs9876781	1	rs4858817	ENSG00000229759.1	MRPS18AP1	-5.89	7.35e-09	1.37e-06	-0.31	-0.26	Longevity;	chr3:48375266	chr3:48256350~48256938:-
THCA	cis	rs16846053	0.792	rs55893794	ENSG00000227403.1	AC009299.3	5.89	7.35e-09	1.37e-06	0.55	0.26	Blood osmolality (transformed sodium);	chr2:161562241	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs57464189	ENSG00000227403.1	AC009299.3	5.89	7.35e-09	1.37e-06	0.55	0.26	Cognitive function;	chr2:161562802	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72870226	ENSG00000227403.1	AC009299.3	5.89	7.35e-09	1.37e-06	0.55	0.26	Cognitive function;	chr2:161563919	chr2:161244739~161249050:+
THCA	cis	rs1876905	0.569	rs354542	ENSG00000230177.1	RP5-1112D6.4	-5.89	7.35e-09	1.37e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.68	rs1216020	ENSG00000230177.1	RP5-1112D6.4	-5.89	7.35e-09	1.37e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.569	rs354541	ENSG00000230177.1	RP5-1112D6.4	-5.89	7.35e-09	1.37e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.68	rs354537	ENSG00000230177.1	RP5-1112D6.4	-5.89	7.35e-09	1.37e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.68	rs354536	ENSG00000230177.1	RP5-1112D6.4	-5.89	7.35e-09	1.37e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.68	rs1215848	ENSG00000230177.1	RP5-1112D6.4	-5.89	7.35e-09	1.37e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111277932~111278742:+
THCA	cis	rs4689592	0.546	rs10937784	ENSG00000245468.3	RP11-367J11.3	5.89	7.36e-09	1.37e-06	0.21	0.26	Monocyte percentage of white cells;	chr4:7059208	chr4:7094571~7103385:-
THCA	cis	rs2136613	0.563	rs1509957	ENSG00000238280.1	RP11-436D10.3	-5.89	7.36e-09	1.37e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62850958	chr10:62793562~62805887:-
THCA	cis	rs6674176	0.628	rs3828146	ENSG00000237950.1	RP11-7O11.3	5.89	7.36e-09	1.37e-06	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43963043	chr1:43944370~43946551:-
THCA	cis	rs6860806	0.531	rs270607	ENSG00000263597.1	MIR3936	5.89	7.36e-09	1.37e-06	0.26	0.26	Breast cancer;	chr5:132313493	chr5:132365490~132365599:-
THCA	cis	rs317865	0.867	rs73234625	ENSG00000263327.5	TAPT1-AS1	-5.89	7.37e-09	1.38e-06	-0.47	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16164583	chr4:16226685~16320140:+
THCA	cis	rs748404	0.697	rs491804	ENSG00000166763.7	STRCP1	5.89	7.37e-09	1.38e-06	0.28	0.26	Lung cancer;	chr15:43268627	chr15:43699488~43718184:-
THCA	cis	rs2337406	0.925	rs34064152	ENSG00000274576.2	IGHV2-70	-5.89	7.37e-09	1.38e-06	-0.25	-0.26	Alzheimer's disease (late onset);	chr14:106700364	chr14:106770577~106771020:-
THCA	cis	rs1061377	0.585	rs1367296	ENSG00000249685.1	RP11-360F5.3	5.89	7.37e-09	1.38e-06	0.32	0.26	Uric acid levels;	chr4:39066895	chr4:39133913~39135608:+
THCA	cis	rs9402743	0.673	rs9483858	ENSG00000231028.7	LINC00271	-5.89	7.37e-09	1.38e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135642670	chr6:135497801~135716055:+
THCA	cis	rs914615	0.529	rs11264338	ENSG00000225855.5	RUSC1-AS1	5.89	7.37e-09	1.38e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155166081	chr1:155316863~155324176:-
THCA	cis	rs9307551	0.817	rs11098766	ENSG00000250334.4	LINC00989	-5.89	7.38e-09	1.38e-06	-0.3	-0.26	Refractive error;	chr4:79579266	chr4:79492416~79576460:+
THCA	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-5.89	7.38e-09	1.38e-06	-0.26	-0.26	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
THCA	cis	rs2337406	0.778	rs58113768	ENSG00000274576.2	IGHV2-70	-5.89	7.39e-09	1.38e-06	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106700213	chr14:106770577~106771020:-
THCA	cis	rs2337406	1	rs75651733	ENSG00000274576.2	IGHV2-70	-5.89	7.39e-09	1.38e-06	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106701309	chr14:106770577~106771020:-
THCA	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-5.89	7.39e-09	1.38e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
THCA	cis	rs11158026	0.567	rs61224609	ENSG00000258413.1	RP11-665C16.6	-5.89	7.39e-09	1.38e-06	-0.37	-0.26	Parkinson's disease;	chr14:54936490	chr14:55262767~55272075:-
THCA	cis	rs9595908	1	rs7332115	ENSG00000212293.1	SNORA16	5.89	7.39e-09	1.38e-06	0.31	0.26	Body mass index;	chr13:32573411	chr13:32420390~32420516:-
THCA	cis	rs6142102	1	rs4911409	ENSG00000275784.1	RP5-1125A11.6	-5.89	7.41e-09	1.38e-06	-0.27	-0.26	Skin pigmentation;	chr20:34122904	chr20:33989480~33991818:-
THCA	cis	rs763567	0.933	rs588837	ENSG00000271811.1	RP1-79C4.4	5.89	7.41e-09	1.38e-06	0.3	0.26	Tonsillectomy;	chr1:170653968	chr1:170667381~170669425:+
THCA	cis	rs8012947	0.917	rs2145600	ENSG00000279636.2	LINC00216	5.89	7.42e-09	1.38e-06	0.29	0.26	Alcohol consumption in current drinkers;	chr14:58284184	chr14:58288033~58289158:+
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000232546.1	RP11-458F8.1	-5.89	7.42e-09	1.38e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66500146	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000232546.1	RP11-458F8.1	-5.89	7.42e-09	1.38e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66500834	chr7:66848496~66858136:+
THCA	cis	rs914615	0.552	rs12752585	ENSG00000225855.5	RUSC1-AS1	5.89	7.42e-09	1.38e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155162930	chr1:155316863~155324176:-
THCA	cis	rs6545883	0.965	rs11887205	ENSG00000271889.1	RP11-493E12.1	5.89	7.42e-09	1.38e-06	0.25	0.26	Tuberculosis;	chr2:61547338	chr2:61151433~61162105:-
THCA	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	5.89	7.44e-09	1.39e-06	0.34	0.26	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
THCA	cis	rs11266744	0.643	rs11575816	ENSG00000223552.1	RP11-24F11.2	5.89	7.44e-09	1.39e-06	0.23	0.26	Monocyte percentage of white cells;	chr3:46378613	chr3:46364955~46407059:-
THCA	cis	rs8042680	0.522	rs8026678	ENSG00000214432.8	AC068831.10	-5.89	7.44e-09	1.39e-06	-0.28	-0.26	Type 2 diabetes;	chr15:91018775	chr15:91022619~91036611:+
THCA	cis	rs9388451	0.591	rs1268792	ENSG00000237742.5	RP11-624M8.1	5.89	7.44e-09	1.39e-06	0.24	0.26	Brugada syndrome;	chr6:125720978	chr6:125578558~125749190:-
THCA	cis	rs10875746	0.669	rs10875772	ENSG00000269514.1	RP11-370I10.12	5.89	7.44e-09	1.39e-06	0.26	0.26	Longevity (90 years and older);	chr12:48215770	chr12:48198387~48202031:+
THCA	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	5.89	7.44e-09	1.39e-06	0.28	0.26	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
THCA	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-5.89	7.45e-09	1.39e-06	-0.4	-0.26	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
THCA	cis	rs34779708	0.741	rs34397613	ENSG00000271335.4	RP11-324I22.4	5.89	7.45e-09	1.39e-06	0.26	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35314552~35336401:-
THCA	cis	rs61677309	0.638	rs59049611	ENSG00000280032.1	RP11-832A4.7	5.89	7.45e-09	1.39e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118268688	chr11:118264593~118266817:+
THCA	cis	rs2243480	1	rs160646	ENSG00000232546.1	RP11-458F8.1	-5.89	7.45e-09	1.39e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66091293	chr7:66848496~66858136:+
THCA	cis	rs9601248	0.711	rs9530937	ENSG00000227676.3	LINC01068	-5.89	7.46e-09	1.39e-06	-0.33	-0.26	Major depressive disorder;	chr13:79603701	chr13:79566727~79571436:+
THCA	cis	rs7824557	0.602	rs35807737	ENSG00000154316.13	TDH	-5.89	7.46e-09	1.39e-06	-0.2	-0.26	Retinal vascular caliber;	chr8:11346902	chr8:11339637~11368452:+
THCA	cis	rs274567	0.501	rs272855	ENSG00000263597.1	MIR3936	5.89	7.47e-09	1.39e-06	0.27	0.26	Blood metabolite levels;	chr5:132351482	chr5:132365490~132365599:-
THCA	cis	rs2276314	0.532	rs11081927	ENSG00000278986.1	RP11-723J4.3	-5.89	7.48e-09	1.4e-06	-0.27	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36034319	chr18:35972151~35973916:+
THCA	cis	rs7824557	0.628	rs11994376	ENSG00000154316.13	TDH	-5.89	7.49e-09	1.4e-06	-0.2	-0.26	Retinal vascular caliber;	chr8:11345451	chr8:11339637~11368452:+
THCA	cis	rs7208859	0.623	rs9914242	ENSG00000263603.1	CTD-2349P21.5	-5.89	7.49e-09	1.4e-06	-0.47	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30729469~30731202:+
THCA	cis	rs838147	0.563	rs2638282	ENSG00000232871.7	SEC1P	5.89	7.49e-09	1.4e-06	0.31	0.26	Dietary macronutrient intake;	chr19:48710576	chr19:48638071~48682245:+
THCA	cis	rs896854	0.714	rs6471503	ENSG00000253528.2	RP11-347C18.4	5.89	7.5e-09	1.4e-06	0.29	0.26	Type 2 diabetes;	chr8:94978055	chr8:94974573~94974853:-
THCA	cis	rs4639966	0.836	rs7943039	ENSG00000255239.1	AP002954.6	-5.89	7.51e-09	1.4e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr11:118732321	chr11:118688039~118690600:-
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000272009.1	RP1-313I6.12	-5.89	7.51e-09	1.4e-06	-0.3	-0.26	Parkinson's disease;	chr6:28055973	chr6:28078792~28081130:-
THCA	cis	rs2976388	0.59	rs10087426	ENSG00000253741.1	CTD-2292P10.4	5.89	7.51e-09	1.4e-06	0.34	0.26	Urinary tract infection frequency;	chr8:142733136	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.59	rs11785290	ENSG00000253741.1	CTD-2292P10.4	5.89	7.51e-09	1.4e-06	0.34	0.26	Urinary tract infection frequency;	chr8:142733431	chr8:142702252~142726973:-
THCA	cis	rs2297363	0.502	rs4709395	ENSG00000213073.4	RP11-288H12.3	-5.89	7.51e-09	1.4e-06	-0.23	-0.26	Total cholesterol levels;Blood protein levels;	chr6:160057757	chr6:160093082~160096212:+
THCA	cis	rs7005380	0.6	rs10955940	ENSG00000245330.4	KB-1471A8.1	5.89	7.52e-09	1.4e-06	0.25	0.26	Interstitial lung disease;	chr8:119890246	chr8:119867419~119874488:-
THCA	cis	rs9813712	0.953	rs9871734	ENSG00000228252.7	COL6A4P2	5.89	7.52e-09	1.4e-06	0.3	0.26	Response to amphetamines;	chr3:130240756	chr3:130212823~130273806:+
THCA	cis	rs758324	0.606	rs101194	ENSG00000237714.1	P4HA2-AS1	-5.89	7.53e-09	1.4e-06	-0.38	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132179720	chr5:132184876~132192808:+
THCA	cis	rs950173	1	rs950173	ENSG00000228389.1	AC068039.4	5.89	7.53e-09	1.4e-06	0.46	0.26	Hippocampal volume;	chr2:171713909	chr2:171773482~171775844:+
THCA	cis	rs2281636	0.929	rs7913190	ENSG00000260475.1	RP11-85A1.3	5.89	7.53e-09	1.4e-06	0.24	0.26	Obesity-related traits;	chr10:99738639	chr10:99621055~99621918:+
THCA	cis	rs748404	0.697	rs572959	ENSG00000166763.7	STRCP1	5.89	7.54e-09	1.41e-06	0.28	0.26	Lung cancer;	chr15:43258304	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs554001	ENSG00000166763.7	STRCP1	5.89	7.54e-09	1.41e-06	0.28	0.26	Lung cancer;	chr15:43259721	chr15:43699488~43718184:-
THCA	cis	rs7493	0.755	rs17883791	ENSG00000233942.1	AC004012.1	5.89	7.54e-09	1.41e-06	0.39	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95370126	chr7:95471835~95473998:+
THCA	cis	rs4971059	0.629	rs11264333	ENSG00000160766.13	GBAP1	-5.89	7.54e-09	1.41e-06	-0.28	-0.26	Breast cancer;	chr1:155135811	chr1:155213821~155227422:-
THCA	cis	rs7202877	0.706	rs4888375	ENSG00000261783.1	RP11-252K23.2	-5.89	7.54e-09	1.41e-06	-0.46	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75288458	chr16:75379818~75381260:-
THCA	cis	rs863750	0.721	rs844085	ENSG00000275389.1	RP11-214K3.24	5.89	7.54e-09	1.41e-06	0.34	0.26	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124080711	chr12:124085761~124088598:+
THCA	cis	rs10875746	0.669	rs10875767	ENSG00000269514.1	RP11-370I10.12	5.89	7.56e-09	1.41e-06	0.26	0.26	Longevity (90 years and older);	chr12:48205474	chr12:48198387~48202031:+
THCA	cis	rs9329221	0.538	rs17750324	ENSG00000261451.1	RP11-981G7.1	-5.89	7.56e-09	1.41e-06	-0.34	-0.26	Neuroticism;	chr8:10243402	chr8:10433672~10438312:+
THCA	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-5.89	7.57e-09	1.41e-06	-0.28	-0.26	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
THCA	cis	rs1865760	0.623	rs12216125	ENSG00000272462.2	U91328.19	-5.89	7.57e-09	1.41e-06	-0.24	-0.26	Height;	chr6:25997230	chr6:25992662~26001775:+
THCA	cis	rs848490	0.889	rs11761707	ENSG00000214293.7	APTR	-5.89	7.57e-09	1.41e-06	-0.21	-0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77608867	chr7:77657660~77696265:-
THCA	cis	rs10895275	0.886	rs2187525	ENSG00000277459.1	RP11-732A21.3	5.89	7.57e-09	1.41e-06	0.2	0.26	Migraine;	chr11:102178985	chr11:102109827~102110457:-
THCA	cis	rs2129782	1	rs59290812	ENSG00000253553.4	RP11-586K2.1	5.88	7.58e-09	1.41e-06	0.45	0.26	Electrodermal activity;	chr8:88429567	chr8:88326836~88737134:+
THCA	cis	rs9467773	1	rs9467787	ENSG00000124549.13	BTN2A3P	5.88	7.58e-09	1.41e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs6941022	ENSG00000124549.13	BTN2A3P	5.88	7.59e-09	1.41e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs2224380	ENSG00000124549.13	BTN2A3P	5.88	7.59e-09	1.41e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs9461271	ENSG00000124549.13	BTN2A3P	5.88	7.59e-09	1.41e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26421391~26432383:+
THCA	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-5.88	7.59e-09	1.41e-06	-0.24	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
THCA	cis	rs9910055	0.762	rs11080007	ENSG00000267080.4	ASB16-AS1	5.88	7.59e-09	1.41e-06	0.24	0.26	Total body bone mineral density;	chr17:44188074	chr17:44175973~44186717:-
THCA	cis	rs11795343	0.509	rs659527	ENSG00000232303.2	DFFBP1	-5.88	7.6e-09	1.42e-06	-0.31	-0.26	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32527326	chr9:32566148~32567126:-
THCA	cis	rs7129556	0.702	rs650171	ENSG00000254691.1	RP11-91P24.5	5.88	7.6e-09	1.42e-06	0.35	0.26	Weight loss (gastric bypass surgery);	chr11:77787440	chr11:77850604~77851511:+
THCA	cis	rs62184315	0.536	rs5742926	ENSG00000273240.1	RP11-455J20.3	-5.88	7.6e-09	1.42e-06	-0.35	-0.26	Alcohol dependence (age at onset);	chr2:189784079	chr2:189763859~189764456:-
THCA	cis	rs73607972	0.866	rs17803830	ENSG00000275191.1	RP11-36I17.2	5.88	7.61e-09	1.42e-06	0.41	0.26	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53608948	chr16:53628256~53628816:-
THCA	cis	rs7809950	1	rs986994	ENSG00000238832.1	snoU109	-5.88	7.62e-09	1.42e-06	-0.28	-0.26	Coronary artery disease;	chr7:107463670	chr7:107603363~107603507:+
THCA	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-5.88	7.62e-09	1.42e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
THCA	cis	rs8033133	0.881	rs3803328	ENSG00000251896.1	SNORD116-27	-5.88	7.62e-09	1.42e-06	-0.3	-0.26	Blood osmolality (transformed sodium);	chr15:25085403	chr15:25101575~25101666:+
THCA	cis	rs7809950	1	rs67982599	ENSG00000238832.1	snoU109	-5.88	7.63e-09	1.42e-06	-0.28	-0.26	Coronary artery disease;	chr7:107459659	chr7:107603363~107603507:+
THCA	cis	rs2976388	0.566	rs2585141	ENSG00000253741.1	CTD-2292P10.4	5.88	7.64e-09	1.42e-06	0.36	0.26	Urinary tract infection frequency;	chr8:142724925	chr8:142702252~142726973:-
THCA	cis	rs9652601	0.959	rs7200940	ENSG00000274038.1	RP11-66H6.4	5.88	7.64e-09	1.42e-06	0.34	0.26	Systemic lupus erythematosus;	chr16:11070710	chr16:11056556~11057034:+
THCA	cis	rs6674176	0.628	rs3791116	ENSG00000237950.1	RP11-7O11.3	5.88	7.65e-09	1.42e-06	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43948484	chr1:43944370~43946551:-
THCA	cis	rs12497850	0.931	rs6446196	ENSG00000229759.1	MRPS18AP1	5.88	7.65e-09	1.42e-06	0.35	0.26	Parkinson's disease;	chr3:48967290	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.805	rs6446198	ENSG00000229759.1	MRPS18AP1	5.88	7.65e-09	1.42e-06	0.35	0.26	Parkinson's disease;	chr3:48970205	chr3:48256350~48256938:-
THCA	cis	rs10129255	0.957	rs67625077	ENSG00000211974.3	IGHV2-70	5.88	7.65e-09	1.42e-06	0.2	0.26	Kawasaki disease;	chr14:106715436	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.869	rs72690553	ENSG00000211974.3	IGHV2-70	5.88	7.65e-09	1.42e-06	0.2	0.26	Kawasaki disease;	chr14:106715491	chr14:106723574~106724093:-
THCA	cis	rs12681366	0.708	rs1813167	ENSG00000253704.1	RP11-267M23.4	-5.88	7.65e-09	1.42e-06	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94336525	chr8:94553722~94569745:+
THCA	cis	rs67478160	0.643	rs8003653	ENSG00000258735.1	LINC00637	-5.88	7.65e-09	1.42e-06	-0.31	-0.26	Schizophrenia;	chr14:103832499	chr14:103847721~103858049:+
THCA	cis	rs4948275	0.773	rs2787738	ENSG00000237233.2	TMEM26-AS1	5.88	7.65e-09	1.43e-06	0.34	0.26	Night sleep phenotypes;	chr10:61493601	chr10:61452639~61481956:+
THCA	cis	rs12497850	0.931	rs7636057	ENSG00000229759.1	MRPS18AP1	5.88	7.66e-09	1.43e-06	0.35	0.26	Parkinson's disease;	chr3:48955149	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs7643368	ENSG00000229759.1	MRPS18AP1	5.88	7.66e-09	1.43e-06	0.35	0.26	Parkinson's disease;	chr3:48955422	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.866	rs6791234	ENSG00000229759.1	MRPS18AP1	5.88	7.66e-09	1.43e-06	0.35	0.26	Parkinson's disease;	chr3:48958704	chr3:48256350~48256938:-
THCA	cis	rs2765539	0.851	rs1325939	ENSG00000231365.4	RP11-418J17.1	5.88	7.66e-09	1.43e-06	0.29	0.26	Waist-hip ratio;	chr1:119041345	chr1:119140396~119275973:+
THCA	cis	rs748404	0.697	rs473554	ENSG00000166763.7	STRCP1	5.88	7.66e-09	1.43e-06	0.28	0.26	Lung cancer;	chr15:43276009	chr15:43699488~43718184:-
THCA	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-5.88	7.66e-09	1.43e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-5.88	7.66e-09	1.43e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-5.88	7.66e-09	1.43e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
THCA	cis	rs7493	0.853	rs17166879	ENSG00000233942.1	AC004012.1	5.88	7.66e-09	1.43e-06	0.4	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424103	chr7:95471835~95473998:+
THCA	cis	rs7267979	0.545	rs6050426	ENSG00000274414.1	RP5-965G21.4	-5.88	7.67e-09	1.43e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25197629	chr20:25239007~25245229:-
THCA	cis	rs9388451	0.868	rs1268083	ENSG00000226409.1	RP11-735G4.1	5.88	7.67e-09	1.43e-06	0.31	0.26	Brugada syndrome;	chr6:125727894	chr6:125370211~125374324:-
THCA	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	5.88	7.67e-09	1.43e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
THCA	cis	rs4713118	0.662	rs149947	ENSG00000272009.1	RP1-313I6.12	-5.88	7.67e-09	1.43e-06	-0.29	-0.26	Parkinson's disease;	chr6:28004655	chr6:28078792~28081130:-
THCA	cis	rs240993	0.516	rs1002481	ENSG00000230177.1	RP5-1112D6.4	-5.88	7.68e-09	1.43e-06	-0.31	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111390819	chr6:111277932~111278742:+
THCA	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	5.88	7.68e-09	1.43e-06	0.26	0.26	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
THCA	cis	rs16949788	1	rs9806600	ENSG00000261351.2	CTD-3185P2.1	-5.88	7.68e-09	1.43e-06	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66302109	chr15:66488658~66492109:-
THCA	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	5.88	7.68e-09	1.43e-06	0.29	0.26	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
THCA	cis	rs4908760	0.86	rs11121202	ENSG00000232912.4	RP5-1115A15.1	5.88	7.68e-09	1.43e-06	0.26	0.26	Vitiligo;	chr1:8579298	chr1:8424645~8434838:+
THCA	cis	rs10844706	0.699	rs10844635	ENSG00000256594.6	RP11-705C15.2	5.88	7.69e-09	1.43e-06	0.22	0.26	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735313	chr12:9633419~9658412:+
THCA	cis	rs10844706	0.699	rs10844637	ENSG00000256594.6	RP11-705C15.2	5.88	7.69e-09	1.43e-06	0.22	0.26	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735495	chr12:9633419~9658412:+
THCA	cis	rs10844706	0.699	rs10844638	ENSG00000256594.6	RP11-705C15.2	5.88	7.69e-09	1.43e-06	0.22	0.26	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735800	chr12:9633419~9658412:+
THCA	cis	rs5751614	0.62	rs1811017	ENSG00000230701.2	FBXW4P1	5.88	7.69e-09	1.43e-06	0.28	0.26	Height;	chr22:23264771	chr22:23262767~23265005:+
THCA	cis	rs6585424	1	rs35483545	ENSG00000225484.5	NUTM2B-AS1	-5.88	7.69e-09	1.43e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179417	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs34386571	ENSG00000225484.5	NUTM2B-AS1	-5.88	7.69e-09	1.43e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179676	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs12779955	ENSG00000225484.5	NUTM2B-AS1	5.88	7.69e-09	1.43e-06	0.42	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80181108	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs34162901	ENSG00000225484.5	NUTM2B-AS1	-5.88	7.69e-09	1.43e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187100	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs61860045	ENSG00000225484.5	NUTM2B-AS1	-5.88	7.69e-09	1.43e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187641	chr10:79663088~79826594:-
THCA	cis	rs7702057	0.53	rs17138850	ENSG00000271918.1	CTD-2287O16.5	5.88	7.69e-09	1.43e-06	0.29	0.26	Amyotrophic lateral sclerosis;	chr5:116085317	chr5:116083807~116085416:-
THCA	cis	rs16976116	0.901	rs3179664	ENSG00000279145.1	RP11-547D13.1	5.88	7.7e-09	1.43e-06	0.27	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55204655	chr15:55171972~55178175:-
THCA	cis	rs9878978	0.722	rs13074595	ENSG00000237990.3	CNTN4-AS1	5.88	7.71e-09	1.43e-06	0.32	0.26	Blood pressure (smoking interaction);	chr3:2460861	chr3:3039033~3069242:-
THCA	cis	rs1322639	0.571	rs13204417	ENSG00000261039.2	RP11-417E7.2	5.88	7.71e-09	1.43e-06	0.29	0.26	Pulse pressure;	chr6:169175260	chr6:169175304~169182740:-
THCA	cis	rs3950186	1	rs3950186	ENSG00000215124.2	RP3-420J14.1	5.88	7.71e-09	1.43e-06	0.29	0.26	Anxiety and major depressive disorder;	chr6:11811081	chr6:11861626~11862970:-
THCA	cis	rs6951245	0.706	rs1133116	ENSG00000229043.2	AC091729.9	-5.88	7.71e-09	1.43e-06	-0.43	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1160374~1165267:+
THCA	cis	rs2976388	0.59	rs3758082	ENSG00000253741.1	CTD-2292P10.4	5.88	7.72e-09	1.44e-06	0.34	0.26	Urinary tract infection frequency;	chr8:142743065	chr8:142702252~142726973:-
THCA	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	5.88	7.73e-09	1.44e-06	0.26	0.26	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
THCA	cis	rs7225151	0.71	rs112065650	ENSG00000234327.6	AC012146.7	-5.88	7.73e-09	1.44e-06	-0.3	-0.26	Alzheimer's disease (late onset);	chr17:5293114	chr17:5111468~5115004:+
THCA	cis	rs6840360	0.642	rs2709838	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2724580	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709834	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs6845648	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2724571	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709833	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.667	rs2709832	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709816	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs10454251	ENSG00000270265.1	RP11-731D1.4	-5.88	7.73e-09	1.44e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151333775~151353224:-
THCA	cis	rs2439831	0.867	rs7170489	ENSG00000275601.1	AC011330.13	-5.88	7.73e-09	1.44e-06	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43344453	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs16957630	ENSG00000275601.1	AC011330.13	-5.88	7.73e-09	1.44e-06	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43350582	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs16957632	ENSG00000275601.1	AC011330.13	-5.88	7.73e-09	1.44e-06	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43350699	chr15:43642389~43643023:-
THCA	cis	rs12893668	0.542	rs12884809	ENSG00000269940.1	RP11-73M18.7	5.88	7.73e-09	1.44e-06	0.27	0.26	Reticulocyte count;	chr14:103628983	chr14:103694560~103695170:+
THCA	cis	rs7267979	0.789	rs62213729	ENSG00000274973.1	RP13-401N8.7	5.88	7.73e-09	1.44e-06	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:25845497~25845862:+
THCA	cis	rs2976388	0.59	rs7828042	ENSG00000253741.1	CTD-2292P10.4	5.88	7.74e-09	1.44e-06	0.34	0.26	Urinary tract infection frequency;	chr8:142737965	chr8:142702252~142726973:-
THCA	cis	rs2303319	0.504	rs56100249	ENSG00000227403.1	AC009299.3	5.88	7.74e-09	1.44e-06	0.55	0.26	Cognitive function;	chr2:161558647	chr2:161244739~161249050:+
THCA	cis	rs317865	0.867	rs10034143	ENSG00000263327.5	TAPT1-AS1	-5.88	7.75e-09	1.44e-06	-0.43	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16158111	chr4:16226685~16320140:+
THCA	cis	rs2976388	0.59	rs10110970	ENSG00000253741.1	CTD-2292P10.4	5.88	7.76e-09	1.44e-06	0.34	0.26	Urinary tract infection frequency;	chr8:142738992	chr8:142702252~142726973:-
THCA	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-5.88	7.77e-09	1.45e-06	-0.47	-0.26	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
THCA	cis	rs10761482	0.5	rs10821790	ENSG00000254271.1	RP11-131N11.4	5.88	7.77e-09	1.45e-06	0.34	0.26	Schizophrenia;	chr10:60529009	chr10:60734342~60741828:+
THCA	cis	rs8014252	0.803	rs58777530	ENSG00000259158.2	ADAM20P1	-5.88	7.77e-09	1.45e-06	-0.33	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70534505	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.803	rs73282153	ENSG00000259158.2	ADAM20P1	-5.88	7.77e-09	1.45e-06	-0.33	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70535593	chr14:70468881~70483756:-
THCA	cis	rs73198271	0.751	rs617813	ENSG00000253893.2	FAM85B	5.88	7.78e-09	1.45e-06	0.35	0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8167819~8226614:-
THCA	cis	rs10491083	0.661	rs4796538	ENSG00000256806.3	C17orf100	-5.88	7.78e-09	1.45e-06	-0.44	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6666073	chr17:6651718~6653473:+
THCA	cis	rs442309	0.841	rs224044	ENSG00000238280.1	RP11-436D10.3	-5.88	7.78e-09	1.45e-06	-0.31	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62765310	chr10:62793562~62805887:-
THCA	cis	rs9880211	1	rs17364492	ENSG00000273486.1	RP11-731C17.2	-5.88	7.78e-09	1.45e-06	-0.27	-0.26	Height;Body mass index;	chr3:136485595	chr3:136837338~136839021:-
THCA	cis	rs7617773	1	rs6442108	ENSG00000228638.1	FCF1P2	5.88	7.8e-09	1.45e-06	0.25	0.26	Coronary artery disease;	chr3:48151469	chr3:48290793~48291375:-
THCA	cis	rs7617773	1	rs6442109	ENSG00000228638.1	FCF1P2	5.88	7.8e-09	1.45e-06	0.25	0.26	Coronary artery disease;	chr3:48151491	chr3:48290793~48291375:-
THCA	cis	rs2243480	1	rs313831	ENSG00000232546.1	RP11-458F8.1	-5.88	7.8e-09	1.45e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66086239	chr7:66848496~66858136:+
THCA	cis	rs67478160	0.643	rs8005594	ENSG00000258735.1	LINC00637	-5.88	7.8e-09	1.45e-06	-0.32	-0.26	Schizophrenia;	chr14:103813552	chr14:103847721~103858049:+
THCA	cis	rs9921338	0.886	rs4780363	ENSG00000262703.1	RP11-485G7.6	5.88	7.8e-09	1.45e-06	0.34	0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322034	chr16:11348143~11349321:-
THCA	cis	rs9381040	0.61	rs2235679	ENSG00000161912.16	ADCY10P1	5.88	7.81e-09	1.45e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41052838	chr6:41101022~41140835:+
THCA	cis	rs2562456	0.876	rs10424079	ENSG00000268555.1	RP11-678G14.3	5.88	7.81e-09	1.45e-06	0.42	0.26	Pain;	chr19:21406377	chr19:21570822~21587322:-
THCA	cis	rs7615952	0.673	rs115942855	ENSG00000241288.6	RP11-379B18.5	-5.88	7.81e-09	1.45e-06	-0.39	-0.26	Blood pressure (smoking interaction);	chr3:125883117	chr3:125827238~125916384:-
THCA	cis	rs6142102	0.961	rs6059651	ENSG00000275784.1	RP5-1125A11.6	-5.88	7.81e-09	1.45e-06	-0.28	-0.26	Skin pigmentation;	chr20:34057246	chr20:33989480~33991818:-
THCA	cis	rs6928977	0.5	rs719885	ENSG00000231028.7	LINC00271	-5.88	7.81e-09	1.45e-06	-0.21	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135618217	chr6:135497801~135716055:+
THCA	cis	rs934734	0.736	rs7559283	ENSG00000237979.1	AC007389.1	5.88	7.81e-09	1.45e-06	0.31	0.26	Rheumatoid arthritis;	chr2:65351234	chr2:65500993~65502138:-
THCA	cis	rs5751614	0.537	rs5759679	ENSG00000230701.2	FBXW4P1	5.88	7.84e-09	1.46e-06	0.29	0.26	Height;	chr22:23286826	chr22:23262767~23265005:+
THCA	cis	rs10029851	0.627	rs6821411	ENSG00000234492.4	RPL34-AS1	5.88	7.84e-09	1.46e-06	0.31	0.26	Amyotrophic lateral sclerosis (sporadic);	chr4:108618352	chr4:108538190~108620460:-
THCA	cis	rs17772222	0.917	rs1998670	ENSG00000222990.1	RNU4-22P	5.88	7.84e-09	1.46e-06	0.35	0.26	Coronary artery calcification;	chr14:88504581	chr14:88513498~88513663:+
THCA	cis	rs7824557	0.602	rs11784544	ENSG00000154316.13	TDH	-5.88	7.85e-09	1.46e-06	-0.19	-0.26	Retinal vascular caliber;	chr8:11346994	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.602	rs11781375	ENSG00000154316.13	TDH	-5.88	7.85e-09	1.46e-06	-0.19	-0.26	Retinal vascular caliber;	chr8:11347023	chr8:11339637~11368452:+
THCA	cis	rs2439831	0.85	rs28718261	ENSG00000166763.7	STRCP1	5.88	7.85e-09	1.46e-06	0.39	0.26	Lung cancer in ever smokers;	chr15:43751595	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs28595038	ENSG00000166763.7	STRCP1	5.88	7.85e-09	1.46e-06	0.39	0.26	Lung cancer in ever smokers;	chr15:43752661	chr15:43699488~43718184:-
THCA	cis	rs7824557	0.602	rs11784458	ENSG00000154316.13	TDH	-5.88	7.85e-09	1.46e-06	-0.19	-0.26	Retinal vascular caliber;	chr8:11346675	chr8:11339637~11368452:+
THCA	cis	rs7560272	0.682	rs2421546	ENSG00000163016.8	ALMS1P	-5.88	7.85e-09	1.46e-06	-0.34	-0.26	Schizophrenia;	chr2:73413949	chr2:73644919~73685576:+
THCA	cis	rs6479891	0.524	rs10740107	ENSG00000232075.1	MRPL35P2	-5.88	7.85e-09	1.46e-06	-0.44	-0.26	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63634317~63634827:-
THCA	cis	rs713477	0.967	rs4901568	ENSG00000258413.1	RP11-665C16.6	5.88	7.85e-09	1.46e-06	0.35	0.26	Pediatric bone mineral content (femoral neck);	chr14:55446071	chr14:55262767~55272075:-
THCA	cis	rs793571	0.505	rs9920042	ENSG00000259250.1	RP11-50C13.1	-5.88	7.85e-09	1.46e-06	-0.28	-0.26	Schizophrenia;	chr15:58609197	chr15:58587507~58591676:+
THCA	cis	rs7809950	1	rs10234355	ENSG00000238832.1	snoU109	-5.88	7.85e-09	1.46e-06	-0.28	-0.26	Coronary artery disease;	chr7:107446072	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs4727680	ENSG00000238832.1	snoU109	-5.88	7.85e-09	1.46e-06	-0.28	-0.26	Coronary artery disease;	chr7:107446962	chr7:107603363~107603507:+
THCA	cis	rs7809950	1	rs2395883	ENSG00000238832.1	snoU109	-5.88	7.85e-09	1.46e-06	-0.28	-0.26	Coronary artery disease;	chr7:107449225	chr7:107603363~107603507:+
THCA	cis	rs10266483	0.562	rs10949887	ENSG00000227986.1	TRIM60P18	-5.88	7.85e-09	1.46e-06	-0.25	-0.26	Response to statin therapy;	chr7:64291702	chr7:64355078~64356199:+
THCA	cis	rs10461617	0.617	rs6874733	ENSG00000271828.1	CTD-2310F14.1	5.88	7.85e-09	1.46e-06	0.37	0.26	Type 2 diabetes;	chr5:56773773	chr5:56927874~56929573:+
THCA	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	5.88	7.86e-09	1.46e-06	0.24	0.26	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
THCA	cis	rs7202877	0.706	rs37599	ENSG00000261783.1	RP11-252K23.2	5.88	7.87e-09	1.46e-06	0.46	0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75468234	chr16:75379818~75381260:-
THCA	cis	rs748404	0.697	rs531910	ENSG00000166763.7	STRCP1	5.88	7.87e-09	1.46e-06	0.28	0.26	Lung cancer;	chr15:43268409	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs492743	ENSG00000166763.7	STRCP1	5.88	7.87e-09	1.46e-06	0.28	0.26	Lung cancer;	chr15:43268747	chr15:43699488~43718184:-
THCA	cis	rs2915864	0.784	rs2961694	ENSG00000280047.1	CTC-463A16.1	-5.88	7.87e-09	1.46e-06	-0.37	-0.26	Facial morphology (factor 20);	chr5:142163786	chr5:142165767~142168387:+
THCA	cis	rs12908161	0.959	rs3748376	ENSG00000259295.5	CSPG4P12	5.88	7.87e-09	1.46e-06	0.4	0.26	Schizophrenia;	chr15:84785121	chr15:85191438~85213905:+
THCA	cis	rs11089937	0.609	rs2213158	ENSG00000211639.2	IGLV4-60	5.88	7.88e-09	1.46e-06	0.19	0.26	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.637	rs2213159	ENSG00000211639.2	IGLV4-60	5.88	7.88e-09	1.46e-06	0.19	0.26	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22162199~22162681:+
THCA	cis	rs2841233	0.681	rs2582558	ENSG00000258701.1	LINC00638	-5.88	7.88e-09	1.46e-06	-0.27	-0.26	IgG glycosylation;	chr14:104881151	chr14:104821201~104823718:+
THCA	cis	rs11158026	0.603	rs57667631	ENSG00000258413.1	RP11-665C16.6	-5.88	7.88e-09	1.46e-06	-0.37	-0.26	Parkinson's disease;	chr14:54976349	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.603	rs56335168	ENSG00000258413.1	RP11-665C16.6	-5.88	7.88e-09	1.46e-06	-0.37	-0.26	Parkinson's disease;	chr14:54978414	chr14:55262767~55272075:-
THCA	cis	rs853679	1	rs853685	ENSG00000226314.6	ZNF192P1	-5.88	7.88e-09	1.46e-06	-0.4	-0.26	Depression;	chr6:28321008	chr6:28161781~28169594:+
THCA	cis	rs4908768	0.501	rs11121186	ENSG00000232912.4	RP5-1115A15.1	5.88	7.88e-09	1.46e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8424645~8434838:+
THCA	cis	rs914615	0.552	rs7556304	ENSG00000225855.5	RUSC1-AS1	5.88	7.88e-09	1.46e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155167033	chr1:155316863~155324176:-
THCA	cis	rs961831	0.539	rs693370	ENSG00000234840.1	LINC01239	-5.88	7.88e-09	1.46e-06	-0.48	-0.26	Personality dimensions;	chr9:22446298	chr9:22646200~22824213:+
THCA	cis	rs17772222	0.917	rs17188046	ENSG00000258789.1	RP11-507K2.3	-5.88	7.88e-09	1.47e-06	-0.26	-0.26	Coronary artery calcification;	chr14:88624417	chr14:88551597~88552493:+
THCA	cis	rs7727544	0.582	rs10052046	ENSG00000233006.5	AC034220.3	5.88	7.89e-09	1.47e-06	0.2	0.26	Blood metabolite levels;	chr5:132208773	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.661	rs3763112	ENSG00000224431.1	AC063976.7	5.88	7.89e-09	1.47e-06	0.22	0.26	Breast cancer;	chr5:132250787	chr5:132199456~132203487:+
THCA	cis	rs4950322	0.58	rs17359629	ENSG00000278811.3	LINC00624	5.88	7.9e-09	1.47e-06	0.32	0.26	Protein quantitative trait loci;	chr1:147121537	chr1:147258885~147517875:-
THCA	cis	rs7115242	0.8	rs6589597	ENSG00000280143.1	AP000892.6	-5.88	7.9e-09	1.47e-06	-0.43	-0.26	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117204967~117210292:+
THCA	cis	rs67340775	0.834	rs13218875	ENSG00000226314.6	ZNF192P1	-5.88	7.91e-09	1.47e-06	-0.57	-0.26	Lung cancer in ever smokers;	chr6:27916234	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs67040724	ENSG00000226314.6	ZNF192P1	-5.88	7.91e-09	1.47e-06	-0.57	-0.26	Depression;	chr6:27937731	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs67662114	ENSG00000226314.6	ZNF192P1	-5.88	7.91e-09	1.47e-06	-0.57	-0.26	Depression;	chr6:27964523	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13216117	ENSG00000226314.6	ZNF192P1	-5.88	7.91e-09	1.47e-06	-0.57	-0.26	Depression;	chr6:27970706	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs36101351	ENSG00000226314.6	ZNF192P1	-5.88	7.91e-09	1.47e-06	-0.57	-0.26	Depression;	chr6:27975591	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs28360499	ENSG00000226314.6	ZNF192P1	-5.88	7.91e-09	1.47e-06	-0.57	-0.26	Depression;	chr6:27977618	chr6:28161781~28169594:+
THCA	cis	rs6545883	0.894	rs2167566	ENSG00000271889.1	RP11-493E12.1	5.88	7.91e-09	1.47e-06	0.25	0.26	Tuberculosis;	chr2:61292273	chr2:61151433~61162105:-
THCA	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	5.88	7.91e-09	1.47e-06	0.27	0.26	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
THCA	cis	rs12612619	0.732	rs11679681	ENSG00000229122.1	AGBL5-IT1	5.88	7.91e-09	1.47e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27075611	chr2:27061038~27061815:+
THCA	cis	rs2765539	0.59	rs912960	ENSG00000231365.4	RP11-418J17.1	-5.88	7.91e-09	1.47e-06	-0.29	-0.26	Waist-hip ratio;	chr1:118935879	chr1:119140396~119275973:+
THCA	cis	rs758324	0.687	rs246351	ENSG00000237714.1	P4HA2-AS1	-5.88	7.91e-09	1.47e-06	-0.39	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132173578	chr5:132184876~132192808:+
THCA	cis	rs3213758	0.708	rs2111119	ENSG00000275191.1	RP11-36I17.2	5.88	7.92e-09	1.47e-06	0.45	0.26	Vitiligo (non-segmental);	chr16:53637842	chr16:53628256~53628816:-
THCA	cis	rs11158026	0.826	rs28417208	ENSG00000258413.1	RP11-665C16.6	-5.88	7.92e-09	1.47e-06	-0.35	-0.26	Parkinson's disease;	chr14:54887070	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.662	rs149901	ENSG00000220721.1	OR1F12	5.88	7.93e-09	1.47e-06	0.33	0.26	Parkinson's disease;	chr6:27997725	chr6:28073316~28074233:+
THCA	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	5.88	7.95e-09	1.48e-06	0.23	0.26	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
THCA	cis	rs10875746	0.859	rs11558768	ENSG00000269514.1	RP11-370I10.12	5.88	7.95e-09	1.48e-06	0.26	0.26	Longevity (90 years and older);	chr12:48184006	chr12:48198387~48202031:+
THCA	cis	rs3785574	0.962	rs2584623	ENSG00000240280.5	TCAM1P	-5.88	7.95e-09	1.48e-06	-0.36	-0.26	Height;	chr17:63829319	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs13030	ENSG00000240280.5	TCAM1P	-5.88	7.95e-09	1.48e-06	-0.36	-0.26	Height;	chr17:63831196	chr17:63849292~63864379:+
THCA	cis	rs853679	0.607	rs35001169	ENSG00000219392.1	RP1-265C24.5	-5.88	7.97e-09	1.48e-06	-0.58	-0.26	Depression;	chr6:28219854	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs35656932	ENSG00000219392.1	RP1-265C24.5	-5.88	7.97e-09	1.48e-06	-0.58	-0.26	Depression;	chr6:28223510	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13208096	ENSG00000219392.1	RP1-265C24.5	-5.88	7.97e-09	1.48e-06	-0.58	-0.26	Depression;	chr6:28257533	chr6:28115628~28116551:+
THCA	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	5.88	7.97e-09	1.48e-06	0.26	0.26	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
THCA	cis	rs3213958	0.509	rs55650073	ENSG00000249274.1	PDLIM1P4	-5.88	7.97e-09	1.48e-06	-0.35	-0.26	Blood protein levels;	chr3:98900476	chr3:98782188~98783193:+
THCA	cis	rs2120243	0.539	rs1869859	ENSG00000244515.1	KRT18P34	-5.88	7.97e-09	1.48e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157389973	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.508	rs1965246	ENSG00000244515.1	KRT18P34	-5.88	7.97e-09	1.48e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157393797	chr3:157162663~157163932:-
THCA	cis	rs10875746	0.587	rs9788082	ENSG00000269514.1	RP11-370I10.12	5.88	7.97e-09	1.48e-06	0.28	0.26	Longevity (90 years and older);	chr12:48358273	chr12:48198387~48202031:+
THCA	cis	rs412050	1	rs239919	ENSG00000224086.5	LL22NC03-86G7.1	-5.88	7.98e-09	1.48e-06	-0.41	-0.26	Attention deficit hyperactivity disorder;	chr22:21958756	chr22:21938293~21977632:+
THCA	cis	rs11651753	0.613	rs3096	ENSG00000264920.1	RP11-6N17.4	-5.88	7.98e-09	1.48e-06	-0.23	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47952066	chr17:47891255~47895812:-
THCA	cis	rs9910055	0.762	rs227579	ENSG00000267080.4	ASB16-AS1	5.88	7.99e-09	1.48e-06	0.24	0.26	Total body bone mineral density;	chr17:44145766	chr17:44175973~44186717:-
THCA	cis	rs7294478	0.648	rs2290237	ENSG00000205885.6	C1RL-AS1	5.88	7.99e-09	1.48e-06	0.19	0.26	Neuritic plaque;	chr12:7124640	chr12:7108052~7122501:+
THCA	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	5.88	7.99e-09	1.48e-06	0.33	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
THCA	cis	rs2029362	0.513	rs10767667	ENSG00000245573.6	BDNF-AS	5.88	7.99e-09	1.48e-06	0.21	0.26	Total body bone mineral density;	chr11:27725002	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.513	rs7931247	ENSG00000245573.6	BDNF-AS	5.88	7.99e-09	1.48e-06	0.21	0.26	Total body bone mineral density;	chr11:27725444	chr11:27506838~27698174:+
THCA	cis	rs4950322	0.58	rs7515160	ENSG00000278811.3	LINC00624	5.88	7.99e-09	1.48e-06	0.32	0.26	Protein quantitative trait loci;	chr1:147120714	chr1:147258885~147517875:-
THCA	cis	rs2018683	0.707	rs917216	ENSG00000228421.2	AC005013.5	5.88	8.01e-09	1.49e-06	0.3	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931855	chr7:28957667~28959345:+
THCA	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	5.87	8.01e-09	1.49e-06	0.37	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
THCA	cis	rs755249	0.614	rs10888798	ENSG00000182109.6	RP11-69E11.4	-5.87	8.02e-09	1.49e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39492408	chr1:39522280~39546187:-
THCA	cis	rs748404	0.666	rs8027748	ENSG00000249839.1	AC011330.5	-5.87	8.03e-09	1.49e-06	-0.37	-0.26	Lung cancer;	chr15:43447622	chr15:43663654~43684339:-
THCA	cis	rs412050	1	rs239916	ENSG00000224086.5	LL22NC03-86G7.1	-5.87	8.04e-09	1.49e-06	-0.41	-0.26	Attention deficit hyperactivity disorder;	chr22:21961900	chr22:21938293~21977632:+
THCA	cis	rs71520386	0.607	rs28660425	ENSG00000228649.7	AC005682.5	-5.87	8.05e-09	1.49e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22818532	chr7:22854178~22861579:+
THCA	cis	rs5751614	0.62	rs5759669	ENSG00000230701.2	FBXW4P1	5.87	8.05e-09	1.49e-06	0.27	0.26	Height;	chr22:23267313	chr22:23262767~23265005:+
THCA	cis	rs5751614	0.56	rs9612269	ENSG00000230701.2	FBXW4P1	5.87	8.05e-09	1.49e-06	0.27	0.26	Height;	chr22:23269170	chr22:23262767~23265005:+
THCA	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	5.87	8.05e-09	1.49e-06	0.32	0.26	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
THCA	cis	rs890448	0.796	rs293200	ENSG00000254531.1	FLJ20021	5.87	8.06e-09	1.5e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101403113	chr4:101347780~101348883:+
THCA	cis	rs595244	0.908	rs689304	ENSG00000259705.1	RP11-227D13.1	5.87	8.06e-09	1.5e-06	0.49	0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48630163	chr15:48645951~48652016:+
THCA	cis	rs6928977	0.5	rs11154810	ENSG00000231028.7	LINC00271	5.87	8.06e-09	1.5e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629234	chr6:135497801~135716055:+
THCA	cis	rs6545883	0.929	rs12713436	ENSG00000271889.1	RP11-493E12.1	5.87	8.06e-09	1.5e-06	0.26	0.26	Tuberculosis;	chr2:61464125	chr2:61151433~61162105:-
THCA	cis	rs4947019	0.688	rs9480937	ENSG00000260273.1	RP11-425D10.10	-5.87	8.06e-09	1.5e-06	-0.67	-0.26	Hematological parameters;	chr6:109358629	chr6:109382795~109383666:+
THCA	cis	rs11148252	0.669	rs61958050	ENSG00000235660.1	LINC00345	-5.87	8.06e-09	1.5e-06	-0.35	-0.26	Lewy body disease;	chr13:52420292	chr13:52484161~52484680:-
THCA	cis	rs4948275	0.743	rs2787735	ENSG00000237233.2	TMEM26-AS1	-5.87	8.06e-09	1.5e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61490277	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.743	rs2650736	ENSG00000237233.2	TMEM26-AS1	-5.87	8.06e-09	1.5e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61490280	chr10:61452639~61481956:+
THCA	cis	rs9813712	0.953	rs6782280	ENSG00000228252.7	COL6A4P2	5.87	8.06e-09	1.5e-06	0.3	0.26	Response to amphetamines;	chr3:130245370	chr3:130212823~130273806:+
THCA	cis	rs853679	0.506	rs1150711	ENSG00000219392.1	RP1-265C24.5	-5.87	8.07e-09	1.5e-06	-0.29	-0.26	Depression;	chr6:28240757	chr6:28115628~28116551:+
THCA	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	5.87	8.07e-09	1.5e-06	0.35	0.26	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
THCA	cis	rs2243480	1	rs316315	ENSG00000232546.1	RP11-458F8.1	5.87	8.07e-09	1.5e-06	0.29	0.26	Diabetic kidney disease;	chr7:66126218	chr7:66848496~66858136:+
THCA	cis	rs9467773	1	rs6940188	ENSG00000124549.13	BTN2A3P	5.87	8.07e-09	1.5e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26421391~26432383:+
THCA	cis	rs9813712	0.574	rs11718032	ENSG00000249846.5	RP11-77P16.4	5.87	8.07e-09	1.5e-06	0.27	0.26	Response to amphetamines;	chr3:130257749	chr3:130112550~130120579:+
THCA	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	5.87	8.08e-09	1.5e-06	0.27	0.26	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	5.87	8.08e-09	1.5e-06	0.27	0.26	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
THCA	cis	rs6500550	1	rs6500550	ENSG00000276754.1	RP11-461A8.5	5.87	8.08e-09	1.5e-06	0.23	0.26	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3696240	chr16:3686998~3687380:+
THCA	cis	rs9467773	1	rs6940053	ENSG00000124549.13	BTN2A3P	5.87	8.08e-09	1.5e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26421391~26432383:+
THCA	cis	rs7809950	0.817	rs2712224	ENSG00000238832.1	snoU109	-5.87	8.09e-09	1.5e-06	-0.3	-0.26	Coronary artery disease;	chr7:107540790	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.861	rs10264412	ENSG00000238832.1	snoU109	-5.87	8.09e-09	1.5e-06	-0.3	-0.26	Coronary artery disease;	chr7:107543432	chr7:107603363~107603507:+
THCA	cis	rs853679	0.546	rs13214023	ENSG00000219392.1	RP1-265C24.5	5.87	8.09e-09	1.5e-06	0.51	0.26	Depression;	chr6:28364364	chr6:28115628~28116551:+
THCA	cis	rs78487399	0.808	rs76282560	ENSG00000234936.1	AC010883.5	5.87	8.1e-09	1.5e-06	0.37	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43455496	chr2:43229573~43233394:+
THCA	cis	rs12497850	0.931	rs13316620	ENSG00000229759.1	MRPS18AP1	5.87	8.1e-09	1.5e-06	0.35	0.26	Parkinson's disease;	chr3:49007922	chr3:48256350~48256938:-
THCA	cis	rs797680	0.786	rs1593512	ENSG00000223745.6	RP4-717I23.3	5.87	8.1e-09	1.5e-06	0.15	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93392817	chr1:93262186~93346025:-
THCA	cis	rs8177876	0.749	rs78707250	ENSG00000261061.1	RP11-303E16.2	-5.87	8.11e-09	1.5e-06	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81030770~81031485:+
THCA	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	5.87	8.12e-09	1.51e-06	0.32	0.26	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
THCA	cis	rs6545883	0.868	rs7608483	ENSG00000271889.1	RP11-493E12.1	5.87	8.12e-09	1.51e-06	0.25	0.26	Tuberculosis;	chr2:61609100	chr2:61151433~61162105:-
THCA	cis	rs2117029	0.898	rs10875914	ENSG00000258017.1	RP11-386G11.10	-5.87	8.12e-09	1.51e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49028311	chr12:49127782~49147869:+
THCA	cis	rs9393777	0.777	rs56114371	ENSG00000226314.6	ZNF192P1	-5.87	8.12e-09	1.51e-06	-0.57	-0.26	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28161781~28169594:+
THCA	cis	rs9467773	1	rs10214634	ENSG00000124549.13	BTN2A3P	5.87	8.13e-09	1.51e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26421391~26432383:+
THCA	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-5.87	8.13e-09	1.51e-06	-0.27	-0.26	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
THCA	cis	rs1552244	0.832	rs61056817	ENSG00000180385.7	EMC3-AS1	5.87	8.14e-09	1.51e-06	0.29	0.26	Alzheimer's disease;	chr3:9985957	chr3:9986893~10006990:+
THCA	cis	rs9467773	0.873	rs9295698	ENSG00000124549.13	BTN2A3P	5.87	8.14e-09	1.51e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26421391~26432383:+
THCA	cis	rs1865760	0.892	rs9379806	ENSG00000272462.2	U91328.19	-5.87	8.14e-09	1.51e-06	-0.22	-0.26	Height;	chr6:25940730	chr6:25992662~26001775:+
THCA	cis	rs2163813	1	rs247778	ENSG00000275540.1	CTC-559E9.12	-5.87	8.14e-09	1.51e-06	-0.32	-0.26	Toenail selenium levels;	chr19:19731244	chr19:19740884~19750127:+
THCA	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-5.87	8.14e-09	1.51e-06	-0.28	-0.26	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
THCA	cis	rs2303759	0.83	rs7257053	ENSG00000268686.1	AC010524.2	-5.87	8.15e-09	1.51e-06	-0.38	-0.26	Multiple sclerosis;	chr19:49391199	chr19:49368705~49388081:-
THCA	cis	rs6545883	0.929	rs2421203	ENSG00000271889.1	RP11-493E12.1	5.87	8.15e-09	1.51e-06	0.26	0.26	Tuberculosis;	chr2:61442113	chr2:61151433~61162105:-
THCA	cis	rs748404	0.666	rs16957715	ENSG00000249839.1	AC011330.5	-5.87	8.15e-09	1.51e-06	-0.37	-0.26	Lung cancer;	chr15:43416539	chr15:43663654~43684339:-
THCA	cis	rs12497850	0.931	rs7627404	ENSG00000229759.1	MRPS18AP1	5.87	8.16e-09	1.51e-06	0.35	0.26	Parkinson's disease;	chr3:48782235	chr3:48256350~48256938:-
THCA	cis	rs9381040	0.61	rs2057002	ENSG00000161912.16	ADCY10P1	5.87	8.16e-09	1.51e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41055223	chr6:41101022~41140835:+
THCA	cis	rs13287066	0.692	rs7031032	ENSG00000227603.1	RP11-165J3.6	5.87	8.17e-09	1.51e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr9:93412186	chr9:93435332~93437121:-
THCA	cis	rs12893668	0.703	rs729438	ENSG00000269910.1	RP11-73M18.10	-5.87	8.17e-09	1.51e-06	-0.25	-0.26	Reticulocyte count;	chr14:103626452	chr14:103694516~103695050:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000228409.4	CCT6P1	5.87	8.17e-09	1.52e-06	0.3	0.26	Diabetic kidney disease;	chr7:65924743	chr7:65751142~65763354:+
THCA	cis	rs7225151	0.614	rs56117162	ENSG00000234327.6	AC012146.7	-5.87	8.17e-09	1.52e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5279135	chr17:5111468~5115004:+
THCA	cis	rs2765539	0.561	rs2645290	ENSG00000231365.4	RP11-418J17.1	5.87	8.17e-09	1.52e-06	0.29	0.26	Waist-hip ratio;	chr1:118929285	chr1:119140396~119275973:+
THCA	cis	rs12612619	0.69	rs6754371	ENSG00000229122.1	AGBL5-IT1	5.87	8.18e-09	1.52e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092196	chr2:27061038~27061815:+
THCA	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	5.87	8.18e-09	1.52e-06	0.29	0.26	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
THCA	cis	rs6545883	0.965	rs3771258	ENSG00000271889.1	RP11-493E12.1	5.87	8.18e-09	1.52e-06	0.25	0.26	Tuberculosis;	chr2:61537005	chr2:61151433~61162105:-
THCA	cis	rs4908768	0.501	rs12061328	ENSG00000232912.4	RP5-1115A15.1	5.87	8.18e-09	1.52e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs6577488	ENSG00000232912.4	RP5-1115A15.1	5.87	8.18e-09	1.52e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs4351668	ENSG00000232912.4	RP5-1115A15.1	5.87	8.18e-09	1.52e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs7551849	ENSG00000232912.4	RP5-1115A15.1	5.87	8.18e-09	1.52e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8424645~8434838:+
THCA	cis	rs2337406	0.929	rs11847182	ENSG00000274576.2	IGHV2-70	-5.87	8.19e-09	1.52e-06	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106697724	chr14:106770577~106771020:-
THCA	cis	rs12893668	0.572	rs4900591	ENSG00000269910.1	RP11-73M18.10	5.87	8.19e-09	1.52e-06	0.24	0.26	Reticulocyte count;	chr14:103688541	chr14:103694516~103695050:-
THCA	cis	rs7005380	0.62	rs13250594	ENSG00000245330.4	KB-1471A8.1	5.87	8.19e-09	1.52e-06	0.25	0.26	Interstitial lung disease;	chr8:119894151	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs13259990	ENSG00000245330.4	KB-1471A8.1	5.87	8.19e-09	1.52e-06	0.25	0.26	Interstitial lung disease;	chr8:119894943	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs13260933	ENSG00000245330.4	KB-1471A8.1	5.87	8.19e-09	1.52e-06	0.25	0.26	Interstitial lung disease;	chr8:119895010	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs13261304	ENSG00000245330.4	KB-1471A8.1	5.87	8.19e-09	1.52e-06	0.25	0.26	Interstitial lung disease;	chr8:119895180	chr8:119867419~119874488:-
THCA	cis	rs763567	0.933	rs608930	ENSG00000271811.1	RP1-79C4.4	5.87	8.19e-09	1.52e-06	0.3	0.26	Tonsillectomy;	chr1:170648165	chr1:170667381~170669425:+
THCA	cis	rs2348418	0.83	rs4930821	ENSG00000247934.4	RP11-967K21.1	5.87	8.2e-09	1.52e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28410948	chr12:28163298~28190738:-
THCA	cis	rs712039	0.652	rs1616371	ENSG00000276054.1	RP11-378E13.3	5.87	8.2e-09	1.52e-06	0.39	0.26	Tuberculosis;	chr17:37413714	chr17:37386886~37387926:+
THCA	cis	rs1707322	0.752	rs6678444	ENSG00000281133.1	AL355480.3	-5.87	8.2e-09	1.52e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45580892~45580996:-
THCA	cis	rs3744061	0.776	rs9916811	ENSG00000267065.2	CTD-2246P4.1	-5.87	8.2e-09	1.52e-06	-0.35	-0.26	Retinal arteriolar caliber;	chr17:76753191	chr17:76799044~76807102:+
THCA	cis	rs7809950	0.678	rs982447	ENSG00000238832.1	snoU109	-5.87	8.2e-09	1.52e-06	-0.31	-0.26	Coronary artery disease;	chr7:107333089	chr7:107603363~107603507:+
THCA	cis	rs12893668	0.603	rs12896171	ENSG00000269910.1	RP11-73M18.10	5.87	8.2e-09	1.52e-06	0.24	0.26	Reticulocyte count;	chr14:103669629	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.572	rs12590968	ENSG00000269910.1	RP11-73M18.10	5.87	8.2e-09	1.52e-06	0.24	0.26	Reticulocyte count;	chr14:103670296	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.572	rs11540512	ENSG00000269910.1	RP11-73M18.10	5.87	8.2e-09	1.52e-06	0.24	0.26	Reticulocyte count;	chr14:103681040	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.572	rs35011804	ENSG00000269910.1	RP11-73M18.10	5.87	8.2e-09	1.52e-06	0.24	0.26	Reticulocyte count;	chr14:103685063	chr14:103694516~103695050:-
THCA	cis	rs2732480	0.5	rs12829841	ENSG00000240399.1	RP1-228P16.1	5.87	8.21e-09	1.52e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.523	rs34286639	ENSG00000240399.1	RP1-228P16.1	5.87	8.21e-09	1.52e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48054813~48055591:-
THCA	cis	rs1387259	0.929	rs11168484	ENSG00000240399.1	RP1-228P16.1	5.87	8.21e-09	1.52e-06	0.27	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48054813~48055591:-
THCA	cis	rs2235642	1	rs2235642	ENSG00000280231.1	LA16c-380F5.3	-5.87	8.21e-09	1.52e-06	-0.3	-0.26	Coronary artery disease;	chr16:1534865	chr16:1553655~1554130:-
THCA	cis	rs1387259	0.931	rs11168474	ENSG00000240399.1	RP1-228P16.1	5.87	8.21e-09	1.52e-06	0.27	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48054813~48055591:-
THCA	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	5.87	8.21e-09	1.52e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
THCA	cis	rs7646881	0.544	rs73024783	ENSG00000240207.5	RP11-379F4.4	-5.87	8.21e-09	1.52e-06	-0.37	-0.26	Tetralogy of Fallot;	chr3:158604426	chr3:158732263~158784070:+
THCA	cis	rs35538253	0.522	rs12934297	ENSG00000260886.1	TAT-AS1	5.87	8.21e-09	1.52e-06	0.51	0.26	Post bronchodilator FEV1;	chr16:71988922	chr16:71565789~71578187:+
THCA	cis	rs5742933	0.948	rs5743063	ENSG00000253559.1	OSGEPL1-AS1	5.87	8.21e-09	1.52e-06	0.3	0.26	Ferritin levels;	chr2:189829723	chr2:189762704~189765556:+
THCA	cis	rs3002142	0.658	rs3008634	ENSG00000272750.1	RP11-378J18.8	5.87	8.22e-09	1.52e-06	0.4	0.26	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:222658867~222661512:-
THCA	cis	rs1707322	0.647	rs6686944	ENSG00000281133.1	AL355480.3	-5.87	8.22e-09	1.52e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45580892~45580996:-
THCA	cis	rs7512898	0.545	rs10800729	ENSG00000260088.1	RP11-92G12.3	-5.87	8.23e-09	1.53e-06	-0.32	-0.26	Electrocardiographic conduction measures;	chr1:200732620	chr1:200669507~200694250:+
THCA	cis	rs2921073	0.509	rs2976931	ENSG00000254153.1	CTA-398F10.2	-5.87	8.23e-09	1.53e-06	-0.27	-0.26	Parkinson's disease;	chr8:8399807	chr8:8456909~8461337:-
THCA	cis	rs10029851	0.627	rs17512211	ENSG00000234492.4	RPL34-AS1	5.87	8.23e-09	1.53e-06	0.31	0.26	Amyotrophic lateral sclerosis (sporadic);	chr4:108607724	chr4:108538190~108620460:-
THCA	cis	rs6993270	0.725	rs59559961	ENSG00000245330.4	KB-1471A8.1	-5.87	8.23e-09	1.53e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119907410	chr8:119867419~119874488:-
THCA	cis	rs7302981	0.746	rs2272391	ENSG00000272368.2	RP4-605O3.4	-5.87	8.23e-09	1.53e-06	-0.15	-0.26	Systolic blood pressure;	chr12:50077847	chr12:50112197~50165618:+
THCA	cis	rs9543976	0.614	rs55983304	ENSG00000261553.4	RP11-29G8.3	-5.87	8.23e-09	1.53e-06	-0.41	-0.26	Diabetic retinopathy;	chr13:75511037	chr13:75549773~75807120:+
THCA	cis	rs9467773	1	rs9467783	ENSG00000124549.13	BTN2A3P	5.87	8.24e-09	1.53e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26421391~26432383:+
THCA	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-5.87	8.24e-09	1.53e-06	-0.48	-0.26	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
THCA	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-5.87	8.24e-09	1.53e-06	-0.24	-0.26	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
THCA	cis	rs12893668	0.572	rs7148857	ENSG00000269910.1	RP11-73M18.10	5.87	8.24e-09	1.53e-06	0.24	0.26	Reticulocyte count;	chr14:103676900	chr14:103694516~103695050:-
THCA	cis	rs111315781	1	rs111315781	ENSG00000183308.6	AC005037.3	5.87	8.24e-09	1.53e-06	0.45	0.26	Triptolide cytotoxicity;	chr2:200874001	chr2:200963263~201009102:+
THCA	cis	rs3950186	1	rs6910363	ENSG00000215124.2	RP3-420J14.1	5.87	8.24e-09	1.53e-06	0.29	0.26	Anxiety and major depressive disorder;	chr6:11809134	chr6:11861626~11862970:-
THCA	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	5.87	8.25e-09	1.53e-06	0.33	0.26	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
THCA	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	5.87	8.25e-09	1.53e-06	0.33	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
THCA	cis	rs2115536	1	rs2115536	ENSG00000278600.1	RP11-81A1.6	-5.87	8.25e-09	1.53e-06	-0.16	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79901905	chr15:79920195~79922455:-
THCA	cis	rs7246657	0.55	rs9941475	ENSG00000267422.1	CTD-2554C21.1	-5.87	8.26e-09	1.53e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37573615	chr19:37779686~37792865:+
THCA	cis	rs875971	0.83	rs427973	ENSG00000232559.3	GS1-124K5.12	5.87	8.26e-09	1.53e-06	0.26	0.26	Aortic root size;	chr7:66061661	chr7:66554588~66576923:-
THCA	cis	rs7760535	0.763	rs10457241	ENSG00000271789.1	RP5-1112D6.7	-5.87	8.26e-09	1.53e-06	-0.25	-0.26	Metabolic traits;	chr6:111527831	chr6:111297126~111298510:+
THCA	cis	rs2145598	1	rs2145598	ENSG00000279636.2	LINC00216	-5.87	8.26e-09	1.53e-06	-0.25	-0.26	Coronary artery disease;	chr14:58327283	chr14:58288033~58289158:+
THCA	cis	rs2145598	1	rs10137475	ENSG00000279636.2	LINC00216	-5.87	8.26e-09	1.53e-06	-0.25	-0.26	Coronary artery disease;	chr14:58331235	chr14:58288033~58289158:+
THCA	cis	rs172166	0.694	rs2791332	ENSG00000226314.6	ZNF192P1	-5.87	8.27e-09	1.53e-06	-0.32	-0.26	Cardiac Troponin-T levels;	chr6:28141010	chr6:28161781~28169594:+
THCA	cis	rs9393777	0.92	rs72839445	ENSG00000226314.6	ZNF192P1	-5.87	8.27e-09	1.53e-06	-0.59	-0.26	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28161781~28169594:+
THCA	cis	rs748404	0.666	rs34178146	ENSG00000249839.1	AC011330.5	-5.87	8.27e-09	1.53e-06	-0.37	-0.26	Lung cancer;	chr15:43384406	chr15:43663654~43684339:-
THCA	cis	rs9595908	0.965	rs7318297	ENSG00000212293.1	SNORA16	5.87	8.27e-09	1.53e-06	0.32	0.26	Body mass index;	chr13:32563835	chr13:32420390~32420516:-
THCA	cis	rs2880765	0.566	rs12911430	ENSG00000259630.2	CTD-2262B20.1	-5.87	8.27e-09	1.53e-06	-0.31	-0.26	Coronary artery disease;	chr15:85468033	chr15:85415228~85415633:+
THCA	cis	rs9402743	0.775	rs6916924	ENSG00000231028.7	LINC00271	-5.87	8.28e-09	1.53e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135656563	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs6916825	ENSG00000231028.7	LINC00271	-5.87	8.28e-09	1.53e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135656739	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs6917005	ENSG00000231028.7	LINC00271	-5.87	8.28e-09	1.53e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135656842	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs9494320	ENSG00000231028.7	LINC00271	-5.87	8.28e-09	1.53e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135657576	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs2068394	ENSG00000231028.7	LINC00271	-5.87	8.28e-09	1.53e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135658279	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs9494321	ENSG00000231028.7	LINC00271	-5.87	8.28e-09	1.53e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135658892	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.781	rs6935190	ENSG00000231028.7	LINC00271	-5.87	8.28e-09	1.53e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135659553	chr6:135497801~135716055:+
THCA	cis	rs13256369	0.802	rs11995449	ENSG00000253893.2	FAM85B	-5.87	8.28e-09	1.53e-06	-0.36	-0.26	Obesity-related traits;	chr8:8702388	chr8:8167819~8226614:-
THCA	cis	rs1865760	0.786	rs1436308	ENSG00000272462.2	U91328.19	-5.87	8.28e-09	1.53e-06	-0.22	-0.26	Height;	chr6:25939339	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.929	rs1436307	ENSG00000272462.2	U91328.19	-5.87	8.28e-09	1.53e-06	-0.22	-0.26	Height;	chr6:25939495	chr6:25992662~26001775:+
THCA	cis	rs6993270	0.779	rs112325385	ENSG00000245330.4	KB-1471A8.1	-5.87	8.29e-09	1.54e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119904415	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.725	rs76299830	ENSG00000245330.4	KB-1471A8.1	-5.87	8.29e-09	1.54e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119905727	chr8:119867419~119874488:-
THCA	cis	rs7809950	1	rs28714607	ENSG00000238832.1	snoU109	-5.87	8.3e-09	1.54e-06	-0.28	-0.26	Coronary artery disease;	chr7:107465808	chr7:107603363~107603507:+
THCA	cis	rs2487032	0.573	rs2164560	ENSG00000226334.1	RP11-217B7.2	-5.87	8.31e-09	1.54e-06	-0.36	-0.26	Glaucoma (high intraocular pressure);	chr9:104945072	chr9:104927553~104928892:+
THCA	cis	rs8072100	0.576	rs7216112	ENSG00000228782.6	CTD-2026D20.3	-5.87	8.32e-09	1.54e-06	-0.25	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47450568~47492492:-
THCA	cis	rs113835537	0.597	rs11227523	ENSG00000255517.5	CTD-3074O7.5	-5.87	8.32e-09	1.54e-06	-0.23	-0.26	Airway imaging phenotypes;	chr11:66538467	chr11:66473490~66480233:-
THCA	cis	rs1707322	0.721	rs7519900	ENSG00000281133.1	AL355480.3	-5.87	8.33e-09	1.54e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45580892~45580996:-
THCA	cis	rs9813712	0.597	rs1453255	ENSG00000249846.5	RP11-77P16.4	-5.87	8.33e-09	1.54e-06	-0.26	-0.26	Response to amphetamines;	chr3:130258815	chr3:130112550~130120579:+
THCA	cis	rs812925	0.826	rs2694633	ENSG00000271889.1	RP11-493E12.1	-5.87	8.34e-09	1.54e-06	-0.27	-0.26	Immature fraction of reticulocytes;	chr2:61313507	chr2:61151433~61162105:-
THCA	cis	rs2732480	0.5	rs7315820	ENSG00000240399.1	RP1-228P16.1	5.87	8.34e-09	1.55e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48054813~48055591:-
THCA	cis	rs11158026	0.603	rs66769866	ENSG00000258413.1	RP11-665C16.6	-5.87	8.34e-09	1.55e-06	-0.37	-0.26	Parkinson's disease;	chr14:54979435	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.603	rs67571433	ENSG00000258413.1	RP11-665C16.6	-5.87	8.34e-09	1.55e-06	-0.37	-0.26	Parkinson's disease;	chr14:54981264	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.603	rs7151670	ENSG00000258413.1	RP11-665C16.6	-5.87	8.34e-09	1.55e-06	-0.37	-0.26	Parkinson's disease;	chr14:54986041	chr14:55262767~55272075:-
THCA	cis	rs748404	0.697	rs530683	ENSG00000166763.7	STRCP1	-5.87	8.35e-09	1.55e-06	-0.28	-0.26	Lung cancer;	chr15:43276801	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs10438303	ENSG00000166763.7	STRCP1	5.87	8.35e-09	1.55e-06	0.39	0.26	Lung cancer in ever smokers;	chr15:43724219	chr15:43699488~43718184:-
THCA	cis	rs6951245	0.554	rs75075857	ENSG00000229043.2	AC091729.9	-5.87	8.35e-09	1.55e-06	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-5.87	8.35e-09	1.55e-06	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
THCA	cis	rs5758659	0.904	rs134877	ENSG00000270083.1	RP1-257I20.14	5.87	8.35e-09	1.55e-06	0.27	0.26	Cognitive function;	chr22:42266365	chr22:42089630~42090028:-
THCA	cis	rs728616	0.867	rs7080405	ENSG00000242600.5	MBL1P	5.87	8.36e-09	1.55e-06	0.36	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142187	chr10:79904898~79950336:+
THCA	cis	rs7005380	0.62	rs28669275	ENSG00000245330.4	KB-1471A8.1	5.87	8.36e-09	1.55e-06	0.25	0.26	Interstitial lung disease;	chr8:119889713	chr8:119867419~119874488:-
THCA	cis	rs950169	0.84	rs12905223	ENSG00000259295.5	CSPG4P12	5.87	8.37e-09	1.55e-06	0.4	0.26	Schizophrenia;	chr15:84571037	chr15:85191438~85213905:+
THCA	cis	rs797680	0.786	rs1559828	ENSG00000223745.6	RP4-717I23.3	5.87	8.37e-09	1.55e-06	0.15	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93360081	chr1:93262186~93346025:-
THCA	cis	rs2179367	0.6	rs9498356	ENSG00000231760.4	RP11-350J20.5	5.87	8.37e-09	1.55e-06	0.41	0.26	Dupuytren's disease;	chr6:149443337	chr6:149796151~149826294:-
THCA	cis	rs180730	0.66	rs10857075	ENSG00000251609.2	SETP12	-5.87	8.38e-09	1.55e-06	-0.44	-0.26	Fasting plasma glucose;	chr4:120930300	chr4:120895494~120897083:-
THCA	cis	rs180730	0.66	rs10857076	ENSG00000251609.2	SETP12	-5.87	8.38e-09	1.55e-06	-0.44	-0.26	Fasting plasma glucose;	chr4:120930379	chr4:120895494~120897083:-
THCA	cis	rs9381040	0.61	rs9381028	ENSG00000161912.16	ADCY10P1	5.87	8.39e-09	1.55e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41057342	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs9357345	ENSG00000161912.16	ADCY10P1	5.87	8.39e-09	1.55e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41057379	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs2268191	ENSG00000161912.16	ADCY10P1	5.87	8.39e-09	1.55e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41059914	chr6:41101022~41140835:+
THCA	cis	rs853679	0.882	rs9461432	ENSG00000272009.1	RP1-313I6.12	-5.87	8.39e-09	1.55e-06	-0.38	-0.26	Depression;	chr6:28119105	chr6:28078792~28081130:-
THCA	cis	rs11671005	0.735	rs12981875	ENSG00000269473.1	CTD-2619J13.19	5.87	8.39e-09	1.55e-06	0.3	0.26	Mean platelet volume;	chr19:58423763	chr19:58440448~58445849:+
THCA	cis	rs12497850	0.863	rs4974084	ENSG00000229759.1	MRPS18AP1	5.87	8.39e-09	1.55e-06	0.35	0.26	Parkinson's disease;	chr3:48901647	chr3:48256350~48256938:-
THCA	cis	rs4650994	0.524	rs2811299	ENSG00000273384.1	RP5-1098D14.1	-5.87	8.39e-09	1.55e-06	-0.33	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178617242	chr1:178651706~178652282:+
THCA	cis	rs7615952	0.546	rs2979306	ENSG00000243429.1	OR7E29P	5.87	8.4e-09	1.56e-06	0.37	0.26	Blood pressure (smoking interaction);	chr3:125593286	chr3:125712139~125713045:+
THCA	cis	rs7267979	0.753	rs404148	ENSG00000274973.1	RP13-401N8.7	-5.87	8.41e-09	1.56e-06	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:25845497~25845862:+
THCA	cis	rs10276381	1	rs10281214	ENSG00000234336.5	JAZF1-AS1	-5.87	8.41e-09	1.56e-06	-0.37	-0.26	Crohn's disease;	chr7:28145925	chr7:28180322~28243917:+
THCA	cis	rs73607972	0.866	rs16952362	ENSG00000275191.1	RP11-36I17.2	-5.87	8.41e-09	1.56e-06	-0.43	-0.26	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53603976	chr16:53628256~53628816:-
THCA	cis	rs7512898	0.545	rs7512279	ENSG00000260088.1	RP11-92G12.3	-5.87	8.41e-09	1.56e-06	-0.32	-0.26	Electrocardiographic conduction measures;	chr1:200733210	chr1:200669507~200694250:+
THCA	cis	rs9926296	0.744	rs6860	ENSG00000274627.1	RP11-104N10.2	5.87	8.41e-09	1.56e-06	0.27	0.26	Vitiligo;	chr16:89644712	chr16:89516797~89522217:+
THCA	cis	rs4713118	0.628	rs12179134	ENSG00000219392.1	RP1-265C24.5	-5.87	8.41e-09	1.56e-06	-0.39	-0.26	Parkinson's disease;	chr6:27707690	chr6:28115628~28116551:+
THCA	cis	rs10043228	0.702	rs2068456	ENSG00000248445.4	SEMA6A-AS1	-5.87	8.41e-09	1.56e-06	-0.29	-0.26	Asthma or chronic obstructive pulmonary disease;	chr5:116291873	chr5:116447547~116508276:+
THCA	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	5.87	8.41e-09	1.56e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
THCA	cis	rs1865760	0.82	rs9348697	ENSG00000272462.2	U91328.19	-5.87	8.42e-09	1.56e-06	-0.22	-0.26	Height;	chr6:25890606	chr6:25992662~26001775:+
THCA	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-5.87	8.42e-09	1.56e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
THCA	cis	rs150992	0.569	rs326482	ENSG00000248489.1	CTD-2007H13.3	5.87	8.42e-09	1.56e-06	0.27	0.26	Body mass index;	chr5:98951115	chr5:98929171~98995013:+
THCA	cis	rs9926296	0.624	rs1110331	ENSG00000260259.1	RP11-368I7.4	5.87	8.42e-09	1.56e-06	0.27	0.26	Vitiligo;	chr16:89707988	chr16:89682620~89686569:-
THCA	cis	rs6968419	0.642	rs67251819	ENSG00000237870.5	AC073130.1	5.87	8.43e-09	1.56e-06	0.29	0.26	Intraocular pressure;	chr7:116265532	chr7:116275606~116286734:-
THCA	cis	rs9921338	0.961	rs7202814	ENSG00000262636.1	CTD-3088G3.4	-5.87	8.43e-09	1.56e-06	-0.38	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11295917	chr16:11380859~11381118:-
THCA	cis	rs763121	0.925	rs5757165	ENSG00000273076.1	RP3-508I15.22	5.87	8.44e-09	1.56e-06	0.25	0.26	Menopause (age at onset);	chr22:38598572	chr22:38743495~38743910:+
THCA	cis	rs17655730	0.52	rs2178798	ENSG00000277290.1	RP11-326C3.16	-5.87	8.44e-09	1.56e-06	-0.26	-0.26	Mean platelet volume;	chr11:254869	chr11:243099~243483:-
THCA	cis	rs67478160	0.644	rs7159810	ENSG00000258735.1	LINC00637	-5.87	8.44e-09	1.56e-06	-0.31	-0.26	Schizophrenia;	chr14:103827780	chr14:103847721~103858049:+
THCA	cis	rs2562456	0.876	rs2359144	ENSG00000268555.1	RP11-678G14.3	5.87	8.44e-09	1.56e-06	0.42	0.26	Pain;	chr19:21407834	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.876	rs4638726	ENSG00000268555.1	RP11-678G14.3	5.87	8.44e-09	1.56e-06	0.42	0.26	Pain;	chr19:21409710	chr19:21570822~21587322:-
THCA	cis	rs71520386	0.607	rs28617621	ENSG00000228649.7	AC005682.5	-5.87	8.44e-09	1.56e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22818063	chr7:22854178~22861579:+
THCA	cis	rs2243480	1	rs2707844	ENSG00000232546.1	RP11-458F8.1	-5.87	8.45e-09	1.56e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66594522	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1796220	ENSG00000232546.1	RP11-458F8.1	-5.87	8.45e-09	1.56e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66597113	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs2707831	ENSG00000232546.1	RP11-458F8.1	-5.87	8.45e-09	1.56e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66597524	chr7:66848496~66858136:+
THCA	cis	rs7646881	0.544	rs16829116	ENSG00000240207.5	RP11-379F4.4	-5.87	8.45e-09	1.56e-06	-0.37	-0.26	Tetralogy of Fallot;	chr3:158570012	chr3:158732263~158784070:+
THCA	cis	rs2559856	1	rs2251187	ENSG00000274560.1	RP11-285E23.2	5.87	8.45e-09	1.56e-06	0.16	0.26	Blood protein levels;	chr12:101688111	chr12:101696002~101696450:-
THCA	cis	rs2559856	0.967	rs2695297	ENSG00000274560.1	RP11-285E23.2	5.87	8.45e-09	1.56e-06	0.16	0.26	Blood protein levels;	chr12:101688440	chr12:101696002~101696450:-
THCA	cis	rs2559856	1	rs2695298	ENSG00000274560.1	RP11-285E23.2	5.87	8.45e-09	1.56e-06	0.16	0.26	Blood protein levels;	chr12:101688811	chr12:101696002~101696450:-
THCA	cis	rs28386778	0.769	rs6504179	ENSG00000240280.5	TCAM1P	-5.87	8.46e-09	1.57e-06	-0.37	-0.26	Prudent dietary pattern;	chr17:63735635	chr17:63849292~63864379:+
THCA	cis	rs7829975	0.514	rs2976929	ENSG00000254153.1	CTA-398F10.2	-5.87	8.46e-09	1.57e-06	-0.27	-0.26	Mood instability;	chr8:8401202	chr8:8456909~8461337:-
THCA	cis	rs763121	0.888	rs2235229	ENSG00000235209.1	CTA-150C2.13	5.87	8.46e-09	1.57e-06	0.33	0.26	Menopause (age at onset);	chr22:38728907	chr22:38921227~38924708:+
THCA	cis	rs3213758	0.541	rs8056869	ENSG00000275191.1	RP11-36I17.2	-5.87	8.47e-09	1.57e-06	-0.37	-0.26	Vitiligo (non-segmental);	chr16:53653467	chr16:53628256~53628816:-
THCA	cis	rs10895275	0.649	rs4561174	ENSG00000277459.1	RP11-732A21.3	-5.87	8.47e-09	1.57e-06	-0.2	-0.26	Migraine;	chr11:102165644	chr11:102109827~102110457:-
THCA	cis	rs9381040	0.61	rs6940462	ENSG00000161912.16	ADCY10P1	5.87	8.47e-09	1.57e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41052484	chr6:41101022~41140835:+
THCA	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	5.87	8.47e-09	1.57e-06	0.33	0.26	Height;	chr4:55489895	chr4:55363971~55395847:-
THCA	cis	rs9402743	0.775	rs7742843	ENSG00000231028.7	LINC00271	-5.87	8.48e-09	1.57e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135654681	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs9494319	ENSG00000231028.7	LINC00271	-5.87	8.48e-09	1.57e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135655122	chr6:135497801~135716055:+
THCA	cis	rs9813712	0.595	rs1453238	ENSG00000253540.4	FAM86HP	5.87	8.48e-09	1.57e-06	0.28	0.26	Response to amphetamines;	chr3:130290494	chr3:130099092~130111472:-
THCA	cis	rs3764400	0.567	rs12600980	ENSG00000278765.1	RP5-890E16.5	-5.86	8.48e-09	1.57e-06	-0.46	-0.26	Body mass index;	chr17:48109779	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs9890691	ENSG00000278765.1	RP5-890E16.5	-5.86	8.48e-09	1.57e-06	-0.46	-0.26	Body mass index;	chr17:48115574	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs8071199	ENSG00000278765.1	RP5-890E16.5	-5.86	8.48e-09	1.57e-06	-0.46	-0.26	Body mass index;	chr17:48117973	chr17:48066704~48067293:-
THCA	cis	rs6993270	0.779	rs111486708	ENSG00000245330.4	KB-1471A8.1	-5.86	8.49e-09	1.57e-06	-0.34	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119917454	chr8:119867419~119874488:-
THCA	cis	rs12893668	0.572	rs1606	ENSG00000269910.1	RP11-73M18.10	5.86	8.49e-09	1.57e-06	0.24	0.26	Reticulocyte count;	chr14:103694944	chr14:103694516~103695050:-
THCA	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	5.86	8.49e-09	1.57e-06	0.33	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
THCA	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-5.86	8.5e-09	1.57e-06	-0.25	-0.26	Height;	chr2:46627225	chr2:46668870~46670778:+
THCA	cis	rs6740322	0.895	rs9309097	ENSG00000234936.1	AC010883.5	5.86	8.5e-09	1.57e-06	0.28	0.26	Coronary artery disease;	chr2:43327258	chr2:43229573~43233394:+
THCA	cis	rs6740322	0.841	rs10210507	ENSG00000234936.1	AC010883.5	5.86	8.5e-09	1.57e-06	0.28	0.26	Coronary artery disease;	chr2:43329497	chr2:43229573~43233394:+
THCA	cis	rs6928977	0.896	rs9321501	ENSG00000231028.7	LINC00271	5.86	8.51e-09	1.57e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320279	chr6:135497801~135716055:+
THCA	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-5.86	8.51e-09	1.57e-06	-0.26	-0.26	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
THCA	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	5.86	8.51e-09	1.57e-06	0.33	0.26	Height;	chr4:55561053	chr4:55363971~55395847:-
THCA	cis	rs4748857	0.685	rs17543456	ENSG00000224215.1	RP11-371A19.2	-5.86	8.52e-09	1.58e-06	-0.37	-0.26	Systemic lupus erythematosus;	chr10:23250274	chr10:23343957~23345181:+
THCA	cis	rs2439831	0.681	rs28578454	ENSG00000249839.1	AC011330.5	-5.86	8.52e-09	1.58e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43310834	chr15:43663654~43684339:-
THCA	cis	rs9595908	1	rs718444	ENSG00000212293.1	SNORA16	5.86	8.52e-09	1.58e-06	0.31	0.26	Body mass index;	chr13:32572915	chr13:32420390~32420516:-
THCA	cis	rs9595908	1	rs7332763	ENSG00000212293.1	SNORA16	5.86	8.52e-09	1.58e-06	0.31	0.26	Body mass index;	chr13:32573751	chr13:32420390~32420516:-
THCA	cis	rs9595908	1	rs9591134	ENSG00000212293.1	SNORA16	5.86	8.52e-09	1.58e-06	0.31	0.26	Body mass index;	chr13:32574079	chr13:32420390~32420516:-
THCA	cis	rs10208649	0.505	rs3770398	ENSG00000272156.1	RP11-477N3.1	5.86	8.53e-09	1.58e-06	0.36	0.26	Body mass index;	chr2:53739111	chr2:54082554~54085066:+
THCA	cis	rs7824557	0.602	rs7833966	ENSG00000154316.13	TDH	-5.86	8.53e-09	1.58e-06	-0.2	-0.26	Retinal vascular caliber;	chr8:11348711	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.568	rs35747588	ENSG00000154316.13	TDH	-5.86	8.53e-09	1.58e-06	-0.2	-0.26	Retinal vascular caliber;	chr8:11349118	chr8:11339637~11368452:+
THCA	cis	rs17772222	0.63	rs8017811	ENSG00000258983.2	RP11-507K2.2	-5.86	8.53e-09	1.58e-06	-0.31	-0.26	Coronary artery calcification;	chr14:88534559	chr14:88499334~88515502:+
THCA	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	5.86	8.53e-09	1.58e-06	0.26	0.26	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
THCA	cis	rs755249	0.761	rs61781390	ENSG00000228060.1	RP11-69E11.8	-5.86	8.53e-09	1.58e-06	-0.29	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39565160~39573203:+
THCA	cis	rs2243480	0.901	rs778730	ENSG00000232546.1	RP11-458F8.1	-5.86	8.55e-09	1.58e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66358338	chr7:66848496~66858136:+
THCA	cis	rs2136613	0.533	rs10995327	ENSG00000238280.1	RP11-436D10.3	-5.86	8.55e-09	1.58e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62842814	chr10:62793562~62805887:-
THCA	cis	rs1876905	0.68	rs783085	ENSG00000255389.1	C6orf3	5.86	8.55e-09	1.58e-06	0.31	0.26	Mean corpuscular hemoglobin;	chr6:111155482	chr6:111599875~111602295:+
THCA	cis	rs755249	0.567	rs72661961	ENSG00000228060.1	RP11-69E11.8	-5.86	8.55e-09	1.58e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39565160~39573203:+
THCA	cis	rs755249	0.532	rs61779277	ENSG00000228060.1	RP11-69E11.8	-5.86	8.55e-09	1.58e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39565160~39573203:+
THCA	cis	rs755249	0.532	rs61779278	ENSG00000228060.1	RP11-69E11.8	-5.86	8.55e-09	1.58e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs2296172	ENSG00000228060.1	RP11-69E11.8	-5.86	8.55e-09	1.58e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs61779279	ENSG00000228060.1	RP11-69E11.8	-5.86	8.55e-09	1.58e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs6668369	ENSG00000228060.1	RP11-69E11.8	-5.86	8.55e-09	1.58e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs61779284	ENSG00000228060.1	RP11-69E11.8	-5.86	8.55e-09	1.58e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39565160~39573203:+
THCA	cis	rs11838725	1	rs11838725	ENSG00000176268.5	CYCSP34	5.86	8.55e-09	1.58e-06	0.28	0.26	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40863599~40863902:-
THCA	cis	rs2742234	0.955	rs2075913	ENSG00000273008.1	RP11-351D16.3	-5.86	8.56e-09	1.58e-06	-0.22	-0.26	Hirschsprung disease;	chr10:43126920	chr10:43136824~43138334:-
THCA	cis	rs2839186	0.967	rs4819222	ENSG00000239415.1	AP001469.9	5.86	8.56e-09	1.58e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46287864	chr21:46251549~46254133:-
THCA	cis	rs228614	0.51	rs223362	ENSG00000251288.2	RP11-10L12.2	-5.86	8.56e-09	1.58e-06	-0.35	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102751401~102752641:+
THCA	cis	rs9402743	0.781	rs10223338	ENSG00000231028.7	LINC00271	-5.86	8.56e-09	1.58e-06	-0.22	-0.26	Systemic lupus erythematosus;	chr6:135680889	chr6:135497801~135716055:+
THCA	cis	rs79464052	0.571	rs75065885	ENSG00000228737.2	AC008781.7	-5.86	8.56e-09	1.58e-06	-0.6	-0.26	Diffuse large B cell lymphoma;	chr5:141555518	chr5:141618414~141626481:+
THCA	cis	rs79464052	0.571	rs10491312	ENSG00000228737.2	AC008781.7	-5.86	8.56e-09	1.58e-06	-0.6	-0.26	Diffuse large B cell lymphoma;	chr5:141561029	chr5:141618414~141626481:+
THCA	cis	rs12682352	0.605	rs60707155	ENSG00000254153.1	CTA-398F10.2	-5.86	8.57e-09	1.58e-06	-0.29	-0.26	Neuroticism;	chr8:8866905	chr8:8456909~8461337:-
THCA	cis	rs1546924	0.647	rs197422	ENSG00000227811.2	FAM212B-AS1	-5.86	8.57e-09	1.58e-06	-0.32	-0.26	Body mass index;	chr1:111774890	chr1:111739841~111747798:+
THCA	cis	rs10971721	0.584	rs10971951	ENSG00000281128.1	PTENP1-AS	5.86	8.57e-09	1.58e-06	0.56	0.26	Body mass index;	chr9:34146527	chr9:33677268~33688011:+
THCA	cis	rs10971721	0.686	rs10971952	ENSG00000281128.1	PTENP1-AS	5.86	8.57e-09	1.58e-06	0.56	0.26	Body mass index;	chr9:34146604	chr9:33677268~33688011:+
THCA	cis	rs13113518	0.783	rs34534635	ENSG00000249700.7	SRD5A3-AS1	5.86	8.58e-09	1.59e-06	0.33	0.26	Height;	chr4:55573424	chr4:55363971~55395847:-
THCA	cis	rs4639966	0.836	rs11217016	ENSG00000255239.1	AP002954.6	-5.86	8.58e-09	1.59e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118756440	chr11:118688039~118690600:-
THCA	cis	rs3204270	0.759	rs77740144	ENSG00000262049.1	RP13-1032I1.7	5.86	8.59e-09	1.59e-06	0.25	0.26	Dental caries;	chr17:81641942	chr17:81701324~81703300:-
THCA	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-5.86	8.59e-09	1.59e-06	-0.23	-0.26	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
THCA	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	5.86	8.59e-09	1.59e-06	0.28	0.26	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
THCA	cis	rs6740322	0.895	rs28456986	ENSG00000234936.1	AC010883.5	5.86	8.59e-09	1.59e-06	0.28	0.26	Coronary artery disease;	chr2:43326182	chr2:43229573~43233394:+
THCA	cis	rs6545883	0.868	rs2427885	ENSG00000271889.1	RP11-493E12.1	5.86	8.6e-09	1.59e-06	0.25	0.26	Tuberculosis;	chr2:61589642	chr2:61151433~61162105:-
THCA	cis	rs9859260	1	rs3804140	ENSG00000226155.1	AC124944.3	-5.86	8.6e-09	1.59e-06	-0.31	-0.26	Mean corpuscular volume;	chr3:196080736	chr3:195912049~195913986:+
THCA	cis	rs9859260	1	rs3804139	ENSG00000226155.1	AC124944.3	-5.86	8.6e-09	1.59e-06	-0.31	-0.26	Mean corpuscular volume;	chr3:196080754	chr3:195912049~195913986:+
THCA	cis	rs2562456	0.917	rs11085463	ENSG00000268081.1	RP11-678G14.2	5.86	8.61e-09	1.59e-06	0.37	0.26	Pain;	chr19:21568500	chr19:21554640~21569237:-
THCA	cis	rs9307551	0.817	rs11098762	ENSG00000250334.4	LINC00989	-5.86	8.61e-09	1.59e-06	-0.3	-0.26	Refractive error;	chr4:79575097	chr4:79492416~79576460:+
THCA	cis	rs4908768	0.501	rs6669503	ENSG00000232912.4	RP5-1115A15.1	5.86	8.61e-09	1.59e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8424645~8434838:+
THCA	cis	rs9813712	0.855	rs10934930	ENSG00000249846.5	RP11-77P16.4	5.86	8.61e-09	1.59e-06	0.31	0.26	Response to amphetamines;	chr3:130259564	chr3:130112550~130120579:+
THCA	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	5.86	8.62e-09	1.59e-06	0.25	0.26	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
THCA	cis	rs2303759	0.874	rs10411630	ENSG00000268686.1	AC010524.2	-5.86	8.63e-09	1.59e-06	-0.38	-0.26	Multiple sclerosis;	chr19:49388057	chr19:49368705~49388081:-
THCA	cis	rs6674176	0.593	rs6675620	ENSG00000237950.1	RP11-7O11.3	5.86	8.63e-09	1.59e-06	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43951958	chr1:43944370~43946551:-
THCA	cis	rs2439831	0.681	rs498837	ENSG00000249839.1	AC011330.5	-5.86	8.63e-09	1.59e-06	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43315826	chr15:43663654~43684339:-
THCA	cis	rs1865760	0.929	rs1816546	ENSG00000272462.2	U91328.19	-5.86	8.63e-09	1.59e-06	-0.22	-0.26	Height;	chr6:25938024	chr6:25992662~26001775:+
THCA	cis	rs9910055	0.762	rs1135215	ENSG00000267080.4	ASB16-AS1	-5.86	8.63e-09	1.59e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44176151	chr17:44175973~44186717:-
THCA	cis	rs11089937	0.597	rs2213156	ENSG00000211638.2	IGLV8-61	-5.86	8.63e-09	1.59e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.626	rs2213157	ENSG00000211638.2	IGLV8-61	-5.86	8.63e-09	1.59e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.626	rs9622955	ENSG00000211638.2	IGLV8-61	-5.86	8.63e-09	1.59e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22098700~22099212:+
THCA	cis	rs4819052	0.572	rs4819027	ENSG00000223768.1	LINC00205	5.86	8.63e-09	1.6e-06	0.28	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45075309	chr21:45293285~45297354:+
THCA	cis	rs9307551	0.817	rs7667469	ENSG00000250334.4	LINC00989	-5.86	8.64e-09	1.6e-06	-0.3	-0.26	Refractive error;	chr4:79576538	chr4:79492416~79576460:+
THCA	cis	rs11971779	0.666	rs7786851	ENSG00000273391.1	RP11-634H22.1	-5.86	8.65e-09	1.6e-06	-0.28	-0.26	Diisocyanate-induced asthma;	chr7:139322274	chr7:139359032~139359566:-
THCA	cis	rs6802315	0.604	rs4680467	ENSG00000272247.1	RP11-379F4.9	-5.86	8.66e-09	1.6e-06	-0.25	-0.26	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158801257~158801935:-
THCA	cis	rs6142102	0.961	rs4911411	ENSG00000275784.1	RP5-1125A11.6	-5.86	8.66e-09	1.6e-06	-0.27	-0.26	Skin pigmentation;	chr20:34128036	chr20:33989480~33991818:-
THCA	cis	rs2412819	0.52	rs17727763	ENSG00000249839.1	AC011330.5	-5.86	8.67e-09	1.6e-06	-0.45	-0.26	Lung cancer;	chr15:43623873	chr15:43663654~43684339:-
THCA	cis	rs34779708	0.801	rs12242110	ENSG00000271335.4	RP11-324I22.4	5.86	8.67e-09	1.6e-06	0.25	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35314552~35336401:-
THCA	cis	rs2348418	0.83	rs7977418	ENSG00000247934.4	RP11-967K21.1	5.86	8.67e-09	1.6e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28435309	chr12:28163298~28190738:-
THCA	cis	rs7829975	0.514	rs2920991	ENSG00000254153.1	CTA-398F10.2	-5.86	8.67e-09	1.6e-06	-0.27	-0.26	Mood instability;	chr8:8401607	chr8:8456909~8461337:-
THCA	cis	rs11148252	0.74	rs7981050	ENSG00000235660.1	LINC00345	-5.86	8.68e-09	1.6e-06	-0.34	-0.26	Lewy body disease;	chr13:52181014	chr13:52484161~52484680:-
THCA	cis	rs3789135	1	rs3789135	ENSG00000226155.1	AC124944.3	-5.86	8.68e-09	1.6e-06	-0.31	-0.26	Mean corpuscular hemoglobin;	chr3:196065999	chr3:195912049~195913986:+
THCA	cis	rs8002861	0.87	rs1348671	ENSG00000274001.1	RP11-5G9.5	5.86	8.69e-09	1.6e-06	0.29	0.26	Leprosy;	chr13:43875369	chr13:43877715~43878163:-
THCA	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	5.86	8.69e-09	1.61e-06	0.26	0.26	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
THCA	cis	rs3764400	0.508	rs978263	ENSG00000278765.1	RP5-890E16.5	-5.86	8.72e-09	1.61e-06	-0.46	-0.26	Body mass index;	chr17:48103302	chr17:48066704~48067293:-
THCA	cis	rs890448	0.726	rs1031035	ENSG00000254531.1	FLJ20021	-5.86	8.72e-09	1.61e-06	-0.24	-0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101301927	chr4:101347780~101348883:+
THCA	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	5.86	8.72e-09	1.61e-06	0.28	0.26	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	5.86	8.72e-09	1.61e-06	0.28	0.26	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
THCA	cis	rs2136613	0.533	rs1967747	ENSG00000238280.1	RP11-436D10.3	-5.86	8.72e-09	1.61e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62844205	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10761663	ENSG00000238280.1	RP11-436D10.3	-5.86	8.72e-09	1.61e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62845239	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs1475084	ENSG00000238280.1	RP11-436D10.3	-5.86	8.72e-09	1.61e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62845974	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs7088066	ENSG00000238280.1	RP11-436D10.3	-5.86	8.72e-09	1.61e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62846097	chr10:62793562~62805887:-
THCA	cis	rs12893668	0.572	rs4906356	ENSG00000269910.1	RP11-73M18.10	5.86	8.73e-09	1.61e-06	0.24	0.26	Reticulocyte count;	chr14:103672364	chr14:103694516~103695050:-
THCA	cis	rs6973609	0.649	rs6973384	ENSG00000271122.1	RP11-379H18.1	5.86	8.74e-09	1.61e-06	0.17	0.26	Obesity-related traits;	chr7:35564216	chr7:35695214~35699413:+
THCA	cis	rs4713118	0.629	rs149899	ENSG00000272009.1	RP1-313I6.12	-5.86	8.74e-09	1.61e-06	-0.29	-0.26	Parkinson's disease;	chr6:28052201	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.629	rs172165	ENSG00000272009.1	RP1-313I6.12	-5.86	8.74e-09	1.61e-06	-0.29	-0.26	Parkinson's disease;	chr6:28053036	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.597	rs172166	ENSG00000272009.1	RP1-313I6.12	-5.86	8.74e-09	1.61e-06	-0.29	-0.26	Parkinson's disease;	chr6:28053042	chr6:28078792~28081130:-
THCA	cis	rs5742933	0.69	rs62183657	ENSG00000253559.1	OSGEPL1-AS1	-5.86	8.74e-09	1.61e-06	-0.35	-0.26	Ferritin levels;	chr2:189669448	chr2:189762704~189765556:+
THCA	cis	rs1799922	0.684	rs339095	ENSG00000271553.1	RP11-274B21.10	-5.86	8.74e-09	1.61e-06	-0.2	-0.26	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128765993	chr7:128667043~128668156:+
THCA	cis	rs9307551	0.948	rs2165386	ENSG00000250334.4	LINC00989	-5.86	8.75e-09	1.61e-06	-0.33	-0.26	Refractive error;	chr4:79582248	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.948	rs1440853	ENSG00000250334.4	LINC00989	-5.86	8.75e-09	1.61e-06	-0.33	-0.26	Refractive error;	chr4:79585493	chr4:79492416~79576460:+
THCA	cis	rs10971721	0.584	rs10971901	ENSG00000281128.1	PTENP1-AS	5.86	8.75e-09	1.62e-06	0.56	0.26	Body mass index;	chr9:34085149	chr9:33677268~33688011:+
THCA	cis	rs2337406	1	rs78631692	ENSG00000211974.3	IGHV2-70	-5.86	8.76e-09	1.62e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106709371	chr14:106723574~106724093:-
THCA	cis	rs317865	0.737	rs73234629	ENSG00000263327.5	TAPT1-AS1	-5.86	8.76e-09	1.62e-06	-0.46	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16168153	chr4:16226685~16320140:+
THCA	cis	rs7598759	0.712	rs6740474	ENSG00000181798.2	LINC00471	-5.86	8.77e-09	1.62e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231467120	chr2:231508426~231514339:-
THCA	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-5.86	8.77e-09	1.62e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
THCA	cis	rs7598759	0.712	rs6727510	ENSG00000181798.2	LINC00471	-5.86	8.77e-09	1.62e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231467305	chr2:231508426~231514339:-
THCA	cis	rs7598759	0.675	rs6727530	ENSG00000181798.2	LINC00471	-5.86	8.77e-09	1.62e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231467347	chr2:231508426~231514339:-
THCA	cis	rs7598759	0.712	rs10933372	ENSG00000181798.2	LINC00471	-5.86	8.77e-09	1.62e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231467614	chr2:231508426~231514339:-
THCA	cis	rs7598759	0.712	rs997400	ENSG00000181798.2	LINC00471	-5.86	8.77e-09	1.62e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231468136	chr2:231508426~231514339:-
THCA	cis	rs5751614	0.62	rs6003598	ENSG00000230701.2	FBXW4P1	5.86	8.79e-09	1.62e-06	0.27	0.26	Height;	chr22:23274529	chr22:23262767~23265005:+
THCA	cis	rs2439831	0.681	rs484029	ENSG00000249839.1	AC011330.5	-5.86	8.79e-09	1.62e-06	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43327362	chr15:43663654~43684339:-
THCA	cis	rs10829156	0.947	rs10764661	ENSG00000240291.1	RP11-499P20.2	5.86	8.8e-09	1.62e-06	0.22	0.26	Sudden cardiac arrest;	chr10:18659018	chr10:18513115~18545651:-
THCA	cis	rs2439831	0.681	rs540031	ENSG00000249839.1	AC011330.5	-5.86	8.8e-09	1.62e-06	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43316657	chr15:43663654~43684339:-
THCA	cis	rs9677476	0.818	rs16827879	ENSG00000224376.1	AC017104.6	5.86	8.81e-09	1.63e-06	0.29	0.26	Food antigen IgG levels;	chr2:231227588	chr2:231388976~231394991:+
THCA	cis	rs8177876	0.749	rs12444969	ENSG00000261061.1	RP11-303E16.2	-5.86	8.81e-09	1.63e-06	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81030770~81031485:+
THCA	cis	rs11976180	1	rs1919949	ENSG00000273234.1	OR2A13P	-5.86	8.81e-09	1.63e-06	-0.29	-0.26	Obesity-related traits;	chr7:144070630	chr7:144142009~144142938:+
THCA	cis	rs595244	1	rs79307111	ENSG00000259705.1	RP11-227D13.1	5.86	8.81e-09	1.63e-06	0.49	0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48449204	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs77105137	ENSG00000259705.1	RP11-227D13.1	5.86	8.81e-09	1.63e-06	0.49	0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48463275	chr15:48645951~48652016:+
THCA	cis	rs748404	0.626	rs35992154	ENSG00000249839.1	AC011330.5	-5.86	8.82e-09	1.63e-06	-0.37	-0.26	Lung cancer;	chr15:43345669	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs17780417	ENSG00000249839.1	AC011330.5	-5.86	8.82e-09	1.63e-06	-0.37	-0.26	Lung cancer;	chr15:43347264	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs7181634	ENSG00000249839.1	AC011330.5	-5.86	8.82e-09	1.63e-06	-0.37	-0.26	Lung cancer;	chr15:43351703	chr15:43663654~43684339:-
THCA	cis	rs748404	0.63	rs35278805	ENSG00000249839.1	AC011330.5	-5.86	8.82e-09	1.63e-06	-0.37	-0.26	Lung cancer;	chr15:43361124	chr15:43663654~43684339:-
THCA	cis	rs4948275	0.773	rs2249689	ENSG00000237233.2	TMEM26-AS1	-5.86	8.82e-09	1.63e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61488782	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2249680	ENSG00000237233.2	TMEM26-AS1	-5.86	8.82e-09	1.63e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61488847	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.743	rs2249671	ENSG00000237233.2	TMEM26-AS1	-5.86	8.82e-09	1.63e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61488975	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.743	rs2249641	ENSG00000237233.2	TMEM26-AS1	-5.86	8.82e-09	1.63e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61489607	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2650737	ENSG00000237233.2	TMEM26-AS1	-5.86	8.82e-09	1.63e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61490549	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2787737	ENSG00000237233.2	TMEM26-AS1	-5.86	8.82e-09	1.63e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61491027	chr10:61452639~61481956:+
THCA	cis	rs4841097	0.806	rs6992247	ENSG00000254153.1	CTA-398F10.2	-5.86	8.83e-09	1.63e-06	-0.3	-0.26	Platelet distribution width;	chr8:9090959	chr8:8456909~8461337:-
THCA	cis	rs7615952	0.641	rs61048217	ENSG00000250012.1	RP11-124N2.1	-5.86	8.83e-09	1.63e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126089062	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs60839048	ENSG00000250012.1	RP11-124N2.1	-5.86	8.83e-09	1.63e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126089095	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs7640158	ENSG00000250012.1	RP11-124N2.1	-5.86	8.83e-09	1.63e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126089168	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.641	rs2365019	ENSG00000250012.1	RP11-124N2.1	-5.86	8.83e-09	1.63e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126089292	chr3:126084220~126095349:+
THCA	cis	rs7246657	0.722	rs35863684	ENSG00000267422.1	CTD-2554C21.1	-5.86	8.83e-09	1.63e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37618876	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs10402671	ENSG00000267422.1	CTD-2554C21.1	-5.86	8.83e-09	1.63e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37626185	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs10417576	ENSG00000267422.1	CTD-2554C21.1	-5.86	8.83e-09	1.63e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37628311	chr19:37779686~37792865:+
THCA	cis	rs2562456	1	rs2359155	ENSG00000268081.1	RP11-678G14.2	-5.86	8.83e-09	1.63e-06	-0.37	-0.26	Pain;	chr19:21489067	chr19:21554640~21569237:-
THCA	cis	rs9381040	0.655	rs9381029	ENSG00000161912.16	ADCY10P1	5.86	8.84e-09	1.63e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41058714	chr6:41101022~41140835:+
THCA	cis	rs4835473	0.932	rs1973608	ENSG00000251600.4	RP11-673E1.1	5.86	8.85e-09	1.63e-06	0.35	0.26	Immature fraction of reticulocytes;	chr4:143913057	chr4:143912331~143982454:+
THCA	cis	rs7129556	1	rs7129556	ENSG00000254691.1	RP11-91P24.5	-5.86	8.85e-09	1.63e-06	-0.37	-0.26	Weight loss (gastric bypass surgery);	chr11:77589003	chr11:77850604~77851511:+
THCA	cis	rs7209700	0.745	rs8074348	ENSG00000228782.6	CTD-2026D20.3	-5.86	8.85e-09	1.63e-06	-0.24	-0.26	IgG glycosylation;	chr17:47276047	chr17:47450568~47492492:-
THCA	cis	rs7493	0.755	rs17886036	ENSG00000233942.1	AC004012.1	5.86	8.86e-09	1.63e-06	0.39	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95358415	chr7:95471835~95473998:+
THCA	cis	rs1125355	0.656	rs72937298	ENSG00000251491.2	OR7E28P	-5.86	8.87e-09	1.64e-06	-0.41	-0.26	Alzheimer's disease in APOE e4+ carriers;	chr2:158779536	chr2:158862311~158863285:+
THCA	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-5.86	8.87e-09	1.64e-06	-0.47	-0.26	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
THCA	cis	rs77972916	0.561	rs13411629	ENSG00000234936.1	AC010883.5	5.86	8.87e-09	1.64e-06	0.33	0.26	Granulocyte percentage of myeloid white cells;	chr2:43339851	chr2:43229573~43233394:+
THCA	cis	rs3785574	0.962	rs2727329	ENSG00000240280.5	TCAM1P	-5.86	8.87e-09	1.64e-06	-0.36	-0.26	Height;	chr17:63847206	chr17:63849292~63864379:+
THCA	cis	rs2439831	0.681	rs528517	ENSG00000249839.1	AC011330.5	-5.86	8.88e-09	1.64e-06	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43320727	chr15:43663654~43684339:-
THCA	cis	rs12893668	0.542	rs12884809	ENSG00000269910.1	RP11-73M18.10	5.86	8.88e-09	1.64e-06	0.24	0.26	Reticulocyte count;	chr14:103628983	chr14:103694516~103695050:-
THCA	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-5.86	8.9e-09	1.64e-06	-0.32	-0.26	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
THCA	cis	rs12893668	0.703	rs4906335	ENSG00000269910.1	RP11-73M18.10	5.86	8.9e-09	1.64e-06	0.25	0.26	Reticulocyte count;	chr14:103554804	chr14:103694516~103695050:-
THCA	cis	rs2562456	0.755	rs2562421	ENSG00000268081.1	RP11-678G14.2	-5.86	8.92e-09	1.64e-06	-0.39	-0.26	Pain;	chr19:21448502	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs2562420	ENSG00000268081.1	RP11-678G14.2	-5.86	8.92e-09	1.64e-06	-0.39	-0.26	Pain;	chr19:21448503	chr19:21554640~21569237:-
THCA	cis	rs6740322	0.748	rs6727631	ENSG00000234936.1	AC010883.5	5.86	8.92e-09	1.64e-06	0.28	0.26	Coronary artery disease;	chr2:43243269	chr2:43229573~43233394:+
THCA	cis	rs9381040	0.61	rs6919961	ENSG00000161912.16	ADCY10P1	5.86	8.92e-09	1.64e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41052622	chr6:41101022~41140835:+
THCA	cis	rs1707322	0.752	rs12024590	ENSG00000281133.1	AL355480.3	-5.86	8.92e-09	1.64e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs12027622	ENSG00000281133.1	AL355480.3	-5.86	8.92e-09	1.64e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs4415615	ENSG00000281133.1	AL355480.3	-5.86	8.92e-09	1.64e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs7529699	ENSG00000281133.1	AL355480.3	-5.86	8.92e-09	1.64e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.716	rs6699444	ENSG00000281133.1	AL355480.3	-5.86	8.92e-09	1.64e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs10430105	ENSG00000281133.1	AL355480.3	-5.86	8.92e-09	1.64e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45580892~45580996:-
THCA	cis	rs12497850	0.543	rs6446218	ENSG00000229759.1	MRPS18AP1	5.86	8.93e-09	1.65e-06	0.35	0.26	Parkinson's disease;	chr3:49038080	chr3:48256350~48256938:-
THCA	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	5.86	8.93e-09	1.65e-06	0.24	0.26	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
THCA	cis	rs12612619	0.732	rs6547401	ENSG00000229122.1	AGBL5-IT1	5.86	8.93e-09	1.65e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27061977	chr2:27061038~27061815:+
THCA	cis	rs9381040	0.61	rs9394758	ENSG00000161912.16	ADCY10P1	5.86	8.93e-09	1.65e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41050082	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs9367094	ENSG00000161912.16	ADCY10P1	5.86	8.93e-09	1.65e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41050121	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.61	rs742495	ENSG00000161912.16	ADCY10P1	5.86	8.93e-09	1.65e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41050494	chr6:41101022~41140835:+
THCA	cis	rs7809950	0.817	rs34325395	ENSG00000238832.1	snoU109	-5.86	8.94e-09	1.65e-06	-0.3	-0.26	Coronary artery disease;	chr7:107473363	chr7:107603363~107603507:+
THCA	cis	rs763512	0.504	rs58201617	ENSG00000276054.1	RP11-378E13.3	5.86	8.95e-09	1.65e-06	0.4	0.26	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37505345	chr17:37386886~37387926:+
THCA	cis	rs7005380	0.62	rs13249122	ENSG00000245330.4	KB-1471A8.1	5.86	8.95e-09	1.65e-06	0.25	0.26	Interstitial lung disease;	chr8:119893679	chr8:119867419~119874488:-
THCA	cis	rs1949733	0.635	rs4358384	ENSG00000205959.3	RP11-689P11.2	5.86	8.95e-09	1.65e-06	0.23	0.26	Response to antineoplastic agents;	chr4:8535186	chr4:8482270~8512610:+
THCA	cis	rs9880211	0.948	rs6806123	ENSG00000273486.1	RP11-731C17.2	5.86	8.95e-09	1.65e-06	0.28	0.26	Height;Body mass index;	chr3:136586634	chr3:136837338~136839021:-
THCA	cis	rs2439831	0.702	rs7171750	ENSG00000166763.7	STRCP1	5.86	8.96e-09	1.65e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43733660	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs11070408	ENSG00000166763.7	STRCP1	5.86	8.96e-09	1.65e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43742590	chr15:43699488~43718184:-
THCA	cis	rs4805272	0.924	rs1363326	ENSG00000267799.1	MAN1A2P1	5.86	8.96e-09	1.65e-06	0.27	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834743	chr19:28790812~28792871:-
THCA	cis	rs853679	0.546	rs13195291	ENSG00000219392.1	RP1-265C24.5	-5.86	8.96e-09	1.65e-06	-0.58	-0.26	Depression;	chr6:28201463	chr6:28115628~28116551:+
THCA	cis	rs853679	0.556	rs13197633	ENSG00000219392.1	RP1-265C24.5	-5.86	8.96e-09	1.65e-06	-0.58	-0.26	Depression;	chr6:28206979	chr6:28115628~28116551:+
THCA	cis	rs3785574	0.962	rs2727331	ENSG00000240280.5	TCAM1P	-5.86	8.96e-09	1.65e-06	-0.36	-0.26	Height;	chr17:63849630	chr17:63849292~63864379:+
THCA	cis	rs12428035	0.656	rs7991405	ENSG00000247400.3	DNAJC3-AS1	-5.86	8.96e-09	1.65e-06	-0.24	-0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95665627	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.772	rs9590310	ENSG00000247400.3	DNAJC3-AS1	-5.86	8.96e-09	1.65e-06	-0.24	-0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95666430	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.772	rs7318892	ENSG00000247400.3	DNAJC3-AS1	-5.86	8.96e-09	1.65e-06	-0.24	-0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95669669	chr13:95648733~95676925:-
THCA	cis	rs2732480	0.5	rs12828309	ENSG00000240399.1	RP1-228P16.1	5.85	8.99e-09	1.66e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48054813~48055591:-
THCA	cis	rs11783469	0.524	rs2235116	ENSG00000253390.1	CTC-756D1.2	5.85	8.99e-09	1.66e-06	0.41	0.26	Reticulocyte count;	chr8:23479897	chr8:23458601~23484971:+
THCA	cis	rs2243480	1	rs160634	ENSG00000232546.1	RP11-458F8.1	5.85	8.99e-09	1.66e-06	0.33	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66848496~66858136:+
THCA	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-5.85	9e-09	1.66e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
THCA	cis	rs1707322	0.682	rs10890335	ENSG00000281133.1	AL355480.3	-5.85	9e-09	1.66e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45580892~45580996:-
THCA	cis	rs2129782	1	rs16883010	ENSG00000253553.4	RP11-586K2.1	-5.85	9e-09	1.66e-06	-0.44	-0.26	Electrodermal activity;	chr8:88448224	chr8:88326836~88737134:+
THCA	cis	rs12428035	0.772	rs12430152	ENSG00000247400.3	DNAJC3-AS1	5.85	9e-09	1.66e-06	0.25	0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95819783	chr13:95648733~95676925:-
THCA	cis	rs7005380	0.62	rs13260088	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119886525	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10103058	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119890830	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10955941	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119891271	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs13257316	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119891494	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.58	rs12681623	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119891616	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10107251	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119892108	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10094455	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119892436	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10094458	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119892448	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10094587	ENSG00000245330.4	KB-1471A8.1	5.85	9.01e-09	1.66e-06	0.25	0.26	Interstitial lung disease;	chr8:119892560	chr8:119867419~119874488:-
THCA	cis	rs12223324	0.654	rs10794338	ENSG00000255142.1	AP006621.6	-5.85	9.01e-09	1.66e-06	-0.24	-0.26	Fuchs's corneal dystrophy;	chr11:746992	chr11:781645~782105:+
THCA	cis	rs16976116	0.901	rs8031949	ENSG00000279145.1	RP11-547D13.1	5.85	9.01e-09	1.66e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55200526	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs11852763	ENSG00000279145.1	RP11-547D13.1	5.85	9.01e-09	1.66e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55202408	chr15:55171972~55178175:-
THCA	cis	rs1707322	0.752	rs11211152	ENSG00000281133.1	AL355480.3	-5.85	9.02e-09	1.66e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs4607935	ENSG00000281133.1	AL355480.3	-5.85	9.02e-09	1.66e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.681	rs12048866	ENSG00000281133.1	AL355480.3	-5.85	9.02e-09	1.66e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs3811436	ENSG00000281133.1	AL355480.3	-5.85	9.02e-09	1.66e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45580892~45580996:-
THCA	cis	rs10808739	0.534	rs36117382	ENSG00000254006.4	RP11-1D12.2	-5.85	9.03e-09	1.66e-06	-0.4	-0.26	HIV-1 susceptibility;	chr8:64812027	chr8:64801236~64817573:-
THCA	cis	rs7129556	0.728	rs628668	ENSG00000254691.1	RP11-91P24.5	5.85	9.03e-09	1.66e-06	0.35	0.26	Weight loss (gastric bypass surgery);	chr11:77866448	chr11:77850604~77851511:+
THCA	cis	rs28510890	0.917	rs12591171	ENSG00000260337.3	RP11-386M24.6	5.85	9.03e-09	1.66e-06	0.31	0.26	Lung cancer in ever smokers;	chr15:92576569	chr15:92592574~92596462:-
THCA	cis	rs6585424	1	rs35180576	ENSG00000225484.5	NUTM2B-AS1	-5.85	9.03e-09	1.66e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163215	chr10:79663088~79826594:-
THCA	cis	rs4266144	0.558	rs4680339	ENSG00000241770.1	RP11-555M1.3	5.85	9.04e-09	1.67e-06	0.32	0.26	Coronary artery disease;	chr3:157117630	chr3:157163452~157169133:+
THCA	cis	rs7809950	1	rs2520269	ENSG00000238832.1	snoU109	-5.85	9.04e-09	1.67e-06	-0.28	-0.26	Coronary artery disease;	chr7:107550882	chr7:107603363~107603507:+
THCA	cis	rs748404	0.666	rs60018990	ENSG00000249839.1	AC011330.5	-5.85	9.04e-09	1.67e-06	-0.37	-0.26	Lung cancer;	chr15:43504606	chr15:43663654~43684339:-
THCA	cis	rs317689	0.718	rs645026	ENSG00000274979.1	RP11-1143G9.5	-5.85	9.04e-09	1.67e-06	-0.31	-0.26	Response to diuretic therapy;	chr12:69364151	chr12:69326574~69331882:-
THCA	cis	rs712039	0.652	rs829161	ENSG00000276054.1	RP11-378E13.3	-5.85	9.04e-09	1.67e-06	-0.4	-0.26	Tuberculosis;	chr17:37403775	chr17:37386886~37387926:+
THCA	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	5.85	9.05e-09	1.67e-06	0.25	0.26	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	5.85	9.05e-09	1.67e-06	0.25	0.26	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	5.85	9.05e-09	1.67e-06	0.25	0.26	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	5.85	9.05e-09	1.67e-06	0.25	0.26	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	5.85	9.05e-09	1.67e-06	0.25	0.26	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	5.85	9.05e-09	1.67e-06	0.25	0.26	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	5.85	9.05e-09	1.67e-06	0.25	0.26	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
THCA	cis	rs4713118	0.629	rs203889	ENSG00000220721.1	OR1F12	5.85	9.05e-09	1.67e-06	0.34	0.26	Parkinson's disease;	chr6:28053997	chr6:28073316~28074233:+
THCA	cis	rs7646881	0.544	rs59973861	ENSG00000240207.5	RP11-379F4.4	-5.85	9.05e-09	1.67e-06	-0.37	-0.26	Tetralogy of Fallot;	chr3:158570314	chr3:158732263~158784070:+
THCA	cis	rs997295	0.535	rs11630854	ENSG00000270964.1	RP11-502I4.3	-5.85	9.05e-09	1.67e-06	-0.21	-0.26	Motion sickness;	chr15:67565778	chr15:67541072~67542604:-
THCA	cis	rs748404	0.697	rs498227	ENSG00000166763.7	STRCP1	5.85	9.06e-09	1.67e-06	0.28	0.26	Lung cancer;	chr15:43280854	chr15:43699488~43718184:-
THCA	cis	rs3760982	1	rs12460161	ENSG00000267058.1	RP11-15A1.3	-5.85	9.06e-09	1.67e-06	-0.22	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789834	chr19:43891804~43901805:-
THCA	cis	rs1949733	0.598	rs16842480	ENSG00000205959.3	RP11-689P11.2	5.85	9.06e-09	1.67e-06	0.23	0.26	Response to antineoplastic agents;	chr4:8533894	chr4:8482270~8512610:+
THCA	cis	rs12999373	0.501	rs11127496	ENSG00000272342.1	RP13-539J13.1	5.85	9.06e-09	1.67e-06	0.31	0.26	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:739588~740164:-
THCA	cis	rs1876905	0.68	rs395564	ENSG00000255389.1	C6orf3	5.85	9.06e-09	1.67e-06	0.31	0.26	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111599875~111602295:+
THCA	cis	rs2439831	0.681	rs11858152	ENSG00000249839.1	AC011330.5	-5.85	9.07e-09	1.67e-06	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43341998	chr15:43663654~43684339:-
THCA	cis	rs7428	0.545	rs9248	ENSG00000246575.2	AC093162.5	5.85	9.07e-09	1.67e-06	0.23	0.26	Ear protrusion;	chr2:85310189	chr2:85315041~85316529:+
THCA	cis	rs4948275	0.773	rs2650738	ENSG00000237233.2	TMEM26-AS1	-5.85	9.07e-09	1.67e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61492554	chr10:61452639~61481956:+
THCA	cis	rs56114371	0.53	rs2056923	ENSG00000219392.1	RP1-265C24.5	-5.85	9.08e-09	1.67e-06	-0.4	-0.26	Breast cancer;	chr6:27722160	chr6:28115628~28116551:+
THCA	cis	rs7523875	0.72	rs34318448	ENSG00000153363.11	LINC00467	-5.85	9.08e-09	1.67e-06	-0.27	-0.26	Mean corpuscular volume;	chr1:211363708	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.72	rs61848982	ENSG00000153363.11	LINC00467	-5.85	9.08e-09	1.67e-06	-0.27	-0.26	Mean corpuscular volume;	chr1:211364221	chr1:211382803~211435333:+
THCA	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-5.85	9.08e-09	1.67e-06	-0.33	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
THCA	cis	rs6860806	1	rs6860806	ENSG00000233006.5	AC034220.3	-5.85	9.08e-09	1.67e-06	-0.19	-0.26	Breast cancer;	chr5:132304843	chr5:132311285~132369916:-
THCA	cis	rs7209700	0.962	rs56327427	ENSG00000228782.6	CTD-2026D20.3	-5.85	9.09e-09	1.67e-06	-0.26	-0.26	IgG glycosylation;	chr17:47277380	chr17:47450568~47492492:-
THCA	cis	rs4908760	0.965	rs1884352	ENSG00000232912.4	RP5-1115A15.1	5.85	9.09e-09	1.67e-06	0.25	0.26	Vitiligo;	chr1:8477229	chr1:8424645~8434838:+
THCA	cis	rs1395	0.744	rs11126936	ENSG00000234072.1	AC074117.10	5.85	9.09e-09	1.67e-06	0.23	0.26	Blood metabolite levels;	chr2:27260233	chr2:27356246~27367622:+
THCA	cis	rs11148252	0.514	rs1886539	ENSG00000235660.1	LINC00345	-5.85	9.09e-09	1.67e-06	-0.33	-0.26	Lewy body disease;	chr13:52151955	chr13:52484161~52484680:-
THCA	cis	rs9326248	0.53	rs7940310	ENSG00000280143.1	AP000892.6	5.85	9.1e-09	1.68e-06	0.42	0.26	Blood protein levels;	chr11:117153765	chr11:117204967~117210292:+
THCA	cis	rs2657294	0.62	rs4746261	ENSG00000226051.5	ZNF503-AS1	5.85	9.1e-09	1.68e-06	0.38	0.26	Pneumonia;	chr10:75085874	chr10:75269819~75373500:+
THCA	cis	rs9400467	0.528	rs459403	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.1e-09	1.68e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111297126~111298510:+
THCA	cis	rs5742933	0.817	rs1233265	ENSG00000253559.1	OSGEPL1-AS1	-5.85	9.1e-09	1.68e-06	-0.29	-0.26	Ferritin levels;	chr2:189796390	chr2:189762704~189765556:+
THCA	cis	rs5742933	0.69	rs62183656	ENSG00000273240.1	RP11-455J20.3	-5.85	9.11e-09	1.68e-06	-0.34	-0.26	Ferritin levels;	chr2:189669387	chr2:189763859~189764456:-
THCA	cis	rs12497850	0.829	rs8926	ENSG00000229759.1	MRPS18AP1	5.85	9.12e-09	1.68e-06	0.35	0.26	Parkinson's disease;	chr3:49015352	chr3:48256350~48256938:-
THCA	cis	rs944289	0.538	rs1169150	ENSG00000257826.1	RP11-116N8.4	-5.85	9.12e-09	1.68e-06	-0.29	-0.26	Thyroid cancer;	chr14:36171384	chr14:36061026~36067190:-
THCA	cis	rs944289	0.6	rs1834855	ENSG00000257826.1	RP11-116N8.4	-5.85	9.12e-09	1.68e-06	-0.29	-0.26	Thyroid cancer;	chr14:36171432	chr14:36061026~36067190:-
THCA	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	5.85	9.12e-09	1.68e-06	0.31	0.26	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
THCA	cis	rs7598759	0.679	rs10202701	ENSG00000181798.2	LINC00471	5.85	9.14e-09	1.68e-06	0.29	0.26	Noise-induced hearing loss;	chr2:231463970	chr2:231508426~231514339:-
THCA	cis	rs10971721	0.822	rs7856487	ENSG00000281128.1	PTENP1-AS	5.85	9.14e-09	1.68e-06	0.58	0.26	Body mass index;	chr9:33870942	chr9:33677268~33688011:+
THCA	cis	rs11096990	0.964	rs6835064	ENSG00000249207.1	RP11-360F5.1	5.85	9.14e-09	1.68e-06	0.33	0.26	Cognitive function;	chr4:39264346	chr4:39112677~39126818:-
THCA	cis	rs853679	0.607	rs13204012	ENSG00000219392.1	RP1-265C24.5	-5.85	9.14e-09	1.68e-06	-0.58	-0.26	Depression;	chr6:28233753	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13205211	ENSG00000219392.1	RP1-265C24.5	-5.85	9.14e-09	1.68e-06	-0.58	-0.26	Depression;	chr6:28235278	chr6:28115628~28116551:+
THCA	cis	rs7403037	0.587	rs4238509	ENSG00000259905.4	PWRN1	5.85	9.14e-09	1.68e-06	0.25	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24317816	chr15:24493137~24652130:+
THCA	cis	rs2303759	0.918	rs2288480	ENSG00000268686.1	AC010524.2	-5.85	9.15e-09	1.68e-06	-0.37	-0.26	Multiple sclerosis;	chr19:49363759	chr19:49368705~49388081:-
THCA	cis	rs2303759	1	rs2303759	ENSG00000268686.1	AC010524.2	-5.85	9.15e-09	1.68e-06	-0.37	-0.26	Multiple sclerosis;	chr19:49365794	chr19:49368705~49388081:-
THCA	cis	rs2348418	0.864	rs11049580	ENSG00000247934.4	RP11-967K21.1	5.85	9.16e-09	1.68e-06	0.22	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28414696	chr12:28163298~28190738:-
THCA	cis	rs67478160	0.643	rs4906369	ENSG00000258735.1	LINC00637	-5.85	9.16e-09	1.68e-06	-0.31	-0.26	Schizophrenia;	chr14:103776121	chr14:103847721~103858049:+
THCA	cis	rs2765539	0.74	rs12045196	ENSG00000231365.4	RP11-418J17.1	-5.85	9.16e-09	1.69e-06	-0.3	-0.26	Waist-hip ratio;	chr1:119077020	chr1:119140396~119275973:+
THCA	cis	rs172166	0.611	rs203882	ENSG00000226314.6	ZNF192P1	-5.85	9.17e-09	1.69e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28110724	chr6:28161781~28169594:+
THCA	cis	rs172166	0.694	rs1770131	ENSG00000226314.6	ZNF192P1	-5.85	9.17e-09	1.69e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28118635	chr6:28161781~28169594:+
THCA	cis	rs2915864	0.747	rs75118828	ENSG00000280047.1	CTC-463A16.1	5.85	9.17e-09	1.69e-06	0.43	0.26	Facial morphology (factor 20);	chr5:142067055	chr5:142165767~142168387:+
THCA	cis	rs7044106	0.762	rs966396	ENSG00000270917.1	RP11-27I1.6	-5.85	9.17e-09	1.69e-06	-0.36	-0.26	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120812475~120812845:-
THCA	cis	rs2732480	0.5	rs1387257	ENSG00000240399.1	RP1-228P16.1	5.85	9.18e-09	1.69e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48054813~48055591:-
THCA	cis	rs7688540	0.771	rs11737268	ENSG00000275426.1	CH17-262A2.1	5.85	9.19e-09	1.69e-06	0.34	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs11726829	ENSG00000275426.1	CH17-262A2.1	5.85	9.19e-09	1.69e-06	0.34	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:149738~150317:+
THCA	cis	rs748404	0.626	rs1814324	ENSG00000249839.1	AC011330.5	-5.85	9.2e-09	1.69e-06	-0.37	-0.26	Lung cancer;	chr15:43314951	chr15:43663654~43684339:-
THCA	cis	rs4805272	0.962	rs8110833	ENSG00000267799.1	MAN1A2P1	5.85	9.21e-09	1.69e-06	0.27	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28831887	chr19:28790812~28792871:-
THCA	cis	rs950169	0.922	rs2033284	ENSG00000259295.5	CSPG4P12	5.85	9.21e-09	1.69e-06	0.41	0.26	Schizophrenia;	chr15:84391575	chr15:85191438~85213905:+
THCA	cis	rs7923837	0.663	rs7903302	ENSG00000236493.2	EIF2S2P3	5.85	9.21e-09	1.69e-06	0.27	0.26	Multiple sclerosis;Body mass index;	chr10:92669754	chr10:92668745~92669743:-
THCA	cis	rs10266483	0.739	rs11765764	ENSG00000227986.1	TRIM60P18	5.85	9.21e-09	1.69e-06	0.24	0.26	Response to statin therapy;	chr7:64368163	chr7:64355078~64356199:+
THCA	cis	rs9400467	0.528	rs462432	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.22e-09	1.7e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111297126~111298510:+
THCA	cis	rs7760535	0.931	rs466923	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.22e-09	1.7e-06	-0.25	-0.26	Metabolic traits;	chr6:111341774	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs1623806	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.22e-09	1.7e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111297126~111298510:+
THCA	cis	rs2562456	1	rs2562456	ENSG00000268081.1	RP11-678G14.2	5.85	9.22e-09	1.7e-06	0.37	0.26	Pain;	chr19:21483408	chr19:21554640~21569237:-
THCA	cis	rs71520386	0.632	rs9691076	ENSG00000228649.7	AC005682.5	-5.85	9.22e-09	1.7e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22829742	chr7:22854178~22861579:+
THCA	cis	rs3213958	0.509	rs73136057	ENSG00000249274.1	PDLIM1P4	-5.85	9.23e-09	1.7e-06	-0.33	-0.26	Blood protein levels;	chr3:98788290	chr3:98782188~98783193:+
THCA	cis	rs7512898	0.51	rs61825263	ENSG00000260088.1	RP11-92G12.3	-5.85	9.23e-09	1.7e-06	-0.35	-0.26	Electrocardiographic conduction measures;	chr1:200872877	chr1:200669507~200694250:+
THCA	cis	rs755249	0.567	rs41270807	ENSG00000228060.1	RP11-69E11.8	-5.85	9.23e-09	1.7e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39565160~39573203:+
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-5.85	9.23e-09	1.7e-06	-0.24	-0.26	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
THCA	cis	rs4845570	0.92	rs11810571	ENSG00000249602.1	RP11-98D18.3	5.85	9.24e-09	1.7e-06	0.33	0.26	Coronary artery disease;	chr1:151789832	chr1:151763384~151769501:-
THCA	cis	rs7809950	0.773	rs9791733	ENSG00000238832.1	snoU109	-5.85	9.24e-09	1.7e-06	-0.31	-0.26	Coronary artery disease;	chr7:107401285	chr7:107603363~107603507:+
THCA	cis	rs7829975	0.623	rs10087493	ENSG00000254153.1	CTA-398F10.2	5.85	9.24e-09	1.7e-06	0.29	0.26	Mood instability;	chr8:8516047	chr8:8456909~8461337:-
THCA	cis	rs8042680	0.688	rs11073964	ENSG00000214432.8	AC068831.10	-5.85	9.25e-09	1.7e-06	-0.28	-0.26	Type 2 diabetes;	chr15:91000531	chr15:91022619~91036611:+
THCA	cis	rs3760982	1	rs11669175	ENSG00000267058.1	RP11-15A1.3	-5.85	9.26e-09	1.7e-06	-0.22	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785672	chr19:43891804~43901805:-
THCA	cis	rs3760982	1	rs4803658	ENSG00000267058.1	RP11-15A1.3	-5.85	9.26e-09	1.7e-06	-0.22	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785861	chr19:43891804~43901805:-
THCA	cis	rs71520386	0.632	rs12532922	ENSG00000228649.7	AC005682.5	-5.85	9.26e-09	1.7e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22820796	chr7:22854178~22861579:+
THCA	cis	rs71520386	0.632	rs10224533	ENSG00000228649.7	AC005682.5	-5.85	9.26e-09	1.7e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22821522	chr7:22854178~22861579:+
THCA	cis	rs71520386	0.632	rs35353454	ENSG00000228649.7	AC005682.5	-5.85	9.26e-09	1.7e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22822120	chr7:22854178~22861579:+
THCA	cis	rs1876905	0.569	rs354523	ENSG00000230177.1	RP5-1112D6.4	-5.85	9.26e-09	1.7e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111277932~111278742:+
THCA	cis	rs67478160	0.595	rs1475007	ENSG00000258735.1	LINC00637	-5.85	9.26e-09	1.7e-06	-0.31	-0.26	Schizophrenia;	chr14:103830810	chr14:103847721~103858049:+
THCA	cis	rs3764400	0.567	rs2240120	ENSG00000278765.1	RP5-890E16.5	5.85	9.26e-09	1.7e-06	0.46	0.26	Body mass index;	chr17:48064782	chr17:48066704~48067293:-
THCA	cis	rs16976116	0.851	rs13380400	ENSG00000279145.1	RP11-547D13.1	5.85	9.26e-09	1.7e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55198320	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.851	rs28393427	ENSG00000279145.1	RP11-547D13.1	5.85	9.26e-09	1.7e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55198783	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.803	rs28590021	ENSG00000279145.1	RP11-547D13.1	5.85	9.26e-09	1.7e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55198795	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs62020097	ENSG00000279145.1	RP11-547D13.1	5.85	9.26e-09	1.7e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55198809	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs2899580	ENSG00000279145.1	RP11-547D13.1	5.85	9.26e-09	1.7e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55199373	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs2899581	ENSG00000279145.1	RP11-547D13.1	5.85	9.26e-09	1.7e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55199445	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs2899582	ENSG00000279145.1	RP11-547D13.1	5.85	9.26e-09	1.7e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55199536	chr15:55171972~55178175:-
THCA	cis	rs1125355	0.655	rs11683568	ENSG00000251491.2	OR7E28P	-5.85	9.26e-09	1.7e-06	-0.42	-0.26	Alzheimer's disease in APOE e4+ carriers;	chr2:158762690	chr2:158862311~158863285:+
THCA	cis	rs7646881	0.544	rs6788046	ENSG00000240207.5	RP11-379F4.4	-5.85	9.27e-09	1.7e-06	-0.37	-0.26	Tetralogy of Fallot;	chr3:158616465	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs6799605	ENSG00000240207.5	RP11-379F4.4	-5.85	9.27e-09	1.7e-06	-0.37	-0.26	Tetralogy of Fallot;	chr3:158616551	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs59601316	ENSG00000240207.5	RP11-379F4.4	-5.85	9.27e-09	1.7e-06	-0.37	-0.26	Tetralogy of Fallot;	chr3:158618847	chr3:158732263~158784070:+
THCA	cis	rs748404	0.666	rs7176923	ENSG00000249839.1	AC011330.5	-5.85	9.27e-09	1.7e-06	-0.38	-0.26	Lung cancer;	chr15:43317679	chr15:43663654~43684339:-
THCA	cis	rs9880211	1	rs12695649	ENSG00000273486.1	RP11-731C17.2	5.85	9.27e-09	1.7e-06	0.27	0.26	Height;Body mass index;	chr3:136553074	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs6774964	ENSG00000273486.1	RP11-731C17.2	5.85	9.27e-09	1.7e-06	0.27	0.26	Height;Body mass index;	chr3:136556740	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs6775314	ENSG00000273486.1	RP11-731C17.2	5.85	9.27e-09	1.7e-06	0.27	0.26	Height;Body mass index;	chr3:136557106	chr3:136837338~136839021:-
THCA	cis	rs9880211	1	rs28641809	ENSG00000273486.1	RP11-731C17.2	5.85	9.27e-09	1.7e-06	0.27	0.26	Height;Body mass index;	chr3:136571647	chr3:136837338~136839021:-
THCA	cis	rs10129255	0.957	rs8005468	ENSG00000211974.3	IGHV2-70	5.85	9.28e-09	1.71e-06	0.21	0.26	Kawasaki disease;	chr14:106686431	chr14:106723574~106724093:-
THCA	cis	rs2303319	0.504	rs62187657	ENSG00000227403.1	AC009299.3	5.85	9.29e-09	1.71e-06	0.55	0.26	Cognitive function;	chr2:161631581	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187658	ENSG00000227403.1	AC009299.3	5.85	9.29e-09	1.71e-06	0.55	0.26	Cognitive function;	chr2:161631585	chr2:161244739~161249050:+
THCA	cis	rs202072	0.652	rs453695	ENSG00000272379.1	RP1-257A7.5	-5.85	9.29e-09	1.71e-06	-0.45	-0.26	HIV-1 viral setpoint;	chr6:13262274	chr6:13290018~13290490:-
THCA	cis	rs9859260	0.71	rs41298097	ENSG00000273009.1	RP11-352G9.1	5.85	9.3e-09	1.71e-06	0.29	0.26	Mean corpuscular volume;	chr3:196052284	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.744	rs557527	ENSG00000273009.1	RP11-352G9.1	5.85	9.3e-09	1.71e-06	0.29	0.26	Mean corpuscular volume;	chr3:196053838	chr3:195913078~195913683:-
THCA	cis	rs9400467	0.528	rs455247	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111297126~111298510:+
THCA	cis	rs7760535	0.811	rs464401	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Metabolic traits;	chr6:111347804	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.509	rs463854	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.509	rs463853	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs456569	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs455335	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs465795	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs110732	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.592	rs462493	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.508	rs456871	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111297126~111298510:+
THCA	cis	rs7760535	0.811	rs455732	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Metabolic traits;	chr6:111374065	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs458486	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs455726	ENSG00000271789.1	RP5-1112D6.7	-5.85	9.3e-09	1.71e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111297126~111298510:+
THCA	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	5.85	9.31e-09	1.71e-06	0.23	0.26	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	5.85	9.31e-09	1.71e-06	0.23	0.26	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
THCA	cis	rs2562456	0.837	rs62110205	ENSG00000213976.4	CTD-2561J22.2	-5.85	9.31e-09	1.71e-06	-0.28	-0.26	Pain;	chr19:21577269	chr19:21382865~21387177:+
THCA	cis	rs67478160	0.619	rs12897150	ENSG00000258735.1	LINC00637	-5.85	9.31e-09	1.71e-06	-0.31	-0.26	Schizophrenia;	chr14:103853193	chr14:103847721~103858049:+
THCA	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-5.85	9.31e-09	1.71e-06	-0.38	-0.26	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
THCA	cis	rs1387259	0.929	rs11168460	ENSG00000240399.1	RP1-228P16.1	5.85	9.31e-09	1.71e-06	0.27	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.5	rs7297824	ENSG00000240399.1	RP1-228P16.1	5.85	9.31e-09	1.71e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48054813~48055591:-
THCA	cis	rs6977955	1	rs917117	ENSG00000234336.5	JAZF1-AS1	-5.85	9.32e-09	1.71e-06	-0.3	-0.26	Allergic disease (asthma, hay fever or eczema);	chr7:28136686	chr7:28180322~28243917:+
THCA	cis	rs631288	0.793	rs6593771	ENSG00000226015.2	CCT8P1	5.85	9.32e-09	1.71e-06	0.6	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr1:147321114	chr1:147203276~147204932:-
THCA	cis	rs631288	0.793	rs10751414	ENSG00000226015.2	CCT8P1	5.85	9.32e-09	1.71e-06	0.6	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr1:147330049	chr1:147203276~147204932:-
THCA	cis	rs1577330	0.561	rs117259914	ENSG00000254396.1	RP11-56F10.3	5.85	9.32e-09	1.71e-06	0.43	0.26	IgG glycosylation;	chr9:27093424	chr9:27102630~27104728:+
THCA	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	5.85	9.32e-09	1.71e-06	0.29	0.26	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	5.85	9.32e-09	1.71e-06	0.29	0.26	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	5.85	9.32e-09	1.71e-06	0.29	0.26	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	5.85	9.32e-09	1.71e-06	0.29	0.26	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
THCA	cis	rs2243480	1	rs10807702	ENSG00000232546.1	RP11-458F8.1	-5.85	9.32e-09	1.71e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66302856	chr7:66848496~66858136:+
THCA	cis	rs1707322	0.682	rs10890334	ENSG00000281133.1	AL355480.3	-5.85	9.32e-09	1.71e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.716	rs6694889	ENSG00000281133.1	AL355480.3	-5.85	9.32e-09	1.71e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.682	rs12041197	ENSG00000281133.1	AL355480.3	-5.85	9.32e-09	1.71e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs11211145	ENSG00000281133.1	AL355480.3	-5.85	9.32e-09	1.71e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs11211146	ENSG00000281133.1	AL355480.3	-5.85	9.32e-09	1.71e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs11211147	ENSG00000281133.1	AL355480.3	-5.85	9.32e-09	1.71e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45580892~45580996:-
THCA	cis	rs1322639	1	rs9689079	ENSG00000261039.2	RP11-417E7.2	5.85	9.33e-09	1.71e-06	0.32	0.26	Pulse pressure;	chr6:169187053	chr6:169175304~169182740:-
THCA	cis	rs8177876	0.658	rs75422577	ENSG00000261061.1	RP11-303E16.2	-5.85	9.34e-09	1.71e-06	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81030770~81031485:+
THCA	cis	rs17826219	0.733	rs7221691	ENSG00000264538.5	SUZ12P1	5.85	9.34e-09	1.72e-06	0.26	0.26	Body mass index;	chr17:30396601	chr17:30709299~30790908:+
THCA	cis	rs6545883	1	rs778762	ENSG00000271889.1	RP11-493E12.1	5.85	9.34e-09	1.72e-06	0.25	0.26	Tuberculosis;	chr2:61555786	chr2:61151433~61162105:-
THCA	cis	rs12893668	0.603	rs61637848	ENSG00000269910.1	RP11-73M18.10	5.85	9.35e-09	1.72e-06	0.24	0.26	Reticulocyte count;	chr14:103629694	chr14:103694516~103695050:-
THCA	cis	rs13256369	0.865	rs13282523	ENSG00000253893.2	FAM85B	-5.85	9.35e-09	1.72e-06	-0.34	-0.26	Obesity-related traits;	chr8:8719783	chr8:8167819~8226614:-
THCA	cis	rs2765539	0.887	rs1325933	ENSG00000231365.4	RP11-418J17.1	-5.85	9.35e-09	1.72e-06	-0.28	-0.26	Waist-hip ratio;	chr1:119013136	chr1:119140396~119275973:+
THCA	cis	rs3785574	0.962	rs2584630	ENSG00000240280.5	TCAM1P	-5.85	9.35e-09	1.72e-06	-0.36	-0.26	Height;	chr17:63810201	chr17:63849292~63864379:+
THCA	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	5.85	9.35e-09	1.72e-06	0.28	0.26	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
THCA	cis	rs1125355	0.69	rs11679019	ENSG00000251491.2	OR7E28P	-5.85	9.36e-09	1.72e-06	-0.43	-0.26	Alzheimer's disease in APOE e4+ carriers;	chr2:158804999	chr2:158862311~158863285:+
THCA	cis	rs3785574	0.962	rs2665799	ENSG00000240280.5	TCAM1P	-5.85	9.37e-09	1.72e-06	-0.36	-0.26	Height;	chr17:63842363	chr17:63849292~63864379:+
THCA	cis	rs6142102	0.961	rs6059649	ENSG00000275784.1	RP5-1125A11.6	-5.85	9.37e-09	1.72e-06	-0.28	-0.26	Skin pigmentation;	chr20:34056071	chr20:33989480~33991818:-
THCA	cis	rs11089937	0.568	rs59356111	ENSG00000211638.2	IGLV8-61	-5.85	9.37e-09	1.72e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.626	rs5757019	ENSG00000211638.2	IGLV8-61	-5.85	9.37e-09	1.72e-06	-0.2	-0.26	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22098700~22099212:+
THCA	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-5.85	9.38e-09	1.72e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
THCA	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-5.85	9.38e-09	1.72e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
THCA	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-5.85	9.38e-09	1.72e-06	-0.38	-0.26	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
THCA	cis	rs2562456	0.917	rs6511253	ENSG00000268119.4	CTD-2561J22.5	-5.85	9.38e-09	1.72e-06	-0.32	-0.26	Pain;	chr19:21495996	chr19:21444241~21463908:-
THCA	cis	rs3760982	0.967	rs12463346	ENSG00000267058.1	RP11-15A1.3	-5.85	9.38e-09	1.72e-06	-0.22	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788092	chr19:43891804~43901805:-
THCA	cis	rs2732480	0.577	rs2634693	ENSG00000240399.1	RP1-228P16.1	5.85	9.39e-09	1.72e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.577	rs2634691	ENSG00000240399.1	RP1-228P16.1	5.85	9.39e-09	1.72e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48054813~48055591:-
THCA	cis	rs7428	0.962	rs3637	ENSG00000273196.1	RP11-717A5.2	5.85	9.39e-09	1.72e-06	0.26	0.26	Ear protrusion;	chr2:85322751	chr2:85387074~85387146:-
THCA	cis	rs755249	0.546	rs7533743	ENSG00000182109.6	RP11-69E11.4	-5.85	9.39e-09	1.72e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39522280~39546187:-
THCA	cis	rs755249	0.565	rs7555699	ENSG00000182109.6	RP11-69E11.4	-5.85	9.39e-09	1.72e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39522280~39546187:-
THCA	cis	rs755249	0.565	rs1809697	ENSG00000182109.6	RP11-69E11.4	-5.85	9.39e-09	1.72e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39493413	chr1:39522280~39546187:-
THCA	cis	rs9813712	0.953	rs9847910	ENSG00000228252.7	COL6A4P2	5.85	9.4e-09	1.73e-06	0.3	0.26	Response to amphetamines;	chr3:130248174	chr3:130212823~130273806:+
THCA	cis	rs2243480	1	rs67536397	ENSG00000232546.1	RP11-458F8.1	-5.85	9.41e-09	1.73e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66482930	chr7:66848496~66858136:+
THCA	cis	rs12497850	0.931	rs13315711	ENSG00000229759.1	MRPS18AP1	5.85	9.41e-09	1.73e-06	0.35	0.26	Parkinson's disease;	chr3:48948966	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs7430198	ENSG00000229759.1	MRPS18AP1	5.85	9.41e-09	1.73e-06	0.35	0.26	Parkinson's disease;	chr3:48951327	chr3:48256350~48256938:-
THCA	cis	rs12908161	0.959	rs12906348	ENSG00000259295.5	CSPG4P12	5.85	9.41e-09	1.73e-06	0.4	0.26	Schizophrenia;	chr15:84786190	chr15:85191438~85213905:+
THCA	cis	rs12908161	0.959	rs34342559	ENSG00000259295.5	CSPG4P12	5.85	9.41e-09	1.73e-06	0.4	0.26	Schizophrenia;	chr15:84788040	chr15:85191438~85213905:+
THCA	cis	rs12908161	0.959	rs62019472	ENSG00000259295.5	CSPG4P12	5.85	9.41e-09	1.73e-06	0.4	0.26	Schizophrenia;	chr15:84788262	chr15:85191438~85213905:+
THCA	cis	rs12908161	0.959	rs35557864	ENSG00000259295.5	CSPG4P12	5.85	9.41e-09	1.73e-06	0.4	0.26	Schizophrenia;	chr15:84788398	chr15:85191438~85213905:+
THCA	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-5.85	9.42e-09	1.73e-06	-0.21	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
THCA	cis	rs438465	0.58	rs12174595	ENSG00000226194.4	RP1-137D17.1	-5.85	9.42e-09	1.73e-06	-0.45	-0.26	Corneal astigmatism;	chr6:169371083	chr6:169369998~169388385:-
THCA	cis	rs712039	0.617	rs36081240	ENSG00000276054.1	RP11-378E13.3	5.85	9.42e-09	1.73e-06	0.4	0.26	Tuberculosis;	chr17:37424955	chr17:37386886~37387926:+
THCA	cis	rs1876905	0.68	rs354540	ENSG00000230177.1	RP5-1112D6.4	-5.85	9.42e-09	1.73e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111277932~111278742:+
THCA	cis	rs67478160	0.679	rs8011109	ENSG00000258735.1	LINC00637	-5.85	9.43e-09	1.73e-06	-0.31	-0.26	Schizophrenia;	chr14:103813637	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.655	rs4900598	ENSG00000258735.1	LINC00637	-5.85	9.43e-09	1.73e-06	-0.31	-0.26	Schizophrenia;	chr14:103815204	chr14:103847721~103858049:+
THCA	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	5.85	9.43e-09	1.73e-06	0.34	0.26	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
THCA	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	5.85	9.44e-09	1.73e-06	0.32	0.26	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
THCA	cis	rs2732480	0.5	rs11168464	ENSG00000240399.1	RP1-228P16.1	5.85	9.44e-09	1.73e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48054813~48055591:-
THCA	cis	rs8002861	0.781	rs3816311	ENSG00000274001.1	RP11-5G9.5	5.85	9.45e-09	1.73e-06	0.29	0.26	Leprosy;	chr13:43879647	chr13:43877715~43878163:-
THCA	cis	rs17772222	0.63	rs1344747	ENSG00000258983.2	RP11-507K2.2	-5.85	9.45e-09	1.73e-06	-0.3	-0.26	Coronary artery calcification;	chr14:88548091	chr14:88499334~88515502:+
THCA	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	5.85	9.45e-09	1.73e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
THCA	cis	rs6860806	0.631	rs6863548	ENSG00000233006.5	AC034220.3	5.85	9.47e-09	1.74e-06	0.2	0.26	Breast cancer;	chr5:132240227	chr5:132311285~132369916:-
THCA	cis	rs17772222	1	rs79579293	ENSG00000258789.1	RP11-507K2.3	-5.85	9.47e-09	1.74e-06	-0.28	-0.26	Coronary artery calcification;	chr14:88355724	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs12436642	ENSG00000258983.2	RP11-507K2.2	-5.85	9.48e-09	1.74e-06	-0.3	-0.26	Coronary artery calcification;	chr14:88559032	chr14:88499334~88515502:+
THCA	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-5.85	9.48e-09	1.74e-06	-0.34	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
THCA	cis	rs6674176	0.696	rs4448553	ENSG00000237950.1	RP11-7O11.3	5.84	9.48e-09	1.74e-06	0.24	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43945917	chr1:43944370~43946551:-
THCA	cis	rs9393777	0.841	rs13207082	ENSG00000280107.1	AL022393.9	-5.84	9.48e-09	1.74e-06	-0.45	-0.26	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28170845~28172521:+
THCA	cis	rs10971721	0.584	rs10971900	ENSG00000281128.1	PTENP1-AS	5.84	9.49e-09	1.74e-06	0.56	0.26	Body mass index;	chr9:34085079	chr9:33677268~33688011:+
THCA	cis	rs8028182	0.501	rs11072553	ENSG00000260269.4	CTD-2323K18.1	-5.84	9.49e-09	1.74e-06	-0.4	-0.26	Sudden cardiac arrest;	chr15:75640436	chr15:75527150~75601205:-
THCA	cis	rs7809950	0.678	rs75617662	ENSG00000238832.1	snoU109	-5.84	9.49e-09	1.74e-06	-0.31	-0.26	Coronary artery disease;	chr7:107389994	chr7:107603363~107603507:+
THCA	cis	rs17508449	0.819	rs79667495	ENSG00000232450.1	RP4-730K3.3	-5.84	9.49e-09	1.74e-06	-0.4	-0.26	Leprosy;	chr1:113648707	chr1:113698884~113699631:-
THCA	cis	rs6430553	0.929	rs6714498	ENSG00000224043.6	CCNT2-AS1	5.84	9.49e-09	1.74e-06	0.26	0.26	Blood metabolite levels;	chr2:134893196	chr2:134735464~134918710:-
THCA	cis	rs6740322	0.748	rs13402621	ENSG00000234936.1	AC010883.5	5.84	9.5e-09	1.74e-06	0.27	0.26	Coronary artery disease;	chr2:43231472	chr2:43229573~43233394:+
THCA	cis	rs12721025	1	rs12721025	ENSG00000254851.1	RP11-109L13.1	5.84	9.51e-09	1.74e-06	0.65	0.26	Infantile hypertrophic pyloric stenosis;	chr11:116835331	chr11:117135528~117138582:+
THCA	cis	rs853679	1	rs853694	ENSG00000226314.6	ZNF192P1	-5.84	9.51e-09	1.74e-06	-0.39	-0.26	Depression;	chr6:28311323	chr6:28161781~28169594:+
THCA	cis	rs9677476	0.863	rs60953838	ENSG00000224376.1	AC017104.6	5.84	9.52e-09	1.75e-06	0.29	0.26	Food antigen IgG levels;	chr2:231201151	chr2:231388976~231394991:+
THCA	cis	rs2281636	0.894	rs2297446	ENSG00000260475.1	RP11-85A1.3	5.84	9.52e-09	1.75e-06	0.23	0.26	Obesity-related traits;	chr10:99610258	chr10:99621055~99621918:+
THCA	cis	rs7617773	0.746	rs11713476	ENSG00000199476.1	Y_RNA	-5.84	9.52e-09	1.75e-06	-0.33	-0.26	Coronary artery disease;	chr3:48333944	chr3:48288587~48288694:+
THCA	cis	rs6142102	0.961	rs6120487	ENSG00000275784.1	RP5-1125A11.6	-5.84	9.52e-09	1.75e-06	-0.27	-0.26	Skin pigmentation;	chr20:34034802	chr20:33989480~33991818:-
THCA	cis	rs9467773	1	rs9467779	ENSG00000124549.13	BTN2A3P	-5.84	9.53e-09	1.75e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26421391~26432383:+
THCA	cis	rs1030877	0.521	rs2576747	ENSG00000235319.1	AC012360.4	-5.84	9.53e-09	1.75e-06	-0.29	-0.26	Obesity-related traits;	chr2:105362219	chr2:105324210~105330529:+
THCA	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	5.84	9.53e-09	1.75e-06	0.33	0.26	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
THCA	cis	rs7849973	0.625	rs62574663	ENSG00000224549.1	RP11-370B11.3	-5.84	9.53e-09	1.75e-06	-0.32	-0.26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22812209	chr9:22767175~22768316:+
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000273796.1	LL21NC02-21A1.1	5.84	9.53e-09	1.75e-06	0.27	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45403809~45404369:-
THCA	cis	rs2276314	0.553	rs12964535	ENSG00000278986.1	RP11-723J4.3	5.84	9.54e-09	1.75e-06	0.26	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36031728	chr18:35972151~35973916:+
THCA	cis	rs79464052	0.571	rs79215142	ENSG00000228737.2	AC008781.7	-5.84	9.55e-09	1.75e-06	-0.61	-0.26	Diffuse large B cell lymphoma;	chr5:141619537	chr5:141618414~141626481:+
THCA	cis	rs4591358	0.618	rs4850625	ENSG00000223466.1	AC064834.2	5.84	9.55e-09	1.75e-06	0.31	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522138	chr2:195533035~195538681:+
THCA	cis	rs2562456	0.917	rs2681392	ENSG00000268119.4	CTD-2561J22.5	-5.84	9.55e-09	1.75e-06	-0.32	-0.26	Pain;	chr19:21513185	chr19:21444241~21463908:-
THCA	cis	rs5758511	0.68	rs1107553	ENSG00000281538.1	RP4-669P10.20	-5.84	9.56e-09	1.75e-06	-0.28	-0.26	Birth weight;	chr22:42271467	chr22:42138060~42139726:+
THCA	cis	rs10875746	0.624	rs10875777	ENSG00000269514.1	RP11-370I10.12	5.84	9.56e-09	1.75e-06	0.25	0.26	Longevity (90 years and older);	chr12:48228288	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.669	rs61941006	ENSG00000269514.1	RP11-370I10.12	5.84	9.56e-09	1.75e-06	0.25	0.26	Longevity (90 years and older);	chr12:48237350	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.669	rs1021313	ENSG00000269514.1	RP11-370I10.12	5.84	9.56e-09	1.75e-06	0.25	0.26	Longevity (90 years and older);	chr12:48244258	chr12:48198387~48202031:+
THCA	cis	rs7246657	0.722	rs2972447	ENSG00000267422.1	CTD-2554C21.1	5.84	9.56e-09	1.75e-06	0.3	0.26	Coronary artery calcification;	chr19:37638835	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs10409605	ENSG00000267422.1	CTD-2554C21.1	-5.84	9.56e-09	1.75e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37632236	chr19:37779686~37792865:+
THCA	cis	rs6142102	0.961	rs2056990	ENSG00000275784.1	RP5-1125A11.6	-5.84	9.57e-09	1.75e-06	-0.28	-0.26	Skin pigmentation;	chr20:34035658	chr20:33989480~33991818:-
THCA	cis	rs7260598	0.642	rs7256265	ENSG00000268442.1	CTD-2027I19.2	5.84	9.59e-09	1.76e-06	0.35	0.26	Response to taxane treatment (placlitaxel);	chr19:23950901	chr19:24162370~24163425:-
THCA	cis	rs2735413	0.564	rs2222897	ENSG00000276007.1	RP11-358L22.3	5.84	9.59e-09	1.76e-06	0.28	0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78058138	chr16:78123243~78124332:+
THCA	cis	rs1046896	0.607	rs12449739	ENSG00000263063.1	RP11-388C12.1	-5.84	9.59e-09	1.76e-06	-0.32	-0.26	Glycated hemoglobin levels;	chr17:82725544	chr17:82713908~82716255:-
THCA	cis	rs17301013	0.507	rs1754354	ENSG00000227373.4	RP11-160H22.5	-5.84	9.59e-09	1.76e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174817196	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.556	rs1754353	ENSG00000227373.4	RP11-160H22.5	-5.84	9.59e-09	1.76e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174822229	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.531	rs1793318	ENSG00000227373.4	RP11-160H22.5	-5.84	9.59e-09	1.76e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174824678	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2987872	ENSG00000227373.4	RP11-160H22.5	-5.84	9.59e-09	1.76e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174840935	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs1793305	ENSG00000227373.4	RP11-160H22.5	-5.84	9.59e-09	1.76e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174841124	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs1894201	ENSG00000227373.4	RP11-160H22.5	-5.84	9.59e-09	1.76e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174841452	chr1:174115300~174160004:-
THCA	cis	rs451417	0.818	rs236103	ENSG00000275632.1	RP5-967N21.11	5.84	9.59e-09	1.76e-06	0.32	0.26	Menopause (age at onset);	chr20:5977341	chr20:6000418~6000941:+
THCA	cis	rs9467773	1	rs9357010	ENSG00000124549.13	BTN2A3P	5.84	9.6e-09	1.76e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26421391~26432383:+
THCA	cis	rs62292953	0.719	rs62291501	ENSG00000248724.5	NPHP3-AS1	-5.84	9.6e-09	1.76e-06	-0.49	-0.26	Red cell distribution width;	chr3:132618265	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.719	rs41272321	ENSG00000248724.5	NPHP3-AS1	-5.84	9.6e-09	1.76e-06	-0.49	-0.26	Red cell distribution width;	chr3:132619502	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.719	rs62291504	ENSG00000248724.5	NPHP3-AS1	-5.84	9.6e-09	1.76e-06	-0.49	-0.26	Red cell distribution width;	chr3:132626638	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.719	rs2305626	ENSG00000248724.5	NPHP3-AS1	-5.84	9.6e-09	1.76e-06	-0.49	-0.26	Red cell distribution width;	chr3:132626918	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.719	rs17413620	ENSG00000248724.5	NPHP3-AS1	-5.84	9.6e-09	1.76e-06	-0.49	-0.26	Red cell distribution width;	chr3:132628857	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.719	rs62291553	ENSG00000248724.5	NPHP3-AS1	-5.84	9.6e-09	1.76e-06	-0.49	-0.26	Red cell distribution width;	chr3:132632036	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.719	rs11926381	ENSG00000248724.5	NPHP3-AS1	-5.84	9.6e-09	1.76e-06	-0.49	-0.26	Red cell distribution width;	chr3:132635778	chr3:132721750~132874223:+
THCA	cis	rs9813712	0.909	rs1453257	ENSG00000228252.7	COL6A4P2	-5.84	9.6e-09	1.76e-06	-0.3	-0.26	Response to amphetamines;	chr3:130258730	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.953	rs1453256	ENSG00000228252.7	COL6A4P2	-5.84	9.6e-09	1.76e-06	-0.3	-0.26	Response to amphetamines;	chr3:130258787	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.953	rs935916	ENSG00000228252.7	COL6A4P2	-5.84	9.6e-09	1.76e-06	-0.3	-0.26	Response to amphetamines;	chr3:130258931	chr3:130212823~130273806:+
THCA	cis	rs7615952	0.576	rs4646748	ENSG00000250012.1	RP11-124N2.1	-5.84	9.6e-09	1.76e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126107486	chr3:126084220~126095349:+
THCA	cis	rs79464052	0.571	rs76945386	ENSG00000228737.2	AC008781.7	-5.84	9.61e-09	1.76e-06	-0.6	-0.26	Diffuse large B cell lymphoma;	chr5:141589524	chr5:141618414~141626481:+
THCA	cis	rs2976388	0.566	rs13250661	ENSG00000253741.1	CTD-2292P10.4	5.84	9.61e-09	1.76e-06	0.35	0.26	Urinary tract infection frequency;	chr8:142722716	chr8:142702252~142726973:-
THCA	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	5.84	9.62e-09	1.76e-06	0.34	0.26	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
THCA	cis	rs6142102	0.961	rs1883524	ENSG00000275784.1	RP5-1125A11.6	-5.84	9.62e-09	1.76e-06	-0.27	-0.26	Skin pigmentation;	chr20:34038301	chr20:33989480~33991818:-
THCA	cis	rs6545883	0.929	rs2593626	ENSG00000271889.1	RP11-493E12.1	5.84	9.62e-09	1.76e-06	0.26	0.26	Tuberculosis;	chr2:61438049	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.929	rs2592352	ENSG00000271889.1	RP11-493E12.1	5.84	9.62e-09	1.76e-06	0.26	0.26	Tuberculosis;	chr2:61438201	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.929	rs2264100	ENSG00000271889.1	RP11-493E12.1	5.84	9.62e-09	1.76e-06	0.26	0.26	Tuberculosis;	chr2:61443694	chr2:61151433~61162105:-
THCA	cis	rs172166	0.611	rs203883	ENSG00000226314.6	ZNF192P1	-5.84	9.62e-09	1.76e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28110578	chr6:28161781~28169594:+
THCA	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-5.84	9.63e-09	1.76e-06	-0.28	-0.26	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
THCA	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	5.84	9.63e-09	1.76e-06	0.16	0.26	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
THCA	cis	rs7688540	0.723	rs80316648	ENSG00000211553.1	AC253576.2	-5.84	9.64e-09	1.77e-06	-0.39	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:136461~136568:+
THCA	cis	rs4713118	0.662	rs464312	ENSG00000220721.1	OR1F12	5.84	9.64e-09	1.77e-06	0.33	0.26	Parkinson's disease;	chr6:27999813	chr6:28073316~28074233:+
THCA	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	5.84	9.64e-09	1.77e-06	0.33	0.26	Height;	chr4:55483718	chr4:55363971~55395847:-
THCA	cis	rs7809950	0.678	rs7790080	ENSG00000238832.1	snoU109	-5.84	9.65e-09	1.77e-06	-0.31	-0.26	Coronary artery disease;	chr7:107390877	chr7:107603363~107603507:+
THCA	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	5.84	9.65e-09	1.77e-06	0.28	0.26	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
THCA	cis	rs6674176	0.597	rs4660262	ENSG00000237950.1	RP11-7O11.3	5.84	9.65e-09	1.77e-06	0.23	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43916852	chr1:43944370~43946551:-
THCA	cis	rs2120243	0.539	rs9878474	ENSG00000244515.1	KRT18P34	5.84	9.65e-09	1.77e-06	0.31	0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157405358	chr3:157162663~157163932:-
THCA	cis	rs6585424	1	rs35025775	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164529	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs34749786	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164634	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs61860024	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165607	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs61860025	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165798	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs12411386	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166475	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs2228427	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166962	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs34332933	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166994	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs61860035	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172697	chr10:79663088~79826594:-
THCA	cis	rs6585424	0.85	rs75804987	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172753	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs12769115	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173745	chr10:79663088~79826594:-
THCA	cis	rs6585424	0.85	rs61860036	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175103	chr10:79663088~79826594:-
THCA	cis	rs728616	0.51	rs12411989	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.66e-09	1.77e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178094	chr10:79663088~79826594:-
THCA	cis	rs9402743	0.577	rs111373814	ENSG00000231028.7	LINC00271	-5.84	9.66e-09	1.77e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135644459	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.608	rs6918917	ENSG00000231028.7	LINC00271	-5.84	9.66e-09	1.77e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135644473	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.673	rs56071012	ENSG00000231028.7	LINC00271	-5.84	9.66e-09	1.77e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135646213	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.673	rs56976899	ENSG00000231028.7	LINC00271	-5.84	9.66e-09	1.77e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135646262	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.673	rs9494312	ENSG00000231028.7	LINC00271	-5.84	9.66e-09	1.77e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135646826	chr6:135497801~135716055:+
THCA	cis	rs17772222	1	rs12433464	ENSG00000258789.1	RP11-507K2.3	-5.84	9.67e-09	1.77e-06	-0.27	-0.26	Coronary artery calcification;	chr14:88357671	chr14:88551597~88552493:+
THCA	cis	rs454422	0.812	rs13041190	ENSG00000275632.1	RP5-967N21.11	5.84	9.67e-09	1.77e-06	0.26	0.26	HIV-1 viral setpoint;	chr20:5980812	chr20:6000418~6000941:+
THCA	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	5.84	9.68e-09	1.77e-06	0.27	0.26	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
THCA	cis	rs757978	1	rs73116394	ENSG00000223374.1	AC005104.3	5.84	9.69e-09	1.78e-06	0.28	0.26	Chronic lymphocytic leukemia;	chr2:241428500	chr2:241351340~241353104:-
THCA	cis	rs757978	1	rs73116396	ENSG00000223374.1	AC005104.3	5.84	9.69e-09	1.78e-06	0.28	0.26	Chronic lymphocytic leukemia;	chr2:241429278	chr2:241351340~241353104:-
THCA	cis	rs2380205	0.546	rs636578	ENSG00000232807.2	RP11-536K7.3	-5.84	9.69e-09	1.78e-06	-0.24	-0.26	Breast cancer;	chr10:5896581	chr10:5934270~5945900:-
THCA	cis	rs7044106	0.762	rs7024046	ENSG00000270917.1	RP11-27I1.6	-5.84	9.69e-09	1.78e-06	-0.36	-0.26	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120812475~120812845:-
THCA	cis	rs3213758	0.541	rs1344504	ENSG00000275191.1	RP11-36I17.2	-5.84	9.7e-09	1.78e-06	-0.37	-0.26	Vitiligo (non-segmental);	chr16:53627958	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.5	rs8054063	ENSG00000275191.1	RP11-36I17.2	-5.84	9.7e-09	1.78e-06	-0.37	-0.26	Vitiligo (non-segmental);	chr16:53628978	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.541	rs7200859	ENSG00000275191.1	RP11-36I17.2	-5.84	9.7e-09	1.78e-06	-0.37	-0.26	Vitiligo (non-segmental);	chr16:53634663	chr16:53628256~53628816:-
THCA	cis	rs1865760	0.573	rs7450342	ENSG00000272462.2	U91328.19	-5.84	9.7e-09	1.78e-06	-0.2	-0.26	Height;	chr6:25919252	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.613	rs7749342	ENSG00000272462.2	U91328.19	-5.84	9.7e-09	1.78e-06	-0.2	-0.26	Height;	chr6:25920037	chr6:25992662~26001775:+
THCA	cis	rs2255336	0.938	rs61917723	ENSG00000245648.1	RP11-277P12.20	-5.84	9.72e-09	1.78e-06	-0.32	-0.26	Blood protein levels;	chr12:10472728	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs61917750	ENSG00000245648.1	RP11-277P12.20	-5.84	9.72e-09	1.78e-06	-0.32	-0.26	Blood protein levels;	chr12:10480824	chr12:10363769~10398506:+
THCA	cis	rs4950322	0.57	rs7554833	ENSG00000278811.3	LINC00624	-5.84	9.72e-09	1.78e-06	-0.32	-0.26	Protein quantitative trait loci;	chr1:147289362	chr1:147258885~147517875:-
THCA	cis	rs7267979	0.789	rs2260197	ENSG00000274973.1	RP13-401N8.7	-5.84	9.72e-09	1.78e-06	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:25845497~25845862:+
THCA	cis	rs4227	0.565	rs858524	ENSG00000233223.2	AC113189.5	5.84	9.73e-09	1.78e-06	0.21	0.26	IgA nephropathy;	chr17:7607969	chr17:7581964~7584072:-
THCA	cis	rs4227	0.527	rs858523	ENSG00000233223.2	AC113189.5	5.84	9.73e-09	1.78e-06	0.21	0.26	IgA nephropathy;	chr17:7608211	chr17:7581964~7584072:-
THCA	cis	rs2303319	0.582	rs62187608	ENSG00000227403.1	AC009299.3	5.84	9.73e-09	1.78e-06	0.54	0.26	Cognitive function;	chr2:161574628	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.582	rs62187614	ENSG00000227403.1	AC009299.3	5.84	9.73e-09	1.78e-06	0.54	0.26	Cognitive function;	chr2:161579775	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs1515182	ENSG00000227403.1	AC009299.3	5.84	9.73e-09	1.78e-06	0.54	0.26	Cognitive function;	chr2:161580424	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12465645	ENSG00000227403.1	AC009299.3	5.84	9.73e-09	1.78e-06	0.54	0.26	Cognitive function;	chr2:161581129	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12465734	ENSG00000227403.1	AC009299.3	5.84	9.73e-09	1.78e-06	0.54	0.26	Cognitive function;	chr2:161581349	chr2:161244739~161249050:+
THCA	cis	rs11671005	0.695	rs11673069	ENSG00000269473.1	CTD-2619J13.19	5.84	9.73e-09	1.78e-06	0.31	0.26	Mean platelet volume;	chr19:58423551	chr19:58440448~58445849:+
THCA	cis	rs4845570	0.92	rs1196456	ENSG00000249602.1	RP11-98D18.3	5.84	9.73e-09	1.78e-06	0.35	0.26	Coronary artery disease;	chr1:151764873	chr1:151763384~151769501:-
THCA	cis	rs6973609	0.649	rs889937	ENSG00000271122.1	RP11-379H18.1	5.84	9.74e-09	1.78e-06	0.17	0.26	Obesity-related traits;	chr7:35557351	chr7:35695214~35699413:+
THCA	cis	rs6973609	0.649	rs7792142	ENSG00000271122.1	RP11-379H18.1	5.84	9.75e-09	1.79e-06	0.17	0.26	Obesity-related traits;	chr7:35555997	chr7:35695214~35699413:+
THCA	cis	rs1799922	0.708	rs339046	ENSG00000271553.1	RP11-274B21.10	-5.84	9.76e-09	1.79e-06	-0.2	-0.26	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128750509	chr7:128667043~128668156:+
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000228409.4	CCT6P1	5.84	9.76e-09	1.79e-06	0.3	0.26	Diabetic kidney disease;	chr7:65892097	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs35391607	ENSG00000228409.4	CCT6P1	5.84	9.76e-09	1.79e-06	0.3	0.26	Diabetic kidney disease;	chr7:65895842	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs13220979	ENSG00000228409.4	CCT6P1	5.84	9.76e-09	1.79e-06	0.3	0.26	Diabetic kidney disease;	chr7:65898217	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs34974928	ENSG00000228409.4	CCT6P1	5.84	9.76e-09	1.79e-06	0.3	0.26	Diabetic kidney disease;	chr7:65899019	chr7:65751142~65763354:+
THCA	cis	rs6963495	0.585	rs1728653	ENSG00000272604.1	RP11-251G23.5	5.84	9.76e-09	1.79e-06	0.29	0.26	Bipolar disorder (body mass index interaction);	chr7:105550888	chr7:105571083~105573660:+
THCA	cis	rs12908161	0.959	rs61074241	ENSG00000259295.5	CSPG4P12	5.84	9.77e-09	1.79e-06	0.41	0.26	Schizophrenia;	chr15:84790165	chr15:85191438~85213905:+
THCA	cis	rs2029362	0.611	rs10767665	ENSG00000245573.6	BDNF-AS	5.84	9.77e-09	1.79e-06	0.21	0.26	Total body bone mineral density;	chr11:27712311	chr11:27506838~27698174:+
THCA	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-5.84	9.77e-09	1.79e-06	-0.44	-0.26	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000229886.1	RP5-1132H15.3	5.84	9.78e-09	1.79e-06	0.39	0.26	Diabetic kidney disease;	chr7:65988305	chr7:66025126~66031544:-
THCA	cis	rs10761482	0.544	rs1938544	ENSG00000254271.1	RP11-131N11.4	5.84	9.78e-09	1.79e-06	0.34	0.26	Schizophrenia;	chr10:60524901	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.5	rs1938543	ENSG00000254271.1	RP11-131N11.4	5.84	9.78e-09	1.79e-06	0.34	0.26	Schizophrenia;	chr10:60524902	chr10:60734342~60741828:+
THCA	cis	rs9380516	1	rs1540909	ENSG00000228559.1	RP3-340B19.3	-5.84	9.78e-09	1.79e-06	-0.4	-0.26	Hepatitis C induced liver fibrosis;	chr6:35521076	chr6:35544632~35545669:+
THCA	cis	rs6545883	0.931	rs778765	ENSG00000271889.1	RP11-493E12.1	5.84	9.79e-09	1.79e-06	0.25	0.26	Tuberculosis;	chr2:61559250	chr2:61151433~61162105:-
THCA	cis	rs7202877	0.656	rs977986	ENSG00000261783.1	RP11-252K23.2	-5.84	9.79e-09	1.79e-06	-0.46	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75472798	chr16:75379818~75381260:-
THCA	cis	rs7202877	0.706	rs37602	ENSG00000261783.1	RP11-252K23.2	5.84	9.79e-09	1.79e-06	0.46	0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75471148	chr16:75379818~75381260:-
THCA	cis	rs75422866	0.51	rs35784744	ENSG00000276691.1	RP5-1057I20.5	5.84	9.79e-09	1.79e-06	0.45	0.26	Pneumonia;	chr12:47729646	chr12:47788426~47788971:+
THCA	cis	rs17798991	0.721	rs11664741	ENSG00000267674.1	RP11-813F20.2	5.84	9.8e-09	1.79e-06	0.27	0.26	Obesity-related traits;	chr18:49608095	chr18:49739823~49742063:-
THCA	cis	rs8025790	0.508	rs28673019	ENSG00000270964.1	RP11-502I4.3	-5.84	9.8e-09	1.79e-06	-0.22	-0.26	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67517485	chr15:67541072~67542604:-
THCA	cis	rs12893668	0.663	rs12889731	ENSG00000269910.1	RP11-73M18.10	5.84	9.8e-09	1.79e-06	0.25	0.26	Reticulocyte count;	chr14:103621145	chr14:103694516~103695050:-
THCA	cis	rs61677309	0.638	rs17122021	ENSG00000280032.1	RP11-832A4.7	5.84	9.8e-09	1.79e-06	0.26	0.26	Lung cancer in ever smokers;	chr11:118274971	chr11:118264593~118266817:+
THCA	cis	rs7202877	0.61	rs3851735	ENSG00000261783.1	RP11-252K23.2	-5.84	9.8e-09	1.79e-06	-0.46	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75338194	chr16:75379818~75381260:-
THCA	cis	rs7202877	0.706	rs11149812	ENSG00000261783.1	RP11-252K23.2	-5.84	9.81e-09	1.79e-06	-0.45	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75289747	chr16:75379818~75381260:-
THCA	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-5.84	9.81e-09	1.8e-06	-0.29	-0.26	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
THCA	cis	rs9400467	0.528	rs6568680	ENSG00000271789.1	RP5-1112D6.7	-5.84	9.82e-09	1.8e-06	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111297126~111298510:+
THCA	cis	rs8177876	0.749	rs10459871	ENSG00000261061.1	RP11-303E16.2	-5.84	9.82e-09	1.8e-06	-0.37	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81030770~81031485:+
THCA	cis	rs890448	0.796	rs12649313	ENSG00000254531.1	FLJ20021	5.84	9.82e-09	1.8e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101420352	chr4:101347780~101348883:+
THCA	cis	rs1823913	0.927	rs1454761	ENSG00000280083.1	RP11-317J9.1	-5.84	9.82e-09	1.8e-06	-0.32	-0.26	Obesity-related traits;	chr2:191237092	chr2:191154118~191156070:-
THCA	cis	rs12428035	0.772	rs3848077	ENSG00000247400.3	DNAJC3-AS1	-5.84	9.83e-09	1.8e-06	-0.24	-0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95799680	chr13:95648733~95676925:-
THCA	cis	rs1552244	0.938	rs7652951	ENSG00000232901.1	CYCSP10	5.84	9.83e-09	1.8e-06	0.35	0.26	Alzheimer's disease;	chr3:10022079	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs7611218	ENSG00000232901.1	CYCSP10	5.84	9.83e-09	1.8e-06	0.35	0.26	Alzheimer's disease;	chr3:10022276	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.872	rs6803517	ENSG00000232901.1	CYCSP10	5.84	9.83e-09	1.8e-06	0.35	0.26	Alzheimer's disease;	chr3:10023742	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs9834980	ENSG00000232901.1	CYCSP10	5.84	9.83e-09	1.8e-06	0.35	0.26	Alzheimer's disease;	chr3:10023844	chr3:10000647~10000940:-
THCA	cis	rs9381040	0.655	rs2294696	ENSG00000161912.16	ADCY10P1	-5.84	9.83e-09	1.8e-06	-0.17	-0.26	Alzheimer's disease (late onset);	chr6:41069249	chr6:41101022~41140835:+
THCA	cis	rs6545883	0.868	rs6545887	ENSG00000271889.1	RP11-493E12.1	5.84	9.84e-09	1.8e-06	0.25	0.26	Tuberculosis;	chr2:61601683	chr2:61151433~61162105:-
THCA	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-5.84	9.84e-09	1.8e-06	-0.27	-0.26	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
THCA	cis	rs7809950	0.862	rs58391518	ENSG00000238832.1	snoU109	-5.84	9.84e-09	1.8e-06	-0.28	-0.26	Coronary artery disease;	chr7:107390342	chr7:107603363~107603507:+
THCA	cis	rs6928977	0.896	rs2746429	ENSG00000231028.7	LINC00271	5.84	9.85e-09	1.8e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352146	chr6:135497801~135716055:+
THCA	cis	rs34779708	0.801	rs12255409	ENSG00000271335.4	RP11-324I22.4	5.84	9.85e-09	1.8e-06	0.25	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35314552~35336401:-
THCA	cis	rs17772222	0.917	rs77382318	ENSG00000258789.1	RP11-507K2.3	-5.84	9.86e-09	1.8e-06	-0.28	-0.26	Coronary artery calcification;	chr14:88355785	chr14:88551597~88552493:+
THCA	cis	rs9467773	1	rs767471	ENSG00000124549.13	BTN2A3P	5.84	9.87e-09	1.81e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26421391~26432383:+
THCA	cis	rs1707322	0.686	rs61784833	ENSG00000281133.1	AL355480.3	-5.84	9.87e-09	1.81e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45580892~45580996:-
THCA	cis	rs10895275	0.923	rs10895272	ENSG00000277459.1	RP11-732A21.3	-5.84	9.87e-09	1.81e-06	-0.21	-0.26	Migraine;	chr11:102203883	chr11:102109827~102110457:-
THCA	cis	rs1707322	0.721	rs10890341	ENSG00000281133.1	AL355480.3	-5.84	9.88e-09	1.81e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45580892~45580996:-
THCA	cis	rs287982	0.611	rs80238678	ENSG00000269973.1	RP11-95D17.1	-5.84	9.88e-09	1.81e-06	-0.23	-0.26	Nonsyndromic cleft lip with cleft palate;	chr2:9836053	chr2:9936360~9939590:+
THCA	cis	rs6928977	0.827	rs2614265	ENSG00000231028.7	LINC00271	5.84	9.89e-09	1.81e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135394237	chr6:135497801~135716055:+
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000232546.1	RP11-458F8.1	-5.84	9.89e-09	1.81e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66100518	chr7:66848496~66858136:+
THCA	cis	rs2120243	0.539	rs1545596	ENSG00000244515.1	KRT18P34	-5.84	9.89e-09	1.81e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157400737	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs1456108	ENSG00000244515.1	KRT18P34	-5.84	9.89e-09	1.81e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157401265	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs1563420	ENSG00000244515.1	KRT18P34	-5.84	9.89e-09	1.81e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157401537	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.51	rs7623173	ENSG00000244515.1	KRT18P34	-5.84	9.89e-09	1.81e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402160	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs2168431	ENSG00000244515.1	KRT18P34	-5.84	9.89e-09	1.81e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402240	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs2124497	ENSG00000244515.1	KRT18P34	-5.84	9.89e-09	1.81e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402470	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs2168430	ENSG00000244515.1	KRT18P34	-5.84	9.89e-09	1.81e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402619	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs2305622	ENSG00000244515.1	KRT18P34	-5.84	9.89e-09	1.81e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157404715	chr3:157162663~157163932:-
THCA	cis	rs273909	0.622	rs2662314	ENSG00000233006.5	AC034220.3	-5.84	9.89e-09	1.81e-06	-0.3	-0.26	Coronary artery disease;	chr5:132289476	chr5:132311285~132369916:-
THCA	cis	rs9921338	0.961	rs4780357	ENSG00000262703.1	RP11-485G7.6	-5.84	9.89e-09	1.81e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11277114	chr16:11348143~11349321:-
THCA	cis	rs6928977	0.896	rs2064431	ENSG00000231028.7	LINC00271	5.84	9.89e-09	1.81e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135324065	chr6:135497801~135716055:+
THCA	cis	rs1823913	0.963	rs4146105	ENSG00000280083.1	RP11-317J9.1	-5.84	9.9e-09	1.81e-06	-0.32	-0.26	Obesity-related traits;	chr2:191245240	chr2:191154118~191156070:-
THCA	cis	rs1823913	1	rs13019004	ENSG00000280083.1	RP11-317J9.1	-5.84	9.9e-09	1.81e-06	-0.32	-0.26	Obesity-related traits;	chr2:191245493	chr2:191154118~191156070:-
THCA	cis	rs10078	0.515	rs6872510	ENSG00000221990.4	EXOC3-AS1	5.84	9.9e-09	1.81e-06	0.27	0.26	Fat distribution (HIV);	chr5:481495	chr5:441498~443160:-
THCA	cis	rs11976180	1	rs2951372	ENSG00000273234.1	OR2A13P	-5.84	9.9e-09	1.81e-06	-0.29	-0.26	Obesity-related traits;	chr7:144052410	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs1320894	ENSG00000273234.1	OR2A13P	-5.84	9.9e-09	1.81e-06	-0.29	-0.26	Obesity-related traits;	chr7:144054709	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2951369	ENSG00000273234.1	OR2A13P	-5.84	9.9e-09	1.81e-06	-0.29	-0.26	Obesity-related traits;	chr7:144055545	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2951368	ENSG00000273234.1	OR2A13P	-5.84	9.9e-09	1.81e-06	-0.29	-0.26	Obesity-related traits;	chr7:144055728	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2961115	ENSG00000273234.1	OR2A13P	-5.84	9.9e-09	1.81e-06	-0.29	-0.26	Obesity-related traits;	chr7:144056278	chr7:144142009~144142938:+
THCA	cis	rs11976180	1	rs2951364	ENSG00000273234.1	OR2A13P	-5.84	9.9e-09	1.81e-06	-0.29	-0.26	Obesity-related traits;	chr7:144057390	chr7:144142009~144142938:+
THCA	cis	rs7833787	1	rs6993404	ENSG00000278886.1	RP11-108A14.1	5.84	9.91e-09	1.81e-06	0.34	0.26	Obesity-related traits;	chr8:18848213	chr8:18864681~18865247:-
THCA	cis	rs9910055	0.762	rs2631299	ENSG00000267080.4	ASB16-AS1	-5.84	9.91e-09	1.81e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44142405	chr17:44175973~44186717:-
THCA	cis	rs8141529	0.673	rs132548	ENSG00000272858.1	CTA-292E10.8	5.84	9.91e-09	1.81e-06	0.26	0.26	Lymphocyte counts;	chr22:28921571	chr22:28814914~28815662:+
THCA	cis	rs7809950	0.724	rs1858888	ENSG00000238832.1	snoU109	-5.84	9.92e-09	1.81e-06	-0.31	-0.26	Coronary artery disease;	chr7:107405617	chr7:107603363~107603507:+
THCA	cis	rs2036707	1	rs2036708	ENSG00000276740.1	RP11-381O6.1	5.84	9.92e-09	1.81e-06	0.47	0.26	Obesity-related traits;	chr13:107832890	chr13:107465984~107466674:-
THCA	cis	rs1949733	0.598	rs869602	ENSG00000205959.3	RP11-689P11.2	5.84	9.92e-09	1.81e-06	0.23	0.26	Response to antineoplastic agents;	chr4:8533644	chr4:8482270~8512610:+
THCA	cis	rs2348418	0.733	rs7955080	ENSG00000247934.4	RP11-967K21.1	-5.84	9.92e-09	1.81e-06	-0.23	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28153972	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.701	rs1463570	ENSG00000247934.4	RP11-967K21.1	-5.84	9.92e-09	1.81e-06	-0.23	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28156095	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.733	rs12229219	ENSG00000247934.4	RP11-967K21.1	-5.84	9.92e-09	1.81e-06	-0.23	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28158414	chr12:28163298~28190738:-
THCA	cis	rs2735413	0.564	rs73578735	ENSG00000276007.1	RP11-358L22.3	5.84	9.92e-09	1.81e-06	0.28	0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78071039	chr16:78123243~78124332:+
THCA	cis	rs2243480	1	rs34815098	ENSG00000228409.4	CCT6P1	5.84	9.92e-09	1.81e-06	0.3	0.26	Diabetic kidney disease;	chr7:65827267	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs35735127	ENSG00000228409.4	CCT6P1	5.84	9.92e-09	1.81e-06	0.3	0.26	Diabetic kidney disease;	chr7:65835436	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs35256305	ENSG00000228409.4	CCT6P1	5.84	9.92e-09	1.81e-06	0.3	0.26	Diabetic kidney disease;	chr7:65841418	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.803	rs34004500	ENSG00000228409.4	CCT6P1	5.84	9.92e-09	1.81e-06	0.3	0.26	Diabetic kidney disease;	chr7:65847191	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs35825738	ENSG00000228409.4	CCT6P1	5.84	9.92e-09	1.81e-06	0.3	0.26	Diabetic kidney disease;	chr7:65853040	chr7:65751142~65763354:+
THCA	cis	rs17301013	0.507	rs1474575	ENSG00000227373.4	RP11-160H22.5	-5.84	9.94e-09	1.82e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174569563	chr1:174115300~174160004:-
THCA	cis	rs947583	0.573	rs55789102	ENSG00000231028.7	LINC00271	-5.84	9.94e-09	1.82e-06	-0.2	-0.26	Phosphorus levels;	chr6:135699954	chr6:135497801~135716055:+
THCA	cis	rs317865	0.737	rs16893097	ENSG00000263327.5	TAPT1-AS1	-5.84	9.94e-09	1.82e-06	-0.46	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16155341	chr4:16226685~16320140:+
THCA	cis	rs6585424	1	rs35497678	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.95e-09	1.82e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80161322	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs2304410	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.95e-09	1.82e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162054	chr10:79663088~79826594:-
THCA	cis	rs6585424	0.778	rs12257082	ENSG00000225484.5	NUTM2B-AS1	-5.84	9.95e-09	1.82e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162365	chr10:79663088~79826594:-
THCA	cis	rs4654783	0.505	rs4655025	ENSG00000218510.5	LINC00339	-5.84	9.95e-09	1.82e-06	-0.28	-0.26	Endometriosis;	chr1:22133261	chr1:22025188~22031223:+
THCA	cis	rs3020264	0.74	rs2515563	ENSG00000271743.1	CTD-2541M15.3	-5.84	9.95e-09	1.82e-06	-0.35	-0.26	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6637329	chr8:6615604~6617198:-
THCA	cis	rs1707322	0.721	rs28501477	ENSG00000281133.1	AL355480.3	-5.84	9.95e-09	1.82e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45580892~45580996:-
THCA	cis	rs2915864	0.8	rs57547939	ENSG00000280047.1	CTC-463A16.1	5.84	9.95e-09	1.82e-06	0.41	0.26	Facial morphology (factor 20);	chr5:142155176	chr5:142165767~142168387:+
THCA	cis	rs2281636	0.894	rs1541598	ENSG00000260475.1	RP11-85A1.3	-5.84	9.95e-09	1.82e-06	-0.24	-0.26	Obesity-related traits;	chr10:99630733	chr10:99621055~99621918:+
THCA	cis	rs2742234	0.91	rs2505513	ENSG00000273008.1	RP11-351D16.3	-5.84	9.96e-09	1.82e-06	-0.22	-0.26	Hirschsprung disease;	chr10:43138089	chr10:43136824~43138334:-
THCA	cis	rs11668609	0.938	rs28720079	ENSG00000268442.1	CTD-2027I19.2	5.84	9.96e-09	1.82e-06	0.32	0.26	Response to taxane treatment (docetaxel);	chr19:24184823	chr19:24162370~24163425:-
THCA	cis	rs6545883	0.929	rs13413337	ENSG00000270820.4	RP11-355B11.2	5.84	9.96e-09	1.82e-06	0.22	0.26	Tuberculosis;	chr2:61519988	chr2:61471188~61484130:+
THCA	cis	rs7712401	0.755	rs3213794	ENSG00000249996.1	RP11-359P5.1	5.84	9.96e-09	1.82e-06	0.25	0.26	Mean platelet volume;	chr5:122825943	chr5:123036271~123054667:+
THCA	cis	rs1876905	0.597	rs354551	ENSG00000230177.1	RP5-1112D6.4	-5.84	9.97e-09	1.82e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111277932~111278742:+
THCA	cis	rs13113518	0.783	rs13111128	ENSG00000249700.7	SRD5A3-AS1	5.84	9.97e-09	1.82e-06	0.33	0.26	Height;	chr4:55578154	chr4:55363971~55395847:-
THCA	cis	rs7045881	0.935	rs7872881	ENSG00000254396.1	RP11-56F10.3	5.84	9.97e-09	1.82e-06	0.37	0.26	Schizophrenia;	chr9:26838841	chr9:27102630~27104728:+
THCA	cis	rs79040073	0.563	rs73392233	ENSG00000259531.2	RP11-295H24.3	5.84	9.98e-09	1.82e-06	0.35	0.26	Lung cancer in ever smokers;	chr15:49214881	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.53	rs79452929	ENSG00000259531.2	RP11-295H24.3	5.84	9.98e-09	1.82e-06	0.35	0.26	Lung cancer in ever smokers;	chr15:49216166	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.53	rs57560518	ENSG00000259531.2	RP11-295H24.3	5.84	9.98e-09	1.82e-06	0.35	0.26	Lung cancer in ever smokers;	chr15:49218760	chr15:49365124~49366685:-
THCA	cis	rs7809950	0.731	rs2712196	ENSG00000238832.1	snoU109	-5.84	9.98e-09	1.82e-06	-0.29	-0.26	Coronary artery disease;	chr7:107488352	chr7:107603363~107603507:+
THCA	cis	rs4748857	0.588	rs7075896	ENSG00000224215.1	RP11-371A19.2	-5.84	9.99e-09	1.83e-06	-0.34	-0.26	Systemic lupus erythematosus;	chr10:23239628	chr10:23343957~23345181:+
THCA	cis	rs812925	0.859	rs2593624	ENSG00000271889.1	RP11-493E12.1	-5.84	9.99e-09	1.83e-06	-0.27	-0.26	Immature fraction of reticulocytes;	chr2:61325349	chr2:61151433~61162105:-
THCA	cis	rs7529073	0.545	rs340884	ENSG00000274895.1	RP11-478J18.2	5.84	9.99e-09	1.83e-06	0.21	0.26	Schizophrenia;	chr1:213972046	chr1:213983793~213986419:-
THCA	cis	rs2439831	0.717	rs28495368	ENSG00000166763.7	STRCP1	5.84	9.99e-09	1.83e-06	0.36	0.26	Lung cancer in ever smokers;	chr15:43603444	chr15:43699488~43718184:-
THCA	cis	rs12681366	0.595	rs2450580	ENSG00000253704.1	RP11-267M23.4	-5.84	1e-08	1.83e-06	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94351548	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.708	rs2515165	ENSG00000253704.1	RP11-267M23.4	-5.84	1e-08	1.83e-06	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94352616	chr8:94553722~94569745:+
THCA	cis	rs7824557	0.628	rs17797894	ENSG00000154316.13	TDH	-5.84	1e-08	1.83e-06	-0.19	-0.26	Retinal vascular caliber;	chr8:11354572	chr8:11339637~11368452:+
THCA	cis	rs7246657	0.654	rs10407568	ENSG00000267422.1	CTD-2554C21.1	-5.84	1e-08	1.83e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37632108	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.722	rs16958863	ENSG00000267422.1	CTD-2554C21.1	-5.84	1e-08	1.83e-06	-0.3	-0.26	Coronary artery calcification;	chr19:37633334	chr19:37779686~37792865:+
THCA	cis	rs1329650	1	rs10881926	ENSG00000228701.1	TNKS2-AS1	-5.84	1e-08	1.83e-06	-0.31	-0.26	Smoking behavior;	chr10:91584497	chr10:91782839~91798291:-
THCA	cis	rs17508449	0.819	rs76726048	ENSG00000232450.1	RP4-730K3.3	-5.84	1e-08	1.83e-06	-0.4	-0.26	Leprosy;	chr1:113664077	chr1:113698884~113699631:-
THCA	cis	rs6840360	0.642	rs1470280	ENSG00000270265.1	RP11-731D1.4	-5.84	1e-08	1.83e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151333775~151353224:-
THCA	cis	rs4664293	0.667	rs2042782	ENSG00000226266.5	AC009961.3	5.84	1e-08	1.83e-06	0.3	0.26	Monocyte percentage of white cells;	chr2:159789781	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.642	rs6732598	ENSG00000226266.5	AC009961.3	5.84	1e-08	1.83e-06	0.3	0.26	Monocyte percentage of white cells;	chr2:159790370	chr2:159670708~159712435:-
THCA	cis	rs12681963	0.688	rs12541087	ENSG00000248159.1	HSPA8P11	5.84	1e-08	1.83e-06	0.47	0.26	Migraine;	chr8:30172398	chr8:30237382~30240997:+
THCA	cis	rs228614	0.51	rs150893	ENSG00000251288.2	RP11-10L12.2	5.83	1e-08	1.83e-06	0.35	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102751401~102752641:+
THCA	cis	rs8177876	0.822	rs79926943	ENSG00000261061.1	RP11-303E16.2	-5.83	1e-08	1.83e-06	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81030770~81031485:+
THCA	cis	rs4908768	0.501	rs7527389	ENSG00000232912.4	RP5-1115A15.1	5.83	1e-08	1.84e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8424645~8434838:+
THCA	cis	rs3213958	0.574	rs73138082	ENSG00000249274.1	PDLIM1P4	-5.83	1e-08	1.84e-06	-0.34	-0.26	Blood protein levels;	chr3:98898313	chr3:98782188~98783193:+
THCA	cis	rs4683346	0.616	rs11922832	ENSG00000173811.9	CCDC13-AS1	-5.83	1e-08	1.84e-06	-0.27	-0.26	Granulocyte percentage of myeloid white cells;	chr3:42775829	chr3:42732575~42746768:+
THCA	cis	rs2179367	0.959	rs2262617	ENSG00000231760.4	RP11-350J20.5	5.83	1.01e-08	1.84e-06	0.35	0.26	Dupuytren's disease;	chr6:149438590	chr6:149796151~149826294:-
THCA	cis	rs9494145	0.838	rs9494142	ENSG00000232876.1	CTA-212D2.2	-5.83	1.01e-08	1.84e-06	-0.37	-0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135110502	chr6:135055033~135060550:+
THCA	cis	rs10276381	1	rs7796417	ENSG00000234336.5	JAZF1-AS1	-5.83	1.01e-08	1.84e-06	-0.37	-0.26	Crohn's disease;	chr7:28146500	chr7:28180322~28243917:+
THCA	cis	rs28472312	0.685	rs11642638	ENSG00000251417.2	RP11-1348G14.4	5.83	1.01e-08	1.84e-06	0.25	0.26	Intelligence (multi-trait analysis);	chr16:28973624	chr16:28802743~28817828:+
THCA	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	5.83	1.01e-08	1.84e-06	0.28	0.26	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
THCA	cis	rs1707322	0.685	rs11211177	ENSG00000281133.1	AL355480.3	-5.83	1.01e-08	1.84e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45580892~45580996:-
THCA	cis	rs55665837	0.502	rs4757269	ENSG00000251991.1	RNU7-49P	5.83	1.01e-08	1.84e-06	0.29	0.26	Vitamin D levels;	chr11:14814646	chr11:14478892~14478953:+
THCA	cis	rs758324	0.687	rs152053	ENSG00000237714.1	P4HA2-AS1	-5.83	1.01e-08	1.84e-06	-0.4	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132191043	chr5:132184876~132192808:+
THCA	cis	rs890448	0.796	rs4235418	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101420762	chr4:101347780~101348883:+
THCA	cis	rs890448	0.793	rs2433297	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101421153	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2433299	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101421313	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs10213549	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422041	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs1365382	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422729	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs1365383	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422850	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs1365384	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423238	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs13102837	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423377	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs10003315	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423887	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2162338	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101424411	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2433302	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425038	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2433304	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425309	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2433305	ENSG00000254531.1	FLJ20021	5.83	1.01e-08	1.84e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425472	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs4699215	ENSG00000254531.1	FLJ20021	-5.83	1.01e-08	1.84e-06	-0.23	-0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422414	chr4:101347780~101348883:+
THCA	cis	rs13113518	0.812	rs13140173	ENSG00000249700.7	SRD5A3-AS1	5.83	1.01e-08	1.84e-06	0.33	0.26	Height;	chr4:55527164	chr4:55363971~55395847:-
THCA	cis	rs17345786	1	rs3804778	ENSG00000256628.3	ZBTB11-AS1	5.83	1.01e-08	1.84e-06	0.34	0.26	Colonoscopy-negative controls vs population controls;	chr3:101575728	chr3:101676475~101679217:+
THCA	cis	rs7615952	0.576	rs2276727	ENSG00000250012.1	RP11-124N2.1	-5.83	1.01e-08	1.85e-06	-0.25	-0.26	Blood pressure (smoking interaction);	chr3:126107400	chr3:126084220~126095349:+
THCA	cis	rs6928977	0.863	rs2746430	ENSG00000231028.7	LINC00271	5.83	1.01e-08	1.85e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135352154	chr6:135497801~135716055:+
THCA	cis	rs6714710	0.603	rs17488897	ENSG00000230606.9	AC159540.1	-5.83	1.01e-08	1.85e-06	-0.31	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97748701	chr2:97416165~97433527:-
THCA	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	5.83	1.01e-08	1.85e-06	0.24	0.26	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	5.83	1.01e-08	1.85e-06	0.24	0.26	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	5.83	1.01e-08	1.85e-06	0.24	0.26	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	5.83	1.01e-08	1.85e-06	0.24	0.26	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
THCA	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	5.83	1.01e-08	1.85e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	5.83	1.01e-08	1.85e-06	0.24	0.26	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	5.83	1.01e-08	1.85e-06	0.24	0.26	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
THCA	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	5.83	1.01e-08	1.85e-06	0.24	0.26	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
THCA	cis	rs9880211	1	rs9826454	ENSG00000273486.1	RP11-731C17.2	5.83	1.01e-08	1.85e-06	0.27	0.26	Height;Body mass index;	chr3:136234378	chr3:136837338~136839021:-
THCA	cis	rs7809950	1	rs2712200	ENSG00000238832.1	snoU109	-5.83	1.01e-08	1.85e-06	-0.27	-0.26	Coronary artery disease;	chr7:107501990	chr7:107603363~107603507:+
THCA	cis	rs10208649	0.808	rs11886366	ENSG00000233266.1	HMGB1P31	5.83	1.01e-08	1.85e-06	0.6	0.26	Body mass index;	chr2:53997126	chr2:54051334~54051760:+
THCA	cis	rs9816784	0.596	rs11185511	ENSG00000226155.1	AC124944.3	-5.83	1.01e-08	1.85e-06	-0.33	-0.26	Mean corpuscular hemoglobin;	chr3:196108388	chr3:195912049~195913986:+
THCA	cis	rs2117029	0.965	rs2293446	ENSG00000258017.1	RP11-386G11.10	-5.83	1.01e-08	1.85e-06	-0.34	-0.26	Intelligence (multi-trait analysis);	chr12:49018926	chr12:49127782~49147869:+
THCA	cis	rs9381040	0.655	rs2268194	ENSG00000161912.16	ADCY10P1	5.83	1.01e-08	1.85e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41056708	chr6:41101022~41140835:+
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000232546.1	RP11-458F8.1	-5.83	1.01e-08	1.85e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66528779	chr7:66848496~66858136:+
THCA	cis	rs642803	0.591	rs620088	ENSG00000255557.1	RP11-770G2.2	-5.83	1.01e-08	1.85e-06	-0.29	-0.26	Urate levels;	chr11:65741515	chr11:65745729~65771585:+
THCA	cis	rs6928977	0.896	rs2179779	ENSG00000231028.7	LINC00271	5.83	1.02e-08	1.85e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135328678	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.896	rs2746425	ENSG00000231028.7	LINC00271	5.83	1.02e-08	1.85e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135343227	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.86	rs2746426	ENSG00000231028.7	LINC00271	5.83	1.02e-08	1.85e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135345294	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.832	rs2746427	ENSG00000231028.7	LINC00271	5.83	1.02e-08	1.85e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135347959	chr6:135497801~135716055:+
THCA	cis	rs2380205	0.504	rs591878	ENSG00000232807.2	RP11-536K7.3	5.83	1.02e-08	1.85e-06	0.24	0.26	Breast cancer;	chr10:5893474	chr10:5934270~5945900:-
THCA	cis	rs7809950	0.817	rs2237678	ENSG00000238832.1	snoU109	-5.83	1.02e-08	1.85e-06	-0.3	-0.26	Coronary artery disease;	chr7:107562820	chr7:107603363~107603507:+
THCA	cis	rs7111546	0.533	rs41486349	ENSG00000246225.5	RP11-17A1.3	5.83	1.02e-08	1.86e-06	0.41	0.26	Dialysis-related mortality;	chr11:22884149	chr11:22829380~22945393:+
THCA	cis	rs12612619	0.704	rs2384572	ENSG00000229122.1	AGBL5-IT1	5.83	1.02e-08	1.86e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27101883	chr2:27061038~27061815:+
THCA	cis	rs2562456	0.874	rs9304986	ENSG00000268119.4	CTD-2561J22.5	-5.83	1.02e-08	1.86e-06	-0.32	-0.26	Pain;	chr19:21499260	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.917	rs2650805	ENSG00000268119.4	CTD-2561J22.5	-5.83	1.02e-08	1.86e-06	-0.32	-0.26	Pain;	chr19:21505137	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.917	rs10420016	ENSG00000268119.4	CTD-2561J22.5	-5.83	1.02e-08	1.86e-06	-0.32	-0.26	Pain;	chr19:21505800	chr19:21444241~21463908:-
THCA	cis	rs934734	0.699	rs268138	ENSG00000234255.7	AC012370.3	-5.83	1.02e-08	1.86e-06	-0.29	-0.26	Rheumatoid arthritis;	chr2:65380160	chr2:65439888~65456571:-
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000280069.1	CTD-2349P21.3	-5.83	1.02e-08	1.86e-06	-0.39	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30738182~30740275:+
THCA	cis	rs2732480	0.5	rs11168468	ENSG00000240399.1	RP1-228P16.1	5.83	1.02e-08	1.86e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48054813~48055591:-
THCA	cis	rs6430585	0.528	rs309167	ENSG00000231890.6	DARS-AS1	-5.83	1.02e-08	1.86e-06	-0.32	-0.26	Corneal structure;	chr2:135911694	chr2:135985176~136022593:+
THCA	cis	rs6585424	1	rs34148644	ENSG00000225484.5	NUTM2B-AS1	-5.83	1.02e-08	1.86e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163700	chr10:79663088~79826594:-
THCA	cis	rs77972916	0.561	rs4372955	ENSG00000234936.1	AC010883.5	5.83	1.02e-08	1.86e-06	0.32	0.26	Granulocyte percentage of myeloid white cells;	chr2:43339007	chr2:43229573~43233394:+
THCA	cis	rs7809950	0.678	rs7777950	ENSG00000238832.1	snoU109	-5.83	1.02e-08	1.86e-06	-0.3	-0.26	Coronary artery disease;	chr7:107364227	chr7:107603363~107603507:+
THCA	cis	rs11018904	0.575	rs12797899	ENSG00000280385.1	AP000648.5	-5.83	1.02e-08	1.87e-06	-0.3	-0.26	Intelligence (multi-trait analysis);	chr11:90242309	chr11:90193614~90198120:+
THCA	cis	rs3760982	0.935	rs10422990	ENSG00000267058.1	RP11-15A1.3	-5.83	1.02e-08	1.87e-06	-0.22	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43791121	chr19:43891804~43901805:-
THCA	cis	rs2243480	1	rs4718317	ENSG00000232546.1	RP11-458F8.1	5.83	1.03e-08	1.87e-06	0.33	0.26	Diabetic kidney disease;	chr7:66183914	chr7:66848496~66858136:+
THCA	cis	rs6740322	0.841	rs10211126	ENSG00000234936.1	AC010883.5	5.83	1.03e-08	1.87e-06	0.28	0.26	Coronary artery disease;	chr2:43324277	chr2:43229573~43233394:+
THCA	cis	rs6545883	0.868	rs28749199	ENSG00000271889.1	RP11-493E12.1	5.83	1.03e-08	1.87e-06	0.25	0.26	Tuberculosis;	chr2:61599917	chr2:61151433~61162105:-
THCA	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	5.83	1.03e-08	1.87e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	5.83	1.03e-08	1.87e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	5.83	1.03e-08	1.87e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	5.83	1.03e-08	1.87e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
THCA	cis	rs9921338	0.961	rs6498185	ENSG00000262703.1	RP11-485G7.6	-5.83	1.03e-08	1.87e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350869	chr16:11348143~11349321:-
THCA	cis	rs7560272	0.669	rs7598660	ENSG00000163016.8	ALMS1P	5.83	1.03e-08	1.87e-06	0.33	0.26	Schizophrenia;	chr2:73513298	chr2:73644919~73685576:+
THCA	cis	rs9595908	0.9	rs7981943	ENSG00000212293.1	SNORA16	5.83	1.03e-08	1.87e-06	0.3	0.26	Body mass index;	chr13:32593754	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.9	rs7327429	ENSG00000212293.1	SNORA16	5.83	1.03e-08	1.87e-06	0.3	0.26	Body mass index;	chr13:32595259	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.9	rs731413	ENSG00000212293.1	SNORA16	5.83	1.03e-08	1.87e-06	0.3	0.26	Body mass index;	chr13:32601519	chr13:32420390~32420516:-
THCA	cis	rs593531	0.592	rs3168173	ENSG00000212961.4	HNRNPA1P40	5.83	1.03e-08	1.88e-06	0.33	0.26	Neuroticism;	chr11:74331742	chr11:74354443~74355720:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	5.83	1.03e-08	1.88e-06	0.2	0.26	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
THCA	cis	rs62184315	0.536	rs2278591	ENSG00000273240.1	RP11-455J20.3	-5.83	1.03e-08	1.88e-06	-0.35	-0.26	Alcohol dependence (age at onset);	chr2:189755778	chr2:189763859~189764456:-
THCA	cis	rs62184315	0.536	rs16831972	ENSG00000273240.1	RP11-455J20.3	-5.83	1.03e-08	1.88e-06	-0.35	-0.26	Alcohol dependence (age at onset);	chr2:189756707	chr2:189763859~189764456:-
THCA	cis	rs4713118	0.662	rs469228	ENSG00000220721.1	OR1F12	5.83	1.03e-08	1.88e-06	0.33	0.26	Parkinson's disease;	chr6:28002926	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.54	rs469227	ENSG00000220721.1	OR1F12	5.83	1.03e-08	1.88e-06	0.33	0.26	Parkinson's disease;	chr6:28002927	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs149948	ENSG00000220721.1	OR1F12	5.83	1.03e-08	1.88e-06	0.33	0.26	Parkinson's disease;	chr6:28007039	chr6:28073316~28074233:+
THCA	cis	rs4648045	0.594	rs62327180	ENSG00000246560.2	RP11-10L12.4	5.83	1.03e-08	1.88e-06	0.34	0.26	Lymphocyte percentage of white cells;	chr4:102619605	chr4:102828055~102844075:+
THCA	cis	rs77972916	0.505	rs6719754	ENSG00000234936.1	AC010883.5	5.83	1.03e-08	1.88e-06	0.29	0.26	Granulocyte percentage of myeloid white cells;	chr2:43299247	chr2:43229573~43233394:+
THCA	cis	rs67340775	0.541	rs169287	ENSG00000280107.1	AL022393.9	-5.83	1.03e-08	1.88e-06	-0.36	-0.26	Lung cancer in ever smokers;	chr6:27886982	chr6:28170845~28172521:+
THCA	cis	rs12908161	0.853	rs11633788	ENSG00000259728.4	LINC00933	5.83	1.03e-08	1.88e-06	0.33	0.26	Schizophrenia;	chr15:84761911	chr15:84570649~84580175:+
THCA	cis	rs964184	0.63	rs7930786	ENSG00000254851.1	RP11-109L13.1	-5.83	1.03e-08	1.88e-06	-0.52	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116754011	chr11:117135528~117138582:+
THCA	cis	rs111649495	1	rs111649495	ENSG00000250678.1	CTB-161M19.1	-5.83	1.03e-08	1.88e-06	-0.46	-0.26	Response to amphetamines;	chr5:119020720	chr5:119010060~119010542:+
THCA	cis	rs12893668	0.703	rs35498576	ENSG00000269910.1	RP11-73M18.10	5.83	1.03e-08	1.88e-06	0.25	0.26	Reticulocyte count;	chr14:103559556	chr14:103694516~103695050:-
THCA	cis	rs2559856	1	rs2695299	ENSG00000274560.1	RP11-285E23.2	5.83	1.03e-08	1.88e-06	0.16	0.26	Blood protein levels;	chr12:101688886	chr12:101696002~101696450:-
THCA	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	5.83	1.03e-08	1.88e-06	0.25	0.26	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
THCA	cis	rs12497850	0.931	rs7616815	ENSG00000229759.1	MRPS18AP1	5.83	1.03e-08	1.89e-06	0.35	0.26	Parkinson's disease;	chr3:48742282	chr3:48256350~48256938:-
THCA	cis	rs7615952	0.558	rs7641353	ENSG00000171084.14	FAM86JP	5.83	1.03e-08	1.89e-06	0.31	0.26	Blood pressure (smoking interaction);	chr3:125621035	chr3:125916620~125930024:+
THCA	cis	rs79040073	0.53	rs73394357	ENSG00000259531.2	RP11-295H24.3	5.83	1.03e-08	1.89e-06	0.36	0.26	Lung cancer in ever smokers;	chr15:49300314	chr15:49365124~49366685:-
THCA	cis	rs17508449	0.819	rs4839329	ENSG00000232450.1	RP4-730K3.3	-5.83	1.03e-08	1.89e-06	-0.41	-0.26	Leprosy;	chr1:113593083	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.865	rs76308249	ENSG00000232450.1	RP4-730K3.3	-5.83	1.03e-08	1.89e-06	-0.41	-0.26	Leprosy;	chr1:113605059	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.779	rs78703286	ENSG00000232450.1	RP4-730K3.3	-5.83	1.03e-08	1.89e-06	-0.41	-0.26	Leprosy;	chr1:113605493	chr1:113698884~113699631:-
THCA	cis	rs7225151	0.803	rs16954560	ENSG00000234327.6	AC012146.7	-5.83	1.03e-08	1.89e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5349516	chr17:5111468~5115004:+
THCA	cis	rs6142102	1	rs12480839	ENSG00000275784.1	RP5-1125A11.6	-5.83	1.03e-08	1.89e-06	-0.27	-0.26	Skin pigmentation;	chr20:34139624	chr20:33989480~33991818:-
THCA	cis	rs763121	0.889	rs4820335	ENSG00000235209.1	CTA-150C2.13	-5.83	1.03e-08	1.89e-06	-0.33	-0.26	Menopause (age at onset);	chr22:38539922	chr22:38921227~38924708:+
THCA	cis	rs1876905	0.68	rs9400468	ENSG00000230177.1	RP5-1112D6.4	-5.83	1.04e-08	1.89e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111138766	chr6:111277932~111278742:+
THCA	cis	rs2303319	0.504	rs62188961	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Cognitive function;	chr2:161638889	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs16845960	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Cognitive function;	chr2:161645103	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188984	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Cognitive function;	chr2:161658008	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56039028	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Cognitive function;	chr2:161659853	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs16845997	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Cognitive function;	chr2:161664536	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72875528	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Blood osmolality (transformed sodium);	chr2:161677013	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56274002	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Cognitive function;	chr2:161680205	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188990	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Cognitive function;	chr2:161684125	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189003	ENSG00000227403.1	AC009299.3	5.83	1.04e-08	1.89e-06	0.54	0.26	Cognitive function;	chr2:161691594	chr2:161244739~161249050:+
THCA	cis	rs7246657	0.663	rs9304568	ENSG00000267422.1	CTD-2554C21.1	-5.83	1.04e-08	1.89e-06	-0.29	-0.26	Coronary artery calcification;	chr19:37563606	chr19:37779686~37792865:+
THCA	cis	rs6545883	0.929	rs7563678	ENSG00000270820.4	RP11-355B11.2	-5.83	1.04e-08	1.89e-06	-0.21	-0.26	Tuberculosis;	chr2:61514676	chr2:61471188~61484130:+
THCA	cis	rs6968419	0.674	rs6466571	ENSG00000237870.5	AC073130.1	-5.83	1.04e-08	1.89e-06	-0.28	-0.26	Intraocular pressure;	chr7:116269991	chr7:116275606~116286734:-
THCA	cis	rs4266144	0.581	rs1806867	ENSG00000241770.1	RP11-555M1.3	-5.83	1.04e-08	1.89e-06	-0.33	-0.26	Coronary artery disease;	chr3:157110513	chr3:157163452~157169133:+
THCA	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	5.83	1.04e-08	1.89e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
THCA	cis	rs9467773	1	rs4713008	ENSG00000124549.13	BTN2A3P	5.83	1.04e-08	1.89e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26421391~26432383:+
THCA	cis	rs2029362	0.967	rs10835189	ENSG00000245573.6	BDNF-AS	5.83	1.04e-08	1.89e-06	0.21	0.26	Total body bone mineral density;	chr11:27520448	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.901	rs11030042	ENSG00000245573.6	BDNF-AS	5.83	1.04e-08	1.89e-06	0.21	0.26	Total body bone mineral density;	chr11:27520781	chr11:27506838~27698174:+
THCA	cis	rs12681963	0.688	rs12544416	ENSG00000248159.1	HSPA8P11	5.83	1.04e-08	1.89e-06	0.47	0.26	Migraine;	chr8:30182057	chr8:30237382~30240997:+
THCA	cis	rs890448	0.76	rs7699920	ENSG00000254531.1	FLJ20021	-5.83	1.04e-08	1.9e-06	-0.23	-0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422302	chr4:101347780~101348883:+
THCA	cis	rs6977955	1	rs11495981	ENSG00000234336.5	JAZF1-AS1	5.83	1.04e-08	1.9e-06	0.3	0.26	Allergic disease (asthma, hay fever or eczema);	chr7:28137682	chr7:28180322~28243917:+
THCA	cis	rs7083	0.935	rs523366	ENSG00000254851.1	RP11-109L13.1	5.83	1.04e-08	1.9e-06	0.35	0.26	Blood protein levels;	chr11:117248836	chr11:117135528~117138582:+
THCA	cis	rs12664251	0.706	rs2357021	ENSG00000253194.1	RP11-351A11.1	-5.83	1.04e-08	1.9e-06	-0.35	-0.26	Schizophrenia;	chr6:119018949	chr6:118934785~119031541:+
THCA	cis	rs7493	0.755	rs116306774	ENSG00000233942.1	AC004012.1	5.83	1.04e-08	1.9e-06	0.39	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95387664	chr7:95471835~95473998:+
THCA	cis	rs2348418	0.798	rs4930826	ENSG00000247934.4	RP11-967K21.1	5.83	1.04e-08	1.9e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28574385	chr12:28163298~28190738:-
THCA	cis	rs8062405	0.789	rs28676837	ENSG00000278665.1	RP11-666O2.4	-5.83	1.04e-08	1.9e-06	-0.3	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28599241~28601881:-
THCA	cis	rs934734	0.736	rs6738087	ENSG00000234255.7	AC012370.3	5.83	1.04e-08	1.9e-06	0.3	0.26	Rheumatoid arthritis;	chr2:65365191	chr2:65439888~65456571:-
THCA	cis	rs1876905	0.68	rs3749867	ENSG00000230177.1	RP5-1112D6.4	-5.83	1.04e-08	1.9e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111103615	chr6:111277932~111278742:+
THCA	cis	rs7211079	0.505	rs60323863	ENSG00000279259.1	RP11-334C17.3	5.83	1.04e-08	1.9e-06	0.33	0.26	Myocardial infarction;	chr17:80151287	chr17:80147250~80148596:+
THCA	cis	rs9549367	0.713	rs3024757	ENSG00000269125.1	RP11-98F14.11	-5.83	1.04e-08	1.9e-06	-0.32	-0.26	Platelet distribution width;	chr13:113168872	chr13:113165002~113165183:-
THCA	cis	rs9880211	1	rs9880211	ENSG00000273486.1	RP11-731C17.2	5.83	1.04e-08	1.9e-06	0.27	0.26	Height;Body mass index;	chr3:136388707	chr3:136837338~136839021:-
THCA	cis	rs6928977	0.5	rs6925161	ENSG00000231028.7	LINC00271	-5.83	1.04e-08	1.9e-06	-0.21	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135615496	chr6:135497801~135716055:+
THCA	cis	rs755249	0.565	rs12138051	ENSG00000182109.6	RP11-69E11.4	-5.83	1.04e-08	1.9e-06	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39522280~39546187:-
THCA	cis	rs755249	0.564	rs6691194	ENSG00000182109.6	RP11-69E11.4	-5.83	1.04e-08	1.9e-06	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39522280~39546187:-
THCA	cis	rs6963495	0.615	rs1728645	ENSG00000272604.1	RP11-251G23.5	5.83	1.04e-08	1.9e-06	0.29	0.26	Bipolar disorder (body mass index interaction);	chr7:105564668	chr7:105571083~105573660:+
THCA	cis	rs79040073	0.53	rs3784630	ENSG00000259531.2	RP11-295H24.3	5.83	1.05e-08	1.9e-06	0.35	0.26	Lung cancer in ever smokers;	chr15:49322952	chr15:49365124~49366685:-
THCA	cis	rs7169304	0.531	rs59356430	ENSG00000259531.2	RP11-295H24.3	5.83	1.05e-08	1.9e-06	0.35	0.26	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49324835	chr15:49365124~49366685:-
THCA	cis	rs6088580	0.524	rs6088575	ENSG00000269202.1	RP4-614O4.12	-5.83	1.05e-08	1.91e-06	-0.23	-0.26	Glomerular filtration rate (creatinine);	chr20:34685599	chr20:35201747~35203288:-
THCA	cis	rs17301013	0.507	rs7414200	ENSG00000227373.4	RP11-160H22.5	5.83	1.05e-08	1.91e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174569820	chr1:174115300~174160004:-
THCA	cis	rs755249	0.565	rs722357	ENSG00000182109.6	RP11-69E11.4	-5.83	1.05e-08	1.91e-06	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39522280~39546187:-
THCA	cis	rs9402743	0.748	rs11754958	ENSG00000231028.7	LINC00271	-5.83	1.05e-08	1.91e-06	-0.23	-0.26	Systemic lupus erythematosus;	chr6:135651462	chr6:135497801~135716055:+
THCA	cis	rs62184315	0.536	rs62183653	ENSG00000273240.1	RP11-455J20.3	-5.83	1.05e-08	1.91e-06	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189650099	chr2:189763859~189764456:-
THCA	cis	rs62184315	0.536	rs72920421	ENSG00000273240.1	RP11-455J20.3	-5.83	1.05e-08	1.91e-06	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189650292	chr2:189763859~189764456:-
THCA	cis	rs2243480	1	rs383402	ENSG00000232546.1	RP11-458F8.1	5.83	1.05e-08	1.91e-06	0.33	0.26	Diabetic kidney disease;	chr7:66121666	chr7:66848496~66858136:+
THCA	cis	rs4650994	1	rs4650994	ENSG00000273384.1	RP5-1098D14.1	-5.83	1.05e-08	1.91e-06	-0.32	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178546177	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.967	rs4650992	ENSG00000273384.1	RP5-1098D14.1	5.83	1.05e-08	1.91e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178546000	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.935	rs12039531	ENSG00000273384.1	RP5-1098D14.1	5.83	1.05e-08	1.91e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178546477	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs10798616	ENSG00000273384.1	RP5-1098D14.1	5.83	1.05e-08	1.91e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178546507	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs10798617	ENSG00000273384.1	RP5-1098D14.1	5.83	1.05e-08	1.91e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178546671	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs4650995	ENSG00000273384.1	RP5-1098D14.1	5.83	1.05e-08	1.91e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178548181	chr1:178651706~178652282:+
THCA	cis	rs2348418	0.832	rs4930822	ENSG00000247934.4	RP11-967K21.1	5.83	1.05e-08	1.91e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28421789	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.832	rs4930823	ENSG00000247934.4	RP11-967K21.1	5.83	1.05e-08	1.91e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28421892	chr12:28163298~28190738:-
THCA	cis	rs2129782	1	rs73287345	ENSG00000253553.4	RP11-586K2.1	5.83	1.05e-08	1.91e-06	0.44	0.26	Electrodermal activity;	chr8:88408955	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs80231582	ENSG00000253553.4	RP11-586K2.1	5.83	1.05e-08	1.91e-06	0.44	0.26	Electrodermal activity;	chr8:88412535	chr8:88326836~88737134:+
THCA	cis	rs4664293	0.667	rs10169681	ENSG00000226266.5	AC009961.3	5.83	1.05e-08	1.91e-06	0.3	0.26	Monocyte percentage of white cells;	chr2:159782065	chr2:159670708~159712435:-
THCA	cis	rs2136613	0.505	rs10761674	ENSG00000238280.1	RP11-436D10.3	-5.83	1.05e-08	1.91e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62858580	chr10:62793562~62805887:-
THCA	cis	rs3213958	0.621	rs17278047	ENSG00000249274.1	PDLIM1P4	-5.83	1.05e-08	1.91e-06	-0.34	-0.26	Blood protein levels;	chr3:98880100	chr3:98782188~98783193:+
THCA	cis	rs3213958	0.574	rs6805605	ENSG00000249274.1	PDLIM1P4	-5.83	1.05e-08	1.91e-06	-0.34	-0.26	Blood protein levels;	chr3:98884146	chr3:98782188~98783193:+
THCA	cis	rs9467773	1	rs1321481	ENSG00000124549.13	BTN2A3P	5.83	1.05e-08	1.91e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.967	rs6932865	ENSG00000124549.13	BTN2A3P	5.83	1.05e-08	1.91e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6933176	ENSG00000124549.13	BTN2A3P	5.83	1.05e-08	1.91e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26421391~26432383:+
THCA	cis	rs12999373	0.956	rs34848618	ENSG00000272342.1	RP13-539J13.1	-5.83	1.05e-08	1.91e-06	-0.38	-0.26	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:672745	chr2:739588~740164:-
THCA	cis	rs1979679	0.719	rs11049489	ENSG00000278733.1	RP11-425D17.1	5.83	1.05e-08	1.92e-06	0.26	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28259482	chr12:28185625~28186190:-
THCA	cis	rs1876905	0.68	rs373526	ENSG00000230177.1	RP5-1112D6.4	5.83	1.05e-08	1.92e-06	0.27	0.26	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111277932~111278742:+
THCA	cis	rs74233809	0.901	rs17115100	ENSG00000213277.3	MARCKSL1P1	5.83	1.05e-08	1.92e-06	0.4	0.26	Birth weight;	chr10:102831636	chr10:103175554~103176094:+
THCA	cis	rs1979679	0.842	rs12049916	ENSG00000278733.1	RP11-425D17.1	5.83	1.05e-08	1.92e-06	0.27	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:28185625~28186190:-
THCA	cis	rs6585424	1	rs34100029	ENSG00000225484.5	NUTM2B-AS1	-5.83	1.05e-08	1.92e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163842	chr10:79663088~79826594:-
THCA	cis	rs9467773	0.572	rs9467737	ENSG00000124549.13	BTN2A3P	-5.83	1.05e-08	1.92e-06	-0.25	-0.26	Intelligence (multi-trait analysis);	chr6:26381402	chr6:26421391~26432383:+
THCA	cis	rs12893668	0.572	rs34000399	ENSG00000269910.1	RP11-73M18.10	5.83	1.05e-08	1.92e-06	0.24	0.26	Reticulocyte count;	chr14:103635080	chr14:103694516~103695050:-
THCA	cis	rs4639966	0.836	rs11217014	ENSG00000255239.1	AP002954.6	-5.83	1.05e-08	1.92e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118755577	chr11:118688039~118690600:-
THCA	cis	rs67478160	0.619	rs12885018	ENSG00000258735.1	LINC00637	-5.83	1.05e-08	1.92e-06	-0.31	-0.26	Schizophrenia;	chr14:103807475	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs12891175	ENSG00000258735.1	LINC00637	-5.83	1.05e-08	1.92e-06	-0.31	-0.26	Schizophrenia;	chr14:103807829	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.595	rs12889993	ENSG00000258735.1	LINC00637	-5.83	1.05e-08	1.92e-06	-0.31	-0.26	Schizophrenia;	chr14:103807957	chr14:103847721~103858049:+
THCA	cis	rs7760535	0.763	rs10457240	ENSG00000271789.1	RP5-1112D6.7	-5.83	1.05e-08	1.92e-06	-0.25	-0.26	Metabolic traits;	chr6:111527671	chr6:111297126~111298510:+
THCA	cis	rs9813712	0.953	rs7619208	ENSG00000228252.7	COL6A4P2	-5.83	1.05e-08	1.92e-06	-0.3	-0.26	Response to amphetamines;	chr3:130258163	chr3:130212823~130273806:+
THCA	cis	rs712039	0.652	rs1829453	ENSG00000276054.1	RP11-378E13.3	5.83	1.05e-08	1.92e-06	0.39	0.26	Tuberculosis;	chr17:37449741	chr17:37386886~37387926:+
THCA	cis	rs7809950	0.817	rs4727678	ENSG00000238832.1	snoU109	-5.83	1.05e-08	1.92e-06	-0.3	-0.26	Coronary artery disease;	chr7:107443190	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.817	rs4727679	ENSG00000238832.1	snoU109	-5.83	1.05e-08	1.92e-06	-0.3	-0.26	Coronary artery disease;	chr7:107444573	chr7:107603363~107603507:+
THCA	cis	rs4908768	0.501	rs1922983	ENSG00000232912.4	RP5-1115A15.1	5.83	1.06e-08	1.92e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8424645~8434838:+
THCA	cis	rs748404	0.666	rs7177146	ENSG00000249839.1	AC011330.5	-5.83	1.06e-08	1.92e-06	-0.38	-0.26	Lung cancer;	chr15:43506110	chr15:43663654~43684339:-
THCA	cis	rs8049040	0.609	rs4258624	ENSG00000260886.1	TAT-AS1	-5.83	1.06e-08	1.92e-06	-0.36	-0.26	Blood protein levels;	chr16:71434048	chr16:71565789~71578187:+
THCA	cis	rs1865760	0.964	rs9295677	ENSG00000272462.2	U91328.19	-5.83	1.06e-08	1.93e-06	-0.22	-0.26	Height;	chr6:25933484	chr6:25992662~26001775:+
THCA	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-5.83	1.06e-08	1.93e-06	-0.25	-0.26	Height;	chr2:46629946	chr2:46668870~46670778:+
THCA	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-5.83	1.06e-08	1.93e-06	-0.25	-0.26	Height;	chr2:46630262	chr2:46668870~46670778:+
THCA	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-5.83	1.06e-08	1.93e-06	-0.25	-0.26	Height;	chr2:46631182	chr2:46668870~46670778:+
THCA	cis	rs7809950	0.678	rs2301801	ENSG00000238832.1	snoU109	-5.83	1.06e-08	1.93e-06	-0.31	-0.26	Coronary artery disease;	chr7:107230301	chr7:107603363~107603507:+
THCA	cis	rs2303759	0.918	rs1054770	ENSG00000268686.1	AC010524.2	-5.83	1.06e-08	1.93e-06	-0.37	-0.26	Multiple sclerosis;	chr19:49374858	chr19:49368705~49388081:-
THCA	cis	rs138024639	1	rs138024639	ENSG00000219392.1	RP1-265C24.5	-5.83	1.06e-08	1.93e-06	-0.57	-0.26	Breast cancer;	chr6:28468244	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs55690788	ENSG00000219392.1	RP1-265C24.5	-5.83	1.06e-08	1.93e-06	-0.57	-0.26	Depression;	chr6:28468368	chr6:28115628~28116551:+
THCA	cis	rs2129782	1	rs9297465	ENSG00000253553.4	RP11-586K2.1	5.83	1.06e-08	1.93e-06	0.44	0.26	Electrodermal activity;	chr8:88404597	chr8:88326836~88737134:+
THCA	cis	rs9926296	0.712	rs459920	ENSG00000274627.1	RP11-104N10.2	5.82	1.06e-08	1.93e-06	0.27	0.26	Vitiligo;	chr16:89664419	chr16:89516797~89522217:+
THCA	cis	rs9677476	1	rs12621280	ENSG00000224376.1	AC017104.6	5.82	1.06e-08	1.93e-06	0.29	0.26	Food antigen IgG levels;	chr2:231268271	chr2:231388976~231394991:+
THCA	cis	rs78487399	0.808	rs12105394	ENSG00000234936.1	AC010883.5	5.82	1.06e-08	1.93e-06	0.37	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43449651	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs76171330	ENSG00000234936.1	AC010883.5	5.82	1.06e-08	1.93e-06	0.37	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43450301	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs12105626	ENSG00000234936.1	AC010883.5	5.82	1.06e-08	1.93e-06	0.37	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451620	chr2:43229573~43233394:+
THCA	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	5.82	1.06e-08	1.93e-06	0.3	0.26	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
THCA	cis	rs2765539	0.74	rs10047100	ENSG00000231365.4	RP11-418J17.1	-5.82	1.06e-08	1.93e-06	-0.3	-0.26	Waist-hip ratio;	chr1:119077734	chr1:119140396~119275973:+
THCA	cis	rs9467773	1	rs1884946	ENSG00000124549.13	BTN2A3P	5.82	1.06e-08	1.93e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26421391~26432383:+
THCA	cis	rs6142102	0.961	rs6119447	ENSG00000275784.1	RP5-1125A11.6	-5.82	1.06e-08	1.93e-06	-0.27	-0.26	Skin pigmentation;	chr20:34080770	chr20:33989480~33991818:-
THCA	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-5.82	1.06e-08	1.94e-06	-0.28	-0.26	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
THCA	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	5.82	1.06e-08	1.94e-06	0.26	0.26	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
THCA	cis	rs7727544	0.508	rs10900804	ENSG00000233006.5	AC034220.3	5.82	1.06e-08	1.94e-06	0.21	0.26	Blood metabolite levels;	chr5:132066152	chr5:132311285~132369916:-
THCA	cis	rs792448	0.728	rs2252044	ENSG00000226251.4	RP11-15I11.3	-5.82	1.06e-08	1.94e-06	-0.32	-0.26	White blood cell count (basophil);	chr1:212342903	chr1:212225278~212238977:-
THCA	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-5.82	1.06e-08	1.94e-06	-0.49	-0.26	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
THCA	cis	rs172166	0.694	rs1150666	ENSG00000220721.1	OR1F12	5.82	1.06e-08	1.94e-06	0.32	0.26	Cardiac Troponin-T levels;	chr6:28156150	chr6:28073316~28074233:+
THCA	cis	rs9813712	0.585	rs9855392	ENSG00000249846.5	RP11-77P16.4	-5.82	1.06e-08	1.94e-06	-0.33	-0.26	Response to amphetamines;	chr3:130214403	chr3:130112550~130120579:+
THCA	cis	rs7809950	1	rs2894475	ENSG00000238832.1	snoU109	-5.82	1.06e-08	1.94e-06	-0.28	-0.26	Coronary artery disease;	chr7:107622113	chr7:107603363~107603507:+
THCA	cis	rs2303319	0.504	rs62188988	ENSG00000227403.1	AC009299.3	5.82	1.06e-08	1.94e-06	0.54	0.26	Cognitive function;	chr2:161674558	chr2:161244739~161249050:+
THCA	cis	rs4713118	0.513	rs149989	ENSG00000220721.1	OR1F12	5.82	1.06e-08	1.94e-06	0.31	0.26	Parkinson's disease;	chr6:28030406	chr6:28073316~28074233:+
THCA	cis	rs79349575	0.715	rs1058018	ENSG00000248278.1	SUMO2P17	5.82	1.07e-08	1.94e-06	0.3	0.26	Type 2 diabetes;	chr17:48922889	chr17:48874860~48908983:-
THCA	cis	rs2303319	0.504	rs55840249	ENSG00000227403.1	AC009299.3	5.82	1.07e-08	1.94e-06	0.54	0.26	Cognitive function;	chr2:161570339	chr2:161244739~161249050:+
THCA	cis	rs1707322	0.717	rs11211161	ENSG00000281133.1	AL355480.3	-5.82	1.07e-08	1.94e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs61784793	ENSG00000281133.1	AL355480.3	-5.82	1.07e-08	1.94e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs4586014	ENSG00000281133.1	AL355480.3	-5.82	1.07e-08	1.94e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.648	rs4439382	ENSG00000281133.1	AL355480.3	-5.82	1.07e-08	1.94e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45580892~45580996:-
THCA	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-5.82	1.07e-08	1.94e-06	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
THCA	cis	rs9880211	0.706	rs67382287	ENSG00000273486.1	RP11-731C17.2	5.82	1.07e-08	1.94e-06	0.28	0.26	Height;Body mass index;	chr3:136661617	chr3:136837338~136839021:-
THCA	cis	rs7176527	0.848	rs72630461	ENSG00000188388.10	GOLGA6L3	5.82	1.07e-08	1.94e-06	0.46	0.26	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84696913	chr15:85240472~85247170:+
THCA	cis	rs4819052	0.635	rs2838808	ENSG00000223768.1	LINC00205	-5.82	1.07e-08	1.94e-06	-0.24	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45201191	chr21:45293285~45297354:+
THCA	cis	rs10276381	1	rs10280937	ENSG00000234336.5	JAZF1-AS1	-5.82	1.07e-08	1.94e-06	-0.37	-0.26	Crohn's disease;	chr7:28142687	chr7:28180322~28243917:+
THCA	cis	rs9921338	0.887	rs7189044	ENSG00000262703.1	RP11-485G7.6	-5.82	1.07e-08	1.94e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348339	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs57579443	ENSG00000262703.1	RP11-485G7.6	-5.82	1.07e-08	1.94e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11349140	chr16:11348143~11349321:-
THCA	cis	rs9880211	0.699	rs9809269	ENSG00000273486.1	RP11-731C17.2	5.82	1.07e-08	1.94e-06	0.29	0.26	Height;Body mass index;	chr3:136711064	chr3:136837338~136839021:-
THCA	cis	rs7829975	0.902	rs777707	ENSG00000254153.1	CTA-398F10.2	-5.82	1.07e-08	1.95e-06	-0.28	-0.26	Mood instability;	chr8:8726834	chr8:8456909~8461337:-
THCA	cis	rs748404	0.589	rs3862138	ENSG00000249839.1	AC011330.5	-5.82	1.07e-08	1.95e-06	-0.37	-0.26	Lung cancer;	chr15:43523801	chr15:43663654~43684339:-
THCA	cis	rs12101261	0.583	rs917985	ENSG00000259167.2	NMNAT1P1	5.82	1.07e-08	1.95e-06	0.39	0.26	Graves' disease;	chr14:81003955	chr14:81032529~81033404:+
THCA	cis	rs6545883	0.929	rs2593625	ENSG00000271889.1	RP11-493E12.1	5.82	1.07e-08	1.95e-06	0.26	0.26	Tuberculosis;	chr2:61441634	chr2:61151433~61162105:-
THCA	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	5.82	1.07e-08	1.95e-06	0.28	0.26	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	5.82	1.07e-08	1.95e-06	0.28	0.26	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
THCA	cis	rs13256369	0.762	rs13278972	ENSG00000253893.2	FAM85B	-5.82	1.07e-08	1.95e-06	-0.35	-0.26	Obesity-related traits;	chr8:8739670	chr8:8167819~8226614:-
THCA	cis	rs911555	0.504	rs8006526	ENSG00000269940.1	RP11-73M18.7	5.82	1.07e-08	1.95e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr14:103608678	chr14:103694560~103695170:+
THCA	cis	rs950169	0.58	rs2271431	ENSG00000259295.5	CSPG4P12	5.82	1.07e-08	1.95e-06	0.4	0.26	Schizophrenia;	chr15:84646233	chr15:85191438~85213905:+
THCA	cis	rs2439831	0.681	rs526450	ENSG00000249839.1	AC011330.5	-5.82	1.07e-08	1.95e-06	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43307127	chr15:43663654~43684339:-
THCA	cis	rs1889642	0.743	rs9530960	ENSG00000227354.5	RBM26-AS1	5.82	1.07e-08	1.95e-06	0.24	0.26	Colonoscopy-negative controls vs population controls;	chr13:79799773	chr13:79406309~79424328:+
THCA	cis	rs10043228	0.702	rs6866938	ENSG00000248445.4	SEMA6A-AS1	-5.82	1.07e-08	1.95e-06	-0.28	-0.26	Asthma or chronic obstructive pulmonary disease;	chr5:116292420	chr5:116447547~116508276:+
THCA	cis	rs10971721	0.822	rs72729357	ENSG00000281128.1	PTENP1-AS	5.82	1.07e-08	1.95e-06	0.59	0.26	Body mass index;	chr9:34041170	chr9:33677268~33688011:+
THCA	cis	rs2562456	0.917	rs2681389	ENSG00000268119.4	CTD-2561J22.5	-5.82	1.07e-08	1.95e-06	-0.32	-0.26	Pain;	chr19:21509773	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.917	rs6511256	ENSG00000268119.4	CTD-2561J22.5	-5.82	1.07e-08	1.95e-06	-0.32	-0.26	Pain;	chr19:21510513	chr19:21444241~21463908:-
THCA	cis	rs172166	0.637	rs1233691	ENSG00000226314.6	ZNF192P1	-5.82	1.07e-08	1.95e-06	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28186119	chr6:28161781~28169594:+
THCA	cis	rs7560272	0.723	rs6722867	ENSG00000163016.8	ALMS1P	5.82	1.08e-08	1.96e-06	0.33	0.26	Schizophrenia;	chr2:73589158	chr2:73644919~73685576:+
THCA	cis	rs7809950	0.817	rs2237671	ENSG00000238832.1	snoU109	-5.82	1.08e-08	1.96e-06	-0.29	-0.26	Coronary artery disease;	chr7:107491083	chr7:107603363~107603507:+
THCA	cis	rs4591358	0.608	rs13003168	ENSG00000223466.1	AC064834.2	-5.82	1.08e-08	1.96e-06	-0.4	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195496394	chr2:195533035~195538681:+
THCA	cis	rs4934494	0.727	rs1590566	ENSG00000240996.1	RP11-80H5.7	-5.82	1.08e-08	1.96e-06	-0.28	-0.26	Red blood cell count;	chr10:89778781	chr10:89694295~89697928:-
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000228409.4	CCT6P1	5.82	1.08e-08	1.96e-06	0.3	0.26	Diabetic kidney disease;	chr7:65947955	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000228409.4	CCT6P1	5.82	1.08e-08	1.96e-06	0.3	0.26	Diabetic kidney disease;	chr7:65950886	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000228409.4	CCT6P1	5.82	1.08e-08	1.96e-06	0.3	0.26	Diabetic kidney disease;	chr7:65951525	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000228409.4	CCT6P1	5.82	1.08e-08	1.96e-06	0.3	0.26	Diabetic kidney disease;	chr7:65951549	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000228409.4	CCT6P1	5.82	1.08e-08	1.96e-06	0.3	0.26	Diabetic kidney disease;	chr7:65956884	chr7:65751142~65763354:+
THCA	cis	rs8014252	0.803	rs7158201	ENSG00000259158.2	ADAM20P1	5.82	1.08e-08	1.96e-06	0.31	0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70543829	chr14:70468881~70483756:-
THCA	cis	rs6802315	0.604	rs9863103	ENSG00000272247.1	RP11-379F4.9	5.82	1.08e-08	1.96e-06	0.25	0.26	Periodontitis (CDC/AAP);	chr3:158746014	chr3:158801257~158801935:-
THCA	cis	rs7493	0.853	rs11770901	ENSG00000233942.1	AC004012.1	5.82	1.08e-08	1.96e-06	0.4	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95425168	chr7:95471835~95473998:+
THCA	cis	rs12908161	1	rs17601029	ENSG00000259295.5	CSPG4P12	5.82	1.08e-08	1.96e-06	0.39	0.26	Schizophrenia;	chr15:84804478	chr15:85191438~85213905:+
THCA	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-5.82	1.08e-08	1.96e-06	-0.25	-0.26	Height;	chr2:46640019	chr2:46668870~46670778:+
THCA	cis	rs11976180	1	rs2961144	ENSG00000273234.1	OR2A13P	5.82	1.08e-08	1.96e-06	0.29	0.26	Obesity-related traits;	chr7:144050777	chr7:144142009~144142938:+
THCA	cis	rs4950322	0.57	rs72691004	ENSG00000278811.3	LINC00624	5.82	1.08e-08	1.96e-06	0.31	0.26	Protein quantitative trait loci;	chr1:147234309	chr1:147258885~147517875:-
THCA	cis	rs4713118	0.513	rs1225591	ENSG00000226314.6	ZNF192P1	-5.82	1.08e-08	1.96e-06	-0.31	-0.26	Parkinson's disease;	chr6:28180974	chr6:28161781~28169594:+
THCA	cis	rs2243480	1	rs4548056	ENSG00000228409.4	CCT6P1	5.82	1.08e-08	1.96e-06	0.3	0.26	Diabetic kidney disease;	chr7:65833886	chr7:65751142~65763354:+
THCA	cis	rs9813712	0.595	rs1453240	ENSG00000253540.4	FAM86HP	-5.82	1.08e-08	1.96e-06	-0.28	-0.26	Response to amphetamines;	chr3:130282849	chr3:130099092~130111472:-
THCA	cis	rs7598759	0.679	rs6437018	ENSG00000181798.2	LINC00471	-5.82	1.08e-08	1.96e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231462980	chr2:231508426~231514339:-
THCA	cis	rs7598759	0.679	rs6437019	ENSG00000181798.2	LINC00471	-5.82	1.08e-08	1.96e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231462996	chr2:231508426~231514339:-
THCA	cis	rs9926296	0.715	rs467035	ENSG00000274627.1	RP11-104N10.2	-5.82	1.08e-08	1.96e-06	-0.27	-0.26	Vitiligo;	chr16:89673877	chr16:89516797~89522217:+
THCA	cis	rs442309	0.783	rs224095	ENSG00000238280.1	RP11-436D10.3	-5.82	1.08e-08	1.97e-06	-0.31	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62782299	chr10:62793562~62805887:-
THCA	cis	rs12478296	1	rs56292923	ENSG00000261186.2	RP11-341N2.1	-5.82	1.08e-08	1.97e-06	-0.41	-0.26	Obesity-related traits;	chr2:242097835	chr2:242087351~242088457:-
THCA	cis	rs317865	0.737	rs73234642	ENSG00000263327.5	TAPT1-AS1	-5.82	1.08e-08	1.97e-06	-0.46	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16185107	chr4:16226685~16320140:+
THCA	cis	rs317865	0.737	rs73234644	ENSG00000263327.5	TAPT1-AS1	-5.82	1.08e-08	1.97e-06	-0.46	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16189038	chr4:16226685~16320140:+
THCA	cis	rs317865	0.737	rs73234648	ENSG00000263327.5	TAPT1-AS1	-5.82	1.08e-08	1.97e-06	-0.46	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16191979	chr4:16226685~16320140:+
THCA	cis	rs317865	0.737	rs73234651	ENSG00000263327.5	TAPT1-AS1	-5.82	1.08e-08	1.97e-06	-0.46	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16195028	chr4:16226685~16320140:+
THCA	cis	rs317865	0.737	rs55949632	ENSG00000263327.5	TAPT1-AS1	-5.82	1.08e-08	1.97e-06	-0.46	-0.26	Kidney disease (early stage) in type 1 diabetes;	chr4:16205449	chr4:16226685~16320140:+
THCA	cis	rs8002861	0.87	rs2875541	ENSG00000274001.1	RP11-5G9.5	5.82	1.08e-08	1.97e-06	0.29	0.26	Leprosy;	chr13:43843305	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.754	rs4053664	ENSG00000274001.1	RP11-5G9.5	5.82	1.08e-08	1.97e-06	0.29	0.26	Leprosy;	chr13:43855036	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.87	rs9525855	ENSG00000274001.1	RP11-5G9.5	5.82	1.08e-08	1.97e-06	0.29	0.26	Leprosy;	chr13:43857524	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.781	rs9525857	ENSG00000274001.1	RP11-5G9.5	5.82	1.08e-08	1.97e-06	0.29	0.26	Leprosy;	chr13:43862936	chr13:43877715~43878163:-
THCA	cis	rs11603691	0.551	rs12576878	ENSG00000254662.1	RP11-872D17.4	-5.82	1.08e-08	1.97e-06	-0.41	-0.26	Low high density lipoprotein cholesterol levels;	chr11:57331222	chr11:57325603~57327958:+
THCA	cis	rs793571	0.554	rs17301954	ENSG00000259250.1	RP11-50C13.1	-5.82	1.08e-08	1.97e-06	-0.29	-0.26	Schizophrenia;	chr15:58708232	chr15:58587507~58591676:+
THCA	cis	rs8007846	0.588	rs1075566	ENSG00000276116.2	FUT8-AS1	-5.82	1.08e-08	1.97e-06	-0.27	-0.26	Multiple sclerosis--Brain Glutamate Levels;	chr14:65772739	chr14:65411170~65412690:-
THCA	cis	rs17214007	0.597	rs4781677	ENSG00000263335.1	AF001548.5	-5.82	1.09e-08	1.97e-06	-0.36	-0.26	Cognitive function;	chr16:15636388	chr16:15726674~15732993:+
THCA	cis	rs7119038	0.58	rs7123726	ENSG00000255239.1	AP002954.6	-5.82	1.09e-08	1.97e-06	-0.38	-0.26	Sjögren's syndrome;	chr11:118823838	chr11:118688039~118690600:-
THCA	cis	rs9467773	1	rs9467782	ENSG00000124549.13	BTN2A3P	5.82	1.09e-08	1.97e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.935	rs9461270	ENSG00000124549.13	BTN2A3P	5.82	1.09e-08	1.97e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26421391~26432383:+
THCA	cis	rs748404	0.697	rs1095389	ENSG00000166763.7	STRCP1	5.82	1.09e-08	1.97e-06	0.28	0.26	Lung cancer;	chr15:43274473	chr15:43699488~43718184:-
THCA	cis	rs5751614	0.577	rs2330369	ENSG00000230701.2	FBXW4P1	5.82	1.09e-08	1.97e-06	0.27	0.26	Height;	chr22:23265255	chr22:23262767~23265005:+
THCA	cis	rs3847687	0.546	rs12832254	ENSG00000279128.1	RP11-76C10.4	5.82	1.09e-08	1.97e-06	0.29	0.26	Longevity;	chr12:131034843	chr12:131022769~131024741:-
THCA	cis	rs2993535	1	rs4951436	ENSG00000233626.2	RP11-565J7.1	-5.82	1.09e-08	1.97e-06	-0.74	-0.26	Hip circumference adjusted for BMI;	chr1:212062815	chr1:211936249~211936634:+
THCA	cis	rs2303319	0.504	rs56405014	ENSG00000227403.1	AC009299.3	5.82	1.09e-08	1.97e-06	0.55	0.26	Cognitive function;	chr2:161641093	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs55638078	ENSG00000227403.1	AC009299.3	5.82	1.09e-08	1.97e-06	0.55	0.26	Cognitive function;	chr2:161668487	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12474470	ENSG00000227403.1	AC009299.3	5.82	1.09e-08	1.97e-06	0.55	0.26	Cognitive function;	chr2:161678826	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs16846026	ENSG00000227403.1	AC009299.3	5.82	1.09e-08	1.97e-06	0.55	0.26	Cognitive function;	chr2:161681181	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12467279	ENSG00000227403.1	AC009299.3	5.82	1.09e-08	1.97e-06	0.55	0.26	Cognitive function;	chr2:161688234	chr2:161244739~161249050:+
THCA	cis	rs12291225	0.535	rs12806025	ENSG00000251991.1	RNU7-49P	5.82	1.09e-08	1.97e-06	0.3	0.26	Sense of smell;	chr11:14392271	chr11:14478892~14478953:+
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000232559.3	GS1-124K5.12	5.82	1.09e-08	1.98e-06	0.4	0.26	Gout;	chr7:66732812	chr7:66554588~66576923:-
THCA	cis	rs1322639	0.806	rs1322640	ENSG00000261039.2	RP11-417E7.2	5.82	1.09e-08	1.98e-06	0.31	0.26	Pulse pressure;	chr6:169186792	chr6:169175304~169182740:-
THCA	cis	rs11148252	0.84	rs3886077	ENSG00000235660.1	LINC00345	-5.82	1.09e-08	1.98e-06	-0.32	-0.26	Lewy body disease;	chr13:52374918	chr13:52484161~52484680:-
THCA	cis	rs1707322	0.685	rs28617418	ENSG00000281133.1	AL355480.3	-5.82	1.09e-08	1.98e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.682	rs28490344	ENSG00000281133.1	AL355480.3	-5.82	1.09e-08	1.98e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs28641748	ENSG00000281133.1	AL355480.3	-5.82	1.09e-08	1.98e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs6697821	ENSG00000281133.1	AL355480.3	-5.82	1.09e-08	1.98e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs4330955	ENSG00000281133.1	AL355480.3	-5.82	1.09e-08	1.98e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.691	rs12031182	ENSG00000281133.1	AL355480.3	-5.82	1.09e-08	1.98e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45580892~45580996:-
THCA	cis	rs7045881	0.935	rs7851582	ENSG00000254396.1	RP11-56F10.3	5.82	1.09e-08	1.98e-06	0.38	0.26	Schizophrenia;	chr9:26902782	chr9:27102630~27104728:+
THCA	cis	rs62184315	0.536	rs62183651	ENSG00000273240.1	RP11-455J20.3	-5.82	1.09e-08	1.98e-06	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189647251	chr2:189763859~189764456:-
THCA	cis	rs62184315	0.536	rs62183652	ENSG00000273240.1	RP11-455J20.3	-5.82	1.09e-08	1.98e-06	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189648877	chr2:189763859~189764456:-
THCA	cis	rs75422866	0.51	rs73105829	ENSG00000276691.1	RP5-1057I20.5	5.82	1.09e-08	1.98e-06	0.44	0.26	Pneumonia;	chr12:47734162	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.51	rs75424057	ENSG00000276691.1	RP5-1057I20.5	5.82	1.09e-08	1.98e-06	0.44	0.26	Pneumonia;	chr12:47737294	chr12:47788426~47788971:+
THCA	cis	rs11976180	1	rs11976180	ENSG00000273234.1	OR2A13P	-5.82	1.09e-08	1.98e-06	-0.3	-0.26	Obesity-related traits;	chr7:144044487	chr7:144142009~144142938:+
THCA	cis	rs2915864	1	rs2906076	ENSG00000280047.1	CTC-463A16.1	-5.82	1.09e-08	1.98e-06	-0.41	-0.26	Facial morphology (factor 20);	chr5:142192400	chr5:142165767~142168387:+
THCA	cis	rs9402743	0.775	rs12196952	ENSG00000231028.7	LINC00271	-5.82	1.09e-08	1.98e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135662235	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs9494323	ENSG00000231028.7	LINC00271	-5.82	1.09e-08	1.98e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135663249	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs6917604	ENSG00000231028.7	LINC00271	-5.82	1.09e-08	1.98e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135664161	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.775	rs7768645	ENSG00000231028.7	LINC00271	-5.82	1.09e-08	1.98e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135664656	chr6:135497801~135716055:+
THCA	cis	rs935334	1	rs12879642	ENSG00000258454.1	RP11-361H10.3	5.82	1.09e-08	1.98e-06	0.38	0.26	Blood pressure;	chr14:76216624	chr14:76235817~76263474:+
THCA	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	5.82	1.09e-08	1.98e-06	0.32	0.26	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
THCA	cis	rs7727544	0.735	rs270605	ENSG00000224431.1	AC063976.7	5.82	1.09e-08	1.98e-06	0.22	0.26	Blood metabolite levels;	chr5:132316118	chr5:132199456~132203487:+
THCA	cis	rs4639966	0.756	rs61219050	ENSG00000255239.1	AP002954.6	-5.82	1.09e-08	1.98e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118777915	chr11:118688039~118690600:-
THCA	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-5.82	1.09e-08	1.98e-06	-0.27	-0.26	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
THCA	cis	rs77972916	0.505	rs6753197	ENSG00000234936.1	AC010883.5	5.82	1.09e-08	1.98e-06	0.28	0.26	Granulocyte percentage of myeloid white cells;	chr2:43300823	chr2:43229573~43233394:+
THCA	cis	rs1823913	1	rs7574570	ENSG00000280083.1	RP11-317J9.1	5.82	1.09e-08	1.98e-06	0.32	0.26	Obesity-related traits;	chr2:191233790	chr2:191154118~191156070:-
THCA	cis	rs874628	0.851	rs28666607	ENSG00000268650.3	AC068499.10	5.82	1.09e-08	1.99e-06	0.29	0.26	Multiple sclerosis;	chr19:18222995	chr19:18204730~18220480:+
THCA	cis	rs7615952	0.599	rs2333408	ENSG00000250012.1	RP11-124N2.1	-5.82	1.09e-08	1.99e-06	-0.24	-0.26	Blood pressure (smoking interaction);	chr3:126013255	chr3:126084220~126095349:+
THCA	cis	rs12928939	0.636	rs11639902	ENSG00000260886.1	TAT-AS1	-5.82	1.09e-08	1.99e-06	-0.32	-0.26	Post bronchodilator FEV1;	chr16:71721949	chr16:71565789~71578187:+
THCA	cis	rs67478160	0.619	rs12878682	ENSG00000258735.1	LINC00637	-5.82	1.09e-08	1.99e-06	-0.31	-0.26	Schizophrenia;	chr14:103767290	chr14:103847721~103858049:+
THCA	cis	rs6968419	0.674	rs1918912	ENSG00000237870.5	AC073130.1	5.82	1.1e-08	1.99e-06	0.29	0.26	Intraocular pressure;	chr7:116266319	chr7:116275606~116286734:-
THCA	cis	rs7493	0.755	rs62467350	ENSG00000233942.1	AC004012.1	5.82	1.1e-08	1.99e-06	0.39	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95340802	chr7:95471835~95473998:+
THCA	cis	rs2562456	0.92	rs2650784	ENSG00000268119.4	CTD-2561J22.5	-5.82	1.1e-08	1.99e-06	-0.31	-0.26	Pain;	chr19:21483795	chr19:21444241~21463908:-
THCA	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-5.82	1.1e-08	1.99e-06	-0.23	-0.26	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
THCA	cis	rs9467773	1	rs4871	ENSG00000124549.13	BTN2A3P	5.82	1.1e-08	1.99e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26421391~26432383:+
THCA	cis	rs1823913	0.927	rs34765012	ENSG00000280083.1	RP11-317J9.1	-5.82	1.1e-08	1.99e-06	-0.32	-0.26	Obesity-related traits;	chr2:191247926	chr2:191154118~191156070:-
THCA	cis	rs2120243	0.539	rs7629293	ENSG00000244515.1	KRT18P34	-5.82	1.1e-08	1.99e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157396673	chr3:157162663~157163932:-
THCA	cis	rs12497850	0.931	rs12493289	ENSG00000229759.1	MRPS18AP1	5.82	1.1e-08	1.99e-06	0.35	0.26	Parkinson's disease;	chr3:48867728	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.865	rs7649458	ENSG00000229759.1	MRPS18AP1	5.82	1.1e-08	1.99e-06	0.35	0.26	Parkinson's disease;	chr3:48882694	chr3:48256350~48256938:-
THCA	cis	rs2348418	0.832	rs11049559	ENSG00000247934.4	RP11-967K21.1	5.82	1.1e-08	2e-06	0.22	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28372264	chr12:28163298~28190738:-
THCA	cis	rs7208859	0.614	rs216477	ENSG00000264538.5	SUZ12P1	5.82	1.1e-08	2e-06	0.25	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30709299~30790908:+
THCA	cis	rs375092	0.543	rs6461708	ENSG00000230658.1	KLHL7-AS1	-5.82	1.1e-08	2e-06	-0.4	-0.26	Personality dimensions;	chr7:23375698	chr7:23101228~23105703:-
THCA	cis	rs9311474	0.935	rs7622851	ENSG00000243224.1	RP5-1157M23.2	-5.82	1.1e-08	2e-06	-0.27	-0.26	Electroencephalogram traits;	chr3:52299655	chr3:52239258~52241097:+
THCA	cis	rs1707322	0.716	rs10890342	ENSG00000281133.1	AL355480.3	-5.82	1.1e-08	2e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs6658700	ENSG00000281133.1	AL355480.3	-5.82	1.1e-08	2e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs12047629	ENSG00000281133.1	AL355480.3	-5.82	1.1e-08	2e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs11211169	ENSG00000281133.1	AL355480.3	-5.82	1.1e-08	2e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs11211171	ENSG00000281133.1	AL355480.3	-5.82	1.1e-08	2e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs28623463	ENSG00000281133.1	AL355480.3	-5.82	1.1e-08	2e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.716	rs28370457	ENSG00000281133.1	AL355480.3	-5.82	1.1e-08	2e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.691	rs61784799	ENSG00000281133.1	AL355480.3	5.82	1.1e-08	2e-06	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45580892~45580996:-
THCA	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	5.82	1.1e-08	2e-06	0.27	0.26	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
THCA	cis	rs9843304	0.585	rs9842139	ENSG00000244503.1	RP11-278L15.6	-5.82	1.1e-08	2e-06	-0.32	-0.26	Gallstone disease;	chr3:149489730	chr3:149494660~149495995:+
THCA	cis	rs796395	0.641	rs519709	ENSG00000228208.5	C1orf143	-5.82	1.1e-08	2e-06	-0.31	-0.26	Post bronchodilator FEV1/FVC ratio;	chr1:218481392	chr1:218510096~218525978:+
THCA	cis	rs2129782	1	rs57092235	ENSG00000253553.4	RP11-586K2.1	5.82	1.1e-08	2e-06	0.44	0.26	Electrodermal activity;	chr8:88438976	chr8:88326836~88737134:+
THCA	cis	rs875971	0.564	rs313804	ENSG00000232559.3	GS1-124K5.12	5.82	1.1e-08	2e-06	0.26	0.26	Aortic root size;	chr7:66049635	chr7:66554588~66576923:-
THCA	cis	rs7404843	0.852	rs111259294	ENSG00000263335.1	AF001548.5	5.82	1.1e-08	2e-06	0.43	0.26	Testicular germ cell tumor;	chr16:15418073	chr16:15726674~15732993:+
THCA	cis	rs7404843	0.778	rs72774864	ENSG00000263335.1	AF001548.5	5.82	1.1e-08	2e-06	0.43	0.26	Testicular germ cell tumor;	chr16:15418465	chr16:15726674~15732993:+
THCA	cis	rs9990333	0.544	rs11915082	ENSG00000231464.1	AC024937.4	5.82	1.1e-08	2e-06	0.33	0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195996738~195998233:+
THCA	cis	rs7763441	0.545	rs9392392	ENSG00000272465.1	RP1-136B1.1	-5.82	1.11e-08	2.01e-06	-0.34	-0.26	Monobrow;	chr6:2453199	chr6:2437549~2438249:+
THCA	cis	rs7829975	0.688	rs6995407	ENSG00000254153.1	CTA-398F10.2	-5.82	1.11e-08	2.01e-06	-0.29	-0.26	Mood instability;	chr8:8527137	chr8:8456909~8461337:-
THCA	cis	rs17345786	0.906	rs72946021	ENSG00000256628.3	ZBTB11-AS1	5.82	1.11e-08	2.01e-06	0.33	0.26	Colonoscopy-negative controls vs population controls;	chr3:101531164	chr3:101676475~101679217:+
THCA	cis	rs62292953	0.79	rs17348055	ENSG00000248724.5	NPHP3-AS1	-5.82	1.11e-08	2.01e-06	-0.49	-0.26	Red cell distribution width;	chr3:132645887	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.719	rs62292460	ENSG00000248724.5	NPHP3-AS1	-5.82	1.11e-08	2.01e-06	-0.49	-0.26	Red cell distribution width;	chr3:132649172	chr3:132721750~132874223:+
THCA	cis	rs16958440	0.521	rs62095426	ENSG00000267800.1	RP11-49K24.5	-5.82	1.11e-08	2.01e-06	-0.54	-0.26	Sitting height ratio;	chr18:47059110	chr18:47137018~47137290:+
THCA	cis	rs950169	0.58	rs17598114	ENSG00000275120.1	RP11-182J1.17	5.82	1.11e-08	2.01e-06	0.31	0.26	Schizophrenia;	chr15:84628086	chr15:84599434~84606463:-
THCA	cis	rs950169	0.58	rs11634322	ENSG00000275120.1	RP11-182J1.17	5.82	1.11e-08	2.01e-06	0.31	0.26	Schizophrenia;	chr15:84628978	chr15:84599434~84606463:-
THCA	cis	rs2562456	0.92	rs2650784	ENSG00000268081.1	RP11-678G14.2	-5.82	1.11e-08	2.01e-06	-0.36	-0.26	Pain;	chr19:21483795	chr19:21554640~21569237:-
THCA	cis	rs9393777	0.844	rs72839477	ENSG00000219392.1	RP1-265C24.5	-5.82	1.11e-08	2.01e-06	-0.59	-0.26	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28115628~28116551:+
THCA	cis	rs12101261	0.66	rs11850464	ENSG00000259167.2	NMNAT1P1	5.82	1.11e-08	2.01e-06	0.36	0.26	Graves' disease;	chr14:80973118	chr14:81032529~81033404:+
THCA	cis	rs875971	0.8	rs427557	ENSG00000232559.3	GS1-124K5.12	5.82	1.11e-08	2.01e-06	0.25	0.26	Aortic root size;	chr7:66054263	chr7:66554588~66576923:-
THCA	cis	rs9595908	1	rs7999125	ENSG00000212293.1	SNORA16	5.82	1.11e-08	2.01e-06	0.31	0.26	Body mass index;	chr13:32571858	chr13:32420390~32420516:-
THCA	cis	rs2562456	0.876	rs62110202	ENSG00000268081.1	RP11-678G14.2	5.82	1.11e-08	2.01e-06	0.37	0.26	Pain;	chr19:21571799	chr19:21554640~21569237:-
THCA	cis	rs748404	0.589	rs62020612	ENSG00000249839.1	AC011330.5	-5.82	1.11e-08	2.02e-06	-0.37	-0.26	Lung cancer;	chr15:43525881	chr15:43663654~43684339:-
THCA	cis	rs9990343	0.543	rs11575815	ENSG00000223552.1	RP11-24F11.2	5.82	1.11e-08	2.02e-06	0.23	0.26	Brain structure;	chr3:46378679	chr3:46364955~46407059:-
THCA	cis	rs890448	0.796	rs2471683	ENSG00000254531.1	FLJ20021	5.82	1.11e-08	2.02e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436777	chr4:101347780~101348883:+
THCA	cis	rs4713118	0.512	rs2622319	ENSG00000220721.1	OR1F12	5.82	1.11e-08	2.02e-06	0.32	0.26	Parkinson's disease;	chr6:28152623	chr6:28073316~28074233:+
THCA	cis	rs17772222	0.958	rs74074098	ENSG00000222990.1	RNU4-22P	5.82	1.11e-08	2.02e-06	0.35	0.26	Coronary artery calcification;	chr14:88484213	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.876	rs12587528	ENSG00000222990.1	RNU4-22P	5.82	1.11e-08	2.02e-06	0.35	0.26	Coronary artery calcification;	chr14:88487652	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.916	rs77306894	ENSG00000222990.1	RNU4-22P	5.82	1.11e-08	2.02e-06	0.35	0.26	Coronary artery calcification;	chr14:88494507	chr14:88513498~88513663:+
THCA	cis	rs61677309	0.929	rs58983315	ENSG00000280032.1	RP11-832A4.7	5.82	1.11e-08	2.02e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118297044	chr11:118264593~118266817:+
THCA	cis	rs712039	0.652	rs11656503	ENSG00000276054.1	RP11-378E13.3	5.82	1.11e-08	2.02e-06	0.4	0.26	Tuberculosis;	chr17:37411934	chr17:37386886~37387926:+
THCA	cis	rs7809950	0.954	rs12673675	ENSG00000238832.1	snoU109	-5.82	1.11e-08	2.02e-06	-0.28	-0.26	Coronary artery disease;	chr7:107472775	chr7:107603363~107603507:+
THCA	cis	rs2117029	0.767	rs10875912	ENSG00000258017.1	RP11-386G11.10	-5.82	1.11e-08	2.02e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49023161	chr12:49127782~49147869:+
THCA	cis	rs890448	0.796	rs2471673	ENSG00000254531.1	FLJ20021	5.82	1.12e-08	2.02e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101432430	chr4:101347780~101348883:+
THCA	cis	rs2911132	0.511	rs7063	ENSG00000248734.2	CTD-2260A17.1	5.82	1.12e-08	2.02e-06	0.29	0.26	Urate levels (BMI interaction);	chr5:96774507	chr5:96784777~96785999:+
THCA	cis	rs7246657	0.663	rs4803287	ENSG00000267422.1	CTD-2554C21.1	-5.82	1.12e-08	2.02e-06	-0.29	-0.26	Coronary artery calcification;	chr19:37588534	chr19:37779686~37792865:+
THCA	cis	rs9990333	0.544	rs112577972	ENSG00000231464.1	AC024937.4	5.82	1.12e-08	2.03e-06	0.33	0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195996738~195998233:+
THCA	cis	rs11148252	0.875	rs9526913	ENSG00000235660.1	LINC00345	-5.82	1.12e-08	2.03e-06	-0.32	-0.26	Lewy body disease;	chr13:52401702	chr13:52484161~52484680:-
THCA	cis	rs792448	0.534	rs6702347	ENSG00000226251.4	RP11-15I11.3	-5.82	1.12e-08	2.03e-06	-0.36	-0.26	White blood cell count (basophil);	chr1:212439569	chr1:212225278~212238977:-
THCA	cis	rs7225151	0.71	rs76420897	ENSG00000234327.6	AC012146.7	-5.81	1.12e-08	2.04e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5293281	chr17:5111468~5115004:+
THCA	cis	rs2243480	1	rs316322	ENSG00000232546.1	RP11-458F8.1	-5.81	1.12e-08	2.04e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66146246	chr7:66848496~66858136:+
THCA	cis	rs9859260	0.71	rs419068	ENSG00000273009.1	RP11-352G9.1	5.81	1.12e-08	2.04e-06	0.29	0.26	Mean corpuscular volume;	chr3:196055305	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.71	rs366268	ENSG00000273009.1	RP11-352G9.1	5.81	1.12e-08	2.04e-06	0.29	0.26	Mean corpuscular volume;	chr3:196055306	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.744	rs419059	ENSG00000273009.1	RP11-352G9.1	5.81	1.12e-08	2.04e-06	0.29	0.26	Mean corpuscular volume;	chr3:196055313	chr3:195913078~195913683:-
THCA	cis	rs6585424	1	rs6585424	ENSG00000225484.5	NUTM2B-AS1	-5.81	1.12e-08	2.04e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173992	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs56190825	ENSG00000225484.5	NUTM2B-AS1	-5.81	1.12e-08	2.04e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80174980	chr10:79663088~79826594:-
THCA	cis	rs9307551	0.817	rs12507375	ENSG00000250334.4	LINC00989	-5.81	1.12e-08	2.04e-06	-0.3	-0.26	Refractive error;	chr4:79575206	chr4:79492416~79576460:+
THCA	cis	rs9475752	1	rs55786720	ENSG00000231441.1	RP11-472M19.2	5.81	1.12e-08	2.04e-06	0.33	0.26	Menarche (age at onset);	chr6:56918849	chr6:56844002~56864078:+
THCA	cis	rs9475752	1	rs56030203	ENSG00000231441.1	RP11-472M19.2	5.81	1.12e-08	2.04e-06	0.33	0.26	Menarche (age at onset);	chr6:56919059	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.895	rs34259328	ENSG00000231441.1	RP11-472M19.2	5.81	1.12e-08	2.04e-06	0.33	0.26	Menarche (age at onset);	chr6:56921705	chr6:56844002~56864078:+
THCA	cis	rs6142102	0.923	rs3787230	ENSG00000275784.1	RP5-1125A11.6	-5.81	1.13e-08	2.04e-06	-0.27	-0.26	Skin pigmentation;	chr20:34052466	chr20:33989480~33991818:-
THCA	cis	rs713477	0.967	rs6573028	ENSG00000258413.1	RP11-665C16.6	5.81	1.13e-08	2.04e-06	0.35	0.26	Pediatric bone mineral content (femoral neck);	chr14:55446679	chr14:55262767~55272075:-
THCA	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	5.81	1.13e-08	2.04e-06	0.28	0.26	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
THCA	cis	rs1322639	0.614	rs9689800	ENSG00000261039.2	RP11-417E7.2	5.81	1.13e-08	2.04e-06	0.29	0.26	Pulse pressure;	chr6:169172850	chr6:169175304~169182740:-
THCA	cis	rs10875746	0.556	rs4760619	ENSG00000269514.1	RP11-370I10.12	5.81	1.13e-08	2.04e-06	0.29	0.26	Longevity (90 years and older);	chr12:48106148	chr12:48198387~48202031:+
THCA	cis	rs2439831	0.867	rs3213990	ENSG00000275601.1	AC011330.13	-5.81	1.13e-08	2.04e-06	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43378028	chr15:43642389~43643023:-
THCA	cis	rs7702057	0.53	rs17138848	ENSG00000271918.1	CTD-2287O16.5	5.81	1.13e-08	2.04e-06	0.28	0.26	Amyotrophic lateral sclerosis;	chr5:116083606	chr5:116083807~116085416:-
THCA	cis	rs832187	0.666	rs2241823	ENSG00000280620.1	SCAANT1	5.81	1.13e-08	2.05e-06	0.36	0.26	Schizophrenia;	chr3:63979417	chr3:63911518~63911772:-
THCA	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	5.81	1.13e-08	2.05e-06	0.26	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
THCA	cis	rs79040073	0.53	rs17475228	ENSG00000259531.2	RP11-295H24.3	5.81	1.13e-08	2.05e-06	0.35	0.26	Lung cancer in ever smokers;	chr15:49269619	chr15:49365124~49366685:-
THCA	cis	rs12681366	0.708	rs2445699	ENSG00000253704.1	RP11-267M23.4	-5.81	1.13e-08	2.05e-06	-0.25	-0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94334289	chr8:94553722~94569745:+
THCA	cis	rs7617773	1	rs9832957	ENSG00000228638.1	FCF1P2	5.81	1.13e-08	2.05e-06	0.25	0.26	Coronary artery disease;	chr3:48143776	chr3:48290793~48291375:-
THCA	cis	rs12435908	1	rs17826736	ENSG00000276116.2	FUT8-AS1	-5.81	1.13e-08	2.05e-06	-0.41	-0.26	Ischemic stroke;	chr14:65615484	chr14:65411170~65412690:-
THCA	cis	rs6951245	0.58	rs78894484	ENSG00000229043.2	AC091729.9	-5.81	1.13e-08	2.05e-06	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.554	rs4724294	ENSG00000229043.2	AC091729.9	-5.81	1.13e-08	2.05e-06	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1160374~1165267:+
THCA	cis	rs853679	0.546	rs34676049	ENSG00000280107.1	AL022393.9	-5.81	1.13e-08	2.05e-06	-0.54	-0.26	Depression;	chr6:28485841	chr6:28170845~28172521:+
THCA	cis	rs7209700	0.708	rs2292865	ENSG00000228782.6	CTD-2026D20.3	-5.81	1.13e-08	2.05e-06	-0.25	-0.26	IgG glycosylation;	chr17:47287356	chr17:47450568~47492492:-
THCA	cis	rs2839186	0.934	rs13049797	ENSG00000239415.1	AP001469.9	5.81	1.13e-08	2.05e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46287668	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.732	rs55904887	ENSG00000239415.1	AP001469.9	5.81	1.13e-08	2.05e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46287897	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.934	rs2839197	ENSG00000239415.1	AP001469.9	5.81	1.13e-08	2.05e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46288219	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.868	rs2839199	ENSG00000239415.1	AP001469.9	5.81	1.13e-08	2.05e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46288355	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.933	rs4818832	ENSG00000239415.1	AP001469.9	5.81	1.13e-08	2.05e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46288720	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.9	rs59828751	ENSG00000239415.1	AP001469.9	5.81	1.13e-08	2.05e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46289004	chr21:46251549~46254133:-
THCA	cis	rs9326248	0.53	rs1242229	ENSG00000280143.1	AP000892.6	5.81	1.13e-08	2.05e-06	0.43	0.26	Blood protein levels;	chr11:117191654	chr11:117204967~117210292:+
THCA	cis	rs9601248	0.756	rs9601252	ENSG00000227676.3	LINC01068	-5.81	1.13e-08	2.05e-06	-0.33	-0.26	Major depressive disorder;	chr13:79615607	chr13:79566727~79571436:+
THCA	cis	rs757978	1	rs3732276	ENSG00000223374.1	AC005104.3	5.81	1.13e-08	2.05e-06	0.28	0.26	Chronic lymphocytic leukemia;	chr2:241403989	chr2:241351340~241353104:-
THCA	cis	rs748404	0.697	rs501884	ENSG00000166763.7	STRCP1	5.81	1.14e-08	2.06e-06	0.28	0.26	Lung cancer;	chr15:43261784	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs504417	ENSG00000166763.7	STRCP1	5.81	1.14e-08	2.06e-06	0.28	0.26	Lung cancer;	chr15:43262028	chr15:43699488~43718184:-
THCA	cis	rs748404	0.723	rs560134	ENSG00000166763.7	STRCP1	5.81	1.14e-08	2.06e-06	0.28	0.26	Lung cancer;	chr15:43263501	chr15:43699488~43718184:-
THCA	cis	rs12188164	0.747	rs12188321	ENSG00000225138.6	CTD-2228K2.7	5.81	1.14e-08	2.06e-06	0.25	0.26	Cystic fibrosis severity;	chr5:428303	chr5:473236~480884:+
THCA	cis	rs3742264	1	rs9316180	ENSG00000235903.6	CPB2-AS1	5.81	1.14e-08	2.06e-06	0.35	0.26	Blood protein levels;	chr13:46067550	chr13:46052806~46113332:+
THCA	cis	rs10771431	0.597	rs10843144	ENSG00000256069.6	A2MP1	5.81	1.14e-08	2.06e-06	0.29	0.26	Breast size;	chr12:9204981	chr12:9228533~9275817:-
THCA	cis	rs7523875	0.72	rs17017361	ENSG00000153363.11	LINC00467	5.81	1.14e-08	2.06e-06	0.26	0.26	Mean corpuscular volume;	chr1:211306211	chr1:211382803~211435333:+
THCA	cis	rs2120243	0.539	rs35218020	ENSG00000244515.1	KRT18P34	-5.81	1.14e-08	2.06e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157397627	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs1840673	ENSG00000244515.1	KRT18P34	-5.81	1.14e-08	2.06e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157400188	chr3:157162663~157163932:-
THCA	cis	rs3213758	0.541	rs1421092	ENSG00000275191.1	RP11-36I17.2	-5.81	1.14e-08	2.06e-06	-0.38	-0.26	Vitiligo (non-segmental);	chr16:53700309	chr16:53628256~53628816:-
THCA	cis	rs1861628	1	rs1861628	ENSG00000237930.1	AC007563.4	5.81	1.14e-08	2.06e-06	0.3	0.26	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216763707	chr2:216785774~216786144:-
THCA	cis	rs3785574	0.962	rs2584628	ENSG00000240280.5	TCAM1P	-5.81	1.14e-08	2.06e-06	-0.35	-0.26	Height;	chr17:63817218	chr17:63849292~63864379:+
THCA	cis	rs7712401	0.791	rs6887101	ENSG00000249996.1	RP11-359P5.1	-5.81	1.14e-08	2.06e-06	-0.25	-0.26	Mean platelet volume;	chr5:122773512	chr5:123036271~123054667:+
THCA	cis	rs713477	0.935	rs4901567	ENSG00000258413.1	RP11-665C16.6	5.81	1.14e-08	2.07e-06	0.34	0.26	Pediatric bone mineral content (femoral neck);	chr14:55445980	chr14:55262767~55272075:-
THCA	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-5.81	1.14e-08	2.07e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	5.81	1.14e-08	2.07e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	5.81	1.14e-08	2.07e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	5.81	1.14e-08	2.07e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	5.81	1.14e-08	2.07e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	5.81	1.14e-08	2.07e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
THCA	cis	rs2252790	0.56	rs2187813	ENSG00000233558.1	RP3-486I3.4	-5.81	1.14e-08	2.07e-06	-0.3	-0.26	Fast beta electroencephalogram;	chr6:116361344	chr6:116258493~116259115:-
THCA	cis	rs526231	0.726	rs35800	ENSG00000175749.11	EIF3KP1	5.81	1.14e-08	2.07e-06	0.35	0.26	Primary biliary cholangitis;	chr5:103272980	chr5:103032376~103033031:+
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	5.81	1.14e-08	2.07e-06	0.32	0.26	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
THCA	cis	rs7727544	0.735	rs272842	ENSG00000224431.1	AC063976.7	5.81	1.14e-08	2.07e-06	0.22	0.26	Blood metabolite levels;	chr5:132320824	chr5:132199456~132203487:+
THCA	cis	rs728616	0.867	rs7906286	ENSG00000242600.5	MBL1P	5.81	1.15e-08	2.07e-06	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80074279	chr10:79904898~79950336:+
THCA	cis	rs2029362	1	rs4528277	ENSG00000245573.6	BDNF-AS	5.81	1.15e-08	2.08e-06	0.2	0.26	Total body bone mineral density;	chr11:27543899	chr11:27506838~27698174:+
THCA	cis	rs2029362	1	rs11603350	ENSG00000245573.6	BDNF-AS	5.81	1.15e-08	2.08e-06	0.2	0.26	Total body bone mineral density;	chr11:27545699	chr11:27506838~27698174:+
THCA	cis	rs875971	0.8	rs427557	ENSG00000223473.2	GS1-124K5.3	5.81	1.15e-08	2.08e-06	0.18	0.26	Aortic root size;	chr7:66054263	chr7:66491049~66493566:-
THCA	cis	rs138024639	1	rs138024639	ENSG00000226314.6	ZNF192P1	-5.81	1.15e-08	2.08e-06	-0.56	-0.26	Breast cancer;	chr6:28468244	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs55690788	ENSG00000226314.6	ZNF192P1	-5.81	1.15e-08	2.08e-06	-0.56	-0.26	Depression;	chr6:28468368	chr6:28161781~28169594:+
THCA	cis	rs847577	0.722	rs1013887	ENSG00000272950.1	RP11-307C18.1	5.81	1.15e-08	2.08e-06	0.31	0.26	Breast cancer;	chr7:98080033	chr7:98322853~98323430:+
THCA	cis	rs11668609	0.748	rs16982728	ENSG00000268442.1	CTD-2027I19.2	5.81	1.15e-08	2.08e-06	0.32	0.26	Response to taxane treatment (docetaxel);	chr19:24186760	chr19:24162370~24163425:-
THCA	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-5.81	1.15e-08	2.08e-06	-0.36	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000232546.1	RP11-458F8.1	-5.81	1.15e-08	2.08e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66521515	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs13237037	ENSG00000232546.1	RP11-458F8.1	-5.81	1.15e-08	2.08e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66532895	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1796228	ENSG00000232546.1	RP11-458F8.1	-5.81	1.15e-08	2.08e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66568097	chr7:66848496~66858136:+
THCA	cis	rs2839186	0.869	rs17176513	ENSG00000239415.1	AP001469.9	5.81	1.15e-08	2.08e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46262514	chr21:46251549~46254133:-
THCA	cis	rs1876905	0.539	rs240985	ENSG00000255389.1	C6orf3	-5.81	1.15e-08	2.08e-06	-0.33	-0.26	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111599875~111602295:+
THCA	cis	rs1979679	0.801	rs2881787	ENSG00000278733.1	RP11-425D17.1	-5.81	1.15e-08	2.08e-06	-0.25	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28145489	chr12:28185625~28186190:-
THCA	cis	rs7829975	0.535	rs4841005	ENSG00000253893.2	FAM85B	5.81	1.15e-08	2.09e-06	0.32	0.26	Mood instability;	chr8:8643720	chr8:8167819~8226614:-
THCA	cis	rs9527	0.571	rs4917985	ENSG00000236937.2	PTGES3P4	5.81	1.15e-08	2.09e-06	0.34	0.26	Arsenic metabolism;	chr10:102864315	chr10:102845595~102845950:+
THCA	cis	rs6908034	0.607	rs77791009	ENSG00000237404.1	RP3-471C18.2	-5.81	1.15e-08	2.09e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812371	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs75060331	ENSG00000237404.1	RP3-471C18.2	-5.81	1.15e-08	2.09e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812725	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs77753186	ENSG00000237404.1	RP3-471C18.2	-5.81	1.15e-08	2.09e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812749	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs79162793	ENSG00000237404.1	RP3-471C18.2	-5.81	1.15e-08	2.09e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812834	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs76245225	ENSG00000237404.1	RP3-471C18.2	-5.81	1.15e-08	2.09e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812957	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs75110577	ENSG00000237404.1	RP3-471C18.2	-5.81	1.15e-08	2.09e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814292	chr6:19689825~19753113:-
THCA	cis	rs2029362	0.611	rs10835215	ENSG00000245573.6	BDNF-AS	5.81	1.15e-08	2.09e-06	0.21	0.26	Total body bone mineral density;	chr11:27718402	chr11:27506838~27698174:+
THCA	cis	rs442309	0.846	rs224143	ENSG00000238280.1	RP11-436D10.3	-5.81	1.15e-08	2.09e-06	-0.31	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62718076	chr10:62793562~62805887:-
THCA	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	5.81	1.15e-08	2.09e-06	0.33	0.26	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
THCA	cis	rs748404	0.666	rs12905220	ENSG00000249839.1	AC011330.5	-5.81	1.15e-08	2.09e-06	-0.37	-0.26	Lung cancer;	chr15:43465641	chr15:43663654~43684339:-
THCA	cis	rs890448	0.796	rs2433298	ENSG00000254531.1	FLJ20021	5.81	1.15e-08	2.09e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101421169	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2114365	ENSG00000254531.1	FLJ20021	5.81	1.15e-08	2.09e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101424489	chr4:101347780~101348883:+
THCA	cis	rs1876905	0.68	rs783085	ENSG00000230177.1	RP5-1112D6.4	-5.81	1.15e-08	2.09e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111155482	chr6:111277932~111278742:+
THCA	cis	rs890448	0.796	rs7698946	ENSG00000254531.1	FLJ20021	5.81	1.16e-08	2.09e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436919	chr4:101347780~101348883:+
THCA	cis	rs2839186	0.9	rs56840278	ENSG00000239415.1	AP001469.9	5.81	1.16e-08	2.09e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46289019	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.933	rs56955294	ENSG00000239415.1	AP001469.9	5.81	1.16e-08	2.09e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46289039	chr21:46251549~46254133:-
THCA	cis	rs2129782	1	rs10111179	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88408851	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1875903	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88405181	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73287339	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88406580	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs28446827	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88407787	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs28539549	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88408007	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10089941	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88408632	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10093818	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88408781	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73287349	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88409751	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73692561	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88409857	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73287352	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88409998	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73692563	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88410082	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73692564	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88410083	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs76655667	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88410098	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73692565	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88410155	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs73287353	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88410246	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs74743307	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88410269	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs78268237	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88410282	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73287358	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88411424	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73287359	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88411556	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7825171	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88411869	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1112163	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88413034	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs28581869	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88415027	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs28414285	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88415107	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs16882334	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88415779	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73289232	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88416502	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs16882368	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88417354	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10098834	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88418608	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10099075	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88419019	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10112810	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88419176	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs9297470	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88419807	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10113214	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88420192	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10095262	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88420309	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10095499	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88420531	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882408	ENSG00000253553.4	RP11-586K2.1	5.81	1.16e-08	2.09e-06	0.44	0.26	Electrodermal activity;	chr8:88420766	chr8:88326836~88737134:+
THCA	cis	rs10971721	0.822	rs10971788	ENSG00000281128.1	PTENP1-AS	5.81	1.16e-08	2.09e-06	0.58	0.26	Body mass index;	chr9:33915087	chr9:33677268~33688011:+
THCA	cis	rs13201294	1	rs13201294	ENSG00000280107.1	AL022393.9	-5.81	1.16e-08	2.09e-06	-0.41	-0.26	Squamous cell lung carcinoma;	chr6:27588362	chr6:28170845~28172521:+
THCA	cis	rs7727544	0.735	rs272879	ENSG00000224431.1	AC063976.7	5.81	1.16e-08	2.09e-06	0.22	0.26	Blood metabolite levels;	chr5:132334853	chr5:132199456~132203487:+
THCA	cis	rs17214007	0.877	rs11075280	ENSG00000263335.1	AF001548.5	-5.81	1.16e-08	2.1e-06	-0.35	-0.26	Cognitive function;	chr16:15776630	chr16:15726674~15732993:+
THCA	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-5.81	1.16e-08	2.1e-06	-0.35	-0.26	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
THCA	cis	rs914615	0.552	rs4460629	ENSG00000225855.5	RUSC1-AS1	5.81	1.16e-08	2.1e-06	0.17	0.26	Urinary albumin-to-creatinine ratio;	chr1:155162859	chr1:155316863~155324176:-
THCA	cis	rs77972916	0.536	rs11679731	ENSG00000234936.1	AC010883.5	5.81	1.16e-08	2.1e-06	0.3	0.26	Granulocyte percentage of myeloid white cells;	chr2:43361925	chr2:43229573~43233394:+
THCA	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-5.81	1.16e-08	2.1e-06	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
THCA	cis	rs6928977	0.86	rs2746438	ENSG00000231028.7	LINC00271	5.81	1.16e-08	2.1e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135396930	chr6:135497801~135716055:+
THCA	cis	rs10760158	0.51	rs7020643	ENSG00000226752.6	PSMD5-AS1	-5.81	1.16e-08	2.1e-06	-0.3	-0.26	Pulse pressure;	chr9:121099578	chr9:120824828~120854385:+
THCA	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	5.81	1.16e-08	2.1e-06	0.35	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
THCA	cis	rs2880765	0.545	rs17553734	ENSG00000259630.2	CTD-2262B20.1	5.81	1.16e-08	2.1e-06	0.3	0.26	Coronary artery disease;	chr15:85469828	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.566	rs17553790	ENSG00000259630.2	CTD-2262B20.1	5.81	1.16e-08	2.1e-06	0.3	0.26	Coronary artery disease;	chr15:85470434	chr15:85415228~85415633:+
THCA	cis	rs2562456	0.755	rs1879234	ENSG00000268119.4	CTD-2561J22.5	-5.81	1.16e-08	2.1e-06	-0.32	-0.26	Pain;	chr19:21521677	chr19:21444241~21463908:-
THCA	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-5.81	1.16e-08	2.1e-06	-0.33	-0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
THCA	cis	rs9813712	0.953	rs1453258	ENSG00000228252.7	COL6A4P2	5.81	1.16e-08	2.1e-06	0.3	0.26	Response to amphetamines;	chr3:130256454	chr3:130212823~130273806:+
THCA	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	5.81	1.16e-08	2.1e-06	0.32	0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
THCA	cis	rs34779708	0.733	rs60616028	ENSG00000230534.5	RP11-297A16.2	5.81	1.16e-08	2.1e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35254874	chr10:35098006~35127020:-
THCA	cis	rs2243480	1	rs937108	ENSG00000228409.4	CCT6P1	5.81	1.16e-08	2.11e-06	0.3	0.26	Diabetic kidney disease;	chr7:65963465	chr7:65751142~65763354:+
THCA	cis	rs1125355	0.656	rs17809948	ENSG00000251491.2	OR7E28P	5.81	1.17e-08	2.11e-06	0.4	0.26	Alzheimer's disease in APOE e4+ carriers;	chr2:158776903	chr2:158862311~158863285:+
THCA	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	5.81	1.17e-08	2.11e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
THCA	cis	rs6921919	0.673	rs13201681	ENSG00000219392.1	RP1-265C24.5	-5.81	1.17e-08	2.11e-06	-0.57	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.778	rs67381177	ENSG00000219392.1	RP1-265C24.5	-5.81	1.17e-08	2.11e-06	-0.57	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28115628~28116551:+
THCA	cis	rs7005380	0.62	rs13265367	ENSG00000245330.4	KB-1471A8.1	5.81	1.17e-08	2.11e-06	0.25	0.26	Interstitial lung disease;	chr8:119891769	chr8:119867419~119874488:-
THCA	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	5.81	1.17e-08	2.11e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
THCA	cis	rs9595908	0.931	rs11839309	ENSG00000212293.1	SNORA16	5.81	1.17e-08	2.11e-06	0.31	0.26	Body mass index;	chr13:32473853	chr13:32420390~32420516:-
THCA	cis	rs7688540	0.739	rs11729659	ENSG00000211553.1	AC253576.2	-5.81	1.17e-08	2.11e-06	-0.38	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:136461~136568:+
THCA	cis	rs12428035	0.772	rs7331549	ENSG00000247400.3	DNAJC3-AS1	-5.81	1.17e-08	2.11e-06	-0.24	-0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95814247	chr13:95648733~95676925:-
THCA	cis	rs2562456	0.917	rs2562466	ENSG00000268119.4	CTD-2561J22.5	-5.81	1.17e-08	2.11e-06	-0.32	-0.26	Pain;	chr19:21531402	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.917	rs2562468	ENSG00000268119.4	CTD-2561J22.5	-5.81	1.17e-08	2.11e-06	-0.32	-0.26	Pain;	chr19:21532048	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.917	rs2562471	ENSG00000268119.4	CTD-2561J22.5	-5.81	1.17e-08	2.11e-06	-0.32	-0.26	Pain;	chr19:21533017	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.917	rs2681377	ENSG00000268119.4	CTD-2561J22.5	-5.81	1.17e-08	2.11e-06	-0.32	-0.26	Pain;	chr19:21533718	chr19:21444241~21463908:-
THCA	cis	rs7044106	0.762	rs4837789	ENSG00000270917.1	RP11-27I1.6	-5.81	1.17e-08	2.11e-06	-0.36	-0.26	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120812475~120812845:-
THCA	cis	rs2880765	0.566	rs11630381	ENSG00000259630.2	CTD-2262B20.1	-5.81	1.17e-08	2.11e-06	-0.3	-0.26	Coronary artery disease;	chr15:85469272	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.545	rs11631739	ENSG00000259630.2	CTD-2262B20.1	-5.81	1.17e-08	2.11e-06	-0.3	-0.26	Coronary artery disease;	chr15:85469347	chr15:85415228~85415633:+
THCA	cis	rs61677309	1	rs56318049	ENSG00000280032.1	RP11-832A4.7	5.81	1.17e-08	2.11e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118295893	chr11:118264593~118266817:+
THCA	cis	rs34119086	1	rs34119086	ENSG00000219392.1	RP1-265C24.5	-5.81	1.17e-08	2.11e-06	-0.58	-0.26	Breast cancer;	chr6:28594471	chr6:28115628~28116551:+
THCA	cis	rs4908768	0.501	rs12046643	ENSG00000232912.4	RP5-1115A15.1	5.81	1.17e-08	2.11e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8424645~8434838:+
THCA	cis	rs4908760	0.965	rs10864353	ENSG00000232912.4	RP5-1115A15.1	5.81	1.17e-08	2.11e-06	0.25	0.26	Vitiligo;	chr1:8489656	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs6677736	ENSG00000232912.4	RP5-1115A15.1	5.81	1.17e-08	2.11e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8424645~8434838:+
THCA	cis	rs9329221	0.682	rs6982308	ENSG00000261451.1	RP11-981G7.1	-5.81	1.17e-08	2.12e-06	-0.32	-0.26	Neuroticism;	chr8:10336262	chr8:10433672~10438312:+
THCA	cis	rs4950322	0.748	rs56392137	ENSG00000278811.3	LINC00624	5.81	1.17e-08	2.12e-06	0.32	0.26	Protein quantitative trait loci;	chr1:147352450	chr1:147258885~147517875:-
THCA	cis	rs595244	1	rs8026752	ENSG00000259705.1	RP11-227D13.1	-5.81	1.17e-08	2.12e-06	-0.42	-0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48531573	chr15:48645951~48652016:+
THCA	cis	rs5751614	0.577	rs6003600	ENSG00000230701.2	FBXW4P1	5.81	1.17e-08	2.12e-06	0.27	0.26	Height;	chr22:23275893	chr22:23262767~23265005:+
THCA	cis	rs5751614	0.577	rs5759675	ENSG00000230701.2	FBXW4P1	5.81	1.17e-08	2.12e-06	0.27	0.26	Height;	chr22:23278154	chr22:23262767~23265005:+
THCA	cis	rs467650	0.553	rs469731	ENSG00000246763.5	RGMB-AS1	-5.81	1.17e-08	2.12e-06	-0.31	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr5:98651703	chr5:98769618~98773469:-
THCA	cis	rs172166	0.694	rs1225716	ENSG00000220721.1	OR1F12	5.81	1.17e-08	2.12e-06	0.32	0.26	Cardiac Troponin-T levels;	chr6:28145968	chr6:28073316~28074233:+
THCA	cis	rs8062405	0.824	rs240702	ENSG00000278665.1	RP11-666O2.4	5.81	1.17e-08	2.12e-06	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28599241~28601881:-
THCA	cis	rs7746199	0.736	rs72845070	ENSG00000226314.6	ZNF192P1	-5.81	1.17e-08	2.12e-06	-0.61	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28161781~28169594:+
THCA	cis	rs1876905	0.539	rs240958	ENSG00000272356.1	RP5-1112D6.8	5.81	1.17e-08	2.12e-06	0.27	0.26	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111309203~111313517:+
THCA	cis	rs2129782	1	rs1394515	ENSG00000253553.4	RP11-586K2.1	5.81	1.17e-08	2.12e-06	0.45	0.26	Electrodermal activity;	chr8:88397764	chr8:88326836~88737134:+
THCA	cis	rs7131987	0.644	rs6487817	ENSG00000257176.2	RP11-996F15.2	5.81	1.17e-08	2.12e-06	0.26	0.26	QT interval;	chr12:29395277	chr12:29280418~29317848:-
THCA	cis	rs2276314	0.512	rs1789515	ENSG00000278986.1	RP11-723J4.3	5.81	1.17e-08	2.12e-06	0.26	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36055930	chr18:35972151~35973916:+
THCA	cis	rs9677476	0.863	rs2006780	ENSG00000224376.1	AC017104.6	5.81	1.18e-08	2.12e-06	0.29	0.26	Food antigen IgG levels;	chr2:231201991	chr2:231388976~231394991:+
THCA	cis	rs1499614	1	rs1267818	ENSG00000232559.3	GS1-124K5.12	5.81	1.18e-08	2.12e-06	0.4	0.26	Gout;	chr7:66642037	chr7:66554588~66576923:-
THCA	cis	rs2439831	0.867	rs6493085	ENSG00000275601.1	AC011330.13	-5.81	1.18e-08	2.12e-06	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43361984	chr15:43642389~43643023:-
THCA	cis	rs9381040	0.655	rs2268193	ENSG00000161912.16	ADCY10P1	5.81	1.18e-08	2.12e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41056886	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.655	rs2268192	ENSG00000161912.16	ADCY10P1	5.81	1.18e-08	2.12e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41056887	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.655	rs879491	ENSG00000161912.16	ADCY10P1	5.81	1.18e-08	2.12e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41059214	chr6:41101022~41140835:+
THCA	cis	rs9381040	0.655	rs2268190	ENSG00000161912.16	ADCY10P1	5.81	1.18e-08	2.12e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41062487	chr6:41101022~41140835:+
THCA	cis	rs2554380	0.55	rs4572348	ENSG00000230373.7	GOLGA6L5P	-5.81	1.18e-08	2.12e-06	-0.27	-0.26	Height;	chr15:83871411	chr15:84507885~84516814:-
THCA	cis	rs9921338	0.961	rs8056282	ENSG00000262636.1	CTD-3088G3.4	-5.81	1.18e-08	2.13e-06	-0.38	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11313379	chr16:11380859~11381118:-
THCA	cis	rs9307551	0.817	rs1440864	ENSG00000250334.4	LINC00989	-5.81	1.18e-08	2.13e-06	-0.3	-0.26	Refractive error;	chr4:79571830	chr4:79492416~79576460:+
THCA	cis	rs2562456	0.617	rs34203148	ENSG00000213976.4	CTD-2561J22.2	-5.81	1.18e-08	2.13e-06	-0.29	-0.26	Pain;	chr19:21590743	chr19:21382865~21387177:+
THCA	cis	rs13256369	0.865	rs13277708	ENSG00000253893.2	FAM85B	-5.81	1.18e-08	2.13e-06	-0.34	-0.26	Obesity-related traits;	chr8:8716426	chr8:8167819~8226614:-
THCA	cis	rs853679	0.546	rs71537572	ENSG00000226314.6	ZNF192P1	-5.81	1.18e-08	2.13e-06	-0.57	-0.26	Depression;	chr6:28002937	chr6:28161781~28169594:+
THCA	cis	rs9467773	1	rs6922824	ENSG00000124549.13	BTN2A3P	-5.81	1.18e-08	2.13e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26421391~26432383:+
THCA	cis	rs6740322	0.748	rs6544635	ENSG00000234936.1	AC010883.5	5.81	1.18e-08	2.13e-06	0.28	0.26	Coronary artery disease;	chr2:43259565	chr2:43229573~43233394:+
THCA	cis	rs17772222	0.582	rs11625009	ENSG00000258983.2	RP11-507K2.2	-5.81	1.18e-08	2.13e-06	-0.31	-0.26	Coronary artery calcification;	chr14:88521018	chr14:88499334~88515502:+
THCA	cis	rs9813712	0.574	rs35856399	ENSG00000249846.5	RP11-77P16.4	-5.81	1.18e-08	2.13e-06	-0.26	-0.26	Response to amphetamines;	chr3:130241961	chr3:130112550~130120579:+
THCA	cis	rs7119038	0.818	rs11217040	ENSG00000255239.1	AP002954.6	-5.81	1.18e-08	2.13e-06	-0.38	-0.26	Sjögren's syndrome;	chr11:118809939	chr11:118688039~118690600:-
THCA	cis	rs4650994	1	rs4650993	ENSG00000273384.1	RP5-1098D14.1	5.81	1.18e-08	2.13e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178546052	chr1:178651706~178652282:+
THCA	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	5.81	1.18e-08	2.13e-06	0.25	0.26	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
THCA	cis	rs77972916	0.505	rs3851318	ENSG00000234936.1	AC010883.5	5.81	1.18e-08	2.13e-06	0.28	0.26	Granulocyte percentage of myeloid white cells;	chr2:43305669	chr2:43229573~43233394:+
THCA	cis	rs9859260	0.744	rs406271	ENSG00000273009.1	RP11-352G9.1	5.81	1.18e-08	2.13e-06	0.29	0.26	Mean corpuscular volume;	chr3:196050105	chr3:195913078~195913683:-
THCA	cis	rs9876781	1	rs7653691	ENSG00000229759.1	MRPS18AP1	-5.81	1.18e-08	2.13e-06	-0.3	-0.26	Longevity;	chr3:48378199	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs6442117	ENSG00000229759.1	MRPS18AP1	-5.81	1.18e-08	2.13e-06	-0.3	-0.26	Longevity;	chr3:48378407	chr3:48256350~48256938:-
THCA	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-5.81	1.18e-08	2.14e-06	-0.26	-0.26	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
THCA	cis	rs4683346	0.616	rs7641046	ENSG00000173811.9	CCDC13-AS1	-5.81	1.18e-08	2.14e-06	-0.27	-0.26	Granulocyte percentage of myeloid white cells;	chr3:42789838	chr3:42732575~42746768:+
THCA	cis	rs4683346	0.585	rs11129975	ENSG00000173811.9	CCDC13-AS1	-5.81	1.18e-08	2.14e-06	-0.27	-0.26	Granulocyte percentage of myeloid white cells;	chr3:42794493	chr3:42732575~42746768:+
THCA	cis	rs4683346	0.616	rs13096498	ENSG00000173811.9	CCDC13-AS1	-5.81	1.18e-08	2.14e-06	-0.27	-0.26	Granulocyte percentage of myeloid white cells;	chr3:42795494	chr3:42732575~42746768:+
THCA	cis	rs17818399	0.708	rs13000706	ENSG00000279254.1	RP11-536C12.1	-5.81	1.18e-08	2.14e-06	-0.25	-0.26	Height;	chr2:46611108	chr2:46668870~46670778:+
THCA	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	5.81	1.18e-08	2.14e-06	0.28	0.26	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
THCA	cis	rs6545883	0.931	rs778768	ENSG00000271889.1	RP11-493E12.1	5.8	1.19e-08	2.14e-06	0.25	0.26	Tuberculosis;	chr2:61563154	chr2:61151433~61162105:-
THCA	cis	rs9921338	0.961	rs4780358	ENSG00000262703.1	RP11-485G7.6	-5.8	1.19e-08	2.14e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11280355	chr16:11348143~11349321:-
THCA	cis	rs75422866	0.541	rs12425816	ENSG00000276691.1	RP5-1057I20.5	5.8	1.19e-08	2.14e-06	0.44	0.26	Pneumonia;	chr12:47731419	chr12:47788426~47788971:+
THCA	cis	rs2717559	0.542	rs2717590	ENSG00000253741.1	CTD-2292P10.4	5.8	1.19e-08	2.14e-06	0.33	0.26	Urinary tract infection frequency;	chr8:142819296	chr8:142702252~142726973:-
THCA	cis	rs5751614	0.537	rs3788358	ENSG00000230701.2	FBXW4P1	5.8	1.19e-08	2.15e-06	0.29	0.26	Height;	chr22:23274168	chr22:23262767~23265005:+
THCA	cis	rs934734	0.967	rs702875	ENSG00000234255.7	AC012370.3	5.8	1.19e-08	2.15e-06	0.29	0.26	Rheumatoid arthritis;	chr2:65387063	chr2:65439888~65456571:-
THCA	cis	rs2439831	1	rs7173487	ENSG00000275601.1	AC011330.13	-5.8	1.19e-08	2.15e-06	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43458041	chr15:43642389~43643023:-
THCA	cis	rs10129255	0.913	rs10140943	ENSG00000211974.3	IGHV2-70	5.8	1.19e-08	2.15e-06	0.2	0.26	Kawasaki disease;	chr14:106767441	chr14:106723574~106724093:-
THCA	cis	rs7119038	0.818	rs10892294	ENSG00000255239.1	AP002954.6	5.8	1.19e-08	2.15e-06	0.39	0.26	Sjögren's syndrome;	chr11:118796648	chr11:118688039~118690600:-
THCA	cis	rs8025790	0.508	rs12441823	ENSG00000270964.1	RP11-502I4.3	-5.8	1.19e-08	2.15e-06	-0.23	-0.26	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67620639	chr15:67541072~67542604:-
THCA	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-5.8	1.19e-08	2.15e-06	-0.32	-0.26	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
THCA	cis	rs7131987	0.868	rs7958210	ENSG00000257176.2	RP11-996F15.2	-5.8	1.19e-08	2.15e-06	-0.26	-0.26	QT interval;	chr12:29242248	chr12:29280418~29317848:-
THCA	cis	rs12893668	0.603	rs61637848	ENSG00000269940.1	RP11-73M18.7	5.8	1.19e-08	2.15e-06	0.27	0.26	Reticulocyte count;	chr14:103629694	chr14:103694560~103695170:+
THCA	cis	rs6545883	1	rs778763	ENSG00000271889.1	RP11-493E12.1	5.8	1.19e-08	2.15e-06	0.25	0.26	Tuberculosis;	chr2:61558504	chr2:61151433~61162105:-
THCA	cis	rs6142102	0.961	rs2284387	ENSG00000275784.1	RP5-1125A11.6	-5.8	1.19e-08	2.15e-06	-0.27	-0.26	Skin pigmentation;	chr20:34056782	chr20:33989480~33991818:-
THCA	cis	rs10043228	0.702	rs6873950	ENSG00000248445.4	SEMA6A-AS1	-5.8	1.19e-08	2.16e-06	-0.28	-0.26	Asthma or chronic obstructive pulmonary disease;	chr5:116293998	chr5:116447547~116508276:+
THCA	cis	rs7829975	0.511	rs2980426	ENSG00000254153.1	CTA-398F10.2	-5.8	1.2e-08	2.16e-06	-0.28	-0.26	Mood instability;	chr8:8288087	chr8:8456909~8461337:-
THCA	cis	rs853679	0.628	rs9368560	ENSG00000220721.1	OR1F12	5.8	1.2e-08	2.16e-06	0.36	0.26	Depression;	chr6:28192182	chr6:28073316~28074233:+
THCA	cis	rs4591358	0.559	rs2133858	ENSG00000223466.1	AC064834.2	5.8	1.2e-08	2.16e-06	0.31	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519925	chr2:195533035~195538681:+
THCA	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	5.8	1.2e-08	2.16e-06	0.28	0.26	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
THCA	cis	rs6585424	1	rs12268619	ENSG00000225484.5	NUTM2B-AS1	-5.8	1.2e-08	2.16e-06	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80160904	chr10:79663088~79826594:-
THCA	cis	rs1707322	0.721	rs28817701	ENSG00000281133.1	AL355480.3	-5.8	1.2e-08	2.16e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.691	rs28495425	ENSG00000281133.1	AL355480.3	-5.8	1.2e-08	2.16e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.691	rs61784803	ENSG00000281133.1	AL355480.3	5.8	1.2e-08	2.16e-06	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.663	rs3935296	ENSG00000281133.1	AL355480.3	5.8	1.2e-08	2.16e-06	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45580892~45580996:-
THCA	cis	rs4835473	0.742	rs7695853	ENSG00000251600.4	RP11-673E1.1	5.8	1.2e-08	2.16e-06	0.35	0.26	Immature fraction of reticulocytes;	chr4:143883243	chr4:143912331~143982454:+
THCA	cis	rs12497850	0.931	rs7647813	ENSG00000229759.1	MRPS18AP1	5.8	1.2e-08	2.17e-06	0.34	0.26	Parkinson's disease;	chr3:48795915	chr3:48256350~48256938:-
THCA	cis	rs4950322	0.57	rs4593887	ENSG00000278811.3	LINC00624	5.8	1.2e-08	2.17e-06	0.31	0.26	Protein quantitative trait loci;	chr1:147234246	chr1:147258885~147517875:-
THCA	cis	rs7615952	0.576	rs1127717	ENSG00000250012.1	RP11-124N2.1	-5.8	1.2e-08	2.17e-06	-0.24	-0.26	Blood pressure (smoking interaction);	chr3:126107216	chr3:126084220~126095349:+
THCA	cis	rs6675668	0.645	rs2298162	ENSG00000235501.4	RP4-639F20.1	-5.8	1.2e-08	2.17e-06	-0.28	-0.26	Stearic acid (18:0) levels;	chr1:94983477	chr1:94927566~94963270:+
THCA	cis	rs7617773	1	rs7617773	ENSG00000199476.1	Y_RNA	5.8	1.2e-08	2.17e-06	0.33	0.26	Coronary artery disease;	chr3:48152025	chr3:48288587~48288694:+
THCA	cis	rs3847687	0.546	rs6486621	ENSG00000279128.1	RP11-76C10.4	5.8	1.2e-08	2.17e-06	0.29	0.26	Longevity;	chr12:131035663	chr12:131022769~131024741:-
THCA	cis	rs7246657	0.722	rs8100646	ENSG00000267422.1	CTD-2554C21.1	-5.8	1.2e-08	2.17e-06	-0.29	-0.26	Coronary artery calcification;	chr19:37617042	chr19:37779686~37792865:+
THCA	cis	rs758324	0.732	rs152056	ENSG00000237714.1	P4HA2-AS1	-5.8	1.2e-08	2.17e-06	-0.39	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132181789	chr5:132184876~132192808:+
THCA	cis	rs911555	0.511	rs2296483	ENSG00000269958.1	RP11-73M18.8	5.8	1.21e-08	2.18e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103696353~103697163:+
THCA	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	5.8	1.21e-08	2.18e-06	0.28	0.26	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
THCA	cis	rs7688540	0.665	rs11731933	ENSG00000211553.1	AC253576.2	-5.8	1.21e-08	2.18e-06	-0.38	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:136461~136568:+
THCA	cis	rs6951245	0.554	rs35126802	ENSG00000229043.2	AC091729.9	-5.8	1.21e-08	2.18e-06	-0.34	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1160374~1165267:+
THCA	cis	rs17772222	0.675	rs1099698	ENSG00000258983.2	RP11-507K2.2	-5.8	1.21e-08	2.18e-06	-0.3	-0.26	Coronary artery calcification;	chr14:88414904	chr14:88499334~88515502:+
THCA	cis	rs758747	0.626	rs7200737	ENSG00000276754.1	RP11-461A8.5	5.8	1.21e-08	2.18e-06	0.24	0.26	Body mass index;	chr16:3661655	chr16:3686998~3687380:+
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000232546.1	RP11-458F8.1	5.8	1.21e-08	2.19e-06	0.33	0.26	Diabetic kidney disease;	chr7:66158142	chr7:66848496~66858136:+
THCA	cis	rs2559856	1	rs2559860	ENSG00000274560.1	RP11-285E23.2	5.8	1.21e-08	2.19e-06	0.16	0.26	Blood protein levels;	chr12:101693858	chr12:101696002~101696450:-
THCA	cis	rs71520386	0.632	rs28526185	ENSG00000228649.7	AC005682.5	-5.8	1.21e-08	2.19e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22831699	chr7:22854178~22861579:+
THCA	cis	rs3760982	1	rs4802200	ENSG00000267058.1	RP11-15A1.3	-5.8	1.21e-08	2.19e-06	-0.22	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785366	chr19:43891804~43901805:-
THCA	cis	rs16958440	0.867	rs2117373	ENSG00000267800.1	RP11-49K24.5	-5.8	1.21e-08	2.19e-06	-0.52	-0.26	Sitting height ratio;	chr18:47145463	chr18:47137018~47137290:+
THCA	cis	rs2839186	0.585	rs2839154	ENSG00000215424.8	MCM3AP-AS1	-5.8	1.21e-08	2.19e-06	-0.15	-0.26	Testicular germ cell tumor;	chr21:46217846	chr21:46229217~46259390:+
THCA	cis	rs10916248	0.511	rs1060386	ENSG00000232628.4	RP11-365O16.3	5.8	1.21e-08	2.19e-06	0.38	0.26	QT interval (drug interaction);	chr1:224192776	chr1:224208747~224213279:-
THCA	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	5.8	1.21e-08	2.19e-06	0.32	0.26	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
THCA	cis	rs12428035	0.772	rs7323408	ENSG00000247400.3	DNAJC3-AS1	-5.8	1.21e-08	2.19e-06	-0.24	-0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95808681	chr13:95648733~95676925:-
THCA	cis	rs7727544	0.582	rs10075459	ENSG00000233006.5	AC034220.3	5.8	1.21e-08	2.19e-06	0.2	0.26	Blood metabolite levels;	chr5:132205670	chr5:132311285~132369916:-
THCA	cis	rs6430585	0.528	rs12464050	ENSG00000231890.6	DARS-AS1	-5.8	1.21e-08	2.19e-06	-0.32	-0.26	Corneal structure;	chr2:135905540	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.591	rs77096272	ENSG00000231890.6	DARS-AS1	-5.8	1.21e-08	2.19e-06	-0.32	-0.26	Corneal structure;	chr2:135906035	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.528	rs79826902	ENSG00000231890.6	DARS-AS1	-5.8	1.21e-08	2.19e-06	-0.32	-0.26	Corneal structure;	chr2:135912849	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.528	rs16832205	ENSG00000231890.6	DARS-AS1	-5.8	1.21e-08	2.19e-06	-0.32	-0.26	Corneal structure;	chr2:135927062	chr2:135985176~136022593:+
THCA	cis	rs9475752	0.895	rs17752412	ENSG00000231441.1	RP11-472M19.2	5.8	1.22e-08	2.19e-06	0.31	0.26	Menarche (age at onset);	chr6:56916294	chr6:56844002~56864078:+
THCA	cis	rs62184315	0.52	rs62184268	ENSG00000273240.1	RP11-455J20.3	-5.8	1.22e-08	2.2e-06	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189767451	chr2:189763859~189764456:-
THCA	cis	rs4950322	0.547	rs56864370	ENSG00000278811.3	LINC00624	5.8	1.22e-08	2.2e-06	0.31	0.26	Protein quantitative trait loci;	chr1:147111847	chr1:147258885~147517875:-
THCA	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	5.8	1.22e-08	2.2e-06	0.15	0.26	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
THCA	cis	rs253959	0.545	rs4920905	ENSG00000272265.1	CTD-2287O16.4	5.8	1.22e-08	2.2e-06	0.3	0.26	Bipolar disorder and schizophrenia;	chr5:116090771	chr5:116078110~116078570:-
THCA	cis	rs253959	0.607	rs1396497	ENSG00000272265.1	CTD-2287O16.4	5.8	1.22e-08	2.2e-06	0.3	0.26	Bipolar disorder and schizophrenia;	chr5:116091719	chr5:116078110~116078570:-
THCA	cis	rs7829975	0.633	rs2979181	ENSG00000254153.1	CTA-398F10.2	-5.8	1.22e-08	2.2e-06	-0.29	-0.26	Mood instability;	chr8:8465578	chr8:8456909~8461337:-
THCA	cis	rs9859260	0.744	rs3933	ENSG00000273009.1	RP11-352G9.1	5.8	1.22e-08	2.2e-06	0.29	0.26	Mean corpuscular volume;	chr3:196058126	chr3:195913078~195913683:-
THCA	cis	rs11089937	0.626	rs9619800	ENSG00000211638.2	IGLV8-61	-5.8	1.22e-08	2.2e-06	-0.21	-0.26	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22098700~22099212:+
THCA	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	5.8	1.22e-08	2.2e-06	0.27	0.26	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
THCA	cis	rs2117029	1	rs3782357	ENSG00000258017.1	RP11-386G11.10	-5.8	1.22e-08	2.2e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49033869	chr12:49127782~49147869:+
THCA	cis	rs2337406	1	rs11846866	ENSG00000274576.2	IGHV2-70	-5.8	1.22e-08	2.2e-06	-0.23	-0.26	Alzheimer's disease (late onset);	chr14:106703003	chr14:106770577~106771020:-
THCA	cis	rs12188164	0.812	rs9313065	ENSG00000225138.6	CTD-2228K2.7	5.8	1.22e-08	2.21e-06	0.25	0.26	Cystic fibrosis severity;	chr5:423311	chr5:473236~480884:+
THCA	cis	rs6674176	0.597	rs9326136	ENSG00000237950.1	RP11-7O11.3	-5.8	1.22e-08	2.21e-06	-0.23	-0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43924720	chr1:43944370~43946551:-
THCA	cis	rs1395	0.778	rs1978881	ENSG00000234072.1	AC074117.10	-5.8	1.22e-08	2.21e-06	-0.23	-0.26	Blood metabolite levels;	chr2:27177982	chr2:27356246~27367622:+
THCA	cis	rs1395	0.778	rs72810794	ENSG00000234072.1	AC074117.10	-5.8	1.22e-08	2.21e-06	-0.23	-0.26	Blood metabolite levels;	chr2:27178392	chr2:27356246~27367622:+
THCA	cis	rs4650994	0.544	rs4132058	ENSG00000273384.1	RP5-1098D14.1	5.8	1.22e-08	2.21e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178536422	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.544	rs4075631	ENSG00000273384.1	RP5-1098D14.1	5.8	1.22e-08	2.21e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178537459	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.525	rs4316329	ENSG00000273384.1	RP5-1098D14.1	5.8	1.22e-08	2.21e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178540198	chr1:178651706~178652282:+
THCA	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	5.8	1.22e-08	2.21e-06	0.14	0.26	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
THCA	cis	rs2243480	1	rs10807702	ENSG00000229886.1	RP5-1132H15.3	5.8	1.23e-08	2.21e-06	0.42	0.26	Diabetic kidney disease;	chr7:66302856	chr7:66025126~66031544:-
THCA	cis	rs17772222	0.636	rs3850390	ENSG00000258983.2	RP11-507K2.2	5.8	1.23e-08	2.21e-06	0.34	0.26	Coronary artery calcification;	chr14:88829185	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.597	rs17700296	ENSG00000258983.2	RP11-507K2.2	5.8	1.23e-08	2.21e-06	0.34	0.26	Coronary artery calcification;	chr14:88840976	chr14:88499334~88515502:+
THCA	cis	rs1979679	1	rs11049487	ENSG00000278733.1	RP11-425D17.1	5.8	1.23e-08	2.21e-06	0.26	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28254157	chr12:28185625~28186190:-
THCA	cis	rs7403037	0.583	rs8042000	ENSG00000259905.4	PWRN1	5.8	1.23e-08	2.21e-06	0.26	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24347476	chr15:24493137~24652130:+
THCA	cis	rs2839186	0.843	rs17182671	ENSG00000239415.1	AP001469.9	5.8	1.23e-08	2.22e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46276324	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.739	rs7282763	ENSG00000239415.1	AP001469.9	5.8	1.23e-08	2.22e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46276886	chr21:46251549~46254133:-
THCA	cis	rs7246657	0.678	rs2972446	ENSG00000267422.1	CTD-2554C21.1	5.8	1.23e-08	2.22e-06	0.29	0.26	Coronary artery calcification;	chr19:37638992	chr19:37779686~37792865:+
THCA	cis	rs6504622	0.902	rs1052586	ENSG00000262879.4	RP11-156P1.3	-5.8	1.23e-08	2.22e-06	-0.24	-0.26	Orofacial clefts;	chr17:46941097	chr17:46984045~47100323:-
THCA	cis	rs7829975	0.806	rs2428	ENSG00000254153.1	CTA-398F10.2	-5.8	1.23e-08	2.22e-06	-0.27	-0.26	Mood instability;	chr8:8783635	chr8:8456909~8461337:-
THCA	cis	rs7267979	0.565	rs6107059	ENSG00000125804.12	FAM182A	5.8	1.23e-08	2.22e-06	0.34	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26054655~26086917:+
THCA	cis	rs2562456	0.917	rs2650793	ENSG00000268119.4	CTD-2561J22.5	-5.8	1.23e-08	2.22e-06	-0.31	-0.26	Pain;	chr19:21493313	chr19:21444241~21463908:-
THCA	cis	rs1030877	0.557	rs2576752	ENSG00000235319.1	AC012360.4	-5.8	1.23e-08	2.22e-06	-0.28	-0.26	Obesity-related traits;	chr2:105362304	chr2:105324210~105330529:+
THCA	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-5.8	1.23e-08	2.22e-06	-0.26	-0.26	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
THCA	cis	rs7688014	1	rs7688014	ENSG00000230069.3	LRRC37A15P	-5.8	1.23e-08	2.22e-06	-0.28	-0.26	Schizophrenia;	chr4:103053903	chr4:102727274~102730721:-
THCA	cis	rs875971	0.83	rs427575	ENSG00000223473.2	GS1-124K5.3	5.8	1.23e-08	2.23e-06	0.18	0.26	Aortic root size;	chr7:66054232	chr7:66491049~66493566:-
THCA	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-5.8	1.23e-08	2.23e-06	-0.27	-0.26	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
THCA	cis	rs7044106	0.762	rs10760110	ENSG00000270917.1	RP11-27I1.6	5.8	1.24e-08	2.23e-06	0.36	0.26	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120812475~120812845:-
THCA	cis	rs9880211	0.8	rs34324561	ENSG00000273486.1	RP11-731C17.2	5.8	1.24e-08	2.23e-06	0.26	0.26	Height;Body mass index;	chr3:136382400	chr3:136837338~136839021:-
THCA	cis	rs2562456	0.652	rs4809145	ENSG00000268119.4	CTD-2561J22.5	5.8	1.24e-08	2.23e-06	0.35	0.26	Pain;	chr19:21597907	chr19:21444241~21463908:-
THCA	cis	rs890448	0.796	rs1426541	ENSG00000254531.1	FLJ20021	5.8	1.24e-08	2.23e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101435702	chr4:101347780~101348883:+
THCA	cis	rs1979679	1	rs1979679	ENSG00000278733.1	RP11-425D17.1	5.8	1.24e-08	2.23e-06	0.26	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28253582	chr12:28185625~28186190:-
THCA	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	5.8	1.24e-08	2.23e-06	0.33	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
THCA	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-5.8	1.24e-08	2.23e-06	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
THCA	cis	rs2439831	0.867	rs2412778	ENSG00000275601.1	AC011330.13	-5.8	1.24e-08	2.23e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43368784	chr15:43642389~43643023:-
THCA	cis	rs2839186	0.967	rs2839191	ENSG00000239415.1	AP001469.9	5.8	1.24e-08	2.23e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46275481	chr21:46251549~46254133:-
THCA	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	5.8	1.24e-08	2.23e-06	0.33	0.26	Height;	chr4:55540928	chr4:55363971~55395847:-
THCA	cis	rs1876905	0.62	rs354525	ENSG00000230177.1	RP5-1112D6.4	-5.8	1.24e-08	2.23e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111186193	chr6:111277932~111278742:+
THCA	cis	rs6545883	0.868	rs7574631	ENSG00000271889.1	RP11-493E12.1	5.8	1.24e-08	2.23e-06	0.25	0.26	Tuberculosis;	chr2:61598007	chr2:61151433~61162105:-
THCA	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	5.8	1.24e-08	2.24e-06	0.28	0.26	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
THCA	cis	rs9595908	0.931	rs35555940	ENSG00000212293.1	SNORA16	5.8	1.24e-08	2.24e-06	0.31	0.26	Body mass index;	chr13:32492975	chr13:32420390~32420516:-
THCA	cis	rs13256369	0.951	rs10503394	ENSG00000253893.2	FAM85B	-5.8	1.24e-08	2.24e-06	-0.35	-0.26	Obesity-related traits;	chr8:8708265	chr8:8167819~8226614:-
THCA	cis	rs9652601	0.748	rs8064154	ENSG00000274038.1	RP11-66H6.4	-5.8	1.24e-08	2.24e-06	-0.32	-0.26	Systemic lupus erythematosus;	chr16:11125562	chr16:11056556~11057034:+
THCA	cis	rs10971721	0.822	rs307673	ENSG00000281128.1	PTENP1-AS	5.8	1.25e-08	2.24e-06	0.58	0.26	Body mass index;	chr9:33968821	chr9:33677268~33688011:+
THCA	cis	rs793571	0.554	rs12906714	ENSG00000259250.1	RP11-50C13.1	-5.8	1.25e-08	2.24e-06	-0.28	-0.26	Schizophrenia;	chr15:58632821	chr15:58587507~58591676:+
THCA	cis	rs4908768	0.501	rs6577491	ENSG00000232912.4	RP5-1115A15.1	5.8	1.25e-08	2.24e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8424645~8434838:+
THCA	cis	rs330048	0.545	rs11774353	ENSG00000254153.1	CTA-398F10.2	-5.8	1.25e-08	2.24e-06	-0.28	-0.26	Systemic lupus erythematosus;	chr8:9295617	chr8:8456909~8461337:-
THCA	cis	rs2985684	0.841	rs7158577	ENSG00000278009.1	RP11-649E7.8	5.8	1.25e-08	2.25e-06	0.36	0.26	Carotid intima media thickness;	chr14:49591915	chr14:49601011~49601124:-
THCA	cis	rs9910055	0.747	rs2905981	ENSG00000267080.4	ASB16-AS1	-5.8	1.25e-08	2.25e-06	-0.23	-0.26	Total body bone mineral density;	chr17:44161257	chr17:44175973~44186717:-
THCA	cis	rs7225151	0.634	rs78813154	ENSG00000234327.6	AC012146.7	-5.8	1.25e-08	2.25e-06	-0.28	-0.26	Alzheimer's disease (late onset);	chr17:5363707	chr17:5111468~5115004:+
THCA	cis	rs3020264	0.962	rs1974946	ENSG00000271743.1	CTD-2541M15.3	-5.8	1.25e-08	2.25e-06	-0.34	-0.26	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631266	chr8:6615604~6617198:-
THCA	cis	rs2735413	0.564	rs74316728	ENSG00000276007.1	RP11-358L22.3	5.8	1.25e-08	2.25e-06	0.28	0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78065756	chr16:78123243~78124332:+
THCA	cis	rs172166	0.637	rs1225597	ENSG00000226314.6	ZNF192P1	-5.8	1.25e-08	2.25e-06	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28194309	chr6:28161781~28169594:+
THCA	cis	rs172166	0.637	rs1071893	ENSG00000226314.6	ZNF192P1	-5.8	1.25e-08	2.25e-06	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28199857	chr6:28161781~28169594:+
THCA	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	5.8	1.25e-08	2.25e-06	0.4	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
THCA	cis	rs1387259	0.899	rs7307566	ENSG00000240399.1	RP1-228P16.1	5.8	1.25e-08	2.25e-06	0.27	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs316307	ENSG00000232546.1	RP11-458F8.1	-5.8	1.25e-08	2.25e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66105184	chr7:66848496~66858136:+
THCA	cis	rs2562456	0.833	rs2562487	ENSG00000268081.1	RP11-678G14.2	5.8	1.25e-08	2.25e-06	0.38	0.26	Pain;	chr19:21468580	chr19:21554640~21569237:-
THCA	cis	rs1862618	0.853	rs1833896	ENSG00000271828.1	CTD-2310F14.1	5.8	1.25e-08	2.25e-06	0.39	0.26	Initial pursuit acceleration;	chr5:56801842	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.853	rs1862619	ENSG00000271828.1	CTD-2310F14.1	5.8	1.25e-08	2.25e-06	0.39	0.26	Initial pursuit acceleration;	chr5:56802429	chr5:56927874~56929573:+
THCA	cis	rs763121	0.853	rs4821810	ENSG00000273076.1	RP3-508I15.22	5.8	1.25e-08	2.25e-06	0.26	0.26	Menopause (age at onset);	chr22:38676093	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757234	ENSG00000273076.1	RP3-508I15.22	5.8	1.25e-08	2.25e-06	0.26	0.26	Menopause (age at onset);	chr22:38676681	chr22:38743495~38743910:+
THCA	cis	rs7615952	0.932	rs13086087	ENSG00000241288.6	RP11-379B18.5	-5.8	1.25e-08	2.25e-06	-0.33	-0.26	Blood pressure (smoking interaction);	chr3:125927438	chr3:125827238~125916384:-
THCA	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	5.79	1.25e-08	2.26e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
THCA	cis	rs1499614	1	rs1267817	ENSG00000232559.3	GS1-124K5.12	5.79	1.25e-08	2.26e-06	0.39	0.26	Gout;	chr7:66645053	chr7:66554588~66576923:-
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000232559.3	GS1-124K5.12	5.79	1.25e-08	2.26e-06	0.39	0.26	Gout;	chr7:66654674	chr7:66554588~66576923:-
THCA	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-5.79	1.25e-08	2.26e-06	-0.2	-0.26	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
THCA	cis	rs6908034	0.66	rs74795718	ENSG00000237404.1	RP3-471C18.2	-5.79	1.26e-08	2.26e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782068	chr6:19689825~19753113:-
THCA	cis	rs9910055	0.762	rs2240226	ENSG00000267080.4	ASB16-AS1	-5.79	1.26e-08	2.26e-06	-0.23	-0.26	Total body bone mineral density;	chr17:44188850	chr17:44175973~44186717:-
THCA	cis	rs12612619	0.696	rs11678188	ENSG00000229122.1	AGBL5-IT1	5.79	1.26e-08	2.26e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27024964	chr2:27061038~27061815:+
THCA	cis	rs1823913	0.963	rs12614848	ENSG00000280083.1	RP11-317J9.1	5.79	1.26e-08	2.27e-06	0.32	0.26	Obesity-related traits;	chr2:191231993	chr2:191154118~191156070:-
THCA	cis	rs897984	0.762	rs1870293	ENSG00000279196.1	RP11-1072A3.3	-5.79	1.26e-08	2.27e-06	-0.26	-0.26	Dementia with Lewy bodies;	chr16:30959620	chr16:30984630~30988270:-
THCA	cis	rs812925	0.714	rs1900573	ENSG00000271889.1	RP11-493E12.1	-5.79	1.26e-08	2.27e-06	-0.27	-0.26	Immature fraction of reticulocytes;	chr2:61369777	chr2:61151433~61162105:-
THCA	cis	rs8017455	0.523	rs61978750	ENSG00000259167.2	NMNAT1P1	5.79	1.26e-08	2.27e-06	0.47	0.26	Hair morphology;	chr14:81069918	chr14:81032529~81033404:+
THCA	cis	rs9307551	0.901	rs6850999	ENSG00000250334.4	LINC00989	-5.79	1.26e-08	2.27e-06	-0.32	-0.26	Refractive error;	chr4:79580784	chr4:79492416~79576460:+
THCA	cis	rs4948275	0.773	rs2249816	ENSG00000237233.2	TMEM26-AS1	5.79	1.26e-08	2.27e-06	0.33	0.26	Night sleep phenotypes;	chr10:61488037	chr10:61452639~61481956:+
THCA	cis	rs11158026	0.826	rs10136545	ENSG00000258413.1	RP11-665C16.6	-5.79	1.26e-08	2.27e-06	-0.35	-0.26	Parkinson's disease;	chr14:54886145	chr14:55262767~55272075:-
THCA	cis	rs9601248	0.627	rs2876741	ENSG00000227354.5	RBM26-AS1	-5.79	1.26e-08	2.27e-06	-0.26	-0.26	Major depressive disorder;	chr13:79612577	chr13:79406309~79424328:+
THCA	cis	rs4683346	0.616	rs34868846	ENSG00000173811.9	CCDC13-AS1	-5.79	1.26e-08	2.27e-06	-0.27	-0.26	Granulocyte percentage of myeloid white cells;	chr3:42791723	chr3:42732575~42746768:+
THCA	cis	rs17772222	1	rs12589480	ENSG00000222990.1	RNU4-22P	5.79	1.26e-08	2.27e-06	0.35	0.26	Coronary artery calcification;	chr14:88414926	chr14:88513498~88513663:+
THCA	cis	rs11671005	0.735	rs11670871	ENSG00000269473.1	CTD-2619J13.19	-5.79	1.26e-08	2.27e-06	-0.29	-0.26	Mean platelet volume;	chr19:58429147	chr19:58440448~58445849:+
THCA	cis	rs258324	0.79	rs258318	ENSG00000260259.1	RP11-368I7.4	5.79	1.26e-08	2.27e-06	0.36	0.26	Height;	chr16:89665642	chr16:89682620~89686569:-
THCA	cis	rs7809950	0.678	rs62482507	ENSG00000238832.1	snoU109	-5.79	1.27e-08	2.28e-06	-0.3	-0.26	Coronary artery disease;	chr7:107384043	chr7:107603363~107603507:+
THCA	cis	rs11051970	0.838	rs2651369	ENSG00000274964.1	RP11-817I4.1	-5.79	1.27e-08	2.28e-06	-0.29	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32399835	chr12:32339368~32340724:+
THCA	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	5.79	1.27e-08	2.28e-06	0.28	0.26	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
THCA	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	5.79	1.27e-08	2.28e-06	0.16	0.26	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
THCA	cis	rs4908768	0.501	rs7518608	ENSG00000232912.4	RP5-1115A15.1	5.79	1.27e-08	2.28e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8424645~8434838:+
THCA	cis	rs642803	0.551	rs1308020	ENSG00000255557.1	RP11-770G2.2	-5.79	1.27e-08	2.28e-06	-0.29	-0.26	Urate levels;	chr11:65730087	chr11:65745729~65771585:+
THCA	cis	rs7665090	0.51	rs223498	ENSG00000251288.2	RP11-10L12.2	5.79	1.27e-08	2.28e-06	0.35	0.26	Primary biliary cholangitis;	chr4:102730805	chr4:102751401~102752641:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000273142.1	RP11-458F8.4	-5.79	1.27e-08	2.28e-06	-0.2	-0.26	Aortic root size;	chr7:66692033	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs7785213	ENSG00000273142.1	RP11-458F8.4	5.79	1.27e-08	2.28e-06	0.2	0.26	Aortic root size;	chr7:66673991	chr7:66902857~66906297:+
THCA	cis	rs442309	0.846	rs224050	ENSG00000238280.1	RP11-436D10.3	5.79	1.27e-08	2.29e-06	0.31	0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62733462	chr10:62793562~62805887:-
THCA	cis	rs2120243	0.504	rs1824058	ENSG00000244515.1	KRT18P34	-5.79	1.27e-08	2.29e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157406991	chr3:157162663~157163932:-
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	5.79	1.27e-08	2.29e-06	0.23	0.26	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
THCA	cis	rs9595908	0.965	rs11840502	ENSG00000212293.1	SNORA16	5.79	1.27e-08	2.29e-06	0.3	0.26	Body mass index;	chr13:32624572	chr13:32420390~32420516:-
THCA	cis	rs7586673	0.621	rs4999196	ENSG00000227403.1	AC009299.3	-5.79	1.27e-08	2.29e-06	-0.43	-0.26	Intelligence (multi-trait analysis);	chr2:161114824	chr2:161244739~161249050:+
THCA	cis	rs9388451	0.626	rs1935983	ENSG00000226409.1	RP11-735G4.1	-5.79	1.27e-08	2.29e-06	-0.32	-0.26	Brugada syndrome;	chr6:125747768	chr6:125370211~125374324:-
THCA	cis	rs9388451	0.626	rs1343116	ENSG00000226409.1	RP11-735G4.1	-5.79	1.27e-08	2.29e-06	-0.32	-0.26	Brugada syndrome;	chr6:125748556	chr6:125370211~125374324:-
THCA	cis	rs9388451	0.626	rs1343115	ENSG00000226409.1	RP11-735G4.1	-5.79	1.27e-08	2.29e-06	-0.32	-0.26	Brugada syndrome;	chr6:125748671	chr6:125370211~125374324:-
THCA	cis	rs9388451	0.626	rs2875881	ENSG00000226409.1	RP11-735G4.1	-5.79	1.27e-08	2.29e-06	-0.32	-0.26	Brugada syndrome;	chr6:125751707	chr6:125370211~125374324:-
THCA	cis	rs853679	0.556	rs13200214	ENSG00000226314.6	ZNF192P1	-5.79	1.27e-08	2.29e-06	-0.56	-0.26	Depression;	chr6:28049472	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs71559070	ENSG00000226314.6	ZNF192P1	-5.79	1.27e-08	2.29e-06	-0.56	-0.26	Depression;	chr6:28071151	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34166054	ENSG00000226314.6	ZNF192P1	-5.79	1.27e-08	2.29e-06	-0.56	-0.26	Depression;	chr6:28098023	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34662244	ENSG00000226314.6	ZNF192P1	-5.79	1.27e-08	2.29e-06	-0.56	-0.26	Depression;	chr6:28106103	chr6:28161781~28169594:+
THCA	cis	rs35952432	1	rs35952432	ENSG00000226314.6	ZNF192P1	-5.79	1.27e-08	2.29e-06	-0.56	-0.26	Lung cancer;	chr6:28107123	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13203816	ENSG00000226314.6	ZNF192P1	-5.79	1.27e-08	2.29e-06	-0.56	-0.26	Depression;	chr6:28111820	chr6:28161781~28169594:+
THCA	cis	rs853679	0.556	rs34588114	ENSG00000226314.6	ZNF192P1	-5.79	1.27e-08	2.29e-06	-0.56	-0.26	Depression;	chr6:28112850	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs34371502	ENSG00000226314.6	ZNF192P1	-5.79	1.27e-08	2.29e-06	-0.56	-0.26	Depression;	chr6:28113980	chr6:28161781~28169594:+
THCA	cis	rs4908768	0.501	rs7520617	ENSG00000232912.4	RP5-1115A15.1	5.79	1.27e-08	2.29e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8424645~8434838:+
THCA	cis	rs748404	0.666	rs34591748	ENSG00000249839.1	AC011330.5	-5.79	1.27e-08	2.29e-06	-0.37	-0.26	Lung cancer;	chr15:43334917	chr15:43663654~43684339:-
THCA	cis	rs9381040	0.655	rs9394756	ENSG00000161912.16	ADCY10P1	5.79	1.27e-08	2.29e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41048444	chr6:41101022~41140835:+
THCA	cis	rs12612619	0.732	rs7560144	ENSG00000229122.1	AGBL5-IT1	5.79	1.28e-08	2.29e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057592	chr2:27061038~27061815:+
THCA	cis	rs934734	0.789	rs2661798	ENSG00000281920.1	RP11-418H16.1	-5.79	1.28e-08	2.3e-06	-0.33	-0.26	Rheumatoid arthritis;	chr2:65408554	chr2:65623272~65628424:+
THCA	cis	rs6951245	0.638	rs74976697	ENSG00000229043.2	AC091729.9	-5.79	1.28e-08	2.3e-06	-0.4	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1160374~1165267:+
THCA	cis	rs6740322	0.643	rs13390381	ENSG00000234936.1	AC010883.5	5.79	1.28e-08	2.3e-06	0.27	0.26	Coronary artery disease;	chr2:43307275	chr2:43229573~43233394:+
THCA	cis	rs7404843	0.925	rs12600043	ENSG00000263335.1	AF001548.5	5.79	1.28e-08	2.3e-06	0.43	0.26	Testicular germ cell tumor;	chr16:15446095	chr16:15726674~15732993:+
THCA	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-5.79	1.28e-08	2.3e-06	-0.32	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
THCA	cis	rs2129782	1	rs6987711	ENSG00000253553.4	RP11-586K2.1	5.79	1.28e-08	2.3e-06	0.44	0.26	Electrodermal activity;	chr8:88413482	chr8:88326836~88737134:+
THCA	cis	rs11089937	0.626	rs5757051	ENSG00000211638.2	IGLV8-61	5.79	1.28e-08	2.31e-06	0.2	0.26	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22098700~22099212:+
THCA	cis	rs9307551	0.744	rs10004226	ENSG00000250334.4	LINC00989	-5.79	1.28e-08	2.31e-06	-0.3	-0.26	Refractive error;	chr4:79569654	chr4:79492416~79576460:+
THCA	cis	rs6840360	0.642	rs2709820	ENSG00000270265.1	RP11-731D1.4	-5.79	1.28e-08	2.31e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151333775~151353224:-
THCA	cis	rs6977955	1	rs6977955	ENSG00000234336.5	JAZF1-AS1	5.79	1.28e-08	2.31e-06	0.3	0.26	Allergic disease (asthma, hay fever or eczema);	chr7:28117268	chr7:28180322~28243917:+
THCA	cis	rs6951245	0.554	rs78999139	ENSG00000229043.2	AC091729.9	-5.79	1.29e-08	2.31e-06	-0.34	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1160374~1165267:+
THCA	cis	rs6957923	0.655	rs10232644	ENSG00000234286.1	AC006026.13	-5.79	1.29e-08	2.31e-06	-0.32	-0.26	Height;	chr7:23552301	chr7:23680195~23680786:-
THCA	cis	rs7493	0.755	rs17166861	ENSG00000233942.1	AC004012.1	5.79	1.29e-08	2.31e-06	0.39	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95391290	chr7:95471835~95473998:+
THCA	cis	rs7493	0.755	rs740264	ENSG00000233942.1	AC004012.1	5.79	1.29e-08	2.31e-06	0.39	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95392491	chr7:95471835~95473998:+
THCA	cis	rs9381040	0.655	rs2294695	ENSG00000161912.16	ADCY10P1	5.79	1.29e-08	2.31e-06	0.18	0.26	Alzheimer's disease (late onset);	chr6:41069031	chr6:41101022~41140835:+
THCA	cis	rs2280018	0.963	rs11075255	ENSG00000188599.16	NPIPP1	-5.79	1.29e-08	2.31e-06	-0.19	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15104312~15123498:-
THCA	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	5.79	1.29e-08	2.31e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
THCA	cis	rs875971	0.83	rs587360	ENSG00000223473.2	GS1-124K5.3	5.79	1.29e-08	2.31e-06	0.18	0.26	Aortic root size;	chr7:66057711	chr7:66491049~66493566:-
THCA	cis	rs7412746	0.634	rs4451553	ENSG00000231073.1	RP11-316M1.3	5.79	1.29e-08	2.31e-06	0.31	0.26	Melanoma;	chr1:150964853	chr1:150973123~150975534:+
THCA	cis	rs934734	0.736	rs1396210	ENSG00000234255.7	AC012370.3	5.79	1.29e-08	2.32e-06	0.29	0.26	Rheumatoid arthritis;	chr2:65357140	chr2:65439888~65456571:-
THCA	cis	rs9921338	0.923	rs7186455	ENSG00000262703.1	RP11-485G7.6	-5.79	1.29e-08	2.32e-06	-0.33	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333891	chr16:11348143~11349321:-
THCA	cis	rs6479901	0.557	rs12773283	ENSG00000232075.1	MRPL35P2	-5.79	1.29e-08	2.32e-06	-0.43	-0.26	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63634317~63634827:-
THCA	cis	rs3758785	0.623	rs13447720	ENSG00000255893.1	RP11-685N10.1	-5.79	1.29e-08	2.32e-06	-0.31	-0.26	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94432160	chr11:94472908~94473570:-
THCA	cis	rs16958440	0.521	rs16950323	ENSG00000267800.1	RP11-49K24.5	-5.79	1.29e-08	2.32e-06	-0.48	-0.26	Sitting height ratio;	chr18:47050956	chr18:47137018~47137290:+
THCA	cis	rs728616	0.614	rs55720611	ENSG00000225484.5	NUTM2B-AS1	-5.79	1.29e-08	2.32e-06	-0.44	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030543	chr10:79663088~79826594:-
THCA	cis	rs7044106	0.762	rs7849566	ENSG00000270917.1	RP11-27I1.6	-5.79	1.29e-08	2.32e-06	-0.36	-0.26	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120812475~120812845:-
THCA	cis	rs16976116	0.901	rs8027098	ENSG00000279145.1	RP11-547D13.1	5.79	1.29e-08	2.32e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55200071	chr15:55171972~55178175:-
THCA	cis	rs2348418	0.832	rs1032391	ENSG00000247934.4	RP11-967K21.1	5.79	1.29e-08	2.32e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28383775	chr12:28163298~28190738:-
THCA	cis	rs2439831	0.85	rs60883262	ENSG00000166763.7	STRCP1	5.79	1.29e-08	2.32e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43784305	chr15:43699488~43718184:-
THCA	cis	rs61677309	0.964	rs56292628	ENSG00000280032.1	RP11-832A4.7	5.79	1.29e-08	2.32e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118293157	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs55940627	ENSG00000280032.1	RP11-832A4.7	5.79	1.29e-08	2.32e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118293205	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs12577820	ENSG00000280032.1	RP11-832A4.7	5.79	1.29e-08	2.32e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118293518	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs59450866	ENSG00000280032.1	RP11-832A4.7	5.79	1.29e-08	2.32e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118296992	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs58093803	ENSG00000280032.1	RP11-832A4.7	5.79	1.29e-08	2.32e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118297441	chr11:118264593~118266817:+
THCA	cis	rs2288884	0.806	rs11084141	ENSG00000275055.1	CTC-471J1.11	-5.79	1.29e-08	2.32e-06	-0.25	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084654	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.806	rs11084142	ENSG00000275055.1	CTC-471J1.11	-5.79	1.29e-08	2.32e-06	-0.25	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084664	chr19:52049007~52049754:+
THCA	cis	rs1268083	0.546	rs9398785	ENSG00000237742.5	RP11-624M8.1	-5.79	1.29e-08	2.32e-06	-0.24	-0.26	Migraine;	chr6:125736602	chr6:125578558~125749190:-
THCA	cis	rs4604234	0.708	rs79583027	ENSG00000272129.1	RP11-250B2.6	-5.79	1.29e-08	2.32e-06	-0.63	-0.26	Cancer;	chr6:80326323	chr6:80355424~80356859:+
THCA	cis	rs4925386	0.819	rs2890083	ENSG00000273619.1	RP5-908M14.9	5.79	1.29e-08	2.33e-06	0.2	0.26	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62336902	chr20:62386303~62386970:-
THCA	cis	rs17214007	0.877	rs1569300	ENSG00000263335.1	AF001548.5	-5.79	1.29e-08	2.33e-06	-0.35	-0.26	Cognitive function;	chr16:15776891	chr16:15726674~15732993:+
THCA	cis	rs17711722	0.523	rs313812	ENSG00000275400.1	RP4-756H11.5	5.79	1.3e-08	2.33e-06	0.25	0.26	Calcium levels;	chr7:66040056	chr7:66553805~66554199:-
THCA	cis	rs12908161	1	rs35808647	ENSG00000259295.5	CSPG4P12	5.79	1.3e-08	2.33e-06	0.4	0.26	Schizophrenia;	chr15:84834210	chr15:85191438~85213905:+
THCA	cis	rs6840360	0.642	rs2724567	ENSG00000270265.1	RP11-731D1.4	5.79	1.3e-08	2.33e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.617	rs2724563	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.617	rs2724564	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.607	rs2724565	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2724568	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7677131	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7657670	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709828	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2724551	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.667	rs2709829	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.606	rs2709813	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.606	rs2724550	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709815	ENSG00000270265.1	RP11-731D1.4	-5.79	1.3e-08	2.33e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151333775~151353224:-
THCA	cis	rs6802315	0.604	rs2115941	ENSG00000272247.1	RP11-379F4.9	-5.79	1.3e-08	2.33e-06	-0.25	-0.26	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158801257~158801935:-
THCA	cis	rs9921338	0.961	rs9936328	ENSG00000262703.1	RP11-485G7.6	-5.79	1.3e-08	2.33e-06	-0.33	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11344364	chr16:11348143~11349321:-
THCA	cis	rs12188164	0.812	rs10072668	ENSG00000225138.6	CTD-2228K2.7	5.79	1.3e-08	2.33e-06	0.25	0.26	Cystic fibrosis severity;	chr5:422637	chr5:473236~480884:+
THCA	cis	rs7188861	0.626	rs7193871	ENSG00000262636.1	CTD-3088G3.4	5.79	1.3e-08	2.34e-06	0.33	0.26	HDL cholesterol;	chr16:11361749	chr16:11380859~11381118:-
THCA	cis	rs8028182	0.583	rs9944207	ENSG00000260269.4	CTD-2323K18.1	-5.79	1.3e-08	2.34e-06	-0.39	-0.26	Sudden cardiac arrest;	chr15:75620548	chr15:75527150~75601205:-
THCA	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-5.79	1.3e-08	2.34e-06	-0.33	-0.26	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
THCA	cis	rs7688540	0.8	rs28429717	ENSG00000275426.1	CH17-262A2.1	5.79	1.3e-08	2.34e-06	0.33	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:149738~150317:+
THCA	cis	rs853679	0.882	rs4713139	ENSG00000272009.1	RP1-313I6.12	-5.79	1.3e-08	2.34e-06	-0.38	-0.26	Depression;	chr6:28124907	chr6:28078792~28081130:-
THCA	cis	rs56037433	1	rs56037433	ENSG00000227403.1	AC009299.3	5.79	1.3e-08	2.34e-06	0.54	0.26	Bipolar disorder or attention deficit hyperactivity disorder;	chr2:161719475	chr2:161244739~161249050:+
THCA	cis	rs17508449	0.819	rs79220465	ENSG00000232450.1	RP4-730K3.3	-5.79	1.3e-08	2.34e-06	-0.4	-0.26	Leprosy;	chr1:113628719	chr1:113698884~113699631:-
THCA	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-5.79	1.3e-08	2.34e-06	-0.22	-0.26	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
THCA	cis	rs12291225	0.535	rs11023203	ENSG00000251991.1	RNU7-49P	5.79	1.3e-08	2.34e-06	0.3	0.26	Sense of smell;	chr11:14388269	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.583	rs78843135	ENSG00000251991.1	RNU7-49P	5.79	1.3e-08	2.34e-06	0.3	0.26	Vitamin D levels;	chr11:14389708	chr11:14478892~14478953:+
THCA	cis	rs10771431	0.597	rs10843142	ENSG00000256069.6	A2MP1	5.79	1.3e-08	2.34e-06	0.29	0.26	Breast size;	chr12:9204906	chr12:9228533~9275817:-
THCA	cis	rs2029362	0.846	rs1140711	ENSG00000245573.6	BDNF-AS	5.79	1.31e-08	2.34e-06	0.21	0.26	Total body bone mineral density;	chr11:27495862	chr11:27506838~27698174:+
THCA	cis	rs12908161	1	rs3803405	ENSG00000259295.5	CSPG4P12	5.79	1.31e-08	2.34e-06	0.4	0.26	Schizophrenia;	chr15:84840409	chr15:85191438~85213905:+
THCA	cis	rs11722779	0.844	rs7694724	ENSG00000230069.3	LRRC37A15P	-5.79	1.31e-08	2.35e-06	-0.27	-0.26	Schizophrenia;	chr4:103041375	chr4:102727274~102730721:-
THCA	cis	rs6545883	0.931	rs12713438	ENSG00000270820.4	RP11-355B11.2	5.79	1.31e-08	2.35e-06	0.22	0.26	Tuberculosis;	chr2:61498366	chr2:61471188~61484130:+
THCA	cis	rs6840360	0.642	rs4235219	ENSG00000270265.1	RP11-731D1.4	-5.79	1.31e-08	2.35e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs6851814	ENSG00000270265.1	RP11-731D1.4	-5.79	1.31e-08	2.35e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.606	rs10028035	ENSG00000270265.1	RP11-731D1.4	-5.79	1.31e-08	2.35e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.667	rs4266275	ENSG00000270265.1	RP11-731D1.4	-5.79	1.31e-08	2.35e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7684462	ENSG00000270265.1	RP11-731D1.4	-5.79	1.31e-08	2.35e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151333775~151353224:-
THCA	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	5.79	1.31e-08	2.35e-06	0.32	0.26	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
THCA	cis	rs593531	0.592	rs598869	ENSG00000255440.1	RP11-632K5.2	5.79	1.31e-08	2.35e-06	0.3	0.26	Neuroticism;	chr11:74335930	chr11:74409060~74416379:+
THCA	cis	rs1823913	1	rs68014803	ENSG00000280083.1	RP11-317J9.1	-5.79	1.31e-08	2.35e-06	-0.32	-0.26	Obesity-related traits;	chr2:191241877	chr2:191154118~191156070:-
THCA	cis	rs71520386	0.561	rs10274260	ENSG00000228649.7	AC005682.5	-5.79	1.31e-08	2.35e-06	-0.32	-0.26	Fibrinogen levels;	chr7:22805227	chr7:22854178~22861579:+
THCA	cis	rs442309	0.846	rs224070	ENSG00000238280.1	RP11-436D10.3	-5.79	1.31e-08	2.35e-06	-0.3	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62748658	chr10:62793562~62805887:-
THCA	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-5.79	1.31e-08	2.35e-06	-0.3	-0.26	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
THCA	cis	rs2361718	0.501	rs11869566	ENSG00000279259.1	RP11-334C17.3	5.79	1.31e-08	2.35e-06	0.26	0.26	Yeast infection;	chr17:80169449	chr17:80147250~80148596:+
THCA	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-5.79	1.31e-08	2.35e-06	-0.34	-0.26	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
THCA	cis	rs71520386	0.579	rs4394299	ENSG00000228649.7	AC005682.5	-5.79	1.31e-08	2.35e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22825763	chr7:22854178~22861579:+
THCA	cis	rs2765539	0.887	rs2765541	ENSG00000231365.4	RP11-418J17.1	-5.79	1.31e-08	2.36e-06	-0.28	-0.26	Waist-hip ratio;	chr1:119016034	chr1:119140396~119275973:+
THCA	cis	rs13256369	0.901	rs12679831	ENSG00000253893.2	FAM85B	-5.79	1.31e-08	2.36e-06	-0.35	-0.26	Obesity-related traits;	chr8:8708901	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.901	rs12681327	ENSG00000253893.2	FAM85B	-5.79	1.31e-08	2.36e-06	-0.35	-0.26	Obesity-related traits;	chr8:8708904	chr8:8167819~8226614:-
THCA	cis	rs7430456	0.674	rs9814974	ENSG00000228221.4	LINC00578	5.79	1.31e-08	2.36e-06	0.37	0.26	Breast cancer;	chr3:177774073	chr3:177441921~177752305:+
THCA	cis	rs7225151	0.71	rs77318561	ENSG00000234327.6	AC012146.7	-5.79	1.31e-08	2.36e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5281172	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs113151753	ENSG00000234327.6	AC012146.7	-5.79	1.31e-08	2.36e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5282070	chr17:5111468~5115004:+
THCA	cis	rs10200159	1	rs1045920	ENSG00000272606.1	RP11-554J4.1	5.79	1.32e-08	2.36e-06	0.51	0.26	Vitiligo;	chr2:55544033	chr2:55617909~55618373:+
THCA	cis	rs748404	0.666	rs12908460	ENSG00000249839.1	AC011330.5	-5.79	1.32e-08	2.36e-06	-0.37	-0.26	Lung cancer;	chr15:43413472	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs2230451	ENSG00000249839.1	AC011330.5	-5.79	1.32e-08	2.36e-06	-0.37	-0.26	Lung cancer;	chr15:43415610	chr15:43663654~43684339:-
THCA	cis	rs748404	0.666	rs62021180	ENSG00000249839.1	AC011330.5	-5.79	1.32e-08	2.36e-06	-0.37	-0.26	Lung cancer;	chr15:43420139	chr15:43663654~43684339:-
THCA	cis	rs2562456	0.833	rs8106025	ENSG00000268081.1	RP11-678G14.2	-5.79	1.32e-08	2.37e-06	-0.38	-0.26	Pain;	chr19:21451922	chr19:21554640~21569237:-
THCA	cis	rs7809950	0.773	rs2237668	ENSG00000238832.1	snoU109	-5.79	1.32e-08	2.37e-06	-0.3	-0.26	Coronary artery disease;	chr7:107409764	chr7:107603363~107603507:+
THCA	cis	rs4683346	0.616	rs3843369	ENSG00000173811.9	CCDC13-AS1	-5.79	1.32e-08	2.37e-06	-0.26	-0.26	Granulocyte percentage of myeloid white cells;	chr3:42765556	chr3:42732575~42746768:+
THCA	cis	rs2120243	0.539	rs6441126	ENSG00000244515.1	KRT18P34	-5.79	1.32e-08	2.37e-06	-0.31	-0.26	Hepatocellular carcinoma in hepatitis B infection;	chr3:157377227	chr3:157162663~157163932:-
THCA	cis	rs8002861	0.87	rs4942251	ENSG00000274001.1	RP11-5G9.5	5.79	1.32e-08	2.37e-06	0.29	0.26	Leprosy;	chr13:43865912	chr13:43877715~43878163:-
THCA	cis	rs874628	0.851	rs4808762	ENSG00000268650.3	AC068499.10	5.79	1.32e-08	2.37e-06	0.29	0.26	Multiple sclerosis;	chr19:18215412	chr19:18204730~18220480:+
THCA	cis	rs896854	0.684	rs2340534	ENSG00000253528.2	RP11-347C18.4	5.79	1.32e-08	2.37e-06	0.29	0.26	Type 2 diabetes;	chr8:94980102	chr8:94974573~94974853:-
THCA	cis	rs4664293	0.51	rs2042776	ENSG00000226266.5	AC009961.3	5.79	1.32e-08	2.37e-06	0.39	0.26	Monocyte percentage of white cells;	chr2:159653793	chr2:159670708~159712435:-
THCA	cis	rs8025790	0.508	rs12905371	ENSG00000270964.1	RP11-502I4.3	-5.79	1.32e-08	2.37e-06	-0.22	-0.26	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67553592	chr15:67541072~67542604:-
THCA	cis	rs8002861	0.81	rs9533664	ENSG00000274001.1	RP11-5G9.5	5.79	1.32e-08	2.37e-06	0.29	0.26	Leprosy;	chr13:43866391	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.84	rs7989353	ENSG00000274001.1	RP11-5G9.5	5.79	1.32e-08	2.37e-06	0.29	0.26	Leprosy;	chr13:43864821	chr13:43877715~43878163:-
THCA	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	5.79	1.32e-08	2.37e-06	0.28	0.26	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
THCA	cis	rs2554380	0.628	rs12914377	ENSG00000230373.7	GOLGA6L5P	-5.79	1.32e-08	2.37e-06	-0.28	-0.26	Height;	chr15:83791941	chr15:84507885~84516814:-
THCA	cis	rs10276381	1	rs10260837	ENSG00000234336.5	JAZF1-AS1	-5.79	1.32e-08	2.38e-06	-0.37	-0.26	Crohn's disease;	chr7:28141510	chr7:28180322~28243917:+
THCA	cis	rs10771431	0.713	rs17794353	ENSG00000111788.10	RP11-22B23.1	-5.79	1.32e-08	2.38e-06	-0.25	-0.26	Breast size;	chr12:9209187	chr12:9277235~9313241:+
THCA	cis	rs9990333	0.862	rs6806599	ENSG00000231464.1	AC024937.4	-5.79	1.32e-08	2.38e-06	-0.32	-0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195996738~195998233:+
THCA	cis	rs7560272	0.723	rs6744697	ENSG00000163016.8	ALMS1P	5.79	1.32e-08	2.38e-06	0.34	0.26	Schizophrenia;	chr2:73538311	chr2:73644919~73685576:+
THCA	cis	rs11651753	0.636	rs4793731	ENSG00000264920.1	RP11-6N17.4	-5.78	1.33e-08	2.38e-06	-0.23	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956327	chr17:47891255~47895812:-
THCA	cis	rs11651753	0.636	rs4793733	ENSG00000264920.1	RP11-6N17.4	-5.78	1.33e-08	2.38e-06	-0.23	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956616	chr17:47891255~47895812:-
THCA	cis	rs11651753	0.636	rs35280206	ENSG00000264920.1	RP11-6N17.4	-5.78	1.33e-08	2.38e-06	-0.23	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47957645	chr17:47891255~47895812:-
THCA	cis	rs5758659	1	rs5758660	ENSG00000270083.1	RP1-257I20.14	5.78	1.33e-08	2.38e-06	0.28	0.26	Cognitive function;	chr22:42227712	chr22:42089630~42090028:-
THCA	cis	rs9813712	0.78	rs7625942	ENSG00000228252.7	COL6A4P2	5.78	1.33e-08	2.38e-06	0.3	0.26	Response to amphetamines;	chr3:130232611	chr3:130212823~130273806:+
THCA	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	5.78	1.33e-08	2.38e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	5.78	1.33e-08	2.38e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
THCA	cis	rs2041895	0.509	rs1838445	ENSG00000260329.1	RP11-412D9.4	-5.78	1.33e-08	2.38e-06	-0.25	-0.26	Glaucoma (low intraocular pressure);	chr12:106920807	chr12:106954029~106955497:-
THCA	cis	rs7246657	0.722	rs16958861	ENSG00000267422.1	CTD-2554C21.1	-5.78	1.33e-08	2.38e-06	-0.29	-0.26	Coronary artery calcification;	chr19:37633278	chr19:37779686~37792865:+
THCA	cis	rs7246657	0.663	rs9304568	ENSG00000276846.1	CTD-3220F14.3	5.78	1.33e-08	2.38e-06	0.26	0.26	Coronary artery calcification;	chr19:37563606	chr19:37314868~37315620:-
THCA	cis	rs2136613	0.728	rs10761664	ENSG00000238280.1	RP11-436D10.3	5.78	1.33e-08	2.38e-06	0.31	0.26	Selective IgA deficiency;	chr10:62847301	chr10:62793562~62805887:-
THCA	cis	rs2439831	0.681	rs478104	ENSG00000249839.1	AC011330.5	-5.78	1.33e-08	2.38e-06	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43302702	chr15:43663654~43684339:-
THCA	cis	rs3742264	0.961	rs1326400	ENSG00000235903.6	CPB2-AS1	-5.78	1.33e-08	2.38e-06	-0.34	-0.26	Blood protein levels;	chr13:46074388	chr13:46052806~46113332:+
THCA	cis	rs699371	0.55	rs11851117	ENSG00000259005.1	RP3-449M8.6	5.78	1.33e-08	2.39e-06	0.23	0.26	Height;	chr14:74454856	chr14:74474007~74474864:-
THCA	cis	rs6928977	0.896	rs2064430	ENSG00000231028.7	LINC00271	-5.78	1.33e-08	2.39e-06	-0.2	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135321618	chr6:135497801~135716055:+
THCA	cis	rs10208649	0.536	rs12162343	ENSG00000272156.1	RP11-477N3.1	5.78	1.33e-08	2.39e-06	0.34	0.26	Body mass index;	chr2:53900617	chr2:54082554~54085066:+
THCA	cis	rs4664293	0.541	rs12692551	ENSG00000226266.5	AC009961.3	5.78	1.33e-08	2.39e-06	0.3	0.26	Monocyte percentage of white cells;	chr2:159501263	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.541	rs2113859	ENSG00000226266.5	AC009961.3	5.78	1.33e-08	2.39e-06	0.3	0.26	Monocyte percentage of white cells;	chr2:159502199	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.541	rs62173243	ENSG00000226266.5	AC009961.3	5.78	1.33e-08	2.39e-06	0.3	0.26	Monocyte percentage of white cells;	chr2:159502693	chr2:159670708~159712435:-
THCA	cis	rs2337406	0.85	rs75196489	ENSG00000274576.2	IGHV2-70	-5.78	1.33e-08	2.39e-06	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106699438	chr14:106770577~106771020:-
THCA	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	5.78	1.33e-08	2.39e-06	0.32	0.26	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
THCA	cis	rs2243480	1	rs410128	ENSG00000232546.1	RP11-458F8.1	-5.78	1.33e-08	2.39e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66138186	chr7:66848496~66858136:+
THCA	cis	rs11158026	0.603	rs4325453	ENSG00000258413.1	RP11-665C16.6	-5.78	1.33e-08	2.39e-06	-0.36	-0.26	Parkinson's disease;	chr14:54972600	chr14:55262767~55272075:-
THCA	cis	rs6740322	0.793	rs9808360	ENSG00000234936.1	AC010883.5	5.78	1.33e-08	2.39e-06	0.27	0.26	Coronary artery disease;	chr2:43319696	chr2:43229573~43233394:+
THCA	cis	rs10829156	1	rs10829157	ENSG00000240291.1	RP11-499P20.2	5.78	1.34e-08	2.39e-06	0.23	0.26	Sudden cardiac arrest;	chr10:18662534	chr10:18513115~18545651:-
THCA	cis	rs2251188	0.837	rs1474419	ENSG00000187953.9	PMS2CL	-5.78	1.34e-08	2.4e-06	-0.29	-0.26	Sum basophil neutrophil counts;Neutrophil count;	chr7:6652974	chr7:6710128~6753862:+
THCA	cis	rs35538253	0.522	rs10492823	ENSG00000260886.1	TAT-AS1	5.78	1.34e-08	2.4e-06	0.5	0.26	Post bronchodilator FEV1;	chr16:71984961	chr16:71565789~71578187:+
THCA	cis	rs6908034	0.607	rs77386860	ENSG00000237404.1	RP3-471C18.2	-5.78	1.34e-08	2.4e-06	-0.54	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814524	chr6:19689825~19753113:-
THCA	cis	rs4950322	0.748	rs17356680	ENSG00000278811.3	LINC00624	5.78	1.34e-08	2.4e-06	0.32	0.26	Protein quantitative trait loci;	chr1:147354934	chr1:147258885~147517875:-
THCA	cis	rs7044106	0.762	rs12003646	ENSG00000270917.1	RP11-27I1.6	-5.78	1.34e-08	2.4e-06	-0.36	-0.26	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120812475~120812845:-
THCA	cis	rs1823913	1	rs10445783	ENSG00000280083.1	RP11-317J9.1	5.78	1.34e-08	2.4e-06	0.32	0.26	Obesity-related traits;	chr2:191236772	chr2:191154118~191156070:-
THCA	cis	rs2439831	0.85	rs16965120	ENSG00000166763.7	STRCP1	5.78	1.34e-08	2.4e-06	0.37	0.26	Lung cancer in ever smokers;	chr15:43808144	chr15:43699488~43718184:-
THCA	cis	rs28472312	0.723	rs11150675	ENSG00000251417.2	RP11-1348G14.4	5.78	1.34e-08	2.4e-06	0.25	0.26	Intelligence (multi-trait analysis);	chr16:28969210	chr16:28802743~28817828:+
THCA	cis	rs28472312	0.685	rs4788111	ENSG00000251417.2	RP11-1348G14.4	5.78	1.34e-08	2.4e-06	0.25	0.26	Intelligence (multi-trait analysis);	chr16:28969372	chr16:28802743~28817828:+
THCA	cis	rs17301013	0.507	rs10912777	ENSG00000227373.4	RP11-160H22.5	5.78	1.34e-08	2.4e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174393764	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs10912778	ENSG00000227373.4	RP11-160H22.5	5.78	1.34e-08	2.4e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174393827	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2205937	ENSG00000227373.4	RP11-160H22.5	5.78	1.34e-08	2.4e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174394440	chr1:174115300~174160004:-
THCA	cis	rs7829975	0.559	rs4841025	ENSG00000254153.1	CTA-398F10.2	5.78	1.34e-08	2.4e-06	0.28	0.26	Mood instability;	chr8:8745650	chr8:8456909~8461337:-
THCA	cis	rs2562456	0.917	rs11085463	ENSG00000213976.4	CTD-2561J22.2	-5.78	1.34e-08	2.4e-06	-0.27	-0.26	Pain;	chr19:21568500	chr19:21382865~21387177:+
THCA	cis	rs748404	0.697	rs505249	ENSG00000166763.7	STRCP1	5.78	1.34e-08	2.4e-06	0.27	0.26	Lung cancer;	chr15:43267762	chr15:43699488~43718184:-
THCA	cis	rs17345786	0.953	rs78645744	ENSG00000256628.3	ZBTB11-AS1	5.78	1.34e-08	2.4e-06	0.32	0.26	Colonoscopy-negative controls vs population controls;	chr3:101608945	chr3:101676475~101679217:+
THCA	cis	rs17345786	0.817	rs11720560	ENSG00000256628.3	ZBTB11-AS1	5.78	1.34e-08	2.4e-06	0.32	0.26	Colonoscopy-negative controls vs population controls;	chr3:101609640	chr3:101676475~101679217:+
THCA	cis	rs1275468	0.731	rs1679384	ENSG00000257497.2	RP11-585P4.5	-5.78	1.34e-08	2.4e-06	-0.39	-0.26	Polycystic ovary syndrome;	chr12:75567552	chr12:75483454~75489820:-
THCA	cis	rs1499614	1	rs2707832	ENSG00000232559.3	GS1-124K5.12	5.78	1.34e-08	2.41e-06	0.39	0.26	Gout;	chr7:66671562	chr7:66554588~66576923:-
THCA	cis	rs712039	0.652	rs1102920	ENSG00000276054.1	RP11-378E13.3	5.78	1.34e-08	2.41e-06	0.4	0.26	Tuberculosis;	chr17:37400850	chr17:37386886~37387926:+
THCA	cis	rs9311474	0.713	rs352166	ENSG00000243224.1	RP5-1157M23.2	-5.78	1.34e-08	2.41e-06	-0.26	-0.26	Electroencephalogram traits;	chr3:52204661	chr3:52239258~52241097:+
THCA	cis	rs2239547	0.522	rs6771610	ENSG00000242142.1	SERBP1P3	5.78	1.35e-08	2.41e-06	0.32	0.26	Schizophrenia;	chr3:52992088	chr3:53064283~53065091:-
THCA	cis	rs12612619	0.621	rs4665943	ENSG00000229122.1	AGBL5-IT1	-5.78	1.35e-08	2.41e-06	-0.19	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27073017	chr2:27061038~27061815:+
THCA	cis	rs3742264	1	rs9567613	ENSG00000235903.6	CPB2-AS1	5.78	1.35e-08	2.41e-06	0.34	0.26	Blood protein levels;	chr13:46075263	chr13:46052806~46113332:+
THCA	cis	rs950169	0.58	rs17532346	ENSG00000275120.1	RP11-182J1.17	5.78	1.35e-08	2.41e-06	0.31	0.26	Schizophrenia;	chr15:84628264	chr15:84599434~84606463:-
THCA	cis	rs4805272	0.962	rs1363327	ENSG00000267799.1	MAN1A2P1	5.78	1.35e-08	2.41e-06	0.27	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834664	chr19:28790812~28792871:-
THCA	cis	rs67478160	0.619	rs10083370	ENSG00000258735.1	LINC00637	5.78	1.35e-08	2.42e-06	0.31	0.26	Schizophrenia;	chr14:103847845	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.619	rs10083367	ENSG00000258735.1	LINC00637	5.78	1.35e-08	2.42e-06	0.31	0.26	Schizophrenia;	chr14:103847846	chr14:103847721~103858049:+
THCA	cis	rs2439831	0.681	rs2242067	ENSG00000275601.1	AC011330.13	-5.78	1.35e-08	2.42e-06	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43407105	chr15:43642389~43643023:-
THCA	cis	rs755249	0.567	rs76111861	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs72661965	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39565160~39573203:+
THCA	cis	rs8027521	0.818	rs2725587	ENSG00000280362.1	RP11-643A5.3	-5.78	1.35e-08	2.42e-06	-0.31	-0.26	Circulating chemerin levels;	chr15:53978448	chr15:53910769~53914712:+
THCA	cis	rs7809950	0.731	rs4730238	ENSG00000238832.1	snoU109	-5.78	1.35e-08	2.42e-06	-0.3	-0.26	Coronary artery disease;	chr7:107414342	chr7:107603363~107603507:+
THCA	cis	rs7493	0.95	rs17166868	ENSG00000233942.1	AC004012.1	5.78	1.35e-08	2.42e-06	0.38	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404104	chr7:95471835~95473998:+
THCA	cis	rs7493	0.95	rs7785705	ENSG00000233942.1	AC004012.1	5.78	1.35e-08	2.42e-06	0.38	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404491	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs7786401	ENSG00000233942.1	AC004012.1	5.78	1.35e-08	2.42e-06	0.38	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404689	chr7:95471835~95473998:+
THCA	cis	rs2911132	0.511	rs3198304	ENSG00000248734.2	CTD-2260A17.1	5.78	1.35e-08	2.42e-06	0.29	0.26	Urate levels (BMI interaction);	chr5:96775524	chr5:96784777~96785999:+
THCA	cis	rs2911132	0.511	rs13160562	ENSG00000248734.2	CTD-2260A17.1	5.78	1.35e-08	2.42e-06	0.29	0.26	Urate levels (BMI interaction);	chr5:96775667	chr5:96784777~96785999:+
THCA	cis	rs755249	0.529	rs4660732	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs61779285	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs3768301	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs113214136	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs3768302	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39565160~39573203:+
THCA	cis	rs755249	0.532	rs17343193	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs61779300	ENSG00000228060.1	RP11-69E11.8	-5.78	1.35e-08	2.42e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39565160~39573203:+
THCA	cis	rs7225151	0.71	rs75262874	ENSG00000234327.6	AC012146.7	-5.78	1.35e-08	2.42e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5339906	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs78650284	ENSG00000234327.6	AC012146.7	-5.78	1.35e-08	2.42e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5340167	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs79346409	ENSG00000234327.6	AC012146.7	-5.78	1.35e-08	2.42e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5342744	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs55913010	ENSG00000234327.6	AC012146.7	-5.78	1.35e-08	2.42e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5342855	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs111676379	ENSG00000234327.6	AC012146.7	-5.78	1.35e-08	2.42e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5343710	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs112888134	ENSG00000234327.6	AC012146.7	-5.78	1.35e-08	2.42e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5344437	chr17:5111468~5115004:+
THCA	cis	rs17772222	0.63	rs816069	ENSG00000258983.2	RP11-507K2.2	-5.78	1.35e-08	2.42e-06	-0.3	-0.26	Coronary artery calcification;	chr14:88500992	chr14:88499334~88515502:+
THCA	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	5.78	1.35e-08	2.42e-06	0.25	0.26	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
THCA	cis	rs792448	0.545	rs6679796	ENSG00000226251.4	RP11-15I11.3	-5.78	1.35e-08	2.42e-06	-0.32	-0.26	White blood cell count (basophil);	chr1:212229182	chr1:212225278~212238977:-
THCA	cis	rs4689592	0.554	rs3822270	ENSG00000245468.3	RP11-367J11.3	5.78	1.35e-08	2.43e-06	0.21	0.26	Monocyte percentage of white cells;	chr4:7068077	chr4:7094571~7103385:-
THCA	cis	rs7727544	0.505	rs721121	ENSG00000233006.5	AC034220.3	5.78	1.36e-08	2.43e-06	0.2	0.26	Blood metabolite levels;	chr5:132070740	chr5:132311285~132369916:-
THCA	cis	rs1876905	0.539	rs240962	ENSG00000272356.1	RP5-1112D6.8	5.78	1.36e-08	2.43e-06	0.27	0.26	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111309203~111313517:+
THCA	cis	rs6545883	0.929	rs1186711	ENSG00000271889.1	RP11-493E12.1	5.78	1.36e-08	2.43e-06	0.26	0.26	Tuberculosis;	chr2:61461370	chr2:61151433~61162105:-
THCA	cis	rs6921919	0.673	rs13201681	ENSG00000226314.6	ZNF192P1	-5.78	1.36e-08	2.43e-06	-0.56	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28161781~28169594:+
THCA	cis	rs6921919	0.778	rs67381177	ENSG00000226314.6	ZNF192P1	-5.78	1.36e-08	2.43e-06	-0.56	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28161781~28169594:+
THCA	cis	rs17818399	0.735	rs11894342	ENSG00000279254.1	RP11-536C12.1	-5.78	1.36e-08	2.43e-06	-0.24	-0.26	Height;	chr2:46609300	chr2:46668870~46670778:+
THCA	cis	rs8062405	0.754	rs28410083	ENSG00000278665.1	RP11-666O2.4	-5.78	1.36e-08	2.43e-06	-0.29	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.789	rs1968751	ENSG00000278665.1	RP11-666O2.4	-5.78	1.36e-08	2.43e-06	-0.29	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28599241~28601881:-
THCA	cis	rs13256369	0.951	rs13270852	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	2.43e-06	-0.35	-0.26	Obesity-related traits;	chr8:8709343	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs13271698	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	2.43e-06	-0.35	-0.26	Obesity-related traits;	chr8:8710029	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs12550458	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	2.43e-06	-0.35	-0.26	Obesity-related traits;	chr8:8710322	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs12545771	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	2.43e-06	-0.35	-0.26	Obesity-related traits;	chr8:8710467	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.95	rs12548792	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	2.43e-06	-0.35	-0.26	Obesity-related traits;	chr8:8710521	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.901	rs13251887	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	2.43e-06	-0.35	-0.26	Obesity-related traits;	chr8:8711168	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs883648	ENSG00000253893.2	FAM85B	-5.78	1.36e-08	2.43e-06	-0.35	-0.26	Obesity-related traits;	chr8:8712011	chr8:8167819~8226614:-
THCA	cis	rs9527	0.571	rs3740400	ENSG00000236937.2	PTGES3P4	5.78	1.36e-08	2.43e-06	0.34	0.26	Arsenic metabolism;	chr10:102869708	chr10:102845595~102845950:+
THCA	cis	rs9527	0.571	rs7904113	ENSG00000236937.2	PTGES3P4	5.78	1.36e-08	2.43e-06	0.34	0.26	Arsenic metabolism;	chr10:102873357	chr10:102845595~102845950:+
THCA	cis	rs17214007	0.518	rs56374730	ENSG00000263335.1	AF001548.5	-5.78	1.36e-08	2.43e-06	-0.34	-0.26	Cognitive function;	chr16:15773795	chr16:15726674~15732993:+
THCA	cis	rs2839186	0.786	rs7409792	ENSG00000239415.1	AP001469.9	5.78	1.36e-08	2.43e-06	0.27	0.26	Testicular germ cell tumor;	chr21:46271815	chr21:46251549~46254133:-
THCA	cis	rs7119038	0.818	rs10892287	ENSG00000255239.1	AP002954.6	5.78	1.36e-08	2.44e-06	0.4	0.26	Sjögren's syndrome;	chr11:118772290	chr11:118688039~118690600:-
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000232546.1	RP11-458F8.1	-5.78	1.36e-08	2.44e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66557269	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1267820	ENSG00000232546.1	RP11-458F8.1	-5.78	1.36e-08	2.44e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66585308	chr7:66848496~66858136:+
THCA	cis	rs600231	0.613	rs12803915	ENSG00000245532.5	NEAT1	5.78	1.36e-08	2.44e-06	0.23	0.26	Bone mineral density;	chr11:65444508	chr11:65422774~65445540:+
THCA	cis	rs2276314	0.512	rs12458709	ENSG00000278986.1	RP11-723J4.3	5.78	1.36e-08	2.44e-06	0.27	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35861928	chr18:35972151~35973916:+
THCA	cis	rs712039	0.652	rs853197	ENSG00000276054.1	RP11-378E13.3	5.78	1.36e-08	2.44e-06	0.4	0.26	Tuberculosis;	chr17:37488610	chr17:37386886~37387926:+
THCA	cis	rs984222	0.741	rs1886914	ENSG00000231365.4	RP11-418J17.1	-5.78	1.36e-08	2.44e-06	-0.25	-0.26	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998829	chr1:119140396~119275973:+
THCA	cis	rs755249	0.567	rs2018212	ENSG00000228060.1	RP11-69E11.8	-5.78	1.37e-08	2.44e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs4660751	ENSG00000228060.1	RP11-69E11.8	-5.78	1.37e-08	2.44e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39565160~39573203:+
THCA	cis	rs7712401	0.755	rs1545697	ENSG00000249996.1	RP11-359P5.1	5.78	1.37e-08	2.44e-06	0.25	0.26	Mean platelet volume;	chr5:122766582	chr5:123036271~123054667:+
THCA	cis	rs2765539	0.59	rs1325942	ENSG00000231365.4	RP11-418J17.1	-5.78	1.37e-08	2.45e-06	-0.29	-0.26	Waist-hip ratio;	chr1:118941210	chr1:119140396~119275973:+
THCA	cis	rs17772222	0.597	rs17700521	ENSG00000258789.1	RP11-507K2.3	-5.78	1.37e-08	2.45e-06	-0.27	-0.26	Coronary artery calcification;	chr14:88849531	chr14:88551597~88552493:+
THCA	cis	rs934734	0.736	rs6738087	ENSG00000237979.1	AC007389.1	5.78	1.37e-08	2.45e-06	0.3	0.26	Rheumatoid arthritis;	chr2:65365191	chr2:65500993~65502138:-
THCA	cis	rs9921338	0.923	rs72771877	ENSG00000262703.1	RP11-485G7.6	-5.78	1.37e-08	2.45e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11274759	chr16:11348143~11349321:-
THCA	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	5.78	1.37e-08	2.45e-06	0.47	0.26	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
THCA	cis	rs12497850	0.931	rs4974080	ENSG00000229759.1	MRPS18AP1	5.78	1.37e-08	2.45e-06	0.34	0.26	Parkinson's disease;	chr3:48993395	chr3:48256350~48256938:-
THCA	cis	rs4845570	1	rs3790514	ENSG00000203288.3	RP11-98D18.9	-5.78	1.37e-08	2.45e-06	-0.29	-0.26	Coronary artery disease;	chr1:151771692	chr1:151790804~151794402:+
THCA	cis	rs16976116	0.901	rs28499113	ENSG00000279145.1	RP11-547D13.1	5.78	1.37e-08	2.45e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55211423	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28589609	ENSG00000279145.1	RP11-547D13.1	5.78	1.37e-08	2.45e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55211432	chr15:55171972~55178175:-
THCA	cis	rs11671005	0.57	rs73062110	ENSG00000269473.1	CTD-2619J13.19	5.78	1.37e-08	2.45e-06	0.3	0.26	Mean platelet volume;	chr19:58425275	chr19:58440448~58445849:+
THCA	cis	rs714027	0.967	rs193477	ENSG00000279159.1	RP3-394A18.1	-5.78	1.37e-08	2.46e-06	-0.18	-0.26	Lymphocyte counts;	chr22:30055497	chr22:29978950~30028236:-
THCA	cis	rs875971	1	rs1167612	ENSG00000223473.2	GS1-124K5.3	-5.78	1.37e-08	2.46e-06	-0.18	-0.26	Aortic root size;	chr7:66102989	chr7:66491049~66493566:-
THCA	cis	rs11158026	0.603	rs8022049	ENSG00000258413.1	RP11-665C16.6	5.78	1.37e-08	2.46e-06	0.36	0.26	Parkinson's disease;	chr14:54996151	chr14:55262767~55272075:-
THCA	cis	rs6957923	0.655	rs7781714	ENSG00000234286.1	AC006026.13	-5.78	1.37e-08	2.46e-06	-0.31	-0.26	Height;	chr7:23553860	chr7:23680195~23680786:-
THCA	cis	rs2412819	0.52	rs17727763	ENSG00000205771.5	CATSPER2P1	-5.78	1.37e-08	2.46e-06	-0.39	-0.26	Lung cancer;	chr15:43623873	chr15:43726918~43747094:-
THCA	cis	rs6142102	0.961	rs1319363	ENSG00000275784.1	RP5-1125A11.6	-5.78	1.37e-08	2.46e-06	-0.26	-0.26	Skin pigmentation;	chr20:33954070	chr20:33989480~33991818:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000182722.5	SEPHS1P1	-5.78	1.38e-08	2.46e-06	-0.31	-0.26	Calcium levels;	chr7:65751755	chr7:64852397~64853354:-
THCA	cis	rs75422866	0.51	rs73105803	ENSG00000276691.1	RP5-1057I20.5	5.78	1.38e-08	2.46e-06	0.44	0.26	Pneumonia;	chr12:47722135	chr12:47788426~47788971:+
THCA	cis	rs4604234	0.803	rs73465567	ENSG00000272129.1	RP11-250B2.6	-5.78	1.38e-08	2.46e-06	-0.63	-0.26	Cancer;	chr6:80330975	chr6:80355424~80356859:+
THCA	cis	rs2765539	0.545	rs1623409	ENSG00000231365.4	RP11-418J17.1	-5.78	1.38e-08	2.46e-06	-0.29	-0.26	Waist-hip ratio;	chr1:118962218	chr1:119140396~119275973:+
THCA	cis	rs4948275	0.773	rs2085347	ENSG00000237233.2	TMEM26-AS1	-5.78	1.38e-08	2.46e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61524888	chr10:61452639~61481956:+
THCA	cis	rs9307551	0.857	rs2218212	ENSG00000250334.4	LINC00989	-5.78	1.38e-08	2.47e-06	-0.3	-0.26	Refractive error;	chr4:79614887	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.857	rs2218213	ENSG00000250334.4	LINC00989	-5.78	1.38e-08	2.47e-06	-0.3	-0.26	Refractive error;	chr4:79614890	chr4:79492416~79576460:+
THCA	cis	rs944289	0.509	rs934075	ENSG00000257826.1	RP11-116N8.4	-5.78	1.38e-08	2.47e-06	-0.29	-0.26	Thyroid cancer;	chr14:36169016	chr14:36061026~36067190:-
THCA	cis	rs11148252	0.514	rs3818422	ENSG00000235660.1	LINC00345	5.78	1.38e-08	2.47e-06	0.33	0.26	Lewy body disease;	chr13:52145079	chr13:52484161~52484680:-
THCA	cis	rs5758659	1	rs5758677	ENSG00000270083.1	RP1-257I20.14	5.78	1.38e-08	2.47e-06	0.28	0.26	Cognitive function;	chr22:42247033	chr22:42089630~42090028:-
THCA	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-5.78	1.38e-08	2.47e-06	-0.34	-0.26	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
THCA	cis	rs7225151	0.71	rs59587437	ENSG00000234327.6	AC012146.7	-5.78	1.38e-08	2.47e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5326822	chr17:5111468~5115004:+
THCA	cis	rs1889642	0.743	rs9574484	ENSG00000227354.5	RBM26-AS1	-5.78	1.38e-08	2.47e-06	-0.23	-0.26	Colonoscopy-negative controls vs population controls;	chr13:79795111	chr13:79406309~79424328:+
THCA	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	5.78	1.38e-08	2.47e-06	0.27	0.26	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
THCA	cis	rs667920	0.557	rs35849216	ENSG00000239213.4	NCK1-AS1	-5.78	1.38e-08	2.47e-06	-0.37	-0.26	Coronary artery disease;	chr3:136608727	chr3:136841726~136862054:-
THCA	cis	rs1707322	0.721	rs12069121	ENSG00000281133.1	AL355480.3	-5.78	1.39e-08	2.48e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45580892~45580996:-
THCA	cis	rs853679	0.599	rs202906	ENSG00000280107.1	AL022393.9	5.78	1.39e-08	2.48e-06	0.36	0.26	Depression;	chr6:28043874	chr6:28170845~28172521:+
THCA	cis	rs55665837	0.539	rs10500804	ENSG00000251991.1	RNU7-49P	5.78	1.39e-08	2.48e-06	0.28	0.26	Vitamin D levels;	chr11:14888727	chr11:14478892~14478953:+
THCA	cis	rs2735413	0.599	rs76440854	ENSG00000276007.1	RP11-358L22.3	5.78	1.39e-08	2.48e-06	0.28	0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78046986	chr16:78123243~78124332:+
THCA	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-5.78	1.39e-08	2.48e-06	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
THCA	cis	rs12612619	0.704	rs6742004	ENSG00000229122.1	AGBL5-IT1	5.78	1.39e-08	2.48e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086791	chr2:27061038~27061815:+
THCA	cis	rs4639966	0.836	rs3825057	ENSG00000255239.1	AP002954.6	-5.78	1.39e-08	2.49e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118752276	chr11:118688039~118690600:-
THCA	cis	rs28472312	0.723	rs1137843	ENSG00000251417.2	RP11-1348G14.4	5.78	1.39e-08	2.49e-06	0.25	0.26	Intelligence (multi-trait analysis);	chr16:28966392	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.824	rs62034319	ENSG00000278665.1	RP11-666O2.4	5.78	1.39e-08	2.49e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28599241~28601881:-
THCA	cis	rs240993	0.909	rs11153279	ENSG00000272356.1	RP5-1112D6.8	5.78	1.39e-08	2.49e-06	0.22	0.26	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111309203~111313517:+
THCA	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	5.78	1.39e-08	2.49e-06	0.33	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
THCA	cis	rs12530	0.715	rs5749416	ENSG00000230736.2	RP1-149A16.3	5.78	1.39e-08	2.49e-06	0.34	0.26	IgG glycosylation;	chr22:32381136	chr22:32376664~32384343:+
THCA	cis	rs12612619	0.732	rs11679069	ENSG00000229122.1	AGBL5-IT1	5.78	1.39e-08	2.49e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27047443	chr2:27061038~27061815:+
THCA	cis	rs812925	0.784	rs7588041	ENSG00000271889.1	RP11-493E12.1	-5.78	1.39e-08	2.49e-06	-0.26	-0.26	Immature fraction of reticulocytes;	chr2:61234277	chr2:61151433~61162105:-
THCA	cis	rs758324	0.732	rs159903	ENSG00000237714.1	P4HA2-AS1	5.78	1.39e-08	2.49e-06	0.39	0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132204360	chr5:132184876~132192808:+
THCA	cis	rs3758785	0.512	rs11600240	ENSG00000255893.1	RP11-685N10.1	-5.78	1.39e-08	2.49e-06	-0.32	-0.26	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94365167	chr11:94472908~94473570:-
THCA	cis	rs172166	0.694	rs1631552	ENSG00000226314.6	ZNF192P1	-5.78	1.39e-08	2.49e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28121921	chr6:28161781~28169594:+
THCA	cis	rs113835537	0.597	rs3825065	ENSG00000255517.5	CTD-3074O7.5	-5.78	1.4e-08	2.49e-06	-0.23	-0.26	Airway imaging phenotypes;	chr11:66543540	chr11:66473490~66480233:-
THCA	cis	rs17301013	0.507	rs12082012	ENSG00000227373.4	RP11-160H22.5	5.78	1.4e-08	2.49e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174588729	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12085652	ENSG00000227373.4	RP11-160H22.5	5.78	1.4e-08	2.49e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174588864	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4451598	ENSG00000227373.4	RP11-160H22.5	5.78	1.4e-08	2.49e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174606576	chr1:174115300~174160004:-
THCA	cis	rs2243480	1	rs160633	ENSG00000232546.1	RP11-458F8.1	-5.78	1.4e-08	2.49e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66063241	chr7:66848496~66858136:+
THCA	cis	rs1876905	0.68	rs193281	ENSG00000230177.1	RP5-1112D6.4	5.78	1.4e-08	2.49e-06	0.27	0.26	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111277932~111278742:+
THCA	cis	rs7727544	0.582	rs3792894	ENSG00000233006.5	AC034220.3	5.78	1.4e-08	2.49e-06	0.19	0.26	Blood metabolite levels;	chr5:132211578	chr5:132311285~132369916:-
THCA	cis	rs4845570	1	rs6673002	ENSG00000203288.3	RP11-98D18.9	5.78	1.4e-08	2.5e-06	0.29	0.26	Coronary artery disease;	chr1:151770799	chr1:151790804~151794402:+
THCA	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-5.78	1.4e-08	2.5e-06	-0.28	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
THCA	cis	rs2348418	0.733	rs2019011	ENSG00000247934.4	RP11-967K21.1	5.78	1.4e-08	2.5e-06	0.23	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28228144	chr12:28163298~28190738:-
THCA	cis	rs7512898	0.545	rs12047681	ENSG00000260088.1	RP11-92G12.3	-5.78	1.4e-08	2.5e-06	-0.32	-0.26	Electrocardiographic conduction measures;	chr1:200727731	chr1:200669507~200694250:+
THCA	cis	rs260461	1	rs260461	ENSG00000268201.1	CTD-3138B18.6	-5.78	1.4e-08	2.5e-06	-0.35	-0.26	Attention deficit hyperactivity disorder;	chr19:58259517	chr19:58266635~58267685:+
THCA	cis	rs7760535	0.93	rs10872069	ENSG00000230177.1	RP5-1112D6.4	-5.78	1.4e-08	2.5e-06	-0.22	-0.26	Metabolic traits;	chr6:111540523	chr6:111277932~111278742:+
THCA	cis	rs6674176	0.628	rs4660758	ENSG00000237950.1	RP11-7O11.3	5.78	1.4e-08	2.5e-06	0.23	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43959207	chr1:43944370~43946551:-
THCA	cis	rs10131894	0.611	rs175001	ENSG00000279594.1	RP11-950C14.10	5.78	1.4e-08	2.5e-06	0.24	0.26	Coronary artery disease;	chr14:74969749	chr14:75011269~75012851:-
THCA	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-5.78	1.4e-08	2.5e-06	-0.35	-0.26	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
THCA	cis	rs17772222	0.636	rs3850390	ENSG00000258789.1	RP11-507K2.3	-5.77	1.4e-08	2.5e-06	-0.27	-0.26	Coronary artery calcification;	chr14:88829185	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.597	rs17700296	ENSG00000258789.1	RP11-507K2.3	-5.77	1.4e-08	2.5e-06	-0.27	-0.26	Coronary artery calcification;	chr14:88840976	chr14:88551597~88552493:+
THCA	cis	rs6928977	0.896	rs2746421	ENSG00000231028.7	LINC00271	5.77	1.4e-08	2.5e-06	0.2	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135340491	chr6:135497801~135716055:+
THCA	cis	rs1876905	0.68	rs354528	ENSG00000230177.1	RP5-1112D6.4	-5.77	1.4e-08	2.51e-06	-0.27	-0.26	Mean corpuscular hemoglobin;	chr6:111184068	chr6:111277932~111278742:+
THCA	cis	rs7727544	0.582	rs3828675	ENSG00000233006.5	AC034220.3	5.77	1.4e-08	2.51e-06	0.2	0.26	Blood metabolite levels;	chr5:132211175	chr5:132311285~132369916:-
THCA	cis	rs2029362	0.875	rs10767644	ENSG00000245573.6	BDNF-AS	5.77	1.4e-08	2.51e-06	0.2	0.26	Total body bone mineral density;	chr11:27499124	chr11:27506838~27698174:+
THCA	cis	rs7615952	0.932	rs7630077	ENSG00000241288.6	RP11-379B18.5	-5.77	1.4e-08	2.51e-06	-0.33	-0.26	Blood pressure (smoking interaction);	chr3:125930833	chr3:125827238~125916384:-
THCA	cis	rs5742933	0.69	rs16831821	ENSG00000273240.1	RP11-455J20.3	-5.77	1.41e-08	2.51e-06	-0.34	-0.26	Ferritin levels;	chr2:189641087	chr2:189763859~189764456:-
THCA	cis	rs6740322	0.895	rs10210125	ENSG00000234936.1	AC010883.5	5.77	1.41e-08	2.51e-06	0.27	0.26	Coronary artery disease;	chr2:43329294	chr2:43229573~43233394:+
THCA	cis	rs6674176	0.597	rs2352990	ENSG00000237950.1	RP11-7O11.3	5.77	1.41e-08	2.51e-06	0.23	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927604	chr1:43944370~43946551:-
THCA	cis	rs748404	0.697	rs555001	ENSG00000166763.7	STRCP1	5.77	1.41e-08	2.52e-06	0.27	0.26	Lung cancer;	chr15:43253530	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs475261	ENSG00000166763.7	STRCP1	5.77	1.41e-08	2.52e-06	0.27	0.26	Lung cancer;	chr15:43254258	chr15:43699488~43718184:-
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000261839.1	RP1-265C24.8	5.77	1.41e-08	2.52e-06	0.31	0.26	Parkinson's disease;	chr6:28110633	chr6:28136849~28139678:+
THCA	cis	rs2136613	0.533	rs10995333	ENSG00000238280.1	RP11-436D10.3	-5.77	1.41e-08	2.52e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62858034	chr10:62793562~62805887:-
THCA	cis	rs8014252	0.803	rs8012025	ENSG00000259158.2	ADAM20P1	-5.77	1.41e-08	2.52e-06	-0.32	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70545488	chr14:70468881~70483756:-
THCA	cis	rs2243480	1	rs2533288	ENSG00000232559.3	GS1-124K5.12	5.77	1.41e-08	2.52e-06	0.39	0.26	Diabetic kidney disease;	chr7:66591724	chr7:66554588~66576923:-
THCA	cis	rs7403037	0.602	rs4778287	ENSG00000259905.4	PWRN1	5.77	1.41e-08	2.52e-06	0.28	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24191055	chr15:24493137~24652130:+
THCA	cis	rs8177876	0.822	rs56166222	ENSG00000261061.1	RP11-303E16.2	-5.77	1.41e-08	2.52e-06	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81030770~81031485:+
THCA	cis	rs7833787	0.896	rs2029610	ENSG00000278886.1	RP11-108A14.1	-5.77	1.41e-08	2.52e-06	-0.34	-0.26	Obesity-related traits;	chr8:18849471	chr8:18864681~18865247:-
THCA	cis	rs3742264	1	rs9562635	ENSG00000235903.6	CPB2-AS1	-5.77	1.41e-08	2.52e-06	-0.34	-0.26	Blood protein levels;	chr13:46068857	chr13:46052806~46113332:+
THCA	cis	rs9309473	0.5	rs4852308	ENSG00000163016.8	ALMS1P	-5.77	1.41e-08	2.52e-06	-0.33	-0.26	Metabolite levels;	chr2:73606908	chr2:73644919~73685576:+
THCA	cis	rs13113518	0.783	rs12510400	ENSG00000249700.7	SRD5A3-AS1	5.77	1.41e-08	2.52e-06	0.33	0.26	Height;	chr4:55577294	chr4:55363971~55395847:-
THCA	cis	rs911555	0.511	rs2296483	ENSG00000269940.1	RP11-73M18.7	5.77	1.41e-08	2.52e-06	0.26	0.26	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103694560~103695170:+
THCA	cis	rs17772222	0.917	rs58550317	ENSG00000222990.1	RNU4-22P	5.77	1.41e-08	2.52e-06	0.33	0.26	Coronary artery calcification;	chr14:88775243	chr14:88513498~88513663:+
THCA	cis	rs11148252	0.634	rs1571189	ENSG00000278238.1	RP11-245D16.4	-5.77	1.41e-08	2.53e-06	-0.29	-0.26	Lewy body disease;	chr13:52156869	chr13:52454775~52455331:-
THCA	cis	rs6928977	0.863	rs7772681	ENSG00000231028.7	LINC00271	-5.77	1.42e-08	2.53e-06	-0.2	-0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135327875	chr6:135497801~135716055:+
THCA	cis	rs7809950	0.635	rs62483629	ENSG00000238832.1	snoU109	-5.77	1.42e-08	2.53e-06	-0.31	-0.26	Coronary artery disease;	chr7:107225733	chr7:107603363~107603507:+
THCA	cis	rs7083	1	rs655023	ENSG00000254851.1	RP11-109L13.1	5.77	1.42e-08	2.53e-06	0.35	0.26	Blood protein levels;	chr11:117256904	chr11:117135528~117138582:+
THCA	cis	rs7083	1	rs505045	ENSG00000254851.1	RP11-109L13.1	5.77	1.42e-08	2.53e-06	0.35	0.26	Blood protein levels;	chr11:117281824	chr11:117135528~117138582:+
THCA	cis	rs11148252	0.583	rs9536048	ENSG00000235660.1	LINC00345	-5.77	1.42e-08	2.53e-06	-0.36	-0.26	Lewy body disease;	chr13:52384653	chr13:52484161~52484680:-
THCA	cis	rs16846053	0.642	rs72877356	ENSG00000227403.1	AC009299.3	5.77	1.42e-08	2.53e-06	0.45	0.26	Blood osmolality (transformed sodium);	chr2:161771952	chr2:161244739~161249050:+
THCA	cis	rs6740322	0.895	rs6744746	ENSG00000234936.1	AC010883.5	-5.77	1.42e-08	2.53e-06	-0.27	-0.26	Coronary artery disease;	chr2:43328666	chr2:43229573~43233394:+
THCA	cis	rs10612751	1	rs10612751	ENSG00000277863.1	RP11-282A11.4	5.77	1.42e-08	2.53e-06	0.33	0.26	Lobe attachment (rater-scored or self-reported);	chr13:106993686	chr13:106903150~106904099:-
THCA	cis	rs4948275	0.773	rs2256066	ENSG00000237233.2	TMEM26-AS1	-5.77	1.42e-08	2.53e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61507370	chr10:61452639~61481956:+
THCA	cis	rs2029362	0.611	rs7934165	ENSG00000245573.6	BDNF-AS	5.77	1.42e-08	2.53e-06	0.2	0.26	Total body bone mineral density;	chr11:27710436	chr11:27506838~27698174:+
THCA	cis	rs6902257	0.744	rs2444805	ENSG00000272129.1	RP11-250B2.6	5.77	1.42e-08	2.53e-06	0.69	0.26	Obesity-related traits;	chr6:80620633	chr6:80355424~80356859:+
THCA	cis	rs12612619	0.704	rs7602823	ENSG00000229122.1	AGBL5-IT1	-5.77	1.42e-08	2.54e-06	-0.19	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086538	chr2:27061038~27061815:+
THCA	cis	rs935334	1	rs2289836	ENSG00000258454.1	RP11-361H10.3	-5.77	1.42e-08	2.54e-06	-0.37	-0.26	Blood pressure;	chr14:76173782	chr14:76235817~76263474:+
THCA	cis	rs4748857	0.685	rs958425	ENSG00000224215.1	RP11-371A19.2	-5.77	1.42e-08	2.54e-06	-0.34	-0.26	Systemic lupus erythematosus;	chr10:23222997	chr10:23343957~23345181:+
THCA	cis	rs412050	0.947	rs239914	ENSG00000224086.5	LL22NC03-86G7.1	-5.77	1.42e-08	2.54e-06	-0.41	-0.26	Attention deficit hyperactivity disorder;	chr22:21962965	chr22:21938293~21977632:+
THCA	cis	rs6908034	0.607	rs78774173	ENSG00000237404.1	RP3-471C18.2	-5.77	1.42e-08	2.54e-06	-0.55	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19820455	chr6:19689825~19753113:-
THCA	cis	rs758324	0.732	rs152055	ENSG00000237714.1	P4HA2-AS1	-5.77	1.42e-08	2.54e-06	-0.39	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132183150	chr5:132184876~132192808:+
THCA	cis	rs758324	0.582	rs152054	ENSG00000237714.1	P4HA2-AS1	-5.77	1.42e-08	2.54e-06	-0.39	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132183847	chr5:132184876~132192808:+
THCA	cis	rs7209700	0.894	rs7212751	ENSG00000228782.6	CTD-2026D20.3	-5.77	1.42e-08	2.54e-06	-0.24	-0.26	IgG glycosylation;	chr17:47278133	chr17:47450568~47492492:-
THCA	cis	rs793571	0.554	rs12908261	ENSG00000259250.1	RP11-50C13.1	-5.77	1.42e-08	2.54e-06	-0.28	-0.26	Schizophrenia;	chr15:58701582	chr15:58587507~58591676:+
THCA	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	5.77	1.42e-08	2.54e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
THCA	cis	rs758324	0.645	rs754127	ENSG00000237714.1	P4HA2-AS1	-5.77	1.43e-08	2.54e-06	-0.38	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132180037	chr5:132184876~132192808:+
THCA	cis	rs1387259	0.79	rs2732445	ENSG00000240399.1	RP1-228P16.1	5.77	1.43e-08	2.54e-06	0.26	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48054813~48055591:-
THCA	cis	rs875971	0.83	rs427973	ENSG00000223473.2	GS1-124K5.3	5.77	1.43e-08	2.54e-06	0.18	0.26	Aortic root size;	chr7:66061661	chr7:66491049~66493566:-
THCA	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	5.77	1.43e-08	2.55e-06	0.28	0.26	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
THCA	cis	rs9601248	0.756	rs9601251	ENSG00000227676.3	LINC01068	-5.77	1.43e-08	2.55e-06	-0.33	-0.26	Major depressive disorder;	chr13:79615582	chr13:79566727~79571436:+
THCA	cis	rs4227	0.565	rs858526	ENSG00000233223.2	AC113189.5	-5.77	1.43e-08	2.55e-06	-0.21	-0.26	IgA nephropathy;	chr17:7596064	chr17:7581964~7584072:-
THCA	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	5.77	1.43e-08	2.55e-06	0.25	0.26	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
THCA	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-5.77	1.43e-08	2.55e-06	-0.47	-0.26	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
THCA	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	5.77	1.43e-08	2.55e-06	0.47	0.26	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
THCA	cis	rs7727544	0.604	rs2069803	ENSG00000233006.5	AC034220.3	5.77	1.43e-08	2.55e-06	0.21	0.26	Blood metabolite levels;	chr5:132064740	chr5:132311285~132369916:-
THCA	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	5.77	1.43e-08	2.55e-06	0.33	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
THCA	cis	rs812925	0.784	rs1177304	ENSG00000271889.1	RP11-493E12.1	5.77	1.43e-08	2.55e-06	0.27	0.26	Immature fraction of reticulocytes;	chr2:61161029	chr2:61151433~61162105:-
THCA	cis	rs9813712	0.78	rs55929137	ENSG00000249846.5	RP11-77P16.4	5.77	1.43e-08	2.56e-06	0.3	0.26	Response to amphetamines;	chr3:130236002	chr3:130112550~130120579:+
THCA	cis	rs16949788	1	rs16949793	ENSG00000261351.2	CTD-3185P2.1	5.77	1.43e-08	2.56e-06	0.31	0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66301610	chr15:66488658~66492109:-
THCA	cis	rs6445975	0.726	rs6764512	ENSG00000272360.1	RP11-359I18.5	5.77	1.43e-08	2.56e-06	0.28	0.26	Systemic lupus erythematosus;	chr3:58482509	chr3:58490830~58491291:-
THCA	cis	rs4639966	0.723	rs11217022	ENSG00000255239.1	AP002954.6	-5.77	1.43e-08	2.56e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118770897	chr11:118688039~118690600:-
THCA	cis	rs2562456	0.833	rs2968078	ENSG00000268081.1	RP11-678G14.2	-5.77	1.43e-08	2.56e-06	-0.38	-0.26	Pain;	chr19:21458942	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.755	rs2650773	ENSG00000268081.1	RP11-678G14.2	-5.77	1.43e-08	2.56e-06	-0.38	-0.26	Pain;	chr19:21461286	chr19:21554640~21569237:-
THCA	cis	rs7617773	0.962	rs6797587	ENSG00000228638.1	FCF1P2	5.77	1.44e-08	2.56e-06	0.25	0.26	Coronary artery disease;	chr3:48156124	chr3:48290793~48291375:-
THCA	cis	rs2243480	1	rs709607	ENSG00000232546.1	RP11-458F8.1	5.77	1.44e-08	2.56e-06	0.34	0.26	Diabetic kidney disease;	chr7:65984554	chr7:66848496~66858136:+
THCA	cis	rs6963495	0.615	rs7384092	ENSG00000272604.1	RP11-251G23.5	-5.77	1.44e-08	2.56e-06	-0.29	-0.26	Bipolar disorder (body mass index interaction);	chr7:105562637	chr7:105571083~105573660:+
THCA	cis	rs62292953	0.79	rs2270801	ENSG00000248724.5	NPHP3-AS1	-5.77	1.44e-08	2.56e-06	-0.48	-0.26	Red cell distribution width;	chr3:132559022	chr3:132721750~132874223:+
THCA	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	5.77	1.44e-08	2.56e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	5.77	1.44e-08	2.56e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	5.77	1.44e-08	2.56e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
THCA	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	5.77	1.44e-08	2.56e-06	0.27	0.26	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
THCA	cis	rs75422866	0.51	rs73105812	ENSG00000276691.1	RP5-1057I20.5	5.77	1.44e-08	2.56e-06	0.44	0.26	Pneumonia;	chr12:47724404	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.51	rs74733564	ENSG00000276691.1	RP5-1057I20.5	5.77	1.44e-08	2.56e-06	0.44	0.26	Pneumonia;	chr12:47724644	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.51	rs73105814	ENSG00000276691.1	RP5-1057I20.5	5.77	1.44e-08	2.56e-06	0.44	0.26	Pneumonia;	chr12:47725817	chr12:47788426~47788971:+
THCA	cis	rs67478160	0.619	rs1040813	ENSG00000258735.1	LINC00637	-5.77	1.44e-08	2.57e-06	-0.31	-0.26	Schizophrenia;	chr14:103840359	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.619	rs1187416	ENSG00000258735.1	LINC00637	-5.77	1.44e-08	2.57e-06	-0.31	-0.26	Schizophrenia;	chr14:103845128	chr14:103847721~103858049:+
THCA	cis	rs757978	1	rs2074771	ENSG00000223374.1	AC005104.3	5.77	1.44e-08	2.57e-06	0.28	0.26	Chronic lymphocytic leukemia;	chr2:241411529	chr2:241351340~241353104:-
THCA	cis	rs17772222	1	rs61977058	ENSG00000222990.1	RNU4-22P	5.77	1.44e-08	2.57e-06	0.34	0.26	Coronary artery calcification;	chr14:88415571	chr14:88513498~88513663:+
THCA	cis	rs12893668	0.703	rs4906335	ENSG00000269940.1	RP11-73M18.7	5.77	1.44e-08	2.57e-06	0.28	0.26	Reticulocyte count;	chr14:103554804	chr14:103694560~103695170:+
THCA	cis	rs758324	0.732	rs154724	ENSG00000237714.1	P4HA2-AS1	-5.77	1.44e-08	2.57e-06	-0.39	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132109967	chr5:132184876~132192808:+
THCA	cis	rs9921338	0.924	rs7193645	ENSG00000262703.1	RP11-485G7.6	-5.77	1.44e-08	2.57e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11287179	chr16:11348143~11349321:-
THCA	cis	rs2280018	1	rs2280018	ENSG00000188599.16	NPIPP1	-5.77	1.44e-08	2.57e-06	-0.19	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15104312~15123498:-
THCA	cis	rs847577	0.63	rs6967926	ENSG00000272950.1	RP11-307C18.1	5.77	1.44e-08	2.57e-06	0.32	0.26	Breast cancer;	chr7:98085776	chr7:98322853~98323430:+
THCA	cis	rs9549367	0.713	rs3024745	ENSG00000269125.1	RP11-98F14.11	-5.77	1.44e-08	2.57e-06	-0.32	-0.26	Platelet distribution width;	chr13:113167284	chr13:113165002~113165183:-
THCA	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-5.77	1.44e-08	2.58e-06	-0.23	-0.26	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
THCA	cis	rs848490	0.928	rs2960455	ENSG00000214293.7	APTR	-5.77	1.45e-08	2.58e-06	-0.2	-0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77892630	chr7:77657660~77696265:-
THCA	cis	rs2243480	1	rs1546059	ENSG00000232546.1	RP11-458F8.1	5.77	1.45e-08	2.58e-06	0.33	0.26	Diabetic kidney disease;	chr7:66189722	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs2420170	ENSG00000232546.1	RP11-458F8.1	5.77	1.45e-08	2.58e-06	0.33	0.26	Diabetic kidney disease;	chr7:66191066	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6958289	ENSG00000232546.1	RP11-458F8.1	5.77	1.45e-08	2.58e-06	0.33	0.26	Diabetic kidney disease;	chr7:66192124	chr7:66848496~66858136:+
THCA	cis	rs4908768	0.539	rs6670508	ENSG00000232912.4	RP5-1115A15.1	5.77	1.45e-08	2.58e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8424645~8434838:+
THCA	cis	rs150992	0.536	rs161729	ENSG00000248489.1	CTD-2007H13.3	5.77	1.45e-08	2.58e-06	0.27	0.26	Body mass index;	chr5:98982477	chr5:98929171~98995013:+
THCA	cis	rs2273788	0.837	rs1053968	ENSG00000204173.9	LRRC37A5P	5.77	1.45e-08	2.58e-06	0.32	0.26	Monocyte count;	chr9:111590312	chr9:111602831~111631289:-
THCA	cis	rs8077577	0.789	rs62072546	ENSG00000273018.4	CTD-2303H24.2	-5.77	1.45e-08	2.58e-06	-0.44	-0.26	Obesity-related traits;	chr17:18350525	chr17:18511221~18551705:-
THCA	cis	rs13287066	0.692	rs4563950	ENSG00000227603.1	RP11-165J3.6	5.77	1.45e-08	2.58e-06	0.26	0.26	Intelligence (multi-trait analysis);	chr9:93405359	chr9:93435332~93437121:-
THCA	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-5.77	1.45e-08	2.58e-06	-0.21	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
THCA	cis	rs12497850	0.931	rs11920534	ENSG00000229759.1	MRPS18AP1	5.77	1.45e-08	2.59e-06	0.34	0.26	Parkinson's disease;	chr3:48900328	chr3:48256350~48256938:-
THCA	cis	rs793571	0.554	rs12441912	ENSG00000259250.1	RP11-50C13.1	-5.77	1.45e-08	2.59e-06	-0.28	-0.26	Schizophrenia;	chr15:58701495	chr15:58587507~58591676:+
THCA	cis	rs67478160	0.572	rs8015603	ENSG00000258735.1	LINC00637	-5.77	1.45e-08	2.59e-06	-0.31	-0.26	Schizophrenia;	chr14:103827341	chr14:103847721~103858049:+
THCA	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	5.77	1.45e-08	2.59e-06	0.33	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	5.77	1.45e-08	2.59e-06	0.33	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	5.77	1.45e-08	2.59e-06	0.33	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
THCA	cis	rs7307902	0.554	rs10875663	ENSG00000280054.1	RP1-197B17.7	-5.77	1.46e-08	2.59e-06	-0.28	-0.26	Obesity-related traits;	chr12:47571275	chr12:47728151~47730598:-
THCA	cis	rs6968419	0.674	rs4730726	ENSG00000237870.5	AC073130.1	5.77	1.46e-08	2.59e-06	0.28	0.26	Intraocular pressure;	chr7:116273282	chr7:116275606~116286734:-
THCA	cis	rs9878978	0.685	rs11711409	ENSG00000237990.3	CNTN4-AS1	5.77	1.46e-08	2.59e-06	0.31	0.26	Blood pressure (smoking interaction);	chr3:2460513	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.691	rs11716315	ENSG00000237990.3	CNTN4-AS1	5.77	1.46e-08	2.59e-06	0.31	0.26	Blood pressure (smoking interaction);	chr3:2460571	chr3:3039033~3069242:-
THCA	cis	rs2839186	0.814	rs2276257	ENSG00000239415.1	AP001469.9	5.77	1.46e-08	2.6e-06	0.26	0.26	Testicular germ cell tumor;	chr21:46291315	chr21:46251549~46254133:-
THCA	cis	rs9309473	0.519	rs12618600	ENSG00000163016.8	ALMS1P	-5.77	1.46e-08	2.6e-06	-0.33	-0.26	Metabolite levels;	chr2:73663555	chr2:73644919~73685576:+
THCA	cis	rs9475752	0.948	rs58338781	ENSG00000231441.1	RP11-472M19.2	5.77	1.46e-08	2.6e-06	0.32	0.26	Menarche (age at onset);	chr6:56922884	chr6:56844002~56864078:+
THCA	cis	rs9475752	1	rs35202312	ENSG00000231441.1	RP11-472M19.2	5.77	1.46e-08	2.6e-06	0.32	0.26	Menarche (age at onset);	chr6:56924139	chr6:56844002~56864078:+
THCA	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-5.77	1.46e-08	2.6e-06	-0.26	-0.26	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
THCA	cis	rs11096990	0.821	rs76235093	ENSG00000249685.1	RP11-360F5.3	-5.77	1.46e-08	2.6e-06	-0.33	-0.26	Cognitive function;	chr4:39281157	chr4:39133913~39135608:+
THCA	cis	rs6968419	0.755	rs10500059	ENSG00000237870.5	AC073130.1	5.77	1.46e-08	2.6e-06	0.28	0.26	Intraocular pressure;	chr7:116260340	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.692	rs10500060	ENSG00000237870.5	AC073130.1	5.77	1.46e-08	2.6e-06	0.28	0.26	Intraocular pressure;	chr7:116260632	chr7:116275606~116286734:-
THCA	cis	rs7688540	0.8	rs7694325	ENSG00000211553.1	AC253576.2	-5.77	1.46e-08	2.6e-06	-0.36	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:136461~136568:+
THCA	cis	rs847577	0.569	rs12674083	ENSG00000272950.1	RP11-307C18.1	5.77	1.46e-08	2.6e-06	0.33	0.26	Breast cancer;	chr7:98067022	chr7:98322853~98323430:+
THCA	cis	rs853679	0.607	rs13199649	ENSG00000226314.6	ZNF192P1	-5.77	1.46e-08	2.6e-06	-0.57	-0.26	Depression;	chr6:27901014	chr6:28161781~28169594:+
THCA	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	5.77	1.46e-08	2.6e-06	0.24	0.26	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
THCA	cis	rs7809950	0.817	rs2712195	ENSG00000238832.1	snoU109	-5.77	1.46e-08	2.6e-06	-0.29	-0.26	Coronary artery disease;	chr7:107487051	chr7:107603363~107603507:+
THCA	cis	rs13256369	1	rs13266699	ENSG00000253893.2	FAM85B	5.77	1.46e-08	2.6e-06	0.34	0.26	Obesity-related traits;	chr8:8712803	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.951	rs13260947	ENSG00000253893.2	FAM85B	-5.77	1.46e-08	2.6e-06	-0.34	-0.26	Obesity-related traits;	chr8:8708373	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.951	rs13259955	ENSG00000253893.2	FAM85B	-5.77	1.46e-08	2.6e-06	-0.34	-0.26	Obesity-related traits;	chr8:8708375	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs885000	ENSG00000253893.2	FAM85B	-5.77	1.46e-08	2.6e-06	-0.34	-0.26	Obesity-related traits;	chr8:8711365	chr8:8167819~8226614:-
THCA	cis	rs2303319	0.504	rs62187611	ENSG00000227403.1	AC009299.3	5.77	1.46e-08	2.61e-06	0.53	0.26	Cognitive function;	chr2:161575436	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12473497	ENSG00000227403.1	AC009299.3	5.77	1.46e-08	2.61e-06	0.53	0.26	Cognitive function;	chr2:161577256	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12469302	ENSG00000227403.1	AC009299.3	5.77	1.46e-08	2.61e-06	0.53	0.26	Cognitive function;	chr2:161577321	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187613	ENSG00000227403.1	AC009299.3	5.77	1.46e-08	2.61e-06	0.53	0.26	Cognitive function;	chr2:161577964	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.582	rs72870248	ENSG00000227403.1	AC009299.3	5.77	1.46e-08	2.61e-06	0.53	0.26	Cognitive function;	chr2:161579339	chr2:161244739~161249050:+
THCA	cis	rs442309	0.846	rs224049	ENSG00000238280.1	RP11-436D10.3	-5.77	1.46e-08	2.61e-06	-0.31	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62732673	chr10:62793562~62805887:-
THCA	cis	rs4948275	0.773	rs2650724	ENSG00000237233.2	TMEM26-AS1	-5.77	1.46e-08	2.61e-06	-0.34	-0.26	Night sleep phenotypes;	chr10:61513024	chr10:61452639~61481956:+
THCA	cis	rs6840360	0.642	rs10857260	ENSG00000270265.1	RP11-731D1.4	-5.77	1.46e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7676493	ENSG00000270265.1	RP11-731D1.4	-5.77	1.46e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs11735957	ENSG00000270265.1	RP11-731D1.4	-5.77	1.46e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.607	rs6815320	ENSG00000270265.1	RP11-731D1.4	-5.77	1.46e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs11726254	ENSG00000270265.1	RP11-731D1.4	-5.77	1.46e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2053566	ENSG00000270265.1	RP11-731D1.4	-5.77	1.46e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.607	rs1561918	ENSG00000270265.1	RP11-731D1.4	-5.77	1.46e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs1443089	ENSG00000270265.1	RP11-731D1.4	-5.77	1.46e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151333775~151353224:-
THCA	cis	rs9307551	0.779	rs12501981	ENSG00000250334.4	LINC00989	-5.77	1.46e-08	2.61e-06	-0.3	-0.26	Refractive error;	chr4:79591850	chr4:79492416~79576460:+
THCA	cis	rs12101261	0.744	rs72693080	ENSG00000259167.2	NMNAT1P1	5.77	1.47e-08	2.61e-06	0.38	0.26	Graves' disease;	chr14:80987375	chr14:81032529~81033404:+
THCA	cis	rs12101261	0.744	rs2024427	ENSG00000259167.2	NMNAT1P1	5.77	1.47e-08	2.61e-06	0.38	0.26	Graves' disease;	chr14:80987892	chr14:81032529~81033404:+
THCA	cis	rs6840360	0.642	rs2724578	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.574	rs2709844	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.693	rs28622593	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709831	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709817	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709818	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2709819	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7682770	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7676059	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7657747	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs4696089	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs11932398	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs4263379	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs12647555	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs1899550	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7680013	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7680236	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs4696092	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs6843639	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs28666858	ENSG00000270265.1	RP11-731D1.4	-5.77	1.47e-08	2.61e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs2724574	ENSG00000270265.1	RP11-731D1.4	5.77	1.47e-08	2.61e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151333775~151353224:-
THCA	cis	rs2562456	0.874	rs2562408	ENSG00000268119.4	CTD-2561J22.5	-5.77	1.47e-08	2.61e-06	-0.32	-0.26	Pain;	chr19:21527079	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.874	rs2562417	ENSG00000268119.4	CTD-2561J22.5	-5.77	1.47e-08	2.61e-06	-0.32	-0.26	Pain;	chr19:21528400	chr19:21444241~21463908:-
THCA	cis	rs867529	0.924	rs1913671	ENSG00000234028.3	AC062029.1	5.77	1.47e-08	2.61e-06	0.2	0.26	Height;	chr2:88600365	chr2:88627539~88631821:+
THCA	cis	rs172166	0.694	rs203884	ENSG00000226314.6	ZNF192P1	-5.77	1.47e-08	2.61e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28109596	chr6:28161781~28169594:+
THCA	cis	rs4639966	0.836	rs7110526	ENSG00000255239.1	AP002954.6	-5.77	1.47e-08	2.61e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118762824	chr11:118688039~118690600:-
THCA	cis	rs4639966	0.836	rs11217018	ENSG00000255239.1	AP002954.6	-5.77	1.47e-08	2.61e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118764656	chr11:118688039~118690600:-
THCA	cis	rs4639966	0.797	rs11217021	ENSG00000255239.1	AP002954.6	-5.77	1.47e-08	2.61e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118770119	chr11:118688039~118690600:-
THCA	cis	rs847577	0.569	rs2394817	ENSG00000272950.1	RP11-307C18.1	5.77	1.47e-08	2.61e-06	0.33	0.26	Breast cancer;	chr7:98061126	chr7:98322853~98323430:+
THCA	cis	rs847577	0.569	rs35101190	ENSG00000272950.1	RP11-307C18.1	5.77	1.47e-08	2.61e-06	0.33	0.26	Breast cancer;	chr7:98066576	chr7:98322853~98323430:+
THCA	cis	rs67478160	0.643	rs12434686	ENSG00000258735.1	LINC00637	5.77	1.47e-08	2.62e-06	0.31	0.26	Schizophrenia;	chr14:103849696	chr14:103847721~103858049:+
THCA	cis	rs2559856	0.935	rs2695287	ENSG00000274560.1	RP11-285E23.2	5.77	1.47e-08	2.62e-06	0.16	0.26	Blood protein levels;	chr12:101694583	chr12:101696002~101696450:-
THCA	cis	rs2559856	1	rs2695286	ENSG00000274560.1	RP11-285E23.2	5.77	1.47e-08	2.62e-06	0.16	0.26	Blood protein levels;	chr12:101694729	chr12:101696002~101696450:-
THCA	cis	rs7615952	0.609	rs13088451	ENSG00000241288.6	RP11-379B18.5	-5.77	1.47e-08	2.62e-06	-0.31	-0.26	Blood pressure (smoking interaction);	chr3:125834656	chr3:125827238~125916384:-
THCA	cis	rs853679	0.607	rs67998226	ENSG00000226314.6	ZNF192P1	-5.77	1.47e-08	2.62e-06	-0.56	-0.26	Depression;	chr6:28270281	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34878803	ENSG00000226314.6	ZNF192P1	-5.77	1.47e-08	2.62e-06	-0.56	-0.26	Depression;	chr6:28282402	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34396849	ENSG00000226314.6	ZNF192P1	-5.77	1.47e-08	2.62e-06	-0.56	-0.26	Depression;	chr6:28283178	chr6:28161781~28169594:+
THCA	cis	rs4908768	0.501	rs11121201	ENSG00000232912.4	RP5-1115A15.1	5.77	1.47e-08	2.62e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8424645~8434838:+
THCA	cis	rs62158211	0.565	rs2121243	ENSG00000272563.1	RP11-480C16.1	-5.77	1.47e-08	2.62e-06	-0.3	-0.26	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113341769	chr2:113432600~113436042:+
THCA	cis	rs4604234	0.803	rs73465590	ENSG00000272129.1	RP11-250B2.6	-5.77	1.47e-08	2.62e-06	-0.63	-0.26	Cancer;	chr6:80337459	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.708	rs3805862	ENSG00000272129.1	RP11-250B2.6	-5.77	1.47e-08	2.62e-06	-0.63	-0.26	Cancer;	chr6:80338534	chr6:80355424~80356859:+
THCA	cis	rs7246657	0.722	rs1291	ENSG00000267422.1	CTD-2554C21.1	5.77	1.47e-08	2.62e-06	0.28	0.26	Coronary artery calcification;	chr19:37738477	chr19:37779686~37792865:+
THCA	cis	rs7615952	0.8	rs13086460	ENSG00000241288.6	RP11-379B18.5	-5.77	1.47e-08	2.62e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125927574	chr3:125827238~125916384:-
THCA	cis	rs763121	0.524	rs760645	ENSG00000235209.1	CTA-150C2.13	5.77	1.47e-08	2.62e-06	0.33	0.26	Menopause (age at onset);	chr22:38636265	chr22:38921227~38924708:+
THCA	cis	rs4748857	0.685	rs7071484	ENSG00000224215.1	RP11-371A19.2	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Systemic lupus erythematosus;	chr10:23276966	chr10:23343957~23345181:+
THCA	cis	rs9388451	0.807	rs1269175	ENSG00000226409.1	RP11-735G4.1	5.77	1.48e-08	2.63e-06	0.31	0.26	Brugada syndrome;	chr6:125719289	chr6:125370211~125374324:-
THCA	cis	rs7202877	0.61	rs11149814	ENSG00000261783.1	RP11-252K23.2	-5.77	1.48e-08	2.63e-06	-0.45	-0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75299083	chr16:75379818~75381260:-
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66433290	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs58669269	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66486966	chr7:66848496~66858136:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000206090.4	AP000350.7	5.77	1.48e-08	2.63e-06	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23939998~23942798:+
THCA	cis	rs934734	0.789	rs906579	ENSG00000237979.1	AC007389.1	-5.77	1.48e-08	2.63e-06	-0.3	-0.26	Rheumatoid arthritis;	chr2:65374464	chr2:65500993~65502138:-
THCA	cis	rs934734	0.789	rs906578	ENSG00000237979.1	AC007389.1	-5.77	1.48e-08	2.63e-06	-0.3	-0.26	Rheumatoid arthritis;	chr2:65374466	chr2:65500993~65502138:-
THCA	cis	rs2129782	1	rs16882273	ENSG00000253553.4	RP11-586K2.1	5.77	1.48e-08	2.63e-06	0.44	0.26	Electrodermal activity;	chr8:88412121	chr8:88326836~88737134:+
THCA	cis	rs2243480	1	rs422164	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66121618	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316313	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66128561	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316312	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66131504	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs419603	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66132354	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs387676	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66133233	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66133553	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs431076	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66135333	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66136518	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316334	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66137139	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316330	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66140385	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316326	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66144466	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316325	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66144531	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316321	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66146626	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316318	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66147917	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316317	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66148650	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316304	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66151907	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs2465120	ENSG00000232546.1	RP11-458F8.1	-5.77	1.48e-08	2.63e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66155987	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66157859	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs4718309	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66162777	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6460274	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66163497	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs7787230	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66164112	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66170354	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6974723	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66172952	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs9769882	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66177938	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6966322	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66181767	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs4145008	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66182524	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs4718315	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66183554	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs4718316	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66183744	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs1873494	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66184912	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs6959002	ENSG00000232546.1	RP11-458F8.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Diabetic kidney disease;	chr7:66185509	chr7:66848496~66858136:+
THCA	cis	rs7225151	0.71	rs79970806	ENSG00000234327.6	AC012146.7	-5.77	1.48e-08	2.63e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5296937	chr17:5111468~5115004:+
THCA	cis	rs9876781	1	rs6442123	ENSG00000229759.1	MRPS18AP1	5.77	1.48e-08	2.63e-06	0.3	0.26	Longevity;	chr3:48458887	chr3:48256350~48256938:-
THCA	cis	rs2281636	1	rs11190263	ENSG00000260475.1	RP11-85A1.3	5.77	1.48e-08	2.63e-06	0.23	0.26	Obesity-related traits;	chr10:99746626	chr10:99621055~99621918:+
THCA	cis	rs7763441	0.545	rs9391949	ENSG00000272465.1	RP1-136B1.1	5.77	1.48e-08	2.63e-06	0.33	0.26	Monobrow;	chr6:2451790	chr6:2437549~2438249:+
THCA	cis	rs78487399	0.808	rs76856054	ENSG00000234936.1	AC010883.5	5.77	1.48e-08	2.63e-06	0.37	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43537045	chr2:43229573~43233394:+
THCA	cis	rs9876781	1	rs898225	ENSG00000229759.1	MRPS18AP1	-5.77	1.48e-08	2.63e-06	-0.3	-0.26	Longevity;	chr3:48371689	chr3:48256350~48256938:-
THCA	cis	rs6860806	0.661	rs6890009	ENSG00000233006.5	AC034220.3	5.77	1.48e-08	2.63e-06	0.2	0.26	Breast cancer;	chr5:132244340	chr5:132311285~132369916:-
THCA	cis	rs2735413	0.564	rs78769909	ENSG00000276007.1	RP11-358L22.3	5.76	1.48e-08	2.64e-06	0.28	0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78070105	chr16:78123243~78124332:+
THCA	cis	rs2029362	0.806	rs3763965	ENSG00000245573.6	BDNF-AS	5.76	1.48e-08	2.64e-06	0.2	0.26	Total body bone mineral density;	chr11:27507440	chr11:27506838~27698174:+
THCA	cis	rs16976116	0.901	rs9920219	ENSG00000279145.1	RP11-547D13.1	5.76	1.48e-08	2.64e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55211766	chr15:55171972~55178175:-
THCA	cis	rs7225151	0.71	rs16954523	ENSG00000234327.6	AC012146.7	-5.76	1.48e-08	2.64e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5313703	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs77752862	ENSG00000234327.6	AC012146.7	-5.76	1.48e-08	2.64e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5318776	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs56125028	ENSG00000234327.6	AC012146.7	-5.76	1.48e-08	2.64e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5327572	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.52	rs55993740	ENSG00000234327.6	AC012146.7	-5.76	1.48e-08	2.64e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5328117	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs55947703	ENSG00000234327.6	AC012146.7	-5.76	1.48e-08	2.64e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5328323	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs12600505	ENSG00000234327.6	AC012146.7	-5.76	1.48e-08	2.64e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5330522	chr17:5111468~5115004:+
THCA	cis	rs7225151	0.71	rs112421661	ENSG00000234327.6	AC012146.7	-5.76	1.48e-08	2.64e-06	-0.29	-0.26	Alzheimer's disease (late onset);	chr17:5338555	chr17:5111468~5115004:+
THCA	cis	rs935334	0.877	rs3813546	ENSG00000258454.1	RP11-361H10.3	-5.76	1.48e-08	2.64e-06	-0.37	-0.26	Blood pressure;	chr14:76153618	chr14:76235817~76263474:+
THCA	cis	rs755249	0.567	rs3118014	ENSG00000228060.1	RP11-69E11.8	-5.76	1.48e-08	2.64e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39565160~39573203:+
THCA	cis	rs1707322	0.721	rs11211149	ENSG00000281133.1	AL355480.3	-5.76	1.48e-08	2.64e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45580892~45580996:-
THCA	cis	rs2559856	1	rs2695288	ENSG00000274560.1	RP11-285E23.2	5.76	1.48e-08	2.64e-06	0.16	0.26	Blood protein levels;	chr12:101694334	chr12:101696002~101696450:-
THCA	cis	rs10808739	0.541	rs9650212	ENSG00000254006.4	RP11-1D12.2	5.76	1.49e-08	2.64e-06	0.4	0.26	HIV-1 susceptibility;	chr8:64756213	chr8:64801236~64817573:-
THCA	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-5.76	1.49e-08	2.64e-06	-0.19	-0.26	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
THCA	cis	rs2243480	1	rs313824	ENSG00000232546.1	RP11-458F8.1	-5.76	1.49e-08	2.64e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66116220	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs186378	ENSG00000232546.1	RP11-458F8.1	-5.76	1.49e-08	2.64e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66117071	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs160637	ENSG00000232546.1	RP11-458F8.1	-5.76	1.49e-08	2.64e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66119331	chr7:66848496~66858136:+
THCA	cis	rs4713118	0.513	rs149878	ENSG00000280107.1	AL022393.9	-5.76	1.49e-08	2.64e-06	-0.27	-0.26	Parkinson's disease;	chr6:27910960	chr6:28170845~28172521:+
THCA	cis	rs7712401	0.791	rs4836244	ENSG00000249996.1	RP11-359P5.1	5.76	1.49e-08	2.65e-06	0.24	0.26	Mean platelet volume;	chr5:122780537	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.791	rs4835897	ENSG00000249996.1	RP11-359P5.1	5.76	1.49e-08	2.65e-06	0.24	0.26	Mean platelet volume;	chr5:122785809	chr5:123036271~123054667:+
THCA	cis	rs2136613	0.533	rs1509956	ENSG00000238280.1	RP11-436D10.3	-5.76	1.49e-08	2.65e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62843574	chr10:62793562~62805887:-
THCA	cis	rs17345786	1	rs7641261	ENSG00000256628.3	ZBTB11-AS1	5.76	1.49e-08	2.65e-06	0.33	0.26	Colonoscopy-negative controls vs population controls;	chr3:101560162	chr3:101676475~101679217:+
THCA	cis	rs10875746	0.903	rs11168420	ENSG00000269514.1	RP11-370I10.12	5.76	1.49e-08	2.65e-06	0.26	0.26	Longevity (90 years and older);	chr12:48122113	chr12:48198387~48202031:+
THCA	cis	rs6973609	0.649	rs7796226	ENSG00000271122.1	RP11-379H18.1	5.76	1.49e-08	2.65e-06	0.17	0.26	Obesity-related traits;	chr7:35562531	chr7:35695214~35699413:+
THCA	cis	rs10895275	0.625	rs4754836	ENSG00000277459.1	RP11-732A21.3	5.76	1.49e-08	2.65e-06	0.19	0.26	Migraine;	chr11:102170092	chr11:102109827~102110457:-
THCA	cis	rs758324	0.645	rs156033	ENSG00000237714.1	P4HA2-AS1	-5.76	1.49e-08	2.65e-06	-0.38	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132191628	chr5:132184876~132192808:+
THCA	cis	rs1862618	0.853	rs1559282	ENSG00000271828.1	CTD-2310F14.1	5.76	1.49e-08	2.65e-06	0.38	0.26	Initial pursuit acceleration;	chr5:56803548	chr5:56927874~56929573:+
THCA	cis	rs3950186	0.834	rs1569735	ENSG00000215124.2	RP3-420J14.1	5.76	1.49e-08	2.65e-06	0.31	0.26	Anxiety and major depressive disorder;	chr6:11825804	chr6:11861626~11862970:-
THCA	cis	rs4713118	0.629	rs149899	ENSG00000220721.1	OR1F12	5.76	1.49e-08	2.65e-06	0.34	0.26	Parkinson's disease;	chr6:28052201	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000220721.1	OR1F12	5.76	1.49e-08	2.65e-06	0.34	0.26	Parkinson's disease;	chr6:28053036	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000220721.1	OR1F12	5.76	1.49e-08	2.65e-06	0.34	0.26	Parkinson's disease;	chr6:28053042	chr6:28073316~28074233:+
THCA	cis	rs9393777	0.92	rs67859638	ENSG00000219392.1	RP1-265C24.5	-5.76	1.49e-08	2.65e-06	-0.59	-0.26	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28115628~28116551:+
THCA	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	5.76	1.49e-08	2.66e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	5.76	1.49e-08	2.66e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	5.76	1.49e-08	2.66e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
THCA	cis	rs3213958	0.574	rs56290036	ENSG00000249274.1	PDLIM1P4	-5.76	1.49e-08	2.66e-06	-0.34	-0.26	Blood protein levels;	chr3:98845479	chr3:98782188~98783193:+
THCA	cis	rs9467773	0.967	rs7753565	ENSG00000124549.13	BTN2A3P	5.76	1.5e-08	2.66e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26421391~26432383:+
THCA	cis	rs9393777	0.844	rs72839477	ENSG00000226314.6	ZNF192P1	-5.76	1.5e-08	2.66e-06	-0.58	-0.26	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28161781~28169594:+
THCA	cis	rs7202877	0.61	rs4536500	ENSG00000261783.1	RP11-252K23.2	5.76	1.5e-08	2.66e-06	0.45	0.26	Type 1 diabetes;Type 2 diabetes;	chr16:75309299	chr16:75379818~75381260:-
THCA	cis	rs7809950	0.954	rs2520242	ENSG00000238832.1	snoU109	5.76	1.5e-08	2.67e-06	0.27	0.26	Coronary artery disease;	chr7:107495875	chr7:107603363~107603507:+
THCA	cis	rs4908768	0.501	rs6577494	ENSG00000232912.4	RP5-1115A15.1	5.76	1.5e-08	2.67e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8424645~8434838:+
THCA	cis	rs6951245	0.678	rs28600085	ENSG00000229043.2	AC091729.9	-5.76	1.5e-08	2.67e-06	-0.4	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.706	rs28483034	ENSG00000229043.2	AC091729.9	-5.76	1.5e-08	2.67e-06	-0.4	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1160374~1165267:+
THCA	cis	rs7809950	0.678	rs79902674	ENSG00000238832.1	snoU109	-5.76	1.5e-08	2.67e-06	-0.31	-0.26	Coronary artery disease;	chr7:107226053	chr7:107603363~107603507:+
THCA	cis	rs7529073	0.815	rs1431984	ENSG00000274895.1	RP11-478J18.2	-5.76	1.5e-08	2.67e-06	-0.21	-0.26	Schizophrenia;	chr1:213975285	chr1:213983793~213986419:-
THCA	cis	rs755249	0.53	rs16826087	ENSG00000228060.1	RP11-69E11.8	-5.76	1.5e-08	2.67e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39565160~39573203:+
THCA	cis	rs172166	0.637	rs1225592	ENSG00000226314.6	ZNF192P1	-5.76	1.5e-08	2.67e-06	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28182464	chr6:28161781~28169594:+
THCA	cis	rs172166	0.637	rs1225595	ENSG00000226314.6	ZNF192P1	-5.76	1.5e-08	2.67e-06	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28183562	chr6:28161781~28169594:+
THCA	cis	rs6565180	0.962	rs35480350	ENSG00000273724.1	RP11-347C12.12	-5.76	1.5e-08	2.67e-06	-0.28	-0.26	Tonsillectomy;	chr16:30354718	chr16:30336400~30343336:+
THCA	cis	rs11096990	0.964	rs11096986	ENSG00000249207.1	RP11-360F5.1	5.76	1.5e-08	2.67e-06	0.33	0.26	Cognitive function;	chr4:39257122	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.964	rs6828598	ENSG00000249207.1	RP11-360F5.1	5.76	1.5e-08	2.67e-06	0.33	0.26	Cognitive function;	chr4:39259850	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	5.76	1.5e-08	2.67e-06	0.33	0.26	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.964	rs16988409	ENSG00000249207.1	RP11-360F5.1	-5.76	1.5e-08	2.67e-06	-0.33	-0.26	Cognitive function;	chr4:39267730	chr4:39112677~39126818:-
THCA	cis	rs1866631	0.647	rs2289397	ENSG00000238133.5	MLK7-AS1	5.76	1.51e-08	2.68e-06	0.33	0.26	Lung cancer in ever smokers;	chr2:173209647	chr2:173166446~173282036:-
THCA	cis	rs6740322	0.948	rs6722694	ENSG00000234936.1	AC010883.5	5.76	1.51e-08	2.68e-06	0.26	0.26	Coronary artery disease;	chr2:43342659	chr2:43229573~43233394:+
THCA	cis	rs75920871	0.528	rs7109649	ENSG00000254851.1	RP11-109L13.1	5.76	1.51e-08	2.68e-06	0.37	0.26	Subjective well-being;	chr11:117072828	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs1531706	ENSG00000254851.1	RP11-109L13.1	5.76	1.51e-08	2.68e-06	0.37	0.26	Subjective well-being;	chr11:117073236	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs7484045	ENSG00000254851.1	RP11-109L13.1	5.76	1.51e-08	2.68e-06	0.37	0.26	Subjective well-being;	chr11:117076174	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs7935913	ENSG00000254851.1	RP11-109L13.1	-5.76	1.51e-08	2.68e-06	-0.37	-0.26	Subjective well-being;	chr11:117073632	chr11:117135528~117138582:+
THCA	cis	rs7523875	0.72	rs61851033	ENSG00000153363.11	LINC00467	-5.76	1.51e-08	2.68e-06	-0.26	-0.26	Mean corpuscular volume;	chr1:211335876	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.872	rs55654731	ENSG00000153363.11	LINC00467	-5.76	1.51e-08	2.68e-06	-0.26	-0.26	Mean corpuscular volume;	chr1:211341728	chr1:211382803~211435333:+
THCA	cis	rs6430585	0.528	rs586964	ENSG00000231890.6	DARS-AS1	-5.76	1.51e-08	2.68e-06	-0.31	-0.26	Corneal structure;	chr2:135894921	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.528	rs499483	ENSG00000231890.6	DARS-AS1	-5.76	1.51e-08	2.68e-06	-0.31	-0.26	Corneal structure;	chr2:135894954	chr2:135985176~136022593:+
THCA	cis	rs3742264	1	rs7990092	ENSG00000235903.6	CPB2-AS1	-5.76	1.51e-08	2.68e-06	-0.34	-0.26	Blood protein levels;	chr13:46069154	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs7988836	ENSG00000235903.6	CPB2-AS1	-5.76	1.51e-08	2.68e-06	-0.34	-0.26	Blood protein levels;	chr13:46069238	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs7993537	ENSG00000235903.6	CPB2-AS1	-5.76	1.51e-08	2.68e-06	-0.34	-0.26	Blood protein levels;	chr13:46069426	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs7993567	ENSG00000235903.6	CPB2-AS1	-5.76	1.51e-08	2.68e-06	-0.34	-0.26	Blood protein levels;	chr13:46069471	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs7995615	ENSG00000235903.6	CPB2-AS1	-5.76	1.51e-08	2.68e-06	-0.34	-0.26	Blood protein levels;	chr13:46069673	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs9526139	ENSG00000235903.6	CPB2-AS1	-5.76	1.51e-08	2.68e-06	-0.34	-0.26	Blood protein levels;	chr13:46069921	chr13:46052806~46113332:+
THCA	cis	rs925255	0.81	rs7574996	ENSG00000270210.1	RP11-373D23.3	5.76	1.51e-08	2.68e-06	0.27	0.26	Inflammatory bowel disease;Crohn's disease;	chr2:28420656	chr2:28425945~28426719:+
THCA	cis	rs67478160	0.619	rs8018062	ENSG00000258735.1	LINC00637	-5.76	1.51e-08	2.68e-06	-0.31	-0.26	Schizophrenia;	chr14:103815617	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs2223937	ENSG00000258735.1	LINC00637	-5.76	1.51e-08	2.68e-06	-0.31	-0.26	Schizophrenia;	chr14:103820043	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs4900600	ENSG00000258735.1	LINC00637	-5.76	1.51e-08	2.68e-06	-0.31	-0.26	Schizophrenia;	chr14:103825502	chr14:103847721~103858049:+
THCA	cis	rs1185460	0.967	rs11217137	ENSG00000272186.1	RP11-110I1.13	-5.76	1.51e-08	2.69e-06	-0.25	-0.26	Coronary artery disease;	chr11:119060319	chr11:119067374~119067698:-
THCA	cis	rs7598759	0.712	rs12991636	ENSG00000181798.2	LINC00471	-5.76	1.51e-08	2.69e-06	-0.28	-0.26	Noise-induced hearing loss;	chr2:231468955	chr2:231508426~231514339:-
THCA	cis	rs6545883	0.965	rs6718887	ENSG00000270820.4	RP11-355B11.2	5.76	1.51e-08	2.69e-06	0.21	0.26	Tuberculosis;	chr2:61500080	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.965	rs6734830	ENSG00000270820.4	RP11-355B11.2	5.76	1.51e-08	2.69e-06	0.21	0.26	Tuberculosis;	chr2:61503977	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.931	rs9807965	ENSG00000270820.4	RP11-355B11.2	5.76	1.51e-08	2.69e-06	0.21	0.26	Tuberculosis;	chr2:61505024	chr2:61471188~61484130:+
THCA	cis	rs2145598	0.967	rs1051861	ENSG00000279636.2	LINC00216	-5.76	1.51e-08	2.69e-06	-0.25	-0.26	Coronary artery disease;	chr14:58371983	chr14:58288033~58289158:+
THCA	cis	rs9625935	0.7	rs9625921	ENSG00000279159.1	RP3-394A18.1	-5.76	1.51e-08	2.69e-06	-0.18	-0.26	Tonsillectomy;	chr22:30112286	chr22:29978950~30028236:-
THCA	cis	rs4266144	0.558	rs7623382	ENSG00000241770.1	RP11-555M1.3	-5.76	1.51e-08	2.69e-06	-0.32	-0.26	Coronary artery disease;	chr3:157115105	chr3:157163452~157169133:+
THCA	cis	rs2179367	0.959	rs4897125	ENSG00000231760.4	RP11-350J20.5	5.76	1.51e-08	2.69e-06	0.35	0.26	Dupuytren's disease;	chr6:149445072	chr6:149796151~149826294:-
THCA	cis	rs7727544	0.735	rs273914	ENSG00000224431.1	AC063976.7	5.76	1.52e-08	2.69e-06	0.22	0.26	Blood metabolite levels;	chr5:132324738	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.735	rs272894	ENSG00000224431.1	AC063976.7	5.76	1.52e-08	2.69e-06	0.22	0.26	Blood metabolite levels;	chr5:132326767	chr5:132199456~132203487:+
THCA	cis	rs4748857	0.945	rs4748860	ENSG00000224215.1	RP11-371A19.2	5.76	1.52e-08	2.7e-06	0.3	0.26	Systemic lupus erythematosus;	chr10:23316787	chr10:23343957~23345181:+
THCA	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-5.76	1.52e-08	2.7e-06	-0.29	-0.26	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
THCA	cis	rs9307551	0.894	rs6812760	ENSG00000250334.4	LINC00989	-5.76	1.52e-08	2.7e-06	-0.33	-0.26	Refractive error;	chr4:79560702	chr4:79492416~79576460:+
THCA	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-5.76	1.52e-08	2.7e-06	-0.49	-0.26	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
THCA	cis	rs792448	1	rs1086893	ENSG00000226251.4	RP11-15I11.3	-5.76	1.52e-08	2.7e-06	-0.33	-0.26	White blood cell count (basophil);	chr1:212389772	chr1:212225278~212238977:-
THCA	cis	rs1876905	0.539	rs240987	ENSG00000255389.1	C6orf3	5.76	1.52e-08	2.7e-06	0.33	0.26	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111599875~111602295:+
THCA	cis	rs61677309	1	rs1318166	ENSG00000280032.1	RP11-832A4.7	5.76	1.52e-08	2.7e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118300343	chr11:118264593~118266817:+
THCA	cis	rs9890032	0.967	rs7342976	ENSG00000263531.1	RP13-753N3.1	5.76	1.52e-08	2.7e-06	0.33	0.26	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30863921~30864940:-
THCA	cis	rs9890032	1	rs28539246	ENSG00000263531.1	RP13-753N3.1	5.76	1.52e-08	2.7e-06	0.33	0.26	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30863921~30864940:-
THCA	cis	rs9890032	0.967	rs9897628	ENSG00000263531.1	RP13-753N3.1	5.76	1.52e-08	2.7e-06	0.33	0.26	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30863921~30864940:-
THCA	cis	rs7727544	0.57	rs7701237	ENSG00000233006.5	AC034220.3	5.76	1.52e-08	2.71e-06	0.19	0.26	Blood metabolite levels;	chr5:132198688	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.582	rs3749756	ENSG00000233006.5	AC034220.3	5.76	1.52e-08	2.71e-06	0.19	0.26	Blood metabolite levels;	chr5:132198806	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.582	rs3805683	ENSG00000233006.5	AC034220.3	5.76	1.52e-08	2.71e-06	0.19	0.26	Blood metabolite levels;	chr5:132199432	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.582	rs2278398	ENSG00000233006.5	AC034220.3	-5.76	1.52e-08	2.71e-06	-0.19	-0.26	Blood metabolite levels;	chr5:132194748	chr5:132311285~132369916:-
THCA	cis	rs5758659	1	rs134869	ENSG00000270083.1	RP1-257I20.14	5.76	1.52e-08	2.71e-06	0.27	0.26	Cognitive function;	chr22:42256068	chr22:42089630~42090028:-
THCA	cis	rs7829975	0.617	rs4841072	ENSG00000233609.3	RP11-62H7.2	-5.76	1.52e-08	2.71e-06	-0.25	-0.26	Mood instability;	chr8:8933743	chr8:8961200~8979025:+
THCA	cis	rs853679	0.55	rs34477097	ENSG00000220721.1	OR1F12	5.76	1.52e-08	2.71e-06	0.34	0.26	Depression;	chr6:28229408	chr6:28073316~28074233:+
THCA	cis	rs801193	1	rs2659912	ENSG00000273142.1	RP11-458F8.4	-5.76	1.53e-08	2.71e-06	-0.2	-0.26	Aortic root size;	chr7:66693012	chr7:66902857~66906297:+
THCA	cis	rs9921338	0.961	rs4781055	ENSG00000262703.1	RP11-485G7.6	-5.76	1.53e-08	2.71e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11275571	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs8060767	ENSG00000262703.1	RP11-485G7.6	-5.76	1.53e-08	2.71e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11276741	chr16:11348143~11349321:-
THCA	cis	rs1823913	0.927	rs35092718	ENSG00000280083.1	RP11-317J9.1	-5.76	1.53e-08	2.71e-06	-0.32	-0.26	Obesity-related traits;	chr2:191243882	chr2:191154118~191156070:-
THCA	cis	rs935334	1	rs4442739	ENSG00000258454.1	RP11-361H10.3	5.76	1.53e-08	2.71e-06	0.35	0.26	Blood pressure;	chr14:76181302	chr14:76235817~76263474:+
THCA	cis	rs7809950	0.817	rs3779495	ENSG00000238832.1	snoU109	5.76	1.53e-08	2.71e-06	0.3	0.26	Coronary artery disease;	chr7:107609815	chr7:107603363~107603507:+
THCA	cis	rs2243480	1	rs1638734	ENSG00000232559.3	GS1-124K5.12	5.76	1.53e-08	2.71e-06	0.39	0.26	Diabetic kidney disease;	chr7:66632552	chr7:66554588~66576923:-
THCA	cis	rs17772222	1	rs2295135	ENSG00000222990.1	RNU4-22P	5.76	1.53e-08	2.72e-06	0.34	0.26	Coronary artery calcification;	chr14:88427866	chr14:88513498~88513663:+
THCA	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	5.76	1.53e-08	2.72e-06	0.44	0.26	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
THCA	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	5.76	1.53e-08	2.72e-06	0.44	0.26	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
THCA	cis	rs4713118	0.513	rs149897	ENSG00000220721.1	OR1F12	5.76	1.53e-08	2.72e-06	0.31	0.26	Parkinson's disease;	chr6:28038872	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.513	rs149944	ENSG00000220721.1	OR1F12	5.76	1.53e-08	2.72e-06	0.31	0.26	Parkinson's disease;	chr6:28035040	chr6:28073316~28074233:+
THCA	cis	rs9326246	0.556	rs662799	ENSG00000254851.1	RP11-109L13.1	-5.76	1.53e-08	2.72e-06	-0.52	-0.26	Coronary artery disease;	chr11:116792991	chr11:117135528~117138582:+
THCA	cis	rs13256369	0.708	rs11249886	ENSG00000253893.2	FAM85B	-5.76	1.53e-08	2.72e-06	-0.35	-0.26	Obesity-related traits;	chr8:8704511	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.802	rs11249887	ENSG00000253893.2	FAM85B	-5.76	1.53e-08	2.72e-06	-0.35	-0.26	Obesity-related traits;	chr8:8704674	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.755	rs12550057	ENSG00000253893.2	FAM85B	-5.76	1.53e-08	2.72e-06	-0.35	-0.26	Obesity-related traits;	chr8:8704758	chr8:8167819~8226614:-
THCA	cis	rs7760535	0.826	rs7753887	ENSG00000271789.1	RP5-1112D6.7	-5.76	1.53e-08	2.72e-06	-0.25	-0.26	Metabolic traits;	chr6:111533904	chr6:111297126~111298510:+
THCA	cis	rs9921338	0.961	rs7206749	ENSG00000262703.1	RP11-485G7.6	-5.76	1.53e-08	2.72e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11283065	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs55707838	ENSG00000262703.1	RP11-485G7.6	-5.76	1.53e-08	2.72e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11284218	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs56010295	ENSG00000262703.1	RP11-485G7.6	-5.76	1.53e-08	2.72e-06	-0.34	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11285050	chr16:11348143~11349321:-
THCA	cis	rs67478160	0.625	rs7141473	ENSG00000258735.1	LINC00637	5.76	1.53e-08	2.72e-06	0.31	0.26	Schizophrenia;	chr14:103849718	chr14:103847721~103858049:+
THCA	cis	rs934734	0.736	rs10186240	ENSG00000234255.7	AC012370.3	5.76	1.53e-08	2.72e-06	0.29	0.26	Rheumatoid arthritis;	chr2:65350517	chr2:65439888~65456571:-
THCA	cis	rs1707322	0.717	rs12023439	ENSG00000281133.1	AL355480.3	-5.76	1.53e-08	2.72e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45580892~45580996:-
THCA	cis	rs10411161	0.63	rs12462816	ENSG00000269483.1	AC006272.1	-5.76	1.53e-08	2.72e-06	-0.49	-0.26	Breast cancer;	chr19:51929462	chr19:51839924~51843324:-
THCA	cis	rs1499614	0.901	rs3936	ENSG00000230295.1	RP11-458F8.2	-5.76	1.54e-08	2.73e-06	-0.32	-0.26	Gout;	chr7:66661502	chr7:66880708~66882981:+
THCA	cis	rs1499614	1	rs1638731	ENSG00000230295.1	RP11-458F8.2	-5.76	1.54e-08	2.73e-06	-0.32	-0.26	Gout;	chr7:66679692	chr7:66880708~66882981:+
THCA	cis	rs1499614	1	rs1882655	ENSG00000230295.1	RP11-458F8.2	5.76	1.54e-08	2.73e-06	0.32	0.26	Gout;	chr7:66682070	chr7:66880708~66882981:+
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000230295.1	RP11-458F8.2	5.76	1.54e-08	2.73e-06	0.32	0.26	Gout;	chr7:66682162	chr7:66880708~66882981:+
THCA	cis	rs3820443	0.563	rs3738304	ENSG00000234020.1	CHIAP3	-5.76	1.54e-08	2.73e-06	-0.41	-0.26	Late-onset Alzheimer's disease;	chr1:111348319	chr1:111353275~111367409:-
THCA	cis	rs7615952	0.558	rs7641353	ENSG00000241278.1	ENPP7P4	5.76	1.54e-08	2.73e-06	0.33	0.26	Blood pressure (smoking interaction);	chr3:125621035	chr3:125848223~125909372:+
THCA	cis	rs7746199	0.736	rs17693963	ENSG00000280107.1	AL022393.9	-5.76	1.54e-08	2.73e-06	-0.47	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28170845~28172521:+
THCA	cis	rs2337406	1	rs78857163	ENSG00000211974.3	IGHV2-70	-5.76	1.54e-08	2.73e-06	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106707435	chr14:106723574~106724093:-
THCA	cis	rs4908768	0.501	rs6577492	ENSG00000232912.4	RP5-1115A15.1	5.76	1.54e-08	2.73e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8515005	chr1:8424645~8434838:+
THCA	cis	rs6545883	0.965	rs10186325	ENSG00000271889.1	RP11-493E12.1	5.76	1.54e-08	2.74e-06	0.25	0.26	Tuberculosis;	chr2:61530586	chr2:61151433~61162105:-
THCA	cis	rs2562456	0.834	rs13346641	ENSG00000268555.1	RP11-678G14.3	5.76	1.54e-08	2.74e-06	0.41	0.26	Pain;	chr19:21409481	chr19:21570822~21587322:-
THCA	cis	rs11096990	0.964	rs16995206	ENSG00000249207.1	RP11-360F5.1	5.76	1.54e-08	2.74e-06	0.33	0.26	Cognitive function;	chr4:39262887	chr4:39112677~39126818:-
THCA	cis	rs9859260	0.614	rs493661	ENSG00000273009.1	RP11-352G9.1	5.76	1.54e-08	2.74e-06	0.29	0.26	Mean corpuscular volume;	chr3:196059618	chr3:195913078~195913683:-
THCA	cis	rs7598759	0.617	rs6437017	ENSG00000181798.2	LINC00471	-5.76	1.55e-08	2.74e-06	-0.29	-0.26	Noise-induced hearing loss;	chr2:231462873	chr2:231508426~231514339:-
THCA	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-5.76	1.55e-08	2.74e-06	-0.48	-0.26	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
THCA	cis	rs7849973	0.667	rs12346016	ENSG00000224549.1	RP11-370B11.3	-5.76	1.55e-08	2.74e-06	-0.32	-0.26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22785142	chr9:22767175~22768316:+
THCA	cis	rs4805272	0.849	rs17591205	ENSG00000267799.1	MAN1A2P1	5.76	1.55e-08	2.74e-06	0.27	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830562	chr19:28790812~28792871:-
THCA	cis	rs4759375	1	rs4759375	ENSG00000256092.2	RP13-942N8.1	-5.76	1.55e-08	2.74e-06	-0.3	-0.26	HDL cholesterol;	chr12:123311691	chr12:123363868~123366113:+
THCA	cis	rs9649465	0.934	rs34030532	ENSG00000272686.1	RP11-390E23.6	5.76	1.55e-08	2.74e-06	0.17	0.26	Migraine;	chr7:123634938	chr7:123749068~123751166:+
THCA	cis	rs934734	0.789	rs10188563	ENSG00000237979.1	AC007389.1	5.76	1.55e-08	2.74e-06	0.3	0.26	Rheumatoid arthritis;	chr2:65342805	chr2:65500993~65502138:-
THCA	cis	rs897984	0.609	rs72800847	ENSG00000279196.1	RP11-1072A3.3	5.76	1.55e-08	2.75e-06	0.27	0.26	Dementia with Lewy bodies;	chr16:31011318	chr16:30984630~30988270:-
THCA	cis	rs5758659	0.967	rs5751250	ENSG00000270083.1	RP1-257I20.14	5.76	1.55e-08	2.75e-06	0.27	0.26	Cognitive function;	chr22:42243639	chr22:42089630~42090028:-
THCA	cis	rs60678552	0.748	rs9481617	ENSG00000233558.1	RP3-486I3.4	5.76	1.55e-08	2.75e-06	0.37	0.26	Heschl's gyrus morphology;	chr6:116268461	chr6:116258493~116259115:-
THCA	cis	rs12612619	0.732	rs11680096	ENSG00000229122.1	AGBL5-IT1	5.76	1.55e-08	2.75e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27050703	chr2:27061038~27061815:+
THCA	cis	rs6430585	0.528	rs6750549	ENSG00000231890.6	DARS-AS1	-5.76	1.55e-08	2.75e-06	-0.31	-0.26	Corneal structure;	chr2:135949910	chr2:135985176~136022593:+
THCA	cis	rs6860806	0.661	rs4705929	ENSG00000233006.5	AC034220.3	5.76	1.55e-08	2.75e-06	0.2	0.26	Breast cancer;	chr5:132248485	chr5:132311285~132369916:-
THCA	cis	rs17301013	0.507	rs1754352	ENSG00000227373.4	RP11-160H22.5	5.76	1.55e-08	2.76e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174835984	chr1:174115300~174160004:-
THCA	cis	rs11089937	0.597	rs5757007	ENSG00000211639.2	IGLV4-60	5.76	1.55e-08	2.76e-06	0.18	0.26	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22162199~22162681:+
THCA	cis	rs7688540	0.713	rs12511388	ENSG00000211553.1	AC253576.2	-5.76	1.56e-08	2.76e-06	-0.38	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:136461~136568:+
THCA	cis	rs62184315	0.536	rs62184265	ENSG00000273240.1	RP11-455J20.3	-5.76	1.56e-08	2.76e-06	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189756231	chr2:189763859~189764456:-
THCA	cis	rs6545883	0.965	rs778752	ENSG00000271889.1	RP11-493E12.1	5.76	1.56e-08	2.76e-06	0.25	0.26	Tuberculosis;	chr2:61549767	chr2:61151433~61162105:-
THCA	cis	rs9402743	0.781	rs9494326	ENSG00000231028.7	LINC00271	-5.76	1.56e-08	2.76e-06	-0.21	-0.26	Systemic lupus erythematosus;	chr6:135673400	chr6:135497801~135716055:+
THCA	cis	rs12497850	0.931	rs9311434	ENSG00000229759.1	MRPS18AP1	5.76	1.56e-08	2.76e-06	0.34	0.26	Parkinson's disease;	chr3:48846714	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.931	rs7623023	ENSG00000229759.1	MRPS18AP1	5.76	1.56e-08	2.76e-06	0.34	0.26	Parkinson's disease;	chr3:48876805	chr3:48256350~48256938:-
THCA	cis	rs12101261	0.744	rs2284718	ENSG00000259167.2	NMNAT1P1	5.76	1.56e-08	2.76e-06	0.37	0.26	Graves' disease;	chr14:80968545	chr14:81032529~81033404:+
THCA	cis	rs12101261	0.744	rs2284719	ENSG00000259167.2	NMNAT1P1	5.76	1.56e-08	2.76e-06	0.37	0.26	Graves' disease;	chr14:80969254	chr14:81032529~81033404:+
THCA	cis	rs12101261	0.744	rs72693057	ENSG00000259167.2	NMNAT1P1	5.76	1.56e-08	2.76e-06	0.37	0.26	Graves' disease;	chr14:80970149	chr14:81032529~81033404:+
THCA	cis	rs763512	0.504	rs11652399	ENSG00000276054.1	RP11-378E13.3	5.76	1.56e-08	2.76e-06	0.41	0.26	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37509679	chr17:37386886~37387926:+
THCA	cis	rs7646881	0.544	rs41272617	ENSG00000240207.5	RP11-379F4.4	-5.76	1.56e-08	2.76e-06	-0.36	-0.26	Tetralogy of Fallot;	chr3:158603103	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs73024790	ENSG00000240207.5	RP11-379F4.4	-5.76	1.56e-08	2.76e-06	-0.36	-0.26	Tetralogy of Fallot;	chr3:158606615	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs16829135	ENSG00000240207.5	RP11-379F4.4	-5.76	1.56e-08	2.76e-06	-0.36	-0.26	Tetralogy of Fallot;	chr3:158608049	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs13315529	ENSG00000240207.5	RP11-379F4.4	-5.76	1.56e-08	2.76e-06	-0.36	-0.26	Tetralogy of Fallot;	chr3:158610485	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.5	rs2082838	ENSG00000240207.5	RP11-379F4.4	5.76	1.56e-08	2.76e-06	0.36	0.26	Tetralogy of Fallot;	chr3:158588105	chr3:158732263~158784070:+
THCA	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-5.76	1.56e-08	2.76e-06	-0.19	-0.26	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.824	rs4788084	ENSG00000278665.1	RP11-666O2.4	5.76	1.56e-08	2.77e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28599241~28601881:-
THCA	cis	rs12549025	0.536	rs35742726	ENSG00000253390.1	CTC-756D1.2	-5.76	1.56e-08	2.77e-06	-0.43	-0.26	Reticulocyte fraction of red cells;	chr8:23509429	chr8:23458601~23484971:+
THCA	cis	rs7201929	1	rs8061877	ENSG00000251417.2	RP11-1348G14.4	5.76	1.56e-08	2.77e-06	0.28	0.26	QT interval;	chr16:28845498	chr16:28802743~28817828:+
THCA	cis	rs4948275	0.773	rs2787733	ENSG00000237233.2	TMEM26-AS1	-5.76	1.56e-08	2.77e-06	-0.33	-0.26	Night sleep phenotypes;	chr10:61488649	chr10:61452639~61481956:+
THCA	cis	rs7225151	0.634	rs76253980	ENSG00000234327.6	AC012146.7	-5.76	1.56e-08	2.77e-06	-0.28	-0.26	Alzheimer's disease (late onset);	chr17:5306215	chr17:5111468~5115004:+
THCA	cis	rs7615952	0.866	rs1976459	ENSG00000241288.6	RP11-379B18.5	-5.76	1.56e-08	2.77e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125928643	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.932	rs1976458	ENSG00000241288.6	RP11-379B18.5	-5.76	1.56e-08	2.77e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125928669	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.673	rs3811677	ENSG00000241288.6	RP11-379B18.5	-5.76	1.56e-08	2.77e-06	-0.32	-0.26	Blood pressure (smoking interaction);	chr3:125929237	chr3:125827238~125916384:-
THCA	cis	rs6840360	0.642	rs7698816	ENSG00000270265.1	RP11-731D1.4	-5.76	1.56e-08	2.77e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151333775~151353224:-
THCA	cis	rs728616	0.764	rs79529820	ENSG00000242600.5	MBL1P	5.75	1.57e-08	2.77e-06	0.33	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060773	chr10:79904898~79950336:+
THCA	cis	rs6902257	0.744	rs2496679	ENSG00000272129.1	RP11-250B2.6	5.75	1.57e-08	2.78e-06	0.69	0.26	Obesity-related traits;	chr6:80609375	chr6:80355424~80356859:+
THCA	cis	rs2735413	0.564	rs73574780	ENSG00000276007.1	RP11-358L22.3	5.75	1.57e-08	2.78e-06	0.27	0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78054207	chr16:78123243~78124332:+
THCA	cis	rs13256369	0.802	rs12153	ENSG00000253893.2	FAM85B	-5.75	1.57e-08	2.78e-06	-0.35	-0.26	Obesity-related traits;	chr8:8703399	chr8:8167819~8226614:-
THCA	cis	rs2911132	0.564	rs1057569	ENSG00000248734.2	CTD-2260A17.1	5.75	1.57e-08	2.78e-06	0.29	0.26	Urate levels (BMI interaction);	chr5:96773906	chr5:96784777~96785999:+
THCA	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	5.75	1.57e-08	2.78e-06	0.24	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
THCA	cis	rs3950186	1	rs1883324	ENSG00000215124.2	RP3-420J14.1	5.75	1.57e-08	2.78e-06	0.29	0.26	Anxiety and major depressive disorder;	chr6:11806200	chr6:11861626~11862970:-
THCA	cis	rs9880211	0.752	rs9881831	ENSG00000273486.1	RP11-731C17.2	5.75	1.57e-08	2.78e-06	0.28	0.26	Height;Body mass index;	chr3:136670876	chr3:136837338~136839021:-
THCA	cis	rs7824557	0.569	rs7816601	ENSG00000154316.13	TDH	-5.75	1.57e-08	2.78e-06	-0.19	-0.26	Retinal vascular caliber;	chr8:11348084	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.602	rs7816636	ENSG00000154316.13	TDH	-5.75	1.57e-08	2.78e-06	-0.19	-0.26	Retinal vascular caliber;	chr8:11348145	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.602	rs7828711	ENSG00000154316.13	TDH	-5.75	1.57e-08	2.78e-06	-0.19	-0.26	Retinal vascular caliber;	chr8:11348156	chr8:11339637~11368452:+
THCA	cis	rs1395	0.71	rs11682913	ENSG00000234072.1	AC074117.10	-5.75	1.57e-08	2.78e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27250781	chr2:27356246~27367622:+
THCA	cis	rs1395	0.744	rs11679220	ENSG00000234072.1	AC074117.10	-5.75	1.57e-08	2.78e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27253510	chr2:27356246~27367622:+
THCA	cis	rs1395	0.71	rs58965570	ENSG00000234072.1	AC074117.10	-5.75	1.57e-08	2.78e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27258592	chr2:27356246~27367622:+
THCA	cis	rs1395	0.71	rs72817533	ENSG00000234072.1	AC074117.10	-5.75	1.57e-08	2.78e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27259744	chr2:27356246~27367622:+
THCA	cis	rs4663866	0.901	rs4663298	ENSG00000186235.9	AC016757.3	5.75	1.57e-08	2.78e-06	0.56	0.26	Irritable bowel syndrome;	chr2:238231266	chr2:238224552~238231677:-
THCA	cis	rs2029362	0.836	rs10767651	ENSG00000245573.6	BDNF-AS	5.75	1.57e-08	2.78e-06	0.2	0.26	Total body bone mineral density;	chr11:27607060	chr11:27506838~27698174:+
THCA	cis	rs890448	0.796	rs293217	ENSG00000254531.1	FLJ20021	5.75	1.57e-08	2.79e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391036	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs293216	ENSG00000254531.1	FLJ20021	5.75	1.57e-08	2.79e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391116	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs833949	ENSG00000254531.1	FLJ20021	5.75	1.57e-08	2.79e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391363	chr4:101347780~101348883:+
THCA	cis	rs17301013	0.507	rs11802092	ENSG00000227373.4	RP11-160H22.5	5.75	1.57e-08	2.79e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174601773	chr1:174115300~174160004:-
THCA	cis	rs12101261	0.744	rs2268458	ENSG00000259167.2	NMNAT1P1	5.75	1.58e-08	2.79e-06	0.39	0.26	Graves' disease;	chr14:80996551	chr14:81032529~81033404:+
THCA	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	5.75	1.58e-08	2.8e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	5.75	1.58e-08	2.8e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	5.75	1.58e-08	2.8e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	5.75	1.58e-08	2.8e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	5.75	1.58e-08	2.8e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	5.75	1.58e-08	2.8e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
THCA	cis	rs260461	0.92	rs260455	ENSG00000268201.1	CTD-3138B18.6	-5.75	1.58e-08	2.8e-06	-0.35	-0.26	Attention deficit hyperactivity disorder;	chr19:58256126	chr19:58266635~58267685:+
THCA	cis	rs2732480	0.577	rs2634678	ENSG00000240399.1	RP1-228P16.1	5.75	1.58e-08	2.8e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.5	rs1552550	ENSG00000240399.1	RP1-228P16.1	5.75	1.58e-08	2.8e-06	0.26	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.5	rs2450991	ENSG00000240399.1	RP1-228P16.1	5.75	1.58e-08	2.8e-06	0.26	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48054813~48055591:-
THCA	cis	rs4664293	0.632	rs7588230	ENSG00000226266.5	AC009961.3	5.75	1.58e-08	2.8e-06	0.29	0.26	Monocyte percentage of white cells;	chr2:159797209	chr2:159670708~159712435:-
THCA	cis	rs7809950	0.817	rs2807	ENSG00000238832.1	snoU109	5.75	1.58e-08	2.8e-06	0.3	0.26	Coronary artery disease;	chr7:107620333	chr7:107603363~107603507:+
THCA	cis	rs11672691	0.67	rs4802119	ENSG00000270164.1	LINC01480	-5.75	1.58e-08	2.8e-06	-0.25	-0.26	Prostate cancer;	chr19:41484417	chr19:41535183~41536904:+
THCA	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-5.75	1.58e-08	2.8e-06	-0.32	-0.26	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
THCA	cis	rs11671005	0.735	rs11671591	ENSG00000269473.1	CTD-2619J13.19	-5.75	1.58e-08	2.8e-06	-0.29	-0.26	Mean platelet volume;	chr19:58406970	chr19:58440448~58445849:+
THCA	cis	rs9307551	0.817	rs12507160	ENSG00000250334.4	LINC00989	-5.75	1.58e-08	2.81e-06	-0.3	-0.26	Refractive error;	chr4:79573647	chr4:79492416~79576460:+
THCA	cis	rs10043228	1	rs57434520	ENSG00000248445.4	SEMA6A-AS1	-5.75	1.58e-08	2.81e-06	-0.28	-0.26	Asthma or chronic obstructive pulmonary disease;	chr5:116313068	chr5:116447547~116508276:+
THCA	cis	rs1865760	0.566	rs2032449	ENSG00000272462.2	U91328.19	-5.75	1.59e-08	2.81e-06	-0.21	-0.26	Height;	chr6:26026371	chr6:25992662~26001775:+
THCA	cis	rs9311474	0.596	rs524986	ENSG00000243224.1	RP5-1157M23.2	-5.75	1.59e-08	2.81e-06	-0.26	-0.26	Electroencephalogram traits;	chr3:52194480	chr3:52239258~52241097:+
THCA	cis	rs2115536	0.73	rs4573897	ENSG00000278600.1	RP11-81A1.6	-5.75	1.59e-08	2.81e-06	-0.17	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79894883	chr15:79920195~79922455:-
THCA	cis	rs13256369	0.802	rs1060107	ENSG00000253893.2	FAM85B	-5.75	1.59e-08	2.81e-06	-0.35	-0.26	Obesity-related traits;	chr8:8703889	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.802	rs4840350	ENSG00000253893.2	FAM85B	-5.75	1.59e-08	2.81e-06	-0.35	-0.26	Obesity-related traits;	chr8:8703932	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.802	rs1060106	ENSG00000253893.2	FAM85B	-5.75	1.59e-08	2.81e-06	-0.35	-0.26	Obesity-related traits;	chr8:8703942	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.802	rs11249883	ENSG00000253893.2	FAM85B	-5.75	1.59e-08	2.81e-06	-0.35	-0.26	Obesity-related traits;	chr8:8704027	chr8:8167819~8226614:-
THCA	cis	rs4803480	0.542	rs7255742	ENSG00000270164.1	LINC01480	-5.75	1.59e-08	2.81e-06	-0.25	-0.26	Schizophrenia;	chr19:41543459	chr19:41535183~41536904:+
THCA	cis	rs748404	0.666	rs55748552	ENSG00000249839.1	AC011330.5	-5.75	1.59e-08	2.81e-06	-0.36	-0.26	Lung cancer;	chr15:43359428	chr15:43663654~43684339:-
THCA	cis	rs890448	0.726	rs2583397	ENSG00000254531.1	FLJ20021	-5.75	1.59e-08	2.81e-06	-0.23	-0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101308565	chr4:101347780~101348883:+
THCA	cis	rs7809950	1	rs4730245	ENSG00000238832.1	snoU109	-5.75	1.59e-08	2.81e-06	-0.27	-0.26	Coronary artery disease;	chr7:107446849	chr7:107603363~107603507:+
THCA	cis	rs10043228	0.702	rs10054989	ENSG00000248445.4	SEMA6A-AS1	-5.75	1.59e-08	2.81e-06	-0.28	-0.26	Asthma or chronic obstructive pulmonary disease;	chr5:116327428	chr5:116447547~116508276:+
THCA	cis	rs11671005	0.735	rs3764529	ENSG00000269473.1	CTD-2619J13.19	5.75	1.59e-08	2.81e-06	0.29	0.26	Mean platelet volume;	chr19:58433722	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs1122955	ENSG00000269473.1	CTD-2619J13.19	5.75	1.59e-08	2.81e-06	0.29	0.26	Mean platelet volume;	chr19:58434836	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.735	rs11668814	ENSG00000269473.1	CTD-2619J13.19	5.75	1.59e-08	2.81e-06	0.29	0.26	Mean platelet volume;	chr19:58435466	chr19:58440448~58445849:+
THCA	cis	rs712039	0.652	rs853227	ENSG00000276054.1	RP11-378E13.3	5.75	1.59e-08	2.81e-06	0.39	0.26	Tuberculosis;	chr17:37437428	chr17:37386886~37387926:+
THCA	cis	rs13256369	0.802	rs12681326	ENSG00000253893.2	FAM85B	-5.75	1.59e-08	2.81e-06	-0.35	-0.26	Obesity-related traits;	chr8:8708879	chr8:8167819~8226614:-
THCA	cis	rs6840360	0.606	rs2709814	ENSG00000270265.1	RP11-731D1.4	-5.75	1.59e-08	2.81e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151333775~151353224:-
THCA	cis	rs712039	0.652	rs853224	ENSG00000276054.1	RP11-378E13.3	5.75	1.59e-08	2.81e-06	0.4	0.26	Tuberculosis;	chr17:37431229	chr17:37386886~37387926:+
THCA	cis	rs6928977	0.733	rs9321500	ENSG00000231028.7	LINC00271	5.75	1.59e-08	2.81e-06	0.2	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135320231	chr6:135497801~135716055:+
THCA	cis	rs801193	1	rs62466794	ENSG00000273142.1	RP11-458F8.4	-5.75	1.59e-08	2.82e-06	-0.2	-0.26	Aortic root size;	chr7:66726592	chr7:66902857~66906297:+
THCA	cis	rs4950322	0.748	rs17360812	ENSG00000278811.3	LINC00624	-5.75	1.59e-08	2.82e-06	-0.32	-0.26	Protein quantitative trait loci;	chr1:147355010	chr1:147258885~147517875:-
THCA	cis	rs8062405	0.824	rs28698667	ENSG00000278665.1	RP11-666O2.4	5.75	1.59e-08	2.82e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28599241~28601881:-
THCA	cis	rs6908034	0.66	rs6918235	ENSG00000237404.1	RP3-471C18.2	-5.75	1.59e-08	2.82e-06	-0.51	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19788196	chr6:19689825~19753113:-
THCA	cis	rs1707322	0.752	rs11488313	ENSG00000281133.1	AL355480.3	-5.75	1.59e-08	2.82e-06	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45580892~45580996:-
THCA	cis	rs9910055	0.762	rs7213436	ENSG00000267080.4	ASB16-AS1	5.75	1.59e-08	2.82e-06	0.23	0.26	Total body bone mineral density;	chr17:44174795	chr17:44175973~44186717:-
THCA	cis	rs9910055	0.718	rs2526022	ENSG00000267080.4	ASB16-AS1	-5.75	1.59e-08	2.82e-06	-0.23	-0.26	Total body bone mineral density;	chr17:44135848	chr17:44175973~44186717:-
THCA	cis	rs9910055	0.762	rs2526021	ENSG00000267080.4	ASB16-AS1	-5.75	1.59e-08	2.82e-06	-0.23	-0.26	Total body bone mineral density;	chr17:44135979	chr17:44175973~44186717:-
THCA	cis	rs1577330	0.561	rs62542709	ENSG00000254396.1	RP11-56F10.3	5.75	1.6e-08	2.83e-06	0.43	0.26	IgG glycosylation;	chr9:27079174	chr9:27102630~27104728:+
THCA	cis	rs6585424	1	rs12777867	ENSG00000225484.5	NUTM2B-AS1	-5.75	1.6e-08	2.83e-06	-0.41	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175774	chr10:79663088~79826594:-
THCA	cis	rs11723261	0.582	rs6599293	ENSG00000211553.1	AC253576.2	-5.75	1.6e-08	2.83e-06	-0.36	-0.26	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:136461~136568:+
THCA	cis	rs17772222	1	rs74071851	ENSG00000222990.1	RNU4-22P	5.75	1.6e-08	2.83e-06	0.35	0.26	Coronary artery calcification;	chr14:88415858	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.92	rs61975260	ENSG00000222990.1	RNU4-22P	5.75	1.6e-08	2.83e-06	0.35	0.26	Coronary artery calcification;	chr14:88429597	chr14:88513498~88513663:+
THCA	cis	rs9880211	0.66	rs34645606	ENSG00000273486.1	RP11-731C17.2	5.75	1.6e-08	2.83e-06	0.33	0.26	Height;Body mass index;	chr3:136811260	chr3:136837338~136839021:-
THCA	cis	rs7208859	0.673	rs28588622	ENSG00000263603.1	CTD-2349P21.5	-5.75	1.6e-08	2.83e-06	-0.47	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30729469~30731202:+
THCA	cis	rs9859260	0.71	rs34906439	ENSG00000273009.1	RP11-352G9.1	5.75	1.6e-08	2.83e-06	0.29	0.26	Mean corpuscular volume;	chr3:196052835	chr3:195913078~195913683:-
THCA	cis	rs4663866	0.901	rs71426513	ENSG00000186235.9	AC016757.3	5.75	1.6e-08	2.83e-06	0.59	0.26	Irritable bowel syndrome;	chr2:238289506	chr2:238224552~238231677:-
THCA	cis	rs6539288	0.674	rs989560	ENSG00000260329.1	RP11-412D9.4	-5.75	1.6e-08	2.83e-06	-0.23	-0.26	Total body bone mineral density;	chr12:106891973	chr12:106954029~106955497:-
THCA	cis	rs7615952	0.576	rs2276726	ENSG00000250012.1	RP11-124N2.1	-5.75	1.6e-08	2.83e-06	-0.24	-0.26	Blood pressure (smoking interaction);	chr3:126107444	chr3:126084220~126095349:+
THCA	cis	rs934734	0.789	rs11689314	ENSG00000237979.1	AC007389.1	-5.75	1.6e-08	2.84e-06	-0.3	-0.26	Rheumatoid arthritis;	chr2:65378274	chr2:65500993~65502138:-
THCA	cis	rs7809950	0.637	rs3801964	ENSG00000238832.1	snoU109	-5.75	1.6e-08	2.84e-06	-0.31	-0.26	Coronary artery disease;	chr7:107195797	chr7:107603363~107603507:+
THCA	cis	rs7404843	0.925	rs72774861	ENSG00000263335.1	AF001548.5	5.75	1.6e-08	2.84e-06	0.43	0.26	Testicular germ cell tumor;	chr16:15415777	chr16:15726674~15732993:+
THCA	cis	rs375066	0.623	rs10421861	ENSG00000267058.1	RP11-15A1.3	5.75	1.61e-08	2.84e-06	0.22	0.26	Breast cancer;	chr19:43846955	chr19:43891804~43901805:-
THCA	cis	rs7665090	0.728	rs227275	ENSG00000251288.2	RP11-10L12.2	5.75	1.61e-08	2.84e-06	0.33	0.26	Primary biliary cholangitis;	chr4:102672741	chr4:102751401~102752641:+
THCA	cis	rs1125355	0.69	rs62183662	ENSG00000251491.2	OR7E28P	-5.75	1.61e-08	2.84e-06	-0.39	-0.26	Alzheimer's disease in APOE e4+ carriers;	chr2:158785067	chr2:158862311~158863285:+
THCA	cis	rs1005277	0.579	rs176838	ENSG00000276805.1	RP11-291L22.6	-5.75	1.61e-08	2.84e-06	-0.28	-0.26	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38451030~38451785:+
THCA	cis	rs2179367	0.568	rs6932778	ENSG00000231760.4	RP11-350J20.5	5.75	1.61e-08	2.84e-06	0.4	0.26	Dupuytren's disease;	chr6:149328293	chr6:149796151~149826294:-
THCA	cis	rs9813712	0.78	rs7625942	ENSG00000249846.5	RP11-77P16.4	5.75	1.61e-08	2.84e-06	0.31	0.26	Response to amphetamines;	chr3:130232611	chr3:130112550~130120579:+
THCA	cis	rs2243480	1	rs67728539	ENSG00000228409.4	CCT6P1	5.75	1.61e-08	2.85e-06	0.29	0.26	Diabetic kidney disease;	chr7:65913137	chr7:65751142~65763354:+
THCA	cis	rs12497850	0.931	rs7431710	ENSG00000229759.1	MRPS18AP1	5.75	1.61e-08	2.85e-06	0.34	0.26	Parkinson's disease;	chr3:48898150	chr3:48256350~48256938:-
THCA	cis	rs12435908	1	rs17826724	ENSG00000276116.2	FUT8-AS1	-5.75	1.61e-08	2.85e-06	-0.4	-0.26	Ischemic stroke;	chr14:65601602	chr14:65411170~65412690:-
THCA	cis	rs1853665	1	rs6933094	ENSG00000218358.2	RAET1K	5.75	1.61e-08	2.85e-06	0.65	0.26	Radiation response;	chr6:149976467	chr6:149998019~150005157:-
THCA	cis	rs9990333	0.544	rs73208092	ENSG00000242086.7	LINC00969	5.75	1.61e-08	2.85e-06	0.26	0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195658062~195739964:+
THCA	cis	rs7131987	0.903	rs7970390	ENSG00000257176.2	RP11-996F15.2	-5.75	1.62e-08	2.86e-06	-0.25	-0.26	QT interval;	chr12:29245722	chr12:29280418~29317848:-
THCA	cis	rs935334	1	rs12147952	ENSG00000258454.1	RP11-361H10.3	-5.75	1.62e-08	2.86e-06	-0.37	-0.26	Blood pressure;	chr14:76158541	chr14:76235817~76263474:+
THCA	cis	rs2439831	0.867	rs12323999	ENSG00000275601.1	AC011330.13	-5.75	1.62e-08	2.86e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43390917	chr15:43642389~43643023:-
THCA	cis	rs2303319	0.504	rs12473088	ENSG00000227403.1	AC009299.3	5.75	1.62e-08	2.86e-06	0.54	0.26	Cognitive function;	chr2:161628563	chr2:161244739~161249050:+
THCA	cis	rs75422866	0.541	rs61918136	ENSG00000257433.4	RP1-197B17.3	5.75	1.62e-08	2.86e-06	0.4	0.26	Pneumonia;	chr12:47566798	chr12:47706085~47742294:+
THCA	cis	rs17772222	0.636	rs77528165	ENSG00000258789.1	RP11-507K2.3	-5.75	1.62e-08	2.86e-06	-0.27	-0.26	Coronary artery calcification;	chr14:88794249	chr14:88551597~88552493:+
THCA	cis	rs2029362	0.684	rs7103873	ENSG00000245573.6	BDNF-AS	5.75	1.62e-08	2.86e-06	0.2	0.26	Total body bone mineral density;	chr11:27678770	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.684	rs7104207	ENSG00000245573.6	BDNF-AS	5.75	1.62e-08	2.86e-06	0.2	0.26	Total body bone mineral density;	chr11:27679248	chr11:27506838~27698174:+
THCA	cis	rs7176527	0.747	rs28363946	ENSG00000188388.10	GOLGA6L3	5.75	1.62e-08	2.86e-06	0.46	0.26	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:85240472~85247170:+
THCA	cis	rs78487399	0.808	rs78886764	ENSG00000234936.1	AC010883.5	5.75	1.62e-08	2.86e-06	0.37	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43426360	chr2:43229573~43233394:+
THCA	cis	rs890448	0.796	rs4594730	ENSG00000254531.1	FLJ20021	5.75	1.62e-08	2.87e-06	0.23	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417303	chr4:101347780~101348883:+
THCA	cis	rs7560272	0.723	rs1320374	ENSG00000163016.8	ALMS1P	-5.75	1.62e-08	2.87e-06	-0.33	-0.26	Schizophrenia;	chr2:73601183	chr2:73644919~73685576:+
THCA	cis	rs12497850	0.931	rs6414613	ENSG00000229759.1	MRPS18AP1	5.75	1.62e-08	2.87e-06	0.34	0.26	Parkinson's disease;	chr3:48998452	chr3:48256350~48256938:-
THCA	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	5.75	1.62e-08	2.87e-06	0.23	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
THCA	cis	rs4948275	0.806	rs1953748	ENSG00000237233.2	TMEM26-AS1	-5.75	1.62e-08	2.87e-06	-0.33	-0.26	Night sleep phenotypes;	chr10:61494529	chr10:61452639~61481956:+
THCA	cis	rs3742264	1	rs9562633	ENSG00000235903.6	CPB2-AS1	-5.75	1.62e-08	2.87e-06	-0.34	-0.26	Blood protein levels;	chr13:46068624	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs9567610	ENSG00000235903.6	CPB2-AS1	-5.75	1.62e-08	2.87e-06	-0.34	-0.26	Blood protein levels;	chr13:46068632	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs9562636	ENSG00000235903.6	CPB2-AS1	-5.75	1.62e-08	2.87e-06	-0.34	-0.26	Blood protein levels;	chr13:46068889	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs3742264	ENSG00000235903.6	CPB2-AS1	-5.75	1.62e-08	2.87e-06	-0.34	-0.26	Blood protein levels;	chr13:46073959	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs1326399	ENSG00000235903.6	CPB2-AS1	-5.75	1.62e-08	2.87e-06	-0.34	-0.26	Blood protein levels;	chr13:46074472	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs9534310	ENSG00000235903.6	CPB2-AS1	-5.75	1.62e-08	2.87e-06	-0.34	-0.26	Blood protein levels;	chr13:46074840	chr13:46052806~46113332:+
THCA	cis	rs8042680	1	rs4544218	ENSG00000214432.8	AC068831.10	-5.75	1.62e-08	2.87e-06	-0.29	-0.26	Type 2 diabetes;	chr15:90977143	chr15:91022619~91036611:+
THCA	cis	rs853679	0.607	rs66868086	ENSG00000226314.6	ZNF192P1	-5.75	1.62e-08	2.87e-06	-0.57	-0.26	Depression;	chr6:27898124	chr6:28161781~28169594:+
THCA	cis	rs7826238	0.539	rs2945891	ENSG00000254153.1	CTA-398F10.2	-5.75	1.62e-08	2.87e-06	-0.27	-0.26	Systolic blood pressure;	chr8:8297953	chr8:8456909~8461337:-
THCA	cis	rs755249	0.532	rs2296173	ENSG00000228060.1	RP11-69E11.8	-5.75	1.62e-08	2.87e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39565160~39573203:+
THCA	cis	rs6430585	0.528	rs309119	ENSG00000231890.6	DARS-AS1	-5.75	1.62e-08	2.87e-06	-0.3	-0.26	Corneal structure;	chr2:135952802	chr2:135985176~136022593:+
THCA	cis	rs11266744	0.756	rs2856765	ENSG00000223552.1	RP11-24F11.2	5.75	1.63e-08	2.88e-06	0.23	0.26	Monocyte percentage of white cells;	chr3:46372459	chr3:46364955~46407059:-
THCA	cis	rs2136613	0.533	rs10995332	ENSG00000238280.1	RP11-436D10.3	-5.75	1.63e-08	2.88e-06	-0.3	-0.26	Selective IgA deficiency;	chr10:62857905	chr10:62793562~62805887:-
THCA	cis	rs7520050	0.667	rs11211176	ENSG00000234329.1	RP11-767N6.2	-5.75	1.63e-08	2.88e-06	-0.23	-0.26	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45651039~45651826:-
THCA	cis	rs7083	1	rs535602	ENSG00000254851.1	RP11-109L13.1	5.75	1.63e-08	2.88e-06	0.35	0.26	Blood protein levels;	chr11:117237059	chr11:117135528~117138582:+
THCA	cis	rs3758785	0.512	rs79702466	ENSG00000255893.1	RP11-685N10.1	-5.75	1.63e-08	2.88e-06	-0.32	-0.26	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94368030	chr11:94472908~94473570:-
THCA	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-5.75	1.63e-08	2.88e-06	-0.24	-0.26	Height;	chr2:46635327	chr2:46668870~46670778:+
THCA	cis	rs8005677	0.649	rs11629120	ENSG00000279656.1	RP11-298I3.6	-5.75	1.63e-08	2.88e-06	-0.33	-0.26	Cognitive ability (multi-trait analysis);	chr14:22989248	chr14:23023083~23024217:-
THCA	cis	rs7702057	0.53	rs1567330	ENSG00000271918.1	CTD-2287O16.5	5.75	1.63e-08	2.89e-06	0.28	0.26	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116083807~116085416:-
THCA	cis	rs11651753	0.636	rs4793737	ENSG00000264920.1	RP11-6N17.4	-5.75	1.64e-08	2.89e-06	-0.23	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964891	chr17:47891255~47895812:-
THCA	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	5.75	1.64e-08	2.89e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	5.75	1.64e-08	2.89e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	5.75	1.64e-08	2.89e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	5.75	1.64e-08	2.89e-06	0.31	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
THCA	cis	rs2243480	0.908	rs313822	ENSG00000232546.1	RP11-458F8.1	-5.75	1.64e-08	2.9e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66108952	chr7:66848496~66858136:+
THCA	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	5.75	1.64e-08	2.9e-06	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
THCA	cis	rs17122021	0.625	rs3759001	ENSG00000280032.1	RP11-832A4.7	5.75	1.64e-08	2.9e-06	0.27	0.26	Pain;	chr11:118265030	chr11:118264593~118266817:+
THCA	cis	rs2348418	0.733	rs11049508	ENSG00000247934.4	RP11-967K21.1	5.75	1.64e-08	2.9e-06	0.22	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28289633	chr12:28163298~28190738:-
THCA	cis	rs4780355	1	rs4780355	ENSG00000262703.1	RP11-485G7.6	5.75	1.64e-08	2.9e-06	0.3	0.26	Crohn's disease and psoriasis;	chr16:11254001	chr16:11348143~11349321:-
THCA	cis	rs2303319	0.504	rs62188147	ENSG00000227403.1	AC009299.3	5.75	1.64e-08	2.9e-06	0.57	0.26	Cognitive function;	chr2:161430041	chr2:161244739~161249050:+
THCA	cis	rs9649465	0.934	rs7799354	ENSG00000272686.1	RP11-390E23.6	5.75	1.65e-08	2.91e-06	0.17	0.26	Migraine;	chr7:123629765	chr7:123749068~123751166:+
THCA	cis	rs4639966	0.684	rs487177	ENSG00000255239.1	AP002954.6	-5.75	1.65e-08	2.91e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr11:118786588	chr11:118688039~118690600:-
THCA	cis	rs2732480	0.557	rs2732441	ENSG00000240399.1	RP1-228P16.1	5.75	1.65e-08	2.91e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.577	rs2732448	ENSG00000240399.1	RP1-228P16.1	5.75	1.65e-08	2.91e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.577	rs2732466	ENSG00000240399.1	RP1-228P16.1	5.75	1.65e-08	2.91e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.557	rs2634682	ENSG00000240399.1	RP1-228P16.1	5.75	1.65e-08	2.91e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48054813~48055591:-
THCA	cis	rs712039	0.652	rs853232	ENSG00000276054.1	RP11-378E13.3	5.75	1.65e-08	2.91e-06	0.39	0.26	Tuberculosis;	chr17:37481076	chr17:37386886~37387926:+
THCA	cis	rs1552244	1	rs9849434	ENSG00000232901.1	CYCSP10	-5.75	1.65e-08	2.91e-06	-0.33	-0.26	Alzheimer's disease;	chr3:10092026	chr3:10000647~10000940:-
THCA	cis	rs1395	0.778	rs34618115	ENSG00000234072.1	AC074117.10	-5.75	1.65e-08	2.91e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27195421	chr2:27356246~27367622:+
THCA	cis	rs1395	0.778	rs2580761	ENSG00000234072.1	AC074117.10	-5.75	1.65e-08	2.91e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27203494	chr2:27356246~27367622:+
THCA	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	5.75	1.65e-08	2.91e-06	0.32	0.26	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
THCA	cis	rs2742234	1	rs1864395	ENSG00000273008.1	RP11-351D16.3	-5.75	1.65e-08	2.91e-06	-0.22	-0.26	Hirschsprung disease;	chr10:43160249	chr10:43136824~43138334:-
THCA	cis	rs2117029	1	rs2293445	ENSG00000258017.1	RP11-386G11.10	-5.75	1.65e-08	2.91e-06	-0.34	-0.26	Intelligence (multi-trait analysis);	chr12:49005079	chr12:49127782~49147869:+
THCA	cis	rs11148252	0.514	rs2296347	ENSG00000235660.1	LINC00345	5.75	1.65e-08	2.92e-06	0.32	0.26	Lewy body disease;	chr13:52154288	chr13:52484161~52484680:-
THCA	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-5.75	1.65e-08	2.92e-06	-0.31	-0.26	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
THCA	cis	rs9402743	0.673	rs9483860	ENSG00000231028.7	LINC00271	5.75	1.65e-08	2.92e-06	0.21	0.26	Systemic lupus erythematosus;	chr6:135646872	chr6:135497801~135716055:+
THCA	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	5.75	1.65e-08	2.92e-06	0.32	0.26	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
THCA	cis	rs10129255	0.957	rs10142918	ENSG00000211974.3	IGHV2-70	5.75	1.65e-08	2.92e-06	0.2	0.26	Kawasaki disease;	chr14:106782206	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.957	rs10142859	ENSG00000211974.3	IGHV2-70	5.75	1.65e-08	2.92e-06	0.2	0.26	Kawasaki disease;	chr14:106782238	chr14:106723574~106724093:-
THCA	cis	rs874628	0.851	rs55973594	ENSG00000268650.3	AC068499.10	5.74	1.66e-08	2.92e-06	0.28	0.26	Multiple sclerosis;	chr19:18219858	chr19:18204730~18220480:+
THCA	cis	rs1865760	0.566	rs3752420	ENSG00000272462.2	U91328.19	-5.74	1.66e-08	2.92e-06	-0.21	-0.26	Height;	chr6:26026907	chr6:25992662~26001775:+
THCA	cis	rs74233809	0.901	rs77335224	ENSG00000213277.3	MARCKSL1P1	5.74	1.66e-08	2.93e-06	0.44	0.26	Birth weight;	chr10:102876519	chr10:103175554~103176094:+
THCA	cis	rs6565180	1	rs12930787	ENSG00000273724.1	RP11-347C12.12	-5.74	1.66e-08	2.93e-06	-0.27	-0.26	Tonsillectomy;	chr16:30369982	chr16:30336400~30343336:+
THCA	cis	rs2337406	0.81	rs7161739	ENSG00000211974.3	IGHV2-70	-5.74	1.66e-08	2.93e-06	-0.25	-0.26	Alzheimer's disease (late onset);	chr14:106776118	chr14:106723574~106724093:-
THCA	cis	rs12497850	0.931	rs9846123	ENSG00000229759.1	MRPS18AP1	-5.74	1.66e-08	2.93e-06	-0.34	-0.26	Parkinson's disease;	chr3:49050679	chr3:48256350~48256938:-
THCA	cis	rs7246657	0.722	rs12979640	ENSG00000267422.1	CTD-2554C21.1	5.74	1.66e-08	2.93e-06	0.29	0.26	Coronary artery calcification;	chr19:37688255	chr19:37779686~37792865:+
THCA	cis	rs9813712	0.672	rs73210789	ENSG00000228252.7	COL6A4P2	5.74	1.66e-08	2.93e-06	0.3	0.26	Response to amphetamines;	chr3:130243418	chr3:130212823~130273806:+
THCA	cis	rs8027521	0.871	rs7169118	ENSG00000280362.1	RP11-643A5.3	5.74	1.66e-08	2.93e-06	0.31	0.26	Circulating chemerin levels;	chr15:53969733	chr15:53910769~53914712:+
THCA	cis	rs9467773	1	rs1078679	ENSG00000124549.13	BTN2A3P	5.74	1.66e-08	2.93e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6932156	ENSG00000124549.13	BTN2A3P	5.74	1.66e-08	2.93e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6924838	ENSG00000124549.13	BTN2A3P	5.74	1.66e-08	2.93e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs6925895	ENSG00000124549.13	BTN2A3P	5.74	1.66e-08	2.93e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26421391~26432383:+
THCA	cis	rs755249	0.588	rs2275767	ENSG00000182109.6	RP11-69E11.4	-5.74	1.66e-08	2.93e-06	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39522280~39546187:-
THCA	cis	rs8014252	0.667	rs12588623	ENSG00000259158.2	ADAM20P1	-5.74	1.66e-08	2.94e-06	-0.28	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70351197	chr14:70468881~70483756:-
THCA	cis	rs9381040	0.655	rs6939989	ENSG00000161912.16	ADCY10P1	5.74	1.67e-08	2.94e-06	0.17	0.26	Alzheimer's disease (late onset);	chr6:41052466	chr6:41101022~41140835:+
THCA	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-5.74	1.67e-08	2.94e-06	-0.41	-0.26	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
THCA	cis	rs375066	0.623	rs239948	ENSG00000267058.1	RP11-15A1.3	-5.74	1.67e-08	2.95e-06	-0.22	-0.26	Breast cancer;	chr19:43852735	chr19:43891804~43901805:-
THCA	cis	rs2243480	0.708	rs781141	ENSG00000228409.4	CCT6P1	5.74	1.67e-08	2.95e-06	0.29	0.26	Diabetic kidney disease;	chr7:65973566	chr7:65751142~65763354:+
THCA	cis	rs6740322	0.748	rs6720087	ENSG00000234936.1	AC010883.5	-5.74	1.67e-08	2.95e-06	-0.27	-0.26	Coronary artery disease;	chr2:43241606	chr2:43229573~43233394:+
THCA	cis	rs12908161	0.959	rs17534709	ENSG00000259295.5	CSPG4P12	5.74	1.67e-08	2.95e-06	0.4	0.26	Schizophrenia;	chr15:84771166	chr15:85191438~85213905:+
THCA	cis	rs5751614	0.537	rs7292656	ENSG00000230701.2	FBXW4P1	5.74	1.67e-08	2.95e-06	0.28	0.26	Height;	chr22:23287415	chr22:23262767~23265005:+
THCA	cis	rs2129782	1	rs73291181	ENSG00000253553.4	RP11-586K2.1	5.74	1.67e-08	2.95e-06	0.43	0.26	Electrodermal activity;	chr8:88435847	chr8:88326836~88737134:+
THCA	cis	rs9890032	1	rs3764419	ENSG00000263531.1	RP13-753N3.1	5.74	1.67e-08	2.95e-06	0.33	0.26	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30863921~30864940:-
THCA	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	5.74	1.67e-08	2.95e-06	0.4	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
THCA	cis	rs7727544	0.582	rs4361509	ENSG00000233006.5	AC034220.3	-5.74	1.67e-08	2.95e-06	-0.19	-0.26	Blood metabolite levels;	chr5:132201060	chr5:132311285~132369916:-
THCA	cis	rs9652601	0.748	rs35294447	ENSG00000274038.1	RP11-66H6.4	-5.74	1.67e-08	2.95e-06	-0.33	-0.26	Systemic lupus erythematosus;	chr16:11146997	chr16:11056556~11057034:+
THCA	cis	rs7727544	0.625	rs4705916	ENSG00000233006.5	AC034220.3	5.74	1.67e-08	2.95e-06	0.2	0.26	Blood metabolite levels;	chr5:132071800	chr5:132311285~132369916:-
THCA	cis	rs442309	0.846	rs224072	ENSG00000238280.1	RP11-436D10.3	-5.74	1.67e-08	2.95e-06	-0.31	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62748961	chr10:62793562~62805887:-
THCA	cis	rs9921338	0.961	rs8048768	ENSG00000262636.1	CTD-3088G3.4	-5.74	1.67e-08	2.96e-06	-0.37	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11302983	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs11074958	ENSG00000262636.1	CTD-3088G3.4	-5.74	1.67e-08	2.96e-06	-0.37	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11303222	chr16:11380859~11381118:-
THCA	cis	rs11671005	0.735	rs34188294	ENSG00000269473.1	CTD-2619J13.19	5.74	1.68e-08	2.96e-06	0.3	0.26	Mean platelet volume;	chr19:58408190	chr19:58440448~58445849:+
THCA	cis	rs7824557	0.602	rs7817658	ENSG00000154316.13	TDH	-5.74	1.68e-08	2.96e-06	-0.19	-0.26	Retinal vascular caliber;	chr8:11349034	chr8:11339637~11368452:+
THCA	cis	rs4713118	0.513	rs149941	ENSG00000220721.1	OR1F12	5.74	1.68e-08	2.96e-06	0.31	0.26	Parkinson's disease;	chr6:28033255	chr6:28073316~28074233:+
THCA	cis	rs667920	0.512	rs13069695	ENSG00000239213.4	NCK1-AS1	-5.74	1.68e-08	2.96e-06	-0.37	-0.26	Coronary artery disease;	chr3:136572720	chr3:136841726~136862054:-
THCA	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	5.74	1.68e-08	2.96e-06	0.31	0.26	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
THCA	cis	rs7615952	0.688	rs9754526	ENSG00000241288.6	RP11-379B18.5	-5.74	1.68e-08	2.96e-06	-0.3	-0.26	Blood pressure (smoking interaction);	chr3:125824023	chr3:125827238~125916384:-
THCA	cis	rs6674176	0.597	rs4031031	ENSG00000237950.1	RP11-7O11.3	5.74	1.68e-08	2.96e-06	0.22	0.26	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927861	chr1:43944370~43946551:-
THCA	cis	rs728616	0.867	rs77376252	ENSG00000225484.5	NUTM2B-AS1	-5.74	1.68e-08	2.96e-06	-0.51	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80049626	chr10:79663088~79826594:-
THCA	cis	rs7129556	0.815	rs11607715	ENSG00000254691.1	RP11-91P24.5	5.74	1.68e-08	2.96e-06	0.35	0.26	Weight loss (gastric bypass surgery);	chr11:77527814	chr11:77850604~77851511:+
THCA	cis	rs79040073	0.637	rs73392288	ENSG00000259531.2	RP11-295H24.3	5.74	1.68e-08	2.96e-06	0.37	0.26	Lung cancer in ever smokers;	chr15:49250842	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs17396747	ENSG00000259531.2	RP11-295H24.3	5.74	1.68e-08	2.96e-06	0.37	0.26	Lung cancer in ever smokers;	chr15:49269330	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs75612464	ENSG00000259531.2	RP11-295H24.3	5.74	1.68e-08	2.96e-06	0.37	0.26	Lung cancer in ever smokers;	chr15:49270727	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73394324	ENSG00000259531.2	RP11-295H24.3	5.74	1.68e-08	2.96e-06	0.37	0.26	Lung cancer in ever smokers;	chr15:49274894	chr15:49365124~49366685:-
THCA	cis	rs875971	1	rs2420820	ENSG00000223473.2	GS1-124K5.3	-5.74	1.68e-08	2.96e-06	-0.17	-0.26	Aortic root size;	chr7:66626920	chr7:66491049~66493566:-
THCA	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-5.74	1.68e-08	2.96e-06	-0.29	-0.26	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
THCA	cis	rs78487399	0.731	rs75050485	ENSG00000234936.1	AC010883.5	5.74	1.68e-08	2.96e-06	0.37	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43551331	chr2:43229573~43233394:+
THCA	cis	rs2839186	0.934	rs17182538	ENSG00000239415.1	AP001469.9	5.74	1.68e-08	2.96e-06	0.26	0.26	Testicular germ cell tumor;	chr21:46285759	chr21:46251549~46254133:-
THCA	cis	rs6840360	0.642	rs11099819	ENSG00000270265.1	RP11-731D1.4	-5.74	1.68e-08	2.97e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151333775~151353224:-
THCA	cis	rs11671005	0.735	rs45617039	ENSG00000269473.1	CTD-2619J13.19	5.74	1.68e-08	2.97e-06	0.29	0.26	Mean platelet volume;	chr19:58439729	chr19:58440448~58445849:+
THCA	cis	rs12612619	0.732	rs13021112	ENSG00000229122.1	AGBL5-IT1	5.74	1.68e-08	2.97e-06	0.18	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27036926	chr2:27061038~27061815:+
THCA	cis	rs2145598	0.874	rs58231973	ENSG00000279636.2	LINC00216	-5.74	1.68e-08	2.97e-06	-0.25	-0.26	Coronary artery disease;	chr14:58330929	chr14:58288033~58289158:+
THCA	cis	rs2993535	1	rs1586660	ENSG00000233626.2	RP11-565J7.1	5.74	1.68e-08	2.97e-06	0.74	0.26	Hip circumference adjusted for BMI;	chr1:212093189	chr1:211936249~211936634:+
THCA	cis	rs8014252	0.667	rs10133282	ENSG00000259158.2	ADAM20P1	-5.74	1.68e-08	2.97e-06	-0.28	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70361182	chr14:70468881~70483756:-
THCA	cis	rs7809950	0.817	rs62483725	ENSG00000238832.1	snoU109	-5.74	1.69e-08	2.97e-06	-0.29	-0.26	Coronary artery disease;	chr7:107561130	chr7:107603363~107603507:+
THCA	cis	rs74400468	0.529	rs11239742	ENSG00000272319.1	AL022345.7	5.74	1.69e-08	2.97e-06	0.55	0.26	Cannabis dependence symptom count;	chr10:42710205	chr10:42579724~42582772:+
THCA	cis	rs4227	0.565	rs2270341	ENSG00000233223.2	AC113189.5	5.74	1.69e-08	2.98e-06	0.21	0.26	IgA nephropathy;	chr17:7577229	chr17:7581964~7584072:-
THCA	cis	rs7712401	0.791	rs1531340	ENSG00000249996.1	RP11-359P5.1	5.74	1.69e-08	2.98e-06	0.24	0.26	Mean platelet volume;	chr5:122772322	chr5:123036271~123054667:+
THCA	cis	rs875971	0.545	rs73378304	ENSG00000228409.4	CCT6P1	-5.74	1.69e-08	2.98e-06	-0.21	-0.26	Aortic root size;	chr7:66175760	chr7:65751142~65763354:+
THCA	cis	rs12101261	0.744	rs724169	ENSG00000259167.2	NMNAT1P1	5.74	1.69e-08	2.98e-06	0.36	0.26	Graves' disease;	chr14:80991512	chr14:81032529~81033404:+
THCA	cis	rs9990333	1	rs9990333	ENSG00000231464.1	AC024937.4	-5.74	1.69e-08	2.98e-06	-0.31	-0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195996738~195998233:+
THCA	cis	rs853679	0.527	rs213228	ENSG00000219392.1	RP1-265C24.5	-5.74	1.69e-08	2.98e-06	-0.28	-0.26	Depression;	chr6:28363475	chr6:28115628~28116551:+
THCA	cis	rs7849973	0.864	rs4571809	ENSG00000224549.1	RP11-370B11.3	-5.74	1.69e-08	2.98e-06	-0.3	-0.26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22819065	chr9:22767175~22768316:+
THCA	cis	rs11089937	0.597	rs6001072	ENSG00000211639.2	IGLV4-60	5.74	1.69e-08	2.99e-06	0.18	0.26	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22162199~22162681:+
THCA	cis	rs150992	0.571	rs34488	ENSG00000248489.1	CTD-2007H13.3	5.74	1.7e-08	2.99e-06	0.27	0.26	Body mass index;	chr5:98977773	chr5:98929171~98995013:+
THCA	cis	rs150992	0.536	rs179053	ENSG00000248489.1	CTD-2007H13.3	5.74	1.7e-08	2.99e-06	0.27	0.26	Body mass index;	chr5:98979890	chr5:98929171~98995013:+
THCA	cis	rs875971	1	rs697970	ENSG00000223473.2	GS1-124K5.3	-5.74	1.7e-08	2.99e-06	-0.18	-0.26	Aortic root size;	chr7:66095065	chr7:66491049~66493566:-
THCA	cis	rs748404	0.666	rs7180812	ENSG00000249839.1	AC011330.5	-5.74	1.7e-08	2.99e-06	-0.36	-0.26	Lung cancer;	chr15:43403033	chr15:43663654~43684339:-
THCA	cis	rs7267979	0.528	rs2387976	ENSG00000125804.12	FAM182A	5.74	1.7e-08	2.99e-06	0.33	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26054655~26086917:+
THCA	cis	rs6565180	0.962	rs6565182	ENSG00000273724.1	RP11-347C12.12	-5.74	1.7e-08	2.99e-06	-0.28	-0.26	Tonsillectomy;	chr16:30363060	chr16:30336400~30343336:+
THCA	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-5.74	1.7e-08	2.99e-06	-0.3	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
THCA	cis	rs4650994	1	rs4511075	ENSG00000273384.1	RP5-1098D14.1	5.74	1.7e-08	2.99e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178549501	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs12138541	ENSG00000273384.1	RP5-1098D14.1	5.74	1.7e-08	2.99e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178549572	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs12138561	ENSG00000273384.1	RP5-1098D14.1	5.74	1.7e-08	2.99e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178549649	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs17276527	ENSG00000273384.1	RP5-1098D14.1	5.74	1.7e-08	2.99e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178551545	chr1:178651706~178652282:+
THCA	cis	rs2732480	0.538	rs1387260	ENSG00000240399.1	RP1-228P16.1	5.74	1.7e-08	2.99e-06	0.26	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48054813~48055591:-
THCA	cis	rs801193	0.935	rs3800820	ENSG00000273142.1	RP11-458F8.4	5.74	1.7e-08	3e-06	0.2	0.26	Aortic root size;	chr7:66682191	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs2003301	ENSG00000273142.1	RP11-458F8.4	5.74	1.7e-08	3e-06	0.2	0.26	Aortic root size;	chr7:66682669	chr7:66902857~66906297:+
THCA	cis	rs9380516	0.686	rs3800374	ENSG00000228559.1	RP3-340B19.3	-5.74	1.7e-08	3e-06	-0.38	-0.26	Hepatitis C induced liver fibrosis;	chr6:35569629	chr6:35544632~35545669:+
THCA	cis	rs75920871	0.589	rs4938342	ENSG00000254851.1	RP11-109L13.1	-5.74	1.7e-08	3e-06	-0.48	-0.26	Subjective well-being;	chr11:117132704	chr11:117135528~117138582:+
THCA	cis	rs801193	1	rs4717310	ENSG00000273142.1	RP11-458F8.4	-5.74	1.7e-08	3e-06	-0.2	-0.26	Aortic root size;	chr7:66696020	chr7:66902857~66906297:+
THCA	cis	rs17772222	0.636	rs10484010	ENSG00000258983.2	RP11-507K2.2	5.74	1.7e-08	3e-06	0.33	0.26	Coronary artery calcification;	chr14:88831944	chr14:88499334~88515502:+
THCA	cis	rs16949788	1	rs75532475	ENSG00000261351.2	CTD-3185P2.1	-5.74	1.7e-08	3e-06	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66540128	chr15:66488658~66492109:-
THCA	cis	rs5758659	1	rs134873	ENSG00000270083.1	RP1-257I20.14	5.74	1.7e-08	3e-06	0.27	0.26	Cognitive function;	chr22:42261560	chr22:42089630~42090028:-
THCA	cis	rs7246657	0.663	rs4803287	ENSG00000276846.1	CTD-3220F14.3	5.74	1.7e-08	3e-06	0.25	0.26	Coronary artery calcification;	chr19:37588534	chr19:37314868~37315620:-
THCA	cis	rs9307551	0.948	rs4975056	ENSG00000250334.4	LINC00989	-5.74	1.7e-08	3e-06	-0.33	-0.26	Refractive error;	chr4:79563716	chr4:79492416~79576460:+
THCA	cis	rs55665837	0.524	rs2882128	ENSG00000251991.1	RNU7-49P	5.74	1.7e-08	3e-06	0.3	0.26	Vitamin D levels;	chr11:14393088	chr11:14478892~14478953:+
THCA	cis	rs78487399	0.71	rs75330033	ENSG00000234936.1	AC010883.5	5.74	1.71e-08	3.01e-06	0.39	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43470584	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs80147536	ENSG00000234936.1	AC010883.5	5.74	1.71e-08	3.01e-06	0.39	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43470889	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs75135247	ENSG00000234936.1	AC010883.5	5.74	1.71e-08	3.01e-06	0.39	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43472260	chr2:43229573~43233394:+
THCA	cis	rs7615952	0.641	rs4490307	ENSG00000250012.1	RP11-124N2.1	-5.74	1.71e-08	3.01e-06	-0.24	-0.26	Blood pressure (smoking interaction);	chr3:125993833	chr3:126084220~126095349:+
THCA	cis	rs16976116	0.901	rs9920220	ENSG00000279145.1	RP11-547D13.1	5.74	1.71e-08	3.01e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55211784	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.803	rs9920136	ENSG00000279145.1	RP11-547D13.1	5.74	1.71e-08	3.01e-06	0.26	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55211904	chr15:55171972~55178175:-
THCA	cis	rs228614	0.502	rs78573682	ENSG00000246560.2	RP11-10L12.4	-5.74	1.71e-08	3.01e-06	-0.35	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102502510	chr4:102828055~102844075:+
THCA	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	5.74	1.71e-08	3.01e-06	0.35	0.26	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
THCA	cis	rs2243480	1	rs316329	ENSG00000232546.1	RP11-458F8.1	-5.74	1.71e-08	3.01e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66143429	chr7:66848496~66858136:+
THCA	cis	rs17214007	0.735	rs2075513	ENSG00000263335.1	AF001548.5	-5.74	1.71e-08	3.01e-06	-0.35	-0.26	Cognitive function;	chr16:15782614	chr16:15726674~15732993:+
THCA	cis	rs10029851	0.627	rs17584324	ENSG00000234492.4	RPL34-AS1	5.74	1.71e-08	3.01e-06	0.31	0.26	Amyotrophic lateral sclerosis (sporadic);	chr4:108608230	chr4:108538190~108620460:-
THCA	cis	rs172166	0.694	rs188105	ENSG00000226314.6	ZNF192P1	-5.74	1.71e-08	3.01e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28103615	chr6:28161781~28169594:+
THCA	cis	rs62184315	1	rs62184315	ENSG00000273240.1	RP11-455J20.3	-5.74	1.71e-08	3.02e-06	-0.32	-0.26	Alcohol dependence (age at onset);	chr2:189907219	chr2:189763859~189764456:-
THCA	cis	rs17508449	0.821	rs1419231	ENSG00000232450.1	RP4-730K3.3	-5.74	1.71e-08	3.02e-06	-0.41	-0.26	Leprosy;	chr1:113583596	chr1:113698884~113699631:-
THCA	cis	rs853679	0.556	rs45509595	ENSG00000226314.6	ZNF192P1	-5.74	1.71e-08	3.02e-06	-0.57	-0.26	Depression;	chr6:27873148	chr6:28161781~28169594:+
THCA	cis	rs6840360	0.642	rs11729923	ENSG00000270265.1	RP11-731D1.4	-5.74	1.72e-08	3.02e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151333775~151353224:-
THCA	cis	rs11976180	1	rs2951308	ENSG00000273234.1	OR2A13P	5.74	1.72e-08	3.02e-06	0.28	0.26	Obesity-related traits;	chr7:144070056	chr7:144142009~144142938:+
THCA	cis	rs3847687	0.507	rs10773838	ENSG00000279128.1	RP11-76C10.4	5.74	1.72e-08	3.02e-06	0.29	0.26	Longevity;	chr12:131039287	chr12:131022769~131024741:-
THCA	cis	rs7586673	0.866	rs747003	ENSG00000235724.7	AC009299.2	5.74	1.72e-08	3.03e-06	0.28	0.26	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161222785~161308303:-
THCA	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	5.74	1.72e-08	3.03e-06	0.32	0.26	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
THCA	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	5.74	1.72e-08	3.03e-06	0.32	0.26	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
THCA	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-5.74	1.72e-08	3.03e-06	-0.2	-0.26	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
THCA	cis	rs801193	0.935	rs2659899	ENSG00000273142.1	RP11-458F8.4	-5.74	1.72e-08	3.03e-06	-0.2	-0.26	Aortic root size;	chr7:66721734	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs1553609	ENSG00000273142.1	RP11-458F8.4	-5.74	1.72e-08	3.03e-06	-0.2	-0.26	Aortic root size;	chr7:66732152	chr7:66902857~66906297:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000273142.1	RP11-458F8.4	-5.74	1.72e-08	3.03e-06	-0.2	-0.26	Aortic root size;	chr7:66749023	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs2659889	ENSG00000273142.1	RP11-458F8.4	-5.74	1.72e-08	3.03e-06	-0.2	-0.26	Aortic root size;	chr7:66752125	chr7:66902857~66906297:+
THCA	cis	rs686320	0.748	rs481335	ENSG00000245532.5	NEAT1	5.74	1.72e-08	3.03e-06	0.25	0.26	Hip circumference adjusted for BMI;	chr11:65439998	chr11:65422774~65445540:+
THCA	cis	rs6545883	0.895	rs6545871	ENSG00000271889.1	RP11-493E12.1	5.74	1.72e-08	3.04e-06	0.25	0.26	Tuberculosis;	chr2:61465068	chr2:61151433~61162105:-
THCA	cis	rs8014252	0.667	rs10150707	ENSG00000259158.2	ADAM20P1	-5.74	1.72e-08	3.04e-06	-0.28	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70376986	chr14:70468881~70483756:-
THCA	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	5.74	1.73e-08	3.04e-06	0.23	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
THCA	cis	rs12101261	0.744	rs59431750	ENSG00000259167.2	NMNAT1P1	5.74	1.73e-08	3.04e-06	0.37	0.26	Graves' disease;	chr14:80975725	chr14:81032529~81033404:+
THCA	cis	rs934734	0.736	rs1396210	ENSG00000237979.1	AC007389.1	5.74	1.73e-08	3.04e-06	0.3	0.26	Rheumatoid arthritis;	chr2:65357140	chr2:65500993~65502138:-
THCA	cis	rs2303319	0.504	rs12470830	ENSG00000227403.1	AC009299.3	5.74	1.73e-08	3.04e-06	0.54	0.26	Cognitive function;	chr2:161573486	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187609	ENSG00000227403.1	AC009299.3	5.74	1.73e-08	3.04e-06	0.54	0.26	Cognitive function;	chr2:161574990	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187612	ENSG00000227403.1	AC009299.3	5.74	1.73e-08	3.04e-06	0.54	0.26	Cognitive function;	chr2:161575984	chr2:161244739~161249050:+
THCA	cis	rs2732480	0.577	rs2732481	ENSG00000240399.1	RP1-228P16.1	5.74	1.73e-08	3.05e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.557	rs2732484	ENSG00000240399.1	RP1-228P16.1	5.74	1.73e-08	3.05e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.577	rs2732486	ENSG00000240399.1	RP1-228P16.1	5.74	1.73e-08	3.05e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.517	rs2634676	ENSG00000240399.1	RP1-228P16.1	5.74	1.73e-08	3.05e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48054813~48055591:-
THCA	cis	rs3785574	0.962	rs2727280	ENSG00000240280.5	TCAM1P	-5.74	1.73e-08	3.05e-06	-0.37	-0.26	Height;	chr17:63840722	chr17:63849292~63864379:+
THCA	cis	rs11671005	0.735	rs11668420	ENSG00000269473.1	CTD-2619J13.19	5.74	1.73e-08	3.05e-06	0.3	0.26	Mean platelet volume;	chr19:58426469	chr19:58440448~58445849:+
THCA	cis	rs75920871	0.528	rs1531707	ENSG00000254851.1	RP11-109L13.1	5.74	1.73e-08	3.05e-06	0.37	0.26	Subjective well-being;	chr11:117073996	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs12274388	ENSG00000254851.1	RP11-109L13.1	5.74	1.73e-08	3.05e-06	0.37	0.26	Subjective well-being;	chr11:117075522	chr11:117135528~117138582:+
THCA	cis	rs11603691	0.515	rs2230649	ENSG00000254662.1	RP11-872D17.4	5.74	1.73e-08	3.05e-06	0.4	0.26	Low high density lipoprotein cholesterol levels;	chr11:57334622	chr11:57325603~57327958:+
THCA	cis	rs6860806	0.507	rs272872	ENSG00000263597.1	MIR3936	-5.74	1.73e-08	3.05e-06	-0.26	-0.26	Breast cancer;	chr5:132340171	chr5:132365490~132365599:-
THCA	cis	rs9876781	1	rs2362452	ENSG00000229759.1	MRPS18AP1	-5.74	1.73e-08	3.05e-06	-0.3	-0.26	Longevity;	chr3:48376724	chr3:48256350~48256938:-
THCA	cis	rs13256369	0.708	rs11783670	ENSG00000253893.2	FAM85B	-5.74	1.73e-08	3.05e-06	-0.35	-0.26	Obesity-related traits;	chr8:8701884	chr8:8167819~8226614:-
THCA	cis	rs7083	1	rs664011	ENSG00000254851.1	RP11-109L13.1	5.74	1.74e-08	3.05e-06	0.35	0.26	Blood protein levels;	chr11:117237602	chr11:117135528~117138582:+
THCA	cis	rs9652601	0.959	rs9934969	ENSG00000274038.1	RP11-66H6.4	-5.74	1.74e-08	3.06e-06	-0.33	-0.26	Systemic lupus erythematosus;	chr16:11072145	chr16:11056556~11057034:+
THCA	cis	rs2439831	0.85	rs7168158	ENSG00000166763.7	STRCP1	5.74	1.74e-08	3.06e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43758178	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs7174208	ENSG00000166763.7	STRCP1	5.74	1.74e-08	3.06e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43760484	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs12101756	ENSG00000166763.7	STRCP1	5.74	1.74e-08	3.06e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43761689	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs3862142	ENSG00000166763.7	STRCP1	5.74	1.74e-08	3.06e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43772608	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.702	rs2788	ENSG00000166763.7	STRCP1	5.74	1.74e-08	3.06e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43772688	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs28891769	ENSG00000166763.7	STRCP1	5.74	1.74e-08	3.06e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43780662	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs28578398	ENSG00000166763.7	STRCP1	5.74	1.74e-08	3.06e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43782848	chr15:43699488~43718184:-
THCA	cis	rs2354432	0.607	rs4950310	ENSG00000226015.2	CCT8P1	5.74	1.74e-08	3.06e-06	0.49	0.26	Mitochondrial DNA levels;	chr1:147188385	chr1:147203276~147204932:-
THCA	cis	rs6840360	0.642	rs1470281	ENSG00000270265.1	RP11-731D1.4	-5.74	1.74e-08	3.07e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151333775~151353224:-
THCA	cis	rs12893668	0.703	rs2403197	ENSG00000269910.1	RP11-73M18.10	5.74	1.74e-08	3.07e-06	0.24	0.26	Reticulocyte count;	chr14:103587427	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.572	rs4906350	ENSG00000269910.1	RP11-73M18.10	5.74	1.74e-08	3.07e-06	0.24	0.26	Reticulocyte count;	chr14:103645457	chr14:103694516~103695050:-
THCA	cis	rs11723261	0.582	rs11732336	ENSG00000211553.1	AC253576.2	-5.74	1.74e-08	3.07e-06	-0.37	-0.26	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:136461~136568:+
THCA	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-5.74	1.74e-08	3.07e-06	-0.2	-0.26	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-5.74	1.74e-08	3.07e-06	-0.2	-0.26	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
THCA	cis	rs8007846	0.505	rs3742597	ENSG00000276116.2	FUT8-AS1	-5.74	1.74e-08	3.07e-06	-0.31	-0.26	Multiple sclerosis--Brain Glutamate Levels;	chr14:65733459	chr14:65411170~65412690:-
THCA	cis	rs2439831	0.867	rs6493082	ENSG00000275601.1	AC011330.13	-5.74	1.75e-08	3.07e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43342610	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs8041132	ENSG00000275601.1	AC011330.13	-5.74	1.75e-08	3.07e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43342938	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs16957627	ENSG00000275601.1	AC011330.13	-5.74	1.75e-08	3.07e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43350459	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.717	rs7165471	ENSG00000275601.1	AC011330.13	-5.74	1.75e-08	3.07e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43352590	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs4075674	ENSG00000275601.1	AC011330.13	-5.74	1.75e-08	3.07e-06	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43358032	chr15:43642389~43643023:-
THCA	cis	rs1707322	0.721	rs10890346	ENSG00000281133.1	AL355480.3	5.74	1.75e-08	3.07e-06	0.31	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.685	rs56177313	ENSG00000281133.1	AL355480.3	-5.74	1.75e-08	3.07e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs11211178	ENSG00000281133.1	AL355480.3	-5.74	1.75e-08	3.07e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs4660314	ENSG00000281133.1	AL355480.3	-5.74	1.75e-08	3.07e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45580892~45580996:-
THCA	cis	rs6751744	1	rs6751744	ENSG00000226266.5	AC009961.3	-5.74	1.75e-08	3.07e-06	-0.33	-0.26	Dysphagia;	chr2:159550974	chr2:159670708~159712435:-
THCA	cis	rs2303319	0.504	rs56152608	ENSG00000227403.1	AC009299.3	5.73	1.75e-08	3.07e-06	0.57	0.26	Cognitive function;	chr2:161426958	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs2194732	ENSG00000227403.1	AC009299.3	5.73	1.75e-08	3.07e-06	0.57	0.26	Cognitive function;	chr2:161432645	chr2:161244739~161249050:+
THCA	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	5.73	1.75e-08	3.07e-06	0.39	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
THCA	cis	rs9309473	0.519	rs6730785	ENSG00000163016.8	ALMS1P	-5.73	1.75e-08	3.08e-06	-0.33	-0.26	Metabolite levels;	chr2:73415275	chr2:73644919~73685576:+
THCA	cis	rs12612619	0.732	rs11126836	ENSG00000229122.1	AGBL5-IT1	5.73	1.75e-08	3.08e-06	0.18	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27050260	chr2:27061038~27061815:+
THCA	cis	rs67340775	0.541	rs200979	ENSG00000280107.1	AL022393.9	-5.73	1.75e-08	3.08e-06	-0.35	-0.26	Lung cancer in ever smokers;	chr6:27884579	chr6:28170845~28172521:+
THCA	cis	rs3742264	1	rs17844080	ENSG00000235903.6	CPB2-AS1	-5.73	1.75e-08	3.08e-06	-0.34	-0.26	Blood protein levels;	chr13:46070270	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs4942471	ENSG00000235903.6	CPB2-AS1	-5.73	1.75e-08	3.08e-06	-0.34	-0.26	Blood protein levels;	chr13:46070358	chr13:46052806~46113332:+
THCA	cis	rs10895275	0.961	rs17097547	ENSG00000277459.1	RP11-732A21.3	-5.73	1.75e-08	3.08e-06	-0.21	-0.26	Migraine;	chr11:102224158	chr11:102109827~102110457:-
THCA	cis	rs8062405	0.754	rs62034323	ENSG00000278665.1	RP11-666O2.4	5.73	1.75e-08	3.08e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.824	rs62034324	ENSG00000278665.1	RP11-666O2.4	5.73	1.75e-08	3.08e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.824	rs62034326	ENSG00000278665.1	RP11-666O2.4	5.73	1.75e-08	3.08e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28599241~28601881:-
THCA	cis	rs11089937	0.626	rs5757014	ENSG00000211639.2	IGLV4-60	5.73	1.75e-08	3.08e-06	0.18	0.26	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22162199~22162681:+
THCA	cis	rs875971	1	rs7792762	ENSG00000223473.2	GS1-124K5.3	5.73	1.75e-08	3.08e-06	0.17	0.26	Aortic root size;	chr7:66539151	chr7:66491049~66493566:-
THCA	cis	rs10771431	0.597	rs10771412	ENSG00000256069.6	A2MP1	5.73	1.75e-08	3.08e-06	0.29	0.26	Breast size;	chr12:9201757	chr12:9228533~9275817:-
THCA	cis	rs10771431	0.597	rs10771413	ENSG00000256069.6	A2MP1	5.73	1.75e-08	3.08e-06	0.29	0.26	Breast size;	chr12:9201817	chr12:9228533~9275817:-
THCA	cis	rs9843304	0.526	rs9850213	ENSG00000244503.1	RP11-278L15.6	-5.73	1.75e-08	3.08e-06	-0.32	-0.26	Gallstone disease;	chr3:149484803	chr3:149494660~149495995:+
THCA	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	5.73	1.75e-08	3.08e-06	0.32	0.26	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
THCA	cis	rs10844706	0.669	rs10772102	ENSG00000256594.6	RP11-705C15.2	5.73	1.75e-08	3.09e-06	0.22	0.26	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9744357	chr12:9633419~9658412:+
THCA	cis	rs797680	0.754	rs10874777	ENSG00000223745.6	RP4-717I23.3	5.73	1.76e-08	3.09e-06	0.15	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93396463	chr1:93262186~93346025:-
THCA	cis	rs412050	0.744	rs735244	ENSG00000224086.5	LL22NC03-86G7.1	-5.73	1.76e-08	3.09e-06	-0.43	-0.26	Attention deficit hyperactivity disorder;	chr22:21937727	chr22:21938293~21977632:+
THCA	cis	rs2235642	1	rs2076438	ENSG00000280231.1	LA16c-380F5.3	-5.73	1.76e-08	3.09e-06	-0.3	-0.26	Coronary artery disease;	chr16:1534617	chr16:1553655~1554130:-
THCA	cis	rs853679	0.769	rs7752608	ENSG00000219392.1	RP1-265C24.5	-5.73	1.76e-08	3.09e-06	-0.52	-0.26	Depression;	chr6:28333418	chr6:28115628~28116551:+
THCA	cis	rs17772222	0.715	rs10139921	ENSG00000258789.1	RP11-507K2.3	-5.73	1.76e-08	3.09e-06	-0.29	-0.26	Coronary artery calcification;	chr14:88468512	chr14:88551597~88552493:+
THCA	cis	rs9595908	0.931	rs9595628	ENSG00000212293.1	SNORA16	5.73	1.76e-08	3.09e-06	0.3	0.26	Body mass index;	chr13:32491021	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.931	rs9315167	ENSG00000212293.1	SNORA16	5.73	1.76e-08	3.09e-06	0.3	0.26	Body mass index;	chr13:32495051	chr13:32420390~32420516:-
THCA	cis	rs748404	0.697	rs493177	ENSG00000166763.7	STRCP1	5.73	1.76e-08	3.09e-06	0.27	0.26	Lung cancer;	chr15:43251060	chr15:43699488~43718184:-
THCA	cis	rs911555	0.539	rs4374097	ENSG00000269910.1	RP11-73M18.10	5.73	1.76e-08	3.1e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr14:103606429	chr14:103694516~103695050:-
THCA	cis	rs6968419	0.755	rs3173919	ENSG00000237870.5	AC073130.1	5.73	1.76e-08	3.1e-06	0.28	0.26	Intraocular pressure;	chr7:116258123	chr7:116275606~116286734:-
THCA	cis	rs1499614	1	rs2707840	ENSG00000232546.1	RP11-458F8.1	-5.73	1.76e-08	3.1e-06	-0.34	-0.26	Gout;	chr7:66693028	chr7:66848496~66858136:+
THCA	cis	rs875971	0.793	rs460678	ENSG00000223473.2	GS1-124K5.3	5.73	1.76e-08	3.1e-06	0.18	0.26	Aortic root size;	chr7:66062213	chr7:66491049~66493566:-
THCA	cis	rs12612619	0.732	rs1866654	ENSG00000229122.1	AGBL5-IT1	5.73	1.77e-08	3.1e-06	0.19	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27040254	chr2:27061038~27061815:+
THCA	cis	rs748404	0.626	rs17780920	ENSG00000249839.1	AC011330.5	-5.73	1.77e-08	3.1e-06	-0.36	-0.26	Lung cancer;	chr15:43370164	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs68079546	ENSG00000166763.7	STRCP1	5.73	1.77e-08	3.11e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43844759	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs56909447	ENSG00000166763.7	STRCP1	5.73	1.77e-08	3.11e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43845420	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs28476182	ENSG00000166763.7	STRCP1	5.73	1.77e-08	3.11e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43847445	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs28696802	ENSG00000166763.7	STRCP1	5.73	1.77e-08	3.11e-06	0.38	0.26	Lung cancer in ever smokers;	chr15:43848197	chr15:43699488~43718184:-
THCA	cis	rs7267979	0.549	rs6138537	ENSG00000274414.1	RP5-965G21.4	-5.73	1.77e-08	3.11e-06	-0.31	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25203830	chr20:25239007~25245229:-
THCA	cis	rs2243480	1	rs78803505	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65917585	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65920739	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65922691	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65925107	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65926730	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65928032	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65929575	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65929781	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65929865	chr7:65751142~65763354:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000228409.4	CCT6P1	5.73	1.77e-08	3.11e-06	0.29	0.26	Diabetic kidney disease;	chr7:65938222	chr7:65751142~65763354:+
THCA	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-5.73	1.77e-08	3.11e-06	-0.4	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
THCA	cis	rs12497850	0.864	rs4521268	ENSG00000229759.1	MRPS18AP1	5.73	1.77e-08	3.11e-06	0.34	0.26	Parkinson's disease;	chr3:49100471	chr3:48256350~48256938:-
THCA	cis	rs9388451	0.531	rs9375414	ENSG00000237742.5	RP11-624M8.1	-5.73	1.77e-08	3.11e-06	-0.23	-0.26	Brugada syndrome;	chr6:125833329	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.536	rs34725880	ENSG00000237742.5	RP11-624M8.1	-5.73	1.77e-08	3.11e-06	-0.23	-0.26	Brugada syndrome;	chr6:125834091	chr6:125578558~125749190:-
THCA	cis	rs10129255	0.957	rs8009948	ENSG00000211974.3	IGHV2-70	5.73	1.77e-08	3.11e-06	0.2	0.26	Kawasaki disease;	chr14:106805607	chr14:106723574~106724093:-
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000232546.1	RP11-458F8.1	-5.73	1.77e-08	3.12e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66474549	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs1267817	ENSG00000230295.1	RP11-458F8.2	-5.73	1.77e-08	3.12e-06	-0.32	-0.26	Gout;	chr7:66645053	chr7:66880708~66882981:+
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000230295.1	RP11-458F8.2	-5.73	1.77e-08	3.12e-06	-0.32	-0.26	Gout;	chr7:66654674	chr7:66880708~66882981:+
THCA	cis	rs1395	0.778	rs724311	ENSG00000234072.1	AC074117.10	-5.73	1.78e-08	3.12e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27218777	chr2:27356246~27367622:+
THCA	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-5.73	1.78e-08	3.12e-06	-0.25	-0.26	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
THCA	cis	rs6430585	0.528	rs309120	ENSG00000231890.6	DARS-AS1	-5.73	1.78e-08	3.12e-06	-0.29	-0.26	Corneal structure;	chr2:135951217	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.528	rs3112496	ENSG00000231890.6	DARS-AS1	-5.73	1.78e-08	3.12e-06	-0.29	-0.26	Corneal structure;	chr2:135953494	chr2:135985176~136022593:+
THCA	cis	rs9388451	0.531	rs9401850	ENSG00000237742.5	RP11-624M8.1	-5.73	1.78e-08	3.12e-06	-0.23	-0.26	Brugada syndrome;	chr6:125829854	chr6:125578558~125749190:-
THCA	cis	rs6840360	0.582	rs2724555	ENSG00000270265.1	RP11-731D1.4	-5.73	1.78e-08	3.12e-06	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151333775~151353224:-
THCA	cis	rs71327718	1	rs71327718	ENSG00000241288.6	RP11-379B18.5	-5.73	1.78e-08	3.13e-06	-0.37	-0.26	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125827238~125916384:-
THCA	cis	rs11158026	0.603	rs34988865	ENSG00000258413.1	RP11-665C16.6	-5.73	1.78e-08	3.13e-06	-0.36	-0.26	Parkinson's disease;	chr14:55008131	chr14:55262767~55272075:-
THCA	cis	rs1862618	0.853	rs6450409	ENSG00000271828.1	CTD-2310F14.1	5.73	1.78e-08	3.13e-06	0.38	0.26	Initial pursuit acceleration;	chr5:56805572	chr5:56927874~56929573:+
THCA	cis	rs8062405	0.824	rs153106	ENSG00000278665.1	RP11-666O2.4	5.73	1.78e-08	3.13e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28599241~28601881:-
THCA	cis	rs2303319	0.504	rs72873624	ENSG00000227403.1	AC009299.3	5.73	1.78e-08	3.13e-06	0.53	0.26	Cognitive function;	chr2:161624943	chr2:161244739~161249050:+
THCA	cis	rs375066	0.615	rs13344589	ENSG00000267058.1	RP11-15A1.3	5.73	1.79e-08	3.14e-06	0.23	0.26	Breast cancer;	chr19:43843347	chr19:43891804~43901805:-
THCA	cis	rs7615952	0.512	rs4234285	ENSG00000171084.14	FAM86JP	5.73	1.79e-08	3.14e-06	0.3	0.26	Blood pressure (smoking interaction);	chr3:125685633	chr3:125916620~125930024:+
THCA	cis	rs3794924	0.925	rs35293326	ENSG00000266521.1	RP11-650P15.1	5.73	1.79e-08	3.14e-06	0.49	0.26	Survival in colon cancer;	chr18:31466467	chr18:31496645~31497195:-
THCA	cis	rs2348418	0.832	rs2126894	ENSG00000247934.4	RP11-967K21.1	5.73	1.79e-08	3.14e-06	0.22	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28323914	chr12:28163298~28190738:-
THCA	cis	rs7688540	0.771	rs10027325	ENSG00000211553.1	AC253576.2	-5.73	1.79e-08	3.14e-06	-0.37	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs1986557	ENSG00000211553.1	AC253576.2	-5.73	1.79e-08	3.14e-06	-0.37	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:136461~136568:+
THCA	cis	rs12435908	1	rs2300871	ENSG00000276116.2	FUT8-AS1	5.73	1.79e-08	3.14e-06	0.4	0.26	Ischemic stroke;	chr14:65680976	chr14:65411170~65412690:-
THCA	cis	rs875971	1	rs1544549	ENSG00000223473.2	GS1-124K5.3	-5.73	1.79e-08	3.14e-06	-0.17	-0.26	Aortic root size;	chr7:66625676	chr7:66491049~66493566:-
THCA	cis	rs2803122	0.502	rs1329731	ENSG00000273226.1	RP11-513M16.8	-5.73	1.79e-08	3.14e-06	-0.25	-0.26	Pulse pressure;	chr9:19234910	chr9:19375451~19375996:+
THCA	cis	rs2803122	0.502	rs1854552	ENSG00000273226.1	RP11-513M16.8	5.73	1.79e-08	3.14e-06	0.25	0.26	Pulse pressure;	chr9:19235049	chr9:19375451~19375996:+
THCA	cis	rs438465	0.541	rs1028295	ENSG00000226194.4	RP1-137D17.1	-5.73	1.79e-08	3.14e-06	-0.43	-0.26	Corneal astigmatism;	chr6:169356235	chr6:169369998~169388385:-
THCA	cis	rs9843304	0.585	rs9847009	ENSG00000244503.1	RP11-278L15.6	-5.73	1.79e-08	3.14e-06	-0.32	-0.26	Gallstone disease;	chr3:149490380	chr3:149494660~149495995:+
THCA	cis	rs12893668	0.703	rs55751606	ENSG00000269910.1	RP11-73M18.10	5.73	1.79e-08	3.15e-06	0.25	0.26	Reticulocyte count;	chr14:103562469	chr14:103694516~103695050:-
THCA	cis	rs172166	0.694	rs203876	ENSG00000226314.6	ZNF192P1	-5.73	1.79e-08	3.15e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28078895	chr6:28161781~28169594:+
THCA	cis	rs172166	0.694	rs203877	ENSG00000226314.6	ZNF192P1	-5.73	1.79e-08	3.15e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28080846	chr6:28161781~28169594:+
THCA	cis	rs172166	0.652	rs476167	ENSG00000226314.6	ZNF192P1	-5.73	1.79e-08	3.15e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28098110	chr6:28161781~28169594:+
THCA	cis	rs172166	0.694	rs203892	ENSG00000226314.6	ZNF192P1	-5.73	1.79e-08	3.15e-06	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28099418	chr6:28161781~28169594:+
THCA	cis	rs792448	0.798	rs612414	ENSG00000226251.4	RP11-15I11.3	-5.73	1.79e-08	3.15e-06	-0.33	-0.26	White blood cell count (basophil);	chr1:212428834	chr1:212225278~212238977:-
THCA	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-5.73	1.79e-08	3.15e-06	-0.31	-0.26	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
THCA	cis	rs12761761	0.696	rs61865660	ENSG00000279982.1	RP11-45A17.3	-5.73	1.8e-08	3.15e-06	-0.44	-0.26	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131996967	chr10:131996738~131999846:+
THCA	cis	rs2243480	1	rs313820	ENSG00000232546.1	RP11-458F8.1	-5.73	1.8e-08	3.15e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66109479	chr7:66848496~66858136:+
THCA	cis	rs8042680	0.614	rs12910825	ENSG00000214432.8	AC068831.10	5.73	1.8e-08	3.16e-06	0.27	0.26	Type 2 diabetes;	chr15:90968030	chr15:91022619~91036611:+
THCA	cis	rs1499614	1	rs1267818	ENSG00000230295.1	RP11-458F8.2	-5.73	1.8e-08	3.16e-06	-0.32	-0.26	Gout;	chr7:66642037	chr7:66880708~66882981:+
THCA	cis	rs7412746	0.658	rs11581757	ENSG00000231073.1	RP11-316M1.3	5.73	1.8e-08	3.16e-06	0.31	0.26	Melanoma;	chr1:150919768	chr1:150973123~150975534:+
THCA	cis	rs4227	0.545	rs2302661	ENSG00000233223.2	AC113189.5	5.73	1.8e-08	3.16e-06	0.21	0.26	IgA nephropathy;	chr17:7587061	chr17:7581964~7584072:-
THCA	cis	rs4683346	0.616	rs11129976	ENSG00000173811.9	CCDC13-AS1	-5.73	1.8e-08	3.16e-06	-0.26	-0.26	Granulocyte percentage of myeloid white cells;	chr3:42808873	chr3:42732575~42746768:+
THCA	cis	rs67478160	0.643	rs2887282	ENSG00000258735.1	LINC00637	-5.73	1.8e-08	3.16e-06	-0.31	-0.26	Schizophrenia;	chr14:103814397	chr14:103847721~103858049:+
THCA	cis	rs6928977	1	rs6928977	ENSG00000231028.7	LINC00271	5.73	1.8e-08	3.16e-06	0.21	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135305210	chr6:135497801~135716055:+
THCA	cis	rs9400467	0.528	rs7750792	ENSG00000271789.1	RP5-1112D6.7	-5.73	1.8e-08	3.16e-06	-0.24	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:111297126~111298510:+
THCA	cis	rs12497850	0.931	rs11705888	ENSG00000229759.1	MRPS18AP1	5.73	1.8e-08	3.16e-06	0.34	0.26	Parkinson's disease;	chr3:48779856	chr3:48256350~48256938:-
THCA	cis	rs2179367	0.959	rs4895789	ENSG00000231760.4	RP11-350J20.5	5.73	1.8e-08	3.17e-06	0.34	0.26	Dupuytren's disease;	chr6:149443518	chr6:149796151~149826294:-
THCA	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	5.73	1.8e-08	3.17e-06	0.33	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
THCA	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	5.73	1.8e-08	3.17e-06	0.33	0.26	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
THCA	cis	rs4388254	1	rs4388254	ENSG00000279469.1	RP11-215P8.2	5.73	1.81e-08	3.17e-06	0.54	0.26	Systemic lupus erythematosus;	chr5:134092910	chr5:134394360~134395008:-
THCA	cis	rs11148252	0.875	rs4884452	ENSG00000235660.1	LINC00345	5.73	1.81e-08	3.17e-06	0.33	0.26	Lewy body disease;	chr13:52375649	chr13:52484161~52484680:-
THCA	cis	rs9595908	0.897	rs12429688	ENSG00000212293.1	SNORA16	5.73	1.81e-08	3.17e-06	0.32	0.26	Body mass index;	chr13:32572075	chr13:32420390~32420516:-
THCA	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-5.73	1.81e-08	3.17e-06	-0.23	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
THCA	cis	rs748404	0.697	rs471122	ENSG00000166763.7	STRCP1	-5.73	1.81e-08	3.17e-06	-0.27	-0.26	Lung cancer;	chr15:43266376	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs473016	ENSG00000166763.7	STRCP1	5.73	1.81e-08	3.17e-06	0.27	0.26	Lung cancer;	chr15:43266625	chr15:43699488~43718184:-
THCA	cis	rs7826238	0.566	rs2945886	ENSG00000254153.1	CTA-398F10.2	-5.73	1.81e-08	3.17e-06	-0.28	-0.26	Systolic blood pressure;	chr8:8290748	chr8:8456909~8461337:-
THCA	cis	rs6940116	1	rs6940116	ENSG00000219392.1	RP1-265C24.5	-5.73	1.81e-08	3.17e-06	-0.39	-0.26	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28115628~28116551:+
THCA	cis	rs867529	0.924	rs6731022	ENSG00000234028.3	AC062029.1	5.73	1.81e-08	3.17e-06	0.2	0.26	Height;	chr2:88617517	chr2:88627539~88631821:+
THCA	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-5.73	1.81e-08	3.17e-06	-0.23	-0.26	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
THCA	cis	rs3204270	0.639	rs62080199	ENSG00000262049.1	RP13-1032I1.7	5.73	1.81e-08	3.18e-06	0.24	0.26	Dental caries;	chr17:81660876	chr17:81701324~81703300:-
THCA	cis	rs78487399	0.808	rs75386849	ENSG00000234936.1	AC010883.5	5.73	1.81e-08	3.18e-06	0.39	0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43496144	chr2:43229573~43233394:+
THCA	cis	rs9649465	0.967	rs11769381	ENSG00000272686.1	RP11-390E23.6	5.73	1.81e-08	3.18e-06	0.17	0.26	Migraine;	chr7:123624750	chr7:123749068~123751166:+
THCA	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	5.73	1.81e-08	3.18e-06	0.4	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
THCA	cis	rs115344852	0.598	rs2191035	ENSG00000216901.1	AL022393.7	5.73	1.82e-08	3.19e-06	0.32	0.26	Epithelial ovarian cancer;	chr6:28467166	chr6:28176188~28176674:+
THCA	cis	rs115344852	0.598	rs2531815	ENSG00000216901.1	AL022393.7	5.73	1.82e-08	3.19e-06	0.32	0.26	Epithelial ovarian cancer;	chr6:28468283	chr6:28176188~28176674:+
THCA	cis	rs7809950	0.53	rs111865019	ENSG00000238832.1	snoU109	-5.73	1.82e-08	3.19e-06	-0.31	-0.26	Coronary artery disease;	chr7:107171801	chr7:107603363~107603507:+
THCA	cis	rs12478296	0.786	rs28802397	ENSG00000261186.2	RP11-341N2.1	-5.73	1.82e-08	3.19e-06	-0.4	-0.26	Obesity-related traits;	chr2:242107579	chr2:242087351~242088457:-
THCA	cis	rs6545883	0.868	rs6752938	ENSG00000271889.1	RP11-493E12.1	5.73	1.82e-08	3.19e-06	0.24	0.26	Tuberculosis;	chr2:61614453	chr2:61151433~61162105:-
THCA	cis	rs863750	0.687	rs825476	ENSG00000275389.1	RP11-214K3.24	5.73	1.82e-08	3.19e-06	0.34	0.26	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124083909	chr12:124085761~124088598:+
THCA	cis	rs11722779	0.869	rs223323	ENSG00000251288.2	RP11-10L12.2	-5.73	1.82e-08	3.19e-06	-0.35	-0.26	Schizophrenia;	chr4:102878412	chr4:102751401~102752641:+
THCA	cis	rs757978	0.777	rs11693232	ENSG00000223374.1	AC005104.3	5.73	1.82e-08	3.19e-06	0.28	0.26	Chronic lymphocytic leukemia;	chr2:241422825	chr2:241351340~241353104:-
THCA	cis	rs11148252	0.514	rs3783242	ENSG00000235660.1	LINC00345	-5.73	1.82e-08	3.2e-06	-0.33	-0.26	Lewy body disease;	chr13:52143814	chr13:52484161~52484680:-
THCA	cis	rs9876781	1	rs725309	ENSG00000229759.1	MRPS18AP1	-5.73	1.82e-08	3.2e-06	-0.3	-0.26	Longevity;	chr3:48377218	chr3:48256350~48256938:-
THCA	cis	rs9368481	0.524	rs9393768	ENSG00000241549.7	GUSBP2	5.73	1.83e-08	3.2e-06	0.24	0.26	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26871484~26956554:-
THCA	cis	rs7119038	0.818	rs11826521	ENSG00000255239.1	AP002954.6	-5.73	1.83e-08	3.2e-06	-0.4	-0.26	Sjögren's syndrome;	chr11:118739840	chr11:118688039~118690600:-
THCA	cis	rs79040073	0.563	rs7167852	ENSG00000259531.2	RP11-295H24.3	5.73	1.83e-08	3.2e-06	0.34	0.26	Lung cancer in ever smokers;	chr15:49250004	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.53	rs17396612	ENSG00000259531.2	RP11-295H24.3	5.73	1.83e-08	3.2e-06	0.34	0.26	Lung cancer in ever smokers;	chr15:49257746	chr15:49365124~49366685:-
THCA	cis	rs5758659	1	rs134900	ENSG00000270083.1	RP1-257I20.14	5.73	1.83e-08	3.2e-06	0.26	0.26	Cognitive function;	chr22:42287337	chr22:42089630~42090028:-
THCA	cis	rs713477	0.967	rs6573029	ENSG00000258413.1	RP11-665C16.6	5.73	1.83e-08	3.21e-06	0.34	0.26	Pediatric bone mineral content (femoral neck);	chr14:55446832	chr14:55262767~55272075:-
THCA	cis	rs1876905	0.539	rs240969	ENSG00000272356.1	RP5-1112D6.8	5.73	1.83e-08	3.21e-06	0.26	0.26	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111309203~111313517:+
THCA	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	5.73	1.83e-08	3.21e-06	0.25	0.26	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
THCA	cis	rs6993270	0.779	rs59151115	ENSG00000245330.4	KB-1471A8.1	-5.73	1.83e-08	3.21e-06	-0.33	-0.26	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119909776	chr8:119867419~119874488:-
THCA	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	5.73	1.83e-08	3.21e-06	0.33	0.26	Height;	chr6:109430398	chr6:109382795~109383666:+
THCA	cis	rs1707322	0.721	rs4559551	ENSG00000281133.1	AL355480.3	-5.73	1.83e-08	3.21e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45580892~45580996:-
THCA	cis	rs2554380	0.542	rs7164141	ENSG00000230373.7	GOLGA6L5P	5.73	1.83e-08	3.21e-06	0.3	0.26	Height;	chr15:83824253	chr15:84507885~84516814:-
THCA	cis	rs9677476	0.863	rs10181630	ENSG00000224376.1	AC017104.6	5.73	1.83e-08	3.21e-06	0.29	0.26	Food antigen IgG levels;	chr2:231227044	chr2:231388976~231394991:+
THCA	cis	rs7493	0.755	rs34774523	ENSG00000233942.1	AC004012.1	5.73	1.83e-08	3.21e-06	0.39	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95332830	chr7:95471835~95473998:+
THCA	cis	rs6445975	0.726	rs7639532	ENSG00000272360.1	RP11-359I18.5	5.73	1.83e-08	3.21e-06	0.27	0.26	Systemic lupus erythematosus;	chr3:58481929	chr3:58490830~58491291:-
THCA	cis	rs7129556	0.737	rs537811	ENSG00000254691.1	RP11-91P24.5	5.73	1.83e-08	3.22e-06	0.35	0.26	Weight loss (gastric bypass surgery);	chr11:77757043	chr11:77850604~77851511:+
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000232546.1	RP11-458F8.1	-5.73	1.83e-08	3.22e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66136229	chr7:66848496~66858136:+
THCA	cis	rs1395	0.778	rs6709602	ENSG00000234072.1	AC074117.10	-5.73	1.83e-08	3.22e-06	-0.22	-0.26	Blood metabolite levels;	chr2:27182629	chr2:27356246~27367622:+
THCA	cis	rs4648045	0.624	rs1609798	ENSG00000246560.2	RP11-10L12.4	5.73	1.84e-08	3.22e-06	0.33	0.26	Lymphocyte percentage of white cells;	chr4:102616285	chr4:102828055~102844075:+
THCA	cis	rs4650994	1	rs17361251	ENSG00000273384.1	RP5-1098D14.1	5.73	1.84e-08	3.22e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178551442	chr1:178651706~178652282:+
THCA	cis	rs613391	0.561	rs575588	ENSG00000224549.1	RP11-370B11.3	5.73	1.84e-08	3.22e-06	0.29	0.26	Quantitative traits;	chr9:22717306	chr9:22767175~22768316:+
THCA	cis	rs7246657	0.639	rs3112434	ENSG00000267422.1	CTD-2554C21.1	5.73	1.84e-08	3.22e-06	0.29	0.26	Coronary artery calcification;	chr19:37707247	chr19:37779686~37792865:+
THCA	cis	rs2303319	0.504	rs1567421	ENSG00000227403.1	AC009299.3	-5.73	1.84e-08	3.22e-06	-0.53	-0.26	Cognitive function;	chr2:161619107	chr2:161244739~161249050:+
THCA	cis	rs56046484	0.75	rs12900078	ENSG00000259295.5	CSPG4P12	5.73	1.84e-08	3.22e-06	0.51	0.26	Testicular germ cell tumor;	chr15:84980738	chr15:85191438~85213905:+
THCA	cis	rs8062405	0.965	rs8049439	ENSG00000278665.1	RP11-666O2.4	5.73	1.84e-08	3.23e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28599241~28601881:-
THCA	cis	rs934734	0.967	rs1866051	ENSG00000237979.1	AC007389.1	5.73	1.84e-08	3.23e-06	0.3	0.26	Rheumatoid arthritis;	chr2:65375015	chr2:65500993~65502138:-
THCA	cis	rs67478160	0.619	rs28698555	ENSG00000258735.1	LINC00637	5.73	1.84e-08	3.23e-06	0.31	0.26	Schizophrenia;	chr14:103850149	chr14:103847721~103858049:+
THCA	cis	rs9990333	0.562	rs73210005	ENSG00000231464.1	AC024937.4	5.73	1.84e-08	3.23e-06	0.33	0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195996738~195998233:+
THCA	cis	rs61677309	1	rs61706007	ENSG00000280032.1	RP11-832A4.7	5.73	1.84e-08	3.23e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118296563	chr11:118264593~118266817:+
THCA	cis	rs853679	0.517	rs9283884	ENSG00000261839.1	RP1-265C24.8	-5.73	1.84e-08	3.23e-06	-0.31	-0.26	Depression;	chr6:28167882	chr6:28136849~28139678:+
THCA	cis	rs6908034	0.66	rs12525506	ENSG00000237404.1	RP3-471C18.2	-5.73	1.84e-08	3.23e-06	-0.5	-0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19794003	chr6:19689825~19753113:-
THCA	cis	rs893818	0.832	rs893817	ENSG00000261801.4	LOXL1-AS1	-5.73	1.84e-08	3.23e-06	-0.28	-0.26	Exfoliation glaucoma or exfoliation syndrome;	chr15:73936724	chr15:73908071~73928248:-
THCA	cis	rs836788	0.608	rs26779	ENSG00000249655.1	CTC-325J23.2	-5.73	1.84e-08	3.23e-06	-0.26	-0.26	Glomerular filtration rate (creatinine);	chr5:80763384	chr5:80630313~80631590:-
THCA	cis	rs2839186	0.967	rs17176131	ENSG00000239415.1	AP001469.9	5.73	1.84e-08	3.23e-06	0.26	0.26	Testicular germ cell tumor;	chr21:46285323	chr21:46251549~46254133:-
THCA	cis	rs9876781	1	rs725310	ENSG00000229759.1	MRPS18AP1	-5.73	1.85e-08	3.23e-06	-0.3	-0.26	Longevity;	chr3:48377081	chr3:48256350~48256938:-
THCA	cis	rs10266483	0.774	rs642909	ENSG00000227986.1	TRIM60P18	-5.73	1.85e-08	3.23e-06	-0.23	-0.26	Response to statin therapy;	chr7:64309943	chr7:64355078~64356199:+
THCA	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	5.72	1.85e-08	3.24e-06	0.3	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
THCA	cis	rs2041895	0.509	rs7976343	ENSG00000260329.1	RP11-412D9.4	-5.72	1.85e-08	3.24e-06	-0.25	-0.26	Glaucoma (low intraocular pressure);	chr12:106902250	chr12:106954029~106955497:-
THCA	cis	rs6714710	0.603	rs895438	ENSG00000230606.9	AC159540.1	-5.72	1.85e-08	3.24e-06	-0.3	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97766423	chr2:97416165~97433527:-
THCA	cis	rs896854	0.684	rs10098778	ENSG00000253528.2	RP11-347C18.4	5.72	1.85e-08	3.24e-06	0.29	0.26	Type 2 diabetes;	chr8:94979792	chr8:94974573~94974853:-
THCA	cis	rs4748857	0.685	rs4439422	ENSG00000224215.1	RP11-371A19.2	5.72	1.85e-08	3.24e-06	0.34	0.26	Systemic lupus erythematosus;	chr10:23303539	chr10:23343957~23345181:+
THCA	cis	rs9309473	0.519	rs2421670	ENSG00000163016.8	ALMS1P	-5.72	1.85e-08	3.24e-06	-0.33	-0.26	Metabolite levels;	chr2:73659534	chr2:73644919~73685576:+
THCA	cis	rs11671005	0.735	rs34873624	ENSG00000269473.1	CTD-2619J13.19	5.72	1.85e-08	3.24e-06	0.29	0.26	Mean platelet volume;	chr19:58432035	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.693	rs34230465	ENSG00000269473.1	CTD-2619J13.19	5.72	1.85e-08	3.24e-06	0.29	0.26	Mean platelet volume;	chr19:58432209	chr19:58440448~58445849:+
THCA	cis	rs6445975	0.572	rs4320076	ENSG00000272360.1	RP11-359I18.5	5.72	1.85e-08	3.25e-06	0.3	0.26	Systemic lupus erythematosus;	chr3:58419557	chr3:58490830~58491291:-
THCA	cis	rs6430585	0.528	rs111682961	ENSG00000231890.6	DARS-AS1	-5.72	1.86e-08	3.25e-06	-0.32	-0.26	Corneal structure;	chr2:135896278	chr2:135985176~136022593:+
THCA	cis	rs2179367	0.613	rs12207261	ENSG00000268592.3	RAET1E-AS1	5.72	1.86e-08	3.25e-06	0.36	0.26	Dupuytren's disease;	chr6:149423722	chr6:149863494~149919507:+
THCA	cis	rs2839186	0.749	rs62226488	ENSG00000239415.1	AP001469.9	5.72	1.86e-08	3.25e-06	0.26	0.26	Testicular germ cell tumor;	chr21:46290603	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.749	rs62226489	ENSG00000239415.1	AP001469.9	5.72	1.86e-08	3.25e-06	0.26	0.26	Testicular germ cell tumor;	chr21:46290605	chr21:46251549~46254133:-
THCA	cis	rs2018683	0.7	rs13227954	ENSG00000228421.2	AC005013.5	-5.72	1.86e-08	3.25e-06	-0.3	-0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28977572	chr7:28957667~28959345:+
THCA	cis	rs12101261	0.744	rs72693075	ENSG00000259167.2	NMNAT1P1	5.72	1.86e-08	3.25e-06	0.37	0.26	Graves' disease;	chr14:80980224	chr14:81032529~81033404:+
THCA	cis	rs79040073	0.53	rs1055254	ENSG00000259531.2	RP11-295H24.3	5.72	1.86e-08	3.26e-06	0.35	0.26	Lung cancer in ever smokers;	chr15:49328003	chr15:49365124~49366685:-
THCA	cis	rs78487399	0.71	rs17334919	ENSG00000234936.1	AC010883.5	-5.72	1.86e-08	3.26e-06	-0.38	-0.26	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43480246	chr2:43229573~43233394:+
THCA	cis	rs758324	0.732	rs154729	ENSG00000237714.1	P4HA2-AS1	-5.72	1.86e-08	3.26e-06	-0.38	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132113356	chr5:132184876~132192808:+
THCA	cis	rs950169	0.58	rs4603535	ENSG00000275120.1	RP11-182J1.17	5.72	1.86e-08	3.26e-06	0.3	0.26	Schizophrenia;	chr15:84630641	chr15:84599434~84606463:-
THCA	cis	rs4908760	0.965	rs10864356	ENSG00000232912.4	RP5-1115A15.1	5.72	1.87e-08	3.27e-06	0.25	0.26	Vitiligo;	chr1:8509812	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs6668508	ENSG00000232912.4	RP5-1115A15.1	5.72	1.87e-08	3.27e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8424645~8434838:+
THCA	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-5.72	1.87e-08	3.27e-06	-0.45	-0.26	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
THCA	cis	rs67340775	0.541	rs200975	ENSG00000280107.1	AL022393.9	-5.72	1.87e-08	3.27e-06	-0.35	-0.26	Lung cancer in ever smokers;	chr6:27887847	chr6:28170845~28172521:+
THCA	cis	rs67340775	0.541	rs200974	ENSG00000280107.1	AL022393.9	-5.72	1.87e-08	3.27e-06	-0.35	-0.26	Lung cancer in ever smokers;	chr6:27888067	chr6:28170845~28172521:+
THCA	cis	rs7493	0.95	rs17880101	ENSG00000233942.1	AC004012.1	5.72	1.87e-08	3.27e-06	0.38	0.26	Yu-Zhi constitution type in type 2 diabetes;	chr7:95402145	chr7:95471835~95473998:+
THCA	cis	rs6445975	0.617	rs6762478	ENSG00000272360.1	RP11-359I18.5	5.72	1.87e-08	3.27e-06	0.3	0.26	Systemic lupus erythematosus;	chr3:58418084	chr3:58490830~58491291:-
THCA	cis	rs4950322	0.57	rs17360443	ENSG00000278811.3	LINC00624	5.72	1.87e-08	3.27e-06	0.31	0.26	Protein quantitative trait loci;	chr1:147279737	chr1:147258885~147517875:-
THCA	cis	rs12681287	0.752	rs12679266	ENSG00000254231.1	CTD-2284J15.1	5.72	1.87e-08	3.27e-06	0.28	0.26	Caudate activity during reward;	chr8:86246604	chr8:86333274~86343314:-
THCA	cis	rs6585424	0.925	rs11201964	ENSG00000225484.5	NUTM2B-AS1	-5.72	1.87e-08	3.27e-06	-0.41	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80171611	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs11201966	ENSG00000225484.5	NUTM2B-AS1	-5.72	1.87e-08	3.27e-06	-0.41	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172024	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs11201972	ENSG00000225484.5	NUTM2B-AS1	-5.72	1.87e-08	3.27e-06	-0.41	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172924	chr10:79663088~79826594:-
THCA	cis	rs6585424	1	rs3851055	ENSG00000225484.5	NUTM2B-AS1	-5.72	1.87e-08	3.27e-06	-0.41	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178340	chr10:79663088~79826594:-
THCA	cis	rs1876905	0.539	rs240980	ENSG00000272356.1	RP5-1112D6.8	5.72	1.87e-08	3.27e-06	0.28	0.26	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111309203~111313517:+
THCA	cis	rs12893668	0.703	rs34186780	ENSG00000269910.1	RP11-73M18.10	5.72	1.87e-08	3.28e-06	0.25	0.26	Reticulocyte count;	chr14:103561258	chr14:103694516~103695050:-
THCA	cis	rs442309	0.841	rs377859	ENSG00000238280.1	RP11-436D10.3	-5.72	1.87e-08	3.28e-06	-0.31	-0.26	Vogt-Koyanagi-Harada syndrome;	chr10:62756305	chr10:62793562~62805887:-
THCA	cis	rs4266144	0.544	rs13080798	ENSG00000241770.1	RP11-555M1.3	-5.72	1.87e-08	3.28e-06	-0.31	-0.26	Coronary artery disease;	chr3:157114612	chr3:157163452~157169133:+
THCA	cis	rs1949733	0.543	rs62287446	ENSG00000205959.3	RP11-689P11.2	5.72	1.87e-08	3.28e-06	0.22	0.26	Response to antineoplastic agents;	chr4:8534261	chr4:8482270~8512610:+
THCA	cis	rs2562456	1	rs2562456	ENSG00000268119.4	CTD-2561J22.5	5.72	1.87e-08	3.28e-06	0.3	0.26	Pain;	chr19:21483408	chr19:21444241~21463908:-
THCA	cis	rs11783469	0.522	rs11781871	ENSG00000253390.1	CTC-756D1.2	-5.72	1.87e-08	3.28e-06	-0.41	-0.26	Reticulocyte count;	chr8:23399577	chr8:23458601~23484971:+
THCA	cis	rs4683346	0.616	rs4683332	ENSG00000173811.9	CCDC13-AS1	-5.72	1.87e-08	3.28e-06	-0.26	-0.26	Granulocyte percentage of myeloid white cells;	chr3:42785945	chr3:42732575~42746768:+
THCA	cis	rs7560272	0.723	rs6729468	ENSG00000163016.8	ALMS1P	5.72	1.88e-08	3.28e-06	0.33	0.26	Schizophrenia;	chr2:73538126	chr2:73644919~73685576:+
THCA	cis	rs9921338	0.961	rs7198849	ENSG00000262703.1	RP11-485G7.6	-5.72	1.88e-08	3.28e-06	-0.33	-0.26	Vein graft stenosis in coronary artery bypass grafting;	chr16:11279444	chr16:11348143~11349321:-
THCA	cis	rs4650994	1	rs17276513	ENSG00000273384.1	RP5-1098D14.1	-5.72	1.88e-08	3.28e-06	-0.32	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178551469	chr1:178651706~178652282:+
THCA	cis	rs10895275	0.649	rs4420227	ENSG00000277459.1	RP11-732A21.3	5.72	1.88e-08	3.28e-06	0.19	0.26	Migraine;	chr11:102165753	chr11:102109827~102110457:-
THCA	cis	rs4650994	1	rs10913570	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178553991	chr1:178651706~178652282:+
THCA	cis	rs5758659	0.967	rs5758670	ENSG00000270083.1	RP1-257I20.14	5.72	1.88e-08	3.29e-06	0.28	0.26	Cognitive function;	chr22:42240681	chr22:42089630~42090028:-
THCA	cis	rs4845570	0.92	rs1196456	ENSG00000268288.1	RP11-98D18.16	5.72	1.88e-08	3.29e-06	0.34	0.26	Coronary artery disease;	chr1:151764873	chr1:151766486~151767000:-
THCA	cis	rs2839186	0.934	rs2839194	ENSG00000239415.1	AP001469.9	5.72	1.88e-08	3.29e-06	0.26	0.26	Testicular germ cell tumor;	chr21:46279523	chr21:46251549~46254133:-
THCA	cis	rs4650994	0.625	rs6681348	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178557136	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.625	rs6681354	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178557144	chr1:178651706~178652282:+
THCA	cis	rs8014252	0.667	rs55728800	ENSG00000259158.2	ADAM20P1	-5.72	1.88e-08	3.29e-06	-0.28	-0.26	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70346803	chr14:70468881~70483756:-
THCA	cis	rs801193	0.967	rs2420827	ENSG00000273142.1	RP11-458F8.4	5.72	1.88e-08	3.29e-06	0.2	0.26	Aortic root size;	chr7:66682114	chr7:66902857~66906297:+
THCA	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	5.72	1.88e-08	3.29e-06	0.33	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
THCA	cis	rs3742264	1	rs2404964	ENSG00000235903.6	CPB2-AS1	-5.72	1.88e-08	3.29e-06	-0.34	-0.26	Blood protein levels;	chr13:46070739	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs1409434	ENSG00000235903.6	CPB2-AS1	-5.72	1.88e-08	3.29e-06	-0.34	-0.26	Blood protein levels;	chr13:46072309	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.961	rs9534309	ENSG00000235903.6	CPB2-AS1	-5.72	1.88e-08	3.29e-06	-0.34	-0.26	Blood protein levels;	chr13:46073402	chr13:46052806~46113332:+
THCA	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-5.72	1.88e-08	3.29e-06	-0.33	-0.26	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
THCA	cis	rs4650994	1	rs10913572	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178557583	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.935	rs4652306	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178559071	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs6660445	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178559736	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.905	rs12753251	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178560763	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs35810840	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178553507	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs4354501	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178555461	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.967	rs6681043	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178556822	chr1:178651706~178652282:+
THCA	cis	rs4650994	1	rs10913571	ENSG00000273384.1	RP5-1098D14.1	5.72	1.88e-08	3.29e-06	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178557513	chr1:178651706~178652282:+
THCA	cis	rs9813712	0.571	rs9289368	ENSG00000249846.5	RP11-77P16.4	-5.72	1.88e-08	3.29e-06	-0.27	-0.26	Response to amphetamines;	chr3:130225562	chr3:130112550~130120579:+
THCA	cis	rs9813712	0.571	rs6774141	ENSG00000249846.5	RP11-77P16.4	-5.72	1.88e-08	3.29e-06	-0.27	-0.26	Response to amphetamines;	chr3:130225599	chr3:130112550~130120579:+
THCA	cis	rs7674212	0.541	rs2623070	ENSG00000246560.2	RP11-10L12.4	-5.72	1.88e-08	3.29e-06	-0.3	-0.26	Type 2 diabetes;	chr4:103116231	chr4:102828055~102844075:+
THCA	cis	rs2732480	0.538	rs2732462	ENSG00000240399.1	RP1-228P16.1	5.72	1.88e-08	3.29e-06	0.26	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48054813~48055591:-
THCA	cis	rs258324	0.79	rs8062346	ENSG00000260259.1	RP11-368I7.4	-5.72	1.88e-08	3.29e-06	-0.37	-0.26	Height;	chr16:89666260	chr16:89682620~89686569:-
THCA	cis	rs11148252	0.514	rs9526843	ENSG00000235660.1	LINC00345	-5.72	1.88e-08	3.29e-06	-0.32	-0.26	Lewy body disease;	chr13:52155921	chr13:52484161~52484680:-
THCA	cis	rs7688014	1	rs7688014	ENSG00000251288.2	RP11-10L12.2	-5.72	1.88e-08	3.3e-06	-0.35	-0.26	Schizophrenia;	chr4:103053903	chr4:102751401~102752641:+
THCA	cis	rs5758659	1	rs5758659	ENSG00000270083.1	RP1-257I20.14	5.72	1.88e-08	3.3e-06	0.27	0.26	Cognitive function;	chr22:42225997	chr22:42089630~42090028:-
THCA	cis	rs1385374	0.92	rs11059911	ENSG00000274695.1	RP11-21K12.3	5.72	1.88e-08	3.3e-06	0.49	0.26	Systemic lupus erythematosus;	chr12:128787391	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.92	rs61946174	ENSG00000274695.1	RP11-21K12.3	5.72	1.88e-08	3.3e-06	0.49	0.26	Systemic lupus erythematosus;	chr12:128788426	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.92	rs61946175	ENSG00000274695.1	RP11-21K12.3	5.72	1.88e-08	3.3e-06	0.49	0.26	Systemic lupus erythematosus;	chr12:128788476	chr12:128826836~128827579:+
THCA	cis	rs12428035	0.772	rs7316996	ENSG00000247400.3	DNAJC3-AS1	-5.72	1.89e-08	3.3e-06	-0.23	-0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95676584	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.772	rs3886352	ENSG00000247400.3	DNAJC3-AS1	-5.72	1.89e-08	3.3e-06	-0.23	-0.26	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95680397	chr13:95648733~95676925:-
THCA	cis	rs6569038	0.502	rs11967399	ENSG00000253194.1	RP11-351A11.1	5.72	1.89e-08	3.3e-06	0.35	0.26	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118992352	chr6:118934785~119031541:+
THCA	cis	rs2303319	0.504	rs16845945	ENSG00000227403.1	AC009299.3	5.72	1.89e-08	3.3e-06	0.54	0.26	Cognitive function;	chr2:161624174	chr2:161244739~161249050:+
THCA	cis	rs6430585	0.528	rs7573555	ENSG00000231890.6	DARS-AS1	5.72	1.89e-08	3.3e-06	0.31	0.26	Corneal structure;	chr2:135937335	chr2:135985176~136022593:+
THCA	cis	rs9813712	0.571	rs9824426	ENSG00000249846.5	RP11-77P16.4	-5.72	1.89e-08	3.3e-06	-0.26	-0.26	Response to amphetamines;	chr3:130226115	chr3:130112550~130120579:+
THCA	cis	rs10771431	0.817	rs10843149	ENSG00000256069.6	A2MP1	5.72	1.89e-08	3.3e-06	0.28	0.26	Breast size;	chr12:9209471	chr12:9228533~9275817:-
THCA	cis	rs61677309	1	rs4938494	ENSG00000280032.1	RP11-832A4.7	5.72	1.89e-08	3.3e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118280020	chr11:118264593~118266817:+
THCA	cis	rs2562456	0.917	rs2681376	ENSG00000268119.4	CTD-2561J22.5	-5.72	1.89e-08	3.3e-06	-0.31	-0.26	Pain;	chr19:21532723	chr19:21444241~21463908:-
THCA	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-5.72	1.89e-08	3.3e-06	-0.16	-0.26	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
THCA	cis	rs8027521	0.846	rs2725580	ENSG00000280362.1	RP11-643A5.3	5.72	1.89e-08	3.31e-06	0.32	0.26	Circulating chemerin levels;	chr15:53970517	chr15:53910769~53914712:+
THCA	cis	rs1707322	0.721	rs9793568	ENSG00000281133.1	AL355480.3	-5.72	1.89e-08	3.31e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs11211157	ENSG00000281133.1	AL355480.3	-5.72	1.89e-08	3.31e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs11211158	ENSG00000281133.1	AL355480.3	-5.72	1.89e-08	3.31e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs6429575	ENSG00000281133.1	AL355480.3	-5.72	1.89e-08	3.31e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.685	rs6690926	ENSG00000281133.1	AL355480.3	-5.72	1.89e-08	3.31e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs8179402	ENSG00000281133.1	AL355480.3	-5.72	1.89e-08	3.31e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs8179296	ENSG00000281133.1	AL355480.3	-5.72	1.89e-08	3.31e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45580892~45580996:-
THCA	cis	rs10208649	0.908	rs9678301	ENSG00000233266.1	HMGB1P31	5.72	1.89e-08	3.31e-06	0.63	0.26	Body mass index;	chr2:54014373	chr2:54051334~54051760:+
THCA	cis	rs755249	0.567	rs3754346	ENSG00000228060.1	RP11-69E11.8	-5.72	1.89e-08	3.31e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs16826093	ENSG00000228060.1	RP11-69E11.8	-5.72	1.89e-08	3.31e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs41270811	ENSG00000228060.1	RP11-69E11.8	-5.72	1.89e-08	3.31e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs61779274	ENSG00000228060.1	RP11-69E11.8	-5.72	1.89e-08	3.31e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs17264671	ENSG00000228060.1	RP11-69E11.8	-5.72	1.89e-08	3.31e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs4660690	ENSG00000228060.1	RP11-69E11.8	-5.72	1.89e-08	3.31e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs61779275	ENSG00000228060.1	RP11-69E11.8	-5.72	1.89e-08	3.31e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39565160~39573203:+
THCA	cis	rs748404	0.666	rs35158584	ENSG00000249839.1	AC011330.5	-5.72	1.89e-08	3.31e-06	-0.37	-0.26	Lung cancer;	chr15:43392876	chr15:43663654~43684339:-
THCA	cis	rs4948275	0.742	rs2250815	ENSG00000237233.2	TMEM26-AS1	-5.72	1.89e-08	3.31e-06	-0.33	-0.26	Night sleep phenotypes;	chr10:61479806	chr10:61452639~61481956:+
THCA	cis	rs4908760	0.64	rs3795310	ENSG00000232912.4	RP5-1115A15.1	-5.72	1.89e-08	3.31e-06	-0.26	-0.26	Vitiligo;	chr1:8371547	chr1:8424645~8434838:+
THCA	cis	rs7129556	0.737	rs2154972	ENSG00000254691.1	RP11-91P24.5	5.72	1.89e-08	3.31e-06	0.35	0.26	Weight loss (gastric bypass surgery);	chr11:77777779	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.775	rs623907	ENSG00000254691.1	RP11-91P24.5	5.72	1.89e-08	3.31e-06	0.35	0.26	Weight loss (gastric bypass surgery);	chr11:77790402	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.737	rs614495	ENSG00000254691.1	RP11-91P24.5	5.72	1.89e-08	3.31e-06	0.35	0.26	Weight loss (gastric bypass surgery);	chr11:77825840	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.701	rs4945220	ENSG00000254691.1	RP11-91P24.5	-5.72	1.89e-08	3.31e-06	-0.35	-0.26	Weight loss (gastric bypass surgery);	chr11:77817115	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.737	rs7951033	ENSG00000254691.1	RP11-91P24.5	-5.72	1.89e-08	3.31e-06	-0.35	-0.26	Weight loss (gastric bypass surgery);	chr11:77823398	chr11:77850604~77851511:+
THCA	cis	rs796395	0.664	rs2993047	ENSG00000228208.5	C1orf143	-5.72	1.89e-08	3.31e-06	-0.3	-0.26	Post bronchodilator FEV1/FVC ratio;	chr1:218511713	chr1:218510096~218525978:+
THCA	cis	rs935334	1	rs2543387	ENSG00000258454.1	RP11-361H10.3	5.72	1.9e-08	3.32e-06	0.36	0.26	Blood pressure;	chr14:76162703	chr14:76235817~76263474:+
THCA	cis	rs11148252	0.716	rs1887360	ENSG00000235660.1	LINC00345	-5.72	1.9e-08	3.32e-06	-0.34	-0.26	Lewy body disease;	chr13:52205031	chr13:52484161~52484680:-
THCA	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-5.72	1.9e-08	3.32e-06	-0.4	-0.26	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
THCA	cis	rs713477	0.817	rs55868790	ENSG00000258413.1	RP11-665C16.6	5.72	1.9e-08	3.32e-06	0.34	0.26	Pediatric bone mineral content (femoral neck);	chr14:55446557	chr14:55262767~55272075:-
THCA	cis	rs13256369	0.802	rs13281933	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8705155	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.756	rs13282580	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8705393	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs13258283	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8706120	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs13249700	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8706127	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs13254997	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8706243	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs13255061	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8706324	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs12541477	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8706385	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs13266562	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8706555	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs13256611	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8706831	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs11786125	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8707060	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.802	rs11249888	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8707424	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.851	rs11249889	ENSG00000253893.2	FAM85B	-5.72	1.9e-08	3.32e-06	-0.35	-0.26	Obesity-related traits;	chr8:8707482	chr8:8167819~8226614:-
THCA	cis	rs2732480	0.577	rs2634680	ENSG00000240399.1	RP1-228P16.1	5.72	1.9e-08	3.32e-06	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48054813~48055591:-
THCA	cis	rs7208859	0.614	rs216474	ENSG00000264538.5	SUZ12P1	5.72	1.9e-08	3.32e-06	0.26	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30709299~30790908:+
THCA	cis	rs6430585	0.528	rs6430594	ENSG00000231890.6	DARS-AS1	5.72	1.9e-08	3.32e-06	0.31	0.26	Corneal structure;	chr2:135961603	chr2:135985176~136022593:+
THCA	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	5.72	1.9e-08	3.32e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	5.72	1.9e-08	3.32e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	5.72	1.9e-08	3.32e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	5.72	1.9e-08	3.32e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	5.72	1.9e-08	3.32e-06	0.39	0.26	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
THCA	cis	rs9380516	1	rs6935976	ENSG00000228559.1	RP3-340B19.3	-5.72	1.9e-08	3.33e-06	-0.4	-0.26	Hepatitis C induced liver fibrosis;	chr6:35530321	chr6:35544632~35545669:+
THCA	cis	rs9380516	0.853	rs6457827	ENSG00000228559.1	RP3-340B19.3	-5.72	1.9e-08	3.33e-06	-0.4	-0.26	Hepatitis C induced liver fibrosis;	chr6:35531124	chr6:35544632~35545669:+
THCA	cis	rs9380516	1	rs4713882	ENSG00000228559.1	RP3-340B19.3	-5.72	1.9e-08	3.33e-06	-0.4	-0.26	Hepatitis C induced liver fibrosis;	chr6:35533593	chr6:35544632~35545669:+
THCA	cis	rs9380516	1	rs9380516	ENSG00000228559.1	RP3-340B19.3	-5.72	1.9e-08	3.33e-06	-0.4	-0.26	Hepatitis C induced liver fibrosis;	chr6:35534425	chr6:35544632~35545669:+
THCA	cis	rs9380516	0.947	rs9470048	ENSG00000228559.1	RP3-340B19.3	-5.72	1.9e-08	3.33e-06	-0.4	-0.26	Hepatitis C induced liver fibrosis;	chr6:35536852	chr6:35544632~35545669:+
THCA	cis	rs12893668	0.572	rs7148857	ENSG00000269940.1	RP11-73M18.7	5.72	1.9e-08	3.33e-06	0.27	0.26	Reticulocyte count;	chr14:103676900	chr14:103694560~103695170:+
THCA	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	5.72	1.9e-08	3.33e-06	0.44	0.26	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
THCA	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	5.72	1.91e-08	3.33e-06	0.29	0.26	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
THCA	cis	rs867529	0.924	rs6739095	ENSG00000234028.3	AC062029.1	-5.72	1.91e-08	3.33e-06	-0.2	-0.26	Height;	chr2:88580546	chr2:88627539~88631821:+
THCA	cis	rs3204270	0.683	rs13372	ENSG00000262049.1	RP13-1032I1.7	5.72	1.91e-08	3.33e-06	0.24	0.26	Dental caries;	chr17:81650675	chr17:81701324~81703300:-
THCA	cis	rs3204270	0.639	rs1126818	ENSG00000262049.1	RP13-1032I1.7	5.72	1.91e-08	3.33e-06	0.24	0.26	Dental caries;	chr17:81650800	chr17:81701324~81703300:-
THCA	cis	rs1385374	0.92	rs34785537	ENSG00000274695.1	RP11-21K12.3	5.72	1.91e-08	3.33e-06	0.49	0.26	Systemic lupus erythematosus;	chr12:128788549	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.92	rs61946177	ENSG00000274695.1	RP11-21K12.3	5.72	1.91e-08	3.33e-06	0.49	0.26	Systemic lupus erythematosus;	chr12:128788802	chr12:128826836~128827579:+
THCA	cis	rs6860806	0.661	rs6871350	ENSG00000233006.5	AC034220.3	5.72	1.91e-08	3.33e-06	0.2	0.26	Breast cancer;	chr5:132244527	chr5:132311285~132369916:-
THCA	cis	rs17123764	0.539	rs7979262	ENSG00000257464.1	RP11-161H23.8	-5.72	1.91e-08	3.34e-06	-0.41	-0.26	Intelligence (multi-trait analysis);	chr12:49671363	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs12310510	ENSG00000257464.1	RP11-161H23.8	-5.72	1.91e-08	3.34e-06	-0.41	-0.26	Intelligence (multi-trait analysis);	chr12:49672461	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.605	rs7954994	ENSG00000257464.1	RP11-161H23.8	-5.72	1.91e-08	3.34e-06	-0.41	-0.26	Intelligence (multi-trait analysis);	chr12:49674306	chr12:49442424~49442652:-
THCA	cis	rs61677309	1	rs3825051	ENSG00000280032.1	RP11-832A4.7	5.72	1.91e-08	3.34e-06	0.27	0.26	Lung cancer in ever smokers;	chr11:118303914	chr11:118264593~118266817:+
THCA	cis	rs17711722	0.523	rs365896	ENSG00000275400.1	RP4-756H11.5	5.72	1.91e-08	3.34e-06	0.24	0.26	Calcium levels;	chr7:66045710	chr7:66553805~66554199:-
THCA	cis	rs67478160	0.643	rs11847468	ENSG00000258735.1	LINC00637	-5.72	1.91e-08	3.34e-06	-0.31	-0.26	Schizophrenia;	chr14:103753958	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.595	rs67768834	ENSG00000258735.1	LINC00637	-5.72	1.91e-08	3.34e-06	-0.31	-0.26	Schizophrenia;	chr14:103754748	chr14:103847721~103858049:+
THCA	cis	rs6142102	0.923	rs2268078	ENSG00000275784.1	RP5-1125A11.6	-5.72	1.91e-08	3.34e-06	-0.27	-0.26	Skin pigmentation;	chr20:34008898	chr20:33989480~33991818:-
THCA	cis	rs12612619	0.732	rs3806520	ENSG00000229122.1	AGBL5-IT1	5.72	1.91e-08	3.34e-06	0.18	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27053334	chr2:27061038~27061815:+
THCA	cis	rs7131987	0.903	rs7974221	ENSG00000257176.2	RP11-996F15.2	-5.72	1.91e-08	3.34e-06	-0.25	-0.26	QT interval;	chr12:29246515	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.868	rs11050151	ENSG00000257176.2	RP11-996F15.2	-5.72	1.91e-08	3.34e-06	-0.25	-0.26	QT interval;	chr12:29250075	chr12:29280418~29317848:-
THCA	cis	rs6860806	0.661	rs28472559	ENSG00000233006.5	AC034220.3	5.72	1.91e-08	3.34e-06	0.2	0.26	Breast cancer;	chr5:132245918	chr5:132311285~132369916:-
THCA	cis	rs67079557	1	rs67079557	ENSG00000260269.4	CTD-2323K18.1	-5.72	1.91e-08	3.34e-06	-0.38	-0.26	Breast cancer;	chr15:75637966	chr15:75527150~75601205:-
THCA	cis	rs2029362	0.87	rs12223664	ENSG00000245573.6	BDNF-AS	5.72	1.92e-08	3.35e-06	0.2	0.26	Total body bone mineral density;	chr11:27606303	chr11:27506838~27698174:+
THCA	cis	rs9467773	1	rs9467796	ENSG00000124549.13	BTN2A3P	5.72	1.92e-08	3.35e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs9467797	ENSG00000124549.13	BTN2A3P	5.72	1.92e-08	3.35e-06	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26421391~26432383:+
THCA	cis	rs17772222	0.958	rs61579615	ENSG00000222990.1	RNU4-22P	5.72	1.92e-08	3.35e-06	0.34	0.26	Coronary artery calcification;	chr14:88400054	chr14:88513498~88513663:+
THCA	cis	rs12893668	0.645	rs35229468	ENSG00000269910.1	RP11-73M18.10	5.72	1.92e-08	3.35e-06	0.24	0.26	Reticulocyte count;	chr14:103585720	chr14:103694516~103695050:-
THCA	cis	rs11671005	0.735	rs11667591	ENSG00000269473.1	CTD-2619J13.19	5.72	1.92e-08	3.35e-06	0.29	0.26	Mean platelet volume;	chr19:58426270	chr19:58440448~58445849:+
THCA	cis	rs224278	0.764	rs224301	ENSG00000238280.1	RP11-436D10.3	5.72	1.92e-08	3.36e-06	0.3	0.26	Ewing sarcoma;	chr10:62832252	chr10:62793562~62805887:-
THCA	cis	rs1707322	0.721	rs11211151	ENSG00000281133.1	AL355480.3	-5.72	1.92e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs12045096	ENSG00000281133.1	AL355480.3	-5.72	1.92e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs4609469	ENSG00000281133.1	AL355480.3	-5.72	1.92e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs12049027	ENSG00000281133.1	AL355480.3	-5.72	1.92e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs10789467	ENSG00000281133.1	AL355480.3	-5.72	1.92e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs10890337	ENSG00000281133.1	AL355480.3	-5.72	1.92e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs3811435	ENSG00000281133.1	AL355480.3	-5.72	1.92e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45580892~45580996:-
THCA	cis	rs17345786	0.906	rs11708616	ENSG00000256628.3	ZBTB11-AS1	5.72	1.92e-08	3.36e-06	0.32	0.26	Colonoscopy-negative controls vs population controls;	chr3:101512887	chr3:101676475~101679217:+
THCA	cis	rs2980439	0.729	rs2955585	ENSG00000253981.4	ALG1L13P	5.72	1.92e-08	3.36e-06	0.24	0.26	Neuroticism;	chr8:8235989	chr8:8236003~8244667:-
THCA	cis	rs12681287	0.64	rs2953516	ENSG00000254231.1	CTD-2284J15.1	5.72	1.92e-08	3.36e-06	0.29	0.26	Caudate activity during reward;	chr8:86320316	chr8:86333274~86343314:-
THCA	cis	rs712039	0.652	rs853222	ENSG00000276054.1	RP11-378E13.3	5.72	1.92e-08	3.36e-06	0.39	0.26	Tuberculosis;	chr17:37429923	chr17:37386886~37387926:+
THCA	cis	rs712039	0.652	rs853200	ENSG00000276054.1	RP11-378E13.3	5.72	1.92e-08	3.36e-06	0.39	0.26	Tuberculosis;	chr17:37444013	chr17:37386886~37387926:+
THCA	cis	rs58605417	0.526	rs7828497	ENSG00000253553.4	RP11-586K2.1	5.72	1.92e-08	3.36e-06	0.27	0.26	Schizophrenia;	chr8:88327492	chr8:88326836~88737134:+
THCA	cis	rs6445975	0.666	rs13077234	ENSG00000272360.1	RP11-359I18.5	5.72	1.92e-08	3.36e-06	0.3	0.26	Systemic lupus erythematosus;	chr3:58450978	chr3:58490830~58491291:-
THCA	cis	rs12612619	0.732	rs10432697	ENSG00000229122.1	AGBL5-IT1	5.72	1.93e-08	3.36e-06	0.18	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27049184	chr2:27061038~27061815:+
THCA	cis	rs1707322	0.613	rs1473840	ENSG00000234329.1	RP11-767N6.2	-5.72	1.93e-08	3.36e-06	-0.25	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211165	ENSG00000281133.1	AL355480.3	-5.72	1.93e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs11211166	ENSG00000281133.1	AL355480.3	-5.72	1.93e-08	3.36e-06	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45580892~45580996:-
THCA	cis	rs7809950	0.678	rs4730235	ENSG00000238832.1	snoU109	-5.72	1.93e-08	3.37e-06	-0.3	-0.25	Coronary artery disease;	chr7:107382061	chr7:107603363~107603507:+
THCA	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-5.72	1.93e-08	3.38e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
THCA	cis	rs12101261	0.744	rs2268457	ENSG00000259167.2	NMNAT1P1	5.72	1.93e-08	3.38e-06	0.39	0.25	Graves' disease;	chr14:80996428	chr14:81032529~81033404:+
THCA	cis	rs7674212	0.541	rs2720448	ENSG00000246560.2	RP11-10L12.4	5.72	1.93e-08	3.38e-06	0.3	0.25	Type 2 diabetes;	chr4:103109432	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.541	rs2623064	ENSG00000246560.2	RP11-10L12.4	5.72	1.93e-08	3.38e-06	0.3	0.25	Type 2 diabetes;	chr4:103109635	chr4:102828055~102844075:+
THCA	cis	rs2562456	0.792	rs2562398	ENSG00000268119.4	CTD-2561J22.5	-5.72	1.93e-08	3.38e-06	-0.31	-0.25	Pain;	chr19:21540147	chr19:21444241~21463908:-
THCA	cis	rs2439831	0.867	rs2243434	ENSG00000275601.1	AC011330.13	-5.72	1.94e-08	3.38e-06	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43397669	chr15:43642389~43643023:-
THCA	cis	rs6433895	1	rs59395276	ENSG00000236153.1	AC104076.3	-5.72	1.94e-08	3.38e-06	-0.28	-0.25	Lymphocyte counts;	chr2:181155969	chr2:180979427~180980090:-
THCA	cis	rs7829975	0.617	rs4841071	ENSG00000233609.3	RP11-62H7.2	5.72	1.94e-08	3.38e-06	0.25	0.25	Mood instability;	chr8:8933634	chr8:8961200~8979025:+
THCA	cis	rs6669008	1	rs6669008	ENSG00000232450.1	RP4-730K3.3	-5.72	1.94e-08	3.38e-06	-0.28	-0.25	Bacteremia;	chr1:113623939	chr1:113698884~113699631:-
THCA	cis	rs16949788	0.826	rs62625678	ENSG00000261351.2	CTD-3185P2.1	-5.72	1.94e-08	3.39e-06	-0.34	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66335718	chr15:66488658~66492109:-
THCA	cis	rs16949788	0.793	rs62625675	ENSG00000261351.2	CTD-3185P2.1	-5.72	1.94e-08	3.39e-06	-0.34	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66336682	chr15:66488658~66492109:-
THCA	cis	rs12612619	0.761	rs7606840	ENSG00000229122.1	AGBL5-IT1	5.72	1.94e-08	3.39e-06	0.18	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020496	chr2:27061038~27061815:+
THCA	cis	rs3096299	0.754	rs3102382	ENSG00000274627.1	RP11-104N10.2	5.72	1.94e-08	3.39e-06	0.23	0.25	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89516797~89522217:+
THCA	cis	rs1185460	0.967	rs1177563	ENSG00000272186.1	RP11-110I1.13	-5.72	1.94e-08	3.39e-06	-0.24	-0.25	Coronary artery disease;	chr11:119078373	chr11:119067374~119067698:-
THCA	cis	rs2732480	0.5	rs2932093	ENSG00000240399.1	RP1-228P16.1	5.72	1.94e-08	3.39e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48054813~48055591:-
THCA	cis	rs2303759	0.918	rs7251704	ENSG00000268686.1	AC010524.2	-5.72	1.94e-08	3.39e-06	-0.37	-0.25	Multiple sclerosis;	chr19:49387616	chr19:49368705~49388081:-
THCA	cis	rs1395	0.778	rs12465084	ENSG00000234072.1	AC074117.10	-5.72	1.94e-08	3.39e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27191335	chr2:27356246~27367622:+
THCA	cis	rs763121	0.925	rs5750654	ENSG00000235209.1	CTA-150C2.13	5.72	1.94e-08	3.39e-06	0.32	0.25	Menopause (age at onset);	chr22:38655423	chr22:38921227~38924708:+
THCA	cis	rs10771431	0.782	rs10771415	ENSG00000256069.6	A2MP1	5.72	1.94e-08	3.39e-06	0.28	0.25	Breast size;	chr12:9205627	chr12:9228533~9275817:-
THCA	cis	rs4648045	0.796	rs3817685	ENSG00000246560.2	RP11-10L12.4	5.72	1.95e-08	3.4e-06	0.33	0.25	Lymphocyte percentage of white cells;	chr4:102613403	chr4:102828055~102844075:+
THCA	cis	rs7586673	0.866	rs7579662	ENSG00000235724.7	AC009299.2	-5.72	1.95e-08	3.4e-06	-0.27	-0.25	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161222785~161308303:-
THCA	cis	rs7404843	1	rs7404843	ENSG00000263335.1	AF001548.5	-5.72	1.95e-08	3.4e-06	-0.42	-0.25	Testicular germ cell tumor;	chr16:15436851	chr16:15726674~15732993:+
THCA	cis	rs755249	1	rs755249	ENSG00000228060.1	RP11-69E11.8	-5.72	1.95e-08	3.4e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39565160~39573203:+
THCA	cis	rs8062405	0.824	rs7191618	ENSG00000278665.1	RP11-666O2.4	5.72	1.95e-08	3.4e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.754	rs3859172	ENSG00000278665.1	RP11-666O2.4	5.72	1.95e-08	3.4e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28599241~28601881:-
THCA	cis	rs763121	0.853	rs1056610	ENSG00000273076.1	RP3-508I15.22	-5.71	1.95e-08	3.41e-06	-0.25	-0.25	Menopause (age at onset);	chr22:38684073	chr22:38743495~38743910:+
THCA	cis	rs853679	0.55	rs9295762	ENSG00000261839.1	RP1-265C24.8	-5.71	1.95e-08	3.41e-06	-0.3	-0.25	Depression;	chr6:28187640	chr6:28136849~28139678:+
THCA	cis	rs61677309	1	rs2120269	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118280420	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.964	rs55798741	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118283399	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs58520343	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118284285	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.964	rs55815657	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118284359	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs67462512	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118284621	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs1074459	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118285282	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs1074457	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118285402	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs56938099	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118285973	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs61390396	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118286003	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs66832804	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118286334	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs12576947	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118287340	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs12576100	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118287566	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.964	rs12576118	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118287725	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.929	rs12576119	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118287726	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs56357739	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118287792	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs55899310	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118287987	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs56224295	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118291176	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs55806415	ENSG00000280032.1	RP11-832A4.7	5.71	1.95e-08	3.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118292147	chr11:118264593~118266817:+
THCA	cis	rs651907	0.737	rs9844218	ENSG00000256628.3	ZBTB11-AS1	-5.71	1.95e-08	3.41e-06	-0.3	-0.25	Colorectal cancer;	chr3:101866139	chr3:101676475~101679217:+
THCA	cis	rs763121	0.925	rs4821797	ENSG00000273076.1	RP3-508I15.22	5.71	1.95e-08	3.41e-06	0.24	0.25	Menopause (age at onset);	chr22:38620177	chr22:38743495~38743910:+
THCA	cis	rs4713118	0.513	rs149955	ENSG00000226314.6	ZNF192P1	-5.71	1.95e-08	3.41e-06	-0.3	-0.25	Parkinson's disease;	chr6:28068447	chr6:28161781~28169594:+
THCA	cis	rs4748857	0.685	rs7070758	ENSG00000224215.1	RP11-371A19.2	-5.71	1.95e-08	3.41e-06	-0.33	-0.25	Systemic lupus erythematosus;	chr10:23263129	chr10:23343957~23345181:+
THCA	cis	rs5742933	0.803	rs1233302	ENSG00000253559.1	OSGEPL1-AS1	-5.71	1.95e-08	3.41e-06	-0.29	-0.25	Ferritin levels;	chr2:189804154	chr2:189762704~189765556:+
THCA	cis	rs7412746	0.658	rs10305704	ENSG00000231073.1	RP11-316M1.3	5.71	1.95e-08	3.41e-06	0.31	0.25	Melanoma;	chr1:150831953	chr1:150973123~150975534:+
THCA	cis	rs7727544	0.684	rs270602	ENSG00000224431.1	AC063976.7	5.71	1.95e-08	3.41e-06	0.22	0.25	Blood metabolite levels;	chr5:132321007	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.684	rs272893	ENSG00000224431.1	AC063976.7	5.71	1.95e-08	3.41e-06	0.22	0.25	Blood metabolite levels;	chr5:132327369	chr5:132199456~132203487:+
THCA	cis	rs412050	0.895	rs2329886	ENSG00000224086.5	LL22NC03-86G7.1	-5.71	1.95e-08	3.41e-06	-0.42	-0.25	Attention deficit hyperactivity disorder;	chr22:21944102	chr22:21938293~21977632:+
THCA	cis	rs4266144	0.558	rs34696078	ENSG00000241770.1	RP11-555M1.3	-5.71	1.95e-08	3.41e-06	-0.32	-0.25	Coronary artery disease;	chr3:157114875	chr3:157163452~157169133:+
THCA	cis	rs875971	0.564	rs313804	ENSG00000223473.2	GS1-124K5.3	5.71	1.96e-08	3.41e-06	0.18	0.25	Aortic root size;	chr7:66049635	chr7:66491049~66493566:-
THCA	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-5.71	1.96e-08	3.41e-06	-0.32	-0.25	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
THCA	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	5.71	1.96e-08	3.41e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
THCA	cis	rs9880211	0.8	rs28390205	ENSG00000273486.1	RP11-731C17.2	5.71	1.96e-08	3.42e-06	0.27	0.25	Height;Body mass index;	chr3:136646008	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.752	rs35428413	ENSG00000273486.1	RP11-731C17.2	5.71	1.96e-08	3.42e-06	0.27	0.25	Height;Body mass index;	chr3:136661856	chr3:136837338~136839021:-
THCA	cis	rs1499614	0.901	rs3936	ENSG00000232559.3	GS1-124K5.12	5.71	1.96e-08	3.42e-06	0.39	0.25	Gout;	chr7:66661502	chr7:66554588~66576923:-
THCA	cis	rs1499614	1	rs1638731	ENSG00000232559.3	GS1-124K5.12	5.71	1.96e-08	3.42e-06	0.39	0.25	Gout;	chr7:66679692	chr7:66554588~66576923:-
THCA	cis	rs1499614	1	rs1882655	ENSG00000232559.3	GS1-124K5.12	-5.71	1.96e-08	3.42e-06	-0.39	-0.25	Gout;	chr7:66682070	chr7:66554588~66576923:-
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000232559.3	GS1-124K5.12	-5.71	1.96e-08	3.42e-06	-0.39	-0.25	Gout;	chr7:66682162	chr7:66554588~66576923:-
THCA	cis	rs9307551	1	rs11098770	ENSG00000250334.4	LINC00989	-5.71	1.96e-08	3.42e-06	-0.32	-0.25	Refractive error;	chr4:79598850	chr4:79492416~79576460:+
THCA	cis	rs375066	0.623	rs239949	ENSG00000267058.1	RP11-15A1.3	-5.71	1.96e-08	3.42e-06	-0.22	-0.25	Breast cancer;	chr19:43852475	chr19:43891804~43901805:-
THCA	cis	rs7829975	0.902	rs485107	ENSG00000254153.1	CTA-398F10.2	5.71	1.96e-08	3.42e-06	0.27	0.25	Mood instability;	chr8:8723898	chr8:8456909~8461337:-
THCA	cis	rs6545883	0.772	rs1186709	ENSG00000271889.1	RP11-493E12.1	5.71	1.96e-08	3.42e-06	0.25	0.25	Tuberculosis;	chr2:61462245	chr2:61151433~61162105:-
THCA	cis	rs1125355	0.69	rs62183660	ENSG00000251491.2	OR7E28P	-5.71	1.96e-08	3.42e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158782804	chr2:158862311~158863285:+
THCA	cis	rs1552244	1	rs17032268	ENSG00000232901.1	CYCSP10	5.71	1.96e-08	3.42e-06	0.34	0.25	Alzheimer's disease;	chr3:10026288	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs3846177	ENSG00000232901.1	CYCSP10	5.71	1.96e-08	3.42e-06	0.34	0.25	Alzheimer's disease;	chr3:10026888	chr3:10000647~10000940:-
THCA	cis	rs1707322	0.721	rs10430123	ENSG00000281133.1	AL355480.3	-5.71	1.97e-08	3.43e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45580892~45580996:-
THCA	cis	rs9813712	0.818	rs11718381	ENSG00000228252.7	COL6A4P2	5.71	1.97e-08	3.43e-06	0.3	0.25	Response to amphetamines;	chr3:130222660	chr3:130212823~130273806:+
THCA	cis	rs7727544	0.735	rs272884	ENSG00000224431.1	AC063976.7	5.71	1.97e-08	3.43e-06	0.22	0.25	Blood metabolite levels;	chr5:132332961	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.735	rs272881	ENSG00000224431.1	AC063976.7	5.71	1.97e-08	3.43e-06	0.22	0.25	Blood metabolite levels;	chr5:132333571	chr5:132199456~132203487:+
THCA	cis	rs274567	0.602	rs272853	ENSG00000263597.1	MIR3936	5.71	1.97e-08	3.43e-06	0.25	0.25	Blood metabolite levels;	chr5:132352868	chr5:132365490~132365599:-
THCA	cis	rs3785574	0.962	rs7215915	ENSG00000240280.5	TCAM1P	-5.71	1.97e-08	3.43e-06	-0.35	-0.25	Height;	chr17:63751025	chr17:63849292~63864379:+
THCA	cis	rs17772222	0.56	rs3742681	ENSG00000258983.2	RP11-507K2.2	-5.71	1.97e-08	3.44e-06	-0.3	-0.25	Coronary artery calcification;	chr14:88554903	chr14:88499334~88515502:+
THCA	cis	rs9595908	0.931	rs9595595	ENSG00000212293.1	SNORA16	5.71	1.97e-08	3.44e-06	0.31	0.25	Body mass index;	chr13:32473678	chr13:32420390~32420516:-
THCA	cis	rs1387259	0.859	rs2054905	ENSG00000240399.1	RP1-228P16.1	5.71	1.97e-08	3.44e-06	0.26	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.5	rs2732461	ENSG00000240399.1	RP1-228P16.1	5.71	1.97e-08	3.44e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48054813~48055591:-
THCA	cis	rs2439831	0.557	rs13329084	ENSG00000166763.7	STRCP1	-5.71	1.98e-08	3.44e-06	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43858865	chr15:43699488~43718184:-
THCA	cis	rs73242632	1	rs12510703	ENSG00000269949.1	RP11-738E22.3	5.71	1.98e-08	3.45e-06	0.52	0.25	Congenital heart disease (maternal effect);	chr4:56882132	chr4:56960927~56961373:-
THCA	cis	rs78487399	0.71	rs28470852	ENSG00000234936.1	AC010883.5	5.71	1.98e-08	3.45e-06	0.38	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43365861	chr2:43229573~43233394:+
THCA	cis	rs2439831	0.85	rs10163054	ENSG00000166763.7	STRCP1	5.71	1.98e-08	3.45e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43755440	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs12442129	ENSG00000166763.7	STRCP1	5.71	1.98e-08	3.45e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43763658	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.702	rs7175032	ENSG00000166763.7	STRCP1	5.71	1.98e-08	3.45e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43768038	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs2277531	ENSG00000166763.7	STRCP1	5.71	1.98e-08	3.45e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43776871	chr15:43699488~43718184:-
THCA	cis	rs9876781	1	rs1459242	ENSG00000229759.1	MRPS18AP1	-5.71	1.98e-08	3.45e-06	-0.3	-0.25	Longevity;	chr3:48372047	chr3:48256350~48256938:-
THCA	cis	rs2439831	0.681	rs540388	ENSG00000249839.1	AC011330.5	-5.71	1.98e-08	3.45e-06	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43314296	chr15:43663654~43684339:-
THCA	cis	rs8062405	0.792	rs12446550	ENSG00000278665.1	RP11-666O2.4	5.71	1.98e-08	3.45e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28599241~28601881:-
THCA	cis	rs12497850	0.865	rs13072911	ENSG00000229759.1	MRPS18AP1	5.71	1.98e-08	3.45e-06	0.34	0.25	Parkinson's disease;	chr3:48924695	chr3:48256350~48256938:-
THCA	cis	rs7674212	0.541	rs2720464	ENSG00000246560.2	RP11-10L12.4	5.71	1.98e-08	3.46e-06	0.3	0.25	Type 2 diabetes;	chr4:103152044	chr4:102828055~102844075:+
THCA	cis	rs2732480	0.577	rs2732479	ENSG00000240399.1	RP1-228P16.1	5.71	1.98e-08	3.46e-06	0.27	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.537	rs1061986	ENSG00000240399.1	RP1-228P16.1	5.71	1.98e-08	3.46e-06	0.27	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48054813~48055591:-
THCA	cis	rs7727544	0.735	rs272875	ENSG00000224431.1	AC063976.7	5.71	1.98e-08	3.46e-06	0.22	0.25	Blood metabolite levels;	chr5:132339195	chr5:132199456~132203487:+
THCA	cis	rs6840360	0.642	rs11099815	ENSG00000270265.1	RP11-731D1.4	-5.71	1.98e-08	3.46e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151333775~151353224:-
THCA	cis	rs7646881	0.5	rs73022762	ENSG00000240207.5	RP11-379F4.4	-5.71	1.98e-08	3.46e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158572516	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs9881679	ENSG00000240207.5	RP11-379F4.4	-5.71	1.98e-08	3.46e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158580643	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs9849437	ENSG00000240207.5	RP11-379F4.4	-5.71	1.98e-08	3.46e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158581612	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs28856044	ENSG00000240207.5	RP11-379F4.4	-5.71	1.98e-08	3.46e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158584970	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.508	rs6779054	ENSG00000240207.5	RP11-379F4.4	-5.71	1.98e-08	3.46e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158587658	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs9872682	ENSG00000240207.5	RP11-379F4.4	-5.71	1.98e-08	3.46e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158592117	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs13318109	ENSG00000240207.5	RP11-379F4.4	-5.71	1.98e-08	3.46e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158595417	chr3:158732263~158784070:+
THCA	cis	rs1125355	0.653	rs72937273	ENSG00000251491.2	OR7E28P	-5.71	1.98e-08	3.46e-06	-0.41	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158762204	chr2:158862311~158863285:+
THCA	cis	rs2976388	0.566	rs6998746	ENSG00000253741.1	CTD-2292P10.4	-5.71	1.98e-08	3.46e-06	-0.35	-0.25	Urinary tract infection frequency;	chr8:142721038	chr8:142702252~142726973:-
THCA	cis	rs11266744	0.678	rs2856757	ENSG00000223552.1	RP11-24F11.2	5.71	1.99e-08	3.46e-06	0.23	0.25	Monocyte percentage of white cells;	chr3:46369003	chr3:46364955~46407059:-
THCA	cis	rs1707322	0.721	rs10890333	ENSG00000281133.1	AL355480.3	-5.71	1.99e-08	3.46e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs12043945	ENSG00000281133.1	AL355480.3	-5.71	1.99e-08	3.46e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs12091503	ENSG00000281133.1	AL355480.3	-5.71	1.99e-08	3.46e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs10890336	ENSG00000281133.1	AL355480.3	-5.71	1.99e-08	3.46e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45580892~45580996:-
THCA	cis	rs9921338	0.961	rs8056282	ENSG00000262703.1	RP11-485G7.6	-5.71	1.99e-08	3.46e-06	-0.34	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11313379	chr16:11348143~11349321:-
THCA	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	5.71	1.99e-08	3.47e-06	0.2	0.25	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
THCA	cis	rs6740322	0.793	rs13414908	ENSG00000234936.1	AC010883.5	5.71	1.99e-08	3.47e-06	0.27	0.25	Coronary artery disease;	chr2:43319519	chr2:43229573~43233394:+
THCA	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	5.71	1.99e-08	3.47e-06	0.39	0.25	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
THCA	cis	rs1876905	0.68	rs9384787	ENSG00000230177.1	RP5-1112D6.4	5.71	1.99e-08	3.47e-06	0.26	0.25	Mean corpuscular hemoglobin;	chr6:111113707	chr6:111277932~111278742:+
THCA	cis	rs5742933	0.857	rs1233284	ENSG00000273240.1	RP11-455J20.3	-5.71	1.99e-08	3.48e-06	-0.26	-0.25	Ferritin levels;	chr2:189825045	chr2:189763859~189764456:-
THCA	cis	rs5742933	0.817	rs1233288	ENSG00000273240.1	RP11-455J20.3	-5.71	1.99e-08	3.48e-06	-0.26	-0.25	Ferritin levels;	chr2:189825999	chr2:189763859~189764456:-
THCA	cis	rs801193	1	rs7782320	ENSG00000273142.1	RP11-458F8.4	-5.71	2e-08	3.48e-06	-0.2	-0.25	Aortic root size;	chr7:66712111	chr7:66902857~66906297:+
THCA	cis	rs2337406	0.925	rs34064152	ENSG00000211974.3	IGHV2-70	-5.71	2e-08	3.48e-06	-0.27	-0.25	Alzheimer's disease (late onset);	chr14:106700364	chr14:106723574~106724093:-
THCA	cis	rs7829975	0.511	rs2980423	ENSG00000254153.1	CTA-398F10.2	-5.71	2e-08	3.48e-06	-0.28	-0.25	Mood instability;	chr8:8285053	chr8:8456909~8461337:-
THCA	cis	rs9876781	1	rs2885510	ENSG00000229759.1	MRPS18AP1	-5.71	2e-08	3.48e-06	-0.3	-0.25	Longevity;	chr3:48376736	chr3:48256350~48256938:-
THCA	cis	rs7523875	0.572	rs78011846	ENSG00000153363.11	LINC00467	-5.71	2e-08	3.48e-06	-0.32	-0.25	Mean corpuscular volume;	chr1:211432570	chr1:211382803~211435333:+
THCA	cis	rs4776997	0.536	rs11071959	ENSG00000270964.1	RP11-502I4.3	-5.71	2e-08	3.48e-06	-0.23	-0.25	Verbal declarative memory;	chr15:67766565	chr15:67541072~67542604:-
THCA	cis	rs2732480	0.5	rs2450986	ENSG00000240399.1	RP1-228P16.1	5.71	2e-08	3.48e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48054813~48055591:-
THCA	cis	rs801193	1	rs62466793	ENSG00000273142.1	RP11-458F8.4	-5.71	2e-08	3.48e-06	-0.2	-0.25	Aortic root size;	chr7:66726530	chr7:66902857~66906297:+
THCA	cis	rs10895275	0.961	rs11225165	ENSG00000277459.1	RP11-732A21.3	-5.71	2e-08	3.48e-06	-0.2	-0.25	Migraine;	chr11:102213843	chr11:102109827~102110457:-
THCA	cis	rs6928977	0.86	rs2614266	ENSG00000231028.7	LINC00271	5.71	2e-08	3.49e-06	0.21	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135395394	chr6:135497801~135716055:+
THCA	cis	rs2839186	0.867	rs13050387	ENSG00000239415.1	AP001469.9	5.71	2e-08	3.49e-06	0.26	0.25	Testicular germ cell tumor;	chr21:46281509	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.872	rs13046834	ENSG00000239415.1	AP001469.9	5.71	2e-08	3.49e-06	0.26	0.25	Testicular germ cell tumor;	chr21:46281571	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.721	rs13051200	ENSG00000239415.1	AP001469.9	5.71	2e-08	3.49e-06	0.26	0.25	Testicular germ cell tumor;	chr21:46281779	chr21:46251549~46254133:-
THCA	cis	rs17772222	1	rs3814855	ENSG00000222990.1	RNU4-22P	5.71	2e-08	3.49e-06	0.34	0.25	Coronary artery calcification;	chr14:88467016	chr14:88513498~88513663:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000234585.5	CCT6P3	5.71	2e-08	3.49e-06	0.24	0.25	Calcium levels;	chr7:65977808	chr7:65038354~65074713:+
THCA	cis	rs2348418	0.832	rs11049560	ENSG00000247934.4	RP11-967K21.1	5.71	2e-08	3.49e-06	0.22	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28372504	chr12:28163298~28190738:-
THCA	cis	rs9309473	0.519	rs13009035	ENSG00000163016.8	ALMS1P	-5.71	2e-08	3.49e-06	-0.33	-0.25	Metabolite levels;	chr2:73618582	chr2:73644919~73685576:+
THCA	cis	rs11723261	0.582	rs11735742	ENSG00000211553.1	AC253576.2	5.71	2e-08	3.49e-06	0.35	0.25	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:136461~136568:+
THCA	cis	rs934734	1	rs934734	ENSG00000234255.7	AC012370.3	-5.71	2e-08	3.49e-06	-0.28	-0.25	Rheumatoid arthritis;	chr2:65368452	chr2:65439888~65456571:-
THCA	cis	rs875971	0.658	rs432667	ENSG00000223473.2	GS1-124K5.3	5.71	2e-08	3.49e-06	0.18	0.25	Aortic root size;	chr7:66049646	chr7:66491049~66493566:-
THCA	cis	rs9309473	0.5	rs10865398	ENSG00000163016.8	ALMS1P	-5.71	2.01e-08	3.49e-06	-0.33	-0.25	Metabolite levels;	chr2:73514370	chr2:73644919~73685576:+
THCA	cis	rs748404	0.723	rs573169	ENSG00000166763.7	STRCP1	5.71	2.01e-08	3.5e-06	0.27	0.25	Lung cancer;	chr15:43258383	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs524547	ENSG00000166763.7	STRCP1	5.71	2.01e-08	3.5e-06	0.27	0.25	Lung cancer;	chr15:43258825	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs564946	ENSG00000166763.7	STRCP1	5.71	2.01e-08	3.5e-06	0.27	0.25	Lung cancer;	chr15:43264074	chr15:43699488~43718184:-
THCA	cis	rs748404	0.723	rs565658	ENSG00000166763.7	STRCP1	5.71	2.01e-08	3.5e-06	0.27	0.25	Lung cancer;	chr15:43264109	chr15:43699488~43718184:-
THCA	cis	rs748404	0.697	rs579651	ENSG00000166763.7	STRCP1	5.71	2.01e-08	3.5e-06	0.27	0.25	Lung cancer;	chr15:43266178	chr15:43699488~43718184:-
THCA	cis	rs9625935	0.748	rs2412974	ENSG00000279159.1	RP3-394A18.1	-5.71	2.01e-08	3.5e-06	-0.18	-0.25	Tonsillectomy;	chr22:30143832	chr22:29978950~30028236:-
THCA	cis	rs1318937	0.764	rs11128738	ENSG00000224660.1	SH3BP5-AS1	5.71	2.01e-08	3.5e-06	0.16	0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15200989	chr3:15254184~15264493:+
THCA	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-5.71	2.01e-08	3.5e-06	-0.47	-0.25	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
THCA	cis	rs6860806	0.661	rs2171247	ENSG00000233006.5	AC034220.3	5.71	2.01e-08	3.5e-06	0.2	0.25	Breast cancer;	chr5:132244541	chr5:132311285~132369916:-
THCA	cis	rs2348418	0.733	rs4931078	ENSG00000247934.4	RP11-967K21.1	-5.71	2.01e-08	3.51e-06	-0.22	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28215067	chr12:28163298~28190738:-
THCA	cis	rs338389	0.542	rs11071972	ENSG00000260657.2	RP11-315D16.4	-5.71	2.01e-08	3.51e-06	-0.34	-0.25	Survival in rectal cancer;	chr15:67984005	chr15:68267792~68277994:-
THCA	cis	rs950169	0.544	rs62021193	ENSG00000275120.1	RP11-182J1.17	5.71	2.01e-08	3.51e-06	0.3	0.25	Schizophrenia;	chr15:84627352	chr15:84599434~84606463:-
THCA	cis	rs642803	0.613	rs489574	ENSG00000255557.1	RP11-770G2.2	-5.71	2.02e-08	3.51e-06	-0.28	-0.25	Urate levels;	chr11:65775268	chr11:65745729~65771585:+
THCA	cis	rs9506514	0.722	rs4769124	ENSG00000238286.1	SLC35E1P1	5.71	2.02e-08	3.51e-06	0.24	0.25	Coronary artery calcification;	chr13:20652706	chr13:20607268~20608131:+
THCA	cis	rs1823874	0.581	rs12905599	ENSG00000259363.4	CTD-2054N24.2	-5.71	2.02e-08	3.51e-06	-0.34	-0.25	IgG glycosylation;	chr15:99799733	chr15:99807023~99877148:+
THCA	cis	rs9859260	0.921	rs9877119	ENSG00000226155.1	AC124944.3	-5.71	2.02e-08	3.51e-06	-0.3	-0.25	Mean corpuscular volume;	chr3:196075495	chr3:195912049~195913986:+
THCA	cis	rs4950322	0.57	rs72691012	ENSG00000278811.3	LINC00624	5.71	2.02e-08	3.51e-06	0.31	0.25	Protein quantitative trait loci;	chr1:147239751	chr1:147258885~147517875:-
THCA	cis	rs9608946	0.515	rs3804078	ENSG00000279699.1	RP1-102K2.9	-5.71	2.02e-08	3.51e-06	-0.3	-0.25	Red cell distribution width;	chr22:30457895	chr22:30275215~30276951:-
THCA	cis	rs7010876	0.54	rs56187488	ENSG00000253553.4	RP11-586K2.1	5.71	2.02e-08	3.51e-06	0.27	0.25	Schizophrenia;	chr8:88373579	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.511	rs1463923	ENSG00000253553.4	RP11-586K2.1	5.71	2.02e-08	3.51e-06	0.27	0.25	Schizophrenia;	chr8:88379619	chr8:88326836~88737134:+
THCA	cis	rs317689	0.718	rs315130	ENSG00000274979.1	RP11-1143G9.5	-5.71	2.02e-08	3.52e-06	-0.31	-0.25	Response to diuretic therapy;	chr12:69367664	chr12:69326574~69331882:-
THCA	cis	rs713477	0.617	rs11627405	ENSG00000258413.1	RP11-665C16.6	5.71	2.02e-08	3.52e-06	0.35	0.25	Pediatric bone mineral content (femoral neck);	chr14:55444939	chr14:55262767~55272075:-
THCA	cis	rs757978	1	rs11681497	ENSG00000223374.1	AC005104.3	5.71	2.02e-08	3.52e-06	0.28	0.25	Chronic lymphocytic leukemia;	chr2:241404918	chr2:241351340~241353104:-
THCA	cis	rs4689592	0.619	rs2359011	ENSG00000245468.3	RP11-367J11.3	5.71	2.02e-08	3.52e-06	0.21	0.25	Monocyte percentage of white cells;	chr4:7064325	chr4:7094571~7103385:-
THCA	cis	rs13256369	0.802	rs2280560	ENSG00000253893.2	FAM85B	-5.71	2.02e-08	3.52e-06	-0.35	-0.25	Obesity-related traits;	chr8:8703092	chr8:8167819~8226614:-
THCA	cis	rs11089937	0.626	rs5757013	ENSG00000211639.2	IGLV4-60	5.71	2.02e-08	3.52e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22162199~22162681:+
THCA	cis	rs71520386	0.632	rs71520387	ENSG00000228649.7	AC005682.5	-5.71	2.03e-08	3.53e-06	-0.33	-0.25	Fibrinogen levels;	chr7:22830057	chr7:22854178~22861579:+
THCA	cis	rs71520386	0.632	rs10224244	ENSG00000228649.7	AC005682.5	-5.71	2.03e-08	3.53e-06	-0.33	-0.25	Fibrinogen levels;	chr7:22830455	chr7:22854178~22861579:+
THCA	cis	rs4908768	0.539	rs1061039	ENSG00000232912.4	RP5-1115A15.1	5.71	2.03e-08	3.53e-06	0.25	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8424645~8434838:+
THCA	cis	rs748404	0.666	rs34515241	ENSG00000249839.1	AC011330.5	-5.71	2.03e-08	3.53e-06	-0.37	-0.25	Lung cancer;	chr15:43342011	chr15:43663654~43684339:-
THCA	cis	rs499368	0.519	rs216243	ENSG00000256577.2	RP11-283I3.2	-5.71	2.03e-08	3.53e-06	-0.29	-0.25	Metabolite levels;Blood metabolite levels;	chr12:201112	chr12:203642~205094:+
THCA	cis	rs10208649	0.522	rs13395449	ENSG00000272156.1	RP11-477N3.1	5.71	2.03e-08	3.53e-06	0.57	0.25	Body mass index;	chr2:54178063	chr2:54082554~54085066:+
THCA	cis	rs2136613	0.728	rs10995325	ENSG00000238280.1	RP11-436D10.3	-5.71	2.03e-08	3.53e-06	-0.3	-0.25	Selective IgA deficiency;	chr10:62842577	chr10:62793562~62805887:-
THCA	cis	rs317689	0.68	rs315140	ENSG00000274979.1	RP11-1143G9.5	-5.71	2.03e-08	3.54e-06	-0.31	-0.25	Response to diuretic therapy;	chr12:69397000	chr12:69326574~69331882:-
THCA	cis	rs6445975	0.726	rs4330265	ENSG00000272360.1	RP11-359I18.5	-5.71	2.03e-08	3.54e-06	-0.27	-0.25	Systemic lupus erythematosus;	chr3:58482301	chr3:58490830~58491291:-
THCA	cis	rs792448	1	rs518793	ENSG00000226251.4	RP11-15I11.3	-5.71	2.03e-08	3.54e-06	-0.33	-0.25	White blood cell count (basophil);	chr1:212414864	chr1:212225278~212238977:-
THCA	cis	rs9859260	0.845	rs35587059	ENSG00000226155.1	AC124944.3	-5.71	2.03e-08	3.54e-06	-0.3	-0.25	Mean corpuscular volume;	chr3:196077473	chr3:195912049~195913986:+
THCA	cis	rs7809950	0.723	rs2237662	ENSG00000238832.1	snoU109	-5.71	2.04e-08	3.54e-06	-0.3	-0.25	Coronary artery disease;	chr7:107233620	chr7:107603363~107603507:+
THCA	cis	rs712039	0.652	rs853206	ENSG00000276054.1	RP11-378E13.3	5.71	2.04e-08	3.54e-06	0.38	0.25	Tuberculosis;	chr17:37464692	chr17:37386886~37387926:+
THCA	cis	rs7646881	0.544	rs58034569	ENSG00000240207.5	RP11-379F4.4	-5.71	2.04e-08	3.54e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158569900	chr3:158732263~158784070:+
THCA	cis	rs9307551	0.948	rs1371993	ENSG00000250334.4	LINC00989	-5.71	2.04e-08	3.54e-06	-0.33	-0.25	Refractive error;	chr4:79560662	chr4:79492416~79576460:+
THCA	cis	rs7267979	0.528	rs34485039	ENSG00000125804.12	FAM182A	5.71	2.04e-08	3.54e-06	0.33	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26054655~26086917:+
THCA	cis	rs2255336	0.938	rs73070926	ENSG00000245648.1	RP11-277P12.20	-5.71	2.04e-08	3.55e-06	-0.32	-0.25	Blood protein levels;	chr12:10459717	chr12:10363769~10398506:+
THCA	cis	rs758324	0.732	rs45236	ENSG00000237714.1	P4HA2-AS1	-5.71	2.04e-08	3.55e-06	-0.37	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132104927	chr5:132184876~132192808:+
THCA	cis	rs7824557	0.628	rs58283816	ENSG00000154316.13	TDH	-5.71	2.05e-08	3.56e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11335042	chr8:11339637~11368452:+
THCA	cis	rs11096990	0.964	rs56284364	ENSG00000249207.1	RP11-360F5.1	5.71	2.05e-08	3.56e-06	0.32	0.25	Cognitive function;	chr4:39255028	chr4:39112677~39126818:-
THCA	cis	rs763121	0.889	rs9607557	ENSG00000235209.1	CTA-150C2.13	5.71	2.05e-08	3.56e-06	0.32	0.25	Menopause (age at onset);	chr22:38644274	chr22:38921227~38924708:+
THCA	cis	rs12681287	0.752	rs10104138	ENSG00000254231.1	CTD-2284J15.1	5.71	2.05e-08	3.56e-06	0.28	0.25	Caudate activity during reward;	chr8:86235430	chr8:86333274~86343314:-
THCA	cis	rs2562456	0.52	rs279793	ENSG00000268555.1	RP11-678G14.3	5.71	2.05e-08	3.56e-06	0.4	0.25	Pain;	chr19:21272972	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.52	rs660063	ENSG00000268555.1	RP11-678G14.3	-5.71	2.05e-08	3.56e-06	-0.4	-0.25	Pain;	chr19:21271103	chr19:21570822~21587322:-
THCA	cis	rs9813712	0.571	rs6795143	ENSG00000249846.5	RP11-77P16.4	-5.71	2.05e-08	3.56e-06	-0.27	-0.25	Response to amphetamines;	chr3:130224355	chr3:130112550~130120579:+
THCA	cis	rs9813712	0.571	rs9289366	ENSG00000249846.5	RP11-77P16.4	-5.71	2.05e-08	3.56e-06	-0.27	-0.25	Response to amphetamines;	chr3:130225267	chr3:130112550~130120579:+
THCA	cis	rs9813712	0.571	rs9289367	ENSG00000249846.5	RP11-77P16.4	-5.71	2.05e-08	3.56e-06	-0.27	-0.25	Response to amphetamines;	chr3:130225286	chr3:130112550~130120579:+
THCA	cis	rs9876781	0.967	rs2885509	ENSG00000229759.1	MRPS18AP1	-5.71	2.05e-08	3.57e-06	-0.3	-0.25	Longevity;	chr3:48376729	chr3:48256350~48256938:-
THCA	cis	rs7554547	0.778	rs2008113	ENSG00000201801.1	RNU5E-4P	-5.71	2.05e-08	3.57e-06	-0.29	-0.25	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr1:11909808~11909927:-
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000237310.1	GS1-124K5.4	5.71	2.05e-08	3.57e-06	0.19	0.25	Calcium levels;	chr7:65829495	chr7:66493706~66495474:+
THCA	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	5.71	2.06e-08	3.57e-06	0.36	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
THCA	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	5.71	2.06e-08	3.57e-06	0.36	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
THCA	cis	rs7760535	0.826	rs10872068	ENSG00000271789.1	RP5-1112D6.7	5.71	2.06e-08	3.57e-06	0.25	0.25	Metabolic traits;	chr6:111528657	chr6:111297126~111298510:+
THCA	cis	rs4664293	0.541	rs1863218	ENSG00000226266.5	AC009961.3	5.71	2.06e-08	3.58e-06	0.3	0.25	Monocyte percentage of white cells;	chr2:159512276	chr2:159670708~159712435:-
THCA	cis	rs8042680	0.544	rs2034085	ENSG00000214432.8	AC068831.10	-5.71	2.06e-08	3.58e-06	-0.27	-0.25	Type 2 diabetes;	chr15:90963222	chr15:91022619~91036611:+
THCA	cis	rs3764400	0.567	rs12946208	ENSG00000278765.1	RP5-890E16.5	5.71	2.06e-08	3.58e-06	0.46	0.25	Body mass index;	chr17:48234767	chr17:48066704~48067293:-
THCA	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	5.71	2.06e-08	3.58e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
THCA	cis	rs6908034	0.607	rs12526109	ENSG00000237404.1	RP3-471C18.2	-5.71	2.06e-08	3.58e-06	-0.54	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819858	chr6:19689825~19753113:-
THCA	cis	rs9652601	0.959	rs12927355	ENSG00000274038.1	RP11-66H6.4	-5.7	2.06e-08	3.58e-06	-0.34	-0.25	Systemic lupus erythematosus;	chr16:11100914	chr16:11056556~11057034:+
THCA	cis	rs10266483	0.774	rs10253630	ENSG00000227986.1	TRIM60P18	5.7	2.06e-08	3.58e-06	0.22	0.25	Response to statin therapy;	chr7:64366962	chr7:64355078~64356199:+
THCA	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	5.7	2.06e-08	3.59e-06	0.31	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000280069.1	CTD-2349P21.3	-5.7	2.06e-08	3.59e-06	-0.39	-0.25	Body mass index;	chr17:30776148	chr17:30738182~30740275:+
THCA	cis	rs7412746	0.611	rs6660084	ENSG00000231073.1	RP11-316M1.3	5.7	2.06e-08	3.59e-06	0.3	0.25	Melanoma;	chr1:150776327	chr1:150973123~150975534:+
THCA	cis	rs9876781	1	rs6810060	ENSG00000229759.1	MRPS18AP1	5.7	2.07e-08	3.59e-06	0.3	0.25	Longevity;	chr3:48393284	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs6770470	ENSG00000229759.1	MRPS18AP1	5.7	2.07e-08	3.59e-06	0.3	0.25	Longevity;	chr3:48393659	chr3:48256350~48256938:-
THCA	cis	rs4683346	0.616	rs12639142	ENSG00000173811.9	CCDC13-AS1	-5.7	2.07e-08	3.59e-06	-0.26	-0.25	Granulocyte percentage of myeloid white cells;	chr3:42790040	chr3:42732575~42746768:+
THCA	cis	rs4664293	0.541	rs1425047	ENSG00000226266.5	AC009961.3	5.7	2.07e-08	3.59e-06	0.29	0.25	Monocyte percentage of white cells;	chr2:159517946	chr2:159670708~159712435:-
THCA	cis	rs1552244	0.554	rs3774207	ENSG00000180385.7	EMC3-AS1	5.7	2.07e-08	3.6e-06	0.25	0.25	Alzheimer's disease;	chr3:9943972	chr3:9986893~10006990:+
THCA	cis	rs253959	0.545	rs4921057	ENSG00000272265.1	CTD-2287O16.4	5.7	2.07e-08	3.6e-06	0.3	0.25	Bipolar disorder and schizophrenia;	chr5:116090723	chr5:116078110~116078570:-
THCA	cis	rs12497850	0.864	rs3212	ENSG00000229759.1	MRPS18AP1	5.7	2.07e-08	3.6e-06	0.34	0.25	Parkinson's disease;	chr3:49108308	chr3:48256350~48256938:-
THCA	cis	rs67478160	0.654	rs1535097	ENSG00000258735.1	LINC00637	-5.7	2.07e-08	3.6e-06	-0.3	-0.25	Schizophrenia;	chr14:103750312	chr14:103847721~103858049:+
THCA	cis	rs6044112	0.56	rs6080326	ENSG00000273998.1	RP4-777L9.2	5.7	2.07e-08	3.6e-06	0.44	0.25	Response to taxane treatment (docetaxel);	chr20:16614737	chr20:16576068~16579615:+
THCA	cis	rs9921338	0.961	rs7191093	ENSG00000262636.1	CTD-3088G3.4	-5.7	2.07e-08	3.6e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348422	chr16:11380859~11381118:-
THCA	cis	rs7727544	0.66	rs272886	ENSG00000224431.1	AC063976.7	5.7	2.07e-08	3.6e-06	0.22	0.25	Blood metabolite levels;	chr5:132330147	chr5:132199456~132203487:+
THCA	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-5.7	2.08e-08	3.61e-06	-0.35	-0.25	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
THCA	cis	rs180730	0.752	rs3115311	ENSG00000251609.2	SETP12	-5.7	2.08e-08	3.61e-06	-0.5	-0.25	Fasting plasma glucose;	chr4:120880906	chr4:120895494~120897083:-
THCA	cis	rs9902453	0.584	rs3809790	ENSG00000263370.1	RP11-68I3.5	-5.7	2.08e-08	3.61e-06	-0.33	-0.25	Coffee consumption (cups per day);	chr17:29628522	chr17:29639627~29640825:+
THCA	cis	rs10761482	0.515	rs2393642	ENSG00000254271.1	RP11-131N11.4	5.7	2.08e-08	3.61e-06	0.33	0.25	Schizophrenia;	chr10:60522732	chr10:60734342~60741828:+
THCA	cis	rs2303319	0.504	rs12474713	ENSG00000227403.1	AC009299.3	5.7	2.08e-08	3.61e-06	0.53	0.25	Cognitive function;	chr2:161712831	chr2:161244739~161249050:+
THCA	cis	rs1395	0.778	rs62128747	ENSG00000234072.1	AC074117.10	-5.7	2.08e-08	3.61e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27189737	chr2:27356246~27367622:+
THCA	cis	rs1395	0.778	rs11693001	ENSG00000234072.1	AC074117.10	-5.7	2.08e-08	3.61e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27189876	chr2:27356246~27367622:+
THCA	cis	rs642803	0.613	rs565427	ENSG00000255557.1	RP11-770G2.2	-5.7	2.08e-08	3.61e-06	-0.28	-0.25	Urate levels;	chr11:65765354	chr11:65745729~65771585:+
THCA	cis	rs792448	1	rs792448	ENSG00000226251.4	RP11-15I11.3	5.7	2.08e-08	3.61e-06	0.33	0.25	White blood cell count (basophil);	chr1:212385055	chr1:212225278~212238977:-
THCA	cis	rs12612619	0.677	rs67100745	ENSG00000229122.1	AGBL5-IT1	5.7	2.08e-08	3.61e-06	0.19	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027882	chr2:27061038~27061815:+
THCA	cis	rs713477	0.967	rs6573031	ENSG00000258413.1	RP11-665C16.6	5.7	2.08e-08	3.61e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55447045	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs6573032	ENSG00000258413.1	RP11-665C16.6	5.7	2.08e-08	3.61e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55447058	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs7146170	ENSG00000258413.1	RP11-665C16.6	5.7	2.08e-08	3.61e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55447336	chr14:55262767~55272075:-
THCA	cis	rs713477	0.935	rs10144034	ENSG00000258413.1	RP11-665C16.6	5.7	2.08e-08	3.61e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55447555	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs8009706	ENSG00000258413.1	RP11-665C16.6	5.7	2.08e-08	3.61e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55448038	chr14:55262767~55272075:-
THCA	cis	rs713477	0.967	rs4901570	ENSG00000258413.1	RP11-665C16.6	5.7	2.08e-08	3.61e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55448531	chr14:55262767~55272075:-
THCA	cis	rs1499614	1	rs2141924	ENSG00000232546.1	RP11-458F8.1	-5.7	2.08e-08	3.61e-06	-0.34	-0.25	Gout;	chr7:66721259	chr7:66848496~66858136:+
THCA	cis	rs10266483	0.545	rs116760071	ENSG00000227986.1	TRIM60P18	5.7	2.08e-08	3.61e-06	0.24	0.25	Response to statin therapy;	chr7:64289082	chr7:64355078~64356199:+
THCA	cis	rs1552244	1	rs9845756	ENSG00000232901.1	CYCSP10	5.7	2.08e-08	3.61e-06	0.34	0.25	Alzheimer's disease;	chr3:10025864	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs33917318	ENSG00000232901.1	CYCSP10	5.7	2.08e-08	3.61e-06	0.34	0.25	Alzheimer's disease;	chr3:10026113	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs35515831	ENSG00000232901.1	CYCSP10	5.7	2.08e-08	3.61e-06	0.34	0.25	Alzheimer's disease;	chr3:10029678	chr3:10000647~10000940:-
THCA	cis	rs7829975	0.514	rs2979151	ENSG00000254153.1	CTA-398F10.2	5.7	2.08e-08	3.61e-06	0.26	0.25	Mood instability;	chr8:8400509	chr8:8456909~8461337:-
THCA	cis	rs11089937	0.512	rs6001073	ENSG00000211639.2	IGLV4-60	5.7	2.08e-08	3.61e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.539	rs6001075	ENSG00000211639.2	IGLV4-60	5.7	2.08e-08	3.61e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs5757005	ENSG00000211639.2	IGLV4-60	5.7	2.08e-08	3.61e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22162199~22162681:+
THCA	cis	rs2645288	1	rs2645288	ENSG00000231365.4	RP11-418J17.1	-5.7	2.08e-08	3.61e-06	-0.29	-0.25	Breast size;	chr1:118957860	chr1:119140396~119275973:+
THCA	cis	rs6569038	0.502	rs57285368	ENSG00000253194.1	RP11-351A11.1	5.7	2.08e-08	3.62e-06	0.35	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118993517	chr6:118934785~119031541:+
THCA	cis	rs6569038	0.502	rs57100274	ENSG00000253194.1	RP11-351A11.1	5.7	2.08e-08	3.62e-06	0.35	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118993610	chr6:118934785~119031541:+
THCA	cis	rs6569038	0.502	rs9401113	ENSG00000253194.1	RP11-351A11.1	5.7	2.08e-08	3.62e-06	0.35	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118993959	chr6:118934785~119031541:+
THCA	cis	rs6908034	0.607	rs79406203	ENSG00000237404.1	RP3-471C18.2	-5.7	2.08e-08	3.62e-06	-0.53	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19815990	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.607	rs74559916	ENSG00000237404.1	RP3-471C18.2	-5.7	2.08e-08	3.62e-06	-0.53	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818486	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.505	rs76391302	ENSG00000237404.1	RP3-471C18.2	-5.7	2.08e-08	3.62e-06	-0.53	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818885	chr6:19689825~19753113:-
THCA	cis	rs6908034	0.505	rs77880623	ENSG00000237404.1	RP3-471C18.2	-5.7	2.08e-08	3.62e-06	-0.53	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819223	chr6:19689825~19753113:-
THCA	cis	rs3822625	1	rs1017226	ENSG00000271828.1	CTD-2310F14.1	5.7	2.08e-08	3.62e-06	0.63	0.25	Breast cancer (early onset);	chr5:56857565	chr5:56927874~56929573:+
THCA	cis	rs12478296	1	rs56136197	ENSG00000261186.2	RP11-341N2.1	-5.7	2.08e-08	3.62e-06	-0.4	-0.25	Obesity-related traits;	chr2:242101726	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs56387669	ENSG00000261186.2	RP11-341N2.1	-5.7	2.08e-08	3.62e-06	-0.4	-0.25	Obesity-related traits;	chr2:242101738	chr2:242087351~242088457:-
THCA	cis	rs1275468	0.731	rs3912214	ENSG00000257497.2	RP11-585P4.5	-5.7	2.09e-08	3.62e-06	-0.39	-0.25	Polycystic ovary syndrome;	chr12:75550245	chr12:75483454~75489820:-
THCA	cis	rs10027350	0.857	rs3796793	ENSG00000281501.1	SEPSECS-AS1	5.7	2.09e-08	3.62e-06	0.29	0.25	Childhood ear infection;	chr4:25142945	chr4:25160641~25201440:+
THCA	cis	rs997295	0.57	rs737226	ENSG00000270964.1	RP11-502I4.3	-5.7	2.09e-08	3.62e-06	-0.21	-0.25	Motion sickness;	chr15:67548435	chr15:67541072~67542604:-
THCA	cis	rs874628	0.851	rs12461072	ENSG00000268650.3	AC068499.10	5.7	2.09e-08	3.63e-06	0.28	0.25	Multiple sclerosis;	chr19:18219782	chr19:18204730~18220480:+
THCA	cis	rs6840360	0.642	rs2034061	ENSG00000270265.1	RP11-731D1.4	-5.7	2.09e-08	3.63e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs7682837	ENSG00000270265.1	RP11-731D1.4	-5.7	2.09e-08	3.63e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151333775~151353224:-
THCA	cis	rs2735413	0.564	rs7191314	ENSG00000276007.1	RP11-358L22.3	5.7	2.09e-08	3.63e-06	0.27	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78050339	chr16:78123243~78124332:+
THCA	cis	rs6840360	0.642	rs6855845	ENSG00000270265.1	RP11-731D1.4	-5.7	2.09e-08	3.63e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151333775~151353224:-
THCA	cis	rs3764400	0.567	rs1452662	ENSG00000278765.1	RP5-890E16.5	5.7	2.09e-08	3.63e-06	0.46	0.25	Body mass index;	chr17:48215948	chr17:48066704~48067293:-
THCA	cis	rs3742264	1	rs9526137	ENSG00000235903.6	CPB2-AS1	-5.7	2.09e-08	3.63e-06	-0.34	-0.25	Blood protein levels;	chr13:46067114	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs9534305	ENSG00000235903.6	CPB2-AS1	-5.7	2.09e-08	3.63e-06	-0.34	-0.25	Blood protein levels;	chr13:46068021	chr13:46052806~46113332:+
THCA	cis	rs55823223	0.504	rs2034946	ENSG00000267801.1	RP11-552F3.9	5.7	2.09e-08	3.63e-06	0.34	0.25	Psoriasis;	chr17:75867508	chr17:75876372~75879546:+
THCA	cis	rs1499614	1	rs2659913	ENSG00000232546.1	RP11-458F8.1	-5.7	2.09e-08	3.64e-06	-0.34	-0.25	Gout;	chr7:66692349	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs2659911	ENSG00000232546.1	RP11-458F8.1	-5.7	2.09e-08	3.64e-06	-0.34	-0.25	Gout;	chr7:66693433	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs2707838	ENSG00000232546.1	RP11-458F8.1	-5.7	2.09e-08	3.64e-06	-0.34	-0.25	Gout;	chr7:66694214	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs60326618	ENSG00000232546.1	RP11-458F8.1	-5.7	2.09e-08	3.64e-06	-0.34	-0.25	Gout;	chr7:66701371	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs2707830	ENSG00000232546.1	RP11-458F8.1	-5.7	2.09e-08	3.64e-06	-0.34	-0.25	Gout;	chr7:66702658	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs2707828	ENSG00000232546.1	RP11-458F8.1	-5.7	2.09e-08	3.64e-06	-0.34	-0.25	Gout;	chr7:66706390	chr7:66848496~66858136:+
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000232546.1	RP11-458F8.1	-5.7	2.09e-08	3.64e-06	-0.34	-0.25	Gout;	chr7:66710076	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs2659903	ENSG00000232546.1	RP11-458F8.1	-5.7	2.09e-08	3.64e-06	-0.34	-0.25	Gout;	chr7:66715944	chr7:66848496~66858136:+
THCA	cis	rs5742933	0.817	rs1233299	ENSG00000253559.1	OSGEPL1-AS1	-5.7	2.1e-08	3.64e-06	-0.29	-0.25	Ferritin levels;	chr2:189799912	chr2:189762704~189765556:+
THCA	cis	rs2136613	0.533	rs1475082	ENSG00000238280.1	RP11-436D10.3	-5.7	2.1e-08	3.64e-06	-0.29	-0.25	Selective IgA deficiency;	chr10:62845621	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs1475083	ENSG00000238280.1	RP11-436D10.3	-5.7	2.1e-08	3.64e-06	-0.29	-0.25	Selective IgA deficiency;	chr10:62845638	chr10:62793562~62805887:-
THCA	cis	rs6044112	0.701	rs12481403	ENSG00000273998.1	RP4-777L9.2	5.7	2.1e-08	3.64e-06	0.43	0.25	Response to taxane treatment (docetaxel);	chr20:16570306	chr20:16576068~16579615:+
THCA	cis	rs2303319	0.504	rs56153413	ENSG00000227403.1	AC009299.3	5.7	2.1e-08	3.64e-06	0.52	0.25	Cognitive function;	chr2:161583569	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.582	rs12464282	ENSG00000227403.1	AC009299.3	5.7	2.1e-08	3.64e-06	0.52	0.25	Cognitive function;	chr2:161592345	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs2175142	ENSG00000227403.1	AC009299.3	5.7	2.1e-08	3.64e-06	0.52	0.25	Cognitive function;	chr2:161593614	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs55821334	ENSG00000227403.1	AC009299.3	5.7	2.1e-08	3.64e-06	0.52	0.25	Cognitive function;	chr2:161595504	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56407015	ENSG00000227403.1	AC009299.3	5.7	2.1e-08	3.64e-06	0.52	0.25	Cognitive function;	chr2:161599115	chr2:161244739~161249050:+
THCA	cis	rs972578	0.501	rs5759126	ENSG00000230319.1	AL022476.2	5.7	2.1e-08	3.64e-06	0.28	0.25	Mean platelet volume;	chr22:43059659	chr22:43038585~43052366:+
THCA	cis	rs792448	0.926	rs701905	ENSG00000226251.4	RP11-15I11.3	-5.7	2.1e-08	3.65e-06	-0.33	-0.25	White blood cell count (basophil);	chr1:212379769	chr1:212225278~212238977:-
THCA	cis	rs3750082	0.505	rs7807550	ENSG00000231952.3	DPY19L1P2	5.7	2.1e-08	3.65e-06	0.36	0.25	Glomerular filtration rate (creatinine);	chr7:32944860	chr7:32812757~32838570:+
THCA	cis	rs801193	1	rs2659915	ENSG00000273142.1	RP11-458F8.4	-5.7	2.1e-08	3.65e-06	-0.2	-0.25	Aortic root size;	chr7:66688114	chr7:66902857~66906297:+
THCA	cis	rs7208859	0.673	rs999798	ENSG00000263603.1	CTD-2349P21.5	-5.7	2.1e-08	3.65e-06	-0.42	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30729469~30731202:+
THCA	cis	rs9494145	0.531	rs9399136	ENSG00000232876.1	CTA-212D2.2	-5.7	2.1e-08	3.65e-06	-0.37	-0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135081201	chr6:135055033~135060550:+
THCA	cis	rs9813712	0.904	rs6439223	ENSG00000228252.7	COL6A4P2	5.7	2.1e-08	3.65e-06	0.29	0.25	Response to amphetamines;	chr3:130256697	chr3:130212823~130273806:+
THCA	cis	rs7646881	0.544	rs3817373	ENSG00000240207.5	RP11-379F4.4	-5.7	2.11e-08	3.65e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158571246	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs4368546	ENSG00000240207.5	RP11-379F4.4	-5.7	2.11e-08	3.65e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158574361	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs73022770	ENSG00000240207.5	RP11-379F4.4	-5.7	2.11e-08	3.65e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158576506	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.583	rs2115942	ENSG00000240207.5	RP11-379F4.4	-5.7	2.11e-08	3.65e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158588841	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs73022798	ENSG00000240207.5	RP11-379F4.4	-5.7	2.11e-08	3.65e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158590099	chr3:158732263~158784070:+
THCA	cis	rs6545883	0.965	rs11887205	ENSG00000270820.4	RP11-355B11.2	5.7	2.11e-08	3.66e-06	0.21	0.25	Tuberculosis;	chr2:61547338	chr2:61471188~61484130:+
THCA	cis	rs9813712	0.571	rs9855426	ENSG00000249846.5	RP11-77P16.4	5.7	2.11e-08	3.66e-06	0.27	0.25	Response to amphetamines;	chr3:130214475	chr3:130112550~130120579:+
THCA	cis	rs6545883	0.868	rs7594191	ENSG00000271889.1	RP11-493E12.1	-5.7	2.11e-08	3.66e-06	-0.24	-0.25	Tuberculosis;	chr2:61612883	chr2:61151433~61162105:-
THCA	cis	rs4664293	0.625	rs7595852	ENSG00000226266.5	AC009961.3	5.7	2.11e-08	3.66e-06	0.29	0.25	Monocyte percentage of white cells;	chr2:159683656	chr2:159670708~159712435:-
THCA	cis	rs1993293	0.636	rs749516	ENSG00000259363.4	CTD-2054N24.2	5.7	2.11e-08	3.66e-06	0.33	0.25	Coronary artery calcification;	chr15:99754345	chr15:99807023~99877148:+
THCA	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-5.7	2.11e-08	3.66e-06	-0.38	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
THCA	cis	rs867529	0.924	rs11684404	ENSG00000234028.3	AC062029.1	-5.7	2.11e-08	3.66e-06	-0.2	-0.25	Height;	chr2:88625104	chr2:88627539~88631821:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000237310.1	GS1-124K5.4	5.7	2.11e-08	3.67e-06	0.19	0.25	Calcium levels;	chr7:65977808	chr7:66493706~66495474:+
THCA	cis	rs442309	0.875	rs382424	ENSG00000238280.1	RP11-436D10.3	-5.7	2.12e-08	3.67e-06	-0.31	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62730014	chr10:62793562~62805887:-
THCA	cis	rs6430585	0.528	rs309113	ENSG00000231890.6	DARS-AS1	-5.7	2.12e-08	3.67e-06	-0.29	-0.25	Corneal structure;	chr2:135979890	chr2:135985176~136022593:+
THCA	cis	rs863750	0.634	rs825475	ENSG00000275389.1	RP11-214K3.24	5.7	2.12e-08	3.67e-06	0.34	0.25	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124082761	chr12:124085761~124088598:+
THCA	cis	rs7617773	0.78	rs9846818	ENSG00000199476.1	Y_RNA	-5.7	2.12e-08	3.67e-06	-0.32	-0.25	Coronary artery disease;	chr3:48334195	chr3:48288587~48288694:+
THCA	cis	rs7412746	0.611	rs7556661	ENSG00000231073.1	RP11-316M1.3	5.7	2.12e-08	3.67e-06	0.31	0.25	Melanoma;	chr1:150919533	chr1:150973123~150975534:+
THCA	cis	rs6569038	0.502	rs2797352	ENSG00000253194.1	RP11-351A11.1	5.7	2.12e-08	3.68e-06	0.35	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118996678	chr6:118934785~119031541:+
THCA	cis	rs6968419	0.755	rs4730719	ENSG00000237870.5	AC073130.1	-5.7	2.12e-08	3.68e-06	-0.28	-0.25	Intraocular pressure;	chr7:116254956	chr7:116275606~116286734:-
THCA	cis	rs4713118	0.513	rs149945	ENSG00000220721.1	OR1F12	5.7	2.12e-08	3.68e-06	0.31	0.25	Parkinson's disease;	chr6:28035075	chr6:28073316~28074233:+
THCA	cis	rs2976388	0.566	rs4736373	ENSG00000253741.1	CTD-2292P10.4	5.7	2.12e-08	3.68e-06	0.34	0.25	Urinary tract infection frequency;	chr8:142710939	chr8:142702252~142726973:-
THCA	cis	rs2243480	1	rs160643	ENSG00000232559.3	GS1-124K5.12	5.7	2.12e-08	3.68e-06	0.37	0.25	Diabetic kidney disease;	chr7:66093235	chr7:66554588~66576923:-
THCA	cis	rs10808739	0.541	rs13248549	ENSG00000254006.4	RP11-1D12.2	-5.7	2.12e-08	3.68e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64796887	chr8:64801236~64817573:-
THCA	cis	rs4845570	1	rs4845579	ENSG00000268288.1	RP11-98D18.16	-5.7	2.12e-08	3.68e-06	-0.32	-0.25	Coronary artery disease;	chr1:151797662	chr1:151766486~151767000:-
THCA	cis	rs3764400	0.564	rs1452663	ENSG00000278765.1	RP5-890E16.5	5.7	2.12e-08	3.68e-06	0.46	0.25	Body mass index;	chr17:48216024	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs16953941	ENSG00000278765.1	RP5-890E16.5	5.7	2.12e-08	3.68e-06	0.46	0.25	Body mass index;	chr17:48218842	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs67345313	ENSG00000278765.1	RP5-890E16.5	5.7	2.12e-08	3.68e-06	0.46	0.25	Body mass index;	chr17:48224839	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs12939334	ENSG00000278765.1	RP5-890E16.5	5.7	2.12e-08	3.68e-06	0.46	0.25	Body mass index;	chr17:48225307	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs1979897	ENSG00000278765.1	RP5-890E16.5	5.7	2.12e-08	3.68e-06	0.46	0.25	Body mass index;	chr17:48232184	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs3897789	ENSG00000278765.1	RP5-890E16.5	5.7	2.12e-08	3.68e-06	0.46	0.25	Body mass index;	chr17:48235415	chr17:48066704~48067293:-
THCA	cis	rs30380	0.632	rs27640	ENSG00000272109.1	CTD-2260A17.3	-5.7	2.12e-08	3.68e-06	-0.35	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96792202	chr5:96804353~96806105:+
THCA	cis	rs30380	0.666	rs26512	ENSG00000272109.1	CTD-2260A17.3	-5.7	2.12e-08	3.68e-06	-0.35	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96792697	chr5:96804353~96806105:+
THCA	cis	rs30380	0.632	rs27434	ENSG00000272109.1	CTD-2260A17.3	-5.7	2.12e-08	3.68e-06	-0.35	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96793809	chr5:96804353~96806105:+
THCA	cis	rs30380	0.632	rs26489	ENSG00000272109.1	CTD-2260A17.3	-5.7	2.12e-08	3.68e-06	-0.35	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96797724	chr5:96804353~96806105:+
THCA	cis	rs30380	0.632	rs26500	ENSG00000272109.1	CTD-2260A17.3	-5.7	2.12e-08	3.68e-06	-0.35	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96798009	chr5:96804353~96806105:+
THCA	cis	rs2179367	0.613	rs12207047	ENSG00000268592.3	RAET1E-AS1	5.7	2.12e-08	3.68e-06	0.36	0.25	Dupuytren's disease;	chr6:149423496	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.513	rs156734	ENSG00000220721.1	OR1F12	5.7	2.12e-08	3.68e-06	0.31	0.25	Parkinson's disease;	chr6:28039579	chr6:28073316~28074233:+
THCA	cis	rs853679	0.723	rs9366718	ENSG00000226314.6	ZNF192P1	-5.7	2.12e-08	3.68e-06	-0.35	-0.25	Depression;	chr6:28237724	chr6:28161781~28169594:+
THCA	cis	rs4683346	0.616	rs2372110	ENSG00000173811.9	CCDC13-AS1	-5.7	2.12e-08	3.68e-06	-0.26	-0.25	Granulocyte percentage of myeloid white cells;	chr3:42778365	chr3:42732575~42746768:+
THCA	cis	rs2944755	0.723	rs11996672	ENSG00000279766.1	RP11-642A1.2	-5.7	2.12e-08	3.68e-06	-0.33	-0.25	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140576900	chr8:140572142~140572812:-
THCA	cis	rs9307551	0.817	rs4975057	ENSG00000250334.4	LINC00989	-5.7	2.13e-08	3.69e-06	-0.3	-0.25	Refractive error;	chr4:79567191	chr4:79492416~79576460:+
THCA	cis	rs4689592	0.546	rs907523	ENSG00000245468.3	RP11-367J11.3	5.7	2.13e-08	3.69e-06	0.21	0.25	Monocyte percentage of white cells;	chr4:7051050	chr4:7094571~7103385:-
THCA	cis	rs2179367	0.6	rs1001305	ENSG00000223701.3	RAET1E-AS1	5.7	2.13e-08	3.69e-06	0.4	0.25	Dupuytren's disease;	chr6:149436808	chr6:149884431~149919508:+
THCA	cis	rs2337406	0.866	rs78462736	ENSG00000211974.3	IGHV2-70	-5.7	2.13e-08	3.69e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106779942	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs8016203	ENSG00000211974.3	IGHV2-70	-5.7	2.13e-08	3.69e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106780575	chr14:106723574~106724093:-
THCA	cis	rs7674212	0.541	rs2720458	ENSG00000246560.2	RP11-10L12.4	5.7	2.13e-08	3.69e-06	0.3	0.25	Type 2 diabetes;	chr4:103131806	chr4:102828055~102844075:+
THCA	cis	rs7079041	1	rs7079041	ENSG00000273038.2	RP11-479G22.8	-5.7	2.13e-08	3.69e-06	-0.24	-0.25	Suicide in bipolar disorder;	chr10:32704340	chr10:32887255~32889311:-
THCA	cis	rs17772222	0.958	rs60213984	ENSG00000222990.1	RNU4-22P	5.7	2.13e-08	3.69e-06	0.34	0.25	Coronary artery calcification;	chr14:88401473	chr14:88513498~88513663:+
THCA	cis	rs3785574	0.962	rs2665842	ENSG00000240280.5	TCAM1P	-5.7	2.13e-08	3.69e-06	-0.35	-0.25	Height;	chr17:63801175	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs2727332	ENSG00000240280.5	TCAM1P	-5.7	2.13e-08	3.69e-06	-0.35	-0.25	Height;	chr17:63801224	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs2584633	ENSG00000240280.5	TCAM1P	-5.7	2.13e-08	3.69e-06	-0.35	-0.25	Height;	chr17:63802141	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs2584632	ENSG00000240280.5	TCAM1P	-5.7	2.13e-08	3.69e-06	-0.35	-0.25	Height;	chr17:63803281	chr17:63849292~63864379:+
THCA	cis	rs757978	1	rs757978	ENSG00000223374.1	AC005104.3	5.7	2.13e-08	3.69e-06	0.27	0.25	Chronic lymphocytic leukemia;	chr2:241431686	chr2:241351340~241353104:-
THCA	cis	rs6993270	0.779	rs6999724	ENSG00000245330.4	KB-1471A8.1	5.7	2.13e-08	3.69e-06	0.32	0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119908591	chr8:119867419~119874488:-
THCA	cis	rs35934224	0.783	rs35554477	ENSG00000232926.1	AC000078.5	5.7	2.13e-08	3.69e-06	0.28	0.25	Glaucoma (primary open-angle);	chr22:19869038	chr22:19887289~19887970:+
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000232546.1	RP11-458F8.1	-5.7	2.13e-08	3.69e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65946971	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs2961102	ENSG00000232546.1	RP11-458F8.1	-5.7	2.13e-08	3.69e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65959671	chr7:66848496~66858136:+
THCA	cis	rs4689592	0.546	rs10937782	ENSG00000245468.3	RP11-367J11.3	5.7	2.13e-08	3.7e-06	0.21	0.25	Monocyte percentage of white cells;	chr4:7055379	chr4:7094571~7103385:-
THCA	cis	rs7412746	0.611	rs11204726	ENSG00000231073.1	RP11-316M1.3	5.7	2.13e-08	3.7e-06	0.3	0.25	Melanoma;	chr1:150771016	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.553	rs59337856	ENSG00000231073.1	RP11-316M1.3	5.7	2.13e-08	3.7e-06	0.3	0.25	Melanoma;	chr1:150773930	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs10888394	ENSG00000231073.1	RP11-316M1.3	5.7	2.13e-08	3.7e-06	0.3	0.25	Melanoma;	chr1:150777437	chr1:150973123~150975534:+
THCA	cis	rs875971	0.638	rs7793569	ENSG00000273142.1	RP11-458F8.4	5.7	2.13e-08	3.7e-06	0.2	0.25	Aortic root size;	chr7:66651646	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs6975195	ENSG00000273142.1	RP11-458F8.4	5.7	2.13e-08	3.7e-06	0.2	0.25	Aortic root size;	chr7:66659787	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs3857688	ENSG00000273142.1	RP11-458F8.4	5.7	2.13e-08	3.7e-06	0.2	0.25	Aortic root size;	chr7:66662819	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs2286684	ENSG00000273142.1	RP11-458F8.4	5.7	2.13e-08	3.7e-06	0.2	0.25	Aortic root size;	chr7:66664843	chr7:66902857~66906297:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000273142.1	RP11-458F8.4	5.7	2.13e-08	3.7e-06	0.2	0.25	Aortic root size;	chr7:66664856	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs10274773	ENSG00000273142.1	RP11-458F8.4	5.7	2.13e-08	3.7e-06	0.2	0.25	Aortic root size;	chr7:66668591	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs11773829	ENSG00000273142.1	RP11-458F8.4	5.7	2.13e-08	3.7e-06	0.2	0.25	Aortic root size;	chr7:66676087	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs7788576	ENSG00000273142.1	RP11-458F8.4	5.7	2.13e-08	3.7e-06	0.2	0.25	Aortic root size;	chr7:66683315	chr7:66902857~66906297:+
THCA	cis	rs801193	0.935	rs2659916	ENSG00000273142.1	RP11-458F8.4	-5.7	2.13e-08	3.7e-06	-0.2	-0.25	Aortic root size;	chr7:66686365	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs6958520	ENSG00000273142.1	RP11-458F8.4	-5.7	2.13e-08	3.7e-06	-0.2	-0.25	Aortic root size;	chr7:66686466	chr7:66902857~66906297:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000273142.1	RP11-458F8.4	-5.7	2.13e-08	3.7e-06	-0.2	-0.25	Aortic root size;	chr7:66687725	chr7:66902857~66906297:+
THCA	cis	rs2361701	0.929	rs1467979	ENSG00000279259.1	RP11-334C17.3	-5.7	2.13e-08	3.7e-06	-0.29	-0.25	IgG glycosylation;	chr17:80086944	chr17:80147250~80148596:+
THCA	cis	rs801193	1	rs2707836	ENSG00000273142.1	RP11-458F8.4	-5.7	2.14e-08	3.71e-06	-0.2	-0.25	Aortic root size;	chr7:66695448	chr7:66902857~66906297:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000273142.1	RP11-458F8.4	-5.7	2.14e-08	3.71e-06	-0.2	-0.25	Aortic root size;	chr7:66696803	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs2659906	ENSG00000273142.1	RP11-458F8.4	-5.7	2.14e-08	3.71e-06	-0.2	-0.25	Aortic root size;	chr7:66700323	chr7:66902857~66906297:+
THCA	cis	rs1395	0.677	rs113353646	ENSG00000234072.1	AC074117.10	-5.7	2.14e-08	3.71e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27269806	chr2:27356246~27367622:+
THCA	cis	rs17214007	0.778	rs17213271	ENSG00000263335.1	AF001548.5	-5.7	2.14e-08	3.71e-06	-0.36	-0.25	Cognitive function;	chr16:15770487	chr16:15726674~15732993:+
THCA	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	5.7	2.14e-08	3.71e-06	0.25	0.25	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
THCA	cis	rs9910055	0.664	rs433610	ENSG00000267080.4	ASB16-AS1	5.7	2.14e-08	3.71e-06	0.23	0.25	Total body bone mineral density;	chr17:44119913	chr17:44175973~44186717:-
THCA	cis	rs13256369	0.802	rs35382339	ENSG00000253893.2	FAM85B	-5.7	2.14e-08	3.72e-06	-0.35	-0.25	Obesity-related traits;	chr8:8701745	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.802	rs11781257	ENSG00000253893.2	FAM85B	-5.7	2.14e-08	3.72e-06	-0.35	-0.25	Obesity-related traits;	chr8:8702153	chr8:8167819~8226614:-
THCA	cis	rs7529073	0.815	rs1431982	ENSG00000274895.1	RP11-478J18.2	-5.7	2.15e-08	3.72e-06	-0.21	-0.25	Schizophrenia;	chr1:213975718	chr1:213983793~213986419:-
THCA	cis	rs8007846	0.569	rs7151846	ENSG00000276116.2	FUT8-AS1	-5.7	2.15e-08	3.72e-06	-0.26	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65789063	chr14:65411170~65412690:-
THCA	cis	rs1125355	0.539	rs11696015	ENSG00000251491.2	OR7E28P	-5.7	2.15e-08	3.72e-06	-0.45	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158821044	chr2:158862311~158863285:+
THCA	cis	rs11089937	0.609	rs2213158	ENSG00000211638.2	IGLV8-61	-5.7	2.15e-08	3.72e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.637	rs2213159	ENSG00000211638.2	IGLV8-61	-5.7	2.15e-08	3.72e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22098700~22099212:+
THCA	cis	rs13256369	0.802	rs13280101	ENSG00000253893.2	FAM85B	-5.7	2.15e-08	3.72e-06	-0.34	-0.25	Obesity-related traits;	chr8:8705263	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.802	rs13255789	ENSG00000253893.2	FAM85B	-5.7	2.15e-08	3.72e-06	-0.34	-0.25	Obesity-related traits;	chr8:8705281	chr8:8167819~8226614:-
THCA	cis	rs910316	0.503	rs4903273	ENSG00000279594.1	RP11-950C14.10	-5.7	2.15e-08	3.73e-06	-0.24	-0.25	Height;	chr14:74975092	chr14:75011269~75012851:-
THCA	cis	rs1125355	0.69	rs1515929	ENSG00000251491.2	OR7E28P	-5.7	2.15e-08	3.73e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158773125	chr2:158862311~158863285:+
THCA	cis	rs13256369	0.851	rs13267036	ENSG00000253893.2	FAM85B	-5.7	2.15e-08	3.73e-06	-0.35	-0.25	Obesity-related traits;	chr8:8709175	chr8:8167819~8226614:-
THCA	cis	rs7824557	0.591	rs2060457	ENSG00000154316.13	TDH	-5.7	2.15e-08	3.73e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11355741	chr8:11339637~11368452:+
THCA	cis	rs7412746	0.658	rs11582281	ENSG00000231073.1	RP11-316M1.3	5.7	2.16e-08	3.74e-06	0.31	0.25	Melanoma;	chr1:150854355	chr1:150973123~150975534:+
THCA	cis	rs12893668	0.703	rs34896432	ENSG00000269910.1	RP11-73M18.10	5.7	2.16e-08	3.74e-06	0.24	0.25	Reticulocyte count;	chr14:103561658	chr14:103694516~103695050:-
THCA	cis	rs12478296	0.786	rs72620862	ENSG00000261186.2	RP11-341N2.1	-5.7	2.16e-08	3.74e-06	-0.4	-0.25	Obesity-related traits;	chr2:242102636	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs66466023	ENSG00000261186.2	RP11-341N2.1	-5.7	2.16e-08	3.74e-06	-0.4	-0.25	Obesity-related traits;	chr2:242104000	chr2:242087351~242088457:-
THCA	cis	rs12478296	0.901	rs56318767	ENSG00000261186.2	RP11-341N2.1	-5.7	2.16e-08	3.74e-06	-0.4	-0.25	Obesity-related traits;	chr2:242104440	chr2:242087351~242088457:-
THCA	cis	rs9880211	0.571	rs13066401	ENSG00000273486.1	RP11-731C17.2	5.7	2.16e-08	3.74e-06	0.33	0.25	Height;Body mass index;	chr3:136626977	chr3:136837338~136839021:-
THCA	cis	rs6968419	0.641	rs17138519	ENSG00000237870.5	AC073130.1	5.7	2.16e-08	3.74e-06	0.28	0.25	Intraocular pressure;	chr7:116266124	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.674	rs12669768	ENSG00000237870.5	AC073130.1	5.7	2.16e-08	3.74e-06	0.28	0.25	Intraocular pressure;	chr7:116267086	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.674	rs11767092	ENSG00000237870.5	AC073130.1	5.7	2.16e-08	3.74e-06	0.28	0.25	Intraocular pressure;	chr7:116267811	chr7:116275606~116286734:-
THCA	cis	rs6908034	0.66	rs74457659	ENSG00000237404.1	RP3-471C18.2	-5.7	2.16e-08	3.74e-06	-0.53	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19760494	chr6:19689825~19753113:-
THCA	cis	rs4639966	0.836	rs7130875	ENSG00000255239.1	AP002954.6	-5.7	2.16e-08	3.74e-06	-0.36	-0.25	Systemic lupus erythematosus;	chr11:118742965	chr11:118688039~118690600:-
THCA	cis	rs2742234	0.955	rs2503841	ENSG00000273008.1	RP11-351D16.3	-5.7	2.16e-08	3.74e-06	-0.22	-0.25	Hirschsprung disease;	chr10:43180273	chr10:43136824~43138334:-
THCA	cis	rs6539288	0.513	rs7977247	ENSG00000260329.1	RP11-412D9.4	-5.7	2.16e-08	3.74e-06	-0.23	-0.25	Total body bone mineral density;	chr12:106865692	chr12:106954029~106955497:-
THCA	cis	rs4948275	0.773	rs2650726	ENSG00000237233.2	TMEM26-AS1	-5.7	2.16e-08	3.74e-06	-0.34	-0.25	Night sleep phenotypes;	chr10:61511113	chr10:61452639~61481956:+
THCA	cis	rs7131987	0.903	rs918873	ENSG00000257176.2	RP11-996F15.2	-5.7	2.16e-08	3.74e-06	-0.26	-0.25	QT interval;	chr12:29237568	chr12:29280418~29317848:-
THCA	cis	rs1823874	0.581	rs9920347	ENSG00000259363.4	CTD-2054N24.2	5.7	2.16e-08	3.74e-06	0.33	0.25	IgG glycosylation;	chr15:99799126	chr15:99807023~99877148:+
THCA	cis	rs801193	1	rs1553610	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66732246	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs2707845	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66733811	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs2707850	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66738883	chr7:66902857~66906297:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66740595	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs7783924	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66744070	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs7789184	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66745208	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs2707854	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66747610	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs3800812	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66758474	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs4279493	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66761633	chr7:66902857~66906297:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000273142.1	RP11-458F8.4	-5.7	2.16e-08	3.75e-06	-0.2	-0.25	Aortic root size;	chr7:66765184	chr7:66902857~66906297:+
THCA	cis	rs11148252	0.74	rs9596642	ENSG00000235660.1	LINC00345	5.7	2.16e-08	3.75e-06	0.33	0.25	Lewy body disease;	chr13:52326744	chr13:52484161~52484680:-
THCA	cis	rs2129782	1	rs10110453	ENSG00000253553.4	RP11-586K2.1	5.7	2.17e-08	3.75e-06	0.42	0.25	Electrodermal activity;	chr8:88420323	chr8:88326836~88737134:+
THCA	cis	rs8002861	0.81	rs2275252	ENSG00000274001.1	RP11-5G9.5	5.7	2.17e-08	3.75e-06	0.28	0.25	Leprosy;	chr13:43880238	chr13:43877715~43878163:-
THCA	cis	rs2041895	0.509	rs1035236	ENSG00000260329.1	RP11-412D9.4	-5.7	2.17e-08	3.76e-06	-0.25	-0.25	Glaucoma (low intraocular pressure);	chr12:106917019	chr12:106954029~106955497:-
THCA	cis	rs2041895	0.509	rs10861676	ENSG00000260329.1	RP11-412D9.4	-5.7	2.17e-08	3.76e-06	-0.25	-0.25	Glaucoma (low intraocular pressure);	chr12:106917457	chr12:106954029~106955497:-
THCA	cis	rs875971	0.898	rs6977501	ENSG00000223473.2	GS1-124K5.3	-5.7	2.17e-08	3.76e-06	-0.17	-0.25	Aortic root size;	chr7:66228355	chr7:66491049~66493566:-
THCA	cis	rs7129556	0.737	rs643388	ENSG00000254691.1	RP11-91P24.5	5.7	2.17e-08	3.76e-06	0.36	0.25	Weight loss (gastric bypass surgery);	chr11:77759997	chr11:77850604~77851511:+
THCA	cis	rs3169166	0.5	rs12909123	ENSG00000259562.2	RP11-762H8.2	-5.7	2.17e-08	3.76e-06	-0.17	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78267501	chr15:78290527~78291221:-
THCA	cis	rs116095464	0.51	rs7723883	ENSG00000248925.1	CTD-2083E4.6	5.7	2.17e-08	3.76e-06	0.37	0.25	Breast cancer;	chr5:270683	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs28558836	ENSG00000248925.1	CTD-2083E4.6	5.7	2.17e-08	3.76e-06	0.37	0.25	Breast cancer;	chr5:285633	chr5:269858~271516:-
THCA	cis	rs12908161	0.65	rs182517	ENSG00000259728.4	LINC00933	5.7	2.17e-08	3.76e-06	0.35	0.25	Schizophrenia;	chr15:84846400	chr15:84570649~84580175:+
THCA	cis	rs9926296	0.585	rs8058009	ENSG00000260259.1	RP11-368I7.4	-5.7	2.17e-08	3.76e-06	-0.28	-0.25	Vitiligo;	chr16:89790031	chr16:89682620~89686569:-
THCA	cis	rs116095464	0.558	rs55664502	ENSG00000248925.1	CTD-2083E4.6	5.7	2.17e-08	3.76e-06	0.37	0.25	Breast cancer;	chr5:270370	chr5:269858~271516:-
THCA	cis	rs1552244	1	rs113134644	ENSG00000232901.1	CYCSP10	5.7	2.17e-08	3.76e-06	0.34	0.25	Alzheimer's disease;	chr3:10044602	chr3:10000647~10000940:-
THCA	cis	rs6088590	0.707	rs67159833	ENSG00000276073.1	RP5-1125A11.7	-5.7	2.18e-08	3.77e-06	-0.24	-0.25	Coronary artery disease;	chr20:34900276	chr20:33985617~33988989:-
THCA	cis	rs71520386	0.632	rs9692432	ENSG00000228649.7	AC005682.5	-5.7	2.18e-08	3.77e-06	-0.32	-0.25	Fibrinogen levels;	chr7:22829244	chr7:22854178~22861579:+
THCA	cis	rs831571	0.774	rs40610	ENSG00000280620.1	SCAANT1	5.69	2.18e-08	3.77e-06	0.38	0.25	Type 2 diabetes;	chr3:64023832	chr3:63911518~63911772:-
THCA	cis	rs9910055	0.762	rs184478	ENSG00000267080.4	ASB16-AS1	5.69	2.18e-08	3.77e-06	0.23	0.25	Total body bone mineral density;	chr17:44132383	chr17:44175973~44186717:-
THCA	cis	rs9880211	0.752	rs9838884	ENSG00000273486.1	RP11-731C17.2	5.69	2.18e-08	3.77e-06	0.27	0.25	Height;Body mass index;	chr3:136736862	chr3:136837338~136839021:-
THCA	cis	rs2657294	0.62	rs4746261	ENSG00000233313.2	HMGA1P5	5.69	2.18e-08	3.77e-06	0.35	0.25	Pneumonia;	chr10:75085874	chr10:75276376~75276646:-
THCA	cis	rs2243480	1	rs1723269	ENSG00000232546.1	RP11-458F8.1	-5.69	2.18e-08	3.77e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:66007799	chr7:66848496~66858136:+
THCA	cis	rs412050	0.696	rs41283227	ENSG00000224086.5	LL22NC03-86G7.1	-5.69	2.18e-08	3.77e-06	-0.42	-0.25	Attention deficit hyperactivity disorder;	chr22:21921151	chr22:21938293~21977632:+
THCA	cis	rs1880529	0.527	rs62314976	ENSG00000206820.1	RNU1-138P	-5.69	2.18e-08	3.77e-06	-0.28	-0.25	White matter integrity (bipolar disorder risk interaction);	chr4:113464520	chr4:113420323~113420486:+
THCA	cis	rs7202877	0.656	rs4887812	ENSG00000261783.1	RP11-252K23.2	-5.69	2.18e-08	3.77e-06	-0.44	-0.25	Type 1 diabetes;Type 2 diabetes;	chr16:75276154	chr16:75379818~75381260:-
THCA	cis	rs2281558	0.876	rs2274890	ENSG00000274414.1	RP5-965G21.4	-5.69	2.18e-08	3.77e-06	-0.31	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:25239007~25245229:-
THCA	cis	rs7115242	0.514	rs4936367	ENSG00000280143.1	AP000892.6	5.69	2.18e-08	3.77e-06	0.42	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.53	rs4604928	ENSG00000280143.1	AP000892.6	5.69	2.18e-08	3.77e-06	0.42	0.25	Blood protein levels;	chr11:117173487	chr11:117204967~117210292:+
THCA	cis	rs55665837	0.539	rs10832310	ENSG00000251991.1	RNU7-49P	5.69	2.18e-08	3.78e-06	0.28	0.25	Vitamin D levels;	chr11:14856896	chr11:14478892~14478953:+
THCA	cis	rs748404	0.666	rs35160541	ENSG00000249839.1	AC011330.5	-5.69	2.18e-08	3.78e-06	-0.36	-0.25	Lung cancer;	chr15:43365601	chr15:43663654~43684339:-
THCA	cis	rs1322639	0.614	rs6925188	ENSG00000261039.2	RP11-417E7.2	-5.69	2.18e-08	3.78e-06	-0.39	-0.25	Pulse pressure;	chr6:169163242	chr6:169175304~169182740:-
THCA	cis	rs7923837	1	rs4933736	ENSG00000236493.2	EIF2S2P3	5.69	2.19e-08	3.78e-06	0.27	0.25	Multiple sclerosis;Body mass index;	chr10:92711838	chr10:92668745~92669743:-
THCA	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-5.69	2.19e-08	3.78e-06	-0.23	-0.25	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
THCA	cis	rs7202877	0.561	rs4888369	ENSG00000261783.1	RP11-252K23.2	-5.69	2.19e-08	3.78e-06	-0.44	-0.25	Type 1 diabetes;Type 2 diabetes;	chr16:75273379	chr16:75379818~75381260:-
THCA	cis	rs2136613	0.533	rs10822071	ENSG00000238280.1	RP11-436D10.3	-5.69	2.19e-08	3.78e-06	-0.29	-0.25	Selective IgA deficiency;	chr10:62855716	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs10822072	ENSG00000238280.1	RP11-436D10.3	-5.69	2.19e-08	3.78e-06	-0.29	-0.25	Selective IgA deficiency;	chr10:62856010	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs1509958	ENSG00000238280.1	RP11-436D10.3	-5.69	2.19e-08	3.78e-06	-0.29	-0.25	Selective IgA deficiency;	chr10:62856390	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.533	rs12258444	ENSG00000238280.1	RP11-436D10.3	-5.69	2.19e-08	3.78e-06	-0.29	-0.25	Selective IgA deficiency;	chr10:62856825	chr10:62793562~62805887:-
THCA	cis	rs16976116	0.901	rs28489312	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55201850	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28589384	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55202168	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.851	rs11855907	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55202436	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.855	rs11856010	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55202810	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.806	rs28466870	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55202915	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.855	rs28522816	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55202916	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28564077	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55202953	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs1061824	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55203765	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs1061823	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55203845	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs1061822	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55203860	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs1061821	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55203913	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs1061875	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55204080	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs1061873	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55204558	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs1061870	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55204571	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs1050931	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55205493	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28708989	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55206736	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28591259	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55206742	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28508034	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55206812	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28526269	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55206992	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28433503	ENSG00000279145.1	RP11-547D13.1	5.69	2.19e-08	3.79e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55207659	chr15:55171972~55178175:-
THCA	cis	rs17482078	0.918	rs28513759	ENSG00000248734.2	CTD-2260A17.1	5.69	2.19e-08	3.79e-06	0.33	0.25	Behcet's disease;Blood protein levels;	chr5:96825366	chr5:96784777~96785999:+
THCA	cis	rs2559856	1	rs2695285	ENSG00000274560.1	RP11-285E23.2	5.69	2.19e-08	3.79e-06	0.15	0.25	Blood protein levels;	chr12:101695265	chr12:101696002~101696450:-
THCA	cis	rs763121	0.853	rs5750672	ENSG00000228274.3	RP3-508I15.9	5.69	2.19e-08	3.8e-06	0.27	0.25	Menopause (age at onset);	chr22:38708163	chr22:38667585~38681820:-
THCA	cis	rs899997	0.862	rs11072787	ENSG00000261143.1	ADAMTS7P3	-5.69	2.19e-08	3.8e-06	-0.35	-0.25	Coronary artery disease or large artery stroke;	chr15:78680635	chr15:77976042~77993057:+
THCA	cis	rs713477	0.654	rs998871	ENSG00000258413.1	RP11-665C16.6	5.69	2.2e-08	3.8e-06	0.35	0.25	Pediatric bone mineral content (femoral neck);	chr14:55451584	chr14:55262767~55272075:-
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000280069.1	CTD-2349P21.3	-5.69	2.2e-08	3.8e-06	-0.38	-0.25	Body mass index;	chr17:30741407	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000280069.1	CTD-2349P21.3	-5.69	2.2e-08	3.8e-06	-0.38	-0.25	Body mass index;	chr17:30745674	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000280069.1	CTD-2349P21.3	-5.69	2.2e-08	3.8e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30738182~30740275:+
THCA	cis	rs5758659	0.935	rs134879	ENSG00000270083.1	RP1-257I20.14	5.69	2.2e-08	3.8e-06	0.26	0.25	Cognitive function;	chr22:42268195	chr22:42089630~42090028:-
THCA	cis	rs1707322	0.752	rs4660880	ENSG00000281133.1	AL355480.3	-5.69	2.2e-08	3.8e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45580892~45580996:-
THCA	cis	rs2303319	0.504	rs12479001	ENSG00000227403.1	AC009299.3	5.69	2.2e-08	3.8e-06	0.53	0.25	Cognitive function;	chr2:161721815	chr2:161244739~161249050:+
THCA	cis	rs9307551	0.817	rs1031004	ENSG00000250334.4	LINC00989	-5.69	2.21e-08	3.81e-06	-0.29	-0.25	Refractive error;	chr4:79595695	chr4:79492416~79576460:+
THCA	cis	rs5758659	0.716	rs86669	ENSG00000281538.1	RP4-669P10.20	5.69	2.21e-08	3.81e-06	0.22	0.25	Cognitive function;	chr22:42284794	chr22:42138060~42139726:+
THCA	cis	rs12893668	0.703	rs2403197	ENSG00000269940.1	RP11-73M18.7	5.69	2.21e-08	3.81e-06	0.27	0.25	Reticulocyte count;	chr14:103587427	chr14:103694560~103695170:+
THCA	cis	rs9400467	0.528	rs17539197	ENSG00000230177.1	RP5-1112D6.4	-5.69	2.21e-08	3.81e-06	-0.2	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111277932~111278742:+
THCA	cis	rs16976116	0.901	rs73409853	ENSG00000279145.1	RP11-547D13.1	5.69	2.21e-08	3.81e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55210483	chr15:55171972~55178175:-
THCA	cis	rs3096299	0.838	rs3096319	ENSG00000274627.1	RP11-104N10.2	5.69	2.21e-08	3.82e-06	0.24	0.25	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:89516797~89522217:+
THCA	cis	rs11723261	0.582	rs3747693	ENSG00000211553.1	AC253576.2	-5.69	2.21e-08	3.82e-06	-0.36	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:136461~136568:+
THCA	cis	rs4683346	0.616	rs35584330	ENSG00000173811.9	CCDC13-AS1	-5.69	2.21e-08	3.82e-06	-0.26	-0.25	Granulocyte percentage of myeloid white cells;	chr3:42769748	chr3:42732575~42746768:+
THCA	cis	rs758324	0.687	rs185616	ENSG00000237714.1	P4HA2-AS1	-5.69	2.21e-08	3.82e-06	-0.39	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132208073	chr5:132184876~132192808:+
THCA	cis	rs1707322	0.752	rs11211168	ENSG00000281133.1	AL355480.3	-5.69	2.21e-08	3.82e-06	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45580892~45580996:-
THCA	cis	rs934734	0.736	rs7559283	ENSG00000234255.7	AC012370.3	5.69	2.21e-08	3.82e-06	0.29	0.25	Rheumatoid arthritis;	chr2:65351234	chr2:65439888~65456571:-
THCA	cis	rs7131987	0.903	rs2194518	ENSG00000257176.2	RP11-996F15.2	-5.69	2.21e-08	3.82e-06	-0.26	-0.25	QT interval;	chr12:29266527	chr12:29280418~29317848:-
THCA	cis	rs7083	1	rs7083	ENSG00000254851.1	RP11-109L13.1	5.69	2.21e-08	3.82e-06	0.34	0.25	Blood protein levels;	chr11:117285836	chr11:117135528~117138582:+
THCA	cis	rs7824557	0.638	rs4413734	ENSG00000154316.13	TDH	-5.69	2.21e-08	3.83e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11355269	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.578	rs2060458	ENSG00000154316.13	TDH	-5.69	2.21e-08	3.83e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11355302	chr8:11339637~11368452:+
THCA	cis	rs10899021	0.512	rs10219168	ENSG00000279353.1	RP11-864N7.4	-5.69	2.21e-08	3.83e-06	-0.38	-0.25	Response to metformin (IC50);	chr11:74663408	chr11:74698231~74699658:-
THCA	cis	rs412050	0.793	rs74576380	ENSG00000224086.5	LL22NC03-86G7.1	-5.69	2.21e-08	3.83e-06	-0.42	-0.25	Attention deficit hyperactivity disorder;	chr22:21928908	chr22:21938293~21977632:+
THCA	cis	rs6740322	0.895	rs6544643	ENSG00000234936.1	AC010883.5	5.69	2.21e-08	3.83e-06	0.27	0.25	Coronary artery disease;	chr2:43332933	chr2:43229573~43233394:+
THCA	cis	rs2839186	0.9	rs2839200	ENSG00000239415.1	AP001469.9	5.69	2.22e-08	3.83e-06	0.26	0.25	Testicular germ cell tumor;	chr21:46289181	chr21:46251549~46254133:-
THCA	cis	rs9921338	0.961	rs7200667	ENSG00000262636.1	CTD-3088G3.4	-5.69	2.22e-08	3.83e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346547	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.924	rs7202024	ENSG00000262636.1	CTD-3088G3.4	-5.69	2.22e-08	3.83e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346901	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs7206017	ENSG00000262636.1	CTD-3088G3.4	-5.69	2.22e-08	3.83e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11347004	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs7195536	ENSG00000262636.1	CTD-3088G3.4	-5.69	2.22e-08	3.83e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348171	chr16:11380859~11381118:-
THCA	cis	rs2029362	0.623	rs5020127	ENSG00000245573.6	BDNF-AS	5.69	2.22e-08	3.83e-06	0.2	0.25	Total body bone mineral density;	chr11:27440232	chr11:27506838~27698174:+
THCA	cis	rs758324	0.687	rs156023	ENSG00000237714.1	P4HA2-AS1	-5.69	2.22e-08	3.83e-06	-0.39	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132209475	chr5:132184876~132192808:+
THCA	cis	rs1865760	0.622	rs9295685	ENSG00000272462.2	U91328.19	-5.69	2.22e-08	3.84e-06	-0.21	-0.25	Height;	chr6:26071497	chr6:25992662~26001775:+
THCA	cis	rs935334	1	rs2121067	ENSG00000258454.1	RP11-361H10.3	5.69	2.22e-08	3.84e-06	0.37	0.25	Blood pressure;	chr14:76151308	chr14:76235817~76263474:+
THCA	cis	rs748404	0.697	rs574065	ENSG00000166763.7	STRCP1	-5.69	2.22e-08	3.84e-06	-0.27	-0.25	Lung cancer;	chr15:43258457	chr15:43699488~43718184:-
THCA	cis	rs6061231	0.505	rs13037253	ENSG00000273619.1	RP5-908M14.9	-5.69	2.22e-08	3.84e-06	-0.22	-0.25	Colorectal cancer;	chr20:62353668	chr20:62386303~62386970:-
THCA	cis	rs728616	0.681	rs34816332	ENSG00000225484.5	NUTM2B-AS1	-5.69	2.22e-08	3.84e-06	-0.44	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148211	chr10:79663088~79826594:-
THCA	cis	rs2276314	0.512	rs9951125	ENSG00000278986.1	RP11-723J4.3	-5.69	2.22e-08	3.84e-06	-0.26	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35872841	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.512	rs7227264	ENSG00000278986.1	RP11-723J4.3	-5.69	2.22e-08	3.84e-06	-0.26	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35874668	chr18:35972151~35973916:+
THCA	cis	rs853679	1	rs735765	ENSG00000226314.6	ZNF192P1	-5.69	2.22e-08	3.84e-06	-0.42	-0.25	Depression;	chr6:28202519	chr6:28161781~28169594:+
THCA	cis	rs4845570	1	rs1054479	ENSG00000203288.3	RP11-98D18.9	-5.69	2.22e-08	3.84e-06	-0.29	-0.25	Coronary artery disease;	chr1:151773603	chr1:151790804~151794402:+
THCA	cis	rs4845570	1	rs6683364	ENSG00000203288.3	RP11-98D18.9	-5.69	2.22e-08	3.84e-06	-0.29	-0.25	Coronary artery disease;	chr1:151773726	chr1:151790804~151794402:+
THCA	cis	rs613391	0.522	rs593909	ENSG00000224549.1	RP11-370B11.3	-5.69	2.23e-08	3.85e-06	-0.29	-0.25	Quantitative traits;	chr9:22730878	chr9:22767175~22768316:+
THCA	cis	rs9800506	0.584	rs12203632	ENSG00000228559.1	RP3-340B19.3	5.69	2.23e-08	3.85e-06	0.34	0.25	Neutrophil percentage of granulocytes;	chr6:35550961	chr6:35544632~35545669:+
THCA	cis	rs7809950	0.953	rs28687365	ENSG00000238832.1	snoU109	-5.69	2.23e-08	3.85e-06	-0.27	-0.25	Coronary artery disease;	chr7:107466267	chr7:107603363~107603507:+
THCA	cis	rs451417	0.818	rs236117	ENSG00000275632.1	RP5-967N21.11	5.69	2.23e-08	3.85e-06	0.31	0.25	Menopause (age at onset);	chr20:5956529	chr20:6000418~6000941:+
THCA	cis	rs9921338	0.961	rs8048768	ENSG00000262703.1	RP11-485G7.6	-5.69	2.23e-08	3.85e-06	-0.33	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11302983	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.961	rs11074958	ENSG00000262703.1	RP11-485G7.6	-5.69	2.23e-08	3.85e-06	-0.33	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11303222	chr16:11348143~11349321:-
THCA	cis	rs6547741	0.935	rs12714204	ENSG00000234072.1	AC074117.10	5.69	2.23e-08	3.85e-06	0.19	0.25	Oral cavity cancer;	chr2:27564673	chr2:27356246~27367622:+
THCA	cis	rs10829156	0.796	rs6482567	ENSG00000240291.1	RP11-499P20.2	5.69	2.23e-08	3.85e-06	0.22	0.25	Sudden cardiac arrest;	chr10:18625860	chr10:18513115~18545651:-
THCA	cis	rs4948275	0.742	rs2249808	ENSG00000237233.2	TMEM26-AS1	-5.69	2.23e-08	3.86e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61488298	chr10:61452639~61481956:+
THCA	cis	rs4664293	0.836	rs13421392	ENSG00000226266.5	AC009961.3	-5.69	2.23e-08	3.86e-06	-0.32	-0.25	Monocyte percentage of white cells;	chr2:159801785	chr2:159670708~159712435:-
THCA	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	5.69	2.24e-08	3.86e-06	0.44	0.25	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
THCA	cis	rs6968419	0.755	rs1141470	ENSG00000237870.5	AC073130.1	5.69	2.24e-08	3.86e-06	0.28	0.25	Intraocular pressure;	chr7:116258388	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.755	rs3807983	ENSG00000237870.5	AC073130.1	5.69	2.24e-08	3.86e-06	0.28	0.25	Intraocular pressure;	chr7:116258937	chr7:116275606~116286734:-
THCA	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-5.69	2.24e-08	3.86e-06	-0.42	-0.25	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
THCA	cis	rs6951245	0.744	rs10265758	ENSG00000229043.2	AC091729.9	-5.69	2.24e-08	3.87e-06	-0.39	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1160374~1165267:+
THCA	cis	rs1865760	0.964	rs9379802	ENSG00000272462.2	U91328.19	-5.69	2.24e-08	3.87e-06	-0.21	-0.25	Height;	chr6:25933670	chr6:25992662~26001775:+
THCA	cis	rs4842666	0.528	rs7302816	ENSG00000258302.2	RP11-981P6.1	-5.69	2.25e-08	3.88e-06	-0.23	-0.25	Blood pressure;	chr12:89556543	chr12:89561129~89594878:+
THCA	cis	rs9368481	0.569	rs10946868	ENSG00000241549.7	GUSBP2	5.69	2.25e-08	3.88e-06	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26871484~26956554:-
THCA	cis	rs13113518	0.683	rs9761521	ENSG00000273257.1	RP11-177J6.1	5.69	2.25e-08	3.88e-06	0.34	0.25	Height;	chr4:55363436	chr4:55387949~55388271:+
THCA	cis	rs9601248	0.756	rs2146592	ENSG00000227676.3	LINC01068	-5.69	2.25e-08	3.88e-06	-0.33	-0.25	Major depressive disorder;	chr13:79606146	chr13:79566727~79571436:+
THCA	cis	rs7129556	0.737	rs623173	ENSG00000254691.1	RP11-91P24.5	-5.69	2.25e-08	3.88e-06	-0.36	-0.25	Weight loss (gastric bypass surgery);	chr11:77818482	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.737	rs484363	ENSG00000254691.1	RP11-91P24.5	5.69	2.25e-08	3.88e-06	0.36	0.25	Weight loss (gastric bypass surgery);	chr11:77781548	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.728	rs34130561	ENSG00000254691.1	RP11-91P24.5	5.69	2.25e-08	3.88e-06	0.36	0.25	Weight loss (gastric bypass surgery);	chr11:77785645	chr11:77850604~77851511:+
THCA	cis	rs150992	0.536	rs161730	ENSG00000248489.1	CTD-2007H13.3	5.69	2.25e-08	3.88e-06	0.27	0.25	Body mass index;	chr5:98982631	chr5:98929171~98995013:+
THCA	cis	rs10129255	1	rs10141557	ENSG00000211974.3	IGHV2-70	5.69	2.25e-08	3.88e-06	0.2	0.25	Kawasaki disease;	chr14:106767990	chr14:106723574~106724093:-
THCA	cis	rs1499614	1	rs2659913	ENSG00000232559.3	GS1-124K5.12	5.69	2.25e-08	3.88e-06	0.39	0.25	Gout;	chr7:66692349	chr7:66554588~66576923:-
THCA	cis	rs1499614	1	rs2659911	ENSG00000232559.3	GS1-124K5.12	5.69	2.25e-08	3.88e-06	0.39	0.25	Gout;	chr7:66693433	chr7:66554588~66576923:-
THCA	cis	rs1499614	1	rs2707838	ENSG00000232559.3	GS1-124K5.12	5.69	2.25e-08	3.88e-06	0.39	0.25	Gout;	chr7:66694214	chr7:66554588~66576923:-
THCA	cis	rs1499614	1	rs60326618	ENSG00000232559.3	GS1-124K5.12	5.69	2.25e-08	3.88e-06	0.39	0.25	Gout;	chr7:66701371	chr7:66554588~66576923:-
THCA	cis	rs1499614	1	rs2707830	ENSG00000232559.3	GS1-124K5.12	5.69	2.25e-08	3.88e-06	0.39	0.25	Gout;	chr7:66702658	chr7:66554588~66576923:-
THCA	cis	rs1499614	1	rs2707828	ENSG00000232559.3	GS1-124K5.12	5.69	2.25e-08	3.88e-06	0.39	0.25	Gout;	chr7:66706390	chr7:66554588~66576923:-
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000232559.3	GS1-124K5.12	5.69	2.25e-08	3.88e-06	0.39	0.25	Gout;	chr7:66710076	chr7:66554588~66576923:-
THCA	cis	rs1499614	1	rs2659903	ENSG00000232559.3	GS1-124K5.12	5.69	2.25e-08	3.88e-06	0.39	0.25	Gout;	chr7:66715944	chr7:66554588~66576923:-
THCA	cis	rs7615952	0.932	rs3811679	ENSG00000241288.6	RP11-379B18.5	-5.69	2.25e-08	3.88e-06	-0.32	-0.25	Blood pressure (smoking interaction);	chr3:125929440	chr3:125827238~125916384:-
THCA	cis	rs1876905	0.597	rs354546	ENSG00000230177.1	RP5-1112D6.4	-5.69	2.25e-08	3.88e-06	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111211927	chr6:111277932~111278742:+
THCA	cis	rs9652601	0.748	rs12917893	ENSG00000274038.1	RP11-66H6.4	-5.69	2.25e-08	3.88e-06	-0.33	-0.25	Systemic lupus erythematosus;	chr16:11146121	chr16:11056556~11057034:+
THCA	cis	rs5751614	0.62	rs5759670	ENSG00000230701.2	FBXW4P1	5.69	2.25e-08	3.89e-06	0.27	0.25	Height;	chr22:23272239	chr22:23262767~23265005:+
THCA	cis	rs1707322	0.65	rs4553239	ENSG00000281133.1	AL355480.3	-5.69	2.25e-08	3.89e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45580892~45580996:-
THCA	cis	rs896854	0.53	rs10956934	ENSG00000253528.2	RP11-347C18.4	5.69	2.25e-08	3.89e-06	0.29	0.25	Type 2 diabetes;	chr8:94980245	chr8:94974573~94974853:-
THCA	cis	rs12681287	0.752	rs10086569	ENSG00000254231.1	CTD-2284J15.1	5.69	2.26e-08	3.89e-06	0.28	0.25	Caudate activity during reward;	chr8:86234980	chr8:86333274~86343314:-
THCA	cis	rs9843304	0.546	rs56303133	ENSG00000244503.1	RP11-278L15.6	-5.69	2.26e-08	3.89e-06	-0.32	-0.25	Gallstone disease;	chr3:149494692	chr3:149494660~149495995:+
THCA	cis	rs16867253	0.557	rs12470881	ENSG00000188525.3	AC010969.1	-5.69	2.26e-08	3.9e-06	-0.45	-0.25	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr2:10004276	chr2:10003158~10006030:-
THCA	cis	rs7412746	0.658	rs17660092	ENSG00000231073.1	RP11-316M1.3	5.69	2.26e-08	3.9e-06	0.31	0.25	Melanoma;	chr1:150825272	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs2089082	ENSG00000231073.1	RP11-316M1.3	5.69	2.26e-08	3.9e-06	0.31	0.25	Melanoma;	chr1:150827614	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs10305711	ENSG00000231073.1	RP11-316M1.3	5.69	2.26e-08	3.9e-06	0.31	0.25	Melanoma;	chr1:150830520	chr1:150973123~150975534:+
THCA	cis	rs763121	0.925	rs5750654	ENSG00000273076.1	RP3-508I15.22	5.69	2.26e-08	3.9e-06	0.24	0.25	Menopause (age at onset);	chr22:38655423	chr22:38743495~38743910:+
THCA	cis	rs7083	0.905	rs11216338	ENSG00000254851.1	RP11-109L13.1	5.69	2.26e-08	3.9e-06	0.34	0.25	Blood protein levels;	chr11:117261003	chr11:117135528~117138582:+
THCA	cis	rs10875746	0.551	rs3185921	ENSG00000258234.1	RP11-370I10.2	5.69	2.26e-08	3.9e-06	0.31	0.25	Longevity (90 years and older);	chr12:48340948	chr12:48231098~48284210:-
THCA	cis	rs3785574	0.924	rs2584641	ENSG00000240280.5	TCAM1P	-5.69	2.26e-08	3.9e-06	-0.35	-0.25	Height;	chr17:63785529	chr17:63849292~63864379:+
THCA	cis	rs7829975	0.6	rs1719381	ENSG00000254153.1	CTA-398F10.2	5.69	2.26e-08	3.9e-06	0.27	0.25	Mood instability;	chr8:8744834	chr8:8456909~8461337:-
THCA	cis	rs5742933	0.857	rs1233272	ENSG00000273240.1	RP11-455J20.3	-5.69	2.26e-08	3.9e-06	-0.26	-0.25	Ferritin levels;	chr2:189814968	chr2:189763859~189764456:-
THCA	cis	rs10043228	0.702	rs12518094	ENSG00000248445.4	SEMA6A-AS1	5.69	2.26e-08	3.91e-06	0.27	0.25	Asthma or chronic obstructive pulmonary disease;	chr5:116295027	chr5:116447547~116508276:+
THCA	cis	rs16976116	0.901	rs28630909	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55207904	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.855	rs28649719	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55208013	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.851	rs28699327	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55208137	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28535372	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55208404	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28449712	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55208483	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28541469	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55208590	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs62020114	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55208918	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.803	rs7168737	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55209146	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs7172108	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55209353	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.855	rs7172289	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55209507	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs73409851	ENSG00000279145.1	RP11-547D13.1	5.69	2.26e-08	3.91e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55210318	chr15:55171972~55178175:-
THCA	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	5.69	2.27e-08	3.91e-06	0.41	0.25	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
THCA	cis	rs62184315	0.536	rs62185874	ENSG00000273240.1	RP11-455J20.3	-5.69	2.27e-08	3.91e-06	-0.33	-0.25	Alcohol dependence (age at onset);	chr2:189704288	chr2:189763859~189764456:-
THCA	cis	rs62244186	0.516	rs11922470	ENSG00000214820.3	MPRIPP1	5.69	2.27e-08	3.91e-06	0.28	0.25	Depressive symptoms;	chr3:44736303	chr3:44579938~44581026:-
THCA	cis	rs1865760	0.516	rs9379818	ENSG00000272462.2	U91328.19	-5.69	2.27e-08	3.91e-06	-0.21	-0.25	Height;	chr6:26022978	chr6:25992662~26001775:+
THCA	cis	rs3742264	1	rs11618062	ENSG00000235903.6	CPB2-AS1	5.69	2.27e-08	3.92e-06	0.34	0.25	Blood protein levels;	chr13:46075433	chr13:46052806~46113332:+
THCA	cis	rs2255336	0.817	rs7310643	ENSG00000245648.1	RP11-277P12.20	5.69	2.27e-08	3.92e-06	0.34	0.25	Blood protein levels;	chr12:10365501	chr12:10363769~10398506:+
THCA	cis	rs7809950	0.678	rs3801966	ENSG00000238832.1	snoU109	-5.69	2.27e-08	3.92e-06	-0.31	-0.25	Coronary artery disease;	chr7:107184135	chr7:107603363~107603507:+
THCA	cis	rs10771431	0.817	rs17202253	ENSG00000256069.6	A2MP1	5.69	2.27e-08	3.92e-06	0.28	0.25	Breast size;	chr12:9209254	chr12:9228533~9275817:-
THCA	cis	rs10895275	0.924	rs12223991	ENSG00000277459.1	RP11-732A21.3	-5.69	2.27e-08	3.92e-06	-0.2	-0.25	Migraine;	chr11:102234992	chr11:102109827~102110457:-
THCA	cis	rs2243480	1	rs160639	ENSG00000232546.1	RP11-458F8.1	-5.69	2.27e-08	3.92e-06	-0.32	-0.25	Diabetic kidney disease;	chr7:66115000	chr7:66848496~66858136:+
THCA	cis	rs6977955	1	rs10951192	ENSG00000234336.5	JAZF1-AS1	5.69	2.27e-08	3.92e-06	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr7:28121414	chr7:28180322~28243917:+
THCA	cis	rs4689592	0.523	rs3857179	ENSG00000245468.3	RP11-367J11.3	5.69	2.27e-08	3.92e-06	0.21	0.25	Monocyte percentage of white cells;	chr4:7068769	chr4:7094571~7103385:-
THCA	cis	rs2243480	1	rs2257790	ENSG00000232546.1	RP11-458F8.1	-5.69	2.28e-08	3.92e-06	-0.32	-0.25	Diabetic kidney disease;	chr7:66135463	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs316332	ENSG00000232546.1	RP11-458F8.1	-5.69	2.28e-08	3.92e-06	-0.32	-0.25	Diabetic kidney disease;	chr7:66139312	chr7:66848496~66858136:+
THCA	cis	rs442309	0.846	rs224125	ENSG00000238280.1	RP11-436D10.3	-5.69	2.28e-08	3.93e-06	-0.31	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62694329	chr10:62793562~62805887:-
THCA	cis	rs7129556	0.69	rs24356	ENSG00000254691.1	RP11-91P24.5	5.69	2.28e-08	3.93e-06	0.34	0.25	Weight loss (gastric bypass surgery);	chr11:77856482	chr11:77850604~77851511:+
THCA	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-5.69	2.28e-08	3.93e-06	-0.23	-0.25	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
THCA	cis	rs9368481	0.524	rs12530345	ENSG00000241549.7	GUSBP2	5.69	2.28e-08	3.94e-06	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26871484~26956554:-
THCA	cis	rs2255336	0.578	rs7965744	ENSG00000245648.1	RP11-277P12.20	-5.69	2.28e-08	3.94e-06	-0.31	-0.25	Blood protein levels;	chr12:10367580	chr12:10363769~10398506:+
THCA	cis	rs330048	0.545	rs11781008	ENSG00000254153.1	CTA-398F10.2	-5.69	2.28e-08	3.94e-06	-0.28	-0.25	Systemic lupus erythematosus;	chr8:9295729	chr8:8456909~8461337:-
THCA	cis	rs801193	0.904	rs4718405	ENSG00000273142.1	RP11-458F8.4	-5.69	2.29e-08	3.94e-06	-0.2	-0.25	Aortic root size;	chr7:66789659	chr7:66902857~66906297:+
THCA	cis	rs7615952	0.673	rs34072288	ENSG00000241288.6	RP11-379B18.5	-5.69	2.29e-08	3.94e-06	-0.39	-0.25	Blood pressure (smoking interaction);	chr3:125825186	chr3:125827238~125916384:-
THCA	cis	rs9527	0.571	rs7096249	ENSG00000236937.2	PTGES3P4	5.69	2.29e-08	3.94e-06	0.33	0.25	Arsenic metabolism;	chr10:102858767	chr10:102845595~102845950:+
THCA	cis	rs9527	0.571	rs10786715	ENSG00000236937.2	PTGES3P4	5.69	2.29e-08	3.94e-06	0.33	0.25	Arsenic metabolism;	chr10:102860978	chr10:102845595~102845950:+
THCA	cis	rs6121246	0.529	rs6060144	ENSG00000230613.1	HM13-AS1	5.69	2.29e-08	3.94e-06	0.33	0.25	Mean corpuscular hemoglobin;	chr20:31590821	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.529	rs112367115	ENSG00000230613.1	HM13-AS1	5.69	2.29e-08	3.94e-06	0.33	0.25	Mean corpuscular hemoglobin;	chr20:31590824	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.529	rs6060145	ENSG00000230613.1	HM13-AS1	5.69	2.29e-08	3.94e-06	0.33	0.25	Mean corpuscular hemoglobin;	chr20:31590828	chr20:31567707~31573263:-
THCA	cis	rs1050631	0.592	rs13425	ENSG00000260552.1	RP11-49I11.1	5.69	2.29e-08	3.95e-06	0.32	0.25	Esophageal squamous cell cancer (length of survival);	chr18:36180187	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.592	rs14045	ENSG00000260552.1	RP11-49I11.1	5.69	2.29e-08	3.95e-06	0.32	0.25	Esophageal squamous cell cancer (length of survival);	chr18:36180231	chr18:36179996~36187448:-
THCA	cis	rs6714710	0.627	rs11680883	ENSG00000230606.9	AC159540.1	-5.69	2.29e-08	3.95e-06	-0.3	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97856147	chr2:97416165~97433527:-
THCA	cis	rs7412746	0.588	rs10305664	ENSG00000231073.1	RP11-316M1.3	5.69	2.29e-08	3.95e-06	0.31	0.25	Melanoma;	chr1:150867210	chr1:150973123~150975534:+
THCA	cis	rs4780355	1	rs1111186	ENSG00000262703.1	RP11-485G7.6	5.69	2.29e-08	3.96e-06	0.29	0.25	Crohn's disease and psoriasis;	chr16:11253191	chr16:11348143~11349321:-
THCA	cis	rs13256369	0.901	rs12681298	ENSG00000253893.2	FAM85B	5.69	2.3e-08	3.96e-06	0.34	0.25	Obesity-related traits;	chr8:8708725	chr8:8167819~8226614:-
THCA	cis	rs2255336	0.873	rs11053806	ENSG00000245648.1	RP11-277P12.20	-5.69	2.3e-08	3.96e-06	-0.31	-0.25	Blood protein levels;	chr12:10455822	chr12:10363769~10398506:+
THCA	cis	rs9309473	0.519	rs1815027	ENSG00000163016.8	ALMS1P	-5.69	2.3e-08	3.96e-06	-0.33	-0.25	Metabolite levels;	chr2:73604713	chr2:73644919~73685576:+
THCA	cis	rs62184315	0.536	rs56137655	ENSG00000273240.1	RP11-455J20.3	-5.69	2.3e-08	3.96e-06	-0.33	-0.25	Alcohol dependence (age at onset);	chr2:189675844	chr2:189763859~189764456:-
THCA	cis	rs17508449	0.819	rs3761934	ENSG00000232450.1	RP4-730K3.3	-5.69	2.3e-08	3.96e-06	-0.39	-0.25	Leprosy;	chr1:113646445	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.819	rs41352847	ENSG00000232450.1	RP4-730K3.3	-5.69	2.3e-08	3.96e-06	-0.39	-0.25	Leprosy;	chr1:113647258	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.819	rs2146018	ENSG00000232450.1	RP4-730K3.3	-5.69	2.3e-08	3.96e-06	-0.39	-0.25	Leprosy;	chr1:113652708	chr1:113698884~113699631:-
THCA	cis	rs2179367	0.919	rs4897124	ENSG00000231760.4	RP11-350J20.5	5.68	2.3e-08	3.96e-06	0.34	0.25	Dupuytren's disease;	chr6:149442073	chr6:149796151~149826294:-
THCA	cis	rs17508449	0.819	rs17359281	ENSG00000232450.1	RP4-730K3.3	5.68	2.3e-08	3.96e-06	0.39	0.25	Leprosy;	chr1:113643337	chr1:113698884~113699631:-
THCA	cis	rs61677309	1	rs61677309	ENSG00000280032.1	RP11-832A4.7	5.68	2.3e-08	3.96e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118297371	chr11:118264593~118266817:+
THCA	cis	rs12497850	0.931	rs7628719	ENSG00000229759.1	MRPS18AP1	5.68	2.3e-08	3.97e-06	0.34	0.25	Parkinson's disease;	chr3:48958054	chr3:48256350~48256938:-
THCA	cis	rs228614	0.51	rs170565	ENSG00000230069.3	LRRC37A15P	-5.68	2.3e-08	3.97e-06	-0.28	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102727274~102730721:-
THCA	cis	rs1383484	0.545	rs9329363	ENSG00000225151.9	GOLGA2P7	5.68	2.3e-08	3.97e-06	0.32	0.25	Height;	chr15:83974382	chr15:84199311~84230136:-
THCA	cis	rs922182	0.589	rs11071778	ENSG00000275785.1	RP11-111E14.2	-5.68	2.3e-08	3.97e-06	-0.29	-0.25	Blood protein levels;	chr15:63945409	chr15:63890030~63890317:+
THCA	cis	rs2115630	0.875	rs8039472	ENSG00000275120.1	RP11-182J1.17	-5.68	2.3e-08	3.97e-06	-0.26	-0.25	P wave terminal force;	chr15:84818413	chr15:84599434~84606463:-
THCA	cis	rs10875746	0.551	rs1471998	ENSG00000258234.1	RP11-370I10.2	5.68	2.31e-08	3.97e-06	0.3	0.25	Longevity (90 years and older);	chr12:48318219	chr12:48231098~48284210:-
THCA	cis	rs7412746	0.658	rs3768016	ENSG00000231073.1	RP11-316M1.3	5.68	2.31e-08	3.97e-06	0.31	0.25	Melanoma;	chr1:150837443	chr1:150973123~150975534:+
THCA	cis	rs758324	0.687	rs152047	ENSG00000237714.1	P4HA2-AS1	-5.68	2.31e-08	3.97e-06	-0.39	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132213245	chr5:132184876~132192808:+
THCA	cis	rs736408	0.716	rs2239550	ENSG00000243224.1	RP5-1157M23.2	-5.68	2.31e-08	3.98e-06	-0.28	-0.25	Bipolar disorder;	chr3:52788493	chr3:52239258~52241097:+
THCA	cis	rs736408	0.716	rs2300149	ENSG00000243224.1	RP5-1157M23.2	-5.68	2.31e-08	3.98e-06	-0.28	-0.25	Bipolar disorder;	chr3:52788905	chr3:52239258~52241097:+
THCA	cis	rs6840360	0.642	rs7678823	ENSG00000270265.1	RP11-731D1.4	-5.68	2.31e-08	3.98e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151333775~151353224:-
THCA	cis	rs28735056	0.592	rs10853392	ENSG00000261126.6	RP11-795F19.1	-5.68	2.31e-08	3.98e-06	-0.2	-0.25	Schizophrenia;	chr18:79948781	chr18:80046900~80095482:+
THCA	cis	rs7727544	0.582	rs2301579	ENSG00000233006.5	AC034220.3	5.68	2.31e-08	3.98e-06	0.19	0.25	Blood metabolite levels;	chr5:132217647	chr5:132311285~132369916:-
THCA	cis	rs758324	0.687	rs154484	ENSG00000237714.1	P4HA2-AS1	-5.68	2.31e-08	3.98e-06	-0.39	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132214749	chr5:132184876~132192808:+
THCA	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	5.68	2.31e-08	3.98e-06	0.32	0.25	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
THCA	cis	rs7615952	0.576	rs2276729	ENSG00000250012.1	RP11-124N2.1	-5.68	2.31e-08	3.98e-06	-0.24	-0.25	Blood pressure (smoking interaction);	chr3:126107371	chr3:126084220~126095349:+
THCA	cis	rs6993270	0.779	rs7017821	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119908658	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs7017583	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119908740	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs4128183	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119909248	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.606	rs6469869	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Interstitial lung disease;	chr8:119909696	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.817	rs4053280	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119911667	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs16893285	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119912499	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs7011167	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119912823	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs7010899	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119912870	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.725	rs6993186	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119912897	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs56331180	ENSG00000245330.4	KB-1471A8.1	-5.68	2.31e-08	3.98e-06	-0.33	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119913295	chr8:119867419~119874488:-
THCA	cis	rs10771431	0.597	rs3759275	ENSG00000256069.6	A2MP1	5.68	2.31e-08	3.98e-06	0.29	0.25	Breast size;	chr12:9201232	chr12:9228533~9275817:-
THCA	cis	rs10771431	0.597	rs3759274	ENSG00000256069.6	A2MP1	5.68	2.31e-08	3.98e-06	0.29	0.25	Breast size;	chr12:9201279	chr12:9228533~9275817:-
THCA	cis	rs6430585	0.528	rs309162	ENSG00000231890.6	DARS-AS1	-5.68	2.31e-08	3.98e-06	-0.3	-0.25	Corneal structure;	chr2:135933213	chr2:135985176~136022593:+
THCA	cis	rs9813712	0.597	rs10934931	ENSG00000249846.5	RP11-77P16.4	-5.68	2.31e-08	3.98e-06	-0.25	-0.25	Response to amphetamines;	chr3:130261365	chr3:130112550~130120579:+
THCA	cis	rs6714710	0.603	rs34503448	ENSG00000230606.9	AC159540.1	-5.68	2.31e-08	3.98e-06	-0.3	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97970825	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs953320	ENSG00000230606.9	AC159540.1	-5.68	2.31e-08	3.98e-06	-0.3	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97990307	chr2:97416165~97433527:-
THCA	cis	rs8002861	0.781	rs7322781	ENSG00000274001.1	RP11-5G9.5	5.68	2.31e-08	3.99e-06	0.29	0.25	Leprosy;	chr13:43868102	chr13:43877715~43878163:-
THCA	cis	rs78487399	0.71	rs79165612	ENSG00000234936.1	AC010883.5	5.68	2.32e-08	3.99e-06	0.38	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43397113	chr2:43229573~43233394:+
THCA	cis	rs2562456	0.793	rs627522	ENSG00000268081.1	RP11-678G14.2	5.68	2.32e-08	3.99e-06	0.36	0.25	Pain;	chr19:21313002	chr19:21554640~21569237:-
THCA	cis	rs9309473	0.539	rs6745560	ENSG00000163016.8	ALMS1P	5.68	2.32e-08	3.99e-06	0.33	0.25	Metabolite levels;	chr2:73599990	chr2:73644919~73685576:+
THCA	cis	rs7674212	0.541	rs2045746	ENSG00000246560.2	RP11-10L12.4	-5.68	2.32e-08	3.99e-06	-0.3	-0.25	Type 2 diabetes;	chr4:103162421	chr4:102828055~102844075:+
THCA	cis	rs2029362	0.715	rs10835180	ENSG00000245573.6	BDNF-AS	5.68	2.32e-08	3.99e-06	0.2	0.25	Total body bone mineral density;	chr11:27442285	chr11:27506838~27698174:+
THCA	cis	rs10129255	0.957	rs10140904	ENSG00000211974.3	IGHV2-70	5.68	2.32e-08	4e-06	0.19	0.25	Kawasaki disease;	chr14:106776558	chr14:106723574~106724093:-
THCA	cis	rs3794924	0.925	rs35427815	ENSG00000266521.1	RP11-650P15.1	5.68	2.32e-08	4e-06	0.49	0.25	Survival in colon cancer;	chr18:31466438	chr18:31496645~31497195:-
THCA	cis	rs853679	0.882	rs4713140	ENSG00000272009.1	RP1-313I6.12	-5.68	2.32e-08	4e-06	-0.37	-0.25	Depression;	chr6:28129415	chr6:28078792~28081130:-
THCA	cis	rs853679	0.76	rs11967137	ENSG00000226314.6	ZNF192P1	-5.68	2.32e-08	4e-06	-0.34	-0.25	Depression;	chr6:28231986	chr6:28161781~28169594:+
THCA	cis	rs9527	0.525	rs12770034	ENSG00000236937.2	PTGES3P4	5.68	2.32e-08	4e-06	0.33	0.25	Arsenic metabolism;	chr10:102875838	chr10:102845595~102845950:+
THCA	cis	rs79040073	0.637	rs11632211	ENSG00000259531.2	RP11-295H24.3	5.68	2.32e-08	4e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49159178	chr15:49365124~49366685:-
THCA	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	5.68	2.32e-08	4e-06	0.15	0.25	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
THCA	cis	rs224278	0.789	rs224302	ENSG00000238280.1	RP11-436D10.3	5.68	2.33e-08	4e-06	0.29	0.25	Ewing sarcoma;	chr10:62833045	chr10:62793562~62805887:-
THCA	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-5.68	2.33e-08	4e-06	-0.34	-0.25	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
THCA	cis	rs9601248	0.756	rs7997134	ENSG00000227676.3	LINC01068	-5.68	2.33e-08	4e-06	-0.32	-0.25	Major depressive disorder;	chr13:79619594	chr13:79566727~79571436:+
THCA	cis	rs55665837	0.539	rs731042	ENSG00000251991.1	RNU7-49P	5.68	2.33e-08	4.01e-06	0.28	0.25	Vitamin D levels;	chr11:14853429	chr11:14478892~14478953:+
THCA	cis	rs1707322	0.721	rs11211163	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs12037803	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs10789470	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs61784796	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs10749856	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs10890344	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs4564187	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.752	rs28438704	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs28442079	ENSG00000281133.1	AL355480.3	-5.68	2.33e-08	4.01e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45580892~45580996:-
THCA	cis	rs1876905	0.764	rs4947106	ENSG00000230177.1	RP5-1112D6.4	5.68	2.33e-08	4.01e-06	0.25	0.25	Mean corpuscular hemoglobin;	chr6:111100163	chr6:111277932~111278742:+
THCA	cis	rs116095464	0.51	rs10057501	ENSG00000248925.1	CTD-2083E4.6	5.68	2.33e-08	4.01e-06	0.36	0.25	Breast cancer;	chr5:239430	chr5:269858~271516:-
THCA	cis	rs6671200	0.607	rs1927043	ENSG00000228852.5	RP11-57H12.5	-5.68	2.33e-08	4.01e-06	-0.3	-0.25	Stearic acid (18:0) levels;	chr1:95201695	chr1:95243167~95278940:-
THCA	cis	rs4660456	0.572	rs7519348	ENSG00000272145.1	NFYC-AS1	5.68	2.33e-08	4.01e-06	0.16	0.25	Platelet count;	chr1:40694532	chr1:40690380~40692066:-
THCA	cis	rs1889642	0.717	rs7321213	ENSG00000227354.5	RBM26-AS1	5.68	2.33e-08	4.01e-06	0.23	0.25	Colonoscopy-negative controls vs population controls;	chr13:79800953	chr13:79406309~79424328:+
THCA	cis	rs831571	0.534	rs7621907	ENSG00000280620.1	SCAANT1	5.68	2.33e-08	4.01e-06	0.43	0.25	Type 2 diabetes;	chr3:64106541	chr3:63911518~63911772:-
THCA	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	5.68	2.33e-08	4.01e-06	0.2	0.25	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
THCA	cis	rs801193	1	rs17566701	ENSG00000273142.1	RP11-458F8.4	-5.68	2.34e-08	4.02e-06	-0.21	-0.25	Aortic root size;	chr7:66728196	chr7:66902857~66906297:+
THCA	cis	rs9843304	0.508	rs11926459	ENSG00000244503.1	RP11-278L15.6	-5.68	2.34e-08	4.02e-06	-0.32	-0.25	Gallstone disease;	chr3:149494295	chr3:149494660~149495995:+
THCA	cis	rs61677309	1	rs56140791	ENSG00000280032.1	RP11-832A4.7	5.68	2.34e-08	4.03e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118296475	chr11:118264593~118266817:+
THCA	cis	rs75920871	0.528	rs12274465	ENSG00000254851.1	RP11-109L13.1	5.68	2.34e-08	4.03e-06	0.36	0.25	Subjective well-being;	chr11:117086473	chr11:117135528~117138582:+
THCA	cis	rs4713118	0.662	rs149961	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28047791	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28056708	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28056792	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28057501	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28057708	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28058299	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28058358	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28059910	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28060612	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28060704	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000272009.1	RP1-313I6.12	-5.68	2.34e-08	4.03e-06	-0.28	-0.25	Parkinson's disease;	chr6:28062059	chr6:28078792~28081130:-
THCA	cis	rs935334	1	rs2121075	ENSG00000258454.1	RP11-361H10.3	5.68	2.34e-08	4.03e-06	0.36	0.25	Blood pressure;	chr14:76209197	chr14:76235817~76263474:+
THCA	cis	rs757978	1	rs7601738	ENSG00000223374.1	AC005104.3	-5.68	2.35e-08	4.04e-06	-0.27	-0.25	Chronic lymphocytic leukemia;	chr2:241436398	chr2:241351340~241353104:-
THCA	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	5.68	2.35e-08	4.04e-06	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
THCA	cis	rs79040073	0.53	rs73392262	ENSG00000259531.2	RP11-295H24.3	5.68	2.35e-08	4.04e-06	0.34	0.25	Lung cancer in ever smokers;	chr15:49229513	chr15:49365124~49366685:-
THCA	cis	rs11148252	0.669	rs4884320	ENSG00000235660.1	LINC00345	-5.68	2.35e-08	4.05e-06	-0.34	-0.25	Lewy body disease;	chr13:52432779	chr13:52484161~52484680:-
THCA	cis	rs4748857	0.685	rs16923146	ENSG00000224215.1	RP11-371A19.2	-5.68	2.35e-08	4.05e-06	-0.36	-0.25	Systemic lupus erythematosus;	chr10:23248236	chr10:23343957~23345181:+
THCA	cis	rs763567	1	rs1928715	ENSG00000271811.1	RP1-79C4.4	-5.68	2.35e-08	4.05e-06	-0.3	-0.25	Tonsillectomy;	chr1:170598296	chr1:170667381~170669425:+
THCA	cis	rs7829975	0.517	rs12542733	ENSG00000254153.1	CTA-398F10.2	5.68	2.35e-08	4.05e-06	0.27	0.25	Mood instability;	chr8:8967348	chr8:8456909~8461337:-
THCA	cis	rs11603023	0.967	rs7936556	ENSG00000278376.1	RP11-158I9.8	5.68	2.36e-08	4.05e-06	0.19	0.25	Cholesterol, total;	chr11:118630582	chr11:118791254~118793137:+
THCA	cis	rs16976116	0.901	rs56328329	ENSG00000279145.1	RP11-547D13.1	5.68	2.36e-08	4.05e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55210779	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs28864456	ENSG00000279145.1	RP11-547D13.1	5.68	2.36e-08	4.05e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55210894	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.851	rs28889339	ENSG00000279145.1	RP11-547D13.1	5.68	2.36e-08	4.05e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55211007	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.851	rs28784096	ENSG00000279145.1	RP11-547D13.1	5.68	2.36e-08	4.05e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55211114	chr15:55171972~55178175:-
THCA	cis	rs6860806	0.661	rs4705927	ENSG00000233006.5	AC034220.3	5.68	2.36e-08	4.05e-06	0.19	0.25	Breast cancer;	chr5:132242915	chr5:132311285~132369916:-
THCA	cis	rs2559856	0.903	rs10128996	ENSG00000274560.1	RP11-285E23.2	5.68	2.36e-08	4.05e-06	0.16	0.25	Blood protein levels;	chr12:101687720	chr12:101696002~101696450:-
THCA	cis	rs2559856	0.935	rs7957666	ENSG00000274560.1	RP11-285E23.2	5.68	2.36e-08	4.05e-06	0.16	0.25	Blood protein levels;	chr12:101687773	chr12:101696002~101696450:-
THCA	cis	rs2559856	0.967	rs7970837	ENSG00000274560.1	RP11-285E23.2	5.68	2.36e-08	4.05e-06	0.16	0.25	Blood protein levels;	chr12:101687798	chr12:101696002~101696450:-
THCA	cis	rs2559856	0.935	rs7970952	ENSG00000274560.1	RP11-285E23.2	5.68	2.36e-08	4.05e-06	0.16	0.25	Blood protein levels;	chr12:101687799	chr12:101696002~101696450:-
THCA	cis	rs752010	0.841	rs6661784	ENSG00000230638.4	RP11-486B10.4	-5.68	2.36e-08	4.05e-06	-0.27	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41614641	chr1:41542069~41544310:+
THCA	cis	rs9467773	1	rs1884949	ENSG00000124549.13	BTN2A3P	5.68	2.36e-08	4.06e-06	0.24	0.25	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26421391~26432383:+
THCA	cis	rs2944755	0.686	rs11997913	ENSG00000279766.1	RP11-642A1.2	-5.68	2.36e-08	4.06e-06	-0.33	-0.25	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578561	chr8:140572142~140572812:-
THCA	cis	rs1876905	0.62	rs354530	ENSG00000230177.1	RP5-1112D6.4	-5.68	2.36e-08	4.06e-06	-0.26	-0.25	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111277932~111278742:+
THCA	cis	rs6792584	0.889	rs7628838	ENSG00000241316.5	SUCLG2-AS1	-5.68	2.36e-08	4.06e-06	-0.26	-0.25	Corneal astigmatism;	chr3:67455474	chr3:67654697~67947713:+
THCA	cis	rs172166	0.694	rs203893	ENSG00000226314.6	ZNF192P1	-5.68	2.36e-08	4.07e-06	-0.3	-0.25	Cardiac Troponin-T levels;	chr6:28094288	chr6:28161781~28169594:+
THCA	cis	rs2732480	0.557	rs2732454	ENSG00000240399.1	RP1-228P16.1	5.68	2.36e-08	4.07e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48054813~48055591:-
THCA	cis	rs228614	0.51	rs170565	ENSG00000251288.2	RP11-10L12.2	-5.68	2.37e-08	4.07e-06	-0.35	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102751401~102752641:+
THCA	cis	rs748404	0.666	rs7183708	ENSG00000249839.1	AC011330.5	-5.68	2.37e-08	4.07e-06	-0.36	-0.25	Lung cancer;	chr15:43355226	chr15:43663654~43684339:-
THCA	cis	rs6430585	0.528	rs114760827	ENSG00000231890.6	DARS-AS1	-5.68	2.37e-08	4.07e-06	-0.31	-0.25	Corneal structure;	chr2:135903540	chr2:135985176~136022593:+
THCA	cis	rs3785574	0.886	rs62077504	ENSG00000240280.5	TCAM1P	-5.68	2.37e-08	4.07e-06	-0.35	-0.25	Height;	chr17:63760374	chr17:63849292~63864379:+
THCA	cis	rs950169	0.58	rs11634320	ENSG00000259295.5	CSPG4P12	-5.68	2.37e-08	4.07e-06	-0.39	-0.25	Schizophrenia;	chr15:84628952	chr15:85191438~85213905:+
THCA	cis	rs10875746	0.855	rs10875730	ENSG00000269514.1	RP11-370I10.12	5.68	2.37e-08	4.08e-06	0.26	0.25	Longevity (90 years and older);	chr12:48034092	chr12:48198387~48202031:+
THCA	cis	rs11089937	0.597	rs6001076	ENSG00000211639.2	IGLV4-60	5.68	2.37e-08	4.08e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs5995560	ENSG00000211639.2	IGLV4-60	5.68	2.37e-08	4.08e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.568	rs6001078	ENSG00000211639.2	IGLV4-60	5.68	2.37e-08	4.08e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22162199~22162681:+
THCA	cis	rs6840360	0.667	rs9994482	ENSG00000270265.1	RP11-731D1.4	-5.68	2.37e-08	4.08e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151333775~151353224:-
THCA	cis	rs796395	0.65	rs675763	ENSG00000228208.5	C1orf143	-5.68	2.37e-08	4.08e-06	-0.3	-0.25	Post bronchodilator FEV1/FVC ratio;	chr1:218508777	chr1:218510096~218525978:+
THCA	cis	rs2559856	1	rs2559858	ENSG00000274560.1	RP11-285E23.2	5.68	2.37e-08	4.08e-06	0.15	0.25	Blood protein levels;	chr12:101695522	chr12:101696002~101696450:-
THCA	cis	rs9921338	0.961	rs7198849	ENSG00000262636.1	CTD-3088G3.4	-5.68	2.37e-08	4.08e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11279444	chr16:11380859~11381118:-
THCA	cis	rs964184	0.688	rs1558860	ENSG00000254851.1	RP11-109L13.1	-5.68	2.37e-08	4.08e-06	-0.51	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116736652	chr11:117135528~117138582:+
THCA	cis	rs7412746	0.658	rs10305714	ENSG00000231073.1	RP11-316M1.3	-5.68	2.38e-08	4.08e-06	-0.31	-0.25	Melanoma;	chr1:150828179	chr1:150973123~150975534:+
THCA	cis	rs2276314	0.512	rs1789506	ENSG00000278986.1	RP11-723J4.3	5.68	2.38e-08	4.09e-06	0.26	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36045407	chr18:35972151~35973916:+
THCA	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	5.68	2.38e-08	4.09e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
THCA	cis	rs13256369	0.802	rs12681925	ENSG00000253893.2	FAM85B	-5.68	2.38e-08	4.09e-06	-0.35	-0.25	Obesity-related traits;	chr8:8704139	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.802	rs12680019	ENSG00000253893.2	FAM85B	-5.68	2.38e-08	4.09e-06	-0.35	-0.25	Obesity-related traits;	chr8:8704188	chr8:8167819~8226614:-
THCA	cis	rs3742264	0.816	rs9534319	ENSG00000235903.6	CPB2-AS1	5.68	2.38e-08	4.09e-06	0.35	0.25	Blood protein levels;	chr13:46090309	chr13:46052806~46113332:+
THCA	cis	rs17214007	0.877	rs2075514	ENSG00000263335.1	AF001548.5	-5.68	2.38e-08	4.09e-06	-0.35	-0.25	Cognitive function;	chr16:15778752	chr16:15726674~15732993:+
THCA	cis	rs2554380	0.628	rs11853983	ENSG00000230373.7	GOLGA6L5P	5.68	2.38e-08	4.09e-06	0.27	0.25	Height;	chr15:83794058	chr15:84507885~84516814:-
THCA	cis	rs9990343	0.603	rs4683223	ENSG00000223552.1	RP11-24F11.2	5.68	2.38e-08	4.09e-06	0.23	0.25	Brain structure;	chr3:46413243	chr3:46364955~46407059:-
THCA	cis	rs2136613	0.728	rs10761676	ENSG00000238280.1	RP11-436D10.3	5.68	2.38e-08	4.1e-06	0.3	0.25	Selective IgA deficiency;	chr10:62863689	chr10:62793562~62805887:-
THCA	cis	rs2117029	0.638	rs7296288	ENSG00000258017.1	RP11-386G11.10	-5.68	2.38e-08	4.1e-06	-0.31	-0.25	Intelligence (multi-trait analysis);	chr12:49086185	chr12:49127782~49147869:+
THCA	cis	rs2213290	1	rs2213290	ENSG00000223552.1	RP11-24F11.2	5.68	2.38e-08	4.1e-06	0.23	0.25	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr3:46364876	chr3:46364955~46407059:-
THCA	cis	rs9388451	0.807	rs1268070	ENSG00000226409.1	RP11-735G4.1	-5.68	2.39e-08	4.1e-06	-0.3	-0.25	Brugada syndrome;	chr6:125720018	chr6:125370211~125374324:-
THCA	cis	rs7617773	1	rs7617773	ENSG00000228638.1	FCF1P2	5.68	2.39e-08	4.1e-06	0.24	0.25	Coronary artery disease;	chr3:48152025	chr3:48290793~48291375:-
THCA	cis	rs4908768	0.539	rs7526171	ENSG00000232912.4	RP5-1115A15.1	5.68	2.39e-08	4.1e-06	0.25	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8590126	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.539	rs6675443	ENSG00000232912.4	RP5-1115A15.1	5.68	2.39e-08	4.1e-06	0.25	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8591523	chr1:8424645~8434838:+
THCA	cis	rs763121	0.853	rs5750649	ENSG00000235209.1	CTA-150C2.13	5.68	2.39e-08	4.1e-06	0.33	0.25	Menopause (age at onset);	chr22:38640764	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs6519124	ENSG00000235209.1	CTA-150C2.13	5.68	2.39e-08	4.1e-06	0.33	0.25	Menopause (age at onset);	chr22:38649094	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5750652	ENSG00000235209.1	CTA-150C2.13	5.68	2.39e-08	4.1e-06	0.33	0.25	Menopause (age at onset);	chr22:38652311	chr22:38921227~38924708:+
THCA	cis	rs763121	0.814	rs5757212	ENSG00000235209.1	CTA-150C2.13	5.68	2.39e-08	4.1e-06	0.33	0.25	Menopause (age at onset);	chr22:38657752	chr22:38921227~38924708:+
THCA	cis	rs997295	0.57	rs11632574	ENSG00000270964.1	RP11-502I4.3	-5.68	2.39e-08	4.11e-06	-0.21	-0.25	Motion sickness;	chr15:67560067	chr15:67541072~67542604:-
THCA	cis	rs4713118	0.513	rs149942	ENSG00000220721.1	OR1F12	5.68	2.39e-08	4.11e-06	0.3	0.25	Parkinson's disease;	chr6:28033832	chr6:28073316~28074233:+
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000280069.1	CTD-2349P21.3	-5.68	2.39e-08	4.11e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30738182~30740275:+
THCA	cis	rs2835345	0.563	rs12482140	ENSG00000230479.1	AP000695.6	5.68	2.39e-08	4.11e-06	0.3	0.25	Pulmonary function;	chr21:36451735	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.528	rs73204243	ENSG00000230479.1	AP000695.6	5.68	2.39e-08	4.11e-06	0.3	0.25	Pulmonary function;	chr21:36451776	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.595	rs78237434	ENSG00000230479.1	AP000695.6	5.68	2.39e-08	4.11e-06	0.3	0.25	Pulmonary function;	chr21:36451826	chr21:36430360~36481070:+
THCA	cis	rs6569038	0.508	rs4946388	ENSG00000253194.1	RP11-351A11.1	5.68	2.39e-08	4.11e-06	0.35	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119032352	chr6:118934785~119031541:+
THCA	cis	rs13256369	0.851	rs11249890	ENSG00000253893.2	FAM85B	-5.68	2.39e-08	4.11e-06	-0.34	-0.25	Obesity-related traits;	chr8:8707735	chr8:8167819~8226614:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000275400.1	RP4-756H11.5	-5.68	2.39e-08	4.11e-06	-0.24	-0.25	Calcium levels;	chr7:65751755	chr7:66553805~66554199:-
THCA	cis	rs1005277	0.522	rs289647	ENSG00000263064.2	RP11-291L22.7	5.68	2.4e-08	4.12e-06	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38448689~38448949:+
THCA	cis	rs2559856	0.904	rs2695283	ENSG00000274560.1	RP11-285E23.2	5.68	2.4e-08	4.12e-06	0.15	0.25	Blood protein levels;	chr12:101695613	chr12:101696002~101696450:-
THCA	cis	rs2559856	1	rs2559857	ENSG00000274560.1	RP11-285E23.2	5.68	2.4e-08	4.12e-06	0.15	0.25	Blood protein levels;	chr12:101695621	chr12:101696002~101696450:-
THCA	cis	rs9876781	0.933	rs6442124	ENSG00000229759.1	MRPS18AP1	5.68	2.4e-08	4.12e-06	0.3	0.25	Longevity;	chr3:48463903	chr3:48256350~48256938:-
THCA	cis	rs7621025	0.505	rs61789642	ENSG00000239213.4	NCK1-AS1	-5.68	2.4e-08	4.12e-06	-0.36	-0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390854	chr3:136841726~136862054:-
THCA	cis	rs7621025	0.505	rs61789643	ENSG00000239213.4	NCK1-AS1	-5.68	2.4e-08	4.12e-06	-0.36	-0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390910	chr3:136841726~136862054:-
THCA	cis	rs7083	1	rs493139	ENSG00000254851.1	RP11-109L13.1	5.68	2.4e-08	4.12e-06	0.34	0.25	Blood protein levels;	chr11:117275233	chr11:117135528~117138582:+
THCA	cis	rs2562456	1	rs2359155	ENSG00000268119.4	CTD-2561J22.5	-5.68	2.4e-08	4.12e-06	-0.31	-0.25	Pain;	chr19:21489067	chr19:21444241~21463908:-
THCA	cis	rs9388451	0.872	rs2008027	ENSG00000226409.1	RP11-735G4.1	-5.68	2.4e-08	4.12e-06	-0.3	-0.25	Brugada syndrome;	chr6:125731213	chr6:125370211~125374324:-
THCA	cis	rs11148252	0.532	rs9526975	ENSG00000273784.3	RP11-78J21.7	-5.68	2.4e-08	4.13e-06	-0.27	-0.25	Lewy body disease;	chr13:52681669	chr13:52600042~52642542:+
THCA	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	5.68	2.4e-08	4.13e-06	0.28	0.25	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
THCA	cis	rs7184046	0.797	rs13737	ENSG00000260269.4	CTD-2323K18.1	-5.68	2.4e-08	4.13e-06	-0.38	-0.25	Height;	chr15:75639788	chr15:75527150~75601205:-
THCA	cis	rs1387259	0.929	rs2634666	ENSG00000240399.1	RP1-228P16.1	5.68	2.4e-08	4.13e-06	0.26	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48054813~48055591:-
THCA	cis	rs1387259	0.929	rs2956703	ENSG00000240399.1	RP1-228P16.1	5.68	2.4e-08	4.13e-06	0.26	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48054813~48055591:-
THCA	cis	rs1387259	0.931	rs1107654	ENSG00000240399.1	RP1-228P16.1	5.68	2.4e-08	4.13e-06	0.26	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48054813~48055591:-
THCA	cis	rs7615952	0.605	rs34865555	ENSG00000243429.1	OR7E29P	5.68	2.4e-08	4.13e-06	0.44	0.25	Blood pressure (smoking interaction);	chr3:125585290	chr3:125712139~125713045:+
THCA	cis	rs12428035	0.772	rs9584324	ENSG00000247400.3	DNAJC3-AS1	-5.68	2.4e-08	4.13e-06	-0.23	-0.25	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95820917	chr13:95648733~95676925:-
THCA	cis	rs498872	0.507	rs45540840	ENSG00000255239.1	AP002954.6	-5.68	2.4e-08	4.13e-06	-0.38	-0.25	Glioma;	chr11:118615395	chr11:118688039~118690600:-
THCA	cis	rs9307551	1	rs3943669	ENSG00000250334.4	LINC00989	-5.68	2.41e-08	4.13e-06	-0.32	-0.25	Refractive error;	chr4:79595389	chr4:79492416~79576460:+
THCA	cis	rs1499614	1	rs2707840	ENSG00000232559.3	GS1-124K5.12	5.68	2.41e-08	4.13e-06	0.39	0.25	Gout;	chr7:66693028	chr7:66554588~66576923:-
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	5.68	2.41e-08	4.13e-06	0.29	0.25	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
THCA	cis	rs7554547	0.778	rs2008113	ENSG00000199347.1	RNU5E-1	-5.68	2.41e-08	4.14e-06	-0.33	-0.25	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr1:11908152~11908271:+
THCA	cis	rs7829975	0.714	rs12544992	ENSG00000254153.1	CTA-398F10.2	-5.68	2.41e-08	4.14e-06	-0.27	-0.25	Mood instability;	chr8:8804171	chr8:8456909~8461337:-
THCA	cis	rs7083	1	rs619772	ENSG00000254851.1	RP11-109L13.1	5.68	2.41e-08	4.14e-06	0.34	0.25	Blood protein levels;	chr11:117268120	chr11:117135528~117138582:+
THCA	cis	rs55823223	0.564	rs1463485	ENSG00000267801.1	RP11-552F3.9	5.68	2.41e-08	4.14e-06	0.32	0.25	Psoriasis;	chr17:75855710	chr17:75876372~75879546:+
THCA	cis	rs2742234	0.91	rs2503866	ENSG00000273008.1	RP11-351D16.3	-5.68	2.41e-08	4.14e-06	-0.22	-0.25	Hirschsprung disease;	chr10:43150813	chr10:43136824~43138334:-
THCA	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	5.68	2.41e-08	4.14e-06	0.4	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
THCA	cis	rs9859260	0.961	rs41300431	ENSG00000226155.1	AC124944.3	-5.68	2.41e-08	4.14e-06	-0.3	-0.25	Mean corpuscular volume;	chr3:196077427	chr3:195912049~195913986:+
THCA	cis	rs2839186	0.814	rs13052376	ENSG00000239415.1	AP001469.9	5.68	2.41e-08	4.15e-06	0.26	0.25	Testicular germ cell tumor;	chr21:46287489	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.934	rs13046494	ENSG00000239415.1	AP001469.9	5.68	2.41e-08	4.15e-06	0.26	0.25	Testicular germ cell tumor;	chr21:46287516	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.872	rs13052495	ENSG00000239415.1	AP001469.9	5.68	2.41e-08	4.15e-06	0.26	0.25	Testicular germ cell tumor;	chr21:46287560	chr21:46251549~46254133:-
THCA	cis	rs8177876	0.822	rs12443549	ENSG00000261061.1	RP11-303E16.2	5.68	2.42e-08	4.15e-06	0.38	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81030770~81031485:+
THCA	cis	rs748404	0.626	rs72707530	ENSG00000249839.1	AC011330.5	-5.68	2.42e-08	4.15e-06	-0.36	-0.25	Lung cancer;	chr15:43353622	chr15:43663654~43684339:-
THCA	cis	rs75920871	0.528	rs10082609	ENSG00000254851.1	RP11-109L13.1	5.68	2.42e-08	4.15e-06	0.36	0.25	Subjective well-being;	chr11:117078358	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs10892071	ENSG00000254851.1	RP11-109L13.1	5.68	2.42e-08	4.15e-06	0.36	0.25	Subjective well-being;	chr11:117083849	chr11:117135528~117138582:+
THCA	cis	rs10761482	0.5	rs2153525	ENSG00000254271.1	RP11-131N11.4	-5.68	2.42e-08	4.15e-06	-0.34	-0.25	Schizophrenia;	chr10:60509816	chr10:60734342~60741828:+
THCA	cis	rs1865760	0.566	rs9348706	ENSG00000272462.2	U91328.19	-5.68	2.42e-08	4.15e-06	-0.21	-0.25	Height;	chr6:26065253	chr6:25992662~26001775:+
THCA	cis	rs2439831	0.717	rs2470132	ENSG00000166763.7	STRCP1	5.68	2.42e-08	4.16e-06	0.35	0.25	Lung cancer in ever smokers;	chr15:43543283	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2251844	ENSG00000166763.7	STRCP1	5.68	2.42e-08	4.16e-06	0.35	0.25	Lung cancer in ever smokers;	chr15:43544280	chr15:43699488~43718184:-
THCA	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	5.68	2.42e-08	4.16e-06	0.4	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
THCA	cis	rs6991838	0.806	rs17302392	ENSG00000200714.1	Y_RNA	5.68	2.42e-08	4.16e-06	0.3	0.25	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65592731~65592820:+
THCA	cis	rs10895275	0.924	rs12786272	ENSG00000277459.1	RP11-732A21.3	-5.68	2.42e-08	4.16e-06	-0.2	-0.25	Migraine;	chr11:102215632	chr11:102109827~102110457:-
THCA	cis	rs2303759	0.543	rs7255778	ENSG00000268686.1	AC010524.2	-5.68	2.42e-08	4.16e-06	-0.36	-0.25	Multiple sclerosis;	chr19:49403351	chr19:49368705~49388081:-
THCA	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	5.68	2.42e-08	4.16e-06	0.23	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
THCA	cis	rs6840360	0.582	rs11732918	ENSG00000270265.1	RP11-731D1.4	-5.68	2.42e-08	4.16e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.557	rs4696261	ENSG00000270265.1	RP11-731D1.4	-5.68	2.42e-08	4.16e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151333775~151353224:-
THCA	cis	rs6545883	1	rs778758	ENSG00000270820.4	RP11-355B11.2	5.68	2.43e-08	4.16e-06	0.21	0.25	Tuberculosis;	chr2:61555026	chr2:61471188~61484130:+
THCA	cis	rs2439831	0.681	rs1549523	ENSG00000249839.1	AC011330.5	-5.68	2.43e-08	4.17e-06	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43331991	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.681	rs1549525	ENSG00000249839.1	AC011330.5	-5.68	2.43e-08	4.17e-06	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43335657	chr15:43663654~43684339:-
THCA	cis	rs61677309	1	rs7110019	ENSG00000280032.1	RP11-832A4.7	5.68	2.43e-08	4.17e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118297902	chr11:118264593~118266817:+
THCA	cis	rs9876781	1	rs9812647	ENSG00000229759.1	MRPS18AP1	-5.68	2.43e-08	4.17e-06	-0.3	-0.25	Longevity;	chr3:48407507	chr3:48256350~48256938:-
THCA	cis	rs2303319	0.504	rs2389549	ENSG00000227403.1	AC009299.3	-5.68	2.43e-08	4.17e-06	-0.53	-0.25	Cognitive function;	chr2:161605699	chr2:161244739~161249050:+
THCA	cis	rs1499614	1	rs2141924	ENSG00000232559.3	GS1-124K5.12	5.67	2.43e-08	4.17e-06	0.39	0.25	Gout;	chr7:66721259	chr7:66554588~66576923:-
THCA	cis	rs12681287	0.711	rs28420256	ENSG00000254231.1	CTD-2284J15.1	5.67	2.43e-08	4.17e-06	0.28	0.25	Caudate activity during reward;	chr8:86243370	chr8:86333274~86343314:-
THCA	cis	rs9921338	0.961	rs7202814	ENSG00000262703.1	RP11-485G7.6	-5.67	2.43e-08	4.17e-06	-0.33	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11295917	chr16:11348143~11349321:-
THCA	cis	rs13256369	0.755	rs12680167	ENSG00000253893.2	FAM85B	-5.67	2.43e-08	4.17e-06	-0.34	-0.25	Obesity-related traits;	chr8:8704957	chr8:8167819~8226614:-
THCA	cis	rs6740322	0.644	rs11690918	ENSG00000234936.1	AC010883.5	5.67	2.43e-08	4.17e-06	0.28	0.25	Coronary artery disease;	chr2:43246973	chr2:43229573~43233394:+
THCA	cis	rs79040073	0.637	rs73392256	ENSG00000259531.2	RP11-295H24.3	5.67	2.43e-08	4.17e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49228379	chr15:49365124~49366685:-
THCA	cis	rs10129255	0.957	rs8014696	ENSG00000211974.3	IGHV2-70	-5.67	2.43e-08	4.18e-06	-0.19	-0.25	Kawasaki disease;	chr14:106769752	chr14:106723574~106724093:-
THCA	cis	rs2243480	1	rs781150	ENSG00000232546.1	RP11-458F8.1	-5.67	2.43e-08	4.18e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:66015986	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs313798	ENSG00000232546.1	RP11-458F8.1	-5.67	2.43e-08	4.18e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:66028044	chr7:66848496~66858136:+
THCA	cis	rs6569038	0.502	rs794263	ENSG00000253194.1	RP11-351A11.1	5.67	2.43e-08	4.18e-06	0.34	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119001303	chr6:118934785~119031541:+
THCA	cis	rs2742234	0.955	rs2503865	ENSG00000273008.1	RP11-351D16.3	-5.67	2.43e-08	4.18e-06	-0.22	-0.25	Hirschsprung disease;	chr10:43164088	chr10:43136824~43138334:-
THCA	cis	rs4789693	0.873	rs8069111	ENSG00000260011.2	RP13-20L14.1	-5.67	2.43e-08	4.18e-06	-0.26	-0.25	Glucocorticoid-induced osteonecrosis;	chr17:82437581	chr17:82381110~82382690:-
THCA	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-5.67	2.43e-08	4.18e-06	-0.38	-0.25	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
THCA	cis	rs9652601	0.748	rs12924112	ENSG00000274038.1	RP11-66H6.4	-5.67	2.43e-08	4.18e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11125863	chr16:11056556~11057034:+
THCA	cis	rs9307551	1	rs9307545	ENSG00000250334.4	LINC00989	-5.67	2.44e-08	4.18e-06	-0.32	-0.25	Refractive error;	chr4:79595417	chr4:79492416~79576460:+
THCA	cis	rs5758659	1	rs5751255	ENSG00000270083.1	RP1-257I20.14	5.67	2.44e-08	4.18e-06	0.27	0.25	Cognitive function;	chr22:42252402	chr22:42089630~42090028:-
THCA	cis	rs875971	1	rs1565531	ENSG00000223473.2	GS1-124K5.3	-5.67	2.44e-08	4.18e-06	-0.17	-0.25	Aortic root size;	chr7:66198126	chr7:66491049~66493566:-
THCA	cis	rs7923837	0.616	rs12778642	ENSG00000236493.2	EIF2S2P3	5.67	2.44e-08	4.19e-06	0.26	0.25	Multiple sclerosis;Body mass index;	chr10:92704550	chr10:92668745~92669743:-
THCA	cis	rs846111	1	rs846111	ENSG00000225077.2	LINC00337	-5.67	2.44e-08	4.19e-06	-0.35	-0.25	QT interval;	chr1:6219310	chr1:6236240~6239444:+
THCA	cis	rs71520386	0.632	rs10253651	ENSG00000228649.7	AC005682.5	-5.67	2.44e-08	4.19e-06	-0.32	-0.25	Fibrinogen levels;	chr7:22830564	chr7:22854178~22861579:+
THCA	cis	rs7646881	0.544	rs10154917	ENSG00000240207.5	RP11-379F4.4	-5.67	2.44e-08	4.19e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158614911	chr3:158732263~158784070:+
THCA	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-5.67	2.44e-08	4.2e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-5.67	2.44e-08	4.2e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
THCA	cis	rs4948275	0.714	rs2787725	ENSG00000237233.2	TMEM26-AS1	-5.67	2.45e-08	4.2e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61477622	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2650704	ENSG00000237233.2	TMEM26-AS1	-5.67	2.45e-08	4.2e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61477722	chr10:61452639~61481956:+
THCA	cis	rs2212361	0.527	rs12282965	ENSG00000255893.1	RP11-685N10.1	-5.67	2.45e-08	4.2e-06	-0.29	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94528348	chr11:94472908~94473570:-
THCA	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	5.67	2.45e-08	4.2e-06	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
THCA	cis	rs9990333	0.562	rs58079878	ENSG00000231464.1	AC024937.4	5.67	2.45e-08	4.2e-06	0.32	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195996738~195998233:+
THCA	cis	rs12893668	0.572	rs4900590	ENSG00000269940.1	RP11-73M18.7	5.67	2.45e-08	4.2e-06	0.26	0.25	Reticulocyte count;	chr14:103680084	chr14:103694560~103695170:+
THCA	cis	rs11148252	0.532	rs9536262	ENSG00000278238.1	RP11-245D16.4	5.67	2.45e-08	4.2e-06	0.29	0.25	Lewy body disease;	chr13:52728939	chr13:52454775~52455331:-
THCA	cis	rs10800713	0.56	rs10919967	ENSG00000260088.1	RP11-92G12.3	5.67	2.45e-08	4.21e-06	0.41	0.25	Tandem gait;	chr1:200533543	chr1:200669507~200694250:+
THCA	cis	rs7267979	0.668	rs4815398	ENSG00000274973.1	RP13-401N8.7	5.67	2.45e-08	4.21e-06	0.29	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:25845497~25845862:+
THCA	cis	rs13256369	0.802	rs34762800	ENSG00000253893.2	FAM85B	-5.67	2.45e-08	4.21e-06	-0.34	-0.25	Obesity-related traits;	chr8:8701784	chr8:8167819~8226614:-
THCA	cis	rs3785574	0.962	rs57553639	ENSG00000240280.5	TCAM1P	-5.67	2.45e-08	4.21e-06	-0.35	-0.25	Height;	chr17:63771139	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs62077509	ENSG00000240280.5	TCAM1P	-5.67	2.45e-08	4.21e-06	-0.35	-0.25	Height;	chr17:63771613	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs56295011	ENSG00000240280.5	TCAM1P	-5.67	2.45e-08	4.21e-06	-0.35	-0.25	Height;	chr17:63772999	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs62077512	ENSG00000240280.5	TCAM1P	-5.67	2.45e-08	4.21e-06	-0.35	-0.25	Height;	chr17:63774075	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs58131426	ENSG00000240280.5	TCAM1P	-5.67	2.45e-08	4.21e-06	-0.35	-0.25	Height;	chr17:63777015	chr17:63849292~63864379:+
THCA	cis	rs7712401	0.755	rs6595407	ENSG00000249996.1	RP11-359P5.1	5.67	2.45e-08	4.21e-06	0.24	0.25	Mean platelet volume;	chr5:122764703	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.755	rs4283786	ENSG00000249996.1	RP11-359P5.1	5.67	2.45e-08	4.21e-06	0.24	0.25	Mean platelet volume;	chr5:122765355	chr5:123036271~123054667:+
THCA	cis	rs1426063	1	rs10030850	ENSG00000260265.1	RP11-44F21.5	5.67	2.45e-08	4.21e-06	0.47	0.25	QT interval;	chr4:75099199	chr4:75081702~75084717:-
THCA	cis	rs1426063	1	rs9993589	ENSG00000260265.1	RP11-44F21.5	5.67	2.45e-08	4.21e-06	0.47	0.25	QT interval;	chr4:75099556	chr4:75081702~75084717:-
THCA	cis	rs9311474	0.652	rs352158	ENSG00000243224.1	RP5-1157M23.2	-5.67	2.46e-08	4.21e-06	-0.26	-0.25	Electroencephalogram traits;	chr3:52183688	chr3:52239258~52241097:+
THCA	cis	rs2915864	1	rs2906069	ENSG00000280047.1	CTC-463A16.1	5.67	2.46e-08	4.22e-06	0.4	0.25	Facial morphology (factor 20);	chr5:142200084	chr5:142165767~142168387:+
THCA	cis	rs11723261	0.621	rs7692530	ENSG00000211553.1	AC253576.2	-5.67	2.46e-08	4.22e-06	-0.36	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:136461~136568:+
THCA	cis	rs2280018	1	rs2280017	ENSG00000188599.16	NPIPP1	5.67	2.46e-08	4.22e-06	0.18	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15104312~15123498:-
THCA	cis	rs67478160	0.654	rs11628240	ENSG00000258735.1	LINC00637	-5.67	2.46e-08	4.22e-06	-0.3	-0.25	Schizophrenia;	chr14:103751798	chr14:103847721~103858049:+
THCA	cis	rs7246657	0.722	rs10410588	ENSG00000276846.1	CTD-3220F14.3	5.67	2.46e-08	4.22e-06	0.25	0.25	Coronary artery calcification;	chr19:37551508	chr19:37314868~37315620:-
THCA	cis	rs1050631	0.592	rs610492	ENSG00000260552.1	RP11-49I11.1	5.67	2.46e-08	4.23e-06	0.32	0.25	Esophageal squamous cell cancer (length of survival);	chr18:36178473	chr18:36179996~36187448:-
THCA	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	5.67	2.46e-08	4.23e-06	0.4	0.25	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
THCA	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-5.67	2.47e-08	4.23e-06	-0.28	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000182722.5	SEPHS1P1	-5.67	2.47e-08	4.23e-06	-0.3	-0.25	Calcium levels;	chr7:65800652	chr7:64852397~64853354:-
THCA	cis	rs12893668	0.603	rs12896171	ENSG00000269940.1	RP11-73M18.7	5.67	2.47e-08	4.23e-06	0.26	0.25	Reticulocyte count;	chr14:103669629	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.572	rs12590968	ENSG00000269940.1	RP11-73M18.7	5.67	2.47e-08	4.23e-06	0.26	0.25	Reticulocyte count;	chr14:103670296	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.572	rs11540512	ENSG00000269940.1	RP11-73M18.7	5.67	2.47e-08	4.23e-06	0.26	0.25	Reticulocyte count;	chr14:103681040	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.572	rs35011804	ENSG00000269940.1	RP11-73M18.7	5.67	2.47e-08	4.23e-06	0.26	0.25	Reticulocyte count;	chr14:103685063	chr14:103694560~103695170:+
THCA	cis	rs6025590	1	rs6025590	ENSG00000124097.7	HMGB1P1	-5.67	2.47e-08	4.23e-06	-0.32	-0.25	Obesity-related traits;	chr20:57495449	chr20:57488392~57489027:-
THCA	cis	rs1577330	0.615	rs74443054	ENSG00000254396.1	RP11-56F10.3	5.67	2.47e-08	4.23e-06	0.42	0.25	IgG glycosylation;	chr9:27076942	chr9:27102630~27104728:+
THCA	cis	rs17366136	0.895	rs1122913	ENSG00000232759.1	AC002480.3	5.67	2.47e-08	4.23e-06	0.32	0.25	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr7:22563313	chr7:22563337~22573996:+
THCA	cis	rs9326248	0.53	rs2127905	ENSG00000280143.1	AP000892.6	5.67	2.47e-08	4.23e-06	0.42	0.25	Blood protein levels;	chr11:117155658	chr11:117204967~117210292:+
THCA	cis	rs4713118	0.662	rs149969	ENSG00000272009.1	RP1-313I6.12	-5.67	2.47e-08	4.23e-06	-0.28	-0.25	Parkinson's disease;	chr6:28009959	chr6:28078792~28081130:-
THCA	cis	rs3794924	0.925	rs16961977	ENSG00000266521.1	RP11-650P15.1	5.67	2.47e-08	4.24e-06	0.49	0.25	Survival in colon cancer;	chr18:31468251	chr18:31496645~31497195:-
THCA	cis	rs9876781	1	rs13076076	ENSG00000229759.1	MRPS18AP1	5.67	2.47e-08	4.24e-06	0.3	0.25	Longevity;	chr3:48437629	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs9849509	ENSG00000229759.1	MRPS18AP1	5.67	2.47e-08	4.24e-06	0.3	0.25	Longevity;	chr3:48442021	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs60512868	ENSG00000229759.1	MRPS18AP1	5.67	2.47e-08	4.24e-06	0.3	0.25	Longevity;	chr3:48442035	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs7636044	ENSG00000229759.1	MRPS18AP1	5.67	2.47e-08	4.24e-06	0.3	0.25	Longevity;	chr3:48443151	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs4490383	ENSG00000229759.1	MRPS18AP1	5.67	2.47e-08	4.24e-06	0.3	0.25	Longevity;	chr3:48443275	chr3:48256350~48256938:-
THCA	cis	rs9921338	0.961	rs7626	ENSG00000262636.1	CTD-3088G3.4	-5.67	2.47e-08	4.24e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs7193278	ENSG00000262636.1	CTD-3088G3.4	-5.67	2.47e-08	4.24e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11380859~11381118:-
THCA	cis	rs9527	0.571	rs12765337	ENSG00000236937.2	PTGES3P4	5.67	2.47e-08	4.24e-06	0.33	0.25	Arsenic metabolism;	chr10:102875587	chr10:102845595~102845950:+
THCA	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-5.67	2.47e-08	4.24e-06	-0.3	-0.25	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
THCA	cis	rs3760982	1	rs10405457	ENSG00000267058.1	RP11-15A1.3	-5.67	2.47e-08	4.24e-06	-0.22	-0.25	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43792430	chr19:43891804~43901805:-
THCA	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-5.67	2.48e-08	4.24e-06	-0.29	-0.25	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
THCA	cis	rs1499614	0.901	rs3936	ENSG00000232546.1	RP11-458F8.1	-5.67	2.48e-08	4.24e-06	-0.34	-0.25	Gout;	chr7:66661502	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs1638731	ENSG00000232546.1	RP11-458F8.1	-5.67	2.48e-08	4.24e-06	-0.34	-0.25	Gout;	chr7:66679692	chr7:66848496~66858136:+
THCA	cis	rs1499614	1	rs1882655	ENSG00000232546.1	RP11-458F8.1	5.67	2.48e-08	4.24e-06	0.34	0.25	Gout;	chr7:66682070	chr7:66848496~66858136:+
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000232546.1	RP11-458F8.1	5.67	2.48e-08	4.24e-06	0.34	0.25	Gout;	chr7:66682162	chr7:66848496~66858136:+
THCA	cis	rs7824557	0.602	rs10096194	ENSG00000154316.13	TDH	-5.67	2.48e-08	4.24e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11350163	chr8:11339637~11368452:+
THCA	cis	rs10808739	0.614	rs13258738	ENSG00000254006.4	RP11-1D12.2	-5.67	2.48e-08	4.25e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64792101	chr8:64801236~64817573:-
THCA	cis	rs9813712	0.818	rs16845853	ENSG00000228252.7	COL6A4P2	5.67	2.48e-08	4.25e-06	0.29	0.25	Response to amphetamines;	chr3:130229587	chr3:130212823~130273806:+
THCA	cis	rs2562456	0.793	rs2650819	ENSG00000268081.1	RP11-678G14.2	-5.67	2.48e-08	4.25e-06	-0.37	-0.25	Pain;	chr19:21456071	chr19:21554640~21569237:-
THCA	cis	rs1861628	1	rs2712172	ENSG00000237930.1	AC007563.4	-5.67	2.48e-08	4.25e-06	-0.3	-0.25	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216756010	chr2:216785774~216786144:-
THCA	cis	rs950169	0.541	rs10795	ENSG00000275120.1	RP11-182J1.17	5.67	2.48e-08	4.25e-06	0.3	0.25	Schizophrenia;	chr15:84634066	chr15:84599434~84606463:-
THCA	cis	rs950169	0.58	rs36126054	ENSG00000275120.1	RP11-182J1.17	5.67	2.48e-08	4.25e-06	0.3	0.25	Schizophrenia;	chr15:84634492	chr15:84599434~84606463:-
THCA	cis	rs4948275	0.773	rs2650703	ENSG00000237233.2	TMEM26-AS1	-5.67	2.48e-08	4.25e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61476953	chr10:61452639~61481956:+
THCA	cis	rs11148252	0.668	rs6561658	ENSG00000235660.1	LINC00345	-5.67	2.48e-08	4.25e-06	-0.33	-0.25	Lewy body disease;	chr13:52160016	chr13:52484161~52484680:-
THCA	cis	rs12999373	1	rs12999373	ENSG00000272342.1	RP13-539J13.1	5.67	2.48e-08	4.25e-06	0.36	0.25	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:663483	chr2:739588~740164:-
THCA	cis	rs79349575	0.756	rs3848460	ENSG00000270781.1	RP11-501C14.9	5.67	2.48e-08	4.25e-06	0.3	0.25	Type 2 diabetes;	chr17:48969752	chr17:48899131~48899748:+
THCA	cis	rs11266744	1	rs11266744	ENSG00000223552.1	RP11-24F11.2	5.67	2.48e-08	4.25e-06	0.23	0.25	Monocyte percentage of white cells;	chr3:46408487	chr3:46364955~46407059:-
THCA	cis	rs2742234	0.91	rs2505505	ENSG00000273008.1	RP11-351D16.3	-5.67	2.48e-08	4.25e-06	-0.22	-0.25	Hirschsprung disease;	chr10:43152773	chr10:43136824~43138334:-
THCA	cis	rs964184	0.63	rs9326246	ENSG00000254851.1	RP11-109L13.1	-5.67	2.48e-08	4.25e-06	-0.51	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116741017	chr11:117135528~117138582:+
THCA	cis	rs4819052	0.765	rs2838868	ENSG00000273796.1	LL21NC02-21A1.1	5.67	2.48e-08	4.25e-06	0.28	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45403809~45404369:-
THCA	cis	rs2439831	0.85	rs8023458	ENSG00000166763.7	STRCP1	5.67	2.48e-08	4.25e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43788741	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs16963953	ENSG00000166763.7	STRCP1	5.67	2.48e-08	4.25e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43789521	chr15:43699488~43718184:-
THCA	cis	rs3785574	0.962	rs8066463	ENSG00000240280.5	TCAM1P	-5.67	2.48e-08	4.25e-06	-0.35	-0.25	Height;	chr17:63741030	chr17:63849292~63864379:+
THCA	cis	rs2243480	1	rs35542501	ENSG00000228409.4	CCT6P1	5.67	2.48e-08	4.26e-06	0.29	0.25	Diabetic kidney disease;	chr7:65966228	chr7:65751142~65763354:+
THCA	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	5.67	2.48e-08	4.26e-06	0.33	0.25	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
THCA	cis	rs516805	0.528	rs2684245	ENSG00000279453.1	RP3-425C14.4	-5.67	2.48e-08	4.26e-06	-0.29	-0.25	Lymphocyte counts;	chr6:122092990	chr6:122436789~122439223:-
THCA	cis	rs6430585	0.583	rs1435577	ENSG00000231890.6	DARS-AS1	-5.67	2.49e-08	4.26e-06	-0.31	-0.25	Corneal structure;	chr2:135867377	chr2:135985176~136022593:+
THCA	cis	rs2243480	0.706	rs6460257	ENSG00000229886.1	RP5-1132H15.3	5.67	2.49e-08	4.26e-06	0.37	0.25	Diabetic kidney disease;	chr7:65731813	chr7:66025126~66031544:-
THCA	cis	rs6585424	1	rs35483545	ENSG00000242600.5	MBL1P	5.67	2.49e-08	4.26e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179417	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs34386571	ENSG00000242600.5	MBL1P	5.67	2.49e-08	4.26e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179676	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs12779955	ENSG00000242600.5	MBL1P	-5.67	2.49e-08	4.26e-06	-0.3	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80181108	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs34162901	ENSG00000242600.5	MBL1P	5.67	2.49e-08	4.26e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187100	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs61860045	ENSG00000242600.5	MBL1P	5.67	2.49e-08	4.26e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187641	chr10:79904898~79950336:+
THCA	cis	rs875971	1	rs2220626	ENSG00000223473.2	GS1-124K5.3	-5.67	2.49e-08	4.27e-06	-0.17	-0.25	Aortic root size;	chr7:66081075	chr7:66491049~66493566:-
THCA	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	5.67	2.49e-08	4.27e-06	0.2	0.25	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
THCA	cis	rs2439831	0.867	rs2255051	ENSG00000166763.7	STRCP1	5.67	2.49e-08	4.27e-06	0.35	0.25	Lung cancer in ever smokers;	chr15:43553963	chr15:43699488~43718184:-
THCA	cis	rs7824557	0.602	rs7839053	ENSG00000154316.13	TDH	-5.67	2.49e-08	4.27e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11349922	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.602	rs10110557	ENSG00000154316.13	TDH	-5.67	2.49e-08	4.27e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11349999	chr8:11339637~11368452:+
THCA	cis	rs4321325	0.536	rs10198483	ENSG00000236682.1	AC068282.3	-5.67	2.5e-08	4.27e-06	-0.42	-0.25	Protein C levels;	chr2:127176526	chr2:127389130~127400580:+
THCA	cis	rs7225151	0.614	rs80172399	ENSG00000234327.6	AC012146.7	-5.67	2.5e-08	4.28e-06	-0.29	-0.25	Alzheimer's disease (late onset);	chr17:5290954	chr17:5111468~5115004:+
THCA	cis	rs4763879	0.502	rs11052552	ENSG00000256594.6	RP11-705C15.2	5.67	2.5e-08	4.28e-06	0.19	0.25	Type 1 diabetes;	chr12:9703362	chr12:9633419~9658412:+
THCA	cis	rs867529	0.813	rs4972221	ENSG00000234028.3	AC062029.1	-5.67	2.5e-08	4.28e-06	-0.2	-0.25	Height;	chr2:88571114	chr2:88627539~88631821:+
THCA	cis	rs7428	1	rs72840063	ENSG00000273196.1	RP11-717A5.2	5.67	2.5e-08	4.29e-06	0.25	0.25	Ear protrusion;	chr2:85323273	chr2:85387074~85387146:-
THCA	cis	rs10895275	0.847	rs4447144	ENSG00000277459.1	RP11-732A21.3	5.67	2.51e-08	4.29e-06	0.2	0.25	Migraine;	chr11:102179590	chr11:102109827~102110457:-
THCA	cis	rs78487399	0.71	rs114510001	ENSG00000234936.1	AC010883.5	5.67	2.51e-08	4.29e-06	0.39	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43289949	chr2:43229573~43233394:+
THCA	cis	rs8007846	0.505	rs61298903	ENSG00000276116.2	FUT8-AS1	-5.67	2.51e-08	4.29e-06	-0.3	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65751877	chr14:65411170~65412690:-
THCA	cis	rs442309	0.812	rs224090	ENSG00000238280.1	RP11-436D10.3	5.67	2.51e-08	4.29e-06	0.3	0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62781559	chr10:62793562~62805887:-
THCA	cis	rs801193	0.935	rs11772264	ENSG00000273142.1	RP11-458F8.4	-5.67	2.51e-08	4.29e-06	-0.2	-0.25	Aortic root size;	chr7:66711400	chr7:66902857~66906297:+
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000280069.1	CTD-2349P21.3	-5.67	2.51e-08	4.29e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30738182~30740275:+
THCA	cis	rs17508449	0.865	rs75419513	ENSG00000232450.1	RP4-730K3.3	-5.67	2.51e-08	4.3e-06	-0.4	-0.25	Leprosy;	chr1:113590174	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.865	rs4839330	ENSG00000232450.1	RP4-730K3.3	-5.67	2.51e-08	4.3e-06	-0.4	-0.25	Leprosy;	chr1:113594960	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.865	rs75296543	ENSG00000232450.1	RP4-730K3.3	-5.67	2.51e-08	4.3e-06	-0.4	-0.25	Leprosy;	chr1:113595664	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.865	rs76112502	ENSG00000232450.1	RP4-730K3.3	-5.67	2.51e-08	4.3e-06	-0.4	-0.25	Leprosy;	chr1:113607074	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.865	rs80348557	ENSG00000232450.1	RP4-730K3.3	-5.67	2.51e-08	4.3e-06	-0.4	-0.25	Leprosy;	chr1:113608494	chr1:113698884~113699631:-
THCA	cis	rs7726354	1	rs2408651	ENSG00000271828.1	CTD-2310F14.1	5.67	2.51e-08	4.3e-06	0.64	0.25	Breast cancer (early onset);	chr5:56973164	chr5:56927874~56929573:+
THCA	cis	rs11148252	0.634	rs4941727	ENSG00000278238.1	RP11-245D16.4	5.67	2.51e-08	4.3e-06	0.29	0.25	Lewy body disease;	chr13:52146932	chr13:52454775~52455331:-
THCA	cis	rs9876781	0.967	rs7618883	ENSG00000229759.1	MRPS18AP1	5.67	2.51e-08	4.3e-06	0.3	0.25	Longevity;	chr3:48457056	chr3:48256350~48256938:-
THCA	cis	rs7615952	1	rs9289275	ENSG00000241288.6	RP11-379B18.5	-5.67	2.51e-08	4.3e-06	-0.32	-0.25	Blood pressure (smoking interaction);	chr3:125929816	chr3:125827238~125916384:-
THCA	cis	rs6142102	0.961	rs2284386	ENSG00000275784.1	RP5-1125A11.6	-5.67	2.51e-08	4.3e-06	-0.26	-0.25	Skin pigmentation;	chr20:34056590	chr20:33989480~33991818:-
THCA	cis	rs6545883	0.965	rs1562308	ENSG00000270820.4	RP11-355B11.2	5.67	2.51e-08	4.3e-06	0.21	0.25	Tuberculosis;	chr2:61541286	chr2:61471188~61484130:+
THCA	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-5.67	2.51e-08	4.3e-06	-0.23	-0.25	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
THCA	cis	rs1577330	0.516	rs3861015	ENSG00000254396.1	RP11-56F10.3	-5.67	2.51e-08	4.31e-06	-0.43	-0.25	IgG glycosylation;	chr9:27103416	chr9:27102630~27104728:+
THCA	cis	rs10875746	0.551	rs3751273	ENSG00000258234.1	RP11-370I10.2	5.67	2.51e-08	4.31e-06	0.3	0.25	Longevity (90 years and older);	chr12:48345655	chr12:48231098~48284210:-
THCA	cis	rs258324	0.72	rs154663	ENSG00000260259.1	RP11-368I7.4	5.67	2.52e-08	4.31e-06	0.36	0.25	Height;	chr16:89659627	chr16:89682620~89686569:-
THCA	cis	rs3742264	1	rs9316179	ENSG00000235903.6	CPB2-AS1	5.67	2.52e-08	4.31e-06	0.34	0.25	Blood protein levels;	chr13:46067331	chr13:46052806~46113332:+
THCA	cis	rs2136613	0.533	rs10761673	ENSG00000238280.1	RP11-436D10.3	-5.67	2.52e-08	4.32e-06	-0.29	-0.25	Selective IgA deficiency;	chr10:62855691	chr10:62793562~62805887:-
THCA	cis	rs79040073	0.6	rs57785991	ENSG00000259531.2	RP11-295H24.3	5.67	2.52e-08	4.32e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49188443	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs11635814	ENSG00000259531.2	RP11-295H24.3	5.67	2.52e-08	4.32e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49195028	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73392236	ENSG00000259531.2	RP11-295H24.3	5.67	2.52e-08	4.32e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49216829	chr15:49365124~49366685:-
THCA	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	5.67	2.52e-08	4.32e-06	0.43	0.25	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
THCA	cis	rs227932	0.764	rs6945626	ENSG00000234286.1	AC006026.13	5.67	2.52e-08	4.32e-06	0.47	0.25	Schizophrenia;	chr7:23629233	chr7:23680195~23680786:-
THCA	cis	rs7412746	0.658	rs11204750	ENSG00000231073.1	RP11-316M1.3	5.67	2.52e-08	4.32e-06	0.31	0.25	Melanoma;	chr1:150967268	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs6656535	ENSG00000231073.1	RP11-316M1.3	5.67	2.52e-08	4.32e-06	0.31	0.25	Melanoma;	chr1:150967881	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs1027699	ENSG00000231073.1	RP11-316M1.3	5.67	2.52e-08	4.32e-06	0.31	0.25	Melanoma;	chr1:150839236	chr1:150973123~150975534:+
THCA	cis	rs9368481	0.569	rs6907403	ENSG00000241549.7	GUSBP2	5.67	2.52e-08	4.32e-06	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26871484~26956554:-
THCA	cis	rs9368481	0.502	rs3933232	ENSG00000241549.7	GUSBP2	5.67	2.52e-08	4.32e-06	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26871484~26956554:-
THCA	cis	rs2018683	0.707	rs917218	ENSG00000228421.2	AC005013.5	5.67	2.53e-08	4.33e-06	0.29	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935505	chr7:28957667~28959345:+
THCA	cis	rs6545883	0.718	rs2694624	ENSG00000271889.1	RP11-493E12.1	5.67	2.53e-08	4.33e-06	0.25	0.25	Tuberculosis;	chr2:61445178	chr2:61151433~61162105:-
THCA	cis	rs375066	0.623	rs1549953	ENSG00000267058.1	RP11-15A1.3	5.67	2.53e-08	4.33e-06	0.22	0.25	Breast cancer;	chr19:43844616	chr19:43891804~43901805:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000223473.2	GS1-124K5.3	-5.67	2.53e-08	4.33e-06	-0.17	-0.25	Aortic root size;	chr7:66093491	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs1182882	ENSG00000223473.2	GS1-124K5.3	-5.67	2.53e-08	4.33e-06	-0.17	-0.25	Aortic root size;	chr7:66097076	chr7:66491049~66493566:-
THCA	cis	rs7412746	0.611	rs2864873	ENSG00000231073.1	RP11-316M1.3	5.67	2.53e-08	4.33e-06	0.3	0.25	Melanoma;	chr1:150841698	chr1:150973123~150975534:+
THCA	cis	rs451417	0.818	rs236113	ENSG00000275632.1	RP5-967N21.11	5.67	2.53e-08	4.33e-06	0.31	0.25	Menopause (age at onset);	chr20:5953920	chr20:6000418~6000941:+
THCA	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	5.67	2.53e-08	4.33e-06	0.34	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	5.67	2.53e-08	4.33e-06	0.34	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	5.67	2.53e-08	4.33e-06	0.34	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
THCA	cis	rs7085104	0.7	rs3740397	ENSG00000236937.2	PTGES3P4	5.67	2.53e-08	4.34e-06	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102845595~102845950:+
THCA	cis	rs17772222	1	rs17124700	ENSG00000222990.1	RNU4-22P	5.67	2.54e-08	4.34e-06	0.34	0.25	Coronary artery calcification;	chr14:88439285	chr14:88513498~88513663:+
THCA	cis	rs4227	0.565	rs8066665	ENSG00000233223.2	AC113189.5	5.67	2.54e-08	4.34e-06	0.2	0.25	IgA nephropathy;	chr17:7582534	chr17:7581964~7584072:-
THCA	cis	rs7746199	0.736	rs6904596	ENSG00000280107.1	AL022393.9	-5.67	2.54e-08	4.34e-06	-0.43	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28170845~28172521:+
THCA	cis	rs17214007	0.597	rs11649126	ENSG00000263335.1	AF001548.5	-5.67	2.54e-08	4.34e-06	-0.36	-0.25	Cognitive function;	chr16:15626390	chr16:15726674~15732993:+
THCA	cis	rs1499614	1	rs2707840	ENSG00000230295.1	RP11-458F8.2	-5.67	2.54e-08	4.34e-06	-0.32	-0.25	Gout;	chr7:66693028	chr7:66880708~66882981:+
THCA	cis	rs7412746	0.658	rs8444	ENSG00000231073.1	RP11-316M1.3	5.67	2.54e-08	4.34e-06	0.3	0.25	Melanoma;	chr1:150966095	chr1:150973123~150975534:+
THCA	cis	rs2439831	0.681	rs1095386	ENSG00000249839.1	AC011330.5	-5.67	2.54e-08	4.34e-06	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43317311	chr15:43663654~43684339:-
THCA	cis	rs2303319	0.504	rs55853623	ENSG00000227403.1	AC009299.3	5.67	2.54e-08	4.34e-06	0.57	0.25	Cognitive function;	chr2:161429803	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72877963	ENSG00000227403.1	AC009299.3	5.67	2.54e-08	4.34e-06	0.57	0.25	Cognitive function;	chr2:161431807	chr2:161244739~161249050:+
THCA	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	5.67	2.54e-08	4.35e-06	0.14	0.25	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
THCA	cis	rs2303319	0.504	rs62189012	ENSG00000227403.1	AC009299.3	5.67	2.54e-08	4.35e-06	0.53	0.25	Cognitive function;	chr2:161726631	chr2:161244739~161249050:+
THCA	cis	rs997295	0.57	rs7172298	ENSG00000270964.1	RP11-502I4.3	-5.67	2.54e-08	4.35e-06	-0.21	-0.25	Motion sickness;	chr15:67580645	chr15:67541072~67542604:-
THCA	cis	rs4908768	0.539	rs1934138	ENSG00000232912.4	RP5-1115A15.1	5.67	2.54e-08	4.35e-06	0.25	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8424645~8434838:+
THCA	cis	rs17508449	1	rs17508449	ENSG00000232450.1	RP4-730K3.3	-5.67	2.54e-08	4.35e-06	-0.4	-0.25	Leprosy;	chr1:113542523	chr1:113698884~113699631:-
THCA	cis	rs10208649	0.908	rs10181332	ENSG00000233266.1	HMGB1P31	5.67	2.54e-08	4.35e-06	0.61	0.25	Body mass index;	chr2:54118288	chr2:54051334~54051760:+
THCA	cis	rs2337406	1	rs17113331	ENSG00000211974.3	IGHV2-70	-5.67	2.54e-08	4.35e-06	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106703843	chr14:106723574~106724093:-
THCA	cis	rs10829156	0.732	rs10828834	ENSG00000240291.1	RP11-499P20.2	5.67	2.54e-08	4.35e-06	0.22	0.25	Sudden cardiac arrest;	chr10:18523505	chr10:18513115~18545651:-
THCA	cis	rs2559856	1	rs2695284	ENSG00000274560.1	RP11-285E23.2	-5.67	2.54e-08	4.35e-06	-0.15	-0.25	Blood protein levels;	chr12:101695540	chr12:101696002~101696450:-
THCA	cis	rs2070488	0.745	rs7649153	ENSG00000229589.1	ACVR2B-AS1	5.67	2.54e-08	4.35e-06	0.24	0.25	Electrocardiographic conduction measures;	chr3:38426262	chr3:38451027~38454820:-
THCA	cis	rs2276314	0.512	rs7234973	ENSG00000278986.1	RP11-723J4.3	-5.67	2.54e-08	4.35e-06	-0.27	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35870373	chr18:35972151~35973916:+
THCA	cis	rs67478160	0.643	rs8004408	ENSG00000258735.1	LINC00637	-5.67	2.54e-08	4.35e-06	-0.3	-0.25	Schizophrenia;	chr14:103737601	chr14:103847721~103858049:+
THCA	cis	rs997295	0.57	rs28730805	ENSG00000270964.1	RP11-502I4.3	-5.67	2.55e-08	4.36e-06	-0.21	-0.25	Motion sickness;	chr15:67587080	chr15:67541072~67542604:-
THCA	cis	rs12612619	0.724	rs7355650	ENSG00000229122.1	AGBL5-IT1	-5.67	2.55e-08	4.36e-06	-0.19	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27022607	chr2:27061038~27061815:+
THCA	cis	rs6585424	0.929	rs12256429	ENSG00000225484.5	NUTM2B-AS1	-5.67	2.55e-08	4.36e-06	-0.41	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178876	chr10:79663088~79826594:-
THCA	cis	rs62432291	0.681	rs420137	ENSG00000235086.1	FNDC1-IT1	-5.67	2.55e-08	4.37e-06	-0.46	-0.25	Joint mobility (Beighton score);	chr6:159231899	chr6:159240786~159243329:+
THCA	cis	rs7225151	0.71	rs75754694	ENSG00000234327.6	AC012146.7	-5.67	2.55e-08	4.37e-06	-0.28	-0.25	Alzheimer's disease (late onset);	chr17:5356470	chr17:5111468~5115004:+
THCA	cis	rs9368481	0.594	rs7768643	ENSG00000241549.7	GUSBP2	5.67	2.55e-08	4.37e-06	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26871484~26956554:-
THCA	cis	rs9368481	0.594	rs7768814	ENSG00000241549.7	GUSBP2	5.67	2.55e-08	4.37e-06	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26871484~26956554:-
THCA	cis	rs9467773	1	rs9467791	ENSG00000124549.13	BTN2A3P	-5.67	2.56e-08	4.37e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26421391~26432383:+
THCA	cis	rs10761482	0.5	rs2211220	ENSG00000254271.1	RP11-131N11.4	5.67	2.56e-08	4.37e-06	0.34	0.25	Schizophrenia;	chr10:60511733	chr10:60734342~60741828:+
THCA	cis	rs16976116	0.901	rs113679855	ENSG00000279145.1	RP11-547D13.1	5.67	2.56e-08	4.38e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55210230	chr15:55171972~55178175:-
THCA	cis	rs7412746	0.611	rs111905669	ENSG00000231073.1	RP11-316M1.3	5.67	2.56e-08	4.38e-06	0.3	0.25	Melanoma;	chr1:150805089	chr1:150973123~150975534:+
THCA	cis	rs1275468	0.731	rs1480002	ENSG00000257497.2	RP11-585P4.5	-5.67	2.56e-08	4.38e-06	-0.38	-0.25	Polycystic ovary syndrome;	chr12:75587184	chr12:75483454~75489820:-
THCA	cis	rs853679	0.607	rs33932084	ENSG00000226314.6	ZNF192P1	-5.67	2.56e-08	4.38e-06	-0.53	-0.25	Depression;	chr6:28301047	chr6:28161781~28169594:+
THCA	cis	rs2835345	0.563	rs74439245	ENSG00000230479.1	AP000695.6	5.67	2.56e-08	4.38e-06	0.3	0.25	Pulmonary function;	chr21:36452322	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs76422022	ENSG00000230479.1	AP000695.6	5.67	2.56e-08	4.38e-06	0.3	0.25	Pulmonary function;	chr21:36452328	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs73204246	ENSG00000230479.1	AP000695.6	5.67	2.56e-08	4.38e-06	0.3	0.25	Pulmonary function;	chr21:36452402	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs73204248	ENSG00000230479.1	AP000695.6	5.67	2.56e-08	4.38e-06	0.3	0.25	Pulmonary function;	chr21:36452411	chr21:36430360~36481070:+
THCA	cis	rs138171347	1	rs138171347	ENSG00000234327.6	AC012146.7	-5.67	2.56e-08	4.38e-06	-0.21	-0.25	White blood cell count;	chr17:5279912	chr17:5111468~5115004:+
THCA	cis	rs6840360	0.642	rs2709825	ENSG00000270265.1	RP11-731D1.4	-5.67	2.56e-08	4.39e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.607	rs2724547	ENSG00000270265.1	RP11-731D1.4	-5.67	2.56e-08	4.39e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151333775~151353224:-
THCA	cis	rs1876905	0.539	rs241003	ENSG00000255389.1	C6orf3	-5.67	2.56e-08	4.39e-06	-0.32	-0.25	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111599875~111602295:+
THCA	cis	rs1876905	0.539	rs190246	ENSG00000255389.1	C6orf3	-5.67	2.56e-08	4.39e-06	-0.32	-0.25	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111599875~111602295:+
THCA	cis	rs757978	1	rs80085676	ENSG00000223374.1	AC005104.3	5.67	2.57e-08	4.39e-06	0.28	0.25	Chronic lymphocytic leukemia;	chr2:241408492	chr2:241351340~241353104:-
THCA	cis	rs10888838	0.941	rs10888841	ENSG00000198711.5	SSBP3-AS1	5.66	2.57e-08	4.39e-06	0.28	0.25	Mitochondrial DNA levels;	chr1:54221392	chr1:54236440~54239063:+
THCA	cis	rs4713118	0.513	rs1225591	ENSG00000220721.1	OR1F12	5.66	2.57e-08	4.39e-06	0.31	0.25	Parkinson's disease;	chr6:28180974	chr6:28073316~28074233:+
THCA	cis	rs6565180	0.926	rs8046445	ENSG00000273724.1	RP11-347C12.12	-5.66	2.57e-08	4.39e-06	-0.26	-0.25	Tonsillectomy;	chr16:30374941	chr16:30336400~30343336:+
THCA	cis	rs6445975	0.612	rs6763103	ENSG00000272360.1	RP11-359I18.5	5.66	2.57e-08	4.39e-06	0.29	0.25	Systemic lupus erythematosus;	chr3:58451618	chr3:58490830~58491291:-
THCA	cis	rs7202877	0.656	rs6564245	ENSG00000261783.1	RP11-252K23.2	5.66	2.57e-08	4.4e-06	0.44	0.25	Type 1 diabetes;Type 2 diabetes;	chr16:75275001	chr16:75379818~75381260:-
THCA	cis	rs712039	0.652	rs2680719	ENSG00000276054.1	RP11-378E13.3	5.66	2.57e-08	4.4e-06	0.39	0.25	Tuberculosis;	chr17:37451351	chr17:37386886~37387926:+
THCA	cis	rs12893668	0.572	rs4906356	ENSG00000269940.1	RP11-73M18.7	5.66	2.58e-08	4.4e-06	0.26	0.25	Reticulocyte count;	chr14:103672364	chr14:103694560~103695170:+
THCA	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-5.66	2.58e-08	4.41e-06	-0.22	-0.25	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
THCA	cis	rs6142102	0.923	rs6059635	ENSG00000275784.1	RP5-1125A11.6	-5.66	2.58e-08	4.41e-06	-0.26	-0.25	Skin pigmentation;	chr20:34025687	chr20:33989480~33991818:-
THCA	cis	rs728616	0.867	rs41302709	ENSG00000242600.5	MBL1P	5.66	2.58e-08	4.41e-06	0.34	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047522	chr10:79904898~79950336:+
THCA	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-5.66	2.58e-08	4.41e-06	-0.15	-0.25	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-5.66	2.58e-08	4.41e-06	-0.15	-0.25	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
THCA	cis	rs61677309	1	rs4938499	ENSG00000280032.1	RP11-832A4.7	5.66	2.58e-08	4.41e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118291781	chr11:118264593~118266817:+
THCA	cis	rs17214007	0.877	rs10852376	ENSG00000263335.1	AF001548.5	5.66	2.58e-08	4.41e-06	0.34	0.25	Cognitive function;	chr16:15778216	chr16:15726674~15732993:+
THCA	cis	rs1876905	0.764	rs9398265	ENSG00000230177.1	RP5-1112D6.4	-5.66	2.58e-08	4.41e-06	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111101399	chr6:111277932~111278742:+
THCA	cis	rs7617773	1	rs11711766	ENSG00000199476.1	Y_RNA	5.66	2.58e-08	4.42e-06	0.32	0.25	Coronary artery disease;	chr3:48151680	chr3:48288587~48288694:+
THCA	cis	rs3002142	0.658	rs2291833	ENSG00000272750.1	RP11-378J18.8	-5.66	2.58e-08	4.42e-06	-0.38	-0.25	LDL peak particle diameter (total fat intake interaction);	chr1:222653505	chr1:222658867~222661512:-
THCA	cis	rs2179367	0.6	rs9498352	ENSG00000223701.3	RAET1E-AS1	5.66	2.59e-08	4.42e-06	0.4	0.25	Dupuytren's disease;	chr6:149439108	chr6:149884431~149919508:+
THCA	cis	rs2400200	1	rs2400200	ENSG00000249363.1	CTB-78O21.1	-5.66	2.59e-08	4.42e-06	-0.36	-0.25	Rheumatic fever;	chr5:145746604	chr5:145728360~145729349:-
THCA	cis	rs9380516	1	rs3997734	ENSG00000228559.1	RP3-340B19.3	-5.66	2.59e-08	4.42e-06	-0.39	-0.25	Hepatitis C induced liver fibrosis;	chr6:35535698	chr6:35544632~35545669:+
THCA	cis	rs6968419	0.755	rs3807982	ENSG00000237870.5	AC073130.1	5.66	2.59e-08	4.43e-06	0.28	0.25	Intraocular pressure;	chr7:116258831	chr7:116275606~116286734:-
THCA	cis	rs9601248	0.756	rs928640	ENSG00000227676.3	LINC01068	-5.66	2.59e-08	4.43e-06	-0.32	-0.25	Major depressive disorder;	chr13:79603348	chr13:79566727~79571436:+
THCA	cis	rs28472312	0.855	rs12448482	ENSG00000251417.2	RP11-1348G14.4	5.66	2.59e-08	4.43e-06	0.25	0.25	Intelligence (multi-trait analysis);	chr16:28826752	chr16:28802743~28817828:+
THCA	cis	rs4950322	0.512	rs10736839	ENSG00000237188.3	RP11-337C18.8	-5.66	2.59e-08	4.43e-06	-0.27	-0.25	Protein quantitative trait loci;	chr1:147370431	chr1:147172771~147211568:+
THCA	cis	rs7523875	0.72	rs11582143	ENSG00000153363.11	LINC00467	-5.66	2.59e-08	4.43e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211343634	chr1:211382803~211435333:+
THCA	cis	rs2070488	0.662	rs6599203	ENSG00000229589.1	ACVR2B-AS1	5.66	2.59e-08	4.43e-06	0.25	0.25	Electrocardiographic conduction measures;	chr3:38446311	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.662	rs7372545	ENSG00000229589.1	ACVR2B-AS1	5.66	2.59e-08	4.43e-06	0.25	0.25	Electrocardiographic conduction measures;	chr3:38466079	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.636	rs2284817	ENSG00000229589.1	ACVR2B-AS1	5.66	2.59e-08	4.43e-06	0.25	0.25	Electrocardiographic conduction measures;	chr3:38468897	chr3:38451027~38454820:-
THCA	cis	rs595244	1	rs2455925	ENSG00000259705.1	RP11-227D13.1	5.66	2.59e-08	4.43e-06	0.44	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48601452	chr15:48645951~48652016:+
THCA	cis	rs2303319	0.504	rs62189007	ENSG00000227403.1	AC009299.3	5.66	2.59e-08	4.43e-06	0.53	0.25	Cognitive function;	chr2:161717813	chr2:161244739~161249050:+
THCA	cis	rs7412746	0.566	rs11204743	ENSG00000231073.1	RP11-316M1.3	5.66	2.59e-08	4.43e-06	0.31	0.25	Melanoma;	chr1:150917930	chr1:150973123~150975534:+
THCA	cis	rs12549025	0.677	rs62503282	ENSG00000253390.1	CTC-756D1.2	-5.66	2.6e-08	4.44e-06	-0.48	-0.25	Reticulocyte fraction of red cells;	chr8:23529679	chr8:23458601~23484971:+
THCA	cis	rs9652601	0.748	rs12930373	ENSG00000274038.1	RP11-66H6.4	-5.66	2.6e-08	4.44e-06	-0.33	-0.25	Systemic lupus erythematosus;	chr16:11145742	chr16:11056556~11057034:+
THCA	cis	rs6545883	0.931	rs778765	ENSG00000270820.4	RP11-355B11.2	5.66	2.6e-08	4.44e-06	0.21	0.25	Tuberculosis;	chr2:61559250	chr2:61471188~61484130:+
THCA	cis	rs9625935	0.843	rs41172	ENSG00000279159.1	RP3-394A18.1	-5.66	2.6e-08	4.44e-06	-0.18	-0.25	Tonsillectomy;	chr22:30026876	chr22:29978950~30028236:-
THCA	cis	rs62246343	0.786	rs11547584	ENSG00000254485.4	RP11-380O24.1	5.66	2.6e-08	4.44e-06	0.33	0.25	Fibrinogen levels;	chr3:9365020	chr3:9292588~9363303:-
THCA	cis	rs763121	0.853	rs1062687	ENSG00000273076.1	RP3-508I15.22	5.66	2.6e-08	4.44e-06	0.26	0.25	Menopause (age at onset);	chr22:38738710	chr22:38743495~38743910:+
THCA	cis	rs61677309	1	rs894677	ENSG00000280032.1	RP11-832A4.7	5.66	2.6e-08	4.44e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118301820	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.964	rs59138930	ENSG00000280032.1	RP11-832A4.7	5.66	2.6e-08	4.44e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118303068	chr11:118264593~118266817:+
THCA	cis	rs690037	0.809	rs690023	ENSG00000272498.1	RP11-415F23.3	5.66	2.6e-08	4.44e-06	0.27	0.25	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16344847	chr3:16339308~16339871:+
THCA	cis	rs4908768	0.501	rs11121194	ENSG00000232912.4	RP5-1115A15.1	5.66	2.6e-08	4.45e-06	0.25	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8424645~8434838:+
THCA	cis	rs2692947	0.86	rs2579520	ENSG00000232931.4	LINC00342	-5.66	2.61e-08	4.45e-06	-0.2	-0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95994552	chr2:95807118~95816215:-
THCA	cis	rs1707322	0.638	rs1416706	ENSG00000234329.1	RP11-767N6.2	-5.66	2.61e-08	4.45e-06	-0.24	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45651039~45651826:-
THCA	cis	rs793571	0.505	rs28722857	ENSG00000259250.1	RP11-50C13.1	-5.66	2.61e-08	4.45e-06	-0.27	-0.25	Schizophrenia;	chr15:58633876	chr15:58587507~58591676:+
THCA	cis	rs9921338	0.961	rs7206749	ENSG00000262636.1	CTD-3088G3.4	-5.66	2.61e-08	4.46e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11283065	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs55707838	ENSG00000262636.1	CTD-3088G3.4	-5.66	2.61e-08	4.46e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11284218	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs56010295	ENSG00000262636.1	CTD-3088G3.4	-5.66	2.61e-08	4.46e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11285050	chr16:11380859~11381118:-
THCA	cis	rs12030196	0.788	rs11207352	ENSG00000230812.4	LINC01358	5.66	2.61e-08	4.46e-06	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58957939	chr1:59020387~59044614:+
THCA	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	5.66	2.61e-08	4.46e-06	0.33	0.25	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
THCA	cis	rs7512898	0.966	rs6427846	ENSG00000260088.1	RP11-92G12.3	-5.66	2.61e-08	4.46e-06	-0.32	-0.25	Electrocardiographic conduction measures;	chr1:200699170	chr1:200669507~200694250:+
THCA	cis	rs7560272	0.669	rs13008860	ENSG00000163016.8	ALMS1P	5.66	2.61e-08	4.46e-06	0.32	0.25	Schizophrenia;	chr2:73546892	chr2:73644919~73685576:+
THCA	cis	rs7617480	0.648	rs9848268	ENSG00000228638.1	FCF1P2	-5.66	2.61e-08	4.46e-06	-0.33	-0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48724838	chr3:48290793~48291375:-
THCA	cis	rs62432291	0.681	rs445957	ENSG00000235086.1	FNDC1-IT1	-5.66	2.61e-08	4.46e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159241032	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs431205	ENSG00000235086.1	FNDC1-IT1	-5.66	2.61e-08	4.46e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159241467	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs435521	ENSG00000235086.1	FNDC1-IT1	5.66	2.61e-08	4.46e-06	0.45	0.25	Joint mobility (Beighton score);	chr6:159241606	chr6:159240786~159243329:+
THCA	cis	rs2732480	0.5	rs2450989	ENSG00000240399.1	RP1-228P16.1	-5.66	2.61e-08	4.46e-06	-0.26	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48054813~48055591:-
THCA	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-5.66	2.61e-08	4.46e-06	-0.24	-0.25	Height;	chr2:46641180	chr2:46668870~46670778:+
THCA	cis	rs7267979	0.565	rs958075	ENSG00000125804.12	FAM182A	5.66	2.61e-08	4.46e-06	0.33	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26054655~26086917:+
THCA	cis	rs4819052	0.62	rs421619	ENSG00000237664.1	LINC00316	-5.66	2.61e-08	4.46e-06	-0.29	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45126200	chr21:45338590~45341990:-
THCA	cis	rs4948275	0.773	rs2787736	ENSG00000237233.2	TMEM26-AS1	-5.66	2.62e-08	4.46e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61490694	chr10:61452639~61481956:+
THCA	cis	rs465969	1	rs465969	ENSG00000230177.1	RP5-1112D6.4	5.66	2.62e-08	4.47e-06	0.33	0.25	Psoriasis;	chr6:111334327	chr6:111277932~111278742:+
THCA	cis	rs9880211	0.8	rs9873536	ENSG00000273486.1	RP11-731C17.2	5.66	2.62e-08	4.47e-06	0.27	0.25	Height;Body mass index;	chr3:136755425	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs9813376	ENSG00000273486.1	RP11-731C17.2	5.66	2.62e-08	4.47e-06	0.27	0.25	Height;Body mass index;	chr3:136756584	chr3:136837338~136839021:-
THCA	cis	rs7824557	0.628	rs34237267	ENSG00000154316.13	TDH	-5.66	2.62e-08	4.47e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11339792	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.628	rs7008205	ENSG00000154316.13	TDH	-5.66	2.62e-08	4.47e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11339814	chr8:11339637~11368452:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	5.66	2.62e-08	4.47e-06	0.3	0.25	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
THCA	cis	rs2117029	0.782	rs7969091	ENSG00000258017.1	RP11-386G11.10	-5.66	2.62e-08	4.47e-06	-0.33	-0.25	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49127782~49147869:+
THCA	cis	rs10459221	1	rs10459221	ENSG00000258017.1	RP11-386G11.10	-5.66	2.62e-08	4.47e-06	-0.33	-0.25	Bipolar disorder;	chr12:49073211	chr12:49127782~49147869:+
THCA	cis	rs10875746	0.669	rs10875770	ENSG00000258234.1	RP11-370I10.2	5.66	2.62e-08	4.47e-06	0.29	0.25	Longevity (90 years and older);	chr12:48206737	chr12:48231098~48284210:-
THCA	cis	rs793571	0.554	rs28470809	ENSG00000259250.1	RP11-50C13.1	-5.66	2.62e-08	4.47e-06	-0.28	-0.25	Schizophrenia;	chr15:58744059	chr15:58587507~58591676:+
THCA	cis	rs9475752	1	rs9475752	ENSG00000231441.1	RP11-472M19.2	5.66	2.62e-08	4.47e-06	0.3	0.25	Menarche (age at onset);	chr6:56915943	chr6:56844002~56864078:+
THCA	cis	rs710216	0.763	rs12029931	ENSG00000227533.4	SLC2A1-AS1	5.66	2.62e-08	4.47e-06	0.36	0.25	Red cell distribution width;	chr1:42991209	chr1:42959049~42983358:+
THCA	cis	rs4908760	0.899	rs6577496	ENSG00000232912.4	RP5-1115A15.1	5.66	2.62e-08	4.48e-06	0.25	0.25	Vitiligo;	chr1:8521168	chr1:8424645~8434838:+
THCA	cis	rs6714710	0.603	rs7421146	ENSG00000230606.9	AC159540.1	-5.66	2.62e-08	4.48e-06	-0.3	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935808	chr2:97416165~97433527:-
THCA	cis	rs7412746	0.658	rs3768015	ENSG00000231073.1	RP11-316M1.3	5.66	2.63e-08	4.48e-06	0.31	0.25	Melanoma;	chr1:150840478	chr1:150973123~150975534:+
THCA	cis	rs7529073	0.815	rs1431983	ENSG00000274895.1	RP11-478J18.2	5.66	2.63e-08	4.48e-06	0.21	0.25	Schizophrenia;	chr1:213975429	chr1:213983793~213986419:-
THCA	cis	rs9876781	1	rs2290822	ENSG00000229759.1	MRPS18AP1	5.66	2.63e-08	4.49e-06	0.3	0.25	Longevity;	chr3:48431794	chr3:48256350~48256938:-
THCA	cis	rs61677309	1	rs3782040	ENSG00000280032.1	RP11-832A4.7	5.66	2.63e-08	4.49e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118305382	chr11:118264593~118266817:+
THCA	cis	rs6740322	0.748	rs6756625	ENSG00000234936.1	AC010883.5	-5.66	2.63e-08	4.49e-06	-0.28	-0.25	Coronary artery disease;	chr2:43262174	chr2:43229573~43233394:+
THCA	cis	rs9834975	1	rs9834975	ENSG00000272758.4	RP11-299J3.8	-5.66	2.63e-08	4.49e-06	-0.23	-0.25	Diastolic blood pressure;	chr3:122398816	chr3:122416207~122443180:+
THCA	cis	rs9467773	1	rs9986382	ENSG00000124549.13	BTN2A3P	5.66	2.63e-08	4.49e-06	0.23	0.25	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26421391~26432383:+
THCA	cis	rs4938330	0.739	rs11216266	ENSG00000254851.1	RP11-109L13.1	5.66	2.63e-08	4.49e-06	0.36	0.25	Blood protein levels;	chr11:117079434	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.748	rs7106662	ENSG00000254851.1	RP11-109L13.1	5.66	2.63e-08	4.49e-06	0.36	0.25	Subjective well-being;	chr11:117080669	chr11:117135528~117138582:+
THCA	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-5.66	2.63e-08	4.49e-06	-0.32	-0.25	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
THCA	cis	rs6840258	0.689	rs340639	ENSG00000251411.1	RP11-397E7.4	5.66	2.63e-08	4.49e-06	0.26	0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87003827	chr4:86913266~86914817:-
THCA	cis	rs2439831	0.681	rs3742969	ENSG00000249839.1	AC011330.5	-5.66	2.63e-08	4.5e-06	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43329749	chr15:43663654~43684339:-
THCA	cis	rs748404	1	rs17779494	ENSG00000205771.5	CATSPER2P1	5.66	2.63e-08	4.5e-06	0.3	0.25	Lung cancer;	chr15:43287025	chr15:43726918~43747094:-
THCA	cis	rs73198271	0.737	rs535094	ENSG00000253893.2	FAM85B	5.66	2.63e-08	4.5e-06	0.35	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776418	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.765	rs534103	ENSG00000253893.2	FAM85B	5.66	2.63e-08	4.5e-06	0.35	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776559	chr8:8167819~8226614:-
THCA	cis	rs7412746	0.611	rs4509581	ENSG00000231073.1	RP11-316M1.3	5.66	2.64e-08	4.5e-06	0.3	0.25	Melanoma;	chr1:150801989	chr1:150973123~150975534:+
THCA	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	5.66	2.64e-08	4.5e-06	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
THCA	cis	rs3794924	1	rs34350106	ENSG00000266521.1	RP11-650P15.1	5.66	2.64e-08	4.5e-06	0.49	0.25	Survival in colon cancer;	chr18:31462496	chr18:31496645~31497195:-
THCA	cis	rs6545883	0.894	rs1186703	ENSG00000271889.1	RP11-493E12.1	5.66	2.64e-08	4.5e-06	0.25	0.25	Tuberculosis;	chr2:61445830	chr2:61151433~61162105:-
THCA	cis	rs10208649	0.908	rs114837028	ENSG00000233266.1	HMGB1P31	5.66	2.64e-08	4.5e-06	0.67	0.25	Body mass index;	chr2:53983416	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.908	rs74930210	ENSG00000233266.1	HMGB1P31	5.66	2.64e-08	4.5e-06	0.67	0.25	Body mass index;	chr2:53995287	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.808	rs115322634	ENSG00000233266.1	HMGB1P31	5.66	2.64e-08	4.5e-06	0.67	0.25	Body mass index;	chr2:53997572	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.908	rs78688150	ENSG00000233266.1	HMGB1P31	5.66	2.64e-08	4.5e-06	0.67	0.25	Body mass index;	chr2:53997658	chr2:54051334~54051760:+
THCA	cis	rs2129782	1	rs10103178	ENSG00000253553.4	RP11-586K2.1	5.66	2.64e-08	4.51e-06	0.43	0.25	Electrodermal activity;	chr8:88398821	chr8:88326836~88737134:+
THCA	cis	rs758324	0.732	rs156034	ENSG00000237714.1	P4HA2-AS1	-5.66	2.64e-08	4.51e-06	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132192021	chr5:132184876~132192808:+
THCA	cis	rs9890032	1	rs9890032	ENSG00000263531.1	RP13-753N3.1	-5.66	2.65e-08	4.51e-06	-0.33	-0.25	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30863921~30864940:-
THCA	cis	rs442309	0.812	rs224123	ENSG00000238280.1	RP11-436D10.3	-5.66	2.65e-08	4.51e-06	-0.31	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62691473	chr10:62793562~62805887:-
THCA	cis	rs2041895	0.509	rs2024518	ENSG00000260329.1	RP11-412D9.4	-5.66	2.65e-08	4.51e-06	-0.25	-0.25	Glaucoma (low intraocular pressure);	chr12:106903124	chr12:106954029~106955497:-
THCA	cis	rs2337406	1	rs79452530	ENSG00000274576.2	IGHV2-70	-5.66	2.65e-08	4.52e-06	-0.23	-0.25	Alzheimer's disease (late onset);	chr14:106699992	chr14:106770577~106771020:-
THCA	cis	rs10895275	0.961	rs12790399	ENSG00000277459.1	RP11-732A21.3	-5.66	2.65e-08	4.52e-06	-0.2	-0.25	Migraine;	chr11:102229308	chr11:102109827~102110457:-
THCA	cis	rs2645424	1	rs962366	ENSG00000255046.1	RP11-297N6.4	5.66	2.65e-08	4.52e-06	0.26	0.25	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826894	chr8:11797928~11802568:-
THCA	cis	rs3785574	0.962	rs2665840	ENSG00000240280.5	TCAM1P	5.66	2.65e-08	4.52e-06	0.35	0.25	Height;	chr17:63795947	chr17:63849292~63864379:+
THCA	cis	rs7646881	0.508	rs12106885	ENSG00000240207.5	RP11-379F4.4	-5.66	2.65e-08	4.52e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158598854	chr3:158732263~158784070:+
THCA	cis	rs6479901	0.841	rs10995505	ENSG00000232075.1	MRPL35P2	5.66	2.65e-08	4.52e-06	0.36	0.25	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63634317~63634827:-
THCA	cis	rs1866631	0.631	rs4972533	ENSG00000238133.5	MLK7-AS1	-5.66	2.65e-08	4.52e-06	-0.32	-0.25	Lung cancer in ever smokers;	chr2:173206157	chr2:173166446~173282036:-
THCA	cis	rs2243480	0.803	rs160649	ENSG00000230295.1	RP11-458F8.2	-5.66	2.65e-08	4.52e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66078212	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs160648	ENSG00000230295.1	RP11-458F8.2	-5.66	2.65e-08	4.52e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66078397	chr7:66880708~66882981:+
THCA	cis	rs5751614	0.557	rs5759665	ENSG00000230701.2	FBXW4P1	5.66	2.65e-08	4.52e-06	0.3	0.25	Height;	chr22:23260033	chr22:23262767~23265005:+
THCA	cis	rs9400467	0.528	rs7752361	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.65e-08	4.52e-06	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:111297126~111298510:+
THCA	cis	rs7760535	0.811	rs7764591	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.65e-08	4.52e-06	-0.24	-0.25	Metabolic traits;	chr6:111462211	chr6:111297126~111298510:+
THCA	cis	rs8062405	0.72	rs9926245	ENSG00000278665.1	RP11-666O2.4	5.66	2.65e-08	4.52e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28599241~28601881:-
THCA	cis	rs1707322	0.821	rs10749857	ENSG00000281133.1	AL355480.3	-5.66	2.66e-08	4.53e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45580892~45580996:-
THCA	cis	rs792448	0.545	rs7519168	ENSG00000226251.4	RP11-15I11.3	5.66	2.66e-08	4.53e-06	0.32	0.25	White blood cell count (basophil);	chr1:212220043	chr1:212225278~212238977:-
THCA	cis	rs7646881	0.544	rs56973279	ENSG00000240207.5	RP11-379F4.4	-5.66	2.66e-08	4.54e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158632526	chr3:158732263~158784070:+
THCA	cis	rs338389	0.542	rs62002423	ENSG00000260657.2	RP11-315D16.4	5.66	2.66e-08	4.54e-06	0.35	0.25	Survival in rectal cancer;	chr15:67976709	chr15:68267792~68277994:-
THCA	cis	rs34779708	0.771	rs3867218	ENSG00000271335.4	RP11-324I22.4	5.66	2.66e-08	4.54e-06	0.25	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35314552~35336401:-
THCA	cis	rs11671005	0.735	rs11084544	ENSG00000269473.1	CTD-2619J13.19	5.66	2.66e-08	4.54e-06	0.29	0.25	Mean platelet volume;	chr19:58428760	chr19:58440448~58445849:+
THCA	cis	rs728616	0.614	rs35395602	ENSG00000225484.5	NUTM2B-AS1	-5.66	2.66e-08	4.54e-06	-0.44	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147014	chr10:79663088~79826594:-
THCA	cis	rs728616	0.681	rs36023925	ENSG00000225484.5	NUTM2B-AS1	-5.66	2.66e-08	4.54e-06	-0.44	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147090	chr10:79663088~79826594:-
THCA	cis	rs763567	1	rs2022372	ENSG00000271811.1	RP1-79C4.4	-5.66	2.66e-08	4.54e-06	-0.29	-0.25	Tonsillectomy;	chr1:170620769	chr1:170667381~170669425:+
THCA	cis	rs763567	0.967	rs1234274	ENSG00000271811.1	RP1-79C4.4	5.66	2.66e-08	4.54e-06	0.29	0.25	Tonsillectomy;	chr1:170627232	chr1:170667381~170669425:+
THCA	cis	rs7617773	0.817	rs6796490	ENSG00000199476.1	Y_RNA	-5.66	2.66e-08	4.54e-06	-0.32	-0.25	Coronary artery disease;	chr3:48195614	chr3:48288587~48288694:+
THCA	cis	rs375066	0.623	rs1549954	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43844653	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs1549955	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43845709	chr19:43891804~43901805:-
THCA	cis	rs375066	0.599	rs8106802	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43845944	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs6509120	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43846053	chr19:43891804~43901805:-
THCA	cis	rs375066	0.586	rs2883946	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43848536	chr19:43891804~43901805:-
THCA	cis	rs375066	0.585	rs2195981	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43848819	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs2217669	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43848928	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs2356438	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43848931	chr19:43891804~43901805:-
THCA	cis	rs375066	0.599	rs2356439	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43848979	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs7259647	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43849231	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs1549956	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43849986	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs1549957	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43850086	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs1549959	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43850334	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs7247863	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43850366	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs62114569	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43850472	chr19:43891804~43901805:-
THCA	cis	rs375066	0.599	rs10412955	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43850716	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs1036246	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43851112	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs1909	ENSG00000267058.1	RP11-15A1.3	5.66	2.66e-08	4.54e-06	0.22	0.25	Breast cancer;	chr19:43851365	chr19:43891804~43901805:-
THCA	cis	rs62246343	0.786	rs62246267	ENSG00000254485.4	RP11-380O24.1	5.66	2.67e-08	4.55e-06	0.33	0.25	Fibrinogen levels;	chr3:9361477	chr3:9292588~9363303:-
THCA	cis	rs2841277	0.72	rs11160827	ENSG00000258701.1	LINC00638	5.66	2.67e-08	4.55e-06	0.28	0.25	Rheumatoid arthritis;	chr14:104955891	chr14:104821201~104823718:+
THCA	cis	rs3742264	1	rs9534302	ENSG00000235903.6	CPB2-AS1	-5.66	2.67e-08	4.55e-06	-0.34	-0.25	Blood protein levels;	chr13:46065920	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs9534303	ENSG00000235903.6	CPB2-AS1	-5.66	2.67e-08	4.55e-06	-0.34	-0.25	Blood protein levels;	chr13:46066007	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.961	rs9534304	ENSG00000235903.6	CPB2-AS1	-5.66	2.67e-08	4.55e-06	-0.34	-0.25	Blood protein levels;	chr13:46066467	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.922	rs7336360	ENSG00000235903.6	CPB2-AS1	-5.66	2.67e-08	4.55e-06	-0.34	-0.25	Blood protein levels;	chr13:46066946	chr13:46052806~46113332:+
THCA	cis	rs3742264	1	rs9526136	ENSG00000235903.6	CPB2-AS1	-5.66	2.67e-08	4.55e-06	-0.34	-0.25	Blood protein levels;	chr13:46067012	chr13:46052806~46113332:+
THCA	cis	rs17345786	0.906	rs58835747	ENSG00000256628.3	ZBTB11-AS1	5.66	2.67e-08	4.55e-06	0.32	0.25	Colonoscopy-negative controls vs population controls;	chr3:101524790	chr3:101676475~101679217:+
THCA	cis	rs78487399	0.808	rs77787499	ENSG00000234936.1	AC010883.5	5.66	2.67e-08	4.55e-06	0.36	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536670	chr2:43229573~43233394:+
THCA	cis	rs7760535	0.831	rs62420437	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.67e-08	4.55e-06	-0.24	-0.25	Metabolic traits;	chr6:111427577	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs4276544	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.67e-08	4.55e-06	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.508	rs12211763	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.67e-08	4.55e-06	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs10872067	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.67e-08	4.55e-06	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs9689727	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.67e-08	4.55e-06	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.528	rs12214380	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.67e-08	4.55e-06	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111297126~111298510:+
THCA	cis	rs9400467	0.508	rs61269242	ENSG00000271789.1	RP5-1112D6.7	-5.66	2.67e-08	4.55e-06	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:111297126~111298510:+
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000275400.1	RP4-756H11.5	-5.66	2.67e-08	4.56e-06	-0.24	-0.25	Calcium levels;	chr7:65800652	chr7:66553805~66554199:-
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000232546.1	RP11-458F8.1	-5.66	2.67e-08	4.56e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65966800	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs906134	ENSG00000232546.1	RP11-458F8.1	-5.66	2.67e-08	4.56e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65979301	chr7:66848496~66858136:+
THCA	cis	rs7615952	0.512	rs34085484	ENSG00000241288.6	RP11-379B18.5	-5.66	2.68e-08	4.56e-06	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:125825343	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.608	rs35668111	ENSG00000241288.6	RP11-379B18.5	-5.66	2.68e-08	4.56e-06	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:125825792	chr3:125827238~125916384:-
THCA	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	5.66	2.68e-08	4.56e-06	0.23	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	5.66	2.68e-08	4.56e-06	0.23	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
THCA	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	5.66	2.68e-08	4.56e-06	0.31	0.25	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
THCA	cis	rs7702057	0.53	rs56953556	ENSG00000271918.1	CTD-2287O16.5	5.66	2.68e-08	4.56e-06	0.28	0.25	Amyotrophic lateral sclerosis;	chr5:116076903	chr5:116083807~116085416:-
THCA	cis	rs6585424	1	rs34148644	ENSG00000242600.5	MBL1P	5.66	2.68e-08	4.56e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163700	chr10:79904898~79950336:+
THCA	cis	rs2212361	0.558	rs72963816	ENSG00000255893.1	RP11-685N10.1	-5.66	2.68e-08	4.56e-06	-0.31	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94539634	chr11:94472908~94473570:-
THCA	cis	rs6430585	0.528	rs309151	ENSG00000231890.6	DARS-AS1	-5.66	2.68e-08	4.57e-06	-0.31	-0.25	Corneal structure;	chr2:135903580	chr2:135985176~136022593:+
THCA	cis	rs2562456	0.876	rs11085465	ENSG00000268119.4	CTD-2561J22.5	-5.66	2.68e-08	4.57e-06	-0.31	-0.25	Pain;	chr19:21568988	chr19:21444241~21463908:-
THCA	cis	rs2163813	1	rs12986120	ENSG00000275540.1	CTC-559E9.12	-5.66	2.68e-08	4.57e-06	-0.31	-0.25	Toenail selenium levels;	chr19:19709330	chr19:19740884~19750127:+
THCA	cis	rs2439831	0.681	rs3742971	ENSG00000249839.1	AC011330.5	5.66	2.68e-08	4.57e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43330718	chr15:43663654~43684339:-
THCA	cis	rs61677309	1	rs55789743	ENSG00000280032.1	RP11-832A4.7	5.66	2.68e-08	4.57e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118301234	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.964	rs56020103	ENSG00000280032.1	RP11-832A4.7	5.66	2.68e-08	4.57e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118301417	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs56346212	ENSG00000280032.1	RP11-832A4.7	5.66	2.68e-08	4.57e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118301627	chr11:118264593~118266817:+
THCA	cis	rs7428	1	rs7428	ENSG00000273196.1	RP11-717A5.2	-5.66	2.68e-08	4.57e-06	-0.25	-0.25	Ear protrusion;	chr2:85318367	chr2:85387074~85387146:-
THCA	cis	rs4948275	0.742	rs3104841	ENSG00000237233.2	TMEM26-AS1	-5.66	2.68e-08	4.57e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61485227	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs3104842	ENSG00000237233.2	TMEM26-AS1	-5.66	2.68e-08	4.57e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61485229	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2650718	ENSG00000237233.2	TMEM26-AS1	-5.66	2.68e-08	4.57e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61486116	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2787729	ENSG00000237233.2	TMEM26-AS1	-5.66	2.68e-08	4.57e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61486282	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2250017	ENSG00000237233.2	TMEM26-AS1	-5.66	2.68e-08	4.57e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61486696	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2250016	ENSG00000237233.2	TMEM26-AS1	-5.66	2.68e-08	4.57e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61486705	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2249939	ENSG00000237233.2	TMEM26-AS1	-5.66	2.68e-08	4.57e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61486987	chr10:61452639~61481956:+
THCA	cis	rs9990333	0.562	rs12632706	ENSG00000231464.1	AC024937.4	5.66	2.69e-08	4.58e-06	0.32	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195996738~195998233:+
THCA	cis	rs16949788	0.793	rs8035939	ENSG00000261351.2	CTD-3185P2.1	-5.66	2.69e-08	4.58e-06	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66317402	chr15:66488658~66492109:-
THCA	cis	rs2337406	1	rs1858677	ENSG00000211974.3	IGHV2-70	-5.66	2.69e-08	4.58e-06	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106706828	chr14:106723574~106724093:-
THCA	cis	rs7412746	0.658	rs1546376	ENSG00000231073.1	RP11-316M1.3	5.66	2.69e-08	4.58e-06	0.3	0.25	Melanoma;	chr1:150965185	chr1:150973123~150975534:+
THCA	cis	rs595244	1	rs6493325	ENSG00000259705.1	RP11-227D13.1	5.66	2.69e-08	4.58e-06	0.43	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48495048	chr15:48645951~48652016:+
THCA	cis	rs763567	0.933	rs567328	ENSG00000271811.1	RP1-79C4.4	5.66	2.69e-08	4.58e-06	0.29	0.25	Tonsillectomy;	chr1:170644728	chr1:170667381~170669425:+
THCA	cis	rs763567	0.904	rs544478	ENSG00000271811.1	RP1-79C4.4	5.66	2.69e-08	4.58e-06	0.29	0.25	Tonsillectomy;	chr1:170644901	chr1:170667381~170669425:+
THCA	cis	rs1876905	0.68	rs354527	ENSG00000255389.1	C6orf3	5.66	2.69e-08	4.58e-06	0.31	0.25	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111599875~111602295:+
THCA	cis	rs758324	0.732	rs1983246	ENSG00000237714.1	P4HA2-AS1	-5.66	2.69e-08	4.58e-06	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132190188	chr5:132184876~132192808:+
THCA	cis	rs758324	0.633	rs2667737	ENSG00000237714.1	P4HA2-AS1	-5.66	2.69e-08	4.58e-06	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132190190	chr5:132184876~132192808:+
THCA	cis	rs4227	0.565	rs10438740	ENSG00000233223.2	AC113189.5	-5.66	2.69e-08	4.58e-06	-0.2	-0.25	IgA nephropathy;	chr17:7569566	chr17:7581964~7584072:-
THCA	cis	rs7129556	0.702	rs7123080	ENSG00000254691.1	RP11-91P24.5	5.66	2.69e-08	4.59e-06	0.34	0.25	Weight loss (gastric bypass surgery);	chr11:77788341	chr11:77850604~77851511:+
THCA	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-5.66	2.69e-08	4.59e-06	-0.22	-0.25	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-5.66	2.69e-08	4.59e-06	-0.22	-0.25	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
THCA	cis	rs728616	0.681	rs35420115	ENSG00000225484.5	NUTM2B-AS1	-5.66	2.7e-08	4.59e-06	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148432	chr10:79663088~79826594:-
THCA	cis	rs7131987	0.903	rs2194520	ENSG00000257176.2	RP11-996F15.2	-5.66	2.7e-08	4.59e-06	-0.25	-0.25	QT interval;	chr12:29270779	chr12:29280418~29317848:-
THCA	cis	rs11089937	0.54	rs9622920	ENSG00000211638.2	IGLV8-61	5.66	2.7e-08	4.6e-06	0.2	0.25	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22098700~22099212:+
THCA	cis	rs10829156	0.741	rs9731044	ENSG00000240291.1	RP11-499P20.2	5.66	2.7e-08	4.6e-06	0.22	0.25	Sudden cardiac arrest;	chr10:18605356	chr10:18513115~18545651:-
THCA	cis	rs10829156	0.538	rs61840846	ENSG00000240291.1	RP11-499P20.2	5.66	2.7e-08	4.6e-06	0.22	0.25	Sudden cardiac arrest;	chr10:18606393	chr10:18513115~18545651:-
THCA	cis	rs116095464	0.558	rs62347678	ENSG00000248925.1	CTD-2083E4.6	5.66	2.7e-08	4.6e-06	0.36	0.25	Breast cancer;	chr5:227381	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs73031482	ENSG00000248925.1	CTD-2083E4.6	5.66	2.7e-08	4.6e-06	0.36	0.25	Breast cancer;	chr5:227479	chr5:269858~271516:-
THCA	cis	rs2835345	0.563	rs12483690	ENSG00000230479.1	AP000695.6	5.66	2.7e-08	4.6e-06	0.3	0.25	Pulmonary function;	chr21:36451265	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs12482257	ENSG00000230479.1	AP000695.6	5.66	2.7e-08	4.6e-06	0.3	0.25	Pulmonary function;	chr21:36451660	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs78113480	ENSG00000230479.1	AP000695.6	5.66	2.7e-08	4.6e-06	0.3	0.25	Pulmonary function;	chr21:36452022	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs4481073	ENSG00000230479.1	AP000695.6	5.66	2.7e-08	4.6e-06	0.3	0.25	Pulmonary function;	chr21:36452657	chr21:36430360~36481070:+
THCA	cis	rs2041895	0.509	rs10861674	ENSG00000260329.1	RP11-412D9.4	-5.66	2.7e-08	4.6e-06	-0.25	-0.25	Glaucoma (low intraocular pressure);	chr12:106910259	chr12:106954029~106955497:-
THCA	cis	rs3742264	1	rs9316181	ENSG00000235903.6	CPB2-AS1	-5.66	2.7e-08	4.6e-06	-0.34	-0.25	Blood protein levels;	chr13:46071605	chr13:46052806~46113332:+
THCA	cis	rs3742264	0.961	rs9534308	ENSG00000235903.6	CPB2-AS1	-5.66	2.7e-08	4.6e-06	-0.34	-0.25	Blood protein levels;	chr13:46071726	chr13:46052806~46113332:+
THCA	cis	rs897984	0.542	rs59061704	ENSG00000279196.1	RP11-1072A3.3	5.66	2.7e-08	4.61e-06	0.25	0.25	Dementia with Lewy bodies;	chr16:31051383	chr16:30984630~30988270:-
THCA	cis	rs1125355	0.622	rs17203501	ENSG00000251491.2	OR7E28P	-5.66	2.71e-08	4.61e-06	-0.41	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158757125	chr2:158862311~158863285:+
THCA	cis	rs17508449	0.821	rs74114403	ENSG00000232450.1	RP4-730K3.3	-5.66	2.71e-08	4.61e-06	-0.4	-0.25	Leprosy;	chr1:113536161	chr1:113698884~113699631:-
THCA	cis	rs7617773	0.817	rs11130162	ENSG00000199476.1	Y_RNA	-5.66	2.71e-08	4.61e-06	-0.31	-0.25	Coronary artery disease;	chr3:48256121	chr3:48288587~48288694:+
THCA	cis	rs17508449	0.819	rs74524050	ENSG00000232450.1	RP4-730K3.3	-5.66	2.71e-08	4.61e-06	-0.39	-0.25	Leprosy;	chr1:113688585	chr1:113698884~113699631:-
THCA	cis	rs1385374	0.92	rs11059910	ENSG00000274695.1	RP11-21K12.3	5.66	2.71e-08	4.61e-06	0.49	0.25	Systemic lupus erythematosus;	chr12:128787174	chr12:128826836~128827579:+
THCA	cis	rs3794924	1	rs7236328	ENSG00000266521.1	RP11-650P15.1	-5.66	2.71e-08	4.61e-06	-0.47	-0.25	Survival in colon cancer;	chr18:31475130	chr18:31496645~31497195:-
THCA	cis	rs9307551	0.817	rs13142610	ENSG00000250334.4	LINC00989	-5.65	2.71e-08	4.61e-06	-0.29	-0.25	Refractive error;	chr4:79602297	chr4:79492416~79576460:+
THCA	cis	rs10971721	0.822	rs12377078	ENSG00000260947.1	RP11-384P7.7	-5.65	2.71e-08	4.62e-06	-0.64	-0.25	Body mass index;	chr9:33934823	chr9:33697459~33700986:+
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.71e-08	4.62e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30738182~30740275:+
THCA	cis	rs4908768	0.539	rs6666191	ENSG00000232912.4	RP5-1115A15.1	5.65	2.72e-08	4.62e-06	0.25	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8424645~8434838:+
THCA	cis	rs317689	0.718	rs160827	ENSG00000274979.1	RP11-1143G9.5	-5.65	2.72e-08	4.63e-06	-0.3	-0.25	Response to diuretic therapy;	chr12:69376367	chr12:69326574~69331882:-
THCA	cis	rs10129255	0.957	rs8009638	ENSG00000223648.3	IGHV3-64	5.65	2.72e-08	4.63e-06	0.16	0.25	Kawasaki disease;	chr14:106777570	chr14:106643132~106658258:-
THCA	cis	rs8062405	0.69	rs6498089	ENSG00000278665.1	RP11-666O2.4	-5.65	2.72e-08	4.63e-06	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28599241~28601881:-
THCA	cis	rs763121	0.889	rs9607557	ENSG00000273076.1	RP3-508I15.22	5.65	2.72e-08	4.63e-06	0.24	0.25	Menopause (age at onset);	chr22:38644274	chr22:38743495~38743910:+
THCA	cis	rs10895275	0.851	rs12795624	ENSG00000277459.1	RP11-732A21.3	-5.65	2.72e-08	4.63e-06	-0.21	-0.25	Migraine;	chr11:102196224	chr11:102109827~102110457:-
THCA	cis	rs10829156	0.738	rs4748502	ENSG00000240291.1	RP11-499P20.2	5.65	2.72e-08	4.64e-06	0.21	0.25	Sudden cardiac arrest;	chr10:18647032	chr10:18513115~18545651:-
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.73e-08	4.64e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30738182~30740275:+
THCA	cis	rs7763441	0.506	rs9405168	ENSG00000272465.1	RP1-136B1.1	-5.65	2.73e-08	4.64e-06	-0.33	-0.25	Monobrow;	chr6:2453561	chr6:2437549~2438249:+
THCA	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	5.65	2.73e-08	4.64e-06	0.2	0.25	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
THCA	cis	rs12101261	0.744	rs3783945	ENSG00000259167.2	NMNAT1P1	5.65	2.73e-08	4.64e-06	0.37	0.25	Graves' disease;	chr14:80983346	chr14:81032529~81033404:+
THCA	cis	rs9549367	0.673	rs575453	ENSG00000269125.1	RP11-98F14.11	5.65	2.73e-08	4.64e-06	0.3	0.25	Platelet distribution width;	chr13:113183557	chr13:113165002~113165183:-
THCA	cis	rs964184	0.63	rs2075290	ENSG00000254851.1	RP11-109L13.1	-5.65	2.73e-08	4.65e-06	-0.52	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116782580	chr11:117135528~117138582:+
THCA	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	5.65	2.73e-08	4.65e-06	0.25	0.25	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
THCA	cis	rs9494145	0.68	rs11759553	ENSG00000232876.1	CTA-212D2.2	-5.65	2.73e-08	4.65e-06	-0.35	-0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135101158	chr6:135055033~135060550:+
THCA	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-5.65	2.74e-08	4.65e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
THCA	cis	rs10200159	1	rs9309267	ENSG00000272606.1	RP11-554J4.1	-5.65	2.74e-08	4.66e-06	-0.51	-0.25	Vitiligo;	chr2:55623198	chr2:55617909~55618373:+
THCA	cis	rs984222	0.838	rs7553422	ENSG00000231365.4	RP11-418J17.1	-5.65	2.74e-08	4.66e-06	-0.25	-0.25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998096	chr1:119140396~119275973:+
THCA	cis	rs10875746	0.855	rs2269936	ENSG00000269514.1	RP11-370I10.12	5.65	2.74e-08	4.66e-06	0.26	0.25	Longevity (90 years and older);	chr12:48031452	chr12:48198387~48202031:+
THCA	cis	rs6585424	1	rs35025775	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164529	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs34749786	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164634	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs61860024	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165607	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs61860025	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165798	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs12411386	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166475	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs2228427	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166962	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs34332933	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166994	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs61860035	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172697	chr10:79904898~79950336:+
THCA	cis	rs6585424	0.85	rs75804987	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172753	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs12769115	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173745	chr10:79904898~79950336:+
THCA	cis	rs6585424	0.85	rs61860036	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175103	chr10:79904898~79950336:+
THCA	cis	rs728616	0.51	rs12411989	ENSG00000242600.5	MBL1P	5.65	2.74e-08	4.66e-06	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178094	chr10:79904898~79950336:+
THCA	cis	rs2041895	0.509	rs7970139	ENSG00000260329.1	RP11-412D9.4	-5.65	2.74e-08	4.66e-06	-0.25	-0.25	Glaucoma (low intraocular pressure);	chr12:106918652	chr12:106954029~106955497:-
THCA	cis	rs853679	0.546	rs13214023	ENSG00000280107.1	AL022393.9	5.65	2.74e-08	4.67e-06	0.44	0.25	Depression;	chr6:28364364	chr6:28170845~28172521:+
THCA	cis	rs8062405	0.823	rs7202948	ENSG00000278665.1	RP11-666O2.4	5.65	2.74e-08	4.67e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28599241~28601881:-
THCA	cis	rs2303319	0.582	rs16845851	ENSG00000227403.1	AC009299.3	5.65	2.74e-08	4.67e-06	0.55	0.25	Cognitive function;	chr2:161439112	chr2:161244739~161249050:+
THCA	cis	rs2243480	1	rs35820085	ENSG00000232546.1	RP11-458F8.1	-5.65	2.74e-08	4.67e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65977771	chr7:66848496~66858136:+
THCA	cis	rs10463554	0.501	rs6860813	ENSG00000175749.11	EIF3KP1	5.65	2.75e-08	4.67e-06	0.32	0.25	Parkinson's disease;	chr5:103353125	chr5:103032376~103033031:+
THCA	cis	rs13287066	0.692	rs10761225	ENSG00000227603.1	RP11-165J3.6	5.65	2.75e-08	4.67e-06	0.26	0.25	Intelligence (multi-trait analysis);	chr9:93404358	chr9:93435332~93437121:-
THCA	cis	rs7727544	0.735	rs272860	ENSG00000224431.1	AC063976.7	5.65	2.75e-08	4.67e-06	0.22	0.25	Blood metabolite levels;	chr5:132348482	chr5:132199456~132203487:+
THCA	cis	rs7809950	1	rs2293658	ENSG00000238832.1	snoU109	-5.65	2.75e-08	4.67e-06	-0.27	-0.25	Coronary artery disease;	chr7:107630122	chr7:107603363~107603507:+
THCA	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-5.65	2.75e-08	4.67e-06	-0.15	-0.25	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
THCA	cis	rs4227	0.565	rs1142832	ENSG00000233223.2	AC113189.5	5.65	2.75e-08	4.67e-06	0.2	0.25	IgA nephropathy;	chr17:7575897	chr17:7581964~7584072:-
THCA	cis	rs7119038	0.865	rs11217044	ENSG00000255239.1	AP002954.6	-5.65	2.75e-08	4.68e-06	-0.38	-0.25	Sjögren's syndrome;	chr11:118825313	chr11:118688039~118690600:-
THCA	cis	rs801193	1	rs3778909	ENSG00000273142.1	RP11-458F8.4	-5.65	2.75e-08	4.68e-06	-0.2	-0.25	Aortic root size;	chr7:66790659	chr7:66902857~66906297:+
THCA	cis	rs2163813	0.788	rs247774	ENSG00000275540.1	CTC-559E9.12	-5.65	2.75e-08	4.68e-06	-0.28	-0.25	Toenail selenium levels;	chr19:19732742	chr19:19740884~19750127:+
THCA	cis	rs9309473	0.519	rs12991161	ENSG00000163016.8	ALMS1P	-5.65	2.75e-08	4.68e-06	-0.32	-0.25	Metabolite levels;	chr2:73644244	chr2:73644919~73685576:+
THCA	cis	rs800160	0.748	rs800151	ENSG00000199550.1	Y_RNA	5.65	2.75e-08	4.68e-06	0.38	0.25	Bacteremia;	chr11:2350121	chr11:2372638~2372750:+
THCA	cis	rs1075232	1	rs9672214	ENSG00000215302.7	CTD-3092A11.1	-5.65	2.76e-08	4.69e-06	-0.58	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30470779~30507623:+
THCA	cis	rs75920871	0.589	rs2075547	ENSG00000254851.1	RP11-109L13.1	-5.65	2.76e-08	4.69e-06	-0.49	-0.25	Subjective well-being;	chr11:117197818	chr11:117135528~117138582:+
THCA	cis	rs4713118	1	rs13215072	ENSG00000280107.1	AL022393.9	-5.65	2.76e-08	4.7e-06	-0.28	-0.25	Parkinson's disease;	chr6:27709949	chr6:28170845~28172521:+
THCA	cis	rs62432291	0.681	rs404435	ENSG00000235086.1	FNDC1-IT1	-5.65	2.77e-08	4.7e-06	-0.46	-0.25	Joint mobility (Beighton score);	chr6:159233455	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.614	rs370434	ENSG00000235086.1	FNDC1-IT1	-5.65	2.77e-08	4.7e-06	-0.46	-0.25	Joint mobility (Beighton score);	chr6:159233519	chr6:159240786~159243329:+
THCA	cis	rs7119038	0.774	rs73005423	ENSG00000255239.1	AP002954.6	-5.65	2.77e-08	4.7e-06	-0.39	-0.25	Sjögren's syndrome;	chr11:118810370	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.818	rs715412	ENSG00000255239.1	AP002954.6	-5.65	2.77e-08	4.7e-06	-0.39	-0.25	Sjögren's syndrome;	chr11:118813901	chr11:118688039~118690600:-
THCA	cis	rs2029362	0.611	rs2883187	ENSG00000245573.6	BDNF-AS	5.65	2.77e-08	4.7e-06	0.2	0.25	Total body bone mineral density;	chr11:27719545	chr11:27506838~27698174:+
THCA	cis	rs17345786	0.906	rs12638137	ENSG00000256628.3	ZBTB11-AS1	5.65	2.77e-08	4.71e-06	0.33	0.25	Colonoscopy-negative controls vs population controls;	chr3:101432120	chr3:101676475~101679217:+
THCA	cis	rs17345786	0.861	rs79181492	ENSG00000256628.3	ZBTB11-AS1	5.65	2.77e-08	4.71e-06	0.33	0.25	Colonoscopy-negative controls vs population controls;	chr3:101497177	chr3:101676475~101679217:+
THCA	cis	rs1198430	0.562	rs7546989	ENSG00000232482.2	RP4-654C18.1	-5.65	2.77e-08	4.71e-06	-0.36	-0.25	Total cholesterol levels;	chr1:23463205	chr1:23410832~23412146:+
THCA	cis	rs2145598	0.933	rs1051860	ENSG00000279636.2	LINC00216	-5.65	2.77e-08	4.71e-06	-0.25	-0.25	Coronary artery disease;	chr14:58371950	chr14:58288033~58289158:+
THCA	cis	rs7412746	0.611	rs10888395	ENSG00000231073.1	RP11-316M1.3	5.65	2.77e-08	4.71e-06	0.3	0.25	Melanoma;	chr1:150789695	chr1:150973123~150975534:+
THCA	cis	rs17508449	0.865	rs4838994	ENSG00000232450.1	RP4-730K3.3	5.65	2.78e-08	4.72e-06	0.39	0.25	Leprosy;	chr1:113608984	chr1:113698884~113699631:-
THCA	cis	rs1552244	0.872	rs7646073	ENSG00000232901.1	CYCSP10	5.65	2.78e-08	4.72e-06	0.33	0.25	Alzheimer's disease;	chr3:10055721	chr3:10000647~10000940:-
THCA	cis	rs10875746	0.551	rs11168536	ENSG00000258234.1	RP11-370I10.2	5.65	2.78e-08	4.72e-06	0.3	0.25	Longevity (90 years and older);	chr12:48351268	chr12:48231098~48284210:-
THCA	cis	rs10129255	0.872	rs10133674	ENSG00000211974.3	IGHV2-70	5.65	2.78e-08	4.72e-06	0.2	0.25	Kawasaki disease;	chr14:106692788	chr14:106723574~106724093:-
THCA	cis	rs61041384	0.661	rs75338281	ENSG00000256092.2	RP13-942N8.1	-5.65	2.78e-08	4.73e-06	-0.4	-0.25	Schizophrenia;	chr12:123022937	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs4148857	ENSG00000256092.2	RP13-942N8.1	-5.65	2.78e-08	4.73e-06	-0.4	-0.25	Schizophrenia;	chr12:123055408	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs4148858	ENSG00000256092.2	RP13-942N8.1	-5.65	2.78e-08	4.73e-06	-0.4	-0.25	Schizophrenia;	chr12:123055475	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs7967118	ENSG00000256092.2	RP13-942N8.1	-5.65	2.78e-08	4.73e-06	-0.4	-0.25	Schizophrenia;	chr12:123086956	chr12:123363868~123366113:+
THCA	cis	rs11603023	0.967	rs4245184	ENSG00000278376.1	RP11-158I9.8	5.65	2.78e-08	4.73e-06	0.19	0.25	Cholesterol, total;	chr11:118639844	chr11:118791254~118793137:+
THCA	cis	rs11603023	0.967	rs644273	ENSG00000278376.1	RP11-158I9.8	5.65	2.78e-08	4.73e-06	0.19	0.25	Cholesterol, total;	chr11:118640634	chr11:118791254~118793137:+
THCA	cis	rs11603023	0.967	rs654423	ENSG00000278376.1	RP11-158I9.8	5.65	2.78e-08	4.73e-06	0.19	0.25	Cholesterol, total;	chr11:118641039	chr11:118791254~118793137:+
THCA	cis	rs950169	0.58	rs11635597	ENSG00000275120.1	RP11-182J1.17	5.65	2.78e-08	4.73e-06	0.3	0.25	Schizophrenia;	chr15:84622468	chr15:84599434~84606463:-
THCA	cis	rs4948275	0.773	rs1902429	ENSG00000237233.2	TMEM26-AS1	-5.65	2.79e-08	4.74e-06	-0.34	-0.25	Night sleep phenotypes;	chr10:61517317	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2606097	ENSG00000237233.2	TMEM26-AS1	-5.65	2.79e-08	4.74e-06	-0.34	-0.25	Night sleep phenotypes;	chr10:61519195	chr10:61452639~61481956:+
THCA	cis	rs2243480	1	rs73142162	ENSG00000232546.1	RP11-458F8.1	-5.65	2.79e-08	4.74e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65909309	chr7:66848496~66858136:+
THCA	cis	rs7760535	0.757	rs10456875	ENSG00000271789.1	RP5-1112D6.7	-5.65	2.79e-08	4.74e-06	-0.24	-0.25	Metabolic traits;	chr6:111428522	chr6:111297126~111298510:+
THCA	cis	rs1889642	1	rs1360812	ENSG00000227354.5	RBM26-AS1	-5.65	2.79e-08	4.74e-06	-0.24	-0.25	Colonoscopy-negative controls vs population controls;	chr13:79829486	chr13:79406309~79424328:+
THCA	cis	rs6569038	0.502	rs794264	ENSG00000253194.1	RP11-351A11.1	5.65	2.79e-08	4.74e-06	0.34	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119001257	chr6:118934785~119031541:+
THCA	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-5.65	2.8e-08	4.75e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
THCA	cis	rs9307551	1	rs1031005	ENSG00000250334.4	LINC00989	-5.65	2.8e-08	4.76e-06	-0.31	-0.25	Refractive error;	chr4:79595750	chr4:79492416~79576460:+
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Body mass index;	chr17:30739311	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Body mass index;	chr17:30745415	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Body mass index;	chr17:30745654	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.8e-08	4.76e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30738182~30740275:+
THCA	cis	rs9876781	1	rs11130171	ENSG00000229759.1	MRPS18AP1	5.65	2.8e-08	4.76e-06	0.3	0.25	Longevity;	chr3:48421052	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs9883927	ENSG00000229759.1	MRPS18AP1	5.65	2.8e-08	4.76e-06	0.3	0.25	Longevity;	chr3:48422302	chr3:48256350~48256938:-
THCA	cis	rs9388451	0.626	rs3799712	ENSG00000226409.1	RP11-735G4.1	-5.65	2.8e-08	4.76e-06	-0.31	-0.25	Brugada syndrome;	chr6:125753957	chr6:125370211~125374324:-
THCA	cis	rs17345786	1	rs17345528	ENSG00000256628.3	ZBTB11-AS1	-5.65	2.81e-08	4.76e-06	-0.33	-0.25	Colonoscopy-negative controls vs population controls;	chr3:101575986	chr3:101676475~101679217:+
THCA	cis	rs7309	0.87	rs2358016	ENSG00000235724.7	AC009299.2	5.65	2.81e-08	4.77e-06	0.25	0.25	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161222785~161308303:-
THCA	cis	rs7202877	0.706	rs4887813	ENSG00000261783.1	RP11-252K23.2	-5.65	2.81e-08	4.77e-06	-0.45	-0.25	Type 1 diabetes;Type 2 diabetes;	chr16:75278596	chr16:75379818~75381260:-
THCA	cis	rs853679	0.567	rs6905380	ENSG00000219392.1	RP1-265C24.5	-5.65	2.81e-08	4.77e-06	-0.3	-0.25	Depression;	chr6:28407125	chr6:28115628~28116551:+
THCA	cis	rs1395	1	rs1275537	ENSG00000234072.1	AC074117.10	-5.65	2.81e-08	4.77e-06	-0.2	-0.25	Blood metabolite levels;	chr2:27218434	chr2:27356246~27367622:+
THCA	cis	rs10129255	0.828	rs10140989	ENSG00000211974.3	IGHV2-70	5.65	2.81e-08	4.77e-06	0.2	0.25	Kawasaki disease;	chr14:106668657	chr14:106723574~106724093:-
THCA	cis	rs17292804	0.506	rs71417868	ENSG00000269910.1	RP11-73M18.10	5.65	2.81e-08	4.78e-06	0.23	0.25	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103694516~103695050:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000232546.1	RP11-458F8.1	-5.65	2.81e-08	4.78e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65924743	chr7:66848496~66858136:+
THCA	cis	rs6479901	0.841	rs10761720	ENSG00000232075.1	MRPL35P2	-5.65	2.81e-08	4.78e-06	-0.37	-0.25	Intelligence (multi-trait analysis);	chr10:63139023	chr10:63634317~63634827:-
THCA	cis	rs684603	1	rs684603	ENSG00000246174.6	KCTD21-AS1	-5.65	2.82e-08	4.78e-06	-0.36	-0.25	Number of common colds;	chr11:78102803	chr11:78139771~78175323:+
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.82e-08	4.79e-06	-0.38	-0.25	Body mass index;	chr17:30730179	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.82e-08	4.79e-06	-0.38	-0.25	Body mass index;	chr17:30730744	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000280069.1	CTD-2349P21.3	-5.65	2.82e-08	4.79e-06	-0.38	-0.25	Body mass index;	chr17:30731712	chr17:30738182~30740275:+
THCA	cis	rs10129255	0.646	rs55995061	ENSG00000211974.3	IGHV2-70	-5.65	2.82e-08	4.79e-06	-0.25	-0.25	Kawasaki disease;	chr14:106799309	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs76871148	ENSG00000211974.3	IGHV2-70	-5.65	2.82e-08	4.79e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106799722	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs61521632	ENSG00000211974.3	IGHV2-70	-5.65	2.82e-08	4.79e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106801091	chr14:106723574~106724093:-
THCA	cis	rs12497850	0.864	rs4279134	ENSG00000229759.1	MRPS18AP1	5.65	2.82e-08	4.79e-06	0.34	0.25	Parkinson's disease;	chr3:49119243	chr3:48256350~48256938:-
THCA	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	5.65	2.82e-08	4.79e-06	0.2	0.25	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
THCA	cis	rs11089937	0.568	rs12160318	ENSG00000211639.2	IGLV4-60	5.65	2.82e-08	4.79e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22162199~22162681:+
THCA	cis	rs30380	0.586	rs28119	ENSG00000272109.1	CTD-2260A17.3	-5.65	2.83e-08	4.79e-06	-0.34	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96796030	chr5:96804353~96806105:+
THCA	cis	rs30380	0.632	rs26491	ENSG00000272109.1	CTD-2260A17.3	-5.65	2.83e-08	4.79e-06	-0.34	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96798410	chr5:96804353~96806105:+
THCA	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-5.65	2.83e-08	4.8e-06	-0.22	-0.25	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
THCA	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	5.65	2.83e-08	4.81e-06	0.33	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
THCA	cis	rs2717559	0.542	rs2717586	ENSG00000253741.1	CTD-2292P10.4	-5.65	2.83e-08	4.81e-06	-0.32	-0.25	Urinary tract infection frequency;	chr8:142816466	chr8:142702252~142726973:-
THCA	cis	rs7523875	0.72	rs17017399	ENSG00000153363.11	LINC00467	5.65	2.83e-08	4.81e-06	0.26	0.25	Mean corpuscular volume;	chr1:211317998	chr1:211382803~211435333:+
THCA	cis	rs11020821	0.884	rs12286498	ENSG00000255893.1	RP11-685N10.1	-5.65	2.84e-08	4.81e-06	-0.28	-0.25	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94529857	chr11:94472908~94473570:-
THCA	cis	rs6545883	0.931	rs11125885	ENSG00000270820.4	RP11-355B11.2	5.65	2.84e-08	4.82e-06	0.21	0.25	Tuberculosis;	chr2:61528593	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.965	rs9989775	ENSG00000270820.4	RP11-355B11.2	5.65	2.84e-08	4.82e-06	0.21	0.25	Tuberculosis;	chr2:61534639	chr2:61471188~61484130:+
THCA	cis	rs7829975	0.744	rs2409092	ENSG00000254153.1	CTA-398F10.2	-5.65	2.84e-08	4.83e-06	-0.27	-0.25	Mood instability;	chr8:8824682	chr8:8456909~8461337:-
THCA	cis	rs1552244	0.938	rs9873794	ENSG00000232901.1	CYCSP10	5.65	2.85e-08	4.83e-06	0.33	0.25	Alzheimer's disease;	chr3:10032469	chr3:10000647~10000940:-
THCA	cis	rs2129782	1	rs73275337	ENSG00000253553.4	RP11-586K2.1	5.65	2.85e-08	4.83e-06	0.43	0.25	Electrodermal activity;	chr8:88451525	chr8:88326836~88737134:+
THCA	cis	rs595244	0.908	rs35349206	ENSG00000259705.1	RP11-227D13.1	5.65	2.85e-08	4.83e-06	0.41	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48433982	chr15:48645951~48652016:+
THCA	cis	rs12612619	0.704	rs2384571	ENSG00000229122.1	AGBL5-IT1	5.65	2.85e-08	4.83e-06	0.18	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27101856	chr2:27061038~27061815:+
THCA	cis	rs202072	0.722	rs202069	ENSG00000272379.1	RP1-257A7.5	5.65	2.85e-08	4.84e-06	0.4	0.25	HIV-1 viral setpoint;	chr6:13267009	chr6:13290018~13290490:-
THCA	cis	rs890448	0.726	rs2850370	ENSG00000254531.1	FLJ20021	-5.65	2.85e-08	4.84e-06	-0.22	-0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101315584	chr4:101347780~101348883:+
THCA	cis	rs4689592	0.546	rs2359012	ENSG00000245468.3	RP11-367J11.3	5.65	2.85e-08	4.84e-06	0.21	0.25	Monocyte percentage of white cells;	chr4:7064326	chr4:7094571~7103385:-
THCA	cis	rs2439831	0.867	rs2584702	ENSG00000275601.1	AC011330.13	-5.65	2.85e-08	4.84e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43392716	chr15:43642389~43643023:-
THCA	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	5.65	2.86e-08	4.84e-06	0.2	0.25	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	5.65	2.86e-08	4.84e-06	0.2	0.25	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
THCA	cis	rs4639966	0.758	rs11217013	ENSG00000255239.1	AP002954.6	-5.65	2.86e-08	4.85e-06	-0.35	-0.25	Systemic lupus erythematosus;	chr11:118754210	chr11:118688039~118690600:-
THCA	cis	rs78487399	0.71	rs78681698	ENSG00000234936.1	AC010883.5	5.65	2.86e-08	4.85e-06	0.39	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43371021	chr2:43229573~43233394:+
THCA	cis	rs2243480	1	rs160655	ENSG00000230295.1	RP11-458F8.2	-5.65	2.86e-08	4.85e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66068227	chr7:66880708~66882981:+
THCA	cis	rs67517081	1	rs67517081	ENSG00000279196.1	RP11-1072A3.3	-5.65	2.86e-08	4.85e-06	-0.25	-0.25	Mean corpuscular hemoglobin;	chr16:30976060	chr16:30984630~30988270:-
THCA	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	5.64	2.86e-08	4.86e-06	0.2	0.25	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
THCA	cis	rs16976116	0.901	rs1061874	ENSG00000279145.1	RP11-547D13.1	5.64	2.87e-08	4.86e-06	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55204089	chr15:55171972~55178175:-
THCA	cis	rs2255336	0.578	rs7980379	ENSG00000245648.1	RP11-277P12.20	5.64	2.87e-08	4.86e-06	0.31	0.25	Blood protein levels;	chr12:10367591	chr12:10363769~10398506:+
THCA	cis	rs3743772	0.655	rs62048545	ENSG00000279722.1	RP11-44F14.6	5.64	2.87e-08	4.87e-06	0.42	0.25	Depressive symptoms (SSRI exposure interaction);	chr16:53507209	chr16:53487607~53489943:-
THCA	cis	rs412050	0.947	rs239915	ENSG00000224086.5	LL22NC03-86G7.1	-5.64	2.87e-08	4.87e-06	-0.4	-0.25	Attention deficit hyperactivity disorder;	chr22:21962259	chr22:21938293~21977632:+
THCA	cis	rs7824557	0.734	rs2293856	ENSG00000154316.13	TDH	-5.64	2.87e-08	4.87e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11319938	chr8:11339637~11368452:+
THCA	cis	rs12428035	0.772	rs3101570	ENSG00000247400.3	DNAJC3-AS1	5.64	2.87e-08	4.87e-06	0.23	0.25	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95825965	chr13:95648733~95676925:-
THCA	cis	rs4639966	0.836	rs4499035	ENSG00000255239.1	AP002954.6	-5.64	2.87e-08	4.87e-06	-0.35	-0.25	Systemic lupus erythematosus;	chr11:118739754	chr11:118688039~118690600:-
THCA	cis	rs4639966	0.836	rs1893029	ENSG00000255239.1	AP002954.6	-5.64	2.87e-08	4.87e-06	-0.35	-0.25	Systemic lupus erythematosus;	chr11:118740117	chr11:118688039~118690600:-
THCA	cis	rs9880211	0.699	rs13433688	ENSG00000273486.1	RP11-731C17.2	5.64	2.87e-08	4.87e-06	0.27	0.25	Height;Body mass index;	chr3:136690329	chr3:136837338~136839021:-
THCA	cis	rs8027521	0.905	rs2725585	ENSG00000280362.1	RP11-643A5.3	-5.64	2.87e-08	4.87e-06	-0.3	-0.25	Circulating chemerin levels;	chr15:53975805	chr15:53910769~53914712:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	5.64	2.88e-08	4.87e-06	0.29	0.25	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
THCA	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-5.64	2.88e-08	4.88e-06	-0.4	-0.25	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
THCA	cis	rs7688540	0.723	rs7687112	ENSG00000211553.1	AC253576.2	-5.64	2.88e-08	4.88e-06	-0.37	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:136461~136568:+
THCA	cis	rs8113308	0.752	rs11879758	ENSG00000269235.1	ZNF350-AS1	5.64	2.88e-08	4.88e-06	0.36	0.25	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51986911	chr19:51949134~51981367:+
THCA	cis	rs4888671	1	rs113450334	ENSG00000261707.1	RP11-264M12.2	5.64	2.88e-08	4.88e-06	0.47	0.25	Obesity-related traits;	chr16:77746712	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs113269636	ENSG00000261707.1	RP11-264M12.2	5.64	2.88e-08	4.88e-06	0.47	0.25	Obesity-related traits;	chr16:77746713	chr16:77741468~77743000:-
THCA	cis	rs736801	0.808	rs2248116	ENSG00000224431.1	AC063976.7	-5.64	2.88e-08	4.88e-06	-0.22	-0.25	Mosquito bite size;Breast cancer;	chr5:132468655	chr5:132199456~132203487:+
THCA	cis	rs1949733	0.582	rs61258495	ENSG00000205959.3	RP11-689P11.2	5.64	2.88e-08	4.88e-06	0.21	0.25	Response to antineoplastic agents;	chr4:8532290	chr4:8482270~8512610:+
THCA	cis	rs6968419	0.609	rs73716708	ENSG00000237870.5	AC073130.1	5.64	2.88e-08	4.89e-06	0.28	0.25	Intraocular pressure;	chr7:116265689	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.609	rs73716710	ENSG00000237870.5	AC073130.1	5.64	2.88e-08	4.89e-06	0.28	0.25	Intraocular pressure;	chr7:116265690	chr7:116275606~116286734:-
THCA	cis	rs9309473	0.519	rs4852951	ENSG00000163016.8	ALMS1P	-5.64	2.88e-08	4.89e-06	-0.32	-0.25	Metabolite levels;	chr2:73642669	chr2:73644919~73685576:+
THCA	cis	rs62432291	0.681	rs7757530	ENSG00000235086.1	FNDC1-IT1	5.64	2.89e-08	4.89e-06	0.46	0.25	Joint mobility (Beighton score);	chr6:159226897	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs418859	ENSG00000235086.1	FNDC1-IT1	5.64	2.89e-08	4.89e-06	0.46	0.25	Joint mobility (Beighton score);	chr6:159228663	chr6:159240786~159243329:+
THCA	cis	rs6968419	0.714	rs1048508	ENSG00000237870.5	AC073130.1	-5.64	2.89e-08	4.89e-06	-0.28	-0.25	Intraocular pressure;	chr7:116252596	chr7:116275606~116286734:-
THCA	cis	rs7189233	0.955	rs8054299	ENSG00000279722.1	RP11-44F14.6	5.64	2.89e-08	4.9e-06	0.28	0.25	Intelligence (multi-trait analysis);	chr16:53464743	chr16:53487607~53489943:-
THCA	cis	rs17301013	0.507	rs1793316	ENSG00000227373.4	RP11-160H22.5	5.64	2.89e-08	4.9e-06	0.38	0.25	Systemic lupus erythematosus;	chr1:174825006	chr1:174115300~174160004:-
THCA	cis	rs12893668	0.572	rs34000399	ENSG00000269940.1	RP11-73M18.7	5.64	2.89e-08	4.9e-06	0.26	0.25	Reticulocyte count;	chr14:103635080	chr14:103694560~103695170:+
THCA	cis	rs853679	0.546	rs35017208	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28377505	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs13213152	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28381921	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs36092177	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28390030	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs13213986	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28390232	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs2232429	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28391855	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs2232426	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28392882	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs34546986	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28394532	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs34871267	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28396455	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs2232423	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28398374	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs35883476	ENSG00000226314.6	ZNF192P1	-5.64	2.89e-08	4.9e-06	-0.55	-0.25	Depression;	chr6:28400731	chr6:28161781~28169594:+
THCA	cis	rs7829975	0.714	rs59046059	ENSG00000254153.1	CTA-398F10.2	-5.64	2.89e-08	4.9e-06	-0.27	-0.25	Mood instability;	chr8:8813226	chr8:8456909~8461337:-
THCA	cis	rs4792901	0.538	rs34038525	ENSG00000267151.3	RP11-100E5.2	5.64	2.89e-08	4.9e-06	0.29	0.25	Dupuytren's disease;	chr17:43457937	chr17:43444707~43451200:+
THCA	cis	rs13256369	0.802	rs13256404	ENSG00000253893.2	FAM85B	-5.64	2.89e-08	4.9e-06	-0.34	-0.25	Obesity-related traits;	chr8:8705464	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.756	rs13280759	ENSG00000253893.2	FAM85B	-5.64	2.89e-08	4.9e-06	-0.34	-0.25	Obesity-related traits;	chr8:8705485	chr8:8167819~8226614:-
THCA	cis	rs11723261	0.582	rs4634177	ENSG00000211553.1	AC253576.2	-5.64	2.89e-08	4.9e-06	-0.36	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:136461~136568:+
THCA	cis	rs11749327	0.719	rs36111336	ENSG00000221990.4	EXOC3-AS1	5.64	2.89e-08	4.9e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:463501	chr5:441498~443160:-
THCA	cis	rs11749327	0.719	rs72698510	ENSG00000221990.4	EXOC3-AS1	5.64	2.89e-08	4.9e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:464224	chr5:441498~443160:-
THCA	cis	rs10208649	0.908	rs114242964	ENSG00000233266.1	HMGB1P31	5.64	2.9e-08	4.91e-06	0.67	0.25	Body mass index;	chr2:54013985	chr2:54051334~54051760:+
THCA	cis	rs8002861	0.87	rs2121030	ENSG00000274001.1	RP11-5G9.5	-5.64	2.9e-08	4.91e-06	-0.28	-0.25	Leprosy;	chr13:43870438	chr13:43877715~43878163:-
THCA	cis	rs853679	0.607	rs13211507	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28289600	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34691223	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28290431	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13207345	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28297795	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs72854513	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28298177	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs56189111	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28304196	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34950484	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28310911	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs35072899	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28313764	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34661125	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28314117	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13190888	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28318208	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs56075693	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28322551	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34218844	ENSG00000226314.6	ZNF192P1	-5.64	2.9e-08	4.91e-06	-0.54	-0.25	Depression;	chr6:28322870	chr6:28161781~28169594:+
THCA	cis	rs4794202	0.618	rs11079799	ENSG00000264920.1	RP11-6N17.4	5.64	2.9e-08	4.91e-06	0.28	0.25	Alzheimer's disease (cognitive decline);	chr17:47878707	chr17:47891255~47895812:-
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000228409.4	CCT6P1	5.64	2.9e-08	4.91e-06	0.27	0.25	Diabetic kidney disease;	chr7:65988305	chr7:65751142~65763354:+
THCA	cis	rs6969780	0.915	rs2107063	ENSG00000233429.8	HOTAIRM1	-5.64	2.9e-08	4.91e-06	-0.34	-0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127727	chr7:27095647~27100265:+
THCA	cis	rs1552244	1	rs9881859	ENSG00000232901.1	CYCSP10	5.64	2.9e-08	4.91e-06	0.33	0.25	Alzheimer's disease;	chr3:10031130	chr3:10000647~10000940:-
THCA	cis	rs2835345	0.63	rs55681268	ENSG00000230479.1	AP000695.6	5.64	2.9e-08	4.92e-06	0.3	0.25	Pulmonary function;	chr21:36449419	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs12627161	ENSG00000230479.1	AP000695.6	5.64	2.9e-08	4.92e-06	0.3	0.25	Pulmonary function;	chr21:36449649	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs12627241	ENSG00000230479.1	AP000695.6	5.64	2.9e-08	4.92e-06	0.3	0.25	Pulmonary function;	chr21:36449689	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs12627173	ENSG00000230479.1	AP000695.6	5.64	2.9e-08	4.92e-06	0.3	0.25	Pulmonary function;	chr21:36449715	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.528	rs12483650	ENSG00000230479.1	AP000695.6	5.64	2.9e-08	4.92e-06	0.3	0.25	Pulmonary function;	chr21:36450778	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs12483621	ENSG00000230479.1	AP000695.6	5.64	2.9e-08	4.92e-06	0.3	0.25	Pulmonary function;	chr21:36450798	chr21:36430360~36481070:+
THCA	cis	rs6866614	0.627	rs27437	ENSG00000233006.5	AC034220.3	5.64	2.9e-08	4.92e-06	0.19	0.25	Perceived unattractiveness to mosquitoes;	chr5:132101268	chr5:132311285~132369916:-
THCA	cis	rs7412746	0.658	rs11589458	ENSG00000231073.1	RP11-316M1.3	5.64	2.9e-08	4.92e-06	0.31	0.25	Melanoma;	chr1:150820140	chr1:150973123~150975534:+
THCA	cis	rs12550612	0.83	rs10111172	ENSG00000253616.4	RP11-875O11.3	-5.64	2.9e-08	4.92e-06	-0.35	-0.25	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23111578	chr8:23071377~23074488:-
THCA	cis	rs4934494	0.677	rs719909	ENSG00000232936.4	RP11-80H5.2	5.64	2.91e-08	4.92e-06	0.34	0.25	Red blood cell count;	chr10:89585939	chr10:89645282~89650667:+
THCA	cis	rs2276314	0.512	rs9949178	ENSG00000278986.1	RP11-723J4.3	5.64	2.91e-08	4.92e-06	0.26	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35870612	chr18:35972151~35973916:+
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000275400.1	RP4-756H11.5	-5.64	2.91e-08	4.93e-06	-0.28	-0.25	Corneal structure;	chr7:66801919	chr7:66553805~66554199:-
THCA	cis	rs253959	0.532	rs10045890	ENSG00000272265.1	CTD-2287O16.4	5.64	2.91e-08	4.93e-06	0.3	0.25	Bipolar disorder and schizophrenia;	chr5:116112188	chr5:116078110~116078570:-
THCA	cis	rs6058796	1	rs6057614	ENSG00000175730.8	BAK1P1	5.64	2.91e-08	4.93e-06	0.37	0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32667998	chr20:32690180~32690815:-
THCA	cis	rs9910055	0.607	rs13726	ENSG00000267080.4	ASB16-AS1	-5.64	2.91e-08	4.93e-06	-0.23	-0.25	Total body bone mineral density;	chr17:44162193	chr17:44175973~44186717:-
THCA	cis	rs4948275	0.773	rs2185051	ENSG00000237233.2	TMEM26-AS1	-5.64	2.91e-08	4.93e-06	-0.32	-0.25	Night sleep phenotypes;	chr10:61480114	chr10:61452639~61481956:+
THCA	cis	rs853679	0.55	rs6901017	ENSG00000261839.1	RP1-265C24.8	5.64	2.91e-08	4.93e-06	0.29	0.25	Depression;	chr6:28184805	chr6:28136849~28139678:+
THCA	cis	rs755249	0.567	rs16825887	ENSG00000228060.1	RP11-69E11.8	5.64	2.91e-08	4.93e-06	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39565160~39573203:+
THCA	cis	rs714027	1	rs5763767	ENSG00000279159.1	RP3-394A18.1	-5.64	2.91e-08	4.94e-06	-0.17	-0.25	Lymphocyte counts;	chr22:30097893	chr22:29978950~30028236:-
THCA	cis	rs714027	1	rs2412971	ENSG00000279159.1	RP3-394A18.1	-5.64	2.91e-08	4.94e-06	-0.17	-0.25	Lymphocyte counts;	chr22:30098382	chr22:29978950~30028236:-
THCA	cis	rs3743772	0.529	rs28493500	ENSG00000279722.1	RP11-44F14.6	5.64	2.92e-08	4.94e-06	0.39	0.25	Depressive symptoms (SSRI exposure interaction);	chr16:53507510	chr16:53487607~53489943:-
THCA	cis	rs7412746	0.658	rs72704682	ENSG00000231073.1	RP11-316M1.3	5.64	2.92e-08	4.94e-06	0.3	0.25	Melanoma;	chr1:150925201	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs72704685	ENSG00000231073.1	RP11-316M1.3	5.64	2.92e-08	4.94e-06	0.3	0.25	Melanoma;	chr1:150925211	chr1:150973123~150975534:+
THCA	cis	rs2439831	0.717	rs9806227	ENSG00000275601.1	AC011330.13	-5.64	2.92e-08	4.94e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43387917	chr15:43642389~43643023:-
THCA	cis	rs10861661	0.569	rs10778514	ENSG00000260329.1	RP11-412D9.4	-5.64	2.92e-08	4.94e-06	-0.25	-0.25	Triglyceride levels;	chr12:106909799	chr12:106954029~106955497:-
THCA	cis	rs62292953	1	rs16839317	ENSG00000248724.5	NPHP3-AS1	-5.64	2.92e-08	4.94e-06	-0.39	-0.25	Red cell distribution width;	chr3:132500039	chr3:132721750~132874223:+
THCA	cis	rs2562456	0.833	rs2968076	ENSG00000268081.1	RP11-678G14.2	-5.64	2.92e-08	4.94e-06	-0.37	-0.25	Pain;	chr19:21454299	chr19:21554640~21569237:-
THCA	cis	rs1322639	0.614	rs9455889	ENSG00000261039.2	RP11-417E7.2	-5.64	2.92e-08	4.94e-06	-0.37	-0.25	Pulse pressure;	chr6:169165992	chr6:169175304~169182740:-
THCA	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-5.64	2.92e-08	4.94e-06	-0.31	-0.25	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
THCA	cis	rs16949788	1	rs74894249	ENSG00000261351.2	CTD-3185P2.1	-5.64	2.92e-08	4.94e-06	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66526309	chr15:66488658~66492109:-
THCA	cis	rs17772222	0.636	rs10484010	ENSG00000258789.1	RP11-507K2.3	-5.64	2.92e-08	4.95e-06	-0.27	-0.25	Coronary artery calcification;	chr14:88831944	chr14:88551597~88552493:+
THCA	cis	rs317865	0.748	rs73234656	ENSG00000263327.5	TAPT1-AS1	-5.64	2.92e-08	4.95e-06	-0.44	-0.25	Kidney disease (early stage) in type 1 diabetes;	chr4:16211079	chr4:16226685~16320140:+
THCA	cis	rs2439831	0.867	rs3213991	ENSG00000275601.1	AC011330.13	-5.64	2.92e-08	4.95e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43378082	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs7163245	ENSG00000275601.1	AC011330.13	-5.64	2.92e-08	4.95e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43379096	chr15:43642389~43643023:-
THCA	cis	rs9876781	1	rs6794875	ENSG00000229759.1	MRPS18AP1	5.64	2.92e-08	4.95e-06	0.3	0.25	Longevity;	chr3:48414217	chr3:48256350~48256938:-
THCA	cis	rs17767392	0.958	rs34957192	ENSG00000259146.3	RP1-261D10.2	5.64	2.92e-08	4.95e-06	0.33	0.25	Mitral valve prolapse;	chr14:71285619	chr14:71292729~71321814:-
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000280069.1	CTD-2349P21.3	-5.64	2.93e-08	4.95e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30738182~30740275:+
THCA	cis	rs412050	0.948	rs34239349	ENSG00000224086.5	LL22NC03-86G7.1	-5.64	2.93e-08	4.95e-06	-0.42	-0.25	Attention deficit hyperactivity disorder;	chr22:21971252	chr22:21938293~21977632:+
THCA	cis	rs2120243	0.647	rs9289983	ENSG00000244515.1	KRT18P34	-5.64	2.93e-08	4.95e-06	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157428216	chr3:157162663~157163932:-
THCA	cis	rs12428035	0.772	rs17885081	ENSG00000247400.3	DNAJC3-AS1	-5.64	2.93e-08	4.96e-06	-0.23	-0.25	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95678485	chr13:95648733~95676925:-
THCA	cis	rs10829156	0.732	rs7100884	ENSG00000240291.1	RP11-499P20.2	5.64	2.93e-08	4.96e-06	0.21	0.25	Sudden cardiac arrest;	chr10:18523768	chr10:18513115~18545651:-
THCA	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-5.64	2.93e-08	4.96e-06	-0.23	-0.25	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
THCA	cis	rs2243480	1	rs2707844	ENSG00000232559.3	GS1-124K5.12	5.64	2.93e-08	4.96e-06	0.38	0.25	Diabetic kidney disease;	chr7:66594522	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1796220	ENSG00000232559.3	GS1-124K5.12	5.64	2.93e-08	4.96e-06	0.38	0.25	Diabetic kidney disease;	chr7:66597113	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs2707831	ENSG00000232559.3	GS1-124K5.12	5.64	2.93e-08	4.96e-06	0.38	0.25	Diabetic kidney disease;	chr7:66597524	chr7:66554588~66576923:-
THCA	cis	rs944289	0.774	rs1537423	ENSG00000258844.1	RP11-259K15.2	-5.64	2.93e-08	4.96e-06	-0.22	-0.25	Thyroid cancer;	chr14:36104863	chr14:36214607~36235608:+
THCA	cis	rs2129782	1	rs61320020	ENSG00000253553.4	RP11-586K2.1	5.64	2.93e-08	4.96e-06	0.43	0.25	Electrodermal activity;	chr8:88402415	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59030724	ENSG00000253553.4	RP11-586K2.1	5.64	2.93e-08	4.96e-06	0.43	0.25	Electrodermal activity;	chr8:88402473	chr8:88326836~88737134:+
THCA	cis	rs12893668	0.616	rs58033365	ENSG00000269910.1	RP11-73M18.10	5.64	2.93e-08	4.96e-06	0.24	0.25	Reticulocyte count;	chr14:103564564	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.645	rs12889403	ENSG00000269910.1	RP11-73M18.10	5.64	2.93e-08	4.96e-06	0.24	0.25	Reticulocyte count;	chr14:103568409	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.703	rs12894729	ENSG00000269910.1	RP11-73M18.10	5.64	2.93e-08	4.96e-06	0.24	0.25	Reticulocyte count;	chr14:103568955	chr14:103694516~103695050:-
THCA	cis	rs8177876	0.822	rs77475047	ENSG00000261061.1	RP11-303E16.2	-5.64	2.93e-08	4.96e-06	-0.38	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs55939311	ENSG00000261061.1	RP11-303E16.2	-5.64	2.93e-08	4.96e-06	-0.38	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs12444137	ENSG00000261061.1	RP11-303E16.2	-5.64	2.93e-08	4.96e-06	-0.38	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81030770~81031485:+
THCA	cis	rs2337406	0.866	rs7140974	ENSG00000211974.3	IGHV2-70	-5.64	2.94e-08	4.97e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106795976	chr14:106723574~106724093:-
THCA	cis	rs6430585	0.528	rs6743537	ENSG00000231890.6	DARS-AS1	-5.64	2.94e-08	4.97e-06	-0.29	-0.25	Corneal structure;	chr2:135945031	chr2:135985176~136022593:+
THCA	cis	rs2243480	1	rs313809	ENSG00000232546.1	RP11-458F8.1	-5.64	2.94e-08	4.97e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:66034996	chr7:66848496~66858136:+
THCA	cis	rs875971	0.638	rs10249404	ENSG00000273142.1	RP11-458F8.4	5.64	2.94e-08	4.97e-06	0.2	0.25	Aortic root size;	chr7:66581737	chr7:66902857~66906297:+
THCA	cis	rs853679	0.545	rs35949109	ENSG00000280107.1	AL022393.9	-5.64	2.94e-08	4.97e-06	-0.36	-0.25	Depression;	chr6:28058148	chr6:28170845~28172521:+
THCA	cis	rs7129556	0.737	rs72949616	ENSG00000254691.1	RP11-91P24.5	5.64	2.94e-08	4.97e-06	0.36	0.25	Weight loss (gastric bypass surgery);	chr11:77753325	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.737	rs72949618	ENSG00000254691.1	RP11-91P24.5	5.64	2.94e-08	4.97e-06	0.36	0.25	Weight loss (gastric bypass surgery);	chr11:77753485	chr11:77850604~77851511:+
THCA	cis	rs7129556	0.737	rs56218634	ENSG00000254691.1	RP11-91P24.5	5.64	2.94e-08	4.97e-06	0.36	0.25	Weight loss (gastric bypass surgery);	chr11:77753789	chr11:77850604~77851511:+
THCA	cis	rs2303759	0.874	rs8108669	ENSG00000268686.1	AC010524.2	-5.64	2.94e-08	4.97e-06	-0.36	-0.25	Multiple sclerosis;	chr19:49342638	chr19:49368705~49388081:-
THCA	cis	rs997295	0.57	rs7170299	ENSG00000270964.1	RP11-502I4.3	-5.64	2.94e-08	4.98e-06	-0.21	-0.25	Motion sickness;	chr15:67580380	chr15:67541072~67542604:-
THCA	cis	rs10808739	0.541	rs13255280	ENSG00000254006.4	RP11-1D12.2	-5.64	2.94e-08	4.98e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64773982	chr8:64801236~64817573:-
THCA	cis	rs10808739	0.614	rs35504769	ENSG00000254006.4	RP11-1D12.2	-5.64	2.94e-08	4.98e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64775431	chr8:64801236~64817573:-
THCA	cis	rs10808739	0.614	rs72656485	ENSG00000254006.4	RP11-1D12.2	-5.64	2.94e-08	4.98e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64776568	chr8:64801236~64817573:-
THCA	cis	rs10808739	0.614	rs34204608	ENSG00000254006.4	RP11-1D12.2	-5.64	2.94e-08	4.98e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64778944	chr8:64801236~64817573:-
THCA	cis	rs10808739	0.614	rs13259721	ENSG00000254006.4	RP11-1D12.2	-5.64	2.94e-08	4.98e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64783795	chr8:64801236~64817573:-
THCA	cis	rs10808739	0.614	rs62521150	ENSG00000254006.4	RP11-1D12.2	-5.64	2.94e-08	4.98e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64788589	chr8:64801236~64817573:-
THCA	cis	rs10808739	0.614	rs13263496	ENSG00000254006.4	RP11-1D12.2	-5.64	2.94e-08	4.98e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64788945	chr8:64801236~64817573:-
THCA	cis	rs10808739	0.535	rs13265049	ENSG00000254006.4	RP11-1D12.2	-5.64	2.94e-08	4.98e-06	-0.39	-0.25	HIV-1 susceptibility;	chr8:64789583	chr8:64801236~64817573:-
THCA	cis	rs3847687	0.565	rs11061293	ENSG00000279128.1	RP11-76C10.4	5.64	2.95e-08	4.98e-06	0.28	0.25	Longevity;	chr12:131035034	chr12:131022769~131024741:-
THCA	cis	rs9380516	0.686	rs9296157	ENSG00000228559.1	RP3-340B19.3	-5.64	2.95e-08	4.98e-06	-0.37	-0.25	Hepatitis C induced liver fibrosis;	chr6:35568875	chr6:35544632~35545669:+
THCA	cis	rs801193	1	rs4717319	ENSG00000273142.1	RP11-458F8.4	-5.64	2.95e-08	4.98e-06	-0.2	-0.25	Aortic root size;	chr7:66777606	chr7:66902857~66906297:+
THCA	cis	rs801193	0.904	rs4718403	ENSG00000273142.1	RP11-458F8.4	-5.64	2.95e-08	4.98e-06	-0.2	-0.25	Aortic root size;	chr7:66777742	chr7:66902857~66906297:+
THCA	cis	rs796395	0.641	rs3009935	ENSG00000228208.5	C1orf143	-5.64	2.95e-08	4.98e-06	-0.3	-0.25	Post bronchodilator FEV1/FVC ratio;	chr1:218489847	chr1:218510096~218525978:+
THCA	cis	rs17508449	0.819	rs17359378	ENSG00000232450.1	RP4-730K3.3	-5.64	2.95e-08	4.99e-06	-0.39	-0.25	Leprosy;	chr1:113674087	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.819	rs17274627	ENSG00000232450.1	RP4-730K3.3	-5.64	2.95e-08	4.99e-06	-0.39	-0.25	Leprosy;	chr1:113674773	chr1:113698884~113699631:-
THCA	cis	rs3820443	1	rs3820443	ENSG00000234020.1	CHIAP3	-5.64	2.95e-08	4.99e-06	-0.33	-0.25	Late-onset Alzheimer's disease;	chr1:111350283	chr1:111353275~111367409:-
THCA	cis	rs3820443	0.958	rs12033188	ENSG00000234020.1	CHIAP3	-5.64	2.95e-08	4.99e-06	-0.33	-0.25	Late-onset Alzheimer's disease;	chr1:111350372	chr1:111353275~111367409:-
THCA	cis	rs4639966	0.836	rs73001486	ENSG00000255239.1	AP002954.6	-5.64	2.96e-08	5e-06	-0.35	-0.25	Systemic lupus erythematosus;	chr11:118758655	chr11:118688039~118690600:-
THCA	cis	rs6121246	0.529	rs6060142	ENSG00000230613.1	HM13-AS1	5.64	2.96e-08	5e-06	0.31	0.25	Mean corpuscular hemoglobin;	chr20:31590225	chr20:31567707~31573263:-
THCA	cis	rs12612619	0.704	rs2119026	ENSG00000229122.1	AGBL5-IT1	-5.64	2.96e-08	5e-06	-0.18	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27087525	chr2:27061038~27061815:+
THCA	cis	rs7412746	0.658	rs4970986	ENSG00000231073.1	RP11-316M1.3	5.64	2.96e-08	5e-06	0.3	0.25	Melanoma;	chr1:150935479	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs59024312	ENSG00000231073.1	RP11-316M1.3	5.64	2.96e-08	5e-06	0.3	0.25	Melanoma;	chr1:150936529	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs7521719	ENSG00000231073.1	RP11-316M1.3	5.64	2.96e-08	5e-06	0.3	0.25	Melanoma;	chr1:150940658	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs7528773	ENSG00000231073.1	RP11-316M1.3	5.64	2.96e-08	5e-06	0.3	0.25	Melanoma;	chr1:150943399	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs3843843	ENSG00000231073.1	RP11-316M1.3	5.64	2.96e-08	5e-06	0.3	0.25	Melanoma;	chr1:150945608	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.634	rs2124952	ENSG00000231073.1	RP11-316M1.3	5.64	2.96e-08	5e-06	0.3	0.25	Melanoma;	chr1:150951298	chr1:150973123~150975534:+
THCA	cis	rs860295	0.557	rs10796941	ENSG00000160766.13	GBAP1	-5.64	2.96e-08	5.01e-06	-0.3	-0.25	Body mass index;	chr1:155314470	chr1:155213821~155227422:-
THCA	cis	rs79040073	0.607	rs73400205	ENSG00000259531.2	RP11-295H24.3	5.64	2.96e-08	5.01e-06	0.32	0.25	Lung cancer in ever smokers;	chr15:49442346	chr15:49365124~49366685:-
THCA	cis	rs4948275	0.742	rs2650707	ENSG00000237233.2	TMEM26-AS1	-5.64	2.96e-08	5.01e-06	-0.32	-0.25	Night sleep phenotypes;	chr10:61480725	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2650710	ENSG00000237233.2	TMEM26-AS1	-5.64	2.96e-08	5.01e-06	-0.32	-0.25	Night sleep phenotypes;	chr10:61483455	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.678	rs2650711	ENSG00000237233.2	TMEM26-AS1	-5.64	2.96e-08	5.01e-06	-0.32	-0.25	Night sleep phenotypes;	chr10:61483678	chr10:61452639~61481956:+
THCA	cis	rs2742234	0.794	rs17153156	ENSG00000273008.1	RP11-351D16.3	5.64	2.96e-08	5.01e-06	0.21	0.25	Hirschsprung disease;	chr10:43209189	chr10:43136824~43138334:-
THCA	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	5.64	2.96e-08	5.01e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	5.64	2.96e-08	5.01e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	5.64	2.96e-08	5.01e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	5.64	2.96e-08	5.01e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	5.64	2.96e-08	5.01e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
THCA	cis	rs11148252	0.811	rs9536030	ENSG00000235660.1	LINC00345	5.64	2.96e-08	5.01e-06	0.32	0.25	Lewy body disease;	chr13:52364156	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.875	rs9596651	ENSG00000235660.1	LINC00345	5.64	2.96e-08	5.01e-06	0.32	0.25	Lewy body disease;	chr13:52364447	chr13:52484161~52484680:-
THCA	cis	rs9880211	0.8	rs35100027	ENSG00000273486.1	RP11-731C17.2	5.64	2.96e-08	5.01e-06	0.27	0.25	Height;Body mass index;	chr3:136748719	chr3:136837338~136839021:-
THCA	cis	rs9813712	1	rs57804141	ENSG00000228252.7	COL6A4P2	5.64	2.96e-08	5.01e-06	0.29	0.25	Response to amphetamines;	chr3:130243669	chr3:130212823~130273806:+
THCA	cis	rs5758659	1	rs134882	ENSG00000270083.1	RP1-257I20.14	5.64	2.97e-08	5.02e-06	0.26	0.25	Cognitive function;	chr22:42274959	chr22:42089630~42090028:-
THCA	cis	rs7849973	0.581	rs62574662	ENSG00000224549.1	RP11-370B11.3	-5.64	2.97e-08	5.02e-06	-0.31	-0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22812202	chr9:22767175~22768316:+
THCA	cis	rs9990333	0.562	rs56038600	ENSG00000242086.7	LINC00969	5.64	2.97e-08	5.02e-06	0.26	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195658062~195739964:+
THCA	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-5.64	2.97e-08	5.02e-06	-0.24	-0.25	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
THCA	cis	rs875971	0.662	rs448725	ENSG00000223473.2	GS1-124K5.3	5.64	2.97e-08	5.02e-06	0.17	0.25	Aortic root size;	chr7:66049641	chr7:66491049~66493566:-
THCA	cis	rs17826219	0.585	rs8064302	ENSG00000264538.5	SUZ12P1	5.64	2.97e-08	5.03e-06	0.26	0.25	Body mass index;	chr17:30397920	chr17:30709299~30790908:+
THCA	cis	rs78487399	0.808	rs76684055	ENSG00000234936.1	AC010883.5	5.64	2.97e-08	5.03e-06	0.38	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43438804	chr2:43229573~43233394:+
THCA	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	5.64	2.98e-08	5.03e-06	0.38	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
THCA	cis	rs7824557	0.628	rs7815802	ENSG00000154316.13	TDH	-5.64	2.98e-08	5.03e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11333138	chr8:11339637~11368452:+
THCA	cis	rs172166	0.694	rs536704	ENSG00000226314.6	ZNF192P1	-5.64	2.98e-08	5.03e-06	-0.3	-0.25	Cardiac Troponin-T levels;	chr6:28124825	chr6:28161781~28169594:+
THCA	cis	rs7083	0.967	rs558590	ENSG00000254851.1	RP11-109L13.1	5.64	2.98e-08	5.03e-06	0.34	0.25	Blood protein levels;	chr11:117268405	chr11:117135528~117138582:+
THCA	cis	rs875971	0.965	rs28682868	ENSG00000223473.2	GS1-124K5.3	-5.64	2.98e-08	5.03e-06	-0.17	-0.25	Aortic root size;	chr7:66224822	chr7:66491049~66493566:-
THCA	cis	rs2617170	0.922	rs2733852	ENSG00000245648.1	RP11-277P12.20	-5.64	2.98e-08	5.04e-06	-0.27	-0.25	Behcet's disease;	chr12:10375969	chr12:10363769~10398506:+
THCA	cis	rs79040073	0.637	rs73392249	ENSG00000259531.2	RP11-295H24.3	5.64	2.98e-08	5.04e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49224264	chr15:49365124~49366685:-
THCA	cis	rs1499614	1	rs2659913	ENSG00000230295.1	RP11-458F8.2	-5.64	2.98e-08	5.04e-06	-0.31	-0.25	Gout;	chr7:66692349	chr7:66880708~66882981:+
THCA	cis	rs1499614	1	rs2659911	ENSG00000230295.1	RP11-458F8.2	-5.64	2.98e-08	5.04e-06	-0.31	-0.25	Gout;	chr7:66693433	chr7:66880708~66882981:+
THCA	cis	rs1499614	1	rs2707838	ENSG00000230295.1	RP11-458F8.2	-5.64	2.98e-08	5.04e-06	-0.31	-0.25	Gout;	chr7:66694214	chr7:66880708~66882981:+
THCA	cis	rs1499614	1	rs60326618	ENSG00000230295.1	RP11-458F8.2	-5.64	2.98e-08	5.04e-06	-0.31	-0.25	Gout;	chr7:66701371	chr7:66880708~66882981:+
THCA	cis	rs1499614	1	rs2707830	ENSG00000230295.1	RP11-458F8.2	-5.64	2.98e-08	5.04e-06	-0.31	-0.25	Gout;	chr7:66702658	chr7:66880708~66882981:+
THCA	cis	rs1499614	1	rs2707828	ENSG00000230295.1	RP11-458F8.2	-5.64	2.98e-08	5.04e-06	-0.31	-0.25	Gout;	chr7:66706390	chr7:66880708~66882981:+
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000230295.1	RP11-458F8.2	-5.64	2.98e-08	5.04e-06	-0.31	-0.25	Gout;	chr7:66710076	chr7:66880708~66882981:+
THCA	cis	rs1499614	1	rs2659903	ENSG00000230295.1	RP11-458F8.2	-5.64	2.98e-08	5.04e-06	-0.31	-0.25	Gout;	chr7:66715944	chr7:66880708~66882981:+
THCA	cis	rs9309473	0.5	rs4286298	ENSG00000163016.8	ALMS1P	-5.64	2.99e-08	5.05e-06	-0.33	-0.25	Metabolite levels;	chr2:73654981	chr2:73644919~73685576:+
THCA	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	5.64	2.99e-08	5.05e-06	0.28	0.25	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
THCA	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-5.64	2.99e-08	5.05e-06	-0.25	-0.25	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
THCA	cis	rs2439831	0.867	rs2255440	ENSG00000166763.7	STRCP1	5.64	2.99e-08	5.05e-06	0.34	0.25	Lung cancer in ever smokers;	chr15:43538269	chr15:43699488~43718184:-
THCA	cis	rs2212361	0.558	rs7934178	ENSG00000255893.1	RP11-685N10.1	-5.64	3e-08	5.07e-06	-0.28	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531307	chr11:94472908~94473570:-
THCA	cis	rs2212361	0.558	rs7934183	ENSG00000255893.1	RP11-685N10.1	-5.64	3e-08	5.07e-06	-0.28	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531321	chr11:94472908~94473570:-
THCA	cis	rs6600671	0.691	rs6600662	ENSG00000275538.1	RNVU1-19	5.64	3e-08	5.07e-06	0.33	0.25	Hip geometry;	chr1:121488992	chr1:120850819~120850985:-
THCA	cis	rs2029362	0.967	rs901926	ENSG00000245573.6	BDNF-AS	5.64	3e-08	5.07e-06	0.2	0.25	Total body bone mineral density;	chr11:27549006	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.935	rs1304101	ENSG00000245573.6	BDNF-AS	5.64	3e-08	5.07e-06	0.2	0.25	Total body bone mineral density;	chr11:27550047	chr11:27506838~27698174:+
THCA	cis	rs2029362	1	rs10835193	ENSG00000245573.6	BDNF-AS	5.64	3e-08	5.07e-06	0.2	0.25	Total body bone mineral density;	chr11:27550790	chr11:27506838~27698174:+
THCA	cis	rs4845570	1	rs7542898	ENSG00000203288.3	RP11-98D18.9	-5.64	3e-08	5.07e-06	-0.29	-0.25	Coronary artery disease;	chr1:151781146	chr1:151790804~151794402:+
THCA	cis	rs13287066	0.692	rs72743489	ENSG00000227603.1	RP11-165J3.6	5.64	3e-08	5.07e-06	0.26	0.25	Intelligence (multi-trait analysis);	chr9:93406201	chr9:93435332~93437121:-
THCA	cis	rs9381040	0.674	rs4711657	ENSG00000161912.16	ADCY10P1	5.64	3e-08	5.07e-06	0.17	0.25	Alzheimer's disease (late onset);	chr6:41194977	chr6:41101022~41140835:+
THCA	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	5.64	3.01e-08	5.08e-06	0.31	0.25	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
THCA	cis	rs2439831	0.702	rs3759791	ENSG00000166763.7	STRCP1	5.64	3.01e-08	5.08e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43798600	chr15:43699488~43718184:-
THCA	cis	rs853679	0.607	rs35902873	ENSG00000226314.6	ZNF192P1	-5.64	3.01e-08	5.08e-06	-0.55	-0.25	Depression;	chr6:28091171	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13197574	ENSG00000226314.6	ZNF192P1	-5.64	3.01e-08	5.08e-06	-0.55	-0.25	Depression;	chr6:28092461	chr6:28161781~28169594:+
THCA	cis	rs792448	0.743	rs1774249	ENSG00000226251.4	RP11-15I11.3	-5.64	3.01e-08	5.09e-06	-0.32	-0.25	White blood cell count (basophil);	chr1:212342271	chr1:212225278~212238977:-
THCA	cis	rs7246657	0.678	rs2927740	ENSG00000276846.1	CTD-3220F14.3	-5.64	3.01e-08	5.09e-06	-0.25	-0.25	Coronary artery calcification;	chr19:37650065	chr19:37314868~37315620:-
THCA	cis	rs78487399	0.71	rs74382177	ENSG00000234936.1	AC010883.5	5.64	3.02e-08	5.09e-06	0.38	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43300918	chr2:43229573~43233394:+
THCA	cis	rs7403037	0.583	rs4778296	ENSG00000259905.4	PWRN1	5.64	3.02e-08	5.09e-06	0.26	0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24373429	chr15:24493137~24652130:+
THCA	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	5.64	3.02e-08	5.09e-06	0.14	0.25	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
THCA	cis	rs55665837	0.539	rs10766196	ENSG00000251991.1	RNU7-49P	5.64	3.02e-08	5.09e-06	0.27	0.25	Vitamin D levels;	chr11:14891585	chr11:14478892~14478953:+
THCA	cis	rs7166081	0.672	rs12441715	ENSG00000270964.1	RP11-502I4.3	-5.64	3.02e-08	5.1e-06	-0.22	-0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67568249	chr15:67541072~67542604:-
THCA	cis	rs78487399	0.808	rs17406646	ENSG00000234936.1	AC010883.5	5.64	3.02e-08	5.1e-06	0.38	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451478	chr2:43229573~43233394:+
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	5.64	3.02e-08	5.1e-06	0.23	0.25	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
THCA	cis	rs75422866	0.558	rs73104190	ENSG00000276691.1	RP5-1057I20.5	5.63	3.02e-08	5.1e-06	0.43	0.25	Pneumonia;	chr12:47716040	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.51	rs73104197	ENSG00000276691.1	RP5-1057I20.5	5.63	3.02e-08	5.1e-06	0.43	0.25	Pneumonia;	chr12:47717273	chr12:47788426~47788971:+
THCA	cis	rs6908034	0.556	rs7750703	ENSG00000227116.1	RP3-471C18.1	-5.63	3.02e-08	5.1e-06	-0.4	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19730427~19734567:-
THCA	cis	rs9910055	0.762	rs4239142	ENSG00000267080.4	ASB16-AS1	5.63	3.02e-08	5.1e-06	0.23	0.25	Total body bone mineral density;	chr17:44128508	chr17:44175973~44186717:-
THCA	cis	rs875971	1	rs6963646	ENSG00000223473.2	GS1-124K5.3	-5.63	3.02e-08	5.1e-06	-0.17	-0.25	Aortic root size;	chr7:66220780	chr7:66491049~66493566:-
THCA	cis	rs1400745	0.756	rs3783316	ENSG00000258738.1	RP11-73E17.2	5.63	3.03e-08	5.11e-06	0.3	0.25	Monocyte count;	chr14:34867986	chr14:34874343~34876459:+
THCA	cis	rs1400745	0.756	rs3783314	ENSG00000258738.1	RP11-73E17.2	5.63	3.03e-08	5.11e-06	0.3	0.25	Monocyte count;	chr14:34868178	chr14:34874343~34876459:+
THCA	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	5.63	3.03e-08	5.11e-06	0.23	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
THCA	cis	rs1552244	1	rs6768102	ENSG00000180385.7	EMC3-AS1	5.63	3.03e-08	5.11e-06	0.27	0.25	Alzheimer's disease;	chr3:10107696	chr3:9986893~10006990:+
THCA	cis	rs4950322	0.857	rs55790545	ENSG00000278811.3	LINC00624	5.63	3.03e-08	5.11e-06	0.32	0.25	Protein quantitative trait loci;	chr1:147366649	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.857	rs7522219	ENSG00000278811.3	LINC00624	5.63	3.03e-08	5.11e-06	0.32	0.25	Protein quantitative trait loci;	chr1:147366904	chr1:147258885~147517875:-
THCA	cis	rs2303759	0.918	rs4802597	ENSG00000268686.1	AC010524.2	-5.63	3.03e-08	5.11e-06	-0.35	-0.25	Multiple sclerosis;	chr19:49368828	chr19:49368705~49388081:-
THCA	cis	rs3743266	0.613	rs1869485	ENSG00000245534.5	RORA-AS1	5.63	3.03e-08	5.11e-06	0.27	0.25	Menarche (age at onset);	chr15:60454406	chr15:60479178~60630637:+
THCA	cis	rs1552244	1	rs6442146	ENSG00000232901.1	CYCSP10	5.63	3.03e-08	5.12e-06	0.33	0.25	Alzheimer's disease;	chr3:10031860	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs6442148	ENSG00000232901.1	CYCSP10	5.63	3.03e-08	5.12e-06	0.33	0.25	Alzheimer's disease;	chr3:10036605	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs2160869	ENSG00000232901.1	CYCSP10	5.63	3.03e-08	5.12e-06	0.33	0.25	Alzheimer's disease;	chr3:10037571	chr3:10000647~10000940:-
THCA	cis	rs6931421	1	rs6931421	ENSG00000272129.1	RP11-250B2.6	5.63	3.03e-08	5.12e-06	0.33	0.25	Sitting height ratio;	chr6:80170421	chr6:80355424~80356859:+
THCA	cis	rs8062405	1	rs2008514	ENSG00000278665.1	RP11-666O2.4	-5.63	3.03e-08	5.12e-06	-0.27	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28599241~28601881:-
THCA	cis	rs4948275	0.679	rs10994772	ENSG00000237233.2	TMEM26-AS1	-5.63	3.04e-08	5.12e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61456117	chr10:61452639~61481956:+
THCA	cis	rs2303319	0.504	rs56121938	ENSG00000227403.1	AC009299.3	5.63	3.04e-08	5.13e-06	0.57	0.25	Cognitive function;	chr2:161441138	chr2:161244739~161249050:+
THCA	cis	rs9381040	0.599	rs2057001	ENSG00000161912.16	ADCY10P1	5.63	3.04e-08	5.13e-06	0.17	0.25	Alzheimer's disease (late onset);	chr6:41055208	chr6:41101022~41140835:+
THCA	cis	rs964184	0.63	rs1558861	ENSG00000254851.1	RP11-109L13.1	-5.63	3.04e-08	5.13e-06	-0.5	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116736721	chr11:117135528~117138582:+
THCA	cis	rs853679	0.607	rs67340775	ENSG00000226314.6	ZNF192P1	-5.63	3.04e-08	5.13e-06	-0.54	-0.25	Depression;	chr6:28336607	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs35030260	ENSG00000226314.6	ZNF192P1	-5.63	3.04e-08	5.13e-06	-0.54	-0.25	Depression;	chr6:28337731	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13217619	ENSG00000226314.6	ZNF192P1	-5.63	3.04e-08	5.13e-06	-0.54	-0.25	Depression;	chr6:28338894	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs35016036	ENSG00000226314.6	ZNF192P1	-5.63	3.04e-08	5.13e-06	-0.54	-0.25	Depression;	chr6:28347103	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs35744819	ENSG00000226314.6	ZNF192P1	-5.63	3.04e-08	5.13e-06	-0.54	-0.25	Depression;	chr6:28350554	chr6:28161781~28169594:+
THCA	cis	rs9307551	0.948	rs4389603	ENSG00000250334.4	LINC00989	-5.63	3.04e-08	5.13e-06	-0.32	-0.25	Refractive error;	chr4:79567720	chr4:79492416~79576460:+
THCA	cis	rs2163813	1	rs56093876	ENSG00000275540.1	CTC-559E9.12	-5.63	3.04e-08	5.14e-06	-0.31	-0.25	Toenail selenium levels;	chr19:19708306	chr19:19740884~19750127:+
THCA	cis	rs2163813	1	rs1061270	ENSG00000275540.1	CTC-559E9.12	-5.63	3.04e-08	5.14e-06	-0.31	-0.25	Toenail selenium levels;	chr19:19710558	chr19:19740884~19750127:+
THCA	cis	rs150992	0.505	rs167798	ENSG00000248489.1	CTD-2007H13.3	5.63	3.05e-08	5.14e-06	0.27	0.25	Body mass index;	chr5:98972150	chr5:98929171~98995013:+
THCA	cis	rs7976269	0.609	rs10771475	ENSG00000275476.1	RP11-996F15.4	-5.63	3.05e-08	5.14e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29071077	chr12:29277397~29277882:-
THCA	cis	rs2439831	0.867	rs2412780	ENSG00000275601.1	AC011330.13	-5.63	3.05e-08	5.14e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43363596	chr15:43642389~43643023:-
THCA	cis	rs12549025	0.536	rs9644077	ENSG00000253390.1	CTC-756D1.2	-5.63	3.05e-08	5.14e-06	-0.42	-0.25	Reticulocyte fraction of red cells;	chr8:23502819	chr8:23458601~23484971:+
THCA	cis	rs2835345	0.596	rs12482138	ENSG00000230479.1	AP000695.6	5.63	3.05e-08	5.15e-06	0.3	0.25	Pulmonary function;	chr21:36451608	chr21:36430360~36481070:+
THCA	cis	rs2163813	1	rs2013561	ENSG00000275540.1	CTC-559E9.12	-5.63	3.05e-08	5.15e-06	-0.3	-0.25	Toenail selenium levels;	chr19:19715368	chr19:19740884~19750127:+
THCA	cis	rs2163813	0.959	rs12984272	ENSG00000275540.1	CTC-559E9.12	-5.63	3.05e-08	5.15e-06	-0.3	-0.25	Toenail selenium levels;	chr19:19716071	chr19:19740884~19750127:+
THCA	cis	rs2163813	1	rs36006965	ENSG00000275540.1	CTC-559E9.12	-5.63	3.05e-08	5.15e-06	-0.3	-0.25	Toenail selenium levels;	chr19:19719242	chr19:19740884~19750127:+
THCA	cis	rs2163813	1	rs12982273	ENSG00000275540.1	CTC-559E9.12	-5.63	3.05e-08	5.15e-06	-0.3	-0.25	Toenail selenium levels;	chr19:19719335	chr19:19740884~19750127:+
THCA	cis	rs3758785	0.512	rs75719210	ENSG00000255893.1	RP11-685N10.1	-5.63	3.05e-08	5.15e-06	-0.32	-0.25	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94368599	chr11:94472908~94473570:-
THCA	cis	rs6445975	0.726	rs7616659	ENSG00000272360.1	RP11-359I18.5	-5.63	3.05e-08	5.15e-06	-0.27	-0.25	Systemic lupus erythematosus;	chr3:58481860	chr3:58490830~58491291:-
THCA	cis	rs17345786	0.861	rs74768235	ENSG00000256628.3	ZBTB11-AS1	5.63	3.05e-08	5.15e-06	0.32	0.25	Colonoscopy-negative controls vs population controls;	chr3:101423977	chr3:101676475~101679217:+
THCA	cis	rs6545883	1	rs6742276	ENSG00000270820.4	RP11-355B11.2	5.63	3.05e-08	5.15e-06	0.21	0.25	Tuberculosis;	chr2:61541610	chr2:61471188~61484130:+
THCA	cis	rs28735056	0.565	rs12957336	ENSG00000261126.6	RP11-795F19.1	-5.63	3.05e-08	5.15e-06	-0.2	-0.25	Schizophrenia;	chr18:79956889	chr18:80046900~80095482:+
THCA	cis	rs317689	0.684	rs315125	ENSG00000274979.1	RP11-1143G9.5	-5.63	3.06e-08	5.15e-06	-0.3	-0.25	Response to diuretic therapy;	chr12:69365104	chr12:69326574~69331882:-
THCA	cis	rs849141	0.857	rs1708299	ENSG00000234336.5	JAZF1-AS1	-5.63	3.06e-08	5.15e-06	-0.29	-0.25	Height;Hip circumference adjusted for BMI;	chr7:28150327	chr7:28180322~28243917:+
THCA	cis	rs1125355	0.622	rs11678112	ENSG00000251491.2	OR7E28P	-5.63	3.06e-08	5.15e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158756825	chr2:158862311~158863285:+
THCA	cis	rs1125355	0.622	rs10497201	ENSG00000251491.2	OR7E28P	-5.63	3.06e-08	5.15e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158757632	chr2:158862311~158863285:+
THCA	cis	rs1125355	0.622	rs1515921	ENSG00000251491.2	OR7E28P	-5.63	3.06e-08	5.15e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158759156	chr2:158862311~158863285:+
THCA	cis	rs1125355	0.622	rs1515920	ENSG00000251491.2	OR7E28P	-5.63	3.06e-08	5.15e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158759252	chr2:158862311~158863285:+
THCA	cis	rs2562456	0.755	rs2914646	ENSG00000268081.1	RP11-678G14.2	-5.63	3.06e-08	5.16e-06	-0.37	-0.25	Pain;	chr19:21454359	chr19:21554640~21569237:-
THCA	cis	rs9878978	0.722	rs17014540	ENSG00000237990.3	CNTN4-AS1	5.63	3.06e-08	5.16e-06	0.27	0.25	Blood pressure (smoking interaction);	chr3:2452358	chr3:3039033~3069242:-
THCA	cis	rs12761761	0.744	rs12769669	ENSG00000279982.1	RP11-45A17.3	-5.63	3.06e-08	5.16e-06	-0.42	-0.25	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131992356	chr10:131996738~131999846:+
THCA	cis	rs997295	0.513	rs11635495	ENSG00000270964.1	RP11-502I4.3	-5.63	3.06e-08	5.16e-06	-0.21	-0.25	Motion sickness;	chr15:67512344	chr15:67541072~67542604:-
THCA	cis	rs9625935	0.957	rs12167333	ENSG00000279159.1	RP3-394A18.1	5.63	3.06e-08	5.16e-06	0.19	0.25	Tonsillectomy;	chr22:30179823	chr22:29978950~30028236:-
THCA	cis	rs2303319	0.504	rs62189008	ENSG00000227403.1	AC009299.3	5.63	3.06e-08	5.16e-06	0.53	0.25	Cognitive function;	chr2:161717926	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72875596	ENSG00000227403.1	AC009299.3	5.63	3.06e-08	5.16e-06	0.53	0.25	Cognitive function;	chr2:161718547	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72875598	ENSG00000227403.1	AC009299.3	5.63	3.06e-08	5.16e-06	0.53	0.25	Cognitive function;	chr2:161718586	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189009	ENSG00000227403.1	AC009299.3	5.63	3.06e-08	5.16e-06	0.53	0.25	Cognitive function;	chr2:161718668	chr2:161244739~161249050:+
THCA	cis	rs6951245	0.882	rs10252404	ENSG00000229043.2	AC091729.9	-5.63	3.06e-08	5.16e-06	-0.41	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1160374~1165267:+
THCA	cis	rs10895275	0.625	rs11225153	ENSG00000277459.1	RP11-732A21.3	-5.63	3.06e-08	5.16e-06	-0.19	-0.25	Migraine;	chr11:102171568	chr11:102109827~102110457:-
THCA	cis	rs2289700	0.518	rs77362013	ENSG00000252061.1	RNU6-415P	-5.63	3.06e-08	5.17e-06	-0.41	-0.25	Bipolar disorder;	chr15:78874918	chr15:78898840~78898936:-
THCA	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-5.63	3.06e-08	5.17e-06	-0.32	-0.25	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
THCA	cis	rs2732480	0.557	rs2409004	ENSG00000240399.1	RP1-228P16.1	5.63	3.06e-08	5.17e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.577	rs2450994	ENSG00000240399.1	RP1-228P16.1	5.63	3.06e-08	5.17e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48054813~48055591:-
THCA	cis	rs1501911	0.566	rs709388	ENSG00000248489.1	CTD-2007H13.3	5.63	3.07e-08	5.17e-06	0.26	0.25	Lung function (FEV1/FVC);	chr5:98994037	chr5:98929171~98995013:+
THCA	cis	rs7727544	0.684	rs272889	ENSG00000224431.1	AC063976.7	5.63	3.07e-08	5.17e-06	0.22	0.25	Blood metabolite levels;	chr5:132329685	chr5:132199456~132203487:+
THCA	cis	rs6142102	0.812	rs6059574	ENSG00000275784.1	RP5-1125A11.6	5.63	3.07e-08	5.17e-06	0.25	0.25	Skin pigmentation;	chr20:33935366	chr20:33989480~33991818:-
THCA	cis	rs78487399	0.614	rs74907855	ENSG00000234936.1	AC010883.5	5.63	3.07e-08	5.17e-06	0.36	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43529062	chr2:43229573~43233394:+
THCA	cis	rs12935418	0.616	rs2549863	ENSG00000278985.1	RP11-303E16.9	-5.63	3.07e-08	5.18e-06	-0.27	-0.25	Mean corpuscular volume;	chr16:80995762	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.616	rs1469123	ENSG00000278985.1	RP11-303E16.9	-5.63	3.07e-08	5.18e-06	-0.27	-0.25	Mean corpuscular volume;	chr16:80995944	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs1469124	ENSG00000278985.1	RP11-303E16.9	-5.63	3.07e-08	5.18e-06	-0.27	-0.25	Mean corpuscular volume;	chr16:80996049	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs1469125	ENSG00000278985.1	RP11-303E16.9	-5.63	3.07e-08	5.18e-06	-0.27	-0.25	Mean corpuscular volume;	chr16:80996163	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.523	rs1469126	ENSG00000278985.1	RP11-303E16.9	-5.63	3.07e-08	5.18e-06	-0.27	-0.25	Mean corpuscular volume;	chr16:80996284	chr16:80982319~80984094:-
THCA	cis	rs853679	0.607	rs35749575	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28147040	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs72846780	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28151277	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13205911	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28156336	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13197176	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28161454	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs13201308	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28162311	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34765154	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28162672	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs34505829	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28165461	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs35098436	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28166443	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs72846794	ENSG00000226314.6	ZNF192P1	-5.63	3.07e-08	5.18e-06	-0.56	-0.25	Depression;	chr6:28169721	chr6:28161781~28169594:+
THCA	cis	rs11089937	0.626	rs2213161	ENSG00000211639.2	IGLV4-60	5.63	3.08e-08	5.19e-06	0.2	0.25	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22162199~22162681:+
THCA	cis	rs6860806	0.603	rs112300250	ENSG00000233006.5	AC034220.3	5.63	3.08e-08	5.19e-06	0.19	0.25	Breast cancer;	chr5:132247599	chr5:132311285~132369916:-
THCA	cis	rs9813712	0.585	rs16824839	ENSG00000228252.7	COL6A4P2	-5.63	3.08e-08	5.19e-06	-0.32	-0.25	Response to amphetamines;	chr3:130220886	chr3:130212823~130273806:+
THCA	cis	rs55823223	0.564	rs2034947	ENSG00000267801.1	RP11-552F3.9	5.63	3.08e-08	5.2e-06	0.33	0.25	Psoriasis;	chr17:75867848	chr17:75876372~75879546:+
THCA	cis	rs7202877	0.656	rs4888374	ENSG00000261783.1	RP11-252K23.2	-5.63	3.08e-08	5.2e-06	-0.44	-0.25	Type 1 diabetes;Type 2 diabetes;	chr16:75288330	chr16:75379818~75381260:-
THCA	cis	rs4948275	0.742	rs2650694	ENSG00000237233.2	TMEM26-AS1	-5.63	3.08e-08	5.2e-06	-0.34	-0.25	Night sleep phenotypes;	chr10:61527069	chr10:61452639~61481956:+
THCA	cis	rs67340775	0.541	rs200968	ENSG00000280107.1	AL022393.9	-5.63	3.08e-08	5.2e-06	-0.34	-0.25	Lung cancer in ever smokers;	chr6:27891790	chr6:28170845~28172521:+
THCA	cis	rs3213758	1	rs12597693	ENSG00000275191.1	RP11-36I17.2	-5.63	3.08e-08	5.2e-06	-0.5	-0.25	Vitiligo (non-segmental);	chr16:53537558	chr16:53628256~53628816:-
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000280069.1	CTD-2349P21.3	-5.63	3.08e-08	5.2e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30738182~30740275:+
THCA	cis	rs12893668	0.645	rs35229468	ENSG00000269940.1	RP11-73M18.7	5.63	3.09e-08	5.2e-06	0.27	0.25	Reticulocyte count;	chr14:103585720	chr14:103694560~103695170:+
THCA	cis	rs7267979	0.565	rs4815437	ENSG00000125804.12	FAM182A	5.63	3.09e-08	5.2e-06	0.33	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26054655~26086917:+
THCA	cis	rs801193	1	rs2055682	ENSG00000273142.1	RP11-458F8.4	-5.63	3.09e-08	5.2e-06	-0.2	-0.25	Aortic root size;	chr7:66795302	chr7:66902857~66906297:+
THCA	cis	rs453301	0.538	rs7830804	ENSG00000254340.1	RP11-10A14.3	-5.63	3.09e-08	5.21e-06	-0.27	-0.25	Joint mobility (Beighton score);	chr8:9113252	chr8:9141424~9145435:+
THCA	cis	rs12899811	0.53	rs11073967	ENSG00000214432.8	AC068831.10	-5.63	3.09e-08	5.21e-06	-0.28	-0.25	Type 2 diabetes;	chr15:91022574	chr15:91022619~91036611:+
THCA	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	5.63	3.09e-08	5.21e-06	0.27	0.25	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
THCA	cis	rs7829975	0.714	rs60315134	ENSG00000254153.1	CTA-398F10.2	-5.63	3.09e-08	5.21e-06	-0.27	-0.25	Mood instability;	chr8:8813089	chr8:8456909~8461337:-
THCA	cis	rs2212361	0.558	rs56365771	ENSG00000255893.1	RP11-685N10.1	-5.63	3.09e-08	5.21e-06	-0.31	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94529586	chr11:94472908~94473570:-
THCA	cis	rs6968419	0.674	rs17138528	ENSG00000237870.5	AC073130.1	5.63	3.09e-08	5.21e-06	0.28	0.25	Intraocular pressure;	chr7:116267235	chr7:116275606~116286734:-
THCA	cis	rs4664293	0.667	rs3815876	ENSG00000226266.5	AC009961.3	-5.63	3.09e-08	5.21e-06	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159783640	chr2:159670708~159712435:-
THCA	cis	rs12893668	0.703	rs34186780	ENSG00000269940.1	RP11-73M18.7	5.63	3.09e-08	5.21e-06	0.27	0.25	Reticulocyte count;	chr14:103561258	chr14:103694560~103695170:+
THCA	cis	rs78487399	0.71	rs76215753	ENSG00000234936.1	AC010883.5	5.63	3.09e-08	5.21e-06	0.39	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43370003	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs79629200	ENSG00000234936.1	AC010883.5	5.63	3.09e-08	5.21e-06	0.39	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43375793	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs74469180	ENSG00000234936.1	AC010883.5	5.63	3.09e-08	5.21e-06	0.39	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43376228	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs78314405	ENSG00000234936.1	AC010883.5	5.63	3.09e-08	5.21e-06	0.39	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43377602	chr2:43229573~43233394:+
THCA	cis	rs10875746	0.855	rs10875731	ENSG00000269514.1	RP11-370I10.12	5.63	3.09e-08	5.21e-06	0.26	0.25	Longevity (90 years and older);	chr12:48038960	chr12:48198387~48202031:+
THCA	cis	rs2129782	1	rs7006506	ENSG00000253553.4	RP11-586K2.1	5.63	3.09e-08	5.21e-06	0.43	0.25	Electrodermal activity;	chr8:88413873	chr8:88326836~88737134:+
THCA	cis	rs5758659	0.904	rs5758653	ENSG00000270083.1	RP1-257I20.14	5.63	3.09e-08	5.22e-06	0.27	0.25	Cognitive function;	chr22:42217479	chr22:42089630~42090028:-
THCA	cis	rs13256369	0.802	rs11249884	ENSG00000253893.2	FAM85B	5.63	3.1e-08	5.22e-06	0.34	0.25	Obesity-related traits;	chr8:8704042	chr8:8167819~8226614:-
THCA	cis	rs12478296	1	rs12474070	ENSG00000261186.2	RP11-341N2.1	-5.63	3.1e-08	5.22e-06	-0.4	-0.25	Obesity-related traits;	chr2:242097587	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs56102931	ENSG00000261186.2	RP11-341N2.1	-5.63	3.1e-08	5.22e-06	-0.4	-0.25	Obesity-related traits;	chr2:242097785	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs55732177	ENSG00000261186.2	RP11-341N2.1	-5.63	3.1e-08	5.22e-06	-0.4	-0.25	Obesity-related traits;	chr2:242097855	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs55758933	ENSG00000261186.2	RP11-341N2.1	-5.63	3.1e-08	5.22e-06	-0.4	-0.25	Obesity-related traits;	chr2:242098138	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs55717005	ENSG00000261186.2	RP11-341N2.1	-5.63	3.1e-08	5.22e-06	-0.4	-0.25	Obesity-related traits;	chr2:242098920	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs55814222	ENSG00000261186.2	RP11-341N2.1	-5.63	3.1e-08	5.22e-06	-0.4	-0.25	Obesity-related traits;	chr2:242099015	chr2:242087351~242088457:-
THCA	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-5.63	3.1e-08	5.22e-06	-0.32	-0.25	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
THCA	cis	rs12681287	0.608	rs2953511	ENSG00000254231.1	CTD-2284J15.1	5.63	3.1e-08	5.22e-06	0.27	0.25	Caudate activity during reward;	chr8:86328641	chr8:86333274~86343314:-
THCA	cis	rs11089937	0.54	rs2329931	ENSG00000211638.2	IGLV8-61	-5.63	3.1e-08	5.22e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.568	rs2876996	ENSG00000211638.2	IGLV8-61	-5.63	3.1e-08	5.22e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22098700~22099212:+
THCA	cis	rs863750	0.721	rs1716393	ENSG00000275389.1	RP11-214K3.24	5.63	3.1e-08	5.22e-06	0.33	0.25	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124075909	chr12:124085761~124088598:+
THCA	cis	rs863750	0.687	rs1716394	ENSG00000275389.1	RP11-214K3.24	5.63	3.1e-08	5.22e-06	0.33	0.25	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124075910	chr12:124085761~124088598:+
THCA	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-5.63	3.1e-08	5.23e-06	-0.43	-0.25	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
THCA	cis	rs2129782	1	rs10102505	ENSG00000253553.4	RP11-586K2.1	5.63	3.11e-08	5.23e-06	0.43	0.25	Electrodermal activity;	chr8:88404186	chr8:88326836~88737134:+
THCA	cis	rs1383484	0.64	rs12101685	ENSG00000225151.9	GOLGA2P7	5.63	3.11e-08	5.23e-06	0.32	0.25	Height;	chr15:83974905	chr15:84199311~84230136:-
THCA	cis	rs4968361	0.892	rs68025251	ENSG00000266992.1	DHX40P1	5.63	3.11e-08	5.23e-06	0.42	0.25	Schizophrenia;	chr17:59442071	chr17:59976009~60002384:-
THCA	cis	rs17772222	0.917	rs61977053	ENSG00000222990.1	RNU4-22P	5.63	3.11e-08	5.24e-06	0.34	0.25	Coronary artery calcification;	chr14:88380876	chr14:88513498~88513663:+
THCA	cis	rs2439831	0.85	rs7169988	ENSG00000166763.7	STRCP1	5.63	3.11e-08	5.24e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43768237	chr15:43699488~43718184:-
THCA	cis	rs2559856	1	rs10860771	ENSG00000274560.1	RP11-285E23.2	5.63	3.11e-08	5.24e-06	0.15	0.25	Blood protein levels;	chr12:101693464	chr12:101696002~101696450:-
THCA	cis	rs7809950	0.678	rs2237661	ENSG00000238832.1	snoU109	-5.63	3.11e-08	5.24e-06	-0.3	-0.25	Coronary artery disease;	chr7:107222678	chr7:107603363~107603507:+
THCA	cis	rs79040073	0.637	rs35692325	ENSG00000259531.2	RP11-295H24.3	5.63	3.11e-08	5.24e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49316062	chr15:49365124~49366685:-
THCA	cis	rs12594515	0.548	rs55932467	ENSG00000259200.1	RP11-718O11.1	-5.63	3.11e-08	5.24e-06	-0.36	-0.25	Weight;Waist circumference;	chr15:45704926	chr15:45705078~45931069:+
THCA	cis	rs4713118	0.513	rs149954	ENSG00000226314.6	ZNF192P1	-5.63	3.11e-08	5.24e-06	-0.3	-0.25	Parkinson's disease;	chr6:28067468	chr6:28161781~28169594:+
THCA	cis	rs8062405	0.721	rs151181	ENSG00000278665.1	RP11-666O2.4	5.63	3.11e-08	5.25e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28599241~28601881:-
THCA	cis	rs2212361	0.527	rs7931179	ENSG00000255893.1	RP11-685N10.1	-5.63	3.12e-08	5.25e-06	-0.28	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531037	chr11:94472908~94473570:-
THCA	cis	rs2212361	0.558	rs7934286	ENSG00000255893.1	RP11-685N10.1	-5.63	3.12e-08	5.25e-06	-0.28	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531347	chr11:94472908~94473570:-
THCA	cis	rs9393777	0.764	rs35565446	ENSG00000226314.6	ZNF192P1	-5.63	3.12e-08	5.25e-06	-0.56	-0.25	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28161781~28169594:+
THCA	cis	rs7412746	0.658	rs12090215	ENSG00000231073.1	RP11-316M1.3	5.63	3.12e-08	5.25e-06	0.3	0.25	Melanoma;	chr1:150921184	chr1:150973123~150975534:+
THCA	cis	rs4689592	0.587	rs6825954	ENSG00000245468.3	RP11-367J11.3	5.63	3.12e-08	5.25e-06	0.21	0.25	Monocyte percentage of white cells;	chr4:7072499	chr4:7094571~7103385:-
THCA	cis	rs1552244	1	rs6414438	ENSG00000180385.7	EMC3-AS1	5.63	3.12e-08	5.25e-06	0.27	0.25	Alzheimer's disease;	chr3:10032140	chr3:9986893~10006990:+
THCA	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	5.63	3.12e-08	5.26e-06	0.43	0.25	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
THCA	cis	rs7617773	1	rs9832957	ENSG00000199476.1	Y_RNA	5.63	3.13e-08	5.27e-06	0.32	0.25	Coronary artery disease;	chr3:48143776	chr3:48288587~48288694:+
THCA	cis	rs2243480	1	rs2533288	ENSG00000230295.1	RP11-458F8.2	-5.63	3.13e-08	5.27e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66591724	chr7:66880708~66882981:+
THCA	cis	rs6908034	0.607	rs12527834	ENSG00000237404.1	RP3-471C18.2	-5.63	3.13e-08	5.27e-06	-0.54	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821550	chr6:19689825~19753113:-
THCA	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	5.63	3.13e-08	5.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	5.63	3.13e-08	5.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	5.63	3.13e-08	5.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	5.63	3.13e-08	5.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
THCA	cis	rs6545883	0.965	rs6545872	ENSG00000270820.4	RP11-355B11.2	5.63	3.13e-08	5.27e-06	0.21	0.25	Tuberculosis;	chr2:61497433	chr2:61471188~61484130:+
THCA	cis	rs7083	1	rs512188	ENSG00000254851.1	RP11-109L13.1	-5.63	3.13e-08	5.27e-06	-0.34	-0.25	Blood protein levels;	chr11:117255994	chr11:117135528~117138582:+
THCA	cis	rs7083	0.935	rs529470	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117262092	chr11:117135528~117138582:+
THCA	cis	rs7083	0.935	rs529471	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117262093	chr11:117135528~117138582:+
THCA	cis	rs7083	0.935	rs7111678	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117265090	chr11:117135528~117138582:+
THCA	cis	rs7083	1	rs2509210	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117265354	chr11:117135528~117138582:+
THCA	cis	rs7083	1	rs507880	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117266539	chr11:117135528~117138582:+
THCA	cis	rs7083	0.935	rs2509211	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117266917	chr11:117135528~117138582:+
THCA	cis	rs7083	1	rs524085	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117266931	chr11:117135528~117138582:+
THCA	cis	rs7083	1	rs673738	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117272865	chr11:117135528~117138582:+
THCA	cis	rs7083	1	rs495438	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117274011	chr11:117135528~117138582:+
THCA	cis	rs7083	0.935	rs492151	ENSG00000254851.1	RP11-109L13.1	5.63	3.13e-08	5.27e-06	0.34	0.25	Blood protein levels;	chr11:117275099	chr11:117135528~117138582:+
THCA	cis	rs7809615	0.515	rs11772470	ENSG00000244219.5	GS1-259H13.2	-5.63	3.13e-08	5.27e-06	-0.3	-0.25	Blood metabolite ratios;	chr7:99583473	chr7:99598066~99610813:+
THCA	cis	rs442309	0.841	rs224030	ENSG00000238280.1	RP11-436D10.3	-5.63	3.13e-08	5.27e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62760375	chr10:62793562~62805887:-
THCA	cis	rs7078012	0.504	rs10400059	ENSG00000225484.5	NUTM2B-AS1	-5.63	3.13e-08	5.27e-06	-0.57	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79920782	chr10:79663088~79826594:-
THCA	cis	rs7824557	0.627	rs7838897	ENSG00000154316.13	TDH	-5.63	3.13e-08	5.27e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11349817	chr8:11339637~11368452:+
THCA	cis	rs875971	0.965	rs6971509	ENSG00000223473.2	GS1-124K5.3	-5.63	3.13e-08	5.27e-06	-0.17	-0.25	Aortic root size;	chr7:66249983	chr7:66491049~66493566:-
THCA	cis	rs67981189	0.501	rs2810104	ENSG00000269927.1	RP6-91H8.3	5.63	3.14e-08	5.28e-06	0.3	0.25	Schizophrenia;	chr14:70958096	chr14:71141125~71143253:-
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000280069.1	CTD-2349P21.3	-5.63	3.14e-08	5.28e-06	-0.38	-0.25	Body mass index;	chr17:30778787	chr17:30738182~30740275:+
THCA	cis	rs9381040	0.655	rs6903444	ENSG00000161912.16	ADCY10P1	-5.63	3.14e-08	5.28e-06	-0.17	-0.25	Alzheimer's disease (late onset);	chr6:41046481	chr6:41101022~41140835:+
THCA	cis	rs1050631	0.564	rs1785910	ENSG00000260552.1	RP11-49I11.1	5.63	3.14e-08	5.28e-06	0.31	0.25	Esophageal squamous cell cancer (length of survival);	chr18:36149908	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.574	rs1789507	ENSG00000260552.1	RP11-49I11.1	5.63	3.14e-08	5.28e-06	0.31	0.25	Esophageal squamous cell cancer (length of survival);	chr18:36152391	chr18:36179996~36187448:-
THCA	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-5.63	3.14e-08	5.28e-06	-0.35	-0.25	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
THCA	cis	rs338389	0.542	rs12439223	ENSG00000260657.2	RP11-315D16.4	-5.63	3.14e-08	5.28e-06	-0.31	-0.25	Survival in rectal cancer;	chr15:67949308	chr15:68267792~68277994:-
THCA	cis	rs7512898	1	rs7512898	ENSG00000260088.1	RP11-92G12.3	5.63	3.14e-08	5.29e-06	0.32	0.25	Electrocardiographic conduction measures;	chr1:200703778	chr1:200669507~200694250:+
THCA	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	5.63	3.15e-08	5.29e-06	0.15	0.25	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	5.63	3.15e-08	5.29e-06	0.15	0.25	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
THCA	cis	rs2348418	0.8	rs6487667	ENSG00000247934.4	RP11-967K21.1	-5.63	3.15e-08	5.3e-06	-0.22	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28195643	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.701	rs6487670	ENSG00000247934.4	RP11-967K21.1	-5.63	3.15e-08	5.3e-06	-0.22	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28210856	chr12:28163298~28190738:-
THCA	cis	rs2243480	1	rs34193460	ENSG00000232546.1	RP11-458F8.1	-5.63	3.15e-08	5.3e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65928123	chr7:66848496~66858136:+
THCA	cis	rs2243480	1	rs57057549	ENSG00000232546.1	RP11-458F8.1	-5.63	3.15e-08	5.3e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65940751	chr7:66848496~66858136:+
THCA	cis	rs6688613	0.694	rs3820387	ENSG00000225171.2	DUTP6	-5.63	3.15e-08	5.3e-06	-0.34	-0.25	Refractive astigmatism;	chr1:166851047	chr1:166868748~166869209:+
THCA	cis	rs783540	0.609	rs803686	ENSG00000278603.1	RP13-608F4.5	-5.63	3.15e-08	5.3e-06	-0.37	-0.25	Schizophrenia;	chr15:82550590	chr15:82472203~82472426:+
THCA	cis	rs9859260	1	rs9858727	ENSG00000226155.1	AC124944.3	-5.63	3.15e-08	5.3e-06	-0.3	-0.25	Mean corpuscular volume;	chr3:196067370	chr3:195912049~195913986:+
THCA	cis	rs7412746	0.611	rs16827671	ENSG00000231073.1	RP11-316M1.3	5.63	3.15e-08	5.3e-06	0.3	0.25	Melanoma;	chr1:150766283	chr1:150973123~150975534:+
THCA	cis	rs9876781	1	rs13071337	ENSG00000229759.1	MRPS18AP1	5.63	3.15e-08	5.3e-06	0.3	0.25	Longevity;	chr3:48396724	chr3:48256350~48256938:-
THCA	cis	rs2835345	0.596	rs12482097	ENSG00000230479.1	AP000695.6	5.63	3.15e-08	5.3e-06	0.3	0.25	Pulmonary function;	chr21:36451592	chr21:36430360~36481070:+
THCA	cis	rs12478296	1	rs12478296	ENSG00000261186.2	RP11-341N2.1	5.63	3.15e-08	5.3e-06	0.39	0.25	Obesity-related traits;	chr2:242106609	chr2:242087351~242088457:-
THCA	cis	rs7131987	0.903	rs11050163	ENSG00000257176.2	RP11-996F15.2	-5.63	3.15e-08	5.3e-06	-0.25	-0.25	QT interval;	chr12:29267465	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.903	rs10843373	ENSG00000257176.2	RP11-996F15.2	-5.63	3.15e-08	5.3e-06	-0.25	-0.25	QT interval;	chr12:29267675	chr12:29280418~29317848:-
THCA	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	5.63	3.15e-08	5.31e-06	0.44	0.25	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
THCA	cis	rs12893668	0.572	rs4900591	ENSG00000269940.1	RP11-73M18.7	5.63	3.15e-08	5.31e-06	0.26	0.25	Reticulocyte count;	chr14:103688541	chr14:103694560~103695170:+
THCA	cis	rs1552244	1	rs9820598	ENSG00000232901.1	CYCSP10	5.63	3.15e-08	5.31e-06	0.33	0.25	Alzheimer's disease;	chr3:10076228	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs57631744	ENSG00000232901.1	CYCSP10	5.63	3.15e-08	5.31e-06	0.33	0.25	Alzheimer's disease;	chr3:10077278	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs6805869	ENSG00000232901.1	CYCSP10	5.63	3.15e-08	5.31e-06	0.33	0.25	Alzheimer's disease;	chr3:10078233	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs9827740	ENSG00000232901.1	CYCSP10	5.63	3.15e-08	5.31e-06	0.33	0.25	Alzheimer's disease;	chr3:10078847	chr3:10000647~10000940:-
THCA	cis	rs7119038	0.731	rs28409215	ENSG00000255239.1	AP002954.6	-5.63	3.16e-08	5.31e-06	-0.39	-0.25	Sjögren's syndrome;	chr11:118808595	chr11:118688039~118690600:-
THCA	cis	rs17214007	0.877	rs7201553	ENSG00000263335.1	AF001548.5	-5.63	3.16e-08	5.31e-06	-0.35	-0.25	Cognitive function;	chr16:15781186	chr16:15726674~15732993:+
THCA	cis	rs8002861	0.84	rs1819597	ENSG00000274001.1	RP11-5G9.5	5.63	3.16e-08	5.32e-06	0.28	0.25	Leprosy;	chr13:43855417	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.84	rs1819596	ENSG00000274001.1	RP11-5G9.5	5.63	3.16e-08	5.32e-06	0.28	0.25	Leprosy;	chr13:43855418	chr13:43877715~43878163:-
THCA	cis	rs55665837	0.539	rs12794714	ENSG00000251991.1	RNU7-49P	5.63	3.16e-08	5.32e-06	0.27	0.25	Vitamin D levels;	chr11:14892029	chr11:14478892~14478953:+
THCA	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	5.63	3.16e-08	5.32e-06	0.2	0.25	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
THCA	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	5.63	3.16e-08	5.32e-06	0.14	0.25	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
THCA	cis	rs3824488	0.6	rs16909865	ENSG00000237857.2	RP11-435O5.2	5.63	3.16e-08	5.32e-06	0.53	0.25	Neuroticism;	chr9:95445020	chr9:95414834~95426796:-
THCA	cis	rs8007846	0.505	rs1950557	ENSG00000276116.2	FUT8-AS1	-5.63	3.17e-08	5.33e-06	-0.3	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65735039	chr14:65411170~65412690:-
THCA	cis	rs2303319	0.504	rs1567420	ENSG00000227403.1	AC009299.3	-5.63	3.17e-08	5.33e-06	-0.52	-0.25	Cognitive function;	chr2:161619091	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs55782047	ENSG00000227403.1	AC009299.3	5.63	3.17e-08	5.33e-06	0.52	0.25	Cognitive function;	chr2:161583745	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187646	ENSG00000227403.1	AC009299.3	5.63	3.17e-08	5.33e-06	0.52	0.25	Cognitive function;	chr2:161588978	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.786	rs62187647	ENSG00000227403.1	AC009299.3	5.63	3.17e-08	5.33e-06	0.52	0.25	Blood osmolality (transformed sodium);	chr2:161589508	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187653	ENSG00000227403.1	AC009299.3	5.63	3.17e-08	5.33e-06	0.52	0.25	Cognitive function;	chr2:161612618	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72873603	ENSG00000227403.1	AC009299.3	5.63	3.17e-08	5.33e-06	0.52	0.25	Cognitive function;	chr2:161613155	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.786	rs72873607	ENSG00000227403.1	AC009299.3	5.63	3.17e-08	5.33e-06	0.52	0.25	Blood osmolality (transformed sodium);	chr2:161614664	chr2:161244739~161249050:+
THCA	cis	rs317689	0.918	rs610192	ENSG00000274979.1	RP11-1143G9.5	-5.63	3.17e-08	5.33e-06	-0.31	-0.25	Response to diuretic therapy;	chr12:69346161	chr12:69326574~69331882:-
THCA	cis	rs17214007	0.877	rs11644832	ENSG00000263335.1	AF001548.5	-5.63	3.17e-08	5.33e-06	-0.34	-0.25	Cognitive function;	chr16:15778891	chr16:15726674~15732993:+
THCA	cis	rs17214007	0.877	rs11645883	ENSG00000263335.1	AF001548.5	-5.63	3.17e-08	5.33e-06	-0.34	-0.25	Cognitive function;	chr16:15778950	chr16:15726674~15732993:+
THCA	cis	rs2732480	0.577	rs2634684	ENSG00000240399.1	RP1-228P16.1	-5.63	3.17e-08	5.33e-06	-0.26	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48054813~48055591:-
THCA	cis	rs9595908	0.965	rs9595877	ENSG00000212293.1	SNORA16	5.63	3.17e-08	5.33e-06	0.31	0.25	Body mass index;	chr13:32589512	chr13:32420390~32420516:-
THCA	cis	rs12428035	0.772	rs7331211	ENSG00000247400.3	DNAJC3-AS1	-5.63	3.17e-08	5.33e-06	-0.23	-0.25	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95820051	chr13:95648733~95676925:-
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000280069.1	CTD-2349P21.3	-5.63	3.17e-08	5.34e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30738182~30740275:+
THCA	cis	rs890448	0.726	rs2583389	ENSG00000254531.1	FLJ20021	-5.63	3.17e-08	5.34e-06	-0.23	-0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101350304	chr4:101347780~101348883:+
THCA	cis	rs4908768	0.501	rs1463050	ENSG00000232912.4	RP5-1115A15.1	5.63	3.18e-08	5.34e-06	0.25	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8424645~8434838:+
THCA	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-5.63	3.18e-08	5.35e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
THCA	cis	rs2559856	1	rs10745921	ENSG00000274560.1	RP11-285E23.2	5.63	3.18e-08	5.35e-06	0.15	0.25	Blood protein levels;	chr12:101693415	chr12:101696002~101696450:-
THCA	cis	rs7246657	0.722	rs1531549	ENSG00000276846.1	CTD-3220F14.3	5.63	3.18e-08	5.35e-06	0.25	0.25	Coronary artery calcification;	chr19:37597108	chr19:37314868~37315620:-
THCA	cis	rs1499614	1	rs1267817	ENSG00000232546.1	RP11-458F8.1	-5.63	3.18e-08	5.35e-06	-0.34	-0.25	Gout;	chr7:66645053	chr7:66848496~66858136:+
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000232546.1	RP11-458F8.1	-5.63	3.18e-08	5.35e-06	-0.34	-0.25	Gout;	chr7:66654674	chr7:66848496~66858136:+
THCA	cis	rs8007846	0.569	rs56720460	ENSG00000276116.2	FUT8-AS1	-5.63	3.18e-08	5.35e-06	-0.26	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65789618	chr14:65411170~65412690:-
THCA	cis	rs10461617	0.512	rs7715746	ENSG00000271828.1	CTD-2310F14.1	5.63	3.18e-08	5.35e-06	0.35	0.25	Type 2 diabetes;	chr5:56753010	chr5:56927874~56929573:+
THCA	cis	rs752010	0.644	rs6700390	ENSG00000230638.4	RP11-486B10.4	-5.63	3.18e-08	5.35e-06	-0.28	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41646883	chr1:41542069~41544310:+
THCA	cis	rs6928977	0.863	rs2746419	ENSG00000231028.7	LINC00271	5.63	3.18e-08	5.35e-06	0.2	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135332717	chr6:135497801~135716055:+
THCA	cis	rs4819052	0.58	rs419322	ENSG00000237664.1	LINC00316	-5.63	3.18e-08	5.35e-06	-0.29	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45131787	chr21:45338590~45341990:-
THCA	cis	rs755249	0.567	rs66531516	ENSG00000228060.1	RP11-69E11.8	-5.63	3.19e-08	5.36e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39565160~39573203:+
THCA	cis	rs1050631	0.564	rs1785929	ENSG00000260552.1	RP11-49I11.1	5.63	3.19e-08	5.36e-06	0.31	0.25	Esophageal squamous cell cancer (length of survival);	chr18:36145202	chr18:36179996~36187448:-
THCA	cis	rs2439831	0.867	rs4583210	ENSG00000275601.1	AC011330.13	-5.63	3.19e-08	5.36e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43368727	chr15:43642389~43643023:-
THCA	cis	rs12497850	0.931	rs6791542	ENSG00000229759.1	MRPS18AP1	5.63	3.19e-08	5.36e-06	0.34	0.25	Parkinson's disease;	chr3:48749786	chr3:48256350~48256938:-
THCA	cis	rs2299587	0.689	rs6586670	ENSG00000253671.1	RP11-806O11.1	-5.63	3.19e-08	5.36e-06	-0.3	-0.25	Economic and political preferences;	chr8:17914823	chr8:17808941~17820868:+
THCA	cis	rs9876781	1	rs2242150	ENSG00000229759.1	MRPS18AP1	-5.62	3.19e-08	5.36e-06	-0.3	-0.25	Longevity;	chr3:48464565	chr3:48256350~48256938:-
THCA	cis	rs10875746	0.551	rs10875799	ENSG00000258234.1	RP11-370I10.2	5.62	3.19e-08	5.36e-06	0.3	0.25	Longevity (90 years and older);	chr12:48347096	chr12:48231098~48284210:-
THCA	cis	rs9876781	1	rs10470686	ENSG00000229759.1	MRPS18AP1	5.62	3.19e-08	5.37e-06	0.3	0.25	Longevity;	chr3:48408549	chr3:48256350~48256938:-
THCA	cis	rs1395	0.778	rs11126918	ENSG00000234072.1	AC074117.10	-5.62	3.19e-08	5.37e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27215842	chr2:27356246~27367622:+
THCA	cis	rs911119	0.908	rs12624424	ENSG00000270001.1	RP11-218C14.8	-5.62	3.19e-08	5.37e-06	-0.39	-0.25	Chronic kidney disease;	chr20:23621241	chr20:23631826~23632316:-
THCA	cis	rs2212361	0.615	rs6483345	ENSG00000255893.1	RP11-685N10.1	-5.62	3.19e-08	5.37e-06	-0.26	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94530983	chr11:94472908~94473570:-
THCA	cis	rs79040073	0.637	rs79311354	ENSG00000259531.2	RP11-295H24.3	5.62	3.2e-08	5.37e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49255987	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.599	rs73394331	ENSG00000259531.2	RP11-295H24.3	5.62	3.2e-08	5.37e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49278236	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73394339	ENSG00000259531.2	RP11-295H24.3	5.62	3.2e-08	5.37e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49279601	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs17397211	ENSG00000259531.2	RP11-295H24.3	5.62	3.2e-08	5.37e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49279746	chr15:49365124~49366685:-
THCA	cis	rs1799922	0.708	rs339099	ENSG00000271553.1	RP11-274B21.10	-5.62	3.2e-08	5.37e-06	-0.19	-0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128756291	chr7:128667043~128668156:+
THCA	cis	rs2559856	1	rs2695292	ENSG00000274560.1	RP11-285E23.2	5.62	3.2e-08	5.38e-06	0.15	0.25	Blood protein levels;	chr12:101693512	chr12:101696002~101696450:-
THCA	cis	rs8177876	0.57	rs11863158	ENSG00000261061.1	RP11-303E16.2	-5.62	3.2e-08	5.38e-06	-0.34	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr16:81030770~81031485:+
THCA	cis	rs6745190	0.861	rs7349232	ENSG00000236153.1	AC104076.3	-5.62	3.2e-08	5.38e-06	-0.33	-0.25	White blood cell count;	chr2:181088627	chr2:180979427~180980090:-
THCA	cis	rs1889642	0.743	rs4319636	ENSG00000227354.5	RBM26-AS1	5.62	3.21e-08	5.39e-06	0.23	0.25	Colonoscopy-negative controls vs population controls;	chr13:79794720	chr13:79406309~79424328:+
THCA	cis	rs2136613	0.728	rs7078554	ENSG00000238280.1	RP11-436D10.3	-5.62	3.21e-08	5.39e-06	-0.3	-0.25	Selective IgA deficiency;	chr10:62835274	chr10:62793562~62805887:-
THCA	cis	rs7824557	0.602	rs7820895	ENSG00000154316.13	TDH	-5.62	3.21e-08	5.39e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11348753	chr8:11339637~11368452:+
THCA	cis	rs71520386	0.583	rs28799344	ENSG00000228649.7	AC005682.5	-5.62	3.21e-08	5.39e-06	-0.32	-0.25	Fibrinogen levels;	chr7:22805647	chr7:22854178~22861579:+
THCA	cis	rs71520386	0.583	rs35322907	ENSG00000228649.7	AC005682.5	-5.62	3.21e-08	5.39e-06	-0.32	-0.25	Fibrinogen levels;	chr7:22806592	chr7:22854178~22861579:+
THCA	cis	rs2243480	1	rs958550	ENSG00000228409.4	CCT6P1	-5.62	3.21e-08	5.4e-06	-0.29	-0.25	Diabetic kidney disease;	chr7:66170692	chr7:65751142~65763354:+
THCA	cis	rs758324	0.732	rs152051	ENSG00000237714.1	P4HA2-AS1	-5.62	3.21e-08	5.4e-06	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132203332	chr5:132184876~132192808:+
THCA	cis	rs7005380	0.62	rs7462302	ENSG00000245330.4	KB-1471A8.1	5.62	3.21e-08	5.4e-06	0.25	0.25	Interstitial lung disease;	chr8:119905531	chr8:119867419~119874488:-
THCA	cis	rs9595908	0.931	rs9595630	ENSG00000212293.1	SNORA16	-5.62	3.21e-08	5.4e-06	-0.3	-0.25	Body mass index;	chr13:32491306	chr13:32420390~32420516:-
THCA	cis	rs6920965	0.507	rs12203025	ENSG00000237742.5	RP11-624M8.1	-5.62	3.21e-08	5.4e-06	-0.22	-0.25	High light scatter reticulocyte count;	chr6:125870888	chr6:125578558~125749190:-
THCA	cis	rs847577	0.515	rs10953238	ENSG00000272950.1	RP11-307C18.1	5.62	3.21e-08	5.4e-06	0.32	0.25	Breast cancer;	chr7:98046947	chr7:98322853~98323430:+
THCA	cis	rs7493	0.95	rs17879277	ENSG00000233942.1	AC004012.1	5.62	3.21e-08	5.4e-06	0.38	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95401320	chr7:95471835~95473998:+
THCA	cis	rs13256369	0.774	rs11777719	ENSG00000253893.2	FAM85B	-5.62	3.22e-08	5.4e-06	-0.33	-0.25	Obesity-related traits;	chr8:8723528	chr8:8167819~8226614:-
THCA	cis	rs897984	0.683	rs9932572	ENSG00000279196.1	RP11-1072A3.3	5.62	3.22e-08	5.4e-06	0.25	0.25	Dementia with Lewy bodies;	chr16:30830321	chr16:30984630~30988270:-
THCA	cis	rs7474896	0.806	rs1779150	ENSG00000272983.1	RP11-508N22.12	-5.62	3.22e-08	5.4e-06	-0.43	-0.25	Obesity (extreme);	chr10:37749759	chr10:38137337~38144399:+
THCA	cis	rs17123764	0.605	rs6580719	ENSG00000257464.1	RP11-161H23.8	-5.62	3.22e-08	5.4e-06	-0.4	-0.25	Intelligence (multi-trait analysis);	chr12:49677309	chr12:49442424~49442652:-
THCA	cis	rs2562456	0.917	rs2650804	ENSG00000268119.4	CTD-2561J22.5	5.62	3.22e-08	5.41e-06	0.3	0.25	Pain;	chr19:21497382	chr19:21444241~21463908:-
THCA	cis	rs1062753	0.771	rs932376	ENSG00000227370.1	RP4-669P10.19	5.62	3.22e-08	5.41e-06	0.26	0.25	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42218356	chr22:42132543~42132998:+
THCA	cis	rs9859260	0.925	rs2300775	ENSG00000226155.1	AC124944.3	-5.62	3.22e-08	5.41e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196066468	chr3:195912049~195913986:+
THCA	cis	rs9859260	0.921	rs2300774	ENSG00000226155.1	AC124944.3	-5.62	3.22e-08	5.41e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196066841	chr3:195912049~195913986:+
THCA	cis	rs13256369	1	rs873064	ENSG00000253893.2	FAM85B	-5.62	3.22e-08	5.41e-06	-0.33	-0.25	Obesity-related traits;	chr8:8714870	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs4841016	ENSG00000253893.2	FAM85B	-5.62	3.22e-08	5.41e-06	-0.33	-0.25	Obesity-related traits;	chr8:8715051	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs10103769	ENSG00000253893.2	FAM85B	-5.62	3.22e-08	5.41e-06	-0.33	-0.25	Obesity-related traits;	chr8:8715526	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs4840352	ENSG00000253893.2	FAM85B	-5.62	3.22e-08	5.41e-06	-0.33	-0.25	Obesity-related traits;	chr8:8715998	chr8:8167819~8226614:-
THCA	cis	rs1020064	0.609	rs2576748	ENSG00000235319.1	AC012360.4	5.62	3.23e-08	5.42e-06	0.3	0.25	AIDS;	chr2:105294801	chr2:105324210~105330529:+
THCA	cis	rs2281636	1	rs2231675	ENSG00000260475.1	RP11-85A1.3	-5.62	3.23e-08	5.42e-06	-0.23	-0.25	Obesity-related traits;	chr10:99732484	chr10:99621055~99621918:+
THCA	cis	rs2281636	1	rs2281636	ENSG00000260475.1	RP11-85A1.3	-5.62	3.23e-08	5.42e-06	-0.23	-0.25	Obesity-related traits;	chr10:99732646	chr10:99621055~99621918:+
THCA	cis	rs2281636	0.965	rs2006077	ENSG00000260475.1	RP11-85A1.3	-5.62	3.23e-08	5.42e-06	-0.23	-0.25	Obesity-related traits;	chr10:99733076	chr10:99621055~99621918:+
THCA	cis	rs2562456	0.52	rs582992	ENSG00000268555.1	RP11-678G14.3	-5.62	3.23e-08	5.42e-06	-0.4	-0.25	Pain;	chr19:21266744	chr19:21570822~21587322:-
THCA	cis	rs792448	0.501	rs11119880	ENSG00000226251.4	RP11-15I11.3	-5.62	3.23e-08	5.42e-06	-0.32	-0.25	White blood cell count (basophil);	chr1:212205143	chr1:212225278~212238977:-
THCA	cis	rs1125355	0.929	rs11685379	ENSG00000251491.2	OR7E28P	-5.62	3.23e-08	5.42e-06	-0.42	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158826845	chr2:158862311~158863285:+
THCA	cis	rs922182	0.613	rs8028927	ENSG00000275785.1	RP11-111E14.2	-5.62	3.23e-08	5.42e-06	-0.28	-0.25	Blood protein levels;	chr15:63940082	chr15:63890030~63890317:+
THCA	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-5.62	3.23e-08	5.43e-06	-0.29	-0.25	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
THCA	cis	rs2337406	0.866	rs7153964	ENSG00000211974.3	IGHV2-70	-5.62	3.23e-08	5.43e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106790480	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs2301536	ENSG00000211974.3	IGHV2-70	-5.62	3.23e-08	5.43e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106790636	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs7144369	ENSG00000211974.3	IGHV2-70	-5.62	3.23e-08	5.43e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106793065	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs78525520	ENSG00000211974.3	IGHV2-70	-5.62	3.23e-08	5.43e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106795643	chr14:106723574~106724093:-
THCA	cis	rs1552244	0.935	rs28815328	ENSG00000180385.7	EMC3-AS1	5.62	3.24e-08	5.43e-06	0.27	0.25	Alzheimer's disease;	chr3:10020543	chr3:9986893~10006990:+
THCA	cis	rs12612619	0.732	rs11681562	ENSG00000229122.1	AGBL5-IT1	5.62	3.24e-08	5.43e-06	0.18	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027735	chr2:27061038~27061815:+
THCA	cis	rs2129782	1	rs16882621	ENSG00000253553.4	RP11-586K2.1	5.62	3.24e-08	5.44e-06	0.42	0.25	Electrodermal activity;	chr8:88427381	chr8:88326836~88737134:+
THCA	cis	rs801193	0.967	rs3800823	ENSG00000273142.1	RP11-458F8.4	5.62	3.24e-08	5.44e-06	0.2	0.25	Aortic root size;	chr7:66682123	chr7:66902857~66906297:+
THCA	cis	rs116095464	0.558	rs62347677	ENSG00000248925.1	CTD-2083E4.6	5.62	3.25e-08	5.45e-06	0.37	0.25	Breast cancer;	chr5:227338	chr5:269858~271516:-
THCA	cis	rs9381040	0.537	rs9462669	ENSG00000161912.16	ADCY10P1	5.62	3.25e-08	5.45e-06	0.17	0.25	Alzheimer's disease (late onset);	chr6:41045920	chr6:41101022~41140835:+
THCA	cis	rs897984	0.762	rs4889599	ENSG00000260911.2	RP11-196G11.2	-5.62	3.25e-08	5.45e-06	-0.21	-0.25	Dementia with Lewy bodies;	chr16:30957268	chr16:31043150~31049868:+
THCA	cis	rs897984	0.721	rs2305884	ENSG00000260911.2	RP11-196G11.2	-5.62	3.25e-08	5.45e-06	-0.21	-0.25	Dementia with Lewy bodies;	chr16:30959420	chr16:31043150~31049868:+
THCA	cis	rs202072	0.72	rs4602719	ENSG00000272379.1	RP1-257A7.5	5.62	3.25e-08	5.45e-06	0.44	0.25	HIV-1 viral setpoint;	chr6:13295270	chr6:13290018~13290490:-
THCA	cis	rs9859260	1	rs2300778	ENSG00000226155.1	AC124944.3	-5.62	3.25e-08	5.45e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196063866	chr3:195912049~195913986:+
THCA	cis	rs9859260	1	rs2300777	ENSG00000226155.1	AC124944.3	-5.62	3.25e-08	5.45e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196063940	chr3:195912049~195913986:+
THCA	cis	rs713477	0.967	rs10150617	ENSG00000258413.1	RP11-665C16.6	-5.62	3.25e-08	5.45e-06	-0.33	-0.25	Pediatric bone mineral content (femoral neck);	chr14:55449507	chr14:55262767~55272075:-
THCA	cis	rs6005807	0.543	rs2235432	ENSG00000226471.5	CTA-292E10.6	-5.62	3.25e-08	5.45e-06	-0.29	-0.25	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28773432	chr22:28800683~28848559:+
THCA	cis	rs2212361	0.558	rs72980453	ENSG00000255893.1	RP11-685N10.1	-5.62	3.25e-08	5.46e-06	-0.31	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94522923	chr11:94472908~94473570:-
THCA	cis	rs860295	0.58	rs10908463	ENSG00000160766.13	GBAP1	-5.62	3.25e-08	5.46e-06	-0.3	-0.25	Body mass index;	chr1:155316467	chr1:155213821~155227422:-
THCA	cis	rs11089937	0.568	rs12159174	ENSG00000211639.2	IGLV4-60	5.62	3.25e-08	5.46e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22162199~22162681:+
THCA	cis	rs67478160	0.643	rs2295141	ENSG00000258735.1	LINC00637	-5.62	3.25e-08	5.46e-06	-0.3	-0.25	Schizophrenia;	chr14:103746612	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.654	rs1997913	ENSG00000258735.1	LINC00637	-5.62	3.25e-08	5.46e-06	-0.3	-0.25	Schizophrenia;	chr14:103747623	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs3818085	ENSG00000258735.1	LINC00637	-5.62	3.25e-08	5.46e-06	-0.3	-0.25	Schizophrenia;	chr14:103749648	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs1535098	ENSG00000258735.1	LINC00637	-5.62	3.25e-08	5.46e-06	-0.3	-0.25	Schizophrenia;	chr14:103750176	chr14:103847721~103858049:+
THCA	cis	rs1383484	0.545	rs7171383	ENSG00000225151.9	GOLGA2P7	5.62	3.25e-08	5.46e-06	0.32	0.25	Height;	chr15:83976087	chr15:84199311~84230136:-
THCA	cis	rs4934494	0.822	rs3962370	ENSG00000240996.1	RP11-80H5.7	-5.62	3.26e-08	5.46e-06	-0.27	-0.25	Red blood cell count;	chr10:89777763	chr10:89694295~89697928:-
THCA	cis	rs934734	0.752	rs268132	ENSG00000234255.7	AC012370.3	5.62	3.26e-08	5.46e-06	0.29	0.25	Rheumatoid arthritis;	chr2:65382543	chr2:65439888~65456571:-
THCA	cis	rs7560272	0.723	rs1083919	ENSG00000163016.8	ALMS1P	-5.62	3.26e-08	5.46e-06	-0.32	-0.25	Schizophrenia;	chr2:73486736	chr2:73644919~73685576:+
THCA	cis	rs763567	0.967	rs736791	ENSG00000271811.1	RP1-79C4.4	-5.62	3.26e-08	5.46e-06	-0.29	-0.25	Tonsillectomy;	chr1:170617174	chr1:170667381~170669425:+
THCA	cis	rs10895275	0.961	rs10895273	ENSG00000277459.1	RP11-732A21.3	-5.62	3.26e-08	5.47e-06	-0.2	-0.25	Migraine;	chr11:102211945	chr11:102109827~102110457:-
THCA	cis	rs7727544	0.709	rs441969	ENSG00000224431.1	AC063976.7	5.62	3.26e-08	5.47e-06	0.22	0.25	Blood metabolite levels;	chr5:132366428	chr5:132199456~132203487:+
THCA	cis	rs13256369	1	rs1109619	ENSG00000253893.2	FAM85B	-5.62	3.26e-08	5.47e-06	-0.33	-0.25	Obesity-related traits;	chr8:8714106	chr8:8167819~8226614:-
THCA	cis	rs5758659	0.714	rs133373	ENSG00000227370.1	RP4-669P10.19	-5.62	3.26e-08	5.47e-06	-0.23	-0.25	Cognitive function;	chr22:42069784	chr22:42132543~42132998:+
THCA	cis	rs7403037	0.804	rs28861743	ENSG00000259905.4	PWRN1	5.62	3.26e-08	5.47e-06	0.26	0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24583566	chr15:24493137~24652130:+
THCA	cis	rs9644031	1	rs9644031	ENSG00000253390.1	CTC-756D1.2	-5.62	3.26e-08	5.47e-06	-0.44	-0.25	Mean corpuscular volume;	chr8:23501767	chr8:23458601~23484971:+
THCA	cis	rs9393777	0.92	rs66462181	ENSG00000219392.1	RP1-265C24.5	-5.62	3.27e-08	5.48e-06	-0.57	-0.25	Intelligence (multi-trait analysis);	chr6:27123882	chr6:28115628~28116551:+
THCA	cis	rs7829975	0.871	rs777709	ENSG00000254153.1	CTA-398F10.2	5.62	3.27e-08	5.48e-06	0.27	0.25	Mood instability;	chr8:8726362	chr8:8456909~8461337:-
THCA	cis	rs61677309	0.964	rs60652614	ENSG00000280032.1	RP11-832A4.7	5.62	3.27e-08	5.49e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118297828	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs59399105	ENSG00000280032.1	RP11-832A4.7	5.62	3.27e-08	5.49e-06	0.27	0.25	Lung cancer in ever smokers;	chr11:118297853	chr11:118264593~118266817:+
THCA	cis	rs73607972	0.735	rs73603962	ENSG00000275191.1	RP11-36I17.2	-5.62	3.27e-08	5.49e-06	-0.39	-0.25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53562292	chr16:53628256~53628816:-
THCA	cis	rs55665837	0.539	rs10832311	ENSG00000251991.1	RNU7-49P	5.62	3.28e-08	5.49e-06	0.28	0.25	Vitamin D levels;	chr11:14860380	chr11:14478892~14478953:+
THCA	cis	rs10208649	0.908	rs72906778	ENSG00000233266.1	HMGB1P31	5.62	3.28e-08	5.49e-06	0.6	0.25	Body mass index;	chr2:54121865	chr2:54051334~54051760:+
THCA	cis	rs11096990	0.964	rs4974999	ENSG00000249207.1	RP11-360F5.1	-5.62	3.28e-08	5.49e-06	-0.32	-0.25	Cognitive function;	chr4:39262294	chr4:39112677~39126818:-
THCA	cis	rs2993535	0.818	rs3010016	ENSG00000233626.2	RP11-565J7.1	5.62	3.28e-08	5.49e-06	0.69	0.25	Hip circumference adjusted for BMI;	chr1:212053747	chr1:211936249~211936634:+
THCA	cis	rs7246657	0.722	rs8100646	ENSG00000276846.1	CTD-3220F14.3	5.62	3.28e-08	5.5e-06	0.25	0.25	Coronary artery calcification;	chr19:37617042	chr19:37314868~37315620:-
THCA	cis	rs2337406	0.85	rs1858678	ENSG00000211974.3	IGHV2-70	-5.62	3.28e-08	5.51e-06	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106706790	chr14:106723574~106724093:-
THCA	cis	rs950169	0.58	rs11634320	ENSG00000275120.1	RP11-182J1.17	-5.62	3.28e-08	5.51e-06	-0.3	-0.25	Schizophrenia;	chr15:84628952	chr15:84599434~84606463:-
THCA	cis	rs6688613	0.545	rs10800270	ENSG00000225171.2	DUTP6	-5.62	3.29e-08	5.51e-06	-0.34	-0.25	Refractive astigmatism;	chr1:166858365	chr1:166868748~166869209:+
THCA	cis	rs2880765	0.706	rs7172006	ENSG00000259295.5	CSPG4P12	5.62	3.29e-08	5.51e-06	0.33	0.25	Coronary artery disease;	chr15:85510128	chr15:85191438~85213905:+
THCA	cis	rs7129556	0.701	rs4322421	ENSG00000254691.1	RP11-91P24.5	5.62	3.29e-08	5.51e-06	0.34	0.25	Weight loss (gastric bypass surgery);	chr11:77748349	chr11:77850604~77851511:+
THCA	cis	rs1322639	0.618	rs9505942	ENSG00000261039.2	RP11-417E7.2	-5.62	3.29e-08	5.51e-06	-0.37	-0.25	Pulse pressure;	chr6:169191698	chr6:169175304~169182740:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.29e-08	5.51e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.29e-08	5.51e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30738182~30740275:+
THCA	cis	rs712039	0.652	rs8069062	ENSG00000276054.1	RP11-378E13.3	5.62	3.29e-08	5.51e-06	0.39	0.25	Tuberculosis;	chr17:37469202	chr17:37386886~37387926:+
THCA	cis	rs712039	0.652	rs60112577	ENSG00000276054.1	RP11-378E13.3	5.62	3.29e-08	5.51e-06	0.39	0.25	Tuberculosis;	chr17:37473105	chr17:37386886~37387926:+
THCA	cis	rs7412746	0.621	rs72704656	ENSG00000231073.1	RP11-316M1.3	5.62	3.29e-08	5.52e-06	0.3	0.25	Melanoma;	chr1:150855831	chr1:150973123~150975534:+
THCA	cis	rs800160	0.858	rs800143	ENSG00000199550.1	Y_RNA	5.62	3.29e-08	5.52e-06	0.38	0.25	Bacteremia;	chr11:2345992	chr11:2372638~2372750:+
THCA	cis	rs800160	0.858	rs800148	ENSG00000199550.1	Y_RNA	5.62	3.29e-08	5.52e-06	0.38	0.25	Bacteremia;	chr11:2348003	chr11:2372638~2372750:+
THCA	cis	rs755249	0.567	rs3818806	ENSG00000228060.1	RP11-69E11.8	-5.62	3.29e-08	5.52e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39565160~39573203:+
THCA	cis	rs5742933	0.597	rs7568449	ENSG00000253559.1	OSGEPL1-AS1	5.62	3.29e-08	5.52e-06	0.29	0.25	Ferritin levels;	chr2:189656328	chr2:189762704~189765556:+
THCA	cis	rs79040073	0.53	rs113085328	ENSG00000259531.2	RP11-295H24.3	5.62	3.29e-08	5.52e-06	0.34	0.25	Lung cancer in ever smokers;	chr15:49223704	chr15:49365124~49366685:-
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000273796.1	LL21NC02-21A1.1	-5.62	3.3e-08	5.52e-06	-0.26	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45403809~45404369:-
THCA	cis	rs9876781	1	rs28824259	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48384185	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs12487542	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48384586	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs73074358	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48385757	chr3:48256350~48256938:-
THCA	cis	rs9876781	0.967	rs34761139	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48386489	chr3:48256350~48256938:-
THCA	cis	rs9876781	0.868	rs9875280	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48387420	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs6796491	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48388977	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs6804774	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48389129	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs9826195	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48392157	chr3:48256350~48256938:-
THCA	cis	rs9876781	0.967	rs9864815	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48392588	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs9809843	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48392923	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs1563736	ENSG00000229759.1	MRPS18AP1	5.62	3.3e-08	5.53e-06	0.3	0.25	Longevity;	chr3:48395329	chr3:48256350~48256938:-
THCA	cis	rs7727544	0.735	rs274559	ENSG00000224431.1	AC063976.7	-5.62	3.3e-08	5.53e-06	-0.21	-0.25	Blood metabolite levels;	chr5:132384378	chr5:132199456~132203487:+
THCA	cis	rs11089937	0.597	rs6001076	ENSG00000211638.2	IGLV8-61	-5.62	3.3e-08	5.53e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs5995560	ENSG00000211638.2	IGLV8-61	-5.62	3.3e-08	5.53e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.568	rs6001078	ENSG00000211638.2	IGLV8-61	-5.62	3.3e-08	5.53e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22098700~22099212:+
THCA	cis	rs1707322	0.789	rs7540578	ENSG00000281133.1	AL355480.3	-5.62	3.3e-08	5.53e-06	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45580892~45580996:-
THCA	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	5.62	3.3e-08	5.53e-06	0.25	0.25	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
THCA	cis	rs7119038	0.818	rs57494551	ENSG00000255239.1	AP002954.6	-5.62	3.3e-08	5.54e-06	-0.39	-0.25	Sjögren's syndrome;	chr11:118790689	chr11:118688039~118690600:-
THCA	cis	rs4650994	0.544	rs2811314	ENSG00000273384.1	RP5-1098D14.1	-5.62	3.31e-08	5.54e-06	-0.33	-0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178650048	chr1:178651706~178652282:+
THCA	cis	rs116095464	0.614	rs4371799	ENSG00000248925.1	CTD-2083E4.6	5.62	3.31e-08	5.54e-06	0.36	0.25	Breast cancer;	chr5:268077	chr5:269858~271516:-
THCA	cis	rs11651753	0.613	rs4793732	ENSG00000264920.1	RP11-6N17.4	-5.62	3.31e-08	5.55e-06	-0.23	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:47891255~47895812:-
THCA	cis	rs2732480	0.577	rs1489109	ENSG00000240399.1	RP1-228P16.1	5.62	3.31e-08	5.55e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48054813~48055591:-
THCA	cis	rs2732480	0.577	rs1489108	ENSG00000240399.1	RP1-228P16.1	5.62	3.31e-08	5.55e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48054813~48055591:-
THCA	cis	rs1823913	1	rs4853559	ENSG00000280083.1	RP11-317J9.1	5.62	3.31e-08	5.55e-06	0.31	0.25	Obesity-related traits;	chr2:191235965	chr2:191154118~191156070:-
THCA	cis	rs7308116	0.645	rs10861833	ENSG00000257951.1	RP11-554D14.4	5.62	3.31e-08	5.55e-06	0.29	0.25	Pelvic organ prolapse (moderate/severe);	chr12:107902358	chr12:107881242~107883382:+
THCA	cis	rs4639966	0.836	rs10892282	ENSG00000255239.1	AP002954.6	5.62	3.31e-08	5.55e-06	0.35	0.25	Systemic lupus erythematosus;	chr11:118757069	chr11:118688039~118690600:-
THCA	cis	rs896854	0.902	rs726816	ENSG00000253528.2	RP11-347C18.4	5.62	3.31e-08	5.55e-06	0.29	0.25	Type 2 diabetes;	chr8:94956185	chr8:94974573~94974853:-
THCA	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	5.62	3.31e-08	5.55e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	5.62	3.31e-08	5.55e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	5.62	3.31e-08	5.55e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
THCA	cis	rs2070488	0.662	rs7375040	ENSG00000229589.1	ACVR2B-AS1	5.62	3.32e-08	5.56e-06	0.24	0.25	Electrocardiographic conduction measures;	chr3:38427625	chr3:38451027~38454820:-
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Body mass index;	chr17:30750419	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Body mass index;	chr17:30753533	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Body mass index;	chr17:30794616	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Body mass index;	chr17:30815122	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Body mass index;	chr17:30815823	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.32e-08	5.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30738182~30740275:+
THCA	cis	rs7412746	0.622	rs11552229	ENSG00000231073.1	RP11-316M1.3	5.62	3.32e-08	5.56e-06	0.3	0.25	Melanoma;	chr1:150811509	chr1:150973123~150975534:+
THCA	cis	rs1395	0.778	rs4665960	ENSG00000234072.1	AC074117.10	-5.62	3.32e-08	5.57e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27244730	chr2:27356246~27367622:+
THCA	cis	rs11148252	0.683	rs9536006	ENSG00000235660.1	LINC00345	-5.62	3.32e-08	5.57e-06	-0.32	-0.25	Lewy body disease;	chr13:52313572	chr13:52484161~52484680:-
THCA	cis	rs1876905	0.62	rs377716	ENSG00000230177.1	RP5-1112D6.4	-5.62	3.32e-08	5.57e-06	-0.26	-0.25	Mean corpuscular hemoglobin;	chr6:111181705	chr6:111277932~111278742:+
THCA	cis	rs10888838	0.938	rs11206304	ENSG00000198711.5	SSBP3-AS1	-5.62	3.32e-08	5.57e-06	-0.28	-0.25	Mitochondrial DNA levels;	chr1:54213646	chr1:54236440~54239063:+
THCA	cis	rs7083	0.875	rs536648	ENSG00000254851.1	RP11-109L13.1	5.62	3.32e-08	5.57e-06	0.34	0.25	Blood protein levels;	chr11:117272469	chr11:117135528~117138582:+
THCA	cis	rs2559856	1	rs2695291	ENSG00000274560.1	RP11-285E23.2	5.62	3.33e-08	5.57e-06	0.16	0.25	Blood protein levels;	chr12:101693765	chr12:101696002~101696450:-
THCA	cis	rs5751614	0.537	rs5759682	ENSG00000230701.2	FBXW4P1	5.62	3.33e-08	5.57e-06	0.28	0.25	Height;	chr22:23288992	chr22:23262767~23265005:+
THCA	cis	rs7412746	0.658	rs6660845	ENSG00000231073.1	RP11-316M1.3	5.62	3.33e-08	5.57e-06	0.31	0.25	Melanoma;	chr1:150868590	chr1:150973123~150975534:+
THCA	cis	rs9880211	0.8	rs66509730	ENSG00000273486.1	RP11-731C17.2	5.62	3.33e-08	5.57e-06	0.26	0.25	Height;Body mass index;	chr3:136785416	chr3:136837338~136839021:-
THCA	cis	rs758324	0.732	rs156059	ENSG00000237714.1	P4HA2-AS1	-5.62	3.33e-08	5.58e-06	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132143938	chr5:132184876~132192808:+
THCA	cis	rs1198430	0.571	rs1001207	ENSG00000232482.2	RP4-654C18.1	-5.62	3.33e-08	5.58e-06	-0.35	-0.25	Total cholesterol levels;	chr1:23422655	chr1:23410832~23412146:+
THCA	cis	rs2803122	0.745	rs6475325	ENSG00000273226.1	RP11-513M16.8	5.62	3.33e-08	5.58e-06	0.23	0.25	Pulse pressure;	chr9:19386375	chr9:19375451~19375996:+
THCA	cis	rs7119	0.651	rs12909292	ENSG00000259362.2	RP11-307C19.1	-5.62	3.33e-08	5.58e-06	-0.36	-0.25	Type 2 diabetes;	chr15:77545640	chr15:77525540~77534110:+
THCA	cis	rs17214007	0.877	rs2075515	ENSG00000263335.1	AF001548.5	-5.62	3.33e-08	5.58e-06	-0.35	-0.25	Cognitive function;	chr16:15778462	chr16:15726674~15732993:+
THCA	cis	rs690037	0.528	rs568833	ENSG00000271964.1	RP11-415F23.2	-5.62	3.33e-08	5.58e-06	-0.23	-0.25	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16326329	chr3:16314439~16314987:+
THCA	cis	rs2839186	0.934	rs4819221	ENSG00000239415.1	AP001469.9	-5.62	3.34e-08	5.58e-06	-0.26	-0.25	Testicular germ cell tumor;	chr21:46275503	chr21:46251549~46254133:-
THCA	cis	rs6545883	0.965	rs7421663	ENSG00000270820.4	RP11-355B11.2	5.62	3.34e-08	5.58e-06	0.21	0.25	Tuberculosis;	chr2:61526651	chr2:61471188~61484130:+
THCA	cis	rs7523875	0.72	rs7514863	ENSG00000153363.11	LINC00467	-5.62	3.34e-08	5.59e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211310758	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.72	rs17017394	ENSG00000153363.11	LINC00467	-5.62	3.34e-08	5.59e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211317942	chr1:211382803~211435333:+
THCA	cis	rs801193	1	rs13239306	ENSG00000273142.1	RP11-458F8.4	5.62	3.34e-08	5.59e-06	0.21	0.25	Aortic root size;	chr7:66671030	chr7:66902857~66906297:+
THCA	cis	rs7746199	0.736	rs6904596	ENSG00000226314.6	ZNF192P1	-5.62	3.34e-08	5.59e-06	-0.47	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28161781~28169594:+
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000280069.1	CTD-2349P21.3	-5.62	3.34e-08	5.6e-06	-0.39	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30738182~30740275:+
THCA	cis	rs9990333	0.521	rs3862281	ENSG00000242086.7	LINC00969	5.62	3.34e-08	5.6e-06	0.26	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195658062~195739964:+
THCA	cis	rs1395	0.778	rs17005956	ENSG00000234072.1	AC074117.10	-5.62	3.35e-08	5.6e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27228231	chr2:27356246~27367622:+
THCA	cis	rs10875746	0.855	rs11168369	ENSG00000269514.1	RP11-370I10.12	5.62	3.35e-08	5.6e-06	0.26	0.25	Longevity (90 years and older);	chr12:48037385	chr12:48198387~48202031:+
THCA	cis	rs6430585	0.583	rs111837148	ENSG00000231890.6	DARS-AS1	-5.62	3.35e-08	5.61e-06	-0.3	-0.25	Corneal structure;	chr2:135854466	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.583	rs61253125	ENSG00000231890.6	DARS-AS1	-5.62	3.35e-08	5.61e-06	-0.3	-0.25	Corneal structure;	chr2:135860608	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.583	rs4988201	ENSG00000231890.6	DARS-AS1	-5.62	3.35e-08	5.61e-06	-0.3	-0.25	Corneal structure;	chr2:135860937	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.583	rs3087343	ENSG00000231890.6	DARS-AS1	-5.62	3.35e-08	5.61e-06	-0.3	-0.25	Corneal structure;	chr2:135864973	chr2:135985176~136022593:+
THCA	cis	rs7523875	0.572	rs74226113	ENSG00000153363.11	LINC00467	-5.62	3.35e-08	5.61e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211390795	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs76013857	ENSG00000153363.11	LINC00467	-5.62	3.35e-08	5.61e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211392503	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs7529673	ENSG00000153363.11	LINC00467	-5.62	3.35e-08	5.61e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211397056	chr1:211382803~211435333:+
THCA	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	5.62	3.35e-08	5.61e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
THCA	cis	rs1552244	1	rs67569278	ENSG00000180385.7	EMC3-AS1	5.62	3.35e-08	5.61e-06	0.27	0.25	Alzheimer's disease;	chr3:10108209	chr3:9986893~10006990:+
THCA	cis	rs9494145	0.68	rs35959442	ENSG00000232876.1	CTA-212D2.2	-5.62	3.36e-08	5.62e-06	-0.35	-0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135103041	chr6:135055033~135060550:+
THCA	cis	rs1198430	0.636	rs1009590	ENSG00000232482.2	RP4-654C18.1	5.62	3.36e-08	5.62e-06	0.46	0.25	Total cholesterol levels;	chr1:23497305	chr1:23410832~23412146:+
THCA	cis	rs7044106	0.791	rs10984994	ENSG00000270917.1	RP11-27I1.6	5.62	3.36e-08	5.62e-06	0.35	0.25	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120812475~120812845:-
THCA	cis	rs1876905	0.764	rs6934341	ENSG00000230177.1	RP5-1112D6.4	-5.62	3.36e-08	5.62e-06	-0.26	-0.25	Mean corpuscular hemoglobin;	chr6:111098387	chr6:111277932~111278742:+
THCA	cis	rs9307551	0.817	rs2903640	ENSG00000250334.4	LINC00989	-5.62	3.36e-08	5.62e-06	-0.29	-0.25	Refractive error;	chr4:79610171	chr4:79492416~79576460:+
THCA	cis	rs8062405	1	rs7187776	ENSG00000278665.1	RP11-666O2.4	5.62	3.36e-08	5.62e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28599241~28601881:-
THCA	cis	rs12216125	0.554	rs6942196	ENSG00000272462.2	U91328.19	-5.62	3.36e-08	5.62e-06	-0.21	-0.25	Iron status biomarkers;	chr6:26072576	chr6:25992662~26001775:+
THCA	cis	rs7523875	0.688	rs78359235	ENSG00000153363.11	LINC00467	-5.62	3.36e-08	5.63e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211261997	chr1:211382803~211435333:+
THCA	cis	rs9307551	0.817	rs17003985	ENSG00000250334.4	LINC00989	-5.62	3.36e-08	5.63e-06	-0.29	-0.25	Refractive error;	chr4:79602561	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.817	rs35487709	ENSG00000250334.4	LINC00989	-5.62	3.36e-08	5.63e-06	-0.29	-0.25	Refractive error;	chr4:79603180	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.817	rs35631270	ENSG00000250334.4	LINC00989	-5.62	3.36e-08	5.63e-06	-0.29	-0.25	Refractive error;	chr4:79603194	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.817	rs1348086	ENSG00000250334.4	LINC00989	-5.62	3.36e-08	5.63e-06	-0.29	-0.25	Refractive error;	chr4:79605078	chr4:79492416~79576460:+
THCA	cis	rs4908760	0.868	rs12131864	ENSG00000232912.4	RP5-1115A15.1	5.62	3.36e-08	5.63e-06	0.25	0.25	Vitiligo;	chr1:8531103	chr1:8424645~8434838:+
THCA	cis	rs9494145	1	rs9494145	ENSG00000232876.1	CTA-212D2.2	-5.62	3.36e-08	5.63e-06	-0.38	-0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135111414	chr6:135055033~135060550:+
THCA	cis	rs4948275	0.742	rs2937153	ENSG00000237233.2	TMEM26-AS1	-5.62	3.37e-08	5.63e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61478029	chr10:61452639~61481956:+
THCA	cis	rs9311474	0.652	rs614288	ENSG00000243224.1	RP5-1157M23.2	-5.61	3.37e-08	5.63e-06	-0.26	-0.25	Electroencephalogram traits;	chr3:52186187	chr3:52239258~52241097:+
THCA	cis	rs7615952	0.611	rs7632305	ENSG00000241288.6	RP11-379B18.5	-5.61	3.37e-08	5.64e-06	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:125915924	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.673	rs9841194	ENSG00000241288.6	RP11-379B18.5	-5.61	3.37e-08	5.64e-06	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:125916896	chr3:125827238~125916384:-
THCA	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	5.61	3.38e-08	5.65e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
THCA	cis	rs6792584	0.637	rs2634741	ENSG00000241316.5	SUCLG2-AS1	5.61	3.38e-08	5.65e-06	0.26	0.25	Corneal astigmatism;	chr3:67560847	chr3:67654697~67947713:+
THCA	cis	rs7247513	1	rs12459123	ENSG00000213290.4	PGK1P2	-5.61	3.38e-08	5.65e-06	-0.31	-0.25	Bipolar disorder;	chr19:12578927	chr19:12559571~12561105:+
THCA	cis	rs755249	0.567	rs61783378	ENSG00000228060.1	RP11-69E11.8	-5.61	3.38e-08	5.65e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39565160~39573203:+
THCA	cis	rs6430585	0.583	rs4594504	ENSG00000231890.6	DARS-AS1	-5.61	3.38e-08	5.65e-06	-0.3	-0.25	Corneal structure;	chr2:135867543	chr2:135985176~136022593:+
THCA	cis	rs2439831	0.681	rs7175434	ENSG00000249839.1	AC011330.5	-5.61	3.38e-08	5.65e-06	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43336344	chr15:43663654~43684339:-
THCA	cis	rs801193	1	rs2707856	ENSG00000273142.1	RP11-458F8.4	-5.61	3.38e-08	5.66e-06	-0.2	-0.25	Aortic root size;	chr7:66746023	chr7:66902857~66906297:+
THCA	cis	rs1125355	0.69	rs62183016	ENSG00000251491.2	OR7E28P	-5.61	3.38e-08	5.66e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158764018	chr2:158862311~158863285:+
THCA	cis	rs1125355	0.661	rs62183017	ENSG00000251491.2	OR7E28P	-5.61	3.38e-08	5.66e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158766340	chr2:158862311~158863285:+
THCA	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-5.61	3.38e-08	5.66e-06	-0.28	-0.25	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
THCA	cis	rs73607972	0.877	rs1477199	ENSG00000275191.1	RP11-36I17.2	-5.61	3.38e-08	5.66e-06	-0.42	-0.25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53678223	chr16:53628256~53628816:-
THCA	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	5.61	3.39e-08	5.66e-06	0.33	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
THCA	cis	rs3820443	1	rs4839125	ENSG00000234020.1	CHIAP3	-5.61	3.39e-08	5.66e-06	-0.33	-0.25	Late-onset Alzheimer's disease;	chr1:111350768	chr1:111353275~111367409:-
THCA	cis	rs3820443	1	rs4839126	ENSG00000234020.1	CHIAP3	-5.61	3.39e-08	5.66e-06	-0.33	-0.25	Late-onset Alzheimer's disease;	chr1:111350795	chr1:111353275~111367409:-
THCA	cis	rs10888838	0.941	rs10888842	ENSG00000198711.5	SSBP3-AS1	5.61	3.39e-08	5.66e-06	0.28	0.25	Mitochondrial DNA levels;	chr1:54223229	chr1:54236440~54239063:+
THCA	cis	rs77972916	0.611	rs61552842	ENSG00000234936.1	AC010883.5	5.61	3.39e-08	5.66e-06	0.29	0.25	Granulocyte percentage of myeloid white cells;	chr2:43356897	chr2:43229573~43233394:+
THCA	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	5.61	3.39e-08	5.67e-06	0.2	0.25	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	5.61	3.39e-08	5.67e-06	0.2	0.25	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
THCA	cis	rs1866631	0.626	rs17761169	ENSG00000238133.5	MLK7-AS1	5.61	3.39e-08	5.67e-06	0.32	0.25	Lung cancer in ever smokers;	chr2:173169371	chr2:173166446~173282036:-
THCA	cis	rs2070488	0.662	rs6599202	ENSG00000229589.1	ACVR2B-AS1	5.61	3.39e-08	5.67e-06	0.24	0.25	Electrocardiographic conduction measures;	chr3:38439160	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.662	rs7652475	ENSG00000229589.1	ACVR2B-AS1	5.61	3.39e-08	5.67e-06	0.24	0.25	Electrocardiographic conduction measures;	chr3:38439850	chr3:38451027~38454820:-
THCA	cis	rs12893668	0.703	rs4906337	ENSG00000269910.1	RP11-73M18.10	5.61	3.39e-08	5.67e-06	0.24	0.25	Reticulocyte count;	chr14:103574077	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.703	rs7140568	ENSG00000269910.1	RP11-73M18.10	5.61	3.39e-08	5.67e-06	0.24	0.25	Reticulocyte count;	chr14:103575037	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.703	rs35026580	ENSG00000269910.1	RP11-73M18.10	5.61	3.39e-08	5.67e-06	0.24	0.25	Reticulocyte count;	chr14:103576416	chr14:103694516~103695050:-
THCA	cis	rs8007846	0.505	rs60273099	ENSG00000276116.2	FUT8-AS1	-5.61	3.39e-08	5.67e-06	-0.3	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65748132	chr14:65411170~65412690:-
THCA	cis	rs7083	1	rs644215	ENSG00000254851.1	RP11-109L13.1	5.61	3.39e-08	5.67e-06	0.34	0.25	Blood protein levels;	chr11:117275202	chr11:117135528~117138582:+
THCA	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-5.61	3.4e-08	5.68e-06	-0.31	-0.25	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
THCA	cis	rs4970988	0.787	rs1532770	ENSG00000231073.1	RP11-316M1.3	5.61	3.4e-08	5.68e-06	0.31	0.25	Urate levels;	chr1:150752859	chr1:150973123~150975534:+
THCA	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	5.61	3.4e-08	5.68e-06	0.38	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000275400.1	RP4-756H11.5	-5.61	3.4e-08	5.69e-06	-0.24	-0.25	Calcium levels;	chr7:65806798	chr7:66553805~66554199:-
THCA	cis	rs4950322	0.857	rs72693002	ENSG00000278811.3	LINC00624	5.61	3.4e-08	5.69e-06	0.31	0.25	Protein quantitative trait loci;	chr1:147357593	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.857	rs72694703	ENSG00000278811.3	LINC00624	5.61	3.4e-08	5.69e-06	0.31	0.25	Protein quantitative trait loci;	chr1:147358427	chr1:147258885~147517875:-
THCA	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	5.61	3.4e-08	5.69e-06	0.35	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
THCA	cis	rs9859260	1	rs2284890	ENSG00000226155.1	AC124944.3	-5.61	3.4e-08	5.69e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196061276	chr3:195912049~195913986:+
THCA	cis	rs9859260	1	rs2284889	ENSG00000226155.1	AC124944.3	-5.61	3.4e-08	5.69e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196061376	chr3:195912049~195913986:+
THCA	cis	rs9859260	0.961	rs2300780	ENSG00000226155.1	AC124944.3	-5.61	3.4e-08	5.69e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196063420	chr3:195912049~195913986:+
THCA	cis	rs881375	0.501	rs10156413	ENSG00000226752.6	PSMD5-AS1	-5.61	3.4e-08	5.69e-06	-0.35	-0.25	Rheumatoid arthritis;	chr9:121105504	chr9:120824828~120854385:+
THCA	cis	rs881375	0.502	rs4837811	ENSG00000226752.6	PSMD5-AS1	-5.61	3.4e-08	5.69e-06	-0.35	-0.25	Rheumatoid arthritis;	chr9:121139316	chr9:120824828~120854385:+
THCA	cis	rs2029362	0.66	rs2049046	ENSG00000245573.6	BDNF-AS	5.61	3.41e-08	5.69e-06	0.2	0.25	Total body bone mineral density;	chr11:27702228	chr11:27506838~27698174:+
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000280069.1	CTD-2349P21.3	-5.61	3.41e-08	5.69e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30738182~30740275:+
THCA	cis	rs2303759	0.918	rs9749416	ENSG00000268686.1	AC010524.2	-5.61	3.41e-08	5.7e-06	-0.36	-0.25	Multiple sclerosis;	chr19:49381748	chr19:49368705~49388081:-
THCA	cis	rs12893668	0.703	rs34896432	ENSG00000269940.1	RP11-73M18.7	5.61	3.41e-08	5.7e-06	0.27	0.25	Reticulocyte count;	chr14:103561658	chr14:103694560~103695170:+
THCA	cis	rs748404	0.666	rs66629206	ENSG00000249839.1	AC011330.5	-5.61	3.41e-08	5.7e-06	-0.36	-0.25	Lung cancer;	chr15:43458804	chr15:43663654~43684339:-
THCA	cis	rs17345786	0.602	rs11923273	ENSG00000244119.1	PDCL3P4	5.61	3.41e-08	5.7e-06	0.23	0.25	Colonoscopy-negative controls vs population controls;	chr3:101619019	chr3:101712472~101713191:+
THCA	cis	rs2617170	0.885	rs2617150	ENSG00000245648.1	RP11-277P12.20	5.61	3.41e-08	5.7e-06	0.27	0.25	Behcet's disease;	chr12:10376435	chr12:10363769~10398506:+
THCA	cis	rs1395	0.778	rs11693660	ENSG00000234072.1	AC074117.10	-5.61	3.41e-08	5.71e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27245988	chr2:27356246~27367622:+
THCA	cis	rs9388451	0.839	rs980014	ENSG00000226409.1	RP11-735G4.1	-5.61	3.42e-08	5.71e-06	-0.3	-0.25	Brugada syndrome;	chr6:125746855	chr6:125370211~125374324:-
THCA	cis	rs2732480	0.557	rs923397	ENSG00000240399.1	RP1-228P16.1	5.61	3.42e-08	5.71e-06	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48054813~48055591:-
THCA	cis	rs7119	0.717	rs8032405	ENSG00000259362.2	RP11-307C19.1	-5.61	3.42e-08	5.72e-06	-0.36	-0.25	Type 2 diabetes;	chr15:77533002	chr15:77525540~77534110:+
THCA	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	5.61	3.42e-08	5.72e-06	0.24	0.25	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
THCA	cis	rs2136613	0.728	rs10822062	ENSG00000238280.1	RP11-436D10.3	-5.61	3.42e-08	5.72e-06	-0.3	-0.25	Selective IgA deficiency;	chr10:62837761	chr10:62793562~62805887:-
THCA	cis	rs9402743	0.775	rs12210389	ENSG00000231028.7	LINC00271	-5.61	3.42e-08	5.72e-06	-0.2	-0.25	Systemic lupus erythematosus;	chr6:135661977	chr6:135497801~135716055:+
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000234585.5	CCT6P3	5.61	3.42e-08	5.72e-06	0.23	0.25	Calcium levels;	chr7:65751755	chr7:65038354~65074713:+
THCA	cis	rs2179367	0.6	rs9498353	ENSG00000223701.3	RAET1E-AS1	5.61	3.42e-08	5.72e-06	0.39	0.25	Dupuytren's disease;	chr6:149439860	chr6:149884431~149919508:+
THCA	cis	rs8014252	0.667	rs10873230	ENSG00000259158.2	ADAM20P1	-5.61	3.43e-08	5.72e-06	-0.27	-0.25	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70319164	chr14:70468881~70483756:-
THCA	cis	rs763567	1	rs61217505	ENSG00000271811.1	RP1-79C4.4	-5.61	3.43e-08	5.72e-06	-0.29	-0.25	Tonsillectomy;	chr1:170604117	chr1:170667381~170669425:+
THCA	cis	rs6565180	0.926	rs4787643	ENSG00000273724.1	RP11-347C12.12	5.61	3.43e-08	5.73e-06	0.27	0.25	Tonsillectomy;	chr16:30382339	chr16:30336400~30343336:+
THCA	cis	rs6565180	0.926	rs4788409	ENSG00000273724.1	RP11-347C12.12	5.61	3.43e-08	5.73e-06	0.27	0.25	Tonsillectomy;	chr16:30382450	chr16:30336400~30343336:+
THCA	cis	rs9921338	0.961	rs11545336	ENSG00000262636.1	CTD-3088G3.4	-5.61	3.43e-08	5.73e-06	-0.37	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11380859~11381118:-
THCA	cis	rs7412746	0.634	rs72704658	ENSG00000231073.1	RP11-316M1.3	5.61	3.43e-08	5.73e-06	0.31	0.25	Melanoma;	chr1:150860534	chr1:150973123~150975534:+
THCA	cis	rs2915864	0.628	rs7714086	ENSG00000280047.1	CTC-463A16.1	5.61	3.43e-08	5.73e-06	0.38	0.25	Facial morphology (factor 20);	chr5:142053270	chr5:142165767~142168387:+
THCA	cis	rs7209700	0.644	rs7214468	ENSG00000228782.6	CTD-2026D20.3	-5.61	3.43e-08	5.73e-06	-0.24	-0.25	IgG glycosylation;	chr17:47293400	chr17:47450568~47492492:-
THCA	cis	rs9859260	1	rs2239641	ENSG00000226155.1	AC124944.3	-5.61	3.43e-08	5.73e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196062543	chr3:195912049~195913986:+
THCA	cis	rs1862618	0.853	rs1423621	ENSG00000271828.1	CTD-2310F14.1	5.61	3.43e-08	5.73e-06	0.38	0.25	Initial pursuit acceleration;	chr5:56805208	chr5:56927874~56929573:+
THCA	cis	rs6968419	0.755	rs4710	ENSG00000237870.5	AC073130.1	5.61	3.43e-08	5.74e-06	0.27	0.25	Intraocular pressure;	chr7:116257338	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.755	rs2896181	ENSG00000237870.5	AC073130.1	-5.61	3.43e-08	5.74e-06	-0.27	-0.25	Intraocular pressure;	chr7:116257830	chr7:116275606~116286734:-
THCA	cis	rs12478296	0.892	rs60042638	ENSG00000261186.2	RP11-341N2.1	-5.61	3.44e-08	5.74e-06	-0.4	-0.25	Obesity-related traits;	chr2:242096556	chr2:242087351~242088457:-
THCA	cis	rs7428	0.545	rs4832163	ENSG00000246575.2	AC093162.5	5.61	3.44e-08	5.75e-06	0.22	0.25	Ear protrusion;	chr2:85313960	chr2:85315041~85316529:+
THCA	cis	rs4713118	1	rs1139226	ENSG00000280107.1	AL022393.9	-5.61	3.44e-08	5.75e-06	-0.28	-0.25	Parkinson's disease;	chr6:27707511	chr6:28170845~28172521:+
THCA	cis	rs4713118	1	rs9468195	ENSG00000280107.1	AL022393.9	-5.61	3.44e-08	5.75e-06	-0.28	-0.25	Parkinson's disease;	chr6:27708530	chr6:28170845~28172521:+
THCA	cis	rs922182	1	rs62021495	ENSG00000275785.1	RP11-111E14.2	5.61	3.44e-08	5.75e-06	0.29	0.25	Blood protein levels;	chr15:63983210	chr15:63890030~63890317:+
THCA	cis	rs7702057	0.53	rs7728055	ENSG00000271918.1	CTD-2287O16.5	5.61	3.44e-08	5.75e-06	0.28	0.25	Amyotrophic lateral sclerosis;	chr5:116078170	chr5:116083807~116085416:-
THCA	cis	rs934734	0.967	rs702875	ENSG00000237979.1	AC007389.1	5.61	3.44e-08	5.75e-06	0.29	0.25	Rheumatoid arthritis;	chr2:65387063	chr2:65500993~65502138:-
THCA	cis	rs4266144	0.544	rs7340627	ENSG00000241770.1	RP11-555M1.3	-5.61	3.44e-08	5.75e-06	-0.3	-0.25	Coronary artery disease;	chr3:157114604	chr3:157163452~157169133:+
THCA	cis	rs2115630	0.967	rs28595395	ENSG00000225151.9	GOLGA2P7	5.61	3.45e-08	5.75e-06	0.32	0.25	P wave terminal force;	chr15:84791721	chr15:84199311~84230136:-
THCA	cis	rs7809950	0.678	rs17154040	ENSG00000238832.1	snoU109	5.61	3.45e-08	5.76e-06	0.29	0.25	Coronary artery disease;	chr7:107364801	chr7:107603363~107603507:+
THCA	cis	rs9311474	0.775	rs164640	ENSG00000243224.1	RP5-1157M23.2	-5.61	3.45e-08	5.76e-06	-0.26	-0.25	Electroencephalogram traits;	chr3:52213298	chr3:52239258~52241097:+
THCA	cis	rs138249	0.527	rs138251	ENSG00000273253.2	RP3-402G11.26	-5.61	3.45e-08	5.76e-06	-0.27	-0.25	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50132423	chr22:50199090~50200837:-
THCA	cis	rs7688540	0.8	rs11731285	ENSG00000211553.1	AC253576.2	-5.61	3.45e-08	5.76e-06	-0.35	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:136461~136568:+
THCA	cis	rs10888838	0.941	rs11585887	ENSG00000198711.5	SSBP3-AS1	5.61	3.45e-08	5.76e-06	0.27	0.25	Mitochondrial DNA levels;	chr1:54221850	chr1:54236440~54239063:+
THCA	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-5.61	3.45e-08	5.76e-06	-0.26	-0.25	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
THCA	cis	rs4794202	0.618	rs4794224	ENSG00000264920.1	RP11-6N17.4	-5.61	3.45e-08	5.76e-06	-0.27	-0.25	Alzheimer's disease (cognitive decline);	chr17:47880097	chr17:47891255~47895812:-
THCA	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	5.61	3.45e-08	5.77e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	5.61	3.45e-08	5.77e-06	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
THCA	cis	rs12681287	0.64	rs12549332	ENSG00000254231.1	CTD-2284J15.1	5.61	3.46e-08	5.77e-06	0.27	0.25	Caudate activity during reward;	chr8:86341163	chr8:86333274~86343314:-
THCA	cis	rs1395	0.778	rs4665959	ENSG00000234072.1	AC074117.10	-5.61	3.46e-08	5.77e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27220388	chr2:27356246~27367622:+
THCA	cis	rs1395	0.778	rs6749393	ENSG00000234072.1	AC074117.10	-5.61	3.46e-08	5.77e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27228132	chr2:27356246~27367622:+
THCA	cis	rs1395	0.813	rs11685326	ENSG00000234072.1	AC074117.10	-5.61	3.46e-08	5.77e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27230811	chr2:27356246~27367622:+
THCA	cis	rs6545883	1	rs778763	ENSG00000270820.4	RP11-355B11.2	5.61	3.46e-08	5.77e-06	0.21	0.25	Tuberculosis;	chr2:61558504	chr2:61471188~61484130:+
THCA	cis	rs55665837	0.539	rs11023350	ENSG00000251991.1	RNU7-49P	5.61	3.46e-08	5.77e-06	0.28	0.25	Vitamin D levels;	chr11:14839971	chr11:14478892~14478953:+
THCA	cis	rs6545883	0.831	rs1186704	ENSG00000271889.1	RP11-493E12.1	5.61	3.46e-08	5.78e-06	0.25	0.25	Tuberculosis;	chr2:61445856	chr2:61151433~61162105:-
THCA	cis	rs7166081	0.688	rs4776361	ENSG00000270964.1	RP11-502I4.3	-5.61	3.46e-08	5.78e-06	-0.22	-0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67469718	chr15:67541072~67542604:-
THCA	cis	rs12101261	0.71	rs58625998	ENSG00000259167.2	NMNAT1P1	5.61	3.46e-08	5.78e-06	0.36	0.25	Graves' disease;	chr14:80831930	chr14:81032529~81033404:+
THCA	cis	rs1322639	0.614	rs9364361	ENSG00000261039.2	RP11-417E7.2	-5.61	3.47e-08	5.79e-06	-0.36	-0.25	Pulse pressure;	chr6:169180404	chr6:169175304~169182740:-
THCA	cis	rs4460629	0.905	rs4971077	ENSG00000225855.5	RUSC1-AS1	5.61	3.47e-08	5.79e-06	0.16	0.25	Serum magnesium levels;	chr1:155156241	chr1:155316863~155324176:-
THCA	cis	rs7646881	0.544	rs73028934	ENSG00000240207.5	RP11-379F4.4	-5.61	3.47e-08	5.79e-06	-0.36	-0.25	Tetralogy of Fallot;	chr3:158655761	chr3:158732263~158784070:+
THCA	cis	rs27434	0.821	rs28337	ENSG00000272109.1	CTD-2260A17.3	-5.61	3.47e-08	5.79e-06	-0.34	-0.25	Ankylosing spondylitis;	chr5:96789611	chr5:96804353~96806105:+
THCA	cis	rs30380	0.587	rs30185	ENSG00000272109.1	CTD-2260A17.3	-5.61	3.47e-08	5.79e-06	-0.34	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96789762	chr5:96804353~96806105:+
THCA	cis	rs7615952	0.688	rs12638224	ENSG00000241288.6	RP11-379B18.5	-5.61	3.47e-08	5.79e-06	-0.29	-0.25	Blood pressure (smoking interaction);	chr3:125822477	chr3:125827238~125916384:-
THCA	cis	rs911555	0.504	rs745079	ENSG00000269910.1	RP11-73M18.10	5.61	3.47e-08	5.79e-06	0.23	0.25	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103694516~103695050:-
THCA	cis	rs911555	0.504	rs61995761	ENSG00000269910.1	RP11-73M18.10	5.61	3.47e-08	5.79e-06	0.23	0.25	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103694516~103695050:-
THCA	cis	rs890448	0.796	rs2119592	ENSG00000254531.1	FLJ20021	5.61	3.47e-08	5.79e-06	0.23	0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387981	chr4:101347780~101348883:+
THCA	cis	rs10771431	0.597	rs7976807	ENSG00000256069.6	A2MP1	5.61	3.48e-08	5.81e-06	0.28	0.25	Breast size;	chr12:9199863	chr12:9228533~9275817:-
THCA	cis	rs7260598	0.642	rs8102034	ENSG00000268442.1	CTD-2027I19.2	5.61	3.48e-08	5.81e-06	0.34	0.25	Response to taxane treatment (placlitaxel);	chr19:23914417	chr19:24162370~24163425:-
THCA	cis	rs10971721	0.822	rs10971818	ENSG00000281128.1	PTENP1-AS	-5.61	3.48e-08	5.81e-06	-0.55	-0.25	Body mass index;	chr9:33952155	chr9:33677268~33688011:+
THCA	cis	rs9876781	1	rs9817615	ENSG00000229759.1	MRPS18AP1	5.61	3.48e-08	5.81e-06	0.3	0.25	Longevity;	chr3:48429347	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000280069.1	CTD-2349P21.3	5.61	3.48e-08	5.81e-06	0.38	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30738182~30740275:+
THCA	cis	rs9393777	0.764	rs35565446	ENSG00000219392.1	RP1-265C24.5	-5.61	3.48e-08	5.81e-06	-0.57	-0.25	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28115628~28116551:+
THCA	cis	rs7942368	0.941	rs10160769	ENSG00000261578.1	RP11-21L23.2	5.61	3.48e-08	5.81e-06	0.36	0.25	Endometriosis;	chr11:76763783	chr11:76800364~76804555:+
THCA	cis	rs73081554	0.505	rs6807387	ENSG00000272360.1	RP11-359I18.5	5.61	3.48e-08	5.82e-06	0.29	0.25	Rheumatoid arthritis;	chr3:58470992	chr3:58490830~58491291:-
THCA	cis	rs6545883	0.965	rs3771261	ENSG00000270820.4	RP11-355B11.2	5.61	3.49e-08	5.82e-06	0.21	0.25	Tuberculosis;	chr2:61535026	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.718	rs3771260	ENSG00000270820.4	RP11-355B11.2	5.61	3.49e-08	5.82e-06	0.21	0.25	Tuberculosis;	chr2:61535249	chr2:61471188~61484130:+
THCA	cis	rs763121	1	rs138457	ENSG00000235209.1	CTA-150C2.13	-5.61	3.49e-08	5.82e-06	-0.32	-0.25	Menopause (age at onset);	chr22:38502046	chr22:38921227~38924708:+
THCA	cis	rs2337406	0.704	rs1858679	ENSG00000211974.3	IGHV2-70	-5.61	3.49e-08	5.82e-06	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106706726	chr14:106723574~106724093:-
THCA	cis	rs2348418	0.798	rs11049486	ENSG00000247934.4	RP11-967K21.1	-5.61	3.49e-08	5.83e-06	-0.22	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28253224	chr12:28163298~28190738:-
THCA	cis	rs1580019	0.523	rs13236410	ENSG00000231952.3	DPY19L1P2	-5.61	3.5e-08	5.83e-06	-0.31	-0.25	Cognitive ability;	chr7:32651051	chr7:32812757~32838570:+
THCA	cis	rs2163813	0.959	rs2315285	ENSG00000275540.1	CTC-559E9.12	-5.61	3.5e-08	5.83e-06	-0.3	-0.25	Toenail selenium levels;	chr19:19715039	chr19:19740884~19750127:+
THCA	cis	rs2163813	1	rs2163813	ENSG00000275540.1	CTC-559E9.12	-5.61	3.5e-08	5.83e-06	-0.3	-0.25	Toenail selenium levels;	chr19:19718292	chr19:19740884~19750127:+
THCA	cis	rs1322639	0.614	rs6937001	ENSG00000261039.2	RP11-417E7.2	5.61	3.5e-08	5.83e-06	0.37	0.25	Pulse pressure;	chr6:169164991	chr6:169175304~169182740:-
THCA	cis	rs1322639	0.575	rs9294966	ENSG00000261039.2	RP11-417E7.2	-5.61	3.5e-08	5.83e-06	-0.37	-0.25	Pulse pressure;	chr6:169165223	chr6:169175304~169182740:-
THCA	cis	rs1322639	0.614	rs9294967	ENSG00000261039.2	RP11-417E7.2	5.61	3.5e-08	5.83e-06	0.37	0.25	Pulse pressure;	chr6:169165311	chr6:169175304~169182740:-
THCA	cis	rs1322639	0.614	rs7768154	ENSG00000261039.2	RP11-417E7.2	-5.61	3.5e-08	5.83e-06	-0.37	-0.25	Pulse pressure;	chr6:169165375	chr6:169175304~169182740:-
THCA	cis	rs1322639	0.614	rs6900200	ENSG00000261039.2	RP11-417E7.2	-5.61	3.5e-08	5.83e-06	-0.37	-0.25	Pulse pressure;	chr6:169166078	chr6:169175304~169182740:-
THCA	cis	rs1499614	1	rs1267818	ENSG00000232546.1	RP11-458F8.1	-5.61	3.5e-08	5.84e-06	-0.34	-0.25	Gout;	chr7:66642037	chr7:66848496~66858136:+
THCA	cis	rs712039	0.652	rs712038	ENSG00000276054.1	RP11-378E13.3	5.61	3.5e-08	5.84e-06	0.38	0.25	Tuberculosis;	chr17:37402468	chr17:37386886~37387926:+
THCA	cis	rs712039	0.652	rs829160	ENSG00000276054.1	RP11-378E13.3	5.61	3.5e-08	5.84e-06	0.38	0.25	Tuberculosis;	chr17:37403002	chr17:37386886~37387926:+
THCA	cis	rs7617773	0.925	rs6442105	ENSG00000199476.1	Y_RNA	5.61	3.5e-08	5.84e-06	0.32	0.25	Coronary artery disease;	chr3:48140836	chr3:48288587~48288694:+
THCA	cis	rs2303319	0.582	rs56094729	ENSG00000227403.1	AC009299.3	5.61	3.5e-08	5.84e-06	0.52	0.25	Cognitive function;	chr2:161608325	chr2:161244739~161249050:+
THCA	cis	rs4748857	0.627	rs72802159	ENSG00000224215.1	RP11-371A19.2	-5.61	3.5e-08	5.84e-06	-0.34	-0.25	Systemic lupus erythematosus;	chr10:23208814	chr10:23343957~23345181:+
THCA	cis	rs1876905	0.68	rs354527	ENSG00000230177.1	RP5-1112D6.4	-5.61	3.5e-08	5.84e-06	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111277932~111278742:+
THCA	cis	rs10829156	0.732	rs10741086	ENSG00000240291.1	RP11-499P20.2	5.61	3.51e-08	5.85e-06	0.21	0.25	Sudden cardiac arrest;	chr10:18505027	chr10:18513115~18545651:-
THCA	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	5.61	3.51e-08	5.85e-06	0.27	0.25	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	5.61	3.51e-08	5.85e-06	0.27	0.25	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
THCA	cis	rs667920	0.575	rs9861150	ENSG00000239213.4	NCK1-AS1	5.61	3.51e-08	5.85e-06	0.27	0.25	Coronary artery disease;	chr3:136464478	chr3:136841726~136862054:-
THCA	cis	rs9388451	0.839	rs3966775	ENSG00000226409.1	RP11-735G4.1	-5.61	3.51e-08	5.86e-06	-0.3	-0.25	Brugada syndrome;	chr6:125746509	chr6:125370211~125374324:-
THCA	cis	rs9876781	1	rs6442118	ENSG00000229759.1	MRPS18AP1	5.61	3.51e-08	5.86e-06	0.29	0.25	Longevity;	chr3:48398582	chr3:48256350~48256938:-
THCA	cis	rs7246657	0.525	rs1667357	ENSG00000226686.6	LINC01535	-5.61	3.51e-08	5.86e-06	-0.38	-0.25	Coronary artery calcification;	chr19:36993450	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.525	rs1667359	ENSG00000226686.6	LINC01535	-5.61	3.51e-08	5.86e-06	-0.38	-0.25	Coronary artery calcification;	chr19:36995270	chr19:37251912~37265535:+
THCA	cis	rs2562456	0.793	rs2562474	ENSG00000268081.1	RP11-678G14.2	-5.61	3.51e-08	5.86e-06	-0.37	-0.25	Pain;	chr19:21463480	chr19:21554640~21569237:-
THCA	cis	rs6547741	0.904	rs2384628	ENSG00000234072.1	AC074117.10	5.61	3.52e-08	5.87e-06	0.19	0.25	Oral cavity cancer;	chr2:27551835	chr2:27356246~27367622:+
THCA	cis	rs7760535	0.826	rs3851229	ENSG00000271789.1	RP5-1112D6.7	-5.61	3.52e-08	5.87e-06	-0.25	-0.25	Metabolic traits;	chr6:111533457	chr6:111297126~111298510:+
THCA	cis	rs10208649	1	rs78542544	ENSG00000233266.1	HMGB1P31	5.61	3.52e-08	5.87e-06	0.66	0.25	Body mass index;	chr2:53879589	chr2:54051334~54051760:+
THCA	cis	rs9368481	0.546	rs12664610	ENSG00000241549.7	GUSBP2	5.61	3.52e-08	5.87e-06	0.23	0.25	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26871484~26956554:-
THCA	cis	rs4604234	0.803	rs28888768	ENSG00000272129.1	RP11-250B2.6	-5.61	3.52e-08	5.87e-06	-0.61	-0.25	Cancer;	chr6:80311913	chr6:80355424~80356859:+
THCA	cis	rs7523875	0.72	rs11590228	ENSG00000153363.11	LINC00467	-5.61	3.52e-08	5.87e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211268342	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.655	rs55941941	ENSG00000153363.11	LINC00467	-5.61	3.52e-08	5.87e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211272463	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.72	rs11577985	ENSG00000153363.11	LINC00467	-5.61	3.52e-08	5.87e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211278125	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.765	rs78011712	ENSG00000153363.11	LINC00467	-5.61	3.52e-08	5.87e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211288218	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.72	rs11581989	ENSG00000153363.11	LINC00467	-5.61	3.52e-08	5.87e-06	-0.26	-0.25	Mean corpuscular volume;	chr1:211288390	chr1:211382803~211435333:+
THCA	cis	rs2303759	0.559	rs1320302	ENSG00000268686.1	AC010524.2	-5.61	3.52e-08	5.87e-06	-0.36	-0.25	Multiple sclerosis;	chr19:49415557	chr19:49368705~49388081:-
THCA	cis	rs9813712	0.83	rs9755184	ENSG00000228252.7	COL6A4P2	-5.61	3.53e-08	5.88e-06	-0.29	-0.25	Response to amphetamines;	chr3:130262278	chr3:130212823~130273806:+
THCA	cis	rs2915864	0.846	rs2961690	ENSG00000280047.1	CTC-463A16.1	-5.61	3.53e-08	5.88e-06	-0.4	-0.25	Facial morphology (factor 20);	chr5:142190009	chr5:142165767~142168387:+
THCA	cis	rs17345786	1	rs55641278	ENSG00000256628.3	ZBTB11-AS1	5.61	3.53e-08	5.89e-06	0.33	0.25	Colonoscopy-negative controls vs population controls;	chr3:101571733	chr3:101676475~101679217:+
THCA	cis	rs8062405	0.824	rs4788085	ENSG00000278665.1	RP11-666O2.4	5.61	3.53e-08	5.89e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.824	rs28772958	ENSG00000278665.1	RP11-666O2.4	5.61	3.53e-08	5.89e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.789	rs2106480	ENSG00000278665.1	RP11-666O2.4	5.61	3.53e-08	5.89e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28599241~28601881:-
THCA	cis	rs4591358	0.587	rs7604146	ENSG00000223466.1	AC064834.2	5.61	3.54e-08	5.9e-06	0.3	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522900	chr2:195533035~195538681:+
THCA	cis	rs2129782	1	rs10504839	ENSG00000253553.4	RP11-586K2.1	5.61	3.54e-08	5.9e-06	0.42	0.25	Electrodermal activity;	chr8:88427502	chr8:88326836~88737134:+
THCA	cis	rs7646881	0.544	rs7638606	ENSG00000240207.5	RP11-379F4.4	-5.61	3.54e-08	5.9e-06	-0.34	-0.25	Tetralogy of Fallot;	chr3:158569050	chr3:158732263~158784070:+
THCA	cis	rs55823223	0.648	rs11867560	ENSG00000267801.1	RP11-552F3.9	5.61	3.54e-08	5.91e-06	0.34	0.25	Psoriasis;	chr17:75861125	chr17:75876372~75879546:+
THCA	cis	rs55823223	0.648	rs11867582	ENSG00000267801.1	RP11-552F3.9	5.61	3.54e-08	5.91e-06	0.34	0.25	Psoriasis;	chr17:75861225	chr17:75876372~75879546:+
THCA	cis	rs13256369	0.708	rs10903310	ENSG00000253893.2	FAM85B	5.61	3.55e-08	5.91e-06	0.34	0.25	Obesity-related traits;	chr8:8732177	chr8:8167819~8226614:-
THCA	cis	rs16846053	0.605	rs72867006	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161929148	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs58510689	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161931385	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs57300571	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161931599	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs61358430	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161931747	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72867014	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161931986	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs60702957	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161933126	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62189660	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161933491	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs59699314	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161933588	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs62189662	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161933642	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs56160038	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161934332	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.581	rs56378636	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161934482	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs62189666	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161935902	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62189667	ENSG00000227403.1	AC009299.3	5.61	3.55e-08	5.91e-06	0.58	0.25	Blood osmolality (transformed sodium);	chr2:161936527	chr2:161244739~161249050:+
THCA	cis	rs1865760	0.613	rs9358894	ENSG00000272462.2	U91328.19	-5.61	3.55e-08	5.91e-06	-0.19	-0.25	Height;	chr6:25923087	chr6:25992662~26001775:+
THCA	cis	rs2904967	0.636	rs239253	ENSG00000254614.2	AP003068.23	-5.61	3.55e-08	5.92e-06	-0.37	-0.25	Mean corpuscular volume;	chr11:65217272	chr11:65177606~65181834:-
THCA	cis	rs1275468	1	rs1148006	ENSG00000257497.2	RP11-585P4.5	-5.61	3.55e-08	5.92e-06	-0.38	-0.25	Polycystic ovary syndrome;	chr12:75584578	chr12:75483454~75489820:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000182722.5	SEPHS1P1	-5.61	3.55e-08	5.92e-06	-0.3	-0.25	Calcium levels;	chr7:65806798	chr7:64852397~64853354:-
THCA	cis	rs6600671	0.693	rs1853731	ENSG00000275538.1	RNVU1-19	5.61	3.55e-08	5.92e-06	0.33	0.25	Hip geometry;	chr1:121510262	chr1:120850819~120850985:-
THCA	cis	rs73198271	0.737	rs565203	ENSG00000253893.2	FAM85B	5.6	3.56e-08	5.92e-06	0.34	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8775447	chr8:8167819~8226614:-
THCA	cis	rs442309	0.875	rs224061	ENSG00000238280.1	RP11-436D10.3	-5.6	3.56e-08	5.93e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62742409	chr10:62793562~62805887:-
THCA	cis	rs1876905	0.524	rs1084639	ENSG00000230177.1	RP5-1112D6.4	-5.6	3.56e-08	5.93e-06	-0.26	-0.25	Mean corpuscular hemoglobin;	chr6:111165240	chr6:111277932~111278742:+
THCA	cis	rs317865	0.737	rs16893153	ENSG00000263327.5	TAPT1-AS1	-5.6	3.56e-08	5.94e-06	-0.4	-0.25	Kidney disease (early stage) in type 1 diabetes;	chr4:16180175	chr4:16226685~16320140:+
THCA	cis	rs1185460	0.934	rs1006195	ENSG00000272186.1	RP11-110I1.13	5.6	3.56e-08	5.94e-06	0.24	0.25	Coronary artery disease;	chr11:119088159	chr11:119067374~119067698:-
THCA	cis	rs7833787	1	rs17383616	ENSG00000278886.1	RP11-108A14.1	-5.6	3.57e-08	5.94e-06	-0.33	-0.25	Obesity-related traits;	chr8:18847290	chr8:18864681~18865247:-
THCA	cis	rs10971721	0.596	rs72731236	ENSG00000281128.1	PTENP1-AS	5.6	3.57e-08	5.94e-06	0.54	0.25	Body mass index;	chr9:34147214	chr9:33677268~33688011:+
THCA	cis	rs8007846	0.569	rs61988977	ENSG00000276116.2	FUT8-AS1	-5.6	3.57e-08	5.94e-06	-0.27	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65791314	chr14:65411170~65412690:-
THCA	cis	rs6908034	0.607	rs79842087	ENSG00000237404.1	RP3-471C18.2	-5.6	3.57e-08	5.95e-06	-0.54	-0.25	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821085	chr6:19689825~19753113:-
THCA	cis	rs1865760	0.566	rs9295686	ENSG00000272462.2	U91328.19	-5.6	3.57e-08	5.95e-06	-0.2	-0.25	Height;	chr6:26081755	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.532	rs9295687	ENSG00000272462.2	U91328.19	-5.6	3.57e-08	5.95e-06	-0.2	-0.25	Height;	chr6:26082482	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.566	rs4529296	ENSG00000272462.2	U91328.19	-5.6	3.57e-08	5.95e-06	-0.2	-0.25	Height;	chr6:26082907	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.566	rs1971509	ENSG00000272462.2	U91328.19	-5.6	3.57e-08	5.95e-06	-0.2	-0.25	Height;	chr6:26085549	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.532	rs2006736	ENSG00000272462.2	U91328.19	-5.6	3.57e-08	5.95e-06	-0.2	-0.25	Height;	chr6:26085789	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.566	rs1800702	ENSG00000272462.2	U91328.19	-5.6	3.57e-08	5.95e-06	-0.2	-0.25	Height;	chr6:26086235	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.566	rs2794720	ENSG00000272462.2	U91328.19	-5.6	3.57e-08	5.95e-06	-0.2	-0.25	Height;	chr6:26086974	chr6:25992662~26001775:+
THCA	cis	rs12101261	0.744	rs55945219	ENSG00000259167.2	NMNAT1P1	5.6	3.57e-08	5.95e-06	0.37	0.25	Graves' disease;	chr14:80990269	chr14:81032529~81033404:+
THCA	cis	rs78487399	0.71	rs13408002	ENSG00000234936.1	AC010883.5	5.6	3.57e-08	5.95e-06	0.38	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43382888	chr2:43229573~43233394:+
THCA	cis	rs890448	0.796	rs2433310	ENSG00000254531.1	FLJ20021	5.6	3.57e-08	5.95e-06	0.22	0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101431756	chr4:101347780~101348883:+
THCA	cis	rs10208649	0.572	rs2068017	ENSG00000272156.1	RP11-477N3.1	5.6	3.58e-08	5.95e-06	0.34	0.25	Body mass index;	chr2:53892434	chr2:54082554~54085066:+
THCA	cis	rs7246657	0.678	rs2972446	ENSG00000276846.1	CTD-3220F14.3	-5.6	3.58e-08	5.96e-06	-0.25	-0.25	Coronary artery calcification;	chr19:37638992	chr19:37314868~37315620:-
THCA	cis	rs5758511	0.689	rs5758691	ENSG00000281538.1	RP4-669P10.20	-5.6	3.58e-08	5.97e-06	-0.28	-0.25	Birth weight;	chr22:42272498	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.68	rs1001586	ENSG00000281538.1	RP4-669P10.20	-5.6	3.58e-08	5.97e-06	-0.28	-0.25	Birth weight;	chr22:42274287	chr22:42138060~42139726:+
THCA	cis	rs9467773	0.526	rs10946817	ENSG00000124549.13	BTN2A3P	-5.6	3.59e-08	5.97e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26363828	chr6:26421391~26432383:+
THCA	cis	rs12497850	0.931	rs3774628	ENSG00000229759.1	MRPS18AP1	5.6	3.59e-08	5.97e-06	0.33	0.25	Parkinson's disease;	chr3:48764407	chr3:48256350~48256938:-
THCA	cis	rs2337406	0.866	rs4774019	ENSG00000211974.3	IGHV2-70	-5.6	3.59e-08	5.97e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106805386	chr14:106723574~106724093:-
THCA	cis	rs2732480	1	rs2732480	ENSG00000240399.1	RP1-228P16.1	-5.6	3.59e-08	5.98e-06	-0.24	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48054813~48055591:-
THCA	cis	rs79040073	0.637	rs10519221	ENSG00000259531.2	RP11-295H24.3	5.6	3.59e-08	5.98e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49286377	chr15:49365124~49366685:-
THCA	cis	rs1858037	0.836	rs1396209	ENSG00000234255.7	AC012370.3	5.6	3.59e-08	5.98e-06	0.3	0.25	Rheumatoid arthritis;	chr2:65374100	chr2:65439888~65456571:-
THCA	cis	rs863750	0.744	rs1387669	ENSG00000275389.1	RP11-214K3.24	5.6	3.59e-08	5.98e-06	0.33	0.25	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124073248	chr12:124085761~124088598:+
THCA	cis	rs7851660	0.874	rs1955145	ENSG00000214417.4	KRT18P13	5.6	3.6e-08	5.99e-06	0.22	0.25	Strep throat;	chr9:97872469	chr9:97698922~97700734:+
THCA	cis	rs9876781	1	rs7636782	ENSG00000229759.1	MRPS18AP1	5.6	3.6e-08	5.99e-06	0.29	0.25	Longevity;	chr3:48379897	chr3:48256350~48256938:-
THCA	cis	rs11148252	1	rs4886018	ENSG00000235660.1	LINC00345	-5.6	3.6e-08	5.99e-06	-0.31	-0.25	Lewy body disease;	chr13:52416582	chr13:52484161~52484680:-
THCA	cis	rs8396	1	rs6536365	ENSG00000271817.2	U3	5.6	3.6e-08	5.99e-06	0.27	0.25	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158711141	chr4:158700691~158700909:+
THCA	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-5.6	3.6e-08	6e-06	-0.15	-0.25	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
THCA	cis	rs2439831	0.867	rs28729853	ENSG00000275601.1	AC011330.13	-5.6	3.6e-08	6e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43381482	chr15:43642389~43643023:-
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000280069.1	CTD-2349P21.3	-5.6	3.61e-08	6e-06	-0.37	-0.25	Body mass index;	chr17:30806554	chr17:30738182~30740275:+
THCA	cis	rs3794924	1	rs3794924	ENSG00000266521.1	RP11-650P15.1	-5.6	3.61e-08	6e-06	-0.48	-0.25	Survival in colon cancer;	chr18:31461771	chr18:31496645~31497195:-
THCA	cis	rs28510890	0.508	rs8041521	ENSG00000260337.3	RP11-386M24.6	5.6	3.61e-08	6e-06	0.26	0.25	Lung cancer in ever smokers;	chr15:92616397	chr15:92592574~92596462:-
THCA	cis	rs2439831	0.867	rs3809481	ENSG00000249839.1	AC011330.5	-5.6	3.61e-08	6e-06	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43370631	chr15:43663654~43684339:-
THCA	cis	rs13256369	1	rs4841017	ENSG00000253893.2	FAM85B	-5.6	3.61e-08	6.01e-06	-0.33	-0.25	Obesity-related traits;	chr8:8719583	chr8:8167819~8226614:-
THCA	cis	rs7246657	0.722	rs2291002	ENSG00000276846.1	CTD-3220F14.3	5.6	3.61e-08	6.01e-06	0.25	0.25	Coronary artery calcification;	chr19:37543024	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs10404031	ENSG00000276846.1	CTD-3220F14.3	5.6	3.61e-08	6.01e-06	0.25	0.25	Coronary artery calcification;	chr19:37545052	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs10406379	ENSG00000276846.1	CTD-3220F14.3	5.6	3.61e-08	6.01e-06	0.25	0.25	Coronary artery calcification;	chr19:37545823	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs1564206	ENSG00000276846.1	CTD-3220F14.3	5.6	3.61e-08	6.01e-06	0.25	0.25	Coronary artery calcification;	chr19:37549174	chr19:37314868~37315620:-
THCA	cis	rs6792584	0.962	rs9810030	ENSG00000241316.5	SUCLG2-AS1	5.6	3.62e-08	6.02e-06	0.26	0.25	Corneal astigmatism;	chr3:67493994	chr3:67654697~67947713:+
THCA	cis	rs935334	1	rs2543376	ENSG00000258454.1	RP11-361H10.3	5.6	3.62e-08	6.02e-06	0.36	0.25	Blood pressure;	chr14:76143580	chr14:76235817~76263474:+
THCA	cis	rs189798	0.845	rs330904	ENSG00000253893.2	FAM85B	5.6	3.62e-08	6.02e-06	0.33	0.25	Myopia (pathological);	chr8:9134315	chr8:8167819~8226614:-
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000280069.1	CTD-2349P21.3	-5.6	3.62e-08	6.02e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000280069.1	CTD-2349P21.3	-5.6	3.62e-08	6.02e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000280069.1	CTD-2349P21.3	-5.6	3.62e-08	6.02e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000280069.1	CTD-2349P21.3	-5.6	3.62e-08	6.02e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000280069.1	CTD-2349P21.3	-5.6	3.62e-08	6.02e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000280069.1	CTD-2349P21.3	-5.6	3.62e-08	6.02e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000280069.1	CTD-2349P21.3	-5.6	3.62e-08	6.02e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30738182~30740275:+
THCA	cis	rs763567	0.967	rs10919444	ENSG00000271811.1	RP1-79C4.4	-5.6	3.62e-08	6.02e-06	-0.29	-0.25	Tonsillectomy;	chr1:170612493	chr1:170667381~170669425:+
THCA	cis	rs11723261	0.582	rs6830247	ENSG00000211553.1	AC253576.2	-5.6	3.62e-08	6.03e-06	-0.36	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:136461~136568:+
THCA	cis	rs2129782	1	rs73279219	ENSG00000253553.4	RP11-586K2.1	5.6	3.62e-08	6.03e-06	0.43	0.25	Electrodermal activity;	chr8:88390932	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10099233	ENSG00000253553.4	RP11-586K2.1	5.6	3.62e-08	6.03e-06	0.43	0.25	Electrodermal activity;	chr8:88391332	chr8:88326836~88737134:+
THCA	cis	rs9309473	0.5	rs1528169	ENSG00000163016.8	ALMS1P	-5.6	3.62e-08	6.03e-06	-0.32	-0.25	Metabolite levels;	chr2:73442058	chr2:73644919~73685576:+
THCA	cis	rs1876905	1	rs1876905	ENSG00000255389.1	C6orf3	5.6	3.63e-08	6.03e-06	0.29	0.25	Mean corpuscular hemoglobin;	chr6:111096756	chr6:111599875~111602295:+
THCA	cis	rs713477	0.654	rs61976568	ENSG00000258413.1	RP11-665C16.6	5.6	3.63e-08	6.03e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55439500	chr14:55262767~55272075:-
THCA	cis	rs11158026	0.628	rs8023187	ENSG00000258413.1	RP11-665C16.6	-5.6	3.63e-08	6.03e-06	-0.35	-0.25	Parkinson's disease;	chr14:54914944	chr14:55262767~55272075:-
THCA	cis	rs2303319	0.686	rs55732192	ENSG00000227403.1	AC009299.3	5.6	3.63e-08	6.03e-06	0.56	0.25	Cognitive function;	chr2:161421722	chr2:161244739~161249050:+
THCA	cis	rs11089937	0.626	rs5757011	ENSG00000211639.2	IGLV4-60	5.6	3.63e-08	6.04e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22162199~22162681:+
THCA	cis	rs950169	0.58	rs11633762	ENSG00000275120.1	RP11-182J1.17	5.6	3.63e-08	6.04e-06	0.3	0.25	Schizophrenia;	chr15:84643921	chr15:84599434~84606463:-
THCA	cis	rs4713118	1	rs4713118	ENSG00000280107.1	AL022393.9	-5.6	3.63e-08	6.05e-06	-0.28	-0.25	Parkinson's disease;	chr6:27709015	chr6:28170845~28172521:+
THCA	cis	rs758324	0.645	rs154734	ENSG00000237714.1	P4HA2-AS1	-5.6	3.64e-08	6.05e-06	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132136860	chr5:132184876~132192808:+
THCA	cis	rs2115630	1	rs56074163	ENSG00000225151.9	GOLGA2P7	5.6	3.64e-08	6.05e-06	0.32	0.25	P wave terminal force;	chr15:84808101	chr15:84199311~84230136:-
THCA	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-5.6	3.64e-08	6.05e-06	-0.29	-0.25	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
THCA	cis	rs7824557	0.707	rs3808519	ENSG00000154316.13	TDH	-5.6	3.64e-08	6.06e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11285461	chr8:11339637~11368452:+
THCA	cis	rs7131987	0.934	rs2216854	ENSG00000257176.2	RP11-996F15.2	-5.6	3.64e-08	6.06e-06	-0.25	-0.25	QT interval;	chr12:29270527	chr12:29280418~29317848:-
THCA	cis	rs13256369	1	rs10110591	ENSG00000253893.2	FAM85B	5.6	3.64e-08	6.06e-06	0.33	0.25	Obesity-related traits;	chr8:8719098	chr8:8167819~8226614:-
THCA	cis	rs12612619	0.732	rs2289360	ENSG00000229122.1	AGBL5-IT1	5.6	3.65e-08	6.07e-06	0.18	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27079297	chr2:27061038~27061815:+
THCA	cis	rs950169	0.544	rs2036949	ENSG00000275120.1	RP11-182J1.17	5.6	3.65e-08	6.07e-06	0.3	0.25	Schizophrenia;	chr15:84620374	chr15:84599434~84606463:-
THCA	cis	rs6585424	1	rs35180576	ENSG00000242600.5	MBL1P	5.6	3.65e-08	6.07e-06	0.29	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163215	chr10:79904898~79950336:+
THCA	cis	rs2617170	0.883	rs2086099	ENSG00000245648.1	RP11-277P12.20	5.6	3.65e-08	6.07e-06	0.27	0.25	Behcet's disease;	chr12:10373939	chr12:10363769~10398506:+
THCA	cis	rs9494145	0.667	rs1331309	ENSG00000232876.1	CTA-212D2.2	-5.6	3.65e-08	6.07e-06	-0.37	-0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135085040	chr6:135055033~135060550:+
THCA	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	5.6	3.65e-08	6.07e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
THCA	cis	rs896854	0.654	rs2011566	ENSG00000253528.2	RP11-347C18.4	5.6	3.65e-08	6.07e-06	0.28	0.25	Type 2 diabetes;	chr8:94959693	chr8:94974573~94974853:-
THCA	cis	rs12435908	0.737	rs73282250	ENSG00000276116.2	FUT8-AS1	-5.6	3.65e-08	6.07e-06	-0.4	-0.25	Ischemic stroke;	chr14:65390428	chr14:65411170~65412690:-
THCA	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	5.6	3.65e-08	6.07e-06	0.32	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
THCA	cis	rs8014252	0.667	rs8005522	ENSG00000259158.2	ADAM20P1	-5.6	3.66e-08	6.08e-06	-0.27	-0.25	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70317506	chr14:70468881~70483756:-
THCA	cis	rs7523875	0.572	rs75046157	ENSG00000153363.11	LINC00467	-5.6	3.66e-08	6.08e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211388161	chr1:211382803~211435333:+
THCA	cis	rs1400745	0.718	rs1200414	ENSG00000258738.1	RP11-73E17.2	5.6	3.66e-08	6.08e-06	0.3	0.25	Monocyte count;	chr14:34861687	chr14:34874343~34876459:+
THCA	cis	rs12291225	0.535	rs16930126	ENSG00000251991.1	RNU7-49P	-5.6	3.66e-08	6.08e-06	-0.29	-0.25	Sense of smell;	chr11:14383437	chr11:14478892~14478953:+
THCA	cis	rs875971	0.706	rs1643374	ENSG00000273142.1	RP11-458F8.4	-5.6	3.66e-08	6.08e-06	-0.2	-0.25	Aortic root size;	chr7:66407695	chr7:66902857~66906297:+
THCA	cis	rs6433895	1	rs13025711	ENSG00000236153.1	AC104076.3	-5.6	3.66e-08	6.08e-06	-0.28	-0.25	Lymphocyte counts;	chr2:181154734	chr2:180979427~180980090:-
THCA	cis	rs2117029	1	rs2117029	ENSG00000258017.1	RP11-386G11.10	-5.6	3.66e-08	6.08e-06	-0.33	-0.25	Intelligence (multi-trait analysis);	chr12:49014657	chr12:49127782~49147869:+
THCA	cis	rs442309	0.875	rs224064	ENSG00000238280.1	RP11-436D10.3	-5.6	3.66e-08	6.09e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62744452	chr10:62793562~62805887:-
THCA	cis	rs12681287	0.673	rs2976178	ENSG00000254231.1	CTD-2284J15.1	5.6	3.66e-08	6.09e-06	0.29	0.25	Caudate activity during reward;	chr8:86320323	chr8:86333274~86343314:-
THCA	cis	rs9393777	0.92	rs35768595	ENSG00000226314.6	ZNF192P1	-5.6	3.67e-08	6.09e-06	-0.56	-0.25	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28161781~28169594:+
THCA	cis	rs812925	0.859	rs778138	ENSG00000271889.1	RP11-493E12.1	5.6	3.67e-08	6.1e-06	0.25	0.25	Immature fraction of reticulocytes;	chr2:61460079	chr2:61151433~61162105:-
THCA	cis	rs7809950	1	rs2520271	ENSG00000238832.1	snoU109	-5.6	3.67e-08	6.1e-06	-0.26	-0.25	Coronary artery disease;	chr7:107554504	chr7:107603363~107603507:+
THCA	cis	rs4273100	0.541	rs7501702	ENSG00000265185.4	SNORD3B-1	-5.6	3.67e-08	6.11e-06	-0.34	-0.25	Schizophrenia;	chr17:19390414	chr17:19061912~19062669:+
THCA	cis	rs2243480	1	rs2707844	ENSG00000230295.1	RP11-458F8.2	-5.6	3.67e-08	6.11e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66594522	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1796220	ENSG00000230295.1	RP11-458F8.2	-5.6	3.67e-08	6.11e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66597113	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs2707831	ENSG00000230295.1	RP11-458F8.2	-5.6	3.67e-08	6.11e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66597524	chr7:66880708~66882981:+
THCA	cis	rs9309473	0.5	rs2421582	ENSG00000163016.8	ALMS1P	-5.6	3.68e-08	6.11e-06	-0.33	-0.25	Metabolite levels;	chr2:73671293	chr2:73644919~73685576:+
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000232559.3	GS1-124K5.12	-5.6	3.68e-08	6.11e-06	-0.38	-0.25	Diabetic kidney disease;	chr7:66226660	chr7:66554588~66576923:-
THCA	cis	rs763121	0.853	rs2076028	ENSG00000273076.1	RP3-508I15.22	5.6	3.68e-08	6.11e-06	0.27	0.25	Menopause (age at onset);	chr22:38754445	chr22:38743495~38743910:+
THCA	cis	rs752010	0.841	rs7519983	ENSG00000230638.4	RP11-486B10.4	-5.6	3.68e-08	6.11e-06	-0.27	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41617698	chr1:41542069~41544310:+
THCA	cis	rs4950322	0.802	rs72694705	ENSG00000278811.3	LINC00624	5.6	3.68e-08	6.11e-06	0.31	0.25	Protein quantitative trait loci;	chr1:147362313	chr1:147258885~147517875:-
THCA	cis	rs712022	0.534	rs4550218	ENSG00000246225.5	RP11-17A1.3	-5.6	3.68e-08	6.11e-06	-0.33	-0.25	Dialysis-related mortality;	chr11:22842112	chr11:22829380~22945393:+
THCA	cis	rs4834770	0.765	rs1511016	ENSG00000245958.5	RP11-33B1.1	-5.6	3.68e-08	6.11e-06	-0.24	-0.25	Blood protein levels;	chr4:119249200	chr4:119454791~119552025:+
THCA	cis	rs6430585	0.591	rs309118	ENSG00000231890.6	DARS-AS1	-5.6	3.68e-08	6.12e-06	-0.28	-0.25	Corneal structure;	chr2:135988654	chr2:135985176~136022593:+
THCA	cis	rs442309	0.807	rs224069	ENSG00000238280.1	RP11-436D10.3	-5.6	3.68e-08	6.12e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62748366	chr10:62793562~62805887:-
THCA	cis	rs7617773	0.963	rs6771787	ENSG00000199476.1	Y_RNA	5.6	3.68e-08	6.12e-06	0.32	0.25	Coronary artery disease;	chr3:48152752	chr3:48288587~48288694:+
THCA	cis	rs7617773	1	rs6771889	ENSG00000199476.1	Y_RNA	5.6	3.68e-08	6.12e-06	0.32	0.25	Coronary artery disease;	chr3:48152836	chr3:48288587~48288694:+
THCA	cis	rs11749327	0.719	rs72698512	ENSG00000221990.4	EXOC3-AS1	5.6	3.68e-08	6.12e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:467028	chr5:441498~443160:-
THCA	cis	rs11749327	0.688	rs72698513	ENSG00000221990.4	EXOC3-AS1	5.6	3.68e-08	6.12e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:467029	chr5:441498~443160:-
THCA	cis	rs11749327	0.678	rs72698514	ENSG00000221990.4	EXOC3-AS1	5.6	3.68e-08	6.12e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:468629	chr5:441498~443160:-
THCA	cis	rs12188164	0.507	rs115438441	ENSG00000221990.4	EXOC3-AS1	5.6	3.68e-08	6.12e-06	0.26	0.25	Cystic fibrosis severity;	chr5:469537	chr5:441498~443160:-
THCA	cis	rs11749327	0.719	rs11169	ENSG00000221990.4	EXOC3-AS1	5.6	3.68e-08	6.12e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:470548	chr5:441498~443160:-
THCA	cis	rs11749327	0.719	rs3315	ENSG00000221990.4	EXOC3-AS1	5.6	3.68e-08	6.12e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:470580	chr5:441498~443160:-
THCA	cis	rs11749327	0.719	rs72698516	ENSG00000221990.4	EXOC3-AS1	5.6	3.68e-08	6.12e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:472106	chr5:441498~443160:-
THCA	cis	rs847577	0.55	rs12670686	ENSG00000272950.1	RP11-307C18.1	5.6	3.68e-08	6.12e-06	0.32	0.25	Breast cancer;	chr7:98079085	chr7:98322853~98323430:+
THCA	cis	rs6840258	0.628	rs9715807	ENSG00000251411.1	RP11-397E7.4	5.6	3.69e-08	6.13e-06	0.26	0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86991479	chr4:86913266~86914817:-
THCA	cis	rs1865760	0.566	rs1539183	ENSG00000272462.2	U91328.19	-5.6	3.69e-08	6.13e-06	-0.2	-0.25	Height;	chr6:26074823	chr6:25992662~26001775:+
THCA	cis	rs4948275	0.709	rs2249921	ENSG00000237233.2	TMEM26-AS1	-5.6	3.69e-08	6.13e-06	-0.33	-0.25	Night sleep phenotypes;	chr10:61487354	chr10:61452639~61481956:+
THCA	cis	rs224278	0.789	rs224295	ENSG00000238280.1	RP11-436D10.3	5.6	3.69e-08	6.13e-06	0.29	0.25	Ewing sarcoma;	chr10:62830498	chr10:62793562~62805887:-
THCA	cis	rs224278	0.789	rs224299	ENSG00000238280.1	RP11-436D10.3	5.6	3.69e-08	6.13e-06	0.29	0.25	Ewing sarcoma;	chr10:62831059	chr10:62793562~62805887:-
THCA	cis	rs6545883	0.931	rs7557230	ENSG00000270820.4	RP11-355B11.2	5.6	3.69e-08	6.13e-06	0.21	0.25	Tuberculosis;	chr2:61509517	chr2:61471188~61484130:+
THCA	cis	rs4073582	0.595	rs801739	ENSG00000255320.1	RP11-755F10.1	-5.6	3.69e-08	6.13e-06	-0.3	-0.25	Gout;	chr11:66155118	chr11:66244840~66246239:-
THCA	cis	rs4908768	0.539	rs7547411	ENSG00000232912.4	RP5-1115A15.1	5.6	3.69e-08	6.13e-06	0.25	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8424645~8434838:+
THCA	cis	rs1707322	0.691	rs11211174	ENSG00000281133.1	AL355480.3	-5.6	3.7e-08	6.14e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45580892~45580996:-
THCA	cis	rs5751614	0.62	rs1811018	ENSG00000230701.2	FBXW4P1	5.6	3.7e-08	6.14e-06	0.27	0.25	Height;	chr22:23264778	chr22:23262767~23265005:+
THCA	cis	rs2179367	0.632	rs9485389	ENSG00000268592.3	RAET1E-AS1	-5.6	3.7e-08	6.15e-06	-0.36	-0.25	Dupuytren's disease;	chr6:149420078	chr6:149863494~149919507:+
THCA	cis	rs9880211	0.8	rs13314357	ENSG00000273486.1	RP11-731C17.2	5.6	3.7e-08	6.15e-06	0.26	0.25	Height;Body mass index;	chr3:136768717	chr3:136837338~136839021:-
THCA	cis	rs2993535	1	rs7545292	ENSG00000233626.2	RP11-565J7.1	-5.6	3.7e-08	6.15e-06	-0.7	-0.25	Hip circumference adjusted for BMI;	chr1:212105716	chr1:211936249~211936634:+
THCA	cis	rs6840360	0.642	rs7666571	ENSG00000270265.1	RP11-731D1.4	-5.6	3.71e-08	6.16e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151333775~151353224:-
THCA	cis	rs6740322	0.895	rs6738717	ENSG00000234936.1	AC010883.5	5.6	3.71e-08	6.16e-06	0.27	0.25	Coronary artery disease;	chr2:43346531	chr2:43229573~43233394:+
THCA	cis	rs9649465	0.902	rs10253850	ENSG00000272686.1	RP11-390E23.6	5.6	3.71e-08	6.16e-06	0.16	0.25	Migraine;	chr7:123633041	chr7:123749068~123751166:+
THCA	cis	rs7560272	0.723	rs62153184	ENSG00000163016.8	ALMS1P	5.6	3.71e-08	6.16e-06	0.32	0.25	Schizophrenia;	chr2:73546742	chr2:73644919~73685576:+
THCA	cis	rs7591472	1	rs7591472	ENSG00000183308.6	AC005037.3	5.6	3.71e-08	6.16e-06	0.41	0.25	Triptolide cytotoxicity;	chr2:201025028	chr2:200963263~201009102:+
THCA	cis	rs55704346	0.537	rs28404798	ENSG00000281501.1	SEPSECS-AS1	5.6	3.71e-08	6.16e-06	0.27	0.25	Tonsillectomy;	chr4:25143348	chr4:25160641~25201440:+
THCA	cis	rs1499614	1	rs2141924	ENSG00000230295.1	RP11-458F8.2	-5.6	3.71e-08	6.16e-06	-0.31	-0.25	Gout;	chr7:66721259	chr7:66880708~66882981:+
THCA	cis	rs7824557	0.628	rs7831346	ENSG00000154316.13	TDH	-5.6	3.71e-08	6.16e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11336021	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.628	rs6601580	ENSG00000154316.13	TDH	-5.6	3.71e-08	6.16e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11336227	chr8:11339637~11368452:+
THCA	cis	rs9990343	0.543	rs4560336	ENSG00000223552.1	RP11-24F11.2	5.6	3.71e-08	6.17e-06	0.22	0.25	Brain structure;	chr3:46409867	chr3:46364955~46407059:-
THCA	cis	rs12101261	0.744	rs72693093	ENSG00000259167.2	NMNAT1P1	5.6	3.71e-08	6.17e-06	0.38	0.25	Graves' disease;	chr14:80993803	chr14:81032529~81033404:+
THCA	cis	rs317689	0.718	rs315122	ENSG00000274979.1	RP11-1143G9.5	-5.6	3.72e-08	6.17e-06	-0.3	-0.25	Response to diuretic therapy;	chr12:69377293	chr12:69326574~69331882:-
THCA	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	5.6	3.72e-08	6.17e-06	0.46	0.25	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
THCA	cis	rs6430585	0.583	rs3769001	ENSG00000231890.6	DARS-AS1	-5.6	3.72e-08	6.17e-06	-0.31	-0.25	Corneal structure;	chr2:135868508	chr2:135985176~136022593:+
THCA	cis	rs61041384	0.661	rs77193970	ENSG00000256092.2	RP13-942N8.1	-5.6	3.72e-08	6.17e-06	-0.39	-0.25	Schizophrenia;	chr12:123031770	chr12:123363868~123366113:+
THCA	cis	rs10895275	0.924	rs11225167	ENSG00000277459.1	RP11-732A21.3	-5.6	3.72e-08	6.18e-06	-0.2	-0.25	Migraine;	chr11:102220170	chr11:102109827~102110457:-
THCA	cis	rs17508449	0.819	rs4839332	ENSG00000232450.1	RP4-730K3.3	-5.6	3.72e-08	6.18e-06	-0.39	-0.25	Leprosy;	chr1:113619569	chr1:113698884~113699631:-
THCA	cis	rs4604234	0.711	rs73463560	ENSG00000272129.1	RP11-250B2.6	-5.6	3.72e-08	6.18e-06	-0.6	-0.25	Cancer;	chr6:80288806	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.803	rs112533182	ENSG00000272129.1	RP11-250B2.6	-5.6	3.72e-08	6.18e-06	-0.6	-0.25	Cancer;	chr6:80295792	chr6:80355424~80356859:+
THCA	cis	rs79349575	0.721	rs4794004	ENSG00000270781.1	RP11-501C14.9	-5.6	3.72e-08	6.18e-06	-0.3	-0.25	Type 2 diabetes;	chr17:48961109	chr17:48899131~48899748:+
THCA	cis	rs9843304	0.546	rs13071608	ENSG00000244503.1	RP11-278L15.6	-5.6	3.72e-08	6.19e-06	-0.32	-0.25	Gallstone disease;	chr3:149501803	chr3:149494660~149495995:+
THCA	cis	rs2735413	0.564	rs74864339	ENSG00000276007.1	RP11-358L22.3	5.6	3.73e-08	6.19e-06	0.26	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78061174	chr16:78123243~78124332:+
THCA	cis	rs5742933	0.857	rs1233282	ENSG00000253559.1	OSGEPL1-AS1	-5.6	3.73e-08	6.19e-06	-0.28	-0.25	Ferritin levels;	chr2:189823518	chr2:189762704~189765556:+
THCA	cis	rs10266483	0.774	rs11765812	ENSG00000227986.1	TRIM60P18	5.6	3.73e-08	6.19e-06	0.22	0.25	Response to statin therapy;	chr7:64385366	chr7:64355078~64356199:+
THCA	cis	rs10875746	0.81	rs10875732	ENSG00000269514.1	RP11-370I10.12	5.6	3.73e-08	6.2e-06	0.25	0.25	Longevity (90 years and older);	chr12:48048322	chr12:48198387~48202031:+
THCA	cis	rs10129255	0.957	rs61997760	ENSG00000223648.3	IGHV3-64	5.6	3.73e-08	6.2e-06	0.15	0.25	Kawasaki disease;	chr14:106716993	chr14:106643132~106658258:-
THCA	cis	rs10875746	0.669	rs10875767	ENSG00000258234.1	RP11-370I10.2	5.6	3.73e-08	6.2e-06	0.29	0.25	Longevity (90 years and older);	chr12:48205474	chr12:48231098~48284210:-
THCA	cis	rs9307551	0.948	rs13109727	ENSG00000250334.4	LINC00989	-5.6	3.74e-08	6.21e-06	-0.31	-0.25	Refractive error;	chr4:79609563	chr4:79492416~79576460:+
THCA	cis	rs7119038	0.818	rs10892280	ENSG00000255239.1	AP002954.6	-5.6	3.74e-08	6.21e-06	-0.39	-0.25	Sjögren's syndrome;	chr11:118741108	chr11:118688039~118690600:-
THCA	cis	rs1707322	0.752	rs6662164	ENSG00000281133.1	AL355480.3	-5.6	3.74e-08	6.21e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45580892~45580996:-
THCA	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-5.6	3.74e-08	6.21e-06	-0.28	-0.25	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
THCA	cis	rs10895275	0.649	rs7104685	ENSG00000277459.1	RP11-732A21.3	-5.6	3.74e-08	6.21e-06	-0.19	-0.25	Migraine;	chr11:102216432	chr11:102109827~102110457:-
THCA	cis	rs748404	0.55	rs12912505	ENSG00000205771.5	CATSPER2P1	-5.6	3.74e-08	6.22e-06	-0.32	-0.25	Lung cancer;	chr15:43525206	chr15:43726918~43747094:-
THCA	cis	rs1858037	0.867	rs4671660	ENSG00000234255.7	AC012370.3	5.6	3.75e-08	6.22e-06	0.3	0.25	Rheumatoid arthritis;	chr2:65349302	chr2:65439888~65456571:-
THCA	cis	rs1876905	0.68	rs3749867	ENSG00000255389.1	C6orf3	5.6	3.75e-08	6.22e-06	0.29	0.25	Mean corpuscular hemoglobin;	chr6:111103615	chr6:111599875~111602295:+
THCA	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	5.6	3.75e-08	6.22e-06	0.25	0.25	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
THCA	cis	rs3847687	0.546	rs11061295	ENSG00000279128.1	RP11-76C10.4	5.6	3.75e-08	6.22e-06	0.28	0.25	Longevity;	chr12:131035139	chr12:131022769~131024741:-
THCA	cis	rs9311474	0.775	rs352163	ENSG00000243224.1	RP5-1157M23.2	-5.59	3.75e-08	6.23e-06	-0.25	-0.25	Electroencephalogram traits;	chr3:52213094	chr3:52239258~52241097:+
THCA	cis	rs2559856	0.967	rs2695290	ENSG00000274560.1	RP11-285E23.2	-5.59	3.75e-08	6.23e-06	-0.15	-0.25	Blood protein levels;	chr12:101694066	chr12:101696002~101696450:-
THCA	cis	rs9876781	1	rs9876781	ENSG00000229759.1	MRPS18AP1	5.59	3.75e-08	6.23e-06	0.29	0.25	Longevity;	chr3:48445934	chr3:48256350~48256938:-
THCA	cis	rs8014252	0.636	rs67203490	ENSG00000259158.2	ADAM20P1	-5.59	3.76e-08	6.24e-06	-0.27	-0.25	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70328212	chr14:70468881~70483756:-
THCA	cis	rs9987353	0.566	rs6998368	ENSG00000253893.2	FAM85B	5.59	3.76e-08	6.24e-06	0.34	0.25	Recombination measurement;	chr8:9212778	chr8:8167819~8226614:-
THCA	cis	rs66887589	0.592	rs28580295	ENSG00000249244.1	RP11-548H18.2	5.59	3.76e-08	6.24e-06	0.27	0.25	Diastolic blood pressure;	chr4:119357718	chr4:119391831~119395335:-
THCA	cis	rs7119038	0.818	rs11217032	ENSG00000255239.1	AP002954.6	-5.59	3.76e-08	6.24e-06	-0.39	-0.25	Sjögren's syndrome;	chr11:118798896	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.818	rs11217033	ENSG00000255239.1	AP002954.6	-5.59	3.76e-08	6.24e-06	-0.39	-0.25	Sjögren's syndrome;	chr11:118802997	chr11:118688039~118690600:-
THCA	cis	rs11217036	1	rs11217036	ENSG00000255239.1	AP002954.6	-5.59	3.76e-08	6.24e-06	-0.39	-0.25	Allergy;	chr11:118805063	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.774	rs11217038	ENSG00000255239.1	AP002954.6	-5.59	3.76e-08	6.24e-06	-0.39	-0.25	Sjögren's syndrome;	chr11:118806646	chr11:118688039~118690600:-
THCA	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-5.59	3.76e-08	6.24e-06	-0.29	-0.25	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
THCA	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-5.59	3.76e-08	6.24e-06	-0.29	-0.25	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
THCA	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-5.59	3.76e-08	6.24e-06	-0.29	-0.25	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
THCA	cis	rs763567	0.585	rs553905	ENSG00000271811.1	RP1-79C4.4	-5.59	3.76e-08	6.24e-06	-0.29	-0.25	Tonsillectomy;	chr1:170611336	chr1:170667381~170669425:+
THCA	cis	rs7250849	0.688	rs78019331	ENSG00000273837.1	LLNLR-470E3.1	-5.59	3.76e-08	6.25e-06	-0.37	-0.25	Blood protein levels;	chr19:51658484	chr19:51639478~51639931:-
THCA	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	5.59	3.77e-08	6.25e-06	0.24	0.25	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
THCA	cis	rs5752326	0.867	rs1894705	ENSG00000261188.1	CTA-445C9.14	5.59	3.77e-08	6.25e-06	0.31	0.25	Ischemic stroke;	chr22:26458014	chr22:26512537~26514568:+
THCA	cis	rs2732480	0.577	rs2634681	ENSG00000240399.1	RP1-228P16.1	-5.59	3.77e-08	6.25e-06	-0.25	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48054813~48055591:-
THCA	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	5.59	3.77e-08	6.25e-06	0.29	0.25	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
THCA	cis	rs442309	0.875	rs224062	ENSG00000238280.1	RP11-436D10.3	-5.59	3.77e-08	6.26e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62743036	chr10:62793562~62805887:-
THCA	cis	rs8062405	1	rs4451951	ENSG00000278665.1	RP11-666O2.4	5.59	3.77e-08	6.26e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28599241~28601881:-
THCA	cis	rs17772222	0.917	rs61984736	ENSG00000222990.1	RNU4-22P	5.59	3.77e-08	6.26e-06	0.33	0.25	Coronary artery calcification;	chr14:88626359	chr14:88513498~88513663:+
THCA	cis	rs525592	1	rs525592	ENSG00000212093.1	AP000807.1	5.59	3.77e-08	6.26e-06	0.26	0.25	Bone mineral density;	chr11:68427636	chr11:68506083~68506166:-
THCA	cis	rs62432291	0.681	rs447637	ENSG00000235086.1	FNDC1-IT1	-5.59	3.77e-08	6.26e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159237694	chr6:159240786~159243329:+
THCA	cis	rs6565180	0.962	rs11642676	ENSG00000273724.1	RP11-347C12.12	-5.59	3.78e-08	6.27e-06	-0.27	-0.25	Tonsillectomy;	chr16:30360334	chr16:30336400~30343336:+
THCA	cis	rs7246657	0.722	rs954504	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37554492	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs8110865	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37556485	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.678	rs4802024	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37561291	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs4802029	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37564710	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs28512414	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37565672	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs6508736	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37570855	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.765	rs4803262	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37575858	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.712	rs4803263	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37575880	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs10412510	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37585043	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs3829688	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37586199	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs13744	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37587011	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs10403173	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37587779	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.679	rs12461113	ENSG00000276846.1	CTD-3220F14.3	5.59	3.78e-08	6.27e-06	0.25	0.25	Coronary artery calcification;	chr19:37592287	chr19:37314868~37315620:-
THCA	cis	rs4950322	0.512	rs4625342	ENSG00000237188.3	RP11-337C18.8	-5.59	3.78e-08	6.27e-06	-0.27	-0.25	Protein quantitative trait loci;	chr1:147369887	chr1:147172771~147211568:+
THCA	cis	rs7403037	0.848	rs28411795	ENSG00000259905.4	PWRN1	5.59	3.78e-08	6.27e-06	0.26	0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24586810	chr15:24493137~24652130:+
THCA	cis	rs950173	1	rs6716901	ENSG00000228389.1	AC068039.4	5.59	3.78e-08	6.27e-06	0.39	0.25	Hippocampal volume;	chr2:171816943	chr2:171773482~171775844:+
THCA	cis	rs74400468	0.529	rs10128322	ENSG00000272319.1	AL022345.7	5.59	3.78e-08	6.28e-06	0.56	0.25	Cannabis dependence symptom count;	chr10:42711252	chr10:42579724~42582772:+
THCA	cis	rs6968419	0.674	rs57756655	ENSG00000237870.5	AC073130.1	5.59	3.78e-08	6.28e-06	0.28	0.25	Intraocular pressure;	chr7:116287114	chr7:116275606~116286734:-
THCA	cis	rs62432291	0.614	rs420339	ENSG00000235086.1	FNDC1-IT1	-5.59	3.79e-08	6.28e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159236163	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs425906	ENSG00000235086.1	FNDC1-IT1	-5.59	3.79e-08	6.28e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159236543	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs388001	ENSG00000235086.1	FNDC1-IT1	-5.59	3.79e-08	6.28e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159237427	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs378339	ENSG00000235086.1	FNDC1-IT1	-5.59	3.79e-08	6.28e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159237820	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs419836	ENSG00000235086.1	FNDC1-IT1	-5.59	3.79e-08	6.28e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159238449	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs450538	ENSG00000235086.1	FNDC1-IT1	-5.59	3.79e-08	6.28e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159238491	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.764	rs433256	ENSG00000235086.1	FNDC1-IT1	-5.59	3.79e-08	6.28e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159239073	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs429339	ENSG00000235086.1	FNDC1-IT1	-5.59	3.79e-08	6.28e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159239116	chr6:159240786~159243329:+
THCA	cis	rs7412746	0.622	rs72704654	ENSG00000231073.1	RP11-316M1.3	5.59	3.79e-08	6.28e-06	0.3	0.25	Melanoma;	chr1:150853934	chr1:150973123~150975534:+
THCA	cis	rs7617773	0.746	rs4130995	ENSG00000199476.1	Y_RNA	-5.59	3.79e-08	6.28e-06	-0.31	-0.25	Coronary artery disease;	chr3:48316765	chr3:48288587~48288694:+
THCA	cis	rs10043228	0.609	rs78035495	ENSG00000248445.4	SEMA6A-AS1	-5.59	3.79e-08	6.29e-06	-0.26	-0.25	Asthma or chronic obstructive pulmonary disease;	chr5:116361169	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.609	rs1529443	ENSG00000248445.4	SEMA6A-AS1	-5.59	3.79e-08	6.29e-06	-0.26	-0.25	Asthma or chronic obstructive pulmonary disease;	chr5:116361339	chr5:116447547~116508276:+
THCA	cis	rs6545883	1	rs778762	ENSG00000270820.4	RP11-355B11.2	5.59	3.79e-08	6.29e-06	0.21	0.25	Tuberculosis;	chr2:61555786	chr2:61471188~61484130:+
THCA	cis	rs79040073	0.637	rs76069611	ENSG00000259531.2	RP11-295H24.3	5.59	3.79e-08	6.29e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49281322	chr15:49365124~49366685:-
THCA	cis	rs6445975	0.726	rs6762098	ENSG00000272360.1	RP11-359I18.5	-5.59	3.79e-08	6.29e-06	-0.27	-0.25	Systemic lupus erythematosus;	chr3:58482701	chr3:58490830~58491291:-
THCA	cis	rs2115630	1	rs2115630	ENSG00000225151.9	GOLGA2P7	5.59	3.79e-08	6.29e-06	0.32	0.25	P wave terminal force;	chr15:84821285	chr15:84199311~84230136:-
THCA	cis	rs11089937	0.568	rs12160317	ENSG00000211639.2	IGLV4-60	5.59	3.79e-08	6.29e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22162199~22162681:+
THCA	cis	rs7220401	0.512	rs2289629	ENSG00000264007.1	RP11-68I3.10	5.59	3.8e-08	6.3e-06	0.3	0.25	Coronary artery disease;	chr17:29632885	chr17:29621617~29622254:-
THCA	cis	rs1383484	0.606	rs9329364	ENSG00000225151.9	GOLGA2P7	5.59	3.8e-08	6.3e-06	0.32	0.25	Height;	chr15:83974490	chr15:84199311~84230136:-
THCA	cis	rs5758659	0.652	rs4822084	ENSG00000227370.1	RP4-669P10.19	5.59	3.8e-08	6.3e-06	0.24	0.25	Cognitive function;	chr22:42039864	chr22:42132543~42132998:+
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000280069.1	CTD-2349P21.3	-5.59	3.8e-08	6.3e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000280069.1	CTD-2349P21.3	-5.59	3.8e-08	6.3e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30738182~30740275:+
THCA	cis	rs7403037	1	rs28715816	ENSG00000259905.4	PWRN1	5.59	3.8e-08	6.31e-06	0.27	0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24579361	chr15:24493137~24652130:+
THCA	cis	rs7403037	1	rs28456975	ENSG00000259905.4	PWRN1	5.59	3.8e-08	6.31e-06	0.27	0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24579582	chr15:24493137~24652130:+
THCA	cis	rs5742933	0.817	rs1233297	ENSG00000253559.1	OSGEPL1-AS1	-5.59	3.8e-08	6.31e-06	-0.28	-0.25	Ferritin levels;	chr2:189829449	chr2:189762704~189765556:+
THCA	cis	rs853679	0.55	rs1233699	ENSG00000261839.1	RP1-265C24.8	5.59	3.8e-08	6.31e-06	0.29	0.25	Depression;	chr6:28201380	chr6:28136849~28139678:+
THCA	cis	rs6968419	0.755	rs6967695	ENSG00000237870.5	AC073130.1	5.59	3.81e-08	6.31e-06	0.27	0.25	Intraocular pressure;	chr7:116255995	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.755	rs3807981	ENSG00000237870.5	AC073130.1	5.59	3.81e-08	6.31e-06	0.27	0.25	Intraocular pressure;	chr7:116256662	chr7:116275606~116286734:-
THCA	cis	rs6569038	0.502	rs4946383	ENSG00000253194.1	RP11-351A11.1	5.59	3.81e-08	6.31e-06	0.34	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118983460	chr6:118934785~119031541:+
THCA	cis	rs6569038	0.502	rs2357020	ENSG00000253194.1	RP11-351A11.1	5.59	3.81e-08	6.31e-06	0.34	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118986644	chr6:118934785~119031541:+
THCA	cis	rs2255336	0.938	rs10161486	ENSG00000245648.1	RP11-277P12.20	-5.59	3.81e-08	6.32e-06	-0.31	-0.25	Blood protein levels;	chr12:10457167	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.938	rs73070924	ENSG00000245648.1	RP11-277P12.20	-5.59	3.81e-08	6.32e-06	-0.31	-0.25	Blood protein levels;	chr12:10457386	chr12:10363769~10398506:+
THCA	cis	rs28510890	0.917	rs4778012	ENSG00000260337.3	RP11-386M24.6	5.59	3.81e-08	6.32e-06	0.29	0.25	Lung cancer in ever smokers;	chr15:92571951	chr15:92592574~92596462:-
THCA	cis	rs8062405	1	rs62036617	ENSG00000278665.1	RP11-666O2.4	5.59	3.81e-08	6.32e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs4788095	ENSG00000278665.1	RP11-666O2.4	5.59	3.81e-08	6.32e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.964	rs72793809	ENSG00000278665.1	RP11-666O2.4	5.59	3.81e-08	6.32e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62036620	ENSG00000278665.1	RP11-666O2.4	5.59	3.81e-08	6.32e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62036621	ENSG00000278665.1	RP11-666O2.4	5.59	3.81e-08	6.32e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28599241~28601881:-
THCA	cis	rs10875746	0.551	rs2054903	ENSG00000258234.1	RP11-370I10.2	5.59	3.81e-08	6.32e-06	0.3	0.25	Longevity (90 years and older);	chr12:48330710	chr12:48231098~48284210:-
THCA	cis	rs9959145	0.543	rs11664013	ENSG00000267199.1	RP11-861E21.2	-5.59	3.81e-08	6.32e-06	-0.26	-0.25	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12438890~12448205:+
THCA	cis	rs6993270	0.779	rs7818752	ENSG00000245330.4	KB-1471A8.1	-5.59	3.81e-08	6.32e-06	-0.32	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119920791	chr8:119867419~119874488:-
THCA	cis	rs12497850	0.931	rs4974082	ENSG00000229759.1	MRPS18AP1	5.59	3.81e-08	6.32e-06	0.33	0.25	Parkinson's disease;	chr3:48961890	chr3:48256350~48256938:-
THCA	cis	rs5769765	0.526	rs5770722	ENSG00000260613.1	RP3-522J7.6	5.59	3.82e-08	6.33e-06	0.35	0.25	Schizophrenia;	chr22:49859572	chr22:49832616~49837786:-
THCA	cis	rs1552244	0.808	rs17032306	ENSG00000232901.1	CYCSP10	5.59	3.82e-08	6.33e-06	0.33	0.25	Alzheimer's disease;	chr3:10049715	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.938	rs7625049	ENSG00000232901.1	CYCSP10	5.59	3.82e-08	6.33e-06	0.33	0.25	Alzheimer's disease;	chr3:10073935	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs6782602	ENSG00000232901.1	CYCSP10	5.59	3.82e-08	6.33e-06	0.33	0.25	Alzheimer's disease;	chr3:10074857	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs35586456	ENSG00000232901.1	CYCSP10	5.59	3.82e-08	6.33e-06	0.33	0.25	Alzheimer's disease;	chr3:10075254	chr3:10000647~10000940:-
THCA	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	5.59	3.82e-08	6.33e-06	0.31	0.25	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
THCA	cis	rs11148252	1	rs11148252	ENSG00000235660.1	LINC00345	-5.59	3.82e-08	6.33e-06	-0.31	-0.25	Lewy body disease;	chr13:52434913	chr13:52484161~52484680:-
THCA	cis	rs71636778	0.509	rs60659886	ENSG00000260063.1	RP5-968P14.2	-5.59	3.82e-08	6.33e-06	-0.43	-0.25	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26667754	chr1:26692132~26694131:-
THCA	cis	rs1552244	1	rs9875081	ENSG00000232901.1	CYCSP10	5.59	3.82e-08	6.33e-06	0.33	0.25	Alzheimer's disease;	chr3:10042251	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs9809061	ENSG00000232901.1	CYCSP10	5.59	3.82e-08	6.33e-06	0.33	0.25	Alzheimer's disease;	chr3:10043446	chr3:10000647~10000940:-
THCA	cis	rs3847687	0.565	rs11061294	ENSG00000279128.1	RP11-76C10.4	5.59	3.82e-08	6.33e-06	0.28	0.25	Longevity;	chr12:131035116	chr12:131022769~131024741:-
THCA	cis	rs3847687	0.565	rs10848270	ENSG00000279128.1	RP11-76C10.4	5.59	3.82e-08	6.33e-06	0.28	0.25	Longevity;	chr12:131035119	chr12:131022769~131024741:-
THCA	cis	rs3847687	0.565	rs10848271	ENSG00000279128.1	RP11-76C10.4	5.59	3.82e-08	6.33e-06	0.28	0.25	Longevity;	chr12:131035158	chr12:131022769~131024741:-
THCA	cis	rs755249	0.958	rs17264866	ENSG00000228060.1	RP11-69E11.8	-5.59	3.82e-08	6.33e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39565160~39573203:+
THCA	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	5.59	3.82e-08	6.33e-06	0.32	0.25	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
THCA	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-5.59	3.82e-08	6.34e-06	-0.26	-0.25	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
THCA	cis	rs4650994	0.544	rs2476561	ENSG00000273384.1	RP5-1098D14.1	5.59	3.83e-08	6.34e-06	0.33	0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178650765	chr1:178651706~178652282:+
THCA	cis	rs713477	0.678	rs4901566	ENSG00000258413.1	RP11-665C16.6	5.59	3.83e-08	6.34e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55445945	chr14:55262767~55272075:-
THCA	cis	rs11651753	0.805	rs55822955	ENSG00000264920.1	RP11-6N17.4	-5.59	3.83e-08	6.34e-06	-0.21	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47884447	chr17:47891255~47895812:-
THCA	cis	rs2179367	0.568	rs6932778	ENSG00000268592.3	RAET1E-AS1	5.59	3.83e-08	6.35e-06	0.39	0.25	Dupuytren's disease;	chr6:149328293	chr6:149863494~149919507:+
THCA	cis	rs593531	0.504	rs4944041	ENSG00000212961.4	HNRNPA1P40	-5.59	3.84e-08	6.36e-06	-0.32	-0.25	Neuroticism;	chr11:74318814	chr11:74354443~74355720:+
THCA	cis	rs593531	0.513	rs4944887	ENSG00000212961.4	HNRNPA1P40	-5.59	3.84e-08	6.36e-06	-0.32	-0.25	Neuroticism;	chr11:74318838	chr11:74354443~74355720:+
THCA	cis	rs2439831	0.867	rs28461955	ENSG00000275601.1	AC011330.13	-5.59	3.84e-08	6.36e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43369261	chr15:43642389~43643023:-
THCA	cis	rs7727544	0.735	rs4705933	ENSG00000224431.1	AC063976.7	5.59	3.85e-08	6.37e-06	0.21	0.25	Blood metabolite levels;	chr5:132342719	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.735	rs272867	ENSG00000224431.1	AC063976.7	5.59	3.85e-08	6.37e-06	0.21	0.25	Blood metabolite levels;	chr5:132345364	chr5:132199456~132203487:+
THCA	cis	rs4689592	0.619	rs3796908	ENSG00000245468.3	RP11-367J11.3	5.59	3.85e-08	6.37e-06	0.21	0.25	Monocyte percentage of white cells;	chr4:7059651	chr4:7094571~7103385:-
THCA	cis	rs4845570	0.92	rs1196456	ENSG00000203288.3	RP11-98D18.9	5.59	3.85e-08	6.38e-06	0.25	0.25	Coronary artery disease;	chr1:151764873	chr1:151790804~151794402:+
THCA	cis	rs7674212	0.51	rs2720468	ENSG00000251288.2	RP11-10L12.2	-5.59	3.86e-08	6.39e-06	-0.32	-0.25	Type 2 diabetes;	chr4:103163996	chr4:102751401~102752641:+
THCA	cis	rs1546924	0.669	rs6687953	ENSG00000227811.2	FAM212B-AS1	-5.59	3.86e-08	6.39e-06	-0.3	-0.25	Body mass index;	chr1:111750890	chr1:111739841~111747798:+
THCA	cis	rs2799081	1	rs2799081	ENSG00000219392.1	RP1-265C24.5	-5.59	3.86e-08	6.39e-06	-0.29	-0.25	Myopia;	chr6:28302807	chr6:28115628~28116551:+
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000280069.1	CTD-2349P21.3	-5.59	3.86e-08	6.4e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30738182~30740275:+
THCA	cis	rs12893668	0.572	rs4906350	ENSG00000269940.1	RP11-73M18.7	5.59	3.86e-08	6.4e-06	0.26	0.25	Reticulocyte count;	chr14:103645457	chr14:103694560~103695170:+
THCA	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	5.59	3.86e-08	6.4e-06	0.39	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
THCA	cis	rs7824557	0.614	rs2060456	ENSG00000154316.13	TDH	-5.59	3.86e-08	6.4e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11355854	chr8:11339637~11368452:+
THCA	cis	rs2120243	0.647	rs7632702	ENSG00000244515.1	KRT18P34	-5.59	3.87e-08	6.4e-06	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157428114	chr3:157162663~157163932:-
THCA	cis	rs13256369	1	rs873063	ENSG00000253893.2	FAM85B	-5.59	3.87e-08	6.41e-06	-0.33	-0.25	Obesity-related traits;	chr8:8714937	chr8:8167819~8226614:-
THCA	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	5.59	3.87e-08	6.41e-06	0.43	0.25	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
THCA	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	5.59	3.87e-08	6.41e-06	0.43	0.25	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
THCA	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	5.59	3.87e-08	6.41e-06	0.43	0.25	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
THCA	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	5.59	3.87e-08	6.41e-06	0.43	0.25	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
THCA	cis	rs4713118	0.506	rs9366697	ENSG00000219392.1	RP1-265C24.5	-5.59	3.87e-08	6.41e-06	-0.29	-0.25	Parkinson's disease;	chr6:27665239	chr6:28115628~28116551:+
THCA	cis	rs202072	0.652	rs202064	ENSG00000272379.1	RP1-257A7.5	-5.59	3.87e-08	6.41e-06	-0.43	-0.25	HIV-1 viral setpoint;	chr6:13263794	chr6:13290018~13290490:-
THCA	cis	rs30380	0.632	rs30186	ENSG00000272109.1	CTD-2260A17.3	-5.59	3.87e-08	6.42e-06	-0.34	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96788744	chr5:96804353~96806105:+
THCA	cis	rs7824557	0.602	rs7815463	ENSG00000154316.13	TDH	-5.59	3.87e-08	6.42e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11353474	chr8:11339637~11368452:+
THCA	cis	rs7044106	0.791	rs2416797	ENSG00000270917.1	RP11-27I1.6	-5.59	3.88e-08	6.42e-06	-0.35	-0.25	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120812475~120812845:-
THCA	cis	rs7044106	0.791	rs2416798	ENSG00000270917.1	RP11-27I1.6	-5.59	3.88e-08	6.42e-06	-0.35	-0.25	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120812475~120812845:-
THCA	cis	rs2212361	0.529	rs11020821	ENSG00000255893.1	RP11-685N10.1	-5.59	3.88e-08	6.42e-06	-0.29	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94538497	chr11:94472908~94473570:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000272009.1	RP1-313I6.12	-5.59	3.88e-08	6.43e-06	-0.28	-0.25	Parkinson's disease;	chr6:28062721	chr6:28078792~28081130:-
THCA	cis	rs2029362	0.684	rs2203877	ENSG00000245573.6	BDNF-AS	5.59	3.88e-08	6.43e-06	0.2	0.25	Total body bone mineral density;	chr11:27649363	chr11:27506838~27698174:+
THCA	cis	rs2303319	0.504	rs2020027	ENSG00000227403.1	AC009299.3	5.59	3.88e-08	6.43e-06	0.52	0.25	Cognitive function;	chr2:161569368	chr2:161244739~161249050:+
THCA	cis	rs1865760	0.566	rs10807006	ENSG00000272462.2	U91328.19	-5.59	3.89e-08	6.44e-06	-0.21	-0.25	Height;	chr6:26048524	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.566	rs7772312	ENSG00000272462.2	U91328.19	-5.59	3.89e-08	6.44e-06	-0.21	-0.25	Height;	chr6:26049388	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.508	rs9379820	ENSG00000272462.2	U91328.19	-5.59	3.89e-08	6.44e-06	-0.21	-0.25	Height;	chr6:26049696	chr6:25992662~26001775:+
THCA	cis	rs7809950	1	rs2712189	ENSG00000238832.1	snoU109	-5.59	3.89e-08	6.44e-06	-0.26	-0.25	Coronary artery disease;	chr7:107555302	chr7:107603363~107603507:+
THCA	cis	rs7045881	0.877	rs7035755	ENSG00000254396.1	RP11-56F10.3	-5.59	3.89e-08	6.44e-06	-0.34	-0.25	Schizophrenia;	chr9:26945978	chr9:27102630~27104728:+
THCA	cis	rs3950186	0.834	rs1569732	ENSG00000215124.2	RP3-420J14.1	5.59	3.89e-08	6.44e-06	0.29	0.25	Anxiety and major depressive disorder;	chr6:11825433	chr6:11861626~11862970:-
THCA	cis	rs9467773	1	rs1321479	ENSG00000124549.13	BTN2A3P	-5.59	3.89e-08	6.45e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26421391~26432383:+
THCA	cis	rs935334	0.866	rs11850433	ENSG00000258454.1	RP11-361H10.3	-5.59	3.9e-08	6.45e-06	-0.37	-0.25	Blood pressure;	chr14:76215140	chr14:76235817~76263474:+
THCA	cis	rs7674212	0.541	rs2045746	ENSG00000251288.2	RP11-10L12.2	5.59	3.9e-08	6.45e-06	0.32	0.25	Type 2 diabetes;	chr4:103162421	chr4:102751401~102752641:+
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000182722.5	SEPHS1P1	5.59	3.9e-08	6.45e-06	0.3	0.25	Calcium levels;	chr7:65733651	chr7:64852397~64853354:-
THCA	cis	rs6569038	0.502	rs794266	ENSG00000253194.1	RP11-351A11.1	5.59	3.9e-08	6.45e-06	0.34	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118999148	chr6:118934785~119031541:+
THCA	cis	rs7674212	0.541	rs4699050	ENSG00000246560.2	RP11-10L12.4	5.59	3.9e-08	6.46e-06	0.3	0.25	Type 2 diabetes;	chr4:103193140	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.541	rs17217473	ENSG00000246560.2	RP11-10L12.4	5.59	3.9e-08	6.46e-06	0.3	0.25	Type 2 diabetes;	chr4:103193585	chr4:102828055~102844075:+
THCA	cis	rs17301013	0.507	rs2860955	ENSG00000227373.4	RP11-160H22.5	-5.59	3.9e-08	6.46e-06	-0.37	-0.25	Systemic lupus erythematosus;	chr1:174391380	chr1:174115300~174160004:-
THCA	cis	rs712039	0.617	rs853201	ENSG00000276054.1	RP11-378E13.3	5.59	3.9e-08	6.46e-06	0.39	0.25	Tuberculosis;	chr17:37444086	chr17:37386886~37387926:+
THCA	cis	rs7615952	0.688	rs12638240	ENSG00000241288.6	RP11-379B18.5	-5.59	3.9e-08	6.46e-06	-0.29	-0.25	Blood pressure (smoking interaction);	chr3:125822395	chr3:125827238~125916384:-
THCA	cis	rs79040073	0.637	rs112792737	ENSG00000259531.2	RP11-295H24.3	5.59	3.91e-08	6.46e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49198849	chr15:49365124~49366685:-
THCA	cis	rs6044112	0.56	rs6080322	ENSG00000273998.1	RP4-777L9.2	5.59	3.91e-08	6.47e-06	0.43	0.25	Response to taxane treatment (docetaxel);	chr20:16608358	chr20:16576068~16579615:+
THCA	cis	rs13113518	0.738	rs6849883	ENSG00000273257.1	RP11-177J6.1	5.59	3.91e-08	6.47e-06	0.33	0.25	Height;	chr4:55387515	chr4:55387949~55388271:+
THCA	cis	rs2439831	0.681	rs511673	ENSG00000249839.1	AC011330.5	-5.59	3.91e-08	6.47e-06	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43326665	chr15:43663654~43684339:-
THCA	cis	rs2115630	1	rs11073730	ENSG00000225151.9	GOLGA2P7	5.59	3.91e-08	6.47e-06	0.32	0.25	P wave terminal force;	chr15:84811365	chr15:84199311~84230136:-
THCA	cis	rs2282300	1	rs12575085	ENSG00000242353.1	RP4-710M3.1	-5.59	3.91e-08	6.47e-06	-0.23	-0.25	Morning vs. evening chronotype;	chr11:30406715	chr11:30368148~30368646:+
THCA	cis	rs2559856	1	rs2695282	ENSG00000274560.1	RP11-285E23.2	-5.59	3.91e-08	6.47e-06	-0.15	-0.25	Blood protein levels;	chr12:101695724	chr12:101696002~101696450:-
THCA	cis	rs6993270	0.725	rs7016479	ENSG00000245330.4	KB-1471A8.1	-5.59	3.91e-08	6.48e-06	-0.32	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119913927	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.725	rs7016372	ENSG00000245330.4	KB-1471A8.1	-5.59	3.91e-08	6.48e-06	-0.32	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119913977	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.725	rs6983678	ENSG00000245330.4	KB-1471A8.1	-5.59	3.91e-08	6.48e-06	-0.32	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119914835	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs6988573	ENSG00000245330.4	KB-1471A8.1	-5.59	3.91e-08	6.48e-06	-0.32	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119915619	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.779	rs78624653	ENSG00000245330.4	KB-1471A8.1	-5.59	3.91e-08	6.48e-06	-0.32	-0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119916409	chr8:119867419~119874488:-
THCA	cis	rs2439831	0.85	rs28524541	ENSG00000166763.7	STRCP1	5.59	3.91e-08	6.48e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43832633	chr15:43699488~43718184:-
THCA	cis	rs10888838	1	rs2026045	ENSG00000198711.5	SSBP3-AS1	5.59	3.92e-08	6.48e-06	0.27	0.25	Mitochondrial DNA levels;	chr1:54219522	chr1:54236440~54239063:+
THCA	cis	rs4947019	1	rs12192279	ENSG00000223537.2	RP5-919F19.5	5.59	3.92e-08	6.48e-06	0.38	0.25	Hematological parameters;	chr6:109734110	chr6:109487906~109506800:+
THCA	cis	rs2944755	0.723	rs13274041	ENSG00000279766.1	RP11-642A1.2	-5.59	3.92e-08	6.49e-06	-0.32	-0.25	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140577816	chr8:140572142~140572812:-
THCA	cis	rs2944755	0.723	rs13274321	ENSG00000279766.1	RP11-642A1.2	-5.59	3.92e-08	6.49e-06	-0.32	-0.25	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578107	chr8:140572142~140572812:-
THCA	cis	rs2944755	0.723	rs13273553	ENSG00000279766.1	RP11-642A1.2	-5.59	3.92e-08	6.49e-06	-0.32	-0.25	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578166	chr8:140572142~140572812:-
THCA	cis	rs253959	0.564	rs4921064	ENSG00000272265.1	CTD-2287O16.4	5.59	3.92e-08	6.49e-06	0.29	0.25	Bipolar disorder and schizophrenia;	chr5:116111637	chr5:116078110~116078570:-
THCA	cis	rs4713118	0.911	rs9295746	ENSG00000226314.6	ZNF192P1	-5.59	3.93e-08	6.5e-06	-0.33	-0.25	Parkinson's disease;	chr6:27762285	chr6:28161781~28169594:+
THCA	cis	rs9921338	0.961	rs66555362	ENSG00000262703.1	RP11-485G7.6	-5.59	3.93e-08	6.5e-06	-0.32	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11294976	chr16:11348143~11349321:-
THCA	cis	rs9309473	0.539	rs7574268	ENSG00000163016.8	ALMS1P	-5.59	3.93e-08	6.5e-06	-0.32	-0.25	Metabolite levels;	chr2:73677745	chr2:73644919~73685576:+
THCA	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	5.59	3.93e-08	6.51e-06	0.39	0.25	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
THCA	cis	rs2735413	0.599	rs112375862	ENSG00000276007.1	RP11-358L22.3	5.59	3.93e-08	6.51e-06	0.26	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78045340	chr16:78123243~78124332:+
THCA	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-5.59	3.94e-08	6.51e-06	-0.15	-0.25	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
THCA	cis	rs1865760	0.566	rs9379821	ENSG00000272462.2	U91328.19	-5.59	3.94e-08	6.51e-06	-0.21	-0.25	Height;	chr6:26054040	chr6:25992662~26001775:+
THCA	cis	rs853679	0.607	rs68188794	ENSG00000226314.6	ZNF192P1	-5.59	3.94e-08	6.52e-06	-0.55	-0.25	Depression;	chr6:28112999	chr6:28161781~28169594:+
THCA	cis	rs2562456	0.793	rs2562428	ENSG00000268081.1	RP11-678G14.2	-5.59	3.94e-08	6.52e-06	-0.37	-0.25	Pain;	chr19:21442652	chr19:21554640~21569237:-
THCA	cis	rs763567	1	rs12755237	ENSG00000271811.1	RP1-79C4.4	-5.59	3.94e-08	6.52e-06	-0.29	-0.25	Tonsillectomy;	chr1:170599573	chr1:170667381~170669425:+
THCA	cis	rs763567	1	rs12742164	ENSG00000271811.1	RP1-79C4.4	-5.59	3.94e-08	6.52e-06	-0.29	-0.25	Tonsillectomy;	chr1:170599755	chr1:170667381~170669425:+
THCA	cis	rs763567	0.967	rs1952675	ENSG00000271811.1	RP1-79C4.4	-5.59	3.94e-08	6.52e-06	-0.29	-0.25	Tonsillectomy;	chr1:170613434	chr1:170667381~170669425:+
THCA	cis	rs17508449	0.71	rs6699022	ENSG00000232450.1	RP4-730K3.3	-5.59	3.94e-08	6.52e-06	-0.36	-0.25	Leprosy;	chr1:113567013	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.736	rs79470224	ENSG00000232450.1	RP4-730K3.3	-5.59	3.94e-08	6.52e-06	-0.36	-0.25	Leprosy;	chr1:113567163	chr1:113698884~113699631:-
THCA	cis	rs4748857	0.685	rs11013362	ENSG00000224215.1	RP11-371A19.2	-5.59	3.94e-08	6.52e-06	-0.33	-0.25	Systemic lupus erythematosus;	chr10:23275416	chr10:23343957~23345181:+
THCA	cis	rs8141529	1	rs8141529	ENSG00000272858.1	CTA-292E10.8	-5.59	3.94e-08	6.52e-06	-0.26	-0.25	Lymphocyte counts;	chr22:28873704	chr22:28814914~28815662:+
THCA	cis	rs7394190	0.81	rs7394152	ENSG00000271816.1	BMS1P4	-5.59	3.94e-08	6.52e-06	-0.29	-0.25	Incident atrial fibrillation;	chr10:73661688	chr10:73699151~73730487:-
THCA	cis	rs4604234	0.803	rs76568328	ENSG00000272129.1	RP11-250B2.6	-5.59	3.94e-08	6.52e-06	-0.6	-0.25	Cancer;	chr6:80267384	chr6:80355424~80356859:+
THCA	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-5.59	3.94e-08	6.52e-06	-0.15	-0.25	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
THCA	cis	rs1125355	0.622	rs62183665	ENSG00000251491.2	OR7E28P	-5.59	3.95e-08	6.53e-06	-0.41	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158789863	chr2:158862311~158863285:+
THCA	cis	rs8014252	0.667	rs10148586	ENSG00000259158.2	ADAM20P1	-5.59	3.95e-08	6.53e-06	-0.28	-0.25	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70340906	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.667	rs9323536	ENSG00000259158.2	ADAM20P1	-5.59	3.95e-08	6.53e-06	-0.28	-0.25	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70341886	chr14:70468881~70483756:-
THCA	cis	rs7674212	0.507	rs223413	ENSG00000248971.2	KRT8P46	5.59	3.95e-08	6.53e-06	0.3	0.25	Type 2 diabetes;	chr4:102811709	chr4:102728746~102730171:-
THCA	cis	rs8177876	0.731	rs76093926	ENSG00000261061.1	RP11-303E16.2	-5.59	3.95e-08	6.53e-06	-0.38	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.731	rs10514512	ENSG00000261061.1	RP11-303E16.2	-5.59	3.95e-08	6.53e-06	-0.38	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81030770~81031485:+
THCA	cis	rs375066	0.623	rs7254659	ENSG00000267058.1	RP11-15A1.3	5.59	3.95e-08	6.53e-06	0.22	0.25	Breast cancer;	chr19:43846537	chr19:43891804~43901805:-
THCA	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	5.59	3.95e-08	6.54e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
THCA	cis	rs6740322	0.895	rs9309098	ENSG00000234936.1	AC010883.5	-5.59	3.95e-08	6.54e-06	-0.27	-0.25	Coronary artery disease;	chr2:43327833	chr2:43229573~43233394:+
THCA	cis	rs2070488	0.775	rs7647657	ENSG00000229589.1	ACVR2B-AS1	-5.59	3.95e-08	6.54e-06	-0.22	-0.25	Electrocardiographic conduction measures;	chr3:38532255	chr3:38451027~38454820:-
THCA	cis	rs11795343	0.509	rs681481	ENSG00000232303.2	DFFBP1	-5.59	3.95e-08	6.54e-06	-0.29	-0.25	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32503029	chr9:32566148~32567126:-
THCA	cis	rs1501911	0.588	rs709389	ENSG00000248489.1	CTD-2007H13.3	5.59	3.96e-08	6.55e-06	0.25	0.25	Lung function (FEV1/FVC);	chr5:98994011	chr5:98929171~98995013:+
THCA	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	5.59	3.96e-08	6.55e-06	0.29	0.25	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
THCA	cis	rs12681287	0.673	rs4464946	ENSG00000254231.1	CTD-2284J15.1	5.59	3.96e-08	6.55e-06	0.29	0.25	Caudate activity during reward;	chr8:86314030	chr8:86333274~86343314:-
THCA	cis	rs113835537	0.529	rs17495838	ENSG00000255517.5	CTD-3074O7.5	-5.58	3.96e-08	6.56e-06	-0.24	-0.25	Airway imaging phenotypes;	chr11:66428794	chr11:66473490~66480233:-
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.96e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30738182~30740275:+
THCA	cis	rs7727544	0.735	rs2631370	ENSG00000224431.1	AC063976.7	-5.58	3.97e-08	6.56e-06	-0.21	-0.25	Blood metabolite levels;	chr5:132368084	chr5:132199456~132203487:+
THCA	cis	rs1322639	0.697	rs12661910	ENSG00000261039.2	RP11-417E7.2	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Pulse pressure;	chr6:169184293	chr6:169175304~169182740:-
THCA	cis	rs9652601	0.748	rs2903692	ENSG00000274038.1	RP11-66H6.4	-5.58	3.97e-08	6.56e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11144926	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.748	rs4322688	ENSG00000274038.1	RP11-66H6.4	-5.58	3.97e-08	6.56e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11145134	chr16:11056556~11057034:+
THCA	cis	rs16949788	1	rs74521803	ENSG00000261351.2	CTD-3185P2.1	-5.58	3.97e-08	6.56e-06	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66539923	chr15:66488658~66492109:-
THCA	cis	rs934734	0.752	rs268132	ENSG00000237979.1	AC007389.1	5.58	3.97e-08	6.56e-06	0.3	0.25	Rheumatoid arthritis;	chr2:65382543	chr2:65500993~65502138:-
THCA	cis	rs2281636	1	rs10786569	ENSG00000260475.1	RP11-85A1.3	5.58	3.97e-08	6.56e-06	0.23	0.25	Obesity-related traits;	chr10:99753828	chr10:99621055~99621918:+
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Body mass index;	chr17:30758740	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Body mass index;	chr17:30774046	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs12006	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000280069.1	CTD-2349P21.3	-5.58	3.97e-08	6.56e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30738182~30740275:+
THCA	cis	rs7824557	0.602	rs1435273	ENSG00000154316.13	TDH	-5.58	3.98e-08	6.58e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11351990	chr8:11339637~11368452:+
THCA	cis	rs875971	1	rs875971	ENSG00000223473.2	GS1-124K5.3	-5.58	3.98e-08	6.58e-06	-0.17	-0.25	Aortic root size;	chr7:66152608	chr7:66491049~66493566:-
THCA	cis	rs9494145	0.68	rs9376092	ENSG00000232876.1	CTA-212D2.2	5.58	3.98e-08	6.59e-06	0.35	0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106006	chr6:135055033~135060550:+
THCA	cis	rs7727544	0.545	rs4705915	ENSG00000224431.1	AC063976.7	5.58	3.99e-08	6.59e-06	0.24	0.25	Blood metabolite levels;	chr5:132055765	chr5:132199456~132203487:+
THCA	cis	rs593531	0.513	rs7944333	ENSG00000212961.4	HNRNPA1P40	-5.58	3.99e-08	6.59e-06	-0.32	-0.25	Neuroticism;	chr11:74311384	chr11:74354443~74355720:+
THCA	cis	rs116095464	0.51	rs7714944	ENSG00000248925.1	CTD-2083E4.6	5.58	3.99e-08	6.59e-06	0.36	0.25	Breast cancer;	chr5:231650	chr5:269858~271516:-
THCA	cis	rs11089937	0.512	rs6001073	ENSG00000211638.2	IGLV8-61	-5.58	3.99e-08	6.6e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.539	rs6001075	ENSG00000211638.2	IGLV8-61	-5.58	3.99e-08	6.6e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs5757005	ENSG00000211638.2	IGLV8-61	-5.58	3.99e-08	6.6e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22098700~22099212:+
THCA	cis	rs9859260	1	rs2239640	ENSG00000226155.1	AC124944.3	-5.58	3.99e-08	6.6e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196062837	chr3:195912049~195913986:+
THCA	cis	rs9652601	0.879	rs9926367	ENSG00000274038.1	RP11-66H6.4	-5.58	3.99e-08	6.6e-06	-0.33	-0.25	Systemic lupus erythematosus;	chr16:10999322	chr16:11056556~11057034:+
THCA	cis	rs6445975	0.617	rs4470539	ENSG00000272360.1	RP11-359I18.5	5.58	3.99e-08	6.6e-06	0.29	0.25	Systemic lupus erythematosus;	chr3:58418759	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs9822328	ENSG00000272360.1	RP11-359I18.5	5.58	3.99e-08	6.6e-06	0.29	0.25	Systemic lupus erythematosus;	chr3:58422110	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs6767291	ENSG00000272360.1	RP11-359I18.5	5.58	3.99e-08	6.6e-06	0.29	0.25	Systemic lupus erythematosus;	chr3:58423183	chr3:58490830~58491291:-
THCA	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-5.58	4e-08	6.61e-06	-0.27	-0.25	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
THCA	cis	rs9813712	0.595	rs1453240	ENSG00000249846.5	RP11-77P16.4	-5.58	4e-08	6.61e-06	-0.26	-0.25	Response to amphetamines;	chr3:130282849	chr3:130112550~130120579:+
THCA	cis	rs7923837	1	rs11187144	ENSG00000236493.2	EIF2S2P3	5.58	4e-08	6.61e-06	0.26	0.25	Multiple sclerosis;Body mass index;	chr10:92710223	chr10:92668745~92669743:-
THCA	cis	rs9368481	0.594	rs2636425	ENSG00000241549.7	GUSBP2	5.58	4e-08	6.61e-06	0.23	0.25	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26871484~26956554:-
THCA	cis	rs9400467	0.528	rs17539197	ENSG00000271789.1	RP5-1112D6.7	-5.58	4e-08	6.61e-06	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111297126~111298510:+
THCA	cis	rs9307551	0.948	rs1866835	ENSG00000250334.4	LINC00989	-5.58	4e-08	6.62e-06	-0.32	-0.25	Refractive error;	chr4:79626099	chr4:79492416~79576460:+
THCA	cis	rs59406912	1	rs59406912	ENSG00000261485.1	PAN3-AS1	5.58	4.01e-08	6.62e-06	0.37	0.25	Hepcidin/transferrin saturation ratio;	chr13:28269628	chr13:28136843~28138193:-
THCA	cis	rs62184315	0.536	rs16831873	ENSG00000273240.1	RP11-455J20.3	-5.58	4.01e-08	6.62e-06	-0.32	-0.25	Alcohol dependence (age at onset);	chr2:189692172	chr2:189763859~189764456:-
THCA	cis	rs7412746	0.524	rs58304714	ENSG00000231073.1	RP11-316M1.3	5.58	4.01e-08	6.62e-06	0.3	0.25	Melanoma;	chr1:150859085	chr1:150973123~150975534:+
THCA	cis	rs2179367	0.537	rs6911411	ENSG00000223701.3	RAET1E-AS1	5.58	4.01e-08	6.62e-06	0.39	0.25	Dupuytren's disease;	chr6:149366954	chr6:149884431~149919508:+
THCA	cis	rs2904967	0.636	rs514076	ENSG00000254614.2	AP003068.23	-5.58	4.01e-08	6.62e-06	-0.37	-0.25	Mean corpuscular volume;	chr11:65222570	chr11:65177606~65181834:-
THCA	cis	rs12999616	1	rs12999616	ENSG00000230606.9	AC159540.1	-5.58	4.01e-08	6.63e-06	-0.34	-0.25	Colorectal cancer;	chr2:97707918	chr2:97416165~97433527:-
THCA	cis	rs2212361	0.558	rs12294732	ENSG00000255893.1	RP11-685N10.1	-5.58	4.02e-08	6.64e-06	-0.28	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531716	chr11:94472908~94473570:-
THCA	cis	rs2303319	0.504	rs62187652	ENSG00000227403.1	AC009299.3	5.58	4.02e-08	6.64e-06	0.52	0.25	Cognitive function;	chr2:161611523	chr2:161244739~161249050:+
THCA	cis	rs4908768	0.501	rs6577502	ENSG00000232912.4	RP5-1115A15.1	5.58	4.02e-08	6.64e-06	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs1473420	ENSG00000232912.4	RP5-1115A15.1	5.58	4.02e-08	6.64e-06	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8424645~8434838:+
THCA	cis	rs752010	0.545	rs6600379	ENSG00000230638.4	RP11-486B10.4	-5.58	4.02e-08	6.64e-06	-0.27	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41587826	chr1:41542069~41544310:+
THCA	cis	rs7824557	0.614	rs17741537	ENSG00000154316.13	TDH	-5.58	4.02e-08	6.64e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11355583	chr8:11339637~11368452:+
THCA	cis	rs66887589	0.592	rs62320740	ENSG00000249244.1	RP11-548H18.2	5.58	4.02e-08	6.64e-06	0.27	0.25	Diastolic blood pressure;	chr4:119358331	chr4:119391831~119395335:-
THCA	cis	rs12893668	0.667	rs8017628	ENSG00000269910.1	RP11-73M18.10	5.58	4.02e-08	6.65e-06	0.23	0.25	Reticulocyte count;	chr14:103581091	chr14:103694516~103695050:-
THCA	cis	rs9388451	0.531	rs9321057	ENSG00000237742.5	RP11-624M8.1	-5.58	4.02e-08	6.65e-06	-0.22	-0.25	Brugada syndrome;	chr6:125835797	chr6:125578558~125749190:-
THCA	cis	rs1552244	0.935	rs66493421	ENSG00000232901.1	CYCSP10	5.58	4.02e-08	6.65e-06	0.37	0.25	Alzheimer's disease;	chr3:10050885	chr3:10000647~10000940:-
THCA	cis	rs914615	0.508	rs4971079	ENSG00000225855.5	RUSC1-AS1	5.58	4.02e-08	6.65e-06	0.16	0.25	Urinary albumin-to-creatinine ratio;	chr1:155157915	chr1:155316863~155324176:-
THCA	cis	rs9859260	0.961	rs9846149	ENSG00000226155.1	AC124944.3	-5.58	4.03e-08	6.65e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196060437	chr3:195912049~195913986:+
THCA	cis	rs7309	0.622	rs4664396	ENSG00000235724.7	AC009299.2	5.58	4.03e-08	6.65e-06	0.26	0.25	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161222785~161308303:-
THCA	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	5.58	4.03e-08	6.65e-06	0.38	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
THCA	cis	rs6545883	0.868	rs2518932	ENSG00000270820.4	RP11-355B11.2	5.58	4.03e-08	6.65e-06	0.21	0.25	Tuberculosis;	chr2:61574142	chr2:61471188~61484130:+
THCA	cis	rs1865760	0.566	rs9358902	ENSG00000272462.2	U91328.19	-5.58	4.03e-08	6.66e-06	-0.21	-0.25	Height;	chr6:26058342	chr6:25992662~26001775:+
THCA	cis	rs6928977	0.863	rs9389286	ENSG00000231028.7	LINC00271	5.58	4.04e-08	6.67e-06	0.19	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135319827	chr6:135497801~135716055:+
THCA	cis	rs1552244	0.935	rs28815328	ENSG00000232901.1	CYCSP10	5.58	4.04e-08	6.67e-06	0.33	0.25	Alzheimer's disease;	chr3:10020543	chr3:10000647~10000940:-
THCA	cis	rs17772222	0.501	rs17124889	ENSG00000258789.1	RP11-507K2.3	-5.58	4.04e-08	6.67e-06	-0.23	-0.25	Coronary artery calcification;	chr14:88834557	chr14:88551597~88552493:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000224316.1	RP11-479O9.2	5.58	4.05e-08	6.68e-06	0.29	0.25	Aortic root size;	chr7:65960907	chr7:65773620~65802067:+
THCA	cis	rs752010	0.571	rs10890135	ENSG00000230638.4	RP11-486B10.4	-5.58	4.05e-08	6.68e-06	-0.27	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41588413	chr1:41542069~41544310:+
THCA	cis	rs11749327	0.688	rs72700688	ENSG00000221990.4	EXOC3-AS1	5.58	4.05e-08	6.69e-06	0.26	0.25	Hemoglobin concentration;Hypospadias;	chr5:473976	chr5:441498~443160:-
THCA	cis	rs4415084	0.834	rs7711697	ENSG00000272335.1	RP11-53O19.3	-5.58	4.05e-08	6.69e-06	-0.21	-0.25	Breast cancer;	chr5:44780301	chr5:44826076~44828592:+
THCA	cis	rs7412746	0.658	rs6657388	ENSG00000231073.1	RP11-316M1.3	5.58	4.05e-08	6.69e-06	0.31	0.25	Melanoma;	chr1:150776310	chr1:150973123~150975534:+
THCA	cis	rs2303319	0.504	rs66761688	ENSG00000227403.1	AC009299.3	5.58	4.05e-08	6.7e-06	0.51	0.25	Cognitive function;	chr2:161722401	chr2:161244739~161249050:+
THCA	cis	rs1426063	1	rs11941556	ENSG00000260265.1	RP11-44F21.5	5.58	4.06e-08	6.7e-06	0.47	0.25	QT interval;	chr4:75093825	chr4:75081702~75084717:-
THCA	cis	rs9388451	0.903	rs7758115	ENSG00000226409.1	RP11-735G4.1	-5.58	4.06e-08	6.7e-06	-0.3	-0.25	Brugada syndrome;	chr6:125740356	chr6:125370211~125374324:-
THCA	cis	rs79040073	0.637	rs11630318	ENSG00000259531.2	RP11-295H24.3	-5.58	4.06e-08	6.7e-06	-0.36	-0.25	Lung cancer in ever smokers;	chr15:49312606	chr15:49365124~49366685:-
THCA	cis	rs10829156	0.66	rs4338439	ENSG00000240291.1	RP11-499P20.2	5.58	4.06e-08	6.7e-06	0.21	0.25	Sudden cardiac arrest;	chr10:18594220	chr10:18513115~18545651:-
THCA	cis	rs2797160	0.684	rs1832937	ENSG00000237742.5	RP11-624M8.1	5.58	4.06e-08	6.71e-06	0.22	0.25	Endometrial cancer;	chr6:125664788	chr6:125578558~125749190:-
THCA	cis	rs7674212	0.541	rs2720464	ENSG00000251288.2	RP11-10L12.2	-5.58	4.07e-08	6.71e-06	-0.32	-0.25	Type 2 diabetes;	chr4:103152044	chr4:102751401~102752641:+
THCA	cis	rs897984	0.683	rs729482	ENSG00000279196.1	RP11-1072A3.3	5.58	4.07e-08	6.72e-06	0.26	0.25	Dementia with Lewy bodies;	chr16:31005649	chr16:30984630~30988270:-
THCA	cis	rs4266144	0.544	rs6805781	ENSG00000241770.1	RP11-555M1.3	5.58	4.07e-08	6.72e-06	0.3	0.25	Coronary artery disease;	chr3:157112780	chr3:157163452~157169133:+
THCA	cis	rs8062405	0.824	rs4788083	ENSG00000278665.1	RP11-666O2.4	5.58	4.07e-08	6.72e-06	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28599241~28601881:-
THCA	cis	rs1318937	0.764	rs9864422	ENSG00000224660.1	SH3BP5-AS1	5.58	4.07e-08	6.72e-06	0.17	0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15185745	chr3:15254184~15264493:+
THCA	cis	rs7523875	0.572	rs3738203	ENSG00000153363.11	LINC00467	-5.58	4.07e-08	6.72e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211382662	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs17017451	ENSG00000153363.11	LINC00467	-5.58	4.07e-08	6.72e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211384566	chr1:211382803~211435333:+
THCA	cis	rs2115536	0.692	rs6495450	ENSG00000278600.1	RP11-81A1.6	-5.58	4.07e-08	6.72e-06	-0.16	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79870157	chr15:79920195~79922455:-
THCA	cis	rs17345786	1	rs11715368	ENSG00000256628.3	ZBTB11-AS1	5.58	4.07e-08	6.72e-06	0.31	0.25	Colonoscopy-negative controls vs population controls;	chr3:101617536	chr3:101676475~101679217:+
THCA	cis	rs7833787	0.896	rs6586779	ENSG00000278886.1	RP11-108A14.1	5.58	4.07e-08	6.72e-06	0.33	0.25	Obesity-related traits;	chr8:18853629	chr8:18864681~18865247:-
THCA	cis	rs9309473	0.5	rs11126402	ENSG00000163016.8	ALMS1P	5.58	4.07e-08	6.72e-06	0.32	0.25	Metabolite levels;	chr2:73549455	chr2:73644919~73685576:+
THCA	cis	rs2904967	0.562	rs239255	ENSG00000254614.2	AP003068.23	-5.58	4.07e-08	6.72e-06	-0.37	-0.25	Mean corpuscular volume;	chr11:65219657	chr11:65177606~65181834:-
THCA	cis	rs4604234	0.803	rs73463518	ENSG00000272129.1	RP11-250B2.6	-5.58	4.08e-08	6.73e-06	-0.6	-0.25	Cancer;	chr6:80266300	chr6:80355424~80356859:+
THCA	cis	rs9467773	0.526	rs12199613	ENSG00000124549.13	BTN2A3P	-5.58	4.08e-08	6.73e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26366990	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.526	rs9688946	ENSG00000124549.13	BTN2A3P	-5.58	4.08e-08	6.73e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26367217	chr6:26421391~26432383:+
THCA	cis	rs12472274	0.646	rs10929269	ENSG00000279484.1	KLHL30-AS1	5.58	4.08e-08	6.73e-06	0.32	0.25	Phospholipid levels (plasma);	chr2:238188782	chr2:238152889~238155994:-
THCA	cis	rs595244	1	rs1678981	ENSG00000259705.1	RP11-227D13.1	5.58	4.08e-08	6.74e-06	0.44	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48607900	chr15:48645951~48652016:+
THCA	cis	rs10208649	1	rs7599335	ENSG00000233266.1	HMGB1P31	5.58	4.09e-08	6.74e-06	0.57	0.25	Body mass index;	chr2:53914500	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs7560575	ENSG00000233266.1	HMGB1P31	5.58	4.09e-08	6.74e-06	0.57	0.25	Body mass index;	chr2:53914893	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs13389673	ENSG00000233266.1	HMGB1P31	5.58	4.09e-08	6.74e-06	0.57	0.25	Body mass index;	chr2:53916185	chr2:54051334~54051760:+
THCA	cis	rs7131987	0.903	rs67150462	ENSG00000257176.2	RP11-996F15.2	-5.58	4.09e-08	6.75e-06	-0.25	-0.25	QT interval;	chr12:29240392	chr12:29280418~29317848:-
THCA	cis	rs2617170	0.883	rs2733851	ENSG00000245648.1	RP11-277P12.20	5.58	4.09e-08	6.75e-06	0.27	0.25	Behcet's disease;	chr12:10376498	chr12:10363769~10398506:+
THCA	cis	rs3213758	1	rs12447950	ENSG00000275191.1	RP11-36I17.2	-5.58	4.09e-08	6.76e-06	-0.5	-0.25	Vitiligo (non-segmental);	chr16:53537079	chr16:53628256~53628816:-
THCA	cis	rs853679	0.76	rs11962305	ENSG00000226314.6	ZNF192P1	-5.58	4.09e-08	6.76e-06	-0.35	-0.25	Depression;	chr6:28232159	chr6:28161781~28169594:+
THCA	cis	rs17508449	0.819	rs4839331	ENSG00000232450.1	RP4-730K3.3	-5.58	4.1e-08	6.76e-06	-0.38	-0.25	Leprosy;	chr1:113619009	chr1:113698884~113699631:-
THCA	cis	rs7403037	0.848	rs7403467	ENSG00000259905.4	PWRN1	5.58	4.1e-08	6.76e-06	0.27	0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24595276	chr15:24493137~24652130:+
THCA	cis	rs1552244	1	rs35993975	ENSG00000232901.1	CYCSP10	5.58	4.1e-08	6.76e-06	0.34	0.25	Alzheimer's disease;	chr3:10026110	chr3:10000647~10000940:-
THCA	cis	rs6840360	0.582	rs2709827	ENSG00000270265.1	RP11-731D1.4	-5.58	4.1e-08	6.76e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151333775~151353224:-
THCA	cis	rs1426063	1	rs10022814	ENSG00000260265.1	RP11-44F21.5	5.58	4.1e-08	6.76e-06	0.47	0.25	QT interval;	chr4:75094704	chr4:75081702~75084717:-
THCA	cis	rs1426063	1	rs10029141	ENSG00000260265.1	RP11-44F21.5	5.58	4.1e-08	6.76e-06	0.47	0.25	QT interval;	chr4:75097437	chr4:75081702~75084717:-
THCA	cis	rs7617773	0.817	rs6806112	ENSG00000199476.1	Y_RNA	-5.58	4.1e-08	6.77e-06	-0.31	-0.25	Coronary artery disease;	chr3:48234587	chr3:48288587~48288694:+
THCA	cis	rs934734	0.789	rs10188563	ENSG00000234255.7	AC012370.3	5.58	4.1e-08	6.77e-06	0.29	0.25	Rheumatoid arthritis;	chr2:65342805	chr2:65439888~65456571:-
THCA	cis	rs3169166	0.5	rs12901552	ENSG00000259562.2	RP11-762H8.2	-5.58	4.1e-08	6.77e-06	-0.17	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78269818	chr15:78290527~78291221:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	5.58	4.1e-08	6.77e-06	0.28	0.25	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
THCA	cis	rs7246657	0.722	rs2927742	ENSG00000276846.1	CTD-3220F14.3	-5.58	4.11e-08	6.77e-06	-0.25	-0.25	Coronary artery calcification;	chr19:37642717	chr19:37314868~37315620:-
THCA	cis	rs7897654	0.571	rs12765002	ENSG00000213277.3	MARCKSL1P1	5.58	4.11e-08	6.77e-06	0.29	0.25	Schizophrenia;	chr10:102875591	chr10:103175554~103176094:+
THCA	cis	rs12478296	0.792	rs6755390	ENSG00000261186.2	RP11-341N2.1	-5.58	4.11e-08	6.78e-06	-0.4	-0.25	Obesity-related traits;	chr2:242070847	chr2:242087351~242088457:-
THCA	cis	rs2436845	0.627	rs2513920	ENSG00000253669.3	KB-1732A1.1	-5.58	4.11e-08	6.78e-06	-0.27	-0.25	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102818464	chr8:102805517~102809971:+
THCA	cis	rs4663866	0.901	rs3739067	ENSG00000186235.9	AC016757.3	5.58	4.11e-08	6.78e-06	0.57	0.25	Irritable bowel syndrome;	chr2:238275562	chr2:238224552~238231677:-
THCA	cis	rs2179367	0.632	rs9285520	ENSG00000268592.3	RAET1E-AS1	-5.58	4.11e-08	6.78e-06	-0.36	-0.25	Dupuytren's disease;	chr6:149372001	chr6:149863494~149919507:+
THCA	cis	rs7412746	0.634	rs7521592	ENSG00000231073.1	RP11-316M1.3	5.58	4.11e-08	6.78e-06	0.3	0.25	Melanoma;	chr1:150849215	chr1:150973123~150975534:+
THCA	cis	rs2562456	0.55	rs4809143	ENSG00000268119.4	CTD-2561J22.5	5.58	4.11e-08	6.78e-06	0.33	0.25	Pain;	chr19:21589926	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.583	rs4809144	ENSG00000268119.4	CTD-2561J22.5	5.58	4.11e-08	6.78e-06	0.33	0.25	Pain;	chr19:21589928	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.652	rs62110214	ENSG00000268119.4	CTD-2561J22.5	5.58	4.11e-08	6.78e-06	0.33	0.25	Pain;	chr19:21592406	chr19:21444241~21463908:-
THCA	cis	rs9880211	0.615	rs66890203	ENSG00000273486.1	RP11-731C17.2	5.58	4.11e-08	6.78e-06	0.33	0.25	Height;Body mass index;	chr3:136434703	chr3:136837338~136839021:-
THCA	cis	rs55823223	0.564	rs12103594	ENSG00000267801.1	RP11-552F3.9	5.58	4.11e-08	6.78e-06	0.32	0.25	Psoriasis;	chr17:75859198	chr17:75876372~75879546:+
THCA	cis	rs55823223	0.59	rs11870142	ENSG00000267801.1	RP11-552F3.9	5.58	4.11e-08	6.78e-06	0.32	0.25	Psoriasis;	chr17:75862921	chr17:75876372~75879546:+
THCA	cis	rs55823223	0.503	rs55699990	ENSG00000267801.1	RP11-552F3.9	5.58	4.11e-08	6.78e-06	0.32	0.25	Psoriasis;	chr17:75863105	chr17:75876372~75879546:+
THCA	cis	rs55823223	0.504	rs56098714	ENSG00000267801.1	RP11-552F3.9	5.58	4.11e-08	6.78e-06	0.32	0.25	Psoriasis;	chr17:75864222	chr17:75876372~75879546:+
THCA	cis	rs2243480	1	rs73142166	ENSG00000232546.1	RP11-458F8.1	-5.58	4.12e-08	6.8e-06	-0.33	-0.25	Diabetic kidney disease;	chr7:65910845	chr7:66848496~66858136:+
THCA	cis	rs4650994	0.507	rs2811312	ENSG00000273384.1	RP5-1098D14.1	-5.58	4.12e-08	6.8e-06	-0.32	-0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178648468	chr1:178651706~178652282:+
THCA	cis	rs2436845	0.783	rs1062315	ENSG00000253669.3	KB-1732A1.1	-5.58	4.12e-08	6.8e-06	-0.27	-0.25	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102826936	chr8:102805517~102809971:+
THCA	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	5.58	4.13e-08	6.81e-06	0.39	0.25	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	5.58	4.13e-08	6.81e-06	0.39	0.25	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
THCA	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	5.58	4.13e-08	6.81e-06	0.15	0.25	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
THCA	cis	rs71520386	0.632	rs10224419	ENSG00000228649.7	AC005682.5	5.58	4.13e-08	6.81e-06	0.32	0.25	Fibrinogen levels;	chr7:22830397	chr7:22854178~22861579:+
THCA	cis	rs2129782	1	rs10099461	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88391486	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10103336	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88391664	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73279224	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88392037	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73279229	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88392346	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73279231	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88392435	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs16882035	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88392488	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59107062	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88392943	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs73279236	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88394422	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10104706	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88394665	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10086327	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88394726	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs73692252	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88395582	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs10109321	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88396342	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs57283474	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88398060	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs7462228	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88398136	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59725465	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88398268	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10103474	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88399057	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59430846	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88399552	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs57771217	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88399631	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59425875	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88399670	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs60374267	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88400067	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs58984354	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88400128	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs60895850	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88400325	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs28768402	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88400423	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs28877640	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88400726	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10109475	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88402619	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10094278	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88402625	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10087268	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88402659	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10112258	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88402675	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1354521	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88402944	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1354522	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88403264	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs1354524	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88403376	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs9297464	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88403767	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs10088380	ENSG00000253553.4	RP11-586K2.1	5.58	4.13e-08	6.81e-06	0.43	0.25	Electrodermal activity;	chr8:88403789	chr8:88326836~88737134:+
THCA	cis	rs593531	0.524	rs634608	ENSG00000255440.1	RP11-632K5.2	5.58	4.13e-08	6.81e-06	0.29	0.25	Neuroticism;	chr11:74373684	chr11:74409060~74416379:+
THCA	cis	rs4713118	0.662	rs149970	ENSG00000220721.1	OR1F12	5.58	4.13e-08	6.82e-06	0.32	0.25	Parkinson's disease;	chr6:28012442	chr6:28073316~28074233:+
THCA	cis	rs9813712	0.953	rs12635811	ENSG00000228252.7	COL6A4P2	-5.58	4.13e-08	6.82e-06	-0.29	-0.25	Response to amphetamines;	chr3:130262534	chr3:130212823~130273806:+
THCA	cis	rs7927592	0.546	rs497261	ENSG00000212093.1	AP000807.1	5.58	4.14e-08	6.82e-06	0.26	0.25	Total body bone mineral density;	chr11:68424776	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.546	rs599083	ENSG00000212093.1	AP000807.1	5.58	4.14e-08	6.82e-06	0.26	0.25	Total body bone mineral density;	chr11:68424878	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.546	rs683978	ENSG00000212093.1	AP000807.1	5.58	4.14e-08	6.82e-06	0.26	0.25	Total body bone mineral density;	chr11:68424953	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.546	rs554734	ENSG00000212093.1	AP000807.1	5.58	4.14e-08	6.82e-06	0.26	0.25	Total body bone mineral density;	chr11:68425050	chr11:68506083~68506166:-
THCA	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	5.58	4.14e-08	6.82e-06	0.26	0.25	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
THCA	cis	rs7829975	0.511	rs2955578	ENSG00000254153.1	CTA-398F10.2	-5.58	4.14e-08	6.82e-06	-0.27	-0.25	Mood instability;	chr8:8279561	chr8:8456909~8461337:-
THCA	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	5.58	4.15e-08	6.83e-06	0.15	0.25	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	5.58	4.15e-08	6.83e-06	0.15	0.25	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	5.58	4.15e-08	6.83e-06	0.15	0.25	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	5.58	4.15e-08	6.83e-06	0.15	0.25	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
THCA	cis	rs2303319	0.504	rs16846050	ENSG00000227403.1	AC009299.3	-5.58	4.15e-08	6.83e-06	-0.51	-0.25	Cognitive function;	chr2:161707043	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs1515184	ENSG00000227403.1	AC009299.3	5.58	4.15e-08	6.83e-06	0.51	0.25	Cognitive function;	chr2:161704837	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs16846047	ENSG00000227403.1	AC009299.3	5.58	4.15e-08	6.83e-06	0.51	0.25	Cognitive function;	chr2:161705436	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189005	ENSG00000227403.1	AC009299.3	5.58	4.15e-08	6.83e-06	0.51	0.25	Cognitive function;	chr2:161705876	chr2:161244739~161249050:+
THCA	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	5.58	4.15e-08	6.84e-06	0.38	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
THCA	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	5.58	4.15e-08	6.84e-06	0.38	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
THCA	cis	rs12497850	1	rs4858828	ENSG00000229759.1	MRPS18AP1	5.58	4.15e-08	6.84e-06	0.32	0.25	Parkinson's disease;	chr3:48687378	chr3:48256350~48256938:-
THCA	cis	rs12497850	1	rs4858798	ENSG00000229759.1	MRPS18AP1	5.58	4.15e-08	6.84e-06	0.32	0.25	Parkinson's disease;	chr3:48689679	chr3:48256350~48256938:-
THCA	cis	rs62432291	0.681	rs402388	ENSG00000235086.1	FNDC1-IT1	-5.58	4.15e-08	6.84e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159233962	chr6:159240786~159243329:+
THCA	cis	rs67981189	0.546	rs2810075	ENSG00000269927.1	RP6-91H8.3	-5.58	4.15e-08	6.84e-06	-0.3	-0.25	Schizophrenia;	chr14:70908363	chr14:71141125~71143253:-
THCA	cis	rs12101261	0.506	rs1990597	ENSG00000259167.2	NMNAT1P1	5.58	4.15e-08	6.84e-06	0.39	0.25	Graves' disease;	chr14:80996788	chr14:81032529~81033404:+
THCA	cis	rs7760535	0.93	rs7742244	ENSG00000230177.1	RP5-1112D6.4	-5.58	4.15e-08	6.84e-06	-0.21	-0.25	Metabolic traits;	chr6:111531459	chr6:111277932~111278742:+
THCA	cis	rs8177876	0.749	rs79834398	ENSG00000261061.1	RP11-303E16.2	-5.58	4.15e-08	6.84e-06	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81030770~81031485:+
THCA	cis	rs911119	0.913	rs13043610	ENSG00000270001.1	RP11-218C14.8	-5.58	4.15e-08	6.85e-06	-0.39	-0.25	Chronic kidney disease;	chr20:23606304	chr20:23631826~23632316:-
THCA	cis	rs2361701	0.543	rs59252872	ENSG00000275479.1	RP11-334C17.6	5.58	4.16e-08	6.85e-06	0.24	0.25	IgG glycosylation;	chr17:80097448	chr17:80149627~80149798:+
THCA	cis	rs147858478	1	rs147858478	ENSG00000224431.1	AC063976.7	5.58	4.16e-08	6.85e-06	0.21	0.25	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132199456~132203487:+
THCA	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-5.58	4.16e-08	6.85e-06	-0.29	-0.25	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
THCA	cis	rs8062405	0.895	rs56186137	ENSG00000278665.1	RP11-666O2.4	5.58	4.16e-08	6.85e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28599241~28601881:-
THCA	cis	rs7617773	1	rs6442108	ENSG00000199476.1	Y_RNA	5.58	4.16e-08	6.85e-06	0.32	0.25	Coronary artery disease;	chr3:48151469	chr3:48288587~48288694:+
THCA	cis	rs7617773	1	rs6442109	ENSG00000199476.1	Y_RNA	5.58	4.16e-08	6.85e-06	0.32	0.25	Coronary artery disease;	chr3:48151491	chr3:48288587~48288694:+
THCA	cis	rs763567	0.845	rs492804	ENSG00000271811.1	RP1-79C4.4	5.58	4.16e-08	6.86e-06	0.29	0.25	Tonsillectomy;	chr1:170643121	chr1:170667381~170669425:+
THCA	cis	rs763567	0.967	rs654461	ENSG00000271811.1	RP1-79C4.4	5.58	4.16e-08	6.86e-06	0.29	0.25	Tonsillectomy;	chr1:170644709	chr1:170667381~170669425:+
THCA	cis	rs763567	0.967	rs593560	ENSG00000271811.1	RP1-79C4.4	5.58	4.16e-08	6.86e-06	0.29	0.25	Tonsillectomy;	chr1:170646776	chr1:170667381~170669425:+
THCA	cis	rs202072	0.72	rs454563	ENSG00000272379.1	RP1-257A7.5	5.58	4.16e-08	6.86e-06	0.43	0.25	HIV-1 viral setpoint;	chr6:13295304	chr6:13290018~13290490:-
THCA	cis	rs12893668	0.703	rs2274267	ENSG00000269910.1	RP11-73M18.10	5.58	4.16e-08	6.86e-06	0.24	0.25	Reticulocyte count;	chr14:103563112	chr14:103694516~103695050:-
THCA	cis	rs7246657	0.722	rs1975937	ENSG00000276846.1	CTD-3220F14.3	5.58	4.16e-08	6.86e-06	0.25	0.25	Coronary artery calcification;	chr19:37601031	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs8103647	ENSG00000276846.1	CTD-3220F14.3	5.58	4.16e-08	6.86e-06	0.25	0.25	Coronary artery calcification;	chr19:37609551	chr19:37314868~37315620:-
THCA	cis	rs8033133	0.678	rs7496110	ENSG00000251896.1	SNORD116-27	-5.58	4.16e-08	6.86e-06	-0.27	-0.25	Blood osmolality (transformed sodium);	chr15:25101866	chr15:25101575~25101666:+
THCA	cis	rs2720460	0.502	rs223374	ENSG00000248971.2	KRT8P46	-5.58	4.17e-08	6.87e-06	-0.3	-0.25	Testicular germ cell tumor;	chr4:102837144	chr4:102728746~102730171:-
THCA	cis	rs9876781	1	rs9311423	ENSG00000229759.1	MRPS18AP1	5.58	4.17e-08	6.87e-06	0.29	0.25	Longevity;	chr3:48378818	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs7634377	ENSG00000229759.1	MRPS18AP1	5.58	4.17e-08	6.87e-06	0.29	0.25	Longevity;	chr3:48379768	chr3:48256350~48256938:-
THCA	cis	rs2803122	0.756	rs1129101	ENSG00000273226.1	RP11-513M16.8	5.58	4.17e-08	6.88e-06	0.23	0.25	Pulse pressure;	chr9:19372992	chr9:19375451~19375996:+
THCA	cis	rs4776997	0.536	rs11071957	ENSG00000270964.1	RP11-502I4.3	5.58	4.17e-08	6.88e-06	0.23	0.25	Verbal declarative memory;	chr15:67766309	chr15:67541072~67542604:-
THCA	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	5.58	4.18e-08	6.88e-06	0.44	0.25	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
THCA	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	5.58	4.18e-08	6.88e-06	0.44	0.25	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
THCA	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-5.58	4.18e-08	6.88e-06	-0.53	-0.25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
THCA	cis	rs1635	0.826	rs1233710	ENSG00000216901.1	AL022393.7	5.58	4.18e-08	6.88e-06	0.53	0.25	Schizophrenia;	chr6:28247668	chr6:28176188~28176674:+
THCA	cis	rs116095464	0.558	rs10079760	ENSG00000248925.1	CTD-2083E4.6	5.57	4.18e-08	6.89e-06	0.36	0.25	Breast cancer;	chr5:230663	chr5:269858~271516:-
THCA	cis	rs713477	0.967	rs10150596	ENSG00000258413.1	RP11-665C16.6	-5.57	4.18e-08	6.89e-06	-0.33	-0.25	Pediatric bone mineral content (femoral neck);	chr14:55449449	chr14:55262767~55272075:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	5.57	4.18e-08	6.89e-06	0.28	0.25	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
THCA	cis	rs9813712	0.595	rs6439226	ENSG00000249846.5	RP11-77P16.4	5.57	4.18e-08	6.89e-06	0.25	0.25	Response to amphetamines;	chr3:130283686	chr3:130112550~130120579:+
THCA	cis	rs3950186	0.794	rs4557506	ENSG00000215124.2	RP3-420J14.1	5.57	4.19e-08	6.9e-06	0.29	0.25	Anxiety and major depressive disorder;	chr6:11826374	chr6:11861626~11862970:-
THCA	cis	rs35851103	0.507	rs6601649	ENSG00000255052.4	FAM66D	5.57	4.19e-08	6.9e-06	0.34	0.25	Neuroticism;	chr8:11999808	chr8:12115782~12177550:+
THCA	cis	rs67340775	0.541	rs200966	ENSG00000280107.1	AL022393.9	-5.57	4.19e-08	6.91e-06	-0.34	-0.25	Lung cancer in ever smokers;	chr6:27894374	chr6:28170845~28172521:+
THCA	cis	rs4968361	0.892	rs67028302	ENSG00000266992.1	DHX40P1	5.57	4.2e-08	6.91e-06	0.41	0.25	Schizophrenia;	chr17:59443342	chr17:59976009~60002384:-
THCA	cis	rs763567	0.935	rs1234275	ENSG00000271811.1	RP1-79C4.4	-5.57	4.2e-08	6.91e-06	-0.29	-0.25	Tonsillectomy;	chr1:170627117	chr1:170667381~170669425:+
THCA	cis	rs2212361	0.558	rs16924610	ENSG00000255893.1	RP11-685N10.1	-5.57	4.2e-08	6.91e-06	-0.3	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531490	chr11:94472908~94473570:-
THCA	cis	rs2212361	0.558	rs72980480	ENSG00000255893.1	RP11-685N10.1	-5.57	4.2e-08	6.91e-06	-0.3	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94532852	chr11:94472908~94473570:-
THCA	cis	rs890448	0.726	rs28664200	ENSG00000254531.1	FLJ20021	-5.57	4.2e-08	6.92e-06	-0.22	-0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101330344	chr4:101347780~101348883:+
THCA	cis	rs7674212	0.51	rs2720468	ENSG00000246560.2	RP11-10L12.4	5.57	4.2e-08	6.92e-06	0.3	0.25	Type 2 diabetes;	chr4:103163996	chr4:102828055~102844075:+
THCA	cis	rs9818758	0.545	rs9853352	ENSG00000270441.1	RP11-694I15.7	-5.57	4.2e-08	6.92e-06	-0.35	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49775825	chr3:49140086~49160851:-
THCA	cis	rs2281603	0.951	rs73267743	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64511424	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs73267744	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64511461	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs61985707	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64512846	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs12586212	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64513329	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs61615397	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64514346	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs10133243	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64514807	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs12589947	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64515453	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs3783724	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64516759	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs3783723	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64516821	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs12587136	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64518570	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs58893738	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64519093	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs28626711	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64521561	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs10133411	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64522206	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs17101896	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64526205	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs59512674	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64526295	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs61985711	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64526540	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs10142835	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64526733	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs10143170	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64527045	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs10138256	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64528494	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs10149286	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64528518	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs1453009	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64528976	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs11158544	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64529769	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs12588886	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64530226	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.951	rs1453004	ENSG00000272909.1	CTD-2555O16.4	-5.57	4.2e-08	6.92e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64530237	chr14:64440369~64442238:-
THCA	cis	rs4888671	0.901	rs11860267	ENSG00000261707.1	RP11-264M12.2	5.57	4.21e-08	6.93e-06	0.46	0.25	Obesity-related traits;	chr16:77745329	chr16:77741468~77743000:-
THCA	cis	rs6968419	0.755	rs73452247	ENSG00000237870.5	AC073130.1	5.57	4.21e-08	6.93e-06	0.27	0.25	Intraocular pressure;	chr7:116253843	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.755	rs17138486	ENSG00000237870.5	AC073130.1	5.57	4.21e-08	6.93e-06	0.27	0.25	Intraocular pressure;	chr7:116254349	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.755	rs6948556	ENSG00000237870.5	AC073130.1	5.57	4.21e-08	6.93e-06	0.27	0.25	Intraocular pressure;	chr7:116255379	chr7:116275606~116286734:-
THCA	cis	rs2839186	0.596	rs4819217	ENSG00000215424.8	MCM3AP-AS1	5.57	4.21e-08	6.93e-06	0.15	0.25	Testicular germ cell tumor;	chr21:46224178	chr21:46229217~46259390:+
THCA	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	5.57	4.21e-08	6.93e-06	0.23	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
THCA	cis	rs11089937	0.667	rs78549985	ENSG00000211639.2	IGLV4-60	5.57	4.21e-08	6.93e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22162199~22162681:+
THCA	cis	rs6951245	1	rs78185558	ENSG00000229043.2	AC091729.9	-5.57	4.21e-08	6.94e-06	-0.42	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1160374~1165267:+
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	5.57	4.21e-08	6.94e-06	0.31	0.25	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
THCA	cis	rs62184315	0.536	rs5742985	ENSG00000273240.1	RP11-455J20.3	-5.57	4.21e-08	6.94e-06	-0.33	-0.25	Alcohol dependence (age at onset);	chr2:189796383	chr2:189763859~189764456:-
THCA	cis	rs1865760	0.534	rs1541988	ENSG00000272462.2	U91328.19	-5.57	4.21e-08	6.94e-06	-0.2	-0.25	Height;	chr6:25950576	chr6:25992662~26001775:+
THCA	cis	rs714027	1	rs6006356	ENSG00000279159.1	RP3-394A18.1	-5.57	4.21e-08	6.94e-06	-0.17	-0.25	Lymphocyte counts;	chr22:30107182	chr22:29978950~30028236:-
THCA	cis	rs17767392	1	rs34746156	ENSG00000259146.3	RP1-261D10.2	5.57	4.22e-08	6.94e-06	0.32	0.25	Mitral valve prolapse;	chr14:71285643	chr14:71292729~71321814:-
THCA	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	5.57	4.22e-08	6.94e-06	0.35	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
THCA	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	5.57	4.22e-08	6.94e-06	0.35	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
THCA	cis	rs6928977	0.863	rs2179780	ENSG00000231028.7	LINC00271	5.57	4.22e-08	6.95e-06	0.19	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135329128	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.863	rs2614255	ENSG00000231028.7	LINC00271	5.57	4.22e-08	6.95e-06	0.19	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135342443	chr6:135497801~135716055:+
THCA	cis	rs11722228	0.522	rs77691548	ENSG00000261490.1	RP11-448G15.3	5.57	4.22e-08	6.95e-06	0.18	0.25	Urate levels;Serum uric acid levels;Gout;	chr4:10134491	chr4:10068089~10073019:-
THCA	cis	rs7674212	0.531	rs4698876	ENSG00000230069.3	LRRC37A15P	-5.57	4.22e-08	6.95e-06	-0.26	-0.25	Type 2 diabetes;	chr4:103012410	chr4:102727274~102730721:-
THCA	cis	rs7674212	0.531	rs7665026	ENSG00000230069.3	LRRC37A15P	-5.57	4.22e-08	6.95e-06	-0.26	-0.25	Type 2 diabetes;	chr4:103015491	chr4:102727274~102730721:-
THCA	cis	rs11671005	0.695	rs12972898	ENSG00000269473.1	CTD-2619J13.19	5.57	4.22e-08	6.95e-06	0.3	0.25	Mean platelet volume;	chr19:58445521	chr19:58440448~58445849:+
THCA	cis	rs72615157	0.561	rs113401658	ENSG00000078319.8	PMS2P1	-5.57	4.23e-08	6.95e-06	-0.35	-0.25	Lung function (FEV1/FVC);	chr7:100260882	chr7:100320992~100341908:-
THCA	cis	rs72615157	0.561	rs113844570	ENSG00000078319.8	PMS2P1	-5.57	4.23e-08	6.95e-06	-0.35	-0.25	Lung function (FEV1/FVC);	chr7:100276155	chr7:100320992~100341908:-
THCA	cis	rs2115536	0.692	rs6495451	ENSG00000278600.1	RP11-81A1.6	-5.57	4.23e-08	6.96e-06	-0.16	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79871711	chr15:79920195~79922455:-
THCA	cis	rs9652601	0.879	rs8062322	ENSG00000274038.1	RP11-66H6.4	-5.57	4.23e-08	6.96e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr16:10998462	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.779	rs12935413	ENSG00000274038.1	RP11-66H6.4	-5.57	4.23e-08	6.96e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11116590	chr16:11056556~11057034:+
THCA	cis	rs12612619	0.704	rs6746337	ENSG00000229122.1	AGBL5-IT1	-5.57	4.23e-08	6.96e-06	-0.18	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27118195	chr2:27061038~27061815:+
THCA	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-5.57	4.24e-08	6.97e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-5.57	4.24e-08	6.97e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Body mass index;	chr17:30751280	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.97e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.24e-08	6.98e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30738182~30740275:+
THCA	cis	rs11089937	0.597	rs6001072	ENSG00000211638.2	IGLV8-61	-5.57	4.24e-08	6.98e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22098700~22099212:+
THCA	cis	rs61677309	1	rs7480736	ENSG00000280032.1	RP11-832A4.7	5.57	4.24e-08	6.98e-06	0.26	0.25	Lung cancer in ever smokers;	chr11:118301649	chr11:118264593~118266817:+
THCA	cis	rs2179367	0.632	rs997682	ENSG00000268592.3	RAET1E-AS1	-5.57	4.24e-08	6.98e-06	-0.36	-0.25	Dupuytren's disease;	chr6:149345484	chr6:149863494~149919507:+
THCA	cis	rs9952991	0.941	rs2542151	ENSG00000260302.1	RP11-973H7.1	-5.57	4.25e-08	6.99e-06	-0.41	-0.25	Inflammatory skin disease;	chr18:12779948	chr18:12774651~12775923:-
THCA	cis	rs897984	0.542	rs750952	ENSG00000279196.1	RP11-1072A3.3	5.57	4.25e-08	6.99e-06	0.25	0.25	Dementia with Lewy bodies;	chr16:31082633	chr16:30984630~30988270:-
THCA	cis	rs10895275	0.961	rs2282652	ENSG00000277459.1	RP11-732A21.3	5.57	4.25e-08	6.99e-06	0.2	0.25	Migraine;	chr11:102226584	chr11:102109827~102110457:-
THCA	cis	rs2439831	0.867	rs2278860	ENSG00000275601.1	AC011330.13	5.57	4.25e-08	7e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43366848	chr15:43642389~43643023:-
THCA	cis	rs6887276	0.504	rs1003136	ENSG00000245937.6	LINC01184	5.57	4.25e-08	7e-06	0.24	0.25	Height;	chr5:128012123	chr5:127940426~128083172:-
THCA	cis	rs812925	1	rs4672441	ENSG00000271889.1	RP11-493E12.1	-5.57	4.26e-08	7e-06	-0.26	-0.25	Immature fraction of reticulocytes;	chr2:61411817	chr2:61151433~61162105:-
THCA	cis	rs78487399	0.808	rs17030967	ENSG00000234936.1	AC010883.5	5.57	4.26e-08	7e-06	0.35	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43521844	chr2:43229573~43233394:+
THCA	cis	rs5758659	0.633	rs762995	ENSG00000270083.1	RP1-257I20.14	5.57	4.26e-08	7e-06	0.25	0.25	Cognitive function;	chr22:42276118	chr22:42089630~42090028:-
THCA	cis	rs2765539	0.781	rs6428790	ENSG00000231365.4	RP11-418J17.1	-5.57	4.26e-08	7.01e-06	-0.28	-0.25	Waist-hip ratio;	chr1:119063374	chr1:119140396~119275973:+
THCA	cis	rs11795343	0.509	rs630301	ENSG00000232303.2	DFFBP1	-5.57	4.27e-08	7.02e-06	-0.29	-0.25	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32529816	chr9:32566148~32567126:-
THCA	cis	rs755249	0.567	rs67408364	ENSG00000228060.1	RP11-69E11.8	-5.57	4.27e-08	7.02e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39565160~39573203:+
THCA	cis	rs7829975	0.501	rs4840353	ENSG00000253893.2	FAM85B	5.57	4.27e-08	7.02e-06	0.33	0.25	Mood instability;	chr8:8723060	chr8:8167819~8226614:-
THCA	cis	rs613391	0.522	rs1031289	ENSG00000224549.1	RP11-370B11.3	5.57	4.27e-08	7.02e-06	0.28	0.25	Quantitative traits;	chr9:22731107	chr9:22767175~22768316:+
THCA	cis	rs2235642	0.893	rs2143285	ENSG00000280231.1	LA16c-380F5.3	-5.57	4.27e-08	7.02e-06	-0.3	-0.25	Coronary artery disease;	chr16:1543170	chr16:1553655~1554130:-
THCA	cis	rs13256369	1	rs12547721	ENSG00000253893.2	FAM85B	-5.57	4.27e-08	7.02e-06	-0.33	-0.25	Obesity-related traits;	chr8:8713161	chr8:8167819~8226614:-
THCA	cis	rs1552244	1	rs7651058	ENSG00000232901.1	CYCSP10	5.57	4.27e-08	7.03e-06	0.33	0.25	Alzheimer's disease;	chr3:10025280	chr3:10000647~10000940:-
THCA	cis	rs79040073	0.637	rs60594237	ENSG00000259531.2	RP11-295H24.3	5.57	4.28e-08	7.03e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49379916	chr15:49365124~49366685:-
THCA	cis	rs6802315	0.575	rs1864508	ENSG00000272087.1	RP11-379F4.7	5.57	4.28e-08	7.04e-06	0.22	0.25	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158693120~158693768:-
THCA	cis	rs7083	0.967	rs477269	ENSG00000254851.1	RP11-109L13.1	5.57	4.28e-08	7.04e-06	0.34	0.25	Blood protein levels;	chr11:117267575	chr11:117135528~117138582:+
THCA	cis	rs6569038	0.631	rs2357030	ENSG00000253194.1	RP11-351A11.1	5.57	4.28e-08	7.04e-06	0.34	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065138	chr6:118934785~119031541:+
THCA	cis	rs2562456	0.837	rs62110205	ENSG00000268119.4	CTD-2561J22.5	5.57	4.28e-08	7.04e-06	0.31	0.25	Pain;	chr19:21577269	chr19:21444241~21463908:-
THCA	cis	rs11672691	0.627	rs6508981	ENSG00000270164.1	LINC01480	-5.57	4.29e-08	7.04e-06	-0.24	-0.25	Prostate cancer;	chr19:41483668	chr19:41535183~41536904:+
THCA	cis	rs7688540	0.515	rs28415975	ENSG00000211553.1	AC253576.2	-5.57	4.29e-08	7.04e-06	-0.36	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:136461~136568:+
THCA	cis	rs783540	0.632	rs17356528	ENSG00000278603.1	RP13-608F4.5	-5.57	4.29e-08	7.05e-06	-0.35	-0.25	Schizophrenia;	chr15:82636799	chr15:82472203~82472426:+
THCA	cis	rs1322639	0.574	rs9689193	ENSG00000261039.2	RP11-417E7.2	-5.57	4.29e-08	7.05e-06	-0.38	-0.25	Pulse pressure;	chr6:169187979	chr6:169175304~169182740:-
THCA	cis	rs67478160	0.643	rs8005225	ENSG00000258735.1	LINC00637	5.57	4.29e-08	7.06e-06	0.3	0.25	Schizophrenia;	chr14:103833814	chr14:103847721~103858049:+
THCA	cis	rs755249	0.917	rs72663503	ENSG00000228060.1	RP11-69E11.8	-5.57	4.3e-08	7.06e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39565160~39573203:+
THCA	cis	rs755249	0.917	rs61779331	ENSG00000228060.1	RP11-69E11.8	-5.57	4.3e-08	7.06e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39565160~39573203:+
THCA	cis	rs12681287	0.752	rs12548328	ENSG00000254231.1	CTD-2284J15.1	5.57	4.3e-08	7.06e-06	0.28	0.25	Caudate activity during reward;	chr8:86298990	chr8:86333274~86343314:-
THCA	cis	rs2120243	0.572	rs2305620	ENSG00000244515.1	KRT18P34	-5.57	4.3e-08	7.06e-06	-0.3	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157409797	chr3:157162663~157163932:-
THCA	cis	rs8177876	0.686	rs804897	ENSG00000261061.1	RP11-303E16.2	5.57	4.3e-08	7.06e-06	0.35	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067590	chr16:81030770~81031485:+
THCA	cis	rs180730	0.752	rs4639096	ENSG00000251609.2	SETP12	5.57	4.3e-08	7.06e-06	0.49	0.25	Fasting plasma glucose;	chr4:120902221	chr4:120895494~120897083:-
THCA	cis	rs116095464	0.542	rs28650039	ENSG00000248925.1	CTD-2083E4.6	5.57	4.3e-08	7.07e-06	0.36	0.25	Breast cancer;	chr5:273839	chr5:269858~271516:-
THCA	cis	rs6545883	0.868	rs2518933	ENSG00000270820.4	RP11-355B11.2	5.57	4.3e-08	7.07e-06	0.21	0.25	Tuberculosis;	chr2:61569895	chr2:61471188~61484130:+
THCA	cis	rs9595908	1	rs9591143	ENSG00000212293.1	SNORA16	5.57	4.3e-08	7.07e-06	0.29	0.25	Body mass index;	chr13:32585301	chr13:32420390~32420516:-
THCA	cis	rs4841097	0.806	rs6992247	ENSG00000253893.2	FAM85B	-5.57	4.31e-08	7.08e-06	-0.33	-0.25	Platelet distribution width;	chr8:9090959	chr8:8167819~8226614:-
THCA	cis	rs7412746	0.634	rs3754212	ENSG00000231073.1	RP11-316M1.3	5.57	4.31e-08	7.08e-06	0.3	0.25	Melanoma;	chr1:150765724	chr1:150973123~150975534:+
THCA	cis	rs9813712	0.855	rs10934930	ENSG00000228252.7	COL6A4P2	5.57	4.31e-08	7.08e-06	0.28	0.25	Response to amphetamines;	chr3:130259564	chr3:130212823~130273806:+
THCA	cis	rs7976269	0.609	rs10843305	ENSG00000275476.1	RP11-996F15.4	-5.57	4.31e-08	7.09e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29073147	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs10843306	ENSG00000275476.1	RP11-996F15.4	-5.57	4.31e-08	7.09e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29073417	chr12:29277397~29277882:-
THCA	cis	rs7209700	0.708	rs2292699	ENSG00000228782.6	CTD-2026D20.3	5.57	4.32e-08	7.09e-06	0.24	0.25	IgG glycosylation;	chr17:47284929	chr17:47450568~47492492:-
THCA	cis	rs812925	0.762	rs3213951	ENSG00000271889.1	RP11-493E12.1	5.57	4.32e-08	7.09e-06	0.26	0.25	Immature fraction of reticulocytes;	chr2:61395116	chr2:61151433~61162105:-
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.32e-08	7.09e-06	-0.37	-0.25	Body mass index;	chr17:30752751	chr17:30738182~30740275:+
THCA	cis	rs2442825	0.526	rs6443237	ENSG00000206573.7	THUMPD3-AS1	-5.57	4.32e-08	7.09e-06	-0.16	-0.25	Cerebrospinal fluid clusterin levels;	chr3:9395777	chr3:9349689~9398579:-
THCA	cis	rs853679	0.76	rs9357067	ENSG00000226314.6	ZNF192P1	-5.57	4.32e-08	7.09e-06	-0.35	-0.25	Depression;	chr6:28242515	chr6:28161781~28169594:+
THCA	cis	rs853679	0.76	rs967005	ENSG00000226314.6	ZNF192P1	-5.57	4.32e-08	7.09e-06	-0.35	-0.25	Depression;	chr6:28242910	chr6:28161781~28169594:+
THCA	cis	rs4934494	0.911	rs7081788	ENSG00000240996.1	RP11-80H5.7	-5.57	4.32e-08	7.09e-06	-0.27	-0.25	Red blood cell count;	chr10:89648999	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.911	rs34486602	ENSG00000240996.1	RP11-80H5.7	-5.57	4.32e-08	7.09e-06	-0.27	-0.25	Red blood cell count;	chr10:89655895	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.911	rs6586213	ENSG00000240996.1	RP11-80H5.7	-5.57	4.32e-08	7.09e-06	-0.27	-0.25	Red blood cell count;	chr10:89656327	chr10:89694295~89697928:-
THCA	cis	rs7829975	0.533	rs13274028	ENSG00000254153.1	CTA-398F10.2	-5.57	4.32e-08	7.09e-06	-0.27	-0.25	Mood instability;	chr8:8871683	chr8:8456909~8461337:-
THCA	cis	rs10895275	0.625	rs10895269	ENSG00000277459.1	RP11-732A21.3	-5.57	4.32e-08	7.1e-06	-0.19	-0.25	Migraine;	chr11:102168565	chr11:102109827~102110457:-
THCA	cis	rs7712401	0.791	rs9327279	ENSG00000249996.1	RP11-359P5.1	5.57	4.32e-08	7.1e-06	0.24	0.25	Mean platelet volume;	chr5:122786465	chr5:123036271~123054667:+
THCA	cis	rs1707322	0.785	rs10890348	ENSG00000281133.1	AL355480.3	-5.57	4.32e-08	7.1e-06	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45580892~45580996:-
THCA	cis	rs7119038	0.774	rs11217037	ENSG00000255239.1	AP002954.6	-5.57	4.32e-08	7.1e-06	-0.38	-0.25	Sjögren's syndrome;	chr11:118806377	chr11:118688039~118690600:-
THCA	cis	rs2554380	0.628	rs890311	ENSG00000230373.7	GOLGA6L5P	-5.57	4.33e-08	7.1e-06	-0.27	-0.25	Height;	chr15:83772200	chr15:84507885~84516814:-
THCA	cis	rs6545883	0.868	rs2441381	ENSG00000270820.4	RP11-355B11.2	5.57	4.33e-08	7.1e-06	0.21	0.25	Tuberculosis;	chr2:61571694	chr2:61471188~61484130:+
THCA	cis	rs748404	0.666	rs12906017	ENSG00000205771.5	CATSPER2P1	-5.57	4.33e-08	7.11e-06	-0.33	-0.25	Lung cancer;	chr15:43504710	chr15:43726918~43747094:-
THCA	cis	rs10895275	0.649	rs1820454	ENSG00000277459.1	RP11-732A21.3	-5.57	4.33e-08	7.11e-06	-0.19	-0.25	Migraine;	chr11:102221648	chr11:102109827~102110457:-
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000261839.1	RP1-265C24.8	5.57	4.33e-08	7.11e-06	0.29	0.25	Parkinson's disease;	chr6:28065745	chr6:28136849~28139678:+
THCA	cis	rs11089937	0.597	rs9619794	ENSG00000211638.2	IGLV8-61	-5.57	4.33e-08	7.11e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22098700~22099212:+
THCA	cis	rs9307551	1	rs1371989	ENSG00000250334.4	LINC00989	5.57	4.33e-08	7.12e-06	0.31	0.25	Refractive error;	chr4:79600692	chr4:79492416~79576460:+
THCA	cis	rs7688540	0.771	rs77078697	ENSG00000211553.1	AC253576.2	-5.57	4.34e-08	7.12e-06	-0.37	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs61795006	ENSG00000211553.1	AC253576.2	-5.57	4.34e-08	7.12e-06	-0.37	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs61795007	ENSG00000211553.1	AC253576.2	-5.57	4.34e-08	7.12e-06	-0.37	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs7674560	ENSG00000211553.1	AC253576.2	-5.57	4.34e-08	7.12e-06	-0.37	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:136461~136568:+
THCA	cis	rs7824557	0.614	rs2060459	ENSG00000154316.13	TDH	-5.57	4.34e-08	7.12e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11355090	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.614	rs4394351	ENSG00000154316.13	TDH	-5.57	4.34e-08	7.12e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11355366	chr8:11339637~11368452:+
THCA	cis	rs3743266	0.613	rs4775273	ENSG00000245534.5	RORA-AS1	5.57	4.34e-08	7.13e-06	0.27	0.25	Menarche (age at onset);	chr15:60446367	chr15:60479178~60630637:+
THCA	cis	rs1865760	0.566	rs2032445	ENSG00000272462.2	U91328.19	-5.57	4.34e-08	7.13e-06	-0.21	-0.25	Height;	chr6:26044584	chr6:25992662~26001775:+
THCA	cis	rs4648045	0.861	rs230520	ENSG00000246560.2	RP11-10L12.4	-5.57	4.34e-08	7.13e-06	-0.31	-0.25	Lymphocyte percentage of white cells;	chr4:102544455	chr4:102828055~102844075:+
THCA	cis	rs5006884	0.715	rs4243958	ENSG00000167355.6	AC104389.28	-5.57	4.35e-08	7.13e-06	-0.39	-0.25	Fetal hemoglobin levels;	chr11:5353073	chr11:5304976~5505652:-
THCA	cis	rs7829975	0.533	rs1039917	ENSG00000254153.1	CTA-398F10.2	-5.57	4.35e-08	7.14e-06	-0.27	-0.25	Mood instability;	chr8:8861340	chr8:8456909~8461337:-
THCA	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	5.57	4.35e-08	7.14e-06	0.24	0.25	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000273796.1	LL21NC02-21A1.1	-5.57	4.35e-08	7.14e-06	-0.26	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45403809~45404369:-
THCA	cis	rs79040073	0.637	rs57749497	ENSG00000259531.2	RP11-295H24.3	5.57	4.35e-08	7.14e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49297661	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73394355	ENSG00000259531.2	RP11-295H24.3	5.57	4.35e-08	7.14e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49299893	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73394359	ENSG00000259531.2	RP11-295H24.3	5.57	4.35e-08	7.14e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49300941	chr15:49365124~49366685:-
THCA	cis	rs10875746	0.669	rs11168459	ENSG00000269514.1	RP11-370I10.12	5.57	4.35e-08	7.14e-06	0.25	0.25	Longevity (90 years and older);	chr12:48202458	chr12:48198387~48202031:+
THCA	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-5.57	4.35e-08	7.14e-06	-0.22	-0.25	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
THCA	cis	rs2070488	0.775	rs4407366	ENSG00000229589.1	ACVR2B-AS1	5.57	4.36e-08	7.15e-06	0.22	0.25	Electrocardiographic conduction measures;	chr3:38479934	chr3:38451027~38454820:-
THCA	cis	rs67981189	0.542	rs17109053	ENSG00000269927.1	RP6-91H8.3	5.57	4.36e-08	7.15e-06	0.3	0.25	Schizophrenia;	chr14:71142981	chr14:71141125~71143253:-
THCA	cis	rs7617773	0.962	rs6797587	ENSG00000199476.1	Y_RNA	5.57	4.36e-08	7.15e-06	0.32	0.25	Coronary artery disease;	chr3:48156124	chr3:48288587~48288694:+
THCA	cis	rs763121	0.962	rs138703	ENSG00000235209.1	CTA-150C2.13	5.57	4.36e-08	7.15e-06	0.32	0.25	Menopause (age at onset);	chr22:38736743	chr22:38921227~38924708:+
THCA	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-5.57	4.36e-08	7.16e-06	-0.42	-0.25	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
THCA	cis	rs7809615	0.515	rs3843540	ENSG00000244219.5	GS1-259H13.2	-5.57	4.36e-08	7.16e-06	-0.3	-0.25	Blood metabolite ratios;	chr7:99529017	chr7:99598066~99610813:+
THCA	cis	rs1858037	0.867	rs2118305	ENSG00000234255.7	AC012370.3	5.57	4.36e-08	7.16e-06	0.3	0.25	Rheumatoid arthritis;	chr2:65378086	chr2:65439888~65456571:-
THCA	cis	rs763567	0.967	rs473832	ENSG00000271811.1	RP1-79C4.4	5.57	4.37e-08	7.16e-06	0.29	0.25	Tonsillectomy;	chr1:170640049	chr1:170667381~170669425:+
THCA	cis	rs6928977	0.832	rs9402703	ENSG00000231028.7	LINC00271	5.57	4.37e-08	7.17e-06	0.2	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135325097	chr6:135497801~135716055:+
THCA	cis	rs2299587	0.623	rs7009476	ENSG00000253671.1	RP11-806O11.1	-5.57	4.37e-08	7.17e-06	-0.29	-0.25	Economic and political preferences;	chr8:17912867	chr8:17808941~17820868:+
THCA	cis	rs7809950	0.768	rs62482493	ENSG00000238832.1	snoU109	-5.57	4.37e-08	7.17e-06	-0.3	-0.25	Coronary artery disease;	chr7:107311134	chr7:107603363~107603507:+
THCA	cis	rs2115630	1	rs2879828	ENSG00000225151.9	GOLGA2P7	5.57	4.37e-08	7.18e-06	0.31	0.25	P wave terminal force;	chr15:84818746	chr15:84199311~84230136:-
THCA	cis	rs9693857	1	rs9693857	ENSG00000254153.1	CTA-398F10.2	5.57	4.37e-08	7.18e-06	0.28	0.25	Systolic blood pressure;	chr8:9409607	chr8:8456909~8461337:-
THCA	cis	rs4888671	1	rs77464790	ENSG00000261707.1	RP11-264M12.2	5.57	4.37e-08	7.18e-06	0.46	0.25	Obesity-related traits;	chr16:77743712	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs79270274	ENSG00000261707.1	RP11-264M12.2	5.57	4.37e-08	7.18e-06	0.46	0.25	Obesity-related traits;	chr16:77743727	chr16:77741468~77743000:-
THCA	cis	rs7824557	0.614	rs2293858	ENSG00000154316.13	TDH	-5.57	4.38e-08	7.18e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11356372	chr8:11339637~11368452:+
THCA	cis	rs11723261	0.582	rs6814287	ENSG00000211553.1	AC253576.2	-5.57	4.38e-08	7.18e-06	-0.36	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:136461~136568:+
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.38e-08	7.18e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30738182~30740275:+
THCA	cis	rs1865760	0.566	rs9366634	ENSG00000272462.2	U91328.19	-5.57	4.38e-08	7.19e-06	-0.2	-0.25	Height;	chr6:26072168	chr6:25992662~26001775:+
THCA	cis	rs8028182	0.501	rs7166281	ENSG00000260269.4	CTD-2323K18.1	5.57	4.38e-08	7.19e-06	0.37	0.25	Sudden cardiac arrest;	chr15:75635851	chr15:75527150~75601205:-
THCA	cis	rs795484	0.783	rs521048	ENSG00000275409.1	RP11-131L12.4	-5.57	4.38e-08	7.19e-06	-0.23	-0.25	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118393153	chr12:118430147~118430699:+
THCA	cis	rs4713118	0.662	rs149900	ENSG00000272009.1	RP1-313I6.12	-5.57	4.38e-08	7.19e-06	-0.28	-0.25	Parkinson's disease;	chr6:28046819	chr6:28078792~28081130:-
THCA	cis	rs763121	0.853	rs2072794	ENSG00000273076.1	RP3-508I15.22	5.57	4.39e-08	7.2e-06	0.27	0.25	Menopause (age at onset);	chr22:38754538	chr22:38743495~38743910:+
THCA	cis	rs113835537	0.597	rs10896129	ENSG00000255517.5	CTD-3074O7.5	-5.57	4.4e-08	7.21e-06	-0.22	-0.25	Airway imaging phenotypes;	chr11:66570829	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.559	rs57045447	ENSG00000255517.5	CTD-3074O7.5	-5.57	4.4e-08	7.21e-06	-0.22	-0.25	Airway imaging phenotypes;	chr11:66572212	chr11:66473490~66480233:-
THCA	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	5.57	4.4e-08	7.21e-06	0.15	0.25	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	5.57	4.4e-08	7.21e-06	0.15	0.25	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	5.57	4.4e-08	7.21e-06	0.15	0.25	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	5.57	4.4e-08	7.21e-06	0.15	0.25	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.4e-08	7.21e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.4e-08	7.21e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30738182~30740275:+
THCA	cis	rs853679	0.699	rs9468318	ENSG00000226314.6	ZNF192P1	-5.57	4.4e-08	7.21e-06	-0.35	-0.25	Depression;	chr6:28241753	chr6:28161781~28169594:+
THCA	cis	rs6142102	0.961	rs6088361	ENSG00000275784.1	RP5-1125A11.6	-5.57	4.4e-08	7.21e-06	-0.26	-0.25	Skin pigmentation;	chr20:33969520	chr20:33989480~33991818:-
THCA	cis	rs919433	0.929	rs1366836	ENSG00000231621.1	AC013264.2	5.57	4.4e-08	7.21e-06	0.24	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197307424	chr2:197197991~197199273:+
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000280069.1	CTD-2349P21.3	-5.57	4.4e-08	7.21e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30738182~30740275:+
THCA	cis	rs1125355	0.69	rs72939206	ENSG00000251491.2	OR7E28P	-5.57	4.4e-08	7.21e-06	-0.38	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158785799	chr2:158862311~158863285:+
THCA	cis	rs1125355	0.69	rs72939209	ENSG00000251491.2	OR7E28P	-5.57	4.4e-08	7.21e-06	-0.38	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158786291	chr2:158862311~158863285:+
THCA	cis	rs6445975	0.572	rs6768547	ENSG00000272360.1	RP11-359I18.5	-5.57	4.4e-08	7.22e-06	-0.29	-0.25	Systemic lupus erythematosus;	chr3:58449242	chr3:58490830~58491291:-
THCA	cis	rs2288884	0.79	rs7253849	ENSG00000260160.1	CTC-471J1.2	-5.57	4.4e-08	7.22e-06	-0.23	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056992	chr19:52058490~52063703:-
THCA	cis	rs7897654	0.571	rs12771681	ENSG00000213277.3	MARCKSL1P1	5.57	4.4e-08	7.22e-06	0.29	0.25	Schizophrenia;	chr10:102875863	chr10:103175554~103176094:+
THCA	cis	rs2033711	0.503	rs6510141	ENSG00000268912.1	CTD-2619J13.17	5.57	4.4e-08	7.22e-06	0.18	0.25	Uric acid clearance;	chr19:58374419	chr19:58428632~58431148:-
THCA	cis	rs7646881	0.544	rs7638518	ENSG00000240207.5	RP11-379F4.4	5.57	4.4e-08	7.22e-06	0.34	0.25	Tetralogy of Fallot;	chr3:158568953	chr3:158732263~158784070:+
THCA	cis	rs812925	0.893	rs778160	ENSG00000271889.1	RP11-493E12.1	5.57	4.4e-08	7.22e-06	0.26	0.25	Immature fraction of reticulocytes;	chr2:61330029	chr2:61151433~61162105:-
THCA	cis	rs375066	0.623	rs10416116	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43839584	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs57096959	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43839818	chr19:43891804~43901805:-
THCA	cis	rs375066	0.599	rs8112065	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43840070	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs2356432	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43840266	chr19:43891804~43901805:-
THCA	cis	rs375066	0.551	rs2163855	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43840571	chr19:43891804~43901805:-
THCA	cis	rs375066	0.551	rs2356433	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43840585	chr19:43891804~43901805:-
THCA	cis	rs375066	0.551	rs12608578	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43840980	chr19:43891804~43901805:-
THCA	cis	rs375066	0.551	rs10405318	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43841143	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs73052665	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43842069	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs62118371	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43842218	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs1994416	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43842291	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs1994415	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43842391	chr19:43891804~43901805:-
THCA	cis	rs375066	0.599	rs1994414	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43842438	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs62118372	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43842781	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs57133938	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43843046	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs2356434	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43843525	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs4511643	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43843597	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs8099861	ENSG00000267058.1	RP11-15A1.3	5.57	4.4e-08	7.22e-06	0.22	0.25	Breast cancer;	chr19:43844097	chr19:43891804~43901805:-
THCA	cis	rs7493	0.95	rs7785846	ENSG00000233942.1	AC004012.1	5.57	4.41e-08	7.22e-06	0.36	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404529	chr7:95471835~95473998:+
THCA	cis	rs875971	1	rs11971949	ENSG00000223473.2	GS1-124K5.3	-5.57	4.41e-08	7.22e-06	-0.17	-0.25	Aortic root size;	chr7:66161027	chr7:66491049~66493566:-
THCA	cis	rs3794924	0.866	rs1466379	ENSG00000266521.1	RP11-650P15.1	5.57	4.41e-08	7.22e-06	0.42	0.25	Survival in colon cancer;	chr18:31476502	chr18:31496645~31497195:-
THCA	cis	rs9494145	0.648	rs9373124	ENSG00000232876.1	CTA-212D2.2	-5.57	4.41e-08	7.22e-06	-0.34	-0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135102071	chr6:135055033~135060550:+
THCA	cis	rs9326248	0.53	rs7123517	ENSG00000280143.1	AP000892.6	5.57	4.41e-08	7.23e-06	0.41	0.25	Blood protein levels;	chr11:117157039	chr11:117204967~117210292:+
THCA	cis	rs1552244	1	rs28684871	ENSG00000180385.7	EMC3-AS1	5.57	4.41e-08	7.23e-06	0.27	0.25	Alzheimer's disease;	chr3:10030951	chr3:9986893~10006990:+
THCA	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-5.57	4.41e-08	7.23e-06	-0.31	-0.25	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
THCA	cis	rs796395	0.579	rs612295	ENSG00000228208.5	C1orf143	-5.56	4.41e-08	7.23e-06	-0.3	-0.25	Post bronchodilator FEV1/FVC ratio;	chr1:218479648	chr1:218510096~218525978:+
THCA	cis	rs1865760	0.566	rs2032443	ENSG00000272462.2	U91328.19	-5.56	4.42e-08	7.25e-06	-0.21	-0.25	Height;	chr6:26046574	chr6:25992662~26001775:+
THCA	cis	rs7829975	0.774	rs1039915	ENSG00000254153.1	CTA-398F10.2	-5.56	4.42e-08	7.25e-06	-0.27	-0.25	Mood instability;	chr8:8822104	chr8:8456909~8461337:-
THCA	cis	rs2436845	0.627	rs2916559	ENSG00000253669.3	KB-1732A1.1	-5.56	4.42e-08	7.25e-06	-0.27	-0.25	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102814856	chr8:102805517~102809971:+
THCA	cis	rs2436845	0.627	rs2436849	ENSG00000253669.3	KB-1732A1.1	-5.56	4.42e-08	7.25e-06	-0.27	-0.25	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102815320	chr8:102805517~102809971:+
THCA	cis	rs2439831	0.867	rs8039638	ENSG00000275601.1	AC011330.13	-5.56	4.42e-08	7.25e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43342207	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs28415933	ENSG00000275601.1	AC011330.13	-5.56	4.42e-08	7.25e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43343602	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs12324572	ENSG00000275601.1	AC011330.13	-5.56	4.42e-08	7.25e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43344002	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2412779	ENSG00000275601.1	AC011330.13	-5.56	4.42e-08	7.25e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43363729	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2899082	ENSG00000275601.1	AC011330.13	-5.56	4.42e-08	7.25e-06	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43363845	chr15:43642389~43643023:-
THCA	cis	rs116095464	0.558	rs7703803	ENSG00000248925.1	CTD-2083E4.6	5.56	4.42e-08	7.25e-06	0.36	0.25	Breast cancer;	chr5:292196	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs9654452	ENSG00000248925.1	CTD-2083E4.6	5.56	4.42e-08	7.25e-06	0.36	0.25	Breast cancer;	chr5:299446	chr5:269858~271516:-
THCA	cis	rs9990333	0.562	rs56224853	ENSG00000231464.1	AC024937.4	5.56	4.43e-08	7.25e-06	0.32	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195996738~195998233:+
THCA	cis	rs9990333	0.544	rs73210008	ENSG00000231464.1	AC024937.4	5.56	4.43e-08	7.25e-06	0.32	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195996738~195998233:+
THCA	cis	rs2803122	0.846	rs10738535	ENSG00000273226.1	RP11-513M16.8	-5.56	4.43e-08	7.26e-06	-0.23	-0.25	Pulse pressure;	chr9:19299364	chr9:19375451~19375996:+
THCA	cis	rs7267979	0.565	rs3752273	ENSG00000125804.12	FAM182A	5.56	4.43e-08	7.26e-06	0.32	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26054655~26086917:+
THCA	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	5.56	4.43e-08	7.27e-06	0.36	0.25	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
THCA	cis	rs7119	0.717	rs11630916	ENSG00000259362.2	RP11-307C19.1	-5.56	4.43e-08	7.27e-06	-0.36	-0.25	Type 2 diabetes;	chr15:77528989	chr15:77525540~77534110:+
THCA	cis	rs7829975	0.774	rs57312668	ENSG00000254153.1	CTA-398F10.2	-5.56	4.43e-08	7.27e-06	-0.27	-0.25	Mood instability;	chr8:8822967	chr8:8456909~8461337:-
THCA	cis	rs10208649	1	rs72902931	ENSG00000233266.1	HMGB1P31	5.56	4.43e-08	7.27e-06	0.57	0.25	Body mass index;	chr2:53845566	chr2:54051334~54051760:+
THCA	cis	rs763567	0.81	rs638704	ENSG00000271811.1	RP1-79C4.4	5.56	4.44e-08	7.27e-06	0.29	0.25	Tonsillectomy;	chr1:170629046	chr1:170667381~170669425:+
THCA	cis	rs6545883	0.965	rs12713439	ENSG00000270820.4	RP11-355B11.2	5.56	4.44e-08	7.27e-06	0.21	0.25	Tuberculosis;	chr2:61525019	chr2:61471188~61484130:+
THCA	cis	rs9467773	0.506	rs9393709	ENSG00000124549.13	BTN2A3P	-5.56	4.44e-08	7.27e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26364919	chr6:26421391~26432383:+
THCA	cis	rs7615952	0.599	rs6438953	ENSG00000250012.1	RP11-124N2.1	-5.56	4.44e-08	7.27e-06	-0.23	-0.25	Blood pressure (smoking interaction);	chr3:126006108	chr3:126084220~126095349:+
THCA	cis	rs7615952	0.599	rs1044215	ENSG00000250012.1	RP11-124N2.1	-5.56	4.44e-08	7.27e-06	-0.23	-0.25	Blood pressure (smoking interaction);	chr3:126006716	chr3:126084220~126095349:+
THCA	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-5.56	4.44e-08	7.27e-06	-0.29	-0.25	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
THCA	cis	rs9843304	0.546	rs9847773	ENSG00000244503.1	RP11-278L15.6	-5.56	4.44e-08	7.27e-06	-0.32	-0.25	Gallstone disease;	chr3:149500029	chr3:149494660~149495995:+
THCA	cis	rs9843304	0.509	rs6798061	ENSG00000244503.1	RP11-278L15.6	-5.56	4.44e-08	7.27e-06	-0.32	-0.25	Gallstone disease;	chr3:149500683	chr3:149494660~149495995:+
THCA	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-5.56	4.44e-08	7.28e-06	-0.25	-0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
THCA	cis	rs853679	0.824	rs34712084	ENSG00000272009.1	RP1-313I6.12	-5.56	4.44e-08	7.28e-06	-0.37	-0.25	Depression;	chr6:28076050	chr6:28078792~28081130:-
THCA	cis	rs853679	0.824	rs1321505	ENSG00000272009.1	RP1-313I6.12	-5.56	4.44e-08	7.28e-06	-0.37	-0.25	Depression;	chr6:28085045	chr6:28078792~28081130:-
THCA	cis	rs853679	0.882	rs9468287	ENSG00000272009.1	RP1-313I6.12	-5.56	4.44e-08	7.28e-06	-0.37	-0.25	Depression;	chr6:28111963	chr6:28078792~28081130:-
THCA	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	5.56	4.44e-08	7.28e-06	0.3	0.25	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
THCA	cis	rs4660456	0.572	rs10789191	ENSG00000272145.1	NFYC-AS1	-5.56	4.45e-08	7.29e-06	-0.16	-0.25	Platelet count;	chr1:40690819	chr1:40690380~40692066:-
THCA	cis	rs2337406	0.866	rs58850145	ENSG00000211974.3	IGHV2-70	-5.56	4.45e-08	7.29e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106806185	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs2027901	ENSG00000211974.3	IGHV2-70	-5.56	4.45e-08	7.29e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106807164	chr14:106723574~106724093:-
THCA	cis	rs7523875	0.572	rs77104870	ENSG00000153363.11	LINC00467	-5.56	4.45e-08	7.3e-06	-0.3	-0.25	Mean corpuscular volume;	chr1:211445950	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs80316679	ENSG00000153363.11	LINC00467	-5.56	4.45e-08	7.3e-06	-0.3	-0.25	Mean corpuscular volume;	chr1:211449107	chr1:211382803~211435333:+
THCA	cis	rs4654783	0.627	rs66766977	ENSG00000218510.5	LINC00339	-5.56	4.45e-08	7.3e-06	-0.27	-0.25	Endometriosis;	chr1:22104599	chr1:22025188~22031223:+
THCA	cis	rs61041384	1	rs4148865	ENSG00000256092.2	RP13-942N8.1	-5.56	4.45e-08	7.3e-06	-0.4	-0.25	Schizophrenia;	chr12:123111202	chr12:123363868~123366113:+
THCA	cis	rs4663866	1	rs6734408	ENSG00000186235.9	AC016757.3	5.56	4.45e-08	7.3e-06	0.54	0.25	Irritable bowel syndrome;	chr2:238228840	chr2:238224552~238231677:-
THCA	cis	rs12101261	0.744	rs55751898	ENSG00000259167.2	NMNAT1P1	5.56	4.46e-08	7.3e-06	0.35	0.25	Graves' disease;	chr14:80952919	chr14:81032529~81033404:+
THCA	cis	rs36715	0.953	rs2617613	ENSG00000245937.6	LINC01184	5.56	4.46e-08	7.31e-06	0.27	0.25	Breast cancer;	chr5:128216897	chr5:127940426~128083172:-
THCA	cis	rs36715	0.868	rs2546147	ENSG00000245937.6	LINC01184	5.56	4.46e-08	7.31e-06	0.27	0.25	Breast cancer;	chr5:128216898	chr5:127940426~128083172:-
THCA	cis	rs9595908	0.9	rs9591137	ENSG00000212293.1	SNORA16	5.56	4.46e-08	7.31e-06	0.29	0.25	Body mass index;	chr13:32578345	chr13:32420390~32420516:-
THCA	cis	rs935334	0.932	rs8008819	ENSG00000258454.1	RP11-361H10.3	-5.56	4.46e-08	7.31e-06	-0.37	-0.25	Blood pressure;	chr14:76155693	chr14:76235817~76263474:+
THCA	cis	rs8042680	0.637	rs4932182	ENSG00000214432.8	AC068831.10	5.56	4.47e-08	7.32e-06	0.26	0.25	Type 2 diabetes;	chr15:90965573	chr15:91022619~91036611:+
THCA	cis	rs1979679	0.673	rs12229872	ENSG00000278733.1	RP11-425D17.1	5.56	4.47e-08	7.32e-06	0.24	0.25	Ossification of the posterior longitudinal ligament of the spine;	chr12:28137845	chr12:28185625~28186190:-
THCA	cis	rs59868192	0.925	rs2250635	ENSG00000246740.2	PLA2G4E-AS1	5.56	4.47e-08	7.32e-06	0.44	0.25	White blood cell count;	chr15:41969267	chr15:41972763~41999094:+
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	5.56	4.47e-08	7.32e-06	0.22	0.25	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
THCA	cis	rs451417	0.73	rs236128	ENSG00000275632.1	RP5-967N21.11	-5.56	4.47e-08	7.32e-06	-0.3	-0.25	Menopause (age at onset);	chr20:5999007	chr20:6000418~6000941:+
THCA	cis	rs2835345	0.563	rs2835361	ENSG00000230479.1	AP000695.6	5.56	4.47e-08	7.32e-06	0.3	0.25	Pulmonary function;	chr21:36452699	chr21:36430360~36481070:+
THCA	cis	rs12101261	0.744	rs2239610	ENSG00000259167.2	NMNAT1P1	5.56	4.47e-08	7.33e-06	0.34	0.25	Graves' disease;	chr14:80955913	chr14:81032529~81033404:+
THCA	cis	rs2439831	0.85	rs28504496	ENSG00000166763.7	STRCP1	5.56	4.48e-08	7.33e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:43724685	chr15:43699488~43718184:-
THCA	cis	rs919433	1	rs112572902	ENSG00000231621.1	AC013264.2	5.56	4.48e-08	7.33e-06	0.24	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310455	chr2:197197991~197199273:+
THCA	cis	rs919433	0.929	rs7592511	ENSG00000231621.1	AC013264.2	5.56	4.48e-08	7.33e-06	0.24	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313250	chr2:197197991~197199273:+
THCA	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-5.56	4.48e-08	7.33e-06	-0.25	-0.25	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
THCA	cis	rs4748857	0.685	rs7909029	ENSG00000224215.1	RP11-371A19.2	-5.56	4.48e-08	7.34e-06	-0.33	-0.25	Systemic lupus erythematosus;	chr10:23279107	chr10:23343957~23345181:+
THCA	cis	rs7851660	0.654	rs2120264	ENSG00000214417.4	KRT18P13	-5.56	4.49e-08	7.35e-06	-0.21	-0.25	Strep throat;	chr9:97883446	chr9:97698922~97700734:+
THCA	cis	rs4934494	1	rs4934494	ENSG00000240996.1	RP11-80H5.7	-5.56	4.49e-08	7.35e-06	-0.27	-0.25	Red blood cell count;	chr10:89687662	chr10:89694295~89697928:-
THCA	cis	rs62432291	0.764	rs436743	ENSG00000235086.1	FNDC1-IT1	-5.56	4.49e-08	7.35e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159234070	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs3003174	ENSG00000235086.1	FNDC1-IT1	-5.56	4.49e-08	7.35e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159234294	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs2501176	ENSG00000235086.1	FNDC1-IT1	-5.56	4.49e-08	7.35e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159234351	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs2932988	ENSG00000235086.1	FNDC1-IT1	-5.56	4.49e-08	7.35e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159234370	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs2501177	ENSG00000235086.1	FNDC1-IT1	-5.56	4.49e-08	7.35e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159234561	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs439126	ENSG00000235086.1	FNDC1-IT1	-5.56	4.49e-08	7.35e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159235600	chr6:159240786~159243329:+
THCA	cis	rs62246343	0.786	rs73126664	ENSG00000254485.4	RP11-380O24.1	5.56	4.49e-08	7.35e-06	0.33	0.25	Fibrinogen levels;	chr3:9362966	chr3:9292588~9363303:-
THCA	cis	rs2559856	1	rs2559856	ENSG00000274560.1	RP11-285E23.2	5.56	4.5e-08	7.36e-06	0.15	0.25	Blood protein levels;	chr12:101695783	chr12:101696002~101696450:-
THCA	cis	rs7976269	0.515	rs9300183	ENSG00000275476.1	RP11-996F15.4	-5.56	4.5e-08	7.36e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29002316	chr12:29277397~29277882:-
THCA	cis	rs911119	0.913	rs13043266	ENSG00000270001.1	RP11-218C14.8	-5.56	4.5e-08	7.37e-06	-0.38	-0.25	Chronic kidney disease;	chr20:23607490	chr20:23631826~23632316:-
THCA	cis	rs911119	0.818	rs67862677	ENSG00000270001.1	RP11-218C14.8	-5.56	4.5e-08	7.37e-06	-0.38	-0.25	Chronic kidney disease;	chr20:23610449	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs4815224	ENSG00000270001.1	RP11-218C14.8	-5.56	4.5e-08	7.37e-06	-0.38	-0.25	Chronic kidney disease;	chr20:23613475	chr20:23631826~23632316:-
THCA	cis	rs2380205	0.503	rs685852	ENSG00000232807.2	RP11-536K7.3	-5.56	4.5e-08	7.37e-06	-0.23	-0.25	Breast cancer;	chr10:5892654	chr10:5934270~5945900:-
THCA	cis	rs4950322	0.58	rs7541393	ENSG00000278811.3	LINC00624	5.56	4.51e-08	7.38e-06	0.3	0.25	Protein quantitative trait loci;	chr1:147117186	chr1:147258885~147517875:-
THCA	cis	rs12530	0.715	rs5749428	ENSG00000230736.2	RP1-149A16.3	-5.56	4.51e-08	7.38e-06	-0.32	-0.25	IgG glycosylation;	chr22:32403709	chr22:32376664~32384343:+
THCA	cis	rs12530	0.715	rs5998475	ENSG00000230736.2	RP1-149A16.3	-5.56	4.51e-08	7.38e-06	-0.32	-0.25	IgG glycosylation;	chr22:32405345	chr22:32376664~32384343:+
THCA	cis	rs6840360	0.539	rs1443087	ENSG00000270265.1	RP11-731D1.4	-5.56	4.51e-08	7.38e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs1443088	ENSG00000270265.1	RP11-731D1.4	-5.56	4.51e-08	7.38e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151333775~151353224:-
THCA	cis	rs889122	0.55	rs8108431	ENSG00000267289.1	CTD-2623N2.11	5.56	4.51e-08	7.38e-06	0.29	0.25	Menarche (age at onset);	chr19:9886011	chr19:9834079~9835013:-
THCA	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-5.56	4.51e-08	7.39e-06	-0.14	-0.25	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
THCA	cis	rs6545883	0.965	rs2305156	ENSG00000270820.4	RP11-355B11.2	5.56	4.51e-08	7.39e-06	0.21	0.25	Tuberculosis;	chr2:61502133	chr2:61471188~61484130:+
THCA	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	5.56	4.52e-08	7.39e-06	0.33	0.25	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
THCA	cis	rs935334	1	rs2121071	ENSG00000258454.1	RP11-361H10.3	5.56	4.52e-08	7.4e-06	0.35	0.25	Blood pressure;	chr14:76199134	chr14:76235817~76263474:+
THCA	cis	rs758324	0.606	rs804437	ENSG00000237714.1	P4HA2-AS1	-5.56	4.52e-08	7.4e-06	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132165007	chr5:132184876~132192808:+
THCA	cis	rs4604234	0.803	rs79048064	ENSG00000272129.1	RP11-250B2.6	-5.56	4.52e-08	7.4e-06	-0.6	-0.25	Cancer;	chr6:80267381	chr6:80355424~80356859:+
THCA	cis	rs7225151	0.71	rs75367124	ENSG00000234327.6	AC012146.7	-5.56	4.52e-08	7.4e-06	-0.28	-0.25	Alzheimer's disease (late onset);	chr17:5360990	chr17:5111468~5115004:+
THCA	cis	rs1707322	0.821	rs11211182	ENSG00000281133.1	AL355480.3	-5.56	4.52e-08	7.4e-06	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45580892~45580996:-
THCA	cis	rs6928977	0.863	rs2614277	ENSG00000231028.7	LINC00271	5.56	4.53e-08	7.41e-06	0.19	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135333856	chr6:135497801~135716055:+
THCA	cis	rs6928977	0.802	rs2244745	ENSG00000231028.7	LINC00271	5.56	4.53e-08	7.41e-06	0.19	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341683	chr6:135497801~135716055:+
THCA	cis	rs853679	0.76	rs9393910	ENSG00000226314.6	ZNF192P1	-5.56	4.53e-08	7.41e-06	-0.34	-0.25	Depression;	chr6:28240414	chr6:28161781~28169594:+
THCA	cis	rs853679	0.76	rs9368563	ENSG00000226314.6	ZNF192P1	-5.56	4.53e-08	7.41e-06	-0.34	-0.25	Depression;	chr6:28240780	chr6:28161781~28169594:+
THCA	cis	rs853679	0.76	rs9295768	ENSG00000226314.6	ZNF192P1	-5.56	4.53e-08	7.41e-06	-0.34	-0.25	Depression;	chr6:28241324	chr6:28161781~28169594:+
THCA	cis	rs4908768	0.501	rs35865480	ENSG00000232912.4	RP5-1115A15.1	5.56	4.53e-08	7.41e-06	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.501	rs6702060	ENSG00000232912.4	RP5-1115A15.1	5.56	4.53e-08	7.41e-06	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8424645~8434838:+
THCA	cis	rs7617773	0.817	rs11720622	ENSG00000199476.1	Y_RNA	-5.56	4.53e-08	7.42e-06	-0.31	-0.25	Coronary artery disease;	chr3:48205189	chr3:48288587~48288694:+
THCA	cis	rs10888838	1	rs1410896	ENSG00000198711.5	SSBP3-AS1	5.56	4.53e-08	7.42e-06	0.27	0.25	Mitochondrial DNA levels;	chr1:54217341	chr1:54236440~54239063:+
THCA	cis	rs499368	0.519	rs216245	ENSG00000256577.2	RP11-283I3.2	-5.56	4.54e-08	7.42e-06	-0.28	-0.25	Metabolite levels;Blood metabolite levels;	chr12:201253	chr12:203642~205094:+
THCA	cis	rs499368	0.519	rs216246	ENSG00000256577.2	RP11-283I3.2	-5.56	4.54e-08	7.42e-06	-0.28	-0.25	Metabolite levels;Blood metabolite levels;	chr12:201300	chr12:203642~205094:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000230295.1	RP11-458F8.2	-5.56	4.54e-08	7.42e-06	-0.29	-0.25	Diabetic kidney disease;	chr7:66631132	chr7:66880708~66882981:+
THCA	cis	rs2129782	1	rs10504841	ENSG00000253553.4	RP11-586K2.1	-5.56	4.54e-08	7.43e-06	-0.42	-0.25	Electrodermal activity;	chr8:88403592	chr8:88326836~88737134:+
THCA	cis	rs17123764	0.71	rs11169109	ENSG00000257464.1	RP11-161H23.8	-5.56	4.54e-08	7.43e-06	-0.39	-0.25	Intelligence (multi-trait analysis);	chr12:49694580	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.605	rs55812050	ENSG00000257464.1	RP11-161H23.8	-5.56	4.54e-08	7.43e-06	-0.39	-0.25	Intelligence (multi-trait analysis);	chr12:49694757	chr12:49442424~49442652:-
THCA	cis	rs3847687	0.546	rs12815872	ENSG00000279128.1	RP11-76C10.4	5.56	4.54e-08	7.43e-06	0.28	0.25	Longevity;	chr12:131036293	chr12:131022769~131024741:-
THCA	cis	rs7809950	0.678	rs12672451	ENSG00000238832.1	snoU109	-5.56	4.54e-08	7.43e-06	-0.3	-0.25	Coronary artery disease;	chr7:107213372	chr7:107603363~107603507:+
THCA	cis	rs1865760	0.613	rs9379801	ENSG00000272462.2	U91328.19	-5.56	4.54e-08	7.44e-06	-0.19	-0.25	Height;	chr6:25901483	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.613	rs9295674	ENSG00000272462.2	U91328.19	-5.56	4.54e-08	7.44e-06	-0.19	-0.25	Height;	chr6:25912114	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.593	rs3903852	ENSG00000272462.2	U91328.19	-5.56	4.54e-08	7.44e-06	-0.19	-0.25	Height;	chr6:25914919	chr6:25992662~26001775:+
THCA	cis	rs11051970	0.879	rs2088806	ENSG00000274964.1	RP11-817I4.1	-5.56	4.55e-08	7.44e-06	-0.27	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32439191	chr12:32339368~32340724:+
THCA	cis	rs113835537	0.597	rs7939759	ENSG00000255517.5	CTD-3074O7.5	-5.56	4.55e-08	7.44e-06	-0.22	-0.25	Airway imaging phenotypes;	chr11:66570493	chr11:66473490~66480233:-
THCA	cis	rs7474896	1	rs11492508	ENSG00000263064.2	RP11-291L22.7	5.56	4.55e-08	7.45e-06	0.41	0.25	Obesity (extreme);	chr10:37809208	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2891586	ENSG00000263064.2	RP11-291L22.7	5.56	4.55e-08	7.45e-06	0.41	0.25	Obesity (extreme);	chr10:37812715	chr10:38448689~38448949:+
THCA	cis	rs7412746	0.658	rs72704652	ENSG00000231073.1	RP11-316M1.3	5.56	4.55e-08	7.45e-06	0.3	0.25	Melanoma;	chr1:150846994	chr1:150973123~150975534:+
THCA	cis	rs763121	0.925	rs17032	ENSG00000235209.1	CTA-150C2.13	5.56	4.55e-08	7.45e-06	0.32	0.25	Menopause (age at onset);	chr22:38734838	chr22:38921227~38924708:+
THCA	cis	rs6585424	1	rs6585454	ENSG00000225484.5	NUTM2B-AS1	5.56	4.56e-08	7.45e-06	0.41	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180945	chr10:79663088~79826594:-
THCA	cis	rs9902453	0.73	rs2020939	ENSG00000264007.1	RP11-68I3.10	-5.56	4.56e-08	7.46e-06	-0.29	-0.25	Coffee consumption (cups per day);	chr17:30223714	chr17:29621617~29622254:-
THCA	cis	rs7225151	0.634	rs76418084	ENSG00000234327.6	AC012146.7	-5.56	4.56e-08	7.46e-06	-0.28	-0.25	Alzheimer's disease (late onset);	chr17:5365888	chr17:5111468~5115004:+
THCA	cis	rs2281603	0.951	rs60908674	ENSG00000272909.1	CTD-2555O16.4	-5.56	4.56e-08	7.47e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64514181	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.904	rs59440409	ENSG00000272909.1	CTD-2555O16.4	-5.56	4.56e-08	7.47e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64514249	chr14:64440369~64442238:-
THCA	cis	rs4776997	0.536	rs11071958	ENSG00000270964.1	RP11-502I4.3	5.56	4.56e-08	7.47e-06	0.23	0.25	Verbal declarative memory;	chr15:67766524	chr15:67541072~67542604:-
THCA	cis	rs2236295	0.521	rs7075773	ENSG00000238280.1	RP11-436D10.3	-5.56	4.57e-08	7.48e-06	-0.33	-0.25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62838861	chr10:62793562~62805887:-
THCA	cis	rs758324	0.732	rs193685	ENSG00000237714.1	P4HA2-AS1	-5.56	4.58e-08	7.49e-06	-0.37	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132176584	chr5:132184876~132192808:+
THCA	cis	rs4748857	0.685	rs7078858	ENSG00000224215.1	RP11-371A19.2	-5.56	4.58e-08	7.49e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr10:23270123	chr10:23343957~23345181:+
THCA	cis	rs6840360	0.642	rs6535803	ENSG00000270265.1	RP11-731D1.4	-5.56	4.58e-08	7.5e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr4:151520762	chr4:151333775~151353224:-
THCA	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-5.56	4.58e-08	7.5e-06	-0.29	-0.25	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
THCA	cis	rs17301013	0.507	rs2760057	ENSG00000227373.4	RP11-160H22.5	5.56	4.58e-08	7.5e-06	0.38	0.25	Systemic lupus erythematosus;	chr1:174743384	chr1:174115300~174160004:-
THCA	cis	rs6570726	1	rs386678	ENSG00000270638.1	RP3-466P17.1	5.56	4.59e-08	7.5e-06	0.2	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145735570~145737218:+
THCA	cis	rs2243480	1	rs316327	ENSG00000232546.1	RP11-458F8.1	5.56	4.59e-08	7.5e-06	0.32	0.25	Diabetic kidney disease;	chr7:66144214	chr7:66848496~66858136:+
THCA	cis	rs593531	0.571	rs3862799	ENSG00000255440.1	RP11-632K5.2	5.56	4.59e-08	7.5e-06	0.3	0.25	Neuroticism;	chr11:74339217	chr11:74409060~74416379:+
THCA	cis	rs62292953	0.656	rs62293990	ENSG00000248724.5	NPHP3-AS1	-5.56	4.59e-08	7.5e-06	-0.46	-0.25	Red cell distribution width;	chr3:132568756	chr3:132721750~132874223:+
THCA	cis	rs467650	0.553	rs469946	ENSG00000246763.5	RGMB-AS1	5.56	4.59e-08	7.5e-06	0.29	0.25	Venous thromboembolism (SNP x SNP interaction);	chr5:98653345	chr5:98769618~98773469:-
THCA	cis	rs6545883	0.929	rs3821222	ENSG00000270820.4	RP11-355B11.2	5.56	4.6e-08	7.52e-06	0.21	0.25	Tuberculosis;	chr2:61486391	chr2:61471188~61484130:+
THCA	cis	rs79040073	0.637	rs11632303	ENSG00000259531.2	RP11-295H24.3	5.56	4.6e-08	7.52e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49238124	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73392277	ENSG00000259531.2	RP11-295H24.3	5.56	4.6e-08	7.52e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49243772	chr15:49365124~49366685:-
THCA	cis	rs1889642	0.585	rs7324675	ENSG00000227354.5	RBM26-AS1	5.56	4.6e-08	7.52e-06	0.23	0.25	Colonoscopy-negative controls vs population controls;	chr13:79767810	chr13:79406309~79424328:+
THCA	cis	rs1865760	0.566	rs9358904	ENSG00000272462.2	U91328.19	-5.56	4.6e-08	7.52e-06	-0.21	-0.25	Height;	chr6:26068338	chr6:25992662~26001775:+
THCA	cis	rs8014252	0.667	rs57535767	ENSG00000259158.2	ADAM20P1	-5.56	4.6e-08	7.53e-06	-0.27	-0.25	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70324632	chr14:70468881~70483756:-
THCA	cis	rs7493	0.755	rs13228784	ENSG00000233942.1	AC004012.1	5.56	4.6e-08	7.53e-06	0.38	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95331513	chr7:95471835~95473998:+
THCA	cis	rs7493	0.755	rs2375001	ENSG00000233942.1	AC004012.1	5.56	4.6e-08	7.53e-06	0.38	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95335328	chr7:95471835~95473998:+
THCA	cis	rs2904967	0.636	rs239256	ENSG00000254614.2	AP003068.23	-5.56	4.61e-08	7.54e-06	-0.36	-0.25	Mean corpuscular volume;	chr11:65219920	chr11:65177606~65181834:-
THCA	cis	rs3198697	1	rs3198697	ENSG00000207425.1	Y_RNA	5.56	4.61e-08	7.54e-06	0.29	0.25	Triglycerides;	chr16:15036083	chr16:14915457~14915556:-
THCA	cis	rs853679	0.599	rs188015	ENSG00000280107.1	AL022393.9	-5.56	4.61e-08	7.54e-06	-0.36	-0.25	Depression;	chr6:27909668	chr6:28170845~28172521:+
THCA	cis	rs9506514	0.722	rs11147813	ENSG00000238286.1	SLC35E1P1	5.56	4.61e-08	7.54e-06	0.24	0.25	Coronary artery calcification;	chr13:20684419	chr13:20607268~20608131:+
THCA	cis	rs4950322	0.57	rs17160051	ENSG00000278811.3	LINC00624	5.56	4.62e-08	7.54e-06	0.3	0.25	Protein quantitative trait loci;	chr1:147255733	chr1:147258885~147517875:-
THCA	cis	rs10895275	0.924	rs11225174	ENSG00000277459.1	RP11-732A21.3	-5.56	4.62e-08	7.55e-06	-0.2	-0.25	Migraine;	chr11:102231215	chr11:102109827~102110457:-
THCA	cis	rs7911264	0.967	rs2488087	ENSG00000236493.2	EIF2S2P3	-5.56	4.62e-08	7.55e-06	-0.26	-0.25	Inflammatory bowel disease;	chr10:92686284	chr10:92668745~92669743:-
THCA	cis	rs783540	0.656	rs783524	ENSG00000278603.1	RP13-608F4.5	-5.56	4.62e-08	7.56e-06	-0.34	-0.25	Schizophrenia;	chr15:82615393	chr15:82472203~82472426:+
THCA	cis	rs783540	0.592	rs2567632	ENSG00000278603.1	RP13-608F4.5	-5.56	4.62e-08	7.56e-06	-0.34	-0.25	Schizophrenia;	chr15:82616053	chr15:82472203~82472426:+
THCA	cis	rs375092	0.543	rs7808331	ENSG00000230658.1	KLHL7-AS1	5.56	4.63e-08	7.56e-06	0.39	0.25	Personality dimensions;	chr7:23374070	chr7:23101228~23105703:-
THCA	cis	rs7646881	0.544	rs16829283	ENSG00000240207.5	RP11-379F4.4	-5.56	4.63e-08	7.56e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158671339	chr3:158732263~158784070:+
THCA	cis	rs317865	0.867	rs9946	ENSG00000263327.5	TAPT1-AS1	-5.56	4.63e-08	7.56e-06	-0.4	-0.25	Kidney disease (early stage) in type 1 diabetes;	chr4:16161598	chr4:16226685~16320140:+
THCA	cis	rs12935418	0.733	rs11150329	ENSG00000261061.1	RP11-303E16.2	-5.56	4.63e-08	7.57e-06	-0.34	-0.25	Mean corpuscular volume;	chr16:80945189	chr16:81030770~81031485:+
THCA	cis	rs2562456	0.876	rs62110202	ENSG00000213976.4	CTD-2561J22.2	-5.56	4.63e-08	7.57e-06	-0.26	-0.25	Pain;	chr19:21571799	chr19:21382865~21387177:+
THCA	cis	rs1499614	1	rs2707832	ENSG00000232546.1	RP11-458F8.1	-5.56	4.64e-08	7.58e-06	-0.33	-0.25	Gout;	chr7:66671562	chr7:66848496~66858136:+
THCA	cis	rs9952991	0.941	rs2014857	ENSG00000260302.1	RP11-973H7.1	-5.56	4.64e-08	7.58e-06	-0.41	-0.25	Inflammatory skin disease;	chr18:12774327	chr18:12774651~12775923:-
THCA	cis	rs9952991	0.883	rs2847260	ENSG00000260302.1	RP11-973H7.1	-5.56	4.64e-08	7.58e-06	-0.41	-0.25	Inflammatory skin disease;	chr18:12775592	chr18:12774651~12775923:-
THCA	cis	rs9952991	0.883	rs2542147	ENSG00000260302.1	RP11-973H7.1	-5.56	4.64e-08	7.58e-06	-0.41	-0.25	Inflammatory skin disease;	chr18:12775852	chr18:12774651~12775923:-
THCA	cis	rs9311474	0.575	rs4434138	ENSG00000243224.1	RP5-1157M23.2	-5.56	4.64e-08	7.58e-06	-0.28	-0.25	Electroencephalogram traits;	chr3:52522874	chr3:52239258~52241097:+
THCA	cis	rs8062405	1	rs1987472	ENSG00000278665.1	RP11-666O2.4	5.56	4.64e-08	7.58e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28599241~28601881:-
THCA	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	5.56	4.64e-08	7.58e-06	0.23	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
THCA	cis	rs2439831	0.867	rs2255042	ENSG00000166763.7	STRCP1	-5.56	4.64e-08	7.59e-06	-0.34	-0.25	Lung cancer in ever smokers;	chr15:43542120	chr15:43699488~43718184:-
THCA	cis	rs875971	0.666	rs13242072	ENSG00000273142.1	RP11-458F8.4	5.56	4.64e-08	7.59e-06	0.2	0.25	Aortic root size;	chr7:66301001	chr7:66902857~66906297:+
THCA	cis	rs2735413	0.563	rs11646833	ENSG00000276007.1	RP11-358L22.3	5.56	4.64e-08	7.59e-06	0.28	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78023482	chr16:78123243~78124332:+
THCA	cis	rs2839186	0.9	rs2839196	ENSG00000239415.1	AP001469.9	5.56	4.65e-08	7.59e-06	0.25	0.25	Testicular germ cell tumor;	chr21:46288123	chr21:46251549~46254133:-
THCA	cis	rs2041895	0.527	rs10861678	ENSG00000260329.1	RP11-412D9.4	-5.56	4.65e-08	7.6e-06	-0.24	-0.25	Glaucoma (low intraocular pressure);	chr12:106925883	chr12:106954029~106955497:-
THCA	cis	rs763512	0.504	rs1051838	ENSG00000276054.1	RP11-378E13.3	5.56	4.65e-08	7.6e-06	0.39	0.25	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37510731	chr17:37386886~37387926:+
THCA	cis	rs964184	0.63	rs2160669	ENSG00000254851.1	RP11-109L13.1	-5.55	4.66e-08	7.61e-06	-0.51	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116776891	chr11:117135528~117138582:+
THCA	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	5.55	4.66e-08	7.61e-06	0.32	0.25	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
THCA	cis	rs78487399	0.71	rs11899863	ENSG00000234936.1	AC010883.5	5.55	4.66e-08	7.61e-06	0.37	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43391680	chr2:43229573~43233394:+
THCA	cis	rs6430585	0.528	rs309161	ENSG00000231890.6	DARS-AS1	5.55	4.66e-08	7.61e-06	0.29	0.25	Corneal structure;	chr2:135931179	chr2:135985176~136022593:+
THCA	cis	rs7267979	0.657	rs6107073	ENSG00000274973.1	RP13-401N8.7	-5.55	4.66e-08	7.62e-06	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:25845497~25845862:+
THCA	cis	rs4908768	0.52	rs6681362	ENSG00000232912.4	RP5-1115A15.1	5.55	4.66e-08	7.62e-06	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598468	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.539	rs1318218	ENSG00000232912.4	RP5-1115A15.1	5.55	4.66e-08	7.62e-06	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598653	chr1:8424645~8434838:+
THCA	cis	rs8062405	0.964	rs11860513	ENSG00000278665.1	RP11-666O2.4	5.55	4.66e-08	7.62e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28599241~28601881:-
THCA	cis	rs7927592	0.513	rs556442	ENSG00000212093.1	AP000807.1	-5.55	4.67e-08	7.62e-06	-0.26	-0.25	Total body bone mineral density;	chr11:68425222	chr11:68506083~68506166:-
THCA	cis	rs950169	0.58	rs1061737	ENSG00000275120.1	RP11-182J1.17	5.55	4.67e-08	7.63e-06	0.3	0.25	Schizophrenia;	chr15:84640559	chr15:84599434~84606463:-
THCA	cis	rs2029362	1	rs2029362	ENSG00000245573.6	BDNF-AS	5.55	4.67e-08	7.63e-06	0.2	0.25	Total body bone mineral density;	chr11:27584586	chr11:27506838~27698174:+
THCA	cis	rs7824557	0.614	rs5029571	ENSG00000154316.13	TDH	-5.55	4.67e-08	7.64e-06	-0.19	-0.25	Retinal vascular caliber;	chr8:11355880	chr8:11339637~11368452:+
THCA	cis	rs6740322	0.895	rs10196095	ENSG00000234936.1	AC010883.5	5.55	4.68e-08	7.64e-06	0.27	0.25	Coronary artery disease;	chr2:43344746	chr2:43229573~43233394:+
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000280069.1	CTD-2349P21.3	-5.55	4.68e-08	7.65e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30738182~30740275:+
THCA	cis	rs9329221	0.772	rs7824675	ENSG00000261451.1	RP11-981G7.1	-5.55	4.68e-08	7.65e-06	-0.3	-0.25	Neuroticism;	chr8:10385908	chr8:10433672~10438312:+
THCA	cis	rs13256369	0.755	rs11776987	ENSG00000253893.2	FAM85B	-5.55	4.68e-08	7.65e-06	-0.34	-0.25	Obesity-related traits;	chr8:8701891	chr8:8167819~8226614:-
THCA	cis	rs9467773	0.526	rs3734536	ENSG00000124549.13	BTN2A3P	-5.55	4.68e-08	7.65e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26365118	chr6:26421391~26432383:+
THCA	cis	rs9876781	1	rs1109227	ENSG00000229759.1	MRPS18AP1	5.55	4.69e-08	7.65e-06	0.29	0.25	Longevity;	chr3:48437797	chr3:48256350~48256938:-
THCA	cis	rs7829975	0.511	rs1543238	ENSG00000254153.1	CTA-398F10.2	-5.55	4.69e-08	7.65e-06	-0.26	-0.25	Mood instability;	chr8:8277287	chr8:8456909~8461337:-
THCA	cis	rs11089937	0.609	rs9622980	ENSG00000211638.2	IGLV8-61	-5.55	4.69e-08	7.65e-06	-0.21	-0.25	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.667	rs10483107	ENSG00000211638.2	IGLV8-61	-5.55	4.69e-08	7.65e-06	-0.21	-0.25	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.667	rs11704024	ENSG00000211638.2	IGLV8-61	-5.55	4.69e-08	7.65e-06	-0.21	-0.25	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22098700~22099212:+
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000280069.1	CTD-2349P21.3	-5.55	4.69e-08	7.66e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30738182~30740275:+
THCA	cis	rs13113518	0.678	rs13149568	ENSG00000273257.1	RP11-177J6.1	5.55	4.69e-08	7.66e-06	0.33	0.25	Height;	chr4:55370412	chr4:55387949~55388271:+
THCA	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-5.55	4.69e-08	7.66e-06	-0.23	-0.25	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.85	rs8014460	ENSG00000274576.2	IGHV2-70	-5.55	4.69e-08	7.66e-06	-0.23	-0.25	Alzheimer's disease (late onset);	chr14:106697140	chr14:106770577~106771020:-
THCA	cis	rs11089937	0.626	rs9619800	ENSG00000211639.2	IGLV4-60	5.55	4.69e-08	7.66e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22162199~22162681:+
THCA	cis	rs7702057	0.53	rs17138834	ENSG00000271918.1	CTD-2287O16.5	-5.55	4.69e-08	7.66e-06	-0.28	-0.25	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116083807~116085416:-
THCA	cis	rs7119038	0.818	rs10892288	ENSG00000255239.1	AP002954.6	-5.55	4.69e-08	7.66e-06	-0.38	-0.25	Sjögren's syndrome;	chr11:118773985	chr11:118688039~118690600:-
THCA	cis	rs758324	0.68	rs154732	ENSG00000237714.1	P4HA2-AS1	-5.55	4.7e-08	7.67e-06	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132136181	chr5:132184876~132192808:+
THCA	cis	rs2243480	1	rs7778911	ENSG00000232559.3	GS1-124K5.12	-5.55	4.7e-08	7.67e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66229519	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1979823	ENSG00000232559.3	GS1-124K5.12	-5.55	4.7e-08	7.67e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66239626	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6964245	ENSG00000232559.3	GS1-124K5.12	-5.55	4.7e-08	7.67e-06	-0.37	-0.25	Diabetic kidney disease;	chr7:66253730	chr7:66554588~66576923:-
THCA	cis	rs7674212	0.507	rs223471	ENSG00000248971.2	KRT8P46	-5.55	4.7e-08	7.67e-06	-0.3	-0.25	Type 2 diabetes;	chr4:102777629	chr4:102728746~102730171:-
THCA	cis	rs7246657	0.639	rs12459015	ENSG00000276846.1	CTD-3220F14.3	5.55	4.7e-08	7.67e-06	0.25	0.25	Coronary artery calcification;	chr19:37592288	chr19:37314868~37315620:-
THCA	cis	rs2337406	1	rs17113257	ENSG00000211974.3	IGHV2-70	-5.55	4.7e-08	7.68e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106679574	chr14:106723574~106724093:-
THCA	cis	rs860295	0.702	rs11264381	ENSG00000160766.13	GBAP1	5.55	4.7e-08	7.68e-06	0.3	0.25	Body mass index;	chr1:155552781	chr1:155213821~155227422:-
THCA	cis	rs1865760	0.516	rs10807007	ENSG00000272462.2	U91328.19	-5.55	4.71e-08	7.68e-06	-0.2	-0.25	Height;	chr6:26048703	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.516	rs9379819	ENSG00000272462.2	U91328.19	-5.55	4.71e-08	7.68e-06	-0.2	-0.25	Height;	chr6:26049591	chr6:25992662~26001775:+
THCA	cis	rs1876905	0.597	rs191631	ENSG00000230177.1	RP5-1112D6.4	-5.55	4.71e-08	7.69e-06	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111277932~111278742:+
THCA	cis	rs9952991	0.883	rs2847293	ENSG00000260302.1	RP11-973H7.1	-5.55	4.71e-08	7.69e-06	-0.4	-0.25	Inflammatory skin disease;	chr18:12782449	chr18:12774651~12775923:-
THCA	cis	rs758324	0.606	rs247276	ENSG00000237714.1	P4HA2-AS1	-5.55	4.71e-08	7.7e-06	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132133311	chr5:132184876~132192808:+
THCA	cis	rs4713118	0.513	rs149955	ENSG00000220721.1	OR1F12	5.55	4.72e-08	7.7e-06	0.3	0.25	Parkinson's disease;	chr6:28068447	chr6:28073316~28074233:+
THCA	cis	rs853679	0.882	rs3757188	ENSG00000272009.1	RP1-313I6.12	-5.55	4.72e-08	7.7e-06	-0.37	-0.25	Depression;	chr6:28139579	chr6:28078792~28081130:-
THCA	cis	rs2029362	0.874	rs11030053	ENSG00000245573.6	BDNF-AS	5.55	4.72e-08	7.71e-06	0.2	0.25	Total body bone mineral density;	chr11:27572983	chr11:27506838~27698174:+
THCA	cis	rs2029362	1	rs1387145	ENSG00000245573.6	BDNF-AS	5.55	4.72e-08	7.71e-06	0.2	0.25	Total body bone mineral density;	chr11:27578611	chr11:27506838~27698174:+
THCA	cis	rs2029362	0.967	rs10835196	ENSG00000245573.6	BDNF-AS	5.55	4.72e-08	7.71e-06	0.2	0.25	Total body bone mineral density;	chr11:27579788	chr11:27506838~27698174:+
THCA	cis	rs2029362	1	rs2029364	ENSG00000245573.6	BDNF-AS	5.55	4.72e-08	7.71e-06	0.2	0.25	Total body bone mineral density;	chr11:27584181	chr11:27506838~27698174:+
THCA	cis	rs2029362	1	rs2029363	ENSG00000245573.6	BDNF-AS	5.55	4.72e-08	7.71e-06	0.2	0.25	Total body bone mineral density;	chr11:27584497	chr11:27506838~27698174:+
THCA	cis	rs2070488	0.775	rs2051214	ENSG00000229589.1	ACVR2B-AS1	-5.55	4.72e-08	7.71e-06	-0.22	-0.25	Electrocardiographic conduction measures;	chr3:38518812	chr3:38451027~38454820:-
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000275400.1	RP4-756H11.5	5.55	4.73e-08	7.71e-06	0.24	0.25	Calcium levels;	chr7:65733651	chr7:66553805~66554199:-
THCA	cis	rs17123764	0.502	rs11834380	ENSG00000257464.1	RP11-161H23.8	-5.55	4.73e-08	7.72e-06	-0.42	-0.25	Intelligence (multi-trait analysis);	chr12:49687095	chr12:49442424~49442652:-
THCA	cis	rs72615157	0.645	rs76281814	ENSG00000078319.8	PMS2P1	-5.55	4.73e-08	7.72e-06	-0.34	-0.25	Lung function (FEV1/FVC);	chr7:100248791	chr7:100320992~100341908:-
THCA	cis	rs72615157	0.595	rs112241539	ENSG00000078319.8	PMS2P1	-5.55	4.73e-08	7.72e-06	-0.34	-0.25	Lung function (FEV1/FVC);	chr7:100249614	chr7:100320992~100341908:-
THCA	cis	rs853679	0.769	rs7752608	ENSG00000280107.1	AL022393.9	-5.55	4.73e-08	7.72e-06	-0.45	-0.25	Depression;	chr6:28333418	chr6:28170845~28172521:+
THCA	cis	rs10895275	0.961	rs1820455	ENSG00000277459.1	RP11-732A21.3	-5.55	4.73e-08	7.72e-06	-0.2	-0.25	Migraine;	chr11:102221635	chr11:102109827~102110457:-
THCA	cis	rs62432291	0.681	rs385438	ENSG00000235086.1	FNDC1-IT1	-5.55	4.73e-08	7.72e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159235181	chr6:159240786~159243329:+
THCA	cis	rs1577330	0.571	rs637957	ENSG00000254396.1	RP11-56F10.3	-5.55	4.73e-08	7.72e-06	-0.4	-0.25	IgG glycosylation;	chr9:27097543	chr9:27102630~27104728:+
THCA	cis	rs2117029	0.965	rs1138908	ENSG00000258017.1	RP11-386G11.10	-5.55	4.73e-08	7.73e-06	-0.32	-0.25	Intelligence (multi-trait analysis);	chr12:49008516	chr12:49127782~49147869:+
THCA	cis	rs1479090	0.851	rs1463555	ENSG00000250027.1	RP11-563E2.2	-5.55	4.74e-08	7.73e-06	-0.27	-0.25	Lung cancer;	chr4:163128296	chr4:163108785~163119965:+
THCA	cis	rs7617773	0.817	rs11130163	ENSG00000199476.1	Y_RNA	-5.55	4.74e-08	7.74e-06	-0.31	-0.25	Coronary artery disease;	chr3:48271168	chr3:48288587~48288694:+
THCA	cis	rs116095464	0.558	rs7736600	ENSG00000248925.1	CTD-2083E4.6	5.55	4.75e-08	7.74e-06	0.36	0.25	Breast cancer;	chr5:231222	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7725227	ENSG00000248925.1	CTD-2083E4.6	5.55	4.75e-08	7.74e-06	0.36	0.25	Breast cancer;	chr5:233402	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7710005	ENSG00000248925.1	CTD-2083E4.6	5.55	4.75e-08	7.74e-06	0.36	0.25	Breast cancer;	chr5:233457	chr5:269858~271516:-
THCA	cis	rs6688613	0.694	rs2075946	ENSG00000225171.2	DUTP6	-5.55	4.75e-08	7.74e-06	-0.34	-0.25	Refractive astigmatism;	chr1:166849329	chr1:166868748~166869209:+
THCA	cis	rs79040073	0.637	rs73398276	ENSG00000259531.2	RP11-295H24.3	5.55	4.75e-08	7.75e-06	0.35	0.25	Lung cancer in ever smokers;	chr15:49418782	chr15:49365124~49366685:-
THCA	cis	rs6570726	1	rs951143	ENSG00000270638.1	RP3-466P17.1	5.55	4.75e-08	7.75e-06	0.2	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145735570~145737218:+
THCA	cis	rs9843304	0.507	rs56242998	ENSG00000244503.1	RP11-278L15.6	-5.55	4.75e-08	7.75e-06	-0.32	-0.25	Gallstone disease;	chr3:149496693	chr3:149494660~149495995:+
THCA	cis	rs9880211	0.752	rs13062352	ENSG00000273486.1	RP11-731C17.2	5.55	4.75e-08	7.76e-06	0.26	0.25	Height;Body mass index;	chr3:136745920	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs9845862	ENSG00000273486.1	RP11-731C17.2	5.55	4.75e-08	7.76e-06	0.26	0.25	Height;Body mass index;	chr3:136753731	chr3:136837338~136839021:-
THCA	cis	rs2929451	0.566	rs17658270	ENSG00000254153.1	CTA-398F10.2	-5.55	4.76e-08	7.77e-06	-0.28	-0.25	Nose size;	chr8:9296109	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.514	rs2945873	ENSG00000253981.4	ALG1L13P	5.55	4.76e-08	7.77e-06	0.23	0.25	Mood instability;	chr8:8402935	chr8:8236003~8244667:-
THCA	cis	rs4888671	0.901	rs78916165	ENSG00000261707.1	RP11-264M12.2	5.55	4.77e-08	7.77e-06	0.46	0.25	Obesity-related traits;	chr16:77746056	chr16:77741468~77743000:-
THCA	cis	rs7712401	0.755	rs1545696	ENSG00000249996.1	RP11-359P5.1	5.55	4.77e-08	7.78e-06	0.23	0.25	Mean platelet volume;	chr5:122766747	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.655	rs6884312	ENSG00000249996.1	RP11-359P5.1	5.55	4.77e-08	7.78e-06	0.23	0.25	Mean platelet volume;	chr5:122768282	chr5:123036271~123054667:+
THCA	cis	rs6968419	0.755	rs2402057	ENSG00000237870.5	AC073130.1	-5.55	4.77e-08	7.78e-06	-0.27	-0.25	Intraocular pressure;	chr7:116257042	chr7:116275606~116286734:-
THCA	cis	rs934734	0.935	rs6711791	ENSG00000281920.1	RP11-418H16.1	5.55	4.77e-08	7.78e-06	0.3	0.25	Rheumatoid arthritis;	chr2:65352094	chr2:65623272~65628424:+
THCA	cis	rs812925	0.762	rs74181273	ENSG00000271889.1	RP11-493E12.1	5.55	4.77e-08	7.78e-06	0.26	0.25	Immature fraction of reticulocytes;	chr2:61471028	chr2:61151433~61162105:-
THCA	cis	rs79040073	0.637	rs73390360	ENSG00000259531.2	RP11-295H24.3	5.55	4.77e-08	7.78e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49171265	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73390362	ENSG00000259531.2	RP11-295H24.3	5.55	4.77e-08	7.78e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49172292	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.599	rs73390384	ENSG00000259531.2	RP11-295H24.3	5.55	4.77e-08	7.78e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49180905	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs7177624	ENSG00000259531.2	RP11-295H24.3	5.55	4.77e-08	7.78e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49189515	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs78298181	ENSG00000259531.2	RP11-295H24.3	5.55	4.77e-08	7.78e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49213350	chr15:49365124~49366685:-
THCA	cis	rs853679	0.599	rs13193295	ENSG00000226314.6	ZNF192P1	-5.55	4.77e-08	7.78e-06	-0.54	-0.25	Depression;	chr6:28035450	chr6:28161781~28169594:+
THCA	cis	rs12612619	0.761	rs34732613	ENSG00000229122.1	AGBL5-IT1	5.55	4.77e-08	7.78e-06	0.18	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27031928	chr2:27061038~27061815:+
THCA	cis	rs10895275	0.649	rs7110355	ENSG00000277459.1	RP11-732A21.3	-5.55	4.77e-08	7.78e-06	-0.19	-0.25	Migraine;	chr11:102212268	chr11:102109827~102110457:-
THCA	cis	rs9467773	0.626	rs9379860	ENSG00000124549.13	BTN2A3P	-5.55	4.77e-08	7.78e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26370377	chr6:26421391~26432383:+
THCA	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	5.55	4.77e-08	7.78e-06	0.24	0.25	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
THCA	cis	rs755249	0.588	rs6665948	ENSG00000182109.6	RP11-69E11.4	-5.55	4.78e-08	7.79e-06	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39522280~39546187:-
THCA	cis	rs12893668	0.703	rs4906336	ENSG00000269910.1	RP11-73M18.10	5.55	4.78e-08	7.79e-06	0.24	0.25	Reticulocyte count;	chr14:103566928	chr14:103694516~103695050:-
THCA	cis	rs12549025	0.782	rs11781222	ENSG00000253390.1	CTC-756D1.2	-5.55	4.78e-08	7.79e-06	-0.46	-0.25	Reticulocyte fraction of red cells;	chr8:23532058	chr8:23458601~23484971:+
THCA	cis	rs30380	0.553	rs27527	ENSG00000272109.1	CTD-2260A17.3	-5.55	4.78e-08	7.79e-06	-0.34	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96816265	chr5:96804353~96806105:+
THCA	cis	rs10888838	1	rs10888840	ENSG00000198711.5	SSBP3-AS1	5.55	4.78e-08	7.79e-06	0.27	0.25	Mitochondrial DNA levels;	chr1:54217740	chr1:54236440~54239063:+
THCA	cis	rs2765539	0.59	rs4659137	ENSG00000231365.4	RP11-418J17.1	-5.55	4.79e-08	7.8e-06	-0.28	-0.25	Waist-hip ratio;	chr1:118978171	chr1:119140396~119275973:+
THCA	cis	rs7712401	0.791	rs10063253	ENSG00000249996.1	RP11-359P5.1	5.55	4.79e-08	7.81e-06	0.24	0.25	Mean platelet volume;	chr5:122793016	chr5:123036271~123054667:+
THCA	cis	rs7712401	0.755	rs10071705	ENSG00000249996.1	RP11-359P5.1	5.55	4.79e-08	7.81e-06	0.24	0.25	Mean platelet volume;	chr5:122797030	chr5:123036271~123054667:+
THCA	cis	rs1395	0.744	rs3739092	ENSG00000234072.1	AC074117.10	-5.55	4.79e-08	7.81e-06	-0.22	-0.25	Blood metabolite levels;	chr2:27239208	chr2:27356246~27367622:+
THCA	cis	rs6142102	0.607	rs6088408	ENSG00000275784.1	RP5-1125A11.6	5.55	4.79e-08	7.82e-06	0.27	0.25	Skin pigmentation;	chr20:34146800	chr20:33989480~33991818:-
THCA	cis	rs6565180	1	rs11646130	ENSG00000273724.1	RP11-347C12.12	-5.55	4.8e-08	7.82e-06	-0.27	-0.25	Tonsillectomy;	chr16:30365638	chr16:30336400~30343336:+
THCA	cis	rs3950186	0.834	rs2143715	ENSG00000215124.2	RP3-420J14.1	-5.55	4.8e-08	7.82e-06	-0.29	-0.25	Anxiety and major depressive disorder;	chr6:11825975	chr6:11861626~11862970:-
THCA	cis	rs758324	0.732	rs154730	ENSG00000237714.1	P4HA2-AS1	-5.55	4.8e-08	7.83e-06	-0.37	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132132814	chr5:132184876~132192808:+
THCA	cis	rs758324	0.732	rs154733	ENSG00000237714.1	P4HA2-AS1	-5.55	4.8e-08	7.83e-06	-0.37	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132136673	chr5:132184876~132192808:+
THCA	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-5.55	4.81e-08	7.84e-06	-0.28	-0.25	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
THCA	cis	rs10761482	0.5	rs1938535	ENSG00000254271.1	RP11-131N11.4	5.55	4.81e-08	7.84e-06	0.33	0.25	Schizophrenia;	chr10:60514142	chr10:60734342~60741828:+
THCA	cis	rs11089937	0.568	rs11089919	ENSG00000211639.2	IGLV4-60	5.55	4.81e-08	7.85e-06	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22162199~22162681:+
THCA	cis	rs5751614	0.537	rs9624074	ENSG00000230701.2	FBXW4P1	5.55	4.82e-08	7.86e-06	0.27	0.25	Height;	chr22:23283143	chr22:23262767~23265005:+
THCA	cis	rs847577	0.651	rs10464490	ENSG00000272950.1	RP11-307C18.1	5.55	4.82e-08	7.86e-06	0.3	0.25	Breast cancer;	chr7:98086007	chr7:98322853~98323430:+
THCA	cis	rs2735413	0.563	rs11647117	ENSG00000276007.1	RP11-358L22.3	5.55	4.82e-08	7.86e-06	0.28	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78024165	chr16:78123243~78124332:+
THCA	cis	rs4604234	0.803	rs3828750	ENSG00000272129.1	RP11-250B2.6	-5.55	4.82e-08	7.86e-06	-0.59	-0.25	Cancer;	chr6:80253567	chr6:80355424~80356859:+
THCA	cis	rs7824557	0.628	rs7005469	ENSG00000154316.13	TDH	-5.55	4.82e-08	7.86e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11336948	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.628	rs6988922	ENSG00000154316.13	TDH	-5.55	4.82e-08	7.86e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11337402	chr8:11339637~11368452:+
THCA	cis	rs6585424	1	rs10466228	ENSG00000242600.5	MBL1P	5.55	4.82e-08	7.86e-06	0.29	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164617	chr10:79904898~79950336:+
THCA	cis	rs79464052	0.571	rs74903232	ENSG00000228737.2	AC008781.7	-5.55	4.82e-08	7.86e-06	-0.57	-0.25	Diffuse large B cell lymphoma;	chr5:141598318	chr5:141618414~141626481:+
THCA	cis	rs9307551	0.948	rs894055	ENSG00000250334.4	LINC00989	-5.55	4.82e-08	7.86e-06	-0.32	-0.25	Refractive error;	chr4:79621498	chr4:79492416~79576460:+
THCA	cis	rs9307551	1	rs2709847	ENSG00000250334.4	LINC00989	-5.55	4.82e-08	7.86e-06	-0.32	-0.25	Refractive error;	chr4:79621672	chr4:79492416~79576460:+
THCA	cis	rs9402743	0.816	rs9494335	ENSG00000231028.7	LINC00271	5.55	4.83e-08	7.86e-06	0.2	0.25	Systemic lupus erythematosus;	chr6:135690726	chr6:135497801~135716055:+
THCA	cis	rs17345786	0.906	rs56171035	ENSG00000256628.3	ZBTB11-AS1	5.55	4.83e-08	7.87e-06	0.31	0.25	Colonoscopy-negative controls vs population controls;	chr3:101392264	chr3:101676475~101679217:+
THCA	cis	rs807029	0.758	rs807025	ENSG00000272572.1	RP11-179B2.2	-5.55	4.83e-08	7.87e-06	-0.21	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101005064	chr10:100911103~100912739:-
THCA	cis	rs4948275	0.773	rs2787731	ENSG00000237233.2	TMEM26-AS1	-5.55	4.83e-08	7.87e-06	-0.32	-0.25	Night sleep phenotypes;	chr10:61487775	chr10:61452639~61481956:+
THCA	cis	rs499368	0.519	rs216247	ENSG00000256577.2	RP11-283I3.2	5.55	4.83e-08	7.88e-06	0.28	0.25	Metabolite levels;Blood metabolite levels;	chr12:201405	chr12:203642~205094:+
THCA	cis	rs1125355	0.69	rs62183019	ENSG00000251491.2	OR7E28P	-5.55	4.83e-08	7.88e-06	-0.4	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158771854	chr2:158862311~158863285:+
THCA	cis	rs9990333	0.544	rs112577972	ENSG00000242086.7	LINC00969	5.55	4.83e-08	7.88e-06	0.25	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195658062~195739964:+
THCA	cis	rs935334	1	rs4903386	ENSG00000258454.1	RP11-361H10.3	5.55	4.84e-08	7.88e-06	0.35	0.25	Blood pressure;	chr14:76203315	chr14:76235817~76263474:+
THCA	cis	rs4748857	0.685	rs11013389	ENSG00000224215.1	RP11-371A19.2	-5.55	4.84e-08	7.88e-06	-0.33	-0.25	Systemic lupus erythematosus;	chr10:23325411	chr10:23343957~23345181:+
THCA	cis	rs6968419	0.755	rs17138483	ENSG00000237870.5	AC073130.1	5.55	4.84e-08	7.89e-06	0.27	0.25	Intraocular pressure;	chr7:116253791	chr7:116275606~116286734:-
THCA	cis	rs7615952	0.611	rs9681518	ENSG00000241288.6	RP11-379B18.5	-5.55	4.84e-08	7.89e-06	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:125896287	chr3:125827238~125916384:-
THCA	cis	rs8111500	0.793	rs10412111	ENSG00000232871.7	SEC1P	5.55	4.84e-08	7.89e-06	0.3	0.25	Elevated serum carcinoembryonic antigen levels;	chr19:48651999	chr19:48638071~48682245:+
THCA	cis	rs12681287	0.64	rs7816629	ENSG00000254231.1	CTD-2284J15.1	5.55	4.84e-08	7.89e-06	0.27	0.25	Caudate activity during reward;	chr8:86338559	chr8:86333274~86343314:-
THCA	cis	rs4845570	0.92	rs11810571	ENSG00000268288.1	RP11-98D18.16	5.55	4.85e-08	7.9e-06	0.32	0.25	Coronary artery disease;	chr1:151789832	chr1:151766486~151767000:-
THCA	cis	rs2562456	0.876	rs11085467	ENSG00000268119.4	CTD-2561J22.5	5.55	4.85e-08	7.9e-06	0.3	0.25	Pain;	chr19:21569041	chr19:21444241~21463908:-
THCA	cis	rs7412746	0.658	rs897815	ENSG00000231073.1	RP11-316M1.3	-5.55	4.85e-08	7.9e-06	-0.3	-0.25	Melanoma;	chr1:150906625	chr1:150973123~150975534:+
THCA	cis	rs2281603	0.808	rs10132424	ENSG00000272909.1	CTD-2555O16.4	-5.55	4.85e-08	7.91e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64527157	chr14:64440369~64442238:-
THCA	cis	rs3743266	0.507	rs56261931	ENSG00000245534.5	RORA-AS1	-5.55	4.85e-08	7.91e-06	-0.32	-0.25	Menarche (age at onset);	chr15:60439419	chr15:60479178~60630637:+
THCA	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	5.55	4.85e-08	7.91e-06	0.29	0.25	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
THCA	cis	rs3796352	0.571	rs71301816	ENSG00000242142.1	SERBP1P3	-5.55	4.85e-08	7.91e-06	-0.45	-0.25	Immune reponse to smallpox (secreted IL-2);	chr3:53108055	chr3:53064283~53065091:-
THCA	cis	rs2562456	0.561	rs12610883	ENSG00000268119.4	CTD-2561J22.5	5.55	4.86e-08	7.91e-06	0.3	0.25	Pain;	chr19:21567257	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs7259708	ENSG00000268119.4	CTD-2561J22.5	5.55	4.86e-08	7.91e-06	0.3	0.25	Pain;	chr19:21567846	chr19:21444241~21463908:-
THCA	cis	rs2129782	1	rs10099697	ENSG00000253553.4	RP11-586K2.1	5.55	4.86e-08	7.91e-06	0.43	0.25	Electrodermal activity;	chr8:88406096	chr8:88326836~88737134:+
THCA	cis	rs6988985	0.678	rs4072020	ENSG00000247317.3	RP11-273G15.2	-5.55	4.86e-08	7.91e-06	-0.27	-0.25	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142915999	chr8:142981738~143018437:-
THCA	cis	rs8049040	0.609	rs11866859	ENSG00000260886.1	TAT-AS1	5.55	4.86e-08	7.92e-06	0.35	0.25	Blood protein levels;	chr16:71444985	chr16:71565789~71578187:+
THCA	cis	rs9876781	1	rs3214041	ENSG00000229759.1	MRPS18AP1	5.55	4.86e-08	7.92e-06	0.29	0.25	Longevity;	chr3:48413059	chr3:48256350~48256938:-
THCA	cis	rs79040073	0.607	rs7168316	ENSG00000259531.2	RP11-295H24.3	5.55	4.86e-08	7.92e-06	0.32	0.25	Lung cancer in ever smokers;	chr15:49441549	chr15:49365124~49366685:-
THCA	cis	rs12664251	0.683	rs2066408	ENSG00000253194.1	RP11-351A11.1	-5.55	4.86e-08	7.92e-06	-0.34	-0.25	Schizophrenia;	chr6:119021069	chr6:118934785~119031541:+
THCA	cis	rs6968419	0.547	rs72603593	ENSG00000237870.5	AC073130.1	5.55	4.87e-08	7.93e-06	0.27	0.25	Intraocular pressure;	chr7:116254322	chr7:116275606~116286734:-
THCA	cis	rs7809950	0.598	rs2283038	ENSG00000238832.1	snoU109	-5.55	4.87e-08	7.93e-06	-0.3	-0.25	Coronary artery disease;	chr7:107194965	chr7:107603363~107603507:+
THCA	cis	rs17123764	0.71	rs12317646	ENSG00000257464.1	RP11-161H23.8	-5.55	4.87e-08	7.93e-06	-0.39	-0.25	Intelligence (multi-trait analysis);	chr12:49690687	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.54	rs7313738	ENSG00000257464.1	RP11-161H23.8	-5.55	4.87e-08	7.93e-06	-0.39	-0.25	Intelligence (multi-trait analysis);	chr12:49692768	chr12:49442424~49442652:-
THCA	cis	rs9990333	0.562	rs12632706	ENSG00000242086.7	LINC00969	5.55	4.87e-08	7.93e-06	0.25	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195658062~195739964:+
THCA	cis	rs4888671	1	rs59630213	ENSG00000261707.1	RP11-264M12.2	5.55	4.87e-08	7.93e-06	0.46	0.25	Obesity-related traits;	chr16:77743133	chr16:77741468~77743000:-
THCA	cis	rs1479090	0.762	rs4691069	ENSG00000250027.1	RP11-563E2.2	-5.55	4.87e-08	7.94e-06	-0.26	-0.25	Lung cancer;	chr4:163099663	chr4:163108785~163119965:+
THCA	cis	rs6565180	0.791	rs4247355	ENSG00000273724.1	RP11-347C12.12	5.55	4.87e-08	7.94e-06	0.27	0.25	Tonsillectomy;	chr16:30380778	chr16:30336400~30343336:+
THCA	cis	rs4948275	0.773	rs2650709	ENSG00000237233.2	TMEM26-AS1	-5.55	4.87e-08	7.94e-06	-0.32	-0.25	Night sleep phenotypes;	chr10:61483034	chr10:61452639~61481956:+
THCA	cis	rs7085104	0.66	rs3781286	ENSG00000213061.2	PFN1P11	5.55	4.88e-08	7.94e-06	0.3	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102838011~102845473:-
THCA	cis	rs11051970	0.879	rs2088807	ENSG00000274964.1	RP11-817I4.1	-5.55	4.88e-08	7.94e-06	-0.27	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32439167	chr12:32339368~32340724:+
THCA	cis	rs6545883	0.929	rs10173974	ENSG00000270820.4	RP11-355B11.2	5.55	4.88e-08	7.94e-06	0.21	0.25	Tuberculosis;	chr2:61521765	chr2:61471188~61484130:+
THCA	cis	rs875971	1	rs9986696	ENSG00000223473.2	GS1-124K5.3	-5.55	4.88e-08	7.95e-06	-0.16	-0.25	Aortic root size;	chr7:66239589	chr7:66491049~66493566:-
THCA	cis	rs16976116	0.572	rs28802062	ENSG00000279145.1	RP11-547D13.1	5.55	4.88e-08	7.95e-06	0.27	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55160110	chr15:55171972~55178175:-
THCA	cis	rs67981189	0.529	rs2810097	ENSG00000269927.1	RP6-91H8.3	-5.55	4.88e-08	7.96e-06	-0.3	-0.25	Schizophrenia;	chr14:70967397	chr14:71141125~71143253:-
THCA	cis	rs2239547	0.522	rs2336669	ENSG00000242142.1	SERBP1P3	-5.55	4.89e-08	7.96e-06	-0.31	-0.25	Schizophrenia;	chr3:52960122	chr3:53064283~53065091:-
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000280069.1	CTD-2349P21.3	5.55	4.89e-08	7.96e-06	0.38	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30738182~30740275:+
THCA	cis	rs10875746	0.855	rs10875728	ENSG00000269514.1	RP11-370I10.12	5.55	4.89e-08	7.96e-06	0.25	0.25	Longevity (90 years and older);	chr12:48032609	chr12:48198387~48202031:+
THCA	cis	rs16976116	0.502	rs7165565	ENSG00000279145.1	RP11-547D13.1	-5.55	4.89e-08	7.96e-06	-0.26	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55160491	chr15:55171972~55178175:-
THCA	cis	rs67478160	0.634	rs2144080	ENSG00000258735.1	LINC00637	-5.55	4.89e-08	7.96e-06	-0.3	-0.25	Schizophrenia;	chr14:103792424	chr14:103847721~103858049:+
THCA	cis	rs875971	0.545	rs316306	ENSG00000228409.4	CCT6P1	5.55	4.89e-08	7.97e-06	0.21	0.25	Aortic root size;	chr7:66153687	chr7:65751142~65763354:+
THCA	cis	rs4415084	0.834	rs13160259	ENSG00000272335.1	RP11-53O19.3	-5.55	4.89e-08	7.97e-06	-0.2	-0.25	Breast cancer;	chr5:44828862	chr5:44826076~44828592:+
THCA	cis	rs7428	0.502	rs3184781	ENSG00000246575.2	AC093162.5	5.55	4.89e-08	7.97e-06	0.22	0.25	Ear protrusion;	chr2:85322404	chr2:85315041~85316529:+
THCA	cis	rs7428	0.527	rs3184780	ENSG00000246575.2	AC093162.5	5.55	4.89e-08	7.97e-06	0.22	0.25	Ear protrusion;	chr2:85322424	chr2:85315041~85316529:+
THCA	cis	rs7428	0.545	rs2366404	ENSG00000246575.2	AC093162.5	5.55	4.89e-08	7.97e-06	0.22	0.25	Ear protrusion;	chr2:85324656	chr2:85315041~85316529:+
THCA	cis	rs5758659	0.652	rs133349	ENSG00000227370.1	RP4-669P10.19	-5.55	4.89e-08	7.97e-06	-0.23	-0.25	Cognitive function;	chr22:42032723	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.652	rs5758553	ENSG00000227370.1	RP4-669P10.19	-5.55	4.89e-08	7.97e-06	-0.23	-0.25	Cognitive function;	chr22:42035425	chr22:42132543~42132998:+
THCA	cis	rs12478296	1	rs6739247	ENSG00000261186.2	RP11-341N2.1	-5.55	4.9e-08	7.97e-06	-0.39	-0.25	Obesity-related traits;	chr2:242097038	chr2:242087351~242088457:-
THCA	cis	rs9880211	0.571	rs34428695	ENSG00000273486.1	RP11-731C17.2	5.55	4.9e-08	7.98e-06	0.33	0.25	Height;Body mass index;	chr3:136315899	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.571	rs35522825	ENSG00000273486.1	RP11-731C17.2	5.55	4.9e-08	7.98e-06	0.33	0.25	Height;Body mass index;	chr3:136319356	chr3:136837338~136839021:-
THCA	cis	rs10083777	0.551	rs79378252	ENSG00000261061.1	RP11-303E16.2	-5.55	4.9e-08	7.98e-06	-0.46	-0.25	Metabolite levels (small molecules and protein measures);	chr16:81014554	chr16:81030770~81031485:+
THCA	cis	rs6792584	0.925	rs4856867	ENSG00000241316.5	SUCLG2-AS1	5.55	4.9e-08	7.98e-06	0.26	0.25	Corneal astigmatism;	chr3:67499014	chr3:67654697~67947713:+
THCA	cis	rs260461	0.92	rs79259289	ENSG00000268201.1	CTD-3138B18.6	-5.55	4.9e-08	7.98e-06	-0.34	-0.25	Attention deficit hyperactivity disorder;	chr19:58240891	chr19:58266635~58267685:+
THCA	cis	rs3950186	0.834	rs4404760	ENSG00000215124.2	RP3-420J14.1	5.55	4.9e-08	7.99e-06	0.29	0.25	Anxiety and major depressive disorder;	chr6:11826481	chr6:11861626~11862970:-
THCA	cis	rs150992	0.568	rs34498	ENSG00000248489.1	CTD-2007H13.3	5.55	4.91e-08	7.99e-06	0.26	0.25	Body mass index;	chr5:98960690	chr5:98929171~98995013:+
THCA	cis	rs879620	1	rs879620	ENSG00000262888.1	RP11-462G12.2	5.55	4.91e-08	7.99e-06	0.22	0.25	Hip circumference;Body mass index;	chr16:3965728	chr16:3931217~3946305:-
THCA	cis	rs6714710	0.603	rs11681535	ENSG00000230606.9	AC159540.1	-5.55	4.91e-08	7.99e-06	-0.27	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97872486	chr2:97416165~97433527:-
THCA	cis	rs853679	0.567	rs1005126	ENSG00000280107.1	AL022393.9	-5.55	4.91e-08	7.99e-06	-0.27	-0.25	Depression;	chr6:28399846	chr6:28170845~28172521:+
THCA	cis	rs2562456	0.917	rs2650825	ENSG00000268081.1	RP11-678G14.2	5.55	4.91e-08	7.99e-06	0.36	0.25	Pain;	chr19:21516423	chr19:21554640~21569237:-
THCA	cis	rs5751614	0.537	rs11090228	ENSG00000230701.2	FBXW4P1	5.55	4.91e-08	7.99e-06	0.28	0.25	Height;	chr22:23289452	chr22:23262767~23265005:+
THCA	cis	rs5751614	0.537	rs2227939	ENSG00000230701.2	FBXW4P1	5.55	4.91e-08	7.99e-06	0.28	0.25	Height;	chr22:23289614	chr22:23262767~23265005:+
THCA	cis	rs2439831	0.85	rs28590651	ENSG00000166763.7	STRCP1	5.54	4.92e-08	8.01e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:43820818	chr15:43699488~43718184:-
THCA	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-5.54	4.92e-08	8.01e-06	-0.28	-0.25	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
THCA	cis	rs728616	0.681	rs56184245	ENSG00000225484.5	NUTM2B-AS1	-5.54	4.92e-08	8.02e-06	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80258800	chr10:79663088~79826594:-
THCA	cis	rs9990333	1	rs9990333	ENSG00000207650.1	MIR570	-5.54	4.93e-08	8.02e-06	-0.26	-0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195699401~195699497:+
THCA	cis	rs7727544	0.625	rs3091338	ENSG00000233006.5	AC034220.3	5.54	4.93e-08	8.03e-06	0.2	0.25	Blood metabolite levels;	chr5:132067045	chr5:132311285~132369916:-
THCA	cis	rs7246657	0.722	rs35863684	ENSG00000276846.1	CTD-3220F14.3	5.54	4.93e-08	8.03e-06	0.25	0.25	Coronary artery calcification;	chr19:37618876	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs10402671	ENSG00000276846.1	CTD-3220F14.3	5.54	4.93e-08	8.03e-06	0.25	0.25	Coronary artery calcification;	chr19:37626185	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs10417576	ENSG00000276846.1	CTD-3220F14.3	5.54	4.93e-08	8.03e-06	0.25	0.25	Coronary artery calcification;	chr19:37628311	chr19:37314868~37315620:-
THCA	cis	rs4908760	0.965	rs7542312	ENSG00000232912.4	RP5-1115A15.1	5.54	4.93e-08	8.03e-06	0.24	0.25	Vitiligo;	chr1:8513412	chr1:8424645~8434838:+
THCA	cis	rs45509595	0.841	rs370155	ENSG00000226314.6	ZNF192P1	-5.54	4.94e-08	8.03e-06	-0.42	-0.25	Breast cancer;	chr6:27814253	chr6:28161781~28169594:+
THCA	cis	rs9527	0.571	rs12219246	ENSG00000236937.2	PTGES3P4	5.54	4.94e-08	8.03e-06	0.32	0.25	Arsenic metabolism;	chr10:102853598	chr10:102845595~102845950:+
THCA	cis	rs10208649	0.908	rs10193846	ENSG00000233266.1	HMGB1P31	5.54	4.94e-08	8.04e-06	0.6	0.25	Body mass index;	chr2:54127605	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.808	rs72906787	ENSG00000233266.1	HMGB1P31	5.54	4.94e-08	8.04e-06	0.6	0.25	Body mass index;	chr2:54128804	chr2:54051334~54051760:+
THCA	cis	rs595244	1	rs591519	ENSG00000259705.1	RP11-227D13.1	5.54	4.94e-08	8.04e-06	0.43	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48602003	chr15:48645951~48652016:+
THCA	cis	rs890448	0.796	rs2433303	ENSG00000254531.1	FLJ20021	5.54	4.94e-08	8.04e-06	0.22	0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425155	chr4:101347780~101348883:+
THCA	cis	rs62292953	0.79	rs7633214	ENSG00000248724.5	NPHP3-AS1	-5.54	4.94e-08	8.04e-06	-0.45	-0.25	Red cell distribution width;	chr3:132520713	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs11924792	ENSG00000248724.5	NPHP3-AS1	-5.54	4.94e-08	8.04e-06	-0.45	-0.25	Red cell distribution width;	chr3:132521256	chr3:132721750~132874223:+
THCA	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	5.54	4.94e-08	8.04e-06	0.33	0.25	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
THCA	cis	rs6988985	0.678	rs10087214	ENSG00000247317.3	RP11-273G15.2	-5.54	4.95e-08	8.05e-06	-0.27	-0.25	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918310	chr8:142981738~143018437:-
THCA	cis	rs4934494	0.677	rs56160723	ENSG00000232936.4	RP11-80H5.2	5.54	4.95e-08	8.05e-06	0.34	0.25	Red blood cell count;	chr10:89613874	chr10:89645282~89650667:+
THCA	cis	rs13256369	0.826	rs12678414	ENSG00000253893.2	FAM85B	-5.54	4.95e-08	8.06e-06	-0.33	-0.25	Obesity-related traits;	chr8:8728506	chr8:8167819~8226614:-
THCA	cis	rs755249	0.567	rs61779309	ENSG00000228060.1	RP11-69E11.8	-5.54	4.96e-08	8.07e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39565160~39573203:+
THCA	cis	rs9381040	0.701	rs6933231	ENSG00000161912.16	ADCY10P1	5.54	4.96e-08	8.08e-06	0.16	0.25	Alzheimer's disease (late onset);	chr6:41195962	chr6:41101022~41140835:+
THCA	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-5.54	4.96e-08	8.08e-06	-0.42	-0.25	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
THCA	cis	rs4713118	0.513	rs149954	ENSG00000220721.1	OR1F12	5.54	4.97e-08	8.08e-06	0.3	0.25	Parkinson's disease;	chr6:28067468	chr6:28073316~28074233:+
THCA	cis	rs935334	1	rs57844481	ENSG00000258454.1	RP11-361H10.3	-5.54	4.97e-08	8.09e-06	-0.37	-0.25	Blood pressure;	chr14:76218150	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs10137323	ENSG00000258454.1	RP11-361H10.3	-5.54	4.97e-08	8.09e-06	-0.37	-0.25	Blood pressure;	chr14:76219390	chr14:76235817~76263474:+
THCA	cis	rs890448	0.796	rs1549516	ENSG00000254531.1	FLJ20021	5.54	4.97e-08	8.09e-06	0.22	0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417585	chr4:101347780~101348883:+
THCA	cis	rs317865	0.737	rs28483204	ENSG00000263327.5	TAPT1-AS1	-5.54	4.98e-08	8.09e-06	-0.43	-0.25	Kidney disease (early stage) in type 1 diabetes;	chr4:16203475	chr4:16226685~16320140:+
THCA	cis	rs2212361	0.558	rs72963821	ENSG00000255893.1	RP11-685N10.1	-5.54	4.98e-08	8.1e-06	-0.3	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94540820	chr11:94472908~94473570:-
THCA	cis	rs62184315	0.536	rs62185897	ENSG00000273240.1	RP11-455J20.3	-5.54	4.98e-08	8.1e-06	-0.33	-0.25	Alcohol dependence (age at onset);	chr2:189721279	chr2:189763859~189764456:-
THCA	cis	rs12908161	0.65	rs182517	ENSG00000225151.9	GOLGA2P7	-5.54	4.98e-08	8.11e-06	-0.37	-0.25	Schizophrenia;	chr15:84846400	chr15:84199311~84230136:-
THCA	cis	rs7824557	0.737	rs2293855	ENSG00000154316.13	TDH	-5.54	4.98e-08	8.11e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11319901	chr8:11339637~11368452:+
THCA	cis	rs2276314	0.512	rs4393644	ENSG00000278986.1	RP11-723J4.3	-5.54	4.98e-08	8.11e-06	-0.26	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35878684	chr18:35972151~35973916:+
THCA	cis	rs2299587	0.623	rs7816738	ENSG00000253671.1	RP11-806O11.1	-5.54	4.99e-08	8.11e-06	-0.29	-0.25	Economic and political preferences;	chr8:17910973	chr8:17808941~17820868:+
THCA	cis	rs7617773	0.746	rs7619865	ENSG00000199476.1	Y_RNA	-5.54	4.99e-08	8.11e-06	-0.31	-0.25	Coronary artery disease;	chr3:48329090	chr3:48288587~48288694:+
THCA	cis	rs6840360	0.642	rs56301462	ENSG00000270265.1	RP11-731D1.4	-5.54	4.99e-08	8.11e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151333775~151353224:-
THCA	cis	rs7560272	0.549	rs2421554	ENSG00000163016.8	ALMS1P	5.54	4.99e-08	8.12e-06	0.31	0.25	Schizophrenia;	chr2:73579075	chr2:73644919~73685576:+
THCA	cis	rs2029362	1	rs1948186	ENSG00000245573.6	BDNF-AS	5.54	5e-08	8.13e-06	0.2	0.25	Total body bone mineral density;	chr11:27589027	chr11:27506838~27698174:+
THCA	cis	rs6740322	0.748	rs13432574	ENSG00000234936.1	AC010883.5	5.54	5e-08	8.13e-06	0.26	0.25	Coronary artery disease;	chr2:43317189	chr2:43229573~43233394:+
THCA	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	5.54	5e-08	8.13e-06	0.14	0.25	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
THCA	cis	rs61041384	0.661	rs79304919	ENSG00000256092.2	RP13-942N8.1	-5.54	5e-08	8.14e-06	-0.4	-0.25	Schizophrenia;	chr12:122943404	chr12:123363868~123366113:+
THCA	cis	rs2439831	0.85	rs8032649	ENSG00000166763.7	STRCP1	-5.54	5e-08	8.14e-06	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43842724	chr15:43699488~43718184:-
THCA	cis	rs12497850	1	rs10865952	ENSG00000229759.1	MRPS18AP1	5.54	5e-08	8.14e-06	0.32	0.25	Parkinson's disease;	chr3:48707051	chr3:48256350~48256938:-
THCA	cis	rs253959	0.545	rs11241362	ENSG00000272265.1	CTD-2287O16.4	5.54	5e-08	8.14e-06	0.29	0.25	Bipolar disorder and schizophrenia;	chr5:116112630	chr5:116078110~116078570:-
THCA	cis	rs116095464	0.558	rs1541822	ENSG00000248925.1	CTD-2083E4.6	-5.54	5.01e-08	8.14e-06	-0.36	-0.25	Breast cancer;	chr5:269119	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7708182	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:234673	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10058428	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:235493	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10076655	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:239349	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10057492	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:239388	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs28418643	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:240744	chr5:269858~271516:-
THCA	cis	rs116095464	0.614	rs62344339	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:252880	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs9687898	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:253837	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs9688045	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:253920	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs112343653	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:257059	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs73024831	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:257077	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs62344345	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:257305	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs57335027	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:262792	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs6869925	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:263921	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs6875291	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:264077	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs6866776	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:264380	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs6874745	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:264412	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7715108	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:264546	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7730700	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:264598	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10057674	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:266698	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs1812843	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:267543	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs12173244	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:269409	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs56127718	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:270158	chr5:269858~271516:-
THCA	cis	rs116095464	0.614	rs10061564	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:271214	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs55776650	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:273711	chr5:269858~271516:-
THCA	cis	rs116095464	0.614	rs28736753	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:273966	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs59113266	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:279850	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs11959126	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:283765	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7356696	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:284136	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7356561	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:284266	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs59284383	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:284410	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7731089	ENSG00000248925.1	CTD-2083E4.6	5.54	5.01e-08	8.14e-06	0.36	0.25	Breast cancer;	chr5:290307	chr5:269858~271516:-
THCA	cis	rs4748857	0.541	rs10828418	ENSG00000224215.1	RP11-371A19.2	-5.54	5.01e-08	8.14e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr10:23269121	chr10:23343957~23345181:+
THCA	cis	rs7412746	0.587	rs11204722	ENSG00000231073.1	RP11-316M1.3	-5.54	5.01e-08	8.15e-06	-0.3	-0.25	Melanoma;	chr1:150757708	chr1:150973123~150975534:+
THCA	cis	rs2129782	1	rs9297469	ENSG00000253553.4	RP11-586K2.1	5.54	5.01e-08	8.15e-06	0.42	0.25	Electrodermal activity;	chr8:88419558	chr8:88326836~88737134:+
THCA	cis	rs1889642	0.701	rs1158596	ENSG00000227354.5	RBM26-AS1	5.54	5.01e-08	8.15e-06	0.23	0.25	Colonoscopy-negative controls vs population controls;	chr13:79774518	chr13:79406309~79424328:+
THCA	cis	rs7493	1	rs17876123	ENSG00000233942.1	AC004012.1	5.54	5.02e-08	8.16e-06	0.37	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95415995	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs2299265	ENSG00000233942.1	AC004012.1	5.54	5.02e-08	8.16e-06	0.37	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95419558	chr7:95471835~95473998:+
THCA	cis	rs7493	0.853	rs2299266	ENSG00000233942.1	AC004012.1	5.54	5.02e-08	8.16e-06	0.37	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95419761	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs1034809	ENSG00000233942.1	AC004012.1	5.54	5.02e-08	8.16e-06	0.37	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95422340	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs2158806	ENSG00000233942.1	AC004012.1	5.54	5.02e-08	8.16e-06	0.37	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95422686	chr7:95471835~95473998:+
THCA	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	5.54	5.02e-08	8.16e-06	0.25	0.25	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	5.54	5.02e-08	8.16e-06	0.25	0.25	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
THCA	cis	rs713477	0.654	rs7143800	ENSG00000258413.1	RP11-665C16.6	5.54	5.02e-08	8.16e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55451016	chr14:55262767~55272075:-
THCA	cis	rs4971059	0.629	rs9297	ENSG00000160766.13	GBAP1	-5.54	5.03e-08	8.18e-06	-0.27	-0.25	Breast cancer;	chr1:155134074	chr1:155213821~155227422:-
THCA	cis	rs7646881	0.544	rs57522494	ENSG00000240207.5	RP11-379F4.4	-5.54	5.03e-08	8.18e-06	-0.35	-0.25	Tetralogy of Fallot;	chr3:158620701	chr3:158732263~158784070:+
THCA	cis	rs4713118	0.629	rs203888	ENSG00000220721.1	OR1F12	5.54	5.03e-08	8.18e-06	0.32	0.25	Parkinson's disease;	chr6:28053811	chr6:28073316~28074233:+
THCA	cis	rs12497850	0.864	rs6779394	ENSG00000229759.1	MRPS18AP1	5.54	5.03e-08	8.18e-06	0.33	0.25	Parkinson's disease;	chr3:49120338	chr3:48256350~48256938:-
THCA	cis	rs9652601	0.881	rs11860603	ENSG00000274038.1	RP11-66H6.4	-5.54	5.03e-08	8.18e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11071160	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.959	rs11865121	ENSG00000274038.1	RP11-66H6.4	-5.54	5.03e-08	8.18e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11072831	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.959	rs7198621	ENSG00000274038.1	RP11-66H6.4	-5.54	5.03e-08	8.18e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11073601	chr16:11056556~11057034:+
THCA	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	5.54	5.03e-08	8.18e-06	0.43	0.25	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	5.54	5.03e-08	8.18e-06	0.43	0.25	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
THCA	cis	rs78487399	0.71	rs74616425	ENSG00000234936.1	AC010883.5	5.54	5.04e-08	8.18e-06	0.39	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43386443	chr2:43229573~43233394:+
THCA	cis	rs2839186	0.872	rs13052233	ENSG00000239415.1	AP001469.9	5.54	5.04e-08	8.18e-06	0.25	0.25	Testicular germ cell tumor;	chr21:46287370	chr21:46251549~46254133:-
THCA	cis	rs2337406	1	rs7145172	ENSG00000211974.3	IGHV2-70	-5.54	5.04e-08	8.19e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106704924	chr14:106723574~106724093:-
THCA	cis	rs9393777	0.92	rs35716472	ENSG00000219392.1	RP1-265C24.5	-5.54	5.04e-08	8.19e-06	-0.48	-0.25	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28115628~28116551:+
THCA	cis	rs2179367	0.537	rs6911411	ENSG00000268592.3	RAET1E-AS1	5.54	5.05e-08	8.2e-06	0.39	0.25	Dupuytren's disease;	chr6:149366954	chr6:149863494~149919507:+
THCA	cis	rs1876905	0.539	rs240980	ENSG00000230177.1	RP5-1112D6.4	5.54	5.05e-08	8.2e-06	0.28	0.25	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111277932~111278742:+
THCA	cis	rs2360027	0.622	rs17257972	ENSG00000231365.4	RP11-418J17.1	-5.54	5.05e-08	8.2e-06	-0.25	-0.25	Tonsillectomy;	chr1:118563989	chr1:119140396~119275973:+
THCA	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	5.54	5.05e-08	8.21e-06	0.31	0.25	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
THCA	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	5.54	5.05e-08	8.21e-06	0.31	0.25	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
THCA	cis	rs9876781	1	rs9815103	ENSG00000229759.1	MRPS18AP1	5.54	5.05e-08	8.21e-06	0.29	0.25	Longevity;	chr3:48372725	chr3:48256350~48256938:-
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Body mass index;	chr17:30756962	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Body mass index;	chr17:30758695	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Body mass index;	chr17:30772984	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Body mass index;	chr17:30779631	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000280069.1	CTD-2349P21.3	-5.54	5.05e-08	8.21e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000280069.1	CTD-2349P21.3	5.54	5.05e-08	8.21e-06	0.37	0.25	Body mass index;	chr17:30767864	chr17:30738182~30740275:+
THCA	cis	rs2337406	0.866	rs2301535	ENSG00000211974.3	IGHV2-70	-5.54	5.05e-08	8.21e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106790663	chr14:106723574~106724093:-
THCA	cis	rs10208649	0.518	rs11892759	ENSG00000272156.1	RP11-477N3.1	5.54	5.05e-08	8.21e-06	0.36	0.25	Body mass index;	chr2:53943202	chr2:54082554~54085066:+
THCA	cis	rs2179367	0.632	rs2341774	ENSG00000231760.4	RP11-350J20.5	5.54	5.05e-08	8.21e-06	0.36	0.25	Dupuytren's disease;	chr6:149425014	chr6:149796151~149826294:-
THCA	cis	rs6600671	0.719	rs9728991	ENSG00000275538.1	RNVU1-19	5.54	5.05e-08	8.21e-06	0.32	0.25	Hip geometry;	chr1:121522281	chr1:120850819~120850985:-
THCA	cis	rs2439831	0.681	rs2242067	ENSG00000249839.1	AC011330.5	-5.54	5.06e-08	8.21e-06	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43407105	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28413704	ENSG00000166763.7	STRCP1	5.54	5.06e-08	8.21e-06	0.37	0.25	Lung cancer in ever smokers;	chr15:43856229	chr15:43699488~43718184:-
THCA	cis	rs2129782	1	rs73277124	ENSG00000253553.4	RP11-586K2.1	5.54	5.06e-08	8.21e-06	0.43	0.25	Electrodermal activity;	chr8:88374653	chr8:88326836~88737134:+
THCA	cis	rs2562456	0.682	rs11085464	ENSG00000268119.4	CTD-2561J22.5	5.54	5.06e-08	8.22e-06	0.3	0.25	Pain;	chr19:21568976	chr19:21444241~21463908:-
THCA	cis	rs6969780	0.915	rs4722657	ENSG00000233429.8	HOTAIRM1	-5.54	5.06e-08	8.22e-06	-0.33	-0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27118137	chr7:27095647~27100265:+
THCA	cis	rs9402743	0.816	rs9494332	ENSG00000231028.7	LINC00271	-5.54	5.06e-08	8.23e-06	-0.2	-0.25	Systemic lupus erythematosus;	chr6:135687470	chr6:135497801~135716055:+
THCA	cis	rs7615952	0.575	rs35949599	ENSG00000241288.6	RP11-379B18.5	-5.54	5.07e-08	8.23e-06	-0.29	-0.25	Blood pressure (smoking interaction);	chr3:125825359	chr3:125827238~125916384:-
THCA	cis	rs12435908	1	rs73282213	ENSG00000276116.2	FUT8-AS1	-5.54	5.07e-08	8.24e-06	-0.4	-0.25	Ischemic stroke;	chr14:65385421	chr14:65411170~65412690:-
THCA	cis	rs690037	0.78	rs690437	ENSG00000272498.1	RP11-415F23.3	5.54	5.08e-08	8.25e-06	0.26	0.25	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16339383	chr3:16339308~16339871:+
THCA	cis	rs1876905	0.539	rs241003	ENSG00000272356.1	RP5-1112D6.8	5.54	5.08e-08	8.25e-06	0.27	0.25	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111309203~111313517:+
THCA	cis	rs1876905	0.539	rs190246	ENSG00000272356.1	RP5-1112D6.8	5.54	5.08e-08	8.25e-06	0.27	0.25	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111309203~111313517:+
THCA	cis	rs9921338	0.961	rs4780357	ENSG00000262636.1	CTD-3088G3.4	-5.54	5.08e-08	8.25e-06	-0.36	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11277114	chr16:11380859~11381118:-
THCA	cis	rs2281603	0.857	rs3783722	ENSG00000272909.1	CTD-2555O16.4	-5.54	5.08e-08	8.25e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64531248	chr14:64440369~64442238:-
THCA	cis	rs7826238	0.594	rs2948285	ENSG00000254153.1	CTA-398F10.2	-5.54	5.09e-08	8.26e-06	-0.26	-0.25	Systolic blood pressure;	chr8:8273016	chr8:8456909~8461337:-
THCA	cis	rs6993270	0.779	rs16892877	ENSG00000245330.4	KB-1471A8.1	5.54	5.09e-08	8.26e-06	0.31	0.25	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119919111	chr8:119867419~119874488:-
THCA	cis	rs875971	1	rs11974264	ENSG00000223473.2	GS1-124K5.3	-5.54	5.09e-08	8.26e-06	-0.17	-0.25	Aortic root size;	chr7:66182595	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs1540651	ENSG00000223473.2	GS1-124K5.3	-5.54	5.09e-08	8.26e-06	-0.17	-0.25	Aortic root size;	chr7:66185134	chr7:66491049~66493566:-
THCA	cis	rs7162943	0.734	rs420017	ENSG00000260123.1	RP11-326A19.4	5.54	5.09e-08	8.26e-06	0.32	0.25	Mean platelet volume;	chr15:89073850	chr15:89041223~89082819:+
THCA	cis	rs7727544	0.735	rs274559	ENSG00000263597.1	MIR3936	-5.54	5.09e-08	8.26e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132384378	chr5:132365490~132365599:-
THCA	cis	rs1552244	0.608	rs6764807	ENSG00000180385.7	EMC3-AS1	5.54	5.09e-08	8.27e-06	0.24	0.25	Alzheimer's disease;	chr3:9957119	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs34391585	ENSG00000180385.7	EMC3-AS1	5.54	5.09e-08	8.27e-06	0.24	0.25	Alzheimer's disease;	chr3:9957524	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.515	rs7613004	ENSG00000180385.7	EMC3-AS1	5.54	5.09e-08	8.27e-06	0.24	0.25	Alzheimer's disease;	chr3:9958229	chr3:9986893~10006990:+
THCA	cis	rs5769765	0.542	rs1033666	ENSG00000260613.1	RP3-522J7.6	5.54	5.09e-08	8.27e-06	0.35	0.25	Schizophrenia;	chr22:49859135	chr22:49832616~49837786:-
THCA	cis	rs7976269	0.609	rs4141946	ENSG00000257176.2	RP11-996F15.2	-5.54	5.09e-08	8.27e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29066432	chr12:29280418~29317848:-
THCA	cis	rs6928977	0.832	rs2327613	ENSG00000231028.7	LINC00271	5.54	5.1e-08	8.28e-06	0.2	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135341234	chr6:135497801~135716055:+
THCA	cis	rs2562456	0.558	rs62108173	ENSG00000268555.1	RP11-678G14.3	5.54	5.1e-08	8.28e-06	0.4	0.25	Pain;	chr19:21244386	chr19:21570822~21587322:-
THCA	cis	rs4908760	0.864	rs12136766	ENSG00000232912.4	RP5-1115A15.1	5.54	5.1e-08	8.28e-06	0.24	0.25	Vitiligo;	chr1:8603762	chr1:8424645~8434838:+
THCA	cis	rs7246657	0.722	rs4802051	ENSG00000276846.1	CTD-3220F14.3	5.54	5.1e-08	8.28e-06	0.25	0.25	Coronary artery calcification;	chr19:37581427	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.663	rs4803276	ENSG00000276846.1	CTD-3220F14.3	5.54	5.1e-08	8.28e-06	0.25	0.25	Coronary artery calcification;	chr19:37581429	chr19:37314868~37315620:-
THCA	cis	rs1075232	1	rs56396205	ENSG00000215302.7	CTD-3092A11.1	-5.54	5.1e-08	8.28e-06	-0.56	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30470779~30507623:+
THCA	cis	rs4713118	0.662	rs149970	ENSG00000261839.1	RP1-265C24.8	5.54	5.1e-08	8.28e-06	0.27	0.25	Parkinson's disease;	chr6:28012442	chr6:28136849~28139678:+
THCA	cis	rs9813712	0.953	rs6439222	ENSG00000228252.7	COL6A4P2	5.54	5.11e-08	8.29e-06	0.28	0.25	Response to amphetamines;	chr3:130256298	chr3:130212823~130273806:+
THCA	cis	rs9876781	1	rs7635522	ENSG00000229759.1	MRPS18AP1	5.54	5.11e-08	8.29e-06	0.29	0.25	Longevity;	chr3:48382166	chr3:48256350~48256938:-
THCA	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	5.54	5.11e-08	8.29e-06	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
THCA	cis	rs2251188	0.87	rs2246223	ENSG00000187953.9	PMS2CL	-5.54	5.11e-08	8.29e-06	-0.28	-0.25	Sum basophil neutrophil counts;Neutrophil count;	chr7:6661558	chr7:6710128~6753862:+
THCA	cis	rs9309473	0.5	rs12472502	ENSG00000163016.8	ALMS1P	-5.54	5.11e-08	8.3e-06	-0.32	-0.25	Metabolite levels;	chr2:73632057	chr2:73644919~73685576:+
THCA	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	5.54	5.12e-08	8.31e-06	0.29	0.25	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
THCA	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	5.54	5.12e-08	8.31e-06	0.14	0.25	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
THCA	cis	rs8025790	0.508	rs12902812	ENSG00000270964.1	RP11-502I4.3	-5.54	5.12e-08	8.31e-06	-0.21	-0.25	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67616941	chr15:67541072~67542604:-
THCA	cis	rs12612619	0.677	rs3754733	ENSG00000229122.1	AGBL5-IT1	5.54	5.12e-08	8.31e-06	0.18	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27026377	chr2:27061038~27061815:+
THCA	cis	rs911555	0.504	rs8006526	ENSG00000269910.1	RP11-73M18.10	5.54	5.13e-08	8.32e-06	0.23	0.25	Intelligence (multi-trait analysis);	chr14:103608678	chr14:103694516~103695050:-
THCA	cis	rs1167827	0.68	rs1167796	ENSG00000223705.8	NSUN5P1	-5.54	5.13e-08	8.33e-06	-0.16	-0.25	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75410322~75416787:+
THCA	cis	rs2070488	0.775	rs6599204	ENSG00000229589.1	ACVR2B-AS1	5.54	5.13e-08	8.33e-06	0.22	0.25	Electrocardiographic conduction measures;	chr3:38484243	chr3:38451027~38454820:-
THCA	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	5.54	5.13e-08	8.33e-06	0.43	0.25	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
THCA	cis	rs1865760	0.516	rs9358903	ENSG00000272462.2	U91328.19	-5.54	5.14e-08	8.34e-06	-0.2	-0.25	Height;	chr6:26061721	chr6:25992662~26001775:+
THCA	cis	rs67478160	0.643	rs2024667	ENSG00000258735.1	LINC00637	-5.54	5.15e-08	8.35e-06	-0.3	-0.25	Schizophrenia;	chr14:103745192	chr14:103847721~103858049:+
THCA	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-5.54	5.15e-08	8.35e-06	-0.47	-0.25	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
THCA	cis	rs7760535	0.794	rs3851225	ENSG00000271789.1	RP5-1112D6.7	-5.54	5.15e-08	8.35e-06	-0.24	-0.25	Metabolic traits;	chr6:111503929	chr6:111297126~111298510:+
THCA	cis	rs7923837	0.963	rs11187141	ENSG00000236493.2	EIF2S2P3	5.54	5.15e-08	8.35e-06	0.26	0.25	Multiple sclerosis;Body mass index;	chr10:92707388	chr10:92668745~92669743:-
THCA	cis	rs758324	0.68	rs392149	ENSG00000237714.1	P4HA2-AS1	-5.54	5.15e-08	8.36e-06	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132114849	chr5:132184876~132192808:+
THCA	cis	rs62292953	0.79	rs2305625	ENSG00000248724.5	NPHP3-AS1	-5.54	5.15e-08	8.36e-06	-0.46	-0.25	Red cell distribution width;	chr3:132522666	chr3:132721750~132874223:+
THCA	cis	rs2562456	0.917	rs2650825	ENSG00000268119.4	CTD-2561J22.5	5.54	5.16e-08	8.37e-06	0.31	0.25	Pain;	chr19:21516423	chr19:21444241~21463908:-
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000259728.4	LINC00933	5.54	5.17e-08	8.38e-06	0.3	0.25	P wave terminal force;	chr15:84655131	chr15:84570649~84580175:+
THCA	cis	rs6931421	0.8	rs12662365	ENSG00000272129.1	RP11-250B2.6	5.54	5.17e-08	8.39e-06	0.33	0.25	Sitting height ratio;	chr6:80195672	chr6:80355424~80356859:+
THCA	cis	rs7824557	0.628	rs3779891	ENSG00000154316.13	TDH	-5.54	5.17e-08	8.39e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11325996	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.628	rs11782706	ENSG00000154316.13	TDH	-5.54	5.17e-08	8.39e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11328706	chr8:11339637~11368452:+
THCA	cis	rs1125355	0.589	rs11681670	ENSG00000251491.2	OR7E28P	-5.54	5.17e-08	8.39e-06	-0.41	-0.25	Alzheimer's disease in APOE e4+ carriers;	chr2:158753780	chr2:158862311~158863285:+
THCA	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-5.54	5.18e-08	8.4e-06	-0.28	-0.25	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
THCA	cis	rs593531	0.513	rs7120394	ENSG00000212961.4	HNRNPA1P40	-5.54	5.18e-08	8.4e-06	-0.31	-0.25	Neuroticism;	chr11:74323428	chr11:74354443~74355720:+
THCA	cis	rs9952991	0.941	rs8096138	ENSG00000260302.1	RP11-973H7.1	5.54	5.18e-08	8.4e-06	0.41	0.25	Inflammatory skin disease;	chr18:12808141	chr18:12774651~12775923:-
THCA	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	5.54	5.18e-08	8.4e-06	0.33	0.25	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
THCA	cis	rs8062405	0.754	rs151179	ENSG00000278665.1	RP11-666O2.4	5.53	5.18e-08	8.4e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28599241~28601881:-
THCA	cis	rs9326248	0.53	rs7122944	ENSG00000280143.1	AP000892.6	5.53	5.19e-08	8.41e-06	0.41	0.25	Blood protein levels;	chr11:117163903	chr11:117204967~117210292:+
THCA	cis	rs2115630	1	rs11854291	ENSG00000225151.9	GOLGA2P7	5.53	5.19e-08	8.42e-06	0.31	0.25	P wave terminal force;	chr15:84820477	chr15:84199311~84230136:-
THCA	cis	rs2839186	0.559	rs2277826	ENSG00000215424.8	MCM3AP-AS1	-5.53	5.19e-08	8.42e-06	-0.14	-0.25	Testicular germ cell tumor;	chr21:46219578	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.587	rs35679325	ENSG00000215424.8	MCM3AP-AS1	-5.53	5.19e-08	8.42e-06	-0.14	-0.25	Testicular germ cell tumor;	chr21:46221066	chr21:46229217~46259390:+
THCA	cis	rs5742933	0.696	rs17271246	ENSG00000273240.1	RP11-455J20.3	-5.53	5.2e-08	8.43e-06	-0.32	-0.25	Ferritin levels;	chr2:189781481	chr2:189763859~189764456:-
THCA	cis	rs8007846	0.569	rs28616692	ENSG00000276116.2	FUT8-AS1	-5.53	5.2e-08	8.43e-06	-0.26	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65791965	chr14:65411170~65412690:-
THCA	cis	rs9467773	0.566	rs66972160	ENSG00000124549.13	BTN2A3P	-5.53	5.2e-08	8.43e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26359078	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.526	rs9348710	ENSG00000124549.13	BTN2A3P	-5.53	5.2e-08	8.43e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26360258	chr6:26421391~26432383:+
THCA	cis	rs17772222	0.582	rs1288122	ENSG00000258983.2	RP11-507K2.2	-5.53	5.2e-08	8.43e-06	-0.29	-0.25	Coronary artery calcification;	chr14:88472736	chr14:88499334~88515502:+
THCA	cis	rs9381040	0.701	rs4711658	ENSG00000161912.16	ADCY10P1	-5.53	5.2e-08	8.43e-06	-0.16	-0.25	Alzheimer's disease (late onset);	chr6:41195153	chr6:41101022~41140835:+
THCA	cis	rs7493	0.853	rs6973380	ENSG00000233942.1	AC004012.1	5.53	5.2e-08	8.43e-06	0.37	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95414211	chr7:95471835~95473998:+
THCA	cis	rs7727544	0.684	rs272869	ENSG00000224431.1	AC063976.7	5.53	5.2e-08	8.44e-06	0.21	0.25	Blood metabolite levels;	chr5:132342304	chr5:132199456~132203487:+
THCA	cis	rs5769765	0.542	rs1535189	ENSG00000260613.1	RP3-522J7.6	5.53	5.2e-08	8.44e-06	0.35	0.25	Schizophrenia;	chr22:49855483	chr22:49832616~49837786:-
THCA	cis	rs79040073	0.637	rs61442055	ENSG00000259531.2	RP11-295H24.3	5.53	5.21e-08	8.44e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49156901	chr15:49365124~49366685:-
THCA	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	5.53	5.21e-08	8.44e-06	0.43	0.25	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
THCA	cis	rs9307551	1	rs2582681	ENSG00000250334.4	LINC00989	-5.53	5.21e-08	8.45e-06	-0.32	-0.25	Refractive error;	chr4:79623064	chr4:79492416~79576460:+
THCA	cis	rs10208649	1	rs74627832	ENSG00000233266.1	HMGB1P31	5.53	5.21e-08	8.45e-06	0.64	0.25	Body mass index;	chr2:53933972	chr2:54051334~54051760:+
THCA	cis	rs3743266	0.613	rs1869484	ENSG00000245534.5	RORA-AS1	5.53	5.21e-08	8.45e-06	0.27	0.25	Menarche (age at onset);	chr15:60449864	chr15:60479178~60630637:+
THCA	cis	rs1865760	0.516	rs9393683	ENSG00000272462.2	U91328.19	-5.53	5.21e-08	8.45e-06	-0.2	-0.25	Height;	chr6:26065970	chr6:25992662~26001775:+
THCA	cis	rs1552244	1	rs7622966	ENSG00000232901.1	CYCSP10	5.53	5.21e-08	8.45e-06	0.32	0.25	Alzheimer's disease;	chr3:10098149	chr3:10000647~10000940:-
THCA	cis	rs1546924	0.57	rs197419	ENSG00000227811.2	FAM212B-AS1	5.53	5.22e-08	8.46e-06	0.3	0.25	Body mass index;	chr1:111772828	chr1:111739841~111747798:+
THCA	cis	rs7674212	0.541	rs4699050	ENSG00000251288.2	RP11-10L12.2	-5.53	5.22e-08	8.46e-06	-0.32	-0.25	Type 2 diabetes;	chr4:103193140	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.541	rs17217473	ENSG00000251288.2	RP11-10L12.2	-5.53	5.22e-08	8.46e-06	-0.32	-0.25	Type 2 diabetes;	chr4:103193585	chr4:102751401~102752641:+
THCA	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	5.53	5.22e-08	8.46e-06	0.15	0.25	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
THCA	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	5.53	5.22e-08	8.47e-06	0.23	0.25	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
THCA	cis	rs72949976	0.606	rs2178756	ENSG00000270659.1	RP11-105N14.1	-5.53	5.22e-08	8.47e-06	-0.2	-0.25	Squamous cell lung carcinoma;Lung cancer;	chr2:213166699	chr2:213152970~213153659:+
THCA	cis	rs893818	0.832	rs4077284	ENSG00000261801.4	LOXL1-AS1	-5.53	5.22e-08	8.47e-06	-0.27	-0.25	Exfoliation glaucoma or exfoliation syndrome;	chr15:73936050	chr15:73908071~73928248:-
THCA	cis	rs6585424	1	rs12268619	ENSG00000242600.5	MBL1P	5.53	5.23e-08	8.47e-06	0.29	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80160904	chr10:79904898~79950336:+
THCA	cis	rs7976269	0.537	rs2117992	ENSG00000275476.1	RP11-996F15.4	-5.53	5.23e-08	8.47e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29070611	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.537	rs10843303	ENSG00000275476.1	RP11-996F15.4	-5.53	5.23e-08	8.47e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29069435	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.559	rs10843304	ENSG00000275476.1	RP11-996F15.4	-5.53	5.23e-08	8.47e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29071226	chr12:29277397~29277882:-
THCA	cis	rs3742264	1	rs9534307	ENSG00000235903.6	CPB2-AS1	-5.53	5.23e-08	8.48e-06	-0.33	-0.25	Blood protein levels;	chr13:46069995	chr13:46052806~46113332:+
THCA	cis	rs7119038	0.774	rs10892290	ENSG00000255239.1	AP002954.6	-5.53	5.23e-08	8.48e-06	-0.38	-0.25	Sjögren's syndrome;	chr11:118782794	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.774	rs874621	ENSG00000255239.1	AP002954.6	-5.53	5.23e-08	8.48e-06	-0.38	-0.25	Sjögren's syndrome;	chr11:118784936	chr11:118688039~118690600:-
THCA	cis	rs2337406	0.925	rs11851094	ENSG00000211974.3	IGHV2-70	-5.53	5.23e-08	8.48e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106688967	chr14:106723574~106724093:-
THCA	cis	rs2562456	0.876	rs11085468	ENSG00000268119.4	CTD-2561J22.5	5.53	5.23e-08	8.48e-06	0.31	0.25	Pain;	chr19:21569087	chr19:21444241~21463908:-
THCA	cis	rs12497850	0.864	rs4513485	ENSG00000229759.1	MRPS18AP1	5.53	5.23e-08	8.48e-06	0.33	0.25	Parkinson's disease;	chr3:49102533	chr3:48256350~48256938:-
THCA	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-5.53	5.23e-08	8.48e-06	-0.28	-0.25	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
THCA	cis	rs189798	1	rs189798	ENSG00000253893.2	FAM85B	5.53	5.24e-08	8.49e-06	0.32	0.25	Myopia (pathological);	chr8:9133067	chr8:8167819~8226614:-
THCA	cis	rs1979679	0.76	rs16932640	ENSG00000278733.1	RP11-425D17.1	5.53	5.24e-08	8.5e-06	0.25	0.25	Ossification of the posterior longitudinal ligament of the spine;	chr12:28142034	chr12:28185625~28186190:-
THCA	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	5.53	5.24e-08	8.5e-06	0.15	0.25	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
THCA	cis	rs875971	0.838	rs2173570	ENSG00000223473.2	GS1-124K5.3	-5.53	5.25e-08	8.51e-06	-0.17	-0.25	Aortic root size;	chr7:66297976	chr7:66491049~66493566:-
THCA	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-5.53	5.25e-08	8.51e-06	-0.21	-0.25	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
THCA	cis	rs11266744	0.837	rs3204849	ENSG00000223552.1	RP11-24F11.2	5.53	5.25e-08	8.51e-06	0.22	0.25	Monocyte percentage of white cells;	chr3:46408579	chr3:46364955~46407059:-
THCA	cis	rs2212361	0.558	rs11020812	ENSG00000255893.1	RP11-685N10.1	5.53	5.25e-08	8.51e-06	0.28	0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94533951	chr11:94472908~94473570:-
THCA	cis	rs7225151	0.611	rs6502851	ENSG00000234327.6	AC012146.7	5.53	5.26e-08	8.52e-06	0.23	0.25	Alzheimer's disease (late onset);	chr17:5247358	chr17:5111468~5115004:+
THCA	cis	rs6539288	0.589	rs1037013	ENSG00000260329.1	RP11-412D9.4	-5.53	5.26e-08	8.52e-06	-0.22	-0.25	Total body bone mineral density;	chr12:106825530	chr12:106954029~106955497:-
THCA	cis	rs934734	0.789	rs174847	ENSG00000281920.1	RP11-418H16.1	-5.53	5.26e-08	8.53e-06	-0.32	-0.25	Rheumatoid arthritis;	chr2:65378060	chr2:65623272~65628424:+
THCA	cis	rs4971059	0.629	rs12904	ENSG00000160766.13	GBAP1	-5.53	5.26e-08	8.53e-06	-0.27	-0.25	Breast cancer;	chr1:155134221	chr1:155213821~155227422:-
THCA	cis	rs922182	0.613	rs4238401	ENSG00000275785.1	RP11-111E14.2	-5.53	5.26e-08	8.53e-06	-0.27	-0.25	Blood protein levels;	chr15:63940911	chr15:63890030~63890317:+
THCA	cis	rs79040073	0.599	rs17396536	ENSG00000259531.2	RP11-295H24.3	5.53	5.27e-08	8.53e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49256871	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs78881953	ENSG00000259531.2	RP11-295H24.3	5.53	5.27e-08	8.53e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49269019	chr15:49365124~49366685:-
THCA	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-5.53	5.27e-08	8.53e-06	-0.31	-0.25	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
THCA	cis	rs10875746	0.669	rs10467101	ENSG00000258234.1	RP11-370I10.2	5.53	5.27e-08	8.53e-06	0.28	0.25	Longevity (90 years and older);	chr12:48213954	chr12:48231098~48284210:-
THCA	cis	rs7428	0.545	rs17026212	ENSG00000246575.2	AC093162.5	5.53	5.27e-08	8.54e-06	0.22	0.25	Ear protrusion;	chr2:85324573	chr2:85315041~85316529:+
THCA	cis	rs4604234	0.803	rs28839510	ENSG00000272129.1	RP11-250B2.6	-5.53	5.27e-08	8.54e-06	-0.6	-0.25	Cancer;	chr6:80312266	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.803	rs35629704	ENSG00000272129.1	RP11-250B2.6	-5.53	5.27e-08	8.54e-06	-0.6	-0.25	Cancer;	chr6:80319044	chr6:80355424~80356859:+
THCA	cis	rs116095464	0.558	rs10075018	ENSG00000248925.1	CTD-2083E4.6	5.53	5.27e-08	8.54e-06	0.36	0.25	Breast cancer;	chr5:239060	chr5:269858~271516:-
THCA	cis	rs4789693	0.809	rs8071692	ENSG00000260011.2	RP13-20L14.1	-5.53	5.28e-08	8.55e-06	-0.25	-0.25	Glucocorticoid-induced osteonecrosis;	chr17:82434457	chr17:82381110~82382690:-
THCA	cis	rs2070488	0.699	rs6599205	ENSG00000229589.1	ACVR2B-AS1	5.53	5.28e-08	8.55e-06	0.22	0.25	Electrocardiographic conduction measures;	chr3:38487949	chr3:38451027~38454820:-
THCA	cis	rs6860806	0.632	rs4330455	ENSG00000233006.5	AC034220.3	5.53	5.28e-08	8.56e-06	0.19	0.25	Breast cancer;	chr5:132250656	chr5:132311285~132369916:-
THCA	cis	rs1880529	0.764	rs13129893	ENSG00000206820.1	RNU1-138P	-5.53	5.28e-08	8.56e-06	-0.28	-0.25	White matter integrity (bipolar disorder risk interaction);	chr4:113432016	chr4:113420323~113420486:+
THCA	cis	rs7412746	0.611	rs3768018	ENSG00000231073.1	RP11-316M1.3	5.53	5.29e-08	8.56e-06	0.3	0.25	Melanoma;	chr1:150751271	chr1:150973123~150975534:+
THCA	cis	rs9652601	0.843	rs7204643	ENSG00000274038.1	RP11-66H6.4	5.53	5.29e-08	8.57e-06	0.32	0.25	Systemic lupus erythematosus;	chr16:11073746	chr16:11056556~11057034:+
THCA	cis	rs736408	0.716	rs2239549	ENSG00000243224.1	RP5-1157M23.2	-5.53	5.29e-08	8.57e-06	-0.27	-0.25	Bipolar disorder;	chr3:52789110	chr3:52239258~52241097:+
THCA	cis	rs4713118	0.588	rs200994	ENSG00000226314.6	ZNF192P1	5.53	5.29e-08	8.57e-06	0.33	0.25	Parkinson's disease;	chr6:27846035	chr6:28161781~28169594:+
THCA	cis	rs8027521	0.811	rs2251236	ENSG00000280362.1	RP11-643A5.3	-5.53	5.29e-08	8.57e-06	-0.31	-0.25	Circulating chemerin levels;	chr15:53983217	chr15:53910769~53914712:+
THCA	cis	rs9902453	0.505	rs11080107	ENSG00000263370.1	RP11-68I3.5	-5.53	5.29e-08	8.58e-06	-0.33	-0.25	Coffee consumption (cups per day);	chr17:29611406	chr17:29639627~29640825:+
THCA	cis	rs2070488	0.804	rs1870914	ENSG00000229589.1	ACVR2B-AS1	5.53	5.3e-08	8.58e-06	0.22	0.25	Electrocardiographic conduction measures;	chr3:38452729	chr3:38451027~38454820:-
THCA	cis	rs6545883	0.965	rs766447	ENSG00000270820.4	RP11-355B11.2	5.53	5.3e-08	8.59e-06	0.21	0.25	Tuberculosis;	chr2:61508434	chr2:61471188~61484130:+
THCA	cis	rs240993	0.516	rs465646	ENSG00000230177.1	RP5-1112D6.4	-5.53	5.3e-08	8.59e-06	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111299555	chr6:111277932~111278742:+
THCA	cis	rs2041895	0.509	rs12368448	ENSG00000260329.1	RP11-412D9.4	5.53	5.3e-08	8.59e-06	0.25	0.25	Glaucoma (low intraocular pressure);	chr12:106923018	chr12:106954029~106955497:-
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000280069.1	CTD-2349P21.3	-5.53	5.31e-08	8.59e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30738182~30740275:+
THCA	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	5.53	5.31e-08	8.59e-06	0.17	0.25	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
THCA	cis	rs7412746	0.658	rs2275235	ENSG00000231073.1	RP11-316M1.3	5.53	5.31e-08	8.59e-06	0.3	0.25	Melanoma;	chr1:150757803	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs11204723	ENSG00000231073.1	RP11-316M1.3	5.53	5.31e-08	8.59e-06	0.3	0.25	Melanoma;	chr1:150759142	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs4537557	ENSG00000231073.1	RP11-316M1.3	5.53	5.31e-08	8.59e-06	0.3	0.25	Melanoma;	chr1:150761960	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs2864869	ENSG00000231073.1	RP11-316M1.3	5.53	5.31e-08	8.59e-06	0.3	0.25	Melanoma;	chr1:150762179	chr1:150973123~150975534:+
THCA	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	5.53	5.31e-08	8.6e-06	0.23	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
THCA	cis	rs1707322	0.827	rs12125508	ENSG00000281133.1	AL355480.3	-5.53	5.31e-08	8.6e-06	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45580892~45580996:-
THCA	cis	rs2212361	0.558	rs12576083	ENSG00000255893.1	RP11-685N10.1	-5.53	5.31e-08	8.6e-06	-0.3	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94537839	chr11:94472908~94473570:-
THCA	cis	rs2212361	0.558	rs113242956	ENSG00000255893.1	RP11-685N10.1	-5.53	5.31e-08	8.6e-06	-0.3	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94539300	chr11:94472908~94473570:-
THCA	cis	rs71636778	0.543	rs11810321	ENSG00000260063.1	RP5-968P14.2	-5.53	5.32e-08	8.61e-06	-0.34	-0.25	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26894030	chr1:26692132~26694131:-
THCA	cis	rs3169166	0.5	rs3813575	ENSG00000259562.2	RP11-762H8.2	5.53	5.32e-08	8.61e-06	0.17	0.25	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78268400	chr15:78290527~78291221:-
THCA	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	5.53	5.32e-08	8.62e-06	0.24	0.25	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
THCA	cis	rs2559856	1	rs2695281	ENSG00000274560.1	RP11-285E23.2	5.53	5.33e-08	8.62e-06	0.15	0.25	Blood protein levels;	chr12:101696221	chr12:101696002~101696450:-
THCA	cis	rs2562456	0.724	rs58001930	ENSG00000268119.4	CTD-2561J22.5	5.53	5.33e-08	8.63e-06	0.3	0.25	Pain;	chr19:21560061	chr19:21444241~21463908:-
THCA	cis	rs4784934	0.589	rs9940062	ENSG00000260186.4	RP11-481J2.2	-5.53	5.33e-08	8.63e-06	-0.32	-0.25	QT interval;	chr16:58437315	chr16:58421326~58462470:+
THCA	cis	rs8027521	0.846	rs2243799	ENSG00000280362.1	RP11-643A5.3	-5.53	5.33e-08	8.63e-06	-0.3	-0.25	Circulating chemerin levels;	chr15:53979751	chr15:53910769~53914712:+
THCA	cis	rs1075232	1	rs12438318	ENSG00000215302.7	CTD-3092A11.1	-5.53	5.33e-08	8.64e-06	-0.56	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30470779~30507623:+
THCA	cis	rs12681287	0.647	rs2953510	ENSG00000254231.1	CTD-2284J15.1	5.53	5.34e-08	8.64e-06	0.27	0.25	Caudate activity during reward;	chr8:86329685	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.605	rs2953509	ENSG00000254231.1	CTD-2284J15.1	5.53	5.34e-08	8.64e-06	0.27	0.25	Caudate activity during reward;	chr8:86330965	chr8:86333274~86343314:-
THCA	cis	rs1552244	0.515	rs28853661	ENSG00000232901.1	CYCSP10	5.53	5.34e-08	8.64e-06	0.38	0.25	Alzheimer's disease;	chr3:10135975	chr3:10000647~10000940:-
THCA	cis	rs6569038	0.502	rs2051057	ENSG00000253194.1	RP11-351A11.1	5.53	5.34e-08	8.64e-06	0.34	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118978278	chr6:118934785~119031541:+
THCA	cis	rs7523875	0.572	rs79838948	ENSG00000153363.11	LINC00467	-5.53	5.34e-08	8.65e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211467679	chr1:211382803~211435333:+
THCA	cis	rs2562456	0.833	rs516519	ENSG00000268081.1	RP11-678G14.2	-5.53	5.34e-08	8.65e-06	-0.37	-0.25	Pain;	chr19:21298730	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs552800	ENSG00000268081.1	RP11-678G14.2	-5.53	5.34e-08	8.65e-06	-0.37	-0.25	Pain;	chr19:21301840	chr19:21554640~21569237:-
THCA	cis	rs9921338	0.961	rs6498185	ENSG00000262636.1	CTD-3088G3.4	-5.53	5.34e-08	8.65e-06	-0.36	-0.25	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350869	chr16:11380859~11381118:-
THCA	cis	rs7809950	0.678	rs2237660	ENSG00000238832.1	snoU109	-5.53	5.35e-08	8.66e-06	-0.3	-0.25	Coronary artery disease;	chr7:107222518	chr7:107603363~107603507:+
THCA	cis	rs1876905	0.68	rs7767302	ENSG00000230177.1	RP5-1112D6.4	5.53	5.35e-08	8.66e-06	0.26	0.25	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111277932~111278742:+
THCA	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	5.53	5.35e-08	8.66e-06	0.24	0.25	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
THCA	cis	rs1552244	0.872	rs6792951	ENSG00000232901.1	CYCSP10	5.53	5.36e-08	8.67e-06	0.32	0.25	Alzheimer's disease;	chr3:10077919	chr3:10000647~10000940:-
THCA	cis	rs2115536	1	rs11637477	ENSG00000278600.1	RP11-81A1.6	-5.53	5.36e-08	8.67e-06	-0.15	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79900953	chr15:79920195~79922455:-
THCA	cis	rs2212361	0.558	rs72963823	ENSG00000255893.1	RP11-685N10.1	-5.53	5.36e-08	8.67e-06	-0.31	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94540874	chr11:94472908~94473570:-
THCA	cis	rs2562456	0.761	rs35008138	ENSG00000268119.4	CTD-2561J22.5	5.53	5.36e-08	8.68e-06	0.3	0.25	Pain;	chr19:21548822	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs2681388	ENSG00000268119.4	CTD-2561J22.5	5.53	5.36e-08	8.68e-06	0.3	0.25	Pain;	chr19:21549451	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.876	rs2681370	ENSG00000268119.4	CTD-2561J22.5	5.53	5.36e-08	8.68e-06	0.3	0.25	Pain;	chr19:21554036	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.876	rs11668606	ENSG00000268119.4	CTD-2561J22.5	5.53	5.36e-08	8.68e-06	0.3	0.25	Pain;	chr19:21554618	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.876	rs2681395	ENSG00000268119.4	CTD-2561J22.5	5.53	5.36e-08	8.68e-06	0.3	0.25	Pain;	chr19:21555338	chr19:21444241~21463908:-
THCA	cis	rs763121	0.962	rs5757135	ENSG00000235209.1	CTA-150C2.13	5.53	5.37e-08	8.69e-06	0.31	0.25	Menopause (age at onset);	chr22:38556568	chr22:38921227~38924708:+
THCA	cis	rs528808	1	rs528808	ENSG00000228506.1	RP11-98I9.4	5.53	5.37e-08	8.69e-06	0.34	0.25	Age-related hearing impairment;	chr6:99656413	chr6:99424922~99431373:+
THCA	cis	rs7580658	0.521	rs7605733	ENSG00000236682.1	AC068282.3	-5.53	5.37e-08	8.69e-06	-0.32	-0.25	Protein C levels;	chr2:127174211	chr2:127389130~127400580:+
THCA	cis	rs10875746	0.855	rs12296244	ENSG00000269514.1	RP11-370I10.12	5.53	5.37e-08	8.69e-06	0.25	0.25	Longevity (90 years and older);	chr12:48047696	chr12:48198387~48202031:+
THCA	cis	rs6921919	0.562	rs13198809	ENSG00000226314.6	ZNF192P1	-5.53	5.38e-08	8.7e-06	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs35353359	ENSG00000226314.6	ZNF192P1	-5.53	5.38e-08	8.7e-06	-0.53	-0.25	Depression;	chr6:28356601	chr6:28161781~28169594:+
THCA	cis	rs116095464	0.558	rs2288459	ENSG00000248925.1	CTD-2083E4.6	5.53	5.38e-08	8.7e-06	0.36	0.25	Breast cancer;	chr5:231028	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs2288458	ENSG00000248925.1	CTD-2083E4.6	5.53	5.38e-08	8.7e-06	0.36	0.25	Breast cancer;	chr5:231145	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs2288457	ENSG00000248925.1	CTD-2083E4.6	5.53	5.38e-08	8.7e-06	0.36	0.25	Breast cancer;	chr5:231155	chr5:269858~271516:-
THCA	cis	rs12893668	0.543	rs1799796	ENSG00000269910.1	RP11-73M18.10	5.53	5.38e-08	8.71e-06	0.23	0.25	Reticulocyte count;	chr14:103699590	chr14:103694516~103695050:-
THCA	cis	rs12893668	0.514	rs3212090	ENSG00000269910.1	RP11-73M18.10	5.53	5.38e-08	8.71e-06	0.23	0.25	Reticulocyte count;	chr14:103702526	chr14:103694516~103695050:-
THCA	cis	rs1552244	0.882	rs113268531	ENSG00000180385.7	EMC3-AS1	5.53	5.38e-08	8.71e-06	0.27	0.25	Alzheimer's disease;	chr3:10125385	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.938	rs67667957	ENSG00000180385.7	EMC3-AS1	5.53	5.38e-08	8.71e-06	0.27	0.25	Alzheimer's disease;	chr3:10125580	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.938	rs56274701	ENSG00000180385.7	EMC3-AS1	5.53	5.38e-08	8.71e-06	0.27	0.25	Alzheimer's disease;	chr3:10126106	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs2272124	ENSG00000232901.1	CYCSP10	5.53	5.38e-08	8.71e-06	0.32	0.25	Alzheimer's disease;	chr3:10096505	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs55882090	ENSG00000232901.1	CYCSP10	5.53	5.38e-08	8.71e-06	0.32	0.25	Alzheimer's disease;	chr3:10097398	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs7622963	ENSG00000232901.1	CYCSP10	5.53	5.38e-08	8.71e-06	0.32	0.25	Alzheimer's disease;	chr3:10098141	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs34179822	ENSG00000232901.1	CYCSP10	5.53	5.38e-08	8.71e-06	0.32	0.25	Alzheimer's disease;	chr3:10098333	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.938	rs7647987	ENSG00000232901.1	CYCSP10	5.53	5.38e-08	8.71e-06	0.32	0.25	Alzheimer's disease;	chr3:10099012	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs3826	ENSG00000232901.1	CYCSP10	5.53	5.38e-08	8.71e-06	0.32	0.25	Alzheimer's disease;	chr3:10099381	chr3:10000647~10000940:-
THCA	cis	rs12893668	0.572	rs11846404	ENSG00000269940.1	RP11-73M18.7	5.53	5.38e-08	8.71e-06	0.26	0.25	Reticulocyte count;	chr14:103689771	chr14:103694560~103695170:+
THCA	cis	rs62432291	0.681	rs294913	ENSG00000235086.1	FNDC1-IT1	-5.53	5.38e-08	8.71e-06	-0.46	-0.25	Joint mobility (Beighton score);	chr6:159246195	chr6:159240786~159243329:+
THCA	cis	rs4415084	0.834	rs1061310	ENSG00000272335.1	RP11-53O19.3	-5.53	5.38e-08	8.71e-06	-0.2	-0.25	Breast cancer;	chr5:44820748	chr5:44826076~44828592:+
THCA	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-5.53	5.39e-08	8.72e-06	-0.24	-0.25	Height;	chr2:46615271	chr2:46668870~46670778:+
THCA	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-5.53	5.39e-08	8.72e-06	-0.24	-0.25	Height;	chr2:46616492	chr2:46668870~46670778:+
THCA	cis	rs17772222	0.876	rs12587598	ENSG00000222990.1	RNU4-22P	5.53	5.39e-08	8.72e-06	0.31	0.25	Coronary artery calcification;	chr14:88729474	chr14:88513498~88513663:+
THCA	cis	rs11148252	0.875	rs9568728	ENSG00000235660.1	LINC00345	-5.53	5.39e-08	8.72e-06	-0.32	-0.25	Lewy body disease;	chr13:52372458	chr13:52484161~52484680:-
THCA	cis	rs7246657	0.722	rs16958861	ENSG00000276846.1	CTD-3220F14.3	5.53	5.4e-08	8.73e-06	0.25	0.25	Coronary artery calcification;	chr19:37633278	chr19:37314868~37315620:-
THCA	cis	rs890448	0.796	rs2960588	ENSG00000254531.1	FLJ20021	5.53	5.4e-08	8.73e-06	0.22	0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101429307	chr4:101347780~101348883:+
THCA	cis	rs412050	1	rs56138298	ENSG00000224086.5	LL22NC03-86G7.1	-5.53	5.4e-08	8.73e-06	-0.4	-0.25	Attention deficit hyperactivity disorder;	chr22:21962168	chr22:21938293~21977632:+
THCA	cis	rs6433895	0.809	rs35323141	ENSG00000236153.1	AC104076.3	-5.53	5.4e-08	8.74e-06	-0.28	-0.25	Lymphocyte counts;	chr2:181131831	chr2:180979427~180980090:-
THCA	cis	rs2179367	0.6	rs9498355	ENSG00000223701.3	RAET1E-AS1	-5.53	5.4e-08	8.74e-06	-0.39	-0.25	Dupuytren's disease;	chr6:149442274	chr6:149884431~149919508:+
THCA	cis	rs3950186	0.834	rs1883326	ENSG00000215124.2	RP3-420J14.1	5.53	5.41e-08	8.75e-06	0.29	0.25	Anxiety and major depressive disorder;	chr6:11818083	chr6:11861626~11862970:-
THCA	cis	rs62432291	0.681	rs386818	ENSG00000235086.1	FNDC1-IT1	-5.53	5.41e-08	8.75e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159239223	chr6:159240786~159243329:+
THCA	cis	rs2342371	1	rs13094241	ENSG00000273013.1	CTD-2002J20.1	-5.53	5.42e-08	8.76e-06	-0.24	-0.25	Fat distribution (HIV);	chr3:196464022	chr3:196474801~196475394:+
THCA	cis	rs9309473	0.5	rs2421668	ENSG00000163016.8	ALMS1P	-5.53	5.42e-08	8.76e-06	-0.32	-0.25	Metabolite levels;	chr2:73657969	chr2:73644919~73685576:+
THCA	cis	rs17772222	0.655	rs816072	ENSG00000258983.2	RP11-507K2.2	-5.53	5.42e-08	8.76e-06	-0.29	-0.25	Coronary artery calcification;	chr14:88484335	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.655	rs1152376	ENSG00000258983.2	RP11-507K2.2	-5.53	5.42e-08	8.76e-06	-0.29	-0.25	Coronary artery calcification;	chr14:88495121	chr14:88499334~88515502:+
THCA	cis	rs172166	0.694	rs203876	ENSG00000220721.1	OR1F12	5.53	5.42e-08	8.76e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28078895	chr6:28073316~28074233:+
THCA	cis	rs172166	0.694	rs203877	ENSG00000220721.1	OR1F12	5.53	5.42e-08	8.76e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28080846	chr6:28073316~28074233:+
THCA	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	5.53	5.42e-08	8.76e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
THCA	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	5.53	5.42e-08	8.76e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
THCA	cis	rs8113308	0.689	rs8112515	ENSG00000269235.1	ZNF350-AS1	5.53	5.42e-08	8.77e-06	0.34	0.25	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987997	chr19:51949134~51981367:+
THCA	cis	rs7394190	0.748	rs60212594	ENSG00000271816.1	BMS1P4	-5.53	5.43e-08	8.77e-06	-0.29	-0.25	Incident atrial fibrillation;	chr10:73654586	chr10:73699151~73730487:-
THCA	cis	rs7688540	0.8	rs28429717	ENSG00000211553.1	AC253576.2	-5.53	5.43e-08	8.77e-06	-0.35	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:136461~136568:+
THCA	cis	rs3796352	1	rs3796352	ENSG00000242142.1	SERBP1P3	-5.53	5.43e-08	8.78e-06	-0.48	-0.25	Immune reponse to smallpox (secreted IL-2);	chr3:52879263	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs71299622	ENSG00000242142.1	SERBP1P3	-5.53	5.43e-08	8.78e-06	-0.48	-0.25	Immune reponse to smallpox (secreted IL-2);	chr3:52883022	chr3:53064283~53065091:-
THCA	cis	rs6840360	0.582	rs2709826	ENSG00000270265.1	RP11-731D1.4	-5.53	5.44e-08	8.79e-06	-0.23	-0.25	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151333775~151353224:-
THCA	cis	rs2304003	1	rs2304003	ENSG00000235192.1	AC009495.2	5.53	5.44e-08	8.79e-06	0.35	0.25	Social communication problems;	chr2:165857571	chr2:165794851~165810010:+
THCA	cis	rs2179367	0.632	rs997682	ENSG00000231760.4	RP11-350J20.5	-5.53	5.44e-08	8.79e-06	-0.35	-0.25	Dupuytren's disease;	chr6:149345484	chr6:149796151~149826294:-
THCA	cis	rs9843304	0.528	rs11919764	ENSG00000244503.1	RP11-278L15.6	5.53	5.44e-08	8.79e-06	0.31	0.25	Gallstone disease;	chr3:149469448	chr3:149494660~149495995:+
THCA	cis	rs1322639	0.614	rs6903921	ENSG00000261039.2	RP11-417E7.2	-5.53	5.44e-08	8.79e-06	-0.38	-0.25	Pulse pressure;	chr6:169163862	chr6:169175304~169182740:-
THCA	cis	rs1322639	0.614	rs6925950	ENSG00000261039.2	RP11-417E7.2	-5.53	5.44e-08	8.79e-06	-0.38	-0.25	Pulse pressure;	chr6:169163863	chr6:169175304~169182740:-
THCA	cis	rs7404843	0.777	rs6498552	ENSG00000263335.1	AF001548.5	-5.53	5.44e-08	8.8e-06	-0.41	-0.25	Testicular germ cell tumor;	chr16:15446044	chr16:15726674~15732993:+
THCA	cis	rs7404843	0.85	rs6498553	ENSG00000263335.1	AF001548.5	-5.53	5.44e-08	8.8e-06	-0.41	-0.25	Testicular germ cell tumor;	chr16:15446045	chr16:15726674~15732993:+
THCA	cis	rs8396	0.96	rs6839534	ENSG00000271817.2	U3	5.53	5.44e-08	8.8e-06	0.26	0.25	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158716843	chr4:158700691~158700909:+
THCA	cis	rs7829975	0.606	rs11776838	ENSG00000233609.3	RP11-62H7.2	-5.53	5.45e-08	8.8e-06	-0.24	-0.25	Mood instability;	chr8:8937291	chr8:8961200~8979025:+
THCA	cis	rs950169	0.58	rs11636189	ENSG00000275120.1	RP11-182J1.17	5.53	5.45e-08	8.8e-06	0.29	0.25	Schizophrenia;	chr15:84650323	chr15:84599434~84606463:-
THCA	cis	rs950169	0.58	rs35516100	ENSG00000275120.1	RP11-182J1.17	5.53	5.45e-08	8.8e-06	0.29	0.25	Schizophrenia;	chr15:84652199	chr15:84599434~84606463:-
THCA	cis	rs950169	0.58	rs62021208	ENSG00000275120.1	RP11-182J1.17	5.53	5.45e-08	8.8e-06	0.29	0.25	Schizophrenia;	chr15:84653013	chr15:84599434~84606463:-
THCA	cis	rs9813712	0.953	rs6804874	ENSG00000228252.7	COL6A4P2	5.53	5.45e-08	8.8e-06	0.28	0.25	Response to amphetamines;	chr3:130257205	chr3:130212823~130273806:+
THCA	cis	rs9987353	0.589	rs1053036	ENSG00000253893.2	FAM85B	5.53	5.46e-08	8.82e-06	0.33	0.25	Recombination measurement;	chr8:9202567	chr8:8167819~8226614:-
THCA	cis	rs55823223	0.618	rs11867339	ENSG00000267801.1	RP11-552F3.9	5.53	5.46e-08	8.82e-06	0.34	0.25	Psoriasis;	chr17:75866012	chr17:75876372~75879546:+
THCA	cis	rs763121	0.853	rs2179142	ENSG00000235209.1	CTA-150C2.13	5.53	5.46e-08	8.83e-06	0.33	0.25	Menopause (age at onset);	chr22:38641949	chr22:38921227~38924708:+
THCA	cis	rs9595908	1	rs9595908	ENSG00000212293.1	SNORA16	5.53	5.46e-08	8.83e-06	0.29	0.25	Body mass index;	chr13:32610151	chr13:32420390~32420516:-
THCA	cis	rs6547705	0.702	rs4832049	ENSG00000231259.4	AC125232.1	5.53	5.46e-08	8.83e-06	0.31	0.25	Progressive supranuclear palsy;	chr2:86826596	chr2:87031815~87053069:-
THCA	cis	rs4908768	0.539	rs6663123	ENSG00000232912.4	RP5-1115A15.1	5.53	5.46e-08	8.83e-06	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8424645~8434838:+
THCA	cis	rs6545883	0.868	rs28749199	ENSG00000270820.4	RP11-355B11.2	5.53	5.47e-08	8.83e-06	0.21	0.25	Tuberculosis;	chr2:61599917	chr2:61471188~61484130:+
THCA	cis	rs6058796	1	rs6141777	ENSG00000175730.8	BAK1P1	5.52	5.47e-08	8.83e-06	0.37	0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32662145	chr20:32690180~32690815:-
THCA	cis	rs7976269	0.559	rs10843313	ENSG00000275476.1	RP11-996F15.4	-5.52	5.47e-08	8.84e-06	-0.25	-0.25	Male-pattern baldness;	chr12:29078317	chr12:29277397~29277882:-
THCA	cis	rs28510890	1	rs28510890	ENSG00000260337.3	RP11-386M24.6	5.52	5.47e-08	8.84e-06	0.28	0.25	Lung cancer in ever smokers;	chr15:92567899	chr15:92592574~92596462:-
THCA	cis	rs758324	0.732	rs128738	ENSG00000237714.1	P4HA2-AS1	-5.52	5.48e-08	8.84e-06	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132205182	chr5:132184876~132192808:+
THCA	cis	rs9309473	0.519	rs2421584	ENSG00000163016.8	ALMS1P	-5.52	5.48e-08	8.85e-06	-0.32	-0.25	Metabolite levels;	chr2:73671725	chr2:73644919~73685576:+
THCA	cis	rs6545883	0.868	rs2427885	ENSG00000270820.4	RP11-355B11.2	5.52	5.48e-08	8.85e-06	0.21	0.25	Tuberculosis;	chr2:61589642	chr2:61471188~61484130:+
THCA	cis	rs6969780	0.915	rs3801320	ENSG00000233429.8	HOTAIRM1	5.52	5.48e-08	8.85e-06	0.33	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27124745	chr7:27095647~27100265:+
THCA	cis	rs7552393	0.595	rs7551130	ENSG00000233008.4	RP11-475O6.1	5.52	5.48e-08	8.85e-06	0.28	0.25	Select biomarker traits;	chr1:83802945	chr1:83575776~83861023:-
THCA	cis	rs17301013	0.507	rs3118988	ENSG00000227373.4	RP11-160H22.5	-5.52	5.48e-08	8.85e-06	-0.37	-0.25	Systemic lupus erythematosus;	chr1:174819245	chr1:174115300~174160004:-
THCA	cis	rs7809950	0.678	rs2395868	ENSG00000238832.1	snoU109	5.52	5.48e-08	8.85e-06	0.29	0.25	Coronary artery disease;	chr7:107257055	chr7:107603363~107603507:+
THCA	cis	rs2337406	0.587	rs916547	ENSG00000211974.3	IGHV2-70	-5.52	5.48e-08	8.86e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106646735	chr14:106723574~106724093:-
THCA	cis	rs11603023	0.804	rs527619	ENSG00000278376.1	RP11-158I9.8	5.52	5.48e-08	8.86e-06	0.19	0.25	Cholesterol, total;	chr11:118692577	chr11:118791254~118793137:+
THCA	cis	rs5015933	0.815	rs13294021	ENSG00000232630.1	PRPS1P2	-5.52	5.49e-08	8.86e-06	-0.17	-0.25	Body mass index;	chr9:125306109	chr9:125150653~125151589:+
THCA	cis	rs7246657	0.722	rs2972447	ENSG00000276846.1	CTD-3220F14.3	-5.52	5.49e-08	8.86e-06	-0.25	-0.25	Coronary artery calcification;	chr19:37638835	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs10409605	ENSG00000276846.1	CTD-3220F14.3	5.52	5.49e-08	8.86e-06	0.25	0.25	Coronary artery calcification;	chr19:37632236	chr19:37314868~37315620:-
THCA	cis	rs6688613	0.765	rs56229522	ENSG00000225171.2	DUTP6	-5.52	5.49e-08	8.87e-06	-0.32	-0.25	Refractive astigmatism;	chr1:166846871	chr1:166868748~166869209:+
THCA	cis	rs11089937	0.597	rs4821772	ENSG00000211638.2	IGLV8-61	5.52	5.49e-08	8.87e-06	0.19	0.25	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22098700~22099212:+
THCA	cis	rs172166	0.694	rs203893	ENSG00000220721.1	OR1F12	5.52	5.49e-08	8.87e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28094288	chr6:28073316~28074233:+
THCA	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	5.52	5.49e-08	8.87e-06	0.36	0.25	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
THCA	cis	rs9307551	1	rs9307551	ENSG00000250334.4	LINC00989	-5.52	5.49e-08	8.87e-06	-0.31	-0.25	Refractive error;	chr4:79609517	chr4:79492416~79576460:+
THCA	cis	rs9380516	0.945	rs7764472	ENSG00000228559.1	RP3-340B19.3	-5.52	5.5e-08	8.87e-06	-0.39	-0.25	Hepatitis C induced liver fibrosis;	chr6:35511797	chr6:35544632~35545669:+
THCA	cis	rs7615952	0.673	rs35955861	ENSG00000241288.6	RP11-379B18.5	-5.52	5.5e-08	8.88e-06	-0.35	-0.25	Blood pressure (smoking interaction);	chr3:125907358	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.673	rs35001498	ENSG00000241288.6	RP11-379B18.5	-5.52	5.5e-08	8.88e-06	-0.35	-0.25	Blood pressure (smoking interaction);	chr3:125909801	chr3:125827238~125916384:-
THCA	cis	rs2304003	1	rs9973895	ENSG00000235192.1	AC009495.2	5.52	5.5e-08	8.88e-06	0.35	0.25	Social communication problems;	chr2:165860936	chr2:165794851~165810010:+
THCA	cis	rs8007846	0.535	rs28459012	ENSG00000276116.2	FUT8-AS1	-5.52	5.5e-08	8.88e-06	-0.26	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65791810	chr14:65411170~65412690:-
THCA	cis	rs8007846	0.569	rs4073415	ENSG00000276116.2	FUT8-AS1	-5.52	5.5e-08	8.88e-06	-0.26	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65792812	chr14:65411170~65412690:-
THCA	cis	rs2070488	0.775	rs11926767	ENSG00000229589.1	ACVR2B-AS1	-5.52	5.5e-08	8.88e-06	-0.22	-0.25	Electrocardiographic conduction measures;	chr3:38486422	chr3:38451027~38454820:-
THCA	cis	rs79040073	0.637	rs8030457	ENSG00000259531.2	RP11-295H24.3	5.52	5.5e-08	8.88e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49392809	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.599	rs17477722	ENSG00000259531.2	RP11-295H24.3	5.52	5.5e-08	8.88e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49394220	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73398243	ENSG00000259531.2	RP11-295H24.3	5.52	5.5e-08	8.88e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49394344	chr15:49365124~49366685:-
THCA	cis	rs4415084	0.804	rs10044096	ENSG00000272335.1	RP11-53O19.3	5.52	5.5e-08	8.88e-06	0.2	0.25	Breast cancer;	chr5:44927263	chr5:44826076~44828592:+
THCA	cis	rs1598856	0.715	rs1598861	ENSG00000246560.2	RP11-10L12.4	5.52	5.5e-08	8.89e-06	0.33	0.25	Primary biliary cholangitis;	chr4:102565540	chr4:102828055~102844075:+
THCA	cis	rs7824557	0.593	rs11774673	ENSG00000154316.13	TDH	-5.52	5.51e-08	8.89e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11334028	chr8:11339637~11368452:+
THCA	cis	rs2562456	0.876	rs11085468	ENSG00000213976.4	CTD-2561J22.2	-5.52	5.51e-08	8.89e-06	-0.26	-0.25	Pain;	chr19:21569087	chr19:21382865~21387177:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000273142.1	RP11-458F8.4	-5.52	5.51e-08	8.89e-06	-0.2	-0.25	Aortic root size;	chr7:66376994	chr7:66902857~66906297:+
THCA	cis	rs6860806	0.695	rs11952099	ENSG00000233006.5	AC034220.3	5.52	5.51e-08	8.89e-06	0.19	0.25	Breast cancer;	chr5:132241079	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.661	rs2136187	ENSG00000233006.5	AC034220.3	5.52	5.51e-08	8.89e-06	0.19	0.25	Breast cancer;	chr5:132242201	chr5:132311285~132369916:-
THCA	cis	rs7911264	1	rs10786052	ENSG00000236493.2	EIF2S2P3	5.52	5.51e-08	8.9e-06	0.25	0.25	Inflammatory bowel disease;	chr10:92686878	chr10:92668745~92669743:-
THCA	cis	rs9816784	0.696	rs6778081	ENSG00000273009.1	RP11-352G9.1	5.52	5.52e-08	8.9e-06	0.26	0.25	Mean corpuscular hemoglobin;	chr3:196092334	chr3:195913078~195913683:-
THCA	cis	rs1979679	0.918	rs11049513	ENSG00000278733.1	RP11-425D17.1	5.52	5.52e-08	8.9e-06	0.26	0.25	Ossification of the posterior longitudinal ligament of the spine;	chr12:28297218	chr12:28185625~28186190:-
THCA	cis	rs3764400	0.508	rs12601350	ENSG00000278765.1	RP5-890E16.5	5.52	5.52e-08	8.91e-06	0.45	0.25	Body mass index;	chr17:48043057	chr17:48066704~48067293:-
THCA	cis	rs8002861	0.935	rs4942256	ENSG00000274001.1	RP11-5G9.5	5.52	5.52e-08	8.91e-06	0.28	0.25	Leprosy;	chr13:43881784	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.935	rs9567299	ENSG00000274001.1	RP11-5G9.5	5.52	5.52e-08	8.91e-06	0.28	0.25	Leprosy;	chr13:43882833	chr13:43877715~43878163:-
THCA	cis	rs34779708	0.832	rs6481946	ENSG00000271335.4	RP11-324I22.4	5.52	5.52e-08	8.91e-06	0.24	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35314552~35336401:-
THCA	cis	rs6453278	1	rs6453279	ENSG00000250802.5	ZBED3-AS1	-5.52	5.53e-08	8.92e-06	-0.22	-0.25	Autism;	chr5:77121249	chr5:77086740~77166909:+
THCA	cis	rs2944755	0.723	rs9694342	ENSG00000279766.1	RP11-642A1.2	-5.52	5.53e-08	8.93e-06	-0.32	-0.25	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140577305	chr8:140572142~140572812:-
THCA	cis	rs1707322	0.789	rs10789473	ENSG00000281133.1	AL355480.3	-5.52	5.53e-08	8.93e-06	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45580892~45580996:-
THCA	cis	rs2212361	0.558	rs16924599	ENSG00000255893.1	RP11-685N10.1	-5.52	5.54e-08	8.94e-06	-0.29	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94523265	chr11:94472908~94473570:-
THCA	cis	rs1889642	0.743	rs9318656	ENSG00000227354.5	RBM26-AS1	5.52	5.54e-08	8.94e-06	0.23	0.25	Colonoscopy-negative controls vs population controls;	chr13:79801474	chr13:79406309~79424328:+
THCA	cis	rs7923837	1	rs7087591	ENSG00000236493.2	EIF2S2P3	5.52	5.54e-08	8.94e-06	0.26	0.25	Multiple sclerosis;Body mass index;	chr10:92713872	chr10:92668745~92669743:-
THCA	cis	rs7674212	0.541	rs2623070	ENSG00000251288.2	RP11-10L12.2	5.52	5.54e-08	8.94e-06	0.32	0.25	Type 2 diabetes;	chr4:103116231	chr4:102751401~102752641:+
THCA	cis	rs1865760	0.566	rs2051544	ENSG00000272462.2	U91328.19	-5.52	5.54e-08	8.94e-06	-0.2	-0.25	Height;	chr6:26070865	chr6:25992662~26001775:+
THCA	cis	rs375066	0.592	rs349045	ENSG00000267058.1	RP11-15A1.3	5.52	5.55e-08	8.95e-06	0.21	0.25	Breast cancer;	chr19:43795740	chr19:43891804~43901805:-
THCA	cis	rs79040073	0.637	rs113885253	ENSG00000259531.2	RP11-295H24.3	5.52	5.55e-08	8.96e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49402615	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73398250	ENSG00000259531.2	RP11-295H24.3	5.52	5.55e-08	8.96e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49404829	chr15:49365124~49366685:-
THCA	cis	rs4819052	0.851	rs2838867	ENSG00000273796.1	LL21NC02-21A1.1	-5.52	5.55e-08	8.96e-06	-0.27	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:45403809~45404369:-
THCA	cis	rs890448	0.826	rs6532939	ENSG00000254531.1	FLJ20021	-5.52	5.56e-08	8.97e-06	-0.22	-0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101478052	chr4:101347780~101348883:+
THCA	cis	rs1667284	0.58	rs4799589	ENSG00000266521.1	RP11-650P15.1	-5.52	5.56e-08	8.97e-06	-0.31	-0.25	Problematic alcohol use in trauma-exposed individuals;	chr18:31656293	chr18:31496645~31497195:-
THCA	cis	rs847577	0.674	rs7790479	ENSG00000272950.1	RP11-307C18.1	5.52	5.56e-08	8.97e-06	0.3	0.25	Breast cancer;	chr7:98083789	chr7:98322853~98323430:+
THCA	cis	rs6430585	0.528	rs75753154	ENSG00000231890.6	DARS-AS1	-5.52	5.56e-08	8.97e-06	-0.3	-0.25	Corneal structure;	chr2:135908141	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.528	rs7606267	ENSG00000231890.6	DARS-AS1	-5.52	5.56e-08	8.97e-06	-0.3	-0.25	Corneal structure;	chr2:135910553	chr2:135985176~136022593:+
THCA	cis	rs2858942	0.527	rs7198029	ENSG00000268836.1	LA16c-OS12.2	5.52	5.56e-08	8.98e-06	0.22	0.25	Mean corpuscular hemoglobin;	chr16:199465	chr16:185748~186294:-
THCA	cis	rs1552244	0.554	rs2272119	ENSG00000232901.1	CYCSP10	5.52	5.56e-08	8.98e-06	0.29	0.25	Alzheimer's disease;	chr3:10007668	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.608	rs9837460	ENSG00000232901.1	CYCSP10	5.52	5.56e-08	8.98e-06	0.29	0.25	Alzheimer's disease;	chr3:10008238	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs28667821	ENSG00000232901.1	CYCSP10	5.52	5.56e-08	8.98e-06	0.29	0.25	Alzheimer's disease;	chr3:10009083	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.543	rs28719585	ENSG00000232901.1	CYCSP10	5.52	5.56e-08	8.98e-06	0.29	0.25	Alzheimer's disease;	chr3:10009129	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs7349576	ENSG00000232901.1	CYCSP10	5.52	5.56e-08	8.98e-06	0.29	0.25	Alzheimer's disease;	chr3:10009209	chr3:10000647~10000940:-
THCA	cis	rs338389	0.542	rs28694418	ENSG00000260657.2	RP11-315D16.4	-5.52	5.57e-08	8.99e-06	-0.31	-0.25	Survival in rectal cancer;	chr15:67949855	chr15:68267792~68277994:-
THCA	cis	rs338389	0.542	rs12914946	ENSG00000260657.2	RP11-315D16.4	-5.52	5.57e-08	8.99e-06	-0.31	-0.25	Survival in rectal cancer;	chr15:67949990	chr15:68267792~68277994:-
THCA	cis	rs3169166	0.521	rs62007839	ENSG00000259562.2	RP11-762H8.2	5.52	5.57e-08	8.99e-06	0.17	0.25	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78278533	chr15:78290527~78291221:-
THCA	cis	rs7211079	0.505	rs60323863	ENSG00000275479.1	RP11-334C17.6	5.52	5.57e-08	8.99e-06	0.3	0.25	Myocardial infarction;	chr17:80151287	chr17:80149627~80149798:+
THCA	cis	rs6569038	0.502	rs11967889	ENSG00000253194.1	RP11-351A11.1	-5.52	5.58e-08	9e-06	-0.34	-0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118992468	chr6:118934785~119031541:+
THCA	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-5.52	5.58e-08	9e-06	-0.21	-0.25	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
THCA	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-5.52	5.58e-08	9e-06	-0.21	-0.25	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
THCA	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-5.52	5.58e-08	9e-06	-0.21	-0.25	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
THCA	cis	rs4604234	0.803	rs73463519	ENSG00000272129.1	RP11-250B2.6	-5.52	5.58e-08	9.01e-06	-0.6	-0.25	Cancer;	chr6:80266862	chr6:80355424~80356859:+
THCA	cis	rs12935418	0.616	rs2602453	ENSG00000278985.1	RP11-303E16.9	-5.52	5.58e-08	9.01e-06	-0.26	-0.25	Mean corpuscular volume;	chr16:80994358	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2970086	ENSG00000278985.1	RP11-303E16.9	-5.52	5.58e-08	9.01e-06	-0.26	-0.25	Mean corpuscular volume;	chr16:80994835	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2970085	ENSG00000278985.1	RP11-303E16.9	-5.52	5.58e-08	9.01e-06	-0.26	-0.25	Mean corpuscular volume;	chr16:80994842	chr16:80982319~80984094:-
THCA	cis	rs847577	0.722	rs7790120	ENSG00000272950.1	RP11-307C18.1	5.52	5.59e-08	9.01e-06	0.3	0.25	Breast cancer;	chr7:98083519	chr7:98322853~98323430:+
THCA	cis	rs4604234	0.803	rs73463531	ENSG00000272129.1	RP11-250B2.6	-5.52	5.59e-08	9.01e-06	-0.6	-0.25	Cancer;	chr6:80274328	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.803	rs11961345	ENSG00000272129.1	RP11-250B2.6	-5.52	5.59e-08	9.01e-06	-0.6	-0.25	Cancer;	chr6:80294807	chr6:80355424~80356859:+
THCA	cis	rs7615952	0.546	rs11711150	ENSG00000243429.1	OR7E29P	5.52	5.59e-08	9.02e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:125596819	chr3:125712139~125713045:+
THCA	cis	rs7727544	0.735	rs2569266	ENSG00000263597.1	MIR3936	-5.52	5.59e-08	9.02e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132371099	chr5:132365490~132365599:-
THCA	cis	rs853679	0.527	rs853690	ENSG00000273712.1	RP5-874C20.7	5.52	5.6e-08	9.03e-06	0.28	0.25	Depression;	chr6:28317705	chr6:28315613~28315883:-
THCA	cis	rs13256369	1	rs10098234	ENSG00000253893.2	FAM85B	-5.52	5.6e-08	9.03e-06	-0.33	-0.25	Obesity-related traits;	chr8:8719182	chr8:8167819~8226614:-
THCA	cis	rs9990333	0.562	rs58079878	ENSG00000242086.7	LINC00969	5.52	5.6e-08	9.03e-06	0.25	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195658062~195739964:+
THCA	cis	rs6988985	0.647	rs28459852	ENSG00000247317.3	RP11-273G15.2	-5.52	5.6e-08	9.03e-06	-0.27	-0.25	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905020	chr8:142981738~143018437:-
THCA	cis	rs919433	0.929	rs10931779	ENSG00000231621.1	AC013264.2	5.52	5.6e-08	9.04e-06	0.24	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197302101	chr2:197197991~197199273:+
THCA	cis	rs911119	0.913	rs6048928	ENSG00000270001.1	RP11-218C14.8	-5.52	5.61e-08	9.04e-06	-0.39	-0.25	Chronic kidney disease;	chr20:23605351	chr20:23631826~23632316:-
THCA	cis	rs6585424	1	rs34100029	ENSG00000242600.5	MBL1P	5.52	5.61e-08	9.04e-06	0.29	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163842	chr10:79904898~79950336:+
THCA	cis	rs6545883	0.862	rs11691734	ENSG00000270820.4	RP11-355B11.2	5.52	5.61e-08	9.05e-06	0.21	0.25	Tuberculosis;	chr2:61475331	chr2:61471188~61484130:+
THCA	cis	rs1858037	0.836	rs17475335	ENSG00000234255.7	AC012370.3	5.52	5.61e-08	9.05e-06	0.29	0.25	Rheumatoid arthritis;	chr2:65378646	chr2:65439888~65456571:-
THCA	cis	rs4713118	0.614	rs9468209	ENSG00000219392.1	RP1-265C24.5	-5.52	5.61e-08	9.05e-06	-0.28	-0.25	Parkinson's disease;	chr6:27726642	chr6:28115628~28116551:+
THCA	cis	rs1865760	0.593	rs2097273	ENSG00000272462.2	U91328.19	-5.52	5.61e-08	9.05e-06	-0.2	-0.25	Height;	chr6:25941082	chr6:25992662~26001775:+
THCA	cis	rs6688613	0.694	rs1476347	ENSG00000225171.2	DUTP6	-5.52	5.61e-08	9.05e-06	-0.33	-0.25	Refractive astigmatism;	chr1:166846350	chr1:166868748~166869209:+
THCA	cis	rs7412746	0.658	rs6677420	ENSG00000231073.1	RP11-316M1.3	5.52	5.61e-08	9.05e-06	0.3	0.25	Melanoma;	chr1:150974014	chr1:150973123~150975534:+
THCA	cis	rs9952991	0.882	rs2847274	ENSG00000260302.1	RP11-973H7.1	-5.52	5.62e-08	9.05e-06	-0.4	-0.25	Inflammatory skin disease;	chr18:12777604	chr18:12774651~12775923:-
THCA	cis	rs9952991	0.941	rs2847278	ENSG00000260302.1	RP11-973H7.1	-5.52	5.62e-08	9.05e-06	-0.4	-0.25	Inflammatory skin disease;	chr18:12778716	chr18:12774651~12775923:-
THCA	cis	rs9952991	0.941	rs2542149	ENSG00000260302.1	RP11-973H7.1	-5.52	5.62e-08	9.05e-06	-0.4	-0.25	Inflammatory skin disease;	chr18:12779019	chr18:12774651~12775923:-
THCA	cis	rs9952991	0.941	rs2847280	ENSG00000260302.1	RP11-973H7.1	-5.52	5.62e-08	9.05e-06	-0.4	-0.25	Inflammatory skin disease;	chr18:12779343	chr18:12774651~12775923:-
THCA	cis	rs9952991	0.941	rs2542150	ENSG00000260302.1	RP11-973H7.1	-5.52	5.62e-08	9.05e-06	-0.4	-0.25	Inflammatory skin disease;	chr18:12779764	chr18:12774651~12775923:-
THCA	cis	rs756699	0.722	rs30495	ENSG00000279469.1	RP11-215P8.2	-5.52	5.62e-08	9.06e-06	-0.37	-0.25	Multiple sclerosis;	chr5:134108235	chr5:134394360~134395008:-
THCA	cis	rs1546924	0.57	rs197412	ENSG00000227811.2	FAM212B-AS1	-5.52	5.62e-08	9.06e-06	-0.3	-0.25	Body mass index;	chr1:111766331	chr1:111739841~111747798:+
THCA	cis	rs2029362	0.715	rs11030009	ENSG00000245573.6	BDNF-AS	5.52	5.62e-08	9.06e-06	0.2	0.25	Total body bone mineral density;	chr11:27442017	chr11:27506838~27698174:+
THCA	cis	rs11643654	0.745	rs1965024	ENSG00000260818.2	UNGP1	-5.52	5.62e-08	9.07e-06	-0.23	-0.25	Educational attainment (years of education);	chr16:51139648	chr16:51277852~51279112:+
THCA	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	5.52	5.63e-08	9.07e-06	0.24	0.25	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	5.52	5.63e-08	9.07e-06	0.24	0.25	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
THCA	cis	rs713477	0.692	rs56280202	ENSG00000258413.1	RP11-665C16.6	5.52	5.63e-08	9.07e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55444483	chr14:55262767~55272075:-
THCA	cis	rs6430585	0.528	rs614193	ENSG00000231890.6	DARS-AS1	-5.52	5.63e-08	9.07e-06	-0.28	-0.25	Corneal structure;	chr2:135896355	chr2:135985176~136022593:+
THCA	cis	rs875971	1	rs10244498	ENSG00000223473.2	GS1-124K5.3	5.52	5.63e-08	9.08e-06	0.16	0.25	Aortic root size;	chr7:66651069	chr7:66491049~66493566:-
THCA	cis	rs2120243	0.539	rs2085315	ENSG00000244515.1	KRT18P34	-5.52	5.63e-08	9.08e-06	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157394833	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.508	rs12492874	ENSG00000244515.1	KRT18P34	-5.52	5.63e-08	9.08e-06	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157395438	chr3:157162663~157163932:-
THCA	cis	rs10895275	0.566	rs10895270	ENSG00000277459.1	RP11-732A21.3	-5.52	5.63e-08	9.08e-06	-0.18	-0.25	Migraine;	chr11:102191333	chr11:102109827~102110457:-
THCA	cis	rs6445975	0.666	rs11710823	ENSG00000272360.1	RP11-359I18.5	5.52	5.64e-08	9.09e-06	0.28	0.25	Systemic lupus erythematosus;	chr3:58410766	chr3:58490830~58491291:-
THCA	cis	rs6545883	0.965	rs1992765	ENSG00000270820.4	RP11-355B11.2	5.52	5.64e-08	9.09e-06	0.21	0.25	Tuberculosis;	chr2:61524198	chr2:61471188~61484130:+
THCA	cis	rs13113518	0.678	rs7663650	ENSG00000273257.1	RP11-177J6.1	-5.52	5.64e-08	9.09e-06	-0.33	-0.25	Height;	chr4:55364952	chr4:55387949~55388271:+
THCA	cis	rs7403037	1	rs8024039	ENSG00000259905.4	PWRN1	5.52	5.65e-08	9.1e-06	0.27	0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24581198	chr15:24493137~24652130:+
THCA	cis	rs11603023	0.772	rs540800	ENSG00000278376.1	RP11-158I9.8	-5.52	5.65e-08	9.11e-06	-0.19	-0.25	Cholesterol, total;	chr11:118694942	chr11:118791254~118793137:+
THCA	cis	rs7220401	0.789	rs4794859	ENSG00000263370.1	RP11-68I3.5	-5.52	5.65e-08	9.11e-06	-0.32	-0.25	Coronary artery disease;	chr17:29635375	chr17:29639627~29640825:+
THCA	cis	rs12893668	0.543	rs12147645	ENSG00000269910.1	RP11-73M18.10	5.52	5.66e-08	9.12e-06	0.23	0.25	Reticulocyte count;	chr14:103633871	chr14:103694516~103695050:-
THCA	cis	rs9876781	1	rs9881491	ENSG00000229759.1	MRPS18AP1	5.52	5.66e-08	9.12e-06	0.29	0.25	Longevity;	chr3:48446507	chr3:48256350~48256938:-
THCA	cis	rs9309473	0.519	rs2421586	ENSG00000163016.8	ALMS1P	-5.52	5.66e-08	9.12e-06	-0.32	-0.25	Metabolite levels;	chr2:73672592	chr2:73644919~73685576:+
THCA	cis	rs4748857	0.685	rs72802182	ENSG00000224215.1	RP11-371A19.2	-5.52	5.66e-08	9.13e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr10:23263275	chr10:23343957~23345181:+
THCA	cis	rs4748857	0.685	rs11013358	ENSG00000224215.1	RP11-371A19.2	-5.52	5.66e-08	9.13e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr10:23268339	chr10:23343957~23345181:+
THCA	cis	rs9595908	0.965	rs9595903	ENSG00000212293.1	SNORA16	5.52	5.67e-08	9.13e-06	0.3	0.25	Body mass index;	chr13:32608003	chr13:32420390~32420516:-
THCA	cis	rs6968419	0.674	rs7459355	ENSG00000237870.5	AC073130.1	5.52	5.67e-08	9.14e-06	0.27	0.25	Intraocular pressure;	chr7:116266721	chr7:116275606~116286734:-
THCA	cis	rs10208649	1	rs11886024	ENSG00000233266.1	HMGB1P31	5.52	5.67e-08	9.14e-06	0.56	0.25	Body mass index;	chr2:53917682	chr2:54051334~54051760:+
THCA	cis	rs1552244	1	rs4260416	ENSG00000232901.1	CYCSP10	5.52	5.68e-08	9.15e-06	0.32	0.25	Alzheimer's disease;	chr3:10083599	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs4269070	ENSG00000232901.1	CYCSP10	5.52	5.68e-08	9.15e-06	0.32	0.25	Alzheimer's disease;	chr3:10084399	chr3:10000647~10000940:-
THCA	cis	rs847577	0.748	rs940432	ENSG00000272950.1	RP11-307C18.1	5.52	5.68e-08	9.15e-06	0.3	0.25	Breast cancer;	chr7:98087171	chr7:98322853~98323430:+
THCA	cis	rs847577	0.748	rs940431	ENSG00000272950.1	RP11-307C18.1	5.52	5.68e-08	9.15e-06	0.3	0.25	Breast cancer;	chr7:98087183	chr7:98322853~98323430:+
THCA	cis	rs847577	0.748	rs940430	ENSG00000272950.1	RP11-307C18.1	5.52	5.68e-08	9.15e-06	0.3	0.25	Breast cancer;	chr7:98087228	chr7:98322853~98323430:+
THCA	cis	rs847577	0.748	rs55784506	ENSG00000272950.1	RP11-307C18.1	5.52	5.68e-08	9.15e-06	0.3	0.25	Breast cancer;	chr7:98088889	chr7:98322853~98323430:+
THCA	cis	rs847577	0.748	rs13221897	ENSG00000272950.1	RP11-307C18.1	5.52	5.68e-08	9.15e-06	0.3	0.25	Breast cancer;	chr7:98090387	chr7:98322853~98323430:+
THCA	cis	rs442309	0.551	rs10822056	ENSG00000238280.1	RP11-436D10.3	-5.52	5.68e-08	9.15e-06	-0.29	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62754351	chr10:62793562~62805887:-
THCA	cis	rs7829975	0.714	rs11777085	ENSG00000254153.1	CTA-398F10.2	-5.52	5.68e-08	9.15e-06	-0.26	-0.25	Mood instability;	chr8:8814919	chr8:8456909~8461337:-
THCA	cis	rs72772090	1	rs72772090	ENSG00000248734.2	CTD-2260A17.1	-5.52	5.68e-08	9.15e-06	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96700607	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.908	rs76539796	ENSG00000248734.2	CTD-2260A17.1	-5.52	5.68e-08	9.15e-06	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96702971	chr5:96784777~96785999:+
THCA	cis	rs2439831	0.85	rs7183809	ENSG00000166763.7	STRCP1	5.52	5.68e-08	9.15e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:43828670	chr15:43699488~43718184:-
THCA	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	5.52	5.68e-08	9.15e-06	0.24	0.25	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-5.52	5.68e-08	9.15e-06	-0.24	-0.25	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
THCA	cis	rs1050631	0.564	rs1785925	ENSG00000260552.1	RP11-49I11.1	5.52	5.69e-08	9.16e-06	0.3	0.25	Esophageal squamous cell cancer (length of survival);	chr18:36147223	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.564	rs10153377	ENSG00000260552.1	RP11-49I11.1	5.52	5.69e-08	9.16e-06	0.3	0.25	Esophageal squamous cell cancer (length of survival);	chr18:36148021	chr18:36179996~36187448:-
THCA	cis	rs7412746	0.658	rs57818453	ENSG00000231073.1	RP11-316M1.3	5.52	5.69e-08	9.17e-06	0.3	0.25	Melanoma;	chr1:150790663	chr1:150973123~150975534:+
THCA	cis	rs67981189	0.529	rs2810096	ENSG00000269927.1	RP6-91H8.3	-5.52	5.69e-08	9.17e-06	-0.3	-0.25	Schizophrenia;	chr14:70968583	chr14:71141125~71143253:-
THCA	cis	rs442309	0.846	rs224145	ENSG00000238280.1	RP11-436D10.3	-5.52	5.69e-08	9.17e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62718695	chr10:62793562~62805887:-
THCA	cis	rs593531	0.55	rs592644	ENSG00000255440.1	RP11-632K5.2	5.52	5.7e-08	9.18e-06	0.3	0.25	Neuroticism;	chr11:74342502	chr11:74409060~74416379:+
THCA	cis	rs728616	0.614	rs56147535	ENSG00000225484.5	NUTM2B-AS1	-5.52	5.7e-08	9.18e-06	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80267869	chr10:79663088~79826594:-
THCA	cis	rs6860806	0.661	rs1588263	ENSG00000233006.5	AC034220.3	5.52	5.7e-08	9.18e-06	0.19	0.25	Breast cancer;	chr5:132241465	chr5:132311285~132369916:-
THCA	cis	rs7005380	0.6	rs4871772	ENSG00000245330.4	KB-1471A8.1	5.52	5.7e-08	9.18e-06	0.24	0.25	Interstitial lung disease;	chr8:119895655	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs4871773	ENSG00000245330.4	KB-1471A8.1	5.52	5.7e-08	9.18e-06	0.24	0.25	Interstitial lung disease;	chr8:119895671	chr8:119867419~119874488:-
THCA	cis	rs7394190	0.81	rs7394178	ENSG00000271848.1	RP11-464F9.21	-5.52	5.7e-08	9.18e-06	-0.33	-0.25	Incident atrial fibrillation;	chr10:73661822	chr10:73654039~73674719:+
THCA	cis	rs79040073	0.607	rs10519227	ENSG00000259531.2	RP11-295H24.3	5.52	5.71e-08	9.19e-06	0.31	0.25	Lung cancer in ever smokers;	chr15:49454167	chr15:49365124~49366685:-
THCA	cis	rs2559856	1	rs10778139	ENSG00000274560.1	RP11-285E23.2	-5.52	5.71e-08	9.19e-06	-0.15	-0.25	Blood protein levels;	chr12:101689424	chr12:101696002~101696450:-
THCA	cis	rs758324	0.732	rs2550973	ENSG00000237714.1	P4HA2-AS1	-5.52	5.71e-08	9.2e-06	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132175448	chr5:132184876~132192808:+
THCA	cis	rs763121	0.853	rs138716	ENSG00000273076.1	RP3-508I15.22	5.52	5.71e-08	9.2e-06	0.27	0.25	Menopause (age at onset);	chr22:38750522	chr22:38743495~38743910:+
THCA	cis	rs2562456	0.833	rs62109223	ENSG00000268081.1	RP11-678G14.2	5.52	5.71e-08	9.2e-06	0.42	0.25	Pain;	chr19:21349591	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62109225	ENSG00000268081.1	RP11-678G14.2	5.52	5.71e-08	9.2e-06	0.42	0.25	Pain;	chr19:21353861	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.754	rs62109226	ENSG00000268081.1	RP11-678G14.2	5.52	5.71e-08	9.2e-06	0.42	0.25	Pain;	chr19:21354111	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.754	rs62109227	ENSG00000268081.1	RP11-678G14.2	5.52	5.71e-08	9.2e-06	0.42	0.25	Pain;	chr19:21354128	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.754	rs62109228	ENSG00000268081.1	RP11-678G14.2	5.52	5.71e-08	9.2e-06	0.42	0.25	Pain;	chr19:21354129	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs8102783	ENSG00000268081.1	RP11-678G14.2	5.52	5.71e-08	9.2e-06	0.42	0.25	Pain;	chr19:21355751	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs2061916	ENSG00000268081.1	RP11-678G14.2	5.52	5.71e-08	9.2e-06	0.42	0.25	Pain;	chr19:21358906	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs4359573	ENSG00000268081.1	RP11-678G14.2	5.52	5.71e-08	9.2e-06	0.42	0.25	Pain;	chr19:21359494	chr19:21554640~21569237:-
THCA	cis	rs10208649	1	rs11125517	ENSG00000233266.1	HMGB1P31	5.52	5.72e-08	9.2e-06	0.57	0.25	Body mass index;	chr2:53864611	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs1049894	ENSG00000233266.1	HMGB1P31	5.52	5.72e-08	9.2e-06	0.57	0.25	Body mass index;	chr2:53866819	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs7608085	ENSG00000233266.1	HMGB1P31	5.52	5.72e-08	9.2e-06	0.57	0.25	Body mass index;	chr2:53867147	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.803	rs28699646	ENSG00000233266.1	HMGB1P31	5.52	5.72e-08	9.2e-06	0.57	0.25	Body mass index;	chr2:53868313	chr2:54051334~54051760:+
THCA	cis	rs2880765	0.835	rs7178991	ENSG00000259630.2	CTD-2262B20.1	-5.52	5.72e-08	9.21e-06	-0.27	-0.25	Coronary artery disease;	chr15:85507713	chr15:85415228~85415633:+
THCA	cis	rs2243480	1	rs313813	ENSG00000230295.1	RP11-458F8.2	-5.52	5.72e-08	9.21e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66038513	chr7:66880708~66882981:+
THCA	cis	rs9595908	1	rs9591145	ENSG00000212293.1	SNORA16	5.52	5.72e-08	9.22e-06	0.29	0.25	Body mass index;	chr13:32587322	chr13:32420390~32420516:-
THCA	cis	rs9595908	1	rs3742320	ENSG00000212293.1	SNORA16	5.52	5.72e-08	9.22e-06	0.29	0.25	Body mass index;	chr13:32590281	chr13:32420390~32420516:-
THCA	cis	rs79040073	0.637	rs8027094	ENSG00000259531.2	RP11-295H24.3	5.52	5.72e-08	9.22e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49388639	chr15:49365124~49366685:-
THCA	cis	rs7809950	0.953	rs2253271	ENSG00000238832.1	snoU109	-5.52	5.72e-08	9.22e-06	-0.26	-0.25	Coronary artery disease;	chr7:107560807	chr7:107603363~107603507:+
THCA	cis	rs763121	0.853	rs138709	ENSG00000273076.1	RP3-508I15.22	5.52	5.73e-08	9.22e-06	0.26	0.25	Menopause (age at onset);	chr22:38743211	chr22:38743495~38743910:+
THCA	cis	rs6585424	1	rs35497678	ENSG00000242600.5	MBL1P	5.52	5.73e-08	9.23e-06	0.29	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80161322	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs2304410	ENSG00000242600.5	MBL1P	5.52	5.73e-08	9.23e-06	0.29	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162054	chr10:79904898~79950336:+
THCA	cis	rs6585424	0.778	rs12257082	ENSG00000242600.5	MBL1P	5.52	5.73e-08	9.23e-06	0.29	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162365	chr10:79904898~79950336:+
THCA	cis	rs7833787	0.644	rs11785914	ENSG00000278886.1	RP11-108A14.1	5.52	5.74e-08	9.24e-06	0.32	0.25	Obesity-related traits;	chr8:18840521	chr8:18864681~18865247:-
THCA	cis	rs7829975	0.714	rs4840362	ENSG00000254153.1	CTA-398F10.2	5.52	5.74e-08	9.24e-06	0.26	0.25	Mood instability;	chr8:8812572	chr8:8456909~8461337:-
THCA	cis	rs12681287	0.64	rs13280468	ENSG00000254231.1	CTD-2284J15.1	5.52	5.74e-08	9.24e-06	0.27	0.25	Caudate activity during reward;	chr8:86326223	chr8:86333274~86343314:-
THCA	cis	rs4639966	0.836	rs7124498	ENSG00000255239.1	AP002954.6	-5.52	5.74e-08	9.24e-06	-0.35	-0.25	Systemic lupus erythematosus;	chr11:118745544	chr11:118688039~118690600:-
THCA	cis	rs801193	1	rs2659909	ENSG00000273142.1	RP11-458F8.4	-5.52	5.74e-08	9.24e-06	-0.2	-0.25	Aortic root size;	chr7:66695292	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs437889	ENSG00000230295.1	RP11-458F8.2	-5.52	5.74e-08	9.24e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66044247	chr7:66880708~66882981:+
THCA	cis	rs8177876	0.658	rs889516	ENSG00000261061.1	RP11-303E16.2	5.52	5.75e-08	9.25e-06	0.34	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034943	chr16:81030770~81031485:+
THCA	cis	rs997295	0.57	rs60066681	ENSG00000270964.1	RP11-502I4.3	-5.52	5.75e-08	9.25e-06	-0.21	-0.25	Motion sickness;	chr15:67515738	chr15:67541072~67542604:-
THCA	cis	rs2120243	0.508	rs1456106	ENSG00000244515.1	KRT18P34	-5.52	5.75e-08	9.25e-06	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157405667	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs1456105	ENSG00000244515.1	KRT18P34	-5.52	5.75e-08	9.25e-06	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157405672	chr3:157162663~157163932:-
THCA	cis	rs9990333	0.562	rs55970879	ENSG00000242086.7	LINC00969	5.52	5.75e-08	9.25e-06	0.25	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195658062~195739964:+
THCA	cis	rs9990333	0.562	rs75681503	ENSG00000242086.7	LINC00969	5.52	5.75e-08	9.25e-06	0.25	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195658062~195739964:+
THCA	cis	rs748404	0.666	rs10518812	ENSG00000249839.1	AC011330.5	5.52	5.75e-08	9.25e-06	0.36	0.25	Lung cancer;	chr15:43360739	chr15:43663654~43684339:-
THCA	cis	rs258324	0.79	rs2162944	ENSG00000260259.1	RP11-368I7.4	-5.52	5.75e-08	9.26e-06	-0.35	-0.25	Height;	chr16:89651262	chr16:89682620~89686569:-
THCA	cis	rs4789693	0.746	rs4789775	ENSG00000260011.2	RP13-20L14.1	-5.52	5.75e-08	9.26e-06	-0.25	-0.25	Glucocorticoid-induced osteonecrosis;	chr17:82434029	chr17:82381110~82382690:-
THCA	cis	rs2243480	1	rs427044	ENSG00000230295.1	RP11-458F8.2	-5.52	5.75e-08	9.26e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66043558	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs2420824	ENSG00000273142.1	RP11-458F8.4	5.52	5.76e-08	9.26e-06	0.2	0.25	Aortic root size;	chr7:66666129	chr7:66902857~66906297:+
THCA	cis	rs4698048	0.545	rs6811287	ENSG00000261490.1	RP11-448G15.3	-5.52	5.76e-08	9.26e-06	-0.16	-0.25	Skin aging (microtopography measurement);	chr4:10179199	chr4:10068089~10073019:-
THCA	cis	rs7727544	0.709	rs272852	ENSG00000224431.1	AC063976.7	5.52	5.76e-08	9.26e-06	0.21	0.25	Blood metabolite levels;	chr5:132353074	chr5:132199456~132203487:+
THCA	cis	rs1552244	1	rs3895942	ENSG00000232901.1	CYCSP10	5.52	5.76e-08	9.27e-06	0.33	0.25	Alzheimer's disease;	chr3:10067061	chr3:10000647~10000940:-
THCA	cis	rs12101261	0.744	rs2284720	ENSG00000259167.2	NMNAT1P1	5.52	5.76e-08	9.27e-06	0.36	0.25	Graves' disease;	chr14:80976823	chr14:81032529~81033404:+
THCA	cis	rs7829975	0.511	rs2948286	ENSG00000254153.1	CTA-398F10.2	-5.52	5.77e-08	9.28e-06	-0.26	-0.25	Mood instability;	chr8:8272638	chr8:8456909~8461337:-
THCA	cis	rs1707322	0.827	rs6694302	ENSG00000281133.1	AL355480.3	-5.51	5.77e-08	9.28e-06	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45580892~45580996:-
THCA	cis	rs6545883	0.831	rs9309336	ENSG00000270820.4	RP11-355B11.2	5.51	5.77e-08	9.29e-06	0.21	0.25	Tuberculosis;	chr2:61536030	chr2:61471188~61484130:+
THCA	cis	rs228614	0.502	rs4648004	ENSG00000246560.2	RP11-10L12.4	-5.51	5.77e-08	9.29e-06	-0.34	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102539950	chr4:102828055~102844075:+
THCA	cis	rs442309	0.846	rs224130	ENSG00000238280.1	RP11-436D10.3	-5.51	5.78e-08	9.29e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62705211	chr10:62793562~62805887:-
THCA	cis	rs442309	0.846	rs224131	ENSG00000238280.1	RP11-436D10.3	-5.51	5.78e-08	9.29e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62705334	chr10:62793562~62805887:-
THCA	cis	rs442309	0.846	rs224133	ENSG00000238280.1	RP11-436D10.3	-5.51	5.78e-08	9.29e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62706743	chr10:62793562~62805887:-
THCA	cis	rs442309	0.819	rs224134	ENSG00000238280.1	RP11-436D10.3	-5.51	5.78e-08	9.29e-06	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62706867	chr10:62793562~62805887:-
THCA	cis	rs6445975	0.666	rs4553989	ENSG00000272360.1	RP11-359I18.5	5.51	5.78e-08	9.3e-06	0.28	0.25	Systemic lupus erythematosus;	chr3:58395393	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs3922713	ENSG00000272360.1	RP11-359I18.5	5.51	5.78e-08	9.3e-06	0.28	0.25	Systemic lupus erythematosus;	chr3:58398061	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.617	rs60962024	ENSG00000272360.1	RP11-359I18.5	5.51	5.78e-08	9.3e-06	0.28	0.25	Systemic lupus erythematosus;	chr3:58404485	chr3:58490830~58491291:-
THCA	cis	rs2562456	0.754	rs112195516	ENSG00000268081.1	RP11-678G14.2	5.51	5.78e-08	9.3e-06	0.41	0.25	Pain;	chr19:21410849	chr19:21554640~21569237:-
THCA	cis	rs4950322	0.542	rs115179956	ENSG00000271721.1	RP11-337C18.9	5.51	5.78e-08	9.3e-06	0.26	0.25	Protein quantitative trait loci;	chr1:147172620	chr1:147175602~147177740:+
THCA	cis	rs12188164	0.686	rs11741946	ENSG00000225138.6	CTD-2228K2.7	5.51	5.78e-08	9.3e-06	0.27	0.25	Cystic fibrosis severity;	chr5:421288	chr5:473236~480884:+
THCA	cis	rs8059260	0.541	rs12917947	ENSG00000274038.1	RP11-66H6.4	-5.51	5.78e-08	9.3e-06	-0.47	-0.25	Alcohol consumption over the past year;	chr16:11116386	chr16:11056556~11057034:+
THCA	cis	rs2029362	1	rs11030048	ENSG00000245573.6	BDNF-AS	5.51	5.78e-08	9.3e-06	0.2	0.25	Total body bone mineral density;	chr11:27561402	chr11:27506838~27698174:+
THCA	cis	rs9876781	1	rs3774808	ENSG00000229759.1	MRPS18AP1	5.51	5.79e-08	9.31e-06	0.29	0.25	Longevity;	chr3:48440237	chr3:48256350~48256938:-
THCA	cis	rs7129556	0.701	rs72947668	ENSG00000254691.1	RP11-91P24.5	5.51	5.79e-08	9.31e-06	0.35	0.25	Weight loss (gastric bypass surgery);	chr11:77717888	chr11:77850604~77851511:+
THCA	cis	rs4934494	0.677	rs10881608	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89614892	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs10881610	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89615076	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185792	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89615210	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185793	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89615467	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185794	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89615662	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185795	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89615672	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185796	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89615725	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs12219790	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89615734	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185797	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89616041	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185798	ENSG00000232936.4	RP11-80H5.2	5.51	5.79e-08	9.31e-06	0.34	0.25	Red blood cell count;	chr10:89616211	chr10:89645282~89650667:+
THCA	cis	rs7523875	0.572	rs75671661	ENSG00000153363.11	LINC00467	-5.51	5.79e-08	9.31e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211409031	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs75777203	ENSG00000153363.11	LINC00467	-5.51	5.79e-08	9.31e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211410631	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs75756193	ENSG00000153363.11	LINC00467	-5.51	5.79e-08	9.31e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211420236	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs74809519	ENSG00000153363.11	LINC00467	-5.51	5.79e-08	9.31e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211422690	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.515	rs6699139	ENSG00000153363.11	LINC00467	-5.51	5.79e-08	9.31e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211424741	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs78908484	ENSG00000153363.11	LINC00467	-5.51	5.79e-08	9.31e-06	-0.31	-0.25	Mean corpuscular volume;	chr1:211429262	chr1:211382803~211435333:+
THCA	cis	rs9878978	0.722	rs11708578	ENSG00000237990.3	CNTN4-AS1	5.51	5.79e-08	9.31e-06	0.3	0.25	Blood pressure (smoking interaction);	chr3:2474210	chr3:3039033~3069242:-
THCA	cis	rs9467773	0.587	rs10946812	ENSG00000124549.13	BTN2A3P	-5.51	5.79e-08	9.32e-06	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26344747	chr6:26421391~26432383:+
THCA	cis	rs9878978	0.722	rs59986003	ENSG00000237990.3	CNTN4-AS1	5.51	5.8e-08	9.32e-06	0.27	0.25	Blood pressure (smoking interaction);	chr3:2469195	chr3:3039033~3069242:-
THCA	cis	rs7432375	0.566	rs835636	ENSG00000239213.4	NCK1-AS1	5.51	5.8e-08	9.32e-06	0.22	0.25	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136955658	chr3:136841726~136862054:-
THCA	cis	rs2337406	1	rs17113276	ENSG00000211974.3	IGHV2-70	5.51	5.8e-08	9.33e-06	0.24	0.25	Alzheimer's disease (late onset);	chr14:106683485	chr14:106723574~106724093:-
THCA	cis	rs1552244	0.554	rs9878047	ENSG00000180385.7	EMC3-AS1	5.51	5.8e-08	9.33e-06	0.24	0.25	Alzheimer's disease;	chr3:9943773	chr3:9986893~10006990:+
THCA	cis	rs2115536	1	rs2903105	ENSG00000278600.1	RP11-81A1.6	-5.51	5.8e-08	9.33e-06	-0.15	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897181	chr15:79920195~79922455:-
THCA	cis	rs2115536	0.967	rs3826008	ENSG00000278600.1	RP11-81A1.6	-5.51	5.8e-08	9.33e-06	-0.15	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897463	chr15:79920195~79922455:-
THCA	cis	rs2115536	1	rs2115540	ENSG00000278600.1	RP11-81A1.6	-5.51	5.8e-08	9.33e-06	-0.15	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897966	chr15:79920195~79922455:-
THCA	cis	rs1858037	0.867	rs72621551	ENSG00000234255.7	AC012370.3	5.51	5.8e-08	9.33e-06	0.29	0.25	Rheumatoid arthritis;	chr2:65388087	chr2:65439888~65456571:-
THCA	cis	rs2915864	1	rs2906070	ENSG00000280047.1	CTC-463A16.1	-5.51	5.8e-08	9.33e-06	-0.39	-0.25	Facial morphology (factor 20);	chr5:142200032	chr5:142165767~142168387:+
THCA	cis	rs2915864	1	rs2906068	ENSG00000280047.1	CTC-463A16.1	-5.51	5.8e-08	9.33e-06	-0.39	-0.25	Facial morphology (factor 20);	chr5:142200216	chr5:142165767~142168387:+
THCA	cis	rs2915864	0.861	rs2961719	ENSG00000280047.1	CTC-463A16.1	-5.51	5.8e-08	9.33e-06	-0.39	-0.25	Facial morphology (factor 20);	chr5:142200455	chr5:142165767~142168387:+
THCA	cis	rs2915864	1	rs2906067	ENSG00000280047.1	CTC-463A16.1	-5.51	5.8e-08	9.33e-06	-0.39	-0.25	Facial morphology (factor 20);	chr5:142200557	chr5:142165767~142168387:+
THCA	cis	rs2915864	1	rs2961720	ENSG00000280047.1	CTC-463A16.1	-5.51	5.8e-08	9.33e-06	-0.39	-0.25	Facial morphology (factor 20);	chr5:142200665	chr5:142165767~142168387:+
THCA	cis	rs2915864	1	rs2906066	ENSG00000280047.1	CTC-463A16.1	-5.51	5.8e-08	9.33e-06	-0.39	-0.25	Facial morphology (factor 20);	chr5:142200712	chr5:142165767~142168387:+
THCA	cis	rs801193	0.636	rs2659895	ENSG00000223473.2	GS1-124K5.3	5.51	5.8e-08	9.33e-06	0.16	0.25	Aortic root size;	chr7:66731484	chr7:66491049~66493566:-
THCA	cis	rs12030196	0.788	rs2764928	ENSG00000230812.4	LINC01358	-5.51	5.8e-08	9.33e-06	-0.29	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58957117	chr1:59020387~59044614:+
THCA	cis	rs12893668	0.572	rs1606	ENSG00000269940.1	RP11-73M18.7	5.51	5.81e-08	9.34e-06	0.26	0.25	Reticulocyte count;	chr14:103694944	chr14:103694560~103695170:+
THCA	cis	rs2735413	0.599	rs77209133	ENSG00000276007.1	RP11-358L22.3	5.51	5.81e-08	9.34e-06	0.27	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78042827	chr16:78123243~78124332:+
THCA	cis	rs2735413	0.599	rs79414963	ENSG00000276007.1	RP11-358L22.3	5.51	5.81e-08	9.34e-06	0.27	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78043132	chr16:78123243~78124332:+
THCA	cis	rs34779708	0.832	rs12764283	ENSG00000271335.4	RP11-324I22.4	5.51	5.81e-08	9.34e-06	0.24	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35241532	chr10:35314552~35336401:-
THCA	cis	rs7005380	0.62	rs4871012	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119895734	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs4871013	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119895750	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.579	rs7465181	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119896349	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs7462250	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119896367	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs13281299	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119897253	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs7832923	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119897540	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6469861	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119897673	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6469862	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119897796	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6469863	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119897910	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6469864	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119897985	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6469865	ENSG00000245330.4	KB-1471A8.1	5.51	5.81e-08	9.34e-06	0.24	0.25	Interstitial lung disease;	chr8:119897995	chr8:119867419~119874488:-
THCA	cis	rs1707322	0.826	rs10890349	ENSG00000281133.1	AL355480.3	-5.51	5.82e-08	9.35e-06	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.758	rs10789474	ENSG00000281133.1	AL355480.3	-5.51	5.82e-08	9.35e-06	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45580892~45580996:-
THCA	cis	rs8025790	0.508	rs4776943	ENSG00000270964.1	RP11-502I4.3	-5.51	5.82e-08	9.36e-06	-0.21	-0.25	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67543731	chr15:67541072~67542604:-
THCA	cis	rs7246657	0.722	rs2909098	ENSG00000276846.1	CTD-3220F14.3	-5.51	5.82e-08	9.36e-06	-0.25	-0.25	Coronary artery calcification;	chr19:37713347	chr19:37314868~37315620:-
THCA	cis	rs2281603	0.951	rs12385918	ENSG00000272909.1	CTD-2555O16.4	-5.51	5.82e-08	9.36e-06	-0.33	-0.25	Lymphocyte counts;	chr14:64533227	chr14:64440369~64442238:-
THCA	cis	rs7927592	0.513	rs689075	ENSG00000212093.1	AP000807.1	5.51	5.82e-08	9.36e-06	0.26	0.25	Total body bone mineral density;	chr11:68426964	chr11:68506083~68506166:-
THCA	cis	rs883924	1	rs883923	ENSG00000231107.1	LINC01508	5.51	5.82e-08	9.36e-06	0.25	0.25	Hepatitis C induced liver fibrosis;	chr9:90419217	chr9:90300902~90433505:-
THCA	cis	rs883924	1	rs883924	ENSG00000231107.1	LINC01508	5.51	5.82e-08	9.36e-06	0.25	0.25	Hepatitis C induced liver fibrosis;	chr9:90419249	chr9:90300902~90433505:-
THCA	cis	rs6792584	0.889	rs9851569	ENSG00000241316.5	SUCLG2-AS1	5.51	5.83e-08	9.36e-06	0.25	0.25	Corneal astigmatism;	chr3:67468457	chr3:67654697~67947713:+
THCA	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	5.51	5.83e-08	9.37e-06	0.31	0.25	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
THCA	cis	rs4660456	0.529	rs61779237	ENSG00000272145.1	NFYC-AS1	-5.51	5.83e-08	9.37e-06	-0.16	-0.25	Platelet count;	chr1:40685300	chr1:40690380~40692066:-
THCA	cis	rs1880529	0.864	rs13111762	ENSG00000206820.1	RNU1-138P	-5.51	5.83e-08	9.37e-06	-0.28	-0.25	White matter integrity (bipolar disorder risk interaction);	chr4:113447474	chr4:113420323~113420486:+
THCA	cis	rs4789693	0.808	rs12935995	ENSG00000260011.2	RP13-20L14.1	-5.51	5.83e-08	9.37e-06	-0.26	-0.25	Glucocorticoid-induced osteonecrosis;	chr17:82437007	chr17:82381110~82382690:-
THCA	cis	rs1552244	0.872	rs115331527	ENSG00000232901.1	CYCSP10	5.51	5.83e-08	9.38e-06	0.33	0.25	Alzheimer's disease;	chr3:10112820	chr3:10000647~10000940:-
THCA	cis	rs2337406	1	rs1961901	ENSG00000211974.3	IGHV2-70	-5.51	5.83e-08	9.38e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106680856	chr14:106723574~106724093:-
THCA	cis	rs2337406	1	rs4774172	ENSG00000211974.3	IGHV2-70	-5.51	5.83e-08	9.38e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106681320	chr14:106723574~106724093:-
THCA	cis	rs2337406	1	rs4774173	ENSG00000211974.3	IGHV2-70	-5.51	5.83e-08	9.38e-06	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106682029	chr14:106723574~106724093:-
THCA	cis	rs59868192	0.925	rs2598469	ENSG00000246740.2	PLA2G4E-AS1	5.51	5.83e-08	9.38e-06	0.44	0.25	White blood cell count;	chr15:41964391	chr15:41972763~41999094:+
THCA	cis	rs10895275	0.7	rs7933592	ENSG00000277459.1	RP11-732A21.3	-5.51	5.84e-08	9.38e-06	-0.18	-0.25	Migraine;	chr11:102172203	chr11:102109827~102110457:-
THCA	cis	rs9813712	0.78	rs55929137	ENSG00000228252.7	COL6A4P2	5.51	5.84e-08	9.38e-06	0.28	0.25	Response to amphetamines;	chr3:130236002	chr3:130212823~130273806:+
THCA	cis	rs1865760	0.566	rs9379825	ENSG00000272462.2	U91328.19	-5.51	5.84e-08	9.39e-06	-0.2	-0.25	Height;	chr6:26083643	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.566	rs9467672	ENSG00000272462.2	U91328.19	-5.51	5.84e-08	9.39e-06	-0.2	-0.25	Height;	chr6:26083676	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.566	rs9295688	ENSG00000272462.2	U91328.19	-5.51	5.84e-08	9.39e-06	-0.2	-0.25	Height;	chr6:26083989	chr6:25992662~26001775:+
THCA	cis	rs853679	0.527	rs1997660	ENSG00000273712.1	RP5-874C20.7	5.51	5.85e-08	9.4e-06	0.28	0.25	Depression;	chr6:28301886	chr6:28315613~28315883:-
THCA	cis	rs758324	0.687	rs473753	ENSG00000237714.1	P4HA2-AS1	-5.51	5.85e-08	9.4e-06	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132165441	chr5:132184876~132192808:+
THCA	cis	rs758324	0.68	rs156043	ENSG00000237714.1	P4HA2-AS1	-5.51	5.85e-08	9.4e-06	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132156157	chr5:132184876~132192808:+
THCA	cis	rs412050	0.696	rs113366054	ENSG00000224086.5	LL22NC03-86G7.1	-5.51	5.85e-08	9.41e-06	-0.42	-0.25	Attention deficit hyperactivity disorder;	chr22:21912844	chr22:21938293~21977632:+
THCA	cis	rs253959	0.502	rs10478275	ENSG00000272265.1	CTD-2287O16.4	5.51	5.86e-08	9.41e-06	0.29	0.25	Bipolar disorder and schizophrenia;	chr5:116092399	chr5:116078110~116078570:-
THCA	cis	rs253959	0.545	rs10072417	ENSG00000272265.1	CTD-2287O16.4	5.51	5.86e-08	9.41e-06	0.29	0.25	Bipolar disorder and schizophrenia;	chr5:116097906	chr5:116078110~116078570:-
THCA	cis	rs253959	0.576	rs1588268	ENSG00000272265.1	CTD-2287O16.4	5.51	5.86e-08	9.41e-06	0.29	0.25	Bipolar disorder and schizophrenia;	chr5:116101091	chr5:116078110~116078570:-
THCA	cis	rs253959	0.545	rs2416425	ENSG00000272265.1	CTD-2287O16.4	5.51	5.86e-08	9.41e-06	0.29	0.25	Bipolar disorder and schizophrenia;	chr5:116101727	chr5:116078110~116078570:-
THCA	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	5.51	5.86e-08	9.41e-06	0.28	0.25	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
THCA	cis	rs7394190	0.748	rs60632610	ENSG00000271816.1	BMS1P4	-5.51	5.86e-08	9.41e-06	-0.29	-0.25	Incident atrial fibrillation;	chr10:73655919	chr10:73699151~73730487:-
THCA	cis	rs73198271	0.74	rs1039910	ENSG00000253893.2	FAM85B	5.51	5.86e-08	9.41e-06	0.36	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8167819~8226614:-
THCA	cis	rs4748857	0.947	rs4748851	ENSG00000224215.1	RP11-371A19.2	-5.51	5.86e-08	9.41e-06	-0.28	-0.25	Systemic lupus erythematosus;	chr10:23276409	chr10:23343957~23345181:+
THCA	cis	rs4748857	0.891	rs4747456	ENSG00000224215.1	RP11-371A19.2	-5.51	5.86e-08	9.41e-06	-0.28	-0.25	Systemic lupus erythematosus;	chr10:23282207	chr10:23343957~23345181:+
THCA	cis	rs57221529	0.825	rs72703051	ENSG00000225138.6	CTD-2228K2.7	5.51	5.86e-08	9.41e-06	0.33	0.25	Lung disease severity in cystic fibrosis;	chr5:582882	chr5:473236~480884:+
THCA	cis	rs9926296	0.585	rs4785595	ENSG00000260259.1	RP11-368I7.4	5.51	5.86e-08	9.42e-06	0.26	0.25	Vitiligo;	chr16:89769113	chr16:89682620~89686569:-
THCA	cis	rs2337406	0.778	rs58113768	ENSG00000211974.3	IGHV2-70	-5.51	5.86e-08	9.42e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106700213	chr14:106723574~106724093:-
THCA	cis	rs2337406	1	rs75651733	ENSG00000211974.3	IGHV2-70	-5.51	5.86e-08	9.42e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106701309	chr14:106723574~106724093:-
THCA	cis	rs6957923	0.609	rs2390791	ENSG00000234286.1	AC006026.13	-5.51	5.86e-08	9.42e-06	-0.31	-0.25	Height;	chr7:23539883	chr7:23680195~23680786:-
THCA	cis	rs9816784	0.576	rs12631246	ENSG00000242086.7	LINC00969	5.51	5.87e-08	9.43e-06	0.25	0.25	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195658062~195739964:+
THCA	cis	rs7474896	0.616	rs2474561	ENSG00000120555.12	SEPT7P9	5.51	5.87e-08	9.43e-06	0.33	0.25	Obesity (extreme);	chr10:38084616	chr10:38383069~38402916:-
THCA	cis	rs7209700	0.638	rs4629025	ENSG00000228782.6	CTD-2026D20.3	-5.51	5.87e-08	9.43e-06	-0.24	-0.25	IgG glycosylation;	chr17:47260069	chr17:47450568~47492492:-
THCA	cis	rs10208649	1	rs6545372	ENSG00000233266.1	HMGB1P31	5.51	5.87e-08	9.44e-06	0.57	0.25	Body mass index;	chr2:53855124	chr2:54051334~54051760:+
THCA	cis	rs964184	0.564	rs3825041	ENSG00000254851.1	RP11-109L13.1	-5.51	5.87e-08	9.44e-06	-0.51	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116760991	chr11:117135528~117138582:+
THCA	cis	rs847577	0.722	rs6951277	ENSG00000272950.1	RP11-307C18.1	5.51	5.88e-08	9.44e-06	0.3	0.25	Breast cancer;	chr7:98082471	chr7:98322853~98323430:+
THCA	cis	rs847577	0.722	rs7790736	ENSG00000272950.1	RP11-307C18.1	5.51	5.88e-08	9.44e-06	0.3	0.25	Breast cancer;	chr7:98083727	chr7:98322853~98323430:+
THCA	cis	rs7824557	0.767	rs6991606	ENSG00000154316.13	TDH	-5.51	5.88e-08	9.44e-06	-0.18	-0.25	Retinal vascular caliber;	chr8:11318650	chr8:11339637~11368452:+
THCA	cis	rs7617773	0.823	rs9839446	ENSG00000199476.1	Y_RNA	5.51	5.88e-08	9.44e-06	0.31	0.25	Coronary artery disease;	chr3:48153176	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.823	rs9839447	ENSG00000199476.1	Y_RNA	5.51	5.88e-08	9.44e-06	0.31	0.25	Coronary artery disease;	chr3:48153177	chr3:48288587~48288694:+
THCA	cis	rs10129255	0.879	rs7160512	ENSG00000211974.3	IGHV2-70	5.51	5.88e-08	9.45e-06	0.19	0.25	Kawasaki disease;	chr14:106694574	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.879	rs7159157	ENSG00000211974.3	IGHV2-70	5.51	5.88e-08	9.45e-06	0.19	0.25	Kawasaki disease;	chr14:106694578	chr14:106723574~106724093:-
THCA	cis	rs8027521	0.811	rs2061747	ENSG00000280362.1	RP11-643A5.3	-5.51	5.88e-08	9.45e-06	-0.3	-0.25	Circulating chemerin levels;	chr15:53982217	chr15:53910769~53914712:+
THCA	cis	rs17772222	1	rs17772222	ENSG00000222990.1	RNU4-22P	-5.51	5.88e-08	9.45e-06	-0.33	-0.25	Coronary artery calcification;	chr14:88360138	chr14:88513498~88513663:+
THCA	cis	rs853679	0.546	rs200490	ENSG00000226314.6	ZNF192P1	-5.51	5.88e-08	9.45e-06	-0.41	-0.25	Depression;	chr6:27829157	chr6:28161781~28169594:+
THCA	cis	rs5751614	0.537	rs9608100	ENSG00000230701.2	FBXW4P1	5.51	5.88e-08	9.45e-06	0.27	0.25	Height;	chr22:23290070	chr22:23262767~23265005:+
THCA	cis	rs1876905	0.539	rs240980	ENSG00000271789.1	RP5-1112D6.7	5.51	5.89e-08	9.45e-06	0.33	0.25	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111297126~111298510:+
THCA	cis	rs1546924	0.57	rs197413	ENSG00000227811.2	FAM212B-AS1	-5.51	5.89e-08	9.46e-06	-0.3	-0.25	Body mass index;	chr1:111766350	chr1:111739841~111747798:+
THCA	cis	rs4888671	0.803	rs59848833	ENSG00000261707.1	RP11-264M12.2	5.51	5.89e-08	9.46e-06	0.46	0.25	Obesity-related traits;	chr16:77752198	chr16:77741468~77743000:-
THCA	cis	rs10888838	1	rs10888838	ENSG00000198711.5	SSBP3-AS1	5.51	5.89e-08	9.46e-06	0.28	0.25	Mitochondrial DNA levels;	chr1:54207424	chr1:54236440~54239063:+
THCA	cis	rs2120243	0.534	rs35004310	ENSG00000244515.1	KRT18P34	-5.51	5.89e-08	9.46e-06	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157396011	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs12638732	ENSG00000244515.1	KRT18P34	-5.51	5.89e-08	9.46e-06	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157396082	chr3:157162663~157163932:-
THCA	cis	rs62158211	0.565	rs57611236	ENSG00000272563.1	RP11-480C16.1	-5.51	5.89e-08	9.47e-06	-0.29	-0.25	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113346227	chr2:113432600~113436042:+
THCA	cis	rs4908768	0.501	rs1463051	ENSG00000232912.4	RP5-1115A15.1	-5.51	5.9e-08	9.47e-06	-0.24	-0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8424645~8434838:+
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000232559.3	GS1-124K5.12	5.51	5.9e-08	9.47e-06	0.38	0.25	Diabetic kidney disease;	chr7:66521515	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs13237037	ENSG00000232559.3	GS1-124K5.12	5.51	5.9e-08	9.47e-06	0.38	0.25	Diabetic kidney disease;	chr7:66532895	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1796228	ENSG00000232559.3	GS1-124K5.12	5.51	5.9e-08	9.47e-06	0.38	0.25	Diabetic kidney disease;	chr7:66568097	chr7:66554588~66576923:-
THCA	cis	rs2029362	1	rs10430936	ENSG00000245573.6	BDNF-AS	5.51	5.9e-08	9.47e-06	0.2	0.25	Total body bone mineral density;	chr11:27594265	chr11:27506838~27698174:+
THCA	cis	rs8062405	1	rs55991577	ENSG00000278665.1	RP11-666O2.4	5.51	5.9e-08	9.47e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs56358680	ENSG00000278665.1	RP11-666O2.4	5.51	5.9e-08	9.47e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62036626	ENSG00000278665.1	RP11-666O2.4	5.51	5.9e-08	9.47e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62036657	ENSG00000278665.1	RP11-666O2.4	5.51	5.9e-08	9.47e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs12444171	ENSG00000278665.1	RP11-666O2.4	5.51	5.9e-08	9.47e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs56404918	ENSG00000278665.1	RP11-666O2.4	5.51	5.9e-08	9.47e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs55719896	ENSG00000278665.1	RP11-666O2.4	5.51	5.9e-08	9.47e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs55830740	ENSG00000278665.1	RP11-666O2.4	5.51	5.9e-08	9.47e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28599241~28601881:-
THCA	cis	rs1552244	1	rs6789156	ENSG00000180385.7	EMC3-AS1	5.51	5.9e-08	9.47e-06	0.26	0.25	Alzheimer's disease;	chr3:10082436	chr3:9986893~10006990:+
THCA	cis	rs79040073	0.637	rs78050772	ENSG00000259531.2	RP11-295H24.3	5.51	5.9e-08	9.48e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49286380	chr15:49365124~49366685:-
THCA	cis	rs1185460	0.967	rs1168568	ENSG00000272186.1	RP11-110I1.13	-5.51	5.9e-08	9.48e-06	-0.23	-0.25	Coronary artery disease;	chr11:119079089	chr11:119067374~119067698:-
THCA	cis	rs763567	0.869	rs629234	ENSG00000271811.1	RP1-79C4.4	5.51	5.9e-08	9.48e-06	0.28	0.25	Tonsillectomy;	chr1:170662622	chr1:170667381~170669425:+
THCA	cis	rs10808739	0.614	rs13264230	ENSG00000254006.4	RP11-1D12.2	-5.51	5.9e-08	9.48e-06	-0.38	-0.25	HIV-1 susceptibility;	chr8:64750724	chr8:64801236~64817573:-
THCA	cis	rs17772222	0.715	rs10139921	ENSG00000222990.1	RNU4-22P	5.51	5.91e-08	9.48e-06	0.35	0.25	Coronary artery calcification;	chr14:88468512	chr14:88513498~88513663:+
THCA	cis	rs7809950	1	rs2237676	ENSG00000238832.1	snoU109	-5.51	5.91e-08	9.49e-06	-0.26	-0.25	Coronary artery disease;	chr7:107557634	chr7:107603363~107603507:+
THCA	cis	rs2029362	0.811	rs3209593	ENSG00000245573.6	BDNF-AS	5.51	5.91e-08	9.49e-06	0.19	0.25	Total body bone mineral density;	chr11:27495170	chr11:27506838~27698174:+
THCA	cis	rs847577	0.722	rs1013886	ENSG00000272950.1	RP11-307C18.1	-5.51	5.91e-08	9.49e-06	-0.3	-0.25	Breast cancer;	chr7:98080549	chr7:98322853~98323430:+
THCA	cis	rs375066	0.623	rs10415344	ENSG00000267058.1	RP11-15A1.3	5.51	5.91e-08	9.5e-06	0.22	0.25	Breast cancer;	chr19:43846566	chr19:43891804~43901805:-
THCA	cis	rs11051970	0.655	rs10771942	ENSG00000274964.1	RP11-817I4.1	-5.51	5.91e-08	9.5e-06	-0.26	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32375554	chr12:32339368~32340724:+
THCA	cis	rs4604234	0.803	rs73463522	ENSG00000272129.1	RP11-250B2.6	-5.51	5.92e-08	9.51e-06	-0.6	-0.25	Cancer;	chr6:80270041	chr6:80355424~80356859:+
THCA	cis	rs7772486	0.712	rs1292335	ENSG00000270638.1	RP3-466P17.1	5.51	5.93e-08	9.51e-06	0.2	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145735570~145737218:+
THCA	cis	rs7829975	0.511	rs1401390	ENSG00000254153.1	CTA-398F10.2	-5.51	5.93e-08	9.51e-06	-0.26	-0.25	Mood instability;	chr8:8278888	chr8:8456909~8461337:-
THCA	cis	rs16867253	0.557	rs4669517	ENSG00000188525.3	AC010969.1	-5.51	5.93e-08	9.52e-06	-0.44	-0.25	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr2:10006835	chr2:10003158~10006030:-
THCA	cis	rs79040073	0.637	rs12913966	ENSG00000259531.2	RP11-295H24.3	5.51	5.93e-08	9.52e-06	0.36	0.25	Lung cancer in ever smokers;	chr15:49214290	chr15:49365124~49366685:-
THCA	cis	rs7085104	0.7	rs6163	ENSG00000213061.2	PFN1P11	5.51	5.93e-08	9.52e-06	0.3	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102838011~102845473:-
THCA	cis	rs7085104	0.7	rs743572	ENSG00000213061.2	PFN1P11	5.51	5.93e-08	9.52e-06	0.3	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102838011~102845473:-
THCA	cis	rs7727544	0.584	rs7714191	ENSG00000233006.5	AC034220.3	5.51	5.93e-08	9.52e-06	0.2	0.25	Blood metabolite levels;	chr5:132005848	chr5:132311285~132369916:-
THCA	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	5.51	5.94e-08	9.53e-06	0.28	0.25	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
THCA	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	5.51	5.94e-08	9.53e-06	0.28	0.25	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
THCA	cis	rs6430585	0.528	rs309122	ENSG00000231890.6	DARS-AS1	-5.51	5.94e-08	9.53e-06	-0.28	-0.25	Corneal structure;	chr2:136004283	chr2:135985176~136022593:+
THCA	cis	rs2562456	0.833	rs4429400	ENSG00000268081.1	RP11-678G14.2	5.51	5.94e-08	9.53e-06	0.42	0.25	Pain;	chr19:21338163	chr19:21554640~21569237:-
THCA	cis	rs11089937	0.597	rs4821774	ENSG00000211638.2	IGLV8-61	-5.51	5.94e-08	9.54e-06	-0.19	-0.25	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22098700~22099212:+
THCA	cis	rs713477	0.654	rs12886848	ENSG00000258413.1	RP11-665C16.6	5.51	5.95e-08	9.54e-06	0.34	0.25	Pediatric bone mineral content (femoral neck);	chr14:55444420	chr14:55262767~55272075:-
THCA	cis	rs867371	0.929	rs7173852	ENSG00000259429.4	UBE2Q2P2	-5.51	5.95e-08	9.54e-06	-0.2	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82355142~82420075:+
THCA	cis	rs11089937	0.626	rs737840	ENSG00000211639.2	IGLV4-60	5.51	5.95e-08	9.54e-06	0.19	0.25	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.626	rs737841	ENSG00000211639.2	IGLV4-60	5.51	5.95e-08	9.54e-06	0.19	0.25	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22162199~22162681:+
THCA	cis	rs5015933	0.966	rs1965342	ENSG00000232630.1	PRPS1P2	-5.51	5.95e-08	9.55e-06	-0.17	-0.25	Body mass index;	chr9:125371382	chr9:125150653~125151589:+
THCA	cis	rs7829975	0.511	rs2955578	ENSG00000253981.4	ALG1L13P	5.51	5.95e-08	9.56e-06	0.23	0.25	Mood instability;	chr8:8279561	chr8:8236003~8244667:-
THCA	cis	rs62432291	0.867	rs294907	ENSG00000235086.1	FNDC1-IT1	-5.51	5.96e-08	9.56e-06	-0.62	-0.25	Joint mobility (Beighton score);	chr6:159249244	chr6:159240786~159243329:+
THCA	cis	rs10208649	0.831	rs6724214	ENSG00000233266.1	HMGB1P31	5.51	5.96e-08	9.56e-06	0.44	0.25	Body mass index;	chr2:53807744	chr2:54051334~54051760:+
THCA	cis	rs9307551	0.948	rs11098779	ENSG00000250334.4	LINC00989	-5.51	5.96e-08	9.56e-06	-0.32	-0.25	Refractive error;	chr4:79619060	chr4:79492416~79576460:+
THCA	cis	rs67478160	0.609	rs1547604	ENSG00000258735.1	LINC00637	-5.51	5.97e-08	9.58e-06	-0.3	-0.25	Schizophrenia;	chr14:103804322	chr14:103847721~103858049:+
THCA	cis	rs4767841	1	rs4767839	ENSG00000248636.5	RP11-768F21.1	-5.51	5.97e-08	9.58e-06	-0.26	-0.25	Urgency urinary incontinence;	chr12:119722317	chr12:119387987~119668079:-
THCA	cis	rs651907	0.557	rs2303474	ENSG00000244119.1	PDCL3P4	5.51	5.97e-08	9.58e-06	0.23	0.25	Colorectal cancer;	chr3:101653055	chr3:101712472~101713191:+
THCA	cis	rs13256369	1	rs13256369	ENSG00000253893.2	FAM85B	-5.51	5.97e-08	9.58e-06	-0.33	-0.25	Obesity-related traits;	chr8:8719869	chr8:8167819~8226614:-
THCA	cis	rs853679	0.55	rs1233701	ENSG00000261839.1	RP1-265C24.8	-5.51	5.98e-08	9.59e-06	-0.29	-0.25	Depression;	chr6:28200948	chr6:28136849~28139678:+
THCA	cis	rs12612619	0.732	rs3754734	ENSG00000229122.1	AGBL5-IT1	5.51	5.98e-08	9.59e-06	0.18	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27076730	chr2:27061038~27061815:+
THCA	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-5.51	5.98e-08	9.6e-06	-0.26	-0.25	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
THCA	cis	rs4748857	0.685	rs11013359	ENSG00000224215.1	RP11-371A19.2	-5.51	5.98e-08	9.6e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr10:23268782	chr10:23343957~23345181:+
THCA	cis	rs1075232	1	rs4450360	ENSG00000215302.7	CTD-3092A11.1	-5.51	5.98e-08	9.6e-06	-0.57	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30470779~30507623:+
THCA	cis	rs1075232	1	rs72722847	ENSG00000215302.7	CTD-3092A11.1	-5.51	5.98e-08	9.6e-06	-0.57	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30470779~30507623:+
THCA	cis	rs7727544	0.661	rs273900	ENSG00000224431.1	AC063976.7	5.51	5.99e-08	9.6e-06	0.21	0.25	Blood metabolite levels;	chr5:132358913	chr5:132199456~132203487:+
THCA	cis	rs73198271	0.74	rs1039911	ENSG00000253893.2	FAM85B	5.51	5.99e-08	9.6e-06	0.35	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8167819~8226614:-
THCA	cis	rs62432291	0.681	rs420054	ENSG00000235086.1	FNDC1-IT1	-5.51	5.99e-08	9.61e-06	-0.44	-0.25	Joint mobility (Beighton score);	chr6:159234052	chr6:159240786~159243329:+
THCA	cis	rs2029362	1	rs10767652	ENSG00000245573.6	BDNF-AS	5.51	6e-08	9.62e-06	0.2	0.25	Total body bone mineral density;	chr11:27607279	chr11:27506838~27698174:+
THCA	cis	rs7493	0.901	rs17879517	ENSG00000233942.1	AC004012.1	5.51	6e-08	9.63e-06	0.37	0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95401334	chr7:95471835~95473998:+
THCA	cis	rs6921919	0.609	rs9461455	ENSG00000219392.1	RP1-265C24.5	-5.51	6e-08	9.63e-06	-0.28	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28115628~28116551:+
THCA	cis	rs202072	0.72	rs1550526	ENSG00000272379.1	RP1-257A7.5	5.51	6.01e-08	9.63e-06	0.43	0.25	HIV-1 viral setpoint;	chr6:13295283	chr6:13290018~13290490:-
THCA	cis	rs853679	0.607	rs201002	ENSG00000226314.6	ZNF192P1	-5.51	6.01e-08	9.63e-06	-0.41	-0.25	Depression;	chr6:27840414	chr6:28161781~28169594:+
THCA	cis	rs17345786	0.906	rs11710016	ENSG00000256628.3	ZBTB11-AS1	-5.51	6.01e-08	9.63e-06	-0.32	-0.25	Colonoscopy-negative controls vs population controls;	chr3:101401186	chr3:101676475~101679217:+
THCA	cis	rs2732480	0.967	rs2732469	ENSG00000240399.1	RP1-228P16.1	5.51	6.01e-08	9.63e-06	0.24	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48054813~48055591:-
THCA	cis	rs28476539	0.567	rs17005974	ENSG00000270480.1	RP11-57B24.1	-5.51	6.01e-08	9.64e-06	-0.4	-0.25	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82647908	chr4:82691737~82692468:+
THCA	cis	rs9330264	0.508	rs7364869	ENSG00000160766.13	GBAP1	-5.51	6.01e-08	9.64e-06	-0.27	-0.25	1,5-anhydroglucitol levels;	chr1:155114712	chr1:155213821~155227422:-
THCA	cis	rs7824557	0.767	rs3808513	ENSG00000154316.13	TDH	5.51	6.01e-08	9.64e-06	0.18	0.25	Retinal vascular caliber;	chr8:11299951	chr8:11339637~11368452:+
THCA	cis	rs911119	0.955	rs59059917	ENSG00000270001.1	RP11-218C14.8	-5.51	6.01e-08	9.64e-06	-0.38	-0.25	Chronic kidney disease;	chr20:23615038	chr20:23631826~23632316:-
THCA	cis	rs2029362	0.846	rs11030032	ENSG00000245573.6	BDNF-AS	5.51	6.01e-08	9.64e-06	0.19	0.25	Total body bone mineral density;	chr11:27493120	chr11:27506838~27698174:+
THCA	cis	rs67478160	0.608	rs11628787	ENSG00000258735.1	LINC00637	5.51	6.01e-08	9.64e-06	0.3	0.25	Schizophrenia;	chr14:103857647	chr14:103847721~103858049:+
THCA	cis	rs867371	0.656	rs2665103	ENSG00000255769.6	GOLGA2P10	5.51	6.02e-08	9.64e-06	0.27	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472993~82513950:-
THCA	cis	rs9876781	1	rs6784322	ENSG00000229759.1	MRPS18AP1	5.51	6.02e-08	9.64e-06	0.29	0.25	Longevity;	chr3:48380745	chr3:48256350~48256938:-
THCA	cis	rs758324	0.687	rs156057	ENSG00000237714.1	P4HA2-AS1	-5.51	6.02e-08	9.64e-06	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132142341	chr5:132184876~132192808:+
THCA	cis	rs72315235	1	rs72315235	ENSG00000245556.2	SCAMP1-AS1	-5.51	6.02e-08	9.65e-06	-0.19	-0.25	Plateletcrit;Platelet distribution width;Platelet count;	chr5:78489902	chr5:78342365~78360507:-
THCA	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-5.51	6.02e-08	9.65e-06	-0.3	-0.25	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-5.51	6.02e-08	9.65e-06	-0.3	-0.25	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-5.51	6.02e-08	9.65e-06	-0.3	-0.25	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
THCA	cis	rs61041384	0.661	rs75589918	ENSG00000256092.2	RP13-942N8.1	-5.51	6.02e-08	9.65e-06	-0.39	-0.25	Schizophrenia;	chr12:123109855	chr12:123363868~123366113:+
THCA	cis	rs2735413	0.563	rs72800918	ENSG00000276007.1	RP11-358L22.3	5.51	6.02e-08	9.65e-06	0.28	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78026834	chr16:78123243~78124332:+
THCA	cis	rs7429990	0.965	rs319689	ENSG00000228638.1	FCF1P2	-5.51	6.02e-08	9.66e-06	-0.24	-0.25	Educational attainment (years of education);	chr3:47886677	chr3:48290793~48291375:-
THCA	cis	rs812925	0.892	rs4672440	ENSG00000271889.1	RP11-493E12.1	-5.51	6.03e-08	9.67e-06	-0.26	-0.25	Immature fraction of reticulocytes;	chr2:61389518	chr2:61151433~61162105:-
THCA	cis	rs6903823	0.527	rs4713158	ENSG00000273712.1	RP5-874C20.7	5.51	6.03e-08	9.67e-06	0.28	0.25	Pulmonary function;	chr6:28309994	chr6:28315613~28315883:-
THCA	cis	rs7560272	0.589	rs34874205	ENSG00000163016.8	ALMS1P	-5.51	6.03e-08	9.67e-06	-0.32	-0.25	Schizophrenia;	chr2:73648331	chr2:73644919~73685576:+
THCA	cis	rs7412746	0.611	rs10788794	ENSG00000231073.1	RP11-316M1.3	5.51	6.03e-08	9.67e-06	0.3	0.25	Melanoma;	chr1:150756200	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs10888391	ENSG00000231073.1	RP11-316M1.3	5.51	6.03e-08	9.67e-06	0.3	0.25	Melanoma;	chr1:150757507	chr1:150973123~150975534:+
THCA	cis	rs7005380	0.62	rs7459671	ENSG00000245330.4	KB-1471A8.1	5.51	6.03e-08	9.67e-06	0.24	0.25	Interstitial lung disease;	chr8:119896646	chr8:119867419~119874488:-
THCA	cis	rs4415084	0.834	rs2118764	ENSG00000272335.1	RP11-53O19.3	-5.51	6.03e-08	9.67e-06	-0.2	-0.25	Breast cancer;	chr5:44787621	chr5:44826076~44828592:+
THCA	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	5.51	6.03e-08	9.67e-06	0.15	0.25	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
THCA	cis	rs2562456	0.833	rs1932087	ENSG00000268081.1	RP11-678G14.2	5.51	6.04e-08	9.68e-06	0.42	0.25	Pain;	chr19:21338625	chr19:21554640~21569237:-
THCA	cis	rs9475752	0.739	rs2613119	ENSG00000231441.1	RP11-472M19.2	-5.51	6.04e-08	9.68e-06	-0.33	-0.25	Menarche (age at onset);	chr6:56944524	chr6:56844002~56864078:+
THCA	cis	rs9987353	0.522	rs2929466	ENSG00000253893.2	FAM85B	5.51	6.04e-08	9.68e-06	0.32	0.25	Recombination measurement;	chr8:9206389	chr8:8167819~8226614:-
THCA	cis	rs2835345	0.563	rs12482435	ENSG00000230479.1	AP000695.6	5.51	6.04e-08	9.68e-06	0.29	0.25	Pulmonary function;	chr21:36448658	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.563	rs12482423	ENSG00000230479.1	AP000695.6	5.51	6.04e-08	9.68e-06	0.29	0.25	Pulmonary function;	chr21:36448662	chr21:36430360~36481070:+
THCA	cis	rs172166	0.694	rs203884	ENSG00000220721.1	OR1F12	5.51	6.04e-08	9.68e-06	0.31	0.25	Cardiac Troponin-T levels;	chr6:28109596	chr6:28073316~28074233:+
THCA	cis	rs7428	0.847	rs1969260	ENSG00000273196.1	RP11-717A5.2	5.51	6.04e-08	9.69e-06	0.25	0.25	Ear protrusion;	chr2:85341687	chr2:85387074~85387146:-
THCA	cis	rs10792665	0.604	rs7933350	ENSG00000246067.6	RAB30-AS1	-5.51	6.05e-08	9.69e-06	-0.24	-0.25	Obesity-related traits;	chr11:82940951	chr11:83072066~83106719:+
THCA	cis	rs79040073	0.637	rs11632575	ENSG00000259531.2	RP11-295H24.3	5.51	6.05e-08	9.69e-06	0.35	0.25	Lung cancer in ever smokers;	chr15:49380758	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.594	rs59112977	ENSG00000259531.2	RP11-295H24.3	5.51	6.05e-08	9.69e-06	0.35	0.25	Lung cancer in ever smokers;	chr15:49382342	chr15:49365124~49366685:-
THCA	cis	rs1322639	0.614	rs6940913	ENSG00000261039.2	RP11-417E7.2	-5.51	6.05e-08	9.69e-06	-0.38	-0.25	Pulse pressure;	chr6:169163571	chr6:169175304~169182740:-
THCA	cis	rs853679	0.527	rs9468333	ENSG00000273712.1	RP5-874C20.7	5.51	6.05e-08	9.69e-06	0.28	0.25	Depression;	chr6:28303421	chr6:28315613~28315883:-
THCA	cis	rs2562456	0.876	rs62110163	ENSG00000268119.4	CTD-2561J22.5	5.51	6.05e-08	9.69e-06	0.3	0.25	Pain;	chr19:21546020	chr19:21444241~21463908:-
THCA	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	5.51	6.05e-08	9.7e-06	0.43	0.25	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
THCA	cis	rs3785574	0.927	rs2854183	ENSG00000240280.5	TCAM1P	-5.51	6.05e-08	9.7e-06	-0.33	-0.25	Height;	chr17:63890642	chr17:63849292~63864379:+
THCA	cis	rs7520050	0.645	rs1768809	ENSG00000234329.1	RP11-767N6.2	-5.51	6.05e-08	9.7e-06	-0.22	-0.25	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45651039~45651826:-
THCA	cis	rs7162943	0.708	rs293365	ENSG00000260123.1	RP11-326A19.4	-5.51	6.06e-08	9.7e-06	-0.31	-0.25	Mean platelet volume;	chr15:89070777	chr15:89041223~89082819:+
THCA	cis	rs62432291	0.681	rs2932987	ENSG00000235086.1	FNDC1-IT1	5.51	6.07e-08	9.72e-06	0.44	0.25	Joint mobility (Beighton score);	chr6:159234641	chr6:159240786~159243329:+
THCA	cis	rs2735413	0.564	rs78375430	ENSG00000276007.1	RP11-358L22.3	5.51	6.07e-08	9.73e-06	0.27	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78050916	chr16:78123243~78124332:+
THCA	cis	rs72949976	0.646	rs11681232	ENSG00000270659.1	RP11-105N14.1	-5.51	6.07e-08	9.73e-06	-0.2	-0.25	Squamous cell lung carcinoma;Lung cancer;	chr2:213168278	chr2:213152970~213153659:+
THCA	cis	rs7712401	0.755	rs3756362	ENSG00000249996.1	RP11-359P5.1	5.51	6.07e-08	9.73e-06	0.23	0.25	Mean platelet volume;	chr5:122773195	chr5:123036271~123054667:+
THCA	cis	rs5758659	0.652	rs1063392	ENSG00000227370.1	RP4-669P10.19	5.51	6.08e-08	9.74e-06	0.22	0.25	Cognitive function;	chr22:42058946	chr22:42132543~42132998:+
THCA	cis	rs73242632	1	rs2271807	ENSG00000269949.1	RP11-738E22.3	5.51	6.08e-08	9.74e-06	0.56	0.25	Congenital heart disease (maternal effect);	chr4:57032563	chr4:56960927~56961373:-
THCA	cis	rs7005380	0.58	rs13265546	ENSG00000245330.4	KB-1471A8.1	5.5	6.08e-08	9.75e-06	0.24	0.25	Interstitial lung disease;	chr8:119907735	chr8:119867419~119874488:-
THCA	cis	rs10875746	0.855	rs12310999	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48053875	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs61918774	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48054351	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.807	rs12297004	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48060037	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs10875735	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48070023	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.855	rs17122620	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48070692	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.859	rs4760680	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48072914	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs11168386	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48074194	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.807	rs12313300	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48076934	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs12315625	ENSG00000269514.1	RP11-370I10.12	5.5	6.09e-08	9.76e-06	0.25	0.25	Longevity (90 years and older);	chr12:48078670	chr12:48198387~48202031:+
THCA	cis	rs12893668	0.703	rs4906338	ENSG00000269940.1	RP11-73M18.7	5.5	6.09e-08	9.76e-06	0.26	0.25	Reticulocyte count;	chr14:103584020	chr14:103694560~103695170:+
THCA	cis	rs6044112	0.56	rs6080314	ENSG00000273998.1	RP4-777L9.2	5.5	6.09e-08	9.76e-06	0.43	0.25	Response to taxane treatment (docetaxel);	chr20:16597541	chr20:16576068~16579615:+
THCA	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	5.5	6.1e-08	9.76e-06	0.23	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
THCA	cis	rs13256369	1	rs9329165	ENSG00000253893.2	FAM85B	5.5	6.1e-08	9.76e-06	0.33	0.25	Obesity-related traits;	chr8:8719132	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs10088439	ENSG00000253893.2	FAM85B	-5.5	6.1e-08	9.76e-06	-0.33	-0.25	Obesity-related traits;	chr8:8719189	chr8:8167819~8226614:-
THCA	cis	rs1185460	0.967	rs1307145	ENSG00000272186.1	RP11-110I1.13	-5.5	6.1e-08	9.77e-06	-0.23	-0.25	Coronary artery disease;	chr11:119079507	chr11:119067374~119067698:-
THCA	cis	rs10829156	1	rs10829156	ENSG00000240291.1	RP11-499P20.2	5.5	6.1e-08	9.77e-06	0.21	0.25	Sudden cardiac arrest;	chr10:18661626	chr10:18513115~18545651:-
THCA	cis	rs72949976	0.646	rs4673731	ENSG00000270659.1	RP11-105N14.1	-5.5	6.1e-08	9.77e-06	-0.2	-0.25	Squamous cell lung carcinoma;Lung cancer;	chr2:213163820	chr2:213152970~213153659:+
THCA	cis	rs72949976	0.646	rs13029384	ENSG00000270659.1	RP11-105N14.1	-5.5	6.1e-08	9.77e-06	-0.2	-0.25	Squamous cell lung carcinoma;Lung cancer;	chr2:213164440	chr2:213152970~213153659:+
THCA	cis	rs4780355	0.843	rs413024	ENSG00000262703.1	RP11-485G7.6	5.5	6.1e-08	9.77e-06	0.3	0.25	Crohn's disease and psoriasis;	chr16:11260234	chr16:11348143~11349321:-
THCA	cis	rs4460629	0.742	rs11264314	ENSG00000160766.13	GBAP1	-5.5	6.11e-08	9.78e-06	-0.27	-0.25	Serum magnesium levels;	chr1:155105947	chr1:155213821~155227422:-
THCA	cis	rs17508449	1	rs17461918	ENSG00000232450.1	RP4-730K3.3	-5.5	6.11e-08	9.78e-06	-0.38	-0.25	Leprosy;	chr1:113538822	chr1:113698884~113699631:-
THCA	cis	rs11089937	0.597	rs5756991	ENSG00000211638.2	IGLV8-61	-5.5	6.11e-08	9.79e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.54	rs5756992	ENSG00000211638.2	IGLV8-61	-5.5	6.11e-08	9.79e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs9622919	ENSG00000211638.2	IGLV8-61	-5.5	6.11e-08	9.79e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs9619793	ENSG00000211638.2	IGLV8-61	-5.5	6.11e-08	9.79e-06	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22098700~22099212:+
THCA	cis	rs9813712	0.953	rs9883455	ENSG00000228252.7	COL6A4P2	-5.5	6.11e-08	9.79e-06	-0.28	-0.25	Response to amphetamines;	chr3:130260088	chr3:130212823~130273806:+
THCA	cis	rs5758659	0.716	rs86669	ENSG00000270083.1	RP1-257I20.14	5.5	6.12e-08	9.8e-06	0.25	0.25	Cognitive function;	chr22:42284794	chr22:42089630~42090028:-
THCA	cis	rs4948275	0.773	rs2787732	ENSG00000237233.2	TMEM26-AS1	5.5	6.12e-08	9.8e-06	0.32	0.25	Night sleep phenotypes;	chr10:61487841	chr10:61452639~61481956:+
THCA	cis	rs11073619	0.616	rs34602083	ENSG00000230373.7	GOLGA6L5P	-5.5	6.12e-08	9.81e-06	-0.37	-0.25	Positive affect;	chr15:84397156	chr15:84507885~84516814:-
THCA	cis	rs4699052	0.787	rs2169508	ENSG00000246560.2	RP11-10L12.4	5.5	6.13e-08	9.81e-06	0.29	0.25	Testicular germ cell tumor;	chr4:103145733	chr4:102828055~102844075:+
THCA	cis	rs6569038	0.502	rs794261	ENSG00000253194.1	RP11-351A11.1	5.5	6.13e-08	9.81e-06	0.34	0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119007434	chr6:118934785~119031541:+
THCA	cis	rs28510890	0.508	rs28664631	ENSG00000260337.3	RP11-386M24.6	5.5	6.13e-08	9.82e-06	0.26	0.25	Lung cancer in ever smokers;	chr15:92616165	chr15:92592574~92596462:-
THCA	cis	rs714027	1	rs757024	ENSG00000279159.1	RP3-394A18.1	-5.5	6.13e-08	9.82e-06	-0.17	-0.25	Lymphocyte counts;	chr22:30075690	chr22:29978950~30028236:-
THCA	cis	rs935334	0.877	rs7158766	ENSG00000258454.1	RP11-361H10.3	5.5	6.14e-08	9.82e-06	0.35	0.25	Blood pressure;	chr14:76197208	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs6574278	ENSG00000258454.1	RP11-361H10.3	5.5	6.14e-08	9.82e-06	0.35	0.25	Blood pressure;	chr14:76197495	chr14:76235817~76263474:+
THCA	cis	rs935334	0.935	rs6574279	ENSG00000258454.1	RP11-361H10.3	5.5	6.14e-08	9.82e-06	0.35	0.25	Blood pressure;	chr14:76197595	chr14:76235817~76263474:+
THCA	cis	rs55704346	0.565	rs4697551	ENSG00000281501.1	SEPSECS-AS1	5.5	6.14e-08	9.83e-06	0.27	0.25	Tonsillectomy;	chr4:25126938	chr4:25160641~25201440:+
THCA	cis	rs3785574	0.962	rs62077483	ENSG00000240280.5	TCAM1P	-5.5	6.14e-08	9.83e-06	-0.34	-0.25	Height;	chr17:63729020	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.962	rs7219920	ENSG00000240280.5	TCAM1P	-5.5	6.14e-08	9.83e-06	-0.34	-0.25	Height;	chr17:63734282	chr17:63849292~63864379:+
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000273796.1	LL21NC02-21A1.1	-5.5	6.14e-08	9.83e-06	-0.26	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000273796.1	LL21NC02-21A1.1	-5.5	6.14e-08	9.83e-06	-0.26	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45403809~45404369:-
THCA	cis	rs4748857	0.947	rs7084042	ENSG00000224215.1	RP11-371A19.2	-5.5	6.14e-08	9.83e-06	-0.27	-0.25	Systemic lupus erythematosus;	chr10:23220790	chr10:23343957~23345181:+
THCA	cis	rs13256369	1	rs13267501	ENSG00000253893.2	FAM85B	-5.5	6.14e-08	9.83e-06	-0.33	-0.25	Obesity-related traits;	chr8:8716548	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs7004438	ENSG00000253893.2	FAM85B	-5.5	6.14e-08	9.83e-06	-0.33	-0.25	Obesity-related traits;	chr8:8716869	chr8:8167819~8226614:-
THCA	cis	rs13256369	1	rs13271966	ENSG00000253893.2	FAM85B	-5.5	6.14e-08	9.83e-06	-0.33	-0.25	Obesity-related traits;	chr8:8717962	chr8:8167819~8226614:-
THCA	cis	rs6545883	0.929	rs2593627	ENSG00000270820.4	RP11-355B11.2	-5.5	6.14e-08	9.84e-06	-0.21	-0.25	Tuberculosis;	chr2:61391439	chr2:61471188~61484130:+
THCA	cis	rs59868192	0.925	rs2724934	ENSG00000246740.2	PLA2G4E-AS1	5.5	6.14e-08	9.84e-06	0.45	0.25	White blood cell count;	chr15:41959958	chr15:41972763~41999094:+
THCA	cis	rs1858037	0.867	rs1039765	ENSG00000234255.7	AC012370.3	-5.5	6.15e-08	9.84e-06	-0.29	-0.25	Rheumatoid arthritis;	chr2:65387228	chr2:65439888~65456571:-
THCA	cis	rs7712401	0.755	rs965821	ENSG00000249996.1	RP11-359P5.1	5.5	6.15e-08	9.84e-06	0.24	0.25	Mean platelet volume;	chr5:122802013	chr5:123036271~123054667:+
THCA	cis	rs8007846	0.536	rs59636756	ENSG00000276116.2	FUT8-AS1	-5.5	6.15e-08	9.84e-06	-0.25	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65789771	chr14:65411170~65412690:-
THCA	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-5.5	6.15e-08	9.85e-06	-0.21	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
THCA	cis	rs7267979	0.527	rs6076369	ENSG00000125804.12	FAM182A	5.5	6.15e-08	9.85e-06	0.32	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26054655~26086917:+
THCA	cis	rs10895275	0.625	rs61893575	ENSG00000277459.1	RP11-732A21.3	5.5	6.15e-08	9.85e-06	0.18	0.25	Migraine;	chr11:102169372	chr11:102109827~102110457:-
THCA	cis	rs67981189	0.519	rs2526879	ENSG00000269927.1	RP6-91H8.3	-5.5	6.15e-08	9.85e-06	-0.3	-0.25	Schizophrenia;	chr14:70910501	chr14:71141125~71143253:-
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000280069.1	CTD-2349P21.3	-5.5	6.16e-08	9.86e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30738182~30740275:+
THCA	cis	rs763121	0.962	rs6001159	ENSG00000273076.1	RP3-508I15.22	5.5	6.16e-08	9.86e-06	0.24	0.25	Menopause (age at onset);	chr22:38570482	chr22:38743495~38743910:+
THCA	cis	rs807029	0.758	rs807027	ENSG00000272572.1	RP11-179B2.2	-5.5	6.16e-08	9.87e-06	-0.2	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101004850	chr10:100911103~100912739:-
THCA	cis	rs7394190	0.748	rs60212594	ENSG00000271848.1	RP11-464F9.21	-5.5	6.17e-08	9.87e-06	-0.33	-0.25	Incident atrial fibrillation;	chr10:73654586	chr10:73654039~73674719:+
THCA	cis	rs67981189	0.529	rs61990379	ENSG00000269927.1	RP6-91H8.3	5.5	6.17e-08	9.88e-06	0.3	0.25	Schizophrenia;	chr14:71000353	chr14:71141125~71143253:-
THCA	cis	rs10208649	0.908	rs72906786	ENSG00000233266.1	HMGB1P31	5.5	6.17e-08	9.88e-06	0.6	0.25	Body mass index;	chr2:54128523	chr2:54051334~54051760:+
THCA	cis	rs750460	1	rs12441130	ENSG00000261801.4	LOXL1-AS1	-5.5	6.17e-08	9.88e-06	-0.26	-0.25	Height;	chr15:73942561	chr15:73908071~73928248:-
THCA	cis	rs7129556	0.737	rs4344516	ENSG00000254691.1	RP11-91P24.5	5.5	6.17e-08	9.88e-06	0.34	0.25	Weight loss (gastric bypass surgery);	chr11:77727014	chr11:77850604~77851511:+
THCA	cis	rs72949976	0.646	rs1441171	ENSG00000270659.1	RP11-105N14.1	-5.5	6.17e-08	9.88e-06	-0.2	-0.25	Squamous cell lung carcinoma;Lung cancer;	chr2:213168913	chr2:213152970~213153659:+
THCA	cis	rs2348418	0.703	rs10843122	ENSG00000247934.4	RP11-967K21.1	-5.5	6.17e-08	9.88e-06	-0.21	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.765	rs2078016	ENSG00000247934.4	RP11-967K21.1	-5.5	6.17e-08	9.88e-06	-0.21	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28163298~28190738:-
THCA	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	5.5	6.17e-08	9.88e-06	0.24	0.25	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
THCA	cis	rs9595908	1	rs7992980	ENSG00000212293.1	SNORA16	5.5	6.18e-08	9.88e-06	0.29	0.25	Body mass index;	chr13:32607005	chr13:32420390~32420516:-
THCA	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-5.5	6.18e-08	9.89e-06	-0.21	-0.25	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
THCA	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-5.5	6.18e-08	9.89e-06	-0.21	-0.25	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
THCA	cis	rs7809950	0.906	rs2253269	ENSG00000238832.1	snoU109	-5.5	6.18e-08	9.89e-06	-0.26	-0.25	Coronary artery disease;	chr7:107560669	chr7:107603363~107603507:+
THCA	cis	rs116095464	0.558	rs10043002	ENSG00000248925.1	CTD-2083E4.6	5.5	6.18e-08	9.89e-06	0.35	0.25	Breast cancer;	chr5:226638	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs2162870	ENSG00000248925.1	CTD-2083E4.6	5.5	6.18e-08	9.89e-06	0.35	0.25	Breast cancer;	chr5:228014	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs28729548	ENSG00000248925.1	CTD-2083E4.6	5.5	6.18e-08	9.89e-06	0.35	0.25	Breast cancer;	chr5:228910	chr5:269858~271516:-
THCA	cis	rs116095464	0.681	rs9687745	ENSG00000248925.1	CTD-2083E4.6	5.5	6.18e-08	9.89e-06	0.35	0.25	Breast cancer;	chr5:229194	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs9688136	ENSG00000248925.1	CTD-2083E4.6	5.5	6.18e-08	9.89e-06	0.35	0.25	Breast cancer;	chr5:229233	chr5:269858~271516:-
THCA	cis	rs116095464	0.51	rs55750776	ENSG00000248925.1	CTD-2083E4.6	5.5	6.18e-08	9.89e-06	0.35	0.25	Breast cancer;	chr5:230352	chr5:269858~271516:-
THCA	cis	rs116095464	0.764	rs10069197	ENSG00000248925.1	CTD-2083E4.6	5.5	6.18e-08	9.89e-06	0.35	0.25	Breast cancer;	chr5:230707	chr5:269858~271516:-
THCA	cis	rs116095464	0.867	rs10074958	ENSG00000248925.1	CTD-2083E4.6	5.5	6.18e-08	9.89e-06	0.35	0.25	Breast cancer;	chr5:230713	chr5:269858~271516:-
THCA	cis	rs2337406	1	rs7145100	ENSG00000211974.3	IGHV2-70	-5.5	6.2e-08	9.91e-06	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106704673	chr14:106723574~106724093:-
THCA	cis	rs12935418	0.583	rs2098726	ENSG00000278985.1	RP11-303E16.9	-5.5	6.2e-08	9.92e-06	-0.26	-0.25	Mean corpuscular volume;	chr16:80991670	chr16:80982319~80984094:-
THCA	cis	rs2562456	0.52	rs250001	ENSG00000268555.1	RP11-678G14.3	5.5	6.2e-08	9.92e-06	0.39	0.25	Pain;	chr19:21225387	chr19:21570822~21587322:-
THCA	cis	rs3764400	0.508	rs55696440	ENSG00000278765.1	RP5-890E16.5	5.5	6.2e-08	9.92e-06	0.45	0.25	Body mass index;	chr17:48193784	chr17:48066704~48067293:-
THCA	cis	rs4604234	0.803	rs11968568	ENSG00000272129.1	RP11-250B2.6	-5.5	6.21e-08	9.93e-06	-0.6	-0.25	Cancer;	chr6:80276577	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.803	rs3805893	ENSG00000272129.1	RP11-250B2.6	-5.5	6.21e-08	9.93e-06	-0.6	-0.25	Cancer;	chr6:80285761	chr6:80355424~80356859:+
THCA	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-5.5	6.21e-08	9.93e-06	-0.25	-0.25	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
THCA	cis	rs67478160	0.571	rs1155751	ENSG00000258735.1	LINC00637	-5.5	6.21e-08	9.94e-06	-0.3	-0.25	Schizophrenia;	chr14:103820210	chr14:103847721~103858049:+
THCA	cis	rs11098499	0.821	rs56155624	ENSG00000248280.1	RP11-33B1.2	5.5	6.22e-08	9.94e-06	0.21	0.25	Corneal astigmatism;	chr4:119369871	chr4:119440561~119450157:-
THCA	cis	rs5752326	1	rs5761529	ENSG00000261188.1	CTA-445C9.14	5.5	6.22e-08	9.95e-06	0.31	0.25	Ischemic stroke;	chr22:26447742	chr22:26512537~26514568:+
THCA	cis	rs5752326	1	rs5752326	ENSG00000261188.1	CTA-445C9.14	5.5	6.22e-08	9.95e-06	0.31	0.25	Ischemic stroke;	chr22:26448024	chr22:26512537~26514568:+
THCA	cis	rs7727544	0.735	rs274558	ENSG00000224431.1	AC063976.7	-5.5	6.22e-08	9.95e-06	-0.21	-0.25	Blood metabolite levels;	chr5:132385482	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.735	rs274557	ENSG00000224431.1	AC063976.7	-5.5	6.22e-08	9.95e-06	-0.21	-0.25	Blood metabolite levels;	chr5:132385512	chr5:132199456~132203487:+
THCA	cis	rs6728642	0.572	rs1320147	ENSG00000230606.9	AC159540.1	-5.5	6.22e-08	9.96e-06	-0.29	-0.25	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96934889	chr2:97416165~97433527:-
THCA	cis	rs3785574	0.927	rs2727313	ENSG00000240280.5	TCAM1P	-5.5	6.23e-08	9.96e-06	-0.33	-0.25	Height;	chr17:63884554	chr17:63849292~63864379:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000261839.1	RP1-265C24.8	5.5	6.23e-08	9.96e-06	0.29	0.25	Parkinson's disease;	chr6:28066959	chr6:28136849~28139678:+
THCA	cis	rs6540731	0.728	rs12746096	ENSG00000226251.4	RP11-15I11.3	-5.5	6.23e-08	9.96e-06	-0.3	-0.25	Intelligence (childhood);	chr1:212190424	chr1:212225278~212238977:-
THCA	cis	rs448720	0.508	rs17247210	ENSG00000260657.2	RP11-315D16.4	5.5	6.23e-08	9.96e-06	0.33	0.25	Cognitive performance;	chr15:67927734	chr15:68267792~68277994:-
THCA	cis	rs8113308	0.752	rs113374423	ENSG00000269235.1	ZNF350-AS1	5.5	6.23e-08	9.97e-06	0.35	0.25	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987699	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.752	rs73068868	ENSG00000269235.1	ZNF350-AS1	5.5	6.23e-08	9.97e-06	0.35	0.25	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987748	chr19:51949134~51981367:+
THCA	cis	rs6540731	0.782	rs10436976	ENSG00000226251.4	RP11-15I11.3	-5.5	6.23e-08	9.97e-06	-0.31	-0.25	Intelligence (childhood);	chr1:212187066	chr1:212225278~212238977:-
THCA	cis	rs2993535	1	rs2788138	ENSG00000233626.2	RP11-565J7.1	5.5	6.24e-08	9.97e-06	0.67	0.25	Hip circumference adjusted for BMI;	chr1:211942670	chr1:211936249~211936634:+
THCA	cis	rs2439831	0.867	rs45585139	ENSG00000275601.1	AC011330.13	-5.5	6.24e-08	9.98e-06	-0.43	-0.25	Lung cancer in ever smokers;	chr15:43408229	chr15:43642389~43643023:-
THCA	cis	rs28735056	0.508	rs67651675	ENSG00000261126.6	RP11-795F19.1	-5.5	6.24e-08	9.98e-06	-0.21	-0.25	Schizophrenia;	chr18:79913562	chr18:80046900~80095482:+
THCA	cis	rs10875943	0.751	rs11168962	ENSG00000258017.1	RP11-386G11.10	-5.5	6.24e-08	9.98e-06	-0.36	-0.25	Prostate cancer;	chr12:49278956	chr12:49127782~49147869:+
THCA	cis	rs1552244	0.554	rs6800204	ENSG00000180385.7	EMC3-AS1	5.5	6.24e-08	9.98e-06	0.24	0.25	Alzheimer's disease;	chr3:9953720	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs6762594	ENSG00000180385.7	EMC3-AS1	5.5	6.24e-08	9.98e-06	0.24	0.25	Alzheimer's disease;	chr3:9953832	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs3846167	ENSG00000180385.7	EMC3-AS1	5.5	6.24e-08	9.98e-06	0.24	0.25	Alzheimer's disease;	chr3:9954742	chr3:9986893~10006990:+
THCA	cis	rs6860806	0.661	rs2136188	ENSG00000233006.5	AC034220.3	-5.5	6.25e-08	9.99e-06	-0.19	-0.25	Breast cancer;	chr5:132241821	chr5:132311285~132369916:-
THCA	cis	rs2243480	1	rs12698509	ENSG00000230295.1	RP11-458F8.2	-5.5	6.25e-08	9.99e-06	-0.29	-0.25	Diabetic kidney disease;	chr7:65953889	chr7:66880708~66882981:+
THCA	cis	rs7412746	0.658	rs11204739	ENSG00000231073.1	RP11-316M1.3	5.5	6.25e-08	9.99e-06	0.3	0.25	Melanoma;	chr1:150893284	chr1:150973123~150975534:+
THCA	cis	rs890448	0.796	rs1549513	ENSG00000254531.1	FLJ20021	5.5	6.25e-08	9.99e-06	0.22	0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101419773	chr4:101347780~101348883:+
THCA	cis	rs75920871	0.528	rs11216245	ENSG00000254851.1	RP11-109L13.1	5.5	6.26e-08	1e-05	0.35	0.25	Subjective well-being;	chr11:117042486	chr11:117135528~117138582:+
THCA	cis	rs442309	0.812	rs224135	ENSG00000238280.1	RP11-436D10.3	-5.5	6.26e-08	1e-05	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62707042	chr10:62793562~62805887:-
THCA	cis	rs2179367	0.632	rs9498321	ENSG00000268592.3	RAET1E-AS1	5.5	6.26e-08	1e-05	0.35	0.25	Dupuytren's disease;	chr6:149322573	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs62426068	ENSG00000268592.3	RAET1E-AS1	5.5	6.26e-08	1e-05	0.35	0.25	Dupuytren's disease;	chr6:149325795	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs62426069	ENSG00000268592.3	RAET1E-AS1	5.5	6.26e-08	1e-05	0.35	0.25	Dupuytren's disease;	chr6:149325804	chr6:149863494~149919507:+
THCA	cis	rs875971	0.505	rs1167386	ENSG00000273142.1	RP11-458F8.4	5.5	6.27e-08	1e-05	0.2	0.25	Aortic root size;	chr7:66048109	chr7:66902857~66906297:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000273142.1	RP11-458F8.4	5.5	6.27e-08	1e-05	0.2	0.25	Aortic root size;	chr7:66048321	chr7:66902857~66906297:+
THCA	cis	rs2562456	0.833	rs11667361	ENSG00000268081.1	RP11-678G14.2	5.5	6.27e-08	1e-05	0.41	0.25	Pain;	chr19:21356580	chr19:21554640~21569237:-
THCA	cis	rs875971	1	rs1981798	ENSG00000223473.2	GS1-124K5.3	5.5	6.27e-08	1e-05	0.16	0.25	Aortic root size;	chr7:66489916	chr7:66491049~66493566:-
THCA	cis	rs7396835	0.537	rs10892035	ENSG00000280143.1	AP000892.6	5.5	6.27e-08	1e-05	0.35	0.25	Quantitative traits;	chr11:116824222	chr11:117204967~117210292:+
THCA	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-5.5	6.27e-08	1e-05	-0.19	-0.25	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
THCA	cis	rs6547741	1	rs6756238	ENSG00000234072.1	AC074117.10	5.5	6.28e-08	1e-05	0.19	0.25	Oral cavity cancer;	chr2:27618438	chr2:27356246~27367622:+
THCA	cis	rs2033711	0.503	rs7254299	ENSG00000268912.1	CTD-2619J13.17	-5.5	6.28e-08	1e-05	-0.18	-0.25	Uric acid clearance;	chr19:58373598	chr19:58428632~58431148:-
THCA	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	5.5	6.28e-08	1e-05	0.21	0.25	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
THCA	cis	rs2070488	0.662	rs7373930	ENSG00000229589.1	ACVR2B-AS1	5.5	6.29e-08	1e-05	0.24	0.25	Electrocardiographic conduction measures;	chr3:38413440	chr3:38451027~38454820:-
THCA	cis	rs9843304	0.528	rs1317213	ENSG00000244503.1	RP11-278L15.6	-5.5	6.29e-08	1.01e-05	-0.3	-0.25	Gallstone disease;	chr3:149473363	chr3:149494660~149495995:+
THCA	cis	rs4415084	0.834	rs7720787	ENSG00000272335.1	RP11-53O19.3	-5.5	6.29e-08	1.01e-05	-0.2	-0.25	Breast cancer;	chr5:44817207	chr5:44826076~44828592:+
THCA	cis	rs116095464	0.558	rs62347683	ENSG00000248925.1	CTD-2083E4.6	5.5	6.29e-08	1.01e-05	0.36	0.25	Breast cancer;	chr5:230216	chr5:269858~271516:-
THCA	cis	rs35740288	0.514	rs2455561	ENSG00000259295.5	CSPG4P12	-5.5	6.29e-08	1.01e-05	-0.32	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85783117	chr15:85191438~85213905:+
THCA	cis	rs875971	0.522	rs6960048	ENSG00000273142.1	RP11-458F8.4	-5.5	6.3e-08	1.01e-05	-0.2	-0.25	Aortic root size;	chr7:65943052	chr7:66902857~66906297:+
THCA	cis	rs116095464	0.558	rs7713524	ENSG00000248925.1	CTD-2083E4.6	-5.5	6.3e-08	1.01e-05	-0.35	-0.25	Breast cancer;	chr5:276085	chr5:269858~271516:-
THCA	cis	rs76935404	0.811	rs11083589	ENSG00000256612.6	CYP2B7P	-5.5	6.3e-08	1.01e-05	-0.3	-0.25	nicotine metabolite ratio in current smokers;	chr19:40922511	chr19:40924219~40950660:+
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000230295.1	RP11-458F8.2	-5.5	6.3e-08	1.01e-05	-0.31	-0.25	Gout;	chr7:66732812	chr7:66880708~66882981:+
THCA	cis	rs4934494	0.634	rs11185791	ENSG00000232936.4	RP11-80H5.2	5.5	6.3e-08	1.01e-05	0.33	0.25	Red blood cell count;	chr10:89615198	chr10:89645282~89650667:+
THCA	cis	rs7010876	0.511	rs6989866	ENSG00000253553.4	RP11-586K2.1	-5.5	6.31e-08	1.01e-05	-0.26	-0.25	Schizophrenia;	chr8:88360807	chr8:88326836~88737134:+
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000223473.2	GS1-124K5.3	5.5	6.31e-08	1.01e-05	0.24	0.25	Diabetic kidney disease;	chr7:65988305	chr7:66491049~66493566:-
THCA	cis	rs6570726	0.967	rs450973	ENSG00000270638.1	RP3-466P17.1	5.5	6.31e-08	1.01e-05	0.19	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145735570~145737218:+
THCA	cis	rs8059260	0.541	rs6498167	ENSG00000274038.1	RP11-66H6.4	-5.5	6.31e-08	1.01e-05	-0.46	-0.25	Alcohol consumption over the past year;	chr16:11127727	chr16:11056556~11057034:+
THCA	cis	rs4415084	0.834	rs10043344	ENSG00000272335.1	RP11-53O19.3	5.5	6.32e-08	1.01e-05	0.21	0.25	Breast cancer;	chr5:44926416	chr5:44826076~44828592:+
THCA	cis	rs16976116	0.901	rs7165491	ENSG00000279145.1	RP11-547D13.1	5.5	6.32e-08	1.01e-05	0.25	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55208257	chr15:55171972~55178175:-
THCA	cis	rs116095464	0.558	rs10052012	ENSG00000248925.1	CTD-2083E4.6	5.5	6.32e-08	1.01e-05	0.36	0.25	Breast cancer;	chr5:231793	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10077076	ENSG00000248925.1	CTD-2083E4.6	5.5	6.32e-08	1.01e-05	0.36	0.25	Breast cancer;	chr5:231825	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10080225	ENSG00000248925.1	CTD-2083E4.6	5.5	6.32e-08	1.01e-05	0.36	0.25	Breast cancer;	chr5:232060	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10475136	ENSG00000248925.1	CTD-2083E4.6	5.5	6.32e-08	1.01e-05	0.36	0.25	Breast cancer;	chr5:232681	chr5:269858~271516:-
THCA	cis	rs755249	0.917	rs61779330	ENSG00000228060.1	RP11-69E11.8	-5.5	6.33e-08	1.01e-05	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39565160~39573203:+
THCA	cis	rs755249	0.876	rs72662001	ENSG00000228060.1	RP11-69E11.8	-5.5	6.33e-08	1.01e-05	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39565160~39573203:+
THCA	cis	rs9393777	0.92	rs35768595	ENSG00000219392.1	RP1-265C24.5	-5.5	6.33e-08	1.01e-05	-0.56	-0.25	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28115628~28116551:+
THCA	cis	rs758324	0.732	rs149432	ENSG00000237714.1	P4HA2-AS1	-5.5	6.33e-08	1.01e-05	-0.37	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132105807	chr5:132184876~132192808:+
THCA	cis	rs6688613	0.694	rs12062326	ENSG00000225171.2	DUTP6	-5.5	6.33e-08	1.01e-05	-0.33	-0.25	Refractive astigmatism;	chr1:166850949	chr1:166868748~166869209:+
THCA	cis	rs792448	0.527	rs11119887	ENSG00000226251.4	RP11-15I11.3	-5.5	6.34e-08	1.01e-05	-0.3	-0.25	White blood cell count (basophil);	chr1:212234220	chr1:212225278~212238977:-
THCA	cis	rs897984	0.645	rs9938550	ENSG00000260911.2	RP11-196G11.2	-5.5	6.34e-08	1.01e-05	-0.2	-0.25	Dementia with Lewy bodies;	chr16:30987821	chr16:31043150~31049868:+
THCA	cis	rs2129782	1	rs2129782	ENSG00000253553.4	RP11-586K2.1	5.5	6.34e-08	1.01e-05	0.42	0.25	Electrodermal activity;	chr8:88447005	chr8:88326836~88737134:+
THCA	cis	rs7119038	0.818	rs10892289	ENSG00000255239.1	AP002954.6	-5.5	6.35e-08	1.01e-05	-0.38	-0.25	Sjögren's syndrome;	chr11:118775294	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.818	rs56043232	ENSG00000255239.1	AP002954.6	-5.5	6.35e-08	1.01e-05	-0.38	-0.25	Sjögren's syndrome;	chr11:118777664	chr11:118688039~118690600:-
THCA	cis	rs2243480	1	rs2243480	ENSG00000229886.1	RP5-1132H15.3	5.5	6.35e-08	1.01e-05	0.39	0.25	Diabetic kidney disease;	chr7:66134209	chr7:66025126~66031544:-
THCA	cis	rs7617773	0.817	rs6787500	ENSG00000199476.1	Y_RNA	-5.5	6.35e-08	1.01e-05	-0.3	-0.25	Coronary artery disease;	chr3:48257949	chr3:48288587~48288694:+
THCA	cis	rs56114371	0.777	rs200482	ENSG00000226314.6	ZNF192P1	-5.5	6.35e-08	1.01e-05	-0.41	-0.25	Breast cancer;	chr6:27806126	chr6:28161781~28169594:+
THCA	cis	rs7897654	0.571	rs7920697	ENSG00000213277.3	MARCKSL1P1	5.5	6.35e-08	1.01e-05	0.29	0.25	Schizophrenia;	chr10:102873580	chr10:103175554~103176094:+
THCA	cis	rs438465	0.685	rs9371116	ENSG00000226194.4	RP1-137D17.1	-5.5	6.35e-08	1.01e-05	-0.42	-0.25	Corneal astigmatism;	chr6:169365789	chr6:169369998~169388385:-
THCA	cis	rs2921036	0.505	rs35190619	ENSG00000253893.2	FAM85B	5.5	6.36e-08	1.01e-05	0.36	0.25	Neuroticism;	chr8:8504313	chr8:8167819~8226614:-
THCA	cis	rs758324	0.645	rs247317	ENSG00000237714.1	P4HA2-AS1	-5.5	6.36e-08	1.02e-05	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132106612	chr5:132184876~132192808:+
THCA	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	5.5	6.36e-08	1.02e-05	0.25	0.25	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
THCA	cis	rs7412746	0.658	rs2272214	ENSG00000231073.1	RP11-316M1.3	5.5	6.37e-08	1.02e-05	0.3	0.25	Melanoma;	chr1:150958986	chr1:150973123~150975534:+
THCA	cis	rs17508449	1	rs79381435	ENSG00000232450.1	RP4-730K3.3	-5.5	6.37e-08	1.02e-05	-0.38	-0.25	Leprosy;	chr1:113543054	chr1:113698884~113699631:-
THCA	cis	rs6957923	0.655	rs6949019	ENSG00000234286.1	AC006026.13	5.5	6.37e-08	1.02e-05	0.3	0.25	Height;	chr7:23554431	chr7:23680195~23680786:-
THCA	cis	rs997295	0.57	rs72747464	ENSG00000270964.1	RP11-502I4.3	-5.5	6.37e-08	1.02e-05	-0.21	-0.25	Motion sickness;	chr15:67526202	chr15:67541072~67542604:-
THCA	cis	rs897984	0.542	rs7294	ENSG00000279196.1	RP11-1072A3.3	-5.5	6.37e-08	1.02e-05	-0.25	-0.25	Dementia with Lewy bodies;	chr16:31091000	chr16:30984630~30988270:-
THCA	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-5.5	6.37e-08	1.02e-05	-0.21	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
THCA	cis	rs2292342	0.85	rs7255644	ENSG00000232871.7	SEC1P	-5.5	6.37e-08	1.02e-05	-0.53	-0.25	Elevated serum carcinoembryonic antigen levels;	chr19:48644237	chr19:48638071~48682245:+
THCA	cis	rs17508449	0.819	rs75290614	ENSG00000232450.1	RP4-730K3.3	-5.5	6.38e-08	1.02e-05	-0.38	-0.25	Leprosy;	chr1:113700250	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.819	rs78874053	ENSG00000232450.1	RP4-730K3.3	-5.5	6.38e-08	1.02e-05	-0.38	-0.25	Leprosy;	chr1:113700251	chr1:113698884~113699631:-
THCA	cis	rs1876905	0.597	rs1150076	ENSG00000230177.1	RP5-1112D6.4	-5.5	6.38e-08	1.02e-05	-0.26	-0.25	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.764	rs6934341	ENSG00000255389.1	C6orf3	5.5	6.38e-08	1.02e-05	0.29	0.25	Mean corpuscular hemoglobin;	chr6:111098387	chr6:111599875~111602295:+
THCA	cis	rs67981189	0.529	rs2526872	ENSG00000269927.1	RP6-91H8.3	-5.5	6.39e-08	1.02e-05	-0.3	-0.25	Schizophrenia;	chr14:70918168	chr14:71141125~71143253:-
THCA	cis	rs10461617	0.535	rs7709874	ENSG00000271828.1	CTD-2310F14.1	5.5	6.39e-08	1.02e-05	0.35	0.25	Type 2 diabetes;	chr5:56751624	chr5:56927874~56929573:+
THCA	cis	rs1552244	1	rs66838678	ENSG00000180385.7	EMC3-AS1	5.5	6.39e-08	1.02e-05	0.27	0.25	Alzheimer's disease;	chr3:10108666	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs7618815	ENSG00000180385.7	EMC3-AS1	5.5	6.39e-08	1.02e-05	0.27	0.25	Alzheimer's disease;	chr3:10109361	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs7652935	ENSG00000180385.7	EMC3-AS1	5.5	6.39e-08	1.02e-05	0.27	0.25	Alzheimer's disease;	chr3:10109454	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs67134728	ENSG00000180385.7	EMC3-AS1	5.5	6.39e-08	1.02e-05	0.27	0.25	Alzheimer's disease;	chr3:10109747	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs68045038	ENSG00000180385.7	EMC3-AS1	5.5	6.39e-08	1.02e-05	0.27	0.25	Alzheimer's disease;	chr3:10110144	chr3:9986893~10006990:+
THCA	cis	rs7809950	1	rs2253146	ENSG00000238832.1	snoU109	-5.5	6.39e-08	1.02e-05	-0.26	-0.25	Coronary artery disease;	chr7:107559874	chr7:107603363~107603507:+
THCA	cis	rs875971	1	rs12532998	ENSG00000223473.2	GS1-124K5.3	5.5	6.39e-08	1.02e-05	0.16	0.25	Aortic root size;	chr7:66502472	chr7:66491049~66493566:-
THCA	cis	rs1914816	0.878	rs2456078	ENSG00000196274.5	Metazoa_SRP	5.5	6.39e-08	1.02e-05	0.35	0.25	Response to tocilizumab in rheumatoid arthritis;	chr15:76266529	chr15:76230048~76230390:-
THCA	cis	rs934734	0.736	rs10186240	ENSG00000281920.1	RP11-418H16.1	5.5	6.39e-08	1.02e-05	0.31	0.25	Rheumatoid arthritis;	chr2:65350517	chr2:65623272~65628424:+
THCA	cis	rs7727544	0.582	rs10478998	ENSG00000233006.5	AC034220.3	5.5	6.4e-08	1.02e-05	0.18	0.25	Blood metabolite levels;	chr5:132180838	chr5:132311285~132369916:-
THCA	cis	rs1707322	0.827	rs6683274	ENSG00000281133.1	AL355480.3	-5.5	6.4e-08	1.02e-05	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45580892~45580996:-
THCA	cis	rs1185460	0.967	rs1784302	ENSG00000272186.1	RP11-110I1.13	-5.5	6.4e-08	1.02e-05	-0.23	-0.25	Coronary artery disease;	chr11:119070247	chr11:119067374~119067698:-
THCA	cis	rs67981189	0.558	rs56043821	ENSG00000269927.1	RP6-91H8.3	5.5	6.4e-08	1.02e-05	0.3	0.25	Schizophrenia;	chr14:71103835	chr14:71141125~71143253:-
THCA	cis	rs763121	0.853	rs1569492	ENSG00000235209.1	CTA-150C2.13	-5.5	6.4e-08	1.02e-05	-0.3	-0.25	Menopause (age at onset);	chr22:38579506	chr22:38921227~38924708:+
THCA	cis	rs13256369	0.95	rs13255655	ENSG00000253893.2	FAM85B	-5.5	6.41e-08	1.02e-05	-0.33	-0.25	Obesity-related traits;	chr8:8720226	chr8:8167819~8226614:-
THCA	cis	rs11783469	0.524	rs4872139	ENSG00000253390.1	CTC-756D1.2	-5.5	6.41e-08	1.02e-05	-0.41	-0.25	Reticulocyte count;	chr8:23489128	chr8:23458601~23484971:+
THCA	cis	rs853679	0.546	rs34676049	ENSG00000219392.1	RP1-265C24.5	-5.5	6.41e-08	1.02e-05	-0.58	-0.25	Depression;	chr6:28485841	chr6:28115628~28116551:+
THCA	cis	rs4591358	0.618	rs12993381	ENSG00000223466.1	AC064834.2	5.5	6.41e-08	1.02e-05	0.3	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195542171	chr2:195533035~195538681:+
THCA	cis	rs17680741	0.802	rs7088704	ENSG00000226659.1	RP11-137H2.4	-5.49	6.42e-08	1.02e-05	-0.34	-0.25	Coronary artery disease;	chr10:80482174	chr10:80529597~80535942:-
THCA	cis	rs12681287	0.752	rs10092651	ENSG00000254231.1	CTD-2284J15.1	5.49	6.42e-08	1.02e-05	0.27	0.25	Caudate activity during reward;	chr8:86235449	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs10104242	ENSG00000254231.1	CTD-2284J15.1	5.49	6.42e-08	1.02e-05	0.27	0.25	Caudate activity during reward;	chr8:86235485	chr8:86333274~86343314:-
THCA	cis	rs7129556	0.621	rs663674	ENSG00000254691.1	RP11-91P24.5	5.49	6.42e-08	1.02e-05	0.33	0.25	Weight loss (gastric bypass surgery);	chr11:77881476	chr11:77850604~77851511:+
THCA	cis	rs1552244	1	rs2272123	ENSG00000232901.1	CYCSP10	5.49	6.42e-08	1.02e-05	0.33	0.25	Alzheimer's disease;	chr3:10098431	chr3:10000647~10000940:-
THCA	cis	rs442309	0.812	rs448355	ENSG00000238280.1	RP11-436D10.3	-5.49	6.42e-08	1.02e-05	-0.29	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62772835	chr10:62793562~62805887:-
THCA	cis	rs8177876	0.749	rs76892049	ENSG00000261061.1	RP11-303E16.2	-5.49	6.42e-08	1.02e-05	-0.36	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81030770~81031485:+
THCA	cis	rs853679	0.76	rs9468317	ENSG00000226314.6	ZNF192P1	-5.49	6.42e-08	1.02e-05	-0.34	-0.25	Depression;	chr6:28230678	chr6:28161781~28169594:+
THCA	cis	rs2243480	1	rs313814	ENSG00000230295.1	RP11-458F8.2	-5.49	6.43e-08	1.03e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66038306	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316331	ENSG00000232546.1	RP11-458F8.1	5.49	6.43e-08	1.03e-05	0.31	0.25	Diabetic kidney disease;	chr7:66139635	chr7:66848496~66858136:+
THCA	cis	rs897984	0.762	rs12931046	ENSG00000260911.2	RP11-196G11.2	-5.49	6.43e-08	1.03e-05	-0.21	-0.25	Dementia with Lewy bodies;	chr16:30975823	chr16:31043150~31049868:+
THCA	cis	rs2360027	0.622	rs10923614	ENSG00000231365.4	RP11-418J17.1	-5.49	6.43e-08	1.03e-05	-0.24	-0.25	Tonsillectomy;	chr1:118561834	chr1:119140396~119275973:+
THCA	cis	rs17508449	0.775	rs4839336	ENSG00000232450.1	RP4-730K3.3	-5.49	6.43e-08	1.03e-05	-0.38	-0.25	Leprosy;	chr1:113691523	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.819	rs77551704	ENSG00000232450.1	RP4-730K3.3	-5.49	6.43e-08	1.03e-05	-0.38	-0.25	Leprosy;	chr1:113692564	chr1:113698884~113699631:-
THCA	cis	rs6921919	0.551	rs13201753	ENSG00000219392.1	RP1-265C24.5	-5.49	6.43e-08	1.03e-05	-0.28	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28115628~28116551:+
THCA	cis	rs6121246	0.529	rs6060134	ENSG00000230613.1	HM13-AS1	5.49	6.43e-08	1.03e-05	0.29	0.25	Mean corpuscular hemoglobin;	chr20:31588991	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.529	rs6058152	ENSG00000230613.1	HM13-AS1	5.49	6.43e-08	1.03e-05	0.29	0.25	Mean corpuscular hemoglobin;	chr20:31590304	chr20:31567707~31573263:-
THCA	cis	rs2976388	0.566	rs2585146	ENSG00000253741.1	CTD-2292P10.4	-5.49	6.43e-08	1.03e-05	-0.33	-0.25	Urinary tract infection frequency;	chr8:142717223	chr8:142702252~142726973:-
THCA	cis	rs61677309	0.964	rs112753655	ENSG00000280032.1	RP11-832A4.7	5.49	6.43e-08	1.03e-05	0.26	0.25	Lung cancer in ever smokers;	chr11:118284080	chr11:118264593~118266817:+
THCA	cis	rs61677309	0.964	rs113145584	ENSG00000280032.1	RP11-832A4.7	5.49	6.43e-08	1.03e-05	0.26	0.25	Lung cancer in ever smokers;	chr11:118284083	chr11:118264593~118266817:+
THCA	cis	rs9380516	0.645	rs2064318	ENSG00000228559.1	RP3-340B19.3	-5.49	6.43e-08	1.03e-05	-0.38	-0.25	Hepatitis C induced liver fibrosis;	chr6:35509248	chr6:35544632~35545669:+
THCA	cis	rs7976269	0.537	rs4471475	ENSG00000275476.1	RP11-996F15.4	-5.49	6.44e-08	1.03e-05	-0.25	-0.25	Male-pattern baldness;	chr12:29022461	chr12:29277397~29277882:-
THCA	cis	rs4415084	0.834	rs7716571	ENSG00000272335.1	RP11-53O19.3	-5.49	6.44e-08	1.03e-05	-0.2	-0.25	Breast cancer;	chr5:44816882	chr5:44826076~44828592:+
THCA	cis	rs964184	0.564	rs2266788	ENSG00000254851.1	RP11-109L13.1	-5.49	6.44e-08	1.03e-05	-0.51	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117135528~117138582:+
THCA	cis	rs1552244	0.81	rs4019706	ENSG00000232901.1	CYCSP10	5.49	6.44e-08	1.03e-05	0.32	0.25	Alzheimer's disease;	chr3:10071178	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.872	rs6771931	ENSG00000232901.1	CYCSP10	5.49	6.44e-08	1.03e-05	0.32	0.25	Alzheimer's disease;	chr3:10071724	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs9824585	ENSG00000232901.1	CYCSP10	5.49	6.44e-08	1.03e-05	0.32	0.25	Alzheimer's disease;	chr3:10073118	chr3:10000647~10000940:-
THCA	cis	rs12664251	0.706	rs2797356	ENSG00000253194.1	RP11-351A11.1	-5.49	6.44e-08	1.03e-05	-0.34	-0.25	Schizophrenia;	chr6:119014786	chr6:118934785~119031541:+
THCA	cis	rs1400745	0.756	rs10136352	ENSG00000258738.1	RP11-73E17.2	5.49	6.44e-08	1.03e-05	0.29	0.25	Monocyte count;	chr14:34865349	chr14:34874343~34876459:+
THCA	cis	rs2439831	0.867	rs2470134	ENSG00000166763.7	STRCP1	-5.49	6.44e-08	1.03e-05	-0.35	-0.25	Lung cancer in ever smokers;	chr15:43557688	chr15:43699488~43718184:-
THCA	cis	rs3743266	0.613	rs8027901	ENSG00000245534.5	RORA-AS1	5.49	6.44e-08	1.03e-05	0.27	0.25	Menarche (age at onset);	chr15:60441265	chr15:60479178~60630637:+
THCA	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	5.49	6.45e-08	1.03e-05	0.28	0.25	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
THCA	cis	rs9876781	1	rs9883759	ENSG00000229759.1	MRPS18AP1	5.49	6.45e-08	1.03e-05	0.29	0.25	Longevity;	chr3:48422209	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs6442120	ENSG00000229759.1	MRPS18AP1	5.49	6.45e-08	1.03e-05	0.29	0.25	Longevity;	chr3:48423094	chr3:48256350~48256938:-
THCA	cis	rs34057264	1	rs34057264	ENSG00000253390.1	CTC-756D1.2	-5.49	6.45e-08	1.03e-05	-0.47	-0.25	Mean corpuscular hemoglobin;Hemoglobin concentration;	chr8:23515274	chr8:23458601~23484971:+
THCA	cis	rs12681287	0.752	rs4463401	ENSG00000254231.1	CTD-2284J15.1	5.49	6.46e-08	1.03e-05	0.27	0.25	Caudate activity during reward;	chr8:86238080	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs4427148	ENSG00000254231.1	CTD-2284J15.1	5.49	6.46e-08	1.03e-05	0.27	0.25	Caudate activity during reward;	chr8:86238439	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs10111095	ENSG00000254231.1	CTD-2284J15.1	5.49	6.46e-08	1.03e-05	0.27	0.25	Caudate activity during reward;	chr8:86238755	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs4288357	ENSG00000254231.1	CTD-2284J15.1	5.49	6.46e-08	1.03e-05	0.27	0.25	Caudate activity during reward;	chr8:86239604	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs4472493	ENSG00000254231.1	CTD-2284J15.1	5.49	6.46e-08	1.03e-05	0.27	0.25	Caudate activity during reward;	chr8:86239685	chr8:86333274~86343314:-
THCA	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	5.49	6.46e-08	1.03e-05	0.24	0.25	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
THCA	cis	rs11894081	0.799	rs2007718	ENSG00000232835.1	AC107057.1	5.49	6.46e-08	1.03e-05	0.25	0.25	Crohn's disease;	chr2:5533534	chr2:5549780~5556031:-
THCA	cis	rs997295	0.57	rs72747462	ENSG00000270964.1	RP11-502I4.3	-5.49	6.46e-08	1.03e-05	-0.2	-0.25	Motion sickness;	chr15:67526200	chr15:67541072~67542604:-
THCA	cis	rs2243480	1	rs709607	ENSG00000229886.1	RP5-1132H15.3	-5.49	6.46e-08	1.03e-05	-0.4	-0.25	Diabetic kidney disease;	chr7:65984554	chr7:66025126~66031544:-
THCA	cis	rs6740322	0.857	rs11690012	ENSG00000234936.1	AC010883.5	5.49	6.46e-08	1.03e-05	0.25	0.25	Coronary artery disease;	chr2:43315341	chr2:43229573~43233394:+
THCA	cis	rs8062405	0.754	rs149299	ENSG00000278665.1	RP11-666O2.4	5.49	6.46e-08	1.03e-05	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28599241~28601881:-
THCA	cis	rs7829975	0.582	rs6982832	ENSG00000233609.3	RP11-62H7.2	-5.49	6.46e-08	1.03e-05	-0.24	-0.25	Mood instability;	chr8:8934707	chr8:8961200~8979025:+
THCA	cis	rs7428	0.545	rs9248	ENSG00000273196.1	RP11-717A5.2	5.49	6.46e-08	1.03e-05	0.26	0.25	Ear protrusion;	chr2:85310189	chr2:85387074~85387146:-
THCA	cis	rs13113518	1	rs13132420	ENSG00000249700.7	SRD5A3-AS1	-5.49	6.46e-08	1.03e-05	-0.3	-0.25	Height;	chr4:55526646	chr4:55363971~55395847:-
THCA	cis	rs10208649	1	rs13417051	ENSG00000233266.1	HMGB1P31	-5.49	6.46e-08	1.03e-05	-0.54	-0.25	Body mass index;	chr2:53874635	chr2:54051334~54051760:+
THCA	cis	rs2562456	0.833	rs7258099	ENSG00000268081.1	RP11-678G14.2	5.49	6.47e-08	1.03e-05	0.41	0.25	Pain;	chr19:21352941	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62109229	ENSG00000268081.1	RP11-678G14.2	5.49	6.47e-08	1.03e-05	0.41	0.25	Pain;	chr19:21354380	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs11670815	ENSG00000268081.1	RP11-678G14.2	5.49	6.47e-08	1.03e-05	0.41	0.25	Pain;	chr19:21356515	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs11666540	ENSG00000268081.1	RP11-678G14.2	5.49	6.47e-08	1.03e-05	0.41	0.25	Pain;	chr19:21356550	chr19:21554640~21569237:-
THCA	cis	rs1546924	0.57	rs197415	ENSG00000227811.2	FAM212B-AS1	-5.49	6.47e-08	1.03e-05	-0.3	-0.25	Body mass index;	chr1:111768971	chr1:111739841~111747798:+
THCA	cis	rs9813712	0.855	rs6806152	ENSG00000228252.7	COL6A4P2	-5.49	6.47e-08	1.03e-05	-0.29	-0.25	Response to amphetamines;	chr3:130245358	chr3:130212823~130273806:+
THCA	cis	rs853679	0.567	rs16894091	ENSG00000280107.1	AL022393.9	5.49	6.47e-08	1.03e-05	0.27	0.25	Depression;	chr6:28422360	chr6:28170845~28172521:+
THCA	cis	rs4689592	0.513	rs3857177	ENSG00000245468.3	RP11-367J11.3	5.49	6.47e-08	1.03e-05	0.2	0.25	Monocyte percentage of white cells;	chr4:7064605	chr4:7094571~7103385:-
THCA	cis	rs4689592	0.513	rs3857178	ENSG00000245468.3	RP11-367J11.3	5.49	6.47e-08	1.03e-05	0.2	0.25	Monocyte percentage of white cells;	chr4:7064789	chr4:7094571~7103385:-
THCA	cis	rs4689592	0.513	rs4689586	ENSG00000245468.3	RP11-367J11.3	5.49	6.47e-08	1.03e-05	0.2	0.25	Monocyte percentage of white cells;	chr4:7065686	chr4:7094571~7103385:-
THCA	cis	rs8002861	0.935	rs9525865	ENSG00000274001.1	RP11-5G9.5	5.49	6.47e-08	1.03e-05	0.27	0.25	Leprosy;	chr13:43885511	chr13:43877715~43878163:-
THCA	cis	rs9652601	0.92	rs12923098	ENSG00000274038.1	RP11-66H6.4	-5.49	6.48e-08	1.03e-05	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11083196	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.959	rs9888908	ENSG00000274038.1	RP11-66H6.4	-5.49	6.48e-08	1.03e-05	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11087387	chr16:11056556~11057034:+
THCA	cis	rs9506514	0.722	rs10400670	ENSG00000238286.1	SLC35E1P1	5.49	6.48e-08	1.03e-05	0.24	0.25	Coronary artery calcification;	chr13:20679350	chr13:20607268~20608131:+
THCA	cis	rs2029362	0.904	rs11030052	ENSG00000245573.6	BDNF-AS	5.49	6.48e-08	1.03e-05	0.19	0.25	Total body bone mineral density;	chr11:27570265	chr11:27506838~27698174:+
THCA	cis	rs11089937	0.626	rs9619811	ENSG00000211639.2	IGLV4-60	5.49	6.48e-08	1.03e-05	0.18	0.25	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22162199~22162681:+
THCA	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	5.49	6.48e-08	1.03e-05	0.31	0.25	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
THCA	cis	rs7674212	0.57	rs2711899	ENSG00000246560.2	RP11-10L12.4	5.49	6.49e-08	1.03e-05	0.29	0.25	Type 2 diabetes;	chr4:103141257	chr4:102828055~102844075:+
THCA	cis	rs35934224	0.504	rs7288631	ENSG00000232926.1	AC000078.5	5.49	6.49e-08	1.03e-05	0.32	0.25	Glaucoma (primary open-angle);	chr22:19848625	chr22:19887289~19887970:+
THCA	cis	rs17123764	0.892	rs12301824	ENSG00000257464.1	RP11-161H23.8	-5.49	6.49e-08	1.04e-05	-0.39	-0.25	Intelligence (multi-trait analysis);	chr12:49719078	chr12:49442424~49442652:-
THCA	cis	rs253959	0.595	rs11241361	ENSG00000272265.1	CTD-2287O16.4	5.49	6.49e-08	1.04e-05	0.29	0.25	Bipolar disorder and schizophrenia;	chr5:116112611	chr5:116078110~116078570:-
THCA	cis	rs860295	0.58	rs12032720	ENSG00000160766.13	GBAP1	-5.49	6.5e-08	1.04e-05	-0.29	-0.25	Body mass index;	chr1:155305169	chr1:155213821~155227422:-
THCA	cis	rs9652601	1	rs9652601	ENSG00000274038.1	RP11-66H6.4	-5.49	6.5e-08	1.04e-05	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11080508	chr16:11056556~11057034:+
THCA	cis	rs7851660	0.874	rs7037175	ENSG00000214417.4	KRT18P13	-5.49	6.51e-08	1.04e-05	-0.21	-0.25	Strep throat;	chr9:97869380	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs7868534	ENSG00000214417.4	KRT18P13	-5.49	6.51e-08	1.04e-05	-0.21	-0.25	Strep throat;	chr9:97870324	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs10818175	ENSG00000214417.4	KRT18P13	-5.49	6.51e-08	1.04e-05	-0.21	-0.25	Strep throat;	chr9:97871104	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs1955144	ENSG00000214417.4	KRT18P13	-5.49	6.51e-08	1.04e-05	-0.21	-0.25	Strep throat;	chr9:97872307	chr9:97698922~97700734:+
THCA	cis	rs7727544	0.735	rs274558	ENSG00000263597.1	MIR3936	-5.49	6.51e-08	1.04e-05	-0.23	-0.25	Blood metabolite levels;	chr5:132385482	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.735	rs274557	ENSG00000263597.1	MIR3936	-5.49	6.51e-08	1.04e-05	-0.23	-0.25	Blood metabolite levels;	chr5:132385512	chr5:132365490~132365599:-
THCA	cis	rs9843304	0.528	rs12488126	ENSG00000244503.1	RP11-278L15.6	-5.49	6.51e-08	1.04e-05	-0.3	-0.25	Gallstone disease;	chr3:149474889	chr3:149494660~149495995:+
THCA	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-5.49	6.51e-08	1.04e-05	-0.22	-0.25	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
THCA	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	5.49	6.51e-08	1.04e-05	0.18	0.25	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
THCA	cis	rs67478160	0.634	rs2024669	ENSG00000258735.1	LINC00637	-5.49	6.51e-08	1.04e-05	-0.3	-0.25	Schizophrenia;	chr14:103809265	chr14:103847721~103858049:+
THCA	cis	rs950169	0.544	rs12913702	ENSG00000188388.10	GOLGA6L3	5.49	6.52e-08	1.04e-05	0.33	0.25	Schizophrenia;	chr15:84609953	chr15:85240472~85247170:+
THCA	cis	rs12664251	0.706	rs1775620	ENSG00000253194.1	RP11-351A11.1	-5.49	6.52e-08	1.04e-05	-0.34	-0.25	Schizophrenia;	chr6:119012273	chr6:118934785~119031541:+
THCA	cis	rs6545883	0.868	rs6545887	ENSG00000270820.4	RP11-355B11.2	5.49	6.52e-08	1.04e-05	0.21	0.25	Tuberculosis;	chr2:61601683	chr2:61471188~61484130:+
THCA	cis	rs9652601	0.959	rs9652582	ENSG00000274038.1	RP11-66H6.4	-5.49	6.52e-08	1.04e-05	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11080707	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.959	rs2041670	ENSG00000274038.1	RP11-66H6.4	-5.49	6.52e-08	1.04e-05	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11080795	chr16:11056556~11057034:+
THCA	cis	rs2018683	0.509	rs221192	ENSG00000272568.4	CTB-113D17.1	-5.49	6.52e-08	1.04e-05	-0.28	-0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28975293	chr7:28979967~29013367:+
THCA	cis	rs2284219	0.565	rs2284217	ENSG00000226874.1	AC005154.8	-5.49	6.52e-08	1.04e-05	-0.3	-0.25	Type 2 diabetes;	chr7:30673992	chr7:30544053~30544431:+
THCA	cis	rs897984	0.762	rs897986	ENSG00000260911.2	RP11-196G11.2	-5.49	6.52e-08	1.04e-05	-0.2	-0.25	Dementia with Lewy bodies;	chr16:30969581	chr16:31043150~31049868:+
THCA	cis	rs897984	0.721	rs28360557	ENSG00000260911.2	RP11-196G11.2	-5.49	6.52e-08	1.04e-05	-0.2	-0.25	Dementia with Lewy bodies;	chr16:30971939	chr16:31043150~31049868:+
THCA	cis	rs897984	0.684	rs6950	ENSG00000260911.2	RP11-196G11.2	-5.49	6.52e-08	1.04e-05	-0.2	-0.25	Dementia with Lewy bodies;	chr16:30984348	chr16:31043150~31049868:+
THCA	cis	rs897984	0.762	rs2305880	ENSG00000260911.2	RP11-196G11.2	-5.49	6.52e-08	1.04e-05	-0.2	-0.25	Dementia with Lewy bodies;	chr16:30988141	chr16:31043150~31049868:+
THCA	cis	rs7119	0.689	rs11630557	ENSG00000259362.2	RP11-307C19.1	-5.49	6.52e-08	1.04e-05	-0.35	-0.25	Type 2 diabetes;	chr15:77528370	chr15:77525540~77534110:+
THCA	cis	rs853679	0.76	rs2299029	ENSG00000226314.6	ZNF192P1	-5.49	6.52e-08	1.04e-05	-0.34	-0.25	Depression;	chr6:28231053	chr6:28161781~28169594:+
THCA	cis	rs964184	0.507	rs6589565	ENSG00000254851.1	RP11-109L13.1	-5.49	6.52e-08	1.04e-05	-0.51	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116769521	chr11:117135528~117138582:+
THCA	cis	rs12188164	0.714	rs11741954	ENSG00000225138.6	CTD-2228K2.7	5.49	6.53e-08	1.04e-05	0.27	0.25	Cystic fibrosis severity;	chr5:421340	chr5:473236~480884:+
THCA	cis	rs2915864	1	rs2906073	ENSG00000280047.1	CTC-463A16.1	-5.49	6.53e-08	1.04e-05	-0.39	-0.25	Facial morphology (factor 20);	chr5:142197242	chr5:142165767~142168387:+
THCA	cis	rs875971	0.964	rs778735	ENSG00000223473.2	GS1-124K5.3	5.49	6.53e-08	1.04e-05	0.16	0.25	Aortic root size;	chr7:66349822	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs937495	ENSG00000223473.2	GS1-124K5.3	-5.49	6.53e-08	1.04e-05	-0.16	-0.25	Aortic root size;	chr7:66314811	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs2036264	ENSG00000223473.2	GS1-124K5.3	-5.49	6.53e-08	1.04e-05	-0.16	-0.25	Aortic root size;	chr7:66334917	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs7783613	ENSG00000223473.2	GS1-124K5.3	-5.49	6.53e-08	1.04e-05	-0.16	-0.25	Aortic root size;	chr7:66340274	chr7:66491049~66493566:-
THCA	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-5.49	6.53e-08	1.04e-05	-0.46	-0.25	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
THCA	cis	rs77972916	0.536	rs62137421	ENSG00000234936.1	AC010883.5	5.49	6.53e-08	1.04e-05	0.28	0.25	Granulocyte percentage of myeloid white cells;	chr2:43366952	chr2:43229573~43233394:+
THCA	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-5.49	6.54e-08	1.04e-05	-0.38	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
THCA	cis	rs875971	0.505	rs2462573	ENSG00000273142.1	RP11-458F8.4	5.49	6.54e-08	1.04e-05	0.2	0.25	Aortic root size;	chr7:66042405	chr7:66902857~66906297:+
THCA	cis	rs7576126	0.515	rs1866050	ENSG00000234255.7	AC012370.3	5.49	6.54e-08	1.04e-05	0.31	0.25	Severe influenza A (H1N1) infection;	chr2:65450595	chr2:65439888~65456571:-
THCA	cis	rs883924	0.872	rs10126032	ENSG00000231107.1	LINC01508	5.49	6.54e-08	1.04e-05	0.25	0.25	Hepatitis C induced liver fibrosis;	chr9:90419919	chr9:90300902~90433505:-
THCA	cis	rs2243480	1	rs10807701	ENSG00000232559.3	GS1-124K5.12	-5.49	6.55e-08	1.04e-05	-0.37	-0.25	Diabetic kidney disease;	chr7:66259699	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1499613	ENSG00000232559.3	GS1-124K5.12	-5.49	6.55e-08	1.04e-05	-0.37	-0.25	Diabetic kidney disease;	chr7:66265873	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1553174	ENSG00000232559.3	GS1-124K5.12	-5.49	6.55e-08	1.04e-05	-0.37	-0.25	Diabetic kidney disease;	chr7:66266207	chr7:66554588~66576923:-
THCA	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	5.49	6.55e-08	1.04e-05	0.31	0.25	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
THCA	cis	rs16846053	1	rs16846053	ENSG00000227403.1	AC009299.3	5.49	6.55e-08	1.04e-05	0.5	0.25	Blood osmolality (transformed sodium);	chr2:161709535	chr2:161244739~161249050:+
THCA	cis	rs8062405	0.964	rs78613234	ENSG00000278665.1	RP11-666O2.4	5.49	6.55e-08	1.04e-05	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62036624	ENSG00000278665.1	RP11-666O2.4	5.49	6.55e-08	1.04e-05	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28599241~28601881:-
THCA	cis	rs7829975	0.807	rs519019	ENSG00000254153.1	CTA-398F10.2	5.49	6.55e-08	1.04e-05	0.26	0.25	Mood instability;	chr8:8737594	chr8:8456909~8461337:-
THCA	cis	rs763567	1	rs3903239	ENSG00000271811.1	RP1-79C4.4	-5.49	6.55e-08	1.04e-05	-0.29	-0.25	Tonsillectomy;	chr1:170600176	chr1:170667381~170669425:+
THCA	cis	rs763567	1	rs12760630	ENSG00000271811.1	RP1-79C4.4	-5.49	6.55e-08	1.04e-05	-0.29	-0.25	Tonsillectomy;	chr1:170600548	chr1:170667381~170669425:+
THCA	cis	rs763567	0.967	rs7412231	ENSG00000271811.1	RP1-79C4.4	-5.49	6.55e-08	1.04e-05	-0.29	-0.25	Tonsillectomy;	chr1:170601358	chr1:170667381~170669425:+
THCA	cis	rs763567	1	rs10919437	ENSG00000271811.1	RP1-79C4.4	-5.49	6.55e-08	1.04e-05	-0.29	-0.25	Tonsillectomy;	chr1:170603805	chr1:170667381~170669425:+
THCA	cis	rs763567	1	rs2206062	ENSG00000271811.1	RP1-79C4.4	-5.49	6.55e-08	1.04e-05	-0.29	-0.25	Tonsillectomy;	chr1:170606966	chr1:170667381~170669425:+
THCA	cis	rs763567	1	rs6677540	ENSG00000271811.1	RP1-79C4.4	-5.49	6.55e-08	1.04e-05	-0.29	-0.25	Tonsillectomy;	chr1:170614370	chr1:170667381~170669425:+
THCA	cis	rs763567	0.967	rs6690642	ENSG00000271811.1	RP1-79C4.4	-5.49	6.55e-08	1.04e-05	-0.29	-0.25	Tonsillectomy;	chr1:170614803	chr1:170667381~170669425:+
THCA	cis	rs8062405	1	rs4788102	ENSG00000278665.1	RP11-666O2.4	5.49	6.55e-08	1.04e-05	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28599241~28601881:-
THCA	cis	rs7727544	0.645	rs272857	ENSG00000224431.1	AC063976.7	5.49	6.55e-08	1.04e-05	0.21	0.25	Blood metabolite levels;	chr5:132349604	chr5:132199456~132203487:+
THCA	cis	rs442309	0.846	rs382412	ENSG00000238280.1	RP11-436D10.3	-5.49	6.56e-08	1.04e-05	-0.3	-0.25	Vogt-Koyanagi-Harada syndrome;	chr10:62730004	chr10:62793562~62805887:-
THCA	cis	rs16976116	0.572	rs16976015	ENSG00000279145.1	RP11-547D13.1	5.49	6.56e-08	1.04e-05	0.26	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55154852	chr15:55171972~55178175:-
THCA	cis	rs7927592	0.513	rs630225	ENSG00000212093.1	AP000807.1	5.49	6.56e-08	1.04e-05	0.26	0.25	Total body bone mineral density;	chr11:68427143	chr11:68506083~68506166:-
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000275400.1	RP4-756H11.5	-5.49	6.56e-08	1.05e-05	-0.23	-0.25	Calcium levels;	chr7:65829754	chr7:66553805~66554199:-
THCA	cis	rs6445975	0.666	rs9311674	ENSG00000272360.1	RP11-359I18.5	5.49	6.57e-08	1.05e-05	0.28	0.25	Systemic lupus erythematosus;	chr3:58404975	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs4518147	ENSG00000272360.1	RP11-359I18.5	5.49	6.57e-08	1.05e-05	0.28	0.25	Systemic lupus erythematosus;	chr3:58407847	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.617	rs13071422	ENSG00000272360.1	RP11-359I18.5	5.49	6.57e-08	1.05e-05	0.28	0.25	Systemic lupus erythematosus;	chr3:58413086	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs6773099	ENSG00000272360.1	RP11-359I18.5	5.49	6.57e-08	1.05e-05	0.28	0.25	Systemic lupus erythematosus;	chr3:58417725	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.578	rs6772652	ENSG00000272360.1	RP11-359I18.5	5.49	6.57e-08	1.05e-05	0.28	0.25	Systemic lupus erythematosus;	chr3:58420966	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.578	rs6782218	ENSG00000272360.1	RP11-359I18.5	5.49	6.57e-08	1.05e-05	0.28	0.25	Systemic lupus erythematosus;	chr3:58423038	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.572	rs12485999	ENSG00000272360.1	RP11-359I18.5	5.49	6.57e-08	1.05e-05	0.28	0.25	Systemic lupus erythematosus;	chr3:58424036	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs4075152	ENSG00000272360.1	RP11-359I18.5	-5.49	6.57e-08	1.05e-05	-0.28	-0.25	Systemic lupus erythematosus;	chr3:58399467	chr3:58490830~58491291:-
THCA	cis	rs758324	0.687	rs141249	ENSG00000237714.1	P4HA2-AS1	-5.49	6.57e-08	1.05e-05	-0.38	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132149813	chr5:132184876~132192808:+
THCA	cis	rs2342371	0.641	rs4916427	ENSG00000273013.1	CTD-2002J20.1	-5.49	6.57e-08	1.05e-05	-0.24	-0.25	Fat distribution (HIV);	chr3:196367342	chr3:196474801~196475394:+
THCA	cis	rs9393777	0.92	rs34071253	ENSG00000219392.1	RP1-265C24.5	-5.49	6.58e-08	1.05e-05	-0.47	-0.25	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28115628~28116551:+
THCA	cis	rs2281636	0.931	rs2804419	ENSG00000260475.1	RP11-85A1.3	-5.49	6.58e-08	1.05e-05	-0.22	-0.25	Obesity-related traits;	chr10:99749356	chr10:99621055~99621918:+
THCA	cis	rs11795343	0.509	rs7023269	ENSG00000232303.2	DFFBP1	-5.49	6.58e-08	1.05e-05	-0.29	-0.25	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32524171	chr9:32566148~32567126:-
THCA	cis	rs67981189	0.57	rs67188216	ENSG00000269927.1	RP6-91H8.3	5.49	6.58e-08	1.05e-05	0.3	0.25	Schizophrenia;	chr14:71042607	chr14:71141125~71143253:-
THCA	cis	rs5758659	0.652	rs133347	ENSG00000227370.1	RP4-669P10.19	-5.49	6.58e-08	1.05e-05	-0.23	-0.25	Cognitive function;	chr22:42027641	chr22:42132543~42132998:+
THCA	cis	rs7083	1	rs588763	ENSG00000254851.1	RP11-109L13.1	5.49	6.58e-08	1.05e-05	0.33	0.25	Blood protein levels;	chr11:117246065	chr11:117135528~117138582:+
THCA	cis	rs7646881	0.509	rs56321207	ENSG00000240207.5	RP11-379F4.4	-5.49	6.59e-08	1.05e-05	-0.35	-0.25	Tetralogy of Fallot;	chr3:158666944	chr3:158732263~158784070:+
THCA	cis	rs5758511	0.773	rs10154700	ENSG00000281538.1	RP4-669P10.20	-5.49	6.59e-08	1.05e-05	-0.28	-0.25	Birth weight;	chr22:41969069	chr22:42138060~42139726:+
THCA	cis	rs1577330	0.516	rs3861014	ENSG00000254396.1	RP11-56F10.3	5.49	6.59e-08	1.05e-05	0.42	0.25	IgG glycosylation;	chr9:27103334	chr9:27102630~27104728:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000223473.2	GS1-124K5.3	5.49	6.59e-08	1.05e-05	0.16	0.25	Aortic root size;	chr7:66749580	chr7:66491049~66493566:-
THCA	cis	rs801193	0.66	rs4610622	ENSG00000223473.2	GS1-124K5.3	5.49	6.59e-08	1.05e-05	0.16	0.25	Aortic root size;	chr7:66759510	chr7:66491049~66493566:-
THCA	cis	rs595244	1	rs686861	ENSG00000259705.1	RP11-227D13.1	5.49	6.59e-08	1.05e-05	0.43	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48592808	chr15:48645951~48652016:+
THCA	cis	rs595244	1	rs655015	ENSG00000259705.1	RP11-227D13.1	5.49	6.59e-08	1.05e-05	0.43	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48598910	chr15:48645951~48652016:+
THCA	cis	rs4604234	0.708	rs6906392	ENSG00000272129.1	RP11-250B2.6	-5.49	6.6e-08	1.05e-05	-0.62	-0.25	Cancer;	chr6:80337730	chr6:80355424~80356859:+
THCA	cis	rs7085104	0.7	rs10883785	ENSG00000213061.2	PFN1P11	5.49	6.6e-08	1.05e-05	0.3	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102838011~102845473:-
THCA	cis	rs2163813	1	rs12973901	ENSG00000275540.1	CTC-559E9.12	-5.49	6.61e-08	1.05e-05	-0.3	-0.25	Toenail selenium levels;	chr19:19712461	chr19:19740884~19750127:+
THCA	cis	rs1707322	0.638	rs1707302	ENSG00000234329.1	RP11-767N6.2	-5.49	6.61e-08	1.05e-05	-0.24	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000273796.1	LL21NC02-21A1.1	5.49	6.62e-08	1.05e-05	0.26	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45403809~45404369:-
THCA	cis	rs1075232	1	rs67634762	ENSG00000215302.7	CTD-3092A11.1	-5.49	6.62e-08	1.05e-05	-0.54	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30470779~30507623:+
THCA	cis	rs2086824	0.702	rs3114896	ENSG00000274627.1	RP11-104N10.2	-5.49	6.62e-08	1.05e-05	-0.25	-0.25	Multiple myeloma (IgH translocation);	chr16:89327154	chr16:89516797~89522217:+
THCA	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	5.49	6.62e-08	1.05e-05	0.42	0.25	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	5.49	6.62e-08	1.05e-05	0.42	0.25	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	5.49	6.62e-08	1.05e-05	0.42	0.25	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	5.49	6.62e-08	1.05e-05	0.42	0.25	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
THCA	cis	rs10875746	0.551	rs2054904	ENSG00000258234.1	RP11-370I10.2	5.49	6.63e-08	1.05e-05	0.29	0.25	Longevity (90 years and older);	chr12:48330571	chr12:48231098~48284210:-
THCA	cis	rs801193	0.66	rs10950049	ENSG00000223473.2	GS1-124K5.3	5.49	6.63e-08	1.05e-05	0.16	0.25	Aortic root size;	chr7:66765873	chr7:66491049~66493566:-
THCA	cis	rs79040073	0.637	rs73394333	ENSG00000259531.2	RP11-295H24.3	5.49	6.63e-08	1.06e-05	0.35	0.25	Lung cancer in ever smokers;	chr15:49278719	chr15:49365124~49366685:-
THCA	cis	rs6088590	1	rs6088595	ENSG00000276073.1	RP5-1125A11.7	-5.49	6.63e-08	1.06e-05	-0.24	-0.25	Coronary artery disease;	chr20:34770696	chr20:33985617~33988989:-
THCA	cis	rs997295	0.535	rs11632776	ENSG00000270964.1	RP11-502I4.3	-5.49	6.64e-08	1.06e-05	-0.2	-0.25	Motion sickness;	chr15:67560307	chr15:67541072~67542604:-
THCA	cis	rs6968419	0.755	rs4730720	ENSG00000237870.5	AC073130.1	-5.49	6.64e-08	1.06e-05	-0.27	-0.25	Intraocular pressure;	chr7:116255181	chr7:116275606~116286734:-
THCA	cis	rs758324	0.732	rs156044	ENSG00000237714.1	P4HA2-AS1	-5.49	6.65e-08	1.06e-05	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132156834	chr5:132184876~132192808:+
THCA	cis	rs758324	0.732	rs156045	ENSG00000237714.1	P4HA2-AS1	-5.49	6.65e-08	1.06e-05	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132156923	chr5:132184876~132192808:+
THCA	cis	rs758324	0.732	rs156046	ENSG00000237714.1	P4HA2-AS1	-5.49	6.65e-08	1.06e-05	-0.36	-0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132157030	chr5:132184876~132192808:+
THCA	cis	rs7829975	0.606	rs6422352	ENSG00000233609.3	RP11-62H7.2	-5.49	6.65e-08	1.06e-05	-0.24	-0.25	Mood instability;	chr8:8936683	chr8:8961200~8979025:+
THCA	cis	rs7829975	0.606	rs891570	ENSG00000233609.3	RP11-62H7.2	-5.49	6.65e-08	1.06e-05	-0.24	-0.25	Mood instability;	chr8:8936944	chr8:8961200~8979025:+
THCA	cis	rs9302635	0.515	rs36033103	ENSG00000260886.1	TAT-AS1	5.49	6.66e-08	1.06e-05	0.53	0.25	Blood protein levels;	chr16:72108139	chr16:71565789~71578187:+
THCA	cis	rs16976116	0.619	rs7172575	ENSG00000279145.1	RP11-547D13.1	-5.49	6.66e-08	1.06e-05	-0.26	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55170346	chr15:55171972~55178175:-
THCA	cis	rs9329221	0.905	rs4433149	ENSG00000261451.1	RP11-981G7.1	-5.49	6.66e-08	1.06e-05	-0.3	-0.25	Neuroticism;	chr8:10391758	chr8:10433672~10438312:+
THCA	cis	rs28374715	0.635	rs28557159	ENSG00000247556.5	OIP5-AS1	5.49	6.66e-08	1.06e-05	0.23	0.25	Ulcerative colitis;	chr15:41365155	chr15:41283990~41309737:+
THCA	cis	rs2993535	1	rs2993538	ENSG00000233626.2	RP11-565J7.1	5.49	6.67e-08	1.06e-05	0.69	0.25	Hip circumference adjusted for BMI;	chr1:211976919	chr1:211936249~211936634:+
THCA	cis	rs2243480	0.901	rs778730	ENSG00000232559.3	GS1-124K5.12	5.49	6.67e-08	1.06e-05	0.37	0.25	Diabetic kidney disease;	chr7:66358338	chr7:66554588~66576923:-
THCA	cis	rs2732480	0.5	rs7966829	ENSG00000240399.1	RP1-228P16.1	5.49	6.67e-08	1.06e-05	0.25	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48054813~48055591:-
THCA	cis	rs10895275	0.625	rs12222063	ENSG00000277459.1	RP11-732A21.3	-5.49	6.67e-08	1.06e-05	-0.18	-0.25	Migraine;	chr11:102172060	chr11:102109827~102110457:-
THCA	cis	rs17345786	0.906	rs59359251	ENSG00000256628.3	ZBTB11-AS1	5.49	6.67e-08	1.06e-05	0.31	0.25	Colonoscopy-negative controls vs population controls;	chr3:101427518	chr3:101676475~101679217:+
THCA	cis	rs17345786	0.906	rs55710435	ENSG00000256628.3	ZBTB11-AS1	5.49	6.67e-08	1.06e-05	0.31	0.25	Colonoscopy-negative controls vs population controls;	chr3:101461486	chr3:101676475~101679217:+
THCA	cis	rs17345786	0.906	rs72944107	ENSG00000256628.3	ZBTB11-AS1	5.49	6.67e-08	1.06e-05	0.31	0.25	Colonoscopy-negative controls vs population controls;	chr3:101478346	chr3:101676475~101679217:+
THCA	cis	rs7044106	0.791	rs10984997	ENSG00000270917.1	RP11-27I1.6	-5.49	6.68e-08	1.06e-05	-0.35	-0.25	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120812475~120812845:-
THCA	cis	rs6792584	1	rs9818109	ENSG00000241316.5	SUCLG2-AS1	5.49	6.68e-08	1.06e-05	0.25	0.25	Corneal astigmatism;	chr3:67478315	chr3:67654697~67947713:+
THCA	cis	rs7897654	0.571	rs12764049	ENSG00000213277.3	MARCKSL1P1	5.49	6.68e-08	1.06e-05	0.29	0.25	Schizophrenia;	chr10:102875199	chr10:103175554~103176094:+
THCA	cis	rs12497850	1	rs12497850	ENSG00000229759.1	MRPS18AP1	5.49	6.69e-08	1.06e-05	0.32	0.25	Parkinson's disease;	chr3:48711556	chr3:48256350~48256938:-
THCA	cis	rs12497850	1	rs6788650	ENSG00000229759.1	MRPS18AP1	5.49	6.69e-08	1.06e-05	0.32	0.25	Parkinson's disease;	chr3:48712110	chr3:48256350~48256938:-
THCA	cis	rs1552244	1	rs9879080	ENSG00000232901.1	CYCSP10	5.49	6.69e-08	1.06e-05	0.32	0.25	Alzheimer's disease;	chr3:10042540	chr3:10000647~10000940:-
THCA	cis	rs11089937	0.512	rs34963809	ENSG00000211638.2	IGLV8-61	-5.49	6.69e-08	1.06e-05	-0.19	-0.25	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.568	rs35626600	ENSG00000211638.2	IGLV8-61	-5.49	6.69e-08	1.06e-05	-0.19	-0.25	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.539	rs34228957	ENSG00000211638.2	IGLV8-61	-5.49	6.69e-08	1.06e-05	-0.19	-0.25	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22098700~22099212:+
THCA	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	5.49	6.7e-08	1.07e-05	0.35	0.25	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
THCA	cis	rs2243480	1	rs10950032	ENSG00000232559.3	GS1-124K5.12	-5.49	6.7e-08	1.07e-05	-0.37	-0.25	Diabetic kidney disease;	chr7:66273604	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6958420	ENSG00000232559.3	GS1-124K5.12	-5.49	6.7e-08	1.07e-05	-0.37	-0.25	Diabetic kidney disease;	chr7:66286184	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1392104	ENSG00000232559.3	GS1-124K5.12	-5.49	6.7e-08	1.07e-05	-0.37	-0.25	Diabetic kidney disease;	chr7:66294120	chr7:66554588~66576923:-
THCA	cis	rs7824557	0.628	rs3174048	ENSG00000154316.13	TDH	-5.49	6.7e-08	1.07e-05	-0.18	-0.25	Retinal vascular caliber;	chr8:11327428	chr8:11339637~11368452:+
THCA	cis	rs3204270	0.639	rs8074225	ENSG00000262049.1	RP13-1032I1.7	5.49	6.71e-08	1.07e-05	0.23	0.25	Dental caries;	chr17:81651240	chr17:81701324~81703300:-
THCA	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	5.49	6.71e-08	1.07e-05	0.42	0.25	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	5.49	6.71e-08	1.07e-05	0.42	0.25	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
THCA	cis	rs4591358	0.571	rs4850366	ENSG00000223466.1	AC064834.2	-5.49	6.71e-08	1.07e-05	-0.3	-0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195538742	chr2:195533035~195538681:+
THCA	cis	rs9952991	0.941	rs9952749	ENSG00000260302.1	RP11-973H7.1	-5.49	6.71e-08	1.07e-05	-0.4	-0.25	Inflammatory skin disease;	chr18:12780457	chr18:12774651~12775923:-
THCA	cis	rs9952991	0.943	rs9952753	ENSG00000260302.1	RP11-973H7.1	-5.49	6.71e-08	1.07e-05	-0.4	-0.25	Inflammatory skin disease;	chr18:12780464	chr18:12774651~12775923:-
THCA	cis	rs12681287	0.752	rs4534114	ENSG00000254231.1	CTD-2284J15.1	5.49	6.71e-08	1.07e-05	0.28	0.25	Caudate activity during reward;	chr8:86259727	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs12681438	ENSG00000254231.1	CTD-2284J15.1	5.49	6.71e-08	1.07e-05	0.28	0.25	Caudate activity during reward;	chr8:86280860	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs13262673	ENSG00000254231.1	CTD-2284J15.1	5.49	6.71e-08	1.07e-05	0.28	0.25	Caudate activity during reward;	chr8:86281371	chr8:86333274~86343314:-
THCA	cis	rs6957923	0.668	rs6956784	ENSG00000234286.1	AC006026.13	-5.49	6.71e-08	1.07e-05	-0.3	-0.25	Height;	chr7:23534379	chr7:23680195~23680786:-
THCA	cis	rs7267979	0.527	rs6083891	ENSG00000125804.12	FAM182A	5.49	6.71e-08	1.07e-05	0.31	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26054655~26086917:+
THCA	cis	rs12682352	0.535	rs12677550	ENSG00000253893.2	FAM85B	5.49	6.72e-08	1.07e-05	0.32	0.25	Neuroticism;	chr8:8786812	chr8:8167819~8226614:-
THCA	cis	rs593531	0.614	rs623065	ENSG00000255440.1	RP11-632K5.2	5.49	6.72e-08	1.07e-05	0.3	0.25	Neuroticism;	chr11:74360165	chr11:74409060~74416379:+
THCA	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	5.49	6.72e-08	1.07e-05	0.34	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
THCA	cis	rs4713118	0.513	rs9368547	ENSG00000220721.1	OR1F12	5.49	6.73e-08	1.07e-05	0.3	0.25	Parkinson's disease;	chr6:28060289	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.513	rs183244	ENSG00000220721.1	OR1F12	5.49	6.73e-08	1.07e-05	0.3	0.25	Parkinson's disease;	chr6:28064060	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.513	rs149950	ENSG00000220721.1	OR1F12	5.49	6.73e-08	1.07e-05	0.3	0.25	Parkinson's disease;	chr6:28065261	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.513	rs149951	ENSG00000220721.1	OR1F12	5.49	6.73e-08	1.07e-05	0.3	0.25	Parkinson's disease;	chr6:28065309	chr6:28073316~28074233:+
THCA	cis	rs2810114	0.76	rs2810105	ENSG00000269927.1	RP6-91H8.3	-5.49	6.73e-08	1.07e-05	-0.29	-0.25	Alcohol dependence;	chr14:70957934	chr14:71141125~71143253:-
THCA	cis	rs2810114	0.916	rs2810099	ENSG00000269927.1	RP6-91H8.3	-5.49	6.73e-08	1.07e-05	-0.29	-0.25	Alcohol dependence;	chr14:70965704	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.529	rs17108808	ENSG00000269927.1	RP6-91H8.3	5.49	6.73e-08	1.07e-05	0.29	0.25	Schizophrenia;	chr14:70974835	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.501	rs3829954	ENSG00000269927.1	RP6-91H8.3	5.49	6.73e-08	1.07e-05	0.29	0.25	Schizophrenia;	chr14:70988823	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.529	rs17108862	ENSG00000269927.1	RP6-91H8.3	5.49	6.73e-08	1.07e-05	0.29	0.25	Schizophrenia;	chr14:70997949	chr14:71141125~71143253:-
THCA	cis	rs2337406	1	rs11845269	ENSG00000211974.3	IGHV2-70	-5.49	6.73e-08	1.07e-05	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106683851	chr14:106723574~106724093:-
THCA	cis	rs2337406	1	rs3858878	ENSG00000211974.3	IGHV2-70	-5.49	6.73e-08	1.07e-05	-0.24	-0.25	Alzheimer's disease (late onset);	chr14:106688061	chr14:106723574~106724093:-
THCA	cis	rs2993535	1	rs2808388	ENSG00000233626.2	RP11-565J7.1	5.49	6.73e-08	1.07e-05	0.68	0.25	Hip circumference adjusted for BMI;	chr1:211949879	chr1:211936249~211936634:+
THCA	cis	rs1479090	0.805	rs4691895	ENSG00000250027.1	RP11-563E2.2	-5.49	6.73e-08	1.07e-05	-0.26	-0.25	Lung cancer;	chr4:163127047	chr4:163108785~163119965:+
THCA	cis	rs7412746	0.658	rs6669855	ENSG00000231073.1	RP11-316M1.3	5.49	6.74e-08	1.07e-05	0.3	0.25	Melanoma;	chr1:150888753	chr1:150973123~150975534:+
THCA	cis	rs2179367	0.632	rs9498348	ENSG00000268592.3	RAET1E-AS1	5.49	6.74e-08	1.07e-05	0.36	0.25	Dupuytren's disease;	chr6:149418352	chr6:149863494~149919507:+
THCA	cis	rs3806843	0.762	rs3756337	ENSG00000202515.1	VTRNA1-3	-5.49	6.74e-08	1.07e-05	-0.29	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140806853	chr5:140726158~140726246:+
THCA	cis	rs2243480	1	rs402418	ENSG00000230295.1	RP11-458F8.2	-5.49	6.74e-08	1.07e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66044482	chr7:66880708~66882981:+
THCA	cis	rs6928977	0.863	rs6918097	ENSG00000231028.7	LINC00271	5.49	6.74e-08	1.07e-05	0.2	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135314411	chr6:135497801~135716055:+
THCA	cis	rs17301013	0.507	rs7515116	ENSG00000227373.4	RP11-160H22.5	-5.49	6.74e-08	1.07e-05	-0.37	-0.25	Systemic lupus erythematosus;	chr1:174474516	chr1:174115300~174160004:-
THCA	cis	rs853679	0.546	rs200996	ENSG00000226314.6	ZNF192P1	-5.49	6.75e-08	1.07e-05	-0.41	-0.25	Depression;	chr6:27844050	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs200990	ENSG00000226314.6	ZNF192P1	-5.49	6.75e-08	1.07e-05	-0.41	-0.25	Depression;	chr6:27848045	chr6:28161781~28169594:+
THCA	cis	rs7674212	0.541	rs11727498	ENSG00000251288.2	RP11-10L12.2	-5.49	6.75e-08	1.07e-05	-0.32	-0.25	Type 2 diabetes;	chr4:103179830	chr4:102751401~102752641:+
THCA	cis	rs7829975	0.572	rs7005000	ENSG00000233609.3	RP11-62H7.2	-5.49	6.75e-08	1.07e-05	-0.24	-0.25	Mood instability;	chr8:8939092	chr8:8961200~8979025:+
THCA	cis	rs4073416	0.967	rs11850120	ENSG00000276116.2	FUT8-AS1	5.49	6.75e-08	1.07e-05	0.26	0.25	N-glycan levels;	chr14:65793661	chr14:65411170~65412690:-
THCA	cis	rs2029362	0.846	rs11030027	ENSG00000245573.6	BDNF-AS	5.49	6.75e-08	1.07e-05	0.19	0.25	Total body bone mineral density;	chr11:27490177	chr11:27506838~27698174:+
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000280069.1	CTD-2349P21.3	-5.49	6.75e-08	1.07e-05	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30738182~30740275:+
THCA	cis	rs10792665	0.604	rs7933350	ENSG00000255503.1	RP11-113K21.4	-5.49	6.75e-08	1.07e-05	-0.26	-0.25	Obesity-related traits;	chr11:82940951	chr11:83072402~83097196:-
THCA	cis	rs4908760	0.864	rs6701331	ENSG00000232912.4	RP5-1115A15.1	5.49	6.75e-08	1.07e-05	0.24	0.25	Vitiligo;	chr1:8610147	chr1:8424645~8434838:+
THCA	cis	rs7772486	0.686	rs6933161	ENSG00000270638.1	RP3-466P17.1	-5.49	6.76e-08	1.07e-05	-0.19	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs9399565	ENSG00000270638.1	RP3-466P17.1	-5.49	6.76e-08	1.07e-05	-0.19	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145735570~145737218:+
THCA	cis	rs2243480	1	rs383402	ENSG00000232559.3	GS1-124K5.12	-5.49	6.76e-08	1.07e-05	-0.35	-0.25	Diabetic kidney disease;	chr7:66121666	chr7:66554588~66576923:-
THCA	cis	rs6547741	1	rs13026621	ENSG00000234072.1	AC074117.10	5.49	6.76e-08	1.07e-05	0.19	0.25	Oral cavity cancer;	chr2:27584757	chr2:27356246~27367622:+
THCA	cis	rs6547741	0.967	rs4665995	ENSG00000234072.1	AC074117.10	5.49	6.76e-08	1.07e-05	0.19	0.25	Oral cavity cancer;	chr2:27590960	chr2:27356246~27367622:+
THCA	cis	rs6547741	0.967	rs4665996	ENSG00000234072.1	AC074117.10	5.49	6.76e-08	1.07e-05	0.19	0.25	Oral cavity cancer;	chr2:27591476	chr2:27356246~27367622:+
THCA	cis	rs9843304	0.528	rs1317213	ENSG00000240541.2	TM4SF1-AS1	-5.48	6.77e-08	1.08e-05	-0.22	-0.25	Gallstone disease;	chr3:149473363	chr3:149377778~149386583:+
THCA	cis	rs253959	0.545	rs7734133	ENSG00000272265.1	CTD-2287O16.4	5.48	6.78e-08	1.08e-05	0.29	0.25	Bipolar disorder and schizophrenia;	chr5:116096418	chr5:116078110~116078570:-
THCA	cis	rs914615	0.508	rs7535292	ENSG00000225855.5	RUSC1-AS1	5.48	6.78e-08	1.08e-05	0.16	0.25	Urinary albumin-to-creatinine ratio;	chr1:155155273	chr1:155316863~155324176:-
THCA	cis	rs2562456	0.833	rs2562507	ENSG00000268119.4	CTD-2561J22.5	-5.48	6.78e-08	1.08e-05	-0.3	-0.25	Pain;	chr19:21543535	chr19:21444241~21463908:-
THCA	cis	rs7394190	0.81	rs7394152	ENSG00000271848.1	RP11-464F9.21	-5.48	6.79e-08	1.08e-05	-0.32	-0.25	Incident atrial fibrillation;	chr10:73661688	chr10:73654039~73674719:+
THCA	cis	rs12188164	0.686	rs72711370	ENSG00000225138.6	CTD-2228K2.7	5.48	6.8e-08	1.08e-05	0.27	0.25	Cystic fibrosis severity;	chr5:420942	chr5:473236~480884:+
THCA	cis	rs36715	1	rs36710	ENSG00000245937.6	LINC01184	5.48	6.81e-08	1.08e-05	0.26	0.25	Breast cancer;	chr5:128223752	chr5:127940426~128083172:-
THCA	cis	rs6545883	0.868	rs6748003	ENSG00000270820.4	RP11-355B11.2	5.48	6.81e-08	1.08e-05	0.21	0.25	Tuberculosis;	chr2:61579565	chr2:61471188~61484130:+
THCA	cis	rs2839186	0.632	rs17176110	ENSG00000239415.1	AP001469.9	5.48	6.81e-08	1.08e-05	0.26	0.25	Testicular germ cell tumor;	chr21:46286621	chr21:46251549~46254133:-
THCA	cis	rs116095464	0.558	rs6882584	ENSG00000248925.1	CTD-2083E4.6	5.48	6.81e-08	1.08e-05	0.35	0.25	Breast cancer;	chr5:223296	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs3213838	ENSG00000248925.1	CTD-2083E4.6	5.48	6.81e-08	1.08e-05	0.35	0.25	Breast cancer;	chr5:223775	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs6555052	ENSG00000248925.1	CTD-2083E4.6	5.48	6.81e-08	1.08e-05	0.35	0.25	Breast cancer;	chr5:224153	chr5:269858~271516:-
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000273796.1	LL21NC02-21A1.1	-5.48	6.82e-08	1.08e-05	-0.26	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45403809~45404369:-
THCA	cis	rs8007846	0.569	rs11848443	ENSG00000276116.2	FUT8-AS1	-5.48	6.82e-08	1.08e-05	-0.25	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65790701	chr14:65411170~65412690:-
THCA	cis	rs8007846	0.569	rs11848444	ENSG00000276116.2	FUT8-AS1	-5.48	6.82e-08	1.08e-05	-0.25	-0.25	Multiple sclerosis--Brain Glutamate Levels;	chr14:65790749	chr14:65411170~65412690:-
THCA	cis	rs2562456	0.833	rs4334427	ENSG00000268081.1	RP11-678G14.2	5.48	6.82e-08	1.08e-05	0.41	0.25	Pain;	chr19:21338090	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs4644962	ENSG00000268081.1	RP11-678G14.2	5.48	6.82e-08	1.08e-05	0.41	0.25	Pain;	chr19:21338125	chr19:21554640~21569237:-
THCA	cis	rs2288884	0.779	rs10411428	ENSG00000275055.1	CTC-471J1.11	-5.48	6.82e-08	1.08e-05	-0.24	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52104512	chr19:52049007~52049754:+
THCA	cis	rs7702057	0.53	rs17138879	ENSG00000271918.1	CTD-2287O16.5	-5.48	6.82e-08	1.08e-05	-0.28	-0.25	Amyotrophic lateral sclerosis;	chr5:116089730	chr5:116083807~116085416:-
THCA	cis	rs2337406	0.85	rs4774179	ENSG00000211974.3	IGHV2-70	-5.48	6.83e-08	1.08e-05	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106700837	chr14:106723574~106724093:-
THCA	cis	rs11089937	0.597	rs5757007	ENSG00000211638.2	IGLV8-61	-5.48	6.83e-08	1.08e-05	-0.2	-0.25	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22098700~22099212:+
THCA	cis	rs7560272	0.723	rs780395	ENSG00000163016.8	ALMS1P	-5.48	6.84e-08	1.09e-05	-0.32	-0.25	Schizophrenia;	chr2:73473726	chr2:73644919~73685576:+
THCA	cis	rs7560272	0.695	rs780394	ENSG00000163016.8	ALMS1P	-5.48	6.84e-08	1.09e-05	-0.32	-0.25	Schizophrenia;	chr2:73473803	chr2:73644919~73685576:+
THCA	cis	rs7560272	0.723	rs1083923	ENSG00000163016.8	ALMS1P	-5.48	6.84e-08	1.09e-05	-0.32	-0.25	Schizophrenia;	chr2:73476247	chr2:73644919~73685576:+
THCA	cis	rs453301	0.624	rs2288673	ENSG00000254153.1	CTA-398F10.2	-5.48	6.84e-08	1.09e-05	-0.26	-0.25	Joint mobility (Beighton score);	chr8:9002766	chr8:8456909~8461337:-
THCA	cis	rs8027521	0.905	rs2725586	ENSG00000280362.1	RP11-643A5.3	5.48	6.84e-08	1.09e-05	0.29	0.25	Circulating chemerin levels;	chr15:53976379	chr15:53910769~53914712:+
THCA	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	5.48	6.85e-08	1.09e-05	0.42	0.25	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
THCA	cis	rs481331	0.741	rs603671	ENSG00000215146.4	RP11-313J2.1	-5.48	6.85e-08	1.09e-05	-0.4	-0.25	Systemic juvenile idiopathic arthritis;	chr10:42661690	chr10:42331866~42367974:-
THCA	cis	rs9876781	1	rs11130170	ENSG00000229759.1	MRPS18AP1	5.48	6.86e-08	1.09e-05	0.29	0.25	Longevity;	chr3:48408490	chr3:48256350~48256938:-
THCA	cis	rs9467773	0.587	rs10946813	ENSG00000124549.13	BTN2A3P	5.48	6.86e-08	1.09e-05	0.23	0.25	Intelligence (multi-trait analysis);	chr6:26344913	chr6:26421391~26432383:+
THCA	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-5.48	6.86e-08	1.09e-05	-0.27	-0.25	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
THCA	cis	rs2412819	0.545	rs654276	ENSG00000249839.1	AC011330.5	5.48	6.86e-08	1.09e-05	0.38	0.25	Lung cancer;	chr15:43798656	chr15:43663654~43684339:-
THCA	cis	rs890448	0.796	rs2912483	ENSG00000254531.1	FLJ20021	5.48	6.86e-08	1.09e-05	0.22	0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101428540	chr4:101347780~101348883:+
THCA	cis	rs5758659	1	rs134902	ENSG00000270083.1	RP1-257I20.14	5.48	6.87e-08	1.09e-05	0.25	0.25	Cognitive function;	chr22:42287991	chr22:42089630~42090028:-
THCA	cis	rs763121	0.853	rs5750671	ENSG00000273076.1	RP3-508I15.22	5.48	6.87e-08	1.09e-05	0.25	0.25	Menopause (age at onset);	chr22:38698614	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs926299	ENSG00000273076.1	RP3-508I15.22	5.48	6.87e-08	1.09e-05	0.25	0.25	Menopause (age at onset);	chr22:38699693	chr22:38743495~38743910:+
THCA	cis	rs763121	0.785	rs6001203	ENSG00000273076.1	RP3-508I15.22	5.48	6.87e-08	1.09e-05	0.25	0.25	Menopause (age at onset);	chr22:38703597	chr22:38743495~38743910:+
THCA	cis	rs4934494	0.677	rs730287	ENSG00000232936.4	RP11-80H5.2	5.48	6.87e-08	1.09e-05	0.33	0.25	Red blood cell count;	chr10:89616589	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs1815338	ENSG00000232936.4	RP11-80H5.2	5.48	6.87e-08	1.09e-05	0.33	0.25	Red blood cell count;	chr10:89616934	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs1075374	ENSG00000232936.4	RP11-80H5.2	5.48	6.87e-08	1.09e-05	0.33	0.25	Red blood cell count;	chr10:89617218	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185799	ENSG00000232936.4	RP11-80H5.2	5.48	6.87e-08	1.09e-05	0.33	0.25	Red blood cell count;	chr10:89617709	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185801	ENSG00000232936.4	RP11-80H5.2	5.48	6.87e-08	1.09e-05	0.33	0.25	Red blood cell count;	chr10:89618959	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185802	ENSG00000232936.4	RP11-80H5.2	5.48	6.87e-08	1.09e-05	0.33	0.25	Red blood cell count;	chr10:89618997	chr10:89645282~89650667:+
THCA	cis	rs6540731	0.782	rs12038888	ENSG00000226251.4	RP11-15I11.3	-5.48	6.87e-08	1.09e-05	-0.31	-0.25	Intelligence (childhood);	chr1:212192711	chr1:212225278~212238977:-
THCA	cis	rs9876781	1	rs13314659	ENSG00000229759.1	MRPS18AP1	-5.48	6.87e-08	1.09e-05	-0.29	-0.25	Longevity;	chr3:48407742	chr3:48256350~48256938:-
THCA	cis	rs7829975	0.714	rs7823757	ENSG00000254153.1	CTA-398F10.2	-5.48	6.88e-08	1.09e-05	-0.26	-0.25	Mood instability;	chr8:8812667	chr8:8456909~8461337:-
THCA	cis	rs2243480	1	rs431318	ENSG00000230295.1	RP11-458F8.2	-5.48	6.88e-08	1.09e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66046610	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs313803	ENSG00000230295.1	RP11-458F8.2	-5.48	6.88e-08	1.09e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66049744	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs313802	ENSG00000230295.1	RP11-458F8.2	-5.48	6.88e-08	1.09e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66051386	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000230295.1	RP11-458F8.2	-5.48	6.88e-08	1.09e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66052736	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs458291	ENSG00000230295.1	RP11-458F8.2	-5.48	6.88e-08	1.09e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66055492	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs464895	ENSG00000230295.1	RP11-458F8.2	-5.48	6.88e-08	1.09e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66062119	chr7:66880708~66882981:+
THCA	cis	rs9952991	0.883	rs2542148	ENSG00000260302.1	RP11-973H7.1	-5.48	6.88e-08	1.09e-05	-0.4	-0.25	Inflammatory skin disease;	chr18:12777574	chr18:12774651~12775923:-
THCA	cis	rs890448	0.694	rs2850330	ENSG00000254531.1	FLJ20021	-5.48	6.88e-08	1.09e-05	-0.22	-0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101356898	chr4:101347780~101348883:+
THCA	cis	rs890448	0.726	rs2850331	ENSG00000254531.1	FLJ20021	-5.48	6.88e-08	1.09e-05	-0.22	-0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101357211	chr4:101347780~101348883:+
THCA	cis	rs6570726	1	rs1935617	ENSG00000270638.1	RP3-466P17.1	5.48	6.89e-08	1.09e-05	0.19	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145735570~145737218:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	5.48	6.89e-08	1.09e-05	0.28	0.25	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
THCA	cis	rs7727544	0.735	rs2569266	ENSG00000224431.1	AC063976.7	-5.48	6.9e-08	1.09e-05	-0.21	-0.25	Blood metabolite levels;	chr5:132371099	chr5:132199456~132203487:+
THCA	cis	rs9876781	1	rs7651407	ENSG00000229759.1	MRPS18AP1	5.48	6.9e-08	1.09e-05	0.29	0.25	Longevity;	chr3:48402409	chr3:48256350~48256938:-
THCA	cis	rs875971	0.545	rs10950029	ENSG00000232546.1	RP11-458F8.1	5.48	6.9e-08	1.09e-05	0.23	0.25	Aortic root size;	chr7:66169334	chr7:66848496~66858136:+
THCA	cis	rs7493	1	rs7493	ENSG00000233942.1	AC004012.1	-5.48	6.9e-08	1.1e-05	-0.36	-0.25	Yu-Zhi constitution type in type 2 diabetes;	chr7:95405463	chr7:95471835~95473998:+
THCA	cis	rs7552393	0.595	rs6576949	ENSG00000233008.4	RP11-475O6.1	5.48	6.9e-08	1.1e-05	0.27	0.25	Select biomarker traits;	chr1:83807658	chr1:83575776~83861023:-
THCA	cis	rs7552393	0.636	rs6576950	ENSG00000233008.4	RP11-475O6.1	5.48	6.9e-08	1.1e-05	0.27	0.25	Select biomarker traits;	chr1:83807659	chr1:83575776~83861023:-
THCA	cis	rs2835345	0.563	rs58602880	ENSG00000230479.1	AP000695.6	5.48	6.91e-08	1.1e-05	0.3	0.25	Pulmonary function;	chr21:36454610	chr21:36430360~36481070:+
THCA	cis	rs7403037	0.656	rs1846362	ENSG00000259905.4	PWRN1	5.48	6.91e-08	1.1e-05	0.23	0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24323759	chr15:24493137~24652130:+
THCA	cis	rs6545883	0.929	rs12612982	ENSG00000270820.4	RP11-355B11.2	5.48	6.91e-08	1.1e-05	0.21	0.25	Tuberculosis;	chr2:61520220	chr2:61471188~61484130:+
THCA	cis	rs3743772	0.655	rs28497646	ENSG00000279722.1	RP11-44F14.6	5.48	6.91e-08	1.1e-05	0.37	0.25	Depressive symptoms (SSRI exposure interaction);	chr16:53507462	chr16:53487607~53489943:-
THCA	cis	rs2993535	0.749	rs2358439	ENSG00000233626.2	RP11-565J7.1	-5.48	6.91e-08	1.1e-05	-0.69	-0.25	Hip circumference adjusted for BMI;	chr1:212074153	chr1:211936249~211936634:+
THCA	cis	rs2993535	1	rs6675701	ENSG00000233626.2	RP11-565J7.1	-5.48	6.91e-08	1.1e-05	-0.69	-0.25	Hip circumference adjusted for BMI;	chr1:212088350	chr1:211936249~211936634:+
THCA	cis	rs2993535	1	rs7520161	ENSG00000233626.2	RP11-565J7.1	-5.48	6.91e-08	1.1e-05	-0.69	-0.25	Hip circumference adjusted for BMI;	chr1:212092078	chr1:211936249~211936634:+
THCA	cis	rs853679	0.567	rs3799499	ENSG00000280107.1	AL022393.9	-5.48	6.91e-08	1.1e-05	-0.26	-0.25	Depression;	chr6:28386473	chr6:28170845~28172521:+
THCA	cis	rs853679	0.567	rs2232427	ENSG00000280107.1	AL022393.9	-5.48	6.91e-08	1.1e-05	-0.26	-0.25	Depression;	chr6:28391932	chr6:28170845~28172521:+
THCA	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	5.48	6.92e-08	1.1e-05	0.36	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
THCA	cis	rs6500602	0.653	rs4786487	ENSG00000280063.1	RP11-295D4.3	-5.48	6.92e-08	1.1e-05	-0.14	-0.25	Schizophrenia;	chr16:4390396	chr16:4346694~4348648:-
THCA	cis	rs28374715	0.635	rs8023530	ENSG00000247556.5	OIP5-AS1	5.48	6.92e-08	1.1e-05	0.23	0.25	Ulcerative colitis;	chr15:41355577	chr15:41283990~41309737:+
THCA	cis	rs2562456	0.754	rs58338799	ENSG00000268081.1	RP11-678G14.2	5.48	6.92e-08	1.1e-05	0.41	0.25	Pain;	chr19:21339009	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs7259396	ENSG00000268081.1	RP11-678G14.2	5.48	6.92e-08	1.1e-05	0.41	0.25	Pain;	chr19:21340661	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.678	rs7260140	ENSG00000268081.1	RP11-678G14.2	5.48	6.92e-08	1.1e-05	0.41	0.25	Pain;	chr19:21340723	chr19:21554640~21569237:-
THCA	cis	rs2120243	0.539	rs1456097	ENSG00000244515.1	KRT18P34	-5.48	6.92e-08	1.1e-05	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157380841	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs1840668	ENSG00000244515.1	KRT18P34	-5.48	6.92e-08	1.1e-05	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157380932	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.565	rs13087207	ENSG00000244515.1	KRT18P34	-5.48	6.92e-08	1.1e-05	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157381849	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs10936086	ENSG00000244515.1	KRT18P34	-5.48	6.92e-08	1.1e-05	-0.29	-0.25	Hepatocellular carcinoma in hepatitis B infection;	chr3:157382070	chr3:157162663~157163932:-
THCA	cis	rs67478160	0.583	rs12879612	ENSG00000258735.1	LINC00637	-5.48	6.93e-08	1.1e-05	-0.3	-0.25	Schizophrenia;	chr14:103767281	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs4900594	ENSG00000258735.1	LINC00637	-5.48	6.93e-08	1.1e-05	-0.3	-0.25	Schizophrenia;	chr14:103784669	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs3742369	ENSG00000258735.1	LINC00637	-5.48	6.93e-08	1.1e-05	-0.3	-0.25	Schizophrenia;	chr14:103784939	chr14:103847721~103858049:+
THCA	cis	rs67981189	0.529	rs61990380	ENSG00000269927.1	RP6-91H8.3	5.48	6.93e-08	1.1e-05	0.29	0.25	Schizophrenia;	chr14:71005229	chr14:71141125~71143253:-
THCA	cis	rs6058796	1	rs6141772	ENSG00000175730.8	BAK1P1	5.48	6.93e-08	1.1e-05	0.36	0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32658860	chr20:32690180~32690815:-
THCA	cis	rs6058796	1	rs6087963	ENSG00000175730.8	BAK1P1	5.48	6.93e-08	1.1e-05	0.36	0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32661342	chr20:32690180~32690815:-
THCA	cis	rs1865760	0.516	rs9295684	ENSG00000272462.2	U91328.19	-5.48	6.93e-08	1.1e-05	-0.2	-0.25	Height;	chr6:26069441	chr6:25992662~26001775:+
THCA	cis	rs6479891	0.63	rs10995447	ENSG00000232075.1	MRPL35P2	5.48	6.94e-08	1.1e-05	0.39	0.25	Arthritis (juvenile idiopathic);	chr10:63119761	chr10:63634317~63634827:-
THCA	cis	rs2179367	0.632	rs997682	ENSG00000223701.3	RAET1E-AS1	-5.48	6.95e-08	1.1e-05	-0.35	-0.25	Dupuytren's disease;	chr6:149345484	chr6:149884431~149919508:+
THCA	cis	rs860295	0.702	rs11264375	ENSG00000160766.13	GBAP1	5.48	6.95e-08	1.1e-05	0.28	0.25	Body mass index;	chr1:155454274	chr1:155213821~155227422:-
THCA	cis	rs11779988	0.545	rs397096	ENSG00000253671.1	RP11-806O11.1	5.48	6.95e-08	1.1e-05	0.32	0.25	Breast cancer;	chr8:17941339	chr8:17808941~17820868:+
THCA	cis	rs10888838	0.938	rs12033727	ENSG00000198711.5	SSBP3-AS1	5.48	6.95e-08	1.1e-05	0.27	0.25	Mitochondrial DNA levels;	chr1:54214083	chr1:54236440~54239063:+
THCA	cis	rs2179367	0.568	rs6932778	ENSG00000223701.3	RAET1E-AS1	5.48	6.96e-08	1.1e-05	0.38	0.25	Dupuytren's disease;	chr6:149328293	chr6:149884431~149919508:+
THCA	cis	rs67981189	0.529	rs61990387	ENSG00000269927.1	RP6-91H8.3	5.48	6.96e-08	1.1e-05	0.3	0.25	Schizophrenia;	chr14:71024850	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.529	rs8014273	ENSG00000269927.1	RP6-91H8.3	5.48	6.96e-08	1.1e-05	0.3	0.25	Schizophrenia;	chr14:71043113	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.529	rs8010063	ENSG00000269927.1	RP6-91H8.3	5.48	6.96e-08	1.1e-05	0.3	0.25	Schizophrenia;	chr14:71043408	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.529	rs2158996	ENSG00000269927.1	RP6-91H8.3	5.48	6.96e-08	1.1e-05	0.3	0.25	Schizophrenia;	chr14:71062882	chr14:71141125~71143253:-
THCA	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	5.48	6.96e-08	1.1e-05	0.21	0.25	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
THCA	cis	rs13256369	1	rs9329166	ENSG00000253893.2	FAM85B	-5.48	6.96e-08	1.1e-05	-0.34	-0.25	Obesity-related traits;	chr8:8719145	chr8:8167819~8226614:-
THCA	cis	rs2303319	0.504	rs55841284	ENSG00000227403.1	AC009299.3	5.48	6.96e-08	1.1e-05	0.49	0.25	Cognitive function;	chr2:161703501	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.582	rs56315911	ENSG00000227403.1	AC009299.3	5.48	6.96e-08	1.1e-05	0.49	0.25	Cognitive function;	chr2:161703676	chr2:161244739~161249050:+
THCA	cis	rs6058796	0.901	rs6087966	ENSG00000175730.8	BAK1P1	5.48	6.97e-08	1.1e-05	0.36	0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32667233	chr20:32690180~32690815:-
THCA	cis	rs12681287	0.752	rs2917557	ENSG00000254231.1	CTD-2284J15.1	5.48	6.97e-08	1.11e-05	0.28	0.25	Caudate activity during reward;	chr8:86301842	chr8:86333274~86343314:-
THCA	cis	rs1479090	0.805	rs4691896	ENSG00000250027.1	RP11-563E2.2	-5.48	6.97e-08	1.11e-05	-0.25	-0.25	Lung cancer;	chr4:163164273	chr4:163108785~163119965:+
THCA	cis	rs7078012	0.504	rs17878361	ENSG00000225484.5	NUTM2B-AS1	-5.48	6.98e-08	1.11e-05	-0.57	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928721	chr10:79663088~79826594:-
THCA	cis	rs7078012	0.504	rs17878830	ENSG00000225484.5	NUTM2B-AS1	-5.48	6.98e-08	1.11e-05	-0.57	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79931024	chr10:79663088~79826594:-
THCA	cis	rs7078012	0.504	rs17879395	ENSG00000225484.5	NUTM2B-AS1	-5.48	6.98e-08	1.11e-05	-0.57	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79931369	chr10:79663088~79826594:-
THCA	cis	rs13256369	0.76	rs7816171	ENSG00000253893.2	FAM85B	-5.48	6.98e-08	1.11e-05	-0.33	-0.25	Obesity-related traits;	chr8:8718325	chr8:8167819~8226614:-
THCA	cis	rs13256369	0.76	rs7839473	ENSG00000253893.2	FAM85B	-5.48	6.98e-08	1.11e-05	-0.33	-0.25	Obesity-related traits;	chr8:8718326	chr8:8167819~8226614:-
THCA	cis	rs9880211	0.706	rs9289513	ENSG00000273486.1	RP11-731C17.2	5.48	6.98e-08	1.11e-05	0.26	0.25	Height;Body mass index;	chr3:136732904	chr3:136837338~136839021:-
THCA	cis	rs10833905	0.641	rs10833850	ENSG00000246225.5	RP11-17A1.3	-5.48	6.98e-08	1.11e-05	-0.36	-0.25	Sudden cardiac arrest;	chr11:22930969	chr11:22829380~22945393:+
THCA	cis	rs4639966	0.836	rs7943039	ENSG00000255422.1	AP002954.4	5.48	6.98e-08	1.11e-05	0.3	0.25	Systemic lupus erythematosus;	chr11:118732321	chr11:118704607~118750263:+
THCA	cis	rs17772222	0.638	rs11159859	ENSG00000258983.2	RP11-507K2.2	5.48	6.98e-08	1.11e-05	0.29	0.25	Coronary artery calcification;	chr14:88561547	chr14:88499334~88515502:+
THCA	cis	rs9307551	1	rs13104009	ENSG00000250334.4	LINC00989	-5.48	6.99e-08	1.11e-05	-0.31	-0.25	Refractive error;	chr4:79609584	chr4:79492416~79576460:+
THCA	cis	rs7809950	0.817	rs2253833	ENSG00000238832.1	snoU109	5.48	6.99e-08	1.11e-05	0.28	0.25	Coronary artery disease;	chr7:107565224	chr7:107603363~107603507:+
THCA	cis	rs4415084	0.8	rs11949847	ENSG00000272335.1	RP11-53O19.3	-5.48	6.99e-08	1.11e-05	-0.2	-0.25	Breast cancer;	chr5:44752067	chr5:44826076~44828592:+
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000182722.5	SEPHS1P1	-5.48	7e-08	1.11e-05	-0.29	-0.25	Calcium levels;	chr7:65829754	chr7:64852397~64853354:-
THCA	cis	rs795484	0.926	rs556081	ENSG00000275409.1	RP11-131L12.4	5.48	7e-08	1.11e-05	0.21	0.25	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118294870	chr12:118430147~118430699:+
THCA	cis	rs12472274	0.646	rs11677736	ENSG00000279484.1	KLHL30-AS1	5.48	7e-08	1.11e-05	0.31	0.25	Phospholipid levels (plasma);	chr2:238178557	chr2:238152889~238155994:-
THCA	cis	rs7129556	0.701	rs10899399	ENSG00000254691.1	RP11-91P24.5	5.48	7.01e-08	1.11e-05	0.34	0.24	Weight loss (gastric bypass surgery);	chr11:77698787	chr11:77850604~77851511:+
THCA	cis	rs67340775	0.541	rs200964	ENSG00000280107.1	AL022393.9	-5.48	7.01e-08	1.11e-05	-0.34	-0.24	Lung cancer in ever smokers;	chr6:27899165	chr6:28170845~28172521:+
THCA	cis	rs2439831	0.867	rs933941	ENSG00000275601.1	AC011330.13	-5.48	7.01e-08	1.11e-05	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43340028	chr15:43642389~43643023:-
THCA	cis	rs2212361	0.558	rs72963805	ENSG00000255893.1	RP11-685N10.1	-5.48	7.01e-08	1.11e-05	-0.3	-0.24	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535532	chr11:94472908~94473570:-
THCA	cis	rs6545883	0.929	rs3732170	ENSG00000270820.4	RP11-355B11.2	5.48	7.01e-08	1.11e-05	0.21	0.24	Tuberculosis;	chr2:61522581	chr2:61471188~61484130:+
THCA	cis	rs4654783	0.627	rs2092322	ENSG00000218510.5	LINC00339	5.48	7.01e-08	1.11e-05	0.26	0.24	Endometriosis;	chr1:22109230	chr1:22025188~22031223:+
THCA	cis	rs4950322	0.542	rs115179956	ENSG00000180867.10	PDIA3P1	5.48	7.02e-08	1.11e-05	0.22	0.24	Protein quantitative trait loci;	chr1:147172620	chr1:147178113~147179622:+
THCA	cis	rs6545883	0.929	rs55806663	ENSG00000270820.4	RP11-355B11.2	5.48	7.02e-08	1.11e-05	0.21	0.24	Tuberculosis;	chr2:61513352	chr2:61471188~61484130:+
THCA	cis	rs7246657	0.722	rs2909093	ENSG00000276846.1	CTD-3220F14.3	-5.48	7.02e-08	1.11e-05	-0.25	-0.24	Coronary artery calcification;	chr19:37708561	chr19:37314868~37315620:-
THCA	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	5.48	7.03e-08	1.11e-05	0.2	0.24	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
THCA	cis	rs17801127	0.748	rs71413665	ENSG00000231969.1	AC144449.1	5.48	7.03e-08	1.11e-05	0.52	0.24	Liver enzyme levels (alanine transaminase);	chr2:149827099	chr2:149587196~149848233:+
THCA	cis	rs1075232	0.677	rs72714666	ENSG00000215302.7	CTD-3092A11.1	-5.48	7.04e-08	1.12e-05	-0.51	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31200023	chr15:30470779~30507623:+
THCA	cis	rs72772090	0.71	rs56122780	ENSG00000248734.2	CTD-2260A17.1	-5.48	7.04e-08	1.12e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96724191	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.71	rs113710451	ENSG00000248734.2	CTD-2260A17.1	-5.48	7.04e-08	1.12e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96724602	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.71	rs11745122	ENSG00000248734.2	CTD-2260A17.1	-5.48	7.04e-08	1.12e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96725034	chr5:96784777~96785999:+
THCA	cis	rs1552244	0.935	rs41520445	ENSG00000180385.7	EMC3-AS1	-5.48	7.05e-08	1.12e-05	-0.27	-0.24	Alzheimer's disease;	chr3:10111457	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs67006488	ENSG00000180385.7	EMC3-AS1	5.48	7.05e-08	1.12e-05	0.27	0.24	Alzheimer's disease;	chr3:10111309	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs6764068	ENSG00000180385.7	EMC3-AS1	5.48	7.05e-08	1.12e-05	0.27	0.24	Alzheimer's disease;	chr3:10112158	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs113522867	ENSG00000180385.7	EMC3-AS1	5.48	7.05e-08	1.12e-05	0.27	0.24	Alzheimer's disease;	chr3:10112819	chr3:9986893~10006990:+
THCA	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	5.48	7.05e-08	1.12e-05	0.24	0.24	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000230295.1	RP11-458F8.2	-5.48	7.06e-08	1.12e-05	-0.31	-0.24	Diabetic kidney disease;	chr7:66528779	chr7:66880708~66882981:+
THCA	cis	rs935334	1	rs2360977	ENSG00000258454.1	RP11-361H10.3	5.48	7.06e-08	1.12e-05	0.35	0.24	Blood pressure;	chr14:76188138	chr14:76235817~76263474:+
THCA	cis	rs935334	0.935	rs1900124	ENSG00000258454.1	RP11-361H10.3	5.48	7.06e-08	1.12e-05	0.35	0.24	Blood pressure;	chr14:76190323	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs4899586	ENSG00000258454.1	RP11-361H10.3	5.48	7.06e-08	1.12e-05	0.35	0.24	Blood pressure;	chr14:76194513	chr14:76235817~76263474:+
THCA	cis	rs935334	1	rs11159183	ENSG00000258454.1	RP11-361H10.3	5.48	7.06e-08	1.12e-05	0.35	0.24	Blood pressure;	chr14:76196559	chr14:76235817~76263474:+
THCA	cis	rs9876781	1	rs9864371	ENSG00000229759.1	MRPS18AP1	5.48	7.06e-08	1.12e-05	0.29	0.24	Longevity;	chr3:48385276	chr3:48256350~48256938:-
THCA	cis	rs2243480	1	rs316327	ENSG00000232559.3	GS1-124K5.12	-5.48	7.07e-08	1.12e-05	-0.36	-0.24	Diabetic kidney disease;	chr7:66144214	chr7:66554588~66576923:-
THCA	cis	rs1876905	0.597	rs1215964	ENSG00000230177.1	RP5-1112D6.4	-5.48	7.07e-08	1.12e-05	-0.26	-0.24	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111277932~111278742:+
THCA	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-5.48	7.08e-08	1.12e-05	-0.28	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
THCA	cis	rs8062405	0.756	rs151182	ENSG00000278665.1	RP11-666O2.4	5.48	7.08e-08	1.12e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28599241~28601881:-
THCA	cis	rs7829975	0.606	rs10112585	ENSG00000233609.3	RP11-62H7.2	-5.48	7.08e-08	1.12e-05	-0.24	-0.24	Mood instability;	chr8:8937520	chr8:8961200~8979025:+
THCA	cis	rs1552244	1	rs6442147	ENSG00000180385.7	EMC3-AS1	5.48	7.08e-08	1.12e-05	0.26	0.24	Alzheimer's disease;	chr3:10036563	chr3:9986893~10006990:+
THCA	cis	rs853679	0.599	rs188015	ENSG00000226314.6	ZNF192P1	-5.48	7.09e-08	1.12e-05	-0.39	-0.24	Depression;	chr6:27909668	chr6:28161781~28169594:+
THCA	cis	rs7824557	0.767	rs10104728	ENSG00000154316.13	TDH	-5.48	7.09e-08	1.12e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11313791	chr8:11339637~11368452:+
THCA	cis	rs7829975	0.514	rs2976926	ENSG00000253981.4	ALG1L13P	5.48	7.09e-08	1.12e-05	0.23	0.24	Mood instability;	chr8:8404114	chr8:8236003~8244667:-
THCA	cis	rs67340775	0.541	rs200973	ENSG00000280107.1	AL022393.9	-5.48	7.1e-08	1.12e-05	-0.33	-0.24	Lung cancer in ever smokers;	chr6:27890643	chr6:28170845~28172521:+
THCA	cis	rs28510890	0.536	rs8032832	ENSG00000260337.3	RP11-386M24.6	-5.48	7.1e-08	1.12e-05	-0.25	-0.24	Lung cancer in ever smokers;	chr15:92614865	chr15:92592574~92596462:-
THCA	cis	rs7615952	0.599	rs6438955	ENSG00000250012.1	RP11-124N2.1	-5.48	7.1e-08	1.12e-05	-0.23	-0.24	Blood pressure (smoking interaction);	chr3:126011490	chr3:126084220~126095349:+
THCA	cis	rs67478160	0.619	rs12886363	ENSG00000258735.1	LINC00637	-5.48	7.1e-08	1.12e-05	-0.3	-0.24	Schizophrenia;	chr14:103807449	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.643	rs12880821	ENSG00000258735.1	LINC00637	-5.48	7.1e-08	1.12e-05	-0.3	-0.24	Schizophrenia;	chr14:103809712	chr14:103847721~103858049:+
THCA	cis	rs875971	1	rs6961717	ENSG00000223473.2	GS1-124K5.3	-5.48	7.12e-08	1.13e-05	-0.16	-0.24	Aortic root size;	chr7:66122550	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs2087647	ENSG00000223473.2	GS1-124K5.3	-5.48	7.12e-08	1.13e-05	-0.16	-0.24	Aortic root size;	chr7:66128201	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs6958484	ENSG00000223473.2	GS1-124K5.3	-5.48	7.12e-08	1.13e-05	-0.16	-0.24	Aortic root size;	chr7:66134459	chr7:66491049~66493566:-
THCA	cis	rs1865760	0.566	rs3752419	ENSG00000272462.2	U91328.19	-5.48	7.12e-08	1.13e-05	-0.2	-0.24	Height;	chr6:26027205	chr6:25992662~26001775:+
THCA	cis	rs4934494	0.677	rs11185804	ENSG00000232936.4	RP11-80H5.2	-5.48	7.13e-08	1.13e-05	-0.33	-0.24	Red blood cell count;	chr10:89619336	chr10:89645282~89650667:+
THCA	cis	rs758324	0.687	rs246353	ENSG00000237714.1	P4HA2-AS1	-5.48	7.13e-08	1.13e-05	-0.37	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132171379	chr5:132184876~132192808:+
THCA	cis	rs783540	0.656	rs783538	ENSG00000278603.1	RP13-608F4.5	-5.47	7.14e-08	1.13e-05	-0.34	-0.24	Schizophrenia;	chr15:82584394	chr15:82472203~82472426:+
THCA	cis	rs1876905	0.539	rs240985	ENSG00000272356.1	RP5-1112D6.8	5.47	7.14e-08	1.13e-05	0.27	0.24	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111309203~111313517:+
THCA	cis	rs950169	0.656	rs748455	ENSG00000188388.10	GOLGA6L3	5.47	7.14e-08	1.13e-05	0.33	0.24	Schizophrenia;	chr15:84606344	chr15:85240472~85247170:+
THCA	cis	rs7727544	0.547	rs10076758	ENSG00000233006.5	AC034220.3	5.47	7.14e-08	1.13e-05	0.18	0.24	Blood metabolite levels;	chr5:132188606	chr5:132311285~132369916:-
THCA	cis	rs7702057	0.53	rs7703978	ENSG00000271918.1	CTD-2287O16.5	5.47	7.14e-08	1.13e-05	0.28	0.24	Amyotrophic lateral sclerosis;	chr5:116085951	chr5:116083807~116085416:-
THCA	cis	rs2562456	0.837	rs11085462	ENSG00000268119.4	CTD-2561J22.5	5.47	7.14e-08	1.13e-05	0.3	0.24	Pain;	chr19:21567449	chr19:21444241~21463908:-
THCA	cis	rs9733	0.596	rs2867300	ENSG00000231073.1	RP11-316M1.3	5.47	7.15e-08	1.13e-05	0.29	0.24	Tonsillectomy;	chr1:150694514	chr1:150973123~150975534:+
THCA	cis	rs9309473	0.519	rs7598901	ENSG00000163016.8	ALMS1P	-5.47	7.15e-08	1.13e-05	-0.32	-0.24	Metabolite levels;	chr2:73448717	chr2:73644919~73685576:+
THCA	cis	rs1858037	0.836	rs2576923	ENSG00000234255.7	AC012370.3	-5.47	7.16e-08	1.13e-05	-0.29	-0.24	Rheumatoid arthritis;	chr2:65406750	chr2:65439888~65456571:-
THCA	cis	rs6545883	0.965	rs2305155	ENSG00000270820.4	RP11-355B11.2	5.47	7.16e-08	1.13e-05	0.21	0.24	Tuberculosis;	chr2:61502123	chr2:61471188~61484130:+
THCA	cis	rs1552244	0.554	rs6762702	ENSG00000232901.1	CYCSP10	5.47	7.16e-08	1.13e-05	0.29	0.24	Alzheimer's disease;	chr3:10014105	chr3:10000647~10000940:-
THCA	cis	rs6928977	0.863	rs2614275	ENSG00000231028.7	LINC00271	5.47	7.16e-08	1.13e-05	0.2	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135337376	chr6:135497801~135716055:+
THCA	cis	rs1552244	0.554	rs7638846	ENSG00000232901.1	CYCSP10	5.47	7.16e-08	1.13e-05	0.29	0.24	Alzheimer's disease;	chr3:10006917	chr3:10000647~10000940:-
THCA	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-5.47	7.17e-08	1.13e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-5.47	7.17e-08	1.13e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-5.47	7.17e-08	1.13e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-5.47	7.17e-08	1.13e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-5.47	7.17e-08	1.13e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
THCA	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-5.47	7.17e-08	1.13e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
THCA	cis	rs12681287	0.752	rs4389908	ENSG00000254231.1	CTD-2284J15.1	5.47	7.17e-08	1.13e-05	0.28	0.24	Caudate activity during reward;	chr8:86262623	chr8:86333274~86343314:-
THCA	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	5.47	7.17e-08	1.13e-05	0.37	0.24	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
THCA	cis	rs2554380	0.55	rs6602997	ENSG00000230373.7	GOLGA6L5P	-5.47	7.17e-08	1.13e-05	-0.27	-0.24	Height;	chr15:83852646	chr15:84507885~84516814:-
THCA	cis	rs1125355	0.589	rs62183012	ENSG00000251491.2	OR7E28P	-5.47	7.17e-08	1.13e-05	-0.41	-0.24	Alzheimer's disease in APOE e4+ carriers;	chr2:158751248	chr2:158862311~158863285:+
THCA	cis	rs1125355	0.589	rs62183013	ENSG00000251491.2	OR7E28P	-5.47	7.17e-08	1.13e-05	-0.41	-0.24	Alzheimer's disease in APOE e4+ carriers;	chr2:158751362	chr2:158862311~158863285:+
THCA	cis	rs438465	0.629	rs9406322	ENSG00000226194.4	RP1-137D17.1	-5.47	7.19e-08	1.14e-05	-0.4	-0.24	Corneal astigmatism;	chr6:169339638	chr6:169369998~169388385:-
THCA	cis	rs2562456	0.958	rs2562508	ENSG00000268119.4	CTD-2561J22.5	-5.47	7.19e-08	1.14e-05	-0.3	-0.24	Pain;	chr19:21543479	chr19:21444241~21463908:-
THCA	cis	rs801193	0.591	rs9986881	ENSG00000275400.1	RP4-756H11.5	-5.47	7.19e-08	1.14e-05	-0.24	-0.24	Aortic root size;	chr7:66708053	chr7:66553805~66554199:-
THCA	cis	rs7412746	0.611	rs752376	ENSG00000231073.1	RP11-316M1.3	5.47	7.19e-08	1.14e-05	0.29	0.24	Melanoma;	chr1:150968905	chr1:150973123~150975534:+
THCA	cis	rs1823913	0.599	rs13427761	ENSG00000280083.1	RP11-317J9.1	5.47	7.19e-08	1.14e-05	0.28	0.24	Obesity-related traits;	chr2:191269256	chr2:191154118~191156070:-
THCA	cis	rs13256369	1	rs10095733	ENSG00000253893.2	FAM85B	-5.47	7.19e-08	1.14e-05	-0.32	-0.24	Obesity-related traits;	chr8:8717136	chr8:8167819~8226614:-
THCA	cis	rs6792584	0.889	rs9873214	ENSG00000241316.5	SUCLG2-AS1	5.47	7.2e-08	1.14e-05	0.25	0.24	Corneal astigmatism;	chr3:67468963	chr3:67654697~67947713:+
THCA	cis	rs4648045	0.565	rs62327181	ENSG00000246560.2	RP11-10L12.4	5.47	7.2e-08	1.14e-05	0.31	0.24	Lymphocyte percentage of white cells;	chr4:102624981	chr4:102828055~102844075:+
THCA	cis	rs4950322	0.542	rs12046706	ENSG00000271721.1	RP11-337C18.9	5.47	7.2e-08	1.14e-05	0.26	0.24	Protein quantitative trait loci;	chr1:147189758	chr1:147175602~147177740:+
THCA	cis	rs10875746	0.903	rs10875738	ENSG00000269514.1	RP11-370I10.12	5.47	7.21e-08	1.14e-05	0.25	0.24	Longevity (90 years and older);	chr12:48079956	chr12:48198387~48202031:+
THCA	cis	rs6840360	0.582	rs6535796	ENSG00000270265.1	RP11-731D1.4	-5.47	7.21e-08	1.14e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151333775~151353224:-
THCA	cis	rs4908768	0.539	rs1809332	ENSG00000232912.4	RP5-1115A15.1	5.47	7.21e-08	1.14e-05	0.24	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8424645~8434838:+
THCA	cis	rs713477	0.692	rs8019270	ENSG00000258413.1	RP11-665C16.6	5.47	7.21e-08	1.14e-05	0.33	0.24	Pediatric bone mineral content (femoral neck);	chr14:55440454	chr14:55262767~55272075:-
THCA	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	5.47	7.21e-08	1.14e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	5.47	7.21e-08	1.14e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	5.47	7.21e-08	1.14e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
THCA	cis	rs2243480	1	rs316331	ENSG00000232559.3	GS1-124K5.12	-5.47	7.22e-08	1.14e-05	-0.36	-0.24	Diabetic kidney disease;	chr7:66139635	chr7:66554588~66576923:-
THCA	cis	rs116095464	0.558	rs10036253	ENSG00000248925.1	CTD-2083E4.6	5.47	7.22e-08	1.14e-05	0.35	0.24	Breast cancer;	chr5:238404	chr5:269858~271516:-
THCA	cis	rs6545883	0.929	rs10190332	ENSG00000270820.4	RP11-355B11.2	-5.47	7.22e-08	1.14e-05	-0.2	-0.24	Tuberculosis;	chr2:61392132	chr2:61471188~61484130:+
THCA	cis	rs4415084	0.8	rs994793	ENSG00000272335.1	RP11-53O19.3	-5.47	7.22e-08	1.14e-05	-0.2	-0.24	Breast cancer;	chr5:44743145	chr5:44826076~44828592:+
THCA	cis	rs6802315	0.575	rs57932243	ENSG00000272087.1	RP11-379F4.7	5.47	7.22e-08	1.14e-05	0.22	0.24	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158693120~158693768:-
THCA	cis	rs6802315	0.604	rs2364927	ENSG00000272087.1	RP11-379F4.7	5.47	7.22e-08	1.14e-05	0.22	0.24	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158693120~158693768:-
THCA	cis	rs2835345	0.563	rs12627167	ENSG00000230479.1	AP000695.6	5.47	7.22e-08	1.14e-05	0.29	0.24	Pulmonary function;	chr21:36449855	chr21:36430360~36481070:+
THCA	cis	rs7646881	0.544	rs58878998	ENSG00000240207.5	RP11-379F4.4	-5.47	7.22e-08	1.14e-05	-0.35	-0.24	Tetralogy of Fallot;	chr3:158640859	chr3:158732263~158784070:+
THCA	cis	rs651907	0.557	rs1056579	ENSG00000244119.1	PDCL3P4	5.47	7.23e-08	1.14e-05	0.22	0.24	Colorectal cancer;	chr3:101679033	chr3:101712472~101713191:+
THCA	cis	rs6547741	0.967	rs4665999	ENSG00000234072.1	AC074117.10	5.47	7.24e-08	1.14e-05	0.19	0.24	Oral cavity cancer;	chr2:27611577	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs11127071	ENSG00000234072.1	AC074117.10	5.47	7.24e-08	1.14e-05	0.19	0.24	Oral cavity cancer;	chr2:27615191	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs6737921	ENSG00000234072.1	AC074117.10	5.47	7.24e-08	1.14e-05	0.19	0.24	Oral cavity cancer;	chr2:27616240	chr2:27356246~27367622:+
THCA	cis	rs2985684	0.841	rs2281836	ENSG00000278009.1	RP11-649E7.8	5.47	7.24e-08	1.14e-05	0.35	0.24	Carotid intima media thickness;	chr14:49598999	chr14:49601011~49601124:-
THCA	cis	rs801193	0.742	rs9969300	ENSG00000224316.1	RP11-479O9.2	-5.47	7.24e-08	1.14e-05	-0.27	-0.24	Aortic root size;	chr7:66316659	chr7:65773620~65802067:+
THCA	cis	rs9467773	0.587	rs9467722	ENSG00000124549.13	BTN2A3P	-5.47	7.24e-08	1.15e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr6:26352338	chr6:26421391~26432383:+
THCA	cis	rs6714710	0.603	rs1470483	ENSG00000230606.9	AC159540.1	-5.47	7.25e-08	1.15e-05	-0.29	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97777431	chr2:97416165~97433527:-
THCA	cis	rs6860806	0.695	rs6867282	ENSG00000233006.5	AC034220.3	5.47	7.25e-08	1.15e-05	0.19	0.24	Breast cancer;	chr5:132247427	chr5:132311285~132369916:-
THCA	cis	rs4748857	0.891	rs4748858	ENSG00000224215.1	RP11-371A19.2	-5.47	7.25e-08	1.15e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr10:23310991	chr10:23343957~23345181:+
THCA	cis	rs12435908	1	rs61038704	ENSG00000276116.2	FUT8-AS1	-5.47	7.25e-08	1.15e-05	-0.4	-0.24	Ischemic stroke;	chr14:65705582	chr14:65411170~65412690:-
THCA	cis	rs944289	0.6	rs2774166	ENSG00000257826.1	RP11-116N8.4	5.47	7.26e-08	1.15e-05	0.27	0.24	Thyroid cancer;	chr14:36169449	chr14:36061026~36067190:-
THCA	cis	rs4950322	0.542	rs4950382	ENSG00000271721.1	RP11-337C18.9	5.47	7.26e-08	1.15e-05	0.26	0.24	Protein quantitative trait loci;	chr1:147176645	chr1:147175602~147177740:+
THCA	cis	rs2944755	0.723	rs13250299	ENSG00000279766.1	RP11-642A1.2	-5.47	7.27e-08	1.15e-05	-0.32	-0.24	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140579485	chr8:140572142~140572812:-
THCA	cis	rs9990343	0.543	rs66484806	ENSG00000223552.1	RP11-24F11.2	5.47	7.27e-08	1.15e-05	0.22	0.24	Brain structure;	chr3:46417999	chr3:46364955~46407059:-
THCA	cis	rs4950322	0.515	rs17160050	ENSG00000278811.3	LINC00624	5.47	7.27e-08	1.15e-05	0.29	0.24	Protein quantitative trait loci;	chr1:147255558	chr1:147258885~147517875:-
THCA	cis	rs6951245	0.58	rs10257426	ENSG00000229043.2	AC091729.9	-5.47	7.27e-08	1.15e-05	-0.37	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1160374~1165267:+
THCA	cis	rs1552244	1	rs6807846	ENSG00000180385.7	EMC3-AS1	5.47	7.28e-08	1.15e-05	0.26	0.24	Alzheimer's disease;	chr3:10092807	chr3:9986893~10006990:+
THCA	cis	rs7412746	0.646	rs1972060	ENSG00000231073.1	RP11-316M1.3	5.47	7.28e-08	1.15e-05	0.29	0.24	Melanoma;	chr1:150965118	chr1:150973123~150975534:+
THCA	cis	rs7005380	0.62	rs7002839	ENSG00000245330.4	KB-1471A8.1	5.47	7.28e-08	1.15e-05	0.24	0.24	Interstitial lung disease;	chr8:119906508	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs7006905	ENSG00000245330.4	KB-1471A8.1	5.47	7.28e-08	1.15e-05	0.24	0.24	Interstitial lung disease;	chr8:119906683	chr8:119867419~119874488:-
THCA	cis	rs6920965	0.507	rs7754833	ENSG00000237742.5	RP11-624M8.1	-5.47	7.28e-08	1.15e-05	-0.22	-0.24	High light scatter reticulocyte count;	chr6:125869748	chr6:125578558~125749190:-
THCA	cis	rs875971	1	rs4718307	ENSG00000223473.2	GS1-124K5.3	-5.47	7.28e-08	1.15e-05	-0.16	-0.24	Aortic root size;	chr7:66146001	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs7801282	ENSG00000223473.2	GS1-124K5.3	-5.47	7.28e-08	1.15e-05	-0.16	-0.24	Aortic root size;	chr7:66148700	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs55962648	ENSG00000223473.2	GS1-124K5.3	-5.47	7.28e-08	1.15e-05	-0.16	-0.24	Aortic root size;	chr7:66160764	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs2420168	ENSG00000223473.2	GS1-124K5.3	-5.47	7.28e-08	1.15e-05	-0.16	-0.24	Aortic root size;	chr7:66165644	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs11974219	ENSG00000223473.2	GS1-124K5.3	-5.47	7.28e-08	1.15e-05	-0.16	-0.24	Aortic root size;	chr7:66182423	chr7:66491049~66493566:-
THCA	cis	rs7005380	0.62	rs6993375	ENSG00000245330.4	KB-1471A8.1	5.47	7.28e-08	1.15e-05	0.24	0.24	Interstitial lung disease;	chr8:119899390	chr8:119867419~119874488:-
THCA	cis	rs71636778	0.596	rs2095637	ENSG00000260063.1	RP5-968P14.2	-5.47	7.29e-08	1.15e-05	-0.33	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26906354	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.543	rs17162330	ENSG00000260063.1	RP5-968P14.2	-5.47	7.29e-08	1.15e-05	-0.33	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26909721	chr1:26692132~26694131:-
THCA	cis	rs9816784	0.596	rs11185511	ENSG00000231464.1	AC024937.4	5.47	7.29e-08	1.15e-05	0.32	0.24	Mean corpuscular hemoglobin;	chr3:196108388	chr3:195996738~195998233:+
THCA	cis	rs55726902	1	rs55726902	ENSG00000276691.1	RP5-1057I20.5	5.47	7.29e-08	1.15e-05	0.32	0.24	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47788426~47788971:+
THCA	cis	rs2029362	0.846	rs7104230	ENSG00000245573.6	BDNF-AS	5.47	7.29e-08	1.15e-05	0.19	0.24	Total body bone mineral density;	chr11:27493562	chr11:27506838~27698174:+
THCA	cis	rs10208649	1	rs78887562	ENSG00000233266.1	HMGB1P31	5.47	7.29e-08	1.15e-05	0.64	0.24	Body mass index;	chr2:53904409	chr2:54051334~54051760:+
THCA	cis	rs642803	0.933	rs644740	ENSG00000214659.4	KRT8P26	-5.47	7.3e-08	1.15e-05	-0.21	-0.24	Urate levels;	chr11:65793997	chr11:65726939~65728214:+
THCA	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-5.47	7.3e-08	1.15e-05	-0.44	-0.24	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
THCA	cis	rs944289	0.774	rs12050449	ENSG00000258844.1	RP11-259K15.2	5.47	7.3e-08	1.15e-05	0.22	0.24	Thyroid cancer;	chr14:36101949	chr14:36214607~36235608:+
THCA	cis	rs7119038	0.731	rs10892283	ENSG00000255239.1	AP002954.6	-5.47	7.3e-08	1.15e-05	-0.38	-0.24	Sjögren's syndrome;	chr11:118766272	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.818	rs10892286	ENSG00000255239.1	AP002954.6	-5.47	7.3e-08	1.15e-05	-0.38	-0.24	Sjögren's syndrome;	chr11:118771376	chr11:118688039~118690600:-
THCA	cis	rs6792584	1	rs6792584	ENSG00000241316.5	SUCLG2-AS1	-5.47	7.3e-08	1.15e-05	-0.25	-0.24	Corneal astigmatism;	chr3:67480964	chr3:67654697~67947713:+
THCA	cis	rs6570726	0.846	rs409553	ENSG00000270638.1	RP3-466P17.1	5.47	7.31e-08	1.16e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs371186	ENSG00000270638.1	RP3-466P17.1	5.47	7.31e-08	1.16e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs439035	ENSG00000270638.1	RP3-466P17.1	5.47	7.31e-08	1.16e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145735570~145737218:+
THCA	cis	rs7412746	0.586	rs2864882	ENSG00000231073.1	RP11-316M1.3	5.47	7.32e-08	1.16e-05	0.28	0.24	Melanoma;	chr1:150910561	chr1:150973123~150975534:+
THCA	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	5.47	7.32e-08	1.16e-05	0.15	0.24	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
THCA	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	5.47	7.32e-08	1.16e-05	0.15	0.24	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
THCA	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	5.47	7.32e-08	1.16e-05	0.15	0.24	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
THCA	cis	rs2304003	1	rs1560595	ENSG00000235192.1	AC009495.2	-5.47	7.32e-08	1.16e-05	-0.34	-0.24	Social communication problems;	chr2:165843358	chr2:165794851~165810010:+
THCA	cis	rs883924	1	rs10123585	ENSG00000231107.1	LINC01508	5.47	7.32e-08	1.16e-05	0.25	0.24	Hepatitis C induced liver fibrosis;	chr9:90419807	chr9:90300902~90433505:-
THCA	cis	rs883924	1	rs10115760	ENSG00000231107.1	LINC01508	5.47	7.32e-08	1.16e-05	0.25	0.24	Hepatitis C induced liver fibrosis;	chr9:90419844	chr9:90300902~90433505:-
THCA	cis	rs883924	1	rs10123621	ENSG00000231107.1	LINC01508	5.47	7.32e-08	1.16e-05	0.25	0.24	Hepatitis C induced liver fibrosis;	chr9:90419969	chr9:90300902~90433505:-
THCA	cis	rs883924	1	rs12337121	ENSG00000231107.1	LINC01508	5.47	7.32e-08	1.16e-05	0.25	0.24	Hepatitis C induced liver fibrosis;	chr9:90420073	chr9:90300902~90433505:-
THCA	cis	rs883924	1	rs10113888	ENSG00000231107.1	LINC01508	5.47	7.32e-08	1.16e-05	0.25	0.24	Hepatitis C induced liver fibrosis;	chr9:90420081	chr9:90300902~90433505:-
THCA	cis	rs883924	0.748	rs10993405	ENSG00000231107.1	LINC01508	5.47	7.32e-08	1.16e-05	0.25	0.24	Hepatitis C induced liver fibrosis;	chr9:90420127	chr9:90300902~90433505:-
THCA	cis	rs1275468	0.554	rs1147994	ENSG00000257497.2	RP11-585P4.5	-5.47	7.32e-08	1.16e-05	-0.38	-0.24	Polycystic ovary syndrome;	chr12:75566186	chr12:75483454~75489820:-
THCA	cis	rs7005380	0.62	rs7461290	ENSG00000245330.4	KB-1471A8.1	5.47	7.33e-08	1.16e-05	0.24	0.24	Interstitial lung disease;	chr8:119904154	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.58	rs4073560	ENSG00000245330.4	KB-1471A8.1	5.47	7.33e-08	1.16e-05	0.24	0.24	Interstitial lung disease;	chr8:119905148	chr8:119867419~119874488:-
THCA	cis	rs911555	0.504	rs4444269	ENSG00000269910.1	RP11-73M18.10	5.47	7.33e-08	1.16e-05	0.23	0.24	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103694516~103695050:-
THCA	cis	rs1185460	0.967	rs1177562	ENSG00000272186.1	RP11-110I1.13	-5.47	7.33e-08	1.16e-05	-0.23	-0.24	Coronary artery disease;	chr11:119078621	chr11:119067374~119067698:-
THCA	cis	rs812925	0.855	rs6545851	ENSG00000271889.1	RP11-493E12.1	-5.47	7.33e-08	1.16e-05	-0.26	-0.24	Immature fraction of reticulocytes;	chr2:61271222	chr2:61151433~61162105:-
THCA	cis	rs7617773	0.963	rs12494304	ENSG00000199476.1	Y_RNA	5.47	7.33e-08	1.16e-05	0.31	0.24	Coronary artery disease;	chr3:48136539	chr3:48288587~48288694:+
THCA	cis	rs2120243	0.539	rs12486427	ENSG00000244515.1	KRT18P34	-5.47	7.34e-08	1.16e-05	-0.29	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157395487	chr3:157162663~157163932:-
THCA	cis	rs7829975	0.582	rs6983150	ENSG00000233609.3	RP11-62H7.2	-5.47	7.34e-08	1.16e-05	-0.24	-0.24	Mood instability;	chr8:8934916	chr8:8961200~8979025:+
THCA	cis	rs5758511	0.68	rs739147	ENSG00000281538.1	RP4-669P10.20	-5.47	7.34e-08	1.16e-05	-0.27	-0.24	Birth weight;	chr22:42275060	chr22:42138060~42139726:+
THCA	cis	rs1858037	0.867	rs55945621	ENSG00000234255.7	AC012370.3	5.47	7.34e-08	1.16e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65388220	chr2:65439888~65456571:-
THCA	cis	rs10208649	1	rs75213010	ENSG00000233266.1	HMGB1P31	5.47	7.34e-08	1.16e-05	0.66	0.24	Body mass index;	chr2:53709320	chr2:54051334~54051760:+
THCA	cis	rs6951245	0.507	rs11763865	ENSG00000229043.2	AC091729.9	-5.47	7.35e-08	1.16e-05	-0.34	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1154638	chr7:1160374~1165267:+
THCA	cis	rs758324	0.627	rs269900	ENSG00000237714.1	P4HA2-AS1	-5.47	7.35e-08	1.16e-05	-0.36	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132146551	chr5:132184876~132192808:+
THCA	cis	rs4663866	1	rs2304668	ENSG00000186235.9	AC016757.3	5.47	7.35e-08	1.16e-05	0.53	0.24	Irritable bowel syndrome;	chr2:238259807	chr2:238224552~238231677:-
THCA	cis	rs1823913	0.599	rs34840299	ENSG00000280083.1	RP11-317J9.1	-5.47	7.36e-08	1.16e-05	-0.28	-0.24	Obesity-related traits;	chr2:191280379	chr2:191154118~191156070:-
THCA	cis	rs925255	0.747	rs6547850	ENSG00000270210.1	RP11-373D23.3	-5.47	7.36e-08	1.16e-05	-0.26	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28406476	chr2:28425945~28426719:+
THCA	cis	rs7824557	0.591	rs2293859	ENSG00000154316.13	TDH	-5.47	7.36e-08	1.16e-05	-0.19	-0.24	Retinal vascular caliber;	chr8:11359252	chr8:11339637~11368452:+
THCA	cis	rs2993535	1	rs3009997	ENSG00000233626.2	RP11-565J7.1	5.47	7.37e-08	1.16e-05	0.66	0.24	Hip circumference adjusted for BMI;	chr1:211993658	chr1:211936249~211936634:+
THCA	cis	rs8396	1	rs9410	ENSG00000271817.2	U3	5.47	7.37e-08	1.16e-05	0.27	0.24	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158710839	chr4:158700691~158700909:+
THCA	cis	rs442309	0.807	rs224073	ENSG00000238280.1	RP11-436D10.3	-5.47	7.37e-08	1.16e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62750344	chr10:62793562~62805887:-
THCA	cis	rs442309	0.841	rs224074	ENSG00000238280.1	RP11-436D10.3	-5.47	7.37e-08	1.16e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62750627	chr10:62793562~62805887:-
THCA	cis	rs442309	0.841	rs224076	ENSG00000238280.1	RP11-436D10.3	-5.47	7.37e-08	1.16e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62751881	chr10:62793562~62805887:-
THCA	cis	rs442309	0.841	rs224078	ENSG00000238280.1	RP11-436D10.3	-5.47	7.37e-08	1.16e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62752000	chr10:62793562~62805887:-
THCA	cis	rs442309	0.841	rs224079	ENSG00000238280.1	RP11-436D10.3	-5.47	7.37e-08	1.16e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62753470	chr10:62793562~62805887:-
THCA	cis	rs442309	0.775	rs7893375	ENSG00000238280.1	RP11-436D10.3	-5.47	7.37e-08	1.16e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62757846	chr10:62793562~62805887:-
THCA	cis	rs9921338	0.923	rs72771877	ENSG00000262636.1	CTD-3088G3.4	-5.47	7.37e-08	1.16e-05	-0.36	-0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11274759	chr16:11380859~11381118:-
THCA	cis	rs75422866	0.51	rs73105845	ENSG00000276691.1	RP5-1057I20.5	5.47	7.38e-08	1.16e-05	0.43	0.24	Pneumonia;	chr12:47741824	chr12:47788426~47788971:+
THCA	cis	rs12497850	0.931	rs1134591	ENSG00000229759.1	MRPS18AP1	5.47	7.38e-08	1.16e-05	0.32	0.24	Parkinson's disease;	chr3:48935459	chr3:48256350~48256938:-
THCA	cis	rs7403037	0.848	rs6576353	ENSG00000259905.4	PWRN1	5.47	7.38e-08	1.16e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24593378	chr15:24493137~24652130:+
THCA	cis	rs2749592	0.531	rs1208559	ENSG00000276805.1	RP11-291L22.6	-5.47	7.38e-08	1.17e-05	-0.27	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38451030~38451785:+
THCA	cis	rs67478160	0.634	rs2144079	ENSG00000258735.1	LINC00637	-5.47	7.38e-08	1.17e-05	-0.29	-0.24	Schizophrenia;	chr14:103792547	chr14:103847721~103858049:+
THCA	cis	rs7083	1	rs678837	ENSG00000254851.1	RP11-109L13.1	5.47	7.39e-08	1.17e-05	0.33	0.24	Blood protein levels;	chr11:117238554	chr11:117135528~117138582:+
THCA	cis	rs16976116	0.572	rs28704633	ENSG00000279145.1	RP11-547D13.1	5.47	7.39e-08	1.17e-05	0.26	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55154343	chr15:55171972~55178175:-
THCA	cis	rs763121	0.925	rs5757251	ENSG00000235209.1	CTA-150C2.13	5.47	7.4e-08	1.17e-05	0.31	0.24	Menopause (age at onset);	chr22:38704123	chr22:38921227~38924708:+
THCA	cis	rs713477	0.618	rs6573033	ENSG00000258413.1	RP11-665C16.6	5.47	7.4e-08	1.17e-05	0.35	0.24	Pediatric bone mineral content (femoral neck);	chr14:55452342	chr14:55262767~55272075:-
THCA	cis	rs1889642	0.743	rs9318657	ENSG00000227354.5	RBM26-AS1	5.47	7.4e-08	1.17e-05	0.23	0.24	Colonoscopy-negative controls vs population controls;	chr13:79801745	chr13:79406309~79424328:+
THCA	cis	rs3169166	0.5	rs3743084	ENSG00000259562.2	RP11-762H8.2	-5.47	7.41e-08	1.17e-05	-0.17	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78270351	chr15:78290527~78291221:-
THCA	cis	rs6044112	0.56	rs17681978	ENSG00000273998.1	RP4-777L9.2	5.47	7.41e-08	1.17e-05	0.42	0.24	Response to taxane treatment (docetaxel);	chr20:16607929	chr20:16576068~16579615:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000273142.1	RP11-458F8.4	-5.47	7.41e-08	1.17e-05	-0.19	-0.24	Aortic root size;	chr7:66521858	chr7:66902857~66906297:+
THCA	cis	rs17123764	0.892	rs11169097	ENSG00000257464.1	RP11-161H23.8	-5.47	7.42e-08	1.17e-05	-0.39	-0.24	Intelligence (multi-trait analysis);	chr12:49658813	chr12:49442424~49442652:-
THCA	cis	rs728616	0.867	rs12781912	ENSG00000225484.5	NUTM2B-AS1	-5.47	7.42e-08	1.17e-05	-0.42	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158372	chr10:79663088~79826594:-
THCA	cis	rs116095464	0.558	rs61689490	ENSG00000248925.1	CTD-2083E4.6	5.47	7.42e-08	1.17e-05	0.35	0.24	Breast cancer;	chr5:224789	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs61492827	ENSG00000248925.1	CTD-2083E4.6	5.47	7.42e-08	1.17e-05	0.35	0.24	Breast cancer;	chr5:225659	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs56342538	ENSG00000248925.1	CTD-2083E4.6	5.47	7.42e-08	1.17e-05	0.35	0.24	Breast cancer;	chr5:225681	chr5:269858~271516:-
THCA	cis	rs793571	0.554	rs12905110	ENSG00000259250.1	RP11-50C13.1	-5.47	7.42e-08	1.17e-05	-0.26	-0.24	Schizophrenia;	chr15:58713614	chr15:58587507~58591676:+
THCA	cis	rs2281603	0.951	rs1982440	ENSG00000272909.1	CTD-2555O16.4	-5.47	7.42e-08	1.17e-05	-0.32	-0.24	Lymphocyte counts;	chr14:64494049	chr14:64440369~64442238:-
THCA	cis	rs7403037	0.617	rs61993101	ENSG00000259905.4	PWRN1	5.47	7.43e-08	1.17e-05	0.32	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24530788	chr15:24493137~24652130:+
THCA	cis	rs4934494	0.677	rs943125	ENSG00000232936.4	RP11-80H5.2	5.47	7.43e-08	1.17e-05	0.33	0.24	Red blood cell count;	chr10:89619789	chr10:89645282~89650667:+
THCA	cis	rs9402743	1	rs9389318	ENSG00000231028.7	LINC00271	-5.47	7.43e-08	1.17e-05	-0.19	-0.24	Systemic lupus erythematosus;	chr6:135692396	chr6:135497801~135716055:+
THCA	cis	rs7111546	0.618	rs7928533	ENSG00000246225.5	RP11-17A1.3	5.47	7.43e-08	1.17e-05	0.43	0.24	Dialysis-related mortality;	chr11:22873388	chr11:22829380~22945393:+
THCA	cis	rs860295	0.702	rs12239100	ENSG00000160766.13	GBAP1	-5.47	7.43e-08	1.17e-05	-0.29	-0.24	Body mass index;	chr1:155458685	chr1:155213821~155227422:-
THCA	cis	rs7220401	0.789	rs3760456	ENSG00000263370.1	RP11-68I3.5	-5.47	7.44e-08	1.17e-05	-0.31	-0.24	Coronary artery disease;	chr17:29621826	chr17:29639627~29640825:+
THCA	cis	rs6969780	0.915	rs4722659	ENSG00000233429.8	HOTAIRM1	-5.47	7.44e-08	1.17e-05	-0.32	-0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127131	chr7:27095647~27100265:+
THCA	cis	rs4591358	0.871	rs6434780	ENSG00000223466.1	AC064834.2	5.47	7.44e-08	1.17e-05	0.29	0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195470558	chr2:195533035~195538681:+
THCA	cis	rs7412746	0.658	rs4970982	ENSG00000231073.1	RP11-316M1.3	5.47	7.44e-08	1.17e-05	0.29	0.24	Melanoma;	chr1:150892608	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs12097963	ENSG00000231073.1	RP11-316M1.3	5.47	7.44e-08	1.17e-05	0.29	0.24	Melanoma;	chr1:150897974	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs12085336	ENSG00000231073.1	RP11-316M1.3	5.47	7.45e-08	1.17e-05	0.29	0.24	Melanoma;	chr1:150803304	chr1:150973123~150975534:+
THCA	cis	rs9880211	0.528	rs75685279	ENSG00000273486.1	RP11-731C17.2	5.47	7.45e-08	1.17e-05	0.24	0.24	Height;Body mass index;	chr3:136715991	chr3:136837338~136839021:-
THCA	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-5.47	7.45e-08	1.18e-05	-0.23	-0.24	Height;	chr2:46636733	chr2:46668870~46670778:+
THCA	cis	rs6860806	0.507	rs2631372	ENSG00000263597.1	MIR3936	5.47	7.45e-08	1.18e-05	0.24	0.24	Breast cancer;	chr5:132367886	chr5:132365490~132365599:-
THCA	cis	rs79040073	0.637	rs73398223	ENSG00000259531.2	RP11-295H24.3	5.47	7.46e-08	1.18e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49379505	chr15:49365124~49366685:-
THCA	cis	rs6893782	0.83	rs274553	ENSG00000233006.5	AC034220.3	-5.47	7.46e-08	1.18e-05	-0.25	-0.24	Acylcarnitine levels;	chr5:132390140	chr5:132311285~132369916:-
THCA	cis	rs17508449	0.736	rs76038270	ENSG00000232450.1	RP4-730K3.3	-5.47	7.46e-08	1.18e-05	-0.38	-0.24	Leprosy;	chr1:113696298	chr1:113698884~113699631:-
THCA	cis	rs7727544	0.564	rs3852206	ENSG00000233006.5	AC034220.3	5.47	7.47e-08	1.18e-05	0.2	0.24	Blood metabolite levels;	chr5:132079743	chr5:132311285~132369916:-
THCA	cis	rs972578	0.677	rs7287107	ENSG00000274717.1	RP1-47A17.1	-5.47	7.48e-08	1.18e-05	-0.25	-0.24	Mean platelet volume;	chr22:42866507	chr22:42791814~42794313:-
THCA	cis	rs4591358	0.634	rs13034419	ENSG00000223466.1	AC064834.2	5.47	7.48e-08	1.18e-05	0.3	0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546166	chr2:195533035~195538681:+
THCA	cis	rs6723108	0.626	rs1530559	ENSG00000224043.6	CCNT2-AS1	5.47	7.48e-08	1.18e-05	0.27	0.24	Type 2 diabetes;	chr2:134998059	chr2:134735464~134918710:-
THCA	cis	rs5758659	0.692	rs5751251	ENSG00000270083.1	RP1-257I20.14	5.47	7.49e-08	1.18e-05	0.25	0.24	Cognitive function;	chr22:42244600	chr22:42089630~42090028:-
THCA	cis	rs8014252	0.667	rs2332417	ENSG00000259158.2	ADAM20P1	-5.47	7.49e-08	1.18e-05	-0.27	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70313486	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.667	rs9630398	ENSG00000259158.2	ADAM20P1	-5.47	7.49e-08	1.18e-05	-0.27	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70313790	chr14:70468881~70483756:-
THCA	cis	rs17767392	0.918	rs35094946	ENSG00000259146.3	RP1-261D10.2	5.47	7.49e-08	1.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71286073	chr14:71292729~71321814:-
THCA	cis	rs17680741	0.697	rs12264252	ENSG00000225484.5	NUTM2B-AS1	-5.47	7.5e-08	1.18e-05	-0.35	-0.24	Coronary artery disease;	chr10:80517585	chr10:79663088~79826594:-
THCA	cis	rs2436845	0.627	rs3018954	ENSG00000253669.3	KB-1732A1.1	-5.47	7.5e-08	1.18e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102821343	chr8:102805517~102809971:+
THCA	cis	rs2436845	0.627	rs2513915	ENSG00000253669.3	KB-1732A1.1	-5.47	7.5e-08	1.18e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102822312	chr8:102805517~102809971:+
THCA	cis	rs73198271	0.74	rs10094270	ENSG00000253893.2	FAM85B	5.47	7.5e-08	1.18e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.74	rs28521727	ENSG00000253893.2	FAM85B	5.47	7.5e-08	1.18e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.74	rs28402110	ENSG00000253893.2	FAM85B	5.47	7.5e-08	1.18e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.74	rs10112989	ENSG00000253893.2	FAM85B	5.47	7.5e-08	1.18e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.74	rs10113326	ENSG00000253893.2	FAM85B	5.47	7.5e-08	1.18e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8167819~8226614:-
THCA	cis	rs9921338	0.961	rs4780358	ENSG00000262636.1	CTD-3088G3.4	-5.47	7.51e-08	1.18e-05	-0.36	-0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11280355	chr16:11380859~11381118:-
THCA	cis	rs10875746	0.903	rs58952582	ENSG00000269514.1	RP11-370I10.12	5.47	7.51e-08	1.18e-05	0.25	0.24	Longevity (90 years and older);	chr12:48064665	chr12:48198387~48202031:+
THCA	cis	rs1552244	1	rs17032295	ENSG00000232901.1	CYCSP10	5.47	7.52e-08	1.18e-05	0.32	0.24	Alzheimer's disease;	chr3:10044996	chr3:10000647~10000940:-
THCA	cis	rs5742933	0.69	rs6726636	ENSG00000253559.1	OSGEPL1-AS1	-5.47	7.52e-08	1.18e-05	-0.33	-0.24	Ferritin levels;	chr2:189653095	chr2:189762704~189765556:+
THCA	cis	rs7976269	0.609	rs10771474	ENSG00000275476.1	RP11-996F15.4	5.47	7.52e-08	1.18e-05	0.25	0.24	Male-pattern baldness;	chr12:29068776	chr12:29277397~29277882:-
THCA	cis	rs62432291	0.681	rs294912	ENSG00000235086.1	FNDC1-IT1	-5.46	7.53e-08	1.19e-05	-0.45	-0.24	Joint mobility (Beighton score);	chr6:159246305	chr6:159240786~159243329:+
THCA	cis	rs62158211	0.565	rs62158212	ENSG00000272563.1	RP11-480C16.1	-5.46	7.53e-08	1.19e-05	-0.29	-0.24	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348749	chr2:113432600~113436042:+
THCA	cis	rs919433	1	rs919433	ENSG00000231621.1	AC013264.2	5.46	7.53e-08	1.19e-05	0.25	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301841	chr2:197197991~197199273:+
THCA	cis	rs1552244	1	rs28684871	ENSG00000232901.1	CYCSP10	5.46	7.53e-08	1.19e-05	0.32	0.24	Alzheimer's disease;	chr3:10030951	chr3:10000647~10000940:-
THCA	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-5.46	7.53e-08	1.19e-05	-0.27	-0.24	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
THCA	cis	rs875971	0.638	rs801205	ENSG00000273142.1	RP11-458F8.4	5.46	7.53e-08	1.19e-05	0.19	0.24	Aortic root size;	chr7:66557157	chr7:66902857~66906297:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000273142.1	RP11-458F8.4	5.46	7.53e-08	1.19e-05	0.19	0.24	Aortic root size;	chr7:66557902	chr7:66902857~66906297:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000273142.1	RP11-458F8.4	5.46	7.53e-08	1.19e-05	0.19	0.24	Aortic root size;	chr7:66571411	chr7:66902857~66906297:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000273142.1	RP11-458F8.4	5.46	7.53e-08	1.19e-05	0.19	0.24	Aortic root size;	chr7:66572000	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000273142.1	RP11-458F8.4	5.46	7.53e-08	1.19e-05	0.19	0.24	Aortic root size;	chr7:66577454	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000273142.1	RP11-458F8.4	5.46	7.53e-08	1.19e-05	0.19	0.24	Aortic root size;	chr7:66577989	chr7:66902857~66906297:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000273142.1	RP11-458F8.4	5.46	7.53e-08	1.19e-05	0.19	0.24	Aortic root size;	chr7:66591816	chr7:66902857~66906297:+
THCA	cis	rs6545883	0.965	rs7591345	ENSG00000270820.4	RP11-355B11.2	5.46	7.54e-08	1.19e-05	0.21	0.24	Tuberculosis;	chr2:61502506	chr2:61471188~61484130:+
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000280069.1	CTD-2349P21.3	-5.46	7.54e-08	1.19e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30738182~30740275:+
THCA	cis	rs793571	0.58	rs12913383	ENSG00000259250.1	RP11-50C13.1	5.46	7.54e-08	1.19e-05	0.26	0.24	Schizophrenia;	chr15:58751587	chr15:58587507~58591676:+
THCA	cis	rs1050631	0.564	rs1785904	ENSG00000260552.1	RP11-49I11.1	5.46	7.54e-08	1.19e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36133169	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.564	rs1785905	ENSG00000260552.1	RP11-49I11.1	5.46	7.54e-08	1.19e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36133324	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.657	rs1789551	ENSG00000260552.1	RP11-49I11.1	5.46	7.54e-08	1.19e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36136129	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.564	rs1625385	ENSG00000260552.1	RP11-49I11.1	5.46	7.54e-08	1.19e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36137401	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.564	rs1785934	ENSG00000260552.1	RP11-49I11.1	5.46	7.54e-08	1.19e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36138363	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.564	rs8098627	ENSG00000260552.1	RP11-49I11.1	5.46	7.54e-08	1.19e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36141673	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.564	rs1785931	ENSG00000260552.1	RP11-49I11.1	5.46	7.54e-08	1.19e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36142144	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.564	rs1789549	ENSG00000260552.1	RP11-49I11.1	5.46	7.54e-08	1.19e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36142462	chr18:36179996~36187448:-
THCA	cis	rs11089937	0.667	rs10483108	ENSG00000211638.2	IGLV8-61	-5.46	7.54e-08	1.19e-05	-0.21	-0.24	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22098700~22099212:+
THCA	cis	rs79040073	0.637	rs77813839	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49172799	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs79979867	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49177261	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs80214300	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49180767	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs79723325	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49193423	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs77815234	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49193495	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs77965410	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49194450	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs75391491	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49210376	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs75691966	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49214743	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.679	rs76231511	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49222243	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs117582142	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49228624	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.565	rs11638515	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49233530	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs17396119	ENSG00000259531.2	RP11-295H24.3	5.46	7.55e-08	1.19e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49242167	chr15:49365124~49366685:-
THCA	cis	rs16976116	0.901	rs8028525	ENSG00000279145.1	RP11-547D13.1	5.46	7.55e-08	1.19e-05	0.25	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55200119	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.806	rs117064453	ENSG00000279145.1	RP11-547D13.1	5.46	7.55e-08	1.19e-05	0.25	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55200121	chr15:55171972~55178175:-
THCA	cis	rs16976116	0.901	rs8027256	ENSG00000279145.1	RP11-547D13.1	5.46	7.55e-08	1.19e-05	0.25	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55200125	chr15:55171972~55178175:-
THCA	cis	rs9859260	0.689	rs3817672	ENSG00000226155.1	AC124944.3	-5.46	7.55e-08	1.19e-05	-0.29	-0.24	Mean corpuscular volume;	chr3:196073940	chr3:195912049~195913986:+
THCA	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	5.46	7.55e-08	1.19e-05	0.21	0.24	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
THCA	cis	rs755249	0.567	rs16826069	ENSG00000228060.1	RP11-69E11.8	-5.46	7.55e-08	1.19e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39565160~39573203:+
THCA	cis	rs6928977	0.932	rs6931735	ENSG00000231028.7	LINC00271	-5.46	7.56e-08	1.19e-05	-0.2	-0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135303673	chr6:135497801~135716055:+
THCA	cis	rs116095464	0.558	rs1971229	ENSG00000248925.1	CTD-2083E4.6	5.46	7.56e-08	1.19e-05	0.35	0.24	Breast cancer;	chr5:268072	chr5:269858~271516:-
THCA	cis	rs10888838	1	rs33988698	ENSG00000198711.5	SSBP3-AS1	5.46	7.56e-08	1.19e-05	0.27	0.24	Mitochondrial DNA levels;	chr1:54220182	chr1:54236440~54239063:+
THCA	cis	rs2303319	0.504	rs12476631	ENSG00000227403.1	AC009299.3	5.46	7.57e-08	1.19e-05	0.5	0.24	Cognitive function;	chr2:161710426	chr2:161244739~161249050:+
THCA	cis	rs2029362	0.715	rs7945211	ENSG00000245573.6	BDNF-AS	5.46	7.57e-08	1.19e-05	0.2	0.24	Total body bone mineral density;	chr11:27451230	chr11:27506838~27698174:+
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000273796.1	LL21NC02-21A1.1	-5.46	7.57e-08	1.19e-05	-0.26	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45403809~45404369:-
THCA	cis	rs7129556	0.911	rs11237244	ENSG00000254691.1	RP11-91P24.5	5.46	7.57e-08	1.19e-05	0.34	0.24	Weight loss (gastric bypass surgery);	chr11:77624291	chr11:77850604~77851511:+
THCA	cis	rs28530618	0.84	rs11697969	ENSG00000175730.8	BAK1P1	-5.46	7.58e-08	1.19e-05	-0.27	-0.24	Birth weight;	chr20:32651496	chr20:32690180~32690815:-
THCA	cis	rs6479901	0.501	rs7084396	ENSG00000232075.1	MRPL35P2	-5.46	7.58e-08	1.19e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr10:63116965	chr10:63634317~63634827:-
THCA	cis	rs4784934	0.808	rs6499956	ENSG00000260186.4	RP11-481J2.2	5.46	7.58e-08	1.19e-05	0.34	0.24	QT interval;	chr16:58424541	chr16:58421326~58462470:+
THCA	cis	rs9380516	0.853	rs7752728	ENSG00000228559.1	RP3-340B19.3	-5.46	7.58e-08	1.19e-05	-0.33	-0.24	Hepatitis C induced liver fibrosis;	chr6:35509375	chr6:35544632~35545669:+
THCA	cis	rs9876781	1	rs11712561	ENSG00000229759.1	MRPS18AP1	5.46	7.58e-08	1.19e-05	0.29	0.24	Longevity;	chr3:48393807	chr3:48256350~48256938:-
THCA	cis	rs1275468	0.724	rs1611928	ENSG00000257497.2	RP11-585P4.5	-5.46	7.58e-08	1.19e-05	-0.38	-0.24	Polycystic ovary syndrome;	chr12:75561705	chr12:75483454~75489820:-
THCA	cis	rs922182	0.613	rs6494454	ENSG00000275785.1	RP11-111E14.2	-5.46	7.58e-08	1.19e-05	-0.27	-0.24	Blood protein levels;	chr15:63941364	chr15:63890030~63890317:+
THCA	cis	rs922182	0.613	rs894660	ENSG00000275785.1	RP11-111E14.2	-5.46	7.58e-08	1.19e-05	-0.27	-0.24	Blood protein levels;	chr15:63942135	chr15:63890030~63890317:+
THCA	cis	rs8030605	0.925	rs7175969	ENSG00000277245.1	RP11-48G14.3	-5.46	7.59e-08	1.19e-05	-0.4	-0.24	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56079800	chr15:56447120~56447697:+
THCA	cis	rs7824557	0.736	rs10107010	ENSG00000154316.13	TDH	5.46	7.59e-08	1.19e-05	0.18	0.24	Retinal vascular caliber;	chr8:11275203	chr8:11339637~11368452:+
THCA	cis	rs972578	0.715	rs4822205	ENSG00000274717.1	RP1-47A17.1	-5.46	7.6e-08	1.2e-05	-0.26	-0.24	Mean platelet volume;	chr22:42850812	chr22:42791814~42794313:-
THCA	cis	rs7851660	0.679	rs4297160	ENSG00000214417.4	KRT18P13	-5.46	7.6e-08	1.2e-05	-0.21	-0.24	Strep throat;	chr9:97823224	chr9:97698922~97700734:+
THCA	cis	rs7727544	0.582	rs7703009	ENSG00000233006.5	AC034220.3	5.46	7.61e-08	1.2e-05	0.19	0.24	Blood metabolite levels;	chr5:132216692	chr5:132311285~132369916:-
THCA	cis	rs67478160	0.619	rs2368560	ENSG00000258735.1	LINC00637	-5.46	7.61e-08	1.2e-05	-0.3	-0.24	Schizophrenia;	chr14:103806974	chr14:103847721~103858049:+
THCA	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-5.46	7.62e-08	1.2e-05	-0.35	-0.24	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
THCA	cis	rs593531	0.614	rs596976	ENSG00000255440.1	RP11-632K5.2	-5.46	7.62e-08	1.2e-05	-0.3	-0.24	Neuroticism;	chr11:74332663	chr11:74409060~74416379:+
THCA	cis	rs6545883	0.929	rs6545877	ENSG00000270820.4	RP11-355B11.2	5.46	7.62e-08	1.2e-05	0.21	0.24	Tuberculosis;	chr2:61514812	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.929	rs7606167	ENSG00000270820.4	RP11-355B11.2	5.46	7.62e-08	1.2e-05	0.21	0.24	Tuberculosis;	chr2:61515519	chr2:61471188~61484130:+
THCA	cis	rs2129782	0.702	rs73279213	ENSG00000253553.4	RP11-586K2.1	5.46	7.63e-08	1.2e-05	0.42	0.24	Electrodermal activity;	chr8:88388883	chr8:88326836~88737134:+
THCA	cis	rs2120243	0.539	rs4640512	ENSG00000244515.1	KRT18P34	-5.46	7.63e-08	1.2e-05	-0.29	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402277	chr3:157162663~157163932:-
THCA	cis	rs2921073	0.605	rs2976933	ENSG00000253981.4	ALG1L13P	5.46	7.63e-08	1.2e-05	0.24	0.24	Parkinson's disease;	chr8:8397365	chr8:8236003~8244667:-
THCA	cis	rs7712401	0.525	rs193541	ENSG00000249996.1	RP11-359P5.1	5.46	7.63e-08	1.2e-05	0.24	0.24	Mean platelet volume;	chr5:122917609	chr5:123036271~123054667:+
THCA	cis	rs11700536	0.54	rs8132259	ENSG00000236663.1	AP001631.9	5.46	7.63e-08	1.2e-05	0.3	0.24	Interleukin-18 levels;	chr21:43129548	chr21:43140523~43141092:-
THCA	cis	rs801193	0.66	rs2659897	ENSG00000223473.2	GS1-124K5.3	-5.46	7.63e-08	1.2e-05	-0.16	-0.24	Aortic root size;	chr7:66722728	chr7:66491049~66493566:-
THCA	cis	rs10090774	0.76	rs10111852	ENSG00000279766.1	RP11-642A1.2	5.46	7.64e-08	1.2e-05	0.31	0.24	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140927442	chr8:140572142~140572812:-
THCA	cis	rs875971	1	rs6946143	ENSG00000223473.2	GS1-124K5.3	5.46	7.64e-08	1.2e-05	0.17	0.24	Aortic root size;	chr7:66114735	chr7:66491049~66493566:-
THCA	cis	rs10829156	0.786	rs7093907	ENSG00000240291.1	RP11-499P20.2	5.46	7.64e-08	1.2e-05	0.21	0.24	Sudden cardiac arrest;	chr10:18587225	chr10:18513115~18545651:-
THCA	cis	rs6545883	0.931	rs12713437	ENSG00000270820.4	RP11-355B11.2	5.46	7.64e-08	1.2e-05	0.21	0.24	Tuberculosis;	chr2:61495769	chr2:61471188~61484130:+
THCA	cis	rs9425766	0.679	rs12563301	ENSG00000227373.4	RP11-160H22.5	5.46	7.64e-08	1.2e-05	0.34	0.24	Life satisfaction;	chr1:174090924	chr1:174115300~174160004:-
THCA	cis	rs9813712	0.596	rs2587988	ENSG00000249846.5	RP11-77P16.4	-5.46	7.64e-08	1.2e-05	-0.26	-0.24	Response to amphetamines;	chr3:130201415	chr3:130112550~130120579:+
THCA	cis	rs9834975	0.9	rs9878861	ENSG00000272758.4	RP11-299J3.8	-5.46	7.65e-08	1.2e-05	-0.23	-0.24	Diastolic blood pressure;	chr3:122394139	chr3:122416207~122443180:+
THCA	cis	rs9834975	0.967	rs9841311	ENSG00000272758.4	RP11-299J3.8	-5.46	7.65e-08	1.2e-05	-0.23	-0.24	Diastolic blood pressure;	chr3:122394494	chr3:122416207~122443180:+
THCA	cis	rs1075265	0.509	rs10188142	ENSG00000233266.1	HMGB1P31	-5.46	7.65e-08	1.2e-05	-0.31	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53730999	chr2:54051334~54051760:+
THCA	cis	rs1050631	0.536	rs1785928	ENSG00000260552.1	RP11-49I11.1	-5.46	7.65e-08	1.2e-05	-0.3	-0.24	Esophageal squamous cell cancer (length of survival);	chr18:36145968	chr18:36179996~36187448:-
THCA	cis	rs2120243	0.51	rs10936087	ENSG00000244515.1	KRT18P34	-5.46	7.65e-08	1.2e-05	-0.29	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157388839	chr3:157162663~157163932:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000273142.1	RP11-458F8.4	-5.46	7.65e-08	1.2e-05	-0.19	-0.24	Aortic root size;	chr7:66540165	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000273142.1	RP11-458F8.4	-5.46	7.65e-08	1.2e-05	-0.19	-0.24	Aortic root size;	chr7:66542376	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000273142.1	RP11-458F8.4	5.46	7.65e-08	1.2e-05	0.19	0.24	Aortic root size;	chr7:66545590	chr7:66902857~66906297:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000273142.1	RP11-458F8.4	5.46	7.65e-08	1.2e-05	0.19	0.24	Aortic root size;	chr7:66546680	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000273142.1	RP11-458F8.4	5.46	7.65e-08	1.2e-05	0.19	0.24	Aortic root size;	chr7:66550702	chr7:66902857~66906297:+
THCA	cis	rs4819052	0.54	rs7282639	ENSG00000237664.1	LINC00316	5.46	7.66e-08	1.2e-05	0.26	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45071240	chr21:45338590~45341990:-
THCA	cis	rs1552244	1	rs7610821	ENSG00000232901.1	CYCSP10	5.46	7.66e-08	1.2e-05	0.32	0.24	Alzheimer's disease;	chr3:10094466	chr3:10000647~10000940:-
THCA	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-5.46	7.66e-08	1.2e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
THCA	cis	rs755249	0.567	rs41270799	ENSG00000228060.1	RP11-69E11.8	-5.46	7.66e-08	1.2e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39565160~39573203:+
THCA	cis	rs72634501	0.54	rs16826036	ENSG00000228060.1	RP11-69E11.8	-5.46	7.66e-08	1.2e-05	-0.26	-0.24	HDL cholesterol;	chr1:39292127	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs16826038	ENSG00000228060.1	RP11-69E11.8	-5.46	7.66e-08	1.2e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs61782157	ENSG00000228060.1	RP11-69E11.8	-5.46	7.66e-08	1.2e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs41270803	ENSG00000228060.1	RP11-69E11.8	-5.46	7.66e-08	1.2e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs61783376	ENSG00000228060.1	RP11-69E11.8	-5.46	7.66e-08	1.2e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs4660636	ENSG00000228060.1	RP11-69E11.8	-5.46	7.66e-08	1.2e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39565160~39573203:+
THCA	cis	rs6545883	0.929	rs2694625	ENSG00000270820.4	RP11-355B11.2	-5.46	7.66e-08	1.2e-05	-0.21	-0.24	Tuberculosis;	chr2:61388920	chr2:61471188~61484130:+
THCA	cis	rs11977715	0.538	rs43063	ENSG00000233942.1	AC004012.1	-5.46	7.66e-08	1.2e-05	-0.32	-0.24	Middle childhood and early adolescence aggressive behavior;	chr7:95480475	chr7:95471835~95473998:+
THCA	cis	rs4748857	0.685	rs11013336	ENSG00000224215.1	RP11-371A19.2	-5.46	7.66e-08	1.2e-05	-0.33	-0.24	Systemic lupus erythematosus;	chr10:23225776	chr10:23343957~23345181:+
THCA	cis	rs3785574	0.745	rs2854162	ENSG00000240280.5	TCAM1P	5.46	7.67e-08	1.21e-05	0.33	0.24	Height;	chr17:63898250	chr17:63849292~63864379:+
THCA	cis	rs712039	0.652	rs829163	ENSG00000276054.1	RP11-378E13.3	5.46	7.67e-08	1.21e-05	0.38	0.24	Tuberculosis;	chr17:37405936	chr17:37386886~37387926:+
THCA	cis	rs1400745	0.729	rs1741196	ENSG00000258738.1	RP11-73E17.2	5.46	7.67e-08	1.21e-05	0.29	0.24	Monocyte count;	chr14:34877814	chr14:34874343~34876459:+
THCA	cis	rs7727544	0.735	rs273913	ENSG00000237714.1	P4HA2-AS1	5.46	7.67e-08	1.21e-05	0.32	0.24	Blood metabolite levels;	chr5:132325463	chr5:132184876~132192808:+
THCA	cis	rs11795343	0.527	rs657454	ENSG00000232303.2	DFFBP1	-5.46	7.68e-08	1.21e-05	-0.29	-0.24	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32534853	chr9:32566148~32567126:-
THCA	cis	rs3785574	0.925	rs2727340	ENSG00000240280.5	TCAM1P	-5.46	7.68e-08	1.21e-05	-0.33	-0.24	Height;	chr17:63892864	chr17:63849292~63864379:+
THCA	cis	rs2562456	0.833	rs11666828	ENSG00000268081.1	RP11-678G14.2	5.46	7.68e-08	1.21e-05	0.42	0.24	Pain;	chr19:21342218	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs11671609	ENSG00000268081.1	RP11-678G14.2	5.46	7.68e-08	1.21e-05	0.42	0.24	Pain;	chr19:21342769	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs62109212	ENSG00000268081.1	RP11-678G14.2	5.46	7.68e-08	1.21e-05	0.42	0.24	Pain;	chr19:21343716	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs57250002	ENSG00000268081.1	RP11-678G14.2	5.46	7.68e-08	1.21e-05	0.42	0.24	Pain;	chr19:21344048	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62109218	ENSG00000268081.1	RP11-678G14.2	5.46	7.68e-08	1.21e-05	0.42	0.24	Pain;	chr19:21346059	chr19:21554640~21569237:-
THCA	cis	rs6547741	0.967	rs4665986	ENSG00000234072.1	AC074117.10	5.46	7.69e-08	1.21e-05	0.18	0.24	Oral cavity cancer;	chr2:27532301	chr2:27356246~27367622:+
THCA	cis	rs2255336	0.938	rs7953692	ENSG00000245648.1	RP11-277P12.20	-5.46	7.69e-08	1.21e-05	-0.3	-0.24	Blood protein levels;	chr12:10482432	chr12:10363769~10398506:+
THCA	cis	rs442309	0.841	rs224042	ENSG00000238280.1	RP11-436D10.3	-5.46	7.69e-08	1.21e-05	-0.3	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62764530	chr10:62793562~62805887:-
THCA	cis	rs3743266	0.613	rs1063100	ENSG00000245534.5	RORA-AS1	5.46	7.69e-08	1.21e-05	0.26	0.24	Menarche (age at onset);	chr15:60442498	chr15:60479178~60630637:+
THCA	cis	rs9309473	0.519	rs13027816	ENSG00000163016.8	ALMS1P	-5.46	7.7e-08	1.21e-05	-0.31	-0.24	Metabolite levels;	chr2:73670564	chr2:73644919~73685576:+
THCA	cis	rs2299587	0.61	rs7010747	ENSG00000253671.1	RP11-806O11.1	-5.46	7.7e-08	1.21e-05	-0.29	-0.24	Economic and political preferences;	chr8:17921142	chr8:17808941~17820868:+
THCA	cis	rs3847687	0.565	rs11061293	ENSG00000279993.1	RP11-76C10.3	5.46	7.7e-08	1.21e-05	0.27	0.24	Longevity;	chr12:131035034	chr12:131025561~131028060:-
THCA	cis	rs2562456	0.917	rs11085463	ENSG00000268119.4	CTD-2561J22.5	5.46	7.7e-08	1.21e-05	0.3	0.24	Pain;	chr19:21568500	chr19:21444241~21463908:-
THCA	cis	rs9859260	1	rs9859401	ENSG00000226155.1	AC124944.3	-5.46	7.71e-08	1.21e-05	-0.29	-0.24	Mean corpuscular volume;	chr3:196073732	chr3:195912049~195913986:+
THCA	cis	rs1876905	0.597	rs354526	ENSG00000230177.1	RP5-1112D6.4	-5.46	7.71e-08	1.21e-05	-0.26	-0.24	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111277932~111278742:+
THCA	cis	rs8081187	1	rs8081187	ENSG00000266490.1	CTD-2349P21.9	-5.46	7.71e-08	1.21e-05	-0.44	-0.24	Breast cancer;	chr17:30689342	chr17:30792372~30792833:+
THCA	cis	rs9878978	0.691	rs35864306	ENSG00000237990.3	CNTN4-AS1	5.46	7.71e-08	1.21e-05	0.26	0.24	Blood pressure (smoking interaction);	chr3:2470091	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.722	rs56358037	ENSG00000237990.3	CNTN4-AS1	5.46	7.71e-08	1.21e-05	0.26	0.24	Blood pressure (smoking interaction);	chr3:2470524	chr3:3039033~3069242:-
THCA	cis	rs2303759	0.676	rs7248378	ENSG00000268686.1	AC010524.2	-5.46	7.71e-08	1.21e-05	-0.35	-0.24	Multiple sclerosis;	chr19:49404887	chr19:49368705~49388081:-
THCA	cis	rs6993270	0.725	rs1519809	ENSG00000245330.4	KB-1471A8.1	-5.46	7.71e-08	1.21e-05	-0.32	-0.24	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119920095	chr8:119867419~119874488:-
THCA	cis	rs1552244	1	rs56270432	ENSG00000232901.1	CYCSP10	5.46	7.71e-08	1.21e-05	0.32	0.24	Alzheimer's disease;	chr3:10045833	chr3:10000647~10000940:-
THCA	cis	rs2243480	1	rs10247526	ENSG00000232559.3	GS1-124K5.12	-5.46	7.72e-08	1.21e-05	-0.37	-0.24	Diabetic kidney disease;	chr7:66315709	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000232559.3	GS1-124K5.12	-5.46	7.72e-08	1.21e-05	-0.37	-0.24	Diabetic kidney disease;	chr7:66333815	chr7:66554588~66576923:-
THCA	cis	rs6545883	0.929	rs12617911	ENSG00000270820.4	RP11-355B11.2	5.46	7.72e-08	1.21e-05	0.21	0.24	Tuberculosis;	chr2:61513690	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.931	rs778756	ENSG00000270820.4	RP11-355B11.2	5.46	7.72e-08	1.21e-05	0.2	0.24	Tuberculosis;	chr2:61554859	chr2:61471188~61484130:+
THCA	cis	rs71636778	0.509	rs71636795	ENSG00000260063.1	RP5-968P14.2	-5.46	7.72e-08	1.21e-05	-0.33	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26914534	chr1:26692132~26694131:-
THCA	cis	rs2439831	0.85	rs3825783	ENSG00000166763.7	STRCP1	5.46	7.73e-08	1.21e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43810111	chr15:43699488~43718184:-
THCA	cis	rs7005380	0.62	rs6988011	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119898298	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs35272074	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119898543	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs10103660	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119898547	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs6993797	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119899405	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6989741	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119899914	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs13257252	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119899993	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10093230	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119900606	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs9649947	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119901117	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs13279398	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119902030	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs13277947	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119902192	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs13277992	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119902287	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs13253140	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119902668	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs11777705	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119902992	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs12681402	ENSG00000245330.4	KB-1471A8.1	5.46	7.73e-08	1.21e-05	0.24	0.24	Interstitial lung disease;	chr8:119903622	chr8:119867419~119874488:-
THCA	cis	rs7829975	0.714	rs11784052	ENSG00000254153.1	CTA-398F10.2	-5.46	7.73e-08	1.21e-05	-0.26	-0.24	Mood instability;	chr8:8814452	chr8:8456909~8461337:-
THCA	cis	rs7727544	0.557	rs2897096	ENSG00000233006.5	AC034220.3	5.46	7.74e-08	1.22e-05	0.18	0.24	Blood metabolite levels;	chr5:132150591	chr5:132311285~132369916:-
THCA	cis	rs11089937	0.626	rs9619811	ENSG00000211638.2	IGLV8-61	-5.46	7.74e-08	1.22e-05	-0.2	-0.24	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22098700~22099212:+
THCA	cis	rs1865760	0.613	rs2071300	ENSG00000272462.2	U91328.19	-5.46	7.74e-08	1.22e-05	-0.19	-0.24	Height;	chr6:25914344	chr6:25992662~26001775:+
THCA	cis	rs6433895	1	rs11893821	ENSG00000236153.1	AC104076.3	-5.46	7.75e-08	1.22e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181152421	chr2:180979427~180980090:-
THCA	cis	rs3764400	0.567	rs2325784	ENSG00000278765.1	RP5-890E16.5	-5.46	7.75e-08	1.22e-05	-0.45	-0.24	Body mass index;	chr17:48134947	chr17:48066704~48067293:-
THCA	cis	rs3764400	0.567	rs8079616	ENSG00000278765.1	RP5-890E16.5	-5.46	7.75e-08	1.22e-05	-0.45	-0.24	Body mass index;	chr17:48136126	chr17:48066704~48067293:-
THCA	cis	rs7615952	0.546	rs11718647	ENSG00000243429.1	OR7E29P	5.46	7.76e-08	1.22e-05	0.35	0.24	Blood pressure (smoking interaction);	chr3:125633178	chr3:125712139~125713045:+
THCA	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	5.46	7.76e-08	1.22e-05	0.24	0.24	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
THCA	cis	rs758324	0.687	rs156056	ENSG00000237714.1	P4HA2-AS1	-5.46	7.76e-08	1.22e-05	-0.36	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132137957	chr5:132184876~132192808:+
THCA	cis	rs11073619	0.616	rs3994408	ENSG00000230373.7	GOLGA6L5P	-5.46	7.76e-08	1.22e-05	-0.37	-0.24	Positive affect;	chr15:84390854	chr15:84507885~84516814:-
THCA	cis	rs6968419	0.714	rs3807980	ENSG00000237870.5	AC073130.1	5.46	7.76e-08	1.22e-05	0.27	0.24	Intraocular pressure;	chr7:116253593	chr7:116275606~116286734:-
THCA	cis	rs2070488	0.775	rs7649984	ENSG00000229589.1	ACVR2B-AS1	-5.46	7.77e-08	1.22e-05	-0.22	-0.24	Electrocardiographic conduction measures;	chr3:38528730	chr3:38451027~38454820:-
THCA	cis	rs4648045	0.796	rs9790601	ENSG00000246560.2	RP11-10L12.4	5.46	7.77e-08	1.22e-05	0.31	0.24	Lymphocyte percentage of white cells;	chr4:102608806	chr4:102828055~102844075:+
THCA	cis	rs922182	0.578	rs4776266	ENSG00000275785.1	RP11-111E14.2	-5.46	7.77e-08	1.22e-05	-0.27	-0.24	Blood protein levels;	chr15:63943976	chr15:63890030~63890317:+
THCA	cis	rs6928977	0.896	rs2614257	ENSG00000231028.7	LINC00271	5.46	7.77e-08	1.22e-05	0.2	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135355266	chr6:135497801~135716055:+
THCA	cis	rs1552244	0.554	rs6786636	ENSG00000232901.1	CYCSP10	5.46	7.77e-08	1.22e-05	0.29	0.24	Alzheimer's disease;	chr3:10004019	chr3:10000647~10000940:-
THCA	cis	rs7824557	0.603	rs7016671	ENSG00000154316.13	TDH	-5.46	7.77e-08	1.22e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11324946	chr8:11339637~11368452:+
THCA	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	5.46	7.77e-08	1.22e-05	0.15	0.24	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
THCA	cis	rs17270561	0.514	rs10946805	ENSG00000272462.2	U91328.19	-5.46	7.78e-08	1.22e-05	-0.26	-0.24	Iron status biomarkers;	chr6:26077663	chr6:25992662~26001775:+
THCA	cis	rs9859260	1	rs9859260	ENSG00000226155.1	AC124944.3	-5.46	7.78e-08	1.22e-05	-0.29	-0.24	Mean corpuscular volume;	chr3:196073676	chr3:195912049~195913986:+
THCA	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	5.46	7.78e-08	1.22e-05	0.28	0.24	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
THCA	cis	rs801193	0.636	rs10233806	ENSG00000223473.2	GS1-124K5.3	-5.46	7.78e-08	1.22e-05	-0.16	-0.24	Aortic root size;	chr7:66653261	chr7:66491049~66493566:-
THCA	cis	rs9475752	0.793	rs28360538	ENSG00000231441.1	RP11-472M19.2	5.46	7.78e-08	1.22e-05	0.33	0.24	Menarche (age at onset);	chr6:56963138	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs28360537	ENSG00000231441.1	RP11-472M19.2	5.46	7.78e-08	1.22e-05	0.33	0.24	Menarche (age at onset);	chr6:56966734	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs78463359	ENSG00000231441.1	RP11-472M19.2	5.46	7.78e-08	1.22e-05	0.33	0.24	Menarche (age at onset);	chr6:56968685	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs7760385	ENSG00000231441.1	RP11-472M19.2	5.46	7.78e-08	1.22e-05	0.33	0.24	Menarche (age at onset);	chr6:56969387	chr6:56844002~56864078:+
THCA	cis	rs354225	0.565	rs2971880	ENSG00000237887.1	AC092839.1	-5.46	7.78e-08	1.22e-05	-0.27	-0.24	Schizophrenia;	chr2:54658503	chr2:54529343~54529801:+
THCA	cis	rs2243480	1	rs316322	ENSG00000232559.3	GS1-124K5.12	5.46	7.78e-08	1.22e-05	0.36	0.24	Diabetic kidney disease;	chr7:66146246	chr7:66554588~66576923:-
THCA	cis	rs2337406	1	rs11850600	ENSG00000274576.2	IGHV2-70	-5.46	7.79e-08	1.22e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106670765	chr14:106770577~106771020:-
THCA	cis	rs758324	0.732	rs247293	ENSG00000237714.1	P4HA2-AS1	-5.46	7.79e-08	1.22e-05	-0.36	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132121469	chr5:132184876~132192808:+
THCA	cis	rs6570726	0.846	rs446031	ENSG00000270638.1	RP3-466P17.1	5.46	7.79e-08	1.22e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145735570~145737218:+
THCA	cis	rs758324	0.732	rs247285	ENSG00000237714.1	P4HA2-AS1	-5.46	7.79e-08	1.22e-05	-0.36	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132129995	chr5:132184876~132192808:+
THCA	cis	rs849141	0.925	rs1029534	ENSG00000234336.5	JAZF1-AS1	-5.46	7.8e-08	1.23e-05	-0.29	-0.24	Height;Hip circumference adjusted for BMI;	chr7:28149464	chr7:28180322~28243917:+
THCA	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-5.46	7.8e-08	1.23e-05	-0.23	-0.24	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
THCA	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-5.46	7.8e-08	1.23e-05	-0.23	-0.24	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
THCA	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-5.46	7.8e-08	1.23e-05	-0.23	-0.24	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
THCA	cis	rs2835345	0.563	rs73204244	ENSG00000230479.1	AP000695.6	5.46	7.8e-08	1.23e-05	0.29	0.24	Pulmonary function;	chr21:36452373	chr21:36430360~36481070:+
THCA	cis	rs755249	0.567	rs41270821	ENSG00000228060.1	RP11-69E11.8	-5.46	7.81e-08	1.23e-05	-0.27	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs2296175	ENSG00000228060.1	RP11-69E11.8	-5.46	7.81e-08	1.23e-05	-0.27	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39565160~39573203:+
THCA	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	5.46	7.82e-08	1.23e-05	0.31	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
THCA	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	5.46	7.82e-08	1.23e-05	0.31	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
THCA	cis	rs12216125	0.549	rs9358905	ENSG00000272462.2	U91328.19	-5.46	7.82e-08	1.23e-05	-0.2	-0.24	Iron status biomarkers;	chr6:26077611	chr6:25992662~26001775:+
THCA	cis	rs2562456	0.754	rs55771551	ENSG00000268119.4	CTD-2561J22.5	5.46	7.83e-08	1.23e-05	0.3	0.24	Pain;	chr19:21563578	chr19:21444241~21463908:-
THCA	cis	rs7674212	0.541	rs2720448	ENSG00000251288.2	RP11-10L12.2	-5.46	7.83e-08	1.23e-05	-0.31	-0.24	Type 2 diabetes;	chr4:103109432	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.541	rs2623064	ENSG00000251288.2	RP11-10L12.2	-5.46	7.83e-08	1.23e-05	-0.31	-0.24	Type 2 diabetes;	chr4:103109635	chr4:102751401~102752641:+
THCA	cis	rs2129782	1	rs58289747	ENSG00000253553.4	RP11-586K2.1	5.46	7.83e-08	1.23e-05	0.42	0.24	Electrodermal activity;	chr8:88402462	chr8:88326836~88737134:+
THCA	cis	rs4415084	0.8	rs2330572	ENSG00000272335.1	RP11-53O19.3	5.46	7.83e-08	1.23e-05	0.2	0.24	Breast cancer;	chr5:44740887	chr5:44826076~44828592:+
THCA	cis	rs9527	0.551	rs28606370	ENSG00000236937.2	PTGES3P4	5.46	7.83e-08	1.23e-05	0.32	0.24	Arsenic metabolism;	chr10:102911075	chr10:102845595~102845950:+
THCA	cis	rs7403037	0.848	rs12917173	ENSG00000259905.4	PWRN1	5.46	7.84e-08	1.23e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24592422	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.848	rs11629872	ENSG00000259905.4	PWRN1	5.46	7.84e-08	1.23e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24593777	chr15:24493137~24652130:+
THCA	cis	rs116095464	0.558	rs28635197	ENSG00000248925.1	CTD-2083E4.6	5.46	7.84e-08	1.23e-05	0.35	0.24	Breast cancer;	chr5:278956	chr5:269858~271516:-
THCA	cis	rs467650	0.782	rs56264044	ENSG00000248489.1	CTD-2007H13.3	5.46	7.84e-08	1.23e-05	0.24	0.24	Venous thromboembolism (SNP x SNP interaction);	chr5:98724439	chr5:98929171~98995013:+
THCA	cis	rs5758659	1	rs134902	ENSG00000273366.1	CTA-989H11.1	-5.46	7.84e-08	1.23e-05	-0.28	-0.24	Cognitive function;	chr22:42287991	chr22:42278188~42278846:+
THCA	cis	rs62292953	1	rs62292950	ENSG00000248724.5	NPHP3-AS1	-5.46	7.84e-08	1.23e-05	-0.38	-0.24	Red cell distribution width;	chr3:132479151	chr3:132721750~132874223:+
THCA	cis	rs897984	0.542	rs8061047	ENSG00000279196.1	RP11-1072A3.3	5.46	7.84e-08	1.23e-05	0.24	0.24	Dementia with Lewy bodies;	chr16:31057639	chr16:30984630~30988270:-
THCA	cis	rs4889609	0.834	rs72785520	ENSG00000279196.1	RP11-1072A3.3	5.46	7.84e-08	1.23e-05	0.24	0.24	Response to metformin (IC50);	chr16:31059457	chr16:30984630~30988270:-
THCA	cis	rs6585424	1	rs12777867	ENSG00000242600.5	MBL1P	5.46	7.85e-08	1.23e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175774	chr10:79904898~79950336:+
THCA	cis	rs6060960	0.502	rs6057968	ENSG00000230613.1	HM13-AS1	5.46	7.85e-08	1.23e-05	0.29	0.24	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr20:31494976	chr20:31567707~31573263:-
THCA	cis	rs2243480	0.908	rs313822	ENSG00000232559.3	GS1-124K5.12	5.46	7.85e-08	1.23e-05	0.35	0.24	Diabetic kidney disease;	chr7:66108952	chr7:66554588~66576923:-
THCA	cis	rs6545883	0.783	rs7579651	ENSG00000270820.4	RP11-355B11.2	5.46	7.85e-08	1.23e-05	0.2	0.24	Tuberculosis;	chr2:61573144	chr2:61471188~61484130:+
THCA	cis	rs752010	0.619	rs10736421	ENSG00000230638.4	RP11-486B10.4	-5.46	7.85e-08	1.23e-05	-0.29	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41640559	chr1:41542069~41544310:+
THCA	cis	rs4845570	0.92	rs1521185	ENSG00000268288.1	RP11-98D18.16	5.46	7.86e-08	1.23e-05	0.31	0.24	Coronary artery disease;	chr1:151791573	chr1:151766486~151767000:-
THCA	cis	rs4888671	1	rs59945106	ENSG00000261707.1	RP11-264M12.2	5.46	7.86e-08	1.23e-05	0.45	0.24	Obesity-related traits;	chr16:77746257	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs61402842	ENSG00000261707.1	RP11-264M12.2	5.46	7.86e-08	1.23e-05	0.45	0.24	Obesity-related traits;	chr16:77746501	chr16:77741468~77743000:-
THCA	cis	rs4888671	0.803	rs117140693	ENSG00000261707.1	RP11-264M12.2	5.46	7.86e-08	1.23e-05	0.45	0.24	Obesity-related traits;	chr16:77746887	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs76315659	ENSG00000261707.1	RP11-264M12.2	5.46	7.86e-08	1.23e-05	0.45	0.24	Obesity-related traits;	chr16:77747753	chr16:77741468~77743000:-
THCA	cis	rs13287066	0.692	rs7020852	ENSG00000227603.1	RP11-165J3.6	5.46	7.86e-08	1.23e-05	0.25	0.24	Intelligence (multi-trait analysis);	chr9:93400978	chr9:93435332~93437121:-
THCA	cis	rs2255336	0.938	rs9651850	ENSG00000245648.1	RP11-277P12.20	-5.46	7.87e-08	1.23e-05	-0.3	-0.24	Blood protein levels;	chr12:10490533	chr12:10363769~10398506:+
THCA	cis	rs2255336	0.873	rs12301897	ENSG00000245648.1	RP11-277P12.20	-5.46	7.87e-08	1.23e-05	-0.3	-0.24	Blood protein levels;	chr12:10491974	chr12:10363769~10398506:+
THCA	cis	rs736801	0.964	rs17622656	ENSG00000224431.1	AC063976.7	-5.46	7.87e-08	1.23e-05	-0.22	-0.24	Mosquito bite size;Breast cancer;	chr5:132485305	chr5:132199456~132203487:+
THCA	cis	rs1075232	1	rs72722861	ENSG00000215302.7	CTD-3092A11.1	-5.46	7.87e-08	1.23e-05	-0.54	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30470779~30507623:+
THCA	cis	rs1075232	0.826	rs12438813	ENSG00000215302.7	CTD-3092A11.1	-5.46	7.87e-08	1.23e-05	-0.54	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30470779~30507623:+
THCA	cis	rs1075232	1	rs34959140	ENSG00000215302.7	CTD-3092A11.1	-5.46	7.87e-08	1.23e-05	-0.54	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30470779~30507623:+
THCA	cis	rs9625935	0.917	rs41164	ENSG00000279159.1	RP3-394A18.1	5.46	7.87e-08	1.23e-05	0.18	0.24	Tonsillectomy;	chr22:30016476	chr22:29978950~30028236:-
THCA	cis	rs12478296	1	rs6732595	ENSG00000261186.2	RP11-341N2.1	-5.46	7.87e-08	1.23e-05	-0.38	-0.24	Obesity-related traits;	chr2:242093187	chr2:242087351~242088457:-
THCA	cis	rs1479090	0.805	rs10857351	ENSG00000250027.1	RP11-563E2.2	-5.46	7.87e-08	1.24e-05	-0.25	-0.24	Lung cancer;	chr4:163141657	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.805	rs7693533	ENSG00000250027.1	RP11-563E2.2	-5.46	7.87e-08	1.24e-05	-0.25	-0.24	Lung cancer;	chr4:163145558	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.805	rs1479089	ENSG00000250027.1	RP11-563E2.2	-5.46	7.87e-08	1.24e-05	-0.25	-0.24	Lung cancer;	chr4:163146076	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.762	rs7675924	ENSG00000250027.1	RP11-563E2.2	-5.46	7.87e-08	1.24e-05	-0.25	-0.24	Lung cancer;	chr4:163146703	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.805	rs2320615	ENSG00000250027.1	RP11-563E2.2	-5.46	7.87e-08	1.24e-05	-0.25	-0.24	Lung cancer;	chr4:163148797	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.762	rs6536705	ENSG00000250027.1	RP11-563E2.2	-5.46	7.87e-08	1.24e-05	-0.25	-0.24	Lung cancer;	chr4:163164619	chr4:163108785~163119965:+
THCA	cis	rs73108077	0.605	rs2143192	ENSG00000277112.2	RP11-755J8.1	-5.46	7.87e-08	1.24e-05	-0.38	-0.24	Red blood cell density in sickle cell anemia;	chr20:31364639	chr20:30681825~30723932:-
THCA	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-5.46	7.87e-08	1.24e-05	-0.14	-0.24	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
THCA	cis	rs79349575	0.756	rs937301	ENSG00000270781.1	RP11-501C14.9	5.46	7.88e-08	1.24e-05	0.29	0.24	Type 2 diabetes;	chr17:48968914	chr17:48899131~48899748:+
THCA	cis	rs1552244	1	rs61077902	ENSG00000232901.1	CYCSP10	5.46	7.88e-08	1.24e-05	0.33	0.24	Alzheimer's disease;	chr3:10084469	chr3:10000647~10000940:-
THCA	cis	rs9400467	0.509	rs11153287	ENSG00000271789.1	RP5-1112D6.7	-5.46	7.88e-08	1.24e-05	-0.23	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111383334	chr6:111297126~111298510:+
THCA	cis	rs9595908	0.965	rs12323094	ENSG00000212293.1	SNORA16	5.46	7.88e-08	1.24e-05	0.3	0.24	Body mass index;	chr13:32569227	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.965	rs12323101	ENSG00000212293.1	SNORA16	5.46	7.88e-08	1.24e-05	0.3	0.24	Body mass index;	chr13:32569269	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.965	rs1123462	ENSG00000212293.1	SNORA16	5.46	7.88e-08	1.24e-05	0.3	0.24	Body mass index;	chr13:32571325	chr13:32420390~32420516:-
THCA	cis	rs7246657	0.722	rs3101746	ENSG00000276846.1	CTD-3220F14.3	-5.46	7.88e-08	1.24e-05	-0.25	-0.24	Coronary artery calcification;	chr19:37655499	chr19:37314868~37315620:-
THCA	cis	rs3743266	0.613	rs12442393	ENSG00000245534.5	RORA-AS1	5.46	7.89e-08	1.24e-05	0.26	0.24	Menarche (age at onset);	chr15:60442261	chr15:60479178~60630637:+
THCA	cis	rs9506514	0.712	rs11838795	ENSG00000238286.1	SLC35E1P1	5.46	7.89e-08	1.24e-05	0.24	0.24	Coronary artery calcification;	chr13:20684189	chr13:20607268~20608131:+
THCA	cis	rs875971	1	rs4718357	ENSG00000223473.2	GS1-124K5.3	5.46	7.89e-08	1.24e-05	0.16	0.24	Aortic root size;	chr7:66495891	chr7:66491049~66493566:-
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000232559.3	GS1-124K5.12	5.46	7.89e-08	1.24e-05	0.36	0.24	Diabetic kidney disease;	chr7:66136229	chr7:66554588~66576923:-
THCA	cis	rs4650994	0.935	rs2811289	ENSG00000273384.1	RP5-1098D14.1	-5.46	7.9e-08	1.24e-05	-0.31	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178603558	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.935	rs2811290	ENSG00000273384.1	RP5-1098D14.1	-5.46	7.9e-08	1.24e-05	-0.31	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178603843	chr1:178651706~178652282:+
THCA	cis	rs79040073	0.637	rs111375880	ENSG00000259531.2	RP11-295H24.3	5.46	7.9e-08	1.24e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49120197	chr15:49365124~49366685:-
THCA	cis	rs7674212	0.541	rs2720458	ENSG00000251288.2	RP11-10L12.2	-5.46	7.91e-08	1.24e-05	-0.31	-0.24	Type 2 diabetes;	chr4:103131806	chr4:102751401~102752641:+
THCA	cis	rs6430585	0.528	rs309166	ENSG00000231890.6	DARS-AS1	-5.46	7.91e-08	1.24e-05	-0.28	-0.24	Corneal structure;	chr2:135909917	chr2:135985176~136022593:+
THCA	cis	rs897984	0.762	rs7204459	ENSG00000260911.2	RP11-196G11.2	-5.46	7.91e-08	1.24e-05	-0.2	-0.24	Dementia with Lewy bodies;	chr16:30972891	chr16:31043150~31049868:+
THCA	cis	rs897984	0.762	rs4889604	ENSG00000260911.2	RP11-196G11.2	-5.46	7.91e-08	1.24e-05	-0.2	-0.24	Dementia with Lewy bodies;	chr16:30974673	chr16:31043150~31049868:+
THCA	cis	rs4748857	0.947	rs7075197	ENSG00000224215.1	RP11-371A19.2	-5.46	7.92e-08	1.24e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23277116	chr10:23343957~23345181:+
THCA	cis	rs6686643	0.868	rs9333471	ENSG00000236206.1	RP11-306I1.2	5.46	7.92e-08	1.24e-05	0.32	0.24	Total ventricular volume;	chr1:165650475	chr1:165598463~165623331:+
THCA	cis	rs4767841	1	rs2996029	ENSG00000248636.5	RP11-768F21.1	-5.46	7.92e-08	1.24e-05	-0.26	-0.24	Urgency urinary incontinence;	chr12:119727377	chr12:119387987~119668079:-
THCA	cis	rs4950322	0.634	rs4950415	ENSG00000278811.3	LINC00624	5.46	7.93e-08	1.24e-05	0.3	0.24	Protein quantitative trait loci;	chr1:147350951	chr1:147258885~147517875:-
THCA	cis	rs9859260	0.925	rs3761717	ENSG00000226155.1	AC124944.3	-5.46	7.93e-08	1.24e-05	-0.29	-0.24	Mean corpuscular volume;	chr3:196071076	chr3:195912049~195913986:+
THCA	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	5.46	7.93e-08	1.24e-05	0.27	0.24	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
THCA	cis	rs934734	1	rs934734	ENSG00000237979.1	AC007389.1	-5.45	7.93e-08	1.24e-05	-0.28	-0.24	Rheumatoid arthritis;	chr2:65368452	chr2:65500993~65502138:-
THCA	cis	rs17772222	0.917	rs1950806	ENSG00000222990.1	RNU4-22P	5.45	7.94e-08	1.24e-05	0.33	0.24	Coronary artery calcification;	chr14:88774412	chr14:88513498~88513663:+
THCA	cis	rs8062405	1	rs3088215	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs28403629	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs61737565	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs4788099	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs9972693	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.964	rs9972768	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.965	rs62037363	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs7205323	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs4788101	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62037364	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62037365	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.929	rs11150609	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.737	rs11861132	ENSG00000278665.1	RP11-666O2.4	5.45	7.94e-08	1.25e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28599241~28601881:-
THCA	cis	rs9393777	0.92	rs13195040	ENSG00000219392.1	RP1-265C24.5	5.45	7.95e-08	1.25e-05	0.49	0.24	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28115628~28116551:+
THCA	cis	rs79040073	0.637	rs73396235	ENSG00000259531.2	RP11-295H24.3	5.45	7.95e-08	1.25e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49346956	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs73396238	ENSG00000259531.2	RP11-295H24.3	5.45	7.95e-08	1.25e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49347146	chr15:49365124~49366685:-
THCA	cis	rs690037	0.773	rs689779	ENSG00000272498.1	RP11-415F23.3	5.45	7.95e-08	1.25e-05	0.27	0.24	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16351804	chr3:16339308~16339871:+
THCA	cis	rs6545883	0.965	rs3771258	ENSG00000270820.4	RP11-355B11.2	5.45	7.95e-08	1.25e-05	0.21	0.24	Tuberculosis;	chr2:61537005	chr2:61471188~61484130:+
THCA	cis	rs897984	0.762	rs11150601	ENSG00000260911.2	RP11-196G11.2	-5.45	7.95e-08	1.25e-05	-0.2	-0.24	Dementia with Lewy bodies;	chr16:30966478	chr16:31043150~31049868:+
THCA	cis	rs897984	0.721	rs4889525	ENSG00000260911.2	RP11-196G11.2	-5.45	7.95e-08	1.25e-05	-0.2	-0.24	Dementia with Lewy bodies;	chr16:30978537	chr16:31043150~31049868:+
THCA	cis	rs12472274	0.646	rs34465035	ENSG00000279484.1	KLHL30-AS1	5.45	7.95e-08	1.25e-05	0.31	0.24	Phospholipid levels (plasma);	chr2:238205452	chr2:238152889~238155994:-
THCA	cis	rs2835345	0.561	rs5026478	ENSG00000230479.1	AP000695.6	5.45	7.96e-08	1.25e-05	0.29	0.24	Pulmonary function;	chr21:36453531	chr21:36430360~36481070:+
THCA	cis	rs12472274	0.646	rs11688732	ENSG00000279484.1	KLHL30-AS1	5.45	7.96e-08	1.25e-05	0.31	0.24	Phospholipid levels (plasma);	chr2:238187981	chr2:238152889~238155994:-
THCA	cis	rs11051970	0.879	rs2728669	ENSG00000274964.1	RP11-817I4.1	-5.45	7.96e-08	1.25e-05	-0.27	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32437717	chr12:32339368~32340724:+
THCA	cis	rs7302981	0.692	rs1979702	ENSG00000272368.2	RP4-605O3.4	-5.45	7.96e-08	1.25e-05	-0.14	-0.24	Systolic blood pressure;	chr12:50068864	chr12:50112197~50165618:+
THCA	cis	rs116095464	0.558	rs13357299	ENSG00000248925.1	CTD-2083E4.6	5.45	7.96e-08	1.25e-05	0.35	0.24	Breast cancer;	chr5:242096	chr5:269858~271516:-
THCA	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	5.45	7.96e-08	1.25e-05	0.21	0.24	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
THCA	cis	rs853679	0.538	rs13199081	ENSG00000219392.1	RP1-265C24.5	-5.45	7.97e-08	1.25e-05	-0.3	-0.24	Depression;	chr6:28364057	chr6:28115628~28116551:+
THCA	cis	rs7394190	0.748	rs4746139	ENSG00000271848.1	RP11-464F9.21	-5.45	7.97e-08	1.25e-05	-0.33	-0.24	Incident atrial fibrillation;	chr10:73647891	chr10:73654039~73674719:+
THCA	cis	rs763121	0.853	rs5757253	ENSG00000273076.1	RP3-508I15.22	5.45	7.97e-08	1.25e-05	0.25	0.24	Menopause (age at onset);	chr22:38708315	chr22:38743495~38743910:+
THCA	cis	rs7829975	0.742	rs882462	ENSG00000254153.1	CTA-398F10.2	-5.45	7.97e-08	1.25e-05	-0.26	-0.24	Mood instability;	chr8:8821020	chr8:8456909~8461337:-
THCA	cis	rs2436845	0.627	rs34352733	ENSG00000253669.3	KB-1732A1.1	-5.45	7.98e-08	1.25e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102819280	chr8:102805517~102809971:+
THCA	cis	rs2439831	1	rs527921	ENSG00000166763.7	STRCP1	-5.45	7.98e-08	1.25e-05	-0.33	-0.24	Lung cancer in ever smokers;	chr15:43478218	chr15:43699488~43718184:-
THCA	cis	rs72772090	0.71	rs112178674	ENSG00000248734.2	CTD-2260A17.1	-5.45	7.98e-08	1.25e-05	-0.41	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96724651	chr5:96784777~96785999:+
THCA	cis	rs7809615	0.515	rs6961634	ENSG00000244219.5	GS1-259H13.2	-5.45	7.98e-08	1.25e-05	-0.3	-0.24	Blood metabolite ratios;	chr7:99584216	chr7:99598066~99610813:+
THCA	cis	rs7727544	0.636	rs2631365	ENSG00000224431.1	AC063976.7	-5.45	7.99e-08	1.25e-05	-0.21	-0.24	Blood metabolite levels;	chr5:132370257	chr5:132199456~132203487:+
THCA	cis	rs890448	0.796	rs7690316	ENSG00000254531.1	FLJ20021	5.45	8e-08	1.25e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417949	chr4:101347780~101348883:+
THCA	cis	rs11051970	0.879	rs2467065	ENSG00000274964.1	RP11-817I4.1	-5.45	8.01e-08	1.25e-05	-0.27	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32433131	chr12:32339368~32340724:+
THCA	cis	rs12935418	0.616	rs2549857	ENSG00000278985.1	RP11-303E16.9	5.45	8.01e-08	1.25e-05	0.26	0.24	Mean corpuscular volume;	chr16:80993353	chr16:80982319~80984094:-
THCA	cis	rs10090774	0.786	rs11780023	ENSG00000279766.1	RP11-642A1.2	-5.45	8.01e-08	1.26e-05	-0.31	-0.24	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140982679	chr8:140572142~140572812:-
THCA	cis	rs3785574	0.927	rs2008018	ENSG00000240280.5	TCAM1P	-5.45	8.01e-08	1.26e-05	-0.32	-0.24	Height;	chr17:63877111	chr17:63849292~63864379:+
THCA	cis	rs9818758	0.607	rs13068038	ENSG00000270441.1	RP11-694I15.7	5.45	8.01e-08	1.26e-05	0.34	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49256817	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs34343820	ENSG00000270441.1	RP11-694I15.7	5.45	8.01e-08	1.26e-05	0.34	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272101	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs10049462	ENSG00000270441.1	RP11-694I15.7	5.45	8.01e-08	1.26e-05	0.34	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272251	chr3:49140086~49160851:-
THCA	cis	rs67340775	0.541	rs200965	ENSG00000280107.1	AL022393.9	-5.45	8.01e-08	1.26e-05	-0.33	-0.24	Lung cancer in ever smokers;	chr6:27898606	chr6:28170845~28172521:+
THCA	cis	rs73242632	1	rs2227902	ENSG00000269949.1	RP11-738E22.3	5.45	8.02e-08	1.26e-05	0.57	0.24	Congenital heart disease (maternal effect);	chr4:56930934	chr4:56960927~56961373:-
THCA	cis	rs9283706	0.623	rs10041624	ENSG00000229666.1	MAST4-AS1	-5.45	8.02e-08	1.26e-05	-0.33	-0.24	Coronary artery disease;	chr5:67019033	chr5:67001383~67003953:-
THCA	cis	rs2348418	0.702	rs10843116	ENSG00000247934.4	RP11-967K21.1	-5.45	8.02e-08	1.26e-05	-0.21	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28162248	chr12:28163298~28190738:-
THCA	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	5.45	8.02e-08	1.26e-05	0.32	0.24	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
THCA	cis	rs4713118	0.629	rs203888	ENSG00000272009.1	RP1-313I6.12	-5.45	8.02e-08	1.26e-05	-0.27	-0.24	Parkinson's disease;	chr6:28053811	chr6:28078792~28081130:-
THCA	cis	rs2282300	1	rs12796693	ENSG00000242353.1	RP4-710M3.1	-5.45	8.03e-08	1.26e-05	-0.22	-0.24	Morning vs. evening chronotype;	chr11:30408036	chr11:30368148~30368646:+
THCA	cis	rs79040073	0.682	rs12592277	ENSG00000259531.2	RP11-295H24.3	5.45	8.03e-08	1.26e-05	0.32	0.24	Lung cancer in ever smokers;	chr15:49436562	chr15:49365124~49366685:-
THCA	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-5.45	8.03e-08	1.26e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
THCA	cis	rs6445975	0.531	rs6804460	ENSG00000272360.1	RP11-359I18.5	5.45	8.03e-08	1.26e-05	0.28	0.24	Systemic lupus erythematosus;	chr3:58380130	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs6445974	ENSG00000272360.1	RP11-359I18.5	5.45	8.03e-08	1.26e-05	0.28	0.24	Systemic lupus erythematosus;	chr3:58381110	chr3:58490830~58491291:-
THCA	cis	rs2835345	0.596	rs62229441	ENSG00000230479.1	AP000695.6	5.45	8.03e-08	1.26e-05	0.3	0.24	Pulmonary function;	chr21:36447559	chr21:36430360~36481070:+
THCA	cis	rs2281636	1	rs2804418	ENSG00000260475.1	RP11-85A1.3	-5.45	8.03e-08	1.26e-05	-0.22	-0.24	Obesity-related traits;	chr10:99752337	chr10:99621055~99621918:+
THCA	cis	rs11089937	0.667	rs9622981	ENSG00000211638.2	IGLV8-61	-5.45	8.04e-08	1.26e-05	-0.21	-0.24	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22098700~22099212:+
THCA	cis	rs12908161	0.92	rs12904605	ENSG00000275120.1	RP11-182J1.17	5.45	8.04e-08	1.26e-05	0.29	0.24	Schizophrenia;	chr15:84658188	chr15:84599434~84606463:-
THCA	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-5.45	8.04e-08	1.26e-05	-0.3	-0.24	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
THCA	cis	rs7412746	0.611	rs72704679	ENSG00000231073.1	RP11-316M1.3	5.45	8.04e-08	1.26e-05	0.28	0.24	Melanoma;	chr1:150925001	chr1:150973123~150975534:+
THCA	cis	rs16976116	0.619	rs7168057	ENSG00000279145.1	RP11-547D13.1	-5.45	8.04e-08	1.26e-05	-0.26	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55173285	chr15:55171972~55178175:-
THCA	cis	rs1075232	1	rs1075232	ENSG00000215302.7	CTD-3092A11.1	-5.45	8.05e-08	1.26e-05	-0.55	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31449013	chr15:30470779~30507623:+
THCA	cis	rs9876781	0.9	rs1037773	ENSG00000229759.1	MRPS18AP1	5.45	8.05e-08	1.26e-05	0.29	0.24	Longevity;	chr3:48426493	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs2279077	ENSG00000229759.1	MRPS18AP1	5.45	8.05e-08	1.26e-05	0.29	0.24	Longevity;	chr3:48432839	chr3:48256350~48256938:-
THCA	cis	rs6479901	0.793	rs4450077	ENSG00000232075.1	MRPL35P2	-5.45	8.05e-08	1.26e-05	-0.36	-0.24	Intelligence (multi-trait analysis);	chr10:63253976	chr10:63634317~63634827:-
THCA	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-5.45	8.06e-08	1.26e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
THCA	cis	rs2243480	1	rs313820	ENSG00000232559.3	GS1-124K5.12	5.45	8.06e-08	1.26e-05	0.35	0.24	Diabetic kidney disease;	chr7:66109479	chr7:66554588~66576923:-
THCA	cis	rs934734	0.736	rs6738087	ENSG00000281920.1	RP11-418H16.1	5.45	8.06e-08	1.26e-05	0.31	0.24	Rheumatoid arthritis;	chr2:65365191	chr2:65623272~65628424:+
THCA	cis	rs9990333	0.562	rs73210005	ENSG00000242086.7	LINC00969	5.45	8.06e-08	1.26e-05	0.25	0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195658062~195739964:+
THCA	cis	rs10895275	0.649	rs11225169	ENSG00000277459.1	RP11-732A21.3	5.45	8.07e-08	1.26e-05	0.19	0.24	Migraine;	chr11:102220901	chr11:102109827~102110457:-
THCA	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-5.45	8.07e-08	1.26e-05	-0.3	-0.24	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
THCA	cis	rs7824557	0.62	rs6996368	ENSG00000154316.13	TDH	-5.45	8.07e-08	1.26e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11325195	chr8:11339637~11368452:+
THCA	cis	rs2179367	0.632	rs66672129	ENSG00000268592.3	RAET1E-AS1	5.45	8.08e-08	1.26e-05	0.35	0.24	Dupuytren's disease;	chr6:149334387	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498322	ENSG00000268592.3	RAET1E-AS1	5.45	8.08e-08	1.26e-05	0.35	0.24	Dupuytren's disease;	chr6:149335950	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498323	ENSG00000268592.3	RAET1E-AS1	5.45	8.08e-08	1.26e-05	0.35	0.24	Dupuytren's disease;	chr6:149336077	chr6:149863494~149919507:+
THCA	cis	rs1979679	0.879	rs980920	ENSG00000278733.1	RP11-425D17.1	5.45	8.08e-08	1.27e-05	0.25	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28316178	chr12:28185625~28186190:-
THCA	cis	rs10895275	0.886	rs12787996	ENSG00000277459.1	RP11-732A21.3	-5.45	8.08e-08	1.27e-05	-0.19	-0.24	Migraine;	chr11:102186337	chr11:102109827~102110457:-
THCA	cis	rs7702057	0.53	rs61672521	ENSG00000271918.1	CTD-2287O16.5	5.45	8.08e-08	1.27e-05	0.28	0.24	Amyotrophic lateral sclerosis;	chr5:116112548	chr5:116083807~116085416:-
THCA	cis	rs9859260	1	rs11718657	ENSG00000226155.1	AC124944.3	-5.45	8.09e-08	1.27e-05	-0.29	-0.24	Mean corpuscular volume;	chr3:196070682	chr3:195912049~195913986:+
THCA	cis	rs9859260	0.961	rs11185506	ENSG00000226155.1	AC124944.3	-5.45	8.09e-08	1.27e-05	-0.29	-0.24	Mean corpuscular volume;	chr3:196070705	chr3:195912049~195913986:+
THCA	cis	rs2179367	0.552	rs11155652	ENSG00000268592.3	RAET1E-AS1	5.45	8.09e-08	1.27e-05	0.35	0.24	Dupuytren's disease;	chr6:149417849	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12209364	ENSG00000268592.3	RAET1E-AS1	5.45	8.09e-08	1.27e-05	0.35	0.24	Dupuytren's disease;	chr6:149418062	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9322179	ENSG00000268592.3	RAET1E-AS1	5.45	8.09e-08	1.27e-05	0.35	0.24	Dupuytren's disease;	chr6:149418664	chr6:149863494~149919507:+
THCA	cis	rs12681287	0.711	rs28506490	ENSG00000254231.1	CTD-2284J15.1	5.45	8.1e-08	1.27e-05	0.27	0.24	Caudate activity during reward;	chr8:86233889	chr8:86333274~86343314:-
THCA	cis	rs997295	0.57	rs17241808	ENSG00000270964.1	RP11-502I4.3	-5.45	8.1e-08	1.27e-05	-0.2	-0.24	Motion sickness;	chr15:67600454	chr15:67541072~67542604:-
THCA	cis	rs7412746	0.611	rs10888398	ENSG00000231073.1	RP11-316M1.3	-5.45	8.1e-08	1.27e-05	-0.28	-0.24	Melanoma;	chr1:150914306	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs4970984	ENSG00000231073.1	RP11-316M1.3	5.45	8.1e-08	1.27e-05	0.28	0.24	Melanoma;	chr1:150914901	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs4970985	ENSG00000231073.1	RP11-316M1.3	-5.45	8.1e-08	1.27e-05	-0.28	-0.24	Melanoma;	chr1:150914966	chr1:150973123~150975534:+
THCA	cis	rs9733	0.526	rs6587542	ENSG00000231073.1	RP11-316M1.3	5.45	8.1e-08	1.27e-05	0.28	0.24	Tonsillectomy;	chr1:150935225	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs4970931	ENSG00000231073.1	RP11-316M1.3	5.45	8.1e-08	1.27e-05	0.28	0.24	Melanoma;	chr1:150938251	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs9661876	ENSG00000231073.1	RP11-316M1.3	5.45	8.1e-08	1.27e-05	0.28	0.24	Melanoma;	chr1:150938435	chr1:150973123~150975534:+
THCA	cis	rs9733	0.503	rs7556451	ENSG00000231073.1	RP11-316M1.3	5.45	8.1e-08	1.27e-05	0.28	0.24	Tonsillectomy;	chr1:150940666	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs2271076	ENSG00000231073.1	RP11-316M1.3	5.45	8.1e-08	1.27e-05	0.28	0.24	Melanoma;	chr1:150944181	chr1:150973123~150975534:+
THCA	cis	rs6545883	0.899	rs1562309	ENSG00000270820.4	RP11-355B11.2	5.45	8.11e-08	1.27e-05	0.21	0.24	Tuberculosis;	chr2:61542991	chr2:61471188~61484130:+
THCA	cis	rs7267979	0.528	rs6076366	ENSG00000125804.12	FAM182A	5.45	8.11e-08	1.27e-05	0.31	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26054655~26086917:+
THCA	cis	rs10771431	0.81	rs10771418	ENSG00000256069.6	A2MP1	5.45	8.11e-08	1.27e-05	0.27	0.24	Breast size;	chr12:9206399	chr12:9228533~9275817:-
THCA	cis	rs6088590	1	rs11698996	ENSG00000276073.1	RP5-1125A11.7	-5.45	8.12e-08	1.27e-05	-0.24	-0.24	Coronary artery disease;	chr20:34861936	chr20:33985617~33988989:-
THCA	cis	rs6430585	0.583	rs12475516	ENSG00000231890.6	DARS-AS1	-5.45	8.12e-08	1.27e-05	-0.27	-0.24	Corneal structure;	chr2:135803191	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.583	rs2304370	ENSG00000231890.6	DARS-AS1	-5.45	8.12e-08	1.27e-05	-0.27	-0.24	Corneal structure;	chr2:135804165	chr2:135985176~136022593:+
THCA	cis	rs10895275	0.625	rs10791569	ENSG00000277459.1	RP11-732A21.3	-5.45	8.12e-08	1.27e-05	-0.19	-0.24	Migraine;	chr11:102217604	chr11:102109827~102110457:-
THCA	cis	rs6968419	0.755	rs3823977	ENSG00000237870.5	AC073130.1	5.45	8.12e-08	1.27e-05	0.27	0.24	Intraocular pressure;	chr7:116253353	chr7:116275606~116286734:-
THCA	cis	rs6997458	0.742	rs10111039	ENSG00000253549.4	RP11-317J10.2	5.45	8.13e-08	1.27e-05	0.25	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85484427	chr8:85441851~85464915:-
THCA	cis	rs5758659	1	rs134902	ENSG00000182057.4	OGFRP1	5.45	8.14e-08	1.27e-05	0.27	0.24	Cognitive function;	chr22:42287991	chr22:42269753~42275196:+
THCA	cis	rs3785574	0.962	rs4968660	ENSG00000240280.5	TCAM1P	-5.45	8.15e-08	1.27e-05	-0.33	-0.24	Height;	chr17:63714861	chr17:63849292~63864379:+
THCA	cis	rs8017455	0.591	rs2075173	ENSG00000259167.2	NMNAT1P1	-5.45	8.15e-08	1.28e-05	-0.42	-0.24	Hair morphology;	chr14:81088273	chr14:81032529~81033404:+
THCA	cis	rs755249	0.567	rs4660543	ENSG00000228060.1	RP11-69E11.8	-5.45	8.15e-08	1.28e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39565160~39573203:+
THCA	cis	rs527616	0.93	rs604702	ENSG00000260372.5	AQP4-AS1	5.45	8.16e-08	1.28e-05	0.26	0.24	Breast cancer;	chr18:26751502	chr18:26655742~27190698:+
THCA	cis	rs7829975	0.511	rs1543238	ENSG00000253981.4	ALG1L13P	5.45	8.16e-08	1.28e-05	0.23	0.24	Mood instability;	chr8:8277287	chr8:8236003~8244667:-
THCA	cis	rs7824557	0.767	rs6985146	ENSG00000154316.13	TDH	-5.45	8.16e-08	1.28e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11313212	chr8:11339637~11368452:+
THCA	cis	rs1520333	0.602	rs967426	ENSG00000254352.1	RP11-578O24.2	5.45	8.16e-08	1.28e-05	0.25	0.24	Multiple sclerosis;	chr8:78585664	chr8:78723796~78724136:-
THCA	cis	rs9283706	0.623	rs1159201	ENSG00000229666.1	MAST4-AS1	5.45	8.17e-08	1.28e-05	0.33	0.24	Coronary artery disease;	chr5:67015511	chr5:67001383~67003953:-
THCA	cis	rs17772222	0.682	rs1152377	ENSG00000258983.2	RP11-507K2.2	-5.45	8.17e-08	1.28e-05	-0.28	-0.24	Coronary artery calcification;	chr14:88496243	chr14:88499334~88515502:+
THCA	cis	rs867371	1	rs8042464	ENSG00000259429.4	UBE2Q2P2	-5.45	8.17e-08	1.28e-05	-0.2	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82355142~82420075:+
THCA	cis	rs77972916	0.505	rs1322	ENSG00000234936.1	AC010883.5	5.45	8.18e-08	1.28e-05	0.27	0.24	Granulocyte percentage of myeloid white cells;	chr2:43294028	chr2:43229573~43233394:+
THCA	cis	rs890448	0.726	rs1031033	ENSG00000254531.1	FLJ20021	5.45	8.19e-08	1.28e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101327679	chr4:101347780~101348883:+
THCA	cis	rs11089937	0.864	rs5757041	ENSG00000211639.2	IGLV4-60	5.45	8.19e-08	1.28e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22162199~22162681:+
THCA	cis	rs7615952	0.546	rs2979333	ENSG00000243429.1	OR7E29P	5.45	8.19e-08	1.28e-05	0.35	0.24	Blood pressure (smoking interaction);	chr3:125641499	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.546	rs111812401	ENSG00000243429.1	OR7E29P	5.45	8.19e-08	1.28e-05	0.35	0.24	Blood pressure (smoking interaction);	chr3:125642651	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.546	rs2979350	ENSG00000243429.1	OR7E29P	5.45	8.19e-08	1.28e-05	0.35	0.24	Blood pressure (smoking interaction);	chr3:125643371	chr3:125712139~125713045:+
THCA	cis	rs875971	0.545	rs4441996	ENSG00000232546.1	RP11-458F8.1	-5.45	8.19e-08	1.28e-05	-0.23	-0.24	Aortic root size;	chr7:66123233	chr7:66848496~66858136:+
THCA	cis	rs7005380	0.6	rs13267896	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119908414	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs13275524	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119908701	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs6469867	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119909172	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.58	rs6469868	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119909601	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.606	rs6469869	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119909696	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6469870	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119909773	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6469871	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119909839	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs6469872	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119910007	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs7015470	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119910101	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs6995139	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119910157	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10217077	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119910943	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs939242	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119912030	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs939241	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119912297	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs10216503	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119912843	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs7824545	ENSG00000245330.4	KB-1471A8.1	5.45	8.2e-08	1.28e-05	0.24	0.24	Interstitial lung disease;	chr8:119913381	chr8:119867419~119874488:-
THCA	cis	rs1322639	0.614	rs6900964	ENSG00000261039.2	RP11-417E7.2	-5.45	8.22e-08	1.29e-05	-0.36	-0.24	Pulse pressure;	chr6:169166668	chr6:169175304~169182740:-
THCA	cis	rs9843304	0.528	rs9860963	ENSG00000240541.2	TM4SF1-AS1	-5.45	8.22e-08	1.29e-05	-0.22	-0.24	Gallstone disease;	chr3:149479678	chr3:149377778~149386583:+
THCA	cis	rs28476539	0.567	rs6822801	ENSG00000270480.1	RP11-57B24.1	5.45	8.23e-08	1.29e-05	0.39	0.24	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82655676	chr4:82691737~82692468:+
THCA	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	5.45	8.23e-08	1.29e-05	0.15	0.24	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
THCA	cis	rs2289700	0.561	rs16970223	ENSG00000252061.1	RNU6-415P	-5.45	8.23e-08	1.29e-05	-0.37	-0.24	Bipolar disorder;	chr15:78901944	chr15:78898840~78898936:-
THCA	cis	rs12681287	0.752	rs4310184	ENSG00000254231.1	CTD-2284J15.1	5.45	8.23e-08	1.29e-05	0.27	0.24	Caudate activity during reward;	chr8:86233024	chr8:86333274~86343314:-
THCA	cis	rs6657613	0.658	rs3738814	ENSG00000186301.8	MST1P2	-5.45	8.24e-08	1.29e-05	-0.21	-0.24	Hip circumference adjusted for BMI;	chr1:17005181	chr1:16645622~16650289:+
THCA	cis	rs6792584	0.888	rs6548593	ENSG00000241316.5	SUCLG2-AS1	5.45	8.24e-08	1.29e-05	0.25	0.24	Corneal astigmatism;	chr3:67486264	chr3:67654697~67947713:+
THCA	cis	rs7809950	0.817	rs2712230	ENSG00000238832.1	snoU109	5.45	8.24e-08	1.29e-05	0.28	0.24	Coronary artery disease;	chr7:107653706	chr7:107603363~107603507:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000273142.1	RP11-458F8.4	5.45	8.25e-08	1.29e-05	0.19	0.24	Aortic root size;	chr7:66633495	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000273142.1	RP11-458F8.4	5.45	8.25e-08	1.29e-05	0.19	0.24	Aortic root size;	chr7:66638707	chr7:66902857~66906297:+
THCA	cis	rs8033133	0.957	rs3742952	ENSG00000251896.1	SNORD116-27	-5.45	8.25e-08	1.29e-05	-0.27	-0.24	Blood osmolality (transformed sodium);	chr15:25105879	chr15:25101575~25101666:+
THCA	cis	rs1865760	0.686	rs12210098	ENSG00000272462.2	U91328.19	-5.45	8.25e-08	1.29e-05	-0.22	-0.24	Height;	chr6:25963738	chr6:25992662~26001775:+
THCA	cis	rs12908161	0.959	rs1051168	ENSG00000275120.1	RP11-182J1.17	5.45	8.25e-08	1.29e-05	0.29	0.24	Schizophrenia;	chr15:84657289	chr15:84599434~84606463:-
THCA	cis	rs16958440	0.867	rs62095427	ENSG00000267800.1	RP11-49K24.5	-5.45	8.26e-08	1.29e-05	-0.56	-0.24	Sitting height ratio;	chr18:47067850	chr18:47137018~47137290:+
THCA	cis	rs12935418	0.579	rs2123627	ENSG00000278985.1	RP11-303E16.9	-5.45	8.26e-08	1.29e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80988211	chr16:80982319~80984094:-
THCA	cis	rs1125355	0.557	rs4362514	ENSG00000251491.2	OR7E28P	-5.45	8.26e-08	1.29e-05	-0.41	-0.24	Alzheimer's disease in APOE e4+ carriers;	chr2:158750464	chr2:158862311~158863285:+
THCA	cis	rs75920871	0.528	rs7950093	ENSG00000254851.1	RP11-109L13.1	5.45	8.26e-08	1.29e-05	0.35	0.24	Subjective well-being;	chr11:117092803	chr11:117135528~117138582:+
THCA	cis	rs1876905	0.539	rs240958	ENSG00000271789.1	RP5-1112D6.7	5.45	8.26e-08	1.29e-05	0.31	0.24	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111297126~111298510:+
THCA	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	5.45	8.27e-08	1.29e-05	0.26	0.24	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
THCA	cis	rs7727544	0.735	rs274566	ENSG00000224431.1	AC063976.7	-5.45	8.27e-08	1.29e-05	-0.21	-0.24	Blood metabolite levels;	chr5:132379319	chr5:132199456~132203487:+
THCA	cis	rs4748857	0.685	rs11013405	ENSG00000224215.1	RP11-371A19.2	-5.45	8.28e-08	1.29e-05	-0.33	-0.24	Systemic lupus erythematosus;	chr10:23340911	chr10:23343957~23345181:+
THCA	cis	rs1318937	0.51	rs78164273	ENSG00000224660.1	SH3BP5-AS1	5.45	8.28e-08	1.29e-05	0.23	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15203625	chr3:15254184~15264493:+
THCA	cis	rs17345786	0.628	rs11718446	ENSG00000256628.3	ZBTB11-AS1	5.45	8.28e-08	1.29e-05	0.29	0.24	Colonoscopy-negative controls vs population controls;	chr3:101833709	chr3:101676475~101679217:+
THCA	cis	rs7727544	0.735	rs273913	ENSG00000224431.1	AC063976.7	5.45	8.29e-08	1.29e-05	0.21	0.24	Blood metabolite levels;	chr5:132325463	chr5:132199456~132203487:+
THCA	cis	rs6908034	0.607	rs77791009	ENSG00000227116.1	RP3-471C18.1	-5.45	8.29e-08	1.29e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812371	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs75060331	ENSG00000227116.1	RP3-471C18.1	-5.45	8.29e-08	1.29e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812725	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs77753186	ENSG00000227116.1	RP3-471C18.1	-5.45	8.29e-08	1.29e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812749	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs79162793	ENSG00000227116.1	RP3-471C18.1	-5.45	8.29e-08	1.29e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812834	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs76245225	ENSG00000227116.1	RP3-471C18.1	-5.45	8.29e-08	1.29e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812957	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs75110577	ENSG00000227116.1	RP3-471C18.1	-5.45	8.29e-08	1.29e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814292	chr6:19730427~19734567:-
THCA	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	5.45	8.29e-08	1.29e-05	0.35	0.24	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	5.45	8.29e-08	1.29e-05	0.35	0.24	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	5.45	8.29e-08	1.29e-05	0.35	0.24	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	5.45	8.29e-08	1.29e-05	0.35	0.24	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	5.45	8.29e-08	1.29e-05	0.35	0.24	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	5.45	8.29e-08	1.29e-05	0.35	0.24	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	5.45	8.29e-08	1.29e-05	0.35	0.24	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	5.45	8.29e-08	1.29e-05	0.35	0.24	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
THCA	cis	rs6430585	0.583	rs6728946	ENSG00000231890.6	DARS-AS1	-5.45	8.29e-08	1.3e-05	-0.29	-0.24	Corneal structure;	chr2:135877773	chr2:135985176~136022593:+
THCA	cis	rs651907	0.557	rs13081846	ENSG00000244119.1	PDCL3P4	5.45	8.29e-08	1.3e-05	0.22	0.24	Colorectal cancer;	chr3:101664477	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs11711079	ENSG00000244119.1	PDCL3P4	5.45	8.29e-08	1.3e-05	0.22	0.24	Colorectal cancer;	chr3:101668074	chr3:101712472~101713191:+
THCA	cis	rs17345786	0.511	rs13061565	ENSG00000244119.1	PDCL3P4	5.45	8.29e-08	1.3e-05	0.22	0.24	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs7651404	ENSG00000244119.1	PDCL3P4	5.45	8.29e-08	1.3e-05	0.22	0.24	Colorectal cancer;	chr3:101674450	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs3806653	ENSG00000244119.1	PDCL3P4	5.45	8.29e-08	1.3e-05	0.22	0.24	Colorectal cancer;	chr3:101678128	chr3:101712472~101713191:+
THCA	cis	rs10761482	0.544	rs1934760	ENSG00000254271.1	RP11-131N11.4	5.45	8.29e-08	1.3e-05	0.33	0.24	Schizophrenia;	chr10:60496987	chr10:60734342~60741828:+
THCA	cis	rs6545883	0.899	rs12473030	ENSG00000270820.4	RP11-355B11.2	5.45	8.29e-08	1.3e-05	0.21	0.24	Tuberculosis;	chr2:61493362	chr2:61471188~61484130:+
THCA	cis	rs783540	0.681	rs1259178	ENSG00000278603.1	RP13-608F4.5	-5.45	8.29e-08	1.3e-05	-0.34	-0.24	Schizophrenia;	chr15:82603127	chr15:82472203~82472426:+
THCA	cis	rs7851660	0.809	rs7866436	ENSG00000214417.4	KRT18P13	-5.45	8.3e-08	1.3e-05	-0.22	-0.24	Strep throat;	chr9:97887814	chr9:97698922~97700734:+
THCA	cis	rs17345786	0.861	rs11711808	ENSG00000256628.3	ZBTB11-AS1	5.45	8.3e-08	1.3e-05	0.31	0.24	Colonoscopy-negative controls vs population controls;	chr3:101516257	chr3:101676475~101679217:+
THCA	cis	rs748404	0.666	rs12906481	ENSG00000205771.5	CATSPER2P1	-5.45	8.3e-08	1.3e-05	-0.31	-0.24	Lung cancer;	chr15:43467356	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs35958032	ENSG00000205771.5	CATSPER2P1	-5.45	8.3e-08	1.3e-05	-0.31	-0.24	Lung cancer;	chr15:43494397	chr15:43726918~43747094:-
THCA	cis	rs2239547	0.522	rs7652131	ENSG00000242142.1	SERBP1P3	5.45	8.3e-08	1.3e-05	0.31	0.24	Schizophrenia;	chr3:52963138	chr3:53064283~53065091:-
THCA	cis	rs1400745	0.729	rs28472856	ENSG00000258738.1	RP11-73E17.2	5.45	8.3e-08	1.3e-05	0.29	0.24	Monocyte count;	chr14:34862951	chr14:34874343~34876459:+
THCA	cis	rs6908034	0.607	rs77386860	ENSG00000227116.1	RP3-471C18.1	-5.45	8.3e-08	1.3e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814524	chr6:19730427~19734567:-
THCA	cis	rs752010	0.806	rs943375	ENSG00000230638.4	RP11-486B10.4	-5.45	8.31e-08	1.3e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41626481	chr1:41542069~41544310:+
THCA	cis	rs1050631	0.592	rs483583	ENSG00000260552.1	RP11-49I11.1	5.45	8.31e-08	1.3e-05	0.31	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36179054	chr18:36179996~36187448:-
THCA	cis	rs4948275	0.74	rs2787699	ENSG00000237233.2	TMEM26-AS1	-5.45	8.31e-08	1.3e-05	-0.33	-0.24	Night sleep phenotypes;	chr10:61539102	chr10:61452639~61481956:+
THCA	cis	rs2944755	0.58	rs13251004	ENSG00000279766.1	RP11-642A1.2	-5.45	8.31e-08	1.3e-05	-0.33	-0.24	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140576027	chr8:140572142~140572812:-
THCA	cis	rs7727544	0.526	rs4705908	ENSG00000233006.5	AC034220.3	5.45	8.32e-08	1.3e-05	0.2	0.24	Blood metabolite levels;	chr5:132011827	chr5:132311285~132369916:-
THCA	cis	rs11051970	0.879	rs2651378	ENSG00000274964.1	RP11-817I4.1	-5.45	8.32e-08	1.3e-05	-0.27	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32428860	chr12:32339368~32340724:+
THCA	cis	rs8064024	0.676	rs9926458	ENSG00000267077.1	RP11-127I20.5	5.45	8.32e-08	1.3e-05	0.28	0.24	Cancer;	chr16:4822627	chr16:4795265~4796532:-
THCA	cis	rs875971	0.964	rs6978429	ENSG00000223473.2	GS1-124K5.3	5.45	8.32e-08	1.3e-05	0.16	0.24	Aortic root size;	chr7:66494889	chr7:66491049~66493566:-
THCA	cis	rs875971	0.929	rs12535036	ENSG00000223473.2	GS1-124K5.3	5.45	8.32e-08	1.3e-05	0.16	0.24	Aortic root size;	chr7:66499076	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs12698523	ENSG00000223473.2	GS1-124K5.3	5.45	8.32e-08	1.3e-05	0.16	0.24	Aortic root size;	chr7:66503126	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs6970030	ENSG00000223473.2	GS1-124K5.3	5.45	8.32e-08	1.3e-05	0.16	0.24	Aortic root size;	chr7:66503692	chr7:66491049~66493566:-
THCA	cis	rs875971	0.928	rs6970357	ENSG00000223473.2	GS1-124K5.3	5.45	8.32e-08	1.3e-05	0.16	0.24	Aortic root size;	chr7:66503891	chr7:66491049~66493566:-
THCA	cis	rs7403037	0.848	rs7495125	ENSG00000259905.4	PWRN1	5.45	8.32e-08	1.3e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24588489	chr15:24493137~24652130:+
THCA	cis	rs6969780	0.915	rs10085570	ENSG00000233429.8	HOTAIRM1	-5.45	8.32e-08	1.3e-05	-0.32	-0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111569	chr7:27095647~27100265:+
THCA	cis	rs758324	0.687	rs301834	ENSG00000237714.1	P4HA2-AS1	-5.45	8.32e-08	1.3e-05	-0.37	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132166212	chr5:132184876~132192808:+
THCA	cis	rs7403037	0.601	rs4778420	ENSG00000259905.4	PWRN1	5.45	8.32e-08	1.3e-05	0.27	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24193994	chr15:24493137~24652130:+
THCA	cis	rs75920871	0.528	rs11216255	ENSG00000254851.1	RP11-109L13.1	5.45	8.33e-08	1.3e-05	0.35	0.24	Subjective well-being;	chr11:117059279	chr11:117135528~117138582:+
THCA	cis	rs2354432	0.607	rs1890039	ENSG00000226015.2	CCT8P1	5.45	8.34e-08	1.3e-05	0.45	0.24	Mitochondrial DNA levels;	chr1:147210383	chr1:147203276~147204932:-
THCA	cis	rs2354432	0.607	rs1530336	ENSG00000226015.2	CCT8P1	5.45	8.34e-08	1.3e-05	0.45	0.24	Mitochondrial DNA levels;	chr1:147213554	chr1:147203276~147204932:-
THCA	cis	rs2354432	0.607	rs1530335	ENSG00000226015.2	CCT8P1	5.45	8.34e-08	1.3e-05	0.45	0.24	Mitochondrial DNA levels;	chr1:147213721	chr1:147203276~147204932:-
THCA	cis	rs6988985	0.678	rs1799998	ENSG00000247317.3	RP11-273G15.2	-5.45	8.34e-08	1.3e-05	-0.26	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918184	chr8:142981738~143018437:-
THCA	cis	rs6988985	0.678	rs28659182	ENSG00000247317.3	RP11-273G15.2	-5.45	8.34e-08	1.3e-05	-0.26	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918503	chr8:142981738~143018437:-
THCA	cis	rs4748857	0.782	rs4748848	ENSG00000224215.1	RP11-371A19.2	-5.45	8.35e-08	1.3e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23242315	chr10:23343957~23345181:+
THCA	cis	rs1075265	0.509	rs10178643	ENSG00000233266.1	HMGB1P31	5.45	8.35e-08	1.3e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53728341	chr2:54051334~54051760:+
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000273796.1	LL21NC02-21A1.1	-5.45	8.35e-08	1.3e-05	-0.26	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45403809~45404369:-
THCA	cis	rs6951245	0.608	rs10252234	ENSG00000229043.2	AC091729.9	-5.45	8.35e-08	1.3e-05	-0.31	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074745	chr7:1160374~1165267:+
THCA	cis	rs9733	0.519	rs7529194	ENSG00000231073.1	RP11-316M1.3	5.45	8.35e-08	1.3e-05	0.29	0.24	Tonsillectomy;	chr1:150650144	chr1:150973123~150975534:+
THCA	cis	rs5742933	0.696	rs6748102	ENSG00000273240.1	RP11-455J20.3	-5.45	8.35e-08	1.3e-05	-0.33	-0.24	Ferritin levels;	chr2:189760786	chr2:189763859~189764456:-
THCA	cis	rs9990333	0.526	rs11719682	ENSG00000231464.1	AC024937.4	5.45	8.36e-08	1.3e-05	0.32	0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196107331	chr3:195996738~195998233:+
THCA	cis	rs7005380	0.62	rs7387264	ENSG00000245330.4	KB-1471A8.1	5.45	8.36e-08	1.3e-05	0.24	0.24	Interstitial lung disease;	chr8:119913758	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.62	rs7388508	ENSG00000245330.4	KB-1471A8.1	5.45	8.36e-08	1.3e-05	0.24	0.24	Interstitial lung disease;	chr8:119913913	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.6	rs1607624	ENSG00000245330.4	KB-1471A8.1	5.45	8.36e-08	1.3e-05	0.24	0.24	Interstitial lung disease;	chr8:119917049	chr8:119867419~119874488:-
THCA	cis	rs2944755	0.686	rs7824304	ENSG00000279766.1	RP11-642A1.2	-5.45	8.36e-08	1.3e-05	-0.33	-0.24	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140573918	chr8:140572142~140572812:-
THCA	cis	rs440932	0.757	rs330943	ENSG00000254340.1	RP11-10A14.3	5.44	8.36e-08	1.31e-05	0.27	0.24	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:9141424~9145435:+
THCA	cis	rs10888838	0.941	rs11206305	ENSG00000198711.5	SSBP3-AS1	5.44	8.37e-08	1.31e-05	0.27	0.24	Mitochondrial DNA levels;	chr1:54222538	chr1:54236440~54239063:+
THCA	cis	rs1707322	0.721	rs6699418	ENSG00000281133.1	AL355480.3	-5.44	8.37e-08	1.31e-05	-0.3	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs4431884	ENSG00000281133.1	AL355480.3	-5.44	8.37e-08	1.31e-05	-0.3	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.65	rs4660879	ENSG00000281133.1	AL355480.3	-5.44	8.37e-08	1.31e-05	-0.3	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs10789468	ENSG00000281133.1	AL355480.3	-5.44	8.37e-08	1.31e-05	-0.3	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs6429574	ENSG00000281133.1	AL355480.3	-5.44	8.37e-08	1.31e-05	-0.3	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45580892~45580996:-
THCA	cis	rs5006884	0.715	rs4373970	ENSG00000167355.6	AC104389.28	5.44	8.38e-08	1.31e-05	0.38	0.24	Fetal hemoglobin levels;	chr11:5351460	chr11:5304976~5505652:-
THCA	cis	rs2985684	0.894	rs2281837	ENSG00000278009.1	RP11-649E7.8	5.44	8.38e-08	1.31e-05	0.34	0.24	Carotid intima media thickness;	chr14:49598641	chr14:49601011~49601124:-
THCA	cis	rs2243480	0.803	rs423187	ENSG00000230295.1	RP11-458F8.2	-5.44	8.38e-08	1.31e-05	-0.3	-0.24	Diabetic kidney disease;	chr7:66044512	chr7:66880708~66882981:+
THCA	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	5.44	8.39e-08	1.31e-05	0.24	0.24	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
THCA	cis	rs2554380	0.55	rs62025822	ENSG00000230373.7	GOLGA6L5P	5.44	8.39e-08	1.31e-05	0.26	0.24	Height;	chr15:83870162	chr15:84507885~84516814:-
THCA	cis	rs2554380	0.55	rs56159777	ENSG00000230373.7	GOLGA6L5P	5.44	8.39e-08	1.31e-05	0.26	0.24	Height;	chr15:83870527	chr15:84507885~84516814:-
THCA	cis	rs2554380	0.55	rs4842919	ENSG00000230373.7	GOLGA6L5P	5.44	8.39e-08	1.31e-05	0.26	0.24	Height;	chr15:83870668	chr15:84507885~84516814:-
THCA	cis	rs3823536	0.5	rs4728144	ENSG00000275106.1	RP11-309L24.10	-5.44	8.4e-08	1.31e-05	-0.33	-0.24	Sjögren's syndrome;	chr7:129000280	chr7:128952527~128953316:-
THCA	cis	rs4908760	0.931	rs1463049	ENSG00000232912.4	RP5-1115A15.1	5.44	8.4e-08	1.31e-05	0.24	0.24	Vitiligo;	chr1:8537049	chr1:8424645~8434838:+
THCA	cis	rs6570726	0.818	rs952405	ENSG00000270638.1	RP3-466P17.1	5.44	8.4e-08	1.31e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs4896824	ENSG00000270638.1	RP3-466P17.1	5.44	8.4e-08	1.31e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145735570~145737218:+
THCA	cis	rs12893668	0.673	rs2296482	ENSG00000269910.1	RP11-73M18.10	5.44	8.4e-08	1.31e-05	0.23	0.24	Reticulocyte count;	chr14:103563482	chr14:103694516~103695050:-
THCA	cis	rs61677309	1	rs12576941	ENSG00000280032.1	RP11-832A4.7	5.44	8.41e-08	1.31e-05	0.26	0.24	Lung cancer in ever smokers;	chr11:118287287	chr11:118264593~118266817:+
THCA	cis	rs12497850	0.863	rs4858799	ENSG00000229759.1	MRPS18AP1	5.44	8.41e-08	1.31e-05	0.32	0.24	Parkinson's disease;	chr3:48690771	chr3:48256350~48256938:-
THCA	cis	rs564343	0.966	rs486311	ENSG00000255320.1	RP11-755F10.1	-5.44	8.41e-08	1.31e-05	-0.3	-0.24	Obesity (early onset extreme);	chr11:66139771	chr11:66244840~66246239:-
THCA	cis	rs9952991	1	rs9952991	ENSG00000260302.1	RP11-973H7.1	-5.44	8.42e-08	1.31e-05	-0.4	-0.24	Inflammatory skin disease;	chr18:12780465	chr18:12774651~12775923:-
THCA	cis	rs9494145	0.68	rs4895440	ENSG00000232876.1	CTA-212D2.2	-5.44	8.42e-08	1.31e-05	-0.33	-0.24	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105420	chr6:135055033~135060550:+
THCA	cis	rs6570726	0.846	rs453834	ENSG00000270638.1	RP3-466P17.1	5.44	8.42e-08	1.31e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145735570~145737218:+
THCA	cis	rs9475752	0.793	rs13198484	ENSG00000231441.1	RP11-472M19.2	5.44	8.43e-08	1.31e-05	0.33	0.24	Menarche (age at onset);	chr6:56947919	chr6:56844002~56864078:+
THCA	cis	rs71636778	0.543	rs17162333	ENSG00000260063.1	RP5-968P14.2	-5.44	8.43e-08	1.31e-05	-0.33	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26910266	chr1:26692132~26694131:-
THCA	cis	rs6845263	1	rs6845263	ENSG00000254531.1	FLJ20021	5.44	8.43e-08	1.32e-05	0.21	0.24	Superior crus of antihelix expression;	chr4:101355525	chr4:101347780~101348883:+
THCA	cis	rs7617773	0.963	rs6766754	ENSG00000199476.1	Y_RNA	5.44	8.44e-08	1.32e-05	0.3	0.24	Coronary artery disease;	chr3:48141099	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.832	rs6775114	ENSG00000199476.1	Y_RNA	5.44	8.44e-08	1.32e-05	0.3	0.24	Coronary artery disease;	chr3:48141130	chr3:48288587~48288694:+
THCA	cis	rs12935418	0.583	rs2549861	ENSG00000278985.1	RP11-303E16.9	-5.44	8.44e-08	1.32e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80994699	chr16:80982319~80984094:-
THCA	cis	rs12681287	0.752	rs4282548	ENSG00000254231.1	CTD-2284J15.1	5.44	8.44e-08	1.32e-05	0.28	0.24	Caudate activity during reward;	chr8:86258563	chr8:86333274~86343314:-
THCA	cis	rs11073619	0.572	rs35984335	ENSG00000230373.7	GOLGA6L5P	-5.44	8.44e-08	1.32e-05	-0.37	-0.24	Positive affect;	chr15:84393638	chr15:84507885~84516814:-
THCA	cis	rs11020821	0.886	rs16912567	ENSG00000255893.1	RP11-685N10.1	-5.44	8.44e-08	1.32e-05	-0.3	-0.24	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94536839	chr11:94472908~94473570:-
THCA	cis	rs6545883	0.831	rs2592356	ENSG00000270820.4	RP11-355B11.2	5.44	8.44e-08	1.32e-05	0.2	0.24	Tuberculosis;	chr2:61583293	chr2:61471188~61484130:+
THCA	cis	rs7246657	0.722	rs2287229	ENSG00000276846.1	CTD-3220F14.3	-5.44	8.44e-08	1.32e-05	-0.25	-0.24	Coronary artery calcification;	chr19:37697751	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs2075284	ENSG00000276846.1	CTD-3220F14.3	-5.44	8.44e-08	1.32e-05	-0.25	-0.24	Coronary artery calcification;	chr19:37698715	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs968073	ENSG00000276846.1	CTD-3220F14.3	-5.44	8.44e-08	1.32e-05	-0.25	-0.24	Coronary artery calcification;	chr19:37701120	chr19:37314868~37315620:-
THCA	cis	rs934734	0.935	rs6711791	ENSG00000237979.1	AC007389.1	5.44	8.44e-08	1.32e-05	0.28	0.24	Rheumatoid arthritis;	chr2:65352094	chr2:65500993~65502138:-
THCA	cis	rs1275468	0.731	rs1480001	ENSG00000257497.2	RP11-585P4.5	-5.44	8.44e-08	1.32e-05	-0.37	-0.24	Polycystic ovary syndrome;	chr12:75586939	chr12:75483454~75489820:-
THCA	cis	rs2439831	0.867	rs486301	ENSG00000166763.7	STRCP1	5.44	8.45e-08	1.32e-05	0.33	0.24	Lung cancer in ever smokers;	chr15:43544751	chr15:43699488~43718184:-
THCA	cis	rs7162943	0.887	rs293366	ENSG00000260123.1	RP11-326A19.4	5.44	8.45e-08	1.32e-05	0.31	0.24	Mean platelet volume;	chr15:89072556	chr15:89041223~89082819:+
THCA	cis	rs853679	0.567	rs13196606	ENSG00000219392.1	RP1-265C24.5	-5.44	8.46e-08	1.32e-05	-0.29	-0.24	Depression;	chr6:28402301	chr6:28115628~28116551:+
THCA	cis	rs7727544	0.735	rs274568	ENSG00000224431.1	AC063976.7	-5.44	8.46e-08	1.32e-05	-0.21	-0.24	Blood metabolite levels;	chr5:132377886	chr5:132199456~132203487:+
THCA	cis	rs8002861	0.967	rs2166301	ENSG00000274001.1	RP11-5G9.5	5.44	8.46e-08	1.32e-05	0.28	0.24	Leprosy;	chr13:43899819	chr13:43877715~43878163:-
THCA	cis	rs1552244	1	rs113153120	ENSG00000180385.7	EMC3-AS1	5.44	8.47e-08	1.32e-05	0.27	0.24	Alzheimer's disease;	chr3:10114714	chr3:9986893~10006990:+
THCA	cis	rs9921338	0.961	rs4781055	ENSG00000262636.1	CTD-3088G3.4	-5.44	8.47e-08	1.32e-05	-0.36	-0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11275571	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.961	rs8060767	ENSG00000262636.1	CTD-3088G3.4	-5.44	8.47e-08	1.32e-05	-0.36	-0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11276741	chr16:11380859~11381118:-
THCA	cis	rs7772486	0.743	rs1292339	ENSG00000270638.1	RP3-466P17.1	-5.44	8.47e-08	1.32e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145735570~145737218:+
THCA	cis	rs2904967	0.636	rs184734	ENSG00000254614.2	AP003068.23	-5.44	8.47e-08	1.32e-05	-0.36	-0.24	Mean corpuscular volume;	chr11:65214732	chr11:65177606~65181834:-
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000230295.1	RP11-458F8.2	-5.44	8.48e-08	1.32e-05	-0.31	-0.24	Diabetic kidney disease;	chr7:66521515	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs13237037	ENSG00000230295.1	RP11-458F8.2	-5.44	8.48e-08	1.32e-05	-0.31	-0.24	Diabetic kidney disease;	chr7:66532895	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1796228	ENSG00000230295.1	RP11-458F8.2	-5.44	8.48e-08	1.32e-05	-0.31	-0.24	Diabetic kidney disease;	chr7:66568097	chr7:66880708~66882981:+
THCA	cis	rs2120243	0.539	rs6441127	ENSG00000244515.1	KRT18P34	-5.44	8.48e-08	1.32e-05	-0.29	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157377718	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.539	rs7618737	ENSG00000244515.1	KRT18P34	-5.44	8.48e-08	1.32e-05	-0.29	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157377832	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.508	rs4435581	ENSG00000244515.1	KRT18P34	-5.44	8.48e-08	1.32e-05	-0.29	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157378428	chr3:157162663~157163932:-
THCA	cis	rs6430585	0.583	rs7581814	ENSG00000231890.6	DARS-AS1	5.44	8.48e-08	1.32e-05	0.29	0.24	Corneal structure;	chr2:135884023	chr2:135985176~136022593:+
THCA	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-5.44	8.48e-08	1.32e-05	-0.2	-0.24	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
THCA	cis	rs1707322	0.721	rs10890343	ENSG00000281133.1	AL355480.3	-5.44	8.49e-08	1.32e-05	-0.3	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45580892~45580996:-
THCA	cis	rs2243480	1	rs313807	ENSG00000230295.1	RP11-458F8.2	-5.44	8.49e-08	1.32e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66034494	chr7:66880708~66882981:+
THCA	cis	rs4748857	1	rs4633356	ENSG00000224215.1	RP11-371A19.2	-5.44	8.49e-08	1.32e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23259098	chr10:23343957~23345181:+
THCA	cis	rs758324	0.687	rs159905	ENSG00000237714.1	P4HA2-AS1	-5.44	8.49e-08	1.32e-05	-0.36	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132166810	chr5:132184876~132192808:+
THCA	cis	rs2554380	0.55	rs62025825	ENSG00000230373.7	GOLGA6L5P	5.44	8.49e-08	1.32e-05	0.26	0.24	Height;	chr15:83872285	chr15:84507885~84516814:-
THCA	cis	rs11089937	0.597	rs9619812	ENSG00000211638.2	IGLV8-61	-5.44	8.5e-08	1.33e-05	-0.2	-0.24	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22098700~22099212:+
THCA	cis	rs2439831	0.85	rs3759790	ENSG00000166763.7	STRCP1	5.44	8.5e-08	1.33e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43828832	chr15:43699488~43718184:-
THCA	cis	rs2120243	0.539	rs7617727	ENSG00000244515.1	KRT18P34	5.44	8.51e-08	1.33e-05	0.29	0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157387769	chr3:157162663~157163932:-
THCA	cis	rs763121	0.813	rs4821807	ENSG00000228274.3	RP3-508I15.9	-5.44	8.51e-08	1.33e-05	-0.26	-0.24	Menopause (age at onset);	chr22:38669577	chr22:38667585~38681820:-
THCA	cis	rs2915864	0.904	rs2906071	ENSG00000280047.1	CTC-463A16.1	-5.44	8.51e-08	1.33e-05	-0.39	-0.24	Facial morphology (factor 20);	chr5:142199639	chr5:142165767~142168387:+
THCA	cis	rs12497850	0.966	rs6792510	ENSG00000229759.1	MRPS18AP1	5.44	8.51e-08	1.33e-05	0.32	0.24	Parkinson's disease;	chr3:48685869	chr3:48256350~48256938:-
THCA	cis	rs7829975	0.774	rs11775523	ENSG00000254153.1	CTA-398F10.2	-5.44	8.51e-08	1.33e-05	-0.26	-0.24	Mood instability;	chr8:8821666	chr8:8456909~8461337:-
THCA	cis	rs8396	0.96	rs17843902	ENSG00000271817.2	U3	5.44	8.52e-08	1.33e-05	0.26	0.24	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158719996	chr4:158700691~158700909:+
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000259728.4	LINC00933	-5.44	8.52e-08	1.33e-05	-0.29	-0.24	P wave terminal force;	chr15:84654022	chr15:84570649~84580175:+
THCA	cis	rs17711722	0.701	rs781143	ENSG00000273142.1	RP11-458F8.4	-5.44	8.52e-08	1.33e-05	-0.2	-0.24	Calcium levels;	chr7:65974892	chr7:66902857~66906297:+
THCA	cis	rs79040073	0.637	rs57252806	ENSG00000259531.2	RP11-295H24.3	5.44	8.52e-08	1.33e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49352188	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs11633981	ENSG00000259531.2	RP11-295H24.3	5.44	8.52e-08	1.33e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49360903	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs11633282	ENSG00000259531.2	RP11-295H24.3	5.44	8.52e-08	1.33e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49372472	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs11638606	ENSG00000259531.2	RP11-295H24.3	5.44	8.52e-08	1.33e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49372564	chr15:49365124~49366685:-
THCA	cis	rs16958440	0.541	rs62095459	ENSG00000267800.1	RP11-49K24.5	-5.44	8.53e-08	1.33e-05	-0.42	-0.24	Sitting height ratio;	chr18:47095011	chr18:47137018~47137290:+
THCA	cis	rs13256369	0.95	rs13270006	ENSG00000253893.2	FAM85B	-5.44	8.53e-08	1.33e-05	-0.32	-0.24	Obesity-related traits;	chr8:8716687	chr8:8167819~8226614:-
THCA	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-5.44	8.53e-08	1.33e-05	-0.31	-0.24	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
THCA	cis	rs2115630	0.967	rs11073731	ENSG00000225151.9	GOLGA2P7	5.44	8.53e-08	1.33e-05	0.31	0.24	P wave terminal force;	chr15:84811882	chr15:84199311~84230136:-
THCA	cis	rs2115630	1	rs8037423	ENSG00000225151.9	GOLGA2P7	5.44	8.53e-08	1.33e-05	0.31	0.24	P wave terminal force;	chr15:84812263	chr15:84199311~84230136:-
THCA	cis	rs17508449	0.819	rs77892281	ENSG00000232450.1	RP4-730K3.3	-5.44	8.54e-08	1.33e-05	-0.37	-0.24	Leprosy;	chr1:113620995	chr1:113698884~113699631:-
THCA	cis	rs9733	0.519	rs11587444	ENSG00000231073.1	RP11-316M1.3	5.44	8.54e-08	1.33e-05	0.3	0.24	Tonsillectomy;	chr1:150750368	chr1:150973123~150975534:+
THCA	cis	rs1889642	0.669	rs1160131	ENSG00000227354.5	RBM26-AS1	5.44	8.54e-08	1.33e-05	0.22	0.24	Colonoscopy-negative controls vs population controls;	chr13:79773537	chr13:79406309~79424328:+
THCA	cis	rs1580019	0.563	rs10486509	ENSG00000231952.3	DPY19L1P2	5.44	8.54e-08	1.33e-05	0.3	0.24	Cognitive ability;	chr7:32545831	chr7:32812757~32838570:+
THCA	cis	rs2075423	1	rs2075423	ENSG00000274895.1	RP11-478J18.2	5.44	8.54e-08	1.33e-05	0.21	0.24	Type 2 diabetes;	chr1:213981376	chr1:213983793~213986419:-
THCA	cis	rs12935418	0.616	rs77336552	ENSG00000261061.1	RP11-303E16.2	-5.44	8.55e-08	1.33e-05	-0.33	-0.24	Mean corpuscular volume;	chr16:80942989	chr16:81030770~81031485:+
THCA	cis	rs17594362	1	rs12865815	ENSG00000264190.1	MIR5006	5.44	8.55e-08	1.33e-05	0.39	0.24	Multiple sclerosis;	chr13:41560668	chr13:41568286~41568395:-
THCA	cis	rs2243480	1	rs466983	ENSG00000230295.1	RP11-458F8.2	-5.44	8.55e-08	1.33e-05	-0.3	-0.24	Diabetic kidney disease;	chr7:66055509	chr7:66880708~66882981:+
THCA	cis	rs4761702	0.857	rs1135400	ENSG00000257322.4	RP11-511B23.2	5.44	8.55e-08	1.33e-05	0.3	0.24	Immature fraction of reticulocytes;	chr12:93315763	chr12:93003415~93215679:-
THCA	cis	rs6545883	0.929	rs7561229	ENSG00000270820.4	RP11-355B11.2	5.44	8.55e-08	1.33e-05	0.21	0.24	Tuberculosis;	chr2:61510855	chr2:61471188~61484130:+
THCA	cis	rs253959	0.545	rs10072350	ENSG00000272265.1	CTD-2287O16.4	5.44	8.56e-08	1.33e-05	0.28	0.24	Bipolar disorder and schizophrenia;	chr5:116097829	chr5:116078110~116078570:-
THCA	cis	rs1858037	0.867	rs964505	ENSG00000234255.7	AC012370.3	5.44	8.56e-08	1.33e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65396055	chr2:65439888~65456571:-
THCA	cis	rs9307551	0.584	rs12502224	ENSG00000250334.4	LINC00989	-5.44	8.56e-08	1.33e-05	-0.29	-0.24	Refractive error;	chr4:79551688	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.596	rs12510204	ENSG00000250334.4	LINC00989	-5.44	8.56e-08	1.33e-05	-0.29	-0.24	Refractive error;	chr4:79551809	chr4:79492416~79576460:+
THCA	cis	rs79040073	0.637	rs73390343	ENSG00000259531.2	RP11-295H24.3	5.44	8.57e-08	1.34e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49164026	chr15:49365124~49366685:-
THCA	cis	rs4648045	0.894	rs230497	ENSG00000246560.2	RP11-10L12.4	-5.44	8.57e-08	1.34e-05	-0.3	-0.24	Lymphocyte percentage of white cells;	chr4:102567829	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.894	rs230498	ENSG00000246560.2	RP11-10L12.4	-5.44	8.57e-08	1.34e-05	-0.3	-0.24	Lymphocyte percentage of white cells;	chr4:102568446	chr4:102828055~102844075:+
THCA	cis	rs4908768	0.539	rs4480384	ENSG00000232912.4	RP5-1115A15.1	5.44	8.58e-08	1.34e-05	0.24	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8424645~8434838:+
THCA	cis	rs853679	0.825	rs8180562	ENSG00000272009.1	RP1-313I6.12	-5.44	8.58e-08	1.34e-05	-0.36	-0.24	Depression;	chr6:28173682	chr6:28078792~28081130:-
THCA	cis	rs853679	0.882	rs9380064	ENSG00000272009.1	RP1-313I6.12	-5.44	8.58e-08	1.34e-05	-0.36	-0.24	Depression;	chr6:28175340	chr6:28078792~28081130:-
THCA	cis	rs1552244	1	rs56394721	ENSG00000232901.1	CYCSP10	5.44	8.58e-08	1.34e-05	0.32	0.24	Alzheimer's disease;	chr3:10109111	chr3:10000647~10000940:-
THCA	cis	rs6840360	0.582	rs59714108	ENSG00000270265.1	RP11-731D1.4	-5.44	8.58e-08	1.34e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151404787	chr4:151333775~151353224:-
THCA	cis	rs9392556	0.734	rs648900	ENSG00000230648.1	RP3-406P24.3	5.44	8.59e-08	1.34e-05	0.3	0.24	Blood metabolite levels;	chr6:4109188	chr6:4018843~4021215:-
THCA	cis	rs7824557	0.767	rs7837036	ENSG00000154316.13	TDH	-5.44	8.59e-08	1.34e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11317980	chr8:11339637~11368452:+
THCA	cis	rs5769765	0.908	rs4058453	ENSG00000260613.1	RP3-522J7.6	5.44	8.59e-08	1.34e-05	0.34	0.24	Schizophrenia;	chr22:49856649	chr22:49832616~49837786:-
THCA	cis	rs5742933	0.857	rs1233284	ENSG00000253559.1	OSGEPL1-AS1	-5.44	8.59e-08	1.34e-05	-0.27	-0.24	Ferritin levels;	chr2:189825045	chr2:189762704~189765556:+
THCA	cis	rs5742933	0.817	rs1233288	ENSG00000253559.1	OSGEPL1-AS1	-5.44	8.59e-08	1.34e-05	-0.27	-0.24	Ferritin levels;	chr2:189825999	chr2:189762704~189765556:+
THCA	cis	rs12893668	0.628	rs57072546	ENSG00000269940.1	RP11-73M18.7	5.44	8.59e-08	1.34e-05	0.25	0.24	Reticulocyte count;	chr14:103597386	chr14:103694560~103695170:+
THCA	cis	rs2281603	1	rs11849530	ENSG00000272909.1	CTD-2555O16.4	-5.44	8.6e-08	1.34e-05	-0.31	-0.24	Lymphocyte counts;	chr14:64451694	chr14:64440369~64442238:-
THCA	cis	rs8062405	1	rs11861174	ENSG00000278665.1	RP11-666O2.4	5.44	8.6e-08	1.34e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62037367	ENSG00000278665.1	RP11-666O2.4	5.44	8.6e-08	1.34e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs7198606	ENSG00000278665.1	RP11-666O2.4	5.44	8.6e-08	1.34e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.929	rs11864750	ENSG00000278665.1	RP11-666O2.4	5.44	8.6e-08	1.34e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.964	rs7193733	ENSG00000278665.1	RP11-666O2.4	5.44	8.6e-08	1.34e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs8055982	ENSG00000278665.1	RP11-666O2.4	5.44	8.6e-08	1.34e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs7498665	ENSG00000278665.1	RP11-666O2.4	5.44	8.6e-08	1.34e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.964	rs11864107	ENSG00000278665.1	RP11-666O2.4	5.44	8.6e-08	1.34e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28599241~28601881:-
THCA	cis	rs11051970	0.879	rs2728680	ENSG00000274964.1	RP11-817I4.1	-5.44	8.6e-08	1.34e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32430578	chr12:32339368~32340724:+
THCA	cis	rs7727544	0.545	rs10074490	ENSG00000233006.5	AC034220.3	5.44	8.6e-08	1.34e-05	0.2	0.24	Blood metabolite levels;	chr5:132004339	chr5:132311285~132369916:-
THCA	cis	rs4748857	0.541	rs59102191	ENSG00000224215.1	RP11-371A19.2	-5.44	8.61e-08	1.34e-05	-0.33	-0.24	Systemic lupus erythematosus;	chr10:23235353	chr10:23343957~23345181:+
THCA	cis	rs1552244	1	rs13319597	ENSG00000232901.1	CYCSP10	-5.44	8.61e-08	1.34e-05	-0.32	-0.24	Alzheimer's disease;	chr3:10084628	chr3:10000647~10000940:-
THCA	cis	rs116095464	0.558	rs55838121	ENSG00000248925.1	CTD-2083E4.6	5.44	8.61e-08	1.34e-05	0.35	0.24	Breast cancer;	chr5:266775	chr5:269858~271516:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000164669.11	INTS4P1	5.44	8.62e-08	1.34e-05	0.47	0.24	Diabetic kidney disease;	chr7:65924743	chr7:65141225~65234216:+
THCA	cis	rs2029362	0.818	rs10835187	ENSG00000245573.6	BDNF-AS	5.44	8.63e-08	1.34e-05	0.19	0.24	Total body bone mineral density;	chr11:27484130	chr11:27506838~27698174:+
THCA	cis	rs6430585	0.583	rs60253740	ENSG00000231890.6	DARS-AS1	-5.44	8.63e-08	1.34e-05	-0.29	-0.24	Corneal structure;	chr2:135814282	chr2:135985176~136022593:+
THCA	cis	rs17122021	0.74	rs2853009	ENSG00000280032.1	RP11-832A4.7	-5.44	8.63e-08	1.34e-05	-0.25	-0.24	Pain;	chr11:118277431	chr11:118264593~118266817:+
THCA	cis	rs6860806	0.661	rs3763112	ENSG00000233006.5	AC034220.3	5.44	8.64e-08	1.34e-05	0.19	0.24	Breast cancer;	chr5:132250787	chr5:132311285~132369916:-
THCA	cis	rs41307935	0.722	rs12724052	ENSG00000260063.1	RP5-968P14.2	-5.44	8.64e-08	1.35e-05	-0.33	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26908191	chr1:26692132~26694131:-
THCA	cis	rs987724	0.574	rs7638625	ENSG00000240875.4	LINC00886	-5.44	8.64e-08	1.35e-05	-0.19	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156840267	chr3:156747346~156817062:-
THCA	cis	rs7085104	0.7	rs10786712	ENSG00000213061.2	PFN1P11	-5.44	8.65e-08	1.35e-05	-0.29	-0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102838011~102845473:-
THCA	cis	rs1552244	0.515	rs6768768	ENSG00000232901.1	CYCSP10	5.44	8.66e-08	1.35e-05	0.36	0.24	Alzheimer's disease;	chr3:10135969	chr3:10000647~10000940:-
THCA	cis	rs1858037	0.867	rs876933	ENSG00000234255.7	AC012370.3	5.44	8.66e-08	1.35e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65382303	chr2:65439888~65456571:-
THCA	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	5.44	8.66e-08	1.35e-05	0.28	0.24	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
THCA	cis	rs7428	0.545	rs1053561	ENSG00000246575.2	AC093162.5	5.44	8.67e-08	1.35e-05	0.22	0.24	Ear protrusion;	chr2:85318929	chr2:85315041~85316529:+
THCA	cis	rs2562456	0.833	rs2650776	ENSG00000268081.1	RP11-678G14.2	5.44	8.67e-08	1.35e-05	0.41	0.24	Pain;	chr19:21430595	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs2562416	ENSG00000268081.1	RP11-678G14.2	5.44	8.67e-08	1.35e-05	0.41	0.24	Pain;	chr19:21430609	chr19:21554640~21569237:-
THCA	cis	rs875971	0.965	rs10267430	ENSG00000223473.2	GS1-124K5.3	-5.44	8.67e-08	1.35e-05	-0.16	-0.24	Aortic root size;	chr7:66278036	chr7:66491049~66493566:-
THCA	cis	rs7246657	0.722	rs11083432	ENSG00000267422.1	CTD-2554C21.1	5.44	8.67e-08	1.35e-05	0.27	0.24	Coronary artery calcification;	chr19:37691732	chr19:37779686~37792865:+
THCA	cis	rs748404	1	rs66651343	ENSG00000205771.5	CATSPER2P1	-5.44	8.67e-08	1.35e-05	-0.28	-0.24	Lung cancer;	chr15:43265806	chr15:43726918~43747094:-
THCA	cis	rs73242632	1	rs73242618	ENSG00000269949.1	RP11-738E22.3	5.44	8.67e-08	1.35e-05	0.56	0.24	Congenital heart disease (maternal effect);	chr4:56943383	chr4:56960927~56961373:-
THCA	cis	rs73242632	1	rs73242621	ENSG00000269949.1	RP11-738E22.3	5.44	8.67e-08	1.35e-05	0.56	0.24	Congenital heart disease (maternal effect);	chr4:56951915	chr4:56960927~56961373:-
THCA	cis	rs73242632	1	rs73242622	ENSG00000269949.1	RP11-738E22.3	5.44	8.67e-08	1.35e-05	0.56	0.24	Congenital heart disease (maternal effect);	chr4:56952398	chr4:56960927~56961373:-
THCA	cis	rs2348418	0.832	rs11611406	ENSG00000247934.4	RP11-967K21.1	5.44	8.68e-08	1.35e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28310910	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.832	rs11611382	ENSG00000247934.4	RP11-967K21.1	5.44	8.68e-08	1.35e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28310959	chr12:28163298~28190738:-
THCA	cis	rs4819052	0.54	rs7282639	ENSG00000223768.1	LINC00205	5.44	8.69e-08	1.35e-05	0.24	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45071240	chr21:45293285~45297354:+
THCA	cis	rs12935418	0.552	rs2549835	ENSG00000278985.1	RP11-303E16.9	-5.44	8.69e-08	1.35e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80989005	chr16:80982319~80984094:-
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000232559.3	GS1-124K5.12	5.44	8.69e-08	1.35e-05	0.37	0.24	Diabetic kidney disease;	chr7:66528779	chr7:66554588~66576923:-
THCA	cis	rs4663866	1	rs35648651	ENSG00000186235.9	AC016757.3	5.44	8.7e-08	1.35e-05	0.53	0.24	Irritable bowel syndrome;	chr2:238225202	chr2:238224552~238231677:-
THCA	cis	rs8002861	0.967	rs7321596	ENSG00000274001.1	RP11-5G9.5	5.44	8.7e-08	1.35e-05	0.28	0.24	Leprosy;	chr13:43898119	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.905	rs80209017	ENSG00000274001.1	RP11-5G9.5	5.44	8.7e-08	1.35e-05	0.28	0.24	Leprosy;	chr13:43899046	chr13:43877715~43878163:-
THCA	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-5.44	8.7e-08	1.35e-05	-0.25	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
THCA	cis	rs6479901	0.841	rs4469770	ENSG00000232075.1	MRPL35P2	-5.44	8.7e-08	1.35e-05	-0.35	-0.24	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63634317~63634827:-
THCA	cis	rs172166	0.769	rs149965	ENSG00000220721.1	OR1F12	5.44	8.71e-08	1.36e-05	0.29	0.24	Cardiac Troponin-T levels;	chr6:28050911	chr6:28073316~28074233:+
THCA	cis	rs11992186	0.597	rs11781841	ENSG00000253893.2	FAM85B	5.44	8.71e-08	1.36e-05	0.32	0.24	Neuroticism;	chr8:8737753	chr8:8167819~8226614:-
THCA	cis	rs875971	0.964	rs160635	ENSG00000223473.2	GS1-124K5.3	5.44	8.71e-08	1.36e-05	0.17	0.24	Aortic root size;	chr7:66063931	chr7:66491049~66493566:-
THCA	cis	rs17123764	0.71	rs7952734	ENSG00000257464.1	RP11-161H23.8	-5.44	8.71e-08	1.36e-05	-0.39	-0.24	Intelligence (multi-trait analysis);	chr12:49668898	chr12:49442424~49442652:-
THCA	cis	rs7927592	0.513	rs607887	ENSG00000212093.1	AP000807.1	5.44	8.71e-08	1.36e-05	0.25	0.24	Total body bone mineral density;	chr11:68429493	chr11:68506083~68506166:-
THCA	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	5.44	8.72e-08	1.36e-05	0.15	0.24	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
THCA	cis	rs6496044	0.547	rs1564719	ENSG00000259630.2	CTD-2262B20.1	-5.44	8.72e-08	1.36e-05	-0.27	-0.24	Interstitial lung disease;	chr15:85511035	chr15:85415228~85415633:+
THCA	cis	rs2664588	0.595	rs6063195	ENSG00000276923.1	RP11-321P16.1	5.44	8.72e-08	1.36e-05	0.32	0.24	Cerebrospinal fluid AB1-42 levels;	chr20:47999422	chr20:48073869~48074188:+
THCA	cis	rs2243480	1	rs313824	ENSG00000232559.3	GS1-124K5.12	5.44	8.72e-08	1.36e-05	0.35	0.24	Diabetic kidney disease;	chr7:66116220	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs186378	ENSG00000232559.3	GS1-124K5.12	5.44	8.72e-08	1.36e-05	0.35	0.24	Diabetic kidney disease;	chr7:66117071	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs160637	ENSG00000232559.3	GS1-124K5.12	5.44	8.72e-08	1.36e-05	0.35	0.24	Diabetic kidney disease;	chr7:66119331	chr7:66554588~66576923:-
THCA	cis	rs36051354	0.554	rs4687662	ENSG00000242142.1	SERBP1P3	5.44	8.72e-08	1.36e-05	0.32	0.24	Intelligence (multi-trait analysis);	chr3:52836308	chr3:53064283~53065091:-
THCA	cis	rs1552244	1	rs112509186	ENSG00000180385.7	EMC3-AS1	5.44	8.72e-08	1.36e-05	0.27	0.24	Alzheimer's disease;	chr3:10114849	chr3:9986893~10006990:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000273142.1	RP11-458F8.4	5.44	8.73e-08	1.36e-05	0.2	0.24	Aortic root size;	chr7:66039646	chr7:66902857~66906297:+
THCA	cis	rs919433	0.817	rs10931780	ENSG00000231621.1	AC013264.2	5.44	8.73e-08	1.36e-05	0.24	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310573	chr2:197197991~197199273:+
THCA	cis	rs7412746	0.566	rs2864871	ENSG00000231073.1	RP11-316M1.3	5.44	8.73e-08	1.36e-05	0.3	0.24	Melanoma;	chr1:150794488	chr1:150973123~150975534:+
THCA	cis	rs4660456	0.556	rs823674	ENSG00000238287.1	RP11-656D10.3	-5.44	8.73e-08	1.36e-05	-0.27	-0.24	Platelet count;	chr1:40774799	chr1:40493157~40508661:-
THCA	cis	rs11051970	0.877	rs2651360	ENSG00000274964.1	RP11-817I4.1	-5.44	8.73e-08	1.36e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32435986	chr12:32339368~32340724:+
THCA	cis	rs7493	1	rs6961773	ENSG00000233942.1	AC004012.1	5.44	8.73e-08	1.36e-05	0.36	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95408406	chr7:95471835~95473998:+
THCA	cis	rs10129255	0.957	rs1056705	ENSG00000223648.3	IGHV3-64	5.44	8.74e-08	1.36e-05	0.15	0.24	Kawasaki disease;	chr14:106714323	chr14:106643132~106658258:-
THCA	cis	rs2562456	0.833	rs11880624	ENSG00000268081.1	RP11-678G14.2	5.44	8.74e-08	1.36e-05	0.4	0.24	Pain;	chr19:21341028	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62107547	ENSG00000268081.1	RP11-678G14.2	5.44	8.74e-08	1.36e-05	0.4	0.24	Pain;	chr19:21341245	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs56187954	ENSG00000268081.1	RP11-678G14.2	5.44	8.74e-08	1.36e-05	0.4	0.24	Pain;	chr19:21345258	chr19:21554640~21569237:-
THCA	cis	rs4950322	0.57	rs17360443	ENSG00000226015.2	CCT8P1	5.44	8.74e-08	1.36e-05	0.28	0.24	Protein quantitative trait loci;	chr1:147279737	chr1:147203276~147204932:-
THCA	cis	rs10888838	1	rs6621	ENSG00000198711.5	SSBP3-AS1	5.44	8.74e-08	1.36e-05	0.27	0.24	Mitochondrial DNA levels;	chr1:54218252	chr1:54236440~54239063:+
THCA	cis	rs655601	1	rs655601	ENSG00000280161.1	CTC-205M6.1	-5.44	8.75e-08	1.36e-05	-0.26	-0.24	Quantitative traits;	chr5:180799673	chr5:180810401~180811384:+
THCA	cis	rs1865760	0.515	rs2003208	ENSG00000272462.2	U91328.19	-5.44	8.75e-08	1.36e-05	-0.19	-0.24	Height;	chr6:25940491	chr6:25992662~26001775:+
THCA	cis	rs1198430	0.636	rs2156087	ENSG00000232482.2	RP4-654C18.1	5.44	8.75e-08	1.36e-05	0.34	0.24	Total cholesterol levels;	chr1:23417088	chr1:23410832~23412146:+
THCA	cis	rs4713118	0.513	rs202908	ENSG00000220721.1	OR1F12	5.44	8.75e-08	1.36e-05	0.29	0.24	Parkinson's disease;	chr6:28043773	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.513	rs156739	ENSG00000220721.1	OR1F12	5.44	8.75e-08	1.36e-05	0.29	0.24	Parkinson's disease;	chr6:28045632	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.513	rs149958	ENSG00000220721.1	OR1F12	5.44	8.75e-08	1.36e-05	0.29	0.24	Parkinson's disease;	chr6:28045839	chr6:28073316~28074233:+
THCA	cis	rs12030196	0.871	rs11207359	ENSG00000230812.4	LINC01358	5.44	8.76e-08	1.36e-05	0.33	0.24	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58985365	chr1:59020387~59044614:+
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000280069.1	CTD-2349P21.3	-5.44	8.76e-08	1.36e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30738182~30740275:+
THCA	cis	rs9595908	0.931	rs9591001	ENSG00000212293.1	SNORA16	-5.44	8.76e-08	1.36e-05	-0.3	-0.24	Body mass index;	chr13:32468733	chr13:32420390~32420516:-
THCA	cis	rs2562456	0.652	rs4809145	ENSG00000268081.1	RP11-678G14.2	5.44	8.77e-08	1.36e-05	0.39	0.24	Pain;	chr19:21597907	chr19:21554640~21569237:-
THCA	cis	rs1552244	1	rs12374115	ENSG00000232901.1	CYCSP10	-5.44	8.77e-08	1.36e-05	-0.33	-0.24	Alzheimer's disease;	chr3:10093082	chr3:10000647~10000940:-
THCA	cis	rs9990343	0.583	rs2187674	ENSG00000223552.1	RP11-24F11.2	5.44	8.77e-08	1.36e-05	0.22	0.24	Brain structure;	chr3:46402914	chr3:46364955~46407059:-
THCA	cis	rs7045881	0.935	rs7851339	ENSG00000254396.1	RP11-56F10.3	5.44	8.78e-08	1.36e-05	0.34	0.24	Schizophrenia;	chr9:26930066	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.935	rs62544450	ENSG00000254396.1	RP11-56F10.3	5.44	8.78e-08	1.36e-05	0.34	0.24	Schizophrenia;	chr9:26934761	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.935	rs62544451	ENSG00000254396.1	RP11-56F10.3	5.44	8.78e-08	1.36e-05	0.34	0.24	Schizophrenia;	chr9:26934898	chr9:27102630~27104728:+
THCA	cis	rs9952991	0.883	rs11663253	ENSG00000260302.1	RP11-973H7.1	5.44	8.78e-08	1.37e-05	0.41	0.24	Inflammatory skin disease;	chr18:12789557	chr18:12774651~12775923:-
THCA	cis	rs75920871	0.562	rs68137714	ENSG00000254851.1	RP11-109L13.1	-5.44	8.78e-08	1.37e-05	-0.44	-0.24	Subjective well-being;	chr11:117154641	chr11:117135528~117138582:+
THCA	cis	rs2179367	0.632	rs9498324	ENSG00000268592.3	RAET1E-AS1	5.44	8.78e-08	1.37e-05	0.35	0.24	Dupuytren's disease;	chr6:149338973	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.586	rs62426088	ENSG00000268592.3	RAET1E-AS1	5.44	8.78e-08	1.37e-05	0.35	0.24	Dupuytren's disease;	chr6:149339301	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12204793	ENSG00000268592.3	RAET1E-AS1	5.44	8.78e-08	1.37e-05	0.35	0.24	Dupuytren's disease;	chr6:149340102	chr6:149863494~149919507:+
THCA	cis	rs2243480	1	rs781156	ENSG00000230295.1	RP11-458F8.2	-5.44	8.78e-08	1.37e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66014154	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs451396	ENSG00000230295.1	RP11-458F8.2	-5.44	8.78e-08	1.37e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66019087	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1715235	ENSG00000230295.1	RP11-458F8.2	-5.44	8.78e-08	1.37e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66023407	chr7:66880708~66882981:+
THCA	cis	rs11992186	0.57	rs17628941	ENSG00000253893.2	FAM85B	5.44	8.78e-08	1.37e-05	0.33	0.24	Neuroticism;	chr8:8730024	chr8:8167819~8226614:-
THCA	cis	rs10808739	0.614	rs13268326	ENSG00000254006.4	RP11-1D12.2	5.44	8.79e-08	1.37e-05	0.37	0.24	HIV-1 susceptibility;	chr8:64697961	chr8:64801236~64817573:-
THCA	cis	rs9876781	1	rs7630741	ENSG00000229759.1	MRPS18AP1	5.44	8.79e-08	1.37e-05	0.29	0.24	Longevity;	chr3:48378233	chr3:48256350~48256938:-
THCA	cis	rs7412746	0.634	rs12096831	ENSG00000231073.1	RP11-316M1.3	5.44	8.79e-08	1.37e-05	0.29	0.24	Melanoma;	chr1:150891637	chr1:150973123~150975534:+
THCA	cis	rs897984	0.647	rs8060857	ENSG00000260911.2	RP11-196G11.2	-5.44	8.8e-08	1.37e-05	-0.21	-0.24	Dementia with Lewy bodies;	chr16:30991399	chr16:31043150~31049868:+
THCA	cis	rs4660456	0.572	rs1008204	ENSG00000272145.1	NFYC-AS1	-5.44	8.8e-08	1.37e-05	-0.16	-0.24	Platelet count;	chr1:40700189	chr1:40690380~40692066:-
THCA	cis	rs12530	0.715	rs2294311	ENSG00000230736.2	RP1-149A16.3	-5.44	8.8e-08	1.37e-05	-0.32	-0.24	IgG glycosylation;	chr22:32397282	chr22:32376664~32384343:+
THCA	cis	rs12530	0.715	rs2294313	ENSG00000230736.2	RP1-149A16.3	-5.44	8.8e-08	1.37e-05	-0.32	-0.24	IgG glycosylation;	chr22:32398452	chr22:32376664~32384343:+
THCA	cis	rs1350171	1	rs1350171	ENSG00000246523.6	RP11-736K20.6	5.44	8.8e-08	1.37e-05	0.36	0.24	Hepatocellular carcinoma in hepatitis B infection;	chr11:86933347	chr11:86955619~87000959:+
THCA	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-5.44	8.8e-08	1.37e-05	-0.15	-0.24	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
THCA	cis	rs9834975	0.875	rs4678191	ENSG00000272758.4	RP11-299J3.8	-5.44	8.82e-08	1.37e-05	-0.23	-0.24	Diastolic blood pressure;	chr3:122402391	chr3:122416207~122443180:+
THCA	cis	rs7200543	0.848	rs62039480	ENSG00000188599.16	NPIPP1	-5.43	8.82e-08	1.37e-05	-0.18	-0.24	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:15104312~15123498:-
THCA	cis	rs1552244	1	rs17032414	ENSG00000232901.1	CYCSP10	5.43	8.83e-08	1.37e-05	0.31	0.24	Alzheimer's disease;	chr3:10116618	chr3:10000647~10000940:-
THCA	cis	rs2129782	1	rs73291159	ENSG00000253553.4	RP11-586K2.1	5.43	8.84e-08	1.37e-05	0.42	0.24	Electrodermal activity;	chr8:88431578	chr8:88326836~88737134:+
THCA	cis	rs2348418	0.798	rs7310297	ENSG00000247934.4	RP11-967K21.1	5.43	8.84e-08	1.37e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28313638	chr12:28163298~28190738:-
THCA	cis	rs7927592	0.513	rs608343	ENSG00000212093.1	AP000807.1	5.43	8.84e-08	1.37e-05	0.25	0.24	Total body bone mineral density;	chr11:68429362	chr11:68506083~68506166:-
THCA	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	5.43	8.86e-08	1.38e-05	0.42	0.24	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
THCA	cis	rs79040073	0.637	rs73398272	ENSG00000259531.2	RP11-295H24.3	5.43	8.86e-08	1.38e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49416426	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs61259878	ENSG00000259531.2	RP11-295H24.3	5.43	8.86e-08	1.38e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49432564	chr15:49365124~49366685:-
THCA	cis	rs6445975	0.666	rs6793328	ENSG00000272360.1	RP11-359I18.5	5.43	8.86e-08	1.38e-05	0.28	0.24	Systemic lupus erythematosus;	chr3:58429145	chr3:58490830~58491291:-
THCA	cis	rs2179367	0.6	rs58747890	ENSG00000268592.3	RAET1E-AS1	5.43	8.86e-08	1.38e-05	0.39	0.24	Dupuytren's disease;	chr6:149459369	chr6:149863494~149919507:+
THCA	cis	rs116095464	0.558	rs7714335	ENSG00000248925.1	CTD-2083E4.6	5.43	8.86e-08	1.38e-05	0.36	0.24	Breast cancer;	chr5:263398	chr5:269858~271516:-
THCA	cis	rs7523875	0.72	rs61851029	ENSG00000153363.11	LINC00467	-5.43	8.87e-08	1.38e-05	-0.26	-0.24	Mean corpuscular volume;	chr1:211330206	chr1:211382803~211435333:+
THCA	cis	rs714027	1	rs5763821	ENSG00000279159.1	RP3-394A18.1	-5.43	8.87e-08	1.38e-05	-0.16	-0.24	Lymphocyte counts;	chr22:30153082	chr22:29978950~30028236:-
THCA	cis	rs7085104	0.684	rs7092690	ENSG00000213061.2	PFN1P11	5.43	8.87e-08	1.38e-05	0.3	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102838011~102845473:-
THCA	cis	rs9952991	0.941	rs60735058	ENSG00000260302.1	RP11-973H7.1	5.43	8.87e-08	1.38e-05	0.41	0.24	Inflammatory skin disease;	chr18:12795471	chr18:12774651~12775923:-
THCA	cis	rs7829975	0.871	rs572307	ENSG00000254153.1	CTA-398F10.2	5.43	8.89e-08	1.38e-05	0.26	0.24	Mood instability;	chr8:8721301	chr8:8456909~8461337:-
THCA	cis	rs853679	0.55	rs1233704	ENSG00000261839.1	RP1-265C24.8	-5.43	8.89e-08	1.38e-05	-0.28	-0.24	Depression;	chr6:28199145	chr6:28136849~28139678:+
THCA	cis	rs853679	0.55	rs1237875	ENSG00000261839.1	RP1-265C24.8	-5.43	8.89e-08	1.38e-05	-0.28	-0.24	Depression;	chr6:28205232	chr6:28136849~28139678:+
THCA	cis	rs853679	0.55	rs1225598	ENSG00000261839.1	RP1-265C24.8	5.43	8.89e-08	1.38e-05	0.28	0.24	Depression;	chr6:28193021	chr6:28136849~28139678:+
THCA	cis	rs853679	0.55	rs1150689	ENSG00000261839.1	RP1-265C24.8	5.43	8.89e-08	1.38e-05	0.28	0.24	Depression;	chr6:28197321	chr6:28136849~28139678:+
THCA	cis	rs853679	0.55	rs1225599	ENSG00000261839.1	RP1-265C24.8	5.43	8.89e-08	1.38e-05	0.28	0.24	Depression;	chr6:28197412	chr6:28136849~28139678:+
THCA	cis	rs853679	0.574	rs1233705	ENSG00000261839.1	RP1-265C24.8	5.43	8.89e-08	1.38e-05	0.28	0.24	Depression;	chr6:28198669	chr6:28136849~28139678:+
THCA	cis	rs853679	0.55	rs1233707	ENSG00000261839.1	RP1-265C24.8	5.43	8.89e-08	1.38e-05	0.28	0.24	Depression;	chr6:28205175	chr6:28136849~28139678:+
THCA	cis	rs1552244	0.554	rs4488814	ENSG00000180385.7	EMC3-AS1	-5.43	8.89e-08	1.38e-05	-0.24	-0.24	Alzheimer's disease;	chr3:9960716	chr3:9986893~10006990:+
THCA	cis	rs4713118	0.513	rs9368547	ENSG00000226314.6	ZNF192P1	-5.43	8.89e-08	1.38e-05	-0.28	-0.24	Parkinson's disease;	chr6:28060289	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.513	rs183244	ENSG00000226314.6	ZNF192P1	-5.43	8.89e-08	1.38e-05	-0.28	-0.24	Parkinson's disease;	chr6:28064060	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.513	rs149950	ENSG00000226314.6	ZNF192P1	-5.43	8.89e-08	1.38e-05	-0.28	-0.24	Parkinson's disease;	chr6:28065261	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.513	rs149951	ENSG00000226314.6	ZNF192P1	-5.43	8.89e-08	1.38e-05	-0.28	-0.24	Parkinson's disease;	chr6:28065309	chr6:28161781~28169594:+
THCA	cis	rs453301	0.522	rs2929309	ENSG00000248538.5	RP11-10A14.5	5.43	8.89e-08	1.38e-05	0.3	0.24	Joint mobility (Beighton score);	chr8:9226261	chr8:9189011~9202854:+
THCA	cis	rs1552244	1	rs68067759	ENSG00000180385.7	EMC3-AS1	5.43	8.89e-08	1.38e-05	0.26	0.24	Alzheimer's disease;	chr3:10108851	chr3:9986893~10006990:+
THCA	cis	rs1964356	0.967	rs17701675	ENSG00000254153.1	CTA-398F10.2	5.43	8.9e-08	1.38e-05	0.26	0.24	Mean corpuscular volume;	chr8:8993123	chr8:8456909~8461337:-
THCA	cis	rs7412746	0.658	rs7526489	ENSG00000231073.1	RP11-316M1.3	5.43	8.9e-08	1.38e-05	0.3	0.24	Melanoma;	chr1:150753762	chr1:150973123~150975534:+
THCA	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	5.43	8.9e-08	1.38e-05	0.25	0.24	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
THCA	cis	rs7403037	1	rs1498568	ENSG00000259905.4	PWRN1	5.43	8.9e-08	1.38e-05	0.25	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24349740	chr15:24493137~24652130:+
THCA	cis	rs2179367	0.632	rs9498348	ENSG00000231760.4	RP11-350J20.5	5.43	8.9e-08	1.38e-05	0.35	0.24	Dupuytren's disease;	chr6:149418352	chr6:149796151~149826294:-
THCA	cis	rs1198430	0.636	rs2811963	ENSG00000232482.2	RP4-654C18.1	-5.43	8.9e-08	1.38e-05	-0.43	-0.24	Total cholesterol levels;	chr1:23497749	chr1:23410832~23412146:+
THCA	cis	rs1552244	0.507	rs6443274	ENSG00000180385.7	EMC3-AS1	5.43	8.91e-08	1.38e-05	0.24	0.24	Alzheimer's disease;	chr3:9953604	chr3:9986893~10006990:+
THCA	cis	rs10266483	0.545	rs1812912	ENSG00000227986.1	TRIM60P18	5.43	8.91e-08	1.38e-05	0.25	0.24	Response to statin therapy;	chr7:64282891	chr7:64355078~64356199:+
THCA	cis	rs7646881	0.508	rs59602208	ENSG00000240207.5	RP11-379F4.4	-5.43	8.91e-08	1.38e-05	-0.35	-0.24	Tetralogy of Fallot;	chr3:158642319	chr3:158732263~158784070:+
THCA	cis	rs1552244	1	rs6791810	ENSG00000232901.1	CYCSP10	-5.43	8.91e-08	1.38e-05	-0.32	-0.24	Alzheimer's disease;	chr3:10082760	chr3:10000647~10000940:-
THCA	cis	rs73607972	1	rs73607972	ENSG00000275191.1	RP11-36I17.2	-5.43	8.91e-08	1.38e-05	-0.42	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53634741	chr16:53628256~53628816:-
THCA	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
THCA	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	5.43	8.91e-08	1.38e-05	0.21	0.24	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
THCA	cis	rs2980439	0.558	rs2955584	ENSG00000253981.4	ALG1L13P	5.43	8.91e-08	1.38e-05	0.23	0.24	Neuroticism;	chr8:8234652	chr8:8236003~8244667:-
THCA	cis	rs12497850	0.765	rs12487580	ENSG00000229759.1	MRPS18AP1	5.43	8.92e-08	1.39e-05	0.32	0.24	Parkinson's disease;	chr3:49145499	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.797	rs61583136	ENSG00000229759.1	MRPS18AP1	5.43	8.92e-08	1.39e-05	0.32	0.24	Parkinson's disease;	chr3:49151762	chr3:48256350~48256938:-
THCA	cis	rs4650994	0.544	rs2811311	ENSG00000273384.1	RP5-1098D14.1	-5.43	8.92e-08	1.39e-05	-0.32	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178648202	chr1:178651706~178652282:+
THCA	cis	rs9880211	0.898	rs6770476	ENSG00000273486.1	RP11-731C17.2	5.43	8.92e-08	1.39e-05	0.21	0.24	Height;Body mass index;	chr3:136355078	chr3:136837338~136839021:-
THCA	cis	rs2337406	1	rs79452530	ENSG00000211974.3	IGHV2-70	-5.43	8.92e-08	1.39e-05	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106699992	chr14:106723574~106724093:-
THCA	cis	rs6688613	0.694	rs12562794	ENSG00000225171.2	DUTP6	-5.43	8.93e-08	1.39e-05	-0.33	-0.24	Refractive astigmatism;	chr1:166859720	chr1:166868748~166869209:+
THCA	cis	rs1580019	0.539	rs11769109	ENSG00000231952.3	DPY19L1P2	-5.43	8.93e-08	1.39e-05	-0.3	-0.24	Cognitive ability;	chr7:32531740	chr7:32812757~32838570:+
THCA	cis	rs3785574	0.962	rs2727324	ENSG00000240280.5	TCAM1P	-5.43	8.93e-08	1.39e-05	-0.33	-0.24	Height;	chr17:63844742	chr17:63849292~63864379:+
THCA	cis	rs7615952	0.546	rs2979340	ENSG00000243429.1	OR7E29P	5.43	8.94e-08	1.39e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:125622540	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.546	rs2979338	ENSG00000243429.1	OR7E29P	5.43	8.94e-08	1.39e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:125624282	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.546	rs2922171	ENSG00000243429.1	OR7E29P	5.43	8.94e-08	1.39e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:125624349	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.546	rs112919177	ENSG00000243429.1	OR7E29P	5.43	8.94e-08	1.39e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:125627226	chr3:125712139~125713045:+
THCA	cis	rs9380516	0.898	rs4711420	ENSG00000228559.1	RP3-340B19.3	-5.43	8.94e-08	1.39e-05	-0.34	-0.24	Hepatitis C induced liver fibrosis;	chr6:35528034	chr6:35544632~35545669:+
THCA	cis	rs2243480	1	rs7804223	ENSG00000232559.3	GS1-124K5.12	-5.43	8.94e-08	1.39e-05	-0.37	-0.24	Diabetic kidney disease;	chr7:66199572	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000230295.1	RP11-458F8.2	-5.43	8.94e-08	1.39e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65951319	chr7:66880708~66882981:+
THCA	cis	rs6142102	0.923	rs6059586	ENSG00000275784.1	RP5-1125A11.6	-5.43	8.95e-08	1.39e-05	-0.24	-0.24	Skin pigmentation;	chr20:33952695	chr20:33989480~33991818:-
THCA	cis	rs4908760	0.899	rs61783642	ENSG00000232912.4	RP5-1115A15.1	5.43	8.95e-08	1.39e-05	0.24	0.24	Vitiligo;	chr1:8531338	chr1:8424645~8434838:+
THCA	cis	rs11148252	0.875	rs7987115	ENSG00000235660.1	LINC00345	-5.43	8.95e-08	1.39e-05	-0.31	-0.24	Lewy body disease;	chr13:52387962	chr13:52484161~52484680:-
THCA	cis	rs2562456	0.917	rs2650825	ENSG00000213976.4	CTD-2561J22.2	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Pain;	chr19:21516423	chr19:21382865~21387177:+
THCA	cis	rs12935418	0.583	rs2549836	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80989476	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2549837	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80989510	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.552	rs2549838	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80989605	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2549839	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80989630	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2549843	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80990140	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.523	rs2549845	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80990520	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.523	rs2549846	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80990522	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.552	rs2549847	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80990617	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2602449	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80990668	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2549848	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80990693	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2316923	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80991216	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2113197	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80991901	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2549852	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80992410	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.583	rs2549856	ENSG00000278985.1	RP11-303E16.9	-5.43	8.95e-08	1.39e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80993322	chr16:80982319~80984094:-
THCA	cis	rs2179367	0.553	rs7762222	ENSG00000223701.3	RAET1E-AS1	5.43	8.95e-08	1.39e-05	0.38	0.24	Dupuytren's disease;	chr6:149444846	chr6:149884431~149919508:+
THCA	cis	rs2810114	0.916	rs2526851	ENSG00000269927.1	RP6-91H8.3	-5.43	8.96e-08	1.39e-05	-0.29	-0.24	Alcohol dependence;	chr14:70949563	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.529	rs2526850	ENSG00000269927.1	RP6-91H8.3	-5.43	8.96e-08	1.39e-05	-0.29	-0.24	Schizophrenia;	chr14:70950532	chr14:71141125~71143253:-
THCA	cis	rs897984	0.759	rs13708	ENSG00000260911.2	RP11-196G11.2	-5.43	8.96e-08	1.39e-05	-0.2	-0.24	Dementia with Lewy bodies;	chr16:30989488	chr16:31043150~31049868:+
THCA	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	5.43	8.96e-08	1.39e-05	0.21	0.24	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
THCA	cis	rs4713118	0.513	rs149959	ENSG00000220721.1	OR1F12	5.43	8.96e-08	1.39e-05	0.29	0.24	Parkinson's disease;	chr6:28046076	chr6:28073316~28074233:+
THCA	cis	rs4947019	1	rs4947019	ENSG00000223537.2	RP5-919F19.5	-5.43	8.96e-08	1.39e-05	-0.37	-0.24	Hematological parameters;	chr6:109768846	chr6:109487906~109506800:+
THCA	cis	rs17123764	0.71	rs1574326	ENSG00000257464.1	RP11-161H23.8	-5.43	8.96e-08	1.39e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49696760	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs7137976	ENSG00000257464.1	RP11-161H23.8	-5.43	8.96e-08	1.39e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49705284	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs12315224	ENSG00000257464.1	RP11-161H23.8	-5.43	8.96e-08	1.39e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49715734	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs7136052	ENSG00000257464.1	RP11-161H23.8	-5.43	8.96e-08	1.39e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49716953	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.786	rs7980979	ENSG00000257464.1	RP11-161H23.8	-5.43	8.96e-08	1.39e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49728805	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs12304796	ENSG00000257464.1	RP11-161H23.8	-5.43	8.96e-08	1.39e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49729683	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs11169133	ENSG00000257464.1	RP11-161H23.8	-5.43	8.96e-08	1.39e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49732275	chr12:49442424~49442652:-
THCA	cis	rs3847687	0.507	rs10773838	ENSG00000279993.1	RP11-76C10.3	5.43	8.97e-08	1.39e-05	0.27	0.24	Longevity;	chr12:131039287	chr12:131025561~131028060:-
THCA	cis	rs2835345	0.563	rs4378885	ENSG00000230479.1	AP000695.6	5.43	8.97e-08	1.39e-05	0.29	0.24	Pulmonary function;	chr21:36452613	chr21:36430360~36481070:+
THCA	cis	rs1479090	0.509	rs6823527	ENSG00000250027.1	RP11-563E2.2	-5.43	8.97e-08	1.39e-05	-0.25	-0.24	Lung cancer;	chr4:163097415	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.762	rs936564	ENSG00000250027.1	RP11-563E2.2	-5.43	8.97e-08	1.39e-05	-0.25	-0.24	Lung cancer;	chr4:163098611	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.651	rs4485770	ENSG00000250027.1	RP11-563E2.2	-5.43	8.97e-08	1.39e-05	-0.25	-0.24	Lung cancer;	chr4:163099023	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.762	rs10031393	ENSG00000250027.1	RP11-563E2.2	-5.43	8.97e-08	1.39e-05	-0.25	-0.24	Lung cancer;	chr4:163099940	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.722	rs9654227	ENSG00000250027.1	RP11-563E2.2	-5.43	8.97e-08	1.39e-05	-0.25	-0.24	Lung cancer;	chr4:163100413	chr4:163108785~163119965:+
THCA	cis	rs9388451	0.903	rs9388446	ENSG00000226409.1	RP11-735G4.1	-5.43	8.97e-08	1.39e-05	-0.29	-0.24	Brugada syndrome;	chr6:125743774	chr6:125370211~125374324:-
THCA	cis	rs972578	0.715	rs4822202	ENSG00000274717.1	RP1-47A17.1	-5.43	8.98e-08	1.39e-05	-0.25	-0.24	Mean platelet volume;	chr22:42839150	chr22:42791814~42794313:-
THCA	cis	rs2559856	0.967	rs2559863	ENSG00000274560.1	RP11-285E23.2	5.43	8.98e-08	1.39e-05	0.15	0.24	Blood protein levels;	chr12:101693330	chr12:101696002~101696450:-
THCA	cis	rs6969780	0.778	rs11564055	ENSG00000233429.8	HOTAIRM1	5.43	8.98e-08	1.39e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27105731	chr7:27095647~27100265:+
THCA	cis	rs6969780	0.778	rs2428433	ENSG00000233429.8	HOTAIRM1	5.43	8.98e-08	1.39e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27105898	chr7:27095647~27100265:+
THCA	cis	rs2179367	0.632	rs55826712	ENSG00000268592.3	RAET1E-AS1	5.43	8.99e-08	1.4e-05	0.35	0.24	Dupuytren's disease;	chr6:149344716	chr6:149863494~149919507:+
THCA	cis	rs1865760	0.593	rs9295678	ENSG00000272462.2	U91328.19	-5.43	9e-08	1.4e-05	-0.19	-0.24	Height;	chr6:25936805	chr6:25992662~26001775:+
THCA	cis	rs1865760	0.593	rs9393676	ENSG00000272462.2	U91328.19	-5.43	9e-08	1.4e-05	-0.19	-0.24	Height;	chr6:25936716	chr6:25992662~26001775:+
THCA	cis	rs2282300	0.739	rs1222208	ENSG00000242353.1	RP4-710M3.1	-5.43	9e-08	1.4e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30339830	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs1222211	ENSG00000242353.1	RP4-710M3.1	-5.43	9e-08	1.4e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30340692	chr11:30368148~30368646:+
THCA	cis	rs7394190	0.81	rs7394178	ENSG00000271816.1	BMS1P4	-5.43	9e-08	1.4e-05	-0.29	-0.24	Incident atrial fibrillation;	chr10:73661822	chr10:73699151~73730487:-
THCA	cis	rs8062405	0.965	rs56040780	ENSG00000278665.1	RP11-666O2.4	5.43	9e-08	1.4e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28599241~28601881:-
THCA	cis	rs79040073	0.637	rs79365293	ENSG00000259531.2	RP11-295H24.3	5.43	9.01e-08	1.4e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49402268	chr15:49365124~49366685:-
THCA	cis	rs2993535	0.643	rs2970604	ENSG00000233626.2	RP11-565J7.1	5.43	9.01e-08	1.4e-05	0.67	0.24	Hip circumference adjusted for BMI;	chr1:211988364	chr1:211936249~211936634:+
THCA	cis	rs2993535	0.915	rs3009991	ENSG00000233626.2	RP11-565J7.1	5.43	9.01e-08	1.4e-05	0.67	0.24	Hip circumference adjusted for BMI;	chr1:212012003	chr1:211936249~211936634:+
THCA	cis	rs890448	0.796	rs2119591	ENSG00000254531.1	FLJ20021	5.43	9.01e-08	1.4e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101398487	chr4:101347780~101348883:+
THCA	cis	rs2985684	0.789	rs1957979	ENSG00000278009.1	RP11-649E7.8	5.43	9.02e-08	1.4e-05	0.34	0.24	Carotid intima media thickness;	chr14:49596614	chr14:49601011~49601124:-
THCA	cis	rs2985684	0.789	rs7161649	ENSG00000278009.1	RP11-649E7.8	5.43	9.02e-08	1.4e-05	0.34	0.24	Carotid intima media thickness;	chr14:49597310	chr14:49601011~49601124:-
THCA	cis	rs10266483	0.774	rs642909	ENSG00000271550.1	BNIP3P11	5.43	9.02e-08	1.4e-05	0.33	0.24	Response to statin therapy;	chr7:64309943	chr7:64678954~64687393:-
THCA	cis	rs875971	0.522	rs34973832	ENSG00000273142.1	RP11-458F8.4	-5.43	9.03e-08	1.4e-05	-0.2	-0.24	Aortic root size;	chr7:65931217	chr7:66902857~66906297:+
THCA	cis	rs12681287	0.752	rs10112123	ENSG00000254231.1	CTD-2284J15.1	5.43	9.03e-08	1.4e-05	0.27	0.24	Caudate activity during reward;	chr8:86290099	chr8:86333274~86343314:-
THCA	cis	rs919433	0.68	rs7568250	ENSG00000231621.1	AC013264.2	-5.43	9.03e-08	1.4e-05	-0.26	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197544887	chr2:197197991~197199273:+
THCA	cis	rs919433	0.68	rs1563340	ENSG00000231621.1	AC013264.2	-5.43	9.03e-08	1.4e-05	-0.26	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197549989	chr2:197197991~197199273:+
THCA	cis	rs2243480	1	rs316307	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66105184	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs422164	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66121618	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316313	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66128561	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316312	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66131504	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs419603	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66132354	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs387676	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66133233	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs13310597	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66133553	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs431076	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66135333	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs2460422	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66136518	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316334	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66137139	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316330	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66140385	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316326	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66144466	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316325	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66144531	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316321	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66146626	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316318	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66147917	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316317	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66148650	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316304	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66151907	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs2465120	ENSG00000232559.3	GS1-124K5.12	5.43	9.04e-08	1.4e-05	0.35	0.24	Diabetic kidney disease;	chr7:66155987	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66157859	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs4718309	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66162777	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6460274	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66163497	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs7787230	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66164112	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66170354	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6974723	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66172952	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs9769882	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66177938	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6966322	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66181767	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs4145008	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66182524	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs4718315	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66183554	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs4718316	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66183744	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1873494	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66184912	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6959002	ENSG00000232559.3	GS1-124K5.12	-5.43	9.04e-08	1.4e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66185509	chr7:66554588~66576923:-
THCA	cis	rs1914816	0.941	rs2456027	ENSG00000196274.5	Metazoa_SRP	5.43	9.05e-08	1.4e-05	0.33	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76275868	chr15:76230048~76230390:-
THCA	cis	rs875971	0.545	rs6460281	ENSG00000228409.4	CCT6P1	-5.43	9.05e-08	1.4e-05	-0.21	-0.24	Aortic root size;	chr7:66216128	chr7:65751142~65763354:+
THCA	cis	rs7512898	0.583	rs6427852	ENSG00000260088.1	RP11-92G12.3	-5.43	9.05e-08	1.4e-05	-0.3	-0.24	Electrocardiographic conduction measures;	chr1:200707080	chr1:200669507~200694250:+
THCA	cis	rs12900463	0.752	rs12904777	ENSG00000188388.10	GOLGA6L3	5.43	9.06e-08	1.4e-05	0.3	0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:85240472~85247170:+
THCA	cis	rs2735413	0.564	rs74715500	ENSG00000276007.1	RP11-358L22.3	5.43	9.06e-08	1.4e-05	0.26	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78061515	chr16:78123243~78124332:+
THCA	cis	rs75920871	0.512	rs6589583	ENSG00000254851.1	RP11-109L13.1	5.43	9.06e-08	1.41e-05	0.35	0.24	Subjective well-being;	chr11:116993050	chr11:117135528~117138582:+
THCA	cis	rs875971	0.965	rs7794930	ENSG00000223473.2	GS1-124K5.3	-5.43	9.06e-08	1.41e-05	-0.16	-0.24	Aortic root size;	chr7:66313559	chr7:66491049~66493566:-
THCA	cis	rs755249	0.53	rs4660475	ENSG00000228060.1	RP11-69E11.8	-5.43	9.07e-08	1.41e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39565160~39573203:+
THCA	cis	rs755249	0.53	rs66848709	ENSG00000228060.1	RP11-69E11.8	-5.43	9.07e-08	1.41e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39565160~39573203:+
THCA	cis	rs763121	0.962	rs6001159	ENSG00000235209.1	CTA-150C2.13	5.43	9.07e-08	1.41e-05	0.31	0.24	Menopause (age at onset);	chr22:38570482	chr22:38921227~38924708:+
THCA	cis	rs6908034	0.556	rs79028848	ENSG00000227116.1	RP3-471C18.1	-5.43	9.08e-08	1.41e-05	-0.45	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782922	chr6:19730427~19734567:-
THCA	cis	rs11723261	0.582	rs7679573	ENSG00000211553.1	AC253576.2	-5.43	9.08e-08	1.41e-05	-0.35	-0.24	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:136461~136568:+
THCA	cis	rs9901225	1	rs9901225	ENSG00000108785.7	HSD17B1P1	-5.43	9.08e-08	1.41e-05	-0.23	-0.24	Colorectal or endometrial cancer;	chr17:42603793	chr17:42546764~42548706:+
THCA	cis	rs2179367	0.632	rs9485384	ENSG00000268592.3	RAET1E-AS1	5.43	9.08e-08	1.41e-05	0.35	0.24	Dupuytren's disease;	chr6:149328808	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12211357	ENSG00000268592.3	RAET1E-AS1	5.43	9.08e-08	1.41e-05	0.35	0.24	Dupuytren's disease;	chr6:149331148	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs11155642	ENSG00000268592.3	RAET1E-AS1	5.43	9.08e-08	1.41e-05	0.35	0.24	Dupuytren's disease;	chr6:149332984	chr6:149863494~149919507:+
THCA	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	5.43	9.08e-08	1.41e-05	0.21	0.24	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
THCA	cis	rs7617773	0.743	rs11715876	ENSG00000199476.1	Y_RNA	-5.43	9.09e-08	1.41e-05	-0.32	-0.24	Coronary artery disease;	chr3:48336432	chr3:48288587~48288694:+
THCA	cis	rs1858037	0.867	rs67453645	ENSG00000234255.7	AC012370.3	5.43	9.09e-08	1.41e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65358908	chr2:65439888~65456571:-
THCA	cis	rs6545883	0.965	rs778752	ENSG00000270820.4	RP11-355B11.2	5.43	9.09e-08	1.41e-05	0.2	0.24	Tuberculosis;	chr2:61549767	chr2:61471188~61484130:+
THCA	cis	rs17767392	0.846	rs17767398	ENSG00000259146.3	RP1-261D10.2	5.43	9.09e-08	1.41e-05	0.3	0.24	Mitral valve prolapse;	chr14:71303768	chr14:71292729~71321814:-
THCA	cis	rs7045881	0.935	rs62544452	ENSG00000254396.1	RP11-56F10.3	5.43	9.1e-08	1.41e-05	0.34	0.24	Schizophrenia;	chr9:26935320	chr9:27102630~27104728:+
THCA	cis	rs11148252	0.634	rs4941727	ENSG00000235660.1	LINC00345	5.43	9.1e-08	1.41e-05	0.31	0.24	Lewy body disease;	chr13:52146932	chr13:52484161~52484680:-
THCA	cis	rs4947019	1	rs4947015	ENSG00000223537.2	RP5-919F19.5	-5.43	9.1e-08	1.41e-05	-0.37	-0.24	Hematological parameters;	chr6:109731312	chr6:109487906~109506800:+
THCA	cis	rs752010	0.619	rs10789406	ENSG00000230638.4	RP11-486B10.4	5.43	9.1e-08	1.41e-05	0.27	0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41639511	chr1:41542069~41544310:+
THCA	cis	rs3950186	0.789	rs4308554	ENSG00000215124.2	RP3-420J14.1	5.43	9.1e-08	1.41e-05	0.28	0.24	Anxiety and major depressive disorder;	chr6:11826166	chr6:11861626~11862970:-
THCA	cis	rs890448	0.796	rs11097747	ENSG00000254531.1	FLJ20021	5.43	9.1e-08	1.41e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101376639	chr4:101347780~101348883:+
THCA	cis	rs79040073	0.564	rs34606419	ENSG00000259531.2	RP11-295H24.3	5.43	9.11e-08	1.41e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49240390	chr15:49365124~49366685:-
THCA	cis	rs7554547	0.622	rs2179110	ENSG00000199347.1	RNU5E-1	-5.43	9.11e-08	1.41e-05	-0.34	-0.24	Nonsyndromic cleft lip with cleft palate;	chr1:11912754	chr1:11908152~11908271:+
THCA	cis	rs6969780	0.778	rs2428434	ENSG00000233429.8	HOTAIRM1	5.43	9.11e-08	1.41e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106116	chr7:27095647~27100265:+
THCA	cis	rs6969780	0.778	rs79619106	ENSG00000233429.8	HOTAIRM1	5.43	9.11e-08	1.41e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106709	chr7:27095647~27100265:+
THCA	cis	rs7615952	0.546	rs11717632	ENSG00000243429.1	OR7E29P	5.43	9.11e-08	1.41e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:125602286	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.546	rs2922197	ENSG00000243429.1	OR7E29P	5.43	9.11e-08	1.41e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:125603188	chr3:125712139~125713045:+
THCA	cis	rs17345786	0.511	rs1138818	ENSG00000244119.1	PDCL3P4	5.43	9.11e-08	1.41e-05	0.22	0.24	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101712472~101713191:+
THCA	cis	rs7246657	0.722	rs2972430	ENSG00000276846.1	CTD-3220F14.3	-5.43	9.12e-08	1.41e-05	-0.25	-0.24	Coronary artery calcification;	chr19:37691210	chr19:37314868~37315620:-
THCA	cis	rs1210638	0.756	rs2518800	ENSG00000273032.1	DGCR9	5.43	9.12e-08	1.41e-05	0.25	0.24	Response to serotonin reuptake inhibitors in major depressive disorder;	chr22:18985958	chr22:19017834~19020248:+
THCA	cis	rs7403037	0.536	rs34030559	ENSG00000259905.4	PWRN1	5.43	9.12e-08	1.41e-05	0.27	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24177898	chr15:24493137~24652130:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000273024.4	INTS4P2	-5.43	9.12e-08	1.41e-05	-0.27	-0.24	Calcium levels;	chr7:65825628	chr7:65647864~65715661:+
THCA	cis	rs8141529	0.687	rs6005867	ENSG00000272858.1	CTA-292E10.8	-5.43	9.12e-08	1.41e-05	-0.25	-0.24	Lymphocyte counts;	chr22:28769132	chr22:28814914~28815662:+
THCA	cis	rs7829975	0.56	rs6994131	ENSG00000253893.2	FAM85B	5.43	9.13e-08	1.41e-05	0.33	0.24	Mood instability;	chr8:8693448	chr8:8167819~8226614:-
THCA	cis	rs2129782	1	rs59484067	ENSG00000253553.4	RP11-586K2.1	5.43	9.14e-08	1.42e-05	0.43	0.24	Electrodermal activity;	chr8:88397114	chr8:88326836~88737134:+
THCA	cis	rs9388451	0.626	rs3734637	ENSG00000226409.1	RP11-735G4.1	-5.43	9.14e-08	1.42e-05	-0.3	-0.24	Brugada syndrome;	chr6:125760173	chr6:125370211~125374324:-
THCA	cis	rs76935404	0.811	rs4609955	ENSG00000256612.6	CYP2B7P	-5.43	9.14e-08	1.42e-05	-0.3	-0.24	nicotine metabolite ratio in current smokers;	chr19:40927708	chr19:40924219~40950660:+
THCA	cis	rs12101261	0.744	rs12050078	ENSG00000259167.2	NMNAT1P1	-5.43	9.14e-08	1.42e-05	-0.35	-0.24	Graves' disease;	chr14:80950010	chr14:81032529~81033404:+
THCA	cis	rs5752326	1	rs2157586	ENSG00000261188.1	CTA-445C9.14	-5.43	9.14e-08	1.42e-05	-0.3	-0.24	Ischemic stroke;	chr22:26499095	chr22:26512537~26514568:+
THCA	cis	rs62432291	0.681	rs423533	ENSG00000235086.1	FNDC1-IT1	-5.43	9.14e-08	1.42e-05	-0.44	-0.24	Joint mobility (Beighton score);	chr6:159243484	chr6:159240786~159243329:+
THCA	cis	rs202072	0.872	rs202044	ENSG00000272379.1	RP1-257A7.5	5.43	9.16e-08	1.42e-05	0.35	0.24	HIV-1 viral setpoint;	chr6:13275718	chr6:13290018~13290490:-
THCA	cis	rs1790761	0.504	rs61894496	ENSG00000255318.1	RP11-655M14.13	5.43	9.16e-08	1.42e-05	0.27	0.24	Mean corpuscular volume;	chr11:67624436	chr11:67618279~67627304:-
THCA	cis	rs4845570	0.85	rs11204892	ENSG00000268288.1	RP11-98D18.16	5.43	9.17e-08	1.42e-05	0.31	0.24	Coronary artery disease;	chr1:151795572	chr1:151766486~151767000:-
THCA	cis	rs2179367	0.632	rs11155640	ENSG00000268592.3	RAET1E-AS1	5.43	9.18e-08	1.42e-05	0.35	0.24	Dupuytren's disease;	chr6:149323648	chr6:149863494~149919507:+
THCA	cis	rs853679	0.527	rs707907	ENSG00000273712.1	RP5-874C20.7	5.43	9.18e-08	1.42e-05	0.27	0.24	Depression;	chr6:28323463	chr6:28315613~28315883:-
THCA	cis	rs2562456	0.754	rs11666213	ENSG00000268081.1	RP11-678G14.2	5.43	9.18e-08	1.42e-05	0.41	0.24	Pain;	chr19:21422843	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62110429	ENSG00000268081.1	RP11-678G14.2	5.43	9.18e-08	1.42e-05	0.41	0.24	Pain;	chr19:21430984	chr19:21554640~21569237:-
THCA	cis	rs853679	0.607	rs66886492	ENSG00000219392.1	RP1-265C24.5	-5.43	9.19e-08	1.42e-05	-0.56	-0.24	Depression;	chr6:28121953	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs35345226	ENSG00000219392.1	RP1-265C24.5	-5.43	9.19e-08	1.42e-05	-0.56	-0.24	Depression;	chr6:28123802	chr6:28115628~28116551:+
THCA	cis	rs11146838	1	rs11146838	ENSG00000275858.1	RP11-291L22.8	5.43	9.2e-08	1.42e-05	0.29	0.24	Breast cancer;	chr10:38856846	chr10:38450738~38451069:-
THCA	cis	rs7702057	0.53	rs17138866	ENSG00000271918.1	CTD-2287O16.5	5.43	9.2e-08	1.43e-05	0.28	0.24	Amyotrophic lateral sclerosis;	chr5:116088914	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.53	rs59429923	ENSG00000271918.1	CTD-2287O16.5	5.43	9.2e-08	1.43e-05	0.28	0.24	Amyotrophic lateral sclerosis;	chr5:116089241	chr5:116083807~116085416:-
THCA	cis	rs1580019	0.563	rs34319173	ENSG00000231952.3	DPY19L1P2	-5.43	9.21e-08	1.43e-05	-0.3	-0.24	Cognitive ability;	chr7:32546292	chr7:32812757~32838570:+
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	5.43	9.21e-08	1.43e-05	0.27	0.24	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
THCA	cis	rs593531	0.513	rs3867268	ENSG00000212961.4	HNRNPA1P40	-5.43	9.21e-08	1.43e-05	-0.31	-0.24	Neuroticism;	chr11:74322332	chr11:74354443~74355720:+
THCA	cis	rs832187	0.64	rs3774729	ENSG00000280620.1	SCAANT1	5.43	9.21e-08	1.43e-05	0.33	0.24	Schizophrenia;	chr3:63996406	chr3:63911518~63911772:-
THCA	cis	rs2880765	0.835	rs7180923	ENSG00000259630.2	CTD-2262B20.1	-5.43	9.21e-08	1.43e-05	-0.26	-0.24	Coronary artery disease;	chr15:85507659	chr15:85415228~85415633:+
THCA	cis	rs12681287	0.64	rs7820234	ENSG00000254231.1	CTD-2284J15.1	5.43	9.21e-08	1.43e-05	0.27	0.24	Caudate activity during reward;	chr8:86338721	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.571	rs13254675	ENSG00000254231.1	CTD-2284J15.1	5.43	9.21e-08	1.43e-05	0.27	0.24	Caudate activity during reward;	chr8:86341365	chr8:86333274~86343314:-
THCA	cis	rs7246657	0.638	rs7246461	ENSG00000267422.1	CTD-2554C21.1	5.43	9.22e-08	1.43e-05	0.27	0.24	Coronary artery calcification;	chr19:37705680	chr19:37779686~37792865:+
THCA	cis	rs75920871	0.589	rs73008568	ENSG00000254851.1	RP11-109L13.1	-5.43	9.22e-08	1.43e-05	-0.47	-0.24	Subjective well-being;	chr11:117194291	chr11:117135528~117138582:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000232546.1	RP11-458F8.1	-5.43	9.22e-08	1.43e-05	-0.23	-0.24	Aortic root size;	chr7:66112359	chr7:66848496~66858136:+
THCA	cis	rs1823874	0.581	rs11855419	ENSG00000259363.4	CTD-2054N24.2	5.43	9.22e-08	1.43e-05	0.32	0.24	IgG glycosylation;	chr15:99787275	chr15:99807023~99877148:+
THCA	cis	rs10875746	0.669	rs9634261	ENSG00000258234.1	RP11-370I10.2	5.43	9.22e-08	1.43e-05	0.28	0.24	Longevity (90 years and older);	chr12:48293088	chr12:48231098~48284210:-
THCA	cis	rs9381040	0.631	rs13216201	ENSG00000161912.16	ADCY10P1	5.43	9.23e-08	1.43e-05	0.17	0.24	Alzheimer's disease (late onset);	chr6:41194322	chr6:41101022~41140835:+
THCA	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	5.43	9.24e-08	1.43e-05	0.43	0.24	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
THCA	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	5.43	9.24e-08	1.43e-05	0.43	0.24	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
THCA	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	5.43	9.24e-08	1.43e-05	0.43	0.24	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
THCA	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	5.43	9.24e-08	1.43e-05	0.43	0.24	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
THCA	cis	rs12908161	0.959	rs2175567	ENSG00000275120.1	RP11-182J1.17	5.43	9.24e-08	1.43e-05	0.29	0.24	Schizophrenia;	chr15:84657715	chr15:84599434~84606463:-
THCA	cis	rs62246343	0.719	rs1973243	ENSG00000254485.4	RP11-380O24.1	5.43	9.24e-08	1.43e-05	0.31	0.24	Fibrinogen levels;	chr3:9450592	chr3:9292588~9363303:-
THCA	cis	rs6728642	0.572	rs13387563	ENSG00000230606.9	AC159540.1	5.43	9.25e-08	1.43e-05	0.29	0.24	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935179	chr2:97416165~97433527:-
THCA	cis	rs875971	0.619	rs12533585	ENSG00000273142.1	RP11-458F8.4	-5.43	9.25e-08	1.43e-05	-0.19	-0.24	Aortic root size;	chr7:66519618	chr7:66902857~66906297:+
THCA	cis	rs2115630	0.967	rs11073702	ENSG00000225151.9	GOLGA2P7	5.43	9.25e-08	1.43e-05	0.31	0.24	P wave terminal force;	chr15:84766840	chr15:84199311~84230136:-
THCA	cis	rs11096990	0.927	rs56009503	ENSG00000249685.1	RP11-360F5.3	-5.43	9.25e-08	1.43e-05	-0.31	-0.24	Cognitive function;	chr4:39242642	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.964	rs7687651	ENSG00000249685.1	RP11-360F5.3	-5.43	9.25e-08	1.43e-05	-0.31	-0.24	Cognitive function;	chr4:39243072	chr4:39133913~39135608:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-5.43	9.25e-08	1.43e-05	-0.28	-0.24	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
THCA	cis	rs6121246	0.529	rs6060174	ENSG00000230613.1	HM13-AS1	5.43	9.25e-08	1.43e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31595735	chr20:31567707~31573263:-
THCA	cis	rs7727544	0.735	rs274568	ENSG00000263597.1	MIR3936	-5.43	9.26e-08	1.43e-05	-0.23	-0.24	Blood metabolite levels;	chr5:132377886	chr5:132365490~132365599:-
THCA	cis	rs17270561	0.779	rs78589800	ENSG00000272462.2	U91328.19	-5.43	9.26e-08	1.43e-05	-0.23	-0.24	Iron status biomarkers;	chr6:25883272	chr6:25992662~26001775:+
THCA	cis	rs1400745	0.756	rs799683	ENSG00000258738.1	RP11-73E17.2	5.43	9.26e-08	1.43e-05	0.29	0.24	Monocyte count;	chr14:34880030	chr14:34874343~34876459:+
THCA	cis	rs1400745	0.756	rs799682	ENSG00000258738.1	RP11-73E17.2	5.43	9.26e-08	1.43e-05	0.29	0.24	Monocyte count;	chr14:34880778	chr14:34874343~34876459:+
THCA	cis	rs6569038	0.502	rs2051056	ENSG00000253194.1	RP11-351A11.1	-5.43	9.27e-08	1.43e-05	-0.33	-0.24	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118978418	chr6:118934785~119031541:+
THCA	cis	rs5752326	0.867	rs929131	ENSG00000261188.1	CTA-445C9.14	-5.43	9.27e-08	1.43e-05	-0.28	-0.24	Ischemic stroke;	chr22:26448803	chr22:26512537~26514568:+
THCA	cis	rs2243480	1	rs778729	ENSG00000232559.3	GS1-124K5.12	5.43	9.27e-08	1.43e-05	0.37	0.24	Diabetic kidney disease;	chr7:66359432	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs778687	ENSG00000232559.3	GS1-124K5.12	5.43	9.27e-08	1.43e-05	0.37	0.24	Diabetic kidney disease;	chr7:66370832	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs778679	ENSG00000232559.3	GS1-124K5.12	5.43	9.27e-08	1.43e-05	0.37	0.24	Diabetic kidney disease;	chr7:66375924	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs778704	ENSG00000232559.3	GS1-124K5.12	5.43	9.27e-08	1.43e-05	0.37	0.24	Diabetic kidney disease;	chr7:66398480	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs778693	ENSG00000232559.3	GS1-124K5.12	5.43	9.27e-08	1.43e-05	0.37	0.24	Diabetic kidney disease;	chr7:66407358	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs778691	ENSG00000232559.3	GS1-124K5.12	5.43	9.27e-08	1.43e-05	0.37	0.24	Diabetic kidney disease;	chr7:66408105	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs13235972	ENSG00000232559.3	GS1-124K5.12	5.43	9.27e-08	1.43e-05	0.37	0.24	Diabetic kidney disease;	chr7:66418618	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs34192067	ENSG00000232559.3	GS1-124K5.12	5.43	9.27e-08	1.43e-05	0.37	0.24	Diabetic kidney disease;	chr7:66422670	chr7:66554588~66576923:-
THCA	cis	rs849141	0.961	rs506154	ENSG00000234336.5	JAZF1-AS1	-5.43	9.27e-08	1.43e-05	-0.28	-0.24	Height;Hip circumference adjusted for BMI;	chr7:28162460	chr7:28180322~28243917:+
THCA	cis	rs849141	0.961	rs537124	ENSG00000234336.5	JAZF1-AS1	-5.43	9.27e-08	1.43e-05	-0.28	-0.24	Height;Hip circumference adjusted for BMI;	chr7:28163523	chr7:28180322~28243917:+
THCA	cis	rs7688540	0.723	rs9684973	ENSG00000211553.1	AC253576.2	-5.43	9.27e-08	1.44e-05	-0.35	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:136461~136568:+
THCA	cis	rs7824557	0.767	rs6985460	ENSG00000154316.13	TDH	-5.43	9.27e-08	1.44e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11313578	chr8:11339637~11368452:+
THCA	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	5.43	9.28e-08	1.44e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	5.43	9.28e-08	1.44e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
THCA	cis	rs9859260	0.925	rs13072608	ENSG00000226155.1	AC124944.3	-5.43	9.29e-08	1.44e-05	-0.28	-0.24	Mean corpuscular volume;	chr3:196073396	chr3:195912049~195913986:+
THCA	cis	rs9527	0.501	rs12244388	ENSG00000236937.2	PTGES3P4	5.42	9.29e-08	1.44e-05	0.32	0.24	Arsenic metabolism;	chr10:102880295	chr10:102845595~102845950:+
THCA	cis	rs3950186	0.834	rs10947579	ENSG00000215124.2	RP3-420J14.1	5.42	9.3e-08	1.44e-05	0.29	0.24	Anxiety and major depressive disorder;	chr6:11811356	chr6:11861626~11862970:-
THCA	cis	rs2337406	0.85	rs11849578	ENSG00000274576.2	IGHV2-70	-5.42	9.31e-08	1.44e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106670302	chr14:106770577~106771020:-
THCA	cis	rs1552244	1	rs55822690	ENSG00000232901.1	CYCSP10	5.42	9.31e-08	1.44e-05	0.32	0.24	Alzheimer's disease;	chr3:10086319	chr3:10000647~10000940:-
THCA	cis	rs17818399	0.781	rs12105006	ENSG00000279254.1	RP11-536C12.1	5.42	9.32e-08	1.44e-05	0.25	0.24	Height;	chr2:46635447	chr2:46668870~46670778:+
THCA	cis	rs1322639	0.614	rs6908401	ENSG00000261039.2	RP11-417E7.2	5.42	9.32e-08	1.44e-05	0.36	0.24	Pulse pressure;	chr6:169164621	chr6:169175304~169182740:-
THCA	cis	rs10461617	0.617	rs1423623	ENSG00000271828.1	CTD-2310F14.1	-5.42	9.32e-08	1.44e-05	-0.33	-0.24	Type 2 diabetes;	chr5:56769748	chr5:56927874~56929573:+
THCA	cis	rs1979679	0.918	rs2348234	ENSG00000278733.1	RP11-425D17.1	5.42	9.32e-08	1.44e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28354126	chr12:28185625~28186190:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000273142.1	RP11-458F8.4	5.42	9.33e-08	1.44e-05	0.19	0.24	Aortic root size;	chr7:66603522	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000273142.1	RP11-458F8.4	5.42	9.33e-08	1.44e-05	0.19	0.24	Aortic root size;	chr7:66622208	chr7:66902857~66906297:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000273142.1	RP11-458F8.4	5.42	9.33e-08	1.44e-05	0.19	0.24	Aortic root size;	chr7:66624003	chr7:66902857~66906297:+
THCA	cis	rs8062405	1	rs62037371	ENSG00000278665.1	RP11-666O2.4	5.42	9.33e-08	1.44e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28599241~28601881:-
THCA	cis	rs17772222	0.545	rs1758846	ENSG00000258983.2	RP11-507K2.2	-5.42	9.33e-08	1.44e-05	-0.28	-0.24	Coronary artery calcification;	chr14:88449288	chr14:88499334~88515502:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000273142.1	RP11-458F8.4	5.42	9.33e-08	1.44e-05	0.19	0.24	Aortic root size;	chr7:66619753	chr7:66902857~66906297:+
THCA	cis	rs9388451	0.839	rs1811852	ENSG00000226409.1	RP11-735G4.1	-5.42	9.33e-08	1.44e-05	-0.29	-0.24	Brugada syndrome;	chr6:125750429	chr6:125370211~125374324:-
THCA	cis	rs2562456	0.755	rs11670868	ENSG00000268081.1	RP11-678G14.2	5.42	9.33e-08	1.44e-05	0.41	0.24	Pain;	chr19:21373613	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs55961038	ENSG00000268081.1	RP11-678G14.2	5.42	9.33e-08	1.44e-05	0.41	0.24	Pain;	chr19:21375205	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs2358993	ENSG00000268081.1	RP11-678G14.2	5.42	9.33e-08	1.44e-05	0.41	0.24	Pain;	chr19:21375367	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs11672583	ENSG00000268081.1	RP11-678G14.2	5.42	9.33e-08	1.44e-05	0.41	0.24	Pain;	chr19:21379363	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs17680605	ENSG00000268081.1	RP11-678G14.2	5.42	9.33e-08	1.44e-05	0.41	0.24	Pain;	chr19:21379646	chr19:21554640~21569237:-
THCA	cis	rs2348418	0.733	rs7294486	ENSG00000247934.4	RP11-967K21.1	-5.42	9.33e-08	1.44e-05	-0.21	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28181989	chr12:28163298~28190738:-
THCA	cis	rs7674212	0.512	rs2720462	ENSG00000246560.2	RP11-10L12.4	5.42	9.34e-08	1.45e-05	0.29	0.24	Type 2 diabetes;	chr4:103135053	chr4:102828055~102844075:+
THCA	cis	rs919433	0.68	rs2565163	ENSG00000231621.1	AC013264.2	-5.42	9.34e-08	1.45e-05	-0.26	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197489690	chr2:197197991~197199273:+
THCA	cis	rs801193	0.613	rs2659900	ENSG00000223473.2	GS1-124K5.3	5.42	9.34e-08	1.45e-05	0.16	0.24	Aortic root size;	chr7:66719456	chr7:66491049~66493566:-
THCA	cis	rs61677309	1	rs56785719	ENSG00000280032.1	RP11-832A4.7	5.42	9.35e-08	1.45e-05	0.26	0.24	Lung cancer in ever smokers;	chr11:118305908	chr11:118264593~118266817:+
THCA	cis	rs4713118	0.513	rs149962	ENSG00000226314.6	ZNF192P1	-5.42	9.35e-08	1.45e-05	-0.28	-0.24	Parkinson's disease;	chr6:28048140	chr6:28161781~28169594:+
THCA	cis	rs7829975	0.84	rs555617	ENSG00000254153.1	CTA-398F10.2	5.42	9.35e-08	1.45e-05	0.26	0.24	Mood instability;	chr8:8735335	chr8:8456909~8461337:-
THCA	cis	rs6496044	0.526	rs4291869	ENSG00000259630.2	CTD-2262B20.1	-5.42	9.36e-08	1.45e-05	-0.27	-0.24	Interstitial lung disease;	chr15:85511292	chr15:85415228~85415633:+
THCA	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs11155649	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149405830	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs11155650	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149407613	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs11155651	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149408146	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs7896	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149410340	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12196750	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149413335	chr6:149796151~149826294:-
THCA	cis	rs9388451	0.839	rs3757217	ENSG00000226409.1	RP11-735G4.1	-5.42	9.36e-08	1.45e-05	-0.29	-0.24	Brugada syndrome;	chr6:125748490	chr6:125370211~125374324:-
THCA	cis	rs2179367	0.552	rs11155652	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149417849	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12209364	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149418062	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9322179	ENSG00000231760.4	RP11-350J20.5	5.42	9.36e-08	1.45e-05	0.35	0.24	Dupuytren's disease;	chr6:149418664	chr6:149796151~149826294:-
THCA	cis	rs11846409	0.86	rs1858692	ENSG00000211974.3	IGHV2-70	5.42	9.36e-08	1.45e-05	0.24	0.24	Rheumatic heart disease;	chr14:106622776	chr14:106723574~106724093:-
THCA	cis	rs11051970	0.879	rs2651362	ENSG00000274964.1	RP11-817I4.1	-5.42	9.37e-08	1.45e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32434917	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.879	rs950080	ENSG00000274964.1	RP11-817I4.1	-5.42	9.37e-08	1.45e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32435569	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.879	rs950079	ENSG00000274964.1	RP11-817I4.1	-5.42	9.37e-08	1.45e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32435686	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.879	rs1500874	ENSG00000274964.1	RP11-817I4.1	-5.42	9.37e-08	1.45e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32436473	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.877	rs2728671	ENSG00000274964.1	RP11-817I4.1	-5.42	9.37e-08	1.45e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32436781	chr12:32339368~32340724:+
THCA	cis	rs4934494	0.677	rs11185800	ENSG00000232936.4	RP11-80H5.2	5.42	9.37e-08	1.45e-05	0.33	0.24	Red blood cell count;	chr10:89618323	chr10:89645282~89650667:+
THCA	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-5.42	9.37e-08	1.45e-05	-0.25	-0.24	Height;	chr2:46617930	chr2:46668870~46670778:+
THCA	cis	rs613391	0.522	rs1992926	ENSG00000224549.1	RP11-370B11.3	-5.42	9.37e-08	1.45e-05	-0.27	-0.24	Quantitative traits;	chr9:22730294	chr9:22767175~22768316:+
THCA	cis	rs613391	0.522	rs1667083	ENSG00000224549.1	RP11-370B11.3	-5.42	9.37e-08	1.45e-05	-0.27	-0.24	Quantitative traits;	chr9:22730548	chr9:22767175~22768316:+
THCA	cis	rs613391	0.522	rs1470616	ENSG00000224549.1	RP11-370B11.3	-5.42	9.37e-08	1.45e-05	-0.27	-0.24	Quantitative traits;	chr9:22730733	chr9:22767175~22768316:+
THCA	cis	rs613391	0.522	rs491563	ENSG00000224549.1	RP11-370B11.3	-5.42	9.37e-08	1.45e-05	-0.27	-0.24	Quantitative traits;	chr9:22730788	chr9:22767175~22768316:+
THCA	cis	rs10129255	0.576	rs2157616	ENSG00000211972.2	IGHV3-66	5.42	9.38e-08	1.45e-05	0.14	0.24	Kawasaki disease;	chr14:106767802	chr14:106675017~106675544:-
THCA	cis	rs613391	0.561	rs589423	ENSG00000224549.1	RP11-370B11.3	-5.42	9.38e-08	1.45e-05	-0.27	-0.24	Quantitative traits;	chr9:22721049	chr9:22767175~22768316:+
THCA	cis	rs10895275	0.886	rs12420287	ENSG00000277459.1	RP11-732A21.3	-5.42	9.38e-08	1.45e-05	-0.2	-0.24	Migraine;	chr11:102195495	chr11:102109827~102110457:-
THCA	cis	rs453301	0.522	rs2929455	ENSG00000248538.5	RP11-10A14.5	5.42	9.38e-08	1.45e-05	0.3	0.24	Joint mobility (Beighton score);	chr8:9225923	chr8:9189011~9202854:+
THCA	cis	rs2749592	0.918	rs1208653	ENSG00000263064.2	RP11-291L22.7	-5.42	9.38e-08	1.45e-05	-0.29	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37964898	chr10:38448689~38448949:+
THCA	cis	rs763121	0.853	rs2284073	ENSG00000273076.1	RP3-508I15.22	5.42	9.39e-08	1.45e-05	0.25	0.24	Menopause (age at onset);	chr22:38709943	chr22:38743495~38743910:+
THCA	cis	rs79040073	0.636	rs74339964	ENSG00000259531.2	RP11-295H24.3	5.42	9.4e-08	1.45e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49329916	chr15:49365124~49366685:-
THCA	cis	rs763121	1	rs138464	ENSG00000235209.1	CTA-150C2.13	-5.42	9.4e-08	1.45e-05	-0.31	-0.24	Menopause (age at onset);	chr22:38510427	chr22:38921227~38924708:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000273142.1	RP11-458F8.4	5.42	9.41e-08	1.45e-05	0.19	0.24	Aortic root size;	chr7:66566965	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000273142.1	RP11-458F8.4	5.42	9.41e-08	1.45e-05	0.19	0.24	Aortic root size;	chr7:66568046	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000273142.1	RP11-458F8.4	5.42	9.41e-08	1.45e-05	0.19	0.24	Aortic root size;	chr7:66571204	chr7:66902857~66906297:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000273142.1	RP11-458F8.4	5.42	9.41e-08	1.45e-05	0.19	0.24	Aortic root size;	chr7:66595421	chr7:66902857~66906297:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000273142.1	RP11-458F8.4	5.42	9.41e-08	1.45e-05	0.19	0.24	Aortic root size;	chr7:66598087	chr7:66902857~66906297:+
THCA	cis	rs7674212	0.57	rs2069274	ENSG00000246560.2	RP11-10L12.4	5.42	9.41e-08	1.45e-05	0.29	0.24	Type 2 diabetes;	chr4:103099624	chr4:102828055~102844075:+
THCA	cis	rs6908034	0.66	rs6918235	ENSG00000227116.1	RP3-471C18.1	-5.42	9.41e-08	1.45e-05	-0.44	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19788196	chr6:19730427~19734567:-
THCA	cis	rs1858037	0.867	rs67817304	ENSG00000234255.7	AC012370.3	5.42	9.41e-08	1.45e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65346982	chr2:65439888~65456571:-
THCA	cis	rs4460629	0.65	rs11264319	ENSG00000160766.13	GBAP1	-5.42	9.41e-08	1.45e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155111466	chr1:155213821~155227422:-
THCA	cis	rs6951245	0.882	rs10256720	ENSG00000229043.2	AC091729.9	-5.42	9.41e-08	1.46e-05	-0.42	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1171189	chr7:1160374~1165267:+
THCA	cis	rs79349575	0.756	rs2291726	ENSG00000270781.1	RP11-501C14.9	5.42	9.42e-08	1.46e-05	0.29	0.24	Type 2 diabetes;	chr17:48961892	chr17:48899131~48899748:+
THCA	cis	rs2299587	0.662	rs7816769	ENSG00000253671.1	RP11-806O11.1	5.42	9.42e-08	1.46e-05	0.29	0.24	Economic and political preferences;	chr8:17911039	chr8:17808941~17820868:+
THCA	cis	rs593531	0.614	rs486758	ENSG00000255440.1	RP11-632K5.2	5.42	9.43e-08	1.46e-05	0.29	0.24	Neuroticism;	chr11:74347887	chr11:74409060~74416379:+
THCA	cis	rs79040073	0.637	rs17476361	ENSG00000259531.2	RP11-295H24.3	5.42	9.43e-08	1.46e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49302255	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs11634636	ENSG00000259531.2	RP11-295H24.3	5.42	9.43e-08	1.46e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49315407	chr15:49365124~49366685:-
THCA	cis	rs9816784	0.566	rs11720913	ENSG00000231464.1	AC024937.4	5.42	9.44e-08	1.46e-05	0.31	0.24	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195996738~195998233:+
THCA	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	5.42	9.44e-08	1.46e-05	0.15	0.24	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
THCA	cis	rs875971	1	rs1363055	ENSG00000223473.2	GS1-124K5.3	5.42	9.44e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66478288	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs9691480	ENSG00000223473.2	GS1-124K5.3	5.42	9.44e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66479319	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs7789554	ENSG00000223473.2	GS1-124K5.3	5.42	9.44e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66481051	chr7:66491049~66493566:-
THCA	cis	rs875971	0.895	rs1974769	ENSG00000223473.2	GS1-124K5.3	5.42	9.44e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66485627	chr7:66491049~66493566:-
THCA	cis	rs875971	0.895	rs6460300	ENSG00000223473.2	GS1-124K5.3	5.42	9.44e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66487937	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs7803416	ENSG00000223473.2	GS1-124K5.3	5.42	9.44e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66489212	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs1981799	ENSG00000223473.2	GS1-124K5.3	5.42	9.44e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66490572	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs2277911	ENSG00000223473.2	GS1-124K5.3	5.42	9.44e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66493638	chr7:66491049~66493566:-
THCA	cis	rs12935418	0.552	rs2549842	ENSG00000278985.1	RP11-303E16.9	5.42	9.44e-08	1.46e-05	0.28	0.24	Mean corpuscular volume;	chr16:80990054	chr16:80982319~80984094:-
THCA	cis	rs9307551	0.741	rs6824396	ENSG00000250334.4	LINC00989	-5.42	9.45e-08	1.46e-05	-0.3	-0.24	Refractive error;	chr4:79541178	chr4:79492416~79576460:+
THCA	cis	rs875971	1	rs12533997	ENSG00000223473.2	GS1-124K5.3	5.42	9.45e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66500390	chr7:66491049~66493566:-
THCA	cis	rs6445975	0.666	rs12489103	ENSG00000272360.1	RP11-359I18.5	5.42	9.46e-08	1.46e-05	0.28	0.24	Systemic lupus erythematosus;	chr3:58387440	chr3:58490830~58491291:-
THCA	cis	rs875971	1	rs4717300	ENSG00000223473.2	GS1-124K5.3	5.42	9.46e-08	1.46e-05	0.16	0.24	Aortic root size;	chr7:66482393	chr7:66491049~66493566:-
THCA	cis	rs73198271	0.74	rs10098636	ENSG00000253893.2	FAM85B	5.42	9.47e-08	1.46e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8167819~8226614:-
THCA	cis	rs10895275	0.923	rs11225156	ENSG00000277459.1	RP11-732A21.3	-5.42	9.47e-08	1.46e-05	-0.19	-0.24	Migraine;	chr11:102188607	chr11:102109827~102110457:-
THCA	cis	rs67478160	0.609	rs6576003	ENSG00000258735.1	LINC00637	-5.42	9.48e-08	1.46e-05	-0.29	-0.24	Schizophrenia;	chr14:103824993	chr14:103847721~103858049:+
THCA	cis	rs950169	0.509	rs71395455	ENSG00000188388.10	GOLGA6L3	5.42	9.48e-08	1.46e-05	0.33	0.24	Schizophrenia;	chr15:84610573	chr15:85240472~85247170:+
THCA	cis	rs4689592	0.587	rs3822269	ENSG00000245468.3	RP11-367J11.3	5.42	9.49e-08	1.47e-05	0.2	0.24	Monocyte percentage of white cells;	chr4:7068174	chr4:7094571~7103385:-
THCA	cis	rs2070488	0.804	rs6764551	ENSG00000229589.1	ACVR2B-AS1	5.42	9.49e-08	1.47e-05	0.22	0.24	Electrocardiographic conduction measures;	chr3:38418814	chr3:38451027~38454820:-
THCA	cis	rs2348418	0.801	rs7298379	ENSG00000247934.4	RP11-967K21.1	5.42	9.49e-08	1.47e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28270541	chr12:28163298~28190738:-
THCA	cis	rs739496	0.579	rs12319315	ENSG00000226469.1	ADAM1B	5.42	9.5e-08	1.47e-05	0.31	0.24	Platelet count;	chr12:111903215	chr12:111927018~111929017:+
THCA	cis	rs5758511	0.68	rs5758692	ENSG00000281538.1	RP4-669P10.20	-5.42	9.5e-08	1.47e-05	-0.27	-0.24	Birth weight;	chr22:42273023	chr22:42138060~42139726:+
THCA	cis	rs11894081	0.948	rs10194381	ENSG00000232835.1	AC107057.1	5.42	9.5e-08	1.47e-05	0.24	0.24	Crohn's disease;	chr2:5531931	chr2:5549780~5556031:-
THCA	cis	rs9813712	0.595	rs16825656	ENSG00000253540.4	FAM86HP	-5.42	9.5e-08	1.47e-05	-0.26	-0.24	Response to amphetamines;	chr3:130286225	chr3:130099092~130111472:-
THCA	cis	rs12893668	0.703	rs34026011	ENSG00000269910.1	RP11-73M18.10	5.42	9.5e-08	1.47e-05	0.23	0.24	Reticulocyte count;	chr14:103584546	chr14:103694516~103695050:-
THCA	cis	rs7851660	0.844	rs12342417	ENSG00000214417.4	KRT18P13	-5.42	9.51e-08	1.47e-05	-0.21	-0.24	Strep throat;	chr9:97876783	chr9:97698922~97700734:+
THCA	cis	rs11051970	0.879	rs2733682	ENSG00000274964.1	RP11-817I4.1	-5.42	9.51e-08	1.47e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32421674	chr12:32339368~32340724:+
THCA	cis	rs1075232	1	rs12439239	ENSG00000215302.7	CTD-3092A11.1	-5.42	9.51e-08	1.47e-05	-0.56	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30470779~30507623:+
THCA	cis	rs227275	0.526	rs223497	ENSG00000230069.3	LRRC37A15P	-5.42	9.52e-08	1.47e-05	-0.26	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102727274~102730721:-
THCA	cis	rs1106529	0.528	rs1779445	ENSG00000231365.4	RP11-418J17.1	-5.42	9.52e-08	1.47e-05	-0.28	-0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118965789	chr1:119140396~119275973:+
THCA	cis	rs1580019	0.563	rs34201720	ENSG00000231952.3	DPY19L1P2	-5.42	9.52e-08	1.47e-05	-0.3	-0.24	Cognitive ability;	chr7:32529323	chr7:32812757~32838570:+
THCA	cis	rs62432291	0.681	rs404461	ENSG00000235086.1	FNDC1-IT1	5.42	9.52e-08	1.47e-05	0.45	0.24	Joint mobility (Beighton score);	chr6:159219677	chr6:159240786~159243329:+
THCA	cis	rs6740322	0.895	rs10172375	ENSG00000234936.1	AC010883.5	5.42	9.53e-08	1.47e-05	0.26	0.24	Coronary artery disease;	chr2:43344908	chr2:43229573~43233394:+
THCA	cis	rs13113518	0.783	rs1586555	ENSG00000249700.7	SRD5A3-AS1	5.42	9.53e-08	1.47e-05	0.31	0.24	Height;	chr4:55587104	chr4:55363971~55395847:-
THCA	cis	rs1479090	0.805	rs2086240	ENSG00000250027.1	RP11-563E2.2	-5.42	9.53e-08	1.47e-05	-0.25	-0.24	Lung cancer;	chr4:163177165	chr4:163108785~163119965:+
THCA	cis	rs2562456	0.55	rs4809143	ENSG00000268081.1	RP11-678G14.2	5.42	9.53e-08	1.47e-05	0.38	0.24	Pain;	chr19:21589926	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.583	rs4809144	ENSG00000268081.1	RP11-678G14.2	5.42	9.53e-08	1.47e-05	0.38	0.24	Pain;	chr19:21589928	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.652	rs62110214	ENSG00000268081.1	RP11-678G14.2	5.42	9.53e-08	1.47e-05	0.38	0.24	Pain;	chr19:21592406	chr19:21554640~21569237:-
THCA	cis	rs17123764	0.71	rs2336058	ENSG00000257464.1	RP11-161H23.8	-5.42	9.54e-08	1.47e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49697097	chr12:49442424~49442652:-
THCA	cis	rs613391	0.702	rs976731	ENSG00000224549.1	RP11-370B11.3	-5.42	9.55e-08	1.47e-05	-0.28	-0.24	Quantitative traits;	chr9:22695594	chr9:22767175~22768316:+
THCA	cis	rs180730	0.752	rs343170	ENSG00000251609.2	SETP12	5.42	9.55e-08	1.48e-05	0.46	0.24	Fasting plasma glucose;	chr4:120890272	chr4:120895494~120897083:-
THCA	cis	rs9843304	0.528	rs9860963	ENSG00000244503.1	RP11-278L15.6	-5.42	9.56e-08	1.48e-05	-0.3	-0.24	Gallstone disease;	chr3:149479678	chr3:149494660~149495995:+
THCA	cis	rs2439831	1	rs28628574	ENSG00000166763.7	STRCP1	5.42	9.56e-08	1.48e-05	0.37	0.24	Lung cancer in ever smokers;	chr15:43509840	chr15:43699488~43718184:-
THCA	cis	rs875971	0.66	rs28698552	ENSG00000273142.1	RP11-458F8.4	-5.42	9.56e-08	1.48e-05	-0.19	-0.24	Aortic root size;	chr7:66540031	chr7:66902857~66906297:+
THCA	cis	rs4950322	0.542	rs12046706	ENSG00000180867.10	PDIA3P1	5.42	9.56e-08	1.48e-05	0.22	0.24	Protein quantitative trait loci;	chr1:147189758	chr1:147178113~147179622:+
THCA	cis	rs66887589	0.592	rs11731571	ENSG00000249244.1	RP11-548H18.2	5.42	9.56e-08	1.48e-05	0.26	0.24	Diastolic blood pressure;	chr4:119300030	chr4:119391831~119395335:-
THCA	cis	rs10875943	0.751	rs56222401	ENSG00000258017.1	RP11-386G11.10	-5.42	9.56e-08	1.48e-05	-0.35	-0.24	Prostate cancer;	chr12:49278931	chr12:49127782~49147869:+
THCA	cis	rs631288	0.793	rs6667498	ENSG00000226015.2	CCT8P1	-5.42	9.57e-08	1.48e-05	-0.53	-0.24	PR interval in Tripanosoma cruzi seropositivity;	chr1:147236381	chr1:147203276~147204932:-
THCA	cis	rs1552244	1	rs6781811	ENSG00000232901.1	CYCSP10	-5.42	9.57e-08	1.48e-05	-0.32	-0.24	Alzheimer's disease;	chr3:10080238	chr3:10000647~10000940:-
THCA	cis	rs2735413	0.564	rs80225322	ENSG00000276007.1	RP11-358L22.3	5.42	9.58e-08	1.48e-05	0.26	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78061856	chr16:78123243~78124332:+
THCA	cis	rs2735413	0.564	rs2344491	ENSG00000276007.1	RP11-358L22.3	5.42	9.58e-08	1.48e-05	0.26	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78062257	chr16:78123243~78124332:+
THCA	cis	rs2735413	0.564	rs2344492	ENSG00000276007.1	RP11-358L22.3	5.42	9.58e-08	1.48e-05	0.26	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78062329	chr16:78123243~78124332:+
THCA	cis	rs7209700	0.6	rs7218632	ENSG00000228782.6	CTD-2026D20.3	-5.42	9.59e-08	1.48e-05	-0.23	-0.24	IgG glycosylation;	chr17:47287787	chr17:47450568~47492492:-
THCA	cis	rs6714710	0.603	rs13034929	ENSG00000230606.9	AC159540.1	-5.42	9.59e-08	1.48e-05	-0.29	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786309	chr2:97416165~97433527:-
THCA	cis	rs7403037	1	rs35324226	ENSG00000259905.4	PWRN1	5.42	9.6e-08	1.48e-05	0.25	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24364852	chr15:24493137~24652130:+
THCA	cis	rs3785574	0.962	rs16947051	ENSG00000240280.5	TCAM1P	-5.42	9.61e-08	1.48e-05	-0.33	-0.24	Height;	chr17:63713557	chr17:63849292~63864379:+
THCA	cis	rs67981189	0.542	rs1012725	ENSG00000269927.1	RP6-91H8.3	-5.42	9.61e-08	1.48e-05	-0.29	-0.24	Schizophrenia;	chr14:71138994	chr14:71141125~71143253:-
THCA	cis	rs7119	0.678	rs12914098	ENSG00000259362.2	RP11-307C19.1	-5.42	9.62e-08	1.48e-05	-0.35	-0.24	Type 2 diabetes;	chr15:77530671	chr15:77525540~77534110:+
THCA	cis	rs4780355	0.843	rs413024	ENSG00000262636.1	CTD-3088G3.4	5.42	9.62e-08	1.49e-05	0.33	0.24	Crohn's disease and psoriasis;	chr16:11260234	chr16:11380859~11381118:-
THCA	cis	rs2243480	1	rs4718333	ENSG00000232559.3	GS1-124K5.12	-5.42	9.62e-08	1.49e-05	-0.37	-0.24	Diabetic kidney disease;	chr7:66307771	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs7792391	ENSG00000232559.3	GS1-124K5.12	-5.42	9.62e-08	1.49e-05	-0.37	-0.24	Diabetic kidney disease;	chr7:66308442	chr7:66554588~66576923:-
THCA	cis	rs2067615	0.542	rs4346064	ENSG00000260329.1	RP11-412D9.4	-5.42	9.63e-08	1.49e-05	-0.22	-0.24	Heart rate;	chr12:106687821	chr12:106954029~106955497:-
THCA	cis	rs6840360	0.582	rs4696260	ENSG00000270265.1	RP11-731D1.4	-5.42	9.63e-08	1.49e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151397772	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.515	rs11099811	ENSG00000270265.1	RP11-731D1.4	-5.42	9.63e-08	1.49e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151399380	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.582	rs7691601	ENSG00000270265.1	RP11-731D1.4	-5.42	9.63e-08	1.49e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151400479	chr4:151333775~151353224:-
THCA	cis	rs2439831	0.85	rs28513374	ENSG00000166763.7	STRCP1	5.42	9.63e-08	1.49e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43833297	chr15:43699488~43718184:-
THCA	cis	rs1552244	0.554	rs59465469	ENSG00000180385.7	EMC3-AS1	5.42	9.63e-08	1.49e-05	0.23	0.24	Alzheimer's disease;	chr3:9949116	chr3:9986893~10006990:+
THCA	cis	rs1979679	0.879	rs55996833	ENSG00000278733.1	RP11-425D17.1	5.42	9.63e-08	1.49e-05	0.25	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28313303	chr12:28185625~28186190:-
THCA	cis	rs2282300	0.739	rs34951229	ENSG00000242353.1	RP4-710M3.1	-5.42	9.63e-08	1.49e-05	-0.24	-0.24	Morning vs. evening chronotype;	chr11:30243619	chr11:30368148~30368646:+
THCA	cis	rs7927592	0.513	rs7950129	ENSG00000212093.1	AP000807.1	5.42	9.64e-08	1.49e-05	0.25	0.24	Total body bone mineral density;	chr11:68435435	chr11:68506083~68506166:-
THCA	cis	rs7760535	1	rs7760535	ENSG00000230177.1	RP5-1112D6.4	5.42	9.64e-08	1.49e-05	0.2	0.24	Metabolic traits;	chr6:111425880	chr6:111277932~111278742:+
THCA	cis	rs8030379	0.667	rs4842921	ENSG00000230373.7	GOLGA6L5P	-5.42	9.64e-08	1.49e-05	-0.22	-0.24	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83887871	chr15:84507885~84516814:-
THCA	cis	rs10833905	0.697	rs10766983	ENSG00000246225.5	RP11-17A1.3	-5.42	9.64e-08	1.49e-05	-0.35	-0.24	Sudden cardiac arrest;	chr11:22924603	chr11:22829380~22945393:+
THCA	cis	rs7847628	0.55	rs12343516	ENSG00000238181.2	AHCYP2	-5.42	9.65e-08	1.49e-05	-0.31	-0.24	Birth weight;	chr9:120841191	chr9:120720673~120721972:+
THCA	cis	rs17826219	0.733	rs7221691	ENSG00000266490.1	CTD-2349P21.9	-5.42	9.65e-08	1.49e-05	-0.33	-0.24	Body mass index;	chr17:30396601	chr17:30792372~30792833:+
THCA	cis	rs7746199	0.736	rs10484399	ENSG00000220721.1	OR1F12	5.42	9.66e-08	1.49e-05	0.53	0.24	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28073316~28074233:+
THCA	cis	rs2120243	0.539	rs722484	ENSG00000244515.1	KRT18P34	-5.42	9.66e-08	1.49e-05	-0.29	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157382838	chr3:157162663~157163932:-
THCA	cis	rs2292342	0.85	rs2301139	ENSG00000232871.7	SEC1P	-5.42	9.66e-08	1.49e-05	-0.53	-0.24	Elevated serum carcinoembryonic antigen levels;	chr19:48630504	chr19:48638071~48682245:+
THCA	cis	rs9818758	0.607	rs11719220	ENSG00000270441.1	RP11-694I15.7	5.42	9.67e-08	1.49e-05	0.35	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207768	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs35060561	ENSG00000270441.1	RP11-694I15.7	5.42	9.67e-08	1.49e-05	0.35	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49218070	chr3:49140086~49160851:-
THCA	cis	rs1865760	0.566	rs2858993	ENSG00000272462.2	U91328.19	-5.42	9.68e-08	1.49e-05	-0.2	-0.24	Height;	chr6:26087628	chr6:25992662~26001775:+
THCA	cis	rs12681287	0.571	rs10097450	ENSG00000254231.1	CTD-2284J15.1	-5.42	9.68e-08	1.49e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86346448	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7841690	ENSG00000254231.1	CTD-2284J15.1	-5.42	9.68e-08	1.49e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86353130	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7832493	ENSG00000254231.1	CTD-2284J15.1	-5.42	9.68e-08	1.49e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86359304	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7816275	ENSG00000254231.1	CTD-2284J15.1	-5.42	9.68e-08	1.49e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86361175	chr8:86333274~86343314:-
THCA	cis	rs4947019	1	rs12206574	ENSG00000223537.2	RP5-919F19.5	-5.42	9.68e-08	1.49e-05	-0.37	-0.24	Hematological parameters;	chr6:109746570	chr6:109487906~109506800:+
THCA	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	5.42	9.68e-08	1.49e-05	0.21	0.24	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
THCA	cis	rs8062405	1	rs3888190	ENSG00000278665.1	RP11-666O2.4	5.42	9.68e-08	1.49e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28599241~28601881:-
THCA	cis	rs9876781	0.967	rs9876891	ENSG00000229759.1	MRPS18AP1	5.42	9.69e-08	1.49e-05	0.29	0.24	Longevity;	chr3:48440024	chr3:48256350~48256938:-
THCA	cis	rs7760535	0.826	rs3777905	ENSG00000271789.1	RP5-1112D6.7	-5.42	9.69e-08	1.5e-05	-0.24	-0.24	Metabolic traits;	chr6:111549385	chr6:111297126~111298510:+
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000273796.1	LL21NC02-21A1.1	-5.42	9.69e-08	1.5e-05	-0.26	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45403809~45404369:-
THCA	cis	rs2742234	0.759	rs12241923	ENSG00000273008.1	RP11-351D16.3	5.42	9.7e-08	1.5e-05	0.2	0.24	Hirschsprung disease;	chr10:43217599	chr10:43136824~43138334:-
THCA	cis	rs2562456	0.833	rs62110428	ENSG00000268081.1	RP11-678G14.2	5.42	9.7e-08	1.5e-05	0.41	0.24	Pain;	chr19:21430854	chr19:21554640~21569237:-
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000273142.1	RP11-458F8.4	-5.42	9.7e-08	1.5e-05	-0.2	-0.24	Calcium levels;	chr7:65996954	chr7:66902857~66906297:+
THCA	cis	rs9527	0.637	rs11191424	ENSG00000236937.2	PTGES3P4	5.42	9.7e-08	1.5e-05	0.32	0.24	Arsenic metabolism;	chr10:102866129	chr10:102845595~102845950:+
THCA	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	5.42	9.71e-08	1.5e-05	0.39	0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
THCA	cis	rs7712401	0.755	rs10900759	ENSG00000249996.1	RP11-359P5.1	5.42	9.71e-08	1.5e-05	0.23	0.24	Mean platelet volume;	chr5:122769385	chr5:123036271~123054667:+
THCA	cis	rs75920871	0.528	rs11216244	ENSG00000254851.1	RP11-109L13.1	5.42	9.71e-08	1.5e-05	0.35	0.24	Subjective well-being;	chr11:117042014	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs12279066	ENSG00000254851.1	RP11-109L13.1	5.42	9.71e-08	1.5e-05	0.35	0.24	Subjective well-being;	chr11:117043193	chr11:117135528~117138582:+
THCA	cis	rs2179367	0.568	rs9498358	ENSG00000268592.3	RAET1E-AS1	5.42	9.72e-08	1.5e-05	0.39	0.24	Dupuytren's disease;	chr6:149458529	chr6:149863494~149919507:+
THCA	cis	rs7829975	0.742	rs1533058	ENSG00000254153.1	CTA-398F10.2	-5.42	9.72e-08	1.5e-05	-0.26	-0.24	Mood instability;	chr8:8827680	chr8:8456909~8461337:-
THCA	cis	rs875971	0.642	rs35526611	ENSG00000273142.1	RP11-458F8.4	5.42	9.72e-08	1.5e-05	0.19	0.24	Aortic root size;	chr7:66629021	chr7:66902857~66906297:+
THCA	cis	rs12472274	0.591	rs11679528	ENSG00000279484.1	KLHL30-AS1	5.42	9.72e-08	1.5e-05	0.32	0.24	Phospholipid levels (plasma);	chr2:238164865	chr2:238152889~238155994:-
THCA	cis	rs7829975	0.572	rs28730413	ENSG00000233609.3	RP11-62H7.2	-5.42	9.72e-08	1.5e-05	-0.24	-0.24	Mood instability;	chr8:8937937	chr8:8961200~8979025:+
THCA	cis	rs2067615	0.542	rs4433659	ENSG00000260329.1	RP11-412D9.4	-5.42	9.72e-08	1.5e-05	-0.22	-0.24	Heart rate;	chr12:106688718	chr12:106954029~106955497:-
THCA	cis	rs1823874	0.581	rs12910401	ENSG00000259363.4	CTD-2054N24.2	-5.42	9.72e-08	1.5e-05	-0.32	-0.24	IgG glycosylation;	chr15:99799692	chr15:99807023~99877148:+
THCA	cis	rs4748857	0.782	rs1319250	ENSG00000224215.1	RP11-371A19.2	-5.42	9.73e-08	1.5e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23240169	chr10:23343957~23345181:+
THCA	cis	rs875971	0.545	rs316328	ENSG00000228409.4	CCT6P1	5.42	9.73e-08	1.5e-05	0.19	0.24	Aortic root size;	chr7:66143851	chr7:65751142~65763354:+
THCA	cis	rs7851660	0.844	rs10984103	ENSG00000214417.4	KRT18P13	5.42	9.73e-08	1.5e-05	0.21	0.24	Strep throat;	chr9:97876993	chr9:97698922~97700734:+
THCA	cis	rs210138	1	rs210144	ENSG00000197251.3	LINC00336	5.42	9.73e-08	1.5e-05	0.31	0.24	Testicular germ cell tumor;	chr6:33579653	chr6:33586106~33593338:-
THCA	cis	rs4460629	0.742	rs11581730	ENSG00000160766.13	GBAP1	-5.42	9.74e-08	1.5e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155109682	chr1:155213821~155227422:-
THCA	cis	rs4460629	0.742	rs7548955	ENSG00000160766.13	GBAP1	-5.42	9.74e-08	1.5e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155109822	chr1:155213821~155227422:-
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000230295.1	RP11-458F8.2	5.42	9.74e-08	1.5e-05	0.3	0.24	Diabetic kidney disease;	chr7:66219914	chr7:66880708~66882981:+
THCA	cis	rs9843304	0.528	rs9880421	ENSG00000244503.1	RP11-278L15.6	-5.42	9.74e-08	1.5e-05	-0.31	-0.24	Gallstone disease;	chr3:149465572	chr3:149494660~149495995:+
THCA	cis	rs412050	1	rs75599828	ENSG00000224086.5	LL22NC03-86G7.1	-5.42	9.75e-08	1.5e-05	-0.41	-0.24	Attention deficit hyperactivity disorder;	chr22:21978690	chr22:21938293~21977632:+
THCA	cis	rs12681287	0.752	rs7822268	ENSG00000254231.1	CTD-2284J15.1	5.42	9.75e-08	1.5e-05	0.28	0.24	Caudate activity during reward;	chr8:86294211	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs1080170	ENSG00000254231.1	CTD-2284J15.1	5.42	9.75e-08	1.5e-05	0.28	0.24	Caudate activity during reward;	chr8:86297879	chr8:86333274~86343314:-
THCA	cis	rs890448	0.796	rs7663913	ENSG00000254531.1	FLJ20021	5.42	9.75e-08	1.5e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101411954	chr4:101347780~101348883:+
THCA	cis	rs17345786	0.861	rs11707689	ENSG00000256628.3	ZBTB11-AS1	5.42	9.76e-08	1.5e-05	0.3	0.24	Colonoscopy-negative controls vs population controls;	chr3:101367631	chr3:101676475~101679217:+
THCA	cis	rs4888671	0.901	rs17773587	ENSG00000261707.1	RP11-264M12.2	-5.42	9.76e-08	1.51e-05	-0.45	-0.24	Obesity-related traits;	chr16:77738517	chr16:77741468~77743000:-
THCA	cis	rs79040073	0.637	rs77296528	ENSG00000259531.2	RP11-295H24.3	5.42	9.77e-08	1.51e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49381827	chr15:49365124~49366685:-
THCA	cis	rs875971	0.965	rs9969301	ENSG00000223473.2	GS1-124K5.3	-5.42	9.77e-08	1.51e-05	-0.16	-0.24	Aortic root size;	chr7:66316668	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs709595	ENSG00000223473.2	GS1-124K5.3	5.42	9.77e-08	1.51e-05	0.16	0.24	Aortic root size;	chr7:66352346	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs811880	ENSG00000223473.2	GS1-124K5.3	5.42	9.77e-08	1.51e-05	0.16	0.24	Aortic root size;	chr7:66353659	chr7:66491049~66493566:-
THCA	cis	rs12612619	0.677	rs2053386	ENSG00000229122.1	AGBL5-IT1	5.42	9.77e-08	1.51e-05	0.18	0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27021844	chr2:27061038~27061815:+
THCA	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-5.42	9.77e-08	1.51e-05	-0.25	-0.24	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
THCA	cis	rs875971	0.545	rs316324	ENSG00000232546.1	RP11-458F8.1	-5.42	9.77e-08	1.51e-05	-0.23	-0.24	Aortic root size;	chr7:66145627	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000232546.1	RP11-458F8.1	-5.42	9.77e-08	1.51e-05	-0.23	-0.24	Aortic root size;	chr7:66146002	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000232546.1	RP11-458F8.1	-5.42	9.77e-08	1.51e-05	-0.23	-0.24	Aortic root size;	chr7:66152984	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000232546.1	RP11-458F8.1	5.42	9.77e-08	1.51e-05	0.23	0.24	Aortic root size;	chr7:66158946	chr7:66848496~66858136:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000232546.1	RP11-458F8.1	5.42	9.77e-08	1.51e-05	0.23	0.24	Aortic root size;	chr7:66160135	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000232546.1	RP11-458F8.1	5.42	9.77e-08	1.51e-05	0.23	0.24	Aortic root size;	chr7:66161064	chr7:66848496~66858136:+
THCA	cis	rs6121246	0.523	rs6060286	ENSG00000230613.1	HM13-AS1	5.42	9.77e-08	1.51e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31609860	chr20:31567707~31573263:-
THCA	cis	rs4845570	0.831	rs11588258	ENSG00000203288.3	RP11-98D18.9	-5.42	9.77e-08	1.51e-05	-0.29	-0.24	Coronary artery disease;	chr1:151808252	chr1:151790804~151794402:+
THCA	cis	rs6840360	0.582	rs11733820	ENSG00000270265.1	RP11-731D1.4	-5.42	9.78e-08	1.51e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.582	rs4473638	ENSG00000270265.1	RP11-731D1.4	-5.42	9.78e-08	1.51e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151333775~151353224:-
THCA	cis	rs11148252	0.875	rs4885953	ENSG00000235660.1	LINC00345	-5.42	9.78e-08	1.51e-05	-0.31	-0.24	Lewy body disease;	chr13:52402356	chr13:52484161~52484680:-
THCA	cis	rs1580019	0.563	rs13244332	ENSG00000231952.3	DPY19L1P2	-5.42	9.78e-08	1.51e-05	-0.3	-0.24	Cognitive ability;	chr7:32498067	chr7:32812757~32838570:+
THCA	cis	rs9813712	0.523	rs9866942	ENSG00000253540.4	FAM86HP	-5.42	9.79e-08	1.51e-05	-0.26	-0.24	Response to amphetamines;	chr3:130297796	chr3:130099092~130111472:-
THCA	cis	rs62432291	0.681	rs397476	ENSG00000235086.1	FNDC1-IT1	-5.42	9.79e-08	1.51e-05	-0.44	-0.24	Joint mobility (Beighton score);	chr6:159218252	chr6:159240786~159243329:+
THCA	cis	rs17772222	0.511	rs12880017	ENSG00000258789.1	RP11-507K2.3	-5.42	9.8e-08	1.51e-05	-0.23	-0.24	Coronary artery calcification;	chr14:88840228	chr14:88551597~88552493:+
THCA	cis	rs1050631	0.592	rs1010955	ENSG00000260552.1	RP11-49I11.1	5.41	9.8e-08	1.51e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36130647	chr18:36179996~36187448:-
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000232559.3	GS1-124K5.12	5.41	9.8e-08	1.51e-05	0.37	0.24	Diabetic kidney disease;	chr7:66557269	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1267820	ENSG00000232559.3	GS1-124K5.12	5.41	9.8e-08	1.51e-05	0.37	0.24	Diabetic kidney disease;	chr7:66585308	chr7:66554588~66576923:-
THCA	cis	rs2179367	0.537	rs12192159	ENSG00000223701.3	RAET1E-AS1	5.41	9.8e-08	1.51e-05	0.39	0.24	Dupuytren's disease;	chr6:149445969	chr6:149884431~149919508:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000232546.1	RP11-458F8.1	5.41	9.8e-08	1.51e-05	0.23	0.24	Aortic root size;	chr7:66622723	chr7:66848496~66858136:+
THCA	cis	rs2281636	0.595	rs11190169	ENSG00000233690.1	EBAG9P1	5.41	9.8e-08	1.51e-05	0.27	0.24	Obesity-related traits;	chr10:99597878	chr10:99697407~99697949:-
THCA	cis	rs75920871	0.528	rs2513094	ENSG00000254851.1	RP11-109L13.1	5.41	9.81e-08	1.51e-05	0.34	0.24	Subjective well-being;	chr11:116935696	chr11:117135528~117138582:+
THCA	cis	rs1979679	0.837	rs2881860	ENSG00000278733.1	RP11-425D17.1	5.41	9.81e-08	1.51e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28363268	chr12:28185625~28186190:-
THCA	cis	rs1538970	0.504	rs3790585	ENSG00000280836.1	AL355480.1	-5.41	9.81e-08	1.51e-05	-0.36	-0.24	Platelet count;	chr1:45557684	chr1:45581219~45581321:-
THCA	cis	rs2904967	0.598	rs2904978	ENSG00000254614.2	AP003068.23	5.41	9.81e-08	1.51e-05	0.36	0.24	Mean corpuscular volume;	chr11:65233007	chr11:65177606~65181834:-
THCA	cis	rs12681287	0.752	rs13255058	ENSG00000254231.1	CTD-2284J15.1	5.41	9.81e-08	1.51e-05	0.27	0.24	Caudate activity during reward;	chr8:86275216	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs10956786	ENSG00000254231.1	CTD-2284J15.1	5.41	9.81e-08	1.51e-05	0.27	0.24	Caudate activity during reward;	chr8:86289008	chr8:86333274~86343314:-
THCA	cis	rs1395	1	rs1275538	ENSG00000234072.1	AC074117.10	-5.41	9.82e-08	1.51e-05	-0.2	-0.24	Blood metabolite levels;	chr2:27218529	chr2:27356246~27367622:+
THCA	cis	rs6840360	0.582	rs2709812	ENSG00000270265.1	RP11-731D1.4	5.41	9.82e-08	1.51e-05	0.23	0.24	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151333775~151353224:-
THCA	cis	rs75920871	0.528	rs7128772	ENSG00000254851.1	RP11-109L13.1	5.41	9.82e-08	1.51e-05	0.35	0.24	Subjective well-being;	chr11:117018695	chr11:117135528~117138582:+
THCA	cis	rs911555	0.546	rs28798508	ENSG00000269910.1	RP11-73M18.10	5.41	9.82e-08	1.51e-05	0.23	0.24	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103694516~103695050:-
THCA	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	5.41	9.83e-08	1.51e-05	0.2	0.24	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	5.41	9.83e-08	1.51e-05	0.2	0.24	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	5.41	9.83e-08	1.51e-05	0.2	0.24	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
THCA	cis	rs807029	0.72	rs14177	ENSG00000272572.1	RP11-179B2.2	-5.41	9.83e-08	1.52e-05	-0.2	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101007398	chr10:100911103~100912739:-
THCA	cis	rs1865760	0.534	rs72834629	ENSG00000272462.2	U91328.19	-5.41	9.83e-08	1.52e-05	-0.22	-0.24	Height;	chr6:26022804	chr6:25992662~26001775:+
THCA	cis	rs2243480	1	rs35396113	ENSG00000230295.1	RP11-458F8.2	-5.41	9.84e-08	1.52e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66030474	chr7:66880708~66882981:+
THCA	cis	rs613391	0.561	rs10811762	ENSG00000224549.1	RP11-370B11.3	-5.41	9.85e-08	1.52e-05	-0.27	-0.24	Quantitative traits;	chr9:22716471	chr9:22767175~22768316:+
THCA	cis	rs739496	0.512	rs73422315	ENSG00000226469.1	ADAM1B	5.41	9.85e-08	1.52e-05	0.3	0.24	Platelet count;	chr12:111830495	chr12:111927018~111929017:+
THCA	cis	rs4934494	0.834	rs3740033	ENSG00000240996.1	RP11-80H5.7	5.41	9.85e-08	1.52e-05	0.25	0.24	Red blood cell count;	chr10:89634639	chr10:89694295~89697928:-
THCA	cis	rs5006884	0.715	rs71488544	ENSG00000167355.6	AC104389.28	-5.41	9.85e-08	1.52e-05	-0.38	-0.24	Fetal hemoglobin levels;	chr11:5366076	chr11:5304976~5505652:-
THCA	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	5.41	9.85e-08	1.52e-05	0.15	0.24	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
THCA	cis	rs7394190	0.748	rs60632610	ENSG00000271848.1	RP11-464F9.21	-5.41	9.85e-08	1.52e-05	-0.32	-0.24	Incident atrial fibrillation;	chr10:73655919	chr10:73654039~73674719:+
THCA	cis	rs2115536	0.967	rs934137	ENSG00000278600.1	RP11-81A1.6	-5.41	9.86e-08	1.52e-05	-0.16	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79919426	chr15:79920195~79922455:-
THCA	cis	rs755249	0.567	rs4660214	ENSG00000228060.1	RP11-69E11.8	-5.41	9.86e-08	1.52e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39565160~39573203:+
THCA	cis	rs7727544	0.735	rs274566	ENSG00000263597.1	MIR3936	-5.41	9.87e-08	1.52e-05	-0.23	-0.24	Blood metabolite levels;	chr5:132379319	chr5:132365490~132365599:-
THCA	cis	rs9393777	0.778	rs66841633	ENSG00000280107.1	AL022393.9	-5.41	9.88e-08	1.52e-05	-0.44	-0.24	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28170845~28172521:+
THCA	cis	rs79040073	0.51	rs111307556	ENSG00000259531.2	RP11-295H24.3	5.41	9.88e-08	1.52e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49339858	chr15:49365124~49366685:-
THCA	cis	rs6545883	0.868	rs7574631	ENSG00000270820.4	RP11-355B11.2	5.41	9.88e-08	1.52e-05	0.2	0.24	Tuberculosis;	chr2:61598007	chr2:61471188~61484130:+
THCA	cis	rs832187	1	rs832187	ENSG00000280620.1	SCAANT1	-5.41	9.89e-08	1.52e-05	-0.32	-0.24	Schizophrenia;	chr3:63847374	chr3:63911518~63911772:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000273142.1	RP11-458F8.4	-5.41	9.9e-08	1.53e-05	-0.2	-0.24	Calcium levels;	chr7:65975383	chr7:66902857~66906297:+
THCA	cis	rs2348418	0.669	rs7959641	ENSG00000247934.4	RP11-967K21.1	5.41	9.91e-08	1.53e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28163298~28190738:-
THCA	cis	rs4968361	0.892	rs11653976	ENSG00000266992.1	DHX40P1	-5.41	9.92e-08	1.53e-05	-0.39	-0.24	Schizophrenia;	chr17:59439633	chr17:59976009~60002384:-
THCA	cis	rs890448	0.726	rs2850366	ENSG00000254531.1	FLJ20021	-5.41	9.92e-08	1.53e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101309867	chr4:101347780~101348883:+
THCA	cis	rs890448	0.726	rs2850368	ENSG00000254531.1	FLJ20021	-5.41	9.92e-08	1.53e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101311472	chr4:101347780~101348883:+
THCA	cis	rs67478160	0.643	rs6576005	ENSG00000258735.1	LINC00637	-5.41	9.93e-08	1.53e-05	-0.29	-0.24	Schizophrenia;	chr14:103826032	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.575	rs8014294	ENSG00000258735.1	LINC00637	-5.41	9.93e-08	1.53e-05	-0.29	-0.24	Schizophrenia;	chr14:103856646	chr14:103847721~103858049:+
THCA	cis	rs875971	0.545	rs1638724	ENSG00000228409.4	CCT6P1	5.41	9.93e-08	1.53e-05	0.21	0.24	Aortic root size;	chr7:66575494	chr7:65751142~65763354:+
THCA	cis	rs7809950	1	rs2237677	ENSG00000238832.1	snoU109	-5.41	9.93e-08	1.53e-05	-0.26	-0.24	Coronary artery disease;	chr7:107562057	chr7:107603363~107603507:+
THCA	cis	rs7646881	0.544	rs16829118	ENSG00000240207.5	RP11-379F4.4	-5.41	9.94e-08	1.53e-05	-0.34	-0.24	Tetralogy of Fallot;	chr3:158571033	chr3:158732263~158784070:+
THCA	cis	rs934734	0.736	rs1396210	ENSG00000281920.1	RP11-418H16.1	5.41	9.94e-08	1.53e-05	0.31	0.24	Rheumatoid arthritis;	chr2:65357140	chr2:65623272~65628424:+
THCA	cis	rs1876905	0.764	rs9398265	ENSG00000255389.1	C6orf3	5.41	9.94e-08	1.53e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr6:111101399	chr6:111599875~111602295:+
THCA	cis	rs890448	0.796	rs2471681	ENSG00000254531.1	FLJ20021	5.41	9.94e-08	1.53e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426910	chr4:101347780~101348883:+
THCA	cis	rs7976269	0.609	rs10771478	ENSG00000275476.1	RP11-996F15.4	5.41	9.94e-08	1.53e-05	0.24	0.24	Male-pattern baldness;	chr12:29075351	chr12:29277397~29277882:-
THCA	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-5.41	9.94e-08	1.53e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
THCA	cis	rs2067615	0.524	rs1922436	ENSG00000260329.1	RP11-412D9.4	-5.41	9.95e-08	1.53e-05	-0.22	-0.24	Heart rate;	chr12:106671480	chr12:106954029~106955497:-
THCA	cis	rs8062405	1	rs8055138	ENSG00000278665.1	RP11-666O2.4	5.41	9.95e-08	1.53e-05	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28599241~28601881:-
THCA	cis	rs17767294	0.612	rs12332927	ENSG00000219392.1	RP1-265C24.5	-5.41	9.95e-08	1.53e-05	-0.42	-0.24	Parkinson's disease;	chr6:27987337	chr6:28115628~28116551:+
THCA	cis	rs2070488	0.574	rs57754356	ENSG00000229589.1	ACVR2B-AS1	5.41	9.96e-08	1.53e-05	0.22	0.24	Electrocardiographic conduction measures;	chr3:38447215	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.766	rs6808093	ENSG00000229589.1	ACVR2B-AS1	5.41	9.96e-08	1.53e-05	0.22	0.24	Electrocardiographic conduction measures;	chr3:38456669	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.804	rs35463537	ENSG00000229589.1	ACVR2B-AS1	5.41	9.96e-08	1.53e-05	0.22	0.24	Electrocardiographic conduction measures;	chr3:38456757	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.804	rs13059256	ENSG00000229589.1	ACVR2B-AS1	5.41	9.96e-08	1.53e-05	0.22	0.24	Electrocardiographic conduction measures;	chr3:38462824	chr3:38451027~38454820:-
THCA	cis	rs9859260	1	rs2239640	ENSG00000273009.1	RP11-352G9.1	-5.41	9.97e-08	1.53e-05	-0.26	-0.24	Mean corpuscular volume;	chr3:196062837	chr3:195913078~195913683:-
THCA	cis	rs494453	0.6	rs474860	ENSG00000227811.2	FAM212B-AS1	-5.41	9.97e-08	1.53e-05	-0.3	-0.24	Osteoporosis-related phenotypes;	chr1:111672590	chr1:111739841~111747798:+
THCA	cis	rs494453	0.6	rs565612	ENSG00000227811.2	FAM212B-AS1	-5.41	9.97e-08	1.53e-05	-0.3	-0.24	Osteoporosis-related phenotypes;	chr1:111677357	chr1:111739841~111747798:+
THCA	cis	rs2179367	0.632	rs9498325	ENSG00000268592.3	RAET1E-AS1	5.41	9.97e-08	1.54e-05	0.35	0.24	Dupuytren's disease;	chr6:149345993	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498326	ENSG00000268592.3	RAET1E-AS1	5.41	9.97e-08	1.54e-05	0.35	0.24	Dupuytren's disease;	chr6:149346112	chr6:149863494~149919507:+
THCA	cis	rs7829975	0.84	rs572366	ENSG00000254153.1	CTA-398F10.2	-5.41	9.97e-08	1.54e-05	-0.26	-0.24	Mood instability;	chr8:8721284	chr8:8456909~8461337:-
THCA	cis	rs9952991	0.941	rs45450798	ENSG00000260302.1	RP11-973H7.1	5.41	9.97e-08	1.54e-05	0.41	0.24	Inflammatory skin disease;	chr18:12792941	chr18:12774651~12775923:-
THCA	cis	rs8113308	0.752	rs11882377	ENSG00000269235.1	ZNF350-AS1	5.41	9.98e-08	1.54e-05	0.34	0.24	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:52000877	chr19:51949134~51981367:+
THCA	cis	rs12935418	0.583	rs2167889	ENSG00000278985.1	RP11-303E16.9	-5.41	9.98e-08	1.54e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80987867	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.552	rs2911148	ENSG00000278985.1	RP11-303E16.9	-5.41	9.98e-08	1.54e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80988289	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.552	rs2549833	ENSG00000278985.1	RP11-303E16.9	-5.41	9.98e-08	1.54e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80988627	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.552	rs2602448	ENSG00000278985.1	RP11-303E16.9	-5.41	9.98e-08	1.54e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80989067	chr16:80982319~80984094:-
THCA	cis	rs875971	0.545	rs316316	ENSG00000228409.4	CCT6P1	5.41	9.98e-08	1.54e-05	0.2	0.24	Aortic root size;	chr7:66149270	chr7:65751142~65763354:+
THCA	cis	rs2115630	1	rs4633690	ENSG00000225151.9	GOLGA2P7	5.41	9.98e-08	1.54e-05	0.3	0.24	P wave terminal force;	chr15:84818729	chr15:84199311~84230136:-
THCA	cis	rs8027521	0.568	rs1478178	ENSG00000280362.1	RP11-643A5.3	-5.41	9.98e-08	1.54e-05	-0.3	-0.24	Circulating chemerin levels;	chr15:53958708	chr15:53910769~53914712:+
THCA	cis	rs7674212	0.541	rs11727498	ENSG00000246560.2	RP11-10L12.4	5.41	9.98e-08	1.54e-05	0.29	0.24	Type 2 diabetes;	chr4:103179830	chr4:102828055~102844075:+
THCA	cis	rs2439831	0.85	rs28564774	ENSG00000166763.7	STRCP1	5.41	9.99e-08	1.54e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43833277	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs12441984	ENSG00000166763.7	STRCP1	5.41	9.99e-08	1.54e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43834087	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs7169322	ENSG00000166763.7	STRCP1	5.41	9.99e-08	1.54e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43838816	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs28707214	ENSG00000166763.7	STRCP1	5.41	9.99e-08	1.54e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43839425	chr15:43699488~43718184:-
THCA	cis	rs875971	0.545	rs4441996	ENSG00000228409.4	CCT6P1	5.41	9.99e-08	1.54e-05	0.2	0.24	Aortic root size;	chr7:66123233	chr7:65751142~65763354:+
THCA	cis	rs613391	0.522	rs7043015	ENSG00000224549.1	RP11-370B11.3	-5.41	9.99e-08	1.54e-05	-0.27	-0.24	Quantitative traits;	chr9:22729025	chr9:22767175~22768316:+
THCA	cis	rs2337406	1	rs17095456	ENSG00000211974.3	IGHV2-70	-5.41	1e-07	1.54e-05	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106676559	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.925	rs2011167	ENSG00000211974.3	IGHV2-70	-5.41	1e-07	1.54e-05	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106680831	chr14:106723574~106724093:-
THCA	cis	rs7727544	0.557	rs715285	ENSG00000233006.5	AC034220.3	5.41	1e-07	1.54e-05	0.18	0.24	Blood metabolite levels;	chr5:132149690	chr5:132311285~132369916:-
THCA	cis	rs11089937	0.597	rs11704434	ENSG00000211638.2	IGLV8-61	-5.41	1e-07	1.54e-05	-0.2	-0.24	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22098700~22099212:+
THCA	cis	rs7412746	0.587	rs3849279	ENSG00000231073.1	RP11-316M1.3	5.41	1e-07	1.54e-05	0.28	0.24	Melanoma;	chr1:150972231	chr1:150973123~150975534:+
THCA	cis	rs11089937	0.637	rs988200	ENSG00000211639.2	IGLV4-60	5.41	1e-07	1.54e-05	0.19	0.24	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22162199~22162681:+
THCA	cis	rs9859260	0.961	rs9846149	ENSG00000273009.1	RP11-352G9.1	-5.41	1e-07	1.54e-05	-0.26	-0.24	Mean corpuscular volume;	chr3:196060437	chr3:195913078~195913683:-
THCA	cis	rs7824557	0.707	rs3808518	ENSG00000154316.13	TDH	5.41	1e-07	1.54e-05	0.18	0.24	Retinal vascular caliber;	chr8:11285763	chr8:11339637~11368452:+
THCA	cis	rs2439831	0.681	rs28653441	ENSG00000275601.1	AC011330.13	-5.41	1e-07	1.54e-05	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43385064	chr15:43642389~43643023:-
THCA	cis	rs67478160	0.608	rs4906368	ENSG00000258735.1	LINC00637	-5.41	1e-07	1.54e-05	-0.29	-0.24	Schizophrenia;	chr14:103776060	chr14:103847721~103858049:+
THCA	cis	rs2562456	0.833	rs11666447	ENSG00000268081.1	RP11-678G14.2	5.41	1e-07	1.54e-05	0.41	0.24	Pain;	chr19:21416270	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs11666525	ENSG00000268081.1	RP11-678G14.2	5.41	1e-07	1.54e-05	0.41	0.24	Pain;	chr19:21416503	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs62110424	ENSG00000268081.1	RP11-678G14.2	5.41	1e-07	1.54e-05	0.41	0.24	Pain;	chr19:21416835	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs3853837	ENSG00000268081.1	RP11-678G14.2	5.41	1e-07	1.54e-05	0.41	0.24	Pain;	chr19:21419172	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs3853838	ENSG00000268081.1	RP11-678G14.2	5.41	1e-07	1.54e-05	0.41	0.24	Pain;	chr19:21419192	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62110426	ENSG00000268081.1	RP11-678G14.2	5.41	1e-07	1.54e-05	0.41	0.24	Pain;	chr19:21420124	chr19:21554640~21569237:-
THCA	cis	rs763121	1	rs86796	ENSG00000235209.1	CTA-150C2.13	-5.41	1e-07	1.54e-05	-0.31	-0.24	Menopause (age at onset);	chr22:38485449	chr22:38921227~38924708:+
THCA	cis	rs8005677	0.611	rs11624528	ENSG00000279656.1	RP11-298I3.6	5.41	1e-07	1.54e-05	0.3	0.24	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:23023083~23024217:-
THCA	cis	rs13113518	1	rs13132420	ENSG00000273257.1	RP11-177J6.1	-5.41	1e-07	1.54e-05	-0.32	-0.24	Height;	chr4:55526646	chr4:55387949~55388271:+
THCA	cis	rs1185460	0.934	rs10892328	ENSG00000272186.1	RP11-110I1.13	-5.41	1e-07	1.54e-05	-0.23	-0.24	Coronary artery disease;	chr11:119071944	chr11:119067374~119067698:-
THCA	cis	rs801193	0.901	rs4273746	ENSG00000273142.1	RP11-458F8.4	5.41	1e-07	1.54e-05	0.2	0.24	Aortic root size;	chr7:66836124	chr7:66902857~66906297:+
THCA	cis	rs2337406	1	rs10459466	ENSG00000211974.3	IGHV2-70	-5.41	1e-07	1.54e-05	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106689255	chr14:106723574~106724093:-
THCA	cis	rs1889642	1	rs1889642	ENSG00000227354.5	RBM26-AS1	5.41	1e-07	1.54e-05	0.23	0.24	Colonoscopy-negative controls vs population controls;	chr13:79832085	chr13:79406309~79424328:+
THCA	cis	rs890448	0.965	rs11944753	ENSG00000254531.1	FLJ20021	-5.41	1e-07	1.54e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101503451	chr4:101347780~101348883:+
THCA	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	5.41	1e-07	1.54e-05	0.42	0.24	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
THCA	cis	rs2439831	0.85	rs544122	ENSG00000166763.7	STRCP1	5.41	1e-07	1.54e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:43483534	chr15:43699488~43718184:-
THCA	cis	rs116095464	0.558	rs10065239	ENSG00000248925.1	CTD-2083E4.6	5.41	1e-07	1.55e-05	0.39	0.24	Breast cancer;	chr5:275173	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7708515	ENSG00000248925.1	CTD-2083E4.6	5.41	1e-07	1.55e-05	0.34	0.24	Breast cancer;	chr5:234874	chr5:269858~271516:-
THCA	cis	rs1552244	0.554	rs55847233	ENSG00000180385.7	EMC3-AS1	5.41	1e-07	1.55e-05	0.23	0.24	Alzheimer's disease;	chr3:9949417	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs67852463	ENSG00000232901.1	CYCSP10	5.41	1e-07	1.55e-05	0.32	0.24	Alzheimer's disease;	chr3:10115521	chr3:10000647~10000940:-
THCA	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	5.41	1e-07	1.55e-05	0.29	0.24	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
THCA	cis	rs2993535	1	rs2993545	ENSG00000233626.2	RP11-565J7.1	5.41	1e-07	1.55e-05	0.67	0.24	Hip circumference adjusted for BMI;	chr1:211999877	chr1:211936249~211936634:+
THCA	cis	rs11634944	0.714	rs2554430	ENSG00000257151.1	PWAR6	-5.41	1e-07	1.55e-05	-0.18	-0.24	Interleukin-8 levels;	chr15:24949335	chr15:25031873~25036490:+
THCA	cis	rs2980439	0.783	rs2948305	ENSG00000253981.4	ALG1L13P	5.41	1.01e-07	1.55e-05	0.23	0.24	Neuroticism;	chr8:8241055	chr8:8236003~8244667:-
THCA	cis	rs6545883	0.931	rs778768	ENSG00000270820.4	RP11-355B11.2	5.41	1.01e-07	1.55e-05	0.21	0.24	Tuberculosis;	chr2:61563154	chr2:61471188~61484130:+
THCA	cis	rs1322639	0.614	rs9364356	ENSG00000261039.2	RP11-417E7.2	-5.41	1.01e-07	1.55e-05	-0.37	-0.24	Pulse pressure;	chr6:169167013	chr6:169175304~169182740:-
THCA	cis	rs7428	0.527	rs7607284	ENSG00000273196.1	RP11-717A5.2	5.41	1.01e-07	1.55e-05	0.26	0.24	Ear protrusion;	chr2:85320253	chr2:85387074~85387146:-
THCA	cis	rs7428	0.527	rs4459734	ENSG00000273196.1	RP11-717A5.2	5.41	1.01e-07	1.55e-05	0.26	0.24	Ear protrusion;	chr2:85320306	chr2:85387074~85387146:-
THCA	cis	rs7428	0.527	rs1554110	ENSG00000273196.1	RP11-717A5.2	5.41	1.01e-07	1.55e-05	0.26	0.24	Ear protrusion;	chr2:85320840	chr2:85387074~85387146:-
THCA	cis	rs7428	0.545	rs7572750	ENSG00000273196.1	RP11-717A5.2	5.41	1.01e-07	1.55e-05	0.26	0.24	Ear protrusion;	chr2:85325063	chr2:85387074~85387146:-
THCA	cis	rs875971	0.545	rs7787063	ENSG00000232546.1	RP11-458F8.1	5.41	1.01e-07	1.55e-05	0.23	0.24	Aortic root size;	chr7:66164012	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000232546.1	RP11-458F8.1	5.41	1.01e-07	1.55e-05	0.23	0.24	Aortic root size;	chr7:66166374	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000232546.1	RP11-458F8.1	5.41	1.01e-07	1.55e-05	0.23	0.24	Aortic root size;	chr7:66168318	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000232546.1	RP11-458F8.1	5.41	1.01e-07	1.55e-05	0.23	0.24	Aortic root size;	chr7:66169164	chr7:66848496~66858136:+
THCA	cis	rs9843304	0.528	rs12488126	ENSG00000240541.2	TM4SF1-AS1	-5.41	1.01e-07	1.55e-05	-0.22	-0.24	Gallstone disease;	chr3:149474889	chr3:149377778~149386583:+
THCA	cis	rs71636778	0.543	rs34409791	ENSG00000260063.1	RP5-968P14.2	-5.41	1.01e-07	1.55e-05	-0.32	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26918872	chr1:26692132~26694131:-
THCA	cis	rs860295	0.702	rs12025532	ENSG00000160766.13	GBAP1	-5.41	1.01e-07	1.55e-05	-0.29	-0.24	Body mass index;	chr1:155399511	chr1:155213821~155227422:-
THCA	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	5.41	1.01e-07	1.55e-05	0.23	0.24	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
THCA	cis	rs8062405	0.721	rs151303	ENSG00000278665.1	RP11-666O2.4	5.41	1.01e-07	1.55e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28599241~28601881:-
THCA	cis	rs2070488	0.695	rs6599201	ENSG00000229589.1	ACVR2B-AS1	5.41	1.01e-07	1.56e-05	0.22	0.24	Electrocardiographic conduction measures;	chr3:38435123	chr3:38451027~38454820:-
THCA	cis	rs73198271	0.74	rs11781430	ENSG00000253893.2	FAM85B	5.41	1.01e-07	1.56e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8167819~8226614:-
THCA	cis	rs875971	0.545	rs316324	ENSG00000228409.4	CCT6P1	5.41	1.01e-07	1.56e-05	0.2	0.24	Aortic root size;	chr7:66145627	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000228409.4	CCT6P1	5.41	1.01e-07	1.56e-05	0.2	0.24	Aortic root size;	chr7:66146002	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000228409.4	CCT6P1	5.41	1.01e-07	1.56e-05	0.2	0.24	Aortic root size;	chr7:66152984	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000228409.4	CCT6P1	-5.41	1.01e-07	1.56e-05	-0.2	-0.24	Aortic root size;	chr7:66158946	chr7:65751142~65763354:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000228409.4	CCT6P1	-5.41	1.01e-07	1.56e-05	-0.2	-0.24	Aortic root size;	chr7:66160135	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000228409.4	CCT6P1	-5.41	1.01e-07	1.56e-05	-0.2	-0.24	Aortic root size;	chr7:66161064	chr7:65751142~65763354:+
THCA	cis	rs5742933	1	rs5743061	ENSG00000273240.1	RP11-455J20.3	5.41	1.01e-07	1.56e-05	0.26	0.24	Ferritin levels;	chr2:189829540	chr2:189763859~189764456:-
THCA	cis	rs8192917	0.524	rs12878578	ENSG00000258744.1	RP11-80A15.1	5.41	1.01e-07	1.56e-05	0.43	0.24	Vitiligo;	chr14:24576383	chr14:24501594~24508688:+
THCA	cis	rs712039	0.652	rs2946340	ENSG00000276054.1	RP11-378E13.3	5.41	1.01e-07	1.56e-05	0.38	0.24	Tuberculosis;	chr17:37392762	chr17:37386886~37387926:+
THCA	cis	rs9813712	0.585	rs10934929	ENSG00000228252.7	COL6A4P2	5.41	1.01e-07	1.56e-05	0.31	0.24	Response to amphetamines;	chr3:130225231	chr3:130212823~130273806:+
THCA	cis	rs11089937	0.626	rs9622968	ENSG00000211638.2	IGLV8-61	-5.41	1.01e-07	1.56e-05	-0.2	-0.24	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22098700~22099212:+
THCA	cis	rs2243480	1	rs7804223	ENSG00000230295.1	RP11-458F8.2	5.41	1.01e-07	1.56e-05	0.3	0.24	Diabetic kidney disease;	chr7:66199572	chr7:66880708~66882981:+
THCA	cis	rs17772222	0.701	rs1627444	ENSG00000258983.2	RP11-507K2.2	-5.41	1.01e-07	1.56e-05	-0.28	-0.24	Coronary artery calcification;	chr14:88413784	chr14:88499334~88515502:+
THCA	cis	rs651907	0.557	rs17411983	ENSG00000244119.1	PDCL3P4	-5.41	1.02e-07	1.56e-05	-0.22	-0.24	Colorectal cancer;	chr3:101680282	chr3:101712472~101713191:+
THCA	cis	rs1185460	0.967	rs3825061	ENSG00000272186.1	RP11-110I1.13	-5.41	1.02e-07	1.56e-05	-0.23	-0.24	Coronary artery disease;	chr11:119073965	chr11:119067374~119067698:-
THCA	cis	rs8062405	0.756	rs151301	ENSG00000278665.1	RP11-666O2.4	5.41	1.02e-07	1.56e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28599241~28601881:-
THCA	cis	rs12594515	0.591	rs35554150	ENSG00000259200.1	RP11-718O11.1	-5.41	1.02e-07	1.56e-05	-0.33	-0.24	Weight;Waist circumference;	chr15:45698100	chr15:45705078~45931069:+
THCA	cis	rs875971	1	rs10257427	ENSG00000223473.2	GS1-124K5.3	-5.41	1.02e-07	1.56e-05	-0.16	-0.24	Aortic root size;	chr7:66278221	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs10215948	ENSG00000223473.2	GS1-124K5.3	-5.41	1.02e-07	1.56e-05	-0.16	-0.24	Aortic root size;	chr7:66282799	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs55748098	ENSG00000223473.2	GS1-124K5.3	-5.41	1.02e-07	1.56e-05	-0.16	-0.24	Aortic root size;	chr7:66298631	chr7:66491049~66493566:-
THCA	cis	rs13256369	1	rs4840351	ENSG00000253893.2	FAM85B	-5.41	1.02e-07	1.56e-05	-0.32	-0.24	Obesity-related traits;	chr8:8715638	chr8:8167819~8226614:-
THCA	cis	rs1395	0.778	rs2078616	ENSG00000234072.1	AC074117.10	-5.41	1.02e-07	1.56e-05	-0.21	-0.24	Blood metabolite levels;	chr2:27219036	chr2:27356246~27367622:+
THCA	cis	rs453301	0.653	rs1562211	ENSG00000254153.1	CTA-398F10.2	5.41	1.02e-07	1.56e-05	0.25	0.24	Joint mobility (Beighton score);	chr8:9044914	chr8:8456909~8461337:-
THCA	cis	rs12935418	0.616	rs2549853	ENSG00000278985.1	RP11-303E16.9	-5.41	1.02e-07	1.56e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80992850	chr16:80982319~80984094:-
THCA	cis	rs6600671	0.764	rs6600673	ENSG00000270231.3	NBPF8P	5.41	1.02e-07	1.56e-05	0.22	0.24	Hip geometry;	chr1:121426988	chr1:120436353~120467739:+
THCA	cis	rs972578	0.765	rs5758982	ENSG00000274717.1	RP1-47A17.1	-5.41	1.02e-07	1.56e-05	-0.25	-0.24	Mean platelet volume;	chr22:42848717	chr22:42791814~42794313:-
THCA	cis	rs853679	0.506	rs1150693	ENSG00000261839.1	RP1-265C24.8	5.41	1.02e-07	1.56e-05	0.29	0.24	Depression;	chr6:28206812	chr6:28136849~28139678:+
THCA	cis	rs375066	0.599	rs62118368	ENSG00000267058.1	RP11-15A1.3	5.41	1.02e-07	1.56e-05	0.22	0.24	Breast cancer;	chr19:43838290	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs62118369	ENSG00000267058.1	RP11-15A1.3	5.41	1.02e-07	1.56e-05	0.22	0.24	Breast cancer;	chr19:43838352	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs7253002	ENSG00000267058.1	RP11-15A1.3	5.41	1.02e-07	1.56e-05	0.22	0.24	Breast cancer;	chr19:43838825	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs7253384	ENSG00000267058.1	RP11-15A1.3	5.41	1.02e-07	1.56e-05	0.22	0.24	Breast cancer;	chr19:43839091	chr19:43891804~43901805:-
THCA	cis	rs375066	0.623	rs7253606	ENSG00000267058.1	RP11-15A1.3	5.41	1.02e-07	1.56e-05	0.22	0.24	Breast cancer;	chr19:43839126	chr19:43891804~43901805:-
THCA	cis	rs7674212	0.531	rs4699048	ENSG00000230069.3	LRRC37A15P	-5.41	1.02e-07	1.57e-05	-0.26	-0.24	Type 2 diabetes;	chr4:103005570	chr4:102727274~102730721:-
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000232559.3	GS1-124K5.12	-5.41	1.02e-07	1.57e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66158142	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs781157	ENSG00000230295.1	RP11-458F8.2	-5.41	1.02e-07	1.57e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66013324	chr7:66880708~66882981:+
THCA	cis	rs1479090	0.762	rs4691070	ENSG00000250027.1	RP11-563E2.2	-5.41	1.02e-07	1.57e-05	-0.25	-0.24	Lung cancer;	chr4:163100678	chr4:163108785~163119965:+
THCA	cis	rs972578	0.561	rs5759113	ENSG00000230319.1	AL022476.2	5.41	1.02e-07	1.57e-05	0.27	0.24	Mean platelet volume;	chr22:43047946	chr22:43038585~43052366:+
THCA	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	5.41	1.02e-07	1.57e-05	0.31	0.24	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
THCA	cis	rs9380516	0.891	rs9296155	ENSG00000228559.1	RP3-340B19.3	5.41	1.02e-07	1.57e-05	0.37	0.24	Hepatitis C induced liver fibrosis;	chr6:35509526	chr6:35544632~35545669:+
THCA	cis	rs1050631	0.592	rs1789547	ENSG00000260552.1	RP11-49I11.1	5.41	1.02e-07	1.57e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36145742	chr18:36179996~36187448:-
THCA	cis	rs9549367	0.569	rs3024738	ENSG00000269125.1	RP11-98F14.11	5.41	1.02e-07	1.57e-05	0.3	0.24	Platelet distribution width;	chr13:113165607	chr13:113165002~113165183:-
THCA	cis	rs2810114	1	rs2810114	ENSG00000269927.1	RP6-91H8.3	-5.41	1.02e-07	1.57e-05	-0.29	-0.24	Alcohol dependence;	chr14:70928887	chr14:71141125~71143253:-
THCA	cis	rs7727544	0.684	rs272849	ENSG00000224431.1	AC063976.7	5.41	1.02e-07	1.57e-05	0.21	0.24	Blood metabolite levels;	chr5:132354548	chr5:132199456~132203487:+
THCA	cis	rs28374715	0.635	rs112547435	ENSG00000247556.5	OIP5-AS1	5.41	1.02e-07	1.57e-05	0.22	0.24	Ulcerative colitis;	chr15:41356539	chr15:41283990~41309737:+
THCA	cis	rs8059260	0.541	rs8046052	ENSG00000274038.1	RP11-66H6.4	-5.41	1.02e-07	1.57e-05	-0.45	-0.24	Alcohol consumption over the past year;	chr16:11129464	chr16:11056556~11057034:+
THCA	cis	rs6479901	0.793	rs4335432	ENSG00000232075.1	MRPL35P2	-5.41	1.02e-07	1.57e-05	-0.35	-0.24	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.841	rs6479889	ENSG00000232075.1	MRPL35P2	-5.41	1.02e-07	1.57e-05	-0.35	-0.24	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63634317~63634827:-
THCA	cis	rs853679	0.506	rs1150711	ENSG00000273712.1	RP5-874C20.7	5.41	1.02e-07	1.57e-05	0.27	0.24	Depression;	chr6:28240757	chr6:28315613~28315883:-
THCA	cis	rs6565180	0.926	rs12446288	ENSG00000273724.1	RP11-347C12.12	5.41	1.03e-07	1.57e-05	0.25	0.24	Tonsillectomy;	chr16:30377388	chr16:30336400~30343336:+
THCA	cis	rs2243480	1	rs781149	ENSG00000230295.1	RP11-458F8.2	-5.41	1.03e-07	1.57e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66016297	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000230295.1	RP11-458F8.2	-5.41	1.03e-07	1.57e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66021736	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1167613	ENSG00000230295.1	RP11-458F8.2	-5.41	1.03e-07	1.57e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66022452	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs313799	ENSG00000230295.1	RP11-458F8.2	-5.41	1.03e-07	1.57e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66029343	chr7:66880708~66882981:+
THCA	cis	rs4648045	0.535	rs4698861	ENSG00000246560.2	RP11-10L12.4	-5.41	1.03e-07	1.57e-05	-0.3	-0.24	Lymphocyte percentage of white cells;	chr4:102624330	chr4:102828055~102844075:+
THCA	cis	rs9307551	1	rs894054	ENSG00000250334.4	LINC00989	-5.41	1.03e-07	1.58e-05	-0.31	-0.24	Refractive error;	chr4:79621254	chr4:79492416~79576460:+
THCA	cis	rs17345786	0.861	rs17402964	ENSG00000256628.3	ZBTB11-AS1	5.41	1.03e-07	1.58e-05	0.3	0.24	Colonoscopy-negative controls vs population controls;	chr3:101349101	chr3:101676475~101679217:+
THCA	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	5.41	1.03e-07	1.58e-05	0.35	0.24	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
THCA	cis	rs7220401	0.542	rs55644350	ENSG00000264007.1	RP11-68I3.10	5.41	1.03e-07	1.58e-05	0.29	0.24	Coronary artery disease;	chr17:29586350	chr17:29621617~29622254:-
THCA	cis	rs7824557	0.701	rs4568582	ENSG00000154316.13	TDH	-5.41	1.03e-07	1.58e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11302986	chr8:11339637~11368452:+
THCA	cis	rs4660456	0.597	rs7518568	ENSG00000272145.1	NFYC-AS1	-5.41	1.03e-07	1.58e-05	-0.16	-0.24	Platelet count;	chr1:40708508	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.596	rs1534956	ENSG00000272145.1	NFYC-AS1	-5.41	1.03e-07	1.58e-05	-0.16	-0.24	Platelet count;	chr1:40720771	chr1:40690380~40692066:-
THCA	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-5.41	1.03e-07	1.58e-05	-0.35	-0.24	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
THCA	cis	rs6121246	0.542	rs6059761	ENSG00000230613.1	HM13-AS1	5.41	1.03e-07	1.58e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31522719	chr20:31567707~31573263:-
THCA	cis	rs2212361	0.6	rs34185869	ENSG00000255893.1	RP11-685N10.1	-5.41	1.03e-07	1.58e-05	-0.28	-0.24	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535430	chr11:94472908~94473570:-
THCA	cis	rs2212361	0.593	rs34288874	ENSG00000255893.1	RP11-685N10.1	-5.41	1.03e-07	1.58e-05	-0.28	-0.24	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535484	chr11:94472908~94473570:-
THCA	cis	rs2853333	0.935	rs1894232	ENSG00000269553.1	U62631.5	-5.41	1.03e-07	1.58e-05	-0.25	-0.24	Red blood cell count;	chr19:35263608	chr19:35330843~35331920:+
THCA	cis	rs17508449	0.819	rs6678422	ENSG00000232450.1	RP4-730K3.3	-5.41	1.03e-07	1.58e-05	-0.36	-0.24	Leprosy;	chr1:113662078	chr1:113698884~113699631:-
THCA	cis	rs7976269	0.559	rs10771473	ENSG00000275476.1	RP11-996F15.4	-5.41	1.03e-07	1.58e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29068729	chr12:29277397~29277882:-
THCA	cis	rs1858037	0.867	rs1553675	ENSG00000234255.7	AC012370.3	-5.41	1.03e-07	1.58e-05	-0.29	-0.24	Rheumatoid arthritis;	chr2:65343173	chr2:65439888~65456571:-
THCA	cis	rs2439831	0.85	rs12440573	ENSG00000166763.7	STRCP1	5.41	1.03e-07	1.58e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:43816799	chr15:43699488~43718184:-
THCA	cis	rs6988985	0.678	rs9643358	ENSG00000247317.3	RP11-273G15.2	-5.41	1.03e-07	1.58e-05	-0.27	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921722	chr8:142981738~143018437:-
THCA	cis	rs8396	0.96	rs17843919	ENSG00000271817.2	U3	5.41	1.03e-07	1.58e-05	0.26	0.24	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158717814	chr4:158700691~158700909:+
THCA	cis	rs853679	0.567	rs13209596	ENSG00000219392.1	RP1-265C24.5	-5.41	1.03e-07	1.58e-05	-0.29	-0.24	Depression;	chr6:28428413	chr6:28115628~28116551:+
THCA	cis	rs853679	0.567	rs9969098	ENSG00000219392.1	RP1-265C24.5	-5.41	1.03e-07	1.58e-05	-0.29	-0.24	Depression;	chr6:28430971	chr6:28115628~28116551:+
THCA	cis	rs853679	0.567	rs7740429	ENSG00000219392.1	RP1-265C24.5	-5.41	1.03e-07	1.58e-05	-0.29	-0.24	Depression;	chr6:28431469	chr6:28115628~28116551:+
THCA	cis	rs853679	0.567	rs16894106	ENSG00000219392.1	RP1-265C24.5	-5.41	1.03e-07	1.58e-05	-0.29	-0.24	Depression;	chr6:28432562	chr6:28115628~28116551:+
THCA	cis	rs6445975	0.628	rs7231	ENSG00000272360.1	RP11-359I18.5	-5.41	1.03e-07	1.58e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr3:58427738	chr3:58490830~58491291:-
THCA	cis	rs8014252	0.667	rs2877657	ENSG00000259158.2	ADAM20P1	-5.41	1.03e-07	1.58e-05	-0.26	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70357215	chr14:70468881~70483756:-
THCA	cis	rs6121246	0.529	rs58757492	ENSG00000230613.1	HM13-AS1	5.4	1.03e-07	1.58e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31593622	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.529	rs6060171	ENSG00000230613.1	HM13-AS1	5.4	1.03e-07	1.58e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31595466	chr20:31567707~31573263:-
THCA	cis	rs2070488	0.775	rs2070489	ENSG00000229589.1	ACVR2B-AS1	5.4	1.03e-07	1.58e-05	0.22	0.24	Electrocardiographic conduction measures;	chr3:38477933	chr3:38451027~38454820:-
THCA	cis	rs7665090	0.665	rs227277	ENSG00000251288.2	RP11-10L12.2	5.4	1.03e-07	1.59e-05	0.32	0.24	Primary biliary cholangitis;	chr4:102673781	chr4:102751401~102752641:+
THCA	cis	rs5769765	0.542	rs738707	ENSG00000260613.1	RP3-522J7.6	5.4	1.03e-07	1.59e-05	0.34	0.24	Schizophrenia;	chr22:49857179	chr22:49832616~49837786:-
THCA	cis	rs35600665	0.527	rs35791112	ENSG00000259905.4	PWRN1	5.4	1.03e-07	1.59e-05	0.32	0.24	Obesity-related traits;	chr15:24500145	chr15:24493137~24652130:+
THCA	cis	rs9880211	1	rs6805316	ENSG00000273486.1	RP11-731C17.2	5.4	1.03e-07	1.59e-05	0.25	0.24	Height;Body mass index;	chr3:136233270	chr3:136837338~136839021:-
THCA	cis	rs1858037	0.765	rs67404371	ENSG00000234255.7	AC012370.3	5.4	1.03e-07	1.59e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65370137	chr2:65439888~65456571:-
THCA	cis	rs9876781	1	rs13091785	ENSG00000229759.1	MRPS18AP1	5.4	1.03e-07	1.59e-05	0.28	0.24	Longevity;	chr3:48452692	chr3:48256350~48256938:-
THCA	cis	rs9876781	1	rs6776700	ENSG00000229759.1	MRPS18AP1	5.4	1.03e-07	1.59e-05	0.28	0.24	Longevity;	chr3:48455358	chr3:48256350~48256938:-
THCA	cis	rs11051970	0.879	rs2171373	ENSG00000274964.1	RP11-817I4.1	-5.4	1.03e-07	1.59e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32422843	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.879	rs2243815	ENSG00000274964.1	RP11-817I4.1	-5.4	1.03e-07	1.59e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32423224	chr12:32339368~32340724:+
THCA	cis	rs4718428	0.924	rs6971897	ENSG00000232546.1	RP11-458F8.1	-5.4	1.03e-07	1.59e-05	-0.2	-0.24	Corneal structure;	chr7:66947787	chr7:66848496~66858136:+
THCA	cis	rs6430585	0.591	rs309170	ENSG00000231890.6	DARS-AS1	-5.4	1.04e-07	1.59e-05	-0.28	-0.24	Corneal structure;	chr2:135915205	chr2:135985176~136022593:+
THCA	cis	rs875971	0.66	rs10229345	ENSG00000273142.1	RP11-458F8.4	-5.4	1.04e-07	1.59e-05	-0.2	-0.24	Aortic root size;	chr7:66517181	chr7:66902857~66906297:+
THCA	cis	rs2439831	0.85	rs2228368	ENSG00000166763.7	STRCP1	5.4	1.04e-07	1.59e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43809812	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs3736180	ENSG00000166763.7	STRCP1	5.4	1.04e-07	1.59e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43814426	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs28684672	ENSG00000166763.7	STRCP1	5.4	1.04e-07	1.59e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43815464	chr15:43699488~43718184:-
THCA	cis	rs12999616	0.948	rs35958372	ENSG00000230606.9	AC159540.1	-5.4	1.04e-07	1.59e-05	-0.33	-0.24	Colorectal cancer;	chr2:97714395	chr2:97416165~97433527:-
THCA	cis	rs2735413	0.564	rs1882595	ENSG00000276007.1	RP11-358L22.3	5.4	1.04e-07	1.59e-05	0.26	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78066787	chr16:78123243~78124332:+
THCA	cis	rs7523875	0.572	rs7538100	ENSG00000153363.11	LINC00467	-5.4	1.04e-07	1.59e-05	-0.3	-0.24	Mean corpuscular volume;	chr1:211440858	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs77765322	ENSG00000153363.11	LINC00467	-5.4	1.04e-07	1.59e-05	-0.3	-0.24	Mean corpuscular volume;	chr1:211442279	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs80123704	ENSG00000153363.11	LINC00467	-5.4	1.04e-07	1.59e-05	-0.3	-0.24	Mean corpuscular volume;	chr1:211442367	chr1:211382803~211435333:+
THCA	cis	rs30380	0.587	rs469674	ENSG00000272109.1	CTD-2260A17.3	-5.4	1.04e-07	1.59e-05	-0.33	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96794312	chr5:96804353~96806105:+
THCA	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	5.4	1.04e-07	1.59e-05	0.15	0.24	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
THCA	cis	rs4934494	0.911	rs7098233	ENSG00000240996.1	RP11-80H5.7	5.4	1.04e-07	1.59e-05	0.26	0.24	Red blood cell count;	chr10:89663111	chr10:89694295~89697928:-
THCA	cis	rs2243480	0.901	rs313808	ENSG00000230295.1	RP11-458F8.2	-5.4	1.04e-07	1.59e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66034886	chr7:66880708~66882981:+
THCA	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	5.4	1.04e-07	1.59e-05	0.35	0.24	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
THCA	cis	rs9863	0.827	rs7305864	ENSG00000269997.1	RP11-214K3.21	-5.4	1.04e-07	1.59e-05	-0.3	-0.24	White blood cell count;	chr12:123957333	chr12:123966077~123966629:-
THCA	cis	rs2281636	1	rs2804417	ENSG00000260475.1	RP11-85A1.3	-5.4	1.04e-07	1.59e-05	-0.22	-0.24	Obesity-related traits;	chr10:99756458	chr10:99621055~99621918:+
THCA	cis	rs3847687	0.546	rs6486621	ENSG00000279993.1	RP11-76C10.3	5.4	1.04e-07	1.6e-05	0.27	0.24	Longevity;	chr12:131035663	chr12:131025561~131028060:-
THCA	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	5.4	1.04e-07	1.6e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
THCA	cis	rs71636778	0.543	rs12749822	ENSG00000260063.1	RP5-968P14.2	-5.4	1.04e-07	1.6e-05	-0.33	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26895472	chr1:26692132~26694131:-
THCA	cis	rs9813712	0.717	rs9835466	ENSG00000228252.7	COL6A4P2	5.4	1.04e-07	1.6e-05	0.32	0.24	Response to amphetamines;	chr3:130258530	chr3:130212823~130273806:+
THCA	cis	rs2562456	0.526	rs950504	ENSG00000268081.1	RP11-678G14.2	5.4	1.04e-07	1.6e-05	0.31	0.24	Pain;	chr19:21601193	chr19:21554640~21569237:-
THCA	cis	rs9311474	0.607	rs4234633	ENSG00000243224.1	RP5-1157M23.2	-5.4	1.04e-07	1.6e-05	-0.27	-0.24	Electroencephalogram traits;	chr3:52523022	chr3:52239258~52241097:+
THCA	cis	rs12188164	0.686	rs72711369	ENSG00000225138.6	CTD-2228K2.7	5.4	1.04e-07	1.6e-05	0.26	0.24	Cystic fibrosis severity;	chr5:420402	chr5:473236~480884:+
THCA	cis	rs964184	0.63	rs10750096	ENSG00000254851.1	RP11-109L13.1	-5.4	1.04e-07	1.6e-05	-0.49	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117135528~117138582:+
THCA	cis	rs911119	0.955	rs6048933	ENSG00000270001.1	RP11-218C14.8	-5.4	1.04e-07	1.6e-05	-0.38	-0.24	Chronic kidney disease;	chr20:23615000	chr20:23631826~23632316:-
THCA	cis	rs9307551	0.553	rs12639996	ENSG00000250334.4	LINC00989	-5.4	1.04e-07	1.6e-05	-0.29	-0.24	Refractive error;	chr4:79551326	chr4:79492416~79576460:+
THCA	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	5.4	1.04e-07	1.6e-05	0.28	0.24	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
THCA	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	5.4	1.04e-07	1.6e-05	0.28	0.24	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
THCA	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	5.4	1.04e-07	1.6e-05	0.28	0.24	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
THCA	cis	rs11089937	0.597	rs9619794	ENSG00000211639.2	IGLV4-60	5.4	1.04e-07	1.6e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22162199~22162681:+
THCA	cis	rs6433895	1	rs12999974	ENSG00000236153.1	AC104076.3	-5.4	1.04e-07	1.6e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181154810	chr2:180979427~180980090:-
THCA	cis	rs6908034	0.66	rs74457659	ENSG00000227116.1	RP3-471C18.1	-5.4	1.04e-07	1.6e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19760494	chr6:19730427~19734567:-
THCA	cis	rs330048	0.545	rs719409	ENSG00000254153.1	CTA-398F10.2	-5.4	1.04e-07	1.6e-05	-0.26	-0.24	Systemic lupus erythematosus;	chr8:9293716	chr8:8456909~8461337:-
THCA	cis	rs651907	0.557	rs13069443	ENSG00000244119.1	PDCL3P4	5.4	1.04e-07	1.6e-05	0.22	0.24	Colorectal cancer;	chr3:101654461	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs11925001	ENSG00000244119.1	PDCL3P4	5.4	1.04e-07	1.6e-05	0.22	0.24	Colorectal cancer;	chr3:101655122	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs34624546	ENSG00000244119.1	PDCL3P4	5.4	1.04e-07	1.6e-05	0.22	0.24	Colorectal cancer;	chr3:101655382	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs56291106	ENSG00000244119.1	PDCL3P4	5.4	1.04e-07	1.6e-05	0.22	0.24	Colorectal cancer;	chr3:101658630	chr3:101712472~101713191:+
THCA	cis	rs9652601	0.959	rs2058531	ENSG00000274038.1	RP11-66H6.4	-5.4	1.05e-07	1.6e-05	-0.31	-0.24	Systemic lupus erythematosus;	chr16:11078252	chr16:11056556~11057034:+
THCA	cis	rs748404	1	rs748404	ENSG00000205771.5	CATSPER2P1	-5.4	1.05e-07	1.6e-05	-0.28	-0.24	Lung cancer;	chr15:43267033	chr15:43726918~43747094:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000232559.3	GS1-124K5.12	-5.4	1.05e-07	1.6e-05	-0.37	-0.24	Diabetic kidney disease;	chr7:66253864	chr7:66554588~66576923:-
THCA	cis	rs8062405	0.789	rs151174	ENSG00000278665.1	RP11-666O2.4	5.4	1.05e-07	1.6e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28599241~28601881:-
THCA	cis	rs6714710	0.535	rs13006932	ENSG00000230606.9	AC159540.1	-5.4	1.05e-07	1.6e-05	-0.29	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97754235	chr2:97416165~97433527:-
THCA	cis	rs875971	0.522	rs7784623	ENSG00000273142.1	RP11-458F8.4	-5.4	1.05e-07	1.61e-05	-0.19	-0.24	Aortic root size;	chr7:65930047	chr7:66902857~66906297:+
THCA	cis	rs7208859	0.725	rs9891656	ENSG00000263603.1	CTD-2349P21.5	-5.4	1.05e-07	1.61e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30729469~30731202:+
THCA	cis	rs4767841	1	rs2996027	ENSG00000248636.5	RP11-768F21.1	-5.4	1.05e-07	1.61e-05	-0.25	-0.24	Urgency urinary incontinence;	chr12:119726478	chr12:119387987~119668079:-
THCA	cis	rs9309473	0.5	rs6546862	ENSG00000163016.8	ALMS1P	-5.4	1.05e-07	1.61e-05	-0.31	-0.24	Metabolite levels;	chr2:73633221	chr2:73644919~73685576:+
THCA	cis	rs9818758	0.607	rs13077498	ENSG00000270441.1	RP11-694I15.7	5.4	1.05e-07	1.61e-05	0.34	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276545	chr3:49140086~49160851:-
THCA	cis	rs801193	0.66	rs2659914	ENSG00000223473.2	GS1-124K5.3	5.4	1.05e-07	1.61e-05	0.16	0.24	Aortic root size;	chr7:66691927	chr7:66491049~66493566:-
THCA	cis	rs9475752	0.793	rs34616943	ENSG00000231441.1	RP11-472M19.2	5.4	1.05e-07	1.61e-05	0.33	0.24	Menarche (age at onset);	chr6:56958200	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs13214032	ENSG00000231441.1	RP11-472M19.2	5.4	1.05e-07	1.61e-05	0.33	0.24	Menarche (age at onset);	chr6:56958303	chr6:56844002~56864078:+
THCA	cis	rs17772222	0.675	rs845769	ENSG00000258983.2	RP11-507K2.2	-5.4	1.05e-07	1.61e-05	-0.28	-0.24	Coronary artery calcification;	chr14:88461455	chr14:88499334~88515502:+
THCA	cis	rs1858037	0.867	rs61226353	ENSG00000234255.7	AC012370.3	5.4	1.05e-07	1.61e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65363637	chr2:65439888~65456571:-
THCA	cis	rs61677309	1	rs12577045	ENSG00000280032.1	RP11-832A4.7	5.4	1.05e-07	1.61e-05	0.26	0.24	Lung cancer in ever smokers;	chr11:118280731	chr11:118264593~118266817:+
THCA	cis	rs61677309	1	rs67774926	ENSG00000280032.1	RP11-832A4.7	5.4	1.05e-07	1.61e-05	0.26	0.24	Lung cancer in ever smokers;	chr11:118286908	chr11:118264593~118266817:+
THCA	cis	rs2749592	0.531	rs10764134	ENSG00000263064.2	RP11-291L22.7	-5.4	1.05e-07	1.61e-05	-0.27	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38448689~38448949:+
THCA	cis	rs2439831	0.85	rs694985	ENSG00000166763.7	STRCP1	5.4	1.05e-07	1.61e-05	0.33	0.24	Lung cancer in ever smokers;	chr15:43521189	chr15:43699488~43718184:-
THCA	cis	rs8007846	0.536	rs4439682	ENSG00000276116.2	FUT8-AS1	-5.4	1.05e-07	1.61e-05	-0.25	-0.24	Multiple sclerosis--Brain Glutamate Levels;	chr14:65792710	chr14:65411170~65412690:-
THCA	cis	rs79040073	0.563	rs17478618	ENSG00000259531.2	RP11-295H24.3	-5.4	1.05e-07	1.61e-05	-0.34	-0.24	Lung cancer in ever smokers;	chr15:49444621	chr15:49365124~49366685:-
THCA	cis	rs6723108	0.664	rs4953936	ENSG00000224043.6	CCNT2-AS1	-5.4	1.05e-07	1.61e-05	-0.29	-0.24	Type 2 diabetes;	chr2:134823942	chr2:134735464~134918710:-
THCA	cis	rs1552244	1	rs6442147	ENSG00000232901.1	CYCSP10	5.4	1.05e-07	1.61e-05	0.31	0.24	Alzheimer's disease;	chr3:10036563	chr3:10000647~10000940:-
THCA	cis	rs12935418	0.616	rs2549855	ENSG00000278985.1	RP11-303E16.9	5.4	1.05e-07	1.61e-05	0.26	0.24	Mean corpuscular volume;	chr16:80993247	chr16:80982319~80984094:-
THCA	cis	rs72772090	0.71	rs17400685	ENSG00000248734.2	CTD-2260A17.1	5.4	1.05e-07	1.61e-05	0.4	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730662	chr5:96784777~96785999:+
THCA	cis	rs11122895	0.61	rs13397902	ENSG00000236307.2	EEF1E1P1	5.4	1.05e-07	1.61e-05	0.31	0.24	Allergic sensitization;	chr2:111849928	chr2:111887914~111888741:+
THCA	cis	rs7674212	0.54	rs2711897	ENSG00000246560.2	RP11-10L12.4	5.4	1.05e-07	1.61e-05	0.29	0.24	Type 2 diabetes;	chr4:103102410	chr4:102828055~102844075:+
THCA	cis	rs2439831	0.702	rs3784275	ENSG00000166763.7	STRCP1	5.4	1.05e-07	1.62e-05	0.37	0.24	Lung cancer in ever smokers;	chr15:43799188	chr15:43699488~43718184:-
THCA	cis	rs6664467	1	rs6664467	ENSG00000203288.3	RP11-98D18.9	-5.4	1.05e-07	1.62e-05	-0.3	-0.24	Carotid plaque burden;	chr1:151765927	chr1:151790804~151794402:+
THCA	cis	rs890448	0.796	rs2433311	ENSG00000254531.1	FLJ20021	5.4	1.05e-07	1.62e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101434778	chr4:101347780~101348883:+
THCA	cis	rs6545883	0.929	rs6545873	ENSG00000270820.4	RP11-355B11.2	5.4	1.06e-07	1.62e-05	0.2	0.24	Tuberculosis;	chr2:61505877	chr2:61471188~61484130:+
THCA	cis	rs12681287	0.752	rs9283958	ENSG00000254231.1	CTD-2284J15.1	5.4	1.06e-07	1.62e-05	0.27	0.24	Caudate activity during reward;	chr8:86240819	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs13277670	ENSG00000254231.1	CTD-2284J15.1	5.4	1.06e-07	1.62e-05	0.27	0.24	Caudate activity during reward;	chr8:86247691	chr8:86333274~86343314:-
THCA	cis	rs7119	0.717	rs12901471	ENSG00000259362.2	RP11-307C19.1	-5.4	1.06e-07	1.62e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77526650	chr15:77525540~77534110:+
THCA	cis	rs875971	0.929	rs6970860	ENSG00000223473.2	GS1-124K5.3	5.4	1.06e-07	1.62e-05	0.16	0.24	Aortic root size;	chr7:66511647	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs6957199	ENSG00000223473.2	GS1-124K5.3	5.4	1.06e-07	1.62e-05	0.16	0.24	Aortic root size;	chr7:66513532	chr7:66491049~66493566:-
THCA	cis	rs317865	0.609	rs28619251	ENSG00000263327.5	TAPT1-AS1	-5.4	1.06e-07	1.62e-05	-0.38	-0.24	Kidney disease (early stage) in type 1 diabetes;	chr4:16170401	chr4:16226685~16320140:+
THCA	cis	rs2129782	1	rs10093191	ENSG00000253553.4	RP11-586K2.1	5.4	1.06e-07	1.62e-05	0.41	0.24	Electrodermal activity;	chr8:88399336	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs73692253	ENSG00000253553.4	RP11-586K2.1	5.4	1.06e-07	1.62e-05	0.41	0.24	Electrodermal activity;	chr8:88401507	chr8:88326836~88737134:+
THCA	cis	rs858239	0.539	rs10280815	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	1.62e-05	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs10225608	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	1.62e-05	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs28624974	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	1.62e-05	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23129178~23129841:+
THCA	cis	rs5850	0.557	rs10270788	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	1.62e-05	-0.32	-0.24	Blood protein levels;	chr7:23149381	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs28716381	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	1.62e-05	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs1358442	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	1.62e-05	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23129178~23129841:+
THCA	cis	rs7208859	0.673	rs11653955	ENSG00000280069.1	CTD-2349P21.3	-5.4	1.06e-07	1.62e-05	-0.38	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30738182~30740275:+
THCA	cis	rs172166	0.769	rs149965	ENSG00000226314.6	ZNF192P1	-5.4	1.06e-07	1.62e-05	-0.28	-0.24	Cardiac Troponin-T levels;	chr6:28050911	chr6:28161781~28169594:+
THCA	cis	rs2029362	0.967	rs7937150	ENSG00000245573.6	BDNF-AS	5.4	1.06e-07	1.62e-05	0.19	0.24	Total body bone mineral density;	chr11:27598813	chr11:27506838~27698174:+
THCA	cis	rs2029362	1	rs7937485	ENSG00000245573.6	BDNF-AS	5.4	1.06e-07	1.62e-05	0.19	0.24	Total body bone mineral density;	chr11:27598926	chr11:27506838~27698174:+
THCA	cis	rs2029362	1	rs12798439	ENSG00000245573.6	BDNF-AS	5.4	1.06e-07	1.62e-05	0.19	0.24	Total body bone mineral density;	chr11:27600413	chr11:27506838~27698174:+
THCA	cis	rs11148252	0.624	rs6561682	ENSG00000235660.1	LINC00345	5.4	1.06e-07	1.62e-05	0.33	0.24	Lewy body disease;	chr13:52692162	chr13:52484161~52484680:-
THCA	cis	rs4948275	0.741	rs2787695	ENSG00000237233.2	TMEM26-AS1	-5.4	1.06e-07	1.62e-05	-0.33	-0.24	Night sleep phenotypes;	chr10:61532087	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2787696	ENSG00000237233.2	TMEM26-AS1	-5.4	1.06e-07	1.62e-05	-0.33	-0.24	Night sleep phenotypes;	chr10:61533449	chr10:61452639~61481956:+
THCA	cis	rs17005891	0.818	rs6851819	ENSG00000270480.1	RP11-57B24.1	5.4	1.06e-07	1.62e-05	0.39	0.24	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82650898	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.61	rs13135867	ENSG00000270480.1	RP11-57B24.1	5.4	1.06e-07	1.62e-05	0.39	0.24	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82652224	chr4:82691737~82692468:+
THCA	cis	rs6058796	1	rs6087410	ENSG00000175730.8	BAK1P1	5.4	1.06e-07	1.62e-05	0.36	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32670557	chr20:32690180~32690815:-
THCA	cis	rs4713118	0.866	rs9468217	ENSG00000226314.6	ZNF192P1	-5.4	1.06e-07	1.62e-05	-0.32	-0.24	Parkinson's disease;	chr6:27758688	chr6:28161781~28169594:+
THCA	cis	rs4934494	0.871	rs927907	ENSG00000240996.1	RP11-80H5.7	-5.4	1.06e-07	1.62e-05	-0.27	-0.24	Red blood cell count;	chr10:89629981	chr10:89694295~89697928:-
THCA	cis	rs10875746	0.903	rs11168401	ENSG00000269514.1	RP11-370I10.12	5.4	1.06e-07	1.62e-05	0.24	0.24	Longevity (90 years and older);	chr12:48087736	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs12304476	ENSG00000269514.1	RP11-370I10.12	5.4	1.06e-07	1.62e-05	0.24	0.24	Longevity (90 years and older);	chr12:48088370	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs3782911	ENSG00000269514.1	RP11-370I10.12	5.4	1.06e-07	1.62e-05	0.24	0.24	Longevity (90 years and older);	chr12:48089709	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.859	rs3782910	ENSG00000269514.1	RP11-370I10.12	5.4	1.06e-07	1.62e-05	0.24	0.24	Longevity (90 years and older);	chr12:48089724	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs61918806	ENSG00000269514.1	RP11-370I10.12	5.4	1.06e-07	1.62e-05	0.24	0.24	Longevity (90 years and older);	chr12:48090650	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs11168403	ENSG00000269514.1	RP11-370I10.12	5.4	1.06e-07	1.62e-05	0.24	0.24	Longevity (90 years and older);	chr12:48091175	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs10875740	ENSG00000269514.1	RP11-370I10.12	5.4	1.06e-07	1.62e-05	0.24	0.24	Longevity (90 years and older);	chr12:48095334	chr12:48198387~48202031:+
THCA	cis	rs72772090	0.908	rs72772091	ENSG00000248734.2	CTD-2260A17.1	-5.4	1.06e-07	1.62e-05	-0.39	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96704418	chr5:96784777~96785999:+
THCA	cis	rs6969780	1	rs739734	ENSG00000233429.8	HOTAIRM1	5.4	1.06e-07	1.62e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119786	chr7:27095647~27100265:+
THCA	cis	rs11089937	0.597	rs4821768	ENSG00000211638.2	IGLV8-61	-5.4	1.06e-07	1.62e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs4821770	ENSG00000211638.2	IGLV8-61	-5.4	1.06e-07	1.62e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.568	rs4821771	ENSG00000211638.2	IGLV8-61	-5.4	1.06e-07	1.62e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.597	rs4821773	ENSG00000211638.2	IGLV8-61	-5.4	1.06e-07	1.62e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22098700~22099212:+
THCA	cis	rs9527	0.614	rs4919691	ENSG00000236937.2	PTGES3P4	5.4	1.06e-07	1.62e-05	0.32	0.24	Arsenic metabolism;	chr10:102864718	chr10:102845595~102845950:+
THCA	cis	rs4648045	0.894	rs230500	ENSG00000246560.2	RP11-10L12.4	5.4	1.06e-07	1.63e-05	0.29	0.24	Lymphocyte percentage of white cells;	chr4:102570567	chr4:102828055~102844075:+
THCA	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498338	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149376428	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.568	rs11155647	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149384499	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12197598	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.34	0.24	Dupuytren's disease;	chr6:149385418	chr6:149796151~149826294:-
THCA	cis	rs4713118	0.955	rs9393848	ENSG00000226314.6	ZNF192P1	-5.4	1.06e-07	1.63e-05	-0.31	-0.24	Parkinson's disease;	chr6:27720590	chr6:28161781~28169594:+
THCA	cis	rs5769765	0.542	rs761878	ENSG00000260613.1	RP3-522J7.6	5.4	1.06e-07	1.63e-05	0.34	0.24	Schizophrenia;	chr22:49856029	chr22:49832616~49837786:-
THCA	cis	rs9402743	0.816	rs9402737	ENSG00000231028.7	LINC00271	-5.4	1.06e-07	1.63e-05	-0.2	-0.24	Systemic lupus erythematosus;	chr6:135651778	chr6:135497801~135716055:+
THCA	cis	rs10761482	0.5	rs10821779	ENSG00000254271.1	RP11-131N11.4	5.4	1.06e-07	1.63e-05	0.32	0.24	Schizophrenia;	chr10:60514767	chr10:60734342~60741828:+
THCA	cis	rs763121	0.886	rs1013339	ENSG00000273076.1	RP3-508I15.22	5.4	1.06e-07	1.63e-05	0.23	0.24	Menopause (age at onset);	chr22:38578675	chr22:38743495~38743910:+
THCA	cis	rs875971	0.545	rs6460276	ENSG00000232546.1	RP11-458F8.1	5.4	1.06e-07	1.63e-05	0.23	0.24	Aortic root size;	chr7:66182290	chr7:66848496~66858136:+
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000261839.1	RP1-265C24.8	5.4	1.06e-07	1.63e-05	0.28	0.24	Parkinson's disease;	chr6:28066257	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000261839.1	RP1-265C24.8	5.4	1.06e-07	1.63e-05	0.28	0.24	Parkinson's disease;	chr6:28066263	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000261839.1	RP1-265C24.8	5.4	1.06e-07	1.63e-05	0.28	0.24	Parkinson's disease;	chr6:28066343	chr6:28136849~28139678:+
THCA	cis	rs1322639	0.657	rs9355135	ENSG00000261039.2	RP11-417E7.2	-5.4	1.06e-07	1.63e-05	-0.37	-0.24	Pulse pressure;	chr6:169172911	chr6:169175304~169182740:-
THCA	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-5.4	1.06e-07	1.63e-05	-0.15	-0.24	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
THCA	cis	rs9402743	0.816	rs9494327	ENSG00000231028.7	LINC00271	-5.4	1.06e-07	1.63e-05	-0.2	-0.24	Systemic lupus erythematosus;	chr6:135674898	chr6:135497801~135716055:+
THCA	cis	rs919433	0.89	rs979020	ENSG00000231621.1	AC013264.2	5.4	1.06e-07	1.63e-05	0.24	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305025	chr2:197197991~197199273:+
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000273796.1	LL21NC02-21A1.1	-5.4	1.06e-07	1.63e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000273796.1	LL21NC02-21A1.1	-5.4	1.06e-07	1.63e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45403809~45404369:-
THCA	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.35	0.24	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.35	0.24	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	5.4	1.06e-07	1.63e-05	0.35	0.24	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
THCA	cis	rs2554380	0.55	rs56258128	ENSG00000230373.7	GOLGA6L5P	5.4	1.06e-07	1.63e-05	0.26	0.24	Height;	chr15:83874234	chr15:84507885~84516814:-
THCA	cis	rs12893668	0.616	rs58033365	ENSG00000269940.1	RP11-73M18.7	5.4	1.07e-07	1.63e-05	0.26	0.24	Reticulocyte count;	chr14:103564564	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.645	rs12889403	ENSG00000269940.1	RP11-73M18.7	5.4	1.07e-07	1.63e-05	0.26	0.24	Reticulocyte count;	chr14:103568409	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.703	rs12894729	ENSG00000269940.1	RP11-73M18.7	5.4	1.07e-07	1.63e-05	0.26	0.24	Reticulocyte count;	chr14:103568955	chr14:103694560~103695170:+
THCA	cis	rs3785574	1	rs7223257	ENSG00000240280.5	TCAM1P	-5.4	1.07e-07	1.63e-05	-0.33	-0.24	Height;	chr17:63710324	chr17:63849292~63864379:+
THCA	cis	rs812925	1	rs812925	ENSG00000271889.1	RP11-493E12.1	-5.4	1.07e-07	1.63e-05	-0.24	-0.24	Immature fraction of reticulocytes;	chr2:61453858	chr2:61151433~61162105:-
THCA	cis	rs7727544	0.684	rs274546	ENSG00000224431.1	AC063976.7	5.4	1.07e-07	1.63e-05	0.21	0.24	Blood metabolite levels;	chr5:132364175	chr5:132199456~132203487:+
THCA	cis	rs937213	0.643	rs11852600	ENSG00000275636.1	RP11-521C20.5	5.4	1.07e-07	1.63e-05	0.27	0.24	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39998280	chr15:40078892~40079347:+
THCA	cis	rs613391	0.603	rs565595	ENSG00000224549.1	RP11-370B11.3	-5.4	1.07e-07	1.63e-05	-0.27	-0.24	Quantitative traits;	chr9:22724189	chr9:22767175~22768316:+
THCA	cis	rs853679	0.599	rs149949	ENSG00000226314.6	ZNF192P1	-5.4	1.07e-07	1.63e-05	-0.38	-0.24	Depression;	chr6:28043738	chr6:28161781~28169594:+
THCA	cis	rs317865	0.867	rs7668729	ENSG00000263327.5	TAPT1-AS1	5.4	1.07e-07	1.63e-05	0.39	0.24	Kidney disease (early stage) in type 1 diabetes;	chr4:16178768	chr4:16226685~16320140:+
THCA	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-5.4	1.07e-07	1.63e-05	-0.26	-0.24	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
THCA	cis	rs2436845	0.627	rs974758	ENSG00000253669.3	KB-1732A1.1	-5.4	1.07e-07	1.63e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102825263	chr8:102805517~102809971:+
THCA	cis	rs12472274	0.529	rs11677996	ENSG00000279484.1	KLHL30-AS1	5.4	1.07e-07	1.63e-05	0.31	0.24	Phospholipid levels (plasma);	chr2:238209366	chr2:238152889~238155994:-
THCA	cis	rs12893668	0.543	rs12147645	ENSG00000269940.1	RP11-73M18.7	5.4	1.07e-07	1.63e-05	0.25	0.24	Reticulocyte count;	chr14:103633871	chr14:103694560~103695170:+
THCA	cis	rs9880211	0.66	rs9289514	ENSG00000273486.1	RP11-731C17.2	5.4	1.07e-07	1.63e-05	0.25	0.24	Height;Body mass index;	chr3:136774361	chr3:136837338~136839021:-
THCA	cis	rs12893668	0.703	rs7148456	ENSG00000269940.1	RP11-73M18.7	-5.4	1.07e-07	1.64e-05	-0.26	-0.24	Reticulocyte count;	chr14:103561933	chr14:103694560~103695170:+
THCA	cis	rs7412746	0.563	rs3768013	ENSG00000231073.1	RP11-316M1.3	5.4	1.07e-07	1.64e-05	0.28	0.24	Melanoma;	chr1:150842935	chr1:150973123~150975534:+
THCA	cis	rs807029	0.72	rs701836	ENSG00000272572.1	RP11-179B2.2	-5.4	1.07e-07	1.64e-05	-0.2	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101007360	chr10:100911103~100912739:-
THCA	cis	rs6585424	1	rs10466226	ENSG00000225484.5	NUTM2B-AS1	5.4	1.07e-07	1.64e-05	0.39	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164299	chr10:79663088~79826594:-
THCA	cis	rs1704413	1	rs1704413	ENSG00000246740.2	PLA2G4E-AS1	5.4	1.07e-07	1.64e-05	0.43	0.24	Platelet count;	chr15:41972233	chr15:41972763~41999094:+
THCA	cis	rs4460629	0.742	rs6427158	ENSG00000160766.13	GBAP1	-5.4	1.07e-07	1.64e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155102427	chr1:155213821~155227422:-
THCA	cis	rs4784934	0.589	rs11644317	ENSG00000260186.4	RP11-481J2.2	5.4	1.07e-07	1.64e-05	0.32	0.24	QT interval;	chr16:58437182	chr16:58421326~58462470:+
THCA	cis	rs9475752	0.793	rs2817573	ENSG00000231441.1	RP11-472M19.2	-5.4	1.07e-07	1.64e-05	-0.33	-0.24	Menarche (age at onset);	chr6:56946326	chr6:56844002~56864078:+
THCA	cis	rs7119038	0.865	rs11217046	ENSG00000255239.1	AP002954.6	-5.4	1.07e-07	1.64e-05	-0.39	-0.24	Sjögren's syndrome;	chr11:118828198	chr11:118688039~118690600:-
THCA	cis	rs890448	0.896	rs3974654	ENSG00000254531.1	FLJ20021	-5.4	1.07e-07	1.64e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101482523	chr4:101347780~101348883:+
THCA	cis	rs890448	0.86	rs6833608	ENSG00000254531.1	FLJ20021	-5.4	1.07e-07	1.64e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101482978	chr4:101347780~101348883:+
THCA	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	5.4	1.07e-07	1.64e-05	0.15	0.24	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	5.4	1.07e-07	1.64e-05	0.15	0.24	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	5.4	1.07e-07	1.64e-05	0.15	0.24	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	5.4	1.07e-07	1.64e-05	0.15	0.24	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
THCA	cis	rs6445975	0.666	rs12635366	ENSG00000272360.1	RP11-359I18.5	-5.4	1.07e-07	1.64e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr3:58412739	chr3:58490830~58491291:-
THCA	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	5.4	1.07e-07	1.64e-05	0.34	0.24	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
THCA	cis	rs2617170	0.922	rs1049172	ENSG00000245648.1	RP11-277P12.20	5.4	1.07e-07	1.64e-05	0.27	0.24	Behcet's disease;	chr12:10373141	chr12:10363769~10398506:+
THCA	cis	rs911555	0.504	rs8021368	ENSG00000269910.1	RP11-73M18.10	5.4	1.07e-07	1.64e-05	0.22	0.24	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103694516~103695050:-
THCA	cis	rs4908768	0.501	rs12756257	ENSG00000232912.4	RP5-1115A15.1	5.4	1.07e-07	1.64e-05	0.24	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8424645~8434838:+
THCA	cis	rs6560517	0.609	rs11144904	ENSG00000234618.1	RPSAP9	-5.4	1.07e-07	1.64e-05	-0.31	-0.24	Dialysis-related mortality;	chr9:76443710	chr9:76398699~76399586:+
THCA	cis	rs944289	0.774	rs2415313	ENSG00000258844.1	RP11-259K15.2	5.4	1.07e-07	1.64e-05	0.22	0.24	Thyroid cancer;	chr14:36115246	chr14:36214607~36235608:+
THCA	cis	rs7772486	0.743	rs62433835	ENSG00000270638.1	RP3-466P17.1	-5.4	1.07e-07	1.64e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.743	rs2092262	ENSG00000270638.1	RP3-466P17.1	-5.4	1.07e-07	1.64e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.682	rs1337840	ENSG00000270638.1	RP3-466P17.1	-5.4	1.07e-07	1.64e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145735570~145737218:+
THCA	cis	rs7267979	0.816	rs422148	ENSG00000125804.12	FAM182A	-5.4	1.07e-07	1.64e-05	-0.29	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26054655~26086917:+
THCA	cis	rs875971	0.619	rs10278371	ENSG00000273142.1	RP11-458F8.4	5.4	1.07e-07	1.64e-05	0.19	0.24	Aortic root size;	chr7:66586553	chr7:66902857~66906297:+
THCA	cis	rs713477	0.692	rs10146713	ENSG00000258413.1	RP11-665C16.6	5.4	1.07e-07	1.64e-05	0.33	0.24	Pediatric bone mineral content (femoral neck);	chr14:55444879	chr14:55262767~55272075:-
THCA	cis	rs1889642	1	rs9545217	ENSG00000227354.5	RBM26-AS1	5.4	1.07e-07	1.64e-05	0.23	0.24	Colonoscopy-negative controls vs population controls;	chr13:79832424	chr13:79406309~79424328:+
THCA	cis	rs800160	1	rs800158	ENSG00000199550.1	Y_RNA	-5.4	1.08e-07	1.64e-05	-0.37	-0.24	Bacteremia;	chr11:2357217	chr11:2372638~2372750:+
THCA	cis	rs2243480	1	rs2420171	ENSG00000232559.3	GS1-124K5.12	-5.4	1.08e-07	1.64e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66172773	chr7:66554588~66576923:-
THCA	cis	rs10844682	0.603	rs10844673	ENSG00000256594.6	RP11-705C15.2	5.4	1.08e-07	1.64e-05	0.22	0.24	Monocyte percentage of white cells;	chr12:9744969	chr12:9633419~9658412:+
THCA	cis	rs2562456	0.833	rs2359145	ENSG00000268081.1	RP11-678G14.2	5.4	1.08e-07	1.65e-05	0.41	0.24	Pain;	chr19:21409791	chr19:21554640~21569237:-
THCA	cis	rs6751744	0.924	rs13386318	ENSG00000226266.5	AC009961.3	-5.4	1.08e-07	1.65e-05	-0.32	-0.24	Dysphagia;	chr2:159541846	chr2:159670708~159712435:-
THCA	cis	rs7119	0.689	rs12916833	ENSG00000259362.2	RP11-307C19.1	-5.4	1.08e-07	1.65e-05	-0.35	-0.24	Type 2 diabetes;	chr15:77527436	chr15:77525540~77534110:+
THCA	cis	rs12681287	0.785	rs13263353	ENSG00000254231.1	CTD-2284J15.1	5.4	1.08e-07	1.65e-05	0.27	0.24	Caudate activity during reward;	chr8:86232353	chr8:86333274~86343314:-
THCA	cis	rs6547741	0.874	rs28381983	ENSG00000234072.1	AC074117.10	5.4	1.08e-07	1.65e-05	0.19	0.24	Oral cavity cancer;	chr2:27581565	chr2:27356246~27367622:+
THCA	cis	rs2436845	0.627	rs2679750	ENSG00000253669.3	KB-1732A1.1	-5.4	1.08e-07	1.65e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848164	chr8:102805517~102809971:+
THCA	cis	rs6547741	1	rs4665381	ENSG00000234072.1	AC074117.10	5.4	1.08e-07	1.65e-05	0.18	0.24	Oral cavity cancer;	chr2:27534283	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs10165098	ENSG00000234072.1	AC074117.10	5.4	1.08e-07	1.65e-05	0.18	0.24	Oral cavity cancer;	chr2:27573659	chr2:27356246~27367622:+
THCA	cis	rs62432291	0.681	rs433786	ENSG00000235086.1	FNDC1-IT1	-5.4	1.08e-07	1.65e-05	-0.44	-0.24	Joint mobility (Beighton score);	chr6:159244914	chr6:159240786~159243329:+
THCA	cis	rs7829975	0.606	rs7819827	ENSG00000233609.3	RP11-62H7.2	-5.4	1.08e-07	1.65e-05	-0.24	-0.24	Mood instability;	chr8:8939545	chr8:8961200~8979025:+
THCA	cis	rs875971	1	rs3735148	ENSG00000223473.2	GS1-124K5.3	5.4	1.08e-07	1.65e-05	0.16	0.24	Aortic root size;	chr7:66506022	chr7:66491049~66493566:-
THCA	cis	rs12701220	0.895	rs3808348	ENSG00000229043.2	AC091729.9	-5.4	1.08e-07	1.65e-05	-0.32	-0.24	Bronchopulmonary dysplasia;	chr7:988812	chr7:1160374~1165267:+
THCA	cis	rs116095464	0.614	rs78905930	ENSG00000248925.1	CTD-2083E4.6	5.4	1.08e-07	1.65e-05	0.35	0.24	Breast cancer;	chr5:246445	chr5:269858~271516:-
THCA	cis	rs1479090	0.805	rs1824884	ENSG00000250027.1	RP11-563E2.2	-5.4	1.08e-07	1.65e-05	-0.26	-0.24	Lung cancer;	chr4:163176642	chr4:163108785~163119965:+
THCA	cis	rs2342371	0.756	rs28712197	ENSG00000273013.1	CTD-2002J20.1	-5.4	1.08e-07	1.65e-05	-0.23	-0.24	Fat distribution (HIV);	chr3:196380343	chr3:196474801~196475394:+
THCA	cis	rs2342371	0.715	rs9846106	ENSG00000273013.1	CTD-2002J20.1	-5.4	1.08e-07	1.65e-05	-0.23	-0.24	Fat distribution (HIV);	chr3:196399668	chr3:196474801~196475394:+
THCA	cis	rs3785574	0.582	rs62072238	ENSG00000240280.5	TCAM1P	-5.4	1.08e-07	1.65e-05	-0.32	-0.24	Height;	chr17:63871481	chr17:63849292~63864379:+
THCA	cis	rs4073416	0.967	rs11845834	ENSG00000276116.2	FUT8-AS1	-5.4	1.08e-07	1.66e-05	-0.26	-0.24	N-glycan levels;	chr14:65793884	chr14:65411170~65412690:-
THCA	cis	rs7246657	0.55	rs9941475	ENSG00000276846.1	CTD-3220F14.3	5.4	1.08e-07	1.66e-05	0.24	0.24	Coronary artery calcification;	chr19:37573615	chr19:37314868~37315620:-
THCA	cis	rs2436845	0.627	rs2436861	ENSG00000253669.3	KB-1732A1.1	-5.4	1.08e-07	1.66e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102812625	chr8:102805517~102809971:+
THCA	cis	rs2436845	0.603	rs2513923	ENSG00000253669.3	KB-1732A1.1	-5.4	1.08e-07	1.66e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813207	chr8:102805517~102809971:+
THCA	cis	rs875971	1	rs2420591	ENSG00000223473.2	GS1-124K5.3	5.4	1.08e-07	1.66e-05	0.16	0.24	Aortic root size;	chr7:66447394	chr7:66491049~66493566:-
THCA	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	5.4	1.09e-07	1.66e-05	0.2	0.24	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
THCA	cis	rs12664251	0.579	rs1775613	ENSG00000253194.1	RP11-351A11.1	-5.4	1.09e-07	1.66e-05	-0.34	-0.24	Schizophrenia;	chr6:119024845	chr6:118934785~119031541:+
THCA	cis	rs7512898	0.545	rs7518347	ENSG00000260088.1	RP11-92G12.3	-5.4	1.09e-07	1.66e-05	-0.3	-0.24	Electrocardiographic conduction measures;	chr1:200704899	chr1:200669507~200694250:+
THCA	cis	rs6969780	0.908	rs6461987	ENSG00000233429.8	HOTAIRM1	5.4	1.09e-07	1.66e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127337	chr7:27095647~27100265:+
THCA	cis	rs6969780	1	rs929249	ENSG00000233429.8	HOTAIRM1	5.4	1.09e-07	1.66e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127918	chr7:27095647~27100265:+
THCA	cis	rs934734	0.736	rs7559283	ENSG00000281920.1	RP11-418H16.1	5.4	1.09e-07	1.66e-05	0.3	0.24	Rheumatoid arthritis;	chr2:65351234	chr2:65623272~65628424:+
THCA	cis	rs111580313	0.681	rs79805292	ENSG00000270020.1	RP11-463O9.9	5.39	1.09e-07	1.66e-05	0.64	0.24	Systemic juvenile idiopathic arthritis;	chr16:86583746	chr16:86520383~86523897:-
THCA	cis	rs2179367	0.6	rs9498354	ENSG00000223701.3	RAET1E-AS1	-5.39	1.09e-07	1.66e-05	-0.38	-0.24	Dupuytren's disease;	chr6:149441715	chr6:149884431~149919508:+
THCA	cis	rs2337406	0.852	rs12050239	ENSG00000211974.3	IGHV2-70	-5.39	1.09e-07	1.66e-05	-0.23	-0.24	Alzheimer's disease (late onset);	chr14:106781132	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74092535	ENSG00000211974.3	IGHV2-70	-5.39	1.09e-07	1.66e-05	-0.23	-0.24	Alzheimer's disease (late onset);	chr14:106781722	chr14:106723574~106724093:-
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000273796.1	LL21NC02-21A1.1	-5.39	1.09e-07	1.66e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45403809~45404369:-
THCA	cis	rs1858037	0.867	rs57913336	ENSG00000234255.7	AC012370.3	5.39	1.09e-07	1.66e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65360485	chr2:65439888~65456571:-
THCA	cis	rs7119	0.717	rs12910512	ENSG00000259362.2	RP11-307C19.1	-5.39	1.09e-07	1.66e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77524911	chr15:77525540~77534110:+
THCA	cis	rs2436845	0.627	rs1019976	ENSG00000253669.3	KB-1732A1.1	5.39	1.09e-07	1.66e-05	0.27	0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102852043	chr8:102805517~102809971:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000228409.4	CCT6P1	5.39	1.09e-07	1.67e-05	0.21	0.24	Aortic root size;	chr7:66112359	chr7:65751142~65763354:+
THCA	cis	rs11148252	0.553	rs9536236	ENSG00000273784.3	RP11-78J21.7	-5.39	1.09e-07	1.67e-05	-0.27	-0.24	Lewy body disease;	chr13:52680877	chr13:52600042~52642542:+
THCA	cis	rs2562456	0.833	rs55875743	ENSG00000268081.1	RP11-678G14.2	5.39	1.09e-07	1.67e-05	0.41	0.24	Pain;	chr19:21383393	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62110416	ENSG00000268081.1	RP11-678G14.2	5.39	1.09e-07	1.67e-05	0.41	0.24	Pain;	chr19:21401924	chr19:21554640~21569237:-
THCA	cis	rs67981189	0.529	rs2526868	ENSG00000269927.1	RP6-91H8.3	-5.39	1.09e-07	1.67e-05	-0.29	-0.24	Schizophrenia;	chr14:70923672	chr14:71141125~71143253:-
THCA	cis	rs62432291	0.614	rs452112	ENSG00000235086.1	FNDC1-IT1	-5.39	1.09e-07	1.67e-05	-0.44	-0.24	Joint mobility (Beighton score);	chr6:159236996	chr6:159240786~159243329:+
THCA	cis	rs62432291	0.681	rs417719	ENSG00000235086.1	FNDC1-IT1	-5.39	1.09e-07	1.67e-05	-0.44	-0.24	Joint mobility (Beighton score);	chr6:159237010	chr6:159240786~159243329:+
THCA	cis	rs7045881	0.935	rs7023230	ENSG00000254396.1	RP11-56F10.3	5.39	1.09e-07	1.67e-05	0.33	0.24	Schizophrenia;	chr9:26937270	chr9:27102630~27104728:+
THCA	cis	rs6121246	0.567	rs6120815	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31597063	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.529	rs6060195	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31597835	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.529	rs6060210	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31599878	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.567	rs6058187	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31603120	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.567	rs6060249	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31603141	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.528	rs6060252	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31603281	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.567	rs6060260	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31605104	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.567	rs6060261	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31605145	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.567	rs6060263	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31605307	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.567	rs2811	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31606445	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.529	rs6058196	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31606911	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.567	rs6058197	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31607096	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.522	rs6088736	ENSG00000230613.1	HM13-AS1	5.39	1.09e-07	1.67e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31607363	chr20:31567707~31573263:-
THCA	cis	rs10860794	0.569	rs10778143	ENSG00000274560.1	RP11-285E23.2	-5.39	1.09e-07	1.67e-05	-0.16	-0.24	Blood protein levels;	chr12:101700865	chr12:101696002~101696450:-
THCA	cis	rs7772486	0.686	rs9373473	ENSG00000270638.1	RP3-466P17.1	5.39	1.09e-07	1.67e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145735570~145737218:+
THCA	cis	rs890448	0.796	rs13143896	ENSG00000254531.1	FLJ20021	5.39	1.09e-07	1.67e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101440045	chr4:101347780~101348883:+
THCA	cis	rs4748857	0.685	rs11013351	ENSG00000224215.1	RP11-371A19.2	-5.39	1.09e-07	1.67e-05	-0.32	-0.24	Systemic lupus erythematosus;	chr10:23251512	chr10:23343957~23345181:+
THCA	cis	rs853679	0.567	rs1005126	ENSG00000219392.1	RP1-265C24.5	-5.39	1.09e-07	1.67e-05	-0.29	-0.24	Depression;	chr6:28399846	chr6:28115628~28116551:+
THCA	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-5.39	1.09e-07	1.67e-05	-0.4	-0.24	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
THCA	cis	rs16846053	0.792	rs62190671	ENSG00000227403.1	AC009299.3	5.39	1.1e-07	1.67e-05	0.5	0.24	Blood osmolality (transformed sodium);	chr2:161796451	chr2:161244739~161249050:+
THCA	cis	rs7209700	0.547	rs8078614	ENSG00000228782.6	CTD-2026D20.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	IgG glycosylation;	chr17:47274139	chr17:47450568~47492492:-
THCA	cis	rs2067615	0.524	rs4275715	ENSG00000260329.1	RP11-412D9.4	-5.39	1.1e-07	1.67e-05	-0.22	-0.24	Heart rate;	chr12:106668468	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.524	rs4246257	ENSG00000260329.1	RP11-412D9.4	-5.39	1.1e-07	1.67e-05	-0.22	-0.24	Heart rate;	chr12:106668551	chr12:106954029~106955497:-
THCA	cis	rs12101261	0.744	rs74064796	ENSG00000259167.2	NMNAT1P1	5.39	1.1e-07	1.67e-05	0.34	0.24	Graves' disease;	chr14:80984758	chr14:81032529~81033404:+
THCA	cis	rs6433895	1	rs13033467	ENSG00000236153.1	AC104076.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181152030	chr2:180979427~180980090:-
THCA	cis	rs6433895	0.961	rs6746347	ENSG00000236153.1	AC104076.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181152647	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs6759865	ENSG00000236153.1	AC104076.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181152658	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs55954384	ENSG00000236153.1	AC104076.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181152903	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs55900432	ENSG00000236153.1	AC104076.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181153177	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs34714467	ENSG00000236153.1	AC104076.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181153260	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs35543145	ENSG00000236153.1	AC104076.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181153388	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs7598960	ENSG00000236153.1	AC104076.3	-5.39	1.1e-07	1.67e-05	-0.27	-0.24	Lymphocyte counts;	chr2:181153655	chr2:180979427~180980090:-
THCA	cis	rs9843304	0.546	rs9858201	ENSG00000244503.1	RP11-278L15.6	-5.39	1.1e-07	1.67e-05	-0.31	-0.24	Gallstone disease;	chr3:149501881	chr3:149494660~149495995:+
THCA	cis	rs6547741	1	rs6547740	ENSG00000234072.1	AC074117.10	5.39	1.1e-07	1.67e-05	0.18	0.24	Oral cavity cancer;	chr2:27631502	chr2:27356246~27367622:+
THCA	cis	rs4908768	0.539	rs2100888	ENSG00000232912.4	RP5-1115A15.1	5.39	1.1e-07	1.67e-05	0.24	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8424645~8434838:+
THCA	cis	rs7615952	0.604	rs9837847	ENSG00000241288.6	RP11-379B18.5	-5.39	1.1e-07	1.68e-05	-0.34	-0.24	Blood pressure (smoking interaction);	chr3:125905076	chr3:125827238~125916384:-
THCA	cis	rs7246657	0.722	rs1564208	ENSG00000276846.1	CTD-3220F14.3	5.39	1.1e-07	1.68e-05	0.24	0.24	Coronary artery calcification;	chr19:37550319	chr19:37314868~37315620:-
THCA	cis	rs6479901	0.793	rs10761725	ENSG00000232075.1	MRPL35P2	-5.39	1.1e-07	1.68e-05	-0.35	-0.24	Intelligence (multi-trait analysis);	chr10:63214777	chr10:63634317~63634827:-
THCA	cis	rs62292953	0.79	rs62293988	ENSG00000248724.5	NPHP3-AS1	-5.39	1.1e-07	1.68e-05	-0.45	-0.24	Red cell distribution width;	chr3:132551514	chr3:132721750~132874223:+
THCA	cis	rs2439831	0.867	rs2245715	ENSG00000166763.7	STRCP1	5.39	1.1e-07	1.68e-05	0.33	0.24	Lung cancer in ever smokers;	chr15:43525854	chr15:43699488~43718184:-
THCA	cis	rs6545883	0.929	rs2463100	ENSG00000270820.4	RP11-355B11.2	5.39	1.1e-07	1.68e-05	0.21	0.24	Tuberculosis;	chr2:61432064	chr2:61471188~61484130:+
THCA	cis	rs7809615	0.748	rs10240199	ENSG00000244219.5	GS1-259H13.2	-5.39	1.1e-07	1.68e-05	-0.33	-0.24	Blood metabolite ratios;	chr7:99599555	chr7:99598066~99610813:+
THCA	cis	rs412050	0.696	rs76843711	ENSG00000224086.5	LL22NC03-86G7.1	-5.39	1.1e-07	1.68e-05	-0.42	-0.24	Attention deficit hyperactivity disorder;	chr22:21907753	chr22:21938293~21977632:+
THCA	cis	rs2129782	1	rs60936046	ENSG00000253553.4	RP11-586K2.1	5.39	1.1e-07	1.68e-05	0.43	0.24	Electrodermal activity;	chr8:88440953	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs117344347	ENSG00000253553.4	RP11-586K2.1	5.39	1.1e-07	1.68e-05	0.43	0.24	Electrodermal activity;	chr8:88452046	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs117669807	ENSG00000253553.4	RP11-586K2.1	5.39	1.1e-07	1.68e-05	0.43	0.24	Electrodermal activity;	chr8:88452056	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs79562877	ENSG00000253553.4	RP11-586K2.1	5.39	1.1e-07	1.68e-05	0.43	0.24	Electrodermal activity;	chr8:88457042	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs60336907	ENSG00000253553.4	RP11-586K2.1	5.39	1.1e-07	1.68e-05	0.43	0.24	Electrodermal activity;	chr8:88464690	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.702	rs77397538	ENSG00000253553.4	RP11-586K2.1	5.39	1.1e-07	1.68e-05	0.43	0.24	Electrodermal activity;	chr8:88465334	chr8:88326836~88737134:+
THCA	cis	rs9816784	0.901	rs12490036	ENSG00000273009.1	RP11-352G9.1	5.39	1.1e-07	1.68e-05	0.25	0.24	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195913078~195913683:-
THCA	cis	rs12935418	0.583	rs2549841	ENSG00000278985.1	RP11-303E16.9	-5.39	1.1e-07	1.68e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80989967	chr16:80982319~80984094:-
THCA	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	5.39	1.1e-07	1.68e-05	0.21	0.24	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
THCA	cis	rs6430585	0.583	rs2322813	ENSG00000231890.6	DARS-AS1	-5.39	1.1e-07	1.68e-05	-0.3	-0.24	Corneal structure;	chr2:135825239	chr2:135985176~136022593:+
THCA	cis	rs7927592	0.513	rs653056	ENSG00000212093.1	AP000807.1	5.39	1.1e-07	1.68e-05	0.25	0.24	Total body bone mineral density;	chr11:68436157	chr11:68506083~68506166:-
THCA	cis	rs875971	0.545	rs2420456	ENSG00000232546.1	RP11-458F8.1	5.39	1.1e-07	1.68e-05	0.23	0.24	Aortic root size;	chr7:66280619	chr7:66848496~66858136:+
THCA	cis	rs2749592	0.505	rs7915670	ENSG00000263064.2	RP11-291L22.7	-5.39	1.1e-07	1.68e-05	-0.27	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38448689~38448949:+
THCA	cis	rs9438901	0.592	rs1293259	ENSG00000224183.1	SDHDP6	5.39	1.1e-07	1.68e-05	0.42	0.24	Red cell distribution width;	chr1:25369344	chr1:25294164~25294643:-
THCA	cis	rs6988985	0.647	rs28558934	ENSG00000247317.3	RP11-273G15.2	-5.39	1.1e-07	1.68e-05	-0.26	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905139	chr8:142981738~143018437:-
THCA	cis	rs9926296	0.509	rs2159113	ENSG00000260259.1	RP11-368I7.4	-5.39	1.1e-07	1.68e-05	-0.26	-0.24	Vitiligo;	chr16:89765675	chr16:89682620~89686569:-
THCA	cis	rs11098499	0.526	rs10026625	ENSG00000249244.1	RP11-548H18.2	5.39	1.1e-07	1.68e-05	0.26	0.24	Corneal astigmatism;	chr4:119358981	chr4:119391831~119395335:-
THCA	cis	rs7829975	0.539	rs71537846	ENSG00000253893.2	FAM85B	5.39	1.1e-07	1.69e-05	0.33	0.24	Mood instability;	chr8:8684610	chr8:8167819~8226614:-
THCA	cis	rs7976269	0.537	rs10843308	ENSG00000275476.1	RP11-996F15.4	-5.39	1.11e-07	1.69e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29075172	chr12:29277397~29277882:-
THCA	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	5.39	1.11e-07	1.69e-05	0.37	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
THCA	cis	rs2282300	0.739	rs67670125	ENSG00000242353.1	RP4-710M3.1	-5.39	1.11e-07	1.69e-05	-0.24	-0.24	Morning vs. evening chronotype;	chr11:30193367	chr11:30368148~30368646:+
THCA	cis	rs9475752	0.793	rs79207065	ENSG00000231441.1	RP11-472M19.2	5.39	1.11e-07	1.69e-05	0.32	0.24	Menarche (age at onset);	chr6:56977477	chr6:56844002~56864078:+
THCA	cis	rs12681287	0.752	rs7846635	ENSG00000254231.1	CTD-2284J15.1	5.39	1.11e-07	1.69e-05	0.28	0.24	Caudate activity during reward;	chr8:86292052	chr8:86333274~86343314:-
THCA	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	5.39	1.11e-07	1.69e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	5.39	1.11e-07	1.69e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
THCA	cis	rs2749592	0.55	rs10764135	ENSG00000263064.2	RP11-291L22.7	-5.39	1.11e-07	1.69e-05	-0.27	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38448689~38448949:+
THCA	cis	rs853679	0.567	rs7774981	ENSG00000219392.1	RP1-265C24.5	-5.39	1.11e-07	1.69e-05	-0.29	-0.24	Depression;	chr6:28379133	chr6:28115628~28116551:+
THCA	cis	rs853679	0.567	rs7754960	ENSG00000219392.1	RP1-265C24.5	-5.39	1.11e-07	1.69e-05	-0.29	-0.24	Depression;	chr6:28379168	chr6:28115628~28116551:+
THCA	cis	rs4908768	0.539	rs11121205	ENSG00000232912.4	RP5-1115A15.1	5.39	1.11e-07	1.69e-05	0.24	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8424645~8434838:+
THCA	cis	rs890448	0.726	rs1031034	ENSG00000254531.1	FLJ20021	-5.39	1.11e-07	1.69e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101302229	chr4:101347780~101348883:+
THCA	cis	rs55726902	1	rs73107993	ENSG00000276691.1	RP5-1057I20.5	5.39	1.11e-07	1.69e-05	0.32	0.24	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47788426~47788971:+
THCA	cis	rs34787248	1	rs34787248	ENSG00000226314.6	ZNF192P1	-5.39	1.11e-07	1.69e-05	-0.34	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28161781~28169594:+
THCA	cis	rs7111546	0.618	rs7946541	ENSG00000246225.5	RP11-17A1.3	5.39	1.11e-07	1.69e-05	0.42	0.24	Dialysis-related mortality;	chr11:22866002	chr11:22829380~22945393:+
THCA	cis	rs6545883	0.929	rs6705235	ENSG00000270820.4	RP11-355B11.2	5.39	1.11e-07	1.69e-05	0.21	0.24	Tuberculosis;	chr2:61486445	chr2:61471188~61484130:+
THCA	cis	rs9467773	0.933	rs35355150	ENSG00000124549.13	BTN2A3P	5.39	1.11e-07	1.69e-05	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26421391~26432383:+
THCA	cis	rs7577696	0.925	rs408813	ENSG00000276334.1	AL133243.1	5.39	1.11e-07	1.69e-05	0.25	0.24	Inflammatory biomarkers;	chr2:32251321	chr2:32521927~32523547:+
THCA	cis	rs67981189	0.529	rs8181986	ENSG00000269927.1	RP6-91H8.3	5.39	1.11e-07	1.69e-05	0.29	0.24	Schizophrenia;	chr14:71115527	chr14:71141125~71143253:-
THCA	cis	rs7980687	0.628	rs1609520	ENSG00000256092.2	RP13-942N8.1	-5.39	1.11e-07	1.69e-05	-0.18	-0.24	Head circumference (infant);Educational attainment;Height;	chr12:123251390	chr12:123363868~123366113:+
THCA	cis	rs5006884	0.715	rs7112862	ENSG00000167355.6	AC104389.28	-5.39	1.11e-07	1.69e-05	-0.38	-0.24	Fetal hemoglobin levels;	chr11:5365800	chr11:5304976~5505652:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000273142.1	RP11-458F8.4	5.39	1.11e-07	1.69e-05	0.2	0.24	Aortic root size;	chr7:66032447	chr7:66902857~66906297:+
THCA	cis	rs11089937	0.512	rs13054756	ENSG00000211638.2	IGLV8-61	-5.39	1.11e-07	1.69e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22098700~22099212:+
THCA	cis	rs1322639	0.657	rs12203887	ENSG00000261039.2	RP11-417E7.2	-5.39	1.11e-07	1.69e-05	-0.37	-0.24	Pulse pressure;	chr6:169172157	chr6:169175304~169182740:-
THCA	cis	rs890448	0.93	rs4699220	ENSG00000254531.1	FLJ20021	-5.39	1.11e-07	1.69e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101495282	chr4:101347780~101348883:+
THCA	cis	rs858239	0.665	rs6964665	ENSG00000226816.2	AC005082.12	5.39	1.11e-07	1.7e-05	0.35	0.24	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23206013~23208045:+
THCA	cis	rs763567	0.605	rs647438	ENSG00000271811.1	RP1-79C4.4	-5.39	1.11e-07	1.7e-05	-0.27	-0.24	Tonsillectomy;	chr1:170608094	chr1:170667381~170669425:+
THCA	cis	rs2749592	0.55	rs12255038	ENSG00000263064.2	RP11-291L22.7	-5.39	1.11e-07	1.7e-05	-0.27	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38448689~38448949:+
THCA	cis	rs8007846	0.569	rs56922569	ENSG00000276116.2	FUT8-AS1	-5.39	1.11e-07	1.7e-05	-0.25	-0.24	Multiple sclerosis--Brain Glutamate Levels;	chr14:65789754	chr14:65411170~65412690:-
THCA	cis	rs8177876	0.543	rs2317086	ENSG00000261061.1	RP11-303E16.2	5.39	1.11e-07	1.7e-05	0.36	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104468	chr16:81030770~81031485:+
THCA	cis	rs9880211	0.8	rs9865995	ENSG00000273486.1	RP11-731C17.2	5.39	1.11e-07	1.7e-05	0.25	0.24	Height;Body mass index;	chr3:136794508	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs9871184	ENSG00000273486.1	RP11-731C17.2	5.39	1.11e-07	1.7e-05	0.25	0.24	Height;Body mass index;	chr3:136795468	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs115050567	ENSG00000273486.1	RP11-731C17.2	5.39	1.11e-07	1.7e-05	0.25	0.24	Height;Body mass index;	chr3:136796817	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs9858560	ENSG00000273486.1	RP11-731C17.2	5.39	1.11e-07	1.7e-05	0.25	0.24	Height;Body mass index;	chr3:136798312	chr3:136837338~136839021:-
THCA	cis	rs755249	0.567	rs61779306	ENSG00000228060.1	RP11-69E11.8	-5.39	1.11e-07	1.7e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39565160~39573203:+
THCA	cis	rs3950186	0.834	rs6899747	ENSG00000215124.2	RP3-420J14.1	5.39	1.11e-07	1.7e-05	0.28	0.24	Anxiety and major depressive disorder;	chr6:11824864	chr6:11861626~11862970:-
THCA	cis	rs7829975	0.871	rs7829826	ENSG00000254153.1	CTA-398F10.2	5.39	1.11e-07	1.7e-05	0.26	0.24	Mood instability;	chr8:8720610	chr8:8456909~8461337:-
THCA	cis	rs4415084	0.804	rs13177711	ENSG00000272335.1	RP11-53O19.3	-5.39	1.11e-07	1.7e-05	-0.2	-0.24	Breast cancer;	chr5:44796860	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.834	rs6896417	ENSG00000272335.1	RP11-53O19.3	-5.39	1.11e-07	1.7e-05	-0.2	-0.24	Breast cancer;	chr5:44802536	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.834	rs13159598	ENSG00000272335.1	RP11-53O19.3	-5.39	1.11e-07	1.7e-05	-0.2	-0.24	Breast cancer;	chr5:44805824	chr5:44826076~44828592:+
THCA	cis	rs73198271	0.599	rs10103169	ENSG00000253893.2	FAM85B	5.39	1.12e-07	1.7e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.7	rs10103282	ENSG00000253893.2	FAM85B	5.39	1.12e-07	1.7e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.74	rs964771	ENSG00000253893.2	FAM85B	-5.39	1.12e-07	1.7e-05	-0.34	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8167819~8226614:-
THCA	cis	rs3764400	0.508	rs757353	ENSG00000278765.1	RP5-890E16.5	5.39	1.12e-07	1.7e-05	0.45	0.24	Body mass index;	chr17:48044908	chr17:48066704~48067293:-
THCA	cis	rs9952991	0.941	rs7237497	ENSG00000260302.1	RP11-973H7.1	-5.39	1.12e-07	1.7e-05	-0.39	-0.24	Inflammatory skin disease;	chr18:12777326	chr18:12774651~12775923:-
THCA	cis	rs10875746	0.855	rs10875729	ENSG00000269514.1	RP11-370I10.12	5.39	1.12e-07	1.7e-05	0.25	0.24	Longevity (90 years and older);	chr12:48032943	chr12:48198387~48202031:+
THCA	cis	rs57221529	0.766	rs72703075	ENSG00000225138.6	CTD-2228K2.7	5.39	1.12e-07	1.7e-05	0.32	0.24	Lung disease severity in cystic fibrosis;	chr5:592704	chr5:473236~480884:+
THCA	cis	rs1577330	0.571	rs596427	ENSG00000254396.1	RP11-56F10.3	-5.39	1.12e-07	1.7e-05	-0.38	-0.24	IgG glycosylation;	chr9:27099246	chr9:27102630~27104728:+
THCA	cis	rs2243480	1	rs1964692	ENSG00000230295.1	RP11-458F8.2	-5.39	1.12e-07	1.7e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65989196	chr7:66880708~66882981:+
THCA	cis	rs1866631	0.566	rs13008554	ENSG00000238133.5	MLK7-AS1	5.39	1.12e-07	1.7e-05	0.31	0.24	Lung cancer in ever smokers;	chr2:173185266	chr2:173166446~173282036:-
THCA	cis	rs7824557	0.628	rs7841394	ENSG00000154316.13	TDH	-5.39	1.12e-07	1.7e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11328162	chr8:11339637~11368452:+
THCA	cis	rs2436845	0.627	rs1062048	ENSG00000253669.3	KB-1732A1.1	-5.39	1.12e-07	1.7e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102838824	chr8:102805517~102809971:+
THCA	cis	rs2243480	1	rs1638734	ENSG00000230295.1	RP11-458F8.2	-5.39	1.12e-07	1.71e-05	-0.3	-0.24	Diabetic kidney disease;	chr7:66632552	chr7:66880708~66882981:+
THCA	cis	rs6585424	0.925	rs11201964	ENSG00000242600.5	MBL1P	5.39	1.12e-07	1.71e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80171611	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs11201966	ENSG00000242600.5	MBL1P	5.39	1.12e-07	1.71e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172024	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs11201972	ENSG00000242600.5	MBL1P	5.39	1.12e-07	1.71e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172924	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs3851055	ENSG00000242600.5	MBL1P	5.39	1.12e-07	1.71e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178340	chr10:79904898~79950336:+
THCA	cis	rs1707322	0.721	rs4660883	ENSG00000281133.1	AL355480.3	-5.39	1.12e-07	1.71e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45580892~45580996:-
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000273142.1	RP11-458F8.4	-5.39	1.12e-07	1.71e-05	-0.19	-0.24	Calcium levels;	chr7:65903721	chr7:66902857~66906297:+
THCA	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	5.39	1.12e-07	1.71e-05	0.34	0.24	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	5.39	1.12e-07	1.71e-05	0.34	0.24	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	5.39	1.12e-07	1.71e-05	0.34	0.24	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
THCA	cis	rs4950322	0.744	rs2353987	ENSG00000278811.3	LINC00624	5.39	1.12e-07	1.71e-05	0.3	0.24	Protein quantitative trait loci;	chr1:147355845	chr1:147258885~147517875:-
THCA	cis	rs9475752	0.793	rs17685277	ENSG00000231441.1	RP11-472M19.2	5.39	1.12e-07	1.71e-05	0.32	0.24	Menarche (age at onset);	chr6:56958627	chr6:56844002~56864078:+
THCA	cis	rs6445975	0.666	rs11130629	ENSG00000272360.1	RP11-359I18.5	5.39	1.12e-07	1.71e-05	0.28	0.24	Systemic lupus erythematosus;	chr3:58366872	chr3:58490830~58491291:-
THCA	cis	rs67478160	0.634	rs2368558	ENSG00000258735.1	LINC00637	-5.39	1.12e-07	1.71e-05	-0.29	-0.24	Schizophrenia;	chr14:103764181	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.634	rs2368559	ENSG00000258735.1	LINC00637	-5.39	1.12e-07	1.71e-05	-0.29	-0.24	Schizophrenia;	chr14:103764198	chr14:103847721~103858049:+
THCA	cis	rs863750	0.687	rs825485	ENSG00000275389.1	RP11-214K3.24	5.39	1.12e-07	1.71e-05	0.32	0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091865	chr12:124085761~124088598:+
THCA	cis	rs10208649	0.831	rs76039968	ENSG00000233266.1	HMGB1P31	5.39	1.12e-07	1.71e-05	0.64	0.24	Body mass index;	chr2:53694900	chr2:54051334~54051760:+
THCA	cis	rs12478296	1	rs56162244	ENSG00000261186.2	RP11-341N2.1	-5.39	1.12e-07	1.71e-05	-0.37	-0.24	Obesity-related traits;	chr2:242076539	chr2:242087351~242088457:-
THCA	cis	rs4648045	0.828	rs230492	ENSG00000246560.2	RP11-10L12.4	-5.39	1.12e-07	1.71e-05	-0.31	-0.24	Lymphocyte percentage of white cells;	chr4:102564623	chr4:102828055~102844075:+
THCA	cis	rs2985684	0.846	rs10150624	ENSG00000278009.1	RP11-649E7.8	5.39	1.12e-07	1.71e-05	0.33	0.24	Carotid intima media thickness;	chr14:49584847	chr14:49601011~49601124:-
THCA	cis	rs2985684	0.802	rs10150823	ENSG00000278009.1	RP11-649E7.8	5.39	1.12e-07	1.71e-05	0.33	0.24	Carotid intima media thickness;	chr14:49585033	chr14:49601011~49601124:-
THCA	cis	rs7829975	0.511	rs1401390	ENSG00000253981.4	ALG1L13P	5.39	1.12e-07	1.71e-05	0.23	0.24	Mood instability;	chr8:8278888	chr8:8236003~8244667:-
THCA	cis	rs6988985	0.678	rs7831617	ENSG00000247317.3	RP11-273G15.2	-5.39	1.12e-07	1.71e-05	-0.26	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142920867	chr8:142981738~143018437:-
THCA	cis	rs2304003	1	rs4667847	ENSG00000235192.1	AC009495.2	5.39	1.12e-07	1.71e-05	0.34	0.24	Social communication problems;	chr2:165858696	chr2:165794851~165810010:+
THCA	cis	rs6951245	0.832	rs10266519	ENSG00000229043.2	AC091729.9	-5.39	1.13e-07	1.71e-05	-0.38	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1160374~1165267:+
THCA	cis	rs593531	0.614	rs655719	ENSG00000255440.1	RP11-632K5.2	5.39	1.13e-07	1.71e-05	0.29	0.24	Neuroticism;	chr11:74331196	chr11:74409060~74416379:+
THCA	cis	rs2243480	1	rs4718334	ENSG00000232559.3	GS1-124K5.12	-5.39	1.13e-07	1.72e-05	-0.36	-0.24	Diabetic kidney disease;	chr7:66324467	chr7:66554588~66576923:-
THCA	cis	rs7412746	0.611	rs2280627	ENSG00000231073.1	RP11-316M1.3	5.39	1.13e-07	1.72e-05	0.28	0.24	Melanoma;	chr1:150963396	chr1:150973123~150975534:+
THCA	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	5.39	1.13e-07	1.72e-05	0.41	0.24	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	5.39	1.13e-07	1.72e-05	0.41	0.24	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	5.39	1.13e-07	1.72e-05	0.41	0.24	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	5.39	1.13e-07	1.72e-05	0.41	0.24	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
THCA	cis	rs4915077	1	rs77475507	ENSG00000230489.1	VAV3-AS1	5.39	1.13e-07	1.72e-05	0.4	0.24	Hypothyroidism;	chr1:107819485	chr1:107964443~107994607:+
THCA	cis	rs10829156	0.732	rs4747348	ENSG00000240291.1	RP11-499P20.2	5.39	1.13e-07	1.72e-05	0.21	0.24	Sudden cardiac arrest;	chr10:18506126	chr10:18513115~18545651:-
THCA	cis	rs6445975	0.666	rs4390943	ENSG00000272360.1	RP11-359I18.5	-5.39	1.13e-07	1.72e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr3:58390912	chr3:58490830~58491291:-
THCA	cis	rs7951911	1	rs12805504	ENSG00000254427.1	RP11-430H10.1	5.39	1.13e-07	1.72e-05	0.37	0.24	IgG glycosylation;	chr11:45070412	chr11:45355371~45366121:+
THCA	cis	rs67478160	0.619	rs12437066	ENSG00000258735.1	LINC00637	-5.39	1.13e-07	1.72e-05	-0.29	-0.24	Schizophrenia;	chr14:103770507	chr14:103847721~103858049:+
THCA	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	5.39	1.13e-07	1.72e-05	0.15	0.24	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
THCA	cis	rs890448	0.896	rs1016127	ENSG00000254531.1	FLJ20021	-5.39	1.13e-07	1.72e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101484796	chr4:101347780~101348883:+
THCA	cis	rs890448	0.86	rs1863575	ENSG00000254531.1	FLJ20021	-5.39	1.13e-07	1.72e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101485952	chr4:101347780~101348883:+
THCA	cis	rs41307935	0.643	rs57215361	ENSG00000260063.1	RP5-968P14.2	-5.39	1.13e-07	1.72e-05	-0.48	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26988323	chr1:26692132~26694131:-
THCA	cis	rs7119	0.717	rs7180732	ENSG00000259362.2	RP11-307C19.1	-5.39	1.13e-07	1.72e-05	-0.35	-0.24	Type 2 diabetes;	chr15:77537579	chr15:77525540~77534110:+
THCA	cis	rs7246657	0.722	rs2972458	ENSG00000276846.1	CTD-3220F14.3	-5.39	1.13e-07	1.72e-05	-0.24	-0.24	Coronary artery calcification;	chr19:37644502	chr19:37314868~37315620:-
THCA	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	5.39	1.13e-07	1.72e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
THCA	cis	rs2120243	0.572	rs6803628	ENSG00000244515.1	KRT18P34	-5.39	1.13e-07	1.72e-05	-0.29	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157407795	chr3:157162663~157163932:-
THCA	cis	rs2562456	0.793	rs73537884	ENSG00000268081.1	RP11-678G14.2	5.39	1.13e-07	1.72e-05	0.4	0.24	Pain;	chr19:21321908	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs78467454	ENSG00000268081.1	RP11-678G14.2	5.39	1.13e-07	1.72e-05	0.4	0.24	Pain;	chr19:21321930	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs55790393	ENSG00000268081.1	RP11-678G14.2	5.39	1.13e-07	1.72e-05	0.4	0.24	Pain;	chr19:21323382	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs11672341	ENSG00000268081.1	RP11-678G14.2	5.39	1.13e-07	1.72e-05	0.4	0.24	Pain;	chr19:21324502	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.754	rs11673234	ENSG00000268081.1	RP11-678G14.2	5.39	1.13e-07	1.72e-05	0.4	0.24	Pain;	chr19:21324800	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.754	rs11673320	ENSG00000268081.1	RP11-678G14.2	5.39	1.13e-07	1.72e-05	0.4	0.24	Pain;	chr19:21324801	chr19:21554640~21569237:-
THCA	cis	rs1198430	0.602	rs12401753	ENSG00000232482.2	RP4-654C18.1	-5.39	1.13e-07	1.72e-05	-0.34	-0.24	Total cholesterol levels;	chr1:23436186	chr1:23410832~23412146:+
THCA	cis	rs6445975	0.747	rs9852465	ENSG00000272360.1	RP11-359I18.5	-5.39	1.13e-07	1.72e-05	-0.25	-0.24	Systemic lupus erythematosus;	chr3:58479456	chr3:58490830~58491291:-
THCA	cis	rs2243480	1	rs316329	ENSG00000232559.3	GS1-124K5.12	5.39	1.13e-07	1.72e-05	0.35	0.24	Diabetic kidney disease;	chr7:66143429	chr7:66554588~66576923:-
THCA	cis	rs10833905	0.641	rs10766981	ENSG00000246225.5	RP11-17A1.3	-5.39	1.13e-07	1.72e-05	-0.36	-0.24	Sudden cardiac arrest;	chr11:22920950	chr11:22829380~22945393:+
THCA	cis	rs17123764	0.786	rs58446833	ENSG00000257464.1	RP11-161H23.8	-5.39	1.13e-07	1.72e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49722950	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs59849800	ENSG00000257464.1	RP11-161H23.8	-5.39	1.13e-07	1.72e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49722990	chr12:49442424~49442652:-
THCA	cis	rs7829975	0.56	rs17154599	ENSG00000253893.2	FAM85B	5.39	1.13e-07	1.72e-05	0.32	0.24	Mood instability;	chr8:8693908	chr8:8167819~8226614:-
THCA	cis	rs11977715	0.538	rs43067	ENSG00000233942.1	AC004012.1	-5.39	1.13e-07	1.72e-05	-0.32	-0.24	Middle childhood and early adolescence aggressive behavior;	chr7:95485392	chr7:95471835~95473998:+
THCA	cis	rs1552244	0.935	rs2272124	ENSG00000180385.7	EMC3-AS1	5.39	1.13e-07	1.73e-05	0.26	0.24	Alzheimer's disease;	chr3:10096505	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs55882090	ENSG00000180385.7	EMC3-AS1	5.39	1.13e-07	1.73e-05	0.26	0.24	Alzheimer's disease;	chr3:10097398	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs7622963	ENSG00000180385.7	EMC3-AS1	5.39	1.13e-07	1.73e-05	0.26	0.24	Alzheimer's disease;	chr3:10098141	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs34179822	ENSG00000180385.7	EMC3-AS1	5.39	1.13e-07	1.73e-05	0.26	0.24	Alzheimer's disease;	chr3:10098333	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.938	rs7647987	ENSG00000180385.7	EMC3-AS1	5.39	1.13e-07	1.73e-05	0.26	0.24	Alzheimer's disease;	chr3:10099012	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs3826	ENSG00000180385.7	EMC3-AS1	5.39	1.13e-07	1.73e-05	0.26	0.24	Alzheimer's disease;	chr3:10099381	chr3:9986893~10006990:+
THCA	cis	rs7674212	0.531	rs6816370	ENSG00000230069.3	LRRC37A15P	-5.39	1.13e-07	1.73e-05	-0.26	-0.24	Type 2 diabetes;	chr4:103018276	chr4:102727274~102730721:-
THCA	cis	rs2129782	1	rs77846263	ENSG00000253553.4	RP11-586K2.1	5.39	1.13e-07	1.73e-05	0.43	0.24	Electrodermal activity;	chr8:88473947	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs76689818	ENSG00000253553.4	RP11-586K2.1	5.39	1.13e-07	1.73e-05	0.43	0.24	Electrodermal activity;	chr8:88474541	chr8:88326836~88737134:+
THCA	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	5.39	1.13e-07	1.73e-05	0.15	0.24	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	5.39	1.13e-07	1.73e-05	0.15	0.24	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
THCA	cis	rs2303759	0.918	rs10405465	ENSG00000268686.1	AC010524.2	-5.39	1.13e-07	1.73e-05	-0.34	-0.24	Multiple sclerosis;	chr19:49366041	chr19:49368705~49388081:-
THCA	cis	rs4460629	0.742	rs11264312	ENSG00000160766.13	GBAP1	-5.39	1.13e-07	1.73e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155103412	chr1:155213821~155227422:-
THCA	cis	rs4460629	0.742	rs4625273	ENSG00000160766.13	GBAP1	-5.39	1.13e-07	1.73e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155103567	chr1:155213821~155227422:-
THCA	cis	rs4460629	0.742	rs7366355	ENSG00000160766.13	GBAP1	-5.39	1.13e-07	1.73e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155104258	chr1:155213821~155227422:-
THCA	cis	rs9834975	0.935	rs6438724	ENSG00000272758.4	RP11-299J3.8	-5.39	1.13e-07	1.73e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122364841	chr3:122416207~122443180:+
THCA	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-5.39	1.13e-07	1.73e-05	-0.42	-0.24	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
THCA	cis	rs6570726	0.902	rs4895678	ENSG00000270638.1	RP3-466P17.1	5.39	1.13e-07	1.73e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145614374	chr6:145735570~145737218:+
THCA	cis	rs3764400	0.507	rs16954324	ENSG00000278765.1	RP5-890E16.5	5.39	1.13e-07	1.73e-05	0.45	0.24	Body mass index;	chr17:48247222	chr17:48066704~48067293:-
THCA	cis	rs28476539	0.567	rs17006028	ENSG00000270480.1	RP11-57B24.1	5.39	1.14e-07	1.73e-05	0.39	0.24	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82653595	chr4:82691737~82692468:+
THCA	cis	rs6921919	0.583	rs16894060	ENSG00000219392.1	RP1-265C24.5	-5.39	1.14e-07	1.73e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28115628~28116551:+
THCA	cis	rs1479090	0.762	rs4295216	ENSG00000250027.1	RP11-563E2.2	-5.39	1.14e-07	1.73e-05	-0.25	-0.24	Lung cancer;	chr4:163173418	chr4:163108785~163119965:+
THCA	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	5.39	1.14e-07	1.73e-05	0.37	0.24	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
THCA	cis	rs11051970	0.879	rs2728682	ENSG00000274964.1	RP11-817I4.1	-5.39	1.14e-07	1.73e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32427259	chr12:32339368~32340724:+
THCA	cis	rs17826219	0.562	rs719600	ENSG00000266490.1	CTD-2349P21.9	-5.39	1.14e-07	1.73e-05	-0.32	-0.24	Body mass index;	chr17:30404244	chr17:30792372~30792833:+
THCA	cis	rs7119038	0.818	rs1048024	ENSG00000255239.1	AP002954.6	-5.39	1.14e-07	1.73e-05	-0.37	-0.24	Sjögren's syndrome;	chr11:118748067	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.818	rs2077579	ENSG00000255239.1	AP002954.6	-5.39	1.14e-07	1.73e-05	-0.37	-0.24	Sjögren's syndrome;	chr11:118748338	chr11:118688039~118690600:-
THCA	cis	rs10043228	0.702	rs1582430	ENSG00000248445.4	SEMA6A-AS1	-5.39	1.14e-07	1.73e-05	-0.26	-0.24	Asthma or chronic obstructive pulmonary disease;	chr5:116325734	chr5:116447547~116508276:+
THCA	cis	rs17270561	0.723	rs12192635	ENSG00000272462.2	U91328.19	-5.39	1.14e-07	1.73e-05	-0.23	-0.24	Iron status biomarkers;	chr6:25880679	chr6:25992662~26001775:+
THCA	cis	rs9813712	0.595	rs1993217	ENSG00000253540.4	FAM86HP	-5.39	1.14e-07	1.74e-05	-0.26	-0.24	Response to amphetamines;	chr3:130284832	chr3:130099092~130111472:-
THCA	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-5.39	1.14e-07	1.74e-05	-0.28	-0.24	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
THCA	cis	rs3760982	0.813	rs8111664	ENSG00000267058.1	RP11-15A1.3	5.39	1.14e-07	1.74e-05	0.21	0.24	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790940	chr19:43891804~43901805:-
THCA	cis	rs875971	0.66	rs10215132	ENSG00000273142.1	RP11-458F8.4	5.39	1.14e-07	1.74e-05	0.19	0.24	Aortic root size;	chr7:66589419	chr7:66902857~66906297:+
THCA	cis	rs10761482	0.601	rs7922622	ENSG00000254271.1	RP11-131N11.4	-5.39	1.14e-07	1.74e-05	-0.33	-0.24	Schizophrenia;	chr10:60447765	chr10:60734342~60741828:+
THCA	cis	rs890448	0.796	rs6532934	ENSG00000254531.1	FLJ20021	5.39	1.14e-07	1.74e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101386461	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs6847376	ENSG00000254531.1	FLJ20021	5.39	1.14e-07	1.74e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387340	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs6825658	ENSG00000254531.1	FLJ20021	5.39	1.14e-07	1.74e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387944	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs833948	ENSG00000254531.1	FLJ20021	5.39	1.14e-07	1.74e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391529	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs293213	ENSG00000254531.1	FLJ20021	5.39	1.14e-07	1.74e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101393716	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs833946	ENSG00000254531.1	FLJ20021	5.39	1.14e-07	1.74e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395742	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs210811	ENSG00000254531.1	FLJ20021	5.39	1.14e-07	1.74e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395833	chr4:101347780~101348883:+
THCA	cis	rs728616	0.764	rs56196124	ENSG00000225484.5	NUTM2B-AS1	-5.39	1.14e-07	1.74e-05	-0.42	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142899	chr10:79663088~79826594:-
THCA	cis	rs61142792	0.59	rs747861	ENSG00000249109.1	RP11-1026M7.2	-5.39	1.14e-07	1.74e-05	-0.5	-0.24	Alzheimer disease and age of onset;	chr5:177610396	chr5:177782197~177794396:+
THCA	cis	rs2243480	1	rs67536397	ENSG00000232559.3	GS1-124K5.12	5.39	1.14e-07	1.74e-05	0.37	0.24	Diabetic kidney disease;	chr7:66482930	chr7:66554588~66576923:-
THCA	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	5.39	1.14e-07	1.74e-05	0.3	0.24	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
THCA	cis	rs9880211	0.8	rs35422852	ENSG00000273486.1	RP11-731C17.2	5.39	1.14e-07	1.74e-05	0.25	0.24	Height;Body mass index;	chr3:136787073	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs35880395	ENSG00000273486.1	RP11-731C17.2	5.39	1.14e-07	1.74e-05	0.25	0.24	Height;Body mass index;	chr3:136788248	chr3:136837338~136839021:-
THCA	cis	rs10090774	0.965	rs11167005	ENSG00000279766.1	RP11-642A1.2	5.39	1.14e-07	1.74e-05	0.3	0.24	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140873057	chr8:140572142~140572812:-
THCA	cis	rs12908161	0.959	rs11637728	ENSG00000275120.1	RP11-182J1.17	5.39	1.14e-07	1.74e-05	0.29	0.24	Schizophrenia;	chr15:84660161	chr15:84599434~84606463:-
THCA	cis	rs1580019	0.587	rs7805311	ENSG00000231952.3	DPY19L1P2	5.39	1.14e-07	1.74e-05	0.3	0.24	Cognitive ability;	chr7:32518690	chr7:32812757~32838570:+
THCA	cis	rs763121	0.853	rs4821810	ENSG00000235209.1	CTA-150C2.13	5.39	1.14e-07	1.74e-05	0.31	0.24	Menopause (age at onset);	chr22:38676093	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757234	ENSG00000235209.1	CTA-150C2.13	5.39	1.14e-07	1.74e-05	0.31	0.24	Menopause (age at onset);	chr22:38676681	chr22:38921227~38924708:+
THCA	cis	rs919433	1	rs1429414	ENSG00000231621.1	AC013264.2	5.39	1.14e-07	1.74e-05	0.24	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197297706	chr2:197197991~197199273:+
THCA	cis	rs2036707	1	rs58806855	ENSG00000276740.1	RP11-381O6.1	5.39	1.14e-07	1.74e-05	0.44	0.24	Obesity-related traits;	chr13:107831721	chr13:107465984~107466674:-
THCA	cis	rs9652601	0.959	rs12925642	ENSG00000274038.1	RP11-66H6.4	-5.39	1.15e-07	1.74e-05	-0.32	-0.24	Systemic lupus erythematosus;	chr16:11077745	chr16:11056556~11057034:+
THCA	cis	rs7615952	0.558	rs17334039	ENSG00000241288.6	RP11-379B18.5	-5.39	1.15e-07	1.74e-05	-0.28	-0.24	Blood pressure (smoking interaction);	chr3:125821465	chr3:125827238~125916384:-
THCA	cis	rs7523875	0.572	rs7533617	ENSG00000153363.11	LINC00467	-5.39	1.15e-07	1.74e-05	-0.3	-0.24	Mean corpuscular volume;	chr1:211443810	chr1:211382803~211435333:+
THCA	cis	rs6547741	1	rs1080060	ENSG00000234072.1	AC074117.10	5.39	1.15e-07	1.74e-05	0.18	0.24	Oral cavity cancer;	chr2:27545941	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs6749052	ENSG00000234072.1	AC074117.10	5.39	1.15e-07	1.74e-05	0.18	0.24	Oral cavity cancer;	chr2:27550012	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs6706610	ENSG00000234072.1	AC074117.10	5.39	1.15e-07	1.74e-05	0.18	0.24	Oral cavity cancer;	chr2:27555224	chr2:27356246~27367622:+
THCA	cis	rs890448	0.895	rs2465896	ENSG00000254531.1	FLJ20021	-5.39	1.15e-07	1.74e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101463875	chr4:101347780~101348883:+
THCA	cis	rs758747	0.514	rs735830	ENSG00000276754.1	RP11-461A8.5	5.38	1.15e-07	1.74e-05	0.24	0.24	Body mass index;	chr16:3645353	chr16:3686998~3687380:+
THCA	cis	rs10043228	0.702	rs77320865	ENSG00000248445.4	SEMA6A-AS1	-5.38	1.15e-07	1.75e-05	-0.26	-0.24	Asthma or chronic obstructive pulmonary disease;	chr5:116329449	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.51	rs62384495	ENSG00000248445.4	SEMA6A-AS1	-5.38	1.15e-07	1.75e-05	-0.26	-0.24	Asthma or chronic obstructive pulmonary disease;	chr5:116338573	chr5:116447547~116508276:+
THCA	cis	rs10208649	0.831	rs6545368	ENSG00000233266.1	HMGB1P31	5.38	1.15e-07	1.75e-05	0.43	0.24	Body mass index;	chr2:53813267	chr2:54051334~54051760:+
THCA	cis	rs7225151	0.518	rs56176579	ENSG00000234327.6	AC012146.7	-5.38	1.15e-07	1.75e-05	-0.23	-0.24	Alzheimer's disease (late onset);	chr17:5358958	chr17:5111468~5115004:+
THCA	cis	rs7772486	0.713	rs2328704	ENSG00000270638.1	RP3-466P17.1	-5.38	1.15e-07	1.75e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs6919684	ENSG00000270638.1	RP3-466P17.1	5.38	1.15e-07	1.75e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145735570~145737218:+
THCA	cis	rs6547741	1	rs7604798	ENSG00000234072.1	AC074117.10	5.38	1.15e-07	1.75e-05	0.18	0.24	Oral cavity cancer;	chr2:27602073	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs6547734	ENSG00000234072.1	AC074117.10	5.38	1.15e-07	1.75e-05	0.18	0.24	Oral cavity cancer;	chr2:27608123	chr2:27356246~27367622:+
THCA	cis	rs4718428	1	rs4718428	ENSG00000232546.1	RP11-458F8.1	-5.38	1.15e-07	1.75e-05	-0.2	-0.24	Corneal structure;	chr7:66956459	chr7:66848496~66858136:+
THCA	cis	rs4713118	0.911	rs9461406	ENSG00000226314.6	ZNF192P1	5.38	1.15e-07	1.75e-05	0.32	0.24	Parkinson's disease;	chr6:27751985	chr6:28161781~28169594:+
THCA	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-5.38	1.15e-07	1.75e-05	-0.21	-0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
THCA	cis	rs4925386	0.681	rs2427296	ENSG00000273619.1	RP5-908M14.9	-5.38	1.15e-07	1.75e-05	-0.21	-0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62386303~62386970:-
THCA	cis	rs4888671	1	rs17716789	ENSG00000261707.1	RP11-264M12.2	5.38	1.15e-07	1.75e-05	0.45	0.24	Obesity-related traits;	chr16:77735782	chr16:77741468~77743000:-
THCA	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-5.38	1.15e-07	1.75e-05	-0.25	-0.24	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
THCA	cis	rs875971	0.83	rs4718358	ENSG00000223473.2	GS1-124K5.3	5.38	1.15e-07	1.75e-05	0.16	0.24	Aortic root size;	chr7:66508681	chr7:66491049~66493566:-
THCA	cis	rs1479090	0.712	rs10006476	ENSG00000250027.1	RP11-563E2.2	-5.38	1.15e-07	1.75e-05	-0.25	-0.24	Lung cancer;	chr4:163099727	chr4:163108785~163119965:+
THCA	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-5.38	1.15e-07	1.75e-05	-0.41	-0.24	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
THCA	cis	rs2288884	0.505	rs2278415	ENSG00000269483.1	AC006272.1	5.38	1.15e-07	1.75e-05	0.38	0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964950	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.505	rs3764538	ENSG00000269483.1	AC006272.1	5.38	1.15e-07	1.75e-05	0.38	0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965334	chr19:51839924~51843324:-
THCA	cis	rs7005380	0.62	rs6987580	ENSG00000245330.4	KB-1471A8.1	-5.38	1.15e-07	1.75e-05	-0.24	-0.24	Interstitial lung disease;	chr8:119898140	chr8:119867419~119874488:-
THCA	cis	rs12893668	0.628	rs57072546	ENSG00000269958.1	RP11-73M18.8	5.38	1.15e-07	1.75e-05	0.23	0.24	Reticulocyte count;	chr14:103597386	chr14:103696353~103697163:+
THCA	cis	rs7826238	0.594	rs2948285	ENSG00000253981.4	ALG1L13P	5.38	1.15e-07	1.75e-05	0.23	0.24	Systolic blood pressure;	chr8:8273016	chr8:8236003~8244667:-
THCA	cis	rs7529073	1	rs7529073	ENSG00000274895.1	RP11-478J18.2	-5.38	1.15e-07	1.75e-05	-0.2	-0.24	Schizophrenia;	chr1:213974546	chr1:213983793~213986419:-
THCA	cis	rs7772486	0.686	rs9403741	ENSG00000270638.1	RP3-466P17.1	-5.38	1.15e-07	1.75e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs9485019	ENSG00000270638.1	RP3-466P17.1	-5.38	1.15e-07	1.75e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145735570~145737218:+
THCA	cis	rs66887589	0.776	rs10518337	ENSG00000248280.1	RP11-33B1.2	-5.38	1.15e-07	1.75e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119653719	chr4:119440561~119450157:-
THCA	cis	rs8177876	0.749	rs804895	ENSG00000261061.1	RP11-303E16.2	5.38	1.15e-07	1.75e-05	0.34	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81066108	chr16:81030770~81031485:+
THCA	cis	rs6490294	0.808	rs7137270	ENSG00000226469.1	ADAM1B	5.38	1.15e-07	1.76e-05	0.3	0.24	Mean platelet volume;	chr12:111825598	chr12:111927018~111929017:+
THCA	cis	rs739496	0.652	rs10849974	ENSG00000226469.1	ADAM1B	5.38	1.15e-07	1.76e-05	0.3	0.24	Platelet count;	chr12:111826354	chr12:111927018~111929017:+
THCA	cis	rs739496	0.615	rs57303367	ENSG00000226469.1	ADAM1B	5.38	1.15e-07	1.76e-05	0.3	0.24	Platelet count;	chr12:111827279	chr12:111927018~111929017:+
THCA	cis	rs739496	0.563	rs61547643	ENSG00000226469.1	ADAM1B	5.38	1.15e-07	1.76e-05	0.3	0.24	Platelet count;	chr12:111828820	chr12:111927018~111929017:+
THCA	cis	rs889122	0.531	rs8113425	ENSG00000267289.1	CTD-2623N2.11	-5.38	1.15e-07	1.76e-05	-0.27	-0.24	Menarche (age at onset);	chr19:9889630	chr19:9834079~9835013:-
THCA	cis	rs7246657	0.663	rs10408619	ENSG00000276846.1	CTD-3220F14.3	5.38	1.16e-07	1.76e-05	0.24	0.24	Coronary artery calcification;	chr19:37579573	chr19:37314868~37315620:-
THCA	cis	rs6901004	0.565	rs6900341	ENSG00000230177.1	RP5-1112D6.4	-5.38	1.16e-07	1.76e-05	-0.2	-0.24	Blood metabolite levels;	chr6:111473206	chr6:111277932~111278742:+
THCA	cis	rs6993270	0.779	rs73703619	ENSG00000245330.4	KB-1471A8.1	-5.38	1.16e-07	1.76e-05	-0.32	-0.24	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119916591	chr8:119867419~119874488:-
THCA	cis	rs9834975	0.967	rs6768280	ENSG00000272758.4	RP11-299J3.8	5.38	1.16e-07	1.76e-05	0.22	0.24	Diastolic blood pressure;	chr3:122406205	chr3:122416207~122443180:+
THCA	cis	rs4604234	0.803	rs3812123	ENSG00000272129.1	RP11-250B2.6	-5.38	1.16e-07	1.76e-05	-0.57	-0.24	Cancer;	chr6:80253240	chr6:80355424~80356859:+
THCA	cis	rs1479090	0.805	rs6811980	ENSG00000250027.1	RP11-563E2.2	-5.38	1.16e-07	1.76e-05	-0.25	-0.24	Lung cancer;	chr4:163113378	chr4:163108785~163119965:+
THCA	cis	rs4888671	1	rs4888667	ENSG00000261707.1	RP11-264M12.2	5.38	1.16e-07	1.76e-05	0.45	0.24	Obesity-related traits;	chr16:77745583	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs4888668	ENSG00000261707.1	RP11-264M12.2	5.38	1.16e-07	1.76e-05	0.45	0.24	Obesity-related traits;	chr16:77745584	chr16:77741468~77743000:-
THCA	cis	rs2243480	1	rs1499614	ENSG00000232559.3	GS1-124K5.12	5.38	1.16e-07	1.76e-05	0.36	0.24	Diabetic kidney disease;	chr7:66265811	chr7:66554588~66576923:-
THCA	cis	rs4591358	1	rs4591358	ENSG00000223466.1	AC064834.2	-5.38	1.16e-07	1.76e-05	-0.29	-0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195501166	chr2:195533035~195538681:+
THCA	cis	rs2179367	0.543	rs9498328	ENSG00000268592.3	RAET1E-AS1	5.38	1.16e-07	1.76e-05	0.35	0.24	Dupuytren's disease;	chr6:149348715	chr6:149863494~149919507:+
THCA	cis	rs875971	0.545	rs6460276	ENSG00000228409.4	CCT6P1	-5.38	1.16e-07	1.76e-05	-0.2	-0.24	Aortic root size;	chr7:66182290	chr7:65751142~65763354:+
THCA	cis	rs7119	0.717	rs12904348	ENSG00000259362.2	RP11-307C19.1	-5.38	1.16e-07	1.76e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77523396	chr15:77525540~77534110:+
THCA	cis	rs7078012	0.504	rs117047841	ENSG00000225484.5	NUTM2B-AS1	-5.38	1.16e-07	1.77e-05	-0.56	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79905900	chr10:79663088~79826594:-
THCA	cis	rs9595908	0.863	rs11616287	ENSG00000212293.1	SNORA16	5.38	1.16e-07	1.77e-05	0.29	0.24	Body mass index;	chr13:32580139	chr13:32420390~32420516:-
THCA	cis	rs1979679	0.541	rs7956757	ENSG00000247934.4	RP11-967K21.1	5.38	1.16e-07	1.77e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28570071	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.608	rs1581073	ENSG00000247934.4	RP11-967K21.1	5.38	1.16e-07	1.77e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28571106	chr12:28163298~28190738:-
THCA	cis	rs875971	0.66	rs7807930	ENSG00000273142.1	RP11-458F8.4	5.38	1.16e-07	1.77e-05	0.19	0.24	Aortic root size;	chr7:66622178	chr7:66902857~66906297:+
THCA	cis	rs4683346	0.616	rs3846063	ENSG00000173811.9	CCDC13-AS1	5.38	1.16e-07	1.77e-05	0.25	0.24	Granulocyte percentage of myeloid white cells;	chr3:42762336	chr3:42732575~42746768:+
THCA	cis	rs28386778	0.965	rs2854154	ENSG00000240280.5	TCAM1P	5.38	1.17e-07	1.77e-05	0.34	0.24	Prudent dietary pattern;	chr17:63904336	chr17:63849292~63864379:+
THCA	cis	rs7225151	0.517	rs75855990	ENSG00000234327.6	AC012146.7	-5.38	1.17e-07	1.77e-05	-0.26	-0.24	Alzheimer's disease (late onset);	chr17:5359952	chr17:5111468~5115004:+
THCA	cis	rs728616	0.681	rs12769764	ENSG00000242600.5	MBL1P	5.38	1.17e-07	1.77e-05	0.22	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80157357	chr10:79904898~79950336:+
THCA	cis	rs613391	0.561	rs471112	ENSG00000224549.1	RP11-370B11.3	-5.38	1.17e-07	1.77e-05	-0.27	-0.24	Quantitative traits;	chr9:22720808	chr9:22767175~22768316:+
THCA	cis	rs613391	0.561	rs590268	ENSG00000224549.1	RP11-370B11.3	-5.38	1.17e-07	1.77e-05	-0.27	-0.24	Quantitative traits;	chr9:22720861	chr9:22767175~22768316:+
THCA	cis	rs12681287	0.57	rs4961188	ENSG00000254231.1	CTD-2284J15.1	-5.38	1.17e-07	1.77e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86370804	chr8:86333274~86343314:-
THCA	cis	rs875971	0.545	rs73376401	ENSG00000232546.1	RP11-458F8.1	5.38	1.17e-07	1.78e-05	0.23	0.24	Aortic root size;	chr7:66174841	chr7:66848496~66858136:+
THCA	cis	rs897984	0.683	rs8046001	ENSG00000279196.1	RP11-1072A3.3	5.38	1.17e-07	1.78e-05	0.24	0.24	Dementia with Lewy bodies;	chr16:30822000	chr16:30984630~30988270:-
THCA	cis	rs8014252	0.667	rs8014459	ENSG00000259158.2	ADAM20P1	-5.38	1.17e-07	1.78e-05	-0.26	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70315497	chr14:70468881~70483756:-
THCA	cis	rs3950186	0.834	rs1569731	ENSG00000215124.2	RP3-420J14.1	-5.38	1.17e-07	1.78e-05	-0.27	-0.24	Anxiety and major depressive disorder;	chr6:11825181	chr6:11861626~11862970:-
THCA	cis	rs890448	0.93	rs6532941	ENSG00000254531.1	FLJ20021	-5.38	1.17e-07	1.78e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101492469	chr4:101347780~101348883:+
THCA	cis	rs890448	0.93	rs10012311	ENSG00000254531.1	FLJ20021	-5.38	1.17e-07	1.78e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101493140	chr4:101347780~101348883:+
THCA	cis	rs1707322	0.927	rs6690386	ENSG00000281133.1	AL355480.3	-5.38	1.17e-07	1.78e-05	-0.3	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45580892~45580996:-
THCA	cis	rs755249	0.53	rs112205225	ENSG00000228060.1	RP11-69E11.8	-5.38	1.17e-07	1.78e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39121716	chr1:39565160~39573203:+
THCA	cis	rs10829156	0.607	rs7908550	ENSG00000240291.1	RP11-499P20.2	5.38	1.17e-07	1.78e-05	0.21	0.24	Sudden cardiac arrest;	chr10:18573282	chr10:18513115~18545651:-
THCA	cis	rs4934494	0.677	rs72818709	ENSG00000232936.4	RP11-80H5.2	5.38	1.17e-07	1.78e-05	0.33	0.24	Red blood cell count;	chr10:89611689	chr10:89645282~89650667:+
THCA	cis	rs6657613	0.967	rs7550758	ENSG00000186301.8	MST1P2	5.38	1.17e-07	1.78e-05	0.2	0.24	Hip circumference adjusted for BMI;	chr1:17000934	chr1:16645622~16650289:+
THCA	cis	rs6657613	1	rs6657613	ENSG00000186301.8	MST1P2	5.38	1.17e-07	1.78e-05	0.2	0.24	Hip circumference adjusted for BMI;	chr1:17001705	chr1:16645622~16650289:+
THCA	cis	rs7911264	0.967	rs9419741	ENSG00000236493.2	EIF2S2P3	-5.38	1.17e-07	1.78e-05	-0.25	-0.24	Inflammatory bowel disease;	chr10:92670768	chr10:92668745~92669743:-
THCA	cis	rs10208649	1	rs73937421	ENSG00000233266.1	HMGB1P31	5.38	1.17e-07	1.78e-05	0.64	0.24	Body mass index;	chr2:53861798	chr2:54051334~54051760:+
THCA	cis	rs6802315	0.604	rs9881462	ENSG00000272087.1	RP11-379F4.7	5.38	1.17e-07	1.78e-05	0.21	0.24	Periodontitis (CDC/AAP);	chr3:158763333	chr3:158693120~158693768:-
THCA	cis	rs860295	0.651	rs6677385	ENSG00000160766.13	GBAP1	-5.38	1.17e-07	1.78e-05	-0.28	-0.24	Body mass index;	chr1:155334790	chr1:155213821~155227422:-
THCA	cis	rs7727544	0.582	rs10075459	ENSG00000224431.1	AC063976.7	5.38	1.17e-07	1.78e-05	0.2	0.24	Blood metabolite levels;	chr5:132205670	chr5:132199456~132203487:+
THCA	cis	rs2562456	0.833	rs1781872	ENSG00000268119.4	CTD-2561J22.5	5.38	1.17e-07	1.78e-05	0.35	0.24	Pain;	chr19:21294601	chr19:21444241~21463908:-
THCA	cis	rs73198271	0.773	rs66618176	ENSG00000253893.2	FAM85B	5.38	1.18e-07	1.78e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8167819~8226614:-
THCA	cis	rs7209700	0.708	rs15908	ENSG00000228782.6	CTD-2026D20.3	-5.38	1.18e-07	1.79e-05	-0.23	-0.24	IgG glycosylation;	chr17:47290971	chr17:47450568~47492492:-
THCA	cis	rs4693089	0.564	rs480972	ENSG00000213608.5	SLC25A14P1	5.38	1.18e-07	1.79e-05	0.28	0.24	Menopause (age at onset);	chr4:83502552	chr4:83477524~83478424:+
THCA	cis	rs9392556	0.6	rs664299	ENSG00000230648.1	RP3-406P24.3	5.38	1.18e-07	1.79e-05	0.29	0.24	Blood metabolite levels;	chr6:4112007	chr6:4018843~4021215:-
THCA	cis	rs9392556	0.533	rs619439	ENSG00000230648.1	RP3-406P24.3	5.38	1.18e-07	1.79e-05	0.29	0.24	Blood metabolite levels;	chr6:4113695	chr6:4018843~4021215:-
THCA	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	5.38	1.18e-07	1.79e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
THCA	cis	rs2282300	0.739	rs35229181	ENSG00000242353.1	RP4-710M3.1	-5.38	1.18e-07	1.79e-05	-0.24	-0.24	Morning vs. evening chronotype;	chr11:30220151	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs34234618	ENSG00000242353.1	RP4-710M3.1	-5.38	1.18e-07	1.79e-05	-0.24	-0.24	Morning vs. evening chronotype;	chr11:30220154	chr11:30368148~30368646:+
THCA	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	5.38	1.18e-07	1.79e-05	0.34	0.24	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
THCA	cis	rs6453278	0.961	rs6453277	ENSG00000250802.5	ZBED3-AS1	5.38	1.18e-07	1.79e-05	0.22	0.24	Autism;	chr5:77121056	chr5:77086740~77166909:+
THCA	cis	rs6496044	0.547	rs7173125	ENSG00000259630.2	CTD-2262B20.1	5.38	1.18e-07	1.79e-05	0.27	0.24	Interstitial lung disease;	chr15:85512214	chr15:85415228~85415633:+
THCA	cis	rs7202877	0.656	rs4888370	ENSG00000261783.1	RP11-252K23.2	-5.38	1.18e-07	1.79e-05	-0.42	-0.24	Type 1 diabetes;Type 2 diabetes;	chr16:75274332	chr16:75379818~75381260:-
THCA	cis	rs9921338	0.887	rs13330151	ENSG00000262703.1	RP11-485G7.6	-5.38	1.18e-07	1.79e-05	-0.32	-0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11308542	chr16:11348143~11349321:-
THCA	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	5.38	1.18e-07	1.79e-05	0.15	0.24	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
THCA	cis	rs7829975	0.573	rs7842359	ENSG00000233609.3	RP11-62H7.2	-5.38	1.18e-07	1.79e-05	-0.24	-0.24	Mood instability;	chr8:8939568	chr8:8961200~8979025:+
THCA	cis	rs875971	0.867	rs1002053	ENSG00000223473.2	GS1-124K5.3	-5.38	1.18e-07	1.79e-05	-0.16	-0.24	Aortic root size;	chr7:66333558	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs6460292	ENSG00000223473.2	GS1-124K5.3	-5.38	1.18e-07	1.79e-05	-0.16	-0.24	Aortic root size;	chr7:66345088	chr7:66491049~66493566:-
THCA	cis	rs67478160	0.572	rs8016014	ENSG00000258735.1	LINC00637	-5.38	1.18e-07	1.79e-05	-0.29	-0.24	Schizophrenia;	chr14:103827461	chr14:103847721~103858049:+
THCA	cis	rs12497850	0.764	rs6784111	ENSG00000229759.1	MRPS18AP1	5.38	1.18e-07	1.79e-05	0.32	0.24	Parkinson's disease;	chr3:49141413	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.864	rs12493001	ENSG00000229759.1	MRPS18AP1	5.38	1.18e-07	1.79e-05	0.32	0.24	Parkinson's disease;	chr3:49144452	chr3:48256350~48256938:-
THCA	cis	rs12497850	0.829	rs12636030	ENSG00000229759.1	MRPS18AP1	5.38	1.18e-07	1.79e-05	0.32	0.24	Parkinson's disease;	chr3:49144804	chr3:48256350~48256938:-
THCA	cis	rs2933343	0.818	rs6764681	ENSG00000261159.1	RP11-723O4.9	-5.38	1.18e-07	1.79e-05	-0.28	-0.24	IgG glycosylation;	chr3:128849537	chr3:128859716~128860526:-
THCA	cis	rs755249	0.567	rs4660546	ENSG00000228060.1	RP11-69E11.8	-5.38	1.18e-07	1.79e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39565160~39573203:+
THCA	cis	rs1198430	0.562	rs10799795	ENSG00000232482.2	RP4-654C18.1	-5.38	1.18e-07	1.79e-05	-0.34	-0.24	Total cholesterol levels;	chr1:23447505	chr1:23410832~23412146:+
THCA	cis	rs7824557	0.652	rs12677504	ENSG00000154316.13	TDH	5.38	1.18e-07	1.79e-05	0.18	0.24	Retinal vascular caliber;	chr8:11275666	chr8:11339637~11368452:+
THCA	cis	rs6957923	0.659	rs10280508	ENSG00000234286.1	AC006026.13	-5.38	1.18e-07	1.79e-05	-0.29	-0.24	Height;	chr7:23544439	chr7:23680195~23680786:-
THCA	cis	rs7829975	0.582	rs448231	ENSG00000253981.4	ALG1L13P	-5.38	1.18e-07	1.79e-05	-0.24	-0.24	Mood instability;	chr8:8932549	chr8:8236003~8244667:-
THCA	cis	rs2299587	0.689	rs2299588	ENSG00000253671.1	RP11-806O11.1	-5.38	1.18e-07	1.79e-05	-0.29	-0.24	Economic and political preferences;	chr8:17944216	chr8:17808941~17820868:+
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000232546.1	RP11-458F8.1	-5.38	1.18e-07	1.79e-05	-0.32	-0.24	Gout;	chr7:66732812	chr7:66848496~66858136:+
THCA	cis	rs9834975	0.815	rs9874163	ENSG00000272758.4	RP11-299J3.8	-5.38	1.18e-07	1.79e-05	-0.23	-0.24	Diastolic blood pressure;	chr3:122386581	chr3:122416207~122443180:+
THCA	cis	rs17345786	0.906	rs72940399	ENSG00000256628.3	ZBTB11-AS1	5.38	1.18e-07	1.8e-05	0.3	0.24	Colonoscopy-negative controls vs population controls;	chr3:101403731	chr3:101676475~101679217:+
THCA	cis	rs4654783	0.505	rs7544210	ENSG00000218510.5	LINC00339	5.38	1.18e-07	1.8e-05	0.25	0.24	Endometriosis;	chr1:22128649	chr1:22025188~22031223:+
THCA	cis	rs7829975	0.509	rs7838674	ENSG00000233609.3	RP11-62H7.2	-5.38	1.18e-07	1.8e-05	-0.24	-0.24	Mood instability;	chr8:8939563	chr8:8961200~8979025:+
THCA	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	5.38	1.18e-07	1.8e-05	0.36	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
THCA	cis	rs1865760	0.613	rs9379805	ENSG00000272462.2	U91328.19	-5.38	1.18e-07	1.8e-05	-0.19	-0.24	Height;	chr6:25938536	chr6:25992662~26001775:+
THCA	cis	rs4460629	0.71	rs11264318	ENSG00000160766.13	GBAP1	-5.38	1.18e-07	1.8e-05	-0.27	-0.24	Serum magnesium levels;	chr1:155111241	chr1:155213821~155227422:-
THCA	cis	rs10461617	0.541	rs860581	ENSG00000271828.1	CTD-2310F14.1	5.38	1.18e-07	1.8e-05	0.42	0.24	Type 2 diabetes;	chr5:56854710	chr5:56927874~56929573:+
THCA	cis	rs4748857	0.947	rs7089898	ENSG00000224215.1	RP11-371A19.2	-5.38	1.19e-07	1.8e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23302436	chr10:23343957~23345181:+
THCA	cis	rs453301	0.653	rs11784393	ENSG00000254153.1	CTA-398F10.2	-5.38	1.19e-07	1.8e-05	-0.25	-0.24	Joint mobility (Beighton score);	chr8:9045624	chr8:8456909~8461337:-
THCA	cis	rs4713118	0.955	rs9468203	ENSG00000226314.6	ZNF192P1	-5.38	1.19e-07	1.8e-05	-0.3	-0.24	Parkinson's disease;	chr6:27720888	chr6:28161781~28169594:+
THCA	cis	rs2303319	0.504	rs13417851	ENSG00000227403.1	AC009299.3	5.38	1.19e-07	1.8e-05	0.47	0.24	Cognitive function;	chr2:161703409	chr2:161244739~161249050:+
THCA	cis	rs10895275	0.961	rs10895278	ENSG00000277459.1	RP11-732A21.3	-5.38	1.19e-07	1.8e-05	-0.19	-0.24	Migraine;	chr11:102224604	chr11:102109827~102110457:-
THCA	cis	rs935334	0.866	rs12587652	ENSG00000258454.1	RP11-361H10.3	-5.38	1.19e-07	1.8e-05	-0.34	-0.24	Blood pressure;	chr14:76222270	chr14:76235817~76263474:+
THCA	cis	rs7250849	0.565	rs73052859	ENSG00000273837.1	LLNLR-470E3.1	-5.38	1.19e-07	1.8e-05	-0.35	-0.24	Blood protein levels;	chr19:51661210	chr19:51639478~51639931:-
THCA	cis	rs7250849	0.565	rs73052861	ENSG00000273837.1	LLNLR-470E3.1	-5.38	1.19e-07	1.8e-05	-0.35	-0.24	Blood protein levels;	chr19:51661217	chr19:51639478~51639931:-
THCA	cis	rs2797160	0.714	rs1777220	ENSG00000237742.5	RP11-624M8.1	5.38	1.19e-07	1.8e-05	0.21	0.24	Endometrial cancer;	chr6:125701456	chr6:125578558~125749190:-
THCA	cis	rs748404	0.666	rs12899865	ENSG00000249839.1	AC011330.5	-5.38	1.19e-07	1.8e-05	-0.35	-0.24	Lung cancer;	chr15:43448819	chr15:43663654~43684339:-
THCA	cis	rs8042680	0.592	rs2001217	ENSG00000214432.8	AC068831.10	5.38	1.19e-07	1.81e-05	0.25	0.24	Type 2 diabetes;	chr15:90955016	chr15:91022619~91036611:+
THCA	cis	rs875971	0.545	rs2420456	ENSG00000228409.4	CCT6P1	-5.38	1.19e-07	1.81e-05	-0.2	-0.24	Aortic root size;	chr7:66280619	chr7:65751142~65763354:+
THCA	cis	rs2562456	0.833	rs62110367	ENSG00000268081.1	RP11-678G14.2	5.38	1.19e-07	1.81e-05	0.41	0.24	Pain;	chr19:21365829	chr19:21554640~21569237:-
THCA	cis	rs2239547	0.522	rs2581779	ENSG00000242142.1	SERBP1P3	-5.38	1.19e-07	1.81e-05	-0.31	-0.24	Schizophrenia;	chr3:53022183	chr3:53064283~53065091:-
THCA	cis	rs12935418	0.887	rs2873310	ENSG00000261061.1	RP11-303E16.2	5.38	1.19e-07	1.81e-05	0.3	0.24	Mean corpuscular volume;	chr16:81038540	chr16:81030770~81031485:+
THCA	cis	rs1552244	1	rs12152512	ENSG00000232901.1	CYCSP10	5.38	1.19e-07	1.81e-05	0.32	0.24	Alzheimer's disease;	chr3:10102086	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs12152515	ENSG00000232901.1	CYCSP10	5.38	1.19e-07	1.81e-05	0.32	0.24	Alzheimer's disease;	chr3:10102292	chr3:10000647~10000940:-
THCA	cis	rs752010	0.695	rs11210509	ENSG00000230638.4	RP11-486B10.4	-5.38	1.19e-07	1.81e-05	-0.27	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41643640	chr1:41542069~41544310:+
THCA	cis	rs17123764	0.818	rs12321819	ENSG00000257464.1	RP11-161H23.8	-5.38	1.19e-07	1.81e-05	-0.39	-0.24	Intelligence (multi-trait analysis);	chr12:49548214	chr12:49442424~49442652:-
THCA	cis	rs755249	0.567	rs4660603	ENSG00000228060.1	RP11-69E11.8	5.38	1.19e-07	1.81e-05	0.26	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39565160~39573203:+
THCA	cis	rs4748857	0.947	rs4237360	ENSG00000224215.1	RP11-371A19.2	-5.38	1.19e-07	1.81e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23258590	chr10:23343957~23345181:+
THCA	cis	rs875971	0.964	rs60193905	ENSG00000223473.2	GS1-124K5.3	5.38	1.2e-07	1.81e-05	0.16	0.24	Aortic root size;	chr7:66506273	chr7:66491049~66493566:-
THCA	cis	rs875971	0.929	rs10950041	ENSG00000223473.2	GS1-124K5.3	5.38	1.2e-07	1.81e-05	0.16	0.24	Aortic root size;	chr7:66508888	chr7:66491049~66493566:-
THCA	cis	rs79040073	0.637	rs77408643	ENSG00000259531.2	RP11-295H24.3	5.38	1.2e-07	1.81e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49377226	chr15:49365124~49366685:-
THCA	cis	rs613391	0.561	rs682908	ENSG00000224549.1	RP11-370B11.3	-5.38	1.2e-07	1.82e-05	-0.27	-0.24	Quantitative traits;	chr9:22721975	chr9:22767175~22768316:+
THCA	cis	rs62432291	0.681	rs436277	ENSG00000235086.1	FNDC1-IT1	5.38	1.2e-07	1.82e-05	0.45	0.24	Joint mobility (Beighton score);	chr6:159213110	chr6:159240786~159243329:+
THCA	cis	rs1552244	1	rs67006488	ENSG00000232901.1	CYCSP10	5.38	1.2e-07	1.82e-05	0.32	0.24	Alzheimer's disease;	chr3:10111309	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs6764068	ENSG00000232901.1	CYCSP10	5.38	1.2e-07	1.82e-05	0.32	0.24	Alzheimer's disease;	chr3:10112158	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs113522867	ENSG00000232901.1	CYCSP10	5.38	1.2e-07	1.82e-05	0.32	0.24	Alzheimer's disease;	chr3:10112819	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs41520445	ENSG00000232901.1	CYCSP10	-5.38	1.2e-07	1.82e-05	-0.32	-0.24	Alzheimer's disease;	chr3:10111457	chr3:10000647~10000940:-
THCA	cis	rs1580019	0.563	rs896137	ENSG00000231952.3	DPY19L1P2	-5.38	1.2e-07	1.82e-05	-0.3	-0.24	Cognitive ability;	chr7:32539733	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.523	rs9791770	ENSG00000231952.3	DPY19L1P2	-5.38	1.2e-07	1.82e-05	-0.3	-0.24	Cognitive ability;	chr7:32542640	chr7:32812757~32838570:+
THCA	cis	rs390966	1	rs390966	ENSG00000205847.5	OR7E91P	-5.38	1.2e-07	1.82e-05	-0.29	-0.24	Erythema nodosum in inflammatory bowel disease;	chr2:71028561	chr2:71029028~71029893:+
THCA	cis	rs7267979	0.565	rs13040726	ENSG00000125804.12	FAM182A	5.38	1.2e-07	1.82e-05	0.31	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26054655~26086917:+
THCA	cis	rs2337406	1	rs17112416	ENSG00000211974.3	IGHV2-70	5.38	1.2e-07	1.82e-05	0.24	0.24	Alzheimer's disease (late onset);	chr14:106686773	chr14:106723574~106724093:-
THCA	cis	rs4950322	0.542	rs1932977	ENSG00000271721.1	RP11-337C18.9	5.38	1.2e-07	1.82e-05	0.26	0.24	Protein quantitative trait loci;	chr1:147217371	chr1:147175602~147177740:+
THCA	cis	rs4415084	0.834	rs7711136	ENSG00000272335.1	RP11-53O19.3	-5.38	1.2e-07	1.82e-05	-0.2	-0.24	Breast cancer;	chr5:44822977	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.834	rs7730841	ENSG00000272335.1	RP11-53O19.3	-5.38	1.2e-07	1.82e-05	-0.2	-0.24	Breast cancer;	chr5:44823032	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.834	rs10512865	ENSG00000272335.1	RP11-53O19.3	-5.38	1.2e-07	1.82e-05	-0.2	-0.24	Breast cancer;	chr5:44823265	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.834	rs6867533	ENSG00000272335.1	RP11-53O19.3	-5.38	1.2e-07	1.82e-05	-0.2	-0.24	Breast cancer;	chr5:44827190	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.834	rs1048758	ENSG00000272335.1	RP11-53O19.3	-5.38	1.2e-07	1.82e-05	-0.2	-0.24	Breast cancer;	chr5:44828492	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.834	rs7380559	ENSG00000272335.1	RP11-53O19.3	5.38	1.2e-07	1.82e-05	0.2	0.24	Breast cancer;	chr5:44836908	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.744	rs1371023	ENSG00000272335.1	RP11-53O19.3	5.38	1.2e-07	1.82e-05	0.2	0.24	Breast cancer;	chr5:44846473	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.804	rs10077814	ENSG00000272335.1	RP11-53O19.3	5.38	1.2e-07	1.82e-05	0.2	0.24	Breast cancer;	chr5:44916687	chr5:44826076~44828592:+
THCA	cis	rs944289	0.74	rs56400346	ENSG00000258844.1	RP11-259K15.2	5.38	1.2e-07	1.82e-05	0.22	0.24	Thyroid cancer;	chr14:36114681	chr14:36214607~36235608:+
THCA	cis	rs11089937	0.553	rs35336247	ENSG00000211638.2	IGLV8-61	-5.38	1.2e-07	1.82e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.553	rs34088081	ENSG00000211638.2	IGLV8-61	-5.38	1.2e-07	1.82e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22098700~22099212:+
THCA	cis	rs7129556	0.815	rs72947625	ENSG00000254691.1	RP11-91P24.5	5.38	1.2e-07	1.82e-05	0.35	0.24	Weight loss (gastric bypass surgery);	chr11:77688557	chr11:77850604~77851511:+
THCA	cis	rs2136613	0.751	rs1571921	ENSG00000238280.1	RP11-436D10.3	5.38	1.2e-07	1.82e-05	0.28	0.24	Selective IgA deficiency;	chr10:62850893	chr10:62793562~62805887:-
THCA	cis	rs6430585	0.528	rs3098102	ENSG00000231890.6	DARS-AS1	-5.38	1.2e-07	1.82e-05	-0.27	-0.24	Corneal structure;	chr2:135897263	chr2:135985176~136022593:+
THCA	cis	rs853679	0.599	rs202906	ENSG00000226314.6	ZNF192P1	5.38	1.2e-07	1.82e-05	0.37	0.24	Depression;	chr6:28043874	chr6:28161781~28169594:+
THCA	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	5.38	1.2e-07	1.82e-05	0.34	0.24	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	5.38	1.2e-07	1.82e-05	0.34	0.24	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	5.38	1.2e-07	1.82e-05	0.34	0.24	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
THCA	cis	rs7727544	0.548	rs35696821	ENSG00000233006.5	AC034220.3	5.38	1.2e-07	1.82e-05	0.18	0.24	Blood metabolite levels;	chr5:132172324	chr5:132311285~132369916:-
THCA	cis	rs6430585	0.583	rs4988145	ENSG00000231890.6	DARS-AS1	-5.38	1.2e-07	1.82e-05	-0.29	-0.24	Corneal structure;	chr2:135874730	chr2:135985176~136022593:+
THCA	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-5.38	1.2e-07	1.82e-05	-0.21	-0.24	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
THCA	cis	rs6600671	0.692	rs11249430	ENSG00000275538.1	RNVU1-19	5.38	1.2e-07	1.82e-05	0.32	0.24	Hip geometry;	chr1:121547115	chr1:120850819~120850985:-
THCA	cis	rs11089937	0.597	rs5756991	ENSG00000211639.2	IGLV4-60	5.38	1.2e-07	1.82e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.54	rs5756992	ENSG00000211639.2	IGLV4-60	5.38	1.2e-07	1.82e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs9622919	ENSG00000211639.2	IGLV4-60	5.38	1.2e-07	1.82e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs9619793	ENSG00000211639.2	IGLV4-60	5.38	1.2e-07	1.82e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22162199~22162681:+
THCA	cis	rs2281603	1	rs2281603	ENSG00000272909.1	CTD-2555O16.4	-5.38	1.2e-07	1.82e-05	-0.31	-0.24	Lymphocyte counts;	chr14:64459379	chr14:64440369~64442238:-
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000232559.3	GS1-124K5.12	5.38	1.2e-07	1.82e-05	0.37	0.24	Diabetic kidney disease;	chr7:66474549	chr7:66554588~66576923:-
THCA	cis	rs5751614	0.537	rs5996508	ENSG00000230701.2	FBXW4P1	5.38	1.2e-07	1.82e-05	0.28	0.24	Height;	chr22:23270441	chr22:23262767~23265005:+
THCA	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	5.38	1.2e-07	1.82e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
THCA	cis	rs4415084	0.834	rs1438820	ENSG00000272335.1	RP11-53O19.3	-5.38	1.2e-07	1.82e-05	-0.2	-0.24	Breast cancer;	chr5:44797668	chr5:44826076~44828592:+
THCA	cis	rs17818399	0.926	rs7590693	ENSG00000279254.1	RP11-536C12.1	-5.38	1.2e-07	1.82e-05	-0.25	-0.24	Height;	chr2:46596853	chr2:46668870~46670778:+
THCA	cis	rs2120243	0.572	rs6441129	ENSG00000244515.1	KRT18P34	5.38	1.2e-07	1.83e-05	0.29	0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157408039	chr3:157162663~157163932:-
THCA	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	5.38	1.2e-07	1.83e-05	0.28	0.24	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
THCA	cis	rs1075232	1	rs66581165	ENSG00000215302.7	CTD-3092A11.1	-5.38	1.2e-07	1.83e-05	-0.53	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30470779~30507623:+
THCA	cis	rs2243480	1	rs709607	ENSG00000228409.4	CCT6P1	-5.38	1.2e-07	1.83e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65984554	chr7:65751142~65763354:+
THCA	cis	rs35934224	0.724	rs35374520	ENSG00000232926.1	AC000078.5	5.38	1.21e-07	1.83e-05	0.27	0.24	Glaucoma (primary open-angle);	chr22:19863626	chr22:19887289~19887970:+
THCA	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	5.38	1.21e-07	1.83e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
THCA	cis	rs34779708	0.931	rs17583009	ENSG00000271335.4	RP11-324I22.4	5.38	1.21e-07	1.83e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.898	rs11595898	ENSG00000271335.4	RP11-324I22.4	5.38	1.21e-07	1.83e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs35886556	ENSG00000271335.4	RP11-324I22.4	5.38	1.21e-07	1.83e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35314552~35336401:-
THCA	cis	rs875971	0.545	rs17138156	ENSG00000228409.4	CCT6P1	-5.38	1.21e-07	1.83e-05	-0.2	-0.24	Aortic root size;	chr7:66249708	chr7:65751142~65763354:+
THCA	cis	rs7727544	0.582	rs2278398	ENSG00000224431.1	AC063976.7	-5.38	1.21e-07	1.83e-05	-0.2	-0.24	Blood metabolite levels;	chr5:132194748	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.57	rs7701237	ENSG00000224431.1	AC063976.7	5.38	1.21e-07	1.83e-05	0.2	0.24	Blood metabolite levels;	chr5:132198688	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.582	rs3749756	ENSG00000224431.1	AC063976.7	5.38	1.21e-07	1.83e-05	0.2	0.24	Blood metabolite levels;	chr5:132198806	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.582	rs3805683	ENSG00000224431.1	AC063976.7	5.38	1.21e-07	1.83e-05	0.2	0.24	Blood metabolite levels;	chr5:132199432	chr5:132199456~132203487:+
THCA	cis	rs9467773	1	rs6922824	ENSG00000261353.1	CTA-14H9.5	5.38	1.21e-07	1.83e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26527063~26527404:+
THCA	cis	rs849141	0.89	rs481806	ENSG00000234336.5	JAZF1-AS1	-5.38	1.21e-07	1.83e-05	-0.28	-0.24	Height;Hip circumference adjusted for BMI;	chr7:28167681	chr7:28180322~28243917:+
THCA	cis	rs2252521	0.524	rs2214973	ENSG00000272568.4	CTB-113D17.1	5.37	1.21e-07	1.83e-05	0.27	0.24	Cognitive performance;	chr7:29020275	chr7:28979967~29013367:+
THCA	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	5.37	1.21e-07	1.83e-05	0.15	0.24	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
THCA	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	5.37	1.21e-07	1.83e-05	0.15	0.24	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
THCA	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	5.37	1.21e-07	1.83e-05	0.15	0.24	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	5.37	1.21e-07	1.83e-05	0.15	0.24	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	5.37	1.21e-07	1.83e-05	0.15	0.24	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
THCA	cis	rs9880211	0.8	rs9819856	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136773307	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs36109616	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136773561	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs35198484	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136773795	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs79876804	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136775308	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs75901823	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136775309	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.706	rs35716521	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136775828	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs35210994	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136777294	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs17365792	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136778550	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs1872239	ENSG00000273486.1	RP11-731C17.2	5.37	1.21e-07	1.83e-05	0.25	0.24	Height;Body mass index;	chr3:136785069	chr3:136837338~136839021:-
THCA	cis	rs4857855	0.716	rs4634139	ENSG00000239405.1	TMED10P2	5.37	1.21e-07	1.83e-05	0.33	0.24	Eosinophil counts;	chr3:128513631	chr3:128538020~128538631:+
THCA	cis	rs2337406	0.706	rs74090742	ENSG00000274576.2	IGHV2-70	-5.37	1.21e-07	1.83e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106696601	chr14:106770577~106771020:-
THCA	cis	rs17123764	0.71	rs60402517	ENSG00000257464.1	RP11-161H23.8	-5.37	1.21e-07	1.83e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49704688	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs4584654	ENSG00000257464.1	RP11-161H23.8	-5.37	1.21e-07	1.83e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49709763	chr12:49442424~49442652:-
THCA	cis	rs12435908	1	rs11844348	ENSG00000276116.2	FUT8-AS1	-5.37	1.21e-07	1.83e-05	-0.39	-0.24	Ischemic stroke;	chr14:65392762	chr14:65411170~65412690:-
THCA	cis	rs4908768	0.501	rs6577499	ENSG00000232912.4	RP5-1115A15.1	-5.37	1.21e-07	1.84e-05	-0.23	-0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8424645~8434838:+
THCA	cis	rs10895275	0.961	rs10895277	ENSG00000277459.1	RP11-732A21.3	-5.37	1.21e-07	1.84e-05	-0.19	-0.24	Migraine;	chr11:102214209	chr11:102109827~102110457:-
THCA	cis	rs73198271	0.855	rs57301822	ENSG00000253893.2	FAM85B	5.37	1.21e-07	1.84e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8167819~8226614:-
THCA	cis	rs2299587	0.662	rs6586671	ENSG00000253671.1	RP11-806O11.1	-5.37	1.21e-07	1.84e-05	-0.28	-0.24	Economic and political preferences;	chr8:17918575	chr8:17808941~17820868:+
THCA	cis	rs17767392	0.846	rs34911660	ENSG00000259146.3	RP1-261D10.2	5.37	1.21e-07	1.84e-05	0.3	0.24	Mitral valve prolapse;	chr14:71285627	chr14:71292729~71321814:-
THCA	cis	rs72949976	0.606	rs11898263	ENSG00000270659.1	RP11-105N14.1	-5.37	1.21e-07	1.84e-05	-0.19	-0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213165925	chr2:213152970~213153659:+
THCA	cis	rs55704346	0.811	rs11726777	ENSG00000281501.1	SEPSECS-AS1	5.37	1.21e-07	1.84e-05	0.27	0.24	Tonsillectomy;	chr4:25178165	chr4:25160641~25201440:+
THCA	cis	rs7772486	0.686	rs1045820	ENSG00000270638.1	RP3-466P17.1	5.37	1.21e-07	1.84e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs6570703	ENSG00000270638.1	RP3-466P17.1	5.37	1.21e-07	1.84e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs6570705	ENSG00000270638.1	RP3-466P17.1	5.37	1.21e-07	1.84e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145735570~145737218:+
THCA	cis	rs4713118	0.513	rs156738	ENSG00000220721.1	OR1F12	5.37	1.21e-07	1.84e-05	0.29	0.24	Parkinson's disease;	chr6:28046247	chr6:28073316~28074233:+
THCA	cis	rs7403037	0.761	rs61995448	ENSG00000259905.4	PWRN1	5.37	1.21e-07	1.84e-05	0.32	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24504876	chr15:24493137~24652130:+
THCA	cis	rs9834975	0.935	rs6771201	ENSG00000272758.4	RP11-299J3.8	-5.37	1.21e-07	1.84e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122382874	chr3:122416207~122443180:+
THCA	cis	rs7727544	0.684	rs274567	ENSG00000224431.1	AC063976.7	-5.37	1.21e-07	1.84e-05	-0.2	-0.24	Blood metabolite levels;	chr5:132378717	chr5:132199456~132203487:+
THCA	cis	rs1667284	0.555	rs1551006	ENSG00000266521.1	RP11-650P15.1	5.37	1.21e-07	1.84e-05	0.3	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31653282	chr18:31496645~31497195:-
THCA	cis	rs6723226	0.804	rs17428810	ENSG00000276334.1	AL133243.1	-5.37	1.21e-07	1.84e-05	-0.29	-0.24	Intelligence (multi-trait analysis);	chr2:32510976	chr2:32521927~32523547:+
THCA	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-5.37	1.21e-07	1.84e-05	-0.42	-0.24	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
THCA	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	5.37	1.21e-07	1.84e-05	0.36	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
THCA	cis	rs2692947	0.711	rs56791141	ENSG00000232931.4	LINC00342	5.37	1.21e-07	1.84e-05	0.19	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95921748	chr2:95807118~95816215:-
THCA	cis	rs2255336	0.938	rs12298043	ENSG00000245648.1	RP11-277P12.20	-5.37	1.22e-07	1.84e-05	-0.3	-0.24	Blood protein levels;	chr12:10456883	chr12:10363769~10398506:+
THCA	cis	rs7809615	0.551	rs3901286	ENSG00000244219.5	GS1-259H13.2	-5.37	1.22e-07	1.84e-05	-0.29	-0.24	Blood metabolite ratios;	chr7:99510104	chr7:99598066~99610813:+
THCA	cis	rs2239547	0.522	rs6445550	ENSG00000242142.1	SERBP1P3	5.37	1.22e-07	1.84e-05	0.31	0.24	Schizophrenia;	chr3:52949418	chr3:53064283~53065091:-
THCA	cis	rs755249	0.567	rs61779308	ENSG00000228060.1	RP11-69E11.8	-5.37	1.22e-07	1.84e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39565160~39573203:+
THCA	cis	rs6545883	0.862	rs1880866	ENSG00000270820.4	RP11-355B11.2	5.37	1.22e-07	1.84e-05	0.2	0.24	Tuberculosis;	chr2:61471837	chr2:61471188~61484130:+
THCA	cis	rs10875746	0.903	rs12301339	ENSG00000269514.1	RP11-370I10.12	5.37	1.22e-07	1.84e-05	0.24	0.24	Longevity (90 years and older);	chr12:48081450	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.903	rs886588	ENSG00000269514.1	RP11-370I10.12	5.37	1.22e-07	1.84e-05	0.24	0.24	Longevity (90 years and older);	chr12:48083639	chr12:48198387~48202031:+
THCA	cis	rs4908768	0.501	rs11121199	ENSG00000232912.4	RP5-1115A15.1	5.37	1.22e-07	1.85e-05	0.23	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8424645~8434838:+
THCA	cis	rs6565180	0.888	rs8060853	ENSG00000273724.1	RP11-347C12.12	5.37	1.22e-07	1.85e-05	0.27	0.24	Tonsillectomy;	chr16:30392537	chr16:30336400~30343336:+
THCA	cis	rs950169	0.734	rs67119537	ENSG00000230373.7	GOLGA6L5P	-5.37	1.22e-07	1.85e-05	-0.25	-0.24	Schizophrenia;	chr15:84395671	chr15:84507885~84516814:-
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000275400.1	RP4-756H11.5	-5.37	1.22e-07	1.85e-05	-0.24	-0.24	Calcium levels;	chr7:65825628	chr7:66553805~66554199:-
THCA	cis	rs3742264	0.784	rs9534316	ENSG00000235903.6	CPB2-AS1	-5.37	1.22e-07	1.85e-05	-0.34	-0.24	Blood protein levels;	chr13:46088495	chr13:46052806~46113332:+
THCA	cis	rs9859260	0.961	rs34221479	ENSG00000226155.1	AC124944.3	-5.37	1.22e-07	1.85e-05	-0.28	-0.24	Mean corpuscular volume;	chr3:196071729	chr3:195912049~195913986:+
THCA	cis	rs11096990	0.964	rs7678689	ENSG00000249685.1	RP11-360F5.3	-5.37	1.22e-07	1.85e-05	-0.3	-0.24	Cognitive function;	chr4:39261140	chr4:39133913~39135608:+
THCA	cis	rs9910055	0.676	rs11079983	ENSG00000267080.4	ASB16-AS1	-5.37	1.22e-07	1.85e-05	-0.22	-0.24	Total body bone mineral density;	chr17:44120802	chr17:44175973~44186717:-
THCA	cis	rs1075265	0.509	rs10201938	ENSG00000233266.1	HMGB1P31	5.37	1.22e-07	1.85e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53728352	chr2:54051334~54051760:+
THCA	cis	rs1552244	1	rs1552244	ENSG00000180385.7	EMC3-AS1	5.37	1.22e-07	1.85e-05	0.26	0.24	Alzheimer's disease;	chr3:10093893	chr3:9986893~10006990:+
THCA	cis	rs6044112	0.948	rs17743285	ENSG00000273998.1	RP4-777L9.2	5.37	1.22e-07	1.85e-05	0.39	0.24	Response to taxane treatment (docetaxel);	chr20:16559079	chr20:16576068~16579615:+
THCA	cis	rs11634944	0.643	rs975699	ENSG00000257151.1	PWAR6	5.37	1.22e-07	1.85e-05	0.18	0.24	Interleukin-8 levels;	chr15:25015378	chr15:25031873~25036490:+
THCA	cis	rs16958440	1	rs12326600	ENSG00000267800.1	RP11-49K24.5	-5.37	1.22e-07	1.85e-05	-0.56	-0.24	Sitting height ratio;	chr18:47070126	chr18:47137018~47137290:+
THCA	cis	rs16958440	1	rs16952848	ENSG00000267800.1	RP11-49K24.5	-5.37	1.22e-07	1.85e-05	-0.56	-0.24	Sitting height ratio;	chr18:47071458	chr18:47137018~47137290:+
THCA	cis	rs67478160	0.634	rs941475	ENSG00000258735.1	LINC00637	-5.37	1.22e-07	1.85e-05	-0.29	-0.24	Schizophrenia;	chr14:103774281	chr14:103847721~103858049:+
THCA	cis	rs7727544	0.684	rs2516788	ENSG00000224431.1	AC063976.7	-5.37	1.23e-07	1.85e-05	-0.21	-0.24	Blood metabolite levels;	chr5:132379873	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.66	rs274563	ENSG00000224431.1	AC063976.7	-5.37	1.23e-07	1.85e-05	-0.21	-0.24	Blood metabolite levels;	chr5:132382167	chr5:132199456~132203487:+
THCA	cis	rs6430585	0.528	rs660002	ENSG00000231890.6	DARS-AS1	-5.37	1.23e-07	1.86e-05	-0.27	-0.24	Corneal structure;	chr2:135965934	chr2:135985176~136022593:+
THCA	cis	rs7924176	0.601	rs10824107	ENSG00000213731.2	RAB5CP1	-5.37	1.23e-07	1.86e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.564	rs11000920	ENSG00000213731.2	RAB5CP1	-5.37	1.23e-07	1.86e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74423435~74424014:-
THCA	cis	rs73198271	0.74	rs3827807	ENSG00000253893.2	FAM85B	5.37	1.23e-07	1.86e-05	0.36	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8167819~8226614:-
THCA	cis	rs17270561	0.723	rs12213243	ENSG00000272462.2	U91328.19	-5.37	1.23e-07	1.86e-05	-0.23	-0.24	Iron status biomarkers;	chr6:25889880	chr6:25992662~26001775:+
THCA	cis	rs7648466	0.513	rs2201150	ENSG00000223552.1	RP11-24F11.2	5.37	1.23e-07	1.86e-05	0.21	0.24	Eotaxin levels;	chr3:46217411	chr3:46364955~46407059:-
THCA	cis	rs481331	0.741	rs17158044	ENSG00000215146.4	RP11-313J2.1	5.37	1.23e-07	1.86e-05	0.39	0.24	Systemic juvenile idiopathic arthritis;	chr10:42689688	chr10:42331866~42367974:-
THCA	cis	rs7119	0.651	rs12902898	ENSG00000259362.2	RP11-307C19.1	-5.37	1.23e-07	1.86e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77556849	chr15:77525540~77534110:+
THCA	cis	rs2348418	0.832	rs12303069	ENSG00000247934.4	RP11-967K21.1	5.37	1.23e-07	1.86e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28294319	chr12:28163298~28190738:-
THCA	cis	rs755249	0.567	rs1126313	ENSG00000228060.1	RP11-69E11.8	5.37	1.23e-07	1.86e-05	0.26	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs112672438	ENSG00000228060.1	RP11-69E11.8	-5.37	1.23e-07	1.86e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs16825921	ENSG00000228060.1	RP11-69E11.8	-5.37	1.23e-07	1.86e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs16825939	ENSG00000228060.1	RP11-69E11.8	-5.37	1.23e-07	1.86e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs16825942	ENSG00000228060.1	RP11-69E11.8	-5.37	1.23e-07	1.86e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs72661927	ENSG00000228060.1	RP11-69E11.8	-5.37	1.23e-07	1.86e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs2036463	ENSG00000228060.1	RP11-69E11.8	-5.37	1.23e-07	1.86e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs2036464	ENSG00000228060.1	RP11-69E11.8	-5.37	1.23e-07	1.86e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs905381	ENSG00000228060.1	RP11-69E11.8	-5.37	1.23e-07	1.86e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39565160~39573203:+
THCA	cis	rs2839186	0.732	rs8131458	ENSG00000239415.1	AP001469.9	5.37	1.23e-07	1.86e-05	0.25	0.24	Testicular germ cell tumor;	chr21:46274798	chr21:46251549~46254133:-
THCA	cis	rs7267979	0.789	rs9927	ENSG00000274414.1	RP5-965G21.4	-5.37	1.23e-07	1.86e-05	-0.28	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25239007~25245229:-
THCA	cis	rs11894081	0.898	rs33956547	ENSG00000232835.1	AC107057.1	-5.37	1.23e-07	1.86e-05	-0.24	-0.24	Crohn's disease;	chr2:5531052	chr2:5549780~5556031:-
THCA	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	5.37	1.23e-07	1.86e-05	0.35	0.24	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
THCA	cis	rs7523875	0.572	rs79411013	ENSG00000153363.11	LINC00467	-5.37	1.23e-07	1.86e-05	-0.3	-0.24	Mean corpuscular volume;	chr1:211464977	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.572	rs78060732	ENSG00000153363.11	LINC00467	-5.37	1.23e-07	1.86e-05	-0.3	-0.24	Mean corpuscular volume;	chr1:211466127	chr1:211382803~211435333:+
THCA	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-5.37	1.23e-07	1.86e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
THCA	cis	rs11671005	0.735	rs12977592	ENSG00000269473.1	CTD-2619J13.19	5.37	1.23e-07	1.86e-05	0.26	0.24	Mean platelet volume;	chr19:58449689	chr19:58440448~58445849:+
THCA	cis	rs853679	0.882	rs9468300	ENSG00000272009.1	RP1-313I6.12	-5.37	1.23e-07	1.86e-05	-0.35	-0.24	Depression;	chr6:28159062	chr6:28078792~28081130:-
THCA	cis	rs5015933	0.966	rs7870475	ENSG00000232630.1	PRPS1P2	-5.37	1.23e-07	1.86e-05	-0.16	-0.24	Body mass index;	chr9:125371755	chr9:125150653~125151589:+
THCA	cis	rs440932	1	rs378974	ENSG00000253893.2	FAM85B	-5.37	1.23e-07	1.86e-05	-0.31	-0.24	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8167819~8226614:-
THCA	cis	rs1552244	1	rs7648104	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10031627	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs113771705	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10034299	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs111392584	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10034307	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs17032276	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10035291	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs17032277	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10035339	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs17032278	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10036271	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs66797209	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10036842	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs7631678	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10037132	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs7637888	ENSG00000232901.1	CYCSP10	5.37	1.23e-07	1.86e-05	0.32	0.24	Alzheimer's disease;	chr3:10039038	chr3:10000647~10000940:-
THCA	cis	rs1865760	0.516	rs9393684	ENSG00000272462.2	U91328.19	-5.37	1.23e-07	1.86e-05	-0.2	-0.24	Height;	chr6:26075303	chr6:25992662~26001775:+
THCA	cis	rs3847687	0.686	rs71448229	ENSG00000279993.1	RP11-76C10.3	5.37	1.23e-07	1.86e-05	0.27	0.24	Longevity;	chr12:131036984	chr12:131025561~131028060:-
THCA	cis	rs12472274	0.646	rs2305171	ENSG00000279484.1	KLHL30-AS1	5.37	1.23e-07	1.86e-05	0.31	0.24	Phospholipid levels (plasma);	chr2:238188499	chr2:238152889~238155994:-
THCA	cis	rs35934224	0.783	rs7284106	ENSG00000232926.1	AC000078.5	5.37	1.23e-07	1.86e-05	0.26	0.24	Glaucoma (primary open-angle);	chr22:19870026	chr22:19887289~19887970:+
THCA	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	5.37	1.23e-07	1.86e-05	0.15	0.24	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
THCA	cis	rs9818758	0.505	rs67286839	ENSG00000270441.1	RP11-694I15.7	5.37	1.23e-07	1.87e-05	0.34	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49228311	chr3:49140086~49160851:-
THCA	cis	rs7615952	0.546	rs4428131	ENSG00000243429.1	OR7E29P	5.37	1.23e-07	1.87e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:125627635	chr3:125712139~125713045:+
THCA	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	5.37	1.23e-07	1.87e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
THCA	cis	rs12893668	0.703	rs4906338	ENSG00000269910.1	RP11-73M18.10	5.37	1.23e-07	1.87e-05	0.23	0.24	Reticulocyte count;	chr14:103584020	chr14:103694516~103695050:-
THCA	cis	rs890448	0.693	rs4276280	ENSG00000254531.1	FLJ20021	5.37	1.23e-07	1.87e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417442	chr4:101347780~101348883:+
THCA	cis	rs9652601	0.748	rs9927527	ENSG00000274038.1	RP11-66H6.4	-5.37	1.23e-07	1.87e-05	-0.31	-0.24	Systemic lupus erythematosus;	chr16:11118824	chr16:11056556~11057034:+
THCA	cis	rs9859260	1	rs9990392	ENSG00000226155.1	AC124944.3	-5.37	1.23e-07	1.87e-05	-0.28	-0.24	Mean corpuscular volume;	chr3:196071651	chr3:195912049~195913986:+
THCA	cis	rs728616	0.51	rs61860860	ENSG00000242600.5	MBL1P	5.37	1.23e-07	1.87e-05	0.26	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79998816	chr10:79904898~79950336:+
THCA	cis	rs12681287	0.577	rs13257414	ENSG00000254231.1	CTD-2284J15.1	5.37	1.23e-07	1.87e-05	0.26	0.24	Caudate activity during reward;	chr8:86481909	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.609	rs13281414	ENSG00000254231.1	CTD-2284J15.1	5.37	1.23e-07	1.87e-05	0.26	0.24	Caudate activity during reward;	chr8:86483025	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.546	rs12546802	ENSG00000254231.1	CTD-2284J15.1	5.37	1.23e-07	1.87e-05	0.26	0.24	Caudate activity during reward;	chr8:86487106	chr8:86333274~86343314:-
THCA	cis	rs853679	0.607	rs66886492	ENSG00000226314.6	ZNF192P1	-5.37	1.23e-07	1.87e-05	-0.54	-0.24	Depression;	chr6:28121953	chr6:28161781~28169594:+
THCA	cis	rs853679	0.607	rs35345226	ENSG00000226314.6	ZNF192P1	-5.37	1.23e-07	1.87e-05	-0.54	-0.24	Depression;	chr6:28123802	chr6:28161781~28169594:+
THCA	cis	rs9307551	0.619	rs10022309	ENSG00000250334.4	LINC00989	-5.37	1.23e-07	1.87e-05	-0.29	-0.24	Refractive error;	chr4:79550491	chr4:79492416~79576460:+
THCA	cis	rs2439831	0.85	rs28858500	ENSG00000166763.7	STRCP1	5.37	1.24e-07	1.87e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:43864744	chr15:43699488~43718184:-
THCA	cis	rs7772486	0.686	rs9390357	ENSG00000270638.1	RP3-466P17.1	5.37	1.24e-07	1.87e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145735570~145737218:+
THCA	cis	rs9625935	0.957	rs41175	ENSG00000279159.1	RP3-394A18.1	-5.37	1.24e-07	1.87e-05	-0.18	-0.24	Tonsillectomy;	chr22:30036148	chr22:29978950~30028236:-
THCA	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-5.37	1.24e-07	1.87e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
THCA	cis	rs16958440	0.541	rs11876448	ENSG00000267800.1	RP11-49K24.5	-5.37	1.24e-07	1.87e-05	-0.41	-0.24	Sitting height ratio;	chr18:47118159	chr18:47137018~47137290:+
THCA	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-5.37	1.24e-07	1.87e-05	-0.21	-0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
THCA	cis	rs11739663	0.553	rs60444023	ENSG00000225138.6	CTD-2228K2.7	5.37	1.24e-07	1.87e-05	0.24	0.24	Ulcerative colitis;	chr5:586225	chr5:473236~480884:+
THCA	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-5.37	1.24e-07	1.87e-05	-0.15	-0.24	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
THCA	cis	rs3812049	0.532	rs251389	ENSG00000245937.6	LINC01184	5.37	1.24e-07	1.87e-05	0.28	0.24	Lymphocyte counts;Red cell distribution width;	chr5:128206185	chr5:127940426~128083172:-
THCA	cis	rs4604234	0.708	rs11961412	ENSG00000272129.1	RP11-250B2.6	-5.37	1.24e-07	1.87e-05	-0.57	-0.24	Cancer;	chr6:80342179	chr6:80355424~80356859:+
THCA	cis	rs62432291	0.681	rs1699442	ENSG00000235086.1	FNDC1-IT1	5.37	1.24e-07	1.87e-05	0.43	0.24	Joint mobility (Beighton score);	chr6:159234886	chr6:159240786~159243329:+
THCA	cis	rs4748857	0.627	rs11013350	ENSG00000224215.1	RP11-371A19.2	-5.37	1.24e-07	1.87e-05	-0.32	-0.24	Systemic lupus erythematosus;	chr10:23247805	chr10:23343957~23345181:+
THCA	cis	rs4845570	0.831	rs11588634	ENSG00000203288.3	RP11-98D18.9	-5.37	1.24e-07	1.87e-05	-0.29	-0.24	Coronary artery disease;	chr1:151808210	chr1:151790804~151794402:+
THCA	cis	rs7772486	0.651	rs1292338	ENSG00000270638.1	RP3-466P17.1	-5.37	1.24e-07	1.88e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs1292337	ENSG00000270638.1	RP3-466P17.1	-5.37	1.24e-07	1.88e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs857879	ENSG00000270638.1	RP3-466P17.1	-5.37	1.24e-07	1.88e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145735570~145737218:+
THCA	cis	rs4748857	0.947	rs12413144	ENSG00000224215.1	RP11-371A19.2	-5.37	1.24e-07	1.88e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23286320	chr10:23343957~23345181:+
THCA	cis	rs36715	0.953	rs36706	ENSG00000245937.6	LINC01184	5.37	1.24e-07	1.88e-05	0.27	0.24	Breast cancer;	chr5:128221006	chr5:127940426~128083172:-
THCA	cis	rs2436845	0.627	rs2570941	ENSG00000253669.3	KB-1732A1.1	-5.37	1.24e-07	1.88e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102845253	chr8:102805517~102809971:+
THCA	cis	rs2436845	0.627	rs2679747	ENSG00000253669.3	KB-1732A1.1	-5.37	1.24e-07	1.88e-05	-0.27	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102845886	chr8:102805517~102809971:+
THCA	cis	rs12893668	0.644	rs12890820	ENSG00000269940.1	RP11-73M18.7	5.37	1.24e-07	1.88e-05	0.26	0.24	Reticulocyte count;	chr14:103568512	chr14:103694560~103695170:+
THCA	cis	rs17594362	1	rs34756176	ENSG00000264190.1	MIR5006	5.37	1.24e-07	1.88e-05	0.37	0.24	Multiple sclerosis;	chr13:41578409	chr13:41568286~41568395:-
THCA	cis	rs2239547	0.522	rs6770957	ENSG00000242142.1	SERBP1P3	5.37	1.24e-07	1.88e-05	0.3	0.24	Schizophrenia;	chr3:52961400	chr3:53064283~53065091:-
THCA	cis	rs919433	0.68	rs2605039	ENSG00000231621.1	AC013264.2	-5.37	1.24e-07	1.88e-05	-0.25	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197498127	chr2:197197991~197199273:+
THCA	cis	rs4934494	0.677	rs11185790	ENSG00000232936.4	RP11-80H5.2	-5.37	1.24e-07	1.88e-05	-0.32	-0.24	Red blood cell count;	chr10:89612776	chr10:89645282~89650667:+
THCA	cis	rs7577696	0.886	rs443609	ENSG00000276334.1	AL133243.1	5.37	1.24e-07	1.88e-05	0.25	0.24	Inflammatory biomarkers;	chr2:32258524	chr2:32521927~32523547:+
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000232546.1	RP11-458F8.1	-5.37	1.25e-07	1.88e-05	-0.21	-0.24	Corneal structure;	chr7:66925268	chr7:66848496~66858136:+
THCA	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	5.37	1.25e-07	1.88e-05	0.25	0.24	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
THCA	cis	rs75920871	0.528	rs10466590	ENSG00000254851.1	RP11-109L13.1	5.37	1.25e-07	1.88e-05	0.34	0.24	Subjective well-being;	chr11:117023697	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs11216240	ENSG00000254851.1	RP11-109L13.1	5.37	1.25e-07	1.88e-05	0.34	0.24	Subjective well-being;	chr11:117028532	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs11216241	ENSG00000254851.1	RP11-109L13.1	5.37	1.25e-07	1.88e-05	0.34	0.24	Subjective well-being;	chr11:117028533	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs11600552	ENSG00000254851.1	RP11-109L13.1	5.37	1.25e-07	1.88e-05	0.34	0.24	Subjective well-being;	chr11:117030231	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs7941428	ENSG00000254851.1	RP11-109L13.1	5.37	1.25e-07	1.88e-05	0.34	0.24	Subjective well-being;	chr11:117032668	chr11:117135528~117138582:+
THCA	cis	rs6540731	0.782	rs10436962	ENSG00000226251.4	RP11-15I11.3	-5.37	1.25e-07	1.88e-05	-0.3	-0.24	Intelligence (childhood);	chr1:212188280	chr1:212225278~212238977:-
THCA	cis	rs9393777	0.841	rs13191474	ENSG00000219392.1	RP1-265C24.5	-5.37	1.25e-07	1.88e-05	-0.48	-0.24	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28115628~28116551:+
THCA	cis	rs9393777	0.92	rs41269265	ENSG00000219392.1	RP1-265C24.5	-5.37	1.25e-07	1.88e-05	-0.48	-0.24	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28115628~28116551:+
THCA	cis	rs7119038	0.774	rs11217020	ENSG00000255239.1	AP002954.6	-5.37	1.25e-07	1.88e-05	-0.37	-0.24	Sjögren's syndrome;	chr11:118768644	chr11:118688039~118690600:-
THCA	cis	rs7412746	0.658	rs12068264	ENSG00000231073.1	RP11-316M1.3	5.37	1.25e-07	1.88e-05	0.3	0.24	Melanoma;	chr1:150754853	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs2230061	ENSG00000231073.1	RP11-316M1.3	5.37	1.25e-07	1.88e-05	0.3	0.24	Melanoma;	chr1:150755063	chr1:150973123~150975534:+
THCA	cis	rs853679	0.76	rs2299029	ENSG00000220721.1	OR1F12	5.37	1.25e-07	1.89e-05	0.34	0.24	Depression;	chr6:28231053	chr6:28073316~28074233:+
THCA	cis	rs1876905	0.539	rs457497	ENSG00000272356.1	RP5-1112D6.8	5.37	1.25e-07	1.89e-05	0.25	0.24	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111309203~111313517:+
THCA	cis	rs12497850	1	rs4858831	ENSG00000229759.1	MRPS18AP1	5.37	1.25e-07	1.89e-05	0.31	0.24	Parkinson's disease;	chr3:48698125	chr3:48256350~48256938:-
THCA	cis	rs8177876	0.597	rs2317085	ENSG00000261061.1	RP11-303E16.2	5.37	1.25e-07	1.89e-05	0.36	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104460	chr16:81030770~81031485:+
THCA	cis	rs1210638	0.706	rs2518798	ENSG00000273032.1	DGCR9	-5.37	1.25e-07	1.89e-05	-0.26	-0.24	Response to serotonin reuptake inhibitors in major depressive disorder;	chr22:18982890	chr22:19017834~19020248:+
THCA	cis	rs71636778	0.543	rs75305560	ENSG00000260063.1	RP5-968P14.2	-5.37	1.25e-07	1.89e-05	-0.32	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26916030	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.543	rs71636796	ENSG00000260063.1	RP5-968P14.2	-5.37	1.25e-07	1.89e-05	-0.32	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26916604	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.543	rs36109400	ENSG00000260063.1	RP5-968P14.2	-5.37	1.25e-07	1.89e-05	-0.32	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921331	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.543	rs10493037	ENSG00000260063.1	RP5-968P14.2	-5.37	1.25e-07	1.89e-05	-0.32	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26922154	chr1:26692132~26694131:-
THCA	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-5.37	1.25e-07	1.89e-05	-0.28	-0.24	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
THCA	cis	rs1979679	0.918	rs11049529	ENSG00000278733.1	RP11-425D17.1	5.37	1.25e-07	1.89e-05	0.25	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28318571	chr12:28185625~28186190:-
THCA	cis	rs2337406	0.925	rs76288499	ENSG00000211974.3	IGHV2-70	-5.37	1.25e-07	1.89e-05	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106686309	chr14:106723574~106724093:-
THCA	cis	rs34779708	0.931	rs11597392	ENSG00000271335.4	RP11-324I22.4	5.37	1.25e-07	1.89e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35314552~35336401:-
THCA	cis	rs4950322	0.542	rs4950382	ENSG00000180867.10	PDIA3P1	5.37	1.25e-07	1.89e-05	0.22	0.24	Protein quantitative trait loci;	chr1:147176645	chr1:147178113~147179622:+
THCA	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	5.37	1.25e-07	1.89e-05	0.28	0.24	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
THCA	cis	rs651907	0.557	rs7651721	ENSG00000244119.1	PDCL3P4	5.37	1.25e-07	1.89e-05	0.22	0.24	Colorectal cancer;	chr3:101674739	chr3:101712472~101713191:+
THCA	cis	rs7429990	0.965	rs1550914	ENSG00000228638.1	FCF1P2	-5.37	1.25e-07	1.89e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47953678	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs7649981	ENSG00000228638.1	FCF1P2	-5.37	1.25e-07	1.89e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47957847	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.93	rs7374516	ENSG00000228638.1	FCF1P2	-5.37	1.25e-07	1.89e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47961150	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs9811277	ENSG00000228638.1	FCF1P2	-5.37	1.25e-07	1.89e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47970148	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs9814961	ENSG00000228638.1	FCF1P2	-5.37	1.25e-07	1.89e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47976127	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs6770467	ENSG00000228638.1	FCF1P2	5.37	1.25e-07	1.89e-05	0.23	0.24	Educational attainment (years of education);	chr3:47977742	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.932	rs6770477	ENSG00000228638.1	FCF1P2	5.37	1.25e-07	1.89e-05	0.23	0.24	Educational attainment (years of education);	chr3:47977768	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs28637561	ENSG00000228638.1	FCF1P2	5.37	1.25e-07	1.89e-05	0.23	0.24	Educational attainment (years of education);	chr3:47979528	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs7427418	ENSG00000228638.1	FCF1P2	5.37	1.25e-07	1.89e-05	0.23	0.24	Educational attainment (years of education);	chr3:47981217	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs13075795	ENSG00000228638.1	FCF1P2	5.37	1.25e-07	1.89e-05	0.23	0.24	Educational attainment (years of education);	chr3:47983139	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs7431572	ENSG00000228638.1	FCF1P2	5.37	1.25e-07	1.89e-05	0.23	0.24	Educational attainment (years of education);	chr3:47986361	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs13074973	ENSG00000228638.1	FCF1P2	5.37	1.25e-07	1.89e-05	0.23	0.24	Educational attainment (years of education);	chr3:47986654	chr3:48290793~48291375:-
THCA	cis	rs2562456	0.833	rs56179986	ENSG00000268081.1	RP11-678G14.2	5.37	1.25e-07	1.89e-05	0.41	0.24	Pain;	chr19:21337882	chr19:21554640~21569237:-
THCA	cis	rs180730	0.752	rs6857653	ENSG00000251609.2	SETP12	5.37	1.25e-07	1.89e-05	0.47	0.24	Fasting plasma glucose;	chr4:120925764	chr4:120895494~120897083:-
THCA	cis	rs1858037	0.806	rs12612780	ENSG00000234255.7	AC012370.3	5.37	1.25e-07	1.89e-05	0.29	0.24	Rheumatoid arthritis;	chr2:65355967	chr2:65439888~65456571:-
THCA	cis	rs5742933	0.857	rs1233291	ENSG00000253559.1	OSGEPL1-AS1	-5.37	1.25e-07	1.89e-05	-0.27	-0.24	Ferritin levels;	chr2:189826225	chr2:189762704~189765556:+
THCA	cis	rs6570726	0.967	rs6903252	ENSG00000270638.1	RP3-466P17.1	5.37	1.25e-07	1.89e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145735570~145737218:+
THCA	cis	rs1552244	1	rs6764168	ENSG00000232901.1	CYCSP10	5.37	1.26e-07	1.9e-05	0.32	0.24	Alzheimer's disease;	chr3:10082121	chr3:10000647~10000940:-
THCA	cis	rs1150668	0.796	rs213237	ENSG00000273712.1	RP5-874C20.7	5.37	1.26e-07	1.9e-05	0.26	0.24	Pubertal anthropometrics;	chr6:28356161	chr6:28315613~28315883:-
THCA	cis	rs210138	0.832	rs375555	ENSG00000197251.3	LINC00336	5.37	1.26e-07	1.9e-05	0.31	0.24	Testicular germ cell tumor;	chr6:33589964	chr6:33586106~33593338:-
THCA	cis	rs2243480	1	rs34970380	ENSG00000230295.1	RP11-458F8.2	-5.37	1.26e-07	1.9e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65966506	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000230295.1	RP11-458F8.2	-5.37	1.26e-07	1.9e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66004843	chr7:66880708~66882981:+
THCA	cis	rs34779708	0.931	rs72789609	ENSG00000271335.4	RP11-324I22.4	5.37	1.26e-07	1.9e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs7908573	ENSG00000271335.4	RP11-324I22.4	5.37	1.26e-07	1.9e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35314552~35336401:-
THCA	cis	rs202072	0.872	rs202042	ENSG00000272379.1	RP1-257A7.5	-5.37	1.26e-07	1.9e-05	-0.34	-0.24	HIV-1 viral setpoint;	chr6:13277482	chr6:13290018~13290490:-
THCA	cis	rs10875746	0.903	rs2158516	ENSG00000269514.1	RP11-370I10.12	5.37	1.26e-07	1.9e-05	0.24	0.24	Longevity (90 years and older);	chr12:48097051	chr12:48198387~48202031:+
THCA	cis	rs5752326	1	rs722997	ENSG00000261188.1	CTA-445C9.14	5.37	1.26e-07	1.9e-05	0.3	0.24	Ischemic stroke;	chr22:26453700	chr22:26512537~26514568:+
THCA	cis	rs7403037	0.833	rs4778463	ENSG00000259905.4	PWRN1	5.37	1.26e-07	1.9e-05	0.25	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24373557	chr15:24493137~24652130:+
THCA	cis	rs950169	0.58	rs11630887	ENSG00000275120.1	RP11-182J1.17	5.37	1.26e-07	1.9e-05	0.28	0.24	Schizophrenia;	chr15:84649784	chr15:84599434~84606463:-
THCA	cis	rs12681287	0.752	rs6985427	ENSG00000254231.1	CTD-2284J15.1	5.37	1.26e-07	1.9e-05	0.27	0.24	Caudate activity during reward;	chr8:86290516	chr8:86333274~86343314:-
THCA	cis	rs6539288	0.563	rs11113122	ENSG00000260329.1	RP11-412D9.4	-5.37	1.26e-07	1.9e-05	-0.22	-0.24	Total body bone mineral density;	chr12:106817547	chr12:106954029~106955497:-
THCA	cis	rs7412746	0.611	rs11204748	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Melanoma;	chr1:150954893	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.621	rs11204749	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Melanoma;	chr1:150957087	chr1:150973123~150975534:+
THCA	cis	rs6921919	0.515	rs1339898	ENSG00000219392.1	RP1-265C24.5	-5.37	1.26e-07	1.9e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28115628~28116551:+
THCA	cis	rs7429990	0.932	rs9862913	ENSG00000228638.1	FCF1P2	-5.37	1.26e-07	1.9e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47974682	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs7426976	ENSG00000228638.1	FCF1P2	5.37	1.26e-07	1.9e-05	0.23	0.24	Educational attainment (years of education);	chr3:47981083	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs1013431	ENSG00000228638.1	FCF1P2	5.37	1.26e-07	1.9e-05	0.23	0.24	Educational attainment (years of education);	chr3:47987628	chr3:48290793~48291375:-
THCA	cis	rs6840360	0.904	rs6825241	ENSG00000251611.1	RP11-610P16.1	-5.37	1.26e-07	1.9e-05	-0.17	-0.24	Intelligence (multi-trait analysis);	chr4:151622631	chr4:151407551~151408835:-
THCA	cis	rs755249	0.567	rs67020650	ENSG00000228060.1	RP11-69E11.8	-5.37	1.26e-07	1.9e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs72661925	ENSG00000228060.1	RP11-69E11.8	-5.37	1.26e-07	1.9e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39565160~39573203:+
THCA	cis	rs9733	0.525	rs11584184	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150723213	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs6669369	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150723416	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs6681990	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150723453	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs6692960	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150723489	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs72702585	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150723951	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs12086472	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150725234	chr1:150973123~150975534:+
THCA	cis	rs9733	0.628	rs7540874	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150730187	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs1136808	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150730241	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs1415148	ENSG00000231073.1	RP11-316M1.3	5.37	1.26e-07	1.9e-05	0.28	0.24	Tonsillectomy;	chr1:150733279	chr1:150973123~150975534:+
THCA	cis	rs2348418	0.733	rs7137557	ENSG00000247934.4	RP11-967K21.1	5.37	1.26e-07	1.9e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.733	rs12425200	ENSG00000247934.4	RP11-967K21.1	5.37	1.26e-07	1.9e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28163298~28190738:-
THCA	cis	rs7824557	0.579	rs10098322	ENSG00000154316.13	TDH	-5.37	1.26e-07	1.91e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11338786	chr8:11339637~11368452:+
THCA	cis	rs4713118	0.513	rs149962	ENSG00000220721.1	OR1F12	5.37	1.26e-07	1.91e-05	0.29	0.24	Parkinson's disease;	chr6:28048140	chr6:28073316~28074233:+
THCA	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-5.37	1.26e-07	1.91e-05	-0.42	-0.24	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
THCA	cis	rs7927592	0.546	rs638076	ENSG00000212093.1	AP000807.1	5.37	1.26e-07	1.91e-05	0.25	0.24	Total body bone mineral density;	chr11:68435112	chr11:68506083~68506166:-
THCA	cis	rs1979679	0.659	rs11049461	ENSG00000278733.1	RP11-425D17.1	5.37	1.27e-07	1.91e-05	0.26	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207688	chr12:28185625~28186190:-
THCA	cis	rs12935418	0.616	rs9921448	ENSG00000278985.1	RP11-303E16.9	5.37	1.27e-07	1.91e-05	0.26	0.24	Mean corpuscular volume;	chr16:80975593	chr16:80982319~80984094:-
THCA	cis	rs944289	0.774	rs7147401	ENSG00000258844.1	RP11-259K15.2	5.37	1.27e-07	1.91e-05	0.21	0.24	Thyroid cancer;	chr14:36089461	chr14:36214607~36235608:+
THCA	cis	rs944289	0.774	rs34081947	ENSG00000258844.1	RP11-259K15.2	5.37	1.27e-07	1.91e-05	0.21	0.24	Thyroid cancer;	chr14:36090325	chr14:36214607~36235608:+
THCA	cis	rs73198271	0.813	rs56007835	ENSG00000253893.2	FAM85B	5.37	1.27e-07	1.91e-05	0.35	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8167819~8226614:-
THCA	cis	rs6908034	0.607	rs79406203	ENSG00000227116.1	RP3-471C18.1	-5.37	1.27e-07	1.91e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19815990	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.607	rs74559916	ENSG00000227116.1	RP3-471C18.1	-5.37	1.27e-07	1.91e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818486	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.505	rs76391302	ENSG00000227116.1	RP3-471C18.1	-5.37	1.27e-07	1.91e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818885	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.505	rs77880623	ENSG00000227116.1	RP3-471C18.1	-5.37	1.27e-07	1.91e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819223	chr6:19730427~19734567:-
THCA	cis	rs1043099	0.528	rs1046199	ENSG00000279699.1	RP1-102K2.9	-5.37	1.27e-07	1.91e-05	-0.27	-0.24	Rheumatoid arthritis;	chr22:30424562	chr22:30275215~30276951:-
THCA	cis	rs4888671	0.901	rs80192970	ENSG00000261707.1	RP11-264M12.2	5.37	1.27e-07	1.91e-05	0.45	0.24	Obesity-related traits;	chr16:77738961	chr16:77741468~77743000:-
THCA	cis	rs2732480	0.577	rs2732457	ENSG00000240399.1	RP1-228P16.1	-5.37	1.27e-07	1.91e-05	-0.25	-0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48054813~48055591:-
THCA	cis	rs67340775	0.541	rs169287	ENSG00000226314.6	ZNF192P1	-5.37	1.27e-07	1.91e-05	-0.36	-0.24	Lung cancer in ever smokers;	chr6:27886982	chr6:28161781~28169594:+
THCA	cis	rs12497850	0.864	rs4955410	ENSG00000229759.1	MRPS18AP1	5.37	1.27e-07	1.91e-05	0.32	0.24	Parkinson's disease;	chr3:49143785	chr3:48256350~48256938:-
THCA	cis	rs7976269	0.559	rs4930848	ENSG00000275476.1	RP11-996F15.4	-5.37	1.27e-07	1.91e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29068441	chr12:29277397~29277882:-
THCA	cis	rs7847628	0.551	rs10818476	ENSG00000238181.2	AHCYP2	-5.37	1.27e-07	1.92e-05	-0.3	-0.24	Birth weight;	chr9:120809760	chr9:120720673~120721972:+
THCA	cis	rs4409675	1	rs61789695	ENSG00000227050.1	RP11-460I13.2	-5.37	1.27e-07	1.92e-05	-0.36	-0.24	Corneal astigmatism;	chr1:27929182	chr1:27938875~27960193:-
THCA	cis	rs4409675	0.913	rs61789696	ENSG00000227050.1	RP11-460I13.2	-5.37	1.27e-07	1.92e-05	-0.36	-0.24	Corneal astigmatism;	chr1:27932394	chr1:27938875~27960193:-
THCA	cis	rs2235642	0.507	rs2235643	ENSG00000280231.1	LA16c-380F5.3	5.37	1.27e-07	1.92e-05	0.32	0.24	Coronary artery disease;	chr16:1535114	chr16:1553655~1554130:-
THCA	cis	rs6920965	0.507	rs9385388	ENSG00000237742.5	RP11-624M8.1	-5.37	1.27e-07	1.92e-05	-0.22	-0.24	High light scatter reticulocyte count;	chr6:125894150	chr6:125578558~125749190:-
THCA	cis	rs1552244	1	rs6786638	ENSG00000232901.1	CYCSP10	5.37	1.27e-07	1.92e-05	0.32	0.24	Alzheimer's disease;	chr3:10076391	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs6442150	ENSG00000232901.1	CYCSP10	5.37	1.27e-07	1.92e-05	0.32	0.24	Alzheimer's disease;	chr3:10080891	chr3:10000647~10000940:-
THCA	cis	rs9813712	0.595	rs1453239	ENSG00000253540.4	FAM86HP	-5.37	1.27e-07	1.92e-05	-0.26	-0.24	Response to amphetamines;	chr3:130288915	chr3:130099092~130111472:-
THCA	cis	rs9733	0.519	rs7521898	ENSG00000231073.1	RP11-316M1.3	5.37	1.27e-07	1.92e-05	0.29	0.24	Tonsillectomy;	chr1:150735120	chr1:150973123~150975534:+
THCA	cis	rs9733	0.519	rs7511673	ENSG00000231073.1	RP11-316M1.3	5.37	1.27e-07	1.92e-05	0.29	0.24	Tonsillectomy;	chr1:150735160	chr1:150973123~150975534:+
THCA	cis	rs7208859	0.573	rs11654035	ENSG00000280069.1	CTD-2349P21.3	-5.37	1.27e-07	1.92e-05	-0.37	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30738182~30740275:+
THCA	cis	rs7617773	0.78	rs11720026	ENSG00000199476.1	Y_RNA	-5.37	1.27e-07	1.92e-05	-0.31	-0.24	Coronary artery disease;	chr3:48336431	chr3:48288587~48288694:+
THCA	cis	rs7688540	0.771	rs11723615	ENSG00000211553.1	AC253576.2	-5.37	1.27e-07	1.92e-05	-0.36	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:136461~136568:+
THCA	cis	rs867371	0.929	rs1045508	ENSG00000259429.4	UBE2Q2P2	5.36	1.27e-07	1.92e-05	0.19	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82355142~82420075:+
THCA	cis	rs12893668	0.703	rs4906336	ENSG00000269940.1	RP11-73M18.7	5.36	1.27e-07	1.92e-05	0.26	0.24	Reticulocyte count;	chr14:103566928	chr14:103694560~103695170:+
THCA	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-5.36	1.27e-07	1.92e-05	-0.26	-0.24	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
THCA	cis	rs7129556	0.775	rs12286317	ENSG00000254691.1	RP11-91P24.5	5.36	1.28e-07	1.92e-05	0.33	0.24	Weight loss (gastric bypass surgery);	chr11:77677975	chr11:77850604~77851511:+
THCA	cis	rs853679	0.546	rs34295134	ENSG00000226314.6	ZNF192P1	-5.36	1.28e-07	1.92e-05	-0.4	-0.24	Depression;	chr6:27860373	chr6:28161781~28169594:+
THCA	cis	rs853679	0.567	rs13196606	ENSG00000280107.1	AL022393.9	-5.36	1.28e-07	1.92e-05	-0.26	-0.24	Depression;	chr6:28402301	chr6:28170845~28172521:+
THCA	cis	rs7727544	0.684	rs2631363	ENSG00000224431.1	AC063976.7	-5.36	1.28e-07	1.93e-05	-0.2	-0.24	Blood metabolite levels;	chr5:132371403	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.66	rs2631361	ENSG00000224431.1	AC063976.7	-5.36	1.28e-07	1.93e-05	-0.2	-0.24	Blood metabolite levels;	chr5:132371688	chr5:132199456~132203487:+
THCA	cis	rs6840360	0.642	rs1372977	ENSG00000270265.1	RP11-731D1.4	-5.36	1.28e-07	1.93e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151531246	chr4:151333775~151353224:-
THCA	cis	rs4321325	1	rs4321325	ENSG00000236682.1	AC068282.3	-5.36	1.28e-07	1.93e-05	-0.38	-0.24	Protein C levels;	chr2:127193421	chr2:127389130~127400580:+
THCA	cis	rs11672691	0.67	rs758643	ENSG00000270164.1	LINC01480	5.36	1.28e-07	1.93e-05	0.24	0.24	Prostate cancer;	chr19:41485616	chr19:41535183~41536904:+
THCA	cis	rs7617773	0.963	rs12493256	ENSG00000199476.1	Y_RNA	5.36	1.28e-07	1.93e-05	0.3	0.24	Coronary artery disease;	chr3:48135257	chr3:48288587~48288694:+
THCA	cis	rs10895275	0.886	rs11225160	ENSG00000277459.1	RP11-732A21.3	-5.36	1.28e-07	1.93e-05	-0.19	-0.24	Migraine;	chr11:102192009	chr11:102109827~102110457:-
THCA	cis	rs7412746	0.611	rs11204747	ENSG00000231073.1	RP11-316M1.3	-5.36	1.28e-07	1.93e-05	-0.28	-0.24	Melanoma;	chr1:150954676	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs2275236	ENSG00000231073.1	RP11-316M1.3	-5.36	1.28e-07	1.93e-05	-0.28	-0.24	Tonsillectomy;	chr1:150697476	chr1:150973123~150975534:+
THCA	cis	rs1552244	1	rs7610821	ENSG00000180385.7	EMC3-AS1	5.36	1.28e-07	1.93e-05	0.26	0.24	Alzheimer's disease;	chr3:10094466	chr3:9986893~10006990:+
THCA	cis	rs6951245	1	rs74652290	ENSG00000229043.2	AC091729.9	-5.36	1.28e-07	1.93e-05	-0.42	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1160374~1165267:+
THCA	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	5.36	1.28e-07	1.93e-05	0.28	0.24	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	5.36	1.28e-07	1.93e-05	0.28	0.24	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	5.36	1.28e-07	1.93e-05	0.28	0.24	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	5.36	1.28e-07	1.93e-05	0.28	0.24	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	5.36	1.28e-07	1.93e-05	0.28	0.24	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	5.36	1.28e-07	1.93e-05	0.28	0.24	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
THCA	cis	rs67981189	0.529	rs2526858	ENSG00000269927.1	RP6-91H8.3	-5.36	1.28e-07	1.93e-05	-0.29	-0.24	Schizophrenia;	chr14:70945623	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.529	rs2526857	ENSG00000269927.1	RP6-91H8.3	-5.36	1.28e-07	1.93e-05	-0.29	-0.24	Schizophrenia;	chr14:70945909	chr14:71141125~71143253:-
THCA	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	5.36	1.28e-07	1.93e-05	0.28	0.24	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
THCA	cis	rs6921919	0.515	rs1558205	ENSG00000219392.1	RP1-265C24.5	5.36	1.28e-07	1.93e-05	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28115628~28116551:+
THCA	cis	rs17270561	0.779	rs12210620	ENSG00000272462.2	U91328.19	-5.36	1.28e-07	1.93e-05	-0.23	-0.24	Iron status biomarkers;	chr6:25884557	chr6:25992662~26001775:+
THCA	cis	rs9475752	0.793	rs13214255	ENSG00000231441.1	RP11-472M19.2	5.36	1.28e-07	1.94e-05	0.32	0.24	Menarche (age at onset);	chr6:56965751	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs71564871	ENSG00000231441.1	RP11-472M19.2	5.36	1.28e-07	1.94e-05	0.32	0.24	Menarche (age at onset);	chr6:56966097	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs28360536	ENSG00000231441.1	RP11-472M19.2	5.36	1.28e-07	1.94e-05	0.32	0.24	Menarche (age at onset);	chr6:56966849	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs56381984	ENSG00000231441.1	RP11-472M19.2	5.36	1.28e-07	1.94e-05	0.32	0.24	Menarche (age at onset);	chr6:56967910	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs71564872	ENSG00000231441.1	RP11-472M19.2	5.36	1.28e-07	1.94e-05	0.32	0.24	Menarche (age at onset);	chr6:56973686	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs34979183	ENSG00000231441.1	RP11-472M19.2	5.36	1.28e-07	1.94e-05	0.32	0.24	Menarche (age at onset);	chr6:56977965	chr6:56844002~56864078:+
THCA	cis	rs62432291	0.681	rs3003173	ENSG00000235086.1	FNDC1-IT1	-5.36	1.28e-07	1.94e-05	-0.44	-0.24	Joint mobility (Beighton score);	chr6:159244660	chr6:159240786~159243329:+
THCA	cis	rs2070488	0.775	rs9838614	ENSG00000229589.1	ACVR2B-AS1	-5.36	1.28e-07	1.94e-05	-0.21	-0.24	Electrocardiographic conduction measures;	chr3:38496180	chr3:38451027~38454820:-
THCA	cis	rs6887276	0.504	rs28540272	ENSG00000245937.6	LINC01184	-5.36	1.28e-07	1.94e-05	-0.23	-0.24	Height;	chr5:128013207	chr5:127940426~128083172:-
THCA	cis	rs13256369	0.901	rs4841015	ENSG00000253893.2	FAM85B	-5.36	1.28e-07	1.94e-05	-0.32	-0.24	Obesity-related traits;	chr8:8709630	chr8:8167819~8226614:-
THCA	cis	rs7119	0.651	rs8041398	ENSG00000259362.2	RP11-307C19.1	-5.36	1.29e-07	1.94e-05	-0.35	-0.24	Type 2 diabetes;	chr15:77546831	chr15:77525540~77534110:+
THCA	cis	rs6547741	1	rs76784350	ENSG00000234072.1	AC074117.10	5.36	1.29e-07	1.94e-05	0.18	0.24	Oral cavity cancer;	chr2:27541411	chr2:27356246~27367622:+
THCA	cis	rs73198271	0.7	rs10090152	ENSG00000253893.2	FAM85B	5.36	1.29e-07	1.94e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8167819~8226614:-
THCA	cis	rs62432291	0.681	rs378547	ENSG00000235086.1	FNDC1-IT1	5.36	1.29e-07	1.94e-05	0.45	0.24	Joint mobility (Beighton score);	chr6:159241493	chr6:159240786~159243329:+
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000273796.1	LL21NC02-21A1.1	-5.36	1.29e-07	1.94e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000273796.1	LL21NC02-21A1.1	-5.36	1.29e-07	1.94e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000273796.1	LL21NC02-21A1.1	-5.36	1.29e-07	1.94e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000273796.1	LL21NC02-21A1.1	-5.36	1.29e-07	1.94e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45403809~45404369:-
THCA	cis	rs7111546	0.625	rs74557384	ENSG00000246225.5	RP11-17A1.3	5.36	1.29e-07	1.94e-05	0.39	0.24	Dialysis-related mortality;	chr11:22885834	chr11:22829380~22945393:+
THCA	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-5.36	1.29e-07	1.94e-05	-0.37	-0.24	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
THCA	cis	rs7170668	0.597	rs17493093	ENSG00000259134.4	LINC00924	5.36	1.29e-07	1.94e-05	0.29	0.24	Motion sickness;	chr15:95506447	chr15:95433095~95507847:+
THCA	cis	rs2179367	0.6	rs58747890	ENSG00000223701.3	RAET1E-AS1	5.36	1.29e-07	1.94e-05	0.38	0.24	Dupuytren's disease;	chr6:149459369	chr6:149884431~149919508:+
THCA	cis	rs10895275	0.886	rs1893498	ENSG00000277459.1	RP11-732A21.3	5.36	1.29e-07	1.94e-05	0.19	0.24	Migraine;	chr11:102184721	chr11:102109827~102110457:-
THCA	cis	rs72634501	0.716	rs67062906	ENSG00000228060.1	RP11-69E11.8	-5.36	1.29e-07	1.94e-05	-0.25	-0.24	HDL cholesterol;	chr1:39151018	chr1:39565160~39573203:+
THCA	cis	rs7554547	0.714	rs6671723	ENSG00000199347.1	RNU5E-1	-5.36	1.29e-07	1.94e-05	-0.33	-0.24	Nonsyndromic cleft lip with cleft palate;	chr1:11908021	chr1:11908152~11908271:+
THCA	cis	rs4591358	1	rs6713576	ENSG00000223466.1	AC064834.2	-5.36	1.29e-07	1.94e-05	-0.29	-0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195501522	chr2:195533035~195538681:+
THCA	cis	rs9425766	0.64	rs6685314	ENSG00000227373.4	RP11-160H22.5	5.36	1.29e-07	1.95e-05	0.34	0.24	Life satisfaction;	chr1:174089905	chr1:174115300~174160004:-
THCA	cis	rs9834975	0.967	rs12152463	ENSG00000272758.4	RP11-299J3.8	-5.36	1.29e-07	1.95e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122381600	chr3:122416207~122443180:+
THCA	cis	rs28476539	0.567	rs13102081	ENSG00000270480.1	RP11-57B24.1	5.36	1.29e-07	1.95e-05	0.39	0.24	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82652073	chr4:82691737~82692468:+
THCA	cis	rs752010	0.806	rs4641303	ENSG00000230638.4	RP11-486B10.4	-5.36	1.29e-07	1.95e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41625639	chr1:41542069~41544310:+
THCA	cis	rs752010	0.806	rs4457567	ENSG00000230638.4	RP11-486B10.4	-5.36	1.29e-07	1.95e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41625736	chr1:41542069~41544310:+
THCA	cis	rs752010	0.806	rs10890148	ENSG00000230638.4	RP11-486B10.4	-5.36	1.29e-07	1.95e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41625846	chr1:41542069~41544310:+
THCA	cis	rs228614	0.509	rs223486	ENSG00000248971.2	KRT8P46	-5.36	1.29e-07	1.95e-05	-0.29	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102728746~102730171:-
THCA	cis	rs35934224	0.783	rs58714937	ENSG00000232926.1	AC000078.5	5.36	1.29e-07	1.95e-05	0.26	0.24	Glaucoma (primary open-angle);	chr22:19869187	chr22:19887289~19887970:+
THCA	cis	rs35934224	0.783	rs34593728	ENSG00000232926.1	AC000078.5	5.36	1.29e-07	1.95e-05	0.26	0.24	Glaucoma (primary open-angle);	chr22:19869966	chr22:19887289~19887970:+
THCA	cis	rs890448	0.796	rs6840099	ENSG00000254531.1	FLJ20021	5.36	1.29e-07	1.95e-05	0.22	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423356	chr4:101347780~101348883:+
THCA	cis	rs564343	0.832	rs1151530	ENSG00000255320.1	RP11-755F10.1	-5.36	1.29e-07	1.95e-05	-0.29	-0.24	Obesity (early onset extreme);	chr11:66095481	chr11:66244840~66246239:-
THCA	cis	rs564343	0.966	rs537497	ENSG00000255320.1	RP11-755F10.1	-5.36	1.29e-07	1.95e-05	-0.29	-0.24	Obesity (early onset extreme);	chr11:66098716	chr11:66244840~66246239:-
THCA	cis	rs11073619	0.616	rs2401427	ENSG00000230373.7	GOLGA6L5P	-5.36	1.29e-07	1.95e-05	-0.37	-0.24	Positive affect;	chr15:84402427	chr15:84507885~84516814:-
THCA	cis	rs935334	1	rs1900125	ENSG00000258454.1	RP11-361H10.3	-5.36	1.29e-07	1.95e-05	-0.34	-0.24	Blood pressure;	chr14:76191127	chr14:76235817~76263474:+
THCA	cis	rs2282300	0.739	rs1222219	ENSG00000242353.1	RP4-710M3.1	-5.36	1.29e-07	1.95e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30322798	chr11:30368148~30368646:+
THCA	cis	rs9595908	0.965	rs9595795	ENSG00000212293.1	SNORA16	5.36	1.29e-07	1.95e-05	0.3	0.24	Body mass index;	chr13:32548658	chr13:32420390~32420516:-
THCA	cis	rs34779708	0.966	rs11010135	ENSG00000271335.4	RP11-324I22.4	5.36	1.29e-07	1.95e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35314552~35336401:-
THCA	cis	rs8177876	0.658	rs11150337	ENSG00000261061.1	RP11-303E16.2	-5.36	1.3e-07	1.95e-05	-0.33	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81030770~81031485:+
THCA	cis	rs9309473	0.519	rs2421583	ENSG00000163016.8	ALMS1P	-5.36	1.3e-07	1.95e-05	-0.31	-0.24	Metabolite levels;	chr2:73671658	chr2:73644919~73685576:+
THCA	cis	rs875971	0.66	rs1860468	ENSG00000273142.1	RP11-458F8.4	5.36	1.3e-07	1.95e-05	0.19	0.24	Aortic root size;	chr7:66642265	chr7:66902857~66906297:+
THCA	cis	rs1050631	0.564	rs681757	ENSG00000260552.1	RP11-49I11.1	5.36	1.3e-07	1.95e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36164803	chr18:36179996~36187448:-
THCA	cis	rs9393777	0.778	rs66841633	ENSG00000219392.1	RP1-265C24.5	-5.36	1.3e-07	1.95e-05	-0.49	-0.24	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28115628~28116551:+
THCA	cis	rs860295	0.58	rs6672284	ENSG00000160766.13	GBAP1	-5.36	1.3e-07	1.95e-05	-0.28	-0.24	Body mass index;	chr1:155308172	chr1:155213821~155227422:-
THCA	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	5.36	1.3e-07	1.95e-05	0.15	0.24	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
THCA	cis	rs752010	0.871	rs10890149	ENSG00000230638.4	RP11-486B10.4	-5.36	1.3e-07	1.95e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41627120	chr1:41542069~41544310:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	5.36	1.3e-07	1.96e-05	0.28	0.24	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
THCA	cis	rs748404	0.589	rs62020612	ENSG00000205771.5	CATSPER2P1	-5.36	1.3e-07	1.96e-05	-0.31	-0.24	Lung cancer;	chr15:43525881	chr15:43726918~43747094:-
THCA	cis	rs9859260	0.961	rs41300431	ENSG00000273009.1	RP11-352G9.1	-5.36	1.3e-07	1.96e-05	-0.26	-0.24	Mean corpuscular volume;	chr3:196077427	chr3:195913078~195913683:-
THCA	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	5.36	1.3e-07	1.96e-05	0.15	0.24	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
THCA	cis	rs7429990	0.965	rs2053767	ENSG00000228638.1	FCF1P2	-5.36	1.3e-07	1.96e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47958184	chr3:48290793~48291375:-
THCA	cis	rs7824557	0.651	rs6601582	ENSG00000154316.13	TDH	-5.36	1.3e-07	1.96e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11349858	chr8:11339637~11368452:+
THCA	cis	rs1318937	0.588	rs80123042	ENSG00000224660.1	SH3BP5-AS1	5.36	1.3e-07	1.96e-05	0.23	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15241957	chr3:15254184~15264493:+
THCA	cis	rs4965006	0.508	rs75594148	ENSG00000255992.1	RP11-417L19.4	5.36	1.3e-07	1.96e-05	0.38	0.24	Posterior cortical atrophy and Alzheimer's disease;	chr12:131929142	chr12:131924736~131929351:-
THCA	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-5.36	1.3e-07	1.96e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
THCA	cis	rs8177876	0.749	rs12444969	ENSG00000261838.4	RP11-303E16.6	5.36	1.3e-07	1.96e-05	0.44	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81069854~81076598:+
THCA	cis	rs863750	0.744	rs2451321	ENSG00000275389.1	RP11-214K3.24	5.36	1.3e-07	1.96e-05	0.32	0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124060888	chr12:124085761~124088598:+
THCA	cis	rs9921338	0.924	rs7204628	ENSG00000262636.1	CTD-3088G3.4	-5.36	1.3e-07	1.96e-05	-0.35	-0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350715	chr16:11380859~11381118:-
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000273796.1	LL21NC02-21A1.1	-5.36	1.3e-07	1.96e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45403809~45404369:-
THCA	cis	rs748404	1	rs12911132	ENSG00000205771.5	CATSPER2P1	-5.36	1.3e-07	1.96e-05	-0.28	-0.24	Lung cancer;	chr15:43268238	chr15:43726918~43747094:-
THCA	cis	rs7085104	0.7	rs7096183	ENSG00000213061.2	PFN1P11	5.36	1.3e-07	1.96e-05	0.29	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102838011~102845473:-
THCA	cis	rs1552244	1	rs6807846	ENSG00000232901.1	CYCSP10	5.36	1.3e-07	1.96e-05	0.31	0.24	Alzheimer's disease;	chr3:10092807	chr3:10000647~10000940:-
THCA	cis	rs4888671	0.708	rs116932258	ENSG00000261707.1	RP11-264M12.2	5.36	1.3e-07	1.96e-05	0.45	0.24	Obesity-related traits;	chr16:77739427	chr16:77741468~77743000:-
THCA	cis	rs752010	0.841	rs11210498	ENSG00000230638.4	RP11-486B10.4	-5.36	1.3e-07	1.96e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41612287	chr1:41542069~41544310:+
THCA	cis	rs16846053	0.605	rs62188819	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161902799	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs61744553	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161902992	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188820	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161905025	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865241	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161905524	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.539	rs62188821	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161906449	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs55931021	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161907986	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865255	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161909249	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.54	rs72865256	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161909252	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865260	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161910741	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865262	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161910782	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188825	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161910943	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188826	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161911143	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188827	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161911698	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs62188838	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161915131	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188839	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161915158	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs55693861	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161916006	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188842	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161916600	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs1913809	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161917849	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.502	rs56399725	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161918616	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188845	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161918729	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865282	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161918879	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865285	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161919122	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188846	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161919351	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.581	rs62188849	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161921111	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188850	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161922804	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188851	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161922940	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188852	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161923410	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865298	ENSG00000227403.1	AC009299.3	5.36	1.3e-07	1.96e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161924263	chr2:161244739~161249050:+
THCA	cis	rs2562456	0.752	rs7258562	ENSG00000268081.1	RP11-678G14.2	5.36	1.3e-07	1.96e-05	0.4	0.24	Pain;	chr19:21331762	chr19:21554640~21569237:-
THCA	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	5.36	1.3e-07	1.96e-05	0.28	0.24	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
THCA	cis	rs6044112	1	rs6080297	ENSG00000273998.1	RP4-777L9.2	5.36	1.3e-07	1.97e-05	0.39	0.24	Response to taxane treatment (docetaxel);	chr20:16544066	chr20:16576068~16579615:+
THCA	cis	rs10208649	1	rs13402778	ENSG00000233266.1	HMGB1P31	5.36	1.31e-07	1.97e-05	0.57	0.24	Body mass index;	chr2:53900883	chr2:54051334~54051760:+
THCA	cis	rs26528	0.584	rs153103	ENSG00000251417.2	RP11-1348G14.4	5.36	1.31e-07	1.97e-05	0.22	0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28802743~28817828:+
THCA	cis	rs4415084	0.834	rs11746980	ENSG00000272335.1	RP11-53O19.3	-5.36	1.31e-07	1.97e-05	-0.2	-0.24	Breast cancer;	chr5:44777776	chr5:44826076~44828592:+
THCA	cis	rs12681287	0.752	rs10103229	ENSG00000254231.1	CTD-2284J15.1	-5.36	1.31e-07	1.97e-05	-0.27	-0.24	Caudate activity during reward;	chr8:86236725	chr8:86333274~86343314:-
THCA	cis	rs875971	0.545	rs73376401	ENSG00000228409.4	CCT6P1	-5.36	1.31e-07	1.97e-05	-0.2	-0.24	Aortic root size;	chr7:66174841	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs316328	ENSG00000232546.1	RP11-458F8.1	-5.36	1.31e-07	1.97e-05	-0.21	-0.24	Aortic root size;	chr7:66143851	chr7:66848496~66858136:+
THCA	cis	rs10043228	0.702	rs62384478	ENSG00000248445.4	SEMA6A-AS1	-5.36	1.31e-07	1.97e-05	-0.26	-0.24	Asthma or chronic obstructive pulmonary disease;	chr5:116327284	chr5:116447547~116508276:+
THCA	cis	rs10129255	0.646	rs55995061	ENSG00000211970.3	IGHV4-61	-5.36	1.31e-07	1.97e-05	-0.14	-0.24	Kawasaki disease;	chr14:106799309	chr14:106639119~106639657:-
THCA	cis	rs1400745	0.718	rs799681	ENSG00000258738.1	RP11-73E17.2	5.36	1.31e-07	1.97e-05	0.29	0.24	Monocyte count;	chr14:34881373	chr14:34874343~34876459:+
THCA	cis	rs2559856	1	rs2559855	ENSG00000274560.1	RP11-285E23.2	-5.36	1.31e-07	1.97e-05	-0.15	-0.24	Blood protein levels;	chr12:101696302	chr12:101696002~101696450:-
THCA	cis	rs7927592	0.513	rs531163	ENSG00000212093.1	AP000807.1	5.36	1.31e-07	1.97e-05	0.25	0.24	Total body bone mineral density;	chr11:68427028	chr11:68506083~68506166:-
THCA	cis	rs5006884	0.715	rs2467234	ENSG00000167355.6	AC104389.28	-5.36	1.31e-07	1.97e-05	-0.38	-0.24	Fetal hemoglobin levels;	chr11:5364144	chr11:5304976~5505652:-
THCA	cis	rs230501	1	rs230501	ENSG00000246560.2	RP11-10L12.4	-5.36	1.31e-07	1.97e-05	-0.29	-0.24	Neutrophil percentage of white cells;	chr4:102570706	chr4:102828055~102844075:+
THCA	cis	rs6840360	0.87	rs1372978	ENSG00000251611.1	RP11-610P16.1	-5.36	1.31e-07	1.97e-05	-0.18	-0.24	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151407551~151408835:-
THCA	cis	rs853679	0.76	rs11962305	ENSG00000220721.1	OR1F12	5.36	1.31e-07	1.97e-05	0.34	0.24	Depression;	chr6:28232159	chr6:28073316~28074233:+
THCA	cis	rs1865760	0.532	rs1061482	ENSG00000272462.2	U91328.19	-5.36	1.31e-07	1.98e-05	-0.2	-0.24	Height;	chr6:26086471	chr6:25992662~26001775:+
THCA	cis	rs6600671	0.764	rs6600673	ENSG00000275538.1	RNVU1-19	5.36	1.31e-07	1.98e-05	0.31	0.24	Hip geometry;	chr1:121426988	chr1:120850819~120850985:-
THCA	cis	rs752010	0.668	rs10890147	ENSG00000230638.4	RP11-486B10.4	-5.36	1.31e-07	1.98e-05	-0.29	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41624054	chr1:41542069~41544310:+
THCA	cis	rs3760982	0.813	rs8104447	ENSG00000267058.1	RP11-15A1.3	5.36	1.31e-07	1.98e-05	0.21	0.24	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789126	chr19:43891804~43901805:-
THCA	cis	rs2692947	0.832	rs4907212	ENSG00000232931.4	LINC00342	5.36	1.31e-07	1.98e-05	0.19	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95744300	chr2:95807118~95816215:-
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000230295.1	RP11-458F8.2	-5.36	1.31e-07	1.98e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65996588	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1701750	ENSG00000230295.1	RP11-458F8.2	-5.36	1.31e-07	1.98e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66002158	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1701758	ENSG00000230295.1	RP11-458F8.2	-5.36	1.31e-07	1.98e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66005214	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000230295.1	RP11-458F8.2	-5.36	1.31e-07	1.98e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66005945	chr7:66880708~66882981:+
THCA	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	5.36	1.31e-07	1.98e-05	0.15	0.24	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
THCA	cis	rs17772222	0.636	rs77528165	ENSG00000222990.1	RNU4-22P	5.36	1.31e-07	1.98e-05	0.32	0.24	Coronary artery calcification;	chr14:88794249	chr14:88513498~88513663:+
THCA	cis	rs6928977	0.932	rs6914831	ENSG00000231028.7	LINC00271	5.36	1.32e-07	1.98e-05	0.19	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135318506	chr6:135497801~135716055:+
THCA	cis	rs944289	0.624	rs55775461	ENSG00000258844.1	RP11-259K15.2	5.36	1.32e-07	1.98e-05	0.21	0.24	Thyroid cancer;	chr14:36108166	chr14:36214607~36235608:+
THCA	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-5.36	1.32e-07	1.98e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
THCA	cis	rs10405744	0.744	rs7246986	ENSG00000240673.1	AC006539.2	-5.36	1.32e-07	1.98e-05	-0.44	-0.24	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);	chr19:20079158	chr19:20079818~20080539:-
THCA	cis	rs793571	0.505	rs16940589	ENSG00000245975.2	RP11-30K9.6	5.36	1.32e-07	1.98e-05	0.27	0.24	Schizophrenia;	chr15:58606485	chr15:58768072~58770974:-
THCA	cis	rs7976269	0.559	rs10771477	ENSG00000275476.1	RP11-996F15.4	-5.36	1.32e-07	1.98e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29074137	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.559	rs10843307	ENSG00000275476.1	RP11-996F15.4	-5.36	1.32e-07	1.98e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29074710	chr12:29277397~29277882:-
THCA	cis	rs10266483	0.515	rs17689514	ENSG00000227986.1	TRIM60P18	5.36	1.32e-07	1.98e-05	0.24	0.24	Response to statin therapy;	chr7:64279269	chr7:64355078~64356199:+
THCA	cis	rs10875746	0.903	rs989144	ENSG00000269514.1	RP11-370I10.12	5.36	1.32e-07	1.98e-05	0.24	0.24	Longevity (90 years and older);	chr12:48090190	chr12:48198387~48202031:+
THCA	cis	rs10895275	0.809	rs7120067	ENSG00000277459.1	RP11-732A21.3	-5.36	1.32e-07	1.98e-05	-0.2	-0.24	Migraine;	chr11:102194103	chr11:102109827~102110457:-
THCA	cis	rs17594362	0.731	rs9594576	ENSG00000264190.1	MIR5006	5.36	1.32e-07	1.98e-05	0.34	0.24	Multiple sclerosis;	chr13:41568456	chr13:41568286~41568395:-
THCA	cis	rs2797160	0.875	rs12527010	ENSG00000237742.5	RP11-624M8.1	5.36	1.32e-07	1.99e-05	0.21	0.24	Endometrial cancer;	chr6:125670361	chr6:125578558~125749190:-
THCA	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	5.36	1.32e-07	1.99e-05	0.21	0.24	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
THCA	cis	rs10895275	0.961	rs10895274	ENSG00000277459.1	RP11-732A21.3	-5.36	1.32e-07	1.99e-05	-0.19	-0.24	Migraine;	chr11:102212338	chr11:102109827~102110457:-
THCA	cis	rs17772222	0.701	rs845757	ENSG00000258983.2	RP11-507K2.2	-5.36	1.32e-07	1.99e-05	-0.28	-0.24	Coronary artery calcification;	chr14:88455372	chr14:88499334~88515502:+
THCA	cis	rs17264034	0.5	rs1508800	ENSG00000250786.1	SNHG18	5.36	1.32e-07	1.99e-05	0.29	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556349	chr5:9546200~9550609:+
THCA	cis	rs849141	0.925	rs552707	ENSG00000234336.5	JAZF1-AS1	-5.36	1.32e-07	1.99e-05	-0.28	-0.24	Height;Hip circumference adjusted for BMI;	chr7:28165684	chr7:28180322~28243917:+
THCA	cis	rs9733	0.519	rs11204717	ENSG00000231073.1	RP11-316M1.3	5.36	1.32e-07	1.99e-05	0.29	0.24	Tonsillectomy;	chr1:150736653	chr1:150973123~150975534:+
THCA	cis	rs2664588	0.741	rs11086235	ENSG00000276923.1	RP11-321P16.1	-5.36	1.32e-07	1.99e-05	-0.32	-0.24	Cerebrospinal fluid AB1-42 levels;	chr20:47995094	chr20:48073869~48074188:+
THCA	cis	rs12030196	0.788	rs2764929	ENSG00000230812.4	LINC01358	5.36	1.32e-07	1.99e-05	0.29	0.24	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58956345	chr1:59020387~59044614:+
THCA	cis	rs3847687	0.546	rs12832254	ENSG00000279993.1	RP11-76C10.3	5.36	1.32e-07	1.99e-05	0.27	0.24	Longevity;	chr12:131034843	chr12:131025561~131028060:-
THCA	cis	rs10276381	0.892	rs7786444	ENSG00000234336.5	JAZF1-AS1	-5.36	1.32e-07	1.99e-05	-0.34	-0.24	Crohn's disease;	chr7:28114765	chr7:28180322~28243917:+
THCA	cis	rs13088281	1	rs13088281	ENSG00000242142.1	SERBP1P3	5.36	1.32e-07	1.99e-05	0.44	0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53113560	chr3:53064283~53065091:-
THCA	cis	rs1555322	0.53	rs2425049	ENSG00000279253.1	RP4-614O4.13	-5.36	1.32e-07	1.99e-05	-0.28	-0.24	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35262727~35264187:-
THCA	cis	rs7403037	1	rs28786136	ENSG00000259905.4	PWRN1	5.36	1.32e-07	1.99e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24586967	chr15:24493137~24652130:+
THCA	cis	rs7403037	1	rs28625349	ENSG00000259905.4	PWRN1	5.36	1.32e-07	1.99e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24587326	chr15:24493137~24652130:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000228409.4	CCT6P1	-5.36	1.32e-07	1.99e-05	-0.2	-0.24	Aortic root size;	chr7:66164012	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000228409.4	CCT6P1	-5.36	1.32e-07	1.99e-05	-0.2	-0.24	Aortic root size;	chr7:66166374	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000228409.4	CCT6P1	-5.36	1.32e-07	1.99e-05	-0.2	-0.24	Aortic root size;	chr7:66168318	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000228409.4	CCT6P1	-5.36	1.32e-07	1.99e-05	-0.2	-0.24	Aortic root size;	chr7:66169164	chr7:65751142~65763354:+
THCA	cis	rs2617170	0.922	rs1351113	ENSG00000245648.1	RP11-277P12.20	-5.36	1.32e-07	1.99e-05	-0.26	-0.24	Behcet's disease;	chr12:10373045	chr12:10363769~10398506:+
THCA	cis	rs6088590	1	rs2236270	ENSG00000269202.1	RP4-614O4.12	-5.36	1.32e-07	1.99e-05	-0.21	-0.24	Coronary artery disease;	chr20:34935352	chr20:35201747~35203288:-
THCA	cis	rs17292804	0.527	rs12887734	ENSG00000269940.1	RP11-73M18.7	5.36	1.32e-07	1.99e-05	0.25	0.24	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103694560~103695170:+
THCA	cis	rs2179367	0.959	rs4895788	ENSG00000231760.4	RP11-350J20.5	5.36	1.32e-07	1.99e-05	0.32	0.24	Dupuytren's disease;	chr6:149426955	chr6:149796151~149826294:-
THCA	cis	rs6545883	0.811	rs778753	ENSG00000270820.4	RP11-355B11.2	5.36	1.33e-07	2e-05	0.2	0.24	Tuberculosis;	chr2:61553065	chr2:61471188~61484130:+
THCA	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	5.36	1.33e-07	2e-05	0.28	0.24	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	5.36	1.33e-07	2e-05	0.28	0.24	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
THCA	cis	rs763567	0.935	rs580487	ENSG00000271811.1	RP1-79C4.4	5.36	1.33e-07	2e-05	0.27	0.24	Tonsillectomy;	chr1:170640484	chr1:170667381~170669425:+
THCA	cis	rs6968419	0.755	rs2896180	ENSG00000237870.5	AC073130.1	5.36	1.33e-07	2e-05	0.26	0.24	Intraocular pressure;	chr7:116257817	chr7:116275606~116286734:-
THCA	cis	rs9733	0.519	rs1134067	ENSG00000231073.1	RP11-316M1.3	5.36	1.33e-07	2e-05	0.3	0.24	Tonsillectomy;	chr1:150748699	chr1:150973123~150975534:+
THCA	cis	rs7598759	0.548	rs6750795	ENSG00000223198.1	RNU2-22P	-5.36	1.33e-07	2e-05	-0.32	-0.24	Noise-induced hearing loss;	chr2:231513520	chr2:231501990~231502201:-
THCA	cis	rs6750795	0.641	rs10933375	ENSG00000181798.2	LINC00471	5.36	1.33e-07	2e-05	0.34	0.24	Height;	chr2:231502585	chr2:231508426~231514339:-
THCA	cis	rs79040073	0.637	rs17473568	ENSG00000259531.2	RP11-295H24.3	5.36	1.33e-07	2e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49149326	chr15:49365124~49366685:-
THCA	cis	rs75920871	0.528	rs3886960	ENSG00000254851.1	RP11-109L13.1	5.36	1.33e-07	2e-05	0.34	0.24	Subjective well-being;	chr11:117054274	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs723955	ENSG00000254851.1	RP11-109L13.1	5.36	1.33e-07	2e-05	0.34	0.24	Subjective well-being;	chr11:117054326	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs7108912	ENSG00000254851.1	RP11-109L13.1	5.36	1.33e-07	2e-05	0.34	0.24	Subjective well-being;	chr11:117055280	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.502	rs7124996	ENSG00000254851.1	RP11-109L13.1	5.36	1.33e-07	2e-05	0.34	0.24	Subjective well-being;	chr11:117057290	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs7124872	ENSG00000254851.1	RP11-109L13.1	-5.36	1.33e-07	2e-05	-0.34	-0.24	Subjective well-being;	chr11:117057235	chr11:117135528~117138582:+
THCA	cis	rs875971	0.545	rs6460298	ENSG00000232546.1	RP11-458F8.1	5.36	1.33e-07	2e-05	0.23	0.24	Aortic root size;	chr7:66442783	chr7:66848496~66858136:+
THCA	cis	rs7688540	0.771	rs11248013	ENSG00000211553.1	AC253576.2	-5.36	1.33e-07	2e-05	-0.38	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:136461~136568:+
THCA	cis	rs10875746	0.551	rs1471997	ENSG00000258234.1	RP11-370I10.2	5.36	1.33e-07	2e-05	0.28	0.24	Longevity (90 years and older);	chr12:48329812	chr12:48231098~48284210:-
THCA	cis	rs7760535	0.763	rs9487666	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.33e-07	2e-05	-0.19	-0.24	Metabolic traits;	chr6:111547821	chr6:111277932~111278742:+
THCA	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	5.36	1.33e-07	2e-05	0.15	0.24	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
THCA	cis	rs5758659	0.967	rs5758670	ENSG00000281538.1	RP4-669P10.20	5.36	1.33e-07	2e-05	0.23	0.24	Cognitive function;	chr22:42240681	chr22:42138060~42139726:+
THCA	cis	rs7829975	0.514	rs2920991	ENSG00000253981.4	ALG1L13P	5.36	1.33e-07	2e-05	0.22	0.24	Mood instability;	chr8:8401607	chr8:8236003~8244667:-
THCA	cis	rs10771431	0.597	rs10843142	ENSG00000111788.10	RP11-22B23.1	5.36	1.33e-07	2.01e-05	0.23	0.24	Breast size;	chr12:9204906	chr12:9277235~9313241:+
THCA	cis	rs838147	0.563	rs281379	ENSG00000232871.7	SEC1P	5.36	1.33e-07	2.01e-05	0.28	0.24	Dietary macronutrient intake;	chr19:48711017	chr19:48638071~48682245:+
THCA	cis	rs4648045	0.856	rs230499	ENSG00000246560.2	RP11-10L12.4	-5.36	1.33e-07	2.01e-05	-0.29	-0.24	Lymphocyte percentage of white cells;	chr4:102568826	chr4:102828055~102844075:+
THCA	cis	rs4654783	0.521	rs59709264	ENSG00000218510.5	LINC00339	-5.36	1.33e-07	2.01e-05	-0.25	-0.24	Endometriosis;	chr1:22122832	chr1:22025188~22031223:+
THCA	cis	rs3892630	0.824	rs12327732	ENSG00000267567.1	CTD-2538C1.3	5.36	1.33e-07	2.01e-05	0.37	0.24	Red blood cell traits;	chr19:32730861	chr19:32718298~32719595:-
THCA	cis	rs3892630	0.824	rs35654350	ENSG00000267567.1	CTD-2538C1.3	5.36	1.33e-07	2.01e-05	0.37	0.24	Red blood cell traits;	chr19:32732860	chr19:32718298~32719595:-
THCA	cis	rs7829975	0.774	rs35431455	ENSG00000254153.1	CTA-398F10.2	-5.36	1.33e-07	2.01e-05	-0.26	-0.24	Mood instability;	chr8:8816226	chr8:8456909~8461337:-
THCA	cis	rs2282300	0.739	rs7942129	ENSG00000242353.1	RP4-710M3.1	-5.36	1.33e-07	2.01e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30203145	chr11:30368148~30368646:+
THCA	cis	rs748404	1	rs12909095	ENSG00000205771.5	CATSPER2P1	-5.36	1.34e-07	2.01e-05	-0.27	-0.24	Lung cancer;	chr15:43265944	chr15:43726918~43747094:-
THCA	cis	rs1050631	0.564	rs589213	ENSG00000260552.1	RP11-49I11.1	5.36	1.34e-07	2.01e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36163647	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.564	rs684890	ENSG00000260552.1	RP11-49I11.1	5.36	1.34e-07	2.01e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36164714	chr18:36179996~36187448:-
THCA	cis	rs9307551	0.553	rs7673033	ENSG00000250334.4	LINC00989	-5.36	1.34e-07	2.01e-05	-0.29	-0.24	Refractive error;	chr4:79537914	chr4:79492416~79576460:+
THCA	cis	rs651907	0.557	rs3094295	ENSG00000244119.1	PDCL3P4	5.36	1.34e-07	2.01e-05	0.22	0.24	Colorectal cancer;	chr3:101683151	chr3:101712472~101713191:+
THCA	cis	rs4748857	0.947	rs7082900	ENSG00000224215.1	RP11-371A19.2	-5.36	1.34e-07	2.01e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23306604	chr10:23343957~23345181:+
THCA	cis	rs2985684	0.841	rs12894785	ENSG00000278009.1	RP11-649E7.8	5.36	1.34e-07	2.01e-05	0.33	0.24	Carotid intima media thickness;	chr14:49583037	chr14:49601011~49601124:-
THCA	cis	rs6840360	0.582	rs6813735	ENSG00000270265.1	RP11-731D1.4	-5.36	1.34e-07	2.01e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151405838	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.582	rs57585665	ENSG00000270265.1	RP11-731D1.4	-5.36	1.34e-07	2.01e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151405865	chr4:151333775~151353224:-
THCA	cis	rs6973609	0.627	rs1003248	ENSG00000271122.1	RP11-379H18.1	5.36	1.34e-07	2.01e-05	0.15	0.24	Obesity-related traits;	chr7:35570153	chr7:35695214~35699413:+
THCA	cis	rs2839186	0.605	rs2839173	ENSG00000215424.8	MCM3AP-AS1	5.36	1.34e-07	2.01e-05	0.14	0.24	Testicular germ cell tumor;	chr21:46256797	chr21:46229217~46259390:+
THCA	cis	rs7617773	0.963	rs12495221	ENSG00000199476.1	Y_RNA	5.36	1.34e-07	2.01e-05	0.3	0.24	Coronary artery disease;	chr3:48137688	chr3:48288587~48288694:+
THCA	cis	rs6058796	0.892	rs66897337	ENSG00000175730.8	BAK1P1	5.36	1.34e-07	2.01e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32668791	chr20:32690180~32690815:-
THCA	cis	rs6058796	1	rs6087409	ENSG00000175730.8	BAK1P1	5.36	1.34e-07	2.01e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32669750	chr20:32690180~32690815:-
THCA	cis	rs2029362	0.967	rs11030076	ENSG00000245573.6	BDNF-AS	5.36	1.34e-07	2.01e-05	0.19	0.24	Total body bone mineral density;	chr11:27606570	chr11:27506838~27698174:+
THCA	cis	rs5751901	0.929	rs2330805	ENSG00000215481.7	BCRP3	-5.36	1.34e-07	2.01e-05	-0.21	-0.24	Protein quantitative trait loci;	chr22:24602652	chr22:24632915~24653356:+
THCA	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	5.36	1.34e-07	2.01e-05	0.3	0.24	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
THCA	cis	rs2911132	0.564	rs28580505	ENSG00000248734.2	CTD-2260A17.1	5.35	1.34e-07	2.02e-05	0.26	0.24	Urate levels (BMI interaction);	chr5:96765516	chr5:96784777~96785999:+
THCA	cis	rs2911132	0.621	rs28432918	ENSG00000248734.2	CTD-2260A17.1	5.35	1.34e-07	2.02e-05	0.26	0.24	Urate levels (BMI interaction);	chr5:96765522	chr5:96784777~96785999:+
THCA	cis	rs1318937	0.764	rs60896928	ENSG00000224660.1	SH3BP5-AS1	5.35	1.34e-07	2.02e-05	0.15	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15201343	chr3:15254184~15264493:+
THCA	cis	rs9876781	1	rs6442119	ENSG00000229759.1	MRPS18AP1	5.35	1.34e-07	2.02e-05	0.28	0.24	Longevity;	chr3:48398713	chr3:48256350~48256938:-
THCA	cis	rs116095464	0.558	rs6555055	ENSG00000248925.1	CTD-2083E4.6	5.35	1.34e-07	2.02e-05	0.35	0.24	Breast cancer;	chr5:226045	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs6555056	ENSG00000248925.1	CTD-2083E4.6	5.35	1.34e-07	2.02e-05	0.35	0.24	Breast cancer;	chr5:226107	chr5:269858~271516:-
THCA	cis	rs6988985	0.618	rs62525983	ENSG00000247317.3	RP11-273G15.2	-5.35	1.34e-07	2.02e-05	-0.26	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142907570	chr8:142981738~143018437:-
THCA	cis	rs66887589	0.616	rs6822808	ENSG00000249244.1	RP11-548H18.2	5.35	1.34e-07	2.02e-05	0.25	0.24	Diastolic blood pressure;	chr4:119296210	chr4:119391831~119395335:-
THCA	cis	rs2282300	0.739	rs1631451	ENSG00000242353.1	RP4-710M3.1	-5.35	1.34e-07	2.02e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30327586	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs1717775	ENSG00000242353.1	RP4-710M3.1	-5.35	1.34e-07	2.02e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30328707	chr11:30368148~30368646:+
THCA	cis	rs752010	0.806	rs1109255	ENSG00000230638.4	RP11-486B10.4	-5.35	1.34e-07	2.02e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41626037	chr1:41542069~41544310:+
THCA	cis	rs6545883	0.929	rs3732171	ENSG00000270820.4	RP11-355B11.2	5.35	1.34e-07	2.02e-05	0.2	0.24	Tuberculosis;	chr2:61522555	chr2:61471188~61484130:+
THCA	cis	rs752010	0.619	rs1123483	ENSG00000230638.4	RP11-486B10.4	5.35	1.34e-07	2.02e-05	0.29	0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41648527	chr1:41542069~41544310:+
THCA	cis	rs1552244	1	rs68067759	ENSG00000232901.1	CYCSP10	5.35	1.34e-07	2.02e-05	0.31	0.24	Alzheimer's disease;	chr3:10108851	chr3:10000647~10000940:-
THCA	cis	rs442309	0.846	rs224127	ENSG00000238280.1	RP11-436D10.3	-5.35	1.35e-07	2.02e-05	-0.29	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62701513	chr10:62793562~62805887:-
THCA	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	5.35	1.35e-07	2.02e-05	0.28	0.24	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.713	rs2476319	ENSG00000269125.1	RP11-98F14.11	5.35	1.35e-07	2.02e-05	0.28	0.24	Platelet distribution width;	chr13:113182205	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.713	rs553316	ENSG00000269125.1	RP11-98F14.11	5.35	1.35e-07	2.02e-05	0.28	0.24	Platelet distribution width;	chr13:113183701	chr13:113165002~113165183:-
THCA	cis	rs2337406	0.866	rs8003852	ENSG00000211974.3	IGHV2-70	-5.35	1.35e-07	2.02e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106776648	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs988131	ENSG00000211974.3	IGHV2-70	-5.35	1.35e-07	2.02e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106776833	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs8005518	ENSG00000211974.3	IGHV2-70	-5.35	1.35e-07	2.02e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106777009	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs57684263	ENSG00000211974.3	IGHV2-70	-5.35	1.35e-07	2.02e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106777263	chr14:106723574~106724093:-
THCA	cis	rs6866614	0.627	rs27437	ENSG00000224431.1	AC063976.7	5.35	1.35e-07	2.03e-05	0.2	0.24	Perceived unattractiveness to mosquitoes;	chr5:132101268	chr5:132199456~132203487:+
THCA	cis	rs2797160	1	rs2211418	ENSG00000237742.5	RP11-624M8.1	-5.35	1.35e-07	2.03e-05	-0.21	-0.24	Endometrial cancer;	chr6:125674357	chr6:125578558~125749190:-
THCA	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	5.35	1.35e-07	2.03e-05	0.29	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
THCA	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	5.35	1.35e-07	2.03e-05	0.34	0.24	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	5.35	1.35e-07	2.03e-05	0.34	0.24	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	5.35	1.35e-07	2.03e-05	0.34	0.24	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
THCA	cis	rs2361701	0.636	rs1982244	ENSG00000275479.1	RP11-334C17.6	5.35	1.35e-07	2.03e-05	0.24	0.24	IgG glycosylation;	chr17:80095149	chr17:80149627~80149798:+
THCA	cis	rs67478160	0.654	rs4906365	ENSG00000258735.1	LINC00637	-5.35	1.35e-07	2.03e-05	-0.3	-0.24	Schizophrenia;	chr14:103762893	chr14:103847721~103858049:+
THCA	cis	rs72949976	0.646	rs1441170	ENSG00000270659.1	RP11-105N14.1	5.35	1.36e-07	2.03e-05	0.19	0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213168839	chr2:213152970~213153659:+
THCA	cis	rs2255336	0.938	rs7298494	ENSG00000245648.1	RP11-277P12.20	-5.35	1.36e-07	2.03e-05	-0.3	-0.24	Blood protein levels;	chr12:10460666	chr12:10363769~10398506:+
THCA	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	5.35	1.36e-07	2.03e-05	0.38	0.24	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
THCA	cis	rs7824557	0.628	rs11777746	ENSG00000154316.13	TDH	-5.35	1.36e-07	2.04e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11347246	chr8:11339637~11368452:+
THCA	cis	rs875971	0.66	rs801193	ENSG00000273142.1	RP11-458F8.4	5.35	1.36e-07	2.04e-05	0.19	0.24	Aortic root size;	chr7:66565625	chr7:66902857~66906297:+
THCA	cis	rs9733	0.596	rs11204704	ENSG00000231073.1	RP11-316M1.3	5.35	1.36e-07	2.04e-05	0.28	0.24	Tonsillectomy;	chr1:150699154	chr1:150973123~150975534:+
THCA	cis	rs17508449	0.69	rs4839333	ENSG00000232450.1	RP4-730K3.3	-5.35	1.36e-07	2.04e-05	-0.39	-0.24	Leprosy;	chr1:113676539	chr1:113698884~113699631:-
THCA	cis	rs2348418	0.767	rs7972954	ENSG00000247934.4	RP11-967K21.1	5.35	1.36e-07	2.04e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28260273	chr12:28163298~28190738:-
THCA	cis	rs4654783	0.627	rs1046310	ENSG00000218510.5	LINC00339	-5.35	1.36e-07	2.04e-05	-0.26	-0.24	Endometriosis;	chr1:22117394	chr1:22025188~22031223:+
THCA	cis	rs897984	0.683	rs12926237	ENSG00000279196.1	RP11-1072A3.3	-5.35	1.36e-07	2.04e-05	-0.24	-0.24	Dementia with Lewy bodies;	chr16:30826275	chr16:30984630~30988270:-
THCA	cis	rs79040073	0.637	rs11635005	ENSG00000259531.2	RP11-295H24.3	5.35	1.36e-07	2.04e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49309228	chr15:49365124~49366685:-
THCA	cis	rs7512898	0.545	rs6427850	ENSG00000260088.1	RP11-92G12.3	-5.35	1.36e-07	2.04e-05	-0.3	-0.24	Electrocardiographic conduction measures;	chr1:200703282	chr1:200669507~200694250:+
THCA	cis	rs4591358	0.871	rs1500608	ENSG00000223466.1	AC064834.2	-5.35	1.36e-07	2.04e-05	-0.28	-0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195482075	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.834	rs4850621	ENSG00000223466.1	AC064834.2	-5.35	1.36e-07	2.04e-05	-0.28	-0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195484850	chr2:195533035~195538681:+
THCA	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	5.35	1.36e-07	2.04e-05	0.34	0.24	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	5.35	1.36e-07	2.04e-05	0.34	0.24	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
THCA	cis	rs9813712	0.571	rs9866568	ENSG00000253540.4	FAM86HP	-5.35	1.36e-07	2.04e-05	-0.26	-0.24	Response to amphetamines;	chr3:130297539	chr3:130099092~130111472:-
THCA	cis	rs12681287	0.608	rs13270090	ENSG00000254231.1	CTD-2284J15.1	-5.35	1.36e-07	2.04e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86541069	chr8:86333274~86343314:-
THCA	cis	rs7045138	1	rs7045138	ENSG00000214417.4	KRT18P13	-5.35	1.36e-07	2.04e-05	-0.21	-0.24	Thyroid hormone levels;	chr9:97829181	chr9:97698922~97700734:+
THCA	cis	rs12893668	0.638	rs11851616	ENSG00000269958.1	RP11-73M18.8	5.35	1.36e-07	2.04e-05	0.23	0.24	Reticulocyte count;	chr14:103599263	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.667	rs11844466	ENSG00000269958.1	RP11-73M18.8	5.35	1.36e-07	2.04e-05	0.23	0.24	Reticulocyte count;	chr14:103600085	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.637	rs12892038	ENSG00000269958.1	RP11-73M18.8	5.35	1.36e-07	2.04e-05	0.23	0.24	Reticulocyte count;	chr14:103602292	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.637	rs4525427	ENSG00000269958.1	RP11-73M18.8	5.35	1.36e-07	2.04e-05	0.23	0.24	Reticulocyte count;	chr14:103606456	chr14:103696353~103697163:+
THCA	cis	rs7403037	0.583	rs61993093	ENSG00000259905.4	PWRN1	5.35	1.36e-07	2.04e-05	0.32	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24516210	chr15:24493137~24652130:+
THCA	cis	rs9813712	1	rs9864582	ENSG00000228252.7	COL6A4P2	5.35	1.36e-07	2.04e-05	0.28	0.24	Response to amphetamines;	chr3:130251619	chr3:130212823~130273806:+
THCA	cis	rs793571	0.554	rs12905110	ENSG00000245975.2	RP11-30K9.6	5.35	1.36e-07	2.05e-05	0.27	0.24	Schizophrenia;	chr15:58713614	chr15:58768072~58770974:-
THCA	cis	rs7727544	0.582	rs4361509	ENSG00000224431.1	AC063976.7	-5.35	1.36e-07	2.05e-05	-0.2	-0.24	Blood metabolite levels;	chr5:132201060	chr5:132199456~132203487:+
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000273796.1	LL21NC02-21A1.1	-5.35	1.36e-07	2.05e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45403809~45404369:-
THCA	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-5.35	1.36e-07	2.05e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
THCA	cis	rs6908034	0.66	rs7746588	ENSG00000227116.1	RP3-471C18.1	-5.35	1.36e-07	2.05e-05	-0.38	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19730427~19734567:-
THCA	cis	rs6908034	0.66	rs7750716	ENSG00000227116.1	RP3-471C18.1	-5.35	1.36e-07	2.05e-05	-0.38	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19730427~19734567:-
THCA	cis	rs9652601	0.959	rs9931397	ENSG00000274038.1	RP11-66H6.4	-5.35	1.36e-07	2.05e-05	-0.31	-0.24	Systemic lupus erythematosus;	chr16:11083537	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.959	rs12708715	ENSG00000274038.1	RP11-66H6.4	-5.35	1.36e-07	2.05e-05	-0.31	-0.24	Systemic lupus erythematosus;	chr16:11083967	chr16:11056556~11057034:+
THCA	cis	rs9595908	0.965	rs4941612	ENSG00000212293.1	SNORA16	5.35	1.36e-07	2.05e-05	0.3	0.24	Body mass index;	chr13:32549791	chr13:32420390~32420516:-
THCA	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	5.35	1.37e-07	2.05e-05	0.42	0.24	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
THCA	cis	rs860295	0.651	rs6692183	ENSG00000160766.13	GBAP1	-5.35	1.37e-07	2.05e-05	-0.28	-0.24	Body mass index;	chr1:155334536	chr1:155213821~155227422:-
THCA	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	5.35	1.37e-07	2.05e-05	0.15	0.24	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
THCA	cis	rs2251188	1	rs2251188	ENSG00000187953.9	PMS2CL	-5.35	1.37e-07	2.05e-05	-0.27	-0.24	Sum basophil neutrophil counts;Neutrophil count;	chr7:6664701	chr7:6710128~6753862:+
THCA	cis	rs2439831	0.85	rs9944216	ENSG00000166763.7	STRCP1	-5.35	1.37e-07	2.05e-05	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43868575	chr15:43699488~43718184:-
THCA	cis	rs9329221	0.62	rs6601427	ENSG00000261451.1	RP11-981G7.1	-5.35	1.37e-07	2.05e-05	-0.3	-0.24	Neuroticism;	chr8:10298515	chr8:10433672~10438312:+
THCA	cis	rs2179367	0.568	rs9498358	ENSG00000223701.3	RAET1E-AS1	5.35	1.37e-07	2.05e-05	0.38	0.24	Dupuytren's disease;	chr6:149458529	chr6:149884431~149919508:+
THCA	cis	rs890448	0.93	rs28863533	ENSG00000254531.1	FLJ20021	-5.35	1.37e-07	2.05e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101488397	chr4:101347780~101348883:+
THCA	cis	rs6585424	1	rs12763392	ENSG00000225484.5	NUTM2B-AS1	5.35	1.37e-07	2.05e-05	0.39	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175239	chr10:79663088~79826594:-
THCA	cis	rs12612619	0.668	rs2304682	ENSG00000229122.1	AGBL5-IT1	5.35	1.37e-07	2.06e-05	0.17	0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27084901	chr2:27061038~27061815:+
THCA	cis	rs4654783	0.627	rs4655024	ENSG00000218510.5	LINC00339	-5.35	1.37e-07	2.06e-05	-0.26	-0.24	Endometriosis;	chr1:22126221	chr1:22025188~22031223:+
THCA	cis	rs875971	0.502	rs6460311	ENSG00000232546.1	RP11-458F8.1	-5.35	1.37e-07	2.06e-05	-0.23	-0.24	Aortic root size;	chr7:66646886	chr7:66848496~66858136:+
THCA	cis	rs2282300	0.653	rs67745574	ENSG00000242353.1	RP4-710M3.1	-5.35	1.37e-07	2.06e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30213292	chr11:30368148~30368646:+
THCA	cis	rs10875746	0.624	rs10875777	ENSG00000258234.1	RP11-370I10.2	5.35	1.37e-07	2.06e-05	0.27	0.24	Longevity (90 years and older);	chr12:48228288	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.669	rs61941006	ENSG00000258234.1	RP11-370I10.2	5.35	1.37e-07	2.06e-05	0.27	0.24	Longevity (90 years and older);	chr12:48237350	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.669	rs1021313	ENSG00000258234.1	RP11-370I10.2	5.35	1.37e-07	2.06e-05	0.27	0.24	Longevity (90 years and older);	chr12:48244258	chr12:48231098~48284210:-
THCA	cis	rs972578	0.668	rs9611930	ENSG00000274717.1	RP1-47A17.1	-5.35	1.37e-07	2.06e-05	-0.26	-0.24	Mean platelet volume;	chr22:42839972	chr22:42791814~42794313:-
THCA	cis	rs6928977	0.826	rs9321502	ENSG00000231028.7	LINC00271	5.35	1.37e-07	2.06e-05	0.2	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135335114	chr6:135497801~135716055:+
THCA	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-5.35	1.37e-07	2.06e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-5.35	1.37e-07	2.06e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-5.35	1.37e-07	2.06e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
THCA	cis	rs3796352	0.571	rs11713926	ENSG00000242142.1	SERBP1P3	-5.35	1.37e-07	2.06e-05	-0.44	-0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53121056	chr3:53064283~53065091:-
THCA	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-5.35	1.37e-07	2.06e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-5.35	1.37e-07	2.06e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
THCA	cis	rs7429990	0.965	rs9846062	ENSG00000228638.1	FCF1P2	-5.35	1.37e-07	2.06e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47957476	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs9854454	ENSG00000228638.1	FCF1P2	5.35	1.37e-07	2.06e-05	0.23	0.24	Educational attainment (years of education);	chr3:47971307	chr3:48290793~48291375:-
THCA	cis	rs7615952	0.546	rs2922194	ENSG00000243429.1	OR7E29P	5.35	1.37e-07	2.06e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:125613419	chr3:125712139~125713045:+
THCA	cis	rs10875746	0.669	rs11168508	ENSG00000258234.1	RP11-370I10.2	5.35	1.38e-07	2.06e-05	0.27	0.24	Longevity (90 years and older);	chr12:48289728	chr12:48231098~48284210:-
THCA	cis	rs2562456	0.833	rs55920089	ENSG00000268081.1	RP11-678G14.2	5.35	1.38e-07	2.06e-05	0.4	0.24	Pain;	chr19:21337891	chr19:21554640~21569237:-
THCA	cis	rs9315786	0.924	rs7323436	ENSG00000239827.7	SUGT1P3	5.35	1.38e-07	2.06e-05	0.27	0.24	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40908159~40921774:-
THCA	cis	rs4713118	0.868	rs2893928	ENSG00000226314.6	ZNF192P1	-5.35	1.38e-07	2.07e-05	-0.33	-0.24	Parkinson's disease;	chr6:27770651	chr6:28161781~28169594:+
THCA	cis	rs6430585	0.583	rs730005	ENSG00000231890.6	DARS-AS1	-5.35	1.38e-07	2.07e-05	-0.29	-0.24	Corneal structure;	chr2:135825124	chr2:135985176~136022593:+
THCA	cis	rs1914816	0.941	rs2460151	ENSG00000196274.5	Metazoa_SRP	5.35	1.38e-07	2.07e-05	0.34	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76195166	chr15:76230048~76230390:-
THCA	cis	rs30380	0.506	rs469735	ENSG00000272109.1	CTD-2260A17.3	-5.35	1.38e-07	2.07e-05	-0.33	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96794311	chr5:96804353~96806105:+
THCA	cis	rs17767392	1	rs17178045	ENSG00000259146.3	RP1-261D10.2	5.35	1.38e-07	2.07e-05	0.31	0.24	Mitral valve prolapse;	chr14:71289641	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.957	rs35692397	ENSG00000259146.3	RP1-261D10.2	5.35	1.38e-07	2.07e-05	0.31	0.24	Mitral valve prolapse;	chr14:71289966	chr14:71292729~71321814:-
THCA	cis	rs7829975	0.511	rs2980512	ENSG00000253981.4	ALG1L13P	5.35	1.38e-07	2.07e-05	0.23	0.24	Mood instability;	chr8:8283379	chr8:8236003~8244667:-
THCA	cis	rs2179367	0.632	rs9498329	ENSG00000268592.3	RAET1E-AS1	5.35	1.38e-07	2.07e-05	0.34	0.24	Dupuytren's disease;	chr6:149349941	chr6:149863494~149919507:+
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000232559.3	GS1-124K5.12	5.35	1.38e-07	2.07e-05	0.37	0.24	Diabetic kidney disease;	chr7:66433290	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs58669269	ENSG00000232559.3	GS1-124K5.12	5.35	1.38e-07	2.07e-05	0.37	0.24	Diabetic kidney disease;	chr7:66486966	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.615	rs216462	ENSG00000263603.1	CTD-2349P21.5	5.35	1.38e-07	2.07e-05	0.42	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30729469~30731202:+
THCA	cis	rs1198430	0.562	rs10917384	ENSG00000232482.2	RP4-654C18.1	-5.35	1.38e-07	2.07e-05	-0.34	-0.24	Total cholesterol levels;	chr1:23471819	chr1:23410832~23412146:+
THCA	cis	rs56116382	0.604	rs9858428	ENSG00000270441.1	RP11-694I15.7	5.35	1.38e-07	2.07e-05	0.35	0.24	High light scatter reticulocyte count;Intelligence (multi-trait analysis);	chr3:49840152	chr3:49140086~49160851:-
THCA	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	5.35	1.38e-07	2.07e-05	0.14	0.24	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
THCA	cis	rs853679	0.538	rs13199081	ENSG00000280107.1	AL022393.9	-5.35	1.38e-07	2.08e-05	-0.26	-0.24	Depression;	chr6:28364057	chr6:28170845~28172521:+
THCA	cis	rs2337406	1	rs74090714	ENSG00000211974.3	IGHV2-70	-5.35	1.38e-07	2.08e-05	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106691225	chr14:106723574~106724093:-
THCA	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	5.35	1.39e-07	2.08e-05	0.33	0.24	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	5.35	1.39e-07	2.08e-05	0.33	0.24	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	5.35	1.39e-07	2.08e-05	0.33	0.24	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
THCA	cis	rs9307551	0.619	rs11098742	ENSG00000250334.4	LINC00989	-5.35	1.39e-07	2.08e-05	-0.29	-0.24	Refractive error;	chr4:79551637	chr4:79492416~79576460:+
THCA	cis	rs4784934	0.589	rs11649027	ENSG00000260186.4	RP11-481J2.2	5.35	1.39e-07	2.08e-05	0.31	0.24	QT interval;	chr16:58437093	chr16:58421326~58462470:+
THCA	cis	rs16976116	0.619	rs7169407	ENSG00000279145.1	RP11-547D13.1	5.35	1.39e-07	2.08e-05	0.25	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55173454	chr15:55171972~55178175:-
THCA	cis	rs853679	0.567	rs6905380	ENSG00000280107.1	AL022393.9	-5.35	1.39e-07	2.08e-05	-0.26	-0.24	Depression;	chr6:28407125	chr6:28170845~28172521:+
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000273142.1	RP11-458F8.4	-5.35	1.39e-07	2.08e-05	-0.19	-0.24	Calcium levels;	chr7:65967580	chr7:66902857~66906297:+
THCA	cis	rs7111546	0.584	rs7950255	ENSG00000246225.5	RP11-17A1.3	5.35	1.39e-07	2.08e-05	0.39	0.24	Dialysis-related mortality;	chr11:22894368	chr11:22829380~22945393:+
THCA	cis	rs4925386	0.681	rs2427294	ENSG00000273619.1	RP5-908M14.9	-5.35	1.39e-07	2.08e-05	-0.21	-0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352201	chr20:62386303~62386970:-
THCA	cis	rs30380	0.632	rs149189	ENSG00000272109.1	CTD-2260A17.3	-5.35	1.39e-07	2.08e-05	-0.33	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96802101	chr5:96804353~96806105:+
THCA	cis	rs30380	0.632	rs26495	ENSG00000272109.1	CTD-2260A17.3	-5.35	1.39e-07	2.08e-05	-0.33	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96802137	chr5:96804353~96806105:+
THCA	cis	rs30380	0.632	rs26496	ENSG00000272109.1	CTD-2260A17.3	-5.35	1.39e-07	2.08e-05	-0.33	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96802179	chr5:96804353~96806105:+
THCA	cis	rs752010	0.695	rs10890156	ENSG00000230638.4	RP11-486B10.4	-5.35	1.39e-07	2.08e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41642419	chr1:41542069~41544310:+
THCA	cis	rs7829975	0.577	rs7816329	ENSG00000253893.2	FAM85B	5.35	1.39e-07	2.08e-05	0.33	0.24	Mood instability;	chr8:8686333	chr8:8167819~8226614:-
THCA	cis	rs17508449	0.819	rs77042378	ENSG00000232450.1	RP4-730K3.3	-5.35	1.39e-07	2.08e-05	-0.36	-0.24	Leprosy;	chr1:113666479	chr1:113698884~113699631:-
THCA	cis	rs6445975	0.617	rs11130641	ENSG00000272360.1	RP11-359I18.5	5.35	1.39e-07	2.08e-05	0.27	0.24	Systemic lupus erythematosus;	chr3:58432202	chr3:58490830~58491291:-
THCA	cis	rs12681287	0.604	rs41469550	ENSG00000254231.1	CTD-2284J15.1	-5.35	1.39e-07	2.09e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86394315	chr8:86333274~86343314:-
THCA	cis	rs4748857	0.947	rs6482263	ENSG00000224215.1	RP11-371A19.2	-5.35	1.39e-07	2.09e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23315589	chr10:23343957~23345181:+
THCA	cis	rs758324	0.732	rs45512	ENSG00000237714.1	P4HA2-AS1	-5.35	1.39e-07	2.09e-05	-0.36	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132103643	chr5:132184876~132192808:+
THCA	cis	rs1876905	0.539	rs240956	ENSG00000271789.1	RP5-1112D6.7	5.35	1.39e-07	2.09e-05	0.31	0.24	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111297126~111298510:+
THCA	cis	rs1479090	0.762	rs9992504	ENSG00000250027.1	RP11-563E2.2	-5.35	1.39e-07	2.09e-05	-0.25	-0.24	Lung cancer;	chr4:163098463	chr4:163108785~163119965:+
THCA	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-5.35	1.39e-07	2.09e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-5.35	1.39e-07	2.09e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-5.35	1.39e-07	2.09e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-5.35	1.39e-07	2.09e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-5.35	1.39e-07	2.09e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-5.35	1.39e-07	2.09e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-5.35	1.39e-07	2.09e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
THCA	cis	rs7529073	0.683	rs340882	ENSG00000274895.1	RP11-478J18.2	5.35	1.39e-07	2.09e-05	0.2	0.24	Schizophrenia;	chr1:213972388	chr1:213983793~213986419:-
THCA	cis	rs11051970	0.879	rs2651379	ENSG00000274964.1	RP11-817I4.1	-5.35	1.4e-07	2.09e-05	-0.26	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32428844	chr12:32339368~32340724:+
THCA	cis	rs1185460	0.967	rs1184902	ENSG00000272186.1	RP11-110I1.13	-5.35	1.4e-07	2.09e-05	-0.22	-0.24	Coronary artery disease;	chr11:119074627	chr11:119067374~119067698:-
THCA	cis	rs516805	0.528	rs2684235	ENSG00000279453.1	RP3-425C14.4	5.35	1.4e-07	2.09e-05	0.25	0.24	Lymphocyte counts;	chr6:122082083	chr6:122436789~122439223:-
THCA	cis	rs7523875	1	rs55758006	ENSG00000153363.11	LINC00467	-5.35	1.4e-07	2.09e-05	-0.27	-0.24	Mean corpuscular volume;	chr1:211228210	chr1:211382803~211435333:+
THCA	cis	rs1106529	0.51	rs7526102	ENSG00000231365.4	RP11-418J17.1	-5.35	1.4e-07	2.09e-05	-0.27	-0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118984604	chr1:119140396~119275973:+
THCA	cis	rs12497850	1	rs1352420	ENSG00000229759.1	MRPS18AP1	5.35	1.4e-07	2.09e-05	0.32	0.24	Parkinson's disease;	chr3:48719858	chr3:48256350~48256938:-
THCA	cis	rs1322639	0.614	rs7751131	ENSG00000261039.2	RP11-417E7.2	-5.35	1.4e-07	2.1e-05	-0.35	-0.24	Pulse pressure;	chr6:169178615	chr6:169175304~169182740:-
THCA	cis	rs1322639	0.574	rs9364360	ENSG00000261039.2	RP11-417E7.2	-5.35	1.4e-07	2.1e-05	-0.35	-0.24	Pulse pressure;	chr6:169180079	chr6:169175304~169182740:-
THCA	cis	rs17214007	0.592	rs55734390	ENSG00000263335.1	AF001548.5	-5.35	1.4e-07	2.1e-05	-0.38	-0.24	Cognitive function;	chr16:15687235	chr16:15726674~15732993:+
THCA	cis	rs8091660	0.624	rs6507852	ENSG00000278983.1	RP11-426J5.3	-5.35	1.4e-07	2.1e-05	-0.35	-0.24	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48548678	chr18:48564795~48568342:+
THCA	cis	rs10080237	0.564	rs2490224	ENSG00000272129.1	RP11-250B2.6	5.35	1.4e-07	2.1e-05	0.3	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80100116	chr6:80355424~80356859:+
THCA	cis	rs6969780	1	rs6461985	ENSG00000233429.8	HOTAIRM1	5.35	1.4e-07	2.1e-05	0.36	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111015	chr7:27095647~27100265:+
THCA	cis	rs5769765	0.565	rs8137232	ENSG00000260613.1	RP3-522J7.6	5.35	1.4e-07	2.1e-05	0.34	0.24	Schizophrenia;	chr22:49863237	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.657	rs8136116	ENSG00000260613.1	RP3-522J7.6	5.35	1.4e-07	2.1e-05	0.34	0.24	Schizophrenia;	chr22:49863238	chr22:49832616~49837786:-
THCA	cis	rs8062405	0.964	rs62036614	ENSG00000278665.1	RP11-666O2.4	5.35	1.4e-07	2.1e-05	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28599241~28601881:-
THCA	cis	rs79040073	0.637	rs73408143	ENSG00000259531.2	RP11-295H24.3	5.35	1.4e-07	2.1e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49126771	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs3088333	ENSG00000259531.2	RP11-295H24.3	5.35	1.4e-07	2.1e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49140891	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs17394970	ENSG00000259531.2	RP11-295H24.3	5.35	1.4e-07	2.1e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49145371	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs11635455	ENSG00000259531.2	RP11-295H24.3	5.35	1.4e-07	2.1e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49147216	chr15:49365124~49366685:-
THCA	cis	rs7772486	0.654	rs9376958	ENSG00000270638.1	RP3-466P17.1	-5.35	1.4e-07	2.1e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145701904	chr6:145735570~145737218:+
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000273142.1	RP11-458F8.4	-5.35	1.41e-07	2.11e-05	-0.19	-0.24	Calcium levels;	chr7:65941231	chr7:66902857~66906297:+
THCA	cis	rs1580019	0.563	rs764483	ENSG00000231952.3	DPY19L1P2	-5.35	1.41e-07	2.11e-05	-0.3	-0.24	Cognitive ability;	chr7:32538538	chr7:32812757~32838570:+
THCA	cis	rs950169	0.509	rs71395455	ENSG00000275120.1	RP11-182J1.17	5.35	1.41e-07	2.11e-05	0.29	0.24	Schizophrenia;	chr15:84610573	chr15:84599434~84606463:-
THCA	cis	rs4689592	0.622	rs2276968	ENSG00000245468.3	RP11-367J11.3	5.35	1.41e-07	2.11e-05	0.21	0.24	Monocyte percentage of white cells;	chr4:7068391	chr4:7094571~7103385:-
THCA	cis	rs2617170	0.885	rs7975996	ENSG00000245648.1	RP11-277P12.20	5.35	1.41e-07	2.11e-05	0.27	0.24	Behcet's disease;	chr12:10372324	chr12:10363769~10398506:+
THCA	cis	rs3824488	0.599	rs16909856	ENSG00000237857.2	RP11-435O5.2	-5.35	1.41e-07	2.11e-05	-0.4	-0.24	Neuroticism;	chr9:95442211	chr9:95414834~95426796:-
THCA	cis	rs11089937	0.609	rs9622980	ENSG00000211639.2	IGLV4-60	5.35	1.41e-07	2.11e-05	0.19	0.24	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.667	rs10483107	ENSG00000211639.2	IGLV4-60	5.35	1.41e-07	2.11e-05	0.19	0.24	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.667	rs11704024	ENSG00000211639.2	IGLV4-60	5.35	1.41e-07	2.11e-05	0.19	0.24	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22162199~22162681:+
THCA	cis	rs10266483	0.515	rs6949304	ENSG00000227986.1	TRIM60P18	5.35	1.41e-07	2.11e-05	0.24	0.24	Response to statin therapy;	chr7:64257903	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.545	rs73132069	ENSG00000227986.1	TRIM60P18	5.35	1.41e-07	2.11e-05	0.24	0.24	Response to statin therapy;	chr7:64258440	chr7:64355078~64356199:+
THCA	cis	rs2034650	0.544	rs2289330	ENSG00000223313.1	RNU6-516P	5.35	1.41e-07	2.11e-05	0.27	0.24	Interstitial lung disease;	chr15:40412906	chr15:40529570~40529673:+
THCA	cis	rs7119	0.717	rs12916822	ENSG00000259362.2	RP11-307C19.1	-5.35	1.41e-07	2.11e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77526206	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12901732	ENSG00000259362.2	RP11-307C19.1	-5.35	1.41e-07	2.11e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77526591	chr15:77525540~77534110:+
THCA	cis	rs2252521	0.524	rs317744	ENSG00000272568.4	CTB-113D17.1	5.34	1.41e-07	2.12e-05	0.27	0.24	Cognitive performance;	chr7:29027677	chr7:28979967~29013367:+
THCA	cis	rs2252521	0.524	rs317745	ENSG00000272568.4	CTB-113D17.1	5.34	1.41e-07	2.12e-05	0.27	0.24	Cognitive performance;	chr7:29028498	chr7:28979967~29013367:+
THCA	cis	rs2252521	0.524	rs2074782	ENSG00000272568.4	CTB-113D17.1	5.34	1.41e-07	2.12e-05	0.27	0.24	Cognitive performance;	chr7:29031037	chr7:28979967~29013367:+
THCA	cis	rs2067615	0.542	rs4964184	ENSG00000260329.1	RP11-412D9.4	-5.34	1.41e-07	2.12e-05	-0.22	-0.24	Heart rate;	chr12:106676647	chr12:106954029~106955497:-
THCA	cis	rs1546924	0.669	rs197439	ENSG00000227811.2	FAM212B-AS1	-5.34	1.41e-07	2.12e-05	-0.29	-0.24	Body mass index;	chr1:111738368	chr1:111739841~111747798:+
THCA	cis	rs13178541	0.748	rs4317317	ENSG00000250378.1	RP11-119J18.1	-5.34	1.41e-07	2.12e-05	-0.31	-0.24	IgG glycosylation;	chr5:135740765	chr5:135812667~135826582:+
THCA	cis	rs79040073	0.681	rs4775800	ENSG00000259531.2	RP11-295H24.3	5.34	1.41e-07	2.12e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:49117270	chr15:49365124~49366685:-
THCA	cis	rs73198271	0.74	rs10105920	ENSG00000253893.2	FAM85B	-5.34	1.42e-07	2.12e-05	-0.34	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8167819~8226614:-
THCA	cis	rs795484	0.926	rs708865	ENSG00000275409.1	RP11-131L12.4	-5.34	1.42e-07	2.12e-05	-0.21	-0.24	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118245728	chr12:118430147~118430699:+
THCA	cis	rs1552244	1	rs76041173	ENSG00000232901.1	CYCSP10	5.34	1.42e-07	2.12e-05	0.32	0.24	Alzheimer's disease;	chr3:10037011	chr3:10000647~10000940:-
THCA	cis	rs498872	0.507	rs10892247	ENSG00000255239.1	AP002954.6	-5.34	1.42e-07	2.12e-05	-0.36	-0.24	Glioma;	chr11:118619361	chr11:118688039~118690600:-
THCA	cis	rs755249	0.53	rs4660443	ENSG00000228060.1	RP11-69E11.8	-5.34	1.42e-07	2.12e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39126107	chr1:39565160~39573203:+
THCA	cis	rs9549367	0.713	rs3024743	ENSG00000269125.1	RP11-98F14.11	-5.34	1.42e-07	2.12e-05	-0.29	-0.24	Platelet distribution width;	chr13:113167116	chr13:113165002~113165183:-
THCA	cis	rs890448	0.93	rs6532938	ENSG00000254531.1	FLJ20021	5.34	1.42e-07	2.12e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101468422	chr4:101347780~101348883:+
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	5.34	1.42e-07	2.12e-05	0.27	0.24	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
THCA	cis	rs7429990	0.965	rs7430879	ENSG00000228638.1	FCF1P2	5.34	1.42e-07	2.12e-05	0.23	0.24	Educational attainment (years of education);	chr3:47997224	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.932	rs4293721	ENSG00000228638.1	FCF1P2	5.34	1.42e-07	2.12e-05	0.23	0.24	Educational attainment (years of education);	chr3:48003647	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs11130154	ENSG00000228638.1	FCF1P2	5.34	1.42e-07	2.12e-05	0.23	0.24	Educational attainment (years of education);	chr3:48027752	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs5012971	ENSG00000228638.1	FCF1P2	5.34	1.42e-07	2.12e-05	0.23	0.24	Educational attainment (years of education);	chr3:48033057	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.813	rs7637622	ENSG00000228638.1	FCF1P2	5.34	1.42e-07	2.12e-05	0.23	0.24	Educational attainment (years of education);	chr3:48051561	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs7627645	ENSG00000228638.1	FCF1P2	5.34	1.42e-07	2.12e-05	0.23	0.24	Educational attainment (years of education);	chr3:48051643	chr3:48290793~48291375:-
THCA	cis	rs6988985	0.678	rs28491316	ENSG00000247317.3	RP11-273G15.2	-5.34	1.42e-07	2.12e-05	-0.26	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142911245	chr8:142981738~143018437:-
THCA	cis	rs12935418	0.733	rs12448615	ENSG00000261061.1	RP11-303E16.2	-5.34	1.42e-07	2.12e-05	-0.33	-0.24	Mean corpuscular volume;	chr16:80947132	chr16:81030770~81031485:+
THCA	cis	rs667920	0.512	rs13071085	ENSG00000239213.4	NCK1-AS1	-5.34	1.42e-07	2.12e-05	-0.35	-0.24	Coronary artery disease;	chr3:136296081	chr3:136841726~136862054:-
THCA	cis	rs12893668	0.667	rs8017628	ENSG00000269940.1	RP11-73M18.7	5.34	1.42e-07	2.12e-05	0.25	0.24	Reticulocyte count;	chr14:103581091	chr14:103694560~103695170:+
THCA	cis	rs2797160	0.967	rs80303782	ENSG00000237742.5	RP11-624M8.1	-5.34	1.42e-07	2.12e-05	-0.21	-0.24	Endometrial cancer;	chr6:125683047	chr6:125578558~125749190:-
THCA	cis	rs442309	0.553	rs10761660	ENSG00000238280.1	RP11-436D10.3	-5.34	1.42e-07	2.12e-05	-0.31	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62756546	chr10:62793562~62805887:-
THCA	cis	rs6044112	0.606	rs6075076	ENSG00000273998.1	RP4-777L9.2	5.34	1.42e-07	2.12e-05	0.4	0.24	Response to taxane treatment (docetaxel);	chr20:16579700	chr20:16576068~16579615:+
THCA	cis	rs875971	0.545	rs11767262	ENSG00000232546.1	RP11-458F8.1	5.34	1.42e-07	2.12e-05	0.23	0.24	Aortic root size;	chr7:66302237	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000232546.1	RP11-458F8.1	5.34	1.42e-07	2.12e-05	0.23	0.24	Aortic root size;	chr7:66327797	chr7:66848496~66858136:+
THCA	cis	rs6570726	1	rs444564	ENSG00000270638.1	RP3-466P17.1	5.34	1.42e-07	2.12e-05	0.18	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145735570~145737218:+
THCA	cis	rs79040073	0.637	rs11635354	ENSG00000259531.2	RP11-295H24.3	5.34	1.42e-07	2.12e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49419413	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs11638314	ENSG00000259531.2	RP11-295H24.3	5.34	1.42e-07	2.12e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49421747	chr15:49365124~49366685:-
THCA	cis	rs919433	1	rs2889363	ENSG00000231621.1	AC013264.2	5.34	1.42e-07	2.12e-05	0.23	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298975	chr2:197197991~197199273:+
THCA	cis	rs919433	1	rs1346649	ENSG00000231621.1	AC013264.2	5.34	1.42e-07	2.12e-05	0.23	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301393	chr2:197197991~197199273:+
THCA	cis	rs6445975	0.666	rs2070662	ENSG00000272360.1	RP11-359I18.5	5.34	1.42e-07	2.13e-05	0.27	0.24	Systemic lupus erythematosus;	chr3:58429863	chr3:58490830~58491291:-
THCA	cis	rs2243480	1	rs1638734	ENSG00000232546.1	RP11-458F8.1	-5.34	1.42e-07	2.13e-05	-0.32	-0.24	Diabetic kidney disease;	chr7:66632552	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs10234018	ENSG00000273142.1	RP11-458F8.4	5.34	1.42e-07	2.13e-05	0.19	0.24	Aortic root size;	chr7:66681297	chr7:66902857~66906297:+
THCA	cis	rs1552244	1	rs2272125	ENSG00000232901.1	CYCSP10	5.34	1.42e-07	2.13e-05	0.31	0.24	Alzheimer's disease;	chr3:10096385	chr3:10000647~10000940:-
THCA	cis	rs6570726	0.846	rs6570698	ENSG00000270638.1	RP3-466P17.1	5.34	1.42e-07	2.13e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs6914304	ENSG00000270638.1	RP3-466P17.1	5.34	1.42e-07	2.13e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145735570~145737218:+
THCA	cis	rs7202877	0.611	rs7187263	ENSG00000261783.1	RP11-252K23.2	-5.34	1.42e-07	2.13e-05	-0.41	-0.24	Type 1 diabetes;Type 2 diabetes;	chr16:75275080	chr16:75379818~75381260:-
THCA	cis	rs6570726	0.967	rs373704	ENSG00000270638.1	RP3-466P17.1	5.34	1.42e-07	2.13e-05	0.18	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145735570~145737218:+
THCA	cis	rs11733284	0.962	rs4695328	ENSG00000259959.1	RP11-121C2.2	5.34	1.42e-07	2.13e-05	0.2	0.24	Gout;Renal underexcretion gout;	chr4:48028272	chr4:47840122~47844339:-
THCA	cis	rs17594362	1	rs34263535	ENSG00000264190.1	MIR5006	5.34	1.42e-07	2.13e-05	0.38	0.24	Multiple sclerosis;	chr13:41580101	chr13:41568286~41568395:-
THCA	cis	rs8007846	0.505	rs58102398	ENSG00000276116.2	FUT8-AS1	-5.34	1.43e-07	2.13e-05	-0.28	-0.24	Multiple sclerosis--Brain Glutamate Levels;	chr14:65783439	chr14:65411170~65412690:-
THCA	cis	rs8007846	0.505	rs60734251	ENSG00000276116.2	FUT8-AS1	-5.34	1.43e-07	2.13e-05	-0.28	-0.24	Multiple sclerosis--Brain Glutamate Levels;	chr14:65783556	chr14:65411170~65412690:-
THCA	cis	rs1198430	0.599	rs10917382	ENSG00000232482.2	RP4-654C18.1	-5.34	1.43e-07	2.13e-05	-0.34	-0.24	Total cholesterol levels;	chr1:23454146	chr1:23410832~23412146:+
THCA	cis	rs6714710	0.603	rs6757357	ENSG00000230606.9	AC159540.1	-5.34	1.43e-07	2.13e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97875287	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.58	rs55886305	ENSG00000230606.9	AC159540.1	-5.34	1.43e-07	2.13e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97879198	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs13023980	ENSG00000230606.9	AC159540.1	-5.34	1.43e-07	2.13e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97886524	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs35505530	ENSG00000230606.9	AC159540.1	-5.34	1.43e-07	2.13e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97890447	chr2:97416165~97433527:-
THCA	cis	rs79040073	0.637	rs78323502	ENSG00000259531.2	RP11-295H24.3	5.34	1.43e-07	2.13e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49436634	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.517	rs118069527	ENSG00000259531.2	RP11-295H24.3	5.34	1.43e-07	2.13e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49436684	chr15:49365124~49366685:-
THCA	cis	rs7169304	0.559	rs117818498	ENSG00000259531.2	RP11-295H24.3	5.34	1.43e-07	2.13e-05	0.34	0.24	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49436685	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs79404431	ENSG00000259531.2	RP11-295H24.3	5.34	1.43e-07	2.13e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49436689	chr15:49365124~49366685:-
THCA	cis	rs72772090	0.71	rs17479052	ENSG00000248734.2	CTD-2260A17.1	-5.34	1.43e-07	2.13e-05	-0.4	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96729932	chr5:96784777~96785999:+
THCA	cis	rs919433	0.929	rs4850788	ENSG00000231621.1	AC013264.2	5.34	1.43e-07	2.13e-05	0.23	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318216	chr2:197197991~197199273:+
THCA	cis	rs7674212	1	rs7691873	ENSG00000230069.3	LRRC37A15P	5.34	1.43e-07	2.14e-05	0.25	0.24	Type 2 diabetes;	chr4:103066742	chr4:102727274~102730721:-
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000273796.1	LL21NC02-21A1.1	5.34	1.43e-07	2.14e-05	0.25	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000273796.1	LL21NC02-21A1.1	-5.34	1.43e-07	2.14e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45403809~45404369:-
THCA	cis	rs853679	0.546	rs200981	ENSG00000226314.6	ZNF192P1	-5.34	1.43e-07	2.14e-05	-0.4	-0.24	Depression;	chr6:27865396	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs200953	ENSG00000226314.6	ZNF192P1	-5.34	1.43e-07	2.14e-05	-0.4	-0.24	Depression;	chr6:27869489	chr6:28161781~28169594:+
THCA	cis	rs1865760	0.532	rs2794719	ENSG00000272462.2	U91328.19	-5.34	1.43e-07	2.14e-05	-0.2	-0.24	Height;	chr6:26088662	chr6:25992662~26001775:+
THCA	cis	rs7746199	0.736	rs17693963	ENSG00000219392.1	RP1-265C24.5	-5.34	1.43e-07	2.14e-05	-0.5	-0.24	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28115628~28116551:+
THCA	cis	rs7429990	0.901	rs7433678	ENSG00000228638.1	FCF1P2	5.34	1.43e-07	2.14e-05	0.23	0.24	Educational attainment (years of education);	chr3:47995588	chr3:48290793~48291375:-
THCA	cis	rs875971	0.545	rs1547529	ENSG00000232546.1	RP11-458F8.1	5.34	1.43e-07	2.14e-05	0.23	0.24	Aortic root size;	chr7:66258859	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000232546.1	RP11-458F8.1	5.34	1.43e-07	2.14e-05	0.23	0.24	Aortic root size;	chr7:66283366	chr7:66848496~66858136:+
THCA	cis	rs4713118	0.539	rs200951	ENSG00000280107.1	AL022393.9	-5.34	1.43e-07	2.14e-05	-0.26	-0.24	Parkinson's disease;	chr6:27868152	chr6:28170845~28172521:+
THCA	cis	rs6585424	0.929	rs12256429	ENSG00000242600.5	MBL1P	5.34	1.43e-07	2.14e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178876	chr10:79904898~79950336:+
THCA	cis	rs62355901	0.505	rs62355910	ENSG00000271828.1	CTD-2310F14.1	5.34	1.43e-07	2.14e-05	0.59	0.24	Breast cancer;	chr5:56784810	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.505	rs56309635	ENSG00000271828.1	CTD-2310F14.1	5.34	1.43e-07	2.14e-05	0.59	0.24	Breast cancer;	chr5:56789589	chr5:56927874~56929573:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000229886.1	RP5-1132H15.3	5.34	1.43e-07	2.14e-05	0.37	0.24	Diabetic kidney disease;	chr7:66631132	chr7:66025126~66031544:-
THCA	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-5.34	1.43e-07	2.14e-05	-0.15	-0.24	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
THCA	cis	rs494453	0.557	rs2473842	ENSG00000227811.2	FAM212B-AS1	-5.34	1.43e-07	2.14e-05	-0.29	-0.24	Osteoporosis-related phenotypes;	chr1:111684778	chr1:111739841~111747798:+
THCA	cis	rs2562456	0.833	rs11669790	ENSG00000268081.1	RP11-678G14.2	5.34	1.43e-07	2.14e-05	0.41	0.24	Pain;	chr19:21328980	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62107534	ENSG00000268081.1	RP11-678G14.2	5.34	1.43e-07	2.14e-05	0.41	0.24	Pain;	chr19:21329389	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs7258473	ENSG00000268081.1	RP11-678G14.2	5.34	1.43e-07	2.14e-05	0.41	0.24	Pain;	chr19:21331795	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs2219839	ENSG00000268081.1	RP11-678G14.2	5.34	1.43e-07	2.14e-05	0.41	0.24	Pain;	chr19:21333520	chr19:21554640~21569237:-
THCA	cis	rs1580019	0.563	rs4723169	ENSG00000231952.3	DPY19L1P2	-5.34	1.43e-07	2.14e-05	-0.3	-0.24	Cognitive ability;	chr7:32527965	chr7:32812757~32838570:+
THCA	cis	rs7727544	0.684	rs274561	ENSG00000224431.1	AC063976.7	5.34	1.43e-07	2.14e-05	0.21	0.24	Blood metabolite levels;	chr5:132383536	chr5:132199456~132203487:+
THCA	cis	rs6430585	0.646	rs1057031	ENSG00000231890.6	DARS-AS1	-5.34	1.43e-07	2.15e-05	-0.28	-0.24	Corneal structure;	chr2:135876392	chr2:135985176~136022593:+
THCA	cis	rs1050631	0.592	rs1785900	ENSG00000260552.1	RP11-49I11.1	5.34	1.44e-07	2.15e-05	0.29	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36130207	chr18:36179996~36187448:-
THCA	cis	rs6479901	0.789	rs10822146	ENSG00000232075.1	MRPL35P2	-5.34	1.44e-07	2.15e-05	-0.35	-0.24	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.841	rs10465990	ENSG00000232075.1	MRPL35P2	-5.34	1.44e-07	2.15e-05	-0.35	-0.24	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63634317~63634827:-
THCA	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	5.34	1.44e-07	2.15e-05	0.34	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
THCA	cis	rs2212361	0.558	rs11020815	ENSG00000255893.1	RP11-685N10.1	-5.34	1.44e-07	2.15e-05	-0.27	-0.24	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535890	chr11:94472908~94473570:-
THCA	cis	rs3785574	0.962	rs4480868	ENSG00000240280.5	TCAM1P	-5.34	1.44e-07	2.15e-05	-0.32	-0.24	Height;	chr17:63711499	chr17:63849292~63864379:+
THCA	cis	rs1552244	1	rs6414438	ENSG00000232901.1	CYCSP10	5.34	1.44e-07	2.15e-05	0.31	0.24	Alzheimer's disease;	chr3:10032140	chr3:10000647~10000940:-
THCA	cis	rs11089937	0.597	rs4821774	ENSG00000211639.2	IGLV4-60	5.34	1.44e-07	2.15e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22162199~22162681:+
THCA	cis	rs890448	0.796	rs13109704	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101365056	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs6852377	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101365552	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs4698957	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367762	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs4699213	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367950	chr4:101347780~101348883:+
THCA	cis	rs890448	0.792	rs6824603	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101368745	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs6856370	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369529	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs1946946	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101370420	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs4699214	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371077	chr4:101347780~101348883:+
THCA	cis	rs890448	0.726	rs13135441	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371727	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs1822169	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101372107	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs1822168	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101372387	chr4:101347780~101348883:+
THCA	cis	rs890448	0.726	rs6532928	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101373080	chr4:101347780~101348883:+
THCA	cis	rs890448	0.661	rs1583911	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101374542	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs6532929	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101377307	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs7670594	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101378105	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs12499349	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380198	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs13135270	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380602	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs7677595	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382570	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs6532930	ENSG00000254531.1	FLJ20021	5.34	1.44e-07	2.15e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101383758	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs4699212	ENSG00000254531.1	FLJ20021	-5.34	1.44e-07	2.15e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367620	chr4:101347780~101348883:+
THCA	cis	rs330048	0.545	rs10503387	ENSG00000254153.1	CTA-398F10.2	-5.34	1.44e-07	2.15e-05	-0.26	-0.24	Systemic lupus erythematosus;	chr8:9293015	chr8:8456909~8461337:-
THCA	cis	rs7688540	0.771	rs61794997	ENSG00000211553.1	AC253576.2	-5.34	1.44e-07	2.15e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs11724176	ENSG00000211553.1	AC253576.2	-5.34	1.44e-07	2.15e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:136461~136568:+
THCA	cis	rs7688540	0.609	rs77700883	ENSG00000211553.1	AC253576.2	-5.34	1.44e-07	2.15e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:136461~136568:+
THCA	cis	rs7688540	0.609	rs78896226	ENSG00000211553.1	AC253576.2	-5.34	1.44e-07	2.15e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:136461~136568:+
THCA	cis	rs72949976	0.606	rs1922797	ENSG00000270659.1	RP11-105N14.1	-5.34	1.44e-07	2.15e-05	-0.19	-0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213162918	chr2:213152970~213153659:+
THCA	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-5.34	1.44e-07	2.15e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
THCA	cis	rs6973609	0.544	rs6949262	ENSG00000271122.1	RP11-379H18.1	5.34	1.44e-07	2.15e-05	0.16	0.24	Obesity-related traits;	chr7:35547410	chr7:35695214~35699413:+
THCA	cis	rs9467773	1	rs2255070	ENSG00000261353.1	CTA-14H9.5	-5.34	1.44e-07	2.15e-05	-0.25	-0.24	Intelligence (multi-trait analysis);	chr6:26501549	chr6:26527063~26527404:+
THCA	cis	rs3785574	0.638	rs2854182	ENSG00000240280.5	TCAM1P	-5.34	1.44e-07	2.16e-05	-0.32	-0.24	Height;	chr17:63891702	chr17:63849292~63864379:+
THCA	cis	rs6840360	0.558	rs2709821	ENSG00000270265.1	RP11-731D1.4	-5.34	1.44e-07	2.16e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151333775~151353224:-
THCA	cis	rs6969780	0.778	rs2465276	ENSG00000233429.8	HOTAIRM1	5.34	1.44e-07	2.16e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106098	chr7:27095647~27100265:+
THCA	cis	rs6969780	0.778	rs61384251	ENSG00000233429.8	HOTAIRM1	5.34	1.44e-07	2.16e-05	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106583	chr7:27095647~27100265:+
THCA	cis	rs11749327	0.719	rs36111336	ENSG00000188242.4	PP7080	5.34	1.44e-07	2.16e-05	0.28	0.24	Hemoglobin concentration;Hypospadias;	chr5:463501	chr5:466124~473098:-
THCA	cis	rs11749327	0.719	rs72698510	ENSG00000188242.4	PP7080	5.34	1.44e-07	2.16e-05	0.28	0.24	Hemoglobin concentration;Hypospadias;	chr5:464224	chr5:466124~473098:-
THCA	cis	rs1914816	1	rs2456075	ENSG00000196274.5	Metazoa_SRP	5.34	1.44e-07	2.16e-05	0.34	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76263645	chr15:76230048~76230390:-
THCA	cis	rs9438901	0.655	rs609320	ENSG00000224183.1	SDHDP6	5.34	1.44e-07	2.16e-05	0.4	0.24	Red cell distribution width;	chr1:25390874	chr1:25294164~25294643:-
THCA	cis	rs7674212	0.531	rs2866416	ENSG00000230069.3	LRRC37A15P	-5.34	1.45e-07	2.16e-05	-0.25	-0.24	Type 2 diabetes;	chr4:102959554	chr4:102727274~102730721:-
THCA	cis	rs12472274	0.536	rs12619455	ENSG00000279484.1	KLHL30-AS1	5.34	1.45e-07	2.16e-05	0.31	0.24	Phospholipid levels (plasma);	chr2:238171508	chr2:238152889~238155994:-
THCA	cis	rs950169	0.656	rs748455	ENSG00000275120.1	RP11-182J1.17	5.34	1.45e-07	2.16e-05	0.29	0.24	Schizophrenia;	chr15:84606344	chr15:84599434~84606463:-
THCA	cis	rs2439831	0.867	rs496584	ENSG00000166763.7	STRCP1	5.34	1.45e-07	2.16e-05	0.33	0.24	Lung cancer in ever smokers;	chr15:43539725	chr15:43699488~43718184:-
THCA	cis	rs7430456	0.674	rs13079337	ENSG00000228221.4	LINC00578	5.34	1.45e-07	2.16e-05	0.35	0.24	Breast cancer;	chr3:177776996	chr3:177441921~177752305:+
THCA	cis	rs4908768	0.501	rs2016084	ENSG00000232912.4	RP5-1115A15.1	5.34	1.45e-07	2.16e-05	0.23	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8424645~8434838:+
THCA	cis	rs7824557	0.767	rs17797443	ENSG00000154316.13	TDH	-5.34	1.45e-07	2.17e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11306503	chr8:11339637~11368452:+
THCA	cis	rs2243480	1	rs383402	ENSG00000230295.1	RP11-458F8.2	5.34	1.45e-07	2.17e-05	0.28	0.24	Diabetic kidney disease;	chr7:66121666	chr7:66880708~66882981:+
THCA	cis	rs9467773	0.626	rs6935803	ENSG00000124549.13	BTN2A3P	-5.34	1.45e-07	2.17e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr6:26350267	chr6:26421391~26432383:+
THCA	cis	rs9388451	0.807	rs1268065	ENSG00000226409.1	RP11-735G4.1	5.34	1.45e-07	2.17e-05	0.29	0.24	Brugada syndrome;	chr6:125721637	chr6:125370211~125374324:-
THCA	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	5.34	1.45e-07	2.17e-05	0.34	0.24	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	5.34	1.45e-07	2.17e-05	0.34	0.24	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	5.34	1.45e-07	2.17e-05	0.34	0.24	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
THCA	cis	rs8033133	0.881	rs4344720	ENSG00000251896.1	SNORD116-27	-5.34	1.45e-07	2.17e-05	-0.28	-0.24	Blood osmolality (transformed sodium);	chr15:25078994	chr15:25101575~25101666:+
THCA	cis	rs7119038	0.818	rs56758835	ENSG00000255239.1	AP002954.6	-5.34	1.45e-07	2.17e-05	-0.37	-0.24	Sjögren's syndrome;	chr11:118744631	chr11:118688039~118690600:-
THCA	cis	rs8002861	1	rs8002861	ENSG00000274001.1	RP11-5G9.5	5.34	1.45e-07	2.17e-05	0.27	0.24	Leprosy;	chr13:43900381	chr13:43877715~43878163:-
THCA	cis	rs6997458	0.742	rs6988475	ENSG00000253549.4	RP11-317J10.2	5.34	1.45e-07	2.17e-05	0.24	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85471039	chr8:85441851~85464915:-
THCA	cis	rs9634489	0.511	rs9584361	ENSG00000247400.3	DNAJC3-AS1	5.34	1.45e-07	2.17e-05	0.16	0.24	Body mass index;	chr13:96366880	chr13:95648733~95676925:-
THCA	cis	rs4888671	1	rs17696958	ENSG00000261707.1	RP11-264M12.2	5.34	1.45e-07	2.17e-05	0.44	0.24	Obesity-related traits;	chr16:77751116	chr16:77741468~77743000:-
THCA	cis	rs7308116	0.676	rs10861832	ENSG00000257951.1	RP11-554D14.4	5.34	1.45e-07	2.17e-05	0.28	0.24	Pelvic organ prolapse (moderate/severe);	chr12:107901658	chr12:107881242~107883382:+
THCA	cis	rs73198271	0.74	rs10092600	ENSG00000253893.2	FAM85B	5.34	1.46e-07	2.17e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.74	rs10105690	ENSG00000253893.2	FAM85B	5.34	1.46e-07	2.17e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8167819~8226614:-
THCA	cis	rs875971	0.502	rs1796227	ENSG00000232546.1	RP11-458F8.1	-5.34	1.46e-07	2.17e-05	-0.23	-0.24	Aortic root size;	chr7:66622032	chr7:66848496~66858136:+
THCA	cis	rs67981189	0.529	rs17093738	ENSG00000269927.1	RP6-91H8.3	5.34	1.46e-07	2.17e-05	0.29	0.24	Schizophrenia;	chr14:71119931	chr14:71141125~71143253:-
THCA	cis	rs9987353	0.62	rs34455383	ENSG00000248538.5	RP11-10A14.5	5.34	1.46e-07	2.17e-05	0.33	0.24	Recombination measurement;	chr8:9208948	chr8:9189011~9202854:+
THCA	cis	rs9990333	0.862	rs6806599	ENSG00000207650.1	MIR570	-5.34	1.46e-07	2.17e-05	-0.25	-0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195699401~195699497:+
THCA	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	5.34	1.46e-07	2.18e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
THCA	cis	rs494453	0.557	rs508594	ENSG00000227811.2	FAM212B-AS1	5.34	1.46e-07	2.18e-05	0.3	0.24	Osteoporosis-related phenotypes;	chr1:111622549	chr1:111739841~111747798:+
THCA	cis	rs116095464	0.614	rs62344292	ENSG00000248925.1	CTD-2083E4.6	5.34	1.46e-07	2.18e-05	0.35	0.24	Breast cancer;	chr5:244515	chr5:269858~271516:-
THCA	cis	rs5752326	1	rs5752327	ENSG00000261188.1	CTA-445C9.14	5.34	1.46e-07	2.18e-05	0.3	0.24	Ischemic stroke;	chr22:26448104	chr22:26512537~26514568:+
THCA	cis	rs4748857	0.947	rs10764395	ENSG00000224215.1	RP11-371A19.2	-5.34	1.46e-07	2.18e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23222768	chr10:23343957~23345181:+
THCA	cis	rs17767294	0.612	rs9461425	ENSG00000226314.6	ZNF192P1	-5.34	1.46e-07	2.18e-05	-0.43	-0.24	Parkinson's disease;	chr6:27951910	chr6:28161781~28169594:+
THCA	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	5.34	1.46e-07	2.18e-05	0.34	0.24	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
THCA	cis	rs1552244	1	rs58275763	ENSG00000232901.1	CYCSP10	5.34	1.46e-07	2.18e-05	0.32	0.24	Alzheimer's disease;	chr3:10101590	chr3:10000647~10000940:-
THCA	cis	rs17331151	0.541	rs4687676	ENSG00000242142.1	SERBP1P3	5.34	1.46e-07	2.18e-05	0.37	0.24	Immune reponse to smallpox (secreted IL-2);	chr3:52856402	chr3:53064283~53065091:-
THCA	cis	rs4908768	0.52	rs7520025	ENSG00000232912.4	RP5-1115A15.1	5.34	1.46e-07	2.18e-05	0.23	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8424645~8434838:+
THCA	cis	rs7829975	0.686	rs907180	ENSG00000254153.1	CTA-398F10.2	-5.34	1.46e-07	2.18e-05	-0.25	-0.24	Mood instability;	chr8:8845317	chr8:8456909~8461337:-
THCA	cis	rs17767392	0.957	rs7140354	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71292899	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs7142180	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71293178	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.957	rs36057816	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71293829	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.829	rs56363446	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71294860	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs17767392	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71298060	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs723966	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71299193	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs61991203	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71301124	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs34528013	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71301131	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs61991204	ENSG00000259146.3	RP1-261D10.2	5.34	1.46e-07	2.18e-05	0.31	0.24	Mitral valve prolapse;	chr14:71301356	chr14:71292729~71321814:-
THCA	cis	rs8002861	0.901	rs9525867	ENSG00000274001.1	RP11-5G9.5	5.34	1.46e-07	2.18e-05	0.27	0.24	Leprosy;	chr13:43889421	chr13:43877715~43878163:-
THCA	cis	rs6445975	0.666	rs4681680	ENSG00000272360.1	RP11-359I18.5	-5.34	1.46e-07	2.18e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr3:58346490	chr3:58490830~58491291:-
THCA	cis	rs13178541	0.552	rs6881599	ENSG00000250378.1	RP11-119J18.1	-5.34	1.46e-07	2.18e-05	-0.26	-0.24	IgG glycosylation;	chr5:135705961	chr5:135812667~135826582:+
THCA	cis	rs30380	0.632	rs26498	ENSG00000272109.1	CTD-2260A17.3	5.34	1.46e-07	2.18e-05	0.33	0.24	Cerebrospinal fluid biomarker levels;	chr5:96803109	chr5:96804353~96806105:+
THCA	cis	rs8042680	1	rs11853024	ENSG00000214432.8	AC068831.10	-5.34	1.46e-07	2.18e-05	-0.26	-0.24	Type 2 diabetes;	chr15:90971567	chr15:91022619~91036611:+
THCA	cis	rs874628	0.95	rs62120372	ENSG00000268650.3	AC068499.10	5.34	1.46e-07	2.18e-05	0.28	0.24	Multiple sclerosis;	chr19:18194375	chr19:18204730~18220480:+
THCA	cis	rs34779708	0.75	rs35032841	ENSG00000271335.4	RP11-324I22.4	5.34	1.46e-07	2.18e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.742	rs35912711	ENSG00000271335.4	RP11-324I22.4	5.34	1.46e-07	2.18e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4934702	ENSG00000271335.4	RP11-324I22.4	5.34	1.46e-07	2.18e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35314552~35336401:-
THCA	cis	rs9388451	0.657	rs4895799	ENSG00000226409.1	RP11-735G4.1	-5.34	1.46e-07	2.18e-05	-0.29	-0.24	Brugada syndrome;	chr6:125731583	chr6:125370211~125374324:-
THCA	cis	rs11089937	0.626	rs11704092	ENSG00000211639.2	IGLV4-60	5.34	1.46e-07	2.18e-05	0.18	0.24	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22162199~22162681:+
THCA	cis	rs1552244	1	rs7626117	ENSG00000180385.7	EMC3-AS1	5.34	1.46e-07	2.18e-05	0.25	0.24	Alzheimer's disease;	chr3:10098987	chr3:9986893~10006990:+
THCA	cis	rs7512898	0.5	rs10753880	ENSG00000260088.1	RP11-92G12.3	-5.34	1.46e-07	2.18e-05	-0.32	-0.24	Electrocardiographic conduction measures;	chr1:200731246	chr1:200669507~200694250:+
THCA	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-5.34	1.46e-07	2.18e-05	-0.35	-0.24	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
THCA	cis	rs9733	0.519	rs72704603	ENSG00000231073.1	RP11-316M1.3	5.34	1.46e-07	2.18e-05	0.29	0.24	Tonsillectomy;	chr1:150735516	chr1:150973123~150975534:+
THCA	cis	rs3847687	0.686	rs71448229	ENSG00000279128.1	RP11-76C10.4	5.34	1.46e-07	2.18e-05	0.27	0.24	Longevity;	chr12:131036984	chr12:131022769~131024741:-
THCA	cis	rs9329221	0.905	rs4610752	ENSG00000261451.1	RP11-981G7.1	-5.34	1.46e-07	2.18e-05	-0.29	-0.24	Neuroticism;	chr8:10391452	chr8:10433672~10438312:+
THCA	cis	rs748404	0.589	rs3862138	ENSG00000205771.5	CATSPER2P1	-5.34	1.46e-07	2.18e-05	-0.31	-0.24	Lung cancer;	chr15:43523801	chr15:43726918~43747094:-
THCA	cis	rs6728642	0.572	rs7574488	ENSG00000230606.9	AC159540.1	5.34	1.47e-07	2.19e-05	0.29	0.24	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96933881	chr2:97416165~97433527:-
THCA	cis	rs6921919	0.583	rs6928773	ENSG00000219392.1	RP1-265C24.5	-5.34	1.47e-07	2.19e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28115628~28116551:+
THCA	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	5.34	1.47e-07	2.19e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
THCA	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	5.34	1.47e-07	2.19e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
THCA	cis	rs897984	0.762	rs2054213	ENSG00000260911.2	RP11-196G11.2	-5.34	1.47e-07	2.19e-05	-0.2	-0.24	Dementia with Lewy bodies;	chr16:30960489	chr16:31043150~31049868:+
THCA	cis	rs7119	0.689	rs12901765	ENSG00000259362.2	RP11-307C19.1	-5.34	1.47e-07	2.19e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77526761	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12902925	ENSG00000259362.2	RP11-307C19.1	-5.34	1.47e-07	2.19e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77526799	chr15:77525540~77534110:+
THCA	cis	rs56114371	0.53	rs9357045	ENSG00000280107.1	AL022393.9	-5.34	1.47e-07	2.19e-05	-0.3	-0.24	Breast cancer;	chr6:27721148	chr6:28170845~28172521:+
THCA	cis	rs72949976	0.646	rs1441169	ENSG00000270659.1	RP11-105N14.1	-5.34	1.47e-07	2.19e-05	-0.19	-0.24	Squamous cell lung carcinoma;Lung cancer;	chr2:213168806	chr2:213152970~213153659:+
THCA	cis	rs17508449	0.909	rs7514649	ENSG00000232450.1	RP4-730K3.3	-5.34	1.47e-07	2.19e-05	-0.38	-0.24	Leprosy;	chr1:113537200	chr1:113698884~113699631:-
THCA	cis	rs7394190	1	rs7394190	ENSG00000271848.1	RP11-464F9.21	-5.34	1.47e-07	2.19e-05	-0.3	-0.24	Incident atrial fibrillation;	chr10:73661890	chr10:73654039~73674719:+
THCA	cis	rs4648045	0.861	rs230534	ENSG00000246560.2	RP11-10L12.4	-5.34	1.47e-07	2.19e-05	-0.31	-0.24	Lymphocyte percentage of white cells;	chr4:102527884	chr4:102828055~102844075:+
THCA	cis	rs8177876	0.658	rs16954513	ENSG00000261061.1	RP11-303E16.2	-5.34	1.47e-07	2.19e-05	-0.41	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043599	chr16:81030770~81031485:+
THCA	cis	rs1552244	1	rs113153120	ENSG00000232901.1	CYCSP10	5.34	1.47e-07	2.2e-05	0.31	0.24	Alzheimer's disease;	chr3:10114714	chr3:10000647~10000940:-
THCA	cis	rs2243480	1	rs160646	ENSG00000232559.3	GS1-124K5.12	5.34	1.47e-07	2.2e-05	0.34	0.24	Diabetic kidney disease;	chr7:66091293	chr7:66554588~66576923:-
THCA	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	5.34	1.47e-07	2.2e-05	0.22	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
THCA	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-5.34	1.47e-07	2.2e-05	-0.36	-0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
THCA	cis	rs6951245	0.744	rs10265736	ENSG00000229043.2	AC091729.9	-5.34	1.47e-07	2.2e-05	-0.37	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1160374~1165267:+
THCA	cis	rs2797160	1	rs1935773	ENSG00000237742.5	RP11-624M8.1	-5.34	1.47e-07	2.2e-05	-0.21	-0.24	Endometrial cancer;	chr6:125675329	chr6:125578558~125749190:-
THCA	cis	rs890448	0.796	rs10007902	ENSG00000254531.1	FLJ20021	5.34	1.47e-07	2.2e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101414961	chr4:101347780~101348883:+
THCA	cis	rs11051970	0.545	rs2651374	ENSG00000274964.1	RP11-817I4.1	-5.34	1.47e-07	2.2e-05	-0.24	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32429924	chr12:32339368~32340724:+
THCA	cis	rs6545883	0.929	rs9679557	ENSG00000270820.4	RP11-355B11.2	5.34	1.47e-07	2.2e-05	0.21	0.24	Tuberculosis;	chr2:61482214	chr2:61471188~61484130:+
THCA	cis	rs2129782	1	rs11995730	ENSG00000253553.4	RP11-586K2.1	5.34	1.47e-07	2.2e-05	0.39	0.24	Electrodermal activity;	chr8:88458919	chr8:88326836~88737134:+
THCA	cis	rs6479891	0.63	rs4545434	ENSG00000232075.1	MRPL35P2	5.34	1.47e-07	2.2e-05	0.39	0.24	Arthritis (juvenile idiopathic);	chr10:63115985	chr10:63634317~63634827:-
THCA	cis	rs8028182	0.583	rs4886722	ENSG00000260269.4	CTD-2323K18.1	-5.34	1.47e-07	2.2e-05	-0.37	-0.24	Sudden cardiac arrest;	chr15:75629295	chr15:75527150~75601205:-
THCA	cis	rs172166	0.637	rs1225592	ENSG00000220721.1	OR1F12	5.34	1.48e-07	2.2e-05	0.29	0.24	Cardiac Troponin-T levels;	chr6:28182464	chr6:28073316~28074233:+
THCA	cis	rs172166	0.637	rs1225595	ENSG00000220721.1	OR1F12	5.34	1.48e-07	2.2e-05	0.29	0.24	Cardiac Troponin-T levels;	chr6:28183562	chr6:28073316~28074233:+
THCA	cis	rs944289	0.774	rs12589124	ENSG00000258844.1	RP11-259K15.2	5.34	1.48e-07	2.2e-05	0.21	0.24	Thyroid cancer;	chr14:36094718	chr14:36214607~36235608:+
THCA	cis	rs944289	0.74	rs2183451	ENSG00000258844.1	RP11-259K15.2	5.34	1.48e-07	2.2e-05	0.21	0.24	Thyroid cancer;	chr14:36095227	chr14:36214607~36235608:+
THCA	cis	rs944289	0.774	rs884090	ENSG00000258844.1	RP11-259K15.2	5.34	1.48e-07	2.2e-05	0.21	0.24	Thyroid cancer;	chr14:36095741	chr14:36214607~36235608:+
THCA	cis	rs7111546	0.618	rs79784202	ENSG00000246225.5	RP11-17A1.3	5.34	1.48e-07	2.2e-05	0.38	0.24	Dialysis-related mortality;	chr11:22877965	chr11:22829380~22945393:+
THCA	cis	rs12935418	0.552	rs2123626	ENSG00000278985.1	RP11-303E16.9	-5.34	1.48e-07	2.2e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80988205	chr16:80982319~80984094:-
THCA	cis	rs1318937	0.588	rs112820857	ENSG00000224660.1	SH3BP5-AS1	5.34	1.48e-07	2.2e-05	0.22	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15208493	chr3:15254184~15264493:+
THCA	cis	rs1318937	0.748	rs78988883	ENSG00000224660.1	SH3BP5-AS1	5.34	1.48e-07	2.2e-05	0.22	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15236000	chr3:15254184~15264493:+
THCA	cis	rs875971	0.545	rs1796219	ENSG00000232546.1	RP11-458F8.1	-5.34	1.48e-07	2.2e-05	-0.23	-0.24	Aortic root size;	chr7:66645977	chr7:66848496~66858136:+
THCA	cis	rs442309	0.875	rs224065	ENSG00000238280.1	RP11-436D10.3	-5.34	1.48e-07	2.2e-05	-0.28	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62745688	chr10:62793562~62805887:-
THCA	cis	rs61677309	1	rs4938501	ENSG00000280032.1	RP11-832A4.7	5.34	1.48e-07	2.2e-05	0.26	0.24	Lung cancer in ever smokers;	chr11:118295782	chr11:118264593~118266817:+
THCA	cis	rs875971	0.545	rs6460298	ENSG00000228409.4	CCT6P1	-5.34	1.48e-07	2.2e-05	-0.2	-0.24	Aortic root size;	chr7:66442783	chr7:65751142~65763354:+
THCA	cis	rs6968419	0.714	rs17138472	ENSG00000237870.5	AC073130.1	5.34	1.48e-07	2.21e-05	0.26	0.24	Intraocular pressure;	chr7:116252684	chr7:116275606~116286734:-
THCA	cis	rs944289	0.598	rs56359141	ENSG00000258844.1	RP11-259K15.2	5.34	1.48e-07	2.21e-05	0.21	0.24	Thyroid cancer;	chr14:36108167	chr14:36214607~36235608:+
THCA	cis	rs7577696	0.925	rs212717	ENSG00000276334.1	AL133243.1	5.34	1.48e-07	2.21e-05	0.25	0.24	Inflammatory biomarkers;	chr2:32236571	chr2:32521927~32523547:+
THCA	cis	rs11121022	1	rs11121022	ENSG00000269925.1	RP3-467L1.6	-5.34	1.48e-07	2.21e-05	-0.25	-0.24	Morning vs. evening chronotype;	chr1:7776599	chr1:7776383~7776775:+
THCA	cis	rs6058796	1	rs6087406	ENSG00000175730.8	BAK1P1	5.34	1.48e-07	2.21e-05	0.39	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32653223	chr20:32690180~32690815:-
THCA	cis	rs7560272	0.564	rs4852939	ENSG00000163016.8	ALMS1P	5.34	1.48e-07	2.21e-05	0.3	0.24	Schizophrenia;	chr2:73629642	chr2:73644919~73685576:+
THCA	cis	rs1552244	1	rs76041173	ENSG00000180385.7	EMC3-AS1	5.34	1.48e-07	2.21e-05	0.27	0.24	Alzheimer's disease;	chr3:10037011	chr3:9986893~10006990:+
THCA	cis	rs2243480	0.706	rs6460257	ENSG00000228409.4	CCT6P1	5.34	1.48e-07	2.21e-05	0.25	0.24	Diabetic kidney disease;	chr7:65731813	chr7:65751142~65763354:+
THCA	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	5.34	1.48e-07	2.21e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
THCA	cis	rs728616	0.681	rs17100316	ENSG00000225484.5	NUTM2B-AS1	-5.34	1.48e-07	2.21e-05	-0.41	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80153581	chr10:79663088~79826594:-
THCA	cis	rs728616	0.681	rs36073865	ENSG00000225484.5	NUTM2B-AS1	-5.34	1.48e-07	2.21e-05	-0.41	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156299	chr10:79663088~79826594:-
THCA	cis	rs9719620	0.933	rs4731790	ENSG00000236753.4	MKLN1-AS	-5.34	1.48e-07	2.21e-05	-0.23	-0.24	Male-pattern baldness;	chr7:131307288	chr7:131309744~131328222:-
THCA	cis	rs890448	0.796	rs1596061	ENSG00000254531.1	FLJ20021	5.34	1.48e-07	2.21e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101379218	chr4:101347780~101348883:+
THCA	cis	rs934734	0.699	rs268138	ENSG00000281920.1	RP11-418H16.1	-5.34	1.49e-07	2.21e-05	-0.3	-0.24	Rheumatoid arthritis;	chr2:65380160	chr2:65623272~65628424:+
THCA	cis	rs442309	0.875	rs224055	ENSG00000238280.1	RP11-436D10.3	-5.34	1.49e-07	2.22e-05	-0.28	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62737110	chr10:62793562~62805887:-
THCA	cis	rs7129556	0.775	rs11237263	ENSG00000254691.1	RP11-91P24.5	5.34	1.49e-07	2.22e-05	0.33	0.24	Weight loss (gastric bypass surgery);	chr11:77667760	chr11:77850604~77851511:+
THCA	cis	rs6988985	0.678	rs28710914	ENSG00000247317.3	RP11-273G15.2	-5.34	1.49e-07	2.22e-05	-0.25	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921874	chr8:142981738~143018437:-
THCA	cis	rs12681287	0.604	rs7017716	ENSG00000254231.1	CTD-2284J15.1	5.34	1.49e-07	2.22e-05	0.26	0.24	Caudate activity during reward;	chr8:86416772	chr8:86333274~86343314:-
THCA	cis	rs12935418	0.616	rs9931292	ENSG00000278985.1	RP11-303E16.9	5.34	1.49e-07	2.22e-05	0.26	0.24	Mean corpuscular volume;	chr16:80975671	chr16:80982319~80984094:-
THCA	cis	rs62184315	0.938	rs17806132	ENSG00000273240.1	RP11-455J20.3	5.34	1.49e-07	2.22e-05	0.31	0.24	Alcohol dependence (age at onset);	chr2:189843561	chr2:189763859~189764456:-
THCA	cis	rs4948275	0.71	rs2787698	ENSG00000237233.2	TMEM26-AS1	-5.33	1.49e-07	2.22e-05	-0.33	-0.24	Night sleep phenotypes;	chr10:61537692	chr10:61452639~61481956:+
THCA	cis	rs7119	0.717	rs8033654	ENSG00000259362.2	RP11-307C19.1	-5.33	1.49e-07	2.22e-05	-0.35	-0.24	Type 2 diabetes;	chr15:77532908	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs8033067	ENSG00000259362.2	RP11-307C19.1	-5.33	1.49e-07	2.22e-05	-0.35	-0.24	Type 2 diabetes;	chr15:77533153	chr15:77525540~77534110:+
THCA	cis	rs78487399	0.808	rs17030890	ENSG00000234936.1	AC010883.5	5.33	1.49e-07	2.22e-05	0.34	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43476953	chr2:43229573~43233394:+
THCA	cis	rs863750	0.744	rs2460761	ENSG00000275389.1	RP11-214K3.24	5.33	1.49e-07	2.22e-05	0.32	0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124060053	chr12:124085761~124088598:+
THCA	cis	rs899997	1	rs7182567	ENSG00000261143.1	ADAMTS7P3	5.33	1.49e-07	2.22e-05	0.32	0.24	Coronary artery disease or large artery stroke;	chr15:78752712	chr15:77976042~77993057:+
THCA	cis	rs10256972	0.721	rs10435145	ENSG00000199023.2	MIR339	-5.33	1.49e-07	2.22e-05	-0.25	-0.24	Endometriosis;Longevity;	chr7:1026352	chr7:1022935~1023045:-
THCA	cis	rs7923837	1	rs10748582	ENSG00000236493.2	EIF2S2P3	5.33	1.49e-07	2.22e-05	0.25	0.24	Multiple sclerosis;Body mass index;	chr10:92717462	chr10:92668745~92669743:-
THCA	cis	rs4948275	0.773	rs2606078	ENSG00000237233.2	TMEM26-AS1	-5.33	1.49e-07	2.22e-05	-0.32	-0.24	Night sleep phenotypes;	chr10:61529457	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2606079	ENSG00000237233.2	TMEM26-AS1	-5.33	1.49e-07	2.22e-05	-0.32	-0.24	Night sleep phenotypes;	chr10:61529877	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.773	rs2787694	ENSG00000237233.2	TMEM26-AS1	-5.33	1.49e-07	2.22e-05	-0.32	-0.24	Night sleep phenotypes;	chr10:61530078	chr10:61452639~61481956:+
THCA	cis	rs78487399	0.808	rs76993899	ENSG00000234936.1	AC010883.5	5.33	1.49e-07	2.22e-05	0.34	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43444018	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs77620935	ENSG00000234936.1	AC010883.5	5.33	1.49e-07	2.22e-05	0.34	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446626	chr2:43229573~43233394:+
THCA	cis	rs713477	0.654	rs6573030	ENSG00000258413.1	RP11-665C16.6	5.33	1.49e-07	2.22e-05	0.33	0.24	Pediatric bone mineral content (femoral neck);	chr14:55447002	chr14:55262767~55272075:-
THCA	cis	rs713477	0.654	rs11158040	ENSG00000258413.1	RP11-665C16.6	5.33	1.49e-07	2.22e-05	0.33	0.24	Pediatric bone mineral content (femoral neck);	chr14:55447889	chr14:55262767~55272075:-
THCA	cis	rs6714710	0.627	rs6748124	ENSG00000230606.9	AC159540.1	-5.33	1.49e-07	2.23e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97902551	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs58546246	ENSG00000230606.9	AC159540.1	-5.33	1.49e-07	2.23e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97905360	chr2:97416165~97433527:-
THCA	cis	rs6860806	0.631	rs7736284	ENSG00000233006.5	AC034220.3	5.33	1.49e-07	2.23e-05	0.18	0.24	Breast cancer;	chr5:132252458	chr5:132311285~132369916:-
THCA	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	5.33	1.49e-07	2.23e-05	0.26	0.24	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
THCA	cis	rs9719620	0.9	rs13230692	ENSG00000236753.4	MKLN1-AS	-5.33	1.5e-07	2.23e-05	-0.23	-0.24	Male-pattern baldness;	chr7:131311948	chr7:131309744~131328222:-
THCA	cis	rs6921919	0.583	rs6928771	ENSG00000219392.1	RP1-265C24.5	-5.33	1.5e-07	2.23e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28115628~28116551:+
THCA	cis	rs2692947	0.8	rs61409777	ENSG00000232931.4	LINC00342	5.33	1.5e-07	2.23e-05	0.19	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95915625	chr2:95807118~95816215:-
THCA	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-5.33	1.5e-07	2.23e-05	-0.42	-0.24	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
THCA	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-5.33	1.5e-07	2.23e-05	-0.42	-0.24	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
THCA	cis	rs7727544	0.684	rs274560	ENSG00000224431.1	AC063976.7	-5.33	1.5e-07	2.23e-05	-0.2	-0.24	Blood metabolite levels;	chr5:132383758	chr5:132199456~132203487:+
THCA	cis	rs17122278	0.613	rs477106	ENSG00000278376.1	RP11-158I9.8	-5.33	1.5e-07	2.23e-05	-0.22	-0.24	Total cholesterol levels;	chr11:118492709	chr11:118791254~118793137:+
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000280069.1	CTD-2349P21.3	-5.33	1.5e-07	2.23e-05	-0.37	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000280069.1	CTD-2349P21.3	-5.33	1.5e-07	2.23e-05	-0.37	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30738182~30740275:+
THCA	cis	rs12530	0.715	rs2294314	ENSG00000230736.2	RP1-149A16.3	-5.33	1.5e-07	2.24e-05	-0.31	-0.24	IgG glycosylation;	chr22:32398616	chr22:32376664~32384343:+
THCA	cis	rs858239	0.539	rs6975852	ENSG00000226816.2	AC005082.12	5.33	1.5e-07	2.24e-05	0.35	0.24	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23206013~23208045:+
THCA	cis	rs2243480	1	rs316327	ENSG00000230295.1	RP11-458F8.2	5.33	1.5e-07	2.24e-05	0.29	0.24	Diabetic kidney disease;	chr7:66144214	chr7:66880708~66882981:+
THCA	cis	rs7250849	0.565	rs7255319	ENSG00000273837.1	LLNLR-470E3.1	5.33	1.5e-07	2.24e-05	0.33	0.24	Blood protein levels;	chr19:51664653	chr19:51639478~51639931:-
THCA	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	5.33	1.5e-07	2.24e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
THCA	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	5.33	1.5e-07	2.24e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000273796.1	LL21NC02-21A1.1	-5.33	1.5e-07	2.24e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45403809~45404369:-
THCA	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-5.33	1.5e-07	2.24e-05	-0.29	-0.24	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
THCA	cis	rs1198430	0.562	rs7523811	ENSG00000232482.2	RP4-654C18.1	5.33	1.5e-07	2.24e-05	0.34	0.24	Total cholesterol levels;	chr1:23463074	chr1:23410832~23412146:+
THCA	cis	rs875971	0.545	rs2460427	ENSG00000232546.1	RP11-458F8.1	-5.33	1.5e-07	2.24e-05	-0.23	-0.24	Aortic root size;	chr7:66154218	chr7:66848496~66858136:+
THCA	cis	rs12664251	0.666	rs1889561	ENSG00000253194.1	RP11-351A11.1	-5.33	1.5e-07	2.24e-05	-0.33	-0.24	Schizophrenia;	chr6:119014700	chr6:118934785~119031541:+
THCA	cis	rs7829975	0.582	rs11783950	ENSG00000254153.1	CTA-398F10.2	5.33	1.51e-07	2.24e-05	0.27	0.24	Mood instability;	chr8:8740321	chr8:8456909~8461337:-
THCA	cis	rs6445975	0.617	rs9859048	ENSG00000272360.1	RP11-359I18.5	5.33	1.51e-07	2.24e-05	0.28	0.24	Systemic lupus erythematosus;	chr3:58434691	chr3:58490830~58491291:-
THCA	cis	rs2243480	1	rs2462569	ENSG00000230295.1	RP11-458F8.2	5.33	1.51e-07	2.24e-05	0.29	0.24	Diabetic kidney disease;	chr7:66009859	chr7:66880708~66882981:+
THCA	cis	rs7260598	0.535	rs13343732	ENSG00000268442.1	CTD-2027I19.2	5.33	1.51e-07	2.24e-05	0.28	0.24	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:24162370~24163425:-
THCA	cis	rs12036718	0.511	rs11205444	ENSG00000272491.1	RP5-1024N4.4	-5.33	1.51e-07	2.25e-05	-0.3	-0.24	Yu-Zhi constitution type in type 2 diabetes;	chr1:48139025	chr1:48227888~48229561:-
THCA	cis	rs2243480	1	rs313809	ENSG00000230295.1	RP11-458F8.2	-5.33	1.51e-07	2.25e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66034996	chr7:66880708~66882981:+
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000273796.1	LL21NC02-21A1.1	-5.33	1.51e-07	2.25e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45403809~45404369:-
THCA	cis	rs11089937	0.512	rs34963809	ENSG00000211639.2	IGLV4-60	5.33	1.51e-07	2.25e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.568	rs35626600	ENSG00000211639.2	IGLV4-60	5.33	1.51e-07	2.25e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.539	rs34228957	ENSG00000211639.2	IGLV4-60	5.33	1.51e-07	2.25e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22162199~22162681:+
THCA	cis	rs7615952	0.673	rs9821905	ENSG00000241288.6	RP11-379B18.5	5.33	1.51e-07	2.25e-05	0.34	0.24	Blood pressure (smoking interaction);	chr3:125902007	chr3:125827238~125916384:-
THCA	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	5.33	1.51e-07	2.25e-05	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
THCA	cis	rs16846053	0.502	rs62188848	ENSG00000227403.1	AC009299.3	5.33	1.51e-07	2.25e-05	0.55	0.24	Blood osmolality (transformed sodium);	chr2:161920434	chr2:161244739~161249050:+
THCA	cis	rs3864261	0.515	rs57149385	ENSG00000272081.1	CTD-2376I4.2	5.33	1.51e-07	2.25e-05	0.31	0.24	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72955206~72955699:-
THCA	cis	rs3864261	0.515	rs10942539	ENSG00000272081.1	CTD-2376I4.2	5.33	1.51e-07	2.25e-05	0.31	0.24	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72955206~72955699:-
THCA	cis	rs9876781	1	rs2045554	ENSG00000229759.1	MRPS18AP1	-5.33	1.51e-07	2.25e-05	-0.28	-0.24	Longevity;	chr3:48453142	chr3:48256350~48256938:-
THCA	cis	rs1552244	1	rs66838678	ENSG00000232901.1	CYCSP10	5.33	1.51e-07	2.25e-05	0.31	0.24	Alzheimer's disease;	chr3:10108666	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs7618815	ENSG00000232901.1	CYCSP10	5.33	1.51e-07	2.25e-05	0.31	0.24	Alzheimer's disease;	chr3:10109361	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs7652935	ENSG00000232901.1	CYCSP10	5.33	1.51e-07	2.25e-05	0.31	0.24	Alzheimer's disease;	chr3:10109454	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs67134728	ENSG00000232901.1	CYCSP10	5.33	1.51e-07	2.25e-05	0.31	0.24	Alzheimer's disease;	chr3:10109747	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs68045038	ENSG00000232901.1	CYCSP10	5.33	1.51e-07	2.25e-05	0.31	0.24	Alzheimer's disease;	chr3:10110144	chr3:10000647~10000940:-
THCA	cis	rs17123764	0.71	rs11169125	ENSG00000257464.1	RP11-161H23.8	-5.33	1.51e-07	2.25e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49721621	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs12321169	ENSG00000257464.1	RP11-161H23.8	-5.33	1.51e-07	2.25e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49722134	chr12:49442424~49442652:-
THCA	cis	rs1707322	0.963	rs12145287	ENSG00000281133.1	AL355480.3	-5.33	1.51e-07	2.25e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45580892~45580996:-
THCA	cis	rs7688540	0.771	rs11724417	ENSG00000211553.1	AC253576.2	-5.33	1.51e-07	2.25e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:136461~136568:+
THCA	cis	rs7688540	0.623	rs11735968	ENSG00000211553.1	AC253576.2	-5.33	1.51e-07	2.25e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:136461~136568:+
THCA	cis	rs7727544	0.514	rs3846728	ENSG00000233006.5	AC034220.3	5.33	1.51e-07	2.25e-05	0.18	0.24	Blood metabolite levels;	chr5:132100524	chr5:132311285~132369916:-
THCA	cis	rs17818399	1	rs17818399	ENSG00000279254.1	RP11-536C12.1	-5.33	1.51e-07	2.25e-05	-0.24	-0.24	Height;	chr2:46598887	chr2:46668870~46670778:+
THCA	cis	rs9549367	0.673	rs3024735	ENSG00000269125.1	RP11-98F14.11	-5.33	1.51e-07	2.25e-05	-0.3	-0.24	Platelet distribution width;	chr13:113165199	chr13:113165002~113165183:-
THCA	cis	rs12935418	0.616	rs2549858	ENSG00000278985.1	RP11-303E16.9	-5.33	1.51e-07	2.25e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80993389	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.616	rs2549859	ENSG00000278985.1	RP11-303E16.9	-5.33	1.51e-07	2.25e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80993398	chr16:80982319~80984094:-
THCA	cis	rs613391	0.536	rs554191	ENSG00000224549.1	RP11-370B11.3	-5.33	1.51e-07	2.25e-05	-0.27	-0.24	Quantitative traits;	chr9:22720123	chr9:22767175~22768316:+
THCA	cis	rs613391	0.561	rs694541	ENSG00000224549.1	RP11-370B11.3	-5.33	1.51e-07	2.25e-05	-0.27	-0.24	Quantitative traits;	chr9:22722357	chr9:22767175~22768316:+
THCA	cis	rs613391	0.578	rs7874257	ENSG00000224549.1	RP11-370B11.3	-5.33	1.51e-07	2.25e-05	-0.27	-0.24	Quantitative traits;	chr9:22723026	chr9:22767175~22768316:+
THCA	cis	rs4965006	0.591	rs4964913	ENSG00000255992.1	RP11-417L19.4	-5.33	1.51e-07	2.25e-05	-0.37	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr12:131927943	chr12:131924736~131929351:-
THCA	cis	rs5758659	0.819	rs134871	ENSG00000270083.1	RP1-257I20.14	5.33	1.51e-07	2.25e-05	0.25	0.24	Cognitive function;	chr22:42256710	chr22:42089630~42090028:-
THCA	cis	rs34779708	0.966	rs12773647	ENSG00000271335.4	RP11-324I22.4	5.33	1.52e-07	2.26e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35314552~35336401:-
THCA	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-5.33	1.52e-07	2.26e-05	-0.34	-0.24	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
THCA	cis	rs7119038	0.774	rs2004781	ENSG00000255239.1	AP002954.6	-5.33	1.52e-07	2.26e-05	-0.37	-0.24	Sjögren's syndrome;	chr11:118748544	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.818	rs3889239	ENSG00000255239.1	AP002954.6	-5.33	1.52e-07	2.26e-05	-0.37	-0.24	Sjögren's syndrome;	chr11:118749251	chr11:118688039~118690600:-
THCA	cis	rs17767392	0.846	rs61991213	ENSG00000259146.3	RP1-261D10.2	5.33	1.52e-07	2.26e-05	0.3	0.24	Mitral valve prolapse;	chr14:71329724	chr14:71292729~71321814:-
THCA	cis	rs2243480	1	rs160644	ENSG00000232559.3	GS1-124K5.12	5.33	1.52e-07	2.26e-05	0.34	0.24	Diabetic kidney disease;	chr7:66093199	chr7:66554588~66576923:-
THCA	cis	rs4648045	0.894	rs11097789	ENSG00000246560.2	RP11-10L12.4	5.33	1.52e-07	2.26e-05	0.3	0.24	Lymphocyte percentage of white cells;	chr4:102581605	chr4:102828055~102844075:+
THCA	cis	rs2562456	0.617	rs34203148	ENSG00000268119.4	CTD-2561J22.5	5.33	1.52e-07	2.26e-05	0.31	0.24	Pain;	chr19:21590743	chr19:21444241~21463908:-
THCA	cis	rs4915077	1	rs77346255	ENSG00000230489.1	VAV3-AS1	5.33	1.52e-07	2.26e-05	0.39	0.24	Hypothyroidism;	chr1:107833382	chr1:107964443~107994607:+
THCA	cis	rs4908760	0.827	rs7513420	ENSG00000232912.4	RP5-1115A15.1	5.33	1.52e-07	2.26e-05	0.23	0.24	Vitiligo;	chr1:8620985	chr1:8424645~8434838:+
THCA	cis	rs9475752	0.744	rs17685338	ENSG00000231441.1	RP11-472M19.2	5.33	1.52e-07	2.26e-05	0.32	0.24	Menarche (age at onset);	chr6:56986071	chr6:56844002~56864078:+
THCA	cis	rs12893668	0.638	rs11851616	ENSG00000269940.1	RP11-73M18.7	5.33	1.52e-07	2.26e-05	0.25	0.24	Reticulocyte count;	chr14:103599263	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.667	rs11844466	ENSG00000269940.1	RP11-73M18.7	5.33	1.52e-07	2.26e-05	0.25	0.24	Reticulocyte count;	chr14:103600085	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.637	rs12892038	ENSG00000269940.1	RP11-73M18.7	5.33	1.52e-07	2.26e-05	0.25	0.24	Reticulocyte count;	chr14:103602292	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.637	rs4525427	ENSG00000269940.1	RP11-73M18.7	5.33	1.52e-07	2.26e-05	0.25	0.24	Reticulocyte count;	chr14:103606456	chr14:103694560~103695170:+
THCA	cis	rs6840360	0.548	rs4254751	ENSG00000270265.1	RP11-731D1.4	-5.33	1.52e-07	2.26e-05	-0.22	-0.24	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151333775~151353224:-
THCA	cis	rs7429990	0.965	rs7430913	ENSG00000228638.1	FCF1P2	5.33	1.52e-07	2.26e-05	0.23	0.24	Educational attainment (years of education);	chr3:47990867	chr3:48290793~48291375:-
THCA	cis	rs6840360	0.582	rs1372976	ENSG00000270265.1	RP11-731D1.4	-5.33	1.52e-07	2.27e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.642	rs1443090	ENSG00000270265.1	RP11-731D1.4	-5.33	1.52e-07	2.27e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151530667	chr4:151333775~151353224:-
THCA	cis	rs6585424	1	rs6585424	ENSG00000242600.5	MBL1P	5.33	1.52e-07	2.27e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173992	chr10:79904898~79950336:+
THCA	cis	rs6585424	1	rs56190825	ENSG00000242600.5	MBL1P	5.33	1.52e-07	2.27e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80174980	chr10:79904898~79950336:+
THCA	cis	rs375066	0.62	rs10401170	ENSG00000267058.1	RP11-15A1.3	5.33	1.52e-07	2.27e-05	0.21	0.24	Breast cancer;	chr19:43795471	chr19:43891804~43901805:-
THCA	cis	rs4748857	0.891	rs4747458	ENSG00000224215.1	RP11-371A19.2	-5.33	1.53e-07	2.27e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23297985	chr10:23343957~23345181:+
THCA	cis	rs30380	0.587	rs151940	ENSG00000272109.1	CTD-2260A17.3	-5.33	1.53e-07	2.27e-05	-0.33	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96812074	chr5:96804353~96806105:+
THCA	cis	rs6893782	0.887	rs274554	ENSG00000233006.5	AC034220.3	-5.33	1.53e-07	2.27e-05	-0.24	-0.24	Acylcarnitine levels;	chr5:132389258	chr5:132311285~132369916:-
THCA	cis	rs10761482	0.5	rs7098650	ENSG00000254271.1	RP11-131N11.4	5.33	1.53e-07	2.27e-05	0.32	0.24	Schizophrenia;	chr10:60517921	chr10:60734342~60741828:+
THCA	cis	rs7131987	0.676	rs10843407	ENSG00000257176.2	RP11-996F15.2	5.33	1.53e-07	2.27e-05	0.24	0.24	QT interval;	chr12:29397311	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.675	rs2194515	ENSG00000257176.2	RP11-996F15.2	5.33	1.53e-07	2.27e-05	0.24	0.24	QT interval;	chr12:29397450	chr12:29280418~29317848:-
THCA	cis	rs7617773	0.851	rs7647817	ENSG00000199476.1	Y_RNA	-5.33	1.53e-07	2.27e-05	-0.31	-0.24	Coronary artery disease;	chr3:48195017	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs11707606	ENSG00000199476.1	Y_RNA	-5.33	1.53e-07	2.27e-05	-0.31	-0.24	Coronary artery disease;	chr3:48195597	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs17786132	ENSG00000199476.1	Y_RNA	-5.33	1.53e-07	2.27e-05	-0.31	-0.24	Coronary artery disease;	chr3:48207930	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs35456569	ENSG00000199476.1	Y_RNA	-5.33	1.53e-07	2.27e-05	-0.31	-0.24	Coronary artery disease;	chr3:48209409	chr3:48288587~48288694:+
THCA	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	5.33	1.53e-07	2.27e-05	0.42	0.24	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
THCA	cis	rs75920871	0.528	rs682048	ENSG00000254851.1	RP11-109L13.1	5.33	1.53e-07	2.27e-05	0.34	0.24	Subjective well-being;	chr11:116957604	chr11:117135528~117138582:+
THCA	cis	rs6540731	0.521	rs10779572	ENSG00000226251.4	RP11-15I11.3	5.33	1.53e-07	2.27e-05	0.29	0.24	Intelligence (childhood);	chr1:212181070	chr1:212225278~212238977:-
THCA	cis	rs2243480	1	rs4718317	ENSG00000232559.3	GS1-124K5.12	-5.33	1.53e-07	2.28e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66183914	chr7:66554588~66576923:-
THCA	cis	rs4950322	0.57	rs4950315	ENSG00000226015.2	CCT8P1	-5.33	1.53e-07	2.28e-05	-0.28	-0.24	Protein quantitative trait loci;	chr1:147264433	chr1:147203276~147204932:-
THCA	cis	rs11846409	0.872	rs74091715	ENSG00000211974.3	IGHV2-70	-5.33	1.53e-07	2.28e-05	-0.23	-0.24	Rheumatic heart disease;	chr14:106637731	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs74091721	ENSG00000211974.3	IGHV2-70	-5.33	1.53e-07	2.28e-05	-0.23	-0.24	Rheumatic heart disease;	chr14:106638262	chr14:106723574~106724093:-
THCA	cis	rs2243480	1	rs1546059	ENSG00000232559.3	GS1-124K5.12	-5.33	1.53e-07	2.28e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66189722	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs2420170	ENSG00000232559.3	GS1-124K5.12	-5.33	1.53e-07	2.28e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66191066	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6958289	ENSG00000232559.3	GS1-124K5.12	-5.33	1.53e-07	2.28e-05	-0.35	-0.24	Diabetic kidney disease;	chr7:66192124	chr7:66554588~66576923:-
THCA	cis	rs7727544	0.514	rs3846728	ENSG00000224431.1	AC063976.7	5.33	1.53e-07	2.28e-05	0.2	0.24	Blood metabolite levels;	chr5:132100524	chr5:132199456~132203487:+
THCA	cis	rs875971	0.522	rs2008188	ENSG00000273142.1	RP11-458F8.4	-5.33	1.53e-07	2.28e-05	-0.19	-0.24	Aortic root size;	chr7:65964026	chr7:66902857~66906297:+
THCA	cis	rs7976269	0.515	rs11049999	ENSG00000275476.1	RP11-996F15.4	-5.33	1.53e-07	2.28e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29042854	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.559	rs10771471	ENSG00000275476.1	RP11-996F15.4	-5.33	1.53e-07	2.28e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29050894	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.559	rs1344853	ENSG00000275476.1	RP11-996F15.4	-5.33	1.53e-07	2.28e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29058623	chr12:29277397~29277882:-
THCA	cis	rs34779708	0.931	rs17582416	ENSG00000271335.4	RP11-324I22.4	5.33	1.53e-07	2.28e-05	0.22	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35314552~35336401:-
THCA	cis	rs6921919	0.525	rs11760133	ENSG00000219392.1	RP1-265C24.5	-5.33	1.53e-07	2.28e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28115628~28116551:+
THCA	cis	rs2839186	0.605	rs2839170	ENSG00000215424.8	MCM3AP-AS1	5.33	1.53e-07	2.28e-05	0.14	0.24	Testicular germ cell tumor;	chr21:46251391	chr21:46229217~46259390:+
THCA	cis	rs8002861	0.935	rs9533678	ENSG00000274001.1	RP11-5G9.5	5.33	1.53e-07	2.28e-05	0.27	0.24	Leprosy;	chr13:43889273	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.869	rs7989857	ENSG00000274001.1	RP11-5G9.5	5.33	1.53e-07	2.28e-05	0.27	0.24	Leprosy;	chr13:43889954	chr13:43877715~43878163:-
THCA	cis	rs748404	0.589	rs62020616	ENSG00000205771.5	CATSPER2P1	-5.33	1.53e-07	2.28e-05	-0.3	-0.24	Lung cancer;	chr15:43558554	chr15:43726918~43747094:-
THCA	cis	rs748404	0.626	rs60367691	ENSG00000205771.5	CATSPER2P1	-5.33	1.53e-07	2.28e-05	-0.3	-0.24	Lung cancer;	chr15:43559201	chr15:43726918~43747094:-
THCA	cis	rs7246657	0.525	rs10405238	ENSG00000226686.6	LINC01535	-5.33	1.53e-07	2.28e-05	-0.37	-0.24	Coronary artery calcification;	chr19:36997153	chr19:37251912~37265535:+
THCA	cis	rs2179367	0.6	rs11155654	ENSG00000223701.3	RAET1E-AS1	5.33	1.53e-07	2.28e-05	0.38	0.24	Dupuytren's disease;	chr6:149442001	chr6:149884431~149919508:+
THCA	cis	rs79040073	0.607	rs17400706	ENSG00000259531.2	RP11-295H24.3	5.33	1.53e-07	2.28e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49455148	chr15:49365124~49366685:-
THCA	cis	rs922182	1	rs922182	ENSG00000275785.1	RP11-111E14.2	5.33	1.53e-07	2.28e-05	0.27	0.24	Blood protein levels;	chr15:63985443	chr15:63890030~63890317:+
THCA	cis	rs12908161	0.96	rs17599989	ENSG00000275120.1	RP11-182J1.17	5.33	1.53e-07	2.28e-05	0.28	0.24	Schizophrenia;	chr15:84742305	chr15:84599434~84606463:-
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000273796.1	LL21NC02-21A1.1	-5.33	1.53e-07	2.28e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45403809~45404369:-
THCA	cis	rs11051970	0.879	rs2651363	ENSG00000274964.1	RP11-817I4.1	5.33	1.54e-07	2.28e-05	0.26	0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32434616	chr12:32339368~32340724:+
THCA	cis	rs2562456	0.833	rs1626404	ENSG00000268119.4	CTD-2561J22.5	5.33	1.54e-07	2.28e-05	0.35	0.24	Pain;	chr19:21300986	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs1781867	ENSG00000268119.4	CTD-2561J22.5	5.33	1.54e-07	2.28e-05	0.35	0.24	Pain;	chr19:21304368	chr19:21444241~21463908:-
THCA	cis	rs10266483	0.545	rs114664455	ENSG00000227986.1	TRIM60P18	5.33	1.54e-07	2.28e-05	0.24	0.24	Response to statin therapy;	chr7:64263634	chr7:64355078~64356199:+
THCA	cis	rs6802315	0.604	rs9863103	ENSG00000272087.1	RP11-379F4.7	-5.33	1.54e-07	2.28e-05	-0.21	-0.24	Periodontitis (CDC/AAP);	chr3:158746014	chr3:158693120~158693768:-
THCA	cis	rs7760535	0.763	rs9487666	ENSG00000271789.1	RP5-1112D6.7	-5.33	1.54e-07	2.28e-05	-0.22	-0.24	Metabolic traits;	chr6:111547821	chr6:111297126~111298510:+
THCA	cis	rs9467773	1	rs9467773	ENSG00000261353.1	CTA-14H9.5	-5.33	1.54e-07	2.29e-05	-0.25	-0.24	Intelligence (multi-trait analysis);	chr6:26498198	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6926629	ENSG00000261353.1	CTA-14H9.5	-5.33	1.54e-07	2.29e-05	-0.25	-0.24	Intelligence (multi-trait analysis);	chr6:26499675	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6903973	ENSG00000261353.1	CTA-14H9.5	-5.33	1.54e-07	2.29e-05	-0.25	-0.24	Intelligence (multi-trait analysis);	chr6:26499714	chr6:26527063~26527404:+
THCA	cis	rs1552244	0.81	rs7612908	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10047464	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs7649243	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10047786	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs7615646	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10048089	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.81	rs6809572	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10058461	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs112847840	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10059968	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs722509	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10060693	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs6793396	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10069243	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs6772315	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10071960	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs7621551	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10072521	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs35148833	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10075253	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.81	rs35711405	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10075255	chr3:10000647~10000940:-
THCA	cis	rs7760535	0.597	rs9320368	ENSG00000230177.1	RP5-1112D6.4	-5.33	1.54e-07	2.29e-05	-0.19	-0.24	Metabolic traits;	chr6:111583534	chr6:111277932~111278742:+
THCA	cis	rs713477	0.654	rs4901569	ENSG00000258413.1	RP11-665C16.6	5.33	1.54e-07	2.29e-05	0.32	0.24	Pediatric bone mineral content (femoral neck);	chr14:55446162	chr14:55262767~55272075:-
THCA	cis	rs4648045	0.765	rs230511	ENSG00000246560.2	RP11-10L12.4	-5.33	1.54e-07	2.29e-05	-0.3	-0.24	Lymphocyte percentage of white cells;	chr4:102553611	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.789	rs230509	ENSG00000246560.2	RP11-10L12.4	-5.33	1.54e-07	2.29e-05	-0.3	-0.24	Lymphocyte percentage of white cells;	chr4:102557108	chr4:102828055~102844075:+
THCA	cis	rs11634944	0.673	rs1549474	ENSG00000257151.1	PWAR6	5.33	1.54e-07	2.29e-05	0.18	0.24	Interleukin-8 levels;	chr15:25000886	chr15:25031873~25036490:+
THCA	cis	rs748404	0.666	rs7177146	ENSG00000205771.5	CATSPER2P1	-5.33	1.54e-07	2.29e-05	-0.31	-0.24	Lung cancer;	chr15:43506110	chr15:43726918~43747094:-
THCA	cis	rs1552244	1	rs7651058	ENSG00000180385.7	EMC3-AS1	5.33	1.54e-07	2.29e-05	0.27	0.24	Alzheimer's disease;	chr3:10025280	chr3:9986893~10006990:+
THCA	cis	rs453301	0.653	rs7005133	ENSG00000254153.1	CTA-398F10.2	-5.33	1.54e-07	2.29e-05	-0.24	-0.24	Joint mobility (Beighton score);	chr8:9043712	chr8:8456909~8461337:-
THCA	cis	rs7772486	0.686	rs9376961	ENSG00000270638.1	RP3-466P17.1	5.33	1.54e-07	2.29e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145735570~145737218:+
THCA	cis	rs1552244	1	rs7615764	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10040908	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs35220123	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10041485	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs4441636	ENSG00000232901.1	CYCSP10	5.33	1.54e-07	2.29e-05	0.32	0.24	Alzheimer's disease;	chr3:10042192	chr3:10000647~10000940:-
THCA	cis	rs6908034	0.607	rs12526109	ENSG00000227116.1	RP3-471C18.1	-5.33	1.54e-07	2.29e-05	-0.46	-0.24	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819858	chr6:19730427~19734567:-
THCA	cis	rs6973609	0.671	rs889935	ENSG00000271122.1	RP11-379H18.1	5.33	1.54e-07	2.29e-05	0.15	0.24	Obesity-related traits;	chr7:35569538	chr7:35695214~35699413:+
THCA	cis	rs875971	0.965	rs697968	ENSG00000223473.2	GS1-124K5.3	-5.33	1.54e-07	2.29e-05	-0.16	-0.24	Aortic root size;	chr7:66070046	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs1183245	ENSG00000223473.2	GS1-124K5.3	-5.33	1.54e-07	2.29e-05	-0.16	-0.24	Aortic root size;	chr7:66076198	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs1144894	ENSG00000223473.2	GS1-124K5.3	-5.33	1.54e-07	2.29e-05	-0.16	-0.24	Aortic root size;	chr7:66077907	chr7:66491049~66493566:-
THCA	cis	rs61677309	1	rs1599809	ENSG00000280032.1	RP11-832A4.7	5.33	1.54e-07	2.29e-05	0.25	0.24	Lung cancer in ever smokers;	chr11:118308485	chr11:118264593~118266817:+
THCA	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	5.33	1.54e-07	2.29e-05	0.28	0.24	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
THCA	cis	rs10510102	0.935	rs12245528	ENSG00000226864.1	ATE1-AS1	-5.33	1.54e-07	2.29e-05	-0.39	-0.24	Breast cancer;	chr10:121881006	chr10:121928312~121951965:+
THCA	cis	rs8062405	0.679	rs72793818	ENSG00000278665.1	RP11-666O2.4	5.33	1.54e-07	2.29e-05	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28599241~28601881:-
THCA	cis	rs831571	0.653	rs73120967	ENSG00000280620.1	SCAANT1	5.33	1.54e-07	2.3e-05	0.39	0.24	Type 2 diabetes;	chr3:64084696	chr3:63911518~63911772:-
THCA	cis	rs9859260	1	rs3804140	ENSG00000231464.1	AC024937.4	5.33	1.54e-07	2.3e-05	0.29	0.24	Mean corpuscular volume;	chr3:196080736	chr3:195996738~195998233:+
THCA	cis	rs9859260	1	rs3804139	ENSG00000231464.1	AC024937.4	5.33	1.54e-07	2.3e-05	0.29	0.24	Mean corpuscular volume;	chr3:196080754	chr3:195996738~195998233:+
THCA	cis	rs879620	0.929	rs2238435	ENSG00000262888.1	RP11-462G12.2	-5.33	1.54e-07	2.3e-05	-0.22	-0.24	Hip circumference;Body mass index;	chr16:3964281	chr16:3931217~3946305:-
THCA	cis	rs752010	0.644	rs7541348	ENSG00000230638.4	RP11-486B10.4	-5.33	1.55e-07	2.3e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41647544	chr1:41542069~41544310:+
THCA	cis	rs6570726	0.846	rs426874	ENSG00000270638.1	RP3-466P17.1	5.33	1.55e-07	2.3e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145735570~145737218:+
THCA	cis	rs3213758	1	rs58848019	ENSG00000275191.1	RP11-36I17.2	-5.33	1.55e-07	2.3e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53634302	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.881	rs80247559	ENSG00000275191.1	RP11-36I17.2	-5.33	1.55e-07	2.3e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53636729	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs77511317	ENSG00000275191.1	RP11-36I17.2	-5.33	1.55e-07	2.3e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53638676	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.867	rs78596597	ENSG00000275191.1	RP11-36I17.2	-5.33	1.55e-07	2.3e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53639408	chr16:53628256~53628816:-
THCA	cis	rs11643654	0.745	rs1465338	ENSG00000260818.2	UNGP1	5.33	1.55e-07	2.3e-05	0.23	0.24	Educational attainment (years of education);	chr16:51137759	chr16:51277852~51279112:+
THCA	cis	rs116095464	0.558	rs56081398	ENSG00000248925.1	CTD-2083E4.6	5.33	1.55e-07	2.3e-05	0.38	0.24	Breast cancer;	chr5:247203	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10065584	ENSG00000248925.1	CTD-2083E4.6	5.33	1.55e-07	2.3e-05	0.38	0.24	Breast cancer;	chr5:253882	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs56298907	ENSG00000248925.1	CTD-2083E4.6	5.33	1.55e-07	2.3e-05	0.38	0.24	Breast cancer;	chr5:283165	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs7356535	ENSG00000248925.1	CTD-2083E4.6	5.33	1.55e-07	2.3e-05	0.38	0.24	Breast cancer;	chr5:284002	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs55833259	ENSG00000248925.1	CTD-2083E4.6	5.33	1.55e-07	2.3e-05	0.38	0.24	Breast cancer;	chr5:286613	chr5:269858~271516:-
THCA	cis	rs6969780	1	rs1801085	ENSG00000233429.8	HOTAIRM1	5.33	1.55e-07	2.3e-05	0.36	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27128971	chr7:27095647~27100265:+
THCA	cis	rs1417569	0.519	rs3011601	ENSG00000237135.1	DDX10P1	5.33	1.55e-07	2.3e-05	0.3	0.24	Tuberculosis;	chr10:30956400	chr10:30919012~30921235:-
THCA	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	5.33	1.55e-07	2.3e-05	0.31	0.24	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.6	rs9498353	ENSG00000268592.3	RAET1E-AS1	5.33	1.55e-07	2.3e-05	0.38	0.24	Dupuytren's disease;	chr6:149439860	chr6:149863494~149919507:+
THCA	cis	rs12935418	0.672	rs3826048	ENSG00000278985.1	RP11-303E16.9	5.33	1.55e-07	2.3e-05	0.26	0.24	Mean corpuscular volume;	chr16:81023230	chr16:80982319~80984094:-
THCA	cis	rs2439831	0.681	rs484846	ENSG00000275601.1	AC011330.13	-5.33	1.55e-07	2.3e-05	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43308605	chr15:43642389~43643023:-
THCA	cis	rs7727544	0.684	rs611084	ENSG00000224431.1	AC063976.7	-5.33	1.55e-07	2.3e-05	-0.2	-0.24	Blood metabolite levels;	chr5:132374047	chr5:132199456~132203487:+
THCA	cis	rs2282300	0.739	rs1222215	ENSG00000242353.1	RP4-710M3.1	-5.33	1.55e-07	2.3e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30326049	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.696	rs1222214	ENSG00000242353.1	RP4-710M3.1	-5.33	1.55e-07	2.3e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30326148	chr11:30368148~30368646:+
THCA	cis	rs3785574	0.962	rs2955235	ENSG00000240280.5	TCAM1P	-5.33	1.55e-07	2.3e-05	-0.32	-0.24	Height;	chr17:63889590	chr17:63849292~63864379:+
THCA	cis	rs11089937	0.568	rs5756989	ENSG00000211638.2	IGLV8-61	-5.33	1.55e-07	2.31e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22098700~22099212:+
THCA	cis	rs758324	0.732	rs45511	ENSG00000237714.1	P4HA2-AS1	-5.33	1.55e-07	2.31e-05	-0.36	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132103468	chr5:132184876~132192808:+
THCA	cis	rs2029362	0.636	rs11030101	ENSG00000245573.6	BDNF-AS	5.33	1.55e-07	2.31e-05	0.19	0.24	Total body bone mineral density;	chr11:27659197	chr11:27506838~27698174:+
THCA	cis	rs7674212	1	rs7674212	ENSG00000230069.3	LRRC37A15P	-5.33	1.55e-07	2.31e-05	-0.25	-0.24	Type 2 diabetes;	chr4:103067742	chr4:102727274~102730721:-
THCA	cis	rs7554547	0.714	rs926269	ENSG00000199347.1	RNU5E-1	-5.33	1.56e-07	2.31e-05	-0.33	-0.24	Nonsyndromic cleft lip with cleft palate;	chr1:11909691	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.714	rs2878679	ENSG00000199347.1	RNU5E-1	-5.33	1.56e-07	2.31e-05	-0.33	-0.24	Nonsyndromic cleft lip with cleft palate;	chr1:11915586	chr1:11908152~11908271:+
THCA	cis	rs72772090	0.71	rs17400741	ENSG00000248734.2	CTD-2260A17.1	-5.33	1.56e-07	2.31e-05	-0.4	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730872	chr5:96784777~96785999:+
THCA	cis	rs7429990	0.932	rs2166772	ENSG00000228638.1	FCF1P2	5.33	1.56e-07	2.31e-05	0.23	0.24	Educational attainment (years of education);	chr3:48006384	chr3:48290793~48291375:-
THCA	cis	rs875971	0.54	rs35510581	ENSG00000273142.1	RP11-458F8.4	5.33	1.56e-07	2.31e-05	0.19	0.24	Aortic root size;	chr7:66113790	chr7:66902857~66906297:+
THCA	cis	rs12188164	0.62	rs56070387	ENSG00000188242.4	PP7080	5.33	1.56e-07	2.32e-05	0.25	0.24	Cystic fibrosis severity;	chr5:482416	chr5:466124~473098:-
THCA	cis	rs1552244	0.938	rs66915020	ENSG00000232901.1	CYCSP10	5.33	1.56e-07	2.32e-05	0.32	0.24	Alzheimer's disease;	chr3:10068490	chr3:10000647~10000940:-
THCA	cis	rs7403037	1	rs7495122	ENSG00000259905.4	PWRN1	5.33	1.56e-07	2.32e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24588464	chr15:24493137~24652130:+
THCA	cis	rs7403037	1	rs7494918	ENSG00000259905.4	PWRN1	5.33	1.56e-07	2.32e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24588477	chr15:24493137~24652130:+
THCA	cis	rs1707322	1	rs4606257	ENSG00000281133.1	AL355480.3	-5.33	1.56e-07	2.32e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45580892~45580996:-
THCA	cis	rs9475752	0.793	rs75622343	ENSG00000231441.1	RP11-472M19.2	5.33	1.56e-07	2.32e-05	0.32	0.24	Menarche (age at onset);	chr6:56983254	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs34027274	ENSG00000231441.1	RP11-472M19.2	5.33	1.56e-07	2.32e-05	0.32	0.24	Menarche (age at onset);	chr6:56983889	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.744	rs34399458	ENSG00000231441.1	RP11-472M19.2	5.33	1.56e-07	2.32e-05	0.32	0.24	Menarche (age at onset);	chr6:56984044	chr6:56844002~56864078:+
THCA	cis	rs11148252	0.634	rs1571189	ENSG00000235660.1	LINC00345	-5.33	1.56e-07	2.32e-05	-0.3	-0.24	Lewy body disease;	chr13:52156869	chr13:52484161~52484680:-
THCA	cis	rs6921919	0.583	rs11755942	ENSG00000219392.1	RP1-265C24.5	-5.33	1.56e-07	2.32e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28115628~28116551:+
THCA	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-5.33	1.56e-07	2.32e-05	-0.3	-0.24	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
THCA	cis	rs2129782	1	rs79091964	ENSG00000253553.4	RP11-586K2.1	5.33	1.56e-07	2.32e-05	0.43	0.24	Electrodermal activity;	chr8:88385776	chr8:88326836~88737134:+
THCA	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	5.33	1.56e-07	2.32e-05	0.34	0.24	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
THCA	cis	rs4748857	0.898	rs4747462	ENSG00000224215.1	RP11-371A19.2	-5.33	1.56e-07	2.32e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23312963	chr10:23343957~23345181:+
THCA	cis	rs853679	0.567	rs3799499	ENSG00000219392.1	RP1-265C24.5	-5.33	1.56e-07	2.32e-05	-0.29	-0.24	Depression;	chr6:28386473	chr6:28115628~28116551:+
THCA	cis	rs853679	0.567	rs2232427	ENSG00000219392.1	RP1-265C24.5	-5.33	1.56e-07	2.32e-05	-0.29	-0.24	Depression;	chr6:28391932	chr6:28115628~28116551:+
THCA	cis	rs6969780	1	rs6969780	ENSG00000233429.8	HOTAIRM1	5.33	1.56e-07	2.32e-05	0.36	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119517	chr7:27095647~27100265:+
THCA	cis	rs7617773	0.707	rs13061269	ENSG00000199476.1	Y_RNA	-5.33	1.56e-07	2.32e-05	-0.31	-0.24	Coronary artery disease;	chr3:48331853	chr3:48288587~48288694:+
THCA	cis	rs11648785	0.777	rs4433810	ENSG00000222019.6	URAHP	5.33	1.57e-07	2.32e-05	0.21	0.24	Tanning;	chr16:90032058	chr16:90039761~90047773:-
THCA	cis	rs752010	0.841	rs58737163	ENSG00000230638.4	RP11-486B10.4	-5.33	1.57e-07	2.32e-05	-0.25	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41614150	chr1:41542069~41544310:+
THCA	cis	rs7829975	0.511	rs2948286	ENSG00000253981.4	ALG1L13P	5.33	1.57e-07	2.32e-05	0.23	0.24	Mood instability;	chr8:8272638	chr8:8236003~8244667:-
THCA	cis	rs72772090	0.908	rs11750510	ENSG00000248734.2	CTD-2260A17.1	-5.33	1.57e-07	2.32e-05	-0.39	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96706391	chr5:96784777~96785999:+
THCA	cis	rs72772090	1	rs72772092	ENSG00000248734.2	CTD-2260A17.1	-5.33	1.57e-07	2.32e-05	-0.39	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96711208	chr5:96784777~96785999:+
THCA	cis	rs2562456	0.833	rs61035285	ENSG00000268081.1	RP11-678G14.2	5.33	1.57e-07	2.33e-05	0.4	0.24	Pain;	chr19:21329475	chr19:21554640~21569237:-
THCA	cis	rs7412746	0.611	rs111842513	ENSG00000231073.1	RP11-316M1.3	5.33	1.57e-07	2.33e-05	0.29	0.24	Melanoma;	chr1:150740450	chr1:150973123~150975534:+
THCA	cis	rs7824557	0.736	rs35392635	ENSG00000154316.13	TDH	-5.33	1.57e-07	2.33e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11306840	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.767	rs11775635	ENSG00000154316.13	TDH	-5.33	1.57e-07	2.33e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11307356	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.767	rs28507159	ENSG00000154316.13	TDH	-5.33	1.57e-07	2.33e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11308567	chr8:11339637~11368452:+
THCA	cis	rs6951245	0.678	rs4724725	ENSG00000229043.2	AC091729.9	-5.32	1.57e-07	2.33e-05	-0.39	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1175115	chr7:1160374~1165267:+
THCA	cis	rs7493	1	rs12026	ENSG00000233942.1	AC004012.1	5.32	1.57e-07	2.33e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411704	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs17166875	ENSG00000233942.1	AC004012.1	5.32	1.57e-07	2.33e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411959	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs2068604	ENSG00000233942.1	AC004012.1	5.32	1.57e-07	2.33e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95412230	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs6968305	ENSG00000233942.1	AC004012.1	5.32	1.57e-07	2.33e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95413217	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs3779492	ENSG00000233942.1	AC004012.1	5.32	1.57e-07	2.33e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95414871	chr7:95471835~95473998:+
THCA	cis	rs7493	0.95	rs56265549	ENSG00000233942.1	AC004012.1	5.32	1.57e-07	2.33e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417843	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs2040993	ENSG00000233942.1	AC004012.1	5.32	1.57e-07	2.33e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417988	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs2299263	ENSG00000233942.1	AC004012.1	-5.32	1.57e-07	2.33e-05	-0.35	-0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411099	chr7:95471835~95473998:+
THCA	cis	rs6921919	0.609	rs67211468	ENSG00000219392.1	RP1-265C24.5	-5.32	1.57e-07	2.33e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28115628~28116551:+
THCA	cis	rs4648045	0.964	rs11723120	ENSG00000246560.2	RP11-10L12.4	5.32	1.57e-07	2.33e-05	0.29	0.24	Lymphocyte percentage of white cells;	chr4:102581394	chr4:102828055~102844075:+
THCA	cis	rs7851660	0.844	rs12343182	ENSG00000214417.4	KRT18P13	-5.32	1.57e-07	2.33e-05	-0.2	-0.24	Strep throat;	chr9:97861977	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs7860144	ENSG00000214417.4	KRT18P13	-5.32	1.57e-07	2.33e-05	-0.2	-0.24	Strep throat;	chr9:97864602	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs10120412	ENSG00000214417.4	KRT18P13	-5.32	1.57e-07	2.33e-05	-0.2	-0.24	Strep throat;	chr9:97865956	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs2417576	ENSG00000214417.4	KRT18P13	-5.32	1.57e-07	2.33e-05	-0.2	-0.24	Strep throat;	chr9:97866425	chr9:97698922~97700734:+
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000273796.1	LL21NC02-21A1.1	-5.32	1.57e-07	2.33e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45403809~45404369:-
THCA	cis	rs7129556	0.775	rs17752006	ENSG00000254691.1	RP11-91P24.5	5.32	1.57e-07	2.33e-05	0.33	0.24	Weight loss (gastric bypass surgery);	chr11:77682948	chr11:77850604~77851511:+
THCA	cis	rs11148252	0.634	rs66849828	ENSG00000235660.1	LINC00345	-5.32	1.57e-07	2.33e-05	-0.31	-0.24	Lewy body disease;	chr13:52140701	chr13:52484161~52484680:-
THCA	cis	rs7394190	0.748	rs2306325	ENSG00000271816.1	BMS1P4	-5.32	1.57e-07	2.33e-05	-0.29	-0.24	Incident atrial fibrillation;	chr10:73746916	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs11000764	ENSG00000271816.1	BMS1P4	-5.32	1.57e-07	2.33e-05	-0.29	-0.24	Incident atrial fibrillation;	chr10:73747106	chr10:73699151~73730487:-
THCA	cis	rs6545883	0.868	rs778755	ENSG00000270820.4	RP11-355B11.2	-5.32	1.57e-07	2.33e-05	-0.2	-0.24	Tuberculosis;	chr2:61553902	chr2:61471188~61484130:+
THCA	cis	rs1185460	0.967	rs4454730	ENSG00000272186.1	RP11-110I1.13	-5.32	1.57e-07	2.33e-05	-0.22	-0.24	Coronary artery disease;	chr11:119066733	chr11:119067374~119067698:-
THCA	cis	rs1185460	0.967	rs4545564	ENSG00000272186.1	RP11-110I1.13	-5.32	1.57e-07	2.33e-05	-0.22	-0.24	Coronary artery disease;	chr11:119066807	chr11:119067374~119067698:-
THCA	cis	rs1185460	0.967	rs1784461	ENSG00000272186.1	RP11-110I1.13	-5.32	1.57e-07	2.33e-05	-0.22	-0.24	Coronary artery disease;	chr11:119067274	chr11:119067374~119067698:-
THCA	cis	rs1185460	0.967	rs1784459	ENSG00000272186.1	RP11-110I1.13	-5.32	1.57e-07	2.33e-05	-0.22	-0.24	Coronary artery disease;	chr11:119067677	chr11:119067374~119067698:-
THCA	cis	rs30380	0.553	rs152280	ENSG00000272109.1	CTD-2260A17.3	-5.32	1.57e-07	2.33e-05	-0.33	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96826239	chr5:96804353~96806105:+
THCA	cis	rs28476539	0.6	rs67445452	ENSG00000270480.1	RP11-57B24.1	5.32	1.57e-07	2.33e-05	0.38	0.24	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82621463	chr4:82691737~82692468:+
THCA	cis	rs2179367	0.959	rs9377212	ENSG00000231760.4	RP11-350J20.5	5.32	1.57e-07	2.33e-05	0.31	0.24	Dupuytren's disease;	chr6:149383765	chr6:149796151~149826294:-
THCA	cis	rs800160	1	rs1088985	ENSG00000199550.1	Y_RNA	5.32	1.57e-07	2.33e-05	0.36	0.24	Bacteremia;	chr11:2356622	chr11:2372638~2372750:+
THCA	cis	rs6723226	0.842	rs1901355	ENSG00000276334.1	AL133243.1	-5.32	1.57e-07	2.34e-05	-0.29	-0.24	Intelligence (multi-trait analysis);	chr2:32610597	chr2:32521927~32523547:+
THCA	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-5.32	1.57e-07	2.34e-05	-0.33	-0.24	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
THCA	cis	rs6044112	1	rs6075068	ENSG00000273998.1	RP4-777L9.2	5.32	1.58e-07	2.34e-05	0.38	0.24	Response to taxane treatment (docetaxel);	chr20:16537305	chr20:16576068~16579615:+
THCA	cis	rs6560517	0.54	rs35242716	ENSG00000234618.1	RPSAP9	-5.32	1.58e-07	2.34e-05	-0.3	-0.24	Dialysis-related mortality;	chr9:76436738	chr9:76398699~76399586:+
THCA	cis	rs9649465	0.704	rs665867	ENSG00000272686.1	RP11-390E23.6	-5.32	1.58e-07	2.34e-05	-0.16	-0.24	Migraine;	chr7:123792275	chr7:123749068~123751166:+
THCA	cis	rs12681287	0.752	rs13256500	ENSG00000254231.1	CTD-2284J15.1	5.32	1.58e-07	2.34e-05	0.27	0.24	Caudate activity during reward;	chr8:86234834	chr8:86333274~86343314:-
THCA	cis	rs1552244	0.832	rs66597916	ENSG00000180385.7	EMC3-AS1	5.32	1.58e-07	2.34e-05	0.27	0.24	Alzheimer's disease;	chr3:10153723	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.832	rs115415687	ENSG00000180385.7	EMC3-AS1	5.32	1.58e-07	2.34e-05	0.27	0.24	Alzheimer's disease;	chr3:10154020	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.832	rs73024575	ENSG00000180385.7	EMC3-AS1	5.32	1.58e-07	2.34e-05	0.27	0.24	Alzheimer's disease;	chr3:10156516	chr3:9986893~10006990:+
THCA	cis	rs1185460	0.967	rs1786684	ENSG00000272186.1	RP11-110I1.13	-5.32	1.58e-07	2.34e-05	-0.22	-0.24	Coronary artery disease;	chr11:119067724	chr11:119067374~119067698:-
THCA	cis	rs801193	0.66	rs1962050	ENSG00000223473.2	GS1-124K5.3	-5.32	1.58e-07	2.34e-05	-0.16	-0.24	Aortic root size;	chr7:66775021	chr7:66491049~66493566:-
THCA	cis	rs6545883	0.839	rs778764	ENSG00000270820.4	RP11-355B11.2	5.32	1.58e-07	2.34e-05	0.19	0.24	Tuberculosis;	chr2:61558545	chr2:61471188~61484130:+
THCA	cis	rs17123764	0.892	rs57342147	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49735639	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs1470906	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49752272	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs12314795	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49754081	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs7962645	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49757156	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs4563	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49758410	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs7956089	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49759527	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs7688	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49763288	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs1049986	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49764761	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs12316284	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49765083	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.605	rs7967624	ENSG00000257464.1	RP11-161H23.8	-5.32	1.58e-07	2.34e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49765736	chr12:49442424~49442652:-
THCA	cis	rs8141529	0.748	rs6519766	ENSG00000272858.1	CTA-292E10.8	5.32	1.58e-07	2.34e-05	0.24	0.24	Lymphocyte counts;	chr22:28874003	chr22:28814914~28815662:+
THCA	cis	rs6088590	1	rs6120750	ENSG00000269202.1	RP4-614O4.12	-5.32	1.58e-07	2.34e-05	-0.21	-0.24	Coronary artery disease;	chr20:34877486	chr20:35201747~35203288:-
THCA	cis	rs12612619	0.667	rs11126871	ENSG00000229122.1	AGBL5-IT1	-5.32	1.58e-07	2.35e-05	-0.17	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27121589	chr2:27061038~27061815:+
THCA	cis	rs7826238	0.517	rs35144760	ENSG00000253893.2	FAM85B	5.32	1.58e-07	2.35e-05	0.35	0.24	Systolic blood pressure;	chr8:8504213	chr8:8167819~8226614:-
THCA	cis	rs6545883	0.929	rs1838978	ENSG00000270820.4	RP11-355B11.2	-5.32	1.58e-07	2.35e-05	-0.2	-0.24	Tuberculosis;	chr2:61313788	chr2:61471188~61484130:+
THCA	cis	rs2282300	0.739	rs1222210	ENSG00000242353.1	RP4-710M3.1	5.32	1.58e-07	2.35e-05	0.23	0.24	Morning vs. evening chronotype;	chr11:30340578	chr11:30368148~30368646:+
THCA	cis	rs4415084	0.834	rs11957920	ENSG00000272335.1	RP11-53O19.3	5.32	1.58e-07	2.35e-05	0.2	0.24	Breast cancer;	chr5:44904984	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.804	rs10070339	ENSG00000272335.1	RP11-53O19.3	5.32	1.58e-07	2.35e-05	0.2	0.24	Breast cancer;	chr5:44907780	chr5:44826076~44828592:+
THCA	cis	rs863750	0.687	rs825481	ENSG00000275389.1	RP11-214K3.24	5.32	1.58e-07	2.35e-05	0.32	0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091012	chr12:124085761~124088598:+
THCA	cis	rs863750	0.687	rs825484	ENSG00000275389.1	RP11-214K3.24	5.32	1.58e-07	2.35e-05	0.32	0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091607	chr12:124085761~124088598:+
THCA	cis	rs699371	0.525	rs7144263	ENSG00000259005.1	RP3-449M8.6	5.32	1.58e-07	2.35e-05	0.22	0.24	Height;	chr14:74438928	chr14:74474007~74474864:-
THCA	cis	rs875971	0.545	rs10950036	ENSG00000232546.1	RP11-458F8.1	5.32	1.58e-07	2.35e-05	0.23	0.24	Aortic root size;	chr7:66353241	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000232546.1	RP11-458F8.1	5.32	1.58e-07	2.35e-05	0.23	0.24	Aortic root size;	chr7:66390342	chr7:66848496~66858136:+
THCA	cis	rs6585424	1	rs11202031	ENSG00000242600.5	MBL1P	5.32	1.58e-07	2.35e-05	0.28	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184287	chr10:79904898~79950336:+
THCA	cis	rs12101261	0.744	rs2268452	ENSG00000259167.2	NMNAT1P1	5.32	1.58e-07	2.35e-05	0.33	0.24	Graves' disease;	chr14:80957792	chr14:81032529~81033404:+
THCA	cis	rs10256972	0.621	rs2363285	ENSG00000225146.1	AC073957.15	5.32	1.58e-07	2.35e-05	0.24	0.24	Endometriosis;Longevity;	chr7:1052008	chr7:1029025~1043891:+
THCA	cis	rs2029362	1	rs11030065	ENSG00000245573.6	BDNF-AS	5.32	1.58e-07	2.35e-05	0.19	0.24	Total body bone mineral density;	chr11:27596561	chr11:27506838~27698174:+
THCA	cis	rs2029362	1	rs10835202	ENSG00000245573.6	BDNF-AS	5.32	1.58e-07	2.35e-05	0.19	0.24	Total body bone mineral density;	chr11:27597008	chr11:27506838~27698174:+
THCA	cis	rs7617773	0.78	rs13066044	ENSG00000199476.1	Y_RNA	-5.32	1.58e-07	2.35e-05	-0.31	-0.24	Coronary artery disease;	chr3:48335786	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.778	rs11707997	ENSG00000199476.1	Y_RNA	-5.32	1.58e-07	2.35e-05	-0.31	-0.24	Coronary artery disease;	chr3:48336385	chr3:48288587~48288694:+
THCA	cis	rs72799341	1	rs1458201	ENSG00000260911.2	RP11-196G11.2	5.32	1.58e-07	2.35e-05	0.23	0.24	Diastolic blood pressure;	chr16:30904808	chr16:31043150~31049868:+
THCA	cis	rs2348418	0.765	rs6487665	ENSG00000247934.4	RP11-967K21.1	5.32	1.59e-07	2.35e-05	0.21	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28163298~28190738:-
THCA	cis	rs11749327	0.688	rs72700688	ENSG00000188242.4	PP7080	5.32	1.59e-07	2.35e-05	0.28	0.24	Hemoglobin concentration;Hypospadias;	chr5:473976	chr5:466124~473098:-
THCA	cis	rs72945132	0.882	rs72949081	ENSG00000254604.1	AP000487.6	-5.32	1.59e-07	2.35e-05	-0.46	-0.24	Coronary artery disease;	chr11:70372964	chr11:70282367~70363368:-
THCA	cis	rs2803122	0.777	rs6475326	ENSG00000273226.1	RP11-513M16.8	5.32	1.59e-07	2.35e-05	0.22	0.24	Pulse pressure;	chr9:19386567	chr9:19375451~19375996:+
THCA	cis	rs13256369	0.951	rs12679360	ENSG00000253893.2	FAM85B	5.32	1.59e-07	2.35e-05	0.32	0.24	Obesity-related traits;	chr8:8708759	chr8:8167819~8226614:-
THCA	cis	rs9425766	0.665	rs7553788	ENSG00000227373.4	RP11-160H22.5	5.32	1.59e-07	2.35e-05	0.33	0.24	Life satisfaction;	chr1:174093773	chr1:174115300~174160004:-
THCA	cis	rs875971	0.545	rs1638724	ENSG00000232546.1	RP11-458F8.1	-5.32	1.59e-07	2.35e-05	-0.23	-0.24	Aortic root size;	chr7:66575494	chr7:66848496~66858136:+
THCA	cis	rs9425766	0.523	rs6668959	ENSG00000227373.4	RP11-160H22.5	5.32	1.59e-07	2.35e-05	0.33	0.24	Life satisfaction;	chr1:174088488	chr1:174115300~174160004:-
THCA	cis	rs12101261	0.744	rs12050350	ENSG00000259167.2	NMNAT1P1	5.32	1.59e-07	2.35e-05	0.35	0.24	Graves' disease;	chr14:80951427	chr14:81032529~81033404:+
THCA	cis	rs8049040	1	rs7197127	ENSG00000260886.1	TAT-AS1	5.32	1.59e-07	2.35e-05	0.31	0.24	Blood protein levels;	chr16:71439933	chr16:71565789~71578187:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000273142.1	RP11-458F8.4	-5.32	1.59e-07	2.35e-05	-0.19	-0.24	Aortic root size;	chr7:65951183	chr7:66902857~66906297:+
THCA	cis	rs7674212	0.556	rs223401	ENSG00000248971.2	KRT8P46	-5.32	1.59e-07	2.35e-05	-0.29	-0.24	Type 2 diabetes;	chr4:102817815	chr4:102728746~102730171:-
THCA	cis	rs11651753	0.636	rs12602494	ENSG00000264920.1	RP11-6N17.4	-5.32	1.59e-07	2.36e-05	-0.21	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47960241	chr17:47891255~47895812:-
THCA	cis	rs10829156	0.898	rs4748504	ENSG00000240291.1	RP11-499P20.2	5.32	1.59e-07	2.36e-05	0.2	0.24	Sudden cardiac arrest;	chr10:18651868	chr10:18513115~18545651:-
THCA	cis	rs6121246	0.529	rs6060291	ENSG00000230613.1	HM13-AS1	5.32	1.59e-07	2.36e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31610240	chr20:31567707~31573263:-
THCA	cis	rs17508449	0.732	rs74610368	ENSG00000232450.1	RP4-730K3.3	-5.32	1.59e-07	2.36e-05	-0.38	-0.24	Leprosy;	chr1:113742681	chr1:113698884~113699631:-
THCA	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	5.32	1.59e-07	2.36e-05	0.42	0.24	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
THCA	cis	rs2243480	1	rs781142	ENSG00000230295.1	RP11-458F8.2	-5.32	1.59e-07	2.36e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65973791	chr7:66880708~66882981:+
THCA	cis	rs7512898	0.5	rs7516036	ENSG00000260088.1	RP11-92G12.3	-5.32	1.59e-07	2.36e-05	-0.32	-0.24	Electrocardiographic conduction measures;	chr1:200727825	chr1:200669507~200694250:+
THCA	cis	rs7924176	0.521	rs11000959	ENSG00000213731.2	RAB5CP1	-5.32	1.59e-07	2.36e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74287053	chr10:74423435~74424014:-
THCA	cis	rs875971	1	rs6956179	ENSG00000223473.2	GS1-124K5.3	-5.32	1.59e-07	2.36e-05	-0.16	-0.24	Aortic root size;	chr7:66341672	chr7:66491049~66493566:-
THCA	cis	rs2282300	0.739	rs34044331	ENSG00000242353.1	RP4-710M3.1	-5.32	1.59e-07	2.36e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30242939	chr11:30368148~30368646:+
THCA	cis	rs36715	0.953	rs36700	ENSG00000245937.6	LINC01184	5.32	1.59e-07	2.36e-05	0.27	0.24	Breast cancer;	chr5:128215581	chr5:127940426~128083172:-
THCA	cis	rs4950322	0.57	rs72691090	ENSG00000226015.2	CCT8P1	5.32	1.6e-07	2.36e-05	0.28	0.24	Protein quantitative trait loci;	chr1:147297884	chr1:147203276~147204932:-
THCA	cis	rs2749592	0.55	rs4934881	ENSG00000263064.2	RP11-291L22.7	-5.32	1.6e-07	2.37e-05	-0.26	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:38448689~38448949:+
THCA	cis	rs564343	1	rs564343	ENSG00000255320.1	RP11-755F10.1	5.32	1.6e-07	2.37e-05	0.3	0.24	Obesity (early onset extreme);	chr11:66127695	chr11:66244840~66246239:-
THCA	cis	rs6121246	0.567	rs6060295	ENSG00000230613.1	HM13-AS1	5.32	1.6e-07	2.37e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31610670	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.567	rs6060297	ENSG00000230613.1	HM13-AS1	5.32	1.6e-07	2.37e-05	0.29	0.24	Mean corpuscular hemoglobin;	chr20:31610757	chr20:31567707~31573263:-
THCA	cis	rs7403037	0.652	rs12902094	ENSG00000259905.4	PWRN1	5.32	1.6e-07	2.37e-05	0.31	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24518439	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.617	rs12906381	ENSG00000259905.4	PWRN1	5.32	1.6e-07	2.37e-05	0.31	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24518445	chr15:24493137~24652130:+
THCA	cis	rs116095464	0.558	rs6872854	ENSG00000248925.1	CTD-2083E4.6	5.32	1.6e-07	2.37e-05	0.34	0.24	Breast cancer;	chr5:208923	chr5:269858~271516:-
THCA	cis	rs10256972	0.616	rs6957733	ENSG00000199023.2	MIR339	-5.32	1.6e-07	2.37e-05	-0.25	-0.24	Endometriosis;Longevity;	chr7:1066691	chr7:1022935~1023045:-
THCA	cis	rs763121	1	rs1946990	ENSG00000235209.1	CTA-150C2.13	-5.32	1.6e-07	2.37e-05	-0.3	-0.24	Menopause (age at onset);	chr22:38516766	chr22:38921227~38924708:+
THCA	cis	rs7429990	0.965	rs4392441	ENSG00000228638.1	FCF1P2	5.32	1.6e-07	2.37e-05	0.23	0.24	Educational attainment (years of education);	chr3:48036211	chr3:48290793~48291375:-
THCA	cis	rs1350171	0.92	rs7944919	ENSG00000246523.6	RP11-736K20.6	-5.32	1.6e-07	2.37e-05	-0.36	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr11:86931573	chr11:86955619~87000959:+
THCA	cis	rs10208649	1	rs6756424	ENSG00000233266.1	HMGB1P31	5.32	1.6e-07	2.37e-05	0.55	0.24	Body mass index;	chr2:53903698	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs6731911	ENSG00000233266.1	HMGB1P31	5.32	1.6e-07	2.37e-05	0.55	0.24	Body mass index;	chr2:53904575	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs9309251	ENSG00000233266.1	HMGB1P31	5.32	1.6e-07	2.37e-05	0.55	0.24	Body mass index;	chr2:53906501	chr2:54051334~54051760:+
THCA	cis	rs1823874	0.71	rs2902472	ENSG00000259363.4	CTD-2054N24.2	5.32	1.6e-07	2.37e-05	0.3	0.24	IgG glycosylation;	chr15:99824257	chr15:99807023~99877148:+
THCA	cis	rs9329221	0.905	rs17765901	ENSG00000261451.1	RP11-981G7.1	-5.32	1.6e-07	2.37e-05	-0.29	-0.24	Neuroticism;	chr8:10391970	chr8:10433672~10438312:+
THCA	cis	rs9307551	0.744	rs2165388	ENSG00000250334.4	LINC00989	-5.32	1.6e-07	2.37e-05	-0.29	-0.24	Refractive error;	chr4:79552322	chr4:79492416~79576460:+
THCA	cis	rs9527	0.637	rs7085104	ENSG00000236937.2	PTGES3P4	5.32	1.6e-07	2.37e-05	0.32	0.24	Arsenic metabolism;	chr10:102869116	chr10:102845595~102845950:+
THCA	cis	rs6545883	0.895	rs4430924	ENSG00000270820.4	RP11-355B11.2	5.32	1.6e-07	2.37e-05	0.21	0.24	Tuberculosis;	chr2:61476721	chr2:61471188~61484130:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000273142.1	RP11-458F8.4	5.32	1.6e-07	2.38e-05	0.19	0.24	Cotinine glucuronidation;	chr7:66580525	chr7:66902857~66906297:+
THCA	cis	rs793571	0.628	rs12917083	ENSG00000259250.1	RP11-50C13.1	-5.32	1.6e-07	2.38e-05	-0.25	-0.24	Schizophrenia;	chr15:58752341	chr15:58587507~58591676:+
THCA	cis	rs67981189	0.647	rs36555	ENSG00000269927.1	RP6-91H8.3	-5.32	1.61e-07	2.38e-05	-0.28	-0.24	Schizophrenia;	chr14:70897844	chr14:71141125~71143253:-
THCA	cis	rs34779708	0.966	rs12775548	ENSG00000271335.4	RP11-324I22.4	5.32	1.61e-07	2.38e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35314552~35336401:-
THCA	cis	rs12908161	1	rs11638290	ENSG00000275120.1	RP11-182J1.17	5.32	1.61e-07	2.38e-05	0.29	0.24	Schizophrenia;	chr15:84684405	chr15:84599434~84606463:-
THCA	cis	rs12908161	0.959	rs34028043	ENSG00000275120.1	RP11-182J1.17	5.32	1.61e-07	2.38e-05	0.29	0.24	Schizophrenia;	chr15:84688354	chr15:84599434~84606463:-
THCA	cis	rs12908161	0.959	rs34784022	ENSG00000275120.1	RP11-182J1.17	5.32	1.61e-07	2.38e-05	0.29	0.24	Schizophrenia;	chr15:84688675	chr15:84599434~84606463:-
THCA	cis	rs853679	0.607	rs13217984	ENSG00000219392.1	RP1-265C24.5	-5.32	1.61e-07	2.38e-05	-0.55	-0.24	Depression;	chr6:28171932	chr6:28115628~28116551:+
THCA	cis	rs853679	0.556	rs67297533	ENSG00000219392.1	RP1-265C24.5	-5.32	1.61e-07	2.38e-05	-0.55	-0.24	Depression;	chr6:28173475	chr6:28115628~28116551:+
THCA	cis	rs853679	0.505	rs35781323	ENSG00000219392.1	RP1-265C24.5	-5.32	1.61e-07	2.38e-05	-0.55	-0.24	Depression;	chr6:28177054	chr6:28115628~28116551:+
THCA	cis	rs7809615	0.748	rs10265385	ENSG00000244219.5	GS1-259H13.2	-5.32	1.61e-07	2.38e-05	-0.32	-0.24	Blood metabolite ratios;	chr7:99565064	chr7:99598066~99610813:+
THCA	cis	rs12101261	0.614	rs2268460	ENSG00000259167.2	NMNAT1P1	5.32	1.61e-07	2.38e-05	0.37	0.24	Graves' disease;	chr14:80997192	chr14:81032529~81033404:+
THCA	cis	rs9475752	0.793	rs13203479	ENSG00000231441.1	RP11-472M19.2	5.32	1.61e-07	2.38e-05	0.32	0.24	Menarche (age at onset);	chr6:57005675	chr6:56844002~56864078:+
THCA	cis	rs7493	0.95	rs7802171	ENSG00000233942.1	AC004012.1	5.32	1.61e-07	2.39e-05	0.37	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95401009	chr7:95471835~95473998:+
THCA	cis	rs2562456	0.793	rs61445561	ENSG00000268081.1	RP11-678G14.2	5.32	1.61e-07	2.39e-05	0.41	0.24	Pain;	chr19:21321230	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs57299552	ENSG00000268081.1	RP11-678G14.2	5.32	1.61e-07	2.39e-05	0.41	0.24	Pain;	chr19:21321326	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.754	rs76688173	ENSG00000268081.1	RP11-678G14.2	5.32	1.61e-07	2.39e-05	0.41	0.24	Pain;	chr19:21321856	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs74711277	ENSG00000268081.1	RP11-678G14.2	5.32	1.61e-07	2.39e-05	0.41	0.24	Pain;	chr19:21322641	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62107479	ENSG00000268081.1	RP11-678G14.2	5.32	1.61e-07	2.39e-05	0.41	0.24	Pain;	chr19:21323962	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62107531	ENSG00000268081.1	RP11-678G14.2	5.32	1.61e-07	2.39e-05	0.41	0.24	Pain;	chr19:21326263	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs55756795	ENSG00000268081.1	RP11-678G14.2	5.32	1.61e-07	2.39e-05	0.41	0.24	Pain;	chr19:21327257	chr19:21554640~21569237:-
THCA	cis	rs752010	0.756	rs943374	ENSG00000230638.4	RP11-486B10.4	-5.32	1.61e-07	2.39e-05	-0.26	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41590523	chr1:41542069~41544310:+
THCA	cis	rs2179367	0.6	rs9498352	ENSG00000268592.3	RAET1E-AS1	5.32	1.61e-07	2.39e-05	0.38	0.24	Dupuytren's disease;	chr6:149439108	chr6:149863494~149919507:+
THCA	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	5.32	1.62e-07	2.39e-05	0.28	0.24	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
THCA	cis	rs7829975	0.539	rs35571782	ENSG00000253981.4	ALG1L13P	5.32	1.62e-07	2.39e-05	0.23	0.24	Mood instability;	chr8:8284301	chr8:8236003~8244667:-
THCA	cis	rs442309	0.807	rs224029	ENSG00000238280.1	RP11-436D10.3	-5.32	1.62e-07	2.39e-05	-0.28	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62759539	chr10:62793562~62805887:-
THCA	cis	rs7976269	0.559	rs9651838	ENSG00000275476.1	RP11-996F15.4	5.32	1.62e-07	2.4e-05	0.24	0.24	Male-pattern baldness;	chr12:28999700	chr12:29277397~29277882:-
THCA	cis	rs9549367	0.713	rs9577211	ENSG00000269125.1	RP11-98F14.11	-5.32	1.62e-07	2.4e-05	-0.29	-0.24	Platelet distribution width;	chr13:113176404	chr13:113165002~113165183:-
THCA	cis	rs7621331	1	rs73222222	ENSG00000273486.1	RP11-731C17.2	5.32	1.62e-07	2.4e-05	0.23	0.24	Waist circumference adjusted for body mass index;	chr3:136052883	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs9836758	ENSG00000273486.1	RP11-731C17.2	5.32	1.62e-07	2.4e-05	0.23	0.24	Waist circumference adjusted for body mass index;	chr3:136053236	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs36039354	ENSG00000273486.1	RP11-731C17.2	5.32	1.62e-07	2.4e-05	0.23	0.24	Waist circumference adjusted for body mass index;	chr3:136055519	chr3:136837338~136839021:-
THCA	cis	rs9876781	1	rs2045554	ENSG00000244380.1	RP11-24C3.2	-5.32	1.62e-07	2.4e-05	-0.28	-0.24	Longevity;	chr3:48453142	chr3:48440352~48446656:-
THCA	cis	rs12935418	0.616	rs13336629	ENSG00000278985.1	RP11-303E16.9	5.32	1.62e-07	2.4e-05	0.25	0.24	Mean corpuscular volume;	chr16:80971909	chr16:80982319~80984094:-
THCA	cis	rs7924176	0.521	rs11000986	ENSG00000213731.2	RAB5CP1	-5.32	1.62e-07	2.4e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.521	rs10824147	ENSG00000213731.2	RAB5CP1	-5.32	1.62e-07	2.4e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.521	rs12359775	ENSG00000213731.2	RAB5CP1	-5.32	1.62e-07	2.4e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.521	rs11516630	ENSG00000213731.2	RAB5CP1	-5.32	1.62e-07	2.4e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:74423435~74424014:-
THCA	cis	rs4968361	1	rs4968361	ENSG00000266992.1	DHX40P1	5.32	1.62e-07	2.4e-05	0.37	0.24	Schizophrenia;	chr17:59425467	chr17:59976009~60002384:-
THCA	cis	rs75920871	0.513	rs76904522	ENSG00000254851.1	RP11-109L13.1	-5.32	1.62e-07	2.4e-05	-0.43	-0.24	Subjective well-being;	chr11:117144147	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.513	rs113560866	ENSG00000254851.1	RP11-109L13.1	-5.32	1.62e-07	2.4e-05	-0.43	-0.24	Subjective well-being;	chr11:117144473	chr11:117135528~117138582:+
THCA	cis	rs4073582	0.576	rs556595	ENSG00000255320.1	RP11-755F10.1	-5.32	1.62e-07	2.4e-05	-0.3	-0.24	Gout;	chr11:66290611	chr11:66244840~66246239:-
THCA	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	5.32	1.62e-07	2.4e-05	0.36	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
THCA	cis	rs7924176	0.521	rs11000999	ENSG00000213731.2	RAB5CP1	-5.32	1.62e-07	2.4e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:74423435~74424014:-
THCA	cis	rs17767392	0.881	rs34061264	ENSG00000259146.3	RP1-261D10.2	5.32	1.62e-07	2.4e-05	0.29	0.24	Mitral valve prolapse;	chr14:71318559	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.813	rs12891975	ENSG00000259146.3	RP1-261D10.2	5.32	1.62e-07	2.4e-05	0.29	0.24	Mitral valve prolapse;	chr14:71323145	chr14:71292729~71321814:-
THCA	cis	rs1979679	0.918	rs1257741	ENSG00000278733.1	RP11-425D17.1	5.32	1.62e-07	2.4e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28381636	chr12:28185625~28186190:-
THCA	cis	rs6750795	0.87	rs6754952	ENSG00000223198.1	RNU2-22P	5.32	1.62e-07	2.4e-05	0.3	0.24	Height;	chr2:231516534	chr2:231501990~231502201:-
THCA	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-5.32	1.62e-07	2.4e-05	-0.33	-0.24	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
THCA	cis	rs911119	1	rs73318135	ENSG00000270001.1	RP11-218C14.8	-5.32	1.63e-07	2.41e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23637934	chr20:23631826~23632316:-
THCA	cis	rs9813712	0.585	rs16824839	ENSG00000249846.5	RP11-77P16.4	-5.32	1.63e-07	2.41e-05	-0.31	-0.24	Response to amphetamines;	chr3:130220886	chr3:130112550~130120579:+
THCA	cis	rs919433	0.648	rs787975	ENSG00000231621.1	AC013264.2	-5.32	1.63e-07	2.41e-05	-0.26	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197383404	chr2:197197991~197199273:+
THCA	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-5.32	1.63e-07	2.41e-05	-0.34	-0.24	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
THCA	cis	rs34779708	0.931	rs35388511	ENSG00000271335.4	RP11-324I22.4	5.32	1.63e-07	2.41e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs34815241	ENSG00000271335.4	RP11-324I22.4	5.32	1.63e-07	2.41e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35314552~35336401:-
THCA	cis	rs2562456	0.833	rs4321312	ENSG00000268081.1	RP11-678G14.2	5.32	1.63e-07	2.41e-05	0.4	0.24	Pain;	chr19:21336614	chr19:21554640~21569237:-
THCA	cis	rs875971	1	rs6958271	ENSG00000223473.2	GS1-124K5.3	5.32	1.63e-07	2.41e-05	0.16	0.24	Aortic root size;	chr7:66514344	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs6958277	ENSG00000223473.2	GS1-124K5.3	5.32	1.63e-07	2.41e-05	0.16	0.24	Aortic root size;	chr7:66514362	chr7:66491049~66493566:-
THCA	cis	rs6570726	0.846	rs6570700	ENSG00000270638.1	RP3-466P17.1	5.32	1.63e-07	2.41e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs870491	ENSG00000270638.1	RP3-466P17.1	5.32	1.63e-07	2.41e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145735570~145737218:+
THCA	cis	rs453301	0.652	rs2043129	ENSG00000233609.3	RP11-62H7.2	5.32	1.63e-07	2.41e-05	0.23	0.24	Joint mobility (Beighton score);	chr8:8967994	chr8:8961200~8979025:+
THCA	cis	rs2179367	0.6	rs1001305	ENSG00000268592.3	RAET1E-AS1	5.32	1.63e-07	2.41e-05	0.38	0.24	Dupuytren's disease;	chr6:149436808	chr6:149863494~149919507:+
THCA	cis	rs7429990	0.833	rs2280567	ENSG00000228638.1	FCF1P2	5.32	1.63e-07	2.41e-05	0.23	0.24	Educational attainment (years of education);	chr3:47572923	chr3:48290793~48291375:-
THCA	cis	rs801193	0.591	rs2707839	ENSG00000223473.2	GS1-124K5.3	5.32	1.63e-07	2.41e-05	0.16	0.24	Aortic root size;	chr7:66728097	chr7:66491049~66493566:-
THCA	cis	rs853679	0.76	rs9468317	ENSG00000220721.1	OR1F12	5.32	1.63e-07	2.41e-05	0.34	0.24	Depression;	chr6:28230678	chr6:28073316~28074233:+
THCA	cis	rs1823913	1	rs4853559	ENSG00000227542.1	AC092614.2	-5.32	1.63e-07	2.41e-05	-0.29	-0.24	Obesity-related traits;	chr2:191235965	chr2:191229165~191246172:-
THCA	cis	rs935334	1	rs935334	ENSG00000258454.1	RP11-361H10.3	5.32	1.63e-07	2.41e-05	0.34	0.24	Blood pressure;	chr14:76147335	chr14:76235817~76263474:+
THCA	cis	rs849141	0.89	rs849143	ENSG00000234336.5	JAZF1-AS1	-5.32	1.63e-07	2.41e-05	-0.28	-0.24	Height;Hip circumference adjusted for BMI;	chr7:28146854	chr7:28180322~28243917:+
THCA	cis	rs4748857	0.685	rs11013367	ENSG00000224215.1	RP11-371A19.2	-5.32	1.63e-07	2.41e-05	-0.31	-0.24	Systemic lupus erythematosus;	chr10:23286665	chr10:23343957~23345181:+
THCA	cis	rs9813712	1	rs9813712	ENSG00000228252.7	COL6A4P2	5.32	1.63e-07	2.42e-05	0.27	0.24	Response to amphetamines;	chr3:130252258	chr3:130212823~130273806:+
THCA	cis	rs131777	0.545	rs131759	ENSG00000205559.3	CHKB-AS1	-5.32	1.63e-07	2.42e-05	-0.27	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50577052	chr22:50583026~50583877:+
THCA	cis	rs763121	0.962	rs138711	ENSG00000235209.1	CTA-150C2.13	5.32	1.63e-07	2.42e-05	0.33	0.24	Menopause (age at onset);	chr22:38743908	chr22:38921227~38924708:+
THCA	cis	rs890448	0.93	rs57302549	ENSG00000254531.1	FLJ20021	-5.32	1.63e-07	2.42e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101450675	chr4:101347780~101348883:+
THCA	cis	rs957448	1	rs56716157	ENSG00000253175.1	RP11-267M23.6	5.32	1.64e-07	2.42e-05	0.32	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94565036~94565715:+
THCA	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	5.32	1.64e-07	2.42e-05	0.28	0.24	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
THCA	cis	rs7829975	0.536	rs2980439	ENSG00000254153.1	CTA-398F10.2	-5.32	1.64e-07	2.42e-05	-0.24	-0.24	Mood instability;	chr8:8237348	chr8:8456909~8461337:-
THCA	cis	rs12681963	0.688	rs12544416	ENSG00000272375.1	RP11-51J9.6	5.32	1.64e-07	2.42e-05	0.35	0.24	Migraine;	chr8:30182057	chr8:30197404~30198048:+
THCA	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-5.32	1.64e-07	2.43e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
THCA	cis	rs2354432	0.607	rs894471	ENSG00000226015.2	CCT8P1	-5.32	1.64e-07	2.43e-05	-0.44	-0.24	Mitochondrial DNA levels;	chr1:147216343	chr1:147203276~147204932:-
THCA	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-5.32	1.64e-07	2.43e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
THCA	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	5.32	1.64e-07	2.43e-05	0.28	0.24	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
THCA	cis	rs2282300	0.739	rs6484478	ENSG00000242353.1	RP4-710M3.1	5.32	1.64e-07	2.43e-05	0.23	0.24	Morning vs. evening chronotype;	chr11:30284893	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs10742237	ENSG00000242353.1	RP4-710M3.1	5.32	1.64e-07	2.43e-05	0.23	0.24	Morning vs. evening chronotype;	chr11:30289112	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs1933343	ENSG00000242353.1	RP4-710M3.1	5.32	1.64e-07	2.43e-05	0.23	0.24	Morning vs. evening chronotype;	chr11:30289445	chr11:30368148~30368646:+
THCA	cis	rs4654783	1	rs4654783	ENSG00000228397.1	RP1-224A6.3	5.32	1.64e-07	2.43e-05	0.35	0.24	Endometriosis;	chr1:22113027	chr1:22023994~22024968:-
THCA	cis	rs1889642	0.816	rs9601273	ENSG00000227354.5	RBM26-AS1	5.32	1.64e-07	2.43e-05	0.23	0.24	Colonoscopy-negative controls vs population controls;	chr13:79839682	chr13:79406309~79424328:+
THCA	cis	rs9652601	0.719	rs2867880	ENSG00000274038.1	RP11-66H6.4	-5.32	1.64e-07	2.43e-05	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11138000	chr16:11056556~11057034:+
THCA	cis	rs972578	0.668	rs8136252	ENSG00000274717.1	RP1-47A17.1	-5.32	1.65e-07	2.43e-05	-0.25	-0.24	Mean platelet volume;	chr22:42841270	chr22:42791814~42794313:-
THCA	cis	rs11096990	0.892	rs6815686	ENSG00000249685.1	RP11-360F5.3	-5.32	1.65e-07	2.43e-05	-0.31	-0.24	Cognitive function;	chr4:39198171	chr4:39133913~39135608:+
THCA	cis	rs4748857	0.685	rs7090683	ENSG00000224215.1	RP11-371A19.2	-5.32	1.65e-07	2.43e-05	-0.31	-0.24	Systemic lupus erythematosus;	chr10:23290495	chr10:23343957~23345181:+
THCA	cis	rs17772222	0.565	rs845759	ENSG00000258983.2	RP11-507K2.2	-5.32	1.65e-07	2.43e-05	-0.28	-0.24	Coronary artery calcification;	chr14:88415538	chr14:88499334~88515502:+
THCA	cis	rs875971	0.505	rs6955582	ENSG00000273142.1	RP11-458F8.4	-5.32	1.65e-07	2.43e-05	-0.19	-0.24	Aortic root size;	chr7:65966699	chr7:66902857~66906297:+
THCA	cis	rs10461617	0.541	rs860581	ENSG00000234553.1	AC022431.3	-5.32	1.65e-07	2.43e-05	-0.32	-0.24	Type 2 diabetes;	chr5:56854710	chr5:56536583~56537826:-
THCA	cis	rs78487399	0.808	rs17030855	ENSG00000234936.1	AC010883.5	5.32	1.65e-07	2.43e-05	0.34	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43462225	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs17030859	ENSG00000234936.1	AC010883.5	5.32	1.65e-07	2.43e-05	0.34	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43462765	chr2:43229573~43233394:+
THCA	cis	rs875971	1	rs6979382	ENSG00000223473.2	GS1-124K5.3	5.32	1.65e-07	2.44e-05	0.16	0.24	Aortic root size;	chr7:66421388	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs6961990	ENSG00000223473.2	GS1-124K5.3	5.32	1.65e-07	2.44e-05	0.16	0.24	Aortic root size;	chr7:66423583	chr7:66491049~66493566:-
THCA	cis	rs11089937	0.667	rs10483108	ENSG00000211639.2	IGLV4-60	5.32	1.65e-07	2.44e-05	0.19	0.24	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22162199~22162681:+
THCA	cis	rs7520050	0.898	rs4660885	ENSG00000234329.1	RP11-767N6.2	-5.32	1.65e-07	2.44e-05	-0.21	-0.24	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45651039~45651826:-
THCA	cis	rs4748857	0.947	rs6482260	ENSG00000224215.1	RP11-371A19.2	-5.32	1.65e-07	2.44e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23237709	chr10:23343957~23345181:+
THCA	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	5.32	1.65e-07	2.44e-05	0.31	0.24	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
THCA	cis	rs875971	0.545	rs6950988	ENSG00000232546.1	RP11-458F8.1	5.32	1.65e-07	2.44e-05	0.23	0.24	Aortic root size;	chr7:66511428	chr7:66848496~66858136:+
THCA	cis	rs9392556	0.6	rs2326408	ENSG00000230648.1	RP3-406P24.3	5.32	1.65e-07	2.44e-05	0.29	0.24	Blood metabolite levels;	chr6:4119282	chr6:4018843~4021215:-
THCA	cis	rs4713118	0.955	rs9380010	ENSG00000226314.6	ZNF192P1	-5.32	1.65e-07	2.44e-05	-0.3	-0.24	Parkinson's disease;	chr6:27715793	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.955	rs9368528	ENSG00000226314.6	ZNF192P1	-5.32	1.65e-07	2.44e-05	-0.3	-0.24	Parkinson's disease;	chr6:27716019	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.955	rs9380011	ENSG00000226314.6	ZNF192P1	-5.32	1.65e-07	2.44e-05	-0.3	-0.24	Parkinson's disease;	chr6:27716145	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.955	rs9368529	ENSG00000226314.6	ZNF192P1	-5.32	1.65e-07	2.44e-05	-0.3	-0.24	Parkinson's disease;	chr6:27716852	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.955	rs9380012	ENSG00000226314.6	ZNF192P1	-5.32	1.65e-07	2.44e-05	-0.3	-0.24	Parkinson's disease;	chr6:27716875	chr6:28161781~28169594:+
THCA	cis	rs6569038	0.508	rs9398499	ENSG00000253194.1	RP11-351A11.1	5.31	1.65e-07	2.44e-05	0.33	0.24	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119035170	chr6:118934785~119031541:+
THCA	cis	rs13256369	1	rs13282915	ENSG00000253893.2	FAM85B	-5.31	1.66e-07	2.45e-05	-0.32	-0.24	Obesity-related traits;	chr8:8713381	chr8:8167819~8226614:-
THCA	cis	rs12030196	0.871	rs12085896	ENSG00000230812.4	LINC01358	5.31	1.66e-07	2.45e-05	0.31	0.24	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58988034	chr1:59020387~59044614:+
THCA	cis	rs2041895	0.509	rs2072559	ENSG00000260329.1	RP11-412D9.4	-5.31	1.66e-07	2.45e-05	-0.24	-0.24	Glaucoma (low intraocular pressure);	chr12:106913509	chr12:106954029~106955497:-
THCA	cis	rs1125355	0.539	rs11693126	ENSG00000251491.2	OR7E28P	-5.31	1.66e-07	2.45e-05	-0.42	-0.24	Alzheimer's disease in APOE e4+ carriers;	chr2:158814433	chr2:158862311~158863285:+
THCA	cis	rs16852403	0.548	rs10798601	ENSG00000224687.1	RASAL2-AS1	5.31	1.66e-07	2.45e-05	0.36	0.24	Childhood ear infection;	chr1:178217746	chr1:178091508~178093984:-
THCA	cis	rs6988985	0.678	rs7011889	ENSG00000247317.3	RP11-273G15.2	-5.31	1.66e-07	2.45e-05	-0.26	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142923844	chr8:142981738~143018437:-
THCA	cis	rs12893668	0.667	rs71417869	ENSG00000269958.1	RP11-73M18.8	5.31	1.66e-07	2.45e-05	0.23	0.24	Reticulocyte count;	chr14:103611097	chr14:103696353~103697163:+
THCA	cis	rs613391	0.702	rs678038	ENSG00000224549.1	RP11-370B11.3	-5.31	1.66e-07	2.45e-05	-0.27	-0.24	Quantitative traits;	chr9:22707595	chr9:22767175~22768316:+
THCA	cis	rs897984	0.683	rs72799316	ENSG00000279196.1	RP11-1072A3.3	5.31	1.66e-07	2.45e-05	0.24	0.24	Dementia with Lewy bodies;	chr16:30815884	chr16:30984630~30988270:-
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000230295.1	RP11-458F8.2	-5.31	1.66e-07	2.45e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65999249	chr7:66880708~66882981:+
THCA	cis	rs7851660	0.809	rs10512255	ENSG00000214417.4	KRT18P13	-5.31	1.66e-07	2.45e-05	-0.21	-0.24	Strep throat;	chr9:97890300	chr9:97698922~97700734:+
THCA	cis	rs950169	0.544	rs12913702	ENSG00000275120.1	RP11-182J1.17	5.31	1.66e-07	2.45e-05	0.29	0.24	Schizophrenia;	chr15:84609953	chr15:84599434~84606463:-
THCA	cis	rs2337406	0.85	rs75196489	ENSG00000211974.3	IGHV2-70	-5.31	1.66e-07	2.45e-05	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106699438	chr14:106723574~106724093:-
THCA	cis	rs412050	0.547	rs79111189	ENSG00000224086.5	LL22NC03-86G7.1	-5.31	1.66e-07	2.45e-05	-0.42	-0.24	Attention deficit hyperactivity disorder;	chr22:21810308	chr22:21938293~21977632:+
THCA	cis	rs890448	0.796	rs4699209	ENSG00000254531.1	FLJ20021	5.31	1.66e-07	2.45e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363783	chr4:101347780~101348883:+
THCA	cis	rs6714710	0.603	rs12995673	ENSG00000230606.9	AC159540.1	-5.31	1.66e-07	2.45e-05	-0.28	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97792583	chr2:97416165~97433527:-
THCA	cis	rs1030877	0.557	rs2278501	ENSG00000235319.1	AC012360.4	5.31	1.66e-07	2.45e-05	0.26	0.24	Obesity-related traits;	chr2:105363049	chr2:105324210~105330529:+
THCA	cis	rs875971	0.545	rs17138156	ENSG00000232546.1	RP11-458F8.1	5.31	1.66e-07	2.46e-05	0.22	0.24	Aortic root size;	chr7:66249708	chr7:66848496~66858136:+
THCA	cis	rs1185460	0.967	rs1786685	ENSG00000272186.1	RP11-110I1.13	-5.31	1.66e-07	2.46e-05	-0.22	-0.24	Coronary artery disease;	chr11:119068246	chr11:119067374~119067698:-
THCA	cis	rs6570726	1	rs6570699	ENSG00000270638.1	RP3-466P17.1	5.31	1.66e-07	2.46e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145735570~145737218:+
THCA	cis	rs6570726	1	rs1935615	ENSG00000270638.1	RP3-466P17.1	5.31	1.66e-07	2.46e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145735570~145737218:+
THCA	cis	rs9992667	0.955	rs9998440	ENSG00000231160.8	KLF3-AS1	-5.31	1.66e-07	2.46e-05	-0.16	-0.24	Eosinophil percentage of granulocytes;	chr4:38606180	chr4:38612701~38664883:-
THCA	cis	rs4713118	0.955	rs9468204	ENSG00000226314.6	ZNF192P1	-5.31	1.67e-07	2.46e-05	-0.3	-0.24	Parkinson's disease;	chr6:27721030	chr6:28161781~28169594:+
THCA	cis	rs7403037	1	rs7180201	ENSG00000259905.4	PWRN1	-5.31	1.67e-07	2.46e-05	-0.25	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24587524	chr15:24493137~24652130:+
THCA	cis	rs3213758	1	rs80207328	ENSG00000275191.1	RP11-36I17.2	-5.31	1.67e-07	2.46e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53590935	chr16:53628256~53628816:-
THCA	cis	rs911119	1	rs2016161	ENSG00000270001.1	RP11-218C14.8	5.31	1.67e-07	2.46e-05	0.36	0.24	Chronic kidney disease;	chr20:23640537	chr20:23631826~23632316:-
THCA	cis	rs67478160	0.634	rs7141928	ENSG00000258735.1	LINC00637	-5.31	1.67e-07	2.46e-05	-0.29	-0.24	Schizophrenia;	chr14:103753612	chr14:103847721~103858049:+
THCA	cis	rs2243480	1	rs4718317	ENSG00000230295.1	RP11-458F8.2	5.31	1.67e-07	2.46e-05	0.28	0.24	Diabetic kidney disease;	chr7:66183914	chr7:66880708~66882981:+
THCA	cis	rs3177980	0.673	rs35296671	ENSG00000239494.2	RN7SL333P	-5.31	1.67e-07	2.47e-05	-0.22	-0.24	Amyotrophic lateral sclerosis;	chr1:169789148	chr1:169859756~169860052:+
THCA	cis	rs2645424	1	rs2645424	ENSG00000255046.1	RP11-297N6.4	-5.31	1.67e-07	2.47e-05	-0.24	-0.24	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826954	chr8:11797928~11802568:-
THCA	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-5.31	1.67e-07	2.47e-05	-0.32	-0.24	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
THCA	cis	rs7688540	0.771	rs61795001	ENSG00000211553.1	AC253576.2	-5.31	1.67e-07	2.47e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs61795002	ENSG00000211553.1	AC253576.2	-5.31	1.67e-07	2.47e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:136461~136568:+
THCA	cis	rs9733	0.596	rs72702536	ENSG00000231073.1	RP11-316M1.3	5.31	1.67e-07	2.47e-05	0.28	0.24	Tonsillectomy;	chr1:150690098	chr1:150973123~150975534:+
THCA	cis	rs2442825	0.508	rs2648545	ENSG00000214041.4	PGAM1P4	5.31	1.67e-07	2.47e-05	0.23	0.24	Cerebrospinal fluid clusterin levels;	chr3:9347539	chr3:9348443~9349192:+
THCA	cis	rs2179367	0.632	rs7349921	ENSG00000268592.3	RAET1E-AS1	5.31	1.67e-07	2.47e-05	0.34	0.24	Dupuytren's disease;	chr6:149392727	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs60153446	ENSG00000268592.3	RAET1E-AS1	5.31	1.67e-07	2.47e-05	0.34	0.24	Dupuytren's disease;	chr6:149393186	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs61259243	ENSG00000268592.3	RAET1E-AS1	5.31	1.67e-07	2.47e-05	0.34	0.24	Dupuytren's disease;	chr6:149393457	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs62426115	ENSG00000268592.3	RAET1E-AS1	5.31	1.67e-07	2.47e-05	0.34	0.24	Dupuytren's disease;	chr6:149393718	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs68080376	ENSG00000268592.3	RAET1E-AS1	5.31	1.67e-07	2.47e-05	0.34	0.24	Dupuytren's disease;	chr6:149393873	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs763590	ENSG00000268592.3	RAET1E-AS1	5.31	1.67e-07	2.47e-05	0.34	0.24	Dupuytren's disease;	chr6:149398831	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs17506789	ENSG00000268592.3	RAET1E-AS1	5.31	1.67e-07	2.47e-05	0.34	0.24	Dupuytren's disease;	chr6:149399710	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.586	rs34097428	ENSG00000268592.3	RAET1E-AS1	5.31	1.67e-07	2.47e-05	0.34	0.24	Dupuytren's disease;	chr6:149399822	chr6:149863494~149919507:+
THCA	cis	rs1914816	0.941	rs2957037	ENSG00000196274.5	Metazoa_SRP	5.31	1.67e-07	2.47e-05	0.34	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76193195	chr15:76230048~76230390:-
THCA	cis	rs2512987	1	rs2512987	ENSG00000254731.1	CTD-2005H7.1	-5.31	1.67e-07	2.47e-05	-0.29	-0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703240	chr11:86703099~86714092:+
THCA	cis	rs2512987	1	rs2433420	ENSG00000254731.1	CTD-2005H7.1	-5.31	1.67e-07	2.47e-05	-0.29	-0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703319	chr11:86703099~86714092:+
THCA	cis	rs2880765	0.835	rs4360875	ENSG00000259630.2	CTD-2262B20.1	-5.31	1.67e-07	2.47e-05	-0.25	-0.24	Coronary artery disease;	chr15:85497163	chr15:85415228~85415633:+
THCA	cis	rs12935418	0.616	rs13332902	ENSG00000278985.1	RP11-303E16.9	5.31	1.67e-07	2.47e-05	0.25	0.24	Mean corpuscular volume;	chr16:80971903	chr16:80982319~80984094:-
THCA	cis	rs934734	0.725	rs7581149	ENSG00000237979.1	AC007389.1	5.31	1.67e-07	2.47e-05	0.28	0.24	Rheumatoid arthritis;	chr2:65332507	chr2:65500993~65502138:-
THCA	cis	rs6728642	0.572	rs13403225	ENSG00000230606.9	AC159540.1	5.31	1.67e-07	2.47e-05	0.29	0.24	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935090	chr2:97416165~97433527:-
THCA	cis	rs10208649	0.901	rs11894028	ENSG00000233266.1	HMGB1P31	5.31	1.68e-07	2.47e-05	0.54	0.24	Body mass index;	chr2:53926743	chr2:54051334~54051760:+
THCA	cis	rs12681287	0.752	rs10100235	ENSG00000254231.1	CTD-2284J15.1	5.31	1.68e-07	2.47e-05	0.27	0.24	Caudate activity during reward;	chr8:86237065	chr8:86333274~86343314:-
THCA	cis	rs2342371	0.756	rs3973	ENSG00000273013.1	CTD-2002J20.1	5.31	1.68e-07	2.48e-05	0.23	0.24	Fat distribution (HIV);	chr3:196397407	chr3:196474801~196475394:+
THCA	cis	rs7208859	0.725	rs9897673	ENSG00000263603.1	CTD-2349P21.5	-5.31	1.68e-07	2.48e-05	-0.4	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30729469~30731202:+
THCA	cis	rs9549367	0.713	rs3024746	ENSG00000269125.1	RP11-98F14.11	-5.31	1.68e-07	2.48e-05	-0.29	-0.24	Platelet distribution width;	chr13:113167463	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.713	rs3024747	ENSG00000269125.1	RP11-98F14.11	-5.31	1.68e-07	2.48e-05	-0.29	-0.24	Platelet distribution width;	chr13:113167473	chr13:113165002~113165183:-
THCA	cis	rs875971	0.545	rs316316	ENSG00000232546.1	RP11-458F8.1	-5.31	1.68e-07	2.48e-05	-0.22	-0.24	Aortic root size;	chr7:66149270	chr7:66848496~66858136:+
THCA	cis	rs1979679	0.766	rs7299798	ENSG00000247934.4	RP11-967K21.1	5.31	1.68e-07	2.48e-05	0.23	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28559224	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.766	rs10843202	ENSG00000247934.4	RP11-967K21.1	5.31	1.68e-07	2.48e-05	0.23	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28563111	chr12:28163298~28190738:-
THCA	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	5.31	1.68e-07	2.48e-05	0.42	0.24	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
THCA	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	5.31	1.68e-07	2.48e-05	0.42	0.24	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
THCA	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	5.31	1.68e-07	2.48e-05	0.42	0.24	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
THCA	cis	rs7512898	0.5	rs7520984	ENSG00000260088.1	RP11-92G12.3	-5.31	1.68e-07	2.48e-05	-0.33	-0.24	Electrocardiographic conduction measures;	chr1:200741190	chr1:200669507~200694250:+
THCA	cis	rs7246657	0.654	rs10407568	ENSG00000276846.1	CTD-3220F14.3	5.31	1.68e-07	2.48e-05	0.24	0.24	Coronary artery calcification;	chr19:37632108	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs16958863	ENSG00000276846.1	CTD-3220F14.3	5.31	1.68e-07	2.48e-05	0.24	0.24	Coronary artery calcification;	chr19:37633334	chr19:37314868~37315620:-
THCA	cis	rs3950186	0.834	rs4634440	ENSG00000215124.2	RP3-420J14.1	5.31	1.68e-07	2.48e-05	0.28	0.24	Anxiety and major depressive disorder;	chr6:11826253	chr6:11861626~11862970:-
THCA	cis	rs12935418	0.616	rs2549854	ENSG00000278985.1	RP11-303E16.9	5.31	1.68e-07	2.48e-05	0.26	0.24	Mean corpuscular volume;	chr16:80993034	chr16:80982319~80984094:-
THCA	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-5.31	1.68e-07	2.48e-05	-0.34	-0.24	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
THCA	cis	rs442309	0.875	rs224147	ENSG00000238280.1	RP11-436D10.3	5.31	1.68e-07	2.48e-05	0.28	0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62726055	chr10:62793562~62805887:-
THCA	cis	rs12435908	0.618	rs73282248	ENSG00000276116.2	FUT8-AS1	-5.31	1.68e-07	2.48e-05	-0.37	-0.24	Ischemic stroke;	chr14:65390406	chr14:65411170~65412690:-
THCA	cis	rs875971	0.545	rs1796222	ENSG00000232546.1	RP11-458F8.1	-5.31	1.68e-07	2.48e-05	-0.23	-0.24	Aortic root size;	chr7:66592167	chr7:66848496~66858136:+
THCA	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	5.31	1.68e-07	2.48e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	5.31	1.68e-07	2.48e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
THCA	cis	rs875971	0.545	rs75577046	ENSG00000232546.1	RP11-458F8.1	5.31	1.68e-07	2.48e-05	0.23	0.24	Aortic root size;	chr7:66493729	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000232546.1	RP11-458F8.1	5.31	1.68e-07	2.48e-05	0.23	0.24	Aortic root size;	chr7:66505541	chr7:66848496~66858136:+
THCA	cis	rs1823874	0.677	rs8042705	ENSG00000259363.4	CTD-2054N24.2	5.31	1.68e-07	2.48e-05	0.3	0.24	IgG glycosylation;	chr15:99824501	chr15:99807023~99877148:+
THCA	cis	rs9813712	0.571	rs9846596	ENSG00000253540.4	FAM86HP	-5.31	1.68e-07	2.48e-05	-0.26	-0.24	Response to amphetamines;	chr3:130288318	chr3:130099092~130111472:-
THCA	cis	rs2911132	0.564	rs7356594	ENSG00000248734.2	CTD-2260A17.1	5.31	1.68e-07	2.48e-05	0.26	0.24	Urate levels (BMI interaction);	chr5:96760485	chr5:96784777~96785999:+
THCA	cis	rs67478160	0.506	rs6575998	ENSG00000258735.1	LINC00637	-5.31	1.68e-07	2.49e-05	-0.29	-0.24	Schizophrenia;	chr14:103784080	chr14:103847721~103858049:+
THCA	cis	rs442309	0.875	rs224056	ENSG00000238280.1	RP11-436D10.3	-5.31	1.68e-07	2.49e-05	-0.28	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62737240	chr10:62793562~62805887:-
THCA	cis	rs13256369	0.802	rs12541520	ENSG00000253893.2	FAM85B	-5.31	1.68e-07	2.49e-05	-0.32	-0.24	Obesity-related traits;	chr8:8706636	chr8:8167819~8226614:-
THCA	cis	rs295490	0.688	rs184156	ENSG00000272656.1	RP11-219D15.3	-5.31	1.68e-07	2.49e-05	-0.29	-0.24	PR interval in Tripanosoma cruzi seropositivity;	chr3:139519526	chr3:139349024~139349371:-
THCA	cis	rs6714710	0.603	rs11678591	ENSG00000230606.9	AC159540.1	-5.31	1.68e-07	2.49e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97924538	chr2:97416165~97433527:-
THCA	cis	rs7119	0.689	rs8040318	ENSG00000259362.2	RP11-307C19.1	-5.31	1.69e-07	2.49e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77511318	chr15:77525540~77534110:+
THCA	cis	rs911119	1	rs6114208	ENSG00000270001.1	RP11-218C14.8	-5.31	1.69e-07	2.49e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23641097	chr20:23631826~23632316:-
THCA	cis	rs7129556	0.701	rs11237280	ENSG00000254691.1	RP11-91P24.5	5.31	1.69e-07	2.49e-05	0.33	0.24	Weight loss (gastric bypass surgery);	chr11:77745861	chr11:77850604~77851511:+
THCA	cis	rs2070488	0.56	rs1381798	ENSG00000229589.1	ACVR2B-AS1	-5.31	1.69e-07	2.49e-05	-0.23	-0.24	Electrocardiographic conduction measures;	chr3:38395980	chr3:38451027~38454820:-
THCA	cis	rs6570726	0.791	rs6902404	ENSG00000270638.1	RP3-466P17.1	5.31	1.69e-07	2.49e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145735570~145737218:+
THCA	cis	rs2337406	0.789	rs112027230	ENSG00000211974.3	IGHV2-70	-5.31	1.69e-07	2.49e-05	-0.23	-0.24	Alzheimer's disease (late onset);	chr14:106810329	chr14:106723574~106724093:-
THCA	cis	rs944289	0.708	rs1953120	ENSG00000258844.1	RP11-259K15.2	5.31	1.69e-07	2.49e-05	0.21	0.24	Thyroid cancer;	chr14:36105724	chr14:36214607~36235608:+
THCA	cis	rs7119	0.717	rs11635567	ENSG00000259362.2	RP11-307C19.1	-5.31	1.69e-07	2.49e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77527173	chr15:77525540~77534110:+
THCA	cis	rs2281603	0.951	rs12385918	ENSG00000259116.1	RP11-973N13.4	-5.31	1.69e-07	2.49e-05	-0.24	-0.24	Lymphocyte counts;	chr14:64533227	chr14:64514154~64540368:-
THCA	cis	rs12935418	0.523	rs2549840	ENSG00000278985.1	RP11-303E16.9	-5.31	1.69e-07	2.49e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80989817	chr16:80982319~80984094:-
THCA	cis	rs4748857	0.836	rs4748854	ENSG00000224215.1	RP11-371A19.2	-5.31	1.69e-07	2.49e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23309951	chr10:23343957~23345181:+
THCA	cis	rs4748857	0.947	rs4748855	ENSG00000224215.1	RP11-371A19.2	-5.31	1.69e-07	2.49e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23310146	chr10:23343957~23345181:+
THCA	cis	rs4748857	1	rs4748857	ENSG00000224215.1	RP11-371A19.2	-5.31	1.69e-07	2.49e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr10:23310629	chr10:23343957~23345181:+
THCA	cis	rs6545883	0.894	rs12622458	ENSG00000270820.4	RP11-355B11.2	-5.31	1.69e-07	2.49e-05	-0.2	-0.24	Tuberculosis;	chr2:61296419	chr2:61471188~61484130:+
THCA	cis	rs9309711	0.736	rs13412581	ENSG00000225234.1	TRAPPC12-AS1	-5.31	1.69e-07	2.5e-05	-0.25	-0.24	Neurofibrillary tangles;	chr2:3493416	chr2:3481242~3482409:-
THCA	cis	rs972578	0.765	rs1076117	ENSG00000274717.1	RP1-47A17.1	5.31	1.69e-07	2.5e-05	0.24	0.24	Mean platelet volume;	chr22:42903288	chr22:42791814~42794313:-
THCA	cis	rs73081554	0.505	rs7626442	ENSG00000272360.1	RP11-359I18.5	-5.31	1.69e-07	2.5e-05	-0.27	-0.24	Rheumatoid arthritis;	chr3:58352985	chr3:58490830~58491291:-
THCA	cis	rs7772486	0.686	rs2328708	ENSG00000270638.1	RP3-466P17.1	-5.31	1.69e-07	2.5e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145735570~145737218:+
THCA	cis	rs4713118	0.513	rs202908	ENSG00000226314.6	ZNF192P1	-5.31	1.69e-07	2.5e-05	-0.28	-0.24	Parkinson's disease;	chr6:28043773	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.513	rs156739	ENSG00000226314.6	ZNF192P1	-5.31	1.69e-07	2.5e-05	-0.28	-0.24	Parkinson's disease;	chr6:28045632	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.513	rs149958	ENSG00000226314.6	ZNF192P1	-5.31	1.69e-07	2.5e-05	-0.28	-0.24	Parkinson's disease;	chr6:28045839	chr6:28161781~28169594:+
THCA	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	5.31	1.69e-07	2.5e-05	0.3	0.24	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
THCA	cis	rs6973609	0.524	rs11762428	ENSG00000271122.1	RP11-379H18.1	-5.31	1.7e-07	2.5e-05	-0.15	-0.24	Obesity-related traits;	chr7:35610953	chr7:35695214~35699413:+
THCA	cis	rs12478296	1	rs67535150	ENSG00000261186.2	RP11-341N2.1	-5.31	1.7e-07	2.5e-05	-0.38	-0.24	Obesity-related traits;	chr2:242103948	chr2:242087351~242088457:-
THCA	cis	rs6723226	0.961	rs13010404	ENSG00000276334.1	AL133243.1	-5.31	1.7e-07	2.5e-05	-0.28	-0.24	Intelligence (multi-trait analysis);	chr2:32623787	chr2:32521927~32523547:+
THCA	cis	rs4713118	0.955	rs9468201	ENSG00000226314.6	ZNF192P1	-5.31	1.7e-07	2.5e-05	-0.3	-0.24	Parkinson's disease;	chr6:27719256	chr6:28161781~28169594:+
THCA	cis	rs12478296	0.901	rs59477854	ENSG00000261186.2	RP11-341N2.1	-5.31	1.7e-07	2.5e-05	-0.37	-0.24	Obesity-related traits;	chr2:242073339	chr2:242087351~242088457:-
THCA	cis	rs17594362	0.573	rs79034467	ENSG00000264190.1	MIR5006	5.31	1.7e-07	2.51e-05	0.37	0.24	Multiple sclerosis;	chr13:41573399	chr13:41568286~41568395:-
THCA	cis	rs9425766	0.679	rs6682017	ENSG00000227373.4	RP11-160H22.5	5.31	1.7e-07	2.51e-05	0.33	0.24	Life satisfaction;	chr1:174097809	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.655	rs2145376	ENSG00000227373.4	RP11-160H22.5	5.31	1.7e-07	2.51e-05	0.33	0.24	Life satisfaction;	chr1:174098911	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs6663794	ENSG00000227373.4	RP11-160H22.5	5.31	1.7e-07	2.51e-05	0.33	0.24	Life satisfaction;	chr1:174099791	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.64	rs6658769	ENSG00000227373.4	RP11-160H22.5	5.31	1.7e-07	2.51e-05	0.33	0.24	Life satisfaction;	chr1:174100843	chr1:174115300~174160004:-
THCA	cis	rs9990333	0.562	rs56224853	ENSG00000242086.7	LINC00969	5.31	1.7e-07	2.51e-05	0.24	0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195658062~195739964:+
THCA	cis	rs9990333	0.544	rs73210008	ENSG00000242086.7	LINC00969	5.31	1.7e-07	2.51e-05	0.24	0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195658062~195739964:+
THCA	cis	rs4938330	0.68	rs4938329	ENSG00000254851.1	RP11-109L13.1	5.31	1.7e-07	2.51e-05	0.34	0.24	Blood protein levels;	chr11:117057396	chr11:117135528~117138582:+
THCA	cis	rs321358	0.731	rs484021	ENSG00000271584.1	RP11-89C3.4	5.31	1.7e-07	2.51e-05	0.4	0.24	Body mass index;	chr11:111136353	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs7112075	ENSG00000271584.1	RP11-89C3.4	5.31	1.7e-07	2.51e-05	0.4	0.24	Body mass index;	chr11:111136407	chr11:111091932~111097357:-
THCA	cis	rs752010	0.523	rs10890159	ENSG00000230638.4	RP11-486B10.4	-5.31	1.7e-07	2.51e-05	-0.27	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41652611	chr1:41542069~41544310:+
THCA	cis	rs1479090	0.901	rs936562	ENSG00000250027.1	RP11-563E2.2	-5.31	1.7e-07	2.51e-05	-0.26	-0.24	Lung cancer;	chr4:163166802	chr4:163108785~163119965:+
THCA	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	5.31	1.7e-07	2.51e-05	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
THCA	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	5.31	1.7e-07	2.51e-05	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
THCA	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	5.31	1.7e-07	2.51e-05	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
THCA	cis	rs7829975	0.508	rs1594437	ENSG00000233609.3	RP11-62H7.2	5.31	1.7e-07	2.51e-05	0.23	0.24	Mood instability;	chr8:8968365	chr8:8961200~8979025:+
THCA	cis	rs10833905	0.641	rs34946681	ENSG00000246225.5	RP11-17A1.3	-5.31	1.7e-07	2.51e-05	-0.35	-0.24	Sudden cardiac arrest;	chr11:22935960	chr11:22829380~22945393:+
THCA	cis	rs79040073	0.598	rs11636296	ENSG00000259531.2	RP11-295H24.3	5.31	1.7e-07	2.51e-05	0.33	0.24	Lung cancer in ever smokers;	chr15:49034864	chr15:49365124~49366685:-
THCA	cis	rs7394190	0.748	rs3740293	ENSG00000271848.1	RP11-464F9.21	-5.31	1.7e-07	2.51e-05	-0.31	-0.24	Incident atrial fibrillation;	chr10:73646383	chr10:73654039~73674719:+
THCA	cis	rs4648045	0.894	rs230540	ENSG00000246560.2	RP11-10L12.4	-5.31	1.7e-07	2.51e-05	-0.3	-0.24	Lymphocyte percentage of white cells;	chr4:102575510	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.894	rs230542	ENSG00000246560.2	RP11-10L12.4	-5.31	1.7e-07	2.51e-05	-0.3	-0.24	Lymphocyte percentage of white cells;	chr4:102577298	chr4:102828055~102844075:+
THCA	cis	rs17533156	0.626	rs8079872	ENSG00000222808.1	RNU4-47P	-5.31	1.7e-07	2.51e-05	-0.29	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:77119544	chr17:77152561~77152674:-
THCA	cis	rs4748857	0.685	rs11013318	ENSG00000224215.1	RP11-371A19.2	-5.31	1.71e-07	2.51e-05	-0.32	-0.24	Systemic lupus erythematosus;	chr10:23203364	chr10:23343957~23345181:+
THCA	cis	rs755249	0.567	rs72637906	ENSG00000228060.1	RP11-69E11.8	-5.31	1.71e-07	2.51e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs67886352	ENSG00000228060.1	RP11-69E11.8	-5.31	1.71e-07	2.51e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs60323161	ENSG00000228060.1	RP11-69E11.8	-5.31	1.71e-07	2.51e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs66727439	ENSG00000228060.1	RP11-69E11.8	-5.31	1.71e-07	2.51e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39565160~39573203:+
THCA	cis	rs9652601	0.649	rs7403919	ENSG00000274038.1	RP11-66H6.4	5.31	1.71e-07	2.51e-05	0.3	0.24	Systemic lupus erythematosus;	chr16:10992111	chr16:11056556~11057034:+
THCA	cis	rs75920871	0.589	rs115787357	ENSG00000254851.1	RP11-109L13.1	-5.31	1.71e-07	2.52e-05	-0.51	-0.24	Subjective well-being;	chr11:117193790	chr11:117135528~117138582:+
THCA	cis	rs17772222	0.511	rs10150833	ENSG00000258789.1	RP11-507K2.3	-5.31	1.71e-07	2.52e-05	-0.22	-0.24	Coronary artery calcification;	chr14:88843296	chr14:88551597~88552493:+
THCA	cis	rs10266483	0.576	rs2863327	ENSG00000227986.1	TRIM60P18	5.31	1.71e-07	2.52e-05	0.24	0.24	Response to statin therapy;	chr7:64268698	chr7:64355078~64356199:+
THCA	cis	rs9843304	0.528	rs11919764	ENSG00000240541.2	TM4SF1-AS1	5.31	1.71e-07	2.52e-05	0.22	0.24	Gallstone disease;	chr3:149469448	chr3:149377778~149386583:+
THCA	cis	rs613391	0.508	rs10965431	ENSG00000224549.1	RP11-370B11.3	-5.31	1.71e-07	2.52e-05	-0.26	-0.24	Quantitative traits;	chr9:22725850	chr9:22767175~22768316:+
THCA	cis	rs3812049	0.532	rs251216	ENSG00000245937.6	LINC01184	5.31	1.71e-07	2.52e-05	0.28	0.24	Lymphocyte counts;Red cell distribution width;	chr5:128207588	chr5:127940426~128083172:-
THCA	cis	rs8002861	0.967	rs9533691	ENSG00000274001.1	RP11-5G9.5	5.31	1.71e-07	2.52e-05	0.27	0.24	Leprosy;	chr13:43908072	chr13:43877715~43878163:-
THCA	cis	rs17123764	0.605	rs7956181	ENSG00000257464.1	RP11-161H23.8	-5.31	1.71e-07	2.52e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49662556	chr12:49442424~49442652:-
THCA	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-5.31	1.71e-07	2.52e-05	-0.45	-0.24	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
THCA	cis	rs10761482	1	rs10761482	ENSG00000254271.1	RP11-131N11.4	-5.31	1.71e-07	2.52e-05	-0.31	-0.24	Schizophrenia;	chr10:60325579	chr10:60734342~60741828:+
THCA	cis	rs6840360	0.901	rs1561915	ENSG00000251611.1	RP11-610P16.1	-5.31	1.71e-07	2.52e-05	-0.17	-0.24	Intelligence (multi-trait analysis);	chr4:151558572	chr4:151407551~151408835:-
THCA	cis	rs890448	0.896	rs1863573	ENSG00000254531.1	FLJ20021	-5.31	1.71e-07	2.52e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101480630	chr4:101347780~101348883:+
THCA	cis	rs7712401	0.791	rs10071135	ENSG00000249996.1	RP11-359P5.1	5.31	1.71e-07	2.52e-05	0.21	0.24	Mean platelet volume;	chr5:122811283	chr5:123036271~123054667:+
THCA	cis	rs7577696	0.886	rs659239	ENSG00000276334.1	AL133243.1	5.31	1.71e-07	2.52e-05	0.25	0.24	Inflammatory biomarkers;	chr2:32259500	chr2:32521927~32523547:+
THCA	cis	rs1552244	1	rs9811771	ENSG00000232901.1	CYCSP10	5.31	1.71e-07	2.52e-05	0.31	0.24	Alzheimer's disease;	chr3:10092265	chr3:10000647~10000940:-
THCA	cis	rs6445975	0.666	rs4613423	ENSG00000272360.1	RP11-359I18.5	-5.31	1.71e-07	2.52e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr3:58355841	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs57621305	ENSG00000272360.1	RP11-359I18.5	-5.31	1.71e-07	2.52e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr3:58361017	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.666	rs4681683	ENSG00000272360.1	RP11-359I18.5	-5.31	1.71e-07	2.52e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr3:58361958	chr3:58490830~58491291:-
THCA	cis	rs755249	0.567	rs1537817	ENSG00000228060.1	RP11-69E11.8	5.31	1.71e-07	2.52e-05	0.25	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39565160~39573203:+
THCA	cis	rs76935404	0.811	rs28417358	ENSG00000256612.6	CYP2B7P	-5.31	1.71e-07	2.52e-05	-0.29	-0.24	nicotine metabolite ratio in current smokers;	chr19:40922200	chr19:40924219~40950660:+
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000280069.1	CTD-2349P21.3	-5.31	1.71e-07	2.52e-05	-0.36	-0.24	Body mass index;	chr17:30737900	chr17:30738182~30740275:+
THCA	cis	rs793571	0.628	rs12437952	ENSG00000259250.1	RP11-50C13.1	-5.31	1.71e-07	2.52e-05	-0.26	-0.24	Schizophrenia;	chr15:58757147	chr15:58587507~58591676:+
THCA	cis	rs4713118	0.513	rs149975	ENSG00000226314.6	ZNF192P1	-5.31	1.71e-07	2.53e-05	-0.28	-0.24	Parkinson's disease;	chr6:28018562	chr6:28161781~28169594:+
THCA	cis	rs16958440	0.581	rs11082564	ENSG00000267800.1	RP11-49K24.5	-5.31	1.71e-07	2.53e-05	-0.43	-0.24	Sitting height ratio;	chr18:47132778	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.708	rs62096477	ENSG00000267800.1	RP11-49K24.5	-5.31	1.71e-07	2.53e-05	-0.43	-0.24	Sitting height ratio;	chr18:47135939	chr18:47137018~47137290:+
THCA	cis	rs10829156	0.945	rs10741131	ENSG00000240291.1	RP11-499P20.2	5.31	1.71e-07	2.53e-05	0.2	0.24	Sudden cardiac arrest;	chr10:18683130	chr10:18513115~18545651:-
THCA	cis	rs16852403	0.517	rs12047029	ENSG00000224687.1	RASAL2-AS1	5.31	1.71e-07	2.53e-05	0.36	0.24	Childhood ear infection;	chr1:178210582	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.501	rs2862318	ENSG00000224687.1	RASAL2-AS1	5.31	1.71e-07	2.53e-05	0.36	0.24	Childhood ear infection;	chr1:178210992	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.548	rs12410235	ENSG00000224687.1	RASAL2-AS1	5.31	1.71e-07	2.53e-05	0.36	0.24	Childhood ear infection;	chr1:178215647	chr1:178091508~178093984:-
THCA	cis	rs2360027	0.578	rs6428751	ENSG00000231365.4	RP11-418J17.1	5.31	1.71e-07	2.53e-05	0.24	0.24	Tonsillectomy;	chr1:118536943	chr1:119140396~119275973:+
THCA	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-5.31	1.72e-07	2.53e-05	-0.29	-0.24	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
THCA	cis	rs4646450	0.891	rs11976018	ENSG00000244219.5	GS1-259H13.2	-5.31	1.72e-07	2.53e-05	-0.29	-0.24	Blood metabolite levels;	chr7:99524814	chr7:99598066~99610813:+
THCA	cis	rs10043228	0.609	rs79769112	ENSG00000248445.4	SEMA6A-AS1	-5.31	1.72e-07	2.53e-05	-0.27	-0.24	Asthma or chronic obstructive pulmonary disease;	chr5:116381519	chr5:116447547~116508276:+
THCA	cis	rs6565180	0.632	rs8050812	ENSG00000273724.1	RP11-347C12.12	-5.31	1.72e-07	2.53e-05	-0.27	-0.24	Tonsillectomy;	chr16:30374516	chr16:30336400~30343336:+
THCA	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-5.31	1.72e-07	2.53e-05	-0.34	-0.24	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
THCA	cis	rs73198271	0.74	rs10100066	ENSG00000253893.2	FAM85B	5.31	1.72e-07	2.54e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.74	rs10110711	ENSG00000253893.2	FAM85B	5.31	1.72e-07	2.54e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.74	rs10103163	ENSG00000253893.2	FAM85B	5.31	1.72e-07	2.54e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8167819~8226614:-
THCA	cis	rs1552244	1	rs112509186	ENSG00000232901.1	CYCSP10	5.31	1.72e-07	2.54e-05	0.31	0.24	Alzheimer's disease;	chr3:10114849	chr3:10000647~10000940:-
THCA	cis	rs2853333	1	rs2853336	ENSG00000269553.1	U62631.5	-5.31	1.72e-07	2.54e-05	-0.25	-0.24	Red blood cell count;	chr19:35255896	chr19:35330843~35331920:+
THCA	cis	rs2853333	1	rs2853333	ENSG00000269553.1	U62631.5	-5.31	1.72e-07	2.54e-05	-0.25	-0.24	Red blood cell count;	chr19:35256760	chr19:35330843~35331920:+
THCA	cis	rs2243480	1	rs1499614	ENSG00000230295.1	RP11-458F8.2	-5.31	1.72e-07	2.54e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66265811	chr7:66880708~66882981:+
THCA	cis	rs7918232	0.8	rs7907981	ENSG00000262412.1	RP11-85G18.6	5.31	1.72e-07	2.54e-05	0.33	0.24	Breast cancer;	chr10:27155400	chr10:27243130~27250804:+
THCA	cis	rs5006884	0.715	rs11037061	ENSG00000167355.6	AC104389.28	-5.31	1.72e-07	2.54e-05	-0.37	-0.24	Fetal hemoglobin levels;	chr11:5371510	chr11:5304976~5505652:-
THCA	cis	rs11089937	0.559	rs2330014	ENSG00000211638.2	IGLV8-61	-5.31	1.72e-07	2.54e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22098700~22099212:+
THCA	cis	rs17767392	1	rs61991205	ENSG00000259146.3	RP1-261D10.2	5.31	1.72e-07	2.54e-05	0.31	0.24	Mitral valve prolapse;	chr14:71305204	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs17767410	ENSG00000259146.3	RP1-261D10.2	5.31	1.72e-07	2.54e-05	0.31	0.24	Mitral valve prolapse;	chr14:71305250	chr14:71292729~71321814:-
THCA	cis	rs897984	0.574	rs11647284	ENSG00000279196.1	RP11-1072A3.3	5.31	1.73e-07	2.54e-05	0.24	0.24	Dementia with Lewy bodies;	chr16:31066014	chr16:30984630~30988270:-
THCA	cis	rs9475752	0.793	rs34009699	ENSG00000231441.1	RP11-472M19.2	5.31	1.73e-07	2.54e-05	0.32	0.24	Menarche (age at onset);	chr6:57007049	chr6:56844002~56864078:+
THCA	cis	rs2337406	0.866	rs58154560	ENSG00000211974.3	IGHV2-70	-5.31	1.73e-07	2.54e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106799601	chr14:106723574~106724093:-
THCA	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-5.31	1.73e-07	2.54e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
THCA	cis	rs4950322	0.542	rs17159914	ENSG00000180867.10	PDIA3P1	-5.31	1.73e-07	2.54e-05	-0.22	-0.24	Protein quantitative trait loci;	chr1:147183226	chr1:147178113~147179622:+
THCA	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-5.31	1.73e-07	2.55e-05	-0.33	-0.24	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
THCA	cis	rs4819052	0.807	rs1075788	ENSG00000273796.1	LL21NC02-21A1.1	-5.31	1.73e-07	2.55e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45403809~45404369:-
THCA	cis	rs17594362	0.943	rs7331567	ENSG00000264190.1	MIR5006	5.31	1.73e-07	2.55e-05	0.38	0.24	Multiple sclerosis;	chr13:41580910	chr13:41568286~41568395:-
THCA	cis	rs7824557	0.836	rs1435278	ENSG00000154316.13	TDH	5.31	1.73e-07	2.55e-05	0.17	0.24	Retinal vascular caliber;	chr8:11265520	chr8:11339637~11368452:+
THCA	cis	rs10916248	0.559	rs116083281	ENSG00000232628.4	RP11-365O16.3	5.31	1.73e-07	2.55e-05	0.36	0.24	QT interval (drug interaction);	chr1:224199365	chr1:224208747~224213279:-
THCA	cis	rs10129255	0.833	rs61997797	ENSG00000223648.3	IGHV3-64	5.31	1.73e-07	2.55e-05	0.15	0.24	Kawasaki disease;	chr14:106815190	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.833	rs7156689	ENSG00000223648.3	IGHV3-64	5.31	1.73e-07	2.55e-05	0.15	0.24	Kawasaki disease;	chr14:106816039	chr14:106643132~106658258:-
THCA	cis	rs11992162	0.613	rs56094399	ENSG00000206014.6	OR7E161P	5.31	1.73e-07	2.55e-05	0.29	0.24	Monocyte count;	chr8:11939961	chr8:11928597~11929563:-
THCA	cis	rs6840360	0.582	rs4696259	ENSG00000270265.1	RP11-731D1.4	-5.31	1.73e-07	2.55e-05	-0.22	-0.24	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151333775~151353224:-
THCA	cis	rs7617773	0.78	rs71323395	ENSG00000199476.1	Y_RNA	-5.31	1.73e-07	2.55e-05	-0.31	-0.24	Coronary artery disease;	chr3:48332587	chr3:48288587~48288694:+
THCA	cis	rs10510102	0.81	rs11200240	ENSG00000226864.1	ATE1-AS1	5.31	1.73e-07	2.55e-05	0.39	0.24	Breast cancer;	chr10:121903265	chr10:121928312~121951965:+
THCA	cis	rs1552244	0.554	rs2272122	ENSG00000180385.7	EMC3-AS1	5.31	1.73e-07	2.55e-05	0.23	0.24	Alzheimer's disease;	chr3:10006291	chr3:9986893~10006990:+
THCA	cis	rs73242632	1	rs7673980	ENSG00000269949.1	RP11-738E22.3	5.31	1.73e-07	2.55e-05	0.53	0.24	Congenital heart disease (maternal effect);	chr4:56942377	chr4:56960927~56961373:-
THCA	cis	rs73242632	1	rs73242620	ENSG00000269949.1	RP11-738E22.3	5.31	1.73e-07	2.55e-05	0.53	0.24	Congenital heart disease (maternal effect);	chr4:56948884	chr4:56960927~56961373:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000261839.1	RP1-265C24.8	5.31	1.73e-07	2.55e-05	0.28	0.24	Depression;	chr6:28206179	chr6:28136849~28139678:+
THCA	cis	rs10256972	0.521	rs7811577	ENSG00000199023.2	MIR339	-5.31	1.73e-07	2.55e-05	-0.24	-0.24	Endometriosis;Longevity;	chr7:1063193	chr7:1022935~1023045:-
THCA	cis	rs7412746	0.658	rs12410394	ENSG00000231073.1	RP11-316M1.3	5.31	1.73e-07	2.55e-05	0.29	0.24	Melanoma;	chr1:150887710	chr1:150973123~150975534:+
THCA	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-5.31	1.73e-07	2.55e-05	-0.32	-0.24	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
THCA	cis	rs7045881	0.935	rs62544443	ENSG00000254396.1	RP11-56F10.3	5.31	1.73e-07	2.56e-05	0.33	0.24	Schizophrenia;	chr9:26930962	chr9:27102630~27104728:+
THCA	cis	rs12435908	1	rs17826448	ENSG00000276116.2	FUT8-AS1	5.31	1.74e-07	2.56e-05	0.37	0.24	Ischemic stroke;	chr14:65385299	chr14:65411170~65412690:-
THCA	cis	rs7577696	0.85	rs2566483	ENSG00000276334.1	AL133243.1	5.31	1.74e-07	2.56e-05	0.25	0.24	Inflammatory biomarkers;	chr2:32259398	chr2:32521927~32523547:+
THCA	cis	rs58785573	0.57	rs4833078	ENSG00000231160.8	KLF3-AS1	-5.31	1.74e-07	2.56e-05	-0.13	-0.24	Lymphocyte percentage of white cells;	chr4:38644855	chr4:38612701~38664883:-
THCA	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	5.31	1.74e-07	2.56e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
THCA	cis	rs7924176	0.521	rs10509347	ENSG00000213731.2	RAB5CP1	-5.31	1.74e-07	2.56e-05	-0.29	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:74423435~74424014:-
THCA	cis	rs442309	0.553	rs10995278	ENSG00000238280.1	RP11-436D10.3	-5.31	1.74e-07	2.56e-05	-0.31	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62694737	chr10:62793562~62805887:-
THCA	cis	rs8059260	0.736	rs76818150	ENSG00000274038.1	RP11-66H6.4	-5.31	1.74e-07	2.56e-05	-0.49	-0.24	Alcohol consumption over the past year;	chr16:10955006	chr16:11056556~11057034:+
THCA	cis	rs1546924	0.549	rs127204	ENSG00000227811.2	FAM212B-AS1	-5.31	1.74e-07	2.56e-05	-0.29	-0.24	Body mass index;	chr1:111735071	chr1:111739841~111747798:+
THCA	cis	rs2129782	1	rs16882622	ENSG00000253553.4	RP11-586K2.1	5.31	1.74e-07	2.56e-05	0.39	0.24	Electrodermal activity;	chr8:88427413	chr8:88326836~88737134:+
THCA	cis	rs12908161	1	rs12905057	ENSG00000275120.1	RP11-182J1.17	5.31	1.74e-07	2.56e-05	0.28	0.24	Schizophrenia;	chr15:84667534	chr15:84599434~84606463:-
THCA	cis	rs11096990	0.964	rs16995206	ENSG00000249685.1	RP11-360F5.3	-5.3	1.74e-07	2.56e-05	-0.3	-0.24	Cognitive function;	chr4:39262887	chr4:39133913~39135608:+
THCA	cis	rs881375	0.501	rs10739591	ENSG00000226752.6	PSMD5-AS1	-5.3	1.74e-07	2.56e-05	-0.33	-0.24	Rheumatoid arthritis;	chr9:121123450	chr9:120824828~120854385:+
THCA	cis	rs1552244	1	rs56394721	ENSG00000180385.7	EMC3-AS1	5.3	1.74e-07	2.56e-05	0.26	0.24	Alzheimer's disease;	chr3:10109111	chr3:9986893~10006990:+
THCA	cis	rs875971	0.545	rs75577046	ENSG00000228409.4	CCT6P1	-5.3	1.74e-07	2.56e-05	-0.2	-0.24	Aortic root size;	chr7:66493729	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000228409.4	CCT6P1	-5.3	1.74e-07	2.56e-05	-0.2	-0.24	Aortic root size;	chr7:66505541	chr7:65751142~65763354:+
THCA	cis	rs8014252	0.572	rs10138243	ENSG00000259158.2	ADAM20P1	-5.3	1.74e-07	2.56e-05	-0.23	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70492742	chr14:70468881~70483756:-
THCA	cis	rs2749592	0.55	rs7917262	ENSG00000263064.2	RP11-291L22.7	-5.3	1.74e-07	2.56e-05	-0.26	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38448689~38448949:+
THCA	cis	rs2749592	0.55	rs9733309	ENSG00000263064.2	RP11-291L22.7	-5.3	1.74e-07	2.56e-05	-0.26	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38448689~38448949:+
THCA	cis	rs172166	0.637	rs1233691	ENSG00000220721.1	OR1F12	5.3	1.74e-07	2.56e-05	0.29	0.24	Cardiac Troponin-T levels;	chr6:28186119	chr6:28073316~28074233:+
THCA	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-5.3	1.74e-07	2.56e-05	-0.44	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
THCA	cis	rs7045881	0.733	rs78249280	ENSG00000254396.1	RP11-56F10.3	5.3	1.74e-07	2.56e-05	0.43	0.24	Schizophrenia;	chr9:26975647	chr9:27102630~27104728:+
THCA	cis	rs3764400	0.508	rs74412170	ENSG00000278765.1	RP5-890E16.5	5.3	1.74e-07	2.56e-05	0.43	0.24	Body mass index;	chr17:48040147	chr17:48066704~48067293:-
THCA	cis	rs9549367	0.713	rs3024744	ENSG00000269125.1	RP11-98F14.11	-5.3	1.74e-07	2.56e-05	-0.29	-0.24	Platelet distribution width;	chr13:113167163	chr13:113165002~113165183:-
THCA	cis	rs1667284	0.547	rs1449087	ENSG00000266521.1	RP11-650P15.1	-5.3	1.74e-07	2.56e-05	-0.3	-0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31657897	chr18:31496645~31497195:-
THCA	cis	rs7772486	0.686	rs1292336	ENSG00000270638.1	RP3-466P17.1	-5.3	1.74e-07	2.56e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145735570~145737218:+
THCA	cis	rs7250849	0.565	rs73052857	ENSG00000273837.1	LLNLR-470E3.1	-5.3	1.74e-07	2.57e-05	-0.34	-0.24	Blood protein levels;	chr19:51661182	chr19:51639478~51639931:-
THCA	cis	rs11648785	0.777	rs12932473	ENSG00000222019.6	URAHP	5.3	1.74e-07	2.57e-05	0.2	0.24	Tanning;	chr16:90033981	chr16:90039761~90047773:-
THCA	cis	rs34779708	0.931	rs2384283	ENSG00000271335.4	RP11-324I22.4	5.3	1.74e-07	2.57e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35314552~35336401:-
THCA	cis	rs7045881	0.935	rs59274950	ENSG00000254396.1	RP11-56F10.3	5.3	1.74e-07	2.57e-05	0.33	0.24	Schizophrenia;	chr9:26929387	chr9:27102630~27104728:+
THCA	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	5.3	1.74e-07	2.57e-05	0.28	0.24	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
THCA	cis	rs2239547	0.522	rs2581823	ENSG00000242142.1	SERBP1P3	-5.3	1.74e-07	2.57e-05	-0.3	-0.24	Schizophrenia;	chr3:52988060	chr3:53064283~53065091:-
THCA	cis	rs1979679	0.918	rs2169755	ENSG00000278733.1	RP11-425D17.1	5.3	1.75e-07	2.57e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28338224	chr12:28185625~28186190:-
THCA	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	5.3	1.75e-07	2.57e-05	0.33	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
THCA	cis	rs3796352	1	rs71301814	ENSG00000242142.1	SERBP1P3	-5.3	1.75e-07	2.57e-05	-0.44	-0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53083647	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs11710292	ENSG00000242142.1	SERBP1P3	-5.3	1.75e-07	2.57e-05	-0.44	-0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53083782	chr3:53064283~53065091:-
THCA	cis	rs34792	0.688	rs153785	ENSG00000207425.1	Y_RNA	5.3	1.75e-07	2.57e-05	0.26	0.24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499435	chr16:14915457~14915556:-
THCA	cis	rs1350171	0.79	rs12805523	ENSG00000246523.6	RP11-736K20.6	-5.3	1.75e-07	2.57e-05	-0.34	-0.24	Hepatocellular carcinoma in hepatitis B infection;	chr11:86933325	chr11:86955619~87000959:+
THCA	cis	rs2735413	0.563	rs72800915	ENSG00000276007.1	RP11-358L22.3	5.3	1.75e-07	2.57e-05	0.27	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78021880	chr16:78123243~78124332:+
THCA	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	5.3	1.75e-07	2.57e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
THCA	cis	rs9329221	0.905	rs13254263	ENSG00000261451.1	RP11-981G7.1	-5.3	1.75e-07	2.57e-05	-0.29	-0.24	Neuroticism;	chr8:10397671	chr8:10433672~10438312:+
THCA	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	5.3	1.75e-07	2.58e-05	0.59	0.24	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
THCA	cis	rs2278034	0.502	rs3747672	ENSG00000231464.1	AC024937.4	5.3	1.75e-07	2.58e-05	0.28	0.24	Bronchopulmonary dysplasia;	chr3:195885163	chr3:195996738~195998233:+
THCA	cis	rs801193	0.66	rs974239	ENSG00000223473.2	GS1-124K5.3	5.3	1.75e-07	2.58e-05	0.16	0.24	Aortic root size;	chr7:66748504	chr7:66491049~66493566:-
THCA	cis	rs1275468	0.731	rs2652022	ENSG00000257497.2	RP11-585P4.5	-5.3	1.75e-07	2.58e-05	-0.37	-0.24	Polycystic ovary syndrome;	chr12:75586771	chr12:75483454~75489820:-
THCA	cis	rs2282300	0.739	rs34855782	ENSG00000242353.1	RP4-710M3.1	-5.3	1.75e-07	2.58e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30203923	chr11:30368148~30368646:+
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000273796.1	LL21NC02-21A1.1	-5.3	1.75e-07	2.58e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45403809~45404369:-
THCA	cis	rs12893668	0.608	rs12889721	ENSG00000269940.1	RP11-73M18.7	5.3	1.75e-07	2.58e-05	0.25	0.24	Reticulocyte count;	chr14:103568526	chr14:103694560~103695170:+
THCA	cis	rs8141529	0.732	rs2239815	ENSG00000226471.5	CTA-292E10.6	5.3	1.75e-07	2.58e-05	0.2	0.24	Lymphocyte counts;	chr22:28796682	chr22:28800683~28848559:+
THCA	cis	rs714027	1	rs4823073	ENSG00000279159.1	RP3-394A18.1	-5.3	1.75e-07	2.58e-05	-0.16	-0.24	Lymphocyte counts;	chr22:30116269	chr22:29978950~30028236:-
THCA	cis	rs714027	1	rs4823074	ENSG00000279159.1	RP3-394A18.1	-5.3	1.75e-07	2.58e-05	-0.16	-0.24	Lymphocyte counts;	chr22:30116489	chr22:29978950~30028236:-
THCA	cis	rs714027	1	rs4823075	ENSG00000279159.1	RP3-394A18.1	-5.3	1.75e-07	2.58e-05	-0.16	-0.24	Lymphocyte counts;	chr22:30123163	chr22:29978950~30028236:-
THCA	cis	rs875971	0.545	rs2460427	ENSG00000228409.4	CCT6P1	5.3	1.75e-07	2.58e-05	0.2	0.24	Aortic root size;	chr7:66154218	chr7:65751142~65763354:+
THCA	cis	rs763121	0.819	rs5757160	ENSG00000273076.1	RP3-508I15.22	5.3	1.75e-07	2.58e-05	0.23	0.24	Menopause (age at onset);	chr22:38593641	chr22:38743495~38743910:+
THCA	cis	rs28374715	0.681	rs7168307	ENSG00000247556.5	OIP5-AS1	5.3	1.75e-07	2.58e-05	0.21	0.24	Ulcerative colitis;	chr15:41328336	chr15:41283990~41309737:+
THCA	cis	rs7412746	0.597	rs868751	ENSG00000231073.1	RP11-316M1.3	5.3	1.75e-07	2.58e-05	0.29	0.24	Melanoma;	chr1:150696938	chr1:150973123~150975534:+
THCA	cis	rs10043228	0.609	rs12515880	ENSG00000248445.4	SEMA6A-AS1	-5.3	1.76e-07	2.58e-05	-0.26	-0.24	Asthma or chronic obstructive pulmonary disease;	chr5:116379403	chr5:116447547~116508276:+
THCA	cis	rs6840258	0.891	rs3733377	ENSG00000251411.1	RP11-397E7.4	5.3	1.76e-07	2.58e-05	0.29	0.24	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87108330	chr4:86913266~86914817:-
THCA	cis	rs1707322	0.721	rs7520123	ENSG00000281133.1	AL355480.3	-5.3	1.76e-07	2.58e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45580892~45580996:-
THCA	cis	rs2360027	0.599	rs2202578	ENSG00000231365.4	RP11-418J17.1	-5.3	1.76e-07	2.58e-05	-0.24	-0.24	Tonsillectomy;	chr1:118543849	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs2211476	ENSG00000231365.4	RP11-418J17.1	-5.3	1.76e-07	2.58e-05	-0.24	-0.24	Tonsillectomy;	chr1:118544858	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.54	rs6657765	ENSG00000231365.4	RP11-418J17.1	-5.3	1.76e-07	2.58e-05	-0.24	-0.24	Tonsillectomy;	chr1:118547866	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.558	rs35989857	ENSG00000231365.4	RP11-418J17.1	-5.3	1.76e-07	2.58e-05	-0.24	-0.24	Tonsillectomy;	chr1:118548623	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.558	rs12123208	ENSG00000231365.4	RP11-418J17.1	-5.3	1.76e-07	2.58e-05	-0.24	-0.24	Tonsillectomy;	chr1:118549077	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.538	rs56224119	ENSG00000231365.4	RP11-418J17.1	-5.3	1.76e-07	2.58e-05	-0.24	-0.24	Tonsillectomy;	chr1:118552582	chr1:119140396~119275973:+
THCA	cis	rs7829975	0.514	rs2976929	ENSG00000253981.4	ALG1L13P	5.3	1.76e-07	2.58e-05	0.22	0.24	Mood instability;	chr8:8401202	chr8:8236003~8244667:-
THCA	cis	rs11089937	0.553	rs35336247	ENSG00000211639.2	IGLV4-60	5.3	1.76e-07	2.58e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.553	rs34088081	ENSG00000211639.2	IGLV4-60	5.3	1.76e-07	2.58e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22162199~22162681:+
THCA	cis	rs16852403	0.519	rs10913523	ENSG00000224687.1	RASAL2-AS1	5.3	1.76e-07	2.58e-05	0.36	0.24	Childhood ear infection;	chr1:178250865	chr1:178091508~178093984:-
THCA	cis	rs3734266	0.591	rs35684630	ENSG00000272288.4	RP11-140K17.3	-5.3	1.76e-07	2.58e-05	-0.22	-0.24	Systemic lupus erythematosus;	chr6:34702567	chr6:34696317~34697470:+
THCA	cis	rs12534093	0.67	rs11764404	ENSG00000234286.1	AC006026.13	-5.3	1.76e-07	2.59e-05	-0.36	-0.24	Infant length;Height;	chr7:23547541	chr7:23680195~23680786:-
THCA	cis	rs1552244	1	rs1552244	ENSG00000232901.1	CYCSP10	5.3	1.76e-07	2.59e-05	0.31	0.24	Alzheimer's disease;	chr3:10093893	chr3:10000647~10000940:-
THCA	cis	rs2921073	0.509	rs2976931	ENSG00000253981.4	ALG1L13P	5.3	1.76e-07	2.59e-05	0.22	0.24	Parkinson's disease;	chr8:8399807	chr8:8236003~8244667:-
THCA	cis	rs919433	0.68	rs7605813	ENSG00000231621.1	AC013264.2	-5.3	1.76e-07	2.59e-05	-0.25	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197510605	chr2:197197991~197199273:+
THCA	cis	rs3096299	0.754	rs3096320	ENSG00000274627.1	RP11-104N10.2	5.3	1.76e-07	2.59e-05	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89336649	chr16:89516797~89522217:+
THCA	cis	rs2067615	0.524	rs9971765	ENSG00000260329.1	RP11-412D9.4	-5.3	1.76e-07	2.59e-05	-0.22	-0.24	Heart rate;	chr12:106698521	chr12:106954029~106955497:-
THCA	cis	rs613391	0.536	rs682022	ENSG00000224549.1	RP11-370B11.3	-5.3	1.76e-07	2.59e-05	-0.27	-0.24	Quantitative traits;	chr9:22722160	chr9:22767175~22768316:+
THCA	cis	rs9834975	0.967	rs9823467	ENSG00000272758.4	RP11-299J3.8	-5.3	1.76e-07	2.59e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122403245	chr3:122416207~122443180:+
THCA	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-5.3	1.76e-07	2.59e-05	-0.25	-0.24	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
THCA	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	5.3	1.76e-07	2.59e-05	0.27	0.24	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
THCA	cis	rs763567	0.817	rs598993	ENSG00000271811.1	RP1-79C4.4	5.3	1.76e-07	2.59e-05	0.27	0.24	Tonsillectomy;	chr1:170634981	chr1:170667381~170669425:+
THCA	cis	rs763567	0.935	rs541557	ENSG00000271811.1	RP1-79C4.4	5.3	1.76e-07	2.59e-05	0.27	0.24	Tonsillectomy;	chr1:170635797	chr1:170667381~170669425:+
THCA	cis	rs9467773	1	rs9467791	ENSG00000261353.1	CTA-14H9.5	5.3	1.76e-07	2.59e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26527063~26527404:+
THCA	cis	rs7412746	0.634	rs12409208	ENSG00000231073.1	RP11-316M1.3	5.3	1.76e-07	2.59e-05	0.29	0.24	Melanoma;	chr1:150887579	chr1:150973123~150975534:+
THCA	cis	rs1075232	0.826	rs12437800	ENSG00000215302.7	CTD-3092A11.1	-5.3	1.76e-07	2.59e-05	-0.54	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30470779~30507623:+
THCA	cis	rs1211375	0.606	rs1203977	ENSG00000268836.1	LA16c-OS12.2	-5.3	1.76e-07	2.59e-05	-0.2	-0.24	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:185748~186294:-
THCA	cis	rs61677309	1	rs1945765	ENSG00000280032.1	RP11-832A4.7	5.3	1.76e-07	2.59e-05	0.25	0.24	Lung cancer in ever smokers;	chr11:118312114	chr11:118264593~118266817:+
THCA	cis	rs10129255	0.646	rs55995061	ENSG00000223648.3	IGHV3-64	5.3	1.77e-07	2.6e-05	0.15	0.24	Kawasaki disease;	chr14:106799309	chr14:106643132~106658258:-
THCA	cis	rs990871	0.548	rs7549792	ENSG00000227207.2	RPL31P12	5.3	1.77e-07	2.6e-05	0.27	0.24	Subcutaneous adipose tissue;	chr1:72274951	chr1:72301472~72301829:+
THCA	cis	rs990871	0.53	rs11584611	ENSG00000227207.2	RPL31P12	5.3	1.77e-07	2.6e-05	0.27	0.24	Subcutaneous adipose tissue;	chr1:72276146	chr1:72301472~72301829:+
THCA	cis	rs9634489	0.511	rs9516671	ENSG00000247400.3	DNAJC3-AS1	5.3	1.77e-07	2.6e-05	0.16	0.24	Body mass index;	chr13:96377924	chr13:95648733~95676925:-
THCA	cis	rs748404	0.666	rs34633582	ENSG00000205771.5	CATSPER2P1	-5.3	1.77e-07	2.6e-05	-0.3	-0.24	Lung cancer;	chr15:43462683	chr15:43726918~43747094:-
THCA	cis	rs9494145	0.526	rs56002646	ENSG00000232876.1	CTA-212D2.2	-5.3	1.77e-07	2.6e-05	-0.37	-0.24	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135162671	chr6:135055033~135060550:+
THCA	cis	rs2562456	0.833	rs62107539	ENSG00000268081.1	RP11-678G14.2	5.3	1.77e-07	2.6e-05	0.41	0.24	Pain;	chr19:21334910	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs76646508	ENSG00000268081.1	RP11-678G14.2	5.3	1.77e-07	2.6e-05	0.41	0.24	Pain;	chr19:21335247	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs77576302	ENSG00000268081.1	RP11-678G14.2	5.3	1.77e-07	2.6e-05	0.41	0.24	Pain;	chr19:21335385	chr19:21554640~21569237:-
THCA	cis	rs7246657	0.722	rs2927746	ENSG00000276846.1	CTD-3220F14.3	-5.3	1.77e-07	2.6e-05	-0.24	-0.24	Coronary artery calcification;	chr19:37665669	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs2927747	ENSG00000276846.1	CTD-3220F14.3	-5.3	1.77e-07	2.6e-05	-0.24	-0.24	Coronary artery calcification;	chr19:37668629	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs2909102	ENSG00000276846.1	CTD-3220F14.3	-5.3	1.77e-07	2.6e-05	-0.24	-0.24	Coronary artery calcification;	chr19:37676463	chr19:37314868~37315620:-
THCA	cis	rs62292953	0.722	rs62293987	ENSG00000248724.5	NPHP3-AS1	-5.3	1.77e-07	2.6e-05	-0.42	-0.24	Red cell distribution width;	chr3:132550518	chr3:132721750~132874223:+
THCA	cis	rs12612619	0.732	rs11677841	ENSG00000229122.1	AGBL5-IT1	5.3	1.77e-07	2.6e-05	0.17	0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27017081	chr2:27061038~27061815:+
THCA	cis	rs1552244	1	rs67852463	ENSG00000180385.7	EMC3-AS1	5.3	1.77e-07	2.6e-05	0.27	0.24	Alzheimer's disease;	chr3:10115521	chr3:9986893~10006990:+
THCA	cis	rs2179367	0.537	rs12192159	ENSG00000268592.3	RAET1E-AS1	5.3	1.77e-07	2.6e-05	0.38	0.24	Dupuytren's disease;	chr6:149445969	chr6:149863494~149919507:+
THCA	cis	rs116095464	0.558	rs6878087	ENSG00000248925.1	CTD-2083E4.6	-5.3	1.77e-07	2.6e-05	-0.34	-0.24	Breast cancer;	chr5:223002	chr5:269858~271516:-
THCA	cis	rs593531	0.513	rs479968	ENSG00000212961.4	HNRNPA1P40	-5.3	1.77e-07	2.6e-05	-0.3	-0.24	Neuroticism;	chr11:74327229	chr11:74354443~74355720:+
THCA	cis	rs8014252	0.636	rs10139500	ENSG00000259158.2	ADAM20P1	-5.3	1.77e-07	2.61e-05	-0.26	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70392802	chr14:70468881~70483756:-
THCA	cis	rs10266483	0.545	rs7777148	ENSG00000227986.1	TRIM60P18	5.3	1.77e-07	2.61e-05	0.24	0.24	Response to statin therapy;	chr7:64285795	chr7:64355078~64356199:+
THCA	cis	rs116095464	0.681	rs10060016	ENSG00000248925.1	CTD-2083E4.6	5.3	1.77e-07	2.61e-05	0.34	0.24	Breast cancer;	chr5:240985	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10057299	ENSG00000248925.1	CTD-2083E4.6	5.3	1.77e-07	2.61e-05	0.34	0.24	Breast cancer;	chr5:242020	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs13356367	ENSG00000248925.1	CTD-2083E4.6	5.3	1.77e-07	2.61e-05	0.34	0.24	Breast cancer;	chr5:242280	chr5:269858~271516:-
THCA	cis	rs116095464	0.85	rs10055295	ENSG00000248925.1	CTD-2083E4.6	5.3	1.77e-07	2.61e-05	0.34	0.24	Breast cancer;	chr5:243634	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10055354	ENSG00000248925.1	CTD-2083E4.6	5.3	1.77e-07	2.61e-05	0.34	0.24	Breast cancer;	chr5:243679	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs60251075	ENSG00000248925.1	CTD-2083E4.6	5.3	1.77e-07	2.61e-05	0.34	0.24	Breast cancer;	chr5:245177	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs62344300	ENSG00000248925.1	CTD-2083E4.6	5.3	1.77e-07	2.61e-05	0.34	0.24	Breast cancer;	chr5:246221	chr5:269858~271516:-
THCA	cis	rs10875746	0.903	rs12306451	ENSG00000269514.1	RP11-370I10.12	5.3	1.77e-07	2.61e-05	0.24	0.24	Longevity (90 years and older);	chr12:48089458	chr12:48198387~48202031:+
THCA	cis	rs227275	0.554	rs223367	ENSG00000248971.2	KRT8P46	-5.3	1.77e-07	2.61e-05	-0.29	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102728746~102730171:-
THCA	cis	rs2439831	0.85	rs12441861	ENSG00000166763.7	STRCP1	5.3	1.78e-07	2.61e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:43768685	chr15:43699488~43718184:-
THCA	cis	rs3785574	0.743	rs2727334	ENSG00000240280.5	TCAM1P	-5.3	1.78e-07	2.61e-05	-0.32	-0.24	Height;	chr17:63891703	chr17:63849292~63864379:+
THCA	cis	rs7580717	0.785	rs12622630	ENSG00000224376.1	AC017104.6	5.3	1.78e-07	2.61e-05	0.27	0.24	Multiple myeloma;	chr2:231287584	chr2:231388976~231394991:+
THCA	cis	rs874628	1	rs56128769	ENSG00000268650.3	AC068499.10	5.3	1.78e-07	2.61e-05	0.28	0.24	Multiple sclerosis;	chr19:18191451	chr19:18204730~18220480:+
THCA	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-5.3	1.78e-07	2.61e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
THCA	cis	rs12908161	1	rs12911736	ENSG00000275120.1	RP11-182J1.17	5.3	1.78e-07	2.61e-05	0.28	0.24	Schizophrenia;	chr15:84696777	chr15:84599434~84606463:-
THCA	cis	rs12908161	0.959	rs12908699	ENSG00000275120.1	RP11-182J1.17	5.3	1.78e-07	2.61e-05	0.28	0.24	Schizophrenia;	chr15:84697172	chr15:84599434~84606463:-
THCA	cis	rs7412746	0.611	rs1889740	ENSG00000231073.1	RP11-316M1.3	5.3	1.78e-07	2.61e-05	0.28	0.24	Melanoma;	chr1:150827279	chr1:150973123~150975534:+
THCA	cis	rs9733	0.519	rs11800855	ENSG00000231073.1	RP11-316M1.3	5.3	1.78e-07	2.61e-05	0.28	0.24	Tonsillectomy;	chr1:150828519	chr1:150973123~150975534:+
THCA	cis	rs9425766	0.655	rs4652169	ENSG00000227373.4	RP11-160H22.5	5.3	1.78e-07	2.61e-05	0.33	0.24	Life satisfaction;	chr1:174095343	chr1:174115300~174160004:-
THCA	cis	rs8141529	0.871	rs5762877	ENSG00000226471.5	CTA-292E10.6	-5.3	1.78e-07	2.62e-05	-0.2	-0.24	Lymphocyte counts;	chr22:28881567	chr22:28800683~28848559:+
THCA	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	5.3	1.78e-07	2.62e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
THCA	cis	rs375092	0.543	rs449271	ENSG00000230658.1	KLHL7-AS1	5.3	1.78e-07	2.62e-05	0.37	0.24	Personality dimensions;	chr7:23376798	chr7:23101228~23105703:-
THCA	cis	rs1050631	0.592	rs1785921	ENSG00000260552.1	RP11-49I11.1	5.3	1.78e-07	2.62e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36157233	chr18:36179996~36187448:-
THCA	cis	rs9733	0.596	rs12063547	ENSG00000231073.1	RP11-316M1.3	-5.3	1.78e-07	2.62e-05	-0.28	-0.24	Tonsillectomy;	chr1:150701577	chr1:150973123~150975534:+
THCA	cis	rs2342371	0.883	rs11185542	ENSG00000273013.1	CTD-2002J20.1	5.3	1.78e-07	2.62e-05	0.24	0.24	Fat distribution (HIV);	chr3:196461056	chr3:196474801~196475394:+
THCA	cis	rs2243480	1	rs465359	ENSG00000232559.3	GS1-124K5.12	5.3	1.78e-07	2.62e-05	0.34	0.24	Diabetic kidney disease;	chr7:66093177	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs462853	ENSG00000232559.3	GS1-124K5.12	5.3	1.78e-07	2.62e-05	0.34	0.24	Diabetic kidney disease;	chr7:66093180	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs160642	ENSG00000232559.3	GS1-124K5.12	5.3	1.78e-07	2.62e-05	0.34	0.24	Diabetic kidney disease;	chr7:66093386	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000232559.3	GS1-124K5.12	5.3	1.78e-07	2.62e-05	0.34	0.24	Diabetic kidney disease;	chr7:66100154	chr7:66554588~66576923:-
THCA	cis	rs7160336	0.641	rs17782448	ENSG00000259065.1	RP5-1021I20.1	-5.3	1.78e-07	2.62e-05	-0.29	-0.24	Blood protein levels;	chr14:74215998	chr14:73787360~73803270:+
THCA	cis	rs2243480	1	rs781150	ENSG00000230295.1	RP11-458F8.2	-5.3	1.78e-07	2.62e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66015986	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs313798	ENSG00000230295.1	RP11-458F8.2	-5.3	1.78e-07	2.62e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66028044	chr7:66880708~66882981:+
THCA	cis	rs934734	0.725	rs2271198	ENSG00000237979.1	AC007389.1	5.3	1.78e-07	2.62e-05	0.28	0.24	Rheumatoid arthritis;	chr2:65331893	chr2:65500993~65502138:-
THCA	cis	rs1876905	0.539	rs62420362	ENSG00000230177.1	RP5-1112D6.4	-5.3	1.78e-07	2.62e-05	-0.26	-0.24	Mean corpuscular hemoglobin;	chr6:111224167	chr6:111277932~111278742:+
THCA	cis	rs2360027	0.558	rs10923605	ENSG00000231365.4	RP11-418J17.1	-5.3	1.79e-07	2.62e-05	-0.24	-0.24	Tonsillectomy;	chr1:118549333	chr1:119140396~119275973:+
THCA	cis	rs10200159	1	rs10195281	ENSG00000272606.1	RP11-554J4.1	5.3	1.79e-07	2.62e-05	0.47	0.24	Vitiligo;	chr2:55620886	chr2:55617909~55618373:+
THCA	cis	rs7267979	0.565	rs4815432	ENSG00000125804.12	FAM182A	5.3	1.79e-07	2.62e-05	0.3	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.565	rs6076364	ENSG00000125804.12	FAM182A	5.3	1.79e-07	2.62e-05	0.3	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26054655~26086917:+
THCA	cis	rs6772849	0.93	rs4467479	ENSG00000242551.2	POU5F1P6	-5.3	1.79e-07	2.63e-05	-0.3	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128650212	chr3:128674735~128677005:-
THCA	cis	rs6772849	0.93	rs12630379	ENSG00000242551.2	POU5F1P6	-5.3	1.79e-07	2.63e-05	-0.3	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128651361	chr3:128674735~128677005:-
THCA	cis	rs12908161	1	rs4643294	ENSG00000275120.1	RP11-182J1.17	5.3	1.79e-07	2.63e-05	0.28	0.24	Schizophrenia;	chr15:84707022	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs62021219	ENSG00000275120.1	RP11-182J1.17	5.3	1.79e-07	2.63e-05	0.28	0.24	Schizophrenia;	chr15:84712928	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs34900908	ENSG00000275120.1	RP11-182J1.17	5.3	1.79e-07	2.63e-05	0.28	0.24	Schizophrenia;	chr15:84714368	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs35524990	ENSG00000275120.1	RP11-182J1.17	5.3	1.79e-07	2.63e-05	0.28	0.24	Schizophrenia;	chr15:84714972	chr15:84599434~84606463:-
THCA	cis	rs481331	0.799	rs4001029	ENSG00000215146.4	RP11-313J2.1	5.3	1.79e-07	2.63e-05	0.39	0.24	Systemic juvenile idiopathic arthritis;	chr10:42470949	chr10:42331866~42367974:-
THCA	cis	rs4713118	0.513	rs149989	ENSG00000226314.6	ZNF192P1	-5.3	1.79e-07	2.63e-05	-0.28	-0.24	Parkinson's disease;	chr6:28030406	chr6:28161781~28169594:+
THCA	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	5.3	1.79e-07	2.63e-05	0.15	0.24	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
THCA	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	5.3	1.79e-07	2.63e-05	0.15	0.24	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000273142.1	RP11-458F8.4	5.3	1.79e-07	2.63e-05	0.19	0.24	Aortic root size;	chr7:66570949	chr7:66902857~66906297:+
THCA	cis	rs6433895	1	rs7558428	ENSG00000236153.1	AC104076.3	5.3	1.79e-07	2.63e-05	0.27	0.24	Lymphocyte counts;	chr2:181153827	chr2:180979427~180980090:-
THCA	cis	rs8042680	1	rs8042680	ENSG00000214432.8	AC068831.10	5.3	1.79e-07	2.63e-05	0.27	0.24	Type 2 diabetes;	chr15:90978107	chr15:91022619~91036611:+
THCA	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	5.3	1.79e-07	2.63e-05	0.22	0.24	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
THCA	cis	rs9307551	0.741	rs12640638	ENSG00000250334.4	LINC00989	-5.3	1.79e-07	2.63e-05	-0.29	-0.24	Refractive error;	chr4:79551314	chr4:79492416~79576460:+
THCA	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	5.3	1.79e-07	2.63e-05	0.15	0.24	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	5.3	1.79e-07	2.63e-05	0.15	0.24	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
THCA	cis	rs2243480	1	rs1546059	ENSG00000230295.1	RP11-458F8.2	5.3	1.79e-07	2.63e-05	0.29	0.24	Diabetic kidney disease;	chr7:66189722	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs2420170	ENSG00000230295.1	RP11-458F8.2	5.3	1.79e-07	2.63e-05	0.29	0.24	Diabetic kidney disease;	chr7:66191066	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6958289	ENSG00000230295.1	RP11-458F8.2	5.3	1.79e-07	2.63e-05	0.29	0.24	Diabetic kidney disease;	chr7:66192124	chr7:66880708~66882981:+
THCA	cis	rs1914816	1	rs2456072	ENSG00000196274.5	Metazoa_SRP	5.3	1.79e-07	2.63e-05	0.33	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76253503	chr15:76230048~76230390:-
THCA	cis	rs897984	0.542	rs73530203	ENSG00000279196.1	RP11-1072A3.3	5.3	1.79e-07	2.64e-05	0.24	0.24	Dementia with Lewy bodies;	chr16:31088538	chr16:30984630~30988270:-
THCA	cis	rs9388451	0.626	rs9385383	ENSG00000226409.1	RP11-735G4.1	-5.3	1.79e-07	2.64e-05	-0.29	-0.24	Brugada syndrome;	chr6:125765144	chr6:125370211~125374324:-
THCA	cis	rs10875746	0.859	rs11168371	ENSG00000269514.1	RP11-370I10.12	5.3	1.79e-07	2.64e-05	0.24	0.24	Longevity (90 years and older);	chr12:48043903	chr12:48198387~48202031:+
THCA	cis	rs875971	0.895	rs7788984	ENSG00000223473.2	GS1-124K5.3	5.3	1.8e-07	2.64e-05	0.16	0.24	Aortic root size;	chr7:66450629	chr7:66491049~66493566:-
THCA	cis	rs4713118	0.513	rs149972	ENSG00000226314.6	ZNF192P1	-5.3	1.8e-07	2.64e-05	-0.28	-0.24	Parkinson's disease;	chr6:28015449	chr6:28161781~28169594:+
THCA	cis	rs17292804	0.527	rs12887734	ENSG00000269910.1	RP11-73M18.10	5.3	1.8e-07	2.64e-05	0.22	0.24	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103694516~103695050:-
THCA	cis	rs1577917	0.655	rs1059307	ENSG00000220563.1	PKMP3	5.3	1.8e-07	2.64e-05	0.17	0.24	Response to antipsychotic treatment;	chr6:85678170	chr6:85659892~85660606:-
THCA	cis	rs934734	0.789	rs174847	ENSG00000234255.7	AC012370.3	-5.3	1.8e-07	2.64e-05	-0.28	-0.24	Rheumatoid arthritis;	chr2:65378060	chr2:65439888~65456571:-
THCA	cis	rs875971	0.522	rs9530	ENSG00000273142.1	RP11-458F8.4	-5.3	1.8e-07	2.64e-05	-0.2	-0.24	Aortic root size;	chr7:65960907	chr7:66902857~66906297:+
THCA	cis	rs317689	1	rs317689	ENSG00000274979.1	RP11-1143G9.5	-5.3	1.8e-07	2.64e-05	-0.29	-0.24	Response to diuretic therapy;	chr12:69333410	chr12:69326574~69331882:-
THCA	cis	rs12612619	0.667	rs1866559	ENSG00000229122.1	AGBL5-IT1	-5.3	1.8e-07	2.64e-05	-0.18	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27112718	chr2:27061038~27061815:+
THCA	cis	rs1580019	0.547	rs56981934	ENSG00000231952.3	DPY19L1P2	-5.3	1.8e-07	2.64e-05	-0.3	-0.24	Cognitive ability;	chr7:32495590	chr7:32812757~32838570:+
THCA	cis	rs1552244	0.554	rs3846169	ENSG00000180385.7	EMC3-AS1	-5.3	1.8e-07	2.64e-05	-0.23	-0.24	Alzheimer's disease;	chr3:9955370	chr3:9986893~10006990:+
THCA	cis	rs4748857	0.947	rs4748856	ENSG00000224215.1	RP11-371A19.2	5.3	1.8e-07	2.64e-05	0.27	0.24	Systemic lupus erythematosus;	chr10:23310413	chr10:23343957~23345181:+
THCA	cis	rs919433	0.963	rs1429417	ENSG00000231621.1	AC013264.2	5.3	1.8e-07	2.64e-05	0.23	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293447	chr2:197197991~197199273:+
THCA	cis	rs7760535	0.735	rs240974	ENSG00000271789.1	RP5-1112D6.7	-5.3	1.8e-07	2.65e-05	-0.23	-0.24	Metabolic traits;	chr6:111328113	chr6:111297126~111298510:+
THCA	cis	rs1479090	0.805	rs6536702	ENSG00000250027.1	RP11-563E2.2	-5.3	1.8e-07	2.65e-05	-0.24	-0.24	Lung cancer;	chr4:163106953	chr4:163108785~163119965:+
THCA	cis	rs9813712	0.595	rs1453238	ENSG00000249846.5	RP11-77P16.4	5.3	1.8e-07	2.65e-05	0.24	0.24	Response to amphetamines;	chr3:130290494	chr3:130112550~130120579:+
THCA	cis	rs1949733	0.554	rs4259044	ENSG00000205959.3	RP11-689P11.2	5.3	1.8e-07	2.65e-05	0.2	0.24	Response to antineoplastic agents;	chr4:8534461	chr4:8482270~8512610:+
THCA	cis	rs9283706	0.673	rs2006323	ENSG00000229666.1	MAST4-AS1	-5.3	1.8e-07	2.65e-05	-0.32	-0.24	Coronary artery disease;	chr5:67010164	chr5:67001383~67003953:-
THCA	cis	rs9283706	0.655	rs4016246	ENSG00000229666.1	MAST4-AS1	-5.3	1.8e-07	2.65e-05	-0.32	-0.24	Coronary artery disease;	chr5:67014364	chr5:67001383~67003953:-
THCA	cis	rs4722166	0.63	rs2091115	ENSG00000225541.1	AC002480.5	-5.3	1.81e-07	2.65e-05	-0.31	-0.24	Lung cancer;	chr7:22770547	chr7:22571607~22661792:-
THCA	cis	rs863750	0.687	rs825483	ENSG00000275389.1	RP11-214K3.24	5.3	1.81e-07	2.65e-05	0.32	0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091431	chr12:124085761~124088598:+
THCA	cis	rs9467773	1	rs9357010	ENSG00000261353.1	CTA-14H9.5	-5.3	1.81e-07	2.65e-05	-0.25	-0.24	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26527063~26527404:+
THCA	cis	rs7809615	0.515	rs10257273	ENSG00000244219.5	GS1-259H13.2	-5.3	1.81e-07	2.65e-05	-0.29	-0.24	Blood metabolite ratios;	chr7:99590966	chr7:99598066~99610813:+
THCA	cis	rs11051970	0.611	rs56146365	ENSG00000274964.1	RP11-817I4.1	-5.3	1.81e-07	2.65e-05	-0.25	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32376700	chr12:32339368~32340724:+
THCA	cis	rs9834975	0.935	rs6788318	ENSG00000272758.4	RP11-299J3.8	-5.3	1.81e-07	2.66e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122387672	chr3:122416207~122443180:+
THCA	cis	rs6806253	0.524	rs4857852	ENSG00000239405.1	TMED10P2	5.3	1.81e-07	2.66e-05	0.33	0.24	Pit-and-Fissure caries;	chr3:128512728	chr3:128538020~128538631:+
THCA	cis	rs2803122	0.745	rs9802945	ENSG00000273226.1	RP11-513M16.8	5.3	1.81e-07	2.66e-05	0.22	0.24	Pulse pressure;	chr9:19385224	chr9:19375451~19375996:+
THCA	cis	rs6840360	0.901	rs1443094	ENSG00000251611.1	RP11-610P16.1	-5.3	1.81e-07	2.66e-05	-0.17	-0.24	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151407551~151408835:-
THCA	cis	rs12893668	0.581	rs34843146	ENSG00000269940.1	RP11-73M18.7	5.3	1.81e-07	2.66e-05	0.25	0.24	Reticulocyte count;	chr14:103613527	chr14:103694560~103695170:+
THCA	cis	rs6547741	1	rs10205364	ENSG00000234072.1	AC074117.10	5.3	1.82e-07	2.66e-05	0.18	0.24	Oral cavity cancer;	chr2:27571366	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs1919125	ENSG00000234072.1	AC074117.10	5.3	1.82e-07	2.66e-05	0.18	0.24	Oral cavity cancer;	chr2:27578536	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs1919126	ENSG00000234072.1	AC074117.10	5.3	1.82e-07	2.66e-05	0.18	0.24	Oral cavity cancer;	chr2:27578551	chr2:27356246~27367622:+
THCA	cis	rs1707322	1	rs12097761	ENSG00000281133.1	AL355480.3	-5.3	1.82e-07	2.67e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs10789478	ENSG00000281133.1	AL355480.3	-5.3	1.82e-07	2.67e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs10789479	ENSG00000281133.1	AL355480.3	-5.3	1.82e-07	2.67e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.964	rs7512395	ENSG00000281133.1	AL355480.3	-5.3	1.82e-07	2.67e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45580892~45580996:-
THCA	cis	rs12681287	0.605	rs13262672	ENSG00000254231.1	CTD-2284J15.1	5.3	1.82e-07	2.67e-05	0.26	0.24	Caudate activity during reward;	chr8:86343583	chr8:86333274~86343314:-
THCA	cis	rs7493	1	rs2299264	ENSG00000233942.1	AC004012.1	5.3	1.82e-07	2.67e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417396	chr7:95471835~95473998:+
THCA	cis	rs4699052	0.787	rs2169508	ENSG00000251288.2	RP11-10L12.2	-5.3	1.82e-07	2.67e-05	-0.3	-0.24	Testicular germ cell tumor;	chr4:103145733	chr4:102751401~102752641:+
THCA	cis	rs12893668	0.703	rs4906337	ENSG00000269940.1	RP11-73M18.7	5.3	1.82e-07	2.67e-05	0.25	0.24	Reticulocyte count;	chr14:103574077	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.703	rs7140568	ENSG00000269940.1	RP11-73M18.7	5.3	1.82e-07	2.67e-05	0.25	0.24	Reticulocyte count;	chr14:103575037	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.703	rs35026580	ENSG00000269940.1	RP11-73M18.7	5.3	1.82e-07	2.67e-05	0.25	0.24	Reticulocyte count;	chr14:103576416	chr14:103694560~103695170:+
THCA	cis	rs116095464	0.558	rs9687621	ENSG00000248925.1	CTD-2083E4.6	5.3	1.82e-07	2.67e-05	0.38	0.24	Breast cancer;	chr5:229079	chr5:269858~271516:-
THCA	cis	rs2880765	0.835	rs11638498	ENSG00000259630.2	CTD-2262B20.1	-5.3	1.82e-07	2.67e-05	-0.25	-0.24	Coronary artery disease;	chr15:85479787	chr15:85415228~85415633:+
THCA	cis	rs9859260	0.961	rs41300431	ENSG00000231464.1	AC024937.4	5.3	1.82e-07	2.67e-05	0.29	0.24	Mean corpuscular volume;	chr3:196077427	chr3:195996738~195998233:+
THCA	cis	rs1552244	1	rs35741213	ENSG00000232901.1	CYCSP10	5.3	1.82e-07	2.67e-05	0.32	0.24	Alzheimer's disease;	chr3:10045977	chr3:10000647~10000940:-
THCA	cis	rs1479090	0.762	rs6829366	ENSG00000250027.1	RP11-563E2.2	-5.3	1.82e-07	2.67e-05	-0.25	-0.24	Lung cancer;	chr4:163133819	chr4:163108785~163119965:+
THCA	cis	rs7429990	0.965	rs2882668	ENSG00000228638.1	FCF1P2	-5.3	1.82e-07	2.67e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47938816	chr3:48290793~48291375:-
THCA	cis	rs7493	1	rs17876124	ENSG00000233942.1	AC004012.1	5.3	1.82e-07	2.67e-05	0.35	0.24	Yu-Zhi constitution type in type 2 diabetes;	chr7:95415946	chr7:95471835~95473998:+
THCA	cis	rs4460629	0.712	rs11264313	ENSG00000160766.13	GBAP1	-5.3	1.82e-07	2.67e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155104029	chr1:155213821~155227422:-
THCA	cis	rs5006884	0.663	rs2467233	ENSG00000167355.6	AC104389.28	-5.3	1.82e-07	2.68e-05	-0.37	-0.24	Fetal hemoglobin levels;	chr11:5363890	chr11:5304976~5505652:-
THCA	cis	rs7847628	0.587	rs1060817	ENSG00000238181.2	AHCYP2	-5.3	1.82e-07	2.68e-05	-0.3	-0.24	Birth weight;	chr9:120820914	chr9:120720673~120721972:+
THCA	cis	rs11719291	0.833	rs11715835	ENSG00000270441.1	RP11-694I15.7	5.3	1.82e-07	2.68e-05	0.33	0.24	Cognitive function;	chr3:48733299	chr3:49140086~49160851:-
THCA	cis	rs12681288	0.676	rs1562921	ENSG00000260721.1	AF067845.1	5.3	1.83e-07	2.68e-05	0.29	0.24	Schizophrenia;	chr8:1071986	chr8:1368642~1369833:-
THCA	cis	rs11051970	0.566	rs2651372	ENSG00000274964.1	RP11-817I4.1	-5.3	1.83e-07	2.68e-05	-0.24	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32430265	chr12:32339368~32340724:+
THCA	cis	rs1552244	0.554	rs3732964	ENSG00000232901.1	CYCSP10	5.3	1.83e-07	2.68e-05	0.28	0.24	Alzheimer's disease;	chr3:10007155	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs3732963	ENSG00000232901.1	CYCSP10	5.3	1.83e-07	2.68e-05	0.28	0.24	Alzheimer's disease;	chr3:10007201	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.608	rs3732962	ENSG00000232901.1	CYCSP10	5.3	1.83e-07	2.68e-05	0.28	0.24	Alzheimer's disease;	chr3:10007267	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs2272118	ENSG00000232901.1	CYCSP10	5.3	1.83e-07	2.68e-05	0.28	0.24	Alzheimer's disease;	chr3:10007603	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs58020561	ENSG00000232901.1	CYCSP10	5.3	1.83e-07	2.68e-05	0.28	0.24	Alzheimer's disease;	chr3:10012998	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs13081079	ENSG00000232901.1	CYCSP10	5.3	1.83e-07	2.68e-05	0.28	0.24	Alzheimer's disease;	chr3:10014664	chr3:10000647~10000940:-
THCA	cis	rs10256972	0.521	rs10280960	ENSG00000199023.2	MIR339	-5.3	1.83e-07	2.68e-05	-0.24	-0.24	Endometriosis;Longevity;	chr7:1064061	chr7:1022935~1023045:-
THCA	cis	rs831571	0.592	rs73120925	ENSG00000280620.1	SCAANT1	5.3	1.83e-07	2.68e-05	0.36	0.24	Type 2 diabetes;	chr3:64050922	chr3:63911518~63911772:-
THCA	cis	rs7617773	0.78	rs3731489	ENSG00000199476.1	Y_RNA	-5.3	1.83e-07	2.68e-05	-0.31	-0.24	Coronary artery disease;	chr3:48187416	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.779	rs3731487	ENSG00000199476.1	Y_RNA	-5.3	1.83e-07	2.68e-05	-0.31	-0.24	Coronary artery disease;	chr3:48188134	chr3:48288587~48288694:+
THCA	cis	rs4888671	1	rs79282796	ENSG00000261707.1	RP11-264M12.2	5.3	1.83e-07	2.68e-05	0.44	0.24	Obesity-related traits;	chr16:77750385	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs79917044	ENSG00000261707.1	RP11-264M12.2	5.3	1.83e-07	2.68e-05	0.44	0.24	Obesity-related traits;	chr16:77750514	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs74805725	ENSG00000261707.1	RP11-264M12.2	5.3	1.83e-07	2.68e-05	0.44	0.24	Obesity-related traits;	chr16:77750587	chr16:77741468~77743000:-
THCA	cis	rs919433	0.68	rs2564389	ENSG00000231621.1	AC013264.2	-5.3	1.83e-07	2.68e-05	-0.25	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197395374	chr2:197197991~197199273:+
THCA	cis	rs11051970	0.655	rs7298381	ENSG00000274964.1	RP11-817I4.1	-5.3	1.83e-07	2.68e-05	-0.25	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32377323	chr12:32339368~32340724:+
THCA	cis	rs9595908	0.929	rs34916533	ENSG00000212293.1	SNORA16	5.3	1.83e-07	2.68e-05	0.3	0.24	Body mass index;	chr13:32500537	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.965	rs9337	ENSG00000212293.1	SNORA16	5.3	1.83e-07	2.68e-05	0.3	0.24	Body mass index;	chr13:32517104	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.965	rs35193668	ENSG00000212293.1	SNORA16	5.3	1.83e-07	2.68e-05	0.3	0.24	Body mass index;	chr13:32518792	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.965	rs2239748	ENSG00000212293.1	SNORA16	5.3	1.83e-07	2.68e-05	0.3	0.24	Body mass index;	chr13:32527680	chr13:32420390~32420516:-
THCA	cis	rs9876781	0.967	rs1459249	ENSG00000229759.1	MRPS18AP1	5.3	1.83e-07	2.68e-05	0.28	0.24	Longevity;	chr3:48438208	chr3:48256350~48256938:-
THCA	cis	rs3847687	0.546	rs11061295	ENSG00000279993.1	RP11-76C10.3	5.3	1.83e-07	2.68e-05	0.26	0.24	Longevity;	chr12:131035139	chr12:131025561~131028060:-
THCA	cis	rs937213	0.676	rs2412456	ENSG00000275636.1	RP11-521C20.5	5.3	1.83e-07	2.68e-05	0.26	0.24	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39997826	chr15:40078892~40079347:+
THCA	cis	rs28476539	0.567	rs1526061	ENSG00000270480.1	RP11-57B24.1	5.3	1.83e-07	2.68e-05	0.38	0.24	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82660597	chr4:82691737~82692468:+
THCA	cis	rs6430585	0.536	rs3213892	ENSG00000231890.6	DARS-AS1	-5.3	1.83e-07	2.69e-05	-0.29	-0.24	Corneal structure;	chr2:135794947	chr2:135985176~136022593:+
THCA	cis	rs73607972	0.932	rs111886096	ENSG00000275191.1	RP11-36I17.2	-5.29	1.83e-07	2.69e-05	-0.42	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53564398	chr16:53628256~53628816:-
THCA	cis	rs30380	0.632	rs26497	ENSG00000272109.1	CTD-2260A17.3	-5.29	1.83e-07	2.69e-05	-0.33	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96803064	chr5:96804353~96806105:+
THCA	cis	rs7914558	0.752	rs7896519	ENSG00000236937.2	PTGES3P4	5.29	1.83e-07	2.69e-05	0.31	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102845595~102845950:+
THCA	cis	rs2235642	0.821	rs8051895	ENSG00000280231.1	LA16c-380F5.3	-5.29	1.83e-07	2.69e-05	-0.28	-0.24	Coronary artery disease;	chr16:1552810	chr16:1553655~1554130:-
THCA	cis	rs2235642	0.691	rs2281235	ENSG00000280231.1	LA16c-380F5.3	-5.29	1.83e-07	2.69e-05	-0.28	-0.24	Coronary artery disease;	chr16:1553534	chr16:1553655~1554130:-
THCA	cis	rs3020264	0.627	rs2912064	ENSG00000271743.1	CTD-2541M15.3	5.29	1.83e-07	2.69e-05	0.29	0.24	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631189	chr8:6615604~6617198:-
THCA	cis	rs6973609	0.524	rs10279330	ENSG00000271122.1	RP11-379H18.1	-5.29	1.83e-07	2.69e-05	-0.15	-0.24	Obesity-related traits;	chr7:35607370	chr7:35695214~35699413:+
THCA	cis	rs3847687	0.565	rs11061294	ENSG00000279993.1	RP11-76C10.3	5.29	1.83e-07	2.69e-05	0.26	0.24	Longevity;	chr12:131035116	chr12:131025561~131028060:-
THCA	cis	rs3847687	0.565	rs10848270	ENSG00000279993.1	RP11-76C10.3	5.29	1.83e-07	2.69e-05	0.26	0.24	Longevity;	chr12:131035119	chr12:131025561~131028060:-
THCA	cis	rs3847687	0.565	rs10848271	ENSG00000279993.1	RP11-76C10.3	5.29	1.83e-07	2.69e-05	0.26	0.24	Longevity;	chr12:131035158	chr12:131025561~131028060:-
THCA	cis	rs34779708	0.966	rs34630580	ENSG00000271335.4	RP11-324I22.4	5.29	1.83e-07	2.69e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs35126129	ENSG00000271335.4	RP11-324I22.4	5.29	1.83e-07	2.69e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35314552~35336401:-
THCA	cis	rs1552244	1	rs17032414	ENSG00000180385.7	EMC3-AS1	5.29	1.83e-07	2.69e-05	0.26	0.24	Alzheimer's disease;	chr3:10116618	chr3:9986893~10006990:+
THCA	cis	rs2692947	0.77	rs2315421	ENSG00000232931.4	LINC00342	5.29	1.83e-07	2.69e-05	0.19	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95831768	chr2:95807118~95816215:-
THCA	cis	rs6723226	0.882	rs13035097	ENSG00000276334.1	AL133243.1	-5.29	1.83e-07	2.69e-05	-0.28	-0.24	Intelligence (multi-trait analysis);	chr2:32611295	chr2:32521927~32523547:+
THCA	cis	rs3864261	0.515	rs12186995	ENSG00000272081.1	CTD-2376I4.2	5.29	1.83e-07	2.69e-05	0.3	0.24	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72955206~72955699:-
THCA	cis	rs6714710	0.603	rs11123974	ENSG00000230606.9	AC159540.1	-5.29	1.84e-07	2.69e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97989519	chr2:97416165~97433527:-
THCA	cis	rs714027	1	rs2412970	ENSG00000279159.1	RP3-394A18.1	5.29	1.84e-07	2.69e-05	0.16	0.24	Lymphocyte counts;	chr22:30090837	chr22:29978950~30028236:-
THCA	cis	rs9307551	1	rs3109166	ENSG00000250334.4	LINC00989	5.29	1.84e-07	2.69e-05	0.29	0.24	Refractive error;	chr4:79631045	chr4:79492416~79576460:+
THCA	cis	rs9818758	0.556	rs9880309	ENSG00000270441.1	RP11-694I15.7	5.29	1.84e-07	2.69e-05	0.33	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49266896	chr3:49140086~49160851:-
THCA	cis	rs919433	0.68	rs1116734	ENSG00000231621.1	AC013264.2	-5.29	1.84e-07	2.69e-05	-0.25	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197500319	chr2:197197991~197199273:+
THCA	cis	rs9876781	0.967	rs1870444	ENSG00000229759.1	MRPS18AP1	5.29	1.84e-07	2.69e-05	0.28	0.24	Longevity;	chr3:48445369	chr3:48256350~48256938:-
THCA	cis	rs6751744	0.889	rs12692553	ENSG00000226266.5	AC009961.3	-5.29	1.84e-07	2.69e-05	-0.31	-0.24	Dysphagia;	chr2:159534337	chr2:159670708~159712435:-
THCA	cis	rs3742264	0.784	rs9534317	ENSG00000235903.6	CPB2-AS1	-5.29	1.84e-07	2.69e-05	-0.33	-0.24	Blood protein levels;	chr13:46088505	chr13:46052806~46113332:+
THCA	cis	rs11096990	0.964	rs35494908	ENSG00000249685.1	RP11-360F5.3	-5.29	1.84e-07	2.69e-05	-0.3	-0.24	Cognitive function;	chr4:39252574	chr4:39133913~39135608:+
THCA	cis	rs1552244	0.938	rs66915020	ENSG00000180385.7	EMC3-AS1	5.29	1.84e-07	2.7e-05	0.26	0.24	Alzheimer's disease;	chr3:10068490	chr3:9986893~10006990:+
THCA	cis	rs12935418	0.616	rs874053	ENSG00000278985.1	RP11-303E16.9	5.29	1.84e-07	2.7e-05	0.26	0.24	Mean corpuscular volume;	chr16:80972210	chr16:80982319~80984094:-
THCA	cis	rs2562456	0.833	rs7260065	ENSG00000268081.1	RP11-678G14.2	5.29	1.84e-07	2.7e-05	0.4	0.24	Pain;	chr19:21334175	chr19:21554640~21569237:-
THCA	cis	rs71537559	1	rs71537559	ENSG00000219392.1	RP1-265C24.5	-5.29	1.84e-07	2.7e-05	-0.48	-0.24	Squamous cell lung carcinoma;	chr6:27342000	chr6:28115628~28116551:+
THCA	cis	rs2243480	1	rs4149468	ENSG00000232559.3	GS1-124K5.12	5.29	1.84e-07	2.7e-05	0.36	0.24	Diabetic kidney disease;	chr7:66360703	chr7:66554588~66576923:-
THCA	cis	rs8062405	1	rs8062405	ENSG00000278665.1	RP11-666O2.4	-5.29	1.84e-07	2.7e-05	-0.26	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28599241~28601881:-
THCA	cis	rs3213758	1	rs12444460	ENSG00000275191.1	RP11-36I17.2	-5.29	1.84e-07	2.7e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53603142	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs77008584	ENSG00000275191.1	RP11-36I17.2	-5.29	1.84e-07	2.7e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53605296	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs3213758	ENSG00000275191.1	RP11-36I17.2	5.29	1.84e-07	2.7e-05	0.48	0.24	Vitiligo (non-segmental);	chr16:53605526	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.881	rs75524573	ENSG00000275191.1	RP11-36I17.2	-5.29	1.84e-07	2.7e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53623045	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs75586284	ENSG00000275191.1	RP11-36I17.2	-5.29	1.84e-07	2.7e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53641580	chr16:53628256~53628816:-
THCA	cis	rs755249	0.567	rs16826000	ENSG00000228060.1	RP11-69E11.8	-5.29	1.84e-07	2.7e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39565160~39573203:+
THCA	cis	rs755249	0.567	rs16826009	ENSG00000228060.1	RP11-69E11.8	-5.29	1.84e-07	2.7e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39565160~39573203:+
THCA	cis	rs911119	0.955	rs12625716	ENSG00000270001.1	RP11-218C14.8	5.29	1.84e-07	2.7e-05	0.36	0.24	Chronic kidney disease;	chr20:23626208	chr20:23631826~23632316:-
THCA	cis	rs9990333	0.544	rs11915082	ENSG00000242086.7	LINC00969	5.29	1.84e-07	2.7e-05	0.24	0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195658062~195739964:+
THCA	cis	rs8141529	0.748	rs5762874	ENSG00000272858.1	CTA-292E10.8	-5.29	1.84e-07	2.7e-05	-0.24	-0.24	Lymphocyte counts;	chr22:28873670	chr22:28814914~28815662:+
THCA	cis	rs2243480	1	rs4149468	ENSG00000230295.1	RP11-458F8.2	-5.29	1.85e-07	2.71e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66360703	chr7:66880708~66882981:+
THCA	cis	rs1334894	0.71	rs9689798	ENSG00000228559.1	RP3-340B19.3	-5.29	1.85e-07	2.71e-05	-0.42	-0.24	Coronary artery disease;	chr6:35505247	chr6:35544632~35545669:+
THCA	cis	rs11992162	0.967	rs10108320	ENSG00000254948.1	OR7E158P	5.29	1.85e-07	2.71e-05	0.29	0.24	Monocyte count;	chr8:11974754	chr8:11919900~11920809:-
THCA	cis	rs987724	0.593	rs3910072	ENSG00000240875.4	LINC00886	-5.29	1.85e-07	2.71e-05	-0.19	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156843137	chr3:156747346~156817062:-
THCA	cis	rs987724	0.551	rs9876010	ENSG00000240875.4	LINC00886	-5.29	1.85e-07	2.71e-05	-0.19	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156845715	chr3:156747346~156817062:-
THCA	cis	rs987724	0.593	rs7652112	ENSG00000240875.4	LINC00886	-5.29	1.85e-07	2.71e-05	-0.19	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156854774	chr3:156747346~156817062:-
THCA	cis	rs987724	0.593	rs2060015	ENSG00000240875.4	LINC00886	-5.29	1.85e-07	2.71e-05	-0.19	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856141	chr3:156747346~156817062:-
THCA	cis	rs4648045	0.861	rs230491	ENSG00000246560.2	RP11-10L12.4	-5.29	1.85e-07	2.71e-05	-0.29	-0.24	Lymphocyte percentage of white cells;	chr4:102563458	chr4:102828055~102844075:+
THCA	cis	rs75920871	0.528	rs7930264	ENSG00000254851.1	RP11-109L13.1	5.29	1.85e-07	2.71e-05	0.34	0.24	Subjective well-being;	chr11:117000050	chr11:117135528~117138582:+
THCA	cis	rs76935404	0.736	rs57274441	ENSG00000256612.6	CYP2B7P	-5.29	1.85e-07	2.71e-05	-0.29	-0.24	nicotine metabolite ratio in current smokers;	chr19:40925517	chr19:40924219~40950660:+
THCA	cis	rs755249	0.833	rs61779313	ENSG00000228060.1	RP11-69E11.8	-5.29	1.85e-07	2.71e-05	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39565160~39573203:+
THCA	cis	rs12893668	0.581	rs34843146	ENSG00000269958.1	RP11-73M18.8	5.29	1.85e-07	2.71e-05	0.23	0.24	Reticulocyte count;	chr14:103613527	chr14:103696353~103697163:+
THCA	cis	rs2243480	1	rs316322	ENSG00000230295.1	RP11-458F8.2	-5.29	1.85e-07	2.71e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:66146246	chr7:66880708~66882981:+
THCA	cis	rs10200159	1	rs17047094	ENSG00000272606.1	RP11-554J4.1	5.29	1.85e-07	2.71e-05	0.46	0.24	Vitiligo;	chr2:55570701	chr2:55617909~55618373:+
THCA	cis	rs2179367	0.632	rs12154153	ENSG00000268592.3	RAET1E-AS1	5.29	1.85e-07	2.72e-05	0.34	0.24	Dupuytren's disease;	chr6:149401686	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs11155649	ENSG00000268592.3	RAET1E-AS1	5.29	1.85e-07	2.72e-05	0.34	0.24	Dupuytren's disease;	chr6:149405830	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs11155650	ENSG00000268592.3	RAET1E-AS1	5.29	1.85e-07	2.72e-05	0.34	0.24	Dupuytren's disease;	chr6:149407613	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs11155651	ENSG00000268592.3	RAET1E-AS1	5.29	1.85e-07	2.72e-05	0.34	0.24	Dupuytren's disease;	chr6:149408146	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs7896	ENSG00000268592.3	RAET1E-AS1	5.29	1.85e-07	2.72e-05	0.34	0.24	Dupuytren's disease;	chr6:149410340	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12196750	ENSG00000268592.3	RAET1E-AS1	5.29	1.85e-07	2.72e-05	0.34	0.24	Dupuytren's disease;	chr6:149413335	chr6:149863494~149919507:+
THCA	cis	rs6772849	0.896	rs35535737	ENSG00000242551.2	POU5F1P6	-5.29	1.85e-07	2.72e-05	-0.31	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128674735~128677005:-
THCA	cis	rs2018683	0.768	rs10282015	ENSG00000272568.4	CTB-113D17.1	5.29	1.85e-07	2.72e-05	0.22	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.77	rs10951208	ENSG00000272568.4	CTB-113D17.1	5.29	1.85e-07	2.72e-05	0.22	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28979967~29013367:+
THCA	cis	rs1198430	0.562	rs7522616	ENSG00000232482.2	RP4-654C18.1	-5.29	1.85e-07	2.72e-05	-0.34	-0.24	Total cholesterol levels;	chr1:23468421	chr1:23410832~23412146:+
THCA	cis	rs875971	0.545	rs316306	ENSG00000232546.1	RP11-458F8.1	-5.29	1.85e-07	2.72e-05	-0.23	-0.24	Aortic root size;	chr7:66153687	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.708	rs781141	ENSG00000230295.1	RP11-458F8.2	-5.29	1.85e-07	2.72e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65973566	chr7:66880708~66882981:+
THCA	cis	rs748404	0.666	rs7176923	ENSG00000205771.5	CATSPER2P1	-5.29	1.85e-07	2.72e-05	-0.3	-0.24	Lung cancer;	chr15:43317679	chr15:43726918~43747094:-
THCA	cis	rs3950186	0.794	rs4310046	ENSG00000215124.2	RP3-420J14.1	5.29	1.85e-07	2.72e-05	0.28	0.24	Anxiety and major depressive disorder;	chr6:11826371	chr6:11861626~11862970:-
THCA	cis	rs1707322	0.963	rs4630155	ENSG00000281133.1	AL355480.3	-5.29	1.86e-07	2.72e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs4508055	ENSG00000281133.1	AL355480.3	-5.29	1.86e-07	2.72e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs12076580	ENSG00000281133.1	AL355480.3	-5.29	1.86e-07	2.72e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45580892~45580996:-
THCA	cis	rs2348418	0.733	rs2169752	ENSG00000247934.4	RP11-967K21.1	-5.29	1.86e-07	2.72e-05	-0.2	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28163298~28190738:-
THCA	cis	rs875971	1	rs1144895	ENSG00000223473.2	GS1-124K5.3	-5.29	1.86e-07	2.72e-05	-0.16	-0.24	Aortic root size;	chr7:66076320	chr7:66491049~66493566:-
THCA	cis	rs6928977	0.869	rs6912933	ENSG00000231028.7	LINC00271	5.29	1.86e-07	2.72e-05	0.18	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306396	chr6:135497801~135716055:+
THCA	cis	rs2067615	0.599	rs1579808	ENSG00000260329.1	RP11-412D9.4	5.29	1.86e-07	2.72e-05	0.21	0.24	Heart rate;	chr12:106846169	chr12:106954029~106955497:-
THCA	cis	rs4950322	0.515	rs11239954	ENSG00000278811.3	LINC00624	5.29	1.86e-07	2.72e-05	0.28	0.24	Protein quantitative trait loci;	chr1:147246045	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.515	rs76327075	ENSG00000278811.3	LINC00624	5.29	1.86e-07	2.72e-05	0.28	0.24	Protein quantitative trait loci;	chr1:147246319	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.515	rs11239958	ENSG00000278811.3	LINC00624	5.29	1.86e-07	2.72e-05	0.28	0.24	Protein quantitative trait loci;	chr1:147247454	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.515	rs12060046	ENSG00000278811.3	LINC00624	5.29	1.86e-07	2.72e-05	0.28	0.24	Protein quantitative trait loci;	chr1:147249278	chr1:147258885~147517875:-
THCA	cis	rs7772486	0.686	rs10872579	ENSG00000270638.1	RP3-466P17.1	5.29	1.86e-07	2.72e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145735570~145737218:+
THCA	cis	rs7577696	0.85	rs428002	ENSG00000276334.1	AL133243.1	5.29	1.86e-07	2.72e-05	0.25	0.24	Inflammatory biomarkers;	chr2:32262705	chr2:32521927~32523547:+
THCA	cis	rs860295	0.665	rs12079134	ENSG00000160766.13	GBAP1	-5.29	1.86e-07	2.72e-05	-0.28	-0.24	Body mass index;	chr1:155496993	chr1:155213821~155227422:-
THCA	cis	rs7726354	1	rs73122138	ENSG00000271828.1	CTD-2310F14.1	5.29	1.86e-07	2.72e-05	0.61	0.24	Breast cancer (early onset);	chr5:56972122	chr5:56927874~56929573:+
THCA	cis	rs4908760	0.827	rs2401138	ENSG00000232912.4	RP5-1115A15.1	-5.29	1.86e-07	2.72e-05	-0.23	-0.24	Vitiligo;	chr1:8644000	chr1:8424645~8434838:+
THCA	cis	rs2439831	0.681	rs825740	ENSG00000275601.1	AC011330.13	-5.29	1.86e-07	2.72e-05	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43300210	chr15:43642389~43643023:-
THCA	cis	rs7772486	0.686	rs4896833	ENSG00000270638.1	RP3-466P17.1	5.29	1.86e-07	2.73e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145735570~145737218:+
THCA	cis	rs9834975	1	rs9818363	ENSG00000272758.4	RP11-299J3.8	-5.29	1.86e-07	2.73e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122393444	chr3:122416207~122443180:+
THCA	cis	rs438465	0.685	rs9393169	ENSG00000226194.4	RP1-137D17.1	-5.29	1.86e-07	2.73e-05	-0.39	-0.24	Corneal astigmatism;	chr6:169339703	chr6:169369998~169388385:-
THCA	cis	rs3950186	0.834	rs1569734	ENSG00000215124.2	RP3-420J14.1	5.29	1.86e-07	2.73e-05	0.27	0.24	Anxiety and major depressive disorder;	chr6:11825679	chr6:11861626~11862970:-
THCA	cis	rs1538970	0.781	rs12049503	ENSG00000234329.1	RP11-767N6.2	5.29	1.86e-07	2.73e-05	0.24	0.24	Platelet count;	chr1:45555884	chr1:45651039~45651826:-
THCA	cis	rs7523875	1	rs56381832	ENSG00000153363.11	LINC00467	-5.29	1.86e-07	2.73e-05	-0.27	-0.24	Mean corpuscular volume;	chr1:211227037	chr1:211382803~211435333:+
THCA	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	5.29	1.86e-07	2.73e-05	0.15	0.24	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
THCA	cis	rs1979679	0.918	rs78500430	ENSG00000278733.1	RP11-425D17.1	5.29	1.86e-07	2.73e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28369828	chr12:28185625~28186190:-
THCA	cis	rs7688540	0.771	rs6599318	ENSG00000211553.1	AC253576.2	-5.29	1.86e-07	2.73e-05	-0.36	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:136461~136568:+
THCA	cis	rs12612619	0.64	rs7560633	ENSG00000229122.1	AGBL5-IT1	-5.29	1.86e-07	2.73e-05	-0.17	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27119199	chr2:27061038~27061815:+
THCA	cis	rs5751901	0.614	rs4820599	ENSG00000215481.7	BCRP3	-5.29	1.86e-07	2.73e-05	-0.2	-0.24	Protein quantitative trait loci;	chr22:24594246	chr22:24632915~24653356:+
THCA	cis	rs6445975	0.666	rs4681844	ENSG00000272360.1	RP11-359I18.5	-5.29	1.87e-07	2.73e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr3:58346719	chr3:58490830~58491291:-
THCA	cis	rs2354432	0.607	rs4950385	ENSG00000226015.2	CCT8P1	5.29	1.87e-07	2.73e-05	0.44	0.24	Mitochondrial DNA levels;	chr1:147184713	chr1:147203276~147204932:-
THCA	cis	rs2354432	0.607	rs6703847	ENSG00000226015.2	CCT8P1	5.29	1.87e-07	2.73e-05	0.44	0.24	Mitochondrial DNA levels;	chr1:147197865	chr1:147203276~147204932:-
THCA	cis	rs2354432	0.607	rs894469	ENSG00000226015.2	CCT8P1	5.29	1.87e-07	2.73e-05	0.44	0.24	Mitochondrial DNA levels;	chr1:147201324	chr1:147203276~147204932:-
THCA	cis	rs2354432	0.607	rs7537279	ENSG00000226015.2	CCT8P1	5.29	1.87e-07	2.73e-05	0.44	0.24	Mitochondrial DNA levels;	chr1:147202060	chr1:147203276~147204932:-
THCA	cis	rs2354432	0.607	rs7553584	ENSG00000226015.2	CCT8P1	-5.29	1.87e-07	2.73e-05	-0.44	-0.24	Mitochondrial DNA levels;	chr1:147221837	chr1:147203276~147204932:-
THCA	cis	rs916888	0.61	rs199529	ENSG00000261575.2	RP11-259G18.1	5.29	1.87e-07	2.73e-05	0.32	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46267037~46268694:+
THCA	cis	rs7119	0.651	rs34829483	ENSG00000259362.2	RP11-307C19.1	-5.29	1.87e-07	2.73e-05	-0.35	-0.24	Type 2 diabetes;	chr15:77543644	chr15:77525540~77534110:+
THCA	cis	rs6714710	0.603	rs956039	ENSG00000230606.9	AC159540.1	-5.29	1.87e-07	2.73e-05	-0.28	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97800385	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs717417	ENSG00000230606.9	AC159540.1	-5.29	1.87e-07	2.73e-05	-0.28	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97800387	chr2:97416165~97433527:-
THCA	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	5.29	1.87e-07	2.73e-05	0.27	0.24	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
THCA	cis	rs1552244	1	rs7622966	ENSG00000180385.7	EMC3-AS1	5.29	1.87e-07	2.73e-05	0.26	0.24	Alzheimer's disease;	chr3:10098149	chr3:9986893~10006990:+
THCA	cis	rs8028182	0.525	rs9920028	ENSG00000260269.4	CTD-2323K18.1	-5.29	1.87e-07	2.74e-05	-0.36	-0.24	Sudden cardiac arrest;	chr15:75635376	chr15:75527150~75601205:-
THCA	cis	rs6441961	0.501	rs6441958	ENSG00000223552.1	RP11-24F11.2	5.29	1.87e-07	2.74e-05	0.23	0.24	Celiac disease;	chr3:46299844	chr3:46364955~46407059:-
THCA	cis	rs6802315	0.573	rs7635993	ENSG00000272087.1	RP11-379F4.7	5.29	1.87e-07	2.74e-05	0.21	0.24	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158693120~158693768:-
THCA	cis	rs899997	1	rs11072800	ENSG00000261143.1	ADAMTS7P3	-5.29	1.87e-07	2.74e-05	-0.31	-0.24	Coronary artery disease or large artery stroke;	chr15:78753515	chr15:77976042~77993057:+
THCA	cis	rs875971	0.545	rs67775320	ENSG00000228409.4	CCT6P1	-5.29	1.87e-07	2.74e-05	-0.2	-0.24	Aortic root size;	chr7:66193792	chr7:65751142~65763354:+
THCA	cis	rs7674212	0.57	rs2711899	ENSG00000251288.2	RP11-10L12.2	-5.29	1.87e-07	2.74e-05	-0.3	-0.24	Type 2 diabetes;	chr4:103141257	chr4:102751401~102752641:+
THCA	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-5.29	1.87e-07	2.74e-05	-0.32	-0.24	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
THCA	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-5.29	1.87e-07	2.74e-05	-0.32	-0.24	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
THCA	cis	rs6968419	0.755	rs6966770	ENSG00000237870.5	AC073130.1	5.29	1.87e-07	2.74e-05	0.26	0.24	Intraocular pressure;	chr7:116255664	chr7:116275606~116286734:-
THCA	cis	rs4356203	1	rs4356203	ENSG00000272034.1	SNORD14A	5.29	1.87e-07	2.74e-05	0.25	0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17138601	chr11:17074654~17074744:-
THCA	cis	rs2337406	1	rs11846866	ENSG00000211974.3	IGHV2-70	-5.29	1.87e-07	2.74e-05	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106703003	chr14:106723574~106724093:-
THCA	cis	rs72945132	0.714	rs72947077	ENSG00000254604.1	AP000487.6	-5.29	1.87e-07	2.74e-05	-0.45	-0.24	Coronary artery disease;	chr11:70351325	chr11:70282367~70363368:-
THCA	cis	rs16852403	0.548	rs28760457	ENSG00000224687.1	RASAL2-AS1	5.29	1.87e-07	2.74e-05	0.36	0.24	Childhood ear infection;	chr1:178205350	chr1:178091508~178093984:-
THCA	cis	rs9876781	0.967	rs1870444	ENSG00000244380.1	RP11-24C3.2	5.29	1.87e-07	2.74e-05	0.28	0.24	Longevity;	chr3:48445369	chr3:48440352~48446656:-
THCA	cis	rs11634944	0.643	rs975698	ENSG00000257151.1	PWAR6	5.29	1.87e-07	2.74e-05	0.18	0.24	Interleukin-8 levels;	chr15:25015360	chr15:25031873~25036490:+
THCA	cis	rs1552244	1	rs6789156	ENSG00000232901.1	CYCSP10	5.29	1.87e-07	2.74e-05	0.31	0.24	Alzheimer's disease;	chr3:10082436	chr3:10000647~10000940:-
THCA	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-5.29	1.87e-07	2.74e-05	-0.49	-0.24	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
THCA	cis	rs2921073	0.604	rs2979140	ENSG00000253981.4	ALG1L13P	5.29	1.87e-07	2.74e-05	0.22	0.24	Parkinson's disease;	chr8:8409692	chr8:8236003~8244667:-
THCA	cis	rs9307551	0.619	rs4975054	ENSG00000250334.4	LINC00989	-5.29	1.87e-07	2.74e-05	-0.29	-0.24	Refractive error;	chr4:79549923	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.619	rs4975055	ENSG00000250334.4	LINC00989	-5.29	1.87e-07	2.74e-05	-0.29	-0.24	Refractive error;	chr4:79550097	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.619	rs10033410	ENSG00000250334.4	LINC00989	-5.29	1.87e-07	2.74e-05	-0.29	-0.24	Refractive error;	chr4:79550314	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.584	rs10022314	ENSG00000250334.4	LINC00989	-5.29	1.87e-07	2.74e-05	-0.29	-0.24	Refractive error;	chr4:79550505	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.656	rs11098741	ENSG00000250334.4	LINC00989	-5.29	1.87e-07	2.74e-05	-0.29	-0.24	Refractive error;	chr4:79551480	chr4:79492416~79576460:+
THCA	cis	rs17594362	0.887	rs34485273	ENSG00000264190.1	MIR5006	5.29	1.88e-07	2.74e-05	0.37	0.24	Multiple sclerosis;	chr13:41575556	chr13:41568286~41568395:-
THCA	cis	rs4950322	1	rs72694715	ENSG00000278811.3	LINC00624	5.29	1.88e-07	2.75e-05	0.32	0.24	Protein quantitative trait loci;	chr1:147368468	chr1:147258885~147517875:-
THCA	cis	rs12681287	0.64	rs6471309	ENSG00000254231.1	CTD-2284J15.1	5.29	1.88e-07	2.75e-05	0.26	0.24	Caudate activity during reward;	chr8:86375531	chr8:86333274~86343314:-
THCA	cis	rs17214007	0.735	rs8045778	ENSG00000263335.1	AF001548.5	5.29	1.88e-07	2.75e-05	0.31	0.24	Cognitive function;	chr16:15784395	chr16:15726674~15732993:+
THCA	cis	rs2253762	0.54	rs11200351	ENSG00000276742.1	RP11-500G22.4	5.29	1.88e-07	2.75e-05	0.34	0.24	Breast cancer;	chr10:122029957	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs11200353	ENSG00000276742.1	RP11-500G22.4	5.29	1.88e-07	2.75e-05	0.34	0.24	Breast cancer;	chr10:122030181	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs10887053	ENSG00000276742.1	RP11-500G22.4	5.29	1.88e-07	2.75e-05	0.34	0.24	Breast cancer;	chr10:122030997	chr10:121956782~121957098:+
THCA	cis	rs728616	0.681	rs35014047	ENSG00000225484.5	NUTM2B-AS1	-5.29	1.88e-07	2.75e-05	-0.41	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80152641	chr10:79663088~79826594:-
THCA	cis	rs1552244	0.872	rs6792951	ENSG00000180385.7	EMC3-AS1	5.29	1.88e-07	2.75e-05	0.26	0.24	Alzheimer's disease;	chr3:10077919	chr3:9986893~10006990:+
THCA	cis	rs11118620	0.81	rs1603047	ENSG00000257551.1	HLX-AS1	5.29	1.88e-07	2.75e-05	0.32	0.24	Heart failure;	chr1:220849953	chr1:220832763~220880140:-
THCA	cis	rs11749327	0.719	rs72698512	ENSG00000188242.4	PP7080	5.29	1.88e-07	2.75e-05	0.27	0.24	Hemoglobin concentration;Hypospadias;	chr5:467028	chr5:466124~473098:-
THCA	cis	rs11749327	0.688	rs72698513	ENSG00000188242.4	PP7080	5.29	1.88e-07	2.75e-05	0.27	0.24	Hemoglobin concentration;Hypospadias;	chr5:467029	chr5:466124~473098:-
THCA	cis	rs11749327	0.678	rs72698514	ENSG00000188242.4	PP7080	5.29	1.88e-07	2.75e-05	0.27	0.24	Hemoglobin concentration;Hypospadias;	chr5:468629	chr5:466124~473098:-
THCA	cis	rs12188164	0.507	rs115438441	ENSG00000188242.4	PP7080	5.29	1.88e-07	2.75e-05	0.27	0.24	Cystic fibrosis severity;	chr5:469537	chr5:466124~473098:-
THCA	cis	rs11749327	0.719	rs11169	ENSG00000188242.4	PP7080	5.29	1.88e-07	2.75e-05	0.27	0.24	Hemoglobin concentration;Hypospadias;	chr5:470548	chr5:466124~473098:-
THCA	cis	rs11749327	0.719	rs3315	ENSG00000188242.4	PP7080	5.29	1.88e-07	2.75e-05	0.27	0.24	Hemoglobin concentration;Hypospadias;	chr5:470580	chr5:466124~473098:-
THCA	cis	rs11749327	0.719	rs72698516	ENSG00000188242.4	PP7080	5.29	1.88e-07	2.75e-05	0.27	0.24	Hemoglobin concentration;Hypospadias;	chr5:472106	chr5:466124~473098:-
THCA	cis	rs875971	1	rs6945843	ENSG00000223473.2	GS1-124K5.3	-5.29	1.88e-07	2.75e-05	-0.16	-0.24	Aortic root size;	chr7:66269796	chr7:66491049~66493566:-
THCA	cis	rs10895275	0.961	rs17097560	ENSG00000277459.1	RP11-732A21.3	-5.29	1.88e-07	2.75e-05	-0.19	-0.24	Migraine;	chr11:102228764	chr11:102109827~102110457:-
THCA	cis	rs2360027	0.578	rs7555917	ENSG00000231365.4	RP11-418J17.1	-5.29	1.88e-07	2.75e-05	-0.24	-0.24	Tonsillectomy;	chr1:118536620	chr1:119140396~119275973:+
THCA	cis	rs6740322	1	rs6740322	ENSG00000234936.1	AC010883.5	5.29	1.88e-07	2.75e-05	0.27	0.24	Coronary artery disease;	chr2:43334790	chr2:43229573~43233394:+
THCA	cis	rs875971	1	rs1167411	ENSG00000223473.2	GS1-124K5.3	-5.29	1.88e-07	2.75e-05	-0.16	-0.24	Aortic root size;	chr7:66074277	chr7:66491049~66493566:-
THCA	cis	rs7523875	0.572	rs1419090	ENSG00000153363.11	LINC00467	5.29	1.88e-07	2.75e-05	0.29	0.24	Mean corpuscular volume;	chr1:211468608	chr1:211382803~211435333:+
THCA	cis	rs4968361	0.892	rs58003080	ENSG00000266992.1	DHX40P1	5.29	1.88e-07	2.75e-05	0.4	0.24	Schizophrenia;	chr17:59437596	chr17:59976009~60002384:-
THCA	cis	rs4650994	0.816	rs2811301	ENSG00000273384.1	RP5-1098D14.1	-5.29	1.88e-07	2.75e-05	-0.3	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178625061	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.816	rs2761470	ENSG00000273384.1	RP5-1098D14.1	-5.29	1.88e-07	2.75e-05	-0.3	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178626898	chr1:178651706~178652282:+
THCA	cis	rs116095464	0.558	rs13354585	ENSG00000248925.1	CTD-2083E4.6	5.29	1.88e-07	2.76e-05	0.34	0.24	Breast cancer;	chr5:242148	chr5:269858~271516:-
THCA	cis	rs7560272	0.644	rs6749680	ENSG00000163016.8	ALMS1P	-5.29	1.88e-07	2.76e-05	-0.31	-0.24	Schizophrenia;	chr2:73458725	chr2:73644919~73685576:+
THCA	cis	rs4713118	0.513	rs156738	ENSG00000226314.6	ZNF192P1	-5.29	1.88e-07	2.76e-05	-0.28	-0.24	Parkinson's disease;	chr6:28046247	chr6:28161781~28169594:+
THCA	cis	rs317865	0.737	rs28516589	ENSG00000263327.5	TAPT1-AS1	-5.29	1.88e-07	2.76e-05	-0.43	-0.24	Kidney disease (early stage) in type 1 diabetes;	chr4:16232488	chr4:16226685~16320140:+
THCA	cis	rs7772486	0.686	rs702305	ENSG00000270638.1	RP3-466P17.1	-5.29	1.88e-07	2.76e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs857875	ENSG00000270638.1	RP3-466P17.1	-5.29	1.88e-07	2.76e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145735570~145737218:+
THCA	cis	rs2354432	0.607	rs10453880	ENSG00000226015.2	CCT8P1	5.29	1.89e-07	2.76e-05	0.44	0.24	Mitochondrial DNA levels;	chr1:147222097	chr1:147203276~147204932:-
THCA	cis	rs79040073	0.637	rs17394420	ENSG00000259531.2	RP11-295H24.3	5.29	1.89e-07	2.76e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49128619	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs17473148	ENSG00000259531.2	RP11-295H24.3	5.29	1.89e-07	2.76e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49137213	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs74798636	ENSG00000259531.2	RP11-295H24.3	5.29	1.89e-07	2.76e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49143146	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs79455310	ENSG00000259531.2	RP11-295H24.3	5.29	1.89e-07	2.76e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:49146918	chr15:49365124~49366685:-
THCA	cis	rs9475752	0.793	rs35735810	ENSG00000231441.1	RP11-472M19.2	5.29	1.89e-07	2.76e-05	0.32	0.24	Menarche (age at onset);	chr6:56978917	chr6:56844002~56864078:+
THCA	cis	rs860295	0.702	rs11264380	ENSG00000160766.13	GBAP1	-5.29	1.89e-07	2.76e-05	-0.28	-0.24	Body mass index;	chr1:155550353	chr1:155213821~155227422:-
THCA	cis	rs3213758	1	rs1078620	ENSG00000275191.1	RP11-36I17.2	5.29	1.89e-07	2.76e-05	0.47	0.24	Vitiligo (non-segmental);	chr16:53630685	chr16:53628256~53628816:-
THCA	cis	rs7403037	1	rs12904329	ENSG00000259905.4	PWRN1	5.29	1.89e-07	2.76e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24594723	chr15:24493137~24652130:+
THCA	cis	rs7403037	1	rs12372990	ENSG00000259905.4	PWRN1	5.29	1.89e-07	2.76e-05	0.26	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24594990	chr15:24493137~24652130:+
THCA	cis	rs1823913	1	rs10445783	ENSG00000227542.1	AC092614.2	-5.29	1.89e-07	2.76e-05	-0.29	-0.24	Obesity-related traits;	chr2:191236772	chr2:191229165~191246172:-
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000273796.1	LL21NC02-21A1.1	-5.29	1.89e-07	2.76e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45403809~45404369:-
THCA	cis	rs7208859	0.623	rs9914242	ENSG00000280069.1	CTD-2349P21.3	-5.29	1.89e-07	2.77e-05	-0.37	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30738182~30740275:+
THCA	cis	rs4915077	1	rs4915077	ENSG00000230489.1	VAV3-AS1	5.29	1.89e-07	2.77e-05	0.39	0.24	Hypothyroidism;	chr1:107823394	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs4359051	ENSG00000230489.1	VAV3-AS1	5.29	1.89e-07	2.77e-05	0.39	0.24	Hypothyroidism;	chr1:107830792	chr1:107964443~107994607:+
THCA	cis	rs2299587	0.689	rs12546237	ENSG00000253671.1	RP11-806O11.1	-5.29	1.89e-07	2.77e-05	-0.28	-0.24	Economic and political preferences;	chr8:17939546	chr8:17808941~17820868:+
THCA	cis	rs9876781	1	rs2242150	ENSG00000244380.1	RP11-24C3.2	-5.29	1.89e-07	2.77e-05	-0.28	-0.24	Longevity;	chr3:48464565	chr3:48440352~48446656:-
THCA	cis	rs853679	0.657	rs1778483	ENSG00000219392.1	RP1-265C24.5	-5.29	1.89e-07	2.77e-05	-0.27	-0.24	Depression;	chr6:28273214	chr6:28115628~28116551:+
THCA	cis	rs853679	0.657	rs1778482	ENSG00000219392.1	RP1-265C24.5	-5.29	1.89e-07	2.77e-05	-0.27	-0.24	Depression;	chr6:28273215	chr6:28115628~28116551:+
THCA	cis	rs7824557	0.767	rs2060463	ENSG00000154316.13	TDH	-5.29	1.89e-07	2.77e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11304101	chr8:11339637~11368452:+
THCA	cis	rs7702057	0.53	rs17138841	ENSG00000271918.1	CTD-2287O16.5	5.29	1.89e-07	2.77e-05	0.26	0.24	Amyotrophic lateral sclerosis;	chr5:116077109	chr5:116083807~116085416:-
THCA	cis	rs3213758	1	rs12597471	ENSG00000275191.1	RP11-36I17.2	5.29	1.89e-07	2.77e-05	0.47	0.24	Vitiligo (non-segmental);	chr16:53644517	chr16:53628256~53628816:-
THCA	cis	rs76935404	0.868	rs73034462	ENSG00000256612.6	CYP2B7P	-5.29	1.89e-07	2.77e-05	-0.3	-0.24	nicotine metabolite ratio in current smokers;	chr19:40912229	chr19:40924219~40950660:+
THCA	cis	rs76935404	0.899	rs73034465	ENSG00000256612.6	CYP2B7P	-5.29	1.89e-07	2.77e-05	-0.3	-0.24	nicotine metabolite ratio in current smokers;	chr19:40913170	chr19:40924219~40950660:+
THCA	cis	rs17767392	0.846	rs61991200	ENSG00000259146.3	RP1-261D10.2	5.29	1.89e-07	2.77e-05	0.29	0.24	Mitral valve prolapse;	chr14:71295852	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.846	rs2332576	ENSG00000259146.3	RP1-261D10.2	5.29	1.89e-07	2.77e-05	0.29	0.24	Mitral valve prolapse;	chr14:71298790	chr14:71292729~71321814:-
THCA	cis	rs2980436	1	rs2980436	ENSG00000254153.1	CTA-398F10.2	5.29	1.89e-07	2.77e-05	0.24	0.24	Schizophrenia;	chr8:8234503	chr8:8456909~8461337:-
THCA	cis	rs752010	0.619	rs6703992	ENSG00000230638.4	RP11-486B10.4	-5.29	1.89e-07	2.77e-05	-0.28	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41650217	chr1:41542069~41544310:+
THCA	cis	rs7162943	0.734	rs513903	ENSG00000260123.1	RP11-326A19.4	5.29	1.9e-07	2.77e-05	0.3	0.24	Mean platelet volume;	chr15:89063264	chr15:89041223~89082819:+
THCA	cis	rs3764021	1	rs3764021	ENSG00000256594.6	RP11-705C15.2	5.29	1.9e-07	2.77e-05	0.18	0.24	Type 1 diabetes;	chr12:9681032	chr12:9633419~9658412:+
THCA	cis	rs7246657	0.55	rs10411176	ENSG00000226686.6	LINC01535	-5.29	1.9e-07	2.77e-05	-0.43	-0.24	Coronary artery calcification;	chr19:37196051	chr19:37251912~37265535:+
THCA	cis	rs2439831	0.571	rs689883	ENSG00000166763.7	STRCP1	5.29	1.9e-07	2.77e-05	0.32	0.24	Lung cancer in ever smokers;	chr15:43520398	chr15:43699488~43718184:-
THCA	cis	rs10771431	0.597	rs10843144	ENSG00000111788.10	RP11-22B23.1	5.29	1.9e-07	2.77e-05	0.23	0.24	Breast size;	chr12:9204981	chr12:9277235~9313241:+
THCA	cis	rs2360027	0.578	rs4659103	ENSG00000231365.4	RP11-418J17.1	-5.29	1.9e-07	2.78e-05	-0.24	-0.24	Tonsillectomy;	chr1:118558160	chr1:119140396~119275973:+
THCA	cis	rs3864261	0.515	rs55769858	ENSG00000272081.1	CTD-2376I4.2	5.29	1.9e-07	2.78e-05	0.3	0.24	Discordance in emotional problems in monozygotic twins;	chr5:72984937	chr5:72955206~72955699:-
THCA	cis	rs2115536	1	rs11072871	ENSG00000278600.1	RP11-81A1.6	-5.29	1.9e-07	2.78e-05	-0.15	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79905589	chr15:79920195~79922455:-
THCA	cis	rs6585424	1	rs10466226	ENSG00000242600.5	MBL1P	-5.29	1.9e-07	2.78e-05	-0.27	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164299	chr10:79904898~79950336:+
THCA	cis	rs1858037	0.867	rs953312	ENSG00000234255.7	AC012370.3	5.29	1.9e-07	2.78e-05	0.28	0.24	Rheumatoid arthritis;	chr2:65340556	chr2:65439888~65456571:-
THCA	cis	rs1858037	0.867	rs9789444	ENSG00000234255.7	AC012370.3	5.29	1.9e-07	2.78e-05	0.28	0.24	Rheumatoid arthritis;	chr2:65342093	chr2:65439888~65456571:-
THCA	cis	rs17360053	0.859	rs6678085	ENSG00000218510.5	LINC00339	-5.29	1.9e-07	2.78e-05	-0.25	-0.24	Obesity-related traits;	chr1:22182306	chr1:22025188~22031223:+
THCA	cis	rs2243480	1	rs316329	ENSG00000230295.1	RP11-458F8.2	-5.29	1.9e-07	2.78e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:66143429	chr7:66880708~66882981:+
THCA	cis	rs2944755	0.686	rs6983414	ENSG00000279766.1	RP11-642A1.2	-5.29	1.9e-07	2.78e-05	-0.32	-0.24	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140580093	chr8:140572142~140572812:-
THCA	cis	rs875971	0.66	rs10263935	ENSG00000273142.1	RP11-458F8.4	-5.29	1.9e-07	2.78e-05	-0.19	-0.24	Aortic root size;	chr7:66631041	chr7:66902857~66906297:+
THCA	cis	rs7824557	0.767	rs2164272	ENSG00000154316.13	TDH	-5.29	1.9e-07	2.78e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11304987	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.701	rs2060465	ENSG00000154316.13	TDH	-5.29	1.9e-07	2.78e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11305100	chr8:11339637~11368452:+
THCA	cis	rs6445975	0.666	rs9867320	ENSG00000272360.1	RP11-359I18.5	5.29	1.9e-07	2.78e-05	0.28	0.24	Systemic lupus erythematosus;	chr3:58369546	chr3:58490830~58491291:-
THCA	cis	rs8007846	0.569	rs61988978	ENSG00000276116.2	FUT8-AS1	-5.29	1.9e-07	2.78e-05	-0.25	-0.24	Multiple sclerosis--Brain Glutamate Levels;	chr14:65791393	chr14:65411170~65412690:-
THCA	cis	rs9876781	0.967	rs1459249	ENSG00000244380.1	RP11-24C3.2	5.29	1.9e-07	2.78e-05	0.28	0.24	Longevity;	chr3:48438208	chr3:48440352~48446656:-
THCA	cis	rs4950322	1	rs72694750	ENSG00000278811.3	LINC00624	5.29	1.9e-07	2.78e-05	0.31	0.24	Protein quantitative trait loci;	chr1:147396856	chr1:147258885~147517875:-
THCA	cis	rs4950322	1	rs1986987	ENSG00000278811.3	LINC00624	5.29	1.9e-07	2.78e-05	0.31	0.24	Protein quantitative trait loci;	chr1:147397553	chr1:147258885~147517875:-
THCA	cis	rs4950322	1	rs61230354	ENSG00000278811.3	LINC00624	5.29	1.9e-07	2.78e-05	0.31	0.24	Protein quantitative trait loci;	chr1:147398161	chr1:147258885~147517875:-
THCA	cis	rs4950322	1	rs4950429	ENSG00000278811.3	LINC00624	5.29	1.9e-07	2.78e-05	0.31	0.24	Protein quantitative trait loci;	chr1:147400227	chr1:147258885~147517875:-
THCA	cis	rs4950322	1	rs59498179	ENSG00000278811.3	LINC00624	5.29	1.9e-07	2.78e-05	0.31	0.24	Protein quantitative trait loci;	chr1:147400417	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.947	rs58671552	ENSG00000278811.3	LINC00624	5.29	1.9e-07	2.78e-05	0.31	0.24	Protein quantitative trait loci;	chr1:147409534	chr1:147258885~147517875:-
THCA	cis	rs75920871	0.528	rs7935834	ENSG00000254851.1	RP11-109L13.1	5.29	1.91e-07	2.78e-05	0.35	0.24	Subjective well-being;	chr11:117073721	chr11:117135528~117138582:+
THCA	cis	rs6445975	0.666	rs9817356	ENSG00000272360.1	RP11-359I18.5	-5.29	1.91e-07	2.79e-05	-0.27	-0.24	Systemic lupus erythematosus;	chr3:58349846	chr3:58490830~58491291:-
THCA	cis	rs7191700	0.644	rs918738	ENSG00000263080.1	RP11-485G7.5	-5.29	1.91e-07	2.79e-05	-0.27	-0.24	Multiple sclerosis;	chr16:11345822	chr16:11341809~11345211:-
THCA	cis	rs453301	0.624	rs2979265	ENSG00000254153.1	CTA-398F10.2	-5.29	1.91e-07	2.79e-05	-0.25	-0.24	Joint mobility (Beighton score);	chr8:9001207	chr8:8456909~8461337:-
THCA	cis	rs1823913	1	rs4853568	ENSG00000227542.1	AC092614.2	-5.29	1.91e-07	2.79e-05	-0.29	-0.24	Obesity-related traits;	chr2:191261464	chr2:191229165~191246172:-
THCA	cis	rs1979679	0.918	rs1586868	ENSG00000278733.1	RP11-425D17.1	5.29	1.91e-07	2.79e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368176	chr12:28185625~28186190:-
THCA	cis	rs1979679	0.918	rs1586867	ENSG00000278733.1	RP11-425D17.1	5.29	1.91e-07	2.79e-05	0.24	0.24	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368345	chr12:28185625~28186190:-
THCA	cis	rs7849973	1	rs7849973	ENSG00000224549.1	RP11-370B11.3	5.29	1.91e-07	2.79e-05	0.28	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22819577	chr9:22767175~22768316:+
THCA	cis	rs7617773	0.925	rs34513961	ENSG00000199476.1	Y_RNA	-5.29	1.91e-07	2.79e-05	-0.32	-0.24	Coronary artery disease;	chr3:48132163	chr3:48288587~48288694:+
THCA	cis	rs919433	0.68	rs2564383	ENSG00000231621.1	AC013264.2	-5.29	1.91e-07	2.79e-05	-0.25	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197446138	chr2:197197991~197199273:+
THCA	cis	rs1889642	0.661	rs9545193	ENSG00000227354.5	RBM26-AS1	5.29	1.91e-07	2.79e-05	0.22	0.24	Colonoscopy-negative controls vs population controls;	chr13:79781826	chr13:79406309~79424328:+
THCA	cis	rs919433	0.726	rs11904247	ENSG00000231621.1	AC013264.2	-5.29	1.91e-07	2.79e-05	-0.25	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373700	chr2:197197991~197199273:+
THCA	cis	rs9843304	0.526	rs9850213	ENSG00000240541.2	TM4SF1-AS1	-5.29	1.91e-07	2.79e-05	-0.22	-0.24	Gallstone disease;	chr3:149484803	chr3:149377778~149386583:+
THCA	cis	rs7412746	0.552	rs4970980	ENSG00000231073.1	RP11-316M1.3	5.29	1.91e-07	2.79e-05	0.27	0.24	Melanoma;	chr1:150892516	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs1889741	ENSG00000231073.1	RP11-316M1.3	5.29	1.91e-07	2.79e-05	0.27	0.24	Melanoma;	chr1:150896569	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs66847267	ENSG00000231073.1	RP11-316M1.3	5.29	1.91e-07	2.79e-05	0.27	0.24	Melanoma;	chr1:150902697	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs7532045	ENSG00000231073.1	RP11-316M1.3	5.29	1.91e-07	2.79e-05	0.28	0.24	Melanoma;	chr1:150849371	chr1:150973123~150975534:+
THCA	cis	rs879620	1	rs2531995	ENSG00000262888.1	RP11-462G12.2	-5.29	1.91e-07	2.8e-05	-0.22	-0.24	Hip circumference;Body mass index;	chr16:3963466	chr16:3931217~3946305:-
THCA	cis	rs9475752	0.793	rs6904924	ENSG00000231441.1	RP11-472M19.2	5.29	1.91e-07	2.8e-05	0.32	0.24	Menarche (age at onset);	chr6:56948841	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs71564869	ENSG00000231441.1	RP11-472M19.2	5.29	1.91e-07	2.8e-05	0.32	0.24	Menarche (age at onset);	chr6:56949777	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs13218276	ENSG00000231441.1	RP11-472M19.2	5.29	1.91e-07	2.8e-05	0.32	0.24	Menarche (age at onset);	chr6:56950356	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs55952713	ENSG00000231441.1	RP11-472M19.2	5.29	1.91e-07	2.8e-05	0.32	0.24	Menarche (age at onset);	chr6:56950509	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs71564870	ENSG00000231441.1	RP11-472M19.2	5.29	1.91e-07	2.8e-05	0.32	0.24	Menarche (age at onset);	chr6:56954048	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs13193465	ENSG00000231441.1	RP11-472M19.2	5.29	1.91e-07	2.8e-05	0.32	0.24	Menarche (age at onset);	chr6:56955450	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs13193800	ENSG00000231441.1	RP11-472M19.2	5.29	1.91e-07	2.8e-05	0.32	0.24	Menarche (age at onset);	chr6:56955607	chr6:56844002~56864078:+
THCA	cis	rs17767392	0.836	rs17178387	ENSG00000259146.3	RP1-261D10.2	5.29	1.91e-07	2.8e-05	0.29	0.24	Mitral valve prolapse;	chr14:71531006	chr14:71292729~71321814:-
THCA	cis	rs8027521	0.702	rs1478176	ENSG00000280362.1	RP11-643A5.3	5.29	1.91e-07	2.8e-05	0.29	0.24	Circulating chemerin levels;	chr15:53960207	chr15:53910769~53914712:+
THCA	cis	rs6840360	0.516	rs6535794	ENSG00000270265.1	RP11-731D1.4	-5.29	1.91e-07	2.8e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151381631	chr4:151333775~151353224:-
THCA	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	5.29	1.91e-07	2.8e-05	0.36	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
THCA	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	5.29	1.91e-07	2.8e-05	0.36	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
THCA	cis	rs911555	0.655	rs10141157	ENSG00000269940.1	RP11-73M18.7	5.29	1.91e-07	2.8e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr14:103551768	chr14:103694560~103695170:+
THCA	cis	rs7688540	0.771	rs11722521	ENSG00000211553.1	AC253576.2	-5.29	1.92e-07	2.8e-05	-0.36	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:136461~136568:+
THCA	cis	rs6545883	0.801	rs778142	ENSG00000270820.4	RP11-355B11.2	5.29	1.92e-07	2.8e-05	0.2	0.24	Tuberculosis;	chr2:61454293	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.862	rs778141	ENSG00000270820.4	RP11-355B11.2	5.29	1.92e-07	2.8e-05	0.2	0.24	Tuberculosis;	chr2:61455043	chr2:61471188~61484130:+
THCA	cis	rs17508449	0.819	rs4839000	ENSG00000232450.1	RP4-730K3.3	-5.29	1.92e-07	2.8e-05	-0.37	-0.24	Leprosy;	chr1:113737513	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.819	rs78394484	ENSG00000232450.1	RP4-730K3.3	-5.29	1.92e-07	2.8e-05	-0.37	-0.24	Leprosy;	chr1:113740136	chr1:113698884~113699631:-
THCA	cis	rs6997458	0.712	rs9987281	ENSG00000253549.4	RP11-317J10.2	-5.29	1.92e-07	2.8e-05	-0.24	-0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85436601	chr8:85441851~85464915:-
THCA	cis	rs2067615	0.56	rs12298717	ENSG00000260329.1	RP11-412D9.4	5.29	1.92e-07	2.8e-05	0.21	0.24	Heart rate;	chr12:106706105	chr12:106954029~106955497:-
THCA	cis	rs875971	0.619	rs2302918	ENSG00000273142.1	RP11-458F8.4	-5.29	1.92e-07	2.8e-05	-0.19	-0.24	Aortic root size;	chr7:66535945	chr7:66902857~66906297:+
THCA	cis	rs9859260	0.921	rs9877119	ENSG00000231464.1	AC024937.4	5.29	1.92e-07	2.8e-05	0.29	0.24	Mean corpuscular volume;	chr3:196075495	chr3:195996738~195998233:+
THCA	cis	rs6044112	1	rs880800	ENSG00000273998.1	RP4-777L9.2	5.29	1.92e-07	2.8e-05	0.38	0.24	Response to taxane treatment (docetaxel);	chr20:16547892	chr20:16576068~16579615:+
THCA	cis	rs10129255	0.912	rs730099	ENSG00000223648.3	IGHV3-64	5.29	1.92e-07	2.8e-05	0.15	0.24	Kawasaki disease;	chr14:106711838	chr14:106643132~106658258:-
THCA	cis	rs12188164	0.62	rs1043356	ENSG00000188242.4	PP7080	-5.29	1.92e-07	2.8e-05	-0.25	-0.24	Cystic fibrosis severity;	chr5:480833	chr5:466124~473098:-
THCA	cis	rs858239	0.601	rs6971002	ENSG00000230042.1	AK3P3	-5.29	1.92e-07	2.8e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23129178~23129841:+
THCA	cis	rs6545883	0.929	rs778140	ENSG00000270820.4	RP11-355B11.2	5.29	1.92e-07	2.81e-05	0.2	0.24	Tuberculosis;	chr2:61455841	chr2:61471188~61484130:+
THCA	cis	rs1050631	0.592	rs948417	ENSG00000260552.1	RP11-49I11.1	5.29	1.92e-07	2.81e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36131311	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.592	rs1789527	ENSG00000260552.1	RP11-49I11.1	5.29	1.92e-07	2.81e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36132266	chr18:36179996~36187448:-
THCA	cis	rs7429990	0.965	rs34380889	ENSG00000228638.1	FCF1P2	-5.29	1.92e-07	2.81e-05	-0.23	-0.24	Educational attainment (years of education);	chr3:47905692	chr3:48290793~48291375:-
THCA	cis	rs11089937	0.637	rs988200	ENSG00000211638.2	IGLV8-61	-5.29	1.92e-07	2.81e-05	-0.2	-0.24	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22098700~22099212:+
THCA	cis	rs6969780	1	rs73071550	ENSG00000233429.8	HOTAIRM1	5.29	1.92e-07	2.81e-05	0.36	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109480	chr7:27095647~27100265:+
THCA	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	5.29	1.92e-07	2.81e-05	0.15	0.24	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
THCA	cis	rs2179367	0.632	rs9498321	ENSG00000223701.3	RAET1E-AS1	5.29	1.92e-07	2.81e-05	0.34	0.24	Dupuytren's disease;	chr6:149322573	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs62426068	ENSG00000223701.3	RAET1E-AS1	5.29	1.92e-07	2.81e-05	0.34	0.24	Dupuytren's disease;	chr6:149325795	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs62426069	ENSG00000223701.3	RAET1E-AS1	5.29	1.92e-07	2.81e-05	0.34	0.24	Dupuytren's disease;	chr6:149325804	chr6:149884431~149919508:+
THCA	cis	rs6547741	1	rs1972669	ENSG00000234072.1	AC074117.10	5.29	1.92e-07	2.81e-05	0.18	0.24	Oral cavity cancer;	chr2:27544240	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs6750943	ENSG00000234072.1	AC074117.10	5.29	1.92e-07	2.81e-05	0.18	0.24	Oral cavity cancer;	chr2:27555037	chr2:27356246~27367622:+
THCA	cis	rs2008905	1	rs2008905	ENSG00000272034.1	SNORD14A	5.29	1.92e-07	2.81e-05	0.25	0.24	Schizophrenia;	chr11:17163076	chr11:17074654~17074744:-
THCA	cis	rs5751614	0.557	rs5759666	ENSG00000240160.3	RN7SL263P	5.29	1.93e-07	2.81e-05	0.31	0.24	Height;	chr22:23260155	chr22:23261782~23262071:-
THCA	cis	rs890448	0.76	rs1476159	ENSG00000254531.1	FLJ20021	5.29	1.93e-07	2.81e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101359938	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2850334	ENSG00000254531.1	FLJ20021	5.29	1.93e-07	2.81e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101360231	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs2583386	ENSG00000254531.1	FLJ20021	5.29	1.93e-07	2.81e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101360294	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs2583385	ENSG00000254531.1	FLJ20021	5.29	1.93e-07	2.81e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101360655	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs4574415	ENSG00000254531.1	FLJ20021	5.29	1.93e-07	2.81e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101361276	chr4:101347780~101348883:+
THCA	cis	rs890448	0.764	rs2850333	ENSG00000254531.1	FLJ20021	-5.29	1.93e-07	2.81e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101358736	chr4:101347780~101348883:+
THCA	cis	rs2742234	1	rs2742234	ENSG00000273008.1	RP11-351D16.3	5.29	1.93e-07	2.81e-05	0.2	0.24	Hirschsprung disease;	chr10:43117161	chr10:43136824~43138334:-
THCA	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-5.29	1.93e-07	2.81e-05	-0.32	-0.24	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
THCA	cis	rs1707322	0.682	rs28508523	ENSG00000281133.1	AL355480.3	-5.29	1.93e-07	2.82e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.691	rs11211175	ENSG00000281133.1	AL355480.3	-5.29	1.93e-07	2.82e-05	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45580892~45580996:-
THCA	cis	rs890448	0.93	rs2433313	ENSG00000254531.1	FLJ20021	-5.29	1.93e-07	2.82e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101467784	chr4:101347780~101348883:+
THCA	cis	rs12807809	0.588	rs61910607	ENSG00000254941.1	RP11-677M14.5	5.29	1.93e-07	2.82e-05	0.38	0.24	Schizophrenia;	chr11:124739473	chr11:124807822~124808269:-
THCA	cis	rs12682352	0.602	rs635594	ENSG00000254153.1	CTA-398F10.2	5.28	1.93e-07	2.82e-05	0.25	0.24	Neuroticism;	chr8:8755877	chr8:8456909~8461337:-
THCA	cis	rs875971	0.545	rs2707851	ENSG00000232546.1	RP11-458F8.1	-5.28	1.93e-07	2.82e-05	-0.22	-0.24	Aortic root size;	chr7:66624178	chr7:66848496~66858136:+
THCA	cis	rs7429990	0.833	rs3732530	ENSG00000228638.1	FCF1P2	5.28	1.93e-07	2.82e-05	0.22	0.24	Educational attainment (years of education);	chr3:47577463	chr3:48290793~48291375:-
THCA	cis	rs3820928	0.874	rs13423714	ENSG00000212391.1	SNORA48	5.28	1.93e-07	2.82e-05	0.26	0.24	Pulmonary function;	chr2:227031936	chr2:226968989~226969122:-
THCA	cis	rs9813712	0.585	rs10934929	ENSG00000249846.5	RP11-77P16.4	5.28	1.93e-07	2.82e-05	0.31	0.24	Response to amphetamines;	chr3:130225231	chr3:130112550~130120579:+
THCA	cis	rs17508449	0.819	rs17031795	ENSG00000232450.1	RP4-730K3.3	-5.28	1.93e-07	2.82e-05	-0.37	-0.24	Leprosy;	chr1:113713206	chr1:113698884~113699631:-
THCA	cis	rs9813712	0.595	rs1901787	ENSG00000249846.5	RP11-77P16.4	5.28	1.93e-07	2.82e-05	0.24	0.24	Response to amphetamines;	chr3:130288678	chr3:130112550~130120579:+
THCA	cis	rs2239557	0.614	rs73303112	ENSG00000259065.1	RP5-1021I20.1	-5.28	1.93e-07	2.82e-05	-0.32	-0.24	Common traits (Other);	chr14:74013433	chr14:73787360~73803270:+
THCA	cis	rs2239557	0.645	rs3742810	ENSG00000259065.1	RP5-1021I20.1	5.28	1.93e-07	2.82e-05	0.32	0.24	Common traits (Other);	chr14:74010785	chr14:73787360~73803270:+
THCA	cis	rs2562456	0.833	rs2154302	ENSG00000268081.1	RP11-678G14.2	5.28	1.93e-07	2.82e-05	0.39	0.24	Pain;	chr19:21307609	chr19:21554640~21569237:-
THCA	cis	rs3213758	1	rs77865671	ENSG00000275191.1	RP11-36I17.2	-5.28	1.93e-07	2.82e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53577209	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs75141690	ENSG00000275191.1	RP11-36I17.2	-5.28	1.93e-07	2.82e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53580361	chr16:53628256~53628816:-
THCA	cis	rs7246657	0.653	rs10402050	ENSG00000226686.6	LINC01535	-5.28	1.93e-07	2.82e-05	-0.43	-0.24	Coronary artery calcification;	chr19:37198056	chr19:37251912~37265535:+
THCA	cis	rs4713118	0.955	rs9468200	ENSG00000226314.6	ZNF192P1	-5.28	1.93e-07	2.82e-05	-0.3	-0.24	Parkinson's disease;	chr6:27715284	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.955	rs34752872	ENSG00000226314.6	ZNF192P1	-5.28	1.93e-07	2.82e-05	-0.3	-0.24	Parkinson's disease;	chr6:27715465	chr6:28161781~28169594:+
THCA	cis	rs34779708	0.966	rs35079558	ENSG00000271335.4	RP11-324I22.4	5.28	1.94e-07	2.83e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35314552~35336401:-
THCA	cis	rs6570726	0.791	rs4332001	ENSG00000270638.1	RP3-466P17.1	5.28	1.94e-07	2.83e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145735570~145737218:+
THCA	cis	rs2797160	1	rs2797161	ENSG00000237742.5	RP11-624M8.1	5.28	1.94e-07	2.83e-05	0.2	0.24	Endometrial cancer;	chr6:125689643	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2747723	ENSG00000237742.5	RP11-624M8.1	5.28	1.94e-07	2.83e-05	0.2	0.24	Endometrial cancer;	chr6:125689644	chr6:125578558~125749190:-
THCA	cis	rs7674212	0.581	rs10516496	ENSG00000230069.3	LRRC37A15P	-5.28	1.94e-07	2.83e-05	-0.25	-0.24	Type 2 diabetes;	chr4:103021008	chr4:102727274~102730721:-
THCA	cis	rs4713118	0.539	rs200988	ENSG00000280107.1	AL022393.9	-5.28	1.94e-07	2.83e-05	-0.26	-0.24	Parkinson's disease;	chr6:27851575	chr6:28170845~28172521:+
THCA	cis	rs200986	1	rs200986	ENSG00000280107.1	AL022393.9	-5.28	1.94e-07	2.83e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28170845~28172521:+
THCA	cis	rs4660456	0.913	rs556875	ENSG00000272145.1	NFYC-AS1	5.28	1.94e-07	2.83e-05	0.16	0.24	Platelet count;	chr1:40688571	chr1:40690380~40692066:-
THCA	cis	rs12893668	0.703	rs55751606	ENSG00000269958.1	RP11-73M18.8	5.28	1.94e-07	2.84e-05	0.24	0.24	Reticulocyte count;	chr14:103562469	chr14:103696353~103697163:+
THCA	cis	rs752010	0.619	rs7539238	ENSG00000230638.4	RP11-486B10.4	-5.28	1.94e-07	2.84e-05	-0.28	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41647901	chr1:41542069~41544310:+
THCA	cis	rs11640436	0.57	rs1594050	ENSG00000260922.1	RP11-538I12.3	-5.28	1.94e-07	2.84e-05	-0.28	-0.24	Lobe attachment (rater-scored or self-reported);	chr16:77263750	chr16:77234877~77290934:+
THCA	cis	rs66887589	0.616	rs11731675	ENSG00000249244.1	RP11-548H18.2	5.28	1.95e-07	2.84e-05	0.25	0.24	Diastolic blood pressure;	chr4:119291359	chr4:119391831~119395335:-
THCA	cis	rs116095464	0.558	rs10056628	ENSG00000248925.1	CTD-2083E4.6	5.28	1.95e-07	2.84e-05	0.37	0.24	Breast cancer;	chr5:279397	chr5:269858~271516:-
THCA	cis	rs6058796	1	rs6141779	ENSG00000175730.8	BAK1P1	5.28	1.95e-07	2.84e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32671564	chr20:32690180~32690815:-
THCA	cis	rs6058796	1	rs57861317	ENSG00000175730.8	BAK1P1	5.28	1.95e-07	2.84e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32672906	chr20:32690180~32690815:-
THCA	cis	rs6058796	1	rs34311932	ENSG00000175730.8	BAK1P1	5.28	1.95e-07	2.84e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32673195	chr20:32690180~32690815:-
THCA	cis	rs228614	0.536	rs223484	ENSG00000248971.2	KRT8P46	-5.28	1.95e-07	2.84e-05	-0.29	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102728746~102730171:-
THCA	cis	rs10895322	0.561	rs7122793	ENSG00000281655.1	RP11-817J15.3	-5.28	1.95e-07	2.84e-05	-0.31	-0.24	Neuroblastoma (11q deletion);	chr11:102614214	chr11:102681310~102683913:+
THCA	cis	rs10895322	0.561	rs7123742	ENSG00000281655.1	RP11-817J15.3	-5.28	1.95e-07	2.84e-05	-0.31	-0.24	Neuroblastoma (11q deletion);	chr11:102614215	chr11:102681310~102683913:+
THCA	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	5.28	1.95e-07	2.85e-05	0.28	0.24	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
THCA	cis	rs4415084	0.804	rs9790896	ENSG00000272335.1	RP11-53O19.3	-5.28	1.95e-07	2.85e-05	-0.19	-0.24	Breast cancer;	chr5:44899989	chr5:44826076~44828592:+
THCA	cis	rs7924176	0.521	rs12415957	ENSG00000213731.2	RAB5CP1	5.28	1.95e-07	2.85e-05	0.29	0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:74423435~74424014:-
THCA	cis	rs30380	0.632	rs27045	ENSG00000272109.1	CTD-2260A17.3	-5.28	1.95e-07	2.85e-05	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96803158	chr5:96804353~96806105:+
THCA	cis	rs3096299	0.617	rs2353030	ENSG00000274627.1	RP11-104N10.2	-5.28	1.95e-07	2.85e-05	-0.22	-0.24	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89516797~89522217:+
THCA	cis	rs1552244	1	rs6781811	ENSG00000180385.7	EMC3-AS1	-5.28	1.95e-07	2.85e-05	-0.26	-0.24	Alzheimer's disease;	chr3:10080238	chr3:9986893~10006990:+
THCA	cis	rs2803122	0.838	rs7046816	ENSG00000273226.1	RP11-513M16.8	-5.28	1.95e-07	2.85e-05	-0.22	-0.24	Pulse pressure;	chr9:19220506	chr9:19375451~19375996:+
THCA	cis	rs6547741	1	rs4666007	ENSG00000234072.1	AC074117.10	5.28	1.95e-07	2.85e-05	0.18	0.24	Oral cavity cancer;	chr2:27633628	chr2:27356246~27367622:+
THCA	cis	rs6547741	1	rs1528402	ENSG00000234072.1	AC074117.10	5.28	1.95e-07	2.85e-05	0.18	0.24	Oral cavity cancer;	chr2:27634650	chr2:27356246~27367622:+
THCA	cis	rs6445975	1	rs2176082	ENSG00000272360.1	RP11-359I18.5	-5.28	1.95e-07	2.85e-05	-0.26	-0.24	Systemic lupus erythematosus;	chr3:58345459	chr3:58490830~58491291:-
THCA	cis	rs2439831	0.681	rs524527	ENSG00000275601.1	AC011330.13	5.28	1.95e-07	2.85e-05	0.35	0.24	Lung cancer in ever smokers;	chr15:43306918	chr15:43642389~43643023:-
THCA	cis	rs12497850	1	rs12493578	ENSG00000229759.1	MRPS18AP1	-5.28	1.96e-07	2.85e-05	-0.31	-0.24	Parkinson's disease;	chr3:48692683	chr3:48256350~48256938:-
THCA	cis	rs874628	0.95	rs1128099	ENSG00000268650.3	AC068499.10	5.28	1.96e-07	2.85e-05	0.28	0.24	Multiple sclerosis;	chr19:18196658	chr19:18204730~18220480:+
THCA	cis	rs7688540	0.771	rs4582105	ENSG00000211553.1	AC253576.2	-5.28	1.96e-07	2.85e-05	-0.36	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:136461~136568:+
THCA	cis	rs2129782	0.681	rs28986497	ENSG00000253553.4	RP11-586K2.1	5.28	1.96e-07	2.86e-05	0.38	0.24	Electrodermal activity;	chr8:88292492	chr8:88326836~88737134:+
THCA	cis	rs2797160	0.967	rs2226158	ENSG00000237742.5	RP11-624M8.1	-5.28	1.96e-07	2.86e-05	-0.2	-0.24	Endometrial cancer;	chr6:125674321	chr6:125578558~125749190:-
THCA	cis	rs7617480	0.648	rs9882443	ENSG00000228638.1	FCF1P2	-5.28	1.96e-07	2.86e-05	-0.3	-0.24	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48711631	chr3:48290793~48291375:-
THCA	cis	rs3892630	0.878	rs7246451	ENSG00000267567.1	CTD-2538C1.3	5.28	1.96e-07	2.86e-05	0.37	0.24	Red blood cell traits;	chr19:32718708	chr19:32718298~32719595:-
THCA	cis	rs3892630	0.878	rs1559177	ENSG00000267567.1	CTD-2538C1.3	5.28	1.96e-07	2.86e-05	0.37	0.24	Red blood cell traits;	chr19:32719740	chr19:32718298~32719595:-
THCA	cis	rs17767392	0.881	rs35589413	ENSG00000259146.3	RP1-261D10.2	5.28	1.96e-07	2.86e-05	0.29	0.24	Mitral valve prolapse;	chr14:71524959	chr14:71292729~71321814:-
THCA	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	5.28	1.96e-07	2.86e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
THCA	cis	rs6997458	0.742	rs4566	ENSG00000253549.4	RP11-317J10.2	5.28	1.96e-07	2.86e-05	0.24	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85448853	chr8:85441851~85464915:-
THCA	cis	rs7119	0.651	rs12902948	ENSG00000259362.2	RP11-307C19.1	-5.28	1.96e-07	2.86e-05	-0.34	-0.24	Type 2 diabetes;	chr15:77556912	chr15:77525540~77534110:+
THCA	cis	rs9859260	1	rs2239640	ENSG00000231464.1	AC024937.4	5.28	1.96e-07	2.86e-05	0.29	0.24	Mean corpuscular volume;	chr3:196062837	chr3:195996738~195998233:+
THCA	cis	rs55704346	0.875	rs13139513	ENSG00000281501.1	SEPSECS-AS1	5.28	1.96e-07	2.86e-05	0.27	0.24	Tonsillectomy;	chr4:25166795	chr4:25160641~25201440:+
THCA	cis	rs4888671	0.901	rs78017841	ENSG00000261707.1	RP11-264M12.2	5.28	1.96e-07	2.86e-05	0.44	0.24	Obesity-related traits;	chr16:77750268	chr16:77741468~77743000:-
THCA	cis	rs1552244	1	rs17032396	ENSG00000232901.1	CYCSP10	-5.28	1.96e-07	2.86e-05	-0.31	-0.24	Alzheimer's disease;	chr3:10111875	chr3:10000647~10000940:-
THCA	cis	rs987724	0.593	rs11707914	ENSG00000240875.4	LINC00886	-5.28	1.96e-07	2.86e-05	-0.18	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156829982	chr3:156747346~156817062:-
THCA	cis	rs853679	0.713	rs200991	ENSG00000226314.6	ZNF192P1	5.28	1.96e-07	2.86e-05	0.34	0.24	Depression;	chr6:27847716	chr6:28161781~28169594:+
THCA	cis	rs5015933	0.815	rs10819041	ENSG00000232630.1	PRPS1P2	-5.28	1.96e-07	2.86e-05	-0.16	-0.24	Body mass index;	chr9:125268558	chr9:125150653~125151589:+
THCA	cis	rs9393777	0.92	rs34953377	ENSG00000219392.1	RP1-265C24.5	-5.28	1.96e-07	2.86e-05	-0.47	-0.24	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28115628~28116551:+
THCA	cis	rs34779708	0.931	rs17591135	ENSG00000271335.4	RP11-324I22.4	5.28	1.96e-07	2.87e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs55724039	ENSG00000271335.4	RP11-324I22.4	5.28	1.96e-07	2.87e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35314552~35336401:-
THCA	cis	rs853679	0.607	rs13217984	ENSG00000226314.6	ZNF192P1	-5.28	1.96e-07	2.87e-05	-0.54	-0.24	Depression;	chr6:28171932	chr6:28161781~28169594:+
THCA	cis	rs853679	0.556	rs67297533	ENSG00000226314.6	ZNF192P1	-5.28	1.96e-07	2.87e-05	-0.54	-0.24	Depression;	chr6:28173475	chr6:28161781~28169594:+
THCA	cis	rs853679	0.505	rs35781323	ENSG00000226314.6	ZNF192P1	-5.28	1.96e-07	2.87e-05	-0.54	-0.24	Depression;	chr6:28177054	chr6:28161781~28169594:+
THCA	cis	rs28510890	0.917	rs58332472	ENSG00000260337.3	RP11-386M24.6	5.28	1.96e-07	2.87e-05	0.28	0.24	Lung cancer in ever smokers;	chr15:92574861	chr15:92592574~92596462:-
THCA	cis	rs875971	0.54	rs736270	ENSG00000273142.1	RP11-458F8.4	-5.28	1.97e-07	2.87e-05	-0.2	-0.24	Aortic root size;	chr7:65963835	chr7:66902857~66906297:+
THCA	cis	rs9902453	0.838	rs3110495	ENSG00000263370.1	RP11-68I3.5	-5.28	1.97e-07	2.87e-05	-0.3	-0.24	Coffee consumption (cups per day);	chr17:29651437	chr17:29639627~29640825:+
THCA	cis	rs914615	0.508	rs4390169	ENSG00000225855.5	RUSC1-AS1	-5.28	1.97e-07	2.87e-05	-0.15	-0.24	Urinary albumin-to-creatinine ratio;	chr1:155133578	chr1:155316863~155324176:-
THCA	cis	rs763121	0.853	rs1569716	ENSG00000228274.3	RP3-508I15.9	-5.28	1.97e-07	2.87e-05	-0.25	-0.24	Menopause (age at onset);	chr22:38602514	chr22:38667585~38681820:-
THCA	cis	rs4660456	0.913	rs2780950	ENSG00000272145.1	NFYC-AS1	-5.28	1.97e-07	2.87e-05	-0.17	-0.24	Platelet count;	chr1:40686937	chr1:40690380~40692066:-
THCA	cis	rs4415084	0.804	rs4866922	ENSG00000272335.1	RP11-53O19.3	5.28	1.97e-07	2.87e-05	0.2	0.24	Breast cancer;	chr5:44932403	chr5:44826076~44828592:+
THCA	cis	rs12428035	0.881	rs16951334	ENSG00000247400.3	DNAJC3-AS1	-5.28	1.97e-07	2.87e-05	-0.22	-0.24	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95754834	chr13:95648733~95676925:-
THCA	cis	rs8177876	0.597	rs1048194	ENSG00000261061.1	RP11-303E16.2	5.28	1.97e-07	2.87e-05	0.41	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81030770~81031485:+
THCA	cis	rs2436845	0.603	rs2679753	ENSG00000253669.3	KB-1732A1.1	-5.28	1.97e-07	2.87e-05	-0.26	-0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855232	chr8:102805517~102809971:+
THCA	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-5.28	1.97e-07	2.87e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-5.28	1.97e-07	2.87e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
THCA	cis	rs2243480	1	rs160639	ENSG00000232559.3	GS1-124K5.12	5.28	1.97e-07	2.87e-05	0.34	0.24	Diabetic kidney disease;	chr7:66115000	chr7:66554588~66576923:-
THCA	cis	rs4908760	0.827	rs11121210	ENSG00000232912.4	RP5-1115A15.1	5.28	1.97e-07	2.87e-05	0.23	0.24	Vitiligo;	chr1:8648470	chr1:8424645~8434838:+
THCA	cis	rs564343	0.966	rs527962	ENSG00000255320.1	RP11-755F10.1	-5.28	1.97e-07	2.88e-05	-0.29	-0.24	Obesity (early onset extreme);	chr11:66117247	chr11:66244840~66246239:-
THCA	cis	rs10875746	0.669	rs11168516	ENSG00000258234.1	RP11-370I10.2	5.28	1.97e-07	2.88e-05	0.28	0.24	Longevity (90 years and older);	chr12:48308282	chr12:48231098~48284210:-
THCA	cis	rs375066	0.592	rs10401203	ENSG00000267058.1	RP11-15A1.3	5.28	1.97e-07	2.88e-05	0.21	0.24	Breast cancer;	chr19:43795514	chr19:43891804~43901805:-
THCA	cis	rs9400467	0.528	rs240954	ENSG00000271789.1	RP5-1112D6.7	-5.28	1.97e-07	2.88e-05	-0.23	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111338619	chr6:111297126~111298510:+
THCA	cis	rs5015933	0.778	rs10819046	ENSG00000232630.1	PRPS1P2	-5.28	1.97e-07	2.88e-05	-0.16	-0.24	Body mass index;	chr9:125349961	chr9:125150653~125151589:+
THCA	cis	rs934734	0.935	rs6711791	ENSG00000234255.7	AC012370.3	5.28	1.97e-07	2.88e-05	0.26	0.24	Rheumatoid arthritis;	chr2:65352094	chr2:65439888~65456571:-
THCA	cis	rs2179367	0.553	rs7762222	ENSG00000268592.3	RAET1E-AS1	5.28	1.97e-07	2.88e-05	0.38	0.24	Dupuytren's disease;	chr6:149444846	chr6:149863494~149919507:+
THCA	cis	rs853679	0.567	rs16894091	ENSG00000219392.1	RP1-265C24.5	5.28	1.97e-07	2.88e-05	0.29	0.24	Depression;	chr6:28422360	chr6:28115628~28116551:+
THCA	cis	rs2304003	1	rs4667844	ENSG00000235192.1	AC009495.2	5.28	1.97e-07	2.88e-05	0.33	0.24	Social communication problems;	chr2:165844614	chr2:165794851~165810010:+
THCA	cis	rs2304003	1	rs10754968	ENSG00000235192.1	AC009495.2	5.28	1.97e-07	2.88e-05	0.33	0.24	Social communication problems;	chr2:165845956	chr2:165794851~165810010:+
THCA	cis	rs2304003	0.948	rs1432270	ENSG00000235192.1	AC009495.2	5.28	1.97e-07	2.88e-05	0.33	0.24	Social communication problems;	chr2:165847910	chr2:165794851~165810010:+
THCA	cis	rs7617480	0.616	rs9873227	ENSG00000228638.1	FCF1P2	-5.28	1.97e-07	2.88e-05	-0.3	-0.24	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48735675	chr3:48290793~48291375:-
THCA	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	5.28	1.98e-07	2.88e-05	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
THCA	cis	rs11096990	0.929	rs56037933	ENSG00000249685.1	RP11-360F5.3	-5.28	1.98e-07	2.88e-05	-0.31	-0.24	Cognitive function;	chr4:39225653	chr4:39133913~39135608:+
THCA	cis	rs5751614	0.537	rs5759681	ENSG00000230701.2	FBXW4P1	-5.28	1.98e-07	2.88e-05	-0.26	-0.24	Height;	chr22:23287365	chr22:23262767~23265005:+
THCA	cis	rs3213758	0.737	rs57109422	ENSG00000275191.1	RP11-36I17.2	-5.28	1.98e-07	2.88e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53618606	chr16:53628256~53628816:-
THCA	cis	rs7727544	0.617	rs3843503	ENSG00000233006.5	AC034220.3	5.28	1.98e-07	2.88e-05	0.19	0.24	Blood metabolite levels;	chr5:132130936	chr5:132311285~132369916:-
THCA	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	5.28	1.98e-07	2.89e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
THCA	cis	rs1552244	0.554	rs17050704	ENSG00000232901.1	CYCSP10	5.28	1.98e-07	2.89e-05	0.28	0.24	Alzheimer's disease;	chr3:10004050	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs34883592	ENSG00000232901.1	CYCSP10	5.28	1.98e-07	2.89e-05	0.28	0.24	Alzheimer's disease;	chr3:10004481	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs17050705	ENSG00000232901.1	CYCSP10	5.28	1.98e-07	2.89e-05	0.28	0.24	Alzheimer's disease;	chr3:10004714	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs2272120	ENSG00000232901.1	CYCSP10	5.28	1.98e-07	2.89e-05	0.28	0.24	Alzheimer's disease;	chr3:10005019	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs13079240	ENSG00000232901.1	CYCSP10	5.28	1.98e-07	2.89e-05	0.28	0.24	Alzheimer's disease;	chr3:10005562	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs2272121	ENSG00000232901.1	CYCSP10	5.28	1.98e-07	2.89e-05	0.28	0.24	Alzheimer's disease;	chr3:10005996	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs3732965	ENSG00000232901.1	CYCSP10	5.28	1.98e-07	2.89e-05	0.28	0.24	Alzheimer's disease;	chr3:10007076	chr3:10000647~10000940:-
THCA	cis	rs10043228	0.702	rs12521345	ENSG00000248445.4	SEMA6A-AS1	-5.28	1.98e-07	2.89e-05	-0.26	-0.24	Asthma or chronic obstructive pulmonary disease;	chr5:116317162	chr5:116447547~116508276:+
THCA	cis	rs4713118	0.513	rs149959	ENSG00000226314.6	ZNF192P1	-5.28	1.98e-07	2.89e-05	-0.28	-0.24	Parkinson's disease;	chr6:28046076	chr6:28161781~28169594:+
THCA	cis	rs9859260	0.961	rs9846149	ENSG00000231464.1	AC024937.4	5.28	1.99e-07	2.89e-05	0.29	0.24	Mean corpuscular volume;	chr3:196060437	chr3:195996738~195998233:+
THCA	cis	rs16846053	0.605	rs55949502	ENSG00000227403.1	AC009299.3	5.28	1.99e-07	2.89e-05	0.56	0.24	Blood osmolality (transformed sodium);	chr2:161915604	chr2:161244739~161249050:+
THCA	cis	rs9467773	0.511	rs11755443	ENSG00000241549.7	GUSBP2	5.28	1.99e-07	2.89e-05	0.22	0.24	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26871484~26956554:-
THCA	cis	rs442309	0.875	rs224067	ENSG00000238280.1	RP11-436D10.3	5.28	1.99e-07	2.89e-05	0.28	0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62747211	chr10:62793562~62805887:-
THCA	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	5.28	1.99e-07	2.89e-05	0.28	0.24	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
THCA	cis	rs5015933	0.778	rs10819045	ENSG00000232630.1	PRPS1P2	-5.28	1.99e-07	2.9e-05	-0.16	-0.24	Body mass index;	chr9:125321886	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.788	rs10114684	ENSG00000232630.1	PRPS1P2	-5.28	1.99e-07	2.9e-05	-0.16	-0.24	Body mass index;	chr9:125340586	chr9:125150653~125151589:+
THCA	cis	rs9467773	0.844	rs2393669	ENSG00000261353.1	CTA-14H9.5	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26503645	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9461259	ENSG00000261353.1	CTA-14H9.5	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26504607	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9467774	ENSG00000261353.1	CTA-14H9.5	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26504808	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs3736781	ENSG00000261353.1	CTA-14H9.5	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26505134	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs3736782	ENSG00000261353.1	CTA-14H9.5	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26505175	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs2208331	ENSG00000261353.1	CTA-14H9.5	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26507091	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9393728	ENSG00000261353.1	CTA-14H9.5	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26509102	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs1056667	ENSG00000261353.1	CTA-14H9.5	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26510336	chr6:26527063~26527404:+
THCA	cis	rs4713118	0.513	rs149945	ENSG00000226314.6	ZNF192P1	-5.28	1.99e-07	2.9e-05	-0.28	-0.24	Parkinson's disease;	chr6:28035075	chr6:28161781~28169594:+
THCA	cis	rs240993	0.812	rs6568677	ENSG00000271789.1	RP5-1112D6.7	-5.28	1.99e-07	2.9e-05	-0.28	-0.24	Inflammatory skin disease;Psoriasis;	chr6:111392099	chr6:111297126~111298510:+
THCA	cis	rs17772222	0.511	rs12879875	ENSG00000258789.1	RP11-507K2.3	-5.28	1.99e-07	2.9e-05	-0.21	-0.24	Coronary artery calcification;	chr14:88840206	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.511	rs17124903	ENSG00000258789.1	RP11-507K2.3	-5.28	1.99e-07	2.9e-05	-0.21	-0.24	Coronary artery calcification;	chr14:88842934	chr14:88551597~88552493:+
THCA	cis	rs9388451	0.505	rs9372828	ENSG00000237742.5	RP11-624M8.1	-5.28	1.99e-07	2.9e-05	-0.21	-0.24	Brugada syndrome;	chr6:125854039	chr6:125578558~125749190:-
THCA	cis	rs2839186	0.605	rs2839174	ENSG00000215424.8	MCM3AP-AS1	5.28	1.99e-07	2.9e-05	0.14	0.24	Testicular germ cell tumor;	chr21:46257020	chr21:46229217~46259390:+
THCA	cis	rs11089937	0.568	rs12160317	ENSG00000211638.2	IGLV8-61	-5.28	1.99e-07	2.9e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22098700~22099212:+
THCA	cis	rs9926296	0.546	rs9935541	ENSG00000260259.1	RP11-368I7.4	-5.28	1.99e-07	2.9e-05	-0.26	-0.24	Vitiligo;	chr16:89839517	chr16:89682620~89686569:-
THCA	cis	rs2067615	0.579	rs1922438	ENSG00000260329.1	RP11-412D9.4	-5.28	1.99e-07	2.9e-05	-0.21	-0.24	Heart rate;	chr12:106691393	chr12:106954029~106955497:-
THCA	cis	rs2562456	0.876	rs62110202	ENSG00000268119.4	CTD-2561J22.5	5.28	1.99e-07	2.9e-05	0.29	0.24	Pain;	chr19:21571799	chr19:21444241~21463908:-
THCA	cis	rs10256972	0.521	rs7457418	ENSG00000199023.2	MIR339	-5.28	1.99e-07	2.9e-05	-0.25	-0.24	Endometriosis;Longevity;	chr7:1070619	chr7:1022935~1023045:-
THCA	cis	rs2120243	0.572	rs3816528	ENSG00000244515.1	KRT18P34	5.28	1.99e-07	2.9e-05	0.29	0.24	Hepatocellular carcinoma in hepatitis B infection;	chr3:157409501	chr3:157162663~157163932:-
THCA	cis	rs2129782	0.764	rs1915021	ENSG00000253553.4	RP11-586K2.1	5.28	1.99e-07	2.9e-05	0.39	0.24	Electrodermal activity;	chr8:88271636	chr8:88326836~88737134:+
THCA	cis	rs8141529	0.732	rs5762788	ENSG00000272858.1	CTA-292E10.8	-5.28	1.99e-07	2.9e-05	-0.24	-0.24	Lymphocyte counts;	chr22:28778782	chr22:28814914~28815662:+
THCA	cis	rs1552244	1	rs9811771	ENSG00000180385.7	EMC3-AS1	5.28	1.99e-07	2.91e-05	0.25	0.24	Alzheimer's disease;	chr3:10092265	chr3:9986893~10006990:+
THCA	cis	rs2179367	0.632	rs59820585	ENSG00000268592.3	RAET1E-AS1	5.28	1.99e-07	2.91e-05	0.34	0.24	Dupuytren's disease;	chr6:149350249	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs56924465	ENSG00000268592.3	RAET1E-AS1	5.28	1.99e-07	2.91e-05	0.34	0.24	Dupuytren's disease;	chr6:149350270	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.568	rs62426092	ENSG00000268592.3	RAET1E-AS1	5.28	1.99e-07	2.91e-05	0.34	0.24	Dupuytren's disease;	chr6:149352720	chr6:149863494~149919507:+
THCA	cis	rs875971	0.638	rs6960778	ENSG00000273142.1	RP11-458F8.4	5.28	2e-07	2.91e-05	0.19	0.24	Aortic root size;	chr7:66606610	chr7:66902857~66906297:+
THCA	cis	rs6921919	0.583	rs1054372	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs9468354	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs7773051	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs12697938	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs13437294	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.609	rs9468357	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs34513104	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs9461456	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.525	rs9468360	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs16894021	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs11751693	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs7749736	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.525	rs9468361	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs7775132	ENSG00000219392.1	RP1-265C24.5	-5.28	2e-07	2.91e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28115628~28116551:+
THCA	cis	rs7617773	0.817	rs3731555	ENSG00000199476.1	Y_RNA	-5.28	2e-07	2.91e-05	-0.31	-0.24	Coronary artery disease;	chr3:48164612	chr3:48288587~48288694:+
THCA	cis	rs34779708	0.931	rs4934700	ENSG00000271335.4	RP11-324I22.4	5.28	2e-07	2.91e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35314552~35336401:-
THCA	cis	rs12908161	1	rs12908161	ENSG00000275120.1	RP11-182J1.17	5.28	2e-07	2.91e-05	0.28	0.24	Schizophrenia;	chr15:84664594	chr15:84599434~84606463:-
THCA	cis	rs7412746	0.621	rs7518156	ENSG00000231073.1	RP11-316M1.3	5.28	2e-07	2.91e-05	0.28	0.24	Melanoma;	chr1:150973318	chr1:150973123~150975534:+
THCA	cis	rs875971	0.545	rs1796222	ENSG00000228409.4	CCT6P1	5.28	2e-07	2.91e-05	0.2	0.24	Aortic root size;	chr7:66592167	chr7:65751142~65763354:+
THCA	cis	rs2880765	0.835	rs900573	ENSG00000259630.2	CTD-2262B20.1	5.28	2e-07	2.91e-05	0.25	0.24	Coronary artery disease;	chr15:85494762	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs56406982	ENSG00000259630.2	CTD-2262B20.1	-5.28	2e-07	2.91e-05	-0.25	-0.24	Coronary artery disease;	chr15:85493148	chr15:85415228~85415633:+
THCA	cis	rs9467773	1	rs9393731	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs11756120	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9393732	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.967	rs9358954	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs28558133	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs10946834	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs10946835	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9467778	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs2393670	ENSG00000261353.1	CTA-14H9.5	-5.28	2e-07	2.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26527063~26527404:+
THCA	cis	rs10266483	0.741	rs10254313	ENSG00000228653.2	HNRNPCP7	-5.28	2e-07	2.91e-05	-0.2	-0.24	Response to statin therapy;	chr7:64278935	chr7:64500825~64501729:+
THCA	cis	rs10266483	0.741	rs35244017	ENSG00000228653.2	HNRNPCP7	-5.28	2e-07	2.91e-05	-0.2	-0.24	Response to statin therapy;	chr7:64278939	chr7:64500825~64501729:+
THCA	cis	rs10266483	0.843	rs10272639	ENSG00000228653.2	HNRNPCP7	-5.28	2e-07	2.91e-05	-0.2	-0.24	Response to statin therapy;	chr7:64278944	chr7:64500825~64501729:+
THCA	cis	rs9733	0.596	rs72702523	ENSG00000231073.1	RP11-316M1.3	5.28	2e-07	2.91e-05	0.28	0.24	Tonsillectomy;	chr1:150677949	chr1:150973123~150975534:+
THCA	cis	rs4915077	1	rs77125988	ENSG00000230489.1	VAV3-AS1	5.28	2e-07	2.91e-05	0.39	0.24	Hypothyroidism;	chr1:107822089	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs74614887	ENSG00000230489.1	VAV3-AS1	5.28	2e-07	2.91e-05	0.39	0.24	Hypothyroidism;	chr1:107822173	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs10494079	ENSG00000230489.1	VAV3-AS1	5.28	2e-07	2.91e-05	0.39	0.24	Hypothyroidism;	chr1:107832253	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs17020148	ENSG00000230489.1	VAV3-AS1	5.28	2e-07	2.91e-05	0.39	0.24	Hypothyroidism;	chr1:107832388	chr1:107964443~107994607:+
THCA	cis	rs7924176	0.564	rs12569971	ENSG00000213731.2	RAB5CP1	-5.28	2e-07	2.91e-05	-0.28	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74194617	chr10:74423435~74424014:-
THCA	cis	rs8064024	0.87	rs6500635	ENSG00000267077.1	RP11-127I20.5	5.28	2e-07	2.91e-05	0.26	0.24	Cancer;	chr16:4817564	chr16:4795265~4796532:-
THCA	cis	rs6756513	0.5	rs7568485	ENSG00000231024.1	AC092431.3	-5.28	2e-07	2.91e-05	-0.32	-0.24	Breast cancer;Platelet count;	chr2:69870603	chr2:69700192~69713847:-
THCA	cis	rs11634944	0.673	rs1541759	ENSG00000257151.1	PWAR6	5.28	2e-07	2.91e-05	0.18	0.24	Interleukin-8 levels;	chr15:25030210	chr15:25031873~25036490:+
THCA	cis	rs875971	0.558	rs4433015	ENSG00000273142.1	RP11-458F8.4	5.28	2e-07	2.91e-05	0.19	0.24	Aortic root size;	chr7:66174736	chr7:66902857~66906297:+
THCA	cis	rs338389	0.543	rs449487	ENSG00000260657.2	RP11-315D16.4	-5.28	2e-07	2.92e-05	-0.3	-0.24	Survival in rectal cancer;	chr15:67948410	chr15:68267792~68277994:-
THCA	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	5.28	2e-07	2.92e-05	0.4	0.24	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	5.28	2e-07	2.92e-05	0.4	0.24	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	5.28	2e-07	2.92e-05	0.4	0.24	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	5.28	2e-07	2.92e-05	0.4	0.24	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	5.28	2e-07	2.92e-05	0.4	0.24	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	5.28	2e-07	2.92e-05	0.4	0.24	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
THCA	cis	rs12935418	0.616	rs55776427	ENSG00000278985.1	RP11-303E16.9	5.28	2e-07	2.92e-05	0.25	0.24	Mean corpuscular volume;	chr16:80971999	chr16:80982319~80984094:-
THCA	cis	rs593531	0.614	rs10736795	ENSG00000255440.1	RP11-632K5.2	5.28	2e-07	2.92e-05	0.29	0.24	Neuroticism;	chr11:74328501	chr11:74409060~74416379:+
THCA	cis	rs12908161	1	rs35316992	ENSG00000275120.1	RP11-182J1.17	5.28	2e-07	2.92e-05	0.28	0.24	Schizophrenia;	chr15:84704902	chr15:84599434~84606463:-
THCA	cis	rs1050631	0.556	rs4267398	ENSG00000260552.1	RP11-49I11.1	5.28	2e-07	2.92e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36187786	chr18:36179996~36187448:-
THCA	cis	rs9543976	1	rs73223984	ENSG00000261105.4	LMO7-AS1	-5.28	2e-07	2.92e-05	-0.36	-0.24	Diabetic retinopathy;	chr13:75607005	chr13:75604700~75635994:-
THCA	cis	rs9859260	1	rs9858727	ENSG00000231464.1	AC024937.4	5.28	2e-07	2.92e-05	0.29	0.24	Mean corpuscular volume;	chr3:196067370	chr3:195996738~195998233:+
THCA	cis	rs4865169	0.967	rs10023088	ENSG00000269949.1	RP11-738E22.3	5.28	2e-07	2.92e-05	0.27	0.24	Breast cancer;	chr4:57018269	chr4:56960927~56961373:-
THCA	cis	rs5758511	0.773	rs62241023	ENSG00000281538.1	RP4-669P10.20	-5.28	2e-07	2.92e-05	-0.28	-0.24	Birth weight;	chr22:41989425	chr22:42138060~42139726:+
THCA	cis	rs6088580	0.634	rs1205344	ENSG00000276073.1	RP5-1125A11.7	5.28	2.01e-07	2.92e-05	0.2	0.24	Glomerular filtration rate (creatinine);	chr20:34330492	chr20:33985617~33988989:-
THCA	cis	rs919433	0.963	rs4850786	ENSG00000231621.1	AC013264.2	-5.28	2.01e-07	2.92e-05	-0.25	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313884	chr2:197197991~197199273:+
THCA	cis	rs2179367	0.6	rs11155654	ENSG00000268592.3	RAET1E-AS1	5.28	2.01e-07	2.92e-05	0.38	0.24	Dupuytren's disease;	chr6:149442001	chr6:149863494~149919507:+
THCA	cis	rs12935418	0.616	rs874054	ENSG00000278985.1	RP11-303E16.9	5.28	2.01e-07	2.92e-05	0.26	0.24	Mean corpuscular volume;	chr16:80972245	chr16:80982319~80984094:-
THCA	cis	rs2337406	0.866	rs7152038	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106778230	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs7152809	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106778385	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs7152832	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106778427	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.5	rs7152934	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106778702	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.789	rs12050392	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106779073	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74092505	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106779163	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.789	rs74092507	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106779174	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74092511	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106779234	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74092512	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106779306	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.789	rs74092514	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106779385	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74092520	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106779632	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs4583128	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106780669	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.929	rs12050200	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106780983	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.929	rs59263250	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781183	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs58083017	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781256	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.789	rs60390024	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781327	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74092532	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781363	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74092534	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781364	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74092537	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781883	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.81	rs74092538	ENSG00000211974.3	IGHV2-70	-5.28	2.01e-07	2.92e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781942	chr14:106723574~106724093:-
THCA	cis	rs9859260	0.925	rs2300775	ENSG00000231464.1	AC024937.4	5.28	2.01e-07	2.92e-05	0.29	0.24	Mean corpuscular volume;	chr3:196066468	chr3:195996738~195998233:+
THCA	cis	rs9859260	0.921	rs2300774	ENSG00000231464.1	AC024937.4	5.28	2.01e-07	2.92e-05	0.29	0.24	Mean corpuscular volume;	chr3:196066841	chr3:195996738~195998233:+
THCA	cis	rs9733	0.596	rs72702556	ENSG00000231073.1	RP11-316M1.3	5.28	2.01e-07	2.92e-05	0.28	0.24	Tonsillectomy;	chr1:150707639	chr1:150973123~150975534:+
THCA	cis	rs34779708	0.833	rs12777517	ENSG00000271335.4	RP11-324I22.4	5.28	2.01e-07	2.93e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35314552~35336401:-
THCA	cis	rs890448	0.796	rs2044044	ENSG00000254531.1	FLJ20021	5.28	2.01e-07	2.93e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101412708	chr4:101347780~101348883:+
THCA	cis	rs7119038	0.779	rs11217045	ENSG00000255239.1	AP002954.6	-5.28	2.01e-07	2.93e-05	-0.38	-0.24	Sjögren's syndrome;	chr11:118827156	chr11:118688039~118690600:-
THCA	cis	rs7119038	0.779	rs73005502	ENSG00000255239.1	AP002954.6	-5.28	2.01e-07	2.93e-05	-0.38	-0.24	Sjögren's syndrome;	chr11:118827197	chr11:118688039~118690600:-
THCA	cis	rs2179367	0.632	rs9498344	ENSG00000268592.3	RAET1E-AS1	5.28	2.01e-07	2.93e-05	0.34	0.24	Dupuytren's disease;	chr6:149401053	chr6:149863494~149919507:+
THCA	cis	rs442309	0.875	rs224068	ENSG00000238280.1	RP11-436D10.3	-5.28	2.01e-07	2.93e-05	-0.28	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62748340	chr10:62793562~62805887:-
THCA	cis	rs793571	0.628	rs1426652	ENSG00000259250.1	RP11-50C13.1	-5.28	2.01e-07	2.93e-05	-0.25	-0.24	Schizophrenia;	chr15:58764513	chr15:58587507~58591676:+
THCA	cis	rs9813712	0.547	rs6807290	ENSG00000249846.5	RP11-77P16.4	5.28	2.01e-07	2.93e-05	0.24	0.24	Response to amphetamines;	chr3:130297952	chr3:130112550~130120579:+
THCA	cis	rs1964356	0.967	rs2953802	ENSG00000254153.1	CTA-398F10.2	-5.28	2.01e-07	2.93e-05	-0.25	-0.24	Mean corpuscular volume;	chr8:8994371	chr8:8456909~8461337:-
THCA	cis	rs9467773	1	rs9295695	ENSG00000261353.1	CTA-14H9.5	5.28	2.01e-07	2.93e-05	0.24	0.24	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.967	rs9295694	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.967	rs9467775	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9393729	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.967	rs6456732	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs4713006	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.967	rs6924865	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6925703	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6910899	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.967	rs9461267	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.967	rs1056347	ENSG00000261353.1	CTA-14H9.5	-5.28	2.01e-07	2.93e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26527063~26527404:+
THCA	cis	rs7688540	0.771	rs11722197	ENSG00000211553.1	AC253576.2	-5.28	2.01e-07	2.93e-05	-0.36	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs11723261	ENSG00000211553.1	AC253576.2	-5.28	2.01e-07	2.93e-05	-0.36	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:136461~136568:+
THCA	cis	rs1914816	0.941	rs2460146	ENSG00000196274.5	Metazoa_SRP	5.28	2.01e-07	2.93e-05	0.33	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76262414	chr15:76230048~76230390:-
THCA	cis	rs890448	0.93	rs10011201	ENSG00000254531.1	FLJ20021	-5.28	2.01e-07	2.93e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101470298	chr4:101347780~101348883:+
THCA	cis	rs1876905	0.539	rs457497	ENSG00000271789.1	RP5-1112D6.7	5.28	2.01e-07	2.93e-05	0.3	0.24	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111297126~111298510:+
THCA	cis	rs10829156	0.947	rs7081435	ENSG00000240291.1	RP11-499P20.2	5.28	2.02e-07	2.93e-05	0.2	0.24	Sudden cardiac arrest;	chr10:18667411	chr10:18513115~18545651:-
THCA	cis	rs516805	0.528	rs2816088	ENSG00000279453.1	RP3-425C14.4	-5.28	2.02e-07	2.93e-05	-0.25	-0.24	Lymphocyte counts;	chr6:122081706	chr6:122436789~122439223:-
THCA	cis	rs9494145	0.526	rs62429811	ENSG00000232876.1	CTA-212D2.2	-5.28	2.02e-07	2.93e-05	-0.37	-0.24	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135158916	chr6:135055033~135060550:+
THCA	cis	rs2645424	1	rs7009302	ENSG00000255046.1	RP11-297N6.4	5.28	2.02e-07	2.93e-05	0.24	0.24	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11828472	chr8:11797928~11802568:-
THCA	cis	rs2880765	0.835	rs4842887	ENSG00000259630.2	CTD-2262B20.1	-5.28	2.02e-07	2.94e-05	-0.25	-0.24	Coronary artery disease;	chr15:85492579	chr15:85415228~85415633:+
THCA	cis	rs2337406	0.925	rs873534	ENSG00000274576.2	IGHV2-70	-5.28	2.02e-07	2.94e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106667423	chr14:106770577~106771020:-
THCA	cis	rs28476539	0.567	rs6812648	ENSG00000270480.1	RP11-57B24.1	5.28	2.02e-07	2.94e-05	0.37	0.24	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82643383	chr4:82691737~82692468:+
THCA	cis	rs17818399	1	rs62136864	ENSG00000279254.1	RP11-536C12.1	-5.28	2.02e-07	2.94e-05	-0.24	-0.24	Height;	chr2:46601985	chr2:46668870~46670778:+
THCA	cis	rs11795343	0.503	rs11791921	ENSG00000232303.2	DFFBP1	-5.28	2.02e-07	2.94e-05	-0.3	-0.24	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32493029	chr9:32566148~32567126:-
THCA	cis	rs755249	0.53	rs1472662	ENSG00000228060.1	RP11-69E11.8	-5.28	2.02e-07	2.94e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39124737	chr1:39565160~39573203:+
THCA	cis	rs4908768	0.539	rs922366	ENSG00000232912.4	RP5-1115A15.1	5.28	2.02e-07	2.94e-05	0.23	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8424645~8434838:+
THCA	cis	rs7760535	0.764	rs240994	ENSG00000271789.1	RP5-1112D6.7	-5.28	2.02e-07	2.94e-05	-0.23	-0.24	Metabolic traits;	chr6:111354554	chr6:111297126~111298510:+
THCA	cis	rs7760535	0.794	rs463860	ENSG00000271789.1	RP5-1112D6.7	-5.28	2.02e-07	2.94e-05	-0.23	-0.24	Metabolic traits;	chr6:111370518	chr6:111297126~111298510:+
THCA	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	5.28	2.02e-07	2.94e-05	0.27	0.24	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
THCA	cis	rs73198271	0.74	rs10092720	ENSG00000253893.2	FAM85B	5.28	2.02e-07	2.94e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8167819~8226614:-
THCA	cis	rs9467773	1	rs1321480	ENSG00000261353.1	CTA-14H9.5	-5.28	2.03e-07	2.95e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26527063~26527404:+
THCA	cis	rs9719620	0.967	rs11766620	ENSG00000236753.4	MKLN1-AS	-5.28	2.03e-07	2.95e-05	-0.23	-0.24	Male-pattern baldness;	chr7:131316597	chr7:131309744~131328222:-
THCA	cis	rs180730	0.752	rs7689532	ENSG00000251609.2	SETP12	5.28	2.03e-07	2.95e-05	0.47	0.24	Fasting plasma glucose;	chr4:120928441	chr4:120895494~120897083:-
THCA	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-5.28	2.03e-07	2.95e-05	-0.4	-0.24	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
THCA	cis	rs2360027	0.578	rs12137925	ENSG00000231365.4	RP11-418J17.1	-5.28	2.03e-07	2.95e-05	-0.23	-0.24	Tonsillectomy;	chr1:118541247	chr1:119140396~119275973:+
THCA	cis	rs8141529	0.732	rs5762784	ENSG00000272858.1	CTA-292E10.8	-5.28	2.03e-07	2.95e-05	-0.24	-0.24	Lymphocyte counts;	chr22:28775310	chr22:28814914~28815662:+
THCA	cis	rs17360053	0.859	rs9700998	ENSG00000218510.5	LINC00339	-5.28	2.03e-07	2.95e-05	-0.25	-0.24	Obesity-related traits;	chr1:22180828	chr1:22025188~22031223:+
THCA	cis	rs35934224	0.783	rs28360650	ENSG00000232926.1	AC000078.5	5.28	2.03e-07	2.95e-05	0.26	0.24	Glaucoma (primary open-angle);	chr22:19869538	chr22:19887289~19887970:+
THCA	cis	rs4660456	0.913	rs2780952	ENSG00000272145.1	NFYC-AS1	-5.27	2.03e-07	2.95e-05	-0.17	-0.24	Platelet count;	chr1:40689711	chr1:40690380~40692066:-
THCA	cis	rs831571	0.636	rs56228642	ENSG00000280620.1	SCAANT1	5.27	2.03e-07	2.95e-05	0.37	0.24	Type 2 diabetes;	chr3:64090083	chr3:63911518~63911772:-
THCA	cis	rs858239	0.669	rs56400441	ENSG00000226816.2	AC005082.12	5.27	2.03e-07	2.95e-05	0.33	0.24	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23206013~23208045:+
THCA	cis	rs4660456	0.913	rs4660448	ENSG00000272145.1	NFYC-AS1	5.27	2.03e-07	2.95e-05	0.16	0.24	Platelet count;	chr1:40724682	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs7532802	ENSG00000272145.1	NFYC-AS1	5.27	2.03e-07	2.95e-05	0.16	0.24	Platelet count;	chr1:40725528	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs2361648	ENSG00000272145.1	NFYC-AS1	5.27	2.03e-07	2.95e-05	0.16	0.24	Platelet count;	chr1:40726825	chr1:40690380~40692066:-
THCA	cis	rs863750	0.687	rs825482	ENSG00000275389.1	RP11-214K3.24	-5.27	2.03e-07	2.95e-05	-0.31	-0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091069	chr12:124085761~124088598:+
THCA	cis	rs4789693	0.679	rs7217570	ENSG00000260011.2	RP13-20L14.1	5.27	2.03e-07	2.96e-05	0.24	0.24	Glucocorticoid-induced osteonecrosis;	chr17:82421456	chr17:82381110~82382690:-
THCA	cis	rs3213758	1	rs12599436	ENSG00000275191.1	RP11-36I17.2	-5.27	2.03e-07	2.96e-05	-0.48	-0.24	Vitiligo (non-segmental);	chr16:53559959	chr16:53628256~53628816:-
THCA	cis	rs10208649	1	rs6712561	ENSG00000233266.1	HMGB1P31	5.27	2.03e-07	2.96e-05	0.55	0.24	Body mass index;	chr2:53836808	chr2:54051334~54051760:+
THCA	cis	rs10208649	1	rs6740063	ENSG00000233266.1	HMGB1P31	5.27	2.03e-07	2.96e-05	0.55	0.24	Body mass index;	chr2:53841732	chr2:54051334~54051760:+
THCA	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-5.27	2.03e-07	2.96e-05	-0.31	-0.24	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
THCA	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	5.27	2.04e-07	2.96e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
THCA	cis	rs3847687	0.546	rs12815872	ENSG00000279993.1	RP11-76C10.3	5.27	2.04e-07	2.96e-05	0.26	0.24	Longevity;	chr12:131036293	chr12:131025561~131028060:-
THCA	cis	rs2282300	0.667	rs10734405	ENSG00000242353.1	RP4-710M3.1	5.27	2.04e-07	2.96e-05	0.23	0.24	Morning vs. evening chronotype;	chr11:30252203	chr11:30368148~30368646:+
THCA	cis	rs4415084	0.8	rs1821934	ENSG00000272335.1	RP11-53O19.3	-5.27	2.04e-07	2.96e-05	-0.2	-0.24	Breast cancer;	chr5:44789070	chr5:44826076~44828592:+
THCA	cis	rs7923837	0.893	rs10882104	ENSG00000236493.2	EIF2S2P3	5.27	2.04e-07	2.96e-05	0.25	0.24	Multiple sclerosis;Body mass index;	chr10:92710758	chr10:92668745~92669743:-
THCA	cis	rs934734	0.789	rs2661798	ENSG00000237979.1	AC007389.1	-5.27	2.04e-07	2.96e-05	-0.28	-0.24	Rheumatoid arthritis;	chr2:65408554	chr2:65500993~65502138:-
THCA	cis	rs75920871	0.528	rs2513097	ENSG00000254851.1	RP11-109L13.1	5.27	2.04e-07	2.96e-05	0.34	0.24	Subjective well-being;	chr11:116965496	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.528	rs1241655	ENSG00000254851.1	RP11-109L13.1	5.27	2.04e-07	2.96e-05	0.34	0.24	Subjective well-being;	chr11:116967092	chr11:117135528~117138582:+
THCA	cis	rs853679	0.599	rs156743	ENSG00000280107.1	AL022393.9	-5.27	2.04e-07	2.97e-05	-0.34	-0.24	Depression;	chr6:27999311	chr6:28170845~28172521:+
THCA	cis	rs7617480	0.648	rs14018	ENSG00000228638.1	FCF1P2	-5.27	2.04e-07	2.97e-05	-0.3	-0.24	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48746837	chr3:48290793~48291375:-
THCA	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	5.27	2.04e-07	2.97e-05	0.36	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
THCA	cis	rs9876781	1	rs2362450	ENSG00000229759.1	MRPS18AP1	5.27	2.04e-07	2.97e-05	0.27	0.24	Longevity;	chr3:48419904	chr3:48256350~48256938:-
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000273796.1	LL21NC02-21A1.1	-5.27	2.04e-07	2.97e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45403809~45404369:-
THCA	cis	rs1552244	0.832	rs73024591	ENSG00000180385.7	EMC3-AS1	5.27	2.04e-07	2.97e-05	0.27	0.24	Alzheimer's disease;	chr3:10161510	chr3:9986893~10006990:+
THCA	cis	rs7412746	0.503	rs72704639	ENSG00000231073.1	RP11-316M1.3	5.27	2.04e-07	2.97e-05	0.28	0.24	Melanoma;	chr1:150825859	chr1:150973123~150975534:+
THCA	cis	rs7727544	0.582	rs3828675	ENSG00000224431.1	AC063976.7	5.27	2.04e-07	2.97e-05	0.2	0.24	Blood metabolite levels;	chr5:132211175	chr5:132199456~132203487:+
THCA	cis	rs9388451	0.626	rs3799708	ENSG00000226409.1	RP11-735G4.1	-5.27	2.05e-07	2.97e-05	-0.29	-0.24	Brugada syndrome;	chr6:125757384	chr6:125370211~125374324:-
THCA	cis	rs12030196	0.871	rs11207361	ENSG00000230812.4	LINC01358	5.27	2.05e-07	2.97e-05	0.31	0.24	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58991131	chr1:59020387~59044614:+
THCA	cis	rs11096990	0.964	rs11096987	ENSG00000249685.1	RP11-360F5.3	-5.27	2.05e-07	2.98e-05	-0.3	-0.24	Cognitive function;	chr4:39257570	chr4:39133913~39135608:+
THCA	cis	rs11089937	0.568	rs12159174	ENSG00000211638.2	IGLV8-61	-5.27	2.05e-07	2.98e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22098700~22099212:+
THCA	cis	rs12472274	0.646	rs35468889	ENSG00000279484.1	KLHL30-AS1	5.27	2.05e-07	2.98e-05	0.3	0.24	Phospholipid levels (plasma);	chr2:238182318	chr2:238152889~238155994:-
THCA	cis	rs13178541	0.566	rs6879940	ENSG00000250378.1	RP11-119J18.1	-5.27	2.05e-07	2.98e-05	-0.27	-0.24	IgG glycosylation;	chr5:135718040	chr5:135812667~135826582:+
THCA	cis	rs763121	0.853	rs4821798	ENSG00000228274.3	RP3-508I15.9	-5.27	2.05e-07	2.98e-05	-0.25	-0.24	Menopause (age at onset);	chr22:38625160	chr22:38667585~38681820:-
THCA	cis	rs6058796	1	rs6058796	ENSG00000175730.8	BAK1P1	5.27	2.05e-07	2.98e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32668027	chr20:32690180~32690815:-
THCA	cis	rs9733	0.596	rs3087960	ENSG00000231073.1	RP11-316M1.3	5.27	2.05e-07	2.98e-05	0.28	0.24	Tonsillectomy;	chr1:150648093	chr1:150973123~150975534:+
THCA	cis	rs76935404	0.811	rs12150973	ENSG00000256612.6	CYP2B7P	-5.27	2.05e-07	2.98e-05	-0.29	-0.24	nicotine metabolite ratio in current smokers;	chr19:40928619	chr19:40924219~40950660:+
THCA	cis	rs6570726	0.846	rs9376954	ENSG00000270638.1	RP3-466P17.1	5.27	2.05e-07	2.98e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145735570~145737218:+
THCA	cis	rs7412746	0.611	rs2256355	ENSG00000231073.1	RP11-316M1.3	5.27	2.05e-07	2.98e-05	0.28	0.24	Melanoma;	chr1:150839318	chr1:150973123~150975534:+
THCA	cis	rs12681288	0.676	rs34435811	ENSG00000260721.1	AF067845.1	5.27	2.05e-07	2.98e-05	0.29	0.24	Schizophrenia;	chr8:1040630	chr8:1368642~1369833:-
THCA	cis	rs2880765	0.835	rs7163958	ENSG00000259630.2	CTD-2262B20.1	-5.27	2.05e-07	2.98e-05	-0.25	-0.24	Coronary artery disease;	chr15:85501984	chr15:85415228~85415633:+
THCA	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	5.27	2.05e-07	2.99e-05	0.31	0.24	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
THCA	cis	rs17292804	0.506	rs71417868	ENSG00000269940.1	RP11-73M18.7	5.27	2.05e-07	2.99e-05	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103694560~103695170:+
THCA	cis	rs10895275	0.625	rs7106107	ENSG00000277459.1	RP11-732A21.3	-5.27	2.06e-07	2.99e-05	-0.18	-0.24	Migraine;	chr11:102196244	chr11:102109827~102110457:-
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000273796.1	LL21NC02-21A1.1	-5.27	2.06e-07	2.99e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45403809~45404369:-
THCA	cis	rs7923837	0.928	rs10882105	ENSG00000236493.2	EIF2S2P3	5.27	2.06e-07	2.99e-05	0.25	0.24	Multiple sclerosis;Body mass index;	chr10:92714354	chr10:92668745~92669743:-
THCA	cis	rs7772486	0.743	rs9390344	ENSG00000270638.1	RP3-466P17.1	-5.27	2.06e-07	2.99e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145735570~145737218:+
THCA	cis	rs1889642	0.798	rs1414109	ENSG00000227354.5	RBM26-AS1	5.27	2.06e-07	2.99e-05	0.22	0.24	Colonoscopy-negative controls vs population controls;	chr13:79810641	chr13:79406309~79424328:+
THCA	cis	rs2337406	0.789	rs9324095	ENSG00000211974.3	IGHV2-70	-5.27	2.06e-07	2.99e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106795885	chr14:106723574~106724093:-
THCA	cis	rs6921919	0.583	rs7764722	ENSG00000219392.1	RP1-265C24.5	-5.27	2.06e-07	2.99e-05	-0.27	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28115628~28116551:+
THCA	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	5.27	2.06e-07	2.99e-05	0.34	0.24	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	5.27	2.06e-07	2.99e-05	0.34	0.24	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
THCA	cis	rs7976269	0.609	rs6487744	ENSG00000275476.1	RP11-996F15.4	-5.27	2.06e-07	2.99e-05	-0.24	-0.24	Male-pattern baldness;	chr12:29030756	chr12:29277397~29277882:-
THCA	cis	rs7617773	0.817	rs3731497	ENSG00000199476.1	Y_RNA	-5.27	2.06e-07	2.99e-05	-0.31	-0.24	Coronary artery disease;	chr3:48185063	chr3:48288587~48288694:+
THCA	cis	rs5758659	0.716	rs2143138	ENSG00000270083.1	RP1-257I20.14	5.27	2.06e-07	2.99e-05	0.24	0.24	Cognitive function;	chr22:42222334	chr22:42089630~42090028:-
THCA	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	5.27	2.06e-07	3e-05	0.34	0.24	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
THCA	cis	rs875971	0.545	rs1909508	ENSG00000228409.4	CCT6P1	-5.27	2.06e-07	3e-05	-0.2	-0.24	Aortic root size;	chr7:66301366	chr7:65751142~65763354:+
THCA	cis	rs9549367	0.713	rs3024756	ENSG00000269125.1	RP11-98F14.11	-5.27	2.06e-07	3e-05	-0.29	-0.24	Platelet distribution width;	chr13:113168636	chr13:113165002~113165183:-
THCA	cis	rs2243480	1	rs1723267	ENSG00000230295.1	RP11-458F8.2	-5.27	2.06e-07	3e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:66008327	chr7:66880708~66882981:+
THCA	cis	rs2239547	0.522	rs2581780	ENSG00000242142.1	SERBP1P3	-5.27	2.06e-07	3e-05	-0.3	-0.24	Schizophrenia;	chr3:53024944	chr3:53064283~53065091:-
THCA	cis	rs9890032	0.618	rs1979507	ENSG00000263603.1	CTD-2349P21.5	-5.27	2.07e-07	3e-05	-0.3	-0.24	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30729469~30731202:+
THCA	cis	rs2243480	1	rs2257790	ENSG00000232559.3	GS1-124K5.12	5.27	2.07e-07	3e-05	0.34	0.24	Diabetic kidney disease;	chr7:66135463	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs316332	ENSG00000232559.3	GS1-124K5.12	5.27	2.07e-07	3e-05	0.34	0.24	Diabetic kidney disease;	chr7:66139312	chr7:66554588~66576923:-
THCA	cis	rs613391	0.561	rs1020466	ENSG00000224549.1	RP11-370B11.3	-5.27	2.07e-07	3e-05	-0.27	-0.24	Quantitative traits;	chr9:22720922	chr9:22767175~22768316:+
THCA	cis	rs17123764	0.71	rs12299505	ENSG00000257464.1	RP11-161H23.8	-5.27	2.07e-07	3e-05	-0.37	-0.24	Intelligence (multi-trait analysis);	chr12:49626111	chr12:49442424~49442652:-
THCA	cis	rs5758659	0.652	rs133336	ENSG00000227370.1	RP4-669P10.19	-5.27	2.07e-07	3.01e-05	-0.22	-0.24	Cognitive function;	chr22:42020299	chr22:42132543~42132998:+
THCA	cis	rs481331	0.601	rs210300	ENSG00000215146.4	RP11-313J2.1	-5.27	2.07e-07	3.01e-05	-0.38	-0.24	Systemic juvenile idiopathic arthritis;	chr10:42643819	chr10:42331866~42367974:-
THCA	cis	rs9733	0.596	rs6587516	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150650745	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs6678013	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150650809	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs2175615	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150651625	chr1:150973123~150975534:+
THCA	cis	rs9733	0.628	rs72700895	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150653553	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs72700897	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150653562	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs6661872	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150655881	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs11204687	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150657404	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs2867304	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150658519	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs6690725	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150659846	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs72702504	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150662898	chr1:150973123~150975534:+
THCA	cis	rs9733	0.536	rs6661415	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150663393	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs11807058	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150667999	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs34140753	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150670107	chr1:150973123~150975534:+
THCA	cis	rs9733	0.569	rs11204691	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150671863	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs12089731	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150675322	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs11204697	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150686495	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs12403255	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150687936	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs7529998	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150690055	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs11803569	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150691601	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs1336898	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150692574	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs12077833	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150701857	chr1:150973123~150975534:+
THCA	cis	rs9733	0.566	rs112967224	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150704787	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs72702552	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150704986	chr1:150973123~150975534:+
THCA	cis	rs9733	0.566	rs72702554	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150705758	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs11586422	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150706882	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs72702557	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150707654	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs17606613	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150710539	chr1:150973123~150975534:+
THCA	cis	rs9733	0.543	rs72702558	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150710775	chr1:150973123~150975534:+
THCA	cis	rs9733	0.628	rs11807409	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150710947	chr1:150973123~150975534:+
THCA	cis	rs9733	0.565	rs11804276	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150713285	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs12072339	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150713623	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs34600506	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150715332	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs72702570	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150715720	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs11582840	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150716011	chr1:150973123~150975534:+
THCA	cis	rs9733	0.569	rs11588404	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150716053	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs72702573	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150716574	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs72702580	ENSG00000231073.1	RP11-316M1.3	5.27	2.07e-07	3.01e-05	0.28	0.24	Tonsillectomy;	chr1:150718809	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs17658705	ENSG00000231073.1	RP11-316M1.3	-5.27	2.07e-07	3.01e-05	-0.28	-0.24	Tonsillectomy;	chr1:150705595	chr1:150973123~150975534:+
THCA	cis	rs9467773	0.967	rs1535276	ENSG00000261353.1	CTA-14H9.5	-5.27	2.07e-07	3.01e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26520713	chr6:26527063~26527404:+
THCA	cis	rs950169	0.58	rs2271431	ENSG00000275120.1	RP11-182J1.17	5.27	2.07e-07	3.01e-05	0.28	0.24	Schizophrenia;	chr15:84646233	chr15:84599434~84606463:-
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000232559.3	GS1-124K5.12	5.27	2.07e-07	3.01e-05	0.36	0.24	Diabetic kidney disease;	chr7:66500146	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000232559.3	GS1-124K5.12	5.27	2.07e-07	3.01e-05	0.36	0.24	Diabetic kidney disease;	chr7:66500834	chr7:66554588~66576923:-
THCA	cis	rs890448	0.734	rs2013410	ENSG00000254531.1	FLJ20021	-5.27	2.07e-07	3.01e-05	-0.22	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101449026	chr4:101347780~101348883:+
THCA	cis	rs875971	1	rs3981131	ENSG00000223473.2	GS1-124K5.3	5.27	2.07e-07	3.01e-05	0.16	0.24	Aortic root size;	chr7:66486690	chr7:66491049~66493566:-
THCA	cis	rs714027	1	rs714027	ENSG00000279159.1	RP3-394A18.1	5.27	2.08e-07	3.01e-05	0.16	0.24	Lymphocyte counts;	chr22:30181782	chr22:29978950~30028236:-
THCA	cis	rs1580019	0.537	rs7804609	ENSG00000231952.3	DPY19L1P2	-5.27	2.08e-07	3.01e-05	-0.3	-0.24	Cognitive ability;	chr7:32518482	chr7:32812757~32838570:+
THCA	cis	rs10761482	0.859	rs2199210	ENSG00000254271.1	RP11-131N11.4	5.27	2.08e-07	3.01e-05	0.31	0.24	Schizophrenia;	chr10:60334994	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.859	rs2219533	ENSG00000254271.1	RP11-131N11.4	5.27	2.08e-07	3.01e-05	0.31	0.24	Schizophrenia;	chr10:60335156	chr10:60734342~60741828:+
THCA	cis	rs11992162	1	rs11784499	ENSG00000227888.4	FAM66A	5.27	2.08e-07	3.02e-05	0.3	0.24	Monocyte count;	chr8:11977030	chr8:12362019~12388296:+
THCA	cis	rs62246343	0.516	rs2251166	ENSG00000254485.4	RP11-380O24.1	-5.27	2.08e-07	3.02e-05	-0.26	-0.24	Fibrinogen levels;	chr3:9400053	chr3:9292588~9363303:-
THCA	cis	rs7211079	0.582	rs72852528	ENSG00000279259.1	RP11-334C17.3	5.27	2.08e-07	3.02e-05	0.3	0.24	Myocardial infarction;	chr17:80162290	chr17:80147250~80148596:+
THCA	cis	rs5751614	0.517	rs928780	ENSG00000240160.3	RN7SL263P	5.27	2.08e-07	3.02e-05	0.31	0.24	Height;	chr22:23257682	chr22:23261782~23262071:-
THCA	cis	rs11672691	0.756	rs8107333	ENSG00000270164.1	LINC01480	-5.27	2.08e-07	3.02e-05	-0.23	-0.24	Prostate cancer;	chr19:41481965	chr19:41535183~41536904:+
THCA	cis	rs9952991	0.941	rs1893217	ENSG00000260302.1	RP11-973H7.1	5.27	2.08e-07	3.02e-05	0.39	0.24	Inflammatory skin disease;	chr18:12809341	chr18:12774651~12775923:-
THCA	cis	rs9311474	0.502	rs4687624	ENSG00000243224.1	RP5-1157M23.2	-5.27	2.08e-07	3.02e-05	-0.26	-0.24	Electroencephalogram traits;	chr3:52529556	chr3:52239258~52241097:+
THCA	cis	rs7617773	0.963	rs9822496	ENSG00000199476.1	Y_RNA	-5.27	2.08e-07	3.02e-05	-0.3	-0.24	Coronary artery disease;	chr3:48139843	chr3:48288587~48288694:+
THCA	cis	rs7727544	0.647	rs7721882	ENSG00000233006.5	AC034220.3	5.27	2.08e-07	3.02e-05	0.19	0.24	Blood metabolite levels;	chr5:132083255	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.625	rs3864277	ENSG00000233006.5	AC034220.3	5.27	2.08e-07	3.02e-05	0.19	0.24	Blood metabolite levels;	chr5:132084556	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.647	rs6898270	ENSG00000233006.5	AC034220.3	5.27	2.08e-07	3.02e-05	0.19	0.24	Blood metabolite levels;	chr5:132085497	chr5:132311285~132369916:-
THCA	cis	rs5758659	1	rs5758677	ENSG00000281538.1	RP4-669P10.20	5.27	2.08e-07	3.02e-05	0.22	0.24	Cognitive function;	chr22:42247033	chr22:42138060~42139726:+
THCA	cis	rs9876781	1	rs922075	ENSG00000229759.1	MRPS18AP1	-5.27	2.08e-07	3.02e-05	-0.27	-0.24	Longevity;	chr3:48447994	chr3:48256350~48256938:-
THCA	cis	rs564343	0.966	rs484983	ENSG00000255320.1	RP11-755F10.1	-5.27	2.08e-07	3.02e-05	-0.29	-0.24	Obesity (early onset extreme);	chr11:66112992	chr11:66244840~66246239:-
THCA	cis	rs467650	0.817	rs17730306	ENSG00000248489.1	CTD-2007H13.3	5.27	2.08e-07	3.02e-05	0.23	0.24	Venous thromboembolism (SNP x SNP interaction);	chr5:98721327	chr5:98929171~98995013:+
THCA	cis	rs9595908	0.869	rs7337687	ENSG00000212293.1	SNORA16	-5.27	2.08e-07	3.02e-05	-0.28	-0.24	Body mass index;	chr13:32595560	chr13:32420390~32420516:-
THCA	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-5.27	2.08e-07	3.02e-05	-0.29	-0.24	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
THCA	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-5.27	2.08e-07	3.02e-05	-0.29	-0.24	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
THCA	cis	rs875971	0.54	rs1723268	ENSG00000273142.1	RP11-458F8.4	-5.27	2.08e-07	3.02e-05	-0.19	-0.24	Aortic root size;	chr7:66008093	chr7:66902857~66906297:+
THCA	cis	rs1552244	0.935	rs11926481	ENSG00000232901.1	CYCSP10	5.27	2.08e-07	3.02e-05	0.31	0.24	Alzheimer's disease;	chr3:10100418	chr3:10000647~10000940:-
THCA	cis	rs4845570	1	rs3811415	ENSG00000203288.3	RP11-98D18.9	-5.27	2.08e-07	3.03e-05	-0.28	-0.24	Coronary artery disease;	chr1:151791291	chr1:151790804~151794402:+
THCA	cis	rs9733	0.519	rs12095002	ENSG00000231073.1	RP11-316M1.3	5.27	2.08e-07	3.03e-05	0.28	0.24	Tonsillectomy;	chr1:150676773	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs12085275	ENSG00000231073.1	RP11-316M1.3	5.27	2.08e-07	3.03e-05	0.28	0.24	Tonsillectomy;	chr1:150677789	chr1:150973123~150975534:+
THCA	cis	rs9733	0.544	rs2867302	ENSG00000231073.1	RP11-316M1.3	5.27	2.08e-07	3.03e-05	0.28	0.24	Tonsillectomy;	chr1:150681174	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs2867301	ENSG00000231073.1	RP11-316M1.3	5.27	2.08e-07	3.03e-05	0.28	0.24	Tonsillectomy;	chr1:150681319	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs7538493	ENSG00000231073.1	RP11-316M1.3	5.27	2.08e-07	3.03e-05	0.28	0.24	Tonsillectomy;	chr1:150682945	chr1:150973123~150975534:+
THCA	cis	rs4970988	0.64	rs7524734	ENSG00000231073.1	RP11-316M1.3	5.27	2.08e-07	3.03e-05	0.28	0.24	Urate levels;	chr1:150683210	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs6685702	ENSG00000231073.1	RP11-316M1.3	5.27	2.08e-07	3.03e-05	0.28	0.24	Tonsillectomy;	chr1:150683831	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs7549795	ENSG00000231073.1	RP11-316M1.3	5.27	2.08e-07	3.03e-05	0.28	0.24	Tonsillectomy;	chr1:150684397	chr1:150973123~150975534:+
THCA	cis	rs2617170	0.922	rs2086098	ENSG00000245648.1	RP11-277P12.20	5.27	2.09e-07	3.03e-05	0.26	0.24	Behcet's disease;	chr12:10373949	chr12:10363769~10398506:+
THCA	cis	rs2288884	0.505	rs2278414	ENSG00000269483.1	AC006272.1	5.27	2.09e-07	3.03e-05	0.38	0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964569	chr19:51839924~51843324:-
THCA	cis	rs17123764	0.605	rs4133070	ENSG00000257464.1	RP11-161H23.8	-5.27	2.09e-07	3.03e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49684341	chr12:49442424~49442652:-
THCA	cis	rs7246657	0.525	rs10410594	ENSG00000226686.6	LINC01535	-5.27	2.09e-07	3.03e-05	-0.37	-0.24	Coronary artery calcification;	chr19:36986856	chr19:37251912~37265535:+
THCA	cis	rs17772222	0.701	rs453112	ENSG00000258983.2	RP11-507K2.2	-5.27	2.09e-07	3.03e-05	-0.28	-0.24	Coronary artery calcification;	chr14:88392657	chr14:88499334~88515502:+
THCA	cis	rs1707322	0.721	rs61784800	ENSG00000281133.1	AL355480.3	5.27	2.09e-07	3.03e-05	0.29	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45580892~45580996:-
THCA	cis	rs2337406	1	rs61268362	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	3.03e-05	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106697010	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.85	rs8014460	ENSG00000211974.3	IGHV2-70	-5.27	2.09e-07	3.03e-05	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106697140	chr14:106723574~106724093:-
THCA	cis	rs4713118	0.513	rs149944	ENSG00000226314.6	ZNF192P1	-5.27	2.09e-07	3.03e-05	-0.28	-0.24	Parkinson's disease;	chr6:28035040	chr6:28161781~28169594:+
THCA	cis	rs714027	1	rs1003342	ENSG00000279159.1	RP3-394A18.1	5.27	2.09e-07	3.03e-05	0.16	0.24	Lymphocyte counts;	chr22:30174033	chr22:29978950~30028236:-
THCA	cis	rs763567	0.935	rs2988392	ENSG00000271811.1	RP1-79C4.4	5.27	2.09e-07	3.03e-05	0.27	0.24	Tonsillectomy;	chr1:170647214	chr1:170667381~170669425:+
THCA	cis	rs5769707	0.521	rs74351010	ENSG00000235111.1	RP1-29C18.8	5.27	2.09e-07	3.03e-05	0.39	0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49612657~49615716:-
THCA	cis	rs7824557	0.767	rs1897951	ENSG00000154316.13	TDH	-5.27	2.09e-07	3.03e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11312345	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.767	rs11250127	ENSG00000154316.13	TDH	-5.27	2.09e-07	3.03e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11312700	chr8:11339637~11368452:+
THCA	cis	rs8064024	1	rs8064024	ENSG00000267077.1	RP11-127I20.5	-5.27	2.09e-07	3.03e-05	-0.26	-0.24	Cancer;	chr16:4805278	chr16:4795265~4796532:-
THCA	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	5.27	2.09e-07	3.03e-05	0.31	0.24	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
THCA	cis	rs2436845	0.627	rs1897787	ENSG00000253669.3	KB-1732A1.1	5.27	2.09e-07	3.03e-05	0.26	0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102850195	chr8:102805517~102809971:+
THCA	cis	rs2985684	0.846	rs11157693	ENSG00000278009.1	RP11-649E7.8	5.27	2.09e-07	3.03e-05	0.33	0.24	Carotid intima media thickness;	chr14:49581708	chr14:49601011~49601124:-
THCA	cis	rs7617773	0.817	rs13059037	ENSG00000199476.1	Y_RNA	-5.27	2.09e-07	3.03e-05	-0.31	-0.24	Coronary artery disease;	chr3:48246389	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs35414021	ENSG00000199476.1	Y_RNA	-5.27	2.09e-07	3.03e-05	-0.31	-0.24	Coronary artery disease;	chr3:48252034	chr3:48288587~48288694:+
THCA	cis	rs7772486	0.686	rs2179323	ENSG00000270638.1	RP3-466P17.1	-5.27	2.09e-07	3.03e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145735570~145737218:+
THCA	cis	rs11089937	0.597	rs4821768	ENSG00000211639.2	IGLV4-60	5.27	2.09e-07	3.03e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs4821770	ENSG00000211639.2	IGLV4-60	5.27	2.09e-07	3.03e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.568	rs4821771	ENSG00000211639.2	IGLV4-60	5.27	2.09e-07	3.03e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.597	rs4821773	ENSG00000211639.2	IGLV4-60	5.27	2.09e-07	3.03e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22162199~22162681:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000182722.5	SEPHS1P1	-5.27	2.09e-07	3.04e-05	-0.29	-0.24	Calcium levels;	chr7:65829495	chr7:64852397~64853354:-
THCA	cis	rs240993	0.812	rs7764543	ENSG00000271789.1	RP5-1112D6.7	-5.27	2.09e-07	3.04e-05	-0.29	-0.24	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111297126~111298510:+
THCA	cis	rs2115536	0.967	rs4778734	ENSG00000278600.1	RP11-81A1.6	-5.27	2.09e-07	3.04e-05	-0.15	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79918509	chr15:79920195~79922455:-
THCA	cis	rs11096990	0.964	rs11096986	ENSG00000249685.1	RP11-360F5.3	-5.27	2.09e-07	3.04e-05	-0.3	-0.24	Cognitive function;	chr4:39257122	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.964	rs6828598	ENSG00000249685.1	RP11-360F5.3	-5.27	2.09e-07	3.04e-05	-0.3	-0.24	Cognitive function;	chr4:39259850	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.928	rs2008681	ENSG00000249685.1	RP11-360F5.3	-5.27	2.09e-07	3.04e-05	-0.3	-0.24	Cognitive function;	chr4:39266396	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.964	rs16988409	ENSG00000249685.1	RP11-360F5.3	5.27	2.09e-07	3.04e-05	0.3	0.24	Cognitive function;	chr4:39267730	chr4:39133913~39135608:+
THCA	cis	rs11634944	0.705	rs2554441	ENSG00000257151.1	PWAR6	5.27	2.09e-07	3.04e-05	0.18	0.24	Interleukin-8 levels;	chr15:25031500	chr15:25031873~25036490:+
THCA	cis	rs10875746	0.669	rs10875792	ENSG00000258234.1	RP11-370I10.2	5.27	2.09e-07	3.04e-05	0.28	0.24	Longevity (90 years and older);	chr12:48303640	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.623	rs10875793	ENSG00000258234.1	RP11-370I10.2	5.27	2.09e-07	3.04e-05	0.28	0.24	Longevity (90 years and older);	chr12:48303647	chr12:48231098~48284210:-
THCA	cis	rs2854160	0.581	rs2727319	ENSG00000240280.5	TCAM1P	-5.27	2.09e-07	3.04e-05	-0.32	-0.24	Height;	chr17:63882855	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.536	rs2854190	ENSG00000240280.5	TCAM1P	-5.27	2.09e-07	3.04e-05	-0.32	-0.24	Height;	chr17:63882859	chr17:63849292~63864379:+
THCA	cis	rs7308116	0.645	rs10861834	ENSG00000257951.1	RP11-554D14.4	5.27	2.09e-07	3.04e-05	0.27	0.24	Pelvic organ prolapse (moderate/severe);	chr12:107903134	chr12:107881242~107883382:+
THCA	cis	rs16852403	0.502	rs6682970	ENSG00000224687.1	RASAL2-AS1	5.27	2.09e-07	3.04e-05	0.36	0.24	Childhood ear infection;	chr1:178201385	chr1:178091508~178093984:-
THCA	cis	rs7246657	0.525	rs10401417	ENSG00000226686.6	LINC01535	-5.27	2.09e-07	3.04e-05	-0.37	-0.24	Coronary artery calcification;	chr19:36976638	chr19:37251912~37265535:+
THCA	cis	rs2337406	0.866	rs112089985	ENSG00000211974.3	IGHV2-70	-5.27	2.1e-07	3.04e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106780074	chr14:106723574~106724093:-
THCA	cis	rs67478160	0.619	rs3742365	ENSG00000258735.1	LINC00637	-5.27	2.1e-07	3.04e-05	-0.28	-0.24	Schizophrenia;	chr14:103731914	chr14:103847721~103858049:+
THCA	cis	rs6997458	0.742	rs10095352	ENSG00000253549.4	RP11-317J10.2	5.27	2.1e-07	3.04e-05	0.23	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85460203	chr8:85441851~85464915:-
THCA	cis	rs6997458	0.742	rs3758077	ENSG00000253549.4	RP11-317J10.2	5.27	2.1e-07	3.04e-05	0.23	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463274	chr8:85441851~85464915:-
THCA	cis	rs116095464	0.558	rs6879656	ENSG00000248925.1	CTD-2083E4.6	5.27	2.1e-07	3.04e-05	0.36	0.24	Breast cancer;	chr5:264313	chr5:269858~271516:-
THCA	cis	rs11089937	0.626	rs737840	ENSG00000211638.2	IGLV8-61	-5.27	2.1e-07	3.04e-05	-0.2	-0.24	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22098700~22099212:+
THCA	cis	rs11089937	0.626	rs737841	ENSG00000211638.2	IGLV8-61	-5.27	2.1e-07	3.04e-05	-0.2	-0.24	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22098700~22099212:+
THCA	cis	rs442309	0.875	rs224063	ENSG00000238280.1	RP11-436D10.3	5.27	2.1e-07	3.04e-05	0.28	0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62743589	chr10:62793562~62805887:-
THCA	cis	rs595244	0.908	rs7174973	ENSG00000259705.1	RP11-227D13.1	5.27	2.1e-07	3.04e-05	0.38	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48471557	chr15:48645951~48652016:+
THCA	cis	rs875971	0.545	rs6950988	ENSG00000228409.4	CCT6P1	-5.27	2.1e-07	3.04e-05	-0.2	-0.24	Aortic root size;	chr7:66511428	chr7:65751142~65763354:+
THCA	cis	rs793571	0.518	rs12906705	ENSG00000259250.1	RP11-50C13.1	-5.27	2.1e-07	3.05e-05	-0.25	-0.24	Schizophrenia;	chr15:58662837	chr15:58587507~58591676:+
THCA	cis	rs7674212	0.507	rs223361	ENSG00000248971.2	KRT8P46	-5.27	2.1e-07	3.05e-05	-0.29	-0.24	Type 2 diabetes;	chr4:102848147	chr4:102728746~102730171:-
THCA	cis	rs1129187	0.72	rs9471972	ENSG00000272223.1	RP1-20C7.6	5.27	2.1e-07	3.05e-05	0.18	0.24	Alzheimer's disease in APOE e4+ carriers;	chr6:42947283	chr6:43033897~43034405:-
THCA	cis	rs5758511	0.633	rs5758690	ENSG00000281538.1	RP4-669P10.20	-5.27	2.1e-07	3.05e-05	-0.26	-0.24	Birth weight;	chr22:42272289	chr22:42138060~42139726:+
THCA	cis	rs34779708	0.897	rs4934529	ENSG00000271335.4	RP11-324I22.4	5.27	2.1e-07	3.05e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs7920095	ENSG00000271335.4	RP11-324I22.4	5.27	2.1e-07	3.05e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs66887762	ENSG00000271335.4	RP11-324I22.4	5.27	2.1e-07	3.05e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35314552~35336401:-
THCA	cis	rs2853333	0.934	rs2519961	ENSG00000269553.1	U62631.5	-5.27	2.1e-07	3.05e-05	-0.25	-0.24	Red blood cell count;	chr19:35260776	chr19:35330843~35331920:+
THCA	cis	rs7824557	0.872	rs1347410	ENSG00000154316.13	TDH	5.27	2.1e-07	3.05e-05	0.17	0.24	Retinal vascular caliber;	chr8:11253733	chr8:11339637~11368452:+
THCA	cis	rs2239547	0.522	rs2564947	ENSG00000242142.1	SERBP1P3	-5.27	2.1e-07	3.05e-05	-0.29	-0.24	Schizophrenia;	chr3:53012200	chr3:53064283~53065091:-
THCA	cis	rs7772486	0.686	rs702314	ENSG00000270638.1	RP3-466P17.1	-5.27	2.1e-07	3.05e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.624	rs9485018	ENSG00000270638.1	RP3-466P17.1	-5.27	2.1e-07	3.05e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs2092263	ENSG00000270638.1	RP3-466P17.1	-5.27	2.1e-07	3.05e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs9390347	ENSG00000270638.1	RP3-466P17.1	-5.27	2.1e-07	3.05e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs9390348	ENSG00000270638.1	RP3-466P17.1	-5.27	2.1e-07	3.05e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.632	rs9386128	ENSG00000270638.1	RP3-466P17.1	-5.27	2.1e-07	3.05e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145735570~145737218:+
THCA	cis	rs2235642	0.821	rs2281234	ENSG00000280231.1	LA16c-380F5.3	-5.27	2.11e-07	3.05e-05	-0.28	-0.24	Coronary artery disease;	chr16:1552937	chr16:1553655~1554130:-
THCA	cis	rs2243480	1	rs10950032	ENSG00000230295.1	RP11-458F8.2	5.27	2.11e-07	3.05e-05	0.29	0.24	Diabetic kidney disease;	chr7:66273604	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6958420	ENSG00000230295.1	RP11-458F8.2	5.27	2.11e-07	3.05e-05	0.29	0.24	Diabetic kidney disease;	chr7:66286184	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1392104	ENSG00000230295.1	RP11-458F8.2	5.27	2.11e-07	3.05e-05	0.29	0.24	Diabetic kidney disease;	chr7:66294120	chr7:66880708~66882981:+
THCA	cis	rs7646881	0.544	rs1864502	ENSG00000240207.5	RP11-379F4.4	-5.27	2.11e-07	3.05e-05	-0.34	-0.24	Tetralogy of Fallot;	chr3:158648625	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs61107068	ENSG00000240207.5	RP11-379F4.4	-5.27	2.11e-07	3.05e-05	-0.34	-0.24	Tetralogy of Fallot;	chr3:158665915	chr3:158732263~158784070:+
THCA	cis	rs2439831	0.85	rs2957637	ENSG00000205771.5	CATSPER2P1	-5.27	2.11e-07	3.05e-05	-0.33	-0.24	Lung cancer in ever smokers;	chr15:43658920	chr15:43726918~43747094:-
THCA	cis	rs4415084	0.804	rs4518409	ENSG00000272335.1	RP11-53O19.3	5.27	2.11e-07	3.05e-05	0.19	0.24	Breast cancer;	chr5:44870750	chr5:44826076~44828592:+
THCA	cis	rs9329221	0.905	rs13252982	ENSG00000261451.1	RP11-981G7.1	-5.27	2.11e-07	3.05e-05	-0.29	-0.24	Neuroticism;	chr8:10397595	chr8:10433672~10438312:+
THCA	cis	rs9329221	0.87	rs11777976	ENSG00000261451.1	RP11-981G7.1	-5.27	2.11e-07	3.05e-05	-0.29	-0.24	Neuroticism;	chr8:10397892	chr8:10433672~10438312:+
THCA	cis	rs875971	0.545	rs75840613	ENSG00000228409.4	CCT6P1	-5.27	2.11e-07	3.06e-05	-0.2	-0.24	Aortic root size;	chr7:66376399	chr7:65751142~65763354:+
THCA	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	5.27	2.11e-07	3.06e-05	0.27	0.24	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
THCA	cis	rs874628	1	rs874628	ENSG00000268650.3	AC068499.10	5.27	2.11e-07	3.06e-05	0.28	0.24	Multiple sclerosis;	chr19:18193890	chr19:18204730~18220480:+
THCA	cis	rs7829975	0.539	rs883647	ENSG00000253893.2	FAM85B	5.27	2.11e-07	3.06e-05	0.32	0.24	Mood instability;	chr8:8712214	chr8:8167819~8226614:-
THCA	cis	rs11603691	1	rs11228927	ENSG00000254662.1	RP11-872D17.4	-5.27	2.11e-07	3.06e-05	-0.47	-0.24	Low high density lipoprotein cholesterol levels;	chr11:57162889	chr11:57325603~57327958:+
THCA	cis	rs7394190	0.748	rs3781216	ENSG00000271816.1	BMS1P4	-5.27	2.11e-07	3.06e-05	-0.29	-0.24	Incident atrial fibrillation;	chr10:73762646	chr10:73699151~73730487:-
THCA	cis	rs16976116	0.532	rs6493754	ENSG00000279145.1	RP11-547D13.1	-5.27	2.11e-07	3.06e-05	-0.26	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55143600	chr15:55171972~55178175:-
THCA	cis	rs2692947	0.683	rs2315416	ENSG00000232931.4	LINC00342	5.27	2.11e-07	3.06e-05	0.19	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892729	chr2:95807118~95816215:-
THCA	cis	rs34779708	0.966	rs12769484	ENSG00000271335.4	RP11-324I22.4	5.27	2.11e-07	3.06e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35314552~35336401:-
THCA	cis	rs7246657	0.722	rs2909105	ENSG00000276846.1	CTD-3220F14.3	-5.27	2.11e-07	3.06e-05	-0.24	-0.24	Coronary artery calcification;	chr19:37677005	chr19:37314868~37315620:-
THCA	cis	rs481331	0.643	rs209387	ENSG00000215146.4	RP11-313J2.1	-5.27	2.11e-07	3.06e-05	-0.38	-0.24	Systemic juvenile idiopathic arthritis;	chr10:42636784	chr10:42331866~42367974:-
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000230295.1	RP11-458F8.2	-5.27	2.11e-07	3.06e-05	-0.3	-0.24	Diabetic kidney disease;	chr7:66557269	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1267820	ENSG00000230295.1	RP11-458F8.2	-5.27	2.11e-07	3.06e-05	-0.3	-0.24	Diabetic kidney disease;	chr7:66585308	chr7:66880708~66882981:+
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000261839.1	RP1-265C24.8	-5.27	2.11e-07	3.06e-05	-0.27	-0.24	Parkinson's disease;	chr6:28065396	chr6:28136849~28139678:+
THCA	cis	rs875971	0.545	rs11767262	ENSG00000228409.4	CCT6P1	-5.27	2.11e-07	3.06e-05	-0.2	-0.24	Aortic root size;	chr7:66302237	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000228409.4	CCT6P1	-5.27	2.11e-07	3.06e-05	-0.2	-0.24	Aortic root size;	chr7:66327797	chr7:65751142~65763354:+
THCA	cis	rs11089937	0.626	rs2213161	ENSG00000211638.2	IGLV8-61	-5.27	2.11e-07	3.06e-05	-0.2	-0.24	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22098700~22099212:+
THCA	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	5.27	2.11e-07	3.06e-05	0.29	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
THCA	cis	rs17123764	0.605	rs12303310	ENSG00000257464.1	RP11-161H23.8	-5.27	2.11e-07	3.06e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49672210	chr12:49442424~49442652:-
THCA	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	5.27	2.11e-07	3.07e-05	0.15	0.24	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
THCA	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	5.27	2.11e-07	3.07e-05	0.23	0.24	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
THCA	cis	rs7577696	0.814	rs435572	ENSG00000276334.1	AL133243.1	5.27	2.12e-07	3.07e-05	0.25	0.24	Inflammatory biomarkers;	chr2:32263012	chr2:32521927~32523547:+
THCA	cis	rs6479901	0.696	rs931972	ENSG00000232075.1	MRPL35P2	-5.27	2.12e-07	3.07e-05	-0.36	-0.24	Intelligence (multi-trait analysis);	chr10:63150467	chr10:63634317~63634827:-
THCA	cis	rs763121	0.819	rs5750629	ENSG00000273076.1	RP3-508I15.22	5.27	2.12e-07	3.07e-05	0.23	0.24	Menopause (age at onset);	chr22:38589060	chr22:38743495~38743910:+
THCA	cis	rs74225573	1	rs74225573	ENSG00000230337.1	RP4-635E18.6	-5.27	2.12e-07	3.07e-05	-0.51	-0.24	Corneal curvature;	chr1:11220937	chr1:11099675~11102100:+
THCA	cis	rs875971	0.545	rs17138149	ENSG00000228409.4	CCT6P1	-5.27	2.12e-07	3.07e-05	-0.2	-0.24	Aortic root size;	chr7:66228193	chr7:65751142~65763354:+
THCA	cis	rs1552244	1	rs9845756	ENSG00000180385.7	EMC3-AS1	5.27	2.12e-07	3.07e-05	0.26	0.24	Alzheimer's disease;	chr3:10025864	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs33917318	ENSG00000180385.7	EMC3-AS1	5.27	2.12e-07	3.07e-05	0.26	0.24	Alzheimer's disease;	chr3:10026113	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs35515831	ENSG00000180385.7	EMC3-AS1	5.27	2.12e-07	3.07e-05	0.26	0.24	Alzheimer's disease;	chr3:10029678	chr3:9986893~10006990:+
THCA	cis	rs4908760	0.832	rs11121209	ENSG00000232912.4	RP5-1115A15.1	5.27	2.12e-07	3.07e-05	0.23	0.24	Vitiligo;	chr1:8626803	chr1:8424645~8434838:+
THCA	cis	rs4908760	0.864	rs6674832	ENSG00000232912.4	RP5-1115A15.1	5.27	2.12e-07	3.07e-05	0.23	0.24	Vitiligo;	chr1:8631820	chr1:8424645~8434838:+
THCA	cis	rs4908760	0.864	rs1463052	ENSG00000232912.4	RP5-1115A15.1	5.27	2.12e-07	3.07e-05	0.23	0.24	Vitiligo;	chr1:8641172	chr1:8424645~8434838:+
THCA	cis	rs9329221	0.905	rs4841329	ENSG00000261451.1	RP11-981G7.1	-5.27	2.12e-07	3.07e-05	-0.29	-0.24	Neuroticism;	chr8:10395588	chr8:10433672~10438312:+
THCA	cis	rs2562456	0.833	rs62107540	ENSG00000268081.1	RP11-678G14.2	5.27	2.12e-07	3.08e-05	0.41	0.24	Pain;	chr19:21335693	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs62107541	ENSG00000268081.1	RP11-678G14.2	5.27	2.12e-07	3.08e-05	0.41	0.24	Pain;	chr19:21335733	chr19:21554640~21569237:-
THCA	cis	rs7412746	0.571	rs12402939	ENSG00000231073.1	RP11-316M1.3	5.27	2.12e-07	3.08e-05	0.29	0.24	Melanoma;	chr1:150642618	chr1:150973123~150975534:+
THCA	cis	rs12935418	0.583	rs2244452	ENSG00000278985.1	RP11-303E16.9	-5.27	2.12e-07	3.08e-05	-0.25	-0.24	Mean corpuscular volume;	chr16:80991767	chr16:80982319~80984094:-
THCA	cis	rs1129187	0.755	rs4714638	ENSG00000272223.1	RP1-20C7.6	5.27	2.12e-07	3.08e-05	0.18	0.24	Alzheimer's disease in APOE e4+ carriers;	chr6:42949279	chr6:43033897~43034405:-
THCA	cis	rs10761482	0.906	rs2219534	ENSG00000254271.1	RP11-131N11.4	5.27	2.12e-07	3.08e-05	0.31	0.24	Schizophrenia;	chr10:60335167	chr10:60734342~60741828:+
THCA	cis	rs934734	0.725	rs7581149	ENSG00000234255.7	AC012370.3	5.27	2.12e-07	3.08e-05	0.27	0.24	Rheumatoid arthritis;	chr2:65332507	chr2:65439888~65456571:-
THCA	cis	rs858239	0.539	rs6461695	ENSG00000226816.2	AC005082.12	5.27	2.13e-07	3.08e-05	0.34	0.24	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23206013~23208045:+
THCA	cis	rs9311474	0.607	rs28661185	ENSG00000243224.1	RP5-1157M23.2	-5.27	2.13e-07	3.08e-05	-0.26	-0.24	Electroencephalogram traits;	chr3:52533172	chr3:52239258~52241097:+
THCA	cis	rs1823913	1	rs6704784	ENSG00000227542.1	AC092614.2	-5.27	2.13e-07	3.08e-05	-0.29	-0.24	Obesity-related traits;	chr2:191244832	chr2:191229165~191246172:-
THCA	cis	rs7617773	0.963	rs6800730	ENSG00000228638.1	FCF1P2	-5.27	2.13e-07	3.08e-05	-0.21	-0.24	Coronary artery disease;	chr3:48132720	chr3:48290793~48291375:-
THCA	cis	rs897984	0.542	rs35713203	ENSG00000279196.1	RP11-1072A3.3	5.27	2.13e-07	3.09e-05	0.24	0.24	Dementia with Lewy bodies;	chr16:31079086	chr16:30984630~30988270:-
THCA	cis	rs4604234	0.614	rs73482038	ENSG00000272129.1	RP11-250B2.6	-5.27	2.13e-07	3.09e-05	-0.57	-0.24	Cancer;	chr6:80236540	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.803	rs3812124	ENSG00000272129.1	RP11-250B2.6	-5.27	2.13e-07	3.09e-05	-0.57	-0.24	Cancer;	chr6:80248451	chr6:80355424~80356859:+
THCA	cis	rs9475752	0.793	rs6927558	ENSG00000231441.1	RP11-472M19.2	5.27	2.13e-07	3.09e-05	0.31	0.24	Menarche (age at onset);	chr6:56949008	chr6:56844002~56864078:+
THCA	cis	rs11089937	0.589	rs4239891	ENSG00000211639.2	IGLV4-60	5.27	2.13e-07	3.09e-05	0.16	0.24	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22162199~22162681:+
THCA	cis	rs12935418	0.552	rs2113196	ENSG00000278985.1	RP11-303E16.9	-5.27	2.13e-07	3.09e-05	-0.26	-0.24	Mean corpuscular volume;	chr16:80991885	chr16:80982319~80984094:-
THCA	cis	rs5758659	0.967	rs5751250	ENSG00000281538.1	RP4-669P10.20	5.27	2.13e-07	3.09e-05	0.22	0.24	Cognitive function;	chr22:42243639	chr22:42138060~42139726:+
THCA	cis	rs6570726	0.846	rs6899900	ENSG00000270638.1	RP3-466P17.1	5.27	2.13e-07	3.09e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145735570~145737218:+
THCA	cis	rs2439831	0.867	rs2260160	ENSG00000205771.5	CATSPER2P1	-5.27	2.13e-07	3.09e-05	-0.31	-0.24	Lung cancer in ever smokers;	chr15:43603445	chr15:43726918~43747094:-
THCA	cis	rs4648045	0.929	rs230493	ENSG00000246560.2	RP11-10L12.4	5.27	2.13e-07	3.09e-05	0.29	0.24	Lymphocyte percentage of white cells;	chr4:102565059	chr4:102828055~102844075:+
THCA	cis	rs13201294	1	rs13201294	ENSG00000226314.6	ZNF192P1	-5.27	2.14e-07	3.09e-05	-0.41	-0.24	Squamous cell lung carcinoma;	chr6:27588362	chr6:28161781~28169594:+
THCA	cis	rs2360027	0.599	rs12136968	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118540831	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.578	rs12137078	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118541190	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs12137110	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118541253	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs12140512	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118541263	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs2209365	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118541494	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.578	rs2209366	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118541628	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs12135389	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118542071	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs1575615	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118542661	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs1575616	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118542689	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs2102337	ENSG00000231365.4	RP11-418J17.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Tonsillectomy;	chr1:118543266	chr1:119140396~119275973:+
THCA	cis	rs5742933	0.857	rs1233272	ENSG00000253559.1	OSGEPL1-AS1	-5.27	2.14e-07	3.09e-05	-0.27	-0.24	Ferritin levels;	chr2:189814968	chr2:189762704~189765556:+
THCA	cis	rs2282300	0.653	rs12800124	ENSG00000242353.1	RP4-710M3.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30218318	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs35883696	ENSG00000242353.1	RP4-710M3.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30224860	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs34224414	ENSG00000242353.1	RP4-710M3.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30229494	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs12577729	ENSG00000242353.1	RP4-710M3.1	-5.27	2.14e-07	3.09e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30235830	chr11:30368148~30368646:+
THCA	cis	rs2179367	0.632	rs9498325	ENSG00000223701.3	RAET1E-AS1	5.26	2.14e-07	3.1e-05	0.34	0.24	Dupuytren's disease;	chr6:149345993	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498326	ENSG00000223701.3	RAET1E-AS1	5.26	2.14e-07	3.1e-05	0.34	0.24	Dupuytren's disease;	chr6:149346112	chr6:149884431~149919508:+
THCA	cis	rs1580019	0.563	rs2392071	ENSG00000231952.3	DPY19L1P2	-5.26	2.14e-07	3.1e-05	-0.29	-0.24	Cognitive ability;	chr7:32532924	chr7:32812757~32838570:+
THCA	cis	rs2136613	0.751	rs224307	ENSG00000238280.1	RP11-436D10.3	5.26	2.14e-07	3.1e-05	0.27	0.24	Selective IgA deficiency;	chr10:62841675	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.751	rs224308	ENSG00000238280.1	RP11-436D10.3	5.26	2.14e-07	3.1e-05	0.27	0.24	Selective IgA deficiency;	chr10:62843007	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.751	rs224309	ENSG00000238280.1	RP11-436D10.3	5.26	2.14e-07	3.1e-05	0.27	0.24	Selective IgA deficiency;	chr10:62848544	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.751	rs224310	ENSG00000238280.1	RP11-436D10.3	5.26	2.14e-07	3.1e-05	0.27	0.24	Selective IgA deficiency;	chr10:62851821	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.751	rs224311	ENSG00000238280.1	RP11-436D10.3	5.26	2.14e-07	3.1e-05	0.27	0.24	Selective IgA deficiency;	chr10:62854429	chr10:62793562~62805887:-
THCA	cis	rs9890032	0.57	rs8068504	ENSG00000263603.1	CTD-2349P21.5	-5.26	2.14e-07	3.1e-05	-0.3	-0.24	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30729469~30731202:+
THCA	cis	rs8177876	0.749	rs58144189	ENSG00000261838.4	RP11-303E16.6	5.26	2.14e-07	3.1e-05	0.43	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.749	rs1035541	ENSG00000261838.4	RP11-303E16.6	5.26	2.14e-07	3.1e-05	0.43	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81069854~81076598:+
THCA	cis	rs5752326	1	rs5761530	ENSG00000261188.1	CTA-445C9.14	5.26	2.14e-07	3.1e-05	0.27	0.24	Ischemic stroke;	chr22:26447950	chr22:26512537~26514568:+
THCA	cis	rs5752326	0.867	rs5761531	ENSG00000261188.1	CTA-445C9.14	5.26	2.14e-07	3.1e-05	0.27	0.24	Ischemic stroke;	chr22:26448180	chr22:26512537~26514568:+
THCA	cis	rs11733284	0.894	rs321630	ENSG00000259959.1	RP11-121C2.2	5.26	2.14e-07	3.1e-05	0.2	0.24	Gout;Renal underexcretion gout;	chr4:48016153	chr4:47840122~47844339:-
THCA	cis	rs11733284	0.963	rs321631	ENSG00000259959.1	RP11-121C2.2	5.26	2.14e-07	3.1e-05	0.2	0.24	Gout;Renal underexcretion gout;	chr4:48016212	chr4:47840122~47844339:-
THCA	cis	rs9733	0.519	rs10788792	ENSG00000231073.1	RP11-316M1.3	5.26	2.14e-07	3.1e-05	0.28	0.24	Tonsillectomy;	chr1:150666096	chr1:150973123~150975534:+
THCA	cis	rs9733	0.526	rs11204696	ENSG00000231073.1	RP11-316M1.3	5.26	2.14e-07	3.1e-05	0.28	0.24	Tonsillectomy;	chr1:150686245	chr1:150973123~150975534:+
THCA	cis	rs9733	0.526	rs11204698	ENSG00000231073.1	RP11-316M1.3	5.26	2.14e-07	3.1e-05	0.28	0.24	Tonsillectomy;	chr1:150687069	chr1:150973123~150975534:+
THCA	cis	rs9733	0.519	rs2184833	ENSG00000231073.1	RP11-316M1.3	5.26	2.14e-07	3.1e-05	0.28	0.24	Tonsillectomy;	chr1:150703007	chr1:150973123~150975534:+
THCA	cis	rs9733	0.519	rs1336899	ENSG00000231073.1	RP11-316M1.3	5.26	2.14e-07	3.1e-05	0.28	0.24	Tonsillectomy;	chr1:150706434	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs11803940	ENSG00000231073.1	RP11-316M1.3	5.26	2.14e-07	3.1e-05	0.28	0.24	Melanoma;	chr1:150713359	chr1:150973123~150975534:+
THCA	cis	rs6993270	0.779	rs7000890	ENSG00000245330.4	KB-1471A8.1	-5.26	2.15e-07	3.11e-05	-0.31	-0.24	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119911053	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.725	rs76539987	ENSG00000245330.4	KB-1471A8.1	-5.26	2.15e-07	3.11e-05	-0.31	-0.24	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119911058	chr8:119867419~119874488:-
THCA	cis	rs4819052	0.572	rs4819027	ENSG00000237664.1	LINC00316	5.26	2.15e-07	3.11e-05	0.27	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45075309	chr21:45338590~45341990:-
THCA	cis	rs4888671	1	rs76986350	ENSG00000261707.1	RP11-264M12.2	5.26	2.15e-07	3.11e-05	0.44	0.24	Obesity-related traits;	chr16:77750841	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs17769643	ENSG00000261707.1	RP11-264M12.2	5.26	2.15e-07	3.11e-05	0.44	0.24	Obesity-related traits;	chr16:77751078	chr16:77741468~77743000:-
THCA	cis	rs8042680	0.592	rs4381579	ENSG00000214432.8	AC068831.10	-5.26	2.15e-07	3.11e-05	-0.25	-0.24	Type 2 diabetes;	chr15:90955051	chr15:91022619~91036611:+
THCA	cis	rs8042680	0.592	rs4505290	ENSG00000214432.8	AC068831.10	-5.26	2.15e-07	3.11e-05	-0.25	-0.24	Type 2 diabetes;	chr15:90955063	chr15:91022619~91036611:+
THCA	cis	rs10875746	0.625	rs2898065	ENSG00000258234.1	RP11-370I10.2	5.26	2.15e-07	3.11e-05	0.27	0.24	Longevity (90 years and older);	chr12:48250836	chr12:48231098~48284210:-
THCA	cis	rs6570726	0.846	rs1935616	ENSG00000270638.1	RP3-466P17.1	5.26	2.15e-07	3.11e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs9399559	ENSG00000270638.1	RP3-466P17.1	5.26	2.15e-07	3.11e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs9376956	ENSG00000270638.1	RP3-466P17.1	5.26	2.15e-07	3.11e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.658	rs6570706	ENSG00000270638.1	RP3-466P17.1	5.26	2.15e-07	3.11e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145735570~145737218:+
THCA	cis	rs4713118	0.513	rs149941	ENSG00000226314.6	ZNF192P1	-5.26	2.15e-07	3.11e-05	-0.28	-0.24	Parkinson's disease;	chr6:28033255	chr6:28161781~28169594:+
THCA	cis	rs4938303	0.756	rs12802944	ENSG00000254851.1	RP11-109L13.1	5.26	2.15e-07	3.11e-05	0.39	0.24	Triglycerides;	chr11:116705684	chr11:117135528~117138582:+
THCA	cis	rs2436845	0.651	rs2513912	ENSG00000253669.3	KB-1732A1.1	5.26	2.15e-07	3.11e-05	0.26	0.24	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102809260	chr8:102805517~102809971:+
THCA	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	5.26	2.15e-07	3.11e-05	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
THCA	cis	rs478304	0.934	rs570954	ENSG00000214659.4	KRT8P26	-5.26	2.15e-07	3.11e-05	-0.2	-0.24	Acne (severe);	chr11:65730790	chr11:65726939~65728214:+
THCA	cis	rs478304	0.934	rs669742	ENSG00000214659.4	KRT8P26	-5.26	2.15e-07	3.11e-05	-0.2	-0.24	Acne (severe);	chr11:65733820	chr11:65726939~65728214:+
THCA	cis	rs478304	0.903	rs1151502	ENSG00000214659.4	KRT8P26	-5.26	2.15e-07	3.11e-05	-0.2	-0.24	Acne (severe);	chr11:65736014	chr11:65726939~65728214:+
THCA	cis	rs478304	0.934	rs1193692	ENSG00000214659.4	KRT8P26	-5.26	2.15e-07	3.11e-05	-0.2	-0.24	Acne (severe);	chr11:65736598	chr11:65726939~65728214:+
THCA	cis	rs7129556	0.645	rs684813	ENSG00000254691.1	RP11-91P24.5	5.26	2.15e-07	3.11e-05	0.35	0.24	Weight loss (gastric bypass surgery);	chr11:77783708	chr11:77850604~77851511:+
THCA	cis	rs2282300	0.739	rs7925340	ENSG00000242353.1	RP4-710M3.1	5.26	2.15e-07	3.11e-05	0.23	0.24	Morning vs. evening chronotype;	chr11:30258861	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.702	rs4379811	ENSG00000242353.1	RP4-710M3.1	5.26	2.15e-07	3.11e-05	0.23	0.24	Morning vs. evening chronotype;	chr11:30273213	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs3858428	ENSG00000242353.1	RP4-710M3.1	5.26	2.15e-07	3.11e-05	0.23	0.24	Morning vs. evening chronotype;	chr11:30275003	chr11:30368148~30368646:+
THCA	cis	rs9733	0.596	rs12086630	ENSG00000231073.1	RP11-316M1.3	5.26	2.15e-07	3.11e-05	0.28	0.24	Tonsillectomy;	chr1:150678479	chr1:150973123~150975534:+
THCA	cis	rs9733	0.596	rs2065900	ENSG00000231073.1	RP11-316M1.3	5.26	2.15e-07	3.11e-05	0.28	0.24	Tonsillectomy;	chr1:150679726	chr1:150973123~150975534:+
THCA	cis	rs763121	0.853	rs5750649	ENSG00000273076.1	RP3-508I15.22	5.26	2.15e-07	3.11e-05	0.23	0.24	Menopause (age at onset);	chr22:38640764	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs6519124	ENSG00000273076.1	RP3-508I15.22	5.26	2.15e-07	3.11e-05	0.23	0.24	Menopause (age at onset);	chr22:38649094	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5750652	ENSG00000273076.1	RP3-508I15.22	5.26	2.15e-07	3.11e-05	0.23	0.24	Menopause (age at onset);	chr22:38652311	chr22:38743495~38743910:+
THCA	cis	rs763121	0.814	rs5757212	ENSG00000273076.1	RP3-508I15.22	5.26	2.15e-07	3.11e-05	0.23	0.24	Menopause (age at onset);	chr22:38657752	chr22:38743495~38743910:+
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000164669.11	INTS4P1	5.26	2.15e-07	3.11e-05	0.54	0.24	Diabetic kidney disease;	chr7:66009932	chr7:65141225~65234216:+
THCA	cis	rs58785573	0.57	rs1824652	ENSG00000231160.8	KLF3-AS1	-5.26	2.15e-07	3.12e-05	-0.13	-0.24	Lymphocyte percentage of white cells;	chr4:38642976	chr4:38612701~38664883:-
THCA	cis	rs459482	0.534	rs458255	ENSG00000228318.3	AP001610.5	-5.26	2.15e-07	3.12e-05	-0.3	-0.24	IgG glycosylation;	chr21:41429201	chr21:41441056~41445708:-
THCA	cis	rs6921919	0.609	rs1005127	ENSG00000219392.1	RP1-265C24.5	-5.26	2.15e-07	3.12e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28115628~28116551:+
THCA	cis	rs853679	0.515	rs4580862	ENSG00000219392.1	RP1-265C24.5	-5.26	2.15e-07	3.12e-05	-0.26	-0.24	Depression;	chr6:28399886	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs4357130	ENSG00000219392.1	RP1-265C24.5	-5.26	2.15e-07	3.12e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28115628~28116551:+
THCA	cis	rs330048	0.545	rs11249913	ENSG00000254153.1	CTA-398F10.2	5.26	2.15e-07	3.12e-05	0.25	0.24	Systemic lupus erythematosus;	chr8:9286011	chr8:8456909~8461337:-
THCA	cis	rs4857855	0.716	rs35665532	ENSG00000239405.1	TMED10P2	5.26	2.15e-07	3.12e-05	0.33	0.24	Eosinophil counts;	chr3:128511553	chr3:128538020~128538631:+
THCA	cis	rs72772090	0.71	rs11750400	ENSG00000248734.2	CTD-2260A17.1	-5.26	2.15e-07	3.12e-05	-0.4	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742264	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.71	rs10515244	ENSG00000248734.2	CTD-2260A17.1	-5.26	2.15e-07	3.12e-05	-0.4	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742633	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.71	rs1559085	ENSG00000248734.2	CTD-2260A17.1	-5.26	2.15e-07	3.12e-05	-0.4	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742998	chr5:96784777~96785999:+
THCA	cis	rs72945132	0.882	rs17425511	ENSG00000254604.1	AP000487.6	-5.26	2.16e-07	3.12e-05	-0.45	-0.24	Coronary artery disease;	chr11:70337631	chr11:70282367~70363368:-
THCA	cis	rs1552244	0.935	rs11926481	ENSG00000180385.7	EMC3-AS1	5.26	2.16e-07	3.12e-05	0.26	0.24	Alzheimer's disease;	chr3:10100418	chr3:9986893~10006990:+
THCA	cis	rs6545883	0.895	rs796597	ENSG00000270820.4	RP11-355B11.2	5.26	2.16e-07	3.12e-05	0.2	0.24	Tuberculosis;	chr2:61453925	chr2:61471188~61484130:+
THCA	cis	rs7851660	0.805	rs10759981	ENSG00000214417.4	KRT18P13	-5.26	2.16e-07	3.12e-05	-0.21	-0.24	Strep throat;	chr9:97873498	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs925487	ENSG00000214417.4	KRT18P13	-5.26	2.16e-07	3.12e-05	-0.21	-0.24	Strep throat;	chr9:97874116	chr9:97698922~97700734:+
THCA	cis	rs1322639	0.614	rs4708414	ENSG00000261039.2	RP11-417E7.2	-5.26	2.16e-07	3.12e-05	-0.26	-0.24	Pulse pressure;	chr6:169174049	chr6:169175304~169182740:-
THCA	cis	rs6445975	1	rs6445975	ENSG00000272360.1	RP11-359I18.5	5.26	2.16e-07	3.12e-05	0.25	0.24	Systemic lupus erythematosus;	chr3:58384450	chr3:58490830~58491291:-
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000280069.1	CTD-2349P21.3	-5.26	2.16e-07	3.12e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30738182~30740275:+
THCA	cis	rs4888671	1	rs57935196	ENSG00000261707.1	RP11-264M12.2	5.26	2.16e-07	3.12e-05	0.44	0.24	Obesity-related traits;	chr16:77751417	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs57678958	ENSG00000261707.1	RP11-264M12.2	5.26	2.16e-07	3.12e-05	0.44	0.24	Obesity-related traits;	chr16:77751418	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs78841515	ENSG00000261707.1	RP11-264M12.2	5.26	2.16e-07	3.12e-05	0.44	0.24	Obesity-related traits;	chr16:77751558	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs78036474	ENSG00000261707.1	RP11-264M12.2	5.26	2.16e-07	3.12e-05	0.44	0.24	Obesity-related traits;	chr16:77751824	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs59181394	ENSG00000261707.1	RP11-264M12.2	5.26	2.16e-07	3.12e-05	0.44	0.24	Obesity-related traits;	chr16:77752058	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs58729171	ENSG00000261707.1	RP11-264M12.2	5.26	2.16e-07	3.12e-05	0.44	0.24	Obesity-related traits;	chr16:77752121	chr16:77741468~77743000:-
THCA	cis	rs9990333	0.526	rs11719682	ENSG00000242086.7	LINC00969	5.26	2.16e-07	3.12e-05	0.24	0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196107331	chr3:195658062~195739964:+
THCA	cis	rs4713118	0.955	rs9468206	ENSG00000226314.6	ZNF192P1	-5.26	2.16e-07	3.13e-05	-0.3	-0.24	Parkinson's disease;	chr6:27722674	chr6:28161781~28169594:+
THCA	cis	rs5758659	1	rs134902	ENSG00000227370.1	RP4-669P10.19	-5.26	2.16e-07	3.13e-05	-0.21	-0.24	Cognitive function;	chr22:42287991	chr22:42132543~42132998:+
THCA	cis	rs11722228	0.522	rs12503195	ENSG00000261490.1	RP11-448G15.3	5.26	2.16e-07	3.13e-05	0.16	0.24	Urate levels;Serum uric acid levels;Gout;	chr4:10081148	chr4:10068089~10073019:-
THCA	cis	rs240993	0.672	rs6922226	ENSG00000271789.1	RP5-1112D6.7	-5.26	2.16e-07	3.13e-05	-0.29	-0.24	Inflammatory skin disease;Psoriasis;	chr6:111403281	chr6:111297126~111298510:+
THCA	cis	rs5753037	0.801	rs1138120	ENSG00000279699.1	RP1-102K2.9	5.26	2.16e-07	3.13e-05	0.25	0.24	Type 1 diabetes;	chr22:29833965	chr22:30275215~30276951:-
THCA	cis	rs7702057	0.53	rs17138841	ENSG00000272265.1	CTD-2287O16.4	5.26	2.17e-07	3.13e-05	0.42	0.24	Amyotrophic lateral sclerosis;	chr5:116077109	chr5:116078110~116078570:-
THCA	cis	rs7772486	0.743	rs9376955	ENSG00000270638.1	RP3-466P17.1	5.26	2.17e-07	3.13e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.805	rs4896831	ENSG00000270638.1	RP3-466P17.1	5.26	2.17e-07	3.13e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145735570~145737218:+
THCA	cis	rs503425	0.546	rs540716	ENSG00000255239.1	AP002954.6	-5.26	2.17e-07	3.13e-05	-0.35	-0.24	Systemic lupus erythematosus;	chr11:118814306	chr11:118688039~118690600:-
THCA	cis	rs7851660	0.679	rs7033765	ENSG00000214417.4	KRT18P13	5.26	2.17e-07	3.14e-05	0.21	0.24	Strep throat;	chr9:97829423	chr9:97698922~97700734:+
THCA	cis	rs6445975	0.572	rs7642018	ENSG00000272360.1	RP11-359I18.5	5.26	2.17e-07	3.14e-05	0.27	0.24	Systemic lupus erythematosus;	chr3:58367536	chr3:58490830~58491291:-
THCA	cis	rs2562456	0.641	rs62107468	ENSG00000268081.1	RP11-678G14.2	5.26	2.17e-07	3.14e-05	0.39	0.24	Pain;	chr19:21307177	chr19:21554640~21569237:-
THCA	cis	rs17767392	0.846	rs68073803	ENSG00000259146.3	RP1-261D10.2	5.26	2.17e-07	3.14e-05	0.3	0.24	Mitral valve prolapse;	chr14:71290962	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.829	rs35796129	ENSG00000259146.3	RP1-261D10.2	5.26	2.17e-07	3.14e-05	0.3	0.24	Mitral valve prolapse;	chr14:71291881	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs34725136	ENSG00000259146.3	RP1-261D10.2	5.26	2.17e-07	3.14e-05	0.3	0.24	Mitral valve prolapse;	chr14:71293705	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.874	rs34649709	ENSG00000259146.3	RP1-261D10.2	5.26	2.17e-07	3.14e-05	0.3	0.24	Mitral valve prolapse;	chr14:71295579	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.881	rs61991199	ENSG00000259146.3	RP1-261D10.2	5.26	2.17e-07	3.14e-05	0.3	0.24	Mitral valve prolapse;	chr14:71295825	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs61991201	ENSG00000259146.3	RP1-261D10.2	5.26	2.17e-07	3.14e-05	0.3	0.24	Mitral valve prolapse;	chr14:71295906	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs61991202	ENSG00000259146.3	RP1-261D10.2	5.26	2.17e-07	3.14e-05	0.3	0.24	Mitral valve prolapse;	chr14:71299958	chr14:71292729~71321814:-
THCA	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	5.26	2.17e-07	3.14e-05	0.42	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
THCA	cis	rs4660456	0.619	rs753753	ENSG00000272145.1	NFYC-AS1	5.26	2.17e-07	3.14e-05	0.16	0.24	Platelet count;	chr1:40771716	chr1:40690380~40692066:-
THCA	cis	rs11089937	0.512	rs13054756	ENSG00000211639.2	IGLV4-60	5.26	2.17e-07	3.14e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22162199~22162681:+
THCA	cis	rs7772486	0.686	rs9399564	ENSG00000270638.1	RP3-466P17.1	-5.26	2.17e-07	3.14e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145735570~145737218:+
THCA	cis	rs9843304	0.585	rs9842139	ENSG00000240541.2	TM4SF1-AS1	-5.26	2.17e-07	3.14e-05	-0.22	-0.24	Gallstone disease;	chr3:149489730	chr3:149377778~149386583:+
THCA	cis	rs755249	0.874	rs61779310	ENSG00000228060.1	RP11-69E11.8	-5.26	2.17e-07	3.14e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39565160~39573203:+
THCA	cis	rs12478296	1	rs6743297	ENSG00000261186.2	RP11-341N2.1	-5.26	2.17e-07	3.14e-05	-0.36	-0.24	Obesity-related traits;	chr2:242071663	chr2:242087351~242088457:-
THCA	cis	rs12478296	0.892	rs11897561	ENSG00000261186.2	RP11-341N2.1	-5.26	2.17e-07	3.14e-05	-0.36	-0.24	Obesity-related traits;	chr2:242072825	chr2:242087351~242088457:-
THCA	cis	rs6988985	0.678	rs28571827	ENSG00000247317.3	RP11-273G15.2	-5.26	2.17e-07	3.14e-05	-0.25	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921791	chr8:142981738~143018437:-
THCA	cis	rs890448	0.93	rs2471675	ENSG00000254531.1	FLJ20021	-5.26	2.17e-07	3.14e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101467385	chr4:101347780~101348883:+
THCA	cis	rs66887589	0.616	rs11732621	ENSG00000249244.1	RP11-548H18.2	5.26	2.17e-07	3.14e-05	0.25	0.24	Diastolic blood pressure;	chr4:119291728	chr4:119391831~119395335:-
THCA	cis	rs17818399	0.89	rs34544165	ENSG00000279254.1	RP11-536C12.1	-5.26	2.17e-07	3.14e-05	-0.24	-0.24	Height;	chr2:46609767	chr2:46668870~46670778:+
THCA	cis	rs1889642	0.743	rs9601268	ENSG00000227354.5	RBM26-AS1	5.26	2.17e-07	3.15e-05	0.22	0.24	Colonoscopy-negative controls vs population controls;	chr13:79785153	chr13:79406309~79424328:+
THCA	cis	rs875971	0.545	rs35459055	ENSG00000232546.1	RP11-458F8.1	5.26	2.18e-07	3.15e-05	0.22	0.24	Aortic root size;	chr7:66479399	chr7:66848496~66858136:+
THCA	cis	rs11894081	0.715	rs11687637	ENSG00000232835.1	AC107057.1	5.26	2.18e-07	3.15e-05	0.24	0.24	Crohn's disease;	chr2:5537661	chr2:5549780~5556031:-
THCA	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-5.26	2.18e-07	3.15e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
THCA	cis	rs7772486	0.686	rs1004752	ENSG00000270638.1	RP3-466P17.1	-5.26	2.18e-07	3.15e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145735570~145737218:+
THCA	cis	rs6058796	1	rs9636547	ENSG00000175730.8	BAK1P1	5.26	2.18e-07	3.15e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32674231	chr20:32690180~32690815:-
THCA	cis	rs4908768	0.539	rs1381928	ENSG00000232912.4	RP5-1115A15.1	5.26	2.18e-07	3.15e-05	0.23	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8630874	chr1:8424645~8434838:+
THCA	cis	rs2880765	0.835	rs4281668	ENSG00000259630.2	CTD-2262B20.1	-5.26	2.18e-07	3.15e-05	-0.25	-0.24	Coronary artery disease;	chr15:85504055	chr15:85415228~85415633:+
THCA	cis	rs896854	0.967	rs10808671	ENSG00000253528.2	RP11-347C18.4	5.26	2.18e-07	3.15e-05	0.27	0.24	Type 2 diabetes;	chr8:94955144	chr8:94974573~94974853:-
THCA	cis	rs896854	0.967	rs10956933	ENSG00000253528.2	RP11-347C18.4	5.26	2.18e-07	3.15e-05	0.27	0.24	Type 2 diabetes;	chr8:94955460	chr8:94974573~94974853:-
THCA	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	5.26	2.18e-07	3.15e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	5.26	2.18e-07	3.15e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	5.26	2.18e-07	3.15e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	5.26	2.18e-07	3.15e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	5.26	2.18e-07	3.15e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	5.26	2.18e-07	3.15e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	5.26	2.18e-07	3.15e-05	0.37	0.24	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
THCA	cis	rs9834975	0.903	rs9873684	ENSG00000272758.4	RP11-299J3.8	-5.26	2.18e-07	3.15e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122386273	chr3:122416207~122443180:+
THCA	cis	rs9543976	1	rs2031236	ENSG00000261105.4	LMO7-AS1	-5.26	2.18e-07	3.15e-05	-0.35	-0.24	Diabetic retinopathy;	chr13:75595641	chr13:75604700~75635994:-
THCA	cis	rs172166	0.637	rs1233708	ENSG00000226314.6	ZNF192P1	-5.26	2.18e-07	3.15e-05	-0.28	-0.24	Cardiac Troponin-T levels;	chr6:28205441	chr6:28161781~28169594:+
THCA	cis	rs860295	0.541	rs11264359	ENSG00000160766.13	GBAP1	-5.26	2.18e-07	3.15e-05	-0.27	-0.24	Body mass index;	chr1:155313038	chr1:155213821~155227422:-
THCA	cis	rs3096299	0.702	rs2086824	ENSG00000274627.1	RP11-104N10.2	-5.26	2.18e-07	3.15e-05	-0.24	-0.24	Multiple myeloma (IgH translocation);	chr16:89404838	chr16:89516797~89522217:+
THCA	cis	rs60695258	0.726	rs1471251	ENSG00000251411.1	RP11-397E7.4	5.26	2.18e-07	3.15e-05	0.21	0.24	Hematocrit;	chr4:87055207	chr4:86913266~86914817:-
THCA	cis	rs9527	0.637	rs12219247	ENSG00000236937.2	PTGES3P4	5.26	2.18e-07	3.15e-05	0.31	0.24	Arsenic metabolism;	chr10:102853604	chr10:102845595~102845950:+
THCA	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-5.26	2.18e-07	3.15e-05	-0.28	-0.24	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
THCA	cis	rs9990333	0.521	rs3862281	ENSG00000273009.1	RP11-352G9.1	-5.26	2.18e-07	3.15e-05	-0.27	-0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195913078~195913683:-
THCA	cis	rs1552244	1	rs12374115	ENSG00000180385.7	EMC3-AS1	-5.26	2.18e-07	3.16e-05	-0.26	-0.24	Alzheimer's disease;	chr3:10093082	chr3:9986893~10006990:+
THCA	cis	rs17826219	0.561	rs4794869	ENSG00000263531.1	RP13-753N3.1	5.26	2.18e-07	3.16e-05	0.67	0.24	Body mass index;	chr17:30364082	chr17:30863921~30864940:-
THCA	cis	rs6545883	0.868	rs7608483	ENSG00000270820.4	RP11-355B11.2	5.26	2.18e-07	3.16e-05	0.2	0.24	Tuberculosis;	chr2:61609100	chr2:61471188~61484130:+
THCA	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	5.26	2.19e-07	3.16e-05	0.27	0.24	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
THCA	cis	rs5758659	0.679	rs134870	ENSG00000270083.1	RP1-257I20.14	5.26	2.19e-07	3.16e-05	0.24	0.24	Cognitive function;	chr22:42256311	chr22:42089630~42090028:-
THCA	cis	rs10129255	0.5	rs2027903	ENSG00000211970.3	IGHV4-61	-5.26	2.19e-07	3.16e-05	-0.13	-0.24	Kawasaki disease;	chr14:106807047	chr14:106639119~106639657:-
THCA	cis	rs4713118	0.911	rs2394000	ENSG00000226314.6	ZNF192P1	-5.26	2.19e-07	3.16e-05	-0.3	-0.24	Parkinson's disease;	chr6:27719212	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.955	rs9393847	ENSG00000226314.6	ZNF192P1	-5.26	2.19e-07	3.16e-05	-0.3	-0.24	Parkinson's disease;	chr6:27720194	chr6:28161781~28169594:+
THCA	cis	rs7403037	0.798	rs12148562	ENSG00000259905.4	PWRN1	5.26	2.19e-07	3.16e-05	0.27	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24588902	chr15:24493137~24652130:+
THCA	cis	rs944289	0.711	rs7148603	ENSG00000257826.1	RP11-116N8.4	-5.26	2.19e-07	3.16e-05	-0.26	-0.24	Thyroid cancer;	chr14:36214573	chr14:36061026~36067190:-
THCA	cis	rs9816784	0.525	rs41301371	ENSG00000242086.7	LINC00969	5.26	2.19e-07	3.16e-05	0.24	0.24	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195658062~195739964:+
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000273796.1	LL21NC02-21A1.1	-5.26	2.19e-07	3.16e-05	-0.24	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45403809~45404369:-
THCA	cis	rs12681287	0.64	rs4490816	ENSG00000254231.1	CTD-2284J15.1	-5.26	2.19e-07	3.17e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86372709	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs4587306	ENSG00000254231.1	CTD-2284J15.1	-5.26	2.19e-07	3.17e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86373282	chr8:86333274~86343314:-
THCA	cis	rs10129255	0.518	rs28378320	ENSG00000211970.3	IGHV4-61	-5.26	2.19e-07	3.17e-05	-0.13	-0.24	Kawasaki disease;	chr14:106808609	chr14:106639119~106639657:-
THCA	cis	rs763121	0.853	rs5750633	ENSG00000273076.1	RP3-508I15.22	5.26	2.19e-07	3.17e-05	0.23	0.24	Menopause (age at onset);	chr22:38597462	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757166	ENSG00000273076.1	RP3-508I15.22	5.26	2.19e-07	3.17e-05	0.23	0.24	Menopause (age at onset);	chr22:38599380	chr22:38743495~38743910:+
THCA	cis	rs8177876	0.749	rs2549891	ENSG00000261061.1	RP11-303E16.2	5.26	2.19e-07	3.17e-05	0.33	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81030770~81031485:+
THCA	cis	rs6951245	0.832	rs79808627	ENSG00000229043.2	AC091729.9	-5.26	2.19e-07	3.17e-05	-0.39	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052883	chr7:1160374~1165267:+
THCA	cis	rs12188164	0.686	rs72711367	ENSG00000225138.6	CTD-2228K2.7	5.26	2.19e-07	3.17e-05	0.26	0.24	Cystic fibrosis severity;	chr5:418379	chr5:473236~480884:+
THCA	cis	rs2439831	1	rs28628574	ENSG00000275601.1	AC011330.13	-5.26	2.19e-07	3.17e-05	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43509840	chr15:43642389~43643023:-
THCA	cis	rs7617773	0.778	rs11715776	ENSG00000199476.1	Y_RNA	-5.26	2.19e-07	3.17e-05	-0.31	-0.24	Coronary artery disease;	chr3:48336121	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs11716848	ENSG00000199476.1	Y_RNA	-5.26	2.19e-07	3.17e-05	-0.31	-0.24	Coronary artery disease;	chr3:48337010	chr3:48288587~48288694:+
THCA	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-5.26	2.19e-07	3.17e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
THCA	cis	rs944289	0.684	rs8016315	ENSG00000258844.1	RP11-259K15.2	5.26	2.19e-07	3.17e-05	0.21	0.24	Thyroid cancer;	chr14:36101158	chr14:36214607~36235608:+
THCA	cis	rs944289	0.74	rs4982334	ENSG00000258844.1	RP11-259K15.2	5.26	2.19e-07	3.17e-05	0.21	0.24	Thyroid cancer;	chr14:36101396	chr14:36214607~36235608:+
THCA	cis	rs7512898	0.522	rs10800743	ENSG00000260088.1	RP11-92G12.3	-5.26	2.2e-07	3.17e-05	-0.32	-0.24	Electrocardiographic conduction measures;	chr1:200852408	chr1:200669507~200694250:+
THCA	cis	rs4845570	1	rs4845356	ENSG00000203288.3	RP11-98D18.9	5.26	2.2e-07	3.17e-05	0.26	0.24	Coronary artery disease;	chr1:151786747	chr1:151790804~151794402:+
THCA	cis	rs7617773	0.743	rs71323397	ENSG00000199476.1	Y_RNA	-5.26	2.2e-07	3.17e-05	-0.31	-0.24	Coronary artery disease;	chr3:48333384	chr3:48288587~48288694:+
THCA	cis	rs73198271	0.681	rs35457364	ENSG00000253893.2	FAM85B	5.26	2.2e-07	3.18e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.641	rs34473848	ENSG00000253893.2	FAM85B	5.26	2.2e-07	3.18e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.601	rs11997731	ENSG00000253893.2	FAM85B	5.26	2.2e-07	3.18e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.681	rs11987924	ENSG00000253893.2	FAM85B	5.26	2.2e-07	3.18e-05	0.34	0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8167819~8226614:-
THCA	cis	rs6044112	1	rs6080295	ENSG00000273998.1	RP4-777L9.2	5.26	2.2e-07	3.18e-05	0.38	0.24	Response to taxane treatment (docetaxel);	chr20:16540689	chr20:16576068~16579615:+
THCA	cis	rs6044112	1	rs6080296	ENSG00000273998.1	RP4-777L9.2	5.26	2.2e-07	3.18e-05	0.38	0.24	Response to taxane treatment (docetaxel);	chr20:16540883	chr20:16576068~16579615:+
THCA	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-5.26	2.2e-07	3.18e-05	-0.27	-0.24	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
THCA	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-5.26	2.2e-07	3.18e-05	-0.27	-0.24	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
THCA	cis	rs7617773	0.817	rs13072018	ENSG00000199476.1	Y_RNA	-5.26	2.2e-07	3.18e-05	-0.31	-0.24	Coronary artery disease;	chr3:48278842	chr3:48288587~48288694:+
THCA	cis	rs2179367	0.632	rs55836833	ENSG00000268592.3	RAET1E-AS1	5.26	2.2e-07	3.18e-05	0.34	0.24	Dupuytren's disease;	chr6:149403736	chr6:149863494~149919507:+
THCA	cis	rs11089937	0.589	rs4239891	ENSG00000211638.2	IGLV8-61	-5.26	2.2e-07	3.18e-05	-0.18	-0.24	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22098700~22099212:+
THCA	cis	rs9467773	1	rs767471	ENSG00000261353.1	CTA-14H9.5	-5.26	2.2e-07	3.18e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26527063~26527404:+
THCA	cis	rs7923837	1	rs10786053	ENSG00000236493.2	EIF2S2P3	5.26	2.2e-07	3.18e-05	0.25	0.24	Multiple sclerosis;Body mass index;	chr10:92714340	chr10:92668745~92669743:-
THCA	cis	rs6547741	0.874	rs58737572	ENSG00000234072.1	AC074117.10	5.26	2.2e-07	3.18e-05	0.18	0.24	Oral cavity cancer;	chr2:27629251	chr2:27356246~27367622:+
THCA	cis	rs6714710	0.603	rs6746768	ENSG00000230606.9	AC159540.1	-5.26	2.2e-07	3.18e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97850184	chr2:97416165~97433527:-
THCA	cis	rs6479891	0.722	rs4746951	ENSG00000232075.1	MRPL35P2	5.26	2.2e-07	3.18e-05	0.39	0.24	Arthritis (juvenile idiopathic);	chr10:63123839	chr10:63634317~63634827:-
THCA	cis	rs66887589	0.616	rs1052633	ENSG00000249244.1	RP11-548H18.2	5.26	2.2e-07	3.18e-05	0.25	0.24	Diastolic blood pressure;	chr4:119294159	chr4:119391831~119395335:-
THCA	cis	rs66887589	0.592	rs2175383	ENSG00000249244.1	RP11-548H18.2	5.26	2.2e-07	3.18e-05	0.25	0.24	Diastolic blood pressure;	chr4:119294681	chr4:119391831~119395335:-
THCA	cis	rs17767392	0.915	rs1990241	ENSG00000259146.3	RP1-261D10.2	5.26	2.21e-07	3.19e-05	0.31	0.24	Mitral valve prolapse;	chr14:71307335	chr14:71292729~71321814:-
THCA	cis	rs858239	0.6	rs6461691	ENSG00000226816.2	AC005082.12	5.26	2.21e-07	3.19e-05	0.34	0.24	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23206013~23208045:+
THCA	cis	rs2645424	0.93	rs1293315	ENSG00000255046.1	RP11-297N6.4	-5.26	2.21e-07	3.19e-05	-0.24	-0.24	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11832913	chr8:11797928~11802568:-
THCA	cis	rs7674212	0.541	rs4699051	ENSG00000246560.2	RP11-10L12.4	5.26	2.21e-07	3.19e-05	0.28	0.24	Type 2 diabetes;	chr4:103193237	chr4:102828055~102844075:+
THCA	cis	rs1552244	0.882	rs113268531	ENSG00000232901.1	CYCSP10	5.26	2.21e-07	3.19e-05	0.31	0.24	Alzheimer's disease;	chr3:10125385	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.938	rs67667957	ENSG00000232901.1	CYCSP10	5.26	2.21e-07	3.19e-05	0.31	0.24	Alzheimer's disease;	chr3:10125580	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.938	rs56274701	ENSG00000232901.1	CYCSP10	5.26	2.21e-07	3.19e-05	0.31	0.24	Alzheimer's disease;	chr3:10126106	chr3:10000647~10000940:-
THCA	cis	rs17767392	0.914	rs7147668	ENSG00000259146.3	RP1-261D10.2	5.26	2.21e-07	3.19e-05	0.31	0.24	Mitral valve prolapse;	chr14:71390710	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs34524083	ENSG00000259146.3	RP1-261D10.2	5.26	2.21e-07	3.19e-05	0.31	0.24	Mitral valve prolapse;	chr14:71391655	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs61991250	ENSG00000259146.3	RP1-261D10.2	5.26	2.21e-07	3.19e-05	0.31	0.24	Mitral valve prolapse;	chr14:71402967	chr14:71292729~71321814:-
THCA	cis	rs911119	0.955	rs6036474	ENSG00000270001.1	RP11-218C14.8	-5.26	2.21e-07	3.19e-05	-0.35	-0.24	Chronic kidney disease;	chr20:23623777	chr20:23631826~23632316:-
THCA	cis	rs2288884	0.747	rs11668885	ENSG00000275055.1	CTC-471J1.11	-5.26	2.21e-07	3.2e-05	-0.23	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52087848	chr19:52049007~52049754:+
THCA	cis	rs7772486	0.654	rs702321	ENSG00000270638.1	RP3-466P17.1	-5.26	2.22e-07	3.2e-05	-0.19	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145735570~145737218:+
THCA	cis	rs2692947	0.74	rs60452119	ENSG00000232931.4	LINC00342	5.26	2.22e-07	3.2e-05	0.19	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95754302	chr2:95807118~95816215:-
THCA	cis	rs7948661	1	rs7948661	ENSG00000278376.1	RP11-158I9.8	5.26	2.22e-07	3.2e-05	0.37	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118470934	chr11:118791254~118793137:+
THCA	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	5.26	2.22e-07	3.2e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
THCA	cis	rs1889642	0.661	rs9574473	ENSG00000227354.5	RBM26-AS1	5.26	2.22e-07	3.21e-05	0.22	0.24	Colonoscopy-negative controls vs population controls;	chr13:79768051	chr13:79406309~79424328:+
THCA	cis	rs3213758	1	rs78796530	ENSG00000275191.1	RP11-36I17.2	-5.26	2.22e-07	3.21e-05	-0.49	-0.24	Vitiligo (non-segmental);	chr16:53694128	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs12598253	ENSG00000275191.1	RP11-36I17.2	-5.26	2.22e-07	3.21e-05	-0.49	-0.24	Vitiligo (non-segmental);	chr16:53696690	chr16:53628256~53628816:-
THCA	cis	rs1580019	0.587	rs6968990	ENSG00000231952.3	DPY19L1P2	5.26	2.22e-07	3.21e-05	0.3	0.24	Cognitive ability;	chr7:32512547	chr7:32812757~32838570:+
THCA	cis	rs7617773	0.78	rs34630841	ENSG00000199476.1	Y_RNA	-5.26	2.22e-07	3.21e-05	-0.3	-0.24	Coronary artery disease;	chr3:48301771	chr3:48288587~48288694:+
THCA	cis	rs7412746	0.611	rs4319334	ENSG00000231073.1	RP11-316M1.3	5.26	2.22e-07	3.21e-05	0.28	0.24	Melanoma;	chr1:150794346	chr1:150973123~150975534:+
THCA	cis	rs9402743	0.775	rs12198378	ENSG00000231028.7	LINC00271	-5.26	2.23e-07	3.21e-05	-0.2	-0.24	Systemic lupus erythematosus;	chr6:135662479	chr6:135497801~135716055:+
THCA	cis	rs7267979	0.844	rs6115188	ENSG00000125804.12	FAM182A	-5.26	2.23e-07	3.21e-05	-0.29	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26054655~26086917:+
THCA	cis	rs7829975	0.523	rs9644774	ENSG00000253893.2	FAM85B	5.26	2.23e-07	3.21e-05	0.33	0.24	Mood instability;	chr8:8702322	chr8:8167819~8226614:-
THCA	cis	rs6840258	0.723	rs443459	ENSG00000251411.1	RP11-397E7.4	-5.26	2.23e-07	3.21e-05	-0.24	-0.24	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87054903	chr4:86913266~86914817:-
THCA	cis	rs9834975	0.935	rs9863881	ENSG00000272758.4	RP11-299J3.8	-5.26	2.23e-07	3.21e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122381176	chr3:122416207~122443180:+
THCA	cis	rs7166081	0.704	rs2414952	ENSG00000270964.1	RP11-502I4.3	-5.26	2.23e-07	3.21e-05	-0.21	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67432054	chr15:67541072~67542604:-
THCA	cis	rs7267979	0.844	rs6083851	ENSG00000125804.12	FAM182A	5.26	2.23e-07	3.21e-05	0.29	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.844	rs4423675	ENSG00000125804.12	FAM182A	5.26	2.23e-07	3.21e-05	0.29	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26054655~26086917:+
THCA	cis	rs2179367	0.543	rs9498328	ENSG00000223701.3	RAET1E-AS1	5.26	2.23e-07	3.21e-05	0.34	0.24	Dupuytren's disease;	chr6:149348715	chr6:149884431~149919508:+
THCA	cis	rs9393777	0.72	rs56401801	ENSG00000219392.1	RP1-265C24.5	-5.26	2.23e-07	3.21e-05	-0.48	-0.24	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28115628~28116551:+
THCA	cis	rs8059260	0.736	rs113433437	ENSG00000274038.1	RP11-66H6.4	-5.26	2.23e-07	3.22e-05	-0.49	-0.24	Alcohol consumption over the past year;	chr16:10959438	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.736	rs8046423	ENSG00000274038.1	RP11-66H6.4	-5.26	2.23e-07	3.22e-05	-0.49	-0.24	Alcohol consumption over the past year;	chr16:10964016	chr16:11056556~11057034:+
THCA	cis	rs77972916	0.609	rs13414381	ENSG00000234936.1	AC010883.5	5.26	2.23e-07	3.22e-05	0.29	0.24	Granulocyte percentage of myeloid white cells;	chr2:43340079	chr2:43229573~43233394:+
THCA	cis	rs16846053	0.786	rs116099394	ENSG00000227403.1	AC009299.3	5.26	2.23e-07	3.22e-05	0.49	0.24	Blood osmolality (transformed sodium);	chr2:161743572	chr2:161244739~161249050:+
THCA	cis	rs354225	0.532	rs354211	ENSG00000237887.1	AC092839.1	-5.26	2.23e-07	3.22e-05	-0.28	-0.24	Schizophrenia;	chr2:54705379	chr2:54529343~54529801:+
THCA	cis	rs11096990	0.891	rs61691409	ENSG00000249685.1	RP11-360F5.3	-5.26	2.23e-07	3.22e-05	-0.3	-0.24	Cognitive function;	chr4:39243801	chr4:39133913~39135608:+
THCA	cis	rs9595908	0.965	rs9595893	ENSG00000212293.1	SNORA16	5.26	2.23e-07	3.22e-05	0.28	0.24	Body mass index;	chr13:32601656	chr13:32420390~32420516:-
THCA	cis	rs2839186	0.934	rs17176520	ENSG00000239415.1	AP001469.9	5.26	2.23e-07	3.22e-05	0.25	0.24	Testicular germ cell tumor;	chr21:46262167	chr21:46251549~46254133:-
THCA	cis	rs890448	0.93	rs2471677	ENSG00000254531.1	FLJ20021	-5.26	2.23e-07	3.22e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101458438	chr4:101347780~101348883:+
THCA	cis	rs7824557	0.628	rs2572387	ENSG00000154316.13	TDH	-5.26	2.23e-07	3.22e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11346656	chr8:11339637~11368452:+
THCA	cis	rs875971	0.545	rs221986	ENSG00000228409.4	CCT6P1	5.26	2.23e-07	3.22e-05	0.2	0.24	Aortic root size;	chr7:66105323	chr7:65751142~65763354:+
THCA	cis	rs858239	0.6	rs10241208	ENSG00000226816.2	AC005082.12	5.26	2.23e-07	3.22e-05	0.34	0.24	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23206013~23208045:+
THCA	cis	rs7772486	0.686	rs1011596	ENSG00000270638.1	RP3-466P17.1	5.26	2.23e-07	3.22e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145735570~145737218:+
THCA	cis	rs9376098	0.964	rs9494168	ENSG00000232876.1	CTA-212D2.2	-5.26	2.23e-07	3.22e-05	-0.28	-0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135169288	chr6:135055033~135060550:+
THCA	cis	rs6490294	0.528	rs57502306	ENSG00000226469.1	ADAM1B	5.26	2.24e-07	3.22e-05	0.37	0.24	Mean platelet volume;	chr12:111852639	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs35662477	ENSG00000226469.1	ADAM1B	5.26	2.24e-07	3.22e-05	0.37	0.24	Mean platelet volume;	chr12:111875404	chr12:111927018~111929017:+
THCA	cis	rs8141529	0.732	rs11556025	ENSG00000272858.1	CTA-292E10.8	-5.26	2.24e-07	3.22e-05	-0.25	-0.24	Lymphocyte counts;	chr22:28772767	chr22:28814914~28815662:+
THCA	cis	rs12681287	0.604	rs13279589	ENSG00000254231.1	CTD-2284J15.1	5.26	2.24e-07	3.22e-05	0.26	0.24	Caudate activity during reward;	chr8:86465494	chr8:86333274~86343314:-
THCA	cis	rs7403037	1	rs7402804	ENSG00000259905.4	PWRN1	5.26	2.24e-07	3.23e-05	0.25	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24591453	chr15:24493137~24652130:+
THCA	cis	rs7403037	1	rs7402908	ENSG00000259905.4	PWRN1	5.26	2.24e-07	3.23e-05	0.25	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24591833	chr15:24493137~24652130:+
THCA	cis	rs748404	0.666	rs72709871	ENSG00000205771.5	CATSPER2P1	-5.26	2.24e-07	3.23e-05	-0.3	-0.24	Lung cancer;	chr15:43499025	chr15:43726918~43747094:-
THCA	cis	rs1552244	1	rs35198334	ENSG00000232901.1	CYCSP10	5.26	2.24e-07	3.23e-05	0.32	0.24	Alzheimer's disease;	chr3:10062869	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.935	rs7652190	ENSG00000232901.1	CYCSP10	5.26	2.24e-07	3.23e-05	0.32	0.24	Alzheimer's disease;	chr3:10063466	chr3:10000647~10000940:-
THCA	cis	rs1552244	1	rs7619340	ENSG00000232901.1	CYCSP10	5.26	2.24e-07	3.23e-05	0.32	0.24	Alzheimer's disease;	chr3:10066494	chr3:10000647~10000940:-
THCA	cis	rs59868192	0.925	rs1868831	ENSG00000246740.2	PLA2G4E-AS1	-5.26	2.24e-07	3.23e-05	-0.43	-0.24	White blood cell count;	chr15:41965731	chr15:41972763~41999094:+
THCA	cis	rs17772222	0.511	rs1013794	ENSG00000258789.1	RP11-507K2.3	-5.26	2.24e-07	3.23e-05	-0.21	-0.24	Coronary artery calcification;	chr14:88847401	chr14:88551597~88552493:+
THCA	cis	rs7129556	0.737	rs7950873	ENSG00000254691.1	RP11-91P24.5	5.26	2.24e-07	3.23e-05	0.34	0.24	Weight loss (gastric bypass surgery);	chr11:77701806	chr11:77850604~77851511:+
THCA	cis	rs875971	0.545	rs10950036	ENSG00000228409.4	CCT6P1	-5.26	2.24e-07	3.23e-05	-0.2	-0.24	Aortic root size;	chr7:66353241	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000228409.4	CCT6P1	-5.26	2.24e-07	3.23e-05	-0.2	-0.24	Aortic root size;	chr7:66390342	chr7:65751142~65763354:+
THCA	cis	rs2070488	0.761	rs6807940	ENSG00000229589.1	ACVR2B-AS1	5.26	2.24e-07	3.23e-05	0.21	0.24	Electrocardiographic conduction measures;	chr3:38418571	chr3:38451027~38454820:-
THCA	cis	rs1050631	0.592	rs1785903	ENSG00000260552.1	RP11-49I11.1	5.26	2.24e-07	3.23e-05	0.29	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36131679	chr18:36179996~36187448:-
THCA	cis	rs62184315	0.58	rs62185872	ENSG00000273240.1	RP11-455J20.3	-5.26	2.24e-07	3.23e-05	-0.3	-0.24	Alcohol dependence (age at onset);	chr2:189690033	chr2:189763859~189764456:-
THCA	cis	rs6714710	0.603	rs10432626	ENSG00000230606.9	AC159540.1	-5.26	2.24e-07	3.23e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97944690	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs1875699	ENSG00000230606.9	AC159540.1	-5.26	2.24e-07	3.23e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97964261	chr2:97416165~97433527:-
THCA	cis	rs2337406	0.706	rs74090742	ENSG00000211974.3	IGHV2-70	-5.26	2.24e-07	3.24e-05	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106696601	chr14:106723574~106724093:-
THCA	cis	rs75920871	0.589	rs67201490	ENSG00000254851.1	RP11-109L13.1	-5.26	2.24e-07	3.24e-05	-0.45	-0.24	Subjective well-being;	chr11:117212288	chr11:117135528~117138582:+
THCA	cis	rs75920871	0.64	rs4938357	ENSG00000254851.1	RP11-109L13.1	-5.26	2.24e-07	3.24e-05	-0.45	-0.24	Subjective well-being;	chr11:117213324	chr11:117135528~117138582:+
THCA	cis	rs6997458	0.749	rs13270041	ENSG00000253549.4	RP11-317J10.2	5.26	2.25e-07	3.24e-05	0.23	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85450734	chr8:85441851~85464915:-
THCA	cis	rs11992162	0.967	rs11250185	ENSG00000227888.4	FAM66A	5.26	2.25e-07	3.24e-05	0.3	0.24	Monocyte count;	chr8:11975614	chr8:12362019~12388296:+
THCA	cis	rs9475752	0.644	rs35336675	ENSG00000231441.1	RP11-472M19.2	5.26	2.25e-07	3.24e-05	0.32	0.24	Menarche (age at onset);	chr6:56986959	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs6901944	ENSG00000231441.1	RP11-472M19.2	5.26	2.25e-07	3.24e-05	0.32	0.24	Menarche (age at onset);	chr6:56998007	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.793	rs35899012	ENSG00000231441.1	RP11-472M19.2	5.26	2.25e-07	3.24e-05	0.32	0.24	Menarche (age at onset);	chr6:56998111	chr6:56844002~56864078:+
THCA	cis	rs4908768	0.539	rs7537982	ENSG00000232912.4	RP5-1115A15.1	5.26	2.25e-07	3.24e-05	0.23	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8424645~8434838:+
THCA	cis	rs11242704	0.508	rs2569866	ENSG00000272279.1	RP11-157J24.2	-5.26	2.25e-07	3.24e-05	-0.31	-0.24	Response to hepatitis C treatment;	chr6:1529817	chr6:1528364~1528911:-
THCA	cis	rs76935404	1	rs76935404	ENSG00000256612.6	CYP2B7P	-5.25	2.25e-07	3.24e-05	-0.3	-0.24	nicotine metabolite ratio in current smokers;	chr19:40913389	chr19:40924219~40950660:+
THCA	cis	rs12681287	0.64	rs13252046	ENSG00000254231.1	CTD-2284J15.1	5.25	2.25e-07	3.24e-05	0.26	0.24	Caudate activity during reward;	chr8:86465522	chr8:86333274~86343314:-
THCA	cis	rs7824557	0.614	rs2293860	ENSG00000154316.13	TDH	-5.25	2.25e-07	3.25e-05	-0.18	-0.24	Retinal vascular caliber;	chr8:11361877	chr8:11339637~11368452:+
THCA	cis	rs7129556	0.813	rs11237249	ENSG00000254691.1	RP11-91P24.5	5.25	2.25e-07	3.25e-05	0.34	0.24	Weight loss (gastric bypass surgery);	chr11:77630090	chr11:77850604~77851511:+
THCA	cis	rs116095464	0.558	rs10462754	ENSG00000248925.1	CTD-2083E4.6	5.25	2.25e-07	3.25e-05	0.34	0.24	Breast cancer;	chr5:246554	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10462755	ENSG00000248925.1	CTD-2083E4.6	5.25	2.25e-07	3.25e-05	0.34	0.24	Breast cancer;	chr5:246633	chr5:269858~271516:-
THCA	cis	rs17123764	0.71	rs11169106	ENSG00000257464.1	RP11-161H23.8	-5.25	2.25e-07	3.25e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49684784	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.605	rs73306808	ENSG00000257464.1	RP11-161H23.8	-5.25	2.25e-07	3.25e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49684849	chr12:49442424~49442652:-
THCA	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-5.25	2.25e-07	3.25e-05	-0.29	-0.24	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
THCA	cis	rs72799341	1	rs35675346	ENSG00000260911.2	RP11-196G11.2	5.25	2.25e-07	3.25e-05	0.22	0.24	Diastolic blood pressure;	chr16:30924760	chr16:31043150~31049868:+
THCA	cis	rs867371	0.826	rs2047678	ENSG00000259429.4	UBE2Q2P2	-5.25	2.25e-07	3.25e-05	-0.19	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82355142~82420075:+
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000230295.1	RP11-458F8.2	-5.25	2.25e-07	3.25e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65966800	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs906134	ENSG00000230295.1	RP11-458F8.2	-5.25	2.25e-07	3.25e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65979301	chr7:66880708~66882981:+
THCA	cis	rs2282300	0.739	rs1222216	ENSG00000242353.1	RP4-710M3.1	-5.25	2.26e-07	3.25e-05	-0.23	-0.24	Morning vs. evening chronotype;	chr11:30324505	chr11:30368148~30368646:+
THCA	cis	rs896854	0.875	rs4735333	ENSG00000253528.2	RP11-347C18.4	5.25	2.26e-07	3.25e-05	0.27	0.24	Type 2 diabetes;	chr8:94942846	chr8:94974573~94974853:-
THCA	cis	rs12594515	0.548	rs12912226	ENSG00000259200.1	RP11-718O11.1	-5.25	2.26e-07	3.25e-05	-0.32	-0.24	Weight;Waist circumference;	chr15:45693510	chr15:45705078~45931069:+
THCA	cis	rs454217	0.715	rs400708	ENSG00000277851.1	RP11-756G20.1	5.25	2.26e-07	3.25e-05	0.23	0.24	Smoking quantity;	chr12:92320502	chr12:92247756~92363832:-
THCA	cis	rs2136613	0.751	rs10995334	ENSG00000238280.1	RP11-436D10.3	-5.25	2.26e-07	3.25e-05	-0.27	-0.24	Selective IgA deficiency;	chr10:62858052	chr10:62793562~62805887:-
THCA	cis	rs7824557	0.767	rs7003241	ENSG00000154316.13	TDH	-5.25	2.26e-07	3.25e-05	-0.17	-0.24	Retinal vascular caliber;	chr8:11311566	chr8:11339637~11368452:+
THCA	cis	rs7523875	0.516	rs6540683	ENSG00000153363.11	LINC00467	-5.25	2.26e-07	3.25e-05	-0.2	-0.24	Mean corpuscular volume;	chr1:211342920	chr1:211382803~211435333:+
THCA	cis	rs758324	0.732	rs152198	ENSG00000237714.1	P4HA2-AS1	-5.25	2.26e-07	3.25e-05	-0.35	-0.24	Alzheimer's disease in APOE e4- carriers;	chr5:132103117	chr5:132184876~132192808:+
THCA	cis	rs728616	0.51	rs12416084	ENSG00000242600.5	MBL1P	5.25	2.26e-07	3.26e-05	0.25	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79904898~79950336:+
THCA	cis	rs728616	0.51	rs34817075	ENSG00000242600.5	MBL1P	5.25	2.26e-07	3.26e-05	0.25	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79904898~79950336:+
THCA	cis	rs2243480	1	rs35820085	ENSG00000230295.1	RP11-458F8.2	-5.25	2.26e-07	3.26e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:65977771	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs937108	ENSG00000230295.1	RP11-458F8.2	-5.25	2.26e-07	3.26e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65963465	chr7:66880708~66882981:+
THCA	cis	rs442309	0.875	rs224066	ENSG00000238280.1	RP11-436D10.3	-5.25	2.26e-07	3.26e-05	-0.28	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62746419	chr10:62793562~62805887:-
THCA	cis	rs9925964	0.967	rs12716981	ENSG00000260911.2	RP11-196G11.2	-5.25	2.26e-07	3.26e-05	-0.19	-0.24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106703	chr16:31043150~31049868:+
THCA	cis	rs12999373	0.523	rs9678953	ENSG00000272342.1	RP13-539J13.1	-5.25	2.26e-07	3.26e-05	-0.31	-0.24	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694759	chr2:739588~740164:-
THCA	cis	rs11723261	0.546	rs57839456	ENSG00000211553.1	AC253576.2	-5.25	2.26e-07	3.26e-05	-0.34	-0.24	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:136461~136568:+
THCA	cis	rs4660456	0.913	rs16827532	ENSG00000272145.1	NFYC-AS1	5.25	2.26e-07	3.26e-05	0.16	0.24	Platelet count;	chr1:40755064	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs12729696	ENSG00000272145.1	NFYC-AS1	5.25	2.26e-07	3.26e-05	0.16	0.24	Platelet count;	chr1:40755099	chr1:40690380~40692066:-
THCA	cis	rs11977715	0.521	rs1476516	ENSG00000233942.1	AC004012.1	-5.25	2.26e-07	3.26e-05	-0.31	-0.24	Middle childhood and early adolescence aggressive behavior;	chr7:95489898	chr7:95471835~95473998:+
THCA	cis	rs16976116	0.619	rs4774750	ENSG00000279145.1	RP11-547D13.1	-5.25	2.26e-07	3.26e-05	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55173957	chr15:55171972~55178175:-
THCA	cis	rs9843304	0.546	rs13071608	ENSG00000240541.2	TM4SF1-AS1	-5.25	2.26e-07	3.26e-05	-0.22	-0.24	Gallstone disease;	chr3:149501803	chr3:149377778~149386583:+
THCA	cis	rs755249	0.73	rs3916164	ENSG00000237624.1	OXCT2P1	5.25	2.26e-07	3.26e-05	0.3	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39604267	chr1:39514956~39516490:+
THCA	cis	rs6539288	0.803	rs10778517	ENSG00000260329.1	RP11-412D9.4	5.25	2.26e-07	3.26e-05	0.21	0.24	Total body bone mineral density;	chr12:106947886	chr12:106954029~106955497:-
THCA	cis	rs478304	0.903	rs546202	ENSG00000214659.4	KRT8P26	5.25	2.27e-07	3.26e-05	0.2	0.24	Acne (severe);	chr11:65742553	chr11:65726939~65728214:+
THCA	cis	rs7131987	0.903	rs2194519	ENSG00000275476.1	RP11-996F15.4	5.25	2.27e-07	3.26e-05	0.23	0.24	QT interval;	chr12:29270650	chr12:29277397~29277882:-
THCA	cis	rs5758511	0.68	rs5758682	ENSG00000281538.1	RP4-669P10.20	-5.25	2.27e-07	3.26e-05	-0.27	-0.24	Birth weight;	chr22:42249196	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.68	rs34107327	ENSG00000281538.1	RP4-669P10.20	-5.25	2.27e-07	3.26e-05	-0.27	-0.24	Birth weight;	chr22:42252347	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.68	rs5758684	ENSG00000281538.1	RP4-669P10.20	-5.25	2.27e-07	3.26e-05	-0.27	-0.24	Birth weight;	chr22:42253503	chr22:42138060~42139726:+
THCA	cis	rs7160336	0.604	rs10149539	ENSG00000259065.1	RP5-1021I20.1	-5.25	2.27e-07	3.27e-05	-0.28	-0.24	Blood protein levels;	chr14:74215524	chr14:73787360~73803270:+
THCA	cis	rs2179367	0.632	rs10872636	ENSG00000268592.3	RAET1E-AS1	5.25	2.27e-07	3.27e-05	0.34	0.24	Dupuytren's disease;	chr6:149353678	chr6:149863494~149919507:+
THCA	cis	rs6928977	0.932	rs11154799	ENSG00000231028.7	LINC00271	5.25	2.27e-07	3.27e-05	0.19	0.24	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311511	chr6:135497801~135716055:+
THCA	cis	rs564343	0.933	rs526852	ENSG00000255320.1	RP11-755F10.1	-5.25	2.27e-07	3.27e-05	-0.29	-0.24	Obesity (early onset extreme);	chr11:66123961	chr11:66244840~66246239:-
THCA	cis	rs9880211	0.679	rs9818740	ENSG00000273486.1	RP11-731C17.2	5.25	2.27e-07	3.27e-05	0.24	0.24	Height;Body mass index;	chr3:136220744	chr3:136837338~136839021:-
THCA	cis	rs2562456	0.833	rs7246339	ENSG00000268119.4	CTD-2561J22.5	5.25	2.27e-07	3.27e-05	0.34	0.24	Pain;	chr19:21292495	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs55899865	ENSG00000268119.4	CTD-2561J22.5	5.25	2.27e-07	3.27e-05	0.34	0.24	Pain;	chr19:21298933	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs11667103	ENSG00000268119.4	CTD-2561J22.5	5.25	2.27e-07	3.27e-05	0.34	0.24	Pain;	chr19:21303839	chr19:21444241~21463908:-
THCA	cis	rs748404	0.626	rs1814324	ENSG00000205771.5	CATSPER2P1	-5.25	2.27e-07	3.27e-05	-0.3	-0.24	Lung cancer;	chr15:43314951	chr15:43726918~43747094:-
THCA	cis	rs12681287	0.752	rs34279109	ENSG00000254231.1	CTD-2284J15.1	5.25	2.27e-07	3.27e-05	0.26	0.24	Caudate activity during reward;	chr8:86235715	chr8:86333274~86343314:-
THCA	cis	rs2243480	1	rs35542501	ENSG00000230295.1	RP11-458F8.2	-5.25	2.27e-07	3.27e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65966228	chr7:66880708~66882981:+
THCA	cis	rs4845570	1	rs4845570	ENSG00000203288.3	RP11-98D18.9	5.25	2.27e-07	3.27e-05	0.26	0.24	Coronary artery disease;	chr1:151786628	chr1:151790804~151794402:+
THCA	cis	rs12908161	1	rs58416181	ENSG00000275120.1	RP11-182J1.17	5.25	2.27e-07	3.27e-05	0.28	0.24	Schizophrenia;	chr15:84721230	chr15:84599434~84606463:-
THCA	cis	rs1580019	0.522	rs10951340	ENSG00000231952.3	DPY19L1P2	-5.25	2.27e-07	3.28e-05	-0.29	-0.24	Cognitive ability;	chr7:32522796	chr7:32812757~32838570:+
THCA	cis	rs9876781	1	rs2362450	ENSG00000244380.1	RP11-24C3.2	5.25	2.27e-07	3.28e-05	0.27	0.24	Longevity;	chr3:48419904	chr3:48440352~48446656:-
THCA	cis	rs3785574	0.962	rs8079161	ENSG00000240280.5	TCAM1P	-5.25	2.27e-07	3.28e-05	-0.32	-0.24	Height;	chr17:63731201	chr17:63849292~63864379:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000232546.1	RP11-458F8.1	-5.25	2.28e-07	3.28e-05	-0.22	-0.24	Aortic root size;	chr7:66560286	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs73152714	ENSG00000232546.1	RP11-458F8.1	5.25	2.28e-07	3.28e-05	0.22	0.24	Aortic root size;	chr7:66534641	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000232546.1	RP11-458F8.1	5.25	2.28e-07	3.28e-05	0.22	0.24	Aortic root size;	chr7:66536353	chr7:66848496~66858136:+
THCA	cis	rs7674212	0.57	rs2711898	ENSG00000246560.2	RP11-10L12.4	5.25	2.28e-07	3.28e-05	0.28	0.24	Type 2 diabetes;	chr4:103141914	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223485	ENSG00000248971.2	KRT8P46	-5.25	2.28e-07	3.28e-05	-0.28	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102728746~102730171:-
THCA	cis	rs7829975	1	rs7829975	ENSG00000254153.1	CTA-398F10.2	5.25	2.28e-07	3.28e-05	0.25	0.24	Mood instability;	chr8:8690607	chr8:8456909~8461337:-
THCA	cis	rs6570726	0.818	rs9399555	ENSG00000270638.1	RP3-466P17.1	5.25	2.28e-07	3.28e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs441290	ENSG00000270638.1	RP3-466P17.1	5.25	2.28e-07	3.28e-05	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145735570~145737218:+
THCA	cis	rs13178541	0.593	rs6874289	ENSG00000250378.1	RP11-119J18.1	-5.25	2.28e-07	3.28e-05	-0.27	-0.24	IgG glycosylation;	chr5:135708142	chr5:135812667~135826582:+
THCA	cis	rs9816784	0.596	rs11185511	ENSG00000242086.7	LINC00969	5.25	2.28e-07	3.28e-05	0.24	0.24	Mean corpuscular hemoglobin;	chr3:196108388	chr3:195658062~195739964:+
THCA	cis	rs6545883	0.826	rs1186697	ENSG00000270820.4	RP11-355B11.2	5.25	2.28e-07	3.29e-05	0.2	0.24	Tuberculosis;	chr2:61434282	chr2:61471188~61484130:+
THCA	cis	rs4409675	0.913	rs11587731	ENSG00000227050.1	RP11-460I13.2	5.25	2.28e-07	3.29e-05	0.34	0.24	Corneal astigmatism;	chr1:27937239	chr1:27938875~27960193:-
THCA	cis	rs17270561	0.779	rs12209218	ENSG00000272462.2	U91328.19	-5.25	2.28e-07	3.29e-05	-0.23	-0.24	Iron status biomarkers;	chr6:25887548	chr6:25992662~26001775:+
THCA	cis	rs2360027	0.599	rs4658984	ENSG00000231365.4	RP11-418J17.1	-5.25	2.28e-07	3.29e-05	-0.23	-0.24	Tonsillectomy;	chr1:118553198	chr1:119140396~119275973:+
THCA	cis	rs2692947	0.763	rs7570074	ENSG00000232931.4	LINC00342	5.25	2.28e-07	3.29e-05	0.19	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95741289	chr2:95807118~95816215:-
THCA	cis	rs2439831	0.85	rs16950562	ENSG00000166763.7	STRCP1	5.25	2.28e-07	3.29e-05	0.34	0.24	Lung cancer in ever smokers;	chr15:43744166	chr15:43699488~43718184:-
THCA	cis	rs12681287	0.752	rs10085920	ENSG00000254231.1	CTD-2284J15.1	5.25	2.28e-07	3.29e-05	0.26	0.24	Caudate activity during reward;	chr8:86240437	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs9297861	ENSG00000254231.1	CTD-2284J15.1	5.25	2.28e-07	3.29e-05	0.26	0.24	Caudate activity during reward;	chr8:86242501	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs67615966	ENSG00000254231.1	CTD-2284J15.1	5.25	2.28e-07	3.29e-05	0.26	0.24	Caudate activity during reward;	chr8:86242974	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs12677470	ENSG00000254231.1	CTD-2284J15.1	5.25	2.28e-07	3.29e-05	0.26	0.24	Caudate activity during reward;	chr8:86248330	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs10435563	ENSG00000254231.1	CTD-2284J15.1	5.25	2.28e-07	3.29e-05	0.26	0.24	Caudate activity during reward;	chr8:86253831	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.752	rs10435564	ENSG00000254231.1	CTD-2284J15.1	5.25	2.28e-07	3.29e-05	0.26	0.24	Caudate activity during reward;	chr8:86254010	chr8:86333274~86343314:-
THCA	cis	rs890448	0.796	rs6846097	ENSG00000254531.1	FLJ20021	-5.25	2.28e-07	3.29e-05	-0.21	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101364893	chr4:101347780~101348883:+
THCA	cis	rs1552244	0.872	rs35988239	ENSG00000180385.7	EMC3-AS1	5.25	2.28e-07	3.29e-05	0.28	0.24	Alzheimer's disease;	chr3:10032461	chr3:9986893~10006990:+
THCA	cis	rs763121	0.853	rs138702	ENSG00000273076.1	RP3-508I15.22	-5.25	2.28e-07	3.29e-05	-0.24	-0.24	Menopause (age at onset);	chr22:38736596	chr22:38743495~38743910:+
THCA	cis	rs116095464	0.558	rs10068203	ENSG00000248925.1	CTD-2083E4.6	5.25	2.29e-07	3.29e-05	0.37	0.24	Breast cancer;	chr5:206503	chr5:269858~271516:-
THCA	cis	rs4915077	1	rs17020149	ENSG00000230489.1	VAV3-AS1	5.25	2.29e-07	3.29e-05	0.39	0.24	Hypothyroidism;	chr1:107832667	chr1:107964443~107994607:+
THCA	cis	rs4415084	0.804	rs9790879	ENSG00000272335.1	RP11-53O19.3	5.25	2.29e-07	3.29e-05	0.19	0.24	Breast cancer;	chr5:44899783	chr5:44826076~44828592:+
THCA	cis	rs4660214	0.627	rs61779282	ENSG00000228060.1	RP11-69E11.8	-5.25	2.29e-07	3.29e-05	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39374632	chr1:39565160~39573203:+
THCA	cis	rs9834975	0.935	rs6798997	ENSG00000272758.4	RP11-299J3.8	-5.25	2.29e-07	3.29e-05	-0.22	-0.24	Diastolic blood pressure;	chr3:122355857	chr3:122416207~122443180:+
THCA	cis	rs801193	0.844	rs2244022	ENSG00000273142.1	RP11-458F8.4	-5.25	2.29e-07	3.3e-05	-0.18	-0.24	Aortic root size;	chr7:66737443	chr7:66902857~66906297:+
THCA	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	5.25	2.29e-07	3.3e-05	0.28	0.24	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
THCA	cis	rs6969780	1	rs1548497	ENSG00000233429.8	HOTAIRM1	-5.25	2.29e-07	3.3e-05	-0.35	-0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27134697	chr7:27095647~27100265:+
THCA	cis	rs442309	0.875	rs192004	ENSG00000238280.1	RP11-436D10.3	-5.25	2.29e-07	3.3e-05	-0.28	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62745965	chr10:62793562~62805887:-
THCA	cis	rs7824557	0.767	rs3808509	ENSG00000154316.13	TDH	-5.25	2.29e-07	3.3e-05	-0.17	-0.24	Retinal vascular caliber;	chr8:11305747	chr8:11339637~11368452:+
THCA	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	5.25	2.29e-07	3.3e-05	0.32	0.24	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
THCA	cis	rs911119	1	rs1064039	ENSG00000270001.1	RP11-218C14.8	-5.25	2.29e-07	3.3e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23637790	chr20:23631826~23632316:-
THCA	cis	rs228614	0.51	rs223358	ENSG00000248971.2	KRT8P46	-5.25	2.29e-07	3.3e-05	-0.29	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102728746~102730171:-
THCA	cis	rs10771431	0.597	rs3759275	ENSG00000111788.10	RP11-22B23.1	5.25	2.3e-07	3.31e-05	0.23	0.24	Breast size;	chr12:9201232	chr12:9277235~9313241:+
THCA	cis	rs10771431	0.597	rs3759274	ENSG00000111788.10	RP11-22B23.1	5.25	2.3e-07	3.31e-05	0.23	0.24	Breast size;	chr12:9201279	chr12:9277235~9313241:+
THCA	cis	rs919433	0.783	rs788014	ENSG00000231621.1	AC013264.2	-5.25	2.3e-07	3.31e-05	-0.25	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197364273	chr2:197197991~197199273:+
THCA	cis	rs919433	0.68	rs4685	ENSG00000231621.1	AC013264.2	5.25	2.3e-07	3.31e-05	0.25	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197393071	chr2:197197991~197199273:+
THCA	cis	rs4888671	1	rs78900394	ENSG00000261707.1	RP11-264M12.2	5.25	2.3e-07	3.31e-05	0.44	0.24	Obesity-related traits;	chr16:77750212	chr16:77741468~77743000:-
THCA	cis	rs1823874	0.71	rs4246297	ENSG00000259363.4	CTD-2054N24.2	5.25	2.3e-07	3.31e-05	0.3	0.24	IgG glycosylation;	chr15:99826723	chr15:99807023~99877148:+
THCA	cis	rs2337406	0.929	rs12050233	ENSG00000211974.3	IGHV2-70	-5.25	2.3e-07	3.31e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781123	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.852	rs12050466	ENSG00000211974.3	IGHV2-70	-5.25	2.3e-07	3.31e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106781131	chr14:106723574~106724093:-
THCA	cis	rs2439831	0.702	rs28699233	ENSG00000166763.7	STRCP1	5.25	2.3e-07	3.31e-05	0.36	0.24	Lung cancer in ever smokers;	chr15:43830668	chr15:43699488~43718184:-
THCA	cis	rs752010	0.619	rs6702659	ENSG00000230638.4	RP11-486B10.4	-5.25	2.3e-07	3.31e-05	-0.29	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41646565	chr1:41542069~41544310:+
THCA	cis	rs6893782	0.887	rs274552	ENSG00000233006.5	AC034220.3	5.25	2.3e-07	3.31e-05	0.24	0.24	Acylcarnitine levels;	chr5:132391654	chr5:132311285~132369916:-
THCA	cis	rs6893782	0.887	rs6596075	ENSG00000233006.5	AC034220.3	5.25	2.3e-07	3.31e-05	0.24	0.24	Acylcarnitine levels;	chr5:132406536	chr5:132311285~132369916:-
THCA	cis	rs6893782	0.887	rs274548	ENSG00000233006.5	AC034220.3	-5.25	2.3e-07	3.31e-05	-0.24	-0.24	Acylcarnitine levels;	chr5:132395115	chr5:132311285~132369916:-
THCA	cis	rs6893782	0.83	rs2897160	ENSG00000233006.5	AC034220.3	-5.25	2.3e-07	3.31e-05	-0.24	-0.24	Acylcarnitine levels;	chr5:132405806	chr5:132311285~132369916:-
THCA	cis	rs11834862	0.77	rs10444603	ENSG00000256576.2	RP13-977J11.2	-5.25	2.3e-07	3.32e-05	-0.34	-0.24	Anti-saccade response;	chr12:132210365	chr12:132186735~132189695:-
THCA	cis	rs9311474	0.607	rs34005367	ENSG00000243224.1	RP5-1157M23.2	-5.25	2.3e-07	3.32e-05	-0.26	-0.24	Electroencephalogram traits;	chr3:52524888	chr3:52239258~52241097:+
THCA	cis	rs7688540	0.656	rs79657896	ENSG00000211553.1	AC253576.2	-5.25	2.31e-07	3.32e-05	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:136461~136568:+
THCA	cis	rs7085104	0.632	rs6162	ENSG00000213061.2	PFN1P11	5.25	2.31e-07	3.32e-05	0.28	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102838011~102845473:-
THCA	cis	rs9816784	0.696	rs6778081	ENSG00000207650.1	MIR570	-5.25	2.31e-07	3.32e-05	-0.24	-0.24	Mean corpuscular hemoglobin;	chr3:196092334	chr3:195699401~195699497:+
THCA	cis	rs7727544	0.684	rs2631363	ENSG00000263597.1	MIR3936	-5.25	2.31e-07	3.32e-05	-0.22	-0.24	Blood metabolite levels;	chr5:132371403	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.66	rs2631361	ENSG00000263597.1	MIR3936	-5.25	2.31e-07	3.32e-05	-0.22	-0.24	Blood metabolite levels;	chr5:132371688	chr5:132365490~132365599:-
THCA	cis	rs8020095	0.571	rs10136344	ENSG00000258561.1	RP11-72M17.1	-5.25	2.31e-07	3.33e-05	-0.31	-0.24	Depression (quantitative trait);	chr14:66943760	chr14:66212810~66509394:-
THCA	cis	rs6921919	0.583	rs4254981	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.525	rs6929825	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs35599905	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs1124131	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs6899389	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs6922374	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs6899603	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs6922429	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs6922169	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.559	rs13210866	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.609	rs36018474	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs13201726	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs2027361	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs4642462	ENSG00000219392.1	RP1-265C24.5	-5.25	2.31e-07	3.33e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28115628~28116551:+
THCA	cis	rs6545883	0.929	rs2600663	ENSG00000270820.4	RP11-355B11.2	-5.25	2.31e-07	3.33e-05	-0.19	-0.24	Tuberculosis;	chr2:61313552	chr2:61471188~61484130:+
THCA	cis	rs11089937	0.568	rs5756989	ENSG00000211639.2	IGLV4-60	5.25	2.31e-07	3.33e-05	0.17	0.24	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22162199~22162681:+
THCA	cis	rs12681963	0.688	rs12541087	ENSG00000272375.1	RP11-51J9.6	5.25	2.31e-07	3.33e-05	0.34	0.24	Migraine;	chr8:30172398	chr8:30197404~30198048:+
THCA	cis	rs4947019	1	rs74975304	ENSG00000223537.2	RP5-919F19.5	-5.25	2.31e-07	3.33e-05	-0.36	-0.24	Hematological parameters;	chr6:109772836	chr6:109487906~109506800:+
THCA	cis	rs763121	0.853	rs2235230	ENSG00000228274.3	RP3-508I15.9	5.25	2.31e-07	3.33e-05	0.27	0.24	Menopause (age at onset);	chr22:38728462	chr22:38667585~38681820:-
THCA	cis	rs4660456	0.913	rs2223486	ENSG00000272145.1	NFYC-AS1	5.25	2.31e-07	3.33e-05	0.16	0.24	Platelet count;	chr1:40693557	chr1:40690380~40692066:-
THCA	cis	rs6058796	1	rs6087972	ENSG00000175730.8	BAK1P1	5.25	2.31e-07	3.33e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32680300	chr20:32690180~32690815:-
THCA	cis	rs6058796	0.792	rs35938376	ENSG00000175730.8	BAK1P1	5.25	2.31e-07	3.33e-05	0.35	0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32682734	chr20:32690180~32690815:-
THCA	cis	rs60180747	0.909	rs76095247	ENSG00000261318.1	RP11-653J6.1	5.25	2.31e-07	3.33e-05	0.33	0.24	Testicular germ cell tumor;	chr15:66301130	chr15:66278498~66293357:-
THCA	cis	rs853679	0.567	rs13209596	ENSG00000280107.1	AL022393.9	-5.25	2.31e-07	3.33e-05	-0.25	-0.24	Depression;	chr6:28428413	chr6:28170845~28172521:+
THCA	cis	rs853679	0.567	rs9969098	ENSG00000280107.1	AL022393.9	-5.25	2.31e-07	3.33e-05	-0.25	-0.24	Depression;	chr6:28430971	chr6:28170845~28172521:+
THCA	cis	rs853679	0.567	rs7740429	ENSG00000280107.1	AL022393.9	-5.25	2.31e-07	3.33e-05	-0.25	-0.24	Depression;	chr6:28431469	chr6:28170845~28172521:+
THCA	cis	rs853679	0.567	rs16894106	ENSG00000280107.1	AL022393.9	-5.25	2.31e-07	3.33e-05	-0.25	-0.24	Depression;	chr6:28432562	chr6:28170845~28172521:+
THCA	cis	rs1050631	0.564	rs559289	ENSG00000260552.1	RP11-49I11.1	5.25	2.32e-07	3.33e-05	0.29	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36172927	chr18:36179996~36187448:-
THCA	cis	rs12893668	0.703	rs2274267	ENSG00000269940.1	RP11-73M18.7	5.25	2.32e-07	3.33e-05	0.25	0.24	Reticulocyte count;	chr14:103563112	chr14:103694560~103695170:+
THCA	cis	rs2179367	0.632	rs2341774	ENSG00000268592.3	RAET1E-AS1	5.25	2.32e-07	3.33e-05	0.34	0.24	Dupuytren's disease;	chr6:149425014	chr6:149863494~149919507:+
THCA	cis	rs3770081	0.59	rs6747424	ENSG00000272564.1	RP11-548P2.2	-5.25	2.32e-07	3.33e-05	-0.4	-0.24	Facial emotion recognition (sad faces);	chr2:85949101	chr2:85904279~85904727:+
THCA	cis	rs3770081	1	rs6705122	ENSG00000272564.1	RP11-548P2.2	-5.25	2.32e-07	3.33e-05	-0.4	-0.24	Facial emotion recognition (sad faces);	chr2:85949135	chr2:85904279~85904727:+
THCA	cis	rs9878978	0.685	rs6799939	ENSG00000237990.3	CNTN4-AS1	5.25	2.32e-07	3.33e-05	0.25	0.24	Blood pressure (smoking interaction);	chr3:2468560	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.685	rs6787418	ENSG00000237990.3	CNTN4-AS1	5.25	2.32e-07	3.33e-05	0.25	0.24	Blood pressure (smoking interaction);	chr3:2468620	chr3:3039033~3069242:-
THCA	cis	rs1866631	0.566	rs3754741	ENSG00000238133.5	MLK7-AS1	5.25	2.32e-07	3.33e-05	0.31	0.24	Lung cancer in ever smokers;	chr2:173188491	chr2:173166446~173282036:-
THCA	cis	rs6687821	1	rs6687821	ENSG00000261737.1	RP4-612B15.3	5.25	2.32e-07	3.33e-05	0.38	0.24	Yeast infection;	chr1:86741033	chr1:86703502~86704462:-
THCA	cis	rs5758659	1	rs134882	ENSG00000227370.1	RP4-669P10.19	-5.25	2.32e-07	3.34e-05	-0.21	-0.24	Cognitive function;	chr22:42274959	chr22:42132543~42132998:+
THCA	cis	rs1050631	0.592	rs1789508	ENSG00000260552.1	RP11-49I11.1	5.25	2.32e-07	3.34e-05	0.3	0.24	Esophageal squamous cell cancer (length of survival);	chr18:36156882	chr18:36179996~36187448:-
THCA	cis	rs9733	0.544	rs72700902	ENSG00000231073.1	RP11-316M1.3	5.25	2.32e-07	3.34e-05	0.28	0.24	Tonsillectomy;	chr1:150660871	chr1:150973123~150975534:+
THCA	cis	rs922182	0.967	rs17788704	ENSG00000275785.1	RP11-111E14.2	-5.25	2.32e-07	3.34e-05	-0.27	-0.24	Blood protein levels;	chr15:63984898	chr15:63890030~63890317:+
THCA	cis	rs2562456	0.617	rs34203148	ENSG00000268081.1	RP11-678G14.2	5.25	2.32e-07	3.34e-05	0.36	0.24	Pain;	chr19:21590743	chr19:21554640~21569237:-
THCA	cis	rs801193	0.613	rs2016325	ENSG00000229886.1	RP5-1132H15.3	-5.25	2.32e-07	3.34e-05	-0.25	-0.24	Aortic root size;	chr7:66858513	chr7:66025126~66031544:-
THCA	cis	rs2179367	0.632	rs9485384	ENSG00000223701.3	RAET1E-AS1	5.25	2.32e-07	3.34e-05	0.34	0.24	Dupuytren's disease;	chr6:149328808	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12211357	ENSG00000223701.3	RAET1E-AS1	5.25	2.32e-07	3.34e-05	0.34	0.24	Dupuytren's disease;	chr6:149331148	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs11155642	ENSG00000223701.3	RAET1E-AS1	5.25	2.32e-07	3.34e-05	0.34	0.24	Dupuytren's disease;	chr6:149332984	chr6:149884431~149919508:+
THCA	cis	rs6921919	0.583	rs3734563	ENSG00000219392.1	RP1-265C24.5	-5.25	2.32e-07	3.34e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs1591913	ENSG00000219392.1	RP1-265C24.5	-5.25	2.32e-07	3.34e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28115628~28116551:+
THCA	cis	rs4660456	0.826	rs2744802	ENSG00000272145.1	NFYC-AS1	-5.25	2.32e-07	3.34e-05	-0.16	-0.24	Platelet count;	chr1:40687577	chr1:40690380~40692066:-
THCA	cis	rs4648045	0.861	rs230539	ENSG00000246560.2	RP11-10L12.4	-5.25	2.32e-07	3.34e-05	-0.3	-0.24	Lymphocyte percentage of white cells;	chr4:102574375	chr4:102828055~102844075:+
THCA	cis	rs66887589	0.616	rs6843509	ENSG00000249244.1	RP11-548H18.2	5.25	2.33e-07	3.35e-05	0.25	0.24	Diastolic blood pressure;	chr4:119299041	chr4:119391831~119395335:-
THCA	cis	rs5758659	0.716	rs5758661	ENSG00000270083.1	RP1-257I20.14	5.25	2.33e-07	3.35e-05	0.24	0.24	Cognitive function;	chr22:42228439	chr22:42089630~42090028:-
THCA	cis	rs2117029	1	rs10783299	ENSG00000258017.1	RP11-386G11.10	-5.25	2.33e-07	3.35e-05	-0.31	-0.24	Intelligence (multi-trait analysis);	chr12:48996894	chr12:49127782~49147869:+
THCA	cis	rs972578	0.74	rs1983648	ENSG00000274717.1	RP1-47A17.1	-5.25	2.33e-07	3.35e-05	-0.24	-0.24	Mean platelet volume;	chr22:42859391	chr22:42791814~42794313:-
THCA	cis	rs1552244	1	rs3895942	ENSG00000180385.7	EMC3-AS1	5.25	2.33e-07	3.35e-05	0.26	0.24	Alzheimer's disease;	chr3:10067061	chr3:9986893~10006990:+
THCA	cis	rs4415084	0.774	rs11958808	ENSG00000272335.1	RP11-53O19.3	-5.25	2.33e-07	3.35e-05	-0.2	-0.24	Breast cancer;	chr5:44944988	chr5:44826076~44828592:+
THCA	cis	rs9992667	0.955	rs28560778	ENSG00000231160.8	KLF3-AS1	5.25	2.33e-07	3.35e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38609668	chr4:38612701~38664883:-
THCA	cis	rs7129556	0.561	rs621456	ENSG00000254691.1	RP11-91P24.5	5.25	2.33e-07	3.35e-05	0.32	0.24	Weight loss (gastric bypass surgery);	chr11:77841984	chr11:77850604~77851511:+
THCA	cis	rs7772486	0.686	rs1569540	ENSG00000270638.1	RP3-466P17.1	-5.25	2.33e-07	3.35e-05	-0.18	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs2142983	ENSG00000270638.1	RP3-466P17.1	-5.25	2.33e-07	3.35e-05	-0.18	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145735570~145737218:+
THCA	cis	rs7015630	0.657	rs62530908	ENSG00000251136.7	RP11-37B2.1	-5.25	2.33e-07	3.35e-05	-0.28	-0.24	Inflammatory bowel disease;Crohn's disease;	chr8:89835235	chr8:89609409~89757727:-
THCA	cis	rs8002861	0.967	rs2325071	ENSG00000274001.1	RP11-5G9.5	5.25	2.33e-07	3.35e-05	0.26	0.24	Leprosy;	chr13:43902657	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.967	rs9525871	ENSG00000274001.1	RP11-5G9.5	5.25	2.33e-07	3.35e-05	0.26	0.24	Leprosy;	chr13:43903576	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.967	rs9533689	ENSG00000274001.1	RP11-5G9.5	5.25	2.33e-07	3.35e-05	0.26	0.24	Leprosy;	chr13:43906277	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.967	rs9533690	ENSG00000274001.1	RP11-5G9.5	5.25	2.33e-07	3.35e-05	0.26	0.24	Leprosy;	chr13:43906462	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.967	rs7999434	ENSG00000274001.1	RP11-5G9.5	5.25	2.33e-07	3.35e-05	0.26	0.24	Leprosy;	chr13:43908825	chr13:43877715~43878163:-
THCA	cis	rs11992162	0.591	rs34123222	ENSG00000206014.6	OR7E161P	5.25	2.33e-07	3.35e-05	0.28	0.24	Monocyte count;	chr8:11937840	chr8:11928597~11929563:-
THCA	cis	rs4648045	0.565	rs11733293	ENSG00000246560.2	RP11-10L12.4	-5.25	2.33e-07	3.35e-05	-0.29	-0.24	Lymphocyte percentage of white cells;	chr4:102624096	chr4:102828055~102844075:+
THCA	cis	rs12681288	0.712	rs2600488	ENSG00000260721.1	AF067845.1	5.25	2.33e-07	3.35e-05	0.29	0.24	Schizophrenia;	chr8:1071266	chr8:1368642~1369833:-
THCA	cis	rs1552244	0.872	rs115331527	ENSG00000180385.7	EMC3-AS1	5.25	2.33e-07	3.35e-05	0.26	0.24	Alzheimer's disease;	chr3:10112820	chr3:9986893~10006990:+
THCA	cis	rs8141529	0.748	rs5752826	ENSG00000272858.1	CTA-292E10.8	-5.25	2.33e-07	3.35e-05	-0.24	-0.24	Lymphocyte counts;	chr22:28873820	chr22:28814914~28815662:+
THCA	cis	rs863750	0.744	rs825458	ENSG00000275389.1	RP11-214K3.24	5.25	2.33e-07	3.36e-05	0.32	0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124055244	chr12:124085761~124088598:+
THCA	cis	rs863750	0.744	rs825459	ENSG00000275389.1	RP11-214K3.24	5.25	2.33e-07	3.36e-05	0.32	0.24	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124056537	chr12:124085761~124088598:+
THCA	cis	rs6569038	0.528	rs794262	ENSG00000253194.1	RP11-351A11.1	5.25	2.33e-07	3.36e-05	0.32	0.24	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119005947	chr6:118934785~119031541:+
THCA	cis	rs853679	0.567	rs7774981	ENSG00000280107.1	AL022393.9	-5.25	2.34e-07	3.36e-05	-0.25	-0.24	Depression;	chr6:28379133	chr6:28170845~28172521:+
THCA	cis	rs853679	0.567	rs7754960	ENSG00000280107.1	AL022393.9	-5.25	2.34e-07	3.36e-05	-0.25	-0.24	Depression;	chr6:28379168	chr6:28170845~28172521:+
THCA	cis	rs2243480	1	rs410128	ENSG00000232559.3	GS1-124K5.12	5.25	2.34e-07	3.36e-05	0.35	0.24	Diabetic kidney disease;	chr7:66138186	chr7:66554588~66576923:-
THCA	cis	rs17594362	0.573	rs79859984	ENSG00000264190.1	MIR5006	5.25	2.34e-07	3.36e-05	0.37	0.24	Multiple sclerosis;	chr13:41573291	chr13:41568286~41568395:-
THCA	cis	rs1707322	0.827	rs10890347	ENSG00000281133.1	AL355480.3	5.25	2.34e-07	3.37e-05	0.29	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45580892~45580996:-
THCA	cis	rs9307551	0.584	rs1595966	ENSG00000250334.4	LINC00989	-5.25	2.34e-07	3.37e-05	-0.28	-0.24	Refractive error;	chr4:79549502	chr4:79492416~79576460:+
THCA	cis	rs16975963	0.644	rs12151280	ENSG00000226686.6	LINC01535	-5.25	2.34e-07	3.37e-05	-0.31	-0.24	Longevity;	chr19:37576988	chr19:37251912~37265535:+
THCA	cis	rs6547741	0.935	rs12615690	ENSG00000234072.1	AC074117.10	5.25	2.34e-07	3.37e-05	0.18	0.24	Oral cavity cancer;	chr2:27628253	chr2:27356246~27367622:+
THCA	cis	rs72799341	1	rs72799341	ENSG00000260911.2	RP11-196G11.2	5.25	2.34e-07	3.37e-05	0.23	0.24	Diastolic blood pressure;	chr16:30925422	chr16:31043150~31049868:+
THCA	cis	rs1876905	0.539	rs240962	ENSG00000271789.1	RP5-1112D6.7	5.25	2.34e-07	3.37e-05	0.3	0.24	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111297126~111298510:+
THCA	cis	rs116095464	0.558	rs73029475	ENSG00000248925.1	CTD-2083E4.6	5.25	2.34e-07	3.37e-05	0.37	0.24	Breast cancer;	chr5:206854	chr5:269858~271516:-
THCA	cis	rs7731390	0.764	rs75817769	ENSG00000233006.5	AC034220.3	5.25	2.34e-07	3.37e-05	0.31	0.24	IgG glycosylation;	chr5:132371673	chr5:132311285~132369916:-
THCA	cis	rs7731390	0.614	rs34741321	ENSG00000233006.5	AC034220.3	5.25	2.34e-07	3.37e-05	0.31	0.24	IgG glycosylation;	chr5:132381731	chr5:132311285~132369916:-
THCA	cis	rs7731390	0.558	rs78399358	ENSG00000233006.5	AC034220.3	5.25	2.34e-07	3.37e-05	0.31	0.24	IgG glycosylation;	chr5:132384004	chr5:132311285~132369916:-
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000230295.1	RP11-458F8.2	-5.25	2.34e-07	3.37e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65947955	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000230295.1	RP11-458F8.2	-5.25	2.34e-07	3.37e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65950886	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000230295.1	RP11-458F8.2	-5.25	2.34e-07	3.37e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65951525	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000230295.1	RP11-458F8.2	-5.25	2.34e-07	3.37e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65951549	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000230295.1	RP11-458F8.2	-5.25	2.34e-07	3.37e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:65956884	chr7:66880708~66882981:+
THCA	cis	rs4950322	1	rs4448568	ENSG00000278811.3	LINC00624	5.25	2.35e-07	3.37e-05	0.31	0.24	Protein quantitative trait loci;	chr1:147377296	chr1:147258885~147517875:-
THCA	cis	rs17123764	0.605	rs11169104	ENSG00000257464.1	RP11-161H23.8	-5.25	2.35e-07	3.37e-05	-0.38	-0.24	Intelligence (multi-trait analysis);	chr12:49682504	chr12:49442424~49442652:-
THCA	cis	rs7617773	0.817	rs13068265	ENSG00000199476.1	Y_RNA	-5.25	2.35e-07	3.37e-05	-0.3	-0.24	Coronary artery disease;	chr3:48260124	chr3:48288587~48288694:+
THCA	cis	rs3743266	0.613	rs10851681	ENSG00000245534.5	RORA-AS1	-5.25	2.35e-07	3.37e-05	-0.25	-0.24	Menarche (age at onset);	chr15:60439939	chr15:60479178~60630637:+
THCA	cis	rs7727544	0.582	rs3805681	ENSG00000224431.1	AC063976.7	5.25	2.35e-07	3.37e-05	0.2	0.24	Blood metabolite levels;	chr5:132202167	chr5:132199456~132203487:+
THCA	cis	rs28374715	0.58	rs8030228	ENSG00000247556.5	OIP5-AS1	5.25	2.35e-07	3.37e-05	0.21	0.24	Ulcerative colitis;	chr15:41344669	chr15:41283990~41309737:+
THCA	cis	rs10080237	0.564	rs2490230	ENSG00000272129.1	RP11-250B2.6	5.25	2.35e-07	3.37e-05	0.3	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80102747	chr6:80355424~80356859:+
THCA	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-5.25	2.35e-07	3.37e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
THCA	cis	rs2239547	0.563	rs2581820	ENSG00000242142.1	SERBP1P3	-5.25	2.35e-07	3.38e-05	-0.29	-0.24	Schizophrenia;	chr3:52986528	chr3:53064283~53065091:-
THCA	cis	rs6951245	0.542	rs28460147	ENSG00000229043.2	AC091729.9	-5.25	2.35e-07	3.38e-05	-0.4	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1177556	chr7:1160374~1165267:+
THCA	cis	rs7772486	0.686	rs9386131	ENSG00000270638.1	RP3-466P17.1	5.25	2.35e-07	3.38e-05	0.18	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs7739735	ENSG00000270638.1	RP3-466P17.1	5.25	2.35e-07	3.38e-05	0.18	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs7744014	ENSG00000270638.1	RP3-466P17.1	5.25	2.35e-07	3.38e-05	0.18	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs4895684	ENSG00000270638.1	RP3-466P17.1	-5.25	2.35e-07	3.38e-05	-0.18	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145735570~145737218:+
THCA	cis	rs2980439	0.818	rs2948300	ENSG00000254153.1	CTA-398F10.2	-5.25	2.35e-07	3.38e-05	-0.26	-0.24	Neuroticism;	chr8:8248986	chr8:8456909~8461337:-
THCA	cis	rs11096990	0.793	rs9997050	ENSG00000249685.1	RP11-360F5.3	-5.25	2.35e-07	3.38e-05	-0.31	-0.24	Cognitive function;	chr4:39301045	chr4:39133913~39135608:+
THCA	cis	rs1479090	0.652	rs1564313	ENSG00000250027.1	RP11-563E2.2	-5.25	2.35e-07	3.38e-05	-0.24	-0.24	Lung cancer;	chr4:163154598	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.805	rs1351222	ENSG00000250027.1	RP11-563E2.2	-5.25	2.35e-07	3.38e-05	-0.24	-0.24	Lung cancer;	chr4:163155406	chr4:163108785~163119965:+
THCA	cis	rs2243480	1	rs160633	ENSG00000230295.1	RP11-458F8.2	-5.25	2.35e-07	3.38e-05	-0.28	-0.24	Diabetic kidney disease;	chr7:66063241	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs10807701	ENSG00000230295.1	RP11-458F8.2	5.25	2.35e-07	3.38e-05	0.29	0.24	Diabetic kidney disease;	chr7:66259699	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1499613	ENSG00000230295.1	RP11-458F8.2	5.25	2.35e-07	3.38e-05	0.29	0.24	Diabetic kidney disease;	chr7:66265873	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1553174	ENSG00000230295.1	RP11-458F8.2	5.25	2.35e-07	3.38e-05	0.29	0.24	Diabetic kidney disease;	chr7:66266207	chr7:66880708~66882981:+
THCA	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	5.25	2.35e-07	3.38e-05	0.26	0.24	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
THCA	cis	rs1866631	0.566	rs2289399	ENSG00000238133.5	MLK7-AS1	5.25	2.35e-07	3.38e-05	0.3	0.24	Lung cancer in ever smokers;	chr2:173191003	chr2:173166446~173282036:-
THCA	cis	rs7294478	0.71	rs7139082	ENSG00000205885.6	C1RL-AS1	5.25	2.35e-07	3.38e-05	0.17	0.24	Neuritic plaque;	chr12:7104043	chr12:7108052~7122501:+
THCA	cis	rs3213758	1	rs12600159	ENSG00000275191.1	RP11-36I17.2	-5.25	2.36e-07	3.38e-05	-0.47	-0.24	Vitiligo (non-segmental);	chr16:53648603	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.53	rs12600091	ENSG00000275191.1	RP11-36I17.2	-5.25	2.36e-07	3.38e-05	-0.47	-0.24	Vitiligo (non-segmental);	chr16:53648873	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.881	rs12445128	ENSG00000275191.1	RP11-36I17.2	-5.25	2.36e-07	3.38e-05	-0.47	-0.24	Vitiligo (non-segmental);	chr16:53652396	chr16:53628256~53628816:-
THCA	cis	rs934734	0.725	rs2271198	ENSG00000234255.7	AC012370.3	5.25	2.36e-07	3.39e-05	0.27	0.24	Rheumatoid arthritis;	chr2:65331893	chr2:65439888~65456571:-
THCA	cis	rs1635	0.655	rs9380024	ENSG00000216901.1	AL022393.7	5.25	2.36e-07	3.39e-05	0.52	0.24	Schizophrenia;	chr6:27862576	chr6:28176188~28176674:+
THCA	cis	rs1862618	0.853	rs1423620	ENSG00000271828.1	CTD-2310F14.1	5.25	2.36e-07	3.39e-05	0.35	0.24	Initial pursuit acceleration;	chr5:56805169	chr5:56927874~56929573:+
THCA	cis	rs858239	0.536	rs6961109	ENSG00000226816.2	AC005082.12	5.25	2.36e-07	3.39e-05	0.33	0.24	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23206013~23208045:+
THCA	cis	rs9818758	0.607	rs9880088	ENSG00000270441.1	RP11-694I15.7	5.25	2.36e-07	3.39e-05	0.33	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49141557	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs9862483	ENSG00000270441.1	RP11-694I15.7	5.25	2.36e-07	3.39e-05	0.33	0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49158008	chr3:49140086~49160851:-
THCA	cis	rs12681287	0.64	rs6992287	ENSG00000254231.1	CTD-2284J15.1	-5.25	2.36e-07	3.39e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86406731	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs6992944	ENSG00000254231.1	CTD-2284J15.1	-5.25	2.36e-07	3.39e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86407079	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs28561640	ENSG00000254231.1	CTD-2284J15.1	-5.25	2.36e-07	3.39e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86413409	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs10095498	ENSG00000254231.1	CTD-2284J15.1	-5.25	2.36e-07	3.39e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86413422	chr8:86333274~86343314:-
THCA	cis	rs10875746	0.669	rs11168459	ENSG00000258234.1	RP11-370I10.2	5.25	2.36e-07	3.39e-05	0.28	0.24	Longevity (90 years and older);	chr12:48202458	chr12:48231098~48284210:-
THCA	cis	rs6430585	0.583	rs4988163	ENSG00000231890.6	DARS-AS1	-5.25	2.36e-07	3.39e-05	-0.28	-0.24	Corneal structure;	chr2:135870551	chr2:135985176~136022593:+
THCA	cis	rs853679	1	rs1778508	ENSG00000220721.1	OR1F12	-5.25	2.36e-07	3.39e-05	-0.37	-0.24	Depression;	chr6:28262103	chr6:28073316~28074233:+
THCA	cis	rs867371	0.502	rs8025964	ENSG00000259429.4	UBE2Q2P2	-5.25	2.36e-07	3.39e-05	-0.19	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82355142~82420075:+
THCA	cis	rs890448	0.796	rs10433981	ENSG00000254531.1	FLJ20021	5.25	2.36e-07	3.39e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362432	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs7687487	ENSG00000254531.1	FLJ20021	5.25	2.36e-07	3.39e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362824	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs7668224	ENSG00000254531.1	FLJ20021	5.25	2.36e-07	3.39e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363270	chr4:101347780~101348883:+
THCA	cis	rs890448	0.76	rs4699210	ENSG00000254531.1	FLJ20021	5.25	2.36e-07	3.39e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363829	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs4699211	ENSG00000254531.1	FLJ20021	5.25	2.36e-07	3.39e-05	0.21	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363878	chr4:101347780~101348883:+
THCA	cis	rs6893782	0.887	rs274551	ENSG00000233006.5	AC034220.3	-5.25	2.36e-07	3.39e-05	-0.24	-0.24	Acylcarnitine levels;	chr5:132391988	chr5:132311285~132369916:-
THCA	cis	rs73242632	1	rs10023009	ENSG00000269949.1	RP11-738E22.3	5.25	2.36e-07	3.4e-05	0.55	0.24	Congenital heart disease (maternal effect);	chr4:57018172	chr4:56960927~56961373:-
THCA	cis	rs6921919	0.583	rs6907950	ENSG00000219392.1	RP1-265C24.5	-5.25	2.36e-07	3.4e-05	-0.26	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28115628~28116551:+
THCA	cis	rs9921338	0.887	rs13330151	ENSG00000262636.1	CTD-3088G3.4	-5.25	2.36e-07	3.4e-05	-0.35	-0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11308542	chr16:11380859~11381118:-
THCA	cis	rs763121	0.853	rs4821816	ENSG00000273076.1	RP3-508I15.22	5.25	2.36e-07	3.4e-05	0.24	0.24	Menopause (age at onset);	chr22:38717129	chr22:38743495~38743910:+
THCA	cis	rs2070488	0.699	rs13064938	ENSG00000229589.1	ACVR2B-AS1	5.25	2.37e-07	3.4e-05	0.21	0.24	Electrocardiographic conduction measures;	chr3:38398746	chr3:38451027~38454820:-
THCA	cis	rs613391	0.712	rs523296	ENSG00000224549.1	RP11-370B11.3	-5.25	2.37e-07	3.4e-05	-0.27	-0.24	Quantitative traits;	chr9:22688211	chr9:22767175~22768316:+
THCA	cis	rs7942368	1	rs10437754	ENSG00000261578.1	RP11-21L23.2	5.25	2.37e-07	3.4e-05	0.34	0.24	Endometriosis;	chr11:76766823	chr11:76800364~76804555:+
THCA	cis	rs12435908	1	rs60936033	ENSG00000276116.2	FUT8-AS1	-5.25	2.37e-07	3.4e-05	-0.38	-0.24	Ischemic stroke;	chr14:65390265	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs10146374	ENSG00000276116.2	FUT8-AS1	-5.25	2.37e-07	3.4e-05	-0.38	-0.24	Ischemic stroke;	chr14:65390694	chr14:65411170~65412690:-
THCA	cis	rs11992186	0.505	rs7845203	ENSG00000254153.1	CTA-398F10.2	-5.25	2.37e-07	3.4e-05	-0.25	-0.24	Neuroticism;	chr8:8287918	chr8:8456909~8461337:-
THCA	cis	rs12188164	0.582	rs80273890	ENSG00000188242.4	PP7080	5.25	2.37e-07	3.4e-05	0.25	0.24	Cystic fibrosis severity;	chr5:482942	chr5:466124~473098:-
THCA	cis	rs4950322	0.512	rs2353981	ENSG00000237188.3	RP11-337C18.8	-5.24	2.37e-07	3.4e-05	-0.26	-0.24	Protein quantitative trait loci;	chr1:147368365	chr1:147172771~147211568:+
THCA	cis	rs4415084	0.834	rs1438821	ENSG00000272335.1	RP11-53O19.3	5.24	2.37e-07	3.4e-05	0.2	0.24	Breast cancer;	chr5:44858349	chr5:44826076~44828592:+
THCA	cis	rs1823874	0.71	rs58572174	ENSG00000259363.4	CTD-2054N24.2	5.24	2.37e-07	3.4e-05	0.3	0.24	IgG glycosylation;	chr15:99822635	chr15:99807023~99877148:+
THCA	cis	rs1823874	0.677	rs1993295	ENSG00000259363.4	CTD-2054N24.2	5.24	2.37e-07	3.4e-05	0.3	0.24	IgG glycosylation;	chr15:99823332	chr15:99807023~99877148:+
THCA	cis	rs1823874	0.71	rs1993297	ENSG00000259363.4	CTD-2054N24.2	5.24	2.37e-07	3.4e-05	0.3	0.24	IgG glycosylation;	chr15:99823423	chr15:99807023~99877148:+
THCA	cis	rs1823874	0.613	rs4608318	ENSG00000259363.4	CTD-2054N24.2	5.24	2.37e-07	3.4e-05	0.3	0.24	IgG glycosylation;	chr15:99823621	chr15:99807023~99877148:+
THCA	cis	rs1823874	0.677	rs2168069	ENSG00000259363.4	CTD-2054N24.2	5.24	2.37e-07	3.4e-05	0.3	0.24	IgG glycosylation;	chr15:99823798	chr15:99807023~99877148:+
THCA	cis	rs1552244	0.706	rs279545	ENSG00000232901.1	CYCSP10	5.24	2.37e-07	3.4e-05	0.27	0.24	Alzheimer's disease;	chr3:9930809	chr3:10000647~10000940:-
THCA	cis	rs7119	0.717	rs7181283	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77522202	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12899390	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77522896	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12901100	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77523216	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12904212	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77523491	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12904584	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77523649	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs11636529	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77523878	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs11631274	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77524089	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs7176307	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77524342	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12909645	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77524477	chr15:77525540~77534110:+
THCA	cis	rs7119	0.679	rs12909808	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77524602	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12910594	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77524761	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12910513	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77524916	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12911854	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77524946	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12910975	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77525145	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12912386	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77525298	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12915548	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77525700	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12917314	ENSG00000259362.2	RP11-307C19.1	-5.24	2.37e-07	3.4e-05	-0.33	-0.24	Type 2 diabetes;	chr15:77525943	chr15:77525540~77534110:+
THCA	cis	rs62184315	0.938	rs7563391	ENSG00000273240.1	RP11-455J20.3	-5.24	2.37e-07	3.4e-05	-0.29	-0.24	Alcohol dependence (age at onset);	chr2:189915077	chr2:189763859~189764456:-
THCA	cis	rs911119	0.954	rs35966482	ENSG00000270001.1	RP11-218C14.8	-5.24	2.37e-07	3.4e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23640079	chr20:23631826~23632316:-
THCA	cis	rs1552244	1	rs6791810	ENSG00000180385.7	EMC3-AS1	-5.24	2.37e-07	3.4e-05	-0.26	-0.24	Alzheimer's disease;	chr3:10082760	chr3:9986893~10006990:+
THCA	cis	rs6545883	0.929	rs10200055	ENSG00000270820.4	RP11-355B11.2	-5.24	2.37e-07	3.4e-05	-0.2	-0.24	Tuberculosis;	chr2:61400882	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.929	rs10193666	ENSG00000270820.4	RP11-355B11.2	-5.24	2.37e-07	3.4e-05	-0.2	-0.24	Tuberculosis;	chr2:61402273	chr2:61471188~61484130:+
THCA	cis	rs11671005	0.779	rs3794971	ENSG00000269473.1	CTD-2619J13.19	5.24	2.37e-07	3.4e-05	0.27	0.24	Mean platelet volume;	chr19:58474499	chr19:58440448~58445849:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000273142.1	RP11-458F8.4	5.24	2.37e-07	3.4e-05	0.19	0.24	Aortic root size;	chr7:66018255	chr7:66902857~66906297:+
THCA	cis	rs763567	0.845	rs539045	ENSG00000271811.1	RP1-79C4.4	5.24	2.37e-07	3.41e-05	0.27	0.24	Tonsillectomy;	chr1:170638940	chr1:170667381~170669425:+
THCA	cis	rs34779708	0.966	rs17591163	ENSG00000271335.4	RP11-324I22.4	5.24	2.37e-07	3.41e-05	0.23	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35314552~35336401:-
THCA	cis	rs10083777	0.551	rs111889995	ENSG00000261061.1	RP11-303E16.2	-5.24	2.38e-07	3.41e-05	-0.43	-0.24	Metabolite levels (small molecules and protein measures);	chr16:81000166	chr16:81030770~81031485:+
THCA	cis	rs4748857	0.588	rs4614340	ENSG00000224215.1	RP11-371A19.2	-5.24	2.38e-07	3.41e-05	-0.31	-0.24	Systemic lupus erythematosus;	chr10:23299345	chr10:23343957~23345181:+
THCA	cis	rs4767841	0.935	rs2952403	ENSG00000248636.5	RP11-768F21.1	-5.24	2.38e-07	3.41e-05	-0.25	-0.24	Urgency urinary incontinence;	chr12:119738080	chr12:119387987~119668079:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000273142.1	RP11-458F8.4	-5.24	2.38e-07	3.41e-05	-0.19	-0.24	Aortic root size;	chr7:65967557	chr7:66902857~66906297:+
THCA	cis	rs2835345	0.563	rs60727080	ENSG00000230479.1	AP000695.6	5.24	2.38e-07	3.41e-05	0.28	0.24	Pulmonary function;	chr21:36454876	chr21:36430360~36481070:+
THCA	cis	rs6951245	1	rs113575110	ENSG00000229043.2	AC091729.9	-5.24	2.38e-07	3.42e-05	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs1881123	ENSG00000229043.2	AC091729.9	-5.24	2.38e-07	3.42e-05	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.872	rs77569514	ENSG00000229043.2	AC091729.9	-5.24	2.38e-07	3.42e-05	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs11770909	ENSG00000229043.2	AC091729.9	-5.24	2.38e-07	3.42e-05	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1160374~1165267:+
THCA	cis	rs2243480	1	rs160634	ENSG00000230295.1	RP11-458F8.2	5.24	2.38e-07	3.42e-05	0.28	0.24	Diabetic kidney disease;	chr7:66063677	chr7:66880708~66882981:+
THCA	cis	rs9859260	0.845	rs35587059	ENSG00000231464.1	AC024937.4	5.24	2.38e-07	3.42e-05	0.29	0.24	Mean corpuscular volume;	chr3:196077473	chr3:195996738~195998233:+
THCA	cis	rs7523875	1	rs7522532	ENSG00000153363.11	LINC00467	-5.24	2.38e-07	3.42e-05	-0.27	-0.24	Mean corpuscular volume;	chr1:211221709	chr1:211382803~211435333:+
THCA	cis	rs911119	1	rs5030707	ENSG00000270001.1	RP11-218C14.8	-5.24	2.38e-07	3.42e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23638019	chr20:23631826~23632316:-
THCA	cis	rs911119	0.909	rs111360484	ENSG00000270001.1	RP11-218C14.8	-5.24	2.38e-07	3.42e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23638347	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs67567111	ENSG00000270001.1	RP11-218C14.8	-5.24	2.38e-07	3.42e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23638438	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs3827143	ENSG00000270001.1	RP11-218C14.8	-5.24	2.38e-07	3.42e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23638980	chr20:23631826~23632316:-
THCA	cis	rs911119	0.909	rs3761279	ENSG00000270001.1	RP11-218C14.8	-5.24	2.38e-07	3.42e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23639438	chr20:23631826~23632316:-
THCA	cis	rs911119	0.779	rs3761280	ENSG00000270001.1	RP11-218C14.8	-5.24	2.38e-07	3.42e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23639439	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs34897231	ENSG00000270001.1	RP11-218C14.8	-5.24	2.38e-07	3.42e-05	-0.37	-0.24	Chronic kidney disease;	chr20:23639631	chr20:23631826~23632316:-
THCA	cis	rs748404	0.666	rs72709879	ENSG00000205771.5	CATSPER2P1	-5.24	2.38e-07	3.42e-05	-0.3	-0.24	Lung cancer;	chr15:43507777	chr15:43726918~43747094:-
THCA	cis	rs6997458	0.742	rs2307075	ENSG00000253549.4	RP11-317J10.2	5.24	2.39e-07	3.42e-05	0.24	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85475999	chr8:85441851~85464915:-
THCA	cis	rs8049040	0.967	rs8050135	ENSG00000260886.1	TAT-AS1	5.24	2.39e-07	3.42e-05	0.31	0.24	Blood protein levels;	chr16:71438668	chr16:71565789~71578187:+
THCA	cis	rs8014252	0.667	rs10142102	ENSG00000259158.2	ADAM20P1	-5.24	2.39e-07	3.43e-05	-0.26	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70338907	chr14:70468881~70483756:-
THCA	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	5.24	2.39e-07	3.43e-05	0.34	0.24	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
THCA	cis	rs7617773	0.817	rs34728236	ENSG00000199476.1	Y_RNA	-5.24	2.39e-07	3.43e-05	-0.3	-0.24	Coronary artery disease;	chr3:48217618	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs79310258	ENSG00000199476.1	Y_RNA	-5.24	2.39e-07	3.43e-05	-0.3	-0.24	Coronary artery disease;	chr3:48218177	chr3:48288587~48288694:+
THCA	cis	rs9973361	1	rs9677856	ENSG00000232411.1	AC009495.3	-5.24	2.39e-07	3.43e-05	-0.3	-0.24	Total body bone mineral density;	chr2:165859347	chr2:165833048~165839098:-
THCA	cis	rs2337406	0.866	rs988130	ENSG00000211974.3	IGHV2-70	-5.24	2.39e-07	3.43e-05	-0.22	-0.24	Alzheimer's disease (late onset);	chr14:106777154	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	5.24	2.39e-07	3.43e-05	0.13	0.24	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
THCA	cis	rs1866631	0.605	rs13017438	ENSG00000238133.5	MLK7-AS1	5.24	2.39e-07	3.43e-05	0.3	0.24	Lung cancer in ever smokers;	chr2:173195004	chr2:173166446~173282036:-
THCA	cis	rs67478160	0.634	rs2295140	ENSG00000258735.1	LINC00637	-5.24	2.39e-07	3.43e-05	-0.28	-0.24	Schizophrenia;	chr14:103749956	chr14:103847721~103858049:+
THCA	cis	rs2439831	0.681	rs484029	ENSG00000275601.1	AC011330.13	-5.24	2.39e-07	3.43e-05	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43327362	chr15:43642389~43643023:-
THCA	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-5.24	2.39e-07	3.43e-05	-0.22	-0.24	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
THCA	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-5.24	2.39e-07	3.43e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
THCA	cis	rs11089937	0.568	rs12160318	ENSG00000211638.2	IGLV8-61	-5.24	2.39e-07	3.43e-05	-0.19	-0.24	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22098700~22099212:+
THCA	cis	rs2235642	0.821	rs2281236	ENSG00000280231.1	LA16c-380F5.3	-5.24	2.39e-07	3.43e-05	-0.28	-0.24	Coronary artery disease;	chr16:1553575	chr16:1553655~1554130:-
THCA	cis	rs12681287	0.64	rs7460650	ENSG00000254231.1	CTD-2284J15.1	5.24	2.39e-07	3.44e-05	0.26	0.24	Caudate activity during reward;	chr8:86461856	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs6471314	ENSG00000254231.1	CTD-2284J15.1	-5.24	2.39e-07	3.44e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86388230	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7830480	ENSG00000254231.1	CTD-2284J15.1	-5.24	2.39e-07	3.44e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86390908	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.604	rs6471316	ENSG00000254231.1	CTD-2284J15.1	-5.24	2.39e-07	3.44e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86391358	chr8:86333274~86343314:-
THCA	cis	rs2179367	0.632	rs9498329	ENSG00000223701.3	RAET1E-AS1	5.24	2.4e-07	3.44e-05	0.34	0.24	Dupuytren's disease;	chr6:149349941	chr6:149884431~149919508:+
THCA	cis	rs4648045	0.796	rs7683854	ENSG00000246560.2	RP11-10L12.4	5.24	2.4e-07	3.44e-05	0.3	0.24	Lymphocyte percentage of white cells;	chr4:102608899	chr4:102828055~102844075:+
THCA	cis	rs7617773	0.817	rs13100815	ENSG00000199476.1	Y_RNA	-5.24	2.4e-07	3.44e-05	-0.3	-0.24	Coronary artery disease;	chr3:48245959	chr3:48288587~48288694:+
THCA	cis	rs4460629	0.68	rs10796938	ENSG00000160766.13	GBAP1	-5.24	2.4e-07	3.44e-05	-0.26	-0.24	Serum magnesium levels;	chr1:155099579	chr1:155213821~155227422:-
THCA	cis	rs1552244	0.554	rs2272122	ENSG00000232901.1	CYCSP10	5.24	2.4e-07	3.44e-05	0.28	0.24	Alzheimer's disease;	chr3:10006291	chr3:10000647~10000940:-
THCA	cis	rs11722228	0.893	rs6449144	ENSG00000261490.1	RP11-448G15.3	-5.24	2.4e-07	3.45e-05	-0.17	-0.24	Urate levels;Serum uric acid levels;Gout;	chr4:9943026	chr4:10068089~10073019:-
THCA	cis	rs2288884	0.505	rs11666461	ENSG00000269483.1	AC006272.1	5.24	2.4e-07	3.45e-05	0.37	0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51934234	chr19:51839924~51843324:-
THCA	cis	rs34779708	0.931	rs4934724	ENSG00000271335.4	RP11-324I22.4	5.24	2.4e-07	3.45e-05	0.22	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35314552~35336401:-
THCA	cis	rs2512987	1	rs2512985	ENSG00000254731.1	CTD-2005H7.1	-5.24	2.4e-07	3.45e-05	-0.29	-0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703401	chr11:86703099~86714092:+
THCA	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	5.24	2.4e-07	3.45e-05	0.17	0.24	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
THCA	cis	rs12428035	0.772	rs17878753	ENSG00000247400.3	DNAJC3-AS1	-5.24	2.41e-07	3.45e-05	-0.24	-0.24	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95778426	chr13:95648733~95676925:-
THCA	cis	rs12761761	0.739	rs11146471	ENSG00000279982.1	RP11-45A17.3	-5.24	2.41e-07	3.45e-05	-0.39	-0.24	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131993114	chr10:131996738~131999846:+
THCA	cis	rs9859260	0.925	rs3761717	ENSG00000273009.1	RP11-352G9.1	-5.24	2.41e-07	3.45e-05	-0.25	-0.24	Mean corpuscular volume;	chr3:196071076	chr3:195913078~195913683:-
THCA	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-5.24	2.41e-07	3.45e-05	-0.2	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-5.24	2.41e-07	3.45e-05	-0.2	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-5.24	2.41e-07	3.45e-05	-0.2	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
THCA	cis	rs2235642	0.893	rs2076445	ENSG00000280231.1	LA16c-380F5.3	-5.24	2.41e-07	3.45e-05	-0.28	-0.24	Coronary artery disease;	chr16:1542265	chr16:1553655~1554130:-
THCA	cis	rs12681287	0.64	rs7007855	ENSG00000254231.1	CTD-2284J15.1	-5.24	2.41e-07	3.45e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86417262	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.57	rs10956830	ENSG00000254231.1	CTD-2284J15.1	-5.24	2.41e-07	3.45e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86418254	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.604	rs28378899	ENSG00000254231.1	CTD-2284J15.1	-5.24	2.41e-07	3.45e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86422271	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs10098356	ENSG00000254231.1	CTD-2284J15.1	-5.24	2.41e-07	3.45e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86430438	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7833049	ENSG00000254231.1	CTD-2284J15.1	-5.24	2.41e-07	3.45e-05	-0.26	-0.24	Caudate activity during reward;	chr8:86433669	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13253296	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86436016	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.604	rs34227066	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86437137	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs34794500	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86437766	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.608	rs13273338	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86441132	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13258126	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86441149	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs67123356	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86441763	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13256765	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86445604	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs12678720	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86445700	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13253261	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86446271	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13253515	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86446367	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs12541793	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86450329	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs12679811	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86453141	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13264364	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86454156	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7846090	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86455495	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13251006	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86456876	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13269259	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86458224	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7461413	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86458749	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs12550142	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86459632	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7460342	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86462908	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs72606633	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86464007	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs61106663	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86464852	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13261901	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86466488	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs13261956	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86466536	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs71502658	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86466556	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs7017706	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86468661	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs12544463	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86468885	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.608	rs13272148	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86469624	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13267782	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86469658	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.608	rs1135451	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86471379	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs13260345	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86471492	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.64	rs13282351	ENSG00000254231.1	CTD-2284J15.1	5.24	2.41e-07	3.45e-05	0.26	0.24	Caudate activity during reward;	chr8:86472440	chr8:86333274~86343314:-
THCA	cis	rs2235642	0.893	rs2076442	ENSG00000280231.1	LA16c-380F5.3	-5.24	2.41e-07	3.45e-05	-0.28	-0.24	Coronary artery disease;	chr16:1541111	chr16:1553655~1554130:-
THCA	cis	rs12543725	0.799	rs13252660	ENSG00000253307.1	RP11-10J21.4	-5.24	2.41e-07	3.45e-05	-0.34	-0.24	Birth weight;	chr8:141229282	chr8:141252286~141253292:-
THCA	cis	rs115344852	0.585	rs1016069	ENSG00000216901.1	AL022393.7	5.24	2.41e-07	3.45e-05	0.31	0.24	Epithelial ovarian cancer;	chr6:28472641	chr6:28176188~28176674:+
THCA	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-5.24	2.41e-07	3.45e-05	-0.2	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
THCA	cis	rs12935418	0.579	rs1477381	ENSG00000278985.1	RP11-303E16.9	-5.24	2.41e-07	3.46e-05	-0.25	-0.24	Mean corpuscular volume;	chr16:80981095	chr16:80982319~80984094:-
THCA	cis	rs2797160	1	rs1739347	ENSG00000237742.5	RP11-624M8.1	5.24	2.41e-07	3.46e-05	0.2	0.24	Endometrial cancer;	chr6:125693011	chr6:125578558~125749190:-
THCA	cis	rs75920871	0.589	rs56081989	ENSG00000254851.1	RP11-109L13.1	-5.24	2.41e-07	3.46e-05	-0.45	-0.23	Subjective well-being;	chr11:117214589	chr11:117135528~117138582:+
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000230295.1	RP11-458F8.2	-5.24	2.41e-07	3.46e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65970805	chr7:66880708~66882981:+
THCA	cis	rs2342371	0.756	rs12637868	ENSG00000273013.1	CTD-2002J20.1	-5.24	2.41e-07	3.46e-05	-0.23	-0.23	Fat distribution (HIV);	chr3:196379883	chr3:196474801~196475394:+
THCA	cis	rs6714710	0.603	rs7583868	ENSG00000230606.9	AC159540.1	-5.24	2.41e-07	3.46e-05	-0.26	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97971909	chr2:97416165~97433527:-
THCA	cis	rs6997458	0.606	rs1493302	ENSG00000253549.4	RP11-317J10.2	5.24	2.42e-07	3.46e-05	0.23	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85437051	chr8:85441851~85464915:-
THCA	cis	rs16958440	0.541	rs13547	ENSG00000267800.1	RP11-49K24.5	-5.24	2.42e-07	3.46e-05	-0.4	-0.23	Sitting height ratio;	chr18:47108385	chr18:47137018~47137290:+
THCA	cis	rs28476539	0.567	rs17005996	ENSG00000270480.1	RP11-57B24.1	5.24	2.42e-07	3.46e-05	0.38	0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82649147	chr4:82691737~82692468:+
THCA	cis	rs8177876	0.749	rs2287995	ENSG00000261838.4	RP11-303E16.6	5.24	2.42e-07	3.46e-05	0.42	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81069854~81076598:+
THCA	cis	rs9549367	0.601	rs558869	ENSG00000269125.1	RP11-98F14.11	5.24	2.42e-07	3.46e-05	0.28	0.23	Platelet distribution width;	chr13:113195618	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.713	rs2480949	ENSG00000269125.1	RP11-98F14.11	5.24	2.42e-07	3.46e-05	0.28	0.23	Platelet distribution width;	chr13:113198835	chr13:113165002~113165183:-
THCA	cis	rs853679	0.527	rs853683	ENSG00000273712.1	RP5-874C20.7	5.24	2.42e-07	3.46e-05	0.26	0.23	Depression;	chr6:28327262	chr6:28315613~28315883:-
THCA	cis	rs2179367	0.632	rs9498324	ENSG00000223701.3	RAET1E-AS1	5.24	2.42e-07	3.47e-05	0.34	0.23	Dupuytren's disease;	chr6:149338973	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.586	rs62426088	ENSG00000223701.3	RAET1E-AS1	5.24	2.42e-07	3.47e-05	0.34	0.23	Dupuytren's disease;	chr6:149339301	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12204793	ENSG00000223701.3	RAET1E-AS1	5.24	2.42e-07	3.47e-05	0.34	0.23	Dupuytren's disease;	chr6:149340102	chr6:149884431~149919508:+
THCA	cis	rs7552393	0.568	rs2007415	ENSG00000233008.4	RP11-475O6.1	5.24	2.42e-07	3.47e-05	0.25	0.23	Select biomarker traits;	chr1:83801430	chr1:83575776~83861023:-
THCA	cis	rs4660456	0.826	rs507914	ENSG00000272145.1	NFYC-AS1	-5.24	2.42e-07	3.47e-05	-0.16	-0.23	Platelet count;	chr1:40686529	chr1:40690380~40692066:-
THCA	cis	rs7394190	0.748	rs12573448	ENSG00000271816.1	BMS1P4	-5.24	2.42e-07	3.47e-05	-0.29	-0.23	Incident atrial fibrillation;	chr10:73744754	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs12572278	ENSG00000271816.1	BMS1P4	-5.24	2.42e-07	3.47e-05	-0.29	-0.23	Incident atrial fibrillation;	chr10:73744755	chr10:73699151~73730487:-
THCA	cis	rs944289	0.708	rs1958622	ENSG00000258844.1	RP11-259K15.2	5.24	2.42e-07	3.47e-05	0.21	0.23	Thyroid cancer;	chr14:36127289	chr14:36214607~36235608:+
THCA	cis	rs9309473	0.519	rs1083922	ENSG00000163016.8	ALMS1P	-5.24	2.42e-07	3.47e-05	-0.3	-0.23	Metabolite levels;	chr2:73476876	chr2:73644919~73685576:+
THCA	cis	rs8014252	0.708	rs8010473	ENSG00000259158.2	ADAM20P1	-5.24	2.42e-07	3.47e-05	-0.29	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70522276	chr14:70468881~70483756:-
THCA	cis	rs6121246	0.697	rs6060446	ENSG00000230613.1	HM13-AS1	5.24	2.42e-07	3.47e-05	0.26	0.23	Mean corpuscular hemoglobin;	chr20:31643834	chr20:31567707~31573263:-
THCA	cis	rs7674212	0.541	rs2251322	ENSG00000246560.2	RP11-10L12.4	5.24	2.42e-07	3.47e-05	0.28	0.23	Type 2 diabetes;	chr4:103158267	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.57	rs2251634	ENSG00000246560.2	RP11-10L12.4	5.24	2.42e-07	3.47e-05	0.28	0.23	Type 2 diabetes;	chr4:103161192	chr4:102828055~102844075:+
THCA	cis	rs972578	0.765	rs5751391	ENSG00000274717.1	RP1-47A17.1	-5.24	2.42e-07	3.47e-05	-0.24	-0.23	Mean platelet volume;	chr22:42865493	chr22:42791814~42794313:-
THCA	cis	rs17767392	0.958	rs35051046	ENSG00000259146.3	RP1-261D10.2	5.24	2.42e-07	3.47e-05	0.31	0.23	Mitral valve prolapse;	chr14:71382591	chr14:71292729~71321814:-
THCA	cis	rs3213758	1	rs12447949	ENSG00000275191.1	RP11-36I17.2	5.24	2.42e-07	3.47e-05	0.44	0.23	Vitiligo (non-segmental);	chr16:53647325	chr16:53628256~53628816:-
THCA	cis	rs863750	0.744	rs902167	ENSG00000275389.1	RP11-214K3.24	5.24	2.42e-07	3.48e-05	0.31	0.23	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124065504	chr12:124085761~124088598:+
THCA	cis	rs12497850	0.644	rs11928552	ENSG00000229759.1	MRPS18AP1	5.24	2.42e-07	3.48e-05	0.31	0.23	Parkinson's disease;	chr3:48702450	chr3:48256350~48256938:-
THCA	cis	rs2115536	1	rs7163338	ENSG00000278600.1	RP11-81A1.6	-5.24	2.43e-07	3.48e-05	-0.15	-0.23	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79906066	chr15:79920195~79922455:-
THCA	cis	rs7617773	0.71	rs36064160	ENSG00000199476.1	Y_RNA	-5.24	2.43e-07	3.48e-05	-0.31	-0.23	Coronary artery disease;	chr3:48201611	chr3:48288587~48288694:+
THCA	cis	rs6928977	0.932	rs11154798	ENSG00000231028.7	LINC00271	-5.24	2.43e-07	3.48e-05	-0.19	-0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311487	chr6:135497801~135716055:+
THCA	cis	rs12036718	0.511	rs12132019	ENSG00000272491.1	RP5-1024N4.4	5.24	2.43e-07	3.48e-05	0.3	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr1:48190859	chr1:48227888~48229561:-
THCA	cis	rs453301	0.686	rs3989373	ENSG00000254153.1	CTA-398F10.2	5.24	2.43e-07	3.48e-05	0.25	0.23	Joint mobility (Beighton score);	chr8:9053798	chr8:8456909~8461337:-
THCA	cis	rs7474896	0.895	rs2749559	ENSG00000263064.2	RP11-291L22.7	-5.24	2.43e-07	3.48e-05	-0.37	-0.23	Obesity (extreme);	chr10:37922494	chr10:38448689~38448949:+
THCA	cis	rs2251188	0.603	rs6947883	ENSG00000187953.9	PMS2CL	5.24	2.43e-07	3.48e-05	0.24	0.23	Sum basophil neutrophil counts;Neutrophil count;	chr7:6714725	chr7:6710128~6753862:+
THCA	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	5.24	2.43e-07	3.48e-05	0.15	0.23	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
THCA	cis	rs4660456	0.83	rs12742219	ENSG00000272145.1	NFYC-AS1	5.24	2.43e-07	3.48e-05	0.16	0.23	Platelet count;	chr1:40728665	chr1:40690380~40692066:-
THCA	cis	rs1552244	0.832	rs67145301	ENSG00000180385.7	EMC3-AS1	5.24	2.43e-07	3.48e-05	0.27	0.23	Alzheimer's disease;	chr3:10155630	chr3:9986893~10006990:+
THCA	cis	rs6860806	0.631	rs4705931	ENSG00000233006.5	AC034220.3	5.24	2.43e-07	3.48e-05	0.18	0.23	Breast cancer;	chr5:132252652	chr5:132311285~132369916:-
THCA	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-5.24	2.43e-07	3.49e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
THCA	cis	rs13256369	0.802	rs11249885	ENSG00000253893.2	FAM85B	-5.24	2.43e-07	3.49e-05	-0.31	-0.23	Obesity-related traits;	chr8:8704498	chr8:8167819~8226614:-
THCA	cis	rs890448	0.895	rs55962826	ENSG00000254531.1	FLJ20021	-5.24	2.43e-07	3.49e-05	-0.21	-0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101450988	chr4:101347780~101348883:+
THCA	cis	rs6840360	0.901	rs1946999	ENSG00000251611.1	RP11-610P16.1	-5.24	2.43e-07	3.49e-05	-0.17	-0.23	Intelligence (multi-trait analysis);	chr4:151534187	chr4:151407551~151408835:-
THCA	cis	rs9388451	0.505	rs6920965	ENSG00000237742.5	RP11-624M8.1	-5.24	2.43e-07	3.49e-05	-0.21	-0.23	Brugada syndrome;	chr6:125857965	chr6:125578558~125749190:-
THCA	cis	rs34779708	1	rs34779708	ENSG00000271335.4	RP11-324I22.4	5.24	2.43e-07	3.49e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35314552~35336401:-
THCA	cis	rs3213758	1	rs16952304	ENSG00000275191.1	RP11-36I17.2	-5.24	2.44e-07	3.49e-05	-0.46	-0.23	Vitiligo (non-segmental);	chr16:53544801	chr16:53628256~53628816:-
THCA	cis	rs7772486	0.714	rs1883365	ENSG00000270638.1	RP3-466P17.1	-5.24	2.44e-07	3.49e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145735570~145737218:+
THCA	cis	rs8020095	0.528	rs8003327	ENSG00000258561.1	RP11-72M17.1	-5.24	2.44e-07	3.49e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67388881	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs10144122	ENSG00000258561.1	RP11-72M17.1	-5.24	2.44e-07	3.49e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67389973	chr14:66212810~66509394:-
THCA	cis	rs10129255	1	rs10137758	ENSG00000223648.3	IGHV3-64	5.24	2.44e-07	3.49e-05	0.15	0.23	Kawasaki disease;	chr14:106697673	chr14:106643132~106658258:-
THCA	cis	rs7429990	0.932	rs60446735	ENSG00000228638.1	FCF1P2	-5.24	2.44e-07	3.49e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47929958	chr3:48290793~48291375:-
THCA	cis	rs17772222	0.63	rs7141608	ENSG00000258983.2	RP11-507K2.2	-5.24	2.44e-07	3.49e-05	-0.27	-0.23	Coronary artery calcification;	chr14:88514045	chr14:88499334~88515502:+
THCA	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	5.24	2.44e-07	3.49e-05	0.33	0.23	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
THCA	cis	rs7617773	0.78	rs36075665	ENSG00000199476.1	Y_RNA	-5.24	2.44e-07	3.49e-05	-0.3	-0.23	Coronary artery disease;	chr3:48301597	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs36121690	ENSG00000199476.1	Y_RNA	-5.24	2.44e-07	3.49e-05	-0.3	-0.23	Coronary artery disease;	chr3:48304021	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs7632297	ENSG00000199476.1	Y_RNA	-5.24	2.44e-07	3.49e-05	-0.3	-0.23	Coronary artery disease;	chr3:48306673	chr3:48288587~48288694:+
THCA	cis	rs1005277	0.683	rs7923868	ENSG00000226578.1	RP11-258F22.1	-5.24	2.44e-07	3.49e-05	-0.28	-0.23	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:37775371~37784131:-
THCA	cis	rs8020095	0.528	rs6573765	ENSG00000258561.1	RP11-72M17.1	-5.24	2.44e-07	3.49e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67289519	chr14:66212810~66509394:-
THCA	cis	rs6058796	0.892	rs6141780	ENSG00000175730.8	BAK1P1	-5.24	2.44e-07	3.49e-05	-0.35	-0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32674621	chr20:32690180~32690815:-
THCA	cis	rs4748857	0.947	rs9888000	ENSG00000224215.1	RP11-371A19.2	-5.24	2.44e-07	3.5e-05	-0.27	-0.23	Systemic lupus erythematosus;	chr10:23317462	chr10:23343957~23345181:+
THCA	cis	rs79040073	0.637	rs11635308	ENSG00000259531.2	RP11-295H24.3	5.24	2.44e-07	3.5e-05	0.34	0.23	Lung cancer in ever smokers;	chr15:49426531	chr15:49365124~49366685:-
THCA	cis	rs62184315	0.638	rs12475694	ENSG00000273240.1	RP11-455J20.3	5.24	2.44e-07	3.5e-05	0.24	0.23	Alcohol dependence (age at onset);	chr2:189907882	chr2:189763859~189764456:-
THCA	cis	rs7674212	0.556	rs34475639	ENSG00000230069.3	LRRC37A15P	-5.24	2.44e-07	3.5e-05	-0.25	-0.23	Type 2 diabetes;	chr4:103033694	chr4:102727274~102730721:-
THCA	cis	rs875971	1	rs778726	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66363744	chr7:66491049~66493566:-
THCA	cis	rs875971	0.767	rs1695815	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66366357	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs778685	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66371189	chr7:66491049~66493566:-
THCA	cis	rs875971	0.929	rs778682	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66372947	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs11765965	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66377234	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs1643388	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66379575	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs778722	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66379841	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs778721	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66380410	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs778706	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66395437	chr7:66491049~66493566:-
THCA	cis	rs875971	0.895	rs778700	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66401463	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs778699	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66403303	chr7:66491049~66493566:-
THCA	cis	rs875971	0.929	rs778692	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66407462	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs4718343	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66409301	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs1968225	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66409786	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs6460295	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66417741	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs6978721	ENSG00000223473.2	GS1-124K5.3	5.24	2.44e-07	3.5e-05	0.16	0.23	Aortic root size;	chr7:66418217	chr7:66491049~66493566:-
THCA	cis	rs875971	0.545	rs6460281	ENSG00000232546.1	RP11-458F8.1	5.24	2.44e-07	3.5e-05	0.22	0.23	Aortic root size;	chr7:66216128	chr7:66848496~66858136:+
THCA	cis	rs2562456	0.833	rs55875743	ENSG00000268119.4	CTD-2561J22.5	5.24	2.44e-07	3.5e-05	0.34	0.23	Pain;	chr19:21383393	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62110416	ENSG00000268119.4	CTD-2561J22.5	5.24	2.44e-07	3.5e-05	0.34	0.23	Pain;	chr19:21401924	chr19:21444241~21463908:-
THCA	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	5.24	2.44e-07	3.5e-05	0.15	0.23	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
THCA	cis	rs4713118	0.513	rs2294480	ENSG00000216901.1	AL022393.7	5.24	2.44e-07	3.5e-05	0.28	0.23	Parkinson's disease;	chr6:27616182	chr6:28176188~28176674:+
THCA	cis	rs3796352	1	rs6445557	ENSG00000242142.1	SERBP1P3	5.24	2.44e-07	3.5e-05	0.39	0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53049953	chr3:53064283~53065091:-
THCA	cis	rs8037818	1	rs4544214	ENSG00000261064.1	RP11-1000B6.3	5.24	2.44e-07	3.5e-05	0.2	0.23	Obesity-related traits;	chr15:32639703	chr15:32536047~32587613:+
THCA	cis	rs34779708	0.931	rs1926556	ENSG00000271335.4	RP11-324I22.4	5.24	2.44e-07	3.5e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs1926554	ENSG00000271335.4	RP11-324I22.4	5.24	2.44e-07	3.5e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4934710	ENSG00000271335.4	RP11-324I22.4	5.24	2.44e-07	3.5e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.897	rs35784065	ENSG00000271335.4	RP11-324I22.4	5.24	2.44e-07	3.5e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35314552~35336401:-
THCA	cis	rs2360027	0.599	rs2211475	ENSG00000231365.4	RP11-418J17.1	-5.24	2.44e-07	3.5e-05	-0.23	-0.23	Tonsillectomy;	chr1:118544851	chr1:119140396~119275973:+
THCA	cis	rs7711186	0.786	rs10051137	ENSG00000252464.1	RN7SKP70	5.24	2.45e-07	3.5e-05	0.28	0.23	Urate levels in obese individuals;	chr5:178611290	chr5:178619728~178619998:-
THCA	cis	rs9816784	0.566	rs11720913	ENSG00000242086.7	LINC00969	5.24	2.45e-07	3.5e-05	0.24	0.23	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195658062~195739964:+
THCA	cis	rs3764400	0.567	rs2229369	ENSG00000278765.1	RP5-890E16.5	5.24	2.45e-07	3.5e-05	0.43	0.23	Body mass index;	chr17:48058771	chr17:48066704~48067293:-
THCA	cis	rs9813712	0.597	rs1453255	ENSG00000253540.4	FAM86HP	-5.24	2.45e-07	3.5e-05	-0.25	-0.23	Response to amphetamines;	chr3:130258815	chr3:130099092~130111472:-
THCA	cis	rs867371	0.929	rs1501371	ENSG00000259429.4	UBE2Q2P2	-5.24	2.45e-07	3.5e-05	-0.19	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82355142~82420075:+
THCA	cis	rs8396	1	rs12504643	ENSG00000271817.2	U3	-5.24	2.45e-07	3.51e-05	-0.25	-0.23	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158713764	chr4:158700691~158700909:+
THCA	cis	rs7702057	0.53	rs4921060	ENSG00000271918.1	CTD-2287O16.5	5.24	2.45e-07	3.51e-05	0.27	0.23	Amyotrophic lateral sclerosis;	chr5:116109004	chr5:116083807~116085416:-
THCA	cis	rs338389	0.521	rs338381	ENSG00000260657.2	RP11-315D16.4	-5.24	2.45e-07	3.51e-05	-0.3	-0.23	Survival in rectal cancer;	chr15:67951850	chr15:68267792~68277994:-
THCA	cis	rs7428	0.527	rs1053560	ENSG00000273196.1	RP11-717A5.2	5.24	2.46e-07	3.52e-05	0.25	0.23	Ear protrusion;	chr2:85319069	chr2:85387074~85387146:-
THCA	cis	rs4767841	0.904	rs2074052	ENSG00000248636.5	RP11-768F21.1	-5.24	2.46e-07	3.52e-05	-0.24	-0.23	Urgency urinary incontinence;	chr12:119758409	chr12:119387987~119668079:-
THCA	cis	rs13256369	0.853	rs13256216	ENSG00000253893.2	FAM85B	-5.24	2.46e-07	3.52e-05	-0.31	-0.23	Obesity-related traits;	chr8:8720373	chr8:8167819~8226614:-
THCA	cis	rs7246657	0.722	rs2927739	ENSG00000276846.1	CTD-3220F14.3	-5.24	2.46e-07	3.52e-05	-0.24	-0.23	Coronary artery calcification;	chr19:37658429	chr19:37314868~37315620:-
THCA	cis	rs8049040	0.586	rs13333985	ENSG00000260886.1	TAT-AS1	5.24	2.46e-07	3.52e-05	0.34	0.23	Blood protein levels;	chr16:71516950	chr16:71565789~71578187:+
THCA	cis	rs858239	0.699	rs858260	ENSG00000226816.2	AC005082.12	5.24	2.46e-07	3.52e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23206013~23208045:+
THCA	cis	rs6545883	0.894	rs6760075	ENSG00000270820.4	RP11-355B11.2	-5.24	2.46e-07	3.52e-05	-0.2	-0.23	Tuberculosis;	chr2:61385746	chr2:61471188~61484130:+
THCA	cis	rs6657613	0.903	rs2871776	ENSG00000186301.8	MST1P2	-5.24	2.46e-07	3.52e-05	-0.19	-0.23	Hip circumference adjusted for BMI;	chr1:17001806	chr1:16645622~16650289:+
THCA	cis	rs7045881	0.733	rs77568534	ENSG00000254396.1	RP11-56F10.3	5.24	2.46e-07	3.52e-05	0.43	0.23	Schizophrenia;	chr9:26973527	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.733	rs62542663	ENSG00000254396.1	RP11-56F10.3	5.24	2.46e-07	3.52e-05	0.43	0.23	Schizophrenia;	chr9:26973635	chr9:27102630~27104728:+
THCA	cis	rs1866631	0.566	rs3769167	ENSG00000238133.5	MLK7-AS1	5.24	2.46e-07	3.52e-05	0.3	0.23	Lung cancer in ever smokers;	chr2:173193635	chr2:173166446~173282036:-
THCA	cis	rs7614311	1	rs7646324	ENSG00000271843.1	RP11-245J9.5	-5.24	2.46e-07	3.52e-05	-0.36	-0.23	Lung function (FVC);Lung function (FEV1);	chr3:63822442	chr3:64008082~64008692:-
THCA	cis	rs9876781	1	rs9838618	ENSG00000229759.1	MRPS18AP1	5.24	2.46e-07	3.52e-05	0.28	0.23	Longevity;	chr3:48445949	chr3:48256350~48256938:-
THCA	cis	rs12935418	0.616	rs2549828	ENSG00000278985.1	RP11-303E16.9	-5.24	2.46e-07	3.52e-05	-0.25	-0.23	Mean corpuscular volume;	chr16:80985378	chr16:80982319~80984094:-
THCA	cis	rs317689	0.918	rs581911	ENSG00000274979.1	RP11-1143G9.5	-5.24	2.46e-07	3.52e-05	-0.28	-0.23	Response to diuretic therapy;	chr12:69344513	chr12:69326574~69331882:-
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000273796.1	LL21NC02-21A1.1	-5.24	2.46e-07	3.52e-05	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45403809~45404369:-
THCA	cis	rs595244	1	rs6493327	ENSG00000259705.1	RP11-227D13.1	-5.24	2.46e-07	3.52e-05	-0.39	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48517231	chr15:48645951~48652016:+
THCA	cis	rs2815752	0.508	rs3101341	ENSG00000227207.2	RPL31P12	-5.24	2.46e-07	3.53e-05	-0.27	-0.23	Body mass index;	chr1:72282161	chr1:72301472~72301829:+
THCA	cis	rs714027	0.967	rs4823077	ENSG00000279159.1	RP3-394A18.1	-5.24	2.46e-07	3.53e-05	-0.16	-0.23	Lymphocyte counts;	chr22:30149160	chr22:29978950~30028236:-
THCA	cis	rs5015933	0.902	rs2841331	ENSG00000232630.1	PRPS1P2	-5.24	2.47e-07	3.53e-05	-0.16	-0.23	Body mass index;	chr9:125368736	chr9:125150653~125151589:+
THCA	cis	rs62158800	0.778	rs62158769	ENSG00000237880.1	AC096669.2	5.24	2.47e-07	3.53e-05	0.39	0.23	Facial morphology (factor 22);	chr2:107544288	chr2:107385632~107542649:-
THCA	cis	rs12036718	0.511	rs12128656	ENSG00000272491.1	RP5-1024N4.4	5.24	2.47e-07	3.53e-05	0.29	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr1:48159585	chr1:48227888~48229561:-
THCA	cis	rs10043228	0.609	rs78735520	ENSG00000248445.4	SEMA6A-AS1	-5.24	2.47e-07	3.53e-05	-0.24	-0.23	Asthma or chronic obstructive pulmonary disease;	chr5:116356602	chr5:116447547~116508276:+
THCA	cis	rs2342371	0.756	rs4916492	ENSG00000273013.1	CTD-2002J20.1	-5.24	2.47e-07	3.53e-05	-0.23	-0.23	Fat distribution (HIV);	chr3:196379435	chr3:196474801~196475394:+
THCA	cis	rs13178541	0.748	rs4976306	ENSG00000250378.1	RP11-119J18.1	5.24	2.47e-07	3.53e-05	0.3	0.23	IgG glycosylation;	chr5:135728489	chr5:135812667~135826582:+
THCA	cis	rs6545883	0.894	rs7572603	ENSG00000270820.4	RP11-355B11.2	-5.24	2.47e-07	3.53e-05	-0.19	-0.23	Tuberculosis;	chr2:61325010	chr2:61471188~61484130:+
THCA	cis	rs6921919	0.583	rs6908137	ENSG00000219392.1	RP1-265C24.5	-5.24	2.47e-07	3.53e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28115628~28116551:+
THCA	cis	rs17123764	0.605	rs73305085	ENSG00000257464.1	RP11-161H23.8	-5.24	2.47e-07	3.53e-05	-0.38	-0.23	Intelligence (multi-trait analysis);	chr12:49662450	chr12:49442424~49442652:-
THCA	cis	rs714027	1	rs2412975	ENSG00000279159.1	RP3-394A18.1	-5.24	2.47e-07	3.53e-05	-0.16	-0.23	Lymphocyte counts;	chr22:30144601	chr22:29978950~30028236:-
THCA	cis	rs2880765	0.835	rs12708553	ENSG00000259630.2	CTD-2262B20.1	5.24	2.47e-07	3.53e-05	0.25	0.23	Coronary artery disease;	chr15:85503602	chr15:85415228~85415633:+
THCA	cis	rs6920965	0.507	rs4285341	ENSG00000237742.5	RP11-624M8.1	-5.24	2.47e-07	3.54e-05	-0.21	-0.23	High light scatter reticulocyte count;	chr6:125884443	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.772	rs1268064	ENSG00000226409.1	RP11-735G4.1	5.24	2.47e-07	3.54e-05	0.28	0.23	Brugada syndrome;	chr6:125721432	chr6:125370211~125374324:-
THCA	cis	rs12143943	0.934	rs12567161	ENSG00000240219.1	RP11-430C7.5	5.24	2.47e-07	3.54e-05	0.2	0.23	Cognitive performance;	chr1:204608704	chr1:204626775~204629712:+
THCA	cis	rs10510102	0.935	rs12244951	ENSG00000226864.1	ATE1-AS1	5.24	2.47e-07	3.54e-05	0.38	0.23	Breast cancer;	chr10:121896879	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs74362676	ENSG00000226864.1	ATE1-AS1	5.24	2.47e-07	3.54e-05	0.38	0.23	Breast cancer;	chr10:121898216	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs3750837	ENSG00000226864.1	ATE1-AS1	5.24	2.47e-07	3.54e-05	0.38	0.23	Breast cancer;	chr10:121899080	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs3750836	ENSG00000226864.1	ATE1-AS1	5.24	2.47e-07	3.54e-05	0.38	0.23	Breast cancer;	chr10:121899087	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200237	ENSG00000226864.1	ATE1-AS1	5.24	2.47e-07	3.54e-05	0.38	0.23	Breast cancer;	chr10:121900715	chr10:121928312~121951965:+
THCA	cis	rs9859260	1	rs2300778	ENSG00000231464.1	AC024937.4	5.24	2.47e-07	3.54e-05	0.28	0.23	Mean corpuscular volume;	chr3:196063866	chr3:195996738~195998233:+
THCA	cis	rs9859260	1	rs2300777	ENSG00000231464.1	AC024937.4	5.24	2.47e-07	3.54e-05	0.28	0.23	Mean corpuscular volume;	chr3:196063940	chr3:195996738~195998233:+
THCA	cis	rs5742933	0.948	rs5743063	ENSG00000273240.1	RP11-455J20.3	5.24	2.47e-07	3.54e-05	0.25	0.23	Ferritin levels;	chr2:189829723	chr2:189763859~189764456:-
THCA	cis	rs9843304	0.546	rs9847773	ENSG00000240541.2	TM4SF1-AS1	-5.24	2.47e-07	3.54e-05	-0.22	-0.23	Gallstone disease;	chr3:149500029	chr3:149377778~149386583:+
THCA	cis	rs9843304	0.509	rs6798061	ENSG00000240541.2	TM4SF1-AS1	-5.24	2.47e-07	3.54e-05	-0.22	-0.23	Gallstone disease;	chr3:149500683	chr3:149377778~149386583:+
THCA	cis	rs651907	0.514	rs55654108	ENSG00000244119.1	PDCL3P4	5.24	2.47e-07	3.54e-05	0.21	0.23	Colorectal cancer;	chr3:101706859	chr3:101712472~101713191:+
THCA	cis	rs2562456	0.754	rs112195516	ENSG00000268119.4	CTD-2561J22.5	5.24	2.47e-07	3.54e-05	0.34	0.23	Pain;	chr19:21410849	chr19:21444241~21463908:-
THCA	cis	rs2797160	1	rs2747725	ENSG00000237742.5	RP11-624M8.1	5.24	2.47e-07	3.54e-05	0.21	0.23	Endometrial cancer;	chr6:125691251	chr6:125578558~125749190:-
THCA	cis	rs1318937	0.764	rs2129945	ENSG00000224660.1	SH3BP5-AS1	5.24	2.47e-07	3.54e-05	0.15	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15197706	chr3:15254184~15264493:+
THCA	cis	rs875971	0.528	rs801213	ENSG00000232546.1	RP11-458F8.1	-5.24	2.47e-07	3.54e-05	-0.22	-0.23	Aortic root size;	chr7:66549931	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000232546.1	RP11-458F8.1	-5.24	2.47e-07	3.54e-05	-0.22	-0.23	Aortic root size;	chr7:66550643	chr7:66848496~66858136:+
THCA	cis	rs944289	0.74	rs4982333	ENSG00000258844.1	RP11-259K15.2	5.24	2.48e-07	3.54e-05	0.21	0.23	Thyroid cancer;	chr14:36100842	chr14:36214607~36235608:+
THCA	cis	rs4648045	0.964	rs1801	ENSG00000246560.2	RP11-10L12.4	-5.24	2.48e-07	3.54e-05	-0.28	-0.23	Lymphocyte percentage of white cells;	chr4:102579897	chr4:102828055~102844075:+
THCA	cis	rs2253762	0.54	rs10887051	ENSG00000276742.1	RP11-500G22.4	5.24	2.48e-07	3.54e-05	0.33	0.23	Breast cancer;	chr10:122026030	chr10:121956782~121957098:+
THCA	cis	rs11846409	0.587	rs1806881	ENSG00000211974.3	IGHV2-70	5.24	2.48e-07	3.55e-05	0.23	0.23	Rheumatic heart disease;	chr14:106650770	chr14:106723574~106724093:-
THCA	cis	rs7428	0.527	rs7608892	ENSG00000273196.1	RP11-717A5.2	5.24	2.48e-07	3.55e-05	0.25	0.23	Ear protrusion;	chr2:85315595	chr2:85387074~85387146:-
THCA	cis	rs4748857	0.947	rs10828426	ENSG00000224215.1	RP11-371A19.2	-5.24	2.48e-07	3.55e-05	-0.26	-0.23	Systemic lupus erythematosus;	chr10:23313972	chr10:23343957~23345181:+
THCA	cis	rs34779708	0.931	rs59418206	ENSG00000271335.4	RP11-324I22.4	5.24	2.48e-07	3.55e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35314552~35336401:-
THCA	cis	rs860295	0.702	rs34124416	ENSG00000160766.13	GBAP1	-5.24	2.48e-07	3.55e-05	-0.28	-0.23	Body mass index;	chr1:155608258	chr1:155213821~155227422:-
THCA	cis	rs7085104	0.552	rs11191414	ENSG00000213061.2	PFN1P11	5.24	2.48e-07	3.55e-05	0.28	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102838011~102845473:-
THCA	cis	rs10043228	0.702	rs10519454	ENSG00000248445.4	SEMA6A-AS1	-5.24	2.48e-07	3.55e-05	-0.25	-0.23	Asthma or chronic obstructive pulmonary disease;	chr5:116304165	chr5:116447547~116508276:+
THCA	cis	rs442309	0.553	rs10995299	ENSG00000238280.1	RP11-436D10.3	-5.24	2.48e-07	3.55e-05	-0.3	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62744443	chr10:62793562~62805887:-
THCA	cis	rs4648045	0.796	rs3755867	ENSG00000246560.2	RP11-10L12.4	5.24	2.48e-07	3.55e-05	0.29	0.23	Lymphocyte percentage of white cells;	chr4:102605517	chr4:102828055~102844075:+
THCA	cis	rs4748857	0.947	rs4603206	ENSG00000224215.1	RP11-371A19.2	-5.24	2.49e-07	3.55e-05	-0.27	-0.23	Systemic lupus erythematosus;	chr10:23318263	chr10:23343957~23345181:+
THCA	cis	rs12681288	0.676	rs34282191	ENSG00000260721.1	AF067845.1	5.24	2.49e-07	3.56e-05	0.29	0.23	Schizophrenia;	chr8:1041290	chr8:1368642~1369833:-
THCA	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-5.24	2.49e-07	3.56e-05	-0.27	-0.23	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
THCA	cis	rs9467773	1	rs9467783	ENSG00000261353.1	CTA-14H9.5	-5.24	2.49e-07	3.56e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26527063~26527404:+
THCA	cis	rs593531	0.531	rs662393	ENSG00000255440.1	RP11-632K5.2	5.24	2.49e-07	3.56e-05	0.28	0.23	Neuroticism;	chr11:74375263	chr11:74409060~74416379:+
THCA	cis	rs1823913	0.599	rs4146103	ENSG00000280083.1	RP11-317J9.1	-5.24	2.49e-07	3.56e-05	-0.27	-0.23	Obesity-related traits;	chr2:191272000	chr2:191154118~191156070:-
THCA	cis	rs4948275	0.773	rs2606081	ENSG00000237233.2	TMEM26-AS1	-5.24	2.49e-07	3.56e-05	-0.32	-0.23	Night sleep phenotypes;	chr10:61532493	chr10:61452639~61481956:+
THCA	cis	rs2562456	0.755	rs11670868	ENSG00000268119.4	CTD-2561J22.5	5.24	2.49e-07	3.56e-05	0.34	0.23	Pain;	chr19:21373613	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs55961038	ENSG00000268119.4	CTD-2561J22.5	5.24	2.49e-07	3.56e-05	0.34	0.23	Pain;	chr19:21375205	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs2358993	ENSG00000268119.4	CTD-2561J22.5	5.24	2.49e-07	3.56e-05	0.34	0.23	Pain;	chr19:21375367	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs11672583	ENSG00000268119.4	CTD-2561J22.5	5.24	2.49e-07	3.56e-05	0.34	0.23	Pain;	chr19:21379363	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs17680605	ENSG00000268119.4	CTD-2561J22.5	5.24	2.49e-07	3.56e-05	0.34	0.23	Pain;	chr19:21379646	chr19:21444241~21463908:-
THCA	cis	rs1914816	0.941	rs2469544	ENSG00000196274.5	Metazoa_SRP	5.23	2.49e-07	3.56e-05	0.33	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76192606	chr15:76230048~76230390:-
THCA	cis	rs5742933	0.557	rs1233276	ENSG00000253559.1	OSGEPL1-AS1	-5.23	2.49e-07	3.56e-05	-0.29	-0.23	Ferritin levels;	chr2:189820056	chr2:189762704~189765556:+
THCA	cis	rs3213758	1	rs12599095	ENSG00000275191.1	RP11-36I17.2	-5.23	2.49e-07	3.57e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53655728	chr16:53628256~53628816:-
THCA	cis	rs2243480	1	rs1039664	ENSG00000230295.1	RP11-458F8.2	-5.23	2.5e-07	3.57e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65984729	chr7:66880708~66882981:+
THCA	cis	rs7617773	0.784	rs11715799	ENSG00000199476.1	Y_RNA	-5.23	2.5e-07	3.57e-05	-0.3	-0.23	Coronary artery disease;	chr3:48213730	chr3:48288587~48288694:+
THCA	cis	rs2235642	0.859	rs9927529	ENSG00000280231.1	LA16c-380F5.3	-5.23	2.5e-07	3.57e-05	-0.28	-0.23	Coronary artery disease;	chr16:1569487	chr16:1553655~1554130:-
THCA	cis	rs4713118	0.513	rs149942	ENSG00000226314.6	ZNF192P1	-5.23	2.5e-07	3.57e-05	-0.27	-0.23	Parkinson's disease;	chr6:28033832	chr6:28161781~28169594:+
THCA	cis	rs2562456	0.833	rs11666447	ENSG00000268119.4	CTD-2561J22.5	5.23	2.5e-07	3.57e-05	0.34	0.23	Pain;	chr19:21416270	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs11666525	ENSG00000268119.4	CTD-2561J22.5	5.23	2.5e-07	3.57e-05	0.34	0.23	Pain;	chr19:21416503	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs62110424	ENSG00000268119.4	CTD-2561J22.5	5.23	2.5e-07	3.57e-05	0.34	0.23	Pain;	chr19:21416835	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs3853837	ENSG00000268119.4	CTD-2561J22.5	5.23	2.5e-07	3.57e-05	0.34	0.23	Pain;	chr19:21419172	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs3853838	ENSG00000268119.4	CTD-2561J22.5	5.23	2.5e-07	3.57e-05	0.34	0.23	Pain;	chr19:21419192	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62110426	ENSG00000268119.4	CTD-2561J22.5	5.23	2.5e-07	3.57e-05	0.34	0.23	Pain;	chr19:21420124	chr19:21444241~21463908:-
THCA	cis	rs2299587	0.58	rs2427739	ENSG00000253671.1	RP11-806O11.1	-5.23	2.5e-07	3.57e-05	-0.28	-0.23	Economic and political preferences;	chr8:18014320	chr8:17808941~17820868:+
THCA	cis	rs11992162	0.967	rs10108320	ENSG00000227888.4	FAM66A	-5.23	2.5e-07	3.57e-05	-0.3	-0.23	Monocyte count;	chr8:11974754	chr8:12362019~12388296:+
THCA	cis	rs503425	0.818	rs2508922	ENSG00000255239.1	AP002954.6	-5.23	2.5e-07	3.57e-05	-0.35	-0.23	Systemic lupus erythematosus;	chr11:118810379	chr11:118688039~118690600:-
THCA	cis	rs1876905	0.68	rs395564	ENSG00000230177.1	RP5-1112D6.4	-5.23	2.5e-07	3.58e-05	-0.24	-0.23	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111277932~111278742:+
THCA	cis	rs10771431	0.935	rs1117735	ENSG00000256069.6	A2MP1	5.23	2.5e-07	3.58e-05	0.26	0.23	Breast size;	chr12:9220132	chr12:9228533~9275817:-
THCA	cis	rs172166	0.637	rs1225597	ENSG00000220721.1	OR1F12	5.23	2.5e-07	3.58e-05	0.28	0.23	Cardiac Troponin-T levels;	chr6:28194309	chr6:28073316~28074233:+
THCA	cis	rs172166	0.637	rs1071893	ENSG00000220721.1	OR1F12	5.23	2.5e-07	3.58e-05	0.28	0.23	Cardiac Troponin-T levels;	chr6:28199857	chr6:28073316~28074233:+
THCA	cis	rs1552244	0.554	rs17050704	ENSG00000180385.7	EMC3-AS1	5.23	2.5e-07	3.58e-05	0.23	0.23	Alzheimer's disease;	chr3:10004050	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs34883592	ENSG00000180385.7	EMC3-AS1	5.23	2.5e-07	3.58e-05	0.23	0.23	Alzheimer's disease;	chr3:10004481	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs17050705	ENSG00000180385.7	EMC3-AS1	5.23	2.5e-07	3.58e-05	0.23	0.23	Alzheimer's disease;	chr3:10004714	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs2272120	ENSG00000180385.7	EMC3-AS1	5.23	2.5e-07	3.58e-05	0.23	0.23	Alzheimer's disease;	chr3:10005019	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs13079240	ENSG00000180385.7	EMC3-AS1	5.23	2.5e-07	3.58e-05	0.23	0.23	Alzheimer's disease;	chr3:10005562	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs2272121	ENSG00000180385.7	EMC3-AS1	5.23	2.5e-07	3.58e-05	0.23	0.23	Alzheimer's disease;	chr3:10005996	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs3732965	ENSG00000180385.7	EMC3-AS1	5.23	2.5e-07	3.58e-05	0.23	0.23	Alzheimer's disease;	chr3:10007076	chr3:9986893~10006990:+
THCA	cis	rs853679	0.628	rs9368560	ENSG00000261839.1	RP1-265C24.8	5.23	2.51e-07	3.58e-05	0.28	0.23	Depression;	chr6:28192182	chr6:28136849~28139678:+
THCA	cis	rs9876781	1	rs13069724	ENSG00000229759.1	MRPS18AP1	5.23	2.51e-07	3.58e-05	0.28	0.23	Longevity;	chr3:48436629	chr3:48256350~48256938:-
THCA	cis	rs783540	0.521	rs1259176	ENSG00000278603.1	RP13-608F4.5	-5.23	2.51e-07	3.58e-05	-0.34	-0.23	Schizophrenia;	chr15:82602149	chr15:82472203~82472426:+
THCA	cis	rs6545883	0.894	rs2463102	ENSG00000270820.4	RP11-355B11.2	-5.23	2.51e-07	3.58e-05	-0.2	-0.23	Tuberculosis;	chr2:61344160	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.894	rs2593633	ENSG00000270820.4	RP11-355B11.2	-5.23	2.51e-07	3.58e-05	-0.2	-0.23	Tuberculosis;	chr2:61344378	chr2:61471188~61484130:+
THCA	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-5.23	2.51e-07	3.58e-05	-0.25	-0.23	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
THCA	cis	rs875971	0.545	rs1547529	ENSG00000228409.4	CCT6P1	-5.23	2.51e-07	3.58e-05	-0.2	-0.23	Aortic root size;	chr7:66258859	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000228409.4	CCT6P1	-5.23	2.51e-07	3.58e-05	-0.2	-0.23	Aortic root size;	chr7:66283366	chr7:65751142~65763354:+
THCA	cis	rs10208649	0.522	rs59531016	ENSG00000233266.1	HMGB1P31	5.23	2.51e-07	3.59e-05	0.63	0.23	Body mass index;	chr2:54171031	chr2:54051334~54051760:+
THCA	cis	rs7512898	0.5	rs10920046	ENSG00000260088.1	RP11-92G12.3	-5.23	2.51e-07	3.59e-05	-0.32	-0.23	Electrocardiographic conduction measures;	chr1:200840100	chr1:200669507~200694250:+
THCA	cis	rs7085104	0.727	rs12773892	ENSG00000213277.3	MARCKSL1P1	5.23	2.51e-07	3.59e-05	0.27	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102871420	chr10:103175554~103176094:+
THCA	cis	rs7897654	0.571	rs12767543	ENSG00000213277.3	MARCKSL1P1	5.23	2.51e-07	3.59e-05	0.27	0.23	Schizophrenia;	chr10:102871906	chr10:103175554~103176094:+
THCA	cis	rs875971	0.545	rs10950029	ENSG00000228409.4	CCT6P1	-5.23	2.51e-07	3.59e-05	-0.2	-0.23	Aortic root size;	chr7:66169334	chr7:65751142~65763354:+
THCA	cis	rs6445975	0.956	rs7612923	ENSG00000272360.1	RP11-359I18.5	5.23	2.51e-07	3.59e-05	0.25	0.23	Systemic lupus erythematosus;	chr3:58388706	chr3:58490830~58491291:-
THCA	cis	rs1185460	0.967	rs1784460	ENSG00000272186.1	RP11-110I1.13	5.23	2.51e-07	3.59e-05	0.22	0.23	Coronary artery disease;	chr11:119067660	chr11:119067374~119067698:-
THCA	cis	rs13256369	1	rs12550762	ENSG00000253893.2	FAM85B	-5.23	2.51e-07	3.59e-05	-0.31	-0.23	Obesity-related traits;	chr8:8719025	chr8:8167819~8226614:-
THCA	cis	rs10875746	0.669	rs10783244	ENSG00000258234.1	RP11-370I10.2	5.23	2.52e-07	3.59e-05	0.27	0.23	Longevity (90 years and older);	chr12:48271206	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.855	rs73102065	ENSG00000269514.1	RP11-370I10.12	5.23	2.52e-07	3.59e-05	0.24	0.23	Longevity (90 years and older);	chr12:48098824	chr12:48198387~48202031:+
THCA	cis	rs10875746	0.855	rs73102067	ENSG00000269514.1	RP11-370I10.12	5.23	2.52e-07	3.59e-05	0.24	0.23	Longevity (90 years and older);	chr12:48100643	chr12:48198387~48202031:+
THCA	cis	rs4650994	0.789	rs2811300	ENSG00000273384.1	RP5-1098D14.1	-5.23	2.52e-07	3.6e-05	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178621259	chr1:178651706~178652282:+
THCA	cis	rs6772849	0.796	rs9841521	ENSG00000242551.2	POU5F1P6	-5.23	2.52e-07	3.6e-05	-0.3	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128674735~128677005:-
THCA	cis	rs7617480	0.587	rs9311431	ENSG00000228638.1	FCF1P2	-5.23	2.52e-07	3.6e-05	-0.29	-0.23	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48811354	chr3:48290793~48291375:-
THCA	cis	rs7617480	0.648	rs4974088	ENSG00000228638.1	FCF1P2	-5.23	2.52e-07	3.6e-05	-0.29	-0.23	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48861316	chr3:48290793~48291375:-
THCA	cis	rs763121	0.819	rs138700	ENSG00000273076.1	RP3-508I15.22	5.23	2.52e-07	3.6e-05	0.25	0.23	Menopause (age at onset);	chr22:38733994	chr22:38743495~38743910:+
THCA	cis	rs4970988	0.501	rs11204713	ENSG00000231073.1	RP11-316M1.3	5.23	2.52e-07	3.6e-05	0.27	0.23	Urate levels;	chr1:150722147	chr1:150973123~150975534:+
THCA	cis	rs1979679	0.801	rs7979524	ENSG00000247934.4	RP11-967K21.1	5.23	2.52e-07	3.6e-05	0.23	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28550900	chr12:28163298~28190738:-
THCA	cis	rs7429990	0.864	rs34616865	ENSG00000228638.1	FCF1P2	5.23	2.52e-07	3.6e-05	0.22	0.23	Educational attainment (years of education);	chr3:47608508	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs1014228	ENSG00000228638.1	FCF1P2	5.23	2.52e-07	3.6e-05	0.22	0.23	Educational attainment (years of education);	chr3:47611149	chr3:48290793~48291375:-
THCA	cis	rs738144	0.542	rs4303811	ENSG00000235209.1	CTA-150C2.13	-5.23	2.52e-07	3.6e-05	-0.4	-0.23	IgG glycosylation;	chr22:38761750	chr22:38921227~38924708:+
THCA	cis	rs2985684	0.74	rs2883438	ENSG00000278009.1	RP11-649E7.8	5.23	2.53e-07	3.61e-05	0.33	0.23	Carotid intima media thickness;	chr14:49577674	chr14:49601011~49601124:-
THCA	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-5.23	2.53e-07	3.61e-05	-0.28	-0.23	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000261839.1	RP1-265C24.8	5.23	2.53e-07	3.61e-05	0.27	0.23	Parkinson's disease;	chr6:28065618	chr6:28136849~28139678:+
THCA	cis	rs9475752	0.793	rs35090265	ENSG00000231441.1	RP11-472M19.2	5.23	2.53e-07	3.61e-05	0.31	0.23	Menarche (age at onset);	chr6:56983015	chr6:56844002~56864078:+
THCA	cis	rs919433	0.963	rs12469546	ENSG00000231621.1	AC013264.2	5.23	2.53e-07	3.61e-05	0.25	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197314102	chr2:197197991~197199273:+
THCA	cis	rs919433	0.963	rs4850430	ENSG00000231621.1	AC013264.2	5.23	2.53e-07	3.61e-05	0.25	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318072	chr2:197197991~197199273:+
THCA	cis	rs919433	0.963	rs10166569	ENSG00000231621.1	AC013264.2	5.23	2.53e-07	3.61e-05	0.25	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318715	chr2:197197991~197199273:+
THCA	cis	rs7577696	0.962	rs212746	ENSG00000276334.1	AL133243.1	5.23	2.53e-07	3.61e-05	0.25	0.23	Inflammatory biomarkers;	chr2:32187998	chr2:32521927~32523547:+
THCA	cis	rs734999	0.904	rs2477678	ENSG00000225931.3	RP3-395M20.7	5.23	2.53e-07	3.61e-05	0.29	0.23	Ulcerative colitis;	chr1:2547072	chr1:2566410~2569888:+
THCA	cis	rs2235642	0.928	rs9932984	ENSG00000280231.1	LA16c-380F5.3	-5.23	2.53e-07	3.61e-05	-0.28	-0.23	Coronary artery disease;	chr16:1555050	chr16:1553655~1554130:-
THCA	cis	rs7078012	0.504	rs78496266	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.53e-07	3.61e-05	-0.54	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927006	chr10:79663088~79826594:-
THCA	cis	rs7078012	0.504	rs11815922	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.53e-07	3.61e-05	-0.54	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928323	chr10:79663088~79826594:-
THCA	cis	rs7078012	0.504	rs17879405	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.53e-07	3.61e-05	-0.54	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79929784	chr10:79663088~79826594:-
THCA	cis	rs6142102	0.527	rs1015362	ENSG00000275784.1	RP5-1125A11.6	5.23	2.53e-07	3.61e-05	0.25	0.23	Skin pigmentation;	chr20:34150806	chr20:33989480~33991818:-
THCA	cis	rs2337406	0.714	rs117798641	ENSG00000211974.3	IGHV2-70	-5.23	2.53e-07	3.62e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106777984	chr14:106723574~106724093:-
THCA	cis	rs6921919	0.583	rs3800328	ENSG00000219392.1	RP1-265C24.5	-5.23	2.53e-07	3.62e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs740621	ENSG00000219392.1	RP1-265C24.5	-5.23	2.53e-07	3.62e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs740622	ENSG00000219392.1	RP1-265C24.5	-5.23	2.53e-07	3.62e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28115628~28116551:+
THCA	cis	rs11096990	0.892	rs1901404	ENSG00000249685.1	RP11-360F5.3	-5.23	2.53e-07	3.62e-05	-0.3	-0.23	Cognitive function;	chr4:39210990	chr4:39133913~39135608:+
THCA	cis	rs2179367	0.632	rs11155640	ENSG00000223701.3	RAET1E-AS1	5.23	2.53e-07	3.62e-05	0.34	0.23	Dupuytren's disease;	chr6:149323648	chr6:149884431~149919508:+
THCA	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	5.23	2.53e-07	3.62e-05	0.26	0.23	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
THCA	cis	rs6547741	0.935	rs4665384	ENSG00000234072.1	AC074117.10	5.23	2.53e-07	3.62e-05	0.18	0.23	Oral cavity cancer;	chr2:27625530	chr2:27356246~27367622:+
THCA	cis	rs11992162	1	rs12334769	ENSG00000227888.4	FAM66A	5.23	2.53e-07	3.62e-05	0.3	0.23	Monocyte count;	chr8:11975652	chr8:12362019~12388296:+
THCA	cis	rs911119	1	rs13041070	ENSG00000270001.1	RP11-218C14.8	-5.23	2.54e-07	3.62e-05	-0.37	-0.23	Chronic kidney disease;	chr20:23633624	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs35610040	ENSG00000270001.1	RP11-218C14.8	-5.23	2.54e-07	3.62e-05	-0.37	-0.23	Chronic kidney disease;	chr20:23635832	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs3787498	ENSG00000270001.1	RP11-218C14.8	-5.23	2.54e-07	3.62e-05	-0.37	-0.23	Chronic kidney disease;	chr20:23636144	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs3787499	ENSG00000270001.1	RP11-218C14.8	-5.23	2.54e-07	3.62e-05	-0.37	-0.23	Chronic kidney disease;	chr20:23636170	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs3827142	ENSG00000270001.1	RP11-218C14.8	-5.23	2.54e-07	3.62e-05	-0.37	-0.23	Chronic kidney disease;	chr20:23636370	chr20:23631826~23632316:-
THCA	cis	rs56205728	0.582	rs1869901	ENSG00000273855.1	RP11-133K1.12	5.23	2.54e-07	3.62e-05	0.27	0.23	Schizophrenia;	chr15:40303426	chr15:40285468~40285909:-
THCA	cis	rs13113518	0.513	rs13147861	ENSG00000249700.7	SRD5A3-AS1	5.23	2.54e-07	3.62e-05	0.3	0.23	Height;	chr4:55611014	chr4:55363971~55395847:-
THCA	cis	rs4646450	0.838	rs10229569	ENSG00000244219.5	GS1-259H13.2	-5.23	2.54e-07	3.62e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99586081	chr7:99598066~99610813:+
THCA	cis	rs34779708	0.966	rs4934536	ENSG00000271335.4	RP11-324I22.4	5.23	2.54e-07	3.63e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs4934537	ENSG00000271335.4	RP11-324I22.4	5.23	2.54e-07	3.63e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs12784482	ENSG00000271335.4	RP11-324I22.4	5.23	2.54e-07	3.63e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs113170867	ENSG00000271335.4	RP11-324I22.4	5.23	2.54e-07	3.63e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs17499811	ENSG00000271335.4	RP11-324I22.4	5.23	2.54e-07	3.63e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs35146199	ENSG00000271335.4	RP11-324I22.4	5.23	2.54e-07	3.63e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35314552~35336401:-
THCA	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	5.23	2.54e-07	3.63e-05	0.24	0.23	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
THCA	cis	rs1005277	0.579	rs2505257	ENSG00000272983.1	RP11-508N22.12	5.23	2.54e-07	3.63e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38137337~38144399:+
THCA	cis	rs7851660	0.874	rs13299924	ENSG00000214417.4	KRT18P13	-5.23	2.54e-07	3.63e-05	-0.2	-0.23	Strep throat;	chr9:97865280	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs10122541	ENSG00000214417.4	KRT18P13	-5.23	2.54e-07	3.63e-05	-0.2	-0.23	Strep throat;	chr9:97865986	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.839	rs2417575	ENSG00000214417.4	KRT18P13	-5.23	2.54e-07	3.63e-05	-0.2	-0.23	Strep throat;	chr9:97866360	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.874	rs1443436	ENSG00000214417.4	KRT18P13	-5.23	2.54e-07	3.63e-05	-0.2	-0.23	Strep throat;	chr9:97869016	chr9:97698922~97700734:+
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000232559.3	GS1-124K5.12	-5.23	2.54e-07	3.63e-05	-0.35	-0.23	Diabetic kidney disease;	chr7:66219914	chr7:66554588~66576923:-
THCA	cis	rs7727544	0.735	rs272842	ENSG00000263597.1	MIR3936	5.23	2.54e-07	3.63e-05	0.22	0.23	Blood metabolite levels;	chr5:132320824	chr5:132365490~132365599:-
THCA	cis	rs12439619	0.921	rs56042848	ENSG00000255769.6	GOLGA2P10	-5.23	2.54e-07	3.63e-05	-0.3	-0.23	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472993~82513950:-
THCA	cis	rs7617773	0.78	rs13082158	ENSG00000199476.1	Y_RNA	-5.23	2.54e-07	3.63e-05	-0.31	-0.23	Coronary artery disease;	chr3:48330980	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.676	rs13060020	ENSG00000199476.1	Y_RNA	-5.23	2.54e-07	3.63e-05	-0.31	-0.23	Coronary artery disease;	chr3:48331156	chr3:48288587~48288694:+
THCA	cis	rs7267979	0.844	rs35735333	ENSG00000125804.12	FAM182A	5.23	2.54e-07	3.63e-05	0.29	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26054655~26086917:+
THCA	cis	rs6686842	0.56	rs6672508	ENSG00000235358.1	RP11-399E6.1	5.23	2.55e-07	3.63e-05	0.31	0.23	Height;	chr1:41200899	chr1:41242373~41284861:+
THCA	cis	rs2360027	0.599	rs2209364	ENSG00000231365.4	RP11-418J17.1	-5.23	2.55e-07	3.63e-05	-0.23	-0.23	Tonsillectomy;	chr1:118538796	chr1:119140396~119275973:+
THCA	cis	rs1707322	1	rs6672115	ENSG00000281133.1	AL355480.3	-5.23	2.55e-07	3.64e-05	-0.29	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45580892~45580996:-
THCA	cis	rs17767392	0.918	rs72728427	ENSG00000259146.3	RP1-261D10.2	5.23	2.55e-07	3.64e-05	0.3	0.23	Mitral valve prolapse;	chr14:71303272	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs8007068	ENSG00000259146.3	RP1-261D10.2	5.23	2.55e-07	3.64e-05	0.3	0.23	Mitral valve prolapse;	chr14:71303993	chr14:71292729~71321814:-
THCA	cis	rs950169	0.734	rs67119537	ENSG00000259295.5	CSPG4P12	5.23	2.55e-07	3.64e-05	0.34	0.23	Schizophrenia;	chr15:84395671	chr15:85191438~85213905:+
THCA	cis	rs2278034	0.578	rs881753	ENSG00000231464.1	AC024937.4	-5.23	2.55e-07	3.64e-05	-0.28	-0.23	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195996738~195998233:+
THCA	cis	rs7727544	0.507	rs9791170	ENSG00000237714.1	P4HA2-AS1	5.23	2.55e-07	3.64e-05	0.29	0.23	Blood metabolite levels;	chr5:132233934	chr5:132184876~132192808:+
THCA	cis	rs792448	0.545	rs6668866	ENSG00000226251.4	RP11-15I11.3	5.23	2.55e-07	3.64e-05	0.29	0.23	White blood cell count (basophil);	chr1:212231605	chr1:212225278~212238977:-
THCA	cis	rs2299587	0.623	rs12718384	ENSG00000253671.1	RP11-806O11.1	-5.23	2.55e-07	3.64e-05	-0.27	-0.23	Economic and political preferences;	chr8:17923603	chr8:17808941~17820868:+
THCA	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	5.23	2.55e-07	3.64e-05	0.4	0.23	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
THCA	cis	rs4950322	0.57	rs4950401	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147319571	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs4950402	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147319684	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs4950404	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147319834	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692946	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147319966	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692948	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147320298	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692951	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147320551	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs77118461	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147320718	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs78681047	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147321013	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692953	ENSG00000226015.2	CCT8P1	5.23	2.55e-07	3.64e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147321416	chr1:147203276~147204932:-
THCA	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	5.23	2.55e-07	3.64e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
THCA	cis	rs1065852	0.51	rs5751247	ENSG00000227370.1	RP4-669P10.19	5.23	2.55e-07	3.64e-05	0.24	0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42237048	chr22:42132543~42132998:+
THCA	cis	rs7617773	0.817	rs11709691	ENSG00000199476.1	Y_RNA	-5.23	2.55e-07	3.64e-05	-0.3	-0.23	Coronary artery disease;	chr3:48262179	chr3:48288587~48288694:+
THCA	cis	rs116095464	0.51	rs73016876	ENSG00000248925.1	CTD-2083E4.6	5.23	2.55e-07	3.64e-05	0.34	0.23	Breast cancer;	chr5:244360	chr5:269858~271516:-
THCA	cis	rs7267979	0.844	rs4815413	ENSG00000125804.12	FAM182A	5.23	2.55e-07	3.64e-05	0.29	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.844	rs6083824	ENSG00000125804.12	FAM182A	5.23	2.55e-07	3.64e-05	0.29	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.844	rs6076343	ENSG00000125804.12	FAM182A	5.23	2.55e-07	3.64e-05	0.29	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26054655~26086917:+
THCA	cis	rs7727544	0.582	rs10052046	ENSG00000224431.1	AC063976.7	5.23	2.55e-07	3.65e-05	0.2	0.23	Blood metabolite levels;	chr5:132208773	chr5:132199456~132203487:+
THCA	cis	rs7674212	0.57	rs1031804	ENSG00000246560.2	RP11-10L12.4	5.23	2.56e-07	3.65e-05	0.28	0.23	Type 2 diabetes;	chr4:103144892	chr4:102828055~102844075:+
THCA	cis	rs1876905	0.539	rs240969	ENSG00000271789.1	RP5-1112D6.7	5.23	2.56e-07	3.65e-05	0.3	0.23	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111297126~111298510:+
THCA	cis	rs9859260	1	rs2284890	ENSG00000231464.1	AC024937.4	5.23	2.56e-07	3.65e-05	0.28	0.23	Mean corpuscular volume;	chr3:196061276	chr3:195996738~195998233:+
THCA	cis	rs9859260	1	rs2284889	ENSG00000231464.1	AC024937.4	5.23	2.56e-07	3.65e-05	0.28	0.23	Mean corpuscular volume;	chr3:196061376	chr3:195996738~195998233:+
THCA	cis	rs9859260	0.961	rs2300780	ENSG00000231464.1	AC024937.4	5.23	2.56e-07	3.65e-05	0.28	0.23	Mean corpuscular volume;	chr3:196063420	chr3:195996738~195998233:+
THCA	cis	rs11242704	0.508	rs2816282	ENSG00000272279.1	RP11-157J24.2	5.23	2.56e-07	3.65e-05	0.3	0.23	Response to hepatitis C treatment;	chr6:1529423	chr6:1528364~1528911:-
THCA	cis	rs1580019	0.51	rs4723162	ENSG00000231952.3	DPY19L1P2	-5.23	2.56e-07	3.65e-05	-0.29	-0.23	Cognitive ability;	chr7:32504192	chr7:32812757~32838570:+
THCA	cis	rs1552244	1	rs7628448	ENSG00000232901.1	CYCSP10	5.23	2.56e-07	3.65e-05	0.31	0.23	Alzheimer's disease;	chr3:10105144	chr3:10000647~10000940:-
THCA	cis	rs17123764	0.818	rs7975599	ENSG00000257464.1	RP11-161H23.8	-5.23	2.56e-07	3.65e-05	-0.37	-0.23	Intelligence (multi-trait analysis);	chr12:49551143	chr12:49442424~49442652:-
THCA	cis	rs7702057	0.53	rs58510083	ENSG00000271918.1	CTD-2287O16.5	5.23	2.56e-07	3.65e-05	0.28	0.23	Amyotrophic lateral sclerosis;	chr5:116109101	chr5:116083807~116085416:-
THCA	cis	rs10895275	0.81	rs11225177	ENSG00000277459.1	RP11-732A21.3	-5.23	2.56e-07	3.66e-05	-0.19	-0.23	Migraine;	chr11:102238225	chr11:102109827~102110457:-
THCA	cis	rs6565180	0.888	rs12447833	ENSG00000273724.1	RP11-347C12.12	5.23	2.56e-07	3.66e-05	0.26	0.23	Tonsillectomy;	chr16:30378993	chr16:30336400~30343336:+
THCA	cis	rs875971	0.545	rs1267814	ENSG00000232546.1	RP11-458F8.1	-5.23	2.56e-07	3.66e-05	-0.22	-0.23	Aortic root size;	chr7:66579422	chr7:66848496~66858136:+
THCA	cis	rs919433	0.963	rs6738836	ENSG00000231621.1	AC013264.2	5.23	2.57e-07	3.66e-05	0.24	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317708	chr2:197197991~197199273:+
THCA	cis	rs4646450	0.838	rs2272168	ENSG00000244219.5	GS1-259H13.2	-5.23	2.57e-07	3.66e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99505154	chr7:99598066~99610813:+
THCA	cis	rs8177876	0.749	rs11537	ENSG00000261061.1	RP11-303E16.2	-5.23	2.57e-07	3.66e-05	-0.33	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81030770~81031485:+
THCA	cis	rs2179367	0.632	rs55826712	ENSG00000223701.3	RAET1E-AS1	5.23	2.57e-07	3.66e-05	0.34	0.23	Dupuytren's disease;	chr6:149344716	chr6:149884431~149919508:+
THCA	cis	rs2239547	0.657	rs7620706	ENSG00000242142.1	SERBP1P3	5.23	2.57e-07	3.66e-05	0.3	0.23	Schizophrenia;	chr3:52857740	chr3:53064283~53065091:-
THCA	cis	rs12681287	0.604	rs71502657	ENSG00000254231.1	CTD-2284J15.1	5.23	2.57e-07	3.66e-05	0.26	0.23	Caudate activity during reward;	chr8:86466552	chr8:86333274~86343314:-
THCA	cis	rs2360027	0.599	rs12134541	ENSG00000231365.4	RP11-418J17.1	-5.23	2.57e-07	3.66e-05	-0.23	-0.23	Tonsillectomy;	chr1:118541868	chr1:119140396~119275973:+
THCA	cis	rs2880765	0.835	rs11856869	ENSG00000259630.2	CTD-2262B20.1	-5.23	2.57e-07	3.66e-05	-0.25	-0.23	Coronary artery disease;	chr15:85485866	chr15:85415228~85415633:+
THCA	cis	rs7428	0.527	rs4832164	ENSG00000273196.1	RP11-717A5.2	5.23	2.57e-07	3.67e-05	0.25	0.23	Ear protrusion;	chr2:85319809	chr2:85387074~85387146:-
THCA	cis	rs2243480	1	rs778729	ENSG00000230295.1	RP11-458F8.2	-5.23	2.57e-07	3.67e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66359432	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.901	rs778687	ENSG00000230295.1	RP11-458F8.2	-5.23	2.57e-07	3.67e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66370832	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs778679	ENSG00000230295.1	RP11-458F8.2	-5.23	2.57e-07	3.67e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66375924	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs778704	ENSG00000230295.1	RP11-458F8.2	-5.23	2.57e-07	3.67e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66398480	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.901	rs778693	ENSG00000230295.1	RP11-458F8.2	-5.23	2.57e-07	3.67e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66407358	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs778691	ENSG00000230295.1	RP11-458F8.2	-5.23	2.57e-07	3.67e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66408105	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs13235972	ENSG00000230295.1	RP11-458F8.2	-5.23	2.57e-07	3.67e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66418618	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs34192067	ENSG00000230295.1	RP11-458F8.2	-5.23	2.57e-07	3.67e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66422670	chr7:66880708~66882981:+
THCA	cis	rs2280018	0.581	rs7404524	ENSG00000260735.1	RP11-72I8.1	-5.23	2.57e-07	3.67e-05	-0.28	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15094411~15109197:+
THCA	cis	rs8396	1	rs12505475	ENSG00000271817.2	U3	-5.23	2.57e-07	3.67e-05	-0.25	-0.23	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158714092	chr4:158700691~158700909:+
THCA	cis	rs6005807	0.543	rs12168849	ENSG00000226471.5	CTA-292E10.6	-5.23	2.57e-07	3.67e-05	-0.28	-0.23	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28806075	chr22:28800683~28848559:+
THCA	cis	rs7731390	0.614	rs3792884	ENSG00000233006.5	AC034220.3	-5.23	2.58e-07	3.67e-05	-0.3	-0.23	IgG glycosylation;	chr5:132315568	chr5:132311285~132369916:-
THCA	cis	rs13217239	0.534	rs9379968	ENSG00000216901.1	AL022393.7	5.23	2.58e-07	3.68e-05	0.29	0.23	Schizophrenia;	chr6:27276811	chr6:28176188~28176674:+
THCA	cis	rs6547741	0.904	rs2384659	ENSG00000234072.1	AC074117.10	5.23	2.58e-07	3.68e-05	0.18	0.23	Oral cavity cancer;	chr2:27633926	chr2:27356246~27367622:+
THCA	cis	rs34779708	0.966	rs1545757	ENSG00000271335.4	RP11-324I22.4	5.23	2.58e-07	3.68e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35314552~35336401:-
THCA	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-5.23	2.58e-07	3.68e-05	-0.27	-0.23	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
THCA	cis	rs9467773	0.596	rs3001369	ENSG00000261353.1	CTA-14H9.5	-5.23	2.58e-07	3.68e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26527063~26527404:+
THCA	cis	rs6600671	1	rs2319969	ENSG00000226067.5	CH17-118O6.2	5.23	2.58e-07	3.68e-05	0.24	0.23	Hip geometry;	chr1:121465481	chr1:120913275~121009291:+
THCA	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	5.23	2.58e-07	3.68e-05	0.43	0.23	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
THCA	cis	rs4648045	0.964	rs17032850	ENSG00000246560.2	RP11-10L12.4	5.23	2.58e-07	3.68e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102586546	chr4:102828055~102844075:+
THCA	cis	rs4648045	1	rs4648045	ENSG00000246560.2	RP11-10L12.4	5.23	2.58e-07	3.68e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102587546	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.964	rs3774957	ENSG00000246560.2	RP11-10L12.4	5.23	2.58e-07	3.68e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102587868	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.964	rs7667496	ENSG00000246560.2	RP11-10L12.4	5.23	2.58e-07	3.68e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102588298	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.964	rs7692606	ENSG00000246560.2	RP11-10L12.4	5.23	2.58e-07	3.68e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102588524	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.964	rs59123962	ENSG00000246560.2	RP11-10L12.4	5.23	2.58e-07	3.68e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102591294	chr4:102828055~102844075:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000234585.5	CCT6P3	5.23	2.58e-07	3.68e-05	0.22	0.23	Calcium levels;	chr7:65829495	chr7:65038354~65074713:+
THCA	cis	rs6545883	0.86	rs13023037	ENSG00000270820.4	RP11-355B11.2	-5.23	2.58e-07	3.68e-05	-0.2	-0.23	Tuberculosis;	chr2:61393854	chr2:61471188~61484130:+
THCA	cis	rs7617773	0.743	rs11716371	ENSG00000199476.1	Y_RNA	-5.23	2.58e-07	3.68e-05	-0.3	-0.23	Coronary artery disease;	chr3:48321260	chr3:48288587~48288694:+
THCA	cis	rs2337406	0.866	rs79901786	ENSG00000211974.3	IGHV2-70	-5.23	2.58e-07	3.68e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106777623	chr14:106723574~106724093:-
THCA	cis	rs12681287	0.547	rs60982560	ENSG00000254231.1	CTD-2284J15.1	5.23	2.58e-07	3.68e-05	0.26	0.23	Caudate activity during reward;	chr8:86502817	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs56752411	ENSG00000254231.1	CTD-2284J15.1	5.23	2.58e-07	3.68e-05	0.26	0.23	Caudate activity during reward;	chr8:86502927	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs6471360	ENSG00000254231.1	CTD-2284J15.1	-5.23	2.58e-07	3.68e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86501240	chr8:86333274~86343314:-
THCA	cis	rs6570726	0.791	rs4896820	ENSG00000270638.1	RP3-466P17.1	5.23	2.58e-07	3.68e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.764	rs4896821	ENSG00000270638.1	RP3-466P17.1	5.23	2.58e-07	3.68e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145735570~145737218:+
THCA	cis	rs4460629	0.742	rs7368345	ENSG00000160766.13	GBAP1	5.23	2.58e-07	3.68e-05	0.26	0.23	Serum magnesium levels;	chr1:155107614	chr1:155213821~155227422:-
THCA	cis	rs875971	1	rs35149210	ENSG00000223473.2	GS1-124K5.3	5.23	2.58e-07	3.68e-05	0.16	0.23	Aortic root size;	chr7:66464938	chr7:66491049~66493566:-
THCA	cis	rs6860806	1	rs6860806	ENSG00000237714.1	P4HA2-AS1	-5.23	2.58e-07	3.68e-05	-0.29	-0.23	Breast cancer;	chr5:132304843	chr5:132184876~132192808:+
THCA	cis	rs9923856	0.519	rs9923455	ENSG00000274038.1	RP11-66H6.4	-5.23	2.58e-07	3.68e-05	-0.28	-0.23	Atopic dermatitis;Adult asthma;	chr16:11038007	chr16:11056556~11057034:+
THCA	cis	rs867371	0.82	rs7164362	ENSG00000259429.4	UBE2Q2P2	-5.23	2.58e-07	3.68e-05	-0.19	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82355142~82420075:+
THCA	cis	rs12681288	0.676	rs935820	ENSG00000260721.1	AF067845.1	5.23	2.59e-07	3.69e-05	0.28	0.23	Schizophrenia;	chr8:1072168	chr8:1368642~1369833:-
THCA	cis	rs6547741	0.935	rs6749426	ENSG00000234072.1	AC074117.10	5.23	2.59e-07	3.69e-05	0.18	0.23	Oral cavity cancer;	chr2:27624739	chr2:27356246~27367622:+
THCA	cis	rs4648045	0.894	rs230507	ENSG00000246560.2	RP11-10L12.4	-5.23	2.59e-07	3.69e-05	-0.29	-0.23	Lymphocyte percentage of white cells;	chr4:102559089	chr4:102828055~102844075:+
THCA	cis	rs2436845	0.627	rs1991928	ENSG00000253669.3	KB-1732A1.1	-5.23	2.59e-07	3.69e-05	-0.26	-0.23	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102860863	chr8:102805517~102809971:+
THCA	cis	rs12681287	0.752	rs12675974	ENSG00000254231.1	CTD-2284J15.1	5.23	2.59e-07	3.69e-05	0.26	0.23	Caudate activity during reward;	chr8:86235616	chr8:86333274~86343314:-
THCA	cis	rs8177876	0.658	rs12444747	ENSG00000261061.1	RP11-303E16.2	-5.23	2.59e-07	3.69e-05	-0.39	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041299	chr16:81030770~81031485:+
THCA	cis	rs9859260	1	rs11718657	ENSG00000273009.1	RP11-352G9.1	-5.23	2.59e-07	3.69e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196070682	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.961	rs11185506	ENSG00000273009.1	RP11-352G9.1	-5.23	2.59e-07	3.69e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196070705	chr3:195913078~195913683:-
THCA	cis	rs922182	1	rs1460546	ENSG00000275785.1	RP11-111E14.2	5.23	2.59e-07	3.69e-05	0.27	0.23	Blood protein levels;	chr15:63990909	chr15:63890030~63890317:+
THCA	cis	rs922182	0.904	rs9972469	ENSG00000275785.1	RP11-111E14.2	5.23	2.59e-07	3.69e-05	0.27	0.23	Blood protein levels;	chr15:63991594	chr15:63890030~63890317:+
THCA	cis	rs6430585	0.702	rs2015532	ENSG00000231890.6	DARS-AS1	5.23	2.59e-07	3.69e-05	0.28	0.23	Corneal structure;	chr2:135797955	chr2:135985176~136022593:+
THCA	cis	rs2336384	0.613	rs873458	ENSG00000199347.1	RNU5E-1	5.23	2.59e-07	3.69e-05	0.3	0.23	Platelet count;	chr1:11986032	chr1:11908152~11908271:+
THCA	cis	rs9875589	0.509	rs2607761	ENSG00000228242.5	AC093495.4	5.23	2.59e-07	3.69e-05	0.13	0.23	Ovarian reserve;	chr3:14049928	chr3:14144637~14165978:+
THCA	cis	rs10208649	0.611	rs1404994	ENSG00000272156.1	RP11-477N3.1	5.23	2.59e-07	3.69e-05	0.34	0.23	Body mass index;	chr2:53941744	chr2:54082554~54085066:+
THCA	cis	rs17594362	1	rs35516249	ENSG00000264190.1	MIR5006	5.23	2.59e-07	3.69e-05	0.36	0.23	Multiple sclerosis;	chr13:41572081	chr13:41568286~41568395:-
THCA	cis	rs17594362	0.943	rs12430833	ENSG00000264190.1	MIR5006	5.23	2.59e-07	3.69e-05	0.36	0.23	Multiple sclerosis;	chr13:41572911	chr13:41568286~41568395:-
THCA	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	5.23	2.59e-07	3.69e-05	0.27	0.23	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
THCA	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-5.23	2.59e-07	3.7e-05	-0.28	-0.23	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
THCA	cis	rs16852403	0.548	rs10798600	ENSG00000224687.1	RASAL2-AS1	5.23	2.59e-07	3.7e-05	0.35	0.23	Childhood ear infection;	chr1:178211584	chr1:178091508~178093984:-
THCA	cis	rs2299587	0.689	rs1847154	ENSG00000253671.1	RP11-806O11.1	-5.23	2.6e-07	3.7e-05	-0.28	-0.23	Economic and political preferences;	chr8:17922829	chr8:17808941~17820868:+
THCA	cis	rs4650994	0.789	rs2761471	ENSG00000273384.1	RP5-1098D14.1	-5.23	2.6e-07	3.7e-05	-0.3	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178630213	chr1:178651706~178652282:+
THCA	cis	rs8033133	1	rs8033133	ENSG00000251896.1	SNORD116-27	-5.23	2.6e-07	3.7e-05	-0.27	-0.23	Blood osmolality (transformed sodium);	chr15:25105327	chr15:25101575~25101666:+
THCA	cis	rs7428	0.527	rs6547612	ENSG00000273196.1	RP11-717A5.2	5.23	2.6e-07	3.71e-05	0.25	0.23	Ear protrusion;	chr2:85324061	chr2:85387074~85387146:-
THCA	cis	rs55704346	0.84	rs11735095	ENSG00000281501.1	SEPSECS-AS1	5.23	2.6e-07	3.71e-05	0.26	0.23	Tonsillectomy;	chr4:25178498	chr4:25160641~25201440:+
THCA	cis	rs2337406	0.636	rs74090069	ENSG00000211974.3	IGHV2-70	-5.23	2.6e-07	3.71e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106777532	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74090071	ENSG00000211974.3	IGHV2-70	-5.23	2.6e-07	3.71e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106777533	chr14:106723574~106724093:-
THCA	cis	rs6479874	1	rs2339683	ENSG00000223502.1	RP11-96B5.3	-5.23	2.6e-07	3.71e-05	-0.28	-0.23	Migraine;	chr10:51026658	chr10:51062579~51068553:-
THCA	cis	rs7688540	0.8	rs10003142	ENSG00000250892.1	RP11-1365D11.1	5.23	2.6e-07	3.71e-05	0.32	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:201409~205009:-
THCA	cis	rs7688540	0.771	rs11723803	ENSG00000250892.1	RP11-1365D11.1	5.23	2.6e-07	3.71e-05	0.32	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:201409~205009:-
THCA	cis	rs72772090	1	rs72772095	ENSG00000248734.2	CTD-2260A17.1	-5.23	2.6e-07	3.71e-05	-0.4	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96718149	chr5:96784777~96785999:+
THCA	cis	rs2439831	0.867	rs933941	ENSG00000166763.7	STRCP1	5.23	2.6e-07	3.71e-05	0.31	0.23	Lung cancer in ever smokers;	chr15:43340028	chr15:43699488~43718184:-
THCA	cis	rs4646450	0.891	rs7794682	ENSG00000244219.5	GS1-259H13.2	-5.23	2.6e-07	3.71e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99431654	chr7:99598066~99610813:+
THCA	cis	rs890448	0.796	rs6816400	ENSG00000254531.1	FLJ20021	5.23	2.6e-07	3.71e-05	0.21	0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367295	chr4:101347780~101348883:+
THCA	cis	rs7851660	0.809	rs12006522	ENSG00000214417.4	KRT18P13	-5.23	2.61e-07	3.71e-05	-0.21	-0.23	Strep throat;	chr9:97890429	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs12004762	ENSG00000214417.4	KRT18P13	-5.23	2.61e-07	3.71e-05	-0.21	-0.23	Strep throat;	chr9:97890473	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs12550872	ENSG00000214417.4	KRT18P13	-5.23	2.61e-07	3.71e-05	-0.21	-0.23	Strep throat;	chr9:97890846	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs7034249	ENSG00000214417.4	KRT18P13	-5.23	2.61e-07	3.71e-05	-0.21	-0.23	Strep throat;	chr9:97891539	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs7034648	ENSG00000214417.4	KRT18P13	-5.23	2.61e-07	3.71e-05	-0.21	-0.23	Strep throat;	chr9:97891811	chr9:97698922~97700734:+
THCA	cis	rs10200159	0.744	rs6545510	ENSG00000272606.1	RP11-554J4.1	5.23	2.61e-07	3.71e-05	0.47	0.23	Vitiligo;	chr2:55607591	chr2:55617909~55618373:+
THCA	cis	rs9859260	1	rs9859260	ENSG00000273009.1	RP11-352G9.1	-5.23	2.61e-07	3.71e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196073676	chr3:195913078~195913683:-
THCA	cis	rs9868809	0.772	rs9812200	ENSG00000270441.1	RP11-694I15.7	-5.23	2.61e-07	3.72e-05	-0.29	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48658234	chr3:49140086~49160851:-
THCA	cis	rs17767392	1	rs725673	ENSG00000259146.3	RP1-261D10.2	5.23	2.61e-07	3.72e-05	0.31	0.23	Mitral valve prolapse;	chr14:71411751	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs17178206	ENSG00000259146.3	RP1-261D10.2	5.23	2.61e-07	3.72e-05	0.31	0.23	Mitral valve prolapse;	chr14:71413376	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs17767523	ENSG00000259146.3	RP1-261D10.2	5.23	2.61e-07	3.72e-05	0.31	0.23	Mitral valve prolapse;	chr14:71414022	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs34454371	ENSG00000259146.3	RP1-261D10.2	5.23	2.61e-07	3.72e-05	0.31	0.23	Mitral valve prolapse;	chr14:71414785	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs12894016	ENSG00000259146.3	RP1-261D10.2	5.23	2.61e-07	3.72e-05	0.31	0.23	Mitral valve prolapse;	chr14:71416371	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.914	rs35613269	ENSG00000259146.3	RP1-261D10.2	5.23	2.61e-07	3.72e-05	0.31	0.23	Mitral valve prolapse;	chr14:71421097	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs2877729	ENSG00000259146.3	RP1-261D10.2	5.23	2.61e-07	3.72e-05	0.31	0.23	Mitral valve prolapse;	chr14:71421151	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs2109276	ENSG00000259146.3	RP1-261D10.2	5.23	2.61e-07	3.72e-05	0.31	0.23	Mitral valve prolapse;	chr14:71423050	chr14:71292729~71321814:-
THCA	cis	rs17508449	0.819	rs78552134	ENSG00000232450.1	RP4-730K3.3	-5.23	2.61e-07	3.72e-05	-0.37	-0.23	Leprosy;	chr1:113727044	chr1:113698884~113699631:-
THCA	cis	rs2562456	0.52	rs25760	ENSG00000268555.1	RP11-678G14.3	5.23	2.61e-07	3.72e-05	0.37	0.23	Pain;	chr19:21211375	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs2359145	ENSG00000268119.4	CTD-2561J22.5	5.23	2.61e-07	3.72e-05	0.34	0.23	Pain;	chr19:21409791	chr19:21444241~21463908:-
THCA	cis	rs7428	0.527	rs1061782	ENSG00000273196.1	RP11-717A5.2	-5.23	2.61e-07	3.72e-05	-0.25	-0.23	Ear protrusion;	chr2:85319492	chr2:85387074~85387146:-
THCA	cis	rs1426063	0.858	rs7666182	ENSG00000260265.1	RP11-44F21.5	5.23	2.61e-07	3.72e-05	0.42	0.23	QT interval;	chr4:75090989	chr4:75081702~75084717:-
THCA	cis	rs10510102	0.872	rs12264046	ENSG00000226864.1	ATE1-AS1	5.23	2.61e-07	3.72e-05	0.38	0.23	Breast cancer;	chr10:121894996	chr10:121928312~121951965:+
THCA	cis	rs7085104	0.632	rs7096475	ENSG00000213061.2	PFN1P11	5.23	2.61e-07	3.72e-05	0.28	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102838011~102845473:-
THCA	cis	rs1876905	0.764	rs4947106	ENSG00000255389.1	C6orf3	-5.23	2.61e-07	3.72e-05	-0.27	-0.23	Mean corpuscular hemoglobin;	chr6:111100163	chr6:111599875~111602295:+
THCA	cis	rs7200543	0.89	rs4985155	ENSG00000188599.16	NPIPP1	-5.23	2.61e-07	3.72e-05	-0.18	-0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15035602	chr16:15104312~15123498:-
THCA	cis	rs8028182	0.549	rs3809547	ENSG00000260269.4	CTD-2323K18.1	5.23	2.61e-07	3.72e-05	0.35	0.23	Sudden cardiac arrest;	chr15:75336500	chr15:75527150~75601205:-
THCA	cis	rs919433	0.75	rs788012	ENSG00000231621.1	AC013264.2	-5.23	2.62e-07	3.73e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197365132	chr2:197197991~197199273:+
THCA	cis	rs2360027	0.578	rs10458416	ENSG00000231365.4	RP11-418J17.1	-5.23	2.62e-07	3.73e-05	-0.23	-0.23	Tonsillectomy;	chr1:118527533	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs10458408	ENSG00000231365.4	RP11-418J17.1	-5.23	2.62e-07	3.73e-05	-0.23	-0.23	Tonsillectomy;	chr1:118529190	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs7529449	ENSG00000231365.4	RP11-418J17.1	-5.23	2.62e-07	3.73e-05	-0.23	-0.23	Tonsillectomy;	chr1:118530479	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.565	rs7545979	ENSG00000231365.4	RP11-418J17.1	-5.23	2.62e-07	3.73e-05	-0.23	-0.23	Relative hand skill in reading disability;	chr1:118530812	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs10923591	ENSG00000231365.4	RP11-418J17.1	-5.23	2.62e-07	3.73e-05	-0.23	-0.23	Tonsillectomy;	chr1:118532831	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs4659092	ENSG00000231365.4	RP11-418J17.1	-5.23	2.62e-07	3.73e-05	-0.23	-0.23	Tonsillectomy;	chr1:118535440	chr1:119140396~119275973:+
THCA	cis	rs7085104	0.632	rs7097872	ENSG00000213061.2	PFN1P11	5.23	2.62e-07	3.73e-05	0.28	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102838011~102845473:-
THCA	cis	rs11089937	0.597	rs4821772	ENSG00000211639.2	IGLV4-60	-5.23	2.62e-07	3.73e-05	-0.17	-0.23	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22162199~22162681:+
THCA	cis	rs6570726	1	rs404229	ENSG00000270638.1	RP3-466P17.1	5.23	2.62e-07	3.73e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145735570~145737218:+
THCA	cis	rs6570726	1	rs405622	ENSG00000270638.1	RP3-466P17.1	5.23	2.62e-07	3.73e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145735570~145737218:+
THCA	cis	rs10895275	0.884	rs8504	ENSG00000277459.1	RP11-732A21.3	-5.23	2.62e-07	3.73e-05	-0.19	-0.23	Migraine;	chr11:102232869	chr11:102109827~102110457:-
THCA	cis	rs12681287	0.547	rs9942792	ENSG00000254231.1	CTD-2284J15.1	5.23	2.62e-07	3.73e-05	0.26	0.23	Caudate activity during reward;	chr8:86496817	chr8:86333274~86343314:-
THCA	cis	rs9990333	0.6	rs6793116	ENSG00000242086.7	LINC00969	-5.23	2.62e-07	3.73e-05	-0.22	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085217	chr3:195658062~195739964:+
THCA	cis	rs6756513	0.5	rs7596535	ENSG00000231024.1	AC092431.3	-5.23	2.62e-07	3.74e-05	-0.32	-0.23	Breast cancer;Platelet count;	chr2:69858829	chr2:69700192~69713847:-
THCA	cis	rs2282300	0.739	rs16920406	ENSG00000242353.1	RP4-710M3.1	-5.23	2.62e-07	3.74e-05	-0.23	-0.23	Morning vs. evening chronotype;	chr11:30194611	chr11:30368148~30368646:+
THCA	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	5.22	2.62e-07	3.74e-05	0.27	0.23	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
THCA	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-5.22	2.62e-07	3.74e-05	-0.27	-0.23	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
THCA	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-5.22	2.62e-07	3.74e-05	-0.27	-0.23	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
THCA	cis	rs919433	0.854	rs787994	ENSG00000231621.1	AC013264.2	-5.22	2.62e-07	3.74e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197358397	chr2:197197991~197199273:+
THCA	cis	rs7688540	0.8	rs2353599	ENSG00000250892.1	RP11-1365D11.1	5.22	2.62e-07	3.74e-05	0.32	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:201409~205009:-
THCA	cis	rs3177980	0.673	rs10919255	ENSG00000239494.2	RN7SL333P	-5.22	2.63e-07	3.74e-05	-0.23	-0.23	Amyotrophic lateral sclerosis;	chr1:169847041	chr1:169859756~169860052:+
THCA	cis	rs7394190	0.688	rs3812629	ENSG00000271848.1	RP11-464F9.21	-5.22	2.63e-07	3.74e-05	-0.31	-0.23	Incident atrial fibrillation;	chr10:73647532	chr10:73654039~73674719:+
THCA	cis	rs62184315	0.575	rs256546	ENSG00000273240.1	RP11-455J20.3	-5.22	2.63e-07	3.74e-05	-0.24	-0.23	Alcohol dependence (age at onset);	chr2:189886437	chr2:189763859~189764456:-
THCA	cis	rs911119	0.913	rs6048923	ENSG00000270001.1	RP11-218C14.8	-5.22	2.63e-07	3.74e-05	-0.37	-0.23	Chronic kidney disease;	chr20:23597569	chr20:23631826~23632316:-
THCA	cis	rs9475752	0.793	rs28360535	ENSG00000231441.1	RP11-472M19.2	5.22	2.63e-07	3.74e-05	0.32	0.23	Menarche (age at onset);	chr6:57004631	chr6:56844002~56864078:+
THCA	cis	rs2337406	0.789	rs60000589	ENSG00000211974.3	IGHV2-70	-5.22	2.63e-07	3.75e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106782459	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs111881598	ENSG00000211974.3	IGHV2-70	-5.22	2.63e-07	3.75e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106783113	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs61164979	ENSG00000211974.3	IGHV2-70	-5.22	2.63e-07	3.75e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106783133	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs61419485	ENSG00000211974.3	IGHV2-70	-5.22	2.63e-07	3.75e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106783374	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs8015361	ENSG00000211974.3	IGHV2-70	-5.22	2.63e-07	3.75e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106783991	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs74090151	ENSG00000211974.3	IGHV2-70	-5.22	2.63e-07	3.75e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106785377	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.866	rs8012619	ENSG00000211974.3	IGHV2-70	-5.22	2.63e-07	3.75e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106793907	chr14:106723574~106724093:-
THCA	cis	rs2483058	0.515	rs3849275	ENSG00000261000.1	RP11-534L20.5	-5.22	2.63e-07	3.75e-05	-0.26	-0.23	Cholesterol and Triglycerides;	chr1:206432315	chr1:206503948~206504456:+
THCA	cis	rs919433	0.926	rs787996	ENSG00000231621.1	AC013264.2	-5.22	2.63e-07	3.75e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352081	chr2:197197991~197199273:+
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000273796.1	LL21NC02-21A1.1	-5.22	2.63e-07	3.75e-05	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45403809~45404369:-
THCA	cis	rs2512987	1	rs2512986	ENSG00000254731.1	CTD-2005H7.1	-5.22	2.63e-07	3.75e-05	-0.29	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703286	chr11:86703099~86714092:+
THCA	cis	rs8014252	0.667	rs7148445	ENSG00000259158.2	ADAM20P1	-5.22	2.63e-07	3.75e-05	-0.25	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70323483	chr14:70468881~70483756:-
THCA	cis	rs1050631	0.592	rs1785930	ENSG00000260552.1	RP11-49I11.1	5.22	2.64e-07	3.75e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36143755	chr18:36179996~36187448:-
THCA	cis	rs2360027	0.599	rs11590971	ENSG00000231365.4	RP11-418J17.1	5.22	2.64e-07	3.75e-05	0.23	0.23	Tonsillectomy;	chr1:118557264	chr1:119140396~119275973:+
THCA	cis	rs9990333	0.562	rs56038600	ENSG00000273009.1	RP11-352G9.1	-5.22	2.64e-07	3.75e-05	-0.27	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195913078~195913683:-
THCA	cis	rs319690	1	rs319690	ENSG00000228638.1	FCF1P2	-5.22	2.64e-07	3.75e-05	-0.23	-0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs6772396	ENSG00000228638.1	FCF1P2	-5.22	2.64e-07	3.75e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47918280	chr3:48290793~48291375:-
THCA	cis	rs6585424	1	rs6585454	ENSG00000242600.5	MBL1P	-5.22	2.64e-07	3.75e-05	-0.28	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180945	chr10:79904898~79950336:+
THCA	cis	rs9987353	0.519	rs13276350	ENSG00000253893.2	FAM85B	5.22	2.64e-07	3.76e-05	0.31	0.23	Recombination measurement;	chr8:9205647	chr8:8167819~8226614:-
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-5.22	2.64e-07	3.76e-05	-0.26	-0.23	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
THCA	cis	rs2880765	0.835	rs4526974	ENSG00000259630.2	CTD-2262B20.1	-5.22	2.64e-07	3.76e-05	-0.25	-0.23	Coronary artery disease;	chr15:85481053	chr15:85415228~85415633:+
THCA	cis	rs10895275	0.961	rs10895276	ENSG00000277459.1	RP11-732A21.3	-5.22	2.64e-07	3.76e-05	-0.19	-0.23	Migraine;	chr11:102212964	chr11:102109827~102110457:-
THCA	cis	rs9859260	1	rs2239641	ENSG00000231464.1	AC024937.4	5.22	2.65e-07	3.77e-05	0.28	0.23	Mean corpuscular volume;	chr3:196062543	chr3:195996738~195998233:+
THCA	cis	rs9287719	0.747	rs1534400	ENSG00000234818.1	AC092687.5	5.22	2.65e-07	3.77e-05	0.28	0.23	Prostate cancer;	chr2:10556707	chr2:10589166~10604830:+
THCA	cis	rs17767392	1	rs34674149	ENSG00000259146.3	RP1-261D10.2	5.22	2.65e-07	3.77e-05	0.3	0.23	Mitral valve prolapse;	chr14:71310376	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs34011442	ENSG00000259146.3	RP1-261D10.2	5.22	2.65e-07	3.77e-05	0.3	0.23	Mitral valve prolapse;	chr14:71312366	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs34873919	ENSG00000259146.3	RP1-261D10.2	5.22	2.65e-07	3.77e-05	0.3	0.23	Mitral valve prolapse;	chr14:71314024	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs35621718	ENSG00000259146.3	RP1-261D10.2	5.22	2.65e-07	3.77e-05	0.3	0.23	Mitral valve prolapse;	chr14:71314041	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs35122644	ENSG00000259146.3	RP1-261D10.2	5.22	2.65e-07	3.77e-05	0.3	0.23	Mitral valve prolapse;	chr14:71314051	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs2108707	ENSG00000259146.3	RP1-261D10.2	5.22	2.65e-07	3.77e-05	0.3	0.23	Mitral valve prolapse;	chr14:71324453	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.915	rs7147434	ENSG00000259146.3	RP1-261D10.2	5.22	2.65e-07	3.77e-05	0.3	0.23	Mitral valve prolapse;	chr14:71344809	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs17767446	ENSG00000259146.3	RP1-261D10.2	5.22	2.65e-07	3.77e-05	0.3	0.23	Mitral valve prolapse;	chr14:71354246	chr14:71292729~71321814:-
THCA	cis	rs1552244	0.938	rs7652951	ENSG00000180385.7	EMC3-AS1	5.22	2.65e-07	3.77e-05	0.26	0.23	Alzheimer's disease;	chr3:10022079	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs7611218	ENSG00000180385.7	EMC3-AS1	5.22	2.65e-07	3.77e-05	0.26	0.23	Alzheimer's disease;	chr3:10022276	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.872	rs6803517	ENSG00000180385.7	EMC3-AS1	5.22	2.65e-07	3.77e-05	0.26	0.23	Alzheimer's disease;	chr3:10023742	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs9834980	ENSG00000180385.7	EMC3-AS1	5.22	2.65e-07	3.77e-05	0.26	0.23	Alzheimer's disease;	chr3:10023844	chr3:9986893~10006990:+
THCA	cis	rs925255	0.776	rs2279990	ENSG00000270210.1	RP11-373D23.3	5.22	2.65e-07	3.77e-05	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28413873	chr2:28425945~28426719:+
THCA	cis	rs7688540	0.771	rs74984113	ENSG00000211553.1	AC253576.2	-5.22	2.65e-07	3.77e-05	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:136461~136568:+
THCA	cis	rs12036718	0.511	rs12130469	ENSG00000272491.1	RP5-1024N4.4	5.22	2.65e-07	3.77e-05	0.29	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr1:48142214	chr1:48227888~48229561:-
THCA	cis	rs12036718	0.56	rs115210557	ENSG00000272491.1	RP5-1024N4.4	5.22	2.65e-07	3.77e-05	0.29	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr1:48143910	chr1:48227888~48229561:-
THCA	cis	rs12036718	0.511	rs12118572	ENSG00000272491.1	RP5-1024N4.4	5.22	2.65e-07	3.77e-05	0.29	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr1:48144878	chr1:48227888~48229561:-
THCA	cis	rs6570726	1	rs455109	ENSG00000270638.1	RP3-466P17.1	5.22	2.65e-07	3.77e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145735570~145737218:+
THCA	cis	rs6570726	1	rs373778	ENSG00000270638.1	RP3-466P17.1	5.22	2.65e-07	3.77e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145735570~145737218:+
THCA	cis	rs12681287	0.752	rs1436628	ENSG00000254231.1	CTD-2284J15.1	-5.22	2.65e-07	3.77e-05	-0.27	-0.23	Caudate activity during reward;	chr8:86301116	chr8:86333274~86343314:-
THCA	cis	rs6142102	0.59	rs6059691	ENSG00000275784.1	RP5-1125A11.6	5.22	2.65e-07	3.77e-05	0.25	0.23	Skin pigmentation;	chr20:34149161	chr20:33989480~33991818:-
THCA	cis	rs6445975	0.955	rs4681845	ENSG00000272360.1	RP11-359I18.5	-5.22	2.65e-07	3.77e-05	-0.25	-0.23	Systemic lupus erythematosus;	chr3:58346769	chr3:58490830~58491291:-
THCA	cis	rs7429990	0.965	rs796566	ENSG00000228638.1	FCF1P2	-5.22	2.65e-07	3.77e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47896864	chr3:48290793~48291375:-
THCA	cis	rs16846053	0.786	rs72877309	ENSG00000227403.1	AC009299.3	5.22	2.65e-07	3.78e-05	0.49	0.23	Blood osmolality (transformed sodium);	chr2:161731318	chr2:161244739~161249050:+
THCA	cis	rs7160336	0.728	rs4899488	ENSG00000259065.1	RP5-1021I20.1	5.22	2.65e-07	3.78e-05	0.27	0.23	Blood protein levels;	chr14:74008147	chr14:73787360~73803270:+
THCA	cis	rs6545883	0.894	rs6545867	ENSG00000270820.4	RP11-355B11.2	-5.22	2.65e-07	3.78e-05	-0.2	-0.23	Tuberculosis;	chr2:61423892	chr2:61471188~61484130:+
THCA	cis	rs860295	0.702	rs3851912	ENSG00000160766.13	GBAP1	-5.22	2.65e-07	3.78e-05	-0.28	-0.23	Body mass index;	chr1:155616653	chr1:155213821~155227422:-
THCA	cis	rs7209700	0.778	rs3851807	ENSG00000228782.6	CTD-2026D20.3	-5.22	2.65e-07	3.78e-05	-0.22	-0.23	IgG glycosylation;	chr17:47274153	chr17:47450568~47492492:-
THCA	cis	rs17767392	0.781	rs14030	ENSG00000259146.3	RP1-261D10.2	5.22	2.66e-07	3.78e-05	0.29	0.23	Mitral valve prolapse;	chr14:71489424	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.846	rs12127	ENSG00000259146.3	RP1-261D10.2	5.22	2.66e-07	3.78e-05	0.29	0.23	Mitral valve prolapse;	chr14:71489553	chr14:71292729~71321814:-
THCA	cis	rs2797160	1	rs2211420	ENSG00000237742.5	RP11-624M8.1	-5.22	2.66e-07	3.78e-05	-0.2	-0.23	Endometrial cancer;	chr6:125674403	chr6:125578558~125749190:-
THCA	cis	rs5015933	0.788	rs568409	ENSG00000232630.1	PRPS1P2	-5.22	2.66e-07	3.78e-05	-0.16	-0.23	Body mass index;	chr9:125309994	chr9:125150653~125151589:+
THCA	cis	rs853679	0.76	rs9393910	ENSG00000220721.1	OR1F12	5.22	2.66e-07	3.78e-05	0.33	0.23	Depression;	chr6:28240414	chr6:28073316~28074233:+
THCA	cis	rs853679	0.76	rs9368563	ENSG00000220721.1	OR1F12	5.22	2.66e-07	3.78e-05	0.33	0.23	Depression;	chr6:28240780	chr6:28073316~28074233:+
THCA	cis	rs853679	0.76	rs9295768	ENSG00000220721.1	OR1F12	5.22	2.66e-07	3.78e-05	0.33	0.23	Depression;	chr6:28241324	chr6:28073316~28074233:+
THCA	cis	rs564343	0.898	rs576740	ENSG00000255320.1	RP11-755F10.1	-5.22	2.66e-07	3.78e-05	-0.29	-0.23	Obesity (early onset extreme);	chr11:66085100	chr11:66244840~66246239:-
THCA	cis	rs45509595	0.841	rs9368531	ENSG00000226314.6	ZNF192P1	-5.22	2.66e-07	3.78e-05	-0.39	-0.23	Breast cancer;	chr6:27814094	chr6:28161781~28169594:+
THCA	cis	rs45509595	0.749	rs401763	ENSG00000226314.6	ZNF192P1	-5.22	2.66e-07	3.78e-05	-0.39	-0.23	Breast cancer;	chr6:27814750	chr6:28161781~28169594:+
THCA	cis	rs45509595	0.659	rs390764	ENSG00000226314.6	ZNF192P1	-5.22	2.66e-07	3.78e-05	-0.39	-0.23	Breast cancer;	chr6:27814757	chr6:28161781~28169594:+
THCA	cis	rs45509595	0.841	rs401754	ENSG00000226314.6	ZNF192P1	-5.22	2.66e-07	3.78e-05	-0.39	-0.23	Breast cancer;	chr6:27814760	chr6:28161781~28169594:+
THCA	cis	rs45509595	0.841	rs2747054	ENSG00000226314.6	ZNF192P1	-5.22	2.66e-07	3.78e-05	-0.39	-0.23	Breast cancer;	chr6:27815581	chr6:28161781~28169594:+
THCA	cis	rs45509595	0.841	rs200501	ENSG00000226314.6	ZNF192P1	-5.22	2.66e-07	3.78e-05	-0.39	-0.23	Breast cancer;	chr6:27821164	chr6:28161781~28169594:+
THCA	cis	rs35934224	0.504	rs10372	ENSG00000232926.1	AC000078.5	5.22	2.66e-07	3.78e-05	0.28	0.23	Glaucoma (primary open-angle);	chr22:19849775	chr22:19887289~19887970:+
THCA	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	5.22	2.66e-07	3.78e-05	0.29	0.23	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
THCA	cis	rs11051970	0.636	rs188978	ENSG00000274964.1	RP11-817I4.1	-5.22	2.66e-07	3.79e-05	-0.25	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32417693	chr12:32339368~32340724:+
THCA	cis	rs8020095	0.528	rs1044745	ENSG00000258561.1	RP11-72M17.1	-5.22	2.66e-07	3.79e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67334098	chr14:66212810~66509394:-
THCA	cis	rs5015933	0.778	rs1759434	ENSG00000232630.1	PRPS1P2	-5.22	2.66e-07	3.79e-05	-0.16	-0.23	Body mass index;	chr9:125325260	chr9:125150653~125151589:+
THCA	cis	rs7429990	0.866	rs3732529	ENSG00000228638.1	FCF1P2	-5.22	2.66e-07	3.79e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47928619	chr3:48290793~48291375:-
THCA	cis	rs875971	1	rs2077593	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66427543	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs4717292	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66430611	chr7:66491049~66493566:-
THCA	cis	rs875971	0.895	rs10755833	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66448930	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs12668936	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66449417	chr7:66491049~66493566:-
THCA	cis	rs875971	0.895	rs1833495	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66456608	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs6945032	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66457499	chr7:66491049~66493566:-
THCA	cis	rs875971	0.929	rs12673810	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66458866	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs6961155	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66468308	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs7789768	ENSG00000223473.2	GS1-124K5.3	5.22	2.66e-07	3.79e-05	0.16	0.23	Aortic root size;	chr7:66473993	chr7:66491049~66493566:-
THCA	cis	rs2070488	0.804	rs7372452	ENSG00000229589.1	ACVR2B-AS1	5.22	2.67e-07	3.79e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38402807	chr3:38451027~38454820:-
THCA	cis	rs11671005	0.735	rs12981875	ENSG00000265272.2	RN7SL693P	5.22	2.67e-07	3.79e-05	0.33	0.23	Mean platelet volume;	chr19:58423763	chr19:58490797~58491075:+
THCA	cis	rs60695258	0.529	rs340630	ENSG00000251411.1	RP11-397E7.4	5.22	2.67e-07	3.79e-05	0.21	0.23	Hematocrit;	chr4:87037243	chr4:86913266~86914817:-
THCA	cis	rs1395	1	rs1275501	ENSG00000234072.1	AC074117.10	5.22	2.67e-07	3.79e-05	0.19	0.23	Blood metabolite levels;	chr2:27196414	chr2:27356246~27367622:+
THCA	cis	rs2810114	0.834	rs36559	ENSG00000269927.1	RP6-91H8.3	5.22	2.67e-07	3.79e-05	0.28	0.23	Alcohol dependence;	chr14:70888232	chr14:71141125~71143253:-
THCA	cis	rs1499614	1	rs2707832	ENSG00000230295.1	RP11-458F8.2	-5.22	2.67e-07	3.8e-05	-0.29	-0.23	Gout;	chr7:66671562	chr7:66880708~66882981:+
THCA	cis	rs763121	0.853	rs5750673	ENSG00000228274.3	RP3-508I15.9	-5.22	2.67e-07	3.8e-05	-0.26	-0.23	Menopause (age at onset);	chr22:38714119	chr22:38667585~38681820:-
THCA	cis	rs4789693	0.872	rs28612648	ENSG00000260011.2	RP13-20L14.1	-5.22	2.67e-07	3.8e-05	-0.24	-0.23	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82381110~82382690:-
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000259728.4	LINC00933	-5.22	2.67e-07	3.8e-05	-0.28	-0.23	P wave terminal force;	chr15:84631400	chr15:84570649~84580175:+
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000259728.4	LINC00933	-5.22	2.67e-07	3.8e-05	-0.28	-0.23	P wave terminal force;	chr15:84631524	chr15:84570649~84580175:+
THCA	cis	rs7044106	0.887	rs1359328	ENSG00000270917.1	RP11-27I1.6	-5.22	2.67e-07	3.8e-05	-0.36	-0.23	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120812475~120812845:-
THCA	cis	rs7617773	0.925	rs7374376	ENSG00000199476.1	Y_RNA	5.22	2.67e-07	3.8e-05	0.29	0.23	Coronary artery disease;	chr3:48131197	chr3:48288587~48288694:+
THCA	cis	rs4415084	0.804	rs9292913	ENSG00000272335.1	RP11-53O19.3	5.22	2.68e-07	3.8e-05	0.19	0.23	Breast cancer;	chr5:44870777	chr5:44826076~44828592:+
THCA	cis	rs9625935	0.957	rs193481	ENSG00000279159.1	RP3-394A18.1	-5.22	2.68e-07	3.81e-05	-0.18	-0.23	Tonsillectomy;	chr22:30062425	chr22:29978950~30028236:-
THCA	cis	rs34779708	0.931	rs4934709	ENSG00000271335.4	RP11-324I22.4	-5.22	2.68e-07	3.81e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35314552~35336401:-
THCA	cis	rs972578	0.791	rs5751392	ENSG00000274717.1	RP1-47A17.1	-5.22	2.68e-07	3.81e-05	-0.24	-0.23	Mean platelet volume;	chr22:42865688	chr22:42791814~42794313:-
THCA	cis	rs8103278	0.507	rs1865116	ENSG00000267395.4	AC074212.6	-5.22	2.68e-07	3.81e-05	-0.16	-0.23	Coronary artery disease;	chr19:45791252	chr19:45767796~45772504:+
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000230295.1	RP11-458F8.2	-5.22	2.68e-07	3.81e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:65946971	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs2961102	ENSG00000230295.1	RP11-458F8.2	-5.22	2.68e-07	3.81e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:65959671	chr7:66880708~66882981:+
THCA	cis	rs2554380	0.55	rs11853949	ENSG00000230373.7	GOLGA6L5P	-5.22	2.68e-07	3.81e-05	-0.25	-0.23	Height;	chr15:83848152	chr15:84507885~84516814:-
THCA	cis	rs17772222	0.606	rs1955598	ENSG00000258789.1	RP11-507K2.3	-5.22	2.68e-07	3.81e-05	-0.21	-0.23	Coronary artery calcification;	chr14:88357311	chr14:88551597~88552493:+
THCA	cis	rs1552244	0.748	rs113890152	ENSG00000232901.1	CYCSP10	5.22	2.68e-07	3.81e-05	0.31	0.23	Alzheimer's disease;	chr3:10044302	chr3:10000647~10000940:-
THCA	cis	rs72634501	0.574	rs111623477	ENSG00000228060.1	RP11-69E11.8	-5.22	2.68e-07	3.81e-05	-0.28	-0.23	HDL cholesterol;	chr1:39345533	chr1:39565160~39573203:+
THCA	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-5.22	2.68e-07	3.81e-05	-0.28	-0.23	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
THCA	cis	rs73198271	0.694	rs73201840	ENSG00000253893.2	FAM85B	5.22	2.68e-07	3.81e-05	0.34	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.694	rs113694763	ENSG00000253893.2	FAM85B	5.22	2.68e-07	3.81e-05	0.34	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.694	rs115037021	ENSG00000253893.2	FAM85B	5.22	2.68e-07	3.81e-05	0.34	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.694	rs114184516	ENSG00000253893.2	FAM85B	5.22	2.68e-07	3.81e-05	0.34	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.774	rs35039922	ENSG00000254153.1	CTA-398F10.2	-5.22	2.69e-07	3.82e-05	-0.25	-0.23	Mood instability;	chr8:8817815	chr8:8456909~8461337:-
THCA	cis	rs2115630	0.905	rs6496401	ENSG00000225151.9	GOLGA2P7	5.22	2.69e-07	3.82e-05	0.3	0.23	P wave terminal force;	chr15:84754562	chr15:84199311~84230136:-
THCA	cis	rs7119	0.717	rs12901338	ENSG00000259362.2	RP11-307C19.1	-5.22	2.69e-07	3.82e-05	-0.34	-0.23	Type 2 diabetes;	chr15:77512558	chr15:77525540~77534110:+
THCA	cis	rs2303319	0.504	rs72879293	ENSG00000227403.1	AC009299.3	5.22	2.69e-07	3.82e-05	0.58	0.23	Cognitive function;	chr2:161849966	chr2:161244739~161249050:+
THCA	cis	rs7617773	0.746	rs6796343	ENSG00000199476.1	Y_RNA	-5.22	2.69e-07	3.82e-05	-0.3	-0.23	Coronary artery disease;	chr3:48240531	chr3:48288587~48288694:+
THCA	cis	rs1383484	0.575	rs10520571	ENSG00000225151.9	GOLGA2P7	5.22	2.69e-07	3.82e-05	0.3	0.23	Height;	chr15:83947580	chr15:84199311~84230136:-
THCA	cis	rs12893668	0.667	rs71417869	ENSG00000269940.1	RP11-73M18.7	5.22	2.69e-07	3.82e-05	0.24	0.23	Reticulocyte count;	chr14:103611097	chr14:103694560~103695170:+
THCA	cis	rs2120243	0.591	rs9871290	ENSG00000244515.1	KRT18P34	-5.22	2.69e-07	3.82e-05	-0.28	-0.23	Hepatocellular carcinoma in hepatitis B infection;	chr3:157381802	chr3:157162663~157163932:-
THCA	cis	rs6445975	1	rs7653734	ENSG00000272360.1	RP11-359I18.5	5.22	2.69e-07	3.83e-05	0.25	0.23	Systemic lupus erythematosus;	chr3:58387158	chr3:58490830~58491291:-
THCA	cis	rs7429990	0.932	rs7620736	ENSG00000228638.1	FCF1P2	5.22	2.69e-07	3.83e-05	0.22	0.23	Educational attainment (years of education);	chr3:48068479	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs6791834	ENSG00000228638.1	FCF1P2	5.22	2.69e-07	3.83e-05	0.22	0.23	Educational attainment (years of education);	chr3:48073598	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs35689209	ENSG00000228638.1	FCF1P2	5.22	2.69e-07	3.83e-05	0.22	0.23	Educational attainment (years of education);	chr3:48078273	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs4858881	ENSG00000228638.1	FCF1P2	5.22	2.69e-07	3.83e-05	0.22	0.23	Educational attainment (years of education);	chr3:48082306	chr3:48290793~48291375:-
THCA	cis	rs2692947	0.77	rs4527246	ENSG00000232931.4	LINC00342	5.22	2.69e-07	3.83e-05	0.19	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95894555	chr2:95807118~95816215:-
THCA	cis	rs3734266	0.639	rs6914714	ENSG00000272288.4	RP11-140K17.3	-5.22	2.69e-07	3.83e-05	-0.23	-0.23	Systemic lupus erythematosus;	chr6:34676442	chr6:34696317~34697470:+
THCA	cis	rs7220401	0.515	rs8080772	ENSG00000264007.1	RP11-68I3.10	-5.22	2.7e-07	3.83e-05	-0.3	-0.23	Coronary artery disease;	chr17:30086111	chr17:29621617~29622254:-
THCA	cis	rs9307551	0.584	rs6819333	ENSG00000250334.4	LINC00989	-5.22	2.7e-07	3.83e-05	-0.28	-0.23	Refractive error;	chr4:79540995	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.584	rs6534429	ENSG00000250334.4	LINC00989	-5.22	2.7e-07	3.83e-05	-0.28	-0.23	Refractive error;	chr4:79543006	chr4:79492416~79576460:+
THCA	cis	rs8177876	0.749	rs79834398	ENSG00000261838.4	RP11-303E16.6	5.22	2.7e-07	3.83e-05	0.42	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81069854~81076598:+
THCA	cis	rs12935418	0.583	rs2911150	ENSG00000278985.1	RP11-303E16.9	5.22	2.7e-07	3.83e-05	0.25	0.23	Mean corpuscular volume;	chr16:80995194	chr16:80982319~80984094:-
THCA	cis	rs7674212	0.581	rs13150953	ENSG00000230069.3	LRRC37A15P	-5.22	2.7e-07	3.83e-05	-0.24	-0.23	Type 2 diabetes;	chr4:103021341	chr4:102727274~102730721:-
THCA	cis	rs7674212	0.556	rs13151569	ENSG00000230069.3	LRRC37A15P	-5.22	2.7e-07	3.83e-05	-0.24	-0.23	Type 2 diabetes;	chr4:103021633	chr4:102727274~102730721:-
THCA	cis	rs4460629	0.742	rs7365544	ENSG00000160766.13	GBAP1	-5.22	2.7e-07	3.83e-05	-0.26	-0.23	Serum magnesium levels;	chr1:155096272	chr1:155213821~155227422:-
THCA	cis	rs4460629	0.804	rs56112907	ENSG00000160766.13	GBAP1	-5.22	2.7e-07	3.83e-05	-0.26	-0.23	Serum magnesium levels;	chr1:155098386	chr1:155213821~155227422:-
THCA	cis	rs7005380	0.62	rs10217083	ENSG00000245330.4	KB-1471A8.1	5.22	2.7e-07	3.83e-05	0.23	0.23	Interstitial lung disease;	chr8:119911045	chr8:119867419~119874488:-
THCA	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-5.22	2.7e-07	3.83e-05	-0.28	-0.23	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
THCA	cis	rs4794202	0.717	rs6503897	ENSG00000264920.1	RP11-6N17.4	5.22	2.7e-07	3.83e-05	0.27	0.23	Alzheimer's disease (cognitive decline);	chr17:47879683	chr17:47891255~47895812:-
THCA	cis	rs12030196	0.917	rs11207367	ENSG00000230812.4	LINC01358	5.22	2.7e-07	3.84e-05	0.29	0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59004767	chr1:59020387~59044614:+
THCA	cis	rs7924176	0.502	rs10824134	ENSG00000213731.2	RAB5CP1	-5.22	2.7e-07	3.84e-05	-0.29	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74261866	chr10:74423435~74424014:-
THCA	cis	rs12681287	0.547	rs7459877	ENSG00000254231.1	CTD-2284J15.1	5.22	2.7e-07	3.84e-05	0.26	0.23	Caudate activity during reward;	chr8:86493431	chr8:86333274~86343314:-
THCA	cis	rs503425	1	rs503425	ENSG00000255239.1	AP002954.6	5.22	2.7e-07	3.84e-05	0.35	0.23	Systemic lupus erythematosus;	chr11:118822018	chr11:118688039~118690600:-
THCA	cis	rs5758511	0.689	rs17478227	ENSG00000281538.1	RP4-669P10.20	5.22	2.7e-07	3.84e-05	0.31	0.23	Birth weight;	chr22:42258321	chr22:42138060~42139726:+
THCA	cis	rs6547741	0.935	rs4666004	ENSG00000234072.1	AC074117.10	5.22	2.7e-07	3.84e-05	0.18	0.23	Oral cavity cancer;	chr2:27632185	chr2:27356246~27367622:+
THCA	cis	rs7617773	0.78	rs11710257	ENSG00000199476.1	Y_RNA	-5.22	2.7e-07	3.84e-05	-0.3	-0.23	Coronary artery disease;	chr3:48331724	chr3:48288587~48288694:+
THCA	cis	rs9425766	0.631	rs10158289	ENSG00000227373.4	RP11-160H22.5	5.22	2.7e-07	3.84e-05	0.33	0.23	Life satisfaction;	chr1:174081529	chr1:174115300~174160004:-
THCA	cis	rs875971	0.929	rs34406470	ENSG00000223473.2	GS1-124K5.3	5.22	2.71e-07	3.84e-05	0.16	0.23	Aortic root size;	chr7:66464969	chr7:66491049~66493566:-
THCA	cis	rs9813712	0.717	rs9835466	ENSG00000249846.5	RP11-77P16.4	5.22	2.71e-07	3.84e-05	0.31	0.23	Response to amphetamines;	chr3:130258530	chr3:130112550~130120579:+
THCA	cis	rs2360027	0.578	rs7531722	ENSG00000231365.4	RP11-418J17.1	-5.22	2.71e-07	3.85e-05	-0.23	-0.23	Tonsillectomy;	chr1:118536494	chr1:119140396~119275973:+
THCA	cis	rs7429990	0.965	rs4858880	ENSG00000228638.1	FCF1P2	5.22	2.71e-07	3.85e-05	0.22	0.23	Educational attainment (years of education);	chr3:48062959	chr3:48290793~48291375:-
THCA	cis	rs8002861	0.935	rs1373903	ENSG00000274001.1	RP11-5G9.5	5.22	2.71e-07	3.85e-05	0.26	0.23	Leprosy;	chr13:43901378	chr13:43877715~43878163:-
THCA	cis	rs6921919	0.583	rs7740351	ENSG00000219392.1	RP1-265C24.5	-5.22	2.71e-07	3.85e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs16894108	ENSG00000219392.1	RP1-265C24.5	-5.22	2.71e-07	3.85e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28115628~28116551:+
THCA	cis	rs897984	0.683	rs8050330	ENSG00000279196.1	RP11-1072A3.3	5.22	2.71e-07	3.85e-05	0.23	0.23	Dementia with Lewy bodies;	chr16:30813649	chr16:30984630~30988270:-
THCA	cis	rs2179367	0.6	rs9498354	ENSG00000268592.3	RAET1E-AS1	-5.22	2.71e-07	3.85e-05	-0.37	-0.23	Dupuytren's disease;	chr6:149441715	chr6:149863494~149919507:+
THCA	cis	rs3743266	0.634	rs7165874	ENSG00000245534.5	RORA-AS1	-5.22	2.71e-07	3.85e-05	-0.26	-0.23	Menarche (age at onset);	chr15:60492410	chr15:60479178~60630637:+
THCA	cis	rs8028182	0.636	rs11637068	ENSG00000260274.1	RP11-817O13.8	5.22	2.71e-07	3.85e-05	0.17	0.23	Sudden cardiac arrest;	chr15:75450661	chr15:75368155~75369584:+
THCA	cis	rs9992667	0.955	rs1962053	ENSG00000231160.8	KLF3-AS1	5.22	2.71e-07	3.85e-05	0.17	0.23	Eosinophil percentage of granulocytes;	chr4:38610736	chr4:38612701~38664883:-
THCA	cis	rs7429990	0.965	rs319685	ENSG00000228638.1	FCF1P2	-5.22	2.71e-07	3.86e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47890494	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs319684	ENSG00000228638.1	FCF1P2	-5.22	2.71e-07	3.86e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47890784	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.932	rs810334	ENSG00000228638.1	FCF1P2	-5.22	2.71e-07	3.86e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47893813	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs4858871	ENSG00000228638.1	FCF1P2	-5.22	2.71e-07	3.86e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47911915	chr3:48290793~48291375:-
THCA	cis	rs6430585	0.702	rs746857	ENSG00000231890.6	DARS-AS1	5.22	2.72e-07	3.86e-05	0.29	0.23	Corneal structure;	chr2:135797320	chr2:135985176~136022593:+
THCA	cis	rs2243480	1	rs13247184	ENSG00000230295.1	RP11-458F8.2	-5.22	2.72e-07	3.86e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65893941	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs35283677	ENSG00000230295.1	RP11-458F8.2	-5.22	2.72e-07	3.86e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65894246	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs35421653	ENSG00000230295.1	RP11-458F8.2	-5.22	2.72e-07	3.86e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65898442	chr7:66880708~66882981:+
THCA	cis	rs2115630	1	rs10220733	ENSG00000225151.9	GOLGA2P7	5.22	2.72e-07	3.86e-05	0.3	0.23	P wave terminal force;	chr15:84737633	chr15:84199311~84230136:-
THCA	cis	rs2115630	1	rs1030863	ENSG00000225151.9	GOLGA2P7	5.22	2.72e-07	3.86e-05	0.3	0.23	P wave terminal force;	chr15:84739404	chr15:84199311~84230136:-
THCA	cis	rs9309473	0.519	rs13017182	ENSG00000163016.8	ALMS1P	-5.22	2.72e-07	3.87e-05	-0.3	-0.23	Metabolite levels;	chr2:73663877	chr2:73644919~73685576:+
THCA	cis	rs1552244	1	rs9820598	ENSG00000180385.7	EMC3-AS1	5.22	2.73e-07	3.87e-05	0.26	0.23	Alzheimer's disease;	chr3:10076228	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs57631744	ENSG00000180385.7	EMC3-AS1	5.22	2.73e-07	3.87e-05	0.26	0.23	Alzheimer's disease;	chr3:10077278	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs6805869	ENSG00000180385.7	EMC3-AS1	5.22	2.73e-07	3.87e-05	0.26	0.23	Alzheimer's disease;	chr3:10078233	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs9827740	ENSG00000180385.7	EMC3-AS1	5.22	2.73e-07	3.87e-05	0.26	0.23	Alzheimer's disease;	chr3:10078847	chr3:9986893~10006990:+
THCA	cis	rs11096990	0.964	rs56284364	ENSG00000249685.1	RP11-360F5.3	-5.22	2.73e-07	3.87e-05	-0.29	-0.23	Cognitive function;	chr4:39255028	chr4:39133913~39135608:+
THCA	cis	rs2129782	1	rs116196672	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88347651	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs78827343	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88354901	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs74408158	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88356716	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs79744929	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88358050	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs80050131	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88371132	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs77245705	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88372682	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs79089647	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88373885	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs79577870	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88376664	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs78131177	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88377213	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs58337229	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88377844	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs75664917	ENSG00000253553.4	RP11-586K2.1	5.22	2.73e-07	3.87e-05	0.42	0.23	Electrodermal activity;	chr8:88380804	chr8:88326836~88737134:+
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66157859	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs4718309	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66162777	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6460274	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66163497	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs7787230	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66164112	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66170354	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6974723	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66172952	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs9769882	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66177938	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6966322	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66181767	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs4145008	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66182524	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs4718315	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66183554	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs4718316	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66183744	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1873494	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66184912	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6959002	ENSG00000230295.1	RP11-458F8.2	5.22	2.73e-07	3.87e-05	0.28	0.23	Diabetic kidney disease;	chr7:66185509	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs422164	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66121618	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316313	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66128561	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316312	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66131504	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs419603	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66132354	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs387676	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66133233	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66133553	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs431076	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66135333	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66136518	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316334	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66137139	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316330	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66140385	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316326	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66144466	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316325	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66144531	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316321	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66146626	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316318	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66147917	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316317	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66148650	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316304	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66151907	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs2465120	ENSG00000230295.1	RP11-458F8.2	-5.22	2.73e-07	3.87e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66155987	chr7:66880708~66882981:+
THCA	cis	rs7429990	0.965	rs319692	ENSG00000228638.1	FCF1P2	-5.22	2.73e-07	3.87e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47882827	chr3:48290793~48291375:-
THCA	cis	rs7829975	0.533	rs13274028	ENSG00000233609.3	RP11-62H7.2	5.22	2.73e-07	3.87e-05	0.23	0.23	Mood instability;	chr8:8871683	chr8:8961200~8979025:+
THCA	cis	rs10875746	0.669	rs10431526	ENSG00000258234.1	RP11-370I10.2	5.22	2.73e-07	3.87e-05	0.27	0.23	Longevity (90 years and older);	chr12:48296360	chr12:48231098~48284210:-
THCA	cis	rs2880765	0.835	rs7174323	ENSG00000259630.2	CTD-2262B20.1	-5.22	2.73e-07	3.88e-05	-0.25	-0.23	Coronary artery disease;	chr15:85506488	chr15:85415228~85415633:+
THCA	cis	rs7897654	0.571	rs7920697	ENSG00000236937.2	PTGES3P4	5.22	2.73e-07	3.88e-05	0.33	0.23	Schizophrenia;	chr10:102873580	chr10:102845595~102845950:+
THCA	cis	rs919433	1	rs2195510	ENSG00000231621.1	AC013264.2	5.22	2.73e-07	3.88e-05	0.23	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197296471	chr2:197197991~197199273:+
THCA	cis	rs919433	1	rs6761919	ENSG00000231621.1	AC013264.2	5.22	2.73e-07	3.88e-05	0.23	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298604	chr2:197197991~197199273:+
THCA	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	5.22	2.73e-07	3.88e-05	0.28	0.23	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
THCA	cis	rs4865169	0.871	rs9918067	ENSG00000269949.1	RP11-738E22.3	-5.22	2.73e-07	3.88e-05	-0.27	-0.23	Breast cancer;	chr4:57004378	chr4:56960927~56961373:-
THCA	cis	rs10510102	0.935	rs10887018	ENSG00000226864.1	ATE1-AS1	5.22	2.73e-07	3.88e-05	0.38	0.23	Breast cancer;	chr10:121894457	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200230	ENSG00000226864.1	ATE1-AS1	5.22	2.73e-07	3.88e-05	0.38	0.23	Breast cancer;	chr10:121895117	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200234	ENSG00000226864.1	ATE1-AS1	5.22	2.73e-07	3.88e-05	0.38	0.23	Breast cancer;	chr10:121895851	chr10:121928312~121951965:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000234585.5	CCT6P3	5.22	2.73e-07	3.88e-05	0.22	0.23	Calcium levels;	chr7:65825628	chr7:65038354~65074713:+
THCA	cis	rs812925	0.892	rs1186699	ENSG00000271889.1	RP11-493E12.1	5.22	2.73e-07	3.88e-05	0.24	0.23	Immature fraction of reticulocytes;	chr2:61435420	chr2:61151433~61162105:-
THCA	cis	rs10895987	0.531	rs2282498	ENSG00000254614.2	AP003068.23	5.22	2.73e-07	3.88e-05	0.32	0.23	Blood protein levels;	chr11:65088514	chr11:65177606~65181834:-
THCA	cis	rs12030196	0.778	rs12748496	ENSG00000230812.4	LINC01358	5.22	2.74e-07	3.88e-05	0.28	0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59020879	chr1:59020387~59044614:+
THCA	cis	rs228614	0.51	rs223397	ENSG00000248971.2	KRT8P46	-5.22	2.74e-07	3.88e-05	-0.29	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102728746~102730171:-
THCA	cis	rs7131987	0.903	rs7308125	ENSG00000275476.1	RP11-996F15.4	-5.22	2.74e-07	3.88e-05	-0.23	-0.23	QT interval;	chr12:29272278	chr12:29277397~29277882:-
THCA	cis	rs6728642	0.572	rs60621865	ENSG00000230606.9	AC159540.1	5.22	2.74e-07	3.88e-05	0.28	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96932264	chr2:97416165~97433527:-
THCA	cis	rs8059260	0.736	rs77599345	ENSG00000274038.1	RP11-66H6.4	-5.22	2.74e-07	3.88e-05	-0.48	-0.23	Alcohol consumption over the past year;	chr16:10964707	chr16:11056556~11057034:+
THCA	cis	rs9467773	0.525	rs1535274	ENSG00000261353.1	CTA-14H9.5	-5.22	2.74e-07	3.88e-05	-0.25	-0.23	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.565	rs6925047	ENSG00000261353.1	CTA-14H9.5	-5.22	2.74e-07	3.88e-05	-0.25	-0.23	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.565	rs4343916	ENSG00000261353.1	CTA-14H9.5	-5.22	2.74e-07	3.88e-05	-0.25	-0.23	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26527063~26527404:+
THCA	cis	rs72945132	0.882	rs947812	ENSG00000254604.1	AP000487.6	-5.22	2.74e-07	3.88e-05	-0.45	-0.23	Coronary artery disease;	chr11:70363063	chr11:70282367~70363368:-
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000230295.1	RP11-458F8.2	5.22	2.74e-07	3.88e-05	0.29	0.23	Diabetic kidney disease;	chr7:66226660	chr7:66880708~66882981:+
THCA	cis	rs7829975	0.567	rs6601273	ENSG00000233609.3	RP11-62H7.2	-5.22	2.74e-07	3.89e-05	-0.23	-0.23	Mood instability;	chr8:8939009	chr8:8961200~8979025:+
THCA	cis	rs4950322	0.57	rs17356492	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147296089	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72691093	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147297977	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs76236344	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147297989	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72691095	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147298305	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72691097	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147299711	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72691098	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147300142	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72691102	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147301189	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692904	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147301437	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692905	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147301560	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692907	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147301921	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692914	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147302946	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692917	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147304389	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692920	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147308501	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs66580541	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147308828	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs945742	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147313437	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.543	rs4950318	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147316240	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.543	rs4950319	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147316250	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.543	rs4453096	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147316574	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.571	rs4373796	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147316747	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.543	rs4568882	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147316885	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.543	rs2883323	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147316995	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.543	rs2883324	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147317157	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.542	rs72692942	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147318467	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs4950399	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147319302	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs4950403	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147319723	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.517	rs116479391	ENSG00000226015.2	CCT8P1	5.22	2.74e-07	3.89e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147320940	chr1:147203276~147204932:-
THCA	cis	rs34779708	0.931	rs34375045	ENSG00000271335.4	RP11-324I22.4	5.22	2.74e-07	3.89e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35314552~35336401:-
THCA	cis	rs8027521	0.633	rs3943313	ENSG00000280362.1	RP11-643A5.3	5.22	2.74e-07	3.89e-05	0.29	0.23	Circulating chemerin levels;	chr15:53959227	chr15:53910769~53914712:+
THCA	cis	rs2439831	0.85	rs7179388	ENSG00000166763.7	STRCP1	5.22	2.74e-07	3.89e-05	0.35	0.23	Lung cancer in ever smokers;	chr15:43831747	chr15:43699488~43718184:-
THCA	cis	rs17301013	0.932	rs6425280	ENSG00000227373.4	RP11-160H22.5	5.22	2.74e-07	3.89e-05	0.33	0.23	Systemic lupus erythematosus;	chr1:174422186	chr1:174115300~174160004:-
THCA	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-5.22	2.74e-07	3.89e-05	-0.29	-0.23	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
THCA	cis	rs3824488	0.599	rs357523	ENSG00000237857.2	RP11-435O5.2	-5.22	2.75e-07	3.89e-05	-0.42	-0.23	Neuroticism;	chr9:95427053	chr9:95414834~95426796:-
THCA	cis	rs890448	0.796	rs13148645	ENSG00000254531.1	FLJ20021	5.22	2.75e-07	3.9e-05	0.21	0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101385675	chr4:101347780~101348883:+
THCA	cis	rs7246657	0.722	rs2972438	ENSG00000276846.1	CTD-3220F14.3	5.22	2.75e-07	3.9e-05	0.24	0.23	Coronary artery calcification;	chr19:37719946	chr19:37314868~37315620:-
THCA	cis	rs8062405	1	rs8061590	ENSG00000278665.1	RP11-666O2.4	5.22	2.75e-07	3.9e-05	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28599241~28601881:-
THCA	cis	rs470119	1	rs470119	ENSG00000273272.1	CTA-384D8.34	5.22	2.75e-07	3.9e-05	0.2	0.23	Mean corpuscular hemoglobin;	chr22:50528485	chr22:50542650~50543011:+
THCA	cis	rs28374715	0.681	rs7163989	ENSG00000247556.5	OIP5-AS1	5.22	2.75e-07	3.9e-05	0.21	0.23	Ulcerative colitis;	chr15:41322423	chr15:41283990~41309737:+
THCA	cis	rs1552244	0.554	rs3732964	ENSG00000180385.7	EMC3-AS1	5.22	2.75e-07	3.9e-05	0.23	0.23	Alzheimer's disease;	chr3:10007155	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs3732963	ENSG00000180385.7	EMC3-AS1	5.22	2.75e-07	3.9e-05	0.23	0.23	Alzheimer's disease;	chr3:10007201	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.608	rs3732962	ENSG00000180385.7	EMC3-AS1	5.22	2.75e-07	3.9e-05	0.23	0.23	Alzheimer's disease;	chr3:10007267	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs2272118	ENSG00000180385.7	EMC3-AS1	5.22	2.75e-07	3.9e-05	0.23	0.23	Alzheimer's disease;	chr3:10007603	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs58020561	ENSG00000180385.7	EMC3-AS1	5.22	2.75e-07	3.9e-05	0.23	0.23	Alzheimer's disease;	chr3:10012998	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs13081079	ENSG00000180385.7	EMC3-AS1	5.22	2.75e-07	3.9e-05	0.23	0.23	Alzheimer's disease;	chr3:10014664	chr3:9986893~10006990:+
THCA	cis	rs12935418	0.616	rs1127390	ENSG00000278985.1	RP11-303E16.9	5.22	2.75e-07	3.9e-05	0.25	0.23	Mean corpuscular volume;	chr16:80976176	chr16:80982319~80984094:-
THCA	cis	rs3213758	1	rs12598634	ENSG00000275191.1	RP11-36I17.2	-5.22	2.75e-07	3.9e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53658326	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs77726929	ENSG00000275191.1	RP11-36I17.2	-5.22	2.75e-07	3.9e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53660046	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.609	rs12448547	ENSG00000275191.1	RP11-36I17.2	-5.22	2.75e-07	3.9e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53660600	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs80298294	ENSG00000275191.1	RP11-36I17.2	-5.22	2.75e-07	3.9e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53663078	chr16:53628256~53628816:-
THCA	cis	rs3213758	0.867	rs4133018	ENSG00000275191.1	RP11-36I17.2	-5.22	2.75e-07	3.9e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53664803	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs76237088	ENSG00000275191.1	RP11-36I17.2	-5.22	2.75e-07	3.9e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53667251	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs80228590	ENSG00000275191.1	RP11-36I17.2	-5.22	2.75e-07	3.9e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53668402	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs79893137	ENSG00000275191.1	RP11-36I17.2	-5.22	2.75e-07	3.9e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53669888	chr16:53628256~53628816:-
THCA	cis	rs295490	0.688	rs184157	ENSG00000272656.1	RP11-219D15.3	5.22	2.75e-07	3.9e-05	0.28	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr3:139523324	chr3:139349024~139349371:-
THCA	cis	rs1185460	0.967	rs1786141	ENSG00000272186.1	RP11-110I1.13	-5.22	2.75e-07	3.9e-05	-0.22	-0.23	Coronary artery disease;	chr11:119067604	chr11:119067374~119067698:-
THCA	cis	rs35934224	0.783	rs9754418	ENSG00000232926.1	AC000078.5	5.22	2.75e-07	3.91e-05	0.26	0.23	Glaucoma (primary open-angle);	chr22:19867210	chr22:19887289~19887970:+
THCA	cis	rs9388451	0.869	rs7764016	ENSG00000226409.1	RP11-735G4.1	-5.22	2.75e-07	3.91e-05	-0.28	-0.23	Brugada syndrome;	chr6:125749643	chr6:125370211~125374324:-
THCA	cis	rs6058796	0.892	rs6141782	ENSG00000175730.8	BAK1P1	5.22	2.75e-07	3.91e-05	0.34	0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32675705	chr20:32690180~32690815:-
THCA	cis	rs9329221	0.905	rs17709397	ENSG00000261451.1	RP11-981G7.1	-5.22	2.75e-07	3.91e-05	-0.29	-0.23	Neuroticism;	chr8:10392351	chr8:10433672~10438312:+
THCA	cis	rs4950322	0.57	rs80070044	ENSG00000226015.2	CCT8P1	5.22	2.76e-07	3.91e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147330238	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692963	ENSG00000226015.2	CCT8P1	5.22	2.76e-07	3.91e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147331090	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.518	rs72692965	ENSG00000226015.2	CCT8P1	5.22	2.76e-07	3.91e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147332085	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.518	rs72692968	ENSG00000226015.2	CCT8P1	5.22	2.76e-07	3.91e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147332884	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.518	rs72692970	ENSG00000226015.2	CCT8P1	5.22	2.76e-07	3.91e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147332887	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692971	ENSG00000226015.2	CCT8P1	5.22	2.76e-07	3.91e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147333088	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692973	ENSG00000226015.2	CCT8P1	5.22	2.76e-07	3.91e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147333281	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692975	ENSG00000226015.2	CCT8P1	5.22	2.76e-07	3.91e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147333506	chr1:147203276~147204932:-
THCA	cis	rs16846053	0.605	rs62188857	ENSG00000227403.1	AC009299.3	5.22	2.76e-07	3.91e-05	0.51	0.23	Blood osmolality (transformed sodium);	chr2:161927352	chr2:161244739~161249050:+
THCA	cis	rs13113518	0.513	rs13132085	ENSG00000249700.7	SRD5A3-AS1	-5.22	2.76e-07	3.91e-05	-0.3	-0.23	Height;	chr4:55593918	chr4:55363971~55395847:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000273142.1	RP11-458F8.4	5.22	2.76e-07	3.91e-05	0.19	0.23	Aortic root size;	chr7:66144830	chr7:66902857~66906297:+
THCA	cis	rs972578	0.668	rs9607961	ENSG00000274717.1	RP1-47A17.1	-5.22	2.76e-07	3.91e-05	-0.25	-0.23	Mean platelet volume;	chr22:42836812	chr22:42791814~42794313:-
THCA	cis	rs10895275	0.886	rs4754041	ENSG00000277459.1	RP11-732A21.3	5.22	2.76e-07	3.91e-05	0.18	0.23	Migraine;	chr11:102179215	chr11:102109827~102110457:-
THCA	cis	rs1979679	0.608	rs6487691	ENSG00000247934.4	RP11-967K21.1	5.22	2.76e-07	3.91e-05	0.24	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28571283	chr12:28163298~28190738:-
THCA	cis	rs2439831	0.85	rs8042868	ENSG00000166763.7	STRCP1	5.22	2.76e-07	3.91e-05	0.35	0.23	Lung cancer in ever smokers;	chr15:43647444	chr15:43699488~43718184:-
THCA	cis	rs66823261	0.741	rs7841786	ENSG00000253166.2	RP11-585F1.6	-5.22	2.76e-07	3.91e-05	-0.33	-0.23	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:202660~202897:-
THCA	cis	rs2243480	1	rs313832	ENSG00000232559.3	GS1-124K5.12	5.21	2.76e-07	3.92e-05	0.34	0.23	Diabetic kidney disease;	chr7:66085904	chr7:66554588~66576923:-
THCA	cis	rs11089937	0.568	rs11089919	ENSG00000211638.2	IGLV8-61	-5.21	2.76e-07	3.92e-05	-0.19	-0.23	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22098700~22099212:+
THCA	cis	rs911119	0.913	rs34792920	ENSG00000270001.1	RP11-218C14.8	-5.21	2.76e-07	3.92e-05	-0.37	-0.23	Chronic kidney disease;	chr20:23601239	chr20:23631826~23632316:-
THCA	cis	rs375066	0.62	rs349049	ENSG00000267058.1	RP11-15A1.3	5.21	2.76e-07	3.92e-05	0.21	0.23	Breast cancer;	chr19:43797248	chr19:43891804~43901805:-
THCA	cis	rs1050631	0.564	rs948416	ENSG00000260552.1	RP11-49I11.1	5.21	2.76e-07	3.92e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36135710	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.592	rs1785933	ENSG00000260552.1	RP11-49I11.1	5.21	2.76e-07	3.92e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36139228	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.592	rs1785932	ENSG00000260552.1	RP11-49I11.1	5.21	2.76e-07	3.92e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36139471	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.592	rs1789548	ENSG00000260552.1	RP11-49I11.1	5.21	2.76e-07	3.92e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36144333	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.592	rs1785927	ENSG00000260552.1	RP11-49I11.1	5.21	2.76e-07	3.92e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36146484	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.592	rs1785909	ENSG00000260552.1	RP11-49I11.1	5.21	2.76e-07	3.92e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36151210	chr18:36179996~36187448:-
THCA	cis	rs1050631	0.592	rs1539823	ENSG00000260552.1	RP11-49I11.1	5.21	2.76e-07	3.92e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36156298	chr18:36179996~36187448:-
THCA	cis	rs9283706	0.689	rs10041705	ENSG00000229666.1	MAST4-AS1	5.21	2.77e-07	3.92e-05	0.34	0.23	Coronary artery disease;	chr5:67021394	chr5:67001383~67003953:-
THCA	cis	rs10266483	0.545	rs12540100	ENSG00000227986.1	TRIM60P18	-5.21	2.77e-07	3.92e-05	-0.24	-0.23	Response to statin therapy;	chr7:64289924	chr7:64355078~64356199:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66364510	chr7:66491049~66493566:-
THCA	cis	rs875971	0.929	rs778712	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66384991	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs778710	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66389847	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs778708	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66391332	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs778696	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66405826	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs778694	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66406571	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs4718344	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66409394	chr7:66491049~66493566:-
THCA	cis	rs875971	0.737	rs7803424	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66415618	chr7:66491049~66493566:-
THCA	cis	rs875971	0.83	rs7799834	ENSG00000223473.2	GS1-124K5.3	5.21	2.77e-07	3.92e-05	0.16	0.23	Aortic root size;	chr7:66415707	chr7:66491049~66493566:-
THCA	cis	rs9843304	0.585	rs9847009	ENSG00000240541.2	TM4SF1-AS1	-5.21	2.77e-07	3.92e-05	-0.21	-0.23	Gallstone disease;	chr3:149490380	chr3:149377778~149386583:+
THCA	cis	rs11723261	0.582	rs11248005	ENSG00000211553.1	AC253576.2	-5.21	2.77e-07	3.92e-05	-0.33	-0.23	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:136461~136568:+
THCA	cis	rs11723261	0.582	rs11733927	ENSG00000211553.1	AC253576.2	-5.21	2.77e-07	3.92e-05	-0.33	-0.23	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:136461~136568:+
THCA	cis	rs7429990	0.965	rs2166770	ENSG00000228638.1	FCF1P2	-5.21	2.77e-07	3.92e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47964183	chr3:48290793~48291375:-
THCA	cis	rs7520050	0.807	rs28378621	ENSG00000234329.1	RP11-767N6.2	5.21	2.77e-07	3.93e-05	0.21	0.23	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45651039~45651826:-
THCA	cis	rs2337406	1	rs11850709	ENSG00000274576.2	IGHV2-70	-5.21	2.77e-07	3.93e-05	-0.21	-0.23	Alzheimer's disease (late onset);	chr14:106670844	chr14:106770577~106771020:-
THCA	cis	rs17767392	0.813	rs12878989	ENSG00000259146.3	RP1-261D10.2	5.21	2.77e-07	3.93e-05	0.29	0.23	Mitral valve prolapse;	chr14:71389467	chr14:71292729~71321814:-
THCA	cis	rs4908760	0.566	rs7532459	ENSG00000232912.4	RP5-1115A15.1	5.21	2.77e-07	3.93e-05	0.23	0.23	Vitiligo;	chr1:8617714	chr1:8424645~8434838:+
THCA	cis	rs752010	0.695	rs11210508	ENSG00000230638.4	RP11-486B10.4	-5.21	2.77e-07	3.93e-05	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41641264	chr1:41542069~41544310:+
THCA	cis	rs752010	0.695	rs10890155	ENSG00000230638.4	RP11-486B10.4	-5.21	2.77e-07	3.93e-05	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41642172	chr1:41542069~41544310:+
THCA	cis	rs972578	1	rs2038062	ENSG00000230319.1	AL022476.2	5.21	2.77e-07	3.93e-05	0.25	0.23	Mean platelet volume;	chr22:43001960	chr22:43038585~43052366:+
THCA	cis	rs10829156	0.945	rs10829199	ENSG00000240291.1	RP11-499P20.2	5.21	2.77e-07	3.93e-05	0.2	0.23	Sudden cardiac arrest;	chr10:18679012	chr10:18513115~18545651:-
THCA	cis	rs6479901	0.639	rs871690	ENSG00000232075.1	MRPL35P2	-5.21	2.77e-07	3.93e-05	-0.35	-0.23	Intelligence (multi-trait analysis);	chr10:63134299	chr10:63634317~63634827:-
THCA	cis	rs8002861	0.935	rs1811464	ENSG00000274001.1	RP11-5G9.5	5.21	2.77e-07	3.93e-05	0.26	0.23	Leprosy;	chr13:43895154	chr13:43877715~43878163:-
THCA	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	5.21	2.77e-07	3.93e-05	0.27	0.23	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
THCA	cis	rs62432291	0.681	rs400477	ENSG00000235086.1	FNDC1-IT1	5.21	2.77e-07	3.93e-05	0.43	0.23	Joint mobility (Beighton score);	chr6:159214911	chr6:159240786~159243329:+
THCA	cis	rs4950322	0.57	rs17356184	ENSG00000226015.2	CCT8P1	5.21	2.78e-07	3.93e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147262943	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs80270233	ENSG00000226015.2	CCT8P1	5.21	2.78e-07	3.93e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147263320	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs4950392	ENSG00000226015.2	CCT8P1	5.21	2.78e-07	3.93e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147264889	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs17356219	ENSG00000226015.2	CCT8P1	5.21	2.78e-07	3.93e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147265684	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72691041	ENSG00000226015.2	CCT8P1	5.21	2.78e-07	3.93e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147267084	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs17356233	ENSG00000226015.2	CCT8P1	5.21	2.78e-07	3.93e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147268843	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs17356240	ENSG00000226015.2	CCT8P1	5.21	2.78e-07	3.93e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147269877	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs1999820	ENSG00000226015.2	CCT8P1	5.21	2.78e-07	3.93e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147270329	chr1:147203276~147204932:-
THCA	cis	rs919433	0.889	rs788004	ENSG00000231621.1	AC013264.2	-5.21	2.78e-07	3.93e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197354308	chr2:197197991~197199273:+
THCA	cis	rs2120243	0.641	rs7639254	ENSG00000244515.1	KRT18P34	-5.21	2.78e-07	3.94e-05	-0.28	-0.23	Hepatocellular carcinoma in hepatitis B infection;	chr3:157423252	chr3:157162663~157163932:-
THCA	cis	rs1552244	0.81	rs4019706	ENSG00000180385.7	EMC3-AS1	5.21	2.78e-07	3.94e-05	0.26	0.23	Alzheimer's disease;	chr3:10071178	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.872	rs6771931	ENSG00000180385.7	EMC3-AS1	5.21	2.78e-07	3.94e-05	0.26	0.23	Alzheimer's disease;	chr3:10071724	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs9824585	ENSG00000180385.7	EMC3-AS1	5.21	2.78e-07	3.94e-05	0.26	0.23	Alzheimer's disease;	chr3:10073118	chr3:9986893~10006990:+
THCA	cis	rs12807809	0.588	rs3830078	ENSG00000254941.1	RP11-677M14.5	5.21	2.78e-07	3.94e-05	0.38	0.23	Schizophrenia;	chr11:124737639	chr11:124807822~124808269:-
THCA	cis	rs1371614	0.523	rs7585127	ENSG00000229122.1	AGBL5-IT1	5.21	2.78e-07	3.94e-05	0.17	0.23	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956503	chr2:27061038~27061815:+
THCA	cis	rs593531	0.614	rs10793080	ENSG00000255440.1	RP11-632K5.2	5.21	2.78e-07	3.94e-05	0.28	0.23	Neuroticism;	chr11:74377698	chr11:74409060~74416379:+
THCA	cis	rs763567	0.935	rs639652	ENSG00000271811.1	RP1-79C4.4	5.21	2.78e-07	3.94e-05	0.27	0.23	Tonsillectomy;	chr1:170643732	chr1:170667381~170669425:+
THCA	cis	rs34779708	0.733	rs4102764	ENSG00000230534.5	RP11-297A16.2	5.21	2.78e-07	3.94e-05	0.28	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35098006~35127020:-
THCA	cis	rs2749592	0.513	rs1208708	ENSG00000276805.1	RP11-291L22.6	5.21	2.78e-07	3.94e-05	0.25	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38451030~38451785:+
THCA	cis	rs4650994	0.816	rs2209169	ENSG00000273384.1	RP5-1098D14.1	-5.21	2.78e-07	3.94e-05	-0.3	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178632357	chr1:178651706~178652282:+
THCA	cis	rs2439831	0.681	rs825739	ENSG00000205771.5	CATSPER2P1	-5.21	2.78e-07	3.94e-05	-0.3	-0.23	Lung cancer in ever smokers;	chr15:43300230	chr15:43726918~43747094:-
THCA	cis	rs8002861	0.934	rs9533685	ENSG00000274001.1	RP11-5G9.5	5.21	2.79e-07	3.95e-05	0.26	0.23	Leprosy;	chr13:43894195	chr13:43877715~43878163:-
THCA	cis	rs2562456	0.876	rs10424079	ENSG00000268119.4	CTD-2561J22.5	5.21	2.79e-07	3.95e-05	0.33	0.23	Pain;	chr19:21406377	chr19:21444241~21463908:-
THCA	cis	rs893363	1	rs893363	ENSG00000271916.1	RP11-884K10.6	-5.21	2.79e-07	3.95e-05	-0.27	-0.23	Axial length;	chr3:53813035	chr3:53797764~53798019:-
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000273796.1	LL21NC02-21A1.1	-5.21	2.79e-07	3.95e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000273796.1	LL21NC02-21A1.1	-5.21	2.79e-07	3.95e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000273796.1	LL21NC02-21A1.1	-5.21	2.79e-07	3.95e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000273796.1	LL21NC02-21A1.1	-5.21	2.79e-07	3.95e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45403809~45404369:-
THCA	cis	rs34779708	0.966	rs35814343	ENSG00000271335.4	RP11-324I22.4	5.21	2.79e-07	3.95e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4934535	ENSG00000271335.4	RP11-324I22.4	5.21	2.79e-07	3.95e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs4934734	ENSG00000271335.4	RP11-324I22.4	5.21	2.79e-07	3.95e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs12769575	ENSG00000271335.4	RP11-324I22.4	5.21	2.79e-07	3.95e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs4934538	ENSG00000271335.4	RP11-324I22.4	5.21	2.79e-07	3.95e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35314552~35336401:-
THCA	cis	rs6806253	0.524	rs34584352	ENSG00000239405.1	TMED10P2	5.21	2.79e-07	3.95e-05	0.31	0.23	Pit-and-Fissure caries;	chr3:128519786	chr3:128538020~128538631:+
THCA	cis	rs4857855	0.716	rs13060840	ENSG00000239405.1	TMED10P2	5.21	2.79e-07	3.95e-05	0.31	0.23	Eosinophil counts;	chr3:128519839	chr3:128538020~128538631:+
THCA	cis	rs17767392	0.813	rs12880291	ENSG00000259146.3	RP1-261D10.2	5.21	2.79e-07	3.95e-05	0.3	0.23	Mitral valve prolapse;	chr14:71417850	chr14:71292729~71321814:-
THCA	cis	rs2858942	0.527	rs7185345	ENSG00000268836.1	LA16c-OS12.2	5.21	2.79e-07	3.95e-05	0.2	0.23	Mean corpuscular hemoglobin;	chr16:192771	chr16:185748~186294:-
THCA	cis	rs1552244	0.554	rs6443275	ENSG00000180385.7	EMC3-AS1	5.21	2.79e-07	3.96e-05	0.23	0.23	Alzheimer's disease;	chr3:9967135	chr3:9986893~10006990:+
THCA	cis	rs9843304	0.585	rs9837351	ENSG00000240541.2	TM4SF1-AS1	-5.21	2.79e-07	3.96e-05	-0.22	-0.23	Gallstone disease;	chr3:149492312	chr3:149377778~149386583:+
THCA	cis	rs763121	0.853	rs5757231	ENSG00000228274.3	RP3-508I15.9	5.21	2.79e-07	3.96e-05	0.25	0.23	Menopause (age at onset);	chr22:38675653	chr22:38667585~38681820:-
THCA	cis	rs5758659	0.729	rs134866	ENSG00000270083.1	RP1-257I20.14	5.21	2.79e-07	3.96e-05	0.24	0.23	Cognitive function;	chr22:42254657	chr22:42089630~42090028:-
THCA	cis	rs189798	0.807	rs330905	ENSG00000253893.2	FAM85B	-5.21	2.8e-07	3.96e-05	-0.3	-0.23	Myopia (pathological);	chr8:9136041	chr8:8167819~8226614:-
THCA	cis	rs4888671	1	rs79112827	ENSG00000261707.1	RP11-264M12.2	5.21	2.8e-07	3.96e-05	0.43	0.23	Obesity-related traits;	chr16:77748661	chr16:77741468~77743000:-
THCA	cis	rs10510102	0.935	rs10887014	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121892322	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs11818735	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121892472	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.81	rs12259902	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121893017	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200228	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121893358	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200229	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121893519	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs10887016	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121893830	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs78525391	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121901102	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs4627017	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121901878	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs7098562	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121902148	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs7098822	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121902157	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs74914751	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121904496	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200242	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121905378	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12246704	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121906165	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200243	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121906888	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200244	ENSG00000226864.1	ATE1-AS1	5.21	2.8e-07	3.96e-05	0.38	0.23	Breast cancer;	chr10:121906944	chr10:121928312~121951965:+
THCA	cis	rs4888671	1	rs78623713	ENSG00000261707.1	RP11-264M12.2	5.21	2.8e-07	3.96e-05	0.43	0.23	Obesity-related traits;	chr16:77748842	chr16:77741468~77743000:-
THCA	cis	rs6434928	1	rs6434928	ENSG00000231621.1	AC013264.2	-5.21	2.8e-07	3.96e-05	-0.25	-0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr2:197439853	chr2:197197991~197199273:+
THCA	cis	rs1979679	0.959	rs75757272	ENSG00000278733.1	RP11-425D17.1	5.21	2.8e-07	3.96e-05	0.25	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28251809	chr12:28185625~28186190:-
THCA	cis	rs28476539	0.567	rs6813901	ENSG00000270480.1	RP11-57B24.1	-5.21	2.8e-07	3.97e-05	-0.37	-0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82643997	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.567	rs6813051	ENSG00000270480.1	RP11-57B24.1	5.21	2.8e-07	3.97e-05	0.37	0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82643562	chr4:82691737~82692468:+
THCA	cis	rs7617773	0.779	rs77957078	ENSG00000199476.1	Y_RNA	-5.21	2.8e-07	3.97e-05	-0.3	-0.23	Coronary artery disease;	chr3:48289796	chr3:48288587~48288694:+
THCA	cis	rs9859260	1	rs9859401	ENSG00000273009.1	RP11-352G9.1	-5.21	2.8e-07	3.97e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196073732	chr3:195913078~195913683:-
THCA	cis	rs7160336	0.568	rs10146294	ENSG00000259065.1	RP5-1021I20.1	-5.21	2.8e-07	3.97e-05	-0.28	-0.23	Blood protein levels;	chr14:74214679	chr14:73787360~73803270:+
THCA	cis	rs9880211	0.8	rs13433683	ENSG00000273486.1	RP11-731C17.2	-5.21	2.8e-07	3.97e-05	-0.25	-0.23	Height;Body mass index;	chr3:136799828	chr3:136837338~136839021:-
THCA	cis	rs2749592	0.918	rs11011388	ENSG00000263064.2	RP11-291L22.7	-5.21	2.81e-07	3.97e-05	-0.28	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37866282	chr10:38448689~38448949:+
THCA	cis	rs8027521	0.606	rs2126857	ENSG00000280362.1	RP11-643A5.3	5.21	2.81e-07	3.97e-05	0.3	0.23	Circulating chemerin levels;	chr15:53959026	chr15:53910769~53914712:+
THCA	cis	rs4950322	0.57	rs4950400	ENSG00000226015.2	CCT8P1	-5.21	2.81e-07	3.97e-05	-0.27	-0.23	Protein quantitative trait loci;	chr1:147319383	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72692979	ENSG00000226015.2	CCT8P1	5.21	2.81e-07	3.98e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147336094	chr1:147203276~147204932:-
THCA	cis	rs7617480	0.648	rs4974083	ENSG00000228638.1	FCF1P2	-5.21	2.81e-07	3.98e-05	-0.29	-0.23	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48963193	chr3:48290793~48291375:-
THCA	cis	rs4787484	0.593	rs12917712	ENSG00000214725.6	CDIPT-AS1	5.21	2.81e-07	3.98e-05	0.31	0.23	Response to taxane treatment (placlitaxel);	chr16:29871169	chr16:29863593~29868053:+
THCA	cis	rs9307551	0.584	rs2867671	ENSG00000250334.4	LINC00989	-5.21	2.81e-07	3.98e-05	-0.28	-0.23	Refractive error;	chr4:79542000	chr4:79492416~79576460:+
THCA	cis	rs2243480	1	rs160652	ENSG00000230295.1	RP11-458F8.2	-5.21	2.81e-07	3.98e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66073444	chr7:66880708~66882981:+
THCA	cis	rs7160336	0.641	rs10136002	ENSG00000259065.1	RP5-1021I20.1	-5.21	2.81e-07	3.98e-05	-0.28	-0.23	Blood protein levels;	chr14:74215072	chr14:73787360~73803270:+
THCA	cis	rs2933343	0.818	rs6764681	ENSG00000231305.3	RP11-723O4.2	-5.21	2.81e-07	3.98e-05	-0.29	-0.23	IgG glycosylation;	chr3:128849537	chr3:128861313~128871540:-
THCA	cis	rs1501911	0.611	rs1875529	ENSG00000248489.1	CTD-2007H13.3	-5.21	2.81e-07	3.98e-05	-0.24	-0.23	Lung function (FEV1/FVC);	chr5:99033350	chr5:98929171~98995013:+
THCA	cis	rs6545883	0.859	rs2600661	ENSG00000270820.4	RP11-355B11.2	-5.21	2.81e-07	3.98e-05	-0.19	-0.23	Tuberculosis;	chr2:61315946	chr2:61471188~61484130:+
THCA	cis	rs853679	0.607	rs200489	ENSG00000226314.6	ZNF192P1	-5.21	2.81e-07	3.98e-05	-0.39	-0.23	Depression;	chr6:27830479	chr6:28161781~28169594:+
THCA	cis	rs7727544	0.548	rs2069614	ENSG00000233006.5	AC034220.3	5.21	2.81e-07	3.98e-05	0.18	0.23	Blood metabolite levels;	chr5:132071908	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.548	rs2069616	ENSG00000233006.5	AC034220.3	5.21	2.81e-07	3.98e-05	0.18	0.23	Blood metabolite levels;	chr5:132072384	chr5:132311285~132369916:-
THCA	cis	rs7702057	0.53	rs17138879	ENSG00000272265.1	CTD-2287O16.4	-5.21	2.82e-07	3.98e-05	-0.43	-0.23	Amyotrophic lateral sclerosis;	chr5:116089730	chr5:116078110~116078570:-
THCA	cis	rs7980687	0.657	rs10744151	ENSG00000256092.2	RP13-942N8.1	5.21	2.82e-07	3.98e-05	0.18	0.23	Head circumference (infant);Educational attainment;Height;	chr12:123239188	chr12:123363868~123366113:+
THCA	cis	rs7976269	0.583	rs2117997	ENSG00000257176.2	RP11-996F15.2	5.21	2.82e-07	3.99e-05	0.24	0.23	Male-pattern baldness;	chr12:29143428	chr12:29280418~29317848:-
THCA	cis	rs2243480	1	rs937108	ENSG00000164669.11	INTS4P1	5.21	2.82e-07	3.99e-05	0.45	0.23	Diabetic kidney disease;	chr7:65963465	chr7:65141225~65234216:+
THCA	cis	rs73081554	0.505	rs2063644	ENSG00000272360.1	RP11-359I18.5	-5.21	2.82e-07	3.99e-05	-0.27	-0.23	Rheumatoid arthritis;	chr3:58345215	chr3:58490830~58491291:-
THCA	cis	rs7131987	0.903	rs67517901	ENSG00000275476.1	RP11-996F15.4	-5.21	2.82e-07	3.99e-05	-0.23	-0.23	QT interval;	chr12:29268413	chr12:29277397~29277882:-
THCA	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	5.21	2.82e-07	3.99e-05	0.26	0.23	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
THCA	cis	rs2303319	0.504	rs58622044	ENSG00000227403.1	AC009299.3	5.21	2.82e-07	3.99e-05	0.49	0.23	Cognitive function;	chr2:161739777	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56009150	ENSG00000227403.1	AC009299.3	5.21	2.82e-07	3.99e-05	0.49	0.23	Cognitive function;	chr2:161742072	chr2:161244739~161249050:+
THCA	cis	rs4646450	0.891	rs7804551	ENSG00000244219.5	GS1-259H13.2	-5.21	2.82e-07	3.99e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99521487	chr7:99598066~99610813:+
THCA	cis	rs1552244	1	rs4260416	ENSG00000180385.7	EMC3-AS1	5.21	2.82e-07	3.99e-05	0.26	0.23	Alzheimer's disease;	chr3:10083599	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs4269070	ENSG00000180385.7	EMC3-AS1	5.21	2.82e-07	3.99e-05	0.26	0.23	Alzheimer's disease;	chr3:10084399	chr3:9986893~10006990:+
THCA	cis	rs2179367	0.959	rs9285519	ENSG00000231760.4	RP11-350J20.5	5.21	2.82e-07	3.99e-05	0.3	0.23	Dupuytren's disease;	chr6:149371799	chr6:149796151~149826294:-
THCA	cis	rs2029362	0.684	rs7930533	ENSG00000245573.6	BDNF-AS	5.21	2.82e-07	3.99e-05	0.19	0.23	Total body bone mineral density;	chr11:27621777	chr11:27506838~27698174:+
THCA	cis	rs7131987	0.845	rs7299861	ENSG00000257176.2	RP11-996F15.2	-5.21	2.82e-07	3.99e-05	-0.23	-0.23	QT interval;	chr12:29256734	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.934	rs7316004	ENSG00000257176.2	RP11-996F15.2	-5.21	2.82e-07	3.99e-05	-0.23	-0.23	QT interval;	chr12:29258765	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.903	rs2216853	ENSG00000257176.2	RP11-996F15.2	-5.21	2.82e-07	3.99e-05	-0.23	-0.23	QT interval;	chr12:29260315	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.868	rs10771508	ENSG00000257176.2	RP11-996F15.2	-5.21	2.82e-07	3.99e-05	-0.23	-0.23	QT interval;	chr12:29261278	chr12:29280418~29317848:-
THCA	cis	rs6445975	0.956	rs7631010	ENSG00000272360.1	RP11-359I18.5	5.21	2.82e-07	3.99e-05	0.25	0.23	Systemic lupus erythematosus;	chr3:58460283	chr3:58490830~58491291:-
THCA	cis	rs9625935	0.957	rs718772	ENSG00000279159.1	RP3-394A18.1	-5.21	2.82e-07	3.99e-05	-0.17	-0.23	Tonsillectomy;	chr22:30108218	chr22:29978950~30028236:-
THCA	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-5.21	2.82e-07	3.99e-05	-0.27	-0.23	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
THCA	cis	rs1129187	0.755	rs28868299	ENSG00000272223.1	RP1-20C7.6	5.21	2.83e-07	4e-05	0.18	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42953483	chr6:43033897~43034405:-
THCA	cis	rs1129187	0.686	rs6458313	ENSG00000272223.1	RP1-20C7.6	5.21	2.83e-07	4e-05	0.18	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42954280	chr6:43033897~43034405:-
THCA	cis	rs7246657	0.638	rs7246461	ENSG00000276846.1	CTD-3220F14.3	-5.21	2.83e-07	4.01e-05	-0.23	-0.23	Coronary artery calcification;	chr19:37705680	chr19:37314868~37315620:-
THCA	cis	rs7897654	0.571	rs12765002	ENSG00000236937.2	PTGES3P4	5.21	2.83e-07	4.01e-05	0.33	0.23	Schizophrenia;	chr10:102875591	chr10:102845595~102845950:+
THCA	cis	rs896854	0.936	rs10108430	ENSG00000253528.2	RP11-347C18.4	5.21	2.84e-07	4.01e-05	0.26	0.23	Type 2 diabetes;	chr8:94949566	chr8:94974573~94974853:-
THCA	cis	rs7727544	0.735	rs2631370	ENSG00000263597.1	MIR3936	-5.21	2.84e-07	4.01e-05	-0.22	-0.23	Blood metabolite levels;	chr5:132368084	chr5:132365490~132365599:-
THCA	cis	rs9652601	0.779	rs7186106	ENSG00000274038.1	RP11-66H6.4	-5.21	2.84e-07	4.01e-05	-0.31	-0.23	Systemic lupus erythematosus;	chr16:11116974	chr16:11056556~11057034:+
THCA	cis	rs2554380	0.55	rs62025831	ENSG00000230373.7	GOLGA6L5P	5.21	2.84e-07	4.01e-05	0.25	0.23	Height;	chr15:83876933	chr15:84507885~84516814:-
THCA	cis	rs944289	0.576	rs1820604	ENSG00000257826.1	RP11-116N8.4	5.21	2.84e-07	4.01e-05	0.26	0.23	Thyroid cancer;	chr14:36170000	chr14:36061026~36067190:-
THCA	cis	rs911119	1	rs3088162	ENSG00000270001.1	RP11-218C14.8	-5.21	2.84e-07	4.01e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23627115	chr20:23631826~23632316:-
THCA	cis	rs2243480	0.522	rs1638736	ENSG00000229886.1	RP5-1132H15.3	5.21	2.84e-07	4.02e-05	0.48	0.23	Diabetic kidney disease;	chr7:66627321	chr7:66025126~66031544:-
THCA	cis	rs6997458	0.742	rs3758076	ENSG00000253549.4	RP11-317J10.2	5.21	2.84e-07	4.02e-05	0.24	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463306	chr8:85441851~85464915:-
THCA	cis	rs9921338	0.668	rs55870745	ENSG00000262703.1	RP11-485G7.6	-5.21	2.84e-07	4.02e-05	-0.31	-0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261245	chr16:11348143~11349321:-
THCA	cis	rs9921338	0.636	rs56350515	ENSG00000262703.1	RP11-485G7.6	-5.21	2.84e-07	4.02e-05	-0.31	-0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261247	chr16:11348143~11349321:-
THCA	cis	rs4713118	0.662	rs464312	ENSG00000261839.1	RP1-265C24.8	5.21	2.84e-07	4.02e-05	0.26	0.23	Parkinson's disease;	chr6:27999813	chr6:28136849~28139678:+
THCA	cis	rs7617773	0.78	rs7645425	ENSG00000199476.1	Y_RNA	-5.21	2.84e-07	4.02e-05	-0.3	-0.23	Coronary artery disease;	chr3:48320879	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs6793223	ENSG00000199476.1	Y_RNA	-5.21	2.84e-07	4.02e-05	-0.3	-0.23	Coronary artery disease;	chr3:48322611	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs11714944	ENSG00000199476.1	Y_RNA	-5.21	2.84e-07	4.02e-05	-0.3	-0.23	Coronary artery disease;	chr3:48325481	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs7653336	ENSG00000199476.1	Y_RNA	-5.21	2.84e-07	4.02e-05	-0.3	-0.23	Coronary artery disease;	chr3:48327974	chr3:48288587~48288694:+
THCA	cis	rs6832769	0.767	rs6850524	ENSG00000272969.1	RP11-528I4.2	5.21	2.84e-07	4.02e-05	0.27	0.23	Personality dimensions;	chr4:55515830	chr4:55547112~55547889:+
THCA	cis	rs1050631	0.592	rs1789546	ENSG00000260552.1	RP11-49I11.1	5.21	2.84e-07	4.02e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36145911	chr18:36179996~36187448:-
THCA	cis	rs7617773	0.817	rs3731513	ENSG00000199476.1	Y_RNA	-5.21	2.84e-07	4.02e-05	-0.3	-0.23	Coronary artery disease;	chr3:48178047	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs3729577	ENSG00000199476.1	Y_RNA	-5.21	2.84e-07	4.02e-05	-0.3	-0.23	Coronary artery disease;	chr3:48187504	chr3:48288587~48288694:+
THCA	cis	rs755249	0.567	rs4660208	ENSG00000228060.1	RP11-69E11.8	-5.21	2.84e-07	4.02e-05	-0.25	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39565160~39573203:+
THCA	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-5.21	2.84e-07	4.02e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-5.21	2.84e-07	4.02e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-5.21	2.84e-07	4.02e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
THCA	cis	rs73108077	0.736	rs1997742	ENSG00000277112.2	RP11-755J8.1	-5.21	2.85e-07	4.02e-05	-0.37	-0.23	Red blood cell density in sickle cell anemia;	chr20:31347432	chr20:30681825~30723932:-
THCA	cis	rs2252521	0.583	rs1846490	ENSG00000272568.4	CTB-113D17.1	5.21	2.85e-07	4.03e-05	0.26	0.23	Cognitive performance;	chr7:29041211	chr7:28979967~29013367:+
THCA	cis	rs10510102	0.935	rs10510101	ENSG00000226864.1	ATE1-AS1	5.21	2.85e-07	4.03e-05	0.38	0.23	Breast cancer;	chr10:121898614	chr10:121928312~121951965:+
THCA	cis	rs172166	0.543	rs1150691	ENSG00000220721.1	OR1F12	5.21	2.85e-07	4.03e-05	0.26	0.23	Cardiac Troponin-T levels;	chr6:28200255	chr6:28073316~28074233:+
THCA	cis	rs34779708	0.931	rs2244100	ENSG00000271335.4	RP11-324I22.4	-5.21	2.85e-07	4.03e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35314552~35336401:-
THCA	cis	rs73198271	0.751	rs55816468	ENSG00000253893.2	FAM85B	5.21	2.85e-07	4.03e-05	0.34	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748366	chr8:8167819~8226614:-
THCA	cis	rs896854	0.818	rs896855	ENSG00000253528.2	RP11-347C18.4	5.21	2.85e-07	4.03e-05	0.26	0.23	Type 2 diabetes;	chr8:94947580	chr8:94974573~94974853:-
THCA	cis	rs896854	0.967	rs13257021	ENSG00000253528.2	RP11-347C18.4	5.21	2.85e-07	4.03e-05	0.27	0.23	Type 2 diabetes;	chr8:94953467	chr8:94974573~94974853:-
THCA	cis	rs9467773	1	rs1321481	ENSG00000261353.1	CTA-14H9.5	-5.21	2.85e-07	4.03e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.967	rs6932865	ENSG00000261353.1	CTA-14H9.5	-5.21	2.85e-07	4.03e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6933176	ENSG00000261353.1	CTA-14H9.5	-5.21	2.85e-07	4.03e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26527063~26527404:+
THCA	cis	rs8002861	0.902	rs1445557	ENSG00000274001.1	RP11-5G9.5	5.21	2.85e-07	4.03e-05	0.26	0.23	Leprosy;	chr13:43890691	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.905	rs9525869	ENSG00000274001.1	RP11-5G9.5	5.21	2.85e-07	4.03e-05	0.26	0.23	Leprosy;	chr13:43893074	chr13:43877715~43878163:-
THCA	cis	rs4908768	0.501	rs6577513	ENSG00000232912.4	RP5-1115A15.1	5.21	2.85e-07	4.03e-05	0.23	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8642694	chr1:8424645~8434838:+
THCA	cis	rs17772222	0.755	rs12435019	ENSG00000258983.2	RP11-507K2.2	5.21	2.85e-07	4.03e-05	0.26	0.23	Coronary artery calcification;	chr14:88365074	chr14:88499334~88515502:+
THCA	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-5.21	2.85e-07	4.03e-05	-0.31	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
THCA	cis	rs690037	1	rs690037	ENSG00000272498.1	RP11-415F23.3	5.21	2.85e-07	4.03e-05	0.25	0.23	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16354161	chr3:16339308~16339871:+
THCA	cis	rs516805	0.528	rs2684230	ENSG00000279453.1	RP3-425C14.4	-5.21	2.85e-07	4.03e-05	-0.25	-0.23	Lymphocyte counts;	chr6:122078062	chr6:122436789~122439223:-
THCA	cis	rs12681288	0.676	rs2701901	ENSG00000260721.1	AF067845.1	5.21	2.85e-07	4.03e-05	0.29	0.23	Schizophrenia;	chr8:1067816	chr8:1368642~1369833:-
THCA	cis	rs853679	0.699	rs9468318	ENSG00000220721.1	OR1F12	5.21	2.85e-07	4.03e-05	0.33	0.23	Depression;	chr6:28241753	chr6:28073316~28074233:+
THCA	cis	rs6479901	0.894	rs10761747	ENSG00000232075.1	MRPL35P2	5.21	2.85e-07	4.03e-05	0.34	0.23	Intelligence (multi-trait analysis);	chr10:63348396	chr10:63634317~63634827:-
THCA	cis	rs728616	0.681	rs56184245	ENSG00000242600.5	MBL1P	5.21	2.86e-07	4.04e-05	0.29	0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80258800	chr10:79904898~79950336:+
THCA	cis	rs3096299	0.702	rs2086825	ENSG00000274627.1	RP11-104N10.2	5.21	2.86e-07	4.04e-05	0.24	0.23	Multiple myeloma (IgH translocation);	chr16:89405134	chr16:89516797~89522217:+
THCA	cis	rs6832769	0.767	rs11133394	ENSG00000272969.1	RP11-528I4.2	5.21	2.86e-07	4.04e-05	0.27	0.23	Personality dimensions;	chr4:55517071	chr4:55547112~55547889:+
THCA	cis	rs651907	0.514	rs34301719	ENSG00000244119.1	PDCL3P4	5.21	2.86e-07	4.04e-05	0.22	0.23	Colorectal cancer;	chr3:101699149	chr3:101712472~101713191:+
THCA	cis	rs9816784	0.525	rs3326	ENSG00000242086.7	LINC00969	5.21	2.86e-07	4.04e-05	0.24	0.23	Mean corpuscular hemoglobin;	chr3:196054635	chr3:195658062~195739964:+
THCA	cis	rs16975963	1	rs16975963	ENSG00000226686.6	LINC01535	5.21	2.86e-07	4.04e-05	0.29	0.23	Longevity;	chr19:37834896	chr19:37251912~37265535:+
THCA	cis	rs2067615	0.599	rs12369214	ENSG00000260329.1	RP11-412D9.4	-5.21	2.86e-07	4.04e-05	-0.21	-0.23	Heart rate;	chr12:106804833	chr12:106954029~106955497:-
THCA	cis	rs2235642	0.787	rs2235646	ENSG00000280231.1	LA16c-380F5.3	-5.21	2.86e-07	4.04e-05	-0.28	-0.23	Coronary artery disease;	chr16:1551286	chr16:1553655~1554130:-
THCA	cis	rs875971	0.895	rs12698520	ENSG00000223473.2	GS1-124K5.3	5.21	2.86e-07	4.05e-05	0.16	0.23	Aortic root size;	chr7:66453720	chr7:66491049~66493566:-
THCA	cis	rs2179367	0.632	rs66672129	ENSG00000223701.3	RAET1E-AS1	5.21	2.86e-07	4.05e-05	0.33	0.23	Dupuytren's disease;	chr6:149334387	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498322	ENSG00000223701.3	RAET1E-AS1	5.21	2.86e-07	4.05e-05	0.33	0.23	Dupuytren's disease;	chr6:149335950	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498323	ENSG00000223701.3	RAET1E-AS1	5.21	2.86e-07	4.05e-05	0.33	0.23	Dupuytren's disease;	chr6:149336077	chr6:149884431~149919508:+
THCA	cis	rs7674212	0.57	rs6841136	ENSG00000246560.2	RP11-10L12.4	5.21	2.86e-07	4.05e-05	0.28	0.23	Type 2 diabetes;	chr4:103182352	chr4:102828055~102844075:+
THCA	cis	rs1707322	0.638	rs9429095	ENSG00000234329.1	RP11-767N6.2	-5.21	2.87e-07	4.05e-05	-0.22	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45651039~45651826:-
THCA	cis	rs899997	1	rs7182993	ENSG00000261143.1	ADAMTS7P3	5.21	2.87e-07	4.05e-05	0.31	0.23	Coronary artery disease or large artery stroke;	chr15:78752672	chr15:77976042~77993057:+
THCA	cis	rs899997	1	rs7182694	ENSG00000261143.1	ADAMTS7P3	5.21	2.87e-07	4.05e-05	0.31	0.23	Coronary artery disease or large artery stroke;	chr15:78752688	chr15:77976042~77993057:+
THCA	cis	rs858239	0.539	rs10247268	ENSG00000226816.2	AC005082.12	5.21	2.87e-07	4.05e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs6461694	ENSG00000226816.2	AC005082.12	5.21	2.87e-07	4.05e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23206013~23208045:+
THCA	cis	rs858239	0.508	rs7805071	ENSG00000226816.2	AC005082.12	5.21	2.87e-07	4.05e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23206013~23208045:+
THCA	cis	rs858239	0.508	rs7805085	ENSG00000226816.2	AC005082.12	5.21	2.87e-07	4.05e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23206013~23208045:+
THCA	cis	rs1823913	0.637	rs2356354	ENSG00000280083.1	RP11-317J9.1	5.21	2.87e-07	4.05e-05	0.27	0.23	Obesity-related traits;	chr2:191270970	chr2:191154118~191156070:-
THCA	cis	rs4888671	1	rs57110085	ENSG00000261707.1	RP11-264M12.2	5.21	2.87e-07	4.05e-05	0.43	0.23	Obesity-related traits;	chr16:77749416	chr16:77741468~77743000:-
THCA	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	5.21	2.87e-07	4.05e-05	0.28	0.23	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
THCA	cis	rs2562456	0.754	rs62107469	ENSG00000268081.1	RP11-678G14.2	5.21	2.87e-07	4.05e-05	0.4	0.23	Pain;	chr19:21312699	chr19:21554640~21569237:-
THCA	cis	rs2243480	0.522	rs431168	ENSG00000164669.11	INTS4P1	5.21	2.87e-07	4.05e-05	0.53	0.23	Diabetic kidney disease;	chr7:66046617	chr7:65141225~65234216:+
THCA	cis	rs3782123	0.796	rs2280544	ENSG00000277290.1	RP11-326C3.16	5.21	2.87e-07	4.05e-05	0.26	0.23	Red cell distribution width;Glycated hemoglobin levels;	chr11:204062	chr11:243099~243483:-
THCA	cis	rs3782123	0.796	rs4980319	ENSG00000277290.1	RP11-326C3.16	5.21	2.87e-07	4.05e-05	0.26	0.23	Red cell distribution width;Glycated hemoglobin levels;	chr11:204986	chr11:243099~243483:-
THCA	cis	rs55704346	0.875	rs67839486	ENSG00000281501.1	SEPSECS-AS1	5.21	2.87e-07	4.06e-05	0.26	0.23	Tonsillectomy;	chr4:25172786	chr4:25160641~25201440:+
THCA	cis	rs55704346	0.84	rs10517061	ENSG00000281501.1	SEPSECS-AS1	5.21	2.87e-07	4.06e-05	0.26	0.23	Tonsillectomy;	chr4:25176675	chr4:25160641~25201440:+
THCA	cis	rs6921919	0.583	rs7759191	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs7764737	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs9461458	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.609	rs9468365	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs1361385	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs1416918	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs9468367	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs9461459	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs28360638	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs9468368	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.583	rs2041230	ENSG00000219392.1	RP1-265C24.5	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28115628~28116551:+
THCA	cis	rs17406451	0.587	rs6544646	ENSG00000234936.1	AC010883.5	5.21	2.87e-07	4.06e-05	0.2	0.23	Mitochondrial DNA levels;	chr2:43349858	chr2:43229573~43233394:+
THCA	cis	rs2692947	0.832	rs62153679	ENSG00000232931.4	LINC00342	5.21	2.87e-07	4.06e-05	0.19	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892652	chr2:95807118~95816215:-
THCA	cis	rs11992162	0.967	rs4841661	ENSG00000254948.1	OR7E158P	-5.21	2.87e-07	4.06e-05	-0.29	-0.23	Monocyte count;	chr8:11975260	chr8:11919900~11920809:-
THCA	cis	rs11992162	1	rs11994417	ENSG00000254948.1	OR7E158P	-5.21	2.87e-07	4.06e-05	-0.29	-0.23	Monocyte count;	chr8:11975753	chr8:11919900~11920809:-
THCA	cis	rs9859260	1	rs11718657	ENSG00000231464.1	AC024937.4	5.21	2.87e-07	4.06e-05	0.28	0.23	Mean corpuscular volume;	chr3:196070682	chr3:195996738~195998233:+
THCA	cis	rs9859260	0.961	rs11185506	ENSG00000231464.1	AC024937.4	5.21	2.87e-07	4.06e-05	0.28	0.23	Mean corpuscular volume;	chr3:196070705	chr3:195996738~195998233:+
THCA	cis	rs919433	0.783	rs805497	ENSG00000231621.1	AC013264.2	-5.21	2.87e-07	4.06e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197357824	chr2:197197991~197199273:+
THCA	cis	rs4888671	1	rs4888673	ENSG00000261707.1	RP11-264M12.2	5.21	2.87e-07	4.06e-05	0.43	0.23	Obesity-related traits;	chr16:77749806	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs4888674	ENSG00000261707.1	RP11-264M12.2	5.21	2.87e-07	4.06e-05	0.43	0.23	Obesity-related traits;	chr16:77749852	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs4888675	ENSG00000261707.1	RP11-264M12.2	5.21	2.87e-07	4.06e-05	0.43	0.23	Obesity-related traits;	chr16:77749860	chr16:77741468~77743000:-
THCA	cis	rs4218	0.859	rs1809588	ENSG00000277144.1	RP11-59H7.4	-5.21	2.87e-07	4.06e-05	-0.32	-0.23	Social communication problems;	chr15:59121825	chr15:59115547~59116089:-
THCA	cis	rs10875746	0.903	rs12313404	ENSG00000269514.1	RP11-370I10.12	5.21	2.87e-07	4.06e-05	0.24	0.23	Longevity (90 years and older);	chr12:48098265	chr12:48198387~48202031:+
THCA	cis	rs2179367	0.632	rs9285520	ENSG00000223701.3	RAET1E-AS1	-5.21	2.87e-07	4.06e-05	-0.33	-0.23	Dupuytren's disease;	chr6:149372001	chr6:149884431~149919508:+
THCA	cis	rs752010	0.695	rs10789407	ENSG00000230638.4	RP11-486B10.4	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41640867	chr1:41542069~41544310:+
THCA	cis	rs752010	0.695	rs10789408	ENSG00000230638.4	RP11-486B10.4	-5.21	2.87e-07	4.06e-05	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41640908	chr1:41542069~41544310:+
THCA	cis	rs1823874	0.71	rs1840298	ENSG00000259363.4	CTD-2054N24.2	5.21	2.87e-07	4.06e-05	0.29	0.23	IgG glycosylation;	chr15:99821889	chr15:99807023~99877148:+
THCA	cis	rs1823874	0.71	rs67068917	ENSG00000259363.4	CTD-2054N24.2	5.21	2.87e-07	4.06e-05	0.29	0.23	IgG glycosylation;	chr15:99822310	chr15:99807023~99877148:+
THCA	cis	rs62244186	0.545	rs725866	ENSG00000214820.3	MPRIPP1	5.21	2.87e-07	4.06e-05	0.24	0.23	Depressive symptoms;	chr3:44724041	chr3:44579938~44581026:-
THCA	cis	rs2797160	0.935	rs1739379	ENSG00000237742.5	RP11-624M8.1	5.21	2.88e-07	4.06e-05	0.2	0.23	Endometrial cancer;	chr6:125691447	chr6:125578558~125749190:-
THCA	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	5.21	2.88e-07	4.06e-05	0.35	0.23	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
THCA	cis	rs116095464	0.558	rs62346506	ENSG00000248925.1	CTD-2083E4.6	5.21	2.88e-07	4.07e-05	0.37	0.23	Breast cancer;	chr5:201479	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs9312956	ENSG00000248925.1	CTD-2083E4.6	5.21	2.88e-07	4.07e-05	0.37	0.23	Breast cancer;	chr5:201697	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs62346508	ENSG00000248925.1	CTD-2083E4.6	5.21	2.88e-07	4.07e-05	0.37	0.23	Breast cancer;	chr5:203553	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10059907	ENSG00000248925.1	CTD-2083E4.6	5.21	2.88e-07	4.07e-05	0.37	0.23	Breast cancer;	chr5:205245	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10060089	ENSG00000248925.1	CTD-2083E4.6	5.21	2.88e-07	4.07e-05	0.37	0.23	Breast cancer;	chr5:205450	chr5:269858~271516:-
THCA	cis	rs7119	0.689	rs12907630	ENSG00000259362.2	RP11-307C19.1	-5.21	2.88e-07	4.07e-05	-0.34	-0.23	Type 2 diabetes;	chr15:77520564	chr15:77525540~77534110:+
THCA	cis	rs7246657	0.606	rs2972439	ENSG00000276846.1	CTD-3220F14.3	-5.21	2.88e-07	4.07e-05	-0.24	-0.23	Coronary artery calcification;	chr19:37721680	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.722	rs2909100	ENSG00000276846.1	CTD-3220F14.3	-5.21	2.88e-07	4.07e-05	-0.24	-0.23	Coronary artery calcification;	chr19:37721779	chr19:37314868~37315620:-
THCA	cis	rs6088580	0.567	rs6088520	ENSG00000276073.1	RP5-1125A11.7	5.21	2.88e-07	4.07e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34544560	chr20:33985617~33988989:-
THCA	cis	rs10761482	0.906	rs2199209	ENSG00000254271.1	RP11-131N11.4	5.21	2.88e-07	4.07e-05	0.31	0.23	Schizophrenia;	chr10:60334980	chr10:60734342~60741828:+
THCA	cis	rs4888671	1	rs60923631	ENSG00000261707.1	RP11-264M12.2	5.21	2.88e-07	4.07e-05	0.43	0.23	Obesity-related traits;	chr16:77749472	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs4888671	ENSG00000261707.1	RP11-264M12.2	5.21	2.88e-07	4.07e-05	0.43	0.23	Obesity-related traits;	chr16:77749683	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs4888672	ENSG00000261707.1	RP11-264M12.2	5.21	2.88e-07	4.07e-05	0.43	0.23	Obesity-related traits;	chr16:77749769	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs4888676	ENSG00000261707.1	RP11-264M12.2	5.21	2.88e-07	4.07e-05	0.43	0.23	Obesity-related traits;	chr16:77749999	chr16:77741468~77743000:-
THCA	cis	rs752010	0.695	rs12123834	ENSG00000230638.4	RP11-486B10.4	-5.21	2.89e-07	4.08e-05	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41640056	chr1:41542069~41544310:+
THCA	cis	rs752010	0.695	rs12134166	ENSG00000230638.4	RP11-486B10.4	-5.21	2.89e-07	4.08e-05	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41640196	chr1:41542069~41544310:+
THCA	cis	rs919433	0.589	rs7601800	ENSG00000231621.1	AC013264.2	-5.21	2.89e-07	4.08e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197530375	chr2:197197991~197199273:+
THCA	cis	rs757978	0.733	rs11689496	ENSG00000223374.1	AC005104.3	5.21	2.89e-07	4.08e-05	0.23	0.23	Chronic lymphocytic leukemia;	chr2:241486984	chr2:241351340~241353104:-
THCA	cis	rs9300255	0.596	rs1727331	ENSG00000256092.2	RP13-942N8.1	-5.21	2.89e-07	4.08e-05	-0.18	-0.23	Neutrophil percentage of white cells;	chr12:123234332	chr12:123363868~123366113:+
THCA	cis	rs9733	0.519	rs6700022	ENSG00000231073.1	RP11-316M1.3	-5.21	2.89e-07	4.08e-05	-0.28	-0.23	Tonsillectomy;	chr1:150698008	chr1:150973123~150975534:+
THCA	cis	rs890448	0.86	rs6826588	ENSG00000254531.1	FLJ20021	-5.21	2.89e-07	4.08e-05	-0.21	-0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101481713	chr4:101347780~101348883:+
THCA	cis	rs67340775	0.541	rs200966	ENSG00000226314.6	ZNF192P1	-5.21	2.89e-07	4.08e-05	-0.35	-0.23	Lung cancer in ever smokers;	chr6:27894374	chr6:28161781~28169594:+
THCA	cis	rs7976269	0.609	rs2196482	ENSG00000275476.1	RP11-996F15.4	-5.21	2.89e-07	4.08e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29052559	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs2217906	ENSG00000275476.1	RP11-996F15.4	-5.21	2.89e-07	4.08e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29052626	chr12:29277397~29277882:-
THCA	cis	rs4660456	0.913	rs656230	ENSG00000272145.1	NFYC-AS1	-5.21	2.89e-07	4.08e-05	-0.16	-0.23	Platelet count;	chr1:40692701	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs2780953	ENSG00000272145.1	NFYC-AS1	-5.21	2.89e-07	4.08e-05	-0.16	-0.23	Platelet count;	chr1:40694105	chr1:40690380~40692066:-
THCA	cis	rs7618915	0.508	rs7628578	ENSG00000243224.1	RP5-1157M23.2	-5.21	2.89e-07	4.08e-05	-0.25	-0.23	Bipolar disorder;	chr3:52594305	chr3:52239258~52241097:+
THCA	cis	rs860295	0.702	rs12043132	ENSG00000160766.13	GBAP1	-5.21	2.89e-07	4.08e-05	-0.27	-0.23	Body mass index;	chr1:155592576	chr1:155213821~155227422:-
THCA	cis	rs9467773	1	rs4713008	ENSG00000261353.1	CTA-14H9.5	-5.21	2.89e-07	4.09e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9467782	ENSG00000261353.1	CTA-14H9.5	-5.21	2.89e-07	4.09e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.935	rs9461270	ENSG00000261353.1	CTA-14H9.5	-5.21	2.89e-07	4.09e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26527063~26527404:+
THCA	cis	rs6539288	0.674	rs4964494	ENSG00000260329.1	RP11-412D9.4	-5.21	2.89e-07	4.09e-05	-0.21	-0.23	Total body bone mineral density;	chr12:106890682	chr12:106954029~106955497:-
THCA	cis	rs34779708	0.931	rs35848945	ENSG00000271335.4	RP11-324I22.4	5.21	2.89e-07	4.09e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35314552~35336401:-
THCA	cis	rs654950	0.967	rs621727	ENSG00000230638.4	RP11-486B10.4	5.21	2.89e-07	4.09e-05	0.26	0.23	Airway imaging phenotypes;	chr1:41518941	chr1:41542069~41544310:+
THCA	cis	rs7617773	0.817	rs34225441	ENSG00000199476.1	Y_RNA	-5.21	2.89e-07	4.09e-05	-0.3	-0.23	Coronary artery disease;	chr3:48267401	chr3:48288587~48288694:+
THCA	cis	rs17772222	0.582	rs11625009	ENSG00000222990.1	RNU4-22P	-5.21	2.89e-07	4.09e-05	-0.29	-0.23	Coronary artery calcification;	chr14:88521018	chr14:88513498~88513663:+
THCA	cis	rs7727544	0.636	rs2631365	ENSG00000263597.1	MIR3936	-5.21	2.9e-07	4.09e-05	-0.22	-0.23	Blood metabolite levels;	chr5:132370257	chr5:132365490~132365599:-
THCA	cis	rs9494145	0.526	rs62429812	ENSG00000232876.1	CTA-212D2.2	-5.21	2.9e-07	4.09e-05	-0.36	-0.23	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135159009	chr6:135055033~135060550:+
THCA	cis	rs8027521	0.905	rs1841946	ENSG00000280362.1	RP11-643A5.3	5.21	2.9e-07	4.09e-05	0.28	0.23	Circulating chemerin levels;	chr15:53977914	chr15:53910769~53914712:+
THCA	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	5.21	2.9e-07	4.09e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
THCA	cis	rs7429990	0.965	rs2631721	ENSG00000228638.1	FCF1P2	-5.21	2.9e-07	4.1e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47881807	chr3:48290793~48291375:-
THCA	cis	rs972578	0.702	rs2092212	ENSG00000274717.1	RP1-47A17.1	-5.21	2.9e-07	4.1e-05	-0.24	-0.23	Mean platelet volume;	chr22:42922942	chr22:42791814~42794313:-
THCA	cis	rs10411161	0.63	rs76234335	ENSG00000275055.1	CTC-471J1.11	-5.21	2.9e-07	4.1e-05	-0.33	-0.23	Breast cancer;	chr19:51954215	chr19:52049007~52049754:+
THCA	cis	rs7045881	0.675	rs17694499	ENSG00000254396.1	RP11-56F10.3	5.21	2.9e-07	4.1e-05	0.43	0.23	Schizophrenia;	chr9:26990828	chr9:27102630~27104728:+
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000230295.1	RP11-458F8.2	5.2	2.91e-07	4.1e-05	0.28	0.23	Diabetic kidney disease;	chr7:66158142	chr7:66880708~66882981:+
THCA	cis	rs2436845	0.934	rs2436865	ENSG00000253669.3	KB-1732A1.1	-5.2	2.91e-07	4.1e-05	-0.24	-0.23	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102806542	chr8:102805517~102809971:+
THCA	cis	rs2880765	0.835	rs7162502	ENSG00000259630.2	CTD-2262B20.1	-5.2	2.91e-07	4.1e-05	-0.25	-0.23	Coronary artery disease;	chr15:85501242	chr15:85415228~85415633:+
THCA	cis	rs5015933	0.815	rs13297440	ENSG00000232630.1	PRPS1P2	-5.2	2.91e-07	4.1e-05	-0.17	-0.23	Body mass index;	chr9:125324921	chr9:125150653~125151589:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000223473.2	GS1-124K5.3	5.2	2.91e-07	4.1e-05	0.16	0.23	Aortic root size;	chr7:66473171	chr7:66491049~66493566:-
THCA	cis	rs7119	0.717	rs62009069	ENSG00000259362.2	RP11-307C19.1	-5.2	2.91e-07	4.1e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77525535	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs62009070	ENSG00000259362.2	RP11-307C19.1	-5.2	2.91e-07	4.1e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77525542	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs62009071	ENSG00000259362.2	RP11-307C19.1	-5.2	2.91e-07	4.1e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77525544	chr15:77525540~77534110:+
THCA	cis	rs9813712	0.574	rs11718032	ENSG00000253540.4	FAM86HP	5.2	2.91e-07	4.11e-05	0.25	0.23	Response to amphetamines;	chr3:130257749	chr3:130099092~130111472:-
THCA	cis	rs9818758	0.607	rs113186424	ENSG00000270441.1	RP11-694I15.7	5.2	2.91e-07	4.11e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49235293	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs34784192	ENSG00000270441.1	RP11-694I15.7	5.2	2.91e-07	4.11e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49237390	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs9850917	ENSG00000270441.1	RP11-694I15.7	5.2	2.91e-07	4.11e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49249550	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs9847839	ENSG00000270441.1	RP11-694I15.7	5.2	2.91e-07	4.11e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49251570	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs12715434	ENSG00000270441.1	RP11-694I15.7	5.2	2.91e-07	4.11e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49257592	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs9311439	ENSG00000270441.1	RP11-694I15.7	5.2	2.91e-07	4.11e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272975	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs67831908	ENSG00000270441.1	RP11-694I15.7	5.2	2.91e-07	4.11e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276080	chr3:49140086~49160851:-
THCA	cis	rs17123764	0.818	rs4045193	ENSG00000257464.1	RP11-161H23.8	-5.2	2.91e-07	4.11e-05	-0.37	-0.23	Intelligence (multi-trait analysis);	chr12:49610197	chr12:49442424~49442652:-
THCA	cis	rs10090774	0.841	rs13438888	ENSG00000279766.1	RP11-642A1.2	5.2	2.91e-07	4.11e-05	0.29	0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140831843	chr8:140572142~140572812:-
THCA	cis	rs494453	0.6	rs575208	ENSG00000227811.2	FAM212B-AS1	-5.2	2.91e-07	4.11e-05	-0.29	-0.23	Osteoporosis-related phenotypes;	chr1:111663769	chr1:111739841~111747798:+
THCA	cis	rs593531	0.571	rs7934621	ENSG00000255440.1	RP11-632K5.2	5.2	2.91e-07	4.11e-05	0.28	0.23	Neuroticism;	chr11:74379883	chr11:74409060~74416379:+
THCA	cis	rs12893668	0.703	rs34186780	ENSG00000269958.1	RP11-73M18.8	5.2	2.91e-07	4.11e-05	0.23	0.23	Reticulocyte count;	chr14:103561258	chr14:103696353~103697163:+
THCA	cis	rs9859260	1	rs9859401	ENSG00000231464.1	AC024937.4	5.2	2.91e-07	4.11e-05	0.28	0.23	Mean corpuscular volume;	chr3:196073732	chr3:195996738~195998233:+
THCA	cis	rs7209700	0.821	rs2292863	ENSG00000228782.6	CTD-2026D20.3	-5.2	2.91e-07	4.11e-05	-0.24	-0.23	IgG glycosylation;	chr17:47291764	chr17:47450568~47492492:-
THCA	cis	rs7209700	0.821	rs4642	ENSG00000228782.6	CTD-2026D20.3	-5.2	2.91e-07	4.11e-05	-0.24	-0.23	IgG glycosylation;	chr17:47292411	chr17:47450568~47492492:-
THCA	cis	rs7209700	0.821	rs4634	ENSG00000228782.6	CTD-2026D20.3	-5.2	2.91e-07	4.11e-05	-0.24	-0.23	IgG glycosylation;	chr17:47292423	chr17:47450568~47492492:-
THCA	cis	rs763121	0.651	rs738249	ENSG00000235209.1	CTA-150C2.13	5.2	2.91e-07	4.11e-05	0.31	0.23	Menopause (age at onset);	chr22:38641974	chr22:38921227~38924708:+
THCA	cis	rs858239	0.539	rs2103281	ENSG00000226816.2	AC005082.12	5.2	2.91e-07	4.11e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23206013~23208045:+
THCA	cis	rs28476539	0.567	rs17006038	ENSG00000270480.1	RP11-57B24.1	-5.2	2.91e-07	4.11e-05	-0.37	-0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82654754	chr4:82691737~82692468:+
THCA	cis	rs7924176	0.521	rs10762599	ENSG00000213731.2	RAB5CP1	-5.2	2.91e-07	4.11e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:74423435~74424014:-
THCA	cis	rs853679	0.766	rs9368561	ENSG00000272009.1	RP1-313I6.12	-5.2	2.92e-07	4.11e-05	-0.35	-0.23	Depression;	chr6:28200565	chr6:28078792~28081130:-
THCA	cis	rs12935418	0.616	rs2602446	ENSG00000278985.1	RP11-303E16.9	-5.2	2.92e-07	4.12e-05	-0.25	-0.23	Mean corpuscular volume;	chr16:80984310	chr16:80982319~80984094:-
THCA	cis	rs9834975	0.873	rs9882772	ENSG00000272758.4	RP11-299J3.8	-5.2	2.92e-07	4.12e-05	-0.22	-0.23	Diastolic blood pressure;	chr3:122391302	chr3:122416207~122443180:+
THCA	cis	rs34779708	0.931	rs34304999	ENSG00000271335.4	RP11-324I22.4	5.2	2.92e-07	4.12e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35314552~35336401:-
THCA	cis	rs2554380	0.55	rs12904106	ENSG00000230373.7	GOLGA6L5P	-5.2	2.92e-07	4.12e-05	-0.26	-0.23	Height;	chr15:83842571	chr15:84507885~84516814:-
THCA	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	5.2	2.92e-07	4.12e-05	0.3	0.23	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
THCA	cis	rs2282300	1	rs12799529	ENSG00000242353.1	RP4-710M3.1	-5.2	2.92e-07	4.12e-05	-0.22	-0.23	Morning vs. evening chronotype;	chr11:30387005	chr11:30368148~30368646:+
THCA	cis	rs12681288	0.676	rs17740799	ENSG00000260721.1	AF067845.1	-5.2	2.92e-07	4.12e-05	-0.29	-0.23	Schizophrenia;	chr8:1064327	chr8:1368642~1369833:-
THCA	cis	rs1552244	1	rs9881859	ENSG00000180385.7	EMC3-AS1	5.2	2.92e-07	4.12e-05	0.26	0.23	Alzheimer's disease;	chr3:10031130	chr3:9986893~10006990:+
THCA	cis	rs10208649	0.505	rs9309252	ENSG00000272156.1	RP11-477N3.1	5.2	2.92e-07	4.12e-05	0.3	0.23	Body mass index;	chr2:53938635	chr2:54082554~54085066:+
THCA	cis	rs800160	0.748	rs800149	ENSG00000199550.1	Y_RNA	5.2	2.92e-07	4.12e-05	0.36	0.23	Bacteremia;	chr11:2349493	chr11:2372638~2372750:+
THCA	cis	rs7045881	0.733	rs10511795	ENSG00000254396.1	RP11-56F10.3	5.2	2.92e-07	4.13e-05	0.43	0.23	Schizophrenia;	chr9:26953104	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.733	rs10511797	ENSG00000254396.1	RP11-56F10.3	5.2	2.92e-07	4.13e-05	0.43	0.23	Schizophrenia;	chr9:26955663	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.733	rs1541145	ENSG00000254396.1	RP11-56F10.3	5.2	2.92e-07	4.13e-05	0.43	0.23	Schizophrenia;	chr9:26956665	chr9:27102630~27104728:+
THCA	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	5.2	2.93e-07	4.13e-05	0.14	0.23	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
THCA	cis	rs10895987	0.531	rs11227118	ENSG00000254614.2	AP003068.23	5.2	2.93e-07	4.13e-05	0.32	0.23	Blood protein levels;	chr11:65093183	chr11:65177606~65181834:-
THCA	cis	rs6058796	0.681	rs28529295	ENSG00000175730.8	BAK1P1	5.2	2.93e-07	4.13e-05	0.35	0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32686866	chr20:32690180~32690815:-
THCA	cis	rs944289	0.74	rs404131	ENSG00000258844.1	RP11-259K15.2	-5.2	2.93e-07	4.13e-05	-0.21	-0.23	Thyroid cancer;	chr14:36075287	chr14:36214607~36235608:+
THCA	cis	rs7617773	0.817	rs13094727	ENSG00000199476.1	Y_RNA	-5.2	2.93e-07	4.13e-05	-0.3	-0.23	Coronary artery disease;	chr3:48281999	chr3:48288587~48288694:+
THCA	cis	rs2880765	0.835	rs7180213	ENSG00000259630.2	CTD-2262B20.1	-5.2	2.93e-07	4.13e-05	-0.25	-0.23	Coronary artery disease;	chr15:85477956	chr15:85415228~85415633:+
THCA	cis	rs875971	0.545	rs6961853	ENSG00000232546.1	RP11-458F8.1	5.2	2.93e-07	4.14e-05	0.22	0.23	Aortic root size;	chr7:66537035	chr7:66848496~66858136:+
THCA	cis	rs12188164	0.61	rs57433159	ENSG00000225138.6	CTD-2228K2.7	5.2	2.93e-07	4.14e-05	0.25	0.23	Cystic fibrosis severity;	chr5:418610	chr5:473236~480884:+
THCA	cis	rs875971	0.502	rs2465121	ENSG00000232546.1	RP11-458F8.1	-5.2	2.93e-07	4.14e-05	-0.22	-0.23	Aortic root size;	chr7:66156017	chr7:66848496~66858136:+
THCA	cis	rs1552244	1	rs35198334	ENSG00000180385.7	EMC3-AS1	5.2	2.93e-07	4.14e-05	0.26	0.23	Alzheimer's disease;	chr3:10062869	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs7652190	ENSG00000180385.7	EMC3-AS1	5.2	2.93e-07	4.14e-05	0.26	0.23	Alzheimer's disease;	chr3:10063466	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs7619340	ENSG00000180385.7	EMC3-AS1	5.2	2.93e-07	4.14e-05	0.26	0.23	Alzheimer's disease;	chr3:10066494	chr3:9986893~10006990:+
THCA	cis	rs79040073	0.607	rs17479205	ENSG00000259531.2	RP11-295H24.3	5.2	2.94e-07	4.14e-05	0.3	0.23	Lung cancer in ever smokers;	chr15:49456065	chr15:49365124~49366685:-
THCA	cis	rs7045881	0.733	rs73436012	ENSG00000254396.1	RP11-56F10.3	5.2	2.94e-07	4.14e-05	0.42	0.23	Schizophrenia;	chr9:26979521	chr9:27102630~27104728:+
THCA	cis	rs919433	0.68	rs788023	ENSG00000231621.1	AC013264.2	-5.2	2.94e-07	4.14e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197418581	chr2:197197991~197199273:+
THCA	cis	rs919433	0.68	rs2565161	ENSG00000231621.1	AC013264.2	-5.2	2.94e-07	4.14e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197420830	chr2:197197991~197199273:+
THCA	cis	rs919433	0.68	rs2565160	ENSG00000231621.1	AC013264.2	-5.2	2.94e-07	4.14e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197421750	chr2:197197991~197199273:+
THCA	cis	rs919433	0.68	rs2244271	ENSG00000231621.1	AC013264.2	-5.2	2.94e-07	4.14e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197421857	chr2:197197991~197199273:+
THCA	cis	rs5769765	0.542	rs5770725	ENSG00000260613.1	RP3-522J7.6	5.2	2.94e-07	4.14e-05	0.33	0.23	Schizophrenia;	chr22:49862661	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.505	rs4561759	ENSG00000260613.1	RP3-522J7.6	5.2	2.94e-07	4.14e-05	0.33	0.23	Schizophrenia;	chr22:49863038	chr22:49832616~49837786:-
THCA	cis	rs7924176	0.521	rs1904062	ENSG00000213731.2	RAB5CP1	-5.2	2.94e-07	4.14e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:74423435~74424014:-
THCA	cis	rs9859260	1	rs2300778	ENSG00000273009.1	RP11-352G9.1	-5.2	2.94e-07	4.14e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196063866	chr3:195913078~195913683:-
THCA	cis	rs9859260	1	rs2300777	ENSG00000273009.1	RP11-352G9.1	-5.2	2.94e-07	4.14e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196063940	chr3:195913078~195913683:-
THCA	cis	rs2360027	0.599	rs4590660	ENSG00000231365.4	RP11-418J17.1	-5.2	2.94e-07	4.14e-05	-0.23	-0.23	Tonsillectomy;	chr1:118542459	chr1:119140396~119275973:+
THCA	cis	rs7674212	0.541	rs2615539	ENSG00000246560.2	RP11-10L12.4	5.2	2.94e-07	4.14e-05	0.28	0.23	Type 2 diabetes;	chr4:103159949	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.622	rs1292333	ENSG00000270638.1	RP3-466P17.1	-5.2	2.94e-07	4.15e-05	-0.19	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145735570~145737218:+
THCA	cis	rs516805	0.528	rs2679709	ENSG00000279453.1	RP3-425C14.4	-5.2	2.94e-07	4.15e-05	-0.25	-0.23	Lymphocyte counts;	chr6:122080783	chr6:122436789~122439223:-
THCA	cis	rs2797160	0.935	rs1739372	ENSG00000237742.5	RP11-624M8.1	5.2	2.94e-07	4.15e-05	0.2	0.23	Endometrial cancer;	chr6:125690179	chr6:125578558~125749190:-
THCA	cis	rs1580019	0.587	rs7806941	ENSG00000231952.3	DPY19L1P2	-5.2	2.94e-07	4.15e-05	-0.29	-0.23	Cognitive ability;	chr7:32513707	chr7:32812757~32838570:+
THCA	cis	rs34779708	0.931	rs2384287	ENSG00000271335.4	RP11-324I22.4	5.2	2.94e-07	4.15e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35314552~35336401:-
THCA	cis	rs2361718	0.5	rs4889970	ENSG00000275479.1	RP11-334C17.6	-5.2	2.94e-07	4.15e-05	-0.22	-0.23	Yeast infection;	chr17:80122287	chr17:80149627~80149798:+
THCA	cis	rs72799341	1	rs7185007	ENSG00000260911.2	RP11-196G11.2	5.2	2.94e-07	4.15e-05	0.23	0.23	Diastolic blood pressure;	chr16:30916188	chr16:31043150~31049868:+
THCA	cis	rs7924176	0.58	rs12360119	ENSG00000213731.2	RAB5CP1	-5.2	2.94e-07	4.15e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74423435~74424014:-
THCA	cis	rs228614	0.536	rs223477	ENSG00000248971.2	KRT8P46	-5.2	2.94e-07	4.15e-05	-0.29	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102728746~102730171:-
THCA	cis	rs858239	0.508	rs2390754	ENSG00000226816.2	AC005082.12	5.2	2.95e-07	4.16e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23206013~23208045:+
THCA	cis	rs7927592	0.513	rs901823	ENSG00000212093.1	AP000807.1	5.2	2.95e-07	4.16e-05	0.24	0.23	Total body bone mineral density;	chr11:68438110	chr11:68506083~68506166:-
THCA	cis	rs1552244	1	rs113134644	ENSG00000180385.7	EMC3-AS1	5.2	2.95e-07	4.16e-05	0.26	0.23	Alzheimer's disease;	chr3:10044602	chr3:9986893~10006990:+
THCA	cis	rs1426063	0.858	rs11936768	ENSG00000260265.1	RP11-44F21.5	5.2	2.95e-07	4.16e-05	0.42	0.23	QT interval;	chr4:75084506	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.858	rs72662426	ENSG00000260265.1	RP11-44F21.5	5.2	2.95e-07	4.16e-05	0.42	0.23	QT interval;	chr4:75084828	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.858	rs6837969	ENSG00000260265.1	RP11-44F21.5	5.2	2.95e-07	4.16e-05	0.42	0.23	QT interval;	chr4:75085005	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.858	rs6843217	ENSG00000260265.1	RP11-44F21.5	5.2	2.95e-07	4.16e-05	0.42	0.23	QT interval;	chr4:75085201	chr4:75081702~75084717:-
THCA	cis	rs801193	0.548	rs2659904	ENSG00000223473.2	GS1-124K5.3	5.2	2.95e-07	4.16e-05	0.16	0.23	Aortic root size;	chr7:66713615	chr7:66491049~66493566:-
THCA	cis	rs1707322	1	rs12124847	ENSG00000281133.1	AL355480.3	-5.2	2.95e-07	4.16e-05	-0.29	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45580892~45580996:-
THCA	cis	rs9425766	0.679	rs6691711	ENSG00000227373.4	RP11-160H22.5	5.2	2.95e-07	4.16e-05	0.33	0.23	Life satisfaction;	chr1:174100283	chr1:174115300~174160004:-
THCA	cis	rs12681288	0.676	rs6983981	ENSG00000260721.1	AF067845.1	5.2	2.95e-07	4.16e-05	0.29	0.23	Schizophrenia;	chr8:1066011	chr8:1368642~1369833:-
THCA	cis	rs875971	0.522	rs1701760	ENSG00000223473.2	GS1-124K5.3	5.2	2.95e-07	4.16e-05	0.16	0.23	Aortic root size;	chr7:66008701	chr7:66491049~66493566:-
THCA	cis	rs2447820	0.5	rs39818	ENSG00000249996.1	RP11-359P5.1	5.2	2.95e-07	4.16e-05	0.27	0.23	Migraine;	chr5:122968743	chr5:123036271~123054667:+
THCA	cis	rs304029	0.716	rs2307068	ENSG00000231249.1	ITPR1-AS1	5.2	2.95e-07	4.16e-05	0.16	0.23	Diabetic kidney disease;	chr3:4491276	chr3:4490891~4493163:-
THCA	cis	rs11096990	0.855	rs57488936	ENSG00000249685.1	RP11-360F5.3	-5.2	2.95e-07	4.16e-05	-0.3	-0.23	Cognitive function;	chr4:39220626	chr4:39133913~39135608:+
THCA	cis	rs332034	0.508	rs1510933	ENSG00000253893.2	FAM85B	-5.2	2.95e-07	4.17e-05	-0.38	-0.23	Conduct disorder (maternal expressed emotions interaction);	chr8:8835030	chr8:8167819~8226614:-
THCA	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-5.2	2.96e-07	4.17e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
THCA	cis	rs9527	0.637	rs7096169	ENSG00000236937.2	PTGES3P4	5.2	2.96e-07	4.17e-05	0.31	0.23	Arsenic metabolism;	chr10:102858938	chr10:102845595~102845950:+
THCA	cis	rs2797160	1	rs1739374	ENSG00000237742.5	RP11-624M8.1	5.2	2.96e-07	4.17e-05	0.2	0.23	Endometrial cancer;	chr6:125690679	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1739380	ENSG00000237742.5	RP11-624M8.1	5.2	2.96e-07	4.17e-05	0.2	0.23	Endometrial cancer;	chr6:125691712	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1630556	ENSG00000237742.5	RP11-624M8.1	5.2	2.96e-07	4.17e-05	0.2	0.23	Endometrial cancer;	chr6:125692009	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.967	rs1777182	ENSG00000237742.5	RP11-624M8.1	5.2	2.96e-07	4.17e-05	0.2	0.23	Endometrial cancer;	chr6:125692468	chr6:125578558~125749190:-
THCA	cis	rs4660456	0.913	rs6668453	ENSG00000272145.1	NFYC-AS1	5.2	2.96e-07	4.17e-05	0.16	0.23	Platelet count;	chr1:40733299	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs35881320	ENSG00000272145.1	NFYC-AS1	5.2	2.96e-07	4.17e-05	0.16	0.23	Platelet count;	chr1:40733893	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.871	rs34512220	ENSG00000272145.1	NFYC-AS1	5.2	2.96e-07	4.17e-05	0.16	0.23	Platelet count;	chr1:40733912	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs6702983	ENSG00000272145.1	NFYC-AS1	5.2	2.96e-07	4.17e-05	0.16	0.23	Platelet count;	chr1:40735585	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs12566733	ENSG00000272145.1	NFYC-AS1	5.2	2.96e-07	4.17e-05	0.16	0.23	Platelet count;	chr1:40736067	chr1:40690380~40692066:-
THCA	cis	rs9467773	1	rs1884946	ENSG00000261353.1	CTA-14H9.5	-5.2	2.96e-07	4.17e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26527063~26527404:+
THCA	cis	rs7809950	0.678	rs2237659	ENSG00000238832.1	snoU109	5.2	2.96e-07	4.17e-05	0.29	0.23	Coronary artery disease;	chr7:107207047	chr7:107603363~107603507:+
THCA	cis	rs10208649	1	rs10199444	ENSG00000233266.1	HMGB1P31	5.2	2.96e-07	4.17e-05	0.53	0.23	Body mass index;	chr2:53934939	chr2:54051334~54051760:+
THCA	cis	rs73242632	0.881	rs55734441	ENSG00000269949.1	RP11-738E22.3	5.2	2.96e-07	4.17e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:56967551	chr4:56960927~56961373:-
THCA	cis	rs4950322	0.57	rs4950409	ENSG00000226015.2	CCT8P1	5.2	2.96e-07	4.17e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147335879	chr1:147203276~147204932:-
THCA	cis	rs150992	0.536	rs10479348	ENSG00000248489.1	CTD-2007H13.3	-5.2	2.96e-07	4.18e-05	-0.25	-0.23	Body mass index;	chr5:99013022	chr5:98929171~98995013:+
THCA	cis	rs6840360	0.87	rs6814554	ENSG00000251611.1	RP11-610P16.1	-5.2	2.96e-07	4.18e-05	-0.17	-0.23	Intelligence (multi-trait analysis);	chr4:151533182	chr4:151407551~151408835:-
THCA	cis	rs875971	0.545	rs17138149	ENSG00000232546.1	RP11-458F8.1	5.2	2.97e-07	4.18e-05	0.22	0.23	Aortic root size;	chr7:66228193	chr7:66848496~66858136:+
THCA	cis	rs7119	0.717	rs12916682	ENSG00000259362.2	RP11-307C19.1	-5.2	2.97e-07	4.18e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77515595	chr15:77525540~77534110:+
THCA	cis	rs2797160	0.967	rs6910786	ENSG00000237742.5	RP11-624M8.1	5.2	2.97e-07	4.18e-05	0.2	0.23	Endometrial cancer;	chr6:125695995	chr6:125578558~125749190:-
THCA	cis	rs1858037	0.867	rs6727013	ENSG00000234255.7	AC012370.3	5.2	2.97e-07	4.18e-05	0.28	0.23	Rheumatoid arthritis;	chr2:65331241	chr2:65439888~65456571:-
THCA	cis	rs651907	0.557	rs7651406	ENSG00000244119.1	PDCL3P4	5.2	2.97e-07	4.18e-05	0.21	0.23	Colorectal cancer;	chr3:101674452	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs3864012	ENSG00000244119.1	PDCL3P4	5.2	2.97e-07	4.18e-05	0.21	0.23	Colorectal cancer;	chr3:101678779	chr3:101712472~101713191:+
THCA	cis	rs17270561	0.779	rs17271767	ENSG00000272462.2	U91328.19	-5.2	2.97e-07	4.18e-05	-0.22	-0.23	Iron status biomarkers;	chr6:25886693	chr6:25992662~26001775:+
THCA	cis	rs2179367	0.632	rs9485389	ENSG00000223701.3	RAET1E-AS1	-5.2	2.97e-07	4.18e-05	-0.34	-0.23	Dupuytren's disease;	chr6:149420078	chr6:149884431~149919508:+
THCA	cis	rs2554380	0.527	rs7164782	ENSG00000230373.7	GOLGA6L5P	-5.2	2.97e-07	4.18e-05	-0.26	-0.23	Height;	chr15:83833447	chr15:84507885~84516814:-
THCA	cis	rs442309	0.553	rs7088592	ENSG00000238280.1	RP11-436D10.3	-5.2	2.97e-07	4.18e-05	-0.3	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62721530	chr10:62793562~62805887:-
THCA	cis	rs6714710	0.603	rs2044458	ENSG00000230606.9	AC159540.1	-5.2	2.97e-07	4.19e-05	-0.26	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97761049	chr2:97416165~97433527:-
THCA	cis	rs73108077	0.688	rs6119825	ENSG00000277112.2	RP11-755J8.1	-5.2	2.97e-07	4.19e-05	-0.37	-0.23	Red blood cell density in sickle cell anemia;	chr20:31326768	chr20:30681825~30723932:-
THCA	cis	rs2708377	0.656	rs116607079	ENSG00000212125.2	TAS2R15P	5.2	2.97e-07	4.19e-05	0.37	0.23	Bitter taste perception;	chr12:11109445	chr12:10964425~10965352:-
THCA	cis	rs2708377	0.929	rs73066828	ENSG00000212125.2	TAS2R15P	5.2	2.97e-07	4.19e-05	0.37	0.23	Bitter taste perception;	chr12:11118055	chr12:10964425~10965352:-
THCA	cis	rs2708377	0.656	rs73066852	ENSG00000212125.2	TAS2R15P	5.2	2.97e-07	4.19e-05	0.37	0.23	Bitter taste perception;	chr12:11123942	chr12:10964425~10965352:-
THCA	cis	rs2708377	0.858	rs117212341	ENSG00000212125.2	TAS2R15P	5.2	2.97e-07	4.19e-05	0.37	0.23	Bitter taste perception;	chr12:11129957	chr12:10964425~10965352:-
THCA	cis	rs2708377	0.858	rs115781584	ENSG00000212125.2	TAS2R15P	5.2	2.97e-07	4.19e-05	0.37	0.23	Bitter taste perception;	chr12:11151961	chr12:10964425~10965352:-
THCA	cis	rs2797160	1	rs1739377	ENSG00000237742.5	RP11-624M8.1	5.2	2.97e-07	4.19e-05	0.2	0.23	Endometrial cancer;	chr6:125691090	chr6:125578558~125749190:-
THCA	cis	rs17123764	0.71	rs11169118	ENSG00000257464.1	RP11-161H23.8	-5.2	2.97e-07	4.19e-05	-0.37	-0.23	Intelligence (multi-trait analysis);	chr12:49708752	chr12:49442424~49442652:-
THCA	cis	rs9326248	0.53	rs10750101	ENSG00000280143.1	AP000892.6	5.2	2.97e-07	4.19e-05	0.37	0.23	Blood protein levels;	chr11:117108973	chr11:117204967~117210292:+
THCA	cis	rs375066	0.592	rs349047	ENSG00000267058.1	RP11-15A1.3	5.2	2.97e-07	4.19e-05	0.21	0.23	Breast cancer;	chr19:43796732	chr19:43891804~43901805:-
THCA	cis	rs6714710	0.58	rs11680018	ENSG00000230606.9	AC159540.1	-5.2	2.97e-07	4.19e-05	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97863118	chr2:97416165~97433527:-
THCA	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	5.2	2.98e-07	4.19e-05	0.4	0.23	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
THCA	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	5.2	2.98e-07	4.19e-05	0.4	0.23	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
THCA	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-5.2	2.98e-07	4.2e-05	-0.36	-0.23	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
THCA	cis	rs2120243	0.539	rs1585080	ENSG00000244515.1	KRT18P34	-5.2	2.98e-07	4.2e-05	-0.28	-0.23	Hepatocellular carcinoma in hepatitis B infection;	chr3:157389193	chr3:157162663~157163932:-
THCA	cis	rs9595908	0.9	rs9595883	ENSG00000212293.1	SNORA16	5.2	2.98e-07	4.2e-05	0.27	0.23	Body mass index;	chr13:32593563	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.9	rs1324415	ENSG00000212293.1	SNORA16	5.2	2.98e-07	4.2e-05	0.27	0.23	Body mass index;	chr13:32600186	chr13:32420390~32420516:-
THCA	cis	rs7674212	0.57	rs6813563	ENSG00000246560.2	RP11-10L12.4	5.2	2.98e-07	4.2e-05	0.28	0.23	Type 2 diabetes;	chr4:103177953	chr4:102828055~102844075:+
THCA	cis	rs72772090	1	rs56116814	ENSG00000248734.2	CTD-2260A17.1	-5.2	2.98e-07	4.2e-05	-0.38	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96713010	chr5:96784777~96785999:+
THCA	cis	rs4663866	0.901	rs35390666	ENSG00000186235.9	AC016757.3	5.2	2.98e-07	4.2e-05	0.51	0.23	Irritable bowel syndrome;	chr2:238284937	chr2:238224552~238231677:-
THCA	cis	rs9467773	1	rs10214634	ENSG00000261353.1	CTA-14H9.5	-5.2	2.98e-07	4.2e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26527063~26527404:+
THCA	cis	rs9677476	0.731	rs28690417	ENSG00000224376.1	AC017104.6	5.2	2.98e-07	4.2e-05	0.29	0.23	Food antigen IgG levels;	chr2:231199468	chr2:231388976~231394991:+
THCA	cis	rs874628	0.95	rs1044821	ENSG00000268650.3	AC068499.10	5.2	2.98e-07	4.2e-05	0.26	0.23	Multiple sclerosis;	chr19:18196298	chr19:18204730~18220480:+
THCA	cis	rs481331	0.741	rs210282	ENSG00000215146.4	RP11-313J2.1	-5.2	2.98e-07	4.2e-05	-0.38	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42592201	chr10:42331866~42367974:-
THCA	cis	rs481331	0.741	rs210281	ENSG00000215146.4	RP11-313J2.1	-5.2	2.98e-07	4.2e-05	-0.38	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42592315	chr10:42331866~42367974:-
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000230295.1	RP11-458F8.2	-5.2	2.98e-07	4.2e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66136229	chr7:66880708~66882981:+
THCA	cis	rs6453278	1	rs6453278	ENSG00000250802.5	ZBED3-AS1	5.2	2.98e-07	4.2e-05	0.21	0.23	Autism;	chr5:77121217	chr5:77086740~77166909:+
THCA	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	5.2	2.98e-07	4.21e-05	0.27	0.23	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
THCA	cis	rs9959145	1	rs9959145	ENSG00000267108.1	RP11-861E21.1	5.2	2.99e-07	4.21e-05	0.29	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12606464	chr18:12432897~12437635:+
THCA	cis	rs3796352	1	rs750474	ENSG00000242142.1	SERBP1P3	-5.2	2.99e-07	4.21e-05	-0.39	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53051264	chr3:53064283~53065091:-
THCA	cis	rs875971	0.545	rs6961853	ENSG00000228409.4	CCT6P1	-5.2	2.99e-07	4.21e-05	-0.2	-0.23	Aortic root size;	chr7:66537035	chr7:65751142~65763354:+
THCA	cis	rs6570726	0.967	rs365515	ENSG00000270638.1	RP3-466P17.1	-5.2	2.99e-07	4.21e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145735570~145737218:+
THCA	cis	rs12439619	0.705	rs17354185	ENSG00000255769.6	GOLGA2P10	5.2	2.99e-07	4.21e-05	0.34	0.23	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472993~82513950:-
THCA	cis	rs7211079	0.582	rs72852528	ENSG00000275479.1	RP11-334C17.6	5.2	2.99e-07	4.21e-05	0.28	0.23	Myocardial infarction;	chr17:80162290	chr17:80149627~80149798:+
THCA	cis	rs4950322	0.57	rs113498894	ENSG00000226015.2	CCT8P1	5.2	2.99e-07	4.22e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147318880	chr1:147203276~147204932:-
THCA	cis	rs17767392	0.813	rs7152842	ENSG00000259146.3	RP1-261D10.2	5.2	2.99e-07	4.22e-05	0.29	0.23	Mitral valve prolapse;	chr14:71383023	chr14:71292729~71321814:-
THCA	cis	rs6490294	0.528	rs7970181	ENSG00000226469.1	ADAM1B	5.2	3e-07	4.22e-05	0.35	0.23	Mean platelet volume;	chr12:112172194	chr12:111927018~111929017:+
THCA	cis	rs7824557	0.843	rs2572418	ENSG00000154316.13	TDH	5.2	3e-07	4.22e-05	0.17	0.23	Retinal vascular caliber;	chr8:11255580	chr8:11339637~11368452:+
THCA	cis	rs748404	0.666	rs514438	ENSG00000205771.5	CATSPER2P1	-5.2	3e-07	4.22e-05	-0.29	-0.23	Lung cancer;	chr15:43328245	chr15:43726918~43747094:-
THCA	cis	rs1979679	0.553	rs78804134	ENSG00000278733.1	RP11-425D17.1	5.2	3e-07	4.23e-05	0.22	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28113449	chr12:28185625~28186190:-
THCA	cis	rs9467773	0.873	rs9295698	ENSG00000261353.1	CTA-14H9.5	-5.2	3e-07	4.23e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26527063~26527404:+
THCA	cis	rs7010876	0.511	rs7835845	ENSG00000253553.4	RP11-586K2.1	5.2	3e-07	4.23e-05	0.25	0.23	Schizophrenia;	chr8:88325926	chr8:88326836~88737134:+
THCA	cis	rs1417569	0.546	rs2934649	ENSG00000237135.1	DDX10P1	-5.2	3e-07	4.23e-05	-0.29	-0.23	Tuberculosis;	chr10:30937490	chr10:30919012~30921235:-
THCA	cis	rs2243480	1	rs73150014	ENSG00000230295.1	RP11-458F8.2	-5.2	3e-07	4.23e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65985932	chr7:66880708~66882981:+
THCA	cis	rs2880765	0.835	rs7169429	ENSG00000259630.2	CTD-2262B20.1	-5.2	3e-07	4.23e-05	-0.25	-0.23	Coronary artery disease;	chr15:85493417	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs7168860	ENSG00000259630.2	CTD-2262B20.1	-5.2	3e-07	4.23e-05	-0.25	-0.23	Coronary artery disease;	chr15:85493799	chr15:85415228~85415633:+
THCA	cis	rs4950322	0.57	rs4950315	ENSG00000271721.1	RP11-337C18.9	-5.2	3e-07	4.23e-05	-0.27	-0.23	Protein quantitative trait loci;	chr1:147264433	chr1:147175602~147177740:+
THCA	cis	rs7674212	0.541	rs2720471	ENSG00000246560.2	RP11-10L12.4	5.2	3e-07	4.23e-05	0.28	0.23	Type 2 diabetes;	chr4:103102683	chr4:102828055~102844075:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000228409.4	CCT6P1	5.2	3e-07	4.23e-05	0.2	0.23	Aortic root size;	chr7:66560286	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs73152714	ENSG00000228409.4	CCT6P1	-5.2	3e-07	4.23e-05	-0.2	-0.23	Aortic root size;	chr7:66534641	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000228409.4	CCT6P1	-5.2	3e-07	4.23e-05	-0.2	-0.23	Aortic root size;	chr7:66536353	chr7:65751142~65763354:+
THCA	cis	rs3789135	1	rs3789135	ENSG00000273009.1	RP11-352G9.1	-5.2	3e-07	4.23e-05	-0.26	-0.23	Mean corpuscular hemoglobin;	chr3:196065999	chr3:195913078~195913683:-
THCA	cis	rs9467773	1	rs4871	ENSG00000261353.1	CTA-14H9.5	-5.2	3.01e-07	4.23e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26527063~26527404:+
THCA	cis	rs595244	0.908	rs1678983	ENSG00000259705.1	RP11-227D13.1	5.2	3.01e-07	4.23e-05	0.37	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48638448	chr15:48645951~48652016:+
THCA	cis	rs919433	0.68	rs788017	ENSG00000231621.1	AC013264.2	-5.2	3.01e-07	4.23e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197400449	chr2:197197991~197199273:+
THCA	cis	rs9990333	0.87	rs58758084	ENSG00000242086.7	LINC00969	-5.2	3.01e-07	4.23e-05	-0.22	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196086110	chr3:195658062~195739964:+
THCA	cis	rs613391	0.826	rs639548	ENSG00000224549.1	RP11-370B11.3	-5.2	3.01e-07	4.23e-05	-0.27	-0.23	Quantitative traits;	chr9:22680268	chr9:22767175~22768316:+
THCA	cis	rs9300255	0.539	rs1969355	ENSG00000256092.2	RP13-942N8.1	5.2	3.01e-07	4.24e-05	0.18	0.23	Neutrophil percentage of white cells;	chr12:123257514	chr12:123363868~123366113:+
THCA	cis	rs9925964	0.967	rs749767	ENSG00000260911.2	RP11-196G11.2	5.2	3.01e-07	4.24e-05	0.19	0.23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31113086	chr16:31043150~31049868:+
THCA	cis	rs7474896	0.806	rs1779150	ENSG00000226578.1	RP11-258F22.1	-5.2	3.01e-07	4.24e-05	-0.54	-0.23	Obesity (extreme);	chr10:37749759	chr10:37775371~37784131:-
THCA	cis	rs11846409	0.86	rs73378154	ENSG00000274576.2	IGHV2-70	-5.2	3.01e-07	4.24e-05	-0.19	-0.23	Rheumatic heart disease;	chr14:106637687	chr14:106770577~106771020:-
THCA	cis	rs5742933	0.597	rs12471663	ENSG00000253559.1	OSGEPL1-AS1	5.2	3.01e-07	4.24e-05	0.27	0.23	Ferritin levels;	chr2:189642372	chr2:189762704~189765556:+
THCA	cis	rs5742933	0.597	rs6761923	ENSG00000253559.1	OSGEPL1-AS1	5.2	3.01e-07	4.24e-05	0.27	0.23	Ferritin levels;	chr2:189642873	chr2:189762704~189765556:+
THCA	cis	rs9876781	1	rs4858793	ENSG00000229759.1	MRPS18AP1	-5.2	3.01e-07	4.24e-05	-0.27	-0.23	Longevity;	chr3:48373517	chr3:48256350~48256938:-
THCA	cis	rs7520050	0.751	rs2230657	ENSG00000234329.1	RP11-767N6.2	-5.2	3.01e-07	4.24e-05	-0.2	-0.23	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45651039~45651826:-
THCA	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-5.2	3.01e-07	4.24e-05	-0.3	-0.23	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
THCA	cis	rs875971	0.545	rs221986	ENSG00000232546.1	RP11-458F8.1	-5.2	3.01e-07	4.24e-05	-0.22	-0.23	Aortic root size;	chr7:66105323	chr7:66848496~66858136:+
THCA	cis	rs7429990	0.965	rs1061003	ENSG00000228638.1	FCF1P2	-5.2	3.01e-07	4.24e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47851089	chr3:48290793~48291375:-
THCA	cis	rs3820928	1	rs978909	ENSG00000212391.1	SNORA48	-5.2	3.02e-07	4.24e-05	-0.26	-0.23	Pulmonary function;	chr2:226906673	chr2:226968989~226969122:-
THCA	cis	rs2439831	0.717	rs2447198	ENSG00000166763.7	STRCP1	5.2	3.02e-07	4.24e-05	0.32	0.23	Lung cancer in ever smokers;	chr15:43602920	chr15:43699488~43718184:-
THCA	cis	rs4950322	0.57	rs72691054	ENSG00000271721.1	RP11-337C18.9	5.2	3.02e-07	4.24e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147277942	chr1:147175602~147177740:+
THCA	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	5.2	3.02e-07	4.24e-05	0.4	0.23	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
THCA	cis	rs9652601	0.648	rs7197422	ENSG00000274038.1	RP11-66H6.4	-5.2	3.02e-07	4.24e-05	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11027214	chr16:11056556~11057034:+
THCA	cis	rs10771431	0.597	rs10771412	ENSG00000111788.10	RP11-22B23.1	5.2	3.02e-07	4.24e-05	0.23	0.23	Breast size;	chr12:9201757	chr12:9277235~9313241:+
THCA	cis	rs10771431	0.597	rs10771413	ENSG00000111788.10	RP11-22B23.1	5.2	3.02e-07	4.24e-05	0.23	0.23	Breast size;	chr12:9201817	chr12:9277235~9313241:+
THCA	cis	rs763121	0.853	rs138702	ENSG00000228274.3	RP3-508I15.9	5.2	3.02e-07	4.24e-05	0.25	0.23	Menopause (age at onset);	chr22:38736596	chr22:38667585~38681820:-
THCA	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	5.2	3.02e-07	4.24e-05	0.27	0.23	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
THCA	cis	rs1552244	1	rs35993975	ENSG00000180385.7	EMC3-AS1	5.2	3.02e-07	4.25e-05	0.27	0.23	Alzheimer's disease;	chr3:10026110	chr3:9986893~10006990:+
THCA	cis	rs7552393	0.622	rs12134669	ENSG00000233008.4	RP11-475O6.1	-5.2	3.02e-07	4.25e-05	-0.27	-0.23	Select biomarker traits;	chr1:83844510	chr1:83575776~83861023:-
THCA	cis	rs11846409	0.932	rs10151046	ENSG00000211974.3	IGHV2-70	-5.2	3.02e-07	4.25e-05	-0.22	-0.23	Rheumatic heart disease;	chr14:106633095	chr14:106723574~106724093:-
THCA	cis	rs7580717	0.785	rs6728639	ENSG00000224376.1	AC017104.6	5.2	3.02e-07	4.25e-05	0.26	0.23	Multiple myeloma;	chr2:231286053	chr2:231388976~231394991:+
THCA	cis	rs17767392	0.846	rs4453405	ENSG00000259146.3	RP1-261D10.2	5.2	3.02e-07	4.25e-05	0.29	0.23	Mitral valve prolapse;	chr14:71290534	chr14:71292729~71321814:-
THCA	cis	rs9859260	1	rs2284890	ENSG00000273009.1	RP11-352G9.1	-5.2	3.02e-07	4.25e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196061276	chr3:195913078~195913683:-
THCA	cis	rs9859260	1	rs2284889	ENSG00000273009.1	RP11-352G9.1	-5.2	3.02e-07	4.25e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196061376	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.961	rs2300780	ENSG00000273009.1	RP11-352G9.1	-5.2	3.02e-07	4.25e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196063420	chr3:195913078~195913683:-
THCA	cis	rs8141529	0.748	rs132529	ENSG00000272858.1	CTA-292E10.8	5.2	3.02e-07	4.25e-05	0.24	0.23	Lymphocyte counts;	chr22:28900664	chr22:28814914~28815662:+
THCA	cis	rs9859260	1	rs2239641	ENSG00000273009.1	RP11-352G9.1	-5.2	3.02e-07	4.25e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196062543	chr3:195913078~195913683:-
THCA	cis	rs875971	1	rs6460296	ENSG00000223473.2	GS1-124K5.3	5.2	3.02e-07	4.25e-05	0.16	0.23	Aortic root size;	chr7:66430152	chr7:66491049~66493566:-
THCA	cis	rs875971	0.895	rs4718349	ENSG00000223473.2	GS1-124K5.3	5.2	3.02e-07	4.25e-05	0.16	0.23	Aortic root size;	chr7:66444024	chr7:66491049~66493566:-
THCA	cis	rs875971	1	rs2042133	ENSG00000223473.2	GS1-124K5.3	5.2	3.02e-07	4.25e-05	0.16	0.23	Aortic root size;	chr7:66466935	chr7:66491049~66493566:-
THCA	cis	rs875971	0.964	rs2161065	ENSG00000223473.2	GS1-124K5.3	5.2	3.02e-07	4.25e-05	0.16	0.23	Aortic root size;	chr7:66467918	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs12698521	ENSG00000223473.2	GS1-124K5.3	5.2	3.02e-07	4.25e-05	0.16	0.23	Aortic root size;	chr7:66474502	chr7:66491049~66493566:-
THCA	cis	rs10895322	0.656	rs7126560	ENSG00000281655.1	RP11-817J15.3	-5.2	3.02e-07	4.25e-05	-0.3	-0.23	Neuroblastoma (11q deletion);	chr11:102614822	chr11:102681310~102683913:+
THCA	cis	rs12908161	0.92	rs35738019	ENSG00000275120.1	RP11-182J1.17	5.2	3.02e-07	4.25e-05	0.28	0.23	Schizophrenia;	chr15:84736979	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs34570071	ENSG00000275120.1	RP11-182J1.17	5.2	3.02e-07	4.25e-05	0.28	0.23	Schizophrenia;	chr15:84736981	chr15:84599434~84606463:-
THCA	cis	rs1577917	0.655	rs2758849	ENSG00000220563.1	PKMP3	-5.2	3.02e-07	4.25e-05	-0.17	-0.23	Response to antipsychotic treatment;	chr6:85634578	chr6:85659892~85660606:-
THCA	cis	rs17826219	0.789	rs4794873	ENSG00000266490.1	CTD-2349P21.9	5.2	3.02e-07	4.25e-05	0.31	0.23	Body mass index;	chr17:30421334	chr17:30792372~30792833:+
THCA	cis	rs34779708	0.966	rs7913615	ENSG00000271335.4	RP11-324I22.4	5.2	3.03e-07	4.25e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35314552~35336401:-
THCA	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	5.2	3.03e-07	4.25e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	5.2	3.03e-07	4.25e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	5.2	3.03e-07	4.25e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	5.2	3.03e-07	4.25e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	5.2	3.03e-07	4.25e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
THCA	cis	rs9467773	1	rs12526680	ENSG00000261353.1	CTA-14H9.5	-5.2	3.03e-07	4.26e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26527063~26527404:+
THCA	cis	rs7119038	0.818	rs10892293	ENSG00000255239.1	AP002954.6	-5.2	3.03e-07	4.26e-05	-0.36	-0.23	Sjögren's syndrome;	chr11:118794866	chr11:118688039~118690600:-
THCA	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-5.2	3.03e-07	4.26e-05	-0.28	-0.23	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
THCA	cis	rs2439831	0.702	rs9989313	ENSG00000166763.7	STRCP1	5.2	3.03e-07	4.26e-05	0.34	0.23	Lung cancer in ever smokers;	chr15:43860619	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs61390361	ENSG00000166763.7	STRCP1	5.2	3.03e-07	4.26e-05	0.34	0.23	Lung cancer in ever smokers;	chr15:43867644	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs11856795	ENSG00000166763.7	STRCP1	5.2	3.03e-07	4.26e-05	0.34	0.23	Lung cancer in ever smokers;	chr15:43868384	chr15:43699488~43718184:-
THCA	cis	rs7727544	0.507	rs10051679	ENSG00000237714.1	P4HA2-AS1	5.2	3.03e-07	4.26e-05	0.29	0.23	Blood metabolite levels;	chr5:132235238	chr5:132184876~132192808:+
THCA	cis	rs4646450	0.891	rs10238965	ENSG00000244219.5	GS1-259H13.2	-5.2	3.03e-07	4.26e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99548222	chr7:99598066~99610813:+
THCA	cis	rs34779708	0.897	rs12830	ENSG00000271335.4	RP11-324I22.4	5.2	3.03e-07	4.26e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35314552~35336401:-
THCA	cis	rs10461617	0.541	rs832575	ENSG00000271828.1	CTD-2310F14.1	5.2	3.03e-07	4.26e-05	0.41	0.23	Type 2 diabetes;	chr5:56865960	chr5:56927874~56929573:+
THCA	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	5.2	3.03e-07	4.26e-05	0.31	0.23	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
THCA	cis	rs2562456	0.833	rs2650776	ENSG00000268119.4	CTD-2561J22.5	5.2	3.03e-07	4.26e-05	0.33	0.23	Pain;	chr19:21430595	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs2562416	ENSG00000268119.4	CTD-2561J22.5	5.2	3.03e-07	4.26e-05	0.33	0.23	Pain;	chr19:21430609	chr19:21444241~21463908:-
THCA	cis	rs9733	0.596	rs6587518	ENSG00000231073.1	RP11-316M1.3	5.2	3.03e-07	4.27e-05	0.28	0.23	Tonsillectomy;	chr1:150689311	chr1:150973123~150975534:+
THCA	cis	rs7824557	0.767	rs1897950	ENSG00000154316.13	TDH	-5.2	3.04e-07	4.27e-05	-0.17	-0.23	Retinal vascular caliber;	chr8:11312042	chr8:11339637~11368452:+
THCA	cis	rs9595908	0.827	rs9595885	ENSG00000212293.1	SNORA16	5.2	3.04e-07	4.27e-05	0.28	0.23	Body mass index;	chr13:32593913	chr13:32420390~32420516:-
THCA	cis	rs10200159	1	rs17047119	ENSG00000272606.1	RP11-554J4.1	5.2	3.04e-07	4.27e-05	0.47	0.23	Vitiligo;	chr2:55599979	chr2:55617909~55618373:+
THCA	cis	rs7674212	0.57	rs2126470	ENSG00000246560.2	RP11-10L12.4	5.2	3.04e-07	4.27e-05	0.28	0.23	Type 2 diabetes;	chr4:103140605	chr4:102828055~102844075:+
THCA	cis	rs6951245	0.935	rs79143504	ENSG00000229043.2	AC091729.9	-5.2	3.04e-07	4.27e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1160374~1165267:+
THCA	cis	rs2243480	1	rs160634	ENSG00000232559.3	GS1-124K5.12	-5.2	3.04e-07	4.27e-05	-0.34	-0.23	Diabetic kidney disease;	chr7:66063677	chr7:66554588~66576923:-
THCA	cis	rs9652601	0.691	rs7186145	ENSG00000274038.1	RP11-66H6.4	-5.2	3.04e-07	4.27e-05	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11117021	chr16:11056556~11057034:+
THCA	cis	rs28374715	0.681	rs77187862	ENSG00000247556.5	OIP5-AS1	5.2	3.04e-07	4.28e-05	0.22	0.23	Ulcerative colitis;	chr15:41327078	chr15:41283990~41309737:+
THCA	cis	rs7429990	0.965	rs777015	ENSG00000228638.1	FCF1P2	-5.2	3.04e-07	4.28e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47895582	chr3:48290793~48291375:-
THCA	cis	rs4648045	0.565	rs4698862	ENSG00000246560.2	RP11-10L12.4	5.2	3.04e-07	4.28e-05	0.29	0.23	Lymphocyte percentage of white cells;	chr4:102624640	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.565	rs4698863	ENSG00000246560.2	RP11-10L12.4	5.2	3.04e-07	4.28e-05	0.29	0.23	Lymphocyte percentage of white cells;	chr4:102624691	chr4:102828055~102844075:+
THCA	cis	rs1707322	0.963	rs6429581	ENSG00000281133.1	AL355480.3	-5.2	3.04e-07	4.28e-05	-0.29	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45580892~45580996:-
THCA	cis	rs4888671	1	rs59045389	ENSG00000261707.1	RP11-264M12.2	5.2	3.04e-07	4.28e-05	0.43	0.23	Obesity-related traits;	chr16:77748966	chr16:77741468~77743000:-
THCA	cis	rs613391	0.671	rs504121	ENSG00000224549.1	RP11-370B11.3	-5.2	3.04e-07	4.28e-05	-0.27	-0.23	Quantitative traits;	chr9:22705424	chr9:22767175~22768316:+
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000229886.1	RP5-1132H15.3	5.2	3.04e-07	4.28e-05	0.28	0.23	Corneal structure;	chr7:66790251	chr7:66025126~66031544:-
THCA	cis	rs6997458	0.713	rs1543852	ENSG00000253549.4	RP11-317J10.2	5.2	3.05e-07	4.28e-05	0.23	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85440529	chr8:85441851~85464915:-
THCA	cis	rs6969780	1	rs73071548	ENSG00000233429.8	HOTAIRM1	5.2	3.05e-07	4.28e-05	0.36	0.23	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27107811	chr7:27095647~27100265:+
THCA	cis	rs2067615	0.579	rs1922435	ENSG00000260329.1	RP11-412D9.4	-5.2	3.05e-07	4.28e-05	-0.21	-0.23	Heart rate;	chr12:106688677	chr12:106954029~106955497:-
THCA	cis	rs34779708	0.931	rs2490663	ENSG00000271335.4	RP11-324I22.4	-5.2	3.05e-07	4.28e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35314552~35336401:-
THCA	cis	rs9475752	0.744	rs1020548	ENSG00000231441.1	RP11-472M19.2	-5.2	3.05e-07	4.28e-05	-0.31	-0.23	Menarche (age at onset);	chr6:56945741	chr6:56844002~56864078:+
THCA	cis	rs4865169	1	rs4865169	ENSG00000269949.1	RP11-738E22.3	-5.2	3.05e-07	4.29e-05	-0.27	-0.23	Breast cancer;	chr4:57013626	chr4:56960927~56961373:-
THCA	cis	rs1707322	1	rs7539800	ENSG00000281133.1	AL355480.3	5.2	3.05e-07	4.29e-05	0.29	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45580892~45580996:-
THCA	cis	rs9467773	1	rs6940053	ENSG00000261353.1	CTA-14H9.5	-5.2	3.05e-07	4.29e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26527063~26527404:+
THCA	cis	rs911555	0.504	rs4906340	ENSG00000269910.1	RP11-73M18.10	-5.2	3.05e-07	4.29e-05	-0.22	-0.23	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103694516~103695050:-
THCA	cis	rs4886920	0.672	rs11072680	ENSG00000260776.4	RP11-114H24.2	5.2	3.05e-07	4.29e-05	0.29	0.23	Neuroticism;	chr15:77838238	chr15:77914217~77926846:-
THCA	cis	rs4886920	0.672	rs4886933	ENSG00000260776.4	RP11-114H24.2	5.2	3.05e-07	4.29e-05	0.29	0.23	Neuroticism;	chr15:77838898	chr15:77914217~77926846:-
THCA	cis	rs10266483	0.96	rs13221291	ENSG00000228653.2	HNRNPCP7	-5.2	3.05e-07	4.29e-05	-0.19	-0.23	Response to statin therapy;	chr7:64279114	chr7:64500825~64501729:+
THCA	cis	rs10510102	0.935	rs12253283	ENSG00000226864.1	ATE1-AS1	-5.2	3.05e-07	4.29e-05	-0.38	-0.23	Breast cancer;	chr10:121909740	chr10:121928312~121951965:+
THCA	cis	rs2243480	1	rs313831	ENSG00000232559.3	GS1-124K5.12	5.2	3.05e-07	4.29e-05	0.34	0.23	Diabetic kidney disease;	chr7:66086239	chr7:66554588~66576923:-
THCA	cis	rs4308124	1	rs57874285	ENSG00000227992.1	AC108463.2	-5.2	3.06e-07	4.29e-05	-0.29	-0.23	Vitiligo;	chr2:111255095	chr2:111203964~111206215:-
THCA	cis	rs4308124	1	rs57707030	ENSG00000227992.1	AC108463.2	-5.2	3.06e-07	4.29e-05	-0.29	-0.23	Vitiligo;	chr2:111255105	chr2:111203964~111206215:-
THCA	cis	rs11089937	0.568	rs5756988	ENSG00000211639.2	IGLV4-60	-5.2	3.06e-07	4.29e-05	-0.16	-0.23	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22162199~22162681:+
THCA	cis	rs6445975	1	rs4681681	ENSG00000272360.1	RP11-359I18.5	-5.19	3.06e-07	4.3e-05	-0.25	-0.23	Systemic lupus erythematosus;	chr3:58347185	chr3:58490830~58491291:-
THCA	cis	rs7119	0.717	rs12910951	ENSG00000259362.2	RP11-307C19.1	-5.19	3.06e-07	4.3e-05	-0.34	-0.23	Type 2 diabetes;	chr15:77514455	chr15:77525540~77534110:+
THCA	cis	rs7119	0.745	rs12911649	ENSG00000259362.2	RP11-307C19.1	-5.19	3.06e-07	4.3e-05	-0.34	-0.23	Type 2 diabetes;	chr15:77514785	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12911963	ENSG00000259362.2	RP11-307C19.1	-5.19	3.06e-07	4.3e-05	-0.34	-0.23	Type 2 diabetes;	chr15:77514833	chr15:77525540~77534110:+
THCA	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	5.19	3.06e-07	4.3e-05	0.21	0.23	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
THCA	cis	rs6547741	1	rs6547741	ENSG00000234072.1	AC074117.10	5.19	3.06e-07	4.3e-05	0.18	0.23	Oral cavity cancer;	chr2:27633057	chr2:27356246~27367622:+
THCA	cis	rs6928977	0.932	rs4896143	ENSG00000231028.7	LINC00271	5.19	3.06e-07	4.3e-05	0.19	0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135313962	chr6:135497801~135716055:+
THCA	cis	rs2708377	0.79	rs73051387	ENSG00000212125.2	TAS2R15P	5.19	3.06e-07	4.3e-05	0.37	0.23	Bitter taste perception;	chr12:11161864	chr12:10964425~10965352:-
THCA	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-5.19	3.06e-07	4.31e-05	-0.3	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
THCA	cis	rs8062405	1	rs80275162	ENSG00000278665.1	RP11-666O2.4	5.19	3.07e-07	4.31e-05	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28599241~28601881:-
THCA	cis	rs7702057	0.53	rs1129495	ENSG00000271918.1	CTD-2287O16.5	5.19	3.07e-07	4.31e-05	0.27	0.23	Amyotrophic lateral sclerosis;	chr5:116092684	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.53	rs61105089	ENSG00000271918.1	CTD-2287O16.5	5.19	3.07e-07	4.31e-05	0.27	0.23	Amyotrophic lateral sclerosis;	chr5:116096514	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.53	rs2136213	ENSG00000271918.1	CTD-2287O16.5	5.19	3.07e-07	4.31e-05	0.27	0.23	Amyotrophic lateral sclerosis;	chr5:116098716	chr5:116083807~116085416:-
THCA	cis	rs763121	0.853	rs5750627	ENSG00000235209.1	CTA-150C2.13	5.19	3.07e-07	4.31e-05	0.3	0.23	Menopause (age at onset);	chr22:38586316	chr22:38921227~38924708:+
THCA	cis	rs6545883	0.929	rs2252662	ENSG00000270820.4	RP11-355B11.2	5.19	3.07e-07	4.31e-05	0.2	0.23	Tuberculosis;	chr2:61443596	chr2:61471188~61484130:+
THCA	cis	rs2880765	0.835	rs4842886	ENSG00000259630.2	CTD-2262B20.1	-5.19	3.07e-07	4.31e-05	-0.25	-0.23	Coronary artery disease;	chr15:85492542	chr15:85415228~85415633:+
THCA	cis	rs8059260	0.736	rs79361721	ENSG00000274038.1	RP11-66H6.4	-5.19	3.07e-07	4.31e-05	-0.48	-0.23	Alcohol consumption over the past year;	chr16:10968082	chr16:11056556~11057034:+
THCA	cis	rs1552244	1	rs61052895	ENSG00000180385.7	EMC3-AS1	5.19	3.07e-07	4.31e-05	0.26	0.23	Alzheimer's disease;	chr3:10105832	chr3:9986893~10006990:+
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000259728.4	LINC00933	-5.19	3.07e-07	4.31e-05	-0.28	-0.23	P wave terminal force;	chr15:84632519	chr15:84570649~84580175:+
THCA	cis	rs6058796	1	rs6141333	ENSG00000175730.8	BAK1P1	5.19	3.07e-07	4.32e-05	0.34	0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32675522	chr20:32690180~32690815:-
THCA	cis	rs6058796	1	rs6141781	ENSG00000175730.8	BAK1P1	5.19	3.07e-07	4.32e-05	0.34	0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32675540	chr20:32690180~32690815:-
THCA	cis	rs7246657	0.525	rs10410594	ENSG00000276846.1	CTD-3220F14.3	5.19	3.07e-07	4.32e-05	0.25	0.23	Coronary artery calcification;	chr19:36986856	chr19:37314868~37315620:-
THCA	cis	rs9990333	0.544	rs73208092	ENSG00000273009.1	RP11-352G9.1	-5.19	3.07e-07	4.32e-05	-0.27	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195913078~195913683:-
THCA	cis	rs12681287	0.511	rs7839601	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86491610	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs7837569	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86495137	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.517	rs34367154	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86496520	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs9942793	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86496862	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs9942823	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86496948	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs6998303	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86497956	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs13267858	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86498642	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs7461366	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86499456	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs4961197	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86500207	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs13249177	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86500805	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.517	rs13249753	ENSG00000254231.1	CTD-2284J15.1	5.19	3.07e-07	4.32e-05	0.26	0.23	Caudate activity during reward;	chr8:86500987	chr8:86333274~86343314:-
THCA	cis	rs10208649	0.908	rs78244745	ENSG00000233266.1	HMGB1P31	5.19	3.07e-07	4.32e-05	0.62	0.23	Body mass index;	chr2:54056137	chr2:54051334~54051760:+
THCA	cis	rs990871	0.512	rs9424977	ENSG00000227207.2	RPL31P12	-5.19	3.08e-07	4.32e-05	-0.27	-0.23	Subcutaneous adipose tissue;	chr1:72259661	chr1:72301472~72301829:+
THCA	cis	rs516805	0.528	rs2679708	ENSG00000279453.1	RP3-425C14.4	5.19	3.08e-07	4.32e-05	0.25	0.23	Lymphocyte counts;	chr6:122079365	chr6:122436789~122439223:-
THCA	cis	rs17772222	0.701	rs376698	ENSG00000258983.2	RP11-507K2.2	-5.19	3.08e-07	4.32e-05	-0.27	-0.23	Coronary artery calcification;	chr14:88391886	chr14:88499334~88515502:+
THCA	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-5.19	3.08e-07	4.32e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-5.19	3.08e-07	4.32e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
THCA	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-5.19	3.08e-07	4.32e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
THCA	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-5.19	3.08e-07	4.32e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
THCA	cis	rs2348418	0.767	rs1478332	ENSG00000247934.4	RP11-967K21.1	-5.19	3.08e-07	4.33e-05	-0.2	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28255432	chr12:28163298~28190738:-
THCA	cis	rs10043228	0.702	rs6873096	ENSG00000248445.4	SEMA6A-AS1	-5.19	3.08e-07	4.33e-05	-0.25	-0.23	Asthma or chronic obstructive pulmonary disease;	chr5:116293490	chr5:116447547~116508276:+
THCA	cis	rs9311474	0.607	rs4475032	ENSG00000243224.1	RP5-1157M23.2	-5.19	3.08e-07	4.33e-05	-0.26	-0.23	Electroencephalogram traits;	chr3:52526005	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.607	rs4687625	ENSG00000243224.1	RP5-1157M23.2	-5.19	3.08e-07	4.33e-05	-0.26	-0.23	Electroencephalogram traits;	chr3:52529702	chr3:52239258~52241097:+
THCA	cis	rs7617773	0.78	rs13084616	ENSG00000199476.1	Y_RNA	5.19	3.08e-07	4.33e-05	0.3	0.23	Coronary artery disease;	chr3:48298209	chr3:48288587~48288694:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	5.19	3.08e-07	4.33e-05	0.29	0.23	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
THCA	cis	rs6908034	0.607	rs78774173	ENSG00000227116.1	RP3-471C18.1	-5.19	3.08e-07	4.33e-05	-0.45	-0.23	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19820455	chr6:19730427~19734567:-
THCA	cis	rs757081	0.533	rs56030184	ENSG00000184669.7	OR7E14P	-5.19	3.08e-07	4.33e-05	-0.33	-0.23	Systolic blood pressure;	chr11:17046302	chr11:17013998~17053024:+
THCA	cis	rs7727544	0.513	rs10065787	ENSG00000233006.5	AC034220.3	5.19	3.09e-07	4.33e-05	0.18	0.23	Blood metabolite levels;	chr5:132100793	chr5:132311285~132369916:-
THCA	cis	rs2243480	1	rs56016656	ENSG00000230295.1	RP11-458F8.2	-5.19	3.09e-07	4.33e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65918494	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs56291018	ENSG00000230295.1	RP11-458F8.2	-5.19	3.09e-07	4.33e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65925352	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs36033484	ENSG00000230295.1	RP11-458F8.2	-5.19	3.09e-07	4.33e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65925571	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs34560516	ENSG00000230295.1	RP11-458F8.2	-5.19	3.09e-07	4.33e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65939105	chr7:66880708~66882981:+
THCA	cis	rs10208649	0.505	rs3731973	ENSG00000272156.1	RP11-477N3.1	5.19	3.09e-07	4.33e-05	0.3	0.23	Body mass index;	chr2:53932862	chr2:54082554~54085066:+
THCA	cis	rs2815752	0.508	rs9425081	ENSG00000227207.2	RPL31P12	5.19	3.09e-07	4.33e-05	0.27	0.23	Body mass index;	chr1:72276552	chr1:72301472~72301829:+
THCA	cis	rs1979679	0.572	rs6487692	ENSG00000247934.4	RP11-967K21.1	5.19	3.09e-07	4.33e-05	0.24	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28573109	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.608	rs3803087	ENSG00000247934.4	RP11-967K21.1	5.19	3.09e-07	4.33e-05	0.24	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28573701	chr12:28163298~28190738:-
THCA	cis	rs10090774	0.76	rs6993266	ENSG00000279766.1	RP11-642A1.2	5.19	3.09e-07	4.33e-05	0.29	0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140752560	chr8:140572142~140572812:-
THCA	cis	rs2880765	0.805	rs34598679	ENSG00000259630.2	CTD-2262B20.1	-5.19	3.09e-07	4.33e-05	-0.25	-0.23	Coronary artery disease;	chr15:85498974	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs4344688	ENSG00000259630.2	CTD-2262B20.1	-5.19	3.09e-07	4.33e-05	-0.25	-0.23	Coronary artery disease;	chr15:85499776	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs4280192	ENSG00000259630.2	CTD-2262B20.1	-5.19	3.09e-07	4.33e-05	-0.25	-0.23	Coronary artery disease;	chr15:85499789	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs7169632	ENSG00000259630.2	CTD-2262B20.1	-5.19	3.09e-07	4.33e-05	-0.25	-0.23	Coronary artery disease;	chr15:85501436	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs12910373	ENSG00000259630.2	CTD-2262B20.1	-5.19	3.09e-07	4.33e-05	-0.25	-0.23	Coronary artery disease;	chr15:85503571	chr15:85415228~85415633:+
THCA	cis	rs2179367	0.632	rs10872636	ENSG00000223701.3	RAET1E-AS1	5.19	3.09e-07	4.34e-05	0.33	0.23	Dupuytren's disease;	chr6:149353678	chr6:149884431~149919508:+
THCA	cis	rs763121	0.853	rs1013338	ENSG00000228274.3	RP3-508I15.9	-5.19	3.09e-07	4.34e-05	-0.25	-0.23	Menopause (age at onset);	chr22:38578149	chr22:38667585~38681820:-
THCA	cis	rs8020095	0.528	rs73282769	ENSG00000258561.1	RP11-72M17.1	-5.19	3.09e-07	4.34e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67313550	chr14:66212810~66509394:-
THCA	cis	rs9859260	0.925	rs13072608	ENSG00000273009.1	RP11-352G9.1	-5.19	3.09e-07	4.34e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196073396	chr3:195913078~195913683:-
THCA	cis	rs9392556	0.6	rs611500	ENSG00000230648.1	RP3-406P24.3	5.19	3.09e-07	4.34e-05	0.28	0.23	Blood metabolite levels;	chr6:4126529	chr6:4018843~4021215:-
THCA	cis	rs7394190	0.748	rs11000766	ENSG00000271816.1	BMS1P4	-5.19	3.09e-07	4.34e-05	-0.29	-0.23	Incident atrial fibrillation;	chr10:73753194	chr10:73699151~73730487:-
THCA	cis	rs6479874	1	rs4558117	ENSG00000223502.1	RP11-96B5.3	-5.19	3.09e-07	4.34e-05	-0.28	-0.23	Migraine;	chr10:51020524	chr10:51062579~51068553:-
THCA	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	5.19	3.09e-07	4.34e-05	0.17	0.23	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
THCA	cis	rs12612619	0.667	rs7605526	ENSG00000229122.1	AGBL5-IT1	5.19	3.1e-07	4.34e-05	0.17	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27122616	chr2:27061038~27061815:+
THCA	cis	rs7617773	0.817	rs3731534	ENSG00000199476.1	Y_RNA	-5.19	3.1e-07	4.35e-05	-0.3	-0.23	Coronary artery disease;	chr3:48170287	chr3:48288587~48288694:+
THCA	cis	rs12472274	0.646	rs34989058	ENSG00000279484.1	KLHL30-AS1	5.19	3.1e-07	4.35e-05	0.3	0.23	Phospholipid levels (plasma);	chr2:238166057	chr2:238152889~238155994:-
THCA	cis	rs4713118	0.662	rs149901	ENSG00000261839.1	RP1-265C24.8	5.19	3.1e-07	4.35e-05	0.26	0.23	Parkinson's disease;	chr6:27997725	chr6:28136849~28139678:+
THCA	cis	rs16846053	0.579	rs57887363	ENSG00000227403.1	AC009299.3	5.19	3.1e-07	4.35e-05	0.48	0.23	Blood osmolality (transformed sodium);	chr2:161732210	chr2:161244739~161249050:+
THCA	cis	rs2129782	1	rs57040657	ENSG00000253553.4	RP11-586K2.1	5.19	3.1e-07	4.35e-05	0.41	0.23	Electrodermal activity;	chr8:88402761	chr8:88326836~88737134:+
THCA	cis	rs1383484	0.575	rs28694702	ENSG00000225151.9	GOLGA2P7	5.19	3.1e-07	4.35e-05	0.3	0.23	Height;	chr15:83945534	chr15:84199311~84230136:-
THCA	cis	rs1667284	0.58	rs11081706	ENSG00000266521.1	RP11-650P15.1	-5.19	3.1e-07	4.35e-05	-0.3	-0.23	Problematic alcohol use in trauma-exposed individuals;	chr18:31655508	chr18:31496645~31497195:-
THCA	cis	rs6545883	0.929	rs778155	ENSG00000270820.4	RP11-355B11.2	-5.19	3.1e-07	4.35e-05	-0.2	-0.23	Tuberculosis;	chr2:61420766	chr2:61471188~61484130:+
THCA	cis	rs3785574	0.927	rs2854160	ENSG00000240280.5	TCAM1P	-5.19	3.1e-07	4.35e-05	-0.31	-0.23	Height;	chr17:63899888	chr17:63849292~63864379:+
THCA	cis	rs6708331	0.517	rs6743372	ENSG00000179818.12	PCBP1-AS1	-5.19	3.1e-07	4.35e-05	-0.19	-0.23	Obesity-related traits;	chr2:70125508	chr2:69962263~70103220:-
THCA	cis	rs6088580	0.634	rs6087580	ENSG00000276073.1	RP5-1125A11.7	5.19	3.1e-07	4.35e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34404786	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6088498	ENSG00000276073.1	RP5-1125A11.7	-5.19	3.1e-07	4.35e-05	-0.2	-0.23	Glomerular filtration rate (creatinine);	chr20:34432640	chr20:33985617~33988989:-
THCA	cis	rs6545883	0.894	rs2600660	ENSG00000270820.4	RP11-355B11.2	-5.19	3.1e-07	4.35e-05	-0.19	-0.23	Tuberculosis;	chr2:61322465	chr2:61471188~61484130:+
THCA	cis	rs9959145	1	rs111384103	ENSG00000267108.1	RP11-861E21.1	5.19	3.1e-07	4.35e-05	0.28	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12606483	chr18:12432897~12437635:+
THCA	cis	rs6545883	0.929	rs2121660	ENSG00000270820.4	RP11-355B11.2	-5.19	3.1e-07	4.36e-05	-0.2	-0.23	Tuberculosis;	chr2:61425923	chr2:61471188~61484130:+
THCA	cis	rs60695258	0.55	rs388401	ENSG00000251411.1	RP11-397E7.4	5.19	3.1e-07	4.36e-05	0.21	0.23	Hematocrit;	chr4:87053263	chr4:86913266~86914817:-
THCA	cis	rs7412746	0.658	rs6658066	ENSG00000231073.1	RP11-316M1.3	5.19	3.1e-07	4.36e-05	0.28	0.23	Melanoma;	chr1:150946461	chr1:150973123~150975534:+
THCA	cis	rs2993535	1	rs3010029	ENSG00000233626.2	RP11-565J7.1	-5.19	3.11e-07	4.36e-05	-0.64	-0.23	Hip circumference adjusted for BMI;	chr1:212024502	chr1:211936249~211936634:+
THCA	cis	rs6430585	0.528	rs309165	ENSG00000231890.6	DARS-AS1	-5.19	3.11e-07	4.36e-05	-0.26	-0.23	Corneal structure;	chr2:135909731	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.528	rs309158	ENSG00000231890.6	DARS-AS1	-5.19	3.11e-07	4.36e-05	-0.26	-0.23	Corneal structure;	chr2:135922964	chr2:135985176~136022593:+
THCA	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	5.19	3.11e-07	4.36e-05	0.3	0.23	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
THCA	cis	rs7772486	0.654	rs4896829	ENSG00000270638.1	RP3-466P17.1	5.19	3.11e-07	4.36e-05	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145735570~145737218:+
THCA	cis	rs10425738	0.536	rs10426903	ENSG00000256612.6	CYP2B7P	-5.19	3.11e-07	4.36e-05	-0.27	-0.23	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);	chr19:40911814	chr19:40924219~40950660:+
THCA	cis	rs3770081	0.59	rs11891333	ENSG00000272564.1	RP11-548P2.2	-5.19	3.11e-07	4.36e-05	-0.39	-0.23	Facial emotion recognition (sad faces);	chr2:85951271	chr2:85904279~85904727:+
THCA	cis	rs9467773	1	rs6456733	ENSG00000261353.1	CTA-14H9.5	-5.19	3.11e-07	4.36e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6456734	ENSG00000261353.1	CTA-14H9.5	-5.19	3.11e-07	4.36e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs1535277	ENSG00000261353.1	CTA-14H9.5	-5.19	3.11e-07	4.36e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs1884948	ENSG00000261353.1	CTA-14H9.5	-5.19	3.11e-07	4.36e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26527063~26527404:+
THCA	cis	rs11089937	0.54	rs2329931	ENSG00000211639.2	IGLV4-60	5.19	3.11e-07	4.37e-05	0.17	0.23	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.568	rs2876996	ENSG00000211639.2	IGLV4-60	5.19	3.11e-07	4.37e-05	0.17	0.23	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22162199~22162681:+
THCA	cis	rs6121246	0.567	rs6060247	ENSG00000230613.1	HM13-AS1	5.19	3.11e-07	4.37e-05	0.28	0.23	Mean corpuscular hemoglobin;	chr20:31602917	chr20:31567707~31573263:-
THCA	cis	rs763121	0.626	rs5750643	ENSG00000228274.3	RP3-508I15.9	-5.19	3.11e-07	4.37e-05	-0.25	-0.23	Menopause (age at onset);	chr22:38613012	chr22:38667585~38681820:-
THCA	cis	rs8020095	0.571	rs10136026	ENSG00000258561.1	RP11-72M17.1	-5.19	3.11e-07	4.37e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:66943390	chr14:66212810~66509394:-
THCA	cis	rs494453	0.6	rs474077	ENSG00000227811.2	FAM212B-AS1	-5.19	3.11e-07	4.37e-05	-0.29	-0.23	Osteoporosis-related phenotypes;	chr1:111652592	chr1:111739841~111747798:+
THCA	cis	rs494453	0.6	rs530173	ENSG00000227811.2	FAM212B-AS1	-5.19	3.11e-07	4.37e-05	-0.29	-0.23	Osteoporosis-related phenotypes;	chr1:111654908	chr1:111739841~111747798:+
THCA	cis	rs494453	0.6	rs561309	ENSG00000227811.2	FAM212B-AS1	-5.19	3.11e-07	4.37e-05	-0.29	-0.23	Osteoporosis-related phenotypes;	chr1:111655994	chr1:111739841~111747798:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000229886.1	RP5-1132H15.3	5.19	3.12e-07	4.37e-05	0.28	0.23	Corneal structure;	chr7:66789303	chr7:66025126~66031544:-
THCA	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	5.19	3.12e-07	4.37e-05	0.27	0.23	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
THCA	cis	rs4888671	1	rs58484838	ENSG00000261707.1	RP11-264M12.2	5.19	3.12e-07	4.38e-05	0.43	0.23	Obesity-related traits;	chr16:77749240	chr16:77741468~77743000:-
THCA	cis	rs972578	0.668	rs5758990	ENSG00000274717.1	RP1-47A17.1	-5.19	3.12e-07	4.38e-05	-0.24	-0.23	Mean platelet volume;	chr22:42856274	chr22:42791814~42794313:-
THCA	cis	rs4950322	0.57	rs3737855	ENSG00000271721.1	RP11-337C18.9	5.19	3.12e-07	4.38e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147271257	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs4950316	ENSG00000271721.1	RP11-337C18.9	5.19	3.12e-07	4.38e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147273712	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs2354428	ENSG00000271721.1	RP11-337C18.9	5.19	3.12e-07	4.38e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147277512	chr1:147175602~147177740:+
THCA	cis	rs651907	0.557	rs3806654	ENSG00000244119.1	PDCL3P4	5.19	3.12e-07	4.38e-05	0.21	0.23	Colorectal cancer;	chr3:101677685	chr3:101712472~101713191:+
THCA	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-5.19	3.12e-07	4.38e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
THCA	cis	rs4663866	1	rs4663865	ENSG00000186235.9	AC016757.3	-5.19	3.12e-07	4.38e-05	-0.48	-0.23	Irritable bowel syndrome;	chr2:238237319	chr2:238224552~238231677:-
THCA	cis	rs890448	0.694	rs2119593	ENSG00000254531.1	FLJ20021	5.19	3.12e-07	4.38e-05	0.21	0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101381407	chr4:101347780~101348883:+
THCA	cis	rs7829975	0.659	rs4382480	ENSG00000233609.3	RP11-62H7.2	5.19	3.12e-07	4.38e-05	0.23	0.23	Mood instability;	chr8:8863963	chr8:8961200~8979025:+
THCA	cis	rs1552244	1	rs61052895	ENSG00000232901.1	CYCSP10	5.19	3.12e-07	4.38e-05	0.31	0.23	Alzheimer's disease;	chr3:10105832	chr3:10000647~10000940:-
THCA	cis	rs748404	0.626	rs62019432	ENSG00000205771.5	CATSPER2P1	-5.19	3.13e-07	4.38e-05	-0.3	-0.23	Lung cancer;	chr15:43316482	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs7181545	ENSG00000205771.5	CATSPER2P1	-5.19	3.13e-07	4.38e-05	-0.3	-0.23	Lung cancer;	chr15:43321363	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs17723479	ENSG00000205771.5	CATSPER2P1	-5.19	3.13e-07	4.38e-05	-0.3	-0.23	Lung cancer;	chr15:43322114	chr15:43726918~43747094:-
THCA	cis	rs11023332	0.706	rs10766197	ENSG00000251991.1	RNU7-49P	5.19	3.13e-07	4.39e-05	0.26	0.23	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr11:14478892~14478953:+
THCA	cis	rs7942368	1	rs1440977	ENSG00000261578.1	RP11-21L23.2	5.19	3.13e-07	4.39e-05	0.33	0.23	Endometriosis;	chr11:76765385	chr11:76800364~76804555:+
THCA	cis	rs205611	0.511	rs35797811	ENSG00000224646.2	AC007387.2	-5.19	3.13e-07	4.39e-05	-0.38	-0.23	Iris characteristics;	chr2:74770955	chr2:74754670~74754819:-
THCA	cis	rs205611	0.511	rs6733646	ENSG00000224646.2	AC007387.2	-5.19	3.13e-07	4.39e-05	-0.38	-0.23	Iris characteristics;	chr2:74771062	chr2:74754670~74754819:-
THCA	cis	rs481331	0.741	rs209377	ENSG00000215146.4	RP11-313J2.1	-5.19	3.13e-07	4.39e-05	-0.38	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42606258	chr10:42331866~42367974:-
THCA	cis	rs12935418	0.579	rs7197606	ENSG00000278985.1	RP11-303E16.9	5.19	3.13e-07	4.39e-05	0.25	0.23	Mean corpuscular volume;	chr16:81019914	chr16:80982319~80984094:-
THCA	cis	rs6017291	0.59	rs16988857	ENSG00000223891.4	OSER1-AS1	-5.19	3.13e-07	4.39e-05	-0.33	-0.23	Cognitive performance;	chr20:44213153	chr20:44210960~44226027:+
THCA	cis	rs3750082	0.611	rs2392151	ENSG00000231952.3	DPY19L1P2	-5.19	3.13e-07	4.39e-05	-0.29	-0.23	Glomerular filtration rate (creatinine);	chr7:32851070	chr7:32812757~32838570:+
THCA	cis	rs710913	0.604	rs1180343	ENSG00000182109.6	RP11-69E11.4	-5.19	3.13e-07	4.4e-05	-0.21	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527760	chr1:39522280~39546187:-
THCA	cis	rs6728642	1	rs11890407	ENSG00000230606.9	AC159540.1	5.19	3.14e-07	4.4e-05	0.32	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96955910	chr2:97416165~97433527:-
THCA	cis	rs7429990	1	rs1684942	ENSG00000228638.1	FCF1P2	-5.19	3.14e-07	4.4e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47859213	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs800762	ENSG00000228638.1	FCF1P2	-5.19	3.14e-07	4.4e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47864080	chr3:48290793~48291375:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000230295.1	RP11-458F8.2	5.19	3.14e-07	4.4e-05	0.28	0.23	Diabetic kidney disease;	chr7:66172773	chr7:66880708~66882981:+
THCA	cis	rs317689	0.876	rs547332	ENSG00000274979.1	RP11-1143G9.5	-5.19	3.14e-07	4.4e-05	-0.27	-0.23	Response to diuretic therapy;	chr12:69349859	chr12:69326574~69331882:-
THCA	cis	rs7267979	0.844	rs6083845	ENSG00000125804.12	FAM182A	5.19	3.14e-07	4.4e-05	0.28	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26054655~26086917:+
THCA	cis	rs9733	0.519	rs11807450	ENSG00000231073.1	RP11-316M1.3	5.19	3.14e-07	4.4e-05	0.28	0.23	Tonsillectomy;	chr1:150705243	chr1:150973123~150975534:+
THCA	cis	rs9733	0.519	rs3768005	ENSG00000231073.1	RP11-316M1.3	5.19	3.14e-07	4.4e-05	0.28	0.23	Tonsillectomy;	chr1:150708512	chr1:150973123~150975534:+
THCA	cis	rs17798991	0.721	rs8098775	ENSG00000267674.1	RP11-813F20.2	-5.19	3.14e-07	4.4e-05	-0.25	-0.23	Obesity-related traits;	chr18:49605346	chr18:49739823~49742063:-
THCA	cis	rs6121246	0.567	rs6058203	ENSG00000230613.1	HM13-AS1	5.19	3.14e-07	4.41e-05	0.28	0.23	Mean corpuscular hemoglobin;	chr20:31611176	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.529	rs6120862	ENSG00000230613.1	HM13-AS1	5.19	3.14e-07	4.41e-05	0.28	0.23	Mean corpuscular hemoglobin;	chr20:31611656	chr20:31567707~31573263:-
THCA	cis	rs6088590	0.965	rs13040449	ENSG00000276073.1	RP5-1125A11.7	-5.19	3.14e-07	4.41e-05	-0.22	-0.23	Coronary artery disease;	chr20:34771098	chr20:33985617~33988989:-
THCA	cis	rs1395	0.922	rs11608	ENSG00000234072.1	AC074117.10	5.19	3.15e-07	4.41e-05	0.19	0.23	Blood metabolite levels;	chr2:27212506	chr2:27356246~27367622:+
THCA	cis	rs4767841	0.935	rs2952444	ENSG00000248636.5	RP11-768F21.1	-5.19	3.15e-07	4.41e-05	-0.24	-0.23	Urgency urinary incontinence;	chr12:119737986	chr12:119387987~119668079:-
THCA	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-5.19	3.15e-07	4.41e-05	-0.28	-0.23	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
THCA	cis	rs5015933	0.902	rs7872015	ENSG00000232630.1	PRPS1P2	-5.19	3.15e-07	4.41e-05	-0.16	-0.23	Body mass index;	chr9:125368854	chr9:125150653~125151589:+
THCA	cis	rs227275	0.53	rs3960788	ENSG00000230069.3	LRRC37A15P	-5.19	3.15e-07	4.41e-05	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102727274~102730721:-
THCA	cis	rs11722228	0.79	rs13126729	ENSG00000261490.1	RP11-448G15.3	-5.19	3.15e-07	4.41e-05	-0.17	-0.23	Urate levels;Serum uric acid levels;Gout;	chr4:9972562	chr4:10068089~10073019:-
THCA	cis	rs227275	0.554	rs223388	ENSG00000248971.2	KRT8P46	-5.19	3.15e-07	4.42e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102728746~102730171:-
THCA	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	5.19	3.15e-07	4.42e-05	0.27	0.23	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
THCA	cis	rs8064024	0.676	rs2075467	ENSG00000267077.1	RP11-127I20.5	-5.19	3.15e-07	4.42e-05	-0.27	-0.23	Cancer;	chr16:4823241	chr16:4795265~4796532:-
THCA	cis	rs3213758	0.881	rs12445196	ENSG00000275191.1	RP11-36I17.2	-5.19	3.15e-07	4.42e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53624975	chr16:53628256~53628816:-
THCA	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-5.19	3.15e-07	4.42e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
THCA	cis	rs875971	0.545	rs73142245	ENSG00000232546.1	RP11-458F8.1	5.19	3.15e-07	4.42e-05	0.22	0.23	Aortic root size;	chr7:66226662	chr7:66848496~66858136:+
THCA	cis	rs4950322	1	rs72694720	ENSG00000278811.3	LINC00624	5.19	3.16e-07	4.42e-05	0.31	0.23	Protein quantitative trait loci;	chr1:147371939	chr1:147258885~147517875:-
THCA	cis	rs10090774	0.76	rs13257090	ENSG00000279766.1	RP11-642A1.2	-5.19	3.16e-07	4.42e-05	-0.29	-0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140719364	chr8:140572142~140572812:-
THCA	cis	rs34779708	0.966	rs12761675	ENSG00000271335.4	RP11-324I22.4	-5.19	3.16e-07	4.43e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35314552~35336401:-
THCA	cis	rs6570726	0.72	rs412623	ENSG00000270638.1	RP3-466P17.1	5.19	3.16e-07	4.43e-05	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145735570~145737218:+
THCA	cis	rs613391	0.735	rs688066	ENSG00000224549.1	RP11-370B11.3	-5.19	3.16e-07	4.43e-05	-0.27	-0.23	Quantitative traits;	chr9:22713036	chr9:22767175~22768316:+
THCA	cis	rs6997458	0.742	rs10091566	ENSG00000253549.4	RP11-317J10.2	5.19	3.16e-07	4.43e-05	0.23	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85429330	chr8:85441851~85464915:-
THCA	cis	rs6997458	0.742	rs1908075	ENSG00000253549.4	RP11-317J10.2	5.19	3.16e-07	4.43e-05	0.23	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434567	chr8:85441851~85464915:-
THCA	cis	rs6997458	0.742	rs11985733	ENSG00000253549.4	RP11-317J10.2	5.19	3.16e-07	4.43e-05	0.23	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434845	chr8:85441851~85464915:-
THCA	cis	rs6997458	0.742	rs11985029	ENSG00000253549.4	RP11-317J10.2	5.19	3.16e-07	4.43e-05	0.23	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434887	chr8:85441851~85464915:-
THCA	cis	rs5015933	0.815	rs1333055	ENSG00000232630.1	PRPS1P2	-5.19	3.16e-07	4.44e-05	-0.16	-0.23	Body mass index;	chr9:125307948	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.815	rs12553785	ENSG00000232630.1	PRPS1P2	-5.19	3.16e-07	4.44e-05	-0.16	-0.23	Body mass index;	chr9:125314262	chr9:125150653~125151589:+
THCA	cis	rs9625935	0.957	rs8141404	ENSG00000279159.1	RP3-394A18.1	5.19	3.16e-07	4.44e-05	0.18	0.23	Tonsillectomy;	chr22:30078227	chr22:29978950~30028236:-
THCA	cis	rs853679	0.546	rs175597	ENSG00000226314.6	ZNF192P1	-5.19	3.17e-07	4.44e-05	-0.39	-0.23	Depression;	chr6:27842848	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs200989	ENSG00000226314.6	ZNF192P1	-5.19	3.17e-07	4.44e-05	-0.39	-0.23	Depression;	chr6:27848664	chr6:28161781~28169594:+
THCA	cis	rs6772849	0.93	rs6768344	ENSG00000242551.2	POU5F1P6	-5.19	3.17e-07	4.44e-05	-0.3	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:128674735~128677005:-
THCA	cis	rs2797160	1	rs13328298	ENSG00000237742.5	RP11-624M8.1	5.19	3.17e-07	4.44e-05	0.2	0.23	Endometrial cancer;	chr6:125695434	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs6933302	ENSG00000237742.5	RP11-624M8.1	5.19	3.17e-07	4.44e-05	0.2	0.23	Endometrial cancer;	chr6:125695805	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs6933471	ENSG00000237742.5	RP11-624M8.1	5.19	3.17e-07	4.44e-05	0.2	0.23	Endometrial cancer;	chr6:125695883	chr6:125578558~125749190:-
THCA	cis	rs9733	0.596	rs6686525	ENSG00000231073.1	RP11-316M1.3	5.19	3.17e-07	4.44e-05	0.27	0.23	Tonsillectomy;	chr1:150663335	chr1:150973123~150975534:+
THCA	cis	rs5758659	0.652	rs133322	ENSG00000227370.1	RP4-669P10.19	-5.19	3.17e-07	4.44e-05	-0.22	-0.23	Cognitive function;	chr22:42009655	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.623	rs133328	ENSG00000227370.1	RP4-669P10.19	-5.19	3.17e-07	4.44e-05	-0.22	-0.23	Cognitive function;	chr22:42012075	chr22:42132543~42132998:+
THCA	cis	rs12893668	0.543	rs1799796	ENSG00000269940.1	RP11-73M18.7	5.19	3.17e-07	4.44e-05	0.24	0.23	Reticulocyte count;	chr14:103699590	chr14:103694560~103695170:+
THCA	cis	rs12893668	0.514	rs3212090	ENSG00000269940.1	RP11-73M18.7	5.19	3.17e-07	4.44e-05	0.24	0.23	Reticulocyte count;	chr14:103702526	chr14:103694560~103695170:+
THCA	cis	rs72615157	0.629	rs55839153	ENSG00000078319.8	PMS2P1	-5.19	3.17e-07	4.44e-05	-0.33	-0.23	Lung function (FEV1/FVC);	chr7:100154943	chr7:100320992~100341908:-
THCA	cis	rs919433	0.889	rs787998	ENSG00000231621.1	AC013264.2	-5.19	3.17e-07	4.44e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351368	chr2:197197991~197199273:+
THCA	cis	rs919433	0.926	rs787997	ENSG00000231621.1	AC013264.2	-5.19	3.17e-07	4.44e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351547	chr2:197197991~197199273:+
THCA	cis	rs6708331	0.54	rs11890701	ENSG00000179818.12	PCBP1-AS1	-5.19	3.17e-07	4.44e-05	-0.19	-0.23	Obesity-related traits;	chr2:70133325	chr2:69962263~70103220:-
THCA	cis	rs9467773	1	rs6940188	ENSG00000261353.1	CTA-14H9.5	-5.19	3.17e-07	4.44e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26527063~26527404:+
THCA	cis	rs9733	0.527	rs11204694	ENSG00000231073.1	RP11-316M1.3	5.19	3.17e-07	4.44e-05	0.28	0.23	Tonsillectomy;	chr1:150680915	chr1:150973123~150975534:+
THCA	cis	rs16846053	0.584	rs57840078	ENSG00000227403.1	AC009299.3	5.19	3.17e-07	4.44e-05	0.51	0.23	Blood osmolality (transformed sodium);	chr2:161545949	chr2:161244739~161249050:+
THCA	cis	rs11733284	0.894	rs321628	ENSG00000259959.1	RP11-121C2.2	5.19	3.17e-07	4.45e-05	0.19	0.23	Gout;Renal underexcretion gout;	chr4:48014858	chr4:47840122~47844339:-
THCA	cis	rs1979679	0.918	rs7977429	ENSG00000278733.1	RP11-425D17.1	5.19	3.17e-07	4.45e-05	0.23	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28370376	chr12:28185625~28186190:-
THCA	cis	rs10875746	0.669	rs11168496	ENSG00000258234.1	RP11-370I10.2	5.19	3.17e-07	4.45e-05	0.27	0.23	Longevity (90 years and older);	chr12:48257072	chr12:48231098~48284210:-
THCA	cis	rs4650994	0.816	rs1074896	ENSG00000273384.1	RP5-1098D14.1	-5.19	3.18e-07	4.45e-05	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178622055	chr1:178651706~178652282:+
THCA	cis	rs3820928	0.874	rs3752895	ENSG00000212391.1	SNORA48	-5.19	3.18e-07	4.45e-05	-0.25	-0.23	Pulmonary function;	chr2:227022057	chr2:226968989~226969122:-
THCA	cis	rs73198271	0.737	rs506960	ENSG00000253893.2	FAM85B	5.19	3.18e-07	4.45e-05	0.31	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8167819~8226614:-
THCA	cis	rs4950322	0.542	rs17159914	ENSG00000271721.1	RP11-337C18.9	-5.19	3.18e-07	4.45e-05	-0.24	-0.23	Protein quantitative trait loci;	chr1:147183226	chr1:147175602~147177740:+
THCA	cis	rs3020264	1	rs3020264	ENSG00000271743.1	CTD-2541M15.3	5.19	3.18e-07	4.46e-05	0.31	0.23	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6615604~6617198:-
THCA	cis	rs6997458	0.742	rs7841178	ENSG00000253549.4	RP11-317J10.2	-5.19	3.18e-07	4.46e-05	-0.23	-0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85425690	chr8:85441851~85464915:-
THCA	cis	rs10200159	1	rs13428486	ENSG00000272606.1	RP11-554J4.1	5.19	3.18e-07	4.46e-05	0.46	0.23	Vitiligo;	chr2:55569451	chr2:55617909~55618373:+
THCA	cis	rs10256972	0.621	rs10951594	ENSG00000225146.1	AC073957.15	5.19	3.18e-07	4.46e-05	0.24	0.23	Endometriosis;Longevity;	chr7:1048971	chr7:1029025~1043891:+
THCA	cis	rs1832886	1	rs1832886	ENSG00000236493.2	EIF2S2P3	5.19	3.18e-07	4.46e-05	0.24	0.23	Body mass index;	chr10:92717782	chr10:92668745~92669743:-
THCA	cis	rs7923837	0.964	rs10882106	ENSG00000236493.2	EIF2S2P3	5.19	3.18e-07	4.46e-05	0.24	0.23	Multiple sclerosis;Body mass index;	chr10:92720577	chr10:92668745~92669743:-
THCA	cis	rs7923837	1	rs7923837	ENSG00000236493.2	EIF2S2P3	5.19	3.18e-07	4.46e-05	0.24	0.23	Multiple sclerosis;Body mass index;	chr10:92722160	chr10:92668745~92669743:-
THCA	cis	rs7923837	1	rs7923866	ENSG00000236493.2	EIF2S2P3	5.19	3.18e-07	4.46e-05	0.24	0.23	Multiple sclerosis;Body mass index;	chr10:92722319	chr10:92668745~92669743:-
THCA	cis	rs2559856	1	rs2559854	ENSG00000274560.1	RP11-285E23.2	5.19	3.18e-07	4.46e-05	0.14	0.23	Blood protein levels;	chr12:101696468	chr12:101696002~101696450:-
THCA	cis	rs1979679	0.918	rs11049562	ENSG00000278733.1	RP11-425D17.1	5.19	3.19e-07	4.46e-05	0.23	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28375576	chr12:28185625~28186190:-
THCA	cis	rs4646450	0.891	rs917154	ENSG00000244219.5	GS1-259H13.2	-5.19	3.19e-07	4.46e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99423183	chr7:99598066~99610813:+
THCA	cis	rs763121	0.819	rs5757169	ENSG00000228274.3	RP3-508I15.9	-5.19	3.19e-07	4.46e-05	-0.25	-0.23	Menopause (age at onset);	chr22:38607490	chr22:38667585~38681820:-
THCA	cis	rs5015933	0.832	rs2841332	ENSG00000232630.1	PRPS1P2	-5.19	3.19e-07	4.46e-05	-0.16	-0.23	Body mass index;	chr9:125367578	chr9:125150653~125151589:+
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000261839.1	RP1-265C24.8	5.19	3.19e-07	4.46e-05	0.27	0.23	Parkinson's disease;	chr6:28055973	chr6:28136849~28139678:+
THCA	cis	rs7267979	0.844	rs6107027	ENSG00000125804.12	FAM182A	-5.19	3.19e-07	4.47e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26054655~26086917:+
THCA	cis	rs4713118	0.513	rs156734	ENSG00000226314.6	ZNF192P1	-5.19	3.19e-07	4.47e-05	-0.27	-0.23	Parkinson's disease;	chr6:28039579	chr6:28161781~28169594:+
THCA	cis	rs9309473	0.5	rs2421664	ENSG00000163016.8	ALMS1P	-5.19	3.19e-07	4.47e-05	-0.3	-0.23	Metabolite levels;	chr2:73631754	chr2:73644919~73685576:+
THCA	cis	rs11096990	0.892	rs1473364	ENSG00000249685.1	RP11-360F5.3	5.19	3.19e-07	4.47e-05	0.3	0.23	Cognitive function;	chr4:39211259	chr4:39133913~39135608:+
THCA	cis	rs1334894	0.71	rs45493300	ENSG00000228559.1	RP3-340B19.3	-5.19	3.19e-07	4.47e-05	-0.4	-0.23	Coronary artery disease;	chr6:35497803	chr6:35544632~35545669:+
THCA	cis	rs7617773	0.78	rs3731550	ENSG00000199476.1	Y_RNA	-5.19	3.19e-07	4.47e-05	-0.3	-0.23	Coronary artery disease;	chr3:48165093	chr3:48288587~48288694:+
THCA	cis	rs205611	0.511	rs11691168	ENSG00000224646.2	AC007387.2	-5.19	3.19e-07	4.47e-05	-0.38	-0.23	Iris characteristics;	chr2:74771987	chr2:74754670~74754819:-
THCA	cis	rs1552244	0.748	rs9862221	ENSG00000180385.7	EMC3-AS1	5.19	3.2e-07	4.48e-05	0.26	0.23	Alzheimer's disease;	chr3:10017974	chr3:9986893~10006990:+
THCA	cis	rs224278	0.77	rs7076924	ENSG00000238280.1	RP11-436D10.3	-5.19	3.2e-07	4.48e-05	-0.27	-0.23	Ewing sarcoma;	chr10:62819228	chr10:62793562~62805887:-
THCA	cis	rs2029362	0.604	rs7939810	ENSG00000245573.6	BDNF-AS	5.19	3.2e-07	4.48e-05	0.19	0.23	Total body bone mineral density;	chr11:27611862	chr11:27506838~27698174:+
THCA	cis	rs412050	0.547	rs112153746	ENSG00000224086.5	LL22NC03-86G7.1	-5.19	3.2e-07	4.48e-05	-0.42	-0.23	Attention deficit hyperactivity disorder;	chr22:21784402	chr22:21938293~21977632:+
THCA	cis	rs412050	0.547	rs61763401	ENSG00000224086.5	LL22NC03-86G7.1	-5.19	3.2e-07	4.48e-05	-0.42	-0.23	Attention deficit hyperactivity disorder;	chr22:21785558	chr22:21938293~21977632:+
THCA	cis	rs9925964	0.933	rs2303222	ENSG00000260911.2	RP11-196G11.2	-5.19	3.2e-07	4.48e-05	-0.19	-0.23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:31043150~31049868:+
THCA	cis	rs714027	1	rs2412973	ENSG00000279159.1	RP3-394A18.1	-5.19	3.2e-07	4.48e-05	-0.16	-0.23	Lymphocyte counts;	chr22:30133642	chr22:29978950~30028236:-
THCA	cis	rs875971	0.502	rs2946580	ENSG00000228409.4	CCT6P1	5.19	3.2e-07	4.48e-05	0.2	0.23	Aortic root size;	chr7:66066855	chr7:65751142~65763354:+
THCA	cis	rs72627509	0.68	rs3733309	ENSG00000269949.1	RP11-738E22.3	5.19	3.2e-07	4.49e-05	0.37	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56991022	chr4:56960927~56961373:-
THCA	cis	rs2243480	1	rs2257790	ENSG00000230295.1	RP11-458F8.2	-5.19	3.2e-07	4.49e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66135463	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs316332	ENSG00000230295.1	RP11-458F8.2	-5.19	3.2e-07	4.49e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66139312	chr7:66880708~66882981:+
THCA	cis	rs595244	0.908	rs2015637	ENSG00000259705.1	RP11-227D13.1	5.19	3.2e-07	4.49e-05	0.37	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48424656	chr15:48645951~48652016:+
THCA	cis	rs2734839	0.929	rs2734835	ENSG00000270179.1	RP11-159N11.4	-5.19	3.2e-07	4.49e-05	-0.25	-0.23	Information processing speed;	chr11:113420621	chr11:113368478~113369117:+
THCA	cis	rs5015933	1	rs2841329	ENSG00000232630.1	PRPS1P2	-5.19	3.2e-07	4.49e-05	-0.16	-0.23	Body mass index;	chr9:125372053	chr9:125150653~125151589:+
THCA	cis	rs2299587	0.543	rs12546204	ENSG00000253671.1	RP11-806O11.1	-5.19	3.21e-07	4.49e-05	-0.28	-0.23	Economic and political preferences;	chr8:17939362	chr8:17808941~17820868:+
THCA	cis	rs2985684	0.948	rs2883437	ENSG00000278009.1	RP11-649E7.8	5.19	3.21e-07	4.49e-05	0.32	0.23	Carotid intima media thickness;	chr14:49564948	chr14:49601011~49601124:-
THCA	cis	rs2803122	0.745	rs10811143	ENSG00000273226.1	RP11-513M16.8	-5.19	3.21e-07	4.49e-05	-0.21	-0.23	Pulse pressure;	chr9:19240221	chr9:19375451~19375996:+
THCA	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	5.19	3.21e-07	4.49e-05	0.3	0.23	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
THCA	cis	rs6951245	0.507	rs11976805	ENSG00000229043.2	AC091729.9	-5.19	3.21e-07	4.49e-05	-0.3	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1160374~1165267:+
THCA	cis	rs1479090	0.901	rs6835785	ENSG00000250027.1	RP11-563E2.2	-5.19	3.21e-07	4.49e-05	-0.25	-0.23	Lung cancer;	chr4:163134850	chr4:163108785~163119965:+
THCA	cis	rs4415084	0.8	rs930396	ENSG00000272335.1	RP11-53O19.3	5.19	3.21e-07	4.49e-05	0.19	0.23	Breast cancer;	chr5:44856349	chr5:44826076~44828592:+
THCA	cis	rs2136613	0.751	rs10822060	ENSG00000238280.1	RP11-436D10.3	-5.19	3.21e-07	4.49e-05	-0.26	-0.23	Selective IgA deficiency;	chr10:62834625	chr10:62793562~62805887:-
THCA	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	5.19	3.21e-07	4.49e-05	0.27	0.23	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
THCA	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	5.19	3.21e-07	4.5e-05	0.27	0.23	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
THCA	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	5.19	3.21e-07	4.5e-05	0.27	0.23	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
THCA	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	5.19	3.21e-07	4.5e-05	0.27	0.23	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
THCA	cis	rs6951245	0.938	rs11764937	ENSG00000229043.2	AC091729.9	-5.19	3.21e-07	4.5e-05	-0.41	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052438	chr7:1160374~1165267:+
THCA	cis	rs6585424	1	rs12763392	ENSG00000242600.5	MBL1P	-5.19	3.21e-07	4.5e-05	-0.27	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175239	chr10:79904898~79950336:+
THCA	cis	rs2512987	0.967	rs2512984	ENSG00000254731.1	CTD-2005H7.1	-5.19	3.21e-07	4.5e-05	-0.29	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86704172	chr11:86703099~86714092:+
THCA	cis	rs2512987	0.967	rs2512982	ENSG00000254731.1	CTD-2005H7.1	-5.19	3.21e-07	4.5e-05	-0.29	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86704748	chr11:86703099~86714092:+
THCA	cis	rs2512987	0.935	rs2512981	ENSG00000254731.1	CTD-2005H7.1	-5.19	3.21e-07	4.5e-05	-0.29	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86705206	chr11:86703099~86714092:+
THCA	cis	rs944289	0.718	rs12878623	ENSG00000258844.1	RP11-259K15.2	5.19	3.21e-07	4.5e-05	0.21	0.23	Thyroid cancer;	chr14:36081499	chr14:36214607~36235608:+
THCA	cis	rs10895275	0.772	rs10895280	ENSG00000277459.1	RP11-732A21.3	-5.19	3.21e-07	4.5e-05	-0.19	-0.23	Migraine;	chr11:102237691	chr11:102109827~102110457:-
THCA	cis	rs10904908	1	rs7903259	ENSG00000229124.5	VIM-AS1	5.19	3.22e-07	4.5e-05	0.23	0.23	Cholesterol, total;Total cholesterol levels;	chr10:17217643	chr10:17214239~17229985:-
THCA	cis	rs34779708	0.931	rs3740083	ENSG00000271335.4	RP11-324I22.4	5.19	3.22e-07	4.5e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35314552~35336401:-
THCA	cis	rs7897654	0.571	rs12771681	ENSG00000236937.2	PTGES3P4	5.18	3.22e-07	4.51e-05	0.33	0.23	Schizophrenia;	chr10:102875863	chr10:102845595~102845950:+
THCA	cis	rs7772486	0.686	rs4896827	ENSG00000270638.1	RP3-466P17.1	5.18	3.22e-07	4.51e-05	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs4896828	ENSG00000270638.1	RP3-466P17.1	5.18	3.22e-07	4.51e-05	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs6570701	ENSG00000270638.1	RP3-466P17.1	5.18	3.22e-07	4.51e-05	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145735570~145737218:+
THCA	cis	rs1395	1	rs1275530	ENSG00000234072.1	AC074117.10	5.18	3.22e-07	4.51e-05	0.19	0.23	Blood metabolite levels;	chr2:27209679	chr2:27356246~27367622:+
THCA	cis	rs2253762	0.54	rs11200357	ENSG00000276742.1	RP11-500G22.4	5.18	3.22e-07	4.51e-05	0.33	0.23	Breast cancer;	chr10:122034390	chr10:121956782~121957098:+
THCA	cis	rs4950322	0.57	rs72692980	ENSG00000226015.2	CCT8P1	5.18	3.22e-07	4.51e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147337830	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.634	rs7542951	ENSG00000226015.2	CCT8P1	5.18	3.22e-07	4.51e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147340308	chr1:147203276~147204932:-
THCA	cis	rs651907	0.514	rs10936744	ENSG00000244119.1	PDCL3P4	5.18	3.22e-07	4.51e-05	0.21	0.23	Colorectal cancer;	chr3:101714596	chr3:101712472~101713191:+
THCA	cis	rs651907	0.514	rs12636047	ENSG00000244119.1	PDCL3P4	5.18	3.22e-07	4.51e-05	0.21	0.23	Colorectal cancer;	chr3:101715605	chr3:101712472~101713191:+
THCA	cis	rs7208859	0.725	rs9910051	ENSG00000263603.1	CTD-2349P21.5	-5.18	3.23e-07	4.51e-05	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.725	rs7210904	ENSG00000263603.1	CTD-2349P21.5	-5.18	3.23e-07	4.51e-05	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.725	rs9915802	ENSG00000263603.1	CTD-2349P21.5	-5.18	3.23e-07	4.51e-05	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.725	rs7342938	ENSG00000263603.1	CTD-2349P21.5	-5.18	3.23e-07	4.51e-05	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30729469~30731202:+
THCA	cis	rs7208859	0.725	rs6505215	ENSG00000263603.1	CTD-2349P21.5	-5.18	3.23e-07	4.51e-05	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30729469~30731202:+
THCA	cis	rs4845570	1	rs7416415	ENSG00000203288.3	RP11-98D18.9	5.18	3.23e-07	4.52e-05	0.26	0.23	Coronary artery disease;	chr1:151785322	chr1:151790804~151794402:+
THCA	cis	rs10165862	0.537	rs17009372	ENSG00000163016.8	ALMS1P	-5.18	3.23e-07	4.52e-05	-0.34	-0.23	Intelligence (multi-trait analysis);	chr2:73728444	chr2:73644919~73685576:+
THCA	cis	rs5751901	1	rs5751901	ENSG00000215481.7	BCRP3	5.18	3.23e-07	4.52e-05	0.19	0.23	Protein quantitative trait loci;	chr22:24596299	chr22:24632915~24653356:+
THCA	cis	rs17767392	0.781	rs8015644	ENSG00000259146.3	RP1-261D10.2	5.18	3.23e-07	4.52e-05	0.29	0.23	Mitral valve prolapse;	chr14:71376012	chr14:71292729~71321814:-
THCA	cis	rs12137231	0.967	rs1380995	ENSG00000227207.2	RPL31P12	5.18	3.23e-07	4.52e-05	0.27	0.23	Intelligence (multi-trait analysis);	chr1:72268158	chr1:72301472~72301829:+
THCA	cis	rs8141529	0.732	rs6005872	ENSG00000272858.1	CTA-292E10.8	-5.18	3.23e-07	4.52e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28776910	chr22:28814914~28815662:+
THCA	cis	rs1876905	0.539	rs240958	ENSG00000230177.1	RP5-1112D6.4	5.18	3.23e-07	4.52e-05	0.25	0.23	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111277932~111278742:+
THCA	cis	rs9876781	1	rs922075	ENSG00000244380.1	RP11-24C3.2	-5.18	3.23e-07	4.52e-05	-0.27	-0.23	Longevity;	chr3:48447994	chr3:48440352~48446656:-
THCA	cis	rs6142102	0.924	rs6059662	ENSG00000275784.1	RP5-1125A11.6	5.18	3.23e-07	4.52e-05	0.24	0.23	Skin pigmentation;	chr20:34087921	chr20:33989480~33991818:-
THCA	cis	rs4888671	1	rs76412521	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747019	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs79704582	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747262	chr16:77741468~77743000:-
THCA	cis	rs4888671	0.803	rs78291339	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747318	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs79409507	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747583	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs78839411	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747617	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs79885511	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747642	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs74783281	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747704	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs76243942	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747740	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs75936301	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747845	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs78780050	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77747891	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs78515849	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77748101	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs78599153	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77748157	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs80279339	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77748165	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs79116314	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77748535	chr16:77741468~77743000:-
THCA	cis	rs4888671	1	rs77528108	ENSG00000261707.1	RP11-264M12.2	5.18	3.23e-07	4.52e-05	0.43	0.23	Obesity-related traits;	chr16:77748538	chr16:77741468~77743000:-
THCA	cis	rs2299587	0.642	rs2073570	ENSG00000253671.1	RP11-806O11.1	-5.18	3.24e-07	4.53e-05	-0.27	-0.23	Economic and political preferences;	chr8:17925118	chr8:17808941~17820868:+
THCA	cis	rs6088580	0.634	rs1205345	ENSG00000276073.1	RP5-1125A11.7	5.18	3.24e-07	4.53e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34326893	chr20:33985617~33988989:-
THCA	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-5.18	3.24e-07	4.53e-05	-0.31	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
THCA	cis	rs6951245	0.786	rs77943789	ENSG00000229043.2	AC091729.9	-5.18	3.24e-07	4.53e-05	-0.37	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100522	chr7:1160374~1165267:+
THCA	cis	rs7045881	0.675	rs62542665	ENSG00000254396.1	RP11-56F10.3	5.18	3.24e-07	4.53e-05	0.43	0.23	Schizophrenia;	chr9:26992658	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.675	rs73436044	ENSG00000254396.1	RP11-56F10.3	5.18	3.24e-07	4.53e-05	0.43	0.23	Schizophrenia;	chr9:26999116	chr9:27102630~27104728:+
THCA	cis	rs6430585	0.583	rs78364332	ENSG00000231890.6	DARS-AS1	-5.18	3.24e-07	4.53e-05	-0.28	-0.23	Corneal structure;	chr2:135882531	chr2:135985176~136022593:+
THCA	cis	rs4950322	0.57	rs17356184	ENSG00000271721.1	RP11-337C18.9	5.18	3.24e-07	4.54e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147262943	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs80270233	ENSG00000271721.1	RP11-337C18.9	5.18	3.24e-07	4.54e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147263320	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs4950392	ENSG00000271721.1	RP11-337C18.9	5.18	3.24e-07	4.54e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147264889	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs17356219	ENSG00000271721.1	RP11-337C18.9	5.18	3.24e-07	4.54e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147265684	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72691041	ENSG00000271721.1	RP11-337C18.9	5.18	3.24e-07	4.54e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147267084	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs17356233	ENSG00000271721.1	RP11-337C18.9	5.18	3.24e-07	4.54e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147268843	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs17356240	ENSG00000271721.1	RP11-337C18.9	5.18	3.24e-07	4.54e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147269877	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs1999820	ENSG00000271721.1	RP11-337C18.9	5.18	3.24e-07	4.54e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147270329	chr1:147175602~147177740:+
THCA	cis	rs7637701	0.901	rs13071598	ENSG00000240875.4	LINC00886	-5.18	3.24e-07	4.54e-05	-0.18	-0.23	Breast cancer;	chr3:156854426	chr3:156747346~156817062:-
THCA	cis	rs5015933	0.902	rs2270746	ENSG00000232630.1	PRPS1P2	5.18	3.24e-07	4.54e-05	0.16	0.23	Body mass index;	chr9:125359313	chr9:125150653~125151589:+
THCA	cis	rs17767392	0.846	rs4899394	ENSG00000259146.3	RP1-261D10.2	5.18	3.24e-07	4.54e-05	0.28	0.23	Mitral valve prolapse;	chr14:71306780	chr14:71292729~71321814:-
THCA	cis	rs9719620	0.802	rs4731784	ENSG00000236753.4	MKLN1-AS	-5.18	3.24e-07	4.54e-05	-0.22	-0.23	Male-pattern baldness;	chr7:131301022	chr7:131309744~131328222:-
THCA	cis	rs651907	0.535	rs11919389	ENSG00000244119.1	PDCL3P4	5.18	3.24e-07	4.54e-05	0.21	0.23	Colorectal cancer;	chr3:101705614	chr3:101712472~101713191:+
THCA	cis	rs7924176	0.521	rs10824142	ENSG00000213731.2	RAB5CP1	-5.18	3.25e-07	4.54e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.521	rs11000965	ENSG00000213731.2	RAB5CP1	-5.18	3.25e-07	4.54e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.521	rs12357370	ENSG00000213731.2	RAB5CP1	-5.18	3.25e-07	4.54e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:74423435~74424014:-
THCA	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-5.18	3.25e-07	4.54e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
THCA	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-5.18	3.25e-07	4.54e-05	-0.36	-0.23	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
THCA	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	5.18	3.25e-07	4.54e-05	0.17	0.23	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
THCA	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	5.18	3.25e-07	4.54e-05	0.17	0.23	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
THCA	cis	rs7829975	0.617	rs4841072	ENSG00000253981.4	ALG1L13P	-5.18	3.25e-07	4.55e-05	-0.22	-0.23	Mood instability;	chr8:8933743	chr8:8236003~8244667:-
THCA	cis	rs9890032	0.934	rs3760318	ENSG00000263531.1	RP13-753N3.1	5.18	3.25e-07	4.55e-05	0.3	0.23	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30863921~30864940:-
THCA	cis	rs748404	0.666	rs12908460	ENSG00000205771.5	CATSPER2P1	-5.18	3.25e-07	4.55e-05	-0.3	-0.23	Lung cancer;	chr15:43413472	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs2230451	ENSG00000205771.5	CATSPER2P1	-5.18	3.25e-07	4.55e-05	-0.3	-0.23	Lung cancer;	chr15:43415610	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs62021180	ENSG00000205771.5	CATSPER2P1	-5.18	3.25e-07	4.55e-05	-0.3	-0.23	Lung cancer;	chr15:43420139	chr15:43726918~43747094:-
THCA	cis	rs3796352	1	rs116616340	ENSG00000242142.1	SERBP1P3	-5.18	3.25e-07	4.55e-05	-0.42	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53098355	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs113995589	ENSG00000242142.1	SERBP1P3	-5.18	3.25e-07	4.55e-05	-0.42	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53098356	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs75217232	ENSG00000242142.1	SERBP1P3	-5.18	3.25e-07	4.55e-05	-0.42	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53098357	chr3:53064283~53065091:-
THCA	cis	rs17767392	0.918	rs35822724	ENSG00000259146.3	RP1-261D10.2	5.18	3.25e-07	4.55e-05	0.3	0.23	Mitral valve prolapse;	chr14:71310217	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.874	rs34767050	ENSG00000259146.3	RP1-261D10.2	5.18	3.25e-07	4.55e-05	0.3	0.23	Mitral valve prolapse;	chr14:71314240	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.881	rs35054229	ENSG00000259146.3	RP1-261D10.2	5.18	3.25e-07	4.55e-05	0.3	0.23	Mitral valve prolapse;	chr14:71318485	chr14:71292729~71321814:-
THCA	cis	rs11671005	0.779	rs55875034	ENSG00000269473.1	CTD-2619J13.19	5.18	3.25e-07	4.55e-05	0.27	0.23	Mean platelet volume;	chr19:58472191	chr19:58440448~58445849:+
THCA	cis	rs4660456	0.913	rs7551747	ENSG00000272145.1	NFYC-AS1	-5.18	3.25e-07	4.55e-05	-0.16	-0.23	Platelet count;	chr1:40699407	chr1:40690380~40692066:-
THCA	cis	rs13256369	1	rs7820159	ENSG00000253893.2	FAM85B	-5.18	3.26e-07	4.55e-05	-0.31	-0.23	Obesity-related traits;	chr8:8718705	chr8:8167819~8226614:-
THCA	cis	rs6598266	1	rs12907687	ENSG00000259363.4	CTD-2054N24.2	-5.18	3.26e-07	4.55e-05	-0.42	-0.23	Major depressive disorder;	chr15:99764915	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs12910759	ENSG00000259363.4	CTD-2054N24.2	-5.18	3.26e-07	4.55e-05	-0.42	-0.23	Major depressive disorder;	chr15:99765109	chr15:99807023~99877148:+
THCA	cis	rs7474896	0.616	rs1985260	ENSG00000276805.1	RP11-291L22.6	5.18	3.26e-07	4.55e-05	0.32	0.23	Obesity (extreme);	chr10:38145162	chr10:38451030~38451785:+
THCA	cis	rs875971	0.522	rs781144	ENSG00000273142.1	RP11-458F8.4	-5.18	3.26e-07	4.56e-05	-0.19	-0.23	Aortic root size;	chr7:65975357	chr7:66902857~66906297:+
THCA	cis	rs4915077	1	rs17020146	ENSG00000230489.1	VAV3-AS1	5.18	3.26e-07	4.56e-05	0.39	0.23	Hypothyroidism;	chr1:107832080	chr1:107964443~107994607:+
THCA	cis	rs6547741	0.935	rs4666005	ENSG00000234072.1	AC074117.10	5.18	3.26e-07	4.56e-05	0.18	0.23	Oral cavity cancer;	chr2:27632372	chr2:27356246~27367622:+
THCA	cis	rs10895987	0.531	rs11227120	ENSG00000254614.2	AP003068.23	5.18	3.26e-07	4.56e-05	0.32	0.23	Blood protein levels;	chr11:65097387	chr11:65177606~65181834:-
THCA	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	5.18	3.26e-07	4.56e-05	0.27	0.23	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
THCA	cis	rs4660214	0.671	rs72661956	ENSG00000228060.1	RP11-69E11.8	-5.18	3.26e-07	4.56e-05	-0.28	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39319216	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.671	rs16826068	ENSG00000228060.1	RP11-69E11.8	-5.18	3.26e-07	4.56e-05	-0.28	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39326204	chr1:39565160~39573203:+
THCA	cis	rs934734	0.789	rs10188563	ENSG00000281920.1	RP11-418H16.1	5.18	3.26e-07	4.56e-05	0.29	0.23	Rheumatoid arthritis;	chr2:65342805	chr2:65623272~65628424:+
THCA	cis	rs17767392	0.846	rs61991246	ENSG00000259146.3	RP1-261D10.2	5.18	3.27e-07	4.57e-05	0.29	0.23	Mitral valve prolapse;	chr14:71393141	chr14:71292729~71321814:-
THCA	cis	rs919433	0.68	rs7582536	ENSG00000231621.1	AC013264.2	5.18	3.27e-07	4.57e-05	0.25	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197571379	chr2:197197991~197199273:+
THCA	cis	rs6772849	0.93	rs4857914	ENSG00000242551.2	POU5F1P6	-5.18	3.27e-07	4.57e-05	-0.3	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128631841	chr3:128674735~128677005:-
THCA	cis	rs2303319	0.504	rs1006427	ENSG00000227403.1	AC009299.3	5.18	3.27e-07	4.57e-05	0.48	0.23	Cognitive function;	chr2:161735818	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs1006428	ENSG00000227403.1	AC009299.3	5.18	3.27e-07	4.57e-05	0.48	0.23	Cognitive function;	chr2:161736049	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs1023835	ENSG00000227403.1	AC009299.3	5.18	3.27e-07	4.57e-05	0.48	0.23	Cognitive function;	chr2:161737463	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56965753	ENSG00000227403.1	AC009299.3	5.18	3.27e-07	4.57e-05	0.48	0.23	Cognitive function;	chr2:161740741	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189041	ENSG00000227403.1	AC009299.3	5.18	3.27e-07	4.57e-05	0.48	0.23	Cognitive function;	chr2:161742996	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189042	ENSG00000227403.1	AC009299.3	5.18	3.27e-07	4.57e-05	0.48	0.23	Cognitive function;	chr2:161745810	chr2:161244739~161249050:+
THCA	cis	rs2512987	0.967	rs2433421	ENSG00000254731.1	CTD-2005H7.1	-5.18	3.27e-07	4.57e-05	-0.29	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703942	chr11:86703099~86714092:+
THCA	cis	rs7512898	0.5	rs10753881	ENSG00000260088.1	RP11-92G12.3	-5.18	3.27e-07	4.57e-05	-0.31	-0.23	Electrocardiographic conduction measures;	chr1:200796185	chr1:200669507~200694250:+
THCA	cis	rs2336384	0.593	rs28718032	ENSG00000199347.1	RNU5E-1	-5.18	3.27e-07	4.57e-05	-0.3	-0.23	Platelet count;	chr1:11986823	chr1:11908152~11908271:+
THCA	cis	rs17767392	0.813	rs8013161	ENSG00000259146.3	RP1-261D10.2	-5.18	3.27e-07	4.57e-05	-0.29	-0.23	Mitral valve prolapse;	chr14:71554782	chr14:71292729~71321814:-
THCA	cis	rs8141529	0.748	rs715531	ENSG00000272858.1	CTA-292E10.8	-5.18	3.27e-07	4.58e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28886691	chr22:28814914~28815662:+
THCA	cis	rs2439831	0.681	rs2278859	ENSG00000275601.1	AC011330.13	-5.18	3.27e-07	4.58e-05	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43340762	chr15:43642389~43643023:-
THCA	cis	rs6570726	0.967	rs7772286	ENSG00000270638.1	RP3-466P17.1	-5.18	3.27e-07	4.58e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145735570~145737218:+
THCA	cis	rs10875746	0.669	rs4760701	ENSG00000258234.1	RP11-370I10.2	5.18	3.28e-07	4.58e-05	0.27	0.23	Longevity (90 years and older);	chr12:48304735	chr12:48231098~48284210:-
THCA	cis	rs6430585	0.583	rs3769013	ENSG00000231890.6	DARS-AS1	-5.18	3.28e-07	4.58e-05	-0.28	-0.23	Corneal structure;	chr2:135798612	chr2:135985176~136022593:+
THCA	cis	rs1552244	1	rs6804473	ENSG00000180385.7	EMC3-AS1	5.18	3.28e-07	4.59e-05	0.26	0.23	Alzheimer's disease;	chr3:10018741	chr3:9986893~10006990:+
THCA	cis	rs17767392	0.846	rs34281405	ENSG00000259146.3	RP1-261D10.2	5.18	3.28e-07	4.59e-05	0.28	0.23	Mitral valve prolapse;	chr14:71313870	chr14:71292729~71321814:-
THCA	cis	rs10895275	0.961	rs4475891	ENSG00000277459.1	RP11-732A21.3	-5.18	3.28e-07	4.59e-05	-0.19	-0.23	Migraine;	chr11:102225551	chr11:102109827~102110457:-
THCA	cis	rs10895275	0.961	rs7124247	ENSG00000277459.1	RP11-732A21.3	-5.18	3.28e-07	4.59e-05	-0.19	-0.23	Migraine;	chr11:102225685	chr11:102109827~102110457:-
THCA	cis	rs4888671	1	rs17716830	ENSG00000261707.1	RP11-264M12.2	5.18	3.29e-07	4.59e-05	0.43	0.23	Obesity-related traits;	chr16:77738102	chr16:77741468~77743000:-
THCA	cis	rs972578	0.765	rs5758988	ENSG00000274717.1	RP1-47A17.1	-5.18	3.29e-07	4.59e-05	-0.24	-0.23	Mean platelet volume;	chr22:42853087	chr22:42791814~42794313:-
THCA	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-5.18	3.29e-07	4.59e-05	-0.32	-0.23	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000229886.1	RP5-1132H15.3	5.18	3.29e-07	4.59e-05	0.28	0.23	Corneal structure;	chr7:66835665	chr7:66025126~66031544:-
THCA	cis	rs59918340	0.728	rs6987335	ENSG00000253307.1	RP11-10J21.4	-5.18	3.29e-07	4.59e-05	-0.33	-0.23	Immature fraction of reticulocytes;	chr8:141225259	chr8:141252286~141253292:-
THCA	cis	rs7727544	0.684	rs274567	ENSG00000263597.1	MIR3936	-5.18	3.29e-07	4.6e-05	-0.22	-0.23	Blood metabolite levels;	chr5:132378717	chr5:132365490~132365599:-
THCA	cis	rs4713118	0.513	rs2294480	ENSG00000219392.1	RP1-265C24.5	-5.18	3.29e-07	4.6e-05	-0.26	-0.23	Parkinson's disease;	chr6:27616182	chr6:28115628~28116551:+
THCA	cis	rs5015933	0.815	rs10986718	ENSG00000232630.1	PRPS1P2	-5.18	3.29e-07	4.6e-05	-0.16	-0.23	Body mass index;	chr9:125350617	chr9:125150653~125151589:+
THCA	cis	rs202072	0.527	rs366904	ENSG00000272379.1	RP1-257A7.5	5.18	3.29e-07	4.6e-05	0.37	0.23	HIV-1 viral setpoint;	chr6:13267449	chr6:13290018~13290490:-
THCA	cis	rs7824557	0.614	rs7816606	ENSG00000154316.13	TDH	-5.18	3.29e-07	4.6e-05	-0.17	-0.23	Retinal vascular caliber;	chr8:11348093	chr8:11339637~11368452:+
THCA	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-5.18	3.29e-07	4.6e-05	-0.36	-0.23	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
THCA	cis	rs763121	0.853	rs2413546	ENSG00000228274.3	RP3-508I15.9	-5.18	3.29e-07	4.6e-05	-0.26	-0.23	Menopause (age at onset);	chr22:38710996	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2413547	ENSG00000228274.3	RP3-508I15.9	-5.18	3.29e-07	4.6e-05	-0.26	-0.23	Menopause (age at onset);	chr22:38711333	chr22:38667585~38681820:-
THCA	cis	rs2880765	0.835	rs2170735	ENSG00000259630.2	CTD-2262B20.1	-5.18	3.29e-07	4.6e-05	-0.25	-0.23	Coronary artery disease;	chr15:85500254	chr15:85415228~85415633:+
THCA	cis	rs6569038	0.533	rs12526935	ENSG00000253194.1	RP11-351A11.1	-5.18	3.3e-07	4.6e-05	-0.32	-0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119052747	chr6:118934785~119031541:+
THCA	cis	rs911119	1	rs35488434	ENSG00000270001.1	RP11-218C14.8	-5.18	3.3e-07	4.61e-05	-0.36	-0.23	Chronic kidney disease;	chr20:23639764	chr20:23631826~23632316:-
THCA	cis	rs1129187	0.902	rs6907751	ENSG00000272223.1	RP1-20C7.6	5.18	3.3e-07	4.61e-05	0.18	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42977112	chr6:43033897~43034405:-
THCA	cis	rs2439831	0.681	rs1095386	ENSG00000275601.1	AC011330.13	-5.18	3.3e-07	4.61e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43317311	chr15:43642389~43643023:-
THCA	cis	rs9307551	0.741	rs11098735	ENSG00000250334.4	LINC00989	-5.18	3.3e-07	4.61e-05	-0.31	-0.23	Refractive error;	chr4:79537259	chr4:79492416~79576460:+
THCA	cis	rs5015933	0.788	rs416340	ENSG00000232630.1	PRPS1P2	-5.18	3.3e-07	4.61e-05	-0.16	-0.23	Body mass index;	chr9:125339363	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.788	rs487228	ENSG00000232630.1	PRPS1P2	-5.18	3.3e-07	4.61e-05	-0.16	-0.23	Body mass index;	chr9:125340327	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.788	rs430184	ENSG00000232630.1	PRPS1P2	-5.18	3.3e-07	4.61e-05	-0.16	-0.23	Body mass index;	chr9:125340911	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.788	rs828290	ENSG00000232630.1	PRPS1P2	-5.18	3.3e-07	4.61e-05	-0.16	-0.23	Body mass index;	chr9:125341826	chr9:125150653~125151589:+
THCA	cis	rs853679	0.545	rs35949109	ENSG00000226314.6	ZNF192P1	-5.18	3.3e-07	4.61e-05	-0.36	-0.23	Depression;	chr6:28058148	chr6:28161781~28169594:+
THCA	cis	rs7208859	0.673	rs9889755	ENSG00000263603.1	CTD-2349P21.5	5.18	3.3e-07	4.62e-05	0.39	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30729469~30731202:+
THCA	cis	rs9834975	0.967	rs6787230	ENSG00000272758.4	RP11-299J3.8	-5.18	3.31e-07	4.62e-05	-0.22	-0.23	Diastolic blood pressure;	chr3:122392403	chr3:122416207~122443180:+
THCA	cis	rs875971	0.545	rs13311962	ENSG00000232546.1	RP11-458F8.1	-5.18	3.31e-07	4.62e-05	-0.22	-0.23	Aortic root size;	chr7:66603142	chr7:66848496~66858136:+
THCA	cis	rs763121	0.657	rs5995603	ENSG00000228274.3	RP3-508I15.9	-5.18	3.31e-07	4.62e-05	-0.26	-0.23	Menopause (age at onset);	chr22:38644728	chr22:38667585~38681820:-
THCA	cis	rs7617773	0.78	rs13067450	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48295716	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs4479622	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48296683	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs34946886	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48296997	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs34589064	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48298059	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs2541	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48298128	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs13085251	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48298555	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs35297395	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48301392	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs35190747	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48301800	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.743	rs7621785	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48302218	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs4511915	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48302368	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs13066758	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48302387	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs4392440	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48302430	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs13082859	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48303185	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs35778847	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48305495	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs34749846	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48305678	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs79089926	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48307074	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs4511916	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48308876	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.815	rs7624450	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48308885	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.815	rs6793150	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48310070	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs6793239	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48310128	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs6782166	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48310193	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs4130522	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48310823	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.674	rs13069029	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48313534	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs13081169	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48315307	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs35411187	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48318527	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs11714176	ENSG00000199476.1	Y_RNA	-5.18	3.31e-07	4.62e-05	-0.3	-0.23	Coronary artery disease;	chr3:48319372	chr3:48288587~48288694:+
THCA	cis	rs12935418	1	rs2602431	ENSG00000261061.1	RP11-303E16.2	5.18	3.31e-07	4.62e-05	0.28	0.23	Mean corpuscular volume;	chr16:81037092	chr16:81030770~81031485:+
THCA	cis	rs6968419	0.747	rs6953050	ENSG00000237870.5	AC073130.1	5.18	3.31e-07	4.62e-05	0.25	0.23	Intraocular pressure;	chr7:116248108	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs6957561	ENSG00000237870.5	AC073130.1	5.18	3.31e-07	4.62e-05	0.25	0.23	Intraocular pressure;	chr7:116248285	chr7:116275606~116286734:-
THCA	cis	rs8002861	0.967	rs7994883	ENSG00000274001.1	RP11-5G9.5	-5.18	3.31e-07	4.62e-05	-0.26	-0.23	Leprosy;	chr13:43904669	chr13:43877715~43878163:-
THCA	cis	rs7577696	0.924	rs212760	ENSG00000276334.1	AL133243.1	5.18	3.31e-07	4.62e-05	0.24	0.23	Inflammatory biomarkers;	chr2:32204153	chr2:32521927~32523547:+
THCA	cis	rs6430585	0.583	rs7561565	ENSG00000231890.6	DARS-AS1	-5.18	3.31e-07	4.62e-05	-0.28	-0.23	Corneal structure;	chr2:135883217	chr2:135985176~136022593:+
THCA	cis	rs7129556	0.775	rs72945598	ENSG00000254691.1	RP11-91P24.5	5.18	3.31e-07	4.62e-05	0.33	0.23	Weight loss (gastric bypass surgery);	chr11:77656693	chr11:77850604~77851511:+
THCA	cis	rs9816784	0.576	rs12631246	ENSG00000273009.1	RP11-352G9.1	-5.18	3.31e-07	4.63e-05	-0.27	-0.23	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195913078~195913683:-
THCA	cis	rs4934494	0.677	rs12777243	ENSG00000232936.4	RP11-80H5.2	5.18	3.31e-07	4.63e-05	0.32	0.23	Red blood cell count;	chr10:89576360	chr10:89645282~89650667:+
THCA	cis	rs9376098	1	rs1320960	ENSG00000232876.1	CTA-212D2.2	-5.18	3.31e-07	4.63e-05	-0.28	-0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135177063	chr6:135055033~135060550:+
THCA	cis	rs875971	0.545	rs1909508	ENSG00000232546.1	RP11-458F8.1	5.18	3.31e-07	4.63e-05	0.22	0.23	Aortic root size;	chr7:66301366	chr7:66848496~66858136:+
THCA	cis	rs2086824	0.702	rs3114891	ENSG00000274627.1	RP11-104N10.2	5.18	3.32e-07	4.63e-05	0.24	0.23	Multiple myeloma (IgH translocation);	chr16:89333047	chr16:89516797~89522217:+
THCA	cis	rs6540731	0.754	rs6679064	ENSG00000226251.4	RP11-15I11.3	-5.18	3.32e-07	4.63e-05	-0.29	-0.23	Intelligence (childhood);	chr1:212186366	chr1:212225278~212238977:-
THCA	cis	rs763121	0.853	rs138704	ENSG00000273076.1	RP3-508I15.22	5.18	3.32e-07	4.63e-05	0.24	0.23	Menopause (age at onset);	chr22:38737405	chr22:38743495~38743910:+
THCA	cis	rs2253762	0.54	rs75670246	ENSG00000276742.1	RP11-500G22.4	5.18	3.32e-07	4.63e-05	0.33	0.23	Breast cancer;	chr10:122032687	chr10:121956782~121957098:+
THCA	cis	rs6714710	0.603	rs11679828	ENSG00000230606.9	AC159540.1	-5.18	3.32e-07	4.63e-05	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97901163	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.58	rs11692470	ENSG00000230606.9	AC159540.1	-5.18	3.32e-07	4.63e-05	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97904101	chr2:97416165~97433527:-
THCA	cis	rs9388451	0.874	rs3734634	ENSG00000226409.1	RP11-735G4.1	-5.18	3.32e-07	4.63e-05	-0.27	-0.23	Brugada syndrome;	chr6:125790654	chr6:125370211~125374324:-
THCA	cis	rs72945132	0.882	rs72947078	ENSG00000254604.1	AP000487.6	-5.18	3.32e-07	4.63e-05	-0.45	-0.23	Coronary artery disease;	chr11:70351436	chr11:70282367~70363368:-
THCA	cis	rs6545883	0.894	rs2694634	ENSG00000270820.4	RP11-355B11.2	-5.18	3.32e-07	4.64e-05	-0.19	-0.23	Tuberculosis;	chr2:61324300	chr2:61471188~61484130:+
THCA	cis	rs7554547	0.69	rs57044570	ENSG00000199347.1	RNU5E-1	-5.18	3.32e-07	4.64e-05	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr1:11899181	chr1:11908152~11908271:+
THCA	cis	rs34779708	0.931	rs12771399	ENSG00000271335.4	RP11-324I22.4	5.18	3.32e-07	4.64e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35314552~35336401:-
THCA	cis	rs1914816	0.887	rs2460155	ENSG00000196274.5	Metazoa_SRP	5.18	3.32e-07	4.64e-05	0.33	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76186584	chr15:76230048~76230390:-
THCA	cis	rs5015933	0.815	rs3104550	ENSG00000232630.1	PRPS1P2	-5.18	3.32e-07	4.64e-05	-0.16	-0.23	Body mass index;	chr9:125348573	chr9:125150653~125151589:+
THCA	cis	rs2255336	0.748	rs60110638	ENSG00000245648.1	RP11-277P12.20	-5.18	3.33e-07	4.64e-05	-0.26	-0.23	Blood protein levels;	chr12:10444712	chr12:10363769~10398506:+
THCA	cis	rs453301	0.624	rs2288671	ENSG00000254153.1	CTA-398F10.2	-5.18	3.33e-07	4.65e-05	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9003384	chr8:8456909~8461337:-
THCA	cis	rs4713118	0.513	rs149897	ENSG00000226314.6	ZNF192P1	-5.18	3.33e-07	4.65e-05	-0.27	-0.23	Parkinson's disease;	chr6:28038872	chr6:28161781~28169594:+
THCA	cis	rs5751901	0.761	rs2006094	ENSG00000215481.7	BCRP3	-5.18	3.33e-07	4.65e-05	-0.21	-0.23	Protein quantitative trait loci;	chr22:24601119	chr22:24632915~24653356:+
THCA	cis	rs875971	0.545	rs1267814	ENSG00000228409.4	CCT6P1	5.18	3.33e-07	4.65e-05	0.2	0.23	Aortic root size;	chr7:66579422	chr7:65751142~65763354:+
THCA	cis	rs12681287	0.546	rs11539113	ENSG00000254231.1	CTD-2284J15.1	5.18	3.33e-07	4.65e-05	0.26	0.23	Caudate activity during reward;	chr8:86484947	chr8:86333274~86343314:-
THCA	cis	rs4663866	0.901	rs71426512	ENSG00000186235.9	AC016757.3	5.18	3.33e-07	4.65e-05	0.51	0.23	Irritable bowel syndrome;	chr2:238278487	chr2:238224552~238231677:-
THCA	cis	rs4663866	0.901	rs76312449	ENSG00000186235.9	AC016757.3	5.18	3.33e-07	4.65e-05	0.51	0.23	Irritable bowel syndrome;	chr2:238282265	chr2:238224552~238231677:-
THCA	cis	rs4663866	0.901	rs34040298	ENSG00000186235.9	AC016757.3	5.18	3.33e-07	4.65e-05	0.51	0.23	Irritable bowel syndrome;	chr2:238282966	chr2:238224552~238231677:-
THCA	cis	rs651907	0.557	rs11712748	ENSG00000244119.1	PDCL3P4	5.18	3.33e-07	4.65e-05	0.21	0.23	Colorectal cancer;	chr3:101664718	chr3:101712472~101713191:+
THCA	cis	rs6921919	0.583	rs2071965	ENSG00000219392.1	RP1-265C24.5	-5.18	3.33e-07	4.65e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28115628~28116551:+
THCA	cis	rs1552244	1	rs6442146	ENSG00000180385.7	EMC3-AS1	5.18	3.33e-07	4.65e-05	0.25	0.23	Alzheimer's disease;	chr3:10031860	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs6442148	ENSG00000180385.7	EMC3-AS1	5.18	3.33e-07	4.65e-05	0.25	0.23	Alzheimer's disease;	chr3:10036605	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs2160869	ENSG00000180385.7	EMC3-AS1	5.18	3.33e-07	4.65e-05	0.25	0.23	Alzheimer's disease;	chr3:10037571	chr3:9986893~10006990:+
THCA	cis	rs5758659	0.652	rs133300	ENSG00000227370.1	RP4-669P10.19	-5.18	3.34e-07	4.65e-05	-0.22	-0.23	Cognitive function;	chr22:41993835	chr22:42132543~42132998:+
THCA	cis	rs728616	0.614	rs56147535	ENSG00000242600.5	MBL1P	5.18	3.34e-07	4.66e-05	0.29	0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80267869	chr10:79904898~79950336:+
THCA	cis	rs7847628	0.587	rs4837796	ENSG00000238181.2	AHCYP2	5.18	3.34e-07	4.66e-05	0.29	0.23	Birth weight;	chr9:120848010	chr9:120720673~120721972:+
THCA	cis	rs5015933	1	rs5015933	ENSG00000232630.1	PRPS1P2	-5.18	3.34e-07	4.66e-05	-0.16	-0.23	Body mass index;	chr9:125375139	chr9:125150653~125151589:+
THCA	cis	rs6430585	0.64	rs3816155	ENSG00000231890.6	DARS-AS1	5.18	3.34e-07	4.66e-05	0.28	0.23	Corneal structure;	chr2:135794956	chr2:135985176~136022593:+
THCA	cis	rs7688540	0.771	rs11729365	ENSG00000211553.1	AC253576.2	-5.18	3.34e-07	4.66e-05	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:136461~136568:+
THCA	cis	rs17005891	0.549	rs111805711	ENSG00000270480.1	RP11-57B24.1	5.18	3.34e-07	4.66e-05	0.35	0.23	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82654064	chr4:82691737~82692468:+
THCA	cis	rs734999	0.87	rs1974044	ENSG00000225931.3	RP3-395M20.7	5.18	3.34e-07	4.67e-05	0.28	0.23	Ulcerative colitis;	chr1:2548544	chr1:2566410~2569888:+
THCA	cis	rs748404	0.666	rs12905220	ENSG00000205771.5	CATSPER2P1	-5.18	3.35e-07	4.67e-05	-0.3	-0.23	Lung cancer;	chr15:43465641	chr15:43726918~43747094:-
THCA	cis	rs6479874	1	rs6479862	ENSG00000223502.1	RP11-96B5.3	-5.18	3.35e-07	4.67e-05	-0.27	-0.23	Migraine;	chr10:51021121	chr10:51062579~51068553:-
THCA	cis	rs2067615	0.599	rs3759310	ENSG00000260329.1	RP11-412D9.4	-5.18	3.35e-07	4.67e-05	-0.21	-0.23	Heart rate;	chr12:106772344	chr12:106954029~106955497:-
THCA	cis	rs138491296	1	rs138491296	ENSG00000263370.1	RP11-68I3.5	-5.18	3.35e-07	4.67e-05	-0.3	-0.23	White blood cell count;	chr17:29634549	chr17:29639627~29640825:+
THCA	cis	rs56114371	0.777	rs200483	ENSG00000226314.6	ZNF192P1	-5.18	3.35e-07	4.67e-05	-0.39	-0.23	Breast cancer;	chr6:27807046	chr6:28161781~28169594:+
THCA	cis	rs7727544	0.684	rs611084	ENSG00000263597.1	MIR3936	-5.18	3.35e-07	4.67e-05	-0.22	-0.23	Blood metabolite levels;	chr5:132374047	chr5:132365490~132365599:-
THCA	cis	rs72615157	0.561	rs113401658	ENSG00000242294.5	STAG3L5P	5.18	3.35e-07	4.68e-05	0.15	0.23	Lung function (FEV1/FVC);	chr7:100260882	chr7:100336079~100351900:+
THCA	cis	rs72615157	0.561	rs113844570	ENSG00000242294.5	STAG3L5P	5.18	3.35e-07	4.68e-05	0.15	0.23	Lung function (FEV1/FVC);	chr7:100276155	chr7:100336079~100351900:+
THCA	cis	rs35160687	0.623	rs2276625	ENSG00000273080.1	RP11-301O19.1	5.18	3.35e-07	4.68e-05	0.25	0.23	Night sleep phenotypes;	chr2:86254712	chr2:86195590~86196049:+
THCA	cis	rs990871	0.53	rs3101340	ENSG00000227207.2	RPL31P12	5.18	3.35e-07	4.68e-05	0.27	0.23	Subcutaneous adipose tissue;	chr1:72278461	chr1:72301472~72301829:+
THCA	cis	rs62355901	0.505	rs72759725	ENSG00000271828.1	CTD-2310F14.1	5.18	3.35e-07	4.68e-05	0.6	0.23	Breast cancer;	chr5:56941932	chr5:56927874~56929573:+
THCA	cis	rs12935418	0.672	rs9921914	ENSG00000278985.1	RP11-303E16.9	5.18	3.35e-07	4.68e-05	0.26	0.23	Mean corpuscular volume;	chr16:81022506	chr16:80982319~80984094:-
THCA	cis	rs9311474	0.581	rs4687626	ENSG00000243224.1	RP5-1157M23.2	-5.18	3.35e-07	4.68e-05	-0.25	-0.23	Electroencephalogram traits;	chr3:52535082	chr3:52239258~52241097:+
THCA	cis	rs6598266	1	rs12908758	ENSG00000259363.4	CTD-2054N24.2	-5.18	3.35e-07	4.68e-05	-0.41	-0.23	Major depressive disorder;	chr15:99760242	chr15:99807023~99877148:+
THCA	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-5.18	3.35e-07	4.68e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
THCA	cis	rs8002861	0.935	rs4101376	ENSG00000274001.1	RP11-5G9.5	-5.18	3.35e-07	4.68e-05	-0.26	-0.23	Leprosy;	chr13:43895699	chr13:43877715~43878163:-
THCA	cis	rs10510102	0.935	rs11200201	ENSG00000226864.1	ATE1-AS1	5.18	3.36e-07	4.68e-05	0.38	0.23	Breast cancer;	chr10:121864790	chr10:121928312~121951965:+
THCA	cis	rs17767392	1	rs7156460	ENSG00000259146.3	RP1-261D10.2	5.18	3.36e-07	4.68e-05	0.3	0.23	Mitral valve prolapse;	chr14:71388617	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.794	rs61991247	ENSG00000259146.3	RP1-261D10.2	5.18	3.36e-07	4.68e-05	0.3	0.23	Mitral valve prolapse;	chr14:71393601	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs61991248	ENSG00000259146.3	RP1-261D10.2	5.18	3.36e-07	4.68e-05	0.3	0.23	Mitral valve prolapse;	chr14:71393812	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs34528131	ENSG00000259146.3	RP1-261D10.2	5.18	3.36e-07	4.68e-05	0.3	0.23	Mitral valve prolapse;	chr14:71394561	chr14:71292729~71321814:-
THCA	cis	rs2439831	0.867	rs3809481	ENSG00000166763.7	STRCP1	5.18	3.36e-07	4.68e-05	0.33	0.23	Lung cancer in ever smokers;	chr15:43370631	chr15:43699488~43718184:-
THCA	cis	rs45509595	0.841	rs200485	ENSG00000226314.6	ZNF192P1	-5.18	3.36e-07	4.68e-05	-0.39	-0.23	Breast cancer;	chr6:27807919	chr6:28161781~28169594:+
THCA	cis	rs67478160	0.643	rs7156697	ENSG00000258735.1	LINC00637	-5.18	3.36e-07	4.68e-05	-0.28	-0.23	Schizophrenia;	chr14:103744799	chr14:103847721~103858049:+
THCA	cis	rs67478160	0.679	rs7156834	ENSG00000258735.1	LINC00637	-5.18	3.36e-07	4.68e-05	-0.28	-0.23	Schizophrenia;	chr14:103744843	chr14:103847721~103858049:+
THCA	cis	rs849141	0.89	rs860263	ENSG00000234336.5	JAZF1-AS1	-5.18	3.36e-07	4.68e-05	-0.28	-0.23	Height;Hip circumference adjusted for BMI;	chr7:28142727	chr7:28180322~28243917:+
THCA	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	5.18	3.36e-07	4.68e-05	0.28	0.23	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
THCA	cis	rs3796352	1	rs34943350	ENSG00000242142.1	SERBP1P3	-5.18	3.36e-07	4.69e-05	-0.46	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52978872	chr3:53064283~53065091:-
THCA	cis	rs1198430	0.562	rs10917388	ENSG00000232482.2	RP4-654C18.1	-5.18	3.36e-07	4.69e-05	-0.33	-0.23	Total cholesterol levels;	chr1:23476645	chr1:23410832~23412146:+
THCA	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	5.18	3.36e-07	4.69e-05	0.33	0.23	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
THCA	cis	rs4660456	0.913	rs6664044	ENSG00000272145.1	NFYC-AS1	5.18	3.36e-07	4.69e-05	0.16	0.23	Platelet count;	chr1:40735089	chr1:40690380~40692066:-
THCA	cis	rs9532669	0.511	rs3783164	ENSG00000239827.7	SUGT1P3	5.18	3.36e-07	4.69e-05	0.26	0.23	Cervical cancer;	chr13:40806227	chr13:40908159~40921774:-
THCA	cis	rs12135996	0.592	rs2516838	ENSG00000232879.2	RP11-544M22.3	5.18	3.36e-07	4.69e-05	0.25	0.23	Night sleep phenotypes;	chr1:161044580	chr1:161034834~161035006:+
THCA	cis	rs752010	0.715	rs4083592	ENSG00000230638.4	RP11-486B10.4	-5.18	3.37e-07	4.7e-05	-0.29	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41633851	chr1:41542069~41544310:+
THCA	cis	rs752010	0.715	rs4660551	ENSG00000230638.4	RP11-486B10.4	-5.18	3.37e-07	4.7e-05	-0.29	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41634308	chr1:41542069~41544310:+
THCA	cis	rs4886920	0.574	rs34260472	ENSG00000260776.4	RP11-114H24.2	5.18	3.37e-07	4.7e-05	0.36	0.23	Neuroticism;	chr15:77840520	chr15:77914217~77926846:-
THCA	cis	rs756699	1	rs168649	ENSG00000279469.1	RP11-215P8.2	-5.18	3.37e-07	4.7e-05	-0.37	-0.23	Multiple sclerosis;	chr5:134109229	chr5:134394360~134395008:-
THCA	cis	rs756699	1	rs244948	ENSG00000279469.1	RP11-215P8.2	-5.18	3.37e-07	4.7e-05	-0.37	-0.23	Multiple sclerosis;	chr5:134109370	chr5:134394360~134395008:-
THCA	cis	rs756699	1	rs244950	ENSG00000279469.1	RP11-215P8.2	-5.18	3.37e-07	4.7e-05	-0.37	-0.23	Multiple sclerosis;	chr5:134109937	chr5:134394360~134395008:-
THCA	cis	rs756699	0.915	rs244951	ENSG00000279469.1	RP11-215P8.2	-5.18	3.37e-07	4.7e-05	-0.37	-0.23	Multiple sclerosis;	chr5:134110017	chr5:134394360~134395008:-
THCA	cis	rs2070488	0.804	rs13092539	ENSG00000229589.1	ACVR2B-AS1	5.18	3.37e-07	4.7e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38417234	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.804	rs13092473	ENSG00000229589.1	ACVR2B-AS1	5.18	3.37e-07	4.7e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38417467	chr3:38451027~38454820:-
THCA	cis	rs4950322	0.57	rs72691054	ENSG00000226015.2	CCT8P1	5.18	3.37e-07	4.7e-05	0.28	0.23	Protein quantitative trait loci;	chr1:147277942	chr1:147203276~147204932:-
THCA	cis	rs2239547	0.522	rs2710345	ENSG00000242142.1	SERBP1P3	-5.18	3.37e-07	4.7e-05	-0.3	-0.23	Schizophrenia;	chr3:52942059	chr3:53064283~53065091:-
THCA	cis	rs11088226	1	rs11701091	ENSG00000186842.4	LINC00846	-5.18	3.37e-07	4.7e-05	-0.32	-0.23	Gastritis;	chr21:32547934	chr21:32572238~32575881:-
THCA	cis	rs2880765	0.835	rs2170736	ENSG00000259630.2	CTD-2262B20.1	-5.18	3.37e-07	4.7e-05	-0.25	-0.23	Coronary artery disease;	chr15:85500167	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs4340287	ENSG00000259630.2	CTD-2262B20.1	-5.18	3.37e-07	4.7e-05	-0.25	-0.23	Coronary artery disease;	chr15:85500506	chr15:85415228~85415633:+
THCA	cis	rs1318937	0.679	rs9310471	ENSG00000224660.1	SH3BP5-AS1	5.18	3.37e-07	4.7e-05	0.15	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15195342	chr3:15254184~15264493:+
THCA	cis	rs34779708	0.931	rs7923172	ENSG00000271335.4	RP11-324I22.4	5.18	3.37e-07	4.7e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35314552~35336401:-
THCA	cis	rs6969780	0.915	rs17471520	ENSG00000233429.8	HOTAIRM1	5.18	3.37e-07	4.7e-05	0.35	0.23	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27139171	chr7:27095647~27100265:+
THCA	cis	rs6088590	1	rs11698996	ENSG00000269202.1	RP4-614O4.12	-5.18	3.37e-07	4.71e-05	-0.22	-0.23	Coronary artery disease;	chr20:34861936	chr20:35201747~35203288:-
THCA	cis	rs9388451	0.839	rs3799711	ENSG00000226409.1	RP11-735G4.1	5.18	3.38e-07	4.71e-05	0.27	0.23	Brugada syndrome;	chr6:125754167	chr6:125370211~125374324:-
THCA	cis	rs2911132	0.564	rs17401719	ENSG00000248734.2	CTD-2260A17.1	-5.18	3.38e-07	4.71e-05	-0.25	-0.23	Urate levels (BMI interaction);	chr5:96753342	chr5:96784777~96785999:+
THCA	cis	rs2735413	0.563	rs17776016	ENSG00000276007.1	RP11-358L22.3	-5.18	3.38e-07	4.71e-05	-0.26	-0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78013920	chr16:78123243~78124332:+
THCA	cis	rs858239	0.539	rs4559148	ENSG00000226816.2	AC005082.12	5.18	3.38e-07	4.71e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs4377861	ENSG00000226816.2	AC005082.12	5.18	3.38e-07	4.71e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23206013~23208045:+
THCA	cis	rs6969780	1	rs6948297	ENSG00000233429.8	HOTAIRM1	5.18	3.38e-07	4.71e-05	0.36	0.23	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109785	chr7:27095647~27100265:+
THCA	cis	rs7809615	0.901	rs11981478	ENSG00000244219.5	GS1-259H13.2	-5.18	3.38e-07	4.71e-05	-0.41	-0.23	Blood metabolite ratios;	chr7:99566327	chr7:99598066~99610813:+
THCA	cis	rs7688540	0.771	rs61792116	ENSG00000211553.1	AC253576.2	-5.17	3.38e-07	4.72e-05	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:136461~136568:+
THCA	cis	rs1823913	0.599	rs17346475	ENSG00000280083.1	RP11-317J9.1	5.17	3.38e-07	4.72e-05	0.27	0.23	Obesity-related traits;	chr2:191288488	chr2:191154118~191156070:-
THCA	cis	rs11096990	0.819	rs4974991	ENSG00000249685.1	RP11-360F5.3	-5.17	3.39e-07	4.72e-05	-0.3	-0.23	Cognitive function;	chr4:39193147	chr4:39133913~39135608:+
THCA	cis	rs17270561	0.639	rs9356989	ENSG00000272462.2	U91328.19	-5.17	3.39e-07	4.72e-05	-0.2	-0.23	Iron status biomarkers;	chr6:25781722	chr6:25992662~26001775:+
THCA	cis	rs10844706	0.699	rs10844636	ENSG00000256594.6	RP11-705C15.2	-5.17	3.39e-07	4.72e-05	-0.19	-0.23	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735420	chr12:9633419~9658412:+
THCA	cis	rs78487399	0.808	rs77377889	ENSG00000234936.1	AC010883.5	5.17	3.39e-07	4.72e-05	0.33	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43461185	chr2:43229573~43233394:+
THCA	cis	rs17767392	0.881	rs757850	ENSG00000259146.3	RP1-261D10.2	-5.17	3.39e-07	4.72e-05	-0.29	-0.23	Mitral valve prolapse;	chr14:71549289	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.881	rs7152674	ENSG00000259146.3	RP1-261D10.2	-5.17	3.39e-07	4.72e-05	-0.29	-0.23	Mitral valve prolapse;	chr14:71549896	chr14:71292729~71321814:-
THCA	cis	rs1580019	0.587	rs6951955	ENSG00000231952.3	DPY19L1P2	-5.17	3.39e-07	4.72e-05	-0.29	-0.23	Cognitive ability;	chr7:32509149	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.587	rs6972365	ENSG00000231952.3	DPY19L1P2	-5.17	3.39e-07	4.72e-05	-0.29	-0.23	Cognitive ability;	chr7:32509319	chr7:32812757~32838570:+
THCA	cis	rs4950322	0.947	rs72694723	ENSG00000278811.3	LINC00624	5.17	3.39e-07	4.72e-05	0.31	0.23	Protein quantitative trait loci;	chr1:147373174	chr1:147258885~147517875:-
THCA	cis	rs12030196	0.871	rs12042725	ENSG00000230812.4	LINC01358	5.17	3.39e-07	4.72e-05	0.29	0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59004057	chr1:59020387~59044614:+
THCA	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	5.17	3.39e-07	4.73e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	5.17	3.39e-07	4.73e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
THCA	cis	rs6088580	0.634	rs1205338	ENSG00000276073.1	RP5-1125A11.7	5.17	3.39e-07	4.73e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34337819	chr20:33985617~33988989:-
THCA	cis	rs1552244	0.938	rs9873794	ENSG00000180385.7	EMC3-AS1	5.17	3.39e-07	4.73e-05	0.25	0.23	Alzheimer's disease;	chr3:10032469	chr3:9986893~10006990:+
THCA	cis	rs4648045	0.565	rs4698860	ENSG00000246560.2	RP11-10L12.4	5.17	3.39e-07	4.73e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102624170	chr4:102828055~102844075:+
THCA	cis	rs2288884	0.806	rs76094721	ENSG00000275055.1	CTC-471J1.11	-5.17	3.39e-07	4.73e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52089630	chr19:52049007~52049754:+
THCA	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-5.17	3.39e-07	4.73e-05	-0.27	-0.23	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-5.17	3.39e-07	4.73e-05	-0.27	-0.23	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
THCA	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-5.17	3.4e-07	4.73e-05	-0.14	-0.23	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-5.17	3.4e-07	4.73e-05	-0.14	-0.23	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
THCA	cis	rs9859260	0.744	rs406271	ENSG00000207650.1	MIR570	-5.17	3.4e-07	4.73e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196050105	chr3:195699401~195699497:+
THCA	cis	rs919433	0.963	rs4850429	ENSG00000231621.1	AC013264.2	-5.17	3.4e-07	4.73e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313685	chr2:197197991~197199273:+
THCA	cis	rs7512898	0.5	rs4915457	ENSG00000260088.1	RP11-92G12.3	-5.17	3.4e-07	4.73e-05	-0.32	-0.23	Electrocardiographic conduction measures;	chr1:200771742	chr1:200669507~200694250:+
THCA	cis	rs228614	0.51	rs223468	ENSG00000248971.2	KRT8P46	-5.17	3.4e-07	4.73e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223465	ENSG00000248971.2	KRT8P46	-5.17	3.4e-07	4.73e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102728746~102730171:-
THCA	cis	rs2070488	0.804	rs7646429	ENSG00000229589.1	ACVR2B-AS1	5.17	3.4e-07	4.74e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38426222	chr3:38451027~38454820:-
THCA	cis	rs875971	0.66	rs10229345	ENSG00000224316.1	RP11-479O9.2	5.17	3.4e-07	4.74e-05	0.26	0.23	Aortic root size;	chr7:66517181	chr7:65773620~65802067:+
THCA	cis	rs7646881	0.544	rs17630785	ENSG00000240207.5	RP11-379F4.4	-5.17	3.4e-07	4.74e-05	-0.34	-0.23	Tetralogy of Fallot;	chr3:158674437	chr3:158732263~158784070:+
THCA	cis	rs2070488	0.804	rs2276541	ENSG00000229589.1	ACVR2B-AS1	5.17	3.41e-07	4.75e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38471288	chr3:38451027~38454820:-
THCA	cis	rs1005277	0.579	rs1548255	ENSG00000272983.1	RP11-508N22.12	5.17	3.41e-07	4.75e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38137337~38144399:+
THCA	cis	rs6921919	0.583	rs35560946	ENSG00000219392.1	RP1-265C24.5	-5.17	3.41e-07	4.75e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28115628~28116551:+
THCA	cis	rs3734266	0.702	rs205267	ENSG00000272288.4	RP11-140K17.3	-5.17	3.41e-07	4.75e-05	-0.24	-0.23	Systemic lupus erythematosus;	chr6:34591986	chr6:34696317~34697470:+
THCA	cis	rs728616	0.681	rs55855057	ENSG00000225484.5	NUTM2B-AS1	-5.17	3.41e-07	4.75e-05	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80274973	chr10:79663088~79826594:-
THCA	cis	rs12893668	0.703	rs34026011	ENSG00000269940.1	RP11-73M18.7	5.17	3.41e-07	4.75e-05	0.25	0.23	Reticulocyte count;	chr14:103584546	chr14:103694560~103695170:+
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000229886.1	RP5-1132H15.3	-5.17	3.41e-07	4.75e-05	-0.28	-0.23	Corneal structure;	chr7:66821880	chr7:66025126~66031544:-
THCA	cis	rs2070488	0.775	rs4371464	ENSG00000229589.1	ACVR2B-AS1	-5.17	3.41e-07	4.76e-05	-0.21	-0.23	Electrocardiographic conduction measures;	chr3:38506530	chr3:38451027~38454820:-
THCA	cis	rs10129255	0.826	rs7150693	ENSG00000223648.3	IGHV3-64	5.17	3.41e-07	4.76e-05	0.15	0.23	Kawasaki disease;	chr14:106705382	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.869	rs7150549	ENSG00000223648.3	IGHV3-64	5.17	3.41e-07	4.76e-05	0.15	0.23	Kawasaki disease;	chr14:106705441	chr14:106643132~106658258:-
THCA	cis	rs10208649	1	rs6731217	ENSG00000233266.1	HMGB1P31	-5.17	3.42e-07	4.76e-05	-0.52	-0.23	Body mass index;	chr2:53903956	chr2:54051334~54051760:+
THCA	cis	rs12681287	0.517	rs68008113	ENSG00000254231.1	CTD-2284J15.1	5.17	3.42e-07	4.76e-05	0.26	0.23	Caudate activity during reward;	chr8:86508665	chr8:86333274~86343314:-
THCA	cis	rs972578	0.668	rs4822203	ENSG00000274717.1	RP1-47A17.1	-5.17	3.42e-07	4.76e-05	-0.25	-0.23	Mean platelet volume;	chr22:42844800	chr22:42791814~42794313:-
THCA	cis	rs11846409	0.86	rs61686131	ENSG00000211974.3	IGHV2-70	-5.17	3.42e-07	4.76e-05	-0.22	-0.23	Rheumatic heart disease;	chr14:106631568	chr14:106723574~106724093:-
THCA	cis	rs12435908	1	rs12435908	ENSG00000276116.2	FUT8-AS1	5.17	3.42e-07	4.76e-05	0.36	0.23	Ischemic stroke;	chr14:65654750	chr14:65411170~65412690:-
THCA	cis	rs56046484	0.778	rs1606119	ENSG00000259295.5	CSPG4P12	5.17	3.42e-07	4.76e-05	0.34	0.23	Testicular germ cell tumor;	chr15:85128148	chr15:85191438~85213905:+
THCA	cis	rs7577696	0.925	rs212718	ENSG00000276334.1	AL133243.1	5.17	3.42e-07	4.76e-05	0.25	0.23	Inflammatory biomarkers;	chr2:32236764	chr2:32521927~32523547:+
THCA	cis	rs875971	0.964	rs6945019	ENSG00000223473.2	GS1-124K5.3	5.17	3.42e-07	4.76e-05	0.16	0.23	Aortic root size;	chr7:66457471	chr7:66491049~66493566:-
THCA	cis	rs1707322	1	rs1707317	ENSG00000281133.1	AL355480.3	5.17	3.42e-07	4.77e-05	0.29	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45580892~45580996:-
THCA	cis	rs2803122	0.905	rs2772401	ENSG00000273226.1	RP11-513M16.8	5.17	3.42e-07	4.77e-05	0.21	0.23	Pulse pressure;	chr9:19322933	chr9:19375451~19375996:+
THCA	cis	rs2439831	0.85	rs16977798	ENSG00000166763.7	STRCP1	5.17	3.42e-07	4.77e-05	0.33	0.23	Lung cancer in ever smokers;	chr15:43859750	chr15:43699488~43718184:-
THCA	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-5.17	3.42e-07	4.77e-05	-0.28	-0.23	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
THCA	cis	rs2880765	0.835	rs4536419	ENSG00000259630.2	CTD-2262B20.1	-5.17	3.42e-07	4.77e-05	-0.25	-0.23	Coronary artery disease;	chr15:85496240	chr15:85415228~85415633:+
THCA	cis	rs4767841	0.967	rs12296121	ENSG00000248636.5	RP11-768F21.1	-5.17	3.42e-07	4.77e-05	-0.24	-0.23	Urgency urinary incontinence;	chr12:119722116	chr12:119387987~119668079:-
THCA	cis	rs2562456	0.876	rs2650844	ENSG00000268119.4	CTD-2561J22.5	5.17	3.42e-07	4.77e-05	0.33	0.23	Pain;	chr19:21419288	chr19:21444241~21463908:-
THCA	cis	rs1823913	1	rs1454749	ENSG00000227542.1	AC092614.2	5.17	3.43e-07	4.77e-05	0.28	0.23	Obesity-related traits;	chr2:191240909	chr2:191229165~191246172:-
THCA	cis	rs1823913	1	rs4853561	ENSG00000227542.1	AC092614.2	-5.17	3.43e-07	4.77e-05	-0.28	-0.23	Obesity-related traits;	chr2:191242980	chr2:191229165~191246172:-
THCA	cis	rs2243480	1	rs2243480	ENSG00000232559.3	GS1-124K5.12	5.17	3.43e-07	4.77e-05	0.34	0.23	Diabetic kidney disease;	chr7:66134209	chr7:66554588~66576923:-
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000273796.1	LL21NC02-21A1.1	-5.17	3.43e-07	4.78e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45403809~45404369:-
THCA	cis	rs149291347	1	rs149291347	ENSG00000279453.1	RP3-425C14.4	-5.17	3.43e-07	4.78e-05	-0.19	-0.23	Plateletcrit;	chr6:122457804	chr6:122436789~122439223:-
THCA	cis	rs860295	0.702	rs1556488	ENSG00000160766.13	GBAP1	-5.17	3.43e-07	4.78e-05	-0.27	-0.23	Body mass index;	chr1:155570869	chr1:155213821~155227422:-
THCA	cis	rs2562456	0.833	rs62110071	ENSG00000268119.4	CTD-2561J22.5	5.17	3.43e-07	4.78e-05	0.34	0.23	Pain;	chr19:21288101	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs11667392	ENSG00000268119.4	CTD-2561J22.5	5.17	3.43e-07	4.78e-05	0.34	0.23	Pain;	chr19:21289806	chr19:21444241~21463908:-
THCA	cis	rs763121	0.776	rs4820346	ENSG00000228274.3	RP3-508I15.9	5.17	3.43e-07	4.78e-05	0.26	0.23	Menopause (age at onset);	chr22:38729069	chr22:38667585~38681820:-
THCA	cis	rs8141529	0.778	rs5762795	ENSG00000272858.1	CTA-292E10.8	-5.17	3.44e-07	4.79e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28786512	chr22:28814914~28815662:+
THCA	cis	rs7131987	0.834	rs11050167	ENSG00000275476.1	RP11-996F15.4	-5.17	3.44e-07	4.79e-05	-0.24	-0.23	QT interval;	chr12:29273454	chr12:29277397~29277882:-
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000273796.1	LL21NC02-21A1.1	-5.17	3.44e-07	4.79e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45403809~45404369:-
THCA	cis	rs12549025	0.782	rs3736030	ENSG00000253390.1	CTC-756D1.2	-5.17	3.44e-07	4.79e-05	-0.45	-0.23	Reticulocyte fraction of red cells;	chr8:23535220	chr8:23458601~23484971:+
THCA	cis	rs2288884	0.505	rs75919042	ENSG00000269483.1	AC006272.1	5.17	3.44e-07	4.79e-05	0.36	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51973246	chr19:51839924~51843324:-
THCA	cis	rs4915077	1	rs17020139	ENSG00000230489.1	VAV3-AS1	5.17	3.44e-07	4.79e-05	0.38	0.23	Hypothyroidism;	chr1:107826861	chr1:107964443~107994607:+
THCA	cis	rs11974702	1	rs11974702	ENSG00000244219.5	GS1-259H13.2	-5.17	3.44e-07	4.79e-05	-0.41	-0.23	Blood metabolite levels;	chr7:99566328	chr7:99598066~99610813:+
THCA	cis	rs17123764	0.71	rs2278069	ENSG00000257464.1	RP11-161H23.8	-5.17	3.44e-07	4.79e-05	-0.37	-0.23	Intelligence (multi-trait analysis);	chr12:49550725	chr12:49442424~49442652:-
THCA	cis	rs4948275	0.773	rs2650697	ENSG00000237233.2	TMEM26-AS1	-5.17	3.44e-07	4.8e-05	-0.32	-0.23	Night sleep phenotypes;	chr10:61536585	chr10:61452639~61481956:+
THCA	cis	rs2562456	0.754	rs11666213	ENSG00000268119.4	CTD-2561J22.5	5.17	3.45e-07	4.8e-05	0.33	0.23	Pain;	chr19:21422843	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62110429	ENSG00000268119.4	CTD-2561J22.5	5.17	3.45e-07	4.8e-05	0.33	0.23	Pain;	chr19:21430984	chr19:21444241~21463908:-
THCA	cis	rs7688540	0.8	rs10023604	ENSG00000250892.1	RP11-1365D11.1	5.17	3.45e-07	4.8e-05	0.32	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:201409~205009:-
THCA	cis	rs890448	0.796	rs13135111	ENSG00000254531.1	FLJ20021	5.17	3.45e-07	4.8e-05	0.21	0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380662	chr4:101347780~101348883:+
THCA	cis	rs890448	0.796	rs13148622	ENSG00000254531.1	FLJ20021	5.17	3.45e-07	4.8e-05	0.21	0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382421	chr4:101347780~101348883:+
THCA	cis	rs17767392	0.918	rs34533948	ENSG00000259146.3	RP1-261D10.2	5.17	3.45e-07	4.8e-05	0.3	0.23	Mitral valve prolapse;	chr14:71306010	chr14:71292729~71321814:-
THCA	cis	rs9500256	0.655	rs12209098	ENSG00000272541.1	XXbac-BPGBPG55C20.1	5.17	3.45e-07	4.8e-05	0.26	0.23	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57855891~57856468:-
THCA	cis	rs1125355	0.622	rs62183014	ENSG00000251491.2	OR7E28P	-5.17	3.45e-07	4.8e-05	-0.38	-0.23	Alzheimer's disease in APOE e4+ carriers;	chr2:158759029	chr2:158862311~158863285:+
THCA	cis	rs2288884	0.708	rs12460617	ENSG00000260160.1	CTC-471J1.2	-5.17	3.45e-07	4.8e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:52058490~52063703:-
THCA	cis	rs2439831	0.681	rs498837	ENSG00000205771.5	CATSPER2P1	-5.17	3.45e-07	4.8e-05	-0.3	-0.23	Lung cancer in ever smokers;	chr15:43315826	chr15:43726918~43747094:-
THCA	cis	rs17767392	0.881	rs35866366	ENSG00000259146.3	RP1-261D10.2	5.17	3.45e-07	4.8e-05	0.29	0.23	Mitral valve prolapse;	chr14:71382468	chr14:71292729~71321814:-
THCA	cis	rs1552244	0.554	rs3846169	ENSG00000232901.1	CYCSP10	-5.17	3.45e-07	4.8e-05	-0.27	-0.23	Alzheimer's disease;	chr3:9955370	chr3:10000647~10000940:-
THCA	cis	rs7119	0.651	rs12904533	ENSG00000259362.2	RP11-307C19.1	-5.17	3.45e-07	4.81e-05	-0.34	-0.23	Type 2 diabetes;	chr15:77553586	chr15:77525540~77534110:+
THCA	cis	rs919433	0.889	rs787995	ENSG00000231621.1	AC013264.2	-5.17	3.45e-07	4.81e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352129	chr2:197197991~197199273:+
THCA	cis	rs2288884	0.505	rs6509602	ENSG00000269483.1	AC006272.1	5.17	3.46e-07	4.81e-05	0.34	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51956892	chr19:51839924~51843324:-
THCA	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	5.17	3.46e-07	4.81e-05	0.13	0.23	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	5.17	3.46e-07	4.81e-05	0.13	0.23	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	5.17	3.46e-07	4.81e-05	0.13	0.23	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	5.17	3.46e-07	4.81e-05	0.13	0.23	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
THCA	cis	rs2911132	0.564	rs13181579	ENSG00000248734.2	CTD-2260A17.1	5.17	3.46e-07	4.81e-05	0.25	0.23	Urate levels (BMI interaction);	chr5:96755234	chr5:96784777~96785999:+
THCA	cis	rs8141529	0.778	rs763073	ENSG00000272858.1	CTA-292E10.8	-5.17	3.46e-07	4.81e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28819554	chr22:28814914~28815662:+
THCA	cis	rs858239	0.539	rs10254544	ENSG00000226816.2	AC005082.12	5.17	3.46e-07	4.81e-05	0.34	0.23	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23206013~23208045:+
THCA	cis	rs7617773	0.78	rs13079728	ENSG00000199476.1	Y_RNA	-5.17	3.46e-07	4.81e-05	-0.3	-0.23	Coronary artery disease;	chr3:48297870	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs77044321	ENSG00000199476.1	Y_RNA	-5.17	3.46e-07	4.81e-05	-0.3	-0.23	Coronary artery disease;	chr3:48307824	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.746	rs4371540	ENSG00000199476.1	Y_RNA	-5.17	3.46e-07	4.81e-05	-0.3	-0.23	Coronary artery disease;	chr3:48312053	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.743	rs13081633	ENSG00000199476.1	Y_RNA	-5.17	3.46e-07	4.81e-05	-0.3	-0.23	Coronary artery disease;	chr3:48315791	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs11718350	ENSG00000199476.1	Y_RNA	-5.17	3.46e-07	4.81e-05	-0.3	-0.23	Coronary artery disease;	chr3:48319502	chr3:48288587~48288694:+
THCA	cis	rs1552244	0.554	rs9878047	ENSG00000232901.1	CYCSP10	5.17	3.46e-07	4.81e-05	0.27	0.23	Alzheimer's disease;	chr3:9943773	chr3:10000647~10000940:-
THCA	cis	rs8062405	1	rs62036616	ENSG00000278665.1	RP11-666O2.4	5.17	3.46e-07	4.82e-05	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28599241~28601881:-
THCA	cis	rs116095464	0.619	rs2303741	ENSG00000248925.1	CTD-2083E4.6	5.17	3.46e-07	4.82e-05	0.33	0.23	Breast cancer;	chr5:218241	chr5:269858~271516:-
THCA	cis	rs116095464	0.614	rs56299325	ENSG00000248925.1	CTD-2083E4.6	5.17	3.46e-07	4.82e-05	0.33	0.23	Breast cancer;	chr5:220479	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs62346526	ENSG00000248925.1	CTD-2083E4.6	5.17	3.46e-07	4.82e-05	0.33	0.23	Breast cancer;	chr5:220499	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs56043030	ENSG00000248925.1	CTD-2083E4.6	5.17	3.46e-07	4.82e-05	0.33	0.23	Breast cancer;	chr5:220802	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs10067021	ENSG00000248925.1	CTD-2083E4.6	5.17	3.46e-07	4.82e-05	0.33	0.23	Breast cancer;	chr5:221375	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs9312977	ENSG00000248925.1	CTD-2083E4.6	5.17	3.46e-07	4.82e-05	0.33	0.23	Breast cancer;	chr5:221801	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs6881920	ENSG00000248925.1	CTD-2083E4.6	5.17	3.46e-07	4.82e-05	0.33	0.23	Breast cancer;	chr5:222296	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs6878061	ENSG00000248925.1	CTD-2083E4.6	5.17	3.46e-07	4.82e-05	0.33	0.23	Breast cancer;	chr5:222957	chr5:269858~271516:-
THCA	cis	rs12935418	0.672	rs1453328	ENSG00000278985.1	RP11-303E16.9	5.17	3.46e-07	4.82e-05	0.25	0.23	Mean corpuscular volume;	chr16:81019240	chr16:80982319~80984094:-
THCA	cis	rs12893668	0.663	rs12889731	ENSG00000269940.1	RP11-73M18.7	5.17	3.46e-07	4.82e-05	0.24	0.23	Reticulocyte count;	chr14:103621145	chr14:103694560~103695170:+
THCA	cis	rs10078	0.51	rs2278248	ENSG00000221990.4	EXOC3-AS1	5.17	3.46e-07	4.82e-05	0.23	0.23	Fat distribution (HIV);	chr5:469455	chr5:441498~443160:-
THCA	cis	rs7119	0.651	rs12904823	ENSG00000259362.2	RP11-307C19.1	-5.17	3.46e-07	4.82e-05	-0.34	-0.23	Type 2 diabetes;	chr15:77545320	chr15:77525540~77534110:+
THCA	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	5.17	3.46e-07	4.82e-05	0.13	0.23	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
THCA	cis	rs712039	0.565	rs1714988	ENSG00000276054.1	RP11-378E13.3	5.17	3.46e-07	4.82e-05	0.37	0.23	Tuberculosis;	chr17:37387113	chr17:37386886~37387926:+
THCA	cis	rs7829975	0.658	rs907181	ENSG00000254153.1	CTA-398F10.2	-5.17	3.47e-07	4.82e-05	-0.24	-0.23	Mood instability;	chr8:8845365	chr8:8456909~8461337:-
THCA	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	5.17	3.47e-07	4.82e-05	0.13	0.23	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
THCA	cis	rs890448	0.796	rs10433982	ENSG00000254531.1	FLJ20021	5.17	3.47e-07	4.83e-05	0.21	0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362741	chr4:101347780~101348883:+
THCA	cis	rs4950322	0.57	rs17360443	ENSG00000271721.1	RP11-337C18.9	5.17	3.47e-07	4.83e-05	0.26	0.23	Protein quantitative trait loci;	chr1:147279737	chr1:147175602~147177740:+
THCA	cis	rs2239547	0.522	rs2581805	ENSG00000242142.1	SERBP1P3	-5.17	3.47e-07	4.83e-05	-0.29	-0.23	Schizophrenia;	chr3:52945034	chr3:53064283~53065091:-
THCA	cis	rs890448	0.897	rs2953534	ENSG00000254531.1	FLJ20021	-5.17	3.47e-07	4.83e-05	-0.21	-0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101454897	chr4:101347780~101348883:+
THCA	cis	rs587080	0.559	rs12364730	ENSG00000245532.5	NEAT1	5.17	3.47e-07	4.83e-05	0.2	0.23	Plateletcrit;	chr11:65460807	chr11:65422774~65445540:+
THCA	cis	rs3734266	0.702	rs9469820	ENSG00000272288.4	RP11-140K17.3	-5.17	3.47e-07	4.83e-05	-0.23	-0.23	Systemic lupus erythematosus;	chr6:34618986	chr6:34696317~34697470:+
THCA	cis	rs12893668	0.703	rs34896432	ENSG00000269958.1	RP11-73M18.8	5.17	3.47e-07	4.83e-05	0.23	0.23	Reticulocyte count;	chr14:103561658	chr14:103696353~103697163:+
THCA	cis	rs28476539	0.64	rs7691733	ENSG00000270480.1	RP11-57B24.1	-5.17	3.47e-07	4.83e-05	-0.37	-0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82633067	chr4:82691737~82692468:+
THCA	cis	rs9878978	0.685	rs6802636	ENSG00000237990.3	CNTN4-AS1	-5.17	3.47e-07	4.83e-05	-0.25	-0.23	Blood pressure (smoking interaction);	chr3:2468725	chr3:3039033~3069242:-
THCA	cis	rs795484	0.856	rs1151900	ENSG00000275409.1	RP11-131L12.4	-5.17	3.48e-07	4.84e-05	-0.2	-0.23	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118248477	chr12:118430147~118430699:+
THCA	cis	rs34779708	0.931	rs4934693	ENSG00000271335.4	RP11-324I22.4	5.17	3.48e-07	4.84e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35314552~35336401:-
THCA	cis	rs78487399	0.71	rs75607314	ENSG00000234936.1	AC010883.5	5.17	3.48e-07	4.84e-05	0.33	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43492552	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs78497923	ENSG00000234936.1	AC010883.5	5.17	3.48e-07	4.84e-05	0.33	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43495843	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs75097983	ENSG00000234936.1	AC010883.5	5.17	3.48e-07	4.84e-05	0.33	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43498485	chr2:43229573~43233394:+
THCA	cis	rs9677476	0.779	rs10177091	ENSG00000224376.1	AC017104.6	5.17	3.48e-07	4.84e-05	0.29	0.23	Food antigen IgG levels;	chr2:231245176	chr2:231388976~231394991:+
THCA	cis	rs853679	0.607	rs35749575	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28147040	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs72846780	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28151277	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13205911	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28156336	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13197176	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28161454	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs13201308	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28162311	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34765154	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28162672	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs34505829	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28165461	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs35098436	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28166443	chr6:28115628~28116551:+
THCA	cis	rs853679	0.607	rs72846794	ENSG00000219392.1	RP1-265C24.5	-5.17	3.48e-07	4.84e-05	-0.52	-0.23	Depression;	chr6:28169721	chr6:28115628~28116551:+
THCA	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-5.17	3.48e-07	4.84e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-5.17	3.48e-07	4.84e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-5.17	3.48e-07	4.84e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-5.17	3.48e-07	4.84e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-5.17	3.48e-07	4.84e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-5.17	3.48e-07	4.84e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
THCA	cis	rs2282300	0.696	rs12578061	ENSG00000242353.1	RP4-710M3.1	-5.17	3.48e-07	4.85e-05	-0.23	-0.23	Morning vs. evening chronotype;	chr11:30227818	chr11:30368148~30368646:+
THCA	cis	rs860295	0.665	rs11264393	ENSG00000160766.13	GBAP1	-5.17	3.48e-07	4.85e-05	-0.27	-0.23	Body mass index;	chr1:155604680	chr1:155213821~155227422:-
THCA	cis	rs5751614	1	rs2267018	ENSG00000230701.2	FBXW4P1	5.17	3.48e-07	4.85e-05	0.22	0.23	Height;	chr22:23246006	chr22:23262767~23265005:+
THCA	cis	rs7512898	0.5	rs10753882	ENSG00000260088.1	RP11-92G12.3	-5.17	3.49e-07	4.85e-05	-0.31	-0.23	Electrocardiographic conduction measures;	chr1:200821492	chr1:200669507~200694250:+
THCA	cis	rs860295	0.702	rs11264366	ENSG00000160766.13	GBAP1	-5.17	3.49e-07	4.85e-05	-0.27	-0.23	Body mass index;	chr1:155365620	chr1:155213821~155227422:-
THCA	cis	rs6547741	1	rs1528404	ENSG00000234072.1	AC074117.10	-5.17	3.49e-07	4.85e-05	-0.18	-0.23	Oral cavity cancer;	chr2:27623736	chr2:27356246~27367622:+
THCA	cis	rs2179367	0.632	rs6920383	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149356361	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs11155645	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149360056	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs10155766	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149364577	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498332	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149367490	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498333	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149368196	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498334	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149370902	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498335	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149372648	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498336	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149374208	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs1980774	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149375030	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498337	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149375970	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498338	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149376428	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.586	rs9498341	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149379737	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs9498342	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149379806	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12191079	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149380333	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12204461	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149380399	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12196656	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149383104	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12211570	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149383616	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.568	rs11155647	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149384499	chr6:149863494~149919507:+
THCA	cis	rs2179367	0.632	rs12197598	ENSG00000268592.3	RAET1E-AS1	5.17	3.49e-07	4.86e-05	0.33	0.23	Dupuytren's disease;	chr6:149385418	chr6:149863494~149919507:+
THCA	cis	rs613391	0.826	rs2122074	ENSG00000224549.1	RP11-370B11.3	-5.17	3.49e-07	4.86e-05	-0.26	-0.23	Quantitative traits;	chr9:22682046	chr9:22767175~22768316:+
THCA	cis	rs875971	0.545	rs73146609	ENSG00000232546.1	RP11-458F8.1	5.17	3.49e-07	4.86e-05	0.22	0.23	Aortic root size;	chr7:66302477	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000232546.1	RP11-458F8.1	5.17	3.49e-07	4.86e-05	0.22	0.23	Aortic root size;	chr7:66305392	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000232546.1	RP11-458F8.1	5.17	3.49e-07	4.86e-05	0.22	0.23	Aortic root size;	chr7:66318029	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000232546.1	RP11-458F8.1	5.17	3.49e-07	4.86e-05	0.22	0.23	Aortic root size;	chr7:66325577	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000232546.1	RP11-458F8.1	5.17	3.49e-07	4.86e-05	0.22	0.23	Aortic root size;	chr7:66339619	chr7:66848496~66858136:+
THCA	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-5.17	3.5e-07	4.86e-05	-0.3	-0.23	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
THCA	cis	rs7617480	0.616	rs7429596	ENSG00000228638.1	FCF1P2	-5.17	3.5e-07	4.86e-05	-0.3	-0.23	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48771098	chr3:48290793~48291375:-
THCA	cis	rs11089937	0.54	rs9622920	ENSG00000211639.2	IGLV4-60	-5.17	3.5e-07	4.86e-05	-0.17	-0.23	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22162199~22162681:+
THCA	cis	rs9388451	0.626	rs7748729	ENSG00000226409.1	RP11-735G4.1	-5.17	3.5e-07	4.86e-05	-0.28	-0.23	Brugada syndrome;	chr6:125756235	chr6:125370211~125374324:-
THCA	cis	rs7851660	0.874	rs1955143	ENSG00000214417.4	KRT18P13	-5.17	3.5e-07	4.86e-05	-0.2	-0.23	Strep throat;	chr9:97872297	chr9:97698922~97700734:+
THCA	cis	rs7554547	0.667	rs6666533	ENSG00000199347.1	RNU5E-1	-5.17	3.5e-07	4.86e-05	-0.33	-0.23	Nonsyndromic cleft lip with cleft palate;	chr1:11889068	chr1:11908152~11908271:+
THCA	cis	rs613391	0.522	rs525532	ENSG00000224549.1	RP11-370B11.3	-5.17	3.5e-07	4.87e-05	-0.27	-0.23	Quantitative traits;	chr9:22732228	chr9:22767175~22768316:+
THCA	cis	rs875971	0.528	rs801213	ENSG00000228409.4	CCT6P1	5.17	3.5e-07	4.87e-05	0.2	0.23	Aortic root size;	chr7:66549931	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000228409.4	CCT6P1	5.17	3.5e-07	4.87e-05	0.2	0.23	Aortic root size;	chr7:66550643	chr7:65751142~65763354:+
THCA	cis	rs13091206	1	rs13091206	ENSG00000228638.1	FCF1P2	-5.17	3.5e-07	4.87e-05	-0.3	-0.23	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr3:49201285	chr3:48290793~48291375:-
THCA	cis	rs11673344	0.503	rs703531	ENSG00000276846.1	CTD-3220F14.3	5.17	3.5e-07	4.87e-05	0.18	0.23	Obesity-related traits;	chr19:37010050	chr19:37314868~37315620:-
THCA	cis	rs9329221	0.621	rs522483	ENSG00000248538.5	RP11-10A14.5	5.17	3.5e-07	4.87e-05	0.3	0.23	Neuroticism;	chr8:9955459	chr8:9189011~9202854:+
THCA	cis	rs7617773	0.709	rs4404473	ENSG00000199476.1	Y_RNA	-5.17	3.5e-07	4.87e-05	-0.3	-0.23	Coronary artery disease;	chr3:48312136	chr3:48288587~48288694:+
THCA	cis	rs7412746	0.646	rs10399947	ENSG00000231073.1	RP11-316M1.3	5.17	3.5e-07	4.87e-05	0.27	0.23	Melanoma;	chr1:150889484	chr1:150973123~150975534:+
THCA	cis	rs5758659	0.652	rs133347	ENSG00000270083.1	RP1-257I20.14	5.17	3.51e-07	4.87e-05	0.25	0.23	Cognitive function;	chr22:42027641	chr22:42089630~42090028:-
THCA	cis	rs7617773	0.694	rs13099560	ENSG00000199476.1	Y_RNA	5.17	3.51e-07	4.88e-05	0.29	0.23	Coronary artery disease;	chr3:48163278	chr3:48288587~48288694:+
THCA	cis	rs7674212	0.54	rs2720469	ENSG00000246560.2	RP11-10L12.4	5.17	3.51e-07	4.88e-05	0.27	0.23	Type 2 diabetes;	chr4:103165327	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.57	rs12501621	ENSG00000246560.2	RP11-10L12.4	5.17	3.51e-07	4.88e-05	0.27	0.23	Type 2 diabetes;	chr4:103174348	chr4:102828055~102844075:+
THCA	cis	rs9818758	0.556	rs9835439	ENSG00000270441.1	RP11-694I15.7	5.17	3.51e-07	4.88e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49182897	chr3:49140086~49160851:-
THCA	cis	rs34779708	0.931	rs10508815	ENSG00000271335.4	RP11-324I22.4	5.17	3.51e-07	4.88e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35314552~35336401:-
THCA	cis	rs875971	0.502	rs11769702	ENSG00000232546.1	RP11-458F8.1	5.17	3.51e-07	4.88e-05	0.22	0.23	Aortic root size;	chr7:66255529	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs6970498	ENSG00000232546.1	RP11-458F8.1	5.17	3.51e-07	4.88e-05	0.22	0.23	Aortic root size;	chr7:66275908	chr7:66848496~66858136:+
THCA	cis	rs412050	0.501	rs78329092	ENSG00000224086.5	LL22NC03-86G7.1	-5.17	3.51e-07	4.88e-05	-0.42	-0.23	Attention deficit hyperactivity disorder;	chr22:21771914	chr22:21938293~21977632:+
THCA	cis	rs227275	0.554	rs223466	ENSG00000248971.2	KRT8P46	-5.17	3.51e-07	4.88e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102728746~102730171:-
THCA	cis	rs8028313	0.731	rs4776964	ENSG00000270964.1	RP11-502I4.3	-5.17	3.51e-07	4.88e-05	-0.2	-0.23	Obesity;	chr15:67724617	chr15:67541072~67542604:-
THCA	cis	rs1823913	0.637	rs4853583	ENSG00000280083.1	RP11-317J9.1	5.17	3.51e-07	4.88e-05	0.26	0.23	Obesity-related traits;	chr2:191304648	chr2:191154118~191156070:-
THCA	cis	rs1552244	1	rs6786638	ENSG00000180385.7	EMC3-AS1	5.17	3.51e-07	4.88e-05	0.26	0.23	Alzheimer's disease;	chr3:10076391	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs6442150	ENSG00000180385.7	EMC3-AS1	5.17	3.51e-07	4.88e-05	0.26	0.23	Alzheimer's disease;	chr3:10080891	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs17032268	ENSG00000180385.7	EMC3-AS1	5.17	3.51e-07	4.88e-05	0.26	0.23	Alzheimer's disease;	chr3:10026288	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs3846177	ENSG00000180385.7	EMC3-AS1	5.17	3.51e-07	4.88e-05	0.26	0.23	Alzheimer's disease;	chr3:10026888	chr3:9986893~10006990:+
THCA	cis	rs2067615	0.56	rs10431462	ENSG00000260329.1	RP11-412D9.4	-5.17	3.51e-07	4.88e-05	-0.21	-0.23	Heart rate;	chr12:106712768	chr12:106954029~106955497:-
THCA	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-5.17	3.51e-07	4.88e-05	-0.31	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
THCA	cis	rs6430585	0.697	rs1050115	ENSG00000231890.6	DARS-AS1	-5.17	3.51e-07	4.88e-05	-0.29	-0.23	Corneal structure;	chr2:135754247	chr2:135985176~136022593:+
THCA	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	5.17	3.51e-07	4.88e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	5.17	3.51e-07	4.88e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	5.17	3.51e-07	4.88e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-5.17	3.51e-07	4.88e-05	-0.36	-0.23	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
THCA	cis	rs6723108	1	rs1942055	ENSG00000224043.6	CCNT2-AS1	5.17	3.51e-07	4.88e-05	0.28	0.23	Type 2 diabetes;	chr2:134741354	chr2:134735464~134918710:-
THCA	cis	rs4648045	0.964	rs1598859	ENSG00000246560.2	RP11-10L12.4	5.17	3.51e-07	4.89e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102585287	chr4:102828055~102844075:+
THCA	cis	rs7250849	0.529	rs73052877	ENSG00000273837.1	LLNLR-470E3.1	-5.17	3.52e-07	4.89e-05	-0.32	-0.23	Blood protein levels;	chr19:51662744	chr19:51639478~51639931:-
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000273796.1	LL21NC02-21A1.1	5.17	3.52e-07	4.89e-05	0.24	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45403809~45404369:-
THCA	cis	rs12935418	0.672	rs7197370	ENSG00000278985.1	RP11-303E16.9	5.17	3.52e-07	4.89e-05	0.25	0.23	Mean corpuscular volume;	chr16:81017520	chr16:80982319~80984094:-
THCA	cis	rs7474896	1	rs3824585	ENSG00000263064.2	RP11-291L22.7	5.17	3.52e-07	4.89e-05	0.37	0.23	Obesity (extreme);	chr10:37820493	chr10:38448689~38448949:+
THCA	cis	rs9816784	0.525	rs714602	ENSG00000242086.7	LINC00969	5.17	3.52e-07	4.89e-05	0.24	0.23	Mean corpuscular hemoglobin;	chr3:196067108	chr3:195658062~195739964:+
THCA	cis	rs7688540	0.723	rs17521834	ENSG00000211553.1	AC253576.2	5.17	3.52e-07	4.89e-05	0.36	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:136461~136568:+
THCA	cis	rs4604234	0.614	rs2437879	ENSG00000272129.1	RP11-250B2.6	-5.17	3.52e-07	4.89e-05	-0.52	-0.23	Cancer;	chr6:80525999	chr6:80355424~80356859:+
THCA	cis	rs481331	0.741	rs3740329	ENSG00000215146.4	RP11-313J2.1	5.17	3.52e-07	4.89e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42638638	chr10:42331866~42367974:-
THCA	cis	rs10829156	0.898	rs10741120	ENSG00000240291.1	RP11-499P20.2	5.17	3.52e-07	4.89e-05	0.2	0.23	Sudden cardiac arrest;	chr10:18641063	chr10:18513115~18545651:-
THCA	cis	rs2299587	0.689	rs2285303	ENSG00000253671.1	RP11-806O11.1	-5.17	3.52e-07	4.89e-05	-0.28	-0.23	Economic and political preferences;	chr8:17939900	chr8:17808941~17820868:+
THCA	cis	rs1552244	1	rs6764168	ENSG00000180385.7	EMC3-AS1	5.17	3.52e-07	4.9e-05	0.26	0.23	Alzheimer's disease;	chr3:10082121	chr3:9986893~10006990:+
THCA	cis	rs4415084	0.768	rs9292915	ENSG00000272335.1	RP11-53O19.3	5.17	3.52e-07	4.9e-05	0.19	0.23	Breast cancer;	chr5:44871555	chr5:44826076~44828592:+
THCA	cis	rs481331	0.741	rs574720	ENSG00000215146.4	RP11-313J2.1	-5.17	3.53e-07	4.9e-05	-0.37	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42653951	chr10:42331866~42367974:-
THCA	cis	rs4908760	0.73	rs10779704	ENSG00000232912.4	RP5-1115A15.1	5.17	3.53e-07	4.9e-05	0.23	0.23	Vitiligo;	chr1:8633478	chr1:8424645~8434838:+
THCA	cis	rs7809950	0.954	rs2712229	ENSG00000238832.1	snoU109	5.17	3.53e-07	4.9e-05	0.25	0.23	Coronary artery disease;	chr7:107654881	chr7:107603363~107603507:+
THCA	cis	rs2562456	0.641	rs62107468	ENSG00000268119.4	CTD-2561J22.5	5.17	3.53e-07	4.9e-05	0.33	0.23	Pain;	chr19:21307177	chr19:21444241~21463908:-
THCA	cis	rs412050	0.502	rs17759796	ENSG00000224086.5	LL22NC03-86G7.1	5.17	3.53e-07	4.9e-05	0.41	0.23	Attention deficit hyperactivity disorder;	chr22:21835874	chr22:21938293~21977632:+
THCA	cis	rs7829975	0.577	rs940032	ENSG00000253893.2	FAM85B	5.17	3.53e-07	4.91e-05	0.31	0.23	Mood instability;	chr8:8688833	chr8:8167819~8226614:-
THCA	cis	rs853679	0.76	rs9357067	ENSG00000220721.1	OR1F12	5.17	3.53e-07	4.91e-05	0.33	0.23	Depression;	chr6:28242515	chr6:28073316~28074233:+
THCA	cis	rs853679	0.76	rs967005	ENSG00000220721.1	OR1F12	5.17	3.53e-07	4.91e-05	0.33	0.23	Depression;	chr6:28242910	chr6:28073316~28074233:+
THCA	cis	rs6951245	1	rs113146460	ENSG00000229043.2	AC091729.9	-5.17	3.53e-07	4.91e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.935	rs61753396	ENSG00000229043.2	AC091729.9	-5.17	3.53e-07	4.91e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs79327308	ENSG00000229043.2	AC091729.9	-5.17	3.53e-07	4.91e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.938	rs117729148	ENSG00000229043.2	AC091729.9	-5.17	3.53e-07	4.91e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1160374~1165267:+
THCA	cis	rs2115630	1	rs11854313	ENSG00000225151.9	GOLGA2P7	5.17	3.53e-07	4.91e-05	0.3	0.23	P wave terminal force;	chr15:84760817	chr15:84199311~84230136:-
THCA	cis	rs7674212	0.541	rs2720460	ENSG00000251288.2	RP11-10L12.2	5.17	3.53e-07	4.91e-05	0.3	0.23	Type 2 diabetes;	chr4:103133529	chr4:102751401~102752641:+
THCA	cis	rs467650	0.782	rs719246	ENSG00000248489.1	CTD-2007H13.3	-5.17	3.54e-07	4.91e-05	-0.22	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:98722220	chr5:98929171~98995013:+
THCA	cis	rs3796352	1	rs13078971	ENSG00000242142.1	SERBP1P3	-5.17	3.54e-07	4.91e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53069629	chr3:53064283~53065091:-
THCA	cis	rs9843304	0.546	rs9858201	ENSG00000240541.2	TM4SF1-AS1	-5.17	3.54e-07	4.91e-05	-0.22	-0.23	Gallstone disease;	chr3:149501881	chr3:149377778~149386583:+
THCA	cis	rs5758659	0.652	rs1063392	ENSG00000270083.1	RP1-257I20.14	-5.17	3.54e-07	4.92e-05	-0.24	-0.23	Cognitive function;	chr22:42058946	chr22:42089630~42090028:-
THCA	cis	rs1580019	0.587	rs10951338	ENSG00000231952.3	DPY19L1P2	-5.17	3.54e-07	4.92e-05	-0.29	-0.23	Cognitive ability;	chr7:32520477	chr7:32812757~32838570:+
THCA	cis	rs7824557	0.767	rs2164273	ENSG00000154316.13	TDH	-5.17	3.54e-07	4.92e-05	-0.17	-0.23	Retinal vascular caliber;	chr8:11310990	chr8:11339637~11368452:+
THCA	cis	rs6951245	1	rs78158942	ENSG00000229043.2	AC091729.9	-5.17	3.54e-07	4.92e-05	-0.41	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1160374~1165267:+
THCA	cis	rs189798	0.807	rs330912	ENSG00000253893.2	FAM85B	-5.17	3.54e-07	4.92e-05	-0.31	-0.23	Myopia (pathological);	chr8:9138784	chr8:8167819~8226614:-
THCA	cis	rs7246657	0.525	rs10405238	ENSG00000276846.1	CTD-3220F14.3	5.17	3.54e-07	4.92e-05	0.25	0.23	Coronary artery calcification;	chr19:36997153	chr19:37314868~37315620:-
THCA	cis	rs4073416	0.967	rs4131095	ENSG00000276116.2	FUT8-AS1	-5.17	3.54e-07	4.92e-05	-0.25	-0.23	N-glycan levels;	chr14:65792719	chr14:65411170~65412690:-
THCA	cis	rs4971059	0.608	rs7366138	ENSG00000160766.13	GBAP1	-5.17	3.54e-07	4.92e-05	-0.26	-0.23	Breast cancer;	chr1:155115874	chr1:155213821~155227422:-
THCA	cis	rs12681288	0.676	rs2600514	ENSG00000260721.1	AF067845.1	5.17	3.54e-07	4.92e-05	0.28	0.23	Schizophrenia;	chr8:1044175	chr8:1368642~1369833:-
THCA	cis	rs7493	0.95	rs12704794	ENSG00000233942.1	AC004012.1	5.17	3.54e-07	4.92e-05	0.34	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr7:95406821	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs12155103	ENSG00000233942.1	AC004012.1	5.17	3.54e-07	4.92e-05	0.34	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr7:95407819	chr7:95471835~95473998:+
THCA	cis	rs7493	0.95	rs6961624	ENSG00000233942.1	AC004012.1	5.17	3.54e-07	4.92e-05	0.34	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr7:95408349	chr7:95471835~95473998:+
THCA	cis	rs7493	1	rs2286232	ENSG00000233942.1	AC004012.1	5.17	3.54e-07	4.92e-05	0.34	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr7:95410133	chr7:95471835~95473998:+
THCA	cis	rs2070488	0.804	rs1817364	ENSG00000229589.1	ACVR2B-AS1	5.17	3.54e-07	4.92e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38433022	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.804	rs13063978	ENSG00000229589.1	ACVR2B-AS1	5.17	3.54e-07	4.92e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38435047	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.766	rs4679050	ENSG00000229589.1	ACVR2B-AS1	5.17	3.54e-07	4.92e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38440516	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.804	rs13100195	ENSG00000229589.1	ACVR2B-AS1	5.17	3.54e-07	4.92e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38441048	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.804	rs13094715	ENSG00000229589.1	ACVR2B-AS1	5.17	3.54e-07	4.92e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38462939	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.775	rs961179	ENSG00000229589.1	ACVR2B-AS1	5.17	3.54e-07	4.92e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38468127	chr3:38451027~38454820:-
THCA	cis	rs2380205	0.682	rs7919785	ENSG00000232807.2	RP11-536K7.3	5.17	3.54e-07	4.92e-05	0.21	0.23	Breast cancer;	chr10:5884168	chr10:5934270~5945900:-
THCA	cis	rs2070488	0.775	rs2300669	ENSG00000229589.1	ACVR2B-AS1	-5.17	3.55e-07	4.93e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38499827	chr3:38451027~38454820:-
THCA	cis	rs6714710	0.603	rs35255677	ENSG00000230606.9	AC159540.1	-5.17	3.55e-07	4.93e-05	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97951357	chr2:97416165~97433527:-
THCA	cis	rs4950322	0.57	rs72691032	ENSG00000226015.2	CCT8P1	5.17	3.55e-07	4.93e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147261120	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs72691033	ENSG00000226015.2	CCT8P1	5.17	3.55e-07	4.93e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147261267	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs111370771	ENSG00000226015.2	CCT8P1	5.17	3.55e-07	4.93e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147261420	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs4301678	ENSG00000226015.2	CCT8P1	5.17	3.55e-07	4.93e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147261907	chr1:147203276~147204932:-
THCA	cis	rs375066	0.592	rs349048	ENSG00000267058.1	RP11-15A1.3	5.17	3.55e-07	4.93e-05	0.2	0.23	Breast cancer;	chr19:43796785	chr19:43891804~43901805:-
THCA	cis	rs116095464	0.558	rs6555058	ENSG00000248925.1	CTD-2083E4.6	-5.17	3.55e-07	4.93e-05	-0.33	-0.23	Breast cancer;	chr5:226261	chr5:269858~271516:-
THCA	cis	rs2235642	0.928	rs56289115	ENSG00000280231.1	LA16c-380F5.3	-5.17	3.55e-07	4.93e-05	-0.28	-0.23	Coronary artery disease;	chr16:1558933	chr16:1553655~1554130:-
THCA	cis	rs1580019	0.587	rs2392069	ENSG00000231952.3	DPY19L1P2	-5.17	3.55e-07	4.93e-05	-0.29	-0.23	Cognitive ability;	chr7:32507542	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.587	rs34488151	ENSG00000231952.3	DPY19L1P2	-5.17	3.55e-07	4.93e-05	-0.29	-0.23	Cognitive ability;	chr7:32508534	chr7:32812757~32838570:+
THCA	cis	rs6920965	0.507	rs9401853	ENSG00000237742.5	RP11-624M8.1	-5.17	3.55e-07	4.93e-05	-0.21	-0.23	High light scatter reticulocyte count;	chr6:125894051	chr6:125578558~125749190:-
THCA	cis	rs4591358	1	rs4850619	ENSG00000223466.1	AC064834.2	-5.17	3.55e-07	4.93e-05	-0.28	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195468634	chr2:195533035~195538681:+
THCA	cis	rs2436845	0.58	rs2436850	ENSG00000253669.3	KB-1732A1.1	-5.17	3.55e-07	4.93e-05	-0.25	-0.23	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102815152	chr8:102805517~102809971:+
THCA	cis	rs853679	0.723	rs1736904	ENSG00000280107.1	AL022393.9	-5.17	3.55e-07	4.93e-05	-0.27	-0.23	Depression;	chr6:28251492	chr6:28170845~28172521:+
THCA	cis	rs7209700	0.547	rs884696	ENSG00000228782.6	CTD-2026D20.3	-5.17	3.55e-07	4.93e-05	-0.27	-0.23	IgG glycosylation;	chr17:47263878	chr17:47450568~47492492:-
THCA	cis	rs9595908	0.827	rs7321262	ENSG00000212293.1	SNORA16	5.17	3.55e-07	4.94e-05	0.27	0.23	Body mass index;	chr13:32597942	chr13:32420390~32420516:-
THCA	cis	rs6088580	0.668	rs1205340	ENSG00000276073.1	RP5-1125A11.7	5.17	3.55e-07	4.94e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34336065	chr20:33985617~33988989:-
THCA	cis	rs1707322	1	rs1707322	ENSG00000281133.1	AL355480.3	-5.17	3.55e-07	4.94e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45580892~45580996:-
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000230295.1	RP11-458F8.2	-5.17	3.55e-07	4.94e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65924813	chr7:66880708~66882981:+
THCA	cis	rs6430585	0.702	rs1042712	ENSG00000231890.6	DARS-AS1	5.17	3.56e-07	4.94e-05	0.28	0.23	Corneal structure;	chr2:135788274	chr2:135985176~136022593:+
THCA	cis	rs73242632	1	rs73242623	ENSG00000269949.1	RP11-738E22.3	5.16	3.56e-07	4.94e-05	0.54	0.23	Congenital heart disease (maternal effect);	chr4:56974377	chr4:56960927~56961373:-
THCA	cis	rs9859260	0.925	rs3761717	ENSG00000231464.1	AC024937.4	5.16	3.56e-07	4.94e-05	0.28	0.23	Mean corpuscular volume;	chr3:196071076	chr3:195996738~195998233:+
THCA	cis	rs3764400	0.564	rs12602670	ENSG00000278765.1	RP5-890E16.5	5.16	3.56e-07	4.94e-05	0.42	0.23	Body mass index;	chr17:48027514	chr17:48066704~48067293:-
THCA	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	5.16	3.56e-07	4.94e-05	0.43	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
THCA	cis	rs2243480	1	rs34637256	ENSG00000230295.1	RP11-458F8.2	-5.16	3.56e-07	4.94e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65895144	chr7:66880708~66882981:+
THCA	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	5.16	3.56e-07	4.94e-05	0.14	0.23	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
THCA	cis	rs10888838	0.938	rs12031348	ENSG00000198711.5	SSBP3-AS1	5.16	3.56e-07	4.94e-05	0.25	0.23	Mitochondrial DNA levels;	chr1:54203106	chr1:54236440~54239063:+
THCA	cis	rs7577696	0.925	rs212716	ENSG00000276334.1	AL133243.1	5.16	3.56e-07	4.95e-05	0.25	0.23	Inflammatory biomarkers;	chr2:32235865	chr2:32521927~32523547:+
THCA	cis	rs11089937	0.568	rs5756988	ENSG00000211638.2	IGLV8-61	5.16	3.56e-07	4.95e-05	0.18	0.23	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22098700~22099212:+
THCA	cis	rs9818758	0.607	rs9837625	ENSG00000270441.1	RP11-694I15.7	5.16	3.57e-07	4.95e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178533	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs66991555	ENSG00000270441.1	RP11-694I15.7	5.16	3.57e-07	4.95e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49191210	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs9855123	ENSG00000270441.1	RP11-694I15.7	5.16	3.57e-07	4.95e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49192024	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs34566463	ENSG00000270441.1	RP11-694I15.7	5.16	3.57e-07	4.95e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207644	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs11710247	ENSG00000270441.1	RP11-694I15.7	5.16	3.57e-07	4.95e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49212367	chr3:49140086~49160851:-
THCA	cis	rs2179367	0.632	rs59820585	ENSG00000223701.3	RAET1E-AS1	5.16	3.57e-07	4.95e-05	0.33	0.23	Dupuytren's disease;	chr6:149350249	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs56924465	ENSG00000223701.3	RAET1E-AS1	5.16	3.57e-07	4.95e-05	0.33	0.23	Dupuytren's disease;	chr6:149350270	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.568	rs62426092	ENSG00000223701.3	RAET1E-AS1	5.16	3.57e-07	4.95e-05	0.33	0.23	Dupuytren's disease;	chr6:149352720	chr6:149884431~149919508:+
THCA	cis	rs516805	0.683	rs502071	ENSG00000279453.1	RP3-425C14.4	-5.16	3.57e-07	4.95e-05	-0.28	-0.23	Lymphocyte counts;	chr6:122417917	chr6:122436789~122439223:-
THCA	cis	rs1823913	0.637	rs1470962	ENSG00000280083.1	RP11-317J9.1	5.16	3.57e-07	4.95e-05	0.27	0.23	Obesity-related traits;	chr2:191270271	chr2:191154118~191156070:-
THCA	cis	rs2360027	0.599	rs11590559	ENSG00000231365.4	RP11-418J17.1	-5.16	3.57e-07	4.95e-05	-0.22	-0.23	Tonsillectomy;	chr1:118557358	chr1:119140396~119275973:+
THCA	cis	rs755249	0.567	rs72661940	ENSG00000228060.1	RP11-69E11.8	-5.16	3.57e-07	4.96e-05	-0.25	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39262975	chr1:39565160~39573203:+
THCA	cis	rs7824557	0.836	rs2736378	ENSG00000154316.13	TDH	5.16	3.57e-07	4.96e-05	0.17	0.23	Retinal vascular caliber;	chr8:11262251	chr8:11339637~11368452:+
THCA	cis	rs763121	0.853	rs6001175	ENSG00000228274.3	RP3-508I15.9	-5.16	3.57e-07	4.96e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38622329	chr22:38667585~38681820:-
THCA	cis	rs853679	0.599	rs149990	ENSG00000280107.1	AL022393.9	-5.16	3.57e-07	4.96e-05	-0.33	-0.23	Depression;	chr6:28030480	chr6:28170845~28172521:+
THCA	cis	rs12823128	0.646	rs957540	ENSG00000256185.1	RP11-612B6.2	5.16	3.57e-07	4.96e-05	0.21	0.23	Birth weight;	chr12:26757772	chr12:26335864~26336950:-
THCA	cis	rs9990333	0.762	rs6810239	ENSG00000242086.7	LINC00969	-5.16	3.57e-07	4.96e-05	-0.22	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085292	chr3:195658062~195739964:+
THCA	cis	rs10050311	0.8	rs17420966	ENSG00000251411.1	RP11-397E7.4	-5.16	3.57e-07	4.96e-05	-0.29	-0.23	Insulin-related traits;	chr4:86770976	chr4:86913266~86914817:-
THCA	cis	rs72799341	1	rs7200879	ENSG00000260911.2	RP11-196G11.2	5.16	3.57e-07	4.96e-05	0.22	0.23	Diastolic blood pressure;	chr16:30936251	chr16:31043150~31049868:+
THCA	cis	rs1129187	0.902	rs10948059	ENSG00000272223.1	RP1-20C7.6	5.16	3.57e-07	4.96e-05	0.17	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42960723	chr6:43033897~43034405:-
THCA	cis	rs7829975	0.557	rs7816427	ENSG00000253893.2	FAM85B	5.16	3.57e-07	4.96e-05	0.32	0.23	Mood instability;	chr8:8688374	chr8:8167819~8226614:-
THCA	cis	rs7847628	0.587	rs10760117	ENSG00000238181.2	AHCYP2	-5.16	3.57e-07	4.96e-05	-0.29	-0.23	Birth weight;	chr9:120824459	chr9:120720673~120721972:+
THCA	cis	rs1479090	0.802	rs28826687	ENSG00000250027.1	RP11-563E2.2	-5.16	3.58e-07	4.96e-05	-0.25	-0.23	Lung cancer;	chr4:163130618	chr4:163108785~163119965:+
THCA	cis	rs801193	0.613	rs2016325	ENSG00000273142.1	RP11-458F8.4	5.16	3.58e-07	4.96e-05	0.19	0.23	Aortic root size;	chr7:66858513	chr7:66902857~66906297:+
THCA	cis	rs7617773	0.643	rs78159520	ENSG00000199476.1	Y_RNA	-5.16	3.58e-07	4.97e-05	-0.3	-0.23	Coronary artery disease;	chr3:48307533	chr3:48288587~48288694:+
THCA	cis	rs853679	0.769	rs7752448	ENSG00000219392.1	RP1-265C24.5	-5.16	3.58e-07	4.97e-05	-0.42	-0.23	Depression;	chr6:28333322	chr6:28115628~28116551:+
THCA	cis	rs4648045	0.765	rs4699031	ENSG00000246560.2	RP11-10L12.4	5.16	3.58e-07	4.97e-05	0.29	0.23	Lymphocyte percentage of white cells;	chr4:102605271	chr4:102828055~102844075:+
THCA	cis	rs6792584	0.634	rs4455333	ENSG00000241316.5	SUCLG2-AS1	5.16	3.58e-07	4.97e-05	0.25	0.23	Corneal astigmatism;	chr3:67447308	chr3:67654697~67947713:+
THCA	cis	rs9876781	0.872	rs11797	ENSG00000229759.1	MRPS18AP1	5.16	3.58e-07	4.97e-05	0.28	0.23	Longevity;	chr3:48467186	chr3:48256350~48256938:-
THCA	cis	rs4718428	1	rs4718421	ENSG00000232546.1	RP11-458F8.1	-5.16	3.58e-07	4.97e-05	-0.2	-0.23	Corneal structure;	chr7:66885313	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000232546.1	RP11-458F8.1	5.16	3.58e-07	4.97e-05	0.22	0.23	Aortic root size;	chr7:66376216	chr7:66848496~66858136:+
THCA	cis	rs9816784	0.525	rs555412	ENSG00000242086.7	LINC00969	5.16	3.58e-07	4.97e-05	0.24	0.23	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195658062~195739964:+
THCA	cis	rs9816784	0.525	rs422772	ENSG00000242086.7	LINC00969	5.16	3.58e-07	4.97e-05	0.24	0.23	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195658062~195739964:+
THCA	cis	rs7688540	0.771	rs61794996	ENSG00000211553.1	AC253576.2	-5.16	3.58e-07	4.97e-05	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:136461~136568:+
THCA	cis	rs1075265	0.509	rs10178643	ENSG00000272156.1	RP11-477N3.1	5.16	3.59e-07	4.98e-05	0.23	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53728341	chr2:54082554~54085066:+
THCA	cis	rs7474896	1	rs9418299	ENSG00000263064.2	RP11-291L22.7	5.16	3.59e-07	4.98e-05	0.37	0.23	Obesity (extreme);	chr10:37851299	chr10:38448689~38448949:+
THCA	cis	rs2380205	0.651	rs7907053	ENSG00000232807.2	RP11-536K7.3	5.16	3.59e-07	4.98e-05	0.21	0.23	Breast cancer;	chr10:5884191	chr10:5934270~5945900:-
THCA	cis	rs6570726	0.846	rs7773939	ENSG00000270638.1	RP3-466P17.1	-5.16	3.59e-07	4.98e-05	-0.19	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145735570~145737218:+
THCA	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	5.16	3.59e-07	4.98e-05	0.28	0.23	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
THCA	cis	rs17767392	0.846	rs56180634	ENSG00000259146.3	RP1-261D10.2	5.16	3.59e-07	4.98e-05	0.29	0.23	Mitral valve prolapse;	chr14:71523216	chr14:71292729~71321814:-
THCA	cis	rs9652601	0.779	rs12708716	ENSG00000274038.1	RP11-66H6.4	5.16	3.59e-07	4.98e-05	0.3	0.23	Systemic lupus erythematosus;	chr16:11086016	chr16:11056556~11057034:+
THCA	cis	rs9843304	0.508	rs11926459	ENSG00000240541.2	TM4SF1-AS1	-5.16	3.59e-07	4.99e-05	-0.22	-0.23	Gallstone disease;	chr3:149494295	chr3:149377778~149386583:+
THCA	cis	rs9467773	1	rs9467779	ENSG00000261353.1	CTA-14H9.5	5.16	3.59e-07	4.99e-05	0.24	0.23	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26527063~26527404:+
THCA	cis	rs1501911	0.545	rs4703345	ENSG00000248489.1	CTD-2007H13.3	-5.16	3.6e-07	4.99e-05	-0.25	-0.23	Lung function (FEV1/FVC);	chr5:99016679	chr5:98929171~98995013:+
THCA	cis	rs3734266	0.702	rs9461992	ENSG00000272288.4	RP11-140K17.3	-5.16	3.6e-07	5e-05	-0.23	-0.23	Systemic lupus erythematosus;	chr6:34621183	chr6:34696317~34697470:+
THCA	cis	rs12200782	0.725	rs6912853	ENSG00000124549.13	BTN2A3P	5.16	3.6e-07	5e-05	0.3	0.23	Small cell lung carcinoma;	chr6:26401210	chr6:26421391~26432383:+
THCA	cis	rs34779708	0.966	rs11599606	ENSG00000271335.4	RP11-324I22.4	5.16	3.6e-07	5e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35314552~35336401:-
THCA	cis	rs17767392	0.871	rs2108706	ENSG00000259146.3	RP1-261D10.2	5.16	3.6e-07	5e-05	0.28	0.23	Mitral valve prolapse;	chr14:71332458	chr14:71292729~71321814:-
THCA	cis	rs2129782	1	rs61087653	ENSG00000253553.4	RP11-586K2.1	5.16	3.6e-07	5e-05	0.41	0.23	Electrodermal activity;	chr8:88406097	chr8:88326836~88737134:+
THCA	cis	rs9425766	0.679	rs2901785	ENSG00000227373.4	RP11-160H22.5	5.16	3.6e-07	5e-05	0.32	0.23	Life satisfaction;	chr1:174135605	chr1:174115300~174160004:-
THCA	cis	rs2880765	0.835	rs6497206	ENSG00000259630.2	CTD-2262B20.1	-5.16	3.6e-07	5e-05	-0.25	-0.23	Coronary artery disease;	chr15:85485994	chr15:85415228~85415633:+
THCA	cis	rs2797160	0.837	rs1739364	ENSG00000237742.5	RP11-624M8.1	-5.16	3.6e-07	5e-05	-0.2	-0.23	Endometrial cancer;	chr6:125701237	chr6:125578558~125749190:-
THCA	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	5.16	3.6e-07	5e-05	0.27	0.23	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
THCA	cis	rs116095464	0.558	rs34629844	ENSG00000248925.1	CTD-2083E4.6	5.16	3.6e-07	5e-05	0.37	0.23	Breast cancer;	chr5:200714	chr5:269858~271516:-
THCA	cis	rs2985684	1	rs3007030	ENSG00000278009.1	RP11-649E7.8	5.16	3.6e-07	5e-05	0.34	0.23	Carotid intima media thickness;	chr14:49619845	chr14:49601011~49601124:-
THCA	cis	rs7520050	0.807	rs5021934	ENSG00000234329.1	RP11-767N6.2	-5.16	3.6e-07	5e-05	-0.21	-0.23	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45651039~45651826:-
THCA	cis	rs9494145	0.648	rs7758845	ENSG00000232876.1	CTA-212D2.2	-5.16	3.61e-07	5e-05	-0.32	-0.23	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135107399	chr6:135055033~135060550:+
THCA	cis	rs11671005	0.737	rs11673101	ENSG00000269473.1	CTD-2619J13.19	5.16	3.61e-07	5e-05	0.28	0.23	Mean platelet volume;	chr19:58483686	chr19:58440448~58445849:+
THCA	cis	rs9859260	1	rs9859260	ENSG00000231464.1	AC024937.4	5.16	3.61e-07	5e-05	0.28	0.23	Mean corpuscular volume;	chr3:196073676	chr3:195996738~195998233:+
THCA	cis	rs8028182	0.549	rs4886696	ENSG00000260269.4	CTD-2323K18.1	5.16	3.61e-07	5e-05	0.34	0.23	Sudden cardiac arrest;	chr15:75372229	chr15:75527150~75601205:-
THCA	cis	rs1876905	0.539	rs457497	ENSG00000230177.1	RP5-1112D6.4	5.16	3.61e-07	5e-05	0.24	0.23	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111277932~111278742:+
THCA	cis	rs7005380	0.561	rs7818471	ENSG00000245330.4	KB-1471A8.1	5.16	3.61e-07	5e-05	0.23	0.23	Interstitial lung disease;	chr8:119897596	chr8:119867419~119874488:-
THCA	cis	rs4693089	0.564	rs10010720	ENSG00000213608.5	SLC25A14P1	-5.16	3.61e-07	5e-05	-0.26	-0.23	Menopause (age at onset);	chr4:83516178	chr4:83477524~83478424:+
THCA	cis	rs79243044	0.965	rs12274861	ENSG00000224295.2	AC087380.14	5.16	3.61e-07	5.01e-05	0.23	0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5545789	chr11:5518441~5524955:-
THCA	cis	rs796395	0.967	rs1690789	ENSG00000228208.5	C1orf143	-5.16	3.61e-07	5.01e-05	-0.28	-0.23	Post bronchodilator FEV1/FVC ratio;	chr1:218524685	chr1:218510096~218525978:+
THCA	cis	rs7119	0.651	rs17394732	ENSG00000259362.2	RP11-307C19.1	5.16	3.61e-07	5.01e-05	0.34	0.23	Type 2 diabetes;	chr15:77543315	chr15:77525540~77534110:+
THCA	cis	rs9890032	0.52	rs2321926	ENSG00000263603.1	CTD-2349P21.5	-5.16	3.61e-07	5.01e-05	-0.29	-0.23	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30729469~30731202:+
THCA	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	5.16	3.61e-07	5.01e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
THCA	cis	rs9959145	0.706	rs28663159	ENSG00000267108.1	RP11-861E21.1	5.16	3.61e-07	5.01e-05	0.28	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12612441	chr18:12432897~12437635:+
THCA	cis	rs4950322	0.57	rs3737855	ENSG00000226015.2	CCT8P1	5.16	3.61e-07	5.01e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147271257	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs4950316	ENSG00000226015.2	CCT8P1	5.16	3.61e-07	5.01e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147273712	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.57	rs2354428	ENSG00000226015.2	CCT8P1	5.16	3.61e-07	5.01e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147277512	chr1:147203276~147204932:-
THCA	cis	rs1707322	0.721	rs6665808	ENSG00000281133.1	AL355480.3	-5.16	3.62e-07	5.01e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45580892~45580996:-
THCA	cis	rs17772222	0.597	rs17700521	ENSG00000258983.2	RP11-507K2.2	5.16	3.62e-07	5.01e-05	0.29	0.23	Coronary artery calcification;	chr14:88849531	chr14:88499334~88515502:+
THCA	cis	rs875971	0.545	rs67775320	ENSG00000232546.1	RP11-458F8.1	5.16	3.62e-07	5.02e-05	0.22	0.23	Aortic root size;	chr7:66193792	chr7:66848496~66858136:+
THCA	cis	rs763121	0.853	rs5750627	ENSG00000228274.3	RP3-508I15.9	-5.16	3.62e-07	5.02e-05	-0.25	-0.23	Menopause (age at onset);	chr22:38586316	chr22:38667585~38681820:-
THCA	cis	rs11634944	0.643	rs2732044	ENSG00000257151.1	PWAR6	5.16	3.62e-07	5.02e-05	0.17	0.23	Interleukin-8 levels;	chr15:25032169	chr15:25031873~25036490:+
THCA	cis	rs6708331	0.517	rs12999042	ENSG00000179818.12	PCBP1-AS1	-5.16	3.62e-07	5.02e-05	-0.19	-0.23	Obesity-related traits;	chr2:70139679	chr2:69962263~70103220:-
THCA	cis	rs9733	0.596	rs56058687	ENSG00000231073.1	RP11-316M1.3	5.16	3.62e-07	5.02e-05	0.27	0.23	Tonsillectomy;	chr1:150662590	chr1:150973123~150975534:+
THCA	cis	rs5015933	0.788	rs359594	ENSG00000232630.1	PRPS1P2	-5.16	3.62e-07	5.02e-05	-0.16	-0.23	Body mass index;	chr9:125273062	chr9:125150653~125151589:+
THCA	cis	rs2067615	0.579	rs10778502	ENSG00000260329.1	RP11-412D9.4	-5.16	3.62e-07	5.02e-05	-0.21	-0.23	Heart rate;	chr12:106696423	chr12:106954029~106955497:-
THCA	cis	rs1275468	0.731	rs1383098	ENSG00000257497.2	RP11-585P4.5	-5.16	3.62e-07	5.02e-05	-0.36	-0.23	Polycystic ovary syndrome;	chr12:75588107	chr12:75483454~75489820:-
THCA	cis	rs72945132	0.882	rs72949076	ENSG00000254604.1	AP000487.6	-5.16	3.62e-07	5.02e-05	-0.44	-0.23	Coronary artery disease;	chr11:70371589	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs72949078	ENSG00000254604.1	AP000487.6	-5.16	3.62e-07	5.02e-05	-0.44	-0.23	Coronary artery disease;	chr11:70371602	chr11:70282367~70363368:-
THCA	cis	rs897984	0.76	rs11076	ENSG00000260911.2	RP11-196G11.2	-5.16	3.62e-07	5.02e-05	-0.19	-0.23	Dementia with Lewy bodies;	chr16:30984207	chr16:31043150~31049868:+
THCA	cis	rs28374715	0.681	rs59000092	ENSG00000247556.5	OIP5-AS1	5.16	3.62e-07	5.02e-05	0.21	0.23	Ulcerative colitis;	chr15:41333950	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.681	rs11629979	ENSG00000247556.5	OIP5-AS1	5.16	3.62e-07	5.02e-05	0.21	0.23	Ulcerative colitis;	chr15:41334381	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.681	rs8037574	ENSG00000247556.5	OIP5-AS1	5.16	3.62e-07	5.02e-05	0.21	0.23	Ulcerative colitis;	chr15:41338572	chr15:41283990~41309737:+
THCA	cis	rs17767392	0.881	rs8017775	ENSG00000259146.3	RP1-261D10.2	-5.16	3.62e-07	5.02e-05	-0.29	-0.23	Mitral valve prolapse;	chr14:71562719	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.881	rs35625243	ENSG00000259146.3	RP1-261D10.2	5.16	3.62e-07	5.03e-05	0.28	0.23	Mitral valve prolapse;	chr14:71478220	chr14:71292729~71321814:-
THCA	cis	rs228614	0.51	rs223470	ENSG00000248971.2	KRT8P46	-5.16	3.62e-07	5.03e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102728746~102730171:-
THCA	cis	rs10761482	0.906	rs7911934	ENSG00000254271.1	RP11-131N11.4	5.16	3.63e-07	5.03e-05	0.3	0.23	Schizophrenia;	chr10:60332332	chr10:60734342~60741828:+
THCA	cis	rs10200159	1	rs10200159	ENSG00000272606.1	RP11-554J4.1	5.16	3.63e-07	5.04e-05	0.46	0.23	Vitiligo;	chr2:55617974	chr2:55617909~55618373:+
THCA	cis	rs1552244	0.872	rs7646073	ENSG00000180385.7	EMC3-AS1	5.16	3.63e-07	5.04e-05	0.25	0.23	Alzheimer's disease;	chr3:10055721	chr3:9986893~10006990:+
THCA	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	5.16	3.63e-07	5.04e-05	0.13	0.23	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	5.16	3.63e-07	5.04e-05	0.13	0.23	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000223473.2	GS1-124K5.3	-5.16	3.63e-07	5.04e-05	-0.15	-0.23	Aortic root size;	chr7:66032447	chr7:66491049~66493566:-
THCA	cis	rs911555	0.511	rs8007489	ENSG00000269910.1	RP11-73M18.10	-5.16	3.64e-07	5.04e-05	-0.2	-0.23	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103694516~103695050:-
THCA	cis	rs17711722	0.503	rs453835	ENSG00000273024.4	INTS4P2	5.16	3.64e-07	5.04e-05	0.26	0.23	Calcium levels;	chr7:66046172	chr7:65647864~65715661:+
THCA	cis	rs73242632	1	rs10026915	ENSG00000269949.1	RP11-738E22.3	5.16	3.64e-07	5.04e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:56991605	chr4:56960927~56961373:-
THCA	cis	rs1150668	0.796	rs213236	ENSG00000273712.1	RP5-874C20.7	5.16	3.64e-07	5.04e-05	0.25	0.23	Pubertal anthropometrics;	chr6:28356620	chr6:28315613~28315883:-
THCA	cis	rs228614	0.509	rs223480	ENSG00000248971.2	KRT8P46	-5.16	3.64e-07	5.05e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102728746~102730171:-
THCA	cis	rs2235642	0.601	rs2235647	ENSG00000280231.1	LA16c-380F5.3	-5.16	3.64e-07	5.05e-05	-0.29	-0.23	Coronary artery disease;	chr16:1551330	chr16:1553655~1554130:-
THCA	cis	rs12681287	0.547	rs66808088	ENSG00000254231.1	CTD-2284J15.1	5.16	3.64e-07	5.05e-05	0.26	0.23	Caudate activity during reward;	chr8:86508983	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs7465511	ENSG00000254231.1	CTD-2284J15.1	5.16	3.64e-07	5.05e-05	0.26	0.23	Caudate activity during reward;	chr8:86509252	chr8:86333274~86343314:-
THCA	cis	rs453301	0.624	rs7014430	ENSG00000233609.3	RP11-62H7.2	5.16	3.64e-07	5.05e-05	0.23	0.23	Joint mobility (Beighton score);	chr8:8970227	chr8:8961200~8979025:+
THCA	cis	rs12478296	0.901	rs58906257	ENSG00000261186.2	RP11-341N2.1	-5.16	3.64e-07	5.05e-05	-0.36	-0.23	Obesity-related traits;	chr2:242086097	chr2:242087351~242088457:-
THCA	cis	rs7131987	0.903	rs6487796	ENSG00000275476.1	RP11-996F15.4	-5.16	3.64e-07	5.05e-05	-0.22	-0.23	QT interval;	chr12:29269831	chr12:29277397~29277882:-
THCA	cis	rs4845570	1	rs11585294	ENSG00000203288.3	RP11-98D18.9	-5.16	3.64e-07	5.05e-05	-0.28	-0.23	Coronary artery disease;	chr1:151797411	chr1:151790804~151794402:+
THCA	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-5.16	3.65e-07	5.05e-05	-0.3	-0.23	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
THCA	cis	rs10510102	0.935	rs11200260	ENSG00000226864.1	ATE1-AS1	5.16	3.65e-07	5.05e-05	0.38	0.23	Breast cancer;	chr10:121920169	chr10:121928312~121951965:+
THCA	cis	rs858239	0.6	rs13438188	ENSG00000230042.1	AK3P3	5.16	3.65e-07	5.06e-05	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23129178~23129841:+
THCA	cis	rs2288884	0.806	rs78369132	ENSG00000275055.1	CTC-471J1.11	-5.16	3.65e-07	5.06e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52090465	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.806	rs10164297	ENSG00000275055.1	CTC-471J1.11	-5.16	3.65e-07	5.06e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52090996	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.69	rs10164294	ENSG00000275055.1	CTC-471J1.11	-5.16	3.65e-07	5.06e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52091128	chr19:52049007~52049754:+
THCA	cis	rs228614	0.536	rs150897	ENSG00000248971.2	KRT8P46	-5.16	3.65e-07	5.06e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223472	ENSG00000248971.2	KRT8P46	-5.16	3.65e-07	5.06e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102728746~102730171:-
THCA	cis	rs919433	0.68	rs3792159	ENSG00000231621.1	AC013264.2	5.16	3.65e-07	5.06e-05	0.25	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197538973	chr2:197197991~197199273:+
THCA	cis	rs4934494	0.677	rs11185773	ENSG00000232936.4	RP11-80H5.2	5.16	3.65e-07	5.06e-05	0.32	0.23	Red blood cell count;	chr10:89589574	chr10:89645282~89650667:+
THCA	cis	rs9625935	0.957	rs28257	ENSG00000279159.1	RP3-394A18.1	-5.16	3.65e-07	5.06e-05	-0.18	-0.23	Tonsillectomy;	chr22:30033126	chr22:29978950~30028236:-
THCA	cis	rs9843304	0.507	rs56242998	ENSG00000240541.2	TM4SF1-AS1	-5.16	3.65e-07	5.06e-05	-0.22	-0.23	Gallstone disease;	chr3:149496693	chr3:149377778~149386583:+
THCA	cis	rs1979679	0.515	rs17603585	ENSG00000278733.1	RP11-425D17.1	5.16	3.65e-07	5.06e-05	0.22	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28110120	chr12:28185625~28186190:-
THCA	cis	rs757978	0.929	rs111943976	ENSG00000223374.1	AC005104.3	5.16	3.65e-07	5.06e-05	0.25	0.23	Chronic lymphocytic leukemia;	chr2:241439490	chr2:241351340~241353104:-
THCA	cis	rs4660456	0.912	rs658806	ENSG00000272145.1	NFYC-AS1	-5.16	3.65e-07	5.06e-05	-0.16	-0.23	Platelet count;	chr1:40683312	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs489222	ENSG00000272145.1	NFYC-AS1	-5.16	3.65e-07	5.06e-05	-0.16	-0.23	Platelet count;	chr1:40683422	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.871	rs671704	ENSG00000272145.1	NFYC-AS1	-5.16	3.65e-07	5.06e-05	-0.16	-0.23	Platelet count;	chr1:40683974	chr1:40690380~40692066:-
THCA	cis	rs1914816	1	rs1914816	ENSG00000196274.5	Metazoa_SRP	5.16	3.66e-07	5.07e-05	0.33	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76254592	chr15:76230048~76230390:-
THCA	cis	rs7646881	0.544	rs10513527	ENSG00000240207.5	RP11-379F4.4	-5.16	3.66e-07	5.07e-05	-0.33	-0.23	Tetralogy of Fallot;	chr3:158583893	chr3:158732263~158784070:+
THCA	cis	rs11992162	0.967	rs10112888	ENSG00000227888.4	FAM66A	5.16	3.66e-07	5.07e-05	0.29	0.23	Monocyte count;	chr8:11972699	chr8:12362019~12388296:+
THCA	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	5.16	3.66e-07	5.07e-05	0.17	0.23	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
THCA	cis	rs5758511	0.68	rs1107554	ENSG00000237037.8	NDUFA6-AS1	-5.16	3.66e-07	5.07e-05	-0.21	-0.23	Birth weight;	chr22:42271588	chr22:42090931~42137742:+
THCA	cis	rs11992162	0.967	rs10088415	ENSG00000227888.4	FAM66A	-5.16	3.66e-07	5.07e-05	-0.29	-0.23	Monocyte count;	chr8:11973316	chr8:12362019~12388296:+
THCA	cis	rs875971	0.545	rs35459055	ENSG00000228409.4	CCT6P1	-5.16	3.66e-07	5.07e-05	-0.2	-0.23	Aortic root size;	chr7:66479399	chr7:65751142~65763354:+
THCA	cis	rs8033133	0.706	rs12594112	ENSG00000251896.1	SNORD116-27	-5.16	3.66e-07	5.07e-05	-0.25	-0.23	Blood osmolality (transformed sodium);	chr15:25104980	chr15:25101575~25101666:+
THCA	cis	rs66887589	0.616	rs11098498	ENSG00000249244.1	RP11-548H18.2	5.16	3.66e-07	5.07e-05	0.24	0.23	Diastolic blood pressure;	chr4:119265964	chr4:119391831~119395335:-
THCA	cis	rs642858	0.737	rs9376517	ENSG00000234147.1	RP3-460G2.2	-5.16	3.66e-07	5.07e-05	-0.29	-0.23	Type 2 diabetes;	chr6:140355624	chr6:140845958~140852924:-
THCA	cis	rs7829975	0.577	rs17684466	ENSG00000253893.2	FAM85B	5.16	3.66e-07	5.07e-05	0.32	0.23	Mood instability;	chr8:8687723	chr8:8167819~8226614:-
THCA	cis	rs9388451	0.513	rs1268069	ENSG00000226409.1	RP11-735G4.1	-5.16	3.67e-07	5.08e-05	-0.29	-0.23	Brugada syndrome;	chr6:125718848	chr6:125370211~125374324:-
THCA	cis	rs8027521	0.557	rs17633154	ENSG00000280362.1	RP11-643A5.3	5.16	3.67e-07	5.08e-05	0.29	0.23	Circulating chemerin levels;	chr15:53956457	chr15:53910769~53914712:+
THCA	cis	rs7577696	0.925	rs212715	ENSG00000276334.1	AL133243.1	5.16	3.67e-07	5.08e-05	0.25	0.23	Inflammatory biomarkers;	chr2:32235817	chr2:32521927~32523547:+
THCA	cis	rs2337406	1	rs11849532	ENSG00000274576.2	IGHV2-70	-5.16	3.67e-07	5.08e-05	-0.21	-0.23	Alzheimer's disease (late onset);	chr14:106669877	chr14:106770577~106771020:-
THCA	cis	rs2562456	0.834	rs2650848	ENSG00000268119.4	CTD-2561J22.5	5.16	3.67e-07	5.08e-05	0.33	0.23	Pain;	chr19:21403835	chr19:21444241~21463908:-
THCA	cis	rs7267979	0.844	rs2257649	ENSG00000125804.12	FAM182A	-5.16	3.67e-07	5.08e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26054655~26086917:+
THCA	cis	rs3796352	1	rs13072395	ENSG00000242142.1	SERBP1P3	-5.16	3.67e-07	5.08e-05	-0.45	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52946557	chr3:53064283~53065091:-
THCA	cis	rs3796352	0.764	rs34872575	ENSG00000242142.1	SERBP1P3	-5.16	3.67e-07	5.08e-05	-0.45	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52952261	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs11713206	ENSG00000242142.1	SERBP1P3	-5.16	3.67e-07	5.08e-05	-0.45	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52965227	chr3:53064283~53065091:-
THCA	cis	rs17767392	0.871	rs35468256	ENSG00000259146.3	RP1-261D10.2	5.16	3.67e-07	5.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71372807	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs35854505	ENSG00000259146.3	RP1-261D10.2	5.16	3.67e-07	5.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71374760	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.718	rs35609708	ENSG00000259146.3	RP1-261D10.2	5.16	3.67e-07	5.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71377127	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs7145755	ENSG00000259146.3	RP1-261D10.2	5.16	3.67e-07	5.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71381393	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs17767499	ENSG00000259146.3	RP1-261D10.2	5.16	3.67e-07	5.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71400558	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs36093218	ENSG00000259146.3	RP1-261D10.2	5.16	3.67e-07	5.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71405356	chr14:71292729~71321814:-
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000273712.1	RP5-874C20.7	5.16	3.67e-07	5.09e-05	0.25	0.23	Pubertal anthropometrics;	chr6:28128502	chr6:28315613~28315883:-
THCA	cis	rs205611	0.511	rs11680358	ENSG00000224646.2	AC007387.2	-5.16	3.67e-07	5.09e-05	-0.37	-0.23	Iris characteristics;	chr2:74772856	chr2:74754670~74754819:-
THCA	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	5.16	3.67e-07	5.09e-05	0.3	0.23	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
THCA	cis	rs858239	0.601	rs73272053	ENSG00000226816.2	AC005082.12	5.16	3.67e-07	5.09e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23206013~23208045:+
THCA	cis	rs17508449	0.732	rs74533448	ENSG00000232450.1	RP4-730K3.3	-5.16	3.67e-07	5.09e-05	-0.37	-0.23	Leprosy;	chr1:113750266	chr1:113698884~113699631:-
THCA	cis	rs6840360	0.901	rs6826799	ENSG00000251611.1	RP11-610P16.1	-5.16	3.68e-07	5.09e-05	-0.17	-0.23	Intelligence (multi-trait analysis);	chr4:151534548	chr4:151407551~151408835:-
THCA	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	5.16	3.68e-07	5.09e-05	0.27	0.23	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
THCA	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	5.16	3.68e-07	5.09e-05	0.27	0.23	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
THCA	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	5.16	3.68e-07	5.09e-05	0.27	0.23	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
THCA	cis	rs12534093	0.67	rs11773115	ENSG00000234286.1	AC006026.13	-5.16	3.68e-07	5.09e-05	-0.35	-0.23	Infant length;Height;	chr7:23549423	chr7:23680195~23680786:-
THCA	cis	rs3113494	0.569	rs2705619	ENSG00000251411.1	RP11-397E7.4	-5.16	3.68e-07	5.1e-05	-0.23	-0.23	Amyotrophic lateral sclerosis;	chr4:86915499	chr4:86913266~86914817:-
THCA	cis	rs3796352	1	rs35163227	ENSG00000242142.1	SERBP1P3	-5.16	3.68e-07	5.1e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53093860	chr3:53064283~53065091:-
THCA	cis	rs7560272	0.588	rs4852959	ENSG00000163016.8	ALMS1P	-5.16	3.68e-07	5.1e-05	-0.3	-0.23	Schizophrenia;	chr2:73653474	chr2:73644919~73685576:+
THCA	cis	rs7429990	0.965	rs319682	ENSG00000228638.1	FCF1P2	-5.16	3.68e-07	5.1e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47873628	chr3:48290793~48291375:-
THCA	cis	rs7824557	0.67	rs2736381	ENSG00000154316.13	TDH	5.16	3.68e-07	5.1e-05	0.17	0.23	Retinal vascular caliber;	chr8:11275257	chr8:11339637~11368452:+
THCA	cis	rs467650	0.817	rs61637015	ENSG00000248489.1	CTD-2007H13.3	5.16	3.68e-07	5.1e-05	0.23	0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:98716535	chr5:98929171~98995013:+
THCA	cis	rs9634489	0.511	rs9300343	ENSG00000247400.3	DNAJC3-AS1	5.16	3.68e-07	5.1e-05	0.15	0.23	Body mass index;	chr13:96373106	chr13:95648733~95676925:-
THCA	cis	rs4650994	0.789	rs2476559	ENSG00000273384.1	RP5-1098D14.1	-5.16	3.68e-07	5.1e-05	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178623784	chr1:178651706~178652282:+
THCA	cis	rs6893782	0.83	rs274549	ENSG00000233006.5	AC034220.3	5.16	3.69e-07	5.1e-05	0.23	0.23	Acylcarnitine levels;	chr5:132393426	chr5:132311285~132369916:-
THCA	cis	rs8014252	0.505	rs4377098	ENSG00000259158.2	ADAM20P1	-5.16	3.69e-07	5.11e-05	-0.23	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70496048	chr14:70468881~70483756:-
THCA	cis	rs1044573	0.526	rs6050422	ENSG00000274414.1	RP5-965G21.4	-5.16	3.69e-07	5.11e-05	-0.27	-0.23	Allergic rhinitis;	chr20:25197284	chr20:25239007~25245229:-
THCA	cis	rs889122	0.659	rs62106799	ENSG00000267289.1	CTD-2623N2.11	5.16	3.69e-07	5.11e-05	0.31	0.23	Menarche (age at onset);	chr19:9874359	chr19:9834079~9835013:-
THCA	cis	rs2749592	0.531	rs994804	ENSG00000263064.2	RP11-291L22.7	-5.16	3.69e-07	5.11e-05	-0.26	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38448689~38448949:+
THCA	cis	rs9543976	1	rs9573592	ENSG00000261105.4	LMO7-AS1	-5.16	3.69e-07	5.11e-05	-0.35	-0.23	Diabetic retinopathy;	chr13:75623707	chr13:75604700~75635994:-
THCA	cis	rs4218	0.859	rs1486878	ENSG00000277144.1	RP11-59H7.4	-5.16	3.69e-07	5.11e-05	-0.31	-0.23	Social communication problems;	chr15:59123268	chr15:59115547~59116089:-
THCA	cis	rs7181230	0.885	rs28826672	ENSG00000275636.1	RP11-521C20.5	5.16	3.69e-07	5.11e-05	0.26	0.23	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40078892~40079347:+
THCA	cis	rs453301	0.522	rs1964356	ENSG00000254153.1	CTA-398F10.2	-5.16	3.69e-07	5.11e-05	-0.25	-0.23	Joint mobility (Beighton score);	chr8:8995760	chr8:8456909~8461337:-
THCA	cis	rs5751614	0.967	rs5759663	ENSG00000230701.2	FBXW4P1	5.16	3.69e-07	5.11e-05	0.22	0.23	Height;	chr22:23247571	chr22:23262767~23265005:+
THCA	cis	rs1552244	1	rs7628448	ENSG00000180385.7	EMC3-AS1	5.16	3.7e-07	5.12e-05	0.26	0.23	Alzheimer's disease;	chr3:10105144	chr3:9986893~10006990:+
THCA	cis	rs73198271	0.74	rs67766414	ENSG00000253893.2	FAM85B	5.16	3.7e-07	5.12e-05	0.34	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8167819~8226614:-
THCA	cis	rs10090774	0.965	rs11775840	ENSG00000279766.1	RP11-642A1.2	-5.16	3.7e-07	5.12e-05	-0.29	-0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140873134	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs4074812	ENSG00000279766.1	RP11-642A1.2	-5.16	3.7e-07	5.12e-05	-0.29	-0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140873430	chr8:140572142~140572812:-
THCA	cis	rs8077577	0.747	rs11869582	ENSG00000273018.4	CTD-2303H24.2	-5.16	3.7e-07	5.12e-05	-0.4	-0.23	Obesity-related traits;	chr17:18233267	chr17:18511221~18551705:-
THCA	cis	rs7688540	0.771	rs7665727	ENSG00000211553.1	AC253576.2	-5.16	3.7e-07	5.12e-05	-0.35	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:136461~136568:+
THCA	cis	rs6430585	0.697	rs6724569	ENSG00000231890.6	DARS-AS1	-5.16	3.7e-07	5.12e-05	-0.29	-0.23	Corneal structure;	chr2:135759400	chr2:135985176~136022593:+
THCA	cis	rs35160687	0.623	rs11127019	ENSG00000273080.1	RP11-301O19.1	-5.16	3.7e-07	5.12e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86240495	chr2:86195590~86196049:+
THCA	cis	rs944289	0.708	rs8016762	ENSG00000258844.1	RP11-259K15.2	5.16	3.7e-07	5.12e-05	0.2	0.23	Thyroid cancer;	chr14:36108538	chr14:36214607~36235608:+
THCA	cis	rs2243480	0.522	rs778717	ENSG00000229886.1	RP5-1132H15.3	5.16	3.7e-07	5.12e-05	0.48	0.23	Diabetic kidney disease;	chr7:66383164	chr7:66025126~66031544:-
THCA	cis	rs10256972	0.521	rs871019	ENSG00000199023.2	MIR339	-5.16	3.7e-07	5.13e-05	-0.24	-0.23	Endometriosis;Longevity;	chr7:1065594	chr7:1022935~1023045:-
THCA	cis	rs1823913	0.927	rs35092718	ENSG00000227542.1	AC092614.2	5.16	3.7e-07	5.13e-05	0.28	0.23	Obesity-related traits;	chr2:191243882	chr2:191229165~191246172:-
THCA	cis	rs12612619	0.732	rs11897106	ENSG00000229122.1	AGBL5-IT1	-5.16	3.7e-07	5.13e-05	-0.16	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26973431	chr2:27061038~27061815:+
THCA	cis	rs6688613	0.694	rs11576455	ENSG00000225171.2	DUTP6	-5.16	3.71e-07	5.13e-05	-0.32	-0.23	Refractive astigmatism;	chr1:166842733	chr1:166868748~166869209:+
THCA	cis	rs919433	0.963	rs1366837	ENSG00000231621.1	AC013264.2	5.16	3.71e-07	5.13e-05	0.23	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197295777	chr2:197197991~197199273:+
THCA	cis	rs3820928	0.967	rs12622456	ENSG00000212391.1	SNORA48	-5.16	3.71e-07	5.13e-05	-0.26	-0.23	Pulmonary function;	chr2:226904152	chr2:226968989~226969122:-
THCA	cis	rs708547	0.575	rs6847086	ENSG00000269949.1	RP11-738E22.3	-5.16	3.71e-07	5.13e-05	-0.28	-0.23	Response to bleomycin (chromatid breaks);	chr4:56925698	chr4:56960927~56961373:-
THCA	cis	rs12900463	0.813	rs306198	ENSG00000225151.9	GOLGA2P7	5.16	3.71e-07	5.13e-05	0.33	0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862138	chr15:84199311~84230136:-
THCA	cis	rs4713118	0.662	rs469228	ENSG00000261839.1	RP1-265C24.8	5.16	3.71e-07	5.14e-05	0.26	0.23	Parkinson's disease;	chr6:28002926	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.54	rs469227	ENSG00000261839.1	RP1-265C24.8	5.16	3.71e-07	5.14e-05	0.26	0.23	Parkinson's disease;	chr6:28002927	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs149948	ENSG00000261839.1	RP1-265C24.8	5.16	3.71e-07	5.14e-05	0.26	0.23	Parkinson's disease;	chr6:28007039	chr6:28136849~28139678:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000232559.3	GS1-124K5.12	5.16	3.71e-07	5.14e-05	0.32	0.23	Diabetic kidney disease;	chr7:66631132	chr7:66554588~66576923:-
THCA	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	5.16	3.71e-07	5.14e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	5.16	3.71e-07	5.14e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	5.16	3.71e-07	5.14e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	5.16	3.71e-07	5.14e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	5.16	3.71e-07	5.14e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	5.16	3.71e-07	5.14e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
THCA	cis	rs916888	0.61	rs199530	ENSG00000261575.2	RP11-259G18.1	-5.16	3.72e-07	5.14e-05	-0.28	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46267037~46268694:+
THCA	cis	rs1552244	0.608	rs7615408	ENSG00000180385.7	EMC3-AS1	5.16	3.72e-07	5.14e-05	0.23	0.23	Alzheimer's disease;	chr3:9958502	chr3:9986893~10006990:+
THCA	cis	rs7688540	0.8	rs12506277	ENSG00000250892.1	RP11-1365D11.1	5.16	3.72e-07	5.14e-05	0.32	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:201409~205009:-
THCA	cis	rs7688540	0.8	rs12501727	ENSG00000250892.1	RP11-1365D11.1	5.16	3.72e-07	5.14e-05	0.32	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:201409~205009:-
THCA	cis	rs17270561	0.943	rs4478398	ENSG00000272462.2	U91328.19	-5.16	3.72e-07	5.15e-05	-0.23	-0.23	Iron status biomarkers;	chr6:25694456	chr6:25992662~26001775:+
THCA	cis	rs1005277	0.603	rs1998062	ENSG00000272983.1	RP11-508N22.12	5.16	3.72e-07	5.15e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38137337~38144399:+
THCA	cis	rs2288884	0.541	rs72483948	ENSG00000269483.1	AC006272.1	5.16	3.72e-07	5.15e-05	0.34	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51971668	chr19:51839924~51843324:-
THCA	cis	rs7045881	0.733	rs76317869	ENSG00000254396.1	RP11-56F10.3	5.16	3.72e-07	5.15e-05	0.42	0.23	Schizophrenia;	chr9:26955838	chr9:27102630~27104728:+
THCA	cis	rs202072	0.872	rs202046	ENSG00000272379.1	RP1-257A7.5	5.16	3.73e-07	5.15e-05	0.34	0.23	HIV-1 viral setpoint;	chr6:13275338	chr6:13290018~13290490:-
THCA	cis	rs631288	0.793	rs1822312	ENSG00000226015.2	CCT8P1	-5.16	3.73e-07	5.16e-05	-0.5	-0.23	PR interval in Tripanosoma cruzi seropositivity;	chr1:147215680	chr1:147203276~147204932:-
THCA	cis	rs10510102	0.872	rs78369301	ENSG00000226864.1	ATE1-AS1	5.16	3.73e-07	5.16e-05	0.38	0.23	Breast cancer;	chr10:121858527	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs10466217	ENSG00000226864.1	ATE1-AS1	5.16	3.73e-07	5.16e-05	0.38	0.23	Breast cancer;	chr10:121860362	chr10:121928312~121951965:+
THCA	cis	rs10090774	0.76	rs13276886	ENSG00000279766.1	RP11-642A1.2	-5.16	3.73e-07	5.16e-05	-0.29	-0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140720791	chr8:140572142~140572812:-
THCA	cis	rs34779708	0.931	rs11592404	ENSG00000271335.4	RP11-324I22.4	5.16	3.73e-07	5.16e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35314552~35336401:-
THCA	cis	rs10149470	0.549	rs9652403	ENSG00000269958.1	RP11-73M18.8	5.16	3.73e-07	5.16e-05	0.22	0.23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr14:103569687	chr14:103696353~103697163:+
THCA	cis	rs7554547	0.69	rs7524721	ENSG00000199347.1	RNU5E-1	-5.16	3.73e-07	5.16e-05	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr1:11890119	chr1:11908152~11908271:+
THCA	cis	rs7429990	0.965	rs7619882	ENSG00000228638.1	FCF1P2	-5.16	3.73e-07	5.16e-05	-0.23	-0.23	Educational attainment (years of education);	chr3:47943334	chr3:48290793~48291375:-
THCA	cis	rs7119	0.717	rs12916642	ENSG00000259362.2	RP11-307C19.1	-5.16	3.74e-07	5.17e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77526084	chr15:77525540~77534110:+
THCA	cis	rs9859260	0.925	rs13072608	ENSG00000231464.1	AC024937.4	5.16	3.74e-07	5.17e-05	0.28	0.23	Mean corpuscular volume;	chr3:196073396	chr3:195996738~195998233:+
THCA	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-5.16	3.74e-07	5.17e-05	-0.32	-0.23	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
THCA	cis	rs1979679	0.553	rs75547058	ENSG00000278733.1	RP11-425D17.1	5.16	3.74e-07	5.17e-05	0.22	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28109716	chr12:28185625~28186190:-
THCA	cis	rs1979679	0.553	rs17575785	ENSG00000278733.1	RP11-425D17.1	5.16	3.74e-07	5.17e-05	0.22	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28109789	chr12:28185625~28186190:-
THCA	cis	rs1979679	0.553	rs59084530	ENSG00000278733.1	RP11-425D17.1	5.16	3.74e-07	5.17e-05	0.22	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28112117	chr12:28185625~28186190:-
THCA	cis	rs763121	0.819	rs5757169	ENSG00000273076.1	RP3-508I15.22	5.16	3.74e-07	5.17e-05	0.23	0.23	Menopause (age at onset);	chr22:38607490	chr22:38743495~38743910:+
THCA	cis	rs12462428	1	rs12462428	ENSG00000279748.1	CTD-3222D19.9	-5.15	3.74e-07	5.18e-05	-0.27	-0.23	Educational attainment (years of education);	chr19:16583799	chr19:16586905~16589409:+
THCA	cis	rs12534093	0.595	rs11767313	ENSG00000234286.1	AC006026.13	-5.15	3.74e-07	5.18e-05	-0.41	-0.23	Infant length;Height;	chr7:23544903	chr7:23680195~23680786:-
THCA	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-5.15	3.75e-07	5.18e-05	-0.4	-0.23	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
THCA	cis	rs7577696	0.814	rs479333	ENSG00000276334.1	AL133243.1	-5.15	3.75e-07	5.18e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32264089	chr2:32521927~32523547:+
THCA	cis	rs17508449	0.819	rs17359468	ENSG00000232450.1	RP4-730K3.3	-5.15	3.75e-07	5.18e-05	-0.38	-0.23	Leprosy;	chr1:113700084	chr1:113698884~113699631:-
THCA	cis	rs5015933	0.815	rs359597	ENSG00000232630.1	PRPS1P2	-5.15	3.75e-07	5.19e-05	-0.15	-0.23	Body mass index;	chr9:125274312	chr9:125150653~125151589:+
THCA	cis	rs2288884	0.767	rs28379522	ENSG00000260160.1	CTC-471J1.2	-5.15	3.75e-07	5.19e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:52058490~52063703:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000204623.7	ZNRD1-AS1	-5.15	3.75e-07	5.19e-05	-0.16	-0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30001011~30061640:-
THCA	cis	rs6921919	0.525	rs16894095	ENSG00000219392.1	RP1-265C24.5	-5.15	3.75e-07	5.19e-05	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28115628~28116551:+
THCA	cis	rs7428	0.502	rs3184781	ENSG00000273196.1	RP11-717A5.2	5.15	3.75e-07	5.19e-05	0.24	0.23	Ear protrusion;	chr2:85322404	chr2:85387074~85387146:-
THCA	cis	rs7428	0.527	rs3184780	ENSG00000273196.1	RP11-717A5.2	5.15	3.75e-07	5.19e-05	0.24	0.23	Ear protrusion;	chr2:85322424	chr2:85387074~85387146:-
THCA	cis	rs7428	0.545	rs2366404	ENSG00000273196.1	RP11-717A5.2	5.15	3.75e-07	5.19e-05	0.24	0.23	Ear protrusion;	chr2:85324656	chr2:85387074~85387146:-
THCA	cis	rs1580019	0.587	rs7804457	ENSG00000231952.3	DPY19L1P2	-5.15	3.75e-07	5.19e-05	-0.29	-0.23	Cognitive ability;	chr7:32518369	chr7:32812757~32838570:+
THCA	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-5.15	3.76e-07	5.19e-05	-0.3	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
THCA	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	5.15	3.76e-07	5.19e-05	0.13	0.23	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
THCA	cis	rs6088590	1	rs11696546	ENSG00000269202.1	RP4-614O4.12	-5.15	3.76e-07	5.19e-05	-0.21	-0.23	Coronary artery disease;	chr20:34865196	chr20:35201747~35203288:-
THCA	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-5.15	3.76e-07	5.19e-05	-0.3	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
THCA	cis	rs34779708	0.733	rs11597184	ENSG00000271335.4	RP11-324I22.4	5.15	3.76e-07	5.19e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35314552~35336401:-
THCA	cis	rs6977955	0.627	rs1513275	ENSG00000234336.5	JAZF1-AS1	5.15	3.76e-07	5.19e-05	0.27	0.23	Allergic disease (asthma, hay fever or eczema);	chr7:28219614	chr7:28180322~28243917:+
THCA	cis	rs9500256	0.602	rs62414342	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-5.15	3.76e-07	5.19e-05	-0.27	-0.23	Eosinophilic esophagitis (pediatric);	chr6:57917905	chr6:57855891~57856468:-
THCA	cis	rs9959145	1	rs28575715	ENSG00000267108.1	RP11-861E21.1	5.15	3.76e-07	5.2e-05	0.28	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12586349	chr18:12432897~12437635:+
THCA	cis	rs11096990	0.929	rs55976583	ENSG00000249685.1	RP11-360F5.3	-5.15	3.76e-07	5.2e-05	-0.3	-0.23	Cognitive function;	chr4:39222871	chr4:39133913~39135608:+
THCA	cis	rs7976269	0.609	rs7979788	ENSG00000275476.1	RP11-996F15.4	-5.15	3.76e-07	5.2e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29064827	chr12:29277397~29277882:-
THCA	cis	rs7924176	0.564	rs12359146	ENSG00000213731.2	RAB5CP1	-5.15	3.76e-07	5.2e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74205914	chr10:74423435~74424014:-
THCA	cis	rs7637701	0.901	rs4680312	ENSG00000240875.4	LINC00886	-5.15	3.76e-07	5.2e-05	-0.18	-0.23	Breast cancer;	chr3:156888140	chr3:156747346~156817062:-
THCA	cis	rs7637701	0.967	rs11712111	ENSG00000240875.4	LINC00886	-5.15	3.76e-07	5.2e-05	-0.18	-0.23	Breast cancer;	chr3:156891151	chr3:156747346~156817062:-
THCA	cis	rs9467773	1	rs1321479	ENSG00000261353.1	CTA-14H9.5	5.15	3.76e-07	5.2e-05	0.24	0.23	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26527063~26527404:+
THCA	cis	rs34779708	0.931	rs2384275	ENSG00000271335.4	RP11-324I22.4	5.15	3.76e-07	5.2e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35314552~35336401:-
THCA	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	5.15	3.77e-07	5.2e-05	0.31	0.23	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
THCA	cis	rs2282300	0.739	rs1933342	ENSG00000242353.1	RP4-710M3.1	5.15	3.77e-07	5.2e-05	0.22	0.23	Morning vs. evening chronotype;	chr11:30291278	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs2225909	ENSG00000242353.1	RP4-710M3.1	5.15	3.77e-07	5.2e-05	0.22	0.23	Morning vs. evening chronotype;	chr11:30308197	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.702	rs2211018	ENSG00000242353.1	RP4-710M3.1	5.15	3.77e-07	5.2e-05	0.22	0.23	Morning vs. evening chronotype;	chr11:30308532	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs7926465	ENSG00000242353.1	RP4-710M3.1	5.15	3.77e-07	5.2e-05	0.22	0.23	Morning vs. evening chronotype;	chr11:30311469	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs10835647	ENSG00000242353.1	RP4-710M3.1	-5.15	3.77e-07	5.2e-05	-0.22	-0.23	Morning vs. evening chronotype;	chr11:30291721	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs1616223	ENSG00000242353.1	RP4-710M3.1	-5.15	3.77e-07	5.2e-05	-0.22	-0.23	Morning vs. evening chronotype;	chr11:30317236	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs1717772	ENSG00000242353.1	RP4-710M3.1	-5.15	3.77e-07	5.2e-05	-0.22	-0.23	Morning vs. evening chronotype;	chr11:30318586	chr11:30368148~30368646:+
THCA	cis	rs987724	0.515	rs11914959	ENSG00000240875.4	LINC00886	-5.15	3.77e-07	5.2e-05	-0.23	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898616	chr3:156747346~156817062:-
THCA	cis	rs987724	0.501	rs4680313	ENSG00000240875.4	LINC00886	-5.15	3.77e-07	5.2e-05	-0.23	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901348	chr3:156747346~156817062:-
THCA	cis	rs8091660	0.624	rs9948328	ENSG00000278983.1	RP11-426J5.3	5.15	3.77e-07	5.2e-05	0.33	0.23	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569613	chr18:48564795~48568342:+
THCA	cis	rs2886497	0.947	rs72788434	ENSG00000224215.1	RP11-371A19.2	-5.15	3.77e-07	5.2e-05	-0.3	-0.23	Major depression and alcohol dependence;	chr10:23373840	chr10:23343957~23345181:+
THCA	cis	rs11096990	0.855	rs11730771	ENSG00000249685.1	RP11-360F5.3	-5.15	3.77e-07	5.21e-05	-0.3	-0.23	Cognitive function;	chr4:39220787	chr4:39133913~39135608:+
THCA	cis	rs438465	0.617	rs3006177	ENSG00000226194.4	RP1-137D17.1	5.15	3.77e-07	5.21e-05	0.31	0.23	Corneal astigmatism;	chr6:169424656	chr6:169369998~169388385:-
THCA	cis	rs17301013	0.932	rs12077622	ENSG00000227373.4	RP11-160H22.5	5.15	3.77e-07	5.21e-05	0.33	0.23	Systemic lupus erythematosus;	chr1:174442507	chr1:174115300~174160004:-
THCA	cis	rs7772486	0.743	rs111332144	ENSG00000270638.1	RP3-466P17.1	-5.15	3.77e-07	5.21e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145735570~145737218:+
THCA	cis	rs757978	0.733	rs11684403	ENSG00000223374.1	AC005104.3	5.15	3.77e-07	5.21e-05	0.23	0.23	Chronic lymphocytic leukemia;	chr2:241475459	chr2:241351340~241353104:-
THCA	cis	rs6540731	0.754	rs2358452	ENSG00000226251.4	RP11-15I11.3	-5.15	3.77e-07	5.21e-05	-0.28	-0.23	Intelligence (childhood);	chr1:212185707	chr1:212225278~212238977:-
THCA	cis	rs1113500	0.58	rs1781058	ENSG00000226822.1	RP11-356N1.2	5.15	3.77e-07	5.21e-05	0.25	0.23	Growth-regulated protein alpha levels;	chr1:108021437	chr1:108071482~108074519:+
THCA	cis	rs8049040	0.547	rs12934168	ENSG00000260886.1	TAT-AS1	5.15	3.77e-07	5.21e-05	0.33	0.23	Blood protein levels;	chr16:71402875	chr16:71565789~71578187:+
THCA	cis	rs875971	0.545	rs75840613	ENSG00000232546.1	RP11-458F8.1	5.15	3.77e-07	5.21e-05	0.22	0.23	Aortic root size;	chr7:66376399	chr7:66848496~66858136:+
THCA	cis	rs4660456	0.913	rs657149	ENSG00000272145.1	NFYC-AS1	-5.15	3.78e-07	5.22e-05	-0.16	-0.23	Platelet count;	chr1:40692486	chr1:40690380~40692066:-
THCA	cis	rs11671005	0.779	rs11670125	ENSG00000269473.1	CTD-2619J13.19	5.15	3.78e-07	5.22e-05	0.27	0.23	Mean platelet volume;	chr19:58476023	chr19:58440448~58445849:+
THCA	cis	rs10129255	0.957	rs67625077	ENSG00000223648.3	IGHV3-64	5.15	3.78e-07	5.22e-05	0.14	0.23	Kawasaki disease;	chr14:106715436	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.869	rs72690553	ENSG00000223648.3	IGHV3-64	5.15	3.78e-07	5.22e-05	0.14	0.23	Kawasaki disease;	chr14:106715491	chr14:106643132~106658258:-
THCA	cis	rs8002861	0.935	rs7318147	ENSG00000274001.1	RP11-5G9.5	-5.15	3.78e-07	5.22e-05	-0.28	-0.23	Leprosy;	chr13:43871017	chr13:43877715~43878163:-
THCA	cis	rs6708331	0.517	rs9989836	ENSG00000179818.12	PCBP1-AS1	-5.15	3.78e-07	5.22e-05	-0.19	-0.23	Obesity-related traits;	chr2:70115595	chr2:69962263~70103220:-
THCA	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	5.15	3.78e-07	5.22e-05	0.27	0.23	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
THCA	cis	rs2255336	0.808	rs59611026	ENSG00000245648.1	RP11-277P12.20	-5.15	3.78e-07	5.22e-05	-0.26	-0.23	Blood protein levels;	chr12:10445387	chr12:10363769~10398506:+
THCA	cis	rs2708377	0.789	rs3911150	ENSG00000212125.2	TAS2R15P	-5.15	3.78e-07	5.22e-05	-0.35	-0.23	Bitter taste perception;	chr12:11049649	chr12:10964425~10965352:-
THCA	cis	rs3796352	1	rs13069006	ENSG00000242142.1	SERBP1P3	-5.15	3.78e-07	5.23e-05	-0.45	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52939289	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs11710707	ENSG00000242142.1	SERBP1P3	-5.15	3.78e-07	5.23e-05	-0.45	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52941900	chr3:53064283~53065091:-
THCA	cis	rs2303319	0.504	rs12470743	ENSG00000227403.1	AC009299.3	5.15	3.78e-07	5.23e-05	0.48	0.23	Cognitive function;	chr2:161754692	chr2:161244739~161249050:+
THCA	cis	rs8027521	0.557	rs12594813	ENSG00000280362.1	RP11-643A5.3	5.15	3.78e-07	5.23e-05	0.29	0.23	Circulating chemerin levels;	chr15:53958164	chr15:53910769~53914712:+
THCA	cis	rs6728642	0.803	rs11891457	ENSG00000230606.9	AC159540.1	5.15	3.79e-07	5.23e-05	0.29	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96966712	chr2:97416165~97433527:-
THCA	cis	rs6728642	0.803	rs11891458	ENSG00000230606.9	AC159540.1	5.15	3.79e-07	5.23e-05	0.29	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96966713	chr2:97416165~97433527:-
THCA	cis	rs35847492	1	rs35847492	ENSG00000254153.1	CTA-398F10.2	-5.15	3.79e-07	5.23e-05	-0.28	-0.23	Neuroticism;	chr8:9418515	chr8:8456909~8461337:-
THCA	cis	rs5758659	1	rs134900	ENSG00000281538.1	RP4-669P10.20	5.15	3.79e-07	5.23e-05	0.21	0.23	Cognitive function;	chr22:42287337	chr22:42138060~42139726:+
THCA	cis	rs2243480	1	rs12698509	ENSG00000164669.11	INTS4P1	5.15	3.79e-07	5.23e-05	0.44	0.23	Diabetic kidney disease;	chr7:65953889	chr7:65141225~65234216:+
THCA	cis	rs17301013	0.932	rs1653626	ENSG00000227373.4	RP11-160H22.5	-5.15	3.79e-07	5.23e-05	-0.32	-0.23	Systemic lupus erythematosus;	chr1:174770348	chr1:174115300~174160004:-
THCA	cis	rs853679	0.546	rs200995	ENSG00000226314.6	ZNF192P1	5.15	3.79e-07	5.23e-05	0.39	0.23	Depression;	chr6:27845916	chr6:28161781~28169594:+
THCA	cis	rs6997458	0.742	rs9969643	ENSG00000253549.4	RP11-317J10.2	5.15	3.79e-07	5.23e-05	0.23	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85453758	chr8:85441851~85464915:-
THCA	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-5.15	3.79e-07	5.23e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
THCA	cis	rs34779708	0.931	rs12268745	ENSG00000271335.4	RP11-324I22.4	5.15	3.79e-07	5.23e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35314552~35336401:-
THCA	cis	rs3892630	0.878	rs114224536	ENSG00000267567.1	CTD-2538C1.3	5.15	3.79e-07	5.24e-05	0.36	0.23	Red blood cell traits;	chr19:32720326	chr19:32718298~32719595:-
THCA	cis	rs6901004	0.605	rs2297939	ENSG00000230177.1	RP5-1112D6.4	-5.15	3.79e-07	5.24e-05	-0.19	-0.23	Blood metabolite levels;	chr6:111227959	chr6:111277932~111278742:+
THCA	cis	rs17123764	0.818	rs11169092	ENSG00000257464.1	RP11-161H23.8	-5.15	3.79e-07	5.24e-05	-0.37	-0.23	Intelligence (multi-trait analysis);	chr12:49614819	chr12:49442424~49442652:-
THCA	cis	rs9818758	0.607	rs9990153	ENSG00000270441.1	RP11-694I15.7	5.15	3.79e-07	5.24e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49254450	chr3:49140086~49160851:-
THCA	cis	rs156299	0.56	rs2253753	ENSG00000234286.1	AC006026.13	5.15	3.8e-07	5.24e-05	0.3	0.23	Vitamin D levels;	chr7:24212180	chr7:23680195~23680786:-
THCA	cis	rs9506514	0.509	rs9509279	ENSG00000238286.1	SLC35E1P1	5.15	3.8e-07	5.24e-05	0.22	0.23	Coronary artery calcification;	chr13:20559580	chr13:20607268~20608131:+
THCA	cis	rs2911132	0.621	rs17480169	ENSG00000248734.2	CTD-2260A17.1	5.15	3.8e-07	5.25e-05	0.25	0.23	Urate levels (BMI interaction);	chr5:96753363	chr5:96784777~96785999:+
THCA	cis	rs8020095	0.528	rs4636843	ENSG00000258561.1	RP11-72M17.1	-5.15	3.8e-07	5.25e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67263883	chr14:66212810~66509394:-
THCA	cis	rs10800713	0.529	rs10919966	ENSG00000260088.1	RP11-92G12.3	5.15	3.8e-07	5.25e-05	0.4	0.23	Tandem gait;	chr1:200533441	chr1:200669507~200694250:+
THCA	cis	rs16846053	0.71	rs11891120	ENSG00000227403.1	AC009299.3	-5.15	3.8e-07	5.25e-05	-0.39	-0.23	Blood osmolality (transformed sodium);	chr2:161795748	chr2:161244739~161249050:+
THCA	cis	rs240993	0.715	rs7752418	ENSG00000271789.1	RP5-1112D6.7	5.15	3.8e-07	5.25e-05	0.27	0.23	Inflammatory skin disease;Psoriasis;	chr6:111466682	chr6:111297126~111298510:+
THCA	cis	rs17767294	0.612	rs9461424	ENSG00000226314.6	ZNF192P1	-5.15	3.8e-07	5.25e-05	-0.41	-0.23	Parkinson's disease;	chr6:27951623	chr6:28161781~28169594:+
THCA	cis	rs1077514	0.515	rs1767141	ENSG00000232482.2	RP4-654C18.1	5.15	3.8e-07	5.25e-05	0.44	0.23	Cholesterol, total;	chr1:23407857	chr1:23410832~23412146:+
THCA	cis	rs9595908	0.9	rs731414	ENSG00000212293.1	SNORA16	5.15	3.8e-07	5.25e-05	0.27	0.23	Body mass index;	chr13:32601160	chr13:32420390~32420516:-
THCA	cis	rs6772849	0.93	rs9813197	ENSG00000242551.2	POU5F1P6	-5.15	3.8e-07	5.25e-05	-0.3	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:128674735~128677005:-
THCA	cis	rs987724	0.515	rs6787457	ENSG00000240875.4	LINC00886	-5.15	3.81e-07	5.26e-05	-0.23	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156891157	chr3:156747346~156817062:-
THCA	cis	rs227275	0.554	rs223399	ENSG00000248971.2	KRT8P46	-5.15	3.81e-07	5.26e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223386	ENSG00000248971.2	KRT8P46	-5.15	3.81e-07	5.26e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223385	ENSG00000248971.2	KRT8P46	-5.15	3.81e-07	5.26e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.873	rs223384	ENSG00000248971.2	KRT8P46	-5.15	3.81e-07	5.26e-05	-0.28	-0.23	Schizophrenia;	chr4:102829976	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223383	ENSG00000248971.2	KRT8P46	-5.15	3.81e-07	5.26e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223382	ENSG00000248971.2	KRT8P46	-5.15	3.81e-07	5.26e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102728746~102730171:-
THCA	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	5.15	3.81e-07	5.26e-05	0.29	0.23	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
THCA	cis	rs8028182	0.609	rs8038760	ENSG00000260274.1	RP11-817O13.8	5.15	3.81e-07	5.26e-05	0.17	0.23	Sudden cardiac arrest;	chr15:75449754	chr15:75368155~75369584:+
THCA	cis	rs7552393	0.595	rs4140462	ENSG00000233008.4	RP11-475O6.1	-5.15	3.81e-07	5.26e-05	-0.25	-0.23	Select biomarker traits;	chr1:83803616	chr1:83575776~83861023:-
THCA	cis	rs3892630	0.824	rs7247264	ENSG00000267567.1	CTD-2538C1.3	5.15	3.81e-07	5.26e-05	0.36	0.23	Red blood cell traits;	chr19:32748940	chr19:32718298~32719595:-
THCA	cis	rs3892630	0.824	rs34748593	ENSG00000267567.1	CTD-2538C1.3	5.15	3.81e-07	5.26e-05	0.36	0.23	Red blood cell traits;	chr19:32749541	chr19:32718298~32719595:-
THCA	cis	rs7688540	0.771	rs17164747	ENSG00000211553.1	AC253576.2	-5.15	3.81e-07	5.26e-05	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs79366248	ENSG00000211553.1	AC253576.2	-5.15	3.81e-07	5.26e-05	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs78343340	ENSG00000211553.1	AC253576.2	-5.15	3.81e-07	5.26e-05	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:136461~136568:+
THCA	cis	rs8177876	0.658	rs75422577	ENSG00000261838.4	RP11-303E16.6	5.15	3.81e-07	5.26e-05	0.43	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81069854~81076598:+
THCA	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	5.15	3.81e-07	5.26e-05	0.13	0.23	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
THCA	cis	rs2985684	1	rs8014170	ENSG00000278009.1	RP11-649E7.8	5.15	3.81e-07	5.26e-05	0.33	0.23	Carotid intima media thickness;	chr14:49604976	chr14:49601011~49601124:-
THCA	cis	rs6714710	0.603	rs34974566	ENSG00000230606.9	AC159540.1	-5.15	3.81e-07	5.26e-05	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935836	chr2:97416165~97433527:-
THCA	cis	rs6121246	0.529	rs750144	ENSG00000230613.1	HM13-AS1	-5.15	3.82e-07	5.27e-05	-0.28	-0.23	Mean corpuscular hemoglobin;	chr20:31591224	chr20:31567707~31573263:-
THCA	cis	rs1387259	0.723	rs2732488	ENSG00000273765.1	RP11-370I10.11	5.15	3.82e-07	5.27e-05	0.23	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48360920~48361377:+
THCA	cis	rs1387259	0.758	rs2634670	ENSG00000273765.1	RP11-370I10.11	5.15	3.82e-07	5.27e-05	0.23	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48360920~48361377:+
THCA	cis	rs721917	0.531	rs2758553	ENSG00000242600.5	MBL1P	-5.15	3.82e-07	5.27e-05	-0.2	-0.23	Chronic obstructive pulmonary disease;	chr10:79931624	chr10:79904898~79950336:+
THCA	cis	rs721917	0.531	rs2758551	ENSG00000242600.5	MBL1P	-5.15	3.82e-07	5.27e-05	-0.2	-0.23	Chronic obstructive pulmonary disease;	chr10:79932184	chr10:79904898~79950336:+
THCA	cis	rs9595908	0.9	rs1324414	ENSG00000212293.1	SNORA16	5.15	3.82e-07	5.27e-05	0.27	0.23	Body mass index;	chr13:32600088	chr13:32420390~32420516:-
THCA	cis	rs2562456	0.833	rs62110428	ENSG00000268119.4	CTD-2561J22.5	5.15	3.82e-07	5.28e-05	0.33	0.23	Pain;	chr19:21430854	chr19:21444241~21463908:-
THCA	cis	rs7727544	0.684	rs272874	ENSG00000237714.1	P4HA2-AS1	-5.15	3.82e-07	5.28e-05	-0.31	-0.23	Blood metabolite levels;	chr5:132339353	chr5:132184876~132192808:+
THCA	cis	rs8141529	0.732	rs6005881	ENSG00000272858.1	CTA-292E10.8	-5.15	3.82e-07	5.28e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28787145	chr22:28814914~28815662:+
THCA	cis	rs2337406	0.778	rs56965016	ENSG00000274576.2	IGHV2-70	-5.15	3.82e-07	5.28e-05	-0.2	-0.23	Alzheimer's disease (late onset);	chr14:106656649	chr14:106770577~106771020:-
THCA	cis	rs116095464	0.614	rs10067482	ENSG00000248925.1	CTD-2083E4.6	5.15	3.83e-07	5.28e-05	0.33	0.23	Breast cancer;	chr5:219213	chr5:269858~271516:-
THCA	cis	rs651907	0.557	rs7629753	ENSG00000244119.1	PDCL3P4	-5.15	3.83e-07	5.28e-05	-0.21	-0.23	Colorectal cancer;	chr3:101653078	chr3:101712472~101713191:+
THCA	cis	rs7045881	0.733	rs62546685	ENSG00000254396.1	RP11-56F10.3	5.15	3.83e-07	5.28e-05	0.42	0.23	Schizophrenia;	chr9:26949824	chr9:27102630~27104728:+
THCA	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-5.15	3.83e-07	5.29e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-5.15	3.83e-07	5.29e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-5.15	3.83e-07	5.29e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
THCA	cis	rs2797160	1	rs983543	ENSG00000237742.5	RP11-624M8.1	-5.15	3.83e-07	5.29e-05	-0.2	-0.23	Endometrial cancer;	chr6:125684621	chr6:125578558~125749190:-
THCA	cis	rs11073619	0.616	rs116163737	ENSG00000230373.7	GOLGA6L5P	-5.15	3.83e-07	5.29e-05	-0.35	-0.23	Positive affect;	chr15:84531745	chr15:84507885~84516814:-
THCA	cis	rs6893782	0.887	rs274547	ENSG00000233006.5	AC034220.3	-5.15	3.83e-07	5.29e-05	-0.23	-0.23	Acylcarnitine levels;	chr5:132395612	chr5:132311285~132369916:-
THCA	cis	rs4648045	0.861	rs230527	ENSG00000246560.2	RP11-10L12.4	-5.15	3.83e-07	5.29e-05	-0.3	-0.23	Lymphocyte percentage of white cells;	chr4:102537021	chr4:102828055~102844075:+
THCA	cis	rs7897654	0.571	rs12764049	ENSG00000236937.2	PTGES3P4	5.15	3.83e-07	5.29e-05	0.33	0.23	Schizophrenia;	chr10:102875199	chr10:102845595~102845950:+
THCA	cis	rs4915077	1	rs77346255	ENSG00000226822.1	RP11-356N1.2	5.15	3.84e-07	5.29e-05	0.43	0.23	Hypothyroidism;	chr1:107833382	chr1:108071482~108074519:+
THCA	cis	rs11723261	0.621	rs7440274	ENSG00000211553.1	AC253576.2	5.15	3.84e-07	5.29e-05	0.32	0.23	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:136461~136568:+
THCA	cis	rs9393777	0.841	rs13191474	ENSG00000280107.1	AL022393.9	-5.15	3.84e-07	5.29e-05	-0.42	-0.23	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28170845~28172521:+
THCA	cis	rs9393777	0.92	rs41269265	ENSG00000280107.1	AL022393.9	-5.15	3.84e-07	5.29e-05	-0.42	-0.23	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28170845~28172521:+
THCA	cis	rs2562456	0.833	rs2154302	ENSG00000268119.4	CTD-2561J22.5	5.15	3.84e-07	5.29e-05	0.33	0.23	Pain;	chr19:21307609	chr19:21444241~21463908:-
THCA	cis	rs16852403	0.517	rs12733805	ENSG00000224687.1	RASAL2-AS1	5.15	3.84e-07	5.3e-05	0.35	0.23	Childhood ear infection;	chr1:178280718	chr1:178091508~178093984:-
THCA	cis	rs12681287	0.517	rs34596274	ENSG00000254231.1	CTD-2284J15.1	5.15	3.84e-07	5.3e-05	0.25	0.23	Caudate activity during reward;	chr8:86505450	chr8:86333274~86343314:-
THCA	cis	rs6545883	0.894	rs778157	ENSG00000270820.4	RP11-355B11.2	5.15	3.84e-07	5.3e-05	0.19	0.23	Tuberculosis;	chr2:61327154	chr2:61471188~61484130:+
THCA	cis	rs1400745	0.812	rs72678789	ENSG00000258738.1	RP11-73E17.2	-5.15	3.84e-07	5.3e-05	-0.27	-0.23	Monocyte count;	chr14:34878995	chr14:34874343~34876459:+
THCA	cis	rs972578	0.561	rs2072883	ENSG00000230319.1	AL022476.2	5.15	3.84e-07	5.3e-05	0.26	0.23	Mean platelet volume;	chr22:43039662	chr22:43038585~43052366:+
THCA	cis	rs3892630	0.824	rs2287882	ENSG00000267567.1	CTD-2538C1.3	5.15	3.84e-07	5.3e-05	0.36	0.23	Red blood cell traits;	chr19:32842046	chr19:32718298~32719595:-
THCA	cis	rs6708331	0.517	rs11692018	ENSG00000179818.12	PCBP1-AS1	-5.15	3.84e-07	5.3e-05	-0.19	-0.23	Obesity-related traits;	chr2:70142022	chr2:69962263~70103220:-
THCA	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	5.15	3.84e-07	5.3e-05	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000228409.4	CCT6P1	5.15	3.84e-07	5.3e-05	0.19	0.23	Aortic root size;	chr7:66087510	chr7:65751142~65763354:+
THCA	cis	rs1858037	0.867	rs4671658	ENSG00000234255.7	AC012370.3	-5.15	3.84e-07	5.3e-05	-0.28	-0.23	Rheumatoid arthritis;	chr2:65334258	chr2:65439888~65456571:-
THCA	cis	rs736801	0.964	rs17622656	ENSG00000233006.5	AC034220.3	-5.15	3.84e-07	5.3e-05	-0.19	-0.23	Mosquito bite size;Breast cancer;	chr5:132485305	chr5:132311285~132369916:-
THCA	cis	rs7824557	0.585	rs2572385	ENSG00000154316.13	TDH	-5.15	3.85e-07	5.31e-05	-0.18	-0.23	Retinal vascular caliber;	chr8:11351394	chr8:11339637~11368452:+
THCA	cis	rs7617773	0.78	rs7653152	ENSG00000199476.1	Y_RNA	-5.15	3.85e-07	5.31e-05	-0.3	-0.23	Coronary artery disease;	chr3:48320607	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs4541431	ENSG00000199476.1	Y_RNA	-5.15	3.85e-07	5.31e-05	-0.3	-0.23	Coronary artery disease;	chr3:48323728	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.743	rs13071960	ENSG00000199476.1	Y_RNA	-5.15	3.85e-07	5.31e-05	-0.3	-0.23	Coronary artery disease;	chr3:48326047	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.743	rs4632568	ENSG00000199476.1	Y_RNA	-5.15	3.85e-07	5.31e-05	-0.3	-0.23	Coronary artery disease;	chr3:48326329	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.78	rs11130164	ENSG00000199476.1	Y_RNA	-5.15	3.85e-07	5.31e-05	-0.3	-0.23	Coronary artery disease;	chr3:48327544	chr3:48288587~48288694:+
THCA	cis	rs1979679	0.842	rs3741760	ENSG00000278733.1	RP11-425D17.1	-5.15	3.85e-07	5.31e-05	-0.22	-0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28391531	chr12:28185625~28186190:-
THCA	cis	rs11073619	1	rs11073619	ENSG00000230373.7	GOLGA6L5P	-5.15	3.85e-07	5.31e-05	-0.35	-0.23	Positive affect;	chr15:84645608	chr15:84507885~84516814:-
THCA	cis	rs8020095	0.571	rs10130604	ENSG00000258561.1	RP11-72M17.1	-5.15	3.85e-07	5.31e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:66848720	chr14:66212810~66509394:-
THCA	cis	rs2243480	1	rs160646	ENSG00000230295.1	RP11-458F8.2	-5.15	3.86e-07	5.32e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66091293	chr7:66880708~66882981:+
THCA	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-5.15	3.86e-07	5.32e-05	-0.28	-0.23	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
THCA	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-5.15	3.86e-07	5.32e-05	-0.28	-0.23	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
THCA	cis	rs7552393	0.595	rs12116654	ENSG00000233008.4	RP11-475O6.1	5.15	3.86e-07	5.32e-05	0.25	0.23	Select biomarker traits;	chr1:83804532	chr1:83575776~83861023:-
THCA	cis	rs7773456	0.533	rs9368127	ENSG00000237404.1	RP3-471C18.2	5.15	3.86e-07	5.32e-05	0.3	0.23	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19689825~19753113:-
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000235689.1	AP000351.13	5.15	3.86e-07	5.32e-05	0.29	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:24006305~24008258:-
THCA	cis	rs12908161	0.683	rs12903256	ENSG00000225151.9	GOLGA2P7	-5.15	3.86e-07	5.32e-05	-0.31	-0.23	Schizophrenia;	chr15:84764910	chr15:84199311~84230136:-
THCA	cis	rs1580019	0.587	rs1597555	ENSG00000231952.3	DPY19L1P2	-5.15	3.86e-07	5.32e-05	-0.29	-0.23	Cognitive ability;	chr7:32506506	chr7:32812757~32838570:+
THCA	cis	rs11977715	0.521	rs6465466	ENSG00000233942.1	AC004012.1	-5.15	3.86e-07	5.32e-05	-0.31	-0.23	Middle childhood and early adolescence aggressive behavior;	chr7:95502275	chr7:95471835~95473998:+
THCA	cis	rs2439831	0.681	rs7168940	ENSG00000275601.1	AC011330.13	-5.15	3.86e-07	5.32e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43341136	chr15:43642389~43643023:-
THCA	cis	rs763121	0.853	rs6001173	ENSG00000228274.3	RP3-508I15.9	-5.15	3.86e-07	5.32e-05	-0.25	-0.23	Menopause (age at onset);	chr22:38619297	chr22:38667585~38681820:-
THCA	cis	rs2243480	1	rs10247526	ENSG00000230295.1	RP11-458F8.2	5.15	3.86e-07	5.32e-05	0.29	0.23	Diabetic kidney disease;	chr7:66315709	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000230295.1	RP11-458F8.2	5.15	3.86e-07	5.32e-05	0.29	0.23	Diabetic kidney disease;	chr7:66333815	chr7:66880708~66882981:+
THCA	cis	rs7727544	0.506	rs10040809	ENSG00000233006.5	AC034220.3	5.15	3.86e-07	5.32e-05	0.18	0.23	Blood metabolite levels;	chr5:132007324	chr5:132311285~132369916:-
THCA	cis	rs858239	0.601	rs764534	ENSG00000226816.2	AC005082.12	5.15	3.86e-07	5.33e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23206013~23208045:+
THCA	cis	rs858239	0.601	rs2068459	ENSG00000226816.2	AC005082.12	5.15	3.86e-07	5.33e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23206013~23208045:+
THCA	cis	rs4604234	0.614	rs11961937	ENSG00000272129.1	RP11-250B2.6	-5.15	3.87e-07	5.33e-05	-0.56	-0.23	Cancer;	chr6:80119518	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.614	rs73479907	ENSG00000272129.1	RP11-250B2.6	-5.15	3.87e-07	5.33e-05	-0.56	-0.23	Cancer;	chr6:80124706	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.614	rs73479909	ENSG00000272129.1	RP11-250B2.6	-5.15	3.87e-07	5.33e-05	-0.56	-0.23	Cancer;	chr6:80125477	chr6:80355424~80356859:+
THCA	cis	rs4886920	0.672	rs8040443	ENSG00000260776.4	RP11-114H24.2	5.15	3.87e-07	5.33e-05	0.28	0.23	Neuroticism;	chr15:77838573	chr15:77914217~77926846:-
THCA	cis	rs7119	0.717	rs12916515	ENSG00000259362.2	RP11-307C19.1	-5.15	3.87e-07	5.33e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77526176	chr15:77525540~77534110:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000164669.11	INTS4P1	-5.15	3.87e-07	5.33e-05	-0.44	-0.23	Diabetic kidney disease;	chr7:65928187	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65916269	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65918212	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65922114	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65923503	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65925372	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65925938	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65940221	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65943626	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65944004	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000164669.11	INTS4P1	5.15	3.87e-07	5.33e-05	0.44	0.23	Diabetic kidney disease;	chr7:65944182	chr7:65141225~65234216:+
THCA	cis	rs4443100	0.874	rs6003483	ENSG00000230701.2	FBXW4P1	5.15	3.87e-07	5.33e-05	0.27	0.23	Serum parathyroid hormone levels;	chr22:23037448	chr22:23262767~23265005:+
THCA	cis	rs10771431	1	rs10771431	ENSG00000256069.6	A2MP1	5.15	3.87e-07	5.33e-05	0.25	0.23	Breast size;	chr12:9228263	chr12:9228533~9275817:-
THCA	cis	rs7617773	0.925	rs35942721	ENSG00000199476.1	Y_RNA	-5.15	3.87e-07	5.33e-05	-0.31	-0.23	Coronary artery disease;	chr3:48131579	chr3:48288587~48288694:+
THCA	cis	rs10090774	0.965	rs1806949	ENSG00000279766.1	RP11-642A1.2	-5.15	3.87e-07	5.34e-05	-0.29	-0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141004432	chr8:140572142~140572812:-
THCA	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-5.15	3.87e-07	5.34e-05	-0.13	-0.23	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
THCA	cis	rs9876781	1	rs2290822	ENSG00000244380.1	RP11-24C3.2	5.15	3.87e-07	5.34e-05	0.27	0.23	Longevity;	chr3:48431794	chr3:48440352~48446656:-
THCA	cis	rs2337406	0.539	rs2583292	ENSG00000211974.3	IGHV2-70	-5.15	3.87e-07	5.34e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106649040	chr14:106723574~106724093:-
THCA	cis	rs11671005	0.735	rs11668420	ENSG00000265272.2	RN7SL693P	5.15	3.87e-07	5.34e-05	0.32	0.23	Mean platelet volume;	chr19:58426469	chr19:58490797~58491075:+
THCA	cis	rs1707322	0.686	rs11211179	ENSG00000281133.1	AL355480.3	-5.15	3.87e-07	5.34e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.721	rs10157795	ENSG00000281133.1	AL355480.3	-5.15	3.87e-07	5.34e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45580892~45580996:-
THCA	cis	rs11671005	0.693	rs11669665	ENSG00000265272.2	RN7SL693P	5.15	3.88e-07	5.34e-05	0.32	0.23	Mean platelet volume;	chr19:58420518	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.693	rs11084542	ENSG00000265272.2	RN7SL693P	5.15	3.88e-07	5.34e-05	0.32	0.23	Mean platelet volume;	chr19:58420732	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs11084543	ENSG00000265272.2	RN7SL693P	5.15	3.88e-07	5.34e-05	0.32	0.23	Mean platelet volume;	chr19:58421334	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs11881000	ENSG00000265272.2	RN7SL693P	5.15	3.88e-07	5.34e-05	0.32	0.23	Mean platelet volume;	chr19:58421421	chr19:58490797~58491075:+
THCA	cis	rs2886497	0.947	rs11013424	ENSG00000224215.1	RP11-371A19.2	-5.15	3.88e-07	5.34e-05	-0.32	-0.23	Major depression and alcohol dependence;	chr10:23375407	chr10:23343957~23345181:+
THCA	cis	rs34779708	0.771	rs12098283	ENSG00000271335.4	RP11-324I22.4	5.15	3.88e-07	5.35e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35314552~35336401:-
THCA	cis	rs227275	0.554	rs223395	ENSG00000248971.2	KRT8P46	-5.15	3.88e-07	5.35e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102728746~102730171:-
THCA	cis	rs2439831	0.681	rs526450	ENSG00000275601.1	AC011330.13	-5.15	3.88e-07	5.35e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43307127	chr15:43642389~43643023:-
THCA	cis	rs17508449	0.819	rs79198040	ENSG00000232450.1	RP4-730K3.3	-5.15	3.88e-07	5.35e-05	-0.36	-0.23	Leprosy;	chr1:113746069	chr1:113698884~113699631:-
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000280069.1	CTD-2349P21.3	-5.15	3.88e-07	5.35e-05	-0.36	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000280069.1	CTD-2349P21.3	-5.15	3.88e-07	5.35e-05	-0.36	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30738182~30740275:+
THCA	cis	rs1823913	0.963	rs12614848	ENSG00000227542.1	AC092614.2	-5.15	3.88e-07	5.35e-05	-0.28	-0.23	Obesity-related traits;	chr2:191231993	chr2:191229165~191246172:-
THCA	cis	rs7618915	0.547	rs6976	ENSG00000243224.1	RP5-1157M23.2	-5.15	3.89e-07	5.36e-05	-0.25	-0.23	Bipolar disorder;	chr3:52694788	chr3:52239258~52241097:+
THCA	cis	rs4787484	0.964	rs7498372	ENSG00000214725.6	CDIPT-AS1	-5.15	3.89e-07	5.36e-05	-0.31	-0.23	Response to taxane treatment (placlitaxel);	chr16:29899404	chr16:29863593~29868053:+
THCA	cis	rs78773383	0.505	rs10033019	ENSG00000249685.1	RP11-360F5.3	-5.15	3.89e-07	5.36e-05	-0.28	-0.23	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39390320	chr4:39133913~39135608:+
THCA	cis	rs11671005	0.779	rs731259	ENSG00000269473.1	CTD-2619J13.19	5.15	3.89e-07	5.36e-05	0.27	0.23	Mean platelet volume;	chr19:58478057	chr19:58440448~58445849:+
THCA	cis	rs35934224	0.783	rs34675706	ENSG00000232926.1	AC000078.5	5.15	3.89e-07	5.36e-05	0.26	0.23	Glaucoma (primary open-angle);	chr22:19860095	chr22:19887289~19887970:+
THCA	cis	rs763121	0.853	rs7289577	ENSG00000228274.3	RP3-508I15.9	-5.15	3.89e-07	5.36e-05	-0.25	-0.23	Menopause (age at onset);	chr22:38646209	chr22:38667585~38681820:-
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000232559.3	GS1-124K5.12	5.15	3.89e-07	5.36e-05	0.33	0.23	Diabetic kidney disease;	chr7:66100518	chr7:66554588~66576923:-
THCA	cis	rs9307551	0.619	rs12513177	ENSG00000250334.4	LINC00989	-5.15	3.9e-07	5.37e-05	-0.28	-0.23	Refractive error;	chr4:79547660	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.584	rs1440865	ENSG00000250334.4	LINC00989	-5.15	3.9e-07	5.37e-05	-0.28	-0.23	Refractive error;	chr4:79548747	chr4:79492416~79576460:+
THCA	cis	rs16975963	0.644	rs59426132	ENSG00000226686.6	LINC01535	-5.15	3.9e-07	5.37e-05	-0.31	-0.23	Longevity;	chr19:37601869	chr19:37251912~37265535:+
THCA	cis	rs9595908	0.931	rs55645971	ENSG00000212293.1	SNORA16	5.15	3.9e-07	5.37e-05	0.27	0.23	Body mass index;	chr13:32615452	chr13:32420390~32420516:-
THCA	cis	rs11846409	0.799	rs2583330	ENSG00000211974.3	IGHV2-70	5.15	3.9e-07	5.37e-05	0.23	0.23	Rheumatic heart disease;	chr14:106621051	chr14:106723574~106724093:-
THCA	cis	rs2136613	0.751	rs1397030	ENSG00000238280.1	RP11-436D10.3	-5.15	3.9e-07	5.37e-05	-0.26	-0.23	Selective IgA deficiency;	chr10:62838746	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.751	rs10761666	ENSG00000238280.1	RP11-436D10.3	-5.15	3.9e-07	5.37e-05	-0.26	-0.23	Selective IgA deficiency;	chr10:62848601	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.779	rs4141614	ENSG00000238280.1	RP11-436D10.3	-5.15	3.9e-07	5.37e-05	-0.26	-0.23	Selective IgA deficiency;	chr10:62854095	chr10:62793562~62805887:-
THCA	cis	rs34779708	0.966	rs7070427	ENSG00000271335.4	RP11-324I22.4	5.15	3.9e-07	5.37e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35314552~35336401:-
THCA	cis	rs6686842	0.536	rs12121121	ENSG00000235358.1	RP11-399E6.1	-5.15	3.9e-07	5.38e-05	-0.3	-0.23	Height;	chr1:41218784	chr1:41242373~41284861:+
THCA	cis	rs736801	0.521	rs41525648	ENSG00000237714.1	P4HA2-AS1	5.15	3.9e-07	5.38e-05	0.29	0.23	Mosquito bite size;Breast cancer;	chr5:132492083	chr5:132184876~132192808:+
THCA	cis	rs919433	0.68	rs6434930	ENSG00000231621.1	AC013264.2	-5.15	3.91e-07	5.38e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197504646	chr2:197197991~197199273:+
THCA	cis	rs78487399	0.614	rs10166376	ENSG00000234936.1	AC010883.5	5.15	3.91e-07	5.38e-05	0.34	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43395333	chr2:43229573~43233394:+
THCA	cis	rs2235642	0.928	rs2076435	ENSG00000280231.1	LA16c-380F5.3	-5.15	3.91e-07	5.38e-05	-0.28	-0.23	Coronary artery disease;	chr16:1557573	chr16:1553655~1554130:-
THCA	cis	rs3213758	1	rs75954653	ENSG00000275191.1	RP11-36I17.2	-5.15	3.91e-07	5.38e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53550814	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs16952315	ENSG00000275191.1	RP11-36I17.2	-5.15	3.91e-07	5.38e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53554447	chr16:53628256~53628816:-
THCA	cis	rs7617773	0.747	rs34076262	ENSG00000199476.1	Y_RNA	-5.15	3.91e-07	5.39e-05	-0.3	-0.23	Coronary artery disease;	chr3:48328926	chr3:48288587~48288694:+
THCA	cis	rs1005277	0.579	rs2474584	ENSG00000272983.1	RP11-508N22.12	5.15	3.91e-07	5.39e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474586	ENSG00000272983.1	RP11-508N22.12	5.15	3.91e-07	5.39e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38137337~38144399:+
THCA	cis	rs11992162	0.905	rs7836953	ENSG00000254948.1	OR7E158P	-5.15	3.91e-07	5.39e-05	-0.27	-0.23	Monocyte count;	chr8:11978203	chr8:11919900~11920809:-
THCA	cis	rs1062753	0.771	rs5751245	ENSG00000227370.1	RP4-669P10.19	5.15	3.91e-07	5.39e-05	0.23	0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42224934	chr22:42132543~42132998:+
THCA	cis	rs2803122	0.967	rs10123206	ENSG00000273226.1	RP11-513M16.8	5.15	3.91e-07	5.39e-05	0.21	0.23	Pulse pressure;	chr9:19246846	chr9:19375451~19375996:+
THCA	cis	rs858239	0.539	rs870476	ENSG00000230042.1	AK3P3	-5.15	3.91e-07	5.39e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23129178~23129841:+
THCA	cis	rs73242632	1	rs28474684	ENSG00000269949.1	RP11-738E22.3	5.15	3.91e-07	5.39e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:57009303	chr4:56960927~56961373:-
THCA	cis	rs73242632	0.867	rs28545156	ENSG00000269949.1	RP11-738E22.3	5.15	3.91e-07	5.39e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:57013174	chr4:56960927~56961373:-
THCA	cis	rs73242632	1	rs2271806	ENSG00000269949.1	RP11-738E22.3	5.15	3.91e-07	5.39e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:57020984	chr4:56960927~56961373:-
THCA	cis	rs73242632	1	rs28681160	ENSG00000269949.1	RP11-738E22.3	5.15	3.91e-07	5.39e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:57023000	chr4:56960927~56961373:-
THCA	cis	rs228614	0.51	rs223377	ENSG00000248971.2	KRT8P46	-5.15	3.92e-07	5.39e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102728746~102730171:-
THCA	cis	rs11992162	1	rs7460395	ENSG00000227888.4	FAM66A	5.15	3.92e-07	5.39e-05	0.3	0.23	Monocyte count;	chr8:11977866	chr8:12362019~12388296:+
THCA	cis	rs4432245	0.793	rs711906	ENSG00000248508.5	SRP14-AS1	-5.15	3.92e-07	5.4e-05	-0.24	-0.23	Body mass index;	chr15:40033490	chr15:40039311~40067290:+
THCA	cis	rs2067615	0.599	rs10778508	ENSG00000260329.1	RP11-412D9.4	5.15	3.92e-07	5.4e-05	0.21	0.23	Heart rate;	chr12:106765627	chr12:106954029~106955497:-
THCA	cis	rs651907	0.557	rs59596156	ENSG00000244119.1	PDCL3P4	5.15	3.92e-07	5.4e-05	0.21	0.23	Colorectal cancer;	chr3:101675373	chr3:101712472~101713191:+
THCA	cis	rs4845570	0.92	rs10788809	ENSG00000203288.3	RP11-98D18.9	5.15	3.92e-07	5.4e-05	0.26	0.23	Coronary artery disease;	chr1:151788316	chr1:151790804~151794402:+
THCA	cis	rs9595908	0.965	rs9591180	ENSG00000212293.1	SNORA16	5.15	3.92e-07	5.4e-05	0.27	0.23	Body mass index;	chr13:32622864	chr13:32420390~32420516:-
THCA	cis	rs3743772	0.881	rs62048523	ENSG00000279722.1	RP11-44F14.6	5.15	3.93e-07	5.4e-05	0.4	0.23	Depressive symptoms (SSRI exposure interaction);	chr16:53471465	chr16:53487607~53489943:-
THCA	cis	rs2797160	1	rs1954361	ENSG00000237742.5	RP11-624M8.1	-5.15	3.93e-07	5.4e-05	-0.2	-0.23	Endometrial cancer;	chr6:125680277	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1739367	ENSG00000237742.5	RP11-624M8.1	-5.15	3.93e-07	5.4e-05	-0.2	-0.23	Endometrial cancer;	chr6:125683574	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2747724	ENSG00000237742.5	RP11-624M8.1	-5.15	3.93e-07	5.4e-05	-0.2	-0.23	Endometrial cancer;	chr6:125683789	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2797154	ENSG00000237742.5	RP11-624M8.1	-5.15	3.93e-07	5.4e-05	-0.2	-0.23	Endometrial cancer;	chr6:125684051	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1739352	ENSG00000237742.5	RP11-624M8.1	-5.15	3.93e-07	5.4e-05	-0.2	-0.23	Endometrial cancer;	chr6:125684164	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2747714	ENSG00000237742.5	RP11-624M8.1	5.15	3.93e-07	5.4e-05	0.2	0.23	Endometrial cancer;	chr6:125686474	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs61299898	ENSG00000237742.5	RP11-624M8.1	5.15	3.93e-07	5.4e-05	0.2	0.23	Endometrial cancer;	chr6:125686505	chr6:125578558~125749190:-
THCA	cis	rs5758511	0.508	rs2854827	ENSG00000281538.1	RP4-669P10.20	-5.15	3.93e-07	5.41e-05	-0.29	-0.23	Birth weight;	chr22:42065914	chr22:42138060~42139726:+
THCA	cis	rs4748857	0.685	rs72788416	ENSG00000224215.1	RP11-371A19.2	-5.15	3.93e-07	5.41e-05	-0.31	-0.23	Systemic lupus erythematosus;	chr10:23315423	chr10:23343957~23345181:+
THCA	cis	rs2136613	0.751	rs10995328	ENSG00000238280.1	RP11-436D10.3	-5.15	3.93e-07	5.41e-05	-0.26	-0.23	Selective IgA deficiency;	chr10:62842848	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.751	rs1509955	ENSG00000238280.1	RP11-436D10.3	-5.15	3.93e-07	5.41e-05	-0.26	-0.23	Selective IgA deficiency;	chr10:62843559	chr10:62793562~62805887:-
THCA	cis	rs2136613	0.751	rs10761667	ENSG00000238280.1	RP11-436D10.3	-5.15	3.93e-07	5.41e-05	-0.26	-0.23	Selective IgA deficiency;	chr10:62849038	chr10:62793562~62805887:-
THCA	cis	rs9859260	0.845	rs35587059	ENSG00000273009.1	RP11-352G9.1	-5.15	3.93e-07	5.41e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196077473	chr3:195913078~195913683:-
THCA	cis	rs12681287	0.64	rs10086340	ENSG00000254231.1	CTD-2284J15.1	5.15	3.93e-07	5.41e-05	0.25	0.23	Caudate activity during reward;	chr8:86434560	chr8:86333274~86343314:-
THCA	cis	rs2129782	1	rs114166836	ENSG00000253553.4	RP11-586K2.1	5.15	3.93e-07	5.41e-05	0.41	0.23	Electrodermal activity;	chr8:88347152	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs79490511	ENSG00000253553.4	RP11-586K2.1	5.15	3.93e-07	5.41e-05	0.41	0.23	Electrodermal activity;	chr8:88351587	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs56912549	ENSG00000253553.4	RP11-586K2.1	5.15	3.93e-07	5.41e-05	0.41	0.23	Electrodermal activity;	chr8:88353606	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs111966557	ENSG00000253553.4	RP11-586K2.1	5.15	3.93e-07	5.41e-05	0.41	0.23	Electrodermal activity;	chr8:88357969	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs59951423	ENSG00000253553.4	RP11-586K2.1	5.15	3.93e-07	5.41e-05	0.41	0.23	Electrodermal activity;	chr8:88359925	chr8:88326836~88737134:+
THCA	cis	rs2129782	1	rs75145948	ENSG00000253553.4	RP11-586K2.1	5.15	3.93e-07	5.41e-05	0.41	0.23	Electrodermal activity;	chr8:88382004	chr8:88326836~88737134:+
THCA	cis	rs721917	0.531	rs2256167	ENSG00000242600.5	MBL1P	-5.15	3.93e-07	5.41e-05	-0.2	-0.23	Chronic obstructive pulmonary disease;	chr10:79928592	chr10:79904898~79950336:+
THCA	cis	rs5015933	1	rs4289914	ENSG00000232630.1	PRPS1P2	-5.15	3.93e-07	5.41e-05	-0.15	-0.23	Body mass index;	chr9:125373526	chr9:125150653~125151589:+
THCA	cis	rs853679	0.599	rs149943	ENSG00000280107.1	AL022393.9	-5.15	3.93e-07	5.41e-05	-0.33	-0.23	Depression;	chr6:28034610	chr6:28170845~28172521:+
THCA	cis	rs919433	0.783	rs787979	ENSG00000231621.1	AC013264.2	-5.15	3.94e-07	5.42e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197378144	chr2:197197991~197199273:+
THCA	cis	rs8062405	1	rs72793811	ENSG00000278665.1	RP11-666O2.4	5.14	3.94e-07	5.42e-05	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs72793812	ENSG00000278665.1	RP11-666O2.4	5.14	3.94e-07	5.42e-05	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28599241~28601881:-
THCA	cis	rs16852403	0.548	rs10798602	ENSG00000224687.1	RASAL2-AS1	5.14	3.94e-07	5.42e-05	0.35	0.23	Childhood ear infection;	chr1:178257304	chr1:178091508~178093984:-
THCA	cis	rs62025270	0.547	rs338520	ENSG00000202081.1	RNU6-1280P	5.14	3.94e-07	5.42e-05	0.32	0.23	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85651522~85651628:-
THCA	cis	rs4865169	0.934	rs12650737	ENSG00000269949.1	RP11-738E22.3	-5.14	3.94e-07	5.42e-05	-0.27	-0.23	Breast cancer;	chr4:57026309	chr4:56960927~56961373:-
THCA	cis	rs8014252	0.667	rs11844845	ENSG00000259158.2	ADAM20P1	-5.14	3.94e-07	5.42e-05	-0.25	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70372672	chr14:70468881~70483756:-
THCA	cis	rs7688540	0.8	rs9328738	ENSG00000250892.1	RP11-1365D11.1	-5.14	3.94e-07	5.42e-05	-0.32	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:201409~205009:-
THCA	cis	rs11846409	0.932	rs74091728	ENSG00000211974.3	IGHV2-70	-5.14	3.94e-07	5.42e-05	-0.22	-0.23	Rheumatic heart disease;	chr14:106638762	chr14:106723574~106724093:-
THCA	cis	rs2303759	0.958	rs1465697	ENSG00000268686.1	AC010524.2	-5.14	3.94e-07	5.42e-05	-0.34	-0.23	Multiple sclerosis;	chr19:49333989	chr19:49368705~49388081:-
THCA	cis	rs5015933	1	rs11998746	ENSG00000232630.1	PRPS1P2	-5.14	3.94e-07	5.43e-05	-0.15	-0.23	Body mass index;	chr9:125373083	chr9:125150653~125151589:+
THCA	cis	rs35934224	0.783	rs6518585	ENSG00000232926.1	AC000078.5	5.14	3.94e-07	5.43e-05	0.26	0.23	Glaucoma (primary open-angle);	chr22:19861978	chr22:19887289~19887970:+
THCA	cis	rs8020095	0.571	rs9323490	ENSG00000258561.1	RP11-72M17.1	-5.14	3.95e-07	5.43e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:67059620	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs2144061	ENSG00000258561.1	RP11-72M17.1	-5.14	3.95e-07	5.43e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:67059845	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs10150145	ENSG00000258561.1	RP11-72M17.1	-5.14	3.95e-07	5.43e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:67060311	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs9323492	ENSG00000258561.1	RP11-72M17.1	-5.14	3.95e-07	5.43e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:67061740	chr14:66212810~66509394:-
THCA	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	5.14	3.95e-07	5.43e-05	0.25	0.23	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
THCA	cis	rs5758511	0.633	rs5751258	ENSG00000281538.1	RP4-669P10.20	-5.14	3.95e-07	5.43e-05	-0.26	-0.23	Birth weight;	chr22:42267865	chr22:42138060~42139726:+
THCA	cis	rs2034650	0.563	rs2412523	ENSG00000223313.1	RNU6-516P	5.14	3.95e-07	5.43e-05	0.25	0.23	Interstitial lung disease;	chr15:40417487	chr15:40529570~40529673:+
THCA	cis	rs919433	0.68	rs6710530	ENSG00000231621.1	AC013264.2	-5.14	3.95e-07	5.43e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197412827	chr2:197197991~197199273:+
THCA	cis	rs919433	0.648	rs3097384	ENSG00000231621.1	AC013264.2	-5.14	3.95e-07	5.43e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197414110	chr2:197197991~197199273:+
THCA	cis	rs919433	0.68	rs788022	ENSG00000231621.1	AC013264.2	-5.14	3.95e-07	5.43e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197415862	chr2:197197991~197199273:+
THCA	cis	rs919433	0.619	rs699318	ENSG00000231621.1	AC013264.2	-5.14	3.95e-07	5.43e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197417019	chr2:197197991~197199273:+
THCA	cis	rs919433	0.68	rs699319	ENSG00000231621.1	AC013264.2	-5.14	3.95e-07	5.43e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197417052	chr2:197197991~197199273:+
THCA	cis	rs919433	0.68	rs788021	ENSG00000231621.1	AC013264.2	-5.14	3.95e-07	5.43e-05	-0.25	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197428967	chr2:197197991~197199273:+
THCA	cis	rs651907	0.535	rs13059470	ENSG00000244119.1	PDCL3P4	-5.14	3.95e-07	5.43e-05	-0.21	-0.23	Colorectal cancer;	chr3:101705956	chr3:101712472~101713191:+
THCA	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-5.14	3.95e-07	5.43e-05	-0.28	-0.23	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
THCA	cis	rs7646881	0.544	rs12638363	ENSG00000240207.5	RP11-379F4.4	-5.14	3.95e-07	5.44e-05	-0.33	-0.23	Tetralogy of Fallot;	chr3:158686969	chr3:158732263~158784070:+
THCA	cis	rs12478296	1	rs55742408	ENSG00000261186.2	RP11-341N2.1	-5.14	3.95e-07	5.44e-05	-0.36	-0.23	Obesity-related traits;	chr2:242098926	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs12469535	ENSG00000261186.2	RP11-341N2.1	-5.14	3.95e-07	5.44e-05	-0.36	-0.23	Obesity-related traits;	chr2:242101996	chr2:242087351~242088457:-
THCA	cis	rs227275	0.554	rs223454	ENSG00000248971.2	KRT8P46	-5.14	3.95e-07	5.44e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102728746~102730171:-
THCA	cis	rs1552244	0.554	rs6768339	ENSG00000232901.1	CYCSP10	-5.14	3.95e-07	5.44e-05	-0.28	-0.23	Alzheimer's disease;	chr3:9964395	chr3:10000647~10000940:-
THCA	cis	rs8014252	0.667	rs10136230	ENSG00000259158.2	ADAM20P1	-5.14	3.95e-07	5.44e-05	-0.25	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70315349	chr14:70468881~70483756:-
THCA	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	5.14	3.96e-07	5.44e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
THCA	cis	rs763567	0.869	rs680084	ENSG00000271811.1	RP1-79C4.4	5.14	3.96e-07	5.44e-05	0.26	0.23	Tonsillectomy;	chr1:170659114	chr1:170667381~170669425:+
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000229886.1	RP5-1132H15.3	5.14	3.96e-07	5.44e-05	0.27	0.23	Corneal structure;	chr7:66830758	chr7:66025126~66031544:-
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000229886.1	RP5-1132H15.3	5.14	3.96e-07	5.44e-05	0.27	0.23	Corneal structure;	chr7:66845054	chr7:66025126~66031544:-
THCA	cis	rs72627509	0.638	rs78272732	ENSG00000269949.1	RP11-738E22.3	5.14	3.96e-07	5.44e-05	0.37	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57004371	chr4:56960927~56961373:-
THCA	cis	rs12935418	0.672	rs6564814	ENSG00000278985.1	RP11-303E16.9	5.14	3.96e-07	5.45e-05	0.25	0.23	Mean corpuscular volume;	chr16:81016567	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.672	rs2602424	ENSG00000278985.1	RP11-303E16.9	-5.14	3.96e-07	5.45e-05	-0.25	-0.23	Mean corpuscular volume;	chr16:81009600	chr16:80982319~80984094:-
THCA	cis	rs6686842	0.513	rs11579483	ENSG00000235358.1	RP11-399E6.1	-5.14	3.96e-07	5.45e-05	-0.3	-0.23	Height;	chr1:41014192	chr1:41242373~41284861:+
THCA	cis	rs4908760	0.827	rs1463053	ENSG00000232912.4	RP5-1115A15.1	5.14	3.96e-07	5.45e-05	0.23	0.23	Vitiligo;	chr1:8644978	chr1:8424645~8434838:+
THCA	cis	rs72945132	0.882	rs4567496	ENSG00000254604.1	AP000487.6	-5.14	3.96e-07	5.45e-05	-0.44	-0.23	Coronary artery disease;	chr11:70347102	chr11:70282367~70363368:-
THCA	cis	rs28476539	0.61	rs7679857	ENSG00000270480.1	RP11-57B24.1	-5.14	3.96e-07	5.45e-05	-0.38	-0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82648584	chr4:82691737~82692468:+
THCA	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-5.14	3.96e-07	5.45e-05	-0.14	-0.23	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-5.14	3.96e-07	5.45e-05	-0.14	-0.23	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
THCA	cis	rs2562456	0.876	rs2359144	ENSG00000268119.4	CTD-2561J22.5	5.14	3.97e-07	5.45e-05	0.33	0.23	Pain;	chr19:21407834	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.876	rs4638726	ENSG00000268119.4	CTD-2561J22.5	5.14	3.97e-07	5.45e-05	0.33	0.23	Pain;	chr19:21409710	chr19:21444241~21463908:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000230295.1	RP11-458F8.2	5.14	3.97e-07	5.46e-05	0.29	0.23	Diabetic kidney disease;	chr7:66253864	chr7:66880708~66882981:+
THCA	cis	rs12681287	0.64	rs8635	ENSG00000254231.1	CTD-2284J15.1	5.14	3.97e-07	5.46e-05	0.25	0.23	Caudate activity during reward;	chr8:86467581	chr8:86333274~86343314:-
THCA	cis	rs7829975	0.514	rs2920983	ENSG00000253981.4	ALG1L13P	5.14	3.97e-07	5.46e-05	0.21	0.23	Mood instability;	chr8:8410553	chr8:8236003~8244667:-
THCA	cis	rs2034650	0.544	rs661488	ENSG00000223313.1	RNU6-516P	5.14	3.97e-07	5.46e-05	0.25	0.23	Interstitial lung disease;	chr15:40429221	chr15:40529570~40529673:+
THCA	cis	rs7403037	0.565	rs35358454	ENSG00000259905.4	PWRN1	5.14	3.97e-07	5.46e-05	0.29	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24286089	chr15:24493137~24652130:+
THCA	cis	rs35176054	0.73	rs80056983	ENSG00000280693.1	SH3PXD2A-AS1	-5.14	3.97e-07	5.46e-05	-0.38	-0.23	Atrial fibrillation;	chr10:103750144	chr10:103745966~103755423:+
THCA	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	5.14	3.97e-07	5.46e-05	0.28	0.23	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
THCA	cis	rs72945132	0.825	rs947811	ENSG00000254604.1	AP000487.6	-5.14	3.98e-07	5.47e-05	-0.43	-0.23	Coronary artery disease;	chr11:70363036	chr11:70282367~70363368:-
THCA	cis	rs7085104	0.632	rs4290163	ENSG00000213061.2	PFN1P11	5.14	3.98e-07	5.47e-05	0.27	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102838011~102845473:-
THCA	cis	rs11175834	0.655	rs11175839	ENSG00000250748.5	RP11-230G5.2	5.14	3.98e-07	5.47e-05	0.38	0.23	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65613113	chr12:65466820~65642372:-
THCA	cis	rs17767392	0.958	rs7156313	ENSG00000259146.3	RP1-261D10.2	-5.14	3.98e-07	5.47e-05	-0.29	-0.23	Mitral valve prolapse;	chr14:71585593	chr14:71292729~71321814:-
THCA	cis	rs829883	0.898	rs249834	ENSG00000227825.4	SLC9A7P1	-5.14	3.98e-07	5.47e-05	-0.22	-0.23	Colorectal adenoma (advanced);	chr12:98433766	chr12:98453835~98457145:-
THCA	cis	rs972578	0.765	rs738536	ENSG00000274717.1	RP1-47A17.1	-5.14	3.98e-07	5.47e-05	-0.23	-0.23	Mean platelet volume;	chr22:42864421	chr22:42791814~42794313:-
THCA	cis	rs9843304	0.546	rs56303133	ENSG00000240541.2	TM4SF1-AS1	-5.14	3.98e-07	5.47e-05	-0.22	-0.23	Gallstone disease;	chr3:149494692	chr3:149377778~149386583:+
THCA	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-5.14	3.98e-07	5.47e-05	-0.31	-0.23	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
THCA	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-5.14	3.98e-07	5.47e-05	-0.24	-0.23	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
THCA	cis	rs6088590	1	rs6120748	ENSG00000269202.1	RP4-614O4.12	-5.14	3.98e-07	5.48e-05	-0.21	-0.23	Coronary artery disease;	chr20:34870481	chr20:35201747~35203288:-
THCA	cis	rs4950322	0.542	rs4950384	ENSG00000271721.1	RP11-337C18.9	5.14	3.98e-07	5.48e-05	0.26	0.23	Protein quantitative trait loci;	chr1:147177310	chr1:147175602~147177740:+
THCA	cis	rs10090774	0.965	rs10087782	ENSG00000279766.1	RP11-642A1.2	-5.14	3.99e-07	5.48e-05	-0.29	-0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140848521	chr8:140572142~140572812:-
THCA	cis	rs4789693	0.544	rs4789770	ENSG00000260011.2	RP13-20L14.1	-5.14	3.99e-07	5.48e-05	-0.23	-0.23	Glucocorticoid-induced osteonecrosis;	chr17:82418779	chr17:82381110~82382690:-
THCA	cis	rs752010	0.905	rs4525030	ENSG00000230638.4	RP11-486B10.4	-5.14	3.99e-07	5.48e-05	-0.25	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41625636	chr1:41542069~41544310:+
THCA	cis	rs752010	0.875	rs11210501	ENSG00000230638.4	RP11-486B10.4	-5.14	3.99e-07	5.48e-05	-0.25	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41625963	chr1:41542069~41544310:+
THCA	cis	rs35934224	0.783	rs16984299	ENSG00000232926.1	AC000078.5	-5.14	3.99e-07	5.48e-05	-0.26	-0.23	Glaucoma (primary open-angle);	chr22:19876070	chr22:19887289~19887970:+
THCA	cis	rs944289	0.712	rs12050121	ENSG00000258844.1	RP11-259K15.2	5.14	3.99e-07	5.48e-05	0.21	0.23	Thyroid cancer;	chr14:36103742	chr14:36214607~36235608:+
THCA	cis	rs757978	0.81	rs35319025	ENSG00000223374.1	AC005104.3	5.14	3.99e-07	5.49e-05	0.24	0.23	Chronic lymphocytic leukemia;	chr2:241463048	chr2:241351340~241353104:-
THCA	cis	rs7646881	0.544	rs59527167	ENSG00000240207.5	RP11-379F4.4	-5.14	3.99e-07	5.49e-05	-0.33	-0.23	Tetralogy of Fallot;	chr3:158642504	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.544	rs3806642	ENSG00000240207.5	RP11-379F4.4	-5.14	3.99e-07	5.49e-05	-0.33	-0.23	Tetralogy of Fallot;	chr3:158644249	chr3:158732263~158784070:+
THCA	cis	rs516805	0.528	rs2684247	ENSG00000279453.1	RP3-425C14.4	-5.14	3.99e-07	5.49e-05	-0.24	-0.23	Lymphocyte counts;	chr6:122076755	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs7738997	ENSG00000279453.1	RP3-425C14.4	-5.14	3.99e-07	5.49e-05	-0.24	-0.23	Lymphocyte counts;	chr6:122077264	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs13203915	ENSG00000279453.1	RP3-425C14.4	-5.14	3.99e-07	5.49e-05	-0.24	-0.23	Lymphocyte counts;	chr6:122077325	chr6:122436789~122439223:-
THCA	cis	rs56114371	0.568	rs200468	ENSG00000280107.1	AL022393.9	-5.14	3.99e-07	5.49e-05	-0.29	-0.23	Breast cancer;	chr6:27790076	chr6:28170845~28172521:+
THCA	cis	rs748404	0.666	rs12911569	ENSG00000205771.5	CATSPER2P1	-5.14	3.99e-07	5.49e-05	-0.3	-0.23	Lung cancer;	chr15:43305099	chr15:43726918~43747094:-
THCA	cis	rs7772486	0.686	rs9403746	ENSG00000270638.1	RP3-466P17.1	-5.14	3.99e-07	5.49e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.625	rs9390355	ENSG00000270638.1	RP3-466P17.1	-5.14	3.99e-07	5.49e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.658	rs4895683	ENSG00000270638.1	RP3-466P17.1	-5.14	3.99e-07	5.49e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.625	rs2050027	ENSG00000270638.1	RP3-466P17.1	-5.14	3.99e-07	5.49e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145735570~145737218:+
THCA	cis	rs17767392	1	rs34057981	ENSG00000259146.3	RP1-261D10.2	5.14	4e-07	5.49e-05	0.3	0.23	Mitral valve prolapse;	chr14:71357264	chr14:71292729~71321814:-
THCA	cis	rs17767392	1	rs35260692	ENSG00000259146.3	RP1-261D10.2	5.14	4e-07	5.49e-05	0.3	0.23	Mitral valve prolapse;	chr14:71364948	chr14:71292729~71321814:-
THCA	cis	rs8033133	0.958	rs6420956	ENSG00000251896.1	SNORD116-27	-5.14	4e-07	5.49e-05	-0.27	-0.23	Blood osmolality (transformed sodium);	chr15:25064412	chr15:25101575~25101666:+
THCA	cis	rs8020095	0.528	rs13379476	ENSG00000258561.1	RP11-72M17.1	-5.14	4e-07	5.49e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66945016	chr14:66212810~66509394:-
THCA	cis	rs748404	0.666	rs34178146	ENSG00000205771.5	CATSPER2P1	-5.14	4e-07	5.49e-05	-0.29	-0.23	Lung cancer;	chr15:43384406	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs1814538	ENSG00000166763.7	STRCP1	-5.14	4e-07	5.49e-05	-0.31	-0.23	Lung cancer in ever smokers;	chr15:43467576	chr15:43699488~43718184:-
THCA	cis	rs860295	0.639	rs10908469	ENSG00000160766.13	GBAP1	-5.14	4e-07	5.49e-05	-0.27	-0.23	Body mass index;	chr1:155498941	chr1:155213821~155227422:-
THCA	cis	rs763121	0.853	rs4821798	ENSG00000235209.1	CTA-150C2.13	5.14	4e-07	5.49e-05	0.3	0.23	Menopause (age at onset);	chr22:38625160	chr22:38921227~38924708:+
THCA	cis	rs6951245	1	rs74785791	ENSG00000229043.2	AC091729.9	-5.14	4e-07	5.49e-05	-0.41	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs74366004	ENSG00000229043.2	AC091729.9	-5.14	4e-07	5.49e-05	-0.41	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs77702926	ENSG00000229043.2	AC091729.9	-5.14	4e-07	5.49e-05	-0.41	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.935	rs78573577	ENSG00000229043.2	AC091729.9	-5.14	4e-07	5.49e-05	-0.41	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs76129108	ENSG00000229043.2	AC091729.9	-5.14	4e-07	5.49e-05	-0.41	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs78523927	ENSG00000229043.2	AC091729.9	-5.14	4e-07	5.49e-05	-0.41	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1160374~1165267:+
THCA	cis	rs7809615	0.901	rs11973801	ENSG00000244219.5	GS1-259H13.2	-5.14	4e-07	5.49e-05	-0.41	-0.23	Blood metabolite ratios;	chr7:99505288	chr7:99598066~99610813:+
THCA	cis	rs2282300	0.739	rs1765139	ENSG00000242353.1	RP4-710M3.1	-5.14	4e-07	5.5e-05	-0.22	-0.23	Morning vs. evening chronotype;	chr11:30332178	chr11:30368148~30368646:+
THCA	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-5.14	4e-07	5.5e-05	-0.27	-0.23	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
THCA	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	5.14	4e-07	5.5e-05	0.27	0.23	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
THCA	cis	rs10904908	0.965	rs12259979	ENSG00000229124.5	VIM-AS1	-5.14	4e-07	5.5e-05	-0.23	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17225070	chr10:17214239~17229985:-
THCA	cis	rs7772486	0.659	rs9376957	ENSG00000270638.1	RP3-466P17.1	-5.14	4e-07	5.5e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs9497396	ENSG00000270638.1	RP3-466P17.1	-5.14	4e-07	5.5e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145735570~145737218:+
THCA	cis	rs17123764	1	rs11833411	ENSG00000257464.1	RP11-161H23.8	-5.14	4e-07	5.5e-05	-0.37	-0.23	Intelligence (multi-trait analysis);	chr12:49606604	chr12:49442424~49442652:-
THCA	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-5.14	4e-07	5.5e-05	-0.28	-0.23	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
THCA	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	5.14	4e-07	5.5e-05	0.13	0.23	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	5.14	4e-07	5.5e-05	0.13	0.23	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	5.14	4.01e-07	5.5e-05	0.13	0.23	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	5.14	4.01e-07	5.5e-05	0.13	0.23	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
THCA	cis	rs4950322	0.542	rs4950384	ENSG00000180867.10	PDIA3P1	5.14	4.01e-07	5.5e-05	0.23	0.23	Protein quantitative trait loci;	chr1:147177310	chr1:147178113~147179622:+
THCA	cis	rs7713065	0.531	rs2522051	ENSG00000224431.1	AC063976.7	5.14	4.01e-07	5.51e-05	0.19	0.23	Lung function (FEV1/FVC);	chr5:132461886	chr5:132199456~132203487:+
THCA	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	5.14	4.01e-07	5.51e-05	0.13	0.23	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	5.14	4.01e-07	5.51e-05	0.13	0.23	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
THCA	cis	rs2243480	1	rs7778911	ENSG00000230295.1	RP11-458F8.2	5.14	4.01e-07	5.51e-05	0.28	0.23	Diabetic kidney disease;	chr7:66229519	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs1979823	ENSG00000230295.1	RP11-458F8.2	5.14	4.01e-07	5.51e-05	0.28	0.23	Diabetic kidney disease;	chr7:66239626	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6964245	ENSG00000230295.1	RP11-458F8.2	5.14	4.01e-07	5.51e-05	0.28	0.23	Diabetic kidney disease;	chr7:66253730	chr7:66880708~66882981:+
THCA	cis	rs2337406	0.778	rs56658355	ENSG00000274576.2	IGHV2-70	-5.14	4.01e-07	5.51e-05	-0.2	-0.23	Alzheimer's disease (late onset);	chr14:106662151	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.925	rs10131226	ENSG00000274576.2	IGHV2-70	-5.14	4.01e-07	5.51e-05	-0.2	-0.23	Alzheimer's disease (late onset);	chr14:106665764	chr14:106770577~106771020:-
THCA	cis	rs7045881	1	rs7045881	ENSG00000254396.1	RP11-56F10.3	-5.14	4.01e-07	5.51e-05	-0.32	-0.23	Schizophrenia;	chr9:26935998	chr9:27102630~27104728:+
THCA	cis	rs853679	0.546	rs34676049	ENSG00000226314.6	ZNF192P1	-5.14	4.01e-07	5.51e-05	-0.53	-0.23	Depression;	chr6:28485841	chr6:28161781~28169594:+
THCA	cis	rs7394190	0.63	rs78845904	ENSG00000271816.1	BMS1P4	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73757491	chr10:73699151~73730487:-
THCA	cis	rs35160687	0.623	rs35408390	ENSG00000273080.1	RP11-301O19.1	-5.14	4.01e-07	5.51e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86244659	chr2:86195590~86196049:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65916269	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65918212	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65922114	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65923503	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65925372	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65925938	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65940221	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65943626	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65944004	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000230295.1	RP11-458F8.2	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65944182	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000230295.1	RP11-458F8.2	5.14	4.01e-07	5.51e-05	0.28	0.23	Diabetic kidney disease;	chr7:65928187	chr7:66880708~66882981:+
THCA	cis	rs875971	0.597	rs11763224	ENSG00000232546.1	RP11-458F8.1	5.14	4.01e-07	5.51e-05	0.22	0.23	Aortic root size;	chr7:66518628	chr7:66848496~66858136:+
THCA	cis	rs2803122	0.871	rs10733360	ENSG00000273226.1	RP11-513M16.8	-5.14	4.01e-07	5.51e-05	-0.21	-0.23	Pulse pressure;	chr9:19221580	chr9:19375451~19375996:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000182722.5	SEPHS1P1	-5.14	4.01e-07	5.51e-05	-0.28	-0.23	Calcium levels;	chr7:65825628	chr7:64852397~64853354:-
THCA	cis	rs5758659	0.904	rs5758653	ENSG00000281538.1	RP4-669P10.20	5.14	4.01e-07	5.51e-05	0.22	0.23	Cognitive function;	chr22:42217479	chr22:42138060~42139726:+
THCA	cis	rs1799922	0.708	rs339054	ENSG00000271553.1	RP11-274B21.10	5.14	4.02e-07	5.52e-05	0.18	0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128742457	chr7:128667043~128668156:+
THCA	cis	rs9283706	0.623	rs3857275	ENSG00000229666.1	MAST4-AS1	-5.14	4.02e-07	5.52e-05	-0.3	-0.23	Coronary artery disease;	chr5:67019708	chr5:67001383~67003953:-
THCA	cis	rs795484	0.856	rs1699160	ENSG00000275409.1	RP11-131L12.4	-5.14	4.02e-07	5.52e-05	-0.2	-0.23	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118318531	chr12:118430147~118430699:+
THCA	cis	rs11121022	0.965	rs11121021	ENSG00000269925.1	RP3-467L1.6	-5.14	4.02e-07	5.52e-05	-0.24	-0.23	Morning vs. evening chronotype;	chr1:7775639	chr1:7776383~7776775:+
THCA	cis	rs8141529	0.748	rs132531	ENSG00000272858.1	CTA-292E10.8	5.14	4.02e-07	5.52e-05	0.24	0.23	Lymphocyte counts;	chr22:28901377	chr22:28814914~28815662:+
THCA	cis	rs12893668	0.663	rs12889731	ENSG00000269958.1	RP11-73M18.8	5.14	4.02e-07	5.52e-05	0.23	0.23	Reticulocyte count;	chr14:103621145	chr14:103696353~103697163:+
THCA	cis	rs2243480	1	rs781142	ENSG00000164669.11	INTS4P1	5.14	4.02e-07	5.52e-05	0.44	0.23	Diabetic kidney disease;	chr7:65973791	chr7:65141225~65234216:+
THCA	cis	rs11992162	0.967	rs4841661	ENSG00000227888.4	FAM66A	5.14	4.02e-07	5.52e-05	0.29	0.23	Monocyte count;	chr8:11975260	chr8:12362019~12388296:+
THCA	cis	rs11992162	1	rs11994417	ENSG00000227888.4	FAM66A	5.14	4.02e-07	5.52e-05	0.29	0.23	Monocyte count;	chr8:11975753	chr8:12362019~12388296:+
THCA	cis	rs2235642	0.928	rs1057610	ENSG00000280231.1	LA16c-380F5.3	-5.14	4.02e-07	5.53e-05	-0.28	-0.23	Coronary artery disease;	chr16:1555536	chr16:1553655~1554130:-
THCA	cis	rs10256972	0.621	rs2280725	ENSG00000225146.1	AC073957.15	5.14	4.03e-07	5.53e-05	0.24	0.23	Endometriosis;Longevity;	chr7:1047790	chr7:1029025~1043891:+
THCA	cis	rs7429990	0.833	rs6777632	ENSG00000228638.1	FCF1P2	5.14	4.03e-07	5.53e-05	0.22	0.23	Educational attainment (years of education);	chr3:47748775	chr3:48290793~48291375:-
THCA	cis	rs1395	1	rs1659685	ENSG00000234072.1	AC074117.10	5.14	4.03e-07	5.53e-05	0.19	0.23	Blood metabolite levels;	chr2:27197822	chr2:27356246~27367622:+
THCA	cis	rs1395	1	rs1275522	ENSG00000234072.1	AC074117.10	5.14	4.03e-07	5.53e-05	0.19	0.23	Blood metabolite levels;	chr2:27204010	chr2:27356246~27367622:+
THCA	cis	rs1395	1	rs1275528	ENSG00000234072.1	AC074117.10	5.14	4.03e-07	5.53e-05	0.19	0.23	Blood metabolite levels;	chr2:27207913	chr2:27356246~27367622:+
THCA	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-5.14	4.03e-07	5.53e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
THCA	cis	rs240993	0.627	rs174389	ENSG00000255389.1	C6orf3	-5.14	4.03e-07	5.53e-05	-0.26	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111595190	chr6:111599875~111602295:+
THCA	cis	rs16852403	0.517	rs11584886	ENSG00000224687.1	RASAL2-AS1	5.14	4.03e-07	5.53e-05	0.35	0.23	Childhood ear infection;	chr1:178274227	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.517	rs1319918	ENSG00000224687.1	RASAL2-AS1	5.14	4.03e-07	5.53e-05	0.35	0.23	Childhood ear infection;	chr1:178274389	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.519	rs421767	ENSG00000224687.1	RASAL2-AS1	-5.14	4.03e-07	5.54e-05	-0.34	-0.23	Childhood ear infection;	chr1:178127787	chr1:178091508~178093984:-
THCA	cis	rs9876781	1	rs13076076	ENSG00000244380.1	RP11-24C3.2	5.14	4.03e-07	5.54e-05	0.27	0.23	Longevity;	chr3:48437629	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs9849509	ENSG00000244380.1	RP11-24C3.2	5.14	4.03e-07	5.54e-05	0.27	0.23	Longevity;	chr3:48442021	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs60512868	ENSG00000244380.1	RP11-24C3.2	5.14	4.03e-07	5.54e-05	0.27	0.23	Longevity;	chr3:48442035	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs7636044	ENSG00000244380.1	RP11-24C3.2	5.14	4.03e-07	5.54e-05	0.27	0.23	Longevity;	chr3:48443151	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs4490383	ENSG00000244380.1	RP11-24C3.2	5.14	4.03e-07	5.54e-05	0.27	0.23	Longevity;	chr3:48443275	chr3:48440352~48446656:-
THCA	cis	rs10186029	0.657	rs12612034	ENSG00000270659.1	RP11-105N14.1	-5.14	4.03e-07	5.54e-05	-0.19	-0.23	Systemic sclerosis;	chr2:213046397	chr2:213152970~213153659:+
THCA	cis	rs1552244	0.808	rs17032306	ENSG00000180385.7	EMC3-AS1	5.14	4.03e-07	5.54e-05	0.25	0.23	Alzheimer's disease;	chr3:10049715	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.938	rs7625049	ENSG00000180385.7	EMC3-AS1	5.14	4.03e-07	5.54e-05	0.25	0.23	Alzheimer's disease;	chr3:10073935	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs6782602	ENSG00000180385.7	EMC3-AS1	5.14	4.03e-07	5.54e-05	0.25	0.23	Alzheimer's disease;	chr3:10074857	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs35586456	ENSG00000180385.7	EMC3-AS1	5.14	4.03e-07	5.54e-05	0.25	0.23	Alzheimer's disease;	chr3:10075254	chr3:9986893~10006990:+
THCA	cis	rs8020095	0.571	rs7149905	ENSG00000258561.1	RP11-72M17.1	-5.14	4.03e-07	5.54e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:67032999	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs7145295	ENSG00000258561.1	RP11-72M17.1	-5.14	4.03e-07	5.54e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:67034010	chr14:66212810~66509394:-
THCA	cis	rs74233809	0.515	rs72841270	ENSG00000213277.3	MARCKSL1P1	5.14	4.04e-07	5.54e-05	0.32	0.23	Birth weight;	chr10:102882480	chr10:103175554~103176094:+
THCA	cis	rs7824557	0.767	rs4559208	ENSG00000154316.13	TDH	-5.14	4.04e-07	5.55e-05	-0.17	-0.23	Retinal vascular caliber;	chr8:11296416	chr8:11339637~11368452:+
THCA	cis	rs7045881	0.935	rs62544361	ENSG00000254396.1	RP11-56F10.3	5.14	4.04e-07	5.55e-05	0.34	0.23	Schizophrenia;	chr9:26797816	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.935	rs62544362	ENSG00000254396.1	RP11-56F10.3	5.14	4.04e-07	5.55e-05	0.34	0.23	Schizophrenia;	chr9:26797830	chr9:27102630~27104728:+
THCA	cis	rs13178541	0.745	rs6596262	ENSG00000250378.1	RP11-119J18.1	-5.14	4.04e-07	5.55e-05	-0.29	-0.23	IgG glycosylation;	chr5:135723983	chr5:135812667~135826582:+
THCA	cis	rs12143943	0.902	rs7541449	ENSG00000240219.1	RP11-430C7.5	5.14	4.04e-07	5.55e-05	0.2	0.23	Cognitive performance;	chr1:204609180	chr1:204626775~204629712:+
THCA	cis	rs6545883	0.894	rs778158	ENSG00000270820.4	RP11-355B11.2	-5.14	4.04e-07	5.55e-05	-0.19	-0.23	Tuberculosis;	chr2:61328286	chr2:61471188~61484130:+
THCA	cis	rs1962073	0.623	rs7459532	ENSG00000261451.1	RP11-981G7.1	-5.14	4.05e-07	5.55e-05	-0.27	-0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10403558	chr8:10433672~10438312:+
THCA	cis	rs1322639	0.614	rs6925201	ENSG00000261039.2	RP11-417E7.2	5.14	4.05e-07	5.56e-05	0.34	0.23	Pulse pressure;	chr6:169163262	chr6:169175304~169182740:-
THCA	cis	rs228614	0.509	rs223481	ENSG00000248971.2	KRT8P46	-5.14	4.05e-07	5.56e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102728746~102730171:-
THCA	cis	rs12101261	0.614	rs12437005	ENSG00000259167.2	NMNAT1P1	5.14	4.05e-07	5.56e-05	0.36	0.23	Graves' disease;	chr14:80997401	chr14:81032529~81033404:+
THCA	cis	rs875971	1	rs709597	ENSG00000223473.2	GS1-124K5.3	-5.14	4.05e-07	5.56e-05	-0.15	-0.23	Aortic root size;	chr7:66360996	chr7:66491049~66493566:-
THCA	cis	rs972578	0.765	rs7074	ENSG00000274717.1	RP1-47A17.1	-5.14	4.05e-07	5.56e-05	-0.24	-0.23	Mean platelet volume;	chr22:42869821	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs7073	ENSG00000274717.1	RP1-47A17.1	-5.14	4.05e-07	5.56e-05	-0.24	-0.23	Mean platelet volume;	chr22:42870357	chr22:42791814~42794313:-
THCA	cis	rs6686842	0.536	rs10493093	ENSG00000235358.1	RP11-399E6.1	-5.14	4.05e-07	5.56e-05	-0.3	-0.23	Height;	chr1:41236514	chr1:41242373~41284861:+
THCA	cis	rs6088580	0.634	rs6087577	ENSG00000276073.1	RP5-1125A11.7	-5.14	4.06e-07	5.57e-05	-0.2	-0.23	Glomerular filtration rate (creatinine);	chr20:34367617	chr20:33985617~33988989:-
THCA	cis	rs228614	0.509	rs223482	ENSG00000248971.2	KRT8P46	-5.14	4.06e-07	5.57e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102728746~102730171:-
THCA	cis	rs228614	0.536	rs223478	ENSG00000248971.2	KRT8P46	-5.14	4.06e-07	5.57e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102728746~102730171:-
THCA	cis	rs228614	0.536	rs150898	ENSG00000248971.2	KRT8P46	-5.14	4.06e-07	5.57e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102728746~102730171:-
THCA	cis	rs875971	0.545	rs2279757	ENSG00000232546.1	RP11-458F8.1	5.14	4.06e-07	5.57e-05	0.22	0.23	Aortic root size;	chr7:66363676	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000232546.1	RP11-458F8.1	5.14	4.06e-07	5.57e-05	0.22	0.23	Aortic root size;	chr7:66374173	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000232546.1	RP11-458F8.1	5.14	4.06e-07	5.57e-05	0.22	0.23	Aortic root size;	chr7:66387213	chr7:66848496~66858136:+
THCA	cis	rs7429990	0.965	rs7653368	ENSG00000228638.1	FCF1P2	-5.14	4.06e-07	5.57e-05	-0.22	-0.23	Educational attainment (years of education);	chr3:47943871	chr3:48290793~48291375:-
THCA	cis	rs481331	0.741	rs209381	ENSG00000215146.4	RP11-313J2.1	-5.14	4.06e-07	5.57e-05	-0.36	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42619112	chr10:42331866~42367974:-
THCA	cis	rs2288884	0.505	rs12459170	ENSG00000269483.1	AC006272.1	5.14	4.06e-07	5.57e-05	0.35	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51955005	chr19:51839924~51843324:-
THCA	cis	rs116095464	0.558	rs9654453	ENSG00000248925.1	CTD-2083E4.6	5.14	4.06e-07	5.57e-05	0.37	0.23	Breast cancer;	chr5:299506	chr5:269858~271516:-
THCA	cis	rs8141529	0.584	rs58004020	ENSG00000272858.1	CTA-292E10.8	-5.14	4.06e-07	5.57e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28861062	chr22:28814914~28815662:+
THCA	cis	rs6708331	0.517	rs12617812	ENSG00000179818.12	PCBP1-AS1	-5.14	4.06e-07	5.57e-05	-0.19	-0.23	Obesity-related traits;	chr2:70132339	chr2:69962263~70103220:-
THCA	cis	rs6708331	0.517	rs7599072	ENSG00000179818.12	PCBP1-AS1	-5.14	4.06e-07	5.57e-05	-0.19	-0.23	Obesity-related traits;	chr2:70132874	chr2:69962263~70103220:-
THCA	cis	rs6708331	0.517	rs12992553	ENSG00000179818.12	PCBP1-AS1	-5.14	4.06e-07	5.57e-05	-0.19	-0.23	Obesity-related traits;	chr2:70133130	chr2:69962263~70103220:-
THCA	cis	rs6708331	0.517	rs11890741	ENSG00000179818.12	PCBP1-AS1	-5.14	4.06e-07	5.57e-05	-0.19	-0.23	Obesity-related traits;	chr2:70133374	chr2:69962263~70103220:-
THCA	cis	rs987724	0.574	rs2321292	ENSG00000240875.4	LINC00886	-5.14	4.06e-07	5.57e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156925970	chr3:156747346~156817062:-
THCA	cis	rs4767841	0.874	rs10129003	ENSG00000248636.5	RP11-768F21.1	-5.14	4.06e-07	5.58e-05	-0.24	-0.23	Urgency urinary incontinence;	chr12:119759912	chr12:119387987~119668079:-
THCA	cis	rs10452033	0.6	rs6805246	ENSG00000242142.1	SERBP1P3	-5.14	4.06e-07	5.58e-05	-0.31	-0.23	Electrocardiographic traits;	chr3:53405947	chr3:53064283~53065091:-
THCA	cis	rs467650	0.817	rs977028	ENSG00000248489.1	CTD-2007H13.3	5.14	4.06e-07	5.58e-05	0.22	0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:98720804	chr5:98929171~98995013:+
THCA	cis	rs2945232	1	rs2945232	ENSG00000254153.1	CTA-398F10.2	-5.14	4.07e-07	5.58e-05	-0.24	-0.23	Schizophrenia;	chr8:8240516	chr8:8456909~8461337:-
THCA	cis	rs1005277	0.579	rs2504148	ENSG00000272983.1	RP11-508N22.12	5.14	4.07e-07	5.58e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs176886	ENSG00000272983.1	RP11-508N22.12	5.14	4.07e-07	5.58e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.557	rs176887	ENSG00000272983.1	RP11-508N22.12	5.14	4.07e-07	5.58e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474594	ENSG00000272983.1	RP11-508N22.12	5.14	4.07e-07	5.58e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs11011461	ENSG00000272983.1	RP11-508N22.12	5.14	4.07e-07	5.58e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38137337~38144399:+
THCA	cis	rs516805	0.561	rs2816094	ENSG00000279453.1	RP3-425C14.4	-5.14	4.07e-07	5.58e-05	-0.24	-0.23	Lymphocyte counts;	chr6:122077926	chr6:122436789~122439223:-
THCA	cis	rs516805	0.528	rs2816093	ENSG00000279453.1	RP3-425C14.4	-5.14	4.07e-07	5.58e-05	-0.24	-0.23	Lymphocyte counts;	chr6:122078123	chr6:122436789~122439223:-
THCA	cis	rs2360027	0.599	rs1324721	ENSG00000231365.4	RP11-418J17.1	-5.14	4.07e-07	5.58e-05	-0.24	-0.23	Tonsillectomy;	chr1:118539344	chr1:119140396~119275973:+
THCA	cis	rs2742234	0.541	rs10793427	ENSG00000273008.1	RP11-351D16.3	5.14	4.07e-07	5.58e-05	0.22	0.23	Hirschsprung disease;	chr10:43251995	chr10:43136824~43138334:-
THCA	cis	rs7809615	0.901	rs10215765	ENSG00000244219.5	GS1-259H13.2	-5.14	4.07e-07	5.59e-05	-0.41	-0.23	Blood metabolite ratios;	chr7:99503657	chr7:99598066~99610813:+
THCA	cis	rs7809615	0.901	rs10230784	ENSG00000244219.5	GS1-259H13.2	-5.14	4.07e-07	5.59e-05	-0.41	-0.23	Blood metabolite ratios;	chr7:99516049	chr7:99598066~99610813:+
THCA	cis	rs116095464	0.558	rs6866632	ENSG00000248925.1	CTD-2083E4.6	5.14	4.07e-07	5.59e-05	0.34	0.23	Breast cancer;	chr5:264314	chr5:269858~271516:-
THCA	cis	rs240993	0.715	rs9400483	ENSG00000271789.1	RP5-1112D6.7	5.14	4.08e-07	5.59e-05	0.27	0.23	Inflammatory skin disease;Psoriasis;	chr6:111535073	chr6:111297126~111298510:+
THCA	cis	rs925255	0.817	rs12624279	ENSG00000270210.1	RP11-373D23.3	-5.14	4.08e-07	5.59e-05	-0.25	-0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28411923	chr2:28425945~28426719:+
THCA	cis	rs7989336	0.69	rs4771934	ENSG00000247400.3	DNAJC3-AS1	-5.14	4.08e-07	5.59e-05	-0.14	-0.23	Obesity;	chr13:96341502	chr13:95648733~95676925:-
THCA	cis	rs57221529	0.608	rs11749927	ENSG00000225138.6	CTD-2228K2.7	5.14	4.08e-07	5.6e-05	0.29	0.23	Lung disease severity in cystic fibrosis;	chr5:668727	chr5:473236~480884:+
THCA	cis	rs6714710	0.58	rs35564270	ENSG00000230606.9	AC159540.1	-5.14	4.08e-07	5.6e-05	-0.26	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97985702	chr2:97416165~97433527:-
THCA	cis	rs2243480	1	rs465359	ENSG00000230295.1	RP11-458F8.2	-5.14	4.08e-07	5.6e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66093177	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs462853	ENSG00000230295.1	RP11-458F8.2	-5.14	4.08e-07	5.6e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66093180	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs160642	ENSG00000230295.1	RP11-458F8.2	-5.14	4.08e-07	5.6e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66093386	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000230295.1	RP11-458F8.2	-5.14	4.08e-07	5.6e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66100154	chr7:66880708~66882981:+
THCA	cis	rs12435908	1	rs10083525	ENSG00000276116.2	FUT8-AS1	5.14	4.08e-07	5.6e-05	0.36	0.23	Ischemic stroke;	chr14:65384838	chr14:65411170~65412690:-
THCA	cis	rs812925	0.537	rs778139	ENSG00000270820.4	RP11-355B11.2	-5.14	4.08e-07	5.6e-05	-0.19	-0.23	Immature fraction of reticulocytes;	chr2:61457429	chr2:61471188~61484130:+
THCA	cis	rs7267979	0.816	rs443009	ENSG00000125804.12	FAM182A	5.14	4.08e-07	5.6e-05	0.29	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26054655~26086917:+
THCA	cis	rs875971	0.545	rs73142265	ENSG00000232546.1	RP11-458F8.1	5.14	4.08e-07	5.6e-05	0.22	0.23	Aortic root size;	chr7:66234510	chr7:66848496~66858136:+
THCA	cis	rs3796352	1	rs34244302	ENSG00000242142.1	SERBP1P3	-5.14	4.09e-07	5.6e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53068220	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs13072457	ENSG00000242142.1	SERBP1P3	-5.14	4.09e-07	5.6e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53068373	chr3:53064283~53065091:-
THCA	cis	rs10129255	0.957	rs4387509	ENSG00000223648.3	IGHV3-64	5.14	4.09e-07	5.6e-05	0.15	0.23	Kawasaki disease;	chr14:106704386	chr14:106643132~106658258:-
THCA	cis	rs28735056	0.591	rs62101204	ENSG00000261126.6	RP11-795F19.1	5.14	4.09e-07	5.61e-05	0.19	0.23	Schizophrenia;	chr18:79952832	chr18:80046900~80095482:+
THCA	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-5.14	4.09e-07	5.61e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
THCA	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-5.14	4.09e-07	5.61e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
THCA	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-5.14	4.09e-07	5.61e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
THCA	cis	rs240993	0.812	rs383022	ENSG00000271789.1	RP5-1112D6.7	-5.14	4.09e-07	5.61e-05	-0.28	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111382506	chr6:111297126~111298510:+
THCA	cis	rs7989336	0.625	rs943824	ENSG00000247400.3	DNAJC3-AS1	5.14	4.09e-07	5.61e-05	0.15	0.23	Obesity;	chr13:96349417	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.511	rs7999958	ENSG00000247400.3	DNAJC3-AS1	5.14	4.09e-07	5.61e-05	0.15	0.23	Body mass index;	chr13:96353278	chr13:95648733~95676925:-
THCA	cis	rs7394190	0.935	rs6480708	ENSG00000271816.1	BMS1P4	-5.14	4.09e-07	5.61e-05	-0.25	-0.23	Incident atrial fibrillation;	chr10:73660356	chr10:73699151~73730487:-
THCA	cis	rs9813712	0.597	rs10934931	ENSG00000253540.4	FAM86HP	-5.14	4.09e-07	5.61e-05	-0.24	-0.23	Response to amphetamines;	chr3:130261365	chr3:130099092~130111472:-
THCA	cis	rs1707322	0.721	rs56255771	ENSG00000281133.1	AL355480.3	-5.14	4.09e-07	5.61e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45580892~45580996:-
THCA	cis	rs7267979	0.844	rs869358	ENSG00000125804.12	FAM182A	5.14	4.1e-07	5.61e-05	0.28	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26054655~26086917:+
THCA	cis	rs34779708	0.897	rs9787566	ENSG00000271335.4	RP11-324I22.4	5.14	4.1e-07	5.62e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4351760	ENSG00000271335.4	RP11-324I22.4	5.14	4.1e-07	5.62e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.898	rs4934695	ENSG00000271335.4	RP11-324I22.4	5.14	4.1e-07	5.62e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs11597483	ENSG00000271335.4	RP11-324I22.4	5.14	4.1e-07	5.62e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs35317849	ENSG00000271335.4	RP11-324I22.4	5.14	4.1e-07	5.62e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4934524	ENSG00000271335.4	RP11-324I22.4	5.14	4.1e-07	5.62e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35314552~35336401:-
THCA	cis	rs613391	0.612	rs618109	ENSG00000224549.1	RP11-370B11.3	-5.14	4.1e-07	5.62e-05	-0.26	-0.23	Quantitative traits;	chr9:22698066	chr9:22767175~22768316:+
THCA	cis	rs1552244	1	rs56270432	ENSG00000180385.7	EMC3-AS1	5.14	4.1e-07	5.62e-05	0.25	0.23	Alzheimer's disease;	chr3:10045833	chr3:9986893~10006990:+
THCA	cis	rs10129255	0.917	rs7142373	ENSG00000223648.3	IGHV3-64	5.14	4.1e-07	5.62e-05	0.15	0.23	Kawasaki disease;	chr14:106708947	chr14:106643132~106658258:-
THCA	cis	rs1020064	0.945	rs1030878	ENSG00000235319.1	AC012360.4	-5.14	4.1e-07	5.63e-05	-0.3	-0.23	AIDS;	chr2:105294141	chr2:105324210~105330529:+
THCA	cis	rs11096990	0.964	rs6835064	ENSG00000249685.1	RP11-360F5.3	-5.14	4.1e-07	5.63e-05	-0.29	-0.23	Cognitive function;	chr4:39264346	chr4:39133913~39135608:+
THCA	cis	rs73242632	1	rs3775083	ENSG00000269949.1	RP11-738E22.3	5.14	4.11e-07	5.63e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:57002020	chr4:56960927~56961373:-
THCA	cis	rs73242632	1	rs56798906	ENSG00000269949.1	RP11-738E22.3	5.14	4.11e-07	5.63e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:57009559	chr4:56960927~56961373:-
THCA	cis	rs73242632	1	rs28719609	ENSG00000269949.1	RP11-738E22.3	5.14	4.11e-07	5.63e-05	0.53	0.23	Congenital heart disease (maternal effect);	chr4:57015696	chr4:56960927~56961373:-
THCA	cis	rs972578	0.791	rs5759003	ENSG00000274717.1	RP1-47A17.1	-5.14	4.11e-07	5.63e-05	-0.24	-0.23	Mean platelet volume;	chr22:42868845	chr22:42791814~42794313:-
THCA	cis	rs2243480	1	rs1723269	ENSG00000230295.1	RP11-458F8.2	-5.14	4.11e-07	5.63e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66007799	chr7:66880708~66882981:+
THCA	cis	rs9876781	1	rs6794875	ENSG00000244380.1	RP11-24C3.2	5.14	4.11e-07	5.63e-05	0.28	0.23	Longevity;	chr3:48414217	chr3:48440352~48446656:-
THCA	cis	rs10510102	0.872	rs12264952	ENSG00000226864.1	ATE1-AS1	5.14	4.11e-07	5.63e-05	0.38	0.23	Breast cancer;	chr10:121885673	chr10:121928312~121951965:+
THCA	cis	rs2880765	0.835	rs4843063	ENSG00000259630.2	CTD-2262B20.1	-5.14	4.11e-07	5.63e-05	-0.25	-0.23	Coronary artery disease;	chr15:85505517	chr15:85415228~85415633:+
THCA	cis	rs7731390	0.614	rs11748773	ENSG00000233006.5	AC034220.3	5.14	4.11e-07	5.63e-05	0.3	0.23	IgG glycosylation;	chr5:132419069	chr5:132311285~132369916:-
THCA	cis	rs2120243	0.845	rs2305619	ENSG00000244515.1	KRT18P34	-5.14	4.11e-07	5.63e-05	-0.27	-0.23	Hepatocellular carcinoma in hepatitis B infection;	chr3:157437072	chr3:157162663~157163932:-
THCA	cis	rs17767392	0.834	rs61991190	ENSG00000259146.3	RP1-261D10.2	5.14	4.11e-07	5.64e-05	0.31	0.23	Mitral valve prolapse;	chr14:71270561	chr14:71292729~71321814:-
THCA	cis	rs10208649	0.572	rs10432674	ENSG00000272156.1	RP11-477N3.1	5.14	4.11e-07	5.64e-05	0.3	0.23	Body mass index;	chr2:53933145	chr2:54082554~54085066:+
THCA	cis	rs2439831	0.681	rs825740	ENSG00000205771.5	CATSPER2P1	-5.14	4.11e-07	5.64e-05	-0.3	-0.23	Lung cancer in ever smokers;	chr15:43300210	chr15:43726918~43747094:-
THCA	cis	rs34779708	0.966	rs1148245	ENSG00000271335.4	RP11-324I22.4	5.14	4.11e-07	5.64e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35314552~35336401:-
THCA	cis	rs17711722	0.503	rs453835	ENSG00000275400.1	RP4-756H11.5	5.14	4.12e-07	5.64e-05	0.23	0.23	Calcium levels;	chr7:66046172	chr7:66553805~66554199:-
THCA	cis	rs6088580	0.634	rs1890002	ENSG00000276073.1	RP5-1125A11.7	5.14	4.12e-07	5.64e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34331413	chr20:33985617~33988989:-
THCA	cis	rs28476539	0.568	rs13124143	ENSG00000270480.1	RP11-57B24.1	5.14	4.12e-07	5.64e-05	0.37	0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82638289	chr4:82691737~82692468:+
THCA	cis	rs4646450	0.891	rs11972285	ENSG00000244219.5	GS1-259H13.2	-5.14	4.12e-07	5.64e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99427968	chr7:99598066~99610813:+
THCA	cis	rs2797160	1	rs2747717	ENSG00000237742.5	RP11-624M8.1	5.14	4.12e-07	5.64e-05	0.2	0.23	Endometrial cancer;	chr6:125687289	chr6:125578558~125749190:-
THCA	cis	rs481331	0.741	rs683538	ENSG00000215146.4	RP11-313J2.1	-5.14	4.12e-07	5.65e-05	-0.37	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42653406	chr10:42331866~42367974:-
THCA	cis	rs7688540	0.771	rs10021364	ENSG00000211553.1	AC253576.2	5.14	4.12e-07	5.65e-05	0.36	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:136461~136568:+
THCA	cis	rs6686842	0.56	rs12408576	ENSG00000235358.1	RP11-399E6.1	-5.14	4.12e-07	5.65e-05	-0.31	-0.23	Height;	chr1:40998765	chr1:41242373~41284861:+
THCA	cis	rs6928977	0.932	rs6935146	ENSG00000231028.7	LINC00271	-5.14	4.13e-07	5.65e-05	-0.19	-0.23	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135306231	chr6:135497801~135716055:+
THCA	cis	rs7474896	1	rs9417268	ENSG00000263064.2	RP11-291L22.7	5.14	4.13e-07	5.66e-05	0.37	0.23	Obesity (extreme);	chr10:37844266	chr10:38448689~38448949:+
THCA	cis	rs972578	0.765	rs4822210	ENSG00000274717.1	RP1-47A17.1	-5.14	4.13e-07	5.66e-05	-0.24	-0.23	Mean platelet volume;	chr22:42868764	chr22:42791814~42794313:-
THCA	cis	rs748404	0.666	rs8027748	ENSG00000205771.5	CATSPER2P1	-5.14	4.13e-07	5.66e-05	-0.29	-0.23	Lung cancer;	chr15:43447622	chr15:43726918~43747094:-
THCA	cis	rs3213758	1	rs78578929	ENSG00000275191.1	RP11-36I17.2	-5.14	4.13e-07	5.66e-05	-0.46	-0.23	Vitiligo (non-segmental);	chr16:53547207	chr16:53628256~53628816:-
THCA	cis	rs6545883	0.895	rs2421192	ENSG00000270820.4	RP11-355B11.2	-5.14	4.13e-07	5.66e-05	-0.2	-0.23	Tuberculosis;	chr2:61416496	chr2:61471188~61484130:+
THCA	cis	rs1005277	0.579	rs1740735	ENSG00000275858.1	RP11-291L22.8	5.14	4.13e-07	5.66e-05	0.28	0.23	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38450738~38451069:-
THCA	cis	rs6430585	0.528	rs75667274	ENSG00000231890.6	DARS-AS1	-5.14	4.13e-07	5.66e-05	-0.3	-0.23	Corneal structure;	chr2:135924916	chr2:135985176~136022593:+
THCA	cis	rs853679	1	rs7740487	ENSG00000272009.1	RP1-313I6.12	-5.14	4.13e-07	5.66e-05	-0.32	-0.23	Depression;	chr6:28248708	chr6:28078792~28081130:-
THCA	cis	rs853679	1	rs68141011	ENSG00000272009.1	RP1-313I6.12	-5.14	4.13e-07	5.66e-05	-0.32	-0.23	Depression;	chr6:28250019	chr6:28078792~28081130:-
THCA	cis	rs853679	1	rs13200462	ENSG00000272009.1	RP1-313I6.12	-5.14	4.13e-07	5.66e-05	-0.32	-0.23	Depression;	chr6:28250421	chr6:28078792~28081130:-
THCA	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-5.14	4.13e-07	5.66e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
THCA	cis	rs10888838	0.938	rs747753	ENSG00000198711.5	SSBP3-AS1	5.14	4.13e-07	5.66e-05	0.26	0.23	Mitochondrial DNA levels;	chr1:54216816	chr1:54236440~54239063:+
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000230295.1	RP11-458F8.2	-5.14	4.13e-07	5.66e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65892097	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs35391607	ENSG00000230295.1	RP11-458F8.2	-5.14	4.13e-07	5.66e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65895842	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs13220979	ENSG00000230295.1	RP11-458F8.2	-5.14	4.13e-07	5.66e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65898217	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs34974928	ENSG00000230295.1	RP11-458F8.2	-5.14	4.13e-07	5.66e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65899019	chr7:66880708~66882981:+
THCA	cis	rs11603691	0.551	rs67221365	ENSG00000254662.1	RP11-872D17.4	-5.14	4.14e-07	5.67e-05	-0.38	-0.23	Low high density lipoprotein cholesterol levels;	chr11:57242238	chr11:57325603~57327958:+
THCA	cis	rs7246657	0.653	rs10406612	ENSG00000226686.6	LINC01535	-5.14	4.14e-07	5.67e-05	-0.41	-0.23	Coronary artery calcification;	chr19:37225709	chr19:37251912~37265535:+
THCA	cis	rs2067615	0.579	rs10746066	ENSG00000260329.1	RP11-412D9.4	-5.14	4.14e-07	5.67e-05	-0.21	-0.23	Heart rate;	chr12:106735330	chr12:106954029~106955497:-
THCA	cis	rs11673344	0.542	rs826324	ENSG00000276846.1	CTD-3220F14.3	5.14	4.14e-07	5.67e-05	0.18	0.23	Obesity-related traits;	chr19:37014343	chr19:37314868~37315620:-
THCA	cis	rs5015933	0.788	rs558352	ENSG00000232630.1	PRPS1P2	-5.14	4.14e-07	5.67e-05	-0.16	-0.23	Body mass index;	chr9:125258497	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.788	rs372225	ENSG00000232630.1	PRPS1P2	-5.14	4.14e-07	5.67e-05	-0.16	-0.23	Body mass index;	chr9:125261770	chr9:125150653~125151589:+
THCA	cis	rs258324	0.79	rs166297	ENSG00000260259.1	RP11-368I7.4	5.14	4.14e-07	5.67e-05	0.33	0.23	Height;	chr16:89664777	chr16:89682620~89686569:-
THCA	cis	rs6708331	0.54	rs28623550	ENSG00000179818.12	PCBP1-AS1	-5.14	4.14e-07	5.67e-05	-0.19	-0.23	Obesity-related traits;	chr2:70139260	chr2:69962263~70103220:-
THCA	cis	rs11051970	0.545	rs2651375	ENSG00000274964.1	RP11-817I4.1	5.13	4.14e-07	5.67e-05	0.23	0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32429718	chr12:32339368~32340724:+
THCA	cis	rs3794924	0.925	rs71361329	ENSG00000266521.1	RP11-650P15.1	5.13	4.14e-07	5.68e-05	0.48	0.23	Survival in colon cancer;	chr18:31450028	chr18:31496645~31497195:-
THCA	cis	rs6570726	0.791	rs952406	ENSG00000270638.1	RP3-466P17.1	5.13	4.15e-07	5.68e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145735570~145737218:+
THCA	cis	rs1707322	1	rs4074225	ENSG00000281133.1	AL355480.3	-5.13	4.15e-07	5.68e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4134387	ENSG00000281133.1	AL355480.3	-5.13	4.15e-07	5.68e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs10890376	ENSG00000281133.1	AL355480.3	-5.13	4.15e-07	5.68e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs10789485	ENSG00000281133.1	AL355480.3	-5.13	4.15e-07	5.68e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45580892~45580996:-
THCA	cis	rs7111546	0.625	rs17570703	ENSG00000246225.5	RP11-17A1.3	-5.13	4.15e-07	5.68e-05	-0.37	-0.23	Dialysis-related mortality;	chr11:22889074	chr11:22829380~22945393:+
THCA	cis	rs4950322	0.576	rs2353979	ENSG00000278811.3	LINC00624	-5.13	4.15e-07	5.68e-05	-0.25	-0.23	Protein quantitative trait loci;	chr1:147368185	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.576	rs2353980	ENSG00000278811.3	LINC00624	-5.13	4.15e-07	5.68e-05	-0.25	-0.23	Protein quantitative trait loci;	chr1:147368274	chr1:147258885~147517875:-
THCA	cis	rs9990333	0.562	rs55970879	ENSG00000273009.1	RP11-352G9.1	-5.13	4.15e-07	5.68e-05	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195913078~195913683:-
THCA	cis	rs9990333	0.562	rs75681503	ENSG00000273009.1	RP11-352G9.1	-5.13	4.15e-07	5.68e-05	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195913078~195913683:-
THCA	cis	rs7577696	0.962	rs212745	ENSG00000276334.1	AL133243.1	5.13	4.15e-07	5.69e-05	0.24	0.23	Inflammatory biomarkers;	chr2:32187763	chr2:32521927~32523547:+
THCA	cis	rs17767392	0.813	rs61991243	ENSG00000259146.3	RP1-261D10.2	5.13	4.15e-07	5.69e-05	0.28	0.23	Mitral valve prolapse;	chr14:71380400	chr14:71292729~71321814:-
THCA	cis	rs6920965	0.507	rs9385389	ENSG00000237742.5	RP11-624M8.1	-5.13	4.15e-07	5.69e-05	-0.21	-0.23	High light scatter reticulocyte count;	chr6:125894340	chr6:125578558~125749190:-
THCA	cis	rs748404	0.629	rs34657657	ENSG00000205771.5	CATSPER2P1	-5.13	4.15e-07	5.69e-05	-0.29	-0.23	Lung cancer;	chr15:43315763	chr15:43726918~43747094:-
THCA	cis	rs2243480	1	rs34702770	ENSG00000164669.11	INTS4P1	5.13	4.16e-07	5.69e-05	0.44	0.23	Diabetic kidney disease;	chr7:65879836	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs34637256	ENSG00000164669.11	INTS4P1	5.13	4.16e-07	5.69e-05	0.44	0.23	Diabetic kidney disease;	chr7:65895144	chr7:65141225~65234216:+
THCA	cis	rs3177980	0.639	rs12064636	ENSG00000239494.2	RN7SL333P	-5.13	4.16e-07	5.69e-05	-0.22	-0.23	Amyotrophic lateral sclerosis;	chr1:169838480	chr1:169859756~169860052:+
THCA	cis	rs1865760	0.534	rs2032444	ENSG00000272462.2	U91328.19	-5.13	4.16e-07	5.69e-05	-0.22	-0.23	Height;	chr6:26046516	chr6:25992662~26001775:+
THCA	cis	rs5015933	0.788	rs490978	ENSG00000232630.1	PRPS1P2	-5.13	4.16e-07	5.69e-05	-0.16	-0.23	Body mass index;	chr9:125265972	chr9:125150653~125151589:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000275400.1	RP4-756H11.5	-5.13	4.16e-07	5.7e-05	-0.23	-0.23	Calcium levels;	chr7:65829495	chr7:66553805~66554199:-
THCA	cis	rs2235642	0.893	rs2076440	ENSG00000280231.1	LA16c-380F5.3	-5.13	4.16e-07	5.7e-05	-0.27	-0.23	Coronary artery disease;	chr16:1537321	chr16:1553655~1554130:-
THCA	cis	rs9307551	0.584	rs4975053	ENSG00000250334.4	LINC00989	5.13	4.16e-07	5.7e-05	0.28	0.23	Refractive error;	chr4:79546733	chr4:79492416~79576460:+
THCA	cis	rs5758511	0.68	rs5758688	ENSG00000281538.1	RP4-669P10.20	-5.13	4.16e-07	5.7e-05	-0.26	-0.23	Birth weight;	chr22:42266495	chr22:42138060~42139726:+
THCA	cis	rs10200159	0.744	rs7586124	ENSG00000272606.1	RP11-554J4.1	5.13	4.16e-07	5.7e-05	0.44	0.23	Vitiligo;	chr2:55558165	chr2:55617909~55618373:+
THCA	cis	rs9300255	0.596	rs1568427	ENSG00000256092.2	RP13-942N8.1	5.13	4.16e-07	5.7e-05	0.18	0.23	Neutrophil percentage of white cells;	chr12:123254131	chr12:123363868~123366113:+
THCA	cis	rs9380516	0.56	rs1043805	ENSG00000228559.1	RP3-340B19.3	-5.13	4.16e-07	5.7e-05	-0.34	-0.23	Hepatitis C induced liver fibrosis;	chr6:35573655	chr6:35544632~35545669:+
THCA	cis	rs5751614	1	rs2283805	ENSG00000230701.2	FBXW4P1	5.13	4.16e-07	5.7e-05	0.22	0.23	Height;	chr22:23247755	chr22:23262767~23265005:+
THCA	cis	rs6832769	1	rs3805154	ENSG00000272969.1	RP11-528I4.2	5.13	4.16e-07	5.7e-05	0.27	0.23	Personality dimensions;	chr4:55497760	chr4:55547112~55547889:+
THCA	cis	rs9300255	0.55	rs10772997	ENSG00000256092.2	RP13-942N8.1	5.13	4.16e-07	5.7e-05	0.17	0.23	Neutrophil percentage of white cells;	chr12:123235333	chr12:123363868~123366113:+
THCA	cis	rs9300255	0.596	rs11057202	ENSG00000256092.2	RP13-942N8.1	5.13	4.16e-07	5.7e-05	0.17	0.23	Neutrophil percentage of white cells;	chr12:123236228	chr12:123363868~123366113:+
THCA	cis	rs9300255	0.566	rs10744150	ENSG00000256092.2	RP13-942N8.1	5.13	4.16e-07	5.7e-05	0.17	0.23	Neutrophil percentage of white cells;	chr12:123237067	chr12:123363868~123366113:+
THCA	cis	rs9300255	0.596	rs11057207	ENSG00000256092.2	RP13-942N8.1	5.13	4.16e-07	5.7e-05	0.17	0.23	Neutrophil percentage of white cells;	chr12:123246344	chr12:123363868~123366113:+
THCA	cis	rs11532322	1	rs11532322	ENSG00000256092.2	RP13-942N8.1	5.13	4.16e-07	5.7e-05	0.17	0.23	Schizophrenia;	chr12:123246876	chr12:123363868~123366113:+
THCA	cis	rs7474896	0.583	rs10740950	ENSG00000263064.2	RP11-291L22.7	5.13	4.17e-07	5.71e-05	0.31	0.23	Obesity (extreme);	chr10:37714568	chr10:38448689~38448949:+
THCA	cis	rs60695258	0.55	rs340641	ENSG00000251411.1	RP11-397E7.4	5.13	4.17e-07	5.71e-05	0.21	0.23	Hematocrit;	chr4:87030241	chr4:86913266~86914817:-
THCA	cis	rs9425766	0.628	rs6425274	ENSG00000227373.4	RP11-160H22.5	5.13	4.17e-07	5.71e-05	0.32	0.23	Life satisfaction;	chr1:174144270	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.566	rs6696076	ENSG00000227373.4	RP11-160H22.5	5.13	4.17e-07	5.71e-05	0.32	0.23	Life satisfaction;	chr1:174149900	chr1:174115300~174160004:-
THCA	cis	rs453301	0.653	rs1045529	ENSG00000254153.1	CTA-398F10.2	5.13	4.17e-07	5.71e-05	0.24	0.23	Joint mobility (Beighton score);	chr8:9032588	chr8:8456909~8461337:-
THCA	cis	rs12681287	0.64	rs4961193	ENSG00000254231.1	CTD-2284J15.1	-5.13	4.17e-07	5.71e-05	-0.25	-0.23	Caudate activity during reward;	chr8:86473939	chr8:86333274~86343314:-
THCA	cis	rs4784934	0.513	rs2042400	ENSG00000260186.4	RP11-481J2.2	5.13	4.17e-07	5.71e-05	0.31	0.23	QT interval;	chr16:58430436	chr16:58421326~58462470:+
THCA	cis	rs1865760	0.519	rs2275904	ENSG00000272462.2	U91328.19	-5.13	4.18e-07	5.72e-05	-0.2	-0.23	Height;	chr6:25767857	chr6:25992662~26001775:+
THCA	cis	rs7772486	0.623	rs9485021	ENSG00000270638.1	RP3-466P17.1	-5.13	4.18e-07	5.72e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145735570~145737218:+
THCA	cis	rs7474896	1	rs2753878	ENSG00000263064.2	RP11-291L22.7	-5.13	4.18e-07	5.72e-05	-0.37	-0.23	Obesity (extreme);	chr10:37882576	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2738223	ENSG00000263064.2	RP11-291L22.7	-5.13	4.18e-07	5.72e-05	-0.37	-0.23	Obesity (extreme);	chr10:37896970	chr10:38448689~38448949:+
THCA	cis	rs6728642	0.908	rs10203833	ENSG00000230606.9	AC159540.1	5.13	4.18e-07	5.72e-05	0.29	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97356336	chr2:97416165~97433527:-
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000259728.4	LINC00933	-5.13	4.18e-07	5.72e-05	-0.28	-0.23	P wave terminal force;	chr15:84635039	chr15:84570649~84580175:+
THCA	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-5.13	4.18e-07	5.72e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
THCA	cis	rs16958440	0.581	rs60726022	ENSG00000267800.1	RP11-49K24.5	-5.13	4.18e-07	5.72e-05	-0.45	-0.23	Sitting height ratio;	chr18:47153442	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.581	rs72907280	ENSG00000267800.1	RP11-49K24.5	-5.13	4.18e-07	5.72e-05	-0.45	-0.23	Sitting height ratio;	chr18:47154759	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.581	rs11872531	ENSG00000267800.1	RP11-49K24.5	-5.13	4.18e-07	5.72e-05	-0.45	-0.23	Sitting height ratio;	chr18:47162863	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.581	rs11875768	ENSG00000267800.1	RP11-49K24.5	-5.13	4.18e-07	5.72e-05	-0.45	-0.23	Sitting height ratio;	chr18:47162989	chr18:47137018~47137290:+
THCA	cis	rs16958440	0.581	rs11873880	ENSG00000267800.1	RP11-49K24.5	-5.13	4.18e-07	5.72e-05	-0.45	-0.23	Sitting height ratio;	chr18:47166094	chr18:47137018~47137290:+
THCA	cis	rs7088591	0.702	rs1930478	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58014969	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs1029918	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58016106	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs1029917	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58016207	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs1034183	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58016545	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs1475681	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58016572	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.702	rs1034184	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58016785	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs1475683	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58017004	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs16911622	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58017777	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs35991269	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58018467	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs35419144	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58018484	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.717	rs78574804	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58018548	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.571	rs74521286	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58018552	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs7077622	ENSG00000276818.1	AC026393.1	5.13	4.18e-07	5.73e-05	0.45	0.23	Blood pressure;	chr10:58018679	chr10:57095699~57095781:+
THCA	cis	rs10510102	0.935	rs12240893	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121870572	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200203	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121874014	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12243529	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121880321	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12250677	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121880575	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12243874	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121880788	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs7921873	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121881736	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12258426	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121882189	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12266380	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121882559	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200212	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121883145	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200213	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121883228	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12247749	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121884196	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12262776	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121884532	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12244866	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121886013	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12266597	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121886062	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12245018	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121886195	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200217	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121886372	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs10887008	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121886714	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12268872	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121887426	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs9630107	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121887713	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs10887010	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121888542	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12251175	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121889015	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs11200220	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121889949	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200221	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121890134	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs10887011	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121890203	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs10887012	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121890454	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs11200222	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121891177	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200223	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121891416	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs10887013	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121891546	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs11200225	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121891948	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200226	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121891988	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs7906667	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121909142	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs79360006	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121912856	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200252	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121914728	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12254184	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121914971	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200253	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121915114	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200254	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121915241	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs11200258	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121918392	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs12264495	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121919967	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs11200261	ENSG00000226864.1	ATE1-AS1	5.13	4.19e-07	5.73e-05	0.38	0.23	Breast cancer;	chr10:121921133	chr10:121928312~121951965:+
THCA	cis	rs2288884	0.559	rs2903710	ENSG00000269483.1	AC006272.1	5.13	4.19e-07	5.73e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:51839924~51843324:-
THCA	cis	rs7412746	0.658	rs10888397	ENSG00000231073.1	RP11-316M1.3	-5.13	4.19e-07	5.73e-05	-0.26	-0.23	Melanoma;	chr1:150914276	chr1:150973123~150975534:+
THCA	cis	rs613391	0.671	rs2784854	ENSG00000224549.1	RP11-370B11.3	-5.13	4.19e-07	5.73e-05	-0.26	-0.23	Quantitative traits;	chr9:22713834	chr9:22767175~22768316:+
THCA	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-5.13	4.19e-07	5.73e-05	-0.25	-0.23	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
THCA	cis	rs9921338	0.668	rs193779	ENSG00000262703.1	RP11-485G7.6	-5.13	4.19e-07	5.74e-05	-0.3	-0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11257108	chr16:11348143~11349321:-
THCA	cis	rs34779708	0.931	rs34087268	ENSG00000271335.4	RP11-324I22.4	5.13	4.19e-07	5.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs58159560	ENSG00000271335.4	RP11-324I22.4	5.13	4.19e-07	5.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35314552~35336401:-
THCA	cis	rs9867325	0.778	rs9877089	ENSG00000273486.1	RP11-731C17.2	5.13	4.19e-07	5.74e-05	0.25	0.23	Body mass index;	chr3:136937751	chr3:136837338~136839021:-
THCA	cis	rs916888	0.647	rs199523	ENSG00000261575.2	RP11-259G18.1	-5.13	4.2e-07	5.74e-05	-0.27	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46267037~46268694:+
THCA	cis	rs3796352	1	rs35720014	ENSG00000242142.1	SERBP1P3	-5.13	4.2e-07	5.74e-05	-0.45	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52948094	chr3:53064283~53065091:-
THCA	cis	rs481331	0.689	rs209392	ENSG00000215146.4	RP11-313J2.1	-5.13	4.2e-07	5.74e-05	-0.36	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42631193	chr10:42331866~42367974:-
THCA	cis	rs9990333	0.562	rs73210005	ENSG00000273009.1	RP11-352G9.1	-5.13	4.2e-07	5.75e-05	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195913078~195913683:-
THCA	cis	rs73242632	1	rs115267736	ENSG00000269949.1	RP11-738E22.3	5.13	4.2e-07	5.75e-05	0.55	0.23	Congenital heart disease (maternal effect);	chr4:56900757	chr4:56960927~56961373:-
THCA	cis	rs73242632	1	rs3755901	ENSG00000269949.1	RP11-738E22.3	5.13	4.2e-07	5.75e-05	0.55	0.23	Congenital heart disease (maternal effect);	chr4:56909830	chr4:56960927~56961373:-
THCA	cis	rs8141529	0.778	rs7287806	ENSG00000272858.1	CTA-292E10.8	-5.13	4.2e-07	5.75e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28817023	chr22:28814914~28815662:+
THCA	cis	rs9876781	0.933	rs6442124	ENSG00000244380.1	RP11-24C3.2	5.13	4.2e-07	5.75e-05	0.27	0.23	Longevity;	chr3:48463903	chr3:48440352~48446656:-
THCA	cis	rs2797160	1	rs1777195	ENSG00000237742.5	RP11-624M8.1	5.13	4.2e-07	5.75e-05	0.2	0.23	Endometrial cancer;	chr6:125685715	chr6:125578558~125749190:-
THCA	cis	rs4789693	0.546	rs7220204	ENSG00000260011.2	RP13-20L14.1	-5.13	4.21e-07	5.75e-05	-0.23	-0.23	Glucocorticoid-induced osteonecrosis;	chr17:82418254	chr17:82381110~82382690:-
THCA	cis	rs4950322	1	rs1806618	ENSG00000278811.3	LINC00624	5.13	4.21e-07	5.75e-05	0.3	0.23	Protein quantitative trait loci;	chr1:147377075	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.895	rs17356735	ENSG00000278811.3	LINC00624	5.13	4.21e-07	5.75e-05	0.3	0.23	Protein quantitative trait loci;	chr1:147378328	chr1:147258885~147517875:-
THCA	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-5.13	4.21e-07	5.76e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
THCA	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	5.13	4.21e-07	5.76e-05	0.28	0.23	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
THCA	cis	rs12143943	0.835	rs4951383	ENSG00000240219.1	RP11-430C7.5	5.13	4.21e-07	5.76e-05	0.2	0.23	Cognitive performance;	chr1:204483150	chr1:204626775~204629712:+
THCA	cis	rs6121246	0.697	rs6087716	ENSG00000230613.1	HM13-AS1	5.13	4.21e-07	5.76e-05	0.26	0.23	Mean corpuscular hemoglobin;	chr20:31641237	chr20:31567707~31573263:-
THCA	cis	rs8141529	0.748	rs2064261	ENSG00000272858.1	CTA-292E10.8	-5.13	4.21e-07	5.76e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28891742	chr22:28814914~28815662:+
THCA	cis	rs10200159	1	rs6545507	ENSG00000272606.1	RP11-554J4.1	5.13	4.21e-07	5.76e-05	0.46	0.23	Vitiligo;	chr2:55588756	chr2:55617909~55618373:+
THCA	cis	rs6832769	0.961	rs11735267	ENSG00000272969.1	RP11-528I4.2	5.13	4.21e-07	5.76e-05	0.27	0.23	Personality dimensions;	chr4:55481120	chr4:55547112~55547889:+
THCA	cis	rs7512898	0.5	rs10733063	ENSG00000260088.1	RP11-92G12.3	-5.13	4.21e-07	5.76e-05	-0.31	-0.23	Electrocardiographic conduction measures;	chr1:200821181	chr1:200669507~200694250:+
THCA	cis	rs2880765	0.835	rs6496027	ENSG00000259630.2	CTD-2262B20.1	-5.13	4.22e-07	5.77e-05	-0.25	-0.23	Coronary artery disease;	chr15:85506757	chr15:85415228~85415633:+
THCA	cis	rs4660456	0.504	rs587064	ENSG00000272145.1	NFYC-AS1	-5.13	4.22e-07	5.77e-05	-0.17	-0.23	Platelet count;	chr1:40640238	chr1:40690380~40692066:-
THCA	cis	rs1823913	0.637	rs4853574	ENSG00000280083.1	RP11-317J9.1	5.13	4.22e-07	5.77e-05	0.26	0.23	Obesity-related traits;	chr2:191296113	chr2:191154118~191156070:-
THCA	cis	rs10771431	0.597	rs7976807	ENSG00000111788.10	RP11-22B23.1	5.13	4.22e-07	5.77e-05	0.23	0.23	Breast size;	chr12:9199863	chr12:9277235~9313241:+
THCA	cis	rs11088226	0.581	rs2236430	ENSG00000186842.4	LINC00846	5.13	4.22e-07	5.78e-05	0.28	0.23	Gastritis;	chr21:32601098	chr21:32572238~32575881:-
THCA	cis	rs45509595	0.822	rs200484	ENSG00000226314.6	ZNF192P1	-5.13	4.23e-07	5.78e-05	-0.38	-0.23	Breast cancer;	chr6:27807896	chr6:28161781~28169594:+
THCA	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	5.13	4.23e-07	5.78e-05	0.17	0.23	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
THCA	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	5.13	4.23e-07	5.78e-05	0.17	0.23	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
THCA	cis	rs4660456	0.871	rs669072	ENSG00000272145.1	NFYC-AS1	-5.13	4.23e-07	5.78e-05	-0.16	-0.23	Platelet count;	chr1:40679946	chr1:40690380~40692066:-
THCA	cis	rs10844706	0.735	rs11052754	ENSG00000256594.6	RP11-705C15.2	5.13	4.23e-07	5.78e-05	0.2	0.23	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9736046	chr12:9633419~9658412:+
THCA	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	5.13	4.23e-07	5.78e-05	0.24	0.23	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
THCA	cis	rs7976269	0.609	rs11050010	ENSG00000275476.1	RP11-996F15.4	-5.13	4.23e-07	5.78e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29061952	chr12:29277397~29277882:-
THCA	cis	rs2067615	0.524	rs10778498	ENSG00000260329.1	RP11-412D9.4	-5.13	4.23e-07	5.78e-05	-0.22	-0.23	Heart rate;	chr12:106669562	chr12:106954029~106955497:-
THCA	cis	rs2288884	0.767	rs58329304	ENSG00000260160.1	CTC-471J1.2	-5.13	4.23e-07	5.78e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52031919	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.767	rs12460118	ENSG00000260160.1	CTC-471J1.2	-5.13	4.23e-07	5.78e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032550	chr19:52058490~52063703:-
THCA	cis	rs5015933	1	rs10760395	ENSG00000232630.1	PRPS1P2	-5.13	4.23e-07	5.78e-05	-0.15	-0.23	Body mass index;	chr9:125369582	chr9:125150653~125151589:+
THCA	cis	rs5015933	1	rs10760397	ENSG00000232630.1	PRPS1P2	-5.13	4.23e-07	5.78e-05	-0.15	-0.23	Body mass index;	chr9:125370928	chr9:125150653~125151589:+
THCA	cis	rs11915082	0.686	rs7349507	ENSG00000242086.7	LINC00969	5.13	4.23e-07	5.78e-05	0.24	0.23	Mean corpuscular hemoglobin;	chr3:196059617	chr3:195658062~195739964:+
THCA	cis	rs4784934	0.569	rs56139189	ENSG00000260186.4	RP11-481J2.2	5.13	4.23e-07	5.78e-05	0.31	0.23	QT interval;	chr16:58434186	chr16:58421326~58462470:+
THCA	cis	rs4950322	0.542	rs1932977	ENSG00000180867.10	PDIA3P1	5.13	4.23e-07	5.79e-05	0.21	0.23	Protein quantitative trait loci;	chr1:147217371	chr1:147178113~147179622:+
THCA	cis	rs4927850	0.501	rs9881504	ENSG00000273009.1	RP11-352G9.1	-5.13	4.23e-07	5.79e-05	-0.26	-0.23	Pancreatic cancer;	chr3:195929743	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.921	rs9877119	ENSG00000273009.1	RP11-352G9.1	-5.13	4.23e-07	5.79e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196075495	chr3:195913078~195913683:-
THCA	cis	rs16852403	0.517	rs316266	ENSG00000224687.1	RASAL2-AS1	-5.13	4.23e-07	5.79e-05	-0.34	-0.23	Childhood ear infection;	chr1:178133346	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.548	rs316269	ENSG00000224687.1	RASAL2-AS1	-5.13	4.23e-07	5.79e-05	-0.34	-0.23	Childhood ear infection;	chr1:178138727	chr1:178091508~178093984:-
THCA	cis	rs17301013	0.507	rs72713586	ENSG00000227373.4	RP11-160H22.5	5.13	4.23e-07	5.79e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174441265	chr1:174115300~174160004:-
THCA	cis	rs793571	0.505	rs9920042	ENSG00000245975.2	RP11-30K9.6	5.13	4.23e-07	5.79e-05	0.26	0.23	Schizophrenia;	chr15:58609197	chr15:58768072~58770974:-
THCA	cis	rs972578	0.668	rs4822207	ENSG00000274717.1	RP1-47A17.1	-5.13	4.24e-07	5.79e-05	-0.24	-0.23	Mean platelet volume;	chr22:42861255	chr22:42791814~42794313:-
THCA	cis	rs7674212	0.57	rs6810571	ENSG00000246560.2	RP11-10L12.4	5.13	4.24e-07	5.79e-05	0.27	0.23	Type 2 diabetes;	chr4:103165630	chr4:102828055~102844075:+
THCA	cis	rs7523875	0.572	rs17017441	ENSG00000153363.11	LINC00467	5.13	4.24e-07	5.79e-05	0.28	0.23	Mean corpuscular volume;	chr1:211379469	chr1:211382803~211435333:+
THCA	cis	rs12135996	0.592	rs2774279	ENSG00000232879.2	RP11-544M22.3	-5.13	4.24e-07	5.8e-05	-0.25	-0.23	Night sleep phenotypes;	chr1:161047766	chr1:161034834~161035006:+
THCA	cis	rs73108077	0.688	rs6058752	ENSG00000277112.2	RP11-755J8.1	-5.13	4.24e-07	5.8e-05	-0.36	-0.23	Red blood cell density in sickle cell anemia;	chr20:31353900	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.688	rs60840652	ENSG00000277112.2	RP11-755J8.1	-5.13	4.24e-07	5.8e-05	-0.36	-0.23	Red blood cell density in sickle cell anemia;	chr20:31354399	chr20:30681825~30723932:-
THCA	cis	rs6997458	0.652	rs7827051	ENSG00000253549.4	RP11-317J10.2	5.13	4.24e-07	5.8e-05	0.23	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85425619	chr8:85441851~85464915:-
THCA	cis	rs7512898	0.5	rs6691268	ENSG00000260088.1	RP11-92G12.3	-5.13	4.24e-07	5.8e-05	-0.31	-0.23	Electrocardiographic conduction measures;	chr1:200786938	chr1:200669507~200694250:+
THCA	cis	rs2797160	0.905	rs1418641	ENSG00000237742.5	RP11-624M8.1	-5.13	4.25e-07	5.8e-05	-0.2	-0.23	Endometrial cancer;	chr6:125678708	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.905	rs1418640	ENSG00000237742.5	RP11-624M8.1	-5.13	4.25e-07	5.8e-05	-0.2	-0.23	Endometrial cancer;	chr6:125678720	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1418639	ENSG00000237742.5	RP11-624M8.1	-5.13	4.25e-07	5.8e-05	-0.2	-0.23	Endometrial cancer;	chr6:125678794	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs4895798	ENSG00000237742.5	RP11-624M8.1	-5.13	4.25e-07	5.8e-05	-0.2	-0.23	Endometrial cancer;	chr6:125679016	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.967	rs8180614	ENSG00000237742.5	RP11-624M8.1	-5.13	4.25e-07	5.8e-05	-0.2	-0.23	Endometrial cancer;	chr6:125679453	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.935	rs60515555	ENSG00000237742.5	RP11-624M8.1	-5.13	4.25e-07	5.8e-05	-0.2	-0.23	Endometrial cancer;	chr6:125679492	chr6:125578558~125749190:-
THCA	cis	rs3734266	0.639	rs9469813	ENSG00000272288.4	RP11-140K17.3	-5.13	4.25e-07	5.81e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr6:34602037	chr6:34696317~34697470:+
THCA	cis	rs2243480	1	rs313824	ENSG00000230295.1	RP11-458F8.2	-5.13	4.25e-07	5.81e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66116220	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs186378	ENSG00000230295.1	RP11-458F8.2	-5.13	4.25e-07	5.81e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66117071	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs160637	ENSG00000230295.1	RP11-458F8.2	-5.13	4.25e-07	5.81e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66119331	chr7:66880708~66882981:+
THCA	cis	rs9311474	0.607	rs13076398	ENSG00000243224.1	RP5-1157M23.2	-5.13	4.25e-07	5.81e-05	-0.25	-0.23	Electroencephalogram traits;	chr3:52539080	chr3:52239258~52241097:+
THCA	cis	rs1125355	0.69	rs72937289	ENSG00000251491.2	OR7E28P	-5.13	4.25e-07	5.81e-05	-0.38	-0.23	Alzheimer's disease in APOE e4+ carriers;	chr2:158771000	chr2:158862311~158863285:+
THCA	cis	rs13178541	0.748	rs9327727	ENSG00000250378.1	RP11-119J18.1	-5.13	4.25e-07	5.81e-05	-0.3	-0.23	IgG glycosylation;	chr5:135725997	chr5:135812667~135826582:+
THCA	cis	rs16852403	0.548	rs482269	ENSG00000224687.1	RASAL2-AS1	-5.13	4.25e-07	5.81e-05	-0.34	-0.23	Childhood ear infection;	chr1:178257489	chr1:178091508~178093984:-
THCA	cis	rs16975963	0.644	rs112666969	ENSG00000226686.6	LINC01535	-5.13	4.25e-07	5.81e-05	-0.31	-0.23	Longevity;	chr19:37556743	chr19:37251912~37265535:+
THCA	cis	rs10761482	0.6	rs72807911	ENSG00000254271.1	RP11-131N11.4	-5.13	4.25e-07	5.81e-05	-0.31	-0.23	Schizophrenia;	chr10:60468530	chr10:60734342~60741828:+
THCA	cis	rs481331	0.669	rs2186178	ENSG00000215146.4	RP11-313J2.1	5.13	4.26e-07	5.81e-05	0.44	0.23	Systemic juvenile idiopathic arthritis;	chr10:42435111	chr10:42331866~42367974:-
THCA	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	5.13	4.26e-07	5.82e-05	0.27	0.23	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
THCA	cis	rs1005277	0.565	rs2474565	ENSG00000272983.1	RP11-508N22.12	5.13	4.26e-07	5.82e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38137337~38144399:+
THCA	cis	rs2303319	0.504	rs62189055	ENSG00000227403.1	AC009299.3	5.13	4.26e-07	5.82e-05	0.48	0.23	Cognitive function;	chr2:161769239	chr2:161244739~161249050:+
THCA	cis	rs34779708	0.931	rs79749947	ENSG00000271335.4	RP11-324I22.4	5.13	4.26e-07	5.82e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs9663401	ENSG00000271335.4	RP11-324I22.4	5.13	4.26e-07	5.82e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35314552~35336401:-
THCA	cis	rs8031584	0.541	rs2959037	ENSG00000270015.1	RP11-540B6.6	5.13	4.26e-07	5.82e-05	0.17	0.23	Huntington's disease progression;	chr15:30925961	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.505	rs2959036	ENSG00000270015.1	RP11-540B6.6	5.13	4.26e-07	5.82e-05	0.17	0.23	Huntington's disease progression;	chr15:30927539	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.541	rs2955777	ENSG00000270015.1	RP11-540B6.6	5.13	4.26e-07	5.82e-05	0.17	0.23	Huntington's disease progression;	chr15:30927585	chr15:30926514~30928407:+
THCA	cis	rs4683346	0.584	rs339731	ENSG00000173811.9	CCDC13-AS1	-5.13	4.26e-07	5.82e-05	-0.24	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42725867	chr3:42732575~42746768:+
THCA	cis	rs1552244	0.554	rs6786636	ENSG00000180385.7	EMC3-AS1	5.13	4.26e-07	5.82e-05	0.23	0.23	Alzheimer's disease;	chr3:10004019	chr3:9986893~10006990:+
THCA	cis	rs1005277	0.541	rs2505193	ENSG00000272983.1	RP11-508N22.12	5.13	4.26e-07	5.82e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474580	ENSG00000272983.1	RP11-508N22.12	5.13	4.26e-07	5.82e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38137337~38144399:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000273024.4	INTS4P2	-5.13	4.26e-07	5.82e-05	-0.26	-0.23	Calcium levels;	chr7:65829495	chr7:65647864~65715661:+
THCA	cis	rs412050	0.502	rs75034650	ENSG00000224086.5	LL22NC03-86G7.1	-5.13	4.26e-07	5.82e-05	-0.42	-0.23	Attention deficit hyperactivity disorder;	chr22:21823660	chr22:21938293~21977632:+
THCA	cis	rs899997	1	rs11632672	ENSG00000261143.1	ADAMTS7P3	5.13	4.26e-07	5.82e-05	0.31	0.23	Coronary artery disease or large artery stroke;	chr15:78751988	chr15:77976042~77993057:+
THCA	cis	rs2303319	0.504	rs16846073	ENSG00000227403.1	AC009299.3	5.13	4.26e-07	5.83e-05	0.43	0.23	Cognitive function;	chr2:161730038	chr2:161244739~161249050:+
THCA	cis	rs7727544	0.684	rs274560	ENSG00000263597.1	MIR3936	-5.13	4.27e-07	5.83e-05	-0.22	-0.23	Blood metabolite levels;	chr5:132383758	chr5:132365490~132365599:-
THCA	cis	rs11191419	1	rs11191419	ENSG00000236937.2	PTGES3P4	5.13	4.27e-07	5.83e-05	0.31	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102845595~102845950:+
THCA	cis	rs7045881	0.733	rs62546682	ENSG00000254396.1	RP11-56F10.3	5.13	4.27e-07	5.83e-05	0.42	0.23	Schizophrenia;	chr9:26947829	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.733	rs62546683	ENSG00000254396.1	RP11-56F10.3	5.13	4.27e-07	5.83e-05	0.42	0.23	Schizophrenia;	chr9:26947920	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.733	rs10511794	ENSG00000254396.1	RP11-56F10.3	5.13	4.27e-07	5.83e-05	0.42	0.23	Schizophrenia;	chr9:26948136	chr9:27102630~27104728:+
THCA	cis	rs7412746	0.611	rs12410869	ENSG00000231073.1	RP11-316M1.3	5.13	4.27e-07	5.83e-05	0.27	0.23	Melanoma;	chr1:150883677	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.611	rs36008098	ENSG00000231073.1	RP11-316M1.3	5.13	4.27e-07	5.83e-05	0.27	0.23	Melanoma;	chr1:150884330	chr1:150973123~150975534:+
THCA	cis	rs66823261	0.778	rs2906332	ENSG00000253166.2	RP11-585F1.6	-5.13	4.27e-07	5.83e-05	-0.34	-0.23	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:202660~202897:-
THCA	cis	rs972578	0.765	rs8141000	ENSG00000274717.1	RP1-47A17.1	-5.13	4.27e-07	5.84e-05	-0.24	-0.23	Mean platelet volume;	chr22:42819464	chr22:42791814~42794313:-
THCA	cis	rs6973609	0.524	rs10239070	ENSG00000271122.1	RP11-379H18.1	-5.13	4.27e-07	5.84e-05	-0.15	-0.23	Obesity-related traits;	chr7:35606934	chr7:35695214~35699413:+
THCA	cis	rs7924176	0.521	rs11001022	ENSG00000213731.2	RAB5CP1	-5.13	4.27e-07	5.84e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:74423435~74424014:-
THCA	cis	rs6714710	0.603	rs13008968	ENSG00000230606.9	AC159540.1	-5.13	4.28e-07	5.84e-05	-0.26	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97819519	chr2:97416165~97433527:-
THCA	cis	rs11846409	0.818	rs2516909	ENSG00000211974.3	IGHV2-70	5.13	4.28e-07	5.84e-05	0.22	0.23	Rheumatic heart disease;	chr14:106630317	chr14:106723574~106724093:-
THCA	cis	rs9818758	0.607	rs11706052	ENSG00000270441.1	RP11-694I15.7	5.13	4.28e-07	5.84e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49026677	chr3:49140086~49160851:-
THCA	cis	rs10510102	0.935	rs12255859	ENSG00000226864.1	ATE1-AS1	5.13	4.28e-07	5.84e-05	0.37	0.23	Breast cancer;	chr10:121831661	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.935	rs7923634	ENSG00000226864.1	ATE1-AS1	5.13	4.28e-07	5.84e-05	0.37	0.23	Breast cancer;	chr10:121832800	chr10:121928312~121951965:+
THCA	cis	rs7429990	0.864	rs12497826	ENSG00000228638.1	FCF1P2	5.13	4.28e-07	5.84e-05	0.22	0.23	Educational attainment (years of education);	chr3:47628059	chr3:48290793~48291375:-
THCA	cis	rs6569038	0.528	rs1762200	ENSG00000253194.1	RP11-351A11.1	5.13	4.28e-07	5.85e-05	0.32	0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119004753	chr6:118934785~119031541:+
THCA	cis	rs9425766	0.692	rs4652294	ENSG00000227373.4	RP11-160H22.5	5.13	4.28e-07	5.85e-05	0.32	0.23	Life satisfaction;	chr1:174272027	chr1:174115300~174160004:-
THCA	cis	rs7951911	1	rs733094	ENSG00000254427.1	RP11-430H10.1	5.13	4.28e-07	5.85e-05	0.34	0.23	IgG glycosylation;	chr11:45075680	chr11:45355371~45366121:+
THCA	cis	rs1577917	0.681	rs4707211	ENSG00000220563.1	PKMP3	5.13	4.28e-07	5.85e-05	0.17	0.23	Response to antipsychotic treatment;	chr6:85522992	chr6:85659892~85660606:-
THCA	cis	rs1005277	0.579	rs1985707	ENSG00000272983.1	RP11-508N22.12	5.13	4.28e-07	5.85e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38137337~38144399:+
THCA	cis	rs60695258	0.594	rs6531946	ENSG00000251411.1	RP11-397E7.4	-5.13	4.28e-07	5.85e-05	-0.21	-0.23	Hematocrit;	chr4:87044239	chr4:86913266~86914817:-
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000230295.1	RP11-458F8.2	-5.13	4.29e-07	5.85e-05	-0.26	-0.23	Diabetic kidney disease;	chr7:65988305	chr7:66880708~66882981:+
THCA	cis	rs1823913	0.926	rs12615901	ENSG00000227542.1	AC092614.2	-5.13	4.29e-07	5.86e-05	-0.28	-0.23	Obesity-related traits;	chr2:191233381	chr2:191229165~191246172:-
THCA	cis	rs9309473	0.519	rs13022145	ENSG00000163016.8	ALMS1P	-5.13	4.29e-07	5.86e-05	-0.29	-0.23	Metabolite levels;	chr2:73636346	chr2:73644919~73685576:+
THCA	cis	rs7617773	0.78	rs3197223	ENSG00000199476.1	Y_RNA	-5.13	4.29e-07	5.86e-05	-0.3	-0.23	Coronary artery disease;	chr3:48294367	chr3:48288587~48288694:+
THCA	cis	rs9467773	1	rs1078679	ENSG00000261353.1	CTA-14H9.5	-5.13	4.29e-07	5.86e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6932156	ENSG00000261353.1	CTA-14H9.5	-5.13	4.29e-07	5.86e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6924838	ENSG00000261353.1	CTA-14H9.5	-5.13	4.29e-07	5.86e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs6925895	ENSG00000261353.1	CTA-14H9.5	-5.13	4.29e-07	5.86e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26527063~26527404:+
THCA	cis	rs6545883	0.895	rs7588814	ENSG00000270820.4	RP11-355B11.2	5.13	4.29e-07	5.86e-05	0.2	0.23	Tuberculosis;	chr2:61468454	chr2:61471188~61484130:+
THCA	cis	rs6688613	0.579	rs4657609	ENSG00000225171.2	DUTP6	-5.13	4.29e-07	5.86e-05	-0.32	-0.23	Refractive astigmatism;	chr1:166869937	chr1:166868748~166869209:+
THCA	cis	rs721917	0.531	rs2256703	ENSG00000242600.5	MBL1P	5.13	4.29e-07	5.86e-05	0.2	0.23	Chronic obstructive pulmonary disease;	chr10:79924588	chr10:79904898~79950336:+
THCA	cis	rs2797160	0.967	rs2747718	ENSG00000237742.5	RP11-624M8.1	5.13	4.29e-07	5.86e-05	0.2	0.23	Endometrial cancer;	chr6:125687963	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2747719	ENSG00000237742.5	RP11-624M8.1	5.13	4.29e-07	5.86e-05	0.2	0.23	Endometrial cancer;	chr6:125688068	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2797158	ENSG00000237742.5	RP11-624M8.1	5.13	4.29e-07	5.86e-05	0.2	0.23	Endometrial cancer;	chr6:125688252	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2747720	ENSG00000237742.5	RP11-624M8.1	5.13	4.29e-07	5.86e-05	0.2	0.23	Endometrial cancer;	chr6:125688312	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.967	rs2797159	ENSG00000237742.5	RP11-624M8.1	5.13	4.29e-07	5.86e-05	0.2	0.23	Endometrial cancer;	chr6:125688411	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2747722	ENSG00000237742.5	RP11-624M8.1	5.13	4.29e-07	5.86e-05	0.2	0.23	Endometrial cancer;	chr6:125688483	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs2797160	ENSG00000237742.5	RP11-624M8.1	5.13	4.29e-07	5.86e-05	0.2	0.23	Endometrial cancer;	chr6:125688970	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.967	rs2797162	ENSG00000237742.5	RP11-624M8.1	5.13	4.29e-07	5.86e-05	0.2	0.23	Endometrial cancer;	chr6:125690235	chr6:125578558~125749190:-
THCA	cis	rs8141529	0.719	rs9625619	ENSG00000272858.1	CTA-292E10.8	-5.13	4.29e-07	5.86e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28876340	chr22:28814914~28815662:+
THCA	cis	rs1005277	0.579	rs176880	ENSG00000272983.1	RP11-508N22.12	-5.13	4.29e-07	5.86e-05	-0.2	-0.23	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38137337~38144399:+
THCA	cis	rs4650994	0.816	rs2093770	ENSG00000273384.1	RP5-1098D14.1	-5.13	4.3e-07	5.87e-05	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178635498	chr1:178651706~178652282:+
THCA	cis	rs12413361	0.56	rs7084828	ENSG00000272914.1	RP11-330O11.3	5.13	4.3e-07	5.87e-05	0.21	0.23	Height;	chr10:30829136	chr10:30831828~30833387:-
THCA	cis	rs17798991	0.721	rs11082767	ENSG00000267674.1	RP11-813F20.2	-5.13	4.3e-07	5.87e-05	-0.25	-0.23	Obesity-related traits;	chr18:49606949	chr18:49739823~49742063:-
THCA	cis	rs9283706	0.623	rs1567316	ENSG00000229666.1	MAST4-AS1	-5.13	4.3e-07	5.87e-05	-0.31	-0.23	Coronary artery disease;	chr5:67016275	chr5:67001383~67003953:-
THCA	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-5.13	4.3e-07	5.88e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-5.13	4.3e-07	5.88e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
THCA	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-5.13	4.3e-07	5.88e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-5.13	4.3e-07	5.88e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-5.13	4.3e-07	5.88e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-5.13	4.3e-07	5.88e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000223473.2	GS1-124K5.3	-5.13	4.3e-07	5.88e-05	-0.15	-0.23	Aortic root size;	chr7:66039646	chr7:66491049~66493566:-
THCA	cis	rs8022179	0.566	rs62006258	ENSG00000244691.1	RPL10AP1	5.13	4.31e-07	5.88e-05	0.33	0.23	Monocyte count;	chr14:103372572	chr14:103412119~103412761:-
THCA	cis	rs2692947	0.77	rs2315417	ENSG00000232931.4	LINC00342	5.13	4.31e-07	5.88e-05	0.19	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95834541	chr2:95807118~95816215:-
THCA	cis	rs2439831	0.867	rs2243434	ENSG00000205771.5	CATSPER2P1	-5.13	4.31e-07	5.88e-05	-0.31	-0.23	Lung cancer in ever smokers;	chr15:43397669	chr15:43726918~43747094:-
THCA	cis	rs4443100	0.916	rs9612218	ENSG00000230701.2	FBXW4P1	5.13	4.31e-07	5.89e-05	0.28	0.23	Serum parathyroid hormone levels;	chr22:23039637	chr22:23262767~23265005:+
THCA	cis	rs1552244	1	rs7648104	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10031627	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs113771705	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10034299	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs111392584	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10034307	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs17032276	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10035291	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs17032277	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10035339	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs17032278	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10036271	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs66797209	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10036842	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs7631678	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10037132	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs7637888	ENSG00000180385.7	EMC3-AS1	5.13	4.31e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10039038	chr3:9986893~10006990:+
THCA	cis	rs5758659	1	rs5758659	ENSG00000281538.1	RP4-669P10.20	5.13	4.32e-07	5.89e-05	0.22	0.23	Cognitive function;	chr22:42225997	chr22:42138060~42139726:+
THCA	cis	rs131777	0.526	rs86337	ENSG00000272940.1	CTA-384D8.33	5.13	4.32e-07	5.89e-05	0.33	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50597152~50597599:+
THCA	cis	rs7119	0.717	rs11634174	ENSG00000259362.2	RP11-307C19.1	-5.13	4.32e-07	5.89e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77518890	chr15:77525540~77534110:+
THCA	cis	rs4650994	1	rs4077194	ENSG00000273384.1	RP5-1098D14.1	-5.13	4.32e-07	5.89e-05	-0.28	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178564697	chr1:178651706~178652282:+
THCA	cis	rs1552244	1	rs2272125	ENSG00000180385.7	EMC3-AS1	5.13	4.32e-07	5.89e-05	0.25	0.23	Alzheimer's disease;	chr3:10096385	chr3:9986893~10006990:+
THCA	cis	rs757978	0.81	rs2055569	ENSG00000223374.1	AC005104.3	5.13	4.32e-07	5.89e-05	0.23	0.23	Chronic lymphocytic leukemia;	chr2:241462024	chr2:241351340~241353104:-
THCA	cis	rs6430585	0.702	rs73958637	ENSG00000231890.6	DARS-AS1	-5.13	4.32e-07	5.9e-05	-0.28	-0.23	Corneal structure;	chr2:135789357	chr2:135985176~136022593:+
THCA	cis	rs752010	0.523	rs10890160	ENSG00000230638.4	RP11-486B10.4	-5.13	4.32e-07	5.9e-05	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41654340	chr1:41542069~41544310:+
THCA	cis	rs28476539	0.64	rs17005891	ENSG00000270480.1	RP11-57B24.1	5.13	4.32e-07	5.9e-05	0.38	0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82626709	chr4:82691737~82692468:+
THCA	cis	rs1577917	0.655	rs12203963	ENSG00000220563.1	PKMP3	5.13	4.32e-07	5.9e-05	0.17	0.23	Response to antipsychotic treatment;	chr6:85513598	chr6:85659892~85660606:-
THCA	cis	rs62025270	0.522	rs338519	ENSG00000202081.1	RNU6-1280P	-5.13	4.32e-07	5.9e-05	-0.32	-0.23	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85651522~85651628:-
THCA	cis	rs7429990	0.833	rs3755637	ENSG00000228638.1	FCF1P2	5.13	4.32e-07	5.9e-05	0.22	0.23	Educational attainment (years of education);	chr3:47580720	chr3:48290793~48291375:-
THCA	cis	rs34779708	0.931	rs4934697	ENSG00000271335.4	RP11-324I22.4	5.13	4.32e-07	5.9e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35314552~35336401:-
THCA	cis	rs9921338	0.636	rs56069754	ENSG00000262703.1	RP11-485G7.6	-5.13	4.33e-07	5.9e-05	-0.31	-0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11268783	chr16:11348143~11349321:-
THCA	cis	rs34779708	0.966	rs4934735	ENSG00000271335.4	RP11-324I22.4	-5.13	4.33e-07	5.9e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35314552~35336401:-
THCA	cis	rs2797160	1	rs1418951	ENSG00000237742.5	RP11-624M8.1	-5.13	4.33e-07	5.91e-05	-0.2	-0.23	Endometrial cancer;	chr6:125675039	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1832980	ENSG00000237742.5	RP11-624M8.1	-5.13	4.33e-07	5.91e-05	-0.2	-0.23	Endometrial cancer;	chr6:125676298	chr6:125578558~125749190:-
THCA	cis	rs454217	0.74	rs373627	ENSG00000277851.1	RP11-756G20.1	5.13	4.33e-07	5.91e-05	0.23	0.23	Smoking quantity;	chr12:92325837	chr12:92247756~92363832:-
THCA	cis	rs7267979	0.873	rs6037062	ENSG00000277938.1	RP5-965G21.3	5.13	4.33e-07	5.91e-05	0.19	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25229150~25231933:+
THCA	cis	rs34779708	0.966	rs4934725	ENSG00000271335.4	RP11-324I22.4	5.13	4.33e-07	5.91e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35314552~35336401:-
THCA	cis	rs34779708	1	rs12769189	ENSG00000271335.4	RP11-324I22.4	5.13	4.33e-07	5.91e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs12774834	ENSG00000271335.4	RP11-324I22.4	5.13	4.33e-07	5.91e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs12775759	ENSG00000271335.4	RP11-324I22.4	5.13	4.33e-07	5.91e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs34296409	ENSG00000271335.4	RP11-324I22.4	5.13	4.33e-07	5.91e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs35777088	ENSG00000271335.4	RP11-324I22.4	5.13	4.33e-07	5.91e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs11592567	ENSG00000271335.4	RP11-324I22.4	5.13	4.33e-07	5.91e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35314552~35336401:-
THCA	cis	rs7246657	0.524	rs28542490	ENSG00000276846.1	CTD-3220F14.3	5.13	4.33e-07	5.91e-05	0.25	0.23	Coronary artery calcification;	chr19:36965682	chr19:37314868~37315620:-
THCA	cis	rs11096990	0.892	rs11931354	ENSG00000249685.1	RP11-360F5.3	-5.13	4.34e-07	5.92e-05	-0.29	-0.23	Cognitive function;	chr4:39229856	chr4:39133913~39135608:+
THCA	cis	rs889122	0.68	rs4804459	ENSG00000267289.1	CTD-2623N2.11	-5.13	4.34e-07	5.92e-05	-0.31	-0.23	Menarche (age at onset);	chr19:9834111	chr19:9834079~9835013:-
THCA	cis	rs9425766	0.655	rs6666767	ENSG00000227373.4	RP11-160H22.5	5.13	4.34e-07	5.92e-05	0.32	0.23	Life satisfaction;	chr1:174357564	chr1:174115300~174160004:-
THCA	cis	rs412050	0.501	rs2876980	ENSG00000224086.5	LL22NC03-86G7.1	5.13	4.34e-07	5.92e-05	0.41	0.23	Attention deficit hyperactivity disorder;	chr22:21752246	chr22:21938293~21977632:+
THCA	cis	rs1395	0.922	rs1561535	ENSG00000234072.1	AC074117.10	-5.13	4.34e-07	5.92e-05	-0.19	-0.23	Blood metabolite levels;	chr2:27248157	chr2:27356246~27367622:+
THCA	cis	rs7619708	1	rs7619708	ENSG00000207650.1	MIR570	-5.13	4.34e-07	5.92e-05	-0.29	-0.23	Red cell distribution width;	chr3:196083316	chr3:195699401~195699497:+
THCA	cis	rs2797160	1	rs1612249	ENSG00000237742.5	RP11-624M8.1	5.13	4.34e-07	5.92e-05	0.2	0.23	Endometrial cancer;	chr6:125693770	chr6:125578558~125749190:-
THCA	cis	rs4767841	1	rs7961569	ENSG00000248636.5	RP11-768F21.1	5.13	4.34e-07	5.93e-05	0.24	0.23	Urgency urinary incontinence;	chr12:119719540	chr12:119387987~119668079:-
THCA	cis	rs875971	0.545	rs6969224	ENSG00000232546.1	RP11-458F8.1	5.13	4.34e-07	5.93e-05	0.22	0.23	Aortic root size;	chr7:66370011	chr7:66848496~66858136:+
THCA	cis	rs6772849	0.931	rs60825080	ENSG00000242551.2	POU5F1P6	-5.13	4.34e-07	5.93e-05	-0.3	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128665991	chr3:128674735~128677005:-
THCA	cis	rs7914558	0.966	rs10883805	ENSG00000236937.2	PTGES3P4	5.13	4.34e-07	5.93e-05	0.3	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102948494	chr10:102845595~102845950:+
THCA	cis	rs1005277	0.579	rs2474567	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2472175	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2472176	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474568	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2983343	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474569	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.602	rs2504142	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2472181	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474574	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2504140	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474575	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2472182	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.541	rs2263163	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2021649	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2472183	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2505197	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2505196	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.557	rs1854563	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2505237	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474599	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2505240	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.54	rs2224248	ENSG00000272983.1	RP11-508N22.12	5.13	4.34e-07	5.93e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38137337~38144399:+
THCA	cis	rs6496932	0.503	rs7170085	ENSG00000259630.2	CTD-2262B20.1	-5.13	4.34e-07	5.93e-05	-0.29	-0.23	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85415228~85415633:+
THCA	cis	rs613391	0.796	rs622693	ENSG00000224549.1	RP11-370B11.3	5.13	4.35e-07	5.93e-05	0.26	0.23	Quantitative traits;	chr9:22681777	chr9:22767175~22768316:+
THCA	cis	rs62158800	0.778	rs57500779	ENSG00000237880.1	AC096669.2	5.13	4.35e-07	5.93e-05	0.36	0.23	Facial morphology (factor 22);	chr2:107545088	chr2:107385632~107542649:-
THCA	cis	rs1371614	0.566	rs11887401	ENSG00000229122.1	AGBL5-IT1	5.13	4.35e-07	5.93e-05	0.16	0.23	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26958244	chr2:27061038~27061815:+
THCA	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-5.13	4.35e-07	5.93e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
THCA	cis	rs9818758	0.556	rs116432667	ENSG00000270441.1	RP11-694I15.7	5.13	4.35e-07	5.93e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48910156	chr3:49140086~49160851:-
THCA	cis	rs8049040	0.502	rs35885273	ENSG00000260886.1	TAT-AS1	5.13	4.35e-07	5.93e-05	0.32	0.23	Blood protein levels;	chr16:71383880	chr16:71565789~71578187:+
THCA	cis	rs17767392	0.958	rs12894478	ENSG00000259146.3	RP1-261D10.2	5.13	4.35e-07	5.94e-05	0.3	0.23	Mitral valve prolapse;	chr14:71358396	chr14:71292729~71321814:-
THCA	cis	rs11096990	0.927	rs6845858	ENSG00000249685.1	RP11-360F5.3	-5.13	4.35e-07	5.94e-05	-0.3	-0.23	Cognitive function;	chr4:39237099	chr4:39133913~39135608:+
THCA	cis	rs17767392	0.881	rs7157241	ENSG00000259146.3	RP1-261D10.2	5.12	4.35e-07	5.94e-05	0.29	0.23	Mitral valve prolapse;	chr14:71534579	chr14:71292729~71321814:-
THCA	cis	rs10875746	0.669	rs17122812	ENSG00000258234.1	RP11-370I10.2	5.12	4.35e-07	5.94e-05	0.27	0.23	Longevity (90 years and older);	chr12:48203270	chr12:48231098~48284210:-
THCA	cis	rs1577917	0.655	rs2842605	ENSG00000220563.1	PKMP3	-5.12	4.36e-07	5.94e-05	-0.17	-0.23	Response to antipsychotic treatment;	chr6:85625432	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.655	rs2758848	ENSG00000220563.1	PKMP3	-5.12	4.36e-07	5.94e-05	-0.17	-0.23	Response to antipsychotic treatment;	chr6:85637887	chr6:85659892~85660606:-
THCA	cis	rs6993270	0.948	rs7007554	ENSG00000245330.4	KB-1471A8.1	-5.12	4.36e-07	5.94e-05	-0.27	-0.23	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119929713	chr8:119867419~119874488:-
THCA	cis	rs4650994	0.816	rs2811303	ENSG00000273384.1	RP5-1098D14.1	-5.12	4.36e-07	5.94e-05	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178626511	chr1:178651706~178652282:+
THCA	cis	rs987724	0.519	rs1875622	ENSG00000240875.4	LINC00886	-5.12	4.36e-07	5.94e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901217	chr3:156747346~156817062:-
THCA	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-5.12	4.36e-07	5.95e-05	-0.26	-0.23	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
THCA	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	5.12	4.36e-07	5.95e-05	0.27	0.23	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
THCA	cis	rs9652601	0.779	rs725613	ENSG00000274038.1	RP11-66H6.4	-5.12	4.36e-07	5.95e-05	-0.29	-0.23	Systemic lupus erythematosus;	chr16:11075826	chr16:11056556~11057034:+
THCA	cis	rs60695258	0.572	rs375795	ENSG00000251411.1	RP11-397E7.4	-5.12	4.36e-07	5.95e-05	-0.21	-0.23	Hematocrit;	chr4:87051313	chr4:86913266~86914817:-
THCA	cis	rs60695258	0.55	rs2007132	ENSG00000251411.1	RP11-397E7.4	-5.12	4.36e-07	5.95e-05	-0.21	-0.23	Hematocrit;	chr4:87051433	chr4:86913266~86914817:-
THCA	cis	rs60695258	0.55	rs6531948	ENSG00000251411.1	RP11-397E7.4	-5.12	4.36e-07	5.95e-05	-0.21	-0.23	Hematocrit;	chr4:87051816	chr4:86913266~86914817:-
THCA	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	5.12	4.36e-07	5.95e-05	0.27	0.23	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
THCA	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-5.12	4.36e-07	5.95e-05	-0.27	-0.23	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
THCA	cis	rs7772486	0.654	rs6928007	ENSG00000270638.1	RP3-466P17.1	-5.12	4.37e-07	5.95e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145735570~145737218:+
THCA	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	5.12	4.37e-07	5.95e-05	0.3	0.23	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	5.12	4.37e-07	5.95e-05	0.3	0.23	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	5.12	4.37e-07	5.95e-05	0.3	0.23	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
THCA	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	5.12	4.37e-07	5.95e-05	0.13	0.23	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
THCA	cis	rs9929218	0.559	rs55907909	ENSG00000260459.2	FTLP14	5.12	4.37e-07	5.96e-05	0.26	0.23	Colorectal cancer;	chr16:68771902	chr16:68822587~68823070:+
THCA	cis	rs9859260	0.616	rs9867473	ENSG00000231464.1	AC024937.4	5.12	4.37e-07	5.96e-05	0.3	0.23	Mean corpuscular volume;	chr3:196104227	chr3:195996738~195998233:+
THCA	cis	rs734999	0.87	rs3748825	ENSG00000225931.3	RP3-395M20.7	5.12	4.37e-07	5.96e-05	0.28	0.23	Ulcerative colitis;	chr1:2551831	chr1:2566410~2569888:+
THCA	cis	rs454217	0.74	rs430709	ENSG00000277851.1	RP11-756G20.1	5.12	4.37e-07	5.96e-05	0.23	0.23	Smoking quantity;	chr12:92325836	chr12:92247756~92363832:-
THCA	cis	rs944289	0.74	rs10498332	ENSG00000258844.1	RP11-259K15.2	5.12	4.37e-07	5.96e-05	0.21	0.23	Thyroid cancer;	chr14:36102348	chr14:36214607~36235608:+
THCA	cis	rs375066	0.551	rs1565057	ENSG00000267058.1	RP11-15A1.3	5.12	4.38e-07	5.97e-05	0.19	0.23	Breast cancer;	chr19:43829040	chr19:43891804~43901805:-
THCA	cis	rs6545883	0.895	rs2442029	ENSG00000270820.4	RP11-355B11.2	5.12	4.38e-07	5.97e-05	0.2	0.23	Tuberculosis;	chr2:61452417	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.929	rs2256615	ENSG00000270820.4	RP11-355B11.2	5.12	4.38e-07	5.97e-05	0.2	0.23	Tuberculosis;	chr2:61452759	chr2:61471188~61484130:+
THCA	cis	rs4308124	1	rs62160391	ENSG00000227992.1	AC108463.2	-5.12	4.38e-07	5.97e-05	-0.29	-0.23	Vitiligo;	chr2:111251258	chr2:111203964~111206215:-
THCA	cis	rs60695258	0.517	rs867196	ENSG00000251411.1	RP11-397E7.4	-5.12	4.38e-07	5.97e-05	-0.21	-0.23	Hematocrit;	chr4:87050448	chr4:86913266~86914817:-
THCA	cis	rs919433	0.889	rs788001	ENSG00000231621.1	AC013264.2	-5.12	4.38e-07	5.97e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197348996	chr2:197197991~197199273:+
THCA	cis	rs11719291	0.504	rs34571182	ENSG00000270441.1	RP11-694I15.7	5.12	4.38e-07	5.97e-05	0.32	0.23	Cognitive function;	chr3:49171624	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs11706189	ENSG00000270441.1	RP11-694I15.7	5.12	4.38e-07	5.97e-05	0.32	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49173400	chr3:49140086~49160851:-
THCA	cis	rs9467773	0.967	rs6941022	ENSG00000261353.1	CTA-14H9.5	-5.12	4.38e-07	5.97e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs2224380	ENSG00000261353.1	CTA-14H9.5	-5.12	4.38e-07	5.97e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9461271	ENSG00000261353.1	CTA-14H9.5	-5.12	4.38e-07	5.97e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26527063~26527404:+
THCA	cis	rs10510102	0.935	rs75339296	ENSG00000226864.1	ATE1-AS1	5.12	4.38e-07	5.97e-05	0.37	0.23	Breast cancer;	chr10:121859895	chr10:121928312~121951965:+
THCA	cis	rs6430585	0.702	rs3213890	ENSG00000231890.6	DARS-AS1	-5.12	4.38e-07	5.98e-05	-0.28	-0.23	Corneal structure;	chr2:135794618	chr2:135985176~136022593:+
THCA	cis	rs36715	0.953	rs42916	ENSG00000245937.6	LINC01184	5.12	4.38e-07	5.98e-05	0.25	0.23	Breast cancer;	chr5:128224967	chr5:127940426~128083172:-
THCA	cis	rs1005277	0.579	rs2472173	ENSG00000272983.1	RP11-508N22.12	5.12	4.38e-07	5.98e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2472174	ENSG00000272983.1	RP11-508N22.12	5.12	4.38e-07	5.98e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474563	ENSG00000272983.1	RP11-508N22.12	5.12	4.38e-07	5.98e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs9418322	ENSG00000272983.1	RP11-508N22.12	5.12	4.38e-07	5.98e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs9299760	ENSG00000272983.1	RP11-508N22.12	5.12	4.38e-07	5.98e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2023351	ENSG00000272983.1	RP11-508N22.12	5.12	4.38e-07	5.98e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38137337~38144399:+
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000229886.1	RP5-1132H15.3	5.12	4.38e-07	5.98e-05	0.27	0.23	Corneal structure;	chr7:66824628	chr7:66025126~66031544:-
THCA	cis	rs9467773	0.626	rs6936006	ENSG00000124549.13	BTN2A3P	-5.12	4.39e-07	5.98e-05	-0.22	-0.23	Intelligence (multi-trait analysis);	chr6:26350337	chr6:26421391~26432383:+
THCA	cis	rs9929218	0.539	rs1125557	ENSG00000260459.2	FTLP14	5.12	4.39e-07	5.98e-05	0.26	0.23	Colorectal cancer;	chr16:68775696	chr16:68822587~68823070:+
THCA	cis	rs2235642	0.533	rs17135391	ENSG00000280231.1	LA16c-380F5.3	-5.12	4.39e-07	5.98e-05	-0.31	-0.23	Coronary artery disease;	chr16:1555605	chr16:1553655~1554130:-
THCA	cis	rs4660456	0.711	rs12409109	ENSG00000272145.1	NFYC-AS1	5.12	4.39e-07	5.98e-05	0.16	0.23	Platelet count;	chr1:40727216	chr1:40690380~40692066:-
THCA	cis	rs34779708	0.966	rs878264	ENSG00000271335.4	RP11-324I22.4	5.12	4.39e-07	5.98e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35314552~35336401:-
THCA	cis	rs7617773	1	rs12496784	ENSG00000199476.1	Y_RNA	5.12	4.39e-07	5.98e-05	0.29	0.23	Coronary artery disease;	chr3:48144777	chr3:48288587~48288694:+
THCA	cis	rs9307551	0.948	rs13112067	ENSG00000250334.4	LINC00989	-5.12	4.39e-07	5.98e-05	-0.29	-0.23	Refractive error;	chr4:79561744	chr4:79492416~79576460:+
THCA	cis	rs1005277	0.579	rs2505194	ENSG00000272983.1	RP11-508N22.12	5.12	4.39e-07	5.98e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38137337~38144399:+
THCA	cis	rs9467773	1	rs9467787	ENSG00000261353.1	CTA-14H9.5	-5.12	4.39e-07	5.98e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26527063~26527404:+
THCA	cis	rs763121	0.853	rs10135	ENSG00000273076.1	RP3-508I15.22	-5.12	4.39e-07	5.98e-05	-0.23	-0.23	Menopause (age at onset);	chr22:38686169	chr22:38743495~38743910:+
THCA	cis	rs7428	0.545	rs4832163	ENSG00000273196.1	RP11-717A5.2	5.12	4.39e-07	5.99e-05	0.24	0.23	Ear protrusion;	chr2:85313960	chr2:85387074~85387146:-
THCA	cis	rs2380205	0.682	rs3750657	ENSG00000232807.2	RP11-536K7.3	5.12	4.39e-07	5.99e-05	0.21	0.23	Breast cancer;	chr10:5884116	chr10:5934270~5945900:-
THCA	cis	rs4443100	0.837	rs6003490	ENSG00000230701.2	FBXW4P1	5.12	4.39e-07	5.99e-05	0.29	0.23	Serum parathyroid hormone levels;	chr22:23046267	chr22:23262767~23265005:+
THCA	cis	rs34779708	0.931	rs11596502	ENSG00000271335.4	RP11-324I22.4	5.12	4.39e-07	5.99e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35314552~35336401:-
THCA	cis	rs867371	0.519	rs1566560	ENSG00000259429.4	UBE2Q2P2	-5.12	4.39e-07	5.99e-05	-0.19	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82355142~82420075:+
THCA	cis	rs867371	0.519	rs1566559	ENSG00000259429.4	UBE2Q2P2	-5.12	4.39e-07	5.99e-05	-0.19	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82355142~82420075:+
THCA	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-5.12	4.4e-07	5.99e-05	-0.3	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
THCA	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	5.12	4.4e-07	5.99e-05	0.28	0.23	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
THCA	cis	rs67340775	0.541	rs200965	ENSG00000226314.6	ZNF192P1	-5.12	4.4e-07	5.99e-05	-0.35	-0.23	Lung cancer in ever smokers;	chr6:27898606	chr6:28161781~28169594:+
THCA	cis	rs6671200	0.748	rs12753842	ENSG00000235501.4	RP4-639F20.1	-5.12	4.4e-07	5.99e-05	-0.44	-0.23	Stearic acid (18:0) levels;	chr1:95049769	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.748	rs35051418	ENSG00000235501.4	RP4-639F20.1	-5.12	4.4e-07	5.99e-05	-0.44	-0.23	Stearic acid (18:0) levels;	chr1:95061405	chr1:94927566~94963270:+
THCA	cis	rs17767392	0.958	rs8014349	ENSG00000259146.3	RP1-261D10.2	-5.12	4.4e-07	5.99e-05	-0.29	-0.23	Mitral valve prolapse;	chr14:71579779	chr14:71292729~71321814:-
THCA	cis	rs1552244	0.832	rs67145301	ENSG00000232901.1	CYCSP10	5.12	4.4e-07	6e-05	0.32	0.23	Alzheimer's disease;	chr3:10155630	chr3:10000647~10000940:-
THCA	cis	rs9990333	0.562	rs58079878	ENSG00000273009.1	RP11-352G9.1	-5.12	4.4e-07	6e-05	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195913078~195913683:-
THCA	cis	rs6688613	0.649	rs2280995	ENSG00000225171.2	DUTP6	-5.12	4.4e-07	6e-05	-0.32	-0.23	Refractive astigmatism;	chr1:166876832	chr1:166868748~166869209:+
THCA	cis	rs459482	0.587	rs468207	ENSG00000228318.3	AP001610.5	5.12	4.41e-07	6e-05	0.28	0.23	IgG glycosylation;	chr21:41436088	chr21:41441056~41445708:-
THCA	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-5.12	4.41e-07	6e-05	-0.28	-0.23	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
THCA	cis	rs944289	0.74	rs368187	ENSG00000258844.1	RP11-259K15.2	-5.12	4.41e-07	6.01e-05	-0.2	-0.23	Thyroid cancer;	chr14:36063370	chr14:36214607~36235608:+
THCA	cis	rs3734266	0.527	rs9462001	ENSG00000272288.4	RP11-140K17.3	-5.12	4.41e-07	6.01e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr6:34687786	chr6:34696317~34697470:+
THCA	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-5.12	4.41e-07	6.01e-05	-0.13	-0.23	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-5.12	4.41e-07	6.01e-05	-0.13	-0.23	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-5.12	4.41e-07	6.01e-05	-0.13	-0.23	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-5.12	4.41e-07	6.01e-05	-0.13	-0.23	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
THCA	cis	rs875971	0.571	rs78668714	ENSG00000232546.1	RP11-458F8.1	5.12	4.41e-07	6.01e-05	0.22	0.23	Aortic root size;	chr7:66474464	chr7:66848496~66858136:+
THCA	cis	rs10129255	0.784	rs7147210	ENSG00000223648.3	IGHV3-64	5.12	4.41e-07	6.01e-05	0.15	0.23	Kawasaki disease;	chr14:106705271	chr14:106643132~106658258:-
THCA	cis	rs10895275	0.961	rs7122907	ENSG00000277459.1	RP11-732A21.3	5.12	4.41e-07	6.01e-05	0.18	0.23	Migraine;	chr11:102215051	chr11:102109827~102110457:-
THCA	cis	rs4646450	0.891	rs3137	ENSG00000244219.5	GS1-259H13.2	-5.12	4.41e-07	6.01e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99533252	chr7:99598066~99610813:+
THCA	cis	rs6968419	0.65	rs1881287	ENSG00000237870.5	AC073130.1	5.12	4.41e-07	6.01e-05	0.25	0.23	Intraocular pressure;	chr7:116226300	chr7:116275606~116286734:-
THCA	cis	rs79040073	0.563	rs17479003	ENSG00000259531.2	RP11-295H24.3	5.12	4.41e-07	6.01e-05	0.32	0.23	Lung cancer in ever smokers;	chr15:49453223	chr15:49365124~49366685:-
THCA	cis	rs1707322	1	rs785467	ENSG00000281133.1	AL355480.3	5.12	4.42e-07	6.02e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45580892~45580996:-
THCA	cis	rs6728642	0.908	rs6576996	ENSG00000230606.9	AC159540.1	5.12	4.42e-07	6.02e-05	0.29	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96957575	chr2:97416165~97433527:-
THCA	cis	rs6832769	1	rs9312662	ENSG00000272969.1	RP11-528I4.2	-5.12	4.42e-07	6.02e-05	-0.27	-0.23	Personality dimensions;	chr4:55520204	chr4:55547112~55547889:+
THCA	cis	rs3796352	0.686	rs1560333	ENSG00000242142.1	SERBP1P3	5.12	4.42e-07	6.02e-05	0.37	0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53104238	chr3:53064283~53065091:-
THCA	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-5.12	4.42e-07	6.02e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
THCA	cis	rs763121	0.925	rs9611008	ENSG00000235209.1	CTA-150C2.13	5.12	4.42e-07	6.02e-05	0.29	0.23	Menopause (age at onset);	chr22:38702782	chr22:38921227~38924708:+
THCA	cis	rs11096990	1	rs11096990	ENSG00000249685.1	RP11-360F5.3	5.12	4.42e-07	6.02e-05	0.29	0.23	Cognitive function;	chr4:39285329	chr4:39133913~39135608:+
THCA	cis	rs1150668	0.796	rs1005125	ENSG00000273712.1	RP5-874C20.7	5.12	4.42e-07	6.02e-05	0.25	0.23	Pubertal anthropometrics;	chr6:28399578	chr6:28315613~28315883:-
THCA	cis	rs6539288	0.5	rs11113116	ENSG00000260329.1	RP11-412D9.4	-5.12	4.42e-07	6.02e-05	-0.21	-0.23	Total body bone mineral density;	chr12:106802151	chr12:106954029~106955497:-
THCA	cis	rs2070488	0.775	rs2186457	ENSG00000229589.1	ACVR2B-AS1	5.12	4.42e-07	6.02e-05	0.2	0.23	Electrocardiographic conduction measures;	chr3:38512474	chr3:38451027~38454820:-
THCA	cis	rs4646450	0.891	rs13240600	ENSG00000244219.5	GS1-259H13.2	-5.12	4.42e-07	6.02e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99466843	chr7:99598066~99610813:+
THCA	cis	rs4646450	0.891	rs10244158	ENSG00000244219.5	GS1-259H13.2	-5.12	4.42e-07	6.02e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99482621	chr7:99598066~99610813:+
THCA	cis	rs2255336	0.81	rs7959328	ENSG00000245648.1	RP11-277P12.20	5.12	4.42e-07	6.02e-05	0.32	0.23	Blood protein levels;	chr12:10361467	chr12:10363769~10398506:+
THCA	cis	rs3734266	0.702	rs451603	ENSG00000272288.4	RP11-140K17.3	5.12	4.42e-07	6.02e-05	0.23	0.23	Systemic lupus erythematosus;	chr6:34581330	chr6:34696317~34697470:+
THCA	cis	rs79243044	0.901	rs4910817	ENSG00000224295.2	AC087380.14	-5.12	4.42e-07	6.02e-05	-0.23	-0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5544425	chr11:5518441~5524955:-
THCA	cis	rs116095464	0.558	rs9312957	ENSG00000248925.1	CTD-2083E4.6	5.12	4.42e-07	6.03e-05	0.36	0.23	Breast cancer;	chr5:202079	chr5:269858~271516:-
THCA	cis	rs972578	0.765	rs5751378	ENSG00000274717.1	RP1-47A17.1	-5.12	4.42e-07	6.03e-05	-0.24	-0.23	Mean platelet volume;	chr22:42823830	chr22:42791814~42794313:-
THCA	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	5.12	4.43e-07	6.03e-05	0.13	0.23	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
THCA	cis	rs1580019	0.562	rs4720064	ENSG00000231952.3	DPY19L1P2	-5.12	4.43e-07	6.03e-05	-0.29	-0.23	Cognitive ability;	chr7:32520026	chr7:32812757~32838570:+
THCA	cis	rs4950322	0.57	rs11800580	ENSG00000278811.3	LINC00624	-5.12	4.43e-07	6.03e-05	-0.28	-0.23	Protein quantitative trait loci;	chr1:147261053	chr1:147258885~147517875:-
THCA	cis	rs17772222	0.74	rs11845147	ENSG00000222990.1	RNU4-22P	5.12	4.43e-07	6.03e-05	0.28	0.23	Coronary artery calcification;	chr14:88502804	chr14:88513498~88513663:+
THCA	cis	rs7614311	0.681	rs10510903	ENSG00000271843.1	RP11-245J9.5	-5.12	4.43e-07	6.03e-05	-0.41	-0.23	Lung function (FVC);Lung function (FEV1);	chr3:63984516	chr3:64008082~64008692:-
THCA	cis	rs67340775	0.541	rs200973	ENSG00000226314.6	ZNF192P1	-5.12	4.43e-07	6.03e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr6:27890643	chr6:28161781~28169594:+
THCA	cis	rs2439831	0.85	rs3816792	ENSG00000166763.7	STRCP1	-5.12	4.43e-07	6.03e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43824788	chr15:43699488~43718184:-
THCA	cis	rs9634489	0.708	rs11069237	ENSG00000247400.3	DNAJC3-AS1	-5.12	4.43e-07	6.04e-05	-0.14	-0.23	Body mass index;	chr13:96357199	chr13:95648733~95676925:-
THCA	cis	rs8020095	0.528	rs10132093	ENSG00000258561.1	RP11-72M17.1	-5.12	4.44e-07	6.04e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67380794	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs2296561	ENSG00000258561.1	RP11-72M17.1	-5.12	4.44e-07	6.04e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67382422	chr14:66212810~66509394:-
THCA	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	5.12	4.44e-07	6.04e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
THCA	cis	rs17767392	0.756	rs11626445	ENSG00000259146.3	RP1-261D10.2	5.12	4.44e-07	6.05e-05	0.31	0.23	Mitral valve prolapse;	chr14:71272417	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.834	rs61991191	ENSG00000259146.3	RP1-261D10.2	5.12	4.44e-07	6.05e-05	0.31	0.23	Mitral valve prolapse;	chr14:71272487	chr14:71292729~71321814:-
THCA	cis	rs4908769	0.624	rs2120461	ENSG00000232912.4	RP5-1115A15.1	-5.12	4.44e-07	6.05e-05	-0.25	-0.23	Allergy;	chr1:8387662	chr1:8424645~8434838:+
THCA	cis	rs710913	0.774	rs2695319	ENSG00000228060.1	RP11-69E11.8	-5.12	4.44e-07	6.05e-05	-0.22	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39591028	chr1:39565160~39573203:+
THCA	cis	rs3742264	0.816	rs1952187	ENSG00000235903.6	CPB2-AS1	-5.12	4.45e-07	6.05e-05	-0.33	-0.23	Blood protein levels;	chr13:46100774	chr13:46052806~46113332:+
THCA	cis	rs9307551	0.656	rs6818695	ENSG00000250334.4	LINC00989	-5.12	4.45e-07	6.05e-05	-0.31	-0.23	Refractive error;	chr4:79540680	chr4:79492416~79576460:+
THCA	cis	rs7088591	0.867	rs73289193	ENSG00000276818.1	AC026393.1	5.12	4.45e-07	6.05e-05	0.46	0.23	Blood pressure;	chr10:58015798	chr10:57095699~57095781:+
THCA	cis	rs2439831	0.85	rs3742982	ENSG00000166763.7	STRCP1	5.12	4.45e-07	6.06e-05	0.33	0.23	Lung cancer in ever smokers;	chr15:43884483	chr15:43699488~43718184:-
THCA	cis	rs1552244	1	rs6768102	ENSG00000232901.1	CYCSP10	5.12	4.45e-07	6.06e-05	0.3	0.23	Alzheimer's disease;	chr3:10107696	chr3:10000647~10000940:-
THCA	cis	rs2070488	0.775	rs4679066	ENSG00000229589.1	ACVR2B-AS1	-5.12	4.45e-07	6.06e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38527036	chr3:38451027~38454820:-
THCA	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-5.12	4.45e-07	6.06e-05	-0.32	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
THCA	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-5.12	4.45e-07	6.06e-05	-0.32	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
THCA	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-5.12	4.45e-07	6.06e-05	-0.32	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
THCA	cis	rs5751614	1	rs5759664	ENSG00000230701.2	FBXW4P1	5.12	4.45e-07	6.06e-05	0.22	0.23	Height;	chr22:23249536	chr22:23262767~23265005:+
THCA	cis	rs9818758	0.607	rs13087930	ENSG00000270441.1	RP11-694I15.7	5.12	4.45e-07	6.06e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48924293	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.545	rs11717978	ENSG00000270441.1	RP11-694I15.7	5.12	4.45e-07	6.06e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48931603	chr3:49140086~49160851:-
THCA	cis	rs4646450	0.891	rs10271049	ENSG00000244219.5	GS1-259H13.2	-5.12	4.45e-07	6.06e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99428870	chr7:99598066~99610813:+
THCA	cis	rs4646450	0.891	rs7794705	ENSG00000244219.5	GS1-259H13.2	-5.12	4.45e-07	6.06e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99431761	chr7:99598066~99610813:+
THCA	cis	rs5751614	1	rs2267020	ENSG00000230701.2	FBXW4P1	5.12	4.46e-07	6.07e-05	0.22	0.23	Height;	chr22:23250255	chr22:23262767~23265005:+
THCA	cis	rs1823913	1	rs7574570	ENSG00000227542.1	AC092614.2	-5.12	4.46e-07	6.07e-05	-0.28	-0.23	Obesity-related traits;	chr2:191233790	chr2:191229165~191246172:-
THCA	cis	rs2243480	1	rs313820	ENSG00000230295.1	RP11-458F8.2	-5.12	4.46e-07	6.07e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66109479	chr7:66880708~66882981:+
THCA	cis	rs453301	0.624	rs2979256	ENSG00000254153.1	CTA-398F10.2	-5.12	4.46e-07	6.07e-05	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9014200	chr8:8456909~8461337:-
THCA	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	5.12	4.46e-07	6.07e-05	0.36	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
THCA	cis	rs2235642	0.826	rs8053605	ENSG00000280231.1	LA16c-380F5.3	-5.12	4.46e-07	6.07e-05	-0.27	-0.23	Coronary artery disease;	chr16:1544157	chr16:1553655~1554130:-
THCA	cis	rs5758511	0.596	rs55644935	ENSG00000281538.1	RP4-669P10.20	-5.12	4.46e-07	6.07e-05	-0.25	-0.23	Birth weight;	chr22:42270063	chr22:42138060~42139726:+
THCA	cis	rs5758659	1	rs5758660	ENSG00000281538.1	RP4-669P10.20	5.12	4.46e-07	6.07e-05	0.21	0.23	Cognitive function;	chr22:42227712	chr22:42138060~42139726:+
THCA	cis	rs12428035	0.772	rs11616953	ENSG00000247400.3	DNAJC3-AS1	-5.12	4.46e-07	6.07e-05	-0.23	-0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95796703	chr13:95648733~95676925:-
THCA	cis	rs442309	0.553	rs10995281	ENSG00000238280.1	RP11-436D10.3	-5.12	4.46e-07	6.08e-05	-0.3	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62707416	chr10:62793562~62805887:-
THCA	cis	rs17767392	1	rs34748537	ENSG00000259146.3	RP1-261D10.2	5.12	4.46e-07	6.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71364966	chr14:71292729~71321814:-
THCA	cis	rs944289	0.679	rs12050116	ENSG00000258844.1	RP11-259K15.2	5.12	4.47e-07	6.08e-05	0.21	0.23	Thyroid cancer;	chr14:36103725	chr14:36214607~36235608:+
THCA	cis	rs5015933	0.815	rs10819043	ENSG00000232630.1	PRPS1P2	-5.12	4.47e-07	6.08e-05	-0.15	-0.23	Body mass index;	chr9:125274966	chr9:125150653~125151589:+
THCA	cis	rs12188164	0.575	rs112126699	ENSG00000225138.6	CTD-2228K2.7	5.12	4.47e-07	6.09e-05	0.24	0.23	Cystic fibrosis severity;	chr5:419347	chr5:473236~480884:+
THCA	cis	rs911119	1	rs6036476	ENSG00000270001.1	RP11-218C14.8	-5.12	4.47e-07	6.09e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23629671	chr20:23631826~23632316:-
THCA	cis	rs1823913	0.614	rs4853466	ENSG00000280083.1	RP11-317J9.1	5.12	4.47e-07	6.09e-05	0.26	0.23	Obesity-related traits;	chr2:191295943	chr2:191154118~191156070:-
THCA	cis	rs11719291	0.833	rs11713694	ENSG00000270441.1	RP11-694I15.7	5.12	4.48e-07	6.09e-05	0.33	0.23	Cognitive function;	chr3:48796182	chr3:49140086~49160851:-
THCA	cis	rs11719291	0.833	rs11709246	ENSG00000270441.1	RP11-694I15.7	5.12	4.48e-07	6.09e-05	0.33	0.23	Cognitive function;	chr3:48822065	chr3:49140086~49160851:-
THCA	cis	rs11719291	0.504	rs71324924	ENSG00000270441.1	RP11-694I15.7	5.12	4.48e-07	6.09e-05	0.33	0.23	Cognitive function;	chr3:48828011	chr3:49140086~49160851:-
THCA	cis	rs8020095	0.528	rs2319777	ENSG00000258561.1	RP11-72M17.1	-5.12	4.48e-07	6.09e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67343316	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs73284892	ENSG00000258561.1	RP11-72M17.1	-5.12	4.48e-07	6.09e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67366103	chr14:66212810~66509394:-
THCA	cis	rs2243480	1	rs410128	ENSG00000230295.1	RP11-458F8.2	-5.12	4.48e-07	6.09e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66138186	chr7:66880708~66882981:+
THCA	cis	rs6088580	0.634	rs1205336	ENSG00000276073.1	RP5-1125A11.7	5.12	4.48e-07	6.1e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34338530	chr20:33985617~33988989:-
THCA	cis	rs8059260	0.799	rs7194545	ENSG00000274038.1	RP11-66H6.4	-5.12	4.48e-07	6.1e-05	-0.32	-0.23	Alcohol consumption over the past year;	chr16:11030439	chr16:11056556~11057034:+
THCA	cis	rs651907	0.557	rs7612283	ENSG00000244119.1	PDCL3P4	5.12	4.48e-07	6.1e-05	0.21	0.23	Colorectal cancer;	chr3:101716075	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs34457525	ENSG00000244119.1	PDCL3P4	5.12	4.48e-07	6.1e-05	0.21	0.23	Colorectal cancer;	chr3:101716381	chr3:101712472~101713191:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000223473.2	GS1-124K5.3	5.12	4.49e-07	6.1e-05	0.15	0.23	Calcium levels;	chr7:65996954	chr7:66491049~66493566:-
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	5.12	4.49e-07	6.11e-05	0.29	0.23	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
THCA	cis	rs2243480	1	rs10807702	ENSG00000230295.1	RP11-458F8.2	-5.12	4.49e-07	6.11e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66302856	chr7:66880708~66882981:+
THCA	cis	rs1023500	0.551	rs2301521	ENSG00000273366.1	CTA-989H11.1	-5.12	4.5e-07	6.12e-05	-0.3	-0.23	Schizophrenia;	chr22:42027106	chr22:42278188~42278846:+
THCA	cis	rs1005277	0.579	rs2505241	ENSG00000272983.1	RP11-508N22.12	5.12	4.5e-07	6.12e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38137337~38144399:+
THCA	cis	rs11319879	1	rs11319879	ENSG00000236493.2	EIF2S2P3	5.12	4.5e-07	6.12e-05	0.24	0.23	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;	chr10:92693719	chr10:92668745~92669743:-
THCA	cis	rs736801	0.521	rs2070729	ENSG00000237714.1	P4HA2-AS1	-5.12	4.5e-07	6.12e-05	-0.28	-0.23	Mosquito bite size;Breast cancer;	chr5:132484229	chr5:132184876~132192808:+
THCA	cis	rs6878727	0.777	rs6888065	ENSG00000253807.4	LINC01170	-5.12	4.5e-07	6.12e-05	-0.23	-0.23	Breast cancer;	chr5:124384747	chr5:124059794~124405079:-
THCA	cis	rs10129255	0.5	rs10142931	ENSG00000211970.3	IGHV4-61	-5.12	4.5e-07	6.12e-05	-0.13	-0.23	Kawasaki disease;	chr14:106782288	chr14:106639119~106639657:-
THCA	cis	rs858239	0.539	rs4295546	ENSG00000230042.1	AK3P3	-5.12	4.5e-07	6.12e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23129178~23129841:+
THCA	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	5.12	4.5e-07	6.13e-05	0.25	0.23	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
THCA	cis	rs6547741	0.717	rs2178197	ENSG00000234072.1	AC074117.10	5.12	4.5e-07	6.13e-05	0.18	0.23	Oral cavity cancer;	chr2:27637684	chr2:27356246~27367622:+
THCA	cis	rs10129255	0.5	rs8021941	ENSG00000211970.3	IGHV4-61	-5.12	4.51e-07	6.13e-05	-0.13	-0.23	Kawasaki disease;	chr14:106781490	chr14:106639119~106639657:-
THCA	cis	rs987724	0.537	rs9847187	ENSG00000240875.4	LINC00886	-5.12	4.51e-07	6.14e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156873356	chr3:156747346~156817062:-
THCA	cis	rs987724	0.593	rs2321290	ENSG00000240875.4	LINC00886	-5.12	4.51e-07	6.14e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156873765	chr3:156747346~156817062:-
THCA	cis	rs987724	0.574	rs9812895	ENSG00000240875.4	LINC00886	-5.12	4.51e-07	6.14e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156886370	chr3:156747346~156817062:-
THCA	cis	rs987724	0.593	rs17382070	ENSG00000240875.4	LINC00886	-5.12	4.51e-07	6.14e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156890754	chr3:156747346~156817062:-
THCA	cis	rs12887734	0.566	rs3742366	ENSG00000269910.1	RP11-73M18.10	5.12	4.51e-07	6.14e-05	0.21	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103694516~103695050:-
THCA	cis	rs10895275	0.51	rs1942683	ENSG00000277459.1	RP11-732A21.3	5.12	4.52e-07	6.14e-05	0.18	0.23	Migraine;	chr11:102173916	chr11:102109827~102110457:-
THCA	cis	rs7520050	0.807	rs28844317	ENSG00000234329.1	RP11-767N6.2	5.12	4.52e-07	6.15e-05	0.2	0.23	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.807	rs6429576	ENSG00000234329.1	RP11-767N6.2	5.12	4.52e-07	6.15e-05	0.2	0.23	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45651039~45651826:-
THCA	cis	rs726288	1	rs6413523	ENSG00000230091.5	TMEM254-AS1	-5.12	4.52e-07	6.15e-05	-0.5	-0.23	Rheumatoid arthritis;	chr10:79946379	chr10:80046860~80078912:-
THCA	cis	rs7674212	0.537	rs2623060	ENSG00000246560.2	RP11-10L12.4	5.12	4.52e-07	6.15e-05	0.27	0.23	Type 2 diabetes;	chr4:103126347	chr4:102828055~102844075:+
THCA	cis	rs10090774	0.965	rs13265942	ENSG00000279766.1	RP11-642A1.2	-5.12	4.52e-07	6.15e-05	-0.29	-0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140865063	chr8:140572142~140572812:-
THCA	cis	rs1552244	0.554	rs3774207	ENSG00000232901.1	CYCSP10	5.12	4.52e-07	6.15e-05	0.27	0.23	Alzheimer's disease;	chr3:9943972	chr3:10000647~10000940:-
THCA	cis	rs7429990	0.965	rs4599334	ENSG00000228638.1	FCF1P2	5.12	4.52e-07	6.15e-05	0.23	0.23	Educational attainment (years of education);	chr3:48024910	chr3:48290793~48291375:-
THCA	cis	rs7520050	0.902	rs9429088	ENSG00000234329.1	RP11-767N6.2	-5.12	4.53e-07	6.15e-05	-0.21	-0.23	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45651039~45651826:-
THCA	cis	rs752010	0.63	rs11210507	ENSG00000230638.4	RP11-486B10.4	-5.12	4.53e-07	6.15e-05	-0.25	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41639817	chr1:41542069~41544310:+
THCA	cis	rs6951245	1	rs1997243	ENSG00000229043.2	AC091729.9	-5.12	4.53e-07	6.15e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs77760339	ENSG00000229043.2	AC091729.9	-5.12	4.53e-07	6.15e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1160374~1165267:+
THCA	cis	rs2070488	0.804	rs13085153	ENSG00000229589.1	ACVR2B-AS1	5.12	4.53e-07	6.16e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38419788	chr3:38451027~38454820:-
THCA	cis	rs4950322	0.542	rs12046706	ENSG00000226015.2	CCT8P1	5.12	4.53e-07	6.16e-05	0.25	0.23	Protein quantitative trait loci;	chr1:147189758	chr1:147203276~147204932:-
THCA	cis	rs7088591	1	rs76726082	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58026265	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs76080267	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58026269	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs73290947	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58026349	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs77243899	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58026397	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs73292706	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58027207	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs73292709	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58027301	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs60971133	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58027764	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs73292716	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58027967	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs79906959	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58028236	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs60106619	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58028473	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs59474487	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58028774	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs57367361	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58028872	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs61351365	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58028873	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs60184203	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58028914	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs11819308	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58029116	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs11814091	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58029177	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs11819316	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58029182	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs11815367	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58029192	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs11814120	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58029324	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.764	rs11819380	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58029418	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs914766	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58030117	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs113703900	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58032352	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.85	rs59585215	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58035261	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs993114	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58037464	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs73292763	ENSG00000276818.1	AC026393.1	5.12	4.53e-07	6.16e-05	0.44	0.23	Blood pressure;	chr10:58039707	chr10:57095699~57095781:+
THCA	cis	rs8103278	0.507	rs522769	ENSG00000267395.4	AC074212.6	-5.12	4.53e-07	6.16e-05	-0.15	-0.23	Coronary artery disease;	chr19:45781262	chr19:45767796~45772504:+
THCA	cis	rs7824557	0.603	rs6995404	ENSG00000154316.13	TDH	-5.12	4.53e-07	6.16e-05	-0.17	-0.23	Retinal vascular caliber;	chr8:11324639	chr8:11339637~11368452:+
THCA	cis	rs9818758	0.607	rs3923475	ENSG00000270441.1	RP11-694I15.7	5.12	4.53e-07	6.16e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49018355	chr3:49140086~49160851:-
THCA	cis	rs2549003	0.811	rs10035166	ENSG00000237714.1	P4HA2-AS1	5.12	4.53e-07	6.16e-05	0.32	0.23	Asthma (sex interaction);	chr5:132488235	chr5:132184876~132192808:+
THCA	cis	rs2239547	0.657	rs6445538	ENSG00000242142.1	SERBP1P3	5.12	4.53e-07	6.16e-05	0.29	0.23	Schizophrenia;	chr3:52840272	chr3:53064283~53065091:-
THCA	cis	rs16852403	0.548	rs10913524	ENSG00000224687.1	RASAL2-AS1	5.12	4.53e-07	6.16e-05	0.35	0.23	Childhood ear infection;	chr1:178251972	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.581	rs10913525	ENSG00000224687.1	RASAL2-AS1	5.12	4.53e-07	6.16e-05	0.35	0.23	Childhood ear infection;	chr1:178254298	chr1:178091508~178093984:-
THCA	cis	rs2439831	0.681	rs540388	ENSG00000275601.1	AC011330.13	-5.12	4.53e-07	6.16e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43314296	chr15:43642389~43643023:-
THCA	cis	rs2273788	0.583	rs13296201	ENSG00000204173.9	LRRC37A5P	5.12	4.54e-07	6.17e-05	0.3	0.23	Monocyte count;	chr9:111579691	chr9:111602831~111631289:-
THCA	cis	rs9875589	0.509	rs2731305	ENSG00000228242.5	AC093495.4	5.12	4.54e-07	6.17e-05	0.13	0.23	Ovarian reserve;	chr3:14039842	chr3:14144637~14165978:+
THCA	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-5.12	4.54e-07	6.17e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-5.12	4.54e-07	6.17e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
THCA	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	5.12	4.54e-07	6.17e-05	0.28	0.23	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
THCA	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	5.12	4.54e-07	6.17e-05	0.28	0.23	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
THCA	cis	rs7267979	0.932	rs424487	ENSG00000274973.1	RP13-401N8.7	-5.12	4.54e-07	6.17e-05	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25845497~25845862:+
THCA	cis	rs7429990	0.864	rs6442081	ENSG00000228638.1	FCF1P2	5.12	4.54e-07	6.17e-05	0.22	0.23	Educational attainment (years of education);	chr3:47728890	chr3:48290793~48291375:-
THCA	cis	rs75920871	0.589	rs56061158	ENSG00000254851.1	RP11-109L13.1	-5.12	4.54e-07	6.17e-05	-0.46	-0.23	Subjective well-being;	chr11:117216402	chr11:117135528~117138582:+
THCA	cis	rs2439831	0.681	rs540388	ENSG00000205771.5	CATSPER2P1	-5.12	4.54e-07	6.18e-05	-0.3	-0.23	Lung cancer in ever smokers;	chr15:43314296	chr15:43726918~43747094:-
THCA	cis	rs4784934	0.589	rs8057901	ENSG00000260186.4	RP11-481J2.2	5.12	4.55e-07	6.18e-05	0.3	0.23	QT interval;	chr16:58436523	chr16:58421326~58462470:+
THCA	cis	rs12143943	0.934	rs868097	ENSG00000240219.1	RP11-430C7.5	5.12	4.55e-07	6.18e-05	0.2	0.23	Cognitive performance;	chr1:204611011	chr1:204626775~204629712:+
THCA	cis	rs831571	0.519	rs13059603	ENSG00000280620.1	SCAANT1	-5.12	4.55e-07	6.18e-05	-0.34	-0.23	Type 2 diabetes;	chr3:63841705	chr3:63911518~63911772:-
THCA	cis	rs11719291	0.833	rs34037363	ENSG00000270441.1	RP11-694I15.7	5.12	4.55e-07	6.18e-05	0.33	0.23	Cognitive function;	chr3:48783603	chr3:49140086~49160851:-
THCA	cis	rs2337406	0.929	rs11847182	ENSG00000211974.3	IGHV2-70	-5.12	4.55e-07	6.18e-05	-0.24	-0.23	Alzheimer's disease (late onset);	chr14:106697724	chr14:106723574~106724093:-
THCA	cis	rs4950322	0.57	rs6703892	ENSG00000226015.2	CCT8P1	5.12	4.55e-07	6.19e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147287627	chr1:147203276~147204932:-
THCA	cis	rs858239	0.601	rs10239760	ENSG00000226816.2	AC005082.12	5.12	4.56e-07	6.19e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23206013~23208045:+
THCA	cis	rs7772486	0.686	rs9497380	ENSG00000270638.1	RP3-466P17.1	5.12	4.56e-07	6.19e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145735570~145737218:+
THCA	cis	rs7493	1	rs3735586	ENSG00000233942.1	AC004012.1	5.12	4.56e-07	6.19e-05	0.34	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr7:95406270	chr7:95471835~95473998:+
THCA	cis	rs8020095	0.528	rs28521373	ENSG00000258561.1	RP11-72M17.1	-5.12	4.56e-07	6.19e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67271358	chr14:66212810~66509394:-
THCA	cis	rs6860806	0.661	rs334902	ENSG00000233006.5	AC034220.3	5.12	4.56e-07	6.19e-05	0.18	0.23	Breast cancer;	chr5:132250866	chr5:132311285~132369916:-
THCA	cis	rs8141529	0.732	rs5997408	ENSG00000272858.1	CTA-292E10.8	-5.12	4.56e-07	6.2e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28811927	chr22:28814914~28815662:+
THCA	cis	rs4460629	0.742	rs6693477	ENSG00000160766.13	GBAP1	-5.12	4.56e-07	6.2e-05	-0.25	-0.23	Serum magnesium levels;	chr1:155109464	chr1:155213821~155227422:-
THCA	cis	rs6545883	0.929	rs1186700	ENSG00000270820.4	RP11-355B11.2	5.12	4.56e-07	6.2e-05	0.2	0.23	Tuberculosis;	chr2:61436237	chr2:61471188~61484130:+
THCA	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-5.12	4.56e-07	6.2e-05	-0.32	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
THCA	cis	rs5749696	1	rs5749696	ENSG00000224086.5	LL22NC03-86G7.1	-5.12	4.56e-07	6.2e-05	-0.27	-0.23	Schizophrenia;	chr22:21709048	chr22:21938293~21977632:+
THCA	cis	rs4908760	0.669	rs4908506	ENSG00000232912.4	RP5-1115A15.1	5.12	4.56e-07	6.2e-05	0.23	0.23	Vitiligo;	chr1:8668919	chr1:8424645~8434838:+
THCA	cis	rs34779708	0.966	rs34776628	ENSG00000271335.4	RP11-324I22.4	5.12	4.57e-07	6.2e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs17499247	ENSG00000271335.4	RP11-324I22.4	5.12	4.57e-07	6.2e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs10827491	ENSG00000271335.4	RP11-324I22.4	5.12	4.57e-07	6.2e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35314552~35336401:-
THCA	cis	rs62244186	0.545	rs7640654	ENSG00000214820.3	MPRIPP1	5.12	4.57e-07	6.21e-05	0.23	0.23	Depressive symptoms;	chr3:44721545	chr3:44579938~44581026:-
THCA	cis	rs2880765	0.835	rs730372	ENSG00000259630.2	CTD-2262B20.1	5.12	4.57e-07	6.21e-05	0.25	0.23	Coronary artery disease;	chr15:85494962	chr15:85415228~85415633:+
THCA	cis	rs9425766	0.679	rs6681390	ENSG00000227373.4	RP11-160H22.5	5.12	4.57e-07	6.21e-05	0.32	0.23	Life satisfaction;	chr1:174261331	chr1:174115300~174160004:-
THCA	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-5.12	4.57e-07	6.21e-05	-0.28	-0.23	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
THCA	cis	rs6545883	0.929	rs1186707	ENSG00000270820.4	RP11-355B11.2	5.12	4.57e-07	6.21e-05	0.2	0.23	Tuberculosis;	chr2:61446385	chr2:61471188~61484130:+
THCA	cis	rs4663866	1	rs34897410	ENSG00000186235.9	AC016757.3	5.12	4.58e-07	6.22e-05	0.48	0.23	Irritable bowel syndrome;	chr2:238273482	chr2:238224552~238231677:-
THCA	cis	rs1383484	0.545	rs7171383	ENSG00000259728.4	LINC00933	-5.12	4.58e-07	6.22e-05	-0.27	-0.23	Height;	chr15:83976087	chr15:84570649~84580175:+
THCA	cis	rs7924176	0.54	rs61866073	ENSG00000213731.2	RAB5CP1	-5.11	4.58e-07	6.22e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.521	rs7098200	ENSG00000213731.2	RAB5CP1	5.11	4.58e-07	6.22e-05	0.28	0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:74423435~74424014:-
THCA	cis	rs9921338	0.54	rs2868410	ENSG00000263080.1	RP11-485G7.5	5.11	4.58e-07	6.22e-05	0.27	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334244	chr16:11341809~11345211:-
THCA	cis	rs3785574	0.962	rs9944483	ENSG00000240280.5	TCAM1P	5.11	4.58e-07	6.22e-05	0.31	0.23	Height;	chr17:63706193	chr17:63849292~63864379:+
THCA	cis	rs916888	0.779	rs199526	ENSG00000261575.2	RP11-259G18.1	-5.11	4.58e-07	6.23e-05	-0.29	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46267037~46268694:+
THCA	cis	rs1065852	0.51	rs5758666	ENSG00000227370.1	RP4-669P10.19	5.11	4.58e-07	6.23e-05	0.23	0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42236827	chr22:42132543~42132998:+
THCA	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-5.11	4.59e-07	6.23e-05	-0.27	-0.23	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
THCA	cis	rs911119	0.954	rs2254635	ENSG00000270001.1	RP11-218C14.8	-5.11	4.59e-07	6.23e-05	-0.34	-0.23	Chronic kidney disease;	chr20:23642121	chr20:23631826~23632316:-
THCA	cis	rs4591358	1	rs7571836	ENSG00000223466.1	AC064834.2	-5.11	4.59e-07	6.23e-05	-0.27	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195475768	chr2:195533035~195538681:+
THCA	cis	rs17301013	0.932	rs6664764	ENSG00000227373.4	RP11-160H22.5	5.11	4.59e-07	6.23e-05	0.32	0.23	Systemic lupus erythematosus;	chr1:174443402	chr1:174115300~174160004:-
THCA	cis	rs763121	0.853	rs1569716	ENSG00000273076.1	RP3-508I15.22	5.11	4.59e-07	6.23e-05	0.23	0.23	Menopause (age at onset);	chr22:38602514	chr22:38743495~38743910:+
THCA	cis	rs7702057	0.53	rs7703978	ENSG00000272265.1	CTD-2287O16.4	5.11	4.59e-07	6.23e-05	0.42	0.23	Amyotrophic lateral sclerosis;	chr5:116085951	chr5:116078110~116078570:-
THCA	cis	rs34792	0.637	rs34793	ENSG00000207425.1	Y_RNA	5.11	4.59e-07	6.24e-05	0.25	0.23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15491779	chr16:14915457~14915556:-
THCA	cis	rs8020095	0.571	rs2144909	ENSG00000258561.1	RP11-72M17.1	-5.11	4.59e-07	6.24e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66858726	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs7156655	ENSG00000258561.1	RP11-72M17.1	-5.11	4.59e-07	6.24e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66889344	chr14:66212810~66509394:-
THCA	cis	rs4443100	0.958	rs5996455	ENSG00000230701.2	FBXW4P1	5.11	4.59e-07	6.24e-05	0.27	0.23	Serum parathyroid hormone levels;	chr22:23037078	chr22:23262767~23265005:+
THCA	cis	rs2749592	0.55	rs7081464	ENSG00000263064.2	RP11-291L22.7	-5.11	4.59e-07	6.24e-05	-0.25	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38448689~38448949:+
THCA	cis	rs2985684	0.894	rs4581611	ENSG00000278009.1	RP11-649E7.8	5.11	4.59e-07	6.24e-05	0.32	0.23	Carotid intima media thickness;	chr14:49576802	chr14:49601011~49601124:-
THCA	cis	rs2288884	0.731	rs11673450	ENSG00000260160.1	CTC-471J1.2	-5.11	4.6e-07	6.24e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037441	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.731	rs11673398	ENSG00000260160.1	CTC-471J1.2	-5.11	4.6e-07	6.24e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037444	chr19:52058490~52063703:-
THCA	cis	rs34779708	0.931	rs12261654	ENSG00000271335.4	RP11-324I22.4	5.11	4.6e-07	6.24e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35314552~35336401:-
THCA	cis	rs7119	0.717	rs62007348	ENSG00000259362.2	RP11-307C19.1	-5.11	4.6e-07	6.24e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77512159	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs35284122	ENSG00000259362.2	RP11-307C19.1	-5.11	4.6e-07	6.24e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77512226	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs62007350	ENSG00000259362.2	RP11-307C19.1	-5.11	4.6e-07	6.24e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77512248	chr15:77525540~77534110:+
THCA	cis	rs2985684	0.895	rs4900940	ENSG00000278009.1	RP11-649E7.8	5.11	4.6e-07	6.24e-05	0.33	0.23	Carotid intima media thickness;	chr14:49608592	chr14:49601011~49601124:-
THCA	cis	rs1823913	0.637	rs4853573	ENSG00000280083.1	RP11-317J9.1	5.11	4.6e-07	6.25e-05	0.26	0.23	Obesity-related traits;	chr2:191295866	chr2:191154118~191156070:-
THCA	cis	rs7508	0.511	rs2237853	ENSG00000253671.1	RP11-806O11.1	-5.11	4.6e-07	6.25e-05	-0.3	-0.23	Atrial fibrillation;	chr8:18020371	chr8:17808941~17820868:+
THCA	cis	rs34779708	0.966	rs12782948	ENSG00000271335.4	RP11-324I22.4	5.11	4.6e-07	6.25e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4934704	ENSG00000271335.4	RP11-324I22.4	5.11	4.61e-07	6.25e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35314552~35336401:-
THCA	cis	rs67340775	0.541	rs200964	ENSG00000226314.6	ZNF192P1	-5.11	4.61e-07	6.25e-05	-0.35	-0.23	Lung cancer in ever smokers;	chr6:27899165	chr6:28161781~28169594:+
THCA	cis	rs11648785	0.747	rs2241036	ENSG00000222019.6	URAHP	5.11	4.61e-07	6.25e-05	0.19	0.23	Tanning;	chr16:90037611	chr16:90039761~90047773:-
THCA	cis	rs17301013	0.9	rs1754351	ENSG00000227373.4	RP11-160H22.5	-5.11	4.61e-07	6.26e-05	-0.32	-0.23	Systemic lupus erythematosus;	chr1:174762458	chr1:174115300~174160004:-
THCA	cis	rs34779708	0.966	rs12257770	ENSG00000271335.4	RP11-324I22.4	5.11	4.61e-07	6.26e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35314552~35336401:-
THCA	cis	rs2797160	1	rs1777183	ENSG00000237742.5	RP11-624M8.1	5.11	4.61e-07	6.26e-05	0.2	0.23	Endometrial cancer;	chr6:125690849	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1739375	ENSG00000237742.5	RP11-624M8.1	5.11	4.61e-07	6.26e-05	0.2	0.23	Endometrial cancer;	chr6:125690867	chr6:125578558~125749190:-
THCA	cis	rs4660456	0.913	rs1494	ENSG00000272145.1	NFYC-AS1	-5.11	4.61e-07	6.27e-05	-0.16	-0.23	Platelet count;	chr1:40706176	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.869	rs7518344	ENSG00000272145.1	NFYC-AS1	-5.11	4.61e-07	6.27e-05	-0.16	-0.23	Platelet count;	chr1:40708327	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.827	rs10736404	ENSG00000272145.1	NFYC-AS1	-5.11	4.61e-07	6.27e-05	-0.16	-0.23	Platelet count;	chr1:40710331	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs2744799	ENSG00000272145.1	NFYC-AS1	-5.11	4.61e-07	6.27e-05	-0.16	-0.23	Platelet count;	chr1:40719862	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs12727412	ENSG00000272145.1	NFYC-AS1	5.11	4.61e-07	6.27e-05	0.16	0.23	Platelet count;	chr1:40723243	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs6675886	ENSG00000272145.1	NFYC-AS1	5.11	4.61e-07	6.27e-05	0.16	0.23	Platelet count;	chr1:40727955	chr1:40690380~40692066:-
THCA	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-5.11	4.62e-07	6.27e-05	-0.33	-0.23	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
THCA	cis	rs7617773	0.78	rs13090538	ENSG00000199476.1	Y_RNA	-5.11	4.62e-07	6.27e-05	-0.3	-0.23	Coronary artery disease;	chr3:48329279	chr3:48288587~48288694:+
THCA	cis	rs748404	0.626	rs57938858	ENSG00000249839.1	AC011330.5	-5.11	4.62e-07	6.27e-05	-0.34	-0.23	Lung cancer;	chr15:43520259	chr15:43663654~43684339:-
THCA	cis	rs8141529	0.644	rs5752795	ENSG00000272858.1	CTA-292E10.8	-5.11	4.62e-07	6.28e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28782832	chr22:28814914~28815662:+
THCA	cis	rs4409675	0.871	rs10902678	ENSG00000227050.1	RP11-460I13.2	5.11	4.63e-07	6.28e-05	0.33	0.23	Corneal astigmatism;	chr1:27942062	chr1:27938875~27960193:-
THCA	cis	rs10090774	0.965	rs11786116	ENSG00000279766.1	RP11-642A1.2	-5.11	4.63e-07	6.28e-05	-0.29	-0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140853997	chr8:140572142~140572812:-
THCA	cis	rs34779708	0.931	rs10437420	ENSG00000271335.4	RP11-324I22.4	-5.11	4.63e-07	6.28e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35314552~35336401:-
THCA	cis	rs8020095	0.571	rs8012660	ENSG00000258561.1	RP11-72M17.1	-5.11	4.63e-07	6.29e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:66833953	chr14:66212810~66509394:-
THCA	cis	rs858239	0.536	rs6956974	ENSG00000226816.2	AC005082.12	-5.11	4.63e-07	6.29e-05	-0.32	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23206013~23208045:+
THCA	cis	rs12681287	0.927	rs7003059	ENSG00000254231.1	CTD-2284J15.1	5.11	4.63e-07	6.29e-05	0.25	0.23	Caudate activity during reward;	chr8:86318484	chr8:86333274~86343314:-
THCA	cis	rs1005277	0.579	rs2474571	ENSG00000272983.1	RP11-508N22.12	5.11	4.63e-07	6.29e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38137337~38144399:+
THCA	cis	rs4934494	0.677	rs11185760	ENSG00000232936.4	RP11-80H5.2	5.11	4.63e-07	6.29e-05	0.32	0.23	Red blood cell count;	chr10:89571547	chr10:89645282~89650667:+
THCA	cis	rs2243480	1	rs78803505	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65917585	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65920739	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65922691	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65925107	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65926730	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65928032	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65929575	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65929781	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65929865	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000230295.1	RP11-458F8.2	-5.11	4.63e-07	6.29e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65938222	chr7:66880708~66882981:+
THCA	cis	rs2299587	0.552	rs433387	ENSG00000253671.1	RP11-806O11.1	-5.11	4.63e-07	6.29e-05	-0.27	-0.23	Economic and political preferences;	chr8:18012326	chr8:17808941~17820868:+
THCA	cis	rs8103278	0.507	rs62111759	ENSG00000267395.4	AC074212.6	-5.11	4.64e-07	6.29e-05	-0.15	-0.23	Coronary artery disease;	chr19:45792972	chr19:45767796~45772504:+
THCA	cis	rs17301013	0.9	rs1793300	ENSG00000227373.4	RP11-160H22.5	-5.11	4.64e-07	6.29e-05	-0.32	-0.23	Systemic lupus erythematosus;	chr1:174768559	chr1:174115300~174160004:-
THCA	cis	rs2797160	1	rs1739348	ENSG00000237742.5	RP11-624M8.1	5.11	4.64e-07	6.3e-05	0.2	0.23	Endometrial cancer;	chr6:125693427	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1739349	ENSG00000237742.5	RP11-624M8.1	5.11	4.64e-07	6.3e-05	0.2	0.23	Endometrial cancer;	chr6:125693838	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.967	rs1578793	ENSG00000237742.5	RP11-624M8.1	5.11	4.64e-07	6.3e-05	0.2	0.23	Endometrial cancer;	chr6:125693911	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1578794	ENSG00000237742.5	RP11-624M8.1	5.11	4.64e-07	6.3e-05	0.2	0.23	Endometrial cancer;	chr6:125694323	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs6927161	ENSG00000237742.5	RP11-624M8.1	5.11	4.64e-07	6.3e-05	0.2	0.23	Endometrial cancer;	chr6:125694808	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs6904992	ENSG00000237742.5	RP11-624M8.1	5.11	4.64e-07	6.3e-05	0.2	0.23	Endometrial cancer;	chr6:125694857	chr6:125578558~125749190:-
THCA	cis	rs7688540	0.771	rs11248009	ENSG00000211553.1	AC253576.2	-5.11	4.64e-07	6.3e-05	-0.35	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:136461~136568:+
THCA	cis	rs7688540	0.723	rs1986386	ENSG00000211553.1	AC253576.2	-5.11	4.64e-07	6.3e-05	-0.35	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:136461~136568:+
THCA	cis	rs7688540	0.723	rs61794999	ENSG00000211553.1	AC253576.2	-5.11	4.64e-07	6.3e-05	-0.35	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:136461~136568:+
THCA	cis	rs9425766	0.679	rs10912761	ENSG00000227373.4	RP11-160H22.5	5.11	4.64e-07	6.3e-05	0.32	0.23	Life satisfaction;	chr1:174312466	chr1:174115300~174160004:-
THCA	cis	rs6547741	1	rs6718128	ENSG00000234072.1	AC074117.10	-5.11	4.65e-07	6.3e-05	-0.17	-0.23	Oral cavity cancer;	chr2:27610885	chr2:27356246~27367622:+
THCA	cis	rs11722228	0.964	rs10939614	ENSG00000261490.1	RP11-448G15.3	-5.11	4.65e-07	6.3e-05	-0.16	-0.23	Urate levels;Serum uric acid levels;Gout;	chr4:9924989	chr4:10068089~10073019:-
THCA	cis	rs17214007	0.877	rs79295535	ENSG00000263335.1	AF001548.5	-5.11	4.65e-07	6.31e-05	-0.37	-0.23	Cognitive function;	chr16:15750108	chr16:15726674~15732993:+
THCA	cis	rs7474896	1	rs11597286	ENSG00000263064.2	RP11-291L22.7	5.11	4.65e-07	6.31e-05	0.37	0.23	Obesity (extreme);	chr10:37817527	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs9418288	ENSG00000263064.2	RP11-291L22.7	5.11	4.65e-07	6.31e-05	0.37	0.23	Obesity (extreme);	chr10:37818208	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs9418294	ENSG00000263064.2	RP11-291L22.7	5.11	4.65e-07	6.31e-05	0.37	0.23	Obesity (extreme);	chr10:37826658	chr10:38448689~38448949:+
THCA	cis	rs2803122	0.905	rs10123360	ENSG00000273226.1	RP11-513M16.8	-5.11	4.65e-07	6.31e-05	-0.21	-0.23	Pulse pressure;	chr9:19303664	chr9:19375451~19375996:+
THCA	cis	rs10904908	1	rs7920002	ENSG00000229124.5	VIM-AS1	-5.11	4.65e-07	6.31e-05	-0.22	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17217767	chr10:17214239~17229985:-
THCA	cis	rs10904908	1	rs7903402	ENSG00000229124.5	VIM-AS1	-5.11	4.65e-07	6.31e-05	-0.22	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17217773	chr10:17214239~17229985:-
THCA	cis	rs10904908	1	rs7920112	ENSG00000229124.5	VIM-AS1	-5.11	4.65e-07	6.31e-05	-0.22	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17217864	chr10:17214239~17229985:-
THCA	cis	rs7746199	0.736	rs17693963	ENSG00000226314.6	ZNF192P1	-5.11	4.65e-07	6.31e-05	-0.47	-0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28161781~28169594:+
THCA	cis	rs7394190	0.748	rs4746146	ENSG00000271816.1	BMS1P4	-5.11	4.65e-07	6.31e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73767439	chr10:73699151~73730487:-
THCA	cis	rs1707322	1	rs1707337	ENSG00000281133.1	AL355480.3	5.11	4.65e-07	6.31e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs1768807	ENSG00000281133.1	AL355480.3	5.11	4.65e-07	6.31e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45580892~45580996:-
THCA	cis	rs4460629	0.901	rs4745	ENSG00000225855.5	RUSC1-AS1	-5.11	4.65e-07	6.31e-05	-0.15	-0.23	Serum magnesium levels;	chr1:155133751	chr1:155316863~155324176:-
THCA	cis	rs8028182	0.549	rs10775209	ENSG00000260269.4	CTD-2323K18.1	5.11	4.66e-07	6.32e-05	0.34	0.23	Sudden cardiac arrest;	chr15:75342418	chr15:75527150~75601205:-
THCA	cis	rs7688540	0.8	rs2353599	ENSG00000275426.1	CH17-262A2.1	5.11	4.66e-07	6.32e-05	0.28	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:149738~150317:+
THCA	cis	rs1552244	0.554	rs6762702	ENSG00000180385.7	EMC3-AS1	5.11	4.66e-07	6.32e-05	0.22	0.23	Alzheimer's disease;	chr3:10014105	chr3:9986893~10006990:+
THCA	cis	rs7267979	0.789	rs1983974	ENSG00000125804.12	FAM182A	5.11	4.66e-07	6.32e-05	0.28	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26054655~26086917:+
THCA	cis	rs2880765	0.835	rs28874135	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.66e-07	6.32e-05	-0.25	-0.23	Coronary artery disease;	chr15:85488272	chr15:85415228~85415633:+
THCA	cis	rs1876905	0.539	rs240985	ENSG00000230177.1	RP5-1112D6.4	5.11	4.66e-07	6.32e-05	0.26	0.23	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111277932~111278742:+
THCA	cis	rs1552244	1	rs9875081	ENSG00000180385.7	EMC3-AS1	5.11	4.66e-07	6.32e-05	0.25	0.23	Alzheimer's disease;	chr3:10042251	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs9809061	ENSG00000180385.7	EMC3-AS1	5.11	4.66e-07	6.32e-05	0.25	0.23	Alzheimer's disease;	chr3:10043446	chr3:9986893~10006990:+
THCA	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	5.11	4.66e-07	6.32e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
THCA	cis	rs7951911	1	rs966905	ENSG00000254427.1	RP11-430H10.1	5.11	4.66e-07	6.33e-05	0.33	0.23	IgG glycosylation;	chr11:45083490	chr11:45355371~45366121:+
THCA	cis	rs16958440	0.581	rs56395942	ENSG00000267800.1	RP11-49K24.5	-5.11	4.67e-07	6.33e-05	-0.44	-0.23	Sitting height ratio;	chr18:47145928	chr18:47137018~47137290:+
THCA	cis	rs2243480	1	rs316331	ENSG00000230295.1	RP11-458F8.2	5.11	4.67e-07	6.33e-05	0.27	0.23	Diabetic kidney disease;	chr7:66139635	chr7:66880708~66882981:+
THCA	cis	rs9843304	0.565	rs9857136	ENSG00000240541.2	TM4SF1-AS1	-5.11	4.67e-07	6.33e-05	-0.21	-0.23	Gallstone disease;	chr3:149492066	chr3:149377778~149386583:+
THCA	cis	rs2243480	1	rs160644	ENSG00000230295.1	RP11-458F8.2	-5.11	4.67e-07	6.33e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66093199	chr7:66880708~66882981:+
THCA	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-5.11	4.67e-07	6.34e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
THCA	cis	rs7647973	0.769	rs6446204	ENSG00000228638.1	FCF1P2	-5.11	4.67e-07	6.34e-05	-0.29	-0.23	Menarche (age at onset);	chr3:48997446	chr3:48290793~48291375:-
THCA	cis	rs10875746	0.669	rs2279464	ENSG00000258234.1	RP11-370I10.2	5.11	4.67e-07	6.34e-05	0.28	0.23	Longevity (90 years and older);	chr12:48296626	chr12:48231098~48284210:-
THCA	cis	rs1122401	0.532	rs10067633	ENSG00000280159.1	CTD-2591A1.1	5.11	4.67e-07	6.34e-05	0.31	0.23	Smoking initiation;	chr5:54578346	chr5:54643557~54645987:+
THCA	cis	rs3213758	1	rs112654894	ENSG00000275191.1	RP11-36I17.2	-5.11	4.67e-07	6.34e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53694298	chr16:53628256~53628816:-
THCA	cis	rs9634489	0.708	rs2183981	ENSG00000247400.3	DNAJC3-AS1	-5.11	4.68e-07	6.34e-05	-0.14	-0.23	Body mass index;	chr13:96357332	chr13:95648733~95676925:-
THCA	cis	rs875971	0.545	rs1796217	ENSG00000232546.1	RP11-458F8.1	-5.11	4.68e-07	6.35e-05	-0.22	-0.23	Aortic root size;	chr7:66620931	chr7:66848496~66858136:+
THCA	cis	rs7976269	0.609	rs7135891	ENSG00000275476.1	RP11-996F15.4	-5.11	4.68e-07	6.35e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29053944	chr12:29277397~29277882:-
THCA	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-5.11	4.68e-07	6.35e-05	-0.31	-0.23	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-5.11	4.68e-07	6.35e-05	-0.31	-0.23	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-5.11	4.68e-07	6.35e-05	-0.31	-0.23	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-5.11	4.68e-07	6.35e-05	-0.31	-0.23	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-5.11	4.68e-07	6.35e-05	-0.31	-0.23	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-5.11	4.68e-07	6.35e-05	-0.31	-0.23	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
THCA	cis	rs2562456	0.833	rs7246339	ENSG00000268081.1	RP11-678G14.2	5.11	4.68e-07	6.35e-05	0.39	0.23	Pain;	chr19:21292495	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs55899865	ENSG00000268081.1	RP11-678G14.2	5.11	4.68e-07	6.35e-05	0.39	0.23	Pain;	chr19:21298933	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs11667103	ENSG00000268081.1	RP11-678G14.2	5.11	4.68e-07	6.35e-05	0.39	0.23	Pain;	chr19:21303839	chr19:21554640~21569237:-
THCA	cis	rs3213758	1	rs11075982	ENSG00000275191.1	RP11-36I17.2	-5.11	4.68e-07	6.35e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53686212	chr16:53628256~53628816:-
THCA	cis	rs6657613	0.903	rs2076601	ENSG00000186301.8	MST1P2	-5.11	4.68e-07	6.35e-05	-0.19	-0.23	Hip circumference adjusted for BMI;	chr1:17003958	chr1:16645622~16650289:+
THCA	cis	rs3796352	1	rs58660500	ENSG00000242142.1	SERBP1P3	-5.11	4.68e-07	6.35e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53052557	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs71301809	ENSG00000242142.1	SERBP1P3	-5.11	4.68e-07	6.35e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53056296	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs35576914	ENSG00000242142.1	SERBP1P3	-5.11	4.68e-07	6.35e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53058254	chr3:53064283~53065091:-
THCA	cis	rs7429990	0.864	rs35698005	ENSG00000228638.1	FCF1P2	5.11	4.68e-07	6.35e-05	0.22	0.23	Educational attainment (years of education);	chr3:47800558	chr3:48290793~48291375:-
THCA	cis	rs3813579	1	rs3813579	ENSG00000261390.4	RP11-345M22.2	-5.11	4.68e-07	6.35e-05	-0.26	-0.23	Thyroid volume;	chr16:79715379	chr16:79715232~79770563:-
THCA	cis	rs8027521	0.557	rs3985781	ENSG00000280362.1	RP11-643A5.3	5.11	4.68e-07	6.35e-05	0.28	0.23	Circulating chemerin levels;	chr15:53954980	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.557	rs2219756	ENSG00000280362.1	RP11-643A5.3	5.11	4.68e-07	6.35e-05	0.28	0.23	Circulating chemerin levels;	chr15:53955028	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.557	rs2199608	ENSG00000280362.1	RP11-643A5.3	5.11	4.68e-07	6.35e-05	0.28	0.23	Circulating chemerin levels;	chr15:53955120	chr15:53910769~53914712:+
THCA	cis	rs2251381	0.741	rs2735966	ENSG00000176054.6	RPL23P2	5.11	4.68e-07	6.35e-05	0.2	0.23	Selective IgA deficiency;	chr21:29165853	chr21:28997613~28998033:-
THCA	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	5.11	4.68e-07	6.35e-05	0.27	0.23	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
THCA	cis	rs17767392	0.958	rs9323561	ENSG00000259146.3	RP1-261D10.2	-5.11	4.68e-07	6.35e-05	-0.3	-0.23	Mitral valve prolapse;	chr14:71564846	chr14:71292729~71321814:-
THCA	cis	rs9719620	0.834	rs4731785	ENSG00000236753.4	MKLN1-AS	-5.11	4.69e-07	6.35e-05	-0.22	-0.23	Male-pattern baldness;	chr7:131301050	chr7:131309744~131328222:-
THCA	cis	rs7829975	0.617	rs4841071	ENSG00000253981.4	ALG1L13P	5.11	4.69e-07	6.36e-05	0.22	0.23	Mood instability;	chr8:8933634	chr8:8236003~8244667:-
THCA	cis	rs8020095	0.571	rs7145718	ENSG00000258561.1	RP11-72M17.1	-5.11	4.69e-07	6.36e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:66815465	chr14:66212810~66509394:-
THCA	cis	rs2120243	0.539	rs6441128	ENSG00000244515.1	KRT18P34	-5.11	4.69e-07	6.36e-05	-0.28	-0.23	Hepatocellular carcinoma in hepatitis B infection;	chr3:157403469	chr3:157162663~157163932:-
THCA	cis	rs1707322	0.89	rs2297883	ENSG00000281133.1	AL355480.3	5.11	4.69e-07	6.36e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs1707338	ENSG00000281133.1	AL355480.3	5.11	4.69e-07	6.36e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.964	rs1707339	ENSG00000281133.1	AL355480.3	5.11	4.69e-07	6.36e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs1768818	ENSG00000281133.1	AL355480.3	5.11	4.69e-07	6.36e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs1768817	ENSG00000281133.1	AL355480.3	5.11	4.69e-07	6.36e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs785470	ENSG00000281133.1	AL355480.3	5.11	4.69e-07	6.36e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45580892~45580996:-
THCA	cis	rs6908034	1	rs6908034	ENSG00000228412.5	RP4-625H18.2	5.11	4.69e-07	6.36e-05	0.38	0.23	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19773699	chr6:19802164~19804752:-
THCA	cis	rs7829975	0.572	rs28446104	ENSG00000233609.3	RP11-62H7.2	-5.11	4.7e-07	6.37e-05	-0.23	-0.23	Mood instability;	chr8:8938391	chr8:8961200~8979025:+
THCA	cis	rs600231	0.542	rs11227196	ENSG00000245532.5	NEAT1	5.11	4.7e-07	6.37e-05	0.2	0.23	Bone mineral density;	chr11:65467451	chr11:65422774~65445540:+
THCA	cis	rs6479874	1	rs10740093	ENSG00000223502.1	RP11-96B5.3	-5.11	4.7e-07	6.37e-05	-0.28	-0.23	Migraine;	chr10:51010802	chr10:51062579~51068553:-
THCA	cis	rs922182	0.783	rs12438519	ENSG00000275785.1	RP11-111E14.2	5.11	4.7e-07	6.37e-05	0.26	0.23	Blood protein levels;	chr15:64019146	chr15:63890030~63890317:+
THCA	cis	rs4660456	0.576	rs2780948	ENSG00000272145.1	NFYC-AS1	5.11	4.7e-07	6.37e-05	0.15	0.23	Platelet count;	chr1:40776205	chr1:40690380~40692066:-
THCA	cis	rs2255336	0.938	rs2734414	ENSG00000245648.1	RP11-277P12.20	5.11	4.7e-07	6.38e-05	0.25	0.23	Blood protein levels;	chr12:10446203	chr12:10363769~10398506:+
THCA	cis	rs227275	0.554	rs223457	ENSG00000248971.2	KRT8P46	-5.11	4.7e-07	6.38e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102728746~102730171:-
THCA	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	5.11	4.7e-07	6.38e-05	0.27	0.23	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
THCA	cis	rs911119	0.954	rs2405367	ENSG00000270001.1	RP11-218C14.8	5.11	4.71e-07	6.38e-05	0.34	0.23	Chronic kidney disease;	chr20:23642243	chr20:23631826~23632316:-
THCA	cis	rs2562456	0.834	rs2650848	ENSG00000268081.1	RP11-678G14.2	5.11	4.71e-07	6.38e-05	0.38	0.23	Pain;	chr19:21403835	chr19:21554640~21569237:-
THCA	cis	rs3770081	1	rs4292089	ENSG00000272564.1	RP11-548P2.2	-5.11	4.71e-07	6.39e-05	-0.4	-0.23	Facial emotion recognition (sad faces);	chr2:85912057	chr2:85904279~85904727:+
THCA	cis	rs3770081	1	rs7570836	ENSG00000272564.1	RP11-548P2.2	-5.11	4.71e-07	6.39e-05	-0.4	-0.23	Facial emotion recognition (sad faces);	chr2:85914310	chr2:85904279~85904727:+
THCA	cis	rs16852403	0.548	rs1412784	ENSG00000224687.1	RASAL2-AS1	5.11	4.71e-07	6.39e-05	0.35	0.23	Childhood ear infection;	chr1:178237529	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.548	rs1018706	ENSG00000224687.1	RASAL2-AS1	5.11	4.71e-07	6.39e-05	0.35	0.23	Childhood ear infection;	chr1:178240760	chr1:178091508~178093984:-
THCA	cis	rs2145598	0.617	rs9323328	ENSG00000279636.2	LINC00216	5.11	4.71e-07	6.39e-05	0.22	0.23	Coronary artery disease;	chr14:58186796	chr14:58288033~58289158:+
THCA	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-5.11	4.71e-07	6.39e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
THCA	cis	rs28374715	0.681	rs28728213	ENSG00000247556.5	OIP5-AS1	5.11	4.71e-07	6.39e-05	0.21	0.23	Ulcerative colitis;	chr15:41361404	chr15:41283990~41309737:+
THCA	cis	rs1823913	0.637	rs4853578	ENSG00000280083.1	RP11-317J9.1	-5.11	4.72e-07	6.39e-05	-0.26	-0.23	Obesity-related traits;	chr2:191297215	chr2:191154118~191156070:-
THCA	cis	rs972578	0.692	rs4822217	ENSG00000274717.1	RP1-47A17.1	-5.11	4.72e-07	6.39e-05	-0.24	-0.23	Mean platelet volume;	chr22:42882156	chr22:42791814~42794313:-
THCA	cis	rs1865760	0.555	rs2051541	ENSG00000272462.2	U91328.19	5.11	4.72e-07	6.4e-05	0.18	0.23	Height;	chr6:25944983	chr6:25992662~26001775:+
THCA	cis	rs8027521	0.666	rs11630101	ENSG00000280362.1	RP11-643A5.3	5.11	4.72e-07	6.4e-05	0.28	0.23	Circulating chemerin levels;	chr15:53967082	chr15:53910769~53914712:+
THCA	cis	rs240993	0.812	rs118203	ENSG00000271789.1	RP5-1112D6.7	-5.11	4.72e-07	6.4e-05	-0.29	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111337017	chr6:111297126~111298510:+
THCA	cis	rs7727544	0.582	rs6896703	ENSG00000224431.1	AC063976.7	-5.11	4.72e-07	6.4e-05	-0.19	-0.23	Blood metabolite levels;	chr5:132185602	chr5:132199456~132203487:+
THCA	cis	rs919433	0.662	rs2043018	ENSG00000231621.1	AC013264.2	-5.11	4.72e-07	6.4e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372234	chr2:197197991~197199273:+
THCA	cis	rs6565180	0.791	rs4247355	ENSG00000274653.1	RP11-347C12.11	-5.11	4.72e-07	6.4e-05	-0.22	-0.23	Tonsillectomy;	chr16:30380778	chr16:30359825~30360336:+
THCA	cis	rs8028182	0.636	rs7171507	ENSG00000260274.1	RP11-817O13.8	5.11	4.72e-07	6.4e-05	0.16	0.23	Sudden cardiac arrest;	chr15:75444946	chr15:75368155~75369584:+
THCA	cis	rs972578	0.765	rs5751396	ENSG00000274717.1	RP1-47A17.1	-5.11	4.72e-07	6.4e-05	-0.24	-0.23	Mean platelet volume;	chr22:42876079	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs5759006	ENSG00000274717.1	RP1-47A17.1	-5.11	4.72e-07	6.4e-05	-0.24	-0.23	Mean platelet volume;	chr22:42877734	chr22:42791814~42794313:-
THCA	cis	rs34779708	0.931	rs7923217	ENSG00000271335.4	RP11-324I22.4	5.11	4.72e-07	6.4e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35314552~35336401:-
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000230295.1	RP11-458F8.2	-5.11	4.72e-07	6.4e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66100518	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs73142265	ENSG00000228409.4	CCT6P1	-5.11	4.73e-07	6.4e-05	-0.2	-0.23	Aortic root size;	chr7:66234510	chr7:65751142~65763354:+
THCA	cis	rs16852403	0.517	rs2902217	ENSG00000224687.1	RASAL2-AS1	5.11	4.74e-07	6.41e-05	0.35	0.23	Childhood ear infection;	chr1:178279027	chr1:178091508~178093984:-
THCA	cis	rs2880765	0.835	rs11074276	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.74e-07	6.41e-05	-0.25	-0.23	Coronary artery disease;	chr15:85487132	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.805	rs11858817	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.74e-07	6.41e-05	-0.25	-0.23	Coronary artery disease;	chr15:85488029	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs11633604	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.74e-07	6.41e-05	-0.25	-0.23	Coronary artery disease;	chr15:85488348	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs7164106	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.74e-07	6.41e-05	-0.25	-0.23	Coronary artery disease;	chr15:85489359	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs1872074	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.74e-07	6.41e-05	-0.25	-0.23	Coronary artery disease;	chr15:85489953	chr15:85415228~85415633:+
THCA	cis	rs7246657	0.525	rs10401417	ENSG00000276846.1	CTD-3220F14.3	5.11	4.74e-07	6.42e-05	0.25	0.23	Coronary artery calcification;	chr19:36976638	chr19:37314868~37315620:-
THCA	cis	rs6968419	0.714	rs7811984	ENSG00000237870.5	AC073130.1	5.11	4.74e-07	6.42e-05	0.25	0.23	Intraocular pressure;	chr7:116246025	chr7:116275606~116286734:-
THCA	cis	rs4888671	1	rs76751500	ENSG00000261707.1	RP11-264M12.2	5.11	4.74e-07	6.42e-05	0.42	0.23	Obesity-related traits;	chr16:77751874	chr16:77741468~77743000:-
THCA	cis	rs6490294	0.615	rs78729142	ENSG00000226469.1	ADAM1B	5.11	4.74e-07	6.42e-05	0.37	0.23	Mean platelet volume;	chr12:111919456	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs79976090	ENSG00000226469.1	ADAM1B	5.11	4.74e-07	6.42e-05	0.37	0.23	Mean platelet volume;	chr12:111928314	chr12:111927018~111929017:+
THCA	cis	rs1005277	0.505	rs200939	ENSG00000276805.1	RP11-291L22.6	5.11	4.74e-07	6.42e-05	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38451030~38451785:+
THCA	cis	rs16852403	0.548	rs7547504	ENSG00000224687.1	RASAL2-AS1	5.11	4.75e-07	6.43e-05	0.35	0.23	Childhood ear infection;	chr1:178232177	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.548	rs3748788	ENSG00000224687.1	RASAL2-AS1	5.11	4.75e-07	6.43e-05	0.35	0.23	Childhood ear infection;	chr1:178233672	chr1:178091508~178093984:-
THCA	cis	rs6921919	0.609	rs9461455	ENSG00000280107.1	AL022393.9	-5.11	4.75e-07	6.43e-05	-0.23	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28170845~28172521:+
THCA	cis	rs763121	0.853	rs138716	ENSG00000235209.1	CTA-150C2.13	5.11	4.75e-07	6.43e-05	0.33	0.23	Menopause (age at onset);	chr22:38750522	chr22:38921227~38924708:+
THCA	cis	rs7911264	1	rs10882100	ENSG00000236493.2	EIF2S2P3	5.11	4.75e-07	6.43e-05	0.24	0.23	Inflammatory bowel disease;	chr10:92700930	chr10:92668745~92669743:-
THCA	cis	rs2412819	0.571	rs514255	ENSG00000249839.1	AC011330.5	-5.11	4.75e-07	6.43e-05	-0.34	-0.23	Lung cancer;	chr15:43893134	chr15:43663654~43684339:-
THCA	cis	rs7246657	0.525	rs997516	ENSG00000276846.1	CTD-3220F14.3	5.11	4.75e-07	6.43e-05	0.25	0.23	Coronary artery calcification;	chr19:36983362	chr19:37314868~37315620:-
THCA	cis	rs6835098	0.5	rs13112928	ENSG00000245213.5	RP11-10K16.1	5.11	4.75e-07	6.43e-05	0.19	0.23	Dementia and core Alzheimer's disease neuropathologic changes;	chr4:173236981	chr4:173131928~173169652:-
THCA	cis	rs613391	0.702	rs647549	ENSG00000224549.1	RP11-370B11.3	5.11	4.75e-07	6.44e-05	0.26	0.23	Quantitative traits;	chr9:22709757	chr9:22767175~22768316:+
THCA	cis	rs72772090	0.71	rs11739280	ENSG00000248734.2	CTD-2260A17.1	5.11	4.75e-07	6.44e-05	0.38	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96738443	chr5:96784777~96785999:+
THCA	cis	rs17270561	0.666	rs9356988	ENSG00000272462.2	U91328.19	-5.11	4.75e-07	6.44e-05	-0.19	-0.23	Iron status biomarkers;	chr6:25777253	chr6:25992662~26001775:+
THCA	cis	rs6445975	0.915	rs11130633	ENSG00000272360.1	RP11-359I18.5	5.11	4.75e-07	6.44e-05	0.24	0.23	Systemic lupus erythematosus;	chr3:58385065	chr3:58490830~58491291:-
THCA	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-5.11	4.75e-07	6.44e-05	-0.33	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
THCA	cis	rs10510102	0.872	rs7906271	ENSG00000226864.1	ATE1-AS1	-5.11	4.76e-07	6.44e-05	-0.37	-0.23	Breast cancer;	chr10:121948207	chr10:121928312~121951965:+
THCA	cis	rs16852403	0.517	rs7531227	ENSG00000224687.1	RASAL2-AS1	5.11	4.76e-07	6.44e-05	0.35	0.23	Childhood ear infection;	chr1:178263334	chr1:178091508~178093984:-
THCA	cis	rs2944755	0.723	rs34051681	ENSG00000279766.1	RP11-642A1.2	-5.11	4.76e-07	6.44e-05	-0.33	-0.23	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140577602	chr8:140572142~140572812:-
THCA	cis	rs2797160	0.935	rs12717178	ENSG00000237742.5	RP11-624M8.1	5.11	4.76e-07	6.44e-05	0.2	0.23	Endometrial cancer;	chr6:125695353	chr6:125578558~125749190:-
THCA	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	5.11	4.76e-07	6.44e-05	0.14	0.23	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
THCA	cis	rs972578	0.645	rs2007395	ENSG00000274717.1	RP1-47A17.1	-5.11	4.76e-07	6.44e-05	-0.24	-0.23	Mean platelet volume;	chr22:42875165	chr22:42791814~42794313:-
THCA	cis	rs34779708	0.966	rs4934732	ENSG00000271335.4	RP11-324I22.4	5.11	4.76e-07	6.44e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35314552~35336401:-
THCA	cis	rs2179367	0.6	rs9498355	ENSG00000268592.3	RAET1E-AS1	-5.11	4.76e-07	6.45e-05	-0.36	-0.23	Dupuytren's disease;	chr6:149442274	chr6:149863494~149919507:+
THCA	cis	rs12893668	0.703	rs35498576	ENSG00000269958.1	RP11-73M18.8	5.11	4.77e-07	6.45e-05	0.23	0.23	Reticulocyte count;	chr14:103559556	chr14:103696353~103697163:+
THCA	cis	rs7924176	0.668	rs7895133	ENSG00000213731.2	RAB5CP1	-5.11	4.77e-07	6.45e-05	-0.28	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74247697	chr10:74423435~74424014:-
THCA	cis	rs1823913	0.637	rs17348013	ENSG00000280083.1	RP11-317J9.1	5.11	4.77e-07	6.45e-05	0.26	0.23	Obesity-related traits;	chr2:191303726	chr2:191154118~191156070:-
THCA	cis	rs10895275	0.851	rs7110557	ENSG00000277459.1	RP11-732A21.3	-5.11	4.77e-07	6.45e-05	-0.18	-0.23	Migraine;	chr11:102197320	chr11:102109827~102110457:-
THCA	cis	rs13434995	0.588	rs114571142	ENSG00000273257.1	RP11-177J6.1	-5.11	4.77e-07	6.46e-05	-0.34	-0.23	Adiponectin levels;	chr4:55412991	chr4:55387949~55388271:+
THCA	cis	rs72772090	0.71	rs11750399	ENSG00000248734.2	CTD-2260A17.1	-5.11	4.77e-07	6.46e-05	-0.39	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742236	chr5:96784777~96785999:+
THCA	cis	rs8020095	0.571	rs17247792	ENSG00000258561.1	RP11-72M17.1	-5.11	4.77e-07	6.46e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:66767739	chr14:66212810~66509394:-
THCA	cis	rs7336933	0.932	rs7336616	ENSG00000278338.3	VWA8-AS1	5.11	4.77e-07	6.46e-05	0.38	0.23	Calcium levels;	chr13:41984973	chr13:41955808~41981565:+
THCA	cis	rs2880765	0.835	rs4360874	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.77e-07	6.46e-05	-0.25	-0.23	Coronary artery disease;	chr15:85497589	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.835	rs4514633	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.77e-07	6.46e-05	-0.25	-0.23	Coronary artery disease;	chr15:85497786	chr15:85415228~85415633:+
THCA	cis	rs6121246	0.542	rs2376990	ENSG00000230613.1	HM13-AS1	5.11	4.77e-07	6.46e-05	0.26	0.23	Mean corpuscular hemoglobin;	chr20:31650941	chr20:31567707~31573263:-
THCA	cis	rs7824557	0.675	rs2736265	ENSG00000154316.13	TDH	-5.11	4.78e-07	6.46e-05	-0.17	-0.23	Retinal vascular caliber;	chr8:11329165	chr8:11339637~11368452:+
THCA	cis	rs1823913	1	rs10445782	ENSG00000227542.1	AC092614.2	-5.11	4.78e-07	6.47e-05	-0.28	-0.23	Obesity-related traits;	chr2:191236639	chr2:191229165~191246172:-
THCA	cis	rs7246657	0.525	rs997516	ENSG00000226686.6	LINC01535	-5.11	4.78e-07	6.47e-05	-0.36	-0.23	Coronary artery calcification;	chr19:36983362	chr19:37251912~37265535:+
THCA	cis	rs12906542	0.529	rs62008651	ENSG00000259792.1	RP11-114H24.6	-5.11	4.78e-07	6.47e-05	-0.33	-0.23	Breast cancer;	chr15:77984075	chr15:77993405~77995289:+
THCA	cis	rs60695258	0.55	rs340648	ENSG00000251411.1	RP11-397E7.4	5.11	4.78e-07	6.47e-05	0.21	0.23	Hematocrit;	chr4:87019788	chr4:86913266~86914817:-
THCA	cis	rs2880765	0.835	rs4842884	ENSG00000259630.2	CTD-2262B20.1	-5.11	4.78e-07	6.47e-05	-0.25	-0.23	Coronary artery disease;	chr15:85491943	chr15:85415228~85415633:+
THCA	cis	rs7727544	0.684	rs270602	ENSG00000263597.1	MIR3936	5.11	4.78e-07	6.47e-05	0.22	0.23	Blood metabolite levels;	chr5:132321007	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.684	rs272893	ENSG00000263597.1	MIR3936	5.11	4.78e-07	6.47e-05	0.22	0.23	Blood metabolite levels;	chr5:132327369	chr5:132365490~132365599:-
THCA	cis	rs9863	0.861	rs4930725	ENSG00000269997.1	RP11-214K3.21	-5.11	4.78e-07	6.47e-05	-0.28	-0.23	White blood cell count;	chr12:123943615	chr12:123966077~123966629:-
THCA	cis	rs78487399	0.808	rs79845707	ENSG00000234936.1	AC010883.5	5.11	4.78e-07	6.47e-05	0.32	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43561662	chr2:43229573~43233394:+
THCA	cis	rs6545883	0.929	rs1186710	ENSG00000270820.4	RP11-355B11.2	5.11	4.78e-07	6.47e-05	0.19	0.23	Tuberculosis;	chr2:61461592	chr2:61471188~61484130:+
THCA	cis	rs1580019	0.587	rs7806113	ENSG00000231952.3	DPY19L1P2	-5.11	4.78e-07	6.47e-05	-0.28	-0.23	Cognitive ability;	chr7:32513472	chr7:32812757~32838570:+
THCA	cis	rs7221109	0.591	rs803125	ENSG00000278834.1	RP11-458J1.1	-5.11	4.79e-07	6.48e-05	-0.24	-0.23	Type 1 diabetes;	chr17:40581127	chr17:40648300~40649718:+
THCA	cis	rs7267979	0.816	rs405822	ENSG00000125804.12	FAM182A	-5.11	4.79e-07	6.48e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.816	rs6138593	ENSG00000125804.12	FAM182A	-5.11	4.79e-07	6.48e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.816	rs409853	ENSG00000125804.12	FAM182A	-5.11	4.79e-07	6.48e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.816	rs390123	ENSG00000125804.12	FAM182A	-5.11	4.79e-07	6.48e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.816	rs404775	ENSG00000125804.12	FAM182A	-5.11	4.79e-07	6.48e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26054655~26086917:+
THCA	cis	rs2255336	0.81	rs7139147	ENSG00000245648.1	RP11-277P12.20	5.11	4.8e-07	6.49e-05	0.32	0.23	Blood protein levels;	chr12:10361956	chr12:10363769~10398506:+
THCA	cis	rs12188164	0.543	rs2434695	ENSG00000221990.4	EXOC3-AS1	-5.11	4.8e-07	6.49e-05	-0.18	-0.23	Cystic fibrosis severity;	chr5:464062	chr5:441498~443160:-
THCA	cis	rs7824557	0.836	rs765731	ENSG00000154316.13	TDH	5.11	4.8e-07	6.49e-05	0.16	0.23	Retinal vascular caliber;	chr8:11263989	chr8:11339637~11368452:+
THCA	cis	rs1823913	0.614	rs4853576	ENSG00000280083.1	RP11-317J9.1	5.11	4.8e-07	6.5e-05	0.26	0.23	Obesity-related traits;	chr2:191296618	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs4853577	ENSG00000280083.1	RP11-317J9.1	5.11	4.8e-07	6.5e-05	0.26	0.23	Obesity-related traits;	chr2:191297118	chr2:191154118~191156070:-
THCA	cis	rs2797160	1	rs6934435	ENSG00000237742.5	RP11-624M8.1	5.11	4.8e-07	6.5e-05	0.2	0.23	Endometrial cancer;	chr6:125696335	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1739354	ENSG00000237742.5	RP11-624M8.1	5.11	4.8e-07	6.5e-05	0.2	0.23	Endometrial cancer;	chr6:125696662	chr6:125578558~125749190:-
THCA	cis	rs34779708	0.931	rs4934721	ENSG00000271335.4	RP11-324I22.4	5.11	4.8e-07	6.5e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35314552~35336401:-
THCA	cis	rs12908161	1	rs60957376	ENSG00000275120.1	RP11-182J1.17	5.11	4.8e-07	6.5e-05	0.27	0.23	Schizophrenia;	chr15:84737561	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs11632465	ENSG00000275120.1	RP11-182J1.17	5.11	4.8e-07	6.5e-05	0.27	0.23	Schizophrenia;	chr15:84738814	chr15:84599434~84606463:-
THCA	cis	rs11977715	0.538	rs10248407	ENSG00000233942.1	AC004012.1	-5.11	4.8e-07	6.5e-05	-0.3	-0.23	Middle childhood and early adolescence aggressive behavior;	chr7:95499441	chr7:95471835~95473998:+
THCA	cis	rs2067615	0.579	rs10861667	ENSG00000260329.1	RP11-412D9.4	-5.11	4.8e-07	6.5e-05	-0.21	-0.23	Heart rate;	chr12:106800998	chr12:106954029~106955497:-
THCA	cis	rs2554380	0.55	rs4842918	ENSG00000230373.7	GOLGA6L5P	5.11	4.81e-07	6.5e-05	0.25	0.23	Height;	chr15:83868247	chr15:84507885~84516814:-
THCA	cis	rs5771225	0.544	rs13055135	ENSG00000273253.2	RP3-402G11.26	-5.11	4.81e-07	6.5e-05	-0.25	-0.23	Late-onset Alzheimer's disease;	chr22:50234050	chr22:50199090~50200837:-
THCA	cis	rs17556028	0.669	rs17484960	ENSG00000230489.1	VAV3-AS1	5.11	4.81e-07	6.5e-05	0.21	0.23	Night sleep phenotypes;	chr1:107794486	chr1:107964443~107994607:+
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	5.11	4.81e-07	6.51e-05	0.28	0.23	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	5.11	4.81e-07	6.51e-05	0.29	0.23	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
THCA	cis	rs6547741	1	rs2384654	ENSG00000234072.1	AC074117.10	5.11	4.81e-07	6.51e-05	0.18	0.23	Oral cavity cancer;	chr2:27624497	chr2:27356246~27367622:+
THCA	cis	rs2440129	0.611	rs10852889	ENSG00000262089.1	RP11-589P10.5	5.1	4.82e-07	6.51e-05	0.21	0.23	Tonsillectomy;	chr17:6997526	chr17:6994642~6995189:-
THCA	cis	rs77972916	0.561	rs10167415	ENSG00000234936.1	AC010883.5	5.1	4.82e-07	6.51e-05	0.27	0.23	Granulocyte percentage of myeloid white cells;	chr2:43325321	chr2:43229573~43233394:+
THCA	cis	rs2559856	0.967	rs3809260	ENSG00000274560.1	RP11-285E23.2	5.1	4.82e-07	6.51e-05	0.14	0.23	Blood protein levels;	chr12:101697239	chr12:101696002~101696450:-
THCA	cis	rs972578	0.765	rs4822216	ENSG00000274717.1	RP1-47A17.1	-5.1	4.82e-07	6.52e-05	-0.24	-0.23	Mean platelet volume;	chr22:42881141	chr22:42791814~42794313:-
THCA	cis	rs16975963	0.644	rs35205379	ENSG00000226686.6	LINC01535	5.1	4.82e-07	6.52e-05	0.31	0.23	Longevity;	chr19:37685941	chr19:37251912~37265535:+
THCA	cis	rs2880765	0.835	rs4843062	ENSG00000259630.2	CTD-2262B20.1	-5.1	4.82e-07	6.52e-05	-0.25	-0.23	Coronary artery disease;	chr15:85496906	chr15:85415228~85415633:+
THCA	cis	rs5752326	0.51	rs5761541	ENSG00000261188.1	CTA-445C9.14	5.1	4.82e-07	6.52e-05	0.22	0.23	Ischemic stroke;	chr22:26463499	chr22:26512537~26514568:+
THCA	cis	rs5752326	0.51	rs5761542	ENSG00000261188.1	CTA-445C9.14	5.1	4.82e-07	6.52e-05	0.22	0.23	Ischemic stroke;	chr22:26463558	chr22:26512537~26514568:+
THCA	cis	rs5752326	0.51	rs5752330	ENSG00000261188.1	CTA-445C9.14	5.1	4.82e-07	6.52e-05	0.22	0.23	Ischemic stroke;	chr22:26463976	chr22:26512537~26514568:+
THCA	cis	rs5752326	0.51	rs713998	ENSG00000261188.1	CTA-445C9.14	5.1	4.82e-07	6.52e-05	0.22	0.23	Ischemic stroke;	chr22:26466246	chr22:26512537~26514568:+
THCA	cis	rs7088591	0.867	rs73294756	ENSG00000276818.1	AC026393.1	5.1	4.82e-07	6.52e-05	0.45	0.23	Blood pressure;	chr10:58046972	chr10:57095699~57095781:+
THCA	cis	rs7403037	0.55	rs61995439	ENSG00000259905.4	PWRN1	5.1	4.82e-07	6.52e-05	0.31	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24479769	chr15:24493137~24652130:+
THCA	cis	rs7267979	0.844	rs2424703	ENSG00000125804.12	FAM182A	-5.1	4.82e-07	6.52e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.74	rs2259961	ENSG00000125804.12	FAM182A	-5.1	4.82e-07	6.52e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.844	rs2474780	ENSG00000125804.12	FAM182A	-5.1	4.82e-07	6.52e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.789	rs4815400	ENSG00000125804.12	FAM182A	5.1	4.82e-07	6.52e-05	0.28	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26054655~26086917:+
THCA	cis	rs8062405	1	rs62036622	ENSG00000278665.1	RP11-666O2.4	5.1	4.83e-07	6.53e-05	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28599241~28601881:-
THCA	cis	rs11648785	0.735	rs868372	ENSG00000222019.6	URAHP	5.1	4.83e-07	6.53e-05	0.19	0.23	Tanning;	chr16:90031587	chr16:90039761~90047773:-
THCA	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-5.1	4.83e-07	6.53e-05	-0.31	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
THCA	cis	rs34779708	0.931	rs11010130	ENSG00000271335.4	RP11-324I22.4	5.1	4.83e-07	6.53e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.897	rs11010131	ENSG00000271335.4	RP11-324I22.4	5.1	4.83e-07	6.53e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35314552~35336401:-
THCA	cis	rs9859260	0.71	rs419068	ENSG00000207650.1	MIR570	-5.1	4.83e-07	6.53e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196055305	chr3:195699401~195699497:+
THCA	cis	rs9859260	0.71	rs366268	ENSG00000207650.1	MIR570	-5.1	4.83e-07	6.53e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196055306	chr3:195699401~195699497:+
THCA	cis	rs9859260	0.744	rs419059	ENSG00000207650.1	MIR570	-5.1	4.83e-07	6.53e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196055313	chr3:195699401~195699497:+
THCA	cis	rs12664251	0.53	rs794251	ENSG00000253194.1	RP11-351A11.1	-5.1	4.83e-07	6.53e-05	-0.32	-0.23	Schizophrenia;	chr6:119027436	chr6:118934785~119031541:+
THCA	cis	rs919433	0.963	rs4850787	ENSG00000231621.1	AC013264.2	5.1	4.83e-07	6.53e-05	0.24	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317026	chr2:197197991~197199273:+
THCA	cis	rs919433	0.783	rs2565165	ENSG00000231621.1	AC013264.2	-5.1	4.83e-07	6.54e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368851	chr2:197197991~197199273:+
THCA	cis	rs4915077	1	rs75700031	ENSG00000230489.1	VAV3-AS1	5.1	4.83e-07	6.54e-05	0.38	0.23	Hypothyroidism;	chr1:107814381	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs4915076	ENSG00000230489.1	VAV3-AS1	5.1	4.83e-07	6.54e-05	0.38	0.23	Hypothyroidism;	chr1:107816883	chr1:107964443~107994607:+
THCA	cis	rs116095464	1	rs28416084	ENSG00000248925.1	CTD-2083E4.6	5.1	4.83e-07	6.54e-05	0.36	0.23	Breast cancer;	chr5:217525	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs9312978	ENSG00000248925.1	CTD-2083E4.6	5.1	4.83e-07	6.54e-05	0.36	0.23	Breast cancer;	chr5:221815	chr5:269858~271516:-
THCA	cis	rs116095464	0.558	rs9312979	ENSG00000248925.1	CTD-2083E4.6	5.1	4.83e-07	6.54e-05	0.36	0.23	Breast cancer;	chr5:221942	chr5:269858~271516:-
THCA	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	5.1	4.84e-07	6.54e-05	0.3	0.23	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	5.1	4.84e-07	6.54e-05	0.3	0.23	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
THCA	cis	rs548181	0.545	rs4486648	ENSG00000254671.2	STT3A-AS1	5.1	4.84e-07	6.54e-05	0.41	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125740694	chr11:125570284~125592568:-
THCA	cis	rs2303319	0.504	rs62189051	ENSG00000227403.1	AC009299.3	5.1	4.84e-07	6.54e-05	0.47	0.23	Cognitive function;	chr2:161765808	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189052	ENSG00000227403.1	AC009299.3	5.1	4.84e-07	6.54e-05	0.47	0.23	Cognitive function;	chr2:161767359	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189053	ENSG00000227403.1	AC009299.3	5.1	4.84e-07	6.54e-05	0.47	0.23	Cognitive function;	chr2:161767814	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189054	ENSG00000227403.1	AC009299.3	5.1	4.84e-07	6.54e-05	0.47	0.23	Cognitive function;	chr2:161768144	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs961421	ENSG00000227403.1	AC009299.3	5.1	4.84e-07	6.54e-05	0.47	0.23	Cognitive function;	chr2:161769589	chr2:161244739~161249050:+
THCA	cis	rs1198430	0.5	rs968280	ENSG00000232482.2	RP4-654C18.1	-5.1	4.84e-07	6.55e-05	-0.33	-0.23	Total cholesterol levels;	chr1:23475472	chr1:23410832~23412146:+
THCA	cis	rs9902453	0.726	rs3110494	ENSG00000263370.1	RP11-68I3.5	5.1	4.84e-07	6.55e-05	0.29	0.23	Coffee consumption (cups per day);	chr17:29649579	chr17:29639627~29640825:+
THCA	cis	rs8020095	0.571	rs6573736	ENSG00000258561.1	RP11-72M17.1	-5.1	4.84e-07	6.55e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66907967	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs7147570	ENSG00000258561.1	RP11-72M17.1	-5.1	4.84e-07	6.55e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66925186	chr14:66212810~66509394:-
THCA	cis	rs2070488	0.775	rs2268762	ENSG00000229589.1	ACVR2B-AS1	5.1	4.85e-07	6.55e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38474584	chr3:38451027~38454820:-
THCA	cis	rs4787484	1	rs11344	ENSG00000214725.6	CDIPT-AS1	-5.1	4.85e-07	6.55e-05	-0.3	-0.23	Response to taxane treatment (placlitaxel);	chr16:29899197	chr16:29863593~29868053:+
THCA	cis	rs17767392	0.705	rs4899393	ENSG00000259146.3	RP1-261D10.2	5.1	4.85e-07	6.55e-05	0.29	0.23	Mitral valve prolapse;	chr14:71273207	chr14:71292729~71321814:-
THCA	cis	rs317689	0.918	rs689415	ENSG00000274979.1	RP11-1143G9.5	5.1	4.85e-07	6.55e-05	0.28	0.23	Response to diuretic therapy;	chr12:69344359	chr12:69326574~69331882:-
THCA	cis	rs2243480	1	rs10807702	ENSG00000232559.3	GS1-124K5.12	5.1	4.85e-07	6.56e-05	0.34	0.23	Diabetic kidney disease;	chr7:66302856	chr7:66554588~66576923:-
THCA	cis	rs228614	0.534	rs223387	ENSG00000248971.2	KRT8P46	-5.1	4.85e-07	6.56e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223381	ENSG00000248971.2	KRT8P46	-5.1	4.85e-07	6.56e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102728746~102730171:-
THCA	cis	rs10256972	0.684	rs4724039	ENSG00000225146.1	AC073957.15	5.1	4.85e-07	6.56e-05	0.24	0.23	Endometriosis;Longevity;	chr7:1071997	chr7:1029025~1043891:+
THCA	cis	rs375066	0.551	rs10500287	ENSG00000267058.1	RP11-15A1.3	5.1	4.85e-07	6.56e-05	0.19	0.23	Breast cancer;	chr19:43827818	chr19:43891804~43901805:-
THCA	cis	rs6547741	0.816	rs10201652	ENSG00000234072.1	AC074117.10	-5.1	4.85e-07	6.56e-05	-0.18	-0.23	Oral cavity cancer;	chr2:27651465	chr2:27356246~27367622:+
THCA	cis	rs6547741	0.788	rs7595739	ENSG00000234072.1	AC074117.10	-5.1	4.85e-07	6.56e-05	-0.18	-0.23	Oral cavity cancer;	chr2:27651696	chr2:27356246~27367622:+
THCA	cis	rs987724	0.593	rs2874494	ENSG00000240875.4	LINC00886	-5.1	4.85e-07	6.56e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156964340	chr3:156747346~156817062:-
THCA	cis	rs7429990	0.864	rs1403578	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47617997	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs883661	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47618611	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs870622	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47618683	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs868255	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47619074	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs4858842	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47619574	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs11130144	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47626444	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7613934	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47640681	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7621236	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47646677	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7624474	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47647786	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs4858846	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47654591	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.803	rs13081356	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47660067	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.803	rs11130145	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47661780	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs2140335	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47663625	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs11130146	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47666322	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs12633604	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47673308	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs6772301	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47682366	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs13063042	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47683825	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs2133601	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47692525	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs6792497	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47693684	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs2030596	ENSG00000228638.1	FCF1P2	5.1	4.85e-07	6.56e-05	0.22	0.23	Educational attainment (years of education);	chr3:47701712	chr3:48290793~48291375:-
THCA	cis	rs12681287	0.517	rs7462883	ENSG00000254231.1	CTD-2284J15.1	5.1	4.86e-07	6.56e-05	0.25	0.23	Caudate activity during reward;	chr8:86514562	chr8:86333274~86343314:-
THCA	cis	rs7085104	0.727	rs12773892	ENSG00000236937.2	PTGES3P4	5.1	4.86e-07	6.56e-05	0.33	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102871420	chr10:102845595~102845950:+
THCA	cis	rs7897654	0.571	rs12767543	ENSG00000236937.2	PTGES3P4	5.1	4.86e-07	6.56e-05	0.33	0.23	Schizophrenia;	chr10:102871906	chr10:102845595~102845950:+
THCA	cis	rs11671005	0.735	rs34188294	ENSG00000265272.2	RN7SL693P	5.1	4.86e-07	6.56e-05	0.32	0.23	Mean platelet volume;	chr19:58408190	chr19:58490797~58491075:+
THCA	cis	rs9925964	0.933	rs8050894	ENSG00000260911.2	RP11-196G11.2	-5.1	4.86e-07	6.56e-05	-0.19	-0.23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:31043150~31049868:+
THCA	cis	rs8049040	0.609	rs16972805	ENSG00000260886.1	TAT-AS1	-5.1	4.86e-07	6.56e-05	-0.32	-0.23	Blood protein levels;	chr16:71444346	chr16:71565789~71578187:+
THCA	cis	rs2243480	1	rs73142162	ENSG00000230295.1	RP11-458F8.2	-5.1	4.86e-07	6.56e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65909309	chr7:66880708~66882981:+
THCA	cis	rs4660456	0.913	rs2744808	ENSG00000272145.1	NFYC-AS1	5.1	4.86e-07	6.56e-05	0.16	0.23	Platelet count;	chr1:40712271	chr1:40690380~40692066:-
THCA	cis	rs7637701	0.78	rs9858158	ENSG00000240875.4	LINC00886	-5.1	4.86e-07	6.57e-05	-0.18	-0.23	Breast cancer;	chr3:156845538	chr3:156747346~156817062:-
THCA	cis	rs12893668	0.697	rs67899457	ENSG00000269958.1	RP11-73M18.8	5.1	4.86e-07	6.57e-05	0.22	0.23	Reticulocyte count;	chr14:103593729	chr14:103696353~103697163:+
THCA	cis	rs6756513	0.5	rs921711	ENSG00000231024.1	AC092431.3	-5.1	4.86e-07	6.57e-05	-0.31	-0.23	Breast cancer;Platelet count;	chr2:69857845	chr2:69700192~69713847:-
THCA	cis	rs60695258	0.55	rs340636	ENSG00000251411.1	RP11-397E7.4	5.1	4.86e-07	6.57e-05	0.21	0.23	Hematocrit;	chr4:87009608	chr4:86913266~86914817:-
THCA	cis	rs5758511	0.68	rs56111723	ENSG00000281538.1	RP4-669P10.20	-5.1	4.87e-07	6.58e-05	-0.25	-0.23	Birth weight;	chr22:42268877	chr22:42138060~42139726:+
THCA	cis	rs7429990	0.864	rs6806860	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47708218	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs6768699	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47711258	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs6786001	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47718500	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs12495204	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47720540	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7618758	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47720993	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7612219	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47739676	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs35148469	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47739873	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.694	rs7645846	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47740829	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs17079785	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47743160	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs6442082	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47743991	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.747	rs6442083	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47744305	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.786	rs13064183	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47745405	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7637372	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47750385	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs13086149	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47784158	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs3772399	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47826237	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs3915654	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47827132	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs35582375	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47829639	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs13077230	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47832232	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs11710199	ENSG00000228638.1	FCF1P2	5.1	4.87e-07	6.58e-05	0.22	0.23	Educational attainment (years of education);	chr3:47836588	chr3:48290793~48291375:-
THCA	cis	rs6686842	0.56	rs3738368	ENSG00000235358.1	RP11-399E6.1	-5.1	4.87e-07	6.58e-05	-0.3	-0.23	Height;	chr1:41020230	chr1:41242373~41284861:+
THCA	cis	rs17767392	0.958	rs17767553	ENSG00000259146.3	RP1-261D10.2	5.1	4.87e-07	6.58e-05	0.29	0.23	Mitral valve prolapse;	chr14:71443870	chr14:71292729~71321814:-
THCA	cis	rs6832769	0.857	rs28377791	ENSG00000272969.1	RP11-528I4.2	-5.1	4.87e-07	6.58e-05	-0.27	-0.23	Personality dimensions;	chr4:55607014	chr4:55547112~55547889:+
THCA	cis	rs4604234	0.803	rs11967081	ENSG00000272129.1	RP11-250B2.6	5.1	4.87e-07	6.58e-05	0.57	0.23	Cancer;	chr6:80255623	chr6:80355424~80356859:+
THCA	cis	rs9987353	0.876	rs329993	ENSG00000254153.1	CTA-398F10.2	5.1	4.87e-07	6.58e-05	0.26	0.23	Recombination measurement;	chr8:9265928	chr8:8456909~8461337:-
THCA	cis	rs4950322	0.517	rs114823926	ENSG00000226015.2	CCT8P1	5.1	4.87e-07	6.58e-05	0.27	0.23	Protein quantitative trait loci;	chr1:147281805	chr1:147203276~147204932:-
THCA	cis	rs919433	0.68	rs788018	ENSG00000231621.1	AC013264.2	-5.1	4.88e-07	6.59e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197400802	chr2:197197991~197199273:+
THCA	cis	rs9543976	1	rs55927305	ENSG00000261105.4	LMO7-AS1	-5.1	4.88e-07	6.59e-05	-0.34	-0.23	Diabetic retinopathy;	chr13:75561213	chr13:75604700~75635994:-
THCA	cis	rs2288884	0.559	rs12459268	ENSG00000269483.1	AC006272.1	5.1	4.88e-07	6.59e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52002719	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.559	rs8109948	ENSG00000269483.1	AC006272.1	5.1	4.88e-07	6.59e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004796	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.559	rs8109964	ENSG00000269483.1	AC006272.1	5.1	4.88e-07	6.59e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004835	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.559	rs8109854	ENSG00000269483.1	AC006272.1	5.1	4.88e-07	6.59e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004866	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.559	rs12461141	ENSG00000269483.1	AC006272.1	5.1	4.88e-07	6.59e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005712	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.559	rs12459079	ENSG00000269483.1	AC006272.1	5.1	4.88e-07	6.59e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005741	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.559	rs12461226	ENSG00000269483.1	AC006272.1	5.1	4.88e-07	6.59e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005996	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.559	rs12461230	ENSG00000269483.1	AC006272.1	5.1	4.88e-07	6.59e-05	0.26	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006051	chr19:51839924~51843324:-
THCA	cis	rs7727544	0.507	rs11741341	ENSG00000237714.1	P4HA2-AS1	5.1	4.88e-07	6.59e-05	0.29	0.23	Blood metabolite levels;	chr5:132234525	chr5:132184876~132192808:+
THCA	cis	rs16852403	0.548	rs6685012	ENSG00000224687.1	RASAL2-AS1	5.1	4.88e-07	6.59e-05	0.35	0.23	Childhood ear infection;	chr1:178206166	chr1:178091508~178093984:-
THCA	cis	rs6671200	0.748	rs11586384	ENSG00000235501.4	RP4-639F20.1	-5.1	4.88e-07	6.59e-05	-0.44	-0.23	Stearic acid (18:0) levels;	chr1:95006185	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.667	rs12739445	ENSG00000235501.4	RP4-639F20.1	-5.1	4.88e-07	6.59e-05	-0.44	-0.23	Stearic acid (18:0) levels;	chr1:95007082	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.666	rs12724474	ENSG00000235501.4	RP4-639F20.1	-5.1	4.88e-07	6.59e-05	-0.44	-0.23	Stearic acid (18:0) levels;	chr1:95046277	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.748	rs12751061	ENSG00000235501.4	RP4-639F20.1	-5.1	4.88e-07	6.59e-05	-0.44	-0.23	Stearic acid (18:0) levels;	chr1:95065035	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.748	rs79375907	ENSG00000235501.4	RP4-639F20.1	-5.1	4.88e-07	6.59e-05	-0.44	-0.23	Stearic acid (18:0) levels;	chr1:95074005	chr1:94927566~94963270:+
THCA	cis	rs9876781	1	rs6442123	ENSG00000244380.1	RP11-24C3.2	5.1	4.88e-07	6.59e-05	0.27	0.23	Longevity;	chr3:48458887	chr3:48440352~48446656:-
THCA	cis	rs763121	0.626	rs5750643	ENSG00000273076.1	RP3-508I15.22	5.1	4.88e-07	6.59e-05	0.23	0.23	Menopause (age at onset);	chr22:38613012	chr22:38743495~38743910:+
THCA	cis	rs2243480	1	rs4718333	ENSG00000230295.1	RP11-458F8.2	5.1	4.88e-07	6.59e-05	0.28	0.23	Diabetic kidney disease;	chr7:66307771	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs7792391	ENSG00000230295.1	RP11-458F8.2	5.1	4.88e-07	6.59e-05	0.28	0.23	Diabetic kidney disease;	chr7:66308442	chr7:66880708~66882981:+
THCA	cis	rs240993	0.812	rs7751272	ENSG00000271789.1	RP5-1112D6.7	-5.1	4.88e-07	6.59e-05	-0.28	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111419068	chr6:111297126~111298510:+
THCA	cis	rs2880765	0.835	rs12324277	ENSG00000259630.2	CTD-2262B20.1	-5.1	4.88e-07	6.59e-05	-0.25	-0.23	Coronary artery disease;	chr15:85498504	chr15:85415228~85415633:+
THCA	cis	rs4780355	0.776	rs9936459	ENSG00000263080.1	RP11-485G7.5	-5.1	4.88e-07	6.59e-05	-0.28	-0.23	Crohn's disease and psoriasis;	chr16:11343922	chr16:11341809~11345211:-
THCA	cis	rs9952991	0.941	rs34920518	ENSG00000260302.1	RP11-973H7.1	5.1	4.88e-07	6.59e-05	0.39	0.23	Inflammatory skin disease;	chr18:12783087	chr18:12774651~12775923:-
THCA	cis	rs3796352	1	rs59583591	ENSG00000242142.1	SERBP1P3	-5.1	4.88e-07	6.6e-05	-0.41	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53085565	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs7625448	ENSG00000242142.1	SERBP1P3	-5.1	4.88e-07	6.6e-05	-0.41	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53086750	chr3:53064283~53065091:-
THCA	cis	rs1552244	0.938	rs34750074	ENSG00000232901.1	CYCSP10	5.1	4.89e-07	6.6e-05	0.31	0.23	Alzheimer's disease;	chr3:10050056	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs2272119	ENSG00000180385.7	EMC3-AS1	5.1	4.89e-07	6.6e-05	0.22	0.23	Alzheimer's disease;	chr3:10007668	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.608	rs9837460	ENSG00000180385.7	EMC3-AS1	5.1	4.89e-07	6.6e-05	0.22	0.23	Alzheimer's disease;	chr3:10008238	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs28667821	ENSG00000180385.7	EMC3-AS1	5.1	4.89e-07	6.6e-05	0.22	0.23	Alzheimer's disease;	chr3:10009083	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.543	rs28719585	ENSG00000180385.7	EMC3-AS1	5.1	4.89e-07	6.6e-05	0.22	0.23	Alzheimer's disease;	chr3:10009129	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.554	rs7349576	ENSG00000180385.7	EMC3-AS1	5.1	4.89e-07	6.6e-05	0.22	0.23	Alzheimer's disease;	chr3:10009209	chr3:9986893~10006990:+
THCA	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-5.1	4.89e-07	6.6e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
THCA	cis	rs6598266	1	rs6598266	ENSG00000259363.4	CTD-2054N24.2	5.1	4.89e-07	6.6e-05	0.39	0.23	Major depressive disorder;	chr15:99759034	chr15:99807023~99877148:+
THCA	cis	rs6565180	0.926	rs4787643	ENSG00000274653.1	RP11-347C12.11	-5.1	4.89e-07	6.61e-05	-0.22	-0.23	Tonsillectomy;	chr16:30382339	chr16:30359825~30360336:+
THCA	cis	rs6565180	0.926	rs4788409	ENSG00000274653.1	RP11-347C12.11	-5.1	4.89e-07	6.61e-05	-0.22	-0.23	Tonsillectomy;	chr16:30382450	chr16:30359825~30360336:+
THCA	cis	rs7621331	1	rs9837355	ENSG00000273486.1	RP11-731C17.2	5.1	4.89e-07	6.61e-05	0.22	0.23	Waist circumference adjusted for body mass index;	chr3:136046467	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs9842864	ENSG00000273486.1	RP11-731C17.2	5.1	4.89e-07	6.61e-05	0.22	0.23	Waist circumference adjusted for body mass index;	chr3:136047497	chr3:136837338~136839021:-
THCA	cis	rs10904908	0.965	rs11254464	ENSG00000229124.5	VIM-AS1	-5.1	4.9e-07	6.61e-05	-0.23	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17223448	chr10:17214239~17229985:-
THCA	cis	rs7772486	0.712	rs6570726	ENSG00000270638.1	RP3-466P17.1	5.1	4.9e-07	6.61e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145735570~145737218:+
THCA	cis	rs11671005	0.696	rs73066211	ENSG00000269473.1	CTD-2619J13.19	5.1	4.9e-07	6.62e-05	0.27	0.23	Mean platelet volume;	chr19:58485712	chr19:58440448~58445849:+
THCA	cis	rs2018683	0.523	rs886834	ENSG00000272568.4	CTB-113D17.1	5.1	4.9e-07	6.62e-05	0.23	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28981720	chr7:28979967~29013367:+
THCA	cis	rs67340775	0.541	rs200975	ENSG00000226314.6	ZNF192P1	-5.1	4.9e-07	6.62e-05	-0.35	-0.23	Lung cancer in ever smokers;	chr6:27887847	chr6:28161781~28169594:+
THCA	cis	rs67340775	0.541	rs200974	ENSG00000226314.6	ZNF192P1	-5.1	4.9e-07	6.62e-05	-0.35	-0.23	Lung cancer in ever smokers;	chr6:27888067	chr6:28161781~28169594:+
THCA	cis	rs763121	0.853	rs6001173	ENSG00000235209.1	CTA-150C2.13	5.1	4.9e-07	6.62e-05	0.3	0.23	Menopause (age at onset);	chr22:38619297	chr22:38921227~38924708:+
THCA	cis	rs2911132	0.568	rs3797814	ENSG00000248734.2	CTD-2260A17.1	5.1	4.9e-07	6.62e-05	0.25	0.23	Urate levels (BMI interaction);	chr5:96756222	chr5:96784777~96785999:+
THCA	cis	rs7396835	0.5	rs5092	ENSG00000280143.1	AP000892.6	5.1	4.9e-07	6.62e-05	0.34	0.23	Quantitative traits;	chr11:116822748	chr11:117204967~117210292:+
THCA	cis	rs10510102	0.872	rs10887003	ENSG00000226864.1	ATE1-AS1	5.1	4.9e-07	6.62e-05	0.37	0.23	Breast cancer;	chr10:121864660	chr10:121928312~121951965:+
THCA	cis	rs4683346	0.523	rs12491179	ENSG00000173811.9	CCDC13-AS1	-5.1	4.91e-07	6.63e-05	-0.24	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42732470	chr3:42732575~42746768:+
THCA	cis	rs3213758	1	rs76388114	ENSG00000275191.1	RP11-36I17.2	-5.1	4.91e-07	6.63e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53530305	chr16:53628256~53628816:-
THCA	cis	rs1823913	0.637	rs13010441	ENSG00000280083.1	RP11-317J9.1	-5.1	4.92e-07	6.64e-05	-0.27	-0.23	Obesity-related traits;	chr2:191303903	chr2:191154118~191156070:-
THCA	cis	rs16846053	0.685	rs72879226	ENSG00000227403.1	AC009299.3	5.1	4.92e-07	6.64e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161830658	chr2:161244739~161249050:+
THCA	cis	rs4950322	0.542	rs1932977	ENSG00000226015.2	CCT8P1	5.1	4.92e-07	6.64e-05	0.25	0.23	Protein quantitative trait loci;	chr1:147217371	chr1:147203276~147204932:-
THCA	cis	rs10895275	1	rs10895275	ENSG00000277459.1	RP11-732A21.3	-5.1	4.92e-07	6.65e-05	-0.18	-0.23	Migraine;	chr11:102212877	chr11:102109827~102110457:-
THCA	cis	rs10510102	0.935	rs7907871	ENSG00000226864.1	ATE1-AS1	5.1	4.92e-07	6.65e-05	0.37	0.23	Breast cancer;	chr10:121878185	chr10:121928312~121951965:+
THCA	cis	rs12135996	0.592	rs11588189	ENSG00000232879.2	RP11-544M22.3	-5.1	4.92e-07	6.65e-05	-0.25	-0.23	Night sleep phenotypes;	chr1:161049831	chr1:161034834~161035006:+
THCA	cis	rs7824557	0.751	rs2099456	ENSG00000154316.13	TDH	-5.1	4.93e-07	6.65e-05	-0.16	-0.23	Retinal vascular caliber;	chr8:11269492	chr8:11339637~11368452:+
THCA	cis	rs2179367	0.632	rs6920383	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149356361	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs11155645	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149360056	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs10155766	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149364577	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498332	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149367490	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498333	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149368196	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498334	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149370902	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498335	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149372648	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498336	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149374208	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs1980774	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149375030	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498337	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149375970	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498338	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149376428	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.586	rs9498341	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149379737	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9498342	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149379806	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12191079	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149380333	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12204461	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149380399	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12196656	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149383104	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12211570	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149383616	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.568	rs11155647	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149384499	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12197598	ENSG00000223701.3	RAET1E-AS1	5.1	4.93e-07	6.65e-05	0.33	0.23	Dupuytren's disease;	chr6:149385418	chr6:149884431~149919508:+
THCA	cis	rs944289	0.74	rs1467794	ENSG00000258844.1	RP11-259K15.2	-5.1	4.93e-07	6.65e-05	-0.2	-0.23	Thyroid cancer;	chr14:36097617	chr14:36214607~36235608:+
THCA	cis	rs2797160	1	rs1739357	ENSG00000237742.5	RP11-624M8.1	5.1	4.93e-07	6.65e-05	0.2	0.23	Endometrial cancer;	chr6:125698509	chr6:125578558~125749190:-
THCA	cis	rs4950322	0.542	rs2883434	ENSG00000271721.1	RP11-337C18.9	5.1	4.93e-07	6.66e-05	0.24	0.23	Protein quantitative trait loci;	chr1:147177505	chr1:147175602~147177740:+
THCA	cis	rs470119	1	rs131801	ENSG00000273272.1	CTA-384D8.34	-5.1	4.93e-07	6.66e-05	-0.2	-0.23	Mean corpuscular hemoglobin;	chr22:50528205	chr22:50542650~50543011:+
THCA	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	5.1	4.93e-07	6.66e-05	0.3	0.23	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
THCA	cis	rs1552244	1	rs67569278	ENSG00000232901.1	CYCSP10	5.1	4.93e-07	6.66e-05	0.3	0.23	Alzheimer's disease;	chr3:10108209	chr3:10000647~10000940:-
THCA	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-5.1	4.93e-07	6.66e-05	-0.33	-0.23	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
THCA	cis	rs2562456	0.876	rs2650844	ENSG00000268081.1	RP11-678G14.2	5.1	4.93e-07	6.66e-05	0.38	0.23	Pain;	chr19:21419288	chr19:21554640~21569237:-
THCA	cis	rs12701220	1	rs12701220	ENSG00000229043.2	AC091729.9	-5.1	4.93e-07	6.66e-05	-0.31	-0.23	Bronchopulmonary dysplasia;	chr7:983092	chr7:1160374~1165267:+
THCA	cis	rs667920	0.5	rs34498968	ENSG00000273486.1	RP11-731C17.2	-5.1	4.94e-07	6.66e-05	-0.3	-0.23	Coronary artery disease;	chr3:136476288	chr3:136837338~136839021:-
THCA	cis	rs317689	0.69	rs10878947	ENSG00000274979.1	RP11-1143G9.5	-5.1	4.94e-07	6.67e-05	-0.26	-0.23	Response to diuretic therapy;	chr12:69248903	chr12:69326574~69331882:-
THCA	cis	rs10510102	0.935	rs77447688	ENSG00000226864.1	ATE1-AS1	5.1	4.94e-07	6.67e-05	0.38	0.23	Breast cancer;	chr10:121925721	chr10:121928312~121951965:+
THCA	cis	rs6430585	0.528	rs6711493	ENSG00000231890.6	DARS-AS1	-5.1	4.94e-07	6.67e-05	-0.26	-0.23	Corneal structure;	chr2:135934983	chr2:135985176~136022593:+
THCA	cis	rs957448	1	rs12679345	ENSG00000253175.1	RP11-267M23.6	5.1	4.94e-07	6.67e-05	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94565036~94565715:+
THCA	cis	rs8020095	0.571	rs8016186	ENSG00000258561.1	RP11-72M17.1	-5.1	4.94e-07	6.67e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66834480	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs1950689	ENSG00000258561.1	RP11-72M17.1	-5.1	4.94e-07	6.67e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66871960	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs6573728	ENSG00000258561.1	RP11-72M17.1	-5.1	4.94e-07	6.67e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66877185	chr14:66212810~66509394:-
THCA	cis	rs2239547	0.522	rs2581801	ENSG00000242142.1	SERBP1P3	-5.1	4.94e-07	6.67e-05	-0.29	-0.23	Schizophrenia;	chr3:52938891	chr3:53064283~53065091:-
THCA	cis	rs6545883	0.895	rs2256617	ENSG00000270820.4	RP11-355B11.2	5.1	4.94e-07	6.67e-05	0.19	0.23	Tuberculosis;	chr2:61452789	chr2:61471188~61484130:+
THCA	cis	rs875971	0.502	rs2465121	ENSG00000228409.4	CCT6P1	5.1	4.94e-07	6.67e-05	0.2	0.23	Aortic root size;	chr7:66156017	chr7:65751142~65763354:+
THCA	cis	rs442309	0.553	rs7073430	ENSG00000238280.1	RP11-436D10.3	-5.1	4.94e-07	6.67e-05	-0.3	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62695121	chr10:62793562~62805887:-
THCA	cis	rs3750082	0.852	rs7786669	ENSG00000231952.3	DPY19L1P2	5.1	4.94e-07	6.67e-05	0.29	0.23	Glomerular filtration rate (creatinine);	chr7:32858726	chr7:32812757~32838570:+
THCA	cis	rs9500256	0.683	rs10458024	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-5.1	4.95e-07	6.67e-05	-0.26	-0.23	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57855891~57856468:-
THCA	cis	rs12143943	1	rs12143943	ENSG00000240219.1	RP11-430C7.5	5.1	4.95e-07	6.67e-05	0.2	0.23	Cognitive performance;	chr1:204602943	chr1:204626775~204629712:+
THCA	cis	rs9876781	1	rs9817615	ENSG00000244380.1	RP11-24C3.2	5.1	4.95e-07	6.67e-05	0.27	0.23	Longevity;	chr3:48429347	chr3:48440352~48446656:-
THCA	cis	rs2179367	0.632	rs9498348	ENSG00000223701.3	RAET1E-AS1	5.1	4.95e-07	6.68e-05	0.33	0.23	Dupuytren's disease;	chr6:149418352	chr6:149884431~149919508:+
THCA	cis	rs9990333	0.622	rs57783901	ENSG00000185485.13	SDHAP1	5.1	4.95e-07	6.68e-05	0.2	0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195959748~195990318:-
THCA	cis	rs795484	0.856	rs431038	ENSG00000275409.1	RP11-131L12.4	-5.1	4.95e-07	6.68e-05	-0.2	-0.23	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118220002	chr12:118430147~118430699:+
THCA	cis	rs10904908	1	rs10904909	ENSG00000229124.5	VIM-AS1	-5.1	4.95e-07	6.68e-05	-0.23	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17222522	chr10:17214239~17229985:-
THCA	cis	rs2070488	0.699	rs13078966	ENSG00000229589.1	ACVR2B-AS1	5.1	4.95e-07	6.68e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38476423	chr3:38451027~38454820:-
THCA	cis	rs2243480	1	rs160639	ENSG00000230295.1	RP11-458F8.2	-5.1	4.95e-07	6.68e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66115000	chr7:66880708~66882981:+
THCA	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	5.1	4.95e-07	6.68e-05	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
THCA	cis	rs6968419	0.708	rs57321537	ENSG00000237870.5	AC073130.1	5.1	4.95e-07	6.68e-05	0.25	0.23	Intraocular pressure;	chr7:116243399	chr7:116275606~116286734:-
THCA	cis	rs9843304	0.721	rs13062142	ENSG00000244503.1	RP11-278L15.6	5.1	4.95e-07	6.68e-05	0.29	0.23	Gallstone disease;	chr3:149484196	chr3:149494660~149495995:+
THCA	cis	rs11992162	0.56	rs13276386	ENSG00000206014.6	OR7E161P	-5.1	4.96e-07	6.69e-05	-0.27	-0.23	Monocyte count;	chr8:11939912	chr8:11928597~11929563:-
THCA	cis	rs11992162	0.621	rs13268810	ENSG00000206014.6	OR7E161P	-5.1	4.96e-07	6.69e-05	-0.27	-0.23	Monocyte count;	chr8:11939921	chr8:11928597~11929563:-
THCA	cis	rs11992162	0.636	rs13265816	ENSG00000206014.6	OR7E161P	-5.1	4.96e-07	6.69e-05	-0.27	-0.23	Monocyte count;	chr8:11939976	chr8:11928597~11929563:-
THCA	cis	rs11992162	0.905	rs7836953	ENSG00000227888.4	FAM66A	5.1	4.96e-07	6.69e-05	0.28	0.23	Monocyte count;	chr8:11978203	chr8:12362019~12388296:+
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000229886.1	RP5-1132H15.3	-5.1	4.96e-07	6.69e-05	-0.27	-0.23	Corneal structure;	chr7:66872661	chr7:66025126~66031544:-
THCA	cis	rs6671200	0.748	rs34254763	ENSG00000235501.4	RP4-639F20.1	-5.1	4.96e-07	6.69e-05	-0.44	-0.23	Stearic acid (18:0) levels;	chr1:95075405	chr1:94927566~94963270:+
THCA	cis	rs796395	1	rs796395	ENSG00000228208.5	C1orf143	-5.1	4.96e-07	6.69e-05	-0.27	-0.23	Post bronchodilator FEV1/FVC ratio;	chr1:218508629	chr1:218510096~218525978:+
THCA	cis	rs2280018	0.526	rs2966128	ENSG00000263335.1	AF001548.5	-5.1	4.96e-07	6.69e-05	-0.28	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15726674~15732993:+
THCA	cis	rs11023332	0.706	rs11023380	ENSG00000251991.1	RNU7-49P	5.1	4.96e-07	6.7e-05	0.25	0.23	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr11:14478892~14478953:+
THCA	cis	rs11023332	0.8	rs12271890	ENSG00000251991.1	RNU7-49P	5.1	4.96e-07	6.7e-05	0.25	0.23	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr11:14478892~14478953:+
THCA	cis	rs7429990	0.833	rs3755638	ENSG00000228638.1	FCF1P2	5.1	4.96e-07	6.7e-05	0.22	0.23	Educational attainment (years of education);	chr3:47580841	chr3:48290793~48291375:-
THCA	cis	rs9425766	0.679	rs7555067	ENSG00000227373.4	RP11-160H22.5	5.1	4.97e-07	6.7e-05	0.32	0.23	Life satisfaction;	chr1:174297504	chr1:174115300~174160004:-
THCA	cis	rs1383484	0.575	rs8024422	ENSG00000225151.9	GOLGA2P7	5.1	4.97e-07	6.7e-05	0.3	0.23	Height;	chr15:83951228	chr15:84199311~84230136:-
THCA	cis	rs752010	0.811	rs10749836	ENSG00000230638.4	RP11-486B10.4	-5.1	4.97e-07	6.7e-05	-0.25	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41621189	chr1:41542069~41544310:+
THCA	cis	rs919433	0.783	rs2565155	ENSG00000231621.1	AC013264.2	-5.1	4.97e-07	6.7e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371701	chr2:197197991~197199273:+
THCA	cis	rs919433	0.783	rs3097383	ENSG00000231621.1	AC013264.2	-5.1	4.97e-07	6.7e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372163	chr2:197197991~197199273:+
THCA	cis	rs2803122	0.774	rs10757034	ENSG00000273226.1	RP11-513M16.8	-5.1	4.97e-07	6.7e-05	-0.21	-0.23	Pulse pressure;	chr9:19227805	chr9:19375451~19375996:+
THCA	cis	rs3750082	0.852	rs34724897	ENSG00000231952.3	DPY19L1P2	-5.1	4.97e-07	6.7e-05	-0.29	-0.23	Glomerular filtration rate (creatinine);	chr7:32859914	chr7:32812757~32838570:+
THCA	cis	rs7131987	0.903	rs11050161	ENSG00000275476.1	RP11-996F15.4	-5.1	4.97e-07	6.71e-05	-0.22	-0.23	QT interval;	chr12:29267116	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.903	rs11050162	ENSG00000275476.1	RP11-996F15.4	-5.1	4.97e-07	6.71e-05	-0.22	-0.23	QT interval;	chr12:29267121	chr12:29277397~29277882:-
THCA	cis	rs10080237	0.564	rs2490232	ENSG00000272129.1	RP11-250B2.6	-5.1	4.97e-07	6.71e-05	-0.29	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80105085	chr6:80355424~80356859:+
THCA	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	5.1	4.97e-07	6.71e-05	0.22	0.23	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
THCA	cis	rs10510102	0.688	rs56094144	ENSG00000226864.1	ATE1-AS1	5.1	4.97e-07	6.71e-05	0.37	0.23	Breast cancer;	chr10:121903941	chr10:121928312~121951965:+
THCA	cis	rs7394190	0.748	rs4746147	ENSG00000271816.1	BMS1P4	-5.1	4.97e-07	6.71e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73767950	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs3088070	ENSG00000271816.1	BMS1P4	-5.1	4.97e-07	6.71e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73770255	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs11541237	ENSG00000271816.1	BMS1P4	-5.1	4.97e-07	6.71e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73771204	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs11000772	ENSG00000271816.1	BMS1P4	-5.1	4.97e-07	6.71e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73774230	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs11000773	ENSG00000271816.1	BMS1P4	-5.1	4.97e-07	6.71e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73774357	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.688	rs76033784	ENSG00000271816.1	BMS1P4	-5.1	4.97e-07	6.71e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73776212	chr10:73699151~73730487:-
THCA	cis	rs227275	0.554	rs223371	ENSG00000248971.2	KRT8P46	-5.1	4.97e-07	6.71e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102728746~102730171:-
THCA	cis	rs459482	0.508	rs467558	ENSG00000228318.3	AP001610.5	5.1	4.97e-07	6.71e-05	0.28	0.23	IgG glycosylation;	chr21:41439468	chr21:41441056~41445708:-
THCA	cis	rs9500256	0.711	rs6588685	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-5.1	4.98e-07	6.71e-05	-0.26	-0.23	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57855891~57856468:-
THCA	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	5.1	4.98e-07	6.71e-05	0.32	0.23	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
THCA	cis	rs10129255	0.719	rs7156660	ENSG00000211974.3	IGHV2-70	5.1	4.99e-07	6.72e-05	0.17	0.23	Kawasaki disease;	chr14:106673171	chr14:106723574~106724093:-
THCA	cis	rs1552244	1	rs2272123	ENSG00000180385.7	EMC3-AS1	5.1	4.99e-07	6.73e-05	0.25	0.23	Alzheimer's disease;	chr3:10098431	chr3:9986893~10006990:+
THCA	cis	rs12681287	0.609	rs13279850	ENSG00000254231.1	CTD-2284J15.1	5.1	4.99e-07	6.73e-05	0.25	0.23	Caudate activity during reward;	chr8:86465571	chr8:86333274~86343314:-
THCA	cis	rs922182	0.721	rs7180239	ENSG00000275785.1	RP11-111E14.2	5.1	4.99e-07	6.73e-05	0.26	0.23	Blood protein levels;	chr15:64017444	chr15:63890030~63890317:+
THCA	cis	rs721917	0.531	rs2758554	ENSG00000242600.5	MBL1P	5.1	4.99e-07	6.73e-05	0.2	0.23	Chronic obstructive pulmonary disease;	chr10:79931324	chr10:79904898~79950336:+
THCA	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	5.1	4.99e-07	6.73e-05	0.25	0.23	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
THCA	cis	rs7711186	0.786	rs13360296	ENSG00000252464.1	RN7SKP70	5.1	4.99e-07	6.73e-05	0.27	0.23	Urate levels in obese individuals;	chr5:178627929	chr5:178619728~178619998:-
THCA	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	5.1	4.99e-07	6.73e-05	0.27	0.23	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-5.1	4.99e-07	6.73e-05	-0.27	-0.23	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
THCA	cis	rs7267979	0.816	rs374701	ENSG00000125804.12	FAM182A	-5.1	4.99e-07	6.73e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26054655~26086917:+
THCA	cis	rs752010	0.905	rs2038977	ENSG00000230638.4	RP11-486B10.4	-5.1	4.99e-07	6.73e-05	-0.25	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41628988	chr1:41542069~41544310:+
THCA	cis	rs2562456	0.752	rs279809	ENSG00000268119.4	CTD-2561J22.5	5.1	4.99e-07	6.73e-05	0.33	0.23	Pain;	chr19:21284729	chr19:21444241~21463908:-
THCA	cis	rs6679677	0.543	rs1230680	ENSG00000232450.1	RP4-730K3.3	-5.1	5e-07	6.74e-05	-0.35	-0.23	Rheumatoid arthritis;Monokine induced by gamma interferon levels;Type 1 diabetes;Hypothyroidism;Systemic lupus erythematosus;Pediatric autoimmune diseases;Crohn's disease;Antineutrophil cytoplasmic antibody-associated vasculitis;	chr1:113754148	chr1:113698884~113699631:-
THCA	cis	rs7615952	0.673	rs34209763	ENSG00000248787.1	RP11-666A20.4	-5.1	5e-07	6.74e-05	-0.43	-0.23	Blood pressure (smoking interaction);	chr3:125880752	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.8	rs35390120	ENSG00000248787.1	RP11-666A20.4	-5.1	5e-07	6.74e-05	-0.43	-0.23	Blood pressure (smoking interaction);	chr3:125880966	chr3:125908005~125910272:-
THCA	cis	rs4713118	0.55	rs9368527	ENSG00000216901.1	AL022393.7	5.1	5e-07	6.74e-05	0.28	0.23	Parkinson's disease;	chr6:27711666	chr6:28176188~28176674:+
THCA	cis	rs2797160	1	rs1739371	ENSG00000237742.5	RP11-624M8.1	5.1	5e-07	6.74e-05	0.2	0.23	Endometrial cancer;	chr6:125690145	chr6:125578558~125749190:-
THCA	cis	rs8002861	0.967	rs7983109	ENSG00000274001.1	RP11-5G9.5	5.1	5e-07	6.74e-05	0.26	0.23	Leprosy;	chr13:43910215	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.967	rs7984393	ENSG00000274001.1	RP11-5G9.5	5.1	5e-07	6.74e-05	0.26	0.23	Leprosy;	chr13:43910225	chr13:43877715~43878163:-
THCA	cis	rs34779708	0.931	rs67976880	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs72789687	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs35997236	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4934719	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4934720	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.897	rs34481177	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs11593858	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs72789690	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs68039650	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs35136660	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.897	rs12764820	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs67261877	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs12768019	ENSG00000271335.4	RP11-324I22.4	5.1	5e-07	6.74e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35314552~35336401:-
THCA	cis	rs2013441	0.67	rs4924802	ENSG00000261033.1	RP11-209D14.2	-5.1	5e-07	6.74e-05	-0.33	-0.23	Obesity-related traits;	chr17:20052582	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.67	rs35317166	ENSG00000261033.1	RP11-209D14.2	-5.1	5e-07	6.74e-05	-0.33	-0.23	Obesity-related traits;	chr17:20056507	chr17:20008051~20009234:-
THCA	cis	rs8067545	0.532	rs56371654	ENSG00000261033.1	RP11-209D14.2	-5.1	5e-07	6.74e-05	-0.33	-0.23	Schizophrenia;	chr17:20057049	chr17:20008051~20009234:-
THCA	cis	rs6832769	1	rs9684708	ENSG00000272969.1	RP11-528I4.2	-5.1	5e-07	6.75e-05	-0.26	-0.23	Personality dimensions;	chr4:55564214	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs28445925	ENSG00000272969.1	RP11-528I4.2	-5.1	5e-07	6.75e-05	-0.26	-0.23	Personality dimensions;	chr4:55569682	chr4:55547112~55547889:+
THCA	cis	rs800160	1	rs1088984	ENSG00000199550.1	Y_RNA	5.1	5e-07	6.75e-05	0.34	0.23	Bacteremia;	chr11:2356351	chr11:2372638~2372750:+
THCA	cis	rs60695258	0.55	rs4693800	ENSG00000251411.1	RP11-397E7.4	5.1	5e-07	6.75e-05	0.21	0.23	Hematocrit;	chr4:86994468	chr4:86913266~86914817:-
THCA	cis	rs1395	0.767	rs1821986	ENSG00000234072.1	AC074117.10	5.1	5e-07	6.75e-05	0.19	0.23	Blood metabolite levels;	chr2:27182967	chr2:27356246~27367622:+
THCA	cis	rs796395	0.967	rs550238	ENSG00000228208.5	C1orf143	-5.1	5.01e-07	6.75e-05	-0.27	-0.23	Post bronchodilator FEV1/FVC ratio;	chr1:218517606	chr1:218510096~218525978:+
THCA	cis	rs7851660	0.844	rs10123699	ENSG00000214417.4	KRT18P13	-5.1	5.01e-07	6.75e-05	-0.2	-0.23	Strep throat;	chr9:97875577	chr9:97698922~97700734:+
THCA	cis	rs9811423	0.625	rs12695286	ENSG00000243795.1	RP11-572M11.3	5.1	5.01e-07	6.75e-05	0.25	0.23	Psychosis and Alzheimer's disease;	chr3:113097899	chr3:113142350~113167819:-
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000223473.2	GS1-124K5.3	5.1	5.01e-07	6.75e-05	0.15	0.23	Calcium levels;	chr7:65967580	chr7:66491049~66493566:-
THCA	cis	rs34779708	0.966	rs34605125	ENSG00000271335.4	RP11-324I22.4	5.1	5.01e-07	6.75e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.897	rs16935880	ENSG00000271335.4	RP11-324I22.4	5.1	5.01e-07	6.75e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs4934730	ENSG00000271335.4	RP11-324I22.4	5.1	5.01e-07	6.75e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs2045918	ENSG00000271335.4	RP11-324I22.4	5.1	5.01e-07	6.75e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs4294520	ENSG00000271335.4	RP11-324I22.4	5.1	5.01e-07	6.75e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs34876468	ENSG00000271335.4	RP11-324I22.4	5.1	5.01e-07	6.75e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35314552~35336401:-
THCA	cis	rs9843304	0.721	rs4681175	ENSG00000244503.1	RP11-278L15.6	5.1	5.01e-07	6.75e-05	0.29	0.23	Gallstone disease;	chr3:149484076	chr3:149494660~149495995:+
THCA	cis	rs9843304	0.721	rs4681176	ENSG00000244503.1	RP11-278L15.6	5.1	5.01e-07	6.75e-05	0.29	0.23	Gallstone disease;	chr3:149484167	chr3:149494660~149495995:+
THCA	cis	rs4787484	1	rs7189750	ENSG00000214725.6	CDIPT-AS1	-5.1	5.01e-07	6.75e-05	-0.3	-0.23	Response to taxane treatment (placlitaxel);	chr16:29900095	chr16:29863593~29868053:+
THCA	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-5.1	5.02e-07	6.76e-05	-0.24	-0.23	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
THCA	cis	rs62292953	0.79	rs17412738	ENSG00000248724.5	NPHP3-AS1	-5.1	5.02e-07	6.76e-05	-0.42	-0.23	Red cell distribution width;	chr3:132538575	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs17413072	ENSG00000248724.5	NPHP3-AS1	-5.1	5.02e-07	6.76e-05	-0.42	-0.23	Red cell distribution width;	chr3:132542776	chr3:132721750~132874223:+
THCA	cis	rs7474896	1	rs9418289	ENSG00000263064.2	RP11-291L22.7	5.1	5.02e-07	6.76e-05	0.37	0.23	Obesity (extreme);	chr10:37820877	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs10827831	ENSG00000263064.2	RP11-291L22.7	5.1	5.02e-07	6.76e-05	0.37	0.23	Obesity (extreme);	chr10:37821885	chr10:38448689~38448949:+
THCA	cis	rs4950322	0.57	rs7554833	ENSG00000226015.2	CCT8P1	-5.1	5.02e-07	6.76e-05	-0.27	-0.23	Protein quantitative trait loci;	chr1:147289362	chr1:147203276~147204932:-
THCA	cis	rs34779708	0.966	rs1057108	ENSG00000271335.4	RP11-324I22.4	5.1	5.02e-07	6.76e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35314552~35336401:-
THCA	cis	rs7621331	0.857	rs6807058	ENSG00000273486.1	RP11-731C17.2	5.1	5.02e-07	6.77e-05	0.22	0.23	Waist circumference adjusted for body mass index;	chr3:136040027	chr3:136837338~136839021:-
THCA	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	5.1	5.02e-07	6.77e-05	0.35	0.23	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	5.1	5.02e-07	6.77e-05	0.35	0.23	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	5.1	5.02e-07	6.77e-05	0.35	0.23	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
THCA	cis	rs17767392	0.781	rs34388001	ENSG00000259146.3	RP1-261D10.2	5.1	5.03e-07	6.77e-05	0.29	0.23	Mitral valve prolapse;	chr14:71416783	chr14:71292729~71321814:-
THCA	cis	rs3738443	0.868	rs6660351	ENSG00000259865.1	RP11-488L18.10	5.1	5.03e-07	6.77e-05	0.24	0.23	Alcohol dependence;	chr1:247184526	chr1:247187281~247188526:-
THCA	cis	rs9733	0.565	rs7524620	ENSG00000231073.1	RP11-316M1.3	-5.1	5.03e-07	6.78e-05	-0.27	-0.23	Tonsillectomy;	chr1:150644223	chr1:150973123~150975534:+
THCA	cis	rs4950322	0.542	rs17159924	ENSG00000271721.1	RP11-337C18.9	5.1	5.03e-07	6.78e-05	0.26	0.23	Protein quantitative trait loci;	chr1:147199463	chr1:147175602~147177740:+
THCA	cis	rs34779708	0.966	rs11010129	ENSG00000271335.4	RP11-324I22.4	5.1	5.03e-07	6.78e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs4934737	ENSG00000271335.4	RP11-324I22.4	5.1	5.03e-07	6.78e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35314552~35336401:-
THCA	cis	rs1580019	0.587	rs9638880	ENSG00000231952.3	DPY19L1P2	-5.1	5.03e-07	6.78e-05	-0.28	-0.23	Cognitive ability;	chr7:32512789	chr7:32812757~32838570:+
THCA	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	5.1	5.03e-07	6.78e-05	0.13	0.23	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
THCA	cis	rs593531	0.513	rs7947911	ENSG00000212961.4	HNRNPA1P40	-5.1	5.03e-07	6.78e-05	-0.3	-0.23	Neuroticism;	chr11:74312706	chr11:74354443~74355720:+
THCA	cis	rs1707322	1	rs785469	ENSG00000281133.1	AL355480.3	5.1	5.03e-07	6.78e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs785468	ENSG00000281133.1	AL355480.3	5.1	5.03e-07	6.78e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45580892~45580996:-
THCA	cis	rs2252521	0.524	rs2529480	ENSG00000272568.4	CTB-113D17.1	5.1	5.03e-07	6.78e-05	0.26	0.23	Cognitive performance;	chr7:29003504	chr7:28979967~29013367:+
THCA	cis	rs2252521	0.524	rs1719570	ENSG00000272568.4	CTB-113D17.1	5.1	5.03e-07	6.78e-05	0.26	0.23	Cognitive performance;	chr7:29003747	chr7:28979967~29013367:+
THCA	cis	rs79349575	0.783	rs15563	ENSG00000270781.1	RP11-501C14.9	-5.1	5.03e-07	6.78e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48927831	chr17:48899131~48899748:+
THCA	cis	rs1426063	0.858	rs11931653	ENSG00000260265.1	RP11-44F21.5	5.1	5.03e-07	6.78e-05	0.41	0.23	QT interval;	chr4:75080856	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.858	rs55775471	ENSG00000260265.1	RP11-44F21.5	5.1	5.03e-07	6.78e-05	0.41	0.23	QT interval;	chr4:75081074	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.858	rs9990627	ENSG00000260265.1	RP11-44F21.5	5.1	5.03e-07	6.78e-05	0.41	0.23	QT interval;	chr4:75081244	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.858	rs10026994	ENSG00000260265.1	RP11-44F21.5	5.1	5.03e-07	6.78e-05	0.41	0.23	QT interval;	chr4:75081551	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.858	rs6830936	ENSG00000260265.1	RP11-44F21.5	5.1	5.03e-07	6.78e-05	0.41	0.23	QT interval;	chr4:75083952	chr4:75081702~75084717:-
THCA	cis	rs7520050	0.966	rs1707321	ENSG00000234329.1	RP11-767N6.2	-5.1	5.04e-07	6.78e-05	-0.2	-0.23	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000273796.1	LL21NC02-21A1.1	-5.1	5.04e-07	6.79e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45403809~45404369:-
THCA	cis	rs964611	0.882	rs75094472	ENSG00000259488.2	RP11-154J22.1	-5.1	5.04e-07	6.79e-05	-0.21	-0.23	Metabolite levels (Pyroglutamine);	chr15:48351917	chr15:48312353~48331856:-
THCA	cis	rs7429990	0.864	rs1464614	ENSG00000228638.1	FCF1P2	-5.1	5.04e-07	6.79e-05	-0.22	-0.23	Educational attainment (years of education);	chr3:47612885	chr3:48290793~48291375:-
THCA	cis	rs4648045	0.765	rs3774967	ENSG00000246560.2	RP11-10L12.4	5.1	5.04e-07	6.79e-05	0.29	0.23	Lymphocyte percentage of white cells;	chr4:102604774	chr4:102828055~102844075:+
THCA	cis	rs1823913	0.637	rs4853569	ENSG00000280083.1	RP11-317J9.1	5.1	5.04e-07	6.79e-05	0.26	0.23	Obesity-related traits;	chr2:191266970	chr2:191154118~191156070:-
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	5.1	5.04e-07	6.79e-05	0.28	0.23	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
THCA	cis	rs6142102	0.651	rs6088412	ENSG00000275784.1	RP5-1125A11.6	5.1	5.04e-07	6.8e-05	0.25	0.23	Skin pigmentation;	chr20:34154262	chr20:33989480~33991818:-
THCA	cis	rs8020095	0.528	rs1950281	ENSG00000258561.1	RP11-72M17.1	-5.1	5.05e-07	6.8e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66934582	chr14:66212810~66509394:-
THCA	cis	rs240993	0.812	rs9487639	ENSG00000271789.1	RP5-1112D6.7	-5.1	5.05e-07	6.8e-05	-0.28	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111426791	chr6:111297126~111298510:+
THCA	cis	rs11079757	0.681	rs34811916	ENSG00000262879.4	RP11-156P1.3	5.1	5.05e-07	6.8e-05	0.24	0.23	Erythema nodosum in inflammatory bowel disease;	chr17:47111431	chr17:46984045~47100323:-
THCA	cis	rs875971	1	rs7781698	ENSG00000223473.2	GS1-124K5.3	5.1	5.05e-07	6.81e-05	0.15	0.23	Aortic root size;	chr7:66431325	chr7:66491049~66493566:-
THCA	cis	rs4934494	0.677	rs11185806	ENSG00000232936.4	RP11-80H5.2	5.1	5.05e-07	6.81e-05	0.32	0.23	Red blood cell count;	chr10:89620458	chr10:89645282~89650667:+
THCA	cis	rs8020095	0.528	rs8007696	ENSG00000258561.1	RP11-72M17.1	-5.1	5.05e-07	6.81e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67355742	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs10149615	ENSG00000258561.1	RP11-72M17.1	-5.1	5.05e-07	6.81e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67357573	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs6573768	ENSG00000258561.1	RP11-72M17.1	-5.1	5.05e-07	6.81e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67358236	chr14:66212810~66509394:-
THCA	cis	rs2297363	0.502	rs4709393	ENSG00000213073.4	RP11-288H12.3	-5.1	5.06e-07	6.81e-05	-0.19	-0.23	Total cholesterol levels;Blood protein levels;	chr6:160051000	chr6:160093082~160096212:+
THCA	cis	rs9987353	0.519	rs11779181	ENSG00000253893.2	FAM85B	-5.1	5.06e-07	6.81e-05	-0.3	-0.23	Recombination measurement;	chr8:9205517	chr8:8167819~8226614:-
THCA	cis	rs9900062	1	rs2521879	ENSG00000270714.1	MINOS1P2	-5.1	5.06e-07	6.81e-05	-0.35	-0.23	QT interval;	chr17:64746560	chr17:64747264~64747492:-
THCA	cis	rs6430585	0.583	rs79633114	ENSG00000231890.6	DARS-AS1	-5.1	5.06e-07	6.81e-05	-0.28	-0.23	Corneal structure;	chr2:135829255	chr2:135985176~136022593:+
THCA	cis	rs7829975	0.659	rs4382480	ENSG00000253981.4	ALG1L13P	5.1	5.06e-07	6.81e-05	0.23	0.23	Mood instability;	chr8:8863963	chr8:8236003~8244667:-
THCA	cis	rs2562456	0.876	rs2359144	ENSG00000268081.1	RP11-678G14.2	5.09	5.06e-07	6.82e-05	0.38	0.23	Pain;	chr19:21407834	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.876	rs4638726	ENSG00000268081.1	RP11-678G14.2	5.09	5.06e-07	6.82e-05	0.38	0.23	Pain;	chr19:21409710	chr19:21554640~21569237:-
THCA	cis	rs6121246	0.697	rs6088864	ENSG00000230613.1	HM13-AS1	5.09	5.06e-07	6.82e-05	0.25	0.23	Mean corpuscular hemoglobin;	chr20:31640354	chr20:31567707~31573263:-
THCA	cis	rs6088580	0.634	rs2378133	ENSG00000276073.1	RP5-1125A11.7	5.09	5.06e-07	6.82e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34331699	chr20:33985617~33988989:-
THCA	cis	rs11023332	0.706	rs11023379	ENSG00000251991.1	RNU7-49P	5.09	5.07e-07	6.82e-05	0.25	0.23	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr11:14478892~14478953:+
THCA	cis	rs10208649	0.731	rs724387	ENSG00000233266.1	HMGB1P31	5.09	5.07e-07	6.83e-05	0.61	0.23	Body mass index;	chr2:53672707	chr2:54051334~54051760:+
THCA	cis	rs9425766	0.679	rs4650945	ENSG00000227373.4	RP11-160H22.5	-5.09	5.07e-07	6.83e-05	-0.32	-0.23	Life satisfaction;	chr1:174114966	chr1:174115300~174160004:-
THCA	cis	rs7824557	0.679	rs10110008	ENSG00000154316.13	TDH	5.09	5.07e-07	6.83e-05	0.17	0.23	Retinal vascular caliber;	chr8:11276227	chr8:11339637~11368452:+
THCA	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	5.09	5.07e-07	6.83e-05	0.19	0.23	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
THCA	cis	rs17772222	1	rs1955600	ENSG00000222990.1	RNU4-22P	5.09	5.07e-07	6.83e-05	0.3	0.23	Coronary artery calcification;	chr14:88359040	chr14:88513498~88513663:+
THCA	cis	rs4308124	1	rs4308124	ENSG00000227992.1	AC108463.2	-5.09	5.07e-07	6.83e-05	-0.29	-0.23	Vitiligo;	chr2:111252909	chr2:111203964~111206215:-
THCA	cis	rs2360027	0.578	rs10754382	ENSG00000231365.4	RP11-418J17.1	-5.09	5.07e-07	6.83e-05	-0.22	-0.23	Tonsillectomy;	chr1:118556216	chr1:119140396~119275973:+
THCA	cis	rs875971	0.545	rs73142245	ENSG00000228409.4	CCT6P1	-5.09	5.07e-07	6.83e-05	-0.2	-0.23	Aortic root size;	chr7:66226662	chr7:65751142~65763354:+
THCA	cis	rs911119	1	rs71334202	ENSG00000270001.1	RP11-218C14.8	-5.09	5.08e-07	6.84e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23638015	chr20:23631826~23632316:-
THCA	cis	rs9425766	0.679	rs2860846	ENSG00000227373.4	RP11-160H22.5	5.09	5.08e-07	6.84e-05	0.32	0.23	Life satisfaction;	chr1:174106786	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs2860847	ENSG00000227373.4	RP11-160H22.5	5.09	5.08e-07	6.84e-05	0.32	0.23	Life satisfaction;	chr1:174106787	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs6672986	ENSG00000227373.4	RP11-160H22.5	5.09	5.08e-07	6.84e-05	0.32	0.23	Life satisfaction;	chr1:174107726	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs7533430	ENSG00000227373.4	RP11-160H22.5	5.09	5.08e-07	6.84e-05	0.32	0.23	Life satisfaction;	chr1:174109279	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs7526024	ENSG00000227373.4	RP11-160H22.5	5.09	5.08e-07	6.84e-05	0.32	0.23	Life satisfaction;	chr1:174109722	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs12079062	ENSG00000227373.4	RP11-160H22.5	5.09	5.08e-07	6.84e-05	0.32	0.23	Life satisfaction;	chr1:174110446	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs12079063	ENSG00000227373.4	RP11-160H22.5	5.09	5.08e-07	6.84e-05	0.32	0.23	Life satisfaction;	chr1:174110447	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs12094341	ENSG00000227373.4	RP11-160H22.5	5.09	5.08e-07	6.84e-05	0.32	0.23	Life satisfaction;	chr1:174110562	chr1:174115300~174160004:-
THCA	cis	rs6472827	0.645	rs2977070	ENSG00000253983.2	RP1-16A9.1	-5.09	5.08e-07	6.84e-05	-0.33	-0.23	Uterine fibroids;	chr8:74200535	chr8:74199396~74208441:+
THCA	cis	rs12681288	0.676	rs2701923	ENSG00000260721.1	AF067845.1	5.09	5.08e-07	6.84e-05	0.28	0.23	Schizophrenia;	chr8:1044605	chr8:1368642~1369833:-
THCA	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-5.09	5.08e-07	6.84e-05	-0.28	-0.23	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
THCA	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-5.09	5.08e-07	6.84e-05	-0.28	-0.23	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
THCA	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-5.09	5.08e-07	6.84e-05	-0.28	-0.23	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
THCA	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-5.09	5.08e-07	6.84e-05	-0.28	-0.23	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
THCA	cis	rs10510102	0.935	rs11200187	ENSG00000226864.1	ATE1-AS1	5.09	5.08e-07	6.85e-05	0.37	0.23	Breast cancer;	chr10:121843050	chr10:121928312~121951965:+
THCA	cis	rs35934224	0.74	rs35142928	ENSG00000232926.1	AC000078.5	5.09	5.09e-07	6.85e-05	0.25	0.23	Glaucoma (primary open-angle);	chr22:19860228	chr22:19887289~19887970:+
THCA	cis	rs5758511	0.68	rs5758662	ENSG00000281538.1	RP4-669P10.20	-5.09	5.09e-07	6.85e-05	-0.26	-0.23	Birth weight;	chr22:42232082	chr22:42138060~42139726:+
THCA	cis	rs6545883	0.794	rs12053388	ENSG00000270820.4	RP11-355B11.2	-5.09	5.09e-07	6.85e-05	-0.19	-0.23	Tuberculosis;	chr2:61305185	chr2:61471188~61484130:+
THCA	cis	rs4660456	0.913	rs16827552	ENSG00000272145.1	NFYC-AS1	5.09	5.09e-07	6.85e-05	0.16	0.23	Platelet count;	chr1:40758336	chr1:40690380~40692066:-
THCA	cis	rs116095464	0.614	rs10059220	ENSG00000248925.1	CTD-2083E4.6	5.09	5.09e-07	6.85e-05	0.36	0.23	Breast cancer;	chr5:242698	chr5:269858~271516:-
THCA	cis	rs1979679	0.608	rs4931082	ENSG00000247934.4	RP11-967K21.1	5.09	5.09e-07	6.85e-05	0.23	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28567087	chr12:28163298~28190738:-
THCA	cis	rs1876905	0.539	rs240987	ENSG00000272356.1	RP5-1112D6.8	-5.09	5.09e-07	6.86e-05	-0.25	-0.23	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111309203~111313517:+
THCA	cis	rs2067615	0.56	rs2044304	ENSG00000260329.1	RP11-412D9.4	-5.09	5.09e-07	6.86e-05	-0.21	-0.23	Heart rate;	chr12:106790585	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.579	rs10861665	ENSG00000260329.1	RP11-412D9.4	-5.09	5.09e-07	6.86e-05	-0.21	-0.23	Heart rate;	chr12:106800058	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.579	rs10507214	ENSG00000260329.1	RP11-412D9.4	-5.09	5.09e-07	6.86e-05	-0.21	-0.23	Heart rate;	chr12:106800683	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.579	rs66716938	ENSG00000260329.1	RP11-412D9.4	-5.09	5.09e-07	6.86e-05	-0.21	-0.23	Heart rate;	chr12:106803047	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.579	rs11113119	ENSG00000260329.1	RP11-412D9.4	-5.09	5.09e-07	6.86e-05	-0.21	-0.23	Heart rate;	chr12:106806278	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.542	rs11113120	ENSG00000260329.1	RP11-412D9.4	-5.09	5.09e-07	6.86e-05	-0.21	-0.23	Heart rate;	chr12:106809682	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.579	rs1811458	ENSG00000260329.1	RP11-412D9.4	-5.09	5.09e-07	6.86e-05	-0.21	-0.23	Heart rate;	chr12:106809905	chr12:106954029~106955497:-
THCA	cis	rs7924176	0.521	rs7899920	ENSG00000213731.2	RAB5CP1	5.09	5.09e-07	6.86e-05	0.27	0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:74423435~74424014:-
THCA	cis	rs2797160	1	rs1739373	ENSG00000237742.5	RP11-624M8.1	5.09	5.09e-07	6.86e-05	0.2	0.23	Endometrial cancer;	chr6:125690363	chr6:125578558~125749190:-
THCA	cis	rs6772849	0.83	rs7633674	ENSG00000242551.2	POU5F1P6	-5.09	5.1e-07	6.86e-05	-0.29	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:128674735~128677005:-
THCA	cis	rs4915077	1	rs78495697	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107813097	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs75382989	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107814313	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs17020122	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107814769	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs17020123	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107814951	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs74678088	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107815175	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs17020124	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107815389	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs77436627	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107815486	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs75778624	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107817168	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs112590700	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107820073	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs75125154	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107820904	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs79451333	ENSG00000230489.1	VAV3-AS1	5.09	5.1e-07	6.86e-05	0.38	0.23	Hypothyroidism;	chr1:107821014	chr1:107964443~107994607:+
THCA	cis	rs7618915	0.547	rs6762813	ENSG00000243224.1	RP5-1157M23.2	-5.09	5.1e-07	6.86e-05	-0.25	-0.23	Bipolar disorder;	chr3:52692679	chr3:52239258~52241097:+
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000164669.11	INTS4P1	5.09	5.1e-07	6.86e-05	0.44	0.23	Diabetic kidney disease;	chr7:65947955	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000164669.11	INTS4P1	5.09	5.1e-07	6.86e-05	0.44	0.23	Diabetic kidney disease;	chr7:65950886	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000164669.11	INTS4P1	5.09	5.1e-07	6.86e-05	0.44	0.23	Diabetic kidney disease;	chr7:65951525	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000164669.11	INTS4P1	5.09	5.1e-07	6.86e-05	0.44	0.23	Diabetic kidney disease;	chr7:65951549	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000164669.11	INTS4P1	5.09	5.1e-07	6.86e-05	0.44	0.23	Diabetic kidney disease;	chr7:65956884	chr7:65141225~65234216:+
THCA	cis	rs7429990	0.864	rs11130143	ENSG00000228638.1	FCF1P2	5.09	5.1e-07	6.86e-05	0.22	0.23	Educational attainment (years of education);	chr3:47614943	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs6774170	ENSG00000228638.1	FCF1P2	5.09	5.1e-07	6.86e-05	0.22	0.23	Educational attainment (years of education);	chr3:47615977	chr3:48290793~48291375:-
THCA	cis	rs11992162	0.613	rs6601634	ENSG00000206014.6	OR7E161P	5.09	5.1e-07	6.87e-05	0.27	0.23	Monocyte count;	chr8:11948947	chr8:11928597~11929563:-
THCA	cis	rs8177876	0.642	rs4454990	ENSG00000261061.1	RP11-303E16.2	5.09	5.1e-07	6.87e-05	0.31	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81030770~81031485:+
THCA	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	5.09	5.1e-07	6.87e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	5.09	5.1e-07	6.87e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
THCA	cis	rs7403037	0.92	rs34804878	ENSG00000260760.1	PWRN3	5.09	5.1e-07	6.87e-05	0.26	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24579295	chr15:24441127~24447967:+
THCA	cis	rs7727544	0.735	rs272860	ENSG00000263597.1	MIR3936	5.09	5.11e-07	6.87e-05	0.22	0.23	Blood metabolite levels;	chr5:132348482	chr5:132365490~132365599:-
THCA	cis	rs2243480	1	rs7456042	ENSG00000164669.11	INTS4P1	5.09	5.11e-07	6.87e-05	0.44	0.23	Diabetic kidney disease;	chr7:65834791	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs73142121	ENSG00000164669.11	INTS4P1	5.09	5.11e-07	6.87e-05	0.44	0.23	Diabetic kidney disease;	chr7:65846219	chr7:65141225~65234216:+
THCA	cis	rs10888838	0.756	rs2282332	ENSG00000198711.5	SSBP3-AS1	5.09	5.11e-07	6.87e-05	0.28	0.23	Mitochondrial DNA levels;	chr1:54224364	chr1:54236440~54239063:+
THCA	cis	rs748404	0.666	rs60018990	ENSG00000205771.5	CATSPER2P1	-5.09	5.11e-07	6.87e-05	-0.29	-0.23	Lung cancer;	chr15:43504606	chr15:43726918~43747094:-
THCA	cis	rs8062405	1	rs12443881	ENSG00000278665.1	RP11-666O2.4	5.09	5.11e-07	6.87e-05	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28599241~28601881:-
THCA	cis	rs2129782	1	rs16881745	ENSG00000253553.4	RP11-586K2.1	-5.09	5.11e-07	6.87e-05	-0.4	-0.23	Electrodermal activity;	chr8:88364577	chr8:88326836~88737134:+
THCA	cis	rs858239	0.601	rs2141307	ENSG00000226816.2	AC005082.12	5.09	5.11e-07	6.88e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23206013~23208045:+
THCA	cis	rs2067615	0.56	rs10467028	ENSG00000260329.1	RP11-412D9.4	-5.09	5.11e-07	6.88e-05	-0.21	-0.23	Heart rate;	chr12:106682627	chr12:106954029~106955497:-
THCA	cis	rs972578	0.765	rs5751397	ENSG00000274717.1	RP1-47A17.1	-5.09	5.11e-07	6.88e-05	-0.24	-0.23	Mean platelet volume;	chr22:42876786	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs4822215	ENSG00000274717.1	RP1-47A17.1	-5.09	5.11e-07	6.88e-05	-0.24	-0.23	Mean platelet volume;	chr22:42877885	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs5759007	ENSG00000274717.1	RP1-47A17.1	-5.09	5.11e-07	6.88e-05	-0.24	-0.23	Mean platelet volume;	chr22:42878277	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs9611950	ENSG00000274717.1	RP1-47A17.1	-5.09	5.11e-07	6.88e-05	-0.24	-0.23	Mean platelet volume;	chr22:42878716	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs4820492	ENSG00000274717.1	RP1-47A17.1	-5.09	5.11e-07	6.88e-05	-0.24	-0.23	Mean platelet volume;	chr22:42880024	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs2899365	ENSG00000274717.1	RP1-47A17.1	-5.09	5.11e-07	6.88e-05	-0.24	-0.23	Mean platelet volume;	chr22:42882214	chr22:42791814~42794313:-
THCA	cis	rs17767392	0.881	rs2190240	ENSG00000259146.3	RP1-261D10.2	-5.09	5.11e-07	6.88e-05	-0.29	-0.23	Mitral valve prolapse;	chr14:71558172	chr14:71292729~71321814:-
THCA	cis	rs8058578	0.614	rs2878304	ENSG00000279196.1	RP11-1072A3.3	-5.09	5.11e-07	6.88e-05	-0.25	-0.23	Multiple myeloma;	chr16:30867045	chr16:30984630~30988270:-
THCA	cis	rs8028182	0.609	rs10220738	ENSG00000260269.4	CTD-2323K18.1	5.09	5.11e-07	6.88e-05	0.34	0.23	Sudden cardiac arrest;	chr15:75374205	chr15:75527150~75601205:-
THCA	cis	rs7429990	0.774	rs3772402	ENSG00000228638.1	FCF1P2	5.09	5.12e-07	6.88e-05	0.22	0.23	Educational attainment (years of education);	chr3:47574661	chr3:48290793~48291375:-
THCA	cis	rs972578	0.791	rs738538	ENSG00000274717.1	RP1-47A17.1	-5.09	5.12e-07	6.88e-05	-0.23	-0.23	Mean platelet volume;	chr22:42885873	chr22:42791814~42794313:-
THCA	cis	rs972578	0.818	rs2267463	ENSG00000274717.1	RP1-47A17.1	-5.09	5.12e-07	6.88e-05	-0.23	-0.23	Mean platelet volume;	chr22:42887249	chr22:42791814~42794313:-
THCA	cis	rs972578	0.818	rs5751399	ENSG00000274717.1	RP1-47A17.1	-5.09	5.12e-07	6.88e-05	-0.23	-0.23	Mean platelet volume;	chr22:42889303	chr22:42791814~42794313:-
THCA	cis	rs9500256	0.655	rs12208465	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-5.09	5.12e-07	6.88e-05	-0.26	-0.23	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57855891~57856468:-
THCA	cis	rs9500256	0.655	rs12210275	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-5.09	5.12e-07	6.88e-05	-0.26	-0.23	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57855891~57856468:-
THCA	cis	rs911555	0.662	rs4906322	ENSG00000244691.1	RPL10AP1	5.09	5.12e-07	6.89e-05	0.31	0.23	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103412119~103412761:-
THCA	cis	rs17723470	0.513	rs2863165	ENSG00000254427.1	RP11-430H10.1	5.09	5.12e-07	6.89e-05	0.23	0.23	Thyroid hormone levels;	chr11:45207296	chr11:45355371~45366121:+
THCA	cis	rs17270561	0.666	rs4712971	ENSG00000272462.2	U91328.19	-5.09	5.12e-07	6.89e-05	-0.19	-0.23	Iron status biomarkers;	chr6:25771672	chr6:25992662~26001775:+
THCA	cis	rs4908769	0.624	rs3765971	ENSG00000232912.4	RP5-1115A15.1	-5.09	5.12e-07	6.89e-05	-0.24	-0.23	Allergy;	chr1:8385300	chr1:8424645~8434838:+
THCA	cis	rs911119	0.913	rs67483168	ENSG00000270001.1	RP11-218C14.8	-5.09	5.12e-07	6.89e-05	-0.36	-0.23	Chronic kidney disease;	chr20:23600675	chr20:23631826~23632316:-
THCA	cis	rs1005277	0.505	rs7069702	ENSG00000276805.1	RP11-291L22.6	-5.09	5.12e-07	6.89e-05	-0.25	-0.23	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38451030~38451785:+
THCA	cis	rs1150668	1	rs1150668	ENSG00000204709.4	LINC01556	5.09	5.12e-07	6.89e-05	0.28	0.23	Pubertal anthropometrics;	chr6:28162011	chr6:28943877~28944537:+
THCA	cis	rs875971	0.502	rs6460311	ENSG00000228409.4	CCT6P1	5.09	5.12e-07	6.89e-05	0.2	0.23	Aortic root size;	chr7:66646886	chr7:65751142~65763354:+
THCA	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-5.09	5.12e-07	6.89e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
THCA	cis	rs1823913	0.637	rs1947456	ENSG00000280083.1	RP11-317J9.1	5.09	5.12e-07	6.89e-05	0.26	0.23	Obesity-related traits;	chr2:191298759	chr2:191154118~191156070:-
THCA	cis	rs5015933	0.966	rs10986724	ENSG00000232630.1	PRPS1P2	5.09	5.12e-07	6.89e-05	0.15	0.23	Body mass index;	chr9:125369240	chr9:125150653~125151589:+
THCA	cis	rs9859260	1	rs9858727	ENSG00000273009.1	RP11-352G9.1	-5.09	5.12e-07	6.89e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196067370	chr3:195913078~195913683:-
THCA	cis	rs9425766	0.679	rs6670617	ENSG00000227373.4	RP11-160H22.5	5.09	5.12e-07	6.89e-05	0.32	0.23	Life satisfaction;	chr1:174277574	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs4650990	ENSG00000227373.4	RP11-160H22.5	5.09	5.12e-07	6.89e-05	0.32	0.23	Life satisfaction;	chr1:174289943	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs4650989	ENSG00000227373.4	RP11-160H22.5	5.09	5.13e-07	6.9e-05	0.32	0.23	Life satisfaction;	chr1:174289739	chr1:174115300~174160004:-
THCA	cis	rs16975963	0.644	rs73031321	ENSG00000226686.6	LINC01535	-5.09	5.13e-07	6.9e-05	-0.3	-0.23	Longevity;	chr19:37549956	chr19:37251912~37265535:+
THCA	cis	rs651907	0.557	rs3094297	ENSG00000244119.1	PDCL3P4	5.09	5.13e-07	6.9e-05	0.21	0.23	Colorectal cancer;	chr3:101680416	chr3:101712472~101713191:+
THCA	cis	rs11018904	0.608	rs35700249	ENSG00000280385.1	AP000648.5	-5.09	5.13e-07	6.9e-05	-0.34	-0.23	Intelligence (multi-trait analysis);	chr11:90198759	chr11:90193614~90198120:+
THCA	cis	rs7727544	0.513	rs10065787	ENSG00000224431.1	AC063976.7	5.09	5.13e-07	6.9e-05	0.2	0.23	Blood metabolite levels;	chr5:132100793	chr5:132199456~132203487:+
THCA	cis	rs17301013	0.965	rs2179214	ENSG00000227373.4	RP11-160H22.5	5.09	5.13e-07	6.9e-05	0.32	0.23	Systemic lupus erythematosus;	chr1:174413954	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.93	rs7523263	ENSG00000227373.4	RP11-160H22.5	5.09	5.13e-07	6.9e-05	0.32	0.23	Systemic lupus erythematosus;	chr1:174414542	chr1:174115300~174160004:-
THCA	cis	rs7429990	0.864	rs2047559	ENSG00000228638.1	FCF1P2	5.09	5.13e-07	6.91e-05	0.22	0.23	Educational attainment (years of education);	chr3:47704695	chr3:48290793~48291375:-
THCA	cis	rs11671005	0.735	rs12977592	ENSG00000268912.1	CTD-2619J13.17	-5.09	5.13e-07	6.91e-05	-0.2	-0.23	Mean platelet volume;	chr19:58449689	chr19:58428632~58431148:-
THCA	cis	rs793571	0.505	rs16940587	ENSG00000245975.2	RP11-30K9.6	5.09	5.13e-07	6.91e-05	0.26	0.23	Schizophrenia;	chr15:58606464	chr15:58768072~58770974:-
THCA	cis	rs4660456	0.871	rs2274957	ENSG00000272145.1	NFYC-AS1	5.09	5.14e-07	6.91e-05	0.16	0.23	Platelet count;	chr1:40747290	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs4660173	ENSG00000272145.1	NFYC-AS1	5.09	5.14e-07	6.91e-05	0.16	0.23	Platelet count;	chr1:40747876	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs4660452	ENSG00000272145.1	NFYC-AS1	5.09	5.14e-07	6.91e-05	0.16	0.23	Platelet count;	chr1:40748519	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs12567925	ENSG00000272145.1	NFYC-AS1	5.09	5.14e-07	6.91e-05	0.16	0.23	Platelet count;	chr1:40751428	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs12728776	ENSG00000272145.1	NFYC-AS1	5.09	5.14e-07	6.91e-05	0.16	0.23	Platelet count;	chr1:40751718	chr1:40690380~40692066:-
THCA	cis	rs721917	0.531	rs2819105	ENSG00000242600.5	MBL1P	-5.09	5.14e-07	6.91e-05	-0.2	-0.23	Chronic obstructive pulmonary disease;	chr10:79927101	chr10:79904898~79950336:+
THCA	cis	rs7824557	0.585	rs2572382	ENSG00000154316.13	TDH	-5.09	5.14e-07	6.91e-05	-0.18	-0.23	Retinal vascular caliber;	chr8:11353793	chr8:11339637~11368452:+
THCA	cis	rs481331	0.741	rs7072200	ENSG00000215146.4	RP11-313J2.1	5.09	5.14e-07	6.92e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42657970	chr10:42331866~42367974:-
THCA	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-5.09	5.14e-07	6.92e-05	-0.27	-0.23	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
THCA	cis	rs17301013	0.965	rs7548540	ENSG00000227373.4	RP11-160H22.5	5.09	5.14e-07	6.92e-05	0.32	0.23	Systemic lupus erythematosus;	chr1:174411672	chr1:174115300~174160004:-
THCA	cis	rs8020095	0.571	rs6573726	ENSG00000258561.1	RP11-72M17.1	-5.09	5.14e-07	6.92e-05	-0.31	-0.23	Depression (quantitative trait);	chr14:66857810	chr14:66212810~66509394:-
THCA	cis	rs2797160	1	rs1832979	ENSG00000237742.5	RP11-624M8.1	-5.09	5.15e-07	6.92e-05	-0.2	-0.23	Endometrial cancer;	chr6:125676290	chr6:125578558~125749190:-
THCA	cis	rs11096990	0.892	rs11729098	ENSG00000249685.1	RP11-360F5.3	-5.09	5.15e-07	6.92e-05	-0.29	-0.23	Cognitive function;	chr4:39232357	chr4:39133913~39135608:+
THCA	cis	rs12893668	0.703	rs8017993	ENSG00000269910.1	RP11-73M18.10	5.09	5.15e-07	6.93e-05	0.21	0.23	Reticulocyte count;	chr14:103581397	chr14:103694516~103695050:-
THCA	cis	rs9425766	0.64	rs6693423	ENSG00000227373.4	RP11-160H22.5	5.09	5.15e-07	6.93e-05	0.32	0.23	Life satisfaction;	chr1:174364680	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs60363188	ENSG00000227373.4	RP11-160H22.5	5.09	5.15e-07	6.93e-05	0.32	0.23	Life satisfaction;	chr1:174375959	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs12084119	ENSG00000227373.4	RP11-160H22.5	5.09	5.15e-07	6.93e-05	0.32	0.23	Life satisfaction;	chr1:174377138	chr1:174115300~174160004:-
THCA	cis	rs8141529	0.732	rs2347447	ENSG00000272858.1	CTA-292E10.8	-5.09	5.16e-07	6.94e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28783751	chr22:28814914~28815662:+
THCA	cis	rs4648045	0.565	rs17033014	ENSG00000246560.2	RP11-10L12.4	5.09	5.16e-07	6.94e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102625029	chr4:102828055~102844075:+
THCA	cis	rs3820928	0.874	rs4234063	ENSG00000212391.1	SNORA48	5.09	5.16e-07	6.94e-05	0.25	0.23	Pulmonary function;	chr2:226963619	chr2:226968989~226969122:-
THCA	cis	rs5015933	0.788	rs521308	ENSG00000232630.1	PRPS1P2	-5.09	5.17e-07	6.95e-05	-0.16	-0.23	Body mass index;	chr9:125308475	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.815	rs3126227	ENSG00000232630.1	PRPS1P2	-5.09	5.17e-07	6.95e-05	-0.16	-0.23	Body mass index;	chr9:125319157	chr9:125150653~125151589:+
THCA	cis	rs2360027	0.599	rs1408587	ENSG00000231365.4	RP11-418J17.1	-5.09	5.17e-07	6.95e-05	-0.23	-0.23	Tonsillectomy;	chr1:118537139	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs1408588	ENSG00000231365.4	RP11-418J17.1	-5.09	5.17e-07	6.95e-05	-0.23	-0.23	Tonsillectomy;	chr1:118537242	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.599	rs12144108	ENSG00000231365.4	RP11-418J17.1	-5.09	5.17e-07	6.95e-05	-0.23	-0.23	Tonsillectomy;	chr1:118537623	chr1:119140396~119275973:+
THCA	cis	rs1320333	0.772	rs35181861	ENSG00000233296.1	AC092159.2	5.09	5.17e-07	6.95e-05	0.42	0.23	Obesity-related traits;	chr2:679483	chr2:677186~697371:+
THCA	cis	rs17772222	0.638	rs11629164	ENSG00000222990.1	RNU4-22P	-5.09	5.17e-07	6.95e-05	-0.29	-0.23	Coronary artery calcification;	chr14:88564740	chr14:88513498~88513663:+
THCA	cis	rs7044106	1	rs7044106	ENSG00000270917.1	RP11-27I1.6	-5.09	5.17e-07	6.95e-05	-0.36	-0.23	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120812475~120812845:-
THCA	cis	rs10200159	1	rs6760959	ENSG00000272606.1	RP11-554J4.1	5.09	5.17e-07	6.95e-05	0.46	0.23	Vitiligo;	chr2:55594365	chr2:55617909~55618373:+
THCA	cis	rs10200159	1	rs111707510	ENSG00000272606.1	RP11-554J4.1	5.09	5.17e-07	6.95e-05	0.46	0.23	Vitiligo;	chr2:55597100	chr2:55617909~55618373:+
THCA	cis	rs2447820	0.5	rs67324184	ENSG00000249996.1	RP11-359P5.1	5.09	5.17e-07	6.95e-05	0.27	0.23	Migraine;	chr5:122852244	chr5:123036271~123054667:+
THCA	cis	rs4663866	0.901	rs74877878	ENSG00000186235.9	AC016757.3	5.09	5.17e-07	6.95e-05	0.51	0.23	Irritable bowel syndrome;	chr2:238289924	chr2:238224552~238231677:-
THCA	cis	rs1707322	1	rs11211232	ENSG00000281133.1	AL355480.3	-5.09	5.17e-07	6.95e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45580892~45580996:-
THCA	cis	rs1823913	0.614	rs4853463	ENSG00000280083.1	RP11-317J9.1	5.09	5.17e-07	6.95e-05	0.26	0.23	Obesity-related traits;	chr2:191278699	chr2:191154118~191156070:-
THCA	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	5.09	5.18e-07	6.96e-05	0.28	0.23	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
THCA	cis	rs651907	0.557	rs34376498	ENSG00000244119.1	PDCL3P4	5.09	5.18e-07	6.96e-05	0.21	0.23	Colorectal cancer;	chr3:101761312	chr3:101712472~101713191:+
THCA	cis	rs736408	0.5	rs2878762	ENSG00000242142.1	SERBP1P3	5.09	5.18e-07	6.96e-05	0.29	0.23	Bipolar disorder;	chr3:52884986	chr3:53064283~53065091:-
THCA	cis	rs3177980	0.673	rs10489172	ENSG00000239494.2	RN7SL333P	-5.09	5.18e-07	6.96e-05	-0.22	-0.23	Amyotrophic lateral sclerosis;	chr1:169855238	chr1:169859756~169860052:+
THCA	cis	rs4660456	0.913	rs6661855	ENSG00000272145.1	NFYC-AS1	-5.09	5.18e-07	6.96e-05	-0.16	-0.23	Platelet count;	chr1:40703245	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs7542019	ENSG00000272145.1	NFYC-AS1	-5.09	5.18e-07	6.96e-05	-0.16	-0.23	Platelet count;	chr1:40704039	chr1:40690380~40692066:-
THCA	cis	rs4650994	0.816	rs2811304	ENSG00000273384.1	RP5-1098D14.1	-5.09	5.18e-07	6.96e-05	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178627659	chr1:178651706~178652282:+
THCA	cis	rs8028182	0.636	rs4486847	ENSG00000260274.1	RP11-817O13.8	5.09	5.18e-07	6.96e-05	0.16	0.23	Sudden cardiac arrest;	chr15:75436190	chr15:75368155~75369584:+
THCA	cis	rs1577917	0.727	rs9344539	ENSG00000220563.1	PKMP3	-5.09	5.18e-07	6.96e-05	-0.17	-0.23	Response to antipsychotic treatment;	chr6:85643903	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.771	rs9362232	ENSG00000220563.1	PKMP3	-5.09	5.18e-07	6.96e-05	-0.17	-0.23	Response to antipsychotic treatment;	chr6:85643904	chr6:85659892~85660606:-
THCA	cis	rs736801	0.504	rs2070721	ENSG00000237714.1	P4HA2-AS1	-5.09	5.18e-07	6.96e-05	-0.29	-0.23	Mosquito bite size;Breast cancer;	chr5:132490150	chr5:132184876~132192808:+
THCA	cis	rs4604234	0.522	rs73482011	ENSG00000272129.1	RP11-250B2.6	-5.09	5.18e-07	6.97e-05	-0.55	-0.23	Cancer;	chr6:80210306	chr6:80355424~80356859:+
THCA	cis	rs2243480	1	rs313832	ENSG00000230295.1	RP11-458F8.2	-5.09	5.18e-07	6.97e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66085904	chr7:66880708~66882981:+
THCA	cis	rs944289	0.74	rs950319	ENSG00000258844.1	RP11-259K15.2	5.09	5.19e-07	6.97e-05	0.2	0.23	Thyroid cancer;	chr14:36096786	chr14:36214607~36235608:+
THCA	cis	rs10829156	0.945	rs8181345	ENSG00000240291.1	RP11-499P20.2	5.09	5.19e-07	6.97e-05	0.2	0.23	Sudden cardiac arrest;	chr10:18678689	chr10:18513115~18545651:-
THCA	cis	rs875971	0.502	rs2946580	ENSG00000232546.1	RP11-458F8.1	-5.09	5.19e-07	6.97e-05	-0.22	-0.23	Aortic root size;	chr7:66066855	chr7:66848496~66858136:+
THCA	cis	rs34779708	0.966	rs10827492	ENSG00000271335.4	RP11-324I22.4	-5.09	5.19e-07	6.97e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35314552~35336401:-
THCA	cis	rs10208649	0.522	rs7594400	ENSG00000233266.1	HMGB1P31	-5.09	5.19e-07	6.98e-05	-0.6	-0.23	Body mass index;	chr2:54176970	chr2:54051334~54051760:+
THCA	cis	rs270601	0.661	rs10036208	ENSG00000237714.1	P4HA2-AS1	5.09	5.19e-07	6.98e-05	0.3	0.23	Acylcarnitine levels;	chr5:132235630	chr5:132184876~132192808:+
THCA	cis	rs12906542	0.516	rs10444863	ENSG00000260776.4	RP11-114H24.2	5.09	5.19e-07	6.98e-05	0.38	0.23	Breast cancer;	chr15:78066495	chr15:77914217~77926846:-
THCA	cis	rs481331	0.741	rs209386	ENSG00000215146.4	RP11-313J2.1	-5.09	5.19e-07	6.98e-05	-0.37	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42638087	chr10:42331866~42367974:-
THCA	cis	rs1876905	0.539	rs241003	ENSG00000271789.1	RP5-1112D6.7	5.09	5.19e-07	6.98e-05	0.31	0.23	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111297126~111298510:+
THCA	cis	rs1876905	0.539	rs190246	ENSG00000271789.1	RP5-1112D6.7	5.09	5.19e-07	6.98e-05	0.31	0.23	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111297126~111298510:+
THCA	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	5.09	5.2e-07	6.98e-05	0.26	0.23	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
THCA	cis	rs972578	0.765	rs2267461	ENSG00000274717.1	RP1-47A17.1	-5.09	5.2e-07	6.99e-05	-0.24	-0.23	Mean platelet volume;	chr22:42873541	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs2092664	ENSG00000274717.1	RP1-47A17.1	-5.09	5.2e-07	6.99e-05	-0.24	-0.23	Mean platelet volume;	chr22:42874434	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs4822213	ENSG00000274717.1	RP1-47A17.1	-5.09	5.2e-07	6.99e-05	-0.24	-0.23	Mean platelet volume;	chr22:42874813	chr22:42791814~42794313:-
THCA	cis	rs8177876	0.749	rs78707250	ENSG00000261838.4	RP11-303E16.6	5.09	5.2e-07	6.99e-05	0.41	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81069854~81076598:+
THCA	cis	rs6430585	0.697	rs7607174	ENSG00000231890.6	DARS-AS1	-5.09	5.2e-07	6.99e-05	-0.29	-0.23	Corneal structure;	chr2:135756100	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.697	rs115944351	ENSG00000231890.6	DARS-AS1	-5.09	5.2e-07	6.99e-05	-0.29	-0.23	Corneal structure;	chr2:135757888	chr2:135985176~136022593:+
THCA	cis	rs6951245	0.745	rs79788515	ENSG00000229043.2	AC091729.9	-5.09	5.21e-07	7e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1160374~1165267:+
THCA	cis	rs2985684	0.625	rs4900931	ENSG00000278009.1	RP11-649E7.8	5.09	5.21e-07	7e-05	0.31	0.23	Carotid intima media thickness;	chr14:49556075	chr14:49601011~49601124:-
THCA	cis	rs1552244	0.81	rs7612908	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10047464	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs7649243	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10047786	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs7615646	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10048089	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.81	rs6809572	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10058461	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs112847840	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10059968	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs722509	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10060693	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs6793396	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10069243	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs6772315	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10071960	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs7621551	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10072521	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs35148833	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10075253	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.81	rs35711405	ENSG00000180385.7	EMC3-AS1	5.09	5.21e-07	7e-05	0.25	0.23	Alzheimer's disease;	chr3:10075255	chr3:9986893~10006990:+
THCA	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	5.09	5.21e-07	7e-05	0.35	0.23	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
THCA	cis	rs7621331	1	rs7433567	ENSG00000273486.1	RP11-731C17.2	5.09	5.21e-07	7e-05	0.22	0.23	Waist circumference adjusted for body mass index;	chr3:136014775	chr3:136837338~136839021:-
THCA	cis	rs4722166	0.63	rs7808457	ENSG00000225541.1	AC002480.5	5.09	5.21e-07	7e-05	0.32	0.23	Lung cancer;	chr7:22758646	chr7:22571607~22661792:-
THCA	cis	rs4968361	0.892	rs4968363	ENSG00000266992.1	DHX40P1	5.09	5.21e-07	7e-05	0.39	0.23	Schizophrenia;	chr17:59433712	chr17:59976009~60002384:-
THCA	cis	rs972578	0.791	rs9611951	ENSG00000274717.1	RP1-47A17.1	-5.09	5.21e-07	7.01e-05	-0.24	-0.23	Mean platelet volume;	chr22:42878766	chr22:42791814~42794313:-
THCA	cis	rs9467773	1	rs9467796	ENSG00000261353.1	CTA-14H9.5	-5.09	5.22e-07	7.01e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26527063~26527404:+
THCA	cis	rs9467773	1	rs9467797	ENSG00000261353.1	CTA-14H9.5	-5.09	5.22e-07	7.01e-05	-0.24	-0.23	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26527063~26527404:+
THCA	cis	rs2797160	0.967	rs1777224	ENSG00000237742.5	RP11-624M8.1	5.09	5.22e-07	7.01e-05	0.2	0.23	Endometrial cancer;	chr6:125698381	chr6:125578558~125749190:-
THCA	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-5.09	5.22e-07	7.01e-05	-0.26	-0.23	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-5.09	5.22e-07	7.01e-05	-0.26	-0.23	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-5.09	5.22e-07	7.01e-05	-0.26	-0.23	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-5.09	5.22e-07	7.01e-05	-0.26	-0.23	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-5.09	5.22e-07	7.01e-05	-0.26	-0.23	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-5.09	5.22e-07	7.01e-05	-0.26	-0.23	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.622	rs55787447	ENSG00000280083.1	RP11-317J9.1	-5.09	5.22e-07	7.01e-05	-0.26	-0.23	Obesity-related traits;	chr2:191288596	chr2:191154118~191156070:-
THCA	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	5.09	5.22e-07	7.01e-05	0.19	0.23	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
THCA	cis	rs6121246	0.697	rs45557936	ENSG00000230613.1	HM13-AS1	5.09	5.22e-07	7.01e-05	0.26	0.23	Mean corpuscular hemoglobin;	chr20:31638887	chr20:31567707~31573263:-
THCA	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	5.09	5.22e-07	7.01e-05	0.27	0.23	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
THCA	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	5.09	5.22e-07	7.01e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
THCA	cis	rs8020095	0.528	rs10147362	ENSG00000258561.1	RP11-72M17.1	-5.09	5.22e-07	7.01e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67353655	chr14:66212810~66509394:-
THCA	cis	rs9876781	1	rs11130171	ENSG00000244380.1	RP11-24C3.2	5.09	5.22e-07	7.01e-05	0.27	0.23	Longevity;	chr3:48421052	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs9883927	ENSG00000244380.1	RP11-24C3.2	5.09	5.22e-07	7.01e-05	0.27	0.23	Longevity;	chr3:48422302	chr3:48440352~48446656:-
THCA	cis	rs2243480	1	rs316307	ENSG00000230295.1	RP11-458F8.2	-5.09	5.22e-07	7.01e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66105184	chr7:66880708~66882981:+
THCA	cis	rs11858159	0.525	rs7497832	ENSG00000260760.1	PWRN3	5.09	5.22e-07	7.02e-05	0.23	0.23	Platelet thrombus formation;	chr15:24584394	chr15:24441127~24447967:+
THCA	cis	rs2797160	0.967	rs1343120	ENSG00000237742.5	RP11-624M8.1	-5.09	5.23e-07	7.02e-05	-0.2	-0.23	Endometrial cancer;	chr6:125671664	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.967	rs4897151	ENSG00000237742.5	RP11-624M8.1	-5.09	5.23e-07	7.02e-05	-0.2	-0.23	Endometrial cancer;	chr6:125672056	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.935	rs6940748	ENSG00000237742.5	RP11-624M8.1	-5.09	5.23e-07	7.02e-05	-0.2	-0.23	Endometrial cancer;	chr6:125672934	chr6:125578558~125749190:-
THCA	cis	rs7246657	0.524	rs28542490	ENSG00000226686.6	LINC01535	-5.09	5.23e-07	7.02e-05	-0.35	-0.23	Coronary artery calcification;	chr19:36965682	chr19:37251912~37265535:+
THCA	cis	rs2239547	0.657	rs6445539	ENSG00000242142.1	SERBP1P3	5.09	5.23e-07	7.02e-05	0.29	0.23	Schizophrenia;	chr3:52840280	chr3:53064283~53065091:-
THCA	cis	rs2239547	0.657	rs7638524	ENSG00000242142.1	SERBP1P3	5.09	5.23e-07	7.02e-05	0.29	0.23	Schizophrenia;	chr3:52840845	chr3:53064283~53065091:-
THCA	cis	rs2303319	0.504	rs12467613	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161746706	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs12467625	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161746877	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72877343	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161750977	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189043	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161751956	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189046	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161755861	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189047	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161756804	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62189048	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161756984	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs56026147	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161757579	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs35304298	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161760675	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs1449641	ENSG00000227403.1	AC009299.3	5.09	5.23e-07	7.02e-05	0.47	0.23	Cognitive function;	chr2:161763057	chr2:161244739~161249050:+
THCA	cis	rs9859260	0.925	rs2300775	ENSG00000273009.1	RP11-352G9.1	-5.09	5.23e-07	7.02e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196066468	chr3:195913078~195913683:-
THCA	cis	rs9859260	0.921	rs2300774	ENSG00000273009.1	RP11-352G9.1	-5.09	5.23e-07	7.02e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196066841	chr3:195913078~195913683:-
THCA	cis	rs897984	0.806	rs4889571	ENSG00000260911.2	RP11-196G11.2	-5.09	5.23e-07	7.02e-05	-0.19	-0.23	Dementia with Lewy bodies;	chr16:30937726	chr16:31043150~31049868:+
THCA	cis	rs897984	0.806	rs11640534	ENSG00000260911.2	RP11-196G11.2	-5.09	5.23e-07	7.02e-05	-0.19	-0.23	Dementia with Lewy bodies;	chr16:30938194	chr16:31043150~31049868:+
THCA	cis	rs897984	0.762	rs7206511	ENSG00000260911.2	RP11-196G11.2	-5.09	5.23e-07	7.02e-05	-0.19	-0.23	Dementia with Lewy bodies;	chr16:30939031	chr16:31043150~31049868:+
THCA	cis	rs17767392	0.881	rs35620527	ENSG00000259146.3	RP1-261D10.2	5.09	5.23e-07	7.02e-05	0.28	0.23	Mitral valve prolapse;	chr14:71448986	chr14:71292729~71321814:-
THCA	cis	rs3177980	0.639	rs17529513	ENSG00000239494.2	RN7SL333P	-5.09	5.23e-07	7.02e-05	-0.22	-0.23	Amyotrophic lateral sclerosis;	chr1:169829604	chr1:169859756~169860052:+
THCA	cis	rs7267979	0.873	rs7453	ENSG00000277938.1	RP5-965G21.3	5.09	5.23e-07	7.03e-05	0.19	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25229150~25231933:+
THCA	cis	rs896854	0.631	rs10097617	ENSG00000253528.2	RP11-347C18.4	5.09	5.23e-07	7.03e-05	0.26	0.23	Type 2 diabetes;	chr8:94949398	chr8:94974573~94974853:-
THCA	cis	rs748404	0.666	rs12900259	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43427369	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs34921640	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43429187	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs62020574	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43429380	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs16957730	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43438288	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs12913977	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43438913	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs12914122	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43438956	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs34697113	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43442041	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs12907870	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43453971	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs72709850	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43462486	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs36078097	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43466209	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs7181783	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43469723	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs35903301	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43472332	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs34002293	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43472401	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs34181131	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43478527	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs7173383	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43480838	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs55801120	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43495042	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs12911740	ENSG00000205771.5	CATSPER2P1	-5.09	5.24e-07	7.03e-05	-0.29	-0.23	Lung cancer;	chr15:43498254	chr15:43726918~43747094:-
THCA	cis	rs7429990	0.896	rs7427648	ENSG00000228638.1	FCF1P2	5.09	5.24e-07	7.03e-05	0.22	0.23	Educational attainment (years of education);	chr3:48116749	chr3:48290793~48291375:-
THCA	cis	rs8020095	0.571	rs3784078	ENSG00000258561.1	RP11-72M17.1	-5.09	5.24e-07	7.03e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67092993	chr14:66212810~66509394:-
THCA	cis	rs9925964	0.935	rs12597511	ENSG00000260911.2	RP11-196G11.2	-5.09	5.24e-07	7.03e-05	-0.19	-0.23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31133898	chr16:31043150~31049868:+
THCA	cis	rs16846053	0.642	rs72879231	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161831700	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72879233	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161831789	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs2084545	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161831980	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs2100213	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161832308	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs56027511	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161833006	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs56091742	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161833015	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187711	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161834551	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72879248	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161834856	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72879250	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161834857	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187712	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161835383	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187713	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161835607	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs2892796	ENSG00000227403.1	AC009299.3	5.09	5.24e-07	7.04e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161836100	chr2:161244739~161249050:+
THCA	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-5.09	5.24e-07	7.04e-05	-0.29	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
THCA	cis	rs75920871	0.841	rs78442878	ENSG00000254851.1	RP11-109L13.1	-5.09	5.24e-07	7.04e-05	-0.43	-0.23	Subjective well-being;	chr11:117052138	chr11:117135528~117138582:+
THCA	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	5.09	5.24e-07	7.04e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
THCA	cis	rs58605417	0.55	rs1879203	ENSG00000253553.4	RP11-586K2.1	-5.09	5.24e-07	7.04e-05	-0.25	-0.23	Schizophrenia;	chr8:88285970	chr8:88326836~88737134:+
THCA	cis	rs9959145	1	rs11660232	ENSG00000267108.1	RP11-861E21.1	5.09	5.24e-07	7.04e-05	0.28	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12585546	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs28527375	ENSG00000267108.1	RP11-861E21.1	5.09	5.24e-07	7.04e-05	0.28	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12593394	chr18:12432897~12437635:+
THCA	cis	rs9959145	0.925	rs75813125	ENSG00000267108.1	RP11-861E21.1	5.09	5.24e-07	7.04e-05	0.28	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12612326	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs28565322	ENSG00000267108.1	RP11-861E21.1	5.09	5.24e-07	7.04e-05	0.28	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12614184	chr18:12432897~12437635:+
THCA	cis	rs7976269	0.609	rs4931137	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29049701	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs2082943	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29050251	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs10743641	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29050819	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs4930846	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29051306	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs4402335	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29052836	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs2117994	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29054666	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.583	rs6487753	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29056103	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.583	rs6487754	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29056104	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs6487755	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29056156	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs4931142	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29057877	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs2117993	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29060041	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs10843300	ENSG00000275476.1	RP11-996F15.4	-5.09	5.25e-07	7.04e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29060934	chr12:29277397~29277882:-
THCA	cis	rs3892630	0.62	rs10413279	ENSG00000267475.1	CTD-2538C1.2	-5.09	5.25e-07	7.04e-05	-0.3	-0.23	Red blood cell traits;	chr19:32691840	chr19:32687089~32691750:-
THCA	cis	rs7618915	0.508	rs13065851	ENSG00000243224.1	RP5-1157M23.2	-5.09	5.25e-07	7.04e-05	-0.25	-0.23	Bipolar disorder;	chr3:52610820	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs11709448	ENSG00000243224.1	RP5-1157M23.2	-5.09	5.25e-07	7.04e-05	-0.25	-0.23	Bipolar disorder;	chr3:52613433	chr3:52239258~52241097:+
THCA	cis	rs8177876	0.731	rs4889227	ENSG00000261061.1	RP11-303E16.2	5.09	5.25e-07	7.04e-05	0.32	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81030770~81031485:+
THCA	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-5.09	5.25e-07	7.04e-05	-0.18	-0.23	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
THCA	cis	rs972578	0.791	rs9611953	ENSG00000274717.1	RP1-47A17.1	-5.09	5.25e-07	7.05e-05	-0.24	-0.23	Mean platelet volume;	chr22:42883276	chr22:42791814~42794313:-
THCA	cis	rs793571	0.504	rs6494034	ENSG00000259250.1	RP11-50C13.1	-5.09	5.25e-07	7.05e-05	-0.24	-0.23	Schizophrenia;	chr15:58717912	chr15:58587507~58591676:+
THCA	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-5.09	5.25e-07	7.05e-05	-0.26	-0.23	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
THCA	cis	rs7618915	0.547	rs2118540	ENSG00000243224.1	RP5-1157M23.2	-5.09	5.25e-07	7.05e-05	-0.25	-0.23	Bipolar disorder;	chr3:52595370	chr3:52239258~52241097:+
THCA	cis	rs4646450	0.891	rs13227795	ENSG00000244219.5	GS1-259H13.2	-5.09	5.25e-07	7.05e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99451780	chr7:99598066~99610813:+
THCA	cis	rs4646450	0.891	rs2280601	ENSG00000244219.5	GS1-259H13.2	-5.09	5.25e-07	7.05e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99458476	chr7:99598066~99610813:+
THCA	cis	rs9733	0.596	rs12089989	ENSG00000231073.1	RP11-316M1.3	5.09	5.25e-07	7.05e-05	0.27	0.23	Tonsillectomy;	chr1:150743306	chr1:150973123~150975534:+
THCA	cis	rs599083	0.793	rs314750	ENSG00000212093.1	AP000807.1	-5.09	5.25e-07	7.05e-05	-0.24	-0.23	Bone mineral density (spine);	chr11:68414560	chr11:68506083~68506166:-
THCA	cis	rs6968419	0.747	rs56293030	ENSG00000237870.5	AC073130.1	5.09	5.25e-07	7.05e-05	0.25	0.23	Intraocular pressure;	chr7:116217116	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs1004107	ENSG00000237870.5	AC073130.1	5.09	5.25e-07	7.05e-05	0.25	0.23	Intraocular pressure;	chr7:116220729	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs1000966	ENSG00000237870.5	AC073130.1	5.09	5.25e-07	7.05e-05	0.25	0.23	Intraocular pressure;	chr7:116222848	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs3807968	ENSG00000237870.5	AC073130.1	5.09	5.25e-07	7.05e-05	0.25	0.23	Intraocular pressure;	chr7:116223392	chr7:116275606~116286734:-
THCA	cis	rs10083777	0.551	rs79623059	ENSG00000261061.1	RP11-303E16.2	-5.09	5.25e-07	7.05e-05	-0.42	-0.23	Metabolite levels (small molecules and protein measures);	chr16:80973348	chr16:81030770~81031485:+
THCA	cis	rs5758511	0.68	rs17002902	ENSG00000281538.1	RP4-669P10.20	-5.09	5.25e-07	7.05e-05	-0.26	-0.23	Birth weight;	chr22:42229503	chr22:42138060~42139726:+
THCA	cis	rs748404	0.666	rs34591748	ENSG00000205771.5	CATSPER2P1	-5.09	5.25e-07	7.05e-05	-0.29	-0.23	Lung cancer;	chr15:43334917	chr15:43726918~43747094:-
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000273796.1	LL21NC02-21A1.1	-5.09	5.26e-07	7.05e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000273796.1	LL21NC02-21A1.1	-5.09	5.26e-07	7.05e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000273796.1	LL21NC02-21A1.1	-5.09	5.26e-07	7.05e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000273796.1	LL21NC02-21A1.1	-5.09	5.26e-07	7.05e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000273796.1	LL21NC02-21A1.1	-5.09	5.26e-07	7.05e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000273796.1	LL21NC02-21A1.1	-5.09	5.26e-07	7.05e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000273796.1	LL21NC02-21A1.1	5.09	5.26e-07	7.05e-05	0.24	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45403809~45404369:-
THCA	cis	rs2235642	0.891	rs2281231	ENSG00000280231.1	LA16c-380F5.3	-5.09	5.26e-07	7.06e-05	-0.27	-0.23	Coronary artery disease;	chr16:1551878	chr16:1553655~1554130:-
THCA	cis	rs972578	0.818	rs4820493	ENSG00000274717.1	RP1-47A17.1	-5.09	5.26e-07	7.06e-05	-0.23	-0.23	Mean platelet volume;	chr22:42885575	chr22:42791814~42794313:-
THCA	cis	rs7618915	0.547	rs11177	ENSG00000243224.1	RP5-1157M23.2	-5.09	5.26e-07	7.06e-05	-0.25	-0.23	Bipolar disorder;	chr3:52687289	chr3:52239258~52241097:+
THCA	cis	rs11671005	0.735	rs11671591	ENSG00000265272.2	RN7SL693P	-5.09	5.26e-07	7.06e-05	-0.32	-0.23	Mean platelet volume;	chr19:58406970	chr19:58490797~58491075:+
THCA	cis	rs16958440	0.708	rs62096465	ENSG00000267800.1	RP11-49K24.5	-5.09	5.26e-07	7.06e-05	-0.42	-0.23	Sitting height ratio;	chr18:47103253	chr18:47137018~47137290:+
THCA	cis	rs9500256	0.515	rs12207710	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-5.09	5.26e-07	7.06e-05	-0.26	-0.23	Eosinophilic esophagitis (pediatric);	chr6:57943175	chr6:57855891~57856468:-
THCA	cis	rs6121246	0.697	rs6120970	ENSG00000230613.1	HM13-AS1	5.09	5.26e-07	7.06e-05	0.25	0.23	Mean corpuscular hemoglobin;	chr20:31644649	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.697	rs7269866	ENSG00000230613.1	HM13-AS1	5.09	5.26e-07	7.06e-05	0.25	0.23	Mean corpuscular hemoglobin;	chr20:31644701	chr20:31567707~31573263:-
THCA	cis	rs10208649	0.908	rs76073574	ENSG00000233266.1	HMGB1P31	5.09	5.27e-07	7.07e-05	0.63	0.23	Body mass index;	chr2:53980525	chr2:54051334~54051760:+
THCA	cis	rs35160687	0.644	rs17738058	ENSG00000273080.1	RP11-301O19.1	-5.09	5.27e-07	7.07e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86286080	chr2:86195590~86196049:+
THCA	cis	rs793571	0.504	rs28549001	ENSG00000245975.2	RP11-30K9.6	5.09	5.27e-07	7.07e-05	0.26	0.23	Schizophrenia;	chr15:58721969	chr15:58768072~58770974:-
THCA	cis	rs2439831	0.681	rs11858152	ENSG00000275601.1	AC011330.13	-5.09	5.27e-07	7.07e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43341998	chr15:43642389~43643023:-
THCA	cis	rs150992	0.504	rs6878136	ENSG00000248489.1	CTD-2007H13.3	-5.09	5.27e-07	7.07e-05	-0.24	-0.23	Body mass index;	chr5:99022487	chr5:98929171~98995013:+
THCA	cis	rs1005277	0.505	rs13503	ENSG00000276805.1	RP11-291L22.6	-5.09	5.27e-07	7.07e-05	-0.24	-0.23	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38451030~38451785:+
THCA	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	5.09	5.27e-07	7.08e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	5.09	5.27e-07	7.08e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	5.09	5.27e-07	7.08e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
THCA	cis	rs875971	0.545	rs2707851	ENSG00000228409.4	CCT6P1	5.09	5.28e-07	7.08e-05	0.19	0.23	Aortic root size;	chr7:66624178	chr7:65751142~65763354:+
THCA	cis	rs17767392	0.834	rs72728406	ENSG00000259146.3	RP1-261D10.2	5.09	5.28e-07	7.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71268275	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.834	rs56362777	ENSG00000259146.3	RP1-261D10.2	5.09	5.28e-07	7.08e-05	0.3	0.23	Mitral valve prolapse;	chr14:71268701	chr14:71292729~71321814:-
THCA	cis	rs16958440	0.708	rs1434528	ENSG00000267800.1	RP11-49K24.5	-5.09	5.28e-07	7.08e-05	-0.42	-0.23	Sitting height ratio;	chr18:47105952	chr18:47137018~47137290:+
THCA	cis	rs2964991	1	rs2964991	ENSG00000228208.5	C1orf143	-5.09	5.28e-07	7.08e-05	-0.27	-0.23	Post bronchodilator FEV1/FVC ratio;	chr1:218511890	chr1:218510096~218525978:+
THCA	cis	rs16846053	0.792	rs62187736	ENSG00000227403.1	AC009299.3	5.09	5.28e-07	7.09e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161836778	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs55970269	ENSG00000227403.1	AC009299.3	5.09	5.28e-07	7.09e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161837044	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs55658092	ENSG00000227403.1	AC009299.3	5.09	5.28e-07	7.09e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161837049	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs55764479	ENSG00000227403.1	AC009299.3	5.09	5.28e-07	7.09e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161837228	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187739	ENSG00000227403.1	AC009299.3	5.09	5.28e-07	7.09e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161837917	chr2:161244739~161249050:+
THCA	cis	rs6951245	1	rs2363286	ENSG00000229043.2	AC091729.9	-5.09	5.29e-07	7.09e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1160374~1165267:+
THCA	cis	rs9652601	0.845	rs7184615	ENSG00000274038.1	RP11-66H6.4	-5.09	5.29e-07	7.09e-05	-0.29	-0.23	Systemic lupus erythematosus;	chr16:11071685	chr16:11056556~11057034:+
THCA	cis	rs9921338	0.636	rs72771866	ENSG00000262703.1	RP11-485G7.6	-5.09	5.29e-07	7.09e-05	-0.31	-0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261365	chr16:11348143~11349321:-
THCA	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-5.09	5.29e-07	7.09e-05	-0.19	-0.23	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
THCA	cis	rs228614	0.51	rs223455	ENSG00000248971.2	KRT8P46	-5.09	5.29e-07	7.09e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102728746~102730171:-
THCA	cis	rs6088590	0.965	rs6119534	ENSG00000269202.1	RP4-614O4.12	-5.09	5.29e-07	7.09e-05	-0.21	-0.23	Coronary artery disease;	chr20:34853454	chr20:35201747~35203288:-
THCA	cis	rs763121	0.853	rs8140617	ENSG00000228274.3	RP3-508I15.9	5.09	5.29e-07	7.09e-05	0.25	0.23	Menopause (age at onset);	chr22:38574434	chr22:38667585~38681820:-
THCA	cis	rs7829975	0.502	rs11785183	ENSG00000253893.2	FAM85B	5.09	5.29e-07	7.1e-05	0.31	0.23	Mood instability;	chr8:8708447	chr8:8167819~8226614:-
THCA	cis	rs7587476	0.861	rs17488049	ENSG00000229267.2	AC072062.1	-5.09	5.29e-07	7.1e-05	-0.3	-0.23	Neuroblastoma;	chr2:214787026	chr2:214810229~214963274:+
THCA	cis	rs224278	0.801	rs648746	ENSG00000238280.1	RP11-436D10.3	5.09	5.29e-07	7.1e-05	0.27	0.23	Ewing sarcoma;	chr10:62819222	chr10:62793562~62805887:-
THCA	cis	rs224278	0.801	rs648748	ENSG00000238280.1	RP11-436D10.3	5.09	5.29e-07	7.1e-05	0.27	0.23	Ewing sarcoma;	chr10:62819224	chr10:62793562~62805887:-
THCA	cis	rs4660456	0.913	rs3767951	ENSG00000272145.1	NFYC-AS1	5.09	5.29e-07	7.1e-05	0.16	0.23	Platelet count;	chr1:40767359	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs3767950	ENSG00000272145.1	NFYC-AS1	5.09	5.29e-07	7.1e-05	0.16	0.23	Platelet count;	chr1:40767541	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs3754179	ENSG00000272145.1	NFYC-AS1	5.09	5.29e-07	7.1e-05	0.16	0.23	Platelet count;	chr1:40768464	chr1:40690380~40692066:-
THCA	cis	rs34779708	0.966	rs7077242	ENSG00000271335.4	RP11-324I22.4	-5.09	5.29e-07	7.1e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs12775799	ENSG00000271335.4	RP11-324I22.4	5.09	5.29e-07	7.1e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs11010122	ENSG00000271335.4	RP11-324I22.4	5.09	5.29e-07	7.1e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.9	rs73262807	ENSG00000271335.4	RP11-324I22.4	5.09	5.29e-07	7.1e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs4934736	ENSG00000271335.4	RP11-324I22.4	5.09	5.29e-07	7.1e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs17591781	ENSG00000271335.4	RP11-324I22.4	5.09	5.29e-07	7.1e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs17591857	ENSG00000271335.4	RP11-324I22.4	-5.09	5.29e-07	7.1e-05	-0.22	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs11010125	ENSG00000271335.4	RP11-324I22.4	5.09	5.29e-07	7.1e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35314552~35336401:-
THCA	cis	rs7520050	0.807	rs28647556	ENSG00000234329.1	RP11-767N6.2	5.09	5.29e-07	7.1e-05	0.2	0.23	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.807	rs4274104	ENSG00000234329.1	RP11-767N6.2	5.09	5.29e-07	7.1e-05	0.2	0.23	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45651039~45651826:-
THCA	cis	rs1005277	0.579	rs2504143	ENSG00000272983.1	RP11-508N22.12	5.09	5.29e-07	7.1e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38137337~38144399:+
THCA	cis	rs9863	0.931	rs11831913	ENSG00000269997.1	RP11-214K3.21	-5.09	5.29e-07	7.1e-05	-0.28	-0.23	White blood cell count;	chr12:123962351	chr12:123966077~123966629:-
THCA	cis	rs7429990	0.864	rs11130150	ENSG00000228638.1	FCF1P2	5.09	5.29e-07	7.1e-05	0.22	0.23	Educational attainment (years of education);	chr3:47832449	chr3:48290793~48291375:-
THCA	cis	rs17360053	0.859	rs34918796	ENSG00000218510.5	LINC00339	-5.09	5.3e-07	7.11e-05	-0.24	-0.23	Obesity-related traits;	chr1:22183413	chr1:22025188~22031223:+
THCA	cis	rs595244	1	rs7170686	ENSG00000259705.1	RP11-227D13.1	5.09	5.3e-07	7.11e-05	0.38	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48529153	chr15:48645951~48652016:+
THCA	cis	rs3820928	1	rs4673173	ENSG00000212391.1	SNORA48	-5.09	5.3e-07	7.11e-05	-0.26	-0.23	Pulmonary function;	chr2:226904777	chr2:226968989~226969122:-
THCA	cis	rs763121	0.853	rs5750630	ENSG00000228274.3	RP3-508I15.9	-5.09	5.3e-07	7.11e-05	-0.25	-0.23	Menopause (age at onset);	chr22:38589813	chr22:38667585~38681820:-
THCA	cis	rs1005277	0.505	rs10827836	ENSG00000276805.1	RP11-291L22.6	-5.09	5.3e-07	7.11e-05	-0.24	-0.23	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38451030~38451785:+
THCA	cis	rs2067615	0.524	rs10778503	ENSG00000260329.1	RP11-412D9.4	-5.09	5.3e-07	7.11e-05	-0.21	-0.23	Heart rate;	chr12:106696838	chr12:106954029~106955497:-
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000229886.1	RP5-1132H15.3	5.09	5.31e-07	7.12e-05	0.27	0.23	Corneal structure;	chr7:66813271	chr7:66025126~66031544:-
THCA	cis	rs2742234	1	rs1864399	ENSG00000273008.1	RP11-351D16.3	-5.09	5.31e-07	7.12e-05	-0.2	-0.23	Hirschsprung disease;	chr10:43115007	chr10:43136824~43138334:-
THCA	cis	rs9467773	1	rs10484442	ENSG00000261353.1	CTA-14H9.5	-5.09	5.31e-07	7.12e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26527063~26527404:+
THCA	cis	rs4845570	1	rs6659705	ENSG00000203288.3	RP11-98D18.9	-5.09	5.31e-07	7.12e-05	-0.26	-0.23	Coronary artery disease;	chr1:151797274	chr1:151790804~151794402:+
THCA	cis	rs897984	0.646	rs9938088	ENSG00000279196.1	RP11-1072A3.3	5.09	5.31e-07	7.12e-05	0.23	0.23	Dementia with Lewy bodies;	chr16:30818683	chr16:30984630~30988270:-
THCA	cis	rs440932	0.887	rs398801	ENSG00000253893.2	FAM85B	5.09	5.31e-07	7.13e-05	0.29	0.23	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8167819~8226614:-
THCA	cis	rs12681287	0.577	rs11992955	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86518257	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs11992656	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86522641	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs9297921	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86530058	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs9297922	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86530089	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs35871312	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86530991	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs10087788	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86531946	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.577	rs10481197	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86534323	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.547	rs10956873	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86534800	chr8:86333274~86343314:-
THCA	cis	rs12681287	0.511	rs9297923	ENSG00000254231.1	CTD-2284J15.1	-5.09	5.32e-07	7.13e-05	-0.26	-0.23	Caudate activity during reward;	chr8:86536761	chr8:86333274~86343314:-
THCA	cis	rs12036718	0.511	rs214204	ENSG00000272491.1	RP5-1024N4.4	-5.09	5.32e-07	7.13e-05	-0.29	-0.23	Yu-Zhi constitution type in type 2 diabetes;	chr1:48122159	chr1:48227888~48229561:-
THCA	cis	rs2235642	0.859	rs12599207	ENSG00000280231.1	LA16c-380F5.3	-5.08	5.32e-07	7.13e-05	-0.28	-0.23	Coronary artery disease;	chr16:1556444	chr16:1553655~1554130:-
THCA	cis	rs9475752	0.793	rs13220575	ENSG00000231441.1	RP11-472M19.2	-5.08	5.32e-07	7.13e-05	-0.31	-0.23	Menarche (age at onset);	chr6:57002239	chr6:56844002~56864078:+
THCA	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
THCA	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
THCA	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	5.08	5.32e-07	7.14e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
THCA	cis	rs7688540	0.8	rs11723492	ENSG00000275426.1	CH17-262A2.1	5.08	5.32e-07	7.14e-05	0.29	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:149738~150317:+
THCA	cis	rs12893668	0.697	rs67899457	ENSG00000269940.1	RP11-73M18.7	5.08	5.32e-07	7.14e-05	0.24	0.23	Reticulocyte count;	chr14:103593729	chr14:103694560~103695170:+
THCA	cis	rs1707322	1	rs785465	ENSG00000281133.1	AL355480.3	-5.08	5.32e-07	7.14e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45580892~45580996:-
THCA	cis	rs3743266	0.593	rs4775276	ENSG00000245534.5	RORA-AS1	-5.08	5.33e-07	7.14e-05	-0.25	-0.23	Menarche (age at onset);	chr15:60513986	chr15:60479178~60630637:+
THCA	cis	rs4767841	1	rs10849691	ENSG00000248636.5	RP11-768F21.1	-5.08	5.33e-07	7.14e-05	-0.23	-0.23	Urgency urinary incontinence;	chr12:119716449	chr12:119387987~119668079:-
THCA	cis	rs16846053	0.605	rs115071626	ENSG00000227403.1	AC009299.3	5.08	5.33e-07	7.14e-05	0.53	0.23	Blood osmolality (transformed sodium);	chr2:161896092	chr2:161244739~161249050:+
THCA	cis	rs2179367	0.552	rs11155652	ENSG00000223701.3	RAET1E-AS1	5.08	5.33e-07	7.14e-05	0.33	0.23	Dupuytren's disease;	chr6:149417849	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12209364	ENSG00000223701.3	RAET1E-AS1	5.08	5.33e-07	7.14e-05	0.33	0.23	Dupuytren's disease;	chr6:149418062	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs9322179	ENSG00000223701.3	RAET1E-AS1	5.08	5.33e-07	7.14e-05	0.33	0.23	Dupuytren's disease;	chr6:149418664	chr6:149884431~149919508:+
THCA	cis	rs9549367	0.713	rs3024764	ENSG00000269125.1	RP11-98F14.11	-5.08	5.33e-07	7.14e-05	-0.28	-0.23	Platelet distribution width;	chr13:113170000	chr13:113165002~113165183:-
THCA	cis	rs7429990	0.803	rs6773732	ENSG00000228638.1	FCF1P2	5.08	5.33e-07	7.14e-05	0.22	0.23	Educational attainment (years of education);	chr3:47677772	chr3:48290793~48291375:-
THCA	cis	rs860295	0.651	rs12239114	ENSG00000160766.13	GBAP1	-5.08	5.33e-07	7.14e-05	-0.27	-0.23	Body mass index;	chr1:155352351	chr1:155213821~155227422:-
THCA	cis	rs1577917	0.655	rs6454472	ENSG00000220563.1	PKMP3	5.08	5.33e-07	7.14e-05	0.16	0.23	Response to antipsychotic treatment;	chr6:85514335	chr6:85659892~85660606:-
THCA	cis	rs2288884	0.767	rs12462359	ENSG00000260160.1	CTC-471J1.2	-5.08	5.33e-07	7.14e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032168	chr19:52058490~52063703:-
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000164669.11	INTS4P1	5.08	5.33e-07	7.15e-05	0.44	0.23	Diabetic kidney disease;	chr7:65951319	chr7:65141225~65234216:+
THCA	cis	rs10751647	0.804	rs3809112	ENSG00000254910.1	RP11-326C3.7	5.08	5.33e-07	7.15e-05	0.25	0.23	Monocyte count;	chr11:307036	chr11:310139~311141:-
THCA	cis	rs1150668	1	rs1150668	ENSG00000273712.1	RP5-874C20.7	5.08	5.33e-07	7.15e-05	0.25	0.23	Pubertal anthropometrics;	chr6:28162011	chr6:28315613~28315883:-
THCA	cis	rs17798991	0.721	rs11082768	ENSG00000267674.1	RP11-813F20.2	-5.08	5.34e-07	7.16e-05	-0.24	-0.23	Obesity-related traits;	chr18:49607123	chr18:49739823~49742063:-
THCA	cis	rs10510102	1	rs10886994	ENSG00000226864.1	ATE1-AS1	5.08	5.34e-07	7.16e-05	0.37	0.23	Breast cancer;	chr10:121841075	chr10:121928312~121951965:+
THCA	cis	rs7429990	0.864	rs6785669	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47715771	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs6442079	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47721044	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs13094264	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47722723	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs4858851	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47724165	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs34777284	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47726585	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs7649393	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47727501	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7638103	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47727585	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs11130148	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47729797	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs1486915	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47781053	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.828	rs6792350	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47797451	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs4858860	ENSG00000228638.1	FCF1P2	5.08	5.34e-07	7.16e-05	0.22	0.23	Educational attainment (years of education);	chr3:47817344	chr3:48290793~48291375:-
THCA	cis	rs3734266	0.646	rs79139175	ENSG00000272288.4	RP11-140K17.3	-5.08	5.34e-07	7.16e-05	-0.23	-0.23	Systemic lupus erythematosus;	chr6:34601709	chr6:34696317~34697470:+
THCA	cis	rs944289	0.708	rs11622885	ENSG00000258844.1	RP11-259K15.2	5.08	5.34e-07	7.16e-05	0.2	0.23	Thyroid cancer;	chr14:36095036	chr14:36214607~36235608:+
THCA	cis	rs7688540	0.771	rs7686546	ENSG00000211553.1	AC253576.2	-5.08	5.35e-07	7.17e-05	-0.35	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:136461~136568:+
THCA	cis	rs9326248	0.53	rs900012	ENSG00000280143.1	AP000892.6	5.08	5.35e-07	7.17e-05	0.37	0.23	Blood protein levels;	chr11:117095719	chr11:117204967~117210292:+
THCA	cis	rs9818758	0.607	rs5030795	ENSG00000270441.1	RP11-694I15.7	5.08	5.35e-07	7.17e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49103683	chr3:49140086~49160851:-
THCA	cis	rs1426063	0.858	rs6823982	ENSG00000260265.1	RP11-44F21.5	5.08	5.35e-07	7.17e-05	0.41	0.23	QT interval;	chr4:75084961	chr4:75081702~75084717:-
THCA	cis	rs4925166	1	rs4925166	ENSG00000260647.1	RP1-178F10.1	5.08	5.36e-07	7.18e-05	0.22	0.23	Multiple sclerosis;	chr17:18307496	chr17:18268080~18268828:+
THCA	cis	rs481331	0.643	rs209390	ENSG00000215146.4	RP11-313J2.1	-5.08	5.36e-07	7.19e-05	-0.37	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42633432	chr10:42331866~42367974:-
THCA	cis	rs1823913	0.614	rs11693878	ENSG00000280083.1	RP11-317J9.1	5.08	5.36e-07	7.19e-05	0.26	0.23	Obesity-related traits;	chr2:191299399	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs10931494	ENSG00000280083.1	RP11-317J9.1	5.08	5.36e-07	7.19e-05	0.26	0.23	Obesity-related traits;	chr2:191299442	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs10931495	ENSG00000280083.1	RP11-317J9.1	5.08	5.36e-07	7.19e-05	0.26	0.23	Obesity-related traits;	chr2:191299447	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs12623156	ENSG00000280083.1	RP11-317J9.1	5.08	5.36e-07	7.19e-05	0.26	0.23	Obesity-related traits;	chr2:191299661	chr2:191154118~191156070:-
THCA	cis	rs13178541	0.638	rs34295073	ENSG00000250378.1	RP11-119J18.1	-5.08	5.36e-07	7.19e-05	-0.3	-0.23	IgG glycosylation;	chr5:135785964	chr5:135812667~135826582:+
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000273796.1	LL21NC02-21A1.1	-5.08	5.37e-07	7.19e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000273796.1	LL21NC02-21A1.1	-5.08	5.37e-07	7.19e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000273796.1	LL21NC02-21A1.1	-5.08	5.37e-07	7.19e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000273796.1	LL21NC02-21A1.1	-5.08	5.37e-07	7.19e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000273796.1	LL21NC02-21A1.1	-5.08	5.37e-07	7.19e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45403809~45404369:-
THCA	cis	rs748404	0.666	rs7177892	ENSG00000205771.5	CATSPER2P1	-5.08	5.37e-07	7.19e-05	-0.29	-0.23	Lung cancer;	chr15:43321171	chr15:43726918~43747094:-
THCA	cis	rs972578	0.645	rs738534	ENSG00000274717.1	RP1-47A17.1	-5.08	5.37e-07	7.19e-05	-0.24	-0.23	Mean platelet volume;	chr22:42841633	chr22:42791814~42794313:-
THCA	cis	rs783540	0.5	rs1313494	ENSG00000278603.1	RP13-608F4.5	-5.08	5.37e-07	7.19e-05	-0.33	-0.23	Schizophrenia;	chr15:82605530	chr15:82472203~82472426:+
THCA	cis	rs7429990	0.864	rs12492915	ENSG00000228638.1	FCF1P2	5.08	5.37e-07	7.19e-05	0.22	0.23	Educational attainment (years of education);	chr3:47636545	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs12636863	ENSG00000228638.1	FCF1P2	5.08	5.37e-07	7.19e-05	0.22	0.23	Educational attainment (years of education);	chr3:47638629	chr3:48290793~48291375:-
THCA	cis	rs35160687	0.644	rs1863061	ENSG00000273080.1	RP11-301O19.1	-5.08	5.37e-07	7.2e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86285784	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.644	rs4832272	ENSG00000273080.1	RP11-301O19.1	-5.08	5.37e-07	7.2e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86289088	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.644	rs57270703	ENSG00000273080.1	RP11-301O19.1	-5.08	5.37e-07	7.2e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86289750	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.644	rs2113615	ENSG00000273080.1	RP11-301O19.1	-5.08	5.37e-07	7.2e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86290479	chr2:86195590~86196049:+
THCA	cis	rs9467773	0.511	rs17278688	ENSG00000241549.7	GUSBP2	5.08	5.37e-07	7.2e-05	0.21	0.23	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26871484~26956554:-
THCA	cis	rs858239	0.537	rs2286272	ENSG00000226816.2	AC005082.12	5.08	5.37e-07	7.2e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23206013~23208045:+
THCA	cis	rs858239	0.537	rs6955115	ENSG00000226816.2	AC005082.12	5.08	5.37e-07	7.2e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23206013~23208045:+
THCA	cis	rs987724	0.593	rs4680317	ENSG00000240875.4	LINC00886	5.08	5.37e-07	7.2e-05	0.18	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156938964	chr3:156747346~156817062:-
THCA	cis	rs12682352	0.652	rs3789843	ENSG00000254153.1	CTA-398F10.2	-5.08	5.37e-07	7.2e-05	-0.26	-0.23	Neuroticism;	chr8:8866747	chr8:8456909~8461337:-
THCA	cis	rs12682352	0.652	rs3827806	ENSG00000254153.1	CTA-398F10.2	-5.08	5.37e-07	7.2e-05	-0.26	-0.23	Neuroticism;	chr8:8866766	chr8:8456909~8461337:-
THCA	cis	rs10771431	0.967	rs7137443	ENSG00000256069.6	A2MP1	5.08	5.37e-07	7.2e-05	0.25	0.23	Breast size;	chr12:9219433	chr12:9228533~9275817:-
THCA	cis	rs10771431	0.935	rs1988852	ENSG00000256069.6	A2MP1	5.08	5.37e-07	7.2e-05	0.25	0.23	Breast size;	chr12:9220266	chr12:9228533~9275817:-
THCA	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-5.08	5.38e-07	7.2e-05	-0.27	-0.23	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	5.08	5.38e-07	7.2e-05	0.27	0.23	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
THCA	cis	rs8141529	0.748	rs6005936	ENSG00000272858.1	CTA-292E10.8	-5.08	5.38e-07	7.2e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28893262	chr22:28814914~28815662:+
THCA	cis	rs17711722	0.701	rs781143	ENSG00000223473.2	GS1-124K5.3	5.08	5.38e-07	7.2e-05	0.15	0.23	Calcium levels;	chr7:65974892	chr7:66491049~66493566:-
THCA	cis	rs7394190	0.748	rs34163229	ENSG00000271848.1	RP11-464F9.21	-5.08	5.38e-07	7.2e-05	-0.3	-0.23	Incident atrial fibrillation;	chr10:73647154	chr10:73654039~73674719:+
THCA	cis	rs9392556	0.6	rs661404	ENSG00000230648.1	RP3-406P24.3	5.08	5.38e-07	7.2e-05	0.28	0.23	Blood metabolite levels;	chr6:4125863	chr6:4018843~4021215:-
THCA	cis	rs16975963	0.644	rs73031309	ENSG00000226686.6	LINC01535	-5.08	5.38e-07	7.21e-05	-0.31	-0.23	Longevity;	chr19:37541082	chr19:37251912~37265535:+
THCA	cis	rs919433	1	rs7422899	ENSG00000231621.1	AC013264.2	5.08	5.38e-07	7.21e-05	0.24	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298803	chr2:197197991~197199273:+
THCA	cis	rs7829975	0.626	rs907183	ENSG00000233609.3	RP11-62H7.2	-5.08	5.38e-07	7.21e-05	-0.23	-0.23	Mood instability;	chr8:8872251	chr8:8961200~8979025:+
THCA	cis	rs1005277	0.579	rs2008449	ENSG00000275858.1	RP11-291L22.8	-5.08	5.38e-07	7.21e-05	-0.27	-0.23	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38450738~38451069:-
THCA	cis	rs2742234	0.541	rs11238490	ENSG00000273008.1	RP11-351D16.3	5.08	5.38e-07	7.21e-05	0.22	0.23	Hirschsprung disease;	chr10:43252150	chr10:43136824~43138334:-
THCA	cis	rs6792584	0.572	rs12489223	ENSG00000241316.5	SUCLG2-AS1	5.08	5.39e-07	7.21e-05	0.25	0.23	Corneal astigmatism;	chr3:67424673	chr3:67654697~67947713:+
THCA	cis	rs494003	0.553	rs10896045	ENSG00000214659.4	KRT8P26	-5.08	5.39e-07	7.22e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr11:65788053	chr11:65726939~65728214:+
THCA	cis	rs7119	0.679	rs12902698	ENSG00000259362.2	RP11-307C19.1	-5.08	5.39e-07	7.22e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77516668	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12902852	ENSG00000259362.2	RP11-307C19.1	-5.08	5.39e-07	7.22e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77516674	chr15:77525540~77534110:+
THCA	cis	rs7119	0.717	rs12902912	ENSG00000259362.2	RP11-307C19.1	-5.08	5.39e-07	7.22e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77516828	chr15:77525540~77534110:+
THCA	cis	rs6545883	0.708	rs2518936	ENSG00000270820.4	RP11-355B11.2	5.08	5.39e-07	7.22e-05	0.19	0.23	Tuberculosis;	chr2:61565207	chr2:61471188~61484130:+
THCA	cis	rs8064024	0.676	rs56919624	ENSG00000267077.1	RP11-127I20.5	5.08	5.39e-07	7.22e-05	0.26	0.23	Cancer;	chr16:4827592	chr16:4795265~4796532:-
THCA	cis	rs4648045	0.861	rs230525	ENSG00000246560.2	RP11-10L12.4	5.08	5.39e-07	7.22e-05	0.31	0.23	Lymphocyte percentage of white cells;	chr4:102537720	chr4:102828055~102844075:+
THCA	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	5.08	5.4e-07	7.23e-05	0.36	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
THCA	cis	rs7119	0.717	rs8040702	ENSG00000259362.2	RP11-307C19.1	-5.08	5.4e-07	7.23e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77511273	chr15:77525540~77534110:+
THCA	cis	rs8177876	0.822	rs56166222	ENSG00000261838.4	RP11-303E16.6	5.08	5.4e-07	7.23e-05	0.43	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81069854~81076598:+
THCA	cis	rs10129255	0.789	rs61997796	ENSG00000211970.3	IGHV4-61	-5.08	5.4e-07	7.23e-05	-0.14	-0.23	Kawasaki disease;	chr14:106813798	chr14:106639119~106639657:-
THCA	cis	rs752010	0.523	rs10890158	ENSG00000230638.4	RP11-486B10.4	-5.08	5.4e-07	7.23e-05	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41652314	chr1:41542069~41544310:+
THCA	cis	rs2439831	0.681	rs825739	ENSG00000275601.1	AC011330.13	-5.08	5.4e-07	7.23e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43300230	chr15:43642389~43643023:-
THCA	cis	rs801193	0.742	rs9969300	ENSG00000236529.1	RP13-254B10.1	-5.08	5.4e-07	7.24e-05	-0.26	-0.23	Aortic root size;	chr7:66316659	chr7:65840212~65840596:+
THCA	cis	rs4915077	0.892	rs78499451	ENSG00000230489.1	VAV3-AS1	5.08	5.41e-07	7.24e-05	0.38	0.23	Hypothyroidism;	chr1:107817167	chr1:107964443~107994607:+
THCA	cis	rs35160687	0.623	rs7569654	ENSG00000273080.1	RP11-301O19.1	-5.08	5.41e-07	7.24e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86250899	chr2:86195590~86196049:+
THCA	cis	rs4857855	0.716	rs7433900	ENSG00000239405.1	TMED10P2	-5.08	5.41e-07	7.24e-05	-0.31	-0.23	Eosinophil counts;	chr3:128522111	chr3:128538020~128538631:+
THCA	cis	rs79349575	0.756	rs4793605	ENSG00000270781.1	RP11-501C14.9	-5.08	5.41e-07	7.24e-05	-0.28	-0.23	Type 2 diabetes;	chr17:48958507	chr17:48899131~48899748:+
THCA	cis	rs8062405	1	rs12325113	ENSG00000278665.1	RP11-666O2.4	5.08	5.41e-07	7.24e-05	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28599241~28601881:-
THCA	cis	rs56163509	1	rs56163509	ENSG00000278665.1	RP11-666O2.4	5.08	5.41e-07	7.24e-05	0.25	0.23	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs62037369	ENSG00000278665.1	RP11-666O2.4	5.08	5.41e-07	7.24e-05	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28599241~28601881:-
THCA	cis	rs8062405	0.965	rs7359397	ENSG00000278665.1	RP11-666O2.4	5.08	5.41e-07	7.24e-05	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28599241~28601881:-
THCA	cis	rs12188164	0.61	rs6555242	ENSG00000225138.6	CTD-2228K2.7	5.08	5.41e-07	7.24e-05	0.23	0.23	Cystic fibrosis severity;	chr5:416431	chr5:473236~480884:+
THCA	cis	rs17767392	0.756	rs61991195	ENSG00000259146.3	RP1-261D10.2	5.08	5.41e-07	7.25e-05	0.3	0.23	Mitral valve prolapse;	chr14:71280506	chr14:71292729~71321814:-
THCA	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-5.08	5.42e-07	7.25e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
THCA	cis	rs7429990	0.864	rs883663	ENSG00000228638.1	FCF1P2	5.08	5.42e-07	7.25e-05	0.22	0.23	Educational attainment (years of education);	chr3:47619306	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.833	rs6442072	ENSG00000228638.1	FCF1P2	5.08	5.42e-07	7.25e-05	0.22	0.23	Educational attainment (years of education);	chr3:47642960	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs2882611	ENSG00000228638.1	FCF1P2	5.08	5.42e-07	7.25e-05	0.22	0.23	Educational attainment (years of education);	chr3:47651532	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs2049301	ENSG00000228638.1	FCF1P2	5.08	5.42e-07	7.25e-05	0.22	0.23	Educational attainment (years of education);	chr3:47681369	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7429162	ENSG00000228638.1	FCF1P2	5.08	5.42e-07	7.25e-05	0.22	0.23	Educational attainment (years of education);	chr3:47683845	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs4410463	ENSG00000228638.1	FCF1P2	5.08	5.42e-07	7.25e-05	0.22	0.23	Educational attainment (years of education);	chr3:47693907	chr3:48290793~48291375:-
THCA	cis	rs7577696	0.962	rs212679	ENSG00000276334.1	AL133243.1	5.08	5.42e-07	7.25e-05	0.24	0.23	Inflammatory biomarkers;	chr2:32206038	chr2:32521927~32523547:+
THCA	cis	rs467650	1	rs468238	ENSG00000248489.1	CTD-2007H13.3	5.08	5.42e-07	7.25e-05	0.22	0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:98640401	chr5:98929171~98995013:+
THCA	cis	rs12534093	0.67	rs13229167	ENSG00000234286.1	AC006026.13	-5.08	5.42e-07	7.25e-05	-0.34	-0.23	Infant length;Height;	chr7:23552243	chr7:23680195~23680786:-
THCA	cis	rs736408	0.736	rs4687550	ENSG00000243224.1	RP5-1157M23.2	-5.08	5.42e-07	7.25e-05	-0.25	-0.23	Bipolar disorder;	chr3:52789414	chr3:52239258~52241097:+
THCA	cis	rs9863	0.931	rs34180676	ENSG00000269997.1	RP11-214K3.21	-5.08	5.42e-07	7.26e-05	-0.28	-0.23	White blood cell count;	chr12:123946972	chr12:123966077~123966629:-
THCA	cis	rs9863	0.931	rs7955815	ENSG00000269997.1	RP11-214K3.21	-5.08	5.42e-07	7.26e-05	-0.28	-0.23	White blood cell count;	chr12:123948159	chr12:123966077~123966629:-
THCA	cis	rs4604234	0.614	rs73482029	ENSG00000272129.1	RP11-250B2.6	-5.08	5.42e-07	7.26e-05	-0.55	-0.23	Cancer;	chr6:80218143	chr6:80355424~80356859:+
THCA	cis	rs79349575	0.594	rs62078375	ENSG00000270781.1	RP11-501C14.9	-5.08	5.42e-07	7.26e-05	-0.28	-0.23	Type 2 diabetes;	chr17:48957612	chr17:48899131~48899748:+
THCA	cis	rs7833787	0.7	rs11988239	ENSG00000278886.1	RP11-108A14.1	5.08	5.42e-07	7.26e-05	0.29	0.23	Obesity-related traits;	chr8:18852937	chr8:18864681~18865247:-
THCA	cis	rs2735413	0.563	rs11640933	ENSG00000276007.1	RP11-358L22.3	5.08	5.42e-07	7.26e-05	0.25	0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78031710	chr16:78123243~78124332:+
THCA	cis	rs2235642	0.893	rs2076439	ENSG00000280231.1	LA16c-380F5.3	-5.08	5.42e-07	7.26e-05	-0.27	-0.23	Coronary artery disease;	chr16:1537276	chr16:1553655~1554130:-
THCA	cis	rs1823913	0.637	rs1349938	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191299970	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.592	rs1349939	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191300079	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.614	rs6434459	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191300886	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.592	rs7588555	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191300912	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs4853581	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191301533	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.614	rs7565987	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191301815	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.614	rs1973067	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191302021	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs1973068	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191302227	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs7569231	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191302373	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs6434461	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191302661	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.614	rs6434462	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191302705	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs6750360	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191303089	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs11677694	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191303203	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.571	rs6737307	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191303247	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs4853582	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191303483	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs35200176	ENSG00000280083.1	RP11-317J9.1	5.08	5.42e-07	7.26e-05	0.26	0.23	Obesity-related traits;	chr2:191303534	chr2:191154118~191156070:-
THCA	cis	rs8103278	0.507	rs8112282	ENSG00000267395.4	AC074212.6	-5.08	5.43e-07	7.27e-05	-0.15	-0.23	Coronary artery disease;	chr19:45761771	chr19:45767796~45772504:+
THCA	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	5.08	5.43e-07	7.27e-05	0.24	0.23	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
THCA	cis	rs9652601	0.622	rs3901386	ENSG00000274038.1	RP11-66H6.4	-5.08	5.43e-07	7.27e-05	-0.27	-0.23	Systemic lupus erythematosus;	chr16:11048863	chr16:11056556~11057034:+
THCA	cis	rs79349575	0.783	rs12603969	ENSG00000270781.1	RP11-501C14.9	-5.08	5.43e-07	7.27e-05	-0.28	-0.23	Type 2 diabetes;	chr17:48957057	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs12601955	ENSG00000270781.1	RP11-501C14.9	-5.08	5.43e-07	7.27e-05	-0.28	-0.23	Type 2 diabetes;	chr17:48957058	chr17:48899131~48899748:+
THCA	cis	rs897984	0.762	rs12930545	ENSG00000260911.2	RP11-196G11.2	-5.08	5.43e-07	7.27e-05	-0.19	-0.23	Dementia with Lewy bodies;	chr16:30927490	chr16:31043150~31049868:+
THCA	cis	rs897984	0.806	rs10782001	ENSG00000260911.2	RP11-196G11.2	-5.08	5.43e-07	7.27e-05	-0.19	-0.23	Dementia with Lewy bodies;	chr16:30931304	chr16:31043150~31049868:+
THCA	cis	rs897984	0.806	rs12928852	ENSG00000260911.2	RP11-196G11.2	-5.08	5.43e-07	7.27e-05	-0.19	-0.23	Dementia with Lewy bodies;	chr16:30932667	chr16:31043150~31049868:+
THCA	cis	rs16846053	0.792	rs72879227	ENSG00000227403.1	AC009299.3	5.08	5.44e-07	7.28e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161830781	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs55969921	ENSG00000227403.1	AC009299.3	5.08	5.44e-07	7.28e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161830899	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs56299944	ENSG00000227403.1	AC009299.3	5.08	5.44e-07	7.28e-05	0.54	0.23	Blood osmolality (transformed sodium);	chr2:161830949	chr2:161244739~161249050:+
THCA	cis	rs9467773	1	rs1884949	ENSG00000261353.1	CTA-14H9.5	-5.08	5.44e-07	7.28e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26527063~26527404:+
THCA	cis	rs227275	0.556	rs223398	ENSG00000248971.2	KRT8P46	-5.08	5.44e-07	7.28e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102728746~102730171:-
THCA	cis	rs9859260	0.614	rs493661	ENSG00000207650.1	MIR570	-5.08	5.44e-07	7.28e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196059618	chr3:195699401~195699497:+
THCA	cis	rs4604234	0.614	rs3749896	ENSG00000272129.1	RP11-250B2.6	-5.08	5.44e-07	7.28e-05	-0.55	-0.23	Cancer;	chr6:80203260	chr6:80355424~80356859:+
THCA	cis	rs763121	0.853	rs138712	ENSG00000235209.1	CTA-150C2.13	5.08	5.44e-07	7.28e-05	0.32	0.23	Menopause (age at onset);	chr22:38745595	chr22:38921227~38924708:+
THCA	cis	rs9326248	0.861	rs11216172	ENSG00000280143.1	AP000892.6	5.08	5.44e-07	7.29e-05	0.3	0.23	Blood protein levels;	chr11:116879162	chr11:117204967~117210292:+
THCA	cis	rs62244186	0.566	rs3762636	ENSG00000214820.3	MPRIPP1	5.08	5.45e-07	7.29e-05	0.23	0.23	Depressive symptoms;	chr3:44813071	chr3:44579938~44581026:-
THCA	cis	rs6121246	0.58	rs6121016	ENSG00000230613.1	HM13-AS1	5.08	5.45e-07	7.29e-05	0.26	0.23	Mean corpuscular hemoglobin;	chr20:31657436	chr20:31567707~31573263:-
THCA	cis	rs12143943	0.966	rs3795567	ENSG00000240219.1	RP11-430C7.5	5.08	5.45e-07	7.29e-05	0.2	0.23	Cognitive performance;	chr1:204616610	chr1:204626775~204629712:+
THCA	cis	rs79349575	0.783	rs28409394	ENSG00000270781.1	RP11-501C14.9	-5.08	5.45e-07	7.29e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48920756	chr17:48899131~48899748:+
THCA	cis	rs7394190	0.748	rs78985317	ENSG00000271816.1	BMS1P4	-5.08	5.45e-07	7.29e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73754707	chr10:73699151~73730487:-
THCA	cis	rs9990333	0.562	rs56224853	ENSG00000273009.1	RP11-352G9.1	-5.08	5.45e-07	7.29e-05	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195913078~195913683:-
THCA	cis	rs9990333	0.544	rs73210008	ENSG00000273009.1	RP11-352G9.1	-5.08	5.45e-07	7.29e-05	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195913078~195913683:-
THCA	cis	rs7829975	0.742	rs1533059	ENSG00000254153.1	CTA-398F10.2	5.08	5.45e-07	7.29e-05	0.24	0.23	Mood instability;	chr8:8827443	chr8:8456909~8461337:-
THCA	cis	rs412050	0.842	rs1530229	ENSG00000224086.5	LL22NC03-86G7.1	-5.08	5.45e-07	7.3e-05	-0.37	-0.23	Attention deficit hyperactivity disorder;	chr22:21946306	chr22:21938293~21977632:+
THCA	cis	rs6901004	0.592	rs14399	ENSG00000230177.1	RP5-1112D6.4	-5.08	5.45e-07	7.3e-05	-0.19	-0.23	Blood metabolite levels;	chr6:111222741	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.68	rs7767302	ENSG00000255389.1	C6orf3	-5.08	5.45e-07	7.3e-05	-0.28	-0.23	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111599875~111602295:+
THCA	cis	rs4718428	1	rs12534637	ENSG00000232546.1	RP11-458F8.1	-5.08	5.45e-07	7.3e-05	-0.19	-0.23	Corneal structure;	chr7:66862667	chr7:66848496~66858136:+
THCA	cis	rs1552244	0.554	rs6796411	ENSG00000232901.1	CYCSP10	5.08	5.46e-07	7.3e-05	0.27	0.23	Alzheimer's disease;	chr3:9968997	chr3:10000647~10000940:-
THCA	cis	rs703842	0.616	rs871871	ENSG00000270039.1	RP11-571M6.17	-5.08	5.46e-07	7.3e-05	-0.27	-0.23	Multiple sclerosis;	chr12:57825898	chr12:57803838~57804415:+
THCA	cis	rs7552393	0.622	rs2296257	ENSG00000233008.4	RP11-475O6.1	5.08	5.46e-07	7.3e-05	0.27	0.23	Select biomarker traits;	chr1:83845729	chr1:83575776~83861023:-
THCA	cis	rs17123764	0.71	rs2278068	ENSG00000257464.1	RP11-161H23.8	-5.08	5.46e-07	7.31e-05	-0.36	-0.23	Intelligence (multi-trait analysis);	chr12:49550805	chr12:49442424~49442652:-
THCA	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	5.08	5.46e-07	7.31e-05	0.13	0.23	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
THCA	cis	rs6802315	0.604	rs2115941	ENSG00000272087.1	RP11-379F4.7	5.08	5.46e-07	7.31e-05	0.2	0.23	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158693120~158693768:-
THCA	cis	rs7809950	0.822	rs2712228	ENSG00000238832.1	snoU109	5.08	5.46e-07	7.31e-05	0.24	0.23	Coronary artery disease;	chr7:107659895	chr7:107603363~107603507:+
THCA	cis	rs6792584	0.962	rs4258984	ENSG00000241316.5	SUCLG2-AS1	5.08	5.46e-07	7.31e-05	0.24	0.23	Corneal astigmatism;	chr3:67460679	chr3:67654697~67947713:+
THCA	cis	rs7429990	0.864	rs13091913	ENSG00000228638.1	FCF1P2	5.08	5.47e-07	7.31e-05	0.22	0.23	Educational attainment (years of education);	chr3:47762307	chr3:48290793~48291375:-
THCA	cis	rs6545883	0.791	rs2600665	ENSG00000270820.4	RP11-355B11.2	5.08	5.47e-07	7.31e-05	0.19	0.23	Tuberculosis;	chr2:61178660	chr2:61471188~61484130:+
THCA	cis	rs8020095	0.571	rs8006371	ENSG00000258561.1	RP11-72M17.1	-5.08	5.47e-07	7.32e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66908624	chr14:66212810~66509394:-
THCA	cis	rs3820928	0.648	rs1997484	ENSG00000212391.1	SNORA48	-5.08	5.47e-07	7.32e-05	-0.25	-0.23	Pulmonary function;	chr2:227034246	chr2:226968989~226969122:-
THCA	cis	rs2439831	1	rs565007	ENSG00000205771.5	CATSPER2P1	-5.08	5.47e-07	7.32e-05	-0.3	-0.23	Lung cancer in ever smokers;	chr15:43424443	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs550239	ENSG00000205771.5	CATSPER2P1	-5.08	5.47e-07	7.32e-05	-0.3	-0.23	Lung cancer in ever smokers;	chr15:43427999	chr15:43726918~43747094:-
THCA	cis	rs4722166	0.63	rs12537614	ENSG00000225541.1	AC002480.5	-5.08	5.47e-07	7.32e-05	-0.3	-0.23	Lung cancer;	chr7:22749932	chr7:22571607~22661792:-
THCA	cis	rs6714710	0.603	rs11692010	ENSG00000230606.9	AC159540.1	-5.08	5.48e-07	7.33e-05	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97780838	chr2:97416165~97433527:-
THCA	cis	rs10129255	0.701	rs2005643	ENSG00000211974.3	IGHV2-70	5.08	5.48e-07	7.33e-05	0.17	0.23	Kawasaki disease;	chr14:106676288	chr14:106723574~106724093:-
THCA	cis	rs2880765	0.835	rs6497202	ENSG00000259630.2	CTD-2262B20.1	-5.08	5.48e-07	7.33e-05	-0.24	-0.23	Coronary artery disease;	chr15:85478144	chr15:85415228~85415633:+
THCA	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	5.08	5.48e-07	7.33e-05	0.3	0.23	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
THCA	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-5.08	5.48e-07	7.33e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
THCA	cis	rs897984	0.806	rs1458202	ENSG00000260911.2	RP11-196G11.2	5.08	5.48e-07	7.33e-05	0.19	0.23	Dementia with Lewy bodies;	chr16:30941881	chr16:31043150~31049868:+
THCA	cis	rs4443100	0.792	rs9612223	ENSG00000230701.2	FBXW4P1	5.08	5.48e-07	7.33e-05	0.29	0.23	Serum parathyroid hormone levels;	chr22:23046964	chr22:23262767~23265005:+
THCA	cis	rs6545883	0.894	rs2694649	ENSG00000270820.4	RP11-355B11.2	-5.08	5.48e-07	7.33e-05	-0.19	-0.23	Tuberculosis;	chr2:61346691	chr2:61471188~61484130:+
THCA	cis	rs800160	0.748	rs2651811	ENSG00000199550.1	Y_RNA	5.08	5.48e-07	7.33e-05	0.35	0.23	Bacteremia;	chr11:2355407	chr11:2372638~2372750:+
THCA	cis	rs728616	0.558	rs116434658	ENSG00000242600.5	MBL1P	5.08	5.48e-07	7.33e-05	0.24	0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chr10:79904898~79950336:+
THCA	cis	rs9959145	1	rs1592641	ENSG00000267108.1	RP11-861E21.1	-5.08	5.49e-07	7.34e-05	-0.28	-0.23	Immune response to smallpox vaccine (IL-6);	chr18:12647241	chr18:12432897~12437635:+
THCA	cis	rs4748857	0.685	rs7079718	ENSG00000224215.1	RP11-371A19.2	-5.08	5.49e-07	7.34e-05	-0.3	-0.23	Systemic lupus erythematosus;	chr10:23315164	chr10:23343957~23345181:+
THCA	cis	rs2562456	0.754	rs62107469	ENSG00000268119.4	CTD-2561J22.5	5.08	5.49e-07	7.34e-05	0.33	0.23	Pain;	chr19:21312699	chr19:21444241~21463908:-
THCA	cis	rs17767294	1	rs17767294	ENSG00000280107.1	AL022393.9	-5.08	5.49e-07	7.34e-05	-0.44	-0.23	Parkinson's disease;	chr6:28086420	chr6:28170845~28172521:+
THCA	cis	rs8192917	0.623	rs2273843	ENSG00000258744.1	RP11-80A15.1	-5.08	5.49e-07	7.34e-05	-0.37	-0.23	Vitiligo;	chr14:24634203	chr14:24501594~24508688:+
THCA	cis	rs5758511	0.68	rs5758657	ENSG00000281538.1	RP4-669P10.20	-5.08	5.49e-07	7.34e-05	-0.26	-0.23	Birth weight;	chr22:42222663	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.68	rs1033459	ENSG00000281538.1	RP4-669P10.20	-5.08	5.49e-07	7.34e-05	-0.26	-0.23	Birth weight;	chr22:42223061	chr22:42138060~42139726:+
THCA	cis	rs11089937	0.524	rs2877021	ENSG00000211638.2	IGLV8-61	-5.08	5.49e-07	7.34e-05	-0.18	-0.23	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22098700~22099212:+
THCA	cis	rs72949976	0.734	rs62189579	ENSG00000270659.1	RP11-105N14.1	5.08	5.49e-07	7.34e-05	0.18	0.23	Squamous cell lung carcinoma;Lung cancer;	chr2:213152260	chr2:213152970~213153659:+
THCA	cis	rs4888671	0.614	rs75165142	ENSG00000261707.1	RP11-264M12.2	5.08	5.5e-07	7.35e-05	0.42	0.23	Obesity-related traits;	chr16:77741022	chr16:77741468~77743000:-
THCA	cis	rs3796352	1	rs71301808	ENSG00000242142.1	SERBP1P3	-5.08	5.5e-07	7.35e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53051561	chr3:53064283~53065091:-
THCA	cis	rs2243480	1	rs34193460	ENSG00000230295.1	RP11-458F8.2	-5.08	5.5e-07	7.35e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65928123	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs57057549	ENSG00000230295.1	RP11-458F8.2	-5.08	5.5e-07	7.35e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65940751	chr7:66880708~66882981:+
THCA	cis	rs2070488	0.775	rs762318	ENSG00000229589.1	ACVR2B-AS1	5.08	5.5e-07	7.35e-05	0.21	0.23	Electrocardiographic conduction measures;	chr3:38474878	chr3:38451027~38454820:-
THCA	cis	rs3820928	0.874	rs1917127	ENSG00000212391.1	SNORA48	-5.08	5.5e-07	7.35e-05	-0.25	-0.23	Pulmonary function;	chr2:227030409	chr2:226968989~226969122:-
THCA	cis	rs2280018	0.526	rs2966129	ENSG00000263335.1	AF001548.5	5.08	5.5e-07	7.36e-05	0.28	0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15726674~15732993:+
THCA	cis	rs2354432	0.607	rs7523812	ENSG00000226015.2	CCT8P1	-5.08	5.5e-07	7.36e-05	-0.42	-0.23	Mitochondrial DNA levels;	chr1:147201907	chr1:147203276~147204932:-
THCA	cis	rs752010	0.756	rs6600380	ENSG00000230638.4	RP11-486B10.4	5.08	5.5e-07	7.36e-05	0.24	0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41589143	chr1:41542069~41544310:+
THCA	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	5.08	5.5e-07	7.36e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-5.08	5.5e-07	7.36e-05	-0.28	-0.23	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
THCA	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	5.08	5.5e-07	7.36e-05	0.57	0.23	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
THCA	cis	rs853679	0.76	rs11967137	ENSG00000220721.1	OR1F12	5.08	5.51e-07	7.36e-05	0.32	0.23	Depression;	chr6:28231986	chr6:28073316~28074233:+
THCA	cis	rs889122	0.729	rs16996141	ENSG00000267289.1	CTD-2623N2.11	5.08	5.51e-07	7.36e-05	0.31	0.23	Menarche (age at onset);	chr19:9855016	chr19:9834079~9835013:-
THCA	cis	rs1552244	0.554	rs6762397	ENSG00000232901.1	CYCSP10	5.08	5.51e-07	7.36e-05	0.27	0.23	Alzheimer's disease;	chr3:9966156	chr3:10000647~10000940:-
THCA	cis	rs8020095	0.571	rs728647	ENSG00000258561.1	RP11-72M17.1	-5.08	5.51e-07	7.36e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66911338	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs68178754	ENSG00000258561.1	RP11-72M17.1	-5.08	5.51e-07	7.36e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66916377	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs8013943	ENSG00000258561.1	RP11-72M17.1	-5.08	5.51e-07	7.36e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66916618	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs7152422	ENSG00000258561.1	RP11-72M17.1	-5.08	5.51e-07	7.36e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66925540	chr14:66212810~66509394:-
THCA	cis	rs34779708	0.966	rs10827493	ENSG00000271335.4	RP11-324I22.4	5.08	5.51e-07	7.37e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35314552~35336401:-
THCA	cis	rs7429990	0.803	rs11714518	ENSG00000228638.1	FCF1P2	5.08	5.51e-07	7.37e-05	0.22	0.23	Educational attainment (years of education);	chr3:48115145	chr3:48290793~48291375:-
THCA	cis	rs7202877	0.519	rs4887811	ENSG00000261783.1	RP11-252K23.2	-5.08	5.51e-07	7.37e-05	-0.38	-0.23	Type 1 diabetes;Type 2 diabetes;	chr16:75273353	chr16:75379818~75381260:-
THCA	cis	rs6688613	0.649	rs2294195	ENSG00000225171.2	DUTP6	-5.08	5.51e-07	7.37e-05	-0.32	-0.23	Refractive astigmatism;	chr1:166869044	chr1:166868748~166869209:+
THCA	cis	rs228614	0.51	rs223464	ENSG00000248971.2	KRT8P46	-5.08	5.51e-07	7.37e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223463	ENSG00000248971.2	KRT8P46	-5.08	5.51e-07	7.37e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs223462	ENSG00000248971.2	KRT8P46	-5.08	5.51e-07	7.37e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102728746~102730171:-
THCA	cis	rs227275	0.531	rs223460	ENSG00000248971.2	KRT8P46	-5.08	5.51e-07	7.37e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102728746~102730171:-
THCA	cis	rs7267979	0.745	rs6132845	ENSG00000125804.12	FAM182A	-5.08	5.51e-07	7.37e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26054655~26086917:+
THCA	cis	rs875971	0.522	rs1617484	ENSG00000273142.1	RP11-458F8.4	-5.08	5.52e-07	7.37e-05	-0.19	-0.23	Aortic root size;	chr7:65998108	chr7:66902857~66906297:+
THCA	cis	rs12935418	0.672	rs2549883	ENSG00000278985.1	RP11-303E16.9	-5.08	5.52e-07	7.37e-05	-0.25	-0.23	Mean corpuscular volume;	chr16:81022273	chr16:80982319~80984094:-
THCA	cis	rs59918340	0.728	rs35257077	ENSG00000253307.1	RP11-10J21.4	-5.08	5.52e-07	7.38e-05	-0.32	-0.23	Immature fraction of reticulocytes;	chr8:141224950	chr8:141252286~141253292:-
THCA	cis	rs6598266	1	rs7166691	ENSG00000259363.4	CTD-2054N24.2	-5.08	5.52e-07	7.38e-05	-0.39	-0.23	Major depressive disorder;	chr15:99760055	chr15:99807023~99877148:+
THCA	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	5.08	5.52e-07	7.38e-05	0.3	0.23	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
THCA	cis	rs34779708	0.931	rs2001893	ENSG00000271335.4	RP11-324I22.4	5.08	5.52e-07	7.38e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35314552~35336401:-
THCA	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-5.08	5.53e-07	7.39e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
THCA	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-5.08	5.53e-07	7.39e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
THCA	cis	rs76935404	0.811	rs12151139	ENSG00000256612.6	CYP2B7P	5.08	5.53e-07	7.39e-05	0.28	0.23	nicotine metabolite ratio in current smokers;	chr19:40927638	chr19:40924219~40950660:+
THCA	cis	rs763121	0.853	rs5750633	ENSG00000228274.3	RP3-508I15.9	-5.08	5.53e-07	7.39e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38597462	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757166	ENSG00000228274.3	RP3-508I15.9	-5.08	5.53e-07	7.39e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38599380	chr22:38667585~38681820:-
THCA	cis	rs7914558	0.933	rs10786729	ENSG00000236937.2	PTGES3P4	5.08	5.53e-07	7.39e-05	0.29	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102959621	chr10:102845595~102845950:+
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000230295.1	RP11-458F8.2	-5.08	5.53e-07	7.39e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:65914813	chr7:66880708~66882981:+
THCA	cis	rs12681287	0.547	rs6985066	ENSG00000254231.1	CTD-2284J15.1	5.08	5.53e-07	7.39e-05	0.26	0.23	Caudate activity during reward;	chr8:86514210	chr8:86333274~86343314:-
THCA	cis	rs2742234	0.868	rs2505512	ENSG00000273008.1	RP11-351D16.3	-5.08	5.53e-07	7.39e-05	-0.19	-0.23	Hirschsprung disease;	chr10:43138148	chr10:43136824~43138334:-
THCA	cis	rs10895275	0.51	rs11225155	ENSG00000277459.1	RP11-732A21.3	-5.08	5.53e-07	7.39e-05	-0.18	-0.23	Migraine;	chr11:102172669	chr11:102109827~102110457:-
THCA	cis	rs875971	0.545	rs2420612	ENSG00000232546.1	RP11-458F8.1	5.08	5.53e-07	7.39e-05	0.22	0.23	Aortic root size;	chr7:66536825	chr7:66848496~66858136:+
THCA	cis	rs17767392	0.834	rs17767380	ENSG00000259146.3	RP1-261D10.2	5.08	5.53e-07	7.39e-05	0.31	0.23	Mitral valve prolapse;	chr14:71280314	chr14:71292729~71321814:-
THCA	cis	rs3820928	0.874	rs3769646	ENSG00000212391.1	SNORA48	-5.08	5.54e-07	7.4e-05	-0.25	-0.23	Pulmonary function;	chr2:227031614	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs2229812	ENSG00000212391.1	SNORA48	-5.08	5.54e-07	7.4e-05	-0.25	-0.23	Pulmonary function;	chr2:227032170	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.935	rs10203363	ENSG00000212391.1	SNORA48	-5.08	5.54e-07	7.4e-05	-0.25	-0.23	Pulmonary function;	chr2:227032260	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.775	rs10179756	ENSG00000212391.1	SNORA48	-5.08	5.54e-07	7.4e-05	-0.25	-0.23	Pulmonary function;	chr2:227032360	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10166456	ENSG00000212391.1	SNORA48	-5.08	5.54e-07	7.4e-05	-0.25	-0.23	Pulmonary function;	chr2:227035397	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10166736	ENSG00000212391.1	SNORA48	-5.08	5.54e-07	7.4e-05	-0.25	-0.23	Pulmonary function;	chr2:227035703	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs13423046	ENSG00000212391.1	SNORA48	-5.08	5.54e-07	7.4e-05	-0.25	-0.23	Pulmonary function;	chr2:227037089	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10202239	ENSG00000212391.1	SNORA48	-5.08	5.54e-07	7.4e-05	-0.25	-0.23	Pulmonary function;	chr2:227037103	chr2:226968989~226969122:-
THCA	cis	rs972578	0.715	rs4820491	ENSG00000274717.1	RP1-47A17.1	-5.08	5.54e-07	7.4e-05	-0.24	-0.23	Mean platelet volume;	chr22:42865059	chr22:42791814~42794313:-
THCA	cis	rs4648045	0.734	rs4648051	ENSG00000246560.2	RP11-10L12.4	5.08	5.54e-07	7.4e-05	0.3	0.23	Lymphocyte percentage of white cells;	chr4:102593836	chr4:102828055~102844075:+
THCA	cis	rs3213758	1	rs12597721	ENSG00000275191.1	RP11-36I17.2	-5.08	5.54e-07	7.4e-05	-0.47	-0.23	Vitiligo (non-segmental);	chr16:53683262	chr16:53628256~53628816:-
THCA	cis	rs7131987	0.675	rs3847678	ENSG00000257176.2	RP11-996F15.2	5.08	5.54e-07	7.4e-05	0.23	0.23	QT interval;	chr12:29398627	chr12:29280418~29317848:-
THCA	cis	rs7618915	0.547	rs4687636	ENSG00000243224.1	RP5-1157M23.2	-5.08	5.54e-07	7.41e-05	-0.25	-0.23	Bipolar disorder;	chr3:52599913	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs34173654	ENSG00000243224.1	RP5-1157M23.2	-5.08	5.54e-07	7.41e-05	-0.25	-0.23	Bipolar disorder;	chr3:52600589	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs35211965	ENSG00000243224.1	RP5-1157M23.2	-5.08	5.54e-07	7.41e-05	-0.25	-0.23	Bipolar disorder;	chr3:52651289	chr3:52239258~52241097:+
THCA	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-5.08	5.55e-07	7.41e-05	-0.25	-0.23	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
THCA	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-5.08	5.55e-07	7.41e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
THCA	cis	rs5758511	0.68	rs58654759	ENSG00000281538.1	RP4-669P10.20	-5.08	5.55e-07	7.41e-05	-0.26	-0.23	Birth weight;	chr22:42246570	chr22:42138060~42139726:+
THCA	cis	rs3734266	0.702	rs9469814	ENSG00000272288.4	RP11-140K17.3	5.08	5.55e-07	7.41e-05	0.23	0.23	Systemic lupus erythematosus;	chr6:34603868	chr6:34696317~34697470:+
THCA	cis	rs1823913	0.637	rs2067610	ENSG00000280083.1	RP11-317J9.1	-5.08	5.55e-07	7.41e-05	-0.27	-0.23	Obesity-related traits;	chr2:191299251	chr2:191154118~191156070:-
THCA	cis	rs17767392	0.781	rs2108057	ENSG00000259146.3	RP1-261D10.2	-5.08	5.55e-07	7.41e-05	-0.28	-0.23	Mitral valve prolapse;	chr14:71556033	chr14:71292729~71321814:-
THCA	cis	rs944289	0.708	rs34232378	ENSG00000258844.1	RP11-259K15.2	5.08	5.55e-07	7.41e-05	0.2	0.23	Thyroid cancer;	chr14:36102879	chr14:36214607~36235608:+
THCA	cis	rs7429990	0.864	rs3888	ENSG00000228638.1	FCF1P2	5.08	5.55e-07	7.42e-05	0.22	0.23	Educational attainment (years of education);	chr3:47816085	chr3:48290793~48291375:-
THCA	cis	rs9625935	0.879	rs36600	ENSG00000279159.1	RP3-394A18.1	5.08	5.55e-07	7.42e-05	0.18	0.23	Tonsillectomy;	chr22:29941597	chr22:29978950~30028236:-
THCA	cis	rs5751614	0.557	rs928781	ENSG00000240160.3	RN7SL263P	-5.08	5.56e-07	7.42e-05	-0.3	-0.23	Height;	chr22:23257826	chr22:23261782~23262071:-
THCA	cis	rs812925	0.893	rs1186705	ENSG00000271889.1	RP11-493E12.1	5.08	5.56e-07	7.42e-05	0.23	0.23	Immature fraction of reticulocytes;	chr2:61446143	chr2:61151433~61162105:-
THCA	cis	rs7176527	1	rs3762168	ENSG00000225151.9	GOLGA2P7	5.08	5.56e-07	7.42e-05	0.37	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:84199311~84230136:-
THCA	cis	rs7119	0.717	rs8042307	ENSG00000259362.2	RP11-307C19.1	-5.08	5.56e-07	7.43e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77511671	chr15:77525540~77534110:+
THCA	cis	rs17767392	0.881	rs17767680	ENSG00000259146.3	RP1-261D10.2	5.08	5.56e-07	7.43e-05	0.29	0.23	Mitral valve prolapse;	chr14:71530877	chr14:71292729~71321814:-
THCA	cis	rs911119	1	rs6114209	ENSG00000270001.1	RP11-218C14.8	-5.08	5.56e-07	7.43e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23641629	chr20:23631826~23632316:-
THCA	cis	rs4604234	0.614	rs11961506	ENSG00000272129.1	RP11-250B2.6	-5.08	5.56e-07	7.43e-05	-0.55	-0.23	Cancer;	chr6:80224592	chr6:80355424~80356859:+
THCA	cis	rs1979679	0.842	rs11049380	ENSG00000247934.4	RP11-967K21.1	-5.08	5.56e-07	7.43e-05	-0.22	-0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28160904	chr12:28163298~28190738:-
THCA	cis	rs6750795	0.569	rs1797387	ENSG00000223198.1	RNU2-22P	-5.08	5.56e-07	7.43e-05	-0.28	-0.23	Height;	chr2:231549981	chr2:231501990~231502201:-
THCA	cis	rs10266483	0.739	rs12538943	ENSG00000271550.1	BNIP3P11	-5.08	5.57e-07	7.43e-05	-0.33	-0.23	Response to statin therapy;	chr7:64395990	chr7:64678954~64687393:-
THCA	cis	rs795484	0.889	rs353884	ENSG00000275409.1	RP11-131L12.4	-5.08	5.57e-07	7.43e-05	-0.2	-0.23	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118225962	chr12:118430147~118430699:+
THCA	cis	rs972578	0.818	rs9611954	ENSG00000274717.1	RP1-47A17.1	-5.08	5.57e-07	7.44e-05	-0.23	-0.23	Mean platelet volume;	chr22:42887983	chr22:42791814~42794313:-
THCA	cis	rs7403037	0.583	rs35844465	ENSG00000259905.4	PWRN1	5.08	5.57e-07	7.44e-05	0.31	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24423096	chr15:24493137~24652130:+
THCA	cis	rs4908760	0.864	rs1953827	ENSG00000232912.4	RP5-1115A15.1	5.08	5.57e-07	7.44e-05	0.22	0.23	Vitiligo;	chr1:8619789	chr1:8424645~8434838:+
THCA	cis	rs9859260	1	rs3804140	ENSG00000273009.1	RP11-352G9.1	-5.08	5.57e-07	7.44e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196080736	chr3:195913078~195913683:-
THCA	cis	rs9859260	1	rs3804139	ENSG00000273009.1	RP11-352G9.1	-5.08	5.57e-07	7.44e-05	-0.25	-0.23	Mean corpuscular volume;	chr3:196080754	chr3:195913078~195913683:-
THCA	cis	rs6044112	1	rs6080301	ENSG00000273998.1	RP4-777L9.2	5.08	5.57e-07	7.44e-05	0.35	0.23	Response to taxane treatment (docetaxel);	chr20:16555021	chr20:16576068~16579615:+
THCA	cis	rs6044112	1	rs6044111	ENSG00000273998.1	RP4-777L9.2	5.08	5.57e-07	7.44e-05	0.35	0.23	Response to taxane treatment (docetaxel);	chr20:16555679	chr20:16576068~16579615:+
THCA	cis	rs9990333	0.544	rs112577972	ENSG00000273009.1	RP11-352G9.1	-5.08	5.57e-07	7.44e-05	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195913078~195913683:-
THCA	cis	rs2337406	0.866	rs11488879	ENSG00000211974.3	IGHV2-70	-5.08	5.58e-07	7.45e-05	-0.22	-0.23	Alzheimer's disease (late onset);	chr14:106786097	chr14:106723574~106724093:-
THCA	cis	rs4648045	0.796	rs12509403	ENSG00000246560.2	RP11-10L12.4	5.08	5.58e-07	7.45e-05	0.29	0.23	Lymphocyte percentage of white cells;	chr4:102604193	chr4:102828055~102844075:+
THCA	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	5.08	5.58e-07	7.45e-05	0.28	0.23	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
THCA	cis	rs7208859	0.673	rs999796	ENSG00000263603.1	CTD-2349P21.5	-5.08	5.58e-07	7.45e-05	-0.38	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30729469~30731202:+
THCA	cis	rs6792584	0.962	rs4423787	ENSG00000241316.5	SUCLG2-AS1	5.08	5.58e-07	7.45e-05	0.24	0.23	Corneal astigmatism;	chr3:67461690	chr3:67654697~67947713:+
THCA	cis	rs228614	0.51	rs223459	ENSG00000248971.2	KRT8P46	-5.08	5.58e-07	7.45e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102728746~102730171:-
THCA	cis	rs3796352	0.892	rs3821872	ENSG00000242142.1	SERBP1P3	5.08	5.59e-07	7.46e-05	0.39	0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53046539	chr3:53064283~53065091:-
THCA	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-5.08	5.59e-07	7.46e-05	-0.29	-0.23	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
THCA	cis	rs7829975	0.684	rs474892	ENSG00000254153.1	CTA-398F10.2	5.08	5.59e-07	7.46e-05	0.24	0.23	Mood instability;	chr8:8739221	chr8:8456909~8461337:-
THCA	cis	rs1005277	0.505	rs200935	ENSG00000276805.1	RP11-291L22.6	5.08	5.59e-07	7.46e-05	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38451030~38451785:+
THCA	cis	rs9921338	0.632	rs149310	ENSG00000262703.1	RP11-485G7.6	5.08	5.59e-07	7.47e-05	0.31	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11251842	chr16:11348143~11349321:-
THCA	cis	rs763121	0.785	rs5750646	ENSG00000228274.3	RP3-508I15.9	-5.07	5.59e-07	7.47e-05	-0.25	-0.23	Menopause (age at onset);	chr22:38617825	chr22:38667585~38681820:-
THCA	cis	rs2281603	0.951	rs1982440	ENSG00000259116.1	RP11-973N13.4	-5.07	5.59e-07	7.47e-05	-0.22	-0.23	Lymphocyte counts;	chr14:64494049	chr14:64514154~64540368:-
THCA	cis	rs67340775	0.541	rs200979	ENSG00000226314.6	ZNF192P1	-5.07	5.59e-07	7.47e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr6:27884579	chr6:28161781~28169594:+
THCA	cis	rs3820928	0.874	rs4234064	ENSG00000212391.1	SNORA48	-5.07	5.6e-07	7.47e-05	-0.25	-0.23	Pulmonary function;	chr2:226992781	chr2:226968989~226969122:-
THCA	cis	rs34779708	0.897	rs9665538	ENSG00000271335.4	RP11-324I22.4	5.07	5.6e-07	7.47e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35314552~35336401:-
THCA	cis	rs7474896	0.559	rs1735629	ENSG00000263064.2	RP11-291L22.7	-5.07	5.6e-07	7.47e-05	-0.31	-0.23	Obesity (extreme);	chr10:37889381	chr10:38448689~38448949:+
THCA	cis	rs7336933	1	rs7323058	ENSG00000278338.3	VWA8-AS1	5.07	5.6e-07	7.47e-05	0.38	0.23	Calcium levels;	chr13:41974367	chr13:41955808~41981565:+
THCA	cis	rs7336933	1	rs7328352	ENSG00000278338.3	VWA8-AS1	5.07	5.6e-07	7.47e-05	0.38	0.23	Calcium levels;	chr13:41974843	chr13:41955808~41981565:+
THCA	cis	rs7336933	1	rs12372841	ENSG00000278338.3	VWA8-AS1	5.07	5.6e-07	7.47e-05	0.38	0.23	Calcium levels;	chr13:41975676	chr13:41955808~41981565:+
THCA	cis	rs6545883	0.894	rs12997538	ENSG00000270820.4	RP11-355B11.2	-5.07	5.6e-07	7.47e-05	-0.19	-0.23	Tuberculosis;	chr2:61337114	chr2:61471188~61484130:+
THCA	cis	rs6686842	0.56	rs11209361	ENSG00000235358.1	RP11-399E6.1	-5.07	5.6e-07	7.47e-05	-0.3	-0.23	Height;	chr1:41018279	chr1:41242373~41284861:+
THCA	cis	rs4748857	0.853	rs6482261	ENSG00000224215.1	RP11-371A19.2	-5.07	5.6e-07	7.48e-05	-0.26	-0.23	Systemic lupus erythematosus;	chr10:23295559	chr10:23343957~23345181:+
THCA	cis	rs2562456	0.839	rs2562411	ENSG00000268081.1	RP11-678G14.2	5.07	5.6e-07	7.48e-05	0.38	0.23	Pain;	chr19:21419181	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.876	rs2562413	ENSG00000268081.1	RP11-678G14.2	5.07	5.6e-07	7.48e-05	0.38	0.23	Pain;	chr19:21420084	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.916	rs1967182	ENSG00000268081.1	RP11-678G14.2	5.07	5.6e-07	7.48e-05	0.38	0.23	Pain;	chr19:21420337	chr19:21554640~21569237:-
THCA	cis	rs9380516	0.581	rs992105	ENSG00000228559.1	RP3-340B19.3	-5.07	5.6e-07	7.48e-05	-0.33	-0.23	Hepatitis C induced liver fibrosis;	chr6:35587406	chr6:35544632~35545669:+
THCA	cis	rs7829975	0.577	rs79495969	ENSG00000253893.2	FAM85B	5.07	5.6e-07	7.48e-05	0.31	0.23	Mood instability;	chr8:8687740	chr8:8167819~8226614:-
THCA	cis	rs2136613	0.651	rs16917768	ENSG00000238280.1	RP11-436D10.3	-5.07	5.6e-07	7.48e-05	-0.26	-0.23	Selective IgA deficiency;	chr10:62864705	chr10:62793562~62805887:-
THCA	cis	rs6714710	0.535	rs13033383	ENSG00000230606.9	AC159540.1	-5.07	5.6e-07	7.48e-05	-0.28	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97723050	chr2:97416165~97433527:-
THCA	cis	rs7211079	0.664	rs72850889	ENSG00000279259.1	RP11-334C17.3	5.07	5.61e-07	7.48e-05	0.29	0.23	Myocardial infarction;	chr17:80141096	chr17:80147250~80148596:+
THCA	cis	rs4845570	1	rs11586946	ENSG00000203288.3	RP11-98D18.9	-5.07	5.61e-07	7.48e-05	-0.27	-0.23	Coronary artery disease;	chr1:151797330	chr1:151790804~151794402:+
THCA	cis	rs875971	0.545	rs73150604	ENSG00000232546.1	RP11-458F8.1	5.07	5.61e-07	7.49e-05	0.22	0.23	Aortic root size;	chr7:66480545	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000232546.1	RP11-458F8.1	5.07	5.61e-07	7.49e-05	0.22	0.23	Aortic root size;	chr7:66481592	chr7:66848496~66858136:+
THCA	cis	rs2243480	0.901	rs778730	ENSG00000230295.1	RP11-458F8.2	-5.07	5.61e-07	7.49e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66358338	chr7:66880708~66882981:+
THCA	cis	rs2251381	0.778	rs2471947	ENSG00000176054.6	RPL23P2	5.07	5.61e-07	7.49e-05	0.2	0.23	Selective IgA deficiency;	chr21:29161898	chr21:28997613~28998033:-
THCA	cis	rs1050631	0.592	rs1632169	ENSG00000260552.1	RP11-49I11.1	5.07	5.61e-07	7.49e-05	0.29	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36129799	chr18:36179996~36187448:-
THCA	cis	rs911119	0.657	rs2104005	ENSG00000270001.1	RP11-218C14.8	-5.07	5.61e-07	7.49e-05	-0.37	-0.23	Chronic kidney disease;	chr20:23650124	chr20:23631826~23632316:-
THCA	cis	rs227275	0.588	rs223458	ENSG00000248971.2	KRT8P46	-5.07	5.62e-07	7.5e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102728746~102730171:-
THCA	cis	rs911555	0.57	rs11625397	ENSG00000269910.1	RP11-73M18.10	-5.07	5.62e-07	7.5e-05	-0.21	-0.23	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103694516~103695050:-
THCA	cis	rs2288884	0.541	rs8107827	ENSG00000269483.1	AC006272.1	5.07	5.62e-07	7.5e-05	0.33	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51962228	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.505	rs4988334	ENSG00000269483.1	AC006272.1	5.07	5.62e-07	7.5e-05	0.33	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965745	chr19:51839924~51843324:-
THCA	cis	rs481331	0.799	rs113805178	ENSG00000215146.4	RP11-313J2.1	5.07	5.62e-07	7.5e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42473635	chr10:42331866~42367974:-
THCA	cis	rs481331	0.799	rs116662552	ENSG00000215146.4	RP11-313J2.1	5.07	5.62e-07	7.5e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42473781	chr10:42331866~42367974:-
THCA	cis	rs481331	0.799	rs72787861	ENSG00000215146.4	RP11-313J2.1	5.07	5.62e-07	7.5e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42473837	chr10:42331866~42367974:-
THCA	cis	rs481331	0.799	rs72787863	ENSG00000215146.4	RP11-313J2.1	5.07	5.62e-07	7.5e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42475056	chr10:42331866~42367974:-
THCA	cis	rs481331	0.799	rs45491899	ENSG00000215146.4	RP11-313J2.1	5.07	5.62e-07	7.5e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42475687	chr10:42331866~42367974:-
THCA	cis	rs7772486	0.686	rs9390349	ENSG00000270638.1	RP3-466P17.1	-5.07	5.62e-07	7.5e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs2072911	ENSG00000270638.1	RP3-466P17.1	-5.07	5.62e-07	7.5e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145735570~145737218:+
THCA	cis	rs12935418	0.672	rs2549879	ENSG00000278985.1	RP11-303E16.9	-5.07	5.62e-07	7.51e-05	-0.25	-0.23	Mean corpuscular volume;	chr16:81012496	chr16:80982319~80984094:-
THCA	cis	rs849141	1	rs849141	ENSG00000234336.5	JAZF1-AS1	5.07	5.62e-07	7.51e-05	0.27	0.23	Height;Hip circumference adjusted for BMI;	chr7:28145472	chr7:28180322~28243917:+
THCA	cis	rs10129255	0.834	rs10139893	ENSG00000223648.3	IGHV3-64	5.07	5.63e-07	7.51e-05	0.14	0.23	Kawasaki disease;	chr14:106711377	chr14:106643132~106658258:-
THCA	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-5.07	5.63e-07	7.51e-05	-0.22	-0.23	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
THCA	cis	rs990871	0.637	rs10789340	ENSG00000227207.2	RPL31P12	5.07	5.63e-07	7.51e-05	0.29	0.23	Subcutaneous adipose tissue;	chr1:72474590	chr1:72301472~72301829:+
THCA	cis	rs13178541	0.593	rs6862956	ENSG00000250378.1	RP11-119J18.1	-5.07	5.63e-07	7.51e-05	-0.26	-0.23	IgG glycosylation;	chr5:135706119	chr5:135812667~135826582:+
THCA	cis	rs28476539	0.64	rs17005892	ENSG00000270480.1	RP11-57B24.1	5.07	5.63e-07	7.51e-05	0.36	0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82627266	chr4:82691737~82692468:+
THCA	cis	rs2288884	0.505	rs8110213	ENSG00000269483.1	AC006272.1	5.07	5.63e-07	7.51e-05	0.35	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51958730	chr19:51839924~51843324:-
THCA	cis	rs205611	0.511	rs61259578	ENSG00000224646.2	AC007387.2	-5.07	5.63e-07	7.51e-05	-0.37	-0.23	Iris characteristics;	chr2:74770694	chr2:74754670~74754819:-
THCA	cis	rs9329221	0.905	rs28507213	ENSG00000261451.1	RP11-981G7.1	-5.07	5.63e-07	7.51e-05	-0.28	-0.23	Neuroticism;	chr8:10393339	chr8:10433672~10438312:+
THCA	cis	rs9329221	0.905	rs28712068	ENSG00000261451.1	RP11-981G7.1	-5.07	5.63e-07	7.51e-05	-0.28	-0.23	Neuroticism;	chr8:10393635	chr8:10433672~10438312:+
THCA	cis	rs752010	0.523	rs943376	ENSG00000230638.4	RP11-486B10.4	-5.07	5.63e-07	7.52e-05	-0.27	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41656446	chr1:41542069~41544310:+
THCA	cis	rs9921338	0.668	rs193778	ENSG00000262703.1	RP11-485G7.6	-5.07	5.63e-07	7.52e-05	-0.3	-0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11257354	chr16:11348143~11349321:-
THCA	cis	rs17798991	0.721	rs12954469	ENSG00000267674.1	RP11-813F20.2	-5.07	5.64e-07	7.52e-05	-0.24	-0.23	Obesity-related traits;	chr18:49603858	chr18:49739823~49742063:-
THCA	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	5.07	5.64e-07	7.52e-05	0.28	0.23	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
THCA	cis	rs332034	0.507	rs4840366	ENSG00000253893.2	FAM85B	-5.07	5.64e-07	7.53e-05	-0.38	-0.23	Conduct disorder (maternal expressed emotions interaction);	chr8:8832456	chr8:8167819~8226614:-
THCA	cis	rs7554547	0.69	rs17037526	ENSG00000199347.1	RNU5E-1	-5.07	5.64e-07	7.53e-05	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr1:11899305	chr1:11908152~11908271:+
THCA	cis	rs1577917	0.883	rs6454505	ENSG00000220563.1	PKMP3	-5.07	5.64e-07	7.53e-05	-0.17	-0.23	Response to antipsychotic treatment;	chr6:85882644	chr6:85659892~85660606:-
THCA	cis	rs5742933	0.512	rs80277863	ENSG00000273240.1	RP11-455J20.3	-5.07	5.64e-07	7.53e-05	-0.25	-0.23	Ferritin levels;	chr2:189766733	chr2:189763859~189764456:-
THCA	cis	rs9652601	0.622	rs1985372	ENSG00000274038.1	RP11-66H6.4	-5.07	5.65e-07	7.53e-05	-0.27	-0.23	Systemic lupus erythematosus;	chr16:11020982	chr16:11056556~11057034:+
THCA	cis	rs1075265	0.509	rs10188142	ENSG00000272156.1	RP11-477N3.1	-5.07	5.65e-07	7.54e-05	-0.23	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53730999	chr2:54082554~54085066:+
THCA	cis	rs6017291	0.59	rs16988852	ENSG00000223891.4	OSER1-AS1	5.07	5.65e-07	7.54e-05	0.27	0.23	Cognitive performance;	chr20:44212989	chr20:44210960~44226027:+
THCA	cis	rs10946940	0.965	rs6456799	ENSG00000219392.1	RP1-265C24.5	5.07	5.65e-07	7.54e-05	0.26	0.23	Systemic lupus erythematosus;	chr6:27605757	chr6:28115628~28116551:+
THCA	cis	rs1005277	0.579	rs2505248	ENSG00000272983.1	RP11-508N22.12	5.07	5.66e-07	7.55e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38137337~38144399:+
THCA	cis	rs9818758	0.556	rs13086240	ENSG00000270441.1	RP11-694I15.7	5.07	5.66e-07	7.55e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48963976	chr3:49140086~49160851:-
THCA	cis	rs8028182	0.636	rs7166737	ENSG00000260269.4	CTD-2323K18.1	-5.07	5.66e-07	7.55e-05	-0.33	-0.23	Sudden cardiac arrest;	chr15:75390172	chr15:75527150~75601205:-
THCA	cis	rs227275	0.525	rs223461	ENSG00000248971.2	KRT8P46	-5.07	5.66e-07	7.55e-05	-0.27	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102728746~102730171:-
THCA	cis	rs2243480	1	rs313831	ENSG00000230295.1	RP11-458F8.2	-5.07	5.66e-07	7.55e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66086239	chr7:66880708~66882981:+
THCA	cis	rs930395	0.514	rs7703618	ENSG00000272335.1	RP11-53O19.3	5.07	5.67e-07	7.56e-05	0.2	0.23	Breast cancer;	chr5:44914477	chr5:44826076~44828592:+
THCA	cis	rs7554547	0.667	rs12567187	ENSG00000199347.1	RNU5E-1	-5.07	5.67e-07	7.56e-05	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr1:11896095	chr1:11908152~11908271:+
THCA	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	5.07	5.67e-07	7.56e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
THCA	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	5.07	5.67e-07	7.56e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
THCA	cis	rs17123764	0.71	rs12299513	ENSG00000257464.1	RP11-161H23.8	-5.07	5.67e-07	7.56e-05	-0.36	-0.23	Intelligence (multi-trait analysis);	chr12:49626184	chr12:49442424~49442652:-
THCA	cis	rs11634944	0.615	rs2732035	ENSG00000257151.1	PWAR6	5.07	5.67e-07	7.56e-05	0.17	0.23	Interleukin-8 levels;	chr15:25008346	chr15:25031873~25036490:+
THCA	cis	rs338389	0.521	rs8031161	ENSG00000260657.2	RP11-315D16.4	-5.07	5.67e-07	7.56e-05	-0.31	-0.23	Survival in rectal cancer;	chr15:67990789	chr15:68267792~68277994:-
THCA	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	5.07	5.67e-07	7.57e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
THCA	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	5.07	5.67e-07	7.57e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
THCA	cis	rs5758659	0.652	rs133340	ENSG00000227370.1	RP4-669P10.19	5.07	5.67e-07	7.57e-05	0.21	0.23	Cognitive function;	chr22:42021683	chr22:42132543~42132998:+
THCA	cis	rs1552244	0.554	rs6443275	ENSG00000232901.1	CYCSP10	5.07	5.68e-07	7.57e-05	0.27	0.23	Alzheimer's disease;	chr3:9967135	chr3:10000647~10000940:-
THCA	cis	rs7429990	0.87	rs13089844	ENSG00000228638.1	FCF1P2	5.07	5.68e-07	7.57e-05	0.22	0.23	Educational attainment (years of education);	chr3:48098741	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.932	rs12493348	ENSG00000228638.1	FCF1P2	5.07	5.68e-07	7.57e-05	0.22	0.23	Educational attainment (years of education);	chr3:48102048	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.932	rs12486714	ENSG00000228638.1	FCF1P2	5.07	5.68e-07	7.57e-05	0.22	0.23	Educational attainment (years of education);	chr3:48107210	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.932	rs2361684	ENSG00000228638.1	FCF1P2	5.07	5.68e-07	7.57e-05	0.22	0.23	Educational attainment (years of education);	chr3:48111128	chr3:48290793~48291375:-
THCA	cis	rs651907	0.514	rs12636046	ENSG00000244119.1	PDCL3P4	5.07	5.68e-07	7.57e-05	0.21	0.23	Colorectal cancer;	chr3:101715604	chr3:101712472~101713191:+
THCA	cis	rs9425766	0.55	rs57366619	ENSG00000227373.4	RP11-160H22.5	5.07	5.68e-07	7.57e-05	0.32	0.23	Life satisfaction;	chr1:174334929	chr1:174115300~174160004:-
THCA	cis	rs467650	0.782	rs56264044	ENSG00000246763.5	RGMB-AS1	5.07	5.68e-07	7.58e-05	0.23	0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:98724439	chr5:98769618~98773469:-
THCA	cis	rs11992162	0.967	rs10088415	ENSG00000254948.1	OR7E158P	5.07	5.68e-07	7.58e-05	0.28	0.23	Monocyte count;	chr8:11973316	chr8:11919900~11920809:-
THCA	cis	rs9467773	0.967	rs7753565	ENSG00000261353.1	CTA-14H9.5	-5.07	5.69e-07	7.58e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26527063~26527404:+
THCA	cis	rs35740288	0.822	rs4843090	ENSG00000259295.5	CSPG4P12	5.07	5.69e-07	7.58e-05	0.36	0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677398	chr15:85191438~85213905:+
THCA	cis	rs7688540	0.771	rs12505835	ENSG00000211553.1	AC253576.2	-5.07	5.69e-07	7.58e-05	-0.35	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:136461~136568:+
THCA	cis	rs34779708	0.966	rs10508816	ENSG00000271335.4	RP11-324I22.4	5.07	5.69e-07	7.59e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35314552~35336401:-
THCA	cis	rs8028313	0.63	rs7169086	ENSG00000270964.1	RP11-502I4.3	-5.07	5.69e-07	7.59e-05	-0.2	-0.23	Obesity;	chr15:67642116	chr15:67541072~67542604:-
THCA	cis	rs8020095	0.571	rs10136622	ENSG00000258561.1	RP11-72M17.1	-5.07	5.69e-07	7.59e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67038892	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs8021098	ENSG00000258561.1	RP11-72M17.1	-5.07	5.69e-07	7.59e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67039490	chr14:66212810~66509394:-
THCA	cis	rs10510102	0.935	rs11200263	ENSG00000226864.1	ATE1-AS1	5.07	5.69e-07	7.59e-05	0.37	0.23	Breast cancer;	chr10:121922836	chr10:121928312~121951965:+
THCA	cis	rs16975963	0.644	rs73033117	ENSG00000226686.6	LINC01535	-5.07	5.69e-07	7.59e-05	-0.31	-0.23	Longevity;	chr19:37582245	chr19:37251912~37265535:+
THCA	cis	rs763121	0.853	rs2076028	ENSG00000235209.1	CTA-150C2.13	5.07	5.7e-07	7.6e-05	0.32	0.23	Menopause (age at onset);	chr22:38754445	chr22:38921227~38924708:+
THCA	cis	rs2803122	0.84	rs10757036	ENSG00000273226.1	RP11-513M16.8	-5.07	5.7e-07	7.6e-05	-0.2	-0.23	Pulse pressure;	chr9:19236127	chr9:19375451~19375996:+
THCA	cis	rs16846053	0.685	rs62188773	ENSG00000227403.1	AC009299.3	5.07	5.7e-07	7.6e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161879765	chr2:161244739~161249050:+
THCA	cis	rs7809615	0.901	rs28862110	ENSG00000244219.5	GS1-259H13.2	-5.07	5.7e-07	7.6e-05	-0.41	-0.23	Blood metabolite ratios;	chr7:99585908	chr7:99598066~99610813:+
THCA	cis	rs1823913	0.637	rs12624271	ENSG00000280083.1	RP11-317J9.1	5.07	5.7e-07	7.6e-05	0.26	0.23	Obesity-related traits;	chr2:191288586	chr2:191154118~191156070:-
THCA	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-5.07	5.7e-07	7.6e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
THCA	cis	rs3820928	1	rs12615988	ENSG00000212391.1	SNORA48	-5.07	5.71e-07	7.61e-05	-0.26	-0.23	Pulmonary function;	chr2:226904284	chr2:226968989~226969122:-
THCA	cis	rs6088590	0.931	rs12625149	ENSG00000276073.1	RP5-1125A11.7	5.07	5.71e-07	7.61e-05	0.22	0.23	Coronary artery disease;	chr20:34838009	chr20:33985617~33988989:-
THCA	cis	rs919433	0.927	rs7592748	ENSG00000231621.1	AC013264.2	5.07	5.71e-07	7.61e-05	0.24	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305964	chr2:197197991~197199273:+
THCA	cis	rs2749592	0.531	rs1208559	ENSG00000120555.12	SEPT7P9	-5.07	5.71e-07	7.61e-05	-0.25	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38383069~38402916:-
THCA	cis	rs7394190	0.935	rs4746140	ENSG00000271816.1	BMS1P4	-5.07	5.71e-07	7.61e-05	-0.25	-0.23	Incident atrial fibrillation;	chr10:73657491	chr10:73699151~73730487:-
THCA	cis	rs7403037	0.687	rs61993107	ENSG00000259905.4	PWRN1	5.07	5.71e-07	7.61e-05	0.3	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24537990	chr15:24493137~24652130:+
THCA	cis	rs4713118	0.869	rs4713121	ENSG00000226314.6	ZNF192P1	-5.07	5.71e-07	7.61e-05	-0.3	-0.23	Parkinson's disease;	chr6:27754285	chr6:28161781~28169594:+
THCA	cis	rs1707322	0.964	rs6675259	ENSG00000281133.1	AL355480.3	5.07	5.71e-07	7.62e-05	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45580892~45580996:-
THCA	cis	rs72843506	0.591	rs117720402	ENSG00000261033.1	RP11-209D14.2	5.07	5.72e-07	7.62e-05	0.44	0.23	Schizophrenia;	chr17:20444298	chr17:20008051~20009234:-
THCA	cis	rs5758659	0.652	rs133349	ENSG00000270083.1	RP1-257I20.14	5.07	5.72e-07	7.63e-05	0.24	0.23	Cognitive function;	chr22:42032723	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.652	rs5758553	ENSG00000270083.1	RP1-257I20.14	5.07	5.72e-07	7.63e-05	0.24	0.23	Cognitive function;	chr22:42035425	chr22:42089630~42090028:-
THCA	cis	rs6792584	0.572	rs12489897	ENSG00000241316.5	SUCLG2-AS1	5.07	5.72e-07	7.63e-05	0.25	0.23	Corneal astigmatism;	chr3:67424665	chr3:67654697~67947713:+
THCA	cis	rs613391	0.671	rs594958	ENSG00000224549.1	RP11-370B11.3	-5.07	5.73e-07	7.63e-05	-0.26	-0.23	Quantitative traits;	chr9:22714080	chr9:22767175~22768316:+
THCA	cis	rs7429990	0.864	rs17290490	ENSG00000228638.1	FCF1P2	5.07	5.73e-07	7.63e-05	0.22	0.23	Educational attainment (years of education);	chr3:47841237	chr3:48290793~48291375:-
THCA	cis	rs1050631	0.592	rs1631346	ENSG00000260552.1	RP11-49I11.1	5.07	5.73e-07	7.63e-05	0.28	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36129701	chr18:36179996~36187448:-
THCA	cis	rs8141529	0.732	rs5752798	ENSG00000272858.1	CTA-292E10.8	-5.07	5.73e-07	7.63e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28785880	chr22:28814914~28815662:+
THCA	cis	rs11773103	1	rs11983450	ENSG00000224046.1	AC005076.5	5.07	5.73e-07	7.64e-05	0.36	0.23	Bipolar disorder or major depressive disorder (combined);	chr7:87246526	chr7:87151423~87152420:-
THCA	cis	rs11773103	1	rs73212041	ENSG00000224046.1	AC005076.5	5.07	5.73e-07	7.64e-05	0.36	0.23	Bipolar disorder or major depressive disorder (combined);	chr7:87249636	chr7:87151423~87152420:-
THCA	cis	rs1552244	0.938	rs34750074	ENSG00000180385.7	EMC3-AS1	5.07	5.73e-07	7.64e-05	0.26	0.23	Alzheimer's disease;	chr3:10050056	chr3:9986893~10006990:+
THCA	cis	rs7824557	0.872	rs2572417	ENSG00000154316.13	TDH	5.07	5.73e-07	7.64e-05	0.16	0.23	Retinal vascular caliber;	chr8:11253953	chr8:11339637~11368452:+
THCA	cis	rs4646450	0.891	rs1980307	ENSG00000244219.5	GS1-259H13.2	-5.07	5.73e-07	7.64e-05	-0.27	-0.23	Blood metabolite levels;	chr7:99462980	chr7:99598066~99610813:+
THCA	cis	rs8020095	0.571	rs7147690	ENSG00000258561.1	RP11-72M17.1	5.07	5.73e-07	7.64e-05	0.3	0.23	Depression (quantitative trait);	chr14:66775619	chr14:66212810~66509394:-
THCA	cis	rs6832769	0.857	rs61072181	ENSG00000272969.1	RP11-528I4.2	-5.07	5.73e-07	7.64e-05	-0.27	-0.23	Personality dimensions;	chr4:55617210	chr4:55547112~55547889:+
THCA	cis	rs4789693	0.679	rs7213057	ENSG00000260011.2	RP13-20L14.1	-5.07	5.73e-07	7.64e-05	-0.23	-0.23	Glucocorticoid-induced osteonecrosis;	chr17:82421063	chr17:82381110~82382690:-
THCA	cis	rs919433	0.68	rs11680291	ENSG00000231621.1	AC013264.2	-5.07	5.74e-07	7.65e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197545160	chr2:197197991~197199273:+
THCA	cis	rs34779708	0.931	rs4934723	ENSG00000271335.4	RP11-324I22.4	5.07	5.74e-07	7.65e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35314552~35336401:-
THCA	cis	rs7474896	0.609	rs1830612	ENSG00000263064.2	RP11-291L22.7	5.07	5.74e-07	7.65e-05	0.3	0.23	Obesity (extreme);	chr10:37710955	chr10:38448689~38448949:+
THCA	cis	rs7772486	0.686	rs857880	ENSG00000270638.1	RP3-466P17.1	-5.07	5.74e-07	7.65e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145735570~145737218:+
THCA	cis	rs3820928	1	rs3731593	ENSG00000212391.1	SNORA48	-5.07	5.75e-07	7.66e-05	-0.26	-0.23	Pulmonary function;	chr2:226909208	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs6723774	ENSG00000212391.1	SNORA48	5.07	5.75e-07	7.66e-05	0.26	0.23	Pulmonary function;	chr2:226905876	chr2:226968989~226969122:-
THCA	cis	rs7976269	0.583	rs7955393	ENSG00000275476.1	RP11-996F15.4	-5.07	5.75e-07	7.66e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29065773	chr12:29277397~29277882:-
THCA	cis	rs4761702	0.922	rs11106975	ENSG00000257322.4	RP11-511B23.2	-5.07	5.75e-07	7.66e-05	-0.31	-0.23	Immature fraction of reticulocytes;	chr12:93327178	chr12:93003415~93215679:-
THCA	cis	rs8046148	0.694	rs877639	ENSG00000279356.1	RP11-429P3.8	-5.07	5.75e-07	7.66e-05	-0.26	-0.23	Testicular germ cell tumor;	chr16:50084334	chr16:50072862~50074986:+
THCA	cis	rs79040073	0.607	rs17479289	ENSG00000259531.2	RP11-295H24.3	5.07	5.75e-07	7.66e-05	0.29	0.23	Lung cancer in ever smokers;	chr15:49456416	chr15:49365124~49366685:-
THCA	cis	rs6058796	1	rs35220493	ENSG00000175730.8	BAK1P1	5.07	5.75e-07	7.67e-05	0.34	0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32680029	chr20:32690180~32690815:-
THCA	cis	rs8177876	0.749	rs754429	ENSG00000261838.4	RP11-303E16.6	5.07	5.76e-07	7.67e-05	0.41	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81069854~81076598:+
THCA	cis	rs2985684	0.948	rs6572592	ENSG00000278009.1	RP11-649E7.8	5.07	5.76e-07	7.67e-05	0.33	0.23	Carotid intima media thickness;	chr14:49614153	chr14:49601011~49601124:-
THCA	cis	rs2985684	0.948	rs12886130	ENSG00000278009.1	RP11-649E7.8	5.07	5.76e-07	7.67e-05	0.33	0.23	Carotid intima media thickness;	chr14:49616035	chr14:49601011~49601124:-
THCA	cis	rs10896135	0.554	rs3741364	ENSG00000255320.1	RP11-755F10.1	5.07	5.76e-07	7.67e-05	0.34	0.23	Bipolar disorder;	chr11:66683707	chr11:66244840~66246239:-
THCA	cis	rs4648045	0.861	rs230514	ENSG00000246560.2	RP11-10L12.4	-5.07	5.76e-07	7.67e-05	-0.28	-0.23	Lymphocyte percentage of white cells;	chr4:102550782	chr4:102828055~102844075:+
THCA	cis	rs4950322	0.57	rs72691032	ENSG00000271721.1	RP11-337C18.9	5.07	5.77e-07	7.68e-05	0.26	0.23	Protein quantitative trait loci;	chr1:147261120	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72691033	ENSG00000271721.1	RP11-337C18.9	5.07	5.77e-07	7.68e-05	0.26	0.23	Protein quantitative trait loci;	chr1:147261267	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs111370771	ENSG00000271721.1	RP11-337C18.9	5.07	5.77e-07	7.68e-05	0.26	0.23	Protein quantitative trait loci;	chr1:147261420	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs4301678	ENSG00000271721.1	RP11-337C18.9	5.07	5.77e-07	7.68e-05	0.26	0.23	Protein quantitative trait loci;	chr1:147261907	chr1:147175602~147177740:+
THCA	cis	rs362272	0.525	rs2471347	ENSG00000249673.5	NOP14-AS1	-5.07	5.77e-07	7.68e-05	-0.19	-0.23	Serum sulfate level;	chr4:3042708	chr4:2934899~2961738:+
THCA	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	5.07	5.77e-07	7.68e-05	0.21	0.23	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
THCA	cis	rs875971	0.545	rs313828	ENSG00000232546.1	RP11-458F8.1	-5.07	5.77e-07	7.68e-05	-0.22	-0.23	Aortic root size;	chr7:66087627	chr7:66848496~66858136:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000232546.1	RP11-458F8.1	-5.07	5.77e-07	7.68e-05	-0.22	-0.23	Aortic root size;	chr7:66089365	chr7:66848496~66858136:+
THCA	cis	rs227275	0.554	rs223409	ENSG00000248971.2	KRT8P46	-5.07	5.77e-07	7.68e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223404	ENSG00000248971.2	KRT8P46	-5.07	5.77e-07	7.68e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102728746~102730171:-
THCA	cis	rs875971	0.545	rs313828	ENSG00000228409.4	CCT6P1	5.07	5.77e-07	7.68e-05	0.2	0.23	Aortic root size;	chr7:66087627	chr7:65751142~65763354:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000228409.4	CCT6P1	5.07	5.77e-07	7.68e-05	0.2	0.23	Aortic root size;	chr7:66089365	chr7:65751142~65763354:+
THCA	cis	rs330048	0.509	rs36111783	ENSG00000254153.1	CTA-398F10.2	-5.07	5.77e-07	7.69e-05	-0.25	-0.23	Systemic lupus erythematosus;	chr8:9288078	chr8:8456909~8461337:-
THCA	cis	rs2255336	0.873	rs7397310	ENSG00000245648.1	RP11-277P12.20	5.07	5.77e-07	7.69e-05	0.26	0.23	Blood protein levels;	chr12:10368394	chr12:10363769~10398506:+
THCA	cis	rs1707322	1	rs10890381	ENSG00000281133.1	AL355480.3	-5.07	5.77e-07	7.69e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45580892~45580996:-
THCA	cis	rs16846053	0.605	rs62188792	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161881430	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs41267443	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161882271	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.786	rs62188794	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161884073	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188795	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161884497	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188796	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161884652	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72881073	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161885247	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188798	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161886388	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865206	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161886752	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.502	rs115848314	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161888991	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188807	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161889698	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs58909484	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161891599	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188810	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161892568	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs72865220	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161893161	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188811	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161893795	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.539	rs1343883	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161894164	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs4146952	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161897136	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188816	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161897645	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.605	rs62188817	ENSG00000227403.1	AC009299.3	5.07	5.78e-07	7.69e-05	0.52	0.23	Blood osmolality (transformed sodium);	chr2:161897715	chr2:161244739~161249050:+
THCA	cis	rs77972916	0.536	rs11694173	ENSG00000234936.1	AC010883.5	-5.07	5.78e-07	7.69e-05	-0.26	-0.23	Granulocyte percentage of myeloid white cells;	chr2:43363760	chr2:43229573~43233394:+
THCA	cis	rs8027521	0.738	rs11638970	ENSG00000280362.1	RP11-643A5.3	5.07	5.78e-07	7.69e-05	0.28	0.23	Circulating chemerin levels;	chr15:53967354	chr15:53910769~53914712:+
THCA	cis	rs2304003	0.95	rs1863199	ENSG00000235192.1	AC009495.2	5.07	5.78e-07	7.69e-05	0.31	0.23	Social communication problems;	chr2:165810140	chr2:165794851~165810010:+
THCA	cis	rs34779708	0.966	rs4934540	ENSG00000271335.4	RP11-324I22.4	5.07	5.78e-07	7.69e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35314552~35336401:-
THCA	cis	rs8059260	0.541	rs12927046	ENSG00000274038.1	RP11-66H6.4	-5.07	5.78e-07	7.69e-05	-0.46	-0.23	Alcohol consumption over the past year;	chr16:11148334	chr16:11056556~11057034:+
THCA	cis	rs7429990	0.52	rs78838427	ENSG00000228638.1	FCF1P2	5.07	5.78e-07	7.7e-05	0.22	0.23	Educational attainment (years of education);	chr3:47595561	chr3:48290793~48291375:-
THCA	cis	rs228614	0.536	rs223475	ENSG00000248971.2	KRT8P46	-5.07	5.78e-07	7.7e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102728746~102730171:-
THCA	cis	rs228614	0.536	rs223474	ENSG00000248971.2	KRT8P46	-5.07	5.78e-07	7.7e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102728746~102730171:-
THCA	cis	rs17767392	0.881	rs9672060	ENSG00000259146.3	RP1-261D10.2	5.07	5.79e-07	7.7e-05	0.29	0.23	Mitral valve prolapse;	chr14:71543409	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.881	rs35971049	ENSG00000259146.3	RP1-261D10.2	5.07	5.79e-07	7.7e-05	0.29	0.23	Mitral valve prolapse;	chr14:71545502	chr14:71292729~71321814:-
THCA	cis	rs2440129	0.611	rs1042357	ENSG00000262089.1	RP11-589P10.5	5.07	5.79e-07	7.7e-05	0.21	0.23	Tonsillectomy;	chr17:7001742	chr17:6994642~6995189:-
THCA	cis	rs6968419	0.714	rs12666168	ENSG00000237870.5	AC073130.1	5.07	5.79e-07	7.7e-05	0.25	0.23	Intraocular pressure;	chr7:116216627	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs3779509	ENSG00000237870.5	AC073130.1	5.07	5.79e-07	7.7e-05	0.25	0.23	Intraocular pressure;	chr7:116224835	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.649	rs58624059	ENSG00000237870.5	AC073130.1	5.07	5.79e-07	7.7e-05	0.25	0.23	Intraocular pressure;	chr7:116228744	chr7:116275606~116286734:-
THCA	cis	rs972578	0.668	rs4820489	ENSG00000274717.1	RP1-47A17.1	-5.07	5.79e-07	7.7e-05	-0.24	-0.23	Mean platelet volume;	chr22:42844997	chr22:42791814~42794313:-
THCA	cis	rs6728642	1	rs7593754	ENSG00000230606.9	AC159540.1	5.07	5.79e-07	7.71e-05	0.31	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941807	chr2:97416165~97433527:-
THCA	cis	rs2797160	0.967	rs1739355	ENSG00000237742.5	RP11-624M8.1	5.07	5.79e-07	7.71e-05	0.2	0.23	Endometrial cancer;	chr6:125696968	chr6:125578558~125749190:-
THCA	cis	rs1823913	0.637	rs6741454	ENSG00000280083.1	RP11-317J9.1	5.07	5.79e-07	7.71e-05	0.26	0.23	Obesity-related traits;	chr2:191269520	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.614	rs6755243	ENSG00000280083.1	RP11-317J9.1	5.07	5.79e-07	7.71e-05	0.26	0.23	Obesity-related traits;	chr2:191269810	chr2:191154118~191156070:-
THCA	cis	rs4713118	0.629	rs203889	ENSG00000261839.1	RP1-265C24.8	5.07	5.79e-07	7.71e-05	0.26	0.23	Parkinson's disease;	chr6:28053997	chr6:28136849~28139678:+
THCA	cis	rs8020095	0.571	rs1546940	ENSG00000258561.1	RP11-72M17.1	-5.07	5.79e-07	7.71e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67027061	chr14:66212810~66509394:-
THCA	cis	rs4660456	1	rs4660456	ENSG00000272145.1	NFYC-AS1	5.07	5.8e-07	7.72e-05	0.16	0.23	Platelet count;	chr1:40773839	chr1:40690380~40692066:-
THCA	cis	rs12755164	0.724	rs6656687	ENSG00000223479.3	RP4-788P17.1	5.07	5.8e-07	7.72e-05	0.25	0.23	Schizophrenia;	chr1:72841887	chr1:73635216~73715214:+
THCA	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-5.07	5.8e-07	7.72e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
THCA	cis	rs9425766	0.64	rs10912734	ENSG00000227373.4	RP11-160H22.5	5.07	5.8e-07	7.72e-05	0.32	0.23	Life satisfaction;	chr1:174141977	chr1:174115300~174160004:-
THCA	cis	rs4648045	0.861	rs230535	ENSG00000246560.2	RP11-10L12.4	-5.07	5.8e-07	7.72e-05	-0.29	-0.23	Lymphocyte percentage of white cells;	chr4:102527425	chr4:102828055~102844075:+
THCA	cis	rs8141529	0.753	rs5752813	ENSG00000272858.1	CTA-292E10.8	-5.07	5.81e-07	7.73e-05	-0.24	-0.23	Lymphocyte counts;	chr22:28830582	chr22:28814914~28815662:+
THCA	cis	rs7131987	0.834	rs1989478	ENSG00000275476.1	RP11-996F15.4	-5.07	5.81e-07	7.73e-05	-0.22	-0.23	QT interval;	chr12:29289296	chr12:29277397~29277882:-
THCA	cis	rs11191419	1	rs11191419	ENSG00000213061.2	PFN1P11	5.07	5.81e-07	7.73e-05	0.28	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102838011~102845473:-
THCA	cis	rs5758511	0.68	rs5758651	ENSG00000281538.1	RP4-669P10.20	-5.07	5.81e-07	7.73e-05	-0.26	-0.23	Birth weight;	chr22:42213142	chr22:42138060~42139726:+
THCA	cis	rs227275	0.554	rs223436	ENSG00000248971.2	KRT8P46	-5.07	5.81e-07	7.73e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223424	ENSG00000248971.2	KRT8P46	-5.07	5.81e-07	7.73e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102728746~102730171:-
THCA	cis	rs227275	0.524	rs223423	ENSG00000248971.2	KRT8P46	-5.07	5.81e-07	7.73e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223422	ENSG00000248971.2	KRT8P46	-5.07	5.81e-07	7.73e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102728746~102730171:-
THCA	cis	rs440932	1	rs440932	ENSG00000253893.2	FAM85B	-5.07	5.81e-07	7.73e-05	-0.29	-0.23	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8167819~8226614:-
THCA	cis	rs757978	0.81	rs34123564	ENSG00000223374.1	AC005104.3	5.07	5.81e-07	7.73e-05	0.23	0.23	Chronic lymphocytic leukemia;	chr2:241465022	chr2:241351340~241353104:-
THCA	cis	rs481331	0.799	rs1855444	ENSG00000215146.4	RP11-313J2.1	5.07	5.81e-07	7.73e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42479959	chr10:42331866~42367974:-
THCA	cis	rs72945132	0.882	rs67093918	ENSG00000254604.1	AP000487.6	-5.07	5.81e-07	7.73e-05	-0.43	-0.23	Coronary artery disease;	chr11:70352893	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs66627443	ENSG00000254604.1	AP000487.6	-5.07	5.81e-07	7.73e-05	-0.43	-0.23	Coronary artery disease;	chr11:70352930	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs66989619	ENSG00000254604.1	AP000487.6	-5.07	5.81e-07	7.73e-05	-0.43	-0.23	Coronary artery disease;	chr11:70356021	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs56368190	ENSG00000254604.1	AP000487.6	-5.07	5.81e-07	7.73e-05	-0.43	-0.23	Coronary artery disease;	chr11:70358222	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7950916	ENSG00000254604.1	AP000487.6	-5.07	5.81e-07	7.73e-05	-0.43	-0.23	Coronary artery disease;	chr11:70363895	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs60917762	ENSG00000254604.1	AP000487.6	-5.07	5.81e-07	7.73e-05	-0.43	-0.23	Coronary artery disease;	chr11:70365278	chr11:70282367~70363368:-
THCA	cis	rs34779708	0.966	rs6481941	ENSG00000271335.4	RP11-324I22.4	5.07	5.81e-07	7.73e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35314552~35336401:-
THCA	cis	rs2880765	0.835	rs7161880	ENSG00000259630.2	CTD-2262B20.1	-5.07	5.81e-07	7.74e-05	-0.24	-0.23	Coronary artery disease;	chr15:85475515	chr15:85415228~85415633:+
THCA	cis	rs867371	0.502	rs1846908	ENSG00000259429.4	UBE2Q2P2	-5.07	5.81e-07	7.74e-05	-0.18	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82355142~82420075:+
THCA	cis	rs2665103	0.655	rs1501367	ENSG00000259429.4	UBE2Q2P2	-5.07	5.81e-07	7.74e-05	-0.18	-0.23	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82355142~82420075:+
THCA	cis	rs4660456	0.913	rs2361650	ENSG00000272145.1	NFYC-AS1	5.07	5.82e-07	7.74e-05	0.16	0.23	Platelet count;	chr1:40764678	chr1:40690380~40692066:-
THCA	cis	rs4660456	0.913	rs954654	ENSG00000272145.1	NFYC-AS1	5.07	5.82e-07	7.74e-05	0.16	0.23	Platelet count;	chr1:40764979	chr1:40690380~40692066:-
THCA	cis	rs3796352	1	rs36090694	ENSG00000242142.1	SERBP1P3	-5.07	5.82e-07	7.74e-05	-0.44	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52976726	chr3:53064283~53065091:-
THCA	cis	rs11096990	0.892	rs11930865	ENSG00000249685.1	RP11-360F5.3	-5.07	5.82e-07	7.74e-05	-0.29	-0.23	Cognitive function;	chr4:39218711	chr4:39133913~39135608:+
THCA	cis	rs11671005	0.736	rs11668201	ENSG00000269473.1	CTD-2619J13.19	5.07	5.82e-07	7.75e-05	0.26	0.23	Mean platelet volume;	chr19:58492265	chr19:58440448~58445849:+
THCA	cis	rs6802315	0.604	rs4680467	ENSG00000272087.1	RP11-379F4.7	5.07	5.83e-07	7.75e-05	0.2	0.23	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158693120~158693768:-
THCA	cis	rs478304	0.903	rs495961	ENSG00000214659.4	KRT8P26	-5.07	5.83e-07	7.75e-05	-0.19	-0.23	Acne (severe);	chr11:65773415	chr11:65726939~65728214:+
THCA	cis	rs7727544	0.735	rs270605	ENSG00000263597.1	MIR3936	5.07	5.83e-07	7.76e-05	0.22	0.23	Blood metabolite levels;	chr5:132316118	chr5:132365490~132365599:-
THCA	cis	rs6565180	0.888	rs12447833	ENSG00000274653.1	RP11-347C12.11	-5.07	5.83e-07	7.76e-05	-0.22	-0.23	Tonsillectomy;	chr16:30378993	chr16:30359825~30360336:+
THCA	cis	rs7394190	0.748	rs16930909	ENSG00000271816.1	BMS1P4	-5.07	5.83e-07	7.76e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73801824	chr10:73699151~73730487:-
THCA	cis	rs897984	0.806	rs1046276	ENSG00000260911.2	RP11-196G11.2	-5.07	5.83e-07	7.76e-05	-0.19	-0.23	Dementia with Lewy bodies;	chr16:30903305	chr16:31043150~31049868:+
THCA	cis	rs10466239	0.73	rs2243492	ENSG00000230555.2	RP11-517P14.2	5.07	5.83e-07	7.76e-05	0.22	0.23	Telomere length;	chr10:43353910	chr10:43420738~43422100:+
THCA	cis	rs7980687	0.574	rs10744149	ENSG00000235423.7	RP11-282O18.3	5.07	5.83e-07	7.76e-05	0.24	0.23	Head circumference (infant);Educational attainment;Height;	chr12:123223943	chr12:123252030~123261483:-
THCA	cis	rs911119	1	rs6048956	ENSG00000270001.1	RP11-218C14.8	-5.07	5.83e-07	7.76e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23628664	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs34374560	ENSG00000270001.1	RP11-218C14.8	-5.07	5.83e-07	7.76e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23628825	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs13038305	ENSG00000270001.1	RP11-218C14.8	-5.07	5.83e-07	7.76e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23629625	chr20:23631826~23632316:-
THCA	cis	rs755249	0.565	rs2695324	ENSG00000228060.1	RP11-69E11.8	-5.07	5.84e-07	7.76e-05	-0.22	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39565160~39573203:+
THCA	cis	rs6061231	0.518	rs639836	ENSG00000275437.1	RP5-908M14.10	-5.07	5.84e-07	7.76e-05	-0.21	-0.23	Colorectal cancer;	chr20:62351167	chr20:62402236~62405935:-
THCA	cis	rs7554547	0.69	rs12087996	ENSG00000199347.1	RNU5E-1	-5.07	5.84e-07	7.77e-05	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr1:11897152	chr1:11908152~11908271:+
THCA	cis	rs527616	0.965	rs1667550	ENSG00000260372.5	AQP4-AS1	5.07	5.84e-07	7.77e-05	0.24	0.23	Breast cancer;	chr18:26752512	chr18:26655742~27190698:+
THCA	cis	rs478304	0.817	rs524475	ENSG00000214659.4	KRT8P26	-5.07	5.84e-07	7.77e-05	-0.19	-0.23	Acne (severe);	chr11:65750594	chr11:65726939~65728214:+
THCA	cis	rs478304	0.934	rs506853	ENSG00000214659.4	KRT8P26	-5.07	5.84e-07	7.77e-05	-0.19	-0.23	Acne (severe);	chr11:65753776	chr11:65726939~65728214:+
THCA	cis	rs478304	0.903	rs12293022	ENSG00000214659.4	KRT8P26	-5.07	5.84e-07	7.77e-05	-0.19	-0.23	Acne (severe);	chr11:65764227	chr11:65726939~65728214:+
THCA	cis	rs478304	0.934	rs603645	ENSG00000214659.4	KRT8P26	-5.07	5.84e-07	7.77e-05	-0.19	-0.23	Acne (severe);	chr11:65765529	chr11:65726939~65728214:+
THCA	cis	rs2980439	0.783	rs2955587	ENSG00000254153.1	CTA-398F10.2	-5.07	5.84e-07	7.77e-05	-0.24	-0.23	Neuroticism;	chr8:8240557	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.95	rs13248096	ENSG00000253893.2	FAM85B	-5.07	5.84e-07	7.77e-05	-0.3	-0.23	Obesity-related traits;	chr8:8719966	chr8:8167819~8226614:-
THCA	cis	rs7246657	0.722	rs11083432	ENSG00000276846.1	CTD-3220F14.3	-5.07	5.85e-07	7.77e-05	-0.22	-0.23	Coronary artery calcification;	chr19:37691732	chr19:37314868~37315620:-
THCA	cis	rs17767392	0.881	rs35680546	ENSG00000259146.3	RP1-261D10.2	5.07	5.85e-07	7.78e-05	0.3	0.23	Mitral valve prolapse;	chr14:71473902	chr14:71292729~71321814:-
THCA	cis	rs228614	0.51	rs223392	ENSG00000248971.2	KRT8P46	-5.07	5.85e-07	7.78e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223390	ENSG00000248971.2	KRT8P46	-5.07	5.85e-07	7.78e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs50034	ENSG00000248971.2	KRT8P46	-5.07	5.85e-07	7.78e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs223380	ENSG00000248971.2	KRT8P46	-5.07	5.85e-07	7.78e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs223379	ENSG00000248971.2	KRT8P46	-5.07	5.85e-07	7.78e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102728746~102730171:-
THCA	cis	rs227275	0.524	rs150894	ENSG00000248971.2	KRT8P46	-5.07	5.85e-07	7.78e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102728746~102730171:-
THCA	cis	rs8028182	0.609	rs10220738	ENSG00000260274.1	RP11-817O13.8	-5.07	5.85e-07	7.78e-05	-0.16	-0.23	Sudden cardiac arrest;	chr15:75374205	chr15:75368155~75369584:+
THCA	cis	rs5758659	0.652	rs4822084	ENSG00000273366.1	CTA-989H11.1	5.07	5.85e-07	7.78e-05	0.28	0.23	Cognitive function;	chr22:42039864	chr22:42278188~42278846:+
THCA	cis	rs763121	0.853	rs9610986	ENSG00000228274.3	RP3-508I15.9	-5.07	5.85e-07	7.78e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38629272	chr22:38667585~38681820:-
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000273796.1	LL21NC02-21A1.1	-5.07	5.85e-07	7.78e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45403809~45404369:-
THCA	cis	rs6708331	0.54	rs6546576	ENSG00000179818.12	PCBP1-AS1	-5.07	5.86e-07	7.79e-05	-0.18	-0.23	Obesity-related traits;	chr2:70174356	chr2:69962263~70103220:-
THCA	cis	rs897984	0.806	rs12924903	ENSG00000279196.1	RP11-1072A3.3	5.07	5.86e-07	7.79e-05	0.23	0.23	Dementia with Lewy bodies;	chr16:30917649	chr16:30984630~30988270:-
THCA	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	5.07	5.86e-07	7.79e-05	0.4	0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
THCA	cis	rs8027521	0.557	rs7495091	ENSG00000280362.1	RP11-643A5.3	5.07	5.86e-07	7.79e-05	0.28	0.23	Circulating chemerin levels;	chr15:53954924	chr15:53910769~53914712:+
THCA	cis	rs12893668	0.673	rs2296482	ENSG00000269940.1	RP11-73M18.7	5.07	5.86e-07	7.79e-05	0.24	0.23	Reticulocyte count;	chr14:103563482	chr14:103694560~103695170:+
THCA	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	5.07	5.86e-07	7.79e-05	0.3	0.23	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	5.07	5.86e-07	7.79e-05	0.3	0.23	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	5.07	5.86e-07	7.79e-05	0.3	0.23	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
THCA	cis	rs5015933	0.788	rs2945039	ENSG00000232630.1	PRPS1P2	-5.07	5.86e-07	7.79e-05	-0.16	-0.23	Body mass index;	chr9:125281525	chr9:125150653~125151589:+
THCA	cis	rs7429990	0.864	rs7631950	ENSG00000228638.1	FCF1P2	5.07	5.86e-07	7.79e-05	0.22	0.23	Educational attainment (years of education);	chr3:47591865	chr3:48290793~48291375:-
THCA	cis	rs1823913	0.637	rs4853579	ENSG00000280083.1	RP11-317J9.1	5.07	5.86e-07	7.79e-05	0.26	0.23	Obesity-related traits;	chr2:191297413	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs12622194	ENSG00000280083.1	RP11-317J9.1	5.07	5.86e-07	7.79e-05	0.26	0.23	Obesity-related traits;	chr2:191298680	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs13019567	ENSG00000280083.1	RP11-317J9.1	5.07	5.86e-07	7.79e-05	0.26	0.23	Obesity-related traits;	chr2:191298736	chr2:191154118~191156070:-
THCA	cis	rs4663866	0.901	rs2304672	ENSG00000186235.9	AC016757.3	-5.07	5.86e-07	7.79e-05	-0.5	-0.23	Irritable bowel syndrome;	chr2:238277948	chr2:238224552~238231677:-
THCA	cis	rs78905543	0.967	rs4242388	ENSG00000253616.4	RP11-875O11.3	5.07	5.86e-07	7.8e-05	0.26	0.23	Mean corpuscular volume;	chr8:23075198	chr8:23071377~23074488:-
THCA	cis	rs72634501	0.531	rs67758468	ENSG00000228060.1	RP11-69E11.8	-5.07	5.86e-07	7.8e-05	-0.23	-0.23	HDL cholesterol;	chr1:39156916	chr1:39565160~39573203:+
THCA	cis	rs6570726	0.846	rs7762536	ENSG00000270638.1	RP3-466P17.1	5.07	5.86e-07	7.8e-05	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145735570~145737218:+
THCA	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-5.07	5.86e-07	7.8e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
THCA	cis	rs4663866	0.908	rs35093813	ENSG00000186235.9	AC016757.3	5.07	5.87e-07	7.8e-05	0.48	0.23	Irritable bowel syndrome;	chr2:238245124	chr2:238224552~238231677:-
THCA	cis	rs4663866	1	rs4663867	ENSG00000186235.9	AC016757.3	5.07	5.87e-07	7.8e-05	0.48	0.23	Irritable bowel syndrome;	chr2:238251323	chr2:238224552~238231677:-
THCA	cis	rs1050631	0.592	rs9958282	ENSG00000260552.1	RP11-49I11.1	-5.07	5.87e-07	7.8e-05	-0.28	-0.23	Esophageal squamous cell cancer (length of survival);	chr18:36130477	chr18:36179996~36187448:-
THCA	cis	rs957448	1	rs1992370	ENSG00000253175.1	RP11-267M23.6	5.07	5.87e-07	7.8e-05	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94565036~94565715:+
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000280069.1	CTD-2349P21.3	-5.07	5.87e-07	7.8e-05	-0.35	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30738182~30740275:+
THCA	cis	rs227275	0.554	rs223442	ENSG00000248971.2	KRT8P46	-5.07	5.87e-07	7.81e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223441	ENSG00000248971.2	KRT8P46	-5.07	5.87e-07	7.81e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102728746~102730171:-
THCA	cis	rs6433895	1	rs6433895	ENSG00000236153.1	AC104076.3	-5.07	5.87e-07	7.81e-05	-0.25	-0.23	Lymphocyte counts;	chr2:181147287	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs56169464	ENSG00000236153.1	AC104076.3	-5.07	5.87e-07	7.81e-05	-0.25	-0.23	Lymphocyte counts;	chr2:181148101	chr2:180979427~180980090:-
THCA	cis	rs11671005	0.735	rs11670871	ENSG00000265272.2	RN7SL693P	-5.07	5.88e-07	7.81e-05	-0.32	-0.23	Mean platelet volume;	chr19:58429147	chr19:58490797~58491075:+
THCA	cis	rs2243480	1	rs160643	ENSG00000232546.1	RP11-458F8.1	-5.06	5.88e-07	7.81e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66093235	chr7:66848496~66858136:+
THCA	cis	rs4578769	0.55	rs9961760	ENSG00000265939.1	UBE2CP2	5.06	5.88e-07	7.82e-05	0.26	0.23	Eosinophil percentage of white cells;	chr18:23021545	chr18:22900486~22900995:-
THCA	cis	rs7520050	0.807	rs3013595	ENSG00000234329.1	RP11-767N6.2	5.06	5.88e-07	7.82e-05	0.2	0.23	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45651039~45651826:-
THCA	cis	rs317689	0.69	rs317630	ENSG00000274979.1	RP11-1143G9.5	-5.06	5.89e-07	7.82e-05	-0.26	-0.23	Response to diuretic therapy;	chr12:69244067	chr12:69326574~69331882:-
THCA	cis	rs8028182	0.636	rs10152155	ENSG00000260269.4	CTD-2323K18.1	-5.06	5.89e-07	7.82e-05	-0.34	-0.23	Sudden cardiac arrest;	chr15:75409213	chr15:75527150~75601205:-
THCA	cis	rs2179367	0.959	rs564961	ENSG00000231760.4	RP11-350J20.5	5.06	5.89e-07	7.82e-05	0.3	0.23	Dupuytren's disease;	chr6:149336091	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.959	rs504985	ENSG00000231760.4	RP11-350J20.5	5.06	5.89e-07	7.82e-05	0.3	0.23	Dupuytren's disease;	chr6:149337842	chr6:149796151~149826294:-
THCA	cis	rs944289	0.74	rs2780302	ENSG00000258844.1	RP11-259K15.2	5.06	5.89e-07	7.82e-05	0.2	0.23	Thyroid cancer;	chr14:36079456	chr14:36214607~36235608:+
THCA	cis	rs7554547	0.667	rs4304595	ENSG00000199347.1	RNU5E-1	-5.06	5.89e-07	7.82e-05	-0.32	-0.23	Nonsyndromic cleft lip with cleft palate;	chr1:11886332	chr1:11908152~11908271:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000229886.1	RP5-1132H15.3	-5.06	5.89e-07	7.83e-05	-0.23	-0.23	Calcium levels;	chr7:66026136	chr7:66025126~66031544:-
THCA	cis	rs10967586	0.622	rs62542669	ENSG00000254396.1	RP11-56F10.3	5.06	5.89e-07	7.83e-05	0.43	0.23	Schizophrenia;	chr9:27009346	chr9:27102630~27104728:+
THCA	cis	rs10967586	0.622	rs62542670	ENSG00000254396.1	RP11-56F10.3	5.06	5.89e-07	7.83e-05	0.43	0.23	Schizophrenia;	chr9:27014347	chr9:27102630~27104728:+
THCA	cis	rs7772486	0.681	rs9390343	ENSG00000270638.1	RP3-466P17.1	-5.06	5.89e-07	7.83e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145735570~145737218:+
THCA	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-5.06	5.89e-07	7.83e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
THCA	cis	rs13096142	0.516	rs9877860	ENSG00000223552.1	RP11-24F11.2	-5.06	5.89e-07	7.83e-05	-0.23	-0.23	Celiac disease;	chr3:46282580	chr3:46364955~46407059:-
THCA	cis	rs9859260	0.961	rs34221479	ENSG00000231464.1	AC024937.4	5.06	5.9e-07	7.84e-05	0.28	0.23	Mean corpuscular volume;	chr3:196071729	chr3:195996738~195998233:+
THCA	cis	rs2029362	0.684	rs11030096	ENSG00000245573.6	BDNF-AS	-5.06	5.9e-07	7.84e-05	-0.18	-0.23	Total body bone mineral density;	chr11:27643996	chr11:27506838~27698174:+
THCA	cis	rs10875746	0.669	rs10875772	ENSG00000258234.1	RP11-370I10.2	5.06	5.9e-07	7.84e-05	0.27	0.23	Longevity (90 years and older);	chr12:48215770	chr12:48231098~48284210:-
THCA	cis	rs7618915	0.57	rs11130319	ENSG00000243224.1	RP5-1157M23.2	-5.06	5.9e-07	7.84e-05	-0.25	-0.23	Bipolar disorder;	chr3:52721576	chr3:52239258~52241097:+
THCA	cis	rs4073582	0.595	rs3016319	ENSG00000255320.1	RP11-755F10.1	-5.06	5.9e-07	7.84e-05	-0.29	-0.23	Gout;	chr11:66214375	chr11:66244840~66246239:-
THCA	cis	rs12413361	0.967	rs2994655	ENSG00000272914.1	RP11-330O11.3	5.06	5.9e-07	7.84e-05	0.2	0.23	Height;	chr10:30836579	chr10:30831828~30833387:-
THCA	cis	rs3764400	0.508	rs72823528	ENSG00000278765.1	RP5-890E16.5	5.06	5.9e-07	7.84e-05	0.42	0.23	Body mass index;	chr17:48021578	chr17:48066704~48067293:-
THCA	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-5.06	5.9e-07	7.84e-05	-0.27	-0.23	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
THCA	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-5.06	5.91e-07	7.85e-05	-0.21	-0.23	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
THCA	cis	rs11603691	1	rs11228925	ENSG00000254662.1	RP11-872D17.4	-5.06	5.91e-07	7.85e-05	-0.45	-0.23	Low high density lipoprotein cholesterol levels;	chr11:57155887	chr11:57325603~57327958:+
THCA	cis	rs925255	0.817	rs7606480	ENSG00000270210.1	RP11-373D23.3	-5.06	5.91e-07	7.85e-05	-0.24	-0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28409510	chr2:28425945~28426719:+
THCA	cis	rs227275	0.554	rs150895	ENSG00000248971.2	KRT8P46	-5.06	5.91e-07	7.85e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102728746~102730171:-
THCA	cis	rs2803122	0.905	rs10757053	ENSG00000273226.1	RP11-513M16.8	-5.06	5.91e-07	7.85e-05	-0.2	-0.23	Pulse pressure;	chr9:19314156	chr9:19375451~19375996:+
THCA	cis	rs2803122	0.936	rs10117865	ENSG00000273226.1	RP11-513M16.8	-5.06	5.91e-07	7.85e-05	-0.2	-0.23	Pulse pressure;	chr9:19314433	chr9:19375451~19375996:+
THCA	cis	rs240993	0.812	rs459809	ENSG00000271789.1	RP5-1112D6.7	-5.06	5.91e-07	7.85e-05	-0.28	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111297126~111298510:+
THCA	cis	rs17723470	0.513	rs2902426	ENSG00000254427.1	RP11-430H10.1	5.06	5.91e-07	7.86e-05	0.23	0.23	Thyroid hormone levels;	chr11:45207548	chr11:45355371~45366121:+
THCA	cis	rs227275	0.554	rs223439	ENSG00000248971.2	KRT8P46	-5.06	5.91e-07	7.86e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102728746~102730171:-
THCA	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-5.06	5.91e-07	7.86e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
THCA	cis	rs17123764	0.71	rs12315791	ENSG00000257464.1	RP11-161H23.8	-5.06	5.91e-07	7.86e-05	-0.36	-0.23	Intelligence (multi-trait analysis);	chr12:49689764	chr12:49442424~49442652:-
THCA	cis	rs79040073	0.679	rs78135084	ENSG00000259531.2	RP11-295H24.3	5.06	5.91e-07	7.86e-05	0.33	0.23	Lung cancer in ever smokers;	chr15:49169895	chr15:49365124~49366685:-
THCA	cis	rs4948275	0.773	rs2100559	ENSG00000237233.2	TMEM26-AS1	-5.06	5.91e-07	7.86e-05	-0.31	-0.23	Night sleep phenotypes;	chr10:61528566	chr10:61452639~61481956:+
THCA	cis	rs9393777	0.92	rs13195040	ENSG00000280107.1	AL022393.9	5.06	5.91e-07	7.86e-05	0.4	0.23	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28170845~28172521:+
THCA	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	5.06	5.91e-07	7.86e-05	0.26	0.23	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
THCA	cis	rs8141529	0.719	rs2097461	ENSG00000272858.1	CTA-292E10.8	-5.06	5.92e-07	7.86e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28795891	chr22:28814914~28815662:+
THCA	cis	rs4934494	0.677	rs12774378	ENSG00000232936.4	RP11-80H5.2	5.06	5.92e-07	7.86e-05	0.32	0.23	Red blood cell count;	chr10:89571864	chr10:89645282~89650667:+
THCA	cis	rs613391	0.742	rs499501	ENSG00000224549.1	RP11-370B11.3	-5.06	5.92e-07	7.86e-05	-0.26	-0.23	Quantitative traits;	chr9:22688555	chr9:22767175~22768316:+
THCA	cis	rs1876905	0.539	rs240987	ENSG00000230177.1	RP5-1112D6.4	-5.06	5.92e-07	7.87e-05	-0.25	-0.23	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111277932~111278742:+
THCA	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	5.06	5.92e-07	7.87e-05	0.26	0.23	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
THCA	cis	rs34779708	0.966	rs2126984	ENSG00000271335.4	RP11-324I22.4	5.06	5.92e-07	7.87e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35314552~35336401:-
THCA	cis	rs7924176	0.521	rs7477710	ENSG00000213731.2	RAB5CP1	-5.06	5.92e-07	7.87e-05	-0.27	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.521	rs11000960	ENSG00000213731.2	RAB5CP1	-5.06	5.92e-07	7.87e-05	-0.27	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:74423435~74424014:-
THCA	cis	rs858239	0.601	rs12539331	ENSG00000226816.2	AC005082.12	5.06	5.92e-07	7.87e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23206013~23208045:+
THCA	cis	rs78487399	0.808	rs78481334	ENSG00000234936.1	AC010883.5	5.06	5.92e-07	7.87e-05	0.32	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43568996	chr2:43229573~43233394:+
THCA	cis	rs57221529	0.709	rs72707023	ENSG00000225138.6	CTD-2228K2.7	5.06	5.93e-07	7.87e-05	0.29	0.23	Lung disease severity in cystic fibrosis;	chr5:667505	chr5:473236~480884:+
THCA	cis	rs4915077	1	rs76134821	ENSG00000230489.1	VAV3-AS1	5.06	5.93e-07	7.88e-05	0.38	0.23	Hypothyroidism;	chr1:107815121	chr1:107964443~107994607:+
THCA	cis	rs911119	1	rs734801	ENSG00000270001.1	RP11-218C14.8	-5.06	5.93e-07	7.88e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23632154	chr20:23631826~23632316:-
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000176933.5	TOB2P1	-5.06	5.93e-07	7.88e-05	-0.25	-0.23	Pubertal anthropometrics;	chr6:28298372	chr6:28217643~28218634:-
THCA	cis	rs1005277	0.557	rs2983338	ENSG00000275858.1	RP11-291L22.8	5.06	5.93e-07	7.88e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38450738~38451069:-
THCA	cis	rs1479090	0.851	rs2320333	ENSG00000250027.1	RP11-563E2.2	-5.06	5.94e-07	7.88e-05	-0.24	-0.23	Lung cancer;	chr4:163108095	chr4:163108785~163119965:+
THCA	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-5.06	5.94e-07	7.89e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-5.06	5.94e-07	7.89e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-5.06	5.94e-07	7.89e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-5.06	5.94e-07	7.89e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-5.06	5.94e-07	7.89e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-5.06	5.94e-07	7.89e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-5.06	5.94e-07	7.89e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
THCA	cis	rs8028182	0.636	rs8028277	ENSG00000260274.1	RP11-817O13.8	5.06	5.94e-07	7.89e-05	0.16	0.23	Sudden cardiac arrest;	chr15:75391744	chr15:75368155~75369584:+
THCA	cis	rs35740288	0.787	rs2291048	ENSG00000259295.5	CSPG4P12	-5.06	5.94e-07	7.89e-05	-0.36	-0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682427	chr15:85191438~85213905:+
THCA	cis	rs79243044	0.965	rs1995157	ENSG00000224295.2	AC087380.14	-5.06	5.94e-07	7.89e-05	-0.23	-0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5544821	chr11:5518441~5524955:-
THCA	cis	rs651907	0.557	rs13077925	ENSG00000244119.1	PDCL3P4	5.06	5.94e-07	7.89e-05	0.21	0.23	Colorectal cancer;	chr3:101769337	chr3:101712472~101713191:+
THCA	cis	rs1395	0.925	rs1659701	ENSG00000234072.1	AC074117.10	5.06	5.94e-07	7.89e-05	0.19	0.23	Blood metabolite levels;	chr2:27192009	chr2:27356246~27367622:+
THCA	cis	rs7115242	0.8	rs1320668	ENSG00000280143.1	AP000892.6	5.06	5.94e-07	7.89e-05	0.37	0.23	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117204967~117210292:+
THCA	cis	rs13434995	0.513	rs880358	ENSG00000273257.1	RP11-177J6.1	-5.06	5.95e-07	7.9e-05	-0.34	-0.23	Adiponectin levels;	chr4:55410311	chr4:55387949~55388271:+
THCA	cis	rs6714710	0.603	rs35424768	ENSG00000230606.9	AC159540.1	-5.06	5.95e-07	7.9e-05	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97779190	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs13020776	ENSG00000230606.9	AC159540.1	-5.06	5.95e-07	7.9e-05	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786290	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs34502870	ENSG00000230606.9	AC159540.1	-5.06	5.95e-07	7.9e-05	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789466	chr2:97416165~97433527:-
THCA	cis	rs9283706	0.689	rs1030231	ENSG00000229666.1	MAST4-AS1	-5.06	5.95e-07	7.9e-05	-0.32	-0.23	Coronary artery disease;	chr5:67021437	chr5:67001383~67003953:-
THCA	cis	rs4834770	0.668	rs6833072	ENSG00000245958.5	RP11-33B1.1	5.06	5.95e-07	7.9e-05	0.22	0.23	Blood protein levels;	chr4:119212737	chr4:119454791~119552025:+
THCA	cis	rs5015933	0.788	rs13289976	ENSG00000232630.1	PRPS1P2	-5.06	5.95e-07	7.9e-05	-0.15	-0.23	Body mass index;	chr9:125293178	chr9:125150653~125151589:+
THCA	cis	rs1823913	0.637	rs2883912	ENSG00000280083.1	RP11-317J9.1	5.06	5.95e-07	7.9e-05	0.26	0.23	Obesity-related traits;	chr2:191284290	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.637	rs921737	ENSG00000280083.1	RP11-317J9.1	5.06	5.95e-07	7.9e-05	0.26	0.23	Obesity-related traits;	chr2:191286097	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs6736071	ENSG00000280083.1	RP11-317J9.1	5.06	5.95e-07	7.9e-05	0.26	0.23	Obesity-related traits;	chr2:191287265	chr2:191154118~191156070:-
THCA	cis	rs4664293	0.867	rs3771719	ENSG00000226266.5	AC009961.3	5.06	5.95e-07	7.9e-05	0.25	0.23	Monocyte percentage of white cells;	chr2:159774453	chr2:159670708~159712435:-
THCA	cis	rs1823913	0.637	rs11686185	ENSG00000280083.1	RP11-317J9.1	5.06	5.95e-07	7.9e-05	0.26	0.23	Obesity-related traits;	chr2:191289282	chr2:191154118~191156070:-
THCA	cis	rs17270561	0.887	rs12201170	ENSG00000272462.2	U91328.19	-5.06	5.95e-07	7.9e-05	-0.23	-0.23	Iron status biomarkers;	chr6:25866019	chr6:25992662~26001775:+
THCA	cis	rs875971	0.545	rs6979636	ENSG00000232546.1	RP11-458F8.1	5.06	5.95e-07	7.91e-05	0.22	0.23	Aortic root size;	chr7:66276638	chr7:66848496~66858136:+
THCA	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	5.06	5.96e-07	7.91e-05	0.29	0.23	Depression;	chr6:28323463	chr6:28943877~28944537:+
THCA	cis	rs8020095	0.571	rs9323491	ENSG00000258561.1	RP11-72M17.1	-5.06	5.96e-07	7.91e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67060518	chr14:66212810~66509394:-
THCA	cis	rs748802	0.675	rs10972638	ENSG00000235387.1	LINC00961	-5.06	5.96e-07	7.91e-05	-0.26	-0.23	Resting heart rate;	chr9:35948591	chr9:35909483~35911686:+
THCA	cis	rs1005277	0.579	rs932538	ENSG00000275858.1	RP11-291L22.8	5.06	5.96e-07	7.91e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.541	rs2472177	ENSG00000275858.1	RP11-291L22.8	5.06	5.96e-07	7.91e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2472178	ENSG00000275858.1	RP11-291L22.8	5.06	5.96e-07	7.91e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474572	ENSG00000275858.1	RP11-291L22.8	5.06	5.96e-07	7.91e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2505198	ENSG00000275858.1	RP11-291L22.8	5.06	5.96e-07	7.91e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38450738~38451069:-
THCA	cis	rs6840360	0.681	rs4519779	ENSG00000270265.1	RP11-731D1.4	-5.06	5.96e-07	7.91e-05	-0.21	-0.23	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151333775~151353224:-
THCA	cis	rs12893668	0.542	rs12884809	ENSG00000269958.1	RP11-73M18.8	5.06	5.96e-07	7.91e-05	0.22	0.23	Reticulocyte count;	chr14:103628983	chr14:103696353~103697163:+
THCA	cis	rs34792	0.688	rs13339072	ENSG00000207425.1	Y_RNA	-5.06	5.96e-07	7.92e-05	-0.25	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15504090	chr16:14915457~14915556:-
THCA	cis	rs7824557	0.614	rs2736277	ENSG00000154316.13	TDH	5.06	5.96e-07	7.92e-05	0.17	0.23	Retinal vascular caliber;	chr8:11361384	chr8:11339637~11368452:+
THCA	cis	rs7809615	0.901	rs6947941	ENSG00000244219.5	GS1-259H13.2	-5.06	5.96e-07	7.92e-05	-0.41	-0.23	Blood metabolite ratios;	chr7:99558823	chr7:99598066~99610813:+
THCA	cis	rs7809615	0.901	rs17161761	ENSG00000244219.5	GS1-259H13.2	-5.06	5.96e-07	7.92e-05	-0.41	-0.23	Blood metabolite ratios;	chr7:99559311	chr7:99598066~99610813:+
THCA	cis	rs7618915	0.547	rs10865973	ENSG00000243224.1	RP5-1157M23.2	-5.06	5.96e-07	7.92e-05	-0.25	-0.23	Bipolar disorder;	chr3:52684138	chr3:52239258~52241097:+
THCA	cis	rs2243480	0.908	rs313822	ENSG00000230295.1	RP11-458F8.2	-5.06	5.97e-07	7.92e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:66108952	chr7:66880708~66882981:+
THCA	cis	rs6472827	0.645	rs2956052	ENSG00000253983.2	RP1-16A9.1	5.06	5.97e-07	7.92e-05	0.33	0.23	Uterine fibroids;	chr8:74200423	chr8:74199396~74208441:+
THCA	cis	rs11648785	0.81	rs4354938	ENSG00000222019.6	URAHP	5.06	5.97e-07	7.92e-05	0.19	0.23	Tanning;	chr16:90032420	chr16:90039761~90047773:-
THCA	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-5.06	5.97e-07	7.92e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
THCA	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-5.06	5.97e-07	7.92e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
THCA	cis	rs10510102	0.688	rs11812208	ENSG00000226864.1	ATE1-AS1	5.06	5.97e-07	7.93e-05	0.37	0.23	Breast cancer;	chr10:121924831	chr10:121928312~121951965:+
THCA	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-5.06	5.97e-07	7.93e-05	-0.27	-0.23	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
THCA	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	5.06	5.98e-07	7.93e-05	0.27	0.23	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
THCA	cis	rs34779708	0.966	rs1478463	ENSG00000271335.4	RP11-324I22.4	5.06	5.98e-07	7.93e-05	0.22	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35314552~35336401:-
THCA	cis	rs9307551	0.948	rs11941782	ENSG00000250334.4	LINC00989	-5.06	5.98e-07	7.94e-05	-0.29	-0.23	Refractive error;	chr4:79562385	chr4:79492416~79576460:+
THCA	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	5.06	5.98e-07	7.94e-05	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
THCA	cis	rs12900463	0.813	rs187316	ENSG00000225151.9	GOLGA2P7	-5.06	5.98e-07	7.94e-05	-0.33	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862764	chr15:84199311~84230136:-
THCA	cis	rs1979679	0.918	rs786711	ENSG00000278733.1	RP11-425D17.1	5.06	5.98e-07	7.94e-05	0.23	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28406330	chr12:28185625~28186190:-
THCA	cis	rs1552244	0.832	rs66597916	ENSG00000232901.1	CYCSP10	5.06	5.98e-07	7.94e-05	0.31	0.23	Alzheimer's disease;	chr3:10153723	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.832	rs115415687	ENSG00000232901.1	CYCSP10	5.06	5.98e-07	7.94e-05	0.31	0.23	Alzheimer's disease;	chr3:10154020	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.832	rs73024575	ENSG00000232901.1	CYCSP10	5.06	5.98e-07	7.94e-05	0.31	0.23	Alzheimer's disease;	chr3:10156516	chr3:10000647~10000940:-
THCA	cis	rs7429990	0.932	rs11130155	ENSG00000228638.1	FCF1P2	5.06	5.98e-07	7.94e-05	0.22	0.23	Educational attainment (years of education);	chr3:48098938	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.901	rs6442102	ENSG00000228638.1	FCF1P2	5.06	5.98e-07	7.94e-05	0.22	0.23	Educational attainment (years of education);	chr3:48111072	chr3:48290793~48291375:-
THCA	cis	rs1005277	0.505	rs200910	ENSG00000276805.1	RP11-291L22.6	5.06	5.99e-07	7.95e-05	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38451030~38451785:+
THCA	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-5.06	5.99e-07	7.95e-05	-0.29	-0.23	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
THCA	cis	rs4934494	0.591	rs7476027	ENSG00000232936.4	RP11-80H5.2	5.06	5.99e-07	7.95e-05	0.31	0.23	Red blood cell count;	chr10:89621164	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185808	ENSG00000232936.4	RP11-80H5.2	5.06	5.99e-07	7.95e-05	0.31	0.23	Red blood cell count;	chr10:89621353	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185809	ENSG00000232936.4	RP11-80H5.2	5.06	5.99e-07	7.95e-05	0.31	0.23	Red blood cell count;	chr10:89621474	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.677	rs11185810	ENSG00000232936.4	RP11-80H5.2	5.06	5.99e-07	7.95e-05	0.31	0.23	Red blood cell count;	chr10:89621724	chr10:89645282~89650667:+
THCA	cis	rs12188164	0.561	rs2251843	ENSG00000221990.4	EXOC3-AS1	5.06	5.99e-07	7.95e-05	0.18	0.23	Cystic fibrosis severity;	chr5:457840	chr5:441498~443160:-
THCA	cis	rs1005277	0.579	rs2474608	ENSG00000272983.1	RP11-508N22.12	5.06	5.99e-07	7.95e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38137337~38144399:+
THCA	cis	rs12413361	0.583	rs7089982	ENSG00000272914.1	RP11-330O11.3	5.06	5.99e-07	7.95e-05	0.2	0.23	Height;	chr10:30830293	chr10:30831828~30833387:-
THCA	cis	rs73108077	0.736	rs6057603	ENSG00000277112.2	RP11-755J8.1	5.06	5.99e-07	7.95e-05	0.35	0.23	Red blood cell density in sickle cell anemia;	chr20:31354892	chr20:30681825~30723932:-
THCA	cis	rs919433	0.854	rs13013049	ENSG00000231621.1	AC013264.2	5.06	5.99e-07	7.95e-05	0.24	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343940	chr2:197197991~197199273:+
THCA	cis	rs7688540	0.8	rs10023604	ENSG00000275426.1	CH17-262A2.1	5.06	5.99e-07	7.96e-05	0.28	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:149738~150317:+
THCA	cis	rs12413361	1	rs12413361	ENSG00000272914.1	RP11-330O11.3	-5.06	5.99e-07	7.96e-05	-0.2	-0.23	Height;	chr10:30838237	chr10:30831828~30833387:-
THCA	cis	rs1005277	0.505	rs1208689	ENSG00000276805.1	RP11-291L22.6	5.06	6e-07	7.96e-05	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38451030~38451785:+
THCA	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	5.06	6e-07	7.96e-05	0.3	0.23	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
THCA	cis	rs7119	0.717	rs12917175	ENSG00000259362.2	RP11-307C19.1	-5.06	6e-07	7.96e-05	-0.32	-0.23	Type 2 diabetes;	chr15:77525851	chr15:77525540~77534110:+
THCA	cis	rs375066	0.592	rs349046	ENSG00000267058.1	RP11-15A1.3	5.06	6e-07	7.96e-05	0.2	0.23	Breast cancer;	chr19:43796474	chr19:43891804~43901805:-
THCA	cis	rs11118620	1	rs11118620	ENSG00000257551.1	HLX-AS1	5.06	6e-07	7.97e-05	0.31	0.23	Heart failure;	chr1:220855166	chr1:220832763~220880140:-
THCA	cis	rs7429990	0.864	rs13098128	ENSG00000228638.1	FCF1P2	5.06	6e-07	7.97e-05	0.22	0.23	Educational attainment (years of education);	chr3:47756066	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7637950	ENSG00000228638.1	FCF1P2	5.06	6e-07	7.97e-05	0.22	0.23	Educational attainment (years of education);	chr3:47758204	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs6442085	ENSG00000228638.1	FCF1P2	5.06	6e-07	7.97e-05	0.22	0.23	Educational attainment (years of education);	chr3:47760080	chr3:48290793~48291375:-
THCA	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-5.06	6e-07	7.97e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
THCA	cis	rs987724	0.502	rs4680320	ENSG00000240875.4	LINC00886	-5.06	6.01e-07	7.97e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156955813	chr3:156747346~156817062:-
THCA	cis	rs73242632	1	rs2276896	ENSG00000269949.1	RP11-738E22.3	5.06	6.01e-07	7.97e-05	0.52	0.23	Congenital heart disease (maternal effect);	chr4:56978925	chr4:56960927~56961373:-
THCA	cis	rs6832769	1	rs1522111	ENSG00000272969.1	RP11-528I4.2	5.06	6.01e-07	7.97e-05	0.27	0.23	Personality dimensions;	chr4:55463396	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs35767091	ENSG00000272969.1	RP11-528I4.2	5.06	6.01e-07	7.97e-05	0.27	0.23	Personality dimensions;	chr4:55480556	chr4:55547112~55547889:+
THCA	cis	rs7618915	0.57	rs2336145	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.01e-07	7.97e-05	-0.25	-0.23	Bipolar disorder;	chr3:52595734	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs12486847	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.01e-07	7.97e-05	-0.25	-0.23	Bipolar disorder;	chr3:52657096	chr3:52239258~52241097:+
THCA	cis	rs12428035	0.649	rs11618323	ENSG00000247400.3	DNAJC3-AS1	-5.06	6.01e-07	7.97e-05	-0.22	-0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95684096	chr13:95648733~95676925:-
THCA	cis	rs1876905	0.539	rs240985	ENSG00000271789.1	RP5-1112D6.7	5.06	6.01e-07	7.97e-05	0.31	0.23	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111297126~111298510:+
THCA	cis	rs1005277	0.579	rs2103938	ENSG00000275858.1	RP11-291L22.8	5.06	6.01e-07	7.97e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38450738~38451069:-
THCA	cis	rs10895322	0.656	rs3781788	ENSG00000281655.1	RP11-817J15.3	-5.06	6.01e-07	7.98e-05	-0.28	-0.23	Neuroblastoma (11q deletion);	chr11:102606825	chr11:102681310~102683913:+
THCA	cis	rs5758511	0.68	rs5758652	ENSG00000281538.1	RP4-669P10.20	-5.06	6.01e-07	7.98e-05	-0.26	-0.23	Birth weight;	chr22:42216402	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.68	rs1033460	ENSG00000281538.1	RP4-669P10.20	-5.06	6.01e-07	7.98e-05	-0.26	-0.23	Birth weight;	chr22:42223302	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.679	rs55867855	ENSG00000281538.1	RP4-669P10.20	-5.06	6.01e-07	7.98e-05	-0.26	-0.23	Birth weight;	chr22:42227252	chr22:42138060~42139726:+
THCA	cis	rs228614	0.536	rs223375	ENSG00000248971.2	KRT8P46	-5.06	6.01e-07	7.98e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102728746~102730171:-
THCA	cis	rs3734266	0.702	rs36032186	ENSG00000272288.4	RP11-140K17.3	-5.06	6.01e-07	7.98e-05	-0.23	-0.23	Systemic lupus erythematosus;	chr6:34606163	chr6:34696317~34697470:+
THCA	cis	rs451417	0.818	rs236111	ENSG00000275632.1	RP5-967N21.11	5.06	6.01e-07	7.98e-05	0.3	0.23	Menopause (age at onset);	chr20:5952889	chr20:6000418~6000941:+
THCA	cis	rs2251381	0.75	rs2255055	ENSG00000176054.6	RPL23P2	5.06	6.01e-07	7.98e-05	0.2	0.23	Selective IgA deficiency;	chr21:29164724	chr21:28997613~28998033:-
THCA	cis	rs12143943	0.835	rs12402641	ENSG00000240219.1	RP11-430C7.5	5.06	6.01e-07	7.98e-05	0.2	0.23	Cognitive performance;	chr1:204483651	chr1:204626775~204629712:+
THCA	cis	rs4409675	0.826	rs17257252	ENSG00000227050.1	RP11-460I13.2	5.06	6.01e-07	7.98e-05	0.35	0.23	Corneal astigmatism;	chr1:27893973	chr1:27938875~27960193:-
THCA	cis	rs9634489	0.645	rs1925102	ENSG00000247400.3	DNAJC3-AS1	-5.06	6.02e-07	7.98e-05	-0.15	-0.23	Body mass index;	chr13:96368513	chr13:95648733~95676925:-
THCA	cis	rs17772222	1	rs12433464	ENSG00000222990.1	RNU4-22P	5.06	6.02e-07	7.98e-05	0.3	0.23	Coronary artery calcification;	chr14:88357671	chr14:88513498~88513663:+
THCA	cis	rs79243044	1	rs1995156	ENSG00000224295.2	AC087380.14	-5.06	6.02e-07	7.98e-05	-0.23	-0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5544882	chr11:5518441~5524955:-
THCA	cis	rs7809615	0.901	rs6947974	ENSG00000244219.5	GS1-259H13.2	-5.06	6.02e-07	7.98e-05	-0.4	-0.23	Blood metabolite ratios;	chr7:99558883	chr7:99598066~99610813:+
THCA	cis	rs62025270	0.547	rs386346	ENSG00000202081.1	RNU6-1280P	-5.06	6.02e-07	7.98e-05	-0.31	-0.23	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85651522~85651628:-
THCA	cis	rs338389	0.542	rs12594726	ENSG00000260657.2	RP11-315D16.4	-5.06	6.02e-07	7.98e-05	-0.31	-0.23	Survival in rectal cancer;	chr15:67994440	chr15:68267792~68277994:-
THCA	cis	rs972578	0.668	rs4820487	ENSG00000274717.1	RP1-47A17.1	-5.06	6.02e-07	7.98e-05	-0.24	-0.23	Mean platelet volume;	chr22:42842049	chr22:42791814~42794313:-
THCA	cis	rs12462428	0.876	rs5002162	ENSG00000279748.1	CTD-3222D19.9	5.06	6.02e-07	7.99e-05	0.25	0.23	Educational attainment (years of education);	chr19:16627558	chr19:16586905~16589409:+
THCA	cis	rs7727544	0.557	rs715285	ENSG00000224431.1	AC063976.7	5.06	6.02e-07	7.99e-05	0.19	0.23	Blood metabolite levels;	chr5:132149690	chr5:132199456~132203487:+
THCA	cis	rs763121	0.819	rs5757160	ENSG00000228274.3	RP3-508I15.9	-5.06	6.02e-07	7.99e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38593641	chr22:38667585~38681820:-
THCA	cis	rs7618915	0.547	rs11720432	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.02e-07	7.99e-05	-0.25	-0.23	Bipolar disorder;	chr3:52638726	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.524	rs2028216	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.02e-07	7.99e-05	-0.25	-0.23	Bipolar disorder;	chr3:52646807	chr3:52239258~52241097:+
THCA	cis	rs17301013	0.932	rs6425281	ENSG00000227373.4	RP11-160H22.5	5.06	6.02e-07	7.99e-05	0.32	0.23	Systemic lupus erythematosus;	chr1:174449784	chr1:174115300~174160004:-
THCA	cis	rs7942368	0.818	rs10793194	ENSG00000261578.1	RP11-21L23.2	5.06	6.03e-07	7.99e-05	0.33	0.23	Endometriosis;	chr11:76764685	chr11:76800364~76804555:+
THCA	cis	rs748404	0.666	rs514438	ENSG00000249839.1	AC011330.5	-5.06	6.03e-07	7.99e-05	-0.31	-0.23	Lung cancer;	chr15:43328245	chr15:43663654~43684339:-
THCA	cis	rs4218	0.517	rs2899640	ENSG00000259732.1	RP11-59H7.3	-5.06	6.03e-07	7.99e-05	-0.32	-0.23	Social communication problems;	chr15:59060281	chr15:59121034~59133250:+
THCA	cis	rs957448	1	rs55897841	ENSG00000253175.1	RP11-267M23.6	5.06	6.03e-07	7.99e-05	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94565036~94565715:+
THCA	cis	rs957448	0.948	rs72674867	ENSG00000253175.1	RP11-267M23.6	5.06	6.03e-07	7.99e-05	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94565036~94565715:+
THCA	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-5.06	6.03e-07	8e-05	-0.24	-0.23	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
THCA	cis	rs28510890	0.52	rs72753777	ENSG00000260337.3	RP11-386M24.6	5.06	6.03e-07	8e-05	0.26	0.23	Lung cancer in ever smokers;	chr15:92562670	chr15:92592574~92596462:-
THCA	cis	rs2239547	0.521	rs9682464	ENSG00000242142.1	SERBP1P3	5.06	6.03e-07	8e-05	0.28	0.23	Schizophrenia;	chr3:52854469	chr3:53064283~53065091:-
THCA	cis	rs72772090	0.708	rs17082200	ENSG00000248734.2	CTD-2260A17.1	-5.06	6.03e-07	8e-05	-0.37	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96712900	chr5:96784777~96785999:+
THCA	cis	rs2243480	1	rs67536397	ENSG00000230295.1	RP11-458F8.2	-5.06	6.03e-07	8e-05	-0.29	-0.23	Diabetic kidney disease;	chr7:66482930	chr7:66880708~66882981:+
THCA	cis	rs73198271	0.74	rs10109886	ENSG00000253893.2	FAM85B	5.06	6.03e-07	8e-05	0.33	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8167819~8226614:-
THCA	cis	rs7429990	0.932	rs13085054	ENSG00000228638.1	FCF1P2	5.06	6.04e-07	8.01e-05	0.22	0.23	Educational attainment (years of education);	chr3:48092647	chr3:48290793~48291375:-
THCA	cis	rs2803122	0.838	rs10757033	ENSG00000273226.1	RP11-513M16.8	-5.06	6.04e-07	8.01e-05	-0.21	-0.23	Pulse pressure;	chr9:19223306	chr9:19375451~19375996:+
THCA	cis	rs1005277	0.579	rs1621040	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780136	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780138	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780139	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.602	rs1780141	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.541	rs1740741	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.528	rs2057228	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1740742	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.602	rs1740743	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1740745	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1740747	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1740749	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780115	ENSG00000275858.1	RP11-291L22.8	5.06	6.04e-07	8.02e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38450738~38451069:-
THCA	cis	rs1552244	1	rs7615764	ENSG00000180385.7	EMC3-AS1	5.06	6.05e-07	8.02e-05	0.25	0.23	Alzheimer's disease;	chr3:10040908	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs35220123	ENSG00000180385.7	EMC3-AS1	5.06	6.05e-07	8.02e-05	0.25	0.23	Alzheimer's disease;	chr3:10041485	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.935	rs4441636	ENSG00000180385.7	EMC3-AS1	5.06	6.05e-07	8.02e-05	0.25	0.23	Alzheimer's disease;	chr3:10042192	chr3:9986893~10006990:+
THCA	cis	rs7577696	0.925	rs12617290	ENSG00000276334.1	AL133243.1	-5.06	6.05e-07	8.02e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32116339	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.925	rs7573543	ENSG00000276334.1	AL133243.1	-5.06	6.05e-07	8.02e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32117439	chr2:32521927~32523547:+
THCA	cis	rs4713118	0.662	rs464312	ENSG00000272009.1	RP1-313I6.12	-5.06	6.05e-07	8.02e-05	-0.25	-0.23	Parkinson's disease;	chr6:27999813	chr6:28078792~28081130:-
THCA	cis	rs919433	0.783	rs55725278	ENSG00000231621.1	AC013264.2	-5.06	6.05e-07	8.02e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373499	chr2:197197991~197199273:+
THCA	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	5.06	6.05e-07	8.02e-05	0.32	0.23	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
THCA	cis	rs2440129	0.611	rs2292352	ENSG00000262089.1	RP11-589P10.5	5.06	6.06e-07	8.03e-05	0.21	0.23	Tonsillectomy;	chr17:6999568	chr17:6994642~6995189:-
THCA	cis	rs4718428	1	rs1830070	ENSG00000230295.1	RP11-458F8.2	-5.06	6.06e-07	8.03e-05	-0.18	-0.23	Corneal structure;	chr7:66884684	chr7:66880708~66882981:+
THCA	cis	rs62158800	0.85	rs11897300	ENSG00000237880.1	AC096669.2	5.06	6.06e-07	8.03e-05	0.32	0.23	Facial morphology (factor 22);	chr2:107653102	chr2:107385632~107542649:-
THCA	cis	rs748404	0.626	rs62021176	ENSG00000205771.5	CATSPER2P1	-5.06	6.06e-07	8.03e-05	-0.29	-0.23	Lung cancer;	chr15:43388014	chr15:43726918~43747094:-
THCA	cis	rs17767392	0.958	rs10483836	ENSG00000259146.3	RP1-261D10.2	5.06	6.06e-07	8.03e-05	0.29	0.23	Mitral valve prolapse;	chr14:71534897	chr14:71292729~71321814:-
THCA	cis	rs6430585	0.583	rs59243420	ENSG00000231890.6	DARS-AS1	-5.06	6.06e-07	8.03e-05	-0.28	-0.23	Corneal structure;	chr2:135826968	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.583	rs58116536	ENSG00000231890.6	DARS-AS1	-5.06	6.06e-07	8.03e-05	-0.28	-0.23	Corneal structure;	chr2:135827753	chr2:135985176~136022593:+
THCA	cis	rs8028313	0.731	rs6494678	ENSG00000270964.1	RP11-502I4.3	-5.06	6.06e-07	8.04e-05	-0.2	-0.23	Obesity;	chr15:67653909	chr15:67541072~67542604:-
THCA	cis	rs7577696	0.962	rs2235134	ENSG00000276334.1	AL133243.1	-5.06	6.07e-07	8.04e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32107474	chr2:32521927~32523547:+
THCA	cis	rs4693089	0.584	rs781816	ENSG00000213608.5	SLC25A14P1	-5.06	6.07e-07	8.04e-05	-0.26	-0.23	Menopause (age at onset);	chr4:83503129	chr4:83477524~83478424:+
THCA	cis	rs2282300	0.739	rs1765133	ENSG00000242353.1	RP4-710M3.1	-5.06	6.07e-07	8.04e-05	-0.22	-0.23	Morning vs. evening chronotype;	chr11:30317853	chr11:30368148~30368646:+
THCA	cis	rs2562456	0.839	rs2562411	ENSG00000268119.4	CTD-2561J22.5	5.06	6.07e-07	8.04e-05	0.32	0.23	Pain;	chr19:21419181	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.876	rs2562413	ENSG00000268119.4	CTD-2561J22.5	5.06	6.07e-07	8.04e-05	0.32	0.23	Pain;	chr19:21420084	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.916	rs1967182	ENSG00000268119.4	CTD-2561J22.5	5.06	6.07e-07	8.04e-05	0.32	0.23	Pain;	chr19:21420337	chr19:21444241~21463908:-
THCA	cis	rs7618915	0.524	rs12488461	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.07e-07	8.05e-05	-0.25	-0.23	Bipolar disorder;	chr3:52664401	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs6768697	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.07e-07	8.05e-05	-0.25	-0.23	Bipolar disorder;	chr3:52669599	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs34610142	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.07e-07	8.05e-05	-0.25	-0.23	Bipolar disorder;	chr3:52674413	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs12496476	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.07e-07	8.05e-05	-0.25	-0.23	Bipolar disorder;	chr3:52674721	chr3:52239258~52241097:+
THCA	cis	rs763121	0.853	rs6001173	ENSG00000273076.1	RP3-508I15.22	5.06	6.07e-07	8.05e-05	0.23	0.23	Menopause (age at onset);	chr22:38619297	chr22:38743495~38743910:+
THCA	cis	rs8027521	0.557	rs16973888	ENSG00000280362.1	RP11-643A5.3	5.06	6.07e-07	8.05e-05	0.28	0.23	Circulating chemerin levels;	chr15:53953244	chr15:53910769~53914712:+
THCA	cis	rs1552244	1	rs12152512	ENSG00000180385.7	EMC3-AS1	5.06	6.08e-07	8.05e-05	0.25	0.23	Alzheimer's disease;	chr3:10102086	chr3:9986893~10006990:+
THCA	cis	rs1552244	1	rs12152515	ENSG00000180385.7	EMC3-AS1	5.06	6.08e-07	8.05e-05	0.25	0.23	Alzheimer's disease;	chr3:10102292	chr3:9986893~10006990:+
THCA	cis	rs631288	0.557	rs920682	ENSG00000226015.2	CCT8P1	5.06	6.08e-07	8.05e-05	0.5	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr1:147185944	chr1:147203276~147204932:-
THCA	cis	rs631288	0.557	rs6697092	ENSG00000226015.2	CCT8P1	5.06	6.08e-07	8.05e-05	0.5	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr1:147187698	chr1:147203276~147204932:-
THCA	cis	rs631288	0.557	rs894467	ENSG00000226015.2	CCT8P1	5.06	6.08e-07	8.05e-05	0.5	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr1:147190439	chr1:147203276~147204932:-
THCA	cis	rs631288	0.557	rs894470	ENSG00000226015.2	CCT8P1	5.06	6.08e-07	8.05e-05	0.5	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr1:147200366	chr1:147203276~147204932:-
THCA	cis	rs631288	0.557	rs7546434	ENSG00000226015.2	CCT8P1	5.06	6.08e-07	8.05e-05	0.5	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr1:147204758	chr1:147203276~147204932:-
THCA	cis	rs631288	0.557	rs2354434	ENSG00000226015.2	CCT8P1	5.06	6.08e-07	8.05e-05	0.5	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr1:147207869	chr1:147203276~147204932:-
THCA	cis	rs224278	0.624	rs2136613	ENSG00000238280.1	RP11-436D10.3	-5.06	6.08e-07	8.06e-05	-0.26	-0.23	Ewing sarcoma;	chr10:62834404	chr10:62793562~62805887:-
THCA	cis	rs12135996	0.691	rs12130871	ENSG00000232879.2	RP11-544M22.3	-5.06	6.08e-07	8.06e-05	-0.25	-0.23	Night sleep phenotypes;	chr1:161056700	chr1:161034834~161035006:+
THCA	cis	rs600231	0.577	rs12269965	ENSG00000245532.5	NEAT1	5.06	6.08e-07	8.06e-05	0.2	0.23	Bone mineral density;	chr11:65464616	chr11:65422774~65445540:+
THCA	cis	rs2749592	1	rs2749592	ENSG00000263064.2	RP11-291L22.7	5.06	6.08e-07	8.06e-05	0.28	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37969914	chr10:38448689~38448949:+
THCA	cis	rs7267979	0.932	rs431579	ENSG00000274973.1	RP13-401N8.7	-5.06	6.09e-07	8.06e-05	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25845497~25845862:+
THCA	cis	rs6044112	1	rs6075069	ENSG00000273998.1	RP4-777L9.2	-5.06	6.09e-07	8.06e-05	-0.36	-0.23	Response to taxane treatment (docetaxel);	chr20:16548269	chr20:16576068~16579615:+
THCA	cis	rs12143943	0.966	rs2169136	ENSG00000240219.1	RP11-430C7.5	5.06	6.09e-07	8.07e-05	0.19	0.23	Cognitive performance;	chr1:204595109	chr1:204626775~204629712:+
THCA	cis	rs12143943	0.966	rs11240762	ENSG00000240219.1	RP11-430C7.5	5.06	6.09e-07	8.07e-05	0.19	0.23	Cognitive performance;	chr1:204597871	chr1:204626775~204629712:+
THCA	cis	rs2797160	1	rs2211419	ENSG00000237742.5	RP11-624M8.1	5.06	6.09e-07	8.07e-05	0.19	0.23	Endometrial cancer;	chr6:125674387	chr6:125578558~125749190:-
THCA	cis	rs72615157	0.612	rs7786505	ENSG00000078319.8	PMS2P1	-5.06	6.09e-07	8.07e-05	-0.29	-0.23	Lung function (FEV1/FVC);	chr7:100219962	chr7:100320992~100341908:-
THCA	cis	rs72615157	0.613	rs56089143	ENSG00000078319.8	PMS2P1	-5.06	6.09e-07	8.07e-05	-0.29	-0.23	Lung function (FEV1/FVC);	chr7:100222221	chr7:100320992~100341908:-
THCA	cis	rs72615157	0.664	rs6953580	ENSG00000078319.8	PMS2P1	-5.06	6.09e-07	8.07e-05	-0.29	-0.23	Lung function (FEV1/FVC);	chr7:100227652	chr7:100320992~100341908:-
THCA	cis	rs4713118	0.662	rs149970	ENSG00000272009.1	RP1-313I6.12	-5.06	6.1e-07	8.07e-05	-0.24	-0.23	Parkinson's disease;	chr6:28012442	chr6:28078792~28081130:-
THCA	cis	rs16852403	0.517	rs12032786	ENSG00000224687.1	RASAL2-AS1	5.06	6.1e-07	8.08e-05	0.34	0.23	Childhood ear infection;	chr1:178267041	chr1:178091508~178093984:-
THCA	cis	rs412050	0.547	rs78907487	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	6.1e-07	8.08e-05	-0.41	-0.23	Attention deficit hyperactivity disorder;	chr22:21797650	chr22:21938293~21977632:+
THCA	cis	rs412050	0.547	rs17821500	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	6.1e-07	8.08e-05	-0.41	-0.23	Attention deficit hyperactivity disorder;	chr22:21798191	chr22:21938293~21977632:+
THCA	cis	rs412050	0.547	rs76200689	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	6.1e-07	8.08e-05	-0.41	-0.23	Attention deficit hyperactivity disorder;	chr22:21800355	chr22:21938293~21977632:+
THCA	cis	rs2439831	0.867	rs12323999	ENSG00000205771.5	CATSPER2P1	-5.06	6.1e-07	8.08e-05	-0.3	-0.23	Lung cancer in ever smokers;	chr15:43390917	chr15:43726918~43747094:-
THCA	cis	rs494453	0.677	rs548200	ENSG00000227811.2	FAM212B-AS1	5.06	6.1e-07	8.08e-05	0.3	0.23	Osteoporosis-related phenotypes;	chr1:111633409	chr1:111739841~111747798:+
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000273796.1	LL21NC02-21A1.1	-5.06	6.11e-07	8.09e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000273796.1	LL21NC02-21A1.1	-5.06	6.11e-07	8.09e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000273796.1	LL21NC02-21A1.1	-5.06	6.11e-07	8.09e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000273796.1	LL21NC02-21A1.1	-5.06	6.11e-07	8.09e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000273796.1	LL21NC02-21A1.1	-5.06	6.11e-07	8.09e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45403809~45404369:-
THCA	cis	rs1552244	0.554	rs6762397	ENSG00000180385.7	EMC3-AS1	5.06	6.11e-07	8.09e-05	0.23	0.23	Alzheimer's disease;	chr3:9966156	chr3:9986893~10006990:+
THCA	cis	rs55704346	0.703	rs112804393	ENSG00000281501.1	SEPSECS-AS1	5.06	6.11e-07	8.09e-05	0.25	0.23	Tonsillectomy;	chr4:25129600	chr4:25160641~25201440:+
THCA	cis	rs7429990	0.864	rs13061412	ENSG00000228638.1	FCF1P2	5.06	6.11e-07	8.09e-05	0.22	0.23	Educational attainment (years of education);	chr3:47660092	chr3:48290793~48291375:-
THCA	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	5.06	6.11e-07	8.09e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
THCA	cis	rs6430538	0.597	rs6731271	ENSG00000224043.6	CCNT2-AS1	-5.06	6.11e-07	8.09e-05	-0.24	-0.23	Parkinson's disease;	chr2:134802502	chr2:134735464~134918710:-
THCA	cis	rs763121	0.853	rs6001175	ENSG00000235209.1	CTA-150C2.13	5.06	6.11e-07	8.09e-05	0.29	0.23	Menopause (age at onset);	chr22:38622329	chr22:38921227~38924708:+
THCA	cis	rs972578	0.692	rs9607978	ENSG00000274717.1	RP1-47A17.1	-5.06	6.11e-07	8.1e-05	-0.23	-0.23	Mean platelet volume;	chr22:42888328	chr22:42791814~42794313:-
THCA	cis	rs9863	0.931	rs3186071	ENSG00000269997.1	RP11-214K3.21	-5.06	6.11e-07	8.1e-05	-0.28	-0.23	White blood cell count;	chr12:123944732	chr12:123966077~123966629:-
THCA	cis	rs752010	0.841	rs17363834	ENSG00000230638.4	RP11-486B10.4	-5.06	6.12e-07	8.1e-05	-0.24	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41610936	chr1:41542069~41544310:+
THCA	cis	rs4767841	1	rs4767841	ENSG00000248636.5	RP11-768F21.1	-5.06	6.12e-07	8.1e-05	-0.24	-0.23	Urgency urinary incontinence;	chr12:119724394	chr12:119387987~119668079:-
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000273796.1	LL21NC02-21A1.1	-5.06	6.12e-07	8.1e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45403809~45404369:-
THCA	cis	rs11671005	0.695	rs11673069	ENSG00000268912.1	CTD-2619J13.17	-5.06	6.12e-07	8.1e-05	-0.22	-0.23	Mean platelet volume;	chr19:58423551	chr19:58428632~58431148:-
THCA	cis	rs35160687	0.623	rs1863060	ENSG00000273080.1	RP11-301O19.1	-5.06	6.12e-07	8.1e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86284333	chr2:86195590~86196049:+
THCA	cis	rs2797160	1	rs1935774	ENSG00000237742.5	RP11-624M8.1	5.06	6.12e-07	8.1e-05	0.2	0.23	Endometrial cancer;	chr6:125675515	chr6:125578558~125749190:-
THCA	cis	rs9929218	0.581	rs4783676	ENSG00000260459.2	FTLP14	5.06	6.12e-07	8.1e-05	0.26	0.23	Colorectal cancer;	chr16:68767174	chr16:68822587~68823070:+
THCA	cis	rs12681287	0.927	rs2953517	ENSG00000254231.1	CTD-2284J15.1	5.06	6.12e-07	8.11e-05	0.25	0.23	Caudate activity during reward;	chr8:86319784	chr8:86333274~86343314:-
THCA	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	5.06	6.12e-07	8.11e-05	0.3	0.23	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
THCA	cis	rs9300255	0.596	rs7304782	ENSG00000256092.2	RP13-942N8.1	-5.06	6.12e-07	8.11e-05	-0.17	-0.23	Neutrophil percentage of white cells;	chr12:123234897	chr12:123363868~123366113:+
THCA	cis	rs3213758	1	rs79490448	ENSG00000275191.1	RP11-36I17.2	-5.06	6.13e-07	8.11e-05	-0.46	-0.23	Vitiligo (non-segmental);	chr16:53572659	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs75678295	ENSG00000275191.1	RP11-36I17.2	-5.06	6.13e-07	8.11e-05	-0.46	-0.23	Vitiligo (non-segmental);	chr16:53573184	chr16:53628256~53628816:-
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000164669.11	INTS4P1	5.06	6.13e-07	8.11e-05	0.45	0.23	Diabetic kidney disease;	chr7:65946971	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs2961102	ENSG00000164669.11	INTS4P1	5.06	6.13e-07	8.11e-05	0.45	0.23	Diabetic kidney disease;	chr7:65959671	chr7:65141225~65234216:+
THCA	cis	rs10266483	0.921	rs624257	ENSG00000228653.2	HNRNPCP7	5.06	6.13e-07	8.11e-05	0.19	0.23	Response to statin therapy;	chr7:64284848	chr7:64500825~64501729:+
THCA	cis	rs317689	0.69	rs595348	ENSG00000274979.1	RP11-1143G9.5	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Response to diuretic therapy;	chr12:69244830	chr12:69326574~69331882:-
THCA	cis	rs317689	0.6	rs478863	ENSG00000274979.1	RP11-1143G9.5	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Response to diuretic therapy;	chr12:69245427	chr12:69326574~69331882:-
THCA	cis	rs317689	0.6	rs478188	ENSG00000274979.1	RP11-1143G9.5	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Response to diuretic therapy;	chr12:69245435	chr12:69326574~69331882:-
THCA	cis	rs7394190	0.748	rs11000777	ENSG00000271816.1	BMS1P4	-5.06	6.13e-07	8.12e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73785305	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs79936644	ENSG00000271816.1	BMS1P4	-5.06	6.13e-07	8.12e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73785359	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs4114992	ENSG00000271816.1	BMS1P4	-5.06	6.13e-07	8.12e-05	-0.28	-0.23	Incident atrial fibrillation;	chr10:73807071	chr10:73699151~73730487:-
THCA	cis	rs919433	0.684	rs55775495	ENSG00000231621.1	AC013264.2	-5.06	6.13e-07	8.12e-05	-0.23	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197381241	chr2:197197991~197199273:+
THCA	cis	rs651907	0.557	rs62284199	ENSG00000244119.1	PDCL3P4	5.06	6.13e-07	8.12e-05	0.21	0.23	Colorectal cancer;	chr3:101759687	chr3:101712472~101713191:+
THCA	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs34262638	ENSG00000280083.1	RP11-317J9.1	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Obesity-related traits;	chr2:191279442	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs2124093	ENSG00000280083.1	RP11-317J9.1	-5.06	6.13e-07	8.12e-05	-0.26	-0.23	Obesity-related traits;	chr2:191288280	chr2:191154118~191156070:-
THCA	cis	rs3796352	1	rs11707575	ENSG00000242142.1	SERBP1P3	-5.06	6.14e-07	8.13e-05	-0.4	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53079746	chr3:53064283~53065091:-
THCA	cis	rs6044112	0.56	rs112026770	ENSG00000273998.1	RP4-777L9.2	5.06	6.15e-07	8.13e-05	0.39	0.23	Response to taxane treatment (docetaxel);	chr20:16581461	chr20:16576068~16579615:+
THCA	cis	rs10904908	1	rs10795465	ENSG00000229124.5	VIM-AS1	-5.06	6.15e-07	8.13e-05	-0.22	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17218526	chr10:17214239~17229985:-
THCA	cis	rs9929218	0.508	rs1559366	ENSG00000260459.2	FTLP14	5.06	6.15e-07	8.14e-05	0.25	0.23	Colorectal cancer;	chr16:68765708	chr16:68822587~68823070:+
THCA	cis	rs227275	0.554	rs223363	ENSG00000248971.2	KRT8P46	-5.06	6.15e-07	8.14e-05	-0.27	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102728746~102730171:-
THCA	cis	rs7078012	0.504	rs17886602	ENSG00000225484.5	NUTM2B-AS1	-5.06	6.15e-07	8.14e-05	-0.53	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79937421	chr10:79663088~79826594:-
THCA	cis	rs72843506	0.656	rs9901357	ENSG00000231258.2	ZSWIM5P2	5.06	6.15e-07	8.14e-05	0.34	0.23	Schizophrenia;	chr17:20105729	chr17:20583758~20591180:-
THCA	cis	rs6441961	0.55	rs3918361	ENSG00000223552.1	RP11-24F11.2	5.06	6.16e-07	8.15e-05	0.22	0.23	Celiac disease;	chr3:46354295	chr3:46364955~46407059:-
THCA	cis	rs8028182	0.636	rs8028277	ENSG00000260269.4	CTD-2323K18.1	-5.06	6.16e-07	8.15e-05	-0.33	-0.23	Sudden cardiac arrest;	chr15:75391744	chr15:75527150~75601205:-
THCA	cis	rs6772849	0.805	rs61159406	ENSG00000242551.2	POU5F1P6	-5.06	6.16e-07	8.15e-05	-0.29	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:128674735~128677005:-
THCA	cis	rs7111546	0.625	rs78747550	ENSG00000246225.5	RP11-17A1.3	5.06	6.16e-07	8.15e-05	0.37	0.23	Dialysis-related mortality;	chr11:22899990	chr11:22829380~22945393:+
THCA	cis	rs7727544	0.582	rs7703009	ENSG00000224431.1	AC063976.7	5.06	6.16e-07	8.15e-05	0.19	0.23	Blood metabolite levels;	chr5:132216692	chr5:132199456~132203487:+
THCA	cis	rs11671005	0.572	rs11669127	ENSG00000269473.1	CTD-2619J13.19	-5.06	6.16e-07	8.16e-05	-0.26	-0.23	Mean platelet volume;	chr19:58492463	chr19:58440448~58445849:+
THCA	cis	rs3796352	1	rs3097417	ENSG00000242142.1	SERBP1P3	5.06	6.16e-07	8.16e-05	0.41	0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53054585	chr3:53064283~53065091:-
THCA	cis	rs17767392	0.767	rs61989382	ENSG00000259146.3	RP1-261D10.2	5.06	6.16e-07	8.16e-05	0.28	0.23	Mitral valve prolapse;	chr14:71516921	chr14:71292729~71321814:-
THCA	cis	rs4688759	0.719	rs73079018	ENSG00000270441.1	RP11-694I15.7	5.06	6.17e-07	8.16e-05	0.33	0.23	Blood protein levels;	chr3:49837894	chr3:49140086~49160851:-
THCA	cis	rs8046148	0.724	rs8052492	ENSG00000279356.1	RP11-429P3.8	-5.06	6.17e-07	8.16e-05	-0.27	-0.23	Testicular germ cell tumor;	chr16:50065836	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs7186889	ENSG00000279356.1	RP11-429P3.8	5.06	6.17e-07	8.16e-05	0.27	0.23	Testicular germ cell tumor;	chr16:50058380	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs12599260	ENSG00000279356.1	RP11-429P3.8	5.06	6.17e-07	8.16e-05	0.27	0.23	Testicular germ cell tumor;	chr16:50059327	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs1861661	ENSG00000279356.1	RP11-429P3.8	5.06	6.17e-07	8.16e-05	0.27	0.23	Testicular germ cell tumor;	chr16:50060293	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.666	rs8046856	ENSG00000279356.1	RP11-429P3.8	5.06	6.17e-07	8.16e-05	0.27	0.23	Testicular germ cell tumor;	chr16:50064976	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs8051902	ENSG00000279356.1	RP11-429P3.8	5.06	6.17e-07	8.16e-05	0.27	0.23	Testicular germ cell tumor;	chr16:50065866	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs4389139	ENSG00000279356.1	RP11-429P3.8	5.06	6.17e-07	8.16e-05	0.27	0.23	Testicular germ cell tumor;	chr16:50066342	chr16:50072862~50074986:+
THCA	cis	rs2439831	0.717	rs690170	ENSG00000205771.5	CATSPER2P1	-5.06	6.17e-07	8.16e-05	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43518224	chr15:43726918~43747094:-
THCA	cis	rs11719291	0.584	rs13080725	ENSG00000270441.1	RP11-694I15.7	5.06	6.17e-07	8.16e-05	0.33	0.23	Cognitive function;	chr3:49038659	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs35108630	ENSG00000270441.1	RP11-694I15.7	5.06	6.17e-07	8.16e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49050923	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs35283189	ENSG00000270441.1	RP11-694I15.7	5.06	6.17e-07	8.16e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076235	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs34580506	ENSG00000270441.1	RP11-694I15.7	5.06	6.17e-07	8.16e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076280	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs35673421	ENSG00000270441.1	RP11-694I15.7	5.06	6.17e-07	8.16e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49101973	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs11552724	ENSG00000270441.1	RP11-694I15.7	5.06	6.17e-07	8.16e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49119040	chr3:49140086~49160851:-
THCA	cis	rs7214842	0.772	rs7219473	ENSG00000225751.2	AC087501.1	-5.06	6.17e-07	8.16e-05	-0.31	-0.23	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr17:9446859	chr17:9452197~9470014:+
THCA	cis	rs7429990	0.833	rs2293226	ENSG00000228638.1	FCF1P2	-5.06	6.17e-07	8.17e-05	-0.22	-0.23	Educational attainment (years of education);	chr3:47585292	chr3:48290793~48291375:-
THCA	cis	rs748404	0.666	rs7183708	ENSG00000205771.5	CATSPER2P1	-5.06	6.17e-07	8.17e-05	-0.29	-0.23	Lung cancer;	chr15:43355226	chr15:43726918~43747094:-
THCA	cis	rs7618915	0.547	rs4687638	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.18e-07	8.17e-05	-0.25	-0.23	Bipolar disorder;	chr3:52617950	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs62253733	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.18e-07	8.17e-05	-0.25	-0.23	Bipolar disorder;	chr3:52619398	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs34537256	ENSG00000243224.1	RP5-1157M23.2	-5.06	6.18e-07	8.17e-05	-0.25	-0.23	Bipolar disorder;	chr3:52623456	chr3:52239258~52241097:+
THCA	cis	rs2235642	0.75	rs2974845	ENSG00000280231.1	LA16c-380F5.3	-5.06	6.18e-07	8.17e-05	-0.27	-0.23	Coronary artery disease;	chr16:1598161	chr16:1553655~1554130:-
THCA	cis	rs10995505	0.578	rs1533068	ENSG00000232075.1	MRPL35P2	-5.06	6.18e-07	8.17e-05	-0.34	-0.23	Intelligence (multi-trait analysis);	chr10:63132407	chr10:63634317~63634827:-
THCA	cis	rs911119	1	rs6515375	ENSG00000270001.1	RP11-218C14.8	-5.05	6.18e-07	8.17e-05	-0.35	-0.23	Chronic kidney disease;	chr20:23630204	chr20:23631826~23632316:-
THCA	cis	rs8020095	0.571	rs8019510	ENSG00000258561.1	RP11-72M17.1	-5.05	6.18e-07	8.17e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:67057198	chr14:66212810~66509394:-
THCA	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	5.05	6.18e-07	8.17e-05	0.41	0.23	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
THCA	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	5.05	6.18e-07	8.17e-05	0.41	0.23	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
THCA	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	5.05	6.18e-07	8.17e-05	0.41	0.23	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
THCA	cis	rs2921073	0.51	rs2976945	ENSG00000253981.4	ALG1L13P	5.05	6.18e-07	8.17e-05	0.21	0.23	Parkinson's disease;	chr8:8413361	chr8:8236003~8244667:-
THCA	cis	rs4646450	0.891	rs1043466	ENSG00000244219.5	GS1-259H13.2	-5.05	6.18e-07	8.18e-05	-0.27	-0.23	Blood metabolite levels;	chr7:99456666	chr7:99598066~99610813:+
THCA	cis	rs937213	0.608	rs7177179	ENSG00000275636.1	RP11-521C20.5	5.05	6.18e-07	8.18e-05	0.25	0.23	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39995781	chr15:40078892~40079347:+
THCA	cis	rs5758659	1	rs134869	ENSG00000281538.1	RP4-669P10.20	5.05	6.19e-07	8.18e-05	0.21	0.23	Cognitive function;	chr22:42256068	chr22:42138060~42139726:+
THCA	cis	rs4415084	0.804	rs4329028	ENSG00000272335.1	RP11-53O19.3	-5.05	6.19e-07	8.18e-05	-0.19	-0.23	Breast cancer;	chr5:44872251	chr5:44826076~44828592:+
THCA	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	5.05	6.19e-07	8.19e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
THCA	cis	rs11779988	0.545	rs404186	ENSG00000253671.1	RP11-806O11.1	-5.05	6.19e-07	8.19e-05	-0.29	-0.23	Breast cancer;	chr8:17937987	chr8:17808941~17820868:+
THCA	cis	rs11779988	0.545	rs411531	ENSG00000253671.1	RP11-806O11.1	-5.05	6.19e-07	8.19e-05	-0.29	-0.23	Breast cancer;	chr8:17938425	chr8:17808941~17820868:+
THCA	cis	rs17301013	0.93	rs6425279	ENSG00000227373.4	RP11-160H22.5	-5.05	6.19e-07	8.19e-05	-0.32	-0.23	Systemic lupus erythematosus;	chr1:174418717	chr1:174115300~174160004:-
THCA	cis	rs9818758	0.607	rs9837237	ENSG00000270441.1	RP11-694I15.7	5.05	6.19e-07	8.19e-05	0.31	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178150	chr3:49140086~49160851:-
THCA	cis	rs4648045	0.796	rs4648068	ENSG00000246560.2	RP11-10L12.4	5.05	6.19e-07	8.19e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102597148	chr4:102828055~102844075:+
THCA	cis	rs4663866	0.901	rs35713061	ENSG00000186235.9	AC016757.3	5.05	6.19e-07	8.19e-05	0.5	0.23	Irritable bowel syndrome;	chr2:238275133	chr2:238224552~238231677:-
THCA	cis	rs4663866	0.901	rs3739066	ENSG00000186235.9	AC016757.3	5.05	6.19e-07	8.19e-05	0.5	0.23	Irritable bowel syndrome;	chr2:238275483	chr2:238224552~238231677:-
THCA	cis	rs987724	0.593	rs9871817	ENSG00000240875.4	LINC00886	-5.05	6.19e-07	8.19e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156893887	chr3:156747346~156817062:-
THCA	cis	rs4660456	0.826	rs3767952	ENSG00000272145.1	NFYC-AS1	5.05	6.2e-07	8.19e-05	0.16	0.23	Platelet count;	chr1:40765360	chr1:40690380~40692066:-
THCA	cis	rs62292953	0.79	rs3816529	ENSG00000248724.5	NPHP3-AS1	-5.05	6.2e-07	8.19e-05	-0.42	-0.23	Red cell distribution width;	chr3:132531183	chr3:132721750~132874223:+
THCA	cis	rs1005277	0.579	rs2474587	ENSG00000272983.1	RP11-508N22.12	5.05	6.2e-07	8.2e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474588	ENSG00000272983.1	RP11-508N22.12	5.05	6.2e-07	8.2e-05	0.2	0.23	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38137337~38144399:+
THCA	cis	rs7615952	0.932	rs6438948	ENSG00000241288.6	RP11-379B18.5	5.05	6.2e-07	8.21e-05	0.28	0.23	Blood pressure (smoking interaction);	chr3:125931202	chr3:125827238~125916384:-
THCA	cis	rs6472827	0.645	rs7009750	ENSG00000253983.2	RP1-16A9.1	5.05	6.21e-07	8.21e-05	0.32	0.23	Uterine fibroids;	chr8:74199894	chr8:74199396~74208441:+
THCA	cis	rs172166	0.694	rs203884	ENSG00000261839.1	RP1-265C24.8	5.05	6.21e-07	8.21e-05	0.25	0.23	Cardiac Troponin-T levels;	chr6:28109596	chr6:28136849~28139678:+
THCA	cis	rs1350171	1	rs1048338	ENSG00000246523.6	RP11-736K20.6	-5.05	6.21e-07	8.21e-05	-0.34	-0.23	Hepatocellular carcinoma in hepatitis B infection;	chr11:86921775	chr11:86955619~87000959:+
THCA	cis	rs2070488	0.775	rs6599208	ENSG00000229589.1	ACVR2B-AS1	-5.05	6.21e-07	8.21e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38516613	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.775	rs6599211	ENSG00000229589.1	ACVR2B-AS1	-5.05	6.21e-07	8.21e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38517339	chr3:38451027~38454820:-
THCA	cis	rs9425766	0.679	rs2064149	ENSG00000227373.4	RP11-160H22.5	5.05	6.21e-07	8.21e-05	0.32	0.23	Life satisfaction;	chr1:174255856	chr1:174115300~174160004:-
THCA	cis	rs4713118	0.662	rs149901	ENSG00000272009.1	RP1-313I6.12	-5.05	6.21e-07	8.21e-05	-0.25	-0.23	Parkinson's disease;	chr6:27997725	chr6:28078792~28081130:-
THCA	cis	rs11992162	0.967	rs7461062	ENSG00000227888.4	FAM66A	5.05	6.21e-07	8.22e-05	0.29	0.23	Monocyte count;	chr8:11974439	chr8:12362019~12388296:+
THCA	cis	rs12893668	0.572	rs2273175	ENSG00000269958.1	RP11-73M18.8	5.05	6.22e-07	8.22e-05	0.22	0.23	Reticulocyte count;	chr14:103693804	chr14:103696353~103697163:+
THCA	cis	rs3789135	1	rs3789135	ENSG00000231464.1	AC024937.4	5.05	6.22e-07	8.22e-05	0.28	0.23	Mean corpuscular hemoglobin;	chr3:196065999	chr3:195996738~195998233:+
THCA	cis	rs6832769	0.961	rs6817663	ENSG00000272969.1	RP11-528I4.2	-5.05	6.22e-07	8.22e-05	-0.26	-0.23	Personality dimensions;	chr4:55581048	chr4:55547112~55547889:+
THCA	cis	rs2235642	0.701	rs2281230	ENSG00000280231.1	LA16c-380F5.3	-5.05	6.22e-07	8.23e-05	-0.29	-0.23	Coronary artery disease;	chr16:1551766	chr16:1553655~1554130:-
THCA	cis	rs2067615	0.524	rs4964483	ENSG00000260329.1	RP11-412D9.4	-5.05	6.22e-07	8.23e-05	-0.21	-0.23	Heart rate;	chr12:106705279	chr12:106954029~106955497:-
THCA	cis	rs9543976	1	rs73223968	ENSG00000261105.4	LMO7-AS1	-5.05	6.22e-07	8.23e-05	-0.34	-0.23	Diabetic retinopathy;	chr13:75567585	chr13:75604700~75635994:-
THCA	cis	rs9543976	1	rs2296146	ENSG00000261105.4	LMO7-AS1	-5.05	6.22e-07	8.23e-05	-0.34	-0.23	Diabetic retinopathy;	chr13:75569436	chr13:75604700~75635994:-
THCA	cis	rs6490294	0.571	rs7309841	ENSG00000226469.1	ADAM1B	5.05	6.23e-07	8.23e-05	0.34	0.23	Mean platelet volume;	chr12:112127249	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7294753	ENSG00000226469.1	ADAM1B	5.05	6.23e-07	8.23e-05	0.34	0.23	Mean platelet volume;	chr12:112129646	chr12:111927018~111929017:+
THCA	cis	rs2911132	0.506	rs10037212	ENSG00000248734.2	CTD-2260A17.1	-5.05	6.23e-07	8.23e-05	-0.25	-0.23	Urate levels (BMI interaction);	chr5:96749072	chr5:96784777~96785999:+
THCA	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	5.05	6.23e-07	8.24e-05	0.29	0.23	Depression;	chr6:28301886	chr6:28943877~28944537:+
THCA	cis	rs8103278	0.507	rs7260651	ENSG00000267395.4	AC074212.6	-5.05	6.23e-07	8.24e-05	-0.15	-0.23	Coronary artery disease;	chr19:45756987	chr19:45767796~45772504:+
THCA	cis	rs8103278	0.507	rs10401971	ENSG00000267395.4	AC074212.6	-5.05	6.23e-07	8.24e-05	-0.15	-0.23	Coronary artery disease;	chr19:45758724	chr19:45767796~45772504:+
THCA	cis	rs7428	0.545	rs1053561	ENSG00000273196.1	RP11-717A5.2	5.05	6.23e-07	8.24e-05	0.23	0.23	Ear protrusion;	chr2:85318929	chr2:85387074~85387146:-
THCA	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-5.05	6.23e-07	8.24e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
THCA	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	5.05	6.23e-07	8.24e-05	0.3	0.23	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.78	rs35297486	ENSG00000199476.1	Y_RNA	-5.05	6.23e-07	8.24e-05	-0.3	-0.23	Coronary artery disease;	chr3:48336657	chr3:48288587~48288694:+
THCA	cis	rs919433	0.857	rs36071109	ENSG00000231621.1	AC013264.2	5.05	6.24e-07	8.24e-05	0.24	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318467	chr2:197197991~197199273:+
THCA	cis	rs7045881	0.935	rs17693955	ENSG00000254396.1	RP11-56F10.3	-5.05	6.24e-07	8.24e-05	-0.35	-0.23	Schizophrenia;	chr9:26797601	chr9:27102630~27104728:+
THCA	cis	rs4646450	0.838	rs10257758	ENSG00000244219.5	GS1-259H13.2	-5.05	6.24e-07	8.25e-05	-0.28	-0.23	Blood metabolite levels;	chr7:99591365	chr7:99598066~99610813:+
THCA	cis	rs7045881	0.733	rs17756179	ENSG00000254396.1	RP11-56F10.3	5.05	6.24e-07	8.25e-05	0.42	0.23	Schizophrenia;	chr9:26959916	chr9:27102630~27104728:+
THCA	cis	rs6756513	0.5	rs1377996	ENSG00000231024.1	AC092431.3	-5.05	6.24e-07	8.25e-05	-0.31	-0.23	Breast cancer;Platelet count;	chr2:69837795	chr2:69700192~69713847:-
THCA	cis	rs8022179	0.58	rs6575979	ENSG00000244691.1	RPL10AP1	-5.05	6.24e-07	8.25e-05	-0.32	-0.23	Monocyte count;	chr14:103374681	chr14:103412119~103412761:-
THCA	cis	rs875971	0.52	rs160645	ENSG00000232546.1	RP11-458F8.1	-5.05	6.24e-07	8.25e-05	-0.22	-0.23	Aortic root size;	chr7:66091320	chr7:66848496~66858136:+
THCA	cis	rs758747	0.718	rs12445430	ENSG00000276754.1	RP11-461A8.5	-5.05	6.24e-07	8.25e-05	-0.23	-0.23	Body mass index;	chr16:3563125	chr16:3686998~3687380:+
THCA	cis	rs9652601	0.779	rs11648679	ENSG00000274038.1	RP11-66H6.4	-5.05	6.24e-07	8.25e-05	-0.29	-0.23	Systemic lupus erythematosus;	chr16:11082127	chr16:11056556~11057034:+
THCA	cis	rs8028182	0.636	rs7171507	ENSG00000260269.4	CTD-2323K18.1	-5.05	6.24e-07	8.25e-05	-0.34	-0.23	Sudden cardiac arrest;	chr15:75444946	chr15:75527150~75601205:-
THCA	cis	rs7429990	0.833	rs4858801	ENSG00000228638.1	FCF1P2	5.05	6.24e-07	8.25e-05	0.22	0.23	Educational attainment (years of education);	chr3:47599432	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs61620099	ENSG00000228638.1	FCF1P2	5.05	6.24e-07	8.25e-05	0.22	0.23	Educational attainment (years of education);	chr3:47600755	chr3:48290793~48291375:-
THCA	cis	rs7474896	0.559	rs1208645	ENSG00000263064.2	RP11-291L22.7	-5.05	6.25e-07	8.25e-05	-0.3	-0.23	Obesity (extreme);	chr10:37843159	chr10:38448689~38448949:+
THCA	cis	rs4845570	0.92	rs6694952	ENSG00000203288.3	RP11-98D18.9	5.05	6.25e-07	8.26e-05	0.25	0.23	Coronary artery disease;	chr1:151787655	chr1:151790804~151794402:+
THCA	cis	rs317689	0.69	rs607797	ENSG00000274979.1	RP11-1143G9.5	-5.05	6.25e-07	8.26e-05	-0.26	-0.23	Response to diuretic therapy;	chr12:69252230	chr12:69326574~69331882:-
THCA	cis	rs1823874	0.71	rs8042933	ENSG00000259363.4	CTD-2054N24.2	-5.05	6.25e-07	8.26e-05	-0.29	-0.23	IgG glycosylation;	chr15:99824641	chr15:99807023~99877148:+
THCA	cis	rs613391	0.631	rs518020	ENSG00000224549.1	RP11-370B11.3	-5.05	6.25e-07	8.26e-05	-0.26	-0.23	Quantitative traits;	chr9:22698209	chr9:22767175~22768316:+
THCA	cis	rs613391	0.702	rs1448773	ENSG00000224549.1	RP11-370B11.3	-5.05	6.25e-07	8.26e-05	-0.26	-0.23	Quantitative traits;	chr9:22705548	chr9:22767175~22768316:+
THCA	cis	rs35160687	0.644	rs11676515	ENSG00000273080.1	RP11-301O19.1	-5.05	6.25e-07	8.26e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86268934	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.712	rs1863057	ENSG00000273080.1	RP11-301O19.1	-5.05	6.25e-07	8.26e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86274978	chr2:86195590~86196049:+
THCA	cis	rs16976116	0.53	rs11071168	ENSG00000279145.1	RP11-547D13.1	-5.05	6.25e-07	8.26e-05	-0.25	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55124837	chr15:55171972~55178175:-
THCA	cis	rs853679	0.599	rs156743	ENSG00000226314.6	ZNF192P1	-5.05	6.25e-07	8.26e-05	-0.36	-0.23	Depression;	chr6:27999311	chr6:28161781~28169594:+
THCA	cis	rs1635	0.826	rs3800327	ENSG00000216901.1	AL022393.7	5.05	6.25e-07	8.26e-05	0.47	0.23	Schizophrenia;	chr6:28297151	chr6:28176188~28176674:+
THCA	cis	rs1050631	0.564	rs12185396	ENSG00000260552.1	RP11-49I11.1	5.05	6.25e-07	8.27e-05	0.28	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36158533	chr18:36179996~36187448:-
THCA	cis	rs7824557	0.806	rs10503418	ENSG00000154316.13	TDH	5.05	6.26e-07	8.27e-05	0.16	0.23	Retinal vascular caliber;	chr8:11261474	chr8:11339637~11368452:+
THCA	cis	rs7674212	0.539	rs6850461	ENSG00000251288.2	RP11-10L12.2	-5.05	6.26e-07	8.27e-05	-0.29	-0.23	Type 2 diabetes;	chr4:103198884	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.539	rs6533056	ENSG00000251288.2	RP11-10L12.2	-5.05	6.26e-07	8.27e-05	-0.29	-0.23	Type 2 diabetes;	chr4:103199840	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.539	rs2866635	ENSG00000251288.2	RP11-10L12.2	-5.05	6.26e-07	8.27e-05	-0.29	-0.23	Type 2 diabetes;	chr4:103200419	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.539	rs6815783	ENSG00000251288.2	RP11-10L12.2	-5.05	6.26e-07	8.27e-05	-0.29	-0.23	Type 2 diabetes;	chr4:103200989	chr4:102751401~102752641:+
THCA	cis	rs1979679	0.918	rs786712	ENSG00000278733.1	RP11-425D17.1	5.05	6.26e-07	8.27e-05	0.23	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28399664	chr12:28185625~28186190:-
THCA	cis	rs11673344	0.523	rs2562594	ENSG00000276846.1	CTD-3220F14.3	5.05	6.26e-07	8.27e-05	0.17	0.23	Obesity-related traits;	chr19:37023783	chr19:37314868~37315620:-
THCA	cis	rs16852403	0.548	rs543452	ENSG00000224687.1	RASAL2-AS1	-5.05	6.26e-07	8.27e-05	-0.34	-0.23	Childhood ear infection;	chr1:178251743	chr1:178091508~178093984:-
THCA	cis	rs11073619	0.616	rs116665699	ENSG00000230373.7	GOLGA6L5P	-5.05	6.26e-07	8.27e-05	-0.35	-0.23	Positive affect;	chr15:84554498	chr15:84507885~84516814:-
THCA	cis	rs1005277	0.579	rs2800485	ENSG00000275858.1	RP11-291L22.8	5.05	6.26e-07	8.27e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38450738~38451069:-
THCA	cis	rs1577917	0.681	rs4348284	ENSG00000220563.1	PKMP3	-5.05	6.26e-07	8.27e-05	-0.16	-0.23	Response to antipsychotic treatment;	chr6:85640676	chr6:85659892~85660606:-
THCA	cis	rs7829975	0.593	rs2921061	ENSG00000253981.4	ALG1L13P	5.05	6.26e-07	8.27e-05	0.22	0.23	Mood instability;	chr8:8460105	chr8:8236003~8244667:-
THCA	cis	rs240993	0.812	rs7766610	ENSG00000271789.1	RP5-1112D6.7	-5.05	6.26e-07	8.28e-05	-0.28	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111386618	chr6:111297126~111298510:+
THCA	cis	rs7702057	0.53	rs1129495	ENSG00000272265.1	CTD-2287O16.4	5.05	6.26e-07	8.28e-05	0.43	0.23	Amyotrophic lateral sclerosis;	chr5:116092684	chr5:116078110~116078570:-
THCA	cis	rs7702057	0.53	rs61105089	ENSG00000272265.1	CTD-2287O16.4	5.05	6.26e-07	8.28e-05	0.43	0.23	Amyotrophic lateral sclerosis;	chr5:116096514	chr5:116078110~116078570:-
THCA	cis	rs7702057	0.53	rs2136213	ENSG00000272265.1	CTD-2287O16.4	5.05	6.26e-07	8.28e-05	0.43	0.23	Amyotrophic lateral sclerosis;	chr5:116098716	chr5:116078110~116078570:-
THCA	cis	rs972578	0.668	rs4820490	ENSG00000274717.1	RP1-47A17.1	-5.05	6.26e-07	8.28e-05	-0.24	-0.23	Mean platelet volume;	chr22:42847198	chr22:42791814~42794313:-
THCA	cis	rs34779708	0.931	rs11010077	ENSG00000271335.4	RP11-324I22.4	-5.05	6.26e-07	8.28e-05	-0.21	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs4934731	ENSG00000271335.4	RP11-324I22.4	5.05	6.26e-07	8.28e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs57081218	ENSG00000271335.4	RP11-324I22.4	5.05	6.26e-07	8.28e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs12762493	ENSG00000271335.4	RP11-324I22.4	5.05	6.26e-07	8.28e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35314552~35336401:-
THCA	cis	rs858239	0.73	rs858279	ENSG00000226816.2	AC005082.12	5.05	6.27e-07	8.28e-05	0.32	0.23	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23206013~23208045:+
THCA	cis	rs6728642	1	rs6728642	ENSG00000230606.9	AC159540.1	5.05	6.27e-07	8.28e-05	0.3	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941334	chr2:97416165~97433527:-
THCA	cis	rs17772222	1	rs1955599	ENSG00000222990.1	RNU4-22P	5.05	6.27e-07	8.28e-05	0.3	0.23	Coronary artery calcification;	chr14:88358788	chr14:88513498~88513663:+
THCA	cis	rs7088591	0.867	rs3853379	ENSG00000276818.1	AC026393.1	5.05	6.27e-07	8.29e-05	0.42	0.23	Blood pressure;	chr10:57950765	chr10:57095699~57095781:+
THCA	cis	rs9959145	1	rs78908311	ENSG00000267108.1	RP11-861E21.1	5.05	6.27e-07	8.29e-05	0.28	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12688279	chr18:12432897~12437635:+
THCA	cis	rs12036718	0.511	rs12120307	ENSG00000272491.1	RP5-1024N4.4	5.05	6.27e-07	8.29e-05	0.29	0.23	Yu-Zhi constitution type in type 2 diabetes;	chr1:48121743	chr1:48227888~48229561:-
THCA	cis	rs2692947	1	rs2692947	ENSG00000232931.4	LINC00342	5.05	6.27e-07	8.29e-05	0.18	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96008368	chr2:95807118~95816215:-
THCA	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	5.05	6.28e-07	8.29e-05	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
THCA	cis	rs270601	0.633	rs733300	ENSG00000237714.1	P4HA2-AS1	5.05	6.28e-07	8.3e-05	0.3	0.23	Acylcarnitine levels;	chr5:132236550	chr5:132184876~132192808:+
THCA	cis	rs270601	0.633	rs4535443	ENSG00000237714.1	P4HA2-AS1	5.05	6.28e-07	8.3e-05	0.3	0.23	Acylcarnitine levels;	chr5:132236868	chr5:132184876~132192808:+
THCA	cis	rs3750965	0.959	rs3168115	ENSG00000260895.1	RP11-554A11.7	-5.05	6.28e-07	8.3e-05	-0.3	-0.23	Hair color;	chr11:69090622	chr11:69103493~69109094:+
THCA	cis	rs2281603	0.808	rs10132424	ENSG00000259116.1	RP11-973N13.4	-5.05	6.29e-07	8.3e-05	-0.22	-0.23	Lymphocyte counts;	chr14:64527157	chr14:64514154~64540368:-
THCA	cis	rs944289	0.74	rs1537425	ENSG00000258844.1	RP11-259K15.2	-5.05	6.29e-07	8.3e-05	-0.2	-0.23	Thyroid cancer;	chr14:36098954	chr14:36214607~36235608:+
THCA	cis	rs8028182	0.549	rs7402844	ENSG00000260269.4	CTD-2323K18.1	5.05	6.29e-07	8.3e-05	0.34	0.23	Sudden cardiac arrest;	chr15:75345055	chr15:75527150~75601205:-
THCA	cis	rs911555	0.755	rs35233301	ENSG00000244691.1	RPL10AP1	5.05	6.29e-07	8.3e-05	0.31	0.23	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103412119~103412761:-
THCA	cis	rs8028313	0.63	rs8035989	ENSG00000270964.1	RP11-502I4.3	-5.05	6.29e-07	8.3e-05	-0.2	-0.23	Obesity;	chr15:67673282	chr15:67541072~67542604:-
THCA	cis	rs8028313	0.731	rs11857017	ENSG00000270964.1	RP11-502I4.3	-5.05	6.29e-07	8.3e-05	-0.2	-0.23	Obesity;	chr15:67680570	chr15:67541072~67542604:-
THCA	cis	rs8028313	0.731	rs13380201	ENSG00000270964.1	RP11-502I4.3	-5.05	6.29e-07	8.3e-05	-0.2	-0.23	Obesity;	chr15:67681327	chr15:67541072~67542604:-
THCA	cis	rs987724	0.593	rs9867621	ENSG00000240875.4	LINC00886	-5.05	6.29e-07	8.31e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156896774	chr3:156747346~156817062:-
THCA	cis	rs987724	0.555	rs12629380	ENSG00000240875.4	LINC00886	-5.05	6.29e-07	8.31e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898291	chr3:156747346~156817062:-
THCA	cis	rs987724	0.555	rs9866373	ENSG00000240875.4	LINC00886	-5.05	6.29e-07	8.31e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901961	chr3:156747346~156817062:-
THCA	cis	rs35740288	0.787	rs2008916	ENSG00000259295.5	CSPG4P12	5.05	6.29e-07	8.31e-05	0.36	0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677959	chr15:85191438~85213905:+
THCA	cis	rs2439831	1	rs2601014	ENSG00000166763.7	STRCP1	5.05	6.29e-07	8.31e-05	0.33	0.23	Lung cancer in ever smokers;	chr15:43463815	chr15:43699488~43718184:-
THCA	cis	rs2067615	0.579	rs7964605	ENSG00000260329.1	RP11-412D9.4	5.05	6.29e-07	8.31e-05	0.2	0.23	Heart rate;	chr12:106811635	chr12:106954029~106955497:-
THCA	cis	rs2239547	0.657	rs12496077	ENSG00000242142.1	SERBP1P3	5.05	6.29e-07	8.31e-05	0.29	0.23	Schizophrenia;	chr3:52852225	chr3:53064283~53065091:-
THCA	cis	rs2136613	0.751	rs10995324	ENSG00000238280.1	RP11-436D10.3	5.05	6.29e-07	8.31e-05	0.26	0.23	Selective IgA deficiency;	chr10:62838233	chr10:62793562~62805887:-
THCA	cis	rs1129187	0.755	rs9471976	ENSG00000272223.1	RP1-20C7.6	5.05	6.3e-07	8.32e-05	0.17	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42952811	chr6:43033897~43034405:-
THCA	cis	rs3824435	0.783	rs7859081	ENSG00000272866.1	RP11-12D24.10	-5.05	6.3e-07	8.32e-05	-0.3	-0.23	Risky sexual behaviors in alcohol dependence;	chr9:5346352	chr9:5351796~5352410:-
THCA	cis	rs12893668	0.703	rs8017993	ENSG00000269940.1	RP11-73M18.7	5.05	6.3e-07	8.32e-05	0.24	0.23	Reticulocyte count;	chr14:103581397	chr14:103694560~103695170:+
THCA	cis	rs8028182	0.636	rs7166737	ENSG00000260274.1	RP11-817O13.8	5.05	6.3e-07	8.32e-05	0.16	0.23	Sudden cardiac arrest;	chr15:75390172	chr15:75368155~75369584:+
THCA	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-5.05	6.3e-07	8.32e-05	-0.32	-0.23	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.681	rs478104	ENSG00000275601.1	AC011330.13	-5.05	6.3e-07	8.32e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43302702	chr15:43642389~43643023:-
THCA	cis	rs4748857	0.685	rs11013379	ENSG00000224215.1	RP11-371A19.2	-5.05	6.3e-07	8.32e-05	-0.3	-0.23	Systemic lupus erythematosus;	chr10:23309888	chr10:23343957~23345181:+
THCA	cis	rs972578	0.791	rs9607955	ENSG00000274717.1	RP1-47A17.1	-5.05	6.3e-07	8.32e-05	-0.24	-0.23	Mean platelet volume;	chr22:42820727	chr22:42791814~42794313:-
THCA	cis	rs7772486	0.686	rs9497395	ENSG00000270638.1	RP3-466P17.1	-5.05	6.31e-07	8.33e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145735570~145737218:+
THCA	cis	rs4648045	0.796	rs4648058	ENSG00000246560.2	RP11-10L12.4	5.05	6.31e-07	8.33e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102594434	chr4:102828055~102844075:+
THCA	cis	rs763121	0.853	rs6001204	ENSG00000235209.1	CTA-150C2.13	5.05	6.31e-07	8.34e-05	0.3	0.23	Menopause (age at onset);	chr22:38704234	chr22:38921227~38924708:+
THCA	cis	rs202072	0.872	rs202045	ENSG00000272379.1	RP1-257A7.5	5.05	6.31e-07	8.34e-05	0.34	0.23	HIV-1 viral setpoint;	chr6:13275682	chr6:13290018~13290490:-
THCA	cis	rs4787951	0.56	rs3024530	ENSG00000259940.2	CTD-3203P2.1	5.05	6.32e-07	8.34e-05	0.24	0.23	Eosinophil percentage of white cells;	chr16:27339366	chr16:27213308~27214993:-
THCA	cis	rs7617773	0.817	rs17647717	ENSG00000199476.1	Y_RNA	-5.05	6.32e-07	8.34e-05	-0.31	-0.23	Coronary artery disease;	chr3:48263966	chr3:48288587~48288694:+
THCA	cis	rs6547741	0.752	rs7562863	ENSG00000234072.1	AC074117.10	-5.05	6.32e-07	8.34e-05	-0.18	-0.23	Oral cavity cancer;	chr2:27669827	chr2:27356246~27367622:+
THCA	cis	rs7119	0.717	rs12902896	ENSG00000259362.2	RP11-307C19.1	5.05	6.32e-07	8.35e-05	0.33	0.23	Type 2 diabetes;	chr15:77516808	chr15:77525540~77534110:+
THCA	cis	rs944289	0.708	rs34613409	ENSG00000258844.1	RP11-259K15.2	5.05	6.32e-07	8.35e-05	0.2	0.23	Thyroid cancer;	chr14:36096489	chr14:36214607~36235608:+
THCA	cis	rs944289	0.774	rs2415312	ENSG00000258844.1	RP11-259K15.2	5.05	6.32e-07	8.35e-05	0.2	0.23	Thyroid cancer;	chr14:36097145	chr14:36214607~36235608:+
THCA	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	5.05	6.32e-07	8.35e-05	0.13	0.23	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
THCA	cis	rs889398	0.933	rs6499240	ENSG00000226232.7	RP11-419C5.2	-5.05	6.33e-07	8.35e-05	-0.23	-0.23	Body mass index;	chr16:69653009	chr16:69976388~69996188:-
THCA	cis	rs454217	0.765	rs392929	ENSG00000277851.1	RP11-756G20.1	5.05	6.33e-07	8.36e-05	0.22	0.23	Smoking quantity;	chr12:92338016	chr12:92247756~92363832:-
THCA	cis	rs1823913	0.637	rs4853465	ENSG00000280083.1	RP11-317J9.1	5.05	6.33e-07	8.36e-05	0.26	0.23	Obesity-related traits;	chr2:191294768	chr2:191154118~191156070:-
THCA	cis	rs7523875	0.572	rs78372522	ENSG00000153363.11	LINC00467	-5.05	6.33e-07	8.36e-05	-0.31	-0.23	Mean corpuscular volume;	chr1:211397329	chr1:211382803~211435333:+
THCA	cis	rs950169	0.544	rs62021193	ENSG00000188388.10	GOLGA6L3	5.05	6.33e-07	8.36e-05	0.31	0.23	Schizophrenia;	chr15:84627352	chr15:85240472~85247170:+
THCA	cis	rs17826219	0.789	rs4794873	ENSG00000263603.1	CTD-2349P21.5	-5.05	6.33e-07	8.36e-05	-0.38	-0.23	Body mass index;	chr17:30421334	chr17:30729469~30731202:+
THCA	cis	rs3796352	0.881	rs35385050	ENSG00000242142.1	SERBP1P3	-5.05	6.34e-07	8.37e-05	-0.44	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52963929	chr3:53064283~53065091:-
THCA	cis	rs6565180	0.962	rs6565183	ENSG00000274653.1	RP11-347C12.11	5.05	6.34e-07	8.37e-05	0.21	0.23	Tonsillectomy;	chr16:30371434	chr16:30359825~30360336:+
THCA	cis	rs34787248	1	rs34787248	ENSG00000220721.1	OR1F12	5.05	6.34e-07	8.37e-05	0.32	0.23	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28073316~28074233:+
THCA	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	5.05	6.34e-07	8.37e-05	0.19	0.23	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
THCA	cis	rs7267979	0.866	rs437635	ENSG00000274973.1	RP13-401N8.7	-5.05	6.34e-07	8.38e-05	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25845497~25845862:+
THCA	cis	rs7726414	1	rs7726414	ENSG00000279469.1	RP11-215P8.2	5.05	6.35e-07	8.38e-05	0.5	0.23	Systemic lupus erythematosus;	chr5:134096143	chr5:134394360~134395008:-
THCA	cis	rs1979679	0.842	rs2035271	ENSG00000247934.4	RP11-967K21.1	-5.05	6.36e-07	8.39e-05	-0.22	-0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28165638	chr12:28163298~28190738:-
THCA	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-5.05	6.36e-07	8.4e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
THCA	cis	rs9500256	0.655	rs12191043	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-5.05	6.36e-07	8.4e-05	-0.26	-0.23	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57855891~57856468:-
THCA	cis	rs17767392	0.958	rs3825719	ENSG00000259146.3	RP1-261D10.2	5.05	6.36e-07	8.4e-05	0.29	0.23	Mitral valve prolapse;	chr14:71586380	chr14:71292729~71321814:-
THCA	cis	rs6545883	0.929	rs2593635	ENSG00000270820.4	RP11-355B11.2	-5.05	6.37e-07	8.4e-05	-0.2	-0.23	Tuberculosis;	chr2:61407571	chr2:61471188~61484130:+
THCA	cis	rs2239547	0.522	rs6768844	ENSG00000242142.1	SERBP1P3	-5.05	6.37e-07	8.4e-05	-0.28	-0.23	Schizophrenia;	chr3:52970604	chr3:53064283~53065091:-
THCA	cis	rs2911132	0.506	rs1862609	ENSG00000248734.2	CTD-2260A17.1	5.05	6.37e-07	8.4e-05	0.25	0.23	Urate levels (BMI interaction);	chr5:96750986	chr5:96784777~96785999:+
THCA	cis	rs2797160	0.967	rs28629380	ENSG00000237742.5	RP11-624M8.1	-5.05	6.37e-07	8.4e-05	-0.2	-0.23	Endometrial cancer;	chr6:125683051	chr6:125578558~125749190:-
THCA	cis	rs2070488	0.775	rs7374458	ENSG00000229589.1	ACVR2B-AS1	5.05	6.37e-07	8.4e-05	0.2	0.23	Electrocardiographic conduction measures;	chr3:38489720	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.775	rs13072731	ENSG00000229589.1	ACVR2B-AS1	5.05	6.37e-07	8.4e-05	0.2	0.23	Electrocardiographic conduction measures;	chr3:38491844	chr3:38451027~38454820:-
THCA	cis	rs16975963	0.644	rs11083428	ENSG00000226686.6	LINC01535	-5.05	6.37e-07	8.41e-05	-0.3	-0.23	Longevity;	chr19:37593066	chr19:37251912~37265535:+
THCA	cis	rs72772090	1	rs11738135	ENSG00000248734.2	CTD-2260A17.1	-5.05	6.37e-07	8.41e-05	-0.37	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96712632	chr5:96784777~96785999:+
THCA	cis	rs11783469	0.519	rs13250356	ENSG00000253390.1	CTC-756D1.2	-5.05	6.37e-07	8.41e-05	-0.34	-0.23	Reticulocyte count;	chr8:23502318	chr8:23458601~23484971:+
THCA	cis	rs34779708	0.931	rs7099036	ENSG00000271335.4	RP11-324I22.4	5.05	6.37e-07	8.41e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35314552~35336401:-
THCA	cis	rs9307551	0.948	rs13112577	ENSG00000250334.4	LINC00989	-5.05	6.37e-07	8.41e-05	-0.29	-0.23	Refractive error;	chr4:79561246	chr4:79492416~79576460:+
THCA	cis	rs17005891	0.816	rs55825761	ENSG00000270480.1	RP11-57B24.1	5.05	6.38e-07	8.41e-05	0.36	0.23	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82620475	chr4:82691737~82692468:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000273142.1	RP11-458F8.4	5.05	6.38e-07	8.42e-05	0.18	0.23	Aortic root size;	chr7:65950660	chr7:66902857~66906297:+
THCA	cis	rs10129255	0.744	rs28517388	ENSG00000223648.3	IGHV3-64	5.05	6.38e-07	8.42e-05	0.15	0.23	Kawasaki disease;	chr14:106704323	chr14:106643132~106658258:-
THCA	cis	rs12188164	0.84	rs67665078	ENSG00000221990.4	EXOC3-AS1	5.05	6.38e-07	8.42e-05	0.18	0.23	Cystic fibrosis severity;	chr5:428639	chr5:441498~443160:-
THCA	cis	rs9813712	0.597	rs62281648	ENSG00000253540.4	FAM86HP	-5.05	6.38e-07	8.42e-05	-0.24	-0.23	Response to amphetamines;	chr3:130244794	chr3:130099092~130111472:-
THCA	cis	rs62445005	1	rs62445005	ENSG00000211698.2	TRGV4	5.05	6.38e-07	8.42e-05	0.24	0.23	Shingles;	chr7:38346957	chr7:38353715~38354517:-
THCA	cis	rs11671005	0.695	rs12972898	ENSG00000265272.2	RN7SL693P	5.05	6.38e-07	8.42e-05	0.33	0.23	Mean platelet volume;	chr19:58445521	chr19:58490797~58491075:+
THCA	cis	rs72772090	0.908	rs6864233	ENSG00000248734.2	CTD-2260A17.1	5.05	6.38e-07	8.42e-05	0.36	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96708977	chr5:96784777~96785999:+
THCA	cis	rs4366055	1	rs4366055	ENSG00000253175.1	RP11-267M23.6	5.05	6.38e-07	8.42e-05	0.28	0.23	Body mass index;	chr8:94495100	chr8:94565036~94565715:+
THCA	cis	rs858239	0.537	rs10279691	ENSG00000226816.2	AC005082.12	5.05	6.38e-07	8.42e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23206013~23208045:+
THCA	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	5.05	6.38e-07	8.42e-05	0.14	0.23	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
THCA	cis	rs2911132	0.506	rs7705827	ENSG00000248734.2	CTD-2260A17.1	5.05	6.39e-07	8.43e-05	0.25	0.23	Urate levels (BMI interaction);	chr5:96746729	chr5:96784777~96785999:+
THCA	cis	rs72945132	0.882	rs6592552	ENSG00000254604.1	AP000487.6	-5.05	6.39e-07	8.43e-05	-0.42	-0.23	Coronary artery disease;	chr11:70377725	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.825	rs2277273	ENSG00000254604.1	AP000487.6	-5.05	6.39e-07	8.43e-05	-0.42	-0.23	Coronary artery disease;	chr11:70377886	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs6592554	ENSG00000254604.1	AP000487.6	-5.05	6.39e-07	8.43e-05	-0.42	-0.23	Coronary artery disease;	chr11:70379934	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7940090	ENSG00000254604.1	AP000487.6	-5.05	6.39e-07	8.43e-05	-0.42	-0.23	Coronary artery disease;	chr11:70381718	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7943840	ENSG00000254604.1	AP000487.6	-5.05	6.39e-07	8.43e-05	-0.42	-0.23	Coronary artery disease;	chr11:70382509	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs57810426	ENSG00000254604.1	AP000487.6	-5.05	6.39e-07	8.43e-05	-0.42	-0.23	Coronary artery disease;	chr11:70383924	chr11:70282367~70363368:-
THCA	cis	rs2288884	0.505	rs57637334	ENSG00000269483.1	AC006272.1	5.05	6.39e-07	8.43e-05	0.36	0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51977572	chr19:51839924~51843324:-
THCA	cis	rs481331	0.799	rs56319805	ENSG00000215146.4	RP11-313J2.1	5.05	6.39e-07	8.43e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42476557	chr10:42331866~42367974:-
THCA	cis	rs481331	0.799	rs1855460	ENSG00000215146.4	RP11-313J2.1	5.05	6.39e-07	8.43e-05	0.36	0.23	Systemic juvenile idiopathic arthritis;	chr10:42476683	chr10:42331866~42367974:-
THCA	cis	rs6545883	0.895	rs2177961	ENSG00000270820.4	RP11-355B11.2	-5.05	6.39e-07	8.43e-05	-0.19	-0.23	Tuberculosis;	chr2:61333129	chr2:61471188~61484130:+
THCA	cis	rs1979679	0.918	rs786707	ENSG00000278733.1	RP11-425D17.1	5.05	6.39e-07	8.43e-05	0.23	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28420714	chr12:28185625~28186190:-
THCA	cis	rs957448	1	rs72674866	ENSG00000253175.1	RP11-267M23.6	5.05	6.39e-07	8.43e-05	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94565036~94565715:+
THCA	cis	rs752010	0.715	rs11807117	ENSG00000230638.4	RP11-486B10.4	-5.05	6.4e-07	8.44e-05	-0.29	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41635535	chr1:41542069~41544310:+
THCA	cis	rs9467773	1	rs9986382	ENSG00000261353.1	CTA-14H9.5	-5.05	6.4e-07	8.44e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26527063~26527404:+
THCA	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	5.05	6.4e-07	8.45e-05	0.17	0.23	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
THCA	cis	rs875971	0.54	rs781152	ENSG00000273142.1	RP11-458F8.4	-5.05	6.4e-07	8.45e-05	-0.18	-0.23	Aortic root size;	chr7:66014585	chr7:66902857~66906297:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000273142.1	RP11-458F8.4	-5.05	6.4e-07	8.45e-05	-0.18	-0.23	Calcium levels;	chr7:66014891	chr7:66902857~66906297:+
THCA	cis	rs9307551	0.741	rs13128134	ENSG00000250334.4	LINC00989	-5.05	6.4e-07	8.45e-05	-0.3	-0.23	Refractive error;	chr4:79551143	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.741	rs10025630	ENSG00000250334.4	LINC00989	-5.05	6.4e-07	8.45e-05	-0.3	-0.23	Refractive error;	chr4:79551641	chr4:79492416~79576460:+
THCA	cis	rs919433	0.783	rs788007	ENSG00000231621.1	AC013264.2	-5.05	6.41e-07	8.45e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368952	chr2:197197991~197199273:+
THCA	cis	rs2439831	0.681	rs2242067	ENSG00000205771.5	CATSPER2P1	-5.05	6.41e-07	8.45e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43407105	chr15:43726918~43747094:-
THCA	cis	rs757978	0.733	rs41342147	ENSG00000223374.1	AC005104.3	5.05	6.41e-07	8.45e-05	0.23	0.23	Chronic lymphocytic leukemia;	chr2:241468173	chr2:241351340~241353104:-
THCA	cis	rs3734266	0.702	rs13196983	ENSG00000272288.4	RP11-140K17.3	-5.05	6.41e-07	8.46e-05	-0.23	-0.23	Systemic lupus erythematosus;	chr6:34712698	chr6:34696317~34697470:+
THCA	cis	rs987724	0.593	rs13316183	ENSG00000240875.4	LINC00886	-5.05	6.41e-07	8.46e-05	-0.18	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156942983	chr3:156747346~156817062:-
THCA	cis	rs16975963	0.644	rs11665759	ENSG00000226686.6	LINC01535	-5.05	6.42e-07	8.46e-05	-0.31	-0.23	Longevity;	chr19:37548773	chr19:37251912~37265535:+
THCA	cis	rs1015362	0.869	rs6088411	ENSG00000275784.1	RP5-1125A11.6	5.05	6.42e-07	8.47e-05	0.24	0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33989480~33991818:-
THCA	cis	rs17123764	1	rs7301209	ENSG00000257464.1	RP11-161H23.8	-5.05	6.42e-07	8.47e-05	-0.36	-0.23	Intelligence (multi-trait analysis);	chr12:49552268	chr12:49442424~49442652:-
THCA	cis	rs919433	0.68	rs787983	ENSG00000231621.1	AC013264.2	-5.05	6.42e-07	8.47e-05	-0.23	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197481073	chr2:197197991~197199273:+
THCA	cis	rs6142102	0.651	rs6119463	ENSG00000275784.1	RP5-1125A11.6	5.05	6.42e-07	8.47e-05	0.24	0.23	Skin pigmentation;	chr20:34149412	chr20:33989480~33991818:-
THCA	cis	rs7394190	0.935	rs12570126	ENSG00000271816.1	BMS1P4	5.05	6.43e-07	8.47e-05	0.25	0.23	Incident atrial fibrillation;	chr10:73657031	chr10:73699151~73730487:-
THCA	cis	rs10266483	0.739	rs12665990	ENSG00000271550.1	BNIP3P11	-5.05	6.43e-07	8.48e-05	-0.32	-0.23	Response to statin therapy;	chr7:64404622	chr7:64678954~64687393:-
THCA	cis	rs13178541	0.638	rs34465140	ENSG00000250378.1	RP11-119J18.1	-5.05	6.43e-07	8.48e-05	-0.26	-0.23	IgG glycosylation;	chr5:135713707	chr5:135812667~135826582:+
THCA	cis	rs7772486	0.686	rs1337839	ENSG00000270638.1	RP3-466P17.1	-5.05	6.43e-07	8.48e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145735570~145737218:+
THCA	cis	rs713477	0.631	rs7145182	ENSG00000258413.1	RP11-665C16.6	5.05	6.43e-07	8.48e-05	0.3	0.23	Pediatric bone mineral content (femoral neck);	chr14:55438513	chr14:55262767~55272075:-
THCA	cis	rs1395	0.778	rs2580759	ENSG00000234072.1	AC074117.10	5.05	6.44e-07	8.49e-05	0.2	0.23	Blood metabolite levels;	chr2:27209632	chr2:27356246~27367622:+
THCA	cis	rs6005807	0.543	rs2294431	ENSG00000226471.5	CTA-292E10.6	-5.05	6.44e-07	8.49e-05	-0.27	-0.23	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28781212	chr22:28800683~28848559:+
THCA	cis	rs7428	0.545	rs17026212	ENSG00000273196.1	RP11-717A5.2	5.05	6.44e-07	8.49e-05	0.24	0.23	Ear protrusion;	chr2:85324573	chr2:85387074~85387146:-
THCA	cis	rs354225	0.608	rs168505	ENSG00000237887.1	AC092839.1	-5.05	6.44e-07	8.49e-05	-0.27	-0.23	Schizophrenia;	chr2:54693831	chr2:54529343~54529801:+
THCA	cis	rs7474896	0.559	rs1735641	ENSG00000263064.2	RP11-291L22.7	-5.05	6.44e-07	8.49e-05	-0.3	-0.23	Obesity (extreme);	chr10:37895924	chr10:38448689~38448949:+
THCA	cis	rs867371	0.502	rs28610286	ENSG00000259429.4	UBE2Q2P2	-5.05	6.44e-07	8.49e-05	-0.18	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82355142~82420075:+
THCA	cis	rs35160687	0.644	rs4832264	ENSG00000273080.1	RP11-301O19.1	-5.05	6.44e-07	8.49e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86259711	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.623	rs13005014	ENSG00000273080.1	RP11-301O19.1	-5.05	6.44e-07	8.49e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86260093	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.644	rs4832265	ENSG00000273080.1	RP11-301O19.1	-5.05	6.44e-07	8.49e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86261142	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.644	rs1863056	ENSG00000273080.1	RP11-301O19.1	-5.05	6.44e-07	8.49e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86264122	chr2:86195590~86196049:+
THCA	cis	rs3734266	0.702	rs13209544	ENSG00000272288.4	RP11-140K17.3	-5.05	6.44e-07	8.49e-05	-0.23	-0.23	Systemic lupus erythematosus;	chr6:34620190	chr6:34696317~34697470:+
THCA	cis	rs7851660	0.809	rs7037324	ENSG00000214417.4	KRT18P13	-5.05	6.44e-07	8.49e-05	-0.2	-0.23	Strep throat;	chr9:97896036	chr9:97698922~97700734:+
THCA	cis	rs78487399	0.908	rs77888770	ENSG00000234936.1	AC010883.5	5.05	6.44e-07	8.49e-05	0.31	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43559968	chr2:43229573~43233394:+
THCA	cis	rs481331	0.689	rs209376	ENSG00000215146.4	RP11-313J2.1	-5.05	6.44e-07	8.49e-05	-0.36	-0.23	Systemic juvenile idiopathic arthritis;	chr10:42604792	chr10:42331866~42367974:-
THCA	cis	rs728616	0.558	rs55803802	ENSG00000242600.5	MBL1P	5.05	6.44e-07	8.5e-05	0.24	0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79904898~79950336:+
THCA	cis	rs11051970	0.636	rs2733704	ENSG00000274964.1	RP11-817I4.1	-5.05	6.44e-07	8.5e-05	-0.24	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32414924	chr12:32339368~32340724:+
THCA	cis	rs911119	0.913	rs13037490	ENSG00000270001.1	RP11-218C14.8	-5.05	6.45e-07	8.5e-05	-0.36	-0.23	Chronic kidney disease;	chr20:23603088	chr20:23631826~23632316:-
THCA	cis	rs11733284	1	rs11733284	ENSG00000259959.1	RP11-121C2.2	5.05	6.45e-07	8.5e-05	0.19	0.23	Gout;Renal underexcretion gout;	chr4:48026080	chr4:47840122~47844339:-
THCA	cis	rs11733284	1	rs13120847	ENSG00000259959.1	RP11-121C2.2	5.05	6.45e-07	8.5e-05	0.19	0.23	Gout;Renal underexcretion gout;	chr4:48028019	chr4:47840122~47844339:-
THCA	cis	rs11992162	0.933	rs10108075	ENSG00000227888.4	FAM66A	5.05	6.45e-07	8.5e-05	0.29	0.23	Monocyte count;	chr8:11974570	chr8:12362019~12388296:+
THCA	cis	rs1129187	0.755	rs9462856	ENSG00000272223.1	RP1-20C7.6	5.05	6.45e-07	8.5e-05	0.17	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42958286	chr6:43033897~43034405:-
THCA	cis	rs6860806	0.507	rs2631369	ENSG00000237714.1	P4HA2-AS1	-5.05	6.45e-07	8.5e-05	-0.3	-0.23	Breast cancer;	chr5:132369574	chr5:132184876~132192808:+
THCA	cis	rs274567	0.501	rs2631368	ENSG00000237714.1	P4HA2-AS1	-5.05	6.45e-07	8.5e-05	-0.3	-0.23	Blood metabolite levels;	chr5:132369605	chr5:132184876~132192808:+
THCA	cis	rs9923856	0.519	rs720130	ENSG00000274038.1	RP11-66H6.4	5.05	6.45e-07	8.51e-05	0.27	0.23	Atopic dermatitis;Adult asthma;	chr16:11038776	chr16:11056556~11057034:+
THCA	cis	rs228614	0.51	rs223451	ENSG00000248971.2	KRT8P46	-5.05	6.45e-07	8.51e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223450	ENSG00000248971.2	KRT8P46	-5.05	6.45e-07	8.51e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102728746~102730171:-
THCA	cis	rs16852403	0.548	rs623225	ENSG00000224687.1	RASAL2-AS1	-5.05	6.45e-07	8.51e-05	-0.33	-0.23	Childhood ear infection;	chr1:178242187	chr1:178091508~178093984:-
THCA	cis	rs8046148	0.724	rs8051216	ENSG00000279356.1	RP11-429P3.8	5.05	6.46e-07	8.52e-05	0.26	0.23	Testicular germ cell tumor;	chr16:50079862	chr16:50072862~50074986:+
THCA	cis	rs9813712	0.597	rs11711883	ENSG00000253540.4	FAM86HP	-5.05	6.46e-07	8.52e-05	-0.24	-0.23	Response to amphetamines;	chr3:130241367	chr3:130099092~130111472:-
THCA	cis	rs9813712	0.574	rs62281647	ENSG00000253540.4	FAM86HP	-5.05	6.46e-07	8.52e-05	-0.24	-0.23	Response to amphetamines;	chr3:130242670	chr3:130099092~130111472:-
THCA	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	5.05	6.46e-07	8.52e-05	0.3	0.23	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
THCA	cis	rs11992162	1	rs7460395	ENSG00000254948.1	OR7E158P	-5.05	6.46e-07	8.52e-05	-0.28	-0.23	Monocyte count;	chr8:11977866	chr8:11919900~11920809:-
THCA	cis	rs2803122	0.967	rs10757040	ENSG00000273226.1	RP11-513M16.8	-5.05	6.46e-07	8.52e-05	-0.2	-0.23	Pulse pressure;	chr9:19241849	chr9:19375451~19375996:+
THCA	cis	rs2803122	0.934	rs2175378	ENSG00000273226.1	RP11-513M16.8	-5.05	6.46e-07	8.52e-05	-0.2	-0.23	Pulse pressure;	chr9:19241965	chr9:19375451~19375996:+
THCA	cis	rs9393777	0.92	rs34071253	ENSG00000280107.1	AL022393.9	-5.05	6.46e-07	8.52e-05	-0.39	-0.23	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28170845~28172521:+
THCA	cis	rs79243044	1	rs10769054	ENSG00000224295.2	AC087380.14	-5.05	6.46e-07	8.52e-05	-0.23	-0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5545259	chr11:5518441~5524955:-
THCA	cis	rs79243044	0.932	rs10838300	ENSG00000224295.2	AC087380.14	-5.05	6.46e-07	8.52e-05	-0.23	-0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5545659	chr11:5518441~5524955:-
THCA	cis	rs4273100	0.526	rs2074280	ENSG00000265185.4	SNORD3B-1	5.05	6.46e-07	8.52e-05	0.32	0.23	Schizophrenia;	chr17:19014602	chr17:19061912~19062669:+
THCA	cis	rs11950562	0.54	rs157577	ENSG00000237714.1	P4HA2-AS1	5.05	6.47e-07	8.52e-05	0.33	0.23	Mean platelet volume;Blood metabolite levels;	chr5:132227878	chr5:132184876~132192808:+
THCA	cis	rs875971	0.545	rs313830	ENSG00000232546.1	RP11-458F8.1	-5.05	6.47e-07	8.52e-05	-0.22	-0.23	Aortic root size;	chr7:66086944	chr7:66848496~66858136:+
THCA	cis	rs7246657	0.722	rs12979640	ENSG00000276846.1	CTD-3220F14.3	-5.05	6.47e-07	8.52e-05	-0.23	-0.23	Coronary artery calcification;	chr19:37688255	chr19:37314868~37315620:-
THCA	cis	rs783540	0.521	rs28719490	ENSG00000278603.1	RP13-608F4.5	5.05	6.47e-07	8.53e-05	0.33	0.23	Schizophrenia;	chr15:82720688	chr15:82472203~82472426:+
THCA	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-5.05	6.47e-07	8.53e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-5.05	6.47e-07	8.53e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-5.05	6.47e-07	8.53e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
THCA	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-5.05	6.47e-07	8.53e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
THCA	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-5.05	6.47e-07	8.53e-05	-0.31	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
THCA	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-5.05	6.47e-07	8.53e-05	-0.31	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
THCA	cis	rs7523875	0.72	rs17017432	ENSG00000153363.11	LINC00467	5.05	6.47e-07	8.53e-05	0.23	0.23	Mean corpuscular volume;	chr1:211371752	chr1:211382803~211435333:+
THCA	cis	rs7614311	1	rs7614311	ENSG00000271843.1	RP11-245J9.5	-5.05	6.47e-07	8.53e-05	-0.33	-0.23	Lung function (FVC);Lung function (FEV1);	chr3:63827978	chr3:64008082~64008692:-
THCA	cis	rs736408	0.812	rs6778329	ENSG00000243224.1	RP5-1157M23.2	-5.05	6.48e-07	8.54e-05	-0.25	-0.23	Bipolar disorder;	chr3:52790594	chr3:52239258~52241097:+
THCA	cis	rs224278	1	rs7096645	ENSG00000238280.1	RP11-436D10.3	-5.05	6.48e-07	8.54e-05	-0.26	-0.23	Ewing sarcoma;	chr10:62823389	chr10:62793562~62805887:-
THCA	cis	rs16975963	0.644	rs73033145	ENSG00000226686.6	LINC01535	-5.05	6.48e-07	8.54e-05	-0.31	-0.23	Longevity;	chr19:37606412	chr19:37251912~37265535:+
THCA	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	5.05	6.48e-07	8.54e-05	0.3	0.23	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
THCA	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	5.05	6.48e-07	8.54e-05	0.3	0.23	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
THCA	cis	rs11722779	0.81	rs223417	ENSG00000248971.2	KRT8P46	-5.05	6.49e-07	8.55e-05	-0.28	-0.23	Schizophrenia;	chr4:102810568	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.805	rs223416	ENSG00000248971.2	KRT8P46	-5.05	6.49e-07	8.55e-05	-0.28	-0.23	Schizophrenia;	chr4:102810580	chr4:102728746~102730171:-
THCA	cis	rs16975963	0.644	rs73033139	ENSG00000226686.6	LINC01535	-5.05	6.49e-07	8.55e-05	-0.31	-0.23	Longevity;	chr19:37600784	chr19:37251912~37265535:+
THCA	cis	rs59918340	0.764	rs9324542	ENSG00000253307.1	RP11-10J21.4	-5.05	6.49e-07	8.55e-05	-0.32	-0.23	Immature fraction of reticulocytes;	chr8:141217755	chr8:141252286~141253292:-
THCA	cis	rs6951245	1	rs77868187	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs11763793	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs11763835	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs78861357	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.872	rs76713558	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.748	rs79658522	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.935	rs76525951	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs79683221	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs78185801	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs80031817	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs78143408	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.938	rs78351779	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs11761941	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs11767527	ENSG00000229043.2	AC091729.9	-5.05	6.49e-07	8.55e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1160374~1165267:+
THCA	cis	rs8020095	0.528	rs1955604	ENSG00000258561.1	RP11-72M17.1	-5.05	6.49e-07	8.55e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66969723	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs1138802	ENSG00000258561.1	RP11-72M17.1	-5.05	6.49e-07	8.55e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66972952	chr14:66212810~66509394:-
THCA	cis	rs853679	0.546	rs200948	ENSG00000226314.6	ZNF192P1	-5.05	6.49e-07	8.55e-05	-0.38	-0.23	Depression;	chr6:27867494	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs200950	ENSG00000226314.6	ZNF192P1	-5.05	6.49e-07	8.55e-05	-0.38	-0.23	Depression;	chr6:27867994	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs200952	ENSG00000226314.6	ZNF192P1	-5.05	6.49e-07	8.55e-05	-0.38	-0.23	Depression;	chr6:27869198	chr6:28161781~28169594:+
THCA	cis	rs853679	0.546	rs200954	ENSG00000226314.6	ZNF192P1	-5.05	6.49e-07	8.55e-05	-0.38	-0.23	Depression;	chr6:27870986	chr6:28161781~28169594:+
THCA	cis	rs62244186	0.593	rs9814298	ENSG00000214820.3	MPRIPP1	5.04	6.49e-07	8.55e-05	0.23	0.23	Depressive symptoms;	chr3:44830407	chr3:44579938~44581026:-
THCA	cis	rs11977715	0.538	rs3801916	ENSG00000233942.1	AC004012.1	5.04	6.49e-07	8.55e-05	0.3	0.23	Middle childhood and early adolescence aggressive behavior;	chr7:95491707	chr7:95471835~95473998:+
THCA	cis	rs7727544	0.684	rs2516788	ENSG00000263597.1	MIR3936	-5.04	6.49e-07	8.56e-05	-0.22	-0.23	Blood metabolite levels;	chr5:132379873	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.66	rs274563	ENSG00000263597.1	MIR3936	-5.04	6.49e-07	8.56e-05	-0.22	-0.23	Blood metabolite levels;	chr5:132382167	chr5:132365490~132365599:-
THCA	cis	rs736408	0.774	rs4687551	ENSG00000243224.1	RP5-1157M23.2	5.04	6.5e-07	8.56e-05	0.25	0.23	Bipolar disorder;	chr3:52789432	chr3:52239258~52241097:+
THCA	cis	rs10946940	0.632	rs9366698	ENSG00000219392.1	RP1-265C24.5	-5.04	6.5e-07	8.56e-05	-0.27	-0.23	Systemic lupus erythematosus;	chr6:27704256	chr6:28115628~28116551:+
THCA	cis	rs7617773	0.851	rs13068288	ENSG00000199476.1	Y_RNA	-5.04	6.51e-07	8.57e-05	-0.3	-0.23	Coronary artery disease;	chr3:48290261	chr3:48288587~48288694:+
THCA	cis	rs13126694	0.682	rs4504305	ENSG00000248429.4	RP11-597D13.9	5.04	6.51e-07	8.57e-05	0.25	0.23	Blood osmolality (transformed sodium);	chr4:157982801	chr4:158170752~158202877:+
THCA	cis	rs62244186	0.545	rs9284880	ENSG00000214820.3	MPRIPP1	5.04	6.51e-07	8.58e-05	0.23	0.23	Depressive symptoms;	chr3:44717897	chr3:44579938~44581026:-
THCA	cis	rs1552244	1	rs61077902	ENSG00000180385.7	EMC3-AS1	5.04	6.51e-07	8.58e-05	0.25	0.23	Alzheimer's disease;	chr3:10084469	chr3:9986893~10006990:+
THCA	cis	rs2735413	0.522	rs2075737	ENSG00000276007.1	RP11-358L22.3	5.04	6.51e-07	8.58e-05	0.23	0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78023077	chr16:78123243~78124332:+
THCA	cis	rs7727544	0.557	rs2897096	ENSG00000224431.1	AC063976.7	5.04	6.51e-07	8.58e-05	0.19	0.23	Blood metabolite levels;	chr5:132150591	chr5:132199456~132203487:+
THCA	cis	rs180730	0.752	rs2667195	ENSG00000251609.2	SETP12	5.04	6.52e-07	8.58e-05	0.44	0.23	Fasting plasma glucose;	chr4:120886535	chr4:120895494~120897083:-
THCA	cis	rs1005277	0.529	rs1780125	ENSG00000275858.1	RP11-291L22.8	5.04	6.52e-07	8.59e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38450738~38451069:-
THCA	cis	rs950169	0.58	rs17598114	ENSG00000188388.10	GOLGA6L3	5.04	6.53e-07	8.6e-05	0.3	0.23	Schizophrenia;	chr15:84628086	chr15:85240472~85247170:+
THCA	cis	rs950169	0.58	rs11634322	ENSG00000188388.10	GOLGA6L3	5.04	6.53e-07	8.6e-05	0.3	0.23	Schizophrenia;	chr15:84628978	chr15:85240472~85247170:+
THCA	cis	rs1577917	0.655	rs2842600	ENSG00000220563.1	PKMP3	-5.04	6.53e-07	8.6e-05	-0.16	-0.23	Response to antipsychotic treatment;	chr6:85615914	chr6:85659892~85660606:-
THCA	cis	rs7474896	1	rs9417261	ENSG00000263064.2	RP11-291L22.7	5.04	6.53e-07	8.6e-05	0.37	0.23	Obesity (extreme);	chr10:37822841	chr10:38448689~38448949:+
THCA	cis	rs228614	0.509	rs223476	ENSG00000248971.2	KRT8P46	-5.04	6.53e-07	8.6e-05	-0.27	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102728746~102730171:-
THCA	cis	rs228614	0.509	rs150896	ENSG00000248971.2	KRT8P46	-5.04	6.53e-07	8.6e-05	-0.27	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102728746~102730171:-
THCA	cis	rs1823913	0.637	rs897197	ENSG00000280083.1	RP11-317J9.1	5.04	6.53e-07	8.6e-05	0.26	0.23	Obesity-related traits;	chr2:191281456	chr2:191154118~191156070:-
THCA	cis	rs4660261	0.561	rs11210934	ENSG00000237950.1	RP11-7O11.3	5.04	6.53e-07	8.6e-05	0.2	0.23	Intelligence (multi-trait analysis);	chr1:43903763	chr1:43944370~43946551:-
THCA	cis	rs66887589	0.616	rs7659403	ENSG00000249244.1	RP11-548H18.2	5.04	6.54e-07	8.61e-05	0.24	0.23	Diastolic blood pressure;	chr4:119286099	chr4:119391831~119395335:-
THCA	cis	rs1387259	0.69	rs1601985	ENSG00000273765.1	RP11-370I10.11	5.04	6.54e-07	8.61e-05	0.23	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48360920~48361377:+
THCA	cis	rs6121246	0.697	rs6088857	ENSG00000230613.1	HM13-AS1	5.04	6.54e-07	8.61e-05	0.25	0.23	Mean corpuscular hemoglobin;	chr20:31638961	chr20:31567707~31573263:-
THCA	cis	rs613391	0.671	rs488729	ENSG00000224549.1	RP11-370B11.3	-5.04	6.54e-07	8.61e-05	-0.26	-0.23	Quantitative traits;	chr9:22699124	chr9:22767175~22768316:+
THCA	cis	rs613391	0.702	rs1448775	ENSG00000224549.1	RP11-370B11.3	-5.04	6.54e-07	8.61e-05	-0.26	-0.23	Quantitative traits;	chr9:22704376	chr9:22767175~22768316:+
THCA	cis	rs12428035	0.656	rs111904979	ENSG00000247400.3	DNAJC3-AS1	-5.04	6.54e-07	8.61e-05	-0.22	-0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95767820	chr13:95648733~95676925:-
THCA	cis	rs2243480	1	rs160643	ENSG00000229886.1	RP5-1132H15.3	5.04	6.54e-07	8.61e-05	0.36	0.23	Diabetic kidney disease;	chr7:66093235	chr7:66025126~66031544:-
THCA	cis	rs875971	0.54	rs1723268	ENSG00000223473.2	GS1-124K5.3	5.04	6.54e-07	8.62e-05	0.15	0.23	Aortic root size;	chr7:66008093	chr7:66491049~66493566:-
THCA	cis	rs3796352	1	rs13076033	ENSG00000242142.1	SERBP1P3	-5.04	6.54e-07	8.62e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52864411	chr3:53064283~53065091:-
THCA	cis	rs7267979	0.816	rs6037158	ENSG00000125804.12	FAM182A	-5.04	6.55e-07	8.63e-05	-0.28	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26054655~26086917:+
THCA	cis	rs7209700	0.788	rs12949936	ENSG00000228782.6	CTD-2026D20.3	-5.04	6.55e-07	8.63e-05	-0.23	-0.23	IgG glycosylation;	chr17:47295056	chr17:47450568~47492492:-
THCA	cis	rs11051970	0.545	rs2728681	ENSG00000274964.1	RP11-817I4.1	-5.04	6.55e-07	8.63e-05	-0.23	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32430043	chr12:32339368~32340724:+
THCA	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-5.04	6.56e-07	8.63e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
THCA	cis	rs6728642	0.908	rs13400545	ENSG00000230606.9	AC159540.1	5.04	6.56e-07	8.63e-05	0.31	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97205889	chr2:97416165~97433527:-
THCA	cis	rs240993	0.909	rs240991	ENSG00000272356.1	RP5-1112D6.8	-5.04	6.56e-07	8.64e-05	-0.2	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111309203~111313517:+
THCA	cis	rs240993	1	rs240993	ENSG00000272356.1	RP5-1112D6.8	-5.04	6.56e-07	8.64e-05	-0.2	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111309203~111313517:+
THCA	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	5.04	6.56e-07	8.64e-05	0.37	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
THCA	cis	rs1009077	0.68	rs35289699	ENSG00000245958.5	RP11-33B1.1	5.04	6.56e-07	8.64e-05	0.29	0.23	Endometriosis;	chr4:119529235	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.68	rs3775851	ENSG00000245958.5	RP11-33B1.1	5.04	6.56e-07	8.64e-05	0.29	0.23	Endometriosis;	chr4:119532261	chr4:119454791~119552025:+
THCA	cis	rs7394190	0.748	rs4746139	ENSG00000271816.1	BMS1P4	-5.04	6.56e-07	8.64e-05	-0.27	-0.23	Incident atrial fibrillation;	chr10:73647891	chr10:73699151~73730487:-
THCA	cis	rs2439831	0.867	rs45585139	ENSG00000205771.5	CATSPER2P1	-5.04	6.56e-07	8.64e-05	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43408229	chr15:43726918~43747094:-
THCA	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	5.04	6.57e-07	8.65e-05	0.28	0.23	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
THCA	cis	rs1876905	0.539	rs240962	ENSG00000230177.1	RP5-1112D6.4	5.04	6.57e-07	8.65e-05	0.24	0.23	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111277932~111278742:+
THCA	cis	rs5758659	0.652	rs1063392	ENSG00000273366.1	CTA-989H11.1	5.04	6.57e-07	8.65e-05	0.27	0.23	Cognitive function;	chr22:42058946	chr22:42278188~42278846:+
THCA	cis	rs7688540	0.8	rs9328738	ENSG00000275426.1	CH17-262A2.1	-5.04	6.57e-07	8.65e-05	-0.28	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:149738~150317:+
THCA	cis	rs2129782	1	rs79744793	ENSG00000253553.4	RP11-586K2.1	5.04	6.57e-07	8.65e-05	0.41	0.23	Electrodermal activity;	chr8:88332720	chr8:88326836~88737134:+
THCA	cis	rs6832769	1	rs7670225	ENSG00000272969.1	RP11-528I4.2	5.04	6.58e-07	8.66e-05	0.26	0.23	Personality dimensions;	chr4:55501851	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.925	rs3817444	ENSG00000272969.1	RP11-528I4.2	5.04	6.58e-07	8.66e-05	0.26	0.23	Personality dimensions;	chr4:55509814	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.826	rs10462035	ENSG00000272969.1	RP11-528I4.2	5.04	6.58e-07	8.66e-05	0.26	0.23	Personality dimensions;	chr4:55513011	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs2177127	ENSG00000272969.1	RP11-528I4.2	5.04	6.58e-07	8.66e-05	0.26	0.23	Personality dimensions;	chr4:55513792	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs4580704	ENSG00000272969.1	RP11-528I4.2	-5.04	6.58e-07	8.66e-05	-0.26	-0.23	Personality dimensions;	chr4:55460540	chr4:55547112~55547889:+
THCA	cis	rs763121	0.853	rs5750627	ENSG00000273076.1	RP3-508I15.22	5.04	6.58e-07	8.66e-05	0.22	0.23	Menopause (age at onset);	chr22:38586316	chr22:38743495~38743910:+
THCA	cis	rs7851660	0.809	rs1561961	ENSG00000214417.4	KRT18P13	-5.04	6.58e-07	8.66e-05	-0.2	-0.23	Strep throat;	chr9:97905317	chr9:97698922~97700734:+
THCA	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	5.04	6.58e-07	8.66e-05	0.13	0.23	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
THCA	cis	rs2243480	1	rs35542501	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.43	0.23	Diabetic kidney disease;	chr7:65966228	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs78803505	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65917585	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65920739	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65922691	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65925107	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65926730	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65928032	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65929575	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65929781	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65929865	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000164669.11	INTS4P1	5.04	6.58e-07	8.66e-05	0.44	0.23	Diabetic kidney disease;	chr7:65938222	chr7:65141225~65234216:+
THCA	cis	rs9929218	0.559	rs11642362	ENSG00000260459.2	FTLP14	5.04	6.58e-07	8.66e-05	0.26	0.23	Colorectal cancer;	chr16:68777404	chr16:68822587~68823070:+
THCA	cis	rs10904908	0.931	rs7903137	ENSG00000229124.5	VIM-AS1	-5.04	6.59e-07	8.67e-05	-0.22	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17217568	chr10:17214239~17229985:-
THCA	cis	rs897984	0.806	rs12924903	ENSG00000260911.2	RP11-196G11.2	5.04	6.59e-07	8.67e-05	0.19	0.23	Dementia with Lewy bodies;	chr16:30917649	chr16:31043150~31049868:+
THCA	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	5.04	6.59e-07	8.67e-05	0.13	0.23	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	5.04	6.59e-07	8.67e-05	0.13	0.23	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	5.04	6.59e-07	8.67e-05	0.13	0.23	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	5.04	6.59e-07	8.67e-05	0.13	0.23	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
THCA	cis	rs7618915	0.547	rs4130905	ENSG00000243224.1	RP5-1157M23.2	-5.04	6.59e-07	8.67e-05	-0.25	-0.23	Bipolar disorder;	chr3:52675815	chr3:52239258~52241097:+
THCA	cis	rs631288	0.793	rs1530337	ENSG00000226015.2	CCT8P1	5.04	6.59e-07	8.67e-05	0.5	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr1:147211751	chr1:147203276~147204932:-
THCA	cis	rs17404153	0.599	rs11706084	ENSG00000248724.5	NPHP3-AS1	5.04	6.59e-07	8.68e-05	0.33	0.23	LDL cholesterol;HDL cholesterol;	chr3:132413855	chr3:132721750~132874223:+
THCA	cis	rs2243480	1	rs160633	ENSG00000232559.3	GS1-124K5.12	5.04	6.59e-07	8.68e-05	0.33	0.23	Diabetic kidney disease;	chr7:66063241	chr7:66554588~66576923:-
THCA	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	5.04	6.59e-07	8.68e-05	0.13	0.23	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-5.04	6.59e-07	8.68e-05	-0.13	-0.23	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
THCA	cis	rs10186029	0.684	rs13417169	ENSG00000270659.1	RP11-105N14.1	-5.04	6.59e-07	8.68e-05	-0.19	-0.23	Systemic sclerosis;	chr2:213038913	chr2:213152970~213153659:+
THCA	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	5.04	6.6e-07	8.68e-05	0.13	0.23	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
THCA	cis	rs858239	0.6	rs4321896	ENSG00000230042.1	AK3P3	-5.04	6.6e-07	8.69e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs59073109	ENSG00000230042.1	AK3P3	-5.04	6.6e-07	8.69e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs7788821	ENSG00000230042.1	AK3P3	-5.04	6.6e-07	8.69e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs6956595	ENSG00000230042.1	AK3P3	-5.04	6.6e-07	8.69e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23129178~23129841:+
THCA	cis	rs66887589	0.616	rs10032299	ENSG00000249244.1	RP11-548H18.2	5.04	6.6e-07	8.69e-05	0.24	0.23	Diastolic blood pressure;	chr4:119285264	chr4:119391831~119395335:-
THCA	cis	rs8141529	0.732	rs2269577	ENSG00000272858.1	CTA-292E10.8	-5.04	6.6e-07	8.69e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28800769	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.732	rs3788409	ENSG00000272858.1	CTA-292E10.8	-5.04	6.6e-07	8.69e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28802163	chr22:28814914~28815662:+
THCA	cis	rs7824557	0.778	rs3808502	ENSG00000154316.13	TDH	-5.04	6.61e-07	8.69e-05	-0.17	-0.23	Retinal vascular caliber;	chr8:11321949	chr8:11339637~11368452:+
THCA	cis	rs1823913	0.637	rs979967	ENSG00000280083.1	RP11-317J9.1	-5.04	6.61e-07	8.69e-05	-0.26	-0.23	Obesity-related traits;	chr2:191304695	chr2:191154118~191156070:-
THCA	cis	rs4591358	0.684	rs17177643	ENSG00000223466.1	AC064834.2	5.04	6.61e-07	8.69e-05	0.27	0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510796	chr2:195533035~195538681:+
THCA	cis	rs9952991	0.941	rs888270	ENSG00000260302.1	RP11-973H7.1	5.04	6.61e-07	8.7e-05	0.38	0.23	Inflammatory skin disease;	chr18:12774895	chr18:12774651~12775923:-
THCA	cis	rs4693089	0.625	rs541598	ENSG00000213608.5	SLC25A14P1	-5.04	6.61e-07	8.7e-05	-0.26	-0.23	Menopause (age at onset);	chr4:83500559	chr4:83477524~83478424:+
THCA	cis	rs1048886	0.786	rs4706439	ENSG00000271967.1	RP11-134K13.4	5.04	6.61e-07	8.7e-05	0.24	0.23	Type 2 diabetes;	chr6:70387624	chr6:70596438~70596980:+
THCA	cis	rs4660261	0.526	rs803680	ENSG00000237950.1	RP11-7O11.3	5.04	6.61e-07	8.7e-05	0.2	0.23	Intelligence (multi-trait analysis);	chr1:43898698	chr1:43944370~43946551:-
THCA	cis	rs16852403	0.517	rs10494512	ENSG00000224687.1	RASAL2-AS1	5.04	6.61e-07	8.7e-05	0.34	0.23	Childhood ear infection;	chr1:178282545	chr1:178091508~178093984:-
THCA	cis	rs3213758	1	rs1558903	ENSG00000275191.1	RP11-36I17.2	-5.04	6.61e-07	8.7e-05	-0.46	-0.23	Vitiligo (non-segmental);	chr16:53678716	chr16:53628256~53628816:-
THCA	cis	rs17801127	0.515	rs13032416	ENSG00000231969.1	AC144449.1	5.04	6.61e-07	8.7e-05	0.46	0.23	Liver enzyme levels (alanine transaminase);	chr2:149882275	chr2:149587196~149848233:+
THCA	cis	rs5015933	0.902	rs13291306	ENSG00000232630.1	PRPS1P2	-5.04	6.61e-07	8.7e-05	-0.16	-0.23	Body mass index;	chr9:125362519	chr9:125150653~125151589:+
THCA	cis	rs6088580	0.608	rs1205342	ENSG00000276073.1	RP5-1125A11.7	5.04	6.62e-07	8.7e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34334036	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs4258875	ENSG00000276073.1	RP5-1125A11.7	5.04	6.62e-07	8.7e-05	0.2	0.23	Glomerular filtration rate (creatinine);	chr20:34337089	chr20:33985617~33988989:-
THCA	cis	rs7394190	1	rs10824026	ENSG00000271816.1	BMS1P4	-5.04	6.62e-07	8.71e-05	-0.25	-0.23	Incident atrial fibrillation;	chr10:73661450	chr10:73699151~73730487:-
THCA	cis	rs6545883	0.507	rs2123111	ENSG00000270820.4	RP11-355B11.2	-5.04	6.62e-07	8.71e-05	-0.19	-0.23	Tuberculosis;	chr2:61223319	chr2:61471188~61484130:+
THCA	cis	rs2797160	1	rs1418948	ENSG00000237742.5	RP11-624M8.1	5.04	6.62e-07	8.71e-05	0.2	0.23	Endometrial cancer;	chr6:125685872	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs9321050	ENSG00000237742.5	RP11-624M8.1	-5.04	6.62e-07	8.71e-05	-0.2	-0.23	Endometrial cancer;	chr6:125680422	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs4897153	ENSG00000237742.5	RP11-624M8.1	-5.04	6.62e-07	8.71e-05	-0.2	-0.23	Endometrial cancer;	chr6:125682257	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs9401843	ENSG00000237742.5	RP11-624M8.1	-5.04	6.62e-07	8.71e-05	-0.2	-0.23	Endometrial cancer;	chr6:125682978	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1777194	ENSG00000237742.5	RP11-624M8.1	-5.04	6.62e-07	8.71e-05	-0.2	-0.23	Endometrial cancer;	chr6:125683737	chr6:125578558~125749190:-
THCA	cis	rs7577696	0.722	rs466125	ENSG00000276334.1	AL133243.1	5.04	6.62e-07	8.71e-05	0.24	0.23	Inflammatory biomarkers;	chr2:32237023	chr2:32521927~32523547:+
THCA	cis	rs9652601	0.622	rs8056098	ENSG00000274038.1	RP11-66H6.4	-5.04	6.62e-07	8.71e-05	-0.27	-0.23	Systemic lupus erythematosus;	chr16:11044955	chr16:11056556~11057034:+
THCA	cis	rs2439831	0.681	rs484846	ENSG00000205771.5	CATSPER2P1	-5.04	6.62e-07	8.71e-05	-0.29	-0.23	Lung cancer in ever smokers;	chr15:43308605	chr15:43726918~43747094:-
THCA	cis	rs919433	0.783	rs787980	ENSG00000231621.1	AC013264.2	-5.04	6.62e-07	8.71e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197374501	chr2:197197991~197199273:+
THCA	cis	rs7914558	0.966	rs10748836	ENSG00000236937.2	PTGES3P4	5.04	6.63e-07	8.72e-05	0.29	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102934160	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs10786727	ENSG00000236937.2	PTGES3P4	5.04	6.63e-07	8.72e-05	0.29	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102938766	chr10:102845595~102845950:+
THCA	cis	rs7136259	0.678	rs10858915	ENSG00000258302.2	RP11-981P6.1	5.04	6.63e-07	8.72e-05	0.19	0.23	Coronary heart disease;	chr12:89657770	chr12:89561129~89594878:+
THCA	cis	rs6058796	0.892	rs35103329	ENSG00000175730.8	BAK1P1	5.04	6.63e-07	8.72e-05	0.35	0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32650337	chr20:32690180~32690815:-
THCA	cis	rs875971	0.522	rs1701760	ENSG00000273142.1	RP11-458F8.4	-5.04	6.63e-07	8.72e-05	-0.18	-0.23	Aortic root size;	chr7:66008701	chr7:66902857~66906297:+
THCA	cis	rs7806994	1	rs7806994	ENSG00000226278.1	PSPHP1	-5.04	6.63e-07	8.73e-05	-0.34	-0.23	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55764797~55773288:+
THCA	cis	rs4950322	0.542	rs2883434	ENSG00000180867.10	PDIA3P1	5.04	6.64e-07	8.73e-05	0.21	0.23	Protein quantitative trait loci;	chr1:147177505	chr1:147178113~147179622:+
THCA	cis	rs9302635	0.745	rs35909200	ENSG00000260886.1	TAT-AS1	5.04	6.64e-07	8.73e-05	0.37	0.23	Blood protein levels;	chr16:72122767	chr16:71565789~71578187:+
THCA	cis	rs7208859	0.673	rs11656462	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.64e-07	8.73e-05	-0.36	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30738182~30740275:+
THCA	cis	rs875971	0.545	rs313830	ENSG00000228409.4	CCT6P1	5.04	6.64e-07	8.73e-05	0.2	0.23	Aortic root size;	chr7:66086944	chr7:65751142~65763354:+
THCA	cis	rs62292953	0.79	rs62293981	ENSG00000248724.5	NPHP3-AS1	-5.04	6.64e-07	8.74e-05	-0.42	-0.23	Red cell distribution width;	chr3:132532903	chr3:132721750~132874223:+
THCA	cis	rs9307551	0.584	rs2903636	ENSG00000250334.4	LINC00989	-5.04	6.64e-07	8.74e-05	-0.27	-0.23	Refractive error;	chr4:79542125	chr4:79492416~79576460:+
THCA	cis	rs11051970	0.679	rs2733696	ENSG00000274964.1	RP11-817I4.1	-5.04	6.65e-07	8.74e-05	-0.24	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32401701	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.704	rs7312698	ENSG00000274964.1	RP11-817I4.1	-5.04	6.65e-07	8.74e-05	-0.24	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32401761	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.704	rs2733694	ENSG00000274964.1	RP11-817I4.1	-5.04	6.65e-07	8.74e-05	-0.24	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32402296	chr12:32339368~32340724:+
THCA	cis	rs6088590	1	rs6119535	ENSG00000269202.1	RP4-614O4.12	-5.04	6.65e-07	8.74e-05	-0.21	-0.23	Coronary artery disease;	chr20:34854335	chr20:35201747~35203288:-
THCA	cis	rs7731390	0.614	rs77318058	ENSG00000233006.5	AC034220.3	5.04	6.65e-07	8.74e-05	0.3	0.23	IgG glycosylation;	chr5:132361291	chr5:132311285~132369916:-
THCA	cis	rs7045881	0.8	rs1336332	ENSG00000254396.1	RP11-56F10.3	5.04	6.65e-07	8.75e-05	0.41	0.23	Schizophrenia;	chr9:26843344	chr9:27102630~27104728:+
THCA	cis	rs651907	0.557	rs36002990	ENSG00000244119.1	PDCL3P4	5.04	6.65e-07	8.75e-05	0.21	0.23	Colorectal cancer;	chr3:101719018	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs11720745	ENSG00000244119.1	PDCL3P4	5.04	6.65e-07	8.75e-05	0.21	0.23	Colorectal cancer;	chr3:101722846	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs35117343	ENSG00000244119.1	PDCL3P4	5.04	6.65e-07	8.75e-05	0.21	0.23	Colorectal cancer;	chr3:101726282	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs11914318	ENSG00000244119.1	PDCL3P4	5.04	6.65e-07	8.75e-05	0.21	0.23	Colorectal cancer;	chr3:101735014	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs1031710	ENSG00000244119.1	PDCL3P4	5.04	6.65e-07	8.75e-05	0.21	0.23	Colorectal cancer;	chr3:101745051	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs13065944	ENSG00000244119.1	PDCL3P4	5.04	6.65e-07	8.75e-05	0.21	0.23	Colorectal cancer;	chr3:101754244	chr3:101712472~101713191:+
THCA	cis	rs8141529	0.956	rs132539	ENSG00000226471.5	CTA-292E10.6	-5.04	6.65e-07	8.75e-05	-0.19	-0.23	Lymphocyte counts;	chr22:28908265	chr22:28800683~28848559:+
THCA	cis	rs7688540	0.771	rs4129956	ENSG00000211553.1	AC253576.2	-5.04	6.65e-07	8.75e-05	-0.35	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:136461~136568:+
THCA	cis	rs897984	0.806	rs12924903	ENSG00000275263.1	RP11-1072A3.4	-5.04	6.65e-07	8.75e-05	-0.27	-0.23	Dementia with Lewy bodies;	chr16:30917649	chr16:30956872~30957199:-
THCA	cis	rs7608910	0.832	rs6754346	ENSG00000271889.1	RP11-493E12.1	5.04	6.65e-07	8.75e-05	0.24	0.23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60970660	chr2:61151433~61162105:-
THCA	cis	rs1707322	1	rs4660332	ENSG00000281133.1	AL355480.3	-5.04	6.66e-07	8.75e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45580892~45580996:-
THCA	cis	rs2337406	1	rs11850709	ENSG00000211974.3	IGHV2-70	-5.04	6.66e-07	8.75e-05	-0.23	-0.23	Alzheimer's disease (late onset);	chr14:106670844	chr14:106723574~106724093:-
THCA	cis	rs3002142	0.731	rs3008620	ENSG00000272750.1	RP11-378J18.8	-5.04	6.66e-07	8.76e-05	-0.35	-0.23	LDL peak particle diameter (total fat intake interaction);	chr1:222629584	chr1:222658867~222661512:-
THCA	cis	rs4934494	0.677	rs1409360	ENSG00000232936.4	RP11-80H5.2	5.04	6.67e-07	8.76e-05	0.31	0.23	Red blood cell count;	chr10:89625547	chr10:89645282~89650667:+
THCA	cis	rs7688540	0.8	rs61792060	ENSG00000250892.1	RP11-1365D11.1	5.04	6.67e-07	8.76e-05	0.31	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:201409~205009:-
THCA	cis	rs2735413	0.563	rs8046446	ENSG00000276007.1	RP11-358L22.3	5.04	6.67e-07	8.77e-05	0.26	0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78015689	chr16:78123243~78124332:+
THCA	cis	rs875971	0.502	rs1796227	ENSG00000228409.4	CCT6P1	5.04	6.67e-07	8.77e-05	0.19	0.23	Aortic root size;	chr7:66622032	chr7:65751142~65763354:+
THCA	cis	rs8177876	0.822	rs1563077	ENSG00000261061.1	RP11-303E16.2	-5.04	6.67e-07	8.77e-05	-0.32	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81030770~81031485:+
THCA	cis	rs12478296	1	rs6717667	ENSG00000261186.2	RP11-341N2.1	-5.04	6.67e-07	8.77e-05	-0.36	-0.23	Obesity-related traits;	chr2:242055379	chr2:242087351~242088457:-
THCA	cis	rs453301	0.624	rs330058	ENSG00000248538.5	RP11-10A14.5	5.04	6.67e-07	8.77e-05	0.28	0.23	Joint mobility (Beighton score);	chr8:9232299	chr8:9189011~9202854:+
THCA	cis	rs4660456	0.913	rs12567755	ENSG00000272145.1	NFYC-AS1	5.04	6.68e-07	8.78e-05	0.16	0.23	Platelet count;	chr1:40751813	chr1:40690380~40692066:-
THCA	cis	rs4448343	1	rs4448343	ENSG00000271155.1	RP11-435O5.5	-5.04	6.68e-07	8.78e-05	-0.23	-0.23	Height;	chr9:95504088	chr9:95506235~95507636:+
THCA	cis	rs1129187	0.791	rs1129186	ENSG00000272223.1	RP1-20C7.6	5.04	6.68e-07	8.78e-05	0.17	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42964464	chr6:43033897~43034405:-
THCA	cis	rs2337406	0.866	rs4773949	ENSG00000211974.3	IGHV2-70	5.04	6.68e-07	8.78e-05	0.2	0.23	Alzheimer's disease (late onset);	chr14:106808070	chr14:106723574~106724093:-
THCA	cis	rs79040073	0.593	rs11632038	ENSG00000259531.2	RP11-295H24.3	5.04	6.68e-07	8.78e-05	0.33	0.23	Lung cancer in ever smokers;	chr15:49314101	chr15:49365124~49366685:-
THCA	cis	rs2562456	0.833	rs62110367	ENSG00000268119.4	CTD-2561J22.5	5.04	6.68e-07	8.78e-05	0.33	0.23	Pain;	chr19:21365829	chr19:21444241~21463908:-
THCA	cis	rs10435719	0.746	rs58007588	ENSG00000206014.6	OR7E161P	-5.04	6.69e-07	8.79e-05	-0.27	-0.23	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:11928597~11929563:-
THCA	cis	rs3734266	0.702	rs9462002	ENSG00000272288.4	RP11-140K17.3	-5.04	6.69e-07	8.79e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr6:34691457	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs9462003	ENSG00000272288.4	RP11-140K17.3	-5.04	6.69e-07	8.79e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr6:34692161	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs72910111	ENSG00000272288.4	RP11-140K17.3	-5.04	6.69e-07	8.79e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr6:34699627	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs7759985	ENSG00000272288.4	RP11-140K17.3	-5.04	6.69e-07	8.79e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr6:34703009	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs6909393	ENSG00000272288.4	RP11-140K17.3	-5.04	6.69e-07	8.79e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr6:34705719	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.591	rs7749750	ENSG00000272288.4	RP11-140K17.3	-5.04	6.69e-07	8.79e-05	-0.22	-0.23	Systemic lupus erythematosus;	chr6:34709268	chr6:34696317~34697470:+
THCA	cis	rs972578	0.715	rs4820485	ENSG00000274717.1	RP1-47A17.1	-5.04	6.69e-07	8.79e-05	-0.24	-0.23	Mean platelet volume;	chr22:42816426	chr22:42791814~42794313:-
THCA	cis	rs972578	0.715	rs17409550	ENSG00000274717.1	RP1-47A17.1	-5.04	6.69e-07	8.79e-05	-0.24	-0.23	Mean platelet volume;	chr22:42818394	chr22:42791814~42794313:-
THCA	cis	rs736408	0.57	rs11130327	ENSG00000243224.1	RP5-1157M23.2	-5.04	6.69e-07	8.79e-05	-0.25	-0.23	Bipolar disorder;	chr3:52759223	chr3:52239258~52241097:+
THCA	cis	rs4713118	0.513	rs200971	ENSG00000280107.1	AL022393.9	-5.04	6.7e-07	8.8e-05	-0.25	-0.23	Parkinson's disease;	chr6:27891126	chr6:28170845~28172521:+
THCA	cis	rs13138355	1	rs13138355	ENSG00000270480.1	RP11-57B24.1	5.04	6.7e-07	8.8e-05	0.36	0.23	Myeloid white cell count;White blood cell count;Monocyte count;	chr4:82624823	chr4:82691737~82692468:+
THCA	cis	rs1129187	0.755	rs13215983	ENSG00000272223.1	RP1-20C7.6	5.04	6.7e-07	8.81e-05	0.17	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42956455	chr6:43033897~43034405:-
THCA	cis	rs9296404	1	rs9296404	ENSG00000272223.1	RP1-20C7.6	5.04	6.7e-07	8.81e-05	0.17	0.23	Plasma homocysteine levels (post-methionine load test);	chr6:42958065	chr6:43033897~43034405:-
THCA	cis	rs1129187	0.755	rs9462855	ENSG00000272223.1	RP1-20C7.6	5.04	6.7e-07	8.81e-05	0.17	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42958198	chr6:43033897~43034405:-
THCA	cis	rs7727544	0.684	rs272889	ENSG00000263597.1	MIR3936	5.04	6.71e-07	8.81e-05	0.22	0.23	Blood metabolite levels;	chr5:132329685	chr5:132365490~132365599:-
THCA	cis	rs7487637	0.529	rs56389811	ENSG00000276691.1	RP5-1057I20.5	5.04	6.71e-07	8.81e-05	0.31	0.23	Mononucleosis;	chr12:47811575	chr12:47788426~47788971:+
THCA	cis	rs4648045	0.828	rs230508	ENSG00000246560.2	RP11-10L12.4	-5.04	6.71e-07	8.82e-05	-0.28	-0.23	Lymphocyte percentage of white cells;	chr4:102558122	chr4:102828055~102844075:+
THCA	cis	rs858239	0.539	rs2390757	ENSG00000226816.2	AC005082.12	5.04	6.71e-07	8.82e-05	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23206013~23208045:+
THCA	cis	rs6832769	0.961	rs10009593	ENSG00000272969.1	RP11-528I4.2	-5.04	6.71e-07	8.82e-05	-0.26	-0.23	Personality dimensions;	chr4:55570514	chr4:55547112~55547889:+
THCA	cis	rs1387259	0.759	rs7960122	ENSG00000273765.1	RP11-370I10.11	-5.04	6.71e-07	8.82e-05	-0.23	-0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48360920~48361377:+
THCA	cis	rs7512898	0.522	rs7520287	ENSG00000260088.1	RP11-92G12.3	-5.04	6.72e-07	8.82e-05	-0.31	-0.23	Electrocardiographic conduction measures;	chr1:200781448	chr1:200669507~200694250:+
THCA	cis	rs7246657	0.525	rs1667357	ENSG00000276846.1	CTD-3220F14.3	5.04	6.72e-07	8.82e-05	0.24	0.23	Coronary artery calcification;	chr19:36993450	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.525	rs1667359	ENSG00000276846.1	CTD-3220F14.3	5.04	6.72e-07	8.82e-05	0.24	0.23	Coronary artery calcification;	chr19:36995270	chr19:37314868~37315620:-
THCA	cis	rs317689	0.658	rs490872	ENSG00000274979.1	RP11-1143G9.5	-5.04	6.72e-07	8.82e-05	-0.26	-0.23	Response to diuretic therapy;	chr12:69252084	chr12:69326574~69331882:-
THCA	cis	rs6968419	0.747	rs12670683	ENSG00000237870.5	AC073130.1	5.04	6.72e-07	8.83e-05	0.25	0.23	Intraocular pressure;	chr7:116234412	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs2030978	ENSG00000237870.5	AC073130.1	5.04	6.72e-07	8.83e-05	0.25	0.23	Intraocular pressure;	chr7:116234506	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs2030977	ENSG00000237870.5	AC073130.1	5.04	6.72e-07	8.83e-05	0.25	0.23	Intraocular pressure;	chr7:116235305	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs6959237	ENSG00000237870.5	AC073130.1	5.04	6.72e-07	8.83e-05	0.25	0.23	Intraocular pressure;	chr7:116236311	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs3807975	ENSG00000237870.5	AC073130.1	5.04	6.72e-07	8.83e-05	0.25	0.23	Intraocular pressure;	chr7:116240223	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.781	rs66652906	ENSG00000237870.5	AC073130.1	5.04	6.72e-07	8.83e-05	0.25	0.23	Intraocular pressure;	chr7:116241105	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs58595078	ENSG00000237870.5	AC073130.1	5.04	6.72e-07	8.83e-05	0.25	0.23	Intraocular pressure;	chr7:116241404	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.747	rs3757730	ENSG00000237870.5	AC073130.1	5.04	6.72e-07	8.83e-05	0.25	0.23	Intraocular pressure;	chr7:116242269	chr7:116275606~116286734:-
THCA	cis	rs2380220	0.606	rs4571572	ENSG00000261366.1	MANEA-AS1	-5.04	6.72e-07	8.83e-05	-0.22	-0.23	Behavioural disinhibition (generation interaction);	chr6:95556947	chr6:95575183~95577450:-
THCA	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-5.04	6.72e-07	8.83e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-5.04	6.72e-07	8.83e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
THCA	cis	rs1552244	1	rs9849434	ENSG00000180385.7	EMC3-AS1	-5.04	6.72e-07	8.83e-05	-0.25	-0.23	Alzheimer's disease;	chr3:10092026	chr3:9986893~10006990:+
THCA	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	5.04	6.73e-07	8.84e-05	0.36	0.23	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
THCA	cis	rs9875589	0.509	rs9867041	ENSG00000228242.5	AC093495.4	5.04	6.73e-07	8.84e-05	0.13	0.23	Ovarian reserve;	chr3:13973115	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs11718142	ENSG00000228242.5	AC093495.4	5.04	6.73e-07	8.84e-05	0.13	0.23	Ovarian reserve;	chr3:13977293	chr3:14144637~14165978:+
THCA	cis	rs2070488	0.775	rs1073505	ENSG00000229589.1	ACVR2B-AS1	-5.04	6.73e-07	8.84e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38525231	chr3:38451027~38454820:-
THCA	cis	rs4660456	0.913	rs4660449	ENSG00000272145.1	NFYC-AS1	-5.04	6.73e-07	8.84e-05	-0.16	-0.23	Platelet count;	chr1:40739780	chr1:40690380~40692066:-
THCA	cis	rs9425766	0.679	rs6681618	ENSG00000227373.4	RP11-160H22.5	-5.04	6.73e-07	8.84e-05	-0.32	-0.23	Life satisfaction;	chr1:174201203	chr1:174115300~174160004:-
THCA	cis	rs2985684	0.948	rs4900925	ENSG00000278009.1	RP11-649E7.8	-5.04	6.73e-07	8.84e-05	-0.31	-0.23	Carotid intima media thickness;	chr14:49545607	chr14:49601011~49601124:-
THCA	cis	rs2239547	0.522	rs4519686	ENSG00000242142.1	SERBP1P3	5.04	6.73e-07	8.84e-05	0.28	0.23	Schizophrenia;	chr3:52963855	chr3:53064283~53065091:-
THCA	cis	rs8020095	0.528	rs73279056	ENSG00000258561.1	RP11-72M17.1	-5.04	6.73e-07	8.85e-05	-0.29	-0.23	Depression (quantitative trait);	chr14:67234819	chr14:66212810~66509394:-
THCA	cis	rs9467773	1	rs6930120	ENSG00000261353.1	CTA-14H9.5	-5.04	6.73e-07	8.85e-05	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26527063~26527404:+
THCA	cis	rs12030196	0.827	rs932772	ENSG00000230812.4	LINC01358	5.04	6.74e-07	8.85e-05	0.28	0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58968221	chr1:59020387~59044614:+
THCA	cis	rs2255336	0.873	rs10743888	ENSG00000245648.1	RP11-277P12.20	5.04	6.74e-07	8.85e-05	0.27	0.23	Blood protein levels;	chr12:10368255	chr12:10363769~10398506:+
THCA	cis	rs2067615	0.524	rs7309351	ENSG00000260329.1	RP11-412D9.4	5.04	6.74e-07	8.86e-05	0.21	0.23	Heart rate;	chr12:106683654	chr12:106954029~106955497:-
THCA	cis	rs7267979	1	rs6083862	ENSG00000274973.1	RP13-401N8.7	5.04	6.75e-07	8.86e-05	0.25	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25845497~25845862:+
THCA	cis	rs6772849	0.93	rs13434160	ENSG00000242551.2	POU5F1P6	-5.04	6.75e-07	8.86e-05	-0.29	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128655927	chr3:128674735~128677005:-
THCA	cis	rs6772849	0.93	rs4857916	ENSG00000242551.2	POU5F1P6	-5.04	6.75e-07	8.86e-05	-0.29	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128657171	chr3:128674735~128677005:-
THCA	cis	rs7976269	0.609	rs7310276	ENSG00000275476.1	RP11-996F15.4	5.04	6.75e-07	8.87e-05	0.23	0.23	Male-pattern baldness;	chr12:29054128	chr12:29277397~29277882:-
THCA	cis	rs944289	0.74	rs1742869	ENSG00000258844.1	RP11-259K15.2	-5.04	6.76e-07	8.87e-05	-0.2	-0.23	Thyroid cancer;	chr14:36067601	chr14:36214607~36235608:+
THCA	cis	rs1023500	0.596	rs133350	ENSG00000273366.1	CTA-989H11.1	-5.04	6.76e-07	8.88e-05	-0.3	-0.23	Schizophrenia;	chr22:42033045	chr22:42278188~42278846:+
THCA	cis	rs1046896	0.628	rs12452314	ENSG00000263063.1	RP11-388C12.1	-5.04	6.76e-07	8.88e-05	-0.28	-0.23	Glycated hemoglobin levels;	chr17:82765486	chr17:82713908~82716255:-
THCA	cis	rs3770081	1	rs60981340	ENSG00000272564.1	RP11-548P2.2	-5.04	6.76e-07	8.88e-05	-0.38	-0.23	Facial emotion recognition (sad faces);	chr2:85949923	chr2:85904279~85904727:+
THCA	cis	rs3770081	1	rs735737	ENSG00000272564.1	RP11-548P2.2	-5.04	6.76e-07	8.88e-05	-0.38	-0.23	Facial emotion recognition (sad faces);	chr2:85949978	chr2:85904279~85904727:+
THCA	cis	rs2239547	0.563	rs9876403	ENSG00000242142.1	SERBP1P3	5.04	6.76e-07	8.88e-05	0.29	0.23	Schizophrenia;	chr3:52882900	chr3:53064283~53065091:-
THCA	cis	rs6477918	0.598	rs7033032	ENSG00000230185.4	C9orf147	-5.04	6.76e-07	8.88e-05	-0.25	-0.23	Obstetric antiphospholipid syndrome;	chr9:112508389	chr9:112433816~112487204:-
THCA	cis	rs1005277	0.579	rs2474595	ENSG00000272983.1	RP11-508N22.12	-5.04	6.76e-07	8.88e-05	-0.2	-0.23	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38137337~38144399:+
THCA	cis	rs253959	0.545	rs6896147	ENSG00000272265.1	CTD-2287O16.4	-5.04	6.76e-07	8.88e-05	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116078110~116078570:-
THCA	cis	rs7520050	0.966	rs1707340	ENSG00000234329.1	RP11-767N6.2	-5.04	6.76e-07	8.88e-05	-0.2	-0.23	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45651039~45651826:-
THCA	cis	rs7520050	1	rs785473	ENSG00000234329.1	RP11-767N6.2	-5.04	6.76e-07	8.88e-05	-0.2	-0.23	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs785472	ENSG00000234329.1	RP11-767N6.2	-5.04	6.76e-07	8.88e-05	-0.2	-0.23	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45651039~45651826:-
THCA	cis	rs28476539	0.567	rs7669516	ENSG00000270480.1	RP11-57B24.1	5.04	6.77e-07	8.88e-05	0.36	0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82641963	chr4:82691737~82692468:+
THCA	cis	rs17005891	0.877	rs7669538	ENSG00000270480.1	RP11-57B24.1	5.04	6.77e-07	8.88e-05	0.36	0.23	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82642005	chr4:82691737~82692468:+
THCA	cis	rs4713118	0.513	rs149878	ENSG00000220721.1	OR1F12	5.04	6.77e-07	8.89e-05	0.27	0.23	Parkinson's disease;	chr6:27910960	chr6:28073316~28074233:+
THCA	cis	rs7727544	0.547	rs10076758	ENSG00000224431.1	AC063976.7	5.04	6.77e-07	8.89e-05	0.19	0.23	Blood metabolite levels;	chr5:132188606	chr5:132199456~132203487:+
THCA	cis	rs10510102	1	rs6585764	ENSG00000226864.1	ATE1-AS1	5.04	6.77e-07	8.89e-05	0.35	0.23	Breast cancer;	chr10:121837308	chr10:121928312~121951965:+
THCA	cis	rs12681287	0.511	rs4129535	ENSG00000254231.1	CTD-2284J15.1	5.04	6.77e-07	8.89e-05	0.25	0.23	Caudate activity during reward;	chr8:86511865	chr8:86333274~86343314:-
THCA	cis	rs1979679	0.608	rs4931084	ENSG00000247934.4	RP11-967K21.1	5.04	6.77e-07	8.89e-05	0.23	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28569378	chr12:28163298~28190738:-
THCA	cis	rs227932	0.867	rs116981	ENSG00000234286.1	AC006026.13	-5.04	6.78e-07	8.9e-05	-0.41	-0.23	Schizophrenia;	chr7:23590849	chr7:23680195~23680786:-
THCA	cis	rs7088591	0.867	rs2159856	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58021153	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs2159855	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58021238	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs1930487	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58022493	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs16911636	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58022609	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs16911638	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58022768	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs16911644	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58022922	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs16911648	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58023004	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs11815071	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58023828	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs74402014	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58024248	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs74664821	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58024466	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs73290936	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58024636	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs79061453	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58024727	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs73290938	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58024897	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs73290941	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58025059	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs76314630	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58025093	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs75056761	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58025102	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs79643571	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58025139	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs11814795	ENSG00000276818.1	AC026393.1	5.04	6.78e-07	8.9e-05	0.43	0.23	Blood pressure;	chr10:58025558	chr10:57095699~57095781:+
THCA	cis	rs7976269	0.609	rs2196480	ENSG00000275476.1	RP11-996F15.4	-5.04	6.78e-07	8.9e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29062850	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.537	rs10743642	ENSG00000275476.1	RP11-996F15.4	-5.04	6.78e-07	8.9e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29063557	chr12:29277397~29277882:-
THCA	cis	rs7976269	0.609	rs10771472	ENSG00000275476.1	RP11-996F15.4	-5.04	6.78e-07	8.9e-05	-0.23	-0.23	Male-pattern baldness;	chr12:29063930	chr12:29277397~29277882:-
THCA	cis	rs7829975	0.501	rs74345345	ENSG00000253893.2	FAM85B	5.04	6.79e-07	8.91e-05	0.31	0.23	Mood instability;	chr8:8720925	chr8:8167819~8226614:-
THCA	cis	rs4713118	0.662	rs469228	ENSG00000272009.1	RP1-313I6.12	-5.04	6.79e-07	8.91e-05	-0.25	-0.23	Parkinson's disease;	chr6:28002926	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.54	rs469227	ENSG00000272009.1	RP1-313I6.12	-5.04	6.79e-07	8.91e-05	-0.25	-0.23	Parkinson's disease;	chr6:28002927	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.662	rs149948	ENSG00000272009.1	RP1-313I6.12	-5.04	6.79e-07	8.91e-05	-0.25	-0.23	Parkinson's disease;	chr6:28007039	chr6:28078792~28081130:-
THCA	cis	rs6964833	1	rs4717907	ENSG00000278416.1	PMS2L2	5.04	6.79e-07	8.91e-05	0.34	0.23	Menarche (age at onset);	chr7:74672169	chr7:75344015~75359550:-
THCA	cis	rs9393813	1	rs12663650	ENSG00000204789.4	ZNF204P	-5.04	6.79e-07	8.91e-05	-0.18	-0.23	Bipolar disorder;	chr6:27399042	chr6:27357825~27360221:-
THCA	cis	rs2562456	0.793	rs279807	ENSG00000268119.4	CTD-2561J22.5	5.04	6.79e-07	8.91e-05	0.33	0.23	Pain;	chr19:21283020	chr19:21444241~21463908:-
THCA	cis	rs1129187	0.755	rs7760250	ENSG00000272223.1	RP1-20C7.6	5.04	6.79e-07	8.92e-05	0.17	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42962101	chr6:43033897~43034405:-
THCA	cis	rs8027521	0.557	rs2199607	ENSG00000280362.1	RP11-643A5.3	5.04	6.79e-07	8.92e-05	0.28	0.23	Circulating chemerin levels;	chr15:53955136	chr15:53910769~53914712:+
THCA	cis	rs9307551	0.741	rs1440866	ENSG00000250334.4	LINC00989	-5.04	6.79e-07	8.92e-05	-0.3	-0.23	Refractive error;	chr4:79545005	chr4:79492416~79576460:+
THCA	cis	rs10208649	0.611	rs12616263	ENSG00000233266.1	HMGB1P31	5.04	6.79e-07	8.92e-05	0.39	0.23	Body mass index;	chr2:54039235	chr2:54051334~54051760:+
THCA	cis	rs7674212	0.539	rs6850461	ENSG00000246560.2	RP11-10L12.4	5.04	6.8e-07	8.92e-05	0.27	0.23	Type 2 diabetes;	chr4:103198884	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.539	rs6533056	ENSG00000246560.2	RP11-10L12.4	5.04	6.8e-07	8.92e-05	0.27	0.23	Type 2 diabetes;	chr4:103199840	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.539	rs2866635	ENSG00000246560.2	RP11-10L12.4	5.04	6.8e-07	8.92e-05	0.27	0.23	Type 2 diabetes;	chr4:103200419	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.539	rs6815783	ENSG00000246560.2	RP11-10L12.4	5.04	6.8e-07	8.92e-05	0.27	0.23	Type 2 diabetes;	chr4:103200989	chr4:102828055~102844075:+
THCA	cis	rs7577696	0.962	rs7581340	ENSG00000276334.1	AL133243.1	-5.04	6.8e-07	8.93e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32112322	chr2:32521927~32523547:+
THCA	cis	rs78905543	1	rs4872049	ENSG00000253616.4	RP11-875O11.3	-5.04	6.81e-07	8.93e-05	-0.25	-0.23	Mean corpuscular volume;	chr8:23074266	chr8:23071377~23074488:-
THCA	cis	rs1336900	0.513	rs56253522	ENSG00000231073.1	RP11-316M1.3	5.04	6.81e-07	8.93e-05	0.28	0.23	Blood protein levels;	chr1:150642393	chr1:150973123~150975534:+
THCA	cis	rs8020095	0.571	rs10148117	ENSG00000258561.1	RP11-72M17.1	-5.04	6.81e-07	8.93e-05	-0.3	-0.23	Depression (quantitative trait);	chr14:66959511	chr14:66212810~66509394:-
THCA	cis	rs7618915	0.501	rs55678971	ENSG00000243224.1	RP5-1157M23.2	-5.04	6.81e-07	8.94e-05	-0.25	-0.23	Bipolar disorder;	chr3:52683213	chr3:52239258~52241097:+
THCA	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	5.04	6.81e-07	8.94e-05	0.4	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
THCA	cis	rs34779708	0.966	rs17500582	ENSG00000271335.4	RP11-324I22.4	5.04	6.81e-07	8.94e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35314552~35336401:-
THCA	cis	rs9987353	0.566	rs34389718	ENSG00000253893.2	FAM85B	5.04	6.82e-07	8.95e-05	0.31	0.23	Recombination measurement;	chr8:9208015	chr8:8167819~8226614:-
THCA	cis	rs2288884	0.767	rs3752119	ENSG00000260160.1	CTC-471J1.2	-5.03	6.82e-07	8.95e-05	-0.22	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048245	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.767	rs3450	ENSG00000260160.1	CTC-471J1.2	-5.03	6.82e-07	8.95e-05	-0.22	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049746	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.708	rs59104696	ENSG00000260160.1	CTC-471J1.2	-5.03	6.82e-07	8.95e-05	-0.22	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52051917	chr19:52058490~52063703:-
THCA	cis	rs919433	0.68	rs3792160	ENSG00000231621.1	AC013264.2	-5.03	6.83e-07	8.96e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197538795	chr2:197197991~197199273:+
THCA	cis	rs7618915	0.571	rs6778844	ENSG00000243224.1	RP5-1157M23.2	5.03	6.83e-07	8.96e-05	0.25	0.23	Bipolar disorder;	chr3:52562382	chr3:52239258~52241097:+
THCA	cis	rs9527	0.637	rs12219247	ENSG00000213061.2	PFN1P11	5.03	6.83e-07	8.96e-05	0.28	0.23	Arsenic metabolism;	chr10:102853604	chr10:102838011~102845473:-
THCA	cis	rs9595908	0.9	rs61947058	ENSG00000212293.1	SNORA16	5.03	6.83e-07	8.96e-05	0.26	0.23	Body mass index;	chr13:32617419	chr13:32420390~32420516:-
THCA	cis	rs3820928	0.874	rs6707265	ENSG00000212391.1	SNORA48	-5.03	6.83e-07	8.97e-05	-0.25	-0.23	Pulmonary function;	chr2:226984539	chr2:226968989~226969122:-
THCA	cis	rs2562456	0.793	rs279807	ENSG00000268081.1	RP11-678G14.2	5.03	6.84e-07	8.97e-05	0.38	0.23	Pain;	chr19:21283020	chr19:21554640~21569237:-
THCA	cis	rs2732480	0.538	rs2468943	ENSG00000273765.1	RP11-370I10.11	-5.03	6.85e-07	8.99e-05	-0.22	-0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48360920~48361377:+
THCA	cis	rs4865169	0.934	rs3796531	ENSG00000269949.1	RP11-738E22.3	-5.03	6.85e-07	8.99e-05	-0.26	-0.23	Breast cancer;	chr4:56984680	chr4:56960927~56961373:-
THCA	cis	rs2243480	0.708	rs781141	ENSG00000164669.11	INTS4P1	5.03	6.85e-07	8.99e-05	0.44	0.23	Diabetic kidney disease;	chr7:65973566	chr7:65141225~65234216:+
THCA	cis	rs613391	0.702	rs570955	ENSG00000224549.1	RP11-370B11.3	-5.03	6.85e-07	8.99e-05	-0.26	-0.23	Quantitative traits;	chr9:22708312	chr9:22767175~22768316:+
THCA	cis	rs2440129	0.611	rs1042356	ENSG00000262089.1	RP11-589P10.5	5.03	6.86e-07	8.99e-05	0.21	0.23	Tonsillectomy;	chr17:6999424	chr17:6994642~6995189:-
THCA	cis	rs2070488	0.775	rs6599207	ENSG00000229589.1	ACVR2B-AS1	-5.03	6.86e-07	9e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38513410	chr3:38451027~38454820:-
THCA	cis	rs8141529	0.764	rs5762854	ENSG00000272858.1	CTA-292E10.8	-5.03	6.86e-07	9e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28850290	chr22:28814914~28815662:+
THCA	cis	rs45509595	0.841	rs370155	ENSG00000280107.1	AL022393.9	-5.03	6.86e-07	9e-05	-0.35	-0.23	Breast cancer;	chr6:27814253	chr6:28170845~28172521:+
THCA	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-5.03	6.86e-07	9e-05	-0.31	-0.23	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
THCA	cis	rs7726839	0.578	rs10080150	ENSG00000225138.6	CTD-2228K2.7	-5.03	6.86e-07	9e-05	-0.22	-0.23	Obesity-related traits;	chr5:593045	chr5:473236~480884:+
THCA	cis	rs17772222	0.638	rs11159859	ENSG00000222990.1	RNU4-22P	5.03	6.87e-07	9.01e-05	0.28	0.23	Coronary artery calcification;	chr14:88561547	chr14:88513498~88513663:+
THCA	cis	rs1479090	0.774	rs6841345	ENSG00000250027.1	RP11-563E2.2	5.03	6.87e-07	9.01e-05	0.23	0.23	Lung cancer;	chr4:163109121	chr4:163108785~163119965:+
THCA	cis	rs2524005	1	rs2524005	ENSG00000227262.3	HCG4B	-5.03	6.87e-07	9.01e-05	-0.36	-0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29925983~29926973:-
THCA	cis	rs853679	0.546	rs34295134	ENSG00000280107.1	AL022393.9	-5.03	6.88e-07	9.02e-05	-0.34	-0.23	Depression;	chr6:27860373	chr6:28170845~28172521:+
THCA	cis	rs736408	0.688	rs2239551	ENSG00000243224.1	RP5-1157M23.2	5.03	6.88e-07	9.02e-05	0.25	0.23	Bipolar disorder;	chr3:52784563	chr3:52239258~52241097:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000273142.1	RP11-458F8.4	5.03	6.88e-07	9.02e-05	0.18	0.23	Aortic root size;	chr7:66120784	chr7:66902857~66906297:+
THCA	cis	rs3177980	0.673	rs12760399	ENSG00000239494.2	RN7SL333P	-5.03	6.88e-07	9.03e-05	-0.22	-0.23	Amyotrophic lateral sclerosis;	chr1:169832971	chr1:169859756~169860052:+
THCA	cis	rs7208859	0.524	rs8069400	ENSG00000280069.1	CTD-2349P21.3	-5.03	6.89e-07	9.03e-05	-0.36	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30738182~30740275:+
THCA	cis	rs10875746	0.669	rs61941003	ENSG00000258234.1	RP11-370I10.2	5.03	6.89e-07	9.03e-05	0.27	0.23	Longevity (90 years and older);	chr12:48225842	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.579	rs10875778	ENSG00000258234.1	RP11-370I10.2	5.03	6.89e-07	9.03e-05	0.27	0.23	Longevity (90 years and older);	chr12:48230872	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.669	rs10875779	ENSG00000258234.1	RP11-370I10.2	5.03	6.89e-07	9.03e-05	0.27	0.23	Longevity (90 years and older);	chr12:48236086	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.669	rs11168487	ENSG00000258234.1	RP11-370I10.2	5.03	6.89e-07	9.03e-05	0.27	0.23	Longevity (90 years and older);	chr12:48246926	chr12:48231098~48284210:-
THCA	cis	rs600231	0.508	rs35292734	ENSG00000245532.5	NEAT1	5.03	6.89e-07	9.03e-05	0.19	0.23	Bone mineral density;	chr11:65460229	chr11:65422774~65445540:+
THCA	cis	rs1979679	0.842	rs60025108	ENSG00000247934.4	RP11-967K21.1	-5.03	6.89e-07	9.04e-05	-0.22	-0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168238	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.842	rs7487773	ENSG00000247934.4	RP11-967K21.1	-5.03	6.89e-07	9.04e-05	-0.22	-0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168418	chr12:28163298~28190738:-
THCA	cis	rs4971059	0.654	rs4971073	ENSG00000160766.13	GBAP1	-5.03	6.89e-07	9.04e-05	-0.24	-0.23	Breast cancer;	chr1:155140628	chr1:155213821~155227422:-
THCA	cis	rs7829975	0.51	rs332037	ENSG00000254153.1	CTA-398F10.2	-5.03	6.89e-07	9.04e-05	-0.26	-0.23	Mood instability;	chr8:8865165	chr8:8456909~8461337:-
THCA	cis	rs7208859	0.673	rs9915139	ENSG00000280069.1	CTD-2349P21.3	-5.03	6.9e-07	9.05e-05	-0.35	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30738182~30740275:+
THCA	cis	rs9890032	0.618	rs55872374	ENSG00000264538.5	SUZ12P1	-5.03	6.9e-07	9.05e-05	-0.17	-0.23	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30709299~30790908:+
THCA	cis	rs7914558	1	rs12780843	ENSG00000236937.2	PTGES3P4	5.03	6.91e-07	9.06e-05	0.29	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:102845595~102845950:+
THCA	cis	rs736408	0.608	rs2239547	ENSG00000242142.1	SERBP1P3	5.03	6.91e-07	9.06e-05	0.29	0.23	Bipolar disorder;	chr3:52821213	chr3:53064283~53065091:-
THCA	cis	rs288326	0.561	rs77318535	ENSG00000272800.1	RP11-438L19.1	5.03	6.91e-07	9.06e-05	0.42	0.23	Blood protein levels;	chr2:182992591	chr2:183214319~183215400:+
THCA	cis	rs1129187	0.755	rs9471982	ENSG00000272223.1	RP1-20C7.6	5.03	6.92e-07	9.07e-05	0.17	0.23	Alzheimer's disease in APOE e4+ carriers;	chr6:42968260	chr6:43033897~43034405:-
THCA	cis	rs6545883	0.894	rs6734628	ENSG00000270820.4	RP11-355B11.2	-5.03	6.92e-07	9.07e-05	-0.19	-0.23	Tuberculosis;	chr2:61224125	chr2:61471188~61484130:+
THCA	cis	rs613391	0.702	rs584680	ENSG00000224549.1	RP11-370B11.3	-5.03	6.92e-07	9.07e-05	-0.25	-0.23	Quantitative traits;	chr9:22706598	chr9:22767175~22768316:+
THCA	cis	rs4950322	0.57	rs4950315	ENSG00000180867.10	PDIA3P1	-5.03	6.92e-07	9.07e-05	-0.23	-0.23	Protein quantitative trait loci;	chr1:147264433	chr1:147178113~147179622:+
THCA	cis	rs860295	0.702	rs12040100	ENSG00000160766.13	GBAP1	-5.03	6.92e-07	9.07e-05	-0.27	-0.23	Body mass index;	chr1:155642056	chr1:155213821~155227422:-
THCA	cis	rs6792584	1	rs9836548	ENSG00000241316.5	SUCLG2-AS1	5.03	6.92e-07	9.07e-05	0.24	0.23	Corneal astigmatism;	chr3:67460181	chr3:67654697~67947713:+
THCA	cis	rs6490294	0.528	rs60690688	ENSG00000226469.1	ADAM1B	5.03	6.92e-07	9.08e-05	0.33	0.23	Mean platelet volume;	chr12:112104179	chr12:111927018~111929017:+
THCA	cis	rs4950322	1	rs4950322	ENSG00000278811.3	LINC00624	-5.03	6.93e-07	9.08e-05	-0.3	-0.23	Protein quantitative trait loci;	chr1:147383114	chr1:147258885~147517875:-
THCA	cis	rs6044112	1	rs6044112	ENSG00000273998.1	RP4-777L9.2	5.03	6.93e-07	9.08e-05	0.35	0.23	Response to taxane treatment (docetaxel);	chr20:16555769	chr20:16576068~16579615:+
THCA	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-5.03	6.93e-07	9.08e-05	-0.31	-0.23	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
THCA	cis	rs6951245	1	rs78896566	ENSG00000229043.2	AC091729.9	-5.03	6.93e-07	9.08e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs79422648	ENSG00000229043.2	AC091729.9	-5.03	6.93e-07	9.08e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.872	rs113119264	ENSG00000229043.2	AC091729.9	-5.03	6.93e-07	9.08e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs76804143	ENSG00000229043.2	AC091729.9	-5.03	6.93e-07	9.08e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1160374~1165267:+
THCA	cis	rs7429990	0.833	rs11716582	ENSG00000228638.1	FCF1P2	5.03	6.93e-07	9.08e-05	0.22	0.23	Educational attainment (years of education);	chr3:47592269	chr3:48290793~48291375:-
THCA	cis	rs2562456	0.793	rs61445561	ENSG00000268119.4	CTD-2561J22.5	5.03	6.94e-07	9.09e-05	0.33	0.23	Pain;	chr19:21321230	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs57299552	ENSG00000268119.4	CTD-2561J22.5	5.03	6.94e-07	9.09e-05	0.33	0.23	Pain;	chr19:21321326	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.754	rs76688173	ENSG00000268119.4	CTD-2561J22.5	5.03	6.94e-07	9.09e-05	0.33	0.23	Pain;	chr19:21321856	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs74711277	ENSG00000268119.4	CTD-2561J22.5	5.03	6.94e-07	9.09e-05	0.33	0.23	Pain;	chr19:21322641	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62107479	ENSG00000268119.4	CTD-2561J22.5	5.03	6.94e-07	9.09e-05	0.33	0.23	Pain;	chr19:21323962	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62107531	ENSG00000268119.4	CTD-2561J22.5	5.03	6.94e-07	9.09e-05	0.33	0.23	Pain;	chr19:21326263	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs55756795	ENSG00000268119.4	CTD-2561J22.5	5.03	6.94e-07	9.09e-05	0.33	0.23	Pain;	chr19:21327257	chr19:21444241~21463908:-
THCA	cis	rs17772222	1	rs7145588	ENSG00000222990.1	RNU4-22P	5.03	6.94e-07	9.09e-05	0.3	0.23	Coronary artery calcification;	chr14:88360452	chr14:88513498~88513663:+
THCA	cis	rs17772222	1	rs61977049	ENSG00000222990.1	RNU4-22P	5.03	6.94e-07	9.09e-05	0.3	0.23	Coronary artery calcification;	chr14:88360656	chr14:88513498~88513663:+
THCA	cis	rs17772222	1	rs12587386	ENSG00000222990.1	RNU4-22P	5.03	6.94e-07	9.09e-05	0.3	0.23	Coronary artery calcification;	chr14:88361420	chr14:88513498~88513663:+
THCA	cis	rs7520050	0.966	rs785485	ENSG00000234329.1	RP11-767N6.2	-5.03	6.94e-07	9.09e-05	-0.2	-0.23	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45651039~45651826:-
THCA	cis	rs6964833	1	rs36044436	ENSG00000278416.1	PMS2L2	5.03	6.94e-07	9.1e-05	0.36	0.23	Menarche (age at onset);	chr7:74675495	chr7:75344015~75359550:-
THCA	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-5.03	6.94e-07	9.1e-05	-0.29	-0.23	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
THCA	cis	rs930395	0.514	rs9791164	ENSG00000272335.1	RP11-53O19.3	-5.03	6.94e-07	9.1e-05	-0.19	-0.23	Breast cancer;	chr5:44903928	chr5:44826076~44828592:+
THCA	cis	rs34779708	0.931	rs6481935	ENSG00000271335.4	RP11-324I22.4	5.03	6.94e-07	9.1e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs12242882	ENSG00000271335.4	RP11-324I22.4	5.03	6.94e-07	9.1e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35314552~35336401:-
THCA	cis	rs1707322	0.964	rs12067716	ENSG00000281133.1	AL355480.3	-5.03	6.95e-07	9.1e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45580892~45580996:-
THCA	cis	rs8141529	0.702	rs469990	ENSG00000272858.1	CTA-292E10.8	-5.03	6.95e-07	9.11e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28908212	chr22:28814914~28815662:+
THCA	cis	rs17767392	0.881	rs7140501	ENSG00000259146.3	RP1-261D10.2	-5.03	6.95e-07	9.11e-05	-0.28	-0.23	Mitral valve prolapse;	chr14:71556458	chr14:71292729~71321814:-
THCA	cis	rs7727544	0.735	rs273914	ENSG00000263597.1	MIR3936	5.03	6.95e-07	9.11e-05	0.21	0.23	Blood metabolite levels;	chr5:132324738	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.735	rs272894	ENSG00000263597.1	MIR3936	5.03	6.95e-07	9.11e-05	0.21	0.23	Blood metabolite levels;	chr5:132326767	chr5:132365490~132365599:-
THCA	cis	rs5758659	0.653	rs133383	ENSG00000182057.4	OGFRP1	5.03	6.95e-07	9.11e-05	0.26	0.23	Cognitive function;	chr22:42077599	chr22:42269753~42275196:+
THCA	cis	rs79243044	1	rs11037993	ENSG00000224295.2	AC087380.14	-5.03	6.95e-07	9.11e-05	-0.23	-0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5535967	chr11:5518441~5524955:-
THCA	cis	rs6832769	1	rs10016506	ENSG00000272969.1	RP11-528I4.2	-5.03	6.95e-07	9.11e-05	-0.26	-0.23	Personality dimensions;	chr4:55530507	chr4:55547112~55547889:+
THCA	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	5.03	6.95e-07	9.11e-05	0.32	0.23	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
THCA	cis	rs9283706	0.641	rs6414805	ENSG00000229666.1	MAST4-AS1	-5.03	6.96e-07	9.11e-05	-0.33	-0.23	Coronary artery disease;	chr5:67026772	chr5:67001383~67003953:-
THCA	cis	rs9863	0.896	rs12311114	ENSG00000269997.1	RP11-214K3.21	5.03	6.96e-07	9.12e-05	0.28	0.23	White blood cell count;	chr12:123976156	chr12:123966077~123966629:-
THCA	cis	rs6700559	0.74	rs6663322	ENSG00000260088.1	RP11-92G12.3	5.03	6.96e-07	9.12e-05	0.29	0.23	Coronary artery disease;	chr1:200680741	chr1:200669507~200694250:+
THCA	cis	rs7474896	0.583	rs7071147	ENSG00000263064.2	RP11-291L22.7	5.03	6.96e-07	9.12e-05	0.3	0.23	Obesity (extreme);	chr10:37714448	chr10:38448689~38448949:+
THCA	cis	rs7554547	0.818	rs4993566	ENSG00000199347.1	RNU5E-1	5.03	6.96e-07	9.12e-05	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr1:11909937	chr1:11908152~11908271:+
THCA	cis	rs7617773	0.817	rs936427	ENSG00000199476.1	Y_RNA	5.03	6.96e-07	9.12e-05	0.29	0.23	Coronary artery disease;	chr3:48259584	chr3:48288587~48288694:+
THCA	cis	rs12049671	0.929	rs11018410	ENSG00000227076.1	RP11-4C20.4	5.03	6.96e-07	9.12e-05	0.25	0.23	Response to amphetamines;	chr10:127939560	chr10:127934698~127936167:+
THCA	cis	rs2070488	0.775	rs7644530	ENSG00000229589.1	ACVR2B-AS1	-5.03	6.96e-07	9.12e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38516825	chr3:38451027~38454820:-
THCA	cis	rs7577696	0.889	rs2365558	ENSG00000276334.1	AL133243.1	-5.03	6.97e-07	9.13e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32111588	chr2:32521927~32523547:+
THCA	cis	rs6472827	0.645	rs2936683	ENSG00000253983.2	RP1-16A9.1	5.03	6.97e-07	9.13e-05	0.32	0.23	Uterine fibroids;	chr8:74201004	chr8:74199396~74208441:+
THCA	cis	rs2562456	0.876	rs10424079	ENSG00000268081.1	RP11-678G14.2	5.03	6.97e-07	9.13e-05	0.38	0.23	Pain;	chr19:21406377	chr19:21554640~21569237:-
THCA	cis	rs5751901	0.688	rs2017869	ENSG00000215481.7	BCRP3	-5.03	6.97e-07	9.13e-05	-0.2	-0.23	Protein quantitative trait loci;	chr22:24601342	chr22:24632915~24653356:+
THCA	cis	rs875971	0.545	rs12670811	ENSG00000228409.4	CCT6P1	-5.03	6.98e-07	9.14e-05	-0.19	-0.23	Aortic root size;	chr7:66358032	chr7:65751142~65763354:+
THCA	cis	rs1040393	0.522	rs2049909	ENSG00000225171.2	DUTP6	5.03	6.98e-07	9.14e-05	0.34	0.23	Schizophrenia;	chr1:166862708	chr1:166868748~166869209:+
THCA	cis	rs8177876	0.749	rs76892049	ENSG00000261838.4	RP11-303E16.6	5.03	6.98e-07	9.14e-05	0.41	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81069854~81076598:+
THCA	cis	rs2797160	1	rs1739378	ENSG00000237742.5	RP11-624M8.1	5.03	6.98e-07	9.14e-05	0.19	0.23	Endometrial cancer;	chr6:125691116	chr6:125578558~125749190:-
THCA	cis	rs6547741	0.935	rs6547738	ENSG00000234072.1	AC074117.10	5.03	6.98e-07	9.14e-05	0.17	0.23	Oral cavity cancer;	chr2:27629770	chr2:27356246~27367622:+
THCA	cis	rs3750082	0.748	rs10248427	ENSG00000231952.3	DPY19L1P2	5.03	6.98e-07	9.15e-05	0.28	0.23	Glomerular filtration rate (creatinine);	chr7:32859357	chr7:32812757~32838570:+
THCA	cis	rs4713118	0.539	rs200967	ENSG00000280107.1	AL022393.9	-5.03	6.99e-07	9.15e-05	-0.25	-0.23	Parkinson's disease;	chr6:27894349	chr6:28170845~28172521:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000228409.4	CCT6P1	-5.03	6.99e-07	9.15e-05	-0.2	-0.23	Aortic root size;	chr7:66221293	chr7:65751142~65763354:+
THCA	cis	rs9900062	1	rs9900062	ENSG00000270714.1	MINOS1P2	-5.03	6.99e-07	9.16e-05	-0.35	-0.23	QT interval;	chr17:64743456	chr17:64747264~64747492:-
THCA	cis	rs3177980	0.554	rs11576078	ENSG00000239494.2	RN7SL333P	-5.03	6.99e-07	9.16e-05	-0.22	-0.23	Amyotrophic lateral sclerosis;	chr1:169812968	chr1:169859756~169860052:+
THCA	cis	rs9388451	0.626	rs1739384	ENSG00000226409.1	RP11-735G4.1	-5.03	6.99e-07	9.16e-05	-0.27	-0.23	Brugada syndrome;	chr6:125778100	chr6:125370211~125374324:-
THCA	cis	rs9652601	0.691	rs12924985	ENSG00000274038.1	RP11-66H6.4	-5.03	7e-07	9.16e-05	-0.27	-0.23	Systemic lupus erythematosus;	chr16:11114465	chr16:11056556~11057034:+
THCA	cis	rs853679	0.599	rs149990	ENSG00000226314.6	ZNF192P1	-5.03	7e-07	9.16e-05	-0.35	-0.23	Depression;	chr6:28030480	chr6:28161781~28169594:+
THCA	cis	rs2797160	0.967	rs1954360	ENSG00000237742.5	RP11-624M8.1	-5.03	7e-07	9.16e-05	-0.2	-0.23	Endometrial cancer;	chr6:125679918	chr6:125578558~125749190:-
THCA	cis	rs9341808	0.527	rs7453746	ENSG00000272129.1	RP11-250B2.6	5.03	7e-07	9.16e-05	0.28	0.23	Sitting height ratio;	chr6:80100296	chr6:80355424~80356859:+
THCA	cis	rs6951245	0.872	rs112309216	ENSG00000229043.2	AC091729.9	-5.03	7e-07	9.17e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.872	rs76161580	ENSG00000229043.2	AC091729.9	-5.03	7e-07	9.17e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs76388414	ENSG00000229043.2	AC091729.9	-5.03	7e-07	9.17e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs77305932	ENSG00000229043.2	AC091729.9	-5.03	7e-07	9.17e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.872	rs11768486	ENSG00000229043.2	AC091729.9	-5.03	7e-07	9.17e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs11766526	ENSG00000229043.2	AC091729.9	-5.03	7e-07	9.17e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1160374~1165267:+
THCA	cis	rs7577696	0.962	rs12617289	ENSG00000276334.1	AL133243.1	-5.03	7e-07	9.17e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32116330	chr2:32521927~32523547:+
THCA	cis	rs11992162	0.636	rs4841642	ENSG00000206014.6	OR7E161P	-5.03	7e-07	9.17e-05	-0.27	-0.23	Monocyte count;	chr8:11940825	chr8:11928597~11929563:-
THCA	cis	rs11992162	0.636	rs4841646	ENSG00000206014.6	OR7E161P	-5.03	7e-07	9.17e-05	-0.27	-0.23	Monocyte count;	chr8:11941198	chr8:11928597~11929563:-
THCA	cis	rs7403037	0.55	rs61993572	ENSG00000259905.4	PWRN1	5.03	7e-07	9.17e-05	0.31	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24395005	chr15:24493137~24652130:+
THCA	cis	rs34792	0.688	rs153782	ENSG00000207425.1	Y_RNA	5.03	7.01e-07	9.17e-05	0.24	0.23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:14915457~14915556:-
THCA	cis	rs9283706	0.689	rs6889240	ENSG00000229666.1	MAST4-AS1	-5.03	7.01e-07	9.18e-05	-0.33	-0.23	Coronary artery disease;	chr5:67025112	chr5:67001383~67003953:-
THCA	cis	rs79349575	0.783	rs318095	ENSG00000270781.1	RP11-501C14.9	-5.03	7.01e-07	9.18e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48897372	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs318096	ENSG00000270781.1	RP11-501C14.9	-5.03	7.01e-07	9.18e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48898008	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.777	rs28517720	ENSG00000270781.1	RP11-501C14.9	-5.03	7.01e-07	9.18e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48899394	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.749	rs2546491	ENSG00000270781.1	RP11-501C14.9	-5.03	7.01e-07	9.18e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48900554	chr17:48899131~48899748:+
THCA	cis	rs34779708	0.966	rs1213392	ENSG00000271335.4	RP11-324I22.4	5.03	7.01e-07	9.18e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35314552~35336401:-
THCA	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-5.03	7.01e-07	9.18e-05	-0.3	-0.23	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
THCA	cis	rs2179367	0.632	rs2143075	ENSG00000268592.3	RAET1E-AS1	5.03	7.01e-07	9.18e-05	0.33	0.23	Dupuytren's disease;	chr6:149425507	chr6:149863494~149919507:+
THCA	cis	rs79349575	0.749	rs519537	ENSG00000270781.1	RP11-501C14.9	-5.03	7.01e-07	9.18e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48893778	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs832410	ENSG00000270781.1	RP11-501C14.9	-5.03	7.01e-07	9.18e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48895503	chr17:48899131~48899748:+
THCA	cis	rs5751614	1	rs5751614	ENSG00000230701.2	FBXW4P1	5.03	7.02e-07	9.19e-05	0.22	0.23	Height;	chr22:23250864	chr22:23262767~23265005:+
THCA	cis	rs6688613	0.649	rs11584352	ENSG00000225171.2	DUTP6	-5.03	7.02e-07	9.19e-05	-0.31	-0.23	Refractive astigmatism;	chr1:166881135	chr1:166868748~166869209:+
THCA	cis	rs3743266	0.507	rs10162677	ENSG00000245534.5	RORA-AS1	-5.03	7.02e-07	9.19e-05	-0.31	-0.23	Menarche (age at onset);	chr15:60456369	chr15:60479178~60630637:+
THCA	cis	rs7225151	0.803	rs78531165	ENSG00000234327.6	AC012146.7	-5.03	7.02e-07	9.2e-05	-0.25	-0.23	Alzheimer's disease (late onset);	chr17:5276551	chr17:5111468~5115004:+
THCA	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	5.03	7.03e-07	9.21e-05	0.25	0.23	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
THCA	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	5.03	7.03e-07	9.21e-05	0.25	0.23	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
THCA	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	5.03	7.03e-07	9.21e-05	0.25	0.23	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
THCA	cis	rs7646881	0.544	rs16847135	ENSG00000240207.5	RP11-379F4.4	-5.03	7.04e-07	9.21e-05	-0.33	-0.23	Tetralogy of Fallot;	chr3:158706064	chr3:158732263~158784070:+
THCA	cis	rs2834188	0.557	rs3171425	ENSG00000272659.1	AP000295.10	-5.03	7.04e-07	9.21e-05	-0.29	-0.23	Narcolepsy;	chr21:33296442	chr21:33309491~33310181:+
THCA	cis	rs3213758	1	rs2024473	ENSG00000275191.1	RP11-36I17.2	-5.03	7.04e-07	9.22e-05	-0.45	-0.23	Vitiligo (non-segmental);	chr16:53546083	chr16:53628256~53628816:-
THCA	cis	rs3213758	1	rs12445553	ENSG00000275191.1	RP11-36I17.2	-5.03	7.04e-07	9.22e-05	-0.45	-0.23	Vitiligo (non-segmental);	chr16:53546830	chr16:53628256~53628816:-
THCA	cis	rs972578	0.791	rs4822220	ENSG00000274717.1	RP1-47A17.1	-5.03	7.04e-07	9.22e-05	-0.23	-0.23	Mean platelet volume;	chr22:42894577	chr22:42791814~42794313:-
THCA	cis	rs9380516	0.581	rs9470063	ENSG00000228559.1	RP3-340B19.3	-5.03	7.04e-07	9.22e-05	-0.33	-0.23	Hepatitis C induced liver fibrosis;	chr6:35573091	chr6:35544632~35545669:+
THCA	cis	rs2562456	0.833	rs62107540	ENSG00000268119.4	CTD-2561J22.5	5.03	7.04e-07	9.22e-05	0.33	0.23	Pain;	chr19:21335693	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62107541	ENSG00000268119.4	CTD-2561J22.5	5.03	7.04e-07	9.22e-05	0.33	0.23	Pain;	chr19:21335733	chr19:21444241~21463908:-
THCA	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-5.03	7.05e-07	9.23e-05	-0.29	-0.23	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
THCA	cis	rs1005277	0.505	rs10827835	ENSG00000276805.1	RP11-291L22.6	-5.03	7.05e-07	9.23e-05	-0.24	-0.23	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38451030~38451785:+
THCA	cis	rs919433	0.68	rs2124317	ENSG00000231621.1	AC013264.2	-5.03	7.05e-07	9.23e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197612882	chr2:197197991~197199273:+
THCA	cis	rs71636778	0.722	rs116491347	ENSG00000260063.1	RP5-968P14.2	-5.03	7.05e-07	9.23e-05	-0.31	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26846193	chr1:26692132~26694131:-
THCA	cis	rs1395	1	rs1659695	ENSG00000234072.1	AC074117.10	5.03	7.05e-07	9.23e-05	0.18	0.23	Blood metabolite levels;	chr2:27184076	chr2:27356246~27367622:+
THCA	cis	rs1395	0.925	rs1659696	ENSG00000234072.1	AC074117.10	5.03	7.05e-07	9.23e-05	0.18	0.23	Blood metabolite levels;	chr2:27184963	chr2:27356246~27367622:+
THCA	cis	rs28510890	0.52	rs12594820	ENSG00000260337.3	RP11-386M24.6	5.03	7.05e-07	9.23e-05	0.26	0.23	Lung cancer in ever smokers;	chr15:92562359	chr15:92592574~92596462:-
THCA	cis	rs28510890	0.52	rs58674097	ENSG00000260337.3	RP11-386M24.6	5.03	7.05e-07	9.23e-05	0.26	0.23	Lung cancer in ever smokers;	chr15:92562445	chr15:92592574~92596462:-
THCA	cis	rs4356203	0.933	rs12801545	ENSG00000272034.1	SNORD14A	5.03	7.06e-07	9.24e-05	0.24	0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17244629	chr11:17074654~17074744:-
THCA	cis	rs270601	0.69	rs162904	ENSG00000237714.1	P4HA2-AS1	-5.03	7.06e-07	9.24e-05	-0.29	-0.23	Acylcarnitine levels;	chr5:132260091	chr5:132184876~132192808:+
THCA	cis	rs16976116	0.619	rs10518801	ENSG00000279145.1	RP11-547D13.1	5.03	7.06e-07	9.24e-05	0.25	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55176419	chr15:55171972~55178175:-
THCA	cis	rs2742234	0.955	rs1800861	ENSG00000273008.1	RP11-351D16.3	-5.03	7.06e-07	9.24e-05	-0.19	-0.23	Hirschsprung disease;	chr10:43118395	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.955	rs2075910	ENSG00000273008.1	RP11-351D16.3	-5.03	7.06e-07	9.24e-05	-0.19	-0.23	Hirschsprung disease;	chr10:43118782	chr10:43136824~43138334:-
THCA	cis	rs919433	0.713	rs2045245	ENSG00000231621.1	AC013264.2	-5.03	7.06e-07	9.24e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197620617	chr2:197197991~197199273:+
THCA	cis	rs7618915	0.547	rs8906	ENSG00000243224.1	RP5-1157M23.2	-5.03	7.06e-07	9.24e-05	-0.25	-0.23	Bipolar disorder;	chr3:52705504	chr3:52239258~52241097:+
THCA	cis	rs9875589	0.509	rs7651599	ENSG00000228242.5	AC093495.4	5.03	7.06e-07	9.25e-05	0.13	0.23	Ovarian reserve;	chr3:13969474	chr3:14144637~14165978:+
THCA	cis	rs9987353	0.566	rs13260067	ENSG00000253893.2	FAM85B	5.03	7.06e-07	9.25e-05	0.31	0.23	Recombination measurement;	chr8:9213523	chr8:8167819~8226614:-
THCA	cis	rs79349575	0.783	rs962272	ENSG00000270781.1	RP11-501C14.9	-5.03	7.07e-07	9.25e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48900921	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs903567	ENSG00000270781.1	RP11-501C14.9	-5.03	7.07e-07	9.25e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48902956	chr17:48899131~48899748:+
THCA	cis	rs919433	0.927	rs13032495	ENSG00000231621.1	AC013264.2	5.03	7.07e-07	9.25e-05	0.24	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197324622	chr2:197197991~197199273:+
THCA	cis	rs4648045	0.894	rs230504	ENSG00000246560.2	RP11-10L12.4	5.03	7.07e-07	9.25e-05	0.28	0.23	Lymphocyte percentage of white cells;	chr4:102560404	chr4:102828055~102844075:+
THCA	cis	rs919433	0.783	rs2565158	ENSG00000231621.1	AC013264.2	-5.03	7.07e-07	9.25e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371379	chr2:197197991~197199273:+
THCA	cis	rs453301	0.624	rs330049	ENSG00000248538.5	RP11-10A14.5	-5.03	7.07e-07	9.26e-05	-0.28	-0.23	Joint mobility (Beighton score);	chr8:9229789	chr8:9189011~9202854:+
THCA	cis	rs7474896	0.583	rs10827817	ENSG00000226578.1	RP11-258F22.1	-5.03	7.07e-07	9.26e-05	-0.31	-0.23	Obesity (extreme);	chr10:37709046	chr10:37775371~37784131:-
THCA	cis	rs6686842	0.536	rs17358157	ENSG00000235358.1	RP11-399E6.1	-5.03	7.08e-07	9.26e-05	-0.3	-0.23	Height;	chr1:41233850	chr1:41242373~41284861:+
THCA	cis	rs6728642	0.572	rs2872686	ENSG00000230606.9	AC159540.1	5.03	7.08e-07	9.27e-05	0.28	0.23	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935287	chr2:97416165~97433527:-
THCA	cis	rs67478160	0.643	rs11624184	ENSG00000258735.1	LINC00637	-5.03	7.08e-07	9.27e-05	-0.28	-0.23	Schizophrenia;	chr14:103774661	chr14:103847721~103858049:+
THCA	cis	rs7474896	1	rs2749564	ENSG00000263064.2	RP11-291L22.7	-5.03	7.08e-07	9.27e-05	-0.37	-0.23	Obesity (extreme);	chr10:37889887	chr10:38448689~38448949:+
THCA	cis	rs6832769	1	rs6554286	ENSG00000272969.1	RP11-528I4.2	-5.03	7.08e-07	9.27e-05	-0.26	-0.23	Personality dimensions;	chr4:55534137	chr4:55547112~55547889:+
THCA	cis	rs4660456	0.913	rs6667368	ENSG00000272145.1	NFYC-AS1	-5.03	7.08e-07	9.27e-05	-0.16	-0.23	Platelet count;	chr1:40694887	chr1:40690380~40692066:-
THCA	cis	rs78487399	0.808	rs78098795	ENSG00000234936.1	AC010883.5	5.03	7.09e-07	9.27e-05	0.31	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43613222	chr2:43229573~43233394:+
THCA	cis	rs202072	1	rs202074	ENSG00000272379.1	RP1-257A7.5	5.03	7.09e-07	9.27e-05	0.35	0.23	HIV-1 viral setpoint;	chr6:13269131	chr6:13290018~13290490:-
THCA	cis	rs2797160	1	rs4897152	ENSG00000237742.5	RP11-624M8.1	-5.03	7.09e-07	9.28e-05	-0.2	-0.23	Endometrial cancer;	chr6:125681254	chr6:125578558~125749190:-
THCA	cis	rs2154319	0.559	rs183334	ENSG00000235358.1	RP11-399E6.1	5.03	7.09e-07	9.28e-05	0.3	0.23	Height;	chr1:41146431	chr1:41242373~41284861:+
THCA	cis	rs4443100	0.67	rs3788338	ENSG00000230701.2	FBXW4P1	5.03	7.09e-07	9.28e-05	0.28	0.23	Serum parathyroid hormone levels;	chr22:23069879	chr22:23262767~23265005:+
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000164669.11	INTS4P1	5.03	7.09e-07	9.28e-05	0.43	0.23	Diabetic kidney disease;	chr7:65892097	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs35391607	ENSG00000164669.11	INTS4P1	5.03	7.09e-07	9.28e-05	0.43	0.23	Diabetic kidney disease;	chr7:65895842	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs13220979	ENSG00000164669.11	INTS4P1	5.03	7.09e-07	9.28e-05	0.43	0.23	Diabetic kidney disease;	chr7:65898217	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs34974928	ENSG00000164669.11	INTS4P1	5.03	7.09e-07	9.28e-05	0.43	0.23	Diabetic kidney disease;	chr7:65899019	chr7:65141225~65234216:+
THCA	cis	rs889122	0.765	rs889162	ENSG00000267289.1	CTD-2623N2.11	5.03	7.09e-07	9.28e-05	0.3	0.23	Menarche (age at onset);	chr19:9841240	chr19:9834079~9835013:-
THCA	cis	rs593531	0.571	rs10898981	ENSG00000255440.1	RP11-632K5.2	5.03	7.1e-07	9.28e-05	0.28	0.23	Neuroticism;	chr11:74381420	chr11:74409060~74416379:+
THCA	cis	rs5758659	1	rs5751255	ENSG00000281538.1	RP4-669P10.20	5.03	7.1e-07	9.28e-05	0.21	0.23	Cognitive function;	chr22:42252402	chr22:42138060~42139726:+
THCA	cis	rs3734266	0.646	rs205266	ENSG00000272288.4	RP11-140K17.3	-5.03	7.1e-07	9.29e-05	-0.23	-0.23	Systemic lupus erythematosus;	chr6:34592516	chr6:34696317~34697470:+
THCA	cis	rs79349575	0.783	rs61576918	ENSG00000270781.1	RP11-501C14.9	-5.03	7.1e-07	9.29e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48908231	chr17:48899131~48899748:+
THCA	cis	rs10904908	1	rs7081155	ENSG00000229124.5	VIM-AS1	-5.03	7.1e-07	9.29e-05	-0.22	-0.23	Cholesterol, total;Total cholesterol levels;	chr10:17221141	chr10:17214239~17229985:-
THCA	cis	rs4824093	0.544	rs73443951	ENSG00000278869.1	CITF22-49E9.3	5.03	7.1e-07	9.29e-05	0.39	0.23	Amyotrophic lateral sclerosis (sporadic);	chr22:49907603	chr22:49933198~49934074:-
THCA	cis	rs16976116	0.619	rs11071172	ENSG00000279145.1	RP11-547D13.1	-5.03	7.1e-07	9.29e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55174987	chr15:55171972~55178175:-
THCA	cis	rs8177876	0.658	rs77874075	ENSG00000261838.4	RP11-303E16.6	5.03	7.11e-07	9.3e-05	0.4	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81069854~81076598:+
THCA	cis	rs858239	0.601	rs6969733	ENSG00000230042.1	AK3P3	-5.03	7.11e-07	9.3e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23129178~23129841:+
THCA	cis	rs858239	0.601	rs4440529	ENSG00000230042.1	AK3P3	-5.03	7.11e-07	9.3e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23129178~23129841:+
THCA	cis	rs858239	0.571	rs6953020	ENSG00000230042.1	AK3P3	-5.03	7.11e-07	9.3e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23129178~23129841:+
THCA	cis	rs10200159	0.744	rs75365186	ENSG00000272606.1	RP11-554J4.1	5.03	7.11e-07	9.3e-05	0.44	0.23	Vitiligo;	chr2:55575834	chr2:55617909~55618373:+
THCA	cis	rs2439831	0.681	rs7175434	ENSG00000275601.1	AC011330.13	-5.03	7.11e-07	9.3e-05	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43336344	chr15:43642389~43643023:-
THCA	cis	rs11088226	1	rs78679088	ENSG00000186842.4	LINC00846	-5.03	7.11e-07	9.31e-05	-0.32	-0.23	Gastritis;	chr21:32538517	chr21:32572238~32575881:-
THCA	cis	rs7474896	0.583	rs1735621	ENSG00000263064.2	RP11-291L22.7	-5.03	7.12e-07	9.31e-05	-0.3	-0.23	Obesity (extreme);	chr10:37878795	chr10:38448689~38448949:+
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000273796.1	LL21NC02-21A1.1	-5.03	7.12e-07	9.31e-05	-0.23	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45403809~45404369:-
THCA	cis	rs11118620	0.81	rs4587570	ENSG00000257551.1	HLX-AS1	5.03	7.12e-07	9.31e-05	0.31	0.23	Heart failure;	chr1:220860693	chr1:220832763~220880140:-
THCA	cis	rs79349575	0.783	rs62075818	ENSG00000270781.1	RP11-501C14.9	-5.03	7.12e-07	9.31e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48904965	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs9912829	ENSG00000270781.1	RP11-501C14.9	-5.03	7.12e-07	9.31e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48905387	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs62075820	ENSG00000270781.1	RP11-501C14.9	-5.03	7.12e-07	9.31e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48905809	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs4294857	ENSG00000270781.1	RP11-501C14.9	-5.03	7.12e-07	9.31e-05	-0.27	-0.23	Type 2 diabetes;	chr17:48906029	chr17:48899131~48899748:+
THCA	cis	rs17301013	0.932	rs1754349	ENSG00000227373.4	RP11-160H22.5	-5.03	7.12e-07	9.31e-05	-0.32	-0.23	Systemic lupus erythematosus;	chr1:174837663	chr1:174115300~174160004:-
THCA	cis	rs1046896	0.621	rs7216058	ENSG00000263063.1	RP11-388C12.1	-5.03	7.12e-07	9.31e-05	-0.29	-0.23	Glycated hemoglobin levels;	chr17:82738746	chr17:82713908~82716255:-
THCA	cis	rs453301	0.624	rs2915251	ENSG00000254153.1	CTA-398F10.2	-5.03	7.12e-07	9.32e-05	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9009901	chr8:8456909~8461337:-
THCA	cis	rs922182	0.748	rs1380839	ENSG00000275785.1	RP11-111E14.2	5.03	7.12e-07	9.32e-05	0.26	0.23	Blood protein levels;	chr15:64019965	chr15:63890030~63890317:+
THCA	cis	rs972578	0.791	rs4588289	ENSG00000274717.1	RP1-47A17.1	-5.03	7.12e-07	9.32e-05	-0.23	-0.23	Mean platelet volume;	chr22:42896626	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs4822223	ENSG00000274717.1	RP1-47A17.1	-5.03	7.12e-07	9.32e-05	-0.23	-0.23	Mean platelet volume;	chr22:42898738	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs2002595	ENSG00000274717.1	RP1-47A17.1	-5.03	7.12e-07	9.32e-05	-0.23	-0.23	Mean platelet volume;	chr22:42900045	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs6519351	ENSG00000274717.1	RP1-47A17.1	-5.03	7.12e-07	9.32e-05	-0.23	-0.23	Mean platelet volume;	chr22:42900468	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs9611957	ENSG00000274717.1	RP1-47A17.1	-5.03	7.12e-07	9.32e-05	-0.23	-0.23	Mean platelet volume;	chr22:42901391	chr22:42791814~42794313:-
THCA	cis	rs3743266	0.507	rs34092508	ENSG00000245534.5	RORA-AS1	-5.03	7.13e-07	9.32e-05	-0.31	-0.23	Menarche (age at onset);	chr15:60430780	chr15:60479178~60630637:+
THCA	cis	rs7727544	0.709	rs272852	ENSG00000263597.1	MIR3936	5.03	7.13e-07	9.32e-05	0.22	0.23	Blood metabolite levels;	chr5:132353074	chr5:132365490~132365599:-
THCA	cis	rs2797160	0.967	rs2747715	ENSG00000237742.5	RP11-624M8.1	5.03	7.13e-07	9.32e-05	0.2	0.23	Endometrial cancer;	chr6:125686573	chr6:125578558~125749190:-
THCA	cis	rs11096990	0.964	rs4974999	ENSG00000249685.1	RP11-360F5.3	5.03	7.13e-07	9.32e-05	0.28	0.23	Cognitive function;	chr4:39262294	chr4:39133913~39135608:+
THCA	cis	rs8028182	0.636	rs4486847	ENSG00000260269.4	CTD-2323K18.1	-5.03	7.13e-07	9.33e-05	-0.33	-0.23	Sudden cardiac arrest;	chr15:75436190	chr15:75527150~75601205:-
THCA	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-5.03	7.13e-07	9.33e-05	-0.32	-0.23	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
THCA	cis	rs7267979	0.899	rs442834	ENSG00000274973.1	RP13-401N8.7	-5.03	7.14e-07	9.33e-05	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.932	rs417110	ENSG00000274973.1	RP13-401N8.7	-5.03	7.14e-07	9.33e-05	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.932	rs449703	ENSG00000274973.1	RP13-401N8.7	-5.03	7.14e-07	9.33e-05	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25845497~25845862:+
THCA	cis	rs6951245	1	rs75016635	ENSG00000229043.2	AC091729.9	-5.03	7.14e-07	9.34e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs113066613	ENSG00000229043.2	AC091729.9	-5.03	7.14e-07	9.34e-05	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1160374~1165267:+
THCA	cis	rs613391	0.702	rs474342	ENSG00000224549.1	RP11-370B11.3	-5.03	7.14e-07	9.34e-05	-0.25	-0.23	Quantitative traits;	chr9:22711949	chr9:22767175~22768316:+
THCA	cis	rs613391	0.702	rs560220	ENSG00000224549.1	RP11-370B11.3	-5.03	7.14e-07	9.34e-05	-0.25	-0.23	Quantitative traits;	chr9:22712304	chr9:22767175~22768316:+
THCA	cis	rs1866631	0.605	rs10930579	ENSG00000238133.5	MLK7-AS1	5.03	7.15e-07	9.34e-05	0.29	0.23	Lung cancer in ever smokers;	chr2:173210466	chr2:173166446~173282036:-
THCA	cis	rs972578	0.56	rs8136052	ENSG00000274717.1	RP1-47A17.1	-5.03	7.15e-07	9.35e-05	-0.23	-0.23	Mean platelet volume;	chr22:42927576	chr22:42791814~42794313:-
THCA	cis	rs6545883	0.929	rs2593626	ENSG00000270820.4	RP11-355B11.2	5.03	7.15e-07	9.35e-05	0.19	0.23	Tuberculosis;	chr2:61438049	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.929	rs2592352	ENSG00000270820.4	RP11-355B11.2	5.03	7.15e-07	9.35e-05	0.19	0.23	Tuberculosis;	chr2:61438201	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.929	rs2264100	ENSG00000270820.4	RP11-355B11.2	5.03	7.15e-07	9.35e-05	0.19	0.23	Tuberculosis;	chr2:61443694	chr2:61471188~61484130:+
THCA	cis	rs227275	0.554	rs149576	ENSG00000248971.2	KRT8P46	-5.03	7.15e-07	9.35e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102728746~102730171:-
THCA	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	5.03	7.15e-07	9.35e-05	0.27	0.23	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
THCA	cis	rs2179367	0.632	rs12154153	ENSG00000223701.3	RAET1E-AS1	5.03	7.16e-07	9.35e-05	0.32	0.23	Dupuytren's disease;	chr6:149401686	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs11155649	ENSG00000223701.3	RAET1E-AS1	5.03	7.16e-07	9.35e-05	0.32	0.23	Dupuytren's disease;	chr6:149405830	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs11155650	ENSG00000223701.3	RAET1E-AS1	5.03	7.16e-07	9.35e-05	0.32	0.23	Dupuytren's disease;	chr6:149407613	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs11155651	ENSG00000223701.3	RAET1E-AS1	5.03	7.16e-07	9.35e-05	0.32	0.23	Dupuytren's disease;	chr6:149408146	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs7896	ENSG00000223701.3	RAET1E-AS1	5.03	7.16e-07	9.35e-05	0.32	0.23	Dupuytren's disease;	chr6:149410340	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs12196750	ENSG00000223701.3	RAET1E-AS1	5.03	7.16e-07	9.35e-05	0.32	0.23	Dupuytren's disease;	chr6:149413335	chr6:149884431~149919508:+
THCA	cis	rs2447820	0.541	rs3756357	ENSG00000249996.1	RP11-359P5.1	-5.03	7.16e-07	9.35e-05	-0.27	-0.23	Migraine;	chr5:122997454	chr5:123036271~123054667:+
THCA	cis	rs7615952	0.673	rs16834637	ENSG00000248787.1	RP11-666A20.4	-5.03	7.16e-07	9.36e-05	-0.42	-0.23	Blood pressure (smoking interaction);	chr3:125886628	chr3:125908005~125910272:-
THCA	cis	rs9425766	0.679	rs7552830	ENSG00000227373.4	RP11-160H22.5	5.03	7.16e-07	9.36e-05	0.32	0.23	Life satisfaction;	chr1:174321643	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs7523938	ENSG00000227373.4	RP11-160H22.5	5.03	7.16e-07	9.36e-05	0.32	0.23	Life satisfaction;	chr1:174327373	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.64	rs6681780	ENSG00000227373.4	RP11-160H22.5	5.03	7.16e-07	9.36e-05	0.32	0.23	Life satisfaction;	chr1:174328980	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.64	rs17301013	ENSG00000227373.4	RP11-160H22.5	5.03	7.16e-07	9.36e-05	0.32	0.23	Life satisfaction;	chr1:174343675	chr1:174115300~174160004:-
THCA	cis	rs875971	0.508	rs10242423	ENSG00000273142.1	RP11-458F8.4	5.03	7.16e-07	9.36e-05	0.18	0.23	Aortic root size;	chr7:66594188	chr7:66902857~66906297:+
THCA	cis	rs875971	0.508	rs10253883	ENSG00000273142.1	RP11-458F8.4	5.03	7.16e-07	9.36e-05	0.18	0.23	Aortic root size;	chr7:66596151	chr7:66902857~66906297:+
THCA	cis	rs189798	0.592	rs10111263	ENSG00000233609.3	RP11-62H7.2	-5.03	7.17e-07	9.37e-05	-0.21	-0.23	Myopia (pathological);	chr8:9111923	chr8:8961200~8979025:+
THCA	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	5.03	7.17e-07	9.37e-05	0.19	0.23	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
THCA	cis	rs2303319	0.504	rs41267437	ENSG00000227403.1	AC009299.3	5.02	7.17e-07	9.37e-05	0.48	0.23	Cognitive function;	chr2:161770881	chr2:161244739~161249050:+
THCA	cis	rs7267979	0.903	rs6050482	ENSG00000274973.1	RP13-401N8.7	-5.02	7.17e-07	9.37e-05	-0.25	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.706	rs6037069	ENSG00000274973.1	RP13-401N8.7	-5.02	7.17e-07	9.37e-05	-0.25	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25845497~25845862:+
THCA	cis	rs7552393	0.636	rs12406928	ENSG00000233008.4	RP11-475O6.1	5.02	7.17e-07	9.38e-05	0.26	0.23	Select biomarker traits;	chr1:83832774	chr1:83575776~83861023:-
THCA	cis	rs224278	1	rs224277	ENSG00000238280.1	RP11-436D10.3	5.02	7.18e-07	9.38e-05	0.26	0.23	Ewing sarcoma;	chr10:62820301	chr10:62793562~62805887:-
THCA	cis	rs9425766	0.679	rs6695636	ENSG00000227373.4	RP11-160H22.5	5.02	7.18e-07	9.38e-05	0.32	0.23	Life satisfaction;	chr1:174303087	chr1:174115300~174160004:-
THCA	cis	rs62244186	0.52	rs2372828	ENSG00000214820.3	MPRIPP1	-5.02	7.18e-07	9.38e-05	-0.23	-0.23	Depressive symptoms;	chr3:44743457	chr3:44579938~44581026:-
THCA	cis	rs62244186	0.52	rs9311361	ENSG00000214820.3	MPRIPP1	5.02	7.18e-07	9.38e-05	0.23	0.23	Depressive symptoms;	chr3:44754640	chr3:44579938~44581026:-
THCA	cis	rs1552244	0.608	rs7615408	ENSG00000232901.1	CYCSP10	5.02	7.18e-07	9.38e-05	0.27	0.23	Alzheimer's disease;	chr3:9958502	chr3:10000647~10000940:-
THCA	cis	rs9425766	0.64	rs7512930	ENSG00000227373.4	RP11-160H22.5	5.02	7.18e-07	9.38e-05	0.32	0.23	Life satisfaction;	chr1:174319464	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs7523460	ENSG00000227373.4	RP11-160H22.5	5.02	7.18e-07	9.38e-05	0.32	0.23	Life satisfaction;	chr1:174319664	chr1:174115300~174160004:-
THCA	cis	rs6993244	1	rs6993244	ENSG00000254153.1	CTA-398F10.2	-5.02	7.18e-07	9.38e-05	-0.24	-0.23	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8456909~8461337:-
THCA	cis	rs2797160	1	rs1418642	ENSG00000237742.5	RP11-624M8.1	-5.02	7.19e-07	9.39e-05	-0.19	-0.23	Endometrial cancer;	chr6:125678622	chr6:125578558~125749190:-
THCA	cis	rs1030877	0.515	rs920217	ENSG00000235319.1	AC012360.4	5.02	7.19e-07	9.39e-05	0.29	0.23	Obesity-related traits;	chr2:105288205	chr2:105324210~105330529:+
THCA	cis	rs5758659	0.569	rs133294	ENSG00000227370.1	RP4-669P10.19	-5.02	7.19e-07	9.39e-05	-0.21	-0.23	Cognitive function;	chr22:41986801	chr22:42132543~42132998:+
THCA	cis	rs919433	0.713	rs13411968	ENSG00000231621.1	AC013264.2	-5.02	7.19e-07	9.39e-05	-0.23	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197602417	chr2:197197991~197199273:+
THCA	cis	rs6686842	0.56	rs213751	ENSG00000235358.1	RP11-399E6.1	-5.02	7.19e-07	9.4e-05	-0.29	-0.23	Height;	chr1:41144214	chr1:41242373~41284861:+
THCA	cis	rs7688540	0.8	rs9328737	ENSG00000275426.1	CH17-262A2.1	5.02	7.19e-07	9.4e-05	0.28	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:149738~150317:+
THCA	cis	rs6973609	0.554	rs28731457	ENSG00000271122.1	RP11-379H18.1	-5.02	7.19e-07	9.4e-05	-0.16	-0.23	Obesity-related traits;	chr7:35567426	chr7:35695214~35699413:+
THCA	cis	rs9878978	0.964	rs79638226	ENSG00000237990.3	CNTN4-AS1	5.02	7.19e-07	9.4e-05	0.25	0.23	Blood pressure (smoking interaction);	chr3:2451462	chr3:3039033~3069242:-
THCA	cis	rs9863	0.861	rs11057393	ENSG00000270061.1	RP11-214K3.19	-5.02	7.19e-07	9.4e-05	-0.3	-0.23	White blood cell count;	chr12:123919222	chr12:123969990~123970344:-
THCA	cis	rs6951245	0.935	rs61910751	ENSG00000229043.2	AC091729.9	-5.02	7.2e-07	9.4e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.872	rs77434655	ENSG00000229043.2	AC091729.9	-5.02	7.2e-07	9.4e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.872	rs75398423	ENSG00000229043.2	AC091729.9	-5.02	7.2e-07	9.4e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1160374~1165267:+
THCA	cis	rs8103278	0.507	rs7246377	ENSG00000267395.4	AC074212.6	-5.02	7.2e-07	9.4e-05	-0.15	-0.23	Coronary artery disease;	chr19:45789001	chr19:45767796~45772504:+
THCA	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	5.02	7.2e-07	9.41e-05	0.27	0.23	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
THCA	cis	rs1005277	0.579	rs1740732	ENSG00000275858.1	RP11-291L22.8	5.02	7.2e-07	9.41e-05	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.505	rs7917943	ENSG00000276805.1	RP11-291L22.6	-5.02	7.2e-07	9.41e-05	-0.24	-0.23	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38451030~38451785:+
THCA	cis	rs7688540	0.8	rs6837796	ENSG00000250892.1	RP11-1365D11.1	5.02	7.21e-07	9.42e-05	0.32	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:201409~205009:-
THCA	cis	rs2742234	0.541	rs12220534	ENSG00000273008.1	RP11-351D16.3	-5.02	7.21e-07	9.42e-05	-0.21	-0.23	Hirschsprung disease;	chr10:43238858	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.955	rs1272142	ENSG00000273008.1	RP11-351D16.3	-5.02	7.21e-07	9.42e-05	-0.2	-0.23	Hirschsprung disease;	chr10:43200036	chr10:43136824~43138334:-
THCA	cis	rs9388451	0.559	rs1777210	ENSG00000226409.1	RP11-735G4.1	-5.02	7.21e-07	9.42e-05	-0.27	-0.23	Brugada syndrome;	chr6:125777770	chr6:125370211~125374324:-
THCA	cis	rs7688540	0.76	rs28460123	ENSG00000275426.1	CH17-262A2.1	5.02	7.21e-07	9.42e-05	0.28	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:149738~150317:+
THCA	cis	rs2070488	0.689	rs6809352	ENSG00000229589.1	ACVR2B-AS1	-5.02	7.21e-07	9.42e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38502858	chr3:38451027~38454820:-
THCA	cis	rs9959145	1	rs76195993	ENSG00000267108.1	RP11-861E21.1	5.02	7.21e-07	9.42e-05	0.27	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12651888	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs74732619	ENSG00000267108.1	RP11-861E21.1	5.02	7.21e-07	9.42e-05	0.27	0.23	Immune response to smallpox vaccine (IL-6);	chr18:12652017	chr18:12432897~12437635:+
THCA	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	5.02	7.22e-07	9.43e-05	0.25	0.23	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
THCA	cis	rs5771225	0.505	rs2341111	ENSG00000273253.2	RP3-402G11.26	-5.02	7.22e-07	9.43e-05	-0.27	-0.23	Late-onset Alzheimer's disease;	chr22:50251893	chr22:50199090~50200837:-
THCA	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-5.02	7.22e-07	9.43e-05	-0.32	-0.23	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000223473.2	GS1-124K5.3	5.02	7.22e-07	9.43e-05	0.15	0.23	Calcium levels;	chr7:65975383	chr7:66491049~66493566:-
THCA	cis	rs911555	0.755	rs975892	ENSG00000244691.1	RPL10AP1	-5.02	7.22e-07	9.43e-05	-0.3	-0.23	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103412119~103412761:-
THCA	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	5.02	7.22e-07	9.43e-05	0.31	0.23	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
THCA	cis	rs2797160	0.874	rs58305111	ENSG00000237742.5	RP11-624M8.1	5.02	7.22e-07	9.44e-05	0.19	0.23	Endometrial cancer;	chr6:125687240	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.967	rs1739368	ENSG00000237742.5	RP11-624M8.1	5.02	7.22e-07	9.44e-05	0.19	0.23	Endometrial cancer;	chr6:125689933	chr6:125578558~125749190:-
THCA	cis	rs6860806	1	rs6860806	ENSG00000224431.1	AC063976.7	-5.02	7.22e-07	9.44e-05	-0.19	-0.23	Breast cancer;	chr5:132304843	chr5:132199456~132203487:+
THCA	cis	rs8028313	0.63	rs4776373	ENSG00000270964.1	RP11-502I4.3	-5.02	7.22e-07	9.44e-05	-0.2	-0.23	Obesity;	chr15:67668185	chr15:67541072~67542604:-
THCA	cis	rs795484	0.824	rs428073	ENSG00000275409.1	RP11-131L12.4	-5.02	7.23e-07	9.44e-05	-0.2	-0.23	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118244946	chr12:118430147~118430699:+
THCA	cis	rs972578	0.715	rs5758956	ENSG00000274717.1	RP1-47A17.1	-5.02	7.23e-07	9.45e-05	-0.24	-0.23	Mean platelet volume;	chr22:42821949	chr22:42791814~42794313:-
THCA	cis	rs1836229	0.594	rs1434256	ENSG00000225706.1	PTPRD-AS1	-5.02	7.23e-07	9.45e-05	-0.26	-0.23	Restless legs syndrome;	chr9:8830796	chr9:8858130~8862255:+
THCA	cis	rs972578	0.791	rs5759015	ENSG00000274717.1	RP1-47A17.1	-5.02	7.23e-07	9.45e-05	-0.23	-0.23	Mean platelet volume;	chr22:42895523	chr22:42791814~42794313:-
THCA	cis	rs1580019	0.534	rs13237495	ENSG00000231952.3	DPY19L1P2	-5.02	7.23e-07	9.45e-05	-0.28	-0.23	Cognitive ability;	chr7:32521075	chr7:32812757~32838570:+
THCA	cis	rs1552244	1	rs9879080	ENSG00000180385.7	EMC3-AS1	5.02	7.23e-07	9.45e-05	0.25	0.23	Alzheimer's disease;	chr3:10042540	chr3:9986893~10006990:+
THCA	cis	rs4908769	0.624	rs1763838	ENSG00000232912.4	RP5-1115A15.1	5.02	7.24e-07	9.45e-05	0.25	0.23	Allergy;	chr1:8413271	chr1:8424645~8434838:+
THCA	cis	rs2067615	0.507	rs10746063	ENSG00000260329.1	RP11-412D9.4	-5.02	7.24e-07	9.45e-05	-0.21	-0.23	Heart rate;	chr12:106692462	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.507	rs10746064	ENSG00000260329.1	RP11-412D9.4	-5.02	7.24e-07	9.45e-05	-0.21	-0.23	Heart rate;	chr12:106692467	chr12:106954029~106955497:-
THCA	cis	rs1552244	1	rs13319597	ENSG00000180385.7	EMC3-AS1	-5.02	7.24e-07	9.45e-05	-0.25	-0.23	Alzheimer's disease;	chr3:10084628	chr3:9986893~10006990:+
THCA	cis	rs9380516	0.812	rs749522	ENSG00000228559.1	RP3-340B19.3	-5.02	7.24e-07	9.46e-05	-0.34	-0.23	Hepatitis C induced liver fibrosis;	chr6:35522077	chr6:35544632~35545669:+
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000273796.1	LL21NC02-21A1.1	-5.02	7.24e-07	9.46e-05	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45403809~45404369:-
THCA	cis	rs17767392	0.813	rs12887261	ENSG00000259146.3	RP1-261D10.2	5.02	7.24e-07	9.46e-05	0.28	0.23	Mitral valve prolapse;	chr14:71475262	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.813	rs61989379	ENSG00000259146.3	RP1-261D10.2	5.02	7.24e-07	9.46e-05	0.28	0.23	Mitral valve prolapse;	chr14:71497689	chr14:71292729~71321814:-
THCA	cis	rs224278	1	rs224282	ENSG00000238280.1	RP11-436D10.3	5.02	7.25e-07	9.46e-05	0.26	0.23	Ewing sarcoma;	chr10:62822803	chr10:62793562~62805887:-
THCA	cis	rs224278	1	rs224289	ENSG00000238280.1	RP11-436D10.3	5.02	7.25e-07	9.46e-05	0.26	0.23	Ewing sarcoma;	chr10:62827327	chr10:62793562~62805887:-
THCA	cis	rs2243480	0.706	rs6460257	ENSG00000223473.2	GS1-124K5.3	5.02	7.25e-07	9.46e-05	0.21	0.23	Diabetic kidney disease;	chr7:65731813	chr7:66491049~66493566:-
THCA	cis	rs1003719	0.788	rs7275582	ENSG00000230366.8	DSCR9	-5.02	7.25e-07	9.46e-05	-0.23	-0.23	Eye color traits;	chr21:37078830	chr21:37208503~37221736:+
THCA	cis	rs736408	0.66	rs2019065	ENSG00000243224.1	RP5-1157M23.2	5.02	7.25e-07	9.46e-05	0.24	0.23	Bipolar disorder;	chr3:52775509	chr3:52239258~52241097:+
THCA	cis	rs9863	0.931	rs11057401	ENSG00000269997.1	RP11-214K3.21	-5.02	7.25e-07	9.47e-05	-0.28	-0.23	White blood cell count;	chr12:123942759	chr12:123966077~123966629:-
THCA	cis	rs897984	0.806	rs8050588	ENSG00000260911.2	RP11-196G11.2	5.02	7.25e-07	9.47e-05	0.19	0.23	Dementia with Lewy bodies;	chr16:30926478	chr16:31043150~31049868:+
THCA	cis	rs12935418	0.672	rs9888895	ENSG00000278985.1	RP11-303E16.9	5.02	7.25e-07	9.47e-05	0.24	0.23	Mean corpuscular volume;	chr16:81017496	chr16:80982319~80984094:-
THCA	cis	rs79243044	0.965	rs12419693	ENSG00000224295.2	AC087380.14	-5.02	7.25e-07	9.47e-05	-0.22	-0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5535726	chr11:5518441~5524955:-
THCA	cis	rs9816784	0.901	rs12490036	ENSG00000207650.1	MIR570	-5.02	7.26e-07	9.48e-05	-0.23	-0.23	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195699401~195699497:+
THCA	cis	rs9859260	1	rs9990392	ENSG00000231464.1	AC024937.4	5.02	7.26e-07	9.48e-05	0.27	0.23	Mean corpuscular volume;	chr3:196071651	chr3:195996738~195998233:+
THCA	cis	rs763121	0.925	rs5757165	ENSG00000235209.1	CTA-150C2.13	5.02	7.26e-07	9.48e-05	0.28	0.23	Menopause (age at onset);	chr22:38598572	chr22:38921227~38924708:+
THCA	cis	rs4819052	0.62	rs421619	ENSG00000215447.6	BX322557.10	-5.02	7.26e-07	9.48e-05	-0.21	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45126200	chr21:45288052~45291738:+
THCA	cis	rs6832769	1	rs6834676	ENSG00000272969.1	RP11-528I4.2	5.02	7.27e-07	9.49e-05	0.26	0.23	Personality dimensions;	chr4:55432247	chr4:55547112~55547889:+
THCA	cis	rs3796352	1	rs35737577	ENSG00000242142.1	SERBP1P3	-5.02	7.27e-07	9.49e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52968541	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs35849389	ENSG00000242142.1	SERBP1P3	-5.02	7.27e-07	9.49e-05	-0.43	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:52971219	chr3:53064283~53065091:-
THCA	cis	rs4824093	0.535	rs73441802	ENSG00000278869.1	CITF22-49E9.3	5.02	7.27e-07	9.5e-05	0.43	0.23	Amyotrophic lateral sclerosis (sporadic);	chr22:49880268	chr22:49933198~49934074:-
THCA	cis	rs1048886	0.872	rs7740873	ENSG00000271967.1	RP11-134K13.4	-5.02	7.27e-07	9.5e-05	-0.23	-0.23	Type 2 diabetes;	chr6:70526513	chr6:70596438~70596980:+
THCA	cis	rs1979679	0.842	rs981494	ENSG00000247934.4	RP11-967K21.1	5.02	7.27e-07	9.5e-05	0.22	0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28172916	chr12:28163298~28190738:-
THCA	cis	rs228614	0.51	rs223453	ENSG00000248971.2	KRT8P46	-5.02	7.27e-07	9.5e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102728746~102730171:-
THCA	cis	rs2243480	0.803	rs160649	ENSG00000164669.11	INTS4P1	5.02	7.27e-07	9.5e-05	0.43	0.23	Diabetic kidney disease;	chr7:66078212	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs160648	ENSG00000164669.11	INTS4P1	5.02	7.27e-07	9.5e-05	0.43	0.23	Diabetic kidney disease;	chr7:66078397	chr7:65141225~65234216:+
THCA	cis	rs11603023	0.625	rs633683	ENSG00000278376.1	RP11-158I9.8	-5.02	7.27e-07	9.5e-05	-0.18	-0.23	Cholesterol, total;	chr11:118634025	chr11:118791254~118793137:+
THCA	cis	rs911119	1	rs6036478	ENSG00000270001.1	RP11-218C14.8	-5.02	7.27e-07	9.5e-05	-0.34	-0.23	Chronic kidney disease;	chr20:23630722	chr20:23631826~23632316:-
THCA	cis	rs911119	1	rs6114206	ENSG00000270001.1	RP11-218C14.8	-5.02	7.27e-07	9.5e-05	-0.34	-0.23	Chronic kidney disease;	chr20:23631152	chr20:23631826~23632316:-
THCA	cis	rs7621025	0.505	rs13063893	ENSG00000273486.1	RP11-731C17.2	-5.02	7.28e-07	9.5e-05	-0.29	-0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136668796	chr3:136837338~136839021:-
THCA	cis	rs7520050	0.807	rs72688483	ENSG00000234329.1	RP11-767N6.2	5.02	7.28e-07	9.5e-05	0.2	0.23	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45651039~45651826:-
THCA	cis	rs67478160	0.643	rs2295145	ENSG00000258735.1	LINC00637	-5.02	7.28e-07	9.5e-05	-0.28	-0.23	Schizophrenia;	chr14:103735967	chr14:103847721~103858049:+
THCA	cis	rs6496932	0.503	rs11074205	ENSG00000259630.2	CTD-2262B20.1	-5.02	7.28e-07	9.51e-05	-0.28	-0.23	Central corneal thickness;Corneal structure;	chr15:85401381	chr15:85415228~85415633:+
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000273796.1	LL21NC02-21A1.1	-5.02	7.28e-07	9.51e-05	-0.23	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45403809~45404369:-
THCA	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-5.02	7.28e-07	9.51e-05	-0.29	-0.23	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
THCA	cis	rs2303319	0.504	rs62187754	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161854674	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs41267441	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161855172	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187756	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161855632	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187757	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161857779	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187759	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161859499	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188760	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161861243	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.581	rs62188761	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161862319	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188762	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161863580	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72881015	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161866033	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62188765	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161866675	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72881021	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Cognitive function;	chr2:161867540	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs55736476	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161868274	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs56063742	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161868447	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs62188767	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161869362	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs62188768	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161869414	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs72881030	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161869558	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs72881034	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161870456	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs72881037	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161870510	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs62188769	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161873159	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs72881042	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161873493	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs56078948	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161874482	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs72881046	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161875251	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.581	rs55711310	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161876140	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs56140629	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161877499	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs72881053	ENSG00000227403.1	AC009299.3	5.02	7.29e-07	9.51e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161878249	chr2:161244739~161249050:+
THCA	cis	rs853679	0.723	rs9366718	ENSG00000220721.1	OR1F12	5.02	7.29e-07	9.52e-05	0.32	0.23	Depression;	chr6:28237724	chr6:28073316~28074233:+
THCA	cis	rs2070488	0.775	rs1132064	ENSG00000229589.1	ACVR2B-AS1	-5.02	7.3e-07	9.53e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38525028	chr3:38451027~38454820:-
THCA	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	5.02	7.3e-07	9.53e-05	0.27	0.23	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
THCA	cis	rs8177876	0.822	rs1563075	ENSG00000261061.1	RP11-303E16.2	-5.02	7.3e-07	9.53e-05	-0.32	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81030770~81031485:+
THCA	cis	rs748404	0.666	rs35158584	ENSG00000205771.5	CATSPER2P1	-5.02	7.3e-07	9.53e-05	-0.29	-0.23	Lung cancer;	chr15:43392876	chr15:43726918~43747094:-
THCA	cis	rs9818758	0.607	rs34326553	ENSG00000270441.1	RP11-694I15.7	5.02	7.3e-07	9.53e-05	0.33	0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49096996	chr3:49140086~49160851:-
THCA	cis	rs8002861	0.905	rs12874590	ENSG00000274001.1	RP11-5G9.5	-5.02	7.3e-07	9.53e-05	-0.27	-0.23	Leprosy;	chr13:43859227	chr13:43877715~43878163:-
THCA	cis	rs1499614	0.522	rs13247442	ENSG00000229886.1	RP5-1132H15.3	5.02	7.3e-07	9.53e-05	0.48	0.23	Gout;	chr7:66723871	chr7:66025126~66031544:-
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000230295.1	RP11-458F8.2	-5.02	7.31e-07	9.54e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66433290	chr7:66880708~66882981:+
THCA	cis	rs2243480	1	rs58669269	ENSG00000230295.1	RP11-458F8.2	-5.02	7.31e-07	9.54e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66486966	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs73136346	ENSG00000232546.1	RP11-458F8.1	-5.02	7.31e-07	9.54e-05	-0.22	-0.23	Aortic root size;	chr7:66101095	chr7:66848496~66858136:+
THCA	cis	rs7914558	0.966	rs7096269	ENSG00000236937.2	PTGES3P4	5.02	7.31e-07	9.54e-05	0.29	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102976964	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.933	rs10883814	ENSG00000236937.2	PTGES3P4	5.02	7.31e-07	9.54e-05	0.29	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102977647	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs1971589	ENSG00000236937.2	PTGES3P4	5.02	7.31e-07	9.54e-05	0.29	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102984649	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs1890185	ENSG00000236937.2	PTGES3P4	5.02	7.31e-07	9.54e-05	0.29	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102845595~102845950:+
THCA	cis	rs950880	0.71	rs3732129	ENSG00000234389.1	AC007278.3	-5.02	7.31e-07	9.55e-05	-0.28	-0.23	Serum protein levels (sST2);	chr2:102341072	chr2:102438713~102440475:+
THCA	cis	rs17767392	0.958	rs3784064	ENSG00000259146.3	RP1-261D10.2	-5.02	7.32e-07	9.55e-05	-0.29	-0.23	Mitral valve prolapse;	chr14:71592834	chr14:71292729~71321814:-
THCA	cis	rs9952991	0.527	rs2847259	ENSG00000260302.1	RP11-973H7.1	-5.02	7.32e-07	9.55e-05	-0.29	-0.23	Inflammatory skin disease;	chr18:12775822	chr18:12774651~12775923:-
THCA	cis	rs11096990	0.892	rs11932351	ENSG00000249685.1	RP11-360F5.3	-5.02	7.32e-07	9.55e-05	-0.29	-0.23	Cognitive function;	chr4:39229837	chr4:39133913~39135608:+
THCA	cis	rs2303319	0.504	rs2090270	ENSG00000227403.1	AC009299.3	5.02	7.32e-07	9.56e-05	0.55	0.23	Cognitive function;	chr2:161846717	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187747	ENSG00000227403.1	AC009299.3	5.02	7.32e-07	9.56e-05	0.55	0.23	Cognitive function;	chr2:161849564	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187748	ENSG00000227403.1	AC009299.3	5.02	7.32e-07	9.56e-05	0.55	0.23	Cognitive function;	chr2:161850544	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.581	rs62187749	ENSG00000227403.1	AC009299.3	5.02	7.32e-07	9.56e-05	0.55	0.23	Blood osmolality (transformed sodium);	chr2:161850678	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187750	ENSG00000227403.1	AC009299.3	5.02	7.32e-07	9.56e-05	0.55	0.23	Cognitive function;	chr2:161850840	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187751	ENSG00000227403.1	AC009299.3	5.02	7.32e-07	9.56e-05	0.55	0.23	Cognitive function;	chr2:161850953	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187752	ENSG00000227403.1	AC009299.3	5.02	7.32e-07	9.56e-05	0.55	0.23	Cognitive function;	chr2:161852523	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs55961814	ENSG00000227403.1	AC009299.3	5.02	7.32e-07	9.56e-05	0.55	0.23	Cognitive function;	chr2:161853677	chr2:161244739~161249050:+
THCA	cis	rs13126694	0.682	rs9991381	ENSG00000248429.4	RP11-597D13.9	5.02	7.32e-07	9.56e-05	0.25	0.23	Blood osmolality (transformed sodium);	chr4:157982239	chr4:158170752~158202877:+
THCA	cis	rs224278	1	rs224278	ENSG00000238280.1	RP11-436D10.3	5.02	7.32e-07	9.56e-05	0.26	0.23	Ewing sarcoma;	chr10:62820815	chr10:62793562~62805887:-
THCA	cis	rs2797160	1	rs6904069	ENSG00000237742.5	RP11-624M8.1	-5.02	7.32e-07	9.56e-05	-0.19	-0.23	Endometrial cancer;	chr6:125673988	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs6569435	ENSG00000237742.5	RP11-624M8.1	-5.02	7.32e-07	9.56e-05	-0.19	-0.23	Endometrial cancer;	chr6:125677040	chr6:125578558~125749190:-
THCA	cis	rs160451	0.782	rs160409	ENSG00000251136.7	RP11-37B2.1	5.02	7.33e-07	9.56e-05	0.21	0.23	Leprosy;	chr8:89636342	chr8:89609409~89757727:-
THCA	cis	rs651907	0.557	rs12629954	ENSG00000244119.1	PDCL3P4	5.02	7.33e-07	9.57e-05	0.21	0.23	Colorectal cancer;	chr3:101641779	chr3:101712472~101713191:+
THCA	cis	rs4915077	0.892	rs17020086	ENSG00000230489.1	VAV3-AS1	5.02	7.33e-07	9.57e-05	0.33	0.23	Hypothyroidism;	chr1:107809179	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs17020088	ENSG00000230489.1	VAV3-AS1	5.02	7.33e-07	9.57e-05	0.33	0.23	Hypothyroidism;	chr1:107809190	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs6691039	ENSG00000230489.1	VAV3-AS1	5.02	7.33e-07	9.57e-05	0.33	0.23	Hypothyroidism;	chr1:107809270	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs6703923	ENSG00000230489.1	VAV3-AS1	5.02	7.33e-07	9.57e-05	0.33	0.23	Hypothyroidism;	chr1:107809630	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs4914962	ENSG00000230489.1	VAV3-AS1	5.02	7.33e-07	9.57e-05	0.33	0.23	Hypothyroidism;	chr1:107809974	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs17020100	ENSG00000230489.1	VAV3-AS1	5.02	7.33e-07	9.57e-05	0.33	0.23	Hypothyroidism;	chr1:107810229	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs17020103	ENSG00000230489.1	VAV3-AS1	5.02	7.33e-07	9.57e-05	0.33	0.23	Hypothyroidism;	chr1:107810405	chr1:107964443~107994607:+
THCA	cis	rs2243480	1	rs7794661	ENSG00000230295.1	RP11-458F8.2	-5.02	7.33e-07	9.57e-05	-0.27	-0.23	Diabetic kidney disease;	chr7:65924743	chr7:66880708~66882981:+
THCA	cis	rs440932	0.798	rs330942	ENSG00000254340.1	RP11-10A14.3	5.02	7.34e-07	9.57e-05	0.24	0.23	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:9141424~9145435:+
THCA	cis	rs7520050	0.966	rs1707304	ENSG00000234329.1	RP11-767N6.2	-5.02	7.34e-07	9.57e-05	-0.2	-0.23	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45651039~45651826:-
THCA	cis	rs72615157	0.634	rs11762932	ENSG00000078319.8	PMS2P1	5.02	7.34e-07	9.58e-05	0.3	0.23	Lung function (FEV1/FVC);	chr7:100195043	chr7:100320992~100341908:-
THCA	cis	rs228614	0.51	rs65671	ENSG00000248971.2	KRT8P46	-5.02	7.35e-07	9.59e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102728746~102730171:-
THCA	cis	rs2303319	0.504	rs62187745	ENSG00000227403.1	AC009299.3	5.02	7.35e-07	9.59e-05	0.55	0.23	Cognitive function;	chr2:161846296	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs4455163	ENSG00000227403.1	AC009299.3	5.02	7.35e-07	9.59e-05	0.55	0.23	Cognitive function;	chr2:161846488	chr2:161244739~161249050:+
THCA	cis	rs7403037	0.55	rs61993575	ENSG00000259905.4	PWRN1	5.02	7.36e-07	9.6e-05	0.31	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24399038	chr15:24493137~24652130:+
THCA	cis	rs11992162	1	rs12334769	ENSG00000254948.1	OR7E158P	-5.02	7.36e-07	9.6e-05	-0.28	-0.23	Monocyte count;	chr8:11975652	chr8:11919900~11920809:-
THCA	cis	rs2797160	1	rs6910933	ENSG00000237742.5	RP11-624M8.1	5.02	7.36e-07	9.6e-05	0.19	0.23	Endometrial cancer;	chr6:125696009	chr6:125578558~125749190:-
THCA	cis	rs1707322	0.963	rs10890373	ENSG00000281133.1	AL355480.3	-5.02	7.36e-07	9.6e-05	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45580892~45580996:-
THCA	cis	rs6832769	1	rs6812042	ENSG00000272969.1	RP11-528I4.2	5.02	7.36e-07	9.6e-05	0.26	0.23	Personality dimensions;	chr4:55529912	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs7667849	ENSG00000272969.1	RP11-528I4.2	-5.02	7.36e-07	9.6e-05	-0.26	-0.23	Personality dimensions;	chr4:55522032	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs10002541	ENSG00000272969.1	RP11-528I4.2	-5.02	7.36e-07	9.6e-05	-0.26	-0.23	Personality dimensions;	chr4:55528844	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs9998146	ENSG00000272969.1	RP11-528I4.2	-5.02	7.36e-07	9.6e-05	-0.26	-0.23	Personality dimensions;	chr4:55531810	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs28790098	ENSG00000272969.1	RP11-528I4.2	-5.02	7.36e-07	9.6e-05	-0.26	-0.23	Personality dimensions;	chr4:55531942	chr4:55547112~55547889:+
THCA	cis	rs987724	0.593	rs13088978	ENSG00000240875.4	LINC00886	-5.02	7.36e-07	9.6e-05	-0.17	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156951007	chr3:156747346~156817062:-
THCA	cis	rs987724	0.593	rs9878585	ENSG00000240875.4	LINC00886	-5.02	7.36e-07	9.6e-05	-0.17	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156952028	chr3:156747346~156817062:-
THCA	cis	rs987724	0.574	rs2874492	ENSG00000240875.4	LINC00886	-5.02	7.36e-07	9.6e-05	-0.17	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156953387	chr3:156747346~156817062:-
THCA	cis	rs987724	0.574	rs9856725	ENSG00000240875.4	LINC00886	-5.02	7.36e-07	9.6e-05	-0.17	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156954781	chr3:156747346~156817062:-
THCA	cis	rs17767392	0.881	rs12881957	ENSG00000259146.3	RP1-261D10.2	5.02	7.36e-07	9.61e-05	0.28	0.23	Mitral valve prolapse;	chr14:71443137	chr14:71292729~71321814:-
THCA	cis	rs950169	0.58	rs11636189	ENSG00000188388.10	GOLGA6L3	5.02	7.36e-07	9.61e-05	0.3	0.23	Schizophrenia;	chr15:84650323	chr15:85240472~85247170:+
THCA	cis	rs950169	0.58	rs35516100	ENSG00000188388.10	GOLGA6L3	5.02	7.36e-07	9.61e-05	0.3	0.23	Schizophrenia;	chr15:84652199	chr15:85240472~85247170:+
THCA	cis	rs950169	0.58	rs62021208	ENSG00000188388.10	GOLGA6L3	5.02	7.36e-07	9.61e-05	0.3	0.23	Schizophrenia;	chr15:84653013	chr15:85240472~85247170:+
THCA	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-5.02	7.37e-07	9.61e-05	-0.32	-0.23	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-5.02	7.37e-07	9.61e-05	-0.32	-0.23	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-5.02	7.37e-07	9.61e-05	-0.32	-0.23	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-5.02	7.37e-07	9.61e-05	-0.32	-0.23	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
THCA	cis	rs62025270	0.547	rs338536	ENSG00000202081.1	RNU6-1280P	-5.02	7.37e-07	9.61e-05	-0.31	-0.23	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85651522~85651628:-
THCA	cis	rs2880765	0.525	rs2062234	ENSG00000259630.2	CTD-2262B20.1	-5.02	7.37e-07	9.61e-05	-0.29	-0.23	Coronary artery disease;	chr15:85511259	chr15:85415228~85415633:+
THCA	cis	rs8046148	0.614	rs8047504	ENSG00000279356.1	RP11-429P3.8	5.02	7.37e-07	9.61e-05	0.26	0.23	Testicular germ cell tumor;	chr16:50073724	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.54	rs59059423	ENSG00000279356.1	RP11-429P3.8	5.02	7.37e-07	9.61e-05	0.26	0.23	Testicular germ cell tumor;	chr16:50074191	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs9939688	ENSG00000279356.1	RP11-429P3.8	5.02	7.37e-07	9.61e-05	0.26	0.23	Testicular germ cell tumor;	chr16:50075189	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs12931497	ENSG00000279356.1	RP11-429P3.8	5.02	7.37e-07	9.61e-05	0.26	0.23	Testicular germ cell tumor;	chr16:50075567	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs7203348	ENSG00000279356.1	RP11-429P3.8	5.02	7.37e-07	9.61e-05	0.26	0.23	Testicular germ cell tumor;	chr16:50078356	chr16:50072862~50074986:+
THCA	cis	rs2337406	1	rs11849532	ENSG00000211974.3	IGHV2-70	-5.02	7.37e-07	9.62e-05	-0.23	-0.23	Alzheimer's disease (late onset);	chr14:106669877	chr14:106723574~106724093:-
THCA	cis	rs875971	0.545	rs13311962	ENSG00000228409.4	CCT6P1	5.02	7.37e-07	9.62e-05	0.19	0.23	Aortic root size;	chr7:66603142	chr7:65751142~65763354:+
THCA	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	5.02	7.38e-07	9.62e-05	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
THCA	cis	rs7136259	1	rs7136259	ENSG00000258302.2	RP11-981P6.1	-5.02	7.38e-07	9.62e-05	-0.19	-0.23	Coronary heart disease;	chr12:89687411	chr12:89561129~89594878:+
THCA	cis	rs116095464	0.558	rs10055993	ENSG00000248925.1	CTD-2083E4.6	5.02	7.38e-07	9.62e-05	0.36	0.23	Breast cancer;	chr5:264181	chr5:269858~271516:-
THCA	cis	rs13113518	0.507	rs4549456	ENSG00000273257.1	RP11-177J6.1	5.02	7.38e-07	9.62e-05	0.3	0.23	Height;	chr4:55398586	chr4:55387949~55388271:+
THCA	cis	rs919433	0.963	rs12617117	ENSG00000231621.1	AC013264.2	5.02	7.38e-07	9.63e-05	0.23	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197290446	chr2:197197991~197199273:+
THCA	cis	rs11671005	0.735	rs11084544	ENSG00000268912.1	CTD-2619J13.17	-5.02	7.38e-07	9.63e-05	-0.21	-0.23	Mean platelet volume;	chr19:58428760	chr19:58428632~58431148:-
THCA	cis	rs4693089	0.564	rs541024	ENSG00000213608.5	SLC25A14P1	-5.02	7.39e-07	9.63e-05	-0.26	-0.23	Menopause (age at onset);	chr4:83505367	chr4:83477524~83478424:+
THCA	cis	rs2067615	0.579	rs3782709	ENSG00000260329.1	RP11-412D9.4	-5.02	7.39e-07	9.63e-05	-0.2	-0.23	Heart rate;	chr12:106811975	chr12:106954029~106955497:-
THCA	cis	rs2797160	1	rs1777225	ENSG00000237742.5	RP11-624M8.1	5.02	7.39e-07	9.63e-05	0.19	0.23	Endometrial cancer;	chr6:125697124	chr6:125578558~125749190:-
THCA	cis	rs2797160	1	rs1739362	ENSG00000237742.5	RP11-624M8.1	5.02	7.39e-07	9.63e-05	0.19	0.23	Endometrial cancer;	chr6:125699557	chr6:125578558~125749190:-
THCA	cis	rs5758659	0.714	rs5751220	ENSG00000182057.4	OGFRP1	-5.02	7.39e-07	9.63e-05	-0.26	-0.23	Cognitive function;	chr22:42120201	chr22:42269753~42275196:+
THCA	cis	rs1023500	0.505	rs134901	ENSG00000273366.1	CTA-989H11.1	-5.02	7.39e-07	9.64e-05	-0.28	-0.23	Schizophrenia;	chr22:42287514	chr22:42278188~42278846:+
THCA	cis	rs7429990	0.932	rs936428	ENSG00000228638.1	FCF1P2	5.02	7.39e-07	9.64e-05	0.22	0.23	Educational attainment (years of education);	chr3:48125791	chr3:48290793~48291375:-
THCA	cis	rs8141529	0.748	rs132528	ENSG00000272858.1	CTA-292E10.8	5.02	7.4e-07	9.64e-05	0.23	0.23	Lymphocyte counts;	chr22:28899910	chr22:28814914~28815662:+
THCA	cis	rs7688540	0.771	rs11730202	ENSG00000211553.1	AC253576.2	-5.02	7.4e-07	9.64e-05	-0.35	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:136461~136568:+
THCA	cis	rs7160336	0.641	rs4899503	ENSG00000259065.1	RP5-1021I20.1	5.02	7.4e-07	9.65e-05	0.27	0.23	Blood protein levels;	chr14:74217234	chr14:73787360~73803270:+
THCA	cis	rs8028182	0.636	rs4451914	ENSG00000260274.1	RP11-817O13.8	5.02	7.4e-07	9.65e-05	0.16	0.23	Sudden cardiac arrest;	chr15:75447483	chr15:75368155~75369584:+
THCA	cis	rs11671005	0.735	rs11084544	ENSG00000265272.2	RN7SL693P	5.02	7.4e-07	9.65e-05	0.31	0.23	Mean platelet volume;	chr19:58428760	chr19:58490797~58491075:+
THCA	cis	rs7688540	0.74	rs28784663	ENSG00000275426.1	CH17-262A2.1	5.02	7.4e-07	9.65e-05	0.29	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:149738~150317:+
THCA	cis	rs4671400	0.571	rs68020555	ENSG00000271889.1	RP11-493E12.1	-5.02	7.4e-07	9.65e-05	-0.22	-0.23	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258647	chr2:61151433~61162105:-
THCA	cis	rs897984	0.806	rs1046276	ENSG00000279196.1	RP11-1072A3.3	-5.02	7.4e-07	9.65e-05	-0.23	-0.23	Dementia with Lewy bodies;	chr16:30903305	chr16:30984630~30988270:-
THCA	cis	rs28510890	0.547	rs35070516	ENSG00000258676.4	RP11-386M24.3	-5.02	7.4e-07	9.65e-05	-0.25	-0.23	Lung cancer in ever smokers;	chr15:92607968	chr15:92580829~92600545:+
THCA	cis	rs2243480	1	rs35820085	ENSG00000164669.11	INTS4P1	5.02	7.41e-07	9.65e-05	0.44	0.23	Diabetic kidney disease;	chr7:65977771	chr7:65141225~65234216:+
THCA	cis	rs2070488	0.775	rs13098946	ENSG00000229589.1	ACVR2B-AS1	5.02	7.41e-07	9.65e-05	0.2	0.23	Electrocardiographic conduction measures;	chr3:38476293	chr3:38451027~38454820:-
THCA	cis	rs7181230	0.848	rs62004114	ENSG00000275636.1	RP11-521C20.5	5.02	7.41e-07	9.66e-05	0.25	0.23	Dehydroepiandrosterone sulphate levels;	chr15:40041154	chr15:40078892~40079347:+
THCA	cis	rs7181230	0.848	rs75509561	ENSG00000275636.1	RP11-521C20.5	5.02	7.41e-07	9.66e-05	0.25	0.23	Dehydroepiandrosterone sulphate levels;	chr15:40041268	chr15:40078892~40079347:+
THCA	cis	rs7181230	0.848	rs7497289	ENSG00000275636.1	RP11-521C20.5	5.02	7.41e-07	9.66e-05	0.25	0.23	Dehydroepiandrosterone sulphate levels;	chr15:40041456	chr15:40078892~40079347:+
THCA	cis	rs2255336	0.817	rs10743889	ENSG00000245648.1	RP11-277P12.20	5.02	7.41e-07	9.66e-05	0.26	0.23	Blood protein levels;	chr12:10368790	chr12:10363769~10398506:+
THCA	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-5.02	7.41e-07	9.66e-05	-0.22	-0.23	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
THCA	cis	rs9890032	0.564	rs62070652	ENSG00000266490.1	CTD-2349P21.9	5.02	7.41e-07	9.66e-05	0.23	0.23	Hip circumference adjusted for BMI;	chr17:30894259	chr17:30792372~30792833:+
THCA	cis	rs72945132	0.882	rs17853270	ENSG00000254604.1	AP000487.6	-5.02	7.41e-07	9.66e-05	-0.43	-0.23	Coronary artery disease;	chr11:70354423	chr11:70282367~70363368:-
THCA	cis	rs2304003	0.95	rs6742727	ENSG00000235192.1	AC009495.2	5.02	7.41e-07	9.66e-05	0.32	0.23	Social communication problems;	chr2:165836176	chr2:165794851~165810010:+
THCA	cis	rs2299587	0.552	rs1978054	ENSG00000253671.1	RP11-806O11.1	-5.02	7.41e-07	9.67e-05	-0.27	-0.23	Economic and political preferences;	chr8:18011012	chr8:17808941~17820868:+
THCA	cis	rs12143943	0.934	rs1563827	ENSG00000240219.1	RP11-430C7.5	5.02	7.42e-07	9.67e-05	0.2	0.23	Cognitive performance;	chr1:204610011	chr1:204626775~204629712:+
THCA	cis	rs27434	0.66	rs42398	ENSG00000272109.1	CTD-2260A17.3	-5.02	7.42e-07	9.67e-05	-0.35	-0.23	Ankylosing spondylitis;	chr5:96784751	chr5:96804353~96806105:+
THCA	cis	rs9309473	0.5	rs4852952	ENSG00000163016.8	ALMS1P	-5.02	7.42e-07	9.67e-05	-0.29	-0.23	Metabolite levels;	chr2:73642780	chr2:73644919~73685576:+
THCA	cis	rs7665090	0.51	rs223498	ENSG00000230069.3	LRRC37A15P	5.02	7.42e-07	9.67e-05	0.24	0.23	Primary biliary cholangitis;	chr4:102730805	chr4:102727274~102730721:-
THCA	cis	rs7731390	0.614	rs3792881	ENSG00000233006.5	AC034220.3	5.02	7.42e-07	9.67e-05	0.3	0.23	IgG glycosylation;	chr5:132309412	chr5:132311285~132369916:-
THCA	cis	rs11795343	0.524	rs7024980	ENSG00000232303.2	DFFBP1	-5.02	7.42e-07	9.67e-05	-0.29	-0.23	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32533377	chr9:32566148~32567126:-
THCA	cis	rs972578	0.715	rs8141176	ENSG00000274717.1	RP1-47A17.1	-5.02	7.42e-07	9.68e-05	-0.24	-0.23	Mean platelet volume;	chr22:42819686	chr22:42791814~42794313:-
THCA	cis	rs944289	0.708	rs1930765	ENSG00000258844.1	RP11-259K15.2	5.02	7.43e-07	9.68e-05	0.2	0.23	Thyroid cancer;	chr14:36110053	chr14:36214607~36235608:+
THCA	cis	rs1050631	0.563	rs685042	ENSG00000260552.1	RP11-49I11.1	5.02	7.43e-07	9.68e-05	0.28	0.23	Esophageal squamous cell cancer (length of survival);	chr18:36164035	chr18:36179996~36187448:-
THCA	cis	rs9307551	1	rs6855486	ENSG00000250334.4	LINC00989	5.02	7.43e-07	9.68e-05	0.28	0.23	Refractive error;	chr4:79612886	chr4:79492416~79576460:+
THCA	cis	rs2439831	0.867	rs6493085	ENSG00000166763.7	STRCP1	5.02	7.43e-07	9.69e-05	0.31	0.23	Lung cancer in ever smokers;	chr15:43361984	chr15:43699488~43718184:-
THCA	cis	rs227275	0.586	rs223448	ENSG00000248971.2	KRT8P46	-5.02	7.43e-07	9.69e-05	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102728746~102730171:-
THCA	cis	rs6714710	0.603	rs12988571	ENSG00000230606.9	AC159540.1	-5.02	7.43e-07	9.69e-05	-0.26	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789232	chr2:97416165~97433527:-
THCA	cis	rs17345786	0.511	rs12639028	ENSG00000244119.1	PDCL3P4	5.02	7.43e-07	9.69e-05	0.21	0.23	Colonoscopy-negative controls vs population controls;	chr3:101627189	chr3:101712472~101713191:+
THCA	cis	rs6772849	0.896	rs4557179	ENSG00000242551.2	POU5F1P6	-5.02	7.44e-07	9.69e-05	-0.29	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128647883	chr3:128674735~128677005:-
THCA	cis	rs2243480	1	rs160655	ENSG00000164669.11	INTS4P1	5.02	7.44e-07	9.69e-05	0.43	0.23	Diabetic kidney disease;	chr7:66068227	chr7:65141225~65234216:+
THCA	cis	rs1876905	0.539	rs241003	ENSG00000230177.1	RP5-1112D6.4	5.02	7.44e-07	9.7e-05	0.25	0.23	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111277932~111278742:+
THCA	cis	rs1876905	0.539	rs190246	ENSG00000230177.1	RP5-1112D6.4	5.02	7.44e-07	9.7e-05	0.25	0.23	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111277932~111278742:+
THCA	cis	rs2070488	0.775	rs1073506	ENSG00000229589.1	ACVR2B-AS1	-5.02	7.44e-07	9.7e-05	-0.2	-0.23	Electrocardiographic conduction measures;	chr3:38524744	chr3:38451027~38454820:-
THCA	cis	rs6547741	0.935	rs56001553	ENSG00000234072.1	AC074117.10	-5.02	7.45e-07	9.7e-05	-0.17	-0.23	Oral cavity cancer;	chr2:27637059	chr2:27356246~27367622:+
THCA	cis	rs2735413	0.563	rs2072663	ENSG00000276007.1	RP11-358L22.3	5.02	7.45e-07	9.71e-05	0.25	0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78030836	chr16:78123243~78124332:+
THCA	cis	rs9923856	0.519	rs2867168	ENSG00000274038.1	RP11-66H6.4	-5.02	7.45e-07	9.71e-05	-0.27	-0.23	Atopic dermatitis;Adult asthma;	chr16:11029932	chr16:11056556~11057034:+
THCA	cis	rs17404153	0.599	rs6794333	ENSG00000248724.5	NPHP3-AS1	5.02	7.45e-07	9.71e-05	0.33	0.23	LDL cholesterol;HDL cholesterol;	chr3:132441813	chr3:132721750~132874223:+
THCA	cis	rs972578	0.791	rs5751380	ENSG00000274717.1	RP1-47A17.1	-5.02	7.46e-07	9.72e-05	-0.23	-0.23	Mean platelet volume;	chr22:42831861	chr22:42791814~42794313:-
THCA	cis	rs972578	0.715	rs5758969	ENSG00000274717.1	RP1-47A17.1	-5.02	7.46e-07	9.72e-05	-0.23	-0.23	Mean platelet volume;	chr22:42832963	chr22:42791814~42794313:-
THCA	cis	rs6686842	0.56	rs61781833	ENSG00000235358.1	RP11-399E6.1	-5.02	7.46e-07	9.72e-05	-0.29	-0.23	Height;	chr1:41175418	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.56	rs74069080	ENSG00000235358.1	RP11-399E6.1	-5.02	7.46e-07	9.72e-05	-0.29	-0.23	Height;	chr1:41185358	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.56	rs11209659	ENSG00000235358.1	RP11-399E6.1	-5.02	7.46e-07	9.72e-05	-0.29	-0.23	Height;	chr1:41194607	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.56	rs6672914	ENSG00000235358.1	RP11-399E6.1	-5.02	7.46e-07	9.72e-05	-0.29	-0.23	Height;	chr1:41201257	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.56	rs60351276	ENSG00000235358.1	RP11-399E6.1	-5.02	7.46e-07	9.72e-05	-0.29	-0.23	Height;	chr1:41202879	chr1:41242373~41284861:+
THCA	cis	rs972578	0.74	rs5758972	ENSG00000274717.1	RP1-47A17.1	-5.02	7.47e-07	9.73e-05	-0.23	-0.23	Mean platelet volume;	chr22:42836967	chr22:42791814~42794313:-
THCA	cis	rs8028182	0.636	rs4243034	ENSG00000260274.1	RP11-817O13.8	5.02	7.47e-07	9.73e-05	0.16	0.23	Sudden cardiac arrest;	chr15:75458628	chr15:75368155~75369584:+
THCA	cis	rs9733	0.519	rs1336900	ENSG00000231073.1	RP11-316M1.3	5.02	7.47e-07	9.73e-05	0.27	0.23	Tonsillectomy;	chr1:150706557	chr1:150973123~150975534:+
THCA	cis	rs7208859	0.614	rs73265646	ENSG00000280069.1	CTD-2349P21.3	-5.02	7.47e-07	9.73e-05	-0.36	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30738182~30740275:+
THCA	cis	rs919433	0.963	rs10199410	ENSG00000231621.1	AC013264.2	5.02	7.47e-07	9.73e-05	0.22	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197291052	chr2:197197991~197199273:+
THCA	cis	rs2281603	0.951	rs60908674	ENSG00000259116.1	RP11-973N13.4	-5.02	7.47e-07	9.73e-05	-0.22	-0.23	Lymphocyte counts;	chr14:64514181	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.904	rs59440409	ENSG00000259116.1	RP11-973N13.4	-5.02	7.47e-07	9.73e-05	-0.22	-0.23	Lymphocyte counts;	chr14:64514249	chr14:64514154~64540368:-
THCA	cis	rs763121	0.853	rs7289577	ENSG00000235209.1	CTA-150C2.13	5.02	7.47e-07	9.74e-05	0.29	0.23	Menopause (age at onset);	chr22:38646209	chr22:38921227~38924708:+
THCA	cis	rs2067615	0.524	rs4964187	ENSG00000260329.1	RP11-412D9.4	-5.02	7.48e-07	9.74e-05	-0.21	-0.23	Heart rate;	chr12:106686535	chr12:106954029~106955497:-
THCA	cis	rs2439831	1	rs689826	ENSG00000166763.7	STRCP1	5.02	7.48e-07	9.74e-05	0.3	0.23	Lung cancer in ever smokers;	chr15:43457718	chr15:43699488~43718184:-
THCA	cis	rs911119	0.908	rs8121147	ENSG00000270001.1	RP11-218C14.8	-5.02	7.48e-07	9.74e-05	-0.34	-0.23	Chronic kidney disease;	chr20:23621071	chr20:23631826~23632316:-
THCA	cis	rs911119	0.908	rs8114619	ENSG00000270001.1	RP11-218C14.8	-5.02	7.48e-07	9.74e-05	-0.34	-0.23	Chronic kidney disease;	chr20:23621176	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs6048945	ENSG00000270001.1	RP11-218C14.8	-5.02	7.48e-07	9.74e-05	-0.34	-0.23	Chronic kidney disease;	chr20:23621591	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs6048946	ENSG00000270001.1	RP11-218C14.8	-5.02	7.48e-07	9.74e-05	-0.34	-0.23	Chronic kidney disease;	chr20:23621670	chr20:23631826~23632316:-
THCA	cis	rs763121	0.853	rs6001214	ENSG00000235209.1	CTA-150C2.13	5.02	7.48e-07	9.74e-05	0.31	0.23	Menopause (age at onset);	chr22:38753150	chr22:38921227~38924708:+
THCA	cis	rs6545883	0.86	rs6545847	ENSG00000270820.4	RP11-355B11.2	-5.02	7.48e-07	9.75e-05	-0.19	-0.23	Tuberculosis;	chr2:61218198	chr2:61471188~61484130:+
THCA	cis	rs11153306	0.677	rs3777921	ENSG00000230177.1	RP5-1112D6.4	5.02	7.48e-07	9.75e-05	0.18	0.23	Tonsillectomy;	chr6:111603207	chr6:111277932~111278742:+
THCA	cis	rs4803480	0.507	rs10420992	ENSG00000267107.5	PCAT19	5.02	7.48e-07	9.75e-05	0.23	0.23	Schizophrenia;	chr19:41558092	chr19:41454169~41500649:-
THCA	cis	rs7621331	1	rs9848322	ENSG00000273486.1	RP11-731C17.2	5.02	7.49e-07	9.75e-05	0.22	0.23	Waist circumference adjusted for body mass index;	chr3:135988314	chr3:136837338~136839021:-
THCA	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-5.02	7.49e-07	9.75e-05	-0.32	-0.23	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
THCA	cis	rs34779708	0.931	rs11010067	ENSG00000271335.4	RP11-324I22.4	-5.02	7.49e-07	9.75e-05	-0.21	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35314552~35336401:-
THCA	cis	rs4648045	0.734	rs11722146	ENSG00000246560.2	RP11-10L12.4	5.02	7.49e-07	9.76e-05	0.29	0.23	Lymphocyte percentage of white cells;	chr4:102603472	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.734	rs12509517	ENSG00000246560.2	RP11-10L12.4	5.02	7.49e-07	9.76e-05	0.29	0.23	Lymphocyte percentage of white cells;	chr4:102604351	chr4:102828055~102844075:+
THCA	cis	rs4415084	0.834	rs13362132	ENSG00000272335.1	RP11-53O19.3	-5.02	7.49e-07	9.76e-05	-0.19	-0.23	Breast cancer;	chr5:44858158	chr5:44826076~44828592:+
THCA	cis	rs4144027	0.791	rs11160770	ENSG00000269940.1	RP11-73M18.7	5.02	7.5e-07	9.77e-05	0.22	0.23	Blood metabolite levels;	chr14:103895954	chr14:103694560~103695170:+
THCA	cis	rs896854	0.812	rs12546365	ENSG00000253528.2	RP11-347C18.4	5.02	7.5e-07	9.77e-05	0.26	0.23	Type 2 diabetes;	chr8:94899249	chr8:94974573~94974853:-
THCA	cis	rs12935418	0.672	rs2602423	ENSG00000278985.1	RP11-303E16.9	-5.02	7.51e-07	9.78e-05	-0.25	-0.23	Mean corpuscular volume;	chr16:81008423	chr16:80982319~80984094:-
THCA	cis	rs11722779	0.692	rs223414	ENSG00000248971.2	KRT8P46	-5.02	7.51e-07	9.78e-05	-0.28	-0.23	Schizophrenia;	chr4:102811688	chr4:102728746~102730171:-
THCA	cis	rs28386778	0.799	rs2955234	ENSG00000240280.5	TCAM1P	5.02	7.51e-07	9.78e-05	0.31	0.23	Prudent dietary pattern;	chr17:63906241	chr17:63849292~63864379:+
THCA	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	5.02	7.51e-07	9.78e-05	0.25	0.23	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
THCA	cis	rs11992162	0.967	rs7836456	ENSG00000227888.4	FAM66A	5.02	7.51e-07	9.78e-05	0.29	0.23	Monocyte count;	chr8:11971666	chr8:12362019~12388296:+
THCA	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	5.02	7.52e-07	9.79e-05	0.36	0.23	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
THCA	cis	rs4767841	1	rs4766947	ENSG00000248636.5	RP11-768F21.1	-5.02	7.53e-07	9.8e-05	-0.24	-0.23	Urgency urinary incontinence;	chr12:119723596	chr12:119387987~119668079:-
THCA	cis	rs11992162	0.636	rs4841645	ENSG00000206014.6	OR7E161P	5.02	7.53e-07	9.8e-05	0.27	0.23	Monocyte count;	chr8:11941175	chr8:11928597~11929563:-
THCA	cis	rs2664588	0.741	rs4810744	ENSG00000276923.1	RP11-321P16.1	-5.02	7.53e-07	9.8e-05	-0.3	-0.23	Cerebrospinal fluid AB1-42 levels;	chr20:47991053	chr20:48073869~48074188:+
THCA	cis	rs79243044	1	rs12294369	ENSG00000224295.2	AC087380.14	5.02	7.53e-07	9.8e-05	0.23	0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5545838	chr11:5518441~5524955:-
THCA	cis	rs2243480	1	rs1723269	ENSG00000164669.11	INTS4P1	5.02	7.53e-07	9.8e-05	0.44	0.23	Diabetic kidney disease;	chr7:66007799	chr7:65141225~65234216:+
THCA	cis	rs228614	0.51	rs223412	ENSG00000248971.2	KRT8P46	-5.01	7.53e-07	9.81e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102728746~102730171:-
THCA	cis	rs1823913	0.599	rs17511445	ENSG00000280083.1	RP11-317J9.1	5.01	7.54e-07	9.81e-05	0.26	0.23	Obesity-related traits;	chr2:191279831	chr2:191154118~191156070:-
THCA	cis	rs2239547	0.603	rs2276825	ENSG00000242142.1	SERBP1P3	5.01	7.54e-07	9.81e-05	0.28	0.23	Schizophrenia;	chr3:52852589	chr3:53064283~53065091:-
THCA	cis	rs9388451	0.626	rs1268074	ENSG00000226409.1	RP11-735G4.1	-5.01	7.54e-07	9.81e-05	-0.27	-0.23	Brugada syndrome;	chr6:125786645	chr6:125370211~125374324:-
THCA	cis	rs2361701	1	rs2361701	ENSG00000275479.1	RP11-334C17.6	5.01	7.54e-07	9.81e-05	0.24	0.23	IgG glycosylation;	chr17:80092818	chr17:80149627~80149798:+
THCA	cis	rs9388451	0.537	rs1739383	ENSG00000226409.1	RP11-735G4.1	-5.01	7.54e-07	9.81e-05	-0.27	-0.23	Brugada syndrome;	chr6:125777769	chr6:125370211~125374324:-
THCA	cis	rs17767392	0.813	rs36052007	ENSG00000259146.3	RP1-261D10.2	5.01	7.54e-07	9.81e-05	0.28	0.23	Mitral valve prolapse;	chr14:71517988	chr14:71292729~71321814:-
THCA	cis	rs116095464	0.867	rs7726582	ENSG00000248925.1	CTD-2083E4.6	5.01	7.54e-07	9.81e-05	0.32	0.23	Breast cancer;	chr5:215234	chr5:269858~271516:-
THCA	cis	rs911119	1	rs911119	ENSG00000270001.1	RP11-218C14.8	5.01	7.54e-07	9.81e-05	0.34	0.23	Chronic kidney disease;	chr20:23632100	chr20:23631826~23632316:-
THCA	cis	rs10129255	0.912	rs61996059	ENSG00000223648.3	IGHV3-64	5.01	7.54e-07	9.82e-05	0.14	0.23	Kawasaki disease;	chr14:106716897	chr14:106643132~106658258:-
THCA	cis	rs7208859	0.673	rs75142521	ENSG00000280069.1	CTD-2349P21.3	-5.01	7.54e-07	9.82e-05	-0.36	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30738182~30740275:+
THCA	cis	rs4535700	0.501	rs10245725	ENSG00000226278.1	PSPHP1	-5.01	7.54e-07	9.82e-05	-0.26	-0.23	Macular telangiectasia type 2;	chr7:55908855	chr7:55764797~55773288:+
THCA	cis	rs13113518	0.841	rs11133400	ENSG00000273257.1	RP11-177J6.1	5.01	7.54e-07	9.82e-05	0.3	0.23	Height;	chr4:55578787	chr4:55387949~55388271:+
THCA	cis	rs12935418	0.672	rs11150334	ENSG00000278985.1	RP11-303E16.9	5.01	7.55e-07	9.82e-05	0.25	0.23	Mean corpuscular volume;	chr16:81008937	chr16:80982319~80984094:-
THCA	cis	rs34779708	0.931	rs7084196	ENSG00000271335.4	RP11-324I22.4	5.01	7.55e-07	9.82e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35314552~35336401:-
THCA	cis	rs12935418	0.672	rs11866803	ENSG00000278985.1	RP11-303E16.9	5.01	7.55e-07	9.83e-05	0.24	0.23	Mean corpuscular volume;	chr16:81017598	chr16:80982319~80984094:-
THCA	cis	rs2252521	0.524	rs719675	ENSG00000272568.4	CTB-113D17.1	5.01	7.55e-07	9.83e-05	0.25	0.23	Cognitive performance;	chr7:29002315	chr7:28979967~29013367:+
THCA	cis	rs2439831	0.681	rs478104	ENSG00000205771.5	CATSPER2P1	-5.01	7.55e-07	9.83e-05	-0.29	-0.23	Lung cancer in ever smokers;	chr15:43302702	chr15:43726918~43747094:-
THCA	cis	rs34779708	0.931	rs12773169	ENSG00000271335.4	RP11-324I22.4	5.01	7.55e-07	9.83e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35314552~35336401:-
THCA	cis	rs12681288	0.676	rs6559208	ENSG00000260721.1	AF067845.1	5.01	7.55e-07	9.83e-05	0.28	0.23	Schizophrenia;	chr8:1068833	chr8:1368642~1369833:-
THCA	cis	rs793571	0.628	rs7171482	ENSG00000259250.1	RP11-50C13.1	-5.01	7.55e-07	9.83e-05	-0.23	-0.23	Schizophrenia;	chr15:58814296	chr15:58587507~58591676:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000234585.5	CCT6P3	5.01	7.56e-07	9.83e-05	0.2	0.23	Aortic root size;	chr7:66014585	chr7:65038354~65074713:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000234585.5	CCT6P3	5.01	7.56e-07	9.83e-05	0.2	0.23	Calcium levels;	chr7:66014891	chr7:65038354~65074713:+
THCA	cis	rs7772486	0.654	rs1011597	ENSG00000270638.1	RP3-466P17.1	-5.01	7.56e-07	9.84e-05	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145735570~145737218:+
THCA	cis	rs10149470	0.549	rs9652403	ENSG00000269940.1	RP11-73M18.7	5.01	7.56e-07	9.84e-05	0.23	0.23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr14:103569687	chr14:103694560~103695170:+
THCA	cis	rs3820928	0.874	rs10177995	ENSG00000212391.1	SNORA48	-5.01	7.56e-07	9.84e-05	-0.25	-0.23	Pulmonary function;	chr2:226916884	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.845	rs10165767	ENSG00000212391.1	SNORA48	-5.01	7.56e-07	9.84e-05	-0.25	-0.23	Pulmonary function;	chr2:226917147	chr2:226968989~226969122:-
THCA	cis	rs4915077	1	rs17020141	ENSG00000230489.1	VAV3-AS1	-5.01	7.56e-07	9.84e-05	-0.36	-0.23	Hypothyroidism;	chr1:107827250	chr1:107964443~107994607:+
THCA	cis	rs224278	1	rs224297	ENSG00000238280.1	RP11-436D10.3	5.01	7.56e-07	9.84e-05	0.26	0.23	Ewing sarcoma;	chr10:62830899	chr10:62793562~62805887:-
THCA	cis	rs2243480	0.901	rs3813708	ENSG00000232559.3	GS1-124K5.12	5.01	7.56e-07	9.84e-05	0.34	0.23	Diabetic kidney disease;	chr7:65840645	chr7:66554588~66576923:-
THCA	cis	rs1552244	0.554	rs59465469	ENSG00000232901.1	CYCSP10	5.01	7.56e-07	9.84e-05	0.26	0.23	Alzheimer's disease;	chr3:9949116	chr3:10000647~10000940:-
THCA	cis	rs7577696	0.962	rs4952248	ENSG00000276334.1	AL133243.1	-5.01	7.56e-07	9.84e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32118600	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.962	rs4952250	ENSG00000276334.1	AL133243.1	-5.01	7.56e-07	9.84e-05	-0.24	-0.23	Inflammatory biomarkers;	chr2:32118630	chr2:32521927~32523547:+
THCA	cis	rs13178541	0.593	rs6860305	ENSG00000250378.1	RP11-119J18.1	-5.01	7.56e-07	9.84e-05	-0.26	-0.23	IgG glycosylation;	chr5:135710654	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.593	rs5027775	ENSG00000250378.1	RP11-119J18.1	-5.01	7.56e-07	9.84e-05	-0.26	-0.23	IgG glycosylation;	chr5:135710995	chr5:135812667~135826582:+
THCA	cis	rs6565180	1	rs8049108	ENSG00000274653.1	RP11-347C12.11	5.01	7.56e-07	9.85e-05	0.2	0.23	Tonsillectomy;	chr16:30365165	chr16:30359825~30360336:+
THCA	cis	rs734999	0.87	rs2985858	ENSG00000225931.3	RP3-395M20.7	5.01	7.57e-07	9.85e-05	0.28	0.23	Ulcerative colitis;	chr1:2551859	chr1:2566410~2569888:+
THCA	cis	rs3770081	1	rs6759489	ENSG00000272564.1	RP11-548P2.2	-5.01	7.57e-07	9.85e-05	-0.38	-0.23	Facial emotion recognition (sad faces);	chr2:85948909	chr2:85904279~85904727:+
THCA	cis	rs3770081	1	rs6718632	ENSG00000272564.1	RP11-548P2.2	-5.01	7.57e-07	9.85e-05	-0.38	-0.23	Facial emotion recognition (sad faces);	chr2:85948961	chr2:85904279~85904727:+
THCA	cis	rs1707322	0.721	rs11211181	ENSG00000281133.1	AL355480.3	-5.01	7.57e-07	9.85e-05	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45580892~45580996:-
THCA	cis	rs8141529	0.732	rs5762815	ENSG00000272858.1	CTA-292E10.8	-5.01	7.57e-07	9.85e-05	-0.23	-0.23	Lymphocyte counts;	chr22:28809088	chr22:28814914~28815662:+
THCA	cis	rs2439831	0.702	rs495175	ENSG00000166763.7	STRCP1	5.01	7.57e-07	9.85e-05	0.3	0.23	Lung cancer in ever smokers;	chr15:43506486	chr15:43699488~43718184:-
THCA	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-5.01	7.57e-07	9.85e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
THCA	cis	rs526231	0.718	rs402962	ENSG00000175749.11	EIF3KP1	5.01	7.57e-07	9.86e-05	0.29	0.23	Primary biliary cholangitis;	chr5:103288307	chr5:103032376~103033031:+
THCA	cis	rs7951911	1	rs4755312	ENSG00000254427.1	RP11-430H10.1	5.01	7.58e-07	9.86e-05	0.35	0.23	IgG glycosylation;	chr11:45072063	chr11:45355371~45366121:+
THCA	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	5.01	7.58e-07	9.86e-05	0.25	0.23	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
THCA	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	5.01	7.58e-07	9.86e-05	0.25	0.23	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
THCA	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	5.01	7.58e-07	9.86e-05	0.25	0.23	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
THCA	cis	rs78487399	0.71	rs57696714	ENSG00000234936.1	AC010883.5	5.01	7.58e-07	9.87e-05	0.33	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399382	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs57381820	ENSG00000234936.1	AC010883.5	5.01	7.58e-07	9.87e-05	0.33	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399529	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs72879276	ENSG00000234936.1	AC010883.5	5.01	7.58e-07	9.87e-05	0.33	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399962	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs7607777	ENSG00000234936.1	AC010883.5	5.01	7.58e-07	9.87e-05	0.33	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43402792	chr2:43229573~43233394:+
THCA	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	5.01	7.58e-07	9.87e-05	0.19	0.23	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
THCA	cis	rs9527	0.637	rs7096169	ENSG00000213061.2	PFN1P11	5.01	7.59e-07	9.87e-05	0.28	0.23	Arsenic metabolism;	chr10:102858938	chr10:102838011~102845473:-
THCA	cis	rs10266483	0.515	rs6948710	ENSG00000271550.1	BNIP3P11	-5.01	7.59e-07	9.87e-05	-0.32	-0.23	Response to statin therapy;	chr7:64405625	chr7:64678954~64687393:-
THCA	cis	rs11673344	0.504	rs1667378	ENSG00000276846.1	CTD-3220F14.3	5.01	7.59e-07	9.87e-05	0.17	0.23	Obesity-related traits;	chr19:37001171	chr19:37314868~37315620:-
THCA	cis	rs11992162	0.933	rs10108075	ENSG00000206014.6	OR7E161P	-5.01	7.59e-07	9.88e-05	-0.26	-0.23	Monocyte count;	chr8:11974570	chr8:11928597~11929563:-
THCA	cis	rs1552244	1	rs35741213	ENSG00000180385.7	EMC3-AS1	5.01	7.59e-07	9.88e-05	0.25	0.23	Alzheimer's disease;	chr3:10045977	chr3:9986893~10006990:+
THCA	cis	rs13178541	0.748	rs4360035	ENSG00000250378.1	RP11-119J18.1	-5.01	7.59e-07	9.88e-05	-0.29	-0.23	IgG glycosylation;	chr5:135760843	chr5:135812667~135826582:+
THCA	cis	rs7088591	0.614	rs77495276	ENSG00000276818.1	AC026393.1	5.01	7.59e-07	9.88e-05	0.37	0.23	Blood pressure;	chr10:58001195	chr10:57095699~57095781:+
THCA	cis	rs763121	0.853	rs5757196	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38643850	chr22:38667585~38681820:-
THCA	cis	rs763121	0.785	rs5757199	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38644612	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs9610993	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38646813	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757200	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38647486	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757203	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38648147	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2205802	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38650322	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757204	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38650695	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs8138996	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38651430	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs6001182	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38651438	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757208	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38653225	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757211	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38655700	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs6001184	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38656111	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs6001185	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38656150	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2294296	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38657044	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2064088	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38657377	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757213	ENSG00000228274.3	RP3-508I15.9	-5.01	7.6e-07	9.88e-05	-0.24	-0.23	Menopause (age at onset);	chr22:38657883	chr22:38667585~38681820:-
THCA	cis	rs1865760	0.622	rs9968910	ENSG00000272462.2	U91328.19	-5.01	7.6e-07	9.88e-05	-0.21	-0.23	Height;	chr6:26071867	chr6:25992662~26001775:+
THCA	cis	rs12554020	0.786	rs12551314	ENSG00000227603.1	RP11-165J3.6	5.01	7.6e-07	9.88e-05	0.34	0.23	Schizophrenia;	chr9:93617515	chr9:93435332~93437121:-
THCA	cis	rs6044112	0.56	rs6075083	ENSG00000273998.1	RP4-777L9.2	5.01	7.6e-07	9.89e-05	0.38	0.23	Response to taxane treatment (docetaxel);	chr20:16605097	chr20:16576068~16579615:+
THCA	cis	rs7849973	0.7	rs7865016	ENSG00000224549.1	RP11-370B11.3	-5.01	7.6e-07	9.89e-05	-0.26	-0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22819408	chr9:22767175~22768316:+
THCA	cis	rs11795343	0.503	rs4013911	ENSG00000232303.2	DFFBP1	-5.01	7.6e-07	9.89e-05	-0.29	-0.23	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32496039	chr9:32566148~32567126:-
THCA	cis	rs11795343	0.503	rs6476364	ENSG00000232303.2	DFFBP1	-5.01	7.6e-07	9.89e-05	-0.29	-0.23	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32496409	chr9:32566148~32567126:-
THCA	cis	rs28476539	0.567	rs6824723	ENSG00000270480.1	RP11-57B24.1	5.01	7.6e-07	9.89e-05	0.36	0.23	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82641160	chr4:82691737~82692468:+
THCA	cis	rs10266483	0.654	rs6962076	ENSG00000234338.1	RP11-797H7.1	-5.01	7.61e-07	9.89e-05	-0.18	-0.23	Response to statin therapy;	chr7:64559214	chr7:64835280~64836882:-
THCA	cis	rs11673344	0.542	rs826331	ENSG00000276846.1	CTD-3220F14.3	5.01	7.61e-07	9.89e-05	0.17	0.23	Obesity-related traits;	chr19:37007360	chr19:37314868~37315620:-
THCA	cis	rs4660456	0.913	rs34212676	ENSG00000272145.1	NFYC-AS1	5.01	7.61e-07	9.89e-05	0.16	0.23	Platelet count;	chr1:40766522	chr1:40690380~40692066:-
THCA	cis	rs7119	0.679	rs12914932	ENSG00000259362.2	RP11-307C19.1	-5.01	7.61e-07	9.9e-05	-0.33	-0.23	Type 2 diabetes;	chr15:77546709	chr15:77525540~77534110:+
THCA	cis	rs919433	0.68	rs12621129	ENSG00000231621.1	AC013264.2	5.01	7.61e-07	9.9e-05	0.24	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197400626	chr2:197197991~197199273:+
THCA	cis	rs875971	0.52	rs160645	ENSG00000228409.4	CCT6P1	5.01	7.61e-07	9.9e-05	0.2	0.23	Aortic root size;	chr7:66091320	chr7:65751142~65763354:+
THCA	cis	rs2243480	0.901	rs2900904	ENSG00000232559.3	GS1-124K5.12	5.01	7.62e-07	9.9e-05	0.33	0.23	Diabetic kidney disease;	chr7:65739282	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6460260	ENSG00000232559.3	GS1-124K5.12	-5.01	7.62e-07	9.9e-05	-0.33	-0.23	Diabetic kidney disease;	chr7:65750468	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6460261	ENSG00000232559.3	GS1-124K5.12	-5.01	7.62e-07	9.9e-05	-0.33	-0.23	Diabetic kidney disease;	chr7:65750593	chr7:66554588~66576923:-
THCA	cis	rs6490294	0.571	rs73421065	ENSG00000226469.1	ADAM1B	5.01	7.62e-07	9.91e-05	0.34	0.23	Mean platelet volume;	chr12:112121575	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs58047810	ENSG00000226469.1	ADAM1B	5.01	7.62e-07	9.91e-05	0.34	0.23	Mean platelet volume;	chr12:112124682	chr12:111927018~111929017:+
THCA	cis	rs9388451	0.587	rs1739385	ENSG00000226409.1	RP11-735G4.1	-5.01	7.62e-07	9.91e-05	-0.27	-0.23	Brugada syndrome;	chr6:125778793	chr6:125370211~125374324:-
THCA	cis	rs10129255	0.913	rs28861466	ENSG00000223648.3	IGHV3-64	5.01	7.62e-07	9.91e-05	0.14	0.23	Kawasaki disease;	chr14:106718572	chr14:106643132~106658258:-
THCA	cis	rs16976116	0.53	rs28441971	ENSG00000279145.1	RP11-547D13.1	5.01	7.62e-07	9.91e-05	0.25	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55127114	chr15:55171972~55178175:-
THCA	cis	rs9990333	0.526	rs11719682	ENSG00000273009.1	RP11-352G9.1	-5.01	7.62e-07	9.91e-05	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196107331	chr3:195913078~195913683:-
THCA	cis	rs6954895	0.954	rs6972576	ENSG00000271122.1	RP11-379H18.1	5.01	7.63e-07	9.92e-05	0.16	0.23	Anger;	chr7:35546418	chr7:35695214~35699413:+
THCA	cis	rs6973609	0.513	rs6954737	ENSG00000271122.1	RP11-379H18.1	5.01	7.63e-07	9.92e-05	0.16	0.23	Obesity-related traits;	chr7:35546457	chr7:35695214~35699413:+
THCA	cis	rs7942368	0.793	rs12273016	ENSG00000261578.1	RP11-21L23.2	-5.01	7.63e-07	9.92e-05	-0.32	-0.23	Endometriosis;	chr11:76779672	chr11:76800364~76804555:+
THCA	cis	rs6545883	0.894	rs12615783	ENSG00000270820.4	RP11-355B11.2	-5.01	7.63e-07	9.92e-05	-0.19	-0.23	Tuberculosis;	chr2:61213812	chr2:61471188~61484130:+
THCA	cis	rs7429990	0.901	rs7374482	ENSG00000228638.1	FCF1P2	5.01	7.63e-07	9.92e-05	0.22	0.23	Educational attainment (years of education);	chr3:48126900	chr3:48290793~48291375:-
THCA	cis	rs8028182	0.636	rs4886703	ENSG00000260274.1	RP11-817O13.8	5.01	7.63e-07	9.92e-05	0.16	0.23	Sudden cardiac arrest;	chr15:75438025	chr15:75368155~75369584:+
THCA	cis	rs34779708	0.966	rs12260130	ENSG00000271335.4	RP11-324I22.4	5.01	7.63e-07	9.92e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35314552~35336401:-
THCA	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-5.01	7.63e-07	9.92e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-5.01	7.63e-07	9.92e-05	-0.27	-0.23	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
THCA	cis	rs897984	0.568	rs4889651	ENSG00000260911.2	RP11-196G11.2	5.01	7.63e-07	9.92e-05	0.2	0.23	Dementia with Lewy bodies;	chr16:30884224	chr16:31043150~31049868:+
THCA	cis	rs17767392	0.67	rs61991192	ENSG00000259146.3	RP1-261D10.2	5.01	7.64e-07	9.93e-05	0.28	0.23	Mitral valve prolapse;	chr14:71276206	chr14:71292729~71321814:-
THCA	cis	rs13256369	0.95	rs1522839	ENSG00000253893.2	FAM85B	-5.01	7.64e-07	9.93e-05	-0.3	-0.23	Obesity-related traits;	chr8:8722943	chr8:8167819~8226614:-
THCA	cis	rs6479901	0.639	rs10995450	ENSG00000232075.1	MRPL35P2	5.01	7.64e-07	9.94e-05	0.34	0.23	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63634317~63634827:-
THCA	cis	rs228614	0.51	rs223410	ENSG00000248971.2	KRT8P46	-5.01	7.64e-07	9.94e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223400	ENSG00000248971.2	KRT8P46	-5.01	7.64e-07	9.94e-05	-0.28	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102728746~102730171:-
THCA	cis	rs7621025	0.542	rs71336078	ENSG00000273486.1	RP11-731C17.2	-5.01	7.65e-07	9.94e-05	-0.29	-0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136770760	chr3:136837338~136839021:-
THCA	cis	rs8027521	0.738	rs1478177	ENSG00000280362.1	RP11-643A5.3	5.01	7.65e-07	9.95e-05	0.28	0.23	Circulating chemerin levels;	chr15:53959605	chr15:53910769~53914712:+
THCA	cis	rs763121	0.819	rs5757161	ENSG00000235209.1	CTA-150C2.13	5.01	7.65e-07	9.95e-05	0.28	0.23	Menopause (age at onset);	chr22:38594657	chr22:38921227~38924708:+
THCA	cis	rs7731390	0.614	rs75539158	ENSG00000233006.5	AC034220.3	5.01	7.66e-07	9.95e-05	0.3	0.23	IgG glycosylation;	chr5:132312899	chr5:132311285~132369916:-
THCA	cis	rs8049040	0.967	rs7203200	ENSG00000260886.1	TAT-AS1	5.01	7.66e-07	9.96e-05	0.3	0.23	Blood protein levels;	chr16:71431710	chr16:71565789~71578187:+
THCA	cis	rs4908768	0.539	rs11121204	ENSG00000232912.4	RP5-1115A15.1	-5.01	7.66e-07	9.96e-05	-0.23	-0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8424645~8434838:+
THCA	cis	rs16975963	0.644	rs78644049	ENSG00000226686.6	LINC01535	-5.01	7.66e-07	9.96e-05	-0.31	-0.23	Longevity;	chr19:37622141	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.644	rs75499934	ENSG00000226686.6	LINC01535	-5.01	7.66e-07	9.96e-05	-0.31	-0.23	Longevity;	chr19:37622142	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.604	rs17305326	ENSG00000226686.6	LINC01535	-5.01	7.66e-07	9.96e-05	-0.31	-0.23	Longevity;	chr19:37628646	chr19:37251912~37265535:+
THCA	cis	rs763121	0.853	rs138713	ENSG00000235209.1	CTA-150C2.13	5.01	7.66e-07	9.96e-05	0.31	0.23	Menopause (age at onset);	chr22:38746610	chr22:38921227~38924708:+
THCA	cis	rs755249	0.565	rs9729677	ENSG00000228060.1	RP11-69E11.8	5.01	7.66e-07	9.96e-05	0.21	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39565160~39573203:+
THCA	cis	rs12291225	0.546	rs11023199	ENSG00000251991.1	RNU7-49P	5.01	7.66e-07	9.96e-05	0.26	0.23	Sense of smell;	chr11:14372712	chr11:14478892~14478953:+
THCA	cis	rs8064024	0.901	rs930855	ENSG00000267077.1	RP11-127I20.5	5.01	7.67e-07	9.96e-05	0.25	0.23	Cancer;	chr16:4814178	chr16:4795265~4796532:-
THCA	cis	rs7577696	0.962	rs11681731	ENSG00000276334.1	AL133243.1	-5.01	7.67e-07	9.97e-05	-0.23	-0.23	Inflammatory biomarkers;	chr2:32120256	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.962	rs212739	ENSG00000276334.1	AL133243.1	5.01	7.67e-07	9.97e-05	0.23	0.23	Inflammatory biomarkers;	chr2:32179634	chr2:32521927~32523547:+
THCA	cis	rs4713118	0.869	rs2056925	ENSG00000226314.6	ZNF192P1	-5.01	7.68e-07	9.98e-05	-0.28	-0.23	Parkinson's disease;	chr6:27723126	chr6:28161781~28169594:+
THCA	cis	rs12893668	0.703	rs729438	ENSG00000269940.1	RP11-73M18.7	-5.01	7.68e-07	9.98e-05	-0.24	-0.23	Reticulocyte count;	chr14:103626452	chr14:103694560~103695170:+
THCA	cis	rs12760731	0.582	rs34016755	ENSG00000213057.5	C1orf220	5.01	7.68e-07	9.98e-05	0.26	0.23	Obesity-related traits;	chr1:178547870	chr1:178542752~178548889:+
THCA	cis	rs6951245	0.81	rs117800627	ENSG00000229043.2	AC091729.9	-5.01	7.68e-07	9.98e-05	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1041439	chr7:1160374~1165267:+
THCA	cis	rs34779708	0.931	rs7079205	ENSG00000271335.4	RP11-324I22.4	5.01	7.68e-07	9.99e-05	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35314552~35336401:-
THCA	cis	rs2288884	0.708	rs61574510	ENSG00000260160.1	CTC-471J1.2	-5.01	7.68e-07	9.99e-05	-0.23	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017354	chr19:52058490~52063703:-
THCA	cis	rs919433	0.75	rs788010	ENSG00000231621.1	AC013264.2	-5.01	7.68e-07	9.99e-05	-0.24	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366225	chr2:197197991~197199273:+
THCA	cis	rs9309473	0.5	rs4852953	ENSG00000163016.8	ALMS1P	-5.01	7.68e-07	9.99e-05	-0.29	-0.23	Metabolite levels;	chr2:73642781	chr2:73644919~73685576:+
THCA	cis	rs1552244	1	rs55822690	ENSG00000180385.7	EMC3-AS1	5.01	7.69e-07	9.99e-05	0.25	0.23	Alzheimer's disease;	chr3:10086319	chr3:9986893~10006990:+
THCA	cis	rs11733284	0.962	rs4694879	ENSG00000259959.1	RP11-121C2.2	5.01	7.69e-07	9.99e-05	0.19	0.23	Gout;Renal underexcretion gout;	chr4:48030339	chr4:47840122~47844339:-
THCA	cis	rs748404	0.706	rs57728767	ENSG00000249839.1	AC011330.5	-5.01	7.69e-07	9.99e-05	-0.34	-0.23	Lung cancer;	chr15:43473639	chr15:43663654~43684339:-
THCA	cis	rs11992162	0.967	rs11250185	ENSG00000254948.1	OR7E158P	-5.01	7.69e-07	9.99e-05	-0.28	-0.23	Monocyte count;	chr8:11975614	chr8:11919900~11920809:-
THCA	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	5.01	7.69e-07	9.99e-05	0.35	0.23	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
THCA	cis	rs8020095	0.528	rs6573724	ENSG00000258561.1	RP11-72M17.1	-5.01	7.7e-07	1e-04	-0.3	-0.23	Depression (quantitative trait);	chr14:66773847	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs8008773	ENSG00000258561.1	RP11-72M17.1	-5.01	7.7e-07	1e-04	-0.3	-0.23	Depression (quantitative trait);	chr14:66796445	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs9671368	ENSG00000258561.1	RP11-72M17.1	-5.01	7.7e-07	1e-04	-0.3	-0.23	Depression (quantitative trait);	chr14:66796737	chr14:66212810~66509394:-
THCA	cis	rs227275	0.554	rs223421	ENSG00000248971.2	KRT8P46	-5.01	7.7e-07	1e-04	-0.28	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102728746~102730171:-
THCA	cis	rs8396	1	rs11737481	ENSG00000271817.2	U3	-5.01	7.7e-07	1e-04	-0.24	-0.23	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700098	chr4:158700691~158700909:+
THCA	cis	rs8002861	0.875	rs12872943	ENSG00000274001.1	RP11-5G9.5	-5.01	7.7e-07	1e-04	-0.27	-0.23	Leprosy;	chr13:43836417	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.905	rs12429722	ENSG00000274001.1	RP11-5G9.5	-5.01	7.7e-07	1e-04	-0.27	-0.23	Leprosy;	chr13:43838330	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.905	rs12430629	ENSG00000274001.1	RP11-5G9.5	-5.01	7.7e-07	1e-04	-0.27	-0.23	Leprosy;	chr13:43841783	chr13:43877715~43878163:-
THCA	cis	rs7617773	0.78	rs71323396	ENSG00000199476.1	Y_RNA	-5.01	7.71e-07	1e-04	-0.29	-0.23	Coronary artery disease;	chr3:48333244	chr3:48288587~48288694:+
THCA	cis	rs8091660	0.624	rs1028010	ENSG00000278983.1	RP11-426J5.3	5.01	7.72e-07	1e-04	0.33	0.23	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48559459	chr18:48564795~48568342:+
THCA	cis	rs6565180	0.507	rs4471699	ENSG00000273724.1	RP11-347C12.12	-5.01	7.72e-07	1e-04	-0.24	-0.23	Tonsillectomy;	chr16:30308986	chr16:30336400~30343336:+
THCA	cis	rs7637701	0.967	rs9837038	ENSG00000240875.4	LINC00886	5.01	7.72e-07	1e-04	0.18	0.23	Breast cancer;	chr3:156850680	chr3:156747346~156817062:-
THCA	cis	rs62184315	0.536	rs62185897	ENSG00000253559.1	OSGEPL1-AS1	-5.01	7.72e-07	1e-04	-0.33	-0.23	Alcohol dependence (age at onset);	chr2:189721279	chr2:189762704~189765556:+
THCA	cis	rs6951245	1	rs76214082	ENSG00000229043.2	AC091729.9	-5.01	7.72e-07	1e-04	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs74887741	ENSG00000229043.2	AC091729.9	-5.01	7.72e-07	1e-04	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs79617366	ENSG00000229043.2	AC091729.9	-5.01	7.72e-07	1e-04	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs111899361	ENSG00000229043.2	AC091729.9	-5.01	7.72e-07	1e-04	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1160374~1165267:+
THCA	cis	rs858239	0.568	rs6970694	ENSG00000226816.2	AC005082.12	5.01	7.72e-07	1e-04	0.33	0.23	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23206013~23208045:+
THCA	cis	rs17767392	0.958	rs12879243	ENSG00000259146.3	RP1-261D10.2	5.01	7.72e-07	1e-04	0.29	0.23	Mitral valve prolapse;	chr14:71439098	chr14:71292729~71321814:-
THCA	cis	rs9601248	0.756	rs2146592	ENSG00000227354.5	RBM26-AS1	-5.01	7.72e-07	1e-04	-0.22	-0.23	Major depressive disorder;	chr13:79606146	chr13:79406309~79424328:+
THCA	cis	rs890448	0.93	rs2433312	ENSG00000254531.1	FLJ20021	-5.01	7.73e-07	1e-04	-0.2	-0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101464975	chr4:101347780~101348883:+
THCA	cis	rs3213758	1	rs75953755	ENSG00000275191.1	RP11-36I17.2	-5.01	7.73e-07	1e-04	-0.46	-0.23	Vitiligo (non-segmental);	chr16:53550817	chr16:53628256~53628816:-
THCA	cis	rs453301	0.598	rs10104303	ENSG00000254153.1	CTA-398F10.2	-5.01	7.73e-07	1e-04	-0.24	-0.23	Joint mobility (Beighton score);	chr8:8977018	chr8:8456909~8461337:-
THCA	cis	rs8177876	0.749	rs10459872	ENSG00000261838.4	RP11-303E16.6	-5.01	7.73e-07	1e-04	-0.4	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81069854~81076598:+
THCA	cis	rs763121	0.853	rs5750671	ENSG00000235209.1	CTA-150C2.13	5.01	7.73e-07	1e-04	0.3	0.23	Menopause (age at onset);	chr22:38698614	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs926299	ENSG00000235209.1	CTA-150C2.13	5.01	7.73e-07	1e-04	0.3	0.23	Menopause (age at onset);	chr22:38699693	chr22:38921227~38924708:+
THCA	cis	rs763121	0.785	rs6001203	ENSG00000235209.1	CTA-150C2.13	5.01	7.73e-07	1e-04	0.3	0.23	Menopause (age at onset);	chr22:38703597	chr22:38921227~38924708:+
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000164669.11	INTS4P1	5.01	7.73e-07	1e-04	0.44	0.23	Diabetic kidney disease;	chr7:65966800	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs906134	ENSG00000164669.11	INTS4P1	5.01	7.73e-07	1e-04	0.44	0.23	Diabetic kidney disease;	chr7:65979301	chr7:65141225~65234216:+
THCA	cis	rs17767392	0.881	rs17767686	ENSG00000259146.3	RP1-261D10.2	5.01	7.74e-07	1e-04	0.28	0.23	Mitral valve prolapse;	chr14:71540027	chr14:71292729~71321814:-
THCA	cis	rs613391	0.561	rs496615	ENSG00000224549.1	RP11-370B11.3	-5.01	7.74e-07	1e-04	-0.25	-0.23	Quantitative traits;	chr9:22718466	chr9:22767175~22768316:+
THCA	cis	rs6870983	0.749	rs6452794	ENSG00000247828.6	TMEM161B-AS1	5.01	7.74e-07	0.000101	0.2	0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88527481	chr5:88268895~88436685:+
THCA	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	5.01	7.74e-07	0.000101	0.22	0.23	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
THCA	cis	rs4908760	0.827	rs6692693	ENSG00000232912.4	RP5-1115A15.1	5.01	7.74e-07	0.000101	0.22	0.23	Vitiligo;	chr1:8647057	chr1:8424645~8434838:+
THCA	cis	rs9843304	0.624	rs13061914	ENSG00000244503.1	RP11-278L15.6	5.01	7.74e-07	0.000101	0.27	0.23	Gallstone disease;	chr3:149484345	chr3:149494660~149495995:+
THCA	cis	rs9843304	0.529	rs61382471	ENSG00000244503.1	RP11-278L15.6	5.01	7.74e-07	0.000101	0.27	0.23	Gallstone disease;	chr3:149484373	chr3:149494660~149495995:+
THCA	cis	rs28735056	0.935	rs552957	ENSG00000261126.6	RP11-795F19.1	-5.01	7.74e-07	0.000101	-0.19	-0.23	Schizophrenia;	chr18:79835748	chr18:80046900~80095482:+
THCA	cis	rs748404	0.666	rs34515241	ENSG00000205771.5	CATSPER2P1	-5.01	7.74e-07	0.000101	-0.29	-0.23	Lung cancer;	chr15:43342011	chr15:43726918~43747094:-
THCA	cis	rs763121	0.853	rs5757253	ENSG00000235209.1	CTA-150C2.13	5.01	7.75e-07	0.000101	0.3	0.23	Menopause (age at onset);	chr22:38708315	chr22:38921227~38924708:+
THCA	cis	rs72945132	0.882	rs67822447	ENSG00000254604.1	AP000487.6	-5.01	7.75e-07	0.000101	-0.42	-0.23	Coronary artery disease;	chr11:70384866	chr11:70282367~70363368:-
THCA	cis	rs35847492	1	rs17730481	ENSG00000254153.1	CTA-398F10.2	5.01	7.75e-07	0.000101	0.27	0.23	Neuroticism;	chr8:9418653	chr8:8456909~8461337:-
THCA	cis	rs9494145	0.838	rs9483788	ENSG00000232876.1	CTA-212D2.2	-5.01	7.75e-07	0.000101	-0.33	-0.23	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135114363	chr6:135055033~135060550:+
THCA	cis	rs950169	0.58	rs4603535	ENSG00000188388.10	GOLGA6L3	5.01	7.76e-07	0.000101	0.3	0.23	Schizophrenia;	chr15:84630641	chr15:85240472~85247170:+
THCA	cis	rs12030196	0.827	rs12025175	ENSG00000230812.4	LINC01358	5.01	7.76e-07	0.000101	0.28	0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58967225	chr1:59020387~59044614:+
THCA	cis	rs8141529	0.748	rs5997412	ENSG00000272858.1	CTA-292E10.8	-5.01	7.76e-07	0.000101	-0.23	-0.23	Lymphocyte counts;	chr22:28880759	chr22:28814914~28815662:+
THCA	cis	rs7809615	0.901	rs1581492	ENSG00000244219.5	GS1-259H13.2	-5.01	7.76e-07	0.000101	-0.4	-0.23	Blood metabolite ratios;	chr7:99589203	chr7:99598066~99610813:+
THCA	cis	rs7772486	0.686	rs857883	ENSG00000270638.1	RP3-466P17.1	-5.01	7.76e-07	0.000101	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs857882	ENSG00000270638.1	RP3-466P17.1	-5.01	7.76e-07	0.000101	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.686	rs857877	ENSG00000270638.1	RP3-466P17.1	-5.01	7.76e-07	0.000101	-0.18	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145735570~145737218:+
THCA	cis	rs34779708	0.897	rs4934527	ENSG00000271335.4	RP11-324I22.4	5.01	7.77e-07	0.000101	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35314552~35336401:-
THCA	cis	rs3820928	0.9	rs6754155	ENSG00000212391.1	SNORA48	-5.01	7.77e-07	0.000101	-0.25	-0.23	Pulmonary function;	chr2:226920245	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs12614648	ENSG00000212391.1	SNORA48	-5.01	7.77e-07	0.000101	-0.25	-0.23	Pulmonary function;	chr2:226920819	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs1114562	ENSG00000212391.1	SNORA48	-5.01	7.77e-07	0.000101	-0.25	-0.23	Pulmonary function;	chr2:226923876	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.845	rs13384342	ENSG00000212391.1	SNORA48	-5.01	7.77e-07	0.000101	-0.25	-0.23	Pulmonary function;	chr2:226940294	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs4675128	ENSG00000212391.1	SNORA48	-5.01	7.77e-07	0.000101	-0.25	-0.23	Pulmonary function;	chr2:226950041	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.904	rs4414671	ENSG00000212391.1	SNORA48	-5.01	7.77e-07	0.000101	-0.25	-0.23	Pulmonary function;	chr2:226951484	chr2:226968989~226969122:-
THCA	cis	rs7394190	0.748	rs11000728	ENSG00000271848.1	RP11-464F9.21	-5.01	7.77e-07	0.000101	-0.3	-0.23	Incident atrial fibrillation;	chr10:73644542	chr10:73654039~73674719:+
THCA	cis	rs7429990	0.864	rs4274776	ENSG00000228638.1	FCF1P2	-5.01	7.78e-07	0.000101	-0.22	-0.23	Educational attainment (years of education);	chr3:47605868	chr3:48290793~48291375:-
THCA	cis	rs2797160	0.651	rs1268066	ENSG00000226409.1	RP11-735G4.1	5.01	7.78e-07	0.000101	0.28	0.23	Endometrial cancer;	chr6:125713895	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.651	rs1343121	ENSG00000226409.1	RP11-735G4.1	5.01	7.78e-07	0.000101	0.28	0.23	Endometrial cancer;	chr6:125715038	chr6:125370211~125374324:-
THCA	cis	rs1395	1	rs2014252	ENSG00000234072.1	AC074117.10	-5.01	7.78e-07	0.000101	-0.18	-0.23	Blood metabolite levels;	chr2:27239537	chr2:27356246~27367622:+
THCA	cis	rs2562456	0.793	rs73537884	ENSG00000268119.4	CTD-2561J22.5	5.01	7.79e-07	0.000101	0.32	0.23	Pain;	chr19:21321908	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs78467454	ENSG00000268119.4	CTD-2561J22.5	5.01	7.79e-07	0.000101	0.32	0.23	Pain;	chr19:21321930	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs55790393	ENSG00000268119.4	CTD-2561J22.5	5.01	7.79e-07	0.000101	0.32	0.23	Pain;	chr19:21323382	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs11672341	ENSG00000268119.4	CTD-2561J22.5	5.01	7.79e-07	0.000101	0.32	0.23	Pain;	chr19:21324502	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.754	rs11673234	ENSG00000268119.4	CTD-2561J22.5	5.01	7.79e-07	0.000101	0.32	0.23	Pain;	chr19:21324800	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.754	rs11673320	ENSG00000268119.4	CTD-2561J22.5	5.01	7.79e-07	0.000101	0.32	0.23	Pain;	chr19:21324801	chr19:21444241~21463908:-
THCA	cis	rs16975963	0.644	rs111694872	ENSG00000226686.6	LINC01535	-5.01	7.79e-07	0.000101	-0.3	-0.23	Longevity;	chr19:37555429	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.644	rs12162238	ENSG00000226686.6	LINC01535	-5.01	7.79e-07	0.000101	-0.3	-0.23	Longevity;	chr19:37591484	chr19:37251912~37265535:+
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000230295.1	RP11-458F8.2	-5.01	7.79e-07	0.000101	-0.28	-0.23	Diabetic kidney disease;	chr7:66500146	chr7:66880708~66882981:+
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000230295.1	RP11-458F8.2	-5.01	7.79e-07	0.000101	-0.28	-0.23	Diabetic kidney disease;	chr7:66500834	chr7:66880708~66882981:+
THCA	cis	rs34779708	0.931	rs13377158	ENSG00000271335.4	RP11-324I22.4	-5.01	7.79e-07	0.000101	-0.21	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35314552~35336401:-
THCA	cis	rs7989336	0.625	rs1925108	ENSG00000247400.3	DNAJC3-AS1	5.01	7.79e-07	0.000101	0.15	0.23	Obesity;	chr13:96354744	chr13:95648733~95676925:-
THCA	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-5.01	7.8e-07	0.000101	-0.23	-0.23	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
THCA	cis	rs62025270	0.547	rs338540	ENSG00000202081.1	RNU6-1280P	5.01	7.8e-07	0.000101	0.31	0.23	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85651522~85651628:-
THCA	cis	rs2243480	1	rs781150	ENSG00000232559.3	GS1-124K5.12	5.01	7.8e-07	0.000101	0.33	0.23	Diabetic kidney disease;	chr7:66015986	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs313798	ENSG00000232559.3	GS1-124K5.12	5.01	7.8e-07	0.000101	0.33	0.23	Diabetic kidney disease;	chr7:66028044	chr7:66554588~66576923:-
THCA	cis	rs1823874	0.677	rs4381582	ENSG00000259363.4	CTD-2054N24.2	5.01	7.8e-07	0.000101	0.28	0.23	IgG glycosylation;	chr15:99820308	chr15:99807023~99877148:+
THCA	cis	rs728616	0.558	rs61859793	ENSG00000225484.5	NUTM2B-AS1	-5.01	7.8e-07	0.000101	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927007	chr10:79663088~79826594:-
THCA	cis	rs7617773	0.817	rs936426	ENSG00000199476.1	Y_RNA	-5.01	7.8e-07	0.000101	-0.29	-0.23	Coronary artery disease;	chr3:48173763	chr3:48288587~48288694:+
THCA	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-5.01	7.8e-07	0.000101	-0.14	-0.23	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
THCA	cis	rs755249	0.517	rs56809193	ENSG00000228060.1	RP11-69E11.8	-5.01	7.81e-07	0.000101	-0.26	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39143626	chr1:39565160~39573203:+
THCA	cis	rs34779708	0.931	rs12240347	ENSG00000271335.4	RP11-324I22.4	5.01	7.82e-07	0.000102	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs12248333	ENSG00000271335.4	RP11-324I22.4	5.01	7.82e-07	0.000102	0.21	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35314552~35336401:-
THCA	cis	rs2115630	0.691	rs61322921	ENSG00000259728.4	LINC00933	-5.01	7.83e-07	0.000102	-0.27	-0.23	P wave terminal force;	chr15:84620407	chr15:84570649~84580175:+
THCA	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	5.01	7.83e-07	0.000102	0.19	0.23	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
THCA	cis	rs7618915	0.547	rs2878726	ENSG00000243224.1	RP5-1157M23.2	-5.01	7.83e-07	0.000102	-0.25	-0.23	Bipolar disorder;	chr3:52714255	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs10780035	ENSG00000243224.1	RP5-1157M23.2	-5.01	7.83e-07	0.000102	-0.25	-0.23	Bipolar disorder;	chr3:52730608	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs2268027	ENSG00000243224.1	RP5-1157M23.2	-5.01	7.83e-07	0.000102	-0.25	-0.23	Bipolar disorder;	chr3:52732590	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs2286800	ENSG00000243224.1	RP5-1157M23.2	-5.01	7.83e-07	0.000102	-0.25	-0.23	Bipolar disorder;	chr3:52744035	chr3:52239258~52241097:+
THCA	cis	rs1862618	1	rs1862618	ENSG00000271828.1	CTD-2310F14.1	5.01	7.83e-07	0.000102	0.32	0.23	Initial pursuit acceleration;	chr5:56800488	chr5:56927874~56929573:+
THCA	cis	rs972578	0.818	rs5759012	ENSG00000274717.1	RP1-47A17.1	-5.01	7.83e-07	0.000102	-0.23	-0.23	Mean platelet volume;	chr22:42890870	chr22:42791814~42794313:-
THCA	cis	rs12893668	0.572	rs34000399	ENSG00000269958.1	RP11-73M18.8	5.01	7.83e-07	0.000102	0.22	0.23	Reticulocyte count;	chr14:103635080	chr14:103696353~103697163:+
THCA	cis	rs62292953	0.79	rs4854559	ENSG00000248724.5	NPHP3-AS1	5.01	7.83e-07	0.000102	0.41	0.23	Red cell distribution width;	chr3:132531974	chr3:132721750~132874223:+
THCA	cis	rs7429990	0.901	rs6442091	ENSG00000228638.1	FCF1P2	5.01	7.83e-07	0.000102	0.22	0.23	Educational attainment (years of education);	chr3:48001568	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs4858810	ENSG00000228638.1	FCF1P2	5.01	7.83e-07	0.000102	0.22	0.23	Educational attainment (years of education);	chr3:48002247	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs4296617	ENSG00000228638.1	FCF1P2	5.01	7.83e-07	0.000102	0.22	0.23	Educational attainment (years of education);	chr3:48026818	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs7642590	ENSG00000228638.1	FCF1P2	5.01	7.83e-07	0.000102	0.22	0.23	Educational attainment (years of education);	chr3:48058260	chr3:48290793~48291375:-
THCA	cis	rs8046148	0.641	rs1547478	ENSG00000279356.1	RP11-429P3.8	5.01	7.83e-07	0.000102	0.26	0.23	Testicular germ cell tumor;	chr16:50067104	chr16:50072862~50074986:+
THCA	cis	rs17366136	1	rs17366136	ENSG00000232759.1	AC002480.3	-5.01	7.83e-07	0.000102	-0.3	-0.23	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr7:22561508	chr7:22563337~22573996:+
THCA	cis	rs9425766	0.679	rs6656188	ENSG00000227373.4	RP11-160H22.5	5.01	7.83e-07	0.000102	0.32	0.23	Life satisfaction;	chr1:174183550	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs12087441	ENSG00000227373.4	RP11-160H22.5	5.01	7.83e-07	0.000102	0.32	0.23	Life satisfaction;	chr1:174188696	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs4652237	ENSG00000227373.4	RP11-160H22.5	5.01	7.83e-07	0.000102	0.32	0.23	Life satisfaction;	chr1:174189718	chr1:174115300~174160004:-
THCA	cis	rs12188164	0.686	rs56279338	ENSG00000225138.6	CTD-2228K2.7	5.01	7.83e-07	0.000102	0.24	0.23	Cystic fibrosis severity;	chr5:416003	chr5:473236~480884:+
THCA	cis	rs12188164	0.686	rs72711365	ENSG00000225138.6	CTD-2228K2.7	5.01	7.83e-07	0.000102	0.24	0.23	Cystic fibrosis severity;	chr5:416557	chr5:473236~480884:+
THCA	cis	rs55704346	0.715	rs3822221	ENSG00000281501.1	SEPSECS-AS1	5.01	7.83e-07	0.000102	0.25	0.23	Tonsillectomy;	chr4:25130195	chr4:25160641~25201440:+
THCA	cis	rs853679	0.599	rs149943	ENSG00000226314.6	ZNF192P1	-5.01	7.84e-07	0.000102	-0.35	-0.23	Depression;	chr6:28034610	chr6:28161781~28169594:+
THCA	cis	rs3011225	0.691	rs3791102	ENSG00000237950.1	RP11-7O11.3	5.01	7.84e-07	0.000102	0.2	0.23	Amyotrophic lateral sclerosis (age of onset);	chr1:43900945	chr1:43944370~43946551:-
THCA	cis	rs13083990	0.747	rs6438720	ENSG00000272758.4	RP11-299J3.8	-5.01	7.84e-07	0.000102	-0.21	-0.23	Cardiac Troponin-T levels;	chr3:122298385	chr3:122416207~122443180:+
THCA	cis	rs654950	1	rs654950	ENSG00000230638.4	RP11-486B10.4	5.01	7.84e-07	0.000102	0.26	0.23	Airway imaging phenotypes;	chr1:41522197	chr1:41542069~41544310:+
THCA	cis	rs6671200	0.831	rs11582082	ENSG00000235501.4	RP4-639F20.1	-5.01	7.84e-07	0.000102	-0.43	-0.23	Stearic acid (18:0) levels;	chr1:95129141	chr1:94927566~94963270:+
THCA	cis	rs12439619	0.883	rs62012045	ENSG00000255769.6	GOLGA2P10	-5.01	7.84e-07	0.000102	-0.29	-0.23	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472993~82513950:-
THCA	cis	rs875971	0.545	rs4718348	ENSG00000228409.4	CCT6P1	-5.01	7.84e-07	0.000102	-0.2	-0.23	Aortic root size;	chr7:66441589	chr7:65751142~65763354:+
THCA	cis	rs6545883	0.894	rs7566035	ENSG00000270820.4	RP11-355B11.2	-5.01	7.84e-07	0.000102	-0.19	-0.23	Tuberculosis;	chr2:61293680	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.894	rs2121661	ENSG00000270820.4	RP11-355B11.2	-5.01	7.84e-07	0.000102	-0.19	-0.23	Tuberculosis;	chr2:61334523	chr2:61471188~61484130:+
THCA	cis	rs11671005	0.779	rs3794970	ENSG00000269473.1	CTD-2619J13.19	-5.01	7.84e-07	0.000102	-0.26	-0.23	Mean platelet volume;	chr19:58474893	chr19:58440448~58445849:+
THCA	cis	rs9393777	0.92	rs34953377	ENSG00000280107.1	AL022393.9	-5.01	7.84e-07	0.000102	-0.4	-0.23	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28170845~28172521:+
THCA	cis	rs9425766	0.679	rs2143114	ENSG00000227373.4	RP11-160H22.5	5.01	7.85e-07	0.000102	0.32	0.23	Life satisfaction;	chr1:174192292	chr1:174115300~174160004:-
THCA	cis	rs13126694	0.933	rs6830475	ENSG00000248429.4	RP11-597D13.9	5.01	7.85e-07	0.000102	0.24	0.23	Blood osmolality (transformed sodium);	chr4:158155527	chr4:158170752~158202877:+
THCA	cis	rs7394190	0.748	rs11000771	ENSG00000271816.1	BMS1P4	-5.01	7.85e-07	0.000102	-0.28	-0.23	Incident atrial fibrillation;	chr10:73764700	chr10:73699151~73730487:-
THCA	cis	rs5758659	0.714	rs133376	ENSG00000182057.4	OGFRP1	5.01	7.85e-07	0.000102	0.25	0.23	Cognitive function;	chr22:42070901	chr22:42269753~42275196:+
THCA	cis	rs2067615	0.579	rs4964489	ENSG00000260329.1	RP11-412D9.4	-5.01	7.85e-07	0.000102	-0.2	-0.23	Heart rate;	chr12:106778030	chr12:106954029~106955497:-
THCA	cis	rs17767392	0.747	rs61989240	ENSG00000259146.3	RP1-261D10.2	5.01	7.85e-07	0.000102	0.3	0.23	Mitral valve prolapse;	chr14:71241893	chr14:71292729~71321814:-
THCA	cis	rs9876781	1	rs9876781	ENSG00000244380.1	RP11-24C3.2	5.01	7.85e-07	0.000102	0.27	0.23	Longevity;	chr3:48445934	chr3:48440352~48446656:-
THCA	cis	rs911119	0.657	rs13039144	ENSG00000270001.1	RP11-218C14.8	-5.01	7.85e-07	0.000102	-0.36	-0.23	Chronic kidney disease;	chr20:23653118	chr20:23631826~23632316:-
THCA	cis	rs763121	0.853	rs5750649	ENSG00000228274.3	RP3-508I15.9	-5.01	7.85e-07	0.000102	-0.24	-0.23	Menopause (age at onset);	chr22:38640764	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs6519124	ENSG00000228274.3	RP3-508I15.9	-5.01	7.85e-07	0.000102	-0.24	-0.23	Menopause (age at onset);	chr22:38649094	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5750652	ENSG00000228274.3	RP3-508I15.9	-5.01	7.85e-07	0.000102	-0.24	-0.23	Menopause (age at onset);	chr22:38652311	chr22:38667585~38681820:-
THCA	cis	rs763121	0.814	rs5757212	ENSG00000228274.3	RP3-508I15.9	-5.01	7.85e-07	0.000102	-0.24	-0.23	Menopause (age at onset);	chr22:38657752	chr22:38667585~38681820:-
THCA	cis	rs6674176	1	rs11210937	ENSG00000237950.1	RP11-7O11.3	5.01	7.85e-07	0.000102	0.22	0.23	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43939891	chr1:43944370~43946551:-
THCA	cis	rs1823913	0.599	rs13027086	ENSG00000280083.1	RP11-317J9.1	-5.01	7.86e-07	0.000102	-0.26	-0.23	Obesity-related traits;	chr2:191294058	chr2:191154118~191156070:-
THCA	cis	rs202072	0.872	rs375661	ENSG00000272379.1	RP1-257A7.5	5.01	7.86e-07	0.000102	0.33	0.23	HIV-1 viral setpoint;	chr6:13279199	chr6:13290018~13290490:-
THCA	cis	rs2235642	0.75	rs2755185	ENSG00000280231.1	LA16c-380F5.3	-5.01	7.86e-07	0.000102	-0.27	-0.23	Coronary artery disease;	chr16:1595826	chr16:1553655~1554130:-
THCA	cis	rs72843506	0.722	rs74255392	ENSG00000261033.1	RP11-209D14.2	5.01	7.86e-07	0.000102	0.4	0.23	Schizophrenia;	chr17:20425739	chr17:20008051~20009234:-
THCA	cis	rs2281603	0.951	rs73267743	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64511424	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs73267744	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64511461	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs61985707	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64512846	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs12586212	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64513329	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs61615397	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64514346	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs10133243	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64514807	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs12589947	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64515453	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs3783724	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64516759	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs3783723	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64516821	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs12587136	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64518570	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs58893738	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64519093	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs28626711	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64521561	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs10133411	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64522206	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs17101896	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64526205	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs59512674	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64526295	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs61985711	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64526540	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs10142835	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64526733	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs10143170	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64527045	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs10138256	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64528494	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs10149286	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64528518	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs1453009	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64528976	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs11158544	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64529769	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs12588886	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64530226	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.951	rs1453004	ENSG00000259116.1	RP11-973N13.4	-5.01	7.86e-07	0.000102	-0.22	-0.23	Lymphocyte counts;	chr14:64530237	chr14:64514154~64540368:-
THCA	cis	rs227275	0.554	rs223357	ENSG00000248971.2	KRT8P46	-5.01	7.86e-07	0.000102	-0.27	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102728746~102730171:-
THCA	cis	rs853679	0.546	rs200981	ENSG00000280107.1	AL022393.9	-5.01	7.86e-07	0.000102	-0.34	-0.23	Depression;	chr6:27865396	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs200953	ENSG00000280107.1	AL022393.9	-5.01	7.86e-07	0.000102	-0.34	-0.23	Depression;	chr6:27869489	chr6:28170845~28172521:+
THCA	cis	rs7614311	0.731	rs73130534	ENSG00000271843.1	RP11-245J9.5	-5.01	7.86e-07	0.000102	-0.4	-0.23	Lung function (FVC);Lung function (FEV1);	chr3:63874137	chr3:64008082~64008692:-
THCA	cis	rs9987353	0.589	rs1053036	ENSG00000248538.5	RP11-10A14.5	5.01	7.86e-07	0.000102	0.29	0.22	Recombination measurement;	chr8:9202567	chr8:9189011~9202854:+
THCA	cis	rs2439831	1	rs2439841	ENSG00000166763.7	STRCP1	5.01	7.86e-07	0.000102	0.3	0.22	Lung cancer in ever smokers;	chr15:43442551	chr15:43699488~43718184:-
THCA	cis	rs3820928	0.874	rs10199655	ENSG00000212391.1	SNORA48	-5.01	7.86e-07	0.000102	-0.25	-0.22	Pulmonary function;	chr2:227027712	chr2:226968989~226969122:-
THCA	cis	rs13178541	0.748	rs4976308	ENSG00000250378.1	RP11-119J18.1	-5.01	7.87e-07	0.000102	-0.29	-0.22	IgG glycosylation;	chr5:135729915	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.748	rs13158124	ENSG00000250378.1	RP11-119J18.1	-5.01	7.87e-07	0.000102	-0.29	-0.22	IgG glycosylation;	chr5:135730290	chr5:135812667~135826582:+
THCA	cis	rs3764400	0.506	rs2036521	ENSG00000278765.1	RP5-890E16.5	5.01	7.87e-07	0.000102	0.43	0.22	Body mass index;	chr17:48251614	chr17:48066704~48067293:-
THCA	cis	rs7181230	0.848	rs1010879	ENSG00000275636.1	RP11-521C20.5	5.01	7.87e-07	0.000102	0.25	0.22	Dehydroepiandrosterone sulphate levels;	chr15:40041714	chr15:40078892~40079347:+
THCA	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-5.01	7.87e-07	0.000102	-0.26	-0.22	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
THCA	cis	rs12428035	0.881	rs17879875	ENSG00000247400.3	DNAJC3-AS1	-5.01	7.87e-07	0.000102	-0.22	-0.22	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95710979	chr13:95648733~95676925:-
THCA	cis	rs1005277	0.505	rs200936	ENSG00000276805.1	RP11-291L22.6	5.01	7.87e-07	0.000102	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.505	rs200937	ENSG00000276805.1	RP11-291L22.6	5.01	7.87e-07	0.000102	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38451030~38451785:+
THCA	cis	rs4646450	0.891	rs1011024	ENSG00000244219.5	GS1-259H13.2	-5.01	7.87e-07	0.000102	-0.28	-0.22	Blood metabolite levels;	chr7:99599778	chr7:99598066~99610813:+
THCA	cis	rs853679	1	rs9986596	ENSG00000272009.1	RP1-313I6.12	-5.01	7.88e-07	0.000102	-0.31	-0.22	Depression;	chr6:28251883	chr6:28078792~28081130:-
THCA	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	5.01	7.88e-07	0.000102	0.26	0.22	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
THCA	cis	rs71636778	0.584	rs17162316	ENSG00000260063.1	RP5-968P14.2	-5.01	7.88e-07	0.000102	-0.31	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26851416	chr1:26692132~26694131:-
THCA	cis	rs2562456	0.833	rs7260065	ENSG00000268119.4	CTD-2561J22.5	5.01	7.88e-07	0.000102	0.32	0.22	Pain;	chr19:21334175	chr19:21444241~21463908:-
THCA	cis	rs763121	0.925	rs4821815	ENSG00000235209.1	CTA-150C2.13	5.01	7.88e-07	0.000102	0.29	0.22	Menopause (age at onset);	chr22:38709702	chr22:38921227~38924708:+
THCA	cis	rs763121	0.819	rs6001205	ENSG00000228274.3	RP3-508I15.9	-5.01	7.88e-07	0.000102	-0.25	-0.22	Menopause (age at onset);	chr22:38704259	chr22:38667585~38681820:-
THCA	cis	rs6714710	0.58	rs13032265	ENSG00000230606.9	AC159540.1	-5.01	7.89e-07	0.000102	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97793102	chr2:97416165~97433527:-
THCA	cis	rs1714507	0.515	rs2731112	ENSG00000272087.1	RP11-379F4.7	5.01	7.89e-07	0.000102	0.2	0.22	Subjective well-being;	chr3:158572439	chr3:158693120~158693768:-
THCA	cis	rs1714507	0.533	rs2731122	ENSG00000272087.1	RP11-379F4.7	5.01	7.89e-07	0.000102	0.2	0.22	Subjective well-being;	chr3:158577491	chr3:158693120~158693768:-
THCA	cis	rs1714507	0.533	rs2731120	ENSG00000272087.1	RP11-379F4.7	-5.01	7.89e-07	0.000102	-0.2	-0.22	Subjective well-being;	chr3:158579844	chr3:158693120~158693768:-
THCA	cis	rs7429990	0.93	rs71323371	ENSG00000228638.1	FCF1P2	-5.01	7.89e-07	0.000102	-0.23	-0.22	Educational attainment (years of education);	chr3:47904327	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.932	rs34025851	ENSG00000228638.1	FCF1P2	-5.01	7.89e-07	0.000102	-0.23	-0.22	Educational attainment (years of education);	chr3:47912243	chr3:48290793~48291375:-
THCA	cis	rs2179367	0.632	rs9498344	ENSG00000223701.3	RAET1E-AS1	5.01	7.89e-07	0.000102	0.32	0.22	Dupuytren's disease;	chr6:149401053	chr6:149884431~149919508:+
THCA	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-5.01	7.89e-07	0.000102	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
THCA	cis	rs4748857	0.685	rs60845874	ENSG00000224215.1	RP11-371A19.2	-5.01	7.89e-07	0.000102	-0.3	-0.22	Systemic lupus erythematosus;	chr10:23317270	chr10:23343957~23345181:+
THCA	cis	rs7088591	0.541	rs11815948	ENSG00000276818.1	AC026393.1	5.01	7.89e-07	0.000102	0.37	0.22	Blood pressure;	chr10:58000652	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.614	rs11812322	ENSG00000276818.1	AC026393.1	5.01	7.89e-07	0.000102	0.37	0.22	Blood pressure;	chr10:58000667	chr10:57095699~57095781:+
THCA	cis	rs9300255	0.596	rs10734900	ENSG00000256092.2	RP13-942N8.1	5.01	7.89e-07	0.000102	0.17	0.22	Neutrophil percentage of white cells;	chr12:123258898	chr12:123363868~123366113:+
THCA	cis	rs9300255	0.596	rs10734901	ENSG00000256092.2	RP13-942N8.1	5.01	7.89e-07	0.000102	0.17	0.22	Neutrophil percentage of white cells;	chr12:123258900	chr12:123363868~123366113:+
THCA	cis	rs9300255	0.596	rs10732573	ENSG00000256092.2	RP13-942N8.1	5.01	7.89e-07	0.000102	0.17	0.22	Neutrophil percentage of white cells;	chr12:123259336	chr12:123363868~123366113:+
THCA	cis	rs860295	0.702	rs10796945	ENSG00000160766.13	GBAP1	-5.01	7.9e-07	0.000102	-0.26	-0.22	Body mass index;	chr1:155457897	chr1:155213821~155227422:-
THCA	cis	rs12887734	0.566	rs8548	ENSG00000269910.1	RP11-73M18.10	5.01	7.9e-07	0.000102	0.21	0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694516~103695050:-
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000280069.1	CTD-2349P21.3	-5.01	7.9e-07	0.000102	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30738182~30740275:+
THCA	cis	rs2070488	0.804	rs13092164	ENSG00000229589.1	ACVR2B-AS1	5.01	7.9e-07	0.000102	0.2	0.22	Electrocardiographic conduction measures;	chr3:38417042	chr3:38451027~38454820:-
THCA	cis	rs2281603	0.694	rs12385910	ENSG00000259116.1	RP11-973N13.4	-5.01	7.9e-07	0.000102	-0.22	-0.22	Lymphocyte counts;	chr14:64533252	chr14:64514154~64540368:-
THCA	cis	rs9816784	0.566	rs11720913	ENSG00000273009.1	RP11-352G9.1	-5.01	7.9e-07	0.000102	-0.26	-0.22	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195913078~195913683:-
THCA	cis	rs7976269	0.583	rs4931131	ENSG00000275476.1	RP11-996F15.4	-5.01	7.91e-07	0.000103	-0.23	-0.22	Male-pattern baldness;	chr12:29015898	chr12:29277397~29277882:-
THCA	cis	rs8028182	0.549	rs11072542	ENSG00000260269.4	CTD-2323K18.1	5.01	7.91e-07	0.000103	0.33	0.22	Sudden cardiac arrest;	chr15:75342258	chr15:75527150~75601205:-
THCA	cis	rs8062405	0.964	rs7187333	ENSG00000278665.1	RP11-666O2.4	5.01	7.91e-07	0.000103	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28599241~28601881:-
THCA	cis	rs8062405	1	rs12446589	ENSG00000278665.1	RP11-666O2.4	5.01	7.91e-07	0.000103	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28599241~28601881:-
THCA	cis	rs3734266	0.702	rs16892384	ENSG00000272288.4	RP11-140K17.3	-5.01	7.91e-07	0.000103	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34651226	chr6:34696317~34697470:+
THCA	cis	rs12435908	1	rs10083421	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65384440	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs17826466	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65385452	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs10083485	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65386396	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs10083343	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65386415	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs10083346	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65386555	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs10083348	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65386683	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs12433416	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65387457	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs73282223	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65387837	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs10136947	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65387893	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs10136953	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65387958	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs8017202	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65388240	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs73282230	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65389297	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs73282232	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65389359	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs80068722	ENSG00000276116.2	FUT8-AS1	-5.01	7.91e-07	0.000103	-0.35	-0.22	Ischemic stroke;	chr14:65389393	chr14:65411170~65412690:-
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000273712.1	RP5-874C20.7	5.01	7.91e-07	0.000103	0.25	0.22	Pubertal anthropometrics;	chr6:28294921	chr6:28315613~28315883:-
THCA	cis	rs853679	0.882	rs9461432	ENSG00000220721.1	OR1F12	5	7.91e-07	0.000103	0.38	0.22	Depression;	chr6:28119105	chr6:28073316~28074233:+
THCA	cis	rs28510890	0.52	rs10852175	ENSG00000260337.3	RP11-386M24.6	5	7.91e-07	0.000103	0.26	0.22	Lung cancer in ever smokers;	chr15:92562212	chr15:92592574~92596462:-
THCA	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-5	7.92e-07	0.000103	-0.26	-0.22	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
THCA	cis	rs453301	0.624	rs6987558	ENSG00000254153.1	CTA-398F10.2	-5	7.92e-07	0.000103	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9005011	chr8:8456909~8461337:-
THCA	cis	rs2067615	0.579	rs10778506	ENSG00000260329.1	RP11-412D9.4	-5	7.92e-07	0.000103	-0.2	-0.22	Heart rate;	chr12:106749482	chr12:106954029~106955497:-
THCA	cis	rs35740288	0.822	rs34734963	ENSG00000259295.5	CSPG4P12	5	7.92e-07	0.000103	0.36	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85674413	chr15:85191438~85213905:+
THCA	cis	rs736408	0.677	rs1042779	ENSG00000243224.1	RP5-1157M23.2	-5	7.92e-07	0.000103	-0.24	-0.22	Bipolar disorder;	chr3:52786995	chr3:52239258~52241097:+
THCA	cis	rs6545883	0.929	rs12713436	ENSG00000270820.4	RP11-355B11.2	5	7.93e-07	0.000103	0.19	0.22	Tuberculosis;	chr2:61464125	chr2:61471188~61484130:+
THCA	cis	rs3734266	0.702	rs9469836	ENSG00000272288.4	RP11-140K17.3	5	7.94e-07	0.000103	0.22	0.22	Systemic lupus erythematosus;	chr6:34647002	chr6:34696317~34697470:+
THCA	cis	rs6951245	0.938	rs113642700	ENSG00000229043.2	AC091729.9	-5	7.94e-07	0.000103	-0.39	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1160374~1165267:+
THCA	cis	rs7085104	0.632	rs3781287	ENSG00000213061.2	PFN1P11	5	7.94e-07	0.000103	0.27	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102838011~102845473:-
THCA	cis	rs2985684	0.894	rs4900932	ENSG00000278009.1	RP11-649E7.8	5	7.94e-07	0.000103	0.31	0.22	Carotid intima media thickness;	chr14:49556210	chr14:49601011~49601124:-
THCA	cis	rs9890032	0.542	rs113934718	ENSG00000266490.1	CTD-2349P21.9	5	7.94e-07	0.000103	0.23	0.22	Hip circumference adjusted for BMI;	chr17:30887862	chr17:30792372~30792833:+
THCA	cis	rs6598266	1	rs12903750	ENSG00000259363.4	CTD-2054N24.2	-5	7.94e-07	0.000103	-0.4	-0.22	Major depressive disorder;	chr15:99760136	chr15:99807023~99877148:+
THCA	cis	rs2439831	0.867	rs6493082	ENSG00000166763.7	STRCP1	5	7.94e-07	0.000103	0.31	0.22	Lung cancer in ever smokers;	chr15:43342610	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs8041132	ENSG00000166763.7	STRCP1	5	7.94e-07	0.000103	0.31	0.22	Lung cancer in ever smokers;	chr15:43342938	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs16957627	ENSG00000166763.7	STRCP1	5	7.94e-07	0.000103	0.31	0.22	Lung cancer in ever smokers;	chr15:43350459	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.717	rs7165471	ENSG00000166763.7	STRCP1	5	7.94e-07	0.000103	0.31	0.22	Lung cancer in ever smokers;	chr15:43352590	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs4075674	ENSG00000166763.7	STRCP1	5	7.94e-07	0.000103	0.31	0.22	Lung cancer in ever smokers;	chr15:43358032	chr15:43699488~43718184:-
THCA	cis	rs7403037	0.837	rs11857739	ENSG00000260760.1	PWRN3	5	7.95e-07	0.000103	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24330727	chr15:24441127~24447967:+
THCA	cis	rs13113518	0.545	rs6810483	ENSG00000273257.1	RP11-177J6.1	5	7.95e-07	0.000103	0.3	0.22	Height;	chr4:55424406	chr4:55387949~55388271:+
THCA	cis	rs919433	0.713	rs6719483	ENSG00000231621.1	AC013264.2	-5	7.96e-07	0.000103	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197608162	chr2:197197991~197199273:+
THCA	cis	rs34779708	0.766	rs7897088	ENSG00000230534.5	RP11-297A16.2	5	7.96e-07	0.000103	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35098006~35127020:-
THCA	cis	rs2243480	1	rs4718334	ENSG00000230295.1	RP11-458F8.2	5	7.96e-07	0.000103	0.28	0.22	Diabetic kidney disease;	chr7:66324467	chr7:66880708~66882981:+
THCA	cis	rs6894268	1	rs6894268	ENSG00000250999.1	RP11-1379J22.5	5	7.96e-07	0.000103	0.28	0.22	Eating disorders;	chr5:179605487	chr5:179657762~179664432:+
THCA	cis	rs728616	1	rs12768613	ENSG00000225484.5	NUTM2B-AS1	-5	7.96e-07	0.000103	-0.38	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156810	chr10:79663088~79826594:-
THCA	cis	rs12935418	0.55	rs35595567	ENSG00000261061.1	RP11-303E16.2	-5	7.97e-07	0.000103	-0.27	-0.22	Mean corpuscular volume;	chr16:80999761	chr16:81030770~81031485:+
THCA	cis	rs16846053	0.605	rs62188818	ENSG00000227403.1	AC009299.3	5	7.97e-07	0.000103	0.51	0.22	Blood osmolality (transformed sodium);	chr2:161899685	chr2:161244739~161249050:+
THCA	cis	rs2439831	0.867	rs7170489	ENSG00000166763.7	STRCP1	5	7.97e-07	0.000103	0.31	0.22	Lung cancer in ever smokers;	chr15:43344453	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs16957630	ENSG00000166763.7	STRCP1	5	7.97e-07	0.000103	0.31	0.22	Lung cancer in ever smokers;	chr15:43350582	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs16957632	ENSG00000166763.7	STRCP1	5	7.97e-07	0.000103	0.31	0.22	Lung cancer in ever smokers;	chr15:43350699	chr15:43699488~43718184:-
THCA	cis	rs2190422	0.577	rs6465922	ENSG00000234715.1	CTB-107G13.1	-5	7.97e-07	0.000103	-0.26	-0.22	Morning vs. evening chronotype;	chr7:103454521	chr7:103445207~103514007:+
THCA	cis	rs7829975	0.582	rs6983150	ENSG00000253981.4	ALG1L13P	-5	7.97e-07	0.000103	-0.22	-0.22	Mood instability;	chr8:8934916	chr8:8236003~8244667:-
THCA	cis	rs858239	0.6	rs6461692	ENSG00000230042.1	AK3P3	-5	7.97e-07	0.000103	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23129178~23129841:+
THCA	cis	rs1707322	1	rs785510	ENSG00000281133.1	AL355480.3	5	7.97e-07	0.000103	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45580892~45580996:-
THCA	cis	rs5015933	0.872	rs2648328	ENSG00000232630.1	PRPS1P2	-5	7.97e-07	0.000103	-0.16	-0.22	Body mass index;	chr9:125361341	chr9:125150653~125151589:+
THCA	cis	rs2243480	1	rs160652	ENSG00000232559.3	GS1-124K5.12	5	7.98e-07	0.000103	0.33	0.22	Diabetic kidney disease;	chr7:66073444	chr7:66554588~66576923:-
THCA	cis	rs55704346	0.715	rs7666342	ENSG00000281501.1	SEPSECS-AS1	5	7.98e-07	0.000103	0.25	0.22	Tonsillectomy;	chr4:25140078	chr4:25160641~25201440:+
THCA	cis	rs17767392	0.748	rs55896578	ENSG00000259146.3	RP1-261D10.2	5	7.98e-07	0.000103	0.3	0.22	Mitral valve prolapse;	chr14:71245468	chr14:71292729~71321814:-
THCA	cis	rs224278	1	rs224296	ENSG00000238280.1	RP11-436D10.3	5	7.98e-07	0.000103	0.26	0.22	Ewing sarcoma;	chr10:62830803	chr10:62793562~62805887:-
THCA	cis	rs224278	1	rs224298	ENSG00000238280.1	RP11-436D10.3	5	7.98e-07	0.000103	0.26	0.22	Ewing sarcoma;	chr10:62830957	chr10:62793562~62805887:-
THCA	cis	rs11700536	0.518	rs4920051	ENSG00000236663.1	AP001631.9	-5	7.99e-07	0.000103	-0.28	-0.22	Interleukin-18 levels;	chr21:43144605	chr21:43140523~43141092:-
THCA	cis	rs7819412	0.807	rs9657519	ENSG00000206014.6	OR7E161P	5	7.99e-07	0.000103	0.26	0.22	Triglycerides;	chr8:11087929	chr8:11928597~11929563:-
THCA	cis	rs2067615	0.579	rs7486905	ENSG00000260329.1	RP11-412D9.4	-5	7.99e-07	0.000103	-0.2	-0.22	Heart rate;	chr12:106766391	chr12:106954029~106955497:-
THCA	cis	rs13113518	0.507	rs11943456	ENSG00000273257.1	RP11-177J6.1	5	7.99e-07	0.000103	0.3	0.22	Height;	chr4:55410167	chr4:55387949~55388271:+
THCA	cis	rs1979679	0.842	rs36097532	ENSG00000247934.4	RP11-967K21.1	-5	7.99e-07	0.000104	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28228557	chr12:28163298~28190738:-
THCA	cis	rs1395	1	rs4665958	ENSG00000234072.1	AC074117.10	-5	7.99e-07	0.000104	-0.18	-0.22	Blood metabolite levels;	chr2:27220328	chr2:27356246~27367622:+
THCA	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	5	8e-07	0.000104	0.22	0.22	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
THCA	cis	rs3734266	0.702	rs205265	ENSG00000272288.4	RP11-140K17.3	-5	8e-07	0.000104	-0.23	-0.22	Systemic lupus erythematosus;	chr6:34593808	chr6:34696317~34697470:+
THCA	cis	rs7621331	1	rs9825239	ENSG00000273486.1	RP11-731C17.2	5	8e-07	0.000104	0.22	0.22	Waist circumference adjusted for body mass index;	chr3:135975929	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs7621396	ENSG00000273486.1	RP11-731C17.2	5	8e-07	0.000104	0.22	0.22	Waist circumference adjusted for body mass index;	chr3:135976176	chr3:136837338~136839021:-
THCA	cis	rs240993	0.715	rs7742724	ENSG00000271789.1	RP5-1112D6.7	5	8e-07	0.000104	0.26	0.22	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111297126~111298510:+
THCA	cis	rs987724	0.593	rs13322318	ENSG00000240875.4	LINC00886	-5	8e-07	0.000104	-0.17	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156906481	chr3:156747346~156817062:-
THCA	cis	rs7403037	0.794	rs66500833	ENSG00000260760.1	PWRN3	5	8e-07	0.000104	0.27	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24218264	chr15:24441127~24447967:+
THCA	cis	rs3796352	1	rs11718752	ENSG00000242142.1	SERBP1P3	-5	8e-07	0.000104	-0.41	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53096729	chr3:53064283~53065091:-
THCA	cis	rs17767392	0.792	rs61991249	ENSG00000259146.3	RP1-261D10.2	5	8.01e-07	0.000104	0.28	0.22	Mitral valve prolapse;	chr14:71402829	chr14:71292729~71321814:-
THCA	cis	rs5758659	0.714	rs6002626	ENSG00000182057.4	OGFRP1	-5	8.01e-07	0.000104	-0.26	-0.22	Cognitive function;	chr22:42121985	chr22:42269753~42275196:+
THCA	cis	rs16846053	0.792	rs72879222	ENSG00000227403.1	AC009299.3	5	8.01e-07	0.000104	0.52	0.22	Blood osmolality (transformed sodium);	chr2:161828728	chr2:161244739~161249050:+
THCA	cis	rs748404	0.666	rs16957715	ENSG00000205771.5	CATSPER2P1	-5	8.01e-07	0.000104	-0.28	-0.22	Lung cancer;	chr15:43416539	chr15:43726918~43747094:-
THCA	cis	rs987724	0.57	rs4680318	ENSG00000240875.4	LINC00886	-5	8.01e-07	0.000104	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156953850	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs4234315	ENSG00000240875.4	LINC00886	-5	8.01e-07	0.000104	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156955749	chr3:156747346~156817062:-
THCA	cis	rs4713118	0.629	rs203888	ENSG00000261839.1	RP1-265C24.8	5	8.01e-07	0.000104	0.25	0.22	Parkinson's disease;	chr6:28053811	chr6:28136849~28139678:+
THCA	cis	rs4073582	0.595	rs1151540	ENSG00000255320.1	RP11-755F10.1	-5	8.01e-07	0.000104	-0.28	-0.22	Gout;	chr11:66274336	chr11:66244840~66246239:-
THCA	cis	rs73242632	1	rs73242632	ENSG00000269949.1	RP11-738E22.3	5	8.02e-07	0.000104	0.52	0.22	Congenital heart disease (maternal effect);	chr4:57027604	chr4:56960927~56961373:-
THCA	cis	rs7727544	0.66	rs272886	ENSG00000263597.1	MIR3936	5	8.02e-07	0.000104	0.21	0.22	Blood metabolite levels;	chr5:132330147	chr5:132365490~132365599:-
THCA	cis	rs1707322	1	rs10890382	ENSG00000281133.1	AL355480.3	-5	8.02e-07	0.000104	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4660335	ENSG00000281133.1	AL355480.3	-5	8.02e-07	0.000104	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45580892~45580996:-
THCA	cis	rs11992162	0.613	rs6998690	ENSG00000206014.6	OR7E161P	-5	8.02e-07	0.000104	-0.27	-0.22	Monocyte count;	chr8:11941287	chr8:11928597~11929563:-
THCA	cis	rs9309473	0.519	rs4852950	ENSG00000163016.8	ALMS1P	-5	8.02e-07	0.000104	-0.29	-0.22	Metabolite levels;	chr2:73637543	chr2:73644919~73685576:+
THCA	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	5	8.03e-07	0.000104	0.28	0.22	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
THCA	cis	rs28476539	0.567	rs7679380	ENSG00000270480.1	RP11-57B24.1	5	8.03e-07	0.000104	0.36	0.22	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82642145	chr4:82691737~82692468:+
THCA	cis	rs12435908	1	rs12433423	ENSG00000276116.2	FUT8-AS1	-5	8.03e-07	0.000104	-0.35	-0.22	Ischemic stroke;	chr14:65387519	chr14:65411170~65412690:-
THCA	cis	rs4660456	0.913	rs16827569	ENSG00000272145.1	NFYC-AS1	5	8.03e-07	0.000104	0.16	0.22	Platelet count;	chr1:40761655	chr1:40690380~40692066:-
THCA	cis	rs2562456	0.834	rs13346641	ENSG00000268119.4	CTD-2561J22.5	5	8.04e-07	0.000104	0.32	0.22	Pain;	chr19:21409481	chr19:21444241~21463908:-
THCA	cis	rs6490294	0.571	rs6489830	ENSG00000226469.1	ADAM1B	5	8.04e-07	0.000104	0.34	0.22	Mean platelet volume;	chr12:112144736	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs12422864	ENSG00000226469.1	ADAM1B	5	8.04e-07	0.000104	0.34	0.22	Mean platelet volume;	chr12:112146397	chr12:111927018~111929017:+
THCA	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-5	8.04e-07	0.000104	-0.27	-0.22	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
THCA	cis	rs2243480	1	rs34193460	ENSG00000164669.11	INTS4P1	5	8.04e-07	0.000104	0.44	0.22	Diabetic kidney disease;	chr7:65928123	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs57057549	ENSG00000164669.11	INTS4P1	5	8.04e-07	0.000104	0.44	0.22	Diabetic kidney disease;	chr7:65940751	chr7:65141225~65234216:+
THCA	cis	rs72945132	0.882	rs55915603	ENSG00000254604.1	AP000487.6	-5	8.05e-07	0.000104	-0.43	-0.22	Coronary artery disease;	chr11:70363961	chr11:70282367~70363368:-
THCA	cis	rs79349575	0.783	rs55771415	ENSG00000270781.1	RP11-501C14.9	-5	8.05e-07	0.000104	-0.27	-0.22	Type 2 diabetes;	chr17:48922575	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs2088139	ENSG00000270781.1	RP11-501C14.9	-5	8.05e-07	0.000104	-0.27	-0.22	Type 2 diabetes;	chr17:48922748	chr17:48899131~48899748:+
THCA	cis	rs3820928	0.967	rs16822905	ENSG00000212391.1	SNORA48	-5	8.05e-07	0.000104	-0.26	-0.22	Pulmonary function;	chr2:226906011	chr2:226968989~226969122:-
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000280069.1	CTD-2349P21.3	-5	8.05e-07	0.000104	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000280069.1	CTD-2349P21.3	-5	8.05e-07	0.000104	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000280069.1	CTD-2349P21.3	-5	8.05e-07	0.000104	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30738182~30740275:+
THCA	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-5	8.05e-07	0.000104	-0.13	-0.22	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
THCA	cis	rs875971	0.545	rs73146609	ENSG00000228409.4	CCT6P1	-5	8.06e-07	0.000104	-0.19	-0.22	Aortic root size;	chr7:66302477	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000228409.4	CCT6P1	-5	8.06e-07	0.000104	-0.19	-0.22	Aortic root size;	chr7:66305392	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000228409.4	CCT6P1	-5	8.06e-07	0.000104	-0.19	-0.22	Aortic root size;	chr7:66318029	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000228409.4	CCT6P1	-5	8.06e-07	0.000104	-0.19	-0.22	Aortic root size;	chr7:66325577	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000228409.4	CCT6P1	-5	8.06e-07	0.000104	-0.19	-0.22	Aortic root size;	chr7:66339619	chr7:65751142~65763354:+
THCA	cis	rs7914558	0.966	rs2065977	ENSG00000236937.2	PTGES3P4	5	8.06e-07	0.000104	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs12569617	ENSG00000236937.2	PTGES3P4	5	8.06e-07	0.000104	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102970239	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.933	rs1538204	ENSG00000236937.2	PTGES3P4	5	8.06e-07	0.000104	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102845595~102845950:+
THCA	cis	rs911119	0.657	rs6114214	ENSG00000270001.1	RP11-218C14.8	-5	8.06e-07	0.000104	-0.36	-0.22	Chronic kidney disease;	chr20:23647287	chr20:23631826~23632316:-
THCA	cis	rs875971	0.789	rs28815324	ENSG00000232546.1	RP11-458F8.1	-5	8.06e-07	0.000104	-0.22	-0.22	Aortic root size;	chr7:66100789	chr7:66848496~66858136:+
THCA	cis	rs7246657	0.722	rs12974225	ENSG00000276846.1	CTD-3220F14.3	-5	8.06e-07	0.000104	-0.22	-0.22	Coronary artery calcification;	chr19:37749458	chr19:37314868~37315620:-
THCA	cis	rs7976269	0.609	rs10771470	ENSG00000275476.1	RP11-996F15.4	-5	8.06e-07	0.000104	-0.23	-0.22	Male-pattern baldness;	chr12:29050620	chr12:29277397~29277882:-
THCA	cis	rs875971	0.505	rs2462573	ENSG00000223473.2	GS1-124K5.3	-5	8.06e-07	0.000104	-0.15	-0.22	Aortic root size;	chr7:66042405	chr7:66491049~66493566:-
THCA	cis	rs4660456	0.83	rs12566786	ENSG00000272145.1	NFYC-AS1	5	8.06e-07	0.000104	0.16	0.22	Platelet count;	chr1:40742709	chr1:40690380~40692066:-
THCA	cis	rs17767392	0.958	rs722633	ENSG00000259146.3	RP1-261D10.2	5	8.07e-07	0.000104	0.29	0.22	Mitral valve prolapse;	chr14:71432071	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.918	rs17178234	ENSG00000259146.3	RP1-261D10.2	5	8.07e-07	0.000104	0.29	0.22	Mitral valve prolapse;	chr14:71433647	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs61989367	ENSG00000259146.3	RP1-261D10.2	5	8.07e-07	0.000104	0.29	0.22	Mitral valve prolapse;	chr14:71440578	chr14:71292729~71321814:-
THCA	cis	rs4663866	1	rs6741269	ENSG00000186235.9	AC016757.3	5	8.07e-07	0.000104	0.47	0.22	Irritable bowel syndrome;	chr2:238270777	chr2:238224552~238231677:-
THCA	cis	rs3177980	0.608	rs10919250	ENSG00000239494.2	RN7SL333P	-5	8.07e-07	0.000104	-0.22	-0.22	Amyotrophic lateral sclerosis;	chr1:169815422	chr1:169859756~169860052:+
THCA	cis	rs8020095	0.571	rs10136043	ENSG00000258561.1	RP11-72M17.1	-5	8.08e-07	0.000105	-0.3	-0.22	Depression (quantitative trait);	chr14:66973521	chr14:66212810~66509394:-
THCA	cis	rs3845817	0.868	rs702938	ENSG00000237979.1	AC007389.1	-5	8.08e-07	0.000105	-0.26	-0.22	Bipolar disorder;	chr2:65520308	chr2:65500993~65502138:-
THCA	cis	rs7474896	0.559	rs10740949	ENSG00000263064.2	RP11-291L22.7	5	8.08e-07	0.000105	0.3	0.22	Obesity (extreme);	chr10:37689507	chr10:38448689~38448949:+
THCA	cis	rs8020095	0.528	rs6573747	ENSG00000258561.1	RP11-72M17.1	-5	8.08e-07	0.000105	-0.3	-0.22	Depression (quantitative trait);	chr14:67051131	chr14:66212810~66509394:-
THCA	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	5	8.08e-07	0.000105	0.29	0.22	Depression;	chr6:28317705	chr6:28943877~28944537:+
THCA	cis	rs72945132	0.825	rs57871058	ENSG00000254604.1	AP000487.6	-5	8.08e-07	0.000105	-0.42	-0.22	Coronary artery disease;	chr11:70346238	chr11:70282367~70363368:-
THCA	cis	rs17767392	0.813	rs35831373	ENSG00000259146.3	RP1-261D10.2	5	8.09e-07	0.000105	0.28	0.22	Mitral valve prolapse;	chr14:71451704	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.813	rs34991781	ENSG00000259146.3	RP1-261D10.2	5	8.09e-07	0.000105	0.28	0.22	Mitral valve prolapse;	chr14:71454859	chr14:71292729~71321814:-
THCA	cis	rs1005277	0.522	rs200943	ENSG00000276805.1	RP11-291L22.6	5	8.09e-07	0.000105	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.505	rs719569	ENSG00000276805.1	RP11-291L22.6	-5	8.09e-07	0.000105	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.505	rs7099777	ENSG00000276805.1	RP11-291L22.6	-5	8.09e-07	0.000105	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38451030~38451785:+
THCA	cis	rs2562456	0.833	rs7258099	ENSG00000268119.4	CTD-2561J22.5	5	8.09e-07	0.000105	0.32	0.22	Pain;	chr19:21352941	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62109229	ENSG00000268119.4	CTD-2561J22.5	5	8.09e-07	0.000105	0.32	0.22	Pain;	chr19:21354380	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs11670815	ENSG00000268119.4	CTD-2561J22.5	5	8.09e-07	0.000105	0.32	0.22	Pain;	chr19:21356515	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs11666540	ENSG00000268119.4	CTD-2561J22.5	5	8.09e-07	0.000105	0.32	0.22	Pain;	chr19:21356550	chr19:21444241~21463908:-
THCA	cis	rs13126694	0.682	rs6536288	ENSG00000248429.4	RP11-597D13.9	-5	8.09e-07	0.000105	-0.25	-0.22	Blood osmolality (transformed sodium);	chr4:157949748	chr4:158170752~158202877:+
THCA	cis	rs11779988	0.545	rs439374	ENSG00000253671.1	RP11-806O11.1	-5	8.09e-07	0.000105	-0.29	-0.22	Breast cancer;	chr8:17929309	chr8:17808941~17820868:+
THCA	cis	rs2797160	1	rs1777226	ENSG00000237742.5	RP11-624M8.1	5	8.09e-07	0.000105	0.19	0.22	Endometrial cancer;	chr6:125696545	chr6:125578558~125749190:-
THCA	cis	rs7674212	0.54	rs2711897	ENSG00000251288.2	RP11-10L12.2	-5	8.09e-07	0.000105	-0.29	-0.22	Type 2 diabetes;	chr4:103102410	chr4:102751401~102752641:+
THCA	cis	rs875971	0.545	rs4718325	ENSG00000228409.4	CCT6P1	-5	8.09e-07	0.000105	-0.19	-0.22	Aortic root size;	chr7:66215323	chr7:65751142~65763354:+
THCA	cis	rs6441961	0.501	rs7371987	ENSG00000223552.1	RP11-24F11.2	5	8.09e-07	0.000105	0.23	0.22	Celiac disease;	chr3:46277017	chr3:46364955~46407059:-
THCA	cis	rs12893668	0.603	rs61637848	ENSG00000269958.1	RP11-73M18.8	5	8.1e-07	0.000105	0.21	0.22	Reticulocyte count;	chr14:103629694	chr14:103696353~103697163:+
THCA	cis	rs2243480	1	rs316315	ENSG00000230295.1	RP11-458F8.2	5	8.1e-07	0.000105	0.24	0.22	Diabetic kidney disease;	chr7:66126218	chr7:66880708~66882981:+
THCA	cis	rs1129187	0.755	rs2274514	ENSG00000272223.1	RP1-20C7.6	5	8.1e-07	0.000105	0.17	0.22	Alzheimer's disease in APOE e4+ carriers;	chr6:42966762	chr6:43033897~43034405:-
THCA	cis	rs651907	0.557	rs13099674	ENSG00000244119.1	PDCL3P4	5	8.1e-07	0.000105	0.2	0.22	Colorectal cancer;	chr3:101770785	chr3:101712472~101713191:+
THCA	cis	rs7924176	0.564	rs6480727	ENSG00000213731.2	RAB5CP1	-5	8.11e-07	0.000105	-0.27	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74423435~74424014:-
THCA	cis	rs4819052	0.851	rs914218	ENSG00000273796.1	LL21NC02-21A1.1	-5	8.11e-07	0.000105	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45403809~45404369:-
THCA	cis	rs2243480	1	rs67728539	ENSG00000230295.1	RP11-458F8.2	-5	8.11e-07	0.000105	-0.27	-0.22	Diabetic kidney disease;	chr7:65913137	chr7:66880708~66882981:+
THCA	cis	rs8028182	0.636	rs4462560	ENSG00000260269.4	CTD-2323K18.1	5	8.11e-07	0.000105	0.33	0.22	Sudden cardiac arrest;	chr15:75355623	chr15:75527150~75601205:-
THCA	cis	rs6598266	1	rs12903402	ENSG00000259363.4	CTD-2054N24.2	-5	8.12e-07	0.000105	-0.4	-0.22	Major depressive disorder;	chr15:99760601	chr15:99807023~99877148:+
THCA	cis	rs4660261	0.545	rs803682	ENSG00000237950.1	RP11-7O11.3	5	8.12e-07	0.000105	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43896951	chr1:43944370~43946551:-
THCA	cis	rs9425766	0.679	rs6667267	ENSG00000227373.4	RP11-160H22.5	5	8.12e-07	0.000105	0.32	0.22	Life satisfaction;	chr1:174243623	chr1:174115300~174160004:-
THCA	cis	rs354225	0.586	rs966003	ENSG00000237887.1	AC092839.1	-5	8.12e-07	0.000105	-0.25	-0.22	Schizophrenia;	chr2:54657733	chr2:54529343~54529801:+
THCA	cis	rs6472827	0.645	rs16836	ENSG00000253983.2	RP1-16A9.1	5	8.12e-07	0.000105	0.32	0.22	Uterine fibroids;	chr8:74201827	chr8:74199396~74208441:+
THCA	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	5	8.13e-07	0.000105	0.27	0.22	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
THCA	cis	rs1823913	0.599	rs1454754	ENSG00000280083.1	RP11-317J9.1	-5	8.13e-07	0.000105	-0.26	-0.22	Obesity-related traits;	chr2:191303562	chr2:191154118~191156070:-
THCA	cis	rs4693089	0.522	rs566072	ENSG00000213608.5	SLC25A14P1	-5	8.13e-07	0.000105	-0.26	-0.22	Menopause (age at onset);	chr4:83507760	chr4:83477524~83478424:+
THCA	cis	rs4693089	0.564	rs474979	ENSG00000213608.5	SLC25A14P1	-5	8.13e-07	0.000105	-0.26	-0.22	Menopause (age at onset);	chr4:83507911	chr4:83477524~83478424:+
THCA	cis	rs8028182	0.636	rs6495182	ENSG00000260274.1	RP11-817O13.8	5	8.13e-07	0.000105	0.16	0.22	Sudden cardiac arrest;	chr15:75522047	chr15:75368155~75369584:+
THCA	cis	rs6044112	0.769	rs12479533	ENSG00000273998.1	RP4-777L9.2	5	8.13e-07	0.000105	0.34	0.22	Response to taxane treatment (docetaxel);	chr20:16556970	chr20:16576068~16579615:+
THCA	cis	rs12612619	0.695	rs4665935	ENSG00000229122.1	AGBL5-IT1	-5	8.14e-07	0.000105	-0.16	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27007024	chr2:27061038~27061815:+
THCA	cis	rs748404	0.666	rs35326382	ENSG00000205771.5	CATSPER2P1	-5	8.14e-07	0.000105	-0.28	-0.22	Lung cancer;	chr15:43338686	chr15:43726918~43747094:-
THCA	cis	rs7772486	0.623	rs735535	ENSG00000270638.1	RP3-466P17.1	-5	8.14e-07	0.000105	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.566	rs735536	ENSG00000270638.1	RP3-466P17.1	-5	8.14e-07	0.000105	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145735570~145737218:+
THCA	cis	rs2067615	0.579	rs3910854	ENSG00000260329.1	RP11-412D9.4	-5	8.14e-07	0.000105	-0.2	-0.22	Heart rate;	chr12:106771891	chr12:106954029~106955497:-
THCA	cis	rs8020095	0.571	rs7157126	ENSG00000258561.1	RP11-72M17.1	-5	8.14e-07	0.000105	-0.3	-0.22	Depression (quantitative trait);	chr14:67021513	chr14:66212810~66509394:-
THCA	cis	rs78487399	0.71	rs72879290	ENSG00000234936.1	AC010883.5	5	8.15e-07	0.000105	0.33	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43406129	chr2:43229573~43233394:+
THCA	cis	rs1707322	1	rs1622208	ENSG00000281133.1	AL355480.3	5	8.15e-07	0.000105	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45580892~45580996:-
THCA	cis	rs7005380	0.733	rs10107579	ENSG00000245330.4	KB-1471A8.1	-5	8.16e-07	0.000105	-0.22	-0.22	Interstitial lung disease;	chr8:119922329	chr8:119867419~119874488:-
THCA	cis	rs8042680	0.592	rs11073960	ENSG00000214432.8	AC068831.10	-5	8.16e-07	0.000105	-0.24	-0.22	Type 2 diabetes;	chr15:90940027	chr15:91022619~91036611:+
THCA	cis	rs593531	0.571	rs35170680	ENSG00000255440.1	RP11-632K5.2	5	8.16e-07	0.000105	0.27	0.22	Neuroticism;	chr11:74374375	chr11:74409060~74416379:+
THCA	cis	rs593531	0.571	rs6592557	ENSG00000255440.1	RP11-632K5.2	5	8.16e-07	0.000105	0.27	0.22	Neuroticism;	chr11:74375597	chr11:74409060~74416379:+
THCA	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-5	8.16e-07	0.000106	-0.28	-0.22	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
THCA	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-5	8.16e-07	0.000106	-0.28	-0.22	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
THCA	cis	rs950880	0.71	rs873022	ENSG00000234389.1	AC007278.3	-5	8.16e-07	0.000106	-0.27	-0.22	Serum protein levels (sST2);	chr2:102339223	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs3771177	ENSG00000234389.1	AC007278.3	-5	8.16e-07	0.000106	-0.27	-0.22	Serum protein levels (sST2);	chr2:102339400	chr2:102438713~102440475:+
THCA	cis	rs10090774	0.71	rs10107434	ENSG00000280303.2	ERICD	-5	8.16e-07	0.000106	-0.21	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140662466	chr8:140636281~140638283:+
THCA	cis	rs858239	0.601	rs7805206	ENSG00000226816.2	AC005082.12	5	8.17e-07	0.000106	0.32	0.22	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23206013~23208045:+
THCA	cis	rs16867253	0.557	rs12618788	ENSG00000188525.3	AC010969.1	-5	8.17e-07	0.000106	-0.37	-0.22	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr2:9993156	chr2:10003158~10006030:-
THCA	cis	rs8049040	0.547	rs891131	ENSG00000260886.1	TAT-AS1	5	8.17e-07	0.000106	0.32	0.22	Blood protein levels;	chr16:71398514	chr16:71565789~71578187:+
THCA	cis	rs16846053	0.792	rs62187702	ENSG00000227403.1	AC009299.3	5	8.17e-07	0.000106	0.52	0.22	Blood osmolality (transformed sodium);	chr2:161826653	chr2:161244739~161249050:+
THCA	cis	rs2154319	0.609	rs78715416	ENSG00000235358.1	RP11-399E6.1	-5	8.17e-07	0.000106	-0.3	-0.22	Height;	chr1:41272417	chr1:41242373~41284861:+
THCA	cis	rs2154319	0.609	rs13374676	ENSG00000235358.1	RP11-399E6.1	-5	8.17e-07	0.000106	-0.3	-0.22	Height;	chr1:41275223	chr1:41242373~41284861:+
THCA	cis	rs4689592	0.513	rs2358718	ENSG00000245468.3	RP11-367J11.3	-5	8.17e-07	0.000106	-0.18	-0.22	Monocyte percentage of white cells;	chr4:7067016	chr4:7094571~7103385:-
THCA	cis	rs17767392	0.788	rs61989239	ENSG00000259146.3	RP1-261D10.2	5	8.17e-07	0.000106	0.3	0.22	Mitral valve prolapse;	chr14:71239211	chr14:71292729~71321814:-
THCA	cis	rs2985684	0.748	rs2985686	ENSG00000278009.1	RP11-649E7.8	5	8.17e-07	0.000106	0.32	0.22	Carotid intima media thickness;	chr14:49633965	chr14:49601011~49601124:-
THCA	cis	rs11853189	0.938	rs16969705	ENSG00000259562.2	RP11-762H8.2	5	8.18e-07	0.000106	0.23	0.22	Red cell distribution width;	chr15:78301020	chr15:78290527~78291221:-
THCA	cis	rs1979679	0.842	rs2127315	ENSG00000247934.4	RP11-967K21.1	-5	8.18e-07	0.000106	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28156247	chr12:28163298~28190738:-
THCA	cis	rs4713118	0.629	rs149899	ENSG00000261839.1	RP1-265C24.8	5	8.18e-07	0.000106	0.26	0.22	Parkinson's disease;	chr6:28052201	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000261839.1	RP1-265C24.8	5	8.18e-07	0.000106	0.26	0.22	Parkinson's disease;	chr6:28053036	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000261839.1	RP1-265C24.8	5	8.18e-07	0.000106	0.26	0.22	Parkinson's disease;	chr6:28053042	chr6:28136849~28139678:+
THCA	cis	rs793571	0.518	rs12906705	ENSG00000245975.2	RP11-30K9.6	5	8.18e-07	0.000106	0.25	0.22	Schizophrenia;	chr15:58662837	chr15:58768072~58770974:-
THCA	cis	rs17767392	0.958	rs4902938	ENSG00000259146.3	RP1-261D10.2	-5	8.18e-07	0.000106	-0.29	-0.22	Mitral valve prolapse;	chr14:71548061	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs8010616	ENSG00000259146.3	RP1-261D10.2	-5	8.18e-07	0.000106	-0.29	-0.22	Mitral valve prolapse;	chr14:71552391	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs12885344	ENSG00000259146.3	RP1-261D10.2	5	8.18e-07	0.000106	0.29	0.22	Mitral valve prolapse;	chr14:71536507	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs3784066	ENSG00000259146.3	RP1-261D10.2	5	8.18e-07	0.000106	0.29	0.22	Mitral valve prolapse;	chr14:71540737	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.836	rs35415083	ENSG00000259146.3	RP1-261D10.2	5	8.18e-07	0.000106	0.29	0.22	Mitral valve prolapse;	chr14:71542479	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs34169215	ENSG00000259146.3	RP1-261D10.2	5	8.18e-07	0.000106	0.29	0.22	Mitral valve prolapse;	chr14:71544431	chr14:71292729~71321814:-
THCA	cis	rs12534093	0.67	rs11773147	ENSG00000234286.1	AC006026.13	-5	8.18e-07	0.000106	-0.34	-0.22	Infant length;Height;	chr7:23549567	chr7:23680195~23680786:-
THCA	cis	rs8002861	0.905	rs12874535	ENSG00000274001.1	RP11-5G9.5	-5	8.18e-07	0.000106	-0.27	-0.22	Leprosy;	chr13:43859429	chr13:43877715~43878163:-
THCA	cis	rs3796352	1	rs34933390	ENSG00000242142.1	SERBP1P3	-5	8.18e-07	0.000106	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52972249	chr3:53064283~53065091:-
THCA	cis	rs7474896	0.583	rs12776092	ENSG00000263064.2	RP11-291L22.7	5	8.18e-07	0.000106	0.3	0.22	Obesity (extreme);	chr10:37726867	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.583	rs11011347	ENSG00000263064.2	RP11-291L22.7	5	8.18e-07	0.000106	0.3	0.22	Obesity (extreme);	chr10:37730336	chr10:38448689~38448949:+
THCA	cis	rs1150668	0.764	rs9368565	ENSG00000273712.1	RP5-874C20.7	-5	8.18e-07	0.000106	-0.25	-0.22	Pubertal anthropometrics;	chr6:28377433	chr6:28315613~28315883:-
THCA	cis	rs2360027	0.644	rs60865692	ENSG00000231365.4	RP11-418J17.1	-5	8.18e-07	0.000106	-0.23	-0.22	Tonsillectomy;	chr1:118564312	chr1:119140396~119275973:+
THCA	cis	rs800160	1	rs800157	ENSG00000199550.1	Y_RNA	5	8.18e-07	0.000106	0.34	0.22	Bacteremia;	chr11:2355372	chr11:2372638~2372750:+
THCA	cis	rs800160	0.748	rs2521242	ENSG00000199550.1	Y_RNA	5	8.18e-07	0.000106	0.34	0.22	Bacteremia;	chr11:2355410	chr11:2372638~2372750:+
THCA	cis	rs4443100	0.958	rs13057385	ENSG00000230701.2	FBXW4P1	5	8.18e-07	0.000106	0.27	0.22	Serum parathyroid hormone levels;	chr22:23038778	chr22:23262767~23265005:+
THCA	cis	rs11073619	0.773	rs28612692	ENSG00000230373.7	GOLGA6L5P	-5	8.18e-07	0.000106	-0.33	-0.22	Positive affect;	chr15:84601836	chr15:84507885~84516814:-
THCA	cis	rs9307551	0.948	rs10022663	ENSG00000250334.4	LINC00989	-5	8.19e-07	0.000106	-0.28	-0.22	Refractive error;	chr4:79568460	chr4:79492416~79576460:+
THCA	cis	rs2562456	0.833	rs11669790	ENSG00000268119.4	CTD-2561J22.5	5	8.19e-07	0.000106	0.33	0.22	Pain;	chr19:21328980	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62107534	ENSG00000268119.4	CTD-2561J22.5	5	8.19e-07	0.000106	0.33	0.22	Pain;	chr19:21329389	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs7258473	ENSG00000268119.4	CTD-2561J22.5	5	8.19e-07	0.000106	0.33	0.22	Pain;	chr19:21331795	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs2219839	ENSG00000268119.4	CTD-2561J22.5	5	8.19e-07	0.000106	0.33	0.22	Pain;	chr19:21333520	chr19:21444241~21463908:-
THCA	cis	rs4934494	0.588	rs10881683	ENSG00000240996.1	RP11-80H5.7	-5	8.19e-07	0.000106	-0.24	-0.22	Red blood cell count;	chr10:89827231	chr10:89694295~89697928:-
THCA	cis	rs2664588	0.773	rs11086234	ENSG00000276923.1	RP11-321P16.1	5	8.2e-07	0.000106	0.3	0.22	Cerebrospinal fluid AB1-42 levels;	chr20:47992187	chr20:48073869~48074188:+
THCA	cis	rs1577917	0.655	rs9444354	ENSG00000220563.1	PKMP3	5	8.2e-07	0.000106	0.16	0.22	Response to antipsychotic treatment;	chr6:85582217	chr6:85659892~85660606:-
THCA	cis	rs7260598	0.539	rs11665842	ENSG00000268442.1	CTD-2027I19.2	5	8.2e-07	0.000106	0.33	0.22	Response to taxane treatment (placlitaxel);	chr19:23911846	chr19:24162370~24163425:-
THCA	cis	rs800160	0.925	rs800163	ENSG00000199550.1	Y_RNA	5	8.2e-07	0.000106	0.34	0.22	Bacteremia;	chr11:2361739	chr11:2372638~2372750:+
THCA	cis	rs9291683	0.61	rs993172	ENSG00000261490.1	RP11-448G15.3	5	8.2e-07	0.000106	0.14	0.22	Bone mineral density;	chr4:10322737	chr4:10068089~10073019:-
THCA	cis	rs4660261	0.526	rs3094954	ENSG00000237950.1	RP11-7O11.3	5	8.2e-07	0.000106	0.2	0.22	Intelligence (multi-trait analysis);	chr1:43855247	chr1:43944370~43946551:-
THCA	cis	rs4660456	0.871	rs7549789	ENSG00000272145.1	NFYC-AS1	5	8.2e-07	0.000106	0.16	0.22	Platelet count;	chr1:40759362	chr1:40690380~40692066:-
THCA	cis	rs1714507	0.533	rs2731118	ENSG00000272087.1	RP11-379F4.7	-5	8.21e-07	0.000106	-0.2	-0.22	Subjective well-being;	chr3:158589942	chr3:158693120~158693768:-
THCA	cis	rs1714507	0.533	rs2573179	ENSG00000272087.1	RP11-379F4.7	-5	8.21e-07	0.000106	-0.2	-0.22	Subjective well-being;	chr3:158590018	chr3:158693120~158693768:-
THCA	cis	rs3820928	0.874	rs12105952	ENSG00000212391.1	SNORA48	-5	8.21e-07	0.000106	-0.24	-0.22	Pulmonary function;	chr2:226999805	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs9288618	ENSG00000212391.1	SNORA48	-5	8.21e-07	0.000106	-0.24	-0.22	Pulmonary function;	chr2:227007901	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs1054413	ENSG00000212391.1	SNORA48	5	8.21e-07	0.000106	0.24	0.22	Pulmonary function;	chr2:227003003	chr2:226968989~226969122:-
THCA	cis	rs16852403	0.548	rs387917	ENSG00000224687.1	RASAL2-AS1	-5	8.21e-07	0.000106	-0.33	-0.22	Childhood ear infection;	chr1:178148407	chr1:178091508~178093984:-
THCA	cis	rs736408	0.609	rs13087772	ENSG00000243224.1	RP5-1157M23.2	-5	8.21e-07	0.000106	-0.25	-0.22	Bipolar disorder;	chr3:52748258	chr3:52239258~52241097:+
THCA	cis	rs736408	0.609	rs13095332	ENSG00000243224.1	RP5-1157M23.2	-5	8.21e-07	0.000106	-0.25	-0.22	Bipolar disorder;	chr3:52753226	chr3:52239258~52241097:+
THCA	cis	rs11992162	0.967	rs7461062	ENSG00000206014.6	OR7E161P	-5	8.21e-07	0.000106	-0.26	-0.22	Monocyte count;	chr8:11974439	chr8:11928597~11929563:-
THCA	cis	rs858239	0.509	rs57611130	ENSG00000230042.1	AK3P3	-5	8.21e-07	0.000106	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23129178~23129841:+
THCA	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	5	8.22e-07	0.000106	0.25	0.22	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
THCA	cis	rs9890032	0.564	rs111305917	ENSG00000266490.1	CTD-2349P21.9	5	8.22e-07	0.000106	0.23	0.22	Hip circumference adjusted for BMI;	chr17:30887777	chr17:30792372~30792833:+
THCA	cis	rs2070488	0.775	rs6794397	ENSG00000229589.1	ACVR2B-AS1	5	8.22e-07	0.000106	0.2	0.22	Electrocardiographic conduction measures;	chr3:38517816	chr3:38451027~38454820:-
THCA	cis	rs6969780	1	rs6973182	ENSG00000233429.8	HOTAIRM1	5	8.22e-07	0.000106	0.34	0.22	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27132702	chr7:27095647~27100265:+
THCA	cis	rs9859260	0.71	rs41298097	ENSG00000207650.1	MIR570	-5	8.22e-07	0.000106	-0.24	-0.22	Mean corpuscular volume;	chr3:196052284	chr3:195699401~195699497:+
THCA	cis	rs9859260	0.744	rs557527	ENSG00000207650.1	MIR570	-5	8.22e-07	0.000106	-0.24	-0.22	Mean corpuscular volume;	chr3:196053838	chr3:195699401~195699497:+
THCA	cis	rs6545883	0.929	rs1186711	ENSG00000270820.4	RP11-355B11.2	5	8.22e-07	0.000106	0.2	0.22	Tuberculosis;	chr2:61461370	chr2:61471188~61484130:+
THCA	cis	rs2985684	0.948	rs11623263	ENSG00000278009.1	RP11-649E7.8	5	8.22e-07	0.000106	0.32	0.22	Carotid intima media thickness;	chr14:49616577	chr14:49601011~49601124:-
THCA	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-5	8.22e-07	0.000106	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-5	8.22e-07	0.000106	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-5	8.22e-07	0.000106	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-5	8.22e-07	0.000106	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
THCA	cis	rs6772849	0.805	rs13325747	ENSG00000242551.2	POU5F1P6	-5	8.23e-07	0.000106	-0.29	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:128674735~128677005:-
THCA	cis	rs6728642	1	rs17037402	ENSG00000230606.9	AC159540.1	5	8.23e-07	0.000106	0.34	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97358816	chr2:97416165~97433527:-
THCA	cis	rs4948102	0.597	rs12669623	ENSG00000226278.1	PSPHP1	-5	8.23e-07	0.000106	-0.26	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55764797~55773288:+
THCA	cis	rs801193	0.844	rs732465	ENSG00000273142.1	RP11-458F8.4	-5	8.23e-07	0.000106	-0.17	-0.22	Aortic root size;	chr7:66533463	chr7:66902857~66906297:+
THCA	cis	rs801193	0.773	rs801207	ENSG00000273142.1	RP11-458F8.4	5	8.23e-07	0.000106	0.17	0.22	Aortic root size;	chr7:66555603	chr7:66902857~66906297:+
THCA	cis	rs875971	0.543	rs801191	ENSG00000273142.1	RP11-458F8.4	5	8.23e-07	0.000106	0.17	0.22	Aortic root size;	chr7:66567968	chr7:66902857~66906297:+
THCA	cis	rs875971	0.508	rs6947808	ENSG00000273142.1	RP11-458F8.4	5	8.23e-07	0.000106	0.17	0.22	Aortic root size;	chr7:66580095	chr7:66902857~66906297:+
THCA	cis	rs7702057	0.53	rs58510083	ENSG00000272265.1	CTD-2287O16.4	5	8.24e-07	0.000106	0.43	0.22	Amyotrophic lateral sclerosis;	chr5:116109101	chr5:116078110~116078570:-
THCA	cis	rs7621331	0.963	rs13081105	ENSG00000273486.1	RP11-731C17.2	5	8.24e-07	0.000106	0.21	0.22	Waist circumference adjusted for body mass index;	chr3:135951730	chr3:136837338~136839021:-
THCA	cis	rs7621331	0.963	rs28430744	ENSG00000273486.1	RP11-731C17.2	5	8.24e-07	0.000106	0.21	0.22	Waist circumference adjusted for body mass index;	chr3:135953978	chr3:136837338~136839021:-
THCA	cis	rs4144027	0.904	rs35551424	ENSG00000269910.1	RP11-73M18.10	-5	8.24e-07	0.000106	-0.21	-0.22	Blood metabolite levels;	chr14:103875332	chr14:103694516~103695050:-
THCA	cis	rs6088590	1	rs2076668	ENSG00000269202.1	RP4-614O4.12	-5	8.24e-07	0.000106	-0.2	-0.22	Coronary artery disease;	chr20:34849818	chr20:35201747~35203288:-
THCA	cis	rs796395	0.934	rs1690791	ENSG00000228208.5	C1orf143	-5	8.25e-07	0.000107	-0.27	-0.22	Post bronchodilator FEV1/FVC ratio;	chr1:218471980	chr1:218510096~218525978:+
THCA	cis	rs2179367	0.632	rs55836833	ENSG00000223701.3	RAET1E-AS1	5	8.25e-07	0.000107	0.32	0.22	Dupuytren's disease;	chr6:149403736	chr6:149884431~149919508:+
THCA	cis	rs4648045	0.734	rs4235406	ENSG00000246560.2	RP11-10L12.4	5	8.25e-07	0.000107	0.29	0.22	Lymphocyte percentage of white cells;	chr4:102605374	chr4:102828055~102844075:+
THCA	cis	rs2835345	0.63	rs73204235	ENSG00000230479.1	AP000695.6	5	8.25e-07	0.000107	0.28	0.22	Pulmonary function;	chr21:36446920	chr21:36430360~36481070:+
THCA	cis	rs2835345	0.63	rs73204236	ENSG00000230479.1	AP000695.6	5	8.25e-07	0.000107	0.28	0.22	Pulmonary function;	chr21:36446921	chr21:36430360~36481070:+
THCA	cis	rs240993	0.715	rs9487627	ENSG00000271789.1	RP5-1112D6.7	-5	8.25e-07	0.000107	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111408846	chr6:111297126~111298510:+
THCA	cis	rs6545883	0.826	rs2694617	ENSG00000270820.4	RP11-355B11.2	-5	8.25e-07	0.000107	-0.19	-0.22	Tuberculosis;	chr2:61310079	chr2:61471188~61484130:+
THCA	cis	rs17507216	1	rs17158413	ENSG00000255769.6	GOLGA2P10	-5	8.25e-07	0.000107	-0.32	-0.22	Excessive daytime sleepiness;	chr15:82566658	chr15:82472993~82513950:-
THCA	cis	rs3820928	0.874	rs4675131	ENSG00000212391.1	SNORA48	-5	8.25e-07	0.000107	-0.25	-0.22	Pulmonary function;	chr2:226972026	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs2396452	ENSG00000212391.1	SNORA48	-5	8.25e-07	0.000107	-0.25	-0.22	Pulmonary function;	chr2:226973324	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs7421491	ENSG00000212391.1	SNORA48	-5	8.25e-07	0.000107	-0.25	-0.22	Pulmonary function;	chr2:226974562	chr2:226968989~226969122:-
THCA	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	5	8.26e-07	0.000107	0.28	0.22	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
THCA	cis	rs6088590	0.931	rs6088624	ENSG00000269202.1	RP4-614O4.12	-5	8.26e-07	0.000107	-0.2	-0.22	Coronary artery disease;	chr20:34849049	chr20:35201747~35203288:-
THCA	cis	rs7119038	1	rs7119038	ENSG00000255239.1	AP002954.6	5	8.26e-07	0.000107	0.34	0.22	Sjögren's syndrome;	chr11:118867572	chr11:118688039~118690600:-
THCA	cis	rs763121	0.853	rs5757196	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38643850	chr22:38921227~38924708:+
THCA	cis	rs763121	0.785	rs5757199	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38644612	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs9610993	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38646813	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757200	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38647486	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757203	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38648147	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2205802	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38650322	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757204	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38650695	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs8138996	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38651430	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs6001182	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38651438	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757208	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38653225	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757211	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38655700	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs6001184	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38656111	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs6001185	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38656150	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2294296	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38657044	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2064088	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38657377	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757213	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38657883	chr22:38921227~38924708:+
THCA	cis	rs5742933	0.557	rs6756571	ENSG00000253559.1	OSGEPL1-AS1	5	8.26e-07	0.000107	0.26	0.22	Ferritin levels;	chr2:189640971	chr2:189762704~189765556:+
THCA	cis	rs9652601	0.622	rs8049882	ENSG00000274038.1	RP11-66H6.4	-5	8.26e-07	0.000107	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11025629	chr16:11056556~11057034:+
THCA	cis	rs763121	0.853	rs138706	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.31	0.22	Menopause (age at onset);	chr22:38741829	chr22:38921227~38924708:+
THCA	cis	rs270601	0.837	rs367805	ENSG00000237714.1	P4HA2-AS1	5	8.26e-07	0.000107	0.3	0.22	Acylcarnitine levels;	chr5:132365587	chr5:132184876~132192808:+
THCA	cis	rs228614	0.51	rs223446	ENSG00000248971.2	KRT8P46	-5	8.26e-07	0.000107	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102728746~102730171:-
THCA	cis	rs228614	0.536	rs223437	ENSG00000248971.2	KRT8P46	-5	8.26e-07	0.000107	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102728746~102730171:-
THCA	cis	rs228614	0.536	rs223419	ENSG00000248971.2	KRT8P46	-5	8.26e-07	0.000107	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102728746~102730171:-
THCA	cis	rs763121	0.819	rs5750629	ENSG00000235209.1	CTA-150C2.13	5	8.26e-07	0.000107	0.29	0.22	Menopause (age at onset);	chr22:38589060	chr22:38921227~38924708:+
THCA	cis	rs763121	0.889	rs6001209	ENSG00000228274.3	RP3-508I15.9	5	8.26e-07	0.000107	0.24	0.22	Menopause (age at onset);	chr22:38725247	chr22:38667585~38681820:-
THCA	cis	rs16852403	0.517	rs12034044	ENSG00000224687.1	RASAL2-AS1	5	8.27e-07	0.000107	0.34	0.22	Childhood ear infection;	chr1:178265274	chr1:178091508~178093984:-
THCA	cis	rs10771431	1	rs11611670	ENSG00000256069.6	A2MP1	5	8.27e-07	0.000107	0.25	0.22	Breast size;	chr12:9232939	chr12:9228533~9275817:-
THCA	cis	rs9863	0.896	rs4765148	ENSG00000269997.1	RP11-214K3.21	-5	8.27e-07	0.000107	-0.28	-0.22	White blood cell count;	chr12:123994090	chr12:123966077~123966629:-
THCA	cis	rs6088580	0.668	rs1205337	ENSG00000276073.1	RP5-1125A11.7	5	8.27e-07	0.000107	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34338235	chr20:33985617~33988989:-
THCA	cis	rs8067545	0.553	rs4577147	ENSG00000261033.1	RP11-209D14.2	-5	8.27e-07	0.000107	-0.32	-0.22	Schizophrenia;	chr17:20040710	chr17:20008051~20009234:-
THCA	cis	rs8067545	0.536	rs62067482	ENSG00000261033.1	RP11-209D14.2	-5	8.27e-07	0.000107	-0.32	-0.22	Schizophrenia;	chr17:20043962	chr17:20008051~20009234:-
THCA	cis	rs8020095	0.571	rs8012063	ENSG00000258561.1	RP11-72M17.1	-5	8.27e-07	0.000107	-0.3	-0.22	Depression (quantitative trait);	chr14:66967753	chr14:66212810~66509394:-
THCA	cis	rs4915077	0.892	rs17020107	ENSG00000230489.1	VAV3-AS1	5	8.27e-07	0.000107	0.33	0.22	Hypothyroidism;	chr1:107811226	chr1:107964443~107994607:+
THCA	cis	rs7851660	0.844	rs10119760	ENSG00000214417.4	KRT18P13	-5	8.28e-07	0.000107	-0.2	-0.22	Strep throat;	chr9:97862320	chr9:97698922~97700734:+
THCA	cis	rs3820928	1	rs10193316	ENSG00000212391.1	SNORA48	-5	8.28e-07	0.000107	-0.25	-0.22	Pulmonary function;	chr2:226912934	chr2:226968989~226969122:-
THCA	cis	rs17680741	0.697	rs36113069	ENSG00000225484.5	NUTM2B-AS1	-5	8.28e-07	0.000107	-0.32	-0.22	Coronary artery disease;	chr10:80516039	chr10:79663088~79826594:-
THCA	cis	rs453301	0.592	rs4841084	ENSG00000254153.1	CTA-398F10.2	-5	8.28e-07	0.000107	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9026395	chr8:8456909~8461337:-
THCA	cis	rs453301	0.653	rs2956244	ENSG00000254153.1	CTA-398F10.2	-5	8.28e-07	0.000107	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9027656	chr8:8456909~8461337:-
THCA	cis	rs6012564	0.783	rs6125575	ENSG00000227431.4	CSE1L-AS1	5	8.28e-07	0.000107	0.27	0.22	Anger;	chr20:49159159	chr20:49040463~49046044:-
THCA	cis	rs919433	0.68	rs7590010	ENSG00000231621.1	AC013264.2	-5	8.29e-07	0.000107	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197535944	chr2:197197991~197199273:+
THCA	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-5	8.29e-07	0.000107	-0.43	-0.22	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
THCA	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	5	8.29e-07	0.000107	0.25	0.22	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
THCA	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-5	8.29e-07	0.000107	-0.25	-0.22	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
THCA	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-5	8.29e-07	0.000107	-0.25	-0.22	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
THCA	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-5	8.29e-07	0.000107	-0.25	-0.22	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
THCA	cis	rs9677476	0.528	rs62197317	ENSG00000224376.1	AC017104.6	5	8.29e-07	0.000107	0.29	0.22	Food antigen IgG levels;	chr2:231189753	chr2:231388976~231394991:+
THCA	cis	rs2243480	1	rs160633	ENSG00000164669.11	INTS4P1	5	8.29e-07	0.000107	0.43	0.22	Diabetic kidney disease;	chr7:66063241	chr7:65141225~65234216:+
THCA	cis	rs12908161	0.96	rs62019463	ENSG00000275120.1	RP11-182J1.17	5	8.29e-07	0.000107	0.26	0.22	Schizophrenia;	chr15:84744856	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs62019464	ENSG00000275120.1	RP11-182J1.17	5	8.29e-07	0.000107	0.26	0.22	Schizophrenia;	chr15:84751238	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs11637142	ENSG00000275120.1	RP11-182J1.17	5	8.29e-07	0.000107	0.26	0.22	Schizophrenia;	chr15:84752696	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs12910012	ENSG00000275120.1	RP11-182J1.17	5	8.29e-07	0.000107	0.26	0.22	Schizophrenia;	chr15:84755431	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs12899981	ENSG00000275120.1	RP11-182J1.17	5	8.29e-07	0.000107	0.26	0.22	Schizophrenia;	chr15:84759142	chr15:84599434~84606463:-
THCA	cis	rs853679	0.546	rs13214023	ENSG00000226314.6	ZNF192P1	5	8.29e-07	0.000107	0.43	0.22	Depression;	chr6:28364364	chr6:28161781~28169594:+
THCA	cis	rs763121	0.853	rs2072794	ENSG00000235209.1	CTA-150C2.13	5	8.3e-07	0.000107	0.31	0.22	Menopause (age at onset);	chr22:38754538	chr22:38921227~38924708:+
THCA	cis	rs853679	1	rs2799077	ENSG00000220721.1	OR1F12	5	8.3e-07	0.000107	0.36	0.22	Depression;	chr6:28266819	chr6:28073316~28074233:+
THCA	cis	rs454422	0.767	rs236119	ENSG00000275632.1	RP5-967N21.11	5	8.3e-07	0.000107	0.22	0.22	HIV-1 viral setpoint;	chr20:5958008	chr20:6000418~6000941:+
THCA	cis	rs9890032	0.618	rs55872374	ENSG00000263603.1	CTD-2349P21.5	-5	8.3e-07	0.000107	-0.29	-0.22	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30729469~30731202:+
THCA	cis	rs6832769	0.922	rs60797008	ENSG00000272969.1	RP11-528I4.2	-5	8.3e-07	0.000107	-0.27	-0.22	Personality dimensions;	chr4:55522505	chr4:55547112~55547889:+
THCA	cis	rs11673344	0.583	rs7254411	ENSG00000276846.1	CTD-3220F14.3	5	8.3e-07	0.000107	0.17	0.22	Obesity-related traits;	chr19:37034969	chr19:37314868~37315620:-
THCA	cis	rs11153306	0.515	rs3213575	ENSG00000230177.1	RP5-1112D6.4	-5	8.3e-07	0.000107	-0.18	-0.22	Tonsillectomy;	chr6:111598068	chr6:111277932~111278742:+
THCA	cis	rs16846053	0.605	rs72865293	ENSG00000227403.1	AC009299.3	5	8.31e-07	0.000107	0.48	0.22	Blood osmolality (transformed sodium);	chr2:161921589	chr2:161244739~161249050:+
THCA	cis	rs17767392	0.958	rs7144829	ENSG00000259146.3	RP1-261D10.2	-5	8.31e-07	0.000107	-0.29	-0.22	Mitral valve prolapse;	chr14:71599739	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs4899398	ENSG00000259146.3	RP1-261D10.2	-5	8.31e-07	0.000107	-0.29	-0.22	Mitral valve prolapse;	chr14:71616724	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.914	rs10139519	ENSG00000259146.3	RP1-261D10.2	-5	8.31e-07	0.000107	-0.29	-0.22	Mitral valve prolapse;	chr14:71642553	chr14:71292729~71321814:-
THCA	cis	rs9625935	0.957	rs9620943	ENSG00000279159.1	RP3-394A18.1	-5	8.31e-07	0.000107	-0.17	-0.22	Tonsillectomy;	chr22:30071777	chr22:29978950~30028236:-
THCA	cis	rs796395	0.967	rs575544	ENSG00000228208.5	C1orf143	-5	8.31e-07	0.000107	-0.27	-0.22	Post bronchodilator FEV1/FVC ratio;	chr1:218469799	chr1:218510096~218525978:+
THCA	cis	rs10090774	0.965	rs13276704	ENSG00000279766.1	RP11-642A1.2	-4.99	8.31e-07	0.000107	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140983597	chr8:140572142~140572812:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000223473.2	GS1-124K5.3	-4.99	8.31e-07	0.000107	-0.15	-0.22	Aortic root size;	chr7:66048109	chr7:66491049~66493566:-
THCA	cis	rs875971	0.505	rs1167385	ENSG00000223473.2	GS1-124K5.3	-4.99	8.31e-07	0.000107	-0.15	-0.22	Aortic root size;	chr7:66048321	chr7:66491049~66493566:-
THCA	cis	rs7914558	0.966	rs3902934	ENSG00000236937.2	PTGES3P4	4.99	8.31e-07	0.000107	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102986892	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs1890184	ENSG00000236937.2	PTGES3P4	4.99	8.31e-07	0.000107	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988702	chr10:102845595~102845950:+
THCA	cis	rs240993	0.812	rs9487632	ENSG00000271789.1	RP5-1112D6.7	-4.99	8.32e-07	0.000107	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs11153295	ENSG00000271789.1	RP5-1112D6.7	-4.99	8.32e-07	0.000107	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs6915753	ENSG00000271789.1	RP5-1112D6.7	-4.99	8.32e-07	0.000107	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs4620159	ENSG00000271789.1	RP5-1112D6.7	-4.99	8.32e-07	0.000107	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111297126~111298510:+
THCA	cis	rs7403037	0.652	rs4778457	ENSG00000260760.1	PWRN3	4.99	8.32e-07	0.000107	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24318136	chr15:24441127~24447967:+
THCA	cis	rs13126694	0.649	rs4615226	ENSG00000248429.4	RP11-597D13.9	4.99	8.32e-07	0.000107	0.24	0.22	Blood osmolality (transformed sodium);	chr4:157979297	chr4:158170752~158202877:+
THCA	cis	rs9329221	0.683	rs525726	ENSG00000248538.5	RP11-10A14.5	4.99	8.32e-07	0.000107	0.28	0.22	Neuroticism;	chr8:10030287	chr8:9189011~9202854:+
THCA	cis	rs11603023	0.967	rs494560	ENSG00000278376.1	RP11-158I9.8	4.99	8.32e-07	0.000107	0.17	0.22	Cholesterol, total;	chr11:118650844	chr11:118791254~118793137:+
THCA	cis	rs4650994	0.593	rs12033086	ENSG00000273384.1	RP5-1098D14.1	-4.99	8.32e-07	0.000107	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178571790	chr1:178651706~178652282:+
THCA	cis	rs9595908	0.832	rs2032495	ENSG00000212293.1	SNORA16	4.99	8.32e-07	0.000107	0.26	0.22	Body mass index;	chr13:32630605	chr13:32420390~32420516:-
THCA	cis	rs1559040	1	rs72800739	ENSG00000272156.1	RP11-477N3.1	-4.99	8.33e-07	0.000107	-0.37	-0.22	Sudden cardiac arrest;	chr2:54102162	chr2:54082554~54085066:+
THCA	cis	rs7688540	0.771	rs77234191	ENSG00000211553.1	AC253576.2	-4.99	8.33e-07	0.000107	-0.35	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:136461~136568:+
THCA	cis	rs9300255	0.739	rs4759417	ENSG00000235423.7	RP11-282O18.3	4.99	8.33e-07	0.000107	0.23	0.22	Neutrophil percentage of white cells;	chr12:123261963	chr12:123252030~123261483:-
THCA	cis	rs7727544	0.507	rs9791170	ENSG00000224431.1	AC063976.7	4.99	8.33e-07	0.000107	0.19	0.22	Blood metabolite levels;	chr5:132233934	chr5:132199456~132203487:+
THCA	cis	rs17767392	0.958	rs2214836	ENSG00000259146.3	RP1-261D10.2	-4.99	8.33e-07	0.000107	-0.29	-0.22	Mitral valve prolapse;	chr14:71558361	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs2332638	ENSG00000259146.3	RP1-261D10.2	-4.99	8.33e-07	0.000107	-0.29	-0.22	Mitral valve prolapse;	chr14:71562198	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs2332641	ENSG00000259146.3	RP1-261D10.2	-4.99	8.33e-07	0.000107	-0.29	-0.22	Mitral valve prolapse;	chr14:71578011	chr14:71292729~71321814:-
THCA	cis	rs16975963	0.594	rs73039018	ENSG00000226686.6	LINC01535	-4.99	8.33e-07	0.000107	-0.3	-0.22	Longevity;	chr19:37726993	chr19:37251912~37265535:+
THCA	cis	rs883924	0.572	rs7037338	ENSG00000231107.1	LINC01508	4.99	8.33e-07	0.000107	0.27	0.22	Hepatitis C induced liver fibrosis;	chr9:90450280	chr9:90300902~90433505:-
THCA	cis	rs4443100	0.958	rs11090217	ENSG00000230701.2	FBXW4P1	4.99	8.34e-07	0.000108	0.27	0.22	Serum parathyroid hormone levels;	chr22:23036329	chr22:23262767~23265005:+
THCA	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-4.99	8.34e-07	0.000108	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-4.99	8.34e-07	0.000108	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-4.99	8.34e-07	0.000108	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-4.99	8.34e-07	0.000108	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-4.99	8.34e-07	0.000108	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-4.99	8.34e-07	0.000108	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-4.99	8.34e-07	0.000108	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
THCA	cis	rs11634944	0.508	rs10451029	ENSG00000257151.1	PWAR6	4.99	8.34e-07	0.000108	0.17	0.22	Interleukin-8 levels;	chr15:24992196	chr15:25031873~25036490:+
THCA	cis	rs6545883	0.772	rs1186709	ENSG00000270820.4	RP11-355B11.2	4.99	8.34e-07	0.000108	0.19	0.22	Tuberculosis;	chr2:61462245	chr2:61471188~61484130:+
THCA	cis	rs4664293	0.632	rs2059697	ENSG00000226266.5	AC009961.3	4.99	8.34e-07	0.000108	0.27	0.22	Monocyte percentage of white cells;	chr2:159799079	chr2:159670708~159712435:-
THCA	cis	rs8020095	0.571	rs11158653	ENSG00000258561.1	RP11-72M17.1	4.99	8.34e-07	0.000108	0.3	0.22	Depression (quantitative trait);	chr14:67192178	chr14:66212810~66509394:-
THCA	cis	rs2742234	0.91	rs2505511	ENSG00000273008.1	RP11-351D16.3	-4.99	8.34e-07	0.000108	-0.19	-0.22	Hirschsprung disease;	chr10:43145581	chr10:43136824~43138334:-
THCA	cis	rs9300255	0.739	rs2337934	ENSG00000235423.7	RP11-282O18.3	4.99	8.34e-07	0.000108	0.23	0.22	Neutrophil percentage of white cells;	chr12:123260812	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.698	rs4759416	ENSG00000235423.7	RP11-282O18.3	4.99	8.34e-07	0.000108	0.23	0.22	Neutrophil percentage of white cells;	chr12:123261810	chr12:123252030~123261483:-
THCA	cis	rs7809615	1	rs7809615	ENSG00000244219.5	GS1-259H13.2	-4.99	8.34e-07	0.000108	-0.41	-0.22	Blood metabolite ratios;	chr7:99587155	chr7:99598066~99610813:+
THCA	cis	rs2803122	0.846	rs10757032	ENSG00000273226.1	RP11-513M16.8	-4.99	8.34e-07	0.000108	-0.2	-0.22	Pulse pressure;	chr9:19213350	chr9:19375451~19375996:+
THCA	cis	rs4713118	0.869	rs9461405	ENSG00000226314.6	ZNF192P1	-4.99	8.35e-07	0.000108	-0.28	-0.22	Parkinson's disease;	chr6:27751596	chr6:28161781~28169594:+
THCA	cis	rs6565180	1	rs11863150	ENSG00000274653.1	RP11-347C12.11	-4.99	8.35e-07	0.000108	-0.2	-0.22	Tonsillectomy;	chr16:30374182	chr16:30359825~30360336:+
THCA	cis	rs8141529	0.764	rs5762824	ENSG00000272858.1	CTA-292E10.8	-4.99	8.35e-07	0.000108	-0.23	-0.22	Lymphocyte counts;	chr22:28826942	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.764	rs5752807	ENSG00000272858.1	CTA-292E10.8	-4.99	8.35e-07	0.000108	-0.23	-0.22	Lymphocyte counts;	chr22:28827181	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.719	rs5762825	ENSG00000272858.1	CTA-292E10.8	-4.99	8.35e-07	0.000108	-0.23	-0.22	Lymphocyte counts;	chr22:28827654	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.764	rs5752809	ENSG00000272858.1	CTA-292E10.8	-4.99	8.35e-07	0.000108	-0.23	-0.22	Lymphocyte counts;	chr22:28829512	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.764	rs5752812	ENSG00000272858.1	CTA-292E10.8	-4.99	8.35e-07	0.000108	-0.23	-0.22	Lymphocyte counts;	chr22:28829615	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.764	rs8137969	ENSG00000272858.1	CTA-292E10.8	-4.99	8.35e-07	0.000108	-0.23	-0.22	Lymphocyte counts;	chr22:28832496	chr22:28814914~28815662:+
THCA	cis	rs875971	0.789	rs28815324	ENSG00000228409.4	CCT6P1	4.99	8.36e-07	0.000108	0.2	0.22	Aortic root size;	chr7:66100789	chr7:65751142~65763354:+
THCA	cis	rs1876905	0.539	rs240958	ENSG00000255389.1	C6orf3	-4.99	8.36e-07	0.000108	-0.27	-0.22	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111599875~111602295:+
THCA	cis	rs2439831	0.681	rs511673	ENSG00000275601.1	AC011330.13	-4.99	8.36e-07	0.000108	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43326665	chr15:43642389~43643023:-
THCA	cis	rs7474896	0.609	rs11011336	ENSG00000263064.2	RP11-291L22.7	4.99	8.36e-07	0.000108	0.3	0.22	Obesity (extreme);	chr10:37696388	chr10:38448689~38448949:+
THCA	cis	rs3750082	0.852	rs6462425	ENSG00000231952.3	DPY19L1P2	4.99	8.37e-07	0.000108	0.28	0.22	Glomerular filtration rate (creatinine);	chr7:32858983	chr7:32812757~32838570:+
THCA	cis	rs3796352	1	rs34313969	ENSG00000242142.1	SERBP1P3	-4.99	8.37e-07	0.000108	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52961150	chr3:53064283~53065091:-
THCA	cis	rs3796352	0.892	rs58515094	ENSG00000242142.1	SERBP1P3	-4.99	8.37e-07	0.000108	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52961559	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs61172708	ENSG00000242142.1	SERBP1P3	-4.99	8.37e-07	0.000108	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52962036	chr3:53064283~53065091:-
THCA	cis	rs7520050	0.771	rs4660882	ENSG00000234329.1	RP11-767N6.2	4.99	8.37e-07	0.000108	0.2	0.22	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45651039~45651826:-
THCA	cis	rs990871	0.512	rs1870676	ENSG00000227207.2	RPL31P12	-4.99	8.37e-07	0.000108	-0.26	-0.22	Subcutaneous adipose tissue;	chr1:72279313	chr1:72301472~72301829:+
THCA	cis	rs8020095	0.571	rs7145917	ENSG00000258561.1	RP11-72M17.1	-4.99	8.37e-07	0.000108	-0.3	-0.22	Depression (quantitative trait);	chr14:66905809	chr14:66212810~66509394:-
THCA	cis	rs9291683	0.61	rs993173	ENSG00000261490.1	RP11-448G15.3	-4.99	8.38e-07	0.000108	-0.14	-0.22	Bone mineral density;	chr4:10322311	chr4:10068089~10073019:-
THCA	cis	rs7208859	0.573	rs73277960	ENSG00000280069.1	CTD-2349P21.3	-4.99	8.38e-07	0.000108	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73263788	ENSG00000280069.1	CTD-2349P21.3	-4.99	8.38e-07	0.000108	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs12949860	ENSG00000280069.1	CTD-2349P21.3	-4.99	8.38e-07	0.000108	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30738182~30740275:+
THCA	cis	rs858239	0.601	rs11984129	ENSG00000230042.1	AK3P3	-4.99	8.38e-07	0.000108	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23129178~23129841:+
THCA	cis	rs4663866	1	rs71426509	ENSG00000186235.9	AC016757.3	4.99	8.38e-07	0.000108	0.47	0.22	Irritable bowel syndrome;	chr2:238266693	chr2:238224552~238231677:-
THCA	cis	rs4663866	1	rs13026475	ENSG00000186235.9	AC016757.3	4.99	8.38e-07	0.000108	0.47	0.22	Irritable bowel syndrome;	chr2:238269814	chr2:238224552~238231677:-
THCA	cis	rs4663866	1	rs71426510	ENSG00000186235.9	AC016757.3	4.99	8.38e-07	0.000108	0.47	0.22	Irritable bowel syndrome;	chr2:238270268	chr2:238224552~238231677:-
THCA	cis	rs2562456	0.833	rs62107539	ENSG00000268119.4	CTD-2561J22.5	4.99	8.38e-07	0.000108	0.33	0.22	Pain;	chr19:21334910	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs76646508	ENSG00000268119.4	CTD-2561J22.5	4.99	8.38e-07	0.000108	0.33	0.22	Pain;	chr19:21335247	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs77576302	ENSG00000268119.4	CTD-2561J22.5	4.99	8.38e-07	0.000108	0.33	0.22	Pain;	chr19:21335385	chr19:21444241~21463908:-
THCA	cis	rs2034650	0.563	rs11070270	ENSG00000223313.1	RNU6-516P	-4.99	8.39e-07	0.000108	-0.25	-0.22	Interstitial lung disease;	chr15:40416223	chr15:40529570~40529673:+
THCA	cis	rs16975963	0.644	rs73033129	ENSG00000226686.6	LINC01535	-4.99	8.39e-07	0.000108	-0.3	-0.22	Longevity;	chr19:37589634	chr19:37251912~37265535:+
THCA	cis	rs5742933	1	rs4666783	ENSG00000273240.1	RP11-455J20.3	-4.99	8.39e-07	0.000108	-0.25	-0.22	Ferritin levels;	chr2:189748254	chr2:189763859~189764456:-
THCA	cis	rs1336149	0.935	rs945508	ENSG00000211581.1	MIR765	-4.99	8.39e-07	0.000108	-0.28	-0.22	Chin dimples;	chr1:156937289	chr1:156936131~156936244:-
THCA	cis	rs9875589	0.509	rs11927267	ENSG00000228242.5	AC093495.4	4.99	8.39e-07	0.000108	0.13	0.22	Ovarian reserve;	chr3:14032492	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs11128679	ENSG00000228242.5	AC093495.4	4.99	8.39e-07	0.000108	0.13	0.22	Ovarian reserve;	chr3:14033745	chr3:14144637~14165978:+
THCA	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-4.99	8.39e-07	0.000108	-0.26	-0.22	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
THCA	cis	rs2562456	0.833	rs62109223	ENSG00000268119.4	CTD-2561J22.5	4.99	8.39e-07	0.000108	0.32	0.22	Pain;	chr19:21349591	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62109225	ENSG00000268119.4	CTD-2561J22.5	4.99	8.39e-07	0.000108	0.32	0.22	Pain;	chr19:21353861	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.754	rs62109226	ENSG00000268119.4	CTD-2561J22.5	4.99	8.39e-07	0.000108	0.32	0.22	Pain;	chr19:21354111	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.754	rs62109227	ENSG00000268119.4	CTD-2561J22.5	4.99	8.39e-07	0.000108	0.32	0.22	Pain;	chr19:21354128	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.754	rs62109228	ENSG00000268119.4	CTD-2561J22.5	4.99	8.39e-07	0.000108	0.32	0.22	Pain;	chr19:21354129	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs8102783	ENSG00000268119.4	CTD-2561J22.5	4.99	8.39e-07	0.000108	0.32	0.22	Pain;	chr19:21355751	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs2061916	ENSG00000268119.4	CTD-2561J22.5	4.99	8.39e-07	0.000108	0.32	0.22	Pain;	chr19:21358906	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs4359573	ENSG00000268119.4	CTD-2561J22.5	4.99	8.39e-07	0.000108	0.32	0.22	Pain;	chr19:21359494	chr19:21444241~21463908:-
THCA	cis	rs12530	0.651	rs2072816	ENSG00000230736.2	RP1-149A16.3	-4.99	8.39e-07	0.000108	-0.29	-0.22	IgG glycosylation;	chr22:32394411	chr22:32376664~32384343:+
THCA	cis	rs8067545	0.574	rs62067483	ENSG00000261033.1	RP11-209D14.2	-4.99	8.39e-07	0.000108	-0.32	-0.22	Schizophrenia;	chr17:20045081	chr17:20008051~20009234:-
THCA	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	4.99	8.4e-07	0.000108	0.13	0.22	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
THCA	cis	rs9326248	0.581	rs10892076	ENSG00000280143.1	AP000892.6	4.99	8.4e-07	0.000108	0.27	0.22	Blood protein levels;	chr11:117118220	chr11:117204967~117210292:+
THCA	cis	rs1979679	0.553	rs10459089	ENSG00000278733.1	RP11-425D17.1	4.99	8.4e-07	0.000108	0.22	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28115957	chr12:28185625~28186190:-
THCA	cis	rs2070488	0.804	rs4678605	ENSG00000229589.1	ACVR2B-AS1	4.99	8.4e-07	0.000108	0.2	0.22	Electrocardiographic conduction measures;	chr3:38402998	chr3:38451027~38454820:-
THCA	cis	rs3743266	0.507	rs9630426	ENSG00000245534.5	RORA-AS1	-4.99	8.4e-07	0.000108	-0.3	-0.22	Menarche (age at onset);	chr15:60446854	chr15:60479178~60630637:+
THCA	cis	rs228614	0.51	rs223445	ENSG00000248971.2	KRT8P46	-4.99	8.41e-07	0.000108	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223443	ENSG00000248971.2	KRT8P46	-4.99	8.41e-07	0.000108	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102728746~102730171:-
THCA	cis	rs6968419	0.747	rs9969224	ENSG00000237870.5	AC073130.1	4.99	8.41e-07	0.000108	0.25	0.22	Intraocular pressure;	chr7:116221606	chr7:116275606~116286734:-
THCA	cis	rs34779708	0.931	rs7897457	ENSG00000271335.4	RP11-324I22.4	4.99	8.42e-07	0.000108	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35314552~35336401:-
THCA	cis	rs11671005	0.57	rs73062110	ENSG00000268912.1	CTD-2619J13.17	-4.99	8.42e-07	0.000109	-0.22	-0.22	Mean platelet volume;	chr19:58425275	chr19:58428632~58431148:-
THCA	cis	rs240993	0.812	rs10214442	ENSG00000271789.1	RP5-1112D6.7	-4.99	8.42e-07	0.000109	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111297126~111298510:+
THCA	cis	rs11673344	0.542	rs2562585	ENSG00000276846.1	CTD-3220F14.3	4.99	8.42e-07	0.000109	0.17	0.22	Obesity-related traits;	chr19:37018321	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs8101392	ENSG00000276846.1	CTD-3220F14.3	4.99	8.42e-07	0.000109	0.17	0.22	Obesity-related traits;	chr19:37024416	chr19:37314868~37315620:-
THCA	cis	rs654950	1	rs600401	ENSG00000230638.4	RP11-486B10.4	-4.99	8.42e-07	0.000109	-0.25	-0.22	Airway imaging phenotypes;	chr1:41518987	chr1:41542069~41544310:+
THCA	cis	rs858239	0.509	rs6962213	ENSG00000230042.1	AK3P3	-4.99	8.43e-07	0.000109	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23129178~23129841:+
THCA	cis	rs6903823	0.508	rs1150724	ENSG00000273712.1	RP5-874C20.7	4.99	8.43e-07	0.000109	0.25	0.22	Pulmonary function;	chr6:28282459	chr6:28315613~28315883:-
THCA	cis	rs796395	0.934	rs622912	ENSG00000228208.5	C1orf143	-4.99	8.43e-07	0.000109	-0.27	-0.22	Post bronchodilator FEV1/FVC ratio;	chr1:218497015	chr1:218510096~218525978:+
THCA	cis	rs2288884	0.767	rs17835716	ENSG00000260160.1	CTC-471J1.2	-4.99	8.43e-07	0.000109	-0.22	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047789	chr19:52058490~52063703:-
THCA	cis	rs7577696	0.924	rs7605242	ENSG00000276334.1	AL133243.1	-4.99	8.43e-07	0.000109	-0.23	-0.22	Inflammatory biomarkers;	chr2:32099066	chr2:32521927~32523547:+
THCA	cis	rs4663866	1	rs4663868	ENSG00000186235.9	AC016757.3	4.99	8.43e-07	0.000109	0.47	0.22	Irritable bowel syndrome;	chr2:238252450	chr2:238224552~238231677:-
THCA	cis	rs4761702	1	rs4761701	ENSG00000257322.4	RP11-511B23.2	-4.99	8.43e-07	0.000109	-0.29	-0.22	Immature fraction of reticulocytes;	chr12:93315956	chr12:93003415~93215679:-
THCA	cis	rs2288884	0.559	rs7257830	ENSG00000269483.1	AC006272.1	4.99	8.44e-07	0.000109	0.25	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:51839924~51843324:-
THCA	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-4.99	8.44e-07	0.000109	-0.29	-0.22	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
THCA	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-4.99	8.45e-07	0.000109	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
THCA	cis	rs72772090	0.908	rs17086588	ENSG00000248734.2	CTD-2260A17.1	4.99	8.45e-07	0.000109	0.35	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96709210	chr5:96784777~96785999:+
THCA	cis	rs34779708	0.931	rs4007289	ENSG00000271335.4	RP11-324I22.4	4.99	8.45e-07	0.000109	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35314552~35336401:-
THCA	cis	rs4915077	0.892	rs17020105	ENSG00000230489.1	VAV3-AS1	4.99	8.45e-07	0.000109	0.33	0.22	Hypothyroidism;	chr1:107811106	chr1:107964443~107994607:+
THCA	cis	rs3213758	1	rs76216690	ENSG00000275191.1	RP11-36I17.2	-4.99	8.45e-07	0.000109	-0.45	-0.22	Vitiligo (non-segmental);	chr16:53550640	chr16:53628256~53628816:-
THCA	cis	rs7580717	0.785	rs28541349	ENSG00000224376.1	AC017104.6	4.99	8.45e-07	0.000109	0.25	0.22	Multiple myeloma;	chr2:231289110	chr2:231388976~231394991:+
THCA	cis	rs73242632	1	rs12511480	ENSG00000269949.1	RP11-738E22.3	-4.99	8.45e-07	0.000109	-0.46	-0.22	Congenital heart disease (maternal effect);	chr4:56881977	chr4:56960927~56961373:-
THCA	cis	rs17270561	0.609	rs2154218	ENSG00000272462.2	U91328.19	-4.99	8.45e-07	0.000109	-0.19	-0.22	Iron status biomarkers;	chr6:25776062	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs1317510	ENSG00000272462.2	U91328.19	-4.99	8.45e-07	0.000109	-0.19	-0.22	Iron status biomarkers;	chr6:25778696	chr6:25992662~26001775:+
THCA	cis	rs12935418	0.672	rs1453327	ENSG00000278985.1	RP11-303E16.9	-4.99	8.45e-07	0.000109	-0.25	-0.22	Mean corpuscular volume;	chr16:81014959	chr16:80982319~80984094:-
THCA	cis	rs8141529	0.748	rs5762882	ENSG00000272858.1	CTA-292E10.8	-4.99	8.46e-07	0.000109	-0.23	-0.22	Lymphocyte counts;	chr22:28894692	chr22:28814914~28815662:+
THCA	cis	rs6121246	0.647	rs6088855	ENSG00000230613.1	HM13-AS1	4.99	8.46e-07	0.000109	0.25	0.22	Mean corpuscular hemoglobin;	chr20:31637989	chr20:31567707~31573263:-
THCA	cis	rs858239	0.614	rs2014816	ENSG00000226816.2	AC005082.12	4.99	8.46e-07	0.000109	0.31	0.22	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23206013~23208045:+
THCA	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-4.99	8.46e-07	0.000109	-0.13	-0.22	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-4.99	8.46e-07	0.000109	-0.13	-0.22	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-4.99	8.46e-07	0.000109	-0.13	-0.22	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-4.99	8.46e-07	0.000109	-0.13	-0.22	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
THCA	cis	rs2179367	0.6	rs9498356	ENSG00000268592.3	RAET1E-AS1	4.99	8.46e-07	0.000109	0.36	0.22	Dupuytren's disease;	chr6:149443337	chr6:149863494~149919507:+
THCA	cis	rs10200159	0.744	rs12616502	ENSG00000272606.1	RP11-554J4.1	4.99	8.47e-07	0.000109	0.44	0.22	Vitiligo;	chr2:55581879	chr2:55617909~55618373:+
THCA	cis	rs2980439	0.818	rs2948300	ENSG00000253981.4	ALG1L13P	4.99	8.47e-07	0.000109	0.22	0.22	Neuroticism;	chr8:8248986	chr8:8236003~8244667:-
THCA	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-4.99	8.47e-07	0.000109	-0.27	-0.22	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
THCA	cis	rs12554020	0.892	rs75678521	ENSG00000227603.1	RP11-165J3.6	4.99	8.48e-07	0.000109	0.34	0.22	Schizophrenia;	chr9:93600744	chr9:93435332~93437121:-
THCA	cis	rs5758659	0.652	rs133313	ENSG00000227370.1	RP4-669P10.19	-4.99	8.48e-07	0.000109	-0.21	-0.22	Cognitive function;	chr22:42005745	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.652	rs133314	ENSG00000227370.1	RP4-669P10.19	-4.99	8.48e-07	0.000109	-0.21	-0.22	Cognitive function;	chr22:42005837	chr22:42132543~42132998:+
THCA	cis	rs6708331	0.564	rs4632370	ENSG00000179818.12	PCBP1-AS1	-4.99	8.48e-07	0.000109	-0.18	-0.22	Obesity-related traits;	chr2:70149693	chr2:69962263~70103220:-
THCA	cis	rs6445975	0.715	rs13320332	ENSG00000272360.1	RP11-359I18.5	-4.99	8.48e-07	0.000109	-0.24	-0.22	Systemic lupus erythematosus;	chr3:58282617	chr3:58490830~58491291:-
THCA	cis	rs478304	0.934	rs1193496	ENSG00000214659.4	KRT8P26	4.99	8.48e-07	0.000109	0.19	0.22	Acne (severe);	chr11:65770085	chr11:65726939~65728214:+
THCA	cis	rs459482	0.587	rs469083	ENSG00000228318.3	AP001610.5	4.99	8.48e-07	0.000109	0.28	0.22	IgG glycosylation;	chr21:41436789	chr21:41441056~41445708:-
THCA	cis	rs919433	1	rs6741380	ENSG00000231621.1	AC013264.2	-4.99	8.49e-07	0.000109	-0.22	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197300397	chr2:197197991~197199273:+
THCA	cis	rs987724	0.613	rs1384538	ENSG00000240875.4	LINC00886	-4.99	8.49e-07	0.000109	-0.17	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156977820	chr3:156747346~156817062:-
THCA	cis	rs7637701	1	rs7637701	ENSG00000240875.4	LINC00886	-4.99	8.49e-07	0.000109	-0.18	-0.22	Breast cancer;	chr3:156927968	chr3:156747346~156817062:-
THCA	cis	rs7637701	0.967	rs9865905	ENSG00000240875.4	LINC00886	-4.99	8.49e-07	0.000109	-0.18	-0.22	Breast cancer;	chr3:156931805	chr3:156747346~156817062:-
THCA	cis	rs7637701	0.967	rs6784421	ENSG00000240875.4	LINC00886	-4.99	8.49e-07	0.000109	-0.18	-0.22	Breast cancer;	chr3:156937705	chr3:156747346~156817062:-
THCA	cis	rs9890032	0.542	rs35958868	ENSG00000266490.1	CTD-2349P21.9	4.99	8.5e-07	0.000109	0.23	0.22	Hip circumference adjusted for BMI;	chr17:30909727	chr17:30792372~30792833:+
THCA	cis	rs240993	0.812	rs9487626	ENSG00000271789.1	RP5-1112D6.7	-4.99	8.5e-07	0.000109	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111395665	chr6:111297126~111298510:+
THCA	cis	rs6832769	0.961	rs3805147	ENSG00000272969.1	RP11-528I4.2	4.99	8.5e-07	0.000109	0.26	0.22	Personality dimensions;	chr4:55440563	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs3736544	ENSG00000272969.1	RP11-528I4.2	4.99	8.5e-07	0.000109	0.26	0.22	Personality dimensions;	chr4:55443825	chr4:55547112~55547889:+
THCA	cis	rs2734839	0.964	rs1800498	ENSG00000270179.1	RP11-159N11.4	-4.99	8.5e-07	0.000109	-0.24	-0.22	Information processing speed;	chr11:113420866	chr11:113368478~113369117:+
THCA	cis	rs2734839	0.964	rs2234690	ENSG00000270179.1	RP11-159N11.4	-4.99	8.5e-07	0.000109	-0.24	-0.22	Information processing speed;	chr11:113421026	chr11:113368478~113369117:+
THCA	cis	rs2734839	0.964	rs2587548	ENSG00000270179.1	RP11-159N11.4	-4.99	8.5e-07	0.000109	-0.24	-0.22	Information processing speed;	chr11:113421490	chr11:113368478~113369117:+
THCA	cis	rs6598266	1	rs12908539	ENSG00000259363.4	CTD-2054N24.2	-4.99	8.5e-07	0.000109	-0.4	-0.22	Major depressive disorder;	chr15:99760063	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs12903765	ENSG00000259363.4	CTD-2054N24.2	-4.99	8.5e-07	0.000109	-0.4	-0.22	Major depressive disorder;	chr15:99760157	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs12904259	ENSG00000259363.4	CTD-2054N24.2	-4.99	8.5e-07	0.000109	-0.4	-0.22	Major depressive disorder;	chr15:99760401	chr15:99807023~99877148:+
THCA	cis	rs16976116	0.619	rs11071173	ENSG00000279145.1	RP11-547D13.1	-4.99	8.51e-07	0.00011	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55175360	chr15:55171972~55178175:-
THCA	cis	rs853679	0.824	rs34712084	ENSG00000220721.1	OR1F12	4.99	8.52e-07	0.00011	0.39	0.22	Depression;	chr6:28076050	chr6:28073316~28074233:+
THCA	cis	rs853679	0.824	rs1321505	ENSG00000220721.1	OR1F12	4.99	8.52e-07	0.00011	0.39	0.22	Depression;	chr6:28085045	chr6:28073316~28074233:+
THCA	cis	rs853679	0.882	rs9468287	ENSG00000220721.1	OR1F12	4.99	8.52e-07	0.00011	0.39	0.22	Depression;	chr6:28111963	chr6:28073316~28074233:+
THCA	cis	rs10875746	0.669	rs11168510	ENSG00000258234.1	RP11-370I10.2	4.99	8.52e-07	0.00011	0.26	0.22	Longevity (90 years and older);	chr12:48291772	chr12:48231098~48284210:-
THCA	cis	rs6686842	0.56	rs2802549	ENSG00000235358.1	RP11-399E6.1	4.99	8.52e-07	0.00011	0.29	0.22	Height;	chr1:41034874	chr1:41242373~41284861:+
THCA	cis	rs1914816	0.941	rs2938691	ENSG00000196274.5	Metazoa_SRP	4.99	8.52e-07	0.00011	0.32	0.22	Response to tocilizumab in rheumatoid arthritis;	chr15:76214865	chr15:76230048~76230390:-
THCA	cis	rs4073582	0.595	rs10896104	ENSG00000255320.1	RP11-755F10.1	-4.99	8.52e-07	0.00011	-0.28	-0.22	Gout;	chr11:66234398	chr11:66244840~66246239:-
THCA	cis	rs8067545	0.553	rs35254155	ENSG00000261033.1	RP11-209D14.2	-4.99	8.52e-07	0.00011	-0.32	-0.22	Schizophrenia;	chr17:20020320	chr17:20008051~20009234:-
THCA	cis	rs7246657	0.722	rs2972437	ENSG00000276846.1	CTD-3220F14.3	4.99	8.53e-07	0.00011	0.22	0.22	Coronary artery calcification;	chr19:37719610	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.639	rs3112434	ENSG00000276846.1	CTD-3220F14.3	-4.99	8.53e-07	0.00011	-0.23	-0.22	Coronary artery calcification;	chr19:37707247	chr19:37314868~37315620:-
THCA	cis	rs79349575	0.783	rs62075838	ENSG00000270781.1	RP11-501C14.9	-4.99	8.53e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48919070	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs62075839	ENSG00000270781.1	RP11-501C14.9	-4.99	8.53e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48919072	chr17:48899131~48899748:+
THCA	cis	rs858239	0.601	rs10224327	ENSG00000226816.2	AC005082.12	4.99	8.54e-07	0.00011	0.32	0.22	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23206013~23208045:+
THCA	cis	rs227275	0.554	rs223359	ENSG00000248971.2	KRT8P46	-4.99	8.54e-07	0.00011	-0.27	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102728746~102730171:-
THCA	cis	rs4713118	0.619	rs200486	ENSG00000280107.1	AL022393.9	-4.99	8.54e-07	0.00011	-0.28	-0.22	Parkinson's disease;	chr6:27811728	chr6:28170845~28172521:+
THCA	cis	rs9875589	0.509	rs4685061	ENSG00000228242.5	AC093495.4	4.99	8.54e-07	0.00011	0.13	0.22	Ovarian reserve;	chr3:14002323	chr3:14144637~14165978:+
THCA	cis	rs3950186	0.834	rs6941812	ENSG00000215124.2	RP3-420J14.1	4.99	8.54e-07	0.00011	0.26	0.22	Anxiety and major depressive disorder;	chr6:11806726	chr6:11861626~11862970:-
THCA	cis	rs3950186	0.834	rs6942235	ENSG00000215124.2	RP3-420J14.1	4.99	8.54e-07	0.00011	0.26	0.22	Anxiety and major depressive disorder;	chr6:11806996	chr6:11861626~11862970:-
THCA	cis	rs7674212	0.539	rs6821617	ENSG00000251288.2	RP11-10L12.2	-4.99	8.54e-07	0.00011	-0.29	-0.22	Type 2 diabetes;	chr4:103207253	chr4:102751401~102752641:+
THCA	cis	rs59918340	0.667	rs12544863	ENSG00000253307.1	RP11-10J21.4	-4.99	8.55e-07	0.00011	-0.32	-0.22	Immature fraction of reticulocytes;	chr8:141226958	chr8:141252286~141253292:-
THCA	cis	rs7208859	0.673	rs11654331	ENSG00000280069.1	CTD-2349P21.3	-4.99	8.55e-07	0.00011	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30738182~30740275:+
THCA	cis	rs595244	1	rs4775769	ENSG00000259705.1	RP11-227D13.1	-4.99	8.55e-07	0.00011	-0.46	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48647691	chr15:48645951~48652016:+
THCA	cis	rs4218	1	rs4218	ENSG00000259732.1	RP11-59H7.3	-4.99	8.55e-07	0.00011	-0.3	-0.22	Social communication problems;	chr15:59136459	chr15:59121034~59133250:+
THCA	cis	rs763121	0.853	rs5750677	ENSG00000235209.1	CTA-150C2.13	4.99	8.55e-07	0.00011	0.31	0.22	Menopause (age at onset);	chr22:38751710	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2072798	ENSG00000235209.1	CTA-150C2.13	4.99	8.55e-07	0.00011	0.31	0.22	Menopause (age at onset);	chr22:38752478	chr22:38921227~38924708:+
THCA	cis	rs4713118	0.869	rs9366700	ENSG00000226314.6	ZNF192P1	-4.99	8.56e-07	0.00011	-0.28	-0.22	Parkinson's disease;	chr6:27729172	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs6456802	ENSG00000226314.6	ZNF192P1	-4.99	8.56e-07	0.00011	-0.28	-0.22	Parkinson's disease;	chr6:27730576	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs9393851	ENSG00000226314.6	ZNF192P1	-4.99	8.56e-07	0.00011	-0.28	-0.22	Parkinson's disease;	chr6:27731802	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs9461400	ENSG00000226314.6	ZNF192P1	-4.99	8.56e-07	0.00011	-0.28	-0.22	Parkinson's disease;	chr6:27732780	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs9295742	ENSG00000226314.6	ZNF192P1	-4.99	8.56e-07	0.00011	-0.28	-0.22	Parkinson's disease;	chr6:27735053	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs9461401	ENSG00000226314.6	ZNF192P1	-4.99	8.56e-07	0.00011	-0.28	-0.22	Parkinson's disease;	chr6:27735512	chr6:28161781~28169594:+
THCA	cis	rs7119	0.717	rs11639293	ENSG00000259362.2	RP11-307C19.1	-4.99	8.56e-07	0.00011	-0.32	-0.22	Type 2 diabetes;	chr15:77518503	chr15:77525540~77534110:+
THCA	cis	rs8028182	0.549	rs7402293	ENSG00000260269.4	CTD-2323K18.1	4.99	8.56e-07	0.00011	0.33	0.22	Sudden cardiac arrest;	chr15:75343796	chr15:75527150~75601205:-
THCA	cis	rs2562456	0.833	rs4321312	ENSG00000268119.4	CTD-2561J22.5	4.99	8.56e-07	0.00011	0.32	0.22	Pain;	chr19:21336614	chr19:21444241~21463908:-
THCA	cis	rs6887276	0.538	rs35897671	ENSG00000245937.6	LINC01184	-4.99	8.57e-07	0.00011	-0.22	-0.22	Height;	chr5:128014053	chr5:127940426~128083172:-
THCA	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-4.99	8.57e-07	0.00011	-0.27	-0.22	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
THCA	cis	rs911555	0.755	rs8018400	ENSG00000244691.1	RPL10AP1	4.99	8.57e-07	0.00011	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103412119~103412761:-
THCA	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	4.99	8.57e-07	0.00011	0.25	0.22	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
THCA	cis	rs3796352	1	rs11717619	ENSG00000242142.1	SERBP1P3	-4.99	8.57e-07	0.00011	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52969163	chr3:53064283~53065091:-
THCA	cis	rs79349575	0.749	rs46521	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48911167	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.749	rs318093	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48911992	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.745	rs170319	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48914169	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs318090	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48914390	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.651	rs4378658	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48916008	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs12453374	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48917484	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs12453394	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48917608	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.811	rs12601072	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48920636	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.749	rs58838744	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48921540	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.811	rs60708039	ENSG00000270781.1	RP11-501C14.9	-4.99	8.57e-07	0.00011	-0.27	-0.22	Type 2 diabetes;	chr17:48922011	chr17:48899131~48899748:+
THCA	cis	rs11733284	1	rs13146880	ENSG00000259959.1	RP11-121C2.2	4.99	8.57e-07	0.00011	0.19	0.22	Gout;Renal underexcretion gout;	chr4:48029482	chr4:47840122~47844339:-
THCA	cis	rs1714507	0.533	rs1714516	ENSG00000272087.1	RP11-379F4.7	4.99	8.57e-07	0.00011	0.2	0.22	Subjective well-being;	chr3:158575835	chr3:158693120~158693768:-
THCA	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-4.99	8.57e-07	0.00011	-0.25	-0.22	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
THCA	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-4.99	8.57e-07	0.00011	-0.25	-0.22	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
THCA	cis	rs227275	0.556	rs223449	ENSG00000248971.2	KRT8P46	-4.99	8.57e-07	0.00011	-0.28	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102728746~102730171:-
THCA	cis	rs4713118	0.581	rs200504	ENSG00000280107.1	AL022393.9	-4.99	8.58e-07	0.00011	-0.28	-0.22	Parkinson's disease;	chr6:27818042	chr6:28170845~28172521:+
THCA	cis	rs4650994	0.593	rs6694406	ENSG00000273384.1	RP5-1098D14.1	-4.99	8.58e-07	0.00011	-0.3	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178562875	chr1:178651706~178652282:+
THCA	cis	rs10466239	0.73	rs12221341	ENSG00000230555.2	RP11-517P14.2	4.99	8.59e-07	0.00011	0.21	0.22	Telomere length;	chr10:43361882	chr10:43420738~43422100:+
THCA	cis	rs5015933	1	rs7357647	ENSG00000232630.1	PRPS1P2	-4.99	8.59e-07	0.00011	-0.15	-0.22	Body mass index;	chr9:125374554	chr9:125150653~125151589:+
THCA	cis	rs8007846	0.502	rs4073416	ENSG00000276116.2	FUT8-AS1	-4.99	8.59e-07	0.000111	-0.24	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr14:65792676	chr14:65411170~65412690:-
THCA	cis	rs972578	0.765	rs6519349	ENSG00000274717.1	RP1-47A17.1	-4.99	8.59e-07	0.000111	-0.23	-0.22	Mean platelet volume;	chr22:42900311	chr22:42791814~42794313:-
THCA	cis	rs2034650	0.563	rs12914710	ENSG00000223313.1	RNU6-516P	4.99	8.59e-07	0.000111	0.24	0.22	Interstitial lung disease;	chr15:40421650	chr15:40529570~40529673:+
THCA	cis	rs4415084	1	rs6861560	ENSG00000272335.1	RP11-53O19.3	-4.99	8.59e-07	0.000111	-0.18	-0.22	Breast cancer;	chr5:44708276	chr5:44826076~44828592:+
THCA	cis	rs34779708	0.931	rs4934533	ENSG00000271335.4	RP11-324I22.4	4.99	8.6e-07	0.000111	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35314552~35336401:-
THCA	cis	rs1334894	0.818	rs56313753	ENSG00000228559.1	RP3-340B19.3	-4.99	8.6e-07	0.000111	-0.41	-0.22	Coronary artery disease;	chr6:35540882	chr6:35544632~35545669:+
THCA	cis	rs911555	0.755	rs8014013	ENSG00000244691.1	RPL10AP1	4.99	8.6e-07	0.000111	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103412119~103412761:-
THCA	cis	rs240993	0.761	rs6920014	ENSG00000271789.1	RP5-1112D6.7	-4.99	8.6e-07	0.000111	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111385198	chr6:111297126~111298510:+
THCA	cis	rs853679	1	rs1936365	ENSG00000220721.1	OR1F12	-4.99	8.6e-07	0.000111	-0.35	-0.22	Depression;	chr6:28300675	chr6:28073316~28074233:+
THCA	cis	rs763121	0.785	rs5750646	ENSG00000273076.1	RP3-508I15.22	4.99	8.6e-07	0.000111	0.22	0.22	Menopause (age at onset);	chr22:38617825	chr22:38743495~38743910:+
THCA	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	4.99	8.6e-07	0.000111	0.22	0.22	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
THCA	cis	rs4604234	0.614	rs73479950	ENSG00000272129.1	RP11-250B2.6	-4.99	8.61e-07	0.000111	-0.54	-0.22	Cancer;	chr6:80167590	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.614	rs73479953	ENSG00000272129.1	RP11-250B2.6	-4.99	8.61e-07	0.000111	-0.54	-0.22	Cancer;	chr6:80167654	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.614	rs78131248	ENSG00000272129.1	RP11-250B2.6	-4.99	8.61e-07	0.000111	-0.54	-0.22	Cancer;	chr6:80176949	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.614	rs3805923	ENSG00000272129.1	RP11-250B2.6	-4.99	8.61e-07	0.000111	-0.54	-0.22	Cancer;	chr6:80177802	chr6:80355424~80356859:+
THCA	cis	rs7520050	0.778	rs3013597	ENSG00000234329.1	RP11-767N6.2	4.99	8.61e-07	0.000111	0.2	0.22	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45651039~45651826:-
THCA	cis	rs9677476	0.779	rs12612219	ENSG00000224376.1	AC017104.6	4.99	8.61e-07	0.000111	0.27	0.22	Food antigen IgG levels;	chr2:231242650	chr2:231388976~231394991:+
THCA	cis	rs9813712	0.595	rs12490957	ENSG00000253540.4	FAM86HP	4.99	8.61e-07	0.000111	0.24	0.22	Response to amphetamines;	chr3:130287851	chr3:130099092~130111472:-
THCA	cis	rs72615157	0.606	rs941288	ENSG00000078319.8	PMS2P1	-4.99	8.61e-07	0.000111	-0.29	-0.22	Lung function (FEV1/FVC);	chr7:100179185	chr7:100320992~100341908:-
THCA	cis	rs12906542	0.507	rs4395040	ENSG00000259792.1	RP11-114H24.6	-4.99	8.61e-07	0.000111	-0.31	-0.22	Breast cancer;	chr15:77990191	chr15:77993405~77995289:+
THCA	cis	rs2562456	0.833	rs11880624	ENSG00000268119.4	CTD-2561J22.5	4.99	8.61e-07	0.000111	0.32	0.22	Pain;	chr19:21341028	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62107547	ENSG00000268119.4	CTD-2561J22.5	4.99	8.61e-07	0.000111	0.32	0.22	Pain;	chr19:21341245	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs56187954	ENSG00000268119.4	CTD-2561J22.5	4.99	8.61e-07	0.000111	0.32	0.22	Pain;	chr19:21345258	chr19:21444241~21463908:-
THCA	cis	rs17767294	0.708	rs9380018	ENSG00000219392.1	RP1-265C24.5	-4.99	8.62e-07	0.000111	-0.52	-0.22	Parkinson's disease;	chr6:27772867	chr6:28115628~28116551:+
THCA	cis	rs4646450	0.891	rs2240384	ENSG00000244219.5	GS1-259H13.2	4.99	8.62e-07	0.000111	0.27	0.22	Blood metabolite levels;	chr7:99429421	chr7:99598066~99610813:+
THCA	cis	rs10256972	0.758	rs2280724	ENSG00000225146.1	AC073957.15	4.99	8.62e-07	0.000111	0.23	0.22	Endometriosis;Longevity;	chr7:1025084	chr7:1029025~1043891:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000273142.1	RP11-458F8.4	4.99	8.62e-07	0.000111	0.18	0.22	Calcium levels;	chr7:66026136	chr7:66902857~66906297:+
THCA	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	4.99	8.62e-07	0.000111	0.14	0.22	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
THCA	cis	rs8049040	1	rs8049040	ENSG00000260886.1	TAT-AS1	4.99	8.63e-07	0.000111	0.29	0.22	Blood protein levels;	chr16:71438801	chr16:71565789~71578187:+
THCA	cis	rs11671005	0.735	rs35652377	ENSG00000265272.2	RN7SL693P	4.99	8.63e-07	0.000111	0.31	0.22	Mean platelet volume;	chr19:58417833	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs3764532	ENSG00000265272.2	RN7SL693P	4.99	8.63e-07	0.000111	0.31	0.22	Mean platelet volume;	chr19:58417855	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs3088284	ENSG00000265272.2	RN7SL693P	4.99	8.63e-07	0.000111	0.31	0.22	Mean platelet volume;	chr19:58418060	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs12981649	ENSG00000265272.2	RN7SL693P	4.99	8.63e-07	0.000111	0.31	0.22	Mean platelet volume;	chr19:58418676	chr19:58490797~58491075:+
THCA	cis	rs340630	0.967	rs13126334	ENSG00000251411.1	RP11-397E7.4	4.99	8.63e-07	0.000111	0.21	0.22	Systemic lupus erythematosus;	chr4:86988738	chr4:86913266~86914817:-
THCA	cis	rs7951911	0.915	rs12791538	ENSG00000254427.1	RP11-430H10.1	4.99	8.63e-07	0.000111	0.43	0.22	IgG glycosylation;	chr11:45083915	chr11:45355371~45366121:+
THCA	cis	rs2734839	0.964	rs2734838	ENSG00000270179.1	RP11-159N11.4	-4.99	8.63e-07	0.000111	-0.24	-0.22	Information processing speed;	chr11:113415779	chr11:113368478~113369117:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000229886.1	RP5-1132H15.3	-4.99	8.64e-07	0.000111	-0.23	-0.22	Aortic root size;	chr7:66018255	chr7:66025126~66031544:-
THCA	cis	rs6772849	0.93	rs9873888	ENSG00000242551.2	POU5F1P6	-4.99	8.64e-07	0.000111	-0.29	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:128674735~128677005:-
THCA	cis	rs7646881	0.544	rs16847130	ENSG00000240207.5	RP11-379F4.4	-4.99	8.64e-07	0.000111	-0.32	-0.22	Tetralogy of Fallot;	chr3:158705785	chr3:158732263~158784070:+
THCA	cis	rs3892630	0.824	rs12976069	ENSG00000267567.1	CTD-2538C1.3	4.99	8.64e-07	0.000111	0.35	0.22	Red blood cell traits;	chr19:32789178	chr19:32718298~32719595:-
THCA	cis	rs11671005	0.735	rs11667591	ENSG00000265272.2	RN7SL693P	4.99	8.64e-07	0.000111	0.31	0.22	Mean platelet volume;	chr19:58426270	chr19:58490797~58491075:+
THCA	cis	rs667920	0.512	rs13065626	ENSG00000273486.1	RP11-731C17.2	-4.99	8.64e-07	0.000111	-0.29	-0.22	Coronary artery disease;	chr3:136575915	chr3:136837338~136839021:-
THCA	cis	rs3796352	1	rs13058817	ENSG00000242142.1	SERBP1P3	-4.99	8.64e-07	0.000111	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52990123	chr3:53064283~53065091:-
THCA	cis	rs3796352	0.892	rs35076015	ENSG00000242142.1	SERBP1P3	-4.99	8.64e-07	0.000111	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52992350	chr3:53064283~53065091:-
THCA	cis	rs3796352	0.881	rs34238610	ENSG00000242142.1	SERBP1P3	-4.99	8.64e-07	0.000111	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52992464	chr3:53064283~53065091:-
THCA	cis	rs651907	0.557	rs12629658	ENSG00000244119.1	PDCL3P4	4.99	8.64e-07	0.000111	0.2	0.22	Colorectal cancer;	chr3:101637691	chr3:101712472~101713191:+
THCA	cis	rs2243480	1	rs73142162	ENSG00000164669.11	INTS4P1	4.99	8.65e-07	0.000111	0.44	0.22	Diabetic kidney disease;	chr7:65909309	chr7:65141225~65234216:+
THCA	cis	rs7119	0.623	rs12905318	ENSG00000259362.2	RP11-307C19.1	-4.99	8.65e-07	0.000111	-0.32	-0.22	Type 2 diabetes;	chr15:77553531	chr15:77525540~77534110:+
THCA	cis	rs7119	0.651	rs12904200	ENSG00000259362.2	RP11-307C19.1	-4.99	8.65e-07	0.000111	-0.32	-0.22	Type 2 diabetes;	chr15:77553560	chr15:77525540~77534110:+
THCA	cis	rs7119	0.651	rs12904208	ENSG00000259362.2	RP11-307C19.1	-4.99	8.65e-07	0.000111	-0.32	-0.22	Type 2 diabetes;	chr15:77553569	chr15:77525540~77534110:+
THCA	cis	rs7119	0.651	rs12905044	ENSG00000259362.2	RP11-307C19.1	-4.99	8.65e-07	0.000111	-0.32	-0.22	Type 2 diabetes;	chr15:77553873	chr15:77525540~77534110:+
THCA	cis	rs7119	0.623	rs11637932	ENSG00000259362.2	RP11-307C19.1	-4.99	8.65e-07	0.000111	-0.32	-0.22	Type 2 diabetes;	chr15:77555011	chr15:77525540~77534110:+
THCA	cis	rs7119	0.651	rs12915057	ENSG00000259362.2	RP11-307C19.1	-4.99	8.65e-07	0.000111	-0.32	-0.22	Type 2 diabetes;	chr15:77555403	chr15:77525540~77534110:+
THCA	cis	rs7119	0.651	rs35657172	ENSG00000259362.2	RP11-307C19.1	-4.99	8.65e-07	0.000111	-0.32	-0.22	Type 2 diabetes;	chr15:77555471	chr15:77525540~77534110:+
THCA	cis	rs7119	0.651	rs34607443	ENSG00000259362.2	RP11-307C19.1	-4.99	8.65e-07	0.000111	-0.32	-0.22	Type 2 diabetes;	chr15:77555550	chr15:77525540~77534110:+
THCA	cis	rs7731390	0.681	rs60934439	ENSG00000233006.5	AC034220.3	4.99	8.65e-07	0.000111	0.3	0.22	IgG glycosylation;	chr5:132304150	chr5:132311285~132369916:-
THCA	cis	rs6545883	0.894	rs6739427	ENSG00000270820.4	RP11-355B11.2	-4.99	8.65e-07	0.000111	-0.19	-0.22	Tuberculosis;	chr2:61225744	chr2:61471188~61484130:+
THCA	cis	rs6430585	0.759	rs4954623	ENSG00000231890.6	DARS-AS1	4.99	8.65e-07	0.000111	0.27	0.22	Corneal structure;	chr2:135778306	chr2:135985176~136022593:+
THCA	cis	rs6997458	0.785	rs6996345	ENSG00000253549.4	RP11-317J10.2	4.99	8.65e-07	0.000111	0.22	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85418846	chr8:85441851~85464915:-
THCA	cis	rs2797160	1	rs1777222	ENSG00000237742.5	RP11-624M8.1	4.99	8.65e-07	0.000111	0.19	0.22	Endometrial cancer;	chr6:125699884	chr6:125578558~125749190:-
THCA	cis	rs1150668	0.796	rs2531825	ENSG00000273712.1	RP5-874C20.7	4.99	8.65e-07	0.000111	0.24	0.22	Pubertal anthropometrics;	chr6:28381487	chr6:28315613~28315883:-
THCA	cis	rs8062405	0.895	rs62036658	ENSG00000278665.1	RP11-666O2.4	4.99	8.65e-07	0.000111	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28599241~28601881:-
THCA	cis	rs9863	0.861	rs7312404	ENSG00000269997.1	RP11-214K3.21	-4.99	8.65e-07	0.000111	-0.27	-0.22	White blood cell count;	chr12:123962181	chr12:123966077~123966629:-
THCA	cis	rs9863	0.827	rs7134121	ENSG00000269997.1	RP11-214K3.21	-4.99	8.65e-07	0.000111	-0.27	-0.22	White blood cell count;	chr12:123962799	chr12:123966077~123966629:-
THCA	cis	rs8022179	0.58	rs8013228	ENSG00000244691.1	RPL10AP1	-4.99	8.66e-07	0.000111	-0.32	-0.22	Monocyte count;	chr14:103376313	chr14:103412119~103412761:-
THCA	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	4.99	8.66e-07	0.000111	0.26	0.22	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	4.99	8.66e-07	0.000111	0.26	0.22	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	4.99	8.66e-07	0.000111	0.26	0.22	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	4.99	8.66e-07	0.000111	0.26	0.22	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	4.99	8.66e-07	0.000111	0.26	0.22	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	4.99	8.66e-07	0.000111	0.26	0.22	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	4.99	8.66e-07	0.000111	0.26	0.22	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
THCA	cis	rs73242632	1	rs10002090	ENSG00000269949.1	RP11-738E22.3	4.99	8.66e-07	0.000111	0.52	0.22	Congenital heart disease (maternal effect);	chr4:56993426	chr4:56960927~56961373:-
THCA	cis	rs73242632	0.881	rs10034395	ENSG00000269949.1	RP11-738E22.3	4.99	8.66e-07	0.000111	0.52	0.22	Congenital heart disease (maternal effect);	chr4:56996965	chr4:56960927~56961373:-
THCA	cis	rs752010	0.619	rs4393146	ENSG00000230638.4	RP11-486B10.4	-4.99	8.66e-07	0.000111	-0.28	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41653095	chr1:41542069~41544310:+
THCA	cis	rs2243480	1	rs34815098	ENSG00000164669.11	INTS4P1	4.99	8.66e-07	0.000111	0.43	0.22	Diabetic kidney disease;	chr7:65827267	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs35735127	ENSG00000164669.11	INTS4P1	4.99	8.66e-07	0.000111	0.43	0.22	Diabetic kidney disease;	chr7:65835436	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.901	rs35256305	ENSG00000164669.11	INTS4P1	4.99	8.66e-07	0.000111	0.43	0.22	Diabetic kidney disease;	chr7:65841418	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.803	rs34004500	ENSG00000164669.11	INTS4P1	4.99	8.66e-07	0.000111	0.43	0.22	Diabetic kidney disease;	chr7:65847191	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs35825738	ENSG00000164669.11	INTS4P1	4.99	8.66e-07	0.000111	0.43	0.22	Diabetic kidney disease;	chr7:65853040	chr7:65141225~65234216:+
THCA	cis	rs7727544	0.661	rs273900	ENSG00000263597.1	MIR3936	4.99	8.66e-07	0.000111	0.21	0.22	Blood metabolite levels;	chr5:132358913	chr5:132365490~132365599:-
THCA	cis	rs1048886	0.872	rs9455160	ENSG00000271967.1	RP11-134K13.4	4.99	8.66e-07	0.000111	0.22	0.22	Type 2 diabetes;	chr6:70564116	chr6:70596438~70596980:+
THCA	cis	rs7267979	0.816	rs6076358	ENSG00000125804.12	FAM182A	4.99	8.67e-07	0.000111	0.27	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26054655~26086917:+
THCA	cis	rs4915077	1	rs17020127	ENSG00000230489.1	VAV3-AS1	4.99	8.67e-07	0.000111	0.37	0.22	Hypothyroidism;	chr1:107815461	chr1:107964443~107994607:+
THCA	cis	rs8177876	0.686	rs804897	ENSG00000261838.4	RP11-303E16.6	-4.99	8.67e-07	0.000111	-0.38	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067590	chr16:81069854~81076598:+
THCA	cis	rs60695258	0.512	rs2053770	ENSG00000251411.1	RP11-397E7.4	4.99	8.67e-07	0.000111	0.21	0.22	Hematocrit;	chr4:86986933	chr4:86913266~86914817:-
THCA	cis	rs9813712	0.571	rs9866568	ENSG00000249846.5	RP11-77P16.4	-4.99	8.67e-07	0.000111	-0.23	-0.22	Response to amphetamines;	chr3:130297539	chr3:130112550~130120579:+
THCA	cis	rs919433	0.889	rs10931782	ENSG00000231621.1	AC013264.2	4.99	8.67e-07	0.000111	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197346855	chr2:197197991~197199273:+
THCA	cis	rs3820928	0.874	rs1949807	ENSG00000212391.1	SNORA48	-4.99	8.67e-07	0.000111	-0.25	-0.22	Pulmonary function;	chr2:227027145	chr2:226968989~226969122:-
THCA	cis	rs919433	0.713	rs10178946	ENSG00000231621.1	AC013264.2	-4.99	8.67e-07	0.000111	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197598366	chr2:197197991~197199273:+
THCA	cis	rs763121	0.853	rs6001175	ENSG00000273076.1	RP3-508I15.22	4.99	8.67e-07	0.000111	0.22	0.22	Menopause (age at onset);	chr22:38622329	chr22:38743495~38743910:+
THCA	cis	rs354225	0.546	rs10170646	ENSG00000237887.1	AC092839.1	-4.99	8.67e-07	0.000112	-0.26	-0.22	Schizophrenia;	chr2:54572469	chr2:54529343~54529801:+
THCA	cis	rs7702057	0.53	rs4921060	ENSG00000272265.1	CTD-2287O16.4	4.99	8.68e-07	0.000112	0.42	0.22	Amyotrophic lateral sclerosis;	chr5:116109004	chr5:116078110~116078570:-
THCA	cis	rs4819052	0.851	rs2236444	ENSG00000273796.1	LL21NC02-21A1.1	-4.99	8.68e-07	0.000112	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45403809~45404369:-
THCA	cis	rs7208859	0.623	rs609063	ENSG00000280069.1	CTD-2349P21.3	-4.99	8.68e-07	0.000112	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs383436	ENSG00000280069.1	CTD-2349P21.3	-4.99	8.68e-07	0.000112	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000280069.1	CTD-2349P21.3	-4.99	8.68e-07	0.000112	-0.34	-0.22	Body mass index;	chr17:30641132	chr17:30738182~30740275:+
THCA	cis	rs651907	0.535	rs36060163	ENSG00000244119.1	PDCL3P4	4.99	8.68e-07	0.000112	0.21	0.22	Colorectal cancer;	chr3:101642119	chr3:101712472~101713191:+
THCA	cis	rs6866614	0.608	rs17132288	ENSG00000233006.5	AC034220.3	4.99	8.68e-07	0.000112	0.18	0.22	Perceived unattractiveness to mosquitoes;	chr5:132000412	chr5:132311285~132369916:-
THCA	cis	rs9875589	0.509	rs56071023	ENSG00000228242.5	AC093495.4	4.99	8.68e-07	0.000112	0.13	0.22	Ovarian reserve;	chr3:14034420	chr3:14144637~14165978:+
THCA	cis	rs1714507	0.533	rs1435642	ENSG00000272087.1	RP11-379F4.7	-4.99	8.68e-07	0.000112	-0.2	-0.22	Subjective well-being;	chr3:158582432	chr3:158693120~158693768:-
THCA	cis	rs796395	0.905	rs10047116	ENSG00000228208.5	C1orf143	4.99	8.69e-07	0.000112	0.27	0.22	Post bronchodilator FEV1/FVC ratio;	chr1:218464949	chr1:218510096~218525978:+
THCA	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-4.99	8.69e-07	0.000112	-0.25	-0.22	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
THCA	cis	rs8141529	0.748	rs7287918	ENSG00000272858.1	CTA-292E10.8	-4.99	8.69e-07	0.000112	-0.23	-0.22	Lymphocyte counts;	chr22:28885722	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.748	rs1318025	ENSG00000272858.1	CTA-292E10.8	-4.99	8.69e-07	0.000112	-0.23	-0.22	Lymphocyte counts;	chr22:28887769	chr22:28814914~28815662:+
THCA	cis	rs9388451	0.839	rs9321054	ENSG00000226409.1	RP11-735G4.1	4.99	8.69e-07	0.000112	0.27	0.22	Brugada syndrome;	chr6:125758822	chr6:125370211~125374324:-
THCA	cis	rs3820928	0.874	rs7594505	ENSG00000212391.1	SNORA48	-4.99	8.69e-07	0.000112	-0.24	-0.22	Pulmonary function;	chr2:227013846	chr2:226968989~226969122:-
THCA	cis	rs2847297	1	rs2847297	ENSG00000260302.1	RP11-973H7.1	4.99	8.69e-07	0.000112	0.28	0.22	Rheumatoid arthritis;	chr18:12797695	chr18:12774651~12775923:-
THCA	cis	rs4648045	0.861	rs230532	ENSG00000246560.2	RP11-10L12.4	-4.99	8.7e-07	0.000112	-0.28	-0.22	Lymphocyte percentage of white cells;	chr4:102529010	chr4:102828055~102844075:+
THCA	cis	rs13434995	0.513	rs17776975	ENSG00000273257.1	RP11-177J6.1	-4.99	8.7e-07	0.000112	-0.33	-0.22	Adiponectin levels;	chr4:55410728	chr4:55387949~55388271:+
THCA	cis	rs8033133	0.881	rs8031260	ENSG00000251896.1	SNORD116-27	-4.99	8.7e-07	0.000112	-0.26	-0.22	Blood osmolality (transformed sodium);	chr15:25071684	chr15:25101575~25101666:+
THCA	cis	rs227275	0.555	rs223403	ENSG00000248971.2	KRT8P46	-4.99	8.7e-07	0.000112	-0.28	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102728746~102730171:-
THCA	cis	rs227275	0.555	rs223402	ENSG00000248971.2	KRT8P46	-4.99	8.7e-07	0.000112	-0.28	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102728746~102730171:-
THCA	cis	rs62184315	0.638	rs12475694	ENSG00000253559.1	OSGEPL1-AS1	4.99	8.71e-07	0.000112	0.25	0.22	Alcohol dependence (age at onset);	chr2:189907882	chr2:189762704~189765556:+
THCA	cis	rs957448	1	rs12678305	ENSG00000253175.1	RP11-267M23.6	4.99	8.71e-07	0.000112	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94565036~94565715:+
THCA	cis	rs8103278	0.507	rs16939	ENSG00000267395.4	AC074212.6	-4.99	8.71e-07	0.000112	-0.15	-0.22	Coronary artery disease;	chr19:45772798	chr19:45767796~45772504:+
THCA	cis	rs5758511	0.633	rs5758689	ENSG00000281538.1	RP4-669P10.20	-4.99	8.71e-07	0.000112	-0.25	-0.22	Birth weight;	chr22:42268966	chr22:42138060~42139726:+
THCA	cis	rs763121	0.853	rs10135	ENSG00000235209.1	CTA-150C2.13	-4.99	8.71e-07	0.000112	-0.3	-0.22	Menopause (age at onset);	chr22:38686169	chr22:38921227~38924708:+
THCA	cis	rs4578769	0.55	rs9949333	ENSG00000265939.1	UBE2CP2	4.99	8.71e-07	0.000112	0.26	0.22	Eosinophil percentage of white cells;	chr18:22815080	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs9962620	ENSG00000265939.1	UBE2CP2	4.99	8.71e-07	0.000112	0.26	0.22	Eosinophil percentage of white cells;	chr18:22815811	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs4800433	ENSG00000265939.1	UBE2CP2	4.99	8.71e-07	0.000112	0.26	0.22	Eosinophil percentage of white cells;	chr18:22816691	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs11082155	ENSG00000265939.1	UBE2CP2	4.99	8.71e-07	0.000112	0.26	0.22	Eosinophil percentage of white cells;	chr18:22824527	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs4289091	ENSG00000265939.1	UBE2CP2	4.99	8.71e-07	0.000112	0.26	0.22	Eosinophil percentage of white cells;	chr18:22825856	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.589	rs12606787	ENSG00000265939.1	UBE2CP2	4.99	8.71e-07	0.000112	0.26	0.22	Eosinophil percentage of white cells;	chr18:22830392	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs12956367	ENSG00000265939.1	UBE2CP2	4.99	8.71e-07	0.000112	0.26	0.22	Eosinophil percentage of white cells;	chr18:22833742	chr18:22900486~22900995:-
THCA	cis	rs6545883	0.826	rs777590	ENSG00000270820.4	RP11-355B11.2	4.99	8.71e-07	0.000112	0.18	0.22	Tuberculosis;	chr2:61190010	chr2:61471188~61484130:+
THCA	cis	rs1395	1	rs1141313	ENSG00000234072.1	AC074117.10	-4.99	8.71e-07	0.000112	-0.18	-0.22	Blood metabolite levels;	chr2:27238100	chr2:27356246~27367622:+
THCA	cis	rs8046148	0.666	rs10852606	ENSG00000279356.1	RP11-429P3.8	4.99	8.71e-07	0.000112	0.26	0.22	Testicular germ cell tumor;	chr16:50094961	chr16:50072862~50074986:+
THCA	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-4.99	8.72e-07	0.000112	-0.27	-0.22	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
THCA	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-4.99	8.72e-07	0.000112	-0.31	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
THCA	cis	rs17826219	0.733	rs7221691	ENSG00000263603.1	CTD-2349P21.5	4.99	8.72e-07	0.000112	0.39	0.22	Body mass index;	chr17:30396601	chr17:30729469~30731202:+
THCA	cis	rs16846053	0.792	rs62187704	ENSG00000227403.1	AC009299.3	4.99	8.72e-07	0.000112	0.52	0.22	Blood osmolality (transformed sodium);	chr2:161829817	chr2:161244739~161249050:+
THCA	cis	rs228614	0.51	rs223435	ENSG00000248971.2	KRT8P46	-4.99	8.72e-07	0.000112	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223434	ENSG00000248971.2	KRT8P46	-4.99	8.72e-07	0.000112	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102728746~102730171:-
THCA	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	4.99	8.72e-07	0.000112	0.29	0.22	Depression;	chr6:28303421	chr6:28943877~28944537:+
THCA	cis	rs9973361	0.513	rs13399960	ENSG00000232411.1	AC009495.3	-4.99	8.72e-07	0.000112	-0.27	-0.22	Total body bone mineral density;	chr2:165842209	chr2:165833048~165839098:-
THCA	cis	rs5758659	0.652	rs129857	ENSG00000227370.1	RP4-669P10.19	4.99	8.72e-07	0.000112	0.21	0.22	Cognitive function;	chr22:42003682	chr22:42132543~42132998:+
THCA	cis	rs3764400	0.506	rs72827851	ENSG00000278765.1	RP5-890E16.5	4.99	8.73e-07	0.000112	0.43	0.22	Body mass index;	chr17:48375133	chr17:48066704~48067293:-
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000230295.1	RP11-458F8.2	-4.99	8.73e-07	0.000112	-0.28	-0.22	Diabetic kidney disease;	chr7:66474549	chr7:66880708~66882981:+
THCA	cis	rs8046148	0.724	rs2080504	ENSG00000279356.1	RP11-429P3.8	4.99	8.73e-07	0.000112	0.26	0.22	Testicular germ cell tumor;	chr16:50085259	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.789	rs2005402	ENSG00000279356.1	RP11-429P3.8	4.99	8.73e-07	0.000112	0.26	0.22	Testicular germ cell tumor;	chr16:50086757	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs2356835	ENSG00000279356.1	RP11-429P3.8	4.99	8.73e-07	0.000112	0.26	0.22	Testicular germ cell tumor;	chr16:50086956	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs2356836	ENSG00000279356.1	RP11-429P3.8	4.99	8.73e-07	0.000112	0.26	0.22	Testicular germ cell tumor;	chr16:50086958	chr16:50072862~50074986:+
THCA	cis	rs10852606	0.685	rs2356838	ENSG00000279356.1	RP11-429P3.8	4.99	8.73e-07	0.000112	0.26	0.22	Glioma;Glioblastoma;	chr16:50087072	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs8057524	ENSG00000279356.1	RP11-429P3.8	4.99	8.73e-07	0.000112	0.26	0.22	Testicular germ cell tumor;	chr16:50089035	chr16:50072862~50074986:+
THCA	cis	rs4308124	1	rs56830046	ENSG00000227992.1	AC108463.2	-4.98	8.73e-07	0.000112	-0.28	-0.22	Vitiligo;	chr2:111252513	chr2:111203964~111206215:-
THCA	cis	rs6545883	0.859	rs13004855	ENSG00000270820.4	RP11-355B11.2	-4.98	8.74e-07	0.000112	-0.19	-0.22	Tuberculosis;	chr2:61277937	chr2:61471188~61484130:+
THCA	cis	rs17767392	0.67	rs11845249	ENSG00000259146.3	RP1-261D10.2	4.98	8.74e-07	0.000112	0.28	0.22	Mitral valve prolapse;	chr14:71256520	chr14:71292729~71321814:-
THCA	cis	rs11846409	0.872	rs74091715	ENSG00000274576.2	IGHV2-70	-4.98	8.74e-07	0.000112	-0.19	-0.22	Rheumatic heart disease;	chr14:106637731	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs74091721	ENSG00000274576.2	IGHV2-70	-4.98	8.74e-07	0.000112	-0.19	-0.22	Rheumatic heart disease;	chr14:106638262	chr14:106770577~106771020:-
THCA	cis	rs73242632	1	rs73242625	ENSG00000269949.1	RP11-738E22.3	4.98	8.74e-07	0.000112	0.52	0.22	Congenital heart disease (maternal effect);	chr4:56990173	chr4:56960927~56961373:-
THCA	cis	rs5758659	0.652	rs133321	ENSG00000227370.1	RP4-669P10.19	-4.98	8.74e-07	0.000112	-0.21	-0.22	Cognitive function;	chr22:42009318	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.652	rs133323	ENSG00000227370.1	RP4-669P10.19	-4.98	8.74e-07	0.000112	-0.21	-0.22	Cognitive function;	chr22:42009918	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.652	rs133327	ENSG00000227370.1	RP4-669P10.19	-4.98	8.74e-07	0.000112	-0.21	-0.22	Cognitive function;	chr22:42011685	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.652	rs133330	ENSG00000227370.1	RP4-669P10.19	-4.98	8.74e-07	0.000112	-0.21	-0.22	Cognitive function;	chr22:42013452	chr22:42132543~42132998:+
THCA	cis	rs9959145	1	rs17595746	ENSG00000267108.1	RP11-861E21.1	4.98	8.74e-07	0.000112	0.28	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12707859	chr18:12432897~12437635:+
THCA	cis	rs12893668	0.572	rs11846404	ENSG00000269958.1	RP11-73M18.8	4.98	8.74e-07	0.000112	0.21	0.22	Reticulocyte count;	chr14:103689771	chr14:103696353~103697163:+
THCA	cis	rs6479874	0.92	rs7893612	ENSG00000223502.1	RP11-96B5.3	-4.98	8.74e-07	0.000112	-0.27	-0.22	Migraine;	chr10:51001698	chr10:51062579~51068553:-
THCA	cis	rs6479874	1	rs6479841	ENSG00000223502.1	RP11-96B5.3	-4.98	8.74e-07	0.000112	-0.27	-0.22	Migraine;	chr10:51002206	chr10:51062579~51068553:-
THCA	cis	rs7429990	0.965	rs184388	ENSG00000228638.1	FCF1P2	-4.98	8.74e-07	0.000112	-0.23	-0.22	Educational attainment (years of education);	chr3:47898136	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs319696	ENSG00000228638.1	FCF1P2	-4.98	8.74e-07	0.000112	-0.23	-0.22	Educational attainment (years of education);	chr3:47902371	chr3:48290793~48291375:-
THCA	cis	rs12681288	0.676	rs935819	ENSG00000260721.1	AF067845.1	4.98	8.75e-07	0.000112	0.28	0.22	Schizophrenia;	chr8:1071814	chr8:1368642~1369833:-
THCA	cis	rs224278	0.966	rs224294	ENSG00000238280.1	RP11-436D10.3	4.98	8.75e-07	0.000112	0.26	0.22	Ewing sarcoma;	chr10:62830107	chr10:62793562~62805887:-
THCA	cis	rs143626010	1	rs143626010	ENSG00000261766.1	RP11-22P6.2	-4.98	8.75e-07	0.000112	-0.22	-0.22	Mosquito bite size;	chr16:28528081	chr16:28862166~28863340:-
THCA	cis	rs6973609	0.524	rs11772625	ENSG00000271122.1	RP11-379H18.1	-4.98	8.75e-07	0.000112	-0.14	-0.22	Obesity-related traits;	chr7:35601941	chr7:35695214~35699413:+
THCA	cis	rs6547741	1	rs4666009	ENSG00000234072.1	AC074117.10	4.98	8.75e-07	0.000112	0.17	0.22	Oral cavity cancer;	chr2:27635125	chr2:27356246~27367622:+
THCA	cis	rs13178541	0.81	rs4976465	ENSG00000250378.1	RP11-119J18.1	-4.98	8.75e-07	0.000112	-0.28	-0.22	IgG glycosylation;	chr5:135815226	chr5:135812667~135826582:+
THCA	cis	rs1005277	0.691	rs2474558	ENSG00000275858.1	RP11-291L22.8	-4.98	8.75e-07	0.000112	-0.27	-0.22	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38450738~38451069:-
THCA	cis	rs875971	0.545	rs4718325	ENSG00000232546.1	RP11-458F8.1	4.98	8.75e-07	0.000112	0.22	0.22	Aortic root size;	chr7:66215323	chr7:66848496~66858136:+
THCA	cis	rs911555	0.574	rs34251103	ENSG00000244691.1	RPL10AP1	4.98	8.75e-07	0.000112	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103412119~103412761:-
THCA	cis	rs7267979	0.816	rs376742	ENSG00000125804.12	FAM182A	-4.98	8.76e-07	0.000112	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26054655~26086917:+
THCA	cis	rs7809615	0.901	rs6947826	ENSG00000244219.5	GS1-259H13.2	-4.98	8.76e-07	0.000112	-0.4	-0.22	Blood metabolite ratios;	chr7:99558897	chr7:99598066~99610813:+
THCA	cis	rs16975963	0.644	rs73031322	ENSG00000226686.6	LINC01535	-4.98	8.76e-07	0.000113	-0.3	-0.22	Longevity;	chr19:37549977	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.644	rs73031326	ENSG00000226686.6	LINC01535	-4.98	8.76e-07	0.000113	-0.3	-0.22	Longevity;	chr19:37552120	chr19:37251912~37265535:+
THCA	cis	rs34792	0.678	rs153787	ENSG00000207425.1	Y_RNA	4.98	8.76e-07	0.000113	0.24	0.22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499916	chr16:14915457~14915556:-
THCA	cis	rs10411161	0.752	rs8107388	ENSG00000275055.1	CTC-471J1.11	-4.98	8.77e-07	0.000113	-0.23	-0.22	Breast cancer;	chr19:51904033	chr19:52049007~52049754:+
THCA	cis	rs6479901	0.588	rs10740105	ENSG00000232075.1	MRPL35P2	-4.98	8.77e-07	0.000113	-0.34	-0.22	Intelligence (multi-trait analysis);	chr10:63129957	chr10:63634317~63634827:-
THCA	cis	rs6723108	0.738	rs6430538	ENSG00000224043.6	CCNT2-AS1	4.98	8.77e-07	0.000113	0.25	0.22	Type 2 diabetes;	chr2:134782397	chr2:134735464~134918710:-
THCA	cis	rs752010	0.574	rs6671999	ENSG00000230638.4	RP11-486B10.4	-4.98	8.77e-07	0.000113	-0.25	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41654745	chr1:41542069~41544310:+
THCA	cis	rs4646450	0.838	rs1589739	ENSG00000244219.5	GS1-259H13.2	-4.98	8.78e-07	0.000113	-0.27	-0.22	Blood metabolite levels;	chr7:99588124	chr7:99598066~99610813:+
THCA	cis	rs5758659	0.652	rs133324	ENSG00000227370.1	RP4-669P10.19	-4.98	8.78e-07	0.000113	-0.21	-0.22	Cognitive function;	chr22:42010367	chr22:42132543~42132998:+
THCA	cis	rs8031584	0.541	rs2955797	ENSG00000270015.1	RP11-540B6.6	4.98	8.78e-07	0.000113	0.16	0.22	Huntington's disease progression;	chr15:30918778	chr15:30926514~30928407:+
THCA	cis	rs9890032	0.532	rs1808257	ENSG00000263603.1	CTD-2349P21.5	-4.98	8.78e-07	0.000113	-0.28	-0.22	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30729469~30731202:+
THCA	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-4.98	8.78e-07	0.000113	-0.35	-0.22	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
THCA	cis	rs1005277	0.563	rs2505215	ENSG00000272983.1	RP11-508N22.12	4.98	8.78e-07	0.000113	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.563	rs2505216	ENSG00000272983.1	RP11-508N22.12	4.98	8.78e-07	0.000113	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2749612	ENSG00000272983.1	RP11-508N22.12	4.98	8.78e-07	0.000113	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38137337~38144399:+
THCA	cis	rs7688540	0.8	rs10028482	ENSG00000275426.1	CH17-262A2.1	4.98	8.78e-07	0.000113	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:149738~150317:+
THCA	cis	rs5751614	0.557	rs16802	ENSG00000230701.2	FBXW4P1	-4.98	8.79e-07	0.000113	-0.25	-0.22	Height;	chr22:23290326	chr22:23262767~23265005:+
THCA	cis	rs972578	0.521	rs2413725	ENSG00000274717.1	RP1-47A17.1	-4.98	8.79e-07	0.000113	-0.24	-0.22	Mean platelet volume;	chr22:42806333	chr22:42791814~42794313:-
THCA	cis	rs2034650	0.525	rs11790	ENSG00000223313.1	RNU6-516P	4.98	8.79e-07	0.000113	0.24	0.22	Interstitial lung disease;	chr15:40420538	chr15:40529570~40529673:+
THCA	cis	rs7005380	0.733	rs9987332	ENSG00000245330.4	KB-1471A8.1	-4.98	8.79e-07	0.000113	-0.22	-0.22	Interstitial lung disease;	chr8:119921723	chr8:119867419~119874488:-
THCA	cis	rs6772849	0.93	rs4857912	ENSG00000242551.2	POU5F1P6	-4.98	8.79e-07	0.000113	-0.28	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128610381	chr3:128674735~128677005:-
THCA	cis	rs12823128	0.766	rs7978980	ENSG00000256185.1	RP11-612B6.2	4.98	8.79e-07	0.000113	0.21	0.22	Birth weight;	chr12:26762524	chr12:26335864~26336950:-
THCA	cis	rs2797160	1	rs1935772	ENSG00000237742.5	RP11-624M8.1	-4.98	8.79e-07	0.000113	-0.19	-0.22	Endometrial cancer;	chr6:125673562	chr6:125578558~125749190:-
THCA	cis	rs7141336	0.791	rs2180773	ENSG00000258884.1	CTD-3035D6.2	4.98	8.8e-07	0.000113	0.3	0.22	Anxiety disorder;	chr14:90747882	chr14:90822365~90828128:-
THCA	cis	rs10895275	0.851	rs11225163	ENSG00000277459.1	RP11-732A21.3	-4.98	8.8e-07	0.000113	-0.18	-0.22	Migraine;	chr11:102200112	chr11:102109827~102110457:-
THCA	cis	rs34779708	0.966	rs4934539	ENSG00000271335.4	RP11-324I22.4	4.98	8.8e-07	0.000113	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35314552~35336401:-
THCA	cis	rs3764400	0.508	rs1473117	ENSG00000278765.1	RP5-890E16.5	4.98	8.8e-07	0.000113	0.42	0.22	Body mass index;	chr17:48015173	chr17:48066704~48067293:-
THCA	cis	rs3820928	0.874	rs2229813	ENSG00000212391.1	SNORA48	-4.98	8.8e-07	0.000113	-0.25	-0.22	Pulmonary function;	chr2:227028004	chr2:226968989~226969122:-
THCA	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	4.98	8.8e-07	0.000113	0.33	0.22	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
THCA	cis	rs227275	0.556	rs223426	ENSG00000248971.2	KRT8P46	-4.98	8.8e-07	0.000113	-0.28	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223425	ENSG00000248971.2	KRT8P46	-4.98	8.8e-07	0.000113	-0.28	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102728746~102730171:-
THCA	cis	rs228614	0.536	rs223418	ENSG00000248971.2	KRT8P46	-4.98	8.8e-07	0.000113	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102728746~102730171:-
THCA	cis	rs875971	0.522	rs2949690	ENSG00000223473.2	GS1-124K5.3	-4.98	8.81e-07	0.000113	-0.15	-0.22	Aortic root size;	chr7:66018255	chr7:66491049~66493566:-
THCA	cis	rs2708377	0.858	rs68045377	ENSG00000212125.2	TAS2R15P	4.98	8.81e-07	0.000113	0.35	0.22	Bitter taste perception;	chr12:11141853	chr12:10964425~10965352:-
THCA	cis	rs3750965	0.92	rs10896420	ENSG00000260895.1	RP11-554A11.7	4.98	8.81e-07	0.000113	0.3	0.22	Hair color;	chr11:69095579	chr11:69103493~69109094:+
THCA	cis	rs3750965	0.92	rs10896421	ENSG00000260895.1	RP11-554A11.7	4.98	8.81e-07	0.000113	0.3	0.22	Hair color;	chr11:69095580	chr11:69103493~69109094:+
THCA	cis	rs6490294	0.571	rs58886972	ENSG00000226469.1	ADAM1B	4.98	8.81e-07	0.000113	0.36	0.22	Mean platelet volume;	chr12:112071477	chr12:111927018~111929017:+
THCA	cis	rs2243480	1	rs34703416	ENSG00000164669.11	INTS4P1	4.98	8.82e-07	0.000113	0.43	0.22	Diabetic kidney disease;	chr7:65835655	chr7:65141225~65234216:+
THCA	cis	rs57221529	0.766	rs72703026	ENSG00000225138.6	CTD-2228K2.7	4.98	8.82e-07	0.000113	0.29	0.22	Lung disease severity in cystic fibrosis;	chr5:572268	chr5:473236~480884:+
THCA	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	4.98	8.82e-07	0.000113	0.29	0.22	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
THCA	cis	rs9890032	0.564	rs62070643	ENSG00000266490.1	CTD-2349P21.9	4.98	8.83e-07	0.000113	0.23	0.22	Hip circumference adjusted for BMI;	chr17:30839284	chr17:30792372~30792833:+
THCA	cis	rs228614	0.51	rs223378	ENSG00000248971.2	KRT8P46	-4.98	8.83e-07	0.000113	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102728746~102730171:-
THCA	cis	rs13113518	0.902	rs12642716	ENSG00000273257.1	RP11-177J6.1	4.98	8.83e-07	0.000113	0.29	0.22	Height;	chr4:55479996	chr4:55387949~55388271:+
THCA	cis	rs17767392	0.836	rs2332640	ENSG00000259146.3	RP1-261D10.2	-4.98	8.83e-07	0.000113	-0.28	-0.22	Mitral valve prolapse;	chr14:71577830	chr14:71292729~71321814:-
THCA	cis	rs11992162	0.56	rs7846248	ENSG00000206014.6	OR7E161P	-4.98	8.84e-07	0.000113	-0.27	-0.22	Monocyte count;	chr8:11936540	chr8:11928597~11929563:-
THCA	cis	rs11992162	0.597	rs7011924	ENSG00000206014.6	OR7E161P	4.98	8.84e-07	0.000113	0.27	0.22	Monocyte count;	chr8:11923084	chr8:11928597~11929563:-
THCA	cis	rs62292953	0.79	rs12163639	ENSG00000248724.5	NPHP3-AS1	-4.98	8.84e-07	0.000114	-0.41	-0.22	Red cell distribution width;	chr3:132512689	chr3:132721750~132874223:+
THCA	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	4.98	8.85e-07	0.000114	0.29	0.22	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
THCA	cis	rs9467773	0.549	rs9461273	ENSG00000124549.13	BTN2A3P	-4.98	8.85e-07	0.000114	-0.21	-0.22	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26421391~26432383:+
THCA	cis	rs10510102	0.935	rs11818001	ENSG00000226864.1	ATE1-AS1	-4.98	8.85e-07	0.000114	-0.36	-0.22	Breast cancer;	chr10:121884830	chr10:121928312~121951965:+
THCA	cis	rs4663866	0.908	rs2304670	ENSG00000186235.9	AC016757.3	4.98	8.85e-07	0.000114	0.47	0.22	Irritable bowel syndrome;	chr2:238256995	chr2:238224552~238231677:-
THCA	cis	rs9388451	0.874	rs13209968	ENSG00000226409.1	RP11-735G4.1	-4.98	8.85e-07	0.000114	-0.26	-0.22	Brugada syndrome;	chr6:125768139	chr6:125370211~125374324:-
THCA	cis	rs8103278	0.507	rs4802275	ENSG00000267395.4	AC074212.6	-4.98	8.85e-07	0.000114	-0.15	-0.22	Coronary artery disease;	chr19:45757117	chr19:45767796~45772504:+
THCA	cis	rs2252521	0.583	rs317763	ENSG00000272568.4	CTB-113D17.1	4.98	8.85e-07	0.000114	0.26	0.22	Cognitive performance;	chr7:29042687	chr7:28979967~29013367:+
THCA	cis	rs12030196	0.827	rs12737137	ENSG00000230812.4	LINC01358	4.98	8.86e-07	0.000114	0.3	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58981534	chr1:59020387~59044614:+
THCA	cis	rs3820928	0.874	rs4675134	ENSG00000212391.1	SNORA48	-4.98	8.86e-07	0.000114	-0.25	-0.22	Pulmonary function;	chr2:226978773	chr2:226968989~226969122:-
THCA	cis	rs593531	0.571	rs10793081	ENSG00000255440.1	RP11-632K5.2	4.98	8.86e-07	0.000114	0.27	0.22	Neuroticism;	chr11:74381358	chr11:74409060~74416379:+
THCA	cis	rs9425766	0.679	rs2049992	ENSG00000227373.4	RP11-160H22.5	4.98	8.87e-07	0.000114	0.31	0.22	Life satisfaction;	chr1:174356554	chr1:174115300~174160004:-
THCA	cis	rs9844666	0.512	rs1403770	ENSG00000273486.1	RP11-731C17.2	4.98	8.87e-07	0.000114	0.21	0.22	Height;	chr3:135959783	chr3:136837338~136839021:-
THCA	cis	rs1005277	0.638	rs1005278	ENSG00000226578.1	RP11-258F22.1	4.98	8.87e-07	0.000114	0.27	0.22	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:37775371~37784131:-
THCA	cis	rs919433	0.68	rs67580728	ENSG00000231621.1	AC013264.2	-4.98	8.87e-07	0.000114	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197566534	chr2:197197991~197199273:+
THCA	cis	rs3824435	0.783	rs1322220	ENSG00000272866.1	RP11-12D24.10	-4.98	8.88e-07	0.000114	-0.3	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5340596	chr9:5351796~5352410:-
THCA	cis	rs12935418	0.672	rs9934957	ENSG00000278985.1	RP11-303E16.9	-4.98	8.88e-07	0.000114	-0.24	-0.22	Mean corpuscular volume;	chr16:81016078	chr16:80982319~80984094:-
THCA	cis	rs9843304	0.529	rs72996050	ENSG00000244503.1	RP11-278L15.6	4.98	8.88e-07	0.000114	0.27	0.22	Gallstone disease;	chr3:149484846	chr3:149494660~149495995:+
THCA	cis	rs7688540	0.8	rs28531997	ENSG00000275426.1	CH17-262A2.1	4.98	8.88e-07	0.000114	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:149738~150317:+
THCA	cis	rs13256369	0.774	rs13260303	ENSG00000254153.1	CTA-398F10.2	-4.98	8.88e-07	0.000114	-0.25	-0.22	Obesity-related traits;	chr8:8729832	chr8:8456909~8461337:-
THCA	cis	rs12682352	0.65	rs13265731	ENSG00000254153.1	CTA-398F10.2	-4.98	8.89e-07	0.000114	-0.25	-0.22	Neuroticism;	chr8:8815810	chr8:8456909~8461337:-
THCA	cis	rs12760731	0.582	rs4433354	ENSG00000213057.5	C1orf220	-4.98	8.89e-07	0.000114	-0.26	-0.22	Obesity-related traits;	chr1:178563349	chr1:178542752~178548889:+
THCA	cis	rs875971	0.508	rs10950045	ENSG00000273142.1	RP11-458F8.4	4.98	8.89e-07	0.000114	0.17	0.22	Aortic root size;	chr7:66601386	chr7:66902857~66906297:+
THCA	cis	rs801193	0.839	rs6968619	ENSG00000273142.1	RP11-458F8.4	4.98	8.89e-07	0.000114	0.17	0.22	Aortic root size;	chr7:66603880	chr7:66902857~66906297:+
THCA	cis	rs801193	0.805	rs12532355	ENSG00000273142.1	RP11-458F8.4	4.98	8.89e-07	0.000114	0.17	0.22	Aortic root size;	chr7:66605597	chr7:66902857~66906297:+
THCA	cis	rs9813712	0.574	rs35856399	ENSG00000253540.4	FAM86HP	-4.98	8.89e-07	0.000114	-0.23	-0.22	Response to amphetamines;	chr3:130241961	chr3:130099092~130111472:-
THCA	cis	rs7552393	0.636	rs6696585	ENSG00000233008.4	RP11-475O6.1	4.98	8.89e-07	0.000114	0.26	0.22	Select biomarker traits;	chr1:83822167	chr1:83575776~83861023:-
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000273712.1	RP5-874C20.7	4.98	8.89e-07	0.000114	0.24	0.22	Pubertal anthropometrics;	chr6:28420988	chr6:28315613~28315883:-
THCA	cis	rs6598266	1	rs7168539	ENSG00000259363.4	CTD-2054N24.2	-4.98	8.89e-07	0.000114	-0.4	-0.22	Major depressive disorder;	chr15:99754995	chr15:99807023~99877148:+
THCA	cis	rs228614	0.51	rs223415	ENSG00000248971.2	KRT8P46	-4.98	8.89e-07	0.000114	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102728746~102730171:-
THCA	cis	rs801193	0.839	rs12534943	ENSG00000273142.1	RP11-458F8.4	4.98	8.89e-07	0.000114	0.17	0.22	Aortic root size;	chr7:66605533	chr7:66902857~66906297:+
THCA	cis	rs6951245	1	rs77346188	ENSG00000229043.2	AC091729.9	-4.98	8.89e-07	0.000114	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1160374~1165267:+
THCA	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	4.98	8.89e-07	0.000114	0.24	0.22	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
THCA	cis	rs453301	0.653	rs2956244	ENSG00000254340.1	RP11-10A14.3	4.98	8.89e-07	0.000114	0.24	0.22	Joint mobility (Beighton score);	chr8:9027656	chr8:9141424~9145435:+
THCA	cis	rs10946940	0.965	rs6921256	ENSG00000219392.1	RP1-265C24.5	-4.98	8.89e-07	0.000114	-0.26	-0.22	Systemic lupus erythematosus;	chr6:27619739	chr6:28115628~28116551:+
THCA	cis	rs10510102	0.872	rs7906462	ENSG00000226864.1	ATE1-AS1	4.98	8.9e-07	0.000114	0.36	0.22	Breast cancer;	chr10:121948098	chr10:121928312~121951965:+
THCA	cis	rs17045328	1	rs7543834	ENSG00000274245.1	RP11-357P18.2	4.98	8.9e-07	0.000114	0.42	0.22	Type 2 diabetes;	chr1:207230495	chr1:207372559~207373252:+
THCA	cis	rs8020095	0.571	rs8006669	ENSG00000258561.1	RP11-72M17.1	-4.98	8.9e-07	0.000114	-0.3	-0.22	Depression (quantitative trait);	chr14:66799810	chr14:66212810~66509394:-
THCA	cis	rs6840360	0.904	rs73862064	ENSG00000251611.1	RP11-610P16.1	-4.98	8.9e-07	0.000114	-0.16	-0.22	Intelligence (multi-trait analysis);	chr4:151581948	chr4:151407551~151408835:-
THCA	cis	rs11153306	0.529	rs11153303	ENSG00000230177.1	RP5-1112D6.4	-4.98	8.9e-07	0.000114	-0.17	-0.22	Tonsillectomy;	chr6:111616672	chr6:111277932~111278742:+
THCA	cis	rs7615952	0.688	rs17334074	ENSG00000241288.6	RP11-379B18.5	4.98	8.9e-07	0.000114	0.26	0.22	Blood pressure (smoking interaction);	chr3:125821617	chr3:125827238~125916384:-
THCA	cis	rs332034	0.507	rs13259619	ENSG00000253893.2	FAM85B	-4.98	8.91e-07	0.000114	-0.37	-0.22	Conduct disorder (maternal expressed emotions interaction);	chr8:8832916	chr8:8167819~8226614:-
THCA	cis	rs7711186	0.708	rs776153	ENSG00000252464.1	RN7SKP70	4.98	8.91e-07	0.000114	0.24	0.22	Urate levels in obese individuals;	chr5:178601816	chr5:178619728~178619998:-
THCA	cis	rs9990343	0.967	rs6803980	ENSG00000223552.1	RP11-24F11.2	-4.98	8.91e-07	0.000114	-0.2	-0.22	Brain structure;	chr3:46301144	chr3:46364955~46407059:-
THCA	cis	rs7088591	1	rs11816094	ENSG00000276818.1	AC026393.1	4.98	8.91e-07	0.000114	0.43	0.22	Blood pressure;	chr10:58025645	chr10:57095699~57095781:+
THCA	cis	rs6545883	0.826	rs2694651	ENSG00000270820.4	RP11-355B11.2	-4.98	8.91e-07	0.000114	-0.19	-0.22	Tuberculosis;	chr2:61361507	chr2:61471188~61484130:+
THCA	cis	rs8007846	0.569	rs11848463	ENSG00000276116.2	FUT8-AS1	4.98	8.91e-07	0.000114	0.23	0.22	Multiple sclerosis--Brain Glutamate Levels;	chr14:65790576	chr14:65411170~65412690:-
THCA	cis	rs394563	0.601	rs431978	ENSG00000268592.3	RAET1E-AS1	-4.98	8.91e-07	0.000114	-0.31	-0.22	Dupuytren's disease;	chr6:149471864	chr6:149863494~149919507:+
THCA	cis	rs9388451	0.839	rs3799709	ENSG00000226409.1	RP11-735G4.1	-4.98	8.92e-07	0.000114	-0.26	-0.22	Brugada syndrome;	chr6:125757215	chr6:125370211~125374324:-
THCA	cis	rs7552393	0.636	rs6680860	ENSG00000233008.4	RP11-475O6.1	4.98	8.92e-07	0.000114	0.25	0.22	Select biomarker traits;	chr1:83817634	chr1:83575776~83861023:-
THCA	cis	rs2439831	0.702	rs16977724	ENSG00000166763.7	STRCP1	4.98	8.92e-07	0.000114	0.33	0.22	Lung cancer in ever smokers;	chr15:43859101	chr15:43699488~43718184:-
THCA	cis	rs860295	0.702	rs11264397	ENSG00000160766.13	GBAP1	-4.98	8.92e-07	0.000114	-0.27	-0.22	Body mass index;	chr1:155641694	chr1:155213821~155227422:-
THCA	cis	rs972578	0.715	rs5758985	ENSG00000274717.1	RP1-47A17.1	-4.98	8.92e-07	0.000114	-0.24	-0.22	Mean platelet volume;	chr22:42851994	chr22:42791814~42794313:-
THCA	cis	rs4845570	0.85	rs4618976	ENSG00000203288.3	RP11-98D18.9	4.98	8.92e-07	0.000114	0.25	0.22	Coronary artery disease;	chr1:151794112	chr1:151790804~151794402:+
THCA	cis	rs10808739	0.541	rs13276608	ENSG00000254006.4	RP11-1D12.2	-4.98	8.92e-07	0.000114	-0.47	-0.22	HIV-1 susceptibility;	chr8:64769294	chr8:64801236~64817573:-
THCA	cis	rs2562456	0.833	rs11666828	ENSG00000268119.4	CTD-2561J22.5	4.98	8.93e-07	0.000115	0.32	0.22	Pain;	chr19:21342218	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs11671609	ENSG00000268119.4	CTD-2561J22.5	4.98	8.93e-07	0.000115	0.32	0.22	Pain;	chr19:21342769	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs62109212	ENSG00000268119.4	CTD-2561J22.5	4.98	8.93e-07	0.000115	0.32	0.22	Pain;	chr19:21343716	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs57250002	ENSG00000268119.4	CTD-2561J22.5	4.98	8.93e-07	0.000115	0.32	0.22	Pain;	chr19:21344048	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs62109218	ENSG00000268119.4	CTD-2561J22.5	4.98	8.93e-07	0.000115	0.32	0.22	Pain;	chr19:21346059	chr19:21444241~21463908:-
THCA	cis	rs6061231	0.571	rs482010	ENSG00000275437.1	RP5-908M14.10	-4.98	8.93e-07	0.000115	-0.21	-0.22	Colorectal cancer;	chr20:62352495	chr20:62402236~62405935:-
THCA	cis	rs7614311	0.639	rs111234932	ENSG00000271843.1	RP11-245J9.5	-4.98	8.93e-07	0.000115	-0.41	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63856773	chr3:64008082~64008692:-
THCA	cis	rs972578	0.791	rs9607980	ENSG00000274717.1	RP1-47A17.1	-4.98	8.93e-07	0.000115	-0.23	-0.22	Mean platelet volume;	chr22:42921562	chr22:42791814~42794313:-
THCA	cis	rs972578	0.791	rs2092209	ENSG00000274717.1	RP1-47A17.1	-4.98	8.93e-07	0.000115	-0.23	-0.22	Mean platelet volume;	chr22:42922642	chr22:42791814~42794313:-
THCA	cis	rs972578	0.791	rs2092210	ENSG00000274717.1	RP1-47A17.1	-4.98	8.93e-07	0.000115	-0.23	-0.22	Mean platelet volume;	chr22:42922694	chr22:42791814~42794313:-
THCA	cis	rs972578	0.791	rs738385	ENSG00000274717.1	RP1-47A17.1	-4.98	8.93e-07	0.000115	-0.23	-0.22	Mean platelet volume;	chr22:42923314	chr22:42791814~42794313:-
THCA	cis	rs17767392	0.881	rs8006300	ENSG00000259146.3	RP1-261D10.2	-4.98	8.93e-07	0.000115	-0.28	-0.22	Mitral valve prolapse;	chr14:71583445	chr14:71292729~71321814:-
THCA	cis	rs7674212	0.51	rs55715738	ENSG00000251288.2	RP11-10L12.2	-4.98	8.94e-07	0.000115	-0.29	-0.22	Type 2 diabetes;	chr4:103209032	chr4:102751401~102752641:+
THCA	cis	rs7646881	0.544	rs59492803	ENSG00000240207.5	RP11-379F4.4	-4.98	8.94e-07	0.000115	-0.33	-0.22	Tetralogy of Fallot;	chr3:158702908	chr3:158732263~158784070:+
THCA	cis	rs11992162	0.508	rs7003792	ENSG00000206014.6	OR7E161P	4.98	8.94e-07	0.000115	0.26	0.22	Monocyte count;	chr8:11923955	chr8:11928597~11929563:-
THCA	cis	rs17301013	0.896	rs6425292	ENSG00000227373.4	RP11-160H22.5	4.98	8.94e-07	0.000115	0.32	0.22	Systemic lupus erythematosus;	chr1:174618364	chr1:174115300~174160004:-
THCA	cis	rs17123764	0.818	rs59960493	ENSG00000257464.1	RP11-161H23.8	-4.98	8.94e-07	0.000115	-0.38	-0.22	Intelligence (multi-trait analysis);	chr12:49548096	chr12:49442424~49442652:-
THCA	cis	rs853679	0.882	rs9393908	ENSG00000220721.1	OR1F12	4.98	8.94e-07	0.000115	0.4	0.22	Depression;	chr6:28223052	chr6:28073316~28074233:+
THCA	cis	rs853679	0.882	rs9366717	ENSG00000220721.1	OR1F12	4.98	8.94e-07	0.000115	0.4	0.22	Depression;	chr6:28223279	chr6:28073316~28074233:+
THCA	cis	rs853679	0.882	rs9393908	ENSG00000272009.1	RP1-313I6.12	-4.98	8.96e-07	0.000115	-0.34	-0.22	Depression;	chr6:28223052	chr6:28078792~28081130:-
THCA	cis	rs853679	0.882	rs9366717	ENSG00000272009.1	RP1-313I6.12	-4.98	8.96e-07	0.000115	-0.34	-0.22	Depression;	chr6:28223279	chr6:28078792~28081130:-
THCA	cis	rs2348418	0.681	rs10771435	ENSG00000247934.4	RP11-967K21.1	4.98	8.96e-07	0.000115	0.19	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28582769	chr12:28163298~28190738:-
THCA	cis	rs6142102	1	rs2378078	ENSG00000275784.1	RP5-1125A11.6	-4.98	8.96e-07	0.000115	-0.25	-0.22	Skin pigmentation;	chr20:34126922	chr20:33989480~33991818:-
THCA	cis	rs7429990	0.864	rs12495520	ENSG00000228638.1	FCF1P2	4.98	8.97e-07	0.000115	0.22	0.22	Educational attainment (years of education);	chr3:47766269	chr3:48290793~48291375:-
THCA	cis	rs9329221	0.683	rs555200	ENSG00000248538.5	RP11-10A14.5	4.98	8.97e-07	0.000115	0.28	0.22	Neuroticism;	chr8:10031219	chr8:9189011~9202854:+
THCA	cis	rs6545883	0.929	rs778154	ENSG00000270820.4	RP11-355B11.2	-4.98	8.97e-07	0.000115	-0.19	-0.22	Tuberculosis;	chr2:61419496	chr2:61471188~61484130:+
THCA	cis	rs7674212	0.539	rs7676041	ENSG00000251288.2	RP11-10L12.2	-4.98	8.97e-07	0.000115	-0.29	-0.22	Type 2 diabetes;	chr4:103205264	chr4:102751401~102752641:+
THCA	cis	rs7412746	0.658	rs4970988	ENSG00000231073.1	RP11-316M1.3	-4.98	8.97e-07	0.000115	-0.28	-0.22	Melanoma;	chr1:150977586	chr1:150973123~150975534:+
THCA	cis	rs9859260	0.689	rs3817672	ENSG00000231464.1	AC024937.4	4.98	8.98e-07	0.000115	0.28	0.22	Mean corpuscular volume;	chr3:196073940	chr3:195996738~195998233:+
THCA	cis	rs10510102	0.935	rs7083278	ENSG00000226864.1	ATE1-AS1	4.98	8.98e-07	0.000115	0.37	0.22	Breast cancer;	chr10:121853758	chr10:121928312~121951965:+
THCA	cis	rs11634944	0.676	rs2732031	ENSG00000257151.1	PWAR6	4.98	8.98e-07	0.000115	0.17	0.22	Interleukin-8 levels;	chr15:24997789	chr15:25031873~25036490:+
THCA	cis	rs1005277	0.579	rs1780133	ENSG00000275858.1	RP11-291L22.8	4.98	8.98e-07	0.000115	0.27	0.22	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38450738~38451069:-
THCA	cis	rs12612619	0.732	rs6716275	ENSG00000229122.1	AGBL5-IT1	-4.98	8.98e-07	0.000115	-0.16	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004839	chr2:27061038~27061815:+
THCA	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-4.98	8.98e-07	0.000115	-0.28	-0.22	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
THCA	cis	rs17301013	0.932	rs6664864	ENSG00000227373.4	RP11-160H22.5	4.98	8.98e-07	0.000115	0.32	0.22	Systemic lupus erythematosus;	chr1:174622912	chr1:174115300~174160004:-
THCA	cis	rs919433	0.963	rs1896854	ENSG00000231621.1	AC013264.2	4.98	8.98e-07	0.000115	0.22	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283052	chr2:197197991~197199273:+
THCA	cis	rs8141529	0.748	rs1318026	ENSG00000272858.1	CTA-292E10.8	-4.98	8.98e-07	0.000115	-0.23	-0.22	Lymphocyte counts;	chr22:28887530	chr22:28814914~28815662:+
THCA	cis	rs2120243	1	rs2873258	ENSG00000244515.1	KRT18P34	-4.98	8.98e-07	0.000115	-0.26	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157427197	chr3:157162663~157163932:-
THCA	cis	rs8050907	0.744	rs7192051	ENSG00000278434.1	RP11-709D24.8	-4.98	8.98e-07	0.000115	-0.48	-0.22	Obesity-related traits;	chr16:4492116	chr16:4532216~4533670:-
THCA	cis	rs10904908	1	rs10904908	ENSG00000229124.5	VIM-AS1	-4.98	8.98e-07	0.000115	-0.22	-0.22	Cholesterol, total;Total cholesterol levels;	chr10:17218291	chr10:17214239~17229985:-
THCA	cis	rs12935418	0.672	rs9889194	ENSG00000278985.1	RP11-303E16.9	4.98	8.99e-07	0.000115	0.24	0.22	Mean corpuscular volume;	chr16:81017212	chr16:80982319~80984094:-
THCA	cis	rs853679	0.546	rs200490	ENSG00000280107.1	AL022393.9	-4.98	8.99e-07	0.000115	-0.34	-0.22	Depression;	chr6:27829157	chr6:28170845~28172521:+
THCA	cis	rs919433	0.713	rs11900232	ENSG00000231621.1	AC013264.2	-4.98	8.99e-07	0.000115	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197601549	chr2:197197991~197199273:+
THCA	cis	rs6772849	0.896	rs9816260	ENSG00000242551.2	POU5F1P6	-4.98	8.99e-07	0.000115	-0.29	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:128674735~128677005:-
THCA	cis	rs9959145	0.925	rs11664431	ENSG00000267108.1	RP11-861E21.1	4.98	9e-07	0.000115	0.27	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12635886	chr18:12432897~12437635:+
THCA	cis	rs7727544	0.582	rs10478998	ENSG00000224431.1	AC063976.7	4.98	9e-07	0.000115	0.19	0.22	Blood metabolite levels;	chr5:132180838	chr5:132199456~132203487:+
THCA	cis	rs2797160	0.935	rs926855	ENSG00000237742.5	RP11-624M8.1	4.98	9e-07	0.000115	0.19	0.22	Endometrial cancer;	chr6:125700636	chr6:125578558~125749190:-
THCA	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	4.98	9.01e-07	0.000115	0.22	0.22	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
THCA	cis	rs1005277	0.522	rs1208684	ENSG00000276805.1	RP11-291L22.6	4.98	9.01e-07	0.000115	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38451030~38451785:+
THCA	cis	rs4718428	1	rs4718428	ENSG00000230295.1	RP11-458F8.2	-4.98	9.01e-07	0.000115	-0.18	-0.22	Corneal structure;	chr7:66956459	chr7:66880708~66882981:+
THCA	cis	rs800160	0.925	rs1088989	ENSG00000199550.1	Y_RNA	4.98	9.01e-07	0.000115	0.33	0.22	Bacteremia;	chr11:2359825	chr11:2372638~2372750:+
THCA	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-4.98	9.01e-07	0.000115	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
THCA	cis	rs7637701	0.967	rs12638253	ENSG00000240875.4	LINC00886	4.98	9.01e-07	0.000115	0.18	0.22	Breast cancer;	chr3:156908302	chr3:156747346~156817062:-
THCA	cis	rs7211079	0.664	rs72850889	ENSG00000275479.1	RP11-334C17.6	4.98	9.01e-07	0.000116	0.27	0.22	Myocardial infarction;	chr17:80141096	chr17:80149627~80149798:+
THCA	cis	rs6714710	0.603	rs17489454	ENSG00000230606.9	AC159540.1	-4.98	9.02e-07	0.000116	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97790887	chr2:97416165~97433527:-
THCA	cis	rs3820928	0.934	rs66959645	ENSG00000212391.1	SNORA48	-4.98	9.02e-07	0.000116	-0.25	-0.22	Pulmonary function;	chr2:226896866	chr2:226968989~226969122:-
THCA	cis	rs8046148	0.756	rs8047742	ENSG00000279356.1	RP11-429P3.8	4.98	9.02e-07	0.000116	0.26	0.22	Testicular germ cell tumor;	chr16:50083405	chr16:50072862~50074986:+
THCA	cis	rs453301	0.571	rs2929456	ENSG00000248538.5	RP11-10A14.5	4.98	9.02e-07	0.000116	0.27	0.22	Joint mobility (Beighton score);	chr8:9225906	chr8:9189011~9202854:+
THCA	cis	rs55704346	0.668	rs12510492	ENSG00000281501.1	SEPSECS-AS1	4.98	9.02e-07	0.000116	0.25	0.22	Tonsillectomy;	chr4:25116244	chr4:25160641~25201440:+
THCA	cis	rs11846409	0.655	rs79296226	ENSG00000274576.2	IGHV2-70	4.98	9.02e-07	0.000116	0.19	0.22	Rheumatic heart disease;	chr14:106650436	chr14:106770577~106771020:-
THCA	cis	rs600231	0.508	rs34582634	ENSG00000245532.5	NEAT1	4.98	9.02e-07	0.000116	0.19	0.22	Bone mineral density;	chr11:65452735	chr11:65422774~65445540:+
THCA	cis	rs28476539	0.64	rs17005923	ENSG00000270480.1	RP11-57B24.1	-4.98	9.02e-07	0.000116	-0.36	-0.22	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82634721	chr4:82691737~82692468:+
THCA	cis	rs34779708	0.931	rs12776390	ENSG00000271335.4	RP11-324I22.4	4.98	9.02e-07	0.000116	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35314552~35336401:-
THCA	cis	rs1930961	0.702	rs6004684	ENSG00000272977.1	CTA-390C10.10	4.98	9.02e-07	0.000116	0.52	0.22	Bipolar disorder with mood-incongruent psychosis;	chr22:25503972	chr22:25476218~25479971:+
THCA	cis	rs7403037	0.583	rs61993131	ENSG00000259905.4	PWRN1	4.98	9.02e-07	0.000116	0.29	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24541287	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.652	rs61993134	ENSG00000259905.4	PWRN1	4.98	9.02e-07	0.000116	0.29	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24544682	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.583	rs34466529	ENSG00000259905.4	PWRN1	4.98	9.02e-07	0.000116	0.29	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24554698	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.571	rs34414719	ENSG00000259905.4	PWRN1	4.98	9.02e-07	0.000116	0.29	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24555095	chr15:24493137~24652130:+
THCA	cis	rs7403037	0.687	rs36080197	ENSG00000259905.4	PWRN1	4.98	9.02e-07	0.000116	0.29	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24561951	chr15:24493137~24652130:+
THCA	cis	rs12931792	0.682	rs12373113	ENSG00000273724.1	RP11-347C12.12	4.98	9.02e-07	0.000116	0.23	0.22	Tonsillectomy;	chr16:30176192	chr16:30336400~30343336:+
THCA	cis	rs12931792	0.682	rs12373078	ENSG00000273724.1	RP11-347C12.12	4.98	9.02e-07	0.000116	0.23	0.22	Tonsillectomy;	chr16:30176355	chr16:30336400~30343336:+
THCA	cis	rs7924176	0.564	rs10762588	ENSG00000213731.2	RAB5CP1	-4.98	9.03e-07	0.000116	-0.27	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.564	rs4564273	ENSG00000213731.2	RAB5CP1	-4.98	9.03e-07	0.000116	-0.27	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74423435~74424014:-
THCA	cis	rs34779708	0.931	rs11010083	ENSG00000271335.4	RP11-324I22.4	4.98	9.03e-07	0.000116	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35314552~35336401:-
THCA	cis	rs793571	0.504	rs6494034	ENSG00000245975.2	RP11-30K9.6	4.98	9.03e-07	0.000116	0.26	0.22	Schizophrenia;	chr15:58717912	chr15:58768072~58770974:-
THCA	cis	rs3820928	0.839	rs13413292	ENSG00000212391.1	SNORA48	-4.98	9.03e-07	0.000116	-0.25	-0.22	Pulmonary function;	chr2:227029031	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs13413235	ENSG00000212391.1	SNORA48	-4.98	9.03e-07	0.000116	-0.25	-0.22	Pulmonary function;	chr2:227029147	chr2:226968989~226969122:-
THCA	cis	rs6598266	1	rs7182154	ENSG00000259363.4	CTD-2054N24.2	-4.98	9.03e-07	0.000116	-0.39	-0.22	Major depressive disorder;	chr15:99760048	chr15:99807023~99877148:+
THCA	cis	rs9393777	0.841	rs13207082	ENSG00000219392.1	RP1-265C24.5	-4.98	9.03e-07	0.000116	-0.44	-0.22	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28115628~28116551:+
THCA	cis	rs631288	0.793	rs894473	ENSG00000226015.2	CCT8P1	4.98	9.04e-07	0.000116	0.49	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr1:147216219	chr1:147203276~147204932:-
THCA	cis	rs9393813	0.626	rs12664996	ENSG00000204789.4	ZNF204P	-4.98	9.04e-07	0.000116	-0.18	-0.22	Bipolar disorder;	chr6:27395865	chr6:27357825~27360221:-
THCA	cis	rs6430585	0.528	rs309123	ENSG00000231890.6	DARS-AS1	-4.98	9.04e-07	0.000116	-0.26	-0.22	Corneal structure;	chr2:136003605	chr2:135985176~136022593:+
THCA	cis	rs8020095	0.571	rs9323484	ENSG00000258561.1	RP11-72M17.1	-4.98	9.05e-07	0.000116	-0.3	-0.22	Depression (quantitative trait);	chr14:66772914	chr14:66212810~66509394:-
THCA	cis	rs3734266	0.702	rs205264	ENSG00000272288.4	RP11-140K17.3	-4.98	9.05e-07	0.000116	-0.23	-0.22	Systemic lupus erythematosus;	chr6:34594419	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs205263	ENSG00000272288.4	RP11-140K17.3	-4.98	9.05e-07	0.000116	-0.23	-0.22	Systemic lupus erythematosus;	chr6:34594746	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs205261	ENSG00000272288.4	RP11-140K17.3	-4.98	9.05e-07	0.000116	-0.23	-0.22	Systemic lupus erythematosus;	chr6:34596110	chr6:34696317~34697470:+
THCA	cis	rs957448	0.948	rs1470153	ENSG00000253175.1	RP11-267M23.6	4.98	9.05e-07	0.000116	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94565036~94565715:+
THCA	cis	rs972578	0.765	rs8142102	ENSG00000274717.1	RP1-47A17.1	-4.98	9.05e-07	0.000116	-0.23	-0.22	Mean platelet volume;	chr22:42916609	chr22:42791814~42794313:-
THCA	cis	rs11671005	0.735	rs34873624	ENSG00000265272.2	RN7SL693P	4.98	9.05e-07	0.000116	0.31	0.22	Mean platelet volume;	chr19:58432035	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.693	rs34230465	ENSG00000265272.2	RN7SL693P	4.98	9.05e-07	0.000116	0.31	0.22	Mean platelet volume;	chr19:58432209	chr19:58490797~58491075:+
THCA	cis	rs6728642	0.908	rs11901495	ENSG00000230606.9	AC159540.1	-4.98	9.05e-07	0.000116	-0.29	-0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97355895	chr2:97416165~97433527:-
THCA	cis	rs752010	0.662	rs10890154	ENSG00000230638.4	RP11-486B10.4	-4.98	9.05e-07	0.000116	-0.25	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41641069	chr1:41542069~41544310:+
THCA	cis	rs919433	0.51	rs34631382	ENSG00000231621.1	AC013264.2	-4.98	9.06e-07	0.000116	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197525285	chr2:197197991~197199273:+
THCA	cis	rs453301	0.624	rs4841083	ENSG00000254153.1	CTA-398F10.2	-4.98	9.06e-07	0.000116	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9012918	chr8:8456909~8461337:-
THCA	cis	rs6686842	0.56	rs10889885	ENSG00000235358.1	RP11-399E6.1	-4.98	9.06e-07	0.000116	-0.3	-0.22	Height;	chr1:41199081	chr1:41242373~41284861:+
THCA	cis	rs11671653	1	rs1560734	ENSG00000267100.1	ILF3-AS1	-4.98	9.07e-07	0.000116	-0.24	-0.22	LDL cholesterol;	chr19:10730373	chr19:10651862~10653844:-
THCA	cis	rs9601248	0.756	rs928640	ENSG00000227354.5	RBM26-AS1	-4.98	9.07e-07	0.000116	-0.22	-0.22	Major depressive disorder;	chr13:79603348	chr13:79406309~79424328:+
THCA	cis	rs4713118	0.869	rs7773070	ENSG00000226314.6	ZNF192P1	-4.98	9.07e-07	0.000116	-0.28	-0.22	Parkinson's disease;	chr6:27761048	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs7776351	ENSG00000226314.6	ZNF192P1	4.98	9.07e-07	0.000116	0.28	0.22	Parkinson's disease;	chr6:27758952	chr6:28161781~28169594:+
THCA	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-4.98	9.07e-07	0.000116	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
THCA	cis	rs950169	0.58	rs11634320	ENSG00000188388.10	GOLGA6L3	-4.98	9.07e-07	0.000116	-0.3	-0.22	Schizophrenia;	chr15:84628952	chr15:85240472~85247170:+
THCA	cis	rs7267979	0.753	rs400357	ENSG00000125804.12	FAM182A	-4.98	9.08e-07	0.000116	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26054655~26086917:+
THCA	cis	rs875971	0.545	rs1796219	ENSG00000228409.4	CCT6P1	4.98	9.08e-07	0.000116	0.19	0.22	Aortic root size;	chr7:66645977	chr7:65751142~65763354:+
THCA	cis	rs7520050	0.807	rs12025621	ENSG00000234329.1	RP11-767N6.2	-4.98	9.08e-07	0.000116	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45651039~45651826:-
THCA	cis	rs7474896	1	rs1322319	ENSG00000263064.2	RP11-291L22.7	4.98	9.09e-07	0.000116	0.36	0.22	Obesity (extreme);	chr10:37856581	chr10:38448689~38448949:+
THCA	cis	rs1538970	0.748	rs11211137	ENSG00000234329.1	RP11-767N6.2	4.98	9.09e-07	0.000116	0.23	0.22	Platelet count;	chr1:45548220	chr1:45651039~45651826:-
THCA	cis	rs6441961	0.501	rs6441959	ENSG00000223552.1	RP11-24F11.2	-4.98	9.09e-07	0.000116	-0.22	-0.22	Celiac disease;	chr3:46300938	chr3:46364955~46407059:-
THCA	cis	rs3796352	0.881	rs35384050	ENSG00000242142.1	SERBP1P3	-4.98	9.09e-07	0.000116	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52974753	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs13091844	ENSG00000242142.1	SERBP1P3	-4.98	9.09e-07	0.000116	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52976255	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs11706035	ENSG00000242142.1	SERBP1P3	-4.98	9.09e-07	0.000116	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52977852	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs11720191	ENSG00000242142.1	SERBP1P3	-4.98	9.09e-07	0.000116	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52979823	chr3:53064283~53065091:-
THCA	cis	rs3796352	0.881	rs11710394	ENSG00000242142.1	SERBP1P3	-4.98	9.09e-07	0.000116	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52981823	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs60942590	ENSG00000242142.1	SERBP1P3	-4.98	9.09e-07	0.000116	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52982405	chr3:53064283~53065091:-
THCA	cis	rs270601	0.77	rs932019	ENSG00000224431.1	AC063976.7	4.98	9.09e-07	0.000116	0.19	0.22	Acylcarnitine levels;	chr5:132263677	chr5:132199456~132203487:+
THCA	cis	rs2562456	0.834	rs13346641	ENSG00000268081.1	RP11-678G14.2	4.98	9.09e-07	0.000116	0.37	0.22	Pain;	chr19:21409481	chr19:21554640~21569237:-
THCA	cis	rs7119	0.679	rs34075648	ENSG00000259362.2	RP11-307C19.1	-4.98	9.09e-07	0.000116	-0.32	-0.22	Type 2 diabetes;	chr15:77555460	chr15:77525540~77534110:+
THCA	cis	rs4713118	0.525	rs9357042	ENSG00000219392.1	RP1-265C24.5	-4.98	9.09e-07	0.000116	-0.26	-0.22	Parkinson's disease;	chr6:27615016	chr6:28115628~28116551:+
THCA	cis	rs35160687	0.644	rs11687392	ENSG00000273080.1	RP11-301O19.1	-4.98	9.09e-07	0.000116	-0.24	-0.22	Night sleep phenotypes;	chr2:86275540	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.644	rs1863058	ENSG00000273080.1	RP11-301O19.1	-4.98	9.09e-07	0.000116	-0.24	-0.22	Night sleep phenotypes;	chr2:86282144	chr2:86195590~86196049:+
THCA	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-4.98	9.1e-07	0.000116	-0.26	-0.22	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
THCA	cis	rs17767392	0.881	rs1029570	ENSG00000259146.3	RP1-261D10.2	-4.98	9.1e-07	0.000116	-0.28	-0.22	Mitral valve prolapse;	chr14:71576483	chr14:71292729~71321814:-
THCA	cis	rs7474896	0.616	rs2505239	ENSG00000276805.1	RP11-291L22.6	4.98	9.1e-07	0.000116	0.3	0.22	Obesity (extreme);	chr10:38151837	chr10:38451030~38451785:+
THCA	cis	rs7474896	0.561	rs2474603	ENSG00000276805.1	RP11-291L22.6	4.98	9.1e-07	0.000116	0.3	0.22	Obesity (extreme);	chr10:38156754	chr10:38451030~38451785:+
THCA	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	4.98	9.1e-07	0.000117	0.31	0.22	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
THCA	cis	rs9875589	0.509	rs7653289	ENSG00000228242.5	AC093495.4	4.98	9.1e-07	0.000117	0.13	0.22	Ovarian reserve;	chr3:13944833	chr3:14144637~14165978:+
THCA	cis	rs2439831	1	rs2256764	ENSG00000166763.7	STRCP1	4.98	9.1e-07	0.000117	0.33	0.22	Lung cancer in ever smokers;	chr15:43443565	chr15:43699488~43718184:-
THCA	cis	rs756699	1	rs244691	ENSG00000279469.1	RP11-215P8.2	-4.98	9.11e-07	0.000117	-0.35	-0.22	Multiple sclerosis;	chr5:134116804	chr5:134394360~134395008:-
THCA	cis	rs9925964	0.869	rs2288004	ENSG00000260911.2	RP11-196G11.2	-4.98	9.11e-07	0.000117	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31043150~31049868:+
THCA	cis	rs9890032	0.542	rs11867227	ENSG00000266490.1	CTD-2349P21.9	4.98	9.11e-07	0.000117	0.23	0.22	Hip circumference adjusted for BMI;	chr17:30923893	chr17:30792372~30792833:+
THCA	cis	rs6545883	0.868	rs6752938	ENSG00000270820.4	RP11-355B11.2	4.98	9.11e-07	0.000117	0.18	0.22	Tuberculosis;	chr2:61614453	chr2:61471188~61484130:+
THCA	cis	rs10761482	0.532	rs1938533	ENSG00000254271.1	RP11-131N11.4	4.98	9.11e-07	0.000117	0.3	0.22	Schizophrenia;	chr10:60474351	chr10:60734342~60741828:+
THCA	cis	rs2129782	1	rs1354523	ENSG00000253553.4	RP11-586K2.1	4.98	9.11e-07	0.000117	0.38	0.22	Electrodermal activity;	chr8:88403312	chr8:88326836~88737134:+
THCA	cis	rs17594362	1	rs12869969	ENSG00000264190.1	MIR5006	-4.98	9.11e-07	0.000117	-0.33	-0.22	Multiple sclerosis;	chr13:41566204	chr13:41568286~41568395:-
THCA	cis	rs2439831	0.85	rs524417	ENSG00000166763.7	STRCP1	4.98	9.12e-07	0.000117	0.3	0.22	Lung cancer in ever smokers;	chr15:43480176	chr15:43699488~43718184:-
THCA	cis	rs11673344	0.504	rs4805205	ENSG00000276846.1	CTD-3220F14.3	4.98	9.12e-07	0.000117	0.17	0.22	Obesity-related traits;	chr19:37136693	chr19:37314868~37315620:-
THCA	cis	rs987724	0.593	rs10936040	ENSG00000240875.4	LINC00886	-4.98	9.12e-07	0.000117	-0.17	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156959236	chr3:156747346~156817062:-
THCA	cis	rs987724	0.593	rs9289973	ENSG00000240875.4	LINC00886	-4.98	9.12e-07	0.000117	-0.17	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156960726	chr3:156747346~156817062:-
THCA	cis	rs987724	0.593	rs9875585	ENSG00000240875.4	LINC00886	-4.98	9.12e-07	0.000117	-0.17	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156963334	chr3:156747346~156817062:-
THCA	cis	rs11671005	0.651	rs11878203	ENSG00000265272.2	RN7SL693P	4.98	9.12e-07	0.000117	0.31	0.22	Mean platelet volume;	chr19:58408683	chr19:58490797~58491075:+
THCA	cis	rs1030877	0.515	rs2679895	ENSG00000235319.1	AC012360.4	-4.98	9.12e-07	0.000117	-0.29	-0.22	Obesity-related traits;	chr2:105290023	chr2:105324210~105330529:+
THCA	cis	rs11673344	0.504	rs2118208	ENSG00000276846.1	CTD-3220F14.3	4.98	9.13e-07	0.000117	0.17	0.22	Obesity-related traits;	chr19:37135573	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs2118209	ENSG00000276846.1	CTD-3220F14.3	4.98	9.13e-07	0.000117	0.17	0.22	Obesity-related traits;	chr19:37135618	chr19:37314868~37315620:-
THCA	cis	rs7824557	0.843	rs2736375	ENSG00000154316.13	TDH	4.98	9.13e-07	0.000117	0.16	0.22	Retinal vascular caliber;	chr8:11258240	chr8:11339637~11368452:+
THCA	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-4.98	9.13e-07	0.000117	-0.27	-0.22	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
THCA	cis	rs1876905	0.539	rs240956	ENSG00000230177.1	RP5-1112D6.4	4.98	9.13e-07	0.000117	0.24	0.22	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111277932~111278742:+
THCA	cis	rs11051970	0.636	rs325421	ENSG00000274964.1	RP11-817I4.1	-4.98	9.14e-07	0.000117	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32418661	chr12:32339368~32340724:+
THCA	cis	rs1383484	0.64	rs12101685	ENSG00000259728.4	LINC00933	-4.98	9.14e-07	0.000117	-0.26	-0.22	Height;	chr15:83974905	chr15:84570649~84580175:+
THCA	cis	rs394563	0.69	rs237010	ENSG00000231760.4	RP11-350J20.5	4.98	9.14e-07	0.000117	0.29	0.22	Dupuytren's disease;	chr6:149437614	chr6:149796151~149826294:-
THCA	cis	rs5006884	0.627	rs11037070	ENSG00000167355.6	AC104389.28	-4.98	9.14e-07	0.000117	-0.36	-0.22	Fetal hemoglobin levels;	chr11:5373002	chr11:5304976~5505652:-
THCA	cis	rs6012564	1	rs56131635	ENSG00000227431.4	CSE1L-AS1	4.98	9.14e-07	0.000117	0.27	0.22	Anger;	chr20:49157806	chr20:49040463~49046044:-
THCA	cis	rs7587476	0.906	rs16852750	ENSG00000229267.2	AC072062.1	-4.98	9.14e-07	0.000117	-0.29	-0.22	Neuroblastoma;	chr2:214781959	chr2:214810229~214963274:+
THCA	cis	rs13178541	0.638	rs6861738	ENSG00000250378.1	RP11-119J18.1	-4.98	9.15e-07	0.000117	-0.25	-0.22	IgG glycosylation;	chr5:135714486	chr5:135812667~135826582:+
THCA	cis	rs1129187	0.755	rs2274517	ENSG00000272223.1	RP1-20C7.6	-4.98	9.15e-07	0.000117	-0.17	-0.22	Alzheimer's disease in APOE e4+ carriers;	chr6:42964977	chr6:43033897~43034405:-
THCA	cis	rs7942368	1	rs56228827	ENSG00000261578.1	RP11-21L23.2	4.98	9.15e-07	0.000117	0.33	0.22	Endometriosis;	chr11:76756479	chr11:76800364~76804555:+
THCA	cis	rs2243480	1	rs67728539	ENSG00000164669.11	INTS4P1	4.98	9.15e-07	0.000117	0.43	0.22	Diabetic kidney disease;	chr7:65913137	chr7:65141225~65234216:+
THCA	cis	rs12612619	0.732	rs7560595	ENSG00000229122.1	AGBL5-IT1	4.98	9.15e-07	0.000117	0.16	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006504	chr2:27061038~27061815:+
THCA	cis	rs6517329	0.52	rs8132958	ENSG00000236830.5	CBR3-AS1	-4.98	9.15e-07	0.000117	-0.21	-0.22	Schizophrenia;	chr21:36157982	chr21:36131767~36175815:-
THCA	cis	rs6600671	0.899	rs2319971	ENSG00000226067.5	CH17-118O6.2	4.98	9.16e-07	0.000117	0.23	0.22	Hip geometry;	chr1:121485184	chr1:120913275~121009291:+
THCA	cis	rs8062405	1	rs7498555	ENSG00000278665.1	RP11-666O2.4	4.98	9.16e-07	0.000117	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28599241~28601881:-
THCA	cis	rs12049671	0.858	rs12413597	ENSG00000227076.1	RP11-4C20.4	4.98	9.16e-07	0.000117	0.25	0.22	Response to amphetamines;	chr10:127941763	chr10:127934698~127936167:+
THCA	cis	rs7976269	0.609	rs1344854	ENSG00000275476.1	RP11-996F15.4	4.98	9.16e-07	0.000117	0.22	0.22	Male-pattern baldness;	chr12:29065440	chr12:29277397~29277882:-
THCA	cis	rs394563	0.69	rs237009	ENSG00000231760.4	RP11-350J20.5	4.98	9.16e-07	0.000117	0.29	0.22	Dupuytren's disease;	chr6:149438416	chr6:149796151~149826294:-
THCA	cis	rs17767392	0.958	rs12433040	ENSG00000259146.3	RP1-261D10.2	-4.98	9.17e-07	0.000117	-0.29	-0.22	Mitral valve prolapse;	chr14:71563838	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs10135680	ENSG00000259146.3	RP1-261D10.2	-4.98	9.17e-07	0.000117	-0.29	-0.22	Mitral valve prolapse;	chr14:71564092	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs6574016	ENSG00000259146.3	RP1-261D10.2	-4.98	9.17e-07	0.000117	-0.29	-0.22	Mitral valve prolapse;	chr14:71573808	chr14:71292729~71321814:-
THCA	cis	rs10129255	0.5	rs1974468	ENSG00000211970.3	IGHV4-61	-4.98	9.17e-07	0.000117	-0.13	-0.22	Kawasaki disease;	chr14:106686149	chr14:106639119~106639657:-
THCA	cis	rs79349575	0.729	rs62075824	ENSG00000270781.1	RP11-501C14.9	-4.97	9.17e-07	0.000117	-0.27	-0.22	Type 2 diabetes;	chr17:48909317	chr17:48899131~48899748:+
THCA	cis	rs5758659	0.652	rs133301	ENSG00000227370.1	RP4-669P10.19	-4.97	9.17e-07	0.000117	-0.21	-0.22	Cognitive function;	chr22:41994089	chr22:42132543~42132998:+
THCA	cis	rs2190422	0.677	rs2190419	ENSG00000234715.1	CTB-107G13.1	-4.97	9.17e-07	0.000117	-0.26	-0.22	Morning vs. evening chronotype;	chr7:103432640	chr7:103445207~103514007:+
THCA	cis	rs11673344	0.504	rs4805204	ENSG00000276846.1	CTD-3220F14.3	4.97	9.17e-07	0.000117	0.17	0.22	Obesity-related traits;	chr19:37136666	chr19:37314868~37315620:-
THCA	cis	rs150992	0.537	rs1604450	ENSG00000248489.1	CTD-2007H13.3	-4.97	9.17e-07	0.000117	-0.24	-0.22	Body mass index;	chr5:99036274	chr5:98929171~98995013:+
THCA	cis	rs150992	0.504	rs7719649	ENSG00000248489.1	CTD-2007H13.3	4.97	9.17e-07	0.000117	0.24	0.22	Body mass index;	chr5:99036711	chr5:98929171~98995013:+
THCA	cis	rs10090774	0.965	rs11991796	ENSG00000279766.1	RP11-642A1.2	4.97	9.18e-07	0.000117	0.26	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140888419	chr8:140572142~140572812:-
THCA	cis	rs1865760	0.622	rs10946807	ENSG00000272462.2	U91328.19	-4.97	9.18e-07	0.000117	-0.21	-0.22	Height;	chr6:26079410	chr6:25992662~26001775:+
THCA	cis	rs4578769	0.569	rs1597239	ENSG00000265939.1	UBE2CP2	4.97	9.18e-07	0.000117	0.26	0.22	Eosinophil percentage of white cells;	chr18:22805673	chr18:22900486~22900995:-
THCA	cis	rs13434995	0.513	rs11240	ENSG00000273257.1	RP11-177J6.1	-4.97	9.18e-07	0.000117	-0.33	-0.22	Adiponectin levels;	chr4:55453183	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs7676245	ENSG00000273257.1	RP11-177J6.1	-4.97	9.18e-07	0.000117	-0.33	-0.22	Adiponectin levels;	chr4:55455150	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62303711	ENSG00000273257.1	RP11-177J6.1	-4.97	9.18e-07	0.000117	-0.33	-0.22	Adiponectin levels;	chr4:55458325	chr4:55387949~55388271:+
THCA	cis	rs12681287	0.927	rs2976177	ENSG00000254231.1	CTD-2284J15.1	4.97	9.18e-07	0.000117	0.24	0.22	Caudate activity during reward;	chr8:86320103	chr8:86333274~86343314:-
THCA	cis	rs6951245	0.935	rs113365567	ENSG00000229043.2	AC091729.9	-4.97	9.18e-07	0.000117	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1160374~1165267:+
THCA	cis	rs9475752	0.793	rs17685380	ENSG00000231441.1	RP11-472M19.2	4.97	9.18e-07	0.000117	0.31	0.22	Menarche (age at onset);	chr6:57010991	chr6:56844002~56864078:+
THCA	cis	rs7267979	0.789	rs4815429	ENSG00000125804.12	FAM182A	4.97	9.19e-07	0.000118	0.27	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26054655~26086917:+
THCA	cis	rs2153535	0.585	rs6932720	ENSG00000230939.1	RP11-314C16.1	-4.97	9.19e-07	0.000118	-0.23	-0.22	Motion sickness;	chr6:8644999	chr6:8784178~8785445:+
THCA	cis	rs55704346	0.74	rs3733548	ENSG00000281501.1	SEPSECS-AS1	4.97	9.19e-07	0.000118	0.25	0.22	Tonsillectomy;	chr4:25154861	chr4:25160641~25201440:+
THCA	cis	rs72843506	0.586	rs75128113	ENSG00000261033.1	RP11-209D14.2	4.97	9.19e-07	0.000118	0.44	0.22	Schizophrenia;	chr17:20000172	chr17:20008051~20009234:-
THCA	cis	rs72945132	0.882	rs7114200	ENSG00000254604.1	AP000487.6	-4.97	9.19e-07	0.000118	-0.43	-0.22	Coronary artery disease;	chr11:70339993	chr11:70282367~70363368:-
THCA	cis	rs4415084	0.804	rs4412123	ENSG00000272335.1	RP11-53O19.3	4.97	9.19e-07	0.000118	0.18	0.22	Breast cancer;	chr5:44876186	chr5:44826076~44828592:+
THCA	cis	rs7598759	0.548	rs1584462	ENSG00000223198.1	RNU2-22P	-4.97	9.2e-07	0.000118	-0.29	-0.22	Noise-induced hearing loss;	chr2:231505087	chr2:231501990~231502201:-
THCA	cis	rs9878978	0.722	rs11719351	ENSG00000237990.3	CNTN4-AS1	4.97	9.2e-07	0.000118	0.27	0.22	Blood pressure (smoking interaction);	chr3:2418188	chr3:3039033~3069242:-
THCA	cis	rs7191700	0.509	rs415595	ENSG00000263080.1	RP11-485G7.5	4.97	9.2e-07	0.000118	0.25	0.22	Multiple sclerosis;	chr16:11269835	chr16:11341809~11345211:-
THCA	cis	rs7191700	0.509	rs416603	ENSG00000263080.1	RP11-485G7.5	-4.97	9.2e-07	0.000118	-0.25	-0.22	Multiple sclerosis;	chr16:11270222	chr16:11341809~11345211:-
THCA	cis	rs7621331	1	rs28449384	ENSG00000273486.1	RP11-731C17.2	4.97	9.2e-07	0.000118	0.21	0.22	Waist circumference adjusted for body mass index;	chr3:135974349	chr3:136837338~136839021:-
THCA	cis	rs7520050	0.966	rs785464	ENSG00000234329.1	RP11-767N6.2	-4.97	9.2e-07	0.000118	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45651039~45651826:-
THCA	cis	rs5742933	0.69	rs62183658	ENSG00000253559.1	OSGEPL1-AS1	-4.97	9.2e-07	0.000118	-0.32	-0.22	Ferritin levels;	chr2:189669491	chr2:189762704~189765556:+
THCA	cis	rs62184315	0.536	rs62183659	ENSG00000253559.1	OSGEPL1-AS1	-4.97	9.2e-07	0.000118	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189672131	chr2:189762704~189765556:+
THCA	cis	rs62184315	0.536	rs62185869	ENSG00000253559.1	OSGEPL1-AS1	-4.97	9.2e-07	0.000118	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189672330	chr2:189762704~189765556:+
THCA	cis	rs2129782	1	rs10096195	ENSG00000253553.4	RP11-586K2.1	-4.97	9.2e-07	0.000118	-0.36	-0.22	Electrodermal activity;	chr8:88420358	chr8:88326836~88737134:+
THCA	cis	rs8028182	0.636	rs11634863	ENSG00000260274.1	RP11-817O13.8	4.97	9.21e-07	0.000118	0.16	0.22	Sudden cardiac arrest;	chr15:75474331	chr15:75368155~75369584:+
THCA	cis	rs763121	0.819	rs5750629	ENSG00000228274.3	RP3-508I15.9	-4.97	9.21e-07	0.000118	-0.24	-0.22	Menopause (age at onset);	chr22:38589060	chr22:38667585~38681820:-
THCA	cis	rs2562456	0.833	rs62110071	ENSG00000268081.1	RP11-678G14.2	4.97	9.21e-07	0.000118	0.38	0.22	Pain;	chr19:21288101	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.793	rs11667392	ENSG00000268081.1	RP11-678G14.2	4.97	9.21e-07	0.000118	0.38	0.22	Pain;	chr19:21289806	chr19:21554640~21569237:-
THCA	cis	rs34779708	0.931	rs2384289	ENSG00000271335.4	RP11-324I22.4	4.97	9.21e-07	0.000118	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs11010082	ENSG00000271335.4	RP11-324I22.4	4.97	9.21e-07	0.000118	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35314552~35336401:-
THCA	cis	rs8020095	0.571	rs6573734	ENSG00000258561.1	RP11-72M17.1	-4.97	9.21e-07	0.000118	-0.3	-0.22	Depression (quantitative trait);	chr14:66900212	chr14:66212810~66509394:-
THCA	cis	rs2243480	0.522	rs73150635	ENSG00000229886.1	RP5-1132H15.3	4.97	9.22e-07	0.000118	0.47	0.22	Diabetic kidney disease;	chr7:66507503	chr7:66025126~66031544:-
THCA	cis	rs9634489	0.739	rs7989336	ENSG00000247400.3	DNAJC3-AS1	-4.97	9.22e-07	0.000118	-0.14	-0.22	Body mass index;	chr13:96365294	chr13:95648733~95676925:-
THCA	cis	rs2439831	0.557	rs13329084	ENSG00000275601.1	AC011330.13	4.97	9.22e-07	0.000118	0.41	0.22	Lung cancer in ever smokers;	chr15:43858865	chr15:43642389~43643023:-
THCA	cis	rs12413361	0.967	rs10763841	ENSG00000272914.1	RP11-330O11.3	-4.97	9.23e-07	0.000118	-0.19	-0.22	Height;	chr10:30826078	chr10:30831828~30833387:-
THCA	cis	rs1577917	0.655	rs9450311	ENSG00000220563.1	PKMP3	4.97	9.23e-07	0.000118	0.16	0.22	Response to antipsychotic treatment;	chr6:85666868	chr6:85659892~85660606:-
THCA	cis	rs755249	0.545	rs12037073	ENSG00000228060.1	RP11-69E11.8	4.97	9.23e-07	0.000118	0.21	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39565160~39573203:+
THCA	cis	rs1113500	0.748	rs1781048	ENSG00000226822.1	RP11-356N1.2	4.97	9.23e-07	0.000118	0.24	0.22	Growth-regulated protein alpha levels;	chr1:108012428	chr1:108071482~108074519:+
THCA	cis	rs6565180	0.963	rs4787642	ENSG00000274653.1	RP11-347C12.11	4.97	9.23e-07	0.000118	0.21	0.22	Tonsillectomy;	chr16:30348087	chr16:30359825~30360336:+
THCA	cis	rs990871	0.512	rs1776012	ENSG00000227207.2	RPL31P12	4.97	9.23e-07	0.000118	0.26	0.22	Subcutaneous adipose tissue;	chr1:72252060	chr1:72301472~72301829:+
THCA	cis	rs5752326	0.51	rs739289	ENSG00000261188.1	CTA-445C9.14	-4.97	9.23e-07	0.000118	-0.22	-0.22	Ischemic stroke;	chr22:26466187	chr22:26512537~26514568:+
THCA	cis	rs8028182	0.636	rs4886699	ENSG00000260274.1	RP11-817O13.8	4.97	9.24e-07	0.000118	0.16	0.22	Sudden cardiac arrest;	chr15:75399962	chr15:75368155~75369584:+
THCA	cis	rs1320333	0.772	rs111825088	ENSG00000233296.1	AC092159.2	4.97	9.24e-07	0.000118	0.41	0.22	Obesity-related traits;	chr2:695785	chr2:677186~697371:+
THCA	cis	rs9388451	0.839	rs10457469	ENSG00000226409.1	RP11-735G4.1	-4.97	9.24e-07	0.000118	-0.26	-0.22	Brugada syndrome;	chr6:125762512	chr6:125370211~125374324:-
THCA	cis	rs12428035	0.764	rs3087341	ENSG00000247400.3	DNAJC3-AS1	-4.97	9.24e-07	0.000118	-0.22	-0.22	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95709426	chr13:95648733~95676925:-
THCA	cis	rs172166	0.538	rs149956	ENSG00000176933.5	TOB2P1	-4.97	9.24e-07	0.000118	-0.24	-0.22	Cardiac Troponin-T levels;	chr6:28068473	chr6:28217643~28218634:-
THCA	cis	rs8177876	0.822	rs9925940	ENSG00000261061.1	RP11-303E16.2	-4.97	9.24e-07	0.000118	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs9925943	ENSG00000261061.1	RP11-303E16.2	-4.97	9.24e-07	0.000118	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81030770~81031485:+
THCA	cis	rs7688540	0.8	rs12506277	ENSG00000275426.1	CH17-262A2.1	4.97	9.24e-07	0.000118	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:149738~150317:+
THCA	cis	rs7688540	0.8	rs12501727	ENSG00000275426.1	CH17-262A2.1	4.97	9.24e-07	0.000118	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:149738~150317:+
THCA	cis	rs34779708	0.966	rs2505639	ENSG00000271335.4	RP11-324I22.4	-4.97	9.25e-07	0.000118	-0.21	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35314552~35336401:-
THCA	cis	rs1859596	0.691	rs10231884	ENSG00000234456.6	MAGI2-AS3	4.97	9.25e-07	0.000118	0.22	0.22	Reading or mathematical ability;	chr7:79455484	chr7:79452877~79471208:+
THCA	cis	rs8177876	0.822	rs77475047	ENSG00000261838.4	RP11-303E16.6	4.97	9.25e-07	0.000118	0.41	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs55939311	ENSG00000261838.4	RP11-303E16.6	4.97	9.25e-07	0.000118	0.41	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs12444137	ENSG00000261838.4	RP11-303E16.6	4.97	9.25e-07	0.000118	0.41	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81069854~81076598:+
THCA	cis	rs8067545	0.532	rs12946508	ENSG00000261033.1	RP11-209D14.2	-4.97	9.25e-07	0.000118	-0.32	-0.22	Schizophrenia;	chr17:20048746	chr17:20008051~20009234:-
THCA	cis	rs8067545	0.512	rs4925071	ENSG00000261033.1	RP11-209D14.2	-4.97	9.25e-07	0.000118	-0.32	-0.22	Schizophrenia;	chr17:20051186	chr17:20008051~20009234:-
THCA	cis	rs8067545	0.532	rs3862151	ENSG00000261033.1	RP11-209D14.2	-4.97	9.25e-07	0.000118	-0.32	-0.22	Schizophrenia;	chr17:20053976	chr17:20008051~20009234:-
THCA	cis	rs8067545	0.532	rs17759041	ENSG00000261033.1	RP11-209D14.2	-4.97	9.25e-07	0.000118	-0.32	-0.22	Schizophrenia;	chr17:20056653	chr17:20008051~20009234:-
THCA	cis	rs8067545	0.532	rs4925074	ENSG00000261033.1	RP11-209D14.2	-4.97	9.25e-07	0.000118	-0.32	-0.22	Schizophrenia;	chr17:20059241	chr17:20008051~20009234:-
THCA	cis	rs9840812	0.592	rs1711161	ENSG00000239213.4	NCK1-AS1	4.97	9.25e-07	0.000118	0.21	0.22	Fibrinogen levels;	chr3:136361695	chr3:136841726~136862054:-
THCA	cis	rs3820928	0.874	rs4675132	ENSG00000212391.1	SNORA48	-4.97	9.25e-07	0.000118	-0.25	-0.22	Pulmonary function;	chr2:226977076	chr2:226968989~226969122:-
THCA	cis	rs4073582	0.595	rs708472	ENSG00000255320.1	RP11-755F10.1	-4.97	9.26e-07	0.000118	-0.28	-0.22	Gout;	chr11:66163519	chr11:66244840~66246239:-
THCA	cis	rs4073582	0.595	rs708471	ENSG00000255320.1	RP11-755F10.1	-4.97	9.26e-07	0.000118	-0.28	-0.22	Gout;	chr11:66163537	chr11:66244840~66246239:-
THCA	cis	rs1850744	0.536	rs6448858	ENSG00000250942.1	ENPP7P11	4.97	9.26e-07	0.000118	0.24	0.22	Economic and political preferences;	chr4:9594294	chr4:9677308~9677934:+
THCA	cis	rs7621331	0.963	rs10212530	ENSG00000273486.1	RP11-731C17.2	4.97	9.26e-07	0.000118	0.21	0.22	Waist circumference adjusted for body mass index;	chr3:135952575	chr3:136837338~136839021:-
THCA	cis	rs9843304	0.529	rs4681512	ENSG00000244503.1	RP11-278L15.6	4.97	9.27e-07	0.000118	0.27	0.22	Gallstone disease;	chr3:149485654	chr3:149494660~149495995:+
THCA	cis	rs2190422	0.677	rs2906639	ENSG00000234715.1	CTB-107G13.1	-4.97	9.27e-07	0.000118	-0.26	-0.22	Morning vs. evening chronotype;	chr7:103434133	chr7:103445207~103514007:+
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000273796.1	LL21NC02-21A1.1	-4.97	9.27e-07	0.000118	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45403809~45404369:-
THCA	cis	rs35160687	0.644	rs9309635	ENSG00000273080.1	RP11-301O19.1	4.97	9.27e-07	0.000119	0.24	0.22	Night sleep phenotypes;	chr2:86272279	chr2:86195590~86196049:+
THCA	cis	rs2243480	1	rs1723269	ENSG00000232559.3	GS1-124K5.12	4.97	9.27e-07	0.000119	0.33	0.22	Diabetic kidney disease;	chr7:66007799	chr7:66554588~66576923:-
THCA	cis	rs860295	0.676	rs11264374	ENSG00000160766.13	GBAP1	-4.97	9.27e-07	0.000119	-0.26	-0.22	Body mass index;	chr1:155451721	chr1:155213821~155227422:-
THCA	cis	rs2239547	0.522	rs9846976	ENSG00000242142.1	SERBP1P3	4.97	9.27e-07	0.000119	0.28	0.22	Schizophrenia;	chr3:52973979	chr3:53064283~53065091:-
THCA	cis	rs919433	0.783	rs788011	ENSG00000231621.1	AC013264.2	-4.97	9.27e-07	0.000119	-0.24	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366047	chr2:197197991~197199273:+
THCA	cis	rs4950322	0.517	rs114823926	ENSG00000271721.1	RP11-337C18.9	4.97	9.28e-07	0.000119	0.26	0.22	Protein quantitative trait loci;	chr1:147281805	chr1:147175602~147177740:+
THCA	cis	rs17767392	0.628	rs61989247	ENSG00000259146.3	RP1-261D10.2	4.97	9.28e-07	0.000119	0.28	0.22	Mitral valve prolapse;	chr14:71253632	chr14:71292729~71321814:-
THCA	cis	rs8091660	0.624	rs907547	ENSG00000278983.1	RP11-426J5.3	4.97	9.28e-07	0.000119	0.33	0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48549725	chr18:48564795~48568342:+
THCA	cis	rs2058059	0.512	rs3015937	ENSG00000205578.5	POM121B	-4.97	9.28e-07	0.000119	-0.34	-0.22	Subcutaneous adipose tissue;	chr7:72698883	chr7:73293497~73301161:+
THCA	cis	rs2058059	0.513	rs2960965	ENSG00000205578.5	POM121B	-4.97	9.28e-07	0.000119	-0.34	-0.22	Subcutaneous adipose tissue;	chr7:72701360	chr7:73293497~73301161:+
THCA	cis	rs2058059	0.639	rs2960966	ENSG00000205578.5	POM121B	-4.97	9.28e-07	0.000119	-0.34	-0.22	Subcutaneous adipose tissue;	chr7:72701555	chr7:73293497~73301161:+
THCA	cis	rs2058059	0.553	rs2960967	ENSG00000205578.5	POM121B	-4.97	9.28e-07	0.000119	-0.34	-0.22	Subcutaneous adipose tissue;	chr7:72701793	chr7:73293497~73301161:+
THCA	cis	rs2058059	0.595	rs3015844	ENSG00000205578.5	POM121B	-4.97	9.28e-07	0.000119	-0.34	-0.22	Subcutaneous adipose tissue;	chr7:72708751	chr7:73293497~73301161:+
THCA	cis	rs7119	0.717	rs12904254	ENSG00000259362.2	RP11-307C19.1	-4.97	9.28e-07	0.000119	-0.32	-0.22	Type 2 diabetes;	chr15:77510243	chr15:77525540~77534110:+
THCA	cis	rs4648045	0.796	rs3774963	ENSG00000246560.2	RP11-10L12.4	4.97	9.28e-07	0.000119	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102598208	chr4:102828055~102844075:+
THCA	cis	rs7520050	0.898	rs785502	ENSG00000234329.1	RP11-767N6.2	-4.97	9.28e-07	0.000119	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45651039~45651826:-
THCA	cis	rs860295	0.702	rs3738590	ENSG00000160766.13	GBAP1	-4.97	9.28e-07	0.000119	-0.26	-0.22	Body mass index;	chr1:155660961	chr1:155213821~155227422:-
THCA	cis	rs875971	0.545	rs73136346	ENSG00000228409.4	CCT6P1	4.97	9.28e-07	0.000119	0.19	0.22	Aortic root size;	chr7:66101095	chr7:65751142~65763354:+
THCA	cis	rs6832769	0.961	rs2412647	ENSG00000272969.1	RP11-528I4.2	4.97	9.28e-07	0.000119	0.26	0.22	Personality dimensions;	chr4:55452938	chr4:55547112~55547889:+
THCA	cis	rs875971	0.929	rs4122249	ENSG00000223473.2	GS1-124K5.3	4.97	9.29e-07	0.000119	0.15	0.22	Aortic root size;	chr7:66455949	chr7:66491049~66493566:-
THCA	cis	rs7045881	0.8	rs62544401	ENSG00000254396.1	RP11-56F10.3	4.97	9.29e-07	0.000119	0.4	0.22	Schizophrenia;	chr9:26850495	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.8	rs75671435	ENSG00000254396.1	RP11-56F10.3	4.97	9.29e-07	0.000119	0.4	0.22	Schizophrenia;	chr9:26852062	chr9:27102630~27104728:+
THCA	cis	rs2742234	0.915	rs2742233	ENSG00000273008.1	RP11-351D16.3	-4.97	9.29e-07	0.000119	-0.19	-0.22	Hirschsprung disease;	chr10:43115110	chr10:43136824~43138334:-
THCA	cis	rs11671005	0.693	rs11668757	ENSG00000268049.1	CTD-2619J13.9	-4.97	9.29e-07	0.000119	-0.35	-0.22	Mean platelet volume;	chr19:58416932	chr19:58357999~58359603:+
THCA	cis	rs481331	0.643	rs549167	ENSG00000215146.4	RP11-313J2.1	-4.97	9.29e-07	0.000119	-0.36	-0.22	Systemic juvenile idiopathic arthritis;	chr10:42691373	chr10:42331866~42367974:-
THCA	cis	rs7474896	0.583	rs11011341	ENSG00000263064.2	RP11-291L22.7	4.97	9.3e-07	0.000119	0.3	0.22	Obesity (extreme);	chr10:37709572	chr10:38448689~38448949:+
THCA	cis	rs6903823	0.508	rs1150718	ENSG00000273712.1	RP5-874C20.7	4.97	9.3e-07	0.000119	0.25	0.22	Pulmonary function;	chr6:28289170	chr6:28315613~28315883:-
THCA	cis	rs12823128	0.646	rs12582913	ENSG00000256185.1	RP11-612B6.2	-4.97	9.3e-07	0.000119	-0.21	-0.22	Birth weight;	chr12:26724326	chr12:26335864~26336950:-
THCA	cis	rs17123764	0.818	rs12314878	ENSG00000257464.1	RP11-161H23.8	-4.97	9.3e-07	0.000119	-0.37	-0.22	Intelligence (multi-trait analysis);	chr12:49548425	chr12:49442424~49442652:-
THCA	cis	rs9283706	0.548	rs10044452	ENSG00000229666.1	MAST4-AS1	-4.97	9.3e-07	0.000119	-0.31	-0.22	Coronary artery disease;	chr5:67006777	chr5:67001383~67003953:-
THCA	cis	rs10860794	0.627	rs12299074	ENSG00000274560.1	RP11-285E23.2	-4.97	9.31e-07	0.000119	-0.15	-0.22	Blood protein levels;	chr12:101858685	chr12:101696002~101696450:-
THCA	cis	rs1577917	0.56	rs12193777	ENSG00000220563.1	PKMP3	4.97	9.31e-07	0.000119	0.16	0.22	Response to antipsychotic treatment;	chr6:85536991	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.655	rs9444351	ENSG00000220563.1	PKMP3	4.97	9.31e-07	0.000119	0.16	0.22	Response to antipsychotic treatment;	chr6:85538081	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.655	rs7766485	ENSG00000220563.1	PKMP3	4.97	9.31e-07	0.000119	0.16	0.22	Response to antipsychotic treatment;	chr6:85553837	chr6:85659892~85660606:-
THCA	cis	rs6517329	0.509	rs2242808	ENSG00000236830.5	CBR3-AS1	-4.97	9.31e-07	0.000119	-0.21	-0.22	Schizophrenia;	chr21:36158235	chr21:36131767~36175815:-
THCA	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-4.97	9.32e-07	0.000119	-0.31	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
THCA	cis	rs12413361	0.967	rs10826875	ENSG00000272914.1	RP11-330O11.3	-4.97	9.32e-07	0.000119	-0.19	-0.22	Height;	chr10:30830785	chr10:30831828~30833387:-
THCA	cis	rs3796352	1	rs13092352	ENSG00000242142.1	SERBP1P3	-4.97	9.32e-07	0.000119	-0.42	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52935681	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs11713290	ENSG00000242142.1	SERBP1P3	-4.97	9.32e-07	0.000119	-0.42	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52937563	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs13074524	ENSG00000242142.1	SERBP1P3	-4.97	9.32e-07	0.000119	-0.42	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52940168	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs2336540	ENSG00000242142.1	SERBP1P3	-4.97	9.32e-07	0.000119	-0.42	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52940573	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs2336541	ENSG00000242142.1	SERBP1P3	-4.97	9.32e-07	0.000119	-0.42	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52940614	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs11718538	ENSG00000242142.1	SERBP1P3	-4.97	9.32e-07	0.000119	-0.42	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52941971	chr3:53064283~53065091:-
THCA	cis	rs55704346	0.715	rs3796792	ENSG00000281501.1	SEPSECS-AS1	4.97	9.33e-07	0.000119	0.25	0.22	Tonsillectomy;	chr4:25142697	chr4:25160641~25201440:+
THCA	cis	rs55704346	0.691	rs6826204	ENSG00000281501.1	SEPSECS-AS1	4.97	9.33e-07	0.000119	0.25	0.22	Tonsillectomy;	chr4:25149233	chr4:25160641~25201440:+
THCA	cis	rs8014252	0.732	rs7141636	ENSG00000259158.2	ADAM20P1	-4.97	9.33e-07	0.000119	-0.25	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70389518	chr14:70468881~70483756:-
THCA	cis	rs7267979	0.932	rs367666	ENSG00000274973.1	RP13-401N8.7	-4.97	9.33e-07	0.000119	-0.26	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25845497~25845862:+
THCA	cis	rs944289	0.745	rs1537427	ENSG00000258844.1	RP11-259K15.2	-4.97	9.33e-07	0.000119	-0.2	-0.22	Thyroid cancer;	chr14:36117640	chr14:36214607~36235608:+
THCA	cis	rs2337406	0.587	rs10150642	ENSG00000211974.3	IGHV2-70	4.97	9.33e-07	0.000119	0.21	0.22	Alzheimer's disease (late onset);	chr14:106647269	chr14:106723574~106724093:-
THCA	cis	rs9652601	0.622	rs8045749	ENSG00000274038.1	RP11-66H6.4	-4.97	9.33e-07	0.000119	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11025796	chr16:11056556~11057034:+
THCA	cis	rs6806253	0.589	rs4532151	ENSG00000239405.1	TMED10P2	4.97	9.33e-07	0.000119	0.33	0.22	Pit-and-Fissure caries;	chr3:128513836	chr3:128538020~128538631:+
THCA	cis	rs62184315	0.575	rs256546	ENSG00000253559.1	OSGEPL1-AS1	-4.97	9.33e-07	0.000119	-0.25	-0.22	Alcohol dependence (age at onset);	chr2:189886437	chr2:189762704~189765556:+
THCA	cis	rs7555523	0.83	rs6426936	ENSG00000224358.1	RP11-466F5.8	4.97	9.34e-07	0.000119	0.36	0.22	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165715470	chr1:165768929~165775176:+
THCA	cis	rs860295	0.702	rs12746592	ENSG00000160766.13	GBAP1	-4.97	9.34e-07	0.000119	-0.26	-0.22	Body mass index;	chr1:155536176	chr1:155213821~155227422:-
THCA	cis	rs2154319	0.609	rs61774718	ENSG00000235358.1	RP11-399E6.1	-4.97	9.34e-07	0.000119	-0.29	-0.22	Height;	chr1:41274060	chr1:41242373~41284861:+
THCA	cis	rs317689	0.69	rs10878946	ENSG00000274979.1	RP11-1143G9.5	-4.97	9.34e-07	0.000119	-0.25	-0.22	Response to diuretic therapy;	chr12:69248535	chr12:69326574~69331882:-
THCA	cis	rs8020095	0.571	rs10131614	ENSG00000258561.1	RP11-72M17.1	-4.97	9.35e-07	0.000119	-0.3	-0.22	Depression (quantitative trait);	chr14:66896825	chr14:66212810~66509394:-
THCA	cis	rs8141529	0.632	rs5762803	ENSG00000226471.5	CTA-292E10.6	-4.97	9.35e-07	0.000119	-0.19	-0.22	Lymphocyte counts;	chr22:28797650	chr22:28800683~28848559:+
THCA	cis	rs6490294	0.528	rs57866673	ENSG00000226469.1	ADAM1B	4.97	9.35e-07	0.000119	0.37	0.22	Mean platelet volume;	chr12:112195500	chr12:111927018~111929017:+
THCA	cis	rs11992162	0.529	rs6995037	ENSG00000206014.6	OR7E161P	4.97	9.35e-07	0.000119	0.27	0.22	Monocyte count;	chr8:11923378	chr8:11928597~11929563:-
THCA	cis	rs8024893	0.764	rs7182545	ENSG00000270055.1	CTD-3092A11.2	-4.97	9.35e-07	0.000119	-0.3	-0.22	Red cell distribution width;	chr15:31239638	chr15:30487963~30490313:+
THCA	cis	rs12906542	0.516	rs4886992	ENSG00000260776.4	RP11-114H24.2	4.97	9.35e-07	0.000119	0.37	0.22	Breast cancer;	chr15:78032887	chr15:77914217~77926846:-
THCA	cis	rs6951245	1	rs80212261	ENSG00000229043.2	AC091729.9	-4.97	9.35e-07	0.000119	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1160374~1165267:+
THCA	cis	rs9393777	0.844	rs28360634	ENSG00000219392.1	RP1-265C24.5	-4.97	9.35e-07	0.000119	-0.47	-0.22	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28115628~28116551:+
THCA	cis	rs5742933	0.69	rs62183656	ENSG00000253559.1	OSGEPL1-AS1	-4.97	9.35e-07	0.000119	-0.32	-0.22	Ferritin levels;	chr2:189669387	chr2:189762704~189765556:+
THCA	cis	rs911555	0.692	rs60235428	ENSG00000244691.1	RPL10AP1	4.97	9.35e-07	0.000119	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103412119~103412761:-
THCA	cis	rs2348418	0.639	rs2347595	ENSG00000247934.4	RP11-967K21.1	-4.97	9.35e-07	0.000119	-0.19	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28109947	chr12:28163298~28190738:-
THCA	cis	rs987724	0.593	rs9853479	ENSG00000240875.4	LINC00886	-4.97	9.36e-07	0.00012	-0.17	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156966135	chr3:156747346~156817062:-
THCA	cis	rs8022179	0.58	rs58153827	ENSG00000244691.1	RPL10AP1	4.97	9.36e-07	0.00012	0.32	0.22	Monocyte count;	chr14:103378293	chr14:103412119~103412761:-
THCA	cis	rs7580717	0.785	rs13428268	ENSG00000224376.1	AC017104.6	4.97	9.36e-07	0.00012	0.25	0.22	Multiple myeloma;	chr2:231290928	chr2:231388976~231394991:+
THCA	cis	rs1979679	0.578	rs2127316	ENSG00000278733.1	RP11-425D17.1	4.97	9.36e-07	0.00012	0.22	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28121472	chr12:28185625~28186190:-
THCA	cis	rs858239	0.6	rs61292332	ENSG00000230042.1	AK3P3	-4.97	9.36e-07	0.00012	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23129178~23129841:+
THCA	cis	rs111580313	0.534	rs4843170	ENSG00000270020.1	RP11-463O9.9	4.97	9.37e-07	0.00012	0.47	0.22	Systemic juvenile idiopathic arthritis;	chr16:86576660	chr16:86520383~86523897:-
THCA	cis	rs7208859	0.673	rs73277964	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11652409	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9896095	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs58920731	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73277984	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73277986	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs12103588	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.614	rs9914534	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs4131618	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11658344	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9900144	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs11656121	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11650973	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs56085216	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11650305	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11654914	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9914271	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.37e-07	0.00012	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30738182~30740275:+
THCA	cis	rs7115242	0.925	rs7925256	ENSG00000280143.1	AP000892.6	4.97	9.37e-07	0.00012	0.43	0.22	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117204967~117210292:+
THCA	cis	rs4415084	0.617	rs10039173	ENSG00000272335.1	RP11-53O19.3	4.97	9.37e-07	0.00012	0.19	0.22	Breast cancer;	chr5:44903274	chr5:44826076~44828592:+
THCA	cis	rs6545883	0.86	rs6749226	ENSG00000270820.4	RP11-355B11.2	-4.97	9.38e-07	0.00012	-0.19	-0.22	Tuberculosis;	chr2:61282648	chr2:61471188~61484130:+
THCA	cis	rs4218	0.701	rs7174277	ENSG00000259732.1	RP11-59H7.3	-4.97	9.38e-07	0.00012	-0.28	-0.22	Social communication problems;	chr15:59150390	chr15:59121034~59133250:+
THCA	cis	rs2841277	0.741	rs9672139	ENSG00000258701.1	LINC00638	4.97	9.38e-07	0.00012	0.24	0.22	Rheumatoid arthritis;	chr14:104941845	chr14:104821201~104823718:+
THCA	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-4.97	9.38e-07	0.00012	-0.27	-0.22	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
THCA	cis	rs10872587	0.657	rs11155459	ENSG00000235652.6	RP11-545I5.3	-4.97	9.38e-07	0.00012	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:146257615	chr6:145799409~145886585:+
THCA	cis	rs6545883	0.507	rs6545855	ENSG00000270820.4	RP11-355B11.2	-4.97	9.39e-07	0.00012	-0.19	-0.22	Tuberculosis;	chr2:61305725	chr2:61471188~61484130:+
THCA	cis	rs972578	0.715	rs1807592	ENSG00000274717.1	RP1-47A17.1	-4.97	9.39e-07	0.00012	-0.24	-0.22	Mean platelet volume;	chr22:42830906	chr22:42791814~42794313:-
THCA	cis	rs17772222	0.63	rs2778936	ENSG00000258983.2	RP11-507K2.2	-4.97	9.39e-07	0.00012	-0.26	-0.22	Coronary artery calcification;	chr14:88505959	chr14:88499334~88515502:+
THCA	cis	rs62025270	0.632	rs3169119	ENSG00000259295.5	CSPG4P12	-4.97	9.4e-07	0.00012	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85191438~85213905:+
THCA	cis	rs6545883	0.894	rs9677047	ENSG00000270820.4	RP11-355B11.2	-4.97	9.4e-07	0.00012	-0.19	-0.22	Tuberculosis;	chr2:61358160	chr2:61471188~61484130:+
THCA	cis	rs7260598	0.502	rs17725202	ENSG00000268442.1	CTD-2027I19.2	4.97	9.4e-07	0.00012	0.32	0.22	Response to taxane treatment (placlitaxel);	chr19:23876474	chr19:24162370~24163425:-
THCA	cis	rs338389	0.586	rs10851782	ENSG00000260657.2	RP11-315D16.4	-4.97	9.41e-07	0.00012	-0.28	-0.22	Survival in rectal cancer;	chr15:67972711	chr15:68267792~68277994:-
THCA	cis	rs7688540	0.8	rs12510827	ENSG00000250892.1	RP11-1365D11.1	4.97	9.41e-07	0.00012	0.31	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:201409~205009:-
THCA	cis	rs944289	0.74	rs7150440	ENSG00000258844.1	RP11-259K15.2	4.97	9.41e-07	0.00012	0.2	0.22	Thyroid cancer;	chr14:36114691	chr14:36214607~36235608:+
THCA	cis	rs944289	0.74	rs7150768	ENSG00000258844.1	RP11-259K15.2	4.97	9.41e-07	0.00012	0.2	0.22	Thyroid cancer;	chr14:36114699	chr14:36214607~36235608:+
THCA	cis	rs12435908	0.786	rs11846546	ENSG00000276116.2	FUT8-AS1	-4.97	9.41e-07	0.00012	-0.29	-0.22	Ischemic stroke;	chr14:65709675	chr14:65411170~65412690:-
THCA	cis	rs7621331	1	rs9814557	ENSG00000273486.1	RP11-731C17.2	4.97	9.42e-07	0.00012	0.21	0.22	Waist circumference adjusted for body mass index;	chr3:136001698	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs10935175	ENSG00000273486.1	RP11-731C17.2	4.97	9.42e-07	0.00012	0.21	0.22	Waist circumference adjusted for body mass index;	chr3:136005619	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs34522617	ENSG00000273486.1	RP11-731C17.2	4.97	9.42e-07	0.00012	0.21	0.22	Waist circumference adjusted for body mass index;	chr3:136005999	chr3:136837338~136839021:-
THCA	cis	rs8067545	0.532	rs35915823	ENSG00000261033.1	RP11-209D14.2	-4.97	9.42e-07	0.00012	-0.32	-0.22	Schizophrenia;	chr17:20070084	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.67	rs12937327	ENSG00000261033.1	RP11-209D14.2	-4.97	9.42e-07	0.00012	-0.32	-0.22	Obesity-related traits;	chr17:20075671	chr17:20008051~20009234:-
THCA	cis	rs2803122	0.967	rs10811148	ENSG00000273226.1	RP11-513M16.8	-4.97	9.42e-07	0.00012	-0.2	-0.22	Pulse pressure;	chr9:19246469	chr9:19375451~19375996:+
THCA	cis	rs9719620	0.834	rs4731787	ENSG00000236753.4	MKLN1-AS	4.97	9.42e-07	0.00012	0.21	0.22	Male-pattern baldness;	chr7:131301629	chr7:131309744~131328222:-
THCA	cis	rs2239547	0.563	rs4687560	ENSG00000242142.1	SERBP1P3	4.97	9.43e-07	0.00012	0.28	0.22	Schizophrenia;	chr3:52864105	chr3:53064283~53065091:-
THCA	cis	rs4144027	0.904	rs55696130	ENSG00000269910.1	RP11-73M18.10	-4.97	9.43e-07	0.00012	-0.21	-0.22	Blood metabolite levels;	chr14:103875527	chr14:103694516~103695050:-
THCA	cis	rs763121	0.819	rs4560233	ENSG00000235209.1	CTA-150C2.13	4.97	9.43e-07	0.00012	0.3	0.22	Menopause (age at onset);	chr22:38586437	chr22:38921227~38924708:+
THCA	cis	rs12413361	0.967	rs2994653	ENSG00000272914.1	RP11-330O11.3	-4.97	9.43e-07	0.00012	-0.19	-0.22	Height;	chr10:30835310	chr10:30831828~30833387:-
THCA	cis	rs72945132	0.882	rs55738915	ENSG00000254604.1	AP000487.6	-4.97	9.43e-07	0.00012	-0.42	-0.22	Coronary artery disease;	chr11:70343913	chr11:70282367~70363368:-
THCA	cis	rs3750082	0.852	rs2392152	ENSG00000231952.3	DPY19L1P2	-4.97	9.44e-07	0.00012	-0.28	-0.22	Glomerular filtration rate (creatinine);	chr7:32860937	chr7:32812757~32838570:+
THCA	cis	rs875971	0.545	rs73376394	ENSG00000228409.4	CCT6P1	-4.97	9.44e-07	0.00012	-0.19	-0.22	Aortic root size;	chr7:66172694	chr7:65751142~65763354:+
THCA	cis	rs7942368	0.941	rs12290350	ENSG00000261578.1	RP11-21L23.2	-4.97	9.44e-07	0.00012	-0.33	-0.22	Endometriosis;	chr11:76769211	chr11:76800364~76804555:+
THCA	cis	rs4950322	0.542	rs17159924	ENSG00000180867.10	PDIA3P1	4.97	9.44e-07	0.00012	0.22	0.22	Protein quantitative trait loci;	chr1:147199463	chr1:147178113~147179622:+
THCA	cis	rs17360053	0.859	rs35849962	ENSG00000218510.5	LINC00339	-4.97	9.44e-07	0.00012	-0.24	-0.22	Obesity-related traits;	chr1:22177156	chr1:22025188~22031223:+
THCA	cis	rs17360053	0.826	rs34026022	ENSG00000218510.5	LINC00339	-4.97	9.44e-07	0.00012	-0.24	-0.22	Obesity-related traits;	chr1:22177411	chr1:22025188~22031223:+
THCA	cis	rs896854	1	rs13255935	ENSG00000253528.2	RP11-347C18.4	4.97	9.44e-07	0.00012	0.25	0.22	Type 2 diabetes;	chr8:94953457	chr8:94974573~94974853:-
THCA	cis	rs9595908	0.9	rs9595890	ENSG00000212293.1	SNORA16	4.97	9.45e-07	0.000121	0.26	0.22	Body mass index;	chr13:32597518	chr13:32420390~32420516:-
THCA	cis	rs8141529	0.748	rs132533	ENSG00000272858.1	CTA-292E10.8	4.97	9.45e-07	0.000121	0.23	0.22	Lymphocyte counts;	chr22:28903583	chr22:28814914~28815662:+
THCA	cis	rs957448	1	rs12680965	ENSG00000253175.1	RP11-267M23.6	4.97	9.45e-07	0.000121	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94565036~94565715:+
THCA	cis	rs2179367	0.632	rs7349921	ENSG00000223701.3	RAET1E-AS1	4.97	9.45e-07	0.000121	0.32	0.22	Dupuytren's disease;	chr6:149392727	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs60153446	ENSG00000223701.3	RAET1E-AS1	4.97	9.45e-07	0.000121	0.32	0.22	Dupuytren's disease;	chr6:149393186	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs61259243	ENSG00000223701.3	RAET1E-AS1	4.97	9.45e-07	0.000121	0.32	0.22	Dupuytren's disease;	chr6:149393457	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs62426115	ENSG00000223701.3	RAET1E-AS1	4.97	9.45e-07	0.000121	0.32	0.22	Dupuytren's disease;	chr6:149393718	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs68080376	ENSG00000223701.3	RAET1E-AS1	4.97	9.45e-07	0.000121	0.32	0.22	Dupuytren's disease;	chr6:149393873	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs763590	ENSG00000223701.3	RAET1E-AS1	4.97	9.45e-07	0.000121	0.32	0.22	Dupuytren's disease;	chr6:149398831	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.632	rs17506789	ENSG00000223701.3	RAET1E-AS1	4.97	9.45e-07	0.000121	0.32	0.22	Dupuytren's disease;	chr6:149399710	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.586	rs34097428	ENSG00000223701.3	RAET1E-AS1	4.97	9.45e-07	0.000121	0.32	0.22	Dupuytren's disease;	chr6:149399822	chr6:149884431~149919508:+
THCA	cis	rs1005277	0.54	rs2474598	ENSG00000272983.1	RP11-508N22.12	-4.97	9.45e-07	0.000121	-0.19	-0.22	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38137337~38144399:+
THCA	cis	rs2562456	0.833	rs61035285	ENSG00000268119.4	CTD-2561J22.5	4.97	9.46e-07	0.000121	0.32	0.22	Pain;	chr19:21329475	chr19:21444241~21463908:-
THCA	cis	rs6792584	0.572	rs4377498	ENSG00000241316.5	SUCLG2-AS1	4.97	9.46e-07	0.000121	0.24	0.22	Corneal astigmatism;	chr3:67424450	chr3:67654697~67947713:+
THCA	cis	rs7208859	0.673	rs79541516	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.46e-07	0.000121	-0.36	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30738182~30740275:+
THCA	cis	rs2190422	0.677	rs2382693	ENSG00000234715.1	CTB-107G13.1	4.97	9.46e-07	0.000121	0.26	0.22	Morning vs. evening chronotype;	chr7:103436522	chr7:103445207~103514007:+
THCA	cis	rs748404	0.706	rs35975365	ENSG00000249839.1	AC011330.5	-4.97	9.46e-07	0.000121	-0.35	-0.22	Lung cancer;	chr15:43379347	chr15:43663654~43684339:-
THCA	cis	rs3820928	0.874	rs13383070	ENSG00000212391.1	SNORA48	-4.97	9.47e-07	0.000121	-0.25	-0.22	Pulmonary function;	chr2:227040223	chr2:226968989~226969122:-
THCA	cis	rs6901004	0.605	rs2297939	ENSG00000271789.1	RP5-1112D6.7	-4.97	9.48e-07	0.000121	-0.22	-0.22	Blood metabolite levels;	chr6:111227959	chr6:111297126~111298510:+
THCA	cis	rs1555322	0.556	rs7272884	ENSG00000279253.1	RP4-614O4.13	-4.97	9.48e-07	0.000121	-0.27	-0.22	Attention deficit hyperactivity disorder;	chr20:35295212	chr20:35262727~35264187:-
THCA	cis	rs9487094	0.67	rs749517	ENSG00000223537.2	RP5-919F19.5	4.97	9.49e-07	0.000121	0.23	0.22	Height;	chr6:109531713	chr6:109487906~109506800:+
THCA	cis	rs78487399	0.908	rs12471904	ENSG00000234936.1	AC010883.5	4.97	9.49e-07	0.000121	0.29	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43613534	chr2:43229573~43233394:+
THCA	cis	rs1552244	0.554	rs4488814	ENSG00000232901.1	CYCSP10	-4.97	9.49e-07	0.000121	-0.26	-0.22	Alzheimer's disease;	chr3:9960716	chr3:10000647~10000940:-
THCA	cis	rs7552393	0.636	rs12135529	ENSG00000233008.4	RP11-475O6.1	4.97	9.5e-07	0.000121	0.26	0.22	Select biomarker traits;	chr1:83827430	chr1:83575776~83861023:-
THCA	cis	rs6750795	0.542	rs1797388	ENSG00000223198.1	RNU2-22P	-4.97	9.5e-07	0.000121	-0.28	-0.22	Height;	chr2:231551270	chr2:231501990~231502201:-
THCA	cis	rs6832769	0.961	rs1873092	ENSG00000272969.1	RP11-528I4.2	-4.97	9.5e-07	0.000121	-0.26	-0.22	Personality dimensions;	chr4:55578133	chr4:55547112~55547889:+
THCA	cis	rs7976269	0.609	rs2349574	ENSG00000275476.1	RP11-996F15.4	-4.97	9.5e-07	0.000121	-0.22	-0.22	Male-pattern baldness;	chr12:29053805	chr12:29277397~29277882:-
THCA	cis	rs2154319	0.666	rs11209765	ENSG00000235358.1	RP11-399E6.1	-4.97	9.5e-07	0.000121	-0.3	-0.22	Height;	chr1:41262424	chr1:41242373~41284861:+
THCA	cis	rs7806994	1	rs7806994	ENSG00000273720.1	RP11-613E4.4	-4.97	9.5e-07	0.000121	-0.39	-0.22	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55743073~55743457:+
THCA	cis	rs8028182	0.636	rs4886699	ENSG00000260269.4	CTD-2323K18.1	-4.97	9.51e-07	0.000121	-0.33	-0.22	Sudden cardiac arrest;	chr15:75399962	chr15:75527150~75601205:-
THCA	cis	rs17270561	0.887	rs717551	ENSG00000272462.2	U91328.19	-4.97	9.51e-07	0.000121	-0.22	-0.22	Iron status biomarkers;	chr6:25855396	chr6:25992662~26001775:+
THCA	cis	rs3213758	1	rs74393433	ENSG00000275191.1	RP11-36I17.2	-4.97	9.51e-07	0.000121	-0.45	-0.22	Vitiligo (non-segmental);	chr16:53687994	chr16:53628256~53628816:-
THCA	cis	rs11992162	1	rs11784499	ENSG00000254948.1	OR7E158P	-4.97	9.51e-07	0.000121	-0.28	-0.22	Monocyte count;	chr8:11977030	chr8:11919900~11920809:-
THCA	cis	rs16958440	0.581	rs12386097	ENSG00000267800.1	RP11-49K24.5	-4.97	9.51e-07	0.000121	-0.43	-0.22	Sitting height ratio;	chr18:47146897	chr18:47137018~47137290:+
THCA	cis	rs8028313	0.63	rs3784700	ENSG00000270964.1	RP11-502I4.3	-4.97	9.51e-07	0.000121	-0.2	-0.22	Obesity;	chr15:67725414	chr15:67541072~67542604:-
THCA	cis	rs4713118	0.869	rs10214440	ENSG00000226314.6	ZNF192P1	-4.97	9.51e-07	0.000121	-0.28	-0.22	Parkinson's disease;	chr6:27734661	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs6902689	ENSG00000226314.6	ZNF192P1	-4.97	9.51e-07	0.000121	-0.28	-0.22	Parkinson's disease;	chr6:27741662	chr6:28161781~28169594:+
THCA	cis	rs6969780	1	rs6976129	ENSG00000233429.8	HOTAIRM1	4.97	9.51e-07	0.000121	0.34	0.22	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27138127	chr7:27095647~27100265:+
THCA	cis	rs6138458	1	rs4273288	ENSG00000274173.1	RP4-568C11.4	-4.97	9.51e-07	0.000121	-0.21	-0.22	Blood protein levels;	chr20:24920237	chr20:24931840~24932983:+
THCA	cis	rs6138458	0.962	rs6036976	ENSG00000274173.1	RP4-568C11.4	-4.97	9.51e-07	0.000121	-0.21	-0.22	Blood protein levels;	chr20:24920931	chr20:24931840~24932983:+
THCA	cis	rs7208859	0.673	rs11655623	ENSG00000280069.1	CTD-2349P21.3	-4.97	9.51e-07	0.000121	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30738182~30740275:+
THCA	cis	rs13126694	0.679	rs4072170	ENSG00000248429.4	RP11-597D13.9	4.97	9.52e-07	0.000121	0.24	0.22	Blood osmolality (transformed sodium);	chr4:157980683	chr4:158170752~158202877:+
THCA	cis	rs2034650	0.544	rs600791	ENSG00000223313.1	RNU6-516P	4.97	9.52e-07	0.000121	0.24	0.22	Interstitial lung disease;	chr15:40428868	chr15:40529570~40529673:+
THCA	cis	rs79243044	0.901	rs2879824	ENSG00000224295.2	AC087380.14	-4.97	9.52e-07	0.000121	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5537412	chr11:5518441~5524955:-
THCA	cis	rs79243044	0.932	rs2879825	ENSG00000224295.2	AC087380.14	-4.97	9.52e-07	0.000121	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5537413	chr11:5518441~5524955:-
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000273796.1	LL21NC02-21A1.1	-4.97	9.52e-07	0.000121	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000273796.1	LL21NC02-21A1.1	-4.97	9.52e-07	0.000121	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000273796.1	LL21NC02-21A1.1	-4.97	9.52e-07	0.000121	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45403809~45404369:-
THCA	cis	rs12030196	0.827	rs2094078	ENSG00000230812.4	LINC01358	4.97	9.52e-07	0.000121	0.29	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58975722	chr1:59020387~59044614:+
THCA	cis	rs1538970	0.781	rs34768551	ENSG00000234329.1	RP11-767N6.2	4.97	9.52e-07	0.000121	0.23	0.22	Platelet count;	chr1:45554736	chr1:45651039~45651826:-
THCA	cis	rs3738443	0.83	rs58405512	ENSG00000259865.1	RP11-488L18.10	4.97	9.52e-07	0.000121	0.23	0.22	Alcohol dependence;	chr1:247198454	chr1:247187281~247188526:-
THCA	cis	rs2742234	0.614	rs3026750	ENSG00000273008.1	RP11-351D16.3	-4.97	9.53e-07	0.000121	-0.19	-0.22	Hirschsprung disease;	chr10:43112308	chr10:43136824~43138334:-
THCA	cis	rs111580313	0.71	rs77733759	ENSG00000270020.1	RP11-463O9.9	4.97	9.53e-07	0.000121	0.5	0.22	Systemic juvenile idiopathic arthritis;	chr16:86590513	chr16:86520383~86523897:-
THCA	cis	rs10510102	0.935	rs11200257	ENSG00000226864.1	ATE1-AS1	4.97	9.53e-07	0.000122	0.36	0.22	Breast cancer;	chr10:121917232	chr10:121928312~121951965:+
THCA	cis	rs793571	0.554	rs8033691	ENSG00000259250.1	RP11-50C13.1	-4.97	9.53e-07	0.000122	-0.24	-0.22	Schizophrenia;	chr15:58711112	chr15:58587507~58591676:+
THCA	cis	rs6472827	0.645	rs2956059	ENSG00000253983.2	RP1-16A9.1	4.97	9.53e-07	0.000122	0.32	0.22	Uterine fibroids;	chr8:74197795	chr8:74199396~74208441:+
THCA	cis	rs12188164	0.747	rs12188321	ENSG00000221990.4	EXOC3-AS1	4.97	9.53e-07	0.000122	0.17	0.22	Cystic fibrosis severity;	chr5:428303	chr5:441498~443160:-
THCA	cis	rs922182	0.633	rs4776698	ENSG00000275785.1	RP11-111E14.2	-4.97	9.54e-07	0.000122	-0.25	-0.22	Blood protein levels;	chr15:63975335	chr15:63890030~63890317:+
THCA	cis	rs17767392	0.958	rs1981588	ENSG00000259146.3	RP1-261D10.2	-4.97	9.54e-07	0.000122	-0.29	-0.22	Mitral valve prolapse;	chr14:71572972	chr14:71292729~71321814:-
THCA	cis	rs6012564	1	rs2295714	ENSG00000227431.4	CSE1L-AS1	4.97	9.54e-07	0.000122	0.27	0.22	Anger;	chr20:49123277	chr20:49040463~49046044:-
THCA	cis	rs916888	0.61	rs199444	ENSG00000261575.2	RP11-259G18.1	4.97	9.54e-07	0.000122	0.27	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46267037~46268694:+
THCA	cis	rs916888	0.61	rs199442	ENSG00000261575.2	RP11-259G18.1	4.97	9.54e-07	0.000122	0.27	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46267037~46268694:+
THCA	cis	rs1552244	1	rs17032396	ENSG00000180385.7	EMC3-AS1	-4.97	9.54e-07	0.000122	-0.25	-0.22	Alzheimer's disease;	chr3:10111875	chr3:9986893~10006990:+
THCA	cis	rs11992162	0.967	rs10112888	ENSG00000254948.1	OR7E158P	-4.97	9.54e-07	0.000122	-0.27	-0.22	Monocyte count;	chr8:11972699	chr8:11919900~11920809:-
THCA	cis	rs35740288	0.787	rs11637768	ENSG00000259295.5	CSPG4P12	4.97	9.55e-07	0.000122	0.35	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85680179	chr15:85191438~85213905:+
THCA	cis	rs919433	0.713	rs6714697	ENSG00000231621.1	AC013264.2	-4.97	9.55e-07	0.000122	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197619762	chr2:197197991~197199273:+
THCA	cis	rs944289	0.774	rs1958624	ENSG00000258844.1	RP11-259K15.2	-4.97	9.55e-07	0.000122	-0.2	-0.22	Thyroid cancer;	chr14:36128692	chr14:36214607~36235608:+
THCA	cis	rs4218	0.597	rs4775114	ENSG00000259732.1	RP11-59H7.3	-4.97	9.55e-07	0.000122	-0.31	-0.22	Social communication problems;	chr15:59059635	chr15:59121034~59133250:+
THCA	cis	rs539096	0.54	rs3011217	ENSG00000237950.1	RP11-7O11.3	-4.97	9.55e-07	0.000122	-0.19	-0.22	Intelligence (multi-trait analysis);	chr1:43837594	chr1:43944370~43946551:-
THCA	cis	rs453301	0.624	rs330060	ENSG00000253981.4	ALG1L13P	-4.97	9.55e-07	0.000122	-0.21	-0.22	Joint mobility (Beighton score);	chr8:9233392	chr8:8236003~8244667:-
THCA	cis	rs79349575	0.756	rs2643361	ENSG00000270781.1	RP11-501C14.9	-4.97	9.55e-07	0.000122	-0.27	-0.22	Type 2 diabetes;	chr17:48900100	chr17:48899131~48899748:+
THCA	cis	rs453301	0.605	rs7843024	ENSG00000254153.1	CTA-398F10.2	4.97	9.56e-07	0.000122	0.26	0.22	Joint mobility (Beighton score);	chr8:8942466	chr8:8456909~8461337:-
THCA	cis	rs453301	0.631	rs7843789	ENSG00000254153.1	CTA-398F10.2	4.97	9.56e-07	0.000122	0.26	0.22	Joint mobility (Beighton score);	chr8:8943051	chr8:8456909~8461337:-
THCA	cis	rs890448	0.93	rs11937097	ENSG00000254531.1	FLJ20021	-4.97	9.56e-07	0.000122	-0.2	-0.22	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101460780	chr4:101347780~101348883:+
THCA	cis	rs6545883	0.859	rs7561672	ENSG00000270820.4	RP11-355B11.2	-4.97	9.56e-07	0.000122	-0.19	-0.22	Tuberculosis;	chr2:61291959	chr2:61471188~61484130:+
THCA	cis	rs957448	1	rs72674861	ENSG00000253175.1	RP11-267M23.6	4.97	9.57e-07	0.000122	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94565036~94565715:+
THCA	cis	rs875971	0.502	rs11769702	ENSG00000228409.4	CCT6P1	-4.97	9.57e-07	0.000122	-0.19	-0.22	Aortic root size;	chr7:66255529	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs6970498	ENSG00000228409.4	CCT6P1	-4.97	9.57e-07	0.000122	-0.19	-0.22	Aortic root size;	chr7:66275908	chr7:65751142~65763354:+
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000176933.5	TOB2P1	-4.97	9.57e-07	0.000122	-0.24	-0.22	Pubertal anthropometrics;	chr6:28230503	chr6:28217643~28218634:-
THCA	cis	rs875971	0.522	rs4502988	ENSG00000223473.2	GS1-124K5.3	4.97	9.58e-07	0.000122	0.15	0.22	Aortic root size;	chr7:65832759	chr7:66491049~66493566:-
THCA	cis	rs875971	0.522	rs10807697	ENSG00000223473.2	GS1-124K5.3	4.97	9.58e-07	0.000122	0.15	0.22	Aortic root size;	chr7:65951183	chr7:66491049~66493566:-
THCA	cis	rs4578769	0.569	rs12605341	ENSG00000265939.1	UBE2CP2	-4.97	9.58e-07	0.000122	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22803011	chr18:22900486~22900995:-
THCA	cis	rs6496932	0.503	rs7164354	ENSG00000259630.2	CTD-2262B20.1	-4.97	9.58e-07	0.000122	-0.28	-0.22	Central corneal thickness;Corneal structure;	chr15:85405217	chr15:85415228~85415633:+
THCA	cis	rs8046148	0.724	rs7190890	ENSG00000279356.1	RP11-429P3.8	4.97	9.59e-07	0.000122	0.26	0.22	Testicular germ cell tumor;	chr16:50091945	chr16:50072862~50074986:+
THCA	cis	rs875971	0.545	rs2420612	ENSG00000228409.4	CCT6P1	-4.97	9.59e-07	0.000122	-0.19	-0.22	Aortic root size;	chr7:66536825	chr7:65751142~65763354:+
THCA	cis	rs703842	0.616	rs870392	ENSG00000270039.1	RP11-571M6.17	-4.97	9.59e-07	0.000122	-0.26	-0.22	Multiple sclerosis;	chr12:57825390	chr12:57803838~57804415:+
THCA	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-4.97	9.59e-07	0.000122	-0.23	-0.22	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
THCA	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	4.97	9.59e-07	0.000122	0.25	0.22	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
THCA	cis	rs8177876	0.822	rs9923732	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs9933184	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs9926174	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.642	rs8052490	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs8056972	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs74437879	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs76948085	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs80315956	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.642	rs16954572	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs9929586	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs9938965	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs7204040	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.731	rs7188508	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.642	rs10514513	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs28672349	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs4306521	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs4324142	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.642	rs4324143	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.818	rs59177227	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs59685942	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs10514514	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs10514515	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs1410	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs1412	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs1414	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs8177950	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.731	rs8177948	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs8177940	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.73	rs76656387	ENSG00000261061.1	RP11-303E16.2	-4.97	9.59e-07	0.000122	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81030770~81031485:+
THCA	cis	rs6430585	0.528	rs309142	ENSG00000231890.6	DARS-AS1	-4.97	9.59e-07	0.000122	-0.25	-0.22	Corneal structure;	chr2:135957754	chr2:135985176~136022593:+
THCA	cis	rs3177980	0.673	rs17603022	ENSG00000239494.2	RN7SL333P	-4.97	9.6e-07	0.000122	-0.22	-0.22	Amyotrophic lateral sclerosis;	chr1:169869137	chr1:169859756~169860052:+
THCA	cis	rs5015933	0.778	rs2184062	ENSG00000232630.1	PRPS1P2	-4.97	9.6e-07	0.000122	-0.15	-0.22	Body mass index;	chr9:125308231	chr9:125150653~125151589:+
THCA	cis	rs8031584	0.56	rs1056118	ENSG00000270015.1	RP11-540B6.6	4.97	9.6e-07	0.000122	0.16	0.22	Huntington's disease progression;	chr15:30911583	chr15:30926514~30928407:+
THCA	cis	rs1979679	0.842	rs11049411	ENSG00000247934.4	RP11-967K21.1	-4.97	9.6e-07	0.000122	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28184723	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.515	rs17434556	ENSG00000247934.4	RP11-967K21.1	4.97	9.6e-07	0.000122	0.23	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28442760	chr12:28163298~28190738:-
THCA	cis	rs7083	0.716	rs574603	ENSG00000254851.1	RP11-109L13.1	4.97	9.6e-07	0.000122	0.31	0.22	Blood protein levels;	chr11:117307025	chr11:117135528~117138582:+
THCA	cis	rs1707322	0.963	rs1768815	ENSG00000281133.1	AL355480.3	4.97	9.61e-07	0.000122	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs9429183	ENSG00000234329.1	RP11-767N6.2	-4.97	9.61e-07	0.000122	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45651039~45651826:-
THCA	cis	rs8027521	0.846	rs2725581	ENSG00000280362.1	RP11-643A5.3	-4.97	9.61e-07	0.000122	-0.27	-0.22	Circulating chemerin levels;	chr15:53971074	chr15:53910769~53914712:+
THCA	cis	rs763121	0.925	rs4821797	ENSG00000235209.1	CTA-150C2.13	4.97	9.61e-07	0.000122	0.28	0.22	Menopause (age at onset);	chr22:38620177	chr22:38921227~38924708:+
THCA	cis	rs2067615	0.524	rs7959062	ENSG00000260329.1	RP11-412D9.4	-4.97	9.62e-07	0.000122	-0.21	-0.22	Heart rate;	chr12:106713556	chr12:106954029~106955497:-
THCA	cis	rs763121	0.886	rs1013339	ENSG00000235209.1	CTA-150C2.13	4.97	9.63e-07	0.000123	0.28	0.22	Menopause (age at onset);	chr22:38578675	chr22:38921227~38924708:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000229886.1	RP5-1132H15.3	4.97	9.63e-07	0.000123	0.27	0.22	Corneal structure;	chr7:66887678	chr7:66025126~66031544:-
THCA	cis	rs1979679	0.918	rs2169755	ENSG00000247934.4	RP11-967K21.1	-4.96	9.63e-07	0.000123	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28338224	chr12:28163298~28190738:-
THCA	cis	rs9863	0.861	rs4930723	ENSG00000269997.1	RP11-214K3.21	-4.96	9.63e-07	0.000123	-0.28	-0.22	White blood cell count;	chr12:123939053	chr12:123966077~123966629:-
THCA	cis	rs17801127	0.636	rs4667408	ENSG00000231969.1	AC144449.1	-4.96	9.63e-07	0.000123	-0.35	-0.22	Liver enzyme levels (alanine transaminase);	chr2:149694352	chr2:149587196~149848233:+
THCA	cis	rs875971	0.522	rs4718286	ENSG00000213640.3	EEF1DP4	-4.96	9.64e-07	0.000123	-0.26	-0.22	Aortic root size;	chr7:65827777	chr7:64862999~64864370:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000213640.3	EEF1DP4	-4.96	9.64e-07	0.000123	-0.26	-0.22	Calcium levels;	chr7:65837419	chr7:64862999~64864370:+
THCA	cis	rs6686842	0.56	rs7534059	ENSG00000235358.1	RP11-399E6.1	-4.96	9.64e-07	0.000123	-0.3	-0.22	Height;	chr1:41015223	chr1:41242373~41284861:+
THCA	cis	rs1005277	0.522	rs289650	ENSG00000226578.1	RP11-258F22.1	-4.96	9.64e-07	0.000123	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:37775371~37784131:-
THCA	cis	rs7618915	0.571	rs1961959	ENSG00000243224.1	RP5-1157M23.2	-4.96	9.65e-07	0.000123	-0.24	-0.22	Bipolar disorder;	chr3:52551744	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.571	rs6798246	ENSG00000243224.1	RP5-1157M23.2	-4.96	9.65e-07	0.000123	-0.24	-0.22	Bipolar disorder;	chr3:52565906	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.571	rs7623199	ENSG00000243224.1	RP5-1157M23.2	-4.96	9.65e-07	0.000123	-0.24	-0.22	Bipolar disorder;	chr3:52571958	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.571	rs11130307	ENSG00000243224.1	RP5-1157M23.2	-4.96	9.65e-07	0.000123	-0.24	-0.22	Bipolar disorder;	chr3:52573666	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.571	rs12632381	ENSG00000243224.1	RP5-1157M23.2	-4.96	9.65e-07	0.000123	-0.24	-0.22	Bipolar disorder;	chr3:52573669	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.571	rs17264436	ENSG00000243224.1	RP5-1157M23.2	-4.96	9.65e-07	0.000123	-0.24	-0.22	Bipolar disorder;	chr3:52576635	chr3:52239258~52241097:+
THCA	cis	rs6545883	0.929	rs1209434	ENSG00000270820.4	RP11-355B11.2	4.96	9.65e-07	0.000123	0.19	0.22	Tuberculosis;	chr2:61445823	chr2:61471188~61484130:+
THCA	cis	rs9341808	0.527	rs2505946	ENSG00000272129.1	RP11-250B2.6	4.96	9.65e-07	0.000123	0.28	0.22	Sitting height ratio;	chr6:80100966	chr6:80355424~80356859:+
THCA	cis	rs6806253	0.589	rs13078209	ENSG00000239405.1	TMED10P2	4.96	9.65e-07	0.000123	0.33	0.22	Pit-and-Fissure caries;	chr3:128513541	chr3:128538020~128538631:+
THCA	cis	rs7809615	0.901	rs10261661	ENSG00000244219.5	GS1-259H13.2	-4.96	9.66e-07	0.000123	-0.4	-0.22	Blood metabolite ratios;	chr7:99592099	chr7:99598066~99610813:+
THCA	cis	rs651907	0.557	rs7645391	ENSG00000244119.1	PDCL3P4	4.96	9.66e-07	0.000123	0.2	0.22	Colorectal cancer;	chr3:101642662	chr3:101712472~101713191:+
THCA	cis	rs227275	0.554	rs223467	ENSG00000248971.2	KRT8P46	-4.96	9.66e-07	0.000123	-0.27	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102728746~102730171:-
THCA	cis	rs111756027	0.838	rs889707	ENSG00000260922.1	RP11-538I12.3	4.96	9.66e-07	0.000123	0.35	0.22	Bone mineral density (Ward's triangle area);	chr16:77283859	chr16:77234877~77290934:+
THCA	cis	rs2067615	0.579	rs10778510	ENSG00000260329.1	RP11-412D9.4	4.96	9.66e-07	0.000123	0.2	0.22	Heart rate;	chr12:106769187	chr12:106954029~106955497:-
THCA	cis	rs796395	0.967	rs1764705	ENSG00000228208.5	C1orf143	-4.96	9.66e-07	0.000123	-0.27	-0.22	Post bronchodilator FEV1/FVC ratio;	chr1:218475214	chr1:218510096~218525978:+
THCA	cis	rs11051970	0.679	rs2651377	ENSG00000274964.1	RP11-817I4.1	-4.96	9.66e-07	0.000123	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32403985	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.679	rs2651366	ENSG00000274964.1	RP11-817I4.1	-4.96	9.66e-07	0.000123	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32407497	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.636	rs2651368	ENSG00000274964.1	RP11-817I4.1	-4.96	9.66e-07	0.000123	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32408572	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.636	rs2733705	ENSG00000274964.1	RP11-817I4.1	-4.96	9.66e-07	0.000123	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32408630	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.636	rs2733703	ENSG00000274964.1	RP11-817I4.1	-4.96	9.66e-07	0.000123	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32408860	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.636	rs10844198	ENSG00000274964.1	RP11-817I4.1	-4.96	9.66e-07	0.000123	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32410545	chr12:32339368~32340724:+
THCA	cis	rs10923574	0.521	rs6660988	ENSG00000231365.4	RP11-418J17.1	-4.96	9.67e-07	0.000123	-0.23	-0.22	Breast cancer;Folding of antihelix;	chr1:118526054	chr1:119140396~119275973:+
THCA	cis	rs11051970	0.611	rs10844197	ENSG00000274964.1	RP11-817I4.1	-4.96	9.67e-07	0.000123	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32408081	chr12:32339368~32340724:+
THCA	cis	rs17214007	0.627	rs28593034	ENSG00000263335.1	AF001548.5	-4.96	9.67e-07	0.000123	-0.31	-0.22	Cognitive function;	chr16:15597329	chr16:15726674~15732993:+
THCA	cis	rs2562456	0.754	rs58338799	ENSG00000268119.4	CTD-2561J22.5	4.96	9.67e-07	0.000123	0.32	0.22	Pain;	chr19:21339009	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs7259396	ENSG00000268119.4	CTD-2561J22.5	4.96	9.67e-07	0.000123	0.32	0.22	Pain;	chr19:21340661	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.678	rs7260140	ENSG00000268119.4	CTD-2561J22.5	4.96	9.67e-07	0.000123	0.32	0.22	Pain;	chr19:21340723	chr19:21444241~21463908:-
THCA	cis	rs11051970	0.679	rs2931554	ENSG00000274964.1	RP11-817I4.1	-4.96	9.67e-07	0.000123	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32403228	chr12:32339368~32340724:+
THCA	cis	rs17767392	0.746	rs61989246	ENSG00000259146.3	RP1-261D10.2	4.96	9.67e-07	0.000123	0.28	0.22	Mitral valve prolapse;	chr14:71253526	chr14:71292729~71321814:-
THCA	cis	rs763121	0.819	rs5757133	ENSG00000235209.1	CTA-150C2.13	-4.96	9.68e-07	0.000123	-0.28	-0.22	Menopause (age at onset);	chr22:38551830	chr22:38921227~38924708:+
THCA	cis	rs4713118	0.539	rs510987	ENSG00000280107.1	AL022393.9	-4.96	9.68e-07	0.000123	-0.25	-0.22	Parkinson's disease;	chr6:27879739	chr6:28170845~28172521:+
THCA	cis	rs7520050	0.807	rs4660312	ENSG00000234329.1	RP11-767N6.2	4.96	9.68e-07	0.000123	0.2	0.22	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.807	rs4468203	ENSG00000234329.1	RP11-767N6.2	4.96	9.68e-07	0.000123	0.2	0.22	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45651039~45651826:-
THCA	cis	rs2070488	0.775	rs6780349	ENSG00000229589.1	ACVR2B-AS1	-4.96	9.68e-07	0.000123	-0.2	-0.22	Electrocardiographic conduction measures;	chr3:38513687	chr3:38451027~38454820:-
THCA	cis	rs7512898	0.5	rs7519783	ENSG00000260088.1	RP11-92G12.3	-4.96	9.68e-07	0.000123	-0.3	-0.22	Electrocardiographic conduction measures;	chr1:200715929	chr1:200669507~200694250:+
THCA	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	4.96	9.68e-07	0.000123	0.26	0.22	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
THCA	cis	rs6545883	0.894	rs778144	ENSG00000270820.4	RP11-355B11.2	-4.96	9.69e-07	0.000123	-0.19	-0.22	Tuberculosis;	chr2:61355993	chr2:61471188~61484130:+
THCA	cis	rs2239547	0.657	rs4687672	ENSG00000242142.1	SERBP1P3	4.96	9.69e-07	0.000123	0.28	0.22	Schizophrenia;	chr3:52846527	chr3:53064283~53065091:-
THCA	cis	rs7727544	0.582	rs6896703	ENSG00000233006.5	AC034220.3	-4.96	9.69e-07	0.000123	-0.17	-0.22	Blood metabolite levels;	chr5:132185602	chr5:132311285~132369916:-
THCA	cis	rs8017455	0.591	rs2300527	ENSG00000259167.2	NMNAT1P1	-4.96	9.69e-07	0.000123	-0.36	-0.22	Hair morphology;	chr14:81084544	chr14:81032529~81033404:+
THCA	cis	rs9283706	0.676	rs6449842	ENSG00000229666.1	MAST4-AS1	-4.96	9.69e-07	0.000123	-0.33	-0.22	Coronary artery disease;	chr5:67027331	chr5:67001383~67003953:-
THCA	cis	rs2562456	0.833	rs1626404	ENSG00000268081.1	RP11-678G14.2	4.96	9.7e-07	0.000123	0.38	0.22	Pain;	chr19:21300986	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.833	rs1781867	ENSG00000268081.1	RP11-678G14.2	4.96	9.7e-07	0.000123	0.38	0.22	Pain;	chr19:21304368	chr19:21554640~21569237:-
THCA	cis	rs153734	0.768	rs7625805	ENSG00000280620.1	SCAANT1	4.96	9.7e-07	0.000123	0.34	0.22	Folate pathway vitamin levels;	chr3:64102556	chr3:63911518~63911772:-
THCA	cis	rs10090774	0.965	rs11780030	ENSG00000279766.1	RP11-642A1.2	-4.96	9.7e-07	0.000123	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140997644	chr8:140572142~140572812:-
THCA	cis	rs66887589	0.616	rs11098497	ENSG00000249244.1	RP11-548H18.2	4.96	9.7e-07	0.000123	0.23	0.22	Diastolic blood pressure;	chr4:119265913	chr4:119391831~119395335:-
THCA	cis	rs459482	0.508	rs461093	ENSG00000228318.3	AP001610.5	4.96	9.7e-07	0.000123	0.27	0.22	IgG glycosylation;	chr21:41428263	chr21:41441056~41445708:-
THCA	cis	rs8058578	0.633	rs113448632	ENSG00000260911.2	RP11-196G11.2	4.96	9.7e-07	0.000123	0.21	0.22	Multiple myeloma;	chr16:30886898	chr16:31043150~31049868:+
THCA	cis	rs4908769	0.624	rs1763839	ENSG00000232912.4	RP5-1115A15.1	4.96	9.71e-07	0.000123	0.24	0.22	Allergy;	chr1:8413276	chr1:8424645~8434838:+
THCA	cis	rs6686842	0.536	rs11209720	ENSG00000235358.1	RP11-399E6.1	-4.96	9.71e-07	0.000124	-0.29	-0.22	Height;	chr1:41224745	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.536	rs11209721	ENSG00000235358.1	RP11-399E6.1	-4.96	9.71e-07	0.000124	-0.29	-0.22	Height;	chr1:41224972	chr1:41242373~41284861:+
THCA	cis	rs736408	0.561	rs2276815	ENSG00000242142.1	SERBP1P3	4.96	9.71e-07	0.000124	0.29	0.22	Bipolar disorder;	chr3:52819731	chr3:53064283~53065091:-
THCA	cis	rs3734266	0.702	rs7765969	ENSG00000272288.4	RP11-140K17.3	-4.96	9.71e-07	0.000124	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34667078	chr6:34696317~34697470:+
THCA	cis	rs7618915	0.571	rs34115864	ENSG00000243224.1	RP5-1157M23.2	-4.96	9.72e-07	0.000124	-0.24	-0.22	Bipolar disorder;	chr3:52578162	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.533	rs35107891	ENSG00000243224.1	RP5-1157M23.2	-4.96	9.72e-07	0.000124	-0.24	-0.22	Bipolar disorder;	chr3:52579640	chr3:52239258~52241097:+
THCA	cis	rs1185460	1	rs15818	ENSG00000272186.1	RP11-110I1.13	-4.96	9.72e-07	0.000124	-0.22	-0.22	Coronary artery disease;	chr11:119081463	chr11:119067374~119067698:-
THCA	cis	rs6088590	0.735	rs2273684	ENSG00000269202.1	RP4-614O4.12	4.96	9.72e-07	0.000124	0.19	0.22	Coronary artery disease;	chr20:34941963	chr20:35201747~35203288:-
THCA	cis	rs2303319	0.504	rs56190932	ENSG00000227403.1	AC009299.3	4.96	9.72e-07	0.000124	0.55	0.22	Cognitive function;	chr2:161843894	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72879281	ENSG00000227403.1	AC009299.3	4.96	9.72e-07	0.000124	0.55	0.22	Cognitive function;	chr2:161844643	chr2:161244739~161249050:+
THCA	cis	rs1880529	0.83	rs6533687	ENSG00000206820.1	RNU1-138P	4.96	9.72e-07	0.000124	0.25	0.22	White matter integrity (bipolar disorder risk interaction);	chr4:113444119	chr4:113420323~113420486:+
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000273712.1	RP5-874C20.7	4.96	9.72e-07	0.000124	0.23	0.22	Pubertal anthropometrics;	chr6:28411584	chr6:28315613~28315883:-
THCA	cis	rs728616	0.681	rs11815284	ENSG00000225484.5	NUTM2B-AS1	-4.96	9.72e-07	0.000124	-0.35	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80263386	chr10:79663088~79826594:-
THCA	cis	rs7809615	0.901	rs13243267	ENSG00000244219.5	GS1-259H13.2	4.96	9.73e-07	0.000124	0.4	0.22	Blood metabolite ratios;	chr7:99455691	chr7:99598066~99610813:+
THCA	cis	rs7773456	0.533	rs9350190	ENSG00000237404.1	RP3-471C18.2	4.96	9.73e-07	0.000124	0.29	0.22	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19689825~19753113:-
THCA	cis	rs10090774	0.87	rs11782305	ENSG00000279766.1	RP11-642A1.2	-4.96	9.73e-07	0.000124	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140995572	chr8:140572142~140572812:-
THCA	cis	rs793571	0.554	rs7163939	ENSG00000259250.1	RP11-50C13.1	-4.96	9.73e-07	0.000124	-0.24	-0.22	Schizophrenia;	chr15:58707956	chr15:58587507~58591676:+
THCA	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-4.96	9.74e-07	0.000124	-0.31	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
THCA	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-4.96	9.74e-07	0.000124	-0.31	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
THCA	cis	rs3738443	0.817	rs61839996	ENSG00000259865.1	RP11-488L18.10	4.96	9.74e-07	0.000124	0.23	0.22	Alcohol dependence;	chr1:247197571	chr1:247187281~247188526:-
THCA	cis	rs7942368	1	rs7933092	ENSG00000261578.1	RP11-21L23.2	4.96	9.74e-07	0.000124	0.32	0.22	Endometriosis;	chr11:76764444	chr11:76800364~76804555:+
THCA	cis	rs4748857	0.685	rs12358964	ENSG00000224215.1	RP11-371A19.2	-4.96	9.74e-07	0.000124	-0.29	-0.22	Systemic lupus erythematosus;	chr10:23295491	chr10:23343957~23345181:+
THCA	cis	rs467650	0.853	rs456470	ENSG00000248489.1	CTD-2007H13.3	4.96	9.74e-07	0.000124	0.21	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98687777	chr5:98929171~98995013:+
THCA	cis	rs467650	0.853	rs457260	ENSG00000248489.1	CTD-2007H13.3	4.96	9.74e-07	0.000124	0.21	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98689031	chr5:98929171~98995013:+
THCA	cis	rs467650	0.853	rs294031	ENSG00000248489.1	CTD-2007H13.3	4.96	9.74e-07	0.000124	0.21	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98690903	chr5:98929171~98995013:+
THCA	cis	rs467650	0.747	rs382202	ENSG00000248489.1	CTD-2007H13.3	4.96	9.74e-07	0.000124	0.21	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98693015	chr5:98929171~98995013:+
THCA	cis	rs6686842	0.56	rs213744	ENSG00000235358.1	RP11-399E6.1	4.96	9.75e-07	0.000124	0.3	0.22	Height;	chr1:41154222	chr1:41242373~41284861:+
THCA	cis	rs2439831	1	rs471229	ENSG00000166763.7	STRCP1	4.96	9.75e-07	0.000124	0.3	0.22	Lung cancer in ever smokers;	chr15:43441796	chr15:43699488~43718184:-
THCA	cis	rs4718428	1	rs12534637	ENSG00000230295.1	RP11-458F8.2	-4.96	9.75e-07	0.000124	-0.18	-0.22	Corneal structure;	chr7:66862667	chr7:66880708~66882981:+
THCA	cis	rs763121	0.853	rs2267395	ENSG00000228274.3	RP3-508I15.9	-4.96	9.75e-07	0.000124	-0.25	-0.22	Menopause (age at onset);	chr22:38717898	chr22:38667585~38681820:-
THCA	cis	rs2029362	0.591	rs10835210	ENSG00000245573.6	BDNF-AS	4.96	9.75e-07	0.000124	0.18	0.22	Total body bone mineral density;	chr11:27674363	chr11:27506838~27698174:+
THCA	cis	rs1129187	0.719	rs3805953	ENSG00000272223.1	RP1-20C7.6	4.96	9.75e-07	0.000124	0.17	0.22	Alzheimer's disease in APOE e4+ carriers;	chr6:42969162	chr6:43033897~43034405:-
THCA	cis	rs8177876	0.584	rs2549899	ENSG00000261061.1	RP11-303E16.2	4.96	9.76e-07	0.000124	0.29	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81030770~81031485:+
THCA	cis	rs7474896	0.559	rs1212108	ENSG00000263064.2	RP11-291L22.7	4.96	9.76e-07	0.000124	0.31	0.22	Obesity (extreme);	chr10:37805394	chr10:38448689~38448949:+
THCA	cis	rs6686842	0.536	rs12123384	ENSG00000235358.1	RP11-399E6.1	-4.96	9.76e-07	0.000124	-0.29	-0.22	Height;	chr1:41239346	chr1:41242373~41284861:+
THCA	cis	rs748404	0.626	rs17780920	ENSG00000205771.5	CATSPER2P1	-4.96	9.76e-07	0.000124	-0.28	-0.22	Lung cancer;	chr15:43370164	chr15:43726918~43747094:-
THCA	cis	rs67340775	0.541	rs200968	ENSG00000226314.6	ZNF192P1	-4.96	9.77e-07	0.000124	-0.33	-0.22	Lung cancer in ever smokers;	chr6:27891790	chr6:28161781~28169594:+
THCA	cis	rs11671005	0.735	rs12986387	ENSG00000265272.2	RN7SL693P	4.96	9.77e-07	0.000124	0.31	0.22	Mean platelet volume;	chr19:58415848	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs11667723	ENSG00000265272.2	RN7SL693P	4.96	9.77e-07	0.000124	0.31	0.22	Mean platelet volume;	chr19:58416122	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs11668789	ENSG00000265272.2	RN7SL693P	4.96	9.77e-07	0.000124	0.31	0.22	Mean platelet volume;	chr19:58416942	chr19:58490797~58491075:+
THCA	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	4.96	9.77e-07	0.000124	0.13	0.22	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
THCA	cis	rs4648045	0.861	rs230533	ENSG00000246560.2	RP11-10L12.4	-4.96	9.78e-07	0.000124	-0.28	-0.22	Lymphocyte percentage of white cells;	chr4:102528926	chr4:102828055~102844075:+
THCA	cis	rs7577696	0.924	rs7566162	ENSG00000276334.1	AL133243.1	-4.96	9.78e-07	0.000124	-0.23	-0.22	Inflammatory biomarkers;	chr2:32099003	chr2:32521927~32523547:+
THCA	cis	rs17767392	0.67	rs4902928	ENSG00000259146.3	RP1-261D10.2	4.96	9.78e-07	0.000124	0.28	0.22	Mitral valve prolapse;	chr14:71265935	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.628	rs72726702	ENSG00000259146.3	RP1-261D10.2	4.96	9.78e-07	0.000124	0.28	0.22	Mitral valve prolapse;	chr14:71266603	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.746	rs72728403	ENSG00000259146.3	RP1-261D10.2	4.96	9.78e-07	0.000124	0.28	0.22	Mitral valve prolapse;	chr14:71266658	chr14:71292729~71321814:-
THCA	cis	rs911555	0.755	rs2756132	ENSG00000244691.1	RPL10AP1	4.96	9.79e-07	0.000124	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103412119~103412761:-
THCA	cis	rs11634944	0.644	rs2554419	ENSG00000257151.1	PWAR6	4.96	9.79e-07	0.000124	0.17	0.22	Interleukin-8 levels;	chr15:24995018	chr15:25031873~25036490:+
THCA	cis	rs2554380	0.55	rs62025854	ENSG00000230373.7	GOLGA6L5P	4.96	9.79e-07	0.000124	0.24	0.22	Height;	chr15:83883763	chr15:84507885~84516814:-
THCA	cis	rs2554380	0.55	rs17296856	ENSG00000230373.7	GOLGA6L5P	4.96	9.79e-07	0.000124	0.24	0.22	Height;	chr15:83888698	chr15:84507885~84516814:-
THCA	cis	rs73198271	1	rs4840356	ENSG00000253893.2	FAM85B	4.96	9.79e-07	0.000124	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750017	chr8:8167819~8226614:-
THCA	cis	rs4415084	0.716	rs987394	ENSG00000272335.1	RP11-53O19.3	-4.96	9.79e-07	0.000124	-0.19	-0.22	Breast cancer;	chr5:44846276	chr5:44826076~44828592:+
THCA	cis	rs916888	0.647	rs199449	ENSG00000261575.2	RP11-259G18.1	4.96	9.79e-07	0.000124	0.27	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46267037~46268694:+
THCA	cis	rs6565180	0.888	rs8060853	ENSG00000274653.1	RP11-347C12.11	-4.96	9.8e-07	0.000125	-0.22	-0.22	Tonsillectomy;	chr16:30392537	chr16:30359825~30360336:+
THCA	cis	rs12030196	0.827	rs7549330	ENSG00000230812.4	LINC01358	4.96	9.8e-07	0.000125	0.28	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58971767	chr1:59020387~59044614:+
THCA	cis	rs55704346	0.582	rs13118730	ENSG00000281501.1	SEPSECS-AS1	4.96	9.8e-07	0.000125	0.25	0.22	Tonsillectomy;	chr4:25128443	chr4:25160641~25201440:+
THCA	cis	rs3096299	0.658	rs4785679	ENSG00000261118.1	RP11-104N10.1	4.96	9.81e-07	0.000125	0.19	0.22	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89492017~89504460:-
THCA	cis	rs2067615	0.507	rs11113083	ENSG00000260329.1	RP11-412D9.4	-4.96	9.81e-07	0.000125	-0.21	-0.22	Heart rate;	chr12:106679538	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.524	rs10467029	ENSG00000260329.1	RP11-412D9.4	-4.96	9.81e-07	0.000125	-0.21	-0.22	Heart rate;	chr12:106684670	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.524	rs4964186	ENSG00000260329.1	RP11-412D9.4	-4.96	9.81e-07	0.000125	-0.21	-0.22	Heart rate;	chr12:106686457	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.524	rs9804754	ENSG00000260329.1	RP11-412D9.4	-4.96	9.81e-07	0.000125	-0.21	-0.22	Heart rate;	chr12:106689253	chr12:106954029~106955497:-
THCA	cis	rs2439831	0.681	rs528517	ENSG00000275601.1	AC011330.13	-4.96	9.81e-07	0.000125	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43320727	chr15:43642389~43643023:-
THCA	cis	rs34779708	0.931	rs2505631	ENSG00000271335.4	RP11-324I22.4	-4.96	9.81e-07	0.000125	-0.21	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35314552~35336401:-
THCA	cis	rs2803122	0.967	rs4977297	ENSG00000273226.1	RP11-513M16.8	-4.96	9.81e-07	0.000125	-0.2	-0.22	Pulse pressure;	chr9:19312326	chr9:19375451~19375996:+
THCA	cis	rs9859260	0.744	rs539816	ENSG00000207650.1	MIR570	-4.96	9.81e-07	0.000125	-0.24	-0.22	Mean corpuscular volume;	chr3:196057205	chr3:195699401~195699497:+
THCA	cis	rs9859260	0.744	rs492349	ENSG00000207650.1	MIR570	-4.96	9.81e-07	0.000125	-0.24	-0.22	Mean corpuscular volume;	chr3:196057321	chr3:195699401~195699497:+
THCA	cis	rs9859260	0.744	rs492288	ENSG00000207650.1	MIR570	-4.96	9.81e-07	0.000125	-0.24	-0.22	Mean corpuscular volume;	chr3:196057339	chr3:195699401~195699497:+
THCA	cis	rs7119	0.689	rs11630926	ENSG00000259362.2	RP11-307C19.1	-4.96	9.81e-07	0.000125	-0.33	-0.22	Type 2 diabetes;	chr15:77527240	chr15:77525540~77534110:+
THCA	cis	rs7119	0.636	rs34020536	ENSG00000259362.2	RP11-307C19.1	-4.96	9.81e-07	0.000125	-0.33	-0.22	Type 2 diabetes;	chr15:77527244	chr15:77525540~77534110:+
THCA	cis	rs7119	0.636	rs11635606	ENSG00000259362.2	RP11-307C19.1	-4.96	9.81e-07	0.000125	-0.33	-0.22	Type 2 diabetes;	chr15:77527249	chr15:77525540~77534110:+
THCA	cis	rs79349575	0.783	rs11079844	ENSG00000270781.1	RP11-501C14.9	-4.96	9.81e-07	0.000125	-0.27	-0.22	Type 2 diabetes;	chr17:48950972	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs62078372	ENSG00000270781.1	RP11-501C14.9	-4.96	9.81e-07	0.000125	-0.27	-0.22	Type 2 diabetes;	chr17:48951627	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs12602933	ENSG00000270781.1	RP11-501C14.9	-4.96	9.81e-07	0.000125	-0.27	-0.22	Type 2 diabetes;	chr17:48951918	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs4794003	ENSG00000270781.1	RP11-501C14.9	-4.96	9.81e-07	0.000125	-0.27	-0.22	Type 2 diabetes;	chr17:48952542	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs12602746	ENSG00000270781.1	RP11-501C14.9	-4.96	9.81e-07	0.000125	-0.27	-0.22	Type 2 diabetes;	chr17:48954379	chr17:48899131~48899748:+
THCA	cis	rs763121	0.819	rs5757160	ENSG00000235209.1	CTA-150C2.13	4.96	9.82e-07	0.000125	0.29	0.22	Menopause (age at onset);	chr22:38593641	chr22:38921227~38924708:+
THCA	cis	rs11671005	0.568	rs73068329	ENSG00000269600.1	AC016629.3	-4.96	9.82e-07	0.000125	-0.32	-0.22	Mean platelet volume;	chr19:58568958	chr19:58593896~58599355:-
THCA	cis	rs9863	0.898	rs11057400	ENSG00000269997.1	RP11-214K3.21	-4.96	9.82e-07	0.000125	-0.28	-0.22	White blood cell count;	chr12:123940602	chr12:123966077~123966629:-
THCA	cis	rs5742933	1	rs5743052	ENSG00000273240.1	RP11-455J20.3	-4.96	9.82e-07	0.000125	-0.25	-0.22	Ferritin levels;	chr2:189824558	chr2:189763859~189764456:-
THCA	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	4.96	9.82e-07	0.000125	0.22	0.22	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
THCA	cis	rs270601	0.77	rs4361510	ENSG00000224431.1	AC063976.7	4.96	9.83e-07	0.000125	0.19	0.22	Acylcarnitine levels;	chr5:132263954	chr5:132199456~132203487:+
THCA	cis	rs270601	0.77	rs61352298	ENSG00000224431.1	AC063976.7	4.96	9.83e-07	0.000125	0.19	0.22	Acylcarnitine levels;	chr5:132264896	chr5:132199456~132203487:+
THCA	cis	rs270601	0.739	rs1979981	ENSG00000224431.1	AC063976.7	4.96	9.83e-07	0.000125	0.19	0.22	Acylcarnitine levels;	chr5:132266027	chr5:132199456~132203487:+
THCA	cis	rs270601	0.77	rs1007602	ENSG00000224431.1	AC063976.7	4.96	9.83e-07	0.000125	0.19	0.22	Acylcarnitine levels;	chr5:132266473	chr5:132199456~132203487:+
THCA	cis	rs270601	0.71	rs4705852	ENSG00000224431.1	AC063976.7	4.96	9.83e-07	0.000125	0.19	0.22	Acylcarnitine levels;	chr5:132267114	chr5:132199456~132203487:+
THCA	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	4.96	9.83e-07	0.000125	0.25	0.22	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
THCA	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	4.96	9.83e-07	0.000125	0.25	0.22	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
THCA	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	4.96	9.83e-07	0.000125	0.25	0.22	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
THCA	cis	rs9902453	0.904	rs4994353	ENSG00000263370.1	RP11-68I3.5	-4.96	9.83e-07	0.000125	-0.29	-0.22	Coffee consumption (cups per day);	chr17:30059262	chr17:29639627~29640825:+
THCA	cis	rs72753537	0.817	rs7874716	ENSG00000214417.4	KRT18P13	4.96	9.83e-07	0.000125	0.25	0.22	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97842747	chr9:97698922~97700734:+
THCA	cis	rs56114371	0.53	rs9348774	ENSG00000226314.6	ZNF192P1	-4.96	9.83e-07	0.000125	-0.3	-0.22	Breast cancer;	chr6:27721151	chr6:28161781~28169594:+
THCA	cis	rs79243044	1	rs10838276	ENSG00000224295.2	AC087380.14	4.96	9.83e-07	0.000125	0.22	0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5534273	chr11:5518441~5524955:-
THCA	cis	rs62158800	0.925	rs7567243	ENSG00000237880.1	AC096669.2	4.96	9.83e-07	0.000125	0.34	0.22	Facial morphology (factor 22);	chr2:107588632	chr2:107385632~107542649:-
THCA	cis	rs8177876	0.658	rs2316730	ENSG00000261061.1	RP11-303E16.2	-4.96	9.83e-07	0.000125	-0.36	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr16:81030770~81031485:+
THCA	cis	rs9925964	0.933	rs9929899	ENSG00000260911.2	RP11-196G11.2	-4.96	9.83e-07	0.000125	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31043150~31049868:+
THCA	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-4.96	9.84e-07	0.000125	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-4.96	9.84e-07	0.000125	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
THCA	cis	rs9843304	0.616	rs67576825	ENSG00000244503.1	RP11-278L15.6	4.96	9.84e-07	0.000125	0.29	0.22	Gallstone disease;	chr3:149484896	chr3:149494660~149495995:+
THCA	cis	rs853679	0.769	rs7752608	ENSG00000226314.6	ZNF192P1	-4.96	9.84e-07	0.000125	-0.44	-0.22	Depression;	chr6:28333418	chr6:28161781~28169594:+
THCA	cis	rs6806253	0.507	rs4266212	ENSG00000239405.1	TMED10P2	4.96	9.84e-07	0.000125	0.33	0.22	Pit-and-Fissure caries;	chr3:128517848	chr3:128538020~128538631:+
THCA	cis	rs1003719	0.751	rs55992706	ENSG00000230366.8	DSCR9	4.96	9.84e-07	0.000125	0.23	0.22	Eye color traits;	chr21:37170447	chr21:37208503~37221736:+
THCA	cis	rs116248771	0.549	rs4680461	ENSG00000271778.1	RP11-379F4.8	4.96	9.84e-07	0.000125	0.31	0.22	diarrhoeal disease at age 2;	chr3:158736371	chr3:158782547~158783124:+
THCA	cis	rs6472827	0.645	rs2956058	ENSG00000253983.2	RP1-16A9.1	4.96	9.84e-07	0.000125	0.32	0.22	Uterine fibroids;	chr8:74197824	chr8:74199396~74208441:+
THCA	cis	rs6012564	0.793	rs6125552	ENSG00000227431.4	CSE1L-AS1	4.96	9.84e-07	0.000125	0.27	0.22	Anger;	chr20:49107788	chr20:49040463~49046044:-
THCA	cis	rs8141529	0.719	rs5762880	ENSG00000272858.1	CTA-292E10.8	-4.96	9.85e-07	0.000125	-0.23	-0.22	Lymphocyte counts;	chr22:28891828	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.702	rs8137262	ENSG00000272858.1	CTA-292E10.8	-4.96	9.85e-07	0.000125	-0.23	-0.22	Lymphocyte counts;	chr22:28896147	chr22:28814914~28815662:+
THCA	cis	rs748802	0.704	rs12339156	ENSG00000235387.1	LINC00961	-4.96	9.85e-07	0.000125	-0.26	-0.22	Resting heart rate;	chr9:35915233	chr9:35909483~35911686:+
THCA	cis	rs748802	0.704	rs74307313	ENSG00000235387.1	LINC00961	-4.96	9.85e-07	0.000125	-0.26	-0.22	Resting heart rate;	chr9:35915326	chr9:35909483~35911686:+
THCA	cis	rs7829975	0.653	rs13259070	ENSG00000254153.1	CTA-398F10.2	-4.96	9.85e-07	0.000125	-0.24	-0.22	Mood instability;	chr8:8833277	chr8:8456909~8461337:-
THCA	cis	rs11992162	0.597	rs7824564	ENSG00000206014.6	OR7E161P	4.96	9.85e-07	0.000125	0.27	0.22	Monocyte count;	chr8:11922671	chr8:11928597~11929563:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000223473.2	GS1-124K5.3	4.96	9.85e-07	0.000125	0.15	0.22	Aortic root size;	chr7:65964026	chr7:66491049~66493566:-
THCA	cis	rs4648045	0.861	rs170731	ENSG00000246560.2	RP11-10L12.4	-4.96	9.85e-07	0.000125	-0.28	-0.22	Lymphocyte percentage of white cells;	chr4:102527746	chr4:102828055~102844075:+
THCA	cis	rs17767392	0.67	rs17767386	ENSG00000259146.3	RP1-261D10.2	4.96	9.85e-07	0.000125	0.28	0.22	Mitral valve prolapse;	chr14:71281636	chr14:71292729~71321814:-
THCA	cis	rs9859260	0.616	rs9867473	ENSG00000226155.1	AC124944.3	-4.96	9.85e-07	0.000125	-0.28	-0.22	Mean corpuscular volume;	chr3:196104227	chr3:195912049~195913986:+
THCA	cis	rs16975963	0.644	rs11666662	ENSG00000226686.6	LINC01535	4.96	9.85e-07	0.000125	0.3	0.22	Longevity;	chr19:37663801	chr19:37251912~37265535:+
THCA	cis	rs2288884	0.708	rs11665783	ENSG00000260160.1	CTC-471J1.2	-4.96	9.86e-07	0.000125	-0.22	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014641	chr19:52058490~52063703:-
THCA	cis	rs412050	0.547	rs61757982	ENSG00000224086.5	LL22NC03-86G7.1	-4.96	9.87e-07	0.000125	-0.4	-0.22	Attention deficit hyperactivity disorder;	chr22:21759451	chr22:21938293~21977632:+
THCA	cis	rs6545883	0.894	rs2694643	ENSG00000270820.4	RP11-355B11.2	4.96	9.87e-07	0.000125	0.19	0.22	Tuberculosis;	chr2:61377248	chr2:61471188~61484130:+
THCA	cis	rs62158800	1	rs62158800	ENSG00000237880.1	AC096669.2	4.96	9.87e-07	0.000125	0.33	0.22	Facial morphology (factor 22);	chr2:107585523	chr2:107385632~107542649:-
THCA	cis	rs17301013	0.612	rs56199565	ENSG00000227373.4	RP11-160H22.5	4.96	9.87e-07	0.000125	0.32	0.22	Systemic lupus erythematosus;	chr1:174640992	chr1:174115300~174160004:-
THCA	cis	rs17767392	0.67	rs11849508	ENSG00000259146.3	RP1-261D10.2	4.96	9.87e-07	0.000125	0.28	0.22	Mitral valve prolapse;	chr14:71256347	chr14:71292729~71321814:-
THCA	cis	rs7403037	0.642	rs61993169	ENSG00000260760.1	PWRN3	4.96	9.87e-07	0.000125	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24231216	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.794	rs12902460	ENSG00000260760.1	PWRN3	4.96	9.87e-07	0.000125	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24254531	chr15:24441127~24447967:+
THCA	cis	rs9283706	0.593	rs10077634	ENSG00000229666.1	MAST4-AS1	-4.96	9.87e-07	0.000125	-0.3	-0.22	Coronary artery disease;	chr5:67007518	chr5:67001383~67003953:-
THCA	cis	rs7246657	0.524	rs10411251	ENSG00000226686.6	LINC01535	-4.96	9.87e-07	0.000125	-0.34	-0.22	Coronary artery calcification;	chr19:36937853	chr19:37251912~37265535:+
THCA	cis	rs2243480	1	rs73142166	ENSG00000230295.1	RP11-458F8.2	-4.96	9.87e-07	0.000125	-0.28	-0.22	Diabetic kidney disease;	chr7:65910845	chr7:66880708~66882981:+
THCA	cis	rs7829975	0.606	rs11776838	ENSG00000253981.4	ALG1L13P	-4.96	9.88e-07	0.000125	-0.21	-0.22	Mood instability;	chr8:8937291	chr8:8236003~8244667:-
THCA	cis	rs7088591	0.867	rs57040613	ENSG00000276818.1	AC026393.1	4.96	9.88e-07	0.000125	0.43	0.22	Blood pressure;	chr10:58040221	chr10:57095699~57095781:+
THCA	cis	rs36715	1	rs36705	ENSG00000245937.6	LINC01184	4.96	9.88e-07	0.000126	0.25	0.22	Breast cancer;	chr5:128218794	chr5:127940426~128083172:-
THCA	cis	rs9283706	0.689	rs12517976	ENSG00000229666.1	MAST4-AS1	-4.96	9.88e-07	0.000126	-0.33	-0.22	Coronary artery disease;	chr5:67025751	chr5:67001383~67003953:-
THCA	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-4.96	9.89e-07	0.000126	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
THCA	cis	rs17005891	0.73	rs7684732	ENSG00000270480.1	RP11-57B24.1	4.96	9.89e-07	0.000126	0.33	0.22	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82654679	chr4:82691737~82692468:+
THCA	cis	rs1836229	0.594	rs7864464	ENSG00000225706.1	PTPRD-AS1	-4.96	9.9e-07	0.000126	-0.26	-0.22	Restless legs syndrome;	chr9:8824274	chr9:8858130~8862255:+
THCA	cis	rs9890032	0.542	rs62068770	ENSG00000266490.1	CTD-2349P21.9	4.96	9.9e-07	0.000126	0.23	0.22	Hip circumference adjusted for BMI;	chr17:30918357	chr17:30792372~30792833:+
THCA	cis	rs4663866	1	rs4663866	ENSG00000186235.9	AC016757.3	4.96	9.9e-07	0.000126	0.47	0.22	Irritable bowel syndrome;	chr2:238242174	chr2:238224552~238231677:-
THCA	cis	rs6479901	0.639	rs10995448	ENSG00000232075.1	MRPL35P2	-4.96	9.9e-07	0.000126	-0.34	-0.22	Intelligence (multi-trait analysis);	chr10:63127299	chr10:63634317~63634827:-
THCA	cis	rs6479901	0.639	rs7082200	ENSG00000232075.1	MRPL35P2	-4.96	9.9e-07	0.000126	-0.34	-0.22	Intelligence (multi-trait analysis);	chr10:63128561	chr10:63634317~63634827:-
THCA	cis	rs2439831	0.681	rs3742969	ENSG00000275601.1	AC011330.13	-4.96	9.9e-07	0.000126	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43329749	chr15:43642389~43643023:-
THCA	cis	rs5758659	0.652	rs133326	ENSG00000227370.1	RP4-669P10.19	-4.96	9.9e-07	0.000126	-0.21	-0.22	Cognitive function;	chr22:42010881	chr22:42132543~42132998:+
THCA	cis	rs7552393	0.636	rs4001466	ENSG00000233008.4	RP11-475O6.1	4.96	9.9e-07	0.000126	0.25	0.22	Select biomarker traits;	chr1:83819557	chr1:83575776~83861023:-
THCA	cis	rs17767392	0.67	rs61989257	ENSG00000259146.3	RP1-261D10.2	4.96	9.91e-07	0.000126	0.27	0.22	Mitral valve prolapse;	chr14:71263753	chr14:71292729~71321814:-
THCA	cis	rs950169	0.541	rs10795	ENSG00000188388.10	GOLGA6L3	4.96	9.91e-07	0.000126	0.3	0.22	Schizophrenia;	chr15:84634066	chr15:85240472~85247170:+
THCA	cis	rs950169	0.58	rs36126054	ENSG00000188388.10	GOLGA6L3	4.96	9.91e-07	0.000126	0.3	0.22	Schizophrenia;	chr15:84634492	chr15:85240472~85247170:+
THCA	cis	rs613391	0.702	rs976730	ENSG00000224549.1	RP11-370B11.3	-4.96	9.91e-07	0.000126	-0.26	-0.22	Quantitative traits;	chr9:22695668	chr9:22767175~22768316:+
THCA	cis	rs736408	0.608	rs4687657	ENSG00000242142.1	SERBP1P3	4.96	9.91e-07	0.000126	0.29	0.22	Bipolar disorder;	chr3:52818522	chr3:53064283~53065091:-
THCA	cis	rs2976388	0.556	rs4736300	ENSG00000253741.1	CTD-2292P10.4	4.96	9.91e-07	0.000126	0.31	0.22	Urinary tract infection frequency;	chr8:142747851	chr8:142702252~142726973:-
THCA	cis	rs6487679	0.526	rs7305336	ENSG00000111788.10	RP11-22B23.1	4.96	9.91e-07	0.000126	0.23	0.22	Non-alcoholic fatty liver disease histology (AST);	chr12:9222493	chr12:9277235~9313241:+
THCA	cis	rs11795343	0.503	rs10813831	ENSG00000232303.2	DFFBP1	-4.96	9.92e-07	0.000126	-0.29	-0.22	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32526148	chr9:32566148~32567126:-
THCA	cis	rs11671005	0.695	rs11673069	ENSG00000268049.1	CTD-2619J13.9	-4.96	9.93e-07	0.000126	-0.35	-0.22	Mean platelet volume;	chr19:58423551	chr19:58357999~58359603:+
THCA	cis	rs2243480	1	rs160643	ENSG00000230295.1	RP11-458F8.2	-4.96	9.93e-07	0.000126	-0.27	-0.22	Diabetic kidney disease;	chr7:66093235	chr7:66880708~66882981:+
THCA	cis	rs17301013	0.932	rs6689170	ENSG00000227373.4	RP11-160H22.5	4.96	9.93e-07	0.000126	0.32	0.22	Systemic lupus erythematosus;	chr1:174639596	chr1:174115300~174160004:-
THCA	cis	rs5006884	0.627	rs12289659	ENSG00000167355.6	AC104389.28	-4.96	9.93e-07	0.000126	-0.34	-0.22	Fetal hemoglobin levels;	chr11:5350192	chr11:5304976~5505652:-
THCA	cis	rs3820928	0.874	rs12467261	ENSG00000212391.1	SNORA48	-4.96	9.93e-07	0.000126	-0.24	-0.22	Pulmonary function;	chr2:227024122	chr2:226968989~226969122:-
THCA	cis	rs11673344	0.523	rs2562607	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37031358	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs2385415	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37035291	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs7246739	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37040829	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs7260488	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37058883	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs8110158	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37063491	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.562	rs7257320	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37080933	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs10403975	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37082172	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs2385375	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37087620	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs35162188	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37088908	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.562	rs7250507	ENSG00000276846.1	CTD-3220F14.3	4.96	9.93e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37095772	chr19:37314868~37315620:-
THCA	cis	rs875971	0.545	rs73142233	ENSG00000232546.1	RP11-458F8.1	4.96	9.93e-07	0.000126	0.22	0.22	Aortic root size;	chr7:66221293	chr7:66848496~66858136:+
THCA	cis	rs4144027	0.791	rs67727470	ENSG00000269940.1	RP11-73M18.7	4.96	9.93e-07	0.000126	0.21	0.22	Blood metabolite levels;	chr14:103895659	chr14:103694560~103695170:+
THCA	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	4.96	9.94e-07	0.000126	0.25	0.22	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
THCA	cis	rs9652601	0.779	rs7203793	ENSG00000274038.1	RP11-66H6.4	-4.96	9.94e-07	0.000126	-0.29	-0.22	Systemic lupus erythematosus;	chr16:11088277	chr16:11056556~11057034:+
THCA	cis	rs12188164	0.812	rs9313065	ENSG00000221990.4	EXOC3-AS1	4.96	9.94e-07	0.000126	0.17	0.22	Cystic fibrosis severity;	chr5:423311	chr5:441498~443160:-
THCA	cis	rs9925964	0.933	rs9939417	ENSG00000260911.2	RP11-196G11.2	-4.96	9.94e-07	0.000126	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042146	chr16:31043150~31049868:+
THCA	cis	rs8020095	0.571	rs8018750	ENSG00000258561.1	RP11-72M17.1	-4.96	9.94e-07	0.000126	-0.3	-0.22	Depression (quantitative trait);	chr14:66968850	chr14:66212810~66509394:-
THCA	cis	rs111756027	0.786	rs16945449	ENSG00000260922.1	RP11-538I12.3	4.96	9.94e-07	0.000126	0.35	0.22	Bone mineral density (Ward's triangle area);	chr16:77285161	chr16:77234877~77290934:+
THCA	cis	rs465969	1	rs465969	ENSG00000272356.1	RP5-1112D6.8	4.96	9.95e-07	0.000126	0.28	0.22	Psoriasis;	chr6:111334327	chr6:111309203~111313517:+
THCA	cis	rs10761482	0.6	rs1572843	ENSG00000254271.1	RP11-131N11.4	4.96	9.95e-07	0.000126	0.3	0.22	Schizophrenia;	chr10:60467222	chr10:60734342~60741828:+
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000273796.1	LL21NC02-21A1.1	-4.96	9.95e-07	0.000126	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45403809~45404369:-
THCA	cis	rs11673344	0.504	rs10403728	ENSG00000276846.1	CTD-3220F14.3	4.96	9.95e-07	0.000126	0.17	0.22	Obesity-related traits;	chr19:37091569	chr19:37314868~37315620:-
THCA	cis	rs28386778	0.734	rs12946669	ENSG00000240280.5	TCAM1P	-4.96	9.96e-07	0.000126	-0.31	-0.22	Prudent dietary pattern;	chr17:63928647	chr17:63849292~63864379:+
THCA	cis	rs9980	0.657	rs62052820	ENSG00000226232.7	RP11-419C5.2	-4.96	9.96e-07	0.000126	-0.3	-0.22	Blood osmolality (transformed sodium);	chr16:69541335	chr16:69976388~69996188:-
THCA	cis	rs763121	0.853	rs5757187	ENSG00000228274.3	RP3-508I15.9	4.96	9.96e-07	0.000126	0.24	0.22	Menopause (age at onset);	chr22:38625517	chr22:38667585~38681820:-
THCA	cis	rs60695258	0.55	rs4693798	ENSG00000251411.1	RP11-397E7.4	4.96	9.96e-07	0.000126	0.21	0.22	Hematocrit;	chr4:86993136	chr4:86913266~86914817:-
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000273796.1	LL21NC02-21A1.1	-4.96	9.96e-07	0.000126	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000273796.1	LL21NC02-21A1.1	-4.96	9.96e-07	0.000126	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000273796.1	LL21NC02-21A1.1	-4.96	9.96e-07	0.000126	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000273796.1	LL21NC02-21A1.1	-4.96	9.96e-07	0.000126	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000273796.1	LL21NC02-21A1.1	-4.96	9.96e-07	0.000126	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000273796.1	LL21NC02-21A1.1	-4.96	9.96e-07	0.000126	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45403809~45404369:-
THCA	cis	rs2439831	0.867	rs2412778	ENSG00000166763.7	STRCP1	4.96	9.97e-07	0.000127	0.3	0.22	Lung cancer in ever smokers;	chr15:43368784	chr15:43699488~43718184:-
THCA	cis	rs5751614	0.537	rs7288846	ENSG00000230701.2	FBXW4P1	-4.96	9.97e-07	0.000127	-0.25	-0.22	Height;	chr22:23281097	chr22:23262767~23265005:+
THCA	cis	rs7942368	0.715	rs12788118	ENSG00000261578.1	RP11-21L23.2	4.96	9.97e-07	0.000127	0.31	0.22	Endometriosis;	chr11:76783176	chr11:76800364~76804555:+
THCA	cis	rs467650	0.553	rs469731	ENSG00000248489.1	CTD-2007H13.3	-4.96	9.97e-07	0.000127	-0.25	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98651703	chr5:98929171~98995013:+
THCA	cis	rs9863	0.931	rs11057407	ENSG00000269997.1	RP11-214K3.21	-4.96	9.97e-07	0.000127	-0.28	-0.22	White blood cell count;	chr12:123965282	chr12:123966077~123966629:-
THCA	cis	rs6477918	0.598	rs4979125	ENSG00000230185.4	C9orf147	-4.96	9.98e-07	0.000127	-0.24	-0.22	Obstetric antiphospholipid syndrome;	chr9:112503050	chr9:112433816~112487204:-
THCA	cis	rs6477918	0.598	rs4584218	ENSG00000230185.4	C9orf147	-4.96	9.98e-07	0.000127	-0.24	-0.22	Obstetric antiphospholipid syndrome;	chr9:112503823	chr9:112433816~112487204:-
THCA	cis	rs2976388	0.578	rs3758081	ENSG00000253741.1	CTD-2292P10.4	4.96	9.98e-07	0.000127	0.31	0.22	Urinary tract infection frequency;	chr8:142742955	chr8:142702252~142726973:-
THCA	cis	rs338389	0.586	rs338390	ENSG00000260657.2	RP11-315D16.4	-4.96	9.98e-07	0.000127	-0.28	-0.22	Survival in rectal cancer;	chr15:67966876	chr15:68267792~68277994:-
THCA	cis	rs1396485	0.66	rs10062588	ENSG00000248445.4	SEMA6A-AS1	-4.96	9.99e-07	0.000127	-0.22	-0.22	Inflammatory biomarkers;	chr5:116272528	chr5:116447547~116508276:+
THCA	cis	rs9494145	0.526	rs17706858	ENSG00000232876.1	CTA-212D2.2	-4.96	9.99e-07	0.000127	-0.35	-0.22	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135163956	chr6:135055033~135060550:+
THCA	cis	rs9549328	0.756	rs2993291	ENSG00000267868.1	RP11-120K24.3	4.96	9.99e-07	0.000127	0.22	0.22	Systolic blood pressure;	chr13:112999532	chr13:112964835~112966131:-
THCA	cis	rs12893668	0.703	rs4906335	ENSG00000269958.1	RP11-73M18.8	4.96	1e-06	0.000127	0.22	0.22	Reticulocyte count;	chr14:103554804	chr14:103696353~103697163:+
THCA	cis	rs17767392	0.958	rs61989377	ENSG00000259146.3	RP1-261D10.2	4.96	1e-06	0.000127	0.29	0.22	Mitral valve prolapse;	chr14:71490645	chr14:71292729~71321814:-
THCA	cis	rs3213758	1	rs2024474	ENSG00000275191.1	RP11-36I17.2	-4.96	1e-06	0.000127	-0.44	-0.22	Vitiligo (non-segmental);	chr16:53546370	chr16:53628256~53628816:-
THCA	cis	rs755249	0.756	rs72637908	ENSG00000228060.1	RP11-69E11.8	-4.96	1e-06	0.000127	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39565160~39573203:+
THCA	cis	rs1122401	0.576	rs766529	ENSG00000280159.1	CTD-2591A1.1	4.96	1e-06	0.000127	0.3	0.22	Smoking initiation;	chr5:54577625	chr5:54643557~54645987:+
THCA	cis	rs4934494	0.677	rs7905163	ENSG00000232936.4	RP11-80H5.2	4.96	1e-06	0.000127	0.31	0.22	Red blood cell count;	chr10:89624173	chr10:89645282~89650667:+
THCA	cis	rs763121	0.719	rs9610995	ENSG00000228274.3	RP3-508I15.9	-4.96	1e-06	0.000127	-0.24	-0.22	Menopause (age at onset);	chr22:38661758	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs8142098	ENSG00000228274.3	RP3-508I15.9	-4.96	1e-06	0.000127	-0.24	-0.22	Menopause (age at onset);	chr22:38662752	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2413544	ENSG00000228274.3	RP3-508I15.9	-4.96	1e-06	0.000127	-0.24	-0.22	Menopause (age at onset);	chr22:38663399	chr22:38667585~38681820:-
THCA	cis	rs763121	0.752	rs5757222	ENSG00000228274.3	RP3-508I15.9	-4.96	1e-06	0.000127	-0.24	-0.22	Menopause (age at onset);	chr22:38664468	chr22:38667585~38681820:-
THCA	cis	rs763121	0.819	rs5750658	ENSG00000228274.3	RP3-508I15.9	-4.96	1e-06	0.000127	-0.24	-0.22	Menopause (age at onset);	chr22:38664912	chr22:38667585~38681820:-
THCA	cis	rs763121	0.819	rs8137829	ENSG00000228274.3	RP3-508I15.9	-4.96	1e-06	0.000127	-0.24	-0.22	Menopause (age at onset);	chr22:38665025	chr22:38667585~38681820:-
THCA	cis	rs7119	0.745	rs11632602	ENSG00000259362.2	RP11-307C19.1	-4.96	1e-06	0.000127	-0.32	-0.22	Type 2 diabetes;	chr15:77517422	chr15:77525540~77534110:+
THCA	cis	rs453301	0.631	rs4840376	ENSG00000254153.1	CTA-398F10.2	4.96	1e-06	0.000127	0.26	0.22	Joint mobility (Beighton score);	chr8:8944591	chr8:8456909~8461337:-
THCA	cis	rs6496932	0.503	rs4842882	ENSG00000259630.2	CTD-2262B20.1	-4.96	1e-06	0.000127	-0.28	-0.22	Central corneal thickness;Corneal structure;	chr15:85440952	chr15:85415228~85415633:+
THCA	cis	rs6496932	0.503	rs7176605	ENSG00000259630.2	CTD-2262B20.1	-4.96	1e-06	0.000127	-0.28	-0.22	Central corneal thickness;Corneal structure;	chr15:85443491	chr15:85415228~85415633:+
THCA	cis	rs1387259	0.723	rs2732488	ENSG00000240399.1	RP1-228P16.1	4.96	1e-06	0.000127	0.23	0.22	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48054813~48055591:-
THCA	cis	rs1387259	0.758	rs2634670	ENSG00000240399.1	RP1-228P16.1	4.96	1e-06	0.000127	0.23	0.22	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48054813~48055591:-
THCA	cis	rs73242632	0.881	rs73242603	ENSG00000269949.1	RP11-738E22.3	4.96	1e-06	0.000127	0.55	0.22	Congenital heart disease (maternal effect);	chr4:56859896	chr4:56960927~56961373:-
THCA	cis	rs73242632	0.881	rs28472594	ENSG00000269949.1	RP11-738E22.3	4.96	1e-06	0.000127	0.55	0.22	Congenital heart disease (maternal effect);	chr4:56859977	chr4:56960927~56961373:-
THCA	cis	rs919433	0.927	rs6759834	ENSG00000231621.1	AC013264.2	4.96	1e-06	0.000127	0.24	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197340136	chr2:197197991~197199273:+
THCA	cis	rs4948102	0.551	rs4275190	ENSG00000226278.1	PSPHP1	-4.96	1e-06	0.000127	-0.25	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55764797~55773288:+
THCA	cis	rs9878978	0.964	rs6762278	ENSG00000237990.3	CNTN4-AS1	4.96	1e-06	0.000127	0.24	0.22	Blood pressure (smoking interaction);	chr3:2451667	chr3:3039033~3069242:-
THCA	cis	rs7119	0.717	rs12898370	ENSG00000259362.2	RP11-307C19.1	-4.96	1e-06	0.000127	-0.32	-0.22	Type 2 diabetes;	chr15:77516256	chr15:77525540~77534110:+
THCA	cis	rs9393777	0.92	rs35716472	ENSG00000280107.1	AL022393.9	-4.96	1e-06	0.000127	-0.39	-0.22	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28170845~28172521:+
THCA	cis	rs11673344	0.504	rs4806408	ENSG00000276846.1	CTD-3220F14.3	4.96	1e-06	0.000127	0.17	0.22	Obesity-related traits;	chr19:37097875	chr19:37314868~37315620:-
THCA	cis	rs72627509	0.638	rs1608165	ENSG00000269949.1	RP11-738E22.3	4.96	1e-06	0.000127	0.36	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57028551	chr4:56960927~56961373:-
THCA	cis	rs728616	0.681	rs17677908	ENSG00000242600.5	MBL1P	4.96	1e-06	0.000127	0.29	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80289847	chr10:79904898~79950336:+
THCA	cis	rs12906542	0.516	rs894301	ENSG00000260776.4	RP11-114H24.2	4.96	1e-06	0.000127	0.37	0.22	Breast cancer;	chr15:78005183	chr15:77914217~77926846:-
THCA	cis	rs12906542	0.516	rs4886989	ENSG00000260776.4	RP11-114H24.2	4.96	1e-06	0.000127	0.37	0.22	Breast cancer;	chr15:78011406	chr15:77914217~77926846:-
THCA	cis	rs12906542	0.516	rs56357772	ENSG00000260776.4	RP11-114H24.2	4.96	1e-06	0.000127	0.37	0.22	Breast cancer;	chr15:78020699	chr15:77914217~77926846:-
THCA	cis	rs12906542	0.516	rs16969422	ENSG00000260776.4	RP11-114H24.2	4.96	1e-06	0.000127	0.37	0.22	Breast cancer;	chr15:78033857	chr15:77914217~77926846:-
THCA	cis	rs9987353	0.566	rs34491841	ENSG00000248538.5	RP11-10A14.5	4.96	1.01e-06	0.000128	0.3	0.22	Recombination measurement;	chr8:9208000	chr8:9189011~9202854:+
THCA	cis	rs2562456	0.752	rs7258562	ENSG00000268119.4	CTD-2561J22.5	4.96	1.01e-06	0.000128	0.32	0.22	Pain;	chr19:21331762	chr19:21444241~21463908:-
THCA	cis	rs2243480	1	rs4548056	ENSG00000164669.11	INTS4P1	4.96	1.01e-06	0.000128	0.43	0.22	Diabetic kidney disease;	chr7:65833886	chr7:65141225~65234216:+
THCA	cis	rs7819412	0.765	rs7000132	ENSG00000261451.1	RP11-981G7.1	-4.96	1.01e-06	0.000128	-0.29	-0.22	Triglycerides;	chr8:11173426	chr8:10433672~10438312:+
THCA	cis	rs7829975	0.502	rs7820738	ENSG00000254153.1	CTA-398F10.2	4.96	1.01e-06	0.000128	0.24	0.22	Mood instability;	chr8:8845097	chr8:8456909~8461337:-
THCA	cis	rs1979679	0.918	rs7135922	ENSG00000278733.1	RP11-425D17.1	-4.96	1.01e-06	0.000128	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28469148	chr12:28185625~28186190:-
THCA	cis	rs4646450	0.891	rs883403	ENSG00000244219.5	GS1-259H13.2	-4.96	1.01e-06	0.000128	-0.27	-0.22	Blood metabolite levels;	chr7:99450355	chr7:99598066~99610813:+
THCA	cis	rs4646450	0.891	rs2280600	ENSG00000244219.5	GS1-259H13.2	-4.96	1.01e-06	0.000128	-0.27	-0.22	Blood metabolite levels;	chr7:99450809	chr7:99598066~99610813:+
THCA	cis	rs6088580	0.619	rs1205335	ENSG00000276073.1	RP5-1125A11.7	4.96	1.01e-06	0.000128	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34339701	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.686	rs1337841	ENSG00000270638.1	RP3-466P17.1	-4.96	1.01e-06	0.000128	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145735570~145737218:+
THCA	cis	rs17767392	0.836	rs61989383	ENSG00000259146.3	RP1-261D10.2	4.96	1.01e-06	0.000128	0.28	0.22	Mitral valve prolapse;	chr14:71516927	chr14:71292729~71321814:-
THCA	cis	rs4819052	0.851	rs914214	ENSG00000273796.1	LL21NC02-21A1.1	-4.96	1.01e-06	0.000128	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45403809~45404369:-
THCA	cis	rs1552244	0.554	rs55847233	ENSG00000232901.1	CYCSP10	4.96	1.01e-06	0.000128	0.26	0.22	Alzheimer's disease;	chr3:9949417	chr3:10000647~10000940:-
THCA	cis	rs193541	0.632	rs246279	ENSG00000263432.2	RN7SL689P	-4.96	1.01e-06	0.000128	-0.35	-0.22	Glucose homeostasis traits;	chr5:122905568	chr5:123022487~123022783:-
THCA	cis	rs763121	0.853	rs4821808	ENSG00000228274.3	RP3-508I15.9	-4.96	1.01e-06	0.000128	-0.24	-0.22	Menopause (age at onset);	chr22:38669734	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs4821809	ENSG00000228274.3	RP3-508I15.9	-4.96	1.01e-06	0.000128	-0.24	-0.22	Menopause (age at onset);	chr22:38669738	chr22:38667585~38681820:-
THCA	cis	rs2839186	0.656	rs8128380	ENSG00000215424.8	MCM3AP-AS1	4.96	1.01e-06	0.000128	0.13	0.22	Testicular germ cell tumor;	chr21:46245779	chr21:46229217~46259390:+
THCA	cis	rs1129187	0.755	rs3293	ENSG00000272223.1	RP1-20C7.6	4.96	1.01e-06	0.000128	0.17	0.22	Alzheimer's disease in APOE e4+ carriers;	chr6:42970639	chr6:43033897~43034405:-
THCA	cis	rs6840258	0.891	rs75921854	ENSG00000251411.1	RP11-397E7.4	-4.96	1.01e-06	0.000128	-0.27	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87110944	chr4:86913266~86914817:-
THCA	cis	rs17095355	0.818	rs1009532	ENSG00000203876.8	ADD3-AS1	4.96	1.01e-06	0.000128	0.23	0.22	Biliary atresia;	chr10:110080967	chr10:109940104~110008381:-
THCA	cis	rs5742933	1	rs3791773	ENSG00000273240.1	RP11-455J20.3	-4.96	1.01e-06	0.000128	-0.25	-0.22	Ferritin levels;	chr2:189817906	chr2:189763859~189764456:-
THCA	cis	rs2803122	0.807	rs4977289	ENSG00000273226.1	RP11-513M16.8	-4.96	1.01e-06	0.000128	-0.2	-0.22	Pulse pressure;	chr9:19225190	chr9:19375451~19375996:+
THCA	cis	rs7773456	0.711	rs9358277	ENSG00000227116.1	RP3-471C18.1	4.96	1.01e-06	0.000128	0.25	0.22	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19730427~19734567:-
THCA	cis	rs867371	0.896	rs8033831	ENSG00000259429.4	UBE2Q2P2	-4.96	1.01e-06	0.000128	-0.18	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82355142~82420075:+
THCA	cis	rs1003719	0.751	rs55740803	ENSG00000230366.8	DSCR9	4.96	1.01e-06	0.000128	0.23	0.22	Eye color traits;	chr21:37170459	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.751	rs56268364	ENSG00000230366.8	DSCR9	4.96	1.01e-06	0.000128	0.23	0.22	Eye color traits;	chr21:37170463	chr21:37208503~37221736:+
THCA	cis	rs2288884	0.579	rs6509603	ENSG00000269483.1	AC006272.1	4.96	1.01e-06	0.000128	0.31	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51960977	chr19:51839924~51843324:-
THCA	cis	rs874628	0.612	rs4808121	ENSG00000268650.3	AC068499.10	4.96	1.01e-06	0.000128	0.25	0.22	Multiple sclerosis;	chr19:18247297	chr19:18204730~18220480:+
THCA	cis	rs2562456	0.833	rs1932087	ENSG00000268119.4	CTD-2561J22.5	4.96	1.01e-06	0.000128	0.33	0.22	Pain;	chr19:21338625	chr19:21444241~21463908:-
THCA	cis	rs11073619	0.616	rs79416421	ENSG00000230373.7	GOLGA6L5P	-4.96	1.01e-06	0.000128	-0.34	-0.22	Positive affect;	chr15:84539090	chr15:84507885~84516814:-
THCA	cis	rs13434995	0.513	rs1048004	ENSG00000273257.1	RP11-177J6.1	-4.96	1.01e-06	0.000128	-0.33	-0.22	Adiponectin levels;	chr4:55434042	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs1801260	ENSG00000273257.1	RP11-177J6.1	-4.96	1.01e-06	0.000128	-0.33	-0.22	Adiponectin levels;	chr4:55435202	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs17721215	ENSG00000273257.1	RP11-177J6.1	-4.96	1.01e-06	0.000128	-0.33	-0.22	Adiponectin levels;	chr4:55437620	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs1021307	ENSG00000273257.1	RP11-177J6.1	4.96	1.01e-06	0.000128	0.33	0.22	Adiponectin levels;	chr4:55529547	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs1021306	ENSG00000273257.1	RP11-177J6.1	4.96	1.01e-06	0.000128	0.33	0.22	Adiponectin levels;	chr4:55529777	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs6554285	ENSG00000273257.1	RP11-177J6.1	4.96	1.01e-06	0.000128	0.33	0.22	Adiponectin levels;	chr4:55533953	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs7660668	ENSG00000273257.1	RP11-177J6.1	4.96	1.01e-06	0.000128	0.33	0.22	Adiponectin levels;	chr4:55535530	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs7698022	ENSG00000273257.1	RP11-177J6.1	4.96	1.01e-06	0.000128	0.33	0.22	Adiponectin levels;	chr4:55541180	chr4:55387949~55388271:+
THCA	cis	rs12965607	0.52	rs28778033	ENSG00000267444.1	SMUG1P1	4.96	1.01e-06	0.000128	0.22	0.22	Myopia;	chr18:49688494	chr18:49650350~49651160:+
THCA	cis	rs6430585	0.528	rs309152	ENSG00000231890.6	DARS-AS1	4.96	1.01e-06	0.000128	0.25	0.22	Corneal structure;	chr2:135899682	chr2:135985176~136022593:+
THCA	cis	rs72799341	0.706	rs1060506	ENSG00000260911.2	RP11-196G11.2	4.96	1.01e-06	0.000128	0.19	0.22	Diastolic blood pressure;	chr16:31122128	chr16:31043150~31049868:+
THCA	cis	rs35264875	0.808	rs2305498	ENSG00000259799.1	RP11-554A11.9	4.96	1.01e-06	0.000128	0.32	0.22	Blond vs. brown hair color;	chr11:69099446	chr11:69155910~69159752:+
THCA	cis	rs13434995	0.513	rs62303681	ENSG00000273257.1	RP11-177J6.1	-4.96	1.01e-06	0.000128	-0.34	-0.22	Adiponectin levels;	chr4:55403812	chr4:55387949~55388271:+
THCA	cis	rs11671005	0.693	rs11668757	ENSG00000268912.1	CTD-2619J13.17	-4.95	1.01e-06	0.000128	-0.21	-0.22	Mean platelet volume;	chr19:58416932	chr19:58428632~58431148:-
THCA	cis	rs7088591	1	rs73290945	ENSG00000276818.1	AC026393.1	4.95	1.01e-06	0.000128	0.43	0.22	Blood pressure;	chr10:58026115	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs80336764	ENSG00000276818.1	AC026393.1	4.95	1.01e-06	0.000128	0.43	0.22	Blood pressure;	chr10:58026145	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs78050826	ENSG00000276818.1	AC026393.1	4.95	1.01e-06	0.000128	0.43	0.22	Blood pressure;	chr10:58026150	chr10:57095699~57095781:+
THCA	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-4.95	1.01e-06	0.000128	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
THCA	cis	rs7614311	0.731	rs1053338	ENSG00000271843.1	RP11-245J9.5	-4.95	1.01e-06	0.000128	-0.4	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63982224	chr3:64008082~64008692:-
THCA	cis	rs6951245	1	rs75488469	ENSG00000229043.2	AC091729.9	-4.95	1.01e-06	0.000128	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1160374~1165267:+
THCA	cis	rs34779708	0.931	rs10466072	ENSG00000271335.4	RP11-324I22.4	4.95	1.01e-06	0.000128	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs998658	ENSG00000271335.4	RP11-324I22.4	4.95	1.01e-06	0.000128	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35314552~35336401:-
THCA	cis	rs12823128	0.646	rs34586734	ENSG00000256185.1	RP11-612B6.2	4.95	1.01e-06	0.000128	0.2	0.22	Birth weight;	chr12:26752688	chr12:26335864~26336950:-
THCA	cis	rs2070488	0.745	rs9838792	ENSG00000229589.1	ACVR2B-AS1	-4.95	1.01e-06	0.000128	-0.2	-0.22	Electrocardiographic conduction measures;	chr3:38505235	chr3:38451027~38454820:-
THCA	cis	rs12049671	1	rs55831625	ENSG00000227076.1	RP11-4C20.4	4.95	1.01e-06	0.000129	0.25	0.22	Response to amphetamines;	chr10:127945799	chr10:127934698~127936167:+
THCA	cis	rs2439831	0.867	rs2584702	ENSG00000205771.5	CATSPER2P1	-4.95	1.01e-06	0.000129	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43392716	chr15:43726918~43747094:-
THCA	cis	rs964611	0.882	rs7182177	ENSG00000259488.2	RP11-154J22.1	-4.95	1.01e-06	0.000129	-0.21	-0.22	Metabolite levels (Pyroglutamine);	chr15:48354357	chr15:48312353~48331856:-
THCA	cis	rs800160	1	rs1088990	ENSG00000199550.1	Y_RNA	4.95	1.01e-06	0.000129	0.33	0.22	Bacteremia;	chr11:2360541	chr11:2372638~2372750:+
THCA	cis	rs8020095	0.571	rs723432	ENSG00000258561.1	RP11-72M17.1	-4.95	1.01e-06	0.000129	-0.29	-0.22	Depression (quantitative trait);	chr14:66912298	chr14:66212810~66509394:-
THCA	cis	rs6832769	1	rs11726609	ENSG00000272969.1	RP11-528I4.2	4.95	1.02e-06	0.000129	0.27	0.22	Personality dimensions;	chr4:55534702	chr4:55547112~55547889:+
THCA	cis	rs11096990	0.964	rs3733280	ENSG00000249685.1	RP11-360F5.3	-4.95	1.02e-06	0.000129	-0.28	-0.22	Cognitive function;	chr4:39269921	chr4:39133913~39135608:+
THCA	cis	rs13434995	0.562	rs73236140	ENSG00000273257.1	RP11-177J6.1	-4.95	1.02e-06	0.000129	-0.34	-0.22	Adiponectin levels;	chr4:55440049	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62303691	ENSG00000273257.1	RP11-177J6.1	-4.95	1.02e-06	0.000129	-0.34	-0.22	Adiponectin levels;	chr4:55442085	chr4:55387949~55388271:+
THCA	cis	rs2447820	0.588	rs1437624	ENSG00000249996.1	RP11-359P5.1	4.95	1.02e-06	0.000129	0.26	0.22	Migraine;	chr5:123040636	chr5:123036271~123054667:+
THCA	cis	rs2447820	0.588	rs12653397	ENSG00000249996.1	RP11-359P5.1	4.95	1.02e-06	0.000129	0.26	0.22	Migraine;	chr5:123041643	chr5:123036271~123054667:+
THCA	cis	rs9902453	0.716	rs3098949	ENSG00000263370.1	RP11-68I3.5	4.95	1.02e-06	0.000129	0.28	0.22	Coffee consumption (cups per day);	chr17:29651676	chr17:29639627~29640825:+
THCA	cis	rs7914558	0.966	rs10450373	ENSG00000236937.2	PTGES3P4	4.95	1.02e-06	0.000129	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102968859	chr10:102845595~102845950:+
THCA	cis	rs4663866	0.803	rs71426511	ENSG00000186235.9	AC016757.3	4.95	1.02e-06	0.000129	0.47	0.22	Irritable bowel syndrome;	chr2:238271559	chr2:238224552~238231677:-
THCA	cis	rs1479090	0.723	rs7675998	ENSG00000250027.1	RP11-563E2.2	-4.95	1.02e-06	0.000129	-0.23	-0.22	Lung cancer;	chr4:163086668	chr4:163108785~163119965:+
THCA	cis	rs2337406	0.587	rs11624678	ENSG00000211974.3	IGHV2-70	4.95	1.02e-06	0.000129	0.22	0.22	Alzheimer's disease (late onset);	chr14:106650408	chr14:106723574~106724093:-
THCA	cis	rs3743162	0.553	rs4842994	ENSG00000225151.9	GOLGA2P7	4.95	1.02e-06	0.000129	0.33	0.22	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84199311~84230136:-
THCA	cis	rs73198271	0.96	rs17154702	ENSG00000253893.2	FAM85B	4.95	1.02e-06	0.000129	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752370	chr8:8167819~8226614:-
THCA	cis	rs4950322	0.515	rs17160050	ENSG00000226015.2	CCT8P1	4.95	1.02e-06	0.000129	0.25	0.22	Protein quantitative trait loci;	chr1:147255558	chr1:147203276~147204932:-
THCA	cis	rs763121	0.819	rs5757237	ENSG00000228274.3	RP3-508I15.9	-4.95	1.02e-06	0.000129	-0.24	-0.22	Menopause (age at onset);	chr22:38677830	chr22:38667585~38681820:-
THCA	cis	rs12760731	0.582	rs35302804	ENSG00000213057.5	C1orf220	4.95	1.02e-06	0.000129	0.26	0.22	Obesity-related traits;	chr1:178544207	chr1:178542752~178548889:+
THCA	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-4.95	1.02e-06	0.000129	-0.13	-0.22	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
THCA	cis	rs6012564	1	rs3092039	ENSG00000227431.4	CSE1L-AS1	-4.95	1.02e-06	0.000129	-0.27	-0.22	Anger;	chr20:49062233	chr20:49040463~49046044:-
THCA	cis	rs9863	0.861	rs7132655	ENSG00000269997.1	RP11-214K3.21	-4.95	1.02e-06	0.000129	-0.27	-0.22	White blood cell count;	chr12:123954426	chr12:123966077~123966629:-
THCA	cis	rs1048886	0.938	rs6915405	ENSG00000271967.1	RP11-134K13.4	-4.95	1.02e-06	0.000129	-0.23	-0.22	Type 2 diabetes;	chr6:70393972	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs6931901	ENSG00000271967.1	RP11-134K13.4	-4.95	1.02e-06	0.000129	-0.23	-0.22	Type 2 diabetes;	chr6:70394035	chr6:70596438~70596980:+
THCA	cis	rs4763879	0.54	rs741200	ENSG00000256673.1	RP11-599J14.2	4.95	1.02e-06	0.000129	0.28	0.22	Type 1 diabetes;	chr12:9717819	chr12:9398355~9414851:-
THCA	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-4.95	1.02e-06	0.000129	-0.28	-0.22	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
THCA	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	4.95	1.02e-06	0.000129	0.19	0.22	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	4.95	1.02e-06	0.000129	0.19	0.22	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
THCA	cis	rs4591358	0.68	rs4277541	ENSG00000223466.1	AC064834.2	-4.95	1.02e-06	0.000129	-0.29	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195449705	chr2:195533035~195538681:+
THCA	cis	rs3734266	0.702	rs34374374	ENSG00000272288.4	RP11-140K17.3	-4.95	1.02e-06	0.000129	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34600259	chr6:34696317~34697470:+
THCA	cis	rs6686842	0.536	rs12128359	ENSG00000235358.1	RP11-399E6.1	-4.95	1.02e-06	0.000129	-0.29	-0.22	Height;	chr1:41243240	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.536	rs59911668	ENSG00000235358.1	RP11-399E6.1	-4.95	1.02e-06	0.000129	-0.29	-0.22	Height;	chr1:41243803	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.536	rs61774707	ENSG00000235358.1	RP11-399E6.1	-4.95	1.02e-06	0.000129	-0.29	-0.22	Height;	chr1:41247552	chr1:41242373~41284861:+
THCA	cis	rs2034650	0.544	rs8034217	ENSG00000223313.1	RNU6-516P	-4.95	1.02e-06	0.000129	-0.24	-0.22	Interstitial lung disease;	chr15:40429501	chr15:40529570~40529673:+
THCA	cis	rs670523	0.722	rs4661079	ENSG00000225855.5	RUSC1-AS1	-4.95	1.02e-06	0.000129	-0.15	-0.22	Crohn's disease;Inflammatory bowel disease;	chr1:156013507	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs56675301	ENSG00000160766.13	GBAP1	-4.95	1.02e-06	0.000129	-0.26	-0.22	Body mass index;	chr1:155394536	chr1:155213821~155227422:-
THCA	cis	rs228614	0.51	rs223362	ENSG00000248971.2	KRT8P46	-4.95	1.02e-06	0.000129	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102728746~102730171:-
THCA	cis	rs7809615	0.551	rs952319	ENSG00000244219.5	GS1-259H13.2	-4.95	1.02e-06	0.000129	-0.31	-0.22	Blood metabolite ratios;	chr7:99573826	chr7:99598066~99610813:+
THCA	cis	rs9840812	0.645	rs9883916	ENSG00000239213.4	NCK1-AS1	4.95	1.02e-06	0.000129	0.23	0.22	Fibrinogen levels;	chr3:136489946	chr3:136841726~136862054:-
THCA	cis	rs2803122	0.807	rs10757035	ENSG00000273226.1	RP11-513M16.8	-4.95	1.02e-06	0.000129	-0.2	-0.22	Pulse pressure;	chr9:19230274	chr9:19375451~19375996:+
THCA	cis	rs6730558	1	rs6730558	ENSG00000236008.1	AC011747.4	-4.95	1.02e-06	0.000129	-0.25	-0.22	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8616053	chr2:8559833~8583792:-
THCA	cis	rs7010876	0.561	rs2134964	ENSG00000253553.4	RP11-586K2.1	-4.95	1.02e-06	0.000129	-0.23	-0.22	Schizophrenia;	chr8:88385408	chr8:88326836~88737134:+
THCA	cis	rs12908161	0.959	rs61074241	ENSG00000275120.1	RP11-182J1.17	4.95	1.02e-06	0.000129	0.27	0.22	Schizophrenia;	chr15:84790165	chr15:84599434~84606463:-
THCA	cis	rs7617773	0.817	rs6794644	ENSG00000199476.1	Y_RNA	-4.95	1.02e-06	0.000129	-0.29	-0.22	Coronary artery disease;	chr3:48288547	chr3:48288587~48288694:+
THCA	cis	rs1150668	0.83	rs2859365	ENSG00000273712.1	RP5-874C20.7	-4.95	1.02e-06	0.000129	-0.23	-0.22	Pubertal anthropometrics;	chr6:28423688	chr6:28315613~28315883:-
THCA	cis	rs763121	0.853	rs6001188	ENSG00000235209.1	CTA-150C2.13	4.95	1.02e-06	0.000129	0.29	0.22	Menopause (age at onset);	chr22:38666189	chr22:38921227~38924708:+
THCA	cis	rs4722166	0.532	rs6461662	ENSG00000179428.2	AC073072.5	-4.95	1.02e-06	0.000129	-0.25	-0.22	Lung cancer;	chr7:22717470	chr7:22725395~22727620:-
THCA	cis	rs2562456	0.833	rs1781872	ENSG00000268081.1	RP11-678G14.2	4.95	1.02e-06	0.000129	0.38	0.22	Pain;	chr19:21294601	chr19:21554640~21569237:-
THCA	cis	rs8062405	0.558	rs3743963	ENSG00000278665.1	RP11-666O2.4	4.95	1.02e-06	0.000129	0.24	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28593365	chr16:28599241~28601881:-
THCA	cis	rs2067615	0.579	rs7975576	ENSG00000260329.1	RP11-412D9.4	-4.95	1.02e-06	0.000129	-0.21	-0.22	Heart rate;	chr12:106738723	chr12:106954029~106955497:-
THCA	cis	rs2915864	0.851	rs2906059	ENSG00000280047.1	CTC-463A16.1	-4.95	1.02e-06	0.000129	-0.37	-0.22	Facial morphology (factor 20);	chr5:142209050	chr5:142165767~142168387:+
THCA	cis	rs3020736	0.5	rs6002597	ENSG00000273366.1	CTA-989H11.1	4.95	1.02e-06	0.000129	0.29	0.22	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42278188~42278846:+
THCA	cis	rs7726354	1	rs59536253	ENSG00000271828.1	CTD-2310F14.1	4.95	1.02e-06	0.000129	0.6	0.22	Breast cancer (early onset);	chr5:56973685	chr5:56927874~56929573:+
THCA	cis	rs13178541	0.745	rs4976326	ENSG00000250378.1	RP11-119J18.1	4.95	1.02e-06	0.00013	0.29	0.22	IgG glycosylation;	chr5:135728800	chr5:135812667~135826582:+
THCA	cis	rs2281603	0.857	rs3783722	ENSG00000259116.1	RP11-973N13.4	-4.95	1.02e-06	0.00013	-0.22	-0.22	Lymphocyte counts;	chr14:64531248	chr14:64514154~64540368:-
THCA	cis	rs2251381	0.778	rs2245021	ENSG00000176054.6	RPL23P2	4.95	1.02e-06	0.00013	0.2	0.22	Selective IgA deficiency;	chr21:29174520	chr21:28997613~28998033:-
THCA	cis	rs10090774	0.965	rs13250888	ENSG00000279766.1	RP11-642A1.2	-4.95	1.02e-06	0.00013	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140888931	chr8:140572142~140572812:-
THCA	cis	rs17772222	1	rs17772064	ENSG00000222990.1	RNU4-22P	4.95	1.02e-06	0.00013	0.29	0.22	Coronary artery calcification;	chr14:88356527	chr14:88513498~88513663:+
THCA	cis	rs7474896	1	rs12358094	ENSG00000263064.2	RP11-291L22.7	4.95	1.02e-06	0.00013	0.38	0.22	Obesity (extreme);	chr10:37726578	chr10:38448689~38448949:+
THCA	cis	rs228614	0.51	rs3774987	ENSG00000248971.2	KRT8P46	-4.95	1.02e-06	0.00013	-0.27	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102728746~102730171:-
THCA	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-4.95	1.02e-06	0.00013	-0.27	-0.22	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
THCA	cis	rs9910055	0.96	rs9911991	ENSG00000267080.4	ASB16-AS1	-4.95	1.02e-06	0.00013	-0.21	-0.22	Total body bone mineral density;	chr17:44201548	chr17:44175973~44186717:-
THCA	cis	rs17711722	1	rs17711722	ENSG00000223473.2	GS1-124K5.3	-4.95	1.02e-06	0.00013	-0.15	-0.22	Calcium levels;	chr7:65806210	chr7:66491049~66493566:-
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000223473.2	GS1-124K5.3	-4.95	1.02e-06	0.00013	-0.15	-0.22	Calcium levels;	chr7:65808508	chr7:66491049~66493566:-
THCA	cis	rs6728642	0.908	rs17842456	ENSG00000230606.9	AC159540.1	-4.95	1.02e-06	0.00013	-0.3	-0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97359380	chr2:97416165~97433527:-
THCA	cis	rs930395	0.514	rs4866784	ENSG00000272335.1	RP11-53O19.3	-4.95	1.02e-06	0.00013	-0.19	-0.22	Breast cancer;	chr5:44901029	chr5:44826076~44828592:+
THCA	cis	rs7520050	0.807	rs6656279	ENSG00000234329.1	RP11-767N6.2	4.95	1.02e-06	0.00013	0.2	0.22	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.807	rs6671802	ENSG00000234329.1	RP11-767N6.2	4.95	1.02e-06	0.00013	0.2	0.22	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45651039~45651826:-
THCA	cis	rs6686842	0.56	rs213738	ENSG00000235358.1	RP11-399E6.1	4.95	1.02e-06	0.00013	0.29	0.22	Height;	chr1:41156676	chr1:41242373~41284861:+
THCA	cis	rs2154319	0.559	rs213746	ENSG00000235358.1	RP11-399E6.1	4.95	1.02e-06	0.00013	0.29	0.22	Height;	chr1:41163143	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.56	rs12127030	ENSG00000235358.1	RP11-399E6.1	-4.95	1.02e-06	0.00013	-0.29	-0.22	Height;	chr1:41172726	chr1:41242373~41284861:+
THCA	cis	rs6686842	0.536	rs61774688	ENSG00000235358.1	RP11-399E6.1	-4.95	1.02e-06	0.00013	-0.29	-0.22	Height;	chr1:41212213	chr1:41242373~41284861:+
THCA	cis	rs16846053	0.792	rs56374905	ENSG00000227403.1	AC009299.3	4.95	1.02e-06	0.00013	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161774935	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62190661	ENSG00000227403.1	AC009299.3	4.95	1.02e-06	0.00013	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161782616	chr2:161244739~161249050:+
THCA	cis	rs11671005	0.735	rs3764529	ENSG00000265272.2	RN7SL693P	4.95	1.02e-06	0.00013	0.31	0.22	Mean platelet volume;	chr19:58433722	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs1122955	ENSG00000265272.2	RN7SL693P	4.95	1.02e-06	0.00013	0.31	0.22	Mean platelet volume;	chr19:58434836	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs11668814	ENSG00000265272.2	RN7SL693P	4.95	1.02e-06	0.00013	0.31	0.22	Mean platelet volume;	chr19:58435466	chr19:58490797~58491075:+
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000223473.2	GS1-124K5.3	4.95	1.02e-06	0.00013	0.15	0.22	Calcium levels;	chr7:65853042	chr7:66491049~66493566:-
THCA	cis	rs875971	0.516	rs6945322	ENSG00000223473.2	GS1-124K5.3	4.95	1.02e-06	0.00013	0.15	0.22	Aortic root size;	chr7:65871069	chr7:66491049~66493566:-
THCA	cis	rs6545883	0.894	rs6709441	ENSG00000270820.4	RP11-355B11.2	-4.95	1.02e-06	0.00013	-0.19	-0.22	Tuberculosis;	chr2:61209795	chr2:61471188~61484130:+
THCA	cis	rs56114371	0.777	rs200482	ENSG00000280107.1	AL022393.9	-4.95	1.02e-06	0.00013	-0.34	-0.22	Breast cancer;	chr6:27806126	chr6:28170845~28172521:+
THCA	cis	rs7665090	0.87	rs227361	ENSG00000251288.2	RP11-10L12.2	-4.95	1.02e-06	0.00013	-0.29	-0.22	Primary biliary cholangitis;	chr4:102665820	chr4:102751401~102752641:+
THCA	cis	rs911555	0.723	rs7144010	ENSG00000244691.1	RPL10AP1	4.95	1.03e-06	0.00013	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103412119~103412761:-
THCA	cis	rs4925386	0.84	rs6142738	ENSG00000273619.1	RP5-908M14.9	4.95	1.03e-06	0.00013	0.19	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62386303~62386970:-
THCA	cis	rs1003719	0.715	rs2051398	ENSG00000230366.8	DSCR9	-4.95	1.03e-06	0.00013	-0.23	-0.22	Eye color traits;	chr21:37177956	chr21:37208503~37221736:+
THCA	cis	rs9307551	0.948	rs1837645	ENSG00000250334.4	LINC00989	-4.95	1.03e-06	0.00013	-0.28	-0.22	Refractive error;	chr4:79560081	chr4:79492416~79576460:+
THCA	cis	rs897984	0.537	rs8045637	ENSG00000279196.1	RP11-1072A3.3	4.95	1.03e-06	0.00013	0.22	0.22	Dementia with Lewy bodies;	chr16:30807341	chr16:30984630~30988270:-
THCA	cis	rs4660456	0.504	rs2253835	ENSG00000272145.1	NFYC-AS1	-4.95	1.03e-06	0.00013	-0.16	-0.22	Platelet count;	chr1:40635900	chr1:40690380~40692066:-
THCA	cis	rs919433	0.963	rs13033821	ENSG00000231621.1	AC013264.2	4.95	1.03e-06	0.00013	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197308812	chr2:197197991~197199273:+
THCA	cis	rs7829975	0.514	rs2979139	ENSG00000253981.4	ALG1L13P	4.95	1.03e-06	0.00013	0.21	0.22	Mood instability;	chr8:8410803	chr8:8236003~8244667:-
THCA	cis	rs13434995	0.513	rs6851971	ENSG00000273257.1	RP11-177J6.1	4.95	1.03e-06	0.00013	0.33	0.22	Adiponectin levels;	chr4:55561897	chr4:55387949~55388271:+
THCA	cis	rs1383484	0.606	rs9329364	ENSG00000259728.4	LINC00933	-4.95	1.03e-06	0.00013	-0.26	-0.22	Height;	chr15:83974490	chr15:84570649~84580175:+
THCA	cis	rs13434995	0.513	rs13134079	ENSG00000273257.1	RP11-177J6.1	4.95	1.03e-06	0.00013	0.33	0.22	Adiponectin levels;	chr4:55542021	chr4:55387949~55388271:+
THCA	cis	rs6832769	1	rs59804446	ENSG00000272969.1	RP11-528I4.2	-4.95	1.03e-06	0.00013	-0.26	-0.22	Personality dimensions;	chr4:55563374	chr4:55547112~55547889:+
THCA	cis	rs416603	0.901	rs149597	ENSG00000263080.1	RP11-485G7.5	-4.95	1.03e-06	0.00013	-0.26	-0.22	Type 1 diabetes;	chr16:11250085	chr16:11341809~11345211:-
THCA	cis	rs12682352	0.602	rs6988939	ENSG00000254153.1	CTA-398F10.2	-4.95	1.03e-06	0.00013	-0.24	-0.22	Neuroticism;	chr8:8809406	chr8:8456909~8461337:-
THCA	cis	rs1889642	0.701	rs12430995	ENSG00000227354.5	RBM26-AS1	4.95	1.03e-06	0.00013	0.21	0.22	Colonoscopy-negative controls vs population controls;	chr13:79856116	chr13:79406309~79424328:+
THCA	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-4.95	1.03e-06	0.00013	-0.26	-0.22	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
THCA	cis	rs4237845	0.611	rs10877036	ENSG00000257159.1	RP11-58A17.3	-4.95	1.03e-06	0.00013	-0.28	-0.22	Intelligence (multi-trait analysis);	chr12:57927867	chr12:57967058~57968399:+
THCA	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-4.95	1.03e-06	0.00013	-0.27	-0.22	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
THCA	cis	rs17767392	0.881	rs1859643	ENSG00000259146.3	RP1-261D10.2	4.95	1.03e-06	0.00013	0.28	0.22	Mitral valve prolapse;	chr14:71588751	chr14:71292729~71321814:-
THCA	cis	rs10090774	0.965	rs13261338	ENSG00000279766.1	RP11-642A1.2	-4.95	1.03e-06	0.00013	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140881722	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs7830394	ENSG00000279766.1	RP11-642A1.2	-4.95	1.03e-06	0.00013	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140884642	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11167006	ENSG00000279766.1	RP11-642A1.2	-4.95	1.03e-06	0.00013	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140885398	chr8:140572142~140572812:-
THCA	cis	rs7617773	0.779	rs9833309	ENSG00000199476.1	Y_RNA	-4.95	1.03e-06	0.00013	-0.29	-0.22	Coronary artery disease;	chr3:48285960	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs4131361	ENSG00000199476.1	Y_RNA	-4.95	1.03e-06	0.00013	-0.29	-0.22	Coronary artery disease;	chr3:48287322	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs4131362	ENSG00000199476.1	Y_RNA	-4.95	1.03e-06	0.00013	-0.29	-0.22	Coronary artery disease;	chr3:48287546	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs6791930	ENSG00000199476.1	Y_RNA	-4.95	1.03e-06	0.00013	-0.29	-0.22	Coronary artery disease;	chr3:48288410	chr3:48288587~48288694:+
THCA	cis	rs17767392	0.67	rs61989245	ENSG00000259146.3	RP1-261D10.2	4.95	1.03e-06	0.00013	0.28	0.22	Mitral valve prolapse;	chr14:71253259	chr14:71292729~71321814:-
THCA	cis	rs1559040	1	rs10172916	ENSG00000272156.1	RP11-477N3.1	-4.95	1.03e-06	0.00013	-0.35	-0.22	Sudden cardiac arrest;	chr2:54101831	chr2:54082554~54085066:+
THCA	cis	rs11673344	0.523	rs2562605	ENSG00000276846.1	CTD-3220F14.3	4.95	1.03e-06	0.00013	0.17	0.22	Obesity-related traits;	chr19:37029302	chr19:37314868~37315620:-
THCA	cis	rs17123764	0.892	rs13906	ENSG00000257464.1	RP11-161H23.8	-4.95	1.03e-06	0.00013	-0.35	-0.22	Intelligence (multi-trait analysis);	chr12:49558611	chr12:49442424~49442652:-
THCA	cis	rs4648045	0.796	rs4648050	ENSG00000246560.2	RP11-10L12.4	4.95	1.03e-06	0.00013	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102593584	chr4:102828055~102844075:+
THCA	cis	rs34779708	0.966	rs11010095	ENSG00000271335.4	RP11-324I22.4	4.95	1.03e-06	0.00013	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35314552~35336401:-
THCA	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	4.95	1.03e-06	0.00013	0.19	0.22	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
THCA	cis	rs72945132	0.882	rs72945194	ENSG00000254604.1	AP000487.6	-4.95	1.03e-06	0.00013	-0.43	-0.22	Coronary artery disease;	chr11:70292515	chr11:70282367~70363368:-
THCA	cis	rs13434995	0.513	rs6802	ENSG00000273257.1	RP11-177J6.1	-4.95	1.03e-06	0.00013	-0.33	-0.22	Adiponectin levels;	chr4:55425934	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62303722	ENSG00000273257.1	RP11-177J6.1	-4.95	1.03e-06	0.00013	-0.33	-0.22	Adiponectin levels;	chr4:55482076	chr4:55387949~55388271:+
THCA	cis	rs2067615	0.524	rs10778500	ENSG00000260329.1	RP11-412D9.4	-4.95	1.03e-06	0.00013	-0.21	-0.22	Heart rate;	chr12:106680632	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.524	rs1922433	ENSG00000260329.1	RP11-412D9.4	-4.95	1.03e-06	0.00013	-0.21	-0.22	Heart rate;	chr12:106683394	chr12:106954029~106955497:-
THCA	cis	rs7520050	0.966	rs785488	ENSG00000234329.1	RP11-767N6.2	-4.95	1.03e-06	0.00013	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs785489	ENSG00000234329.1	RP11-767N6.2	-4.95	1.03e-06	0.00013	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45651039~45651826:-
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000176933.5	TOB2P1	-4.95	1.03e-06	0.00013	-0.24	-0.22	Pubertal anthropometrics;	chr6:28294921	chr6:28217643~28218634:-
THCA	cis	rs6772849	0.93	rs9868579	ENSG00000242551.2	POU5F1P6	4.95	1.03e-06	0.00013	0.28	0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:128674735~128677005:-
THCA	cis	rs2243480	1	rs73142162	ENSG00000232559.3	GS1-124K5.12	4.95	1.03e-06	0.00013	0.33	0.22	Diabetic kidney disease;	chr7:65909309	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.673	rs12103759	ENSG00000280069.1	CTD-2349P21.3	-4.95	1.03e-06	0.000131	-0.36	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs59029591	ENSG00000280069.1	CTD-2349P21.3	-4.95	1.03e-06	0.000131	-0.36	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73265633	ENSG00000280069.1	CTD-2349P21.3	-4.95	1.03e-06	0.000131	-0.36	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9913782	ENSG00000280069.1	CTD-2349P21.3	-4.95	1.03e-06	0.000131	-0.36	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9911989	ENSG00000280069.1	CTD-2349P21.3	4.95	1.03e-06	0.000131	0.36	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30738182~30740275:+
THCA	cis	rs2562456	0.833	rs4334427	ENSG00000268119.4	CTD-2561J22.5	4.95	1.03e-06	0.000131	0.32	0.22	Pain;	chr19:21338090	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs4644962	ENSG00000268119.4	CTD-2561J22.5	4.95	1.03e-06	0.000131	0.32	0.22	Pain;	chr19:21338125	chr19:21444241~21463908:-
THCA	cis	rs6545883	0.895	rs6545871	ENSG00000270820.4	RP11-355B11.2	4.95	1.03e-06	0.000131	0.19	0.22	Tuberculosis;	chr2:61465068	chr2:61471188~61484130:+
THCA	cis	rs16846053	0.792	rs62189059	ENSG00000227403.1	AC009299.3	4.95	1.03e-06	0.000131	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161775657	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62190660	ENSG00000227403.1	AC009299.3	4.95	1.03e-06	0.000131	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161777194	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs12053256	ENSG00000227403.1	AC009299.3	4.95	1.03e-06	0.000131	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161783488	chr2:161244739~161249050:+
THCA	cis	rs6878727	0.589	rs256613	ENSG00000253807.4	LINC01170	4.95	1.03e-06	0.000131	0.21	0.22	Breast cancer;	chr5:124326201	chr5:124059794~124405079:-
THCA	cis	rs7520050	0.966	rs785494	ENSG00000234329.1	RP11-767N6.2	-4.95	1.03e-06	0.000131	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45651039~45651826:-
THCA	cis	rs9307551	0.744	rs4975095	ENSG00000250334.4	LINC00989	-4.95	1.03e-06	0.000131	-0.28	-0.22	Refractive error;	chr4:79563197	chr4:79492416~79576460:+
THCA	cis	rs4646450	0.891	rs34777615	ENSG00000244219.5	GS1-259H13.2	-4.95	1.03e-06	0.000131	-0.27	-0.22	Blood metabolite levels;	chr7:99595834	chr7:99598066~99610813:+
THCA	cis	rs7131987	0.874	rs10843366	ENSG00000275476.1	RP11-996F15.4	-4.95	1.03e-06	0.000131	-0.22	-0.22	QT interval;	chr12:29254970	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.845	rs2042511	ENSG00000275476.1	RP11-996F15.4	-4.95	1.03e-06	0.000131	-0.22	-0.22	QT interval;	chr12:29255847	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.903	rs10843371	ENSG00000275476.1	RP11-996F15.4	-4.95	1.03e-06	0.000131	-0.22	-0.22	QT interval;	chr12:29261299	chr12:29277397~29277882:-
THCA	cis	rs448720	0.508	rs2414978	ENSG00000260657.2	RP11-315D16.4	4.95	1.03e-06	0.000131	0.28	0.22	Cognitive performance;	chr15:67928227	chr15:68267792~68277994:-
THCA	cis	rs6969780	0.915	rs7341470	ENSG00000233429.8	HOTAIRM1	-4.95	1.03e-06	0.000131	-0.3	-0.22	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27145223	chr7:27095647~27100265:+
THCA	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-4.95	1.03e-06	0.000131	-0.26	-0.22	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-4.95	1.03e-06	0.000131	-0.26	-0.22	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-4.95	1.03e-06	0.000131	-0.26	-0.22	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
THCA	cis	rs12682352	0.602	rs13260419	ENSG00000254153.1	CTA-398F10.2	-4.95	1.03e-06	0.000131	-0.25	-0.22	Neuroticism;	chr8:8817666	chr8:8456909~8461337:-
THCA	cis	rs17301013	0.932	rs332771	ENSG00000227373.4	RP11-160H22.5	4.95	1.03e-06	0.000131	0.32	0.22	Systemic lupus erythematosus;	chr1:174704141	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.861	rs332789	ENSG00000227373.4	RP11-160H22.5	4.95	1.03e-06	0.000131	0.32	0.22	Systemic lupus erythematosus;	chr1:174735754	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs461910	ENSG00000227373.4	RP11-160H22.5	4.95	1.03e-06	0.000131	0.32	0.22	Systemic lupus erythematosus;	chr1:174736351	chr1:174115300~174160004:-
THCA	cis	rs202072	0.872	rs377704	ENSG00000272379.1	RP1-257A7.5	4.95	1.03e-06	0.000131	0.33	0.22	HIV-1 viral setpoint;	chr6:13279787	chr6:13290018~13290490:-
THCA	cis	rs60695258	0.512	rs2053769	ENSG00000251411.1	RP11-397E7.4	4.95	1.03e-06	0.000131	0.21	0.22	Hematocrit;	chr4:86986855	chr4:86913266~86914817:-
THCA	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	4.95	1.03e-06	0.000131	0.32	0.22	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
THCA	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	4.95	1.03e-06	0.000131	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
THCA	cis	rs6772849	0.93	rs55987729	ENSG00000242551.2	POU5F1P6	-4.95	1.03e-06	0.000131	-0.29	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128621267	chr3:128674735~128677005:-
THCA	cis	rs793571	0.554	rs8029805	ENSG00000259250.1	RP11-50C13.1	4.95	1.03e-06	0.000131	0.24	0.22	Schizophrenia;	chr15:58713723	chr15:58587507~58591676:+
THCA	cis	rs12893668	0.616	rs58033365	ENSG00000269958.1	RP11-73M18.8	4.95	1.03e-06	0.000131	0.22	0.22	Reticulocyte count;	chr14:103564564	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.645	rs12889403	ENSG00000269958.1	RP11-73M18.8	4.95	1.03e-06	0.000131	0.22	0.22	Reticulocyte count;	chr14:103568409	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.703	rs12894729	ENSG00000269958.1	RP11-73M18.8	4.95	1.03e-06	0.000131	0.22	0.22	Reticulocyte count;	chr14:103568955	chr14:103696353~103697163:+
THCA	cis	rs3820928	0.845	rs2177596	ENSG00000212391.1	SNORA48	-4.95	1.03e-06	0.000131	-0.24	-0.22	Pulmonary function;	chr2:227025567	chr2:226968989~226969122:-
THCA	cis	rs651907	0.535	rs9830943	ENSG00000244119.1	PDCL3P4	4.95	1.04e-06	0.000131	0.2	0.22	Colorectal cancer;	chr3:101710055	chr3:101712472~101713191:+
THCA	cis	rs2742234	0.59	rs2435338	ENSG00000273008.1	RP11-351D16.3	-4.95	1.04e-06	0.000131	-0.21	-0.22	Hirschsprung disease;	chr10:43146667	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.59	rs2435339	ENSG00000273008.1	RP11-351D16.3	-4.95	1.04e-06	0.000131	-0.21	-0.22	Hirschsprung disease;	chr10:43146725	chr10:43136824~43138334:-
THCA	cis	rs7614311	0.689	rs2276863	ENSG00000271843.1	RP11-245J9.5	-4.95	1.04e-06	0.000131	-0.4	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63863367	chr3:64008082~64008692:-
THCA	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-4.95	1.04e-06	0.000131	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
THCA	cis	rs7520050	1	rs785511	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000131	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs809775	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000131	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45651039~45651826:-
THCA	cis	rs7474896	0.526	rs1208716	ENSG00000263064.2	RP11-291L22.7	4.95	1.04e-06	0.000131	0.31	0.22	Obesity (extreme);	chr10:37800345	chr10:38448689~38448949:+
THCA	cis	rs2439831	0.681	rs28578454	ENSG00000205771.5	CATSPER2P1	-4.95	1.04e-06	0.000131	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43310834	chr15:43726918~43747094:-
THCA	cis	rs224278	1	rs224291	ENSG00000238280.1	RP11-436D10.3	4.95	1.04e-06	0.000131	0.25	0.22	Ewing sarcoma;	chr10:62828347	chr10:62793562~62805887:-
THCA	cis	rs9652601	0.779	rs9929994	ENSG00000274038.1	RP11-66H6.4	-4.95	1.04e-06	0.000131	-0.28	-0.22	Systemic lupus erythematosus;	chr16:11084388	chr16:11056556~11057034:+
THCA	cis	rs9880211	1	rs34757183	ENSG00000239213.4	NCK1-AS1	4.95	1.04e-06	0.000131	0.24	0.22	Height;Body mass index;	chr3:136424826	chr3:136841726~136862054:-
THCA	cis	rs7899106	1	rs11201713	ENSG00000270002.1	RP11-93H12.4	4.95	1.04e-06	0.000131	0.44	0.22	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85648915	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs73341071	ENSG00000270002.1	RP11-93H12.4	4.95	1.04e-06	0.000131	0.44	0.22	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85649077	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs12269171	ENSG00000270002.1	RP11-93H12.4	4.95	1.04e-06	0.000131	0.44	0.22	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85649142	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs73326604	ENSG00000270002.1	RP11-93H12.4	4.95	1.04e-06	0.000131	0.44	0.22	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85649578	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs76635691	ENSG00000270002.1	RP11-93H12.4	4.95	1.04e-06	0.000131	0.44	0.22	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85651048	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs7899106	ENSG00000270002.1	RP11-93H12.4	4.95	1.04e-06	0.000131	0.44	0.22	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85651147	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs17105752	ENSG00000270002.1	RP11-93H12.4	-4.95	1.04e-06	0.000131	-0.44	-0.22	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85650865	chr10:85644073~85648066:+
THCA	cis	rs748404	0.666	rs16957680	ENSG00000205771.5	CATSPER2P1	-4.95	1.04e-06	0.000131	-0.28	-0.22	Lung cancer;	chr15:43396207	chr15:43726918~43747094:-
THCA	cis	rs911119	0.954	rs2424582	ENSG00000270001.1	RP11-218C14.8	-4.95	1.04e-06	0.000131	-0.33	-0.22	Chronic kidney disease;	chr20:23641913	chr20:23631826~23632316:-
THCA	cis	rs4144027	0.791	rs66473563	ENSG00000269940.1	RP11-73M18.7	4.95	1.04e-06	0.000131	0.21	0.22	Blood metabolite levels;	chr14:103895534	chr14:103694560~103695170:+
THCA	cis	rs944289	0.74	rs414755	ENSG00000258844.1	RP11-259K15.2	-4.95	1.04e-06	0.000131	-0.2	-0.22	Thyroid cancer;	chr14:36073387	chr14:36214607~36235608:+
THCA	cis	rs1823874	0.71	rs55947799	ENSG00000259363.4	CTD-2054N24.2	4.95	1.04e-06	0.000131	0.28	0.22	IgG glycosylation;	chr15:99820700	chr15:99807023~99877148:+
THCA	cis	rs1823874	0.71	rs4965543	ENSG00000259363.4	CTD-2054N24.2	4.95	1.04e-06	0.000131	0.28	0.22	IgG glycosylation;	chr15:99821050	chr15:99807023~99877148:+
THCA	cis	rs1823874	0.71	rs3919790	ENSG00000259363.4	CTD-2054N24.2	4.95	1.04e-06	0.000131	0.28	0.22	IgG glycosylation;	chr15:99821130	chr15:99807023~99877148:+
THCA	cis	rs17767392	0.67	rs59697713	ENSG00000259146.3	RP1-261D10.2	4.95	1.04e-06	0.000131	0.28	0.22	Mitral valve prolapse;	chr14:71262540	chr14:71292729~71321814:-
THCA	cis	rs11846409	0.587	rs1806881	ENSG00000274576.2	IGHV2-70	4.95	1.04e-06	0.000131	0.19	0.22	Rheumatic heart disease;	chr14:106650770	chr14:106770577~106771020:-
THCA	cis	rs919433	0.927	rs1429418	ENSG00000231621.1	AC013264.2	4.95	1.04e-06	0.000131	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293427	chr2:197197991~197199273:+
THCA	cis	rs4722166	0.695	rs7808122	ENSG00000225541.1	AC002480.5	-4.95	1.04e-06	0.000132	-0.27	-0.22	Lung cancer;	chr7:22758461	chr7:22571607~22661792:-
THCA	cis	rs7493	0.95	rs11981299	ENSG00000233942.1	AC004012.1	4.95	1.04e-06	0.000132	0.34	0.22	Yu-Zhi constitution type in type 2 diabetes;	chr7:95400389	chr7:95471835~95473998:+
THCA	cis	rs786425	0.71	rs11057326	ENSG00000270095.1	RP11-214K3.18	-4.95	1.04e-06	0.000132	-0.27	-0.22	Pubertal anthropometrics;	chr12:123663931	chr12:123971457~123971714:-
THCA	cis	rs8020095	0.571	rs10138952	ENSG00000258561.1	RP11-72M17.1	-4.95	1.04e-06	0.000132	-0.3	-0.22	Depression (quantitative trait);	chr14:67069302	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.528	rs10149600	ENSG00000258561.1	RP11-72M17.1	-4.95	1.04e-06	0.000132	-0.3	-0.22	Depression (quantitative trait);	chr14:67073113	chr14:66212810~66509394:-
THCA	cis	rs228614	0.51	rs223447	ENSG00000248971.2	KRT8P46	-4.95	1.04e-06	0.000132	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102728746~102730171:-
THCA	cis	rs12908161	0.65	rs182517	ENSG00000275120.1	RP11-182J1.17	4.95	1.04e-06	0.000132	0.27	0.22	Schizophrenia;	chr15:84846400	chr15:84599434~84606463:-
THCA	cis	rs4915077	0.892	rs17020078	ENSG00000230489.1	VAV3-AS1	4.95	1.04e-06	0.000132	0.32	0.22	Hypothyroidism;	chr1:107806611	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs17020080	ENSG00000230489.1	VAV3-AS1	4.95	1.04e-06	0.000132	0.32	0.22	Hypothyroidism;	chr1:107806657	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs76568279	ENSG00000230489.1	VAV3-AS1	4.95	1.04e-06	0.000132	0.32	0.22	Hypothyroidism;	chr1:107807112	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs17020081	ENSG00000230489.1	VAV3-AS1	4.95	1.04e-06	0.000132	0.32	0.22	Hypothyroidism;	chr1:107807230	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs78998525	ENSG00000230489.1	VAV3-AS1	4.95	1.04e-06	0.000132	0.32	0.22	Hypothyroidism;	chr1:107807444	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs78088580	ENSG00000230489.1	VAV3-AS1	4.95	1.04e-06	0.000132	0.32	0.22	Hypothyroidism;	chr1:107807764	chr1:107964443~107994607:+
THCA	cis	rs2195987	0.633	rs12976145	ENSG00000268362.4	CTD-2017D11.1	-4.95	1.04e-06	0.000132	-0.3	-0.22	Testicular germ cell tumor;	chr19:24075741	chr19:24033445~24066909:+
THCA	cis	rs6441961	0.501	rs6441950	ENSG00000223552.1	RP11-24F11.2	-4.95	1.04e-06	0.000132	-0.23	-0.22	Celiac disease;	chr3:46277485	chr3:46364955~46407059:-
THCA	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-4.95	1.04e-06	0.000132	-0.31	-0.22	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
THCA	cis	rs2562456	0.833	rs11667361	ENSG00000268119.4	CTD-2561J22.5	4.95	1.04e-06	0.000132	0.31	0.22	Pain;	chr19:21356580	chr19:21444241~21463908:-
THCA	cis	rs1318937	0.764	rs735659	ENSG00000224660.1	SH3BP5-AS1	4.95	1.04e-06	0.000132	0.14	0.22	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15182487	chr3:15254184~15264493:+
THCA	cis	rs1318937	0.764	rs2077619	ENSG00000224660.1	SH3BP5-AS1	4.95	1.04e-06	0.000132	0.14	0.22	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15182835	chr3:15254184~15264493:+
THCA	cis	rs1318937	0.679	rs9849394	ENSG00000224660.1	SH3BP5-AS1	4.95	1.04e-06	0.000132	0.14	0.22	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15183135	chr3:15254184~15264493:+
THCA	cis	rs919433	0.889	rs12472355	ENSG00000231621.1	AC013264.2	4.95	1.04e-06	0.000132	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197341116	chr2:197197991~197199273:+
THCA	cis	rs7674212	0.539	rs6854709	ENSG00000251288.2	RP11-10L12.2	-4.95	1.04e-06	0.000132	-0.28	-0.22	Type 2 diabetes;	chr4:103208629	chr4:102751401~102752641:+
THCA	cis	rs2439831	1	rs2444032	ENSG00000166763.7	STRCP1	4.95	1.04e-06	0.000132	0.3	0.22	Lung cancer in ever smokers;	chr15:43463148	chr15:43699488~43718184:-
THCA	cis	rs11846409	0.652	rs10143549	ENSG00000211974.3	IGHV2-70	-4.95	1.04e-06	0.000132	-0.2	-0.22	Rheumatic heart disease;	chr14:106644643	chr14:106723574~106724093:-
THCA	cis	rs987724	0.593	rs10212230	ENSG00000240875.4	LINC00886	-4.95	1.04e-06	0.000132	-0.17	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973164	chr3:156747346~156817062:-
THCA	cis	rs7394190	0.935	rs4746140	ENSG00000271848.1	RP11-464F9.21	-4.95	1.04e-06	0.000132	-0.27	-0.22	Incident atrial fibrillation;	chr10:73657491	chr10:73654039~73674719:+
THCA	cis	rs6545883	0.826	rs777593	ENSG00000270820.4	RP11-355B11.2	4.95	1.04e-06	0.000132	0.19	0.22	Tuberculosis;	chr2:61191968	chr2:61471188~61484130:+
THCA	cis	rs5015933	0.762	rs515985	ENSG00000232630.1	PRPS1P2	-4.95	1.04e-06	0.000132	-0.15	-0.22	Body mass index;	chr9:125300583	chr9:125150653~125151589:+
THCA	cis	rs7618915	0.571	rs2289249	ENSG00000243224.1	RP5-1157M23.2	-4.95	1.04e-06	0.000132	-0.24	-0.22	Bipolar disorder;	chr3:52563648	chr3:52239258~52241097:+
THCA	cis	rs6728642	1	rs60608738	ENSG00000230606.9	AC159540.1	4.95	1.04e-06	0.000132	0.3	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96942348	chr2:97416165~97433527:-
THCA	cis	rs6728642	1	rs57035274	ENSG00000230606.9	AC159540.1	4.95	1.04e-06	0.000132	0.3	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96942387	chr2:97416165~97433527:-
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000223473.2	GS1-124K5.3	4.95	1.04e-06	0.000132	0.15	0.22	Calcium levels;	chr7:65903721	chr7:66491049~66493566:-
THCA	cis	rs10895275	0.923	rs7931576	ENSG00000277459.1	RP11-732A21.3	-4.95	1.04e-06	0.000132	-0.18	-0.22	Migraine;	chr11:102204150	chr11:102109827~102110457:-
THCA	cis	rs4925386	0.84	rs8124907	ENSG00000273619.1	RP5-908M14.9	-4.95	1.04e-06	0.000132	-0.19	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62386303~62386970:-
THCA	cis	rs7523875	0.572	rs76639491	ENSG00000153363.11	LINC00467	-4.95	1.04e-06	0.000132	-0.3	-0.22	Mean corpuscular volume;	chr1:211392589	chr1:211382803~211435333:+
THCA	cis	rs793571	0.504	rs28549001	ENSG00000259250.1	RP11-50C13.1	-4.95	1.04e-06	0.000132	-0.24	-0.22	Schizophrenia;	chr15:58721969	chr15:58587507~58591676:+
THCA	cis	rs6973609	0.513	rs6972740	ENSG00000271122.1	RP11-379H18.1	4.95	1.04e-06	0.000132	0.16	0.22	Obesity-related traits;	chr7:35546524	chr7:35695214~35699413:+
THCA	cis	rs7520050	0.966	rs1085243	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000132	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs1768803	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000132	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs1707333	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000132	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs4660910	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000132	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs785481	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000132	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6675726	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000132	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs785520	ENSG00000234329.1	RP11-767N6.2	-4.95	1.04e-06	0.000132	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45651039~45651826:-
THCA	cis	rs7394190	0.748	rs4746151	ENSG00000271848.1	RP11-464F9.21	-4.95	1.04e-06	0.000132	-0.31	-0.22	Incident atrial fibrillation;	chr10:73818962	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs3843939	ENSG00000271848.1	RP11-464F9.21	-4.95	1.04e-06	0.000132	-0.31	-0.22	Incident atrial fibrillation;	chr10:73819190	chr10:73654039~73674719:+
THCA	cis	rs8028182	0.636	rs4545784	ENSG00000260274.1	RP11-817O13.8	4.95	1.04e-06	0.000132	0.16	0.22	Sudden cardiac arrest;	chr15:75463310	chr15:75368155~75369584:+
THCA	cis	rs763121	0.853	rs3761454	ENSG00000228274.3	RP3-508I15.9	-4.95	1.04e-06	0.000132	-0.24	-0.22	Menopause (age at onset);	chr22:38670815	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs3747170	ENSG00000228274.3	RP3-508I15.9	-4.95	1.04e-06	0.000132	-0.24	-0.22	Menopause (age at onset);	chr22:38671326	chr22:38667585~38681820:-
THCA	cis	rs593531	0.571	rs10898983	ENSG00000255440.1	RP11-632K5.2	4.95	1.04e-06	0.000132	0.27	0.22	Neuroticism;	chr11:74382947	chr11:74409060~74416379:+
THCA	cis	rs8177876	0.822	rs16954582	ENSG00000261061.1	RP11-303E16.2	-4.95	1.05e-06	0.000132	-0.29	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81030770~81031485:+
THCA	cis	rs8027521	0.905	rs2247125	ENSG00000280362.1	RP11-643A5.3	-4.95	1.05e-06	0.000132	-0.27	-0.22	Circulating chemerin levels;	chr15:53973597	chr15:53910769~53914712:+
THCA	cis	rs763121	0.719	rs9610995	ENSG00000235209.1	CTA-150C2.13	4.95	1.05e-06	0.000132	0.29	0.22	Menopause (age at onset);	chr22:38661758	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs8142098	ENSG00000235209.1	CTA-150C2.13	4.95	1.05e-06	0.000132	0.29	0.22	Menopause (age at onset);	chr22:38662752	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2413544	ENSG00000235209.1	CTA-150C2.13	4.95	1.05e-06	0.000132	0.29	0.22	Menopause (age at onset);	chr22:38663399	chr22:38921227~38924708:+
THCA	cis	rs763121	0.752	rs5757222	ENSG00000235209.1	CTA-150C2.13	4.95	1.05e-06	0.000132	0.29	0.22	Menopause (age at onset);	chr22:38664468	chr22:38921227~38924708:+
THCA	cis	rs763121	0.819	rs5750658	ENSG00000235209.1	CTA-150C2.13	4.95	1.05e-06	0.000132	0.29	0.22	Menopause (age at onset);	chr22:38664912	chr22:38921227~38924708:+
THCA	cis	rs763121	0.819	rs8137829	ENSG00000235209.1	CTA-150C2.13	4.95	1.05e-06	0.000132	0.29	0.22	Menopause (age at onset);	chr22:38665025	chr22:38921227~38924708:+
THCA	cis	rs17767392	0.56	rs1008517	ENSG00000259146.3	RP1-261D10.2	-4.95	1.05e-06	0.000132	-0.28	-0.22	Mitral valve prolapse;	chr14:71574717	chr14:71292729~71321814:-
THCA	cis	rs8020095	0.528	rs2064489	ENSG00000258561.1	RP11-72M17.1	-4.95	1.05e-06	0.000132	-0.29	-0.22	Depression (quantitative trait);	chr14:67009780	chr14:66212810~66509394:-
THCA	cis	rs7474896	1	rs11011344	ENSG00000263064.2	RP11-291L22.7	4.95	1.05e-06	0.000132	0.35	0.22	Obesity (extreme);	chr10:37715918	chr10:38448689~38448949:+
THCA	cis	rs9652601	0.622	rs1861548	ENSG00000274038.1	RP11-66H6.4	-4.95	1.05e-06	0.000132	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11024643	chr16:11056556~11057034:+
THCA	cis	rs2190422	0.651	rs2965086	ENSG00000234715.1	CTB-107G13.1	-4.95	1.05e-06	0.000132	-0.26	-0.22	Morning vs. evening chronotype;	chr7:103444466	chr7:103445207~103514007:+
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-4.95	1.05e-06	0.000132	-0.28	-0.22	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000223473.2	GS1-124K5.3	4.95	1.05e-06	0.000132	0.15	0.22	Calcium levels;	chr7:65941231	chr7:66491049~66493566:-
THCA	cis	rs8020095	0.571	rs9323483	ENSG00000258561.1	RP11-72M17.1	-4.95	1.05e-06	0.000132	-0.3	-0.22	Depression (quantitative trait);	chr14:66772889	chr14:66212810~66509394:-
THCA	cis	rs6772849	0.83	rs4857917	ENSG00000242551.2	POU5F1P6	-4.95	1.05e-06	0.000132	-0.29	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128657335	chr3:128674735~128677005:-
THCA	cis	rs911555	0.755	rs34411783	ENSG00000244691.1	RPL10AP1	4.95	1.05e-06	0.000132	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103412119~103412761:-
THCA	cis	rs6893782	1	rs274550	ENSG00000233006.5	AC034220.3	-4.95	1.05e-06	0.000132	-0.22	-0.22	Acylcarnitine levels;	chr5:132393020	chr5:132311285~132369916:-
THCA	cis	rs6893782	0.945	rs7705826	ENSG00000233006.5	AC034220.3	-4.95	1.05e-06	0.000132	-0.22	-0.22	Acylcarnitine levels;	chr5:132396764	chr5:132311285~132369916:-
THCA	cis	rs6893782	1	rs6893782	ENSG00000233006.5	AC034220.3	-4.95	1.05e-06	0.000132	-0.22	-0.22	Acylcarnitine levels;	chr5:132403741	chr5:132311285~132369916:-
THCA	cis	rs6893782	0.945	rs2405522	ENSG00000233006.5	AC034220.3	-4.95	1.05e-06	0.000132	-0.22	-0.22	Acylcarnitine levels;	chr5:132406004	chr5:132311285~132369916:-
THCA	cis	rs11073619	0.616	rs17597076	ENSG00000230373.7	GOLGA6L5P	-4.95	1.05e-06	0.000132	-0.34	-0.22	Positive affect;	chr15:84572704	chr15:84507885~84516814:-
THCA	cis	rs3743266	0.507	rs62003261	ENSG00000245534.5	RORA-AS1	-4.95	1.05e-06	0.000132	-0.3	-0.22	Menarche (age at onset);	chr15:60469290	chr15:60479178~60630637:+
THCA	cis	rs3743266	0.507	rs11637887	ENSG00000245534.5	RORA-AS1	-4.95	1.05e-06	0.000132	-0.3	-0.22	Menarche (age at onset);	chr15:60473017	chr15:60479178~60630637:+
THCA	cis	rs10833905	0.818	rs10833876	ENSG00000246225.5	RP11-17A1.3	-4.95	1.05e-06	0.000132	-0.33	-0.22	Sudden cardiac arrest;	chr11:22985076	chr11:22829380~22945393:+
THCA	cis	rs972578	0.782	rs5758949	ENSG00000274717.1	RP1-47A17.1	-4.95	1.05e-06	0.000132	-0.23	-0.22	Mean platelet volume;	chr22:42799665	chr22:42791814~42794313:-
THCA	cis	rs72627509	0.68	rs79641006	ENSG00000269949.1	RP11-738E22.3	4.95	1.05e-06	0.000132	0.36	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56981277	chr4:56960927~56961373:-
THCA	cis	rs6012564	0.928	rs8118105	ENSG00000227431.4	CSE1L-AS1	4.95	1.05e-06	0.000133	0.27	0.22	Anger;	chr20:49182127	chr20:49040463~49046044:-
THCA	cis	rs7829975	0.582	rs6982832	ENSG00000253981.4	ALG1L13P	-4.95	1.05e-06	0.000133	-0.22	-0.22	Mood instability;	chr8:8934707	chr8:8236003~8244667:-
THCA	cis	rs916888	0.647	rs199524	ENSG00000261575.2	RP11-259G18.1	-4.95	1.05e-06	0.000133	-0.27	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46267037~46268694:+
THCA	cis	rs10129255	0.5	rs988132	ENSG00000211972.2	IGHV3-66	4.95	1.05e-06	0.000133	0.13	0.22	Kawasaki disease;	chr14:106776758	chr14:106675017~106675544:-
THCA	cis	rs73198271	0.96	rs10503392	ENSG00000253893.2	FAM85B	4.95	1.05e-06	0.000133	0.36	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752045	chr8:8167819~8226614:-
THCA	cis	rs9880211	0.948	rs34282798	ENSG00000239213.4	NCK1-AS1	4.95	1.05e-06	0.000133	0.24	0.22	Height;Body mass index;	chr3:136424515	chr3:136841726~136862054:-
THCA	cis	rs9987353	0.544	rs2929470	ENSG00000253893.2	FAM85B	4.95	1.05e-06	0.000133	0.28	0.22	Recombination measurement;	chr8:9204980	chr8:8167819~8226614:-
THCA	cis	rs763121	0.853	rs4821798	ENSG00000273076.1	RP3-508I15.22	4.95	1.05e-06	0.000133	0.22	0.22	Menopause (age at onset);	chr22:38625160	chr22:38743495~38743910:+
THCA	cis	rs228614	0.536	rs223420	ENSG00000248971.2	KRT8P46	-4.95	1.05e-06	0.000133	-0.27	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102728746~102730171:-
THCA	cis	rs5015933	0.762	rs359587	ENSG00000232630.1	PRPS1P2	-4.95	1.05e-06	0.000133	-0.15	-0.22	Body mass index;	chr9:125296098	chr9:125150653~125151589:+
THCA	cis	rs1005277	0.502	rs2800484	ENSG00000275858.1	RP11-291L22.8	4.95	1.05e-06	0.000133	0.27	0.22	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38450738~38451069:-
THCA	cis	rs17301013	0.896	rs6425287	ENSG00000227373.4	RP11-160H22.5	4.95	1.05e-06	0.000133	0.31	0.22	Systemic lupus erythematosus;	chr1:174566264	chr1:174115300~174160004:-
THCA	cis	rs10761482	0.859	rs972404	ENSG00000254271.1	RP11-131N11.4	4.95	1.05e-06	0.000133	0.29	0.22	Schizophrenia;	chr10:60336093	chr10:60734342~60741828:+
THCA	cis	rs8177876	0.642	rs56032321	ENSG00000261061.1	RP11-303E16.2	-4.95	1.05e-06	0.000133	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81030770~81031485:+
THCA	cis	rs6125597	0.516	rs6019537	ENSG00000227431.4	CSE1L-AS1	-4.95	1.05e-06	0.000133	-0.27	-0.22	Intelligence (multi-trait analysis);	chr20:48927067	chr20:49040463~49046044:-
THCA	cis	rs8020095	0.571	rs10133107	ENSG00000258561.1	RP11-72M17.1	-4.95	1.05e-06	0.000133	-0.29	-0.22	Depression (quantitative trait);	chr14:67010147	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs1955606	ENSG00000258561.1	RP11-72M17.1	-4.95	1.05e-06	0.000133	-0.29	-0.22	Depression (quantitative trait);	chr14:67010930	chr14:66212810~66509394:-
THCA	cis	rs800160	1	rs1088988	ENSG00000199550.1	Y_RNA	4.95	1.05e-06	0.000133	0.33	0.22	Bacteremia;	chr11:2359240	chr11:2372638~2372750:+
THCA	cis	rs2342371	1	rs2342371	ENSG00000273013.1	CTD-2002J20.1	4.95	1.05e-06	0.000133	0.22	0.22	Fat distribution (HIV);	chr3:196460737	chr3:196474801~196475394:+
THCA	cis	rs763121	0.853	rs1013338	ENSG00000235209.1	CTA-150C2.13	4.95	1.05e-06	0.000133	0.29	0.22	Menopause (age at onset);	chr22:38578149	chr22:38921227~38924708:+
THCA	cis	rs728616	0.681	rs55855057	ENSG00000242600.5	MBL1P	4.95	1.05e-06	0.000133	0.27	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80274973	chr10:79904898~79950336:+
THCA	cis	rs17767392	0.67	rs11620632	ENSG00000259146.3	RP1-261D10.2	-4.95	1.05e-06	0.000133	-0.27	-0.22	Mitral valve prolapse;	chr14:71262721	chr14:71292729~71321814:-
THCA	cis	rs1395	0.922	rs6547521	ENSG00000234072.1	AC074117.10	-4.95	1.05e-06	0.000133	-0.18	-0.22	Blood metabolite levels;	chr2:27265564	chr2:27356246~27367622:+
THCA	cis	rs2243480	0.901	rs3813708	ENSG00000164669.11	INTS4P1	4.95	1.05e-06	0.000133	0.44	0.22	Diabetic kidney disease;	chr7:65840645	chr7:65141225~65234216:+
THCA	cis	rs950169	0.58	rs11633762	ENSG00000188388.10	GOLGA6L3	4.95	1.05e-06	0.000133	0.3	0.22	Schizophrenia;	chr15:84643921	chr15:85240472~85247170:+
THCA	cis	rs6545883	0.791	rs4672445	ENSG00000270820.4	RP11-355B11.2	-4.95	1.05e-06	0.000133	-0.19	-0.22	Tuberculosis;	chr2:61427873	chr2:61471188~61484130:+
THCA	cis	rs9902453	0.817	rs2628170	ENSG00000263370.1	RP11-68I3.5	-4.95	1.05e-06	0.000133	-0.28	-0.22	Coffee consumption (cups per day);	chr17:29729594	chr17:29639627~29640825:+
THCA	cis	rs763121	0.853	rs4821810	ENSG00000228274.3	RP3-508I15.9	-4.95	1.06e-06	0.000133	-0.24	-0.22	Menopause (age at onset);	chr22:38676093	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757234	ENSG00000228274.3	RP3-508I15.9	-4.95	1.06e-06	0.000133	-0.24	-0.22	Menopause (age at onset);	chr22:38676681	chr22:38667585~38681820:-
THCA	cis	rs2348418	0.639	rs11049350	ENSG00000247934.4	RP11-967K21.1	-4.95	1.06e-06	0.000133	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28113042	chr12:28163298~28190738:-
THCA	cis	rs7951911	1	rs7952511	ENSG00000254427.1	RP11-430H10.1	-4.95	1.06e-06	0.000133	-0.33	-0.22	IgG glycosylation;	chr11:45063430	chr11:45355371~45366121:+
THCA	cis	rs8064024	0.649	rs9934930	ENSG00000267077.1	RP11-127I20.5	4.95	1.06e-06	0.000133	0.26	0.22	Cancer;	chr16:4852037	chr16:4795265~4796532:-
THCA	cis	rs7520050	0.966	rs785491	ENSG00000234329.1	RP11-767N6.2	-4.95	1.06e-06	0.000133	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs785503	ENSG00000234329.1	RP11-767N6.2	-4.95	1.06e-06	0.000133	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45651039~45651826:-
THCA	cis	rs34779708	0.931	rs7099593	ENSG00000271335.4	RP11-324I22.4	4.95	1.06e-06	0.000133	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs13376871	ENSG00000271335.4	RP11-324I22.4	4.95	1.06e-06	0.000133	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.931	rs13376801	ENSG00000271335.4	RP11-324I22.4	4.95	1.06e-06	0.000133	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35314552~35336401:-
THCA	cis	rs593531	0.571	rs11236088	ENSG00000255440.1	RP11-632K5.2	4.95	1.06e-06	0.000133	0.27	0.22	Neuroticism;	chr11:74383298	chr11:74409060~74416379:+
THCA	cis	rs896854	0.967	rs896853	ENSG00000253528.2	RP11-347C18.4	4.95	1.06e-06	0.000133	0.25	0.22	Type 2 diabetes;	chr8:94948627	chr8:94974573~94974853:-
THCA	cis	rs896854	0.967	rs2879813	ENSG00000253528.2	RP11-347C18.4	4.95	1.06e-06	0.000133	0.25	0.22	Type 2 diabetes;	chr8:94948719	chr8:94974573~94974853:-
THCA	cis	rs73198271	0.96	rs73198286	ENSG00000253893.2	FAM85B	4.95	1.06e-06	0.000133	0.37	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8754512	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.96	rs73198287	ENSG00000253893.2	FAM85B	4.95	1.06e-06	0.000133	0.37	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8755276	chr8:8167819~8226614:-
THCA	cis	rs73198271	1	rs11784958	ENSG00000253893.2	FAM85B	4.95	1.06e-06	0.000134	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750271	chr8:8167819~8226614:-
THCA	cis	rs73198271	1	rs11775476	ENSG00000253893.2	FAM85B	4.95	1.06e-06	0.000134	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750359	chr8:8167819~8226614:-
THCA	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-4.95	1.06e-06	0.000134	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
THCA	cis	rs6545883	0.894	rs2694632	ENSG00000270820.4	RP11-355B11.2	-4.95	1.06e-06	0.000134	-0.19	-0.22	Tuberculosis;	chr2:61331547	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.825	rs7578139	ENSG00000270820.4	RP11-355B11.2	-4.95	1.06e-06	0.000134	-0.19	-0.22	Tuberculosis;	chr2:61336986	chr2:61471188~61484130:+
THCA	cis	rs453301	0.571	rs330048	ENSG00000248538.5	RP11-10A14.5	4.95	1.06e-06	0.000134	0.28	0.22	Joint mobility (Beighton score);	chr8:9229768	chr8:9189011~9202854:+
THCA	cis	rs6044112	0.75	rs6080288	ENSG00000273998.1	RP4-777L9.2	4.95	1.06e-06	0.000134	0.34	0.22	Response to taxane treatment (docetaxel);	chr20:16531408	chr20:16576068~16579615:+
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000273712.1	RP5-874C20.7	4.95	1.06e-06	0.000134	0.24	0.22	Pubertal anthropometrics;	chr6:28298372	chr6:28315613~28315883:-
THCA	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	4.95	1.06e-06	0.000134	0.19	0.22	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	4.95	1.06e-06	0.000134	0.19	0.22	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
THCA	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-4.95	1.06e-06	0.000134	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
THCA	cis	rs7702057	0.53	rs7728055	ENSG00000272265.1	CTD-2287O16.4	4.95	1.06e-06	0.000134	0.41	0.22	Amyotrophic lateral sclerosis;	chr5:116078170	chr5:116078110~116078570:-
THCA	cis	rs595244	0.908	rs1036477	ENSG00000259705.1	RP11-227D13.1	4.95	1.06e-06	0.000134	0.32	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48622729	chr15:48645951~48652016:+
THCA	cis	rs2348418	0.832	rs11049512	ENSG00000247934.4	RP11-967K21.1	4.95	1.06e-06	0.000134	0.19	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28295880	chr12:28163298~28190738:-
THCA	cis	rs6430585	0.64	rs6716070	ENSG00000231890.6	DARS-AS1	4.95	1.06e-06	0.000134	0.27	0.22	Corneal structure;	chr2:135787081	chr2:135985176~136022593:+
THCA	cis	rs3020736	0.5	rs4147638	ENSG00000273366.1	CTA-989H11.1	4.95	1.06e-06	0.000134	0.28	0.22	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42278188~42278846:+
THCA	cis	rs9843304	0.501	rs34540967	ENSG00000244503.1	RP11-278L15.6	4.95	1.06e-06	0.000134	0.27	0.22	Gallstone disease;	chr3:149486594	chr3:149494660~149495995:+
THCA	cis	rs7394190	0.748	rs78790589	ENSG00000271816.1	BMS1P4	-4.95	1.06e-06	0.000134	-0.28	-0.22	Incident atrial fibrillation;	chr10:73779840	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs2292307	ENSG00000271816.1	BMS1P4	-4.95	1.06e-06	0.000134	-0.28	-0.22	Incident atrial fibrillation;	chr10:73790158	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs11000780	ENSG00000271816.1	BMS1P4	-4.95	1.06e-06	0.000134	-0.28	-0.22	Incident atrial fibrillation;	chr10:73799319	chr10:73699151~73730487:-
THCA	cis	rs3950186	0.834	rs7743245	ENSG00000215124.2	RP3-420J14.1	4.95	1.06e-06	0.000134	0.26	0.22	Anxiety and major depressive disorder;	chr6:11807831	chr6:11861626~11862970:-
THCA	cis	rs3892630	0.612	rs10413282	ENSG00000267475.1	CTD-2538C1.2	-4.94	1.06e-06	0.000134	-0.3	-0.22	Red blood cell traits;	chr19:32691845	chr19:32687089~32691750:-
THCA	cis	rs919433	0.963	rs1896857	ENSG00000231621.1	AC013264.2	4.94	1.06e-06	0.000134	0.22	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197299806	chr2:197197991~197199273:+
THCA	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	4.94	1.06e-06	0.000134	0.32	0.22	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
THCA	cis	rs2190422	0.651	rs6945055	ENSG00000234715.1	CTB-107G13.1	-4.94	1.06e-06	0.000134	-0.26	-0.22	Morning vs. evening chronotype;	chr7:103446388	chr7:103445207~103514007:+
THCA	cis	rs2190422	0.651	rs1004245	ENSG00000234715.1	CTB-107G13.1	-4.94	1.06e-06	0.000134	-0.26	-0.22	Morning vs. evening chronotype;	chr7:103447962	chr7:103445207~103514007:+
THCA	cis	rs1859596	0.691	rs10226488	ENSG00000234456.6	MAGI2-AS3	4.94	1.06e-06	0.000134	0.22	0.22	Reading or mathematical ability;	chr7:79459192	chr7:79452877~79471208:+
THCA	cis	rs2070488	0.804	rs2268755	ENSG00000229589.1	ACVR2B-AS1	-4.94	1.06e-06	0.000134	-0.2	-0.22	Electrocardiographic conduction measures;	chr3:38460425	chr3:38451027~38454820:-
THCA	cis	rs17301013	0.932	rs10912804	ENSG00000227373.4	RP11-160H22.5	4.94	1.06e-06	0.000134	0.31	0.22	Systemic lupus erythematosus;	chr1:174527412	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.9	rs12088073	ENSG00000227373.4	RP11-160H22.5	4.94	1.06e-06	0.000134	0.31	0.22	Systemic lupus erythematosus;	chr1:174528504	chr1:174115300~174160004:-
THCA	cis	rs7474896	0.583	rs10827818	ENSG00000263064.2	RP11-291L22.7	4.94	1.06e-06	0.000134	0.3	0.22	Obesity (extreme);	chr10:37711928	chr10:38448689~38448949:+
THCA	cis	rs9843304	0.529	rs34895718	ENSG00000244503.1	RP11-278L15.6	4.94	1.06e-06	0.000134	0.27	0.22	Gallstone disease;	chr3:149487430	chr3:149494660~149495995:+
THCA	cis	rs736408	0.677	rs678	ENSG00000243224.1	RP5-1157M23.2	-4.94	1.07e-06	0.000135	-0.24	-0.22	Bipolar disorder;	chr3:52786965	chr3:52239258~52241097:+
THCA	cis	rs5015933	0.788	rs461961	ENSG00000232630.1	PRPS1P2	-4.94	1.07e-06	0.000135	-0.15	-0.22	Body mass index;	chr9:125290977	chr9:125150653~125151589:+
THCA	cis	rs4948102	0.642	rs766333	ENSG00000226278.1	PSPHP1	-4.94	1.07e-06	0.000135	-0.25	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55764797~55773288:+
THCA	cis	rs7900823	0.601	rs10763657	ENSG00000230500.1	MKX-AS1	4.94	1.07e-06	0.000135	0.32	0.22	Lung cancer;	chr10:28300209	chr10:27744786~27767794:+
THCA	cis	rs6565180	0.926	rs8046445	ENSG00000274653.1	RP11-347C12.11	4.94	1.07e-06	0.000135	0.2	0.22	Tonsillectomy;	chr16:30374941	chr16:30359825~30360336:+
THCA	cis	rs4925386	0.808	rs1760073	ENSG00000275437.1	RP5-908M14.10	-4.94	1.07e-06	0.000135	-0.21	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62351050	chr20:62402236~62405935:-
THCA	cis	rs6908034	0.607	rs12527834	ENSG00000227116.1	RP3-471C18.1	-4.94	1.07e-06	0.000135	-0.44	-0.22	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821550	chr6:19730427~19734567:-
THCA	cis	rs7674212	0.541	rs2251322	ENSG00000251288.2	RP11-10L12.2	-4.94	1.07e-06	0.000135	-0.28	-0.22	Type 2 diabetes;	chr4:103158267	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.57	rs2251634	ENSG00000251288.2	RP11-10L12.2	-4.94	1.07e-06	0.000135	-0.28	-0.22	Type 2 diabetes;	chr4:103161192	chr4:102751401~102752641:+
THCA	cis	rs911119	1	rs1010117	ENSG00000270001.1	RP11-218C14.8	-4.94	1.07e-06	0.000135	-0.34	-0.22	Chronic kidney disease;	chr20:23627784	chr20:23631826~23632316:-
THCA	cis	rs6490294	0.571	rs77176084	ENSG00000226469.1	ADAM1B	4.94	1.07e-06	0.000135	0.36	0.22	Mean platelet volume;	chr12:112077508	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs74636821	ENSG00000226469.1	ADAM1B	4.94	1.07e-06	0.000135	0.36	0.22	Mean platelet volume;	chr12:112078108	chr12:111927018~111929017:+
THCA	cis	rs75920871	0.544	rs76868258	ENSG00000254851.1	RP11-109L13.1	-4.94	1.07e-06	0.000135	-0.46	-0.22	Subjective well-being;	chr11:117122576	chr11:117135528~117138582:+
THCA	cis	rs62184315	0.536	rs62185874	ENSG00000253559.1	OSGEPL1-AS1	-4.94	1.07e-06	0.000135	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189704288	chr2:189762704~189765556:+
THCA	cis	rs78487399	0.908	rs12469959	ENSG00000234936.1	AC010883.5	4.94	1.07e-06	0.000135	0.29	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43576587	chr2:43229573~43233394:+
THCA	cis	rs2067615	0.524	rs10778505	ENSG00000260329.1	RP11-412D9.4	-4.94	1.07e-06	0.000135	-0.21	-0.22	Heart rate;	chr12:106749348	chr12:106954029~106955497:-
THCA	cis	rs453301	0.624	rs330056	ENSG00000253981.4	ALG1L13P	-4.94	1.07e-06	0.000135	-0.21	-0.22	Joint mobility (Beighton score);	chr8:9232185	chr8:8236003~8244667:-
THCA	cis	rs9625935	0.843	rs41178	ENSG00000279159.1	RP3-394A18.1	-4.94	1.07e-06	0.000135	-0.16	-0.22	Tonsillectomy;	chr22:30044544	chr22:29978950~30028236:-
THCA	cis	rs10090774	0.932	rs61307926	ENSG00000279766.1	RP11-642A1.2	-4.94	1.07e-06	0.000135	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140932255	chr8:140572142~140572812:-
THCA	cis	rs7474896	1	rs12358108	ENSG00000263064.2	RP11-291L22.7	4.94	1.07e-06	0.000135	0.38	0.22	Obesity (extreme);	chr10:37726679	chr10:38448689~38448949:+
THCA	cis	rs10129255	0.789	rs61997796	ENSG00000223648.3	IGHV3-64	4.94	1.07e-06	0.000135	0.14	0.22	Kawasaki disease;	chr14:106813798	chr14:106643132~106658258:-
THCA	cis	rs7727544	0.582	rs3792894	ENSG00000224431.1	AC063976.7	4.94	1.07e-06	0.000135	0.19	0.22	Blood metabolite levels;	chr5:132211578	chr5:132199456~132203487:+
THCA	cis	rs11671005	0.735	rs56292587	ENSG00000265272.2	RN7SL693P	4.94	1.07e-06	0.000135	0.31	0.22	Mean platelet volume;	chr19:58407699	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs56290606	ENSG00000265272.2	RN7SL693P	4.94	1.07e-06	0.000135	0.31	0.22	Mean platelet volume;	chr19:58407953	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs11878198	ENSG00000265272.2	RN7SL693P	4.94	1.07e-06	0.000135	0.31	0.22	Mean platelet volume;	chr19:58408935	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs11666716	ENSG00000265272.2	RN7SL693P	4.94	1.07e-06	0.000135	0.31	0.22	Mean platelet volume;	chr19:58409585	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs34511020	ENSG00000265272.2	RN7SL693P	4.94	1.07e-06	0.000135	0.31	0.22	Mean platelet volume;	chr19:58409929	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs11666303	ENSG00000265272.2	RN7SL693P	4.94	1.07e-06	0.000135	0.31	0.22	Mean platelet volume;	chr19:58411135	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs34152946	ENSG00000265272.2	RN7SL693P	4.94	1.07e-06	0.000135	0.31	0.22	Mean platelet volume;	chr19:58411896	chr19:58490797~58491075:+
THCA	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-4.94	1.07e-06	0.000135	-0.24	-0.22	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
THCA	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-4.94	1.07e-06	0.000135	-0.19	-0.22	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
THCA	cis	rs453301	0.624	rs330058	ENSG00000253981.4	ALG1L13P	-4.94	1.07e-06	0.000135	-0.21	-0.22	Joint mobility (Beighton score);	chr8:9232299	chr8:8236003~8244667:-
THCA	cis	rs11722779	0.869	rs223350	ENSG00000248971.2	KRT8P46	-4.94	1.07e-06	0.000135	-0.27	-0.22	Schizophrenia;	chr4:102856899	chr4:102728746~102730171:-
THCA	cis	rs6832769	1	rs4865010	ENSG00000272969.1	RP11-528I4.2	-4.94	1.07e-06	0.000135	-0.26	-0.22	Personality dimensions;	chr4:55548795	chr4:55547112~55547889:+
THCA	cis	rs763121	0.962	rs2071887	ENSG00000273076.1	RP3-508I15.22	4.94	1.07e-06	0.000135	0.21	0.22	Menopause (age at onset);	chr22:38483005	chr22:38743495~38743910:+
THCA	cis	rs8062405	0.755	rs62034325	ENSG00000261766.1	RP11-22P6.2	-4.94	1.07e-06	0.000135	-0.22	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28862166~28863340:-
THCA	cis	rs79243044	0.965	rs10500648	ENSG00000224295.2	AC087380.14	-4.94	1.07e-06	0.000135	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5539775	chr11:5518441~5524955:-
THCA	cis	rs2018683	0.624	rs6462119	ENSG00000272568.4	CTB-113D17.1	4.94	1.07e-06	0.000136	0.21	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28979967~29013367:+
THCA	cis	rs6708331	0.517	rs6546572	ENSG00000179818.12	PCBP1-AS1	-4.94	1.07e-06	0.000136	-0.18	-0.22	Obesity-related traits;	chr2:70146510	chr2:69962263~70103220:-
THCA	cis	rs4803480	0.529	rs4803481	ENSG00000267107.5	PCAT19	4.94	1.07e-06	0.000136	0.22	0.22	Schizophrenia;	chr19:41560186	chr19:41454169~41500649:-
THCA	cis	rs9840812	0.559	rs6439640	ENSG00000239213.4	NCK1-AS1	4.94	1.07e-06	0.000136	0.25	0.22	Fibrinogen levels;	chr3:136466838	chr3:136841726~136862054:-
THCA	cis	rs467650	0.817	rs17730306	ENSG00000246763.5	RGMB-AS1	4.94	1.07e-06	0.000136	0.23	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98721327	chr5:98769618~98773469:-
THCA	cis	rs6714710	0.603	rs2305143	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97797318	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs11691494	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803263	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs11684749	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803679	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.58	rs17489915	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803968	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs4311104	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97808339	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs2278700	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97810919	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs12104810	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97827195	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.58	rs57681139	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838010	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.58	rs1838797	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838109	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs78006955	ENSG00000230606.9	AC159540.1	-4.94	1.07e-06	0.000136	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97839047	chr2:97416165~97433527:-
THCA	cis	rs17301013	0.932	rs1653627	ENSG00000227373.4	RP11-160H22.5	-4.94	1.07e-06	0.000136	-0.32	-0.22	Systemic lupus erythematosus;	chr1:174771879	chr1:174115300~174160004:-
THCA	cis	rs11673344	0.523	rs6510584	ENSG00000276846.1	CTD-3220F14.3	4.94	1.07e-06	0.000136	0.17	0.22	Obesity-related traits;	chr19:37058699	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.503	rs7246720	ENSG00000276846.1	CTD-3220F14.3	4.94	1.07e-06	0.000136	0.17	0.22	Obesity-related traits;	chr19:37073726	chr19:37314868~37315620:-
THCA	cis	rs4713118	0.869	rs9468214	ENSG00000226314.6	ZNF192P1	-4.94	1.08e-06	0.000136	-0.28	-0.22	Parkinson's disease;	chr6:27745520	chr6:28161781~28169594:+
THCA	cis	rs11779988	0.503	rs411173	ENSG00000253671.1	RP11-806O11.1	-4.94	1.08e-06	0.000136	-0.28	-0.22	Breast cancer;	chr8:17910755	chr8:17808941~17820868:+
THCA	cis	rs11779988	0.545	rs375203	ENSG00000253671.1	RP11-806O11.1	-4.94	1.08e-06	0.000136	-0.28	-0.22	Breast cancer;	chr8:17911545	chr8:17808941~17820868:+
THCA	cis	rs2562456	0.833	rs4429400	ENSG00000268119.4	CTD-2561J22.5	4.94	1.08e-06	0.000136	0.33	0.22	Pain;	chr19:21338163	chr19:21444241~21463908:-
THCA	cis	rs79243044	0.965	rs11038005	ENSG00000224295.2	AC087380.14	-4.94	1.08e-06	0.000136	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5536729	chr11:5518441~5524955:-
THCA	cis	rs6921919	0.551	rs13201753	ENSG00000280107.1	AL022393.9	-4.94	1.08e-06	0.000136	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28170845~28172521:+
THCA	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	4.94	1.08e-06	0.000136	0.28	0.22	Depression;	chr6:28327262	chr6:28943877~28944537:+
THCA	cis	rs7131987	0.801	rs6487804	ENSG00000275476.1	RP11-996F15.4	-4.94	1.08e-06	0.000136	-0.22	-0.22	QT interval;	chr12:29302001	chr12:29277397~29277882:-
THCA	cis	rs10510102	0.935	rs11200183	ENSG00000226864.1	ATE1-AS1	4.94	1.08e-06	0.000136	0.37	0.22	Breast cancer;	chr10:121829908	chr10:121928312~121951965:+
THCA	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-4.94	1.08e-06	0.000136	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
THCA	cis	rs79349575	0.749	rs12601672	ENSG00000270781.1	RP11-501C14.9	-4.94	1.08e-06	0.000136	-0.26	-0.22	Type 2 diabetes;	chr17:48929131	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs17635252	ENSG00000270781.1	RP11-501C14.9	-4.94	1.08e-06	0.000136	-0.26	-0.22	Type 2 diabetes;	chr17:48929588	chr17:48899131~48899748:+
THCA	cis	rs10833905	0.641	rs11026854	ENSG00000246225.5	RP11-17A1.3	-4.94	1.08e-06	0.000136	-0.33	-0.22	Sudden cardiac arrest;	chr11:22940325	chr11:22829380~22945393:+
THCA	cis	rs62432291	0.681	rs365045	ENSG00000235086.1	FNDC1-IT1	4.94	1.08e-06	0.000136	0.4	0.22	Joint mobility (Beighton score);	chr6:159211218	chr6:159240786~159243329:+
THCA	cis	rs919433	0.713	rs1455653	ENSG00000231621.1	AC013264.2	-4.94	1.08e-06	0.000136	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197613596	chr2:197197991~197199273:+
THCA	cis	rs667920	0.5	rs34738913	ENSG00000273486.1	RP11-731C17.2	-4.94	1.08e-06	0.000136	-0.29	-0.22	Coronary artery disease;	chr3:136719042	chr3:136837338~136839021:-
THCA	cis	rs7621025	0.505	rs34613715	ENSG00000273486.1	RP11-731C17.2	-4.94	1.08e-06	0.000136	-0.29	-0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136736165	chr3:136837338~136839021:-
THCA	cis	rs7621025	0.505	rs34281413	ENSG00000273486.1	RP11-731C17.2	-4.94	1.08e-06	0.000136	-0.29	-0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136743018	chr3:136837338~136839021:-
THCA	cis	rs17301013	0.932	rs7555533	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000136	0.32	0.22	Systemic lupus erythematosus;	chr1:174589983	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs6671824	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000136	0.32	0.22	Systemic lupus erythematosus;	chr1:174603721	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.861	rs6672148	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000136	0.32	0.22	Systemic lupus erythematosus;	chr1:174604016	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs10912813	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000136	0.32	0.22	Systemic lupus erythematosus;	chr1:174607342	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs67967476	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000136	0.32	0.22	Systemic lupus erythematosus;	chr1:174616119	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs6683602	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000136	0.32	0.22	Systemic lupus erythematosus;	chr1:174617615	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs6696197	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000136	0.32	0.22	Systemic lupus erythematosus;	chr1:174617860	chr1:174115300~174160004:-
THCA	cis	rs4803480	0.554	rs12150975	ENSG00000267107.5	PCAT19	4.94	1.08e-06	0.000136	0.22	0.22	Schizophrenia;	chr19:41563990	chr19:41454169~41500649:-
THCA	cis	rs4803480	0.554	rs12983999	ENSG00000267107.5	PCAT19	4.94	1.08e-06	0.000136	0.22	0.22	Schizophrenia;	chr19:41564158	chr19:41454169~41500649:-
THCA	cis	rs17404153	0.599	rs72992311	ENSG00000248724.5	NPHP3-AS1	-4.94	1.08e-06	0.000136	-0.32	-0.22	LDL cholesterol;HDL cholesterol;	chr3:132439422	chr3:132721750~132874223:+
THCA	cis	rs7727544	0.548	rs35696821	ENSG00000224431.1	AC063976.7	4.94	1.08e-06	0.000136	0.19	0.22	Blood metabolite levels;	chr5:132172324	chr5:132199456~132203487:+
THCA	cis	rs9652601	0.691	rs9888868	ENSG00000274038.1	RP11-66H6.4	-4.94	1.08e-06	0.000136	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11089706	chr16:11056556~11057034:+
THCA	cis	rs11671005	0.61	rs8103813	ENSG00000269600.1	AC016629.3	-4.94	1.08e-06	0.000136	-0.32	-0.22	Mean platelet volume;	chr19:58561317	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs12981875	ENSG00000268912.1	CTD-2619J13.17	-4.94	1.08e-06	0.000136	-0.21	-0.22	Mean platelet volume;	chr19:58423763	chr19:58428632~58431148:-
THCA	cis	rs793571	0.554	rs12442451	ENSG00000245975.2	RP11-30K9.6	4.94	1.08e-06	0.000136	0.25	0.22	Schizophrenia;	chr15:58630196	chr15:58768072~58770974:-
THCA	cis	rs1150668	0.796	rs2247002	ENSG00000273712.1	RP5-874C20.7	4.94	1.08e-06	0.000136	0.23	0.22	Pubertal anthropometrics;	chr6:28430174	chr6:28315613~28315883:-
THCA	cis	rs7819412	0.617	rs10087081	ENSG00000206014.6	OR7E161P	4.94	1.08e-06	0.000136	0.27	0.22	Triglycerides;	chr8:11117407	chr8:11928597~11929563:-
THCA	cis	rs481331	0.799	rs7919712	ENSG00000215146.4	RP11-313J2.1	4.94	1.08e-06	0.000136	0.36	0.22	Systemic juvenile idiopathic arthritis;	chr10:42472862	chr10:42331866~42367974:-
THCA	cis	rs10923574	0.597	rs10754378	ENSG00000231365.4	RP11-418J17.1	-4.94	1.08e-06	0.000136	-0.22	-0.22	Breast cancer;Folding of antihelix;	chr1:118501291	chr1:119140396~119275973:+
THCA	cis	rs412050	0.547	rs5999842	ENSG00000224086.5	LL22NC03-86G7.1	-4.94	1.08e-06	0.000136	-0.4	-0.22	Attention deficit hyperactivity disorder;	chr22:21860600	chr22:21938293~21977632:+
THCA	cis	rs6545883	0.759	rs777585	ENSG00000270820.4	RP11-355B11.2	-4.94	1.08e-06	0.000136	-0.18	-0.22	Tuberculosis;	chr2:61185424	chr2:61471188~61484130:+
THCA	cis	rs8141529	0.748	rs5762881	ENSG00000272858.1	CTA-292E10.8	-4.94	1.08e-06	0.000136	-0.23	-0.22	Lymphocyte counts;	chr22:28893358	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.748	rs9620841	ENSG00000272858.1	CTA-292E10.8	-4.94	1.08e-06	0.000136	-0.23	-0.22	Lymphocyte counts;	chr22:28894993	chr22:28814914~28815662:+
THCA	cis	rs847845	0.535	rs205284	ENSG00000272288.4	RP11-140K17.3	-4.94	1.08e-06	0.000136	-0.28	-0.22	Non-small cell lung cancer;	chr6:34584135	chr6:34696317~34697470:+
THCA	cis	rs224278	1	rs224290	ENSG00000238280.1	RP11-436D10.3	4.94	1.08e-06	0.000136	0.25	0.22	Ewing sarcoma;	chr10:62828310	chr10:62793562~62805887:-
THCA	cis	rs224278	1	rs224293	ENSG00000238280.1	RP11-436D10.3	4.94	1.08e-06	0.000136	0.25	0.22	Ewing sarcoma;	chr10:62828801	chr10:62793562~62805887:-
THCA	cis	rs1864400	0.696	rs2742239	ENSG00000273008.1	RP11-351D16.3	-4.94	1.08e-06	0.000136	-0.21	-0.22	Hirschsprung disease;	chr10:43126264	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.59	rs2075912	ENSG00000273008.1	RP11-351D16.3	-4.94	1.08e-06	0.000136	-0.21	-0.22	Hirschsprung disease;	chr10:43126769	chr10:43136824~43138334:-
THCA	cis	rs2115630	0.764	rs11073716	ENSG00000225151.9	GOLGA2P7	4.94	1.08e-06	0.000136	0.28	0.22	P wave terminal force;	chr15:84792543	chr15:84199311~84230136:-
THCA	cis	rs6430538	0.621	rs6757855	ENSG00000224043.6	CCNT2-AS1	4.94	1.08e-06	0.000137	0.24	0.22	Parkinson's disease;	chr2:134816593	chr2:134735464~134918710:-
THCA	cis	rs2980439	0.818	rs2945249	ENSG00000254153.1	CTA-398F10.2	-4.94	1.08e-06	0.000137	-0.23	-0.22	Neuroticism;	chr8:8237204	chr8:8456909~8461337:-
THCA	cis	rs4713118	0.662	rs175954	ENSG00000261839.1	RP1-265C24.8	4.94	1.08e-06	0.000137	0.25	0.22	Parkinson's disease;	chr6:28043807	chr6:28136849~28139678:+
THCA	cis	rs16975963	0.644	rs7248397	ENSG00000226686.6	LINC01535	-4.94	1.08e-06	0.000137	-0.3	-0.22	Longevity;	chr19:37642310	chr19:37251912~37265535:+
THCA	cis	rs4819052	0.59	rs414743	ENSG00000215447.6	BX322557.10	-4.94	1.08e-06	0.000137	-0.21	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45092160	chr21:45288052~45291738:+
THCA	cis	rs7688540	0.76	rs7687833	ENSG00000275426.1	CH17-262A2.1	4.94	1.08e-06	0.000137	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:149738~150317:+
THCA	cis	rs12682352	0.602	rs4841044	ENSG00000254153.1	CTA-398F10.2	4.94	1.08e-06	0.000137	0.24	0.22	Neuroticism;	chr8:8807430	chr8:8456909~8461337:-
THCA	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-4.94	1.08e-06	0.000137	-0.26	-0.22	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
THCA	cis	rs228614	0.51	rs150893	ENSG00000248971.2	KRT8P46	4.94	1.08e-06	0.000137	0.28	0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102728746~102730171:-
THCA	cis	rs7615952	0.932	rs13321217	ENSG00000248787.1	RP11-666A20.4	-4.94	1.08e-06	0.000137	-0.37	-0.22	Blood pressure (smoking interaction);	chr3:125912928	chr3:125908005~125910272:-
THCA	cis	rs11671005	0.735	rs11667591	ENSG00000268912.1	CTD-2619J13.17	-4.94	1.08e-06	0.000137	-0.21	-0.22	Mean platelet volume;	chr19:58426270	chr19:58428632~58431148:-
THCA	cis	rs7045881	0.8	rs62544404	ENSG00000254396.1	RP11-56F10.3	4.94	1.08e-06	0.000137	0.4	0.22	Schizophrenia;	chr9:26857960	chr9:27102630~27104728:+
THCA	cis	rs2447820	0.588	rs34953289	ENSG00000249996.1	RP11-359P5.1	4.94	1.08e-06	0.000137	0.26	0.22	Migraine;	chr5:123042491	chr5:123036271~123054667:+
THCA	cis	rs7208859	0.573	rs216442	ENSG00000280069.1	CTD-2349P21.3	-4.94	1.08e-06	0.000137	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs216445	ENSG00000280069.1	CTD-2349P21.3	-4.94	1.08e-06	0.000137	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs216446	ENSG00000280069.1	CTD-2349P21.3	-4.94	1.08e-06	0.000137	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30738182~30740275:+
THCA	cis	rs28829049	0.731	rs7537573	ENSG00000270728.1	RP4-657E11.10	-4.94	1.09e-06	0.000137	-0.16	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19047111	chr1:19297080~19297903:+
THCA	cis	rs11633886	0.604	rs10220807	ENSG00000273972.1	CTD-2306A12.1	-4.94	1.09e-06	0.000137	-0.25	-0.22	Diisocyanate-induced asthma;	chr15:45818089	chr15:45702640~45703183:+
THCA	cis	rs7614311	0.731	rs56263032	ENSG00000271843.1	RP11-245J9.5	-4.94	1.09e-06	0.000137	-0.4	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63877346	chr3:64008082~64008692:-
THCA	cis	rs7614311	0.731	rs56126667	ENSG00000271843.1	RP11-245J9.5	-4.94	1.09e-06	0.000137	-0.4	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63880610	chr3:64008082~64008692:-
THCA	cis	rs7614311	0.731	rs73130544	ENSG00000271843.1	RP11-245J9.5	-4.94	1.09e-06	0.000137	-0.4	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63882920	chr3:64008082~64008692:-
THCA	cis	rs2179367	0.632	rs2341774	ENSG00000223701.3	RAET1E-AS1	4.94	1.09e-06	0.000137	0.32	0.22	Dupuytren's disease;	chr6:149425014	chr6:149884431~149919508:+
THCA	cis	rs13256369	0.774	rs11777719	ENSG00000254153.1	CTA-398F10.2	-4.94	1.09e-06	0.000137	-0.25	-0.22	Obesity-related traits;	chr8:8723528	chr8:8456909~8461337:-
THCA	cis	rs34779708	0.931	rs34954932	ENSG00000271335.4	RP11-324I22.4	4.94	1.09e-06	0.000137	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35314552~35336401:-
THCA	cis	rs7085104	0.591	rs4919683	ENSG00000213061.2	PFN1P11	4.94	1.09e-06	0.000137	0.26	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102838011~102845473:-
THCA	cis	rs6472827	0.645	rs2977069	ENSG00000253983.2	RP1-16A9.1	4.94	1.09e-06	0.000137	0.32	0.22	Uterine fibroids;	chr8:74199550	chr8:74199396~74208441:+
THCA	cis	rs6472827	0.645	rs2956056	ENSG00000253983.2	RP1-16A9.1	4.94	1.09e-06	0.000137	0.32	0.22	Uterine fibroids;	chr8:74199608	chr8:74199396~74208441:+
THCA	cis	rs6472827	0.645	rs2956055	ENSG00000253983.2	RP1-16A9.1	4.94	1.09e-06	0.000137	0.32	0.22	Uterine fibroids;	chr8:74199718	chr8:74199396~74208441:+
THCA	cis	rs6472827	0.645	rs2956053	ENSG00000253983.2	RP1-16A9.1	4.94	1.09e-06	0.000137	0.32	0.22	Uterine fibroids;	chr8:74200205	chr8:74199396~74208441:+
THCA	cis	rs17772222	0.63	rs12436642	ENSG00000222990.1	RNU4-22P	-4.94	1.09e-06	0.000137	-0.27	-0.22	Coronary artery calcification;	chr14:88559032	chr14:88513498~88513663:+
THCA	cis	rs9925964	0.933	rs749671	ENSG00000260911.2	RP11-196G11.2	-4.94	1.09e-06	0.000137	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077026	chr16:31043150~31049868:+
THCA	cis	rs890448	0.796	rs10007821	ENSG00000254531.1	FLJ20021	4.94	1.09e-06	0.000137	0.2	0.22	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101414887	chr4:101347780~101348883:+
THCA	cis	rs17301013	0.73	rs12060177	ENSG00000227373.4	RP11-160H22.5	4.94	1.09e-06	0.000137	0.32	0.22	Systemic lupus erythematosus;	chr1:174618545	chr1:174115300~174160004:-
THCA	cis	rs6545883	0.894	rs2177962	ENSG00000270820.4	RP11-355B11.2	-4.94	1.09e-06	0.000137	-0.19	-0.22	Tuberculosis;	chr2:61360935	chr2:61471188~61484130:+
THCA	cis	rs6598266	1	rs6598267	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.09e-06	0.000137	-0.38	-0.22	Major depressive disorder;	chr15:99759090	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs6598268	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.09e-06	0.000137	-0.38	-0.22	Major depressive disorder;	chr15:99759095	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs6598269	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.09e-06	0.000137	-0.38	-0.22	Major depressive disorder;	chr15:99759175	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs8026166	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.09e-06	0.000137	-0.38	-0.22	Major depressive disorder;	chr15:99759209	chr15:99807023~99877148:+
THCA	cis	rs6598266	0.908	rs8040391	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.09e-06	0.000137	-0.38	-0.22	Major depressive disorder;	chr15:99759243	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs6598270	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.09e-06	0.000137	-0.38	-0.22	Major depressive disorder;	chr15:99759391	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs6598271	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.09e-06	0.000137	-0.38	-0.22	Major depressive disorder;	chr15:99759428	chr15:99807023~99877148:+
THCA	cis	rs6598266	1	rs6598272	ENSG00000259363.4	CTD-2054N24.2	-4.94	1.09e-06	0.000137	-0.38	-0.22	Major depressive disorder;	chr15:99759468	chr15:99807023~99877148:+
THCA	cis	rs4604234	0.614	rs59155686	ENSG00000272129.1	RP11-250B2.6	-4.94	1.09e-06	0.000137	-0.54	-0.22	Cancer;	chr6:80141499	chr6:80355424~80356859:+
THCA	cis	rs13434995	0.513	rs12509047	ENSG00000273257.1	RP11-177J6.1	4.94	1.09e-06	0.000137	0.33	0.22	Adiponectin levels;	chr4:55545245	chr4:55387949~55388271:+
THCA	cis	rs972578	0.702	rs2413723	ENSG00000274717.1	RP1-47A17.1	-4.94	1.09e-06	0.000137	-0.23	-0.22	Mean platelet volume;	chr22:42804214	chr22:42791814~42794313:-
THCA	cis	rs4906332	0.782	rs12891288	ENSG00000252469.1	RNU7-160P	4.94	1.09e-06	0.000137	0.27	0.22	Coronary artery disease;	chr14:103533413	chr14:103550345~103550406:+
THCA	cis	rs6901004	0.592	rs14399	ENSG00000271789.1	RP5-1112D6.7	-4.94	1.09e-06	0.000137	-0.22	-0.22	Blood metabolite levels;	chr6:111222741	chr6:111297126~111298510:+
THCA	cis	rs9973361	0.531	rs717027	ENSG00000232411.1	AC009495.3	4.94	1.09e-06	0.000137	0.27	0.22	Total body bone mineral density;	chr2:165829904	chr2:165833048~165839098:-
THCA	cis	rs1150668	0.745	rs213238	ENSG00000280107.1	AL022393.9	-4.94	1.09e-06	0.000137	-0.22	-0.22	Pubertal anthropometrics;	chr6:28354216	chr6:28170845~28172521:+
THCA	cis	rs6964833	1	rs13227433	ENSG00000278416.1	PMS2L2	4.94	1.09e-06	0.000137	0.34	0.22	Menarche (age at onset);	chr7:74680386	chr7:75344015~75359550:-
THCA	cis	rs9863	0.896	rs34854841	ENSG00000269997.1	RP11-214K3.21	-4.94	1.09e-06	0.000137	-0.28	-0.22	White blood cell count;	chr12:123966957	chr12:123966077~123966629:-
THCA	cis	rs9863	0.861	rs11057393	ENSG00000269997.1	RP11-214K3.21	-4.94	1.09e-06	0.000137	-0.28	-0.22	White blood cell count;	chr12:123919222	chr12:123966077~123966629:-
THCA	cis	rs2439831	0.681	rs1549523	ENSG00000275601.1	AC011330.13	-4.94	1.09e-06	0.000137	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43331991	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.681	rs1549525	ENSG00000275601.1	AC011330.13	-4.94	1.09e-06	0.000137	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43335657	chr15:43642389~43643023:-
THCA	cis	rs12823128	0.766	rs12582348	ENSG00000256185.1	RP11-612B6.2	4.94	1.09e-06	0.000137	0.21	0.22	Birth weight;	chr12:26753041	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs57294941	ENSG00000256185.1	RP11-612B6.2	4.94	1.09e-06	0.000137	0.21	0.22	Birth weight;	chr12:26756973	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.729	rs6487572	ENSG00000256185.1	RP11-612B6.2	4.94	1.09e-06	0.000137	0.21	0.22	Birth weight;	chr12:26758491	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs1449568	ENSG00000256185.1	RP11-612B6.2	-4.94	1.09e-06	0.000137	-0.21	-0.22	Birth weight;	chr12:26758772	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs12831325	ENSG00000256185.1	RP11-612B6.2	4.94	1.09e-06	0.000137	0.21	0.22	Birth weight;	chr12:26760014	chr12:26335864~26336950:-
THCA	cis	rs6472827	0.571	rs2936692	ENSG00000253983.2	RP1-16A9.1	4.94	1.09e-06	0.000138	0.32	0.22	Uterine fibroids;	chr8:74199039	chr8:74199396~74208441:+
THCA	cis	rs11722779	0.815	rs223347	ENSG00000248971.2	KRT8P46	-4.94	1.09e-06	0.000138	-0.27	-0.22	Schizophrenia;	chr4:102858815	chr4:102728746~102730171:-
THCA	cis	rs34779708	0.931	rs12767414	ENSG00000271335.4	RP11-324I22.4	4.94	1.09e-06	0.000138	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35314552~35336401:-
THCA	cis	rs10875746	0.669	rs61940962	ENSG00000258234.1	RP11-370I10.2	4.94	1.09e-06	0.000138	0.27	0.22	Longevity (90 years and older);	chr12:48201694	chr12:48231098~48284210:-
THCA	cis	rs4713118	0.662	rs149961	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28047791	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28056708	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28056792	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28057501	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28057708	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28058299	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28058358	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28059910	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28060612	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28060704	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000261839.1	RP1-265C24.8	4.94	1.09e-06	0.000138	0.25	0.22	Parkinson's disease;	chr6:28062059	chr6:28136849~28139678:+
THCA	cis	rs8020095	0.571	rs10144915	ENSG00000258561.1	RP11-72M17.1	-4.94	1.09e-06	0.000138	-0.3	-0.22	Depression (quantitative trait);	chr14:66863489	chr14:66212810~66509394:-
THCA	cis	rs34286592	1	rs9938630	ENSG00000214725.6	CDIPT-AS1	-4.94	1.09e-06	0.000138	-0.4	-0.22	Multiple sclerosis;	chr16:29825787	chr16:29863593~29868053:+
THCA	cis	rs12908161	0.853	rs12912342	ENSG00000259295.5	CSPG4P12	4.94	1.09e-06	0.000138	0.32	0.22	Schizophrenia;	chr15:84704985	chr15:85191438~85213905:+
THCA	cis	rs896854	0.846	rs13254283	ENSG00000253528.2	RP11-347C18.4	4.94	1.1e-06	0.000138	0.25	0.22	Type 2 diabetes;	chr8:94901875	chr8:94974573~94974853:-
THCA	cis	rs1552244	0.554	rs7638846	ENSG00000180385.7	EMC3-AS1	4.94	1.1e-06	0.000138	0.22	0.22	Alzheimer's disease;	chr3:10006917	chr3:9986893~10006990:+
THCA	cis	rs6496932	0.503	rs8037726	ENSG00000259630.2	CTD-2262B20.1	-4.94	1.1e-06	0.000138	-0.28	-0.22	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85415228~85415633:+
THCA	cis	rs150992	0.504	rs11745405	ENSG00000248489.1	CTD-2007H13.3	-4.94	1.1e-06	0.000138	-0.23	-0.22	Body mass index;	chr5:99047700	chr5:98929171~98995013:+
THCA	cis	rs79464052	1	rs12654225	ENSG00000228737.2	AC008781.7	-4.94	1.1e-06	0.000138	-0.55	-0.22	Diffuse large B cell lymphoma;	chr5:141654678	chr5:141618414~141626481:+
THCA	cis	rs7267979	0.586	rs6050429	ENSG00000277938.1	RP5-965G21.3	4.94	1.1e-06	0.000138	0.19	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25229150~25231933:+
THCA	cis	rs911555	0.755	rs8016676	ENSG00000244691.1	RPL10AP1	4.94	1.1e-06	0.000138	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103412119~103412761:-
THCA	cis	rs950169	0.544	rs2036949	ENSG00000188388.10	GOLGA6L3	4.94	1.1e-06	0.000138	0.3	0.22	Schizophrenia;	chr15:84620374	chr15:85240472~85247170:+
THCA	cis	rs4915077	0.892	rs6698523	ENSG00000230489.1	VAV3-AS1	4.94	1.1e-06	0.000138	0.32	0.22	Hypothyroidism;	chr1:107812544	chr1:107964443~107994607:+
THCA	cis	rs72843506	0.656	rs73984573	ENSG00000261033.1	RP11-209D14.2	4.94	1.1e-06	0.000138	0.41	0.22	Schizophrenia;	chr17:20082027	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs78408002	ENSG00000261033.1	RP11-209D14.2	4.94	1.1e-06	0.000138	0.41	0.22	Schizophrenia;	chr17:20082601	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs7210439	ENSG00000261033.1	RP11-209D14.2	4.94	1.1e-06	0.000138	0.41	0.22	Schizophrenia;	chr17:20082728	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs7225605	ENSG00000261033.1	RP11-209D14.2	4.94	1.1e-06	0.000138	0.41	0.22	Schizophrenia;	chr17:20083136	chr17:20008051~20009234:-
THCA	cis	rs17767392	0.958	rs36072220	ENSG00000259146.3	RP1-261D10.2	4.94	1.1e-06	0.000138	0.28	0.22	Mitral valve prolapse;	chr14:71514027	chr14:71292729~71321814:-
THCA	cis	rs3734266	0.702	rs9469852	ENSG00000272288.4	RP11-140K17.3	-4.94	1.1e-06	0.000138	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34709999	chr6:34696317~34697470:+
THCA	cis	rs9311474	0.581	rs13621	ENSG00000243224.1	RP5-1157M23.2	-4.94	1.1e-06	0.000138	-0.24	-0.22	Electroencephalogram traits;	chr3:52524117	chr3:52239258~52241097:+
THCA	cis	rs11157436	0.958	rs12432733	ENSG00000211812.1	TRAV26-2	-4.94	1.1e-06	0.000138	-0.21	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22202583~22203368:+
THCA	cis	rs6088580	0.634	rs6087579	ENSG00000276073.1	RP5-1125A11.7	4.94	1.1e-06	0.000138	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34397349	chr20:33985617~33988989:-
THCA	cis	rs875971	0.508	rs10258739	ENSG00000273142.1	RP11-458F8.4	4.94	1.1e-06	0.000139	0.17	0.22	Aortic root size;	chr7:66597948	chr7:66902857~66906297:+
THCA	cis	rs1823874	0.71	rs2085086	ENSG00000259363.4	CTD-2054N24.2	4.94	1.1e-06	0.000139	0.28	0.22	IgG glycosylation;	chr15:99819887	chr15:99807023~99877148:+
THCA	cis	rs7403037	0.642	rs1976758	ENSG00000259905.4	PWRN1	4.94	1.1e-06	0.000139	0.23	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24180614	chr15:24493137~24652130:+
THCA	cis	rs17767392	0.67	rs11627918	ENSG00000259146.3	RP1-261D10.2	4.94	1.1e-06	0.000139	0.27	0.22	Mitral valve prolapse;	chr14:71257691	chr14:71292729~71321814:-
THCA	cis	rs453301	0.686	rs6601281	ENSG00000254153.1	CTA-398F10.2	4.94	1.1e-06	0.000139	0.24	0.22	Joint mobility (Beighton score);	chr8:9053494	chr8:8456909~8461337:-
THCA	cis	rs7617773	0.78	rs11706277	ENSG00000199476.1	Y_RNA	-4.94	1.1e-06	0.000139	-0.29	-0.22	Coronary artery disease;	chr3:48318943	chr3:48288587~48288694:+
THCA	cis	rs7412746	0.611	rs2228099	ENSG00000231073.1	RP11-316M1.3	4.94	1.1e-06	0.000139	0.27	0.22	Melanoma;	chr1:150836413	chr1:150973123~150975534:+
THCA	cis	rs34779708	0.966	rs2045915	ENSG00000271335.4	RP11-324I22.4	4.94	1.1e-06	0.000139	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35314552~35336401:-
THCA	cis	rs78487399	0.908	rs12466060	ENSG00000234936.1	AC010883.5	4.94	1.1e-06	0.000139	0.29	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43578238	chr2:43229573~43233394:+
THCA	cis	rs3750965	1	rs731974	ENSG00000260895.1	RP11-554A11.7	4.94	1.1e-06	0.000139	0.3	0.22	Hair color;	chr11:69079688	chr11:69103493~69109094:+
THCA	cis	rs7819412	0.811	rs2409691	ENSG00000206014.6	OR7E161P	4.94	1.1e-06	0.000139	0.25	0.22	Triglycerides;	chr8:11085766	chr8:11928597~11929563:-
THCA	cis	rs2282300	0.589	rs1717776	ENSG00000242353.1	RP4-710M3.1	-4.94	1.1e-06	0.000139	-0.18	-0.22	Morning vs. evening chronotype;	chr11:30394229	chr11:30368148~30368646:+
THCA	cis	rs4886920	0.692	rs4625695	ENSG00000260776.4	RP11-114H24.2	4.94	1.1e-06	0.000139	0.29	0.22	Neuroticism;	chr15:77826153	chr15:77914217~77926846:-
THCA	cis	rs4886920	0.723	rs11633959	ENSG00000260776.4	RP11-114H24.2	4.94	1.1e-06	0.000139	0.29	0.22	Neuroticism;	chr15:77826362	chr15:77914217~77926846:-
THCA	cis	rs6442522	0.772	rs3846127	ENSG00000249786.6	EAF1-AS1	4.94	1.1e-06	0.000139	0.23	0.22	Uric acid levels;	chr3:15450020	chr3:15436171~15455940:-
THCA	cis	rs11096990	0.892	rs7680520	ENSG00000249685.1	RP11-360F5.3	-4.94	1.1e-06	0.000139	-0.29	-0.22	Cognitive function;	chr4:39219013	chr4:39133913~39135608:+
THCA	cis	rs72843506	0.586	rs74811834	ENSG00000261033.1	RP11-209D14.2	4.94	1.1e-06	0.000139	0.44	0.22	Schizophrenia;	chr17:19982271	chr17:20008051~20009234:-
THCA	cis	rs9393777	0.92	rs13212562	ENSG00000219392.1	RP1-265C24.5	-4.94	1.1e-06	0.000139	-0.36	-0.22	Intelligence (multi-trait analysis);	chr6:27332531	chr6:28115628~28116551:+
THCA	cis	rs10510102	0.623	rs10159856	ENSG00000226864.1	ATE1-AS1	4.94	1.1e-06	0.000139	0.36	0.22	Breast cancer;	chr10:121988292	chr10:121928312~121951965:+
THCA	cis	rs1823913	0.599	rs55685315	ENSG00000280083.1	RP11-317J9.1	-4.94	1.1e-06	0.000139	-0.26	-0.22	Obesity-related traits;	chr2:191306451	chr2:191154118~191156070:-
THCA	cis	rs17772222	0.63	rs8017811	ENSG00000222990.1	RNU4-22P	-4.94	1.11e-06	0.000139	-0.27	-0.22	Coronary artery calcification;	chr14:88534559	chr14:88513498~88513663:+
THCA	cis	rs2179367	0.632	rs2143075	ENSG00000223701.3	RAET1E-AS1	4.94	1.11e-06	0.000139	0.32	0.22	Dupuytren's disease;	chr6:149425507	chr6:149884431~149919508:+
THCA	cis	rs8062405	0.691	rs743590	ENSG00000261766.1	RP11-22P6.2	-4.94	1.11e-06	0.000139	-0.22	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28862166~28863340:-
THCA	cis	rs9970896	0.826	rs6429432	ENSG00000237845.1	RP5-940F7.2	4.94	1.11e-06	0.000139	0.42	0.22	Monocyte percentage of white cells;	chr1:235943941	chr1:235942553~235943805:-
THCA	cis	rs595244	1	rs11636344	ENSG00000259705.1	RP11-227D13.1	-4.94	1.11e-06	0.000139	-0.35	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48423040	chr15:48645951~48652016:+
THCA	cis	rs9863	0.804	rs80270210	ENSG00000269997.1	RP11-214K3.21	-4.94	1.11e-06	0.000139	-0.28	-0.22	White blood cell count;	chr12:123962850	chr12:123966077~123966629:-
THCA	cis	rs9859260	1	rs9990392	ENSG00000273009.1	RP11-352G9.1	-4.94	1.11e-06	0.000139	-0.24	-0.22	Mean corpuscular volume;	chr3:196071651	chr3:195913078~195913683:-
THCA	cis	rs7615952	0.611	rs2971298	ENSG00000248787.1	RP11-666A20.4	-4.94	1.11e-06	0.000139	-0.42	-0.22	Blood pressure (smoking interaction);	chr3:125883870	chr3:125908005~125910272:-
THCA	cis	rs16846053	0.71	rs62190662	ENSG00000227403.1	AC009299.3	4.94	1.11e-06	0.000139	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161784499	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62190664	ENSG00000227403.1	AC009299.3	4.94	1.11e-06	0.000139	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161787284	chr2:161244739~161249050:+
THCA	cis	rs5006884	0.715	rs4910756	ENSG00000167355.6	AC104389.28	-4.94	1.11e-06	0.000139	-0.34	-0.22	Fetal hemoglobin levels;	chr11:5351626	chr11:5304976~5505652:-
THCA	cis	rs7088591	0.867	rs34755035	ENSG00000276818.1	AC026393.1	4.94	1.11e-06	0.000139	0.44	0.22	Blood pressure;	chr10:58018331	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs35378101	ENSG00000276818.1	AC026393.1	4.94	1.11e-06	0.000139	0.44	0.22	Blood pressure;	chr10:58018340	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs35707322	ENSG00000276818.1	AC026393.1	4.94	1.11e-06	0.000139	0.44	0.22	Blood pressure;	chr10:58018349	chr10:57095699~57095781:+
THCA	cis	rs62184315	0.536	rs56137655	ENSG00000253559.1	OSGEPL1-AS1	-4.94	1.11e-06	0.000139	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189675844	chr2:189762704~189765556:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000223473.2	GS1-124K5.3	-4.94	1.11e-06	0.000139	-0.15	-0.22	Aortic root size;	chr7:65950660	chr7:66491049~66493566:-
THCA	cis	rs7432375	0.641	rs835649	ENSG00000239213.4	NCK1-AS1	4.94	1.11e-06	0.000139	0.2	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136953048	chr3:136841726~136862054:-
THCA	cis	rs763121	0.853	rs11704021	ENSG00000228274.3	RP3-508I15.9	-4.94	1.11e-06	0.000139	-0.24	-0.22	Menopause (age at onset);	chr22:38678711	chr22:38667585~38681820:-
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000273796.1	LL21NC02-21A1.1	-4.94	1.11e-06	0.000139	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45403809~45404369:-
THCA	cis	rs17767392	0.846	rs34281934	ENSG00000259146.3	RP1-261D10.2	4.94	1.11e-06	0.000139	0.28	0.22	Mitral valve prolapse;	chr14:71513039	chr14:71292729~71321814:-
THCA	cis	rs3750965	0.959	rs4930264	ENSG00000260895.1	RP11-554A11.7	4.94	1.11e-06	0.00014	0.3	0.22	Hair color;	chr11:69084713	chr11:69103493~69109094:+
THCA	cis	rs2803122	0.756	rs10757050	ENSG00000273226.1	RP11-513M16.8	-4.94	1.11e-06	0.00014	-0.2	-0.22	Pulse pressure;	chr9:19285652	chr9:19375451~19375996:+
THCA	cis	rs1075232	1	rs12437749	ENSG00000215302.7	CTD-3092A11.1	-4.94	1.11e-06	0.00014	-0.5	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30470779~30507623:+
THCA	cis	rs9625935	0.917	rs5763680	ENSG00000279159.1	RP3-394A18.1	4.94	1.11e-06	0.00014	0.17	0.22	Tonsillectomy;	chr22:29993411	chr22:29978950~30028236:-
THCA	cis	rs6017291	0.59	rs73106287	ENSG00000223891.4	OSER1-AS1	4.94	1.11e-06	0.00014	0.26	0.22	Cognitive performance;	chr20:44213723	chr20:44210960~44226027:+
THCA	cis	rs950169	0.519	rs7237	ENSG00000259295.5	CSPG4P12	4.94	1.11e-06	0.00014	0.35	0.22	Schizophrenia;	chr15:84643346	chr15:85191438~85213905:+
THCA	cis	rs6870983	0.697	rs6870741	ENSG00000247828.6	TMEM161B-AS1	4.94	1.11e-06	0.00014	0.2	0.22	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88513878	chr5:88268895~88436685:+
THCA	cis	rs748802	0.704	rs59205434	ENSG00000235387.1	LINC00961	-4.94	1.11e-06	0.00014	-0.25	-0.22	Resting heart rate;	chr9:35916451	chr9:35909483~35911686:+
THCA	cis	rs17301013	0.507	rs10489255	ENSG00000227373.4	RP11-160H22.5	4.94	1.11e-06	0.00014	0.34	0.22	Systemic lupus erythematosus;	chr1:174341985	chr1:174115300~174160004:-
THCA	cis	rs1005277	0.579	rs176838	ENSG00000272983.1	RP11-508N22.12	-4.94	1.11e-06	0.00014	-0.19	-0.22	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38137337~38144399:+
THCA	cis	rs2154319	0.609	rs2275931	ENSG00000235358.1	RP11-399E6.1	-4.94	1.11e-06	0.00014	-0.29	-0.22	Height;	chr1:41264479	chr1:41242373~41284861:+
THCA	cis	rs2154319	0.609	rs11589478	ENSG00000235358.1	RP11-399E6.1	-4.94	1.11e-06	0.00014	-0.29	-0.22	Height;	chr1:41270555	chr1:41242373~41284861:+
THCA	cis	rs957448	1	rs7829886	ENSG00000253175.1	RP11-267M23.6	4.94	1.11e-06	0.00014	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94565036~94565715:+
THCA	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	4.94	1.11e-06	0.00014	0.13	0.22	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
THCA	cis	rs1129187	0.755	rs9471985	ENSG00000272223.1	RP1-20C7.6	4.94	1.11e-06	0.00014	0.17	0.22	Alzheimer's disease in APOE e4+ carriers;	chr6:42973586	chr6:43033897~43034405:-
THCA	cis	rs16846053	0.792	rs62190663	ENSG00000227403.1	AC009299.3	4.93	1.11e-06	0.00014	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161786376	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62190665	ENSG00000227403.1	AC009299.3	4.93	1.11e-06	0.00014	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161787828	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62190669	ENSG00000227403.1	AC009299.3	4.93	1.11e-06	0.00014	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161795188	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62190670	ENSG00000227403.1	AC009299.3	4.93	1.11e-06	0.00014	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161796232	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72877379	ENSG00000227403.1	AC009299.3	4.93	1.11e-06	0.00014	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161797729	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72877381	ENSG00000227403.1	AC009299.3	4.93	1.11e-06	0.00014	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161799335	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62190672	ENSG00000227403.1	AC009299.3	4.93	1.11e-06	0.00014	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161799459	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62190673	ENSG00000227403.1	AC009299.3	4.93	1.11e-06	0.00014	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161800391	chr2:161244739~161249050:+
THCA	cis	rs72843506	0.722	rs74255392	ENSG00000231258.2	ZSWIM5P2	4.93	1.11e-06	0.00014	0.32	0.22	Schizophrenia;	chr17:20425739	chr17:20583758~20591180:-
THCA	cis	rs3820928	0.874	rs10174073	ENSG00000212391.1	SNORA48	-4.93	1.11e-06	0.00014	-0.24	-0.22	Pulmonary function;	chr2:226930228	chr2:226968989~226969122:-
THCA	cis	rs7674212	0.537	rs2623060	ENSG00000251288.2	RP11-10L12.2	-4.93	1.12e-06	0.00014	-0.28	-0.22	Type 2 diabetes;	chr4:103126347	chr4:102751401~102752641:+
THCA	cis	rs9475752	0.793	rs720884	ENSG00000231441.1	RP11-472M19.2	4.93	1.12e-06	0.00014	0.31	0.22	Menarche (age at onset);	chr6:57012520	chr6:56844002~56864078:+
THCA	cis	rs6430585	0.64	rs58301703	ENSG00000231890.6	DARS-AS1	-4.93	1.12e-06	0.00014	-0.27	-0.22	Corneal structure;	chr2:135774655	chr2:135985176~136022593:+
THCA	cis	rs7554547	0.69	rs1474577	ENSG00000199347.1	RNU5E-1	-4.93	1.12e-06	0.00014	-0.31	-0.22	Nonsyndromic cleft lip with cleft palate;	chr1:11887712	chr1:11908152~11908271:+
THCA	cis	rs752010	0.871	rs2038976	ENSG00000230638.4	RP11-486B10.4	-4.93	1.12e-06	0.00014	-0.24	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41628827	chr1:41542069~41544310:+
THCA	cis	rs6878727	0.589	rs42268	ENSG00000253807.4	LINC01170	4.93	1.12e-06	0.00014	0.21	0.22	Breast cancer;	chr5:124317863	chr5:124059794~124405079:-
THCA	cis	rs516805	0.561	rs2816096	ENSG00000279453.1	RP3-425C14.4	-4.93	1.12e-06	0.00014	-0.24	-0.22	Lymphocyte counts;	chr6:122075731	chr6:122436789~122439223:-
THCA	cis	rs7267979	0.718	rs2983489	ENSG00000125804.12	FAM182A	-4.93	1.12e-06	0.00014	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26054655~26086917:+
THCA	cis	rs763121	0.853	rs138709	ENSG00000235209.1	CTA-150C2.13	4.93	1.12e-06	0.00014	0.31	0.22	Menopause (age at onset);	chr22:38743211	chr22:38921227~38924708:+
THCA	cis	rs860295	0.702	rs2048431	ENSG00000160766.13	GBAP1	-4.93	1.12e-06	0.00014	-0.26	-0.22	Body mass index;	chr1:155648839	chr1:155213821~155227422:-
THCA	cis	rs886427	0.838	rs4149782	ENSG00000272079.2	LA16c-380H5.5	-4.93	1.12e-06	0.00014	-0.23	-0.22	Metabolic syndrome;	chr16:2977295	chr16:3006120~3007388:+
THCA	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-4.93	1.12e-06	0.000141	-0.19	-0.22	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-4.93	1.12e-06	0.000141	-0.19	-0.22	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
THCA	cis	rs17801127	0.748	rs1405219	ENSG00000231969.1	AC144449.1	-4.93	1.12e-06	0.000141	-0.34	-0.22	Liver enzyme levels (alanine transaminase);	chr2:149687563	chr2:149587196~149848233:+
THCA	cis	rs35934224	0.504	rs11704009	ENSG00000232926.1	AC000078.5	4.93	1.12e-06	0.000141	0.26	0.22	Glaucoma (primary open-angle);	chr22:19852600	chr22:19887289~19887970:+
THCA	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	4.93	1.12e-06	0.000141	0.29	0.22	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
THCA	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	4.93	1.12e-06	0.000141	0.29	0.22	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
THCA	cis	rs3743772	1	rs62048488	ENSG00000279722.1	RP11-44F14.6	4.93	1.12e-06	0.000141	0.39	0.22	Depressive symptoms (SSRI exposure interaction);	chr16:53420027	chr16:53487607~53489943:-
THCA	cis	rs10405744	0.744	rs7246986	ENSG00000269154.1	BNIP3P13	4.93	1.12e-06	0.000141	0.37	0.22	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);	chr19:20079158	chr19:20062755~20063320:+
THCA	cis	rs2120243	0.538	rs4680360	ENSG00000244515.1	KRT18P34	4.93	1.12e-06	0.000141	0.27	0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157376690	chr3:157162663~157163932:-
THCA	cis	rs2337406	0.925	rs873533	ENSG00000211974.3	IGHV2-70	-4.93	1.12e-06	0.000141	-0.22	-0.22	Alzheimer's disease (late onset);	chr14:106667442	chr14:106723574~106724093:-
THCA	cis	rs12188164	0.502	rs55929184	ENSG00000225138.6	CTD-2228K2.7	4.93	1.12e-06	0.000141	0.24	0.22	Cystic fibrosis severity;	chr5:405461	chr5:473236~480884:+
THCA	cis	rs7394190	0.748	rs34163229	ENSG00000271816.1	BMS1P4	-4.93	1.12e-06	0.000141	-0.26	-0.22	Incident atrial fibrillation;	chr10:73647154	chr10:73699151~73730487:-
THCA	cis	rs800160	1	rs800156	ENSG00000199550.1	Y_RNA	4.93	1.12e-06	0.000141	0.33	0.22	Bacteremia;	chr11:2355206	chr11:2372638~2372750:+
THCA	cis	rs793571	0.628	rs12917083	ENSG00000245975.2	RP11-30K9.6	4.93	1.12e-06	0.000141	0.26	0.22	Schizophrenia;	chr15:58752341	chr15:58768072~58770974:-
THCA	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-4.93	1.12e-06	0.000141	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-4.93	1.12e-06	0.000141	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
THCA	cis	rs972578	0.728	rs1128013	ENSG00000274717.1	RP1-47A17.1	-4.93	1.12e-06	0.000141	-0.23	-0.22	Mean platelet volume;	chr22:42799141	chr22:42791814~42794313:-
THCA	cis	rs13434995	0.513	rs60097207	ENSG00000273257.1	RP11-177J6.1	-4.93	1.12e-06	0.000141	-0.34	-0.22	Adiponectin levels;	chr4:55406696	chr4:55387949~55388271:+
THCA	cis	rs6968419	0.747	rs1004109	ENSG00000237870.5	AC073130.1	-4.93	1.12e-06	0.000141	-0.24	-0.22	Intraocular pressure;	chr7:116222242	chr7:116275606~116286734:-
THCA	cis	rs72945132	0.882	rs7122057	ENSG00000254604.1	AP000487.6	-4.93	1.12e-06	0.000141	-0.42	-0.22	Coronary artery disease;	chr11:70355324	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.825	rs2298411	ENSG00000254604.1	AP000487.6	-4.93	1.12e-06	0.000141	-0.42	-0.22	Coronary artery disease;	chr11:70359940	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7942613	ENSG00000254604.1	AP000487.6	-4.93	1.12e-06	0.000141	-0.42	-0.22	Coronary artery disease;	chr11:70364569	chr11:70282367~70363368:-
THCA	cis	rs7665090	0.51	rs223498	ENSG00000248971.2	KRT8P46	4.93	1.12e-06	0.000141	0.27	0.22	Primary biliary cholangitis;	chr4:102730805	chr4:102728746~102730171:-
THCA	cis	rs8020095	0.571	rs28539317	ENSG00000258561.1	RP11-72M17.1	-4.93	1.12e-06	0.000141	-0.29	-0.22	Depression (quantitative trait);	chr14:67014115	chr14:66212810~66509394:-
THCA	cis	rs7851660	0.805	rs4255258	ENSG00000214417.4	KRT18P13	-4.93	1.12e-06	0.000141	-0.2	-0.22	Strep throat;	chr9:97885263	chr9:97698922~97700734:+
THCA	cis	rs7429990	0.901	rs7431567	ENSG00000228638.1	FCF1P2	4.93	1.12e-06	0.000141	0.22	0.22	Educational attainment (years of education);	chr3:47986342	chr3:48290793~48291375:-
THCA	cis	rs7045881	0.8	rs62544395	ENSG00000254396.1	RP11-56F10.3	4.93	1.12e-06	0.000141	0.41	0.22	Schizophrenia;	chr9:26829324	chr9:27102630~27104728:+
THCA	cis	rs7615952	0.866	rs6438949	ENSG00000241288.6	RP11-379B18.5	-4.93	1.12e-06	0.000141	-0.28	-0.22	Blood pressure (smoking interaction);	chr3:125931221	chr3:125827238~125916384:-
THCA	cis	rs45509595	0.841	rs9368531	ENSG00000280107.1	AL022393.9	-4.93	1.12e-06	0.000141	-0.34	-0.22	Breast cancer;	chr6:27814094	chr6:28170845~28172521:+
THCA	cis	rs45509595	0.749	rs401763	ENSG00000280107.1	AL022393.9	-4.93	1.12e-06	0.000141	-0.34	-0.22	Breast cancer;	chr6:27814750	chr6:28170845~28172521:+
THCA	cis	rs45509595	0.659	rs390764	ENSG00000280107.1	AL022393.9	-4.93	1.12e-06	0.000141	-0.34	-0.22	Breast cancer;	chr6:27814757	chr6:28170845~28172521:+
THCA	cis	rs45509595	0.841	rs401754	ENSG00000280107.1	AL022393.9	-4.93	1.12e-06	0.000141	-0.34	-0.22	Breast cancer;	chr6:27814760	chr6:28170845~28172521:+
THCA	cis	rs45509595	0.841	rs2747054	ENSG00000280107.1	AL022393.9	-4.93	1.12e-06	0.000141	-0.34	-0.22	Breast cancer;	chr6:27815581	chr6:28170845~28172521:+
THCA	cis	rs45509595	0.841	rs200501	ENSG00000280107.1	AL022393.9	-4.93	1.12e-06	0.000141	-0.34	-0.22	Breast cancer;	chr6:27821164	chr6:28170845~28172521:+
THCA	cis	rs79040073	0.53	rs8025550	ENSG00000259531.2	RP11-295H24.3	-4.93	1.12e-06	0.000141	-0.3	-0.22	Lung cancer in ever smokers;	chr15:49222870	chr15:49365124~49366685:-
THCA	cis	rs2836326	0.954	rs2836316	ENSG00000226012.1	AP001434.2	4.93	1.12e-06	0.000141	0.32	0.22	Metabolite levels (HVA);	chr21:38343867	chr21:38237217~38238201:-
THCA	cis	rs651907	0.557	rs11917569	ENSG00000244119.1	PDCL3P4	4.93	1.12e-06	0.000141	0.2	0.22	Colorectal cancer;	chr3:101636219	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs11917682	ENSG00000244119.1	PDCL3P4	4.93	1.12e-06	0.000141	0.2	0.22	Colorectal cancer;	chr3:101636583	chr3:101712472~101713191:+
THCA	cis	rs987724	0.593	rs9844054	ENSG00000240875.4	LINC00886	4.93	1.12e-06	0.000141	0.17	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156957527	chr3:156747346~156817062:-
THCA	cis	rs2439831	0.681	rs540031	ENSG00000275601.1	AC011330.13	-4.93	1.12e-06	0.000141	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43316657	chr15:43642389~43643023:-
THCA	cis	rs7688540	0.8	rs28531997	ENSG00000250892.1	RP11-1365D11.1	4.93	1.13e-06	0.000141	0.31	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:201409~205009:-
THCA	cis	rs6088813	0.845	rs2378349	ENSG00000279253.1	RP4-614O4.13	-4.93	1.13e-06	0.000141	-0.22	-0.22	Height;	chr20:35338040	chr20:35262727~35264187:-
THCA	cis	rs990871	0.53	rs2797543	ENSG00000227207.2	RPL31P12	-4.93	1.13e-06	0.000141	-0.26	-0.22	Subcutaneous adipose tissue;	chr1:72235417	chr1:72301472~72301829:+
THCA	cis	rs13434995	0.513	rs1979604	ENSG00000273257.1	RP11-177J6.1	4.93	1.13e-06	0.000142	0.33	0.22	Adiponectin levels;	chr4:55552588	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.537	rs4865012	ENSG00000273257.1	RP11-177J6.1	4.93	1.13e-06	0.000142	0.33	0.22	Adiponectin levels;	chr4:55554619	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs6846764	ENSG00000273257.1	RP11-177J6.1	4.93	1.13e-06	0.000142	0.33	0.22	Adiponectin levels;	chr4:55557322	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs6853506	ENSG00000273257.1	RP11-177J6.1	4.93	1.13e-06	0.000142	0.33	0.22	Adiponectin levels;	chr4:55558207	chr4:55387949~55388271:+
THCA	cis	rs10483853	0.806	rs12586996	ENSG00000258695.2	RP3-414A15.2	4.93	1.13e-06	0.000142	0.31	0.22	Coronary artery calcification;	chr14:73342516	chr14:73522878~73530610:+
THCA	cis	rs3750082	0.817	rs4723221	ENSG00000231952.3	DPY19L1P2	-4.93	1.13e-06	0.000142	-0.27	-0.22	Glomerular filtration rate (creatinine);	chr7:32914595	chr7:32812757~32838570:+
THCA	cis	rs875971	0.545	rs2279757	ENSG00000228409.4	CCT6P1	-4.93	1.13e-06	0.000142	-0.19	-0.22	Aortic root size;	chr7:66363676	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000228409.4	CCT6P1	-4.93	1.13e-06	0.000142	-0.19	-0.22	Aortic root size;	chr7:66374173	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000228409.4	CCT6P1	-4.93	1.13e-06	0.000142	-0.19	-0.22	Aortic root size;	chr7:66387213	chr7:65751142~65763354:+
THCA	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	4.93	1.13e-06	0.000142	0.13	0.22	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
THCA	cis	rs3892630	0.824	rs35700505	ENSG00000267567.1	CTD-2538C1.3	4.93	1.13e-06	0.000142	0.35	0.22	Red blood cell traits;	chr19:32834100	chr19:32718298~32719595:-
THCA	cis	rs75422866	0.867	rs57848393	ENSG00000276691.1	RP5-1057I20.5	4.93	1.13e-06	0.000142	0.39	0.22	Pneumonia;	chr12:47714734	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.764	rs67201012	ENSG00000276691.1	RP5-1057I20.5	4.93	1.13e-06	0.000142	0.39	0.22	Pneumonia;	chr12:47715881	chr12:47788426~47788971:+
THCA	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-4.93	1.13e-06	0.000142	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
THCA	cis	rs9926296	0.572	rs8047581	ENSG00000260259.1	RP11-368I7.4	-4.93	1.13e-06	0.000142	-0.23	-0.22	Vitiligo;	chr16:89818094	chr16:89682620~89686569:-
THCA	cis	rs896854	0.846	rs2340584	ENSG00000253528.2	RP11-347C18.4	4.93	1.13e-06	0.000142	0.25	0.22	Type 2 diabetes;	chr8:94904583	chr8:94974573~94974853:-
THCA	cis	rs7809615	0.515	rs10254729	ENSG00000244219.5	GS1-259H13.2	-4.93	1.13e-06	0.000142	-0.27	-0.22	Blood metabolite ratios;	chr7:99598805	chr7:99598066~99610813:+
THCA	cis	rs972578	0.791	rs5751372	ENSG00000274717.1	RP1-47A17.1	-4.93	1.13e-06	0.000142	-0.23	-0.22	Mean platelet volume;	chr22:42797317	chr22:42791814~42794313:-
THCA	cis	rs8103278	0.507	rs3745802	ENSG00000267395.4	AC074212.6	-4.93	1.13e-06	0.000142	-0.15	-0.22	Coronary artery disease;	chr19:45767919	chr19:45767796~45772504:+
THCA	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-4.93	1.13e-06	0.000142	-0.28	-0.22	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
THCA	cis	rs2115630	0.936	rs8033459	ENSG00000275120.1	RP11-182J1.17	-4.93	1.13e-06	0.000142	-0.23	-0.22	P wave terminal force;	chr15:84710027	chr15:84599434~84606463:-
THCA	cis	rs9307551	0.584	rs2119421	ENSG00000250334.4	LINC00989	-4.93	1.13e-06	0.000142	-0.26	-0.22	Refractive error;	chr4:79529168	chr4:79492416~79576460:+
THCA	cis	rs3820928	1	rs59904960	ENSG00000212391.1	SNORA48	-4.93	1.13e-06	0.000142	-0.25	-0.22	Pulmonary function;	chr2:226896553	chr2:226968989~226969122:-
THCA	cis	rs453301	0.571	rs330057	ENSG00000253981.4	ALG1L13P	-4.93	1.13e-06	0.000142	-0.21	-0.22	Joint mobility (Beighton score);	chr8:9232283	chr8:8236003~8244667:-
THCA	cis	rs16846053	0.605	rs16846179	ENSG00000227403.1	AC009299.3	4.93	1.13e-06	0.000142	0.47	0.22	Blood osmolality (transformed sodium);	chr2:161892546	chr2:161244739~161249050:+
THCA	cis	rs7727544	0.735	rs272884	ENSG00000263597.1	MIR3936	4.93	1.13e-06	0.000142	0.21	0.22	Blood metabolite levels;	chr5:132332961	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.735	rs272881	ENSG00000263597.1	MIR3936	4.93	1.13e-06	0.000142	0.21	0.22	Blood metabolite levels;	chr5:132333571	chr5:132365490~132365599:-
THCA	cis	rs172166	0.561	rs149973	ENSG00000273712.1	RP5-874C20.7	4.93	1.13e-06	0.000142	0.24	0.22	Cardiac Troponin-T levels;	chr6:28015835	chr6:28315613~28315883:-
THCA	cis	rs172166	0.561	rs149974	ENSG00000273712.1	RP5-874C20.7	4.93	1.13e-06	0.000142	0.24	0.22	Cardiac Troponin-T levels;	chr6:28017318	chr6:28315613~28315883:-
THCA	cis	rs4915077	0.649	rs4073682	ENSG00000230489.1	VAV3-AS1	4.93	1.13e-06	0.000142	0.38	0.22	Hypothyroidism;	chr1:107830216	chr1:107964443~107994607:+
THCA	cis	rs853679	0.546	rs200948	ENSG00000280107.1	AL022393.9	-4.93	1.13e-06	0.000142	-0.34	-0.22	Depression;	chr6:27867494	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs200950	ENSG00000280107.1	AL022393.9	-4.93	1.13e-06	0.000142	-0.34	-0.22	Depression;	chr6:27867994	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs200952	ENSG00000280107.1	AL022393.9	-4.93	1.13e-06	0.000142	-0.34	-0.22	Depression;	chr6:27869198	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs200954	ENSG00000280107.1	AL022393.9	-4.93	1.13e-06	0.000142	-0.34	-0.22	Depression;	chr6:27870986	chr6:28170845~28172521:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000223473.2	GS1-124K5.3	4.93	1.13e-06	0.000142	0.15	0.22	Aortic root size;	chr7:65827018	chr7:66491049~66493566:-
THCA	cis	rs6490294	0.528	rs16941909	ENSG00000226469.1	ADAM1B	4.93	1.13e-06	0.000142	0.37	0.22	Mean platelet volume;	chr12:112188420	chr12:111927018~111929017:+
THCA	cis	rs12022452	0.822	rs11811369	ENSG00000237899.1	RP4-739H11.3	-4.93	1.13e-06	0.000142	-0.34	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40669089~40687588:-
THCA	cis	rs3096299	0.658	rs3934737	ENSG00000261118.1	RP11-104N10.1	4.93	1.13e-06	0.000142	0.19	0.22	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89492017~89504460:-
THCA	cis	rs13256369	1	rs7843488	ENSG00000253893.2	FAM85B	-4.93	1.13e-06	0.000142	-0.3	-0.22	Obesity-related traits;	chr8:8718707	chr8:8167819~8226614:-
THCA	cis	rs12999616	0.857	rs34459720	ENSG00000230606.9	AC159540.1	-4.93	1.13e-06	0.000142	-0.28	-0.22	Colorectal cancer;	chr2:97708984	chr2:97416165~97433527:-
THCA	cis	rs12999616	0.817	rs62157581	ENSG00000230606.9	AC159540.1	-4.93	1.13e-06	0.000142	-0.28	-0.22	Colorectal cancer;	chr2:97711039	chr2:97416165~97433527:-
THCA	cis	rs12999616	0.817	rs35321033	ENSG00000230606.9	AC159540.1	-4.93	1.13e-06	0.000142	-0.28	-0.22	Colorectal cancer;	chr2:97711349	chr2:97416165~97433527:-
THCA	cis	rs12999616	0.817	rs17695937	ENSG00000230606.9	AC159540.1	-4.93	1.13e-06	0.000142	-0.28	-0.22	Colorectal cancer;	chr2:97711412	chr2:97416165~97433527:-
THCA	cis	rs12999616	0.817	rs35530168	ENSG00000230606.9	AC159540.1	-4.93	1.13e-06	0.000142	-0.28	-0.22	Colorectal cancer;	chr2:97712014	chr2:97416165~97433527:-
THCA	cis	rs12999616	0.817	rs55933640	ENSG00000230606.9	AC159540.1	-4.93	1.13e-06	0.000142	-0.28	-0.22	Colorectal cancer;	chr2:97712258	chr2:97416165~97433527:-
THCA	cis	rs8177876	0.731	rs74878296	ENSG00000261061.1	RP11-303E16.2	-4.93	1.13e-06	0.000142	-0.4	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81030770~81031485:+
THCA	cis	rs10833905	0.756	rs12291247	ENSG00000246225.5	RP11-17A1.3	-4.93	1.13e-06	0.000142	-0.32	-0.22	Sudden cardiac arrest;	chr11:22979817	chr11:22829380~22945393:+
THCA	cis	rs763121	0.853	rs2267393	ENSG00000235209.1	CTA-150C2.13	4.93	1.13e-06	0.000142	0.29	0.22	Menopause (age at onset);	chr22:38705614	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2267394	ENSG00000235209.1	CTA-150C2.13	4.93	1.13e-06	0.000142	0.29	0.22	Menopause (age at onset);	chr22:38705628	chr22:38921227~38924708:+
THCA	cis	rs4845570	0.834	rs1196467	ENSG00000203288.3	RP11-98D18.9	4.93	1.13e-06	0.000142	0.27	0.22	Coronary artery disease;	chr1:151737562	chr1:151790804~151794402:+
THCA	cis	rs28476539	0.567	rs57642298	ENSG00000270480.1	RP11-57B24.1	4.93	1.13e-06	0.000142	0.36	0.22	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82641017	chr4:82691737~82692468:+
THCA	cis	rs11051970	0.636	rs325420	ENSG00000274964.1	RP11-817I4.1	-4.93	1.13e-06	0.000142	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32419060	chr12:32339368~32340724:+
THCA	cis	rs6088590	0.965	rs6087639	ENSG00000269202.1	RP4-614O4.12	-4.93	1.13e-06	0.000142	-0.2	-0.22	Coronary artery disease;	chr20:34856063	chr20:35201747~35203288:-
THCA	cis	rs2439831	0.681	rs498837	ENSG00000275601.1	AC011330.13	-4.93	1.13e-06	0.000142	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43315826	chr15:43642389~43643023:-
THCA	cis	rs13287066	0.74	rs10761223	ENSG00000227603.1	RP11-165J3.6	4.93	1.13e-06	0.000142	0.23	0.22	Intelligence (multi-trait analysis);	chr9:93404028	chr9:93435332~93437121:-
THCA	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-4.93	1.13e-06	0.000142	-0.12	-0.22	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
THCA	cis	rs2243480	1	rs73142166	ENSG00000164669.11	INTS4P1	4.93	1.13e-06	0.000143	0.44	0.22	Diabetic kidney disease;	chr7:65910845	chr7:65141225~65234216:+
THCA	cis	rs2067615	0.56	rs1882542	ENSG00000260329.1	RP11-412D9.4	-4.93	1.13e-06	0.000143	-0.2	-0.22	Heart rate;	chr12:106676271	chr12:106954029~106955497:-
THCA	cis	rs1577917	0.61	rs11752795	ENSG00000220563.1	PKMP3	4.93	1.13e-06	0.000143	0.16	0.22	Response to antipsychotic treatment;	chr6:85577411	chr6:85659892~85660606:-
THCA	cis	rs467650	0.553	rs149508	ENSG00000248489.1	CTD-2007H13.3	4.93	1.14e-06	0.000143	0.25	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98642741	chr5:98929171~98995013:+
THCA	cis	rs467650	0.553	rs40807	ENSG00000248489.1	CTD-2007H13.3	4.93	1.14e-06	0.000143	0.25	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98646095	chr5:98929171~98995013:+
THCA	cis	rs467650	0.553	rs27706	ENSG00000248489.1	CTD-2007H13.3	4.93	1.14e-06	0.000143	0.25	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98646475	chr5:98929171~98995013:+
THCA	cis	rs467650	0.553	rs40173	ENSG00000248489.1	CTD-2007H13.3	4.93	1.14e-06	0.000143	0.25	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98647713	chr5:98929171~98995013:+
THCA	cis	rs467650	0.553	rs27020	ENSG00000248489.1	CTD-2007H13.3	4.93	1.14e-06	0.000143	0.25	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98647962	chr5:98929171~98995013:+
THCA	cis	rs7688540	0.771	rs10005733	ENSG00000275426.1	CH17-262A2.1	4.93	1.14e-06	0.000143	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:149738~150317:+
THCA	cis	rs62292953	0.656	rs17345563	ENSG00000248724.5	NPHP3-AS1	-4.93	1.14e-06	0.000143	-0.41	-0.22	Red cell distribution width;	chr3:132490359	chr3:132721750~132874223:+
THCA	cis	rs131777	0.545	rs140514	ENSG00000205559.3	CHKB-AS1	-4.93	1.14e-06	0.000143	-0.26	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50580150	chr22:50583026~50583877:+
THCA	cis	rs467650	0.927	rs154207	ENSG00000248489.1	CTD-2007H13.3	4.93	1.14e-06	0.000143	0.21	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98627686	chr5:98929171~98995013:+
THCA	cis	rs75920871	0.688	rs55703909	ENSG00000254851.1	RP11-109L13.1	-4.93	1.14e-06	0.000143	-0.46	-0.22	Subjective well-being;	chr11:117114150	chr11:117135528~117138582:+
THCA	cis	rs972578	0.702	rs1984476	ENSG00000274717.1	RP1-47A17.1	-4.93	1.14e-06	0.000143	-0.23	-0.22	Mean platelet volume;	chr22:42794643	chr22:42791814~42794313:-
THCA	cis	rs4803480	0.507	rs11083627	ENSG00000267107.5	PCAT19	4.93	1.14e-06	0.000143	0.22	0.22	Schizophrenia;	chr19:41563530	chr19:41454169~41500649:-
THCA	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-4.93	1.14e-06	0.000143	-0.24	-0.22	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
THCA	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	4.93	1.14e-06	0.000143	0.18	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
THCA	cis	rs240993	0.812	rs118202	ENSG00000271789.1	RP5-1112D6.7	-4.93	1.14e-06	0.000143	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111337168	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs240955	ENSG00000271789.1	RP5-1112D6.7	-4.93	1.14e-06	0.000143	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111339440	chr6:111297126~111298510:+
THCA	cis	rs240993	0.761	rs453776	ENSG00000271789.1	RP5-1112D6.7	-4.93	1.14e-06	0.000143	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111342260	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs240990	ENSG00000271789.1	RP5-1112D6.7	-4.93	1.14e-06	0.000143	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111343820	chr6:111297126~111298510:+
THCA	cis	rs12962334	0.57	rs4800434	ENSG00000265939.1	UBE2CP2	4.93	1.14e-06	0.000143	0.25	0.22	Breast cancer;	chr18:22848311	chr18:22900486~22900995:-
THCA	cis	rs2115630	0.653	rs61394864	ENSG00000259728.4	LINC00933	-4.93	1.14e-06	0.000143	-0.26	-0.22	P wave terminal force;	chr15:84626943	chr15:84570649~84580175:+
THCA	cis	rs853679	1	rs9986596	ENSG00000220721.1	OR1F12	4.93	1.14e-06	0.000143	0.36	0.22	Depression;	chr6:28251883	chr6:28073316~28074233:+
THCA	cis	rs911555	0.511	rs2296483	ENSG00000269910.1	RP11-73M18.10	4.93	1.14e-06	0.000143	0.2	0.22	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103694516~103695050:-
THCA	cis	rs7088591	0.867	rs9943326	ENSG00000276818.1	AC026393.1	4.93	1.14e-06	0.000143	0.43	0.22	Blood pressure;	chr10:58020631	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.717	rs4995515	ENSG00000276818.1	AC026393.1	4.93	1.14e-06	0.000143	0.43	0.22	Blood pressure;	chr10:58020706	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.717	rs4614392	ENSG00000276818.1	AC026393.1	4.93	1.14e-06	0.000143	0.43	0.22	Blood pressure;	chr10:58020833	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs4529850	ENSG00000276818.1	AC026393.1	4.93	1.14e-06	0.000143	0.43	0.22	Blood pressure;	chr10:58020965	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs4503485	ENSG00000276818.1	AC026393.1	4.93	1.14e-06	0.000143	0.43	0.22	Blood pressure;	chr10:58020982	chr10:57095699~57095781:+
THCA	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-4.93	1.14e-06	0.000143	-0.18	-0.22	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
THCA	cis	rs1334894	0.71	rs3777746	ENSG00000228559.1	RP3-340B19.3	4.93	1.14e-06	0.000143	0.39	0.22	Coronary artery disease;	chr6:35501096	chr6:35544632~35545669:+
THCA	cis	rs2803122	0.967	rs10964066	ENSG00000273226.1	RP11-513M16.8	-4.93	1.14e-06	0.000143	-0.2	-0.22	Pulse pressure;	chr9:19250780	chr9:19375451~19375996:+
THCA	cis	rs1979679	0.918	rs7312574	ENSG00000278733.1	RP11-425D17.1	-4.93	1.14e-06	0.000143	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28514977	chr12:28185625~28186190:-
THCA	cis	rs2439831	0.681	rs540031	ENSG00000205771.5	CATSPER2P1	-4.93	1.14e-06	0.000143	-0.29	-0.22	Lung cancer in ever smokers;	chr15:43316657	chr15:43726918~43747094:-
THCA	cis	rs875971	0.522	rs4502988	ENSG00000213640.3	EEF1DP4	-4.93	1.14e-06	0.000143	-0.26	-0.22	Aortic root size;	chr7:65832759	chr7:64862999~64864370:+
THCA	cis	rs7914558	1	rs7071373	ENSG00000236937.2	PTGES3P4	4.93	1.14e-06	0.000143	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103012165	chr10:102845595~102845950:+
THCA	cis	rs1003719	0.708	rs8126491	ENSG00000230366.8	DSCR9	4.93	1.14e-06	0.000143	0.23	0.22	Eye color traits;	chr21:37178917	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs8130643	ENSG00000230366.8	DSCR9	4.93	1.14e-06	0.000143	0.23	0.22	Eye color traits;	chr21:37179413	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs13046581	ENSG00000230366.8	DSCR9	4.93	1.14e-06	0.000143	0.23	0.22	Eye color traits;	chr21:37179683	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs8130069	ENSG00000230366.8	DSCR9	4.93	1.14e-06	0.000143	0.23	0.22	Eye color traits;	chr21:37179814	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.612	rs2835652	ENSG00000230366.8	DSCR9	4.93	1.14e-06	0.000143	0.23	0.22	Eye color traits;	chr21:37185106	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2835653	ENSG00000230366.8	DSCR9	4.93	1.14e-06	0.000143	0.23	0.22	Eye color traits;	chr21:37186335	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs6517405	ENSG00000230366.8	DSCR9	4.93	1.14e-06	0.000143	0.23	0.22	Eye color traits;	chr21:37188033	chr21:37208503~37221736:+
THCA	cis	rs6560517	0.562	rs12378119	ENSG00000234618.1	RPSAP9	-4.93	1.14e-06	0.000144	-0.29	-0.22	Dialysis-related mortality;	chr9:76441087	chr9:76398699~76399586:+
THCA	cis	rs440932	1	rs378974	ENSG00000254340.1	RP11-10A14.3	4.93	1.14e-06	0.000144	0.24	0.22	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:9141424~9145435:+
THCA	cis	rs2985684	0.894	rs8005990	ENSG00000278009.1	RP11-649E7.8	4.93	1.14e-06	0.000144	0.3	0.22	Carotid intima media thickness;	chr14:49555530	chr14:49601011~49601124:-
THCA	cis	rs1003719	0.715	rs8128387	ENSG00000230366.8	DSCR9	4.93	1.14e-06	0.000144	0.23	0.22	Eye color traits;	chr21:37184485	chr21:37208503~37221736:+
THCA	cis	rs12546962	0.654	rs9329191	ENSG00000254153.1	CTA-398F10.2	4.93	1.14e-06	0.000144	0.26	0.22	Body mass index;	chr8:9359074	chr8:8456909~8461337:-
THCA	cis	rs3213758	1	rs13334070	ENSG00000275191.1	RP11-36I17.2	-4.93	1.14e-06	0.000144	-0.42	-0.22	Vitiligo (non-segmental);	chr16:53691058	chr16:53628256~53628816:-
THCA	cis	rs2439831	1	rs2467743	ENSG00000166763.7	STRCP1	4.93	1.14e-06	0.000144	0.3	0.22	Lung cancer in ever smokers;	chr15:43458148	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2245176	ENSG00000166763.7	STRCP1	4.93	1.14e-06	0.000144	0.3	0.22	Lung cancer in ever smokers;	chr15:43458564	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2245054	ENSG00000166763.7	STRCP1	4.93	1.14e-06	0.000144	0.3	0.22	Lung cancer in ever smokers;	chr15:43459711	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2264876	ENSG00000166763.7	STRCP1	4.93	1.14e-06	0.000144	0.3	0.22	Lung cancer in ever smokers;	chr15:43465221	chr15:43699488~43718184:-
THCA	cis	rs7772486	0.754	rs702323	ENSG00000270638.1	RP3-466P17.1	-4.93	1.14e-06	0.000144	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145735570~145737218:+
THCA	cis	rs9863	0.931	rs2178663	ENSG00000269997.1	RP11-214K3.21	-4.93	1.14e-06	0.000144	-0.27	-0.22	White blood cell count;	chr12:123949358	chr12:123966077~123966629:-
THCA	cis	rs4415084	0.635	rs7736952	ENSG00000272335.1	RP11-53O19.3	-4.93	1.15e-06	0.000144	-0.19	-0.22	Breast cancer;	chr5:44790277	chr5:44826076~44828592:+
THCA	cis	rs1048886	0.872	rs9446267	ENSG00000271967.1	RP11-134K13.4	-4.93	1.15e-06	0.000144	-0.22	-0.22	Type 2 diabetes;	chr6:70565337	chr6:70596438~70596980:+
THCA	cis	rs11671005	0.735	rs11670871	ENSG00000268912.1	CTD-2619J13.17	4.93	1.15e-06	0.000144	0.21	0.22	Mean platelet volume;	chr19:58429147	chr19:58428632~58431148:-
THCA	cis	rs9880211	1	rs9828976	ENSG00000239213.4	NCK1-AS1	4.93	1.15e-06	0.000144	0.24	0.22	Height;Body mass index;	chr3:136817993	chr3:136841726~136862054:-
THCA	cis	rs7674212	0.541	rs2615539	ENSG00000251288.2	RP11-10L12.2	-4.93	1.15e-06	0.000144	-0.28	-0.22	Type 2 diabetes;	chr4:103159949	chr4:102751401~102752641:+
THCA	cis	rs11763147	1	rs11763147	ENSG00000223473.2	GS1-124K5.3	-4.93	1.15e-06	0.000144	-0.15	-0.22	Corneal structure;	chr7:65861834	chr7:66491049~66493566:-
THCA	cis	rs28386778	0.799	rs12450683	ENSG00000240280.5	TCAM1P	-4.93	1.15e-06	0.000144	-0.31	-0.22	Prudent dietary pattern;	chr17:63906939	chr17:63849292~63864379:+
THCA	cis	rs9859260	0.71	rs34906439	ENSG00000207650.1	MIR570	-4.93	1.15e-06	0.000144	-0.24	-0.22	Mean corpuscular volume;	chr3:196052835	chr3:195699401~195699497:+
THCA	cis	rs2018683	0.6	rs6948880	ENSG00000272568.4	CTB-113D17.1	4.93	1.15e-06	0.000144	0.21	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28979967~29013367:+
THCA	cis	rs28735056	0.903	rs56185453	ENSG00000261126.6	RP11-795F19.1	-4.93	1.15e-06	0.000144	-0.18	-0.22	Schizophrenia;	chr18:79878297	chr18:80046900~80095482:+
THCA	cis	rs2440129	0.611	rs11571335	ENSG00000262089.1	RP11-589P10.5	4.93	1.15e-06	0.000144	0.2	0.22	Tonsillectomy;	chr17:7000944	chr17:6994642~6995189:-
THCA	cis	rs1707322	1	rs9429186	ENSG00000281133.1	AL355480.3	4.93	1.15e-06	0.000144	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs785506	ENSG00000281133.1	AL355480.3	4.93	1.15e-06	0.000144	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45580892~45580996:-
THCA	cis	rs11733284	0.894	rs11722463	ENSG00000259959.1	RP11-121C2.2	4.93	1.15e-06	0.000144	0.19	0.22	Gout;Renal underexcretion gout;	chr4:48036699	chr4:47840122~47844339:-
THCA	cis	rs6908034	0.607	rs79842087	ENSG00000227116.1	RP3-471C18.1	-4.93	1.15e-06	0.000144	-0.44	-0.22	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821085	chr6:19730427~19734567:-
THCA	cis	rs9475752	1	rs1599281	ENSG00000231441.1	RP11-472M19.2	-4.93	1.15e-06	0.000144	-0.28	-0.22	Menarche (age at onset);	chr6:56924513	chr6:56844002~56864078:+
THCA	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-4.93	1.15e-06	0.000144	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-4.93	1.15e-06	0.000144	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-4.93	1.15e-06	0.000144	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
THCA	cis	rs5758511	0.68	rs5758667	ENSG00000281538.1	RP4-669P10.20	-4.93	1.15e-06	0.000144	-0.26	-0.22	Birth weight;	chr22:42237198	chr22:42138060~42139726:+
THCA	cis	rs748404	0.601	rs530118	ENSG00000166763.7	STRCP1	-4.93	1.15e-06	0.000144	-0.23	-0.22	Lung cancer;	chr15:43186313	chr15:43699488~43718184:-
THCA	cis	rs7208859	0.673	rs3816780	ENSG00000280069.1	CTD-2349P21.3	-4.93	1.15e-06	0.000144	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30738182~30740275:+
THCA	cis	rs10090774	0.965	rs13271554	ENSG00000279766.1	RP11-642A1.2	-4.93	1.15e-06	0.000144	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140863589	chr8:140572142~140572812:-
THCA	cis	rs6490294	0.528	rs78745958	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000144	0.36	0.22	Mean platelet volume;	chr12:111990367	chr12:111927018~111929017:+
THCA	cis	rs1865760	0.533	rs1408270	ENSG00000272462.2	U91328.19	-4.93	1.15e-06	0.000144	-0.19	-0.22	Height;	chr6:25872956	chr6:25992662~26001775:+
THCA	cis	rs7914558	0.966	rs11191471	ENSG00000236937.2	PTGES3P4	4.93	1.15e-06	0.000144	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102942293	chr10:102845595~102845950:+
THCA	cis	rs72945132	0.882	rs7128969	ENSG00000254604.1	AP000487.6	-4.93	1.15e-06	0.000145	-0.41	-0.22	Coronary artery disease;	chr11:70358911	chr11:70282367~70363368:-
THCA	cis	rs2239547	0.522	rs9842974	ENSG00000242142.1	SERBP1P3	4.93	1.15e-06	0.000145	0.28	0.22	Schizophrenia;	chr3:52977034	chr3:53064283~53065091:-
THCA	cis	rs6545883	0.894	rs4672436	ENSG00000270820.4	RP11-355B11.2	-4.93	1.15e-06	0.000145	-0.19	-0.22	Tuberculosis;	chr2:61376222	chr2:61471188~61484130:+
THCA	cis	rs6686842	0.56	rs61781830	ENSG00000235358.1	RP11-399E6.1	-4.93	1.15e-06	0.000145	-0.29	-0.22	Height;	chr1:41167695	chr1:41242373~41284861:+
THCA	cis	rs6756513	0.5	rs4853028	ENSG00000231024.1	AC092431.3	-4.93	1.15e-06	0.000145	-0.32	-0.22	Breast cancer;Platelet count;	chr2:69814308	chr2:69700192~69713847:-
THCA	cis	rs3820928	0.874	rs2228557	ENSG00000212391.1	SNORA48	-4.93	1.15e-06	0.000145	-0.24	-0.22	Pulmonary function;	chr2:227007466	chr2:226968989~226969122:-
THCA	cis	rs73198271	0.92	rs11783112	ENSG00000253893.2	FAM85B	4.93	1.15e-06	0.000145	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748683	chr8:8167819~8226614:-
THCA	cis	rs6490294	0.528	rs77211491	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111884974	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs77030808	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111891224	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs12580175	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111926708	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs61012856	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111927687	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs59131168	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111930559	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs12578195	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111956130	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs12423689	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111965331	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs12423699	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111965357	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs12426312	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111968945	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs57929857	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:111995752	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs60998439	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:112008165	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.528	rs79761579	ENSG00000226469.1	ADAM1B	4.93	1.15e-06	0.000145	0.36	0.22	Mean platelet volume;	chr12:112021081	chr12:111927018~111929017:+
THCA	cis	rs62292953	0.79	rs11926694	ENSG00000248724.5	NPHP3-AS1	-4.93	1.15e-06	0.000145	-0.41	-0.22	Red cell distribution width;	chr3:132498391	chr3:132721750~132874223:+
THCA	cis	rs11673344	0.562	rs6510580	ENSG00000276846.1	CTD-3220F14.3	4.93	1.15e-06	0.000145	0.17	0.22	Obesity-related traits;	chr19:37038452	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs2082009	ENSG00000276846.1	CTD-3220F14.3	4.93	1.15e-06	0.000145	0.17	0.22	Obesity-related traits;	chr19:37039834	chr19:37314868~37315620:-
THCA	cis	rs2803122	0.967	rs4977519	ENSG00000273226.1	RP11-513M16.8	-4.93	1.15e-06	0.000145	-0.2	-0.22	Pulse pressure;	chr9:19241204	chr9:19375451~19375996:+
THCA	cis	rs9868809	0.542	rs9873726	ENSG00000270441.1	RP11-694I15.7	4.93	1.15e-06	0.000145	0.27	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48674934	chr3:49140086~49160851:-
THCA	cis	rs8049040	0.521	rs12935725	ENSG00000260886.1	TAT-AS1	4.93	1.15e-06	0.000145	0.32	0.22	Blood protein levels;	chr16:71535485	chr16:71565789~71578187:+
THCA	cis	rs172166	0.56	rs203878	ENSG00000273712.1	RP5-874C20.7	4.93	1.15e-06	0.000145	0.24	0.22	Cardiac Troponin-T levels;	chr6:28081218	chr6:28315613~28315883:-
THCA	cis	rs2120243	0.647	rs1456099	ENSG00000244515.1	KRT18P34	4.93	1.15e-06	0.000145	0.24	0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157428518	chr3:157162663~157163932:-
THCA	cis	rs11673344	0.504	rs6510593	ENSG00000276846.1	CTD-3220F14.3	4.93	1.16e-06	0.000145	0.17	0.22	Obesity-related traits;	chr19:37143153	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs7259332	ENSG00000276846.1	CTD-3220F14.3	4.93	1.16e-06	0.000145	0.17	0.22	Obesity-related traits;	chr19:37143389	chr19:37314868~37315620:-
THCA	cis	rs13434995	0.513	rs73236142	ENSG00000273257.1	RP11-177J6.1	-4.93	1.16e-06	0.000145	-0.33	-0.22	Adiponectin levels;	chr4:55446143	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs67963898	ENSG00000273257.1	RP11-177J6.1	-4.93	1.16e-06	0.000145	-0.33	-0.22	Adiponectin levels;	chr4:55475520	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62303718	ENSG00000273257.1	RP11-177J6.1	-4.93	1.16e-06	0.000145	-0.33	-0.22	Adiponectin levels;	chr4:55476770	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs17722870	ENSG00000273257.1	RP11-177J6.1	-4.93	1.16e-06	0.000145	-0.33	-0.22	Adiponectin levels;	chr4:55478519	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs55885973	ENSG00000273257.1	RP11-177J6.1	-4.93	1.16e-06	0.000145	-0.33	-0.22	Adiponectin levels;	chr4:55480054	chr4:55387949~55388271:+
THCA	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-4.93	1.16e-06	0.000145	-0.23	-0.22	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
THCA	cis	rs10200159	1	rs6717574	ENSG00000272606.1	RP11-554J4.1	4.93	1.16e-06	0.000145	0.44	0.22	Vitiligo;	chr2:55594710	chr2:55617909~55618373:+
THCA	cis	rs17301013	0.932	rs11804941	ENSG00000227373.4	RP11-160H22.5	-4.93	1.16e-06	0.000145	-0.31	-0.22	Systemic lupus erythematosus;	chr1:174624074	chr1:174115300~174160004:-
THCA	cis	rs7989336	0.625	rs9516662	ENSG00000247400.3	DNAJC3-AS1	4.93	1.16e-06	0.000145	0.14	0.22	Obesity;	chr13:96324887	chr13:95648733~95676925:-
THCA	cis	rs1395	0.778	rs56364136	ENSG00000234072.1	AC074117.10	-4.93	1.16e-06	0.000145	-0.18	-0.22	Blood metabolite levels;	chr2:27228561	chr2:27356246~27367622:+
THCA	cis	rs1395	1	rs6717980	ENSG00000234072.1	AC074117.10	-4.93	1.16e-06	0.000145	-0.18	-0.22	Blood metabolite levels;	chr2:27229916	chr2:27356246~27367622:+
THCA	cis	rs8064024	0.783	rs2341986	ENSG00000267077.1	RP11-127I20.5	4.93	1.16e-06	0.000145	0.25	0.22	Cancer;	chr16:4769495	chr16:4795265~4796532:-
THCA	cis	rs752010	0.574	rs10890161	ENSG00000230638.4	RP11-486B10.4	-4.93	1.16e-06	0.000145	-0.24	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41655952	chr1:41542069~41544310:+
THCA	cis	rs13178541	0.81	rs2304074	ENSG00000250378.1	RP11-119J18.1	4.93	1.16e-06	0.000145	0.28	0.22	IgG glycosylation;	chr5:135824368	chr5:135812667~135826582:+
THCA	cis	rs651907	0.557	rs62284198	ENSG00000244119.1	PDCL3P4	4.93	1.16e-06	0.000145	0.2	0.22	Colorectal cancer;	chr3:101755855	chr3:101712472~101713191:+
THCA	cis	rs651907	0.557	rs2318090	ENSG00000244119.1	PDCL3P4	4.93	1.16e-06	0.000145	0.2	0.22	Colorectal cancer;	chr3:101756089	chr3:101712472~101713191:+
THCA	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	4.93	1.16e-06	0.000145	0.25	0.22	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
THCA	cis	rs34779708	0.931	rs4934711	ENSG00000271335.4	RP11-324I22.4	4.93	1.16e-06	0.000145	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35314552~35336401:-
THCA	cis	rs8103278	0.507	rs4802276	ENSG00000267395.4	AC074212.6	-4.93	1.16e-06	0.000145	-0.15	-0.22	Coronary artery disease;	chr19:45757490	chr19:45767796~45772504:+
THCA	cis	rs13434995	0.536	rs62303712	ENSG00000273257.1	RP11-177J6.1	-4.93	1.16e-06	0.000145	-0.33	-0.22	Adiponectin levels;	chr4:55460484	chr4:55387949~55388271:+
THCA	cis	rs4925386	0.808	rs1741634	ENSG00000275437.1	RP5-908M14.10	-4.93	1.16e-06	0.000145	-0.2	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350923	chr20:62402236~62405935:-
THCA	cis	rs1150668	0.796	rs2531832	ENSG00000273712.1	RP5-874C20.7	4.93	1.16e-06	0.000145	0.24	0.22	Pubertal anthropometrics;	chr6:28421445	chr6:28315613~28315883:-
THCA	cis	rs7914558	1	rs10883826	ENSG00000236937.2	PTGES3P4	4.93	1.16e-06	0.000145	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:102845595~102845950:+
THCA	cis	rs11671005	0.735	rs11671591	ENSG00000268049.1	CTD-2619J13.9	4.93	1.16e-06	0.000145	0.34	0.22	Mean platelet volume;	chr19:58406970	chr19:58357999~58359603:+
THCA	cis	rs6700559	0.643	rs4915451	ENSG00000260088.1	RP11-92G12.3	4.93	1.16e-06	0.000145	0.28	0.22	Coronary artery disease;	chr1:200690726	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.643	rs6427844	ENSG00000260088.1	RP11-92G12.3	4.93	1.16e-06	0.000145	0.28	0.22	Coronary artery disease;	chr1:200692216	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.643	rs1540682	ENSG00000260088.1	RP11-92G12.3	4.93	1.16e-06	0.000145	0.28	0.22	Coronary artery disease;	chr1:200693231	chr1:200669507~200694250:+
THCA	cis	rs34779708	0.966	rs10827487	ENSG00000271335.4	RP11-324I22.4	4.93	1.16e-06	0.000145	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35314552~35336401:-
THCA	cis	rs1479090	0.762	rs4443236	ENSG00000250027.1	RP11-563E2.2	-4.93	1.16e-06	0.000145	-0.23	-0.22	Lung cancer;	chr4:163089984	chr4:163108785~163119965:+
THCA	cis	rs7577696	0.925	rs212695	ENSG00000276334.1	AL133243.1	4.93	1.16e-06	0.000145	0.24	0.22	Inflammatory biomarkers;	chr2:32215799	chr2:32521927~32523547:+
THCA	cis	rs10090774	0.965	rs13258420	ENSG00000279766.1	RP11-642A1.2	-4.93	1.16e-06	0.000145	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140895513	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs11783743	ENSG00000279766.1	RP11-642A1.2	-4.93	1.16e-06	0.000145	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140897118	chr8:140572142~140572812:-
THCA	cis	rs4915077	0.892	rs76257606	ENSG00000230489.1	VAV3-AS1	4.93	1.16e-06	0.000145	0.32	0.22	Hypothyroidism;	chr1:107808055	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs77819196	ENSG00000230489.1	VAV3-AS1	4.93	1.16e-06	0.000145	0.32	0.22	Hypothyroidism;	chr1:107808514	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs77097831	ENSG00000230489.1	VAV3-AS1	4.93	1.16e-06	0.000145	0.32	0.22	Hypothyroidism;	chr1:107808857	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs78788276	ENSG00000230489.1	VAV3-AS1	4.93	1.16e-06	0.000145	0.32	0.22	Hypothyroidism;	chr1:107808863	chr1:107964443~107994607:+
THCA	cis	rs897984	0.806	rs11150600	ENSG00000260911.2	RP11-196G11.2	-4.93	1.16e-06	0.000145	-0.18	-0.22	Dementia with Lewy bodies;	chr16:30929010	chr16:31043150~31049868:+
THCA	cis	rs67478160	0.595	rs12433109	ENSG00000258735.1	LINC00637	-4.93	1.16e-06	0.000145	-0.27	-0.22	Schizophrenia;	chr14:103730270	chr14:103847721~103858049:+
THCA	cis	rs2281603	0.57	rs10133696	ENSG00000259116.1	RP11-973N13.4	-4.93	1.16e-06	0.000145	-0.2	-0.22	Lymphocyte counts;	chr14:64504441	chr14:64514154~64540368:-
THCA	cis	rs10090774	0.965	rs9324537	ENSG00000279766.1	RP11-642A1.2	-4.93	1.16e-06	0.000145	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140964035	chr8:140572142~140572812:-
THCA	cis	rs12435908	1	rs11845794	ENSG00000276116.2	FUT8-AS1	-4.93	1.16e-06	0.000145	-0.35	-0.22	Ischemic stroke;	chr14:65381400	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs11850160	ENSG00000276116.2	FUT8-AS1	-4.93	1.16e-06	0.000145	-0.35	-0.22	Ischemic stroke;	chr14:65381405	chr14:65411170~65412690:-
THCA	cis	rs7474896	0.583	rs4934898	ENSG00000263064.2	RP11-291L22.7	4.93	1.16e-06	0.000145	0.3	0.22	Obesity (extreme);	chr10:37701467	chr10:38448689~38448949:+
THCA	cis	rs11671005	0.568	rs55987239	ENSG00000269600.1	AC016629.3	-4.93	1.16e-06	0.000145	-0.32	-0.22	Mean platelet volume;	chr19:58573678	chr19:58593896~58599355:-
THCA	cis	rs11846409	0.86	rs73378154	ENSG00000211974.3	IGHV2-70	-4.93	1.16e-06	0.000145	-0.21	-0.22	Rheumatic heart disease;	chr14:106637687	chr14:106723574~106724093:-
THCA	cis	rs270601	0.721	rs270621	ENSG00000224431.1	AC063976.7	4.93	1.16e-06	0.000145	0.19	0.22	Acylcarnitine levels;	chr5:132270128	chr5:132199456~132203487:+
THCA	cis	rs34779708	0.931	rs7079498	ENSG00000271335.4	RP11-324I22.4	4.93	1.16e-06	0.000145	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35314552~35336401:-
THCA	cis	rs2253762	0.507	rs10159998	ENSG00000226864.1	ATE1-AS1	4.93	1.16e-06	0.000145	0.35	0.22	Breast cancer;	chr10:121994550	chr10:121928312~121951965:+
THCA	cis	rs2253762	0.54	rs11200311	ENSG00000226864.1	ATE1-AS1	4.93	1.16e-06	0.000145	0.35	0.22	Breast cancer;	chr10:121995094	chr10:121928312~121951965:+
THCA	cis	rs2253762	0.54	rs79069897	ENSG00000226864.1	ATE1-AS1	4.93	1.16e-06	0.000145	0.35	0.22	Breast cancer;	chr10:121995680	chr10:121928312~121951965:+
THCA	cis	rs2253762	0.54	rs77032313	ENSG00000226864.1	ATE1-AS1	4.93	1.16e-06	0.000145	0.35	0.22	Breast cancer;	chr10:121995687	chr10:121928312~121951965:+
THCA	cis	rs1552244	0.935	rs66493421	ENSG00000180385.7	EMC3-AS1	4.93	1.16e-06	0.000146	0.28	0.22	Alzheimer's disease;	chr3:10050885	chr3:9986893~10006990:+
THCA	cis	rs7617773	0.744	rs2125482	ENSG00000199476.1	Y_RNA	-4.93	1.16e-06	0.000146	-0.28	-0.22	Coronary artery disease;	chr3:48281643	chr3:48288587~48288694:+
THCA	cis	rs7618915	0.571	rs12487445	ENSG00000243224.1	RP5-1157M23.2	-4.93	1.16e-06	0.000146	-0.24	-0.22	Bipolar disorder;	chr3:52584303	chr3:52239258~52241097:+
THCA	cis	rs2253762	0.507	rs12264894	ENSG00000226864.1	ATE1-AS1	4.93	1.16e-06	0.000146	0.35	0.22	Breast cancer;	chr10:121992087	chr10:121928312~121951965:+
THCA	cis	rs9625935	0.957	rs4823070	ENSG00000279159.1	RP3-394A18.1	-4.93	1.16e-06	0.000146	-0.17	-0.22	Tonsillectomy;	chr22:30092218	chr22:29978950~30028236:-
THCA	cis	rs1552244	0.832	rs73024591	ENSG00000232901.1	CYCSP10	4.93	1.16e-06	0.000146	0.31	0.22	Alzheimer's disease;	chr3:10161510	chr3:10000647~10000940:-
THCA	cis	rs7394190	0.688	rs3812629	ENSG00000271816.1	BMS1P4	-4.93	1.16e-06	0.000146	-0.26	-0.22	Incident atrial fibrillation;	chr10:73647532	chr10:73699151~73730487:-
THCA	cis	rs7246657	0.508	rs1644702	ENSG00000226686.6	LINC01535	-4.93	1.16e-06	0.000146	-0.37	-0.22	Coronary artery calcification;	chr19:37001005	chr19:37251912~37265535:+
THCA	cis	rs9652601	0.622	rs2286974	ENSG00000274038.1	RP11-66H6.4	-4.93	1.16e-06	0.000146	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11020655	chr16:11056556~11057034:+
THCA	cis	rs5015933	0.788	rs359592	ENSG00000232630.1	PRPS1P2	-4.93	1.16e-06	0.000146	-0.15	-0.22	Body mass index;	chr9:125285007	chr9:125150653~125151589:+
THCA	cis	rs934734	0.725	rs2271198	ENSG00000281920.1	RP11-418H16.1	4.93	1.16e-06	0.000146	0.28	0.22	Rheumatoid arthritis;	chr2:65331893	chr2:65623272~65628424:+
THCA	cis	rs8046148	0.724	rs12933325	ENSG00000279356.1	RP11-429P3.8	-4.93	1.16e-06	0.000146	-0.26	-0.22	Testicular germ cell tumor;	chr16:50063533	chr16:50072862~50074986:+
THCA	cis	rs7119	0.651	rs8041520	ENSG00000259362.2	RP11-307C19.1	-4.93	1.16e-06	0.000146	-0.33	-0.22	Type 2 diabetes;	chr15:77546827	chr15:77525540~77534110:+
THCA	cis	rs2070488	0.73	rs2268759	ENSG00000229589.1	ACVR2B-AS1	4.93	1.16e-06	0.000146	0.2	0.22	Electrocardiographic conduction measures;	chr3:38472836	chr3:38451027~38454820:-
THCA	cis	rs17036350	1	rs17036350	ENSG00000230337.1	RP4-635E18.6	-4.93	1.16e-06	0.000146	-0.46	-0.22	Corneal curvature;	chr1:11111169	chr1:11099675~11102100:+
THCA	cis	rs7702057	0.53	rs17138834	ENSG00000272265.1	CTD-2287O16.4	-4.93	1.16e-06	0.000146	-0.4	-0.22	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116078110~116078570:-
THCA	cis	rs7141336	0.8	rs28688311	ENSG00000258884.1	CTD-3035D6.2	4.93	1.16e-06	0.000146	0.3	0.22	Anxiety disorder;	chr14:90824070	chr14:90822365~90828128:-
THCA	cis	rs62158800	0.852	rs60010278	ENSG00000237880.1	AC096669.2	4.93	1.16e-06	0.000146	0.35	0.22	Facial morphology (factor 22);	chr2:107653600	chr2:107385632~107542649:-
THCA	cis	rs12682352	0.602	rs6993494	ENSG00000254153.1	CTA-398F10.2	-4.93	1.16e-06	0.000146	-0.24	-0.22	Neuroticism;	chr8:8809934	chr8:8456909~8461337:-
THCA	cis	rs6893782	0.719	rs7737937	ENSG00000233006.5	AC034220.3	4.93	1.16e-06	0.000146	0.25	0.22	Acylcarnitine levels;	chr5:132279288	chr5:132311285~132369916:-
THCA	cis	rs728616	0.681	rs55899456	ENSG00000242600.5	MBL1P	4.93	1.16e-06	0.000146	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80290890	chr10:79904898~79950336:+
THCA	cis	rs3820928	0.845	rs13419076	ENSG00000212391.1	SNORA48	-4.93	1.17e-06	0.000146	-0.24	-0.22	Pulmonary function;	chr2:227008312	chr2:226968989~226969122:-
THCA	cis	rs2839186	0.656	rs4819226	ENSG00000239415.1	AP001469.9	4.93	1.17e-06	0.000146	0.24	0.22	Testicular germ cell tumor;	chr21:46292498	chr21:46251549~46254133:-
THCA	cis	rs1577917	0.566	rs2842611	ENSG00000220563.1	PKMP3	-4.93	1.17e-06	0.000146	-0.16	-0.22	Response to antipsychotic treatment;	chr6:85592316	chr6:85659892~85660606:-
THCA	cis	rs2243480	1	rs466983	ENSG00000232559.3	GS1-124K5.12	4.93	1.17e-06	0.000146	0.33	0.22	Diabetic kidney disease;	chr7:66055509	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.673	rs2433	ENSG00000280069.1	CTD-2349P21.3	-4.93	1.17e-06	0.000146	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30738182~30740275:+
THCA	cis	rs7809615	0.901	rs12535424	ENSG00000244219.5	GS1-259H13.2	-4.93	1.17e-06	0.000146	-0.41	-0.22	Blood metabolite ratios;	chr7:99456193	chr7:99598066~99610813:+
THCA	cis	rs853679	1	rs11965538	ENSG00000220721.1	OR1F12	4.93	1.17e-06	0.000146	0.35	0.22	Depression;	chr6:28272137	chr6:28073316~28074233:+
THCA	cis	rs853679	0.882	rs2743555	ENSG00000220721.1	OR1F12	4.93	1.17e-06	0.000146	0.35	0.22	Depression;	chr6:28273304	chr6:28073316~28074233:+
THCA	cis	rs853679	1	rs1419183	ENSG00000220721.1	OR1F12	4.93	1.17e-06	0.000146	0.35	0.22	Depression;	chr6:28275017	chr6:28073316~28074233:+
THCA	cis	rs853679	1	rs6901575	ENSG00000220721.1	OR1F12	4.93	1.17e-06	0.000146	0.35	0.22	Depression;	chr6:28283207	chr6:28073316~28074233:+
THCA	cis	rs853679	1	rs1679709	ENSG00000220721.1	OR1F12	-4.93	1.17e-06	0.000146	-0.35	-0.22	Depression;	chr6:28260564	chr6:28073316~28074233:+
THCA	cis	rs853679	1	rs1778511	ENSG00000220721.1	OR1F12	-4.93	1.17e-06	0.000146	-0.35	-0.22	Depression;	chr6:28261633	chr6:28073316~28074233:+
THCA	cis	rs950169	0.58	rs11630887	ENSG00000188388.10	GOLGA6L3	4.93	1.17e-06	0.000146	0.3	0.22	Schizophrenia;	chr15:84649784	chr15:85240472~85247170:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000223473.2	GS1-124K5.3	4.93	1.17e-06	0.000146	0.15	0.22	Aortic root size;	chr7:65931217	chr7:66491049~66493566:-
THCA	cis	rs2243480	1	rs313809	ENSG00000232559.3	GS1-124K5.12	4.93	1.17e-06	0.000146	0.33	0.22	Diabetic kidney disease;	chr7:66034996	chr7:66554588~66576923:-
THCA	cis	rs79243044	1	rs34822023	ENSG00000224295.2	AC087380.14	-4.93	1.17e-06	0.000146	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5534014	chr11:5518441~5524955:-
THCA	cis	rs79243044	1	rs35601051	ENSG00000224295.2	AC087380.14	-4.93	1.17e-06	0.000146	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5534017	chr11:5518441~5524955:-
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000229886.1	RP5-1132H15.3	4.93	1.17e-06	0.000146	0.26	0.22	Corneal structure;	chr7:66798563	chr7:66025126~66031544:-
THCA	cis	rs10875746	0.537	rs4760625	ENSG00000258234.1	RP11-370I10.2	4.93	1.17e-06	0.000146	0.26	0.22	Longevity (90 years and older);	chr12:48279960	chr12:48231098~48284210:-
THCA	cis	rs17270561	0.609	rs9358887	ENSG00000272462.2	U91328.19	-4.93	1.17e-06	0.000146	-0.19	-0.22	Iron status biomarkers;	chr6:25759178	chr6:25992662~26001775:+
THCA	cis	rs763121	0.853	rs1013338	ENSG00000273076.1	RP3-508I15.22	4.93	1.17e-06	0.000146	0.22	0.22	Menopause (age at onset);	chr22:38578149	chr22:38743495~38743910:+
THCA	cis	rs467650	0.782	rs719246	ENSG00000246763.5	RGMB-AS1	-4.93	1.17e-06	0.000146	-0.22	-0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98722220	chr5:98769618~98773469:-
THCA	cis	rs9859260	0.689	rs3817672	ENSG00000273009.1	RP11-352G9.1	-4.93	1.17e-06	0.000146	-0.25	-0.22	Mean corpuscular volume;	chr3:196073940	chr3:195913078~195913683:-
THCA	cis	rs752010	0.63	rs12134174	ENSG00000230638.4	RP11-486B10.4	-4.93	1.17e-06	0.000146	-0.24	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41640271	chr1:41542069~41544310:+
THCA	cis	rs7924176	0.601	rs12414280	ENSG00000213731.2	RAB5CP1	-4.93	1.17e-06	0.000146	-0.26	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74423435~74424014:-
THCA	cis	rs4648045	0.734	rs4648055	ENSG00000246560.2	RP11-10L12.4	4.93	1.17e-06	0.000146	0.29	0.22	Lymphocyte percentage of white cells;	chr4:102594156	chr4:102828055~102844075:+
THCA	cis	rs8049040	0.524	rs891125	ENSG00000260886.1	TAT-AS1	4.93	1.17e-06	0.000147	0.32	0.22	Blood protein levels;	chr16:71397718	chr16:71565789~71578187:+
THCA	cis	rs8031584	0.541	rs1983459	ENSG00000270015.1	RP11-540B6.6	-4.93	1.17e-06	0.000147	-0.16	-0.22	Huntington's disease progression;	chr15:30916546	chr15:30926514~30928407:+
THCA	cis	rs13434995	0.513	rs6554291	ENSG00000273257.1	RP11-177J6.1	-4.93	1.17e-06	0.000147	-0.33	-0.22	Adiponectin levels;	chr4:55571204	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs7665846	ENSG00000273257.1	RP11-177J6.1	4.93	1.17e-06	0.000147	0.33	0.22	Adiponectin levels;	chr4:55573078	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs2412658	ENSG00000273257.1	RP11-177J6.1	4.93	1.17e-06	0.000147	0.33	0.22	Adiponectin levels;	chr4:55577050	chr4:55387949~55388271:+
THCA	cis	rs736408	0.634	rs11717836	ENSG00000243224.1	RP5-1157M23.2	-4.93	1.17e-06	0.000147	-0.25	-0.22	Bipolar disorder;	chr3:52773720	chr3:52239258~52241097:+
THCA	cis	rs240993	0.715	rs7776346	ENSG00000271789.1	RP5-1112D6.7	4.93	1.17e-06	0.000147	0.26	0.22	Inflammatory skin disease;Psoriasis;	chr6:111540162	chr6:111297126~111298510:+
THCA	cis	rs12823128	0.766	rs7309939	ENSG00000256185.1	RP11-612B6.2	4.92	1.17e-06	0.000147	0.21	0.22	Birth weight;	chr12:26761169	chr12:26335864~26336950:-
THCA	cis	rs853679	0.546	rs200996	ENSG00000280107.1	AL022393.9	-4.92	1.17e-06	0.000147	-0.34	-0.22	Depression;	chr6:27844050	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs200990	ENSG00000280107.1	AL022393.9	-4.92	1.17e-06	0.000147	-0.34	-0.22	Depression;	chr6:27848045	chr6:28170845~28172521:+
THCA	cis	rs11634944	0.738	rs34091931	ENSG00000257151.1	PWAR6	4.92	1.17e-06	0.000147	0.17	0.22	Interleukin-8 levels;	chr15:25006466	chr15:25031873~25036490:+
THCA	cis	rs651907	0.535	rs1460097	ENSG00000244119.1	PDCL3P4	4.92	1.17e-06	0.000147	0.2	0.22	Colorectal cancer;	chr3:101778725	chr3:101712472~101713191:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000223473.2	GS1-124K5.3	-4.92	1.17e-06	0.000147	-0.15	-0.22	Aortic root size;	chr7:65800193	chr7:66491049~66493566:-
THCA	cis	rs17507216	0.56	rs2871011	ENSG00000255769.6	GOLGA2P10	-4.92	1.17e-06	0.000147	-0.27	-0.22	Excessive daytime sleepiness;	chr15:82560792	chr15:82472993~82513950:-
THCA	cis	rs1023500	0.506	rs6002625	ENSG00000273366.1	CTA-989H11.1	4.92	1.17e-06	0.000147	0.29	0.22	Schizophrenia;	chr22:42121685	chr22:42278188~42278846:+
THCA	cis	rs3820928	0.839	rs58580037	ENSG00000212391.1	SNORA48	-4.92	1.17e-06	0.000147	-0.24	-0.22	Pulmonary function;	chr2:227011558	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10188770	ENSG00000212391.1	SNORA48	-4.92	1.17e-06	0.000147	-0.24	-0.22	Pulmonary function;	chr2:227012321	chr2:226968989~226969122:-
THCA	cis	rs9863	0.931	rs35825716	ENSG00000269997.1	RP11-214K3.21	-4.92	1.17e-06	0.000147	-0.27	-0.22	White blood cell count;	chr12:123942977	chr12:123966077~123966629:-
THCA	cis	rs79243044	0.965	rs11037994	ENSG00000224295.2	AC087380.14	-4.92	1.18e-06	0.000147	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5535987	chr11:5518441~5524955:-
THCA	cis	rs11733284	1	rs6832503	ENSG00000259959.1	RP11-121C2.2	-4.92	1.18e-06	0.000147	-0.19	-0.22	Gout;Renal underexcretion gout;	chr4:48026425	chr4:47840122~47844339:-
THCA	cis	rs12908161	1	rs12905057	ENSG00000188388.10	GOLGA6L3	4.92	1.18e-06	0.000147	0.3	0.22	Schizophrenia;	chr15:84667534	chr15:85240472~85247170:+
THCA	cis	rs17767392	0.881	rs34993988	ENSG00000259146.3	RP1-261D10.2	4.92	1.18e-06	0.000147	0.28	0.22	Mitral valve prolapse;	chr14:71456975	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.881	rs67489015	ENSG00000259146.3	RP1-261D10.2	4.92	1.18e-06	0.000147	0.28	0.22	Mitral valve prolapse;	chr14:71497804	chr14:71292729~71321814:-
THCA	cis	rs73198271	1	rs11776513	ENSG00000253893.2	FAM85B	4.92	1.18e-06	0.000147	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8167819~8226614:-
THCA	cis	rs72843506	0.586	rs75721433	ENSG00000261033.1	RP11-209D14.2	4.92	1.18e-06	0.000147	0.45	0.22	Schizophrenia;	chr17:19978747	chr17:20008051~20009234:-
THCA	cis	rs7617773	0.817	rs9853804	ENSG00000199476.1	Y_RNA	-4.92	1.18e-06	0.000147	-0.28	-0.22	Coronary artery disease;	chr3:48286239	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs9834095	ENSG00000199476.1	Y_RNA	-4.92	1.18e-06	0.000147	-0.28	-0.22	Coronary artery disease;	chr3:48286261	chr3:48288587~48288694:+
THCA	cis	rs763121	0.853	rs5750633	ENSG00000235209.1	CTA-150C2.13	4.92	1.18e-06	0.000147	0.29	0.22	Menopause (age at onset);	chr22:38597462	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757166	ENSG00000235209.1	CTA-150C2.13	4.92	1.18e-06	0.000147	0.29	0.22	Menopause (age at onset);	chr22:38599380	chr22:38921227~38924708:+
THCA	cis	rs12900463	0.813	rs186266	ENSG00000225151.9	GOLGA2P7	-4.92	1.18e-06	0.000147	-0.31	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:84199311~84230136:-
THCA	cis	rs796395	0.576	rs903349	ENSG00000228208.5	C1orf143	-4.92	1.18e-06	0.000147	-0.26	-0.22	Post bronchodilator FEV1/FVC ratio;	chr1:218467954	chr1:218510096~218525978:+
THCA	cis	rs9326248	0.52	rs236919	ENSG00000280143.1	AP000892.6	4.92	1.18e-06	0.000147	0.28	0.22	Blood protein levels;	chr11:117224645	chr11:117204967~117210292:+
THCA	cis	rs6545883	0.894	rs10496092	ENSG00000270820.4	RP11-355B11.2	-4.92	1.18e-06	0.000147	-0.18	-0.22	Tuberculosis;	chr2:61297544	chr2:61471188~61484130:+
THCA	cis	rs8192917	0.511	rs7150231	ENSG00000258744.1	RP11-80A15.1	-4.92	1.18e-06	0.000147	-0.39	-0.22	Vitiligo;	chr14:24592407	chr14:24501594~24508688:+
THCA	cis	rs8192917	0.524	rs12884659	ENSG00000258744.1	RP11-80A15.1	-4.92	1.18e-06	0.000147	-0.39	-0.22	Vitiligo;	chr14:24595620	chr14:24501594~24508688:+
THCA	cis	rs79243044	0.965	rs12417988	ENSG00000224295.2	AC087380.14	-4.92	1.18e-06	0.000147	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5538481	chr11:5518441~5524955:-
THCA	cis	rs919433	0.756	rs7575389	ENSG00000231621.1	AC013264.2	4.92	1.18e-06	0.000147	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197333765	chr2:197197991~197199273:+
THCA	cis	rs9863	0.861	rs4405410	ENSG00000269997.1	RP11-214K3.21	-4.92	1.18e-06	0.000147	-0.27	-0.22	White blood cell count;	chr12:123951241	chr12:123966077~123966629:-
THCA	cis	rs7914558	1	rs4917380	ENSG00000236937.2	PTGES3P4	4.92	1.18e-06	0.000148	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103015578	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs7914558	ENSG00000236937.2	PTGES3P4	4.92	1.18e-06	0.000148	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103016151	chr10:102845595~102845950:+
THCA	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-4.92	1.18e-06	0.000148	-0.32	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
THCA	cis	rs1122401	0.515	rs2564983	ENSG00000280159.1	CTD-2591A1.1	4.92	1.18e-06	0.000148	0.31	0.22	Smoking initiation;	chr5:54568610	chr5:54643557~54645987:+
THCA	cis	rs2281558	0.833	rs6115202	ENSG00000125804.12	FAM182A	4.92	1.18e-06	0.000148	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:26054655~26086917:+
THCA	cis	rs7520050	0.966	rs1768816	ENSG00000234329.1	RP11-767N6.2	-4.92	1.18e-06	0.000148	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45651039~45651826:-
THCA	cis	rs763121	0.853	rs1062687	ENSG00000235209.1	CTA-150C2.13	4.92	1.18e-06	0.000148	0.3	0.22	Menopause (age at onset);	chr22:38738710	chr22:38921227~38924708:+
THCA	cis	rs13434995	0.513	rs62310862	ENSG00000273257.1	RP11-177J6.1	-4.92	1.18e-06	0.000148	-0.33	-0.22	Adiponectin levels;	chr4:55572594	chr4:55387949~55388271:+
THCA	cis	rs11992162	0.967	rs10088415	ENSG00000206014.6	OR7E161P	4.92	1.18e-06	0.000148	0.26	0.22	Monocyte count;	chr8:11973316	chr8:11928597~11929563:-
THCA	cis	rs453301	0.624	rs330056	ENSG00000248538.5	RP11-10A14.5	4.92	1.18e-06	0.000148	0.27	0.22	Joint mobility (Beighton score);	chr8:9232185	chr8:9189011~9202854:+
THCA	cis	rs4713118	0.868	rs2893928	ENSG00000220721.1	OR1F12	4.92	1.18e-06	0.000148	0.31	0.22	Parkinson's disease;	chr6:27770651	chr6:28073316~28074233:+
THCA	cis	rs17767392	0.834	rs61991193	ENSG00000259146.3	RP1-261D10.2	4.92	1.18e-06	0.000148	0.29	0.22	Mitral valve prolapse;	chr14:71277072	chr14:71292729~71321814:-
THCA	cis	rs9959145	1	rs78543731	ENSG00000267108.1	RP11-861E21.1	4.92	1.18e-06	0.000148	0.27	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12665565	chr18:12432897~12437635:+
THCA	cis	rs11673344	0.504	rs8105065	ENSG00000276846.1	CTD-3220F14.3	4.92	1.18e-06	0.000148	0.17	0.22	Obesity-related traits;	chr19:37141003	chr19:37314868~37315620:-
THCA	cis	rs9818758	0.607	rs67060340	ENSG00000270441.1	RP11-694I15.7	4.92	1.18e-06	0.000148	0.31	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48877888	chr3:49140086~49160851:-
THCA	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-4.92	1.18e-06	0.000148	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
THCA	cis	rs13113518	1	rs4864547	ENSG00000273257.1	RP11-177J6.1	4.92	1.18e-06	0.000148	0.29	0.22	Height;	chr4:55538228	chr4:55387949~55388271:+
THCA	cis	rs10875746	0.669	rs11168499	ENSG00000258234.1	RP11-370I10.2	4.92	1.18e-06	0.000148	0.26	0.22	Longevity (90 years and older);	chr12:48268887	chr12:48231098~48284210:-
THCA	cis	rs11779988	0.543	rs410445	ENSG00000253671.1	RP11-806O11.1	-4.92	1.18e-06	0.000148	-0.29	-0.22	Breast cancer;	chr8:18024795	chr8:17808941~17820868:+
THCA	cis	rs7192208	0.541	rs111756027	ENSG00000260922.1	RP11-538I12.3	4.92	1.18e-06	0.000148	0.34	0.22	White matter integrity;	chr16:77284214	chr16:77234877~77290934:+
THCA	cis	rs116095464	0.558	rs28636067	ENSG00000248925.1	CTD-2083E4.6	4.92	1.18e-06	0.000148	0.36	0.22	Breast cancer;	chr5:199300	chr5:269858~271516:-
THCA	cis	rs440932	0.757	rs330945	ENSG00000253893.2	FAM85B	-4.92	1.18e-06	0.000148	-0.28	-0.22	High light scatter reticulocyte percentage of red cells;	chr8:9164423	chr8:8167819~8226614:-
THCA	cis	rs228614	0.51	rs223356	ENSG00000248971.2	KRT8P46	-4.92	1.18e-06	0.000148	-0.27	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102728746~102730171:-
THCA	cis	rs10923574	0.521	rs6699115	ENSG00000231365.4	RP11-418J17.1	-4.92	1.18e-06	0.000148	-0.23	-0.22	Breast cancer;Folding of antihelix;	chr1:118522959	chr1:119140396~119275973:+
THCA	cis	rs7617773	0.817	rs6800492	ENSG00000199476.1	Y_RNA	-4.92	1.18e-06	0.000148	-0.28	-0.22	Coronary artery disease;	chr3:48282400	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs9818937	ENSG00000199476.1	Y_RNA	-4.92	1.18e-06	0.000148	-0.28	-0.22	Coronary artery disease;	chr3:48283791	chr3:48288587~48288694:+
THCA	cis	rs12682352	0.602	rs28399241	ENSG00000254153.1	CTA-398F10.2	-4.92	1.18e-06	0.000148	-0.24	-0.22	Neuroticism;	chr8:8805705	chr8:8456909~8461337:-
THCA	cis	rs9859260	0.961	rs34221479	ENSG00000273009.1	RP11-352G9.1	-4.92	1.18e-06	0.000148	-0.24	-0.22	Mean corpuscular volume;	chr3:196071729	chr3:195913078~195913683:-
THCA	cis	rs35160687	0.623	rs11689971	ENSG00000273080.1	RP11-301O19.1	-4.92	1.18e-06	0.000148	-0.24	-0.22	Night sleep phenotypes;	chr2:86247348	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.623	rs11127021	ENSG00000273080.1	RP11-301O19.1	-4.92	1.18e-06	0.000148	-0.24	-0.22	Night sleep phenotypes;	chr2:86247796	chr2:86195590~86196049:+
THCA	cis	rs11846409	0.521	rs10143547	ENSG00000274576.2	IGHV2-70	-4.92	1.18e-06	0.000148	-0.18	-0.22	Rheumatic heart disease;	chr14:106644638	chr14:106770577~106771020:-
THCA	cis	rs7647973	0.848	rs4955426	ENSG00000228638.1	FCF1P2	-4.92	1.18e-06	0.000148	-0.28	-0.22	Menarche (age at onset);	chr3:49106005	chr3:48290793~48291375:-
THCA	cis	rs57221529	0.545	rs55955015	ENSG00000225138.6	CTD-2228K2.7	4.92	1.19e-06	0.000148	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:575067	chr5:473236~480884:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000228409.4	CCT6P1	-4.92	1.19e-06	0.000148	-0.19	-0.22	Aortic root size;	chr7:66376216	chr7:65751142~65763354:+
THCA	cis	rs3796352	1	rs71301804	ENSG00000242142.1	SERBP1P3	-4.92	1.19e-06	0.000148	-0.42	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53039298	chr3:53064283~53065091:-
THCA	cis	rs17270561	0.609	rs4712970	ENSG00000272462.2	U91328.19	-4.92	1.19e-06	0.000148	-0.19	-0.22	Iron status biomarkers;	chr6:25770479	chr6:25992662~26001775:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000229886.1	RP5-1132H15.3	-4.92	1.19e-06	0.000148	-0.23	-0.22	Aortic root size;	chr7:66836124	chr7:66025126~66031544:-
THCA	cis	rs11992162	0.591	rs35657308	ENSG00000206014.6	OR7E161P	4.92	1.19e-06	0.000148	0.26	0.22	Monocyte count;	chr8:11946893	chr8:11928597~11929563:-
THCA	cis	rs897984	0.568	rs67264578	ENSG00000279196.1	RP11-1072A3.3	4.92	1.19e-06	0.000149	0.24	0.22	Dementia with Lewy bodies;	chr16:30868074	chr16:30984630~30988270:-
THCA	cis	rs897984	0.568	rs56083427	ENSG00000279196.1	RP11-1072A3.3	4.92	1.19e-06	0.000149	0.24	0.22	Dementia with Lewy bodies;	chr16:30869977	chr16:30984630~30988270:-
THCA	cis	rs736408	0.812	rs2270197	ENSG00000243224.1	RP5-1157M23.2	-4.92	1.19e-06	0.000149	-0.24	-0.22	Bipolar disorder;	chr3:52790079	chr3:52239258~52241097:+
THCA	cis	rs6545883	0.894	rs12620105	ENSG00000270820.4	RP11-355B11.2	-4.92	1.19e-06	0.000149	-0.19	-0.22	Tuberculosis;	chr2:61285186	chr2:61471188~61484130:+
THCA	cis	rs7829975	0.591	rs12677543	ENSG00000254340.1	RP11-10A14.3	4.92	1.19e-06	0.000149	0.24	0.22	Mood instability;	chr8:8786764	chr8:9141424~9145435:+
THCA	cis	rs6061231	0.597	rs624313	ENSG00000275437.1	RP5-908M14.10	-4.92	1.19e-06	0.000149	-0.2	-0.22	Colorectal cancer;	chr20:62352356	chr20:62402236~62405935:-
THCA	cis	rs12887734	0.524	rs12888002	ENSG00000269910.1	RP11-73M18.10	4.92	1.19e-06	0.000149	0.21	0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103694516~103695050:-
THCA	cis	rs17818399	0.781	rs4952837	ENSG00000279254.1	RP11-536C12.1	-4.92	1.19e-06	0.000149	-0.23	-0.22	Height;	chr2:46638595	chr2:46668870~46670778:+
THCA	cis	rs17818399	0.781	rs6746598	ENSG00000279254.1	RP11-536C12.1	-4.92	1.19e-06	0.000149	-0.23	-0.22	Height;	chr2:46638634	chr2:46668870~46670778:+
THCA	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-4.92	1.19e-06	0.000149	-0.25	-0.22	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-4.92	1.19e-06	0.000149	-0.25	-0.22	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-4.92	1.19e-06	0.000149	-0.25	-0.22	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-4.92	1.19e-06	0.000149	-0.25	-0.22	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-4.92	1.19e-06	0.000149	-0.25	-0.22	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
THCA	cis	rs1979679	0.918	rs10843176	ENSG00000278733.1	RP11-425D17.1	-4.92	1.19e-06	0.000149	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28454984	chr12:28185625~28186190:-
THCA	cis	rs9494145	0.793	rs6920211	ENSG00000232876.1	CTA-212D2.2	-4.92	1.19e-06	0.000149	-0.3	-0.22	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135110180	chr6:135055033~135060550:+
THCA	cis	rs9863	0.861	rs75321546	ENSG00000269997.1	RP11-214K3.21	-4.92	1.19e-06	0.000149	-0.27	-0.22	White blood cell count;	chr12:123962918	chr12:123966077~123966629:-
THCA	cis	rs9863	0.861	rs55990776	ENSG00000269997.1	RP11-214K3.21	-4.92	1.19e-06	0.000149	-0.27	-0.22	White blood cell count;	chr12:123962919	chr12:123966077~123966629:-
THCA	cis	rs270601	0.721	rs270621	ENSG00000237714.1	P4HA2-AS1	4.92	1.19e-06	0.000149	0.29	0.22	Acylcarnitine levels;	chr5:132270128	chr5:132184876~132192808:+
THCA	cis	rs2483058	0.796	rs11120291	ENSG00000261000.1	RP11-534L20.5	4.92	1.19e-06	0.000149	0.24	0.22	Cholesterol and Triglycerides;	chr1:206442751	chr1:206503948~206504456:+
THCA	cis	rs950169	0.519	rs7237	ENSG00000188388.10	GOLGA6L3	4.92	1.19e-06	0.000149	0.3	0.22	Schizophrenia;	chr15:84643346	chr15:85240472~85247170:+
THCA	cis	rs2797160	0.904	rs1777197	ENSG00000237742.5	RP11-624M8.1	4.92	1.19e-06	0.000149	0.19	0.22	Endometrial cancer;	chr6:125686255	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.904	rs1739366	ENSG00000237742.5	RP11-624M8.1	4.92	1.19e-06	0.000149	0.19	0.22	Endometrial cancer;	chr6:125686263	chr6:125578558~125749190:-
THCA	cis	rs4443100	1	rs4443100	ENSG00000230701.2	FBXW4P1	4.92	1.19e-06	0.000149	0.26	0.22	Serum parathyroid hormone levels;	chr22:23030688	chr22:23262767~23265005:+
THCA	cis	rs13256369	0.762	rs13278972	ENSG00000254153.1	CTA-398F10.2	-4.92	1.19e-06	0.000149	-0.25	-0.22	Obesity-related traits;	chr8:8739670	chr8:8456909~8461337:-
THCA	cis	rs79349575	0.783	rs4793991	ENSG00000270781.1	RP11-501C14.9	-4.92	1.19e-06	0.000149	-0.26	-0.22	Type 2 diabetes;	chr17:48924439	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.715	rs62075844	ENSG00000270781.1	RP11-501C14.9	-4.92	1.19e-06	0.000149	-0.26	-0.22	Type 2 diabetes;	chr17:48925027	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.749	rs957557	ENSG00000270781.1	RP11-501C14.9	-4.92	1.19e-06	0.000149	-0.26	-0.22	Type 2 diabetes;	chr17:48925859	chr17:48899131~48899748:+
THCA	cis	rs7246657	0.722	rs3095726	ENSG00000276846.1	CTD-3220F14.3	-4.92	1.19e-06	0.000149	-0.23	-0.22	Coronary artery calcification;	chr19:37738923	chr19:37314868~37315620:-
THCA	cis	rs4664293	0.631	rs13024749	ENSG00000226266.5	AC009961.3	4.92	1.19e-06	0.000149	0.26	0.22	Monocyte percentage of white cells;	chr2:159799606	chr2:159670708~159712435:-
THCA	cis	rs62184315	0.536	rs5743047	ENSG00000253559.1	OSGEPL1-AS1	4.92	1.19e-06	0.000149	0.3	0.22	Alcohol dependence (age at onset);	chr2:189819942	chr2:189762704~189765556:+
THCA	cis	rs1048886	0.745	rs6455370	ENSG00000271967.1	RP11-134K13.4	-4.92	1.19e-06	0.000149	-0.22	-0.22	Type 2 diabetes;	chr6:70563532	chr6:70596438~70596980:+
THCA	cis	rs911555	0.723	rs4906320	ENSG00000244691.1	RPL10AP1	4.92	1.19e-06	0.000149	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103412119~103412761:-
THCA	cis	rs748404	0.666	rs7180812	ENSG00000205771.5	CATSPER2P1	-4.92	1.19e-06	0.000149	-0.28	-0.22	Lung cancer;	chr15:43403033	chr15:43726918~43747094:-
THCA	cis	rs8177876	0.596	rs2317087	ENSG00000261061.1	RP11-303E16.2	4.92	1.19e-06	0.000149	0.38	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104753	chr16:81030770~81031485:+
THCA	cis	rs11634944	0.615	rs1549475	ENSG00000257151.1	PWAR6	4.92	1.19e-06	0.000149	0.16	0.22	Interleukin-8 levels;	chr15:25001297	chr15:25031873~25036490:+
THCA	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	4.92	1.19e-06	0.000149	0.13	0.22	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
THCA	cis	rs2129782	0.85	rs75552369	ENSG00000253553.4	RP11-586K2.1	4.92	1.19e-06	0.000149	0.39	0.22	Electrodermal activity;	chr8:88501044	chr8:88326836~88737134:+
THCA	cis	rs9878978	0.722	rs35014764	ENSG00000237990.3	CNTN4-AS1	4.92	1.19e-06	0.000149	0.27	0.22	Blood pressure (smoking interaction);	chr3:2418916	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.722	rs13072674	ENSG00000237990.3	CNTN4-AS1	4.92	1.19e-06	0.000149	0.27	0.22	Blood pressure (smoking interaction);	chr3:2419028	chr3:3039033~3069242:-
THCA	cis	rs919433	0.963	rs2043016	ENSG00000231621.1	AC013264.2	4.92	1.19e-06	0.000149	0.22	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197281657	chr2:197197991~197199273:+
THCA	cis	rs3177980	0.632	rs1062976	ENSG00000239494.2	RN7SL333P	-4.92	1.19e-06	0.000149	-0.21	-0.22	Amyotrophic lateral sclerosis;	chr1:169854519	chr1:169859756~169860052:+
THCA	cis	rs13434995	0.537	rs7340797	ENSG00000273257.1	RP11-177J6.1	4.92	1.19e-06	0.000149	0.35	0.22	Adiponectin levels;	chr4:55363681	chr4:55387949~55388271:+
THCA	cis	rs2239547	0.563	rs6445547	ENSG00000242142.1	SERBP1P3	4.92	1.2e-06	0.00015	0.29	0.22	Schizophrenia;	chr3:52874561	chr3:53064283~53065091:-
THCA	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-4.92	1.2e-06	0.00015	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
THCA	cis	rs3750965	1	rs7937006	ENSG00000260895.1	RP11-554A11.7	4.92	1.2e-06	0.00015	0.3	0.22	Hair color;	chr11:69076464	chr11:69103493~69109094:+
THCA	cis	rs4950322	0.57	rs6703892	ENSG00000271721.1	RP11-337C18.9	4.92	1.2e-06	0.00015	0.25	0.22	Protein quantitative trait loci;	chr1:147287627	chr1:147175602~147177740:+
THCA	cis	rs5742933	0.69	rs16831821	ENSG00000253559.1	OSGEPL1-AS1	-4.92	1.2e-06	0.00015	-0.32	-0.22	Ferritin levels;	chr2:189641087	chr2:189762704~189765556:+
THCA	cis	rs11671005	0.735	rs3826682	ENSG00000265272.2	RN7SL693P	4.92	1.2e-06	0.00015	0.31	0.22	Mean platelet volume;	chr19:58407381	chr19:58490797~58491075:+
THCA	cis	rs8028182	0.636	rs4886703	ENSG00000260269.4	CTD-2323K18.1	-4.92	1.2e-06	0.00015	-0.33	-0.22	Sudden cardiac arrest;	chr15:75438025	chr15:75527150~75601205:-
THCA	cis	rs12682352	0.652	rs1567398	ENSG00000254153.1	CTA-398F10.2	4.92	1.2e-06	0.00015	0.25	0.22	Neuroticism;	chr8:8869294	chr8:8456909~8461337:-
THCA	cis	rs6545883	0.894	rs4672431	ENSG00000270820.4	RP11-355B11.2	-4.92	1.2e-06	0.00015	-0.18	-0.22	Tuberculosis;	chr2:61292787	chr2:61471188~61484130:+
THCA	cis	rs17301013	0.932	rs6425282	ENSG00000227373.4	RP11-160H22.5	4.92	1.2e-06	0.00015	0.31	0.22	Systemic lupus erythematosus;	chr1:174493387	chr1:174115300~174160004:-
THCA	cis	rs4934494	0.588	rs2026554	ENSG00000240996.1	RP11-80H5.7	-4.92	1.2e-06	0.00015	-0.24	-0.22	Red blood cell count;	chr10:89829699	chr10:89694295~89697928:-
THCA	cis	rs10208649	0.522	rs1001296	ENSG00000272156.1	RP11-477N3.1	-4.92	1.2e-06	0.00015	-0.46	-0.22	Body mass index;	chr2:54172496	chr2:54082554~54085066:+
THCA	cis	rs2252521	0.553	rs2648659	ENSG00000272568.4	CTB-113D17.1	4.92	1.2e-06	0.00015	0.25	0.22	Cognitive performance;	chr7:29001336	chr7:28979967~29013367:+
THCA	cis	rs9910055	0.659	rs2251165	ENSG00000267080.4	ASB16-AS1	-4.92	1.2e-06	0.00015	-0.2	-0.22	Total body bone mineral density;	chr17:44157380	chr17:44175973~44186717:-
THCA	cis	rs972578	0.791	rs8135794	ENSG00000274717.1	RP1-47A17.1	-4.92	1.2e-06	0.00015	-0.23	-0.22	Mean platelet volume;	chr22:42920139	chr22:42791814~42794313:-
THCA	cis	rs7520050	0.778	rs12404197	ENSG00000234329.1	RP11-767N6.2	-4.92	1.2e-06	0.00015	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.801	rs6703960	ENSG00000234329.1	RP11-767N6.2	-4.92	1.2e-06	0.00015	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45651039~45651826:-
THCA	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-4.92	1.2e-06	0.00015	-0.25	-0.22	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
THCA	cis	rs2380220	0.606	rs7754906	ENSG00000261366.1	MANEA-AS1	-4.92	1.2e-06	0.00015	-0.21	-0.22	Behavioural disinhibition (generation interaction);	chr6:95544553	chr6:95575183~95577450:-
THCA	cis	rs897984	0.568	rs4889653	ENSG00000260911.2	RP11-196G11.2	-4.92	1.2e-06	0.00015	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30884392	chr16:31043150~31049868:+
THCA	cis	rs9376098	1	rs9376098	ENSG00000232876.1	CTA-212D2.2	-4.92	1.2e-06	0.00015	-0.26	-0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135178322	chr6:135055033~135060550:+
THCA	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	4.92	1.2e-06	0.00015	0.41	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	4.92	1.2e-06	0.00015	0.41	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
THCA	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	4.92	1.2e-06	0.00015	0.25	0.22	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
THCA	cis	rs3734266	0.702	rs115531193	ENSG00000272288.4	RP11-140K17.3	-4.92	1.2e-06	0.00015	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34683534	chr6:34696317~34697470:+
THCA	cis	rs8042680	0.915	rs7166743	ENSG00000214432.8	AC068831.10	-4.92	1.2e-06	0.00015	-0.23	-0.22	Type 2 diabetes;	chr15:90971584	chr15:91022619~91036611:+
THCA	cis	rs972578	0.765	rs5759029	ENSG00000274717.1	RP1-47A17.1	-4.92	1.2e-06	0.00015	-0.23	-0.22	Mean platelet volume;	chr22:42912520	chr22:42791814~42794313:-
THCA	cis	rs972578	0.765	rs2267473	ENSG00000274717.1	RP1-47A17.1	-4.92	1.2e-06	0.00015	-0.23	-0.22	Mean platelet volume;	chr22:42915004	chr22:42791814~42794313:-
THCA	cis	rs1005277	0.563	rs2800550	ENSG00000272983.1	RP11-508N22.12	4.92	1.2e-06	0.00015	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38137337~38144399:+
THCA	cis	rs683250	0.629	rs681259	ENSG00000254551.1	RP11-727A23.7	4.92	1.2e-06	0.00015	0.26	0.22	Subcortical brain region volumes;	chr11:83222984	chr11:83209431~83213379:-
THCA	cis	rs11976020	1	rs11976020	ENSG00000205578.5	POM121B	-4.92	1.2e-06	0.00015	-0.3	-0.22	Educational attainment (years of education);	chr7:72782785	chr7:73293497~73301161:+
THCA	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-4.92	1.2e-06	0.00015	-0.27	-0.22	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-4.92	1.2e-06	0.00015	-0.27	-0.22	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
THCA	cis	rs9925964	0.933	rs4889530	ENSG00000260911.2	RP11-196G11.2	-4.92	1.2e-06	0.00015	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31043150~31049868:+
THCA	cis	rs7246657	0.524	rs10411251	ENSG00000276846.1	CTD-3220F14.3	4.92	1.2e-06	0.00015	0.23	0.22	Coronary artery calcification;	chr19:36937853	chr19:37314868~37315620:-
THCA	cis	rs8396	1	rs4690909	ENSG00000271817.2	U3	-4.92	1.2e-06	0.00015	-0.23	-0.22	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158707999	chr4:158700691~158700909:+
THCA	cis	rs736408	0.812	rs1076425	ENSG00000243224.1	RP5-1157M23.2	-4.92	1.2e-06	0.00015	-0.24	-0.22	Bipolar disorder;	chr3:52791446	chr3:52239258~52241097:+
THCA	cis	rs10208649	1	rs13401719	ENSG00000233266.1	HMGB1P31	4.92	1.2e-06	0.00015	0.51	0.22	Body mass index;	chr2:53958510	chr2:54051334~54051760:+
THCA	cis	rs6088590	1	rs910870	ENSG00000276073.1	RP5-1125A11.7	-4.92	1.2e-06	0.00015	-0.2	-0.22	Coronary artery disease;	chr20:34705089	chr20:33985617~33988989:-
THCA	cis	rs1005277	0.579	rs1780116	ENSG00000272983.1	RP11-508N22.12	4.92	1.2e-06	0.00015	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780121	ENSG00000272983.1	RP11-508N22.12	4.92	1.2e-06	0.00015	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780122	ENSG00000272983.1	RP11-508N22.12	4.92	1.2e-06	0.00015	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780145	ENSG00000272983.1	RP11-508N22.12	4.92	1.2e-06	0.00015	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38137337~38144399:+
THCA	cis	rs17301013	0.761	rs332805	ENSG00000227373.4	RP11-160H22.5	4.92	1.2e-06	0.00015	0.31	0.22	Systemic lupus erythematosus;	chr1:174652487	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.861	rs34819375	ENSG00000227373.4	RP11-160H22.5	4.92	1.2e-06	0.00015	0.31	0.22	Systemic lupus erythematosus;	chr1:174654958	chr1:174115300~174160004:-
THCA	cis	rs800160	1	rs800153	ENSG00000199550.1	Y_RNA	4.92	1.2e-06	0.00015	0.33	0.22	Bacteremia;	chr11:2352285	chr11:2372638~2372750:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000229886.1	RP5-1132H15.3	4.92	1.2e-06	0.00015	0.23	0.22	Aortic root size;	chr7:66376994	chr7:66025126~66031544:-
THCA	cis	rs6121246	0.697	rs6088856	ENSG00000230613.1	HM13-AS1	4.92	1.2e-06	0.00015	0.25	0.22	Mean corpuscular hemoglobin;	chr20:31638740	chr20:31567707~31573263:-
THCA	cis	rs11673344	0.536	rs62108291	ENSG00000267422.1	CTD-2554C21.1	4.92	1.2e-06	0.00015	0.21	0.22	Obesity-related traits;	chr19:37659457	chr19:37779686~37792865:+
THCA	cis	rs10946940	0.897	rs6456801	ENSG00000219392.1	RP1-265C24.5	-4.92	1.2e-06	0.00015	-0.25	-0.22	Systemic lupus erythematosus;	chr6:27657753	chr6:28115628~28116551:+
THCA	cis	rs10923574	0.521	rs6684700	ENSG00000231365.4	RP11-418J17.1	-4.92	1.21e-06	0.000151	-0.22	-0.22	Breast cancer;Folding of antihelix;	chr1:118526165	chr1:119140396~119275973:+
THCA	cis	rs9300255	0.596	rs10773002	ENSG00000256092.2	RP13-942N8.1	-4.92	1.21e-06	0.000151	-0.17	-0.22	Neutrophil percentage of white cells;	chr12:123262414	chr12:123363868~123366113:+
THCA	cis	rs240993	0.715	rs240995	ENSG00000271789.1	RP5-1112D6.7	-4.92	1.21e-06	0.000151	-0.28	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111355310	chr6:111297126~111298510:+
THCA	cis	rs12188164	0.582	rs72700694	ENSG00000188242.4	PP7080	4.92	1.21e-06	0.000151	0.23	0.22	Cystic fibrosis severity;	chr5:483152	chr5:466124~473098:-
THCA	cis	rs75422866	0.764	rs67408202	ENSG00000276691.1	RP5-1057I20.5	4.92	1.21e-06	0.000151	0.39	0.22	Pneumonia;	chr12:47713564	chr12:47788426~47788971:+
THCA	cis	rs12682352	0.579	rs7006589	ENSG00000254153.1	CTA-398F10.2	-4.92	1.21e-06	0.000151	-0.24	-0.22	Neuroticism;	chr8:8810976	chr8:8456909~8461337:-
THCA	cis	rs9376098	1	rs1040441	ENSG00000232876.1	CTA-212D2.2	-4.92	1.21e-06	0.000151	-0.27	-0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135172740	chr6:135055033~135060550:+
THCA	cis	rs4886920	0.692	rs4625694	ENSG00000260776.4	RP11-114H24.2	4.92	1.21e-06	0.000151	0.29	0.22	Neuroticism;	chr15:77826137	chr15:77914217~77926846:-
THCA	cis	rs916888	0.61	rs199446	ENSG00000261575.2	RP11-259G18.1	-4.92	1.21e-06	0.000151	-0.27	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46267037~46268694:+
THCA	cis	rs6545883	0.86	rs6545848	ENSG00000270820.4	RP11-355B11.2	-4.92	1.21e-06	0.000151	-0.18	-0.22	Tuberculosis;	chr2:61234048	chr2:61471188~61484130:+
THCA	cis	rs9393777	0.778	rs4452638	ENSG00000219392.1	RP1-265C24.5	4.92	1.21e-06	0.000151	0.42	0.22	Intelligence (multi-trait analysis);	chr6:27261486	chr6:28115628~28116551:+
THCA	cis	rs793571	0.628	rs1426652	ENSG00000245975.2	RP11-30K9.6	4.92	1.21e-06	0.000151	0.26	0.22	Schizophrenia;	chr15:58764513	chr15:58768072~58770974:-
THCA	cis	rs270601	0.77	rs10463891	ENSG00000224431.1	AC063976.7	-4.92	1.21e-06	0.000151	-0.19	-0.22	Acylcarnitine levels;	chr5:132261699	chr5:132199456~132203487:+
THCA	cis	rs11051970	0.636	rs1045751	ENSG00000274964.1	RP11-817I4.1	-4.92	1.21e-06	0.000151	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32416562	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.636	rs325424	ENSG00000274964.1	RP11-817I4.1	-4.92	1.21e-06	0.000151	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32417259	chr12:32339368~32340724:+
THCA	cis	rs7914558	0.966	rs11191518	ENSG00000236937.2	PTGES3P4	4.92	1.21e-06	0.000151	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:102845595~102845950:+
THCA	cis	rs1979679	0.842	rs11049373	ENSG00000247934.4	RP11-967K21.1	-4.92	1.21e-06	0.000151	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28163298~28190738:-
THCA	cis	rs12893668	0.703	rs2274267	ENSG00000269958.1	RP11-73M18.8	4.92	1.21e-06	0.000151	0.22	0.22	Reticulocyte count;	chr14:103563112	chr14:103696353~103697163:+
THCA	cis	rs6088590	1	rs55753039	ENSG00000276073.1	RP5-1125A11.7	-4.92	1.21e-06	0.000151	-0.21	-0.22	Coronary artery disease;	chr20:34807137	chr20:33985617~33988989:-
THCA	cis	rs73198271	1	rs73198279	ENSG00000253893.2	FAM85B	4.92	1.21e-06	0.000151	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:8167819~8226614:-
THCA	cis	rs1707322	1	rs785507	ENSG00000281133.1	AL355480.3	4.92	1.21e-06	0.000151	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45580892~45580996:-
THCA	cis	rs972578	0.74	rs9611902	ENSG00000274717.1	RP1-47A17.1	-4.92	1.21e-06	0.000151	-0.23	-0.22	Mean platelet volume;	chr22:42793439	chr22:42791814~42794313:-
THCA	cis	rs6860806	0.507	rs2631362	ENSG00000237714.1	P4HA2-AS1	-4.92	1.21e-06	0.000151	-0.3	-0.22	Breast cancer;	chr5:132371601	chr5:132184876~132192808:+
THCA	cis	rs9652601	0.622	rs9935174	ENSG00000274038.1	RP11-66H6.4	-4.92	1.21e-06	0.000151	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11017490	chr16:11056556~11057034:+
THCA	cis	rs7192208	0.541	rs68045879	ENSG00000260922.1	RP11-538I12.3	4.92	1.21e-06	0.000151	0.34	0.22	White matter integrity;	chr16:77289196	chr16:77234877~77290934:+
THCA	cis	rs8091660	0.624	rs8099285	ENSG00000278983.1	RP11-426J5.3	4.92	1.21e-06	0.000151	0.32	0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48551434	chr18:48564795~48568342:+
THCA	cis	rs4713118	0.869	rs6914924	ENSG00000226314.6	ZNF192P1	-4.92	1.21e-06	0.000151	-0.28	-0.22	Parkinson's disease;	chr6:27743751	chr6:28161781~28169594:+
THCA	cis	rs10946940	0.965	rs62401383	ENSG00000219392.1	RP1-265C24.5	4.92	1.21e-06	0.000151	0.25	0.22	Systemic lupus erythematosus;	chr6:27596768	chr6:28115628~28116551:+
THCA	cis	rs853679	0.546	rs200977	ENSG00000280107.1	AL022393.9	-4.92	1.21e-06	0.000151	-0.35	-0.22	Depression;	chr6:27886523	chr6:28170845~28172521:+
THCA	cis	rs4915077	0.892	rs6682419	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107802487	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs12563210	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107803328	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs12563228	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107803472	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs76359608	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107803932	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs80235198	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107804008	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs4396144	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107804038	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs79548971	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107804915	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs78175580	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107805016	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs74225262	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107805140	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs79458835	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107805180	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs78452835	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107805751	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs77477575	ENSG00000230489.1	VAV3-AS1	4.92	1.21e-06	0.000151	0.32	0.22	Hypothyroidism;	chr1:107806170	chr1:107964443~107994607:+
THCA	cis	rs11733284	0.928	rs11736427	ENSG00000259959.1	RP11-121C2.2	4.92	1.21e-06	0.000151	0.19	0.22	Gout;Renal underexcretion gout;	chr4:48037885	chr4:47840122~47844339:-
THCA	cis	rs12893668	0.572	rs4906350	ENSG00000269958.1	RP11-73M18.8	4.92	1.21e-06	0.000151	0.21	0.22	Reticulocyte count;	chr14:103645457	chr14:103696353~103697163:+
THCA	cis	rs7010876	0.561	rs4246112	ENSG00000253553.4	RP11-586K2.1	-4.92	1.21e-06	0.000151	-0.23	-0.22	Schizophrenia;	chr8:88332565	chr8:88326836~88737134:+
THCA	cis	rs2070488	0.775	rs2051213	ENSG00000229589.1	ACVR2B-AS1	4.92	1.21e-06	0.000151	0.2	0.22	Electrocardiographic conduction measures;	chr3:38518763	chr3:38451027~38454820:-
THCA	cis	rs853679	0.882	rs4713140	ENSG00000220721.1	OR1F12	4.92	1.21e-06	0.000151	0.38	0.22	Depression;	chr6:28129415	chr6:28073316~28074233:+
THCA	cis	rs6490294	0.571	rs7970397	ENSG00000226469.1	ADAM1B	4.92	1.21e-06	0.000152	0.33	0.22	Mean platelet volume;	chr12:112142267	chr12:111927018~111929017:+
THCA	cis	rs362272	0.525	rs2857849	ENSG00000249673.5	NOP14-AS1	4.92	1.21e-06	0.000152	0.18	0.22	Serum sulfate level;	chr4:3041911	chr4:2934899~2961738:+
THCA	cis	rs4950322	0.512	rs2353974	ENSG00000278811.3	LINC00624	-4.92	1.21e-06	0.000152	-0.24	-0.22	Protein quantitative trait loci;	chr1:147384534	chr1:147258885~147517875:-
THCA	cis	rs7914558	0.966	rs7908280	ENSG00000236937.2	PTGES3P4	4.92	1.21e-06	0.000152	0.29	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102845595~102845950:+
THCA	cis	rs7577696	0.925	rs12474443	ENSG00000276334.1	AL133243.1	-4.92	1.21e-06	0.000152	-0.23	-0.22	Inflammatory biomarkers;	chr2:32112803	chr2:32521927~32523547:+
THCA	cis	rs763121	0.785	rs5750646	ENSG00000235209.1	CTA-150C2.13	4.92	1.21e-06	0.000152	0.29	0.22	Menopause (age at onset);	chr22:38617825	chr22:38921227~38924708:+
THCA	cis	rs7474896	0.832	rs11523837	ENSG00000263064.2	RP11-291L22.7	4.92	1.21e-06	0.000152	0.38	0.22	Obesity (extreme);	chr10:37811510	chr10:38448689~38448949:+
THCA	cis	rs7432375	0.61	rs60574021	ENSG00000239213.4	NCK1-AS1	4.92	1.21e-06	0.000152	0.19	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136801439	chr3:136841726~136862054:-
THCA	cis	rs1003719	0.646	rs9985082	ENSG00000230366.8	DSCR9	4.92	1.21e-06	0.000152	0.23	0.22	Eye color traits;	chr21:37128721	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.742	rs8129231	ENSG00000230366.8	DSCR9	4.92	1.21e-06	0.000152	0.23	0.22	Eye color traits;	chr21:37128734	chr21:37208503~37221736:+
THCA	cis	rs4578769	0.55	rs12964830	ENSG00000265939.1	UBE2CP2	4.92	1.21e-06	0.000152	0.25	0.22	Eosinophil percentage of white cells;	chr18:22938970	chr18:22900486~22900995:-
THCA	cis	rs16852403	0.519	rs2791604	ENSG00000224687.1	RASAL2-AS1	-4.92	1.21e-06	0.000152	-0.33	-0.22	Childhood ear infection;	chr1:178089771	chr1:178091508~178093984:-
THCA	cis	rs11051970	0.661	rs188979	ENSG00000274964.1	RP11-817I4.1	-4.92	1.21e-06	0.000152	-0.24	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32416750	chr12:32339368~32340724:+
THCA	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-4.92	1.21e-06	0.000152	-0.26	-0.22	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-4.92	1.21e-06	0.000152	-0.26	-0.22	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-4.92	1.21e-06	0.000152	-0.26	-0.22	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-4.92	1.21e-06	0.000152	-0.26	-0.22	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-4.92	1.21e-06	0.000152	-0.26	-0.22	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-4.92	1.21e-06	0.000152	-0.26	-0.22	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
THCA	cis	rs16975963	0.644	rs11083427	ENSG00000226686.6	LINC01535	-4.92	1.22e-06	0.000152	-0.3	-0.22	Longevity;	chr19:37583251	chr19:37251912~37265535:+
THCA	cis	rs4646450	0.891	rs6962772	ENSG00000244219.5	GS1-259H13.2	-4.92	1.22e-06	0.000152	-0.27	-0.22	Blood metabolite levels;	chr7:99484107	chr7:99598066~99610813:+
THCA	cis	rs763121	0.853	rs9607566	ENSG00000228274.3	RP3-508I15.9	-4.92	1.22e-06	0.000152	-0.24	-0.22	Menopause (age at onset);	chr22:38679429	chr22:38667585~38681820:-
THCA	cis	rs9959145	1	rs78874284	ENSG00000267108.1	RP11-861E21.1	4.92	1.22e-06	0.000152	0.27	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12630717	chr18:12432897~12437635:+
THCA	cis	rs763121	0.853	rs6001188	ENSG00000228274.3	RP3-508I15.9	-4.92	1.22e-06	0.000152	-0.24	-0.22	Menopause (age at onset);	chr22:38666189	chr22:38667585~38681820:-
THCA	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-4.92	1.22e-06	0.000152	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-4.92	1.22e-06	0.000152	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
THCA	cis	rs10090774	0.965	rs7008498	ENSG00000279766.1	RP11-642A1.2	-4.92	1.22e-06	0.000152	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140866929	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs9324536	ENSG00000279766.1	RP11-642A1.2	-4.92	1.22e-06	0.000152	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140868315	chr8:140572142~140572812:-
THCA	cis	rs7088591	0.614	rs10491205	ENSG00000276818.1	AC026393.1	4.92	1.22e-06	0.000152	0.36	0.22	Blood pressure;	chr10:58001040	chr10:57095699~57095781:+
THCA	cis	rs6997458	0.742	rs20571	ENSG00000253549.4	RP11-317J10.2	4.92	1.22e-06	0.000152	0.22	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85439768	chr8:85441851~85464915:-
THCA	cis	rs4950322	0.542	rs115179956	ENSG00000226015.2	CCT8P1	4.92	1.22e-06	0.000152	0.24	0.22	Protein quantitative trait loci;	chr1:147172620	chr1:147203276~147204932:-
THCA	cis	rs17772222	1	rs60310240	ENSG00000222990.1	RNU4-22P	4.92	1.22e-06	0.000152	0.29	0.22	Coronary artery calcification;	chr14:88356365	chr14:88513498~88513663:+
THCA	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	4.92	1.22e-06	0.000152	0.27	0.22	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
THCA	cis	rs2977125	0.553	rs17121349	ENSG00000251468.2	RP11-369K16.1	4.92	1.22e-06	0.000152	0.28	0.22	Schizophrenia;	chr8:12881608	chr8:12958387~12962200:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000229886.1	RP5-1132H15.3	4.92	1.22e-06	0.000152	0.26	0.22	Corneal structure;	chr7:66911108	chr7:66025126~66031544:-
THCA	cis	rs440932	1	rs440932	ENSG00000254340.1	RP11-10A14.3	4.92	1.22e-06	0.000152	0.24	0.22	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9141424~9145435:+
THCA	cis	rs3824435	0.744	rs7859554	ENSG00000272866.1	RP11-12D24.10	-4.92	1.22e-06	0.000152	-0.3	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5346774	chr9:5351796~5352410:-
THCA	cis	rs3824435	0.783	rs10815184	ENSG00000272866.1	RP11-12D24.10	-4.92	1.22e-06	0.000152	-0.3	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5346787	chr9:5351796~5352410:-
THCA	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-4.92	1.22e-06	0.000152	-0.25	-0.22	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
THCA	cis	rs17801127	0.688	rs1405215	ENSG00000231969.1	AC144449.1	-4.92	1.22e-06	0.000152	-0.34	-0.22	Liver enzyme levels (alanine transaminase);	chr2:149681890	chr2:149587196~149848233:+
THCA	cis	rs9818758	0.556	rs9814987	ENSG00000270441.1	RP11-694I15.7	4.92	1.22e-06	0.000152	0.31	0.22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49170416	chr3:49140086~49160851:-
THCA	cis	rs11673344	0.542	rs826325	ENSG00000276846.1	CTD-3220F14.3	4.92	1.22e-06	0.000152	0.17	0.22	Obesity-related traits;	chr19:37003580	chr19:37314868~37315620:-
THCA	cis	rs9468186	1	rs9468186	ENSG00000219392.1	RP1-265C24.5	-4.92	1.22e-06	0.000152	-0.27	-0.22	Neuroticism;	chr6:27658852	chr6:28115628~28116551:+
THCA	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-4.92	1.22e-06	0.000152	-0.19	-0.22	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
THCA	cis	rs62025270	0.632	rs17571078	ENSG00000259295.5	CSPG4P12	-4.92	1.22e-06	0.000152	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85191438~85213905:+
THCA	cis	rs8020095	0.571	rs3784074	ENSG00000258561.1	RP11-72M17.1	-4.92	1.22e-06	0.000152	-0.3	-0.22	Depression (quantitative trait);	chr14:66824436	chr14:66212810~66509394:-
THCA	cis	rs3020736	0.5	rs6002603	ENSG00000273366.1	CTA-989H11.1	4.92	1.22e-06	0.000152	0.29	0.22	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42278188~42278846:+
THCA	cis	rs8177376	0.681	rs678422	ENSG00000254905.1	RP11-712L6.7	4.92	1.22e-06	0.000152	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330009	chr11:126292922~126294254:-
THCA	cis	rs7989336	0.585	rs9513121	ENSG00000247400.3	DNAJC3-AS1	4.92	1.22e-06	0.000152	0.15	0.22	Obesity;	chr13:96323011	chr13:95648733~95676925:-
THCA	cis	rs6750795	0.569	rs1667305	ENSG00000223198.1	RNU2-22P	-4.92	1.22e-06	0.000152	-0.28	-0.22	Height;	chr2:231539118	chr2:231501990~231502201:-
THCA	cis	rs11992162	0.933	rs10108075	ENSG00000254948.1	OR7E158P	-4.92	1.22e-06	0.000152	-0.27	-0.22	Monocyte count;	chr8:11974570	chr8:11919900~11920809:-
THCA	cis	rs6708331	0.517	rs13017427	ENSG00000179818.12	PCBP1-AS1	-4.92	1.22e-06	0.000152	-0.18	-0.22	Obesity-related traits;	chr2:70154399	chr2:69962263~70103220:-
THCA	cis	rs6708331	0.54	rs9677885	ENSG00000179818.12	PCBP1-AS1	-4.92	1.22e-06	0.000152	-0.18	-0.22	Obesity-related traits;	chr2:70154687	chr2:69962263~70103220:-
THCA	cis	rs6708331	0.54	rs9679269	ENSG00000179818.12	PCBP1-AS1	-4.92	1.22e-06	0.000152	-0.18	-0.22	Obesity-related traits;	chr2:70154696	chr2:69962263~70103220:-
THCA	cis	rs8049040	0.547	rs12929335	ENSG00000260886.1	TAT-AS1	4.92	1.22e-06	0.000152	0.31	0.22	Blood protein levels;	chr16:71401849	chr16:71565789~71578187:+
THCA	cis	rs9652601	0.622	rs1003603	ENSG00000274038.1	RP11-66H6.4	-4.92	1.22e-06	0.000152	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11020766	chr16:11056556~11057034:+
THCA	cis	rs79243044	0.965	rs7103458	ENSG00000224295.2	AC087380.14	-4.92	1.22e-06	0.000152	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5534595	chr11:5518441~5524955:-
THCA	cis	rs79243044	1	rs7125746	ENSG00000224295.2	AC087380.14	-4.92	1.22e-06	0.000152	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5534775	chr11:5518441~5524955:-
THCA	cis	rs79243044	1	rs11037984	ENSG00000224295.2	AC087380.14	-4.92	1.22e-06	0.000152	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5535432	chr11:5518441~5524955:-
THCA	cis	rs79243044	0.965	rs11037985	ENSG00000224295.2	AC087380.14	-4.92	1.22e-06	0.000152	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5535490	chr11:5518441~5524955:-
THCA	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-4.92	1.22e-06	0.000152	-0.25	-0.22	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
THCA	cis	rs11955398	0.502	rs4700406	ENSG00000272308.1	RP11-231G3.1	-4.92	1.22e-06	0.000152	-0.23	-0.22	Intelligence (multi-trait analysis);	chr5:61070048	chr5:60866457~60866935:-
THCA	cis	rs4819052	0.851	rs2838864	ENSG00000273796.1	LL21NC02-21A1.1	4.92	1.22e-06	0.000152	0.23	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45403809~45404369:-
THCA	cis	rs9329221	0.683	rs688491	ENSG00000248538.5	RP11-10A14.5	4.92	1.22e-06	0.000153	0.27	0.22	Neuroticism;	chr8:10027313	chr8:9189011~9202854:+
THCA	cis	rs10510102	0.935	rs11200218	ENSG00000226864.1	ATE1-AS1	4.92	1.22e-06	0.000153	0.36	0.22	Breast cancer;	chr10:121886410	chr10:121928312~121951965:+
THCA	cis	rs75920871	0.609	rs1473177	ENSG00000254851.1	RP11-109L13.1	-4.92	1.22e-06	0.000153	-0.49	-0.22	Subjective well-being;	chr11:116888616	chr11:117135528~117138582:+
THCA	cis	rs35740288	0.822	rs2306225	ENSG00000259295.5	CSPG4P12	4.92	1.22e-06	0.000153	0.35	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85684721	chr15:85191438~85213905:+
THCA	cis	rs1707322	1	rs2458400	ENSG00000281133.1	AL355480.3	4.92	1.22e-06	0.000153	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45580892~45580996:-
THCA	cis	rs72843506	0.586	rs76886618	ENSG00000261033.1	RP11-209D14.2	4.92	1.22e-06	0.000153	0.44	0.22	Schizophrenia;	chr17:19975483	chr17:20008051~20009234:-
THCA	cis	rs5742933	0.597	rs6756913	ENSG00000253559.1	OSGEPL1-AS1	4.92	1.22e-06	0.000153	0.26	0.22	Ferritin levels;	chr2:189641040	chr2:189762704~189765556:+
THCA	cis	rs7924176	0.521	rs61863363	ENSG00000213731.2	RAB5CP1	-4.92	1.22e-06	0.000153	-0.27	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:74423435~74424014:-
THCA	cis	rs875971	0.522	rs1617484	ENSG00000275400.1	RP4-756H11.5	-4.92	1.22e-06	0.000153	-0.21	-0.22	Aortic root size;	chr7:65998108	chr7:66553805~66554199:-
THCA	cis	rs17767392	0.958	rs34480562	ENSG00000259146.3	RP1-261D10.2	4.92	1.22e-06	0.000153	0.28	0.22	Mitral valve prolapse;	chr14:71513007	chr14:71292729~71321814:-
THCA	cis	rs228614	0.51	rs170565	ENSG00000248971.2	KRT8P46	-4.92	1.22e-06	0.000153	-0.28	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102728746~102730171:-
THCA	cis	rs28829049	0.536	rs2073105	ENSG00000270728.1	RP4-657E11.10	-4.92	1.22e-06	0.000153	-0.17	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19223370	chr1:19297080~19297903:+
THCA	cis	rs1552244	0.748	rs113890152	ENSG00000180385.7	EMC3-AS1	4.92	1.22e-06	0.000153	0.25	0.22	Alzheimer's disease;	chr3:10044302	chr3:9986893~10006990:+
THCA	cis	rs7122539	0.506	rs11227625	ENSG00000275484.1	CTC-1337H24.4	-4.92	1.22e-06	0.000153	-0.16	-0.22	HIV-1 susceptibility;	chr11:66916680	chr11:67374416~67374932:+
THCA	cis	rs9487094	0.67	rs10782163	ENSG00000223537.2	RP5-919F19.5	-4.92	1.22e-06	0.000153	-0.22	-0.22	Height;	chr6:109533040	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs10457195	ENSG00000223537.2	RP5-919F19.5	-4.92	1.22e-06	0.000153	-0.22	-0.22	Height;	chr6:109534269	chr6:109487906~109506800:+
THCA	cis	rs8002861	0.87	rs12865116	ENSG00000274001.1	RP11-5G9.5	-4.92	1.22e-06	0.000153	-0.27	-0.22	Leprosy;	chr13:43866305	chr13:43877715~43878163:-
THCA	cis	rs34845616	0.52	rs1793680	ENSG00000280237.1	MIR4697HG	4.92	1.22e-06	0.000153	0.2	0.22	Hand grip strength;	chr11:133928867	chr11:133896438~133901601:-
THCA	cis	rs295490	1	rs397940	ENSG00000272656.1	RP11-219D15.3	-4.92	1.23e-06	0.000153	-0.31	-0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520429	chr3:139349024~139349371:-
THCA	cis	rs4604234	0.522	rs79603875	ENSG00000272129.1	RP11-250B2.6	-4.92	1.23e-06	0.000153	-0.55	-0.22	Cancer;	chr6:80243177	chr6:80355424~80356859:+
THCA	cis	rs4698412	0.646	rs4698120	ENSG00000214846.4	RP11-115L11.1	-4.92	1.23e-06	0.000153	-0.27	-0.22	Parkinson's disease;	chr4:15741709	chr4:15730962~15731627:-
THCA	cis	rs13256369	0.511	rs7012395	ENSG00000254153.1	CTA-398F10.2	4.92	1.23e-06	0.000153	0.24	0.22	Obesity-related traits;	chr8:8680499	chr8:8456909~8461337:-
THCA	cis	rs73242632	0.881	rs7654665	ENSG00000269949.1	RP11-738E22.3	4.92	1.23e-06	0.000153	0.56	0.22	Congenital heart disease (maternal effect);	chr4:57057608	chr4:56960927~56961373:-
THCA	cis	rs911119	1	rs13039536	ENSG00000270001.1	RP11-218C14.8	-4.92	1.23e-06	0.000153	-0.34	-0.22	Chronic kidney disease;	chr20:23631668	chr20:23631826~23632316:-
THCA	cis	rs7824557	0.872	rs2572431	ENSG00000154316.13	TDH	4.92	1.23e-06	0.000153	0.15	0.22	Retinal vascular caliber;	chr8:11247568	chr8:11339637~11368452:+
THCA	cis	rs1003719	0.715	rs9980353	ENSG00000230366.8	DSCR9	4.92	1.23e-06	0.000153	0.23	0.22	Eye color traits;	chr21:37186511	chr21:37208503~37221736:+
THCA	cis	rs227275	0.526	rs223497	ENSG00000248971.2	KRT8P46	-4.92	1.23e-06	0.000153	-0.27	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102728746~102730171:-
THCA	cis	rs2154319	0.609	rs12139276	ENSG00000235358.1	RP11-399E6.1	-4.92	1.23e-06	0.000153	-0.29	-0.22	Height;	chr1:41249201	chr1:41242373~41284861:+
THCA	cis	rs5758511	0.68	rs5758686	ENSG00000281538.1	RP4-669P10.20	-4.92	1.23e-06	0.000153	-0.25	-0.22	Birth weight;	chr22:42259371	chr22:42138060~42139726:+
THCA	cis	rs4415084	0.716	rs6868232	ENSG00000272335.1	RP11-53O19.3	-4.91	1.23e-06	0.000153	-0.19	-0.22	Breast cancer;	chr5:44827578	chr5:44826076~44828592:+
THCA	cis	rs6545883	0.825	rs4672426	ENSG00000270820.4	RP11-355B11.2	-4.91	1.23e-06	0.000153	-0.18	-0.22	Tuberculosis;	chr2:61230013	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.86	rs4671399	ENSG00000270820.4	RP11-355B11.2	-4.91	1.23e-06	0.000153	-0.18	-0.22	Tuberculosis;	chr2:61231383	chr2:61471188~61484130:+
THCA	cis	rs957448	1	rs60655325	ENSG00000253175.1	RP11-267M23.6	4.91	1.23e-06	0.000153	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94565036~94565715:+
THCA	cis	rs2803122	1	rs2803122	ENSG00000273226.1	RP11-513M16.8	4.91	1.23e-06	0.000153	0.2	0.22	Pulse pressure;	chr9:19334017	chr9:19375451~19375996:+
THCA	cis	rs6012564	0.964	rs6125577	ENSG00000227431.4	CSE1L-AS1	4.91	1.23e-06	0.000153	0.27	0.22	Anger;	chr20:49166558	chr20:49040463~49046044:-
THCA	cis	rs7924176	0.549	rs2395076	ENSG00000213731.2	RAB5CP1	-4.91	1.23e-06	0.000153	-0.26	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.601	rs7089391	ENSG00000213731.2	RAB5CP1	-4.91	1.23e-06	0.000153	-0.26	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74423435~74424014:-
THCA	cis	rs7924176	0.601	rs7093532	ENSG00000213731.2	RAB5CP1	-4.91	1.23e-06	0.000153	-0.26	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74423435~74424014:-
THCA	cis	rs1129187	0.755	rs9471988	ENSG00000272223.1	RP1-20C7.6	4.91	1.23e-06	0.000153	0.17	0.22	Alzheimer's disease in APOE e4+ carriers;	chr6:42977035	chr6:43033897~43034405:-
THCA	cis	rs736408	0.648	rs2268023	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.23e-06	0.000154	-0.24	-0.22	Bipolar disorder;	chr3:52785311	chr3:52239258~52241097:+
THCA	cis	rs595244	1	rs363820	ENSG00000259705.1	RP11-227D13.1	-4.91	1.23e-06	0.000154	-0.36	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48436833	chr15:48645951~48652016:+
THCA	cis	rs6044112	0.784	rs17674942	ENSG00000273998.1	RP4-777L9.2	4.91	1.23e-06	0.000154	0.34	0.22	Response to taxane treatment (docetaxel);	chr20:16532671	chr20:16576068~16579615:+
THCA	cis	rs12681288	0.644	rs2600494	ENSG00000260721.1	AF067845.1	4.91	1.23e-06	0.000154	0.27	0.22	Schizophrenia;	chr8:1075517	chr8:1368642~1369833:-
THCA	cis	rs7614311	0.731	rs3774727	ENSG00000271843.1	RP11-245J9.5	-4.91	1.23e-06	0.000154	-0.39	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63992199	chr3:64008082~64008692:-
THCA	cis	rs11671005	0.693	rs11668821	ENSG00000265272.2	RN7SL693P	4.91	1.23e-06	0.000154	0.31	0.22	Mean platelet volume;	chr19:58444446	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.616	rs12980907	ENSG00000265272.2	RN7SL693P	4.91	1.23e-06	0.000154	0.31	0.22	Mean platelet volume;	chr19:58444959	chr19:58490797~58491075:+
THCA	cis	rs375066	0.935	rs421512	ENSG00000278917.1	RP11-15A1.4	-4.91	1.23e-06	0.000154	-0.18	-0.22	Breast cancer;	chr19:43911428	chr19:43891233~43895411:+
THCA	cis	rs3796352	0.764	rs11714902	ENSG00000242142.1	SERBP1P3	-4.91	1.23e-06	0.000154	-0.41	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53067528	chr3:53064283~53065091:-
THCA	cis	rs9959145	0.929	rs113240057	ENSG00000267108.1	RP11-861E21.1	4.91	1.23e-06	0.000154	0.27	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12693707	chr18:12432897~12437635:+
THCA	cis	rs763121	0.853	rs2284073	ENSG00000228274.3	RP3-508I15.9	-4.91	1.23e-06	0.000154	-0.24	-0.22	Menopause (age at onset);	chr22:38709943	chr22:38667585~38681820:-
THCA	cis	rs454422	1	rs2326680	ENSG00000275632.1	RP5-967N21.11	4.91	1.23e-06	0.000154	0.22	0.22	HIV-1 viral setpoint;	chr20:5962309	chr20:6000418~6000941:+
THCA	cis	rs454422	1	rs409035	ENSG00000275632.1	RP5-967N21.11	4.91	1.23e-06	0.000154	0.22	0.22	HIV-1 viral setpoint;	chr20:5963003	chr20:6000418~6000941:+
THCA	cis	rs4698412	0.531	rs6852450	ENSG00000214846.4	RP11-115L11.1	-4.91	1.23e-06	0.000154	-0.27	-0.22	Parkinson's disease;	chr4:15741363	chr4:15730962~15731627:-
THCA	cis	rs2797160	1	rs1832938	ENSG00000237742.5	RP11-624M8.1	-4.91	1.23e-06	0.000154	-0.19	-0.22	Endometrial cancer;	chr6:125667818	chr6:125578558~125749190:-
THCA	cis	rs10090774	0.965	rs11785111	ENSG00000279766.1	RP11-642A1.2	-4.91	1.23e-06	0.000154	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140852463	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs13282141	ENSG00000279766.1	RP11-642A1.2	-4.91	1.23e-06	0.000154	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140852692	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13253993	ENSG00000279766.1	RP11-642A1.2	-4.91	1.23e-06	0.000154	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140857417	chr8:140572142~140572812:-
THCA	cis	rs3820928	0.874	rs1917123	ENSG00000212391.1	SNORA48	-4.91	1.23e-06	0.000154	-0.24	-0.22	Pulmonary function;	chr2:227025067	chr2:226968989~226969122:-
THCA	cis	rs72945132	0.825	rs72947052	ENSG00000254604.1	AP000487.6	-4.91	1.24e-06	0.000154	-0.43	-0.22	Coronary artery disease;	chr11:70342469	chr11:70282367~70363368:-
THCA	cis	rs13113518	0.966	rs11133387	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55475130	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs4864999	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55476736	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs12506788	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55477426	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs10517344	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55477545	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs10462032	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55479069	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs12501636	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55482317	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs6858803	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55484534	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13114841	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55485974	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs939823	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55487368	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs6838882	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55489310	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13146987	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55491628	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs7677085	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55495801	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs12510681	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55496737	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs12500162	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55496933	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.934	rs3805155	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55497842	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs7686261	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55500224	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11729220	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55501629	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11133390	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55501726	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11133391	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55501788	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs13133484	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55504176	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.934	rs13127906	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55504201	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs6849433	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55506498	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs12501327	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55507248	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11133392	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55507729	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs6838305	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55508587	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.902	rs12503578	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55509367	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs3828480	ENSG00000273257.1	RP11-177J6.1	4.91	1.24e-06	0.000154	0.29	0.22	Height;	chr4:55510352	chr4:55387949~55388271:+
THCA	cis	rs7267979	1	rs6050547	ENSG00000274973.1	RP13-401N8.7	4.91	1.24e-06	0.000154	0.25	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25845497~25845862:+
THCA	cis	rs1979679	0.842	rs7139154	ENSG00000247934.4	RP11-967K21.1	-4.91	1.24e-06	0.000154	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28181603	chr12:28163298~28190738:-
THCA	cis	rs1383484	0.545	rs9329363	ENSG00000259728.4	LINC00933	-4.91	1.24e-06	0.000154	-0.26	-0.22	Height;	chr15:83974382	chr15:84570649~84580175:+
THCA	cis	rs10090774	0.965	rs7831770	ENSG00000279766.1	RP11-642A1.2	-4.91	1.24e-06	0.000154	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140990088	chr8:140572142~140572812:-
THCA	cis	rs11073619	0.616	rs113031444	ENSG00000230373.7	GOLGA6L5P	-4.91	1.24e-06	0.000154	-0.36	-0.22	Positive affect;	chr15:84391590	chr15:84507885~84516814:-
THCA	cis	rs13126694	0.617	rs10008900	ENSG00000248429.4	RP11-597D13.9	4.91	1.24e-06	0.000154	0.24	0.22	Blood osmolality (transformed sodium);	chr4:157948827	chr4:158170752~158202877:+
THCA	cis	rs6903823	0.508	rs1150721	ENSG00000273712.1	RP5-874C20.7	4.91	1.24e-06	0.000154	0.25	0.22	Pulmonary function;	chr6:28287263	chr6:28315613~28315883:-
THCA	cis	rs6903823	0.508	rs1233660	ENSG00000273712.1	RP5-874C20.7	4.91	1.24e-06	0.000154	0.25	0.22	Pulmonary function;	chr6:28292472	chr6:28315613~28315883:-
THCA	cis	rs17123764	0.818	rs1902330	ENSG00000257464.1	RP11-161H23.8	-4.91	1.24e-06	0.000154	-0.38	-0.22	Intelligence (multi-trait analysis);	chr12:49546170	chr12:49442424~49442652:-
THCA	cis	rs2408955	0.522	rs10875721	ENSG00000273765.1	RP11-370I10.11	-4.91	1.24e-06	0.000154	-0.23	-0.22	Glycated hemoglobin levels;	chr12:48019810	chr12:48360920~48361377:+
THCA	cis	rs1005277	0.579	rs2474587	ENSG00000275858.1	RP11-291L22.8	4.91	1.24e-06	0.000154	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474588	ENSG00000275858.1	RP11-291L22.8	4.91	1.24e-06	0.000154	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38450738~38451069:-
THCA	cis	rs150992	0.504	rs7719562	ENSG00000248489.1	CTD-2007H13.3	-4.91	1.24e-06	0.000154	-0.24	-0.22	Body mass index;	chr5:99029419	chr5:98929171~98995013:+
THCA	cis	rs150992	0.504	rs4583911	ENSG00000248489.1	CTD-2007H13.3	-4.91	1.24e-06	0.000154	-0.24	-0.22	Body mass index;	chr5:99031401	chr5:98929171~98995013:+
THCA	cis	rs11673344	0.504	rs11084874	ENSG00000276846.1	CTD-3220F14.3	4.91	1.24e-06	0.000154	0.17	0.22	Obesity-related traits;	chr19:37096667	chr19:37314868~37315620:-
THCA	cis	rs11073619	0.892	rs12442117	ENSG00000230373.7	GOLGA6L5P	-4.91	1.24e-06	0.000154	-0.33	-0.22	Positive affect;	chr15:84634667	chr15:84507885~84516814:-
THCA	cis	rs7208859	0.623	rs122898	ENSG00000280069.1	CTD-2349P21.3	4.91	1.24e-06	0.000154	0.34	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30738182~30740275:+
THCA	cis	rs4218	0.859	rs755786	ENSG00000259732.1	RP11-59H7.3	-4.91	1.24e-06	0.000154	-0.3	-0.22	Social communication problems;	chr15:59118456	chr15:59121034~59133250:+
THCA	cis	rs8027521	0.905	rs2711593	ENSG00000280362.1	RP11-643A5.3	-4.91	1.24e-06	0.000154	-0.26	-0.22	Circulating chemerin levels;	chr15:53976632	chr15:53910769~53914712:+
THCA	cis	rs7246657	0.524	rs35080624	ENSG00000226686.6	LINC01535	-4.91	1.24e-06	0.000154	-0.39	-0.22	Coronary artery calcification;	chr19:36965680	chr19:37251912~37265535:+
THCA	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-4.91	1.24e-06	0.000155	-0.26	-0.22	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
THCA	cis	rs12823128	0.766	rs4436638	ENSG00000256185.1	RP11-612B6.2	4.91	1.24e-06	0.000155	0.21	0.22	Birth weight;	chr12:26758356	chr12:26335864~26336950:-
THCA	cis	rs9652601	0.622	rs2286973	ENSG00000274038.1	RP11-66H6.4	-4.91	1.24e-06	0.000155	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11060913	chr16:11056556~11057034:+
THCA	cis	rs1003719	0.788	rs9974286	ENSG00000230366.8	DSCR9	4.91	1.24e-06	0.000155	0.22	0.22	Eye color traits;	chr21:37084532	chr21:37208503~37221736:+
THCA	cis	rs8028182	0.609	rs8038760	ENSG00000260269.4	CTD-2323K18.1	-4.91	1.24e-06	0.000155	-0.33	-0.22	Sudden cardiac arrest;	chr15:75449754	chr15:75527150~75601205:-
THCA	cis	rs75920871	0.764	rs17120347	ENSG00000254851.1	RP11-109L13.1	-4.91	1.24e-06	0.000155	-0.46	-0.22	Subjective well-being;	chr11:117125823	chr11:117135528~117138582:+
THCA	cis	rs17597773	0.755	rs4431850	ENSG00000238078.1	LINC01352	-4.91	1.24e-06	0.000155	-0.33	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220847172	chr1:220829255~220832429:+
THCA	cis	rs4663866	1	rs4663300	ENSG00000186235.9	AC016757.3	4.91	1.24e-06	0.000155	0.46	0.22	Irritable bowel syndrome;	chr2:238272850	chr2:238224552~238231677:-
THCA	cis	rs4663866	1	rs13033501	ENSG00000186235.9	AC016757.3	4.91	1.24e-06	0.000155	0.46	0.22	Irritable bowel syndrome;	chr2:238273219	chr2:238224552~238231677:-
THCA	cis	rs4819052	0.851	rs28442024	ENSG00000273796.1	LL21NC02-21A1.1	-4.91	1.24e-06	0.000155	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45403809~45404369:-
THCA	cis	rs1707322	1	rs6677777	ENSG00000281133.1	AL355480.3	-4.91	1.24e-06	0.000155	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45580892~45580996:-
THCA	cis	rs73198271	1	rs11775821	ENSG00000253893.2	FAM85B	4.91	1.24e-06	0.000155	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8167819~8226614:-
THCA	cis	rs710913	0.966	rs3738676	ENSG00000182109.6	RP11-69E11.4	4.91	1.24e-06	0.000155	0.2	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39525916	chr1:39522280~39546187:-
THCA	cis	rs7474896	1	rs10827829	ENSG00000263064.2	RP11-291L22.7	4.91	1.24e-06	0.000155	0.36	0.22	Obesity (extreme);	chr10:37815354	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs9418298	ENSG00000263064.2	RP11-291L22.7	4.91	1.24e-06	0.000155	0.36	0.22	Obesity (extreme);	chr10:37848308	chr10:38448689~38448949:+
THCA	cis	rs7208859	0.673	rs3764420	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.24e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30738182~30740275:+
THCA	cis	rs17005891	0.73	rs6535363	ENSG00000270480.1	RP11-57B24.1	4.91	1.24e-06	0.000155	0.33	0.22	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82641416	chr4:82691737~82692468:+
THCA	cis	rs1048886	0.938	rs2842063	ENSG00000271967.1	RP11-134K13.4	-4.91	1.24e-06	0.000155	-0.22	-0.22	Type 2 diabetes;	chr6:70528674	chr6:70596438~70596980:+
THCA	cis	rs8028313	0.731	rs7172055	ENSG00000270964.1	RP11-502I4.3	-4.91	1.24e-06	0.000155	-0.19	-0.22	Obesity;	chr15:67645996	chr15:67541072~67542604:-
THCA	cis	rs11671005	0.735	rs3826684	ENSG00000268049.1	CTD-2619J13.9	-4.91	1.24e-06	0.000155	-0.34	-0.22	Mean platelet volume;	chr19:58407338	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs3826683	ENSG00000268049.1	CTD-2619J13.9	-4.91	1.24e-06	0.000155	-0.34	-0.22	Mean platelet volume;	chr19:58407366	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs3826681	ENSG00000268049.1	CTD-2619J13.9	-4.91	1.24e-06	0.000155	-0.34	-0.22	Mean platelet volume;	chr19:58407397	chr19:58357999~58359603:+
THCA	cis	rs1979679	0.553	rs10459088	ENSG00000278733.1	RP11-425D17.1	4.91	1.24e-06	0.000155	0.21	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28115920	chr12:28185625~28186190:-
THCA	cis	rs1979679	0.608	rs1581075	ENSG00000247934.4	RP11-967K21.1	4.91	1.24e-06	0.000155	0.23	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28570992	chr12:28163298~28190738:-
THCA	cis	rs6832769	0.961	rs6824955	ENSG00000272969.1	RP11-528I4.2	4.91	1.25e-06	0.000155	0.26	0.22	Personality dimensions;	chr4:55450969	chr4:55547112~55547889:+
THCA	cis	rs72843506	0.656	rs73981807	ENSG00000261033.1	RP11-209D14.2	4.91	1.25e-06	0.000155	0.4	0.22	Schizophrenia;	chr17:20092917	chr17:20008051~20009234:-
THCA	cis	rs7674212	0.54	rs2720469	ENSG00000251288.2	RP11-10L12.2	-4.91	1.25e-06	0.000155	-0.28	-0.22	Type 2 diabetes;	chr4:103165327	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.57	rs12501621	ENSG00000251288.2	RP11-10L12.2	-4.91	1.25e-06	0.000155	-0.28	-0.22	Type 2 diabetes;	chr4:103174348	chr4:102751401~102752641:+
THCA	cis	rs12823128	0.609	rs10842785	ENSG00000256185.1	RP11-612B6.2	4.91	1.25e-06	0.000155	0.2	0.22	Birth weight;	chr12:26755943	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.646	rs12299331	ENSG00000256185.1	RP11-612B6.2	4.91	1.25e-06	0.000155	0.2	0.22	Birth weight;	chr12:26756559	chr12:26335864~26336950:-
THCA	cis	rs1577917	0.629	rs9450285	ENSG00000220563.1	PKMP3	4.91	1.25e-06	0.000155	0.16	0.22	Response to antipsychotic treatment;	chr6:85498378	chr6:85659892~85660606:-
THCA	cis	rs6939532	0.597	rs2273558	ENSG00000124549.13	BTN2A3P	-4.91	1.25e-06	0.000155	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26465807	chr6:26421391~26432383:+
THCA	cis	rs8105895	0.935	rs7259971	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22054517	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs6511316	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22054827	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10406553	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22054999	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10406653	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22055221	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10407250	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22055349	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10412953	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22055680	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs4510150	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22056867	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs4542784	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22056949	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs4257328	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22057288	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10404669	ENSG00000269345.1	VN1R85P	4.91	1.25e-06	0.000155	0.29	0.22	Body mass index (change over time);	chr19:22058416	chr19:22174766~22175191:-
THCA	cis	rs72615157	0.645	rs76281814	ENSG00000242294.5	STAG3L5P	4.91	1.25e-06	0.000155	0.14	0.22	Lung function (FEV1/FVC);	chr7:100248791	chr7:100336079~100351900:+
THCA	cis	rs72615157	0.595	rs112241539	ENSG00000242294.5	STAG3L5P	4.91	1.25e-06	0.000155	0.14	0.22	Lung function (FEV1/FVC);	chr7:100249614	chr7:100336079~100351900:+
THCA	cis	rs9840812	0.596	rs571513	ENSG00000239213.4	NCK1-AS1	4.91	1.25e-06	0.000155	0.21	0.22	Fibrinogen levels;	chr3:136376193	chr3:136841726~136862054:-
THCA	cis	rs16975963	0.644	rs12459013	ENSG00000226686.6	LINC01535	-4.91	1.25e-06	0.000155	-0.29	-0.22	Longevity;	chr19:37638596	chr19:37251912~37265535:+
THCA	cis	rs17270561	0.609	rs1317817	ENSG00000272462.2	U91328.19	-4.91	1.25e-06	0.000155	-0.18	-0.22	Iron status biomarkers;	chr6:25765149	chr6:25992662~26001775:+
THCA	cis	rs79349575	0.721	rs9904645	ENSG00000270781.1	RP11-501C14.9	-4.91	1.25e-06	0.000155	-0.27	-0.22	Type 2 diabetes;	chr17:48892303	chr17:48899131~48899748:+
THCA	cis	rs7208859	0.673	rs11651802	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs17826219	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs61223749	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs3764421	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11651858	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs36056619	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9909497	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11080135	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9894876	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73277967	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs60020217	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.573	rs73277974	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73277978	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.706	rs9905827	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Body mass index;	chr17:30865150	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11657391	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs58089675	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73263755	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9899349	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11652358	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11656845	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9891179	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9891413	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73263776	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11650271	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11657270	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73263785	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs55904046	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9889968	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs61348930	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.614	rs28758251	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9899943	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11080138	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73265612	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11658435	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73265624	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs2269915	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs2269916	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs11649765	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000155	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30738182~30740275:+
THCA	cis	rs1003719	0.715	rs2835649	ENSG00000230366.8	DSCR9	-4.91	1.25e-06	0.000155	-0.22	-0.22	Eye color traits;	chr21:37179928	chr21:37208503~37221736:+
THCA	cis	rs4713118	0.505	rs156740	ENSG00000273712.1	RP5-874C20.7	4.91	1.25e-06	0.000155	0.24	0.22	Parkinson's disease;	chr6:27992657	chr6:28315613~28315883:-
THCA	cis	rs763121	0.853	rs35565791	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000155	-0.24	-0.22	Menopause (age at onset);	chr22:38667006	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs35522482	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000155	-0.24	-0.22	Menopause (age at onset);	chr22:38667010	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2072796	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000155	-0.24	-0.22	Menopause (age at onset);	chr22:38668225	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2281019	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000155	-0.24	-0.22	Menopause (age at onset);	chr22:38668373	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2281020	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000155	-0.24	-0.22	Menopause (age at onset);	chr22:38668401	chr22:38667585~38681820:-
THCA	cis	rs240993	0.812	rs460594	ENSG00000271789.1	RP5-1112D6.7	-4.91	1.25e-06	0.000155	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111348602	chr6:111297126~111298510:+
THCA	cis	rs72945132	0.882	rs947781	ENSG00000254604.1	AP000487.6	-4.91	1.25e-06	0.000155	-0.41	-0.22	Coronary artery disease;	chr11:70366649	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs58039907	ENSG00000254604.1	AP000487.6	-4.91	1.25e-06	0.000155	-0.41	-0.22	Coronary artery disease;	chr11:70337230	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs11235953	ENSG00000254604.1	AP000487.6	-4.91	1.25e-06	0.000155	-0.41	-0.22	Coronary artery disease;	chr11:70338831	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs1061328	ENSG00000254604.1	AP000487.6	-4.91	1.25e-06	0.000155	-0.41	-0.22	Coronary artery disease;	chr11:70339219	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs3900797	ENSG00000254604.1	AP000487.6	-4.91	1.25e-06	0.000155	-0.41	-0.22	Coronary artery disease;	chr11:70340508	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.769	rs680571	ENSG00000254604.1	AP000487.6	-4.91	1.25e-06	0.000155	-0.41	-0.22	Coronary artery disease;	chr11:70341335	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs3133179	ENSG00000254604.1	AP000487.6	-4.91	1.25e-06	0.000155	-0.41	-0.22	Coronary artery disease;	chr11:70341468	chr11:70282367~70363368:-
THCA	cis	rs7208859	0.673	rs78799101	ENSG00000280069.1	CTD-2349P21.3	-4.91	1.25e-06	0.000156	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30738182~30740275:+
THCA	cis	rs1823913	0.637	rs10931497	ENSG00000280083.1	RP11-317J9.1	4.91	1.25e-06	0.000156	0.25	0.22	Obesity-related traits;	chr2:191306254	chr2:191154118~191156070:-
THCA	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-4.91	1.25e-06	0.000156	-0.12	-0.22	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
THCA	cis	rs1836229	0.594	rs10118318	ENSG00000225706.1	PTPRD-AS1	-4.91	1.25e-06	0.000156	-0.26	-0.22	Restless legs syndrome;	chr9:8828297	chr9:8858130~8862255:+
THCA	cis	rs801193	0.967	rs3800823	ENSG00000224316.1	RP11-479O9.2	-4.91	1.25e-06	0.000156	-0.25	-0.22	Aortic root size;	chr7:66682123	chr7:65773620~65802067:+
THCA	cis	rs2562456	0.833	rs55920089	ENSG00000268119.4	CTD-2561J22.5	4.91	1.25e-06	0.000156	0.31	0.22	Pain;	chr19:21337891	chr19:21444241~21463908:-
THCA	cis	rs1009077	0.68	rs62319609	ENSG00000245958.5	RP11-33B1.1	4.91	1.25e-06	0.000156	0.29	0.22	Endometriosis;	chr4:119570485	chr4:119454791~119552025:+
THCA	cis	rs4604234	0.522	rs74614428	ENSG00000272129.1	RP11-250B2.6	-4.91	1.25e-06	0.000156	-0.54	-0.22	Cancer;	chr6:80200459	chr6:80355424~80356859:+
THCA	cis	rs763121	0.853	rs5757232	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000156	-0.24	-0.22	Menopause (age at onset);	chr22:38675672	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs9306329	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000156	-0.24	-0.22	Menopause (age at onset);	chr22:38676449	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5750662	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000156	-0.24	-0.22	Menopause (age at onset);	chr22:38676467	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5750664	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000156	-0.24	-0.22	Menopause (age at onset);	chr22:38676764	chr22:38667585~38681820:-
THCA	cis	rs763121	0.626	rs5757236	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000156	-0.24	-0.22	Menopause (age at onset);	chr22:38677819	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs6001191	ENSG00000228274.3	RP3-508I15.9	-4.91	1.25e-06	0.000156	-0.24	-0.22	Menopause (age at onset);	chr22:38678447	chr22:38667585~38681820:-
THCA	cis	rs2662776	0.521	rs2815268	ENSG00000232995.6	RGS5	-4.91	1.25e-06	0.000156	-0.18	-0.22	Lead levels in blood;	chr1:163190945	chr1:163244505~163321894:-
THCA	cis	rs8177376	0.727	rs645852	ENSG00000254905.1	RP11-712L6.7	4.91	1.25e-06	0.000156	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327509	chr11:126292922~126294254:-
THCA	cis	rs8177376	0.727	rs646775	ENSG00000254905.1	RP11-712L6.7	4.91	1.25e-06	0.000156	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327704	chr11:126292922~126294254:-
THCA	cis	rs7726839	0.507	rs111707179	ENSG00000225138.6	CTD-2228K2.7	4.91	1.25e-06	0.000156	0.28	0.22	Obesity-related traits;	chr5:593193	chr5:473236~480884:+
THCA	cis	rs4415084	0.652	rs10060645	ENSG00000272335.1	RP11-53O19.3	4.91	1.25e-06	0.000156	0.19	0.22	Breast cancer;	chr5:44908097	chr5:44826076~44828592:+
THCA	cis	rs1552244	0.507	rs6443274	ENSG00000232901.1	CYCSP10	4.91	1.25e-06	0.000156	0.26	0.22	Alzheimer's disease;	chr3:9953604	chr3:10000647~10000940:-
THCA	cis	rs17301013	0.896	rs332773	ENSG00000227373.4	RP11-160H22.5	4.91	1.25e-06	0.000156	0.31	0.22	Systemic lupus erythematosus;	chr1:174695711	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs444678	ENSG00000227373.4	RP11-160H22.5	4.91	1.25e-06	0.000156	0.31	0.22	Systemic lupus erythematosus;	chr1:174706080	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.896	rs332791	ENSG00000227373.4	RP11-160H22.5	4.91	1.25e-06	0.000156	0.31	0.22	Systemic lupus erythematosus;	chr1:174709784	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs332795	ENSG00000227373.4	RP11-160H22.5	4.91	1.25e-06	0.000156	0.31	0.22	Systemic lupus erythematosus;	chr1:174726785	chr1:174115300~174160004:-
THCA	cis	rs4950322	0.542	rs4950382	ENSG00000226015.2	CCT8P1	4.91	1.25e-06	0.000156	0.24	0.22	Protein quantitative trait loci;	chr1:147176645	chr1:147203276~147204932:-
THCA	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-4.91	1.25e-06	0.000156	-0.23	-0.22	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
THCA	cis	rs72843506	0.528	rs73981803	ENSG00000231258.2	ZSWIM5P2	4.91	1.25e-06	0.000156	0.33	0.22	Schizophrenia;	chr17:20088952	chr17:20583758~20591180:-
THCA	cis	rs9558942	1	rs1927754	ENSG00000277863.1	RP11-282A11.4	-4.91	1.25e-06	0.000156	-0.29	-0.22	Obesity-related traits;	chr13:107051597	chr13:106903150~106904099:-
THCA	cis	rs752010	0.967	rs2038978	ENSG00000230638.4	RP11-486B10.4	-4.91	1.25e-06	0.000156	-0.24	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41629048	chr1:41542069~41544310:+
THCA	cis	rs6012564	1	rs6012564	ENSG00000227431.4	CSE1L-AS1	4.91	1.25e-06	0.000156	0.27	0.22	Anger;	chr20:48925063	chr20:49040463~49046044:-
THCA	cis	rs35740288	0.787	rs2291047	ENSG00000259295.5	CSPG4P12	4.91	1.25e-06	0.000156	0.35	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682574	chr15:85191438~85213905:+
THCA	cis	rs4761702	1	rs4761702	ENSG00000257322.4	RP11-511B23.2	-4.91	1.25e-06	0.000156	-0.29	-0.22	Immature fraction of reticulocytes;	chr12:93316116	chr12:93003415~93215679:-
THCA	cis	rs72945132	0.882	rs67283107	ENSG00000254604.1	AP000487.6	-4.91	1.25e-06	0.000156	-0.41	-0.22	Coronary artery disease;	chr11:70375098	chr11:70282367~70363368:-
THCA	cis	rs6088590	1	rs6119512	ENSG00000269202.1	RP4-614O4.12	-4.91	1.25e-06	0.000156	-0.2	-0.22	Coronary artery disease;	chr20:34719100	chr20:35201747~35203288:-
THCA	cis	rs1150668	0.799	rs9301	ENSG00000176933.5	TOB2P1	-4.91	1.25e-06	0.000156	-0.24	-0.22	Pubertal anthropometrics;	chr6:28324929	chr6:28217643~28218634:-
THCA	cis	rs138880	0.542	rs9616210	ENSG00000260613.1	RP3-522J7.6	-4.91	1.25e-06	0.000156	-0.39	-0.22	Schizophrenia;	chr22:49923698	chr22:49832616~49837786:-
THCA	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-4.91	1.25e-06	0.000156	-0.26	-0.22	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
THCA	cis	rs17772222	0.56	rs3742681	ENSG00000222990.1	RNU4-22P	-4.91	1.25e-06	0.000156	-0.27	-0.22	Coronary artery calcification;	chr14:88554903	chr14:88513498~88513663:+
THCA	cis	rs7474896	1	rs3824584	ENSG00000263064.2	RP11-291L22.7	4.91	1.25e-06	0.000156	0.37	0.22	Obesity (extreme);	chr10:37802381	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs12763409	ENSG00000263064.2	RP11-291L22.7	4.91	1.25e-06	0.000156	0.37	0.22	Obesity (extreme);	chr10:37803762	chr10:38448689~38448949:+
THCA	cis	rs4824093	0.544	rs73443957	ENSG00000278869.1	CITF22-49E9.3	4.91	1.26e-06	0.000156	0.38	0.22	Amyotrophic lateral sclerosis (sporadic);	chr22:49911867	chr22:49933198~49934074:-
THCA	cis	rs4934494	0.677	rs11185780	ENSG00000232936.4	RP11-80H5.2	-4.91	1.26e-06	0.000156	-0.3	-0.22	Red blood cell count;	chr10:89603867	chr10:89645282~89650667:+
THCA	cis	rs11779988	0.545	rs398806	ENSG00000253671.1	RP11-806O11.1	-4.91	1.26e-06	0.000156	-0.29	-0.22	Breast cancer;	chr8:17928717	chr8:17808941~17820868:+
THCA	cis	rs11779988	0.545	rs438873	ENSG00000253671.1	RP11-806O11.1	-4.91	1.26e-06	0.000156	-0.29	-0.22	Breast cancer;	chr8:17929007	chr8:17808941~17820868:+
THCA	cis	rs7542375	0.534	rs1580685	ENSG00000238078.1	LINC01352	-4.91	1.26e-06	0.000156	-0.32	-0.22	Obesity-related traits;	chr1:220849052	chr1:220829255~220832429:+
THCA	cis	rs11671005	0.61	rs3794966	ENSG00000269600.1	AC016629.3	-4.91	1.26e-06	0.000156	-0.32	-0.22	Mean platelet volume;	chr19:58557629	chr19:58593896~58599355:-
THCA	cis	rs9527	0.637	rs7085104	ENSG00000213061.2	PFN1P11	4.91	1.26e-06	0.000156	0.27	0.22	Arsenic metabolism;	chr10:102869116	chr10:102838011~102845473:-
THCA	cis	rs2880765	0.706	rs7172006	ENSG00000259630.2	CTD-2262B20.1	-4.91	1.26e-06	0.000156	-0.24	-0.22	Coronary artery disease;	chr15:85510128	chr15:85415228~85415633:+
THCA	cis	rs11779988	0.545	rs415840	ENSG00000253671.1	RP11-806O11.1	-4.91	1.26e-06	0.000156	-0.29	-0.22	Breast cancer;	chr8:17924625	chr8:17808941~17820868:+
THCA	cis	rs7772486	0.658	rs9403737	ENSG00000270638.1	RP3-466P17.1	4.91	1.26e-06	0.000156	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs4896832	ENSG00000270638.1	RP3-466P17.1	4.91	1.26e-06	0.000156	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145735570~145737218:+
THCA	cis	rs228614	0.51	rs223353	ENSG00000248971.2	KRT8P46	-4.91	1.26e-06	0.000156	-0.27	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223352	ENSG00000248971.2	KRT8P46	-4.91	1.26e-06	0.000156	-0.27	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102728746~102730171:-
THCA	cis	rs11089937	0.667	rs9622981	ENSG00000211639.2	IGLV4-60	4.91	1.26e-06	0.000156	0.17	0.22	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22162199~22162681:+
THCA	cis	rs3213758	0.588	rs78389273	ENSG00000275191.1	RP11-36I17.2	-4.91	1.26e-06	0.000157	-0.37	-0.22	Vitiligo (non-segmental);	chr16:53529901	chr16:53628256~53628816:-
THCA	cis	rs957448	1	rs16916874	ENSG00000253175.1	RP11-267M23.6	4.91	1.26e-06	0.000157	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94565036~94565715:+
THCA	cis	rs6600671	0.934	rs11249431	ENSG00000226067.5	CH17-118O6.2	-4.91	1.26e-06	0.000157	-0.23	-0.22	Hip geometry;	chr1:121544405	chr1:120913275~121009291:+
THCA	cis	rs7260598	0.539	rs74825083	ENSG00000268442.1	CTD-2027I19.2	4.91	1.26e-06	0.000157	0.34	0.22	Response to taxane treatment (placlitaxel);	chr19:23876705	chr19:24162370~24163425:-
THCA	cis	rs57221529	0.766	rs17563576	ENSG00000225138.6	CTD-2228K2.7	4.91	1.26e-06	0.000157	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:560361	chr5:473236~480884:+
THCA	cis	rs972578	0.765	rs5751402	ENSG00000274717.1	RP1-47A17.1	-4.91	1.26e-06	0.000157	-0.23	-0.22	Mean platelet volume;	chr22:42915517	chr22:42791814~42794313:-
THCA	cis	rs1075232	1	rs72722829	ENSG00000215302.7	CTD-3092A11.1	-4.91	1.26e-06	0.000157	-0.5	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30470779~30507623:+
THCA	cis	rs1075232	1	rs16956707	ENSG00000215302.7	CTD-3092A11.1	-4.91	1.26e-06	0.000157	-0.5	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30470779~30507623:+
THCA	cis	rs1552244	0.608	rs6764807	ENSG00000232901.1	CYCSP10	4.91	1.26e-06	0.000157	0.26	0.22	Alzheimer's disease;	chr3:9957119	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs34391585	ENSG00000232901.1	CYCSP10	4.91	1.26e-06	0.000157	0.26	0.22	Alzheimer's disease;	chr3:9957524	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.515	rs7613004	ENSG00000232901.1	CYCSP10	4.91	1.26e-06	0.000157	0.26	0.22	Alzheimer's disease;	chr3:9958229	chr3:10000647~10000940:-
THCA	cis	rs72843506	0.656	rs9911879	ENSG00000231258.2	ZSWIM5P2	4.91	1.26e-06	0.000157	0.33	0.22	Schizophrenia;	chr17:20086829	chr17:20583758~20591180:-
THCA	cis	rs7615952	0.611	rs35321002	ENSG00000248787.1	RP11-666A20.4	-4.91	1.26e-06	0.000157	-0.42	-0.22	Blood pressure (smoking interaction);	chr3:125893222	chr3:125908005~125910272:-
THCA	cis	rs7980687	0.628	rs1727332	ENSG00000256092.2	RP13-942N8.1	4.91	1.26e-06	0.000157	0.17	0.22	Head circumference (infant);Educational attainment;Height;	chr12:123233754	chr12:123363868~123366113:+
THCA	cis	rs8050907	0.744	rs7194436	ENSG00000278434.1	RP11-709D24.8	-4.91	1.26e-06	0.000157	-0.49	-0.22	Obesity-related traits;	chr16:4489831	chr16:4532216~4533670:-
THCA	cis	rs8028182	0.636	rs7175852	ENSG00000260269.4	CTD-2323K18.1	-4.91	1.26e-06	0.000157	-0.33	-0.22	Sudden cardiac arrest;	chr15:75402194	chr15:75527150~75601205:-
THCA	cis	rs4660456	0.564	rs34320811	ENSG00000272145.1	NFYC-AS1	4.91	1.26e-06	0.000157	0.16	0.22	Platelet count;	chr1:40763288	chr1:40690380~40692066:-
THCA	cis	rs8177876	0.822	rs56198248	ENSG00000261061.1	RP11-303E16.2	-4.91	1.26e-06	0.000157	-0.39	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074869	chr16:81030770~81031485:+
THCA	cis	rs17301013	0.861	rs332770	ENSG00000227373.4	RP11-160H22.5	4.91	1.26e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174681511	chr1:174115300~174160004:-
THCA	cis	rs853679	0.527	rs853693	ENSG00000273712.1	RP5-874C20.7	4.91	1.26e-06	0.000157	0.25	0.22	Depression;	chr6:28314871	chr6:28315613~28315883:-
THCA	cis	rs10090774	0.804	rs4355822	ENSG00000279766.1	RP11-642A1.2	4.91	1.26e-06	0.000157	0.27	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140736225	chr8:140572142~140572812:-
THCA	cis	rs438465	0.73	rs9294997	ENSG00000226194.4	RP1-137D17.1	4.91	1.26e-06	0.000157	0.34	0.22	Corneal astigmatism;	chr6:169380518	chr6:169369998~169388385:-
THCA	cis	rs34779708	0.966	rs12765038	ENSG00000271335.4	RP11-324I22.4	4.91	1.26e-06	0.000157	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs2045917	ENSG00000271335.4	RP11-324I22.4	4.91	1.26e-06	0.000157	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35314552~35336401:-
THCA	cis	rs9973361	1	rs9973361	ENSG00000232411.1	AC009495.3	-4.91	1.26e-06	0.000157	-0.28	-0.22	Total body bone mineral density;	chr2:165859989	chr2:165833048~165839098:-
THCA	cis	rs17301013	0.932	rs10912807	ENSG00000227373.4	RP11-160H22.5	4.91	1.26e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174547228	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.9	rs56347239	ENSG00000227373.4	RP11-160H22.5	4.91	1.26e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174564476	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs7542389	ENSG00000227373.4	RP11-160H22.5	4.91	1.26e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174565104	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs12074753	ENSG00000227373.4	RP11-160H22.5	4.91	1.26e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174565768	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs1016466	ENSG00000227373.4	RP11-160H22.5	4.91	1.26e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174570652	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs10753086	ENSG00000227373.4	RP11-160H22.5	4.91	1.26e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174580802	chr1:174115300~174160004:-
THCA	cis	rs8020095	0.571	rs7142669	ENSG00000258561.1	RP11-72M17.1	-4.91	1.26e-06	0.000157	-0.3	-0.22	Depression (quantitative trait);	chr14:66783674	chr14:66212810~66509394:-
THCA	cis	rs9863	0.931	rs6488914	ENSG00000269997.1	RP11-214K3.21	4.91	1.26e-06	0.000157	0.27	0.22	White blood cell count;	chr12:123963294	chr12:123966077~123966629:-
THCA	cis	rs875971	0.54	rs781152	ENSG00000229886.1	RP5-1132H15.3	4.91	1.26e-06	0.000157	0.23	0.22	Aortic root size;	chr7:66014585	chr7:66025126~66031544:-
THCA	cis	rs17711722	0.727	rs781151	ENSG00000229886.1	RP5-1132H15.3	4.91	1.26e-06	0.000157	0.23	0.22	Calcium levels;	chr7:66014891	chr7:66025126~66031544:-
THCA	cis	rs1383484	0.575	rs8028946	ENSG00000225151.9	GOLGA2P7	4.91	1.26e-06	0.000157	0.29	0.22	Height;	chr15:83948325	chr15:84199311~84230136:-
THCA	cis	rs62292953	0.79	rs10935013	ENSG00000248724.5	NPHP3-AS1	-4.91	1.26e-06	0.000157	-0.4	-0.22	Red cell distribution width;	chr3:132509091	chr3:132721750~132874223:+
THCA	cis	rs1003719	0.715	rs9981715	ENSG00000230366.8	DSCR9	4.91	1.26e-06	0.000157	0.23	0.22	Eye color traits;	chr21:37127310	chr21:37208503~37221736:+
THCA	cis	rs1075265	0.509	rs10201938	ENSG00000272156.1	RP11-477N3.1	4.91	1.26e-06	0.000157	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53728352	chr2:54082554~54085066:+
THCA	cis	rs72843506	0.656	rs73981807	ENSG00000231258.2	ZSWIM5P2	4.91	1.26e-06	0.000157	0.33	0.22	Schizophrenia;	chr17:20092917	chr17:20583758~20591180:-
THCA	cis	rs9925964	0.967	rs14235	ENSG00000260911.2	RP11-196G11.2	-4.91	1.26e-06	0.000157	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31110472	chr16:31043150~31049868:+
THCA	cis	rs9973361	0.55	rs10930185	ENSG00000232411.1	AC009495.3	-4.91	1.27e-06	0.000157	-0.27	-0.22	Total body bone mineral density;	chr2:165852469	chr2:165833048~165839098:-
THCA	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-4.91	1.27e-06	0.000157	-0.29	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
THCA	cis	rs763121	0.853	rs138705	ENSG00000273076.1	RP3-508I15.22	4.91	1.27e-06	0.000157	0.23	0.22	Menopause (age at onset);	chr22:38737798	chr22:38743495~38743910:+
THCA	cis	rs911555	0.655	rs10141157	ENSG00000269910.1	RP11-73M18.10	4.91	1.27e-06	0.000157	0.2	0.22	Intelligence (multi-trait analysis);	chr14:103551768	chr14:103694516~103695050:-
THCA	cis	rs7688540	0.8	rs1578898	ENSG00000275426.1	CH17-262A2.1	4.91	1.27e-06	0.000157	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:149738~150317:+
THCA	cis	rs1048886	0.808	rs6455369	ENSG00000271967.1	RP11-134K13.4	-4.91	1.27e-06	0.000157	-0.22	-0.22	Type 2 diabetes;	chr6:70528850	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.808	rs4496758	ENSG00000271967.1	RP11-134K13.4	-4.91	1.27e-06	0.000157	-0.22	-0.22	Type 2 diabetes;	chr6:70530390	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.745	rs9283835	ENSG00000271967.1	RP11-134K13.4	-4.91	1.27e-06	0.000157	-0.22	-0.22	Type 2 diabetes;	chr6:70533649	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9294876	ENSG00000271967.1	RP11-134K13.4	-4.91	1.27e-06	0.000157	-0.22	-0.22	Type 2 diabetes;	chr6:70541718	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs6942012	ENSG00000271967.1	RP11-134K13.4	-4.91	1.27e-06	0.000157	-0.22	-0.22	Type 2 diabetes;	chr6:70543769	chr6:70596438~70596980:+
THCA	cis	rs7474896	1	rs2295872	ENSG00000263064.2	RP11-291L22.7	4.91	1.27e-06	0.000157	0.36	0.22	Obesity (extreme);	chr10:37857290	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2738219	ENSG00000263064.2	RP11-291L22.7	-4.91	1.27e-06	0.000157	-0.36	-0.22	Obesity (extreme);	chr10:37869332	chr10:38448689~38448949:+
THCA	cis	rs17301013	0.932	rs727279	ENSG00000227373.4	RP11-160H22.5	4.91	1.27e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174496026	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.794	rs6425283	ENSG00000227373.4	RP11-160H22.5	4.91	1.27e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174499853	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs2072760	ENSG00000227373.4	RP11-160H22.5	4.91	1.27e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174510186	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs10912797	ENSG00000227373.4	RP11-160H22.5	4.91	1.27e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174511225	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs6668053	ENSG00000227373.4	RP11-160H22.5	4.91	1.27e-06	0.000157	0.31	0.22	Systemic lupus erythematosus;	chr1:174515139	chr1:174115300~174160004:-
THCA	cis	rs11673344	0.504	rs7245882	ENSG00000276846.1	CTD-3220F14.3	-4.91	1.27e-06	0.000158	-0.17	-0.22	Obesity-related traits;	chr19:37089513	chr19:37314868~37315620:-
THCA	cis	rs2154319	0.609	rs3899207	ENSG00000235358.1	RP11-399E6.1	-4.91	1.27e-06	0.000158	-0.29	-0.22	Height;	chr1:41256005	chr1:41242373~41284861:+
THCA	cis	rs7403037	0.617	rs11634882	ENSG00000259905.4	PWRN1	-4.91	1.27e-06	0.000158	-0.29	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24493092	chr15:24493137~24652130:+
THCA	cis	rs72615157	0.634	rs7789890	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000158	-0.29	-0.22	Lung function (FEV1/FVC);	chr7:100202936	chr7:100320992~100341908:-
THCA	cis	rs72615157	0.634	rs79986079	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000158	-0.29	-0.22	Lung function (FEV1/FVC);	chr7:100204421	chr7:100320992~100341908:-
THCA	cis	rs2051773	0.567	rs12794156	ENSG00000184669.7	OR7E14P	-4.91	1.27e-06	0.000158	-0.31	-0.22	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17041458	chr11:17013998~17053024:+
THCA	cis	rs72843506	0.656	rs9911879	ENSG00000261033.1	RP11-209D14.2	4.91	1.27e-06	0.000158	0.4	0.22	Schizophrenia;	chr17:20086829	chr17:20008051~20009234:-
THCA	cis	rs916888	0.61	rs199438	ENSG00000261575.2	RP11-259G18.1	4.91	1.27e-06	0.000158	0.27	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46267037~46268694:+
THCA	cis	rs79243044	1	rs10838291	ENSG00000224295.2	AC087380.14	-4.91	1.27e-06	0.000158	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5538996	chr11:5518441~5524955:-
THCA	cis	rs728616	0.681	rs117420340	ENSG00000242600.5	MBL1P	4.91	1.27e-06	0.000158	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406739	chr10:79904898~79950336:+
THCA	cis	rs10895322	0.656	rs2280211	ENSG00000281655.1	RP11-817J15.3	-4.91	1.27e-06	0.000158	-0.28	-0.22	Neuroblastoma (11q deletion);	chr11:102617400	chr11:102681310~102683913:+
THCA	cis	rs4767841	0.935	rs3956827	ENSG00000248636.5	RP11-768F21.1	-4.91	1.27e-06	0.000158	-0.23	-0.22	Urgency urinary incontinence;	chr12:119751727	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.935	rs904655	ENSG00000248636.5	RP11-768F21.1	-4.91	1.27e-06	0.000158	-0.23	-0.22	Urgency urinary incontinence;	chr12:119752074	chr12:119387987~119668079:-
THCA	cis	rs889122	0.68	rs1077220	ENSG00000267289.1	CTD-2623N2.11	-4.91	1.27e-06	0.000158	-0.28	-0.22	Menarche (age at onset);	chr19:9836241	chr19:9834079~9835013:-
THCA	cis	rs453301	0.624	rs330060	ENSG00000248538.5	RP11-10A14.5	4.91	1.27e-06	0.000158	0.27	0.22	Joint mobility (Beighton score);	chr8:9233392	chr8:9189011~9202854:+
THCA	cis	rs7085104	0.66	rs7902804	ENSG00000213061.2	PFN1P11	4.91	1.27e-06	0.000158	0.26	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102838011~102845473:-
THCA	cis	rs11665867	0.887	rs113614917	ENSG00000279108.1	CTC-490E21.11	-4.91	1.27e-06	0.000158	-0.32	-0.22	Hematocrit;	chr19:40814070	chr19:40840159~40842039:+
THCA	cis	rs1494961	0.523	rs28798169	ENSG00000213608.5	SLC25A14P1	-4.91	1.27e-06	0.000158	-0.26	-0.22	Oral cavity and pharyngeal cancer;	chr4:83521337	chr4:83477524~83478424:+
THCA	cis	rs3213758	0.643	rs58340747	ENSG00000275191.1	RP11-36I17.2	-4.91	1.27e-06	0.000158	-0.46	-0.22	Vitiligo (non-segmental);	chr16:53705675	chr16:53628256~53628816:-
THCA	cis	rs11779988	0.545	rs431961	ENSG00000253671.1	RP11-806O11.1	-4.91	1.27e-06	0.000158	-0.28	-0.22	Breast cancer;	chr8:17928695	chr8:17808941~17820868:+
THCA	cis	rs10208649	0.831	rs77308271	ENSG00000233266.1	HMGB1P31	4.91	1.27e-06	0.000158	0.6	0.22	Body mass index;	chr2:54075827	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.831	rs75447473	ENSG00000233266.1	HMGB1P31	4.91	1.27e-06	0.000158	0.6	0.22	Body mass index;	chr2:54077507	chr2:54051334~54051760:+
THCA	cis	rs6088590	1	rs11698977	ENSG00000269202.1	RP4-614O4.12	-4.91	1.27e-06	0.000158	-0.2	-0.22	Coronary artery disease;	chr20:34861888	chr20:35201747~35203288:-
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000273796.1	LL21NC02-21A1.1	-4.91	1.27e-06	0.000158	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45403809~45404369:-
THCA	cis	rs2645424	0.866	rs2645426	ENSG00000255046.1	RP11-297N6.4	-4.91	1.27e-06	0.000158	-0.23	-0.22	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11825262	chr8:11797928~11802568:-
THCA	cis	rs73242632	0.881	rs7699276	ENSG00000269949.1	RP11-738E22.3	4.91	1.27e-06	0.000158	0.56	0.22	Congenital heart disease (maternal effect);	chr4:57057391	chr4:56960927~56961373:-
THCA	cis	rs72843506	0.656	rs16960678	ENSG00000261033.1	RP11-209D14.2	4.91	1.27e-06	0.000158	0.4	0.22	Schizophrenia;	chr17:20080378	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs73984571	ENSG00000261033.1	RP11-209D14.2	4.91	1.27e-06	0.000158	0.4	0.22	Schizophrenia;	chr17:20080746	chr17:20008051~20009234:-
THCA	cis	rs11992162	1	rs12334769	ENSG00000206014.6	OR7E161P	-4.91	1.27e-06	0.000158	-0.26	-0.22	Monocyte count;	chr8:11975652	chr8:11928597~11929563:-
THCA	cis	rs7394190	0.935	rs6480708	ENSG00000271848.1	RP11-464F9.21	-4.91	1.27e-06	0.000158	-0.27	-0.22	Incident atrial fibrillation;	chr10:73660356	chr10:73654039~73674719:+
THCA	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	4.91	1.27e-06	0.000158	0.27	0.22	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
THCA	cis	rs2288884	0.559	rs8104890	ENSG00000269483.1	AC006272.1	4.91	1.27e-06	0.000158	0.26	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:51839924~51843324:-
THCA	cis	rs7474896	0.559	rs1212108	ENSG00000226578.1	RP11-258F22.1	-4.91	1.27e-06	0.000158	-0.32	-0.22	Obesity (extreme);	chr10:37805394	chr10:37775371~37784131:-
THCA	cis	rs4415084	0.618	rs6872254	ENSG00000272335.1	RP11-53O19.3	-4.91	1.27e-06	0.000158	-0.19	-0.22	Breast cancer;	chr5:44803682	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs13174122	ENSG00000272335.1	RP11-53O19.3	-4.91	1.27e-06	0.000158	-0.19	-0.22	Breast cancer;	chr5:44810638	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs930394	ENSG00000272335.1	RP11-53O19.3	-4.91	1.27e-06	0.000158	-0.19	-0.22	Breast cancer;	chr5:44822515	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs12513749	ENSG00000272335.1	RP11-53O19.3	-4.91	1.27e-06	0.000158	-0.19	-0.22	Breast cancer;	chr5:44828101	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs16901989	ENSG00000272335.1	RP11-53O19.3	4.91	1.27e-06	0.000158	0.19	0.22	Breast cancer;	chr5:44837027	chr5:44826076~44828592:+
THCA	cis	rs6860806	0.507	rs272878	ENSG00000237714.1	P4HA2-AS1	-4.91	1.27e-06	0.000158	-0.29	-0.22	Breast cancer;	chr5:132336076	chr5:132184876~132192808:+
THCA	cis	rs224278	0.782	rs192007	ENSG00000238280.1	RP11-436D10.3	4.91	1.27e-06	0.000158	0.27	0.22	Ewing sarcoma;	chr10:62826635	chr10:62793562~62805887:-
THCA	cis	rs7074356	0.831	rs12764048	ENSG00000242600.5	MBL1P	4.91	1.27e-06	0.000158	0.28	0.22	Borderline personality disorder;	chr10:80389207	chr10:79904898~79950336:+
THCA	cis	rs728616	0.558	rs61859215	ENSG00000242600.5	MBL1P	4.91	1.27e-06	0.000158	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391392	chr10:79904898~79950336:+
THCA	cis	rs728616	0.558	rs72817596	ENSG00000242600.5	MBL1P	4.91	1.27e-06	0.000158	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391838	chr10:79904898~79950336:+
THCA	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-4.91	1.27e-06	0.000158	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
THCA	cis	rs7554547	0.714	rs4845890	ENSG00000199347.1	RNU5E-1	-4.91	1.27e-06	0.000158	-0.3	-0.22	Nonsyndromic cleft lip with cleft palate;	chr1:11912612	chr1:11908152~11908271:+
THCA	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-4.91	1.27e-06	0.000158	-0.13	-0.22	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
THCA	cis	rs17508449	0.732	rs75746385	ENSG00000232450.1	RP4-730K3.3	-4.91	1.27e-06	0.000158	-0.34	-0.22	Leprosy;	chr1:113758270	chr1:113698884~113699631:-
THCA	cis	rs79349575	0.721	rs3744608	ENSG00000270781.1	RP11-501C14.9	-4.91	1.27e-06	0.000158	-0.27	-0.22	Type 2 diabetes;	chr17:48915871	chr17:48899131~48899748:+
THCA	cis	rs930395	0.514	rs34115673	ENSG00000272335.1	RP11-53O19.3	4.91	1.27e-06	0.000158	0.19	0.22	Breast cancer;	chr5:44892699	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs10035358	ENSG00000272335.1	RP11-53O19.3	4.91	1.27e-06	0.000158	0.19	0.22	Breast cancer;	chr5:44892800	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs13154729	ENSG00000272335.1	RP11-53O19.3	4.91	1.27e-06	0.000158	0.19	0.22	Breast cancer;	chr5:44892827	chr5:44826076~44828592:+
THCA	cis	rs8028313	0.63	rs12438118	ENSG00000270964.1	RP11-502I4.3	4.91	1.28e-06	0.000159	0.19	0.22	Obesity;	chr15:67658812	chr15:67541072~67542604:-
THCA	cis	rs1005277	0.579	rs2474571	ENSG00000275858.1	RP11-291L22.8	4.91	1.28e-06	0.000159	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38450738~38451069:-
THCA	cis	rs2243480	0.803	rs423187	ENSG00000232559.3	GS1-124K5.12	4.91	1.28e-06	0.000159	0.33	0.22	Diabetic kidney disease;	chr7:66044512	chr7:66554588~66576923:-
THCA	cis	rs1211375	0.607	rs1203978	ENSG00000206168.1	Z69890.1	4.91	1.28e-06	0.000159	0.23	0.22	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:231134~231472:+
THCA	cis	rs7474896	0.537	rs1208591	ENSG00000226578.1	RP11-258F22.1	-4.91	1.28e-06	0.000159	-0.31	-0.22	Obesity (extreme);	chr10:37923574	chr10:37775371~37784131:-
THCA	cis	rs911555	0.755	rs17841064	ENSG00000244691.1	RPL10AP1	-4.91	1.28e-06	0.000159	-0.3	-0.22	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103412119~103412761:-
THCA	cis	rs72945132	0.882	rs7129843	ENSG00000254604.1	AP000487.6	-4.91	1.28e-06	0.000159	-0.41	-0.22	Coronary artery disease;	chr11:70334275	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7123602	ENSG00000254604.1	AP000487.6	-4.91	1.28e-06	0.000159	-0.41	-0.22	Coronary artery disease;	chr11:70335383	chr11:70282367~70363368:-
THCA	cis	rs2253762	0.54	rs4752631	ENSG00000226864.1	ATE1-AS1	4.91	1.28e-06	0.000159	0.35	0.22	Breast cancer;	chr10:121996442	chr10:121928312~121951965:+
THCA	cis	rs2253762	0.54	rs11200313	ENSG00000226864.1	ATE1-AS1	4.91	1.28e-06	0.000159	0.35	0.22	Breast cancer;	chr10:121996523	chr10:121928312~121951965:+
THCA	cis	rs1577917	0.655	rs9444352	ENSG00000220563.1	PKMP3	4.91	1.28e-06	0.000159	0.16	0.22	Response to antipsychotic treatment;	chr6:85547817	chr6:85659892~85660606:-
THCA	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-4.91	1.28e-06	0.000159	-0.24	-0.22	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
THCA	cis	rs10510102	1	rs7923678	ENSG00000226864.1	ATE1-AS1	4.91	1.28e-06	0.000159	0.34	0.22	Breast cancer;	chr10:121832546	chr10:121928312~121951965:+
THCA	cis	rs9527	0.637	rs11191424	ENSG00000213061.2	PFN1P11	4.91	1.28e-06	0.000159	0.27	0.22	Arsenic metabolism;	chr10:102866129	chr10:102838011~102845473:-
THCA	cis	rs11846409	0.86	rs1974470	ENSG00000211974.3	IGHV2-70	-4.91	1.28e-06	0.000159	-0.22	-0.22	Rheumatic heart disease;	chr14:106621300	chr14:106723574~106724093:-
THCA	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-4.91	1.28e-06	0.000159	-0.24	-0.22	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
THCA	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-4.91	1.28e-06	0.000159	-0.24	-0.22	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
THCA	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-4.91	1.28e-06	0.000159	-0.24	-0.22	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
THCA	cis	rs6058796	1	rs13042452	ENSG00000175730.8	BAK1P1	4.91	1.28e-06	0.000159	0.33	0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32652266	chr20:32690180~32690815:-
THCA	cis	rs3892630	0.878	rs11878394	ENSG00000267567.1	CTD-2538C1.3	4.91	1.28e-06	0.000159	0.34	0.22	Red blood cell traits;	chr19:32714938	chr19:32718298~32719595:-
THCA	cis	rs12935418	0.672	rs12448656	ENSG00000278985.1	RP11-303E16.9	4.91	1.28e-06	0.000159	0.25	0.22	Mean corpuscular volume;	chr16:81008876	chr16:80982319~80984094:-
THCA	cis	rs1395	1	rs3769143	ENSG00000234072.1	AC074117.10	4.91	1.28e-06	0.000159	0.18	0.22	Blood metabolite levels;	chr2:27227856	chr2:27356246~27367622:+
THCA	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	4.91	1.28e-06	0.000159	0.27	0.22	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
THCA	cis	rs6714710	0.663	rs71429376	ENSG00000230606.9	AC159540.1	-4.91	1.28e-06	0.000159	-0.24	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97917949	chr2:97416165~97433527:-
THCA	cis	rs2251381	0.778	rs722013	ENSG00000176054.6	RPL23P2	4.91	1.28e-06	0.000159	0.2	0.22	Selective IgA deficiency;	chr21:29176924	chr21:28997613~28998033:-
THCA	cis	rs6921919	0.583	rs6908137	ENSG00000280107.1	AL022393.9	-4.91	1.28e-06	0.000159	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.615	rs9295747	ENSG00000216915.2	RP1-97D16.1	4.91	1.28e-06	0.000159	0.31	0.22	Parkinson's disease;	chr6:27769214	chr6:27737000~27738494:-
THCA	cis	rs9890032	0.618	rs1979507	ENSG00000264538.5	SUZ12P1	-4.91	1.28e-06	0.000159	-0.16	-0.22	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30709299~30790908:+
THCA	cis	rs17767392	0.788	rs7155259	ENSG00000259146.3	RP1-261D10.2	4.91	1.28e-06	0.000159	0.29	0.22	Mitral valve prolapse;	chr14:71231373	chr14:71292729~71321814:-
THCA	cis	rs651907	0.557	rs34181125	ENSG00000244119.1	PDCL3P4	4.91	1.28e-06	0.000159	0.2	0.22	Colorectal cancer;	chr3:101771434	chr3:101712472~101713191:+
THCA	cis	rs853679	1	rs1679732	ENSG00000220721.1	OR1F12	-4.91	1.28e-06	0.000159	-0.35	-0.22	Depression;	chr6:28253486	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.868	rs10484401	ENSG00000226314.6	ZNF192P1	4.91	1.28e-06	0.000159	0.29	0.22	Parkinson's disease;	chr6:27778811	chr6:28161781~28169594:+
THCA	cis	rs11673344	0.504	rs4806409	ENSG00000276846.1	CTD-3220F14.3	4.91	1.28e-06	0.000159	0.17	0.22	Obesity-related traits;	chr19:37097923	chr19:37314868~37315620:-
THCA	cis	rs11894081	0.948	rs2083015	ENSG00000232835.1	AC107057.1	4.91	1.28e-06	0.000159	0.23	0.22	Crohn's disease;	chr2:5523441	chr2:5549780~5556031:-
THCA	cis	rs7618915	0.547	rs3755806	ENSG00000243224.1	RP5-1157M23.2	4.91	1.28e-06	0.000159	0.24	0.22	Bipolar disorder;	chr3:52609669	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.571	rs6805539	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52575694	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs68021750	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52590753	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs62253700	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52591003	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs13085331	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52593470	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.508	rs12498066	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52593644	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs2164884	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52595617	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.57	rs4687633	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52596532	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs62253703	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52598341	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.524	rs10433615	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52604466	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs3774365	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52608471	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs13065019	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52651228	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs2590846	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.28e-06	0.000159	-0.24	-0.22	Bipolar disorder;	chr3:52658343	chr3:52239258~52241097:+
THCA	cis	rs72945132	0.769	rs3781645	ENSG00000254604.1	AP000487.6	-4.91	1.28e-06	0.000159	-0.41	-0.22	Coronary artery disease;	chr11:70344268	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs11235967	ENSG00000254604.1	AP000487.6	-4.91	1.28e-06	0.000159	-0.41	-0.22	Coronary artery disease;	chr11:70345585	chr11:70282367~70363368:-
THCA	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-4.91	1.28e-06	0.000159	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
THCA	cis	rs9813712	0.595	rs1453239	ENSG00000249846.5	RP11-77P16.4	-4.91	1.28e-06	0.000159	-0.23	-0.22	Response to amphetamines;	chr3:130288915	chr3:130112550~130120579:+
THCA	cis	rs934734	0.725	rs7581149	ENSG00000281920.1	RP11-418H16.1	4.91	1.28e-06	0.00016	0.28	0.22	Rheumatoid arthritis;	chr2:65332507	chr2:65623272~65628424:+
THCA	cis	rs10946940	1	rs10946940	ENSG00000219392.1	RP1-265C24.5	4.91	1.28e-06	0.00016	0.25	0.22	Systemic lupus erythematosus;	chr6:27592808	chr6:28115628~28116551:+
THCA	cis	rs7474896	0.526	rs1208716	ENSG00000226578.1	RP11-258F22.1	-4.91	1.28e-06	0.00016	-0.32	-0.22	Obesity (extreme);	chr10:37800345	chr10:37775371~37784131:-
THCA	cis	rs17818399	0.815	rs35837037	ENSG00000279254.1	RP11-536C12.1	-4.91	1.29e-06	0.00016	-0.23	-0.22	Height;	chr2:46634161	chr2:46668870~46670778:+
THCA	cis	rs17270561	1	rs12211184	ENSG00000272462.2	U91328.19	-4.91	1.29e-06	0.00016	-0.22	-0.22	Iron status biomarkers;	chr6:25823546	chr6:25992662~26001775:+
THCA	cis	rs17270561	1	rs79867288	ENSG00000272462.2	U91328.19	-4.91	1.29e-06	0.00016	-0.22	-0.22	Iron status biomarkers;	chr6:25828188	chr6:25992662~26001775:+
THCA	cis	rs17270561	1	rs12200962	ENSG00000272462.2	U91328.19	-4.91	1.29e-06	0.00016	-0.22	-0.22	Iron status biomarkers;	chr6:25828758	chr6:25992662~26001775:+
THCA	cis	rs73198271	0.96	rs73198288	ENSG00000253893.2	FAM85B	4.91	1.29e-06	0.00016	0.36	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756430	chr8:8167819~8226614:-
THCA	cis	rs28476539	0.64	rs56396312	ENSG00000270480.1	RP11-57B24.1	4.91	1.29e-06	0.00016	0.35	0.22	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82634486	chr4:82691737~82692468:+
THCA	cis	rs8002861	0.713	rs7339417	ENSG00000274001.1	RP11-5G9.5	4.91	1.29e-06	0.00016	0.26	0.22	Leprosy;	chr13:43839360	chr13:43877715~43878163:-
THCA	cis	rs3796352	1	rs34121720	ENSG00000242142.1	SERBP1P3	-4.91	1.29e-06	0.00016	-0.41	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53038151	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs13072818	ENSG00000242142.1	SERBP1P3	-4.91	1.29e-06	0.00016	-0.41	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53040247	chr3:53064283~53065091:-
THCA	cis	rs3796352	0.881	rs13100714	ENSG00000242142.1	SERBP1P3	-4.91	1.29e-06	0.00016	-0.41	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53040808	chr3:53064283~53065091:-
THCA	cis	rs3796352	0.892	rs11718388	ENSG00000242142.1	SERBP1P3	-4.91	1.29e-06	0.00016	-0.41	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53042399	chr3:53064283~53065091:-
THCA	cis	rs11955398	0.502	rs248683	ENSG00000272308.1	RP11-231G3.1	-4.91	1.29e-06	0.00016	-0.23	-0.22	Intelligence (multi-trait analysis);	chr5:61064331	chr5:60866457~60866935:-
THCA	cis	rs853679	0.882	rs9380069	ENSG00000220721.1	OR1F12	4.91	1.29e-06	0.00016	0.36	0.22	Depression;	chr6:28235522	chr6:28073316~28074233:+
THCA	cis	rs6964833	0.935	rs13238996	ENSG00000278416.1	PMS2L2	4.91	1.29e-06	0.00016	0.36	0.22	Menarche (age at onset);	chr7:74655318	chr7:75344015~75359550:-
THCA	cis	rs2253762	0.54	rs10159634	ENSG00000226864.1	ATE1-AS1	-4.91	1.29e-06	0.00016	-0.35	-0.22	Breast cancer;	chr10:121994520	chr10:121928312~121951965:+
THCA	cis	rs12030196	0.743	rs71646019	ENSG00000230812.4	LINC01358	4.91	1.29e-06	0.00016	0.27	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58967682	chr1:59020387~59044614:+
THCA	cis	rs17301013	0.869	rs3133270	ENSG00000227373.4	RP11-160H22.5	-4.91	1.29e-06	0.00016	-0.31	-0.22	Systemic lupus erythematosus;	chr1:174819547	chr1:174115300~174160004:-
THCA	cis	rs2361718	0.5	rs4889818	ENSG00000275479.1	RP11-334C17.6	4.91	1.29e-06	0.00016	0.21	0.22	Yeast infection;	chr17:80111429	chr17:80149627~80149798:+
THCA	cis	rs6012564	1	rs3092374	ENSG00000227431.4	CSE1L-AS1	-4.91	1.29e-06	0.00016	-0.27	-0.22	Anger;	chr20:49047407	chr20:49040463~49046044:-
THCA	cis	rs2439831	1	rs2584726	ENSG00000205771.5	CATSPER2P1	-4.91	1.29e-06	0.00016	-0.28	-0.22	Lung cancer in ever smokers;	chr15:43423184	chr15:43726918~43747094:-
THCA	cis	rs72843506	0.656	rs74333705	ENSG00000231258.2	ZSWIM5P2	4.91	1.29e-06	0.00016	0.33	0.22	Schizophrenia;	chr17:20097448	chr17:20583758~20591180:-
THCA	cis	rs12554020	0.892	rs75625893	ENSG00000227603.1	RP11-165J3.6	4.91	1.29e-06	0.00016	0.33	0.22	Schizophrenia;	chr9:93605006	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs76488437	ENSG00000227603.1	RP11-165J3.6	4.91	1.29e-06	0.00016	0.33	0.22	Schizophrenia;	chr9:93605514	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.681	rs80062429	ENSG00000227603.1	RP11-165J3.6	4.91	1.29e-06	0.00016	0.33	0.22	Schizophrenia;	chr9:93608830	chr9:93435332~93437121:-
THCA	cis	rs7914558	1	rs10509757	ENSG00000236937.2	PTGES3P4	4.91	1.29e-06	0.00016	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102845595~102845950:+
THCA	cis	rs11673344	0.504	rs2385374	ENSG00000276846.1	CTD-3220F14.3	4.91	1.29e-06	0.00016	0.17	0.22	Obesity-related traits;	chr19:37092115	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs4254428	ENSG00000276846.1	CTD-3220F14.3	4.91	1.29e-06	0.00016	0.17	0.22	Obesity-related traits;	chr19:37093748	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs8109501	ENSG00000276846.1	CTD-3220F14.3	4.91	1.29e-06	0.00016	0.17	0.22	Obesity-related traits;	chr19:37102194	chr19:37314868~37315620:-
THCA	cis	rs2051211	0.895	rs2300670	ENSG00000229589.1	ACVR2B-AS1	-4.91	1.29e-06	0.00016	-0.23	-0.22	QRS duration;	chr3:38514324	chr3:38451027~38454820:-
THCA	cis	rs17767392	0.67	rs72726701	ENSG00000259146.3	RP1-261D10.2	4.91	1.29e-06	0.00016	0.27	0.22	Mitral valve prolapse;	chr14:71261612	chr14:71292729~71321814:-
THCA	cis	rs6490294	0.528	rs74187049	ENSG00000226469.1	ADAM1B	4.91	1.29e-06	0.00016	0.37	0.22	Mean platelet volume;	chr12:112180114	chr12:111927018~111929017:+
THCA	cis	rs9863	0.828	rs7307277	ENSG00000269997.1	RP11-214K3.21	-4.91	1.29e-06	0.00016	-0.27	-0.22	White blood cell count;	chr12:123990609	chr12:123966077~123966629:-
THCA	cis	rs9863	0.828	rs71458830	ENSG00000269997.1	RP11-214K3.21	-4.91	1.29e-06	0.00016	-0.27	-0.22	White blood cell count;	chr12:123992014	chr12:123966077~123966629:-
THCA	cis	rs9863	0.828	rs12809473	ENSG00000269997.1	RP11-214K3.21	-4.91	1.29e-06	0.00016	-0.27	-0.22	White blood cell count;	chr12:123992052	chr12:123966077~123966629:-
THCA	cis	rs9863	0.828	rs12827409	ENSG00000269997.1	RP11-214K3.21	-4.91	1.29e-06	0.00016	-0.27	-0.22	White blood cell count;	chr12:123992159	chr12:123966077~123966629:-
THCA	cis	rs9863	0.828	rs7135314	ENSG00000269997.1	RP11-214K3.21	-4.91	1.29e-06	0.00016	-0.27	-0.22	White blood cell count;	chr12:123994019	chr12:123966077~123966629:-
THCA	cis	rs9863	0.828	rs56041971	ENSG00000269997.1	RP11-214K3.21	-4.91	1.29e-06	0.00016	-0.27	-0.22	White blood cell count;	chr12:123996319	chr12:123966077~123966629:-
THCA	cis	rs2734839	0.929	rs11608185	ENSG00000270179.1	RP11-159N11.4	-4.91	1.29e-06	0.00016	-0.23	-0.22	Information processing speed;	chr11:113424254	chr11:113368478~113369117:+
THCA	cis	rs6012564	1	rs11696396	ENSG00000227431.4	CSE1L-AS1	4.91	1.29e-06	0.00016	0.27	0.22	Anger;	chr20:49136482	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs6066978	ENSG00000227431.4	CSE1L-AS1	4.91	1.29e-06	0.00016	0.27	0.22	Anger;	chr20:49139205	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs6063361	ENSG00000227431.4	CSE1L-AS1	4.91	1.29e-06	0.00016	0.27	0.22	Anger;	chr20:49141426	chr20:49040463~49046044:-
THCA	cis	rs35264875	0.851	rs72930631	ENSG00000259799.1	RP11-554A11.9	4.91	1.29e-06	0.00016	0.32	0.22	Blond vs. brown hair color;	chr11:69100367	chr11:69155910~69159752:+
THCA	cis	rs10129255	1	rs11621409	ENSG00000223648.3	IGHV3-64	4.91	1.29e-06	0.00016	0.14	0.22	Kawasaki disease;	chr14:106695603	chr14:106643132~106658258:-
THCA	cis	rs1150668	0.799	rs853684	ENSG00000176933.5	TOB2P1	-4.9	1.29e-06	0.00016	-0.24	-0.22	Pubertal anthropometrics;	chr6:28326773	chr6:28217643~28218634:-
THCA	cis	rs6138458	1	rs227658	ENSG00000274173.1	RP4-568C11.4	4.9	1.29e-06	0.00016	0.21	0.22	Blood protein levels;	chr20:24951392	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs11906373	ENSG00000274173.1	RP4-568C11.4	4.9	1.29e-06	0.00016	0.21	0.22	Blood protein levels;	chr20:24958196	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs6707	ENSG00000274173.1	RP4-568C11.4	4.9	1.29e-06	0.00016	0.21	0.22	Blood protein levels;	chr20:24963530	chr20:24931840~24932983:+
THCA	cis	rs78487399	0.908	rs76163151	ENSG00000234936.1	AC010883.5	4.9	1.29e-06	0.00016	0.28	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617077	chr2:43229573~43233394:+
THCA	cis	rs2834188	0.737	rs2834179	ENSG00000272659.1	AP000295.10	-4.9	1.29e-06	0.00016	-0.29	-0.22	Narcolepsy;	chr21:33307426	chr21:33309491~33310181:+
THCA	cis	rs972578	0.791	rs8135830	ENSG00000274717.1	RP1-47A17.1	-4.9	1.29e-06	0.00016	-0.23	-0.22	Mean platelet volume;	chr22:42920226	chr22:42791814~42794313:-
THCA	cis	rs8177376	0.727	rs240552	ENSG00000254905.1	RP11-712L6.7	4.9	1.29e-06	0.00016	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126333818	chr11:126292922~126294254:-
THCA	cis	rs7829975	0.533	rs1039917	ENSG00000233609.3	RP11-62H7.2	4.9	1.29e-06	0.00016	0.22	0.22	Mood instability;	chr8:8861340	chr8:8961200~8979025:+
THCA	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-4.9	1.29e-06	0.00016	-0.34	-0.22	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
THCA	cis	rs17594362	1	rs12866839	ENSG00000264190.1	MIR5006	-4.9	1.29e-06	0.00016	-0.34	-0.22	Multiple sclerosis;	chr13:41578118	chr13:41568286~41568395:-
THCA	cis	rs11992162	0.636	rs4841645	ENSG00000254948.1	OR7E158P	4.9	1.29e-06	0.00016	0.27	0.22	Monocyte count;	chr8:11941175	chr8:11919900~11920809:-
THCA	cis	rs12134133	1	rs4844590	ENSG00000237074.1	RP11-6J21.2	4.9	1.29e-06	0.00016	0.23	0.22	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207249067~207309121:+
THCA	cis	rs853679	0.607	rs200489	ENSG00000280107.1	AL022393.9	-4.9	1.29e-06	0.000161	-0.34	-0.22	Depression;	chr6:27830479	chr6:28170845~28172521:+
THCA	cis	rs889398	0.967	rs7359336	ENSG00000226232.7	RP11-419C5.2	-4.9	1.29e-06	0.000161	-0.22	-0.22	Body mass index;	chr16:69699557	chr16:69976388~69996188:-
THCA	cis	rs3734266	0.639	rs9469842	ENSG00000272288.4	RP11-140K17.3	-4.9	1.29e-06	0.000161	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34676304	chr6:34696317~34697470:+
THCA	cis	rs748404	0.626	rs72707530	ENSG00000205771.5	CATSPER2P1	-4.9	1.29e-06	0.000161	-0.28	-0.22	Lung cancer;	chr15:43353622	chr15:43726918~43747094:-
THCA	cis	rs7688540	0.8	rs9328737	ENSG00000250892.1	RP11-1365D11.1	4.9	1.29e-06	0.000161	0.31	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:201409~205009:-
THCA	cis	rs494453	1	rs494453	ENSG00000227811.2	FAM212B-AS1	-4.9	1.29e-06	0.000161	-0.27	-0.22	Osteoporosis-related phenotypes;	chr1:111649500	chr1:111739841~111747798:+
THCA	cis	rs7088591	0.867	rs16911628	ENSG00000276818.1	AC026393.1	4.9	1.29e-06	0.000161	0.42	0.22	Blood pressure;	chr10:58019623	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs73290914	ENSG00000276818.1	AC026393.1	4.9	1.29e-06	0.000161	0.42	0.22	Blood pressure;	chr10:58019740	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs73290915	ENSG00000276818.1	AC026393.1	4.9	1.29e-06	0.000161	0.42	0.22	Blood pressure;	chr10:58019821	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs4284361	ENSG00000276818.1	AC026393.1	4.9	1.29e-06	0.000161	0.42	0.22	Blood pressure;	chr10:58020164	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs4606437	ENSG00000276818.1	AC026393.1	4.9	1.29e-06	0.000161	0.42	0.22	Blood pressure;	chr10:58020216	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs4586100	ENSG00000276818.1	AC026393.1	4.9	1.29e-06	0.000161	0.42	0.22	Blood pressure;	chr10:58020312	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs4586101	ENSG00000276818.1	AC026393.1	4.9	1.29e-06	0.000161	0.42	0.22	Blood pressure;	chr10:58020324	chr10:57095699~57095781:+
THCA	cis	rs9992667	0.955	rs10025499	ENSG00000231160.8	KLF3-AS1	4.9	1.29e-06	0.000161	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38619373	chr4:38612701~38664883:-
THCA	cis	rs71636778	0.722	rs12746395	ENSG00000260063.1	RP5-968P14.2	-4.9	1.29e-06	0.000161	-0.3	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26841697	chr1:26692132~26694131:-
THCA	cis	rs3734266	0.702	rs6909637	ENSG00000272288.4	RP11-140K17.3	-4.9	1.3e-06	0.000161	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34645853	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs9469837	ENSG00000272288.4	RP11-140K17.3	-4.9	1.3e-06	0.000161	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34647755	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs9469838	ENSG00000272288.4	RP11-140K17.3	-4.9	1.3e-06	0.000161	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34655592	chr6:34696317~34697470:+
THCA	cis	rs703842	1	rs2069502	ENSG00000270039.1	RP11-571M6.17	4.9	1.3e-06	0.000161	0.26	0.22	Multiple sclerosis;	chr12:57750882	chr12:57803838~57804415:+
THCA	cis	rs752010	0.53	rs10789401	ENSG00000230638.4	RP11-486B10.4	-4.9	1.3e-06	0.000161	-0.27	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41615440	chr1:41542069~41544310:+
THCA	cis	rs1048886	0.808	rs9455144	ENSG00000271967.1	RP11-134K13.4	-4.9	1.3e-06	0.000161	-0.22	-0.22	Type 2 diabetes;	chr6:70527040	chr6:70596438~70596980:+
THCA	cis	rs6138458	1	rs227651	ENSG00000274173.1	RP4-568C11.4	4.9	1.3e-06	0.000161	0.21	0.22	Blood protein levels;	chr20:24949198	chr20:24931840~24932983:+
THCA	cis	rs916888	0.61	rs199536	ENSG00000261575.2	RP11-259G18.1	-4.9	1.3e-06	0.000161	-0.27	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46267037~46268694:+
THCA	cis	rs34779708	0.897	rs7897827	ENSG00000271335.4	RP11-324I22.4	4.9	1.3e-06	0.000161	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35314552~35336401:-
THCA	cis	rs62432291	0.681	rs438853	ENSG00000235086.1	FNDC1-IT1	-4.9	1.3e-06	0.000161	-0.41	-0.22	Joint mobility (Beighton score);	chr6:159209320	chr6:159240786~159243329:+
THCA	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	4.9	1.3e-06	0.000161	0.24	0.22	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
THCA	cis	rs12999616	0.696	rs56035334	ENSG00000230606.9	AC159540.1	-4.9	1.3e-06	0.000161	-0.28	-0.22	Colorectal cancer;	chr2:97712584	chr2:97416165~97433527:-
THCA	cis	rs7181230	0.885	rs9919974	ENSG00000275636.1	RP11-521C20.5	4.9	1.3e-06	0.000161	0.24	0.22	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40078892~40079347:+
THCA	cis	rs7674212	0.539	rs6821617	ENSG00000246560.2	RP11-10L12.4	4.9	1.3e-06	0.000161	0.26	0.22	Type 2 diabetes;	chr4:103207253	chr4:102828055~102844075:+
THCA	cis	rs13178541	0.752	rs66533013	ENSG00000250378.1	RP11-119J18.1	-4.9	1.3e-06	0.000161	-0.28	-0.22	IgG glycosylation;	chr5:135788933	chr5:135812667~135826582:+
THCA	cis	rs6012564	1	rs6066977	ENSG00000227431.4	CSE1L-AS1	4.9	1.3e-06	0.000161	0.27	0.22	Anger;	chr20:49138538	chr20:49040463~49046044:-
THCA	cis	rs6951245	0.935	rs112554101	ENSG00000229043.2	AC091729.9	-4.9	1.3e-06	0.000161	-0.34	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025899	chr7:1160374~1165267:+
THCA	cis	rs2735413	0.563	rs72800910	ENSG00000276007.1	RP11-358L22.3	4.9	1.3e-06	0.000161	0.25	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78014005	chr16:78123243~78124332:+
THCA	cis	rs77637988	0.578	rs11683099	ENSG00000202227.1	RNU6-282P	4.9	1.3e-06	0.000161	0.23	0.22	Joint mobility (Beighton score);	chr2:48384380	chr2:48501922~48502024:-
THCA	cis	rs9987353	0.544	rs2929469	ENSG00000253893.2	FAM85B	-4.9	1.3e-06	0.000161	-0.29	-0.22	Recombination measurement;	chr8:9205146	chr8:8167819~8226614:-
THCA	cis	rs728616	0.614	rs61859196	ENSG00000242600.5	MBL1P	4.9	1.3e-06	0.000161	0.29	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80349292	chr10:79904898~79950336:+
THCA	cis	rs853679	0.546	rs493161	ENSG00000280107.1	AL022393.9	-4.9	1.3e-06	0.000161	-0.35	-0.22	Depression;	chr6:27882936	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.628	rs9295740	ENSG00000226314.6	ZNF192P1	-4.9	1.3e-06	0.000161	-0.29	-0.22	Parkinson's disease;	chr6:27721723	chr6:28161781~28169594:+
THCA	cis	rs11089937	0.597	rs9619812	ENSG00000211639.2	IGLV4-60	4.9	1.3e-06	0.000161	0.16	0.22	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22162199~22162681:+
THCA	cis	rs853679	0.585	rs201004	ENSG00000280107.1	AL022393.9	-4.9	1.3e-06	0.000161	-0.27	-0.22	Depression;	chr6:27837156	chr6:28170845~28172521:+
THCA	cis	rs3020736	0.5	rs8143153	ENSG00000273366.1	CTA-989H11.1	4.9	1.3e-06	0.000161	0.28	0.22	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42278188~42278846:+
THCA	cis	rs7010876	0.561	rs4246113	ENSG00000253553.4	RP11-586K2.1	-4.9	1.3e-06	0.000161	-0.22	-0.22	Schizophrenia;	chr8:88332572	chr8:88326836~88737134:+
THCA	cis	rs1552244	0.766	rs34232505	ENSG00000232901.1	CYCSP10	4.9	1.3e-06	0.000161	0.3	0.22	Alzheimer's disease;	chr3:10144532	chr3:10000647~10000940:-
THCA	cis	rs5751614	1	rs5996505	ENSG00000230701.2	FBXW4P1	4.9	1.3e-06	0.000161	0.21	0.22	Height;	chr22:23247296	chr22:23262767~23265005:+
THCA	cis	rs1150668	0.796	rs1124132	ENSG00000273712.1	RP5-874C20.7	4.9	1.3e-06	0.000161	0.24	0.22	Pubertal anthropometrics;	chr6:28412544	chr6:28315613~28315883:-
THCA	cis	rs6840258	0.843	rs3755985	ENSG00000251411.1	RP11-397E7.4	-4.9	1.3e-06	0.000161	-0.27	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87103586	chr4:86913266~86914817:-
THCA	cis	rs763121	0.752	rs6001190	ENSG00000228274.3	RP3-508I15.9	-4.9	1.3e-06	0.000161	-0.24	-0.22	Menopause (age at onset);	chr22:38677806	chr22:38667585~38681820:-
THCA	cis	rs12911832	0.958	rs12912003	ENSG00000245975.2	RP11-30K9.6	4.9	1.3e-06	0.000161	0.22	0.22	Schizophrenia;	chr15:58693802	chr15:58768072~58770974:-
THCA	cis	rs4722166	0.63	rs10950916	ENSG00000225541.1	AC002480.5	-4.9	1.3e-06	0.000161	-0.29	-0.22	Lung cancer;	chr7:22760048	chr7:22571607~22661792:-
THCA	cis	rs62292953	0.79	rs62292959	ENSG00000248724.5	NPHP3-AS1	-4.9	1.3e-06	0.000161	-0.41	-0.22	Red cell distribution width;	chr3:132505284	chr3:132721750~132874223:+
THCA	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-4.9	1.3e-06	0.000161	-0.2	-0.22	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
THCA	cis	rs858239	0.6	rs6967475	ENSG00000230042.1	AK3P3	-4.9	1.3e-06	0.000162	-0.29	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23129178~23129841:+
THCA	cis	rs4834770	0.668	rs10007409	ENSG00000245958.5	RP11-33B1.1	4.9	1.3e-06	0.000162	0.21	0.22	Blood protein levels;	chr4:119221151	chr4:119454791~119552025:+
THCA	cis	rs7403037	0.587	rs4238509	ENSG00000260760.1	PWRN3	4.9	1.3e-06	0.000162	0.23	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24317816	chr15:24441127~24447967:+
THCA	cis	rs67478160	0.634	rs941473	ENSG00000258735.1	LINC00637	-4.9	1.3e-06	0.000162	-0.27	-0.22	Schizophrenia;	chr14:103735532	chr14:103847721~103858049:+
THCA	cis	rs11992162	0.636	rs11250182	ENSG00000206014.6	OR7E161P	4.9	1.3e-06	0.000162	0.26	0.22	Monocyte count;	chr8:11950067	chr8:11928597~11929563:-
THCA	cis	rs17772222	1	rs56987357	ENSG00000222990.1	RNU4-22P	4.9	1.3e-06	0.000162	0.29	0.22	Coronary artery calcification;	chr14:88358019	chr14:88513498~88513663:+
THCA	cis	rs853679	1	rs853679	ENSG00000220721.1	OR1F12	4.9	1.3e-06	0.000162	0.34	0.22	Depression;	chr6:28329086	chr6:28073316~28074233:+
THCA	cis	rs853679	1	rs853678	ENSG00000220721.1	OR1F12	4.9	1.3e-06	0.000162	0.34	0.22	Depression;	chr6:28329536	chr6:28073316~28074233:+
THCA	cis	rs11096990	0.892	rs11730558	ENSG00000249685.1	RP11-360F5.3	4.9	1.3e-06	0.000162	0.28	0.22	Cognitive function;	chr4:39228151	chr4:39133913~39135608:+
THCA	cis	rs11633886	0.604	rs59727662	ENSG00000273972.1	CTD-2306A12.1	-4.9	1.31e-06	0.000162	-0.24	-0.22	Diisocyanate-induced asthma;	chr15:45815346	chr15:45702640~45703183:+
THCA	cis	rs72799341	1	rs7200879	ENSG00000279196.1	RP11-1072A3.3	4.9	1.31e-06	0.000162	0.25	0.22	Diastolic blood pressure;	chr16:30936251	chr16:30984630~30988270:-
THCA	cis	rs897984	0.806	rs10782002	ENSG00000260911.2	RP11-196G11.2	-4.9	1.31e-06	0.000162	-0.19	-0.22	Dementia with Lewy bodies;	chr16:30935185	chr16:31043150~31049868:+
THCA	cis	rs9843304	0.529	rs4681510	ENSG00000244503.1	RP11-278L15.6	4.9	1.31e-06	0.000162	0.27	0.22	Gallstone disease;	chr3:149483786	chr3:149494660~149495995:+
THCA	cis	rs9843304	0.529	rs4681511	ENSG00000244503.1	RP11-278L15.6	4.9	1.31e-06	0.000162	0.27	0.22	Gallstone disease;	chr3:149483792	chr3:149494660~149495995:+
THCA	cis	rs2439831	0.571	rs689883	ENSG00000205771.5	CATSPER2P1	-4.9	1.31e-06	0.000162	-0.29	-0.22	Lung cancer in ever smokers;	chr15:43520398	chr15:43726918~43747094:-
THCA	cis	rs1908814	0.509	rs13282439	ENSG00000206014.6	OR7E161P	-4.9	1.31e-06	0.000162	-0.26	-0.22	Neuroticism;	chr8:11937392	chr8:11928597~11929563:-
THCA	cis	rs2239547	0.563	rs9839035	ENSG00000242142.1	SERBP1P3	4.9	1.31e-06	0.000162	0.28	0.22	Schizophrenia;	chr3:52875861	chr3:53064283~53065091:-
THCA	cis	rs1003719	0.788	rs4816560	ENSG00000230366.8	DSCR9	-4.9	1.31e-06	0.000162	-0.22	-0.22	Eye color traits;	chr21:37115261	chr21:37208503~37221736:+
THCA	cis	rs8002861	0.664	rs2184882	ENSG00000274001.1	RP11-5G9.5	4.9	1.31e-06	0.000162	0.26	0.22	Leprosy;	chr13:43876210	chr13:43877715~43878163:-
THCA	cis	rs2281603	0.57	rs9323451	ENSG00000259116.1	RP11-973N13.4	-4.9	1.31e-06	0.000162	-0.2	-0.22	Lymphocyte counts;	chr14:64505031	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.52	rs9323452	ENSG00000259116.1	RP11-973N13.4	-4.9	1.31e-06	0.000162	-0.2	-0.22	Lymphocyte counts;	chr14:64505426	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs28469649	ENSG00000259116.1	RP11-973N13.4	-4.9	1.31e-06	0.000162	-0.2	-0.22	Lymphocyte counts;	chr14:64505531	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs1453007	ENSG00000259116.1	RP11-973N13.4	-4.9	1.31e-06	0.000162	-0.2	-0.22	Lymphocyte counts;	chr14:64507485	chr14:64514154~64540368:-
THCA	cis	rs17767392	0.958	rs34469007	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71450206	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs12896986	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71456176	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.881	rs12880611	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71456632	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs61989373	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71468439	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.871	rs34347034	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71468796	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs12889866	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71470722	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs61989374	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71473864	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs2108049	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71495677	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs56407721	ENSG00000259146.3	RP1-261D10.2	4.9	1.31e-06	0.000162	0.28	0.22	Mitral valve prolapse;	chr14:71496786	chr14:71292729~71321814:-
THCA	cis	rs654950	1	rs646228	ENSG00000230638.4	RP11-486B10.4	-4.9	1.31e-06	0.000162	-0.25	-0.22	Airway imaging phenotypes;	chr1:41520395	chr1:41542069~41544310:+
THCA	cis	rs4722166	0.63	rs6461667	ENSG00000225541.1	AC002480.5	-4.9	1.31e-06	0.000162	-0.28	-0.22	Lung cancer;	chr7:22757124	chr7:22571607~22661792:-
THCA	cis	rs9393777	0.72	rs56401801	ENSG00000280107.1	AL022393.9	-4.9	1.31e-06	0.000162	-0.4	-0.22	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28170845~28172521:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000232546.1	RP11-458F8.1	-4.9	1.31e-06	0.000162	-0.27	-0.22	Diabetic kidney disease;	chr7:66631132	chr7:66848496~66858136:+
THCA	cis	rs13113518	0.967	rs4340844	ENSG00000273257.1	RP11-177J6.1	4.9	1.31e-06	0.000162	0.29	0.22	Height;	chr4:55462689	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs1522112	ENSG00000273257.1	RP11-177J6.1	4.9	1.31e-06	0.000162	0.29	0.22	Height;	chr4:55463606	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs4864997	ENSG00000273257.1	RP11-177J6.1	4.9	1.31e-06	0.000162	0.29	0.22	Height;	chr4:55466010	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs960152	ENSG00000273257.1	RP11-177J6.1	4.9	1.31e-06	0.000162	0.29	0.22	Height;	chr4:55467308	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.967	rs12644948	ENSG00000273257.1	RP11-177J6.1	4.9	1.31e-06	0.000162	0.29	0.22	Height;	chr4:55470266	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs3805151	ENSG00000273257.1	RP11-177J6.1	4.9	1.31e-06	0.000162	0.29	0.22	Height;	chr4:55470874	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13118237	ENSG00000273257.1	RP11-177J6.1	4.9	1.31e-06	0.000162	0.29	0.22	Height;	chr4:55474259	chr4:55387949~55388271:+
THCA	cis	rs8177876	0.749	rs804885	ENSG00000261061.1	RP11-303E16.2	4.9	1.31e-06	0.000162	0.29	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061758	chr16:81030770~81031485:+
THCA	cis	rs4713118	0.629	rs203890	ENSG00000261839.1	RP1-265C24.8	4.9	1.31e-06	0.000162	0.25	0.22	Parkinson's disease;	chr6:28054470	chr6:28136849~28139678:+
THCA	cis	rs11673344	0.502	rs62108306	ENSG00000267422.1	CTD-2554C21.1	4.9	1.31e-06	0.000162	0.2	0.22	Obesity-related traits;	chr19:37691789	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.536	rs7259272	ENSG00000267422.1	CTD-2554C21.1	4.9	1.31e-06	0.000162	0.2	0.22	Obesity-related traits;	chr19:37692214	chr19:37779686~37792865:+
THCA	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-4.9	1.31e-06	0.000162	-0.28	-0.22	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
THCA	cis	rs17301013	0.932	rs1653632	ENSG00000227373.4	RP11-160H22.5	-4.9	1.31e-06	0.000162	-0.31	-0.22	Systemic lupus erythematosus;	chr1:174786459	chr1:174115300~174160004:-
THCA	cis	rs2447820	0.588	rs4385206	ENSG00000249996.1	RP11-359P5.1	4.9	1.31e-06	0.000162	0.26	0.22	Migraine;	chr5:123039302	chr5:123036271~123054667:+
THCA	cis	rs4578769	0.569	rs4800431	ENSG00000265939.1	UBE2CP2	4.9	1.31e-06	0.000162	0.25	0.22	Eosinophil percentage of white cells;	chr18:22803499	chr18:22900486~22900995:-
THCA	cis	rs7430456	0.638	rs13071694	ENSG00000228221.4	LINC00578	-4.9	1.31e-06	0.000162	-0.31	-0.22	Breast cancer;	chr3:177775198	chr3:177441921~177752305:+
THCA	cis	rs7088591	0.867	rs4481980	ENSG00000276818.1	AC026393.1	4.9	1.31e-06	0.000162	0.42	0.22	Blood pressure;	chr10:58021993	chr10:57095699~57095781:+
THCA	cis	rs4660214	0.666	rs588326	ENSG00000182109.6	RP11-69E11.4	4.9	1.31e-06	0.000162	0.21	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39443054	chr1:39522280~39546187:-
THCA	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-4.9	1.31e-06	0.000162	-0.3	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
THCA	cis	rs7587476	0.906	rs62201985	ENSG00000229267.2	AC072062.1	-4.9	1.31e-06	0.000163	-0.29	-0.22	Neuroblastoma;	chr2:214793914	chr2:214810229~214963274:+
THCA	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	4.9	1.31e-06	0.000163	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
THCA	cis	rs467650	0.853	rs316511	ENSG00000248489.1	CTD-2007H13.3	4.9	1.31e-06	0.000163	0.21	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98673338	chr5:98929171~98995013:+
THCA	cis	rs467650	0.853	rs373773	ENSG00000248489.1	CTD-2007H13.3	4.9	1.31e-06	0.000163	0.21	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98684911	chr5:98929171~98995013:+
THCA	cis	rs10043228	0.609	rs12518933	ENSG00000248445.4	SEMA6A-AS1	-4.9	1.31e-06	0.000163	-0.23	-0.22	Asthma or chronic obstructive pulmonary disease;	chr5:116374908	chr5:116447547~116508276:+
THCA	cis	rs12823128	0.766	rs12582043	ENSG00000256185.1	RP11-612B6.2	4.9	1.31e-06	0.000163	0.21	0.22	Birth weight;	chr12:26769140	chr12:26335864~26336950:-
THCA	cis	rs613391	0.702	rs664108	ENSG00000224549.1	RP11-370B11.3	-4.9	1.31e-06	0.000163	-0.25	-0.22	Quantitative traits;	chr9:22708380	chr9:22767175~22768316:+
THCA	cis	rs11992162	0.507	rs60902764	ENSG00000206014.6	OR7E161P	4.9	1.31e-06	0.000163	0.26	0.22	Monocyte count;	chr8:11927482	chr8:11928597~11929563:-
THCA	cis	rs6088590	0.93	rs6087618	ENSG00000276073.1	RP5-1125A11.7	-4.9	1.31e-06	0.000163	-0.2	-0.22	Coronary artery disease;	chr20:34700603	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.965	rs6087619	ENSG00000276073.1	RP5-1125A11.7	-4.9	1.31e-06	0.000163	-0.2	-0.22	Coronary artery disease;	chr20:34700707	chr20:33985617~33988989:-
THCA	cis	rs62184315	0.536	rs62183653	ENSG00000253559.1	OSGEPL1-AS1	-4.9	1.31e-06	0.000163	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189650099	chr2:189762704~189765556:+
THCA	cis	rs62184315	0.536	rs72920421	ENSG00000253559.1	OSGEPL1-AS1	-4.9	1.31e-06	0.000163	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189650292	chr2:189762704~189765556:+
THCA	cis	rs62184315	0.536	rs62183651	ENSG00000253559.1	OSGEPL1-AS1	-4.9	1.31e-06	0.000163	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189647251	chr2:189762704~189765556:+
THCA	cis	rs62184315	0.536	rs62183652	ENSG00000253559.1	OSGEPL1-AS1	-4.9	1.31e-06	0.000163	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189648877	chr2:189762704~189765556:+
THCA	cis	rs11671005	0.735	rs45617039	ENSG00000265272.2	RN7SL693P	4.9	1.32e-06	0.000163	0.31	0.22	Mean platelet volume;	chr19:58439729	chr19:58490797~58491075:+
THCA	cis	rs17345786	0.798	rs9817043	ENSG00000256628.3	ZBTB11-AS1	4.9	1.32e-06	0.000163	0.26	0.22	Colonoscopy-negative controls vs population controls;	chr3:101563008	chr3:101676475~101679217:+
THCA	cis	rs934734	0.789	rs174847	ENSG00000237979.1	AC007389.1	-4.9	1.32e-06	0.000163	-0.27	-0.22	Rheumatoid arthritis;	chr2:65378060	chr2:65500993~65502138:-
THCA	cis	rs17772222	0.636	rs3850390	ENSG00000222990.1	RNU4-22P	4.9	1.32e-06	0.000163	0.3	0.22	Coronary artery calcification;	chr14:88829185	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.597	rs17700296	ENSG00000222990.1	RNU4-22P	4.9	1.32e-06	0.000163	0.3	0.22	Coronary artery calcification;	chr14:88840976	chr14:88513498~88513663:+
THCA	cis	rs11121022	0.601	rs707455	ENSG00000269925.1	RP3-467L1.6	4.9	1.32e-06	0.000163	0.22	0.22	Morning vs. evening chronotype;	chr1:7765251	chr1:7776383~7776775:+
THCA	cis	rs12413361	0.967	rs947100	ENSG00000272914.1	RP11-330O11.3	-4.9	1.32e-06	0.000163	-0.19	-0.22	Height;	chr10:30840980	chr10:30831828~30833387:-
THCA	cis	rs6496932	0.503	rs2086756	ENSG00000259630.2	CTD-2262B20.1	-4.9	1.32e-06	0.000163	-0.28	-0.22	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85415228~85415633:+
THCA	cis	rs2562456	0.834	rs13346641	ENSG00000268117.1	VN1R84P	4.9	1.32e-06	0.000163	0.35	0.22	Pain;	chr19:21409481	chr19:21719801~21720035:-
THCA	cis	rs9890032	0.542	rs62070645	ENSG00000266490.1	CTD-2349P21.9	4.9	1.32e-06	0.000163	0.23	0.22	Hip circumference adjusted for BMI;	chr17:30853978	chr17:30792372~30792833:+
THCA	cis	rs6088590	1	rs12626122	ENSG00000276073.1	RP5-1125A11.7	-4.9	1.32e-06	0.000163	-0.21	-0.22	Coronary artery disease;	chr20:34837997	chr20:33985617~33988989:-
THCA	cis	rs2562456	0.833	rs56179986	ENSG00000268119.4	CTD-2561J22.5	4.9	1.32e-06	0.000163	0.32	0.22	Pain;	chr19:21337882	chr19:21444241~21463908:-
THCA	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-4.9	1.32e-06	0.000163	-0.25	-0.22	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
THCA	cis	rs2386661	0.603	rs11259704	ENSG00000231483.1	RP11-336A10.5	4.9	1.32e-06	0.000163	0.23	0.22	Breast cancer;	chr10:5605036	chr10:5608475~5610793:-
THCA	cis	rs6545883	0.929	rs2593625	ENSG00000270820.4	RP11-355B11.2	4.9	1.32e-06	0.000163	0.19	0.22	Tuberculosis;	chr2:61441634	chr2:61471188~61484130:+
THCA	cis	rs9652601	0.691	rs9926078	ENSG00000274038.1	RP11-66H6.4	-4.9	1.32e-06	0.000163	-0.26	-0.22	Systemic lupus erythematosus;	chr16:11109708	chr16:11056556~11057034:+
THCA	cis	rs5758659	0.652	rs133305	ENSG00000227370.1	RP4-669P10.19	-4.9	1.32e-06	0.000163	-0.2	-0.22	Cognitive function;	chr22:41999956	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.682	rs133306	ENSG00000227370.1	RP4-669P10.19	-4.9	1.32e-06	0.000163	-0.2	-0.22	Cognitive function;	chr22:42000146	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.519	rs133307	ENSG00000227370.1	RP4-669P10.19	-4.9	1.32e-06	0.000163	-0.2	-0.22	Cognitive function;	chr22:42000564	chr22:42132543~42132998:+
THCA	cis	rs5758659	0.622	rs129856	ENSG00000227370.1	RP4-669P10.19	-4.9	1.32e-06	0.000163	-0.2	-0.22	Cognitive function;	chr22:42003392	chr22:42132543~42132998:+
THCA	cis	rs60733400	0.667	rs4385650	ENSG00000225931.3	RP3-395M20.7	4.9	1.32e-06	0.000163	0.26	0.22	Multiple sclerosis;	chr1:2568459	chr1:2566410~2569888:+
THCA	cis	rs34779708	0.931	rs11010101	ENSG00000271335.4	RP11-324I22.4	4.9	1.32e-06	0.000164	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35314552~35336401:-
THCA	cis	rs34779708	0.966	rs11010102	ENSG00000271335.4	RP11-324I22.4	4.9	1.32e-06	0.000164	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35314552~35336401:-
THCA	cis	rs35740288	0.721	rs4843093	ENSG00000259295.5	CSPG4P12	4.9	1.32e-06	0.000164	0.35	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85694202	chr15:85191438~85213905:+
THCA	cis	rs11846409	0.932	rs74091728	ENSG00000274576.2	IGHV2-70	-4.9	1.32e-06	0.000164	-0.18	-0.22	Rheumatic heart disease;	chr14:106638762	chr14:106770577~106771020:-
THCA	cis	rs9910055	0.659	rs7216294	ENSG00000267080.4	ASB16-AS1	-4.9	1.32e-06	0.000164	-0.19	-0.22	Total body bone mineral density;	chr17:44173727	chr17:44175973~44186717:-
THCA	cis	rs9910055	0.683	rs7220138	ENSG00000267080.4	ASB16-AS1	-4.9	1.32e-06	0.000164	-0.19	-0.22	Total body bone mineral density;	chr17:44176643	chr17:44175973~44186717:-
THCA	cis	rs9910055	0.639	rs7217858	ENSG00000267080.4	ASB16-AS1	-4.9	1.32e-06	0.000164	-0.19	-0.22	Total body bone mineral density;	chr17:44177159	chr17:44175973~44186717:-
THCA	cis	rs9910055	0.659	rs7214540	ENSG00000267080.4	ASB16-AS1	-4.9	1.32e-06	0.000164	-0.19	-0.22	Total body bone mineral density;	chr17:44179236	chr17:44175973~44186717:-
THCA	cis	rs13434995	0.513	rs62305265	ENSG00000273257.1	RP11-177J6.1	-4.9	1.32e-06	0.000164	-0.33	-0.22	Adiponectin levels;	chr4:55503474	chr4:55387949~55388271:+
THCA	cis	rs72945132	0.882	rs3781648	ENSG00000254604.1	AP000487.6	-4.9	1.32e-06	0.000164	-0.41	-0.22	Coronary artery disease;	chr11:70343952	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.769	rs3781644	ENSG00000254604.1	AP000487.6	-4.9	1.32e-06	0.000164	-0.41	-0.22	Coronary artery disease;	chr11:70344269	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7935969	ENSG00000254604.1	AP000487.6	-4.9	1.32e-06	0.000164	-0.41	-0.22	Coronary artery disease;	chr11:70348069	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs113472486	ENSG00000254604.1	AP000487.6	-4.9	1.32e-06	0.000164	-0.41	-0.22	Coronary artery disease;	chr11:70348839	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs12099016	ENSG00000254604.1	AP000487.6	-4.9	1.32e-06	0.000164	-0.41	-0.22	Coronary artery disease;	chr11:70349055	chr11:70282367~70363368:-
THCA	cis	rs6759004	1	rs6759004	ENSG00000183308.6	AC005037.3	4.9	1.32e-06	0.000164	0.35	0.22	Triptolide cytotoxicity;	chr2:201139953	chr2:200963263~201009102:+
THCA	cis	rs2797160	0.904	rs1777198	ENSG00000237742.5	RP11-624M8.1	4.9	1.32e-06	0.000164	0.2	0.22	Endometrial cancer;	chr6:125686270	chr6:125578558~125749190:-
THCA	cis	rs4693089	0.542	rs508116	ENSG00000213608.5	SLC25A14P1	-4.9	1.32e-06	0.000164	-0.26	-0.22	Menopause (age at onset);	chr4:83510893	chr4:83477524~83478424:+
THCA	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-4.9	1.32e-06	0.000164	-0.29	-0.22	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
THCA	cis	rs7772486	0.624	rs6930154	ENSG00000270638.1	RP3-466P17.1	-4.9	1.32e-06	0.000164	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145735570~145737218:+
THCA	cis	rs7727544	0.735	rs273913	ENSG00000263597.1	MIR3936	4.9	1.32e-06	0.000164	0.22	0.22	Blood metabolite levels;	chr5:132325463	chr5:132365490~132365599:-
THCA	cis	rs1009077	0.514	rs988146	ENSG00000245958.5	RP11-33B1.1	4.9	1.32e-06	0.000164	0.3	0.22	Endometriosis;	chr4:119478350	chr4:119454791~119552025:+
THCA	cis	rs1048886	0.938	rs7769582	ENSG00000271967.1	RP11-134K13.4	4.9	1.32e-06	0.000164	0.22	0.22	Type 2 diabetes;	chr6:70519956	chr6:70596438~70596980:+
THCA	cis	rs7474896	0.945	rs2749561	ENSG00000263064.2	RP11-291L22.7	-4.9	1.32e-06	0.000164	-0.36	-0.22	Obesity (extreme);	chr10:37909119	chr10:38448689~38448949:+
THCA	cis	rs12893668	0.572	rs4900590	ENSG00000269958.1	RP11-73M18.8	4.9	1.32e-06	0.000164	0.21	0.22	Reticulocyte count;	chr14:103680084	chr14:103696353~103697163:+
THCA	cis	rs7829975	0.606	rs10112585	ENSG00000253981.4	ALG1L13P	-4.9	1.32e-06	0.000164	-0.21	-0.22	Mood instability;	chr8:8937520	chr8:8236003~8244667:-
THCA	cis	rs919433	0.963	rs4850428	ENSG00000231621.1	AC013264.2	4.9	1.32e-06	0.000164	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305048	chr2:197197991~197199273:+
THCA	cis	rs2281603	0.621	rs61985668	ENSG00000259116.1	RP11-973N13.4	-4.9	1.32e-06	0.000164	-0.2	-0.22	Lymphocyte counts;	chr14:64489628	chr14:64514154~64540368:-
THCA	cis	rs1858037	0.867	rs871974	ENSG00000234255.7	AC012370.3	-4.9	1.32e-06	0.000164	-0.26	-0.22	Rheumatoid arthritis;	chr2:65330153	chr2:65439888~65456571:-
THCA	cis	rs11634944	0.716	rs2732045	ENSG00000257151.1	PWAR6	4.9	1.32e-06	0.000164	0.17	0.22	Interleukin-8 levels;	chr15:25036707	chr15:25031873~25036490:+
THCA	cis	rs8059260	0.736	rs77334546	ENSG00000274038.1	RP11-66H6.4	-4.9	1.32e-06	0.000164	-0.46	-0.22	Alcohol consumption over the past year;	chr16:10970061	chr16:11056556~11057034:+
THCA	cis	rs2554380	0.657	rs4530091	ENSG00000176700.18	SCAND2P	-4.9	1.32e-06	0.000164	-0.17	-0.22	Height;	chr15:83814026	chr15:84631451~84647478:+
THCA	cis	rs172166	0.516	rs1225715	ENSG00000273712.1	RP5-874C20.7	-4.9	1.32e-06	0.000164	-0.25	-0.22	Cardiac Troponin-T levels;	chr6:28145595	chr6:28315613~28315883:-
THCA	cis	rs1048886	0.938	rs6936550	ENSG00000271967.1	RP11-134K13.4	-4.9	1.32e-06	0.000164	-0.23	-0.22	Type 2 diabetes;	chr6:70394967	chr6:70596438~70596980:+
THCA	cis	rs5758659	0.652	rs5758537	ENSG00000227370.1	RP4-669P10.19	-4.9	1.33e-06	0.000164	-0.2	-0.22	Cognitive function;	chr22:42001038	chr22:42132543~42132998:+
THCA	cis	rs11846409	0.932	rs73378158	ENSG00000211974.3	IGHV2-70	-4.9	1.33e-06	0.000164	-0.2	-0.22	Rheumatic heart disease;	chr14:106638433	chr14:106723574~106724093:-
THCA	cis	rs12760731	0.622	rs12743256	ENSG00000213057.5	C1orf220	4.9	1.33e-06	0.000164	0.26	0.22	Obesity-related traits;	chr1:178607370	chr1:178542752~178548889:+
THCA	cis	rs2976388	0.556	rs2572876	ENSG00000253741.1	CTD-2292P10.4	4.9	1.33e-06	0.000164	0.3	0.22	Urinary tract infection frequency;	chr8:142749181	chr8:142702252~142726973:-
THCA	cis	rs2337406	1	rs11850600	ENSG00000211974.3	IGHV2-70	-4.9	1.33e-06	0.000164	-0.23	-0.22	Alzheimer's disease (late onset);	chr14:106670765	chr14:106723574~106724093:-
THCA	cis	rs13096142	0.547	rs6788849	ENSG00000223552.1	RP11-24F11.2	4.9	1.33e-06	0.000164	0.23	0.22	Celiac disease;	chr3:46269109	chr3:46364955~46407059:-
THCA	cis	rs224278	0.782	rs224292	ENSG00000238280.1	RP11-436D10.3	4.9	1.33e-06	0.000164	0.27	0.22	Ewing sarcoma;	chr10:62828664	chr10:62793562~62805887:-
THCA	cis	rs4604234	0.614	rs73479918	ENSG00000272129.1	RP11-250B2.6	-4.9	1.33e-06	0.000165	-0.54	-0.22	Cancer;	chr6:80130255	chr6:80355424~80356859:+
THCA	cis	rs72843506	0.656	rs56138907	ENSG00000231258.2	ZSWIM5P2	4.9	1.33e-06	0.000165	0.32	0.22	Schizophrenia;	chr17:20085732	chr17:20583758~20591180:-
THCA	cis	rs77637988	0.578	rs11689645	ENSG00000202227.1	RNU6-282P	4.9	1.33e-06	0.000165	0.24	0.22	Joint mobility (Beighton score);	chr2:48381420	chr2:48501922~48502024:-
THCA	cis	rs5771225	0.563	rs5771281	ENSG00000273253.2	RP3-402G11.26	-4.9	1.33e-06	0.000165	-0.26	-0.22	Late-onset Alzheimer's disease;	chr22:50255050	chr22:50199090~50200837:-
THCA	cis	rs5771225	0.563	rs6010220	ENSG00000273253.2	RP3-402G11.26	-4.9	1.33e-06	0.000165	-0.26	-0.22	Late-onset Alzheimer's disease;	chr22:50255125	chr22:50199090~50200837:-
THCA	cis	rs2742234	0.541	rs10793426	ENSG00000273008.1	RP11-351D16.3	4.9	1.33e-06	0.000165	0.21	0.22	Hirschsprung disease;	chr10:43249832	chr10:43136824~43138334:-
THCA	cis	rs548181	0.545	rs1054997	ENSG00000254671.2	STT3A-AS1	4.9	1.33e-06	0.000165	0.4	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125748918	chr11:125570284~125592568:-
THCA	cis	rs728616	0.614	rs35193855	ENSG00000242600.5	MBL1P	4.9	1.33e-06	0.000165	0.27	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028739	chr10:79904898~79950336:+
THCA	cis	rs12893668	0.703	rs4906337	ENSG00000269958.1	RP11-73M18.8	4.9	1.33e-06	0.000165	0.21	0.22	Reticulocyte count;	chr14:103574077	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.703	rs7140568	ENSG00000269958.1	RP11-73M18.8	4.9	1.33e-06	0.000165	0.21	0.22	Reticulocyte count;	chr14:103575037	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.703	rs35026580	ENSG00000269958.1	RP11-73M18.8	4.9	1.33e-06	0.000165	0.21	0.22	Reticulocyte count;	chr14:103576416	chr14:103696353~103697163:+
THCA	cis	rs2067615	0.524	rs1882543	ENSG00000260329.1	RP11-412D9.4	4.9	1.33e-06	0.000165	0.21	0.22	Heart rate;	chr12:106673382	chr12:106954029~106955497:-
THCA	cis	rs9863	0.896	rs76283024	ENSG00000269997.1	RP11-214K3.21	-4.9	1.33e-06	0.000165	-0.27	-0.22	White blood cell count;	chr12:123982232	chr12:123966077~123966629:-
THCA	cis	rs4604234	0.614	rs73477975	ENSG00000272129.1	RP11-250B2.6	-4.9	1.33e-06	0.000165	-0.54	-0.22	Cancer;	chr6:80108235	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.614	rs73477981	ENSG00000272129.1	RP11-250B2.6	-4.9	1.33e-06	0.000165	-0.54	-0.22	Cancer;	chr6:80109424	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.614	rs73477985	ENSG00000272129.1	RP11-250B2.6	-4.9	1.33e-06	0.000165	-0.54	-0.22	Cancer;	chr6:80111153	chr6:80355424~80356859:+
THCA	cis	rs35160687	0.644	rs4610056	ENSG00000273080.1	RP11-301O19.1	-4.9	1.33e-06	0.000165	-0.24	-0.22	Night sleep phenotypes;	chr2:86326127	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.644	rs7595785	ENSG00000273080.1	RP11-301O19.1	-4.9	1.33e-06	0.000165	-0.24	-0.22	Night sleep phenotypes;	chr2:86329282	chr2:86195590~86196049:+
THCA	cis	rs2905347	0.737	rs2010437	ENSG00000232949.1	AC002480.4	4.9	1.33e-06	0.000165	0.28	0.22	Major depression and alcohol dependence;	chr7:22591561	chr7:22589705~22591622:+
THCA	cis	rs1707322	0.929	rs785513	ENSG00000281133.1	AL355480.3	4.9	1.33e-06	0.000165	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45580892~45580996:-
THCA	cis	rs11992162	0.967	rs4840601	ENSG00000206014.6	OR7E161P	-4.9	1.33e-06	0.000165	-0.26	-0.22	Monocyte count;	chr8:11971221	chr8:11928597~11929563:-
THCA	cis	rs7010876	0.561	rs4961087	ENSG00000253553.4	RP11-586K2.1	-4.9	1.33e-06	0.000165	-0.23	-0.22	Schizophrenia;	chr8:88332393	chr8:88326836~88737134:+
THCA	cis	rs8046148	0.756	rs12918457	ENSG00000279356.1	RP11-429P3.8	4.9	1.33e-06	0.000165	0.26	0.22	Testicular germ cell tumor;	chr16:50054157	chr16:50072862~50074986:+
THCA	cis	rs2440129	0.632	rs2292353	ENSG00000262089.1	RP11-589P10.5	4.9	1.33e-06	0.000165	0.2	0.22	Tonsillectomy;	chr17:7000218	chr17:6994642~6995189:-
THCA	cis	rs12908161	0.853	rs11633788	ENSG00000225151.9	GOLGA2P7	-4.9	1.33e-06	0.000165	-0.3	-0.22	Schizophrenia;	chr15:84761911	chr15:84199311~84230136:-
THCA	cis	rs7674212	0.57	rs6810571	ENSG00000251288.2	RP11-10L12.2	-4.9	1.33e-06	0.000165	-0.28	-0.22	Type 2 diabetes;	chr4:103165630	chr4:102751401~102752641:+
THCA	cis	rs6545883	0.868	rs7594191	ENSG00000270820.4	RP11-355B11.2	-4.9	1.33e-06	0.000165	-0.18	-0.22	Tuberculosis;	chr2:61612883	chr2:61471188~61484130:+
THCA	cis	rs440932	0.757	rs330943	ENSG00000253893.2	FAM85B	-4.9	1.33e-06	0.000165	-0.28	-0.22	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.632	rs477018	ENSG00000253893.2	FAM85B	4.9	1.33e-06	0.000165	0.32	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8743307	chr8:8167819~8226614:-
THCA	cis	rs4660261	0.526	rs2485996	ENSG00000237950.1	RP11-7O11.3	4.9	1.33e-06	0.000165	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43888989	chr1:43944370~43946551:-
THCA	cis	rs10466239	0.667	rs10899792	ENSG00000230555.2	RP11-517P14.2	4.9	1.33e-06	0.000165	0.21	0.22	Telomere length;	chr10:43364722	chr10:43420738~43422100:+
THCA	cis	rs7712401	0.623	rs922140	ENSG00000249996.1	RP11-359P5.1	4.9	1.33e-06	0.000165	0.22	0.22	Mean platelet volume;	chr5:122753195	chr5:123036271~123054667:+
THCA	cis	rs6565180	0.962	rs11642676	ENSG00000274653.1	RP11-347C12.11	4.9	1.33e-06	0.000165	0.21	0.22	Tonsillectomy;	chr16:30360334	chr16:30359825~30360336:+
THCA	cis	rs6545883	0.894	rs7602859	ENSG00000270820.4	RP11-355B11.2	-4.9	1.33e-06	0.000165	-0.18	-0.22	Tuberculosis;	chr2:61231071	chr2:61471188~61484130:+
THCA	cis	rs1979679	0.842	rs10459091	ENSG00000247934.4	RP11-967K21.1	-4.9	1.34e-06	0.000165	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.842	rs35098487	ENSG00000247934.4	RP11-967K21.1	-4.9	1.34e-06	0.000165	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28163298~28190738:-
THCA	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-4.9	1.34e-06	0.000165	-0.25	-0.22	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
THCA	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-4.9	1.34e-06	0.000165	-0.25	-0.22	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
THCA	cis	rs4950322	0.576	rs4950427	ENSG00000278811.3	LINC00624	-4.9	1.34e-06	0.000165	-0.24	-0.22	Protein quantitative trait loci;	chr1:147391175	chr1:147258885~147517875:-
THCA	cis	rs8020095	0.571	rs10141947	ENSG00000258561.1	RP11-72M17.1	-4.9	1.34e-06	0.000165	-0.29	-0.22	Depression (quantitative trait);	chr14:67075961	chr14:66212810~66509394:-
THCA	cis	rs9652601	0.622	rs17804470	ENSG00000274038.1	RP11-66H6.4	-4.9	1.34e-06	0.000165	-0.26	-0.22	Systemic lupus erythematosus;	chr16:11006111	chr16:11056556~11057034:+
THCA	cis	rs2281603	0.57	rs11623457	ENSG00000259116.1	RP11-973N13.4	-4.9	1.34e-06	0.000165	-0.2	-0.22	Lymphocyte counts;	chr14:64491388	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs1980520	ENSG00000259116.1	RP11-973N13.4	-4.9	1.34e-06	0.000165	-0.2	-0.22	Lymphocyte counts;	chr14:64493128	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs1980519	ENSG00000259116.1	RP11-973N13.4	-4.9	1.34e-06	0.000165	-0.2	-0.22	Lymphocyte counts;	chr14:64493137	chr14:64514154~64540368:-
THCA	cis	rs8062405	0.723	rs113208333	ENSG00000261766.1	RP11-22P6.2	-4.9	1.34e-06	0.000165	-0.22	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28862166~28863340:-
THCA	cis	rs11992162	0.548	rs4841631	ENSG00000206014.6	OR7E161P	4.9	1.34e-06	0.000166	0.26	0.22	Monocyte count;	chr8:11924159	chr8:11928597~11929563:-
THCA	cis	rs8028182	0.636	rs28610581	ENSG00000260274.1	RP11-817O13.8	4.9	1.34e-06	0.000166	0.16	0.22	Sudden cardiac arrest;	chr15:75520133	chr15:75368155~75369584:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000229886.1	RP5-1132H15.3	4.9	1.34e-06	0.000166	0.23	0.22	Aortic root size;	chr7:65832759	chr7:66025126~66031544:-
THCA	cis	rs875971	0.522	rs10807697	ENSG00000229886.1	RP5-1132H15.3	4.9	1.34e-06	0.000166	0.23	0.22	Aortic root size;	chr7:65951183	chr7:66025126~66031544:-
THCA	cis	rs4648045	0.565	rs11733749	ENSG00000246560.2	RP11-10L12.4	4.9	1.34e-06	0.000166	0.27	0.22	Lymphocyte percentage of white cells;	chr4:102625985	chr4:102828055~102844075:+
THCA	cis	rs642858	0.737	rs34380839	ENSG00000234147.1	RP3-460G2.2	4.9	1.34e-06	0.000166	0.28	0.22	Type 2 diabetes;	chr6:140368948	chr6:140845958~140852924:-
THCA	cis	rs642858	0.693	rs35927834	ENSG00000234147.1	RP3-460G2.2	4.9	1.34e-06	0.000166	0.28	0.22	Type 2 diabetes;	chr6:140372429	chr6:140845958~140852924:-
THCA	cis	rs72945132	0.714	rs66542029	ENSG00000254604.1	AP000487.6	-4.9	1.34e-06	0.000166	-0.41	-0.22	Coronary artery disease;	chr11:70350196	chr11:70282367~70363368:-
THCA	cis	rs8064024	0.681	rs9925944	ENSG00000267077.1	RP11-127I20.5	4.9	1.34e-06	0.000166	0.25	0.22	Cancer;	chr16:4835228	chr16:4795265~4796532:-
THCA	cis	rs7403037	1	rs7402778	ENSG00000260760.1	PWRN3	4.9	1.34e-06	0.000166	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24529801	chr15:24441127~24447967:+
THCA	cis	rs9816784	0.901	rs56253832	ENSG00000185485.13	SDHAP1	4.9	1.34e-06	0.000166	0.18	0.22	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195959748~195990318:-
THCA	cis	rs7617773	0.638	rs7644414	ENSG00000199476.1	Y_RNA	-4.9	1.34e-06	0.000166	-0.29	-0.22	Coronary artery disease;	chr3:48257589	chr3:48288587~48288694:+
THCA	cis	rs73198271	1	rs4841031	ENSG00000253893.2	FAM85B	4.9	1.34e-06	0.000166	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749885	chr8:8167819~8226614:-
THCA	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	4.9	1.34e-06	0.000166	0.25	0.22	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
THCA	cis	rs728616	0.558	rs34268041	ENSG00000242600.5	MBL1P	4.9	1.34e-06	0.000166	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80388883	chr10:79904898~79950336:+
THCA	cis	rs4819052	0.58	rs419322	ENSG00000215447.6	BX322557.10	-4.9	1.34e-06	0.000166	-0.21	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45131787	chr21:45288052~45291738:+
THCA	cis	rs8177376	0.727	rs240555	ENSG00000254905.1	RP11-712L6.7	4.9	1.34e-06	0.000166	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126332190	chr11:126292922~126294254:-
THCA	cis	rs79349575	0.783	rs4793992	ENSG00000270781.1	RP11-501C14.9	-4.9	1.34e-06	0.000166	-0.26	-0.22	Type 2 diabetes;	chr17:48930845	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs56046215	ENSG00000270781.1	RP11-501C14.9	-4.9	1.34e-06	0.000166	-0.26	-0.22	Type 2 diabetes;	chr17:48931395	chr17:48899131~48899748:+
THCA	cis	rs7474896	1	rs12781703	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37755699	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs12360411	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37757706	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs10827824	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37758111	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.943	rs11011355	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37759257	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011366	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37785230	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011370	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37794090	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11595684	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37794876	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs12763390	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37795504	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011372	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37798355	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs35951606	ENSG00000263064.2	RP11-291L22.7	4.9	1.34e-06	0.000166	0.37	0.22	Obesity (extreme);	chr10:37799419	chr10:38448689~38448949:+
THCA	cis	rs4718428	1	rs1830070	ENSG00000232546.1	RP11-458F8.1	-4.9	1.34e-06	0.000166	-0.19	-0.22	Corneal structure;	chr7:66884684	chr7:66848496~66858136:+
THCA	cis	rs6012564	0.826	rs34778847	ENSG00000227431.4	CSE1L-AS1	4.9	1.34e-06	0.000166	0.27	0.22	Anger;	chr20:49121421	chr20:49040463~49046044:-
THCA	cis	rs9959145	0.925	rs78425322	ENSG00000267108.1	RP11-861E21.1	4.9	1.34e-06	0.000166	0.28	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12725105	chr18:12432897~12437635:+
THCA	cis	rs4819052	0.684	rs914216	ENSG00000273796.1	LL21NC02-21A1.1	-4.9	1.34e-06	0.000166	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45403809~45404369:-
THCA	cis	rs7614311	0.731	rs3733121	ENSG00000271843.1	RP11-245J9.5	-4.9	1.34e-06	0.000166	-0.39	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63864984	chr3:64008082~64008692:-
THCA	cis	rs793571	0.554	rs2414608	ENSG00000245975.2	RP11-30K9.6	4.9	1.34e-06	0.000166	0.26	0.22	Schizophrenia;	chr15:58731413	chr15:58768072~58770974:-
THCA	cis	rs7577696	0.962	rs4952249	ENSG00000276334.1	AL133243.1	-4.9	1.34e-06	0.000166	-0.23	-0.22	Inflammatory biomarkers;	chr2:32118604	chr2:32521927~32523547:+
THCA	cis	rs2787702	1	rs2787703	ENSG00000237233.2	TMEM26-AS1	-4.9	1.34e-06	0.000166	-0.27	-0.22	Response to taxane treatment (placlitaxel);	chr10:61548956	chr10:61452639~61481956:+
THCA	cis	rs9393777	0.777	rs35984974	ENSG00000226314.6	ZNF192P1	-4.9	1.34e-06	0.000166	-0.41	-0.22	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28161781~28169594:+
THCA	cis	rs8020095	0.528	rs6573758	ENSG00000258561.1	RP11-72M17.1	-4.9	1.34e-06	0.000166	-0.29	-0.22	Depression (quantitative trait);	chr14:67201189	chr14:66212810~66509394:-
THCA	cis	rs8028182	0.636	rs62027209	ENSG00000260269.4	CTD-2323K18.1	-4.9	1.34e-06	0.000166	-0.33	-0.22	Sudden cardiac arrest;	chr15:75579285	chr15:75527150~75601205:-
THCA	cis	rs875971	0.54	rs35510581	ENSG00000229886.1	RP5-1132H15.3	-4.9	1.34e-06	0.000166	-0.23	-0.22	Aortic root size;	chr7:66113790	chr7:66025126~66031544:-
THCA	cis	rs13178541	0.872	rs11242285	ENSG00000250378.1	RP11-119J18.1	-4.9	1.34e-06	0.000166	-0.28	-0.22	IgG glycosylation;	chr5:135788267	chr5:135812667~135826582:+
THCA	cis	rs10761482	0.638	rs10761507	ENSG00000254271.1	RP11-131N11.4	-4.9	1.34e-06	0.000166	-0.3	-0.22	Schizophrenia;	chr10:60483474	chr10:60734342~60741828:+
THCA	cis	rs2257011	0.76	rs2585059	ENSG00000274128.1	RP11-342A23.2	-4.9	1.34e-06	0.000166	-0.27	-0.22	Height;	chr15:83616602	chr15:83962176~83962583:+
THCA	cis	rs9309473	0.5	rs12997018	ENSG00000163016.8	ALMS1P	-4.9	1.34e-06	0.000166	-0.28	-0.22	Metabolite levels;	chr2:73685772	chr2:73644919~73685576:+
THCA	cis	rs62244186	0.541	rs62244226	ENSG00000214820.3	MPRIPP1	4.9	1.34e-06	0.000166	0.22	0.22	Depressive symptoms;	chr3:44790339	chr3:44579938~44581026:-
THCA	cis	rs3796352	1	rs7645611	ENSG00000242142.1	SERBP1P3	-4.9	1.34e-06	0.000166	-0.4	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53091281	chr3:53064283~53065091:-
THCA	cis	rs7618915	0.547	rs11714419	ENSG00000243224.1	RP5-1157M23.2	-4.9	1.34e-06	0.000166	-0.24	-0.22	Bipolar disorder;	chr3:52594800	chr3:52239258~52241097:+
THCA	cis	rs72945132	0.882	rs72947012	ENSG00000254604.1	AP000487.6	-4.9	1.34e-06	0.000166	-0.42	-0.22	Coronary artery disease;	chr11:70303366	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.714	rs115143889	ENSG00000254604.1	AP000487.6	-4.9	1.34e-06	0.000166	-0.42	-0.22	Coronary artery disease;	chr11:70304016	chr11:70282367~70363368:-
THCA	cis	rs453301	0.571	rs2929305	ENSG00000248538.5	RP11-10A14.5	4.9	1.34e-06	0.000166	0.27	0.22	Joint mobility (Beighton score);	chr8:9227707	chr8:9189011~9202854:+
THCA	cis	rs7267979	0.586	rs6050431	ENSG00000277938.1	RP5-965G21.3	4.9	1.34e-06	0.000166	0.19	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.586	rs6050432	ENSG00000277938.1	RP5-965G21.3	4.9	1.34e-06	0.000166	0.19	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25229150~25231933:+
THCA	cis	rs57221529	0.766	rs4957053	ENSG00000225138.6	CTD-2228K2.7	4.9	1.34e-06	0.000166	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:575812	chr5:473236~480884:+
THCA	cis	rs57221529	0.709	rs111352378	ENSG00000225138.6	CTD-2228K2.7	4.9	1.34e-06	0.000166	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:576964	chr5:473236~480884:+
THCA	cis	rs57221529	0.709	rs72703034	ENSG00000225138.6	CTD-2228K2.7	4.9	1.34e-06	0.000166	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:576986	chr5:473236~480884:+
THCA	cis	rs57221529	0.825	rs7443550	ENSG00000225138.6	CTD-2228K2.7	4.9	1.34e-06	0.000166	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:578289	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs4245972	ENSG00000225138.6	CTD-2228K2.7	4.9	1.34e-06	0.000166	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:578457	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs72703042	ENSG00000225138.6	CTD-2228K2.7	4.9	1.34e-06	0.000166	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:579154	chr5:473236~480884:+
THCA	cis	rs6714710	0.603	rs11680321	ENSG00000230606.9	AC159540.1	-4.9	1.34e-06	0.000166	-0.24	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97762804	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.58	rs6711101	ENSG00000230606.9	AC159540.1	-4.9	1.34e-06	0.000166	-0.24	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97763350	chr2:97416165~97433527:-
THCA	cis	rs2439831	0.717	rs9806227	ENSG00000205771.5	CATSPER2P1	-4.9	1.35e-06	0.000166	-0.29	-0.22	Lung cancer in ever smokers;	chr15:43387917	chr15:43726918~43747094:-
THCA	cis	rs10090774	0.965	rs7813058	ENSG00000279766.1	RP11-642A1.2	-4.9	1.35e-06	0.000166	-0.28	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994094	chr8:140572142~140572812:-
THCA	cis	rs6686842	0.56	rs213765	ENSG00000235358.1	RP11-399E6.1	4.9	1.35e-06	0.000166	0.29	0.22	Height;	chr1:41116334	chr1:41242373~41284861:+
THCA	cis	rs897984	0.568	rs8063565	ENSG00000279196.1	RP11-1072A3.3	-4.9	1.35e-06	0.000166	-0.24	-0.22	Dementia with Lewy bodies;	chr16:30872644	chr16:30984630~30988270:-
THCA	cis	rs7809615	0.792	rs45618033	ENSG00000244219.5	GS1-259H13.2	-4.9	1.35e-06	0.000166	-0.39	-0.22	Blood metabolite ratios;	chr7:99448994	chr7:99598066~99610813:+
THCA	cis	rs2243480	1	rs6460260	ENSG00000164669.11	INTS4P1	-4.9	1.35e-06	0.000166	-0.43	-0.22	Diabetic kidney disease;	chr7:65750468	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs6460261	ENSG00000164669.11	INTS4P1	-4.9	1.35e-06	0.000166	-0.43	-0.22	Diabetic kidney disease;	chr7:65750593	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.901	rs2900904	ENSG00000164669.11	INTS4P1	4.9	1.35e-06	0.000166	0.43	0.22	Diabetic kidney disease;	chr7:65739282	chr7:65141225~65234216:+
THCA	cis	rs950169	0.58	rs17532346	ENSG00000188388.10	GOLGA6L3	4.9	1.35e-06	0.000167	0.3	0.22	Schizophrenia;	chr15:84628264	chr15:85240472~85247170:+
THCA	cis	rs6708331	0.517	rs6546570	ENSG00000179818.12	PCBP1-AS1	-4.9	1.35e-06	0.000167	-0.18	-0.22	Obesity-related traits;	chr2:70122901	chr2:69962263~70103220:-
THCA	cis	rs13113518	1	rs3762837	ENSG00000273257.1	RP11-177J6.1	4.9	1.35e-06	0.000167	0.29	0.22	Height;	chr4:55511198	chr4:55387949~55388271:+
THCA	cis	rs7577696	0.889	rs212726	ENSG00000276334.1	AL133243.1	4.9	1.35e-06	0.000167	0.24	0.22	Inflammatory biomarkers;	chr2:32244316	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.889	rs212727	ENSG00000276334.1	AL133243.1	4.9	1.35e-06	0.000167	0.24	0.22	Inflammatory biomarkers;	chr2:32244659	chr2:32521927~32523547:+
THCA	cis	rs2303319	0.504	rs62188766	ENSG00000227403.1	AC009299.3	4.9	1.35e-06	0.000167	0.53	0.22	Cognitive function;	chr2:161866709	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.685	rs62188771	ENSG00000227403.1	AC009299.3	4.9	1.35e-06	0.000167	0.53	0.22	Blood osmolality (transformed sodium);	chr2:161874873	chr2:161244739~161249050:+
THCA	cis	rs726288	1	rs61601271	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79968185	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs60721872	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79968288	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs76546854	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79968902	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs112181719	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969173	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs113855569	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969202	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs60000965	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969409	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs57294261	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969586	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs60823703	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969589	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs58704470	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969634	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs59233487	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969694	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs76494403	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969975	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs76964550	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79969977	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs79854439	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79970336	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs77613724	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79970873	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs78449408	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79970943	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs79292725	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79971014	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12247653	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79971305	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12247705	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79971362	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12241958	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79971518	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12242005	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79971534	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12218176	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79971616	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12218952	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79971636	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs11200967	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79971806	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12217477	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79972000	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs11200971	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79972194	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs11200982	ENSG00000230091.5	TMEM254-AS1	-4.9	1.35e-06	0.000167	-0.5	-0.22	Rheumatoid arthritis;	chr10:79972593	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs11200984	ENSG00000230091.5	TMEM254-AS1	-4.9	1.35e-06	0.000167	-0.5	-0.22	Rheumatoid arthritis;	chr10:79972610	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs77565539	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79972848	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12243433	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79973021	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12264259	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79973032	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs12245535	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79973248	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs4466773	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79973808	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs4325265	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79973899	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs4369337	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79973986	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs4466774	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79974030	chr10:80046860~80078912:-
THCA	cis	rs726288	1	rs4335481	ENSG00000230091.5	TMEM254-AS1	4.9	1.35e-06	0.000167	0.5	0.22	Rheumatoid arthritis;	chr10:79974084	chr10:80046860~80078912:-
THCA	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-4.9	1.35e-06	0.000167	-0.32	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000204709.4	LINC01556	4.9	1.35e-06	0.000167	0.28	0.22	Pubertal anthropometrics;	chr6:28197520	chr6:28943877~28944537:+
THCA	cis	rs11673344	0.523	rs7258438	ENSG00000276846.1	CTD-3220F14.3	4.9	1.35e-06	0.000167	0.17	0.22	Obesity-related traits;	chr19:37032534	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.503	rs10414520	ENSG00000276846.1	CTD-3220F14.3	4.9	1.35e-06	0.000167	0.17	0.22	Obesity-related traits;	chr19:37057279	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.503	rs1829603	ENSG00000276846.1	CTD-3220F14.3	4.9	1.35e-06	0.000167	0.17	0.22	Obesity-related traits;	chr19:37065396	chr19:37314868~37315620:-
THCA	cis	rs853679	0.607	rs201002	ENSG00000280107.1	AL022393.9	-4.9	1.35e-06	0.000167	-0.33	-0.22	Depression;	chr6:27840414	chr6:28170845~28172521:+
THCA	cis	rs6012564	1	rs2273653	ENSG00000227431.4	CSE1L-AS1	4.9	1.35e-06	0.000167	0.27	0.22	Anger;	chr20:49154219	chr20:49040463~49046044:-
THCA	cis	rs7674212	0.865	rs13149311	ENSG00000230069.3	LRRC37A15P	-4.9	1.35e-06	0.000167	-0.23	-0.22	Type 2 diabetes;	chr4:103056543	chr4:102727274~102730721:-
THCA	cis	rs4950322	0.512	rs2883318	ENSG00000278811.3	LINC00624	4.9	1.35e-06	0.000167	0.24	0.22	Protein quantitative trait loci;	chr1:147377422	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.512	rs12409455	ENSG00000278811.3	LINC00624	4.9	1.35e-06	0.000167	0.24	0.22	Protein quantitative trait loci;	chr1:147378563	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.6	rs11240014	ENSG00000278811.3	LINC00624	4.9	1.35e-06	0.000167	0.24	0.22	Protein quantitative trait loci;	chr1:147380674	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.576	rs11240015	ENSG00000278811.3	LINC00624	4.9	1.35e-06	0.000167	0.24	0.22	Protein quantitative trait loci;	chr1:147380813	chr1:147258885~147517875:-
THCA	cis	rs4950322	0.553	rs12093870	ENSG00000278811.3	LINC00624	4.9	1.35e-06	0.000167	0.24	0.22	Protein quantitative trait loci;	chr1:147380815	chr1:147258885~147517875:-
THCA	cis	rs7942368	0.941	rs10899279	ENSG00000261578.1	RP11-21L23.2	4.9	1.35e-06	0.000167	0.32	0.22	Endometriosis;	chr11:76766200	chr11:76800364~76804555:+
THCA	cis	rs35160687	0.644	rs4832036	ENSG00000273080.1	RP11-301O19.1	-4.9	1.35e-06	0.000167	-0.24	-0.22	Night sleep phenotypes;	chr2:86324179	chr2:86195590~86196049:+
THCA	cis	rs73198271	1	rs73198271	ENSG00000253893.2	FAM85B	4.9	1.35e-06	0.000167	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749297	chr8:8167819~8226614:-
THCA	cis	rs73198271	1	rs73198272	ENSG00000253893.2	FAM85B	4.9	1.35e-06	0.000167	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749298	chr8:8167819~8226614:-
THCA	cis	rs73198271	1	rs4841030	ENSG00000253893.2	FAM85B	4.9	1.35e-06	0.000167	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8749501	chr8:8167819~8226614:-
THCA	cis	rs1395	1	rs7593448	ENSG00000234072.1	AC074117.10	-4.9	1.35e-06	0.000167	-0.18	-0.22	Blood metabolite levels;	chr2:27226425	chr2:27356246~27367622:+
THCA	cis	rs6545883	0.859	rs2694644	ENSG00000270820.4	RP11-355B11.2	-4.9	1.35e-06	0.000167	-0.19	-0.22	Tuberculosis;	chr2:61377721	chr2:61471188~61484130:+
THCA	cis	rs6997458	0.742	rs955007	ENSG00000253549.4	RP11-317J10.2	4.9	1.35e-06	0.000167	0.22	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85458166	chr8:85441851~85464915:-
THCA	cis	rs2412819	0.571	rs2930529	ENSG00000166763.7	STRCP1	-4.9	1.35e-06	0.000167	-0.29	-0.22	Lung cancer;	chr15:43819467	chr15:43699488~43718184:-
THCA	cis	rs7403037	0.583	rs12904497	ENSG00000259905.4	PWRN1	-4.9	1.35e-06	0.000167	-0.29	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24564703	chr15:24493137~24652130:+
THCA	cis	rs4648045	0.861	rs230531	ENSG00000246560.2	RP11-10L12.4	4.9	1.35e-06	0.000167	0.27	0.22	Lymphocyte percentage of white cells;	chr4:102529220	chr4:102828055~102844075:+
THCA	cis	rs860295	0.529	rs17381047	ENSG00000225855.5	RUSC1-AS1	-4.9	1.35e-06	0.000167	-0.15	-0.22	Body mass index;	chr1:156013857	chr1:155316863~155324176:-
THCA	cis	rs4718428	0.705	rs11028	ENSG00000229886.1	RP5-1132H15.3	4.9	1.35e-06	0.000167	0.26	0.22	Corneal structure;	chr7:66811230	chr7:66025126~66031544:-
THCA	cis	rs2067615	0.524	rs10778499	ENSG00000260329.1	RP11-412D9.4	-4.9	1.35e-06	0.000167	-0.21	-0.22	Heart rate;	chr12:106674609	chr12:106954029~106955497:-
THCA	cis	rs6601450	0.547	rs10105843	ENSG00000261451.1	RP11-981G7.1	4.9	1.35e-06	0.000167	0.26	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10340353	chr8:10433672~10438312:+
THCA	cis	rs972578	0.791	rs732439	ENSG00000274717.1	RP1-47A17.1	-4.9	1.35e-06	0.000167	-0.22	-0.22	Mean platelet volume;	chr22:42907411	chr22:42791814~42794313:-
THCA	cis	rs1009077	0.68	rs13140150	ENSG00000245958.5	RP11-33B1.1	4.9	1.35e-06	0.000167	0.29	0.22	Endometriosis;	chr4:119552036	chr4:119454791~119552025:+
THCA	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-4.89	1.35e-06	0.000167	-0.28	-0.22	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
THCA	cis	rs79243044	0.965	rs11038048	ENSG00000224295.2	AC087380.14	-4.89	1.35e-06	0.000167	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5545656	chr11:5518441~5524955:-
THCA	cis	rs393155	0.517	rs330050	ENSG00000248538.5	RP11-10A14.5	4.89	1.35e-06	0.000167	0.27	0.22	Neuroticism;	chr8:9230169	chr8:9189011~9202854:+
THCA	cis	rs453301	0.571	rs330054	ENSG00000248538.5	RP11-10A14.5	4.89	1.35e-06	0.000167	0.27	0.22	Joint mobility (Beighton score);	chr8:9230781	chr8:9189011~9202854:+
THCA	cis	rs10510102	0.688	rs76573813	ENSG00000226864.1	ATE1-AS1	4.89	1.35e-06	0.000167	0.36	0.22	Breast cancer;	chr10:121928955	chr10:121928312~121951965:+
THCA	cis	rs1836229	0.594	rs1434255	ENSG00000225706.1	PTPRD-AS1	-4.89	1.35e-06	0.000167	-0.26	-0.22	Restless legs syndrome;	chr9:8830508	chr9:8858130~8862255:+
THCA	cis	rs72843506	0.656	rs10459970	ENSG00000231258.2	ZSWIM5P2	4.89	1.35e-06	0.000167	0.34	0.22	Schizophrenia;	chr17:20034028	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs2385960	ENSG00000231258.2	ZSWIM5P2	4.89	1.35e-06	0.000167	0.34	0.22	Schizophrenia;	chr17:20034904	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs8073875	ENSG00000231258.2	ZSWIM5P2	4.89	1.35e-06	0.000167	0.34	0.22	Schizophrenia;	chr17:20035746	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs57040439	ENSG00000231258.2	ZSWIM5P2	4.89	1.35e-06	0.000167	0.34	0.22	Schizophrenia;	chr17:20036522	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs58313980	ENSG00000231258.2	ZSWIM5P2	4.89	1.35e-06	0.000167	0.34	0.22	Schizophrenia;	chr17:20036737	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs73984559	ENSG00000231258.2	ZSWIM5P2	4.89	1.35e-06	0.000167	0.34	0.22	Schizophrenia;	chr17:20043203	chr17:20583758~20591180:-
THCA	cis	rs3820928	1	rs61067328	ENSG00000212391.1	SNORA48	-4.89	1.35e-06	0.000167	-0.25	-0.22	Pulmonary function;	chr2:226896540	chr2:226968989~226969122:-
THCA	cis	rs2018683	1	rs4719963	ENSG00000272568.4	CTB-113D17.1	-4.89	1.36e-06	0.000167	-0.21	-0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28971448	chr7:28979967~29013367:+
THCA	cis	rs1836229	0.594	rs2099406	ENSG00000225706.1	PTPRD-AS1	4.89	1.36e-06	0.000167	0.26	0.22	Restless legs syndrome;	chr9:8829043	chr9:8858130~8862255:+
THCA	cis	rs17772222	1	rs79579293	ENSG00000222990.1	RNU4-22P	4.89	1.36e-06	0.000168	0.3	0.22	Coronary artery calcification;	chr14:88355724	chr14:88513498~88513663:+
THCA	cis	rs875971	0.522	rs2008188	ENSG00000229886.1	RP5-1132H15.3	4.89	1.36e-06	0.000168	0.23	0.22	Aortic root size;	chr7:65964026	chr7:66025126~66031544:-
THCA	cis	rs6088580	0.634	rs6142153	ENSG00000276073.1	RP5-1125A11.7	4.89	1.36e-06	0.000168	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34380941	chr20:33985617~33988989:-
THCA	cis	rs3824435	0.744	rs7048887	ENSG00000272866.1	RP11-12D24.10	-4.89	1.36e-06	0.000168	-0.3	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5343107	chr9:5351796~5352410:-
THCA	cis	rs79349575	0.783	rs2112617	ENSG00000270781.1	RP11-501C14.9	-4.89	1.36e-06	0.000168	-0.27	-0.22	Type 2 diabetes;	chr17:48899763	chr17:48899131~48899748:+
THCA	cis	rs11992162	0.636	rs4841644	ENSG00000206014.6	OR7E161P	-4.89	1.36e-06	0.000168	-0.26	-0.22	Monocyte count;	chr8:11940924	chr8:11928597~11929563:-
THCA	cis	rs748802	0.704	rs10491554	ENSG00000235387.1	LINC00961	-4.89	1.36e-06	0.000168	-0.25	-0.22	Resting heart rate;	chr9:35910693	chr9:35909483~35911686:+
THCA	cis	rs3750965	0.919	rs12280942	ENSG00000260895.1	RP11-554A11.7	-4.89	1.36e-06	0.000168	-0.28	-0.22	Hair color;	chr11:69092215	chr11:69103493~69109094:+
THCA	cis	rs6714710	0.603	rs55776387	ENSG00000230606.9	AC159540.1	-4.89	1.36e-06	0.000168	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97788571	chr2:97416165~97433527:-
THCA	cis	rs752010	0.631	rs4660549	ENSG00000230638.4	RP11-486B10.4	-4.89	1.36e-06	0.000168	-0.27	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41622431	chr1:41542069~41544310:+
THCA	cis	rs57221529	0.6	rs11750269	ENSG00000225138.6	CTD-2228K2.7	4.89	1.36e-06	0.000168	0.28	0.22	Lung disease severity in cystic fibrosis;	chr5:666155	chr5:473236~480884:+
THCA	cis	rs17767392	0.881	rs7142343	ENSG00000259146.3	RP1-261D10.2	-4.89	1.36e-06	0.000168	-0.28	-0.22	Mitral valve prolapse;	chr14:71556772	chr14:71292729~71321814:-
THCA	cis	rs8177376	0.727	rs651034	ENSG00000254905.1	RP11-712L6.7	4.89	1.36e-06	0.000168	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331563	chr11:126292922~126294254:-
THCA	cis	rs10256972	0.869	rs4720158	ENSG00000225146.1	AC073957.15	4.89	1.36e-06	0.000168	0.22	0.22	Endometriosis;Longevity;	chr7:1000689	chr7:1029025~1043891:+
THCA	cis	rs8105895	0.935	rs8110969	ENSG00000269345.1	VN1R85P	4.89	1.36e-06	0.000168	0.29	0.22	Body mass index (change over time);	chr19:22057420	chr19:22174766~22175191:-
THCA	cis	rs7951911	1	rs7951911	ENSG00000254427.1	RP11-430H10.1	4.89	1.36e-06	0.000168	0.33	0.22	IgG glycosylation;	chr11:45062980	chr11:45355371~45366121:+
THCA	cis	rs860295	0.529	rs10908486	ENSG00000225855.5	RUSC1-AS1	-4.89	1.36e-06	0.000168	-0.15	-0.22	Body mass index;	chr1:156008753	chr1:155316863~155324176:-
THCA	cis	rs1823874	0.71	rs56186545	ENSG00000259363.4	CTD-2054N24.2	4.89	1.36e-06	0.000168	0.27	0.22	IgG glycosylation;	chr15:99820554	chr15:99807023~99877148:+
THCA	cis	rs11671005	0.735	rs35652377	ENSG00000268912.1	CTD-2619J13.17	-4.89	1.36e-06	0.000168	-0.21	-0.22	Mean platelet volume;	chr19:58417833	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs3764532	ENSG00000268912.1	CTD-2619J13.17	-4.89	1.36e-06	0.000168	-0.21	-0.22	Mean platelet volume;	chr19:58417855	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs3088284	ENSG00000268912.1	CTD-2619J13.17	-4.89	1.36e-06	0.000168	-0.21	-0.22	Mean platelet volume;	chr19:58418060	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs12981649	ENSG00000268912.1	CTD-2619J13.17	-4.89	1.36e-06	0.000168	-0.21	-0.22	Mean platelet volume;	chr19:58418676	chr19:58428632~58431148:-
THCA	cis	rs467650	0.817	rs977028	ENSG00000246763.5	RGMB-AS1	4.89	1.36e-06	0.000168	0.23	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98720804	chr5:98769618~98773469:-
THCA	cis	rs7260598	0.539	rs7250219	ENSG00000268442.1	CTD-2027I19.2	4.89	1.36e-06	0.000168	0.33	0.22	Response to taxane treatment (placlitaxel);	chr19:23912809	chr19:24162370~24163425:-
THCA	cis	rs5758659	0.652	rs133358	ENSG00000273366.1	CTA-989H11.1	-4.89	1.36e-06	0.000168	-0.27	-0.22	Cognitive function;	chr22:42046535	chr22:42278188~42278846:+
THCA	cis	rs2692947	0.759	rs11687113	ENSG00000232931.4	LINC00342	4.89	1.36e-06	0.000168	0.18	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95992840	chr2:95807118~95816215:-
THCA	cis	rs10888838	0.618	rs13571	ENSG00000198711.5	SSBP3-AS1	-4.89	1.36e-06	0.000168	-0.2	-0.22	Mitochondrial DNA levels;	chr1:54216247	chr1:54236440~54239063:+
THCA	cis	rs62184315	0.536	rs2289405	ENSG00000253559.1	OSGEPL1-AS1	-4.89	1.36e-06	0.000168	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189771313	chr2:189762704~189765556:+
THCA	cis	rs858239	0.508	rs10242104	ENSG00000226816.2	AC005082.12	4.89	1.36e-06	0.000168	0.32	0.22	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23206013~23208045:+
THCA	cis	rs4660214	0.666	rs683135	ENSG00000182109.6	RP11-69E11.4	4.89	1.36e-06	0.000168	0.22	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39429788	chr1:39522280~39546187:-
THCA	cis	rs72945132	0.882	rs55758686	ENSG00000254604.1	AP000487.6	-4.89	1.36e-06	0.000168	-0.41	-0.22	Coronary artery disease;	chr11:70326098	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs6592537	ENSG00000254604.1	AP000487.6	-4.89	1.36e-06	0.000168	-0.41	-0.22	Coronary artery disease;	chr11:70326869	chr11:70282367~70363368:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000229886.1	RP5-1132H15.3	4.89	1.36e-06	0.000168	0.23	0.22	Calcium levels;	chr7:65941231	chr7:66025126~66031544:-
THCA	cis	rs919433	0.648	rs6434933	ENSG00000231621.1	AC013264.2	-4.89	1.36e-06	0.000168	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197562236	chr2:197197991~197199273:+
THCA	cis	rs2067615	0.579	rs10861657	ENSG00000260329.1	RP11-412D9.4	-4.89	1.36e-06	0.000168	-0.2	-0.22	Heart rate;	chr12:106737536	chr12:106954029~106955497:-
THCA	cis	rs4604234	0.614	rs73479932	ENSG00000272129.1	RP11-250B2.6	-4.89	1.36e-06	0.000168	-0.54	-0.22	Cancer;	chr6:80132154	chr6:80355424~80356859:+
THCA	cis	rs7074356	0.525	rs12246441	ENSG00000225484.5	NUTM2B-AS1	4.89	1.36e-06	0.000168	0.31	0.22	Borderline personality disorder;	chr10:80497980	chr10:79663088~79826594:-
THCA	cis	rs9959145	0.706	rs117416781	ENSG00000267108.1	RP11-861E21.1	4.89	1.36e-06	0.000168	0.27	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12684925	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs78421903	ENSG00000267108.1	RP11-861E21.1	4.89	1.36e-06	0.000168	0.27	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12688701	chr18:12432897~12437635:+
THCA	cis	rs2803122	0.775	rs10118150	ENSG00000273226.1	RP11-513M16.8	-4.89	1.36e-06	0.000168	-0.2	-0.22	Pulse pressure;	chr9:19235482	chr9:19375451~19375996:+
THCA	cis	rs2985684	0.894	rs6572586	ENSG00000278009.1	RP11-649E7.8	4.89	1.36e-06	0.000168	0.3	0.22	Carotid intima media thickness;	chr14:49555223	chr14:49601011~49601124:-
THCA	cis	rs13434995	0.513	rs2130040	ENSG00000273257.1	RP11-177J6.1	4.89	1.36e-06	0.000168	0.33	0.22	Adiponectin levels;	chr4:55564036	chr4:55387949~55388271:+
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000229886.1	RP5-1132H15.3	4.89	1.36e-06	0.000169	0.27	0.22	Corneal structure;	chr7:66801919	chr7:66025126~66031544:-
THCA	cis	rs875971	0.522	rs4718286	ENSG00000223473.2	GS1-124K5.3	4.89	1.37e-06	0.000169	0.15	0.22	Aortic root size;	chr7:65827777	chr7:66491049~66493566:-
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000223473.2	GS1-124K5.3	4.89	1.37e-06	0.000169	0.15	0.22	Calcium levels;	chr7:65837419	chr7:66491049~66493566:-
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000223473.2	GS1-124K5.3	4.89	1.37e-06	0.000169	0.15	0.22	Calcium levels;	chr7:65872915	chr7:66491049~66493566:-
THCA	cis	rs2439831	0.867	rs2278860	ENSG00000205771.5	CATSPER2P1	4.89	1.37e-06	0.000169	0.29	0.22	Lung cancer in ever smokers;	chr15:43366848	chr15:43726918~43747094:-
THCA	cis	rs12893668	0.703	rs4906336	ENSG00000269958.1	RP11-73M18.8	4.89	1.37e-06	0.000169	0.22	0.22	Reticulocyte count;	chr14:103566928	chr14:103696353~103697163:+
THCA	cis	rs2439831	0.717	rs690170	ENSG00000166763.7	STRCP1	4.89	1.37e-06	0.000169	0.34	0.22	Lung cancer in ever smokers;	chr15:43518224	chr15:43699488~43718184:-
THCA	cis	rs4908768	0.52	rs6695867	ENSG00000232912.4	RP5-1115A15.1	4.89	1.37e-06	0.000169	0.21	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8670720	chr1:8424645~8434838:+
THCA	cis	rs7772486	0.686	rs1415744	ENSG00000270638.1	RP3-466P17.1	4.89	1.37e-06	0.000169	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145735570~145737218:+
THCA	cis	rs16975963	0.644	rs11666738	ENSG00000226686.6	LINC01535	-4.89	1.37e-06	0.000169	-0.29	-0.22	Longevity;	chr19:37639418	chr19:37251912~37265535:+
THCA	cis	rs875971	0.545	rs6969224	ENSG00000228409.4	CCT6P1	-4.89	1.37e-06	0.000169	-0.19	-0.22	Aortic root size;	chr7:66370011	chr7:65751142~65763354:+
THCA	cis	rs59918340	0.764	rs753779	ENSG00000253307.1	RP11-10J21.4	4.89	1.37e-06	0.000169	0.3	0.22	Immature fraction of reticulocytes;	chr8:141218710	chr8:141252286~141253292:-
THCA	cis	rs28735056	0.587	rs8093548	ENSG00000261126.6	RP11-795F19.1	-4.89	1.37e-06	0.000169	-0.18	-0.22	Schizophrenia;	chr18:79876451	chr18:80046900~80095482:+
THCA	cis	rs11733284	1	rs13142905	ENSG00000259959.1	RP11-121C2.2	4.89	1.37e-06	0.000169	0.18	0.22	Gout;Renal underexcretion gout;	chr4:48023281	chr4:47840122~47844339:-
THCA	cis	rs11733284	1	rs13125949	ENSG00000259959.1	RP11-121C2.2	4.89	1.37e-06	0.000169	0.18	0.22	Gout;Renal underexcretion gout;	chr4:48024543	chr4:47840122~47844339:-
THCA	cis	rs9813712	0.523	rs9866942	ENSG00000249846.5	RP11-77P16.4	-4.89	1.37e-06	0.000169	-0.23	-0.22	Response to amphetamines;	chr3:130297796	chr3:130112550~130120579:+
THCA	cis	rs972578	0.791	rs738383	ENSG00000274717.1	RP1-47A17.1	-4.89	1.37e-06	0.000169	-0.23	-0.22	Mean platelet volume;	chr22:42919387	chr22:42791814~42794313:-
THCA	cis	rs763121	0.853	rs2281021	ENSG00000228274.3	RP3-508I15.9	-4.89	1.37e-06	0.000169	-0.24	-0.22	Menopause (age at onset);	chr22:38668662	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5995610	ENSG00000228274.3	RP3-508I15.9	-4.89	1.37e-06	0.000169	-0.24	-0.22	Menopause (age at onset);	chr22:38668676	chr22:38667585~38681820:-
THCA	cis	rs10256972	0.967	rs7799110	ENSG00000225146.1	AC073957.15	4.89	1.37e-06	0.000169	0.22	0.22	Endometriosis;Longevity;	chr7:999429	chr7:1029025~1043891:+
THCA	cis	rs7088591	0.764	rs73285017	ENSG00000276818.1	AC026393.1	4.89	1.37e-06	0.000169	0.4	0.22	Blood pressure;	chr10:57952548	chr10:57095699~57095781:+
THCA	cis	rs2412819	0.571	rs2930530	ENSG00000166763.7	STRCP1	-4.89	1.37e-06	0.000169	-0.29	-0.22	Lung cancer;	chr15:43823268	chr15:43699488~43718184:-
THCA	cis	rs9388451	0.591	rs1268792	ENSG00000226409.1	RP11-735G4.1	4.89	1.37e-06	0.000169	0.27	0.22	Brugada syndrome;	chr6:125720978	chr6:125370211~125374324:-
THCA	cis	rs6472827	0.645	rs1532577	ENSG00000253983.2	RP1-16A9.1	4.89	1.37e-06	0.000169	0.32	0.22	Uterine fibroids;	chr8:74193907	chr8:74199396~74208441:+
THCA	cis	rs972578	0.715	rs2273142	ENSG00000274717.1	RP1-47A17.1	-4.89	1.37e-06	0.000169	-0.23	-0.22	Mean platelet volume;	chr22:42834134	chr22:42791814~42794313:-
THCA	cis	rs3750965	1	rs3750965	ENSG00000260895.1	RP11-554A11.7	4.89	1.37e-06	0.000169	0.3	0.22	Hair color;	chr11:69072692	chr11:69103493~69109094:+
THCA	cis	rs8028182	0.636	rs4299117	ENSG00000260274.1	RP11-817O13.8	4.89	1.37e-06	0.000169	0.16	0.22	Sudden cardiac arrest;	chr15:75497103	chr15:75368155~75369584:+
THCA	cis	rs481331	0.799	rs1855445	ENSG00000215146.4	RP11-313J2.1	4.89	1.37e-06	0.000169	0.35	0.22	Systemic juvenile idiopathic arthritis;	chr10:42480355	chr10:42331866~42367974:-
THCA	cis	rs4713118	0.662	rs149946	ENSG00000261839.1	RP1-265C24.8	-4.89	1.37e-06	0.000169	-0.25	-0.22	Parkinson's disease;	chr6:28002253	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.662	rs156744	ENSG00000261839.1	RP1-265C24.8	4.89	1.37e-06	0.000169	0.25	0.22	Parkinson's disease;	chr6:27999496	chr6:28136849~28139678:+
THCA	cis	rs7554547	0.69	rs1474576	ENSG00000199347.1	RNU5E-1	-4.89	1.37e-06	0.000169	-0.31	-0.22	Nonsyndromic cleft lip with cleft palate;	chr1:11887572	chr1:11908152~11908271:+
THCA	cis	rs59918340	0.738	rs3739235	ENSG00000253307.1	RP11-10J21.4	4.89	1.37e-06	0.000169	0.3	0.22	Immature fraction of reticulocytes;	chr8:141219046	chr8:141252286~141253292:-
THCA	cis	rs59918340	0.764	rs3824234	ENSG00000253307.1	RP11-10J21.4	4.89	1.37e-06	0.000169	0.3	0.22	Immature fraction of reticulocytes;	chr8:141219271	chr8:141252286~141253292:-
THCA	cis	rs6442522	0.772	rs2278962	ENSG00000249786.6	EAF1-AS1	4.89	1.37e-06	0.000169	0.23	0.22	Uric acid levels;	chr3:15451279	chr3:15436171~15455940:-
THCA	cis	rs2412819	0.597	rs2412821	ENSG00000166763.7	STRCP1	4.89	1.37e-06	0.000169	0.29	0.22	Lung cancer;	chr15:43864966	chr15:43699488~43718184:-
THCA	cis	rs6565180	1	rs68051857	ENSG00000274653.1	RP11-347C12.11	4.89	1.37e-06	0.000169	0.2	0.22	Tonsillectomy;	chr16:30348690	chr16:30359825~30360336:+
THCA	cis	rs6565180	1	rs6565180	ENSG00000274653.1	RP11-347C12.11	4.89	1.37e-06	0.000169	0.2	0.22	Tonsillectomy;	chr16:30350020	chr16:30359825~30360336:+
THCA	cis	rs6545883	0.894	rs35292974	ENSG00000270820.4	RP11-355B11.2	-4.89	1.37e-06	0.000169	-0.18	-0.22	Tuberculosis;	chr2:61294912	chr2:61471188~61484130:+
THCA	cis	rs2033711	0.654	rs734380	ENSG00000268049.1	CTD-2619J13.9	-4.89	1.37e-06	0.000169	-0.28	-0.22	Uric acid clearance;	chr19:58387596	chr19:58357999~58359603:+
THCA	cis	rs6832769	1	rs28514423	ENSG00000272969.1	RP11-528I4.2	-4.89	1.37e-06	0.000169	-0.26	-0.22	Personality dimensions;	chr4:55563072	chr4:55547112~55547889:+
THCA	cis	rs950169	0.58	rs1061737	ENSG00000188388.10	GOLGA6L3	4.89	1.37e-06	0.000169	0.3	0.22	Schizophrenia;	chr15:84640559	chr15:85240472~85247170:+
THCA	cis	rs6598266	1	rs12917342	ENSG00000259363.4	CTD-2054N24.2	-4.89	1.37e-06	0.000169	-0.39	-0.22	Major depressive disorder;	chr15:99757640	chr15:99807023~99877148:+
THCA	cis	rs2440129	0.611	rs1126667	ENSG00000262089.1	RP11-589P10.5	-4.89	1.37e-06	0.000169	-0.2	-0.22	Tonsillectomy;	chr17:6999441	chr17:6994642~6995189:-
THCA	cis	rs4748857	0.588	rs1325588	ENSG00000224215.1	RP11-371A19.2	-4.89	1.37e-06	0.000169	-0.3	-0.22	Systemic lupus erythematosus;	chr10:23218280	chr10:23343957~23345181:+
THCA	cis	rs6545883	0.894	rs6545845	ENSG00000270820.4	RP11-355B11.2	-4.89	1.37e-06	0.000169	-0.18	-0.22	Tuberculosis;	chr2:61209909	chr2:61471188~61484130:+
THCA	cis	rs293377	0.961	rs293370	ENSG00000260123.1	RP11-326A19.4	-4.89	1.37e-06	0.00017	-0.27	-0.22	Gut microbiota (beta diversity);	chr15:89087245	chr15:89041223~89082819:+
THCA	cis	rs12049671	1	rs12049671	ENSG00000227076.1	RP11-4C20.4	4.89	1.37e-06	0.00017	0.24	0.22	Response to amphetamines;	chr10:127939367	chr10:127934698~127936167:+
THCA	cis	rs12049671	1	rs12769331	ENSG00000227076.1	RP11-4C20.4	4.89	1.37e-06	0.00017	0.24	0.22	Response to amphetamines;	chr10:127942404	chr10:127934698~127936167:+
THCA	cis	rs12049671	1	rs12414855	ENSG00000227076.1	RP11-4C20.4	4.89	1.37e-06	0.00017	0.24	0.22	Response to amphetamines;	chr10:127943116	chr10:127934698~127936167:+
THCA	cis	rs12049671	1	rs12414312	ENSG00000227076.1	RP11-4C20.4	4.89	1.37e-06	0.00017	0.24	0.22	Response to amphetamines;	chr10:127943195	chr10:127934698~127936167:+
THCA	cis	rs12049671	1	rs12414866	ENSG00000227076.1	RP11-4C20.4	4.89	1.37e-06	0.00017	0.24	0.22	Response to amphetamines;	chr10:127943241	chr10:127934698~127936167:+
THCA	cis	rs7192208	0.541	rs889706	ENSG00000260922.1	RP11-538I12.3	-4.89	1.37e-06	0.00017	-0.34	-0.22	White matter integrity;	chr16:77283694	chr16:77234877~77290934:+
THCA	cis	rs3770081	1	rs6724025	ENSG00000272564.1	RP11-548P2.2	-4.89	1.38e-06	0.00017	-0.39	-0.22	Facial emotion recognition (sad faces);	chr2:85973712	chr2:85904279~85904727:+
THCA	cis	rs516805	0.52	rs6926219	ENSG00000279453.1	RP3-425C14.4	-4.89	1.38e-06	0.00017	-0.18	-0.22	Lymphocyte counts;	chr6:122399661	chr6:122436789~122439223:-
THCA	cis	rs11673344	0.542	rs826327	ENSG00000276846.1	CTD-3220F14.3	4.89	1.38e-06	0.00017	0.17	0.22	Obesity-related traits;	chr19:37004397	chr19:37314868~37315620:-
THCA	cis	rs9625935	0.957	rs41162	ENSG00000279159.1	RP3-394A18.1	-4.89	1.38e-06	0.00017	-0.16	-0.22	Tonsillectomy;	chr22:30012721	chr22:29978950~30028236:-
THCA	cis	rs11992162	0.56	rs13256329	ENSG00000206014.6	OR7E161P	4.89	1.38e-06	0.00017	0.26	0.22	Monocyte count;	chr8:11924705	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.638	rs67146188	ENSG00000206014.6	OR7E161P	4.89	1.38e-06	0.00017	0.26	0.22	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:11928597~11929563:-
THCA	cis	rs7615952	0.736	rs11921945	ENSG00000248787.1	RP11-666A20.4	-4.89	1.38e-06	0.00017	-0.37	-0.22	Blood pressure (smoking interaction);	chr3:125924876	chr3:125908005~125910272:-
THCA	cis	rs793571	0.554	rs28818840	ENSG00000245975.2	RP11-30K9.6	4.89	1.38e-06	0.00017	0.26	0.22	Schizophrenia;	chr15:58727115	chr15:58768072~58770974:-
THCA	cis	rs793571	0.554	rs28536555	ENSG00000245975.2	RP11-30K9.6	4.89	1.38e-06	0.00017	0.26	0.22	Schizophrenia;	chr15:58730403	chr15:58768072~58770974:-
THCA	cis	rs4713118	0.662	rs149969	ENSG00000261839.1	RP1-265C24.8	4.89	1.38e-06	0.00017	0.25	0.22	Parkinson's disease;	chr6:28009959	chr6:28136849~28139678:+
THCA	cis	rs7010876	0.513	rs4961086	ENSG00000253553.4	RP11-586K2.1	-4.89	1.38e-06	0.00017	-0.22	-0.22	Schizophrenia;	chr8:88332072	chr8:88326836~88737134:+
THCA	cis	rs34779708	0.658	rs4934715	ENSG00000271335.4	RP11-324I22.4	4.89	1.38e-06	0.00017	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35314552~35336401:-
THCA	cis	rs9309473	0.5	rs7608328	ENSG00000163016.8	ALMS1P	-4.89	1.38e-06	0.00017	-0.28	-0.22	Metabolite levels;	chr2:73686892	chr2:73644919~73685576:+
THCA	cis	rs13434995	0.562	rs10529258	ENSG00000273257.1	RP11-177J6.1	-4.89	1.38e-06	0.00017	-0.33	-0.22	Adiponectin levels;	chr4:55546702	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.512	rs115635692	ENSG00000273257.1	RP11-177J6.1	-4.89	1.38e-06	0.00017	-0.33	-0.22	Adiponectin levels;	chr4:55546706	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.626	rs116135676	ENSG00000273257.1	RP11-177J6.1	-4.89	1.38e-06	0.00017	-0.33	-0.22	Adiponectin levels;	chr4:55546707	chr4:55387949~55388271:+
THCA	cis	rs7727544	0.507	rs10051679	ENSG00000224431.1	AC063976.7	4.89	1.38e-06	0.00017	0.18	0.22	Blood metabolite levels;	chr5:132235238	chr5:132199456~132203487:+
THCA	cis	rs7267979	0.78	rs6050679	ENSG00000125804.12	FAM182A	-4.89	1.38e-06	0.00017	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26054655~26086917:+
THCA	cis	rs7621025	0.542	rs13075615	ENSG00000273486.1	RP11-731C17.2	-4.89	1.38e-06	0.00017	-0.28	-0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136786990	chr3:136837338~136839021:-
THCA	cis	rs7208859	0.673	rs7211776	ENSG00000280069.1	CTD-2349P21.3	-4.89	1.38e-06	0.00017	-0.32	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30738182~30740275:+
THCA	cis	rs944289	0.774	rs1958623	ENSG00000258844.1	RP11-259K15.2	4.89	1.38e-06	0.00017	0.2	0.22	Thyroid cancer;	chr14:36128417	chr14:36214607~36235608:+
THCA	cis	rs6545883	0.56	rs11677775	ENSG00000270820.4	RP11-355B11.2	-4.89	1.38e-06	0.000171	-0.19	-0.22	Tuberculosis;	chr2:61275975	chr2:61471188~61484130:+
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000228409.4	CCT6P1	4.89	1.38e-06	0.000171	0.3	0.22	Diabetic kidney disease;	chr7:66009932	chr7:65751142~65763354:+
THCA	cis	rs5758659	0.714	rs7245	ENSG00000182057.4	OGFRP1	-4.89	1.38e-06	0.000171	-0.25	-0.22	Cognitive function;	chr22:42085845	chr22:42269753~42275196:+
THCA	cis	rs7851660	0.809	rs3824495	ENSG00000214417.4	KRT18P13	4.89	1.38e-06	0.000171	0.2	0.22	Strep throat;	chr9:97901418	chr9:97698922~97700734:+
THCA	cis	rs62246343	0.654	rs7631372	ENSG00000254485.4	RP11-380O24.1	4.89	1.38e-06	0.000171	0.29	0.22	Fibrinogen levels;	chr3:9451631	chr3:9292588~9363303:-
THCA	cis	rs7474896	1	rs10827823	ENSG00000263064.2	RP11-291L22.7	4.89	1.38e-06	0.000171	0.37	0.22	Obesity (extreme);	chr10:37750453	chr10:38448689~38448949:+
THCA	cis	rs10083830	0.628	rs4925084	ENSG00000261033.1	RP11-209D14.2	-4.89	1.38e-06	0.000171	-0.3	-0.22	Immature fraction of reticulocytes;	chr17:20095645	chr17:20008051~20009234:-
THCA	cis	rs1876905	0.539	rs240969	ENSG00000230177.1	RP5-1112D6.4	4.89	1.38e-06	0.000171	0.23	0.22	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111277932~111278742:+
THCA	cis	rs11671005	0.568	rs73068325	ENSG00000269600.1	AC016629.3	-4.89	1.38e-06	0.000171	-0.31	-0.22	Mean platelet volume;	chr19:58567729	chr19:58593896~58599355:-
THCA	cis	rs8062405	0.54	rs480400	ENSG00000278665.1	RP11-666O2.4	4.89	1.38e-06	0.000171	0.23	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28599241~28601881:-
THCA	cis	rs860295	0.702	rs12067371	ENSG00000160766.13	GBAP1	-4.89	1.38e-06	0.000171	-0.26	-0.22	Body mass index;	chr1:155467878	chr1:155213821~155227422:-
THCA	cis	rs11168187	0.527	rs7957537	ENSG00000274902.1	RP1-197B17.4	4.89	1.38e-06	0.000171	0.32	0.22	Vertical cup-disc ratio;	chr12:47742199	chr12:47731908~47732351:+
THCA	cis	rs1048886	0.872	rs58370765	ENSG00000271967.1	RP11-134K13.4	-4.89	1.38e-06	0.000171	-0.22	-0.22	Type 2 diabetes;	chr6:70557626	chr6:70596438~70596980:+
THCA	cis	rs79349575	0.783	rs58591767	ENSG00000270781.1	RP11-501C14.9	-4.89	1.39e-06	0.000171	-0.26	-0.22	Type 2 diabetes;	chr17:48948714	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs59270107	ENSG00000270781.1	RP11-501C14.9	-4.89	1.39e-06	0.000171	-0.26	-0.22	Type 2 diabetes;	chr17:48948823	chr17:48899131~48899748:+
THCA	cis	rs8028182	0.636	rs28432989	ENSG00000260274.1	RP11-817O13.8	4.89	1.39e-06	0.000171	0.16	0.22	Sudden cardiac arrest;	chr15:75475956	chr15:75368155~75369584:+
THCA	cis	rs6012564	0.819	rs6012565	ENSG00000227431.4	CSE1L-AS1	-4.89	1.39e-06	0.000171	-0.28	-0.22	Anger;	chr20:48938999	chr20:49040463~49046044:-
THCA	cis	rs2692947	0.567	rs4907276	ENSG00000168992.4	OR7E102P	-4.89	1.39e-06	0.000171	-0.28	-0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95725361	chr2:95546531~95547545:+
THCA	cis	rs7688540	0.8	rs73793597	ENSG00000275426.1	CH17-262A2.1	4.89	1.39e-06	0.000171	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:149738~150317:+
THCA	cis	rs860295	0.702	rs10796946	ENSG00000160766.13	GBAP1	-4.89	1.39e-06	0.000171	-0.26	-0.22	Body mass index;	chr1:155459699	chr1:155213821~155227422:-
THCA	cis	rs860295	0.676	rs10908466	ENSG00000160766.13	GBAP1	-4.89	1.39e-06	0.000171	-0.26	-0.22	Body mass index;	chr1:155459934	chr1:155213821~155227422:-
THCA	cis	rs2985684	1	rs3007031	ENSG00000278009.1	RP11-649E7.8	4.89	1.39e-06	0.000171	0.31	0.22	Carotid intima media thickness;	chr14:49635551	chr14:49601011~49601124:-
THCA	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	4.89	1.39e-06	0.000171	0.19	0.22	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
THCA	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	4.89	1.39e-06	0.000171	0.27	0.22	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
THCA	cis	rs17772222	0.561	rs8020376	ENSG00000258983.2	RP11-507K2.2	4.89	1.39e-06	0.000171	0.26	0.22	Coronary artery calcification;	chr14:88349823	chr14:88499334~88515502:+
THCA	cis	rs6601450	0.522	rs7837979	ENSG00000261451.1	RP11-981G7.1	4.89	1.39e-06	0.000171	0.26	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10341024	chr8:10433672~10438312:+
THCA	cis	rs7618915	0.547	rs4687548	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52632634	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs13069481	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52632850	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.57	rs13068293	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52638151	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.532	rs13060675	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52640284	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs11130311	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52640989	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.57	rs11130312	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52641039	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs11130313	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52642174	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs7642198	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52643944	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs13085895	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.39e-06	0.000171	-0.24	-0.22	Bipolar disorder;	chr3:52644254	chr3:52239258~52241097:+
THCA	cis	rs6479874	0.92	rs2339681	ENSG00000223502.1	RP11-96B5.3	-4.89	1.39e-06	0.000171	-0.25	-0.22	Migraine;	chr10:51032739	chr10:51062579~51068553:-
THCA	cis	rs17767392	0.914	rs28859432	ENSG00000259146.3	RP1-261D10.2	4.89	1.39e-06	0.000171	0.28	0.22	Mitral valve prolapse;	chr14:71543976	chr14:71292729~71321814:-
THCA	cis	rs11673344	0.523	rs8108509	ENSG00000276846.1	CTD-3220F14.3	4.89	1.39e-06	0.000171	0.17	0.22	Obesity-related traits;	chr19:37060370	chr19:37314868~37315620:-
THCA	cis	rs34779708	0.931	rs11010132	ENSG00000271335.4	RP11-324I22.4	4.89	1.39e-06	0.000171	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35314552~35336401:-
THCA	cis	rs4722166	0.63	rs6969258	ENSG00000225541.1	AC002480.5	-4.89	1.39e-06	0.000171	-0.28	-0.22	Lung cancer;	chr7:22742909	chr7:22571607~22661792:-
THCA	cis	rs2243480	1	rs160652	ENSG00000164669.11	INTS4P1	4.89	1.39e-06	0.000171	0.43	0.22	Diabetic kidney disease;	chr7:66073444	chr7:65141225~65234216:+
THCA	cis	rs516805	0.52	rs553889	ENSG00000279453.1	RP3-425C14.4	-4.89	1.39e-06	0.000171	-0.18	-0.22	Lymphocyte counts;	chr6:122407734	chr6:122436789~122439223:-
THCA	cis	rs4950322	0.542	rs56080828	ENSG00000271721.1	RP11-337C18.9	4.89	1.39e-06	0.000171	0.25	0.22	Protein quantitative trait loci;	chr1:147183447	chr1:147175602~147177740:+
THCA	cis	rs67478160	0.643	rs6575997	ENSG00000258735.1	LINC00637	4.89	1.39e-06	0.000171	0.26	0.22	Schizophrenia;	chr14:103762209	chr14:103847721~103858049:+
THCA	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	4.89	1.39e-06	0.000171	0.28	0.22	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
THCA	cis	rs12435908	1	rs10083488	ENSG00000276116.2	FUT8-AS1	-4.89	1.39e-06	0.000171	-0.34	-0.22	Ischemic stroke;	chr14:65386628	chr14:65411170~65412690:-
THCA	cis	rs1005277	0.54	rs1987431	ENSG00000276805.1	RP11-291L22.6	4.89	1.39e-06	0.000171	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38451030~38451785:+
THCA	cis	rs17767392	0.67	rs2159145	ENSG00000259146.3	RP1-261D10.2	4.89	1.39e-06	0.000172	0.28	0.22	Mitral valve prolapse;	chr14:71259634	chr14:71292729~71321814:-
THCA	cis	rs6560517	0.597	rs4526423	ENSG00000234618.1	RPSAP9	-4.89	1.39e-06	0.000172	-0.27	-0.22	Dialysis-related mortality;	chr9:76467489	chr9:76398699~76399586:+
THCA	cis	rs10090774	0.901	rs11997937	ENSG00000279766.1	RP11-642A1.2	-4.89	1.39e-06	0.000172	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140957252	chr8:140572142~140572812:-
THCA	cis	rs3820928	0.874	rs6740108	ENSG00000212391.1	SNORA48	4.89	1.39e-06	0.000172	0.24	0.22	Pulmonary function;	chr2:227024843	chr2:226968989~226969122:-
THCA	cis	rs9992667	0.955	rs28510735	ENSG00000231160.8	KLF3-AS1	4.89	1.39e-06	0.000172	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38612320	chr4:38612701~38664883:-
THCA	cis	rs9992667	0.955	rs6819274	ENSG00000231160.8	KLF3-AS1	4.89	1.39e-06	0.000172	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38614306	chr4:38612701~38664883:-
THCA	cis	rs6442522	0.809	rs12494163	ENSG00000249786.6	EAF1-AS1	4.89	1.39e-06	0.000172	0.23	0.22	Uric acid levels;	chr3:15382327	chr3:15436171~15455940:-
THCA	cis	rs7829975	0.517	rs12542733	ENSG00000233609.3	RP11-62H7.2	-4.89	1.39e-06	0.000172	-0.21	-0.22	Mood instability;	chr8:8967348	chr8:8961200~8979025:+
THCA	cis	rs7045881	0.8	rs17694324	ENSG00000254396.1	RP11-56F10.3	4.89	1.39e-06	0.000172	0.41	0.22	Schizophrenia;	chr9:26916072	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.733	rs62544440	ENSG00000254396.1	RP11-56F10.3	4.89	1.39e-06	0.000172	0.41	0.22	Schizophrenia;	chr9:26916910	chr9:27102630~27104728:+
THCA	cis	rs6477918	0.598	rs16916995	ENSG00000230185.4	C9orf147	4.89	1.4e-06	0.000172	0.24	0.22	Obstetric antiphospholipid syndrome;	chr9:112451422	chr9:112433816~112487204:-
THCA	cis	rs3794924	0.5	rs3907152	ENSG00000266521.1	RP11-650P15.1	4.89	1.4e-06	0.000172	0.54	0.22	Survival in colon cancer;	chr18:31447270	chr18:31496645~31497195:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000261839.1	RP1-265C24.8	4.89	1.4e-06	0.000172	0.25	0.22	Parkinson's disease;	chr6:28062721	chr6:28136849~28139678:+
THCA	cis	rs8046148	0.666	rs2287196	ENSG00000279356.1	RP11-429P3.8	4.89	1.4e-06	0.000172	0.26	0.22	Testicular germ cell tumor;	chr16:50086211	chr16:50072862~50074986:+
THCA	cis	rs73198271	0.92	rs11781542	ENSG00000253893.2	FAM85B	4.89	1.4e-06	0.000172	0.36	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8759671	chr8:8167819~8226614:-
THCA	cis	rs3750965	0.806	rs7107680	ENSG00000260895.1	RP11-554A11.7	4.89	1.4e-06	0.000172	0.3	0.22	Hair color;	chr11:69092426	chr11:69103493~69109094:+
THCA	cis	rs7618915	0.547	rs11130314	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.4e-06	0.000172	-0.24	-0.22	Bipolar disorder;	chr3:52663066	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs11130315	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.4e-06	0.000172	-0.24	-0.22	Bipolar disorder;	chr3:52663147	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs62255362	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.4e-06	0.000172	-0.24	-0.22	Bipolar disorder;	chr3:52665725	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.531	rs77146033	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.4e-06	0.000172	-0.24	-0.22	Bipolar disorder;	chr3:52667485	chr3:52239258~52241097:+
THCA	cis	rs4434138	0.664	rs62255364	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.4e-06	0.000172	-0.24	-0.22	Intelligence (multi-trait analysis);	chr3:52667486	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs12496634	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.4e-06	0.000172	-0.24	-0.22	Bipolar disorder;	chr3:52675243	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs2336542	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.4e-06	0.000172	-0.24	-0.22	Bipolar disorder;	chr3:52676620	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.571	rs67539070	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.4e-06	0.000172	-0.24	-0.22	Bipolar disorder;	chr3:52677958	chr3:52239258~52241097:+
THCA	cis	rs2348418	0.639	rs7969946	ENSG00000247934.4	RP11-967K21.1	-4.89	1.4e-06	0.000172	-0.19	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28111814	chr12:28163298~28190738:-
THCA	cis	rs875971	0.545	rs73376394	ENSG00000232546.1	RP11-458F8.1	4.89	1.4e-06	0.000172	0.2	0.22	Aortic root size;	chr7:66172694	chr7:66848496~66858136:+
THCA	cis	rs4073582	0.555	rs521109	ENSG00000255320.1	RP11-755F10.1	-4.89	1.4e-06	0.000172	-0.28	-0.22	Gout;	chr11:66263477	chr11:66244840~66246239:-
THCA	cis	rs4073582	0.516	rs1151539	ENSG00000255320.1	RP11-755F10.1	-4.89	1.4e-06	0.000172	-0.28	-0.22	Gout;	chr11:66264189	chr11:66244840~66246239:-
THCA	cis	rs4073582	0.595	rs528842	ENSG00000255320.1	RP11-755F10.1	-4.89	1.4e-06	0.000172	-0.28	-0.22	Gout;	chr11:66264919	chr11:66244840~66246239:-
THCA	cis	rs4073582	0.595	rs474005	ENSG00000255320.1	RP11-755F10.1	-4.89	1.4e-06	0.000172	-0.28	-0.22	Gout;	chr11:66265830	chr11:66244840~66246239:-
THCA	cis	rs4073582	0.595	rs2508657	ENSG00000255320.1	RP11-755F10.1	-4.89	1.4e-06	0.000172	-0.28	-0.22	Gout;	chr11:66276427	chr11:66244840~66246239:-
THCA	cis	rs6088590	0.561	rs3891369	ENSG00000276073.1	RP5-1125A11.7	-4.89	1.4e-06	0.000172	-0.19	-0.22	Coronary artery disease;	chr20:34573323	chr20:33985617~33988989:-
THCA	cis	rs35160687	0.644	rs10165626	ENSG00000273080.1	RP11-301O19.1	-4.89	1.4e-06	0.000172	-0.24	-0.22	Night sleep phenotypes;	chr2:86309584	chr2:86195590~86196049:+
THCA	cis	rs786425	0.77	rs12825800	ENSG00000270095.1	RP11-214K3.18	-4.89	1.4e-06	0.000172	-0.26	-0.22	Pubertal anthropometrics;	chr12:123709119	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs6488897	ENSG00000270095.1	RP11-214K3.18	-4.89	1.4e-06	0.000172	-0.26	-0.22	Pubertal anthropometrics;	chr12:123710936	chr12:123971457~123971714:-
THCA	cis	rs6951245	0.872	rs11768895	ENSG00000229043.2	AC091729.9	-4.89	1.4e-06	0.000172	-0.34	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024055	chr7:1160374~1165267:+
THCA	cis	rs2447820	0.588	rs10463761	ENSG00000249996.1	RP11-359P5.1	4.89	1.4e-06	0.000173	0.26	0.22	Migraine;	chr5:123042636	chr5:123036271~123054667:+
THCA	cis	rs6477918	0.598	rs4979115	ENSG00000230185.4	C9orf147	-4.89	1.4e-06	0.000173	-0.24	-0.22	Obstetric antiphospholipid syndrome;	chr9:112445477	chr9:112433816~112487204:-
THCA	cis	rs7260598	0.539	rs10418377	ENSG00000268442.1	CTD-2027I19.2	4.89	1.4e-06	0.000173	0.32	0.22	Response to taxane treatment (placlitaxel);	chr19:23898542	chr19:24162370~24163425:-
THCA	cis	rs7690839	0.803	rs1795736	ENSG00000270720.1	RP11-84C13.2	-4.89	1.4e-06	0.000173	-0.25	-0.22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89011122	chr4:89119284~89119871:+
THCA	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-4.89	1.4e-06	0.000173	-0.12	-0.22	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
THCA	cis	rs8028182	0.636	rs4451914	ENSG00000260269.4	CTD-2323K18.1	-4.89	1.4e-06	0.000173	-0.33	-0.22	Sudden cardiac arrest;	chr15:75447483	chr15:75527150~75601205:-
THCA	cis	rs28476539	0.568	rs6855705	ENSG00000270480.1	RP11-57B24.1	4.89	1.4e-06	0.000173	0.35	0.22	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82635222	chr4:82691737~82692468:+
THCA	cis	rs7989336	0.625	rs9513122	ENSG00000247400.3	DNAJC3-AS1	-4.89	1.4e-06	0.000173	-0.14	-0.22	Obesity;	chr13:96348280	chr13:95648733~95676925:-
THCA	cis	rs9876781	0.874	rs56298324	ENSG00000244380.1	RP11-24C3.2	-4.89	1.4e-06	0.000173	-0.25	-0.22	Longevity;	chr3:48393626	chr3:48440352~48446656:-
THCA	cis	rs1005277	0.522	rs9417256	ENSG00000276805.1	RP11-291L22.6	4.89	1.4e-06	0.000173	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38451030~38451785:+
THCA	cis	rs4886920	0.547	rs56994721	ENSG00000260776.4	RP11-114H24.2	4.89	1.4e-06	0.000173	0.34	0.22	Neuroticism;	chr15:77840138	chr15:77914217~77926846:-
THCA	cis	rs467650	0.817	rs61637015	ENSG00000246763.5	RGMB-AS1	4.89	1.4e-06	0.000173	0.23	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98716535	chr5:98769618~98773469:-
THCA	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-4.89	1.4e-06	0.000173	-0.25	-0.22	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
THCA	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	4.89	1.4e-06	0.000173	0.25	0.22	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
THCA	cis	rs4144027	0.791	rs66473563	ENSG00000269958.1	RP11-73M18.8	4.89	1.4e-06	0.000173	0.2	0.22	Blood metabolite levels;	chr14:103895534	chr14:103696353~103697163:+
THCA	cis	rs16846053	0.792	rs9636285	ENSG00000227403.1	AC009299.3	4.89	1.4e-06	0.000173	0.5	0.22	Blood osmolality (transformed sodium);	chr2:161824192	chr2:161244739~161249050:+
THCA	cis	rs4660214	0.666	rs2275186	ENSG00000182109.6	RP11-69E11.4	-4.89	1.4e-06	0.000173	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39522280~39546187:-
THCA	cis	rs752010	0.543	rs1570355	ENSG00000230638.4	RP11-486B10.4	-4.89	1.4e-06	0.000173	-0.24	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41576646	chr1:41542069~41544310:+
THCA	cis	rs12682352	0.602	rs1473029	ENSG00000254153.1	CTA-398F10.2	-4.89	1.4e-06	0.000173	-0.24	-0.22	Neuroticism;	chr8:8811407	chr8:8456909~8461337:-
THCA	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-4.89	1.4e-06	0.000173	-0.13	-0.22	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-4.89	1.4e-06	0.000173	-0.13	-0.22	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-4.89	1.4e-06	0.000173	-0.13	-0.22	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-4.89	1.4e-06	0.000173	-0.13	-0.22	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
THCA	cis	rs11671005	0.735	rs3826684	ENSG00000265272.2	RN7SL693P	4.89	1.4e-06	0.000173	0.31	0.22	Mean platelet volume;	chr19:58407338	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs3826683	ENSG00000265272.2	RN7SL693P	4.89	1.4e-06	0.000173	0.31	0.22	Mean platelet volume;	chr19:58407366	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.735	rs3826681	ENSG00000265272.2	RN7SL693P	4.89	1.4e-06	0.000173	0.31	0.22	Mean platelet volume;	chr19:58407397	chr19:58490797~58491075:+
THCA	cis	rs30380	1	rs469758	ENSG00000272109.1	CTD-2260A17.3	-4.89	1.4e-06	0.000173	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96804353~96806105:+
THCA	cis	rs987724	0.593	rs12634915	ENSG00000240875.4	LINC00886	-4.89	1.4e-06	0.000173	-0.17	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156974446	chr3:156747346~156817062:-
THCA	cis	rs733592	0.723	rs10875766	ENSG00000258273.1	RP11-370I10.4	-4.89	1.41e-06	0.000173	-0.27	-0.22	Plateletcrit;	chr12:48199797	chr12:48333755~48333901:-
THCA	cis	rs3750965	0.959	rs2253658	ENSG00000260895.1	RP11-554A11.7	4.89	1.41e-06	0.000173	0.3	0.22	Hair color;	chr11:69089336	chr11:69103493~69109094:+
THCA	cis	rs6545883	0.894	rs2694642	ENSG00000270820.4	RP11-355B11.2	-4.89	1.41e-06	0.000173	-0.19	-0.22	Tuberculosis;	chr2:61369045	chr2:61471188~61484130:+
THCA	cis	rs4713118	0.869	rs9283880	ENSG00000226314.6	ZNF192P1	-4.89	1.41e-06	0.000173	-0.28	-0.22	Parkinson's disease;	chr6:27747464	chr6:28161781~28169594:+
THCA	cis	rs2179367	0.6	rs9498356	ENSG00000223701.3	RAET1E-AS1	4.89	1.41e-06	0.000173	0.35	0.22	Dupuytren's disease;	chr6:149443337	chr6:149884431~149919508:+
THCA	cis	rs62184315	0.536	rs2278591	ENSG00000253559.1	OSGEPL1-AS1	-4.89	1.41e-06	0.000173	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189755778	chr2:189762704~189765556:+
THCA	cis	rs62184315	0.536	rs16831972	ENSG00000253559.1	OSGEPL1-AS1	-4.89	1.41e-06	0.000173	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189756707	chr2:189762704~189765556:+
THCA	cis	rs1979679	0.842	rs34043014	ENSG00000247934.4	RP11-967K21.1	-4.89	1.41e-06	0.000173	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171359	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.842	rs10492370	ENSG00000247934.4	RP11-967K21.1	-4.89	1.41e-06	0.000173	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171900	chr12:28163298~28190738:-
THCA	cis	rs7727544	0.645	rs272857	ENSG00000263597.1	MIR3936	4.89	1.41e-06	0.000173	0.21	0.22	Blood metabolite levels;	chr5:132349604	chr5:132365490~132365599:-
THCA	cis	rs5742933	1	rs2289404	ENSG00000273240.1	RP11-455J20.3	-4.89	1.41e-06	0.000173	-0.25	-0.22	Ferritin levels;	chr2:189771288	chr2:189763859~189764456:-
THCA	cis	rs6012564	0.963	rs6063359	ENSG00000227431.4	CSE1L-AS1	4.89	1.41e-06	0.000173	0.27	0.22	Anger;	chr20:49128547	chr20:49040463~49046044:-
THCA	cis	rs6565180	0.962	rs6565182	ENSG00000274653.1	RP11-347C12.11	4.89	1.41e-06	0.000174	0.21	0.22	Tonsillectomy;	chr16:30363060	chr16:30359825~30360336:+
THCA	cis	rs3820928	0.874	rs13430941	ENSG00000212391.1	SNORA48	-4.89	1.41e-06	0.000174	-0.24	-0.22	Pulmonary function;	chr2:227039731	chr2:226968989~226969122:-
THCA	cis	rs2439831	1	rs2444029	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43445286	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2467740	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43454594	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs561863	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43469154	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs689616	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43469703	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs689647	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43469998	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2251538	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43475011	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs2439832	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43487488	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2439850	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43492656	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2467736	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43492719	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2444250	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43492853	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs101094	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43495124	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs689781	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43499899	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2584725	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.29	0.22	Lung cancer in ever smokers;	chr15:43500937	chr15:43699488~43718184:-
THCA	cis	rs2734839	0.964	rs12808482	ENSG00000270179.1	RP11-159N11.4	-4.89	1.41e-06	0.000174	-0.23	-0.22	Information processing speed;	chr11:113424276	chr11:113368478~113369117:+
THCA	cis	rs7833787	0.725	rs12544660	ENSG00000278886.1	RP11-108A14.1	-4.89	1.41e-06	0.000174	-0.28	-0.22	Obesity-related traits;	chr8:18820894	chr8:18864681~18865247:-
THCA	cis	rs2067615	0.524	rs10861646	ENSG00000260329.1	RP11-412D9.4	-4.89	1.41e-06	0.000174	-0.21	-0.22	Heart rate;	chr12:106677404	chr12:106954029~106955497:-
THCA	cis	rs17767392	0.846	rs35151594	ENSG00000259146.3	RP1-261D10.2	4.89	1.41e-06	0.000174	0.28	0.22	Mitral valve prolapse;	chr14:71341866	chr14:71292729~71321814:-
THCA	cis	rs2120243	0.782	rs7609926	ENSG00000244515.1	KRT18P34	-4.89	1.41e-06	0.000174	-0.26	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157431371	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.791	rs7615621	ENSG00000244515.1	KRT18P34	-4.89	1.41e-06	0.000174	-0.26	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157434811	chr3:157162663~157163932:-
THCA	cis	rs375066	0.935	rs399098	ENSG00000278917.1	RP11-15A1.4	-4.89	1.41e-06	0.000174	-0.18	-0.22	Breast cancer;	chr19:43914672	chr19:43891233~43895411:+
THCA	cis	rs9867325	0.895	rs9879531	ENSG00000239213.4	NCK1-AS1	4.89	1.41e-06	0.000174	0.24	0.22	Body mass index;	chr3:136920133	chr3:136841726~136862054:-
THCA	cis	rs2734839	0.964	rs1076563	ENSG00000270179.1	RP11-159N11.4	-4.89	1.41e-06	0.000174	-0.23	-0.22	Information processing speed;	chr11:113425187	chr11:113368478~113369117:+
THCA	cis	rs2734839	0.964	rs1116313	ENSG00000270179.1	RP11-159N11.4	-4.89	1.41e-06	0.000174	-0.23	-0.22	Information processing speed;	chr11:113425385	chr11:113368478~113369117:+
THCA	cis	rs2692947	0.864	rs2579518	ENSG00000232931.4	LINC00342	4.89	1.41e-06	0.000174	0.18	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96009511	chr2:95807118~95816215:-
THCA	cis	rs6044112	0.718	rs73101048	ENSG00000273998.1	RP4-777L9.2	4.89	1.41e-06	0.000174	0.33	0.22	Response to taxane treatment (docetaxel);	chr20:16530595	chr20:16576068~16579615:+
THCA	cis	rs2439831	0.764	rs12324584	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.3	0.22	Lung cancer in ever smokers;	chr15:43391248	chr15:43699488~43718184:-
THCA	cis	rs9863	0.896	rs77112003	ENSG00000269997.1	RP11-214K3.21	-4.89	1.41e-06	0.000174	-0.27	-0.22	White blood cell count;	chr12:124002996	chr12:123966077~123966629:-
THCA	cis	rs12760731	0.582	rs6658398	ENSG00000213057.5	C1orf220	4.89	1.41e-06	0.000174	0.26	0.22	Obesity-related traits;	chr1:178589746	chr1:178542752~178548889:+
THCA	cis	rs28829049	0.536	rs2073106	ENSG00000270728.1	RP4-657E11.10	-4.89	1.41e-06	0.000174	-0.17	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19222849	chr1:19297080~19297903:+
THCA	cis	rs72843506	0.586	rs75836592	ENSG00000261033.1	RP11-209D14.2	4.89	1.41e-06	0.000174	0.42	0.22	Schizophrenia;	chr17:19935039	chr17:20008051~20009234:-
THCA	cis	rs4718428	1	rs4718421	ENSG00000230295.1	RP11-458F8.2	-4.89	1.41e-06	0.000174	-0.17	-0.22	Corneal structure;	chr7:66885313	chr7:66880708~66882981:+
THCA	cis	rs4950322	0.542	rs2883434	ENSG00000226015.2	CCT8P1	4.89	1.41e-06	0.000174	0.24	0.22	Protein quantitative trait loci;	chr1:147177505	chr1:147203276~147204932:-
THCA	cis	rs748404	0.723	rs11853991	ENSG00000166763.7	STRCP1	4.89	1.41e-06	0.000174	0.23	0.22	Lung cancer;	chr15:43265351	chr15:43699488~43718184:-
THCA	cis	rs1334894	0.901	rs76489311	ENSG00000228559.1	RP3-340B19.3	-4.89	1.41e-06	0.000174	-0.45	-0.22	Coronary artery disease;	chr6:35539641	chr6:35544632~35545669:+
THCA	cis	rs6565180	0.962	rs35480350	ENSG00000274653.1	RP11-347C12.11	4.89	1.41e-06	0.000174	0.21	0.22	Tonsillectomy;	chr16:30354718	chr16:30359825~30360336:+
THCA	cis	rs7849973	0.551	rs618398	ENSG00000224549.1	RP11-370B11.3	-4.89	1.41e-06	0.000174	-0.26	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22793908	chr9:22767175~22768316:+
THCA	cis	rs6472827	0.595	rs2936684	ENSG00000253983.2	RP1-16A9.1	4.89	1.41e-06	0.000174	0.31	0.22	Uterine fibroids;	chr8:74201522	chr8:74199396~74208441:+
THCA	cis	rs7474896	1	rs12571820	ENSG00000263064.2	RP11-291L22.7	4.89	1.41e-06	0.000174	0.37	0.22	Obesity (extreme);	chr10:37720426	chr10:38448689~38448949:+
THCA	cis	rs2239547	0.563	rs4302374	ENSG00000242142.1	SERBP1P3	4.89	1.41e-06	0.000174	0.28	0.22	Schizophrenia;	chr3:52871786	chr3:53064283~53065091:-
THCA	cis	rs13325613	0.834	rs34376347	ENSG00000223552.1	RP11-24F11.2	-4.89	1.41e-06	0.000174	-0.31	-0.22	Monocyte count;	chr3:46212488	chr3:46364955~46407059:-
THCA	cis	rs3820928	0.874	rs2276593	ENSG00000212391.1	SNORA48	4.89	1.41e-06	0.000174	0.24	0.22	Pulmonary function;	chr2:227033718	chr2:226968989~226969122:-
THCA	cis	rs11671005	0.735	rs11668420	ENSG00000268912.1	CTD-2619J13.17	-4.89	1.41e-06	0.000174	-0.21	-0.22	Mean platelet volume;	chr19:58426469	chr19:58428632~58431148:-
THCA	cis	rs944289	0.774	rs7150539	ENSG00000258844.1	RP11-259K15.2	4.89	1.41e-06	0.000174	0.2	0.22	Thyroid cancer;	chr14:36086408	chr14:36214607~36235608:+
THCA	cis	rs11992162	0.967	rs7461062	ENSG00000254948.1	OR7E158P	-4.89	1.41e-06	0.000174	-0.27	-0.22	Monocyte count;	chr8:11974439	chr8:11919900~11920809:-
THCA	cis	rs2439831	0.681	rs528517	ENSG00000205771.5	CATSPER2P1	-4.89	1.41e-06	0.000174	-0.28	-0.22	Lung cancer in ever smokers;	chr15:43320727	chr15:43726918~43747094:-
THCA	cis	rs6565180	0.889	rs8051096	ENSG00000274653.1	RP11-347C12.11	4.89	1.41e-06	0.000174	0.2	0.22	Tonsillectomy;	chr16:30336410	chr16:30359825~30360336:+
THCA	cis	rs270601	0.721	rs162894	ENSG00000224431.1	AC063976.7	4.89	1.42e-06	0.000174	0.19	0.22	Acylcarnitine levels;	chr5:132276179	chr5:132199456~132203487:+
THCA	cis	rs7914558	1	rs12255047	ENSG00000236937.2	PTGES3P4	4.89	1.42e-06	0.000174	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103000995	chr10:102845595~102845950:+
THCA	cis	rs16867253	0.557	rs34950562	ENSG00000188525.3	AC010969.1	-4.89	1.42e-06	0.000174	-0.37	-0.22	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr2:9992387	chr2:10003158~10006030:-
THCA	cis	rs16867253	0.557	rs35341467	ENSG00000188525.3	AC010969.1	-4.89	1.42e-06	0.000174	-0.37	-0.22	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr2:9992478	chr2:10003158~10006030:-
THCA	cis	rs16867253	0.557	rs28444564	ENSG00000188525.3	AC010969.1	-4.89	1.42e-06	0.000174	-0.37	-0.22	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr2:9992836	chr2:10003158~10006030:-
THCA	cis	rs8091660	0.624	rs2175565	ENSG00000278983.1	RP11-426J5.3	-4.89	1.42e-06	0.000174	-0.32	-0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48553481	chr18:48564795~48568342:+
THCA	cis	rs3740713	1	rs3740713	ENSG00000256464.1	YWHABP2	4.89	1.42e-06	0.000174	0.4	0.22	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr11:18490243~18490955:-
THCA	cis	rs4915077	1	rs77475507	ENSG00000226822.1	RP11-356N1.2	4.89	1.42e-06	0.000174	0.41	0.22	Hypothyroidism;	chr1:107819485	chr1:108071482~108074519:+
THCA	cis	rs752010	0.645	rs1109254	ENSG00000230638.4	RP11-486B10.4	-4.89	1.42e-06	0.000174	-0.27	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41626099	chr1:41542069~41544310:+
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000229886.1	RP5-1132H15.3	4.89	1.42e-06	0.000174	0.26	0.22	Corneal structure;	chr7:66913899	chr7:66025126~66031544:-
THCA	cis	rs2692947	0.702	rs6717101	ENSG00000232931.4	LINC00342	4.89	1.42e-06	0.000174	0.18	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95839804	chr2:95807118~95816215:-
THCA	cis	rs8002861	0.846	rs12869355	ENSG00000274001.1	RP11-5G9.5	4.89	1.42e-06	0.000174	0.27	0.22	Leprosy;	chr13:43904057	chr13:43877715~43878163:-
THCA	cis	rs6964833	1	rs35203738	ENSG00000278416.1	PMS2L2	4.89	1.42e-06	0.000174	0.34	0.22	Menarche (age at onset);	chr7:74690864	chr7:75344015~75359550:-
THCA	cis	rs793571	0.628	rs12437952	ENSG00000245975.2	RP11-30K9.6	4.89	1.42e-06	0.000174	0.26	0.22	Schizophrenia;	chr15:58757147	chr15:58768072~58770974:-
THCA	cis	rs1003719	0.715	rs8129942	ENSG00000230366.8	DSCR9	4.89	1.42e-06	0.000175	0.22	0.22	Eye color traits;	chr21:37179768	chr21:37208503~37221736:+
THCA	cis	rs4834770	0.668	rs11737086	ENSG00000245958.5	RP11-33B1.1	4.89	1.42e-06	0.000175	0.22	0.22	Blood protein levels;	chr4:119205962	chr4:119454791~119552025:+
THCA	cis	rs4834770	0.668	rs1397610	ENSG00000245958.5	RP11-33B1.1	4.89	1.42e-06	0.000175	0.22	0.22	Blood protein levels;	chr4:119206606	chr4:119454791~119552025:+
THCA	cis	rs7010876	0.561	rs4961093	ENSG00000253553.4	RP11-586K2.1	-4.89	1.42e-06	0.000175	-0.22	-0.22	Schizophrenia;	chr8:88379903	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.537	rs28417952	ENSG00000253553.4	RP11-586K2.1	-4.89	1.42e-06	0.000175	-0.22	-0.22	Schizophrenia;	chr8:88382288	chr8:88326836~88737134:+
THCA	cis	rs9467773	0.523	rs2498399	ENSG00000261353.1	CTA-14H9.5	-4.89	1.42e-06	0.000175	-0.24	-0.22	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26527063~26527404:+
THCA	cis	rs17767392	0.813	rs66645707	ENSG00000259146.3	RP1-261D10.2	4.89	1.42e-06	0.000175	0.28	0.22	Mitral valve prolapse;	chr14:71519214	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.813	rs61989386	ENSG00000259146.3	RP1-261D10.2	4.89	1.42e-06	0.000175	0.28	0.22	Mitral valve prolapse;	chr14:71519828	chr14:71292729~71321814:-
THCA	cis	rs1150668	0.835	rs203869	ENSG00000273712.1	RP5-874C20.7	4.89	1.42e-06	0.000175	0.24	0.22	Pubertal anthropometrics;	chr6:28073041	chr6:28315613~28315883:-
THCA	cis	rs55704346	0.691	rs13109061	ENSG00000281501.1	SEPSECS-AS1	4.89	1.42e-06	0.000175	0.25	0.22	Tonsillectomy;	chr4:25123124	chr4:25160641~25201440:+
THCA	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-4.89	1.42e-06	0.000175	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	4.89	1.42e-06	0.000175	0.33	0.22	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
THCA	cis	rs7618915	0.508	rs11717043	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.42e-06	0.000175	-0.24	-0.22	Bipolar disorder;	chr3:52622076	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs13064064	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.42e-06	0.000175	-0.24	-0.22	Bipolar disorder;	chr3:52622986	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs34215106	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.42e-06	0.000175	-0.24	-0.22	Bipolar disorder;	chr3:52625108	chr3:52239258~52241097:+
THCA	cis	rs13434995	0.589	rs62305201	ENSG00000273257.1	RP11-177J6.1	-4.89	1.42e-06	0.000175	-0.34	-0.22	Adiponectin levels;	chr4:55386778	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.589	rs62305202	ENSG00000273257.1	RP11-177J6.1	-4.89	1.42e-06	0.000175	-0.34	-0.22	Adiponectin levels;	chr4:55386861	chr4:55387949~55388271:+
THCA	cis	rs4072705	0.562	rs7855918	ENSG00000224020.1	MIR181A2HG	-4.89	1.42e-06	0.000175	-0.21	-0.22	Menarche (age at onset);	chr9:124477660	chr9:124658467~124698631:+
THCA	cis	rs9393777	0.777	rs35984974	ENSG00000219392.1	RP1-265C24.5	-4.89	1.42e-06	0.000175	-0.41	-0.22	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28115628~28116551:+
THCA	cis	rs4639966	0.836	rs73001486	ENSG00000255422.1	AP002954.4	4.89	1.42e-06	0.000175	0.26	0.22	Systemic lupus erythematosus;	chr11:118758655	chr11:118704607~118750263:+
THCA	cis	rs11671005	0.735	rs3826682	ENSG00000268049.1	CTD-2619J13.9	-4.89	1.42e-06	0.000175	-0.34	-0.22	Mean platelet volume;	chr19:58407381	chr19:58357999~58359603:+
THCA	cis	rs1552244	0.872	rs35988239	ENSG00000232901.1	CYCSP10	4.89	1.42e-06	0.000175	0.32	0.22	Alzheimer's disease;	chr3:10032461	chr3:10000647~10000940:-
THCA	cis	rs2797160	0.651	rs9491503	ENSG00000226409.1	RP11-735G4.1	4.89	1.42e-06	0.000175	0.27	0.22	Endometrial cancer;	chr6:125710536	chr6:125370211~125374324:-
THCA	cis	rs4950322	0.57	rs4950409	ENSG00000271721.1	RP11-337C18.9	4.88	1.42e-06	0.000175	0.25	0.22	Protein quantitative trait loci;	chr1:147335879	chr1:147175602~147177740:+
THCA	cis	rs6921919	0.583	rs9468370	ENSG00000219392.1	RP1-265C24.5	-4.88	1.42e-06	0.000175	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28115628~28116551:+
THCA	cis	rs748802	0.704	rs10814296	ENSG00000235387.1	LINC00961	-4.88	1.42e-06	0.000175	-0.25	-0.22	Resting heart rate;	chr9:35910804	chr9:35909483~35911686:+
THCA	cis	rs454422	1	rs6053816	ENSG00000275632.1	RP5-967N21.11	4.88	1.42e-06	0.000175	0.22	0.22	HIV-1 viral setpoint;	chr20:5990104	chr20:6000418~6000941:+
THCA	cis	rs454422	1	rs236121	ENSG00000275632.1	RP5-967N21.11	4.88	1.42e-06	0.000175	0.22	0.22	HIV-1 viral setpoint;	chr20:5991948	chr20:6000418~6000941:+
THCA	cis	rs6565180	1	rs11862806	ENSG00000274653.1	RP11-347C12.11	4.88	1.42e-06	0.000175	0.2	0.22	Tonsillectomy;	chr16:30352750	chr16:30359825~30360336:+
THCA	cis	rs6012564	0.826	rs2869715	ENSG00000227431.4	CSE1L-AS1	4.88	1.42e-06	0.000175	0.27	0.22	Anger;	chr20:49143463	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.793	rs6066979	ENSG00000227431.4	CSE1L-AS1	4.88	1.42e-06	0.000175	0.27	0.22	Anger;	chr20:49144319	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.762	rs6066980	ENSG00000227431.4	CSE1L-AS1	4.88	1.42e-06	0.000175	0.27	0.22	Anger;	chr20:49144320	chr20:49040463~49046044:-
THCA	cis	rs8177876	0.731	rs74882687	ENSG00000261061.1	RP11-303E16.2	-4.88	1.42e-06	0.000175	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.642	rs76909932	ENSG00000261061.1	RP11-303E16.2	-4.88	1.42e-06	0.000175	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.822	rs8177939	ENSG00000261061.1	RP11-303E16.2	-4.88	1.42e-06	0.000175	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81030770~81031485:+
THCA	cis	rs3820928	0.874	rs6717168	ENSG00000212391.1	SNORA48	-4.88	1.42e-06	0.000175	-0.24	-0.22	Pulmonary function;	chr2:227036626	chr2:226968989~226969122:-
THCA	cis	rs548181	0.545	rs76179820	ENSG00000254671.2	STT3A-AS1	4.88	1.43e-06	0.000175	0.4	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125746484	chr11:125570284~125592568:-
THCA	cis	rs7015630	0.955	rs10096271	ENSG00000251136.7	RP11-37B2.1	-4.88	1.43e-06	0.000175	-0.21	-0.22	Inflammatory bowel disease;Crohn's disease;	chr8:89863288	chr8:89609409~89757727:-
THCA	cis	rs7809615	0.901	rs10235235	ENSG00000244219.5	GS1-259H13.2	-4.88	1.43e-06	0.000175	-0.39	-0.22	Blood metabolite ratios;	chr7:99478208	chr7:99598066~99610813:+
THCA	cis	rs7809615	0.901	rs10226310	ENSG00000244219.5	GS1-259H13.2	-4.88	1.43e-06	0.000175	-0.39	-0.22	Blood metabolite ratios;	chr7:99520697	chr7:99598066~99610813:+
THCA	cis	rs1009077	0.514	rs13126170	ENSG00000245958.5	RP11-33B1.1	4.88	1.43e-06	0.000175	0.3	0.22	Endometriosis;	chr4:119402033	chr4:119454791~119552025:+
THCA	cis	rs2790457	0.833	rs1265843	ENSG00000254635.4	WAC-AS1	-4.88	1.43e-06	0.000176	-0.22	-0.22	Multiple myeloma;	chr10:28636088	chr10:28522652~28532743:-
THCA	cis	rs858239	0.669	rs1618339	ENSG00000226816.2	AC005082.12	4.88	1.43e-06	0.000176	0.31	0.22	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23206013~23208045:+
THCA	cis	rs6750795	0.569	rs1667308	ENSG00000223198.1	RNU2-22P	-4.88	1.43e-06	0.000176	-0.27	-0.22	Height;	chr2:231541633	chr2:231501990~231502201:-
THCA	cis	rs7674212	0.57	rs2069274	ENSG00000251288.2	RP11-10L12.2	-4.88	1.43e-06	0.000176	-0.28	-0.22	Type 2 diabetes;	chr4:103099624	chr4:102751401~102752641:+
THCA	cis	rs4722166	0.63	rs4722168	ENSG00000225541.1	AC002480.5	-4.88	1.43e-06	0.000176	-0.28	-0.22	Lung cancer;	chr7:22739383	chr7:22571607~22661792:-
THCA	cis	rs3096299	0.503	rs9940093	ENSG00000261118.1	RP11-104N10.1	4.88	1.43e-06	0.000176	0.19	0.22	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89492017~89504460:-
THCA	cis	rs7577696	0.924	rs3769604	ENSG00000276334.1	AL133243.1	-4.88	1.43e-06	0.000176	-0.23	-0.22	Inflammatory biomarkers;	chr2:32097426	chr2:32521927~32523547:+
THCA	cis	rs2348418	0.765	rs10843119	ENSG00000247934.4	RP11-967K21.1	-4.88	1.43e-06	0.000176	-0.19	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28164675	chr12:28163298~28190738:-
THCA	cis	rs35160687	0.623	rs718292	ENSG00000273080.1	RP11-301O19.1	4.88	1.43e-06	0.000176	0.24	0.22	Night sleep phenotypes;	chr2:86246617	chr2:86195590~86196049:+
THCA	cis	rs3820928	1	rs4675115	ENSG00000212391.1	SNORA48	-4.88	1.43e-06	0.000176	-0.25	-0.22	Pulmonary function;	chr2:226904407	chr2:226968989~226969122:-
THCA	cis	rs7572644	0.699	rs6738887	ENSG00000223522.1	AC093690.1	4.88	1.43e-06	0.000176	0.25	0.22	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28045600	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs1395324	ENSG00000223522.1	AC093690.1	4.88	1.43e-06	0.000176	0.25	0.22	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28053776	chr2:28307691~28310459:-
THCA	cis	rs10967586	0.622	rs17756299	ENSG00000254396.1	RP11-56F10.3	4.88	1.43e-06	0.000176	0.41	0.22	Schizophrenia;	chr9:27009740	chr9:27102630~27104728:+
THCA	cis	rs1836229	0.594	rs10758997	ENSG00000225706.1	PTPRD-AS1	-4.88	1.43e-06	0.000176	-0.26	-0.22	Restless legs syndrome;	chr9:8829567	chr9:8858130~8862255:+
THCA	cis	rs7809615	0.901	rs10808111	ENSG00000244219.5	GS1-259H13.2	-4.88	1.43e-06	0.000176	-0.39	-0.22	Blood metabolite ratios;	chr7:99473261	chr7:99598066~99610813:+
THCA	cis	rs7809615	0.901	rs11761528	ENSG00000244219.5	GS1-259H13.2	-4.88	1.43e-06	0.000176	-0.39	-0.22	Blood metabolite ratios;	chr7:99521178	chr7:99598066~99610813:+
THCA	cis	rs2255336	0.938	rs61610254	ENSG00000245648.1	RP11-277P12.20	-4.88	1.43e-06	0.000176	-0.25	-0.22	Blood protein levels;	chr12:10446176	chr12:10363769~10398506:+
THCA	cis	rs9652601	0.549	rs7186295	ENSG00000274038.1	RP11-66H6.4	-4.88	1.43e-06	0.000176	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11117067	chr16:11056556~11057034:+
THCA	cis	rs6441961	0.501	rs4683199	ENSG00000223552.1	RP11-24F11.2	-4.88	1.43e-06	0.000176	-0.22	-0.22	Celiac disease;	chr3:46287886	chr3:46364955~46407059:-
THCA	cis	rs317689	0.819	rs317685	ENSG00000274979.1	RP11-1143G9.5	4.88	1.43e-06	0.000176	0.25	0.22	Response to diuretic therapy;	chr12:69321677	chr12:69326574~69331882:-
THCA	cis	rs240993	0.761	rs462832	ENSG00000271789.1	RP5-1112D6.7	-4.88	1.43e-06	0.000176	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111365088	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs455645	ENSG00000271789.1	RP5-1112D6.7	-4.88	1.43e-06	0.000176	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111373870	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs462779	ENSG00000271789.1	RP5-1112D6.7	-4.88	1.43e-06	0.000176	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111374684	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs461646	ENSG00000271789.1	RP5-1112D6.7	-4.88	1.43e-06	0.000176	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111375054	chr6:111297126~111298510:+
THCA	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-4.88	1.43e-06	0.000176	-0.43	-0.22	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
THCA	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-4.88	1.43e-06	0.000176	-0.43	-0.22	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
THCA	cis	rs2447820	0.588	rs11241670	ENSG00000249996.1	RP11-359P5.1	4.88	1.43e-06	0.000176	0.26	0.22	Migraine;	chr5:123044804	chr5:123036271~123054667:+
THCA	cis	rs2447820	0.643	rs4637543	ENSG00000249996.1	RP11-359P5.1	4.88	1.43e-06	0.000176	0.26	0.22	Migraine;	chr5:123047514	chr5:123036271~123054667:+
THCA	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-4.88	1.43e-06	0.000176	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
THCA	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	4.88	1.43e-06	0.000176	0.15	0.22	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
THCA	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	4.88	1.43e-06	0.000176	0.15	0.22	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
THCA	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-4.88	1.43e-06	0.000176	-0.28	-0.22	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
THCA	cis	rs2154319	0.666	rs3845571	ENSG00000235358.1	RP11-399E6.1	-4.88	1.43e-06	0.000176	-0.29	-0.22	Height;	chr1:41250367	chr1:41242373~41284861:+
THCA	cis	rs763121	0.853	rs1043441	ENSG00000235209.1	CTA-150C2.13	4.88	1.43e-06	0.000176	0.3	0.22	Menopause (age at onset);	chr22:38734959	chr22:38921227~38924708:+
THCA	cis	rs4660456	0.956	rs4660457	ENSG00000272145.1	NFYC-AS1	4.88	1.43e-06	0.000176	0.15	0.22	Platelet count;	chr1:40774121	chr1:40690380~40692066:-
THCA	cis	rs10761482	0.564	rs10733765	ENSG00000254271.1	RP11-131N11.4	4.88	1.43e-06	0.000176	0.29	0.22	Schizophrenia;	chr10:60477641	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.531	rs10740029	ENSG00000254271.1	RP11-131N11.4	4.88	1.43e-06	0.000176	0.29	0.22	Schizophrenia;	chr10:60479144	chr10:60734342~60741828:+
THCA	cis	rs62244186	0.566	rs55852922	ENSG00000214820.3	MPRIPP1	4.88	1.43e-06	0.000176	0.22	0.22	Depressive symptoms;	chr3:44784696	chr3:44579938~44581026:-
THCA	cis	rs62244186	0.566	rs55901755	ENSG00000214820.3	MPRIPP1	4.88	1.43e-06	0.000176	0.22	0.22	Depressive symptoms;	chr3:44793215	chr3:44579938~44581026:-
THCA	cis	rs7122539	0.506	rs7944999	ENSG00000275484.1	CTC-1337H24.4	-4.88	1.43e-06	0.000176	-0.16	-0.22	HIV-1 susceptibility;	chr11:66920392	chr11:67374416~67374932:+
THCA	cis	rs7122539	0.506	rs10791896	ENSG00000275484.1	CTC-1337H24.4	-4.88	1.43e-06	0.000176	-0.16	-0.22	HIV-1 susceptibility;	chr11:66921769	chr11:67374416~67374932:+
THCA	cis	rs1979679	0.744	rs2348236	ENSG00000278733.1	RP11-425D17.1	-4.88	1.43e-06	0.000176	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28441640	chr12:28185625~28186190:-
THCA	cis	rs9863	0.828	rs12311848	ENSG00000269997.1	RP11-214K3.21	-4.88	1.44e-06	0.000177	-0.27	-0.22	White blood cell count;	chr12:124002304	chr12:123966077~123966629:-
THCA	cis	rs9300255	0.602	rs1716172	ENSG00000235423.7	RP11-282O18.3	4.88	1.44e-06	0.000177	0.23	0.22	Neutrophil percentage of white cells;	chr12:123228165	chr12:123252030~123261483:-
THCA	cis	rs2839186	0.526	rs2839297	ENSG00000239415.1	AP001469.9	4.88	1.44e-06	0.000177	0.23	0.22	Testicular germ cell tumor;	chr21:46501926	chr21:46251549~46254133:-
THCA	cis	rs4915077	0.892	rs17020108	ENSG00000230489.1	VAV3-AS1	4.88	1.44e-06	0.000177	0.32	0.22	Hypothyroidism;	chr1:107811339	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs17020112	ENSG00000230489.1	VAV3-AS1	4.88	1.44e-06	0.000177	0.32	0.22	Hypothyroidism;	chr1:107811677	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs6695696	ENSG00000230489.1	VAV3-AS1	4.88	1.44e-06	0.000177	0.32	0.22	Hypothyroidism;	chr1:107812067	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs6683295	ENSG00000230489.1	VAV3-AS1	4.88	1.44e-06	0.000177	0.32	0.22	Hypothyroidism;	chr1:107812317	chr1:107964443~107994607:+
THCA	cis	rs2120243	0.874	rs1840680	ENSG00000244515.1	KRT18P34	-4.88	1.44e-06	0.000177	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157438240	chr3:157162663~157163932:-
THCA	cis	rs8049040	0.564	rs310335	ENSG00000260886.1	TAT-AS1	4.88	1.44e-06	0.000177	0.32	0.22	Blood protein levels;	chr16:71540015	chr16:71565789~71578187:+
THCA	cis	rs2797160	1	rs1739363	ENSG00000237742.5	RP11-624M8.1	4.88	1.44e-06	0.000177	0.19	0.22	Endometrial cancer;	chr6:125699834	chr6:125578558~125749190:-
THCA	cis	rs763121	0.853	rs3747172	ENSG00000228274.3	RP3-508I15.9	-4.88	1.44e-06	0.000177	-0.24	-0.22	Menopause (age at onset);	chr22:38671519	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5750659	ENSG00000228274.3	RP3-508I15.9	-4.88	1.44e-06	0.000177	-0.24	-0.22	Menopause (age at onset);	chr22:38672784	chr22:38667585~38681820:-
THCA	cis	rs763121	0.819	rs3747173	ENSG00000228274.3	RP3-508I15.9	-4.88	1.44e-06	0.000177	-0.24	-0.22	Menopause (age at onset);	chr22:38673040	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs3747174	ENSG00000228274.3	RP3-508I15.9	-4.88	1.44e-06	0.000177	-0.24	-0.22	Menopause (age at onset);	chr22:38673176	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs1065201	ENSG00000228274.3	RP3-508I15.9	-4.88	1.44e-06	0.000177	-0.24	-0.22	Menopause (age at onset);	chr22:38673505	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs5757226	ENSG00000228274.3	RP3-508I15.9	-4.88	1.44e-06	0.000177	-0.24	-0.22	Menopause (age at onset);	chr22:38674545	chr22:38667585~38681820:-
THCA	cis	rs12435908	1	rs28502530	ENSG00000276116.2	FUT8-AS1	-4.88	1.44e-06	0.000177	-0.34	-0.22	Ischemic stroke;	chr14:65384250	chr14:65411170~65412690:-
THCA	cis	rs11665867	0.941	rs112646411	ENSG00000279108.1	CTC-490E21.11	-4.88	1.44e-06	0.000177	-0.31	-0.22	Hematocrit;	chr19:40812744	chr19:40840159~40842039:+
THCA	cis	rs6490294	0.571	rs57168159	ENSG00000226469.1	ADAM1B	4.88	1.44e-06	0.000177	0.32	0.22	Mean platelet volume;	chr12:112189041	chr12:111927018~111929017:+
THCA	cis	rs1823913	0.599	rs12988037	ENSG00000280083.1	RP11-317J9.1	-4.88	1.44e-06	0.000177	-0.25	-0.22	Obesity-related traits;	chr2:191306419	chr2:191154118~191156070:-
THCA	cis	rs2154319	0.666	rs3856251	ENSG00000235358.1	RP11-399E6.1	-4.88	1.44e-06	0.000177	-0.29	-0.22	Height;	chr1:41250375	chr1:41242373~41284861:+
THCA	cis	rs9388451	0.874	rs7739566	ENSG00000226409.1	RP11-735G4.1	-4.88	1.44e-06	0.000177	-0.26	-0.22	Brugada syndrome;	chr6:125773611	chr6:125370211~125374324:-
THCA	cis	rs9388451	0.839	rs4897155	ENSG00000226409.1	RP11-735G4.1	-4.88	1.44e-06	0.000177	-0.26	-0.22	Brugada syndrome;	chr6:125773998	chr6:125370211~125374324:-
THCA	cis	rs9863	0.861	rs4765219	ENSG00000269997.1	RP11-214K3.21	-4.88	1.44e-06	0.000177	-0.27	-0.22	White blood cell count;	chr12:123955563	chr12:123966077~123966629:-
THCA	cis	rs2281603	0.57	rs4632045	ENSG00000259116.1	RP11-973N13.4	-4.88	1.44e-06	0.000177	-0.2	-0.22	Lymphocyte counts;	chr14:64496408	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs12050238	ENSG00000259116.1	RP11-973N13.4	-4.88	1.44e-06	0.000177	-0.2	-0.22	Lymphocyte counts;	chr14:64498157	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs12050358	ENSG00000259116.1	RP11-973N13.4	-4.88	1.44e-06	0.000177	-0.2	-0.22	Lymphocyte counts;	chr14:64499986	chr14:64514154~64540368:-
THCA	cis	rs7829975	0.682	rs7013471	ENSG00000254153.1	CTA-398F10.2	4.88	1.44e-06	0.000177	0.24	0.22	Mood instability;	chr8:8829815	chr8:8456909~8461337:-
THCA	cis	rs1559040	1	rs11677951	ENSG00000272156.1	RP11-477N3.1	-4.88	1.44e-06	0.000177	-0.35	-0.22	Sudden cardiac arrest;	chr2:54075538	chr2:54082554~54085066:+
THCA	cis	rs1823913	0.637	rs4853575	ENSG00000280083.1	RP11-317J9.1	4.88	1.44e-06	0.000177	0.26	0.22	Obesity-related traits;	chr2:191296149	chr2:191154118~191156070:-
THCA	cis	rs6472827	0.645	rs2956060	ENSG00000253983.2	RP1-16A9.1	-4.88	1.44e-06	0.000177	-0.31	-0.22	Uterine fibroids;	chr8:74197550	chr8:74199396~74208441:+
THCA	cis	rs3820928	0.874	rs6728239	ENSG00000212391.1	SNORA48	-4.88	1.44e-06	0.000177	-0.24	-0.22	Pulmonary function;	chr2:226991836	chr2:226968989~226969122:-
THCA	cis	rs1150668	0.83	rs213240	ENSG00000273712.1	RP5-874C20.7	4.88	1.44e-06	0.000177	0.24	0.22	Pubertal anthropometrics;	chr6:28348098	chr6:28315613~28315883:-
THCA	cis	rs2282300	0.637	rs7941828	ENSG00000242353.1	RP4-710M3.1	-4.88	1.44e-06	0.000177	-0.18	-0.22	Morning vs. evening chronotype;	chr11:30408784	chr11:30368148~30368646:+
THCA	cis	rs13434995	0.513	rs17779627	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55483775	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs55729020	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55491681	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs3805156	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55497925	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62303731	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55499667	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62303732	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55499868	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs56196624	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55500340	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62305264	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55502968	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62305268	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55506991	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62305270	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55507842	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs7681414	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55508890	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs62305271	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55509715	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs10462033	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55511552	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs1915905	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55512381	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs1522109	ENSG00000273257.1	RP11-177J6.1	-4.88	1.44e-06	0.000177	-0.33	-0.22	Adiponectin levels;	chr4:55514403	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs6554282	ENSG00000273257.1	RP11-177J6.1	4.88	1.44e-06	0.000177	0.33	0.22	Adiponectin levels;	chr4:55519812	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs6554283	ENSG00000273257.1	RP11-177J6.1	4.88	1.44e-06	0.000177	0.33	0.22	Adiponectin levels;	chr4:55521053	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs1546004	ENSG00000273257.1	RP11-177J6.1	4.88	1.44e-06	0.000177	0.33	0.22	Adiponectin levels;	chr4:55521612	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs4865006	ENSG00000273257.1	RP11-177J6.1	4.88	1.44e-06	0.000177	0.33	0.22	Adiponectin levels;	chr4:55526112	chr4:55387949~55388271:+
THCA	cis	rs9677476	0.779	rs7569597	ENSG00000224376.1	AC017104.6	4.88	1.44e-06	0.000177	0.26	0.22	Food antigen IgG levels;	chr2:231238041	chr2:231388976~231394991:+
THCA	cis	rs1823874	0.677	rs56096943	ENSG00000259363.4	CTD-2054N24.2	4.88	1.44e-06	0.000177	0.27	0.22	IgG glycosylation;	chr15:99820513	chr15:99807023~99877148:+
THCA	cis	rs6723226	1	rs6723226	ENSG00000276334.1	AL133243.1	4.88	1.44e-06	0.000177	0.26	0.22	Intelligence (multi-trait analysis);	chr2:32624140	chr2:32521927~32523547:+
THCA	cis	rs3213758	0.588	rs10521295	ENSG00000275191.1	RP11-36I17.2	-4.88	1.44e-06	0.000177	-0.36	-0.22	Vitiligo (non-segmental);	chr16:53529064	chr16:53628256~53628816:-
THCA	cis	rs7429990	0.965	rs319686	ENSG00000228638.1	FCF1P2	-4.88	1.44e-06	0.000177	-0.22	-0.22	Educational attainment (years of education);	chr3:47888930	chr3:48290793~48291375:-
THCA	cis	rs481331	0.799	rs58501815	ENSG00000215146.4	RP11-313J2.1	4.88	1.44e-06	0.000177	0.35	0.22	Systemic juvenile idiopathic arthritis;	chr10:42475382	chr10:42331866~42367974:-
THCA	cis	rs6973609	0.524	rs2392375	ENSG00000271122.1	RP11-379H18.1	-4.88	1.44e-06	0.000177	-0.14	-0.22	Obesity-related traits;	chr7:35599704	chr7:35695214~35699413:+
THCA	cis	rs10510102	0.872	rs116521083	ENSG00000226864.1	ATE1-AS1	4.88	1.44e-06	0.000177	0.36	0.22	Breast cancer;	chr10:121950611	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.81	rs34738294	ENSG00000226864.1	ATE1-AS1	4.88	1.44e-06	0.000177	0.36	0.22	Breast cancer;	chr10:121951357	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12258234	ENSG00000226864.1	ATE1-AS1	4.88	1.44e-06	0.000177	0.36	0.22	Breast cancer;	chr10:121952828	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.515	rs11200285	ENSG00000226864.1	ATE1-AS1	4.88	1.44e-06	0.000177	0.36	0.22	Breast cancer;	chr10:121953931	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs75831447	ENSG00000226864.1	ATE1-AS1	4.88	1.44e-06	0.000177	0.36	0.22	Breast cancer;	chr10:121953963	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.63	rs79960726	ENSG00000226864.1	ATE1-AS1	4.88	1.44e-06	0.000177	0.36	0.22	Breast cancer;	chr10:121954358	chr10:121928312~121951965:+
THCA	cis	rs72615157	0.716	rs75779608	ENSG00000078319.8	PMS2P1	-4.88	1.44e-06	0.000177	-0.3	-0.22	Lung function (FEV1/FVC);	chr7:100171334	chr7:100320992~100341908:-
THCA	cis	rs793571	0.554	rs12441313	ENSG00000245975.2	RP11-30K9.6	4.88	1.44e-06	0.000178	0.26	0.22	Schizophrenia;	chr15:58723289	chr15:58768072~58770974:-
THCA	cis	rs1009077	0.68	rs3775856	ENSG00000245958.5	RP11-33B1.1	4.88	1.45e-06	0.000178	0.28	0.22	Endometriosis;	chr4:119562006	chr4:119454791~119552025:+
THCA	cis	rs919433	0.963	rs7582736	ENSG00000231621.1	AC013264.2	4.88	1.45e-06	0.000178	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305618	chr2:197197991~197199273:+
THCA	cis	rs919433	0.963	rs12618612	ENSG00000231621.1	AC013264.2	4.88	1.45e-06	0.000178	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306334	chr2:197197991~197199273:+
THCA	cis	rs1005277	0.602	rs1831315	ENSG00000272983.1	RP11-508N22.12	4.88	1.45e-06	0.000178	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780130	ENSG00000272983.1	RP11-508N22.12	4.88	1.45e-06	0.000178	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38137337~38144399:+
THCA	cis	rs67478160	0.643	rs11624184	ENSG00000269910.1	RP11-73M18.10	4.88	1.45e-06	0.000178	0.19	0.22	Schizophrenia;	chr14:103774661	chr14:103694516~103695050:-
THCA	cis	rs2439831	0.681	rs3742971	ENSG00000275601.1	AC011330.13	4.88	1.45e-06	0.000178	0.32	0.22	Lung cancer in ever smokers;	chr15:43330718	chr15:43642389~43643023:-
THCA	cis	rs79243044	1	rs10838277	ENSG00000224295.2	AC087380.14	-4.88	1.45e-06	0.000178	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5534321	chr11:5518441~5524955:-
THCA	cis	rs4664304	0.621	rs72955755	ENSG00000226266.5	AC009961.3	4.88	1.45e-06	0.000178	0.28	0.22	Crohn's disease;Inflammatory bowel disease;	chr2:159861821	chr2:159670708~159712435:-
THCA	cis	rs11665867	0.887	rs73048915	ENSG00000279108.1	CTC-490E21.11	-4.88	1.45e-06	0.000178	-0.32	-0.22	Hematocrit;	chr19:40813886	chr19:40840159~40842039:+
THCA	cis	rs593531	0.571	rs11236087	ENSG00000255440.1	RP11-632K5.2	-4.88	1.45e-06	0.000178	-0.26	-0.22	Neuroticism;	chr11:74383093	chr11:74409060~74416379:+
THCA	cis	rs1383484	0.575	rs986118	ENSG00000225151.9	GOLGA2P7	4.88	1.45e-06	0.000178	0.28	0.22	Height;	chr15:83946437	chr15:84199311~84230136:-
THCA	cis	rs12911832	0.727	rs2604454	ENSG00000245975.2	RP11-30K9.6	4.88	1.45e-06	0.000178	0.21	0.22	Schizophrenia;	chr15:58806533	chr15:58768072~58770974:-
THCA	cis	rs4950322	0.547	rs6660507	ENSG00000271721.1	RP11-337C18.9	4.88	1.45e-06	0.000178	0.23	0.22	Protein quantitative trait loci;	chr1:147148574	chr1:147175602~147177740:+
THCA	cis	rs9467773	0.549	rs9467805	ENSG00000124549.13	BTN2A3P	4.88	1.45e-06	0.000178	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26421391~26432383:+
THCA	cis	rs8002861	0.664	rs4942246	ENSG00000274001.1	RP11-5G9.5	4.88	1.45e-06	0.000178	0.26	0.22	Leprosy;	chr13:43830717	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.664	rs4942247	ENSG00000274001.1	RP11-5G9.5	4.88	1.45e-06	0.000178	0.26	0.22	Leprosy;	chr13:43830971	chr13:43877715~43878163:-
THCA	cis	rs2282300	0.739	rs10835648	ENSG00000242353.1	RP4-710M3.1	4.88	1.45e-06	0.000178	0.21	0.22	Morning vs. evening chronotype;	chr11:30298959	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.739	rs7952339	ENSG00000242353.1	RP4-710M3.1	4.88	1.45e-06	0.000178	0.21	0.22	Morning vs. evening chronotype;	chr11:30305797	chr11:30368148~30368646:+
THCA	cis	rs5758511	0.573	rs1883205	ENSG00000281538.1	RP4-669P10.20	4.88	1.45e-06	0.000178	0.21	0.22	Birth weight;	chr22:41847016	chr22:42138060~42139726:+
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000259295.5	CSPG4P12	-4.88	1.45e-06	0.000178	-0.3	-0.22	P wave terminal force;	chr15:84635039	chr15:85191438~85213905:+
THCA	cis	rs6487679	0.526	rs34362	ENSG00000111788.10	RP11-22B23.1	-4.88	1.45e-06	0.000178	-0.22	-0.22	Non-alcoholic fatty liver disease histology (AST);	chr12:9232829	chr12:9277235~9313241:+
THCA	cis	rs804292	0.695	rs804279	ENSG00000255046.1	RP11-297N6.4	4.88	1.45e-06	0.000178	0.25	0.22	Nicotine use;Alcohol dependence;	chr8:11766380	chr8:11797928~11802568:-
THCA	cis	rs654950	0.875	rs881719	ENSG00000230638.4	RP11-486B10.4	4.88	1.45e-06	0.000178	0.24	0.22	Airway imaging phenotypes;	chr1:41525756	chr1:41542069~41544310:+
THCA	cis	rs2034650	0.544	rs11070272	ENSG00000223313.1	RNU6-516P	4.88	1.45e-06	0.000178	0.24	0.22	Interstitial lung disease;	chr15:40433064	chr15:40529570~40529673:+
THCA	cis	rs6772849	0.896	rs61112519	ENSG00000242551.2	POU5F1P6	-4.88	1.45e-06	0.000178	-0.28	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128619333	chr3:128674735~128677005:-
THCA	cis	rs13113518	0.934	rs10866425	ENSG00000273257.1	RP11-177J6.1	4.88	1.45e-06	0.000178	0.29	0.22	Height;	chr4:55582068	chr4:55387949~55388271:+
THCA	cis	rs9309473	0.519	rs35421685	ENSG00000163016.8	ALMS1P	-4.88	1.45e-06	0.000178	-0.27	-0.22	Metabolite levels;	chr2:73683011	chr2:73644919~73685576:+
THCA	cis	rs6490294	0.528	rs12580246	ENSG00000226469.1	ADAM1B	4.88	1.45e-06	0.000178	0.36	0.22	Mean platelet volume;	chr12:111893513	chr12:111927018~111929017:+
THCA	cis	rs7552393	0.595	rs1830827	ENSG00000233008.4	RP11-475O6.1	4.88	1.45e-06	0.000178	0.25	0.22	Select biomarker traits;	chr1:83813228	chr1:83575776~83861023:-
THCA	cis	rs7552393	0.636	rs1408476	ENSG00000233008.4	RP11-475O6.1	4.88	1.45e-06	0.000178	0.25	0.22	Select biomarker traits;	chr1:83813293	chr1:83575776~83861023:-
THCA	cis	rs62246343	0.719	rs62246275	ENSG00000254485.4	RP11-380O24.1	4.88	1.45e-06	0.000178	0.3	0.22	Fibrinogen levels;	chr3:9399496	chr3:9292588~9363303:-
THCA	cis	rs494453	0.71	rs2477429	ENSG00000227811.2	FAM212B-AS1	-4.88	1.45e-06	0.000179	-0.29	-0.22	Osteoporosis-related phenotypes;	chr1:111663807	chr1:111739841~111747798:+
THCA	cis	rs13434995	0.513	rs62303730	ENSG00000273257.1	RP11-177J6.1	-4.88	1.45e-06	0.000179	-0.33	-0.22	Adiponectin levels;	chr4:55498948	chr4:55387949~55388271:+
THCA	cis	rs8105895	0.935	rs6511314	ENSG00000269345.1	VN1R85P	-4.88	1.45e-06	0.000179	-0.29	-0.22	Body mass index (change over time);	chr19:22053593	chr19:22174766~22175191:-
THCA	cis	rs11992162	0.55	rs61426048	ENSG00000206014.6	OR7E161P	4.88	1.46e-06	0.000179	0.26	0.22	Monocyte count;	chr8:11927447	chr8:11928597~11929563:-
THCA	cis	rs3820928	1	rs11692572	ENSG00000212391.1	SNORA48	-4.88	1.46e-06	0.000179	-0.25	-0.22	Pulmonary function;	chr2:226909787	chr2:226968989~226969122:-
THCA	cis	rs270601	0.721	rs162894	ENSG00000237714.1	P4HA2-AS1	4.88	1.46e-06	0.000179	0.29	0.22	Acylcarnitine levels;	chr5:132276179	chr5:132184876~132192808:+
THCA	cis	rs12908161	0.65	rs182517	ENSG00000259295.5	CSPG4P12	4.88	1.46e-06	0.000179	0.34	0.22	Schizophrenia;	chr15:84846400	chr15:85191438~85213905:+
THCA	cis	rs12030196	0.827	rs12036261	ENSG00000230812.4	LINC01358	4.88	1.46e-06	0.000179	0.28	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58971104	chr1:59020387~59044614:+
THCA	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	4.88	1.46e-06	0.000179	0.26	0.22	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
THCA	cis	rs28476539	0.64	rs17005896	ENSG00000270480.1	RP11-57B24.1	4.88	1.46e-06	0.000179	0.35	0.22	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82629015	chr4:82691737~82692468:+
THCA	cis	rs4761470	0.577	rs55836966	ENSG00000258365.1	RP11-1105G2.3	-4.88	1.46e-06	0.000179	-0.26	-0.22	Estradiol plasma levels (breast cancer);	chr12:94287384	chr12:94277758~94282844:-
THCA	cis	rs1823874	0.677	rs2100446	ENSG00000259363.4	CTD-2054N24.2	4.88	1.46e-06	0.000179	0.27	0.22	IgG glycosylation;	chr15:99820169	chr15:99807023~99877148:+
THCA	cis	rs1823874	0.677	rs2100447	ENSG00000259363.4	CTD-2054N24.2	4.88	1.46e-06	0.000179	0.27	0.22	IgG glycosylation;	chr15:99820188	chr15:99807023~99877148:+
THCA	cis	rs4713118	0.868	rs9468220	ENSG00000226314.6	ZNF192P1	4.88	1.46e-06	0.000179	0.3	0.22	Parkinson's disease;	chr6:27765197	chr6:28161781~28169594:+
THCA	cis	rs748802	0.704	rs10116147	ENSG00000235387.1	LINC00961	-4.88	1.46e-06	0.000179	-0.25	-0.22	Resting heart rate;	chr9:35920643	chr9:35909483~35911686:+
THCA	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-4.88	1.46e-06	0.000179	-0.44	-0.22	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
THCA	cis	rs478304	0.934	rs610037	ENSG00000214659.4	KRT8P26	-4.88	1.46e-06	0.000179	-0.19	-0.22	Acne (severe);	chr11:65779386	chr11:65726939~65728214:+
THCA	cis	rs9300255	0.537	rs1790101	ENSG00000235423.7	RP11-282O18.3	4.88	1.46e-06	0.000179	0.23	0.22	Neutrophil percentage of white cells;	chr12:123220297	chr12:123252030~123261483:-
THCA	cis	rs16975963	0.644	rs12462505	ENSG00000226686.6	LINC01535	-4.88	1.46e-06	0.000179	-0.3	-0.22	Longevity;	chr19:37647224	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.644	rs11083430	ENSG00000226686.6	LINC01535	-4.88	1.46e-06	0.000179	-0.3	-0.22	Longevity;	chr19:37648587	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.644	rs73035158	ENSG00000226686.6	LINC01535	-4.88	1.46e-06	0.000179	-0.3	-0.22	Longevity;	chr19:37650979	chr19:37251912~37265535:+
THCA	cis	rs7618915	0.547	rs2289250	ENSG00000243224.1	RP5-1157M23.2	4.88	1.46e-06	0.000179	0.24	0.22	Bipolar disorder;	chr3:52648930	chr3:52239258~52241097:+
THCA	cis	rs9925964	0.869	rs749670	ENSG00000260911.2	RP11-196G11.2	-4.88	1.46e-06	0.000179	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077304	chr16:31043150~31049868:+
THCA	cis	rs2337406	0.538	rs2015470	ENSG00000211974.3	IGHV2-70	-4.88	1.46e-06	0.000179	-0.2	-0.22	Alzheimer's disease (late onset);	chr14:106631885	chr14:106723574~106724093:-
THCA	cis	rs7665090	0.87	rs228616	ENSG00000251288.2	RP11-10L12.2	4.88	1.46e-06	0.000179	0.29	0.22	Primary biliary cholangitis;	chr4:102658534	chr4:102751401~102752641:+
THCA	cis	rs6600671	0.934	rs12060031	ENSG00000226067.5	CH17-118O6.2	-4.88	1.46e-06	0.000179	-0.23	-0.22	Hip geometry;	chr1:121501652	chr1:120913275~121009291:+
THCA	cis	rs1320333	0.772	rs2903491	ENSG00000233296.1	AC092159.2	4.88	1.46e-06	0.000179	0.4	0.22	Obesity-related traits;	chr2:686688	chr2:677186~697371:+
THCA	cis	rs10090774	0.965	rs13258028	ENSG00000279766.1	RP11-642A1.2	-4.88	1.46e-06	0.00018	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140880414	chr8:140572142~140572812:-
THCA	cis	rs957448	1	rs957448	ENSG00000253175.1	RP11-267M23.6	4.88	1.46e-06	0.00018	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94565036~94565715:+
THCA	cis	rs957448	1	rs72674855	ENSG00000253175.1	RP11-267M23.6	4.88	1.46e-06	0.00018	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94565036~94565715:+
THCA	cis	rs4664304	0.621	rs56186131	ENSG00000226266.5	AC009961.3	4.88	1.46e-06	0.00018	0.28	0.22	Crohn's disease;Inflammatory bowel disease;	chr2:159868900	chr2:159670708~159712435:-
THCA	cis	rs478304	0.934	rs574483	ENSG00000214659.4	KRT8P26	-4.88	1.46e-06	0.00018	-0.19	-0.22	Acne (severe);	chr11:65747806	chr11:65726939~65728214:+
THCA	cis	rs478304	0.934	rs474483	ENSG00000214659.4	KRT8P26	-4.88	1.46e-06	0.00018	-0.19	-0.22	Acne (severe);	chr11:65752589	chr11:65726939~65728214:+
THCA	cis	rs478304	0.9	rs502468	ENSG00000214659.4	KRT8P26	-4.88	1.46e-06	0.00018	-0.19	-0.22	Acne (severe);	chr11:65757648	chr11:65726939~65728214:+
THCA	cis	rs478304	0.934	rs517115	ENSG00000214659.4	KRT8P26	-4.88	1.46e-06	0.00018	-0.19	-0.22	Acne (severe);	chr11:65759517	chr11:65726939~65728214:+
THCA	cis	rs478304	0.934	rs498354	ENSG00000214659.4	KRT8P26	-4.88	1.46e-06	0.00018	-0.19	-0.22	Acne (severe);	chr11:65760742	chr11:65726939~65728214:+
THCA	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-4.88	1.46e-06	0.00018	-0.25	-0.22	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-4.88	1.46e-06	0.00018	-0.25	-0.22	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
THCA	cis	rs7403037	0.754	rs34443849	ENSG00000260760.1	PWRN3	4.88	1.46e-06	0.00018	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24257156	chr15:24441127~24447967:+
THCA	cis	rs28510890	0.52	rs17703847	ENSG00000260337.3	RP11-386M24.6	-4.88	1.46e-06	0.00018	-0.25	-0.22	Lung cancer in ever smokers;	chr15:92562749	chr15:92592574~92596462:-
THCA	cis	rs9843304	0.616	rs4131174	ENSG00000244503.1	RP11-278L15.6	4.88	1.46e-06	0.00018	0.29	0.22	Gallstone disease;	chr3:149486123	chr3:149494660~149495995:+
THCA	cis	rs7726839	0.54	rs72703080	ENSG00000225138.6	CTD-2228K2.7	4.88	1.46e-06	0.00018	0.28	0.22	Obesity-related traits;	chr5:595123	chr5:473236~480884:+
THCA	cis	rs4073582	0.595	rs1115508	ENSG00000255320.1	RP11-755F10.1	-4.88	1.46e-06	0.00018	-0.27	-0.22	Gout;	chr11:66155678	chr11:66244840~66246239:-
THCA	cis	rs4908760	0.792	rs4908505	ENSG00000232912.4	RP5-1115A15.1	4.88	1.47e-06	0.00018	0.21	0.22	Vitiligo;	chr1:8668805	chr1:8424645~8434838:+
THCA	cis	rs11671005	0.695	rs11673069	ENSG00000265272.2	RN7SL693P	4.88	1.47e-06	0.00018	0.31	0.22	Mean platelet volume;	chr19:58423551	chr19:58490797~58491075:+
THCA	cis	rs9875589	0.509	rs2731337	ENSG00000228242.5	AC093495.4	4.88	1.47e-06	0.00018	0.12	0.22	Ovarian reserve;	chr3:14049940	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs2731336	ENSG00000228242.5	AC093495.4	4.88	1.47e-06	0.00018	0.12	0.22	Ovarian reserve;	chr3:14050408	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs2733548	ENSG00000228242.5	AC093495.4	4.88	1.47e-06	0.00018	0.12	0.22	Ovarian reserve;	chr3:14052978	chr3:14144637~14165978:+
THCA	cis	rs4718428	0.924	rs6971897	ENSG00000230295.1	RP11-458F8.2	-4.88	1.47e-06	0.00018	-0.17	-0.22	Corneal structure;	chr7:66947787	chr7:66880708~66882981:+
THCA	cis	rs1334894	0.901	rs12529688	ENSG00000228559.1	RP3-340B19.3	-4.88	1.47e-06	0.00018	-0.45	-0.22	Coronary artery disease;	chr6:35545148	chr6:35544632~35545669:+
THCA	cis	rs763121	0.819	rs5757169	ENSG00000235209.1	CTA-150C2.13	4.88	1.47e-06	0.00018	0.28	0.22	Menopause (age at onset);	chr22:38607490	chr22:38921227~38924708:+
THCA	cis	rs2018683	0.691	rs4722881	ENSG00000228421.2	AC005013.5	-4.88	1.47e-06	0.00018	-0.27	-0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28961944	chr7:28957667~28959345:+
THCA	cis	rs7181230	0.885	rs749748	ENSG00000275636.1	RP11-521C20.5	4.88	1.47e-06	0.00018	0.23	0.22	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40078892~40079347:+
THCA	cis	rs2439831	0.867	rs486301	ENSG00000205771.5	CATSPER2P1	-4.88	1.47e-06	0.00018	-0.29	-0.22	Lung cancer in ever smokers;	chr15:43544751	chr15:43726918~43747094:-
THCA	cis	rs957448	1	rs2381885	ENSG00000253175.1	RP11-267M23.6	4.88	1.47e-06	0.00018	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94565036~94565715:+
THCA	cis	rs10090774	0.672	rs11784581	ENSG00000280303.2	ERICD	-4.88	1.47e-06	0.00018	-0.2	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140657122	chr8:140636281~140638283:+
THCA	cis	rs7577696	0.688	rs9677104	ENSG00000276334.1	AL133243.1	-4.88	1.47e-06	0.00018	-0.23	-0.22	Inflammatory biomarkers;	chr2:32110030	chr2:32521927~32523547:+
THCA	cis	rs2235642	0.685	rs2667681	ENSG00000280231.1	LA16c-380F5.3	-4.88	1.47e-06	0.00018	-0.26	-0.22	Coronary artery disease;	chr16:1603205	chr16:1553655~1554130:-
THCA	cis	rs2439831	0.867	rs935901	ENSG00000166763.7	STRCP1	4.88	1.47e-06	0.00018	0.34	0.22	Lung cancer in ever smokers;	chr15:43359058	chr15:43699488~43718184:-
THCA	cis	rs9532669	0.926	rs2324747	ENSG00000229473.2	RGS17P1	4.88	1.47e-06	0.00018	0.27	0.22	Cervical cancer;	chr13:40988883	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs2324748	ENSG00000229473.2	RGS17P1	4.88	1.47e-06	0.00018	0.27	0.22	Cervical cancer;	chr13:40989452	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4245311	ENSG00000229473.2	RGS17P1	4.88	1.47e-06	0.00018	0.27	0.22	Cervical cancer;	chr13:40990003	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9525439	ENSG00000229473.2	RGS17P1	4.88	1.47e-06	0.00018	0.27	0.22	Cervical cancer;	chr13:40992645	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs35073784	ENSG00000229473.2	RGS17P1	4.88	1.47e-06	0.00018	0.27	0.22	Cervical cancer;	chr13:40993428	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs9594473	ENSG00000229473.2	RGS17P1	4.88	1.47e-06	0.00018	0.27	0.22	Cervical cancer;	chr13:40997997	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs1543589	ENSG00000229473.2	RGS17P1	4.88	1.47e-06	0.00018	0.27	0.22	Cervical cancer;	chr13:40999064	chr13:40992779~40993331:-
THCA	cis	rs5015933	0.902	rs2841333	ENSG00000232630.1	PRPS1P2	-4.88	1.47e-06	0.00018	-0.15	-0.22	Body mass index;	chr9:125364368	chr9:125150653~125151589:+
THCA	cis	rs9859260	0.744	rs3933	ENSG00000207650.1	MIR570	-4.88	1.47e-06	0.00018	-0.24	-0.22	Mean corpuscular volume;	chr3:196058126	chr3:195699401~195699497:+
THCA	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	4.88	1.47e-06	0.00018	0.25	0.22	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
THCA	cis	rs11671005	0.735	rs34873624	ENSG00000268912.1	CTD-2619J13.17	-4.88	1.47e-06	0.00018	-0.21	-0.22	Mean platelet volume;	chr19:58432035	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.693	rs34230465	ENSG00000268912.1	CTD-2619J13.17	-4.88	1.47e-06	0.00018	-0.21	-0.22	Mean platelet volume;	chr19:58432209	chr19:58428632~58431148:-
THCA	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-4.88	1.47e-06	0.00018	-0.13	-0.22	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-4.88	1.47e-06	0.00018	-0.13	-0.22	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
THCA	cis	rs375066	0.935	rs388685	ENSG00000278917.1	RP11-15A1.4	-4.88	1.47e-06	0.00018	-0.18	-0.22	Breast cancer;	chr19:43914528	chr19:43891233~43895411:+
THCA	cis	rs1552244	1	rs17032283	ENSG00000232901.1	CYCSP10	4.88	1.47e-06	0.00018	0.29	0.22	Alzheimer's disease;	chr3:10039861	chr3:10000647~10000940:-
THCA	cis	rs12893668	0.572	rs7148857	ENSG00000269958.1	RP11-73M18.8	4.88	1.47e-06	0.00018	0.21	0.22	Reticulocyte count;	chr14:103676900	chr14:103696353~103697163:+
THCA	cis	rs454422	1	rs6053815	ENSG00000275632.1	RP5-967N21.11	4.88	1.47e-06	0.000181	0.22	0.22	HIV-1 viral setpoint;	chr20:5989792	chr20:6000418~6000941:+
THCA	cis	rs2348418	0.765	rs10843120	ENSG00000247934.4	RP11-967K21.1	-4.88	1.47e-06	0.000181	-0.19	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28165881	chr12:28163298~28190738:-
THCA	cis	rs930395	0.514	rs7707315	ENSG00000272335.1	RP11-53O19.3	4.88	1.47e-06	0.000181	0.19	0.22	Breast cancer;	chr5:44918703	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs4298259	ENSG00000272335.1	RP11-53O19.3	4.88	1.47e-06	0.000181	0.19	0.22	Breast cancer;	chr5:44920609	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs7728431	ENSG00000272335.1	RP11-53O19.3	4.88	1.47e-06	0.000181	0.19	0.22	Breast cancer;	chr5:44922577	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs10038554	ENSG00000272335.1	RP11-53O19.3	4.88	1.47e-06	0.000181	0.19	0.22	Breast cancer;	chr5:44927005	chr5:44826076~44828592:+
THCA	cis	rs853679	1	rs1679732	ENSG00000272009.1	RP1-313I6.12	4.88	1.47e-06	0.000181	0.3	0.22	Depression;	chr6:28253486	chr6:28078792~28081130:-
THCA	cis	rs6477918	0.598	rs13284471	ENSG00000230185.4	C9orf147	-4.88	1.47e-06	0.000181	-0.23	-0.22	Obstetric antiphospholipid syndrome;	chr9:112452384	chr9:112433816~112487204:-
THCA	cis	rs6088590	1	rs6058111	ENSG00000269202.1	RP4-614O4.12	-4.88	1.47e-06	0.000181	-0.2	-0.22	Coronary artery disease;	chr20:34723195	chr20:35201747~35203288:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000223473.2	GS1-124K5.3	4.88	1.47e-06	0.000181	0.15	0.22	Calcium levels;	chr7:65892789	chr7:66491049~66493566:-
THCA	cis	rs4713118	0.869	rs6922574	ENSG00000226314.6	ZNF192P1	-4.88	1.47e-06	0.000181	-0.28	-0.22	Parkinson's disease;	chr6:27725224	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs9348775	ENSG00000226314.6	ZNF192P1	-4.88	1.47e-06	0.000181	-0.28	-0.22	Parkinson's disease;	chr6:27727550	chr6:28161781~28169594:+
THCA	cis	rs6674176	0.932	rs7412307	ENSG00000237950.1	RP11-7O11.3	-4.88	1.47e-06	0.000181	-0.22	-0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43968192	chr1:43944370~43946551:-
THCA	cis	rs453301	0.571	rs2929454	ENSG00000248538.5	RP11-10A14.5	4.88	1.47e-06	0.000181	0.27	0.22	Joint mobility (Beighton score);	chr8:9226344	chr8:9189011~9202854:+
THCA	cis	rs853679	0.882	rs4713139	ENSG00000220721.1	OR1F12	4.88	1.47e-06	0.000181	0.38	0.22	Depression;	chr6:28124907	chr6:28073316~28074233:+
THCA	cis	rs12893668	0.572	rs4900591	ENSG00000269958.1	RP11-73M18.8	4.88	1.47e-06	0.000181	0.21	0.22	Reticulocyte count;	chr14:103688541	chr14:103696353~103697163:+
THCA	cis	rs9923856	0.519	rs7197754	ENSG00000274038.1	RP11-66H6.4	-4.88	1.47e-06	0.000181	-0.26	-0.22	Atopic dermatitis;Adult asthma;	chr16:11036522	chr16:11056556~11057034:+
THCA	cis	rs1150668	0.796	rs728122	ENSG00000273712.1	RP5-874C20.7	4.88	1.47e-06	0.000181	0.23	0.22	Pubertal anthropometrics;	chr6:28431347	chr6:28315613~28315883:-
THCA	cis	rs11733284	1	rs321622	ENSG00000259959.1	RP11-121C2.2	4.88	1.47e-06	0.000181	0.18	0.22	Gout;Renal underexcretion gout;	chr4:48022363	chr4:47840122~47844339:-
THCA	cis	rs7819412	0.749	rs11991118	ENSG00000206014.6	OR7E161P	-4.88	1.47e-06	0.000181	-0.25	-0.22	Triglycerides;	chr8:11081763	chr8:11928597~11929563:-
THCA	cis	rs642858	0.737	rs669704	ENSG00000234147.1	RP3-460G2.2	4.88	1.47e-06	0.000181	0.29	0.22	Type 2 diabetes;	chr6:140293277	chr6:140845958~140852924:-
THCA	cis	rs13434995	0.513	rs62303728	ENSG00000273257.1	RP11-177J6.1	-4.88	1.48e-06	0.000181	-0.33	-0.22	Adiponectin levels;	chr4:55495762	chr4:55387949~55388271:+
THCA	cis	rs11779988	0.545	rs422746	ENSG00000253671.1	RP11-806O11.1	-4.88	1.48e-06	0.000181	-0.28	-0.22	Breast cancer;	chr8:17926977	chr8:17808941~17820868:+
THCA	cis	rs11779988	0.545	rs427168	ENSG00000253671.1	RP11-806O11.1	-4.88	1.48e-06	0.000181	-0.28	-0.22	Breast cancer;	chr8:17927320	chr8:17808941~17820868:+
THCA	cis	rs11779988	0.545	rs4124900	ENSG00000253671.1	RP11-806O11.1	-4.88	1.48e-06	0.000181	-0.28	-0.22	Breast cancer;	chr8:17927757	chr8:17808941~17820868:+
THCA	cis	rs72843506	0.528	rs73981803	ENSG00000261033.1	RP11-209D14.2	4.88	1.48e-06	0.000181	0.4	0.22	Schizophrenia;	chr17:20088952	chr17:20008051~20009234:-
THCA	cis	rs5758511	0.68	rs5758681	ENSG00000281538.1	RP4-669P10.20	-4.88	1.48e-06	0.000181	-0.25	-0.22	Birth weight;	chr22:42249085	chr22:42138060~42139726:+
THCA	cis	rs2034650	0.506	rs1984793	ENSG00000223313.1	RNU6-516P	4.88	1.48e-06	0.000181	0.24	0.22	Interstitial lung disease;	chr15:40407172	chr15:40529570~40529673:+
THCA	cis	rs2235642	0.671	rs2235641	ENSG00000280231.1	LA16c-380F5.3	-4.88	1.48e-06	0.000181	-0.27	-0.22	Coronary artery disease;	chr16:1558176	chr16:1553655~1554130:-
THCA	cis	rs9876781	0.624	rs12491849	ENSG00000229759.1	MRPS18AP1	4.88	1.48e-06	0.000181	0.27	0.22	Longevity;	chr3:48489975	chr3:48256350~48256938:-
THCA	cis	rs9326248	0.52	rs74830	ENSG00000280143.1	AP000892.6	-4.88	1.48e-06	0.000181	-0.27	-0.22	Blood protein levels;	chr11:117219842	chr11:117204967~117210292:+
THCA	cis	rs2880765	0.525	rs35899940	ENSG00000259630.2	CTD-2262B20.1	-4.88	1.48e-06	0.000181	-0.27	-0.22	Coronary artery disease;	chr15:85510466	chr15:85415228~85415633:+
THCA	cis	rs5769765	0.913	rs28670284	ENSG00000260613.1	RP3-522J7.6	-4.88	1.48e-06	0.000181	-0.28	-0.22	Schizophrenia;	chr22:49828325	chr22:49832616~49837786:-
THCA	cis	rs1577917	0.559	rs1173418	ENSG00000220563.1	PKMP3	4.88	1.48e-06	0.000181	0.16	0.22	Response to antipsychotic treatment;	chr6:85693198	chr6:85659892~85660606:-
THCA	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	4.88	1.48e-06	0.000181	0.27	0.22	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
THCA	cis	rs2067615	0.524	rs10861645	ENSG00000260329.1	RP11-412D9.4	-4.88	1.48e-06	0.000181	-0.21	-0.22	Heart rate;	chr12:106677352	chr12:106954029~106955497:-
THCA	cis	rs9878978	0.722	rs11706424	ENSG00000237990.3	CNTN4-AS1	4.88	1.48e-06	0.000181	0.26	0.22	Blood pressure (smoking interaction);	chr3:2417939	chr3:3039033~3069242:-
THCA	cis	rs13126694	0.778	rs6814979	ENSG00000248429.4	RP11-597D13.9	-4.88	1.48e-06	0.000181	-0.23	-0.22	Blood osmolality (transformed sodium);	chr4:158135798	chr4:158170752~158202877:+
THCA	cis	rs11733284	1	rs13140968	ENSG00000259959.1	RP11-121C2.2	4.88	1.48e-06	0.000181	0.18	0.22	Gout;Renal underexcretion gout;	chr4:48023078	chr4:47840122~47844339:-
THCA	cis	rs7403037	0.793	rs4597275	ENSG00000260760.1	PWRN3	4.88	1.48e-06	0.000181	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24217564	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.794	rs35626304	ENSG00000260760.1	PWRN3	4.88	1.48e-06	0.000181	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24220160	chr15:24441127~24447967:+
THCA	cis	rs454422	1	rs454422	ENSG00000275632.1	RP5-967N21.11	4.88	1.48e-06	0.000181	0.22	0.22	HIV-1 viral setpoint;	chr20:5963047	chr20:6000418~6000941:+
THCA	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	4.88	1.48e-06	0.000181	0.24	0.22	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
THCA	cis	rs613391	0.702	rs1448776	ENSG00000224549.1	RP11-370B11.3	-4.88	1.48e-06	0.000181	-0.25	-0.22	Quantitative traits;	chr9:22704231	chr9:22767175~22768316:+
THCA	cis	rs875971	0.545	rs1796217	ENSG00000228409.4	CCT6P1	4.88	1.48e-06	0.000182	0.19	0.22	Aortic root size;	chr7:66620931	chr7:65751142~65763354:+
THCA	cis	rs73242632	1	rs28623722	ENSG00000269949.1	RP11-738E22.3	4.88	1.48e-06	0.000182	0.51	0.22	Congenital heart disease (maternal effect);	chr4:57029598	chr4:56960927~56961373:-
THCA	cis	rs6441961	0.501	rs41276529	ENSG00000223552.1	RP11-24F11.2	4.88	1.48e-06	0.000182	0.23	0.22	Celiac disease;	chr3:46263186	chr3:46364955~46407059:-
THCA	cis	rs7772486	0.727	rs10447449	ENSG00000270638.1	RP3-466P17.1	4.88	1.48e-06	0.000182	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs9386133	ENSG00000270638.1	RP3-466P17.1	4.88	1.48e-06	0.000182	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145735570~145737218:+
THCA	cis	rs7674212	0.507	rs223331	ENSG00000248971.2	KRT8P46	-4.88	1.48e-06	0.000182	-0.27	-0.22	Type 2 diabetes;	chr4:102872408	chr4:102728746~102730171:-
THCA	cis	rs3820928	0.874	rs3752896	ENSG00000212391.1	SNORA48	-4.88	1.48e-06	0.000182	-0.24	-0.22	Pulmonary function;	chr2:227022209	chr2:226968989~226969122:-
THCA	cis	rs9925964	0.933	rs8050894	ENSG00000232748.3	RP11-196G11.6	4.88	1.48e-06	0.000182	0.25	0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:31056460~31062803:+
THCA	cis	rs11175834	0.655	rs12311233	ENSG00000250748.5	RP11-230G5.2	-4.88	1.48e-06	0.000182	-0.35	-0.22	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65607333	chr12:65466820~65642372:-
THCA	cis	rs6903823	0.508	rs1778484	ENSG00000273712.1	RP5-874C20.7	4.88	1.48e-06	0.000182	0.24	0.22	Pulmonary function;	chr6:28273021	chr6:28315613~28315883:-
THCA	cis	rs6088590	0.561	rs6059934	ENSG00000276073.1	RP5-1125A11.7	-4.88	1.48e-06	0.000182	-0.19	-0.22	Coronary artery disease;	chr20:34590520	chr20:33985617~33988989:-
THCA	cis	rs17301013	0.896	rs13375788	ENSG00000227373.4	RP11-160H22.5	4.88	1.48e-06	0.000182	0.31	0.22	Systemic lupus erythematosus;	chr1:174524207	chr1:174115300~174160004:-
THCA	cis	rs34779708	0.897	rs4934716	ENSG00000271335.4	RP11-324I22.4	4.88	1.48e-06	0.000182	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35314552~35336401:-
THCA	cis	rs7403037	0.754	rs2133276	ENSG00000260760.1	PWRN3	4.88	1.48e-06	0.000182	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24247137	chr15:24441127~24447967:+
THCA	cis	rs8028313	0.609	rs28735117	ENSG00000270964.1	RP11-502I4.3	-4.88	1.48e-06	0.000182	-0.19	-0.22	Obesity;	chr15:67641554	chr15:67541072~67542604:-
THCA	cis	rs957448	1	rs2381882	ENSG00000253175.1	RP11-267M23.6	4.88	1.48e-06	0.000182	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94565036~94565715:+
THCA	cis	rs763121	0.819	rs5757126	ENSG00000235209.1	CTA-150C2.13	4.88	1.49e-06	0.000182	0.29	0.22	Menopause (age at onset);	chr22:38527670	chr22:38921227~38924708:+
THCA	cis	rs7474896	0.507	rs2474555	ENSG00000276805.1	RP11-291L22.6	4.88	1.49e-06	0.000182	0.29	0.22	Obesity (extreme);	chr10:38176292	chr10:38451030~38451785:+
THCA	cis	rs6545883	0.831	rs1186704	ENSG00000270820.4	RP11-355B11.2	4.88	1.49e-06	0.000182	0.19	0.22	Tuberculosis;	chr2:61445856	chr2:61471188~61484130:+
THCA	cis	rs950776	0.518	rs28438420	ENSG00000261762.1	RP11-650L12.2	-4.88	1.49e-06	0.000182	-0.27	-0.22	Sudden cardiac arrest;	chr15:78543946	chr15:78589123~78591276:-
THCA	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-4.88	1.49e-06	0.000182	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-4.88	1.49e-06	0.000182	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-4.88	1.49e-06	0.000182	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-4.88	1.49e-06	0.000182	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000223473.2	GS1-124K5.3	4.88	1.49e-06	0.000182	0.15	0.22	Aortic root size;	chr7:65967557	chr7:66491049~66493566:-
THCA	cis	rs911555	0.692	rs7140647	ENSG00000244691.1	RPL10AP1	4.88	1.49e-06	0.000182	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103412119~103412761:-
THCA	cis	rs61743561	0.512	rs2651195	ENSG00000272223.1	RP1-20C7.6	4.88	1.49e-06	0.000182	0.34	0.22	Obesity-related traits;	chr6:43220028	chr6:43033897~43034405:-
THCA	cis	rs734999	1	rs10797432	ENSG00000225931.3	RP3-395M20.7	4.88	1.49e-06	0.000182	0.26	0.22	Ulcerative colitis;	chr1:2569899	chr1:2566410~2569888:+
THCA	cis	rs10895322	0.656	rs17099063	ENSG00000281655.1	RP11-817J15.3	-4.88	1.49e-06	0.000182	-0.27	-0.22	Neuroblastoma (11q deletion);	chr11:102616334	chr11:102681310~102683913:+
THCA	cis	rs1005277	0.579	rs2474595	ENSG00000275858.1	RP11-291L22.8	-4.88	1.49e-06	0.000182	-0.26	-0.22	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38450738~38451069:-
THCA	cis	rs7614311	0.681	rs73119022	ENSG00000271843.1	RP11-245J9.5	-4.88	1.49e-06	0.000182	-0.39	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63994158	chr3:64008082~64008692:-
THCA	cis	rs9467773	0.534	rs34453863	ENSG00000124549.13	BTN2A3P	4.88	1.49e-06	0.000183	0.21	0.22	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26421391~26432383:+
THCA	cis	rs2439831	0.702	rs28699233	ENSG00000275601.1	AC011330.13	-4.88	1.49e-06	0.000183	-0.38	-0.22	Lung cancer in ever smokers;	chr15:43830668	chr15:43642389~43643023:-
THCA	cis	rs16852403	0.548	rs2225586	ENSG00000224687.1	RASAL2-AS1	4.88	1.49e-06	0.000183	0.33	0.22	Childhood ear infection;	chr1:178234997	chr1:178091508~178093984:-
THCA	cis	rs2304003	1	rs1560594	ENSG00000235192.1	AC009495.2	4.88	1.49e-06	0.000183	0.31	0.22	Social communication problems;	chr2:165843288	chr2:165794851~165810010:+
THCA	cis	rs919433	0.68	rs1961558	ENSG00000231621.1	AC013264.2	-4.88	1.49e-06	0.000183	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197622554	chr2:197197991~197199273:+
THCA	cis	rs2018683	0.523	rs1499227	ENSG00000272568.4	CTB-113D17.1	4.88	1.49e-06	0.000183	0.23	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985999	chr7:28979967~29013367:+
THCA	cis	rs13434995	0.589	rs499110	ENSG00000273257.1	RP11-177J6.1	-4.88	1.49e-06	0.000183	-0.34	-0.22	Adiponectin levels;	chr4:55381628	chr4:55387949~55388271:+
THCA	cis	rs11633886	0.604	rs10153018	ENSG00000273972.1	CTD-2306A12.1	-4.88	1.49e-06	0.000183	-0.25	-0.22	Diisocyanate-induced asthma;	chr15:45831938	chr15:45702640~45703183:+
THCA	cis	rs4660261	0.526	rs2906458	ENSG00000237950.1	RP11-7O11.3	-4.88	1.49e-06	0.000183	-0.19	-0.22	Intelligence (multi-trait analysis);	chr1:43870717	chr1:43944370~43946551:-
THCA	cis	rs4660261	0.526	rs810680	ENSG00000237950.1	RP11-7O11.3	4.88	1.49e-06	0.000183	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43882184	chr1:43944370~43946551:-
THCA	cis	rs4144027	0.791	rs67727470	ENSG00000269958.1	RP11-73M18.8	4.88	1.49e-06	0.000183	0.2	0.22	Blood metabolite levels;	chr14:103895659	chr14:103696353~103697163:+
THCA	cis	rs2735413	0.56	rs73562716	ENSG00000276007.1	RP11-358L22.3	4.88	1.49e-06	0.000183	0.21	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78092518	chr16:78123243~78124332:+
THCA	cis	rs357894	0.802	rs357895	ENSG00000266696.1	RP11-30L3.2	4.87	1.49e-06	0.000183	0.25	0.22	Dental caries;	chr18:49053897	chr18:49205912~49208781:+
THCA	cis	rs2439831	1	rs690002	ENSG00000166763.7	STRCP1	4.87	1.49e-06	0.000183	0.29	0.22	Lung cancer in ever smokers;	chr15:43437151	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs537115	ENSG00000166763.7	STRCP1	4.87	1.49e-06	0.000183	0.29	0.22	Lung cancer in ever smokers;	chr15:43437750	chr15:43699488~43718184:-
THCA	cis	rs737008	0.959	rs11865598	ENSG00000263080.1	RP11-485G7.5	4.87	1.49e-06	0.000183	0.27	0.22	Obesity-related traits;	chr16:11309575	chr16:11341809~11345211:-
THCA	cis	rs3750965	0.959	rs3376	ENSG00000260895.1	RP11-554A11.7	4.87	1.49e-06	0.000183	0.3	0.22	Hair color;	chr11:69089212	chr11:69103493~69109094:+
THCA	cis	rs6012564	0.928	rs2038509	ENSG00000230758.1	SNAP23P	4.87	1.49e-06	0.000183	0.27	0.22	Anger;	chr20:49191533	chr20:49038357~49038602:-
THCA	cis	rs7809950	0.871	rs11771278	ENSG00000238832.1	snoU109	4.87	1.49e-06	0.000183	0.23	0.22	Coronary artery disease;	chr7:107645480	chr7:107603363~107603507:+
THCA	cis	rs79996792	0.736	rs79299044	ENSG00000227403.1	AC009299.3	-4.87	1.49e-06	0.000183	-0.39	-0.22	Neuroticism;	chr2:161637672	chr2:161244739~161249050:+
THCA	cis	rs5752326	0.51	rs5761547	ENSG00000261188.1	CTA-445C9.14	4.87	1.49e-06	0.000183	0.22	0.22	Ischemic stroke;	chr22:26467127	chr22:26512537~26514568:+
THCA	cis	rs10888838	0.756	rs11206306	ENSG00000198711.5	SSBP3-AS1	4.87	1.49e-06	0.000183	0.27	0.22	Mitochondrial DNA levels;	chr1:54224092	chr1:54236440~54239063:+
THCA	cis	rs2797160	0.967	rs926854	ENSG00000237742.5	RP11-624M8.1	4.87	1.49e-06	0.000183	0.19	0.22	Endometrial cancer;	chr6:125700634	chr6:125578558~125749190:-
THCA	cis	rs2439831	1	rs689596	ENSG00000166763.7	STRCP1	4.87	1.49e-06	0.000183	0.29	0.22	Lung cancer in ever smokers;	chr15:43469519	chr15:43699488~43718184:-
THCA	cis	rs11671005	0.735	rs56292587	ENSG00000268049.1	CTD-2619J13.9	-4.87	1.49e-06	0.000183	-0.34	-0.22	Mean platelet volume;	chr19:58407699	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs56290606	ENSG00000268049.1	CTD-2619J13.9	-4.87	1.49e-06	0.000183	-0.34	-0.22	Mean platelet volume;	chr19:58407953	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs11878198	ENSG00000268049.1	CTD-2619J13.9	-4.87	1.49e-06	0.000183	-0.34	-0.22	Mean platelet volume;	chr19:58408935	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs11666716	ENSG00000268049.1	CTD-2619J13.9	-4.87	1.49e-06	0.000183	-0.34	-0.22	Mean platelet volume;	chr19:58409585	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs34511020	ENSG00000268049.1	CTD-2619J13.9	-4.87	1.49e-06	0.000183	-0.34	-0.22	Mean platelet volume;	chr19:58409929	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs11666303	ENSG00000268049.1	CTD-2619J13.9	-4.87	1.49e-06	0.000183	-0.34	-0.22	Mean platelet volume;	chr19:58411135	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs34152946	ENSG00000268049.1	CTD-2619J13.9	-4.87	1.49e-06	0.000183	-0.34	-0.22	Mean platelet volume;	chr19:58411896	chr19:58357999~58359603:+
THCA	cis	rs2154319	0.609	rs12131741	ENSG00000235358.1	RP11-399E6.1	-4.87	1.49e-06	0.000183	-0.29	-0.22	Height;	chr1:41249191	chr1:41242373~41284861:+
THCA	cis	rs11763147	1	rs11763147	ENSG00000213640.3	EEF1DP4	4.87	1.49e-06	0.000183	0.26	0.22	Corneal structure;	chr7:65861834	chr7:64862999~64864370:+
THCA	cis	rs1836229	0.594	rs10815965	ENSG00000225706.1	PTPRD-AS1	-4.87	1.49e-06	0.000183	-0.26	-0.22	Restless legs syndrome;	chr9:8826300	chr9:8858130~8862255:+
THCA	cis	rs1836229	0.594	rs10120478	ENSG00000225706.1	PTPRD-AS1	-4.87	1.49e-06	0.000183	-0.26	-0.22	Restless legs syndrome;	chr9:8826654	chr9:8858130~8862255:+
THCA	cis	rs11018904	0.768	rs35389990	ENSG00000280385.1	AP000648.5	-4.87	1.49e-06	0.000183	-0.33	-0.22	Intelligence (multi-trait analysis);	chr11:90245515	chr11:90193614~90198120:+
THCA	cis	rs10266483	1	rs10266483	ENSG00000271550.1	BNIP3P11	4.87	1.49e-06	0.000183	0.27	0.22	Response to statin therapy;	chr7:64272953	chr7:64678954~64687393:-
THCA	cis	rs9307551	0.741	rs9307532	ENSG00000250334.4	LINC00989	-4.87	1.49e-06	0.000183	-0.29	-0.22	Refractive error;	chr4:79510067	chr4:79492416~79576460:+
THCA	cis	rs972578	0.715	rs738537	ENSG00000274717.1	RP1-47A17.1	-4.87	1.49e-06	0.000183	-0.23	-0.22	Mean platelet volume;	chr22:42881916	chr22:42791814~42794313:-
THCA	cis	rs690037	0.966	rs574083	ENSG00000272498.1	RP11-415F23.3	4.87	1.49e-06	0.000183	0.24	0.22	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16354006	chr3:16339308~16339871:+
THCA	cis	rs10510102	1	rs10510102	ENSG00000226864.1	ATE1-AS1	-4.87	1.49e-06	0.000183	-0.33	-0.22	Breast cancer;	chr10:121865675	chr10:121928312~121951965:+
THCA	cis	rs317689	0.819	rs317683	ENSG00000274979.1	RP11-1143G9.5	-4.87	1.49e-06	0.000183	-0.25	-0.22	Response to diuretic therapy;	chr12:69319850	chr12:69326574~69331882:-
THCA	cis	rs2243480	1	rs313820	ENSG00000164669.11	INTS4P1	4.87	1.49e-06	0.000183	0.42	0.22	Diabetic kidney disease;	chr7:66109479	chr7:65141225~65234216:+
THCA	cis	rs111326718	1	rs111326718	ENSG00000236937.2	PTGES3P4	4.87	1.49e-06	0.000183	0.28	0.22	Reticulocyte count;	chr10:103011454	chr10:102845595~102845950:+
THCA	cis	rs654950	0.653	rs2810568	ENSG00000230638.4	RP11-486B10.4	4.87	1.49e-06	0.000183	0.27	0.22	Airway imaging phenotypes;	chr1:41588576	chr1:41542069~41544310:+
THCA	cis	rs4948102	0.686	rs11771788	ENSG00000226278.1	PSPHP1	-4.87	1.5e-06	0.000183	-0.25	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56090347	chr7:55764797~55773288:+
THCA	cis	rs6138458	1	rs227618	ENSG00000274173.1	RP4-568C11.4	4.87	1.5e-06	0.000183	0.21	0.22	Blood protein levels;	chr20:24928836	chr20:24931840~24932983:+
THCA	cis	rs7829975	0.658	rs2409096	ENSG00000254153.1	CTA-398F10.2	-4.87	1.5e-06	0.000183	-0.24	-0.22	Mood instability;	chr8:8834967	chr8:8456909~8461337:-
THCA	cis	rs2562456	0.752	rs279809	ENSG00000268081.1	RP11-678G14.2	4.87	1.5e-06	0.000183	0.37	0.22	Pain;	chr19:21284729	chr19:21554640~21569237:-
THCA	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	4.87	1.5e-06	0.000183	0.25	0.22	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
THCA	cis	rs5015933	0.902	rs10819047	ENSG00000232630.1	PRPS1P2	-4.87	1.5e-06	0.000183	-0.15	-0.22	Body mass index;	chr9:125365133	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.902	rs2291858	ENSG00000232630.1	PRPS1P2	-4.87	1.5e-06	0.000183	-0.15	-0.22	Body mass index;	chr9:125366503	chr9:125150653~125151589:+
THCA	cis	rs2742234	0.541	rs10899786	ENSG00000273008.1	RP11-351D16.3	4.87	1.5e-06	0.000183	0.21	0.22	Hirschsprung disease;	chr10:43249135	chr10:43136824~43138334:-
THCA	cis	rs36715	1	rs36702	ENSG00000245937.6	LINC01184	4.87	1.5e-06	0.000184	0.24	0.22	Breast cancer;	chr5:128217031	chr5:127940426~128083172:-
THCA	cis	rs2447820	0.588	rs6880211	ENSG00000249996.1	RP11-359P5.1	4.87	1.5e-06	0.000184	0.26	0.22	Migraine;	chr5:123055756	chr5:123036271~123054667:+
THCA	cis	rs9326248	0.53	rs9919599	ENSG00000280143.1	AP000892.6	4.87	1.5e-06	0.000184	0.36	0.22	Blood protein levels;	chr11:116874768	chr11:117204967~117210292:+
THCA	cis	rs4713118	0.629	rs203887	ENSG00000261839.1	RP1-265C24.8	4.87	1.5e-06	0.000184	0.27	0.22	Parkinson's disease;	chr6:28053491	chr6:28136849~28139678:+
THCA	cis	rs957448	1	rs10956915	ENSG00000253175.1	RP11-267M23.6	4.87	1.5e-06	0.000184	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94565036~94565715:+
THCA	cis	rs8177376	0.681	rs240548	ENSG00000254905.1	RP11-712L6.7	4.87	1.5e-06	0.000184	0.3	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126335072	chr11:126292922~126294254:-
THCA	cis	rs11143230	1	rs62564005	ENSG00000225434.2	LINC01504	-4.87	1.5e-06	0.000184	-0.34	-0.22	Suicidal ideation;	chr9:72273467	chr9:72305430~72343210:+
THCA	cis	rs3824435	0.783	rs1575278	ENSG00000272866.1	RP11-12D24.10	-4.87	1.5e-06	0.000184	-0.3	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5345540	chr9:5351796~5352410:-
THCA	cis	rs7674212	0.57	rs2126470	ENSG00000251288.2	RP11-10L12.2	-4.87	1.5e-06	0.000184	-0.28	-0.22	Type 2 diabetes;	chr4:103140605	chr4:102751401~102752641:+
THCA	cis	rs494453	0.807	rs1324889	ENSG00000227811.2	FAM212B-AS1	4.87	1.5e-06	0.000184	0.27	0.22	Osteoporosis-related phenotypes;	chr1:111641018	chr1:111739841~111747798:+
THCA	cis	rs3820928	0.874	rs10183633	ENSG00000212391.1	SNORA48	-4.87	1.5e-06	0.000184	-0.24	-0.22	Pulmonary function;	chr2:227023112	chr2:226968989~226969122:-
THCA	cis	rs66887589	0.72	rs2036858	ENSG00000249244.1	RP11-548H18.2	4.87	1.5e-06	0.000184	0.23	0.22	Diastolic blood pressure;	chr4:119328082	chr4:119391831~119395335:-
THCA	cis	rs12893668	0.603	rs12896171	ENSG00000269958.1	RP11-73M18.8	4.87	1.5e-06	0.000184	0.21	0.22	Reticulocyte count;	chr14:103669629	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.572	rs12590968	ENSG00000269958.1	RP11-73M18.8	4.87	1.5e-06	0.000184	0.21	0.22	Reticulocyte count;	chr14:103670296	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.572	rs11540512	ENSG00000269958.1	RP11-73M18.8	4.87	1.5e-06	0.000184	0.21	0.22	Reticulocyte count;	chr14:103681040	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.572	rs35011804	ENSG00000269958.1	RP11-73M18.8	4.87	1.5e-06	0.000184	0.21	0.22	Reticulocyte count;	chr14:103685063	chr14:103696353~103697163:+
THCA	cis	rs6560517	0.813	rs2501928	ENSG00000234618.1	RPSAP9	4.87	1.5e-06	0.000184	0.22	0.22	Dialysis-related mortality;	chr9:76381692	chr9:76398699~76399586:+
THCA	cis	rs11633886	0.604	rs34965865	ENSG00000273972.1	CTD-2306A12.1	-4.87	1.5e-06	0.000184	-0.25	-0.22	Diisocyanate-induced asthma;	chr15:45828976	chr15:45702640~45703183:+
THCA	cis	rs10435719	0.58	rs13260712	ENSG00000206014.6	OR7E161P	4.87	1.5e-06	0.000184	0.26	0.22	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:11928597~11929563:-
THCA	cis	rs11992162	0.551	rs13268217	ENSG00000206014.6	OR7E161P	4.87	1.5e-06	0.000184	0.26	0.22	Monocyte count;	chr8:11925100	chr8:11928597~11929563:-
THCA	cis	rs11992162	0.573	rs13264994	ENSG00000206014.6	OR7E161P	4.87	1.5e-06	0.000184	0.26	0.22	Monocyte count;	chr8:11925250	chr8:11928597~11929563:-
THCA	cis	rs11992162	0.573	rs13275808	ENSG00000206014.6	OR7E161P	4.87	1.5e-06	0.000184	0.26	0.22	Monocyte count;	chr8:11925306	chr8:11928597~11929563:-
THCA	cis	rs2255336	0.81	rs7976624	ENSG00000245648.1	RP11-277P12.20	4.87	1.5e-06	0.000184	0.32	0.22	Blood protein levels;	chr12:10359392	chr12:10363769~10398506:+
THCA	cis	rs35160687	0.644	rs11127024	ENSG00000273080.1	RP11-301O19.1	-4.87	1.5e-06	0.000184	-0.24	-0.22	Night sleep phenotypes;	chr2:86278330	chr2:86195590~86196049:+
THCA	cis	rs330071	0.622	rs898797	ENSG00000254153.1	CTA-398F10.2	-4.87	1.5e-06	0.000184	-0.25	-0.22	Acne (severe);	chr8:9372179	chr8:8456909~8461337:-
THCA	cis	rs270601	0.71	rs371709	ENSG00000237714.1	P4HA2-AS1	4.87	1.5e-06	0.000184	0.28	0.22	Acylcarnitine levels;	chr5:132247547	chr5:132184876~132192808:+
THCA	cis	rs270601	0.69	rs162907	ENSG00000237714.1	P4HA2-AS1	-4.87	1.5e-06	0.000184	-0.28	-0.22	Acylcarnitine levels;	chr5:132244459	chr5:132184876~132192808:+
THCA	cis	rs7819412	0.594	rs60921132	ENSG00000206014.6	OR7E161P	4.87	1.5e-06	0.000184	0.26	0.22	Triglycerides;	chr8:11107459	chr8:11928597~11929563:-
THCA	cis	rs9625935	0.912	rs7292615	ENSG00000279159.1	RP3-394A18.1	-4.87	1.51e-06	0.000184	-0.17	-0.22	Tonsillectomy;	chr22:29889781	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs8141680	ENSG00000279159.1	RP3-394A18.1	-4.87	1.51e-06	0.000184	-0.17	-0.22	Tonsillectomy;	chr22:29904590	chr22:29978950~30028236:-
THCA	cis	rs9311474	0.659	rs1133415	ENSG00000243224.1	RP5-1157M23.2	-4.87	1.51e-06	0.000184	-0.23	-0.22	Electroencephalogram traits;	chr3:52541815	chr3:52239258~52241097:+
THCA	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-4.87	1.51e-06	0.000184	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
THCA	cis	rs62158800	0.925	rs58069412	ENSG00000224568.1	AC096669.3	4.87	1.51e-06	0.000184	0.39	0.22	Facial morphology (factor 22);	chr2:107592297	chr2:107529487~107556326:+
THCA	cis	rs748404	0.666	rs12899865	ENSG00000205771.5	CATSPER2P1	-4.87	1.51e-06	0.000184	-0.28	-0.22	Lung cancer;	chr15:43448819	chr15:43726918~43747094:-
THCA	cis	rs4776997	0.545	rs12592195	ENSG00000270964.1	RP11-502I4.3	4.87	1.51e-06	0.000184	0.18	0.22	Verbal declarative memory;	chr15:67848266	chr15:67541072~67542604:-
THCA	cis	rs1387259	0.69	rs1601985	ENSG00000240399.1	RP1-228P16.1	4.87	1.51e-06	0.000184	0.23	0.22	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48054813~48055591:-
THCA	cis	rs5758659	1	rs134900	ENSG00000227370.1	RP4-669P10.19	-4.87	1.51e-06	0.000184	-0.2	-0.22	Cognitive function;	chr22:42287337	chr22:42132543~42132998:+
THCA	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-4.87	1.51e-06	0.000185	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
THCA	cis	rs9880211	0.563	rs6792630	ENSG00000273486.1	RP11-731C17.2	4.87	1.51e-06	0.000185	0.22	0.22	Height;Body mass index;	chr3:136106059	chr3:136837338~136839021:-
THCA	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	4.87	1.51e-06	0.000185	0.24	0.22	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
THCA	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-4.87	1.51e-06	0.000185	-0.25	-0.22	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
THCA	cis	rs7674212	0.57	rs1031804	ENSG00000251288.2	RP11-10L12.2	-4.87	1.51e-06	0.000185	-0.28	-0.22	Type 2 diabetes;	chr4:103144892	chr4:102751401~102752641:+
THCA	cis	rs8020095	0.571	rs10131292	ENSG00000258561.1	RP11-72M17.1	-4.87	1.51e-06	0.000185	-0.31	-0.22	Depression (quantitative trait);	chr14:66866264	chr14:66212810~66509394:-
THCA	cis	rs10910092	1	rs10910092	ENSG00000225931.3	RP3-395M20.7	4.87	1.51e-06	0.000185	0.26	0.22	Ulcerative colitis;	chr1:2570077	chr1:2566410~2569888:+
THCA	cis	rs8111500	0.793	rs2892233	ENSG00000232871.7	SEC1P	4.87	1.51e-06	0.000185	0.26	0.22	Elevated serum carcinoembryonic antigen levels;	chr19:48656998	chr19:48638071~48682245:+
THCA	cis	rs240993	0.715	rs399219	ENSG00000271789.1	RP5-1112D6.7	-4.87	1.51e-06	0.000185	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111371880	chr6:111297126~111298510:+
THCA	cis	rs7674212	0.57	rs6841136	ENSG00000251288.2	RP11-10L12.2	-4.87	1.51e-06	0.000185	-0.28	-0.22	Type 2 diabetes;	chr4:103182352	chr4:102751401~102752641:+
THCA	cis	rs600231	0.508	rs11227201	ENSG00000245532.5	NEAT1	4.87	1.51e-06	0.000185	0.19	0.22	Bone mineral density;	chr11:65475077	chr11:65422774~65445540:+
THCA	cis	rs1979679	0.801	rs2881787	ENSG00000247934.4	RP11-967K21.1	4.87	1.51e-06	0.000185	0.21	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28145489	chr12:28163298~28190738:-
THCA	cis	rs3745672	1	rs11880710	ENSG00000219665.7	CTD-2006C1.2	4.87	1.51e-06	0.000185	0.31	0.22	Multiple sclerosis;	chr19:12046080	chr19:11987617~12046275:+
THCA	cis	rs8014252	0.667	rs58186506	ENSG00000259158.2	ADAM20P1	-4.87	1.51e-06	0.000185	-0.24	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70399291	chr14:70468881~70483756:-
THCA	cis	rs8014252	0.732	rs10144818	ENSG00000259158.2	ADAM20P1	-4.87	1.51e-06	0.000185	-0.24	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70399558	chr14:70468881~70483756:-
THCA	cis	rs9890032	0.57	rs8068504	ENSG00000264538.5	SUZ12P1	-4.87	1.51e-06	0.000185	-0.16	-0.22	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30709299~30790908:+
THCA	cis	rs2439831	0.85	rs12442297	ENSG00000166763.7	STRCP1	4.87	1.51e-06	0.000185	0.32	0.22	Lung cancer in ever smokers;	chr15:43876272	chr15:43699488~43718184:-
THCA	cis	rs10129255	0.789	rs61997796	ENSG00000211974.3	IGHV2-70	4.87	1.51e-06	0.000185	0.17	0.22	Kawasaki disease;	chr14:106813798	chr14:106723574~106724093:-
THCA	cis	rs9863	0.827	rs6488913	ENSG00000269997.1	RP11-214K3.21	4.87	1.51e-06	0.000185	0.26	0.22	White blood cell count;	chr12:123961022	chr12:123966077~123966629:-
THCA	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-4.87	1.51e-06	0.000185	-0.27	-0.22	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-4.87	1.51e-06	0.000185	-0.27	-0.22	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
THCA	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-4.87	1.51e-06	0.000185	-0.13	-0.22	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
THCA	cis	rs240993	0.812	rs6937734	ENSG00000271789.1	RP5-1112D6.7	4.87	1.51e-06	0.000185	0.27	0.22	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111297126~111298510:+
THCA	cis	rs4713118	0.869	rs6930992	ENSG00000226314.6	ZNF192P1	-4.87	1.51e-06	0.000185	-0.27	-0.22	Parkinson's disease;	chr6:27744341	chr6:28161781~28169594:+
THCA	cis	rs6545883	0.894	rs4672423	ENSG00000270820.4	RP11-355B11.2	-4.87	1.51e-06	0.000185	-0.18	-0.22	Tuberculosis;	chr2:61208140	chr2:61471188~61484130:+
THCA	cis	rs4650994	0.593	rs12096732	ENSG00000273384.1	RP5-1098D14.1	-4.87	1.51e-06	0.000185	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178554029	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.571	rs6425486	ENSG00000273384.1	RP5-1098D14.1	-4.87	1.51e-06	0.000185	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178559687	chr1:178651706~178652282:+
THCA	cis	rs7554547	0.667	rs2050266	ENSG00000199347.1	RNU5E-1	-4.87	1.51e-06	0.000185	-0.31	-0.22	Nonsyndromic cleft lip with cleft palate;	chr1:11886531	chr1:11908152~11908271:+
THCA	cis	rs10208649	0.764	rs7583005	ENSG00000233266.1	HMGB1P31	4.87	1.51e-06	0.000185	0.57	0.22	Body mass index;	chr2:54019051	chr2:54051334~54051760:+
THCA	cis	rs6472827	0.622	rs2956023	ENSG00000253983.2	RP1-16A9.1	4.87	1.51e-06	0.000185	0.32	0.22	Uterine fibroids;	chr8:74193978	chr8:74199396~74208441:+
THCA	cis	rs453301	0.571	rs330048	ENSG00000253981.4	ALG1L13P	-4.87	1.51e-06	0.000185	-0.21	-0.22	Joint mobility (Beighton score);	chr8:9229768	chr8:8236003~8244667:-
THCA	cis	rs4950322	0.57	rs72692980	ENSG00000271721.1	RP11-337C18.9	4.87	1.51e-06	0.000185	0.25	0.22	Protein quantitative trait loci;	chr1:147337830	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.634	rs7542951	ENSG00000271721.1	RP11-337C18.9	4.87	1.51e-06	0.000185	0.25	0.22	Protein quantitative trait loci;	chr1:147340308	chr1:147175602~147177740:+
THCA	cis	rs4578769	0.505	rs4405649	ENSG00000265939.1	UBE2CP2	4.87	1.51e-06	0.000185	0.25	0.22	Eosinophil percentage of white cells;	chr18:23007590	chr18:22900486~22900995:-
THCA	cis	rs9963862	1	rs9963862	ENSG00000265939.1	UBE2CP2	4.87	1.51e-06	0.000185	0.25	0.22	Late-onset myasthenia gravis;	chr18:23007948	chr18:22900486~22900995:-
THCA	cis	rs11671005	0.651	rs11878203	ENSG00000268912.1	CTD-2619J13.17	-4.87	1.51e-06	0.000185	-0.21	-0.22	Mean platelet volume;	chr19:58408683	chr19:58428632~58431148:-
THCA	cis	rs1880529	0.83	rs3796929	ENSG00000206820.1	RNU1-138P	-4.87	1.51e-06	0.000185	-0.25	-0.22	White matter integrity (bipolar disorder risk interaction);	chr4:113446824	chr4:113420323~113420486:+
THCA	cis	rs7727544	0.507	rs11741341	ENSG00000224431.1	AC063976.7	4.87	1.51e-06	0.000185	0.18	0.22	Blood metabolite levels;	chr5:132234525	chr5:132199456~132203487:+
THCA	cis	rs950169	0.58	rs11635597	ENSG00000188388.10	GOLGA6L3	4.87	1.51e-06	0.000185	0.3	0.22	Schizophrenia;	chr15:84622468	chr15:85240472~85247170:+
THCA	cis	rs9926296	0.609	rs4785709	ENSG00000260259.1	RP11-368I7.4	4.87	1.52e-06	0.000185	0.25	0.22	Vitiligo;	chr16:89730257	chr16:89682620~89686569:-
THCA	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-4.87	1.52e-06	0.000185	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-4.87	1.52e-06	0.000185	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-4.87	1.52e-06	0.000185	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-4.87	1.52e-06	0.000185	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
THCA	cis	rs2803122	0.871	rs10481512	ENSG00000273226.1	RP11-513M16.8	-4.87	1.52e-06	0.000186	-0.2	-0.22	Pulse pressure;	chr9:19230741	chr9:19375451~19375996:+
THCA	cis	rs481331	0.799	rs72787858	ENSG00000215146.4	RP11-313J2.1	4.87	1.52e-06	0.000186	0.36	0.22	Systemic juvenile idiopathic arthritis;	chr10:42472544	chr10:42331866~42367974:-
THCA	cis	rs11157436	0.958	rs17183356	ENSG00000211812.1	TRAV26-2	-4.87	1.52e-06	0.000186	-0.2	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22202583~22203368:+
THCA	cis	rs2067615	0.579	rs4964486	ENSG00000260329.1	RP11-412D9.4	-4.87	1.52e-06	0.000186	-0.2	-0.22	Heart rate;	chr12:106747012	chr12:106954029~106955497:-
THCA	cis	rs1005277	0.54	rs2145487	ENSG00000276805.1	RP11-291L22.6	4.87	1.52e-06	0.000186	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38451030~38451785:+
THCA	cis	rs9393777	0.92	rs35120058	ENSG00000280107.1	AL022393.9	-4.87	1.52e-06	0.000186	-0.38	-0.22	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28170845~28172521:+
THCA	cis	rs8028182	0.549	rs4886696	ENSG00000260274.1	RP11-817O13.8	-4.87	1.52e-06	0.000186	-0.16	-0.22	Sudden cardiac arrest;	chr15:75372229	chr15:75368155~75369584:+
THCA	cis	rs911555	0.755	rs12432803	ENSG00000244691.1	RPL10AP1	4.87	1.52e-06	0.000186	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs4906329	ENSG00000244691.1	RPL10AP1	4.87	1.52e-06	0.000186	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103412119~103412761:-
THCA	cis	rs5758511	0.689	rs56906457	ENSG00000281538.1	RP4-669P10.20	-4.87	1.52e-06	0.000186	-0.29	-0.22	Birth weight;	chr22:42232329	chr22:42138060~42139726:+
THCA	cis	rs4819052	0.851	rs875621	ENSG00000273796.1	LL21NC02-21A1.1	-4.87	1.52e-06	0.000186	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45403809~45404369:-
THCA	cis	rs7176527	0.579	rs366717	ENSG00000230373.7	GOLGA6L5P	4.87	1.52e-06	0.000186	0.25	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84507885~84516814:-
THCA	cis	rs9863	0.861	rs7961449	ENSG00000269997.1	RP11-214K3.21	4.87	1.52e-06	0.000186	0.26	0.22	White blood cell count;	chr12:123952668	chr12:123966077~123966629:-
THCA	cis	rs6088590	0.687	rs13044899	ENSG00000269202.1	RP4-614O4.12	-4.87	1.52e-06	0.000186	-0.19	-0.22	Coronary artery disease;	chr20:34699274	chr20:35201747~35203288:-
THCA	cis	rs72945132	0.882	rs2276001	ENSG00000254604.1	AP000487.6	-4.87	1.52e-06	0.000186	-0.41	-0.22	Coronary artery disease;	chr11:70335454	chr11:70282367~70363368:-
THCA	cis	rs3820928	0.874	rs10439363	ENSG00000212391.1	SNORA48	-4.87	1.52e-06	0.000186	-0.24	-0.22	Pulmonary function;	chr2:226950349	chr2:226968989~226969122:-
THCA	cis	rs2439831	1	rs565007	ENSG00000166763.7	STRCP1	4.87	1.52e-06	0.000186	0.29	0.22	Lung cancer in ever smokers;	chr15:43424443	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs550239	ENSG00000166763.7	STRCP1	4.87	1.52e-06	0.000186	0.29	0.22	Lung cancer in ever smokers;	chr15:43427999	chr15:43699488~43718184:-
THCA	cis	rs3738443	0.868	rs60698393	ENSG00000259865.1	RP11-488L18.10	4.87	1.52e-06	0.000186	0.23	0.22	Alcohol dependence;	chr1:247198135	chr1:247187281~247188526:-
THCA	cis	rs453301	0.658	rs12114954	ENSG00000254153.1	CTA-398F10.2	4.87	1.52e-06	0.000186	0.23	0.22	Joint mobility (Beighton score);	chr8:9047352	chr8:8456909~8461337:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000229886.1	RP5-1132H15.3	4.87	1.52e-06	0.000186	0.23	0.22	Calcium levels;	chr7:65892789	chr7:66025126~66031544:-
THCA	cis	rs12893668	0.572	rs4906356	ENSG00000269958.1	RP11-73M18.8	4.87	1.52e-06	0.000186	0.21	0.22	Reticulocyte count;	chr14:103672364	chr14:103696353~103697163:+
THCA	cis	rs8113308	0.752	rs8113758	ENSG00000269235.1	ZNF350-AS1	4.87	1.52e-06	0.000186	0.29	0.22	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51990054	chr19:51949134~51981367:+
THCA	cis	rs4415084	0.932	rs2218080	ENSG00000272335.1	RP11-53O19.3	-4.87	1.52e-06	0.000186	-0.18	-0.22	Breast cancer;	chr5:44714228	chr5:44826076~44828592:+
THCA	cis	rs1823913	0.637	rs6722183	ENSG00000280083.1	RP11-317J9.1	4.87	1.52e-06	0.000186	0.26	0.22	Obesity-related traits;	chr2:191333203	chr2:191154118~191156070:-
THCA	cis	rs7246657	0.508	rs1628959	ENSG00000226686.6	LINC01535	-4.87	1.52e-06	0.000186	-0.37	-0.22	Coronary artery calcification;	chr19:36999474	chr19:37251912~37265535:+
THCA	cis	rs4791641	0.743	rs2270445	ENSG00000178977.3	LINC00324	-4.87	1.52e-06	0.000186	-0.25	-0.22	Red blood cell count;LDL cholesterol;Hematocrit;Hemoglobin concentration;LDL cholesterol levels;	chr17:8316160	chr17:8220642~8224043:-
THCA	cis	rs6413860	0.688	rs10802435	ENSG00000260855.1	RP11-439E19.10	-4.87	1.52e-06	0.000186	-0.25	-0.22	Gut microbiome composition (summer);	chr1:246696102	chr1:246772301~246775772:+
THCA	cis	rs74233809	0.551	rs3740393	ENSG00000213277.3	MARCKSL1P1	4.87	1.52e-06	0.000186	0.31	0.22	Birth weight;	chr10:102876898	chr10:103175554~103176094:+
THCA	cis	rs7412746	0.634	rs12562939	ENSG00000231073.1	RP11-316M1.3	4.87	1.52e-06	0.000186	0.27	0.22	Melanoma;	chr1:150978976	chr1:150973123~150975534:+
THCA	cis	rs7412746	0.658	rs12067685	ENSG00000231073.1	RP11-316M1.3	4.87	1.52e-06	0.000186	0.27	0.22	Melanoma;	chr1:150980441	chr1:150973123~150975534:+
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000232559.3	GS1-124K5.12	4.87	1.53e-06	0.000187	0.33	0.22	Diabetic kidney disease;	chr7:65946971	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs2961102	ENSG00000232559.3	GS1-124K5.12	4.87	1.53e-06	0.000187	0.33	0.22	Diabetic kidney disease;	chr7:65959671	chr7:66554588~66576923:-
THCA	cis	rs9910055	0.659	rs227580	ENSG00000267080.4	ASB16-AS1	4.87	1.53e-06	0.000187	0.2	0.22	Total body bone mineral density;	chr17:44145700	chr17:44175973~44186717:-
THCA	cis	rs7474896	0.832	rs12783666	ENSG00000263064.2	RP11-291L22.7	4.87	1.53e-06	0.000187	0.37	0.22	Obesity (extreme);	chr10:37728160	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs12766567	ENSG00000263064.2	RP11-291L22.7	4.87	1.53e-06	0.000187	0.37	0.22	Obesity (extreme);	chr10:37746294	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.806	rs1779150	ENSG00000263064.2	RP11-291L22.7	4.87	1.53e-06	0.000187	0.37	0.22	Obesity (extreme);	chr10:37749759	chr10:38448689~38448949:+
THCA	cis	rs16846053	0.792	rs62190674	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161808451	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187680	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Cognitive function;	chr2:161809217	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs55647762	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161810807	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs56018438	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161810867	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs3849342	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161811831	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs3849344	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161812034	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187684	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161812361	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs4603779	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161812774	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs59829975	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161815323	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs60050769	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161815379	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs56154342	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161816300	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs60064564	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161816489	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187696	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161819997	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187698	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161820795	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187699	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161820813	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72879207	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161822878	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.71	rs72879209	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161822924	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs9636282	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161823885	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs9636283	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161823892	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs9636284	ENSG00000227403.1	AC009299.3	4.87	1.53e-06	0.000187	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161824002	chr2:161244739~161249050:+
THCA	cis	rs8028313	0.63	rs28418298	ENSG00000270964.1	RP11-502I4.3	-4.87	1.53e-06	0.000187	-0.19	-0.22	Obesity;	chr15:67643407	chr15:67541072~67542604:-
THCA	cis	rs8028313	0.63	rs28565266	ENSG00000270964.1	RP11-502I4.3	-4.87	1.53e-06	0.000187	-0.19	-0.22	Obesity;	chr15:67645673	chr15:67541072~67542604:-
THCA	cis	rs875971	0.571	rs78668714	ENSG00000228409.4	CCT6P1	-4.87	1.53e-06	0.000187	-0.19	-0.22	Aortic root size;	chr7:66474464	chr7:65751142~65763354:+
THCA	cis	rs11723261	0.621	rs11733385	ENSG00000211553.1	AC253576.2	-4.87	1.53e-06	0.000187	-0.32	-0.22	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:136461~136568:+
THCA	cis	rs11723261	0.546	rs4315728	ENSG00000211553.1	AC253576.2	-4.87	1.53e-06	0.000187	-0.32	-0.22	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:136461~136568:+
THCA	cis	rs7246657	0.653	rs10414983	ENSG00000226686.6	LINC01535	-4.87	1.53e-06	0.000187	-0.39	-0.22	Coronary artery calcification;	chr19:37174830	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.598	rs10405372	ENSG00000226686.6	LINC01535	-4.87	1.53e-06	0.000187	-0.39	-0.22	Coronary artery calcification;	chr19:37177873	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.653	rs10425441	ENSG00000226686.6	LINC01535	-4.87	1.53e-06	0.000187	-0.39	-0.22	Coronary artery calcification;	chr19:37179746	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.653	rs4805207	ENSG00000226686.6	LINC01535	-4.87	1.53e-06	0.000187	-0.39	-0.22	Coronary artery calcification;	chr19:37182831	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.653	rs28701616	ENSG00000226686.6	LINC01535	-4.87	1.53e-06	0.000187	-0.39	-0.22	Coronary artery calcification;	chr19:37190196	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.673	rs9895684	ENSG00000280069.1	CTD-2349P21.3	-4.87	1.53e-06	0.000187	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30738182~30740275:+
THCA	cis	rs72945132	0.825	rs58532402	ENSG00000254604.1	AP000487.6	-4.87	1.53e-06	0.000187	-0.41	-0.22	Coronary artery disease;	chr11:70343385	chr11:70282367~70363368:-
THCA	cis	rs3824435	0.772	rs1885499	ENSG00000272866.1	RP11-12D24.10	-4.87	1.53e-06	0.000187	-0.3	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5341556	chr9:5351796~5352410:-
THCA	cis	rs6477918	0.598	rs10817355	ENSG00000230185.4	C9orf147	-4.87	1.53e-06	0.000187	-0.24	-0.22	Obstetric antiphospholipid syndrome;	chr9:112518247	chr9:112433816~112487204:-
THCA	cis	rs2735413	0.563	rs117731654	ENSG00000276007.1	RP11-358L22.3	4.87	1.53e-06	0.000187	0.25	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78013450	chr16:78123243~78124332:+
THCA	cis	rs2735413	0.563	rs72800909	ENSG00000276007.1	RP11-358L22.3	4.87	1.53e-06	0.000187	0.25	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78013605	chr16:78123243~78124332:+
THCA	cis	rs703842	1	rs11172333	ENSG00000270039.1	RP11-571M6.17	-4.87	1.53e-06	0.000187	-0.25	-0.22	Multiple sclerosis;	chr12:57776552	chr12:57803838~57804415:+
THCA	cis	rs72945132	0.882	rs7121012	ENSG00000254604.1	AP000487.6	-4.87	1.53e-06	0.000187	-0.41	-0.22	Coronary artery disease;	chr11:70368315	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs10466703	ENSG00000254604.1	AP000487.6	-4.87	1.53e-06	0.000187	-0.41	-0.22	Coronary artery disease;	chr11:70372442	chr11:70282367~70363368:-
THCA	cis	rs12908161	0.959	rs1051168	ENSG00000188388.10	GOLGA6L3	4.87	1.53e-06	0.000187	0.29	0.22	Schizophrenia;	chr15:84657289	chr15:85240472~85247170:+
THCA	cis	rs4722166	0.695	rs7787893	ENSG00000225541.1	AC002480.5	-4.87	1.53e-06	0.000187	-0.27	-0.22	Lung cancer;	chr7:22734818	chr7:22571607~22661792:-
THCA	cis	rs853679	1	rs10456362	ENSG00000220721.1	OR1F12	-4.87	1.53e-06	0.000187	-0.33	-0.22	Depression;	chr6:28254038	chr6:28073316~28074233:+
THCA	cis	rs897984	0.683	rs13337900	ENSG00000279196.1	RP11-1072A3.3	4.87	1.53e-06	0.000187	0.22	0.22	Dementia with Lewy bodies;	chr16:30811088	chr16:30984630~30988270:-
THCA	cis	rs7829975	0.681	rs2271342	ENSG00000254340.1	RP11-10A14.3	4.87	1.53e-06	0.000187	0.24	0.22	Mood instability;	chr8:8786428	chr8:9141424~9145435:+
THCA	cis	rs2058059	0.636	rs2960948	ENSG00000205578.5	POM121B	-4.87	1.53e-06	0.000187	-0.33	-0.22	Subcutaneous adipose tissue;	chr7:72685439	chr7:73293497~73301161:+
THCA	cis	rs494453	0.922	rs500184	ENSG00000227811.2	FAM212B-AS1	4.87	1.53e-06	0.000187	0.27	0.22	Osteoporosis-related phenotypes;	chr1:111620924	chr1:111739841~111747798:+
THCA	cis	rs2288884	0.559	rs9636139	ENSG00000269483.1	AC006272.1	4.87	1.53e-06	0.000187	0.25	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018043	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.559	rs12610953	ENSG00000269483.1	AC006272.1	4.87	1.53e-06	0.000187	0.25	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018675	chr19:51839924~51843324:-
THCA	cis	rs5758659	0.714	rs133373	ENSG00000182057.4	OGFRP1	4.87	1.53e-06	0.000187	0.25	0.22	Cognitive function;	chr22:42069784	chr22:42269753~42275196:+
THCA	cis	rs11175834	0.655	rs11175839	ENSG00000213344.2	PCNPP3	4.87	1.53e-06	0.000187	0.37	0.22	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65613113	chr12:65645992~65646462:-
THCA	cis	rs9283706	0.607	rs10471696	ENSG00000229666.1	MAST4-AS1	-4.87	1.53e-06	0.000187	-0.3	-0.22	Coronary artery disease;	chr5:67008995	chr5:67001383~67003953:-
THCA	cis	rs4591358	0.705	rs11897464	ENSG00000223466.1	AC064834.2	-4.87	1.53e-06	0.000187	-0.25	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195478572	chr2:195533035~195538681:+
THCA	cis	rs6708331	0.517	rs2028879	ENSG00000179818.12	PCBP1-AS1	-4.87	1.53e-06	0.000187	-0.18	-0.22	Obesity-related traits;	chr2:70127505	chr2:69962263~70103220:-
THCA	cis	rs1005277	0.579	rs1548255	ENSG00000275858.1	RP11-291L22.8	4.87	1.53e-06	0.000187	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38450738~38451069:-
THCA	cis	rs13096142	0.558	rs9839623	ENSG00000223552.1	RP11-24F11.2	-4.87	1.53e-06	0.000187	-0.23	-0.22	Celiac disease;	chr3:46282368	chr3:46364955~46407059:-
THCA	cis	rs10266483	0.739	rs55747800	ENSG00000271550.1	BNIP3P11	-4.87	1.53e-06	0.000187	-0.31	-0.22	Response to statin therapy;	chr7:64410105	chr7:64678954~64687393:-
THCA	cis	rs7191700	0.578	rs243327	ENSG00000263080.1	RP11-485G7.5	-4.87	1.53e-06	0.000187	-0.25	-0.22	Multiple sclerosis;	chr16:11259447	chr16:11341809~11345211:-
THCA	cis	rs9973361	0.531	rs62176288	ENSG00000232411.1	AC009495.3	-4.87	1.53e-06	0.000187	-0.27	-0.22	Total body bone mineral density;	chr2:165838327	chr2:165833048~165839098:-
THCA	cis	rs6496932	0.503	rs10220820	ENSG00000259630.2	CTD-2262B20.1	-4.87	1.53e-06	0.000187	-0.27	-0.22	Central corneal thickness;Corneal structure;	chr15:85441932	chr15:85415228~85415633:+
THCA	cis	rs930395	0.514	rs10044321	ENSG00000272335.1	RP11-53O19.3	4.87	1.53e-06	0.000188	0.19	0.22	Breast cancer;	chr5:44890658	chr5:44826076~44828592:+
THCA	cis	rs8027521	0.519	rs4774678	ENSG00000280362.1	RP11-643A5.3	4.87	1.53e-06	0.000188	0.27	0.22	Circulating chemerin levels;	chr15:53954263	chr15:53910769~53914712:+
THCA	cis	rs1417569	0.517	rs2994627	ENSG00000237135.1	DDX10P1	4.87	1.53e-06	0.000188	0.27	0.22	Tuberculosis;	chr10:30911955	chr10:30919012~30921235:-
THCA	cis	rs9677476	0.779	rs10173555	ENSG00000224376.1	AC017104.6	4.87	1.53e-06	0.000188	0.26	0.22	Food antigen IgG levels;	chr2:231244056	chr2:231388976~231394991:+
THCA	cis	rs753778	0.602	rs9792	ENSG00000253210.1	RP11-809O17.1	4.87	1.53e-06	0.000188	0.26	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141195138	chr8:141126044~141129961:-
THCA	cis	rs7208859	0.623	rs55724095	ENSG00000280069.1	CTD-2349P21.3	-4.87	1.53e-06	0.000188	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.568	rs9903854	ENSG00000280069.1	CTD-2349P21.3	-4.87	1.53e-06	0.000188	-0.34	-0.22	Body mass index;	chr17:30826980	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs80355557	ENSG00000280069.1	CTD-2349P21.3	-4.87	1.53e-06	0.000188	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9911173	ENSG00000280069.1	CTD-2349P21.3	-4.87	1.53e-06	0.000188	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30738182~30740275:+
THCA	cis	rs2287838	1	rs12609594	ENSG00000267289.1	CTD-2623N2.11	4.87	1.54e-06	0.000188	0.26	0.22	Sleep duration;	chr19:9861741	chr19:9834079~9835013:-
THCA	cis	rs7577696	0.693	rs466126	ENSG00000276334.1	AL133243.1	4.87	1.54e-06	0.000188	0.23	0.22	Inflammatory biomarkers;	chr2:32237025	chr2:32521927~32523547:+
THCA	cis	rs6012564	0.964	rs2064853	ENSG00000227431.4	CSE1L-AS1	-4.87	1.54e-06	0.000188	-0.27	-0.22	Anger;	chr20:49058639	chr20:49040463~49046044:-
THCA	cis	rs9992667	0.911	rs28360925	ENSG00000231160.8	KLF3-AS1	4.87	1.54e-06	0.000188	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38615676	chr4:38612701~38664883:-
THCA	cis	rs6973609	0.524	rs12673985	ENSG00000271122.1	RP11-379H18.1	-4.87	1.54e-06	0.000188	-0.14	-0.22	Obesity-related traits;	chr7:35607298	chr7:35695214~35699413:+
THCA	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-4.87	1.54e-06	0.000188	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
THCA	cis	rs3820928	0.874	rs10933165	ENSG00000212391.1	SNORA48	4.87	1.54e-06	0.000188	0.24	0.22	Pulmonary function;	chr2:227018932	chr2:226968989~226969122:-
THCA	cis	rs9652601	0.691	rs9933507	ENSG00000274038.1	RP11-66H6.4	-4.87	1.54e-06	0.000188	-0.26	-0.22	Systemic lupus erythematosus;	chr16:11107571	chr16:11056556~11057034:+
THCA	cis	rs11671005	0.571	rs56243535	ENSG00000269473.1	CTD-2619J13.19	4.87	1.54e-06	0.000188	0.25	0.22	Mean platelet volume;	chr19:58494783	chr19:58440448~58445849:+
THCA	cis	rs6714710	0.58	rs57804205	ENSG00000230606.9	AC159540.1	-4.87	1.54e-06	0.000188	-0.24	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838009	chr2:97416165~97433527:-
THCA	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-4.87	1.54e-06	0.000188	-0.29	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-4.87	1.54e-06	0.000188	-0.29	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
THCA	cis	rs2239547	0.618	rs13083728	ENSG00000242142.1	SERBP1P3	4.87	1.54e-06	0.000188	0.28	0.22	Schizophrenia;	chr3:52834429	chr3:53064283~53065091:-
THCA	cis	rs2797160	0.967	rs1739358	ENSG00000237742.5	RP11-624M8.1	4.87	1.54e-06	0.000188	0.19	0.22	Endometrial cancer;	chr6:125698590	chr6:125578558~125749190:-
THCA	cis	rs12030196	0.827	rs7543260	ENSG00000230812.4	LINC01358	4.87	1.54e-06	0.000188	0.28	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58970016	chr1:59020387~59044614:+
THCA	cis	rs4648045	0.861	rs1585215	ENSG00000246560.2	RP11-10L12.4	4.87	1.54e-06	0.000188	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102523317	chr4:102828055~102844075:+
THCA	cis	rs66887589	0.72	rs11724758	ENSG00000249244.1	RP11-548H18.2	4.87	1.54e-06	0.000188	0.23	0.22	Diastolic blood pressure;	chr4:119318723	chr4:119391831~119395335:-
THCA	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	4.87	1.54e-06	0.000188	0.29	0.22	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
THCA	cis	rs17270561	0.887	rs9358870	ENSG00000272462.2	U91328.19	-4.87	1.54e-06	0.000188	-0.21	-0.22	Iron status biomarkers;	chr6:25718982	chr6:25992662~26001775:+
THCA	cis	rs3796352	1	rs2564926	ENSG00000242142.1	SERBP1P3	4.87	1.54e-06	0.000188	0.38	0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53060714	chr3:53064283~53065091:-
THCA	cis	rs10266483	0.739	rs2692099	ENSG00000228653.2	HNRNPCP7	-4.87	1.54e-06	0.000188	-0.19	-0.22	Response to statin therapy;	chr7:64307384	chr7:64500825~64501729:+
THCA	cis	rs6565180	1	rs11646130	ENSG00000274653.1	RP11-347C12.11	4.87	1.54e-06	0.000188	0.21	0.22	Tonsillectomy;	chr16:30365638	chr16:30359825~30360336:+
THCA	cis	rs11148252	0.574	rs73186430	ENSG00000273784.3	RP11-78J21.7	-4.87	1.54e-06	0.000188	-0.23	-0.22	Lewy body disease;	chr13:52658756	chr13:52600042~52642542:+
THCA	cis	rs4073582	0.595	rs801737	ENSG00000255320.1	RP11-755F10.1	-4.87	1.54e-06	0.000189	-0.27	-0.22	Gout;	chr11:66160722	chr11:66244840~66246239:-
THCA	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	4.87	1.54e-06	0.000189	0.18	0.22	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
THCA	cis	rs2661868	0.918	rs2636314	ENSG00000232912.4	RP5-1115A15.1	-4.87	1.54e-06	0.000189	-0.25	-0.22	Life satisfaction;	chr1:8380583	chr1:8424645~8434838:+
THCA	cis	rs8020095	0.517	rs10047902	ENSG00000258561.1	RP11-72M17.1	-4.87	1.54e-06	0.000189	-0.29	-0.22	Depression (quantitative trait);	chr14:66882429	chr14:66212810~66509394:-
THCA	cis	rs16846053	0.792	rs62187703	ENSG00000227403.1	AC009299.3	4.87	1.54e-06	0.000189	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161829705	chr2:161244739~161249050:+
THCA	cis	rs6012564	1	rs755589	ENSG00000230758.1	SNAP23P	4.87	1.54e-06	0.000189	0.27	0.22	Anger;	chr20:49104848	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.793	rs1043361	ENSG00000230758.1	SNAP23P	4.87	1.54e-06	0.000189	0.27	0.22	Anger;	chr20:49114621	chr20:49038357~49038602:-
THCA	cis	rs755249	0.565	rs7539279	ENSG00000228060.1	RP11-69E11.8	4.87	1.54e-06	0.000189	0.21	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39565160~39573203:+
THCA	cis	rs738144	0.612	rs738142	ENSG00000235209.1	CTA-150C2.13	-4.87	1.55e-06	0.000189	-0.34	-0.22	IgG glycosylation;	chr22:38800932	chr22:38921227~38924708:+
THCA	cis	rs6430585	0.583	rs79176913	ENSG00000231890.6	DARS-AS1	-4.87	1.55e-06	0.000189	-0.26	-0.22	Corneal structure;	chr2:135880543	chr2:135985176~136022593:+
THCA	cis	rs1005277	0.54	rs1987431	ENSG00000226578.1	RP11-258F22.1	-4.87	1.55e-06	0.000189	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:37775371~37784131:-
THCA	cis	rs7119	0.651	rs8025968	ENSG00000259362.2	RP11-307C19.1	-4.87	1.55e-06	0.000189	-0.32	-0.22	Type 2 diabetes;	chr15:77547274	chr15:77525540~77534110:+
THCA	cis	rs2281603	0.57	rs2198347	ENSG00000259116.1	RP11-973N13.4	4.87	1.55e-06	0.000189	0.19	0.22	Lymphocyte counts;	chr14:64502624	chr14:64514154~64540368:-
THCA	cis	rs944289	0.774	rs1958625	ENSG00000258844.1	RP11-259K15.2	4.87	1.55e-06	0.000189	0.2	0.22	Thyroid cancer;	chr14:36133470	chr14:36214607~36235608:+
THCA	cis	rs453301	0.653	rs7853	ENSG00000254153.1	CTA-398F10.2	-4.87	1.55e-06	0.000189	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9033304	chr8:8456909~8461337:-
THCA	cis	rs4660214	0.666	rs4617393	ENSG00000182109.6	RP11-69E11.4	-4.87	1.55e-06	0.000189	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474551	chr1:39522280~39546187:-
THCA	cis	rs4713118	0.869	rs9295743	ENSG00000226314.6	ZNF192P1	-4.87	1.55e-06	0.000189	-0.28	-0.22	Parkinson's disease;	chr6:27747323	chr6:28161781~28169594:+
THCA	cis	rs6860806	0.531	rs270607	ENSG00000237714.1	P4HA2-AS1	4.87	1.55e-06	0.000189	0.29	0.22	Breast cancer;	chr5:132313493	chr5:132184876~132192808:+
THCA	cis	rs7838490	0.504	rs3105407	ENSG00000253553.4	RP11-586K2.1	4.87	1.55e-06	0.000189	0.23	0.22	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88460881	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs3110414	ENSG00000253553.4	RP11-586K2.1	4.87	1.55e-06	0.000189	0.23	0.22	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88460960	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs3110415	ENSG00000253553.4	RP11-586K2.1	4.87	1.55e-06	0.000189	0.23	0.22	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88461102	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.527	rs3110416	ENSG00000253553.4	RP11-586K2.1	4.87	1.55e-06	0.000189	0.23	0.22	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88461342	chr8:88326836~88737134:+
THCA	cis	rs67478160	0.634	rs1955660	ENSG00000258735.1	LINC00637	-4.87	1.55e-06	0.000189	-0.26	-0.22	Schizophrenia;	chr14:103763648	chr14:103847721~103858049:+
THCA	cis	rs763121	0.853	rs1569716	ENSG00000235209.1	CTA-150C2.13	4.87	1.55e-06	0.000189	0.28	0.22	Menopause (age at onset);	chr22:38602514	chr22:38921227~38924708:+
THCA	cis	rs13096142	0.558	rs9840204	ENSG00000223552.1	RP11-24F11.2	-4.87	1.55e-06	0.000189	-0.23	-0.22	Celiac disease;	chr3:46296328	chr3:46364955~46407059:-
THCA	cis	rs11671005	0.57	rs73062110	ENSG00000268049.1	CTD-2619J13.9	-4.87	1.55e-06	0.000189	-0.34	-0.22	Mean platelet volume;	chr19:58425275	chr19:58357999~58359603:+
THCA	cis	rs1005277	0.54	rs4934907	ENSG00000276805.1	RP11-291L22.6	4.87	1.55e-06	0.000189	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.54	rs11011351	ENSG00000276805.1	RP11-291L22.6	4.87	1.55e-06	0.000189	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.522	rs9417256	ENSG00000226578.1	RP11-258F22.1	-4.87	1.55e-06	0.000189	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:37775371~37784131:-
THCA	cis	rs7404843	0.789	rs222909	ENSG00000263335.1	AF001548.5	4.87	1.55e-06	0.000189	0.35	0.22	Testicular germ cell tumor;	chr16:15405432	chr16:15726674~15732993:+
THCA	cis	rs7131987	0.903	rs11050153	ENSG00000257176.2	RP11-996F15.2	-4.87	1.55e-06	0.000189	-0.22	-0.22	QT interval;	chr12:29252215	chr12:29280418~29317848:-
THCA	cis	rs6088590	1	rs6120747	ENSG00000269202.1	RP4-614O4.12	-4.87	1.55e-06	0.000189	-0.2	-0.22	Coronary artery disease;	chr20:34861966	chr20:35201747~35203288:-
THCA	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-4.87	1.55e-06	0.000189	-0.16	-0.22	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
THCA	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	4.87	1.55e-06	0.000189	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
THCA	cis	rs12701220	0.895	rs10262866	ENSG00000229043.2	AC091729.9	-4.87	1.55e-06	0.000189	-0.3	-0.22	Bronchopulmonary dysplasia;	chr7:979900	chr7:1160374~1165267:+
THCA	cis	rs1577330	0.528	rs62542708	ENSG00000254396.1	RP11-56F10.3	4.87	1.55e-06	0.000189	0.42	0.22	IgG glycosylation;	chr9:27072430	chr9:27102630~27104728:+
THCA	cis	rs9902453	0.817	rs2617881	ENSG00000263370.1	RP11-68I3.5	-4.87	1.55e-06	0.000189	-0.28	-0.22	Coffee consumption (cups per day);	chr17:29736257	chr17:29639627~29640825:+
THCA	cis	rs4950322	0.634	rs4950415	ENSG00000226015.2	CCT8P1	4.87	1.55e-06	0.00019	0.26	0.22	Protein quantitative trait loci;	chr1:147350951	chr1:147203276~147204932:-
THCA	cis	rs1005277	0.579	rs1740737	ENSG00000272983.1	RP11-508N22.12	4.87	1.55e-06	0.00019	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38137337~38144399:+
THCA	cis	rs3820928	0.874	rs6706802	ENSG00000212391.1	SNORA48	-4.87	1.55e-06	0.00019	-0.24	-0.22	Pulmonary function;	chr2:226986060	chr2:226968989~226969122:-
THCA	cis	rs442309	0.687	rs10822058	ENSG00000238280.1	RP11-436D10.3	-4.87	1.55e-06	0.00019	-0.27	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62763822	chr10:62793562~62805887:-
THCA	cis	rs2797160	0.967	rs984041	ENSG00000237742.5	RP11-624M8.1	4.87	1.55e-06	0.00019	0.19	0.22	Endometrial cancer;	chr6:125700182	chr6:125578558~125749190:-
THCA	cis	rs1003719	0.788	rs4817844	ENSG00000230366.8	DSCR9	4.87	1.55e-06	0.00019	0.22	0.22	Eye color traits;	chr21:37074764	chr21:37208503~37221736:+
THCA	cis	rs6802315	0.604	rs9861938	ENSG00000272087.1	RP11-379F4.7	4.87	1.55e-06	0.00019	0.19	0.22	Periodontitis (CDC/AAP);	chr3:158745257	chr3:158693120~158693768:-
THCA	cis	rs7989336	0.69	rs7323332	ENSG00000247400.3	DNAJC3-AS1	-4.87	1.55e-06	0.00019	-0.14	-0.22	Obesity;	chr13:96342614	chr13:95648733~95676925:-
THCA	cis	rs4915077	0.892	rs76965144	ENSG00000230489.1	VAV3-AS1	4.87	1.56e-06	0.00019	0.33	0.22	Hypothyroidism;	chr1:107807554	chr1:107964443~107994607:+
THCA	cis	rs16975963	0.639	rs112997435	ENSG00000226686.6	LINC01535	-4.87	1.56e-06	0.00019	-0.3	-0.22	Longevity;	chr19:37713730	chr19:37251912~37265535:+
THCA	cis	rs17345786	0.798	rs1609159	ENSG00000256628.3	ZBTB11-AS1	4.87	1.56e-06	0.00019	0.26	0.22	Colonoscopy-negative controls vs population controls;	chr3:101557058	chr3:101676475~101679217:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000223473.2	GS1-124K5.3	4.87	1.56e-06	0.00019	0.15	0.22	Aortic root size;	chr7:65930047	chr7:66491049~66493566:-
THCA	cis	rs12188164	0.543	rs2672722	ENSG00000221990.4	EXOC3-AS1	-4.87	1.56e-06	0.00019	-0.17	-0.22	Cystic fibrosis severity;	chr5:453452	chr5:441498~443160:-
THCA	cis	rs12188164	0.543	rs2672757	ENSG00000221990.4	EXOC3-AS1	-4.87	1.56e-06	0.00019	-0.17	-0.22	Cystic fibrosis severity;	chr5:454617	chr5:441498~443160:-
THCA	cis	rs6088580	0.584	rs2378203	ENSG00000276073.1	RP5-1125A11.7	4.87	1.56e-06	0.00019	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34406040	chr20:33985617~33988989:-
THCA	cis	rs4925386	0.765	rs6142737	ENSG00000273619.1	RP5-908M14.9	-4.87	1.56e-06	0.00019	-0.19	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62386303~62386970:-
THCA	cis	rs35740288	0.721	rs11636347	ENSG00000259295.5	CSPG4P12	4.87	1.56e-06	0.00019	0.35	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85698002	chr15:85191438~85213905:+
THCA	cis	rs4927850	0.521	rs4927679	ENSG00000260261.1	RP11-480A16.1	4.87	1.56e-06	0.00019	0.12	0.22	Pancreatic cancer;	chr3:195931489	chr3:195949188~195952695:-
THCA	cis	rs972578	0.668	rs2413726	ENSG00000274717.1	RP1-47A17.1	-4.87	1.56e-06	0.00019	-0.23	-0.22	Mean platelet volume;	chr22:42806334	chr22:42791814~42794313:-
THCA	cis	rs7010876	0.561	rs4483202	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88362431	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs4320597	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88362580	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs4275260	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88366452	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs1857753	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88366790	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs1857754	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88370921	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.629	rs1857755	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88371082	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs10283316	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88376106	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs4246115	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88377824	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.537	rs4434662	ENSG00000253553.4	RP11-586K2.1	-4.87	1.56e-06	0.00019	-0.22	-0.22	Schizophrenia;	chr8:88379125	chr8:88326836~88737134:+
THCA	cis	rs11853189	1	rs11853189	ENSG00000259562.2	RP11-762H8.2	4.87	1.56e-06	0.00019	0.22	0.22	Red cell distribution width;	chr15:78273478	chr15:78290527~78291221:-
THCA	cis	rs16852403	0.548	rs615226	ENSG00000224687.1	RASAL2-AS1	4.87	1.56e-06	0.00019	0.32	0.22	Childhood ear infection;	chr1:178225389	chr1:178091508~178093984:-
THCA	cis	rs8028313	0.731	rs4331293	ENSG00000270964.1	RP11-502I4.3	-4.87	1.56e-06	0.00019	-0.19	-0.22	Obesity;	chr15:67695463	chr15:67541072~67542604:-
THCA	cis	rs2380205	0.651	rs6602312	ENSG00000232807.2	RP11-536K7.3	4.87	1.56e-06	0.00019	0.2	0.22	Breast cancer;	chr10:5884968	chr10:5934270~5945900:-
THCA	cis	rs9625935	0.957	rs35705048	ENSG00000279159.1	RP3-394A18.1	-4.87	1.56e-06	0.00019	-0.17	-0.22	Tonsillectomy;	chr22:29874710	chr22:29978950~30028236:-
THCA	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-4.87	1.56e-06	0.00019	-0.19	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
THCA	cis	rs860295	0.702	rs12047756	ENSG00000160766.13	GBAP1	-4.87	1.56e-06	0.00019	-0.26	-0.22	Body mass index;	chr1:155655153	chr1:155213821~155227422:-
THCA	cis	rs755249	0.835	rs4660877	ENSG00000228060.1	RP11-69E11.8	-4.87	1.56e-06	0.00019	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613574	chr1:39565160~39573203:+
THCA	cis	rs11673344	0.543	rs8108429	ENSG00000276846.1	CTD-3220F14.3	4.87	1.56e-06	0.00019	0.17	0.22	Obesity-related traits;	chr19:37145874	chr19:37314868~37315620:-
THCA	cis	rs9910055	0.659	rs7207464	ENSG00000267080.4	ASB16-AS1	-4.87	1.56e-06	0.00019	-0.2	-0.22	Total body bone mineral density;	chr17:44167665	chr17:44175973~44186717:-
THCA	cis	rs4650994	0.517	rs2761473	ENSG00000273384.1	RP5-1098D14.1	-4.87	1.56e-06	0.000191	-0.28	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178640623	chr1:178651706~178652282:+
THCA	cis	rs79349575	0.721	rs2291725	ENSG00000270781.1	RP11-501C14.9	-4.87	1.56e-06	0.000191	-0.26	-0.22	Type 2 diabetes;	chr17:48961770	chr17:48899131~48899748:+
THCA	cis	rs1023500	0.596	rs5751209	ENSG00000273366.1	CTA-989H11.1	-4.87	1.56e-06	0.000191	-0.29	-0.22	Schizophrenia;	chr22:42055599	chr22:42278188~42278846:+
THCA	cis	rs6547741	0.844	rs7382	ENSG00000234072.1	AC074117.10	-4.87	1.56e-06	0.000191	-0.17	-0.22	Oral cavity cancer;	chr2:27650548	chr2:27356246~27367622:+
THCA	cis	rs9910055	1	rs9910055	ENSG00000267080.4	ASB16-AS1	-4.87	1.56e-06	0.000191	-0.21	-0.22	Total body bone mineral density;	chr17:44205669	chr17:44175973~44186717:-
THCA	cis	rs412658	0.812	rs17554725	ENSG00000269345.1	VN1R85P	4.87	1.56e-06	0.000191	0.24	0.22	Telomere length;	chr19:22134957	chr19:22174766~22175191:-
THCA	cis	rs1577917	0.883	rs12214536	ENSG00000220563.1	PKMP3	-4.87	1.56e-06	0.000191	-0.16	-0.22	Response to antipsychotic treatment;	chr6:86080592	chr6:85659892~85660606:-
THCA	cis	rs6496932	0.503	rs4564526	ENSG00000259630.2	CTD-2262B20.1	-4.86	1.57e-06	0.000191	-0.28	-0.22	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85415228~85415633:+
THCA	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-4.86	1.57e-06	0.000191	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
THCA	cis	rs6445975	0.667	rs6772264	ENSG00000272360.1	RP11-359I18.5	-4.86	1.57e-06	0.000191	-0.23	-0.22	Systemic lupus erythematosus;	chr3:58247214	chr3:58490830~58491291:-
THCA	cis	rs11846409	0.932	rs61233250	ENSG00000274576.2	IGHV2-70	-4.86	1.57e-06	0.000191	-0.18	-0.22	Rheumatic heart disease;	chr14:106634072	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs60659763	ENSG00000274576.2	IGHV2-70	-4.86	1.57e-06	0.000191	-0.18	-0.22	Rheumatic heart disease;	chr14:106634172	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs57080270	ENSG00000274576.2	IGHV2-70	-4.86	1.57e-06	0.000191	-0.18	-0.22	Rheumatic heart disease;	chr14:106634215	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs60917084	ENSG00000274576.2	IGHV2-70	-4.86	1.57e-06	0.000191	-0.18	-0.22	Rheumatic heart disease;	chr14:106634621	chr14:106770577~106771020:-
THCA	cis	rs28386778	0.765	rs1974435	ENSG00000240280.5	TCAM1P	4.86	1.57e-06	0.000191	0.3	0.22	Prudent dietary pattern;	chr17:63916736	chr17:63849292~63864379:+
THCA	cis	rs1048886	0.808	rs2842076	ENSG00000271967.1	RP11-134K13.4	-4.86	1.57e-06	0.000191	-0.24	-0.22	Type 2 diabetes;	chr6:70603431	chr6:70596438~70596980:+
THCA	cis	rs9910055	0.531	rs6503490	ENSG00000267080.4	ASB16-AS1	-4.86	1.57e-06	0.000191	-0.19	-0.22	Total body bone mineral density;	chr17:44169288	chr17:44175973~44186717:-
THCA	cis	rs72945132	0.825	rs7941965	ENSG00000254604.1	AP000487.6	-4.86	1.57e-06	0.000191	-0.41	-0.22	Coronary artery disease;	chr11:70367076	chr11:70282367~70363368:-
THCA	cis	rs2985684	1	rs2985687	ENSG00000278009.1	RP11-649E7.8	4.86	1.57e-06	0.000191	0.31	0.22	Carotid intima media thickness;	chr14:49633668	chr14:49601011~49601124:-
THCA	cis	rs2985684	0.948	rs2985685	ENSG00000278009.1	RP11-649E7.8	4.86	1.57e-06	0.000191	0.31	0.22	Carotid intima media thickness;	chr14:49634652	chr14:49601011~49601124:-
THCA	cis	rs2985684	1	rs2985684	ENSG00000278009.1	RP11-649E7.8	4.86	1.57e-06	0.000191	0.31	0.22	Carotid intima media thickness;	chr14:49634964	chr14:49601011~49601124:-
THCA	cis	rs9813712	0.595	rs1993217	ENSG00000249846.5	RP11-77P16.4	-4.86	1.57e-06	0.000191	-0.23	-0.22	Response to amphetamines;	chr3:130284832	chr3:130112550~130120579:+
THCA	cis	rs10923574	0.597	rs10923577	ENSG00000231365.4	RP11-418J17.1	-4.86	1.57e-06	0.000191	-0.22	-0.22	Breast cancer;Folding of antihelix;	chr1:118502644	chr1:119140396~119275973:+
THCA	cis	rs1005277	0.579	rs1780137	ENSG00000275858.1	RP11-291L22.8	4.86	1.57e-06	0.000191	0.27	0.22	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38450738~38451069:-
THCA	cis	rs77637988	0.604	rs78597273	ENSG00000202227.1	RNU6-282P	4.86	1.57e-06	0.000191	0.23	0.22	Joint mobility (Beighton score);	chr2:48380665	chr2:48501922~48502024:-
THCA	cis	rs3734266	0.702	rs6937428	ENSG00000272288.4	RP11-140K17.3	-4.86	1.57e-06	0.000191	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34662468	chr6:34696317~34697470:+
THCA	cis	rs35740288	0.822	rs11638720	ENSG00000259295.5	CSPG4P12	4.86	1.57e-06	0.000191	0.34	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686042	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.822	rs1961601	ENSG00000259295.5	CSPG4P12	4.86	1.57e-06	0.000191	0.34	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686375	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.822	rs2016517	ENSG00000259295.5	CSPG4P12	4.86	1.57e-06	0.000191	0.34	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686387	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.787	rs727379	ENSG00000259295.5	CSPG4P12	4.86	1.57e-06	0.000191	0.34	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686659	chr15:85191438~85213905:+
THCA	cis	rs11853189	0.938	rs79827225	ENSG00000259562.2	RP11-762H8.2	4.86	1.57e-06	0.000191	0.23	0.22	Red cell distribution width;	chr15:78263640	chr15:78290527~78291221:-
THCA	cis	rs7674212	0.57	rs2711898	ENSG00000251288.2	RP11-10L12.2	-4.86	1.57e-06	0.000192	-0.28	-0.22	Type 2 diabetes;	chr4:103141914	chr4:102751401~102752641:+
THCA	cis	rs2742234	0.955	rs2503849	ENSG00000273008.1	RP11-351D16.3	-4.86	1.57e-06	0.000192	-0.19	-0.22	Hirschsprung disease;	chr10:43177328	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.955	rs2435384	ENSG00000273008.1	RP11-351D16.3	-4.86	1.57e-06	0.000192	-0.19	-0.22	Hirschsprung disease;	chr10:43178283	chr10:43136824~43138334:-
THCA	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-4.86	1.57e-06	0.000192	-0.26	-0.22	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
THCA	cis	rs748404	0.666	rs55748552	ENSG00000205771.5	CATSPER2P1	-4.86	1.57e-06	0.000192	-0.27	-0.22	Lung cancer;	chr15:43359428	chr15:43726918~43747094:-
THCA	cis	rs6921919	0.583	rs9468370	ENSG00000280107.1	AL022393.9	-4.86	1.57e-06	0.000192	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28170845~28172521:+
THCA	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-4.86	1.57e-06	0.000192	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-4.86	1.57e-06	0.000192	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
THCA	cis	rs9634489	0.532	rs9516693	ENSG00000247400.3	DNAJC3-AS1	-4.86	1.57e-06	0.000192	-0.15	-0.22	Body mass index;	chr13:96428995	chr13:95648733~95676925:-
THCA	cis	rs4950322	0.542	rs4950384	ENSG00000226015.2	CCT8P1	4.86	1.57e-06	0.000192	0.25	0.22	Protein quantitative trait loci;	chr1:147177310	chr1:147203276~147204932:-
THCA	cis	rs4925386	0.84	rs6143035	ENSG00000273619.1	RP5-908M14.9	4.86	1.57e-06	0.000192	0.19	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62386303~62386970:-
THCA	cis	rs6545883	0.931	rs778756	ENSG00000271889.1	RP11-493E12.1	4.86	1.57e-06	0.000192	0.21	0.22	Tuberculosis;	chr2:61554859	chr2:61151433~61162105:-
THCA	cis	rs12030196	1	rs11207369	ENSG00000230812.4	LINC01358	4.86	1.57e-06	0.000192	0.28	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59019419	chr1:59020387~59044614:+
THCA	cis	rs10510102	0.872	rs3862129	ENSG00000226864.1	ATE1-AS1	4.86	1.57e-06	0.000192	0.35	0.22	Breast cancer;	chr10:121824460	chr10:121928312~121951965:+
THCA	cis	rs3734266	0.702	rs7764921	ENSG00000272288.4	RP11-140K17.3	-4.86	1.57e-06	0.000192	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34636558	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs9461994	ENSG00000272288.4	RP11-140K17.3	-4.86	1.57e-06	0.000192	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34643408	chr6:34696317~34697470:+
THCA	cis	rs9307551	0.619	rs11736348	ENSG00000250334.4	LINC00989	-4.86	1.57e-06	0.000192	-0.27	-0.22	Refractive error;	chr4:79498711	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.619	rs1561639	ENSG00000250334.4	LINC00989	-4.86	1.57e-06	0.000192	-0.27	-0.22	Refractive error;	chr4:79498986	chr4:79492416~79576460:+
THCA	cis	rs651907	0.557	rs11710533	ENSG00000244119.1	PDCL3P4	4.86	1.57e-06	0.000192	0.2	0.22	Colorectal cancer;	chr3:101632628	chr3:101712472~101713191:+
THCA	cis	rs755249	0.762	rs1775654	ENSG00000182109.6	RP11-69E11.4	4.86	1.57e-06	0.000192	0.22	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39522280~39546187:-
THCA	cis	rs1552244	1	rs58275763	ENSG00000180385.7	EMC3-AS1	4.86	1.57e-06	0.000192	0.25	0.22	Alzheimer's disease;	chr3:10101590	chr3:9986893~10006990:+
THCA	cis	rs5015933	0.778	rs867547	ENSG00000232630.1	PRPS1P2	-4.86	1.57e-06	0.000192	-0.15	-0.22	Body mass index;	chr9:125269184	chr9:125150653~125151589:+
THCA	cis	rs72843506	0.586	rs113833946	ENSG00000261033.1	RP11-209D14.2	4.86	1.57e-06	0.000192	0.42	0.22	Schizophrenia;	chr17:19955593	chr17:20008051~20009234:-
THCA	cis	rs12893668	0.608	rs12889721	ENSG00000269958.1	RP11-73M18.8	4.86	1.58e-06	0.000192	0.21	0.22	Reticulocyte count;	chr14:103568526	chr14:103696353~103697163:+
THCA	cis	rs2288884	0.579	rs6509609	ENSG00000269483.1	AC006272.1	4.86	1.58e-06	0.000192	0.31	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51970353	chr19:51839924~51843324:-
THCA	cis	rs2235642	0.533	rs9922661	ENSG00000280231.1	LA16c-380F5.3	-4.86	1.58e-06	0.000192	-0.3	-0.22	Coronary artery disease;	chr16:1555162	chr16:1553655~1554130:-
THCA	cis	rs4906332	0.782	rs12891288	ENSG00000244691.1	RPL10AP1	-4.86	1.58e-06	0.000192	-0.31	-0.22	Coronary artery disease;	chr14:103533413	chr14:103412119~103412761:-
THCA	cis	rs7267979	0.932	rs433352	ENSG00000274973.1	RP13-401N8.7	4.86	1.58e-06	0.000192	0.25	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25845497~25845862:+
THCA	cis	rs34779708	0.931	rs2148482	ENSG00000271335.4	RP11-324I22.4	4.86	1.58e-06	0.000192	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35314552~35336401:-
THCA	cis	rs28510890	0.536	rs8030062	ENSG00000260337.3	RP11-386M24.6	4.86	1.58e-06	0.000192	0.23	0.22	Lung cancer in ever smokers;	chr15:92614403	chr15:92592574~92596462:-
THCA	cis	rs7394190	0.935	rs12570126	ENSG00000271848.1	RP11-464F9.21	4.86	1.58e-06	0.000192	0.27	0.22	Incident atrial fibrillation;	chr10:73657031	chr10:73654039~73674719:+
THCA	cis	rs453301	0.631	rs11780774	ENSG00000254153.1	CTA-398F10.2	4.86	1.58e-06	0.000192	0.25	0.22	Joint mobility (Beighton score);	chr8:8941601	chr8:8456909~8461337:-
THCA	cis	rs8141529	0.719	rs6005916	ENSG00000272858.1	CTA-292E10.8	-4.86	1.58e-06	0.000192	-0.22	-0.22	Lymphocyte counts;	chr22:28837354	chr22:28814914~28815662:+
THCA	cis	rs10208649	0.522	rs59531016	ENSG00000272156.1	RP11-477N3.1	4.86	1.58e-06	0.000192	0.46	0.22	Body mass index;	chr2:54171031	chr2:54082554~54085066:+
THCA	cis	rs728616	0.558	rs12772945	ENSG00000242600.5	MBL1P	4.86	1.58e-06	0.000192	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80394740	chr10:79904898~79950336:+
THCA	cis	rs728616	0.558	rs12414691	ENSG00000242600.5	MBL1P	4.86	1.58e-06	0.000192	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80397226	chr10:79904898~79950336:+
THCA	cis	rs728616	0.558	rs12767261	ENSG00000242600.5	MBL1P	4.86	1.58e-06	0.000192	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80402567	chr10:79904898~79950336:+
THCA	cis	rs9402682	0.77	rs2210366	ENSG00000232876.1	CTA-212D2.2	4.86	1.58e-06	0.000192	0.28	0.22	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135094070	chr6:135055033~135060550:+
THCA	cis	rs930395	0.514	rs10060878	ENSG00000272335.1	RP11-53O19.3	4.86	1.58e-06	0.000193	0.19	0.22	Breast cancer;	chr5:44899322	chr5:44826076~44828592:+
THCA	cis	rs763121	0.626	rs5750643	ENSG00000235209.1	CTA-150C2.13	4.86	1.58e-06	0.000193	0.28	0.22	Menopause (age at onset);	chr22:38613012	chr22:38921227~38924708:+
THCA	cis	rs202072	0.769	rs495895	ENSG00000272379.1	RP1-257A7.5	4.86	1.58e-06	0.000193	0.33	0.22	HIV-1 viral setpoint;	chr6:13277683	chr6:13290018~13290490:-
THCA	cis	rs11992162	0.569	rs11786149	ENSG00000206014.6	OR7E161P	4.86	1.58e-06	0.000193	0.26	0.22	Monocyte count;	chr8:11943309	chr8:11928597~11929563:-
THCA	cis	rs6012564	1	rs6122763	ENSG00000227431.4	CSE1L-AS1	-4.86	1.58e-06	0.000193	-0.26	-0.22	Anger;	chr20:49181116	chr20:49040463~49046044:-
THCA	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-4.86	1.58e-06	0.000193	-0.27	-0.22	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
THCA	cis	rs228614	0.51	rs223349	ENSG00000248971.2	KRT8P46	-4.86	1.58e-06	0.000193	-0.27	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102728746~102730171:-
THCA	cis	rs79243044	0.813	rs4910569	ENSG00000224295.2	AC087380.14	-4.86	1.58e-06	0.000193	-0.23	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5544398	chr11:5518441~5524955:-
THCA	cis	rs1559040	1	rs72800732	ENSG00000272156.1	RP11-477N3.1	-4.86	1.58e-06	0.000193	-0.36	-0.22	Sudden cardiac arrest;	chr2:54090765	chr2:54082554~54085066:+
THCA	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	4.86	1.58e-06	0.000193	0.29	0.22	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
THCA	cis	rs2732480	0.577	rs2732457	ENSG00000273765.1	RP11-370I10.11	-4.86	1.58e-06	0.000193	-0.22	-0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48360920~48361377:+
THCA	cis	rs3734266	0.702	rs9469832	ENSG00000272288.4	RP11-140K17.3	-4.86	1.58e-06	0.000193	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34635384	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs16892386	ENSG00000272288.4	RP11-140K17.3	-4.86	1.58e-06	0.000193	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34651615	chr6:34696317~34697470:+
THCA	cis	rs9425766	0.54	rs2294492	ENSG00000227373.4	RP11-160H22.5	4.86	1.58e-06	0.000193	0.3	0.22	Life satisfaction;	chr1:174157884	chr1:174115300~174160004:-
THCA	cis	rs4660261	0.526	rs2040950	ENSG00000237950.1	RP11-7O11.3	4.86	1.58e-06	0.000193	0.2	0.22	Intelligence (multi-trait analysis);	chr1:43849441	chr1:43944370~43946551:-
THCA	cis	rs4660261	0.562	rs3011223	ENSG00000237950.1	RP11-7O11.3	4.86	1.58e-06	0.000193	0.2	0.22	Intelligence (multi-trait analysis);	chr1:43852614	chr1:43944370~43946551:-
THCA	cis	rs4660261	0.526	rs2906466	ENSG00000237950.1	RP11-7O11.3	4.86	1.58e-06	0.000193	0.2	0.22	Intelligence (multi-trait analysis);	chr1:43856548	chr1:43944370~43946551:-
THCA	cis	rs1005277	0.579	rs2504148	ENSG00000275858.1	RP11-291L22.8	4.86	1.58e-06	0.000193	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs176886	ENSG00000275858.1	RP11-291L22.8	4.86	1.58e-06	0.000193	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.557	rs176887	ENSG00000275858.1	RP11-291L22.8	4.86	1.58e-06	0.000193	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474594	ENSG00000275858.1	RP11-291L22.8	4.86	1.58e-06	0.000193	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs11011461	ENSG00000275858.1	RP11-291L22.8	4.86	1.58e-06	0.000193	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38450738~38451069:-
THCA	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	4.86	1.58e-06	0.000193	0.28	0.22	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
THCA	cis	rs4713118	0.869	rs9283883	ENSG00000226314.6	ZNF192P1	-4.86	1.58e-06	0.000193	-0.28	-0.22	Parkinson's disease;	chr6:27747691	chr6:28161781~28169594:+
THCA	cis	rs8028182	0.636	rs11637586	ENSG00000260274.1	RP11-817O13.8	4.86	1.58e-06	0.000193	0.16	0.22	Sudden cardiac arrest;	chr15:75498771	chr15:75368155~75369584:+
THCA	cis	rs11673344	0.504	rs8110796	ENSG00000276846.1	CTD-3220F14.3	4.86	1.58e-06	0.000193	0.17	0.22	Obesity-related traits;	chr19:37132682	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs8111285	ENSG00000276846.1	CTD-3220F14.3	4.86	1.58e-06	0.000193	0.17	0.22	Obesity-related traits;	chr19:37132747	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs6510591	ENSG00000276846.1	CTD-3220F14.3	4.86	1.58e-06	0.000193	0.17	0.22	Obesity-related traits;	chr19:37133186	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs6510592	ENSG00000276846.1	CTD-3220F14.3	4.86	1.58e-06	0.000193	0.17	0.22	Obesity-related traits;	chr19:37133430	chr19:37314868~37315620:-
THCA	cis	rs800160	0.844	rs2937373	ENSG00000199550.1	Y_RNA	4.86	1.58e-06	0.000193	0.34	0.22	Bacteremia;	chr11:2337391	chr11:2372638~2372750:+
THCA	cis	rs7523875	1	rs7523875	ENSG00000153363.11	LINC00467	-4.86	1.58e-06	0.000193	-0.24	-0.22	Mean corpuscular volume;	chr1:211217974	chr1:211382803~211435333:+
THCA	cis	rs57024841	0.562	rs2071006	ENSG00000238268.2	RP11-229P13.19	-4.86	1.58e-06	0.000193	-0.22	-0.22	Beta-trace protein levels;	chr9:136945452	chr9:136975094~136976981:+
THCA	cis	rs13113518	1	rs4865004	ENSG00000273257.1	RP11-177J6.1	4.86	1.58e-06	0.000193	0.29	0.22	Height;	chr4:55515118	chr4:55387949~55388271:+
THCA	cis	rs4664304	0.621	rs17231342	ENSG00000226266.5	AC009961.3	-4.86	1.58e-06	0.000193	-0.27	-0.22	Crohn's disease;Inflammatory bowel disease;	chr2:159870033	chr2:159670708~159712435:-
THCA	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	4.86	1.58e-06	0.000193	0.24	0.22	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	4.86	1.58e-06	0.000193	0.24	0.22	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
THCA	cis	rs2447820	0.5	rs2024527	ENSG00000249996.1	RP11-359P5.1	4.86	1.58e-06	0.000193	0.25	0.22	Migraine;	chr5:122852642	chr5:123036271~123054667:+
THCA	cis	rs972578	0.765	rs9607973	ENSG00000274717.1	RP1-47A17.1	4.86	1.58e-06	0.000193	0.23	0.22	Mean platelet volume;	chr22:42872496	chr22:42791814~42794313:-
THCA	cis	rs875971	0.522	rs1617484	ENSG00000223473.2	GS1-124K5.3	4.86	1.58e-06	0.000193	0.15	0.22	Aortic root size;	chr7:65998108	chr7:66491049~66493566:-
THCA	cis	rs11673344	0.543	rs1818748	ENSG00000276846.1	CTD-3220F14.3	4.86	1.59e-06	0.000193	0.17	0.22	Obesity-related traits;	chr19:37065416	chr19:37314868~37315620:-
THCA	cis	rs13217239	0.534	rs9379968	ENSG00000219392.1	RP1-265C24.5	-4.86	1.59e-06	0.000193	-0.25	-0.22	Schizophrenia;	chr6:27276811	chr6:28115628~28116551:+
THCA	cis	rs12935418	0.616	rs9937731	ENSG00000278985.1	RP11-303E16.9	4.86	1.59e-06	0.000193	0.24	0.22	Mean corpuscular volume;	chr16:80978406	chr16:80982319~80984094:-
THCA	cis	rs2239547	0.522	rs6792578	ENSG00000242142.1	SERBP1P3	4.86	1.59e-06	0.000193	0.28	0.22	Schizophrenia;	chr3:52970588	chr3:53064283~53065091:-
THCA	cis	rs11096990	0.892	rs2381349	ENSG00000249685.1	RP11-360F5.3	-4.86	1.59e-06	0.000193	-0.27	-0.22	Cognitive function;	chr4:39210390	chr4:39133913~39135608:+
THCA	cis	rs13434995	0.537	rs6554275	ENSG00000273257.1	RP11-177J6.1	4.86	1.59e-06	0.000194	0.35	0.22	Adiponectin levels;	chr4:55362981	chr4:55387949~55388271:+
THCA	cis	rs7772486	0.79	rs7742333	ENSG00000270638.1	RP3-466P17.1	-4.86	1.59e-06	0.000194	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145735570~145737218:+
THCA	cis	rs9425766	0.679	rs57919173	ENSG00000227373.4	RP11-160H22.5	4.86	1.59e-06	0.000194	0.31	0.22	Life satisfaction;	chr1:174159856	chr1:174115300~174160004:-
THCA	cis	rs7914558	1	rs7911789	ENSG00000236937.2	PTGES3P4	4.86	1.59e-06	0.000194	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs67908413	ENSG00000236937.2	PTGES3P4	4.86	1.59e-06	0.000194	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102845595~102845950:+
THCA	cis	rs6138458	1	rs227632	ENSG00000274173.1	RP4-568C11.4	4.86	1.59e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24933093	chr20:24931840~24932983:+
THCA	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-4.86	1.59e-06	0.000194	-0.26	-0.22	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
THCA	cis	rs16846053	0.605	rs16846181	ENSG00000227403.1	AC009299.3	4.86	1.59e-06	0.000194	0.47	0.22	Blood osmolality (transformed sodium);	chr2:161899744	chr2:161244739~161249050:+
THCA	cis	rs8062405	0.54	rs151226	ENSG00000278665.1	RP11-666O2.4	4.86	1.59e-06	0.000194	0.23	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28599241~28601881:-
THCA	cis	rs748802	0.704	rs10814297	ENSG00000235387.1	LINC00961	-4.86	1.59e-06	0.000194	-0.25	-0.22	Resting heart rate;	chr9:35910948	chr9:35909483~35911686:+
THCA	cis	rs7474896	0.526	rs1208633	ENSG00000263064.2	RP11-291L22.7	-4.86	1.59e-06	0.000194	-0.29	-0.22	Obesity (extreme);	chr10:37867945	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.559	rs1779075	ENSG00000263064.2	RP11-291L22.7	-4.86	1.59e-06	0.000194	-0.29	-0.22	Obesity (extreme);	chr10:37878602	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.559	rs2753880	ENSG00000263064.2	RP11-291L22.7	-4.86	1.59e-06	0.000194	-0.29	-0.22	Obesity (extreme);	chr10:37884410	chr10:38448689~38448949:+
THCA	cis	rs59918340	0.764	rs4961339	ENSG00000253307.1	RP11-10J21.4	4.86	1.59e-06	0.000194	0.3	0.22	Immature fraction of reticulocytes;	chr8:141221405	chr8:141252286~141253292:-
THCA	cis	rs7552393	0.636	rs1830825	ENSG00000233008.4	RP11-475O6.1	4.86	1.59e-06	0.000194	0.25	0.22	Select biomarker traits;	chr1:83814102	chr1:83575776~83861023:-
THCA	cis	rs11858159	0.545	rs6576320	ENSG00000260760.1	PWRN3	-4.86	1.59e-06	0.000194	-0.22	-0.22	Platelet thrombus formation;	chr15:24538107	chr15:24441127~24447967:+
THCA	cis	rs7914558	0.899	rs7913682	ENSG00000236937.2	PTGES3P4	4.86	1.59e-06	0.000194	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102924635	chr10:102845595~102845950:+
THCA	cis	rs10208649	0.731	rs6760038	ENSG00000233266.1	HMGB1P31	4.86	1.59e-06	0.000194	0.59	0.22	Body mass index;	chr2:53661017	chr2:54051334~54051760:+
THCA	cis	rs4267450	0.793	rs73017620	ENSG00000261770.1	CTC-459F4.1	4.86	1.59e-06	0.000194	0.38	0.22	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28320420	chr19:27757184~27760849:-
THCA	cis	rs2439831	0.681	rs28578454	ENSG00000275601.1	AC011330.13	-4.86	1.59e-06	0.000194	-0.35	-0.22	Lung cancer in ever smokers;	chr15:43310834	chr15:43642389~43643023:-
THCA	cis	rs6138458	1	rs227615	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24928085	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs227616	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24928175	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs227621	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24929892	chr20:24931840~24932983:+
THCA	cis	rs6138458	0.887	rs227622	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24929961	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs227624	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24930926	chr20:24931840~24932983:+
THCA	cis	rs6138458	0.961	rs227625	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24930982	chr20:24931840~24932983:+
THCA	cis	rs6138458	0.816	rs2151463	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24931183	chr20:24931840~24932983:+
THCA	cis	rs6138458	0.62	rs2151462	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24931187	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs227627	ENSG00000274173.1	RP4-568C11.4	4.86	1.6e-06	0.000194	0.21	0.22	Blood protein levels;	chr20:24931471	chr20:24931840~24932983:+
THCA	cis	rs755249	0.529	rs604316	ENSG00000182109.6	RP11-69E11.4	4.86	1.6e-06	0.000194	0.21	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39413694	chr1:39522280~39546187:-
THCA	cis	rs7520050	0.833	rs1085242	ENSG00000234329.1	RP11-767N6.2	-4.86	1.6e-06	0.000194	-0.2	-0.22	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45651039~45651826:-
THCA	cis	rs11673344	0.504	rs8099987	ENSG00000276846.1	CTD-3220F14.3	4.86	1.6e-06	0.000195	0.17	0.22	Obesity-related traits;	chr19:37132570	chr19:37314868~37315620:-
THCA	cis	rs1005277	0.505	rs10827836	ENSG00000226578.1	RP11-258F22.1	4.86	1.6e-06	0.000195	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:37775371~37784131:-
THCA	cis	rs957448	1	rs957447	ENSG00000253175.1	RP11-267M23.6	4.86	1.6e-06	0.000195	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94565036~94565715:+
THCA	cis	rs957448	1	rs72674852	ENSG00000253175.1	RP11-267M23.6	4.86	1.6e-06	0.000195	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94565036~94565715:+
THCA	cis	rs9307551	0.584	rs7697359	ENSG00000250334.4	LINC00989	-4.86	1.6e-06	0.000195	-0.27	-0.22	Refractive error;	chr4:79546982	chr4:79492416~79576460:+
THCA	cis	rs4415084	1	rs2013513	ENSG00000272335.1	RP11-53O19.3	-4.86	1.6e-06	0.000195	-0.18	-0.22	Breast cancer;	chr5:44702204	chr5:44826076~44828592:+
THCA	cis	rs1003719	0.708	rs3787788	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37130504	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.708	rs2000417	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37130568	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs2835619	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37133080	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs2835620	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37133281	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs7275984	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37133396	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs3992	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37133669	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2252893	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37135272	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs7282195	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37136319	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs35199609	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37137962	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs2835621	ENSG00000230366.8	DSCR9	4.86	1.6e-06	0.000195	0.22	0.22	Eye color traits;	chr21:37138316	chr21:37208503~37221736:+
THCA	cis	rs2742234	0.503	rs1254968	ENSG00000273008.1	RP11-351D16.3	4.86	1.6e-06	0.000195	0.21	0.22	Hirschsprung disease;	chr10:43196243	chr10:43136824~43138334:-
THCA	cis	rs3760982	0.813	rs10426528	ENSG00000267058.1	RP11-15A1.3	-4.86	1.6e-06	0.000195	-0.19	-0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43795146	chr19:43891804~43901805:-
THCA	cis	rs7899106	1	rs11201714	ENSG00000270002.1	RP11-93H12.4	4.86	1.6e-06	0.000195	0.43	0.22	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85649943	chr10:85644073~85648066:+
THCA	cis	rs72843506	0.656	rs16960678	ENSG00000231258.2	ZSWIM5P2	4.86	1.6e-06	0.000195	0.33	0.22	Schizophrenia;	chr17:20080378	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs73984571	ENSG00000231258.2	ZSWIM5P2	4.86	1.6e-06	0.000195	0.33	0.22	Schizophrenia;	chr17:20080746	chr17:20583758~20591180:-
THCA	cis	rs4660214	0.666	rs1775656	ENSG00000182109.6	RP11-69E11.4	4.86	1.6e-06	0.000195	0.21	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39522280~39546187:-
THCA	cis	rs2839186	0.771	rs2280957	ENSG00000215424.8	MCM3AP-AS1	-4.86	1.6e-06	0.000195	-0.13	-0.22	Testicular germ cell tumor;	chr21:46222358	chr21:46229217~46259390:+
THCA	cis	rs6545883	0.507	rs10169662	ENSG00000270820.4	RP11-355B11.2	-4.86	1.6e-06	0.000195	-0.19	-0.22	Tuberculosis;	chr2:61280801	chr2:61471188~61484130:+
THCA	cis	rs2243480	1	rs781150	ENSG00000164669.11	INTS4P1	4.86	1.6e-06	0.000195	0.43	0.22	Diabetic kidney disease;	chr7:66015986	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs313798	ENSG00000164669.11	INTS4P1	4.86	1.6e-06	0.000195	0.43	0.22	Diabetic kidney disease;	chr7:66028044	chr7:65141225~65234216:+
THCA	cis	rs73198271	0.96	rs11778970	ENSG00000253893.2	FAM85B	4.86	1.6e-06	0.000195	0.36	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751824	chr8:8167819~8226614:-
THCA	cis	rs3782089	0.793	rs34789990	ENSG00000245532.5	NEAT1	4.86	1.6e-06	0.000195	0.25	0.22	Height;	chr11:65485006	chr11:65422774~65445540:+
THCA	cis	rs11992162	0.573	rs61468577	ENSG00000206014.6	OR7E161P	4.86	1.6e-06	0.000195	0.26	0.22	Monocyte count;	chr8:11927416	chr8:11928597~11929563:-
THCA	cis	rs2018683	0.523	rs4513881	ENSG00000272568.4	CTB-113D17.1	-4.86	1.6e-06	0.000195	-0.22	-0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985794	chr7:28979967~29013367:+
THCA	cis	rs6430538	0.582	rs11903701	ENSG00000224043.6	CCNT2-AS1	-4.86	1.6e-06	0.000195	-0.23	-0.22	Parkinson's disease;	chr2:134807680	chr2:134735464~134918710:-
THCA	cis	rs7688540	0.76	rs12506250	ENSG00000275426.1	CH17-262A2.1	4.86	1.6e-06	0.000195	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:149738~150317:+
THCA	cis	rs7688540	0.76	rs2883229	ENSG00000275426.1	CH17-262A2.1	4.86	1.6e-06	0.000195	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:149738~150317:+
THCA	cis	rs7688540	0.76	rs4510422	ENSG00000275426.1	CH17-262A2.1	4.86	1.6e-06	0.000195	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:149738~150317:+
THCA	cis	rs7829975	0.582	rs448231	ENSG00000233609.3	RP11-62H7.2	-4.86	1.6e-06	0.000195	-0.22	-0.22	Mood instability;	chr8:8932549	chr8:8961200~8979025:+
THCA	cis	rs6545883	0.56	rs11677776	ENSG00000270820.4	RP11-355B11.2	-4.86	1.6e-06	0.000195	-0.19	-0.22	Tuberculosis;	chr2:61275978	chr2:61471188~61484130:+
THCA	cis	rs4713118	0.615	rs57252182	ENSG00000216915.2	RP1-97D16.1	-4.86	1.61e-06	0.000196	-0.3	-0.22	Parkinson's disease;	chr6:27752470	chr6:27737000~27738494:-
THCA	cis	rs34034915	1	rs34034915	ENSG00000216915.2	RP1-97D16.1	-4.86	1.61e-06	0.000196	-0.3	-0.22	Hepatitis A;	chr6:27752924	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.527	rs36042294	ENSG00000216915.2	RP1-97D16.1	-4.86	1.61e-06	0.000196	-0.3	-0.22	Parkinson's disease;	chr6:27752933	chr6:27737000~27738494:-
THCA	cis	rs526231	0.824	rs253755	ENSG00000175749.11	EIF3KP1	4.86	1.61e-06	0.000196	0.28	0.22	Primary biliary cholangitis;	chr5:103295232	chr5:103032376~103033031:+
THCA	cis	rs202072	1	rs202077	ENSG00000272379.1	RP1-257A7.5	4.86	1.61e-06	0.000196	0.33	0.22	HIV-1 viral setpoint;	chr6:13271206	chr6:13290018~13290490:-
THCA	cis	rs793571	0.554	rs8029805	ENSG00000245975.2	RP11-30K9.6	-4.86	1.61e-06	0.000196	-0.25	-0.22	Schizophrenia;	chr15:58713723	chr15:58768072~58770974:-
THCA	cis	rs4648045	0.828	rs230519	ENSG00000246560.2	RP11-10L12.4	-4.86	1.61e-06	0.000196	-0.27	-0.22	Lymphocyte percentage of white cells;	chr4:102545592	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.785	rs230518	ENSG00000246560.2	RP11-10L12.4	-4.86	1.61e-06	0.000196	-0.27	-0.22	Lymphocyte percentage of white cells;	chr4:102548810	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.861	rs230516	ENSG00000246560.2	RP11-10L12.4	-4.86	1.61e-06	0.000196	-0.27	-0.22	Lymphocyte percentage of white cells;	chr4:102550094	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.861	rs230515	ENSG00000246560.2	RP11-10L12.4	-4.86	1.61e-06	0.000196	-0.27	-0.22	Lymphocyte percentage of white cells;	chr4:102550277	chr4:102828055~102844075:+
THCA	cis	rs11673344	0.523	rs10406110	ENSG00000276846.1	CTD-3220F14.3	4.86	1.61e-06	0.000196	0.17	0.22	Obesity-related traits;	chr19:37160027	chr19:37314868~37315620:-
THCA	cis	rs7674212	0.541	rs2720471	ENSG00000251288.2	RP11-10L12.2	-4.86	1.61e-06	0.000196	-0.28	-0.22	Type 2 diabetes;	chr4:103102683	chr4:102751401~102752641:+
THCA	cis	rs4443100	0.916	rs8139695	ENSG00000230701.2	FBXW4P1	-4.86	1.61e-06	0.000196	-0.26	-0.22	Serum parathyroid hormone levels;	chr22:23031726	chr22:23262767~23265005:+
THCA	cis	rs7614311	0.689	rs56329572	ENSG00000271843.1	RP11-245J9.5	-4.86	1.61e-06	0.000196	-0.39	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63860996	chr3:64008082~64008692:-
THCA	cis	rs4415084	0.966	rs4463188	ENSG00000272335.1	RP11-53O19.3	-4.86	1.61e-06	0.000196	-0.18	-0.22	Breast cancer;	chr5:44642568	chr5:44826076~44828592:+
THCA	cis	rs72799341	0.706	rs59735493	ENSG00000260911.2	RP11-196G11.2	4.86	1.61e-06	0.000196	0.19	0.22	Diastolic blood pressure;	chr16:31121779	chr16:31043150~31049868:+
THCA	cis	rs1005277	0.522	rs1208767	ENSG00000276805.1	RP11-291L22.6	4.86	1.61e-06	0.000196	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38451030~38451785:+
THCA	cis	rs6674176	0.935	rs4314918	ENSG00000237950.1	RP11-7O11.3	4.86	1.61e-06	0.000196	0.21	0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43911831	chr1:43944370~43946551:-
THCA	cis	rs6674176	1	rs6674176	ENSG00000237950.1	RP11-7O11.3	4.86	1.61e-06	0.000196	0.21	0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43914285	chr1:43944370~43946551:-
THCA	cis	rs2348418	0.643	rs7316831	ENSG00000247934.4	RP11-967K21.1	4.86	1.61e-06	0.000196	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28303065	chr12:28163298~28190738:-
THCA	cis	rs8177876	0.822	rs56119129	ENSG00000261061.1	RP11-303E16.2	-4.86	1.61e-06	0.000196	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.731	rs77145371	ENSG00000261061.1	RP11-303E16.2	-4.86	1.61e-06	0.000196	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.908	rs80187824	ENSG00000261061.1	RP11-303E16.2	-4.86	1.61e-06	0.000196	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81030770~81031485:+
THCA	cis	rs9300255	0.739	rs1402275	ENSG00000235423.7	RP11-282O18.3	4.86	1.61e-06	0.000196	0.23	0.22	Neutrophil percentage of white cells;	chr12:123266348	chr12:123252030~123261483:-
THCA	cis	rs7208859	0.623	rs170051	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.61e-06	0.000196	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.51	rs216402	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.61e-06	0.000196	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs216434	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.61e-06	0.000196	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs216436	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.61e-06	0.000196	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.61e-06	0.000196	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs216439	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.61e-06	0.000196	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30738182~30740275:+
THCA	cis	rs10266483	1	rs1960321	ENSG00000271550.1	BNIP3P11	4.86	1.61e-06	0.000196	0.27	0.22	Response to statin therapy;	chr7:64270906	chr7:64678954~64687393:-
THCA	cis	rs1383484	0.575	rs1011102	ENSG00000225151.9	GOLGA2P7	4.86	1.61e-06	0.000196	0.28	0.22	Height;	chr15:83929224	chr15:84199311~84230136:-
THCA	cis	rs1979679	0.578	rs1993936	ENSG00000278733.1	RP11-425D17.1	4.86	1.61e-06	0.000196	0.21	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28120979	chr12:28185625~28186190:-
THCA	cis	rs2839186	0.526	rs59977673	ENSG00000239415.1	AP001469.9	4.86	1.61e-06	0.000196	0.23	0.22	Testicular germ cell tumor;	chr21:46502178	chr21:46251549~46254133:-
THCA	cis	rs1790761	0.501	rs4930210	ENSG00000255318.1	RP11-655M14.13	-4.86	1.61e-06	0.000196	-0.25	-0.22	Mean corpuscular volume;	chr11:67637255	chr11:67618279~67627304:-
THCA	cis	rs5758659	0.967	rs5751250	ENSG00000227370.1	RP4-669P10.19	-4.86	1.61e-06	0.000196	-0.2	-0.22	Cognitive function;	chr22:42243639	chr22:42132543~42132998:+
THCA	cis	rs6012564	1	rs730543	ENSG00000227431.4	CSE1L-AS1	-4.86	1.61e-06	0.000197	-0.27	-0.22	Anger;	chr20:49019178	chr20:49040463~49046044:-
THCA	cis	rs2839186	0.656	rs4819226	ENSG00000215424.8	MCM3AP-AS1	4.86	1.61e-06	0.000197	0.13	0.22	Testicular germ cell tumor;	chr21:46292498	chr21:46229217~46259390:+
THCA	cis	rs12022452	0.822	rs7514623	ENSG00000237899.1	RP4-739H11.3	-4.86	1.61e-06	0.000197	-0.34	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40669089~40687588:-
THCA	cis	rs13126694	0.901	rs4691460	ENSG00000248429.4	RP11-597D13.9	-4.86	1.61e-06	0.000197	-0.23	-0.22	Blood osmolality (transformed sodium);	chr4:158138279	chr4:158170752~158202877:+
THCA	cis	rs1005277	0.579	rs2474584	ENSG00000275858.1	RP11-291L22.8	4.86	1.62e-06	0.000197	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474586	ENSG00000275858.1	RP11-291L22.8	4.86	1.62e-06	0.000197	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38450738~38451069:-
THCA	cis	rs28374715	0.733	rs9568	ENSG00000247556.5	OIP5-AS1	4.86	1.62e-06	0.000197	0.2	0.22	Ulcerative colitis;	chr15:41281414	chr15:41283990~41309737:+
THCA	cis	rs2255336	0.81	rs7956385	ENSG00000245648.1	RP11-277P12.20	4.86	1.62e-06	0.000197	0.31	0.22	Blood protein levels;	chr12:10361398	chr12:10363769~10398506:+
THCA	cis	rs7129556	0.775	rs72945592	ENSG00000254691.1	RP11-91P24.5	4.86	1.62e-06	0.000197	0.3	0.22	Weight loss (gastric bypass surgery);	chr11:77649451	chr11:77850604~77851511:+
THCA	cis	rs7829975	0.572	rs28730413	ENSG00000254153.1	CTA-398F10.2	4.86	1.62e-06	0.000197	0.24	0.22	Mood instability;	chr8:8937937	chr8:8456909~8461337:-
THCA	cis	rs7838490	0.504	rs1685541	ENSG00000253553.4	RP11-586K2.1	4.86	1.62e-06	0.000197	0.22	0.22	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88460166	chr8:88326836~88737134:+
THCA	cis	rs11671005	0.735	rs56292587	ENSG00000268912.1	CTD-2619J13.17	-4.86	1.62e-06	0.000197	-0.21	-0.22	Mean platelet volume;	chr19:58407699	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs56290606	ENSG00000268912.1	CTD-2619J13.17	-4.86	1.62e-06	0.000197	-0.21	-0.22	Mean platelet volume;	chr19:58407953	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs11878198	ENSG00000268912.1	CTD-2619J13.17	-4.86	1.62e-06	0.000197	-0.21	-0.22	Mean platelet volume;	chr19:58408935	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs11666716	ENSG00000268912.1	CTD-2619J13.17	-4.86	1.62e-06	0.000197	-0.21	-0.22	Mean platelet volume;	chr19:58409585	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs34511020	ENSG00000268912.1	CTD-2619J13.17	-4.86	1.62e-06	0.000197	-0.21	-0.22	Mean platelet volume;	chr19:58409929	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs11666303	ENSG00000268912.1	CTD-2619J13.17	-4.86	1.62e-06	0.000197	-0.21	-0.22	Mean platelet volume;	chr19:58411135	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs34152946	ENSG00000268912.1	CTD-2619J13.17	-4.86	1.62e-06	0.000197	-0.21	-0.22	Mean platelet volume;	chr19:58411896	chr19:58428632~58431148:-
THCA	cis	rs210138	1	rs210137	ENSG00000197251.3	LINC00336	4.86	1.62e-06	0.000197	0.28	0.22	Testicular germ cell tumor;	chr6:33574701	chr6:33586106~33593338:-
THCA	cis	rs1005277	0.505	rs7069702	ENSG00000226578.1	RP11-258F22.1	4.86	1.62e-06	0.000197	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:37775371~37784131:-
THCA	cis	rs7208859	0.673	rs9912122	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.62e-06	0.000197	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30738182~30740275:+
THCA	cis	rs5758659	1	rs5758677	ENSG00000227370.1	RP4-669P10.19	-4.86	1.62e-06	0.000197	-0.2	-0.22	Cognitive function;	chr22:42247033	chr22:42132543~42132998:+
THCA	cis	rs6088580	0.634	rs6059867	ENSG00000276073.1	RP5-1125A11.7	-4.86	1.62e-06	0.000197	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34490298	chr20:33985617~33988989:-
THCA	cis	rs10510102	0.748	rs4589226	ENSG00000226864.1	ATE1-AS1	4.86	1.62e-06	0.000197	0.35	0.22	Breast cancer;	chr10:121951073	chr10:121928312~121951965:+
THCA	cis	rs6565653	1	rs6565653	ENSG00000262580.4	RP11-334C17.5	4.86	1.62e-06	0.000197	0.19	0.22	Ischemic stroke;	chr17:80227984	chr17:80200673~80205949:-
THCA	cis	rs12036718	0.511	rs12140113	ENSG00000272491.1	RP5-1024N4.4	4.86	1.62e-06	0.000197	0.28	0.22	Yu-Zhi constitution type in type 2 diabetes;	chr1:48092565	chr1:48227888~48229561:-
THCA	cis	rs6012564	1	rs6063360	ENSG00000227431.4	CSE1L-AS1	4.86	1.62e-06	0.000197	0.27	0.22	Anger;	chr20:49131838	chr20:49040463~49046044:-
THCA	cis	rs4448343	0.963	rs10512248	ENSG00000271155.1	RP11-435O5.5	-4.86	1.62e-06	0.000197	-0.22	-0.22	Height;	chr9:95497421	chr9:95506235~95507636:+
THCA	cis	rs7674212	0.539	rs7676041	ENSG00000246560.2	RP11-10L12.4	4.86	1.62e-06	0.000197	0.26	0.22	Type 2 diabetes;	chr4:103205264	chr4:102828055~102844075:+
THCA	cis	rs13126694	0.778	rs4691454	ENSG00000248429.4	RP11-597D13.9	4.86	1.62e-06	0.000197	0.23	0.22	Blood osmolality (transformed sodium);	chr4:158117101	chr4:158170752~158202877:+
THCA	cis	rs4819052	1	rs2297285	ENSG00000273796.1	LL21NC02-21A1.1	4.86	1.62e-06	0.000197	0.27	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45403809~45404369:-
THCA	cis	rs4722166	0.63	rs12700390	ENSG00000225541.1	AC002480.5	-4.86	1.62e-06	0.000197	-0.28	-0.22	Lung cancer;	chr7:22737510	chr7:22571607~22661792:-
THCA	cis	rs4722166	0.63	rs12700391	ENSG00000225541.1	AC002480.5	-4.86	1.62e-06	0.000197	-0.28	-0.22	Lung cancer;	chr7:22737708	chr7:22571607~22661792:-
THCA	cis	rs4722166	0.63	rs7781534	ENSG00000225541.1	AC002480.5	-4.86	1.62e-06	0.000197	-0.28	-0.22	Lung cancer;	chr7:22738973	chr7:22571607~22661792:-
THCA	cis	rs4722166	0.63	rs1581497	ENSG00000225541.1	AC002480.5	-4.86	1.62e-06	0.000197	-0.28	-0.22	Lung cancer;	chr7:22739884	chr7:22571607~22661792:-
THCA	cis	rs4722166	0.63	rs1829927	ENSG00000225541.1	AC002480.5	-4.86	1.62e-06	0.000197	-0.28	-0.22	Lung cancer;	chr7:22740299	chr7:22571607~22661792:-
THCA	cis	rs9902453	0.753	rs3097118	ENSG00000263370.1	RP11-68I3.5	4.86	1.62e-06	0.000197	0.27	0.22	Coffee consumption (cups per day);	chr17:29651448	chr17:29639627~29640825:+
THCA	cis	rs4650994	0.593	rs12568310	ENSG00000273384.1	RP5-1098D14.1	-4.86	1.62e-06	0.000197	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178545487	chr1:178651706~178652282:+
THCA	cis	rs12908161	1	rs35808647	ENSG00000275120.1	RP11-182J1.17	4.86	1.62e-06	0.000197	0.26	0.22	Schizophrenia;	chr15:84834210	chr15:84599434~84606463:-
THCA	cis	rs7615952	0.546	rs2979306	ENSG00000171084.14	FAM86JP	4.86	1.62e-06	0.000197	0.29	0.22	Blood pressure (smoking interaction);	chr3:125593286	chr3:125916620~125930024:+
THCA	cis	rs11146838	1	rs11146838	ENSG00000120555.12	SEPT7P9	4.86	1.62e-06	0.000198	0.24	0.22	Breast cancer;	chr10:38856846	chr10:38383069~38402916:-
THCA	cis	rs1577917	0.56	rs9450288	ENSG00000220563.1	PKMP3	4.86	1.62e-06	0.000198	0.16	0.22	Response to antipsychotic treatment;	chr6:85511868	chr6:85659892~85660606:-
THCA	cis	rs9487094	0.67	rs34928881	ENSG00000223537.2	RP5-919F19.5	-4.86	1.63e-06	0.000198	-0.22	-0.22	Height;	chr6:109526846	chr6:109487906~109506800:+
THCA	cis	rs2243480	1	rs34703416	ENSG00000232559.3	GS1-124K5.12	4.86	1.63e-06	0.000198	0.32	0.22	Diabetic kidney disease;	chr7:65835655	chr7:66554588~66576923:-
THCA	cis	rs793571	0.554	rs28489732	ENSG00000245975.2	RP11-30K9.6	4.86	1.63e-06	0.000198	0.26	0.22	Schizophrenia;	chr15:58721154	chr15:58768072~58770974:-
THCA	cis	rs793571	0.505	rs12901989	ENSG00000245975.2	RP11-30K9.6	4.86	1.63e-06	0.000198	0.26	0.22	Schizophrenia;	chr15:58603861	chr15:58768072~58770974:-
THCA	cis	rs10510102	0.872	rs10887032	ENSG00000226864.1	ATE1-AS1	-4.86	1.63e-06	0.000198	-0.36	-0.22	Breast cancer;	chr10:121955887	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12246693	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121957373	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12248806	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121958638	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12255832	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121958762	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12240306	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121963391	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12240308	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121963407	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs11814703	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121964774	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12259144	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121965433	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12246728	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121966618	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12261371	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121966686	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs11200292	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121967383	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.808	rs17102804	ENSG00000226864.1	ATE1-AS1	4.86	1.63e-06	0.000198	0.36	0.22	Breast cancer;	chr10:121968365	chr10:121928312~121951965:+
THCA	cis	rs8064024	0.681	rs7194890	ENSG00000267077.1	RP11-127I20.5	4.86	1.63e-06	0.000198	0.25	0.22	Cancer;	chr16:4833780	chr16:4795265~4796532:-
THCA	cis	rs7267979	0.932	rs446649	ENSG00000274973.1	RP13-401N8.7	-4.86	1.63e-06	0.000198	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25845497~25845862:+
THCA	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-4.86	1.63e-06	0.000198	-0.25	-0.22	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
THCA	cis	rs1210638	0.545	rs6518507	ENSG00000273032.1	DGCR9	-4.86	1.63e-06	0.000198	-0.22	-0.22	Response to serotonin reuptake inhibitors in major depressive disorder;	chr22:18988966	chr22:19017834~19020248:+
THCA	cis	rs9880211	0.563	rs67589653	ENSG00000273486.1	RP11-731C17.2	4.86	1.63e-06	0.000198	0.22	0.22	Height;Body mass index;	chr3:136092732	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.563	rs10512990	ENSG00000273486.1	RP11-731C17.2	4.86	1.63e-06	0.000198	0.22	0.22	Height;Body mass index;	chr3:136095785	chr3:136837338~136839021:-
THCA	cis	rs13434995	0.513	rs550144	ENSG00000273257.1	RP11-177J6.1	4.86	1.63e-06	0.000198	0.33	0.22	Adiponectin levels;	chr4:55415317	chr4:55387949~55388271:+
THCA	cis	rs2439831	0.867	rs2255042	ENSG00000205771.5	CATSPER2P1	4.86	1.63e-06	0.000198	0.29	0.22	Lung cancer in ever smokers;	chr15:43542120	chr15:43726918~43747094:-
THCA	cis	rs73242632	1	rs114513553	ENSG00000269949.1	RP11-738E22.3	4.86	1.63e-06	0.000198	0.5	0.22	Congenital heart disease (maternal effect);	chr4:56992292	chr4:56960927~56961373:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000223473.2	GS1-124K5.3	4.86	1.63e-06	0.000198	0.15	0.22	Aortic root size;	chr7:65966699	chr7:66491049~66493566:-
THCA	cis	rs7176527	0.784	rs62021162	ENSG00000225151.9	GOLGA2P7	4.86	1.63e-06	0.000198	0.35	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84199311~84230136:-
THCA	cis	rs62246343	0.719	rs73130116	ENSG00000254485.4	RP11-380O24.1	4.86	1.63e-06	0.000198	0.29	0.22	Fibrinogen levels;	chr3:9452827	chr3:9292588~9363303:-
THCA	cis	rs9300255	0.602	rs11057192	ENSG00000235423.7	RP11-282O18.3	4.86	1.63e-06	0.000198	0.23	0.22	Neutrophil percentage of white cells;	chr12:123208873	chr12:123252030~123261483:-
THCA	cis	rs2239547	0.563	rs6797399	ENSG00000242142.1	SERBP1P3	4.86	1.63e-06	0.000198	0.28	0.22	Schizophrenia;	chr3:52871901	chr3:53064283~53065091:-
THCA	cis	rs459482	1	rs464783	ENSG00000228318.3	AP001610.5	4.86	1.63e-06	0.000198	0.25	0.22	IgG glycosylation;	chr21:41424553	chr21:41441056~41445708:-
THCA	cis	rs3738443	0.768	rs6668154	ENSG00000259865.1	RP11-488L18.10	4.86	1.63e-06	0.000198	0.23	0.22	Alcohol dependence;	chr1:247187981	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.768	rs6665647	ENSG00000259865.1	RP11-488L18.10	4.86	1.63e-06	0.000198	0.23	0.22	Alcohol dependence;	chr1:247188127	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.817	rs1115202	ENSG00000259865.1	RP11-488L18.10	4.86	1.63e-06	0.000198	0.23	0.22	Alcohol dependence;	chr1:247189878	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.868	rs61839994	ENSG00000259865.1	RP11-488L18.10	4.86	1.63e-06	0.000198	0.23	0.22	Alcohol dependence;	chr1:247195479	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.868	rs7536883	ENSG00000259865.1	RP11-488L18.10	4.86	1.63e-06	0.000198	0.23	0.22	Alcohol dependence;	chr1:247196266	chr1:247187281~247188526:-
THCA	cis	rs72843506	0.656	rs78325601	ENSG00000261033.1	RP11-209D14.2	4.86	1.63e-06	0.000198	0.42	0.22	Schizophrenia;	chr17:20018486	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs74648067	ENSG00000261033.1	RP11-209D14.2	4.86	1.63e-06	0.000198	0.42	0.22	Schizophrenia;	chr17:20022938	chr17:20008051~20009234:-
THCA	cis	rs9813712	0.571	rs9846596	ENSG00000249846.5	RP11-77P16.4	-4.86	1.63e-06	0.000198	-0.23	-0.22	Response to amphetamines;	chr3:130288318	chr3:130112550~130120579:+
THCA	cis	rs9425766	0.679	rs4652234	ENSG00000227373.4	RP11-160H22.5	4.86	1.63e-06	0.000198	0.31	0.22	Life satisfaction;	chr1:174181712	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.732	rs6658543	ENSG00000227373.4	RP11-160H22.5	4.86	1.63e-06	0.000198	0.31	0.22	Life satisfaction;	chr1:174183338	chr1:174115300~174160004:-
THCA	cis	rs1005277	0.505	rs13503	ENSG00000226578.1	RP11-258F22.1	4.86	1.63e-06	0.000198	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:37775371~37784131:-
THCA	cis	rs3892630	0.824	rs2287884	ENSG00000267567.1	CTD-2538C1.3	4.86	1.63e-06	0.000198	0.34	0.22	Red blood cell traits;	chr19:32830541	chr19:32718298~32719595:-
THCA	cis	rs11633886	0.604	rs10153045	ENSG00000273972.1	CTD-2306A12.1	-4.86	1.63e-06	0.000198	-0.25	-0.22	Diisocyanate-induced asthma;	chr15:45832078	chr15:45702640~45703183:+
THCA	cis	rs2742234	0.59	rs2565201	ENSG00000273008.1	RP11-351D16.3	-4.86	1.63e-06	0.000198	-0.2	-0.22	Hirschsprung disease;	chr10:43123036	chr10:43136824~43138334:-
THCA	cis	rs8177376	0.727	rs651922	ENSG00000254905.1	RP11-712L6.7	4.86	1.63e-06	0.000198	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331395	chr11:126292922~126294254:-
THCA	cis	rs8177376	0.727	rs616360	ENSG00000254905.1	RP11-712L6.7	4.86	1.63e-06	0.000198	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331508	chr11:126292922~126294254:-
THCA	cis	rs7849973	0.579	rs13285009	ENSG00000234840.1	LINC01239	-4.86	1.63e-06	0.000198	-0.28	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22763642	chr9:22646200~22824213:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000224316.1	RP11-479O9.2	-4.86	1.63e-06	0.000198	-0.25	-0.22	Aortic root size;	chr7:66597493	chr7:65773620~65802067:+
THCA	cis	rs4578769	0.531	rs4800443	ENSG00000265939.1	UBE2CP2	4.86	1.63e-06	0.000199	0.25	0.22	Eosinophil percentage of white cells;	chr18:23015139	chr18:22900486~22900995:-
THCA	cis	rs62184315	0.536	rs62184265	ENSG00000253559.1	OSGEPL1-AS1	-4.86	1.63e-06	0.000199	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189756231	chr2:189762704~189765556:+
THCA	cis	rs11763147	1	rs11763147	ENSG00000229886.1	RP5-1132H15.3	-4.86	1.63e-06	0.000199	-0.23	-0.22	Corneal structure;	chr7:65861834	chr7:66025126~66031544:-
THCA	cis	rs4648045	0.861	rs4235404	ENSG00000246560.2	RP11-10L12.4	4.86	1.63e-06	0.000199	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102518908	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.828	rs4647980	ENSG00000246560.2	RP11-10L12.4	4.86	1.63e-06	0.000199	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102518936	chr4:102828055~102844075:+
THCA	cis	rs1150668	0.83	rs2023493	ENSG00000273712.1	RP5-874C20.7	4.86	1.63e-06	0.000199	0.24	0.22	Pubertal anthropometrics;	chr6:28432385	chr6:28315613~28315883:-
THCA	cis	rs4650994	0.55	rs10913573	ENSG00000273384.1	RP5-1098D14.1	-4.86	1.63e-06	0.000199	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178561320	chr1:178651706~178652282:+
THCA	cis	rs2692947	0.711	rs34639392	ENSG00000232931.4	LINC00342	4.86	1.63e-06	0.000199	0.18	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95843228	chr2:95807118~95816215:-
THCA	cis	rs6708331	0.517	rs9989876	ENSG00000179818.12	PCBP1-AS1	-4.86	1.63e-06	0.000199	-0.18	-0.22	Obesity-related traits;	chr2:70115578	chr2:69962263~70103220:-
THCA	cis	rs6708331	0.517	rs10496178	ENSG00000179818.12	PCBP1-AS1	-4.86	1.63e-06	0.000199	-0.18	-0.22	Obesity-related traits;	chr2:70115683	chr2:69962263~70103220:-
THCA	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-4.86	1.63e-06	0.000199	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
THCA	cis	rs4713118	0.699	rs200969	ENSG00000261839.1	RP1-265C24.8	4.86	1.64e-06	0.000199	0.26	0.22	Parkinson's disease;	chr6:27891675	chr6:28136849~28139678:+
THCA	cis	rs2337406	0.85	rs10131280	ENSG00000274576.2	IGHV2-70	-4.86	1.64e-06	0.000199	-0.19	-0.22	Alzheimer's disease (late onset);	chr14:106665591	chr14:106770577~106771020:-
THCA	cis	rs2380220	0.606	rs7747776	ENSG00000261366.1	MANEA-AS1	-4.86	1.64e-06	0.000199	-0.21	-0.22	Behavioural disinhibition (generation interaction);	chr6:95557976	chr6:95575183~95577450:-
THCA	cis	rs7914558	0.752	rs7896519	ENSG00000213061.2	PFN1P11	4.86	1.64e-06	0.000199	0.27	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102838011~102845473:-
THCA	cis	rs9487094	0.67	rs12192268	ENSG00000223537.2	RP5-919F19.5	-4.86	1.64e-06	0.000199	-0.22	-0.22	Height;	chr6:109690255	chr6:109487906~109506800:+
THCA	cis	rs4648045	0.861	rs118882	ENSG00000246560.2	RP11-10L12.4	-4.86	1.64e-06	0.000199	-0.27	-0.22	Lymphocyte percentage of white cells;	chr4:102541850	chr4:102828055~102844075:+
THCA	cis	rs9925964	0.933	rs881929	ENSG00000260911.2	RP11-196G11.2	-4.86	1.64e-06	0.000199	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31068050	chr16:31043150~31049868:+
THCA	cis	rs6121246	0.559	rs6121038	ENSG00000230613.1	HM13-AS1	4.86	1.64e-06	0.000199	0.21	0.22	Mean corpuscular hemoglobin;	chr20:31666970	chr20:31567707~31573263:-
THCA	cis	rs17767392	0.881	rs10138557	ENSG00000259146.3	RP1-261D10.2	-4.86	1.64e-06	0.000199	-0.28	-0.22	Mitral valve prolapse;	chr14:71595001	chr14:71292729~71321814:-
THCA	cis	rs7191700	0.601	rs243329	ENSG00000263080.1	RP11-485G7.5	4.86	1.64e-06	0.000199	0.25	0.22	Multiple sclerosis;	chr16:11258456	chr16:11341809~11345211:-
THCA	cis	rs911555	0.755	rs6575988	ENSG00000244691.1	RPL10AP1	4.86	1.64e-06	0.000199	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103412119~103412761:-
THCA	cis	rs13434995	0.589	rs496055	ENSG00000273257.1	RP11-177J6.1	-4.86	1.64e-06	0.000199	-0.34	-0.22	Adiponectin levels;	chr4:55383670	chr4:55387949~55388271:+
THCA	cis	rs7829975	0.626	rs332040	ENSG00000233609.3	RP11-62H7.2	4.86	1.64e-06	0.000199	0.22	0.22	Mood instability;	chr8:8872978	chr8:8961200~8979025:+
THCA	cis	rs2348418	0.703	rs12368149	ENSG00000247934.4	RP11-967K21.1	-4.86	1.64e-06	0.000199	-0.19	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28168625	chr12:28163298~28190738:-
THCA	cis	rs72843506	0.586	rs74429763	ENSG00000261033.1	RP11-209D14.2	4.86	1.64e-06	0.000199	0.42	0.22	Schizophrenia;	chr17:19960206	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.586	rs16960554	ENSG00000261033.1	RP11-209D14.2	4.86	1.64e-06	0.000199	0.42	0.22	Schizophrenia;	chr17:19966485	chr17:20008051~20009234:-
THCA	cis	rs7403037	0.527	rs4778426	ENSG00000259905.4	PWRN1	-4.86	1.64e-06	0.000199	-0.24	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24212440	chr15:24493137~24652130:+
THCA	cis	rs17801127	0.688	rs4667407	ENSG00000231969.1	AC144449.1	-4.86	1.64e-06	0.000199	-0.34	-0.22	Liver enzyme levels (alanine transaminase);	chr2:149701332	chr2:149587196~149848233:+
THCA	cis	rs853679	0.585	rs201001	ENSG00000280107.1	AL022393.9	-4.86	1.64e-06	0.000199	-0.27	-0.22	Depression;	chr6:27841121	chr6:28170845~28172521:+
THCA	cis	rs853679	0.585	rs201000	ENSG00000280107.1	AL022393.9	-4.86	1.64e-06	0.000199	-0.27	-0.22	Depression;	chr6:27841381	chr6:28170845~28172521:+
THCA	cis	rs4074961	0.565	rs10908362	ENSG00000233621.1	LINC01137	-4.86	1.64e-06	0.000199	-0.23	-0.22	Axial length;	chr1:37596105	chr1:37454879~37474411:-
THCA	cis	rs12413361	0.967	rs1538951	ENSG00000272914.1	RP11-330O11.3	-4.86	1.64e-06	0.000199	-0.19	-0.22	Height;	chr10:30840556	chr10:30831828~30833387:-
THCA	cis	rs78487399	0.908	rs76621120	ENSG00000234936.1	AC010883.5	4.86	1.64e-06	0.000199	0.28	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583512	chr2:43229573~43233394:+
THCA	cis	rs2985684	1	rs56098064	ENSG00000278009.1	RP11-649E7.8	4.86	1.64e-06	0.000199	0.31	0.22	Carotid intima media thickness;	chr14:49639131	chr14:49601011~49601124:-
THCA	cis	rs8020095	0.571	rs9323493	ENSG00000258561.1	RP11-72M17.1	-4.86	1.64e-06	2e-04	-0.29	-0.22	Depression (quantitative trait);	chr14:67079463	chr14:66212810~66509394:-
THCA	cis	rs11671005	0.569	rs73068335	ENSG00000269600.1	AC016629.3	-4.85	1.64e-06	2e-04	-0.31	-0.22	Mean platelet volume;	chr19:58577941	chr19:58593896~58599355:-
THCA	cis	rs1211375	0.628	rs3859141	ENSG00000206168.1	Z69890.1	-4.85	1.64e-06	2e-04	-0.23	-0.22	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:195080	chr16:231134~231472:+
THCA	cis	rs453301	0.606	rs6601279	ENSG00000254153.1	CTA-398F10.2	4.85	1.64e-06	2e-04	0.23	0.22	Joint mobility (Beighton score);	chr8:9050721	chr8:8456909~8461337:-
THCA	cis	rs453301	0.606	rs6981060	ENSG00000254153.1	CTA-398F10.2	4.85	1.64e-06	2e-04	0.23	0.22	Joint mobility (Beighton score);	chr8:9050725	chr8:8456909~8461337:-
THCA	cis	rs17818399	0.675	rs35949012	ENSG00000279254.1	RP11-536C12.1	-4.85	1.64e-06	2e-04	-0.23	-0.22	Height;	chr2:46633262	chr2:46668870~46670778:+
THCA	cis	rs17818399	0.815	rs17768018	ENSG00000279254.1	RP11-536C12.1	-4.85	1.64e-06	2e-04	-0.23	-0.22	Height;	chr2:46634872	chr2:46668870~46670778:+
THCA	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-4.85	1.64e-06	2e-04	-0.24	-0.22	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
THCA	cis	rs9879311	0.866	rs775017	ENSG00000240288.6	GHRLOS	4.85	1.64e-06	2e-04	0.2	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10357280	chr3:10285754~10293449:+
THCA	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-4.85	1.64e-06	2e-04	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
THCA	cis	rs5742933	1	rs12622902	ENSG00000273240.1	RP11-455J20.3	-4.85	1.65e-06	2e-04	-0.25	-0.22	Ferritin levels;	chr2:189776263	chr2:189763859~189764456:-
THCA	cis	rs7394190	0.748	rs1057410	ENSG00000271816.1	BMS1P4	-4.85	1.65e-06	2e-04	-0.27	-0.22	Incident atrial fibrillation;	chr10:73814321	chr10:73699151~73730487:-
THCA	cis	rs7674212	0.539	rs6854709	ENSG00000246560.2	RP11-10L12.4	4.85	1.65e-06	2e-04	0.26	0.22	Type 2 diabetes;	chr4:103208629	chr4:102828055~102844075:+
THCA	cis	rs613391	0.702	rs1667087	ENSG00000224549.1	RP11-370B11.3	4.85	1.65e-06	2e-04	0.24	0.22	Quantitative traits;	chr9:22696346	chr9:22767175~22768316:+
THCA	cis	rs4886920	0.605	rs12912080	ENSG00000260776.4	RP11-114H24.2	4.85	1.65e-06	2e-04	0.26	0.22	Neuroticism;	chr15:77834416	chr15:77914217~77926846:-
THCA	cis	rs11955398	0.502	rs6868884	ENSG00000272308.1	RP11-231G3.1	-4.85	1.65e-06	2e-04	-0.23	-0.22	Intelligence (multi-trait analysis);	chr5:61087133	chr5:60866457~60866935:-
THCA	cis	rs11955398	0.502	rs295531	ENSG00000272308.1	RP11-231G3.1	-4.85	1.65e-06	2e-04	-0.23	-0.22	Intelligence (multi-trait analysis);	chr5:61099916	chr5:60866457~60866935:-
THCA	cis	rs16975963	0.644	rs1478462	ENSG00000226686.6	LINC01535	-4.85	1.65e-06	2e-04	-0.3	-0.22	Longevity;	chr19:37656124	chr19:37251912~37265535:+
THCA	cis	rs12911832	1	rs12911961	ENSG00000245975.2	RP11-30K9.6	4.85	1.65e-06	2e-04	0.21	0.22	Schizophrenia;	chr15:58693668	chr15:58768072~58770974:-
THCA	cis	rs4950322	0.547	rs6660507	ENSG00000180867.10	PDIA3P1	4.85	1.65e-06	2e-04	0.2	0.22	Protein quantitative trait loci;	chr1:147148574	chr1:147178113~147179622:+
THCA	cis	rs12908161	0.683	rs12903256	ENSG00000259295.5	CSPG4P12	4.85	1.65e-06	2e-04	0.31	0.22	Schizophrenia;	chr15:84764910	chr15:85191438~85213905:+
THCA	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-4.85	1.65e-06	2e-04	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
THCA	cis	rs6840258	0.891	rs151451	ENSG00000251411.1	RP11-397E7.4	-4.85	1.65e-06	2e-04	-0.26	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87085215	chr4:86913266~86914817:-
THCA	cis	rs9880211	1	rs9823373	ENSG00000239213.4	NCK1-AS1	4.85	1.65e-06	2e-04	0.24	0.22	Height;Body mass index;	chr3:136448185	chr3:136841726~136862054:-
THCA	cis	rs6012564	1	rs3818262	ENSG00000227431.4	CSE1L-AS1	4.85	1.65e-06	2e-04	0.26	0.22	Anger;	chr20:49125019	chr20:49040463~49046044:-
THCA	cis	rs7621331	1	rs9853577	ENSG00000273486.1	RP11-731C17.2	4.85	1.65e-06	2e-04	0.21	0.22	Waist circumference adjusted for body mass index;	chr3:135989305	chr3:136837338~136839021:-
THCA	cis	rs4787484	1	rs7189550	ENSG00000214725.6	CDIPT-AS1	4.85	1.65e-06	2e-04	0.29	0.22	Response to taxane treatment (placlitaxel);	chr16:29899939	chr16:29863593~29868053:+
THCA	cis	rs1395	0.922	rs11693052	ENSG00000234072.1	AC074117.10	-4.85	1.65e-06	2e-04	-0.18	-0.22	Blood metabolite levels;	chr2:27261752	chr2:27356246~27367622:+
THCA	cis	rs911555	0.723	rs6575982	ENSG00000244691.1	RPL10AP1	4.85	1.65e-06	2e-04	0.3	0.22	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103412119~103412761:-
THCA	cis	rs6012564	0.89	rs6066976	ENSG00000227431.4	CSE1L-AS1	4.85	1.65e-06	2e-04	0.27	0.22	Anger;	chr20:49134464	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs6066982	ENSG00000227431.4	CSE1L-AS1	4.85	1.65e-06	2e-04	0.27	0.22	Anger;	chr20:49147021	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs7272164	ENSG00000227431.4	CSE1L-AS1	4.85	1.65e-06	2e-04	0.27	0.22	Anger;	chr20:49149660	chr20:49040463~49046044:-
THCA	cis	rs989128	0.6	rs9913430	ENSG00000250286.1	RP11-94C24.8	-4.85	1.65e-06	2e-04	-0.21	-0.22	Type 2 diabetes;	chr17:50551109	chr17:50537294~50538754:-
THCA	cis	rs2664588	0.68	rs4810745	ENSG00000276923.1	RP11-321P16.1	-4.85	1.65e-06	0.000201	-0.29	-0.22	Cerebrospinal fluid AB1-42 levels;	chr20:47991111	chr20:48073869~48074188:+
THCA	cis	rs113835537	0.935	rs79496339	ENSG00000255517.5	CTD-3074O7.5	-4.85	1.65e-06	0.000201	-0.24	-0.22	Airway imaging phenotypes;	chr11:66700298	chr11:66473490~66480233:-
THCA	cis	rs11088226	1	rs11088226	ENSG00000186842.4	LINC00846	-4.85	1.65e-06	0.000201	-0.29	-0.22	Gastritis;	chr21:32553221	chr21:32572238~32575881:-
THCA	cis	rs9876781	0.9	rs1037773	ENSG00000244380.1	RP11-24C3.2	4.85	1.65e-06	0.000201	0.26	0.22	Longevity;	chr3:48426493	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs2279077	ENSG00000244380.1	RP11-24C3.2	4.85	1.65e-06	0.000201	0.26	0.22	Longevity;	chr3:48432839	chr3:48440352~48446656:-
THCA	cis	rs11739663	0.574	rs67276442	ENSG00000225138.6	CTD-2228K2.7	4.85	1.65e-06	0.000201	0.22	0.22	Ulcerative colitis;	chr5:583803	chr5:473236~480884:+
THCA	cis	rs1005277	0.579	rs2504143	ENSG00000275858.1	RP11-291L22.8	4.85	1.65e-06	0.000201	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38450738~38451069:-
THCA	cis	rs6472827	0.595	rs2977068	ENSG00000253983.2	RP1-16A9.1	4.85	1.65e-06	0.000201	0.31	0.22	Uterine fibroids;	chr8:74192817	chr8:74199396~74208441:+
THCA	cis	rs71636778	0.524	rs78614739	ENSG00000260063.1	RP5-968P14.2	-4.85	1.65e-06	0.000201	-0.29	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26847689	chr1:26692132~26694131:-
THCA	cis	rs2120243	0.845	rs2316710	ENSG00000244515.1	KRT18P34	-4.85	1.65e-06	0.000201	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157432391	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.874	rs2316709	ENSG00000244515.1	KRT18P34	-4.85	1.65e-06	0.000201	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157432458	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.874	rs2316708	ENSG00000244515.1	KRT18P34	-4.85	1.65e-06	0.000201	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157432510	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.874	rs9868133	ENSG00000244515.1	KRT18P34	-4.85	1.65e-06	0.000201	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157433672	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.874	rs7616177	ENSG00000244515.1	KRT18P34	-4.85	1.65e-06	0.000201	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157435419	chr3:157162663~157163932:-
THCA	cis	rs494453	0.922	rs486982	ENSG00000227811.2	FAM212B-AS1	-4.85	1.65e-06	0.000201	-0.27	-0.22	Osteoporosis-related phenotypes;	chr1:111710492	chr1:111739841~111747798:+
THCA	cis	rs10090774	0.813	rs10098028	ENSG00000279766.1	RP11-642A1.2	-4.85	1.65e-06	0.000201	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141000954	chr8:140572142~140572812:-
THCA	cis	rs4925386	0.84	rs6143034	ENSG00000273619.1	RP5-908M14.9	-4.85	1.65e-06	0.000201	-0.19	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62386303~62386970:-
THCA	cis	rs7402982	0.625	rs4966009	ENSG00000278022.1	RP11-35O15.2	-4.85	1.65e-06	0.000201	-0.23	-0.22	Birth weight;	chr15:98660267	chr15:98660210~98660668:+
THCA	cis	rs17772222	1	rs12589467	ENSG00000222990.1	RNU4-22P	4.85	1.65e-06	0.000201	0.29	0.22	Coronary artery calcification;	chr14:88357239	chr14:88513498~88513663:+
THCA	cis	rs16846053	0.792	rs3849345	ENSG00000227403.1	AC009299.3	4.85	1.65e-06	0.000201	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161813045	chr2:161244739~161249050:+
THCA	cis	rs7088591	0.867	rs7099096	ENSG00000276818.1	AC026393.1	4.85	1.65e-06	0.000201	0.43	0.22	Blood pressure;	chr10:58018971	chr10:57095699~57095781:+
THCA	cis	rs7772486	0.686	rs9403739	ENSG00000270638.1	RP3-466P17.1	-4.85	1.65e-06	0.000201	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145735570~145737218:+
THCA	cis	rs12908161	0.959	rs17534709	ENSG00000275120.1	RP11-182J1.17	4.85	1.65e-06	0.000201	0.26	0.22	Schizophrenia;	chr15:84771166	chr15:84599434~84606463:-
THCA	cis	rs7618915	0.547	rs11130317	ENSG00000243224.1	RP5-1157M23.2	-4.85	1.65e-06	0.000201	-0.24	-0.22	Bipolar disorder;	chr3:52697467	chr3:52239258~52241097:+
THCA	cis	rs72843506	0.586	rs79246843	ENSG00000261033.1	RP11-209D14.2	4.85	1.66e-06	0.000201	0.42	0.22	Schizophrenia;	chr17:19938749	chr17:20008051~20009234:-
THCA	cis	rs763121	0.853	rs138705	ENSG00000235209.1	CTA-150C2.13	4.85	1.66e-06	0.000201	0.3	0.22	Menopause (age at onset);	chr22:38737798	chr22:38921227~38924708:+
THCA	cis	rs12999616	0.817	rs7425883	ENSG00000230606.9	AC159540.1	4.85	1.66e-06	0.000201	0.27	0.22	Colorectal cancer;	chr2:97715058	chr2:97416165~97433527:-
THCA	cis	rs6832769	0.925	rs2412663	ENSG00000272969.1	RP11-528I4.2	-4.85	1.66e-06	0.000201	-0.25	-0.22	Personality dimensions;	chr4:55589649	chr4:55547112~55547889:+
THCA	cis	rs62158800	0.925	rs884882	ENSG00000237880.1	AC096669.2	4.85	1.66e-06	0.000201	0.34	0.22	Facial morphology (factor 22);	chr2:107596156	chr2:107385632~107542649:-
THCA	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-4.85	1.66e-06	0.000201	-0.27	-0.22	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
THCA	cis	rs13434995	0.513	rs41324951	ENSG00000273257.1	RP11-177J6.1	4.85	1.66e-06	0.000201	0.33	0.22	Adiponectin levels;	chr4:55422576	chr4:55387949~55388271:+
THCA	cis	rs600231	0.542	rs10896009	ENSG00000245532.5	NEAT1	-4.85	1.66e-06	0.000201	-0.19	-0.22	Bone mineral density;	chr11:65478583	chr11:65422774~65445540:+
THCA	cis	rs17772222	0.636	rs10484010	ENSG00000222990.1	RNU4-22P	4.85	1.66e-06	0.000201	0.3	0.22	Coronary artery calcification;	chr14:88831944	chr14:88513498~88513663:+
THCA	cis	rs12935418	0.673	rs2549886	ENSG00000278985.1	RP11-303E16.9	-4.85	1.66e-06	0.000201	-0.24	-0.22	Mean corpuscular volume;	chr16:81027627	chr16:80982319~80984094:-
THCA	cis	rs12681288	0.676	rs2701914	ENSG00000260721.1	AF067845.1	4.85	1.66e-06	0.000201	0.27	0.22	Schizophrenia;	chr8:1049935	chr8:1368642~1369833:-
THCA	cis	rs11673344	0.504	rs6510588	ENSG00000276846.1	CTD-3220F14.3	-4.85	1.66e-06	0.000202	-0.17	-0.22	Obesity-related traits;	chr19:37106493	chr19:37314868~37315620:-
THCA	cis	rs6860806	0.507	rs273901	ENSG00000237714.1	P4HA2-AS1	4.85	1.66e-06	0.000202	0.29	0.22	Breast cancer;	chr5:132358667	chr5:132184876~132192808:+
THCA	cis	rs270601	0.913	rs273899	ENSG00000237714.1	P4HA2-AS1	4.85	1.66e-06	0.000202	0.29	0.22	Acylcarnitine levels;	chr5:132359485	chr5:132184876~132192808:+
THCA	cis	rs736408	0.677	rs2286798	ENSG00000243224.1	RP5-1157M23.2	4.85	1.66e-06	0.000202	0.24	0.22	Bipolar disorder;	chr3:52787161	chr3:52239258~52241097:+
THCA	cis	rs4713118	0.699	rs573179	ENSG00000261839.1	RP1-265C24.8	4.85	1.66e-06	0.000202	0.26	0.22	Parkinson's disease;	chr6:27881898	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.699	rs200978	ENSG00000261839.1	RP1-265C24.8	4.85	1.66e-06	0.000202	0.26	0.22	Parkinson's disease;	chr6:27885390	chr6:28136849~28139678:+
THCA	cis	rs2839186	0.708	rs6518285	ENSG00000215424.8	MCM3AP-AS1	4.85	1.66e-06	0.000202	0.13	0.22	Testicular germ cell tumor;	chr21:46224753	chr21:46229217~46259390:+
THCA	cis	rs113835537	0.935	rs76228630	ENSG00000255517.5	CTD-3074O7.5	-4.85	1.66e-06	0.000202	-0.24	-0.22	Airway imaging phenotypes;	chr11:66691205	chr11:66473490~66480233:-
THCA	cis	rs13113518	0.966	rs4864544	ENSG00000273257.1	RP11-177J6.1	4.85	1.66e-06	0.000202	0.28	0.22	Height;	chr4:55515292	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs6847529	ENSG00000273257.1	RP11-177J6.1	4.85	1.66e-06	0.000202	0.28	0.22	Height;	chr4:55518776	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs6822740	ENSG00000273257.1	RP11-177J6.1	4.85	1.66e-06	0.000202	0.28	0.22	Height;	chr4:55518922	chr4:55387949~55388271:+
THCA	cis	rs11673344	0.523	rs1402468	ENSG00000276846.1	CTD-3220F14.3	4.85	1.66e-06	0.000202	0.17	0.22	Obesity-related traits;	chr19:37129346	chr19:37314868~37315620:-
THCA	cis	rs4950322	0.515	rs11239954	ENSG00000226015.2	CCT8P1	4.85	1.66e-06	0.000202	0.25	0.22	Protein quantitative trait loci;	chr1:147246045	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.515	rs76327075	ENSG00000226015.2	CCT8P1	4.85	1.66e-06	0.000202	0.25	0.22	Protein quantitative trait loci;	chr1:147246319	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.515	rs11239958	ENSG00000226015.2	CCT8P1	4.85	1.66e-06	0.000202	0.25	0.22	Protein quantitative trait loci;	chr1:147247454	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.515	rs12060046	ENSG00000226015.2	CCT8P1	4.85	1.66e-06	0.000202	0.25	0.22	Protein quantitative trait loci;	chr1:147249278	chr1:147203276~147204932:-
THCA	cis	rs240993	0.812	rs459147	ENSG00000271789.1	RP5-1112D6.7	-4.85	1.66e-06	0.000202	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111370285	chr6:111297126~111298510:+
THCA	cis	rs1005277	0.579	rs176880	ENSG00000275858.1	RP11-291L22.8	-4.85	1.66e-06	0.000202	-0.26	-0.22	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38450738~38451069:-
THCA	cis	rs9840812	0.598	rs1145101	ENSG00000239213.4	NCK1-AS1	4.85	1.66e-06	0.000202	0.24	0.22	Fibrinogen levels;	chr3:136350444	chr3:136841726~136862054:-
THCA	cis	rs7083	0.653	rs573442	ENSG00000254851.1	RP11-109L13.1	4.85	1.66e-06	0.000202	0.3	0.22	Blood protein levels;	chr11:117307204	chr11:117135528~117138582:+
THCA	cis	rs1030877	0.515	rs2679893	ENSG00000235319.1	AC012360.4	-4.85	1.66e-06	0.000202	-0.29	-0.22	Obesity-related traits;	chr2:105293097	chr2:105324210~105330529:+
THCA	cis	rs2067615	0.579	rs12312782	ENSG00000260329.1	RP11-412D9.4	-4.85	1.66e-06	0.000202	-0.2	-0.22	Heart rate;	chr12:106741869	chr12:106954029~106955497:-
THCA	cis	rs172166	0.694	rs1150666	ENSG00000261839.1	RP1-265C24.8	4.85	1.66e-06	0.000202	0.24	0.22	Cardiac Troponin-T levels;	chr6:28156150	chr6:28136849~28139678:+
THCA	cis	rs62184315	0.52	rs62184268	ENSG00000253559.1	OSGEPL1-AS1	-4.85	1.66e-06	0.000202	-0.32	-0.22	Alcohol dependence (age at onset);	chr2:189767451	chr2:189762704~189765556:+
THCA	cis	rs1122401	0.515	rs2564985	ENSG00000280159.1	CTD-2591A1.1	4.85	1.66e-06	0.000202	0.31	0.22	Smoking initiation;	chr5:54568467	chr5:54643557~54645987:+
THCA	cis	rs172166	0.585	rs149963	ENSG00000176933.5	TOB2P1	-4.85	1.66e-06	0.000202	-0.24	-0.22	Cardiac Troponin-T levels;	chr6:28049354	chr6:28217643~28218634:-
THCA	cis	rs7267979	0.932	rs6037125	ENSG00000274973.1	RP13-401N8.7	-4.85	1.66e-06	0.000202	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25845497~25845862:+
THCA	cis	rs7674212	0.512	rs2720462	ENSG00000251288.2	RP11-10L12.2	-4.85	1.66e-06	0.000202	-0.28	-0.22	Type 2 diabetes;	chr4:103135053	chr4:102751401~102752641:+
THCA	cis	rs56114371	0.777	rs200483	ENSG00000280107.1	AL022393.9	-4.85	1.66e-06	0.000202	-0.33	-0.22	Breast cancer;	chr6:27807046	chr6:28170845~28172521:+
THCA	cis	rs10833905	0.756	rs10833870	ENSG00000246225.5	RP11-17A1.3	-4.85	1.66e-06	0.000202	-0.32	-0.22	Sudden cardiac arrest;	chr11:22967878	chr11:22829380~22945393:+
THCA	cis	rs10833905	0.701	rs4923047	ENSG00000246225.5	RP11-17A1.3	-4.85	1.66e-06	0.000202	-0.32	-0.22	Sudden cardiac arrest;	chr11:22970056	chr11:22829380~22945393:+
THCA	cis	rs9813712	0.595	rs16825656	ENSG00000249846.5	RP11-77P16.4	-4.85	1.67e-06	0.000202	-0.23	-0.22	Response to amphetamines;	chr3:130286225	chr3:130112550~130120579:+
THCA	cis	rs7131987	0.675	rs1436322	ENSG00000257176.2	RP11-996F15.2	4.85	1.67e-06	0.000202	0.22	0.22	QT interval;	chr12:29401872	chr12:29280418~29317848:-
THCA	cis	rs7429990	0.932	rs6442101	ENSG00000228638.1	FCF1P2	4.85	1.67e-06	0.000202	0.22	0.22	Educational attainment (years of education);	chr3:48089403	chr3:48290793~48291375:-
THCA	cis	rs6430538	0.621	rs6725916	ENSG00000224043.6	CCNT2-AS1	-4.85	1.67e-06	0.000202	-0.23	-0.22	Parkinson's disease;	chr2:134806488	chr2:134735464~134918710:-
THCA	cis	rs79349575	0.783	rs4399576	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48932473	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.687	rs12602179	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48932672	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs17708633	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48934258	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs9747646	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48939520	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs62075852	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48939814	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs12601858	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48940115	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.715	rs55724082	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48940517	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.749	rs8182364	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48940663	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.681	rs56080003	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48941687	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs4793995	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48942037	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs4793996	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48942235	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.715	rs4793997	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48942310	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs4793998	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48942537	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.749	rs2270574	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48944908	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.783	rs4794000	ENSG00000270781.1	RP11-501C14.9	-4.85	1.67e-06	0.000202	-0.26	-0.22	Type 2 diabetes;	chr17:48945393	chr17:48899131~48899748:+
THCA	cis	rs11018904	0.768	rs56160356	ENSG00000280385.1	AP000648.5	-4.85	1.67e-06	0.000202	-0.33	-0.22	Intelligence (multi-trait analysis);	chr11:90254112	chr11:90193614~90198120:+
THCA	cis	rs793571	0.554	rs12900343	ENSG00000245975.2	RP11-30K9.6	4.85	1.67e-06	0.000202	0.26	0.22	Schizophrenia;	chr15:58731507	chr15:58768072~58770974:-
THCA	cis	rs11051970	0.636	rs1128591	ENSG00000274964.1	RP11-817I4.1	-4.85	1.67e-06	0.000202	-0.23	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32416417	chr12:32339368~32340724:+
THCA	cis	rs7394190	0.748	rs11000775	ENSG00000271816.1	BMS1P4	-4.85	1.67e-06	0.000202	-0.27	-0.22	Incident atrial fibrillation;	chr10:73779252	chr10:73699151~73730487:-
THCA	cis	rs28386778	0.765	rs2070680	ENSG00000240280.5	TCAM1P	4.85	1.67e-06	0.000202	0.3	0.22	Prudent dietary pattern;	chr17:63909628	chr17:63849292~63864379:+
THCA	cis	rs4578769	0.55	rs4800435	ENSG00000265939.1	UBE2CP2	4.85	1.67e-06	0.000202	0.25	0.22	Eosinophil percentage of white cells;	chr18:22862923	chr18:22900486~22900995:-
THCA	cis	rs2803122	0.934	rs10119618	ENSG00000273226.1	RP11-513M16.8	-4.85	1.67e-06	0.000202	-0.2	-0.22	Pulse pressure;	chr9:19251643	chr9:19375451~19375996:+
THCA	cis	rs4660214	0.666	rs663892	ENSG00000182109.6	RP11-69E11.4	4.85	1.67e-06	0.000202	0.21	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39424005	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs1180384	ENSG00000182109.6	RP11-69E11.4	4.85	1.67e-06	0.000202	0.21	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427102	chr1:39522280~39546187:-
THCA	cis	rs7260598	0.605	rs78358879	ENSG00000268442.1	CTD-2027I19.2	4.85	1.67e-06	0.000203	0.32	0.22	Response to taxane treatment (placlitaxel);	chr19:23904434	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs10424758	ENSG00000268442.1	CTD-2027I19.2	4.85	1.67e-06	0.000203	0.32	0.22	Response to taxane treatment (placlitaxel);	chr19:23907698	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs10425192	ENSG00000268442.1	CTD-2027I19.2	4.85	1.67e-06	0.000203	0.32	0.22	Response to taxane treatment (placlitaxel);	chr19:23907909	chr19:24162370~24163425:-
THCA	cis	rs13160562	0.527	rs152479	ENSG00000248734.2	CTD-2260A17.1	4.85	1.67e-06	0.000203	0.22	0.22	Alcohol dependence;	chr5:96769339	chr5:96784777~96785999:+
THCA	cis	rs13160562	0.527	rs25863	ENSG00000248734.2	CTD-2260A17.1	4.85	1.67e-06	0.000203	0.22	0.22	Alcohol dependence;	chr5:96770222	chr5:96784777~96785999:+
THCA	cis	rs13160562	0.527	rs27581	ENSG00000248734.2	CTD-2260A17.1	4.85	1.67e-06	0.000203	0.22	0.22	Alcohol dependence;	chr5:96772070	chr5:96784777~96785999:+
THCA	cis	rs829883	0.966	rs249853	ENSG00000227825.4	SLC9A7P1	4.85	1.67e-06	0.000203	0.21	0.22	Colorectal adenoma (advanced);	chr12:98471130	chr12:98453835~98457145:-
THCA	cis	rs2440129	0.632	rs13396	ENSG00000262089.1	RP11-589P10.5	4.85	1.67e-06	0.000203	0.2	0.22	Tonsillectomy;	chr17:7002305	chr17:6994642~6995189:-
THCA	cis	rs3177980	0.559	rs12089057	ENSG00000239494.2	RN7SL333P	-4.85	1.67e-06	0.000203	-0.22	-0.22	Amyotrophic lateral sclerosis;	chr1:169876615	chr1:169859756~169860052:+
THCA	cis	rs7267979	0.873	rs7453	ENSG00000274973.1	RP13-401N8.7	-4.85	1.67e-06	0.000203	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25845497~25845862:+
THCA	cis	rs9921338	0.597	rs181582	ENSG00000262703.1	RP11-485G7.6	-4.85	1.67e-06	0.000203	-0.3	-0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249690	chr16:11348143~11349321:-
THCA	cis	rs944289	0.774	rs8013429	ENSG00000258844.1	RP11-259K15.2	4.85	1.67e-06	0.000203	0.2	0.22	Thyroid cancer;	chr14:36131855	chr14:36214607~36235608:+
THCA	cis	rs957448	0.948	rs11992893	ENSG00000253175.1	RP11-267M23.6	4.85	1.67e-06	0.000203	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94565036~94565715:+
THCA	cis	rs957448	1	rs1048029	ENSG00000253175.1	RP11-267M23.6	4.85	1.67e-06	0.000203	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94565036~94565715:+
THCA	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-4.85	1.67e-06	0.000203	-0.15	-0.22	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
THCA	cis	rs651907	0.535	rs2290859	ENSG00000244119.1	PDCL3P4	4.85	1.67e-06	0.000203	0.2	0.22	Colorectal cancer;	chr3:101806781	chr3:101712472~101713191:+
THCA	cis	rs1707322	0.964	rs785516	ENSG00000281133.1	AL355480.3	4.85	1.67e-06	0.000203	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs785517	ENSG00000281133.1	AL355480.3	4.85	1.67e-06	0.000203	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45580892~45580996:-
THCA	cis	rs2692947	0.759	rs2949885	ENSG00000232931.4	LINC00342	4.85	1.67e-06	0.000203	0.17	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95996667	chr2:95807118~95816215:-
THCA	cis	rs911555	0.655	rs10149470	ENSG00000269940.1	RP11-73M18.7	4.85	1.67e-06	0.000203	0.22	0.22	Intelligence (multi-trait analysis);	chr14:103551616	chr14:103694560~103695170:+
THCA	cis	rs9910055	0.659	rs7212573	ENSG00000267080.4	ASB16-AS1	-4.85	1.67e-06	0.000203	-0.19	-0.22	Total body bone mineral density;	chr17:44176913	chr17:44175973~44186717:-
THCA	cis	rs2239547	0.657	rs3755803	ENSG00000242142.1	SERBP1P3	4.85	1.67e-06	0.000203	0.28	0.22	Schizophrenia;	chr3:52832141	chr3:53064283~53065091:-
THCA	cis	rs9880211	0.635	rs10049233	ENSG00000273486.1	RP11-731C17.2	4.85	1.67e-06	0.000203	0.23	0.22	Height;Body mass index;	chr3:136066627	chr3:136837338~136839021:-
THCA	cis	rs9843304	0.528	rs9880421	ENSG00000240541.2	TM4SF1-AS1	-4.85	1.67e-06	0.000203	-0.21	-0.22	Gallstone disease;	chr3:149465572	chr3:149377778~149386583:+
THCA	cis	rs8062405	0.755	rs2077031	ENSG00000261766.1	RP11-22P6.2	-4.85	1.67e-06	0.000203	-0.22	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28862166~28863340:-
THCA	cis	rs7914558	1	rs10786733	ENSG00000236937.2	PTGES3P4	4.85	1.67e-06	0.000203	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103035190	chr10:102845595~102845950:+
THCA	cis	rs7474896	0.583	rs12783272	ENSG00000263064.2	RP11-291L22.7	4.85	1.67e-06	0.000203	0.3	0.22	Obesity (extreme);	chr10:37735957	chr10:38448689~38448949:+
THCA	cis	rs10510102	0.748	rs11200297	ENSG00000226864.1	ATE1-AS1	4.85	1.67e-06	0.000203	0.36	0.22	Breast cancer;	chr10:121972916	chr10:121928312~121951965:+
THCA	cis	rs11671005	0.695	rs8106061	ENSG00000265272.2	RN7SL693P	4.85	1.67e-06	0.000203	0.3	0.22	Mean platelet volume;	chr19:58406623	chr19:58490797~58491075:+
THCA	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-4.85	1.67e-06	0.000203	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-4.85	1.67e-06	0.000203	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
THCA	cis	rs17818399	0.781	rs13024534	ENSG00000279254.1	RP11-536C12.1	-4.85	1.67e-06	0.000203	-0.23	-0.22	Height;	chr2:46632247	chr2:46668870~46670778:+
THCA	cis	rs9625935	0.957	rs737904	ENSG00000279159.1	RP3-394A18.1	-4.85	1.67e-06	0.000203	-0.17	-0.22	Tonsillectomy;	chr22:29952663	chr22:29978950~30028236:-
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000164669.11	INTS4P1	4.85	1.67e-06	0.000203	0.42	0.22	Diabetic kidney disease;	chr7:65970805	chr7:65141225~65234216:+
THCA	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-4.85	1.68e-06	0.000203	-0.25	-0.22	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
THCA	cis	rs13256369	0.708	rs9644772	ENSG00000253893.2	FAM85B	-4.85	1.68e-06	0.000203	-0.31	-0.22	Obesity-related traits;	chr8:8700175	chr8:8167819~8226614:-
THCA	cis	rs4415084	0.716	rs16901964	ENSG00000272335.1	RP11-53O19.3	-4.85	1.68e-06	0.000203	-0.19	-0.22	Breast cancer;	chr5:44783153	chr5:44826076~44828592:+
THCA	cis	rs1023500	0.596	rs5751204	ENSG00000273366.1	CTA-989H11.1	-4.85	1.68e-06	0.000203	-0.29	-0.22	Schizophrenia;	chr22:42037797	chr22:42278188~42278846:+
THCA	cis	rs6997458	0.774	rs6984619	ENSG00000253549.4	RP11-317J10.2	4.85	1.68e-06	0.000203	0.22	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85419149	chr8:85441851~85464915:-
THCA	cis	rs250518	0.926	rs34749191	ENSG00000272081.1	CTD-2376I4.2	4.85	1.68e-06	0.000203	0.28	0.22	Mean corpuscular hemoglobin concentration;	chr5:72749431	chr5:72955206~72955699:-
THCA	cis	rs12908161	0.959	rs2175567	ENSG00000188388.10	GOLGA6L3	4.85	1.68e-06	0.000203	0.29	0.22	Schizophrenia;	chr15:84657715	chr15:85240472~85247170:+
THCA	cis	rs8020095	0.571	rs7151898	ENSG00000258561.1	RP11-72M17.1	-4.85	1.68e-06	0.000203	-0.29	-0.22	Depression (quantitative trait);	chr14:67159877	chr14:66212810~66509394:-
THCA	cis	rs7429990	0.932	rs11720151	ENSG00000228638.1	FCF1P2	4.85	1.68e-06	0.000203	0.21	0.22	Educational attainment (years of education);	chr3:48099144	chr3:48290793~48291375:-
THCA	cis	rs9329221	0.655	rs656319	ENSG00000248538.5	RP11-10A14.5	4.85	1.68e-06	0.000203	0.28	0.22	Neuroticism;	chr8:9956901	chr8:9189011~9202854:+
THCA	cis	rs45509595	0.841	rs200485	ENSG00000280107.1	AL022393.9	-4.85	1.68e-06	0.000204	-0.33	-0.22	Breast cancer;	chr6:27807919	chr6:28170845~28172521:+
THCA	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-4.85	1.68e-06	0.000204	-0.25	-0.22	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
THCA	cis	rs7412746	0.658	rs4970987	ENSG00000231073.1	RP11-316M1.3	4.85	1.68e-06	0.000204	0.27	0.22	Melanoma;	chr1:150977206	chr1:150973123~150975534:+
THCA	cis	rs875971	0.706	rs1643374	ENSG00000229886.1	RP5-1132H15.3	4.85	1.68e-06	0.000204	0.22	0.22	Aortic root size;	chr7:66407695	chr7:66025126~66031544:-
THCA	cis	rs7223535	1	rs7223535	ENSG00000266490.1	CTD-2349P21.9	4.85	1.68e-06	0.000204	0.22	0.22	Breast cancer;	chr17:30884649	chr17:30792372~30792833:+
THCA	cis	rs8046148	0.724	rs2287197	ENSG00000279356.1	RP11-429P3.8	4.85	1.68e-06	0.000204	0.26	0.22	Testicular germ cell tumor;	chr16:50072683	chr16:50072862~50074986:+
THCA	cis	rs989128	0.6	rs916978	ENSG00000250286.1	RP11-94C24.8	-4.85	1.68e-06	0.000204	-0.21	-0.22	Type 2 diabetes;	chr17:50553091	chr17:50537294~50538754:-
THCA	cis	rs8020095	0.571	rs7161664	ENSG00000258561.1	RP11-72M17.1	4.85	1.68e-06	0.000204	0.29	0.22	Depression (quantitative trait);	chr14:67057770	chr14:66212810~66509394:-
THCA	cis	rs853679	0.546	rs175597	ENSG00000280107.1	AL022393.9	-4.85	1.68e-06	0.000204	-0.33	-0.22	Depression;	chr6:27842848	chr6:28170845~28172521:+
THCA	cis	rs853679	0.546	rs200989	ENSG00000280107.1	AL022393.9	-4.85	1.68e-06	0.000204	-0.33	-0.22	Depression;	chr6:27848664	chr6:28170845~28172521:+
THCA	cis	rs6449502	0.764	rs702564	ENSG00000251279.1	CTC-436P18.1	4.85	1.68e-06	0.000204	0.36	0.22	Mean platelet volume;	chr5:60752147	chr5:61162070~61232040:+
THCA	cis	rs2243480	1	rs1723267	ENSG00000164669.11	INTS4P1	4.85	1.68e-06	0.000204	0.42	0.22	Diabetic kidney disease;	chr7:66008327	chr7:65141225~65234216:+
THCA	cis	rs7394190	1	rs7394190	ENSG00000271816.1	BMS1P4	-4.85	1.68e-06	0.000204	-0.24	-0.22	Incident atrial fibrillation;	chr10:73661890	chr10:73699151~73730487:-
THCA	cis	rs9813712	1	rs9813712	ENSG00000253540.4	FAM86HP	4.85	1.68e-06	0.000204	0.27	0.22	Response to amphetamines;	chr3:130252258	chr3:130099092~130111472:-
THCA	cis	rs728616	0.614	rs55720611	ENSG00000242600.5	MBL1P	4.85	1.68e-06	0.000204	0.27	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030543	chr10:79904898~79950336:+
THCA	cis	rs6490294	0.571	rs2272308	ENSG00000226469.1	ADAM1B	4.85	1.68e-06	0.000204	0.32	0.22	Mean platelet volume;	chr12:112163446	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7973898	ENSG00000226469.1	ADAM1B	4.85	1.68e-06	0.000204	0.32	0.22	Mean platelet volume;	chr12:112178363	chr12:111927018~111929017:+
THCA	cis	rs2985684	0.895	rs3007033	ENSG00000278009.1	RP11-649E7.8	4.85	1.68e-06	0.000204	0.31	0.22	Carotid intima media thickness;	chr14:49637098	chr14:49601011~49601124:-
THCA	cis	rs13434995	0.513	rs62303726	ENSG00000273257.1	RP11-177J6.1	-4.85	1.68e-06	0.000204	-0.33	-0.22	Adiponectin levels;	chr4:55490415	chr4:55387949~55388271:+
THCA	cis	rs10090774	0.965	rs11781505	ENSG00000279766.1	RP11-642A1.2	-4.85	1.68e-06	0.000204	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140923630	chr8:140572142~140572812:-
THCA	cis	rs454422	0.556	rs6053817	ENSG00000275632.1	RP5-967N21.11	4.85	1.68e-06	0.000204	0.24	0.22	HIV-1 viral setpoint;	chr20:6000052	chr20:6000418~6000941:+
THCA	cis	rs9393777	0.841	rs34332556	ENSG00000280107.1	AL022393.9	-4.85	1.68e-06	0.000204	-0.38	-0.22	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28170845~28172521:+
THCA	cis	rs2439831	0.702	rs2467402	ENSG00000166763.7	STRCP1	-4.85	1.68e-06	0.000204	-0.29	-0.22	Lung cancer in ever smokers;	chr15:43732292	chr15:43699488~43718184:-
THCA	cis	rs10510102	0.872	rs11200268	ENSG00000226864.1	ATE1-AS1	4.85	1.68e-06	0.000204	0.36	0.22	Breast cancer;	chr10:121932661	chr10:121928312~121951965:+
THCA	cis	rs1048886	0.872	rs6940416	ENSG00000271967.1	RP11-134K13.4	-4.85	1.69e-06	0.000204	-0.22	-0.22	Type 2 diabetes;	chr6:70543615	chr6:70596438~70596980:+
THCA	cis	rs2742234	0.955	rs2435385	ENSG00000273008.1	RP11-351D16.3	-4.85	1.69e-06	0.000204	-0.19	-0.22	Hirschsprung disease;	chr10:43170302	chr10:43136824~43138334:-
THCA	cis	rs72799341	0.706	rs11865499	ENSG00000260911.2	RP11-196G11.2	4.85	1.69e-06	0.000204	0.19	0.22	Diastolic blood pressure;	chr16:31120929	chr16:31043150~31049868:+
THCA	cis	rs6017291	0.623	rs73106290	ENSG00000223891.4	OSER1-AS1	4.85	1.69e-06	0.000204	0.26	0.22	Cognitive performance;	chr20:44214631	chr20:44210960~44226027:+
THCA	cis	rs6017291	0.793	rs73106293	ENSG00000223891.4	OSER1-AS1	4.85	1.69e-06	0.000204	0.26	0.22	Cognitive performance;	chr20:44215289	chr20:44210960~44226027:+
THCA	cis	rs6017291	0.793	rs12624924	ENSG00000223891.4	OSER1-AS1	4.85	1.69e-06	0.000204	0.26	0.22	Cognitive performance;	chr20:44216629	chr20:44210960~44226027:+
THCA	cis	rs6017291	0.793	rs45472797	ENSG00000223891.4	OSER1-AS1	4.85	1.69e-06	0.000204	0.26	0.22	Cognitive performance;	chr20:44217425	chr20:44210960~44226027:+
THCA	cis	rs440932	0.798	rs330942	ENSG00000253893.2	FAM85B	-4.85	1.69e-06	0.000205	-0.27	-0.22	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8167819~8226614:-
THCA	cis	rs9925964	0.933	rs2303223	ENSG00000260911.2	RP11-196G11.2	-4.85	1.69e-06	0.000205	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31063854	chr16:31043150~31049868:+
THCA	cis	rs8050907	0.744	rs8047271	ENSG00000278434.1	RP11-709D24.8	-4.85	1.69e-06	0.000205	-0.48	-0.22	Obesity-related traits;	chr16:4486633	chr16:4532216~4533670:-
THCA	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	4.85	1.69e-06	0.000205	0.13	0.22	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
THCA	cis	rs1577917	0.561	rs3087978	ENSG00000220563.1	PKMP3	4.85	1.69e-06	0.000205	0.16	0.22	Response to antipsychotic treatment;	chr6:85678505	chr6:85659892~85660606:-
THCA	cis	rs10208649	1	rs13387291	ENSG00000233266.1	HMGB1P31	4.85	1.69e-06	0.000205	0.51	0.22	Body mass index;	chr2:53808114	chr2:54051334~54051760:+
THCA	cis	rs2692947	0.794	rs2692949	ENSG00000232931.4	LINC00342	4.85	1.69e-06	0.000205	0.18	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007777	chr2:95807118~95816215:-
THCA	cis	rs1823874	0.71	rs56160817	ENSG00000259363.4	CTD-2054N24.2	4.85	1.69e-06	0.000205	0.27	0.22	IgG glycosylation;	chr15:99820472	chr15:99807023~99877148:+
THCA	cis	rs911555	0.755	rs1116095	ENSG00000244691.1	RPL10AP1	4.85	1.69e-06	0.000205	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs8010247	ENSG00000244691.1	RPL10AP1	4.85	1.69e-06	0.000205	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs55742283	ENSG00000244691.1	RPL10AP1	4.85	1.69e-06	0.000205	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs8014800	ENSG00000244691.1	RPL10AP1	4.85	1.69e-06	0.000205	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs12435516	ENSG00000244691.1	RPL10AP1	4.85	1.69e-06	0.000205	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs2756135	ENSG00000244691.1	RPL10AP1	4.85	1.69e-06	0.000205	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103412119~103412761:-
THCA	cis	rs13113518	0.902	rs11133386	ENSG00000273257.1	RP11-177J6.1	4.85	1.69e-06	0.000205	0.28	0.22	Height;	chr4:55461320	chr4:55387949~55388271:+
THCA	cis	rs17594362	0.512	rs348247	ENSG00000264190.1	MIR5006	-4.85	1.69e-06	0.000205	-0.33	-0.22	Multiple sclerosis;	chr13:41552478	chr13:41568286~41568395:-
THCA	cis	rs4950322	0.57	rs72691090	ENSG00000271721.1	RP11-337C18.9	4.85	1.69e-06	0.000205	0.25	0.22	Protein quantitative trait loci;	chr1:147297884	chr1:147175602~147177740:+
THCA	cis	rs12681288	0.645	rs2600509	ENSG00000260721.1	AF067845.1	-4.85	1.69e-06	0.000205	-0.27	-0.22	Schizophrenia;	chr8:1039022	chr8:1368642~1369833:-
THCA	cis	rs6545883	0.929	rs2421203	ENSG00000270820.4	RP11-355B11.2	4.85	1.69e-06	0.000205	0.19	0.22	Tuberculosis;	chr2:61442113	chr2:61471188~61484130:+
THCA	cis	rs896854	0.846	rs7845219	ENSG00000253528.2	RP11-347C18.4	4.85	1.69e-06	0.000205	0.25	0.22	Type 2 diabetes;	chr8:94925274	chr8:94974573~94974853:-
THCA	cis	rs72843506	0.656	rs56138907	ENSG00000261033.1	RP11-209D14.2	4.85	1.69e-06	0.000205	0.39	0.22	Schizophrenia;	chr17:20085732	chr17:20008051~20009234:-
THCA	cis	rs2034650	0.544	rs2289331	ENSG00000223313.1	RNU6-516P	4.85	1.69e-06	0.000205	0.24	0.22	Interstitial lung disease;	chr15:40407739	chr15:40529570~40529673:+
THCA	cis	rs6138458	1	rs227629	ENSG00000274173.1	RP4-568C11.4	4.85	1.69e-06	0.000205	0.21	0.22	Blood protein levels;	chr20:24932915	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs227630	ENSG00000274173.1	RP4-568C11.4	4.85	1.69e-06	0.000205	0.21	0.22	Blood protein levels;	chr20:24932948	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs227631	ENSG00000274173.1	RP4-568C11.4	4.85	1.69e-06	0.000205	0.21	0.22	Blood protein levels;	chr20:24933017	chr20:24931840~24932983:+
THCA	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-4.85	1.69e-06	0.000205	-0.32	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
THCA	cis	rs1479090	0.804	rs11941112	ENSG00000250027.1	RP11-563E2.2	-4.85	1.69e-06	0.000205	-0.24	-0.22	Lung cancer;	chr4:163092728	chr4:163108785~163119965:+
THCA	cis	rs12893668	0.703	rs729438	ENSG00000269958.1	RP11-73M18.8	-4.85	1.69e-06	0.000205	-0.21	-0.22	Reticulocyte count;	chr14:103626452	chr14:103696353~103697163:+
THCA	cis	rs11894081	0.808	rs7421626	ENSG00000232835.1	AC107057.1	4.85	1.69e-06	0.000205	0.22	0.22	Crohn's disease;	chr2:5522335	chr2:5549780~5556031:-
THCA	cis	rs9890032	0.532	rs1808257	ENSG00000264538.5	SUZ12P1	-4.85	1.69e-06	0.000205	-0.16	-0.22	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30709299~30790908:+
THCA	cis	rs8030379	0.519	rs11259926	ENSG00000230373.7	GOLGA6L5P	-4.85	1.69e-06	0.000205	-0.23	-0.22	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897496	chr15:84507885~84516814:-
THCA	cis	rs17507216	1	rs17507216	ENSG00000255769.6	GOLGA2P10	4.85	1.69e-06	0.000205	0.32	0.22	Excessive daytime sleepiness;	chr15:82558175	chr15:82472993~82513950:-
THCA	cis	rs4415084	0.804	rs7705343	ENSG00000272335.1	RP11-53O19.3	-4.85	1.69e-06	0.000205	-0.18	-0.22	Breast cancer;	chr5:44879475	chr5:44826076~44828592:+
THCA	cis	rs10833905	0.756	rs12286745	ENSG00000246225.5	RP11-17A1.3	-4.85	1.69e-06	0.000205	-0.32	-0.22	Sudden cardiac arrest;	chr11:22980573	chr11:22829380~22945393:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000213640.3	EEF1DP4	4.85	1.69e-06	0.000205	0.25	0.22	Aortic root size;	chr7:65800193	chr7:64862999~64864370:+
THCA	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-4.85	1.69e-06	0.000205	-0.27	-0.22	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
THCA	cis	rs1395	1	rs1395	ENSG00000234072.1	AC074117.10	4.85	1.69e-06	0.000205	0.18	0.22	Blood metabolite levels;	chr2:27201768	chr2:27356246~27367622:+
THCA	cis	rs8058578	0.887	rs28421305	ENSG00000279196.1	RP11-1072A3.3	4.85	1.69e-06	0.000205	0.22	0.22	Multiple myeloma;	chr16:30826807	chr16:30984630~30988270:-
THCA	cis	rs7131987	1	rs7131987	ENSG00000257176.2	RP11-996F15.2	-4.85	1.7e-06	0.000205	-0.22	-0.22	QT interval;	chr12:29253555	chr12:29280418~29317848:-
THCA	cis	rs2692947	0.832	rs2438972	ENSG00000232931.4	LINC00342	4.85	1.7e-06	0.000205	0.18	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96025125	chr2:95807118~95816215:-
THCA	cis	rs13434995	0.589	rs861029	ENSG00000273257.1	RP11-177J6.1	-4.85	1.7e-06	0.000206	-0.34	-0.22	Adiponectin levels;	chr4:55379470	chr4:55387949~55388271:+
THCA	cis	rs2361701	0.929	rs1561810	ENSG00000275479.1	RP11-334C17.6	4.85	1.7e-06	0.000206	0.23	0.22	IgG glycosylation;	chr17:80095525	chr17:80149627~80149798:+
THCA	cis	rs2337406	0.587	rs10139664	ENSG00000211974.3	IGHV2-70	-4.85	1.7e-06	0.000206	-0.21	-0.22	Alzheimer's disease (late onset);	chr14:106647254	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.587	rs10129888	ENSG00000211974.3	IGHV2-70	-4.85	1.7e-06	0.000206	-0.21	-0.22	Alzheimer's disease (late onset);	chr14:106647421	chr14:106723574~106724093:-
THCA	cis	rs9973361	0.513	rs13421971	ENSG00000232411.1	AC009495.3	-4.85	1.7e-06	0.000206	-0.27	-0.22	Total body bone mineral density;	chr2:165855094	chr2:165833048~165839098:-
THCA	cis	rs1836229	0.594	rs1865338	ENSG00000225706.1	PTPRD-AS1	-4.85	1.7e-06	0.000206	-0.26	-0.22	Restless legs syndrome;	chr9:8829992	chr9:8858130~8862255:+
THCA	cis	rs4061073	1	rs4061073	ENSG00000198711.5	SSBP3-AS1	4.85	1.7e-06	0.000206	0.2	0.22	Body mass index;	chr1:54231070	chr1:54236440~54239063:+
THCA	cis	rs849141	0.961	rs702815	ENSG00000234336.5	JAZF1-AS1	-4.85	1.7e-06	0.000206	-0.25	-0.22	Height;Hip circumference adjusted for BMI;	chr7:28133903	chr7:28180322~28243917:+
THCA	cis	rs849141	0.961	rs849136	ENSG00000234336.5	JAZF1-AS1	-4.85	1.7e-06	0.000206	-0.25	-0.22	Height;Hip circumference adjusted for BMI;	chr7:28135338	chr7:28180322~28243917:+
THCA	cis	rs849141	0.961	rs849137	ENSG00000234336.5	JAZF1-AS1	-4.85	1.7e-06	0.000206	-0.25	-0.22	Height;Hip circumference adjusted for BMI;	chr7:28135671	chr7:28180322~28243917:+
THCA	cis	rs1552244	0.554	rs6800204	ENSG00000232901.1	CYCSP10	4.85	1.7e-06	0.000206	0.26	0.22	Alzheimer's disease;	chr3:9953720	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs6762594	ENSG00000232901.1	CYCSP10	4.85	1.7e-06	0.000206	0.26	0.22	Alzheimer's disease;	chr3:9953832	chr3:10000647~10000940:-
THCA	cis	rs1552244	0.554	rs3846167	ENSG00000232901.1	CYCSP10	4.85	1.7e-06	0.000206	0.26	0.22	Alzheimer's disease;	chr3:9954742	chr3:10000647~10000940:-
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000229886.1	RP5-1132H15.3	4.85	1.7e-06	0.000206	0.23	0.22	Calcium levels;	chr7:65967580	chr7:66025126~66031544:-
THCA	cis	rs6921919	0.609	rs1005127	ENSG00000280107.1	AL022393.9	-4.85	1.7e-06	0.000206	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28170845~28172521:+
THCA	cis	rs853679	0.515	rs4580862	ENSG00000280107.1	AL022393.9	-4.85	1.7e-06	0.000206	-0.22	-0.22	Depression;	chr6:28399886	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs4357130	ENSG00000280107.1	AL022393.9	-4.85	1.7e-06	0.000206	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28170845~28172521:+
THCA	cis	rs11148252	0.574	rs61958118	ENSG00000273784.3	RP11-78J21.7	-4.85	1.7e-06	0.000206	-0.23	-0.22	Lewy body disease;	chr13:52596091	chr13:52600042~52642542:+
THCA	cis	rs27434	0.605	rs39840	ENSG00000272109.1	CTD-2260A17.3	-4.85	1.7e-06	0.000206	-0.34	-0.22	Ankylosing spondylitis;	chr5:96784350	chr5:96804353~96806105:+
THCA	cis	rs2282300	0.637	rs7942037	ENSG00000242353.1	RP4-710M3.1	-4.85	1.7e-06	0.000206	-0.18	-0.22	Morning vs. evening chronotype;	chr11:30408785	chr11:30368148~30368646:+
THCA	cis	rs2734839	0.964	rs4938017	ENSG00000270179.1	RP11-159N11.4	4.85	1.7e-06	0.000206	0.23	0.22	Information processing speed;	chr11:113433207	chr11:113368478~113369117:+
THCA	cis	rs5758659	0.652	rs5751195	ENSG00000227370.1	RP4-669P10.19	-4.85	1.7e-06	0.000206	-0.2	-0.22	Cognitive function;	chr22:41983997	chr22:42132543~42132998:+
THCA	cis	rs6044112	0.718	rs6080286	ENSG00000273998.1	RP4-777L9.2	4.85	1.7e-06	0.000206	0.34	0.22	Response to taxane treatment (docetaxel);	chr20:16529379	chr20:16576068~16579615:+
THCA	cis	rs6570726	0.967	rs9403706	ENSG00000270638.1	RP3-466P17.1	-4.85	1.7e-06	0.000206	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145735570~145737218:+
THCA	cis	rs375066	0.551	rs73052639	ENSG00000267058.1	RP11-15A1.3	4.85	1.7e-06	0.000206	0.2	0.22	Breast cancer;	chr19:43830077	chr19:43891804~43901805:-
THCA	cis	rs6088590	1	rs2378256	ENSG00000276073.1	RP5-1125A11.7	-4.85	1.7e-06	0.000206	-0.2	-0.22	Coronary artery disease;	chr20:34704323	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.965	rs910869	ENSG00000276073.1	RP5-1125A11.7	-4.85	1.7e-06	0.000206	-0.2	-0.22	Coronary artery disease;	chr20:34704973	chr20:33985617~33988989:-
THCA	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	4.85	1.7e-06	0.000206	0.32	0.22	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
THCA	cis	rs8020095	0.528	rs6573760	ENSG00000258561.1	RP11-72M17.1	-4.85	1.7e-06	0.000206	-0.28	-0.22	Depression (quantitative trait);	chr14:67210658	chr14:66212810~66509394:-
THCA	cis	rs6570726	0.967	rs373527	ENSG00000270638.1	RP3-466P17.1	4.85	1.7e-06	0.000206	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145735570~145737218:+
THCA	cis	rs7577696	0.888	rs494569	ENSG00000276334.1	AL133243.1	4.85	1.7e-06	0.000206	0.23	0.22	Inflammatory biomarkers;	chr2:32244553	chr2:32521927~32523547:+
THCA	cis	rs919433	0.927	rs1429412	ENSG00000231621.1	AC013264.2	4.85	1.7e-06	0.000206	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197326170	chr2:197197991~197199273:+
THCA	cis	rs919433	0.927	rs3843857	ENSG00000231621.1	AC013264.2	4.85	1.7e-06	0.000206	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197331241	chr2:197197991~197199273:+
THCA	cis	rs875971	0.505	rs2462573	ENSG00000229886.1	RP5-1132H15.3	-4.85	1.7e-06	0.000206	-0.22	-0.22	Aortic root size;	chr7:66042405	chr7:66025126~66031544:-
THCA	cis	rs9393777	0.841	rs13207082	ENSG00000220721.1	OR1F12	4.85	1.7e-06	0.000206	0.43	0.22	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28073316~28074233:+
THCA	cis	rs752010	0.574	rs2148636	ENSG00000230638.4	RP11-486B10.4	4.85	1.7e-06	0.000206	0.24	0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41654173	chr1:41542069~41544310:+
THCA	cis	rs1150668	0.799	rs1150705	ENSG00000176933.5	TOB2P1	-4.85	1.7e-06	0.000206	-0.24	-0.22	Pubertal anthropometrics;	chr6:28226008	chr6:28217643~28218634:-
THCA	cis	rs10510102	0.872	rs7916008	ENSG00000226864.1	ATE1-AS1	4.85	1.7e-06	0.000206	0.35	0.22	Breast cancer;	chr10:121943578	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs7916380	ENSG00000226864.1	ATE1-AS1	4.85	1.7e-06	0.000206	0.35	0.22	Breast cancer;	chr10:121943773	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.808	rs7920024	ENSG00000226864.1	ATE1-AS1	4.85	1.7e-06	0.000206	0.35	0.22	Breast cancer;	chr10:121944063	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.688	rs74570569	ENSG00000226864.1	ATE1-AS1	4.85	1.7e-06	0.000206	0.35	0.22	Breast cancer;	chr10:121945347	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs7076727	ENSG00000226864.1	ATE1-AS1	4.85	1.7e-06	0.000206	0.35	0.22	Breast cancer;	chr10:121947000	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.745	rs7076882	ENSG00000226864.1	ATE1-AS1	4.85	1.7e-06	0.000206	0.35	0.22	Breast cancer;	chr10:121947039	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs7077035	ENSG00000226864.1	ATE1-AS1	4.85	1.7e-06	0.000206	0.35	0.22	Breast cancer;	chr10:121947130	chr10:121928312~121951965:+
THCA	cis	rs5758659	0.714	rs6002607	ENSG00000182057.4	OGFRP1	-4.85	1.7e-06	0.000206	-0.25	-0.22	Cognitive function;	chr22:42100502	chr22:42269753~42275196:+
THCA	cis	rs950169	0.519	rs7237	ENSG00000275120.1	RP11-182J1.17	4.85	1.7e-06	0.000206	0.26	0.22	Schizophrenia;	chr15:84643346	chr15:84599434~84606463:-
THCA	cis	rs7829975	0.606	rs7819827	ENSG00000254153.1	CTA-398F10.2	4.85	1.7e-06	0.000206	0.24	0.22	Mood instability;	chr8:8939545	chr8:8456909~8461337:-
THCA	cis	rs12612619	0.732	rs2053385	ENSG00000229122.1	AGBL5-IT1	4.85	1.7e-06	0.000206	0.15	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27008277	chr2:27061038~27061815:+
THCA	cis	rs12612619	0.732	rs1465881	ENSG00000229122.1	AGBL5-IT1	4.85	1.7e-06	0.000206	0.15	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27014746	chr2:27061038~27061815:+
THCA	cis	rs1005277	0.579	rs2505248	ENSG00000275858.1	RP11-291L22.8	4.85	1.7e-06	0.000206	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38450738~38451069:-
THCA	cis	rs2742234	0.541	rs61845684	ENSG00000273008.1	RP11-351D16.3	4.85	1.7e-06	0.000206	0.21	0.22	Hirschsprung disease;	chr10:43249535	chr10:43136824~43138334:-
THCA	cis	rs453301	0.571	rs2929452	ENSG00000248538.5	RP11-10A14.5	4.85	1.71e-06	0.000207	0.27	0.22	Joint mobility (Beighton score);	chr8:9226955	chr8:9189011~9202854:+
THCA	cis	rs1009077	0.68	rs11724055	ENSG00000245958.5	RP11-33B1.1	4.85	1.71e-06	0.000207	0.29	0.22	Endometriosis;	chr4:119548880	chr4:119454791~119552025:+
THCA	cis	rs11671005	0.651	rs11878203	ENSG00000268049.1	CTD-2619J13.9	-4.85	1.71e-06	0.000207	-0.34	-0.22	Mean platelet volume;	chr19:58408683	chr19:58357999~58359603:+
THCA	cis	rs9880211	1	rs9828088	ENSG00000239213.4	NCK1-AS1	4.85	1.71e-06	0.000207	0.24	0.22	Height;Body mass index;	chr3:136528948	chr3:136841726~136862054:-
THCA	cis	rs9307551	0.697	rs1992367	ENSG00000250334.4	LINC00989	-4.85	1.71e-06	0.000207	-0.29	-0.22	Refractive error;	chr4:79528495	chr4:79492416~79576460:+
THCA	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-4.85	1.71e-06	0.000207	-0.25	-0.22	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
THCA	cis	rs59918340	0.728	rs2304279	ENSG00000253307.1	RP11-10J21.4	4.85	1.71e-06	0.000207	0.3	0.22	Immature fraction of reticulocytes;	chr8:141219792	chr8:141252286~141253292:-
THCA	cis	rs2235642	0.717	rs2236269	ENSG00000280231.1	LA16c-380F5.3	-4.85	1.71e-06	0.000207	-0.26	-0.22	Coronary artery disease;	chr16:1602613	chr16:1553655~1554130:-
THCA	cis	rs7088591	0.867	rs112062743	ENSG00000276818.1	AC026393.1	4.85	1.71e-06	0.000207	0.42	0.22	Blood pressure;	chr10:58032533	chr10:57095699~57095781:+
THCA	cis	rs7010876	0.561	rs12548636	ENSG00000253553.4	RP11-586K2.1	-4.85	1.71e-06	0.000207	-0.22	-0.22	Schizophrenia;	chr8:88386284	chr8:88326836~88737134:+
THCA	cis	rs8028182	0.636	rs4564532	ENSG00000260269.4	CTD-2323K18.1	-4.85	1.71e-06	0.000207	-0.32	-0.22	Sudden cardiac arrest;	chr15:75413955	chr15:75527150~75601205:-
THCA	cis	rs72843506	0.656	rs28567541	ENSG00000231258.2	ZSWIM5P2	4.85	1.71e-06	0.000207	0.32	0.22	Schizophrenia;	chr17:20051789	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs80250684	ENSG00000231258.2	ZSWIM5P2	4.85	1.71e-06	0.000207	0.32	0.22	Schizophrenia;	chr17:20054983	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs28622601	ENSG00000231258.2	ZSWIM5P2	4.85	1.71e-06	0.000207	0.32	0.22	Schizophrenia;	chr17:20055341	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.586	rs75048432	ENSG00000231258.2	ZSWIM5P2	4.85	1.71e-06	0.000207	0.32	0.22	Schizophrenia;	chr17:20057571	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs16960660	ENSG00000231258.2	ZSWIM5P2	4.85	1.71e-06	0.000207	0.32	0.22	Schizophrenia;	chr17:20062274	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs73984564	ENSG00000231258.2	ZSWIM5P2	4.85	1.71e-06	0.000207	0.32	0.22	Schizophrenia;	chr17:20068535	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs13339684	ENSG00000231258.2	ZSWIM5P2	4.85	1.71e-06	0.000207	0.32	0.22	Schizophrenia;	chr17:20073898	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs73984568	ENSG00000231258.2	ZSWIM5P2	4.85	1.71e-06	0.000207	0.32	0.22	Schizophrenia;	chr17:20074301	chr17:20583758~20591180:-
THCA	cis	rs7474896	0.583	rs1208770	ENSG00000263064.2	RP11-291L22.7	4.85	1.71e-06	0.000207	0.3	0.22	Obesity (extreme);	chr10:37755755	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.526	rs1742235	ENSG00000263064.2	RP11-291L22.7	4.85	1.71e-06	0.000207	0.3	0.22	Obesity (extreme);	chr10:37763328	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.559	rs1208779	ENSG00000263064.2	RP11-291L22.7	4.85	1.71e-06	0.000207	0.3	0.22	Obesity (extreme);	chr10:37788801	chr10:38448689~38448949:+
THCA	cis	rs17270561	0.609	rs1317816	ENSG00000272462.2	U91328.19	-4.85	1.71e-06	0.000207	-0.18	-0.22	Iron status biomarkers;	chr6:25765162	chr6:25992662~26001775:+
THCA	cis	rs2717559	0.622	rs13255523	ENSG00000253741.1	CTD-2292P10.4	4.85	1.71e-06	0.000207	0.28	0.22	Urinary tract infection frequency;	chr8:142805638	chr8:142702252~142726973:-
THCA	cis	rs17767392	0.794	rs17767362	ENSG00000259146.3	RP1-261D10.2	4.85	1.71e-06	0.000207	0.29	0.22	Mitral valve prolapse;	chr14:71267073	chr14:71292729~71321814:-
THCA	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-4.85	1.71e-06	0.000207	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
THCA	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	4.85	1.71e-06	0.000207	0.12	0.22	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
THCA	cis	rs6570726	0.967	rs9497316	ENSG00000270638.1	RP3-466P17.1	-4.85	1.71e-06	0.000207	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145735570~145737218:+
THCA	cis	rs1005277	0.579	rs2474608	ENSG00000275858.1	RP11-291L22.8	4.85	1.71e-06	0.000207	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38450738~38451069:-
THCA	cis	rs8028182	0.636	rs11637068	ENSG00000260269.4	CTD-2323K18.1	-4.85	1.71e-06	0.000207	-0.32	-0.22	Sudden cardiac arrest;	chr15:75450661	chr15:75527150~75601205:-
THCA	cis	rs9863	0.794	rs7978610	ENSG00000269997.1	RP11-214K3.21	4.85	1.71e-06	0.000207	0.27	0.22	White blood cell count;	chr12:123984025	chr12:123966077~123966629:-
THCA	cis	rs9863	0.861	rs12301673	ENSG00000269997.1	RP11-214K3.21	-4.85	1.71e-06	0.000207	-0.27	-0.22	White blood cell count;	chr12:123971271	chr12:123966077~123966629:-
THCA	cis	rs62025270	0.632	rs74025655	ENSG00000259295.5	CSPG4P12	-4.85	1.71e-06	0.000207	-0.36	-0.22	Idiopathic pulmonary fibrosis;	chr15:85674319	chr15:85191438~85213905:+
THCA	cis	rs860295	0.529	rs1475766	ENSG00000225855.5	RUSC1-AS1	-4.85	1.71e-06	0.000207	-0.14	-0.22	Body mass index;	chr1:156011698	chr1:155316863~155324176:-
THCA	cis	rs11992162	0.967	rs11250185	ENSG00000206014.6	OR7E161P	-4.85	1.71e-06	0.000207	-0.26	-0.22	Monocyte count;	chr8:11975614	chr8:11928597~11929563:-
THCA	cis	rs11118620	0.622	rs11118618	ENSG00000257551.1	HLX-AS1	4.85	1.71e-06	0.000207	0.32	0.22	Heart failure;	chr1:220838204	chr1:220832763~220880140:-
THCA	cis	rs763121	0.853	rs2284073	ENSG00000235209.1	CTA-150C2.13	4.85	1.71e-06	0.000207	0.29	0.22	Menopause (age at onset);	chr22:38709943	chr22:38921227~38924708:+
THCA	cis	rs1009077	0.514	rs62319578	ENSG00000245958.5	RP11-33B1.1	4.85	1.71e-06	0.000207	0.29	0.22	Endometriosis;	chr4:119487266	chr4:119454791~119552025:+
THCA	cis	rs10833905	0.756	rs3866928	ENSG00000246225.5	RP11-17A1.3	-4.85	1.71e-06	0.000208	-0.32	-0.22	Sudden cardiac arrest;	chr11:22981094	chr11:22829380~22945393:+
THCA	cis	rs62158800	0.925	rs62158804	ENSG00000237880.1	AC096669.2	4.85	1.71e-06	0.000208	0.37	0.22	Facial morphology (factor 22);	chr2:107594974	chr2:107385632~107542649:-
THCA	cis	rs9923856	0.523	rs11642631	ENSG00000274038.1	RP11-66H6.4	-4.85	1.71e-06	0.000208	-0.26	-0.22	Atopic dermatitis;Adult asthma;	chr16:11104978	chr16:11056556~11057034:+
THCA	cis	rs34779708	0.868	rs2384352	ENSG00000271335.4	RP11-324I22.4	4.85	1.71e-06	0.000208	0.21	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35314552~35336401:-
THCA	cis	rs8177376	0.727	rs586566	ENSG00000254905.1	RP11-712L6.7	4.85	1.71e-06	0.000208	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126329723	chr11:126292922~126294254:-
THCA	cis	rs8177376	0.727	rs667469	ENSG00000254905.1	RP11-712L6.7	4.85	1.71e-06	0.000208	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330171	chr11:126292922~126294254:-
THCA	cis	rs8177376	0.727	rs4937121	ENSG00000254905.1	RP11-712L6.7	4.85	1.71e-06	0.000208	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330659	chr11:126292922~126294254:-
THCA	cis	rs8177376	0.727	rs651983	ENSG00000254905.1	RP11-712L6.7	4.85	1.71e-06	0.000208	0.31	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331343	chr11:126292922~126294254:-
THCA	cis	rs13096142	0.558	rs4682812	ENSG00000223552.1	RP11-24F11.2	-4.85	1.71e-06	0.000208	-0.23	-0.22	Celiac disease;	chr3:46288153	chr3:46364955~46407059:-
THCA	cis	rs453301	0.579	rs10096850	ENSG00000233609.3	RP11-62H7.2	-4.85	1.71e-06	0.000208	-0.23	-0.22	Joint mobility (Beighton score);	chr8:8940712	chr8:8961200~8979025:+
THCA	cis	rs2797160	0.602	rs4897150	ENSG00000237742.5	RP11-624M8.1	-4.85	1.72e-06	0.000208	-0.18	-0.22	Endometrial cancer;	chr6:125664394	chr6:125578558~125749190:-
THCA	cis	rs7119	0.651	rs35577135	ENSG00000259362.2	RP11-307C19.1	-4.85	1.72e-06	0.000208	-0.32	-0.22	Type 2 diabetes;	chr15:77547732	chr15:77525540~77534110:+
THCA	cis	rs6951245	1	rs79443843	ENSG00000229043.2	AC091729.9	-4.85	1.72e-06	0.000208	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1035609	chr7:1160374~1165267:+
THCA	cis	rs8027521	0.64	rs17551796	ENSG00000280362.1	RP11-643A5.3	4.85	1.72e-06	0.000208	0.28	0.22	Circulating chemerin levels;	chr15:53980896	chr15:53910769~53914712:+
THCA	cis	rs736408	0.511	rs12637632	ENSG00000243224.1	RP5-1157M23.2	-4.85	1.72e-06	0.000208	-0.24	-0.22	Bipolar disorder;	chr3:52674057	chr3:52239258~52241097:+
THCA	cis	rs7429990	1	rs319680	ENSG00000228638.1	FCF1P2	-4.85	1.72e-06	0.000208	-0.22	-0.22	Educational attainment (years of education);	chr3:47856817	chr3:48290793~48291375:-
THCA	cis	rs2483058	0.515	rs2987936	ENSG00000261000.1	RP11-534L20.5	-4.85	1.72e-06	0.000208	-0.24	-0.22	Cholesterol and Triglycerides;	chr1:206432728	chr1:206503948~206504456:+
THCA	cis	rs1005277	0.541	rs2505193	ENSG00000275858.1	RP11-291L22.8	4.85	1.72e-06	0.000208	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474580	ENSG00000275858.1	RP11-291L22.8	4.85	1.72e-06	0.000208	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38450738~38451069:-
THCA	cis	rs2665103	0.61	rs56398167	ENSG00000259429.4	UBE2Q2P2	-4.85	1.72e-06	0.000208	-0.17	-0.22	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82355142~82420075:+
THCA	cis	rs17158807	1	rs17158807	ENSG00000274128.1	RP11-342A23.2	-4.85	1.72e-06	0.000208	-0.4	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr15:83580708	chr15:83962176~83962583:+
THCA	cis	rs3845817	0.832	rs702883	ENSG00000237979.1	AC007389.1	4.85	1.72e-06	0.000208	0.25	0.22	Bipolar disorder;	chr2:65524951	chr2:65500993~65502138:-
THCA	cis	rs3845817	0.838	rs702886	ENSG00000237979.1	AC007389.1	4.85	1.72e-06	0.000208	0.25	0.22	Bipolar disorder;	chr2:65526176	chr2:65500993~65502138:-
THCA	cis	rs34792	0.554	rs12919246	ENSG00000207425.1	Y_RNA	-4.85	1.72e-06	0.000208	-0.25	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:14915457~14915556:-
THCA	cis	rs7615952	0.546	rs16836896	ENSG00000171084.14	FAM86JP	4.85	1.72e-06	0.000208	0.29	0.22	Blood pressure (smoking interaction);	chr3:125592418	chr3:125916620~125930024:+
THCA	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-4.85	1.72e-06	0.000208	-0.13	-0.22	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
THCA	cis	rs7618915	0.571	rs1961958	ENSG00000243224.1	RP5-1157M23.2	-4.85	1.72e-06	0.000208	-0.24	-0.22	Bipolar disorder;	chr3:52551974	chr3:52239258~52241097:+
THCA	cis	rs4915077	1	rs17020010	ENSG00000230489.1	VAV3-AS1	4.85	1.72e-06	0.000208	0.37	0.22	Hypothyroidism;	chr1:107778780	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs17020011	ENSG00000230489.1	VAV3-AS1	4.85	1.72e-06	0.000208	0.37	0.22	Hypothyroidism;	chr1:107778919	chr1:107964443~107994607:+
THCA	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-4.85	1.72e-06	0.000208	-0.25	-0.22	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
THCA	cis	rs73198271	1	rs55971558	ENSG00000253893.2	FAM85B	4.85	1.72e-06	0.000208	0.36	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756893	chr8:8167819~8226614:-
THCA	cis	rs28386778	0.735	rs2727336	ENSG00000240280.5	TCAM1P	4.85	1.72e-06	0.000208	0.3	0.22	Prudent dietary pattern;	chr17:63914605	chr17:63849292~63864379:+
THCA	cis	rs6860806	0.507	rs200837	ENSG00000237714.1	P4HA2-AS1	4.85	1.72e-06	0.000208	0.29	0.22	Breast cancer;	chr5:132364266	chr5:132184876~132192808:+
THCA	cis	rs9813712	1	rs9864582	ENSG00000253540.4	FAM86HP	4.84	1.72e-06	0.000208	0.27	0.22	Response to amphetamines;	chr3:130251619	chr3:130099092~130111472:-
THCA	cis	rs763121	0.853	rs4821812	ENSG00000228274.3	RP3-508I15.9	-4.84	1.72e-06	0.000208	-0.24	-0.22	Menopause (age at onset);	chr22:38679230	chr22:38667585~38681820:-
THCA	cis	rs10411161	0.63	rs12462816	ENSG00000275055.1	CTC-471J1.11	4.84	1.72e-06	0.000209	0.29	0.22	Breast cancer;	chr19:51929462	chr19:52049007~52049754:+
THCA	cis	rs1866631	0.565	rs2076857	ENSG00000238133.5	MLK7-AS1	4.84	1.72e-06	0.000209	0.29	0.22	Lung cancer in ever smokers;	chr2:173162167	chr2:173166446~173282036:-
THCA	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-4.84	1.72e-06	0.000209	-0.3	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
THCA	cis	rs7614311	0.731	rs17401592	ENSG00000271843.1	RP11-245J9.5	-4.84	1.72e-06	0.000209	-0.39	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63968814	chr3:64008082~64008692:-
THCA	cis	rs7614311	0.731	rs3774721	ENSG00000271843.1	RP11-245J9.5	-4.84	1.72e-06	0.000209	-0.39	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63968973	chr3:64008082~64008692:-
THCA	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-4.84	1.72e-06	0.000209	-0.13	-0.22	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
THCA	cis	rs5742933	1	rs6717922	ENSG00000253559.1	OSGEPL1-AS1	-4.84	1.72e-06	0.000209	-0.27	-0.22	Ferritin levels;	chr2:189721497	chr2:189762704~189765556:+
THCA	cis	rs7731390	0.681	rs78721012	ENSG00000233006.5	AC034220.3	4.84	1.72e-06	0.000209	0.29	0.22	IgG glycosylation;	chr5:132306033	chr5:132311285~132369916:-
THCA	cis	rs8020095	0.571	rs4141702	ENSG00000258561.1	RP11-72M17.1	-4.84	1.72e-06	0.000209	-0.29	-0.22	Depression (quantitative trait);	chr14:66811001	chr14:66212810~66509394:-
THCA	cis	rs4908760	0.827	rs10864362	ENSG00000232912.4	RP5-1115A15.1	4.84	1.73e-06	0.000209	0.21	0.22	Vitiligo;	chr1:8672395	chr1:8424645~8434838:+
THCA	cis	rs147858478	1	rs147858478	ENSG00000263597.1	MIR3936	4.84	1.73e-06	0.000209	0.21	0.22	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132365490~132365599:-
THCA	cis	rs7614311	0.681	rs73117036	ENSG00000271843.1	RP11-245J9.5	-4.84	1.73e-06	0.000209	-0.39	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63907049	chr3:64008082~64008692:-
THCA	cis	rs6700559	0.643	rs4556395	ENSG00000260088.1	RP11-92G12.3	4.84	1.73e-06	0.000209	0.27	0.22	Coronary artery disease;	chr1:200693813	chr1:200669507~200694250:+
THCA	cis	rs6832769	1	rs473005	ENSG00000272969.1	RP11-528I4.2	4.84	1.73e-06	0.000209	0.26	0.22	Personality dimensions;	chr4:55421958	chr4:55547112~55547889:+
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000273712.1	RP5-874C20.7	4.84	1.73e-06	0.000209	0.24	0.22	Pubertal anthropometrics;	chr6:28197520	chr6:28315613~28315883:-
THCA	cis	rs7520050	0.902	rs4626927	ENSG00000234329.1	RP11-767N6.2	-4.84	1.73e-06	0.000209	-0.19	-0.22	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.902	rs7514192	ENSG00000234329.1	RP11-767N6.2	-4.84	1.73e-06	0.000209	-0.19	-0.22	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45651039~45651826:-
THCA	cis	rs9926296	0.542	rs12599531	ENSG00000260259.1	RP11-368I7.4	4.84	1.73e-06	0.000209	0.24	0.22	Vitiligo;	chr16:89842993	chr16:89682620~89686569:-
THCA	cis	rs11955398	0.502	rs159357	ENSG00000272308.1	RP11-231G3.1	-4.84	1.73e-06	0.000209	-0.23	-0.22	Intelligence (multi-trait analysis);	chr5:61174363	chr5:60866457~60866935:-
THCA	cis	rs3734266	0.702	rs35286877	ENSG00000272288.4	RP11-140K17.3	-4.84	1.73e-06	0.000209	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34673301	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs35987776	ENSG00000272288.4	RP11-140K17.3	-4.84	1.73e-06	0.000209	-0.22	-0.22	Systemic lupus erythematosus;	chr6:34673447	chr6:34696317~34697470:+
THCA	cis	rs2790457	0.958	rs2790455	ENSG00000254635.4	WAC-AS1	-4.84	1.73e-06	0.000209	-0.21	-0.22	Multiple myeloma;	chr10:28558148	chr10:28522652~28532743:-
THCA	cis	rs2790457	1	rs2790457	ENSG00000254635.4	WAC-AS1	-4.84	1.73e-06	0.000209	-0.21	-0.22	Multiple myeloma;	chr10:28567890	chr10:28522652~28532743:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000229886.1	RP5-1132H15.3	-4.84	1.73e-06	0.000209	-0.22	-0.22	Aortic root size;	chr7:66048109	chr7:66025126~66031544:-
THCA	cis	rs875971	0.505	rs1167385	ENSG00000229886.1	RP5-1132H15.3	-4.84	1.73e-06	0.000209	-0.22	-0.22	Aortic root size;	chr7:66048321	chr7:66025126~66031544:-
THCA	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-4.84	1.73e-06	0.000209	-0.24	-0.22	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
THCA	cis	rs9329221	0.683	rs814359	ENSG00000248538.5	RP11-10A14.5	4.84	1.73e-06	0.000209	0.27	0.22	Neuroticism;	chr8:10025622	chr8:9189011~9202854:+
THCA	cis	rs9925964	0.967	rs2032915	ENSG00000260911.2	RP11-196G11.2	-4.84	1.73e-06	0.000209	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106092	chr16:31043150~31049868:+
THCA	cis	rs7577696	0.924	rs11124277	ENSG00000276334.1	AL133243.1	-4.84	1.73e-06	0.000209	-0.23	-0.22	Inflammatory biomarkers;	chr2:32095301	chr2:32521927~32523547:+
THCA	cis	rs12823128	0.646	rs11830336	ENSG00000256185.1	RP11-612B6.2	4.84	1.73e-06	0.000209	0.2	0.22	Birth weight;	chr12:26750089	chr12:26335864~26336950:-
THCA	cis	rs7554547	0.69	rs6669571	ENSG00000199347.1	RNU5E-1	-4.84	1.73e-06	0.000209	-0.31	-0.22	Nonsyndromic cleft lip with cleft palate;	chr1:11887253	chr1:11908152~11908271:+
THCA	cis	rs763121	0.853	rs3788545	ENSG00000228274.3	RP3-508I15.9	-4.84	1.73e-06	0.000209	-0.24	-0.22	Menopause (age at onset);	chr22:38669167	chr22:38667585~38681820:-
THCA	cis	rs6954895	0.565	rs918879	ENSG00000271122.1	RP11-379H18.1	4.84	1.73e-06	0.000209	0.14	0.22	Anger;	chr7:35550717	chr7:35695214~35699413:+
THCA	cis	rs1005277	0.579	rs2472173	ENSG00000275858.1	RP11-291L22.8	4.84	1.73e-06	0.000209	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2472174	ENSG00000275858.1	RP11-291L22.8	4.84	1.73e-06	0.000209	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474563	ENSG00000275858.1	RP11-291L22.8	4.84	1.73e-06	0.000209	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs9418322	ENSG00000275858.1	RP11-291L22.8	4.84	1.73e-06	0.000209	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs9299760	ENSG00000275858.1	RP11-291L22.8	4.84	1.73e-06	0.000209	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2023351	ENSG00000275858.1	RP11-291L22.8	4.84	1.73e-06	0.000209	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38450738~38451069:-
THCA	cis	rs17301013	0.896	rs3118980	ENSG00000227373.4	RP11-160H22.5	-4.84	1.73e-06	0.000209	-0.3	-0.22	Systemic lupus erythematosus;	chr1:174793701	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.932	rs2987874	ENSG00000227373.4	RP11-160H22.5	-4.84	1.73e-06	0.000209	-0.3	-0.22	Systemic lupus erythematosus;	chr1:174801053	chr1:174115300~174160004:-
THCA	cis	rs11671005	0.57	rs73062110	ENSG00000265272.2	RN7SL693P	4.84	1.73e-06	0.000209	0.31	0.22	Mean platelet volume;	chr19:58425275	chr19:58490797~58491075:+
THCA	cis	rs6708331	0.517	rs7579922	ENSG00000179818.12	PCBP1-AS1	-4.84	1.73e-06	0.000209	-0.17	-0.22	Obesity-related traits;	chr2:70134781	chr2:69962263~70103220:-
THCA	cis	rs7809950	0.678	rs12670688	ENSG00000238832.1	snoU109	4.84	1.73e-06	0.000209	0.27	0.22	Coronary artery disease;	chr7:107180571	chr7:107603363~107603507:+
THCA	cis	rs12908161	1	rs11638290	ENSG00000188388.10	GOLGA6L3	4.84	1.73e-06	0.000209	0.29	0.22	Schizophrenia;	chr15:84684405	chr15:85240472~85247170:+
THCA	cis	rs12908161	0.959	rs34028043	ENSG00000188388.10	GOLGA6L3	4.84	1.73e-06	0.000209	0.29	0.22	Schizophrenia;	chr15:84688354	chr15:85240472~85247170:+
THCA	cis	rs12908161	0.959	rs34784022	ENSG00000188388.10	GOLGA6L3	4.84	1.73e-06	0.000209	0.29	0.22	Schizophrenia;	chr15:84688675	chr15:85240472~85247170:+
THCA	cis	rs6490294	0.528	rs12423572	ENSG00000226469.1	ADAM1B	4.84	1.73e-06	0.000209	0.36	0.22	Mean platelet volume;	chr12:112178115	chr12:111927018~111929017:+
THCA	cis	rs2120243	0.935	rs9681270	ENSG00000244515.1	KRT18P34	-4.84	1.73e-06	0.000209	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157426207	chr3:157162663~157163932:-
THCA	cis	rs2120243	1	rs9289982	ENSG00000244515.1	KRT18P34	-4.84	1.73e-06	0.000209	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157426655	chr3:157162663~157163932:-
THCA	cis	rs7727544	0.735	rs272879	ENSG00000263597.1	MIR3936	4.84	1.73e-06	0.00021	0.21	0.22	Blood metabolite levels;	chr5:132334853	chr5:132365490~132365599:-
THCA	cis	rs2243480	1	rs1964692	ENSG00000164669.11	INTS4P1	4.84	1.73e-06	0.00021	0.42	0.22	Diabetic kidney disease;	chr7:65989196	chr7:65141225~65234216:+
THCA	cis	rs786425	0.77	rs7298831	ENSG00000270095.1	RP11-214K3.18	-4.84	1.73e-06	0.00021	-0.26	-0.22	Pubertal anthropometrics;	chr12:123688008	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs11829958	ENSG00000270095.1	RP11-214K3.18	-4.84	1.73e-06	0.00021	-0.26	-0.22	Pubertal anthropometrics;	chr12:123688458	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs35114195	ENSG00000270095.1	RP11-214K3.18	-4.84	1.73e-06	0.00021	-0.26	-0.22	Pubertal anthropometrics;	chr12:123691466	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs12828633	ENSG00000270095.1	RP11-214K3.18	-4.84	1.73e-06	0.00021	-0.26	-0.22	Pubertal anthropometrics;	chr12:123695073	chr12:123971457~123971714:-
THCA	cis	rs62025270	0.632	rs78572940	ENSG00000259295.5	CSPG4P12	-4.84	1.73e-06	0.00021	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85696539	chr15:85191438~85213905:+
THCA	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	4.84	1.73e-06	0.00021	0.25	0.22	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
THCA	cis	rs2243480	1	rs7456042	ENSG00000232559.3	GS1-124K5.12	4.84	1.73e-06	0.00021	0.32	0.22	Diabetic kidney disease;	chr7:65834791	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs73142121	ENSG00000232559.3	GS1-124K5.12	4.84	1.73e-06	0.00021	0.32	0.22	Diabetic kidney disease;	chr7:65846219	chr7:66554588~66576923:-
THCA	cis	rs72799341	1	rs35675346	ENSG00000279196.1	RP11-1072A3.3	4.84	1.73e-06	0.00021	0.24	0.22	Diastolic blood pressure;	chr16:30924760	chr16:30984630~30988270:-
THCA	cis	rs11955398	0.502	rs34610	ENSG00000272308.1	RP11-231G3.1	-4.84	1.73e-06	0.00021	-0.23	-0.22	Intelligence (multi-trait analysis);	chr5:61183854	chr5:60866457~60866935:-
THCA	cis	rs62025270	0.688	rs55738258	ENSG00000259295.5	CSPG4P12	-4.84	1.74e-06	0.00021	-0.35	-0.22	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85191438~85213905:+
THCA	cis	rs62025270	0.688	rs55957626	ENSG00000259295.5	CSPG4P12	-4.84	1.74e-06	0.00021	-0.35	-0.22	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85191438~85213905:+
THCA	cis	rs62025270	0.688	rs62025297	ENSG00000259295.5	CSPG4P12	-4.84	1.74e-06	0.00021	-0.35	-0.22	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85191438~85213905:+
THCA	cis	rs62025270	0.688	rs62025298	ENSG00000259295.5	CSPG4P12	-4.84	1.74e-06	0.00021	-0.35	-0.22	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85191438~85213905:+
THCA	cis	rs62158800	0.925	rs62158826	ENSG00000237880.1	AC096669.2	4.84	1.74e-06	0.00021	0.36	0.22	Facial morphology (factor 22);	chr2:107620746	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.925	rs62158833	ENSG00000237880.1	AC096669.2	4.84	1.74e-06	0.00021	0.36	0.22	Facial morphology (factor 22);	chr2:107635171	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.85	rs72823078	ENSG00000237880.1	AC096669.2	4.84	1.74e-06	0.00021	0.36	0.22	Facial morphology (factor 22);	chr2:107663477	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.703	rs62161268	ENSG00000237880.1	AC096669.2	4.84	1.74e-06	0.00021	0.36	0.22	Facial morphology (factor 22);	chr2:107665854	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.852	rs62161269	ENSG00000237880.1	AC096669.2	4.84	1.74e-06	0.00021	0.36	0.22	Facial morphology (factor 22);	chr2:107667473	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.852	rs62161270	ENSG00000237880.1	AC096669.2	4.84	1.74e-06	0.00021	0.36	0.22	Facial morphology (factor 22);	chr2:107667735	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.777	rs62161274	ENSG00000237880.1	AC096669.2	4.84	1.74e-06	0.00021	0.36	0.22	Facial morphology (factor 22);	chr2:107670011	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.733	rs62161275	ENSG00000237880.1	AC096669.2	4.84	1.74e-06	0.00021	0.36	0.22	Facial morphology (factor 22);	chr2:107671292	chr2:107385632~107542649:-
THCA	cis	rs10771431	0.713	rs17794353	ENSG00000256069.6	A2MP1	-4.84	1.74e-06	0.00021	-0.24	-0.22	Breast size;	chr12:9209187	chr12:9228533~9275817:-
THCA	cis	rs7688540	0.713	rs4624608	ENSG00000211553.1	AC253576.2	-4.84	1.74e-06	0.00021	-0.32	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:136461~136568:+
THCA	cis	rs9990343	1	rs9990343	ENSG00000223552.1	RP11-24F11.2	-4.84	1.74e-06	0.00021	-0.2	-0.22	Brain structure;	chr3:46298321	chr3:46364955~46407059:-
THCA	cis	rs2028299	0.919	rs8026131	ENSG00000259677.1	RP11-493E3.1	4.84	1.74e-06	0.00021	0.28	0.22	Type 2 diabetes;	chr15:89874767	chr15:89876540~89877285:+
THCA	cis	rs2028299	0.879	rs986505	ENSG00000259677.1	RP11-493E3.1	4.84	1.74e-06	0.00021	0.28	0.22	Type 2 diabetes;	chr15:89875181	chr15:89876540~89877285:+
THCA	cis	rs4908768	0.501	rs11121212	ENSG00000232912.4	RP5-1115A15.1	4.84	1.74e-06	0.00021	0.21	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665934	chr1:8424645~8434838:+
THCA	cis	rs11634944	0.676	rs220028	ENSG00000257151.1	PWAR6	4.84	1.74e-06	0.00021	0.16	0.22	Interleukin-8 levels;	chr15:24955890	chr15:25031873~25036490:+
THCA	cis	rs2243480	1	rs313824	ENSG00000164669.11	INTS4P1	4.84	1.74e-06	0.00021	0.41	0.22	Diabetic kidney disease;	chr7:66116220	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs186378	ENSG00000164669.11	INTS4P1	4.84	1.74e-06	0.00021	0.41	0.22	Diabetic kidney disease;	chr7:66117071	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs160637	ENSG00000164669.11	INTS4P1	4.84	1.74e-06	0.00021	0.41	0.22	Diabetic kidney disease;	chr7:66119331	chr7:65141225~65234216:+
THCA	cis	rs783540	0.5	rs7178459	ENSG00000278603.1	RP13-608F4.5	4.84	1.74e-06	0.00021	0.32	0.22	Schizophrenia;	chr15:82729632	chr15:82472203~82472426:+
THCA	cis	rs479844	1	rs479844	ENSG00000214659.4	KRT8P26	-4.84	1.74e-06	0.00021	-0.2	-0.22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);Atopic march;	chr11:65784486	chr11:65726939~65728214:+
THCA	cis	rs1836229	0.594	rs10121702	ENSG00000225706.1	PTPRD-AS1	-4.84	1.74e-06	0.00021	-0.26	-0.22	Restless legs syndrome;	chr9:8825375	chr9:8858130~8862255:+
THCA	cis	rs4794202	0.7	rs11649750	ENSG00000264920.1	RP11-6N17.4	-4.84	1.74e-06	0.00021	-0.26	-0.22	Alzheimer's disease (cognitive decline);	chr17:47872656	chr17:47891255~47895812:-
THCA	cis	rs726288	1	rs11200985	ENSG00000230091.5	TMEM254-AS1	-4.84	1.74e-06	0.00021	-0.5	-0.22	Rheumatoid arthritis;	chr10:79972897	chr10:80046860~80078912:-
THCA	cis	rs4950322	0.542	rs3766520	ENSG00000271721.1	RP11-337C18.9	4.84	1.74e-06	0.00021	0.25	0.22	Protein quantitative trait loci;	chr1:147214658	chr1:147175602~147177740:+
THCA	cis	rs2239547	0.618	rs4687663	ENSG00000242142.1	SERBP1P3	4.84	1.74e-06	0.00021	0.28	0.22	Schizophrenia;	chr3:52836602	chr3:53064283~53065091:-
THCA	cis	rs6728642	1	rs59178801	ENSG00000230606.9	AC159540.1	4.84	1.74e-06	0.00021	0.29	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96938718	chr2:97416165~97433527:-
THCA	cis	rs73198271	0.71	rs7837843	ENSG00000253893.2	FAM85B	4.84	1.74e-06	0.00021	0.3	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.64	rs7838012	ENSG00000253893.2	FAM85B	4.84	1.74e-06	0.00021	0.3	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8167819~8226614:-
THCA	cis	rs6570726	0.967	rs1396648	ENSG00000270638.1	RP3-466P17.1	-4.84	1.74e-06	0.00021	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.902	rs9390326	ENSG00000270638.1	RP3-466P17.1	-4.84	1.74e-06	0.00021	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145735570~145737218:+
THCA	cis	rs11633886	0.569	rs4473118	ENSG00000273972.1	CTD-2306A12.1	-4.84	1.74e-06	0.000211	-0.24	-0.22	Diisocyanate-induced asthma;	chr15:45817925	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.569	rs10220802	ENSG00000273972.1	CTD-2306A12.1	-4.84	1.74e-06	0.000211	-0.24	-0.22	Diisocyanate-induced asthma;	chr15:45817944	chr15:45702640~45703183:+
THCA	cis	rs6413860	0.688	rs10802434	ENSG00000260855.1	RP11-439E19.10	-4.84	1.74e-06	0.000211	-0.25	-0.22	Gut microbiome composition (summer);	chr1:246695880	chr1:246772301~246775772:+
THCA	cis	rs12823128	0.766	rs12814680	ENSG00000256185.1	RP11-612B6.2	4.84	1.74e-06	0.000211	0.21	0.22	Birth weight;	chr12:26769683	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs12813295	ENSG00000256185.1	RP11-612B6.2	4.84	1.74e-06	0.000211	0.21	0.22	Birth weight;	chr12:26769756	chr12:26335864~26336950:-
THCA	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	4.84	1.74e-06	0.000211	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
THCA	cis	rs10833905	0.756	rs11026870	ENSG00000246225.5	RP11-17A1.3	-4.84	1.74e-06	0.000211	-0.32	-0.22	Sudden cardiac arrest;	chr11:22973501	chr11:22829380~22945393:+
THCA	cis	rs10833905	0.756	rs78740029	ENSG00000246225.5	RP11-17A1.3	-4.84	1.74e-06	0.000211	-0.32	-0.22	Sudden cardiac arrest;	chr11:22977330	chr11:22829380~22945393:+
THCA	cis	rs2439831	1	rs2245908	ENSG00000166763.7	STRCP1	4.84	1.74e-06	0.000211	0.29	0.22	Lung cancer in ever smokers;	chr15:43439256	chr15:43699488~43718184:-
THCA	cis	rs7552393	0.636	rs11163849	ENSG00000233008.4	RP11-475O6.1	4.84	1.74e-06	0.000211	0.25	0.22	Select biomarker traits;	chr1:83815514	chr1:83575776~83861023:-
THCA	cis	rs2243480	0.901	rs778732	ENSG00000230295.1	RP11-458F8.2	-4.84	1.74e-06	0.000211	-0.27	-0.22	Diabetic kidney disease;	chr7:66357373	chr7:66880708~66882981:+
THCA	cis	rs9840812	0.645	rs13068119	ENSG00000239213.4	NCK1-AS1	-4.84	1.74e-06	0.000211	-0.23	-0.22	Fibrinogen levels;	chr3:136487527	chr3:136841726~136862054:-
THCA	cis	rs6714710	0.58	rs11690737	ENSG00000230606.9	AC159540.1	-4.84	1.74e-06	0.000211	-0.24	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845490	chr2:97416165~97433527:-
THCA	cis	rs801193	1	rs13239306	ENSG00000229886.1	RP5-1132H15.3	-4.84	1.74e-06	0.000211	-0.23	-0.22	Aortic root size;	chr7:66671030	chr7:66025126~66031544:-
THCA	cis	rs972578	0.715	rs2024645	ENSG00000274717.1	RP1-47A17.1	-4.84	1.74e-06	0.000211	-0.23	-0.22	Mean platelet volume;	chr22:42816775	chr22:42791814~42794313:-
THCA	cis	rs7211079	0.581	rs66994322	ENSG00000279259.1	RP11-334C17.3	4.84	1.74e-06	0.000211	0.27	0.22	Myocardial infarction;	chr17:80157441	chr17:80147250~80148596:+
THCA	cis	rs2051211	0.947	rs73065216	ENSG00000229589.1	ACVR2B-AS1	-4.84	1.74e-06	0.000211	-0.23	-0.22	QRS duration;	chr3:38482703	chr3:38451027~38454820:-
THCA	cis	rs1048886	0.808	rs9455158	ENSG00000271967.1	RP11-134K13.4	-4.84	1.75e-06	0.000211	-0.22	-0.22	Type 2 diabetes;	chr6:70561176	chr6:70596438~70596980:+
THCA	cis	rs10208649	0.803	rs2177791	ENSG00000233266.1	HMGB1P31	4.84	1.75e-06	0.000211	0.51	0.22	Body mass index;	chr2:53832771	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.803	rs2177792	ENSG00000233266.1	HMGB1P31	4.84	1.75e-06	0.000211	0.51	0.22	Body mass index;	chr2:53832776	chr2:54051334~54051760:+
THCA	cis	rs172166	0.561	rs149971	ENSG00000176933.5	TOB2P1	-4.84	1.75e-06	0.000211	-0.24	-0.22	Cardiac Troponin-T levels;	chr6:28014374	chr6:28217643~28218634:-
THCA	cis	rs9380516	0.898	rs2395630	ENSG00000228559.1	RP3-340B19.3	-4.84	1.75e-06	0.000211	-0.32	-0.22	Hepatitis C induced liver fibrosis;	chr6:35536690	chr6:35544632~35545669:+
THCA	cis	rs62244186	0.535	rs59726036	ENSG00000214820.3	MPRIPP1	4.84	1.75e-06	0.000211	0.22	0.22	Depressive symptoms;	chr3:44808582	chr3:44579938~44581026:-
THCA	cis	rs7911264	0.791	rs9420589	ENSG00000236493.2	EIF2S2P3	-4.84	1.75e-06	0.000211	-0.24	-0.22	Inflammatory bowel disease;	chr10:92690476	chr10:92668745~92669743:-
THCA	cis	rs6547741	0.904	rs1528403	ENSG00000234072.1	AC074117.10	4.84	1.75e-06	0.000211	0.17	0.22	Oral cavity cancer;	chr2:27623778	chr2:27356246~27367622:+
THCA	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	4.84	1.75e-06	0.000211	0.25	0.22	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	4.84	1.75e-06	0.000211	0.25	0.22	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
THCA	cis	rs11073619	0.558	rs12440039	ENSG00000230373.7	GOLGA6L5P	-4.84	1.75e-06	0.000211	-0.32	-0.22	Positive affect;	chr15:84144748	chr15:84507885~84516814:-
THCA	cis	rs4061073	1	rs2297026	ENSG00000198711.5	SSBP3-AS1	-4.84	1.75e-06	0.000211	-0.2	-0.22	Body mass index;	chr1:54228541	chr1:54236440~54239063:+
THCA	cis	rs11168187	0.527	rs11168220	ENSG00000274902.1	RP1-197B17.4	4.84	1.75e-06	0.000211	0.31	0.22	Vertical cup-disc ratio;	chr12:47741807	chr12:47731908~47732351:+
THCA	cis	rs10266483	0.774	rs56055804	ENSG00000271550.1	BNIP3P11	-4.84	1.75e-06	0.000211	-0.31	-0.22	Response to statin therapy;	chr7:64410423	chr7:64678954~64687393:-
THCA	cis	rs6496932	0.503	rs10520588	ENSG00000259630.2	CTD-2262B20.1	-4.84	1.75e-06	0.000211	-0.27	-0.22	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85415228~85415633:+
THCA	cis	rs6728642	1	rs113934577	ENSG00000230606.9	AC159540.1	4.84	1.75e-06	0.000211	0.34	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97222310	chr2:97416165~97433527:-
THCA	cis	rs9652601	0.691	rs998592	ENSG00000274038.1	RP11-66H6.4	4.84	1.75e-06	0.000211	0.26	0.22	Systemic lupus erythematosus;	chr16:11105821	chr16:11056556~11057034:+
THCA	cis	rs11779988	0.545	rs448882	ENSG00000253671.1	RP11-806O11.1	-4.84	1.75e-06	0.000211	-0.28	-0.22	Breast cancer;	chr8:17936530	chr8:17808941~17820868:+
THCA	cis	rs7838490	0.504	rs821118	ENSG00000253553.4	RP11-586K2.1	4.84	1.75e-06	0.000212	0.23	0.22	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88467688	chr8:88326836~88737134:+
THCA	cis	rs9595908	0.714	rs1018800	ENSG00000212293.1	SNORA16	4.84	1.75e-06	0.000212	0.27	0.22	Body mass index;	chr13:32624039	chr13:32420390~32420516:-
THCA	cis	rs3734266	0.702	rs6908462	ENSG00000272288.4	RP11-140K17.3	4.84	1.75e-06	0.000212	0.22	0.22	Systemic lupus erythematosus;	chr6:34705372	chr6:34696317~34697470:+
THCA	cis	rs8141529	0.702	rs132536	ENSG00000272858.1	CTA-292E10.8	4.84	1.75e-06	0.000212	0.22	0.22	Lymphocyte counts;	chr22:28906918	chr22:28814914~28815662:+
THCA	cis	rs4648045	0.828	rs230522	ENSG00000246560.2	RP11-10L12.4	-4.84	1.75e-06	0.000212	-0.27	-0.22	Lymphocyte percentage of white cells;	chr4:102541640	chr4:102828055~102844075:+
THCA	cis	rs16867253	0.557	rs12472800	ENSG00000188525.3	AC010969.1	-4.84	1.75e-06	0.000212	-0.37	-0.22	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr2:9993715	chr2:10003158~10006030:-
THCA	cis	rs16867253	0.557	rs3791753	ENSG00000188525.3	AC010969.1	-4.84	1.75e-06	0.000212	-0.37	-0.22	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr2:9994940	chr2:10003158~10006030:-
THCA	cis	rs4950322	0.542	rs56080828	ENSG00000226015.2	CCT8P1	4.84	1.75e-06	0.000212	0.26	0.22	Protein quantitative trait loci;	chr1:147183447	chr1:147203276~147204932:-
THCA	cis	rs1150668	0.799	rs1150707	ENSG00000273712.1	RP5-874C20.7	4.84	1.75e-06	0.000212	0.24	0.22	Pubertal anthropometrics;	chr6:28229827	chr6:28315613~28315883:-
THCA	cis	rs7267979	0.738	rs2892409	ENSG00000274414.1	RP5-965G21.4	-4.84	1.75e-06	0.000212	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:25239007~25245229:-
THCA	cis	rs9951026	0.752	rs2097055	ENSG00000267674.1	RP11-813F20.2	4.84	1.75e-06	0.000212	0.22	0.22	Testicular germ cell tumor;	chr18:49569117	chr18:49739823~49742063:-
THCA	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-4.84	1.75e-06	0.000212	-0.3	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
THCA	cis	rs1823874	0.71	rs2085087	ENSG00000259363.4	CTD-2054N24.2	4.84	1.75e-06	0.000212	0.27	0.22	IgG glycosylation;	chr15:99819938	chr15:99807023~99877148:+
THCA	cis	rs3743162	0.553	rs12900463	ENSG00000259728.4	LINC00933	4.84	1.75e-06	0.000212	0.3	0.22	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84570649~84580175:+
THCA	cis	rs6472827	0.645	rs2936685	ENSG00000253983.2	RP1-16A9.1	4.84	1.75e-06	0.000212	0.31	0.22	Uterine fibroids;	chr8:74202449	chr8:74199396~74208441:+
THCA	cis	rs7727544	0.582	rs2301579	ENSG00000224431.1	AC063976.7	4.84	1.75e-06	0.000212	0.18	0.22	Blood metabolite levels;	chr5:132217647	chr5:132199456~132203487:+
THCA	cis	rs1005277	0.522	rs7090858	ENSG00000276805.1	RP11-291L22.6	-4.84	1.75e-06	0.000212	-0.23	-0.22	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38451030~38451785:+
THCA	cis	rs6545883	0.524	rs7561697	ENSG00000270820.4	RP11-355B11.2	-4.84	1.75e-06	0.000212	-0.18	-0.22	Tuberculosis;	chr2:61292030	chr2:61471188~61484130:+
THCA	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-4.84	1.76e-06	0.000212	-0.12	-0.22	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
THCA	cis	rs2253762	0.54	rs10887036	ENSG00000226864.1	ATE1-AS1	4.84	1.76e-06	0.000212	0.34	0.22	Breast cancer;	chr10:121997570	chr10:121928312~121951965:+
THCA	cis	rs2253762	0.54	rs10887037	ENSG00000226864.1	ATE1-AS1	4.84	1.76e-06	0.000212	0.34	0.22	Breast cancer;	chr10:121997572	chr10:121928312~121951965:+
THCA	cis	rs10090774	0.965	rs11167016	ENSG00000279766.1	RP11-642A1.2	-4.84	1.76e-06	0.000212	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140985081	chr8:140572142~140572812:-
THCA	cis	rs9890032	0.52	rs2321926	ENSG00000264538.5	SUZ12P1	-4.84	1.76e-06	0.000212	-0.16	-0.22	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30709299~30790908:+
THCA	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	4.84	1.76e-06	0.000212	0.27	0.22	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
THCA	cis	rs6728642	0.708	rs56807297	ENSG00000230606.9	AC159540.1	4.84	1.76e-06	0.000212	0.3	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97195603	chr2:97416165~97433527:-
THCA	cis	rs516805	0.52	rs535316	ENSG00000279453.1	RP3-425C14.4	-4.84	1.76e-06	0.000212	-0.18	-0.22	Lymphocyte counts;	chr6:122410673	chr6:122436789~122439223:-
THCA	cis	rs516805	0.52	rs549302	ENSG00000279453.1	RP3-425C14.4	-4.84	1.76e-06	0.000212	-0.18	-0.22	Lymphocyte counts;	chr6:122413827	chr6:122436789~122439223:-
THCA	cis	rs17292804	0.527	rs12887734	ENSG00000269958.1	RP11-73M18.8	4.84	1.76e-06	0.000212	0.21	0.22	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103696353~103697163:+
THCA	cis	rs12887734	0.524	rs17791722	ENSG00000269910.1	RP11-73M18.10	4.84	1.76e-06	0.000212	0.2	0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103819873	chr14:103694516~103695050:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000223473.2	GS1-124K5.3	4.84	1.76e-06	0.000212	0.15	0.22	Aortic root size;	chr7:65975357	chr7:66491049~66493566:-
THCA	cis	rs7208859	0.623	rs73271869	ENSG00000280069.1	CTD-2349P21.3	-4.84	1.76e-06	0.000212	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs73271872	ENSG00000280069.1	CTD-2349P21.3	-4.84	1.76e-06	0.000212	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.568	rs9907834	ENSG00000280069.1	CTD-2349P21.3	-4.84	1.76e-06	0.000212	-0.34	-0.22	Body mass index;	chr17:30826995	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs73271887	ENSG00000280069.1	CTD-2349P21.3	-4.84	1.76e-06	0.000212	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9898858	ENSG00000280069.1	CTD-2349P21.3	-4.84	1.76e-06	0.000212	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs55658077	ENSG00000280069.1	CTD-2349P21.3	-4.84	1.76e-06	0.000212	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9899692	ENSG00000280069.1	CTD-2349P21.3	-4.84	1.76e-06	0.000212	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs9906957	ENSG00000280069.1	CTD-2349P21.3	-4.84	1.76e-06	0.000212	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30738182~30740275:+
THCA	cis	rs250518	0.926	rs7734796	ENSG00000272081.1	CTD-2376I4.2	4.84	1.76e-06	0.000212	0.28	0.22	Mean corpuscular hemoglobin concentration;	chr5:72781261	chr5:72955206~72955699:-
THCA	cis	rs11671005	0.735	rs12986387	ENSG00000268912.1	CTD-2619J13.17	-4.84	1.76e-06	0.000212	-0.21	-0.22	Mean platelet volume;	chr19:58415848	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs11667723	ENSG00000268912.1	CTD-2619J13.17	-4.84	1.76e-06	0.000212	-0.21	-0.22	Mean platelet volume;	chr19:58416122	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs11668789	ENSG00000268912.1	CTD-2619J13.17	-4.84	1.76e-06	0.000212	-0.21	-0.22	Mean platelet volume;	chr19:58416942	chr19:58428632~58431148:-
THCA	cis	rs62158800	0.925	rs908436	ENSG00000237880.1	AC096669.2	4.84	1.76e-06	0.000212	0.37	0.22	Facial morphology (factor 22);	chr2:107595865	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.778	rs884883	ENSG00000237880.1	AC096669.2	4.84	1.76e-06	0.000212	0.37	0.22	Facial morphology (factor 22);	chr2:107596111	chr2:107385632~107542649:-
THCA	cis	rs6445975	0.667	rs6445963	ENSG00000272360.1	RP11-359I18.5	-4.84	1.76e-06	0.000213	-0.23	-0.22	Systemic lupus erythematosus;	chr3:58248752	chr3:58490830~58491291:-
THCA	cis	rs7520050	0.966	rs11211208	ENSG00000234329.1	RP11-767N6.2	-4.84	1.76e-06	0.000213	-0.19	-0.22	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45651039~45651826:-
THCA	cis	rs9901225	1	rs9901225	ENSG00000267185.1	PTP4A2P1	4.84	1.76e-06	0.000213	0.27	0.22	Colorectal or endometrial cancer;	chr17:42603793	chr17:42533532~42534009:+
THCA	cis	rs4650994	0.593	rs28445692	ENSG00000273384.1	RP5-1098D14.1	-4.84	1.76e-06	0.000213	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178542757	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.571	rs35758545	ENSG00000273384.1	RP5-1098D14.1	-4.84	1.76e-06	0.000213	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178542789	chr1:178651706~178652282:+
THCA	cis	rs8020095	0.571	rs12588821	ENSG00000258561.1	RP11-72M17.1	-4.84	1.76e-06	0.000213	-0.29	-0.22	Depression (quantitative trait);	chr14:66957783	chr14:66212810~66509394:-
THCA	cis	rs919433	0.713	rs10172961	ENSG00000231621.1	AC013264.2	-4.84	1.76e-06	0.000213	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197582135	chr2:197197991~197199273:+
THCA	cis	rs1005277	0.579	rs2474567	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2472175	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2472176	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474568	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2983343	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474569	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.602	rs2504142	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2472181	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474574	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2504140	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474575	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2472182	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.541	rs2263163	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2021649	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2472183	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2505197	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2505196	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.557	rs1854563	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2505237	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2474599	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2505240	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.54	rs2224248	ENSG00000275858.1	RP11-291L22.8	4.84	1.76e-06	0.000213	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38450738~38451069:-
THCA	cis	rs3820928	0.874	rs13419455	ENSG00000212391.1	SNORA48	-4.84	1.76e-06	0.000213	-0.24	-0.22	Pulmonary function;	chr2:226985749	chr2:226968989~226969122:-
THCA	cis	rs897984	0.568	rs67456613	ENSG00000279196.1	RP11-1072A3.3	4.84	1.76e-06	0.000213	0.24	0.22	Dementia with Lewy bodies;	chr16:30876974	chr16:30984630~30988270:-
THCA	cis	rs59918340	0.764	rs4961338	ENSG00000253307.1	RP11-10J21.4	-4.84	1.76e-06	0.000213	-0.3	-0.22	Immature fraction of reticulocytes;	chr8:141220093	chr8:141252286~141253292:-
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000273796.1	LL21NC02-21A1.1	-4.84	1.76e-06	0.000213	-0.22	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45403809~45404369:-
THCA	cis	rs2692947	0.77	rs6719831	ENSG00000232931.4	LINC00342	4.84	1.76e-06	0.000213	0.18	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95836842	chr2:95807118~95816215:-
THCA	cis	rs1329650	1	rs4933206	ENSG00000228701.1	TNKS2-AS1	-4.84	1.76e-06	0.000213	-0.26	-0.22	Smoking behavior;	chr10:91578843	chr10:91782839~91798291:-
THCA	cis	rs8020095	0.571	rs7156119	ENSG00000258561.1	RP11-72M17.1	-4.84	1.76e-06	0.000213	-0.29	-0.22	Depression (quantitative trait);	chr14:67183398	chr14:66212810~66509394:-
THCA	cis	rs867371	0.502	rs2047679	ENSG00000259429.4	UBE2Q2P2	-4.84	1.76e-06	0.000213	-0.17	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82355142~82420075:+
THCA	cis	rs1836229	0.57	rs7863423	ENSG00000225706.1	PTPRD-AS1	-4.84	1.76e-06	0.000213	-0.26	-0.22	Restless legs syndrome;	chr9:8824111	chr9:8858130~8862255:+
THCA	cis	rs713477	0.505	rs4901561	ENSG00000258413.1	RP11-665C16.6	4.84	1.76e-06	0.000213	0.31	0.22	Pediatric bone mineral content (femoral neck);	chr14:55421860	chr14:55262767~55272075:-
THCA	cis	rs1005277	0.522	rs1208681	ENSG00000226578.1	RP11-258F22.1	-4.84	1.76e-06	0.000213	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:37775371~37784131:-
THCA	cis	rs12681288	0.676	rs2701913	ENSG00000260721.1	AF067845.1	4.84	1.76e-06	0.000213	0.27	0.22	Schizophrenia;	chr8:1049982	chr8:1368642~1369833:-
THCA	cis	rs654950	1	rs679449	ENSG00000230638.4	RP11-486B10.4	4.84	1.76e-06	0.000213	0.25	0.22	Airway imaging phenotypes;	chr1:41522963	chr1:41542069~41544310:+
THCA	cis	rs6772849	0.775	rs9828414	ENSG00000242551.2	POU5F1P6	-4.84	1.76e-06	0.000213	-0.29	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128693874	chr3:128674735~128677005:-
THCA	cis	rs6772849	0.804	rs9832430	ENSG00000242551.2	POU5F1P6	-4.84	1.76e-06	0.000213	-0.29	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128694054	chr3:128674735~128677005:-
THCA	cis	rs6772849	0.775	rs66822528	ENSG00000242551.2	POU5F1P6	-4.84	1.76e-06	0.000213	-0.29	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128674735~128677005:-
THCA	cis	rs6686842	0.56	rs213758	ENSG00000235358.1	RP11-399E6.1	4.84	1.76e-06	0.000213	0.29	0.22	Height;	chr1:41128452	chr1:41242373~41284861:+
THCA	cis	rs793571	0.58	rs12913383	ENSG00000245975.2	RP11-30K9.6	-4.84	1.77e-06	0.000213	-0.25	-0.22	Schizophrenia;	chr15:58751587	chr15:58768072~58770974:-
THCA	cis	rs17360053	0.927	rs17360017	ENSG00000218510.5	LINC00339	-4.84	1.77e-06	0.000213	-0.24	-0.22	Obesity-related traits;	chr1:22168722	chr1:22025188~22031223:+
THCA	cis	rs12701220	0.744	rs3735683	ENSG00000229043.2	AC091729.9	-4.84	1.77e-06	0.000213	-0.27	-0.22	Bronchopulmonary dysplasia;	chr7:985897	chr7:1160374~1165267:+
THCA	cis	rs736408	0.812	rs9881468	ENSG00000243224.1	RP5-1157M23.2	-4.84	1.77e-06	0.000213	-0.25	-0.22	Bipolar disorder;	chr3:52794612	chr3:52239258~52241097:+
THCA	cis	rs467650	0.853	rs154205	ENSG00000248489.1	CTD-2007H13.3	4.84	1.77e-06	0.000213	0.21	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98649598	chr5:98929171~98995013:+
THCA	cis	rs4950322	0.748	rs56392137	ENSG00000226015.2	CCT8P1	4.84	1.77e-06	0.000214	0.26	0.22	Protein quantitative trait loci;	chr1:147352450	chr1:147203276~147204932:-
THCA	cis	rs7688540	0.8	rs61794998	ENSG00000275426.1	CH17-262A2.1	4.84	1.77e-06	0.000214	0.27	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:149738~150317:+
THCA	cis	rs6430585	0.759	rs12467770	ENSG00000231890.6	DARS-AS1	-4.84	1.77e-06	0.000214	-0.27	-0.22	Corneal structure;	chr2:135778525	chr2:135985176~136022593:+
THCA	cis	rs9637599	1	rs9637599	ENSG00000246375.2	RP11-10L7.1	4.84	1.77e-06	0.000214	0.31	0.22	Metabolite levels (small molecules and protein measures);	chr4:88285078	chr4:88284942~88331421:+
THCA	cis	rs3020736	0.5	rs7292241	ENSG00000273366.1	CTA-989H11.1	4.84	1.77e-06	0.000214	0.28	0.22	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42278188~42278846:+
THCA	cis	rs2742234	0.911	rs3004214	ENSG00000273008.1	RP11-351D16.3	-4.84	1.77e-06	0.000214	-0.19	-0.22	Hirschsprung disease;	chr10:43136250	chr10:43136824~43138334:-
THCA	cis	rs2018683	0.624	rs2286219	ENSG00000272568.4	CTB-113D17.1	4.84	1.77e-06	0.000214	0.21	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.624	rs2286220	ENSG00000272568.4	CTB-113D17.1	4.84	1.77e-06	0.000214	0.21	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28979967~29013367:+
THCA	cis	rs72843506	0.656	rs77540008	ENSG00000261033.1	RP11-209D14.2	4.84	1.77e-06	0.000214	0.4	0.22	Schizophrenia;	chr17:20069886	chr17:20008051~20009234:-
THCA	cis	rs7554547	0.667	rs59952418	ENSG00000201801.1	RNU5E-4P	4.84	1.77e-06	0.000214	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr1:11878153	chr1:11909808~11909927:-
THCA	cis	rs7674212	0.57	rs6813563	ENSG00000251288.2	RP11-10L12.2	-4.84	1.77e-06	0.000214	-0.28	-0.22	Type 2 diabetes;	chr4:103177953	chr4:102751401~102752641:+
THCA	cis	rs2190422	0.677	rs2382694	ENSG00000234715.1	CTB-107G13.1	-4.84	1.77e-06	0.000214	-0.25	-0.22	Morning vs. evening chronotype;	chr7:103430536	chr7:103445207~103514007:+
THCA	cis	rs6560517	0.561	rs4745551	ENSG00000234618.1	RPSAP9	-4.84	1.77e-06	0.000214	-0.26	-0.22	Dialysis-related mortality;	chr9:76460736	chr9:76398699~76399586:+
THCA	cis	rs9527	0.571	rs4917985	ENSG00000213061.2	PFN1P11	4.84	1.77e-06	0.000214	0.27	0.22	Arsenic metabolism;	chr10:102864315	chr10:102838011~102845473:-
THCA	cis	rs7554547	0.69	rs6667637	ENSG00000199347.1	RNU5E-1	-4.84	1.77e-06	0.000214	-0.3	-0.22	Nonsyndromic cleft lip with cleft palate;	chr1:11887900	chr1:11908152~11908271:+
THCA	cis	rs8020095	0.571	rs8012776	ENSG00000258561.1	RP11-72M17.1	-4.84	1.77e-06	0.000214	-0.29	-0.22	Depression (quantitative trait);	chr14:67121161	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs10131984	ENSG00000258561.1	RP11-72M17.1	-4.84	1.77e-06	0.000214	-0.29	-0.22	Depression (quantitative trait);	chr14:67158699	chr14:66212810~66509394:-
THCA	cis	rs5742933	1	rs1317751	ENSG00000253559.1	OSGEPL1-AS1	-4.84	1.77e-06	0.000214	-0.27	-0.22	Ferritin levels;	chr2:189807898	chr2:189762704~189765556:+
THCA	cis	rs2280018	0.609	rs2941253	ENSG00000263335.1	AF001548.5	-4.84	1.77e-06	0.000214	-0.26	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15726674~15732993:+
THCA	cis	rs752010	0.631	rs7515066	ENSG00000230638.4	RP11-486B10.4	4.84	1.77e-06	0.000214	0.26	0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41611244	chr1:41542069~41544310:+
THCA	cis	rs736408	0.648	rs3774354	ENSG00000243224.1	RP5-1157M23.2	-4.84	1.77e-06	0.000214	-0.24	-0.22	Bipolar disorder;	chr3:52783659	chr3:52239258~52241097:+
THCA	cis	rs146699004	1	rs146699004	ENSG00000266490.1	CTD-2349P21.9	4.84	1.77e-06	0.000214	0.22	0.22	Breast cancer;	chr17:30903504	chr17:30792372~30792833:+
THCA	cis	rs7552393	0.585	rs6676587	ENSG00000233008.4	RP11-475O6.1	-4.84	1.77e-06	0.000214	-0.25	-0.22	Select biomarker traits;	chr1:83810746	chr1:83575776~83861023:-
THCA	cis	rs2797160	1	rs984040	ENSG00000237742.5	RP11-624M8.1	4.84	1.77e-06	0.000214	0.18	0.22	Endometrial cancer;	chr6:125700131	chr6:125578558~125749190:-
THCA	cis	rs1005277	0.579	rs2505194	ENSG00000275858.1	RP11-291L22.8	4.84	1.77e-06	0.000214	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38450738~38451069:-
THCA	cis	rs1023500	0.596	rs5758562	ENSG00000273366.1	CTA-989H11.1	-4.84	1.77e-06	0.000214	-0.29	-0.22	Schizophrenia;	chr22:42052234	chr22:42278188~42278846:+
THCA	cis	rs957448	0.904	rs56302978	ENSG00000253175.1	RP11-267M23.6	4.84	1.77e-06	0.000214	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94565036~94565715:+
THCA	cis	rs801193	1	rs17566701	ENSG00000229886.1	RP5-1132H15.3	4.84	1.77e-06	0.000214	0.23	0.22	Aortic root size;	chr7:66728196	chr7:66025126~66031544:-
THCA	cis	rs1150668	0.799	rs7206	ENSG00000273712.1	RP5-874C20.7	4.84	1.78e-06	0.000214	0.24	0.22	Pubertal anthropometrics;	chr6:28233360	chr6:28315613~28315883:-
THCA	cis	rs853679	0.599	rs188015	ENSG00000220721.1	OR1F12	4.84	1.78e-06	0.000214	0.36	0.22	Depression;	chr6:27909668	chr6:28073316~28074233:+
THCA	cis	rs1023500	0.551	rs2301521	ENSG00000237037.8	NDUFA6-AS1	-4.84	1.78e-06	0.000214	-0.19	-0.22	Schizophrenia;	chr22:42027106	chr22:42090931~42137742:+
THCA	cis	rs8020095	0.571	rs28444104	ENSG00000258561.1	RP11-72M17.1	-4.84	1.78e-06	0.000214	-0.3	-0.22	Depression (quantitative trait);	chr14:66866555	chr14:66212810~66509394:-
THCA	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	4.84	1.78e-06	0.000214	0.21	0.22	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs10899782	ENSG00000273008.1	RP11-351D16.3	4.84	1.78e-06	0.000214	0.21	0.22	Hirschsprung disease;	chr10:43240913	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs11528481	ENSG00000273008.1	RP11-351D16.3	4.84	1.78e-06	0.000214	0.21	0.22	Hirschsprung disease;	chr10:43242319	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs7073849	ENSG00000273008.1	RP11-351D16.3	4.84	1.78e-06	0.000214	0.21	0.22	Hirschsprung disease;	chr10:43245026	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs7098236	ENSG00000273008.1	RP11-351D16.3	4.84	1.78e-06	0.000214	0.21	0.22	Hirschsprung disease;	chr10:43245060	chr10:43136824~43138334:-
THCA	cis	rs1864400	0.69	rs7098237	ENSG00000273008.1	RP11-351D16.3	4.84	1.78e-06	0.000214	0.21	0.22	Hirschsprung disease;	chr10:43245065	chr10:43136824~43138334:-
THCA	cis	rs6088580	0.634	rs2378134	ENSG00000276073.1	RP5-1125A11.7	4.84	1.78e-06	0.000214	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34350279	chr20:33985617~33988989:-
THCA	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	4.84	1.78e-06	0.000214	0.28	0.22	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
THCA	cis	rs7914558	0.966	rs4532960	ENSG00000236937.2	PTGES3P4	4.84	1.78e-06	0.000215	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102907649	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs10786724	ENSG00000236937.2	PTGES3P4	4.84	1.78e-06	0.000215	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102909185	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs2297786	ENSG00000236937.2	PTGES3P4	4.84	1.78e-06	0.000215	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102920221	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs10786725	ENSG00000236937.2	PTGES3P4	4.84	1.78e-06	0.000215	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102922600	chr10:102845595~102845950:+
THCA	cis	rs72843506	0.656	rs28567541	ENSG00000261033.1	RP11-209D14.2	4.84	1.78e-06	0.000215	0.4	0.22	Schizophrenia;	chr17:20051789	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs80250684	ENSG00000261033.1	RP11-209D14.2	4.84	1.78e-06	0.000215	0.4	0.22	Schizophrenia;	chr17:20054983	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs28622601	ENSG00000261033.1	RP11-209D14.2	4.84	1.78e-06	0.000215	0.4	0.22	Schizophrenia;	chr17:20055341	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.586	rs75048432	ENSG00000261033.1	RP11-209D14.2	4.84	1.78e-06	0.000215	0.4	0.22	Schizophrenia;	chr17:20057571	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs16960660	ENSG00000261033.1	RP11-209D14.2	4.84	1.78e-06	0.000215	0.4	0.22	Schizophrenia;	chr17:20062274	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs73984564	ENSG00000261033.1	RP11-209D14.2	4.84	1.78e-06	0.000215	0.4	0.22	Schizophrenia;	chr17:20068535	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs13339684	ENSG00000261033.1	RP11-209D14.2	4.84	1.78e-06	0.000215	0.4	0.22	Schizophrenia;	chr17:20073898	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs73984568	ENSG00000261033.1	RP11-209D14.2	4.84	1.78e-06	0.000215	0.4	0.22	Schizophrenia;	chr17:20074301	chr17:20008051~20009234:-
THCA	cis	rs2303319	0.504	rs62187742	ENSG00000227403.1	AC009299.3	4.84	1.78e-06	0.000215	0.54	0.22	Cognitive function;	chr2:161843587	chr2:161244739~161249050:+
THCA	cis	rs4722166	0.598	rs4722171	ENSG00000225541.1	AC002480.5	-4.84	1.78e-06	0.000215	-0.28	-0.22	Lung cancer;	chr7:22746098	chr7:22571607~22661792:-
THCA	cis	rs1005277	0.579	rs2505241	ENSG00000275858.1	RP11-291L22.8	4.84	1.78e-06	0.000215	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38450738~38451069:-
THCA	cis	rs189798	0.807	rs12785	ENSG00000253893.2	FAM85B	-4.84	1.78e-06	0.000215	-0.28	-0.22	Myopia (pathological);	chr8:9137426	chr8:8167819~8226614:-
THCA	cis	rs7542375	0.534	rs34179415	ENSG00000238078.1	LINC01352	-4.84	1.78e-06	0.000215	-0.33	-0.22	Obesity-related traits;	chr1:220870862	chr1:220829255~220832429:+
THCA	cis	rs11671005	0.693	rs11669665	ENSG00000268912.1	CTD-2619J13.17	-4.84	1.78e-06	0.000215	-0.21	-0.22	Mean platelet volume;	chr19:58420518	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.693	rs11084542	ENSG00000268912.1	CTD-2619J13.17	-4.84	1.78e-06	0.000215	-0.21	-0.22	Mean platelet volume;	chr19:58420732	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs11084543	ENSG00000268912.1	CTD-2619J13.17	-4.84	1.78e-06	0.000215	-0.21	-0.22	Mean platelet volume;	chr19:58421334	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs11881000	ENSG00000268912.1	CTD-2619J13.17	-4.84	1.78e-06	0.000215	-0.21	-0.22	Mean platelet volume;	chr19:58421421	chr19:58428632~58431148:-
THCA	cis	rs9625935	0.957	rs41166	ENSG00000279159.1	RP3-394A18.1	-4.84	1.78e-06	0.000215	-0.16	-0.22	Tonsillectomy;	chr22:30017682	chr22:29978950~30028236:-
THCA	cis	rs6044112	0.718	rs73101044	ENSG00000273998.1	RP4-777L9.2	4.84	1.78e-06	0.000215	0.33	0.22	Response to taxane treatment (docetaxel);	chr20:16530131	chr20:16576068~16579615:+
THCA	cis	rs3820928	0.904	rs59135978	ENSG00000212391.1	SNORA48	-4.84	1.78e-06	0.000215	-0.23	-0.22	Pulmonary function;	chr2:226993047	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.81	rs10175929	ENSG00000212391.1	SNORA48	-4.84	1.78e-06	0.000215	-0.23	-0.22	Pulmonary function;	chr2:226993893	chr2:226968989~226969122:-
THCA	cis	rs17095355	1	rs921351	ENSG00000203876.8	ADD3-AS1	-4.84	1.78e-06	0.000215	-0.23	-0.22	Biliary atresia;	chr10:109944957	chr10:109940104~110008381:-
THCA	cis	rs2067615	0.579	rs10778509	ENSG00000260329.1	RP11-412D9.4	-4.84	1.78e-06	0.000215	-0.2	-0.22	Heart rate;	chr12:106769140	chr12:106954029~106955497:-
THCA	cis	rs12906542	0.516	rs12593545	ENSG00000260776.4	RP11-114H24.2	4.84	1.78e-06	0.000215	0.36	0.22	Breast cancer;	chr15:78045597	chr15:77914217~77926846:-
THCA	cis	rs11673344	0.523	rs2562609	ENSG00000276846.1	CTD-3220F14.3	4.84	1.78e-06	0.000215	0.17	0.22	Obesity-related traits;	chr19:37036255	chr19:37314868~37315620:-
THCA	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-4.84	1.78e-06	0.000215	-0.26	-0.22	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
THCA	cis	rs1129187	0.755	rs9471986	ENSG00000272223.1	RP1-20C7.6	4.84	1.78e-06	0.000215	0.17	0.22	Alzheimer's disease in APOE e4+ carriers;	chr6:42976389	chr6:43033897~43034405:-
THCA	cis	rs2243480	1	rs4718270	ENSG00000232559.3	GS1-124K5.12	4.84	1.78e-06	0.000215	0.32	0.22	Diabetic kidney disease;	chr7:65737415	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs4718269	ENSG00000232559.3	GS1-124K5.12	-4.84	1.78e-06	0.000215	-0.32	-0.22	Diabetic kidney disease;	chr7:65735810	chr7:66554588~66576923:-
THCA	cis	rs1005277	0.579	rs1985707	ENSG00000275858.1	RP11-291L22.8	4.84	1.78e-06	0.000215	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38450738~38451069:-
THCA	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	4.84	1.78e-06	0.000215	0.16	0.22	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
THCA	cis	rs2243480	0.908	rs313822	ENSG00000164669.11	INTS4P1	4.84	1.78e-06	0.000215	0.41	0.22	Diabetic kidney disease;	chr7:66108952	chr7:65141225~65234216:+
THCA	cis	rs931127	0.719	rs11227259	ENSG00000214659.4	KRT8P26	4.84	1.78e-06	0.000215	0.19	0.22	Systemic lupus erythematosus;	chr11:65691933	chr11:65726939~65728214:+
THCA	cis	rs1914816	1	rs2255408	ENSG00000196274.5	Metazoa_SRP	-4.84	1.78e-06	0.000215	-0.31	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr15:76210954	chr15:76230048~76230390:-
THCA	cis	rs6714710	0.603	rs6738389	ENSG00000230606.9	AC159540.1	-4.84	1.78e-06	0.000215	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97770268	chr2:97416165~97433527:-
THCA	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	4.84	1.78e-06	0.000215	0.34	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
THCA	cis	rs4908760	0.792	rs6577515	ENSG00000232912.4	RP5-1115A15.1	4.84	1.78e-06	0.000215	0.21	0.22	Vitiligo;	chr1:8654143	chr1:8424645~8434838:+
THCA	cis	rs3820928	0.904	rs2396432	ENSG00000212391.1	SNORA48	-4.84	1.78e-06	0.000215	-0.25	-0.22	Pulmonary function;	chr2:226901175	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.904	rs2894623	ENSG00000212391.1	SNORA48	-4.84	1.78e-06	0.000215	-0.25	-0.22	Pulmonary function;	chr2:226901396	chr2:226968989~226969122:-
THCA	cis	rs1707322	1	rs785504	ENSG00000281133.1	AL355480.3	4.84	1.79e-06	0.000215	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45580892~45580996:-
THCA	cis	rs5758659	0.935	rs134879	ENSG00000227370.1	RP4-669P10.19	-4.84	1.79e-06	0.000215	-0.2	-0.22	Cognitive function;	chr22:42268195	chr22:42132543~42132998:+
THCA	cis	rs757978	0.81	rs1468445	ENSG00000223374.1	AC005104.3	4.84	1.79e-06	0.000216	0.21	0.22	Chronic lymphocytic leukemia;	chr2:241456139	chr2:241351340~241353104:-
THCA	cis	rs7010876	0.513	rs62524548	ENSG00000253553.4	RP11-586K2.1	-4.84	1.79e-06	0.000216	-0.22	-0.22	Schizophrenia;	chr8:88336324	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.615	rs4961090	ENSG00000253553.4	RP11-586K2.1	-4.84	1.79e-06	0.000216	-0.22	-0.22	Schizophrenia;	chr8:88337442	chr8:88326836~88737134:+
THCA	cis	rs4660456	0.913	rs552147	ENSG00000272145.1	NFYC-AS1	4.84	1.79e-06	0.000216	0.16	0.22	Platelet count;	chr1:40689141	chr1:40690380~40692066:-
THCA	cis	rs9487094	0.626	rs1980591	ENSG00000223537.2	RP5-919F19.5	-4.84	1.79e-06	0.000216	-0.22	-0.22	Height;	chr6:109618620	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.696	rs12191353	ENSG00000223537.2	RP5-919F19.5	-4.84	1.79e-06	0.000216	-0.22	-0.22	Height;	chr6:109620772	chr6:109487906~109506800:+
THCA	cis	rs11153306	0.677	rs10872070	ENSG00000230177.1	RP5-1112D6.4	-4.84	1.79e-06	0.000216	-0.17	-0.22	Tonsillectomy;	chr6:111600601	chr6:111277932~111278742:+
THCA	cis	rs7819412	0.654	rs4840550	ENSG00000261451.1	RP11-981G7.1	-4.84	1.79e-06	0.000216	-0.28	-0.22	Triglycerides;	chr8:11171520	chr8:10433672~10438312:+
THCA	cis	rs4660214	0.666	rs7414381	ENSG00000182109.6	RP11-69E11.4	-4.84	1.79e-06	0.000216	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs3116387	ENSG00000182109.6	RP11-69E11.4	-4.84	1.79e-06	0.000216	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.614	rs1537815	ENSG00000182109.6	RP11-69E11.4	-4.84	1.79e-06	0.000216	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.789	rs1984142	ENSG00000182109.6	RP11-69E11.4	-4.84	1.79e-06	0.000216	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs2275188	ENSG00000182109.6	RP11-69E11.4	-4.84	1.79e-06	0.000216	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39522280~39546187:-
THCA	cis	rs950776	0.518	rs4887062	ENSG00000261762.1	RP11-650L12.2	-4.84	1.79e-06	0.000216	-0.27	-0.22	Sudden cardiac arrest;	chr15:78545459	chr15:78589123~78591276:-
THCA	cis	rs13113518	1	rs11133388	ENSG00000273257.1	RP11-177J6.1	-4.84	1.79e-06	0.000216	-0.28	-0.22	Height;	chr4:55477866	chr4:55387949~55388271:+
THCA	cis	rs7914558	0.966	rs10748835	ENSG00000236937.2	PTGES3P4	4.84	1.79e-06	0.000216	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900499	chr10:102845595~102845950:+
THCA	cis	rs2976388	0.578	rs3736010	ENSG00000253741.1	CTD-2292P10.4	4.84	1.79e-06	0.000216	0.3	0.22	Urinary tract infection frequency;	chr8:142736085	chr8:142702252~142726973:-
THCA	cis	rs2380220	0.606	rs9488080	ENSG00000261366.1	MANEA-AS1	-4.84	1.79e-06	0.000216	-0.21	-0.22	Behavioural disinhibition (generation interaction);	chr6:95559097	chr6:95575183~95577450:-
THCA	cis	rs4578769	0.569	rs1448769	ENSG00000265939.1	UBE2CP2	4.84	1.79e-06	0.000216	0.25	0.22	Eosinophil percentage of white cells;	chr18:22838322	chr18:22900486~22900995:-
THCA	cis	rs481331	0.741	rs7088389	ENSG00000215146.4	RP11-313J2.1	4.84	1.79e-06	0.000216	0.35	0.22	Systemic juvenile idiopathic arthritis;	chr10:42695806	chr10:42331866~42367974:-
THCA	cis	rs481331	0.741	rs7099013	ENSG00000215146.4	RP11-313J2.1	4.84	1.79e-06	0.000216	0.35	0.22	Systemic juvenile idiopathic arthritis;	chr10:42696291	chr10:42331866~42367974:-
THCA	cis	rs12760731	0.582	rs12044868	ENSG00000213057.5	C1orf220	4.84	1.79e-06	0.000216	0.25	0.22	Obesity-related traits;	chr1:178545068	chr1:178542752~178548889:+
THCA	cis	rs13434995	0.589	rs62306207	ENSG00000273257.1	RP11-177J6.1	-4.84	1.79e-06	0.000216	-0.33	-0.22	Adiponectin levels;	chr4:55384548	chr4:55387949~55388271:+
THCA	cis	rs79243044	1	rs11038000	ENSG00000224295.2	AC087380.14	-4.84	1.79e-06	0.000216	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5536474	chr11:5518441~5524955:-
THCA	cis	rs79243044	1	rs11038004	ENSG00000224295.2	AC087380.14	-4.84	1.79e-06	0.000216	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5536688	chr11:5518441~5524955:-
THCA	cis	rs79243044	1	rs2201868	ENSG00000224295.2	AC087380.14	-4.84	1.79e-06	0.000216	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5536981	chr11:5518441~5524955:-
THCA	cis	rs79243044	1	rs12275855	ENSG00000224295.2	AC087380.14	-4.84	1.79e-06	0.000216	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5537972	chr11:5518441~5524955:-
THCA	cis	rs9329221	0.868	rs7831557	ENSG00000261451.1	RP11-981G7.1	-4.84	1.79e-06	0.000216	-0.28	-0.22	Neuroticism;	chr8:10422718	chr8:10433672~10438312:+
THCA	cis	rs7849973	0.624	rs1349150	ENSG00000234840.1	LINC01239	-4.84	1.79e-06	0.000216	-0.28	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22757187	chr9:22646200~22824213:+
THCA	cis	rs4715166	0.773	rs4711939	ENSG00000272379.1	RP1-257A7.5	4.84	1.79e-06	0.000216	0.28	0.22	Hip geometry;	chr6:13222645	chr6:13290018~13290490:-
THCA	cis	rs4713118	0.662	rs149947	ENSG00000261839.1	RP1-265C24.8	4.84	1.79e-06	0.000216	0.25	0.22	Parkinson's disease;	chr6:28004655	chr6:28136849~28139678:+
THCA	cis	rs2288884	0.505	rs12460506	ENSG00000269483.1	AC006272.1	4.84	1.79e-06	0.000216	0.32	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51980340	chr19:51839924~51843324:-
THCA	cis	rs4713118	0.506	rs9366697	ENSG00000216915.2	RP1-97D16.1	-4.84	1.79e-06	0.000216	-0.29	-0.22	Parkinson's disease;	chr6:27665239	chr6:27737000~27738494:-
THCA	cis	rs5758659	1	rs5751255	ENSG00000227370.1	RP4-669P10.19	-4.84	1.8e-06	0.000216	-0.2	-0.22	Cognitive function;	chr22:42252402	chr22:42132543~42132998:+
THCA	cis	rs2179367	0.613	rs12207047	ENSG00000223701.3	RAET1E-AS1	4.84	1.8e-06	0.000217	0.31	0.22	Dupuytren's disease;	chr6:149423496	chr6:149884431~149919508:+
THCA	cis	rs4722166	0.604	rs2390715	ENSG00000225541.1	AC002480.5	-4.84	1.8e-06	0.000217	-0.28	-0.22	Lung cancer;	chr7:22744259	chr7:22571607~22661792:-
THCA	cis	rs4722166	0.63	rs4722169	ENSG00000225541.1	AC002480.5	-4.84	1.8e-06	0.000217	-0.28	-0.22	Lung cancer;	chr7:22745800	chr7:22571607~22661792:-
THCA	cis	rs875971	0.545	rs73150604	ENSG00000228409.4	CCT6P1	-4.84	1.8e-06	0.000217	-0.19	-0.22	Aortic root size;	chr7:66480545	chr7:65751142~65763354:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000228409.4	CCT6P1	-4.84	1.8e-06	0.000217	-0.19	-0.22	Aortic root size;	chr7:66481592	chr7:65751142~65763354:+
THCA	cis	rs2745572	0.688	rs2816294	ENSG00000272279.1	RP11-157J24.2	4.84	1.8e-06	0.000217	0.29	0.22	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1538546	chr6:1528364~1528911:-
THCA	cis	rs4415084	0.804	rs57300972	ENSG00000272335.1	RP11-53O19.3	4.84	1.8e-06	0.000217	0.18	0.22	Breast cancer;	chr5:44897734	chr5:44826076~44828592:+
THCA	cis	rs6088580	0.634	rs945673	ENSG00000276073.1	RP5-1125A11.7	4.84	1.8e-06	0.000217	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34376459	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs1890000	ENSG00000276073.1	RP5-1125A11.7	4.84	1.8e-06	0.000217	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34380506	chr20:33985617~33988989:-
THCA	cis	rs3820928	0.845	rs7570869	ENSG00000212391.1	SNORA48	-4.84	1.8e-06	0.000217	-0.24	-0.22	Pulmonary function;	chr2:227014102	chr2:226968989~226969122:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000229886.1	RP5-1132H15.3	-4.84	1.8e-06	0.000217	-0.22	-0.22	Aortic root size;	chr7:66144830	chr7:66025126~66031544:-
THCA	cis	rs6832769	1	rs28572116	ENSG00000272969.1	RP11-528I4.2	-4.84	1.8e-06	0.000217	-0.25	-0.22	Personality dimensions;	chr4:55558177	chr4:55547112~55547889:+
THCA	cis	rs317689	0.69	rs317646	ENSG00000274979.1	RP11-1143G9.5	4.84	1.8e-06	0.000217	0.25	0.22	Response to diuretic therapy;	chr12:69263365	chr12:69326574~69331882:-
THCA	cis	rs4972806	0.849	rs2857535	ENSG00000226363.3	HAGLROS	-4.84	1.8e-06	0.000217	-0.25	-0.22	IgG glycosylation;	chr2:176171483	chr2:176177717~176179008:+
THCA	cis	rs6921919	0.609	rs67211468	ENSG00000280107.1	AL022393.9	-4.84	1.8e-06	0.000217	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28170845~28172521:+
THCA	cis	rs2337406	0.539	rs2583290	ENSG00000211974.3	IGHV2-70	4.84	1.8e-06	0.000217	0.2	0.22	Alzheimer's disease (late onset);	chr14:106650277	chr14:106723574~106724093:-
THCA	cis	rs5015933	0.902	rs1969045	ENSG00000232630.1	PRPS1P2	-4.84	1.8e-06	0.000217	-0.15	-0.22	Body mass index;	chr9:125368261	chr9:125150653~125151589:+
THCA	cis	rs2754412	1	rs2754412	ENSG00000275858.1	RP11-291L22.8	4.84	1.8e-06	0.000217	0.27	0.22	Breast cancer;	chr10:38338906	chr10:38450738~38451069:-
THCA	cis	rs73242632	0.881	rs1277296	ENSG00000269949.1	RP11-738E22.3	-4.84	1.8e-06	0.000217	-0.52	-0.22	Congenital heart disease (maternal effect);	chr4:57062164	chr4:56960927~56961373:-
THCA	cis	rs2797160	1	rs926853	ENSG00000237742.5	RP11-624M8.1	4.84	1.8e-06	0.000217	0.19	0.22	Endometrial cancer;	chr6:125700289	chr6:125578558~125749190:-
THCA	cis	rs72627509	0.638	rs78933653	ENSG00000269949.1	RP11-738E22.3	4.84	1.8e-06	0.000217	0.35	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56988674	chr4:56960927~56961373:-
THCA	cis	rs6600671	0.934	rs67718113	ENSG00000226067.5	CH17-118O6.2	-4.84	1.8e-06	0.000217	-0.23	-0.22	Hip geometry;	chr1:121497112	chr1:120913275~121009291:+
THCA	cis	rs4073582	0.595	rs801731	ENSG00000255320.1	RP11-755F10.1	-4.84	1.8e-06	0.000217	-0.27	-0.22	Gout;	chr11:66170975	chr11:66244840~66246239:-
THCA	cis	rs1714507	0.533	rs1620229	ENSG00000272087.1	RP11-379F4.7	4.84	1.8e-06	0.000217	0.2	0.22	Subjective well-being;	chr3:158575469	chr3:158693120~158693768:-
THCA	cis	rs72753537	0.683	rs12237985	ENSG00000214417.4	KRT18P13	4.84	1.8e-06	0.000217	0.24	0.22	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97844362	chr9:97698922~97700734:+
THCA	cis	rs17711722	1	rs17711722	ENSG00000213640.3	EEF1DP4	4.84	1.8e-06	0.000217	0.25	0.22	Calcium levels;	chr7:65806210	chr7:64862999~64864370:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000213640.3	EEF1DP4	4.84	1.8e-06	0.000217	0.25	0.22	Calcium levels;	chr7:65808508	chr7:64862999~64864370:+
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000204709.4	LINC01556	4.84	1.8e-06	0.000217	0.27	0.22	Pubertal anthropometrics;	chr6:28128502	chr6:28943877~28944537:+
THCA	cis	rs2447820	0.588	rs72798801	ENSG00000249996.1	RP11-359P5.1	4.84	1.8e-06	0.000217	0.26	0.22	Migraine;	chr5:123063737	chr5:123036271~123054667:+
THCA	cis	rs2447820	0.588	rs72798802	ENSG00000249996.1	RP11-359P5.1	4.84	1.8e-06	0.000217	0.26	0.22	Migraine;	chr5:123063848	chr5:123036271~123054667:+
THCA	cis	rs6887276	0.504	rs34145453	ENSG00000245937.6	LINC01184	-4.84	1.8e-06	0.000217	-0.21	-0.22	Height;	chr5:128011321	chr5:127940426~128083172:-
THCA	cis	rs9625935	0.826	rs1978083	ENSG00000279159.1	RP3-394A18.1	-4.84	1.8e-06	0.000217	-0.17	-0.22	Tonsillectomy;	chr22:30174454	chr22:29978950~30028236:-
THCA	cis	rs28475163	1	rs28475163	ENSG00000255328.1	RP11-326C3.12	4.84	1.8e-06	0.000217	0.3	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:327143	chr11:327171~330122:+
THCA	cis	rs78487399	0.908	rs79388962	ENSG00000234936.1	AC010883.5	4.84	1.8e-06	0.000218	0.28	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43580422	chr2:43229573~43233394:+
THCA	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-4.84	1.81e-06	0.000218	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-4.84	1.81e-06	0.000218	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-4.84	1.81e-06	0.000218	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-4.84	1.81e-06	0.000218	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-4.84	1.81e-06	0.000218	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-4.84	1.81e-06	0.000218	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-4.84	1.81e-06	0.000218	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
THCA	cis	rs13083990	1	rs13083990	ENSG00000272758.4	RP11-299J3.8	4.84	1.81e-06	0.000218	0.21	0.22	Cardiac Troponin-T levels;	chr3:122295719	chr3:122416207~122443180:+
THCA	cis	rs897984	0.683	rs12447534	ENSG00000279196.1	RP11-1072A3.3	-4.84	1.81e-06	0.000218	-0.22	-0.22	Dementia with Lewy bodies;	chr16:30792936	chr16:30984630~30988270:-
THCA	cis	rs875971	0.522	rs4718286	ENSG00000229886.1	RP5-1132H15.3	4.84	1.81e-06	0.000218	0.22	0.22	Aortic root size;	chr7:65827777	chr7:66025126~66031544:-
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000229886.1	RP5-1132H15.3	4.84	1.81e-06	0.000218	0.22	0.22	Calcium levels;	chr7:65837419	chr7:66025126~66031544:-
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000229886.1	RP5-1132H15.3	4.84	1.81e-06	0.000218	0.22	0.22	Calcium levels;	chr7:65872915	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs3885839	ENSG00000232559.3	GS1-124K5.12	4.84	1.81e-06	0.000218	0.32	0.22	Diabetic kidney disease;	chr7:65825416	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs73142122	ENSG00000232559.3	GS1-124K5.12	4.84	1.81e-06	0.000218	0.32	0.22	Diabetic kidney disease;	chr7:65846311	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs73142137	ENSG00000232559.3	GS1-124K5.12	4.84	1.81e-06	0.000218	0.32	0.22	Diabetic kidney disease;	chr7:65878455	chr7:66554588~66576923:-
THCA	cis	rs1003719	0.788	rs2251161	ENSG00000230366.8	DSCR9	-4.83	1.81e-06	0.000218	-0.22	-0.22	Eye color traits;	chr21:37095557	chr21:37208503~37221736:+
THCA	cis	rs4915077	1	rs4915077	ENSG00000226822.1	RP11-356N1.2	4.83	1.81e-06	0.000218	0.4	0.22	Hypothyroidism;	chr1:107823394	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs4359051	ENSG00000226822.1	RP11-356N1.2	4.83	1.81e-06	0.000218	0.4	0.22	Hypothyroidism;	chr1:107830792	chr1:108071482~108074519:+
THCA	cis	rs2439831	0.867	rs3213990	ENSG00000166763.7	STRCP1	4.83	1.81e-06	0.000218	0.3	0.22	Lung cancer in ever smokers;	chr15:43378028	chr15:43699488~43718184:-
THCA	cis	rs62246343	0.719	rs62246301	ENSG00000254485.4	RP11-380O24.1	4.83	1.81e-06	0.000218	0.29	0.22	Fibrinogen levels;	chr3:9409599	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.719	rs62246303	ENSG00000254485.4	RP11-380O24.1	4.83	1.81e-06	0.000218	0.29	0.22	Fibrinogen levels;	chr3:9413078	chr3:9292588~9363303:-
THCA	cis	rs9868809	0.772	rs12107252	ENSG00000270441.1	RP11-694I15.7	4.83	1.81e-06	0.000218	0.26	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48653883	chr3:49140086~49160851:-
THCA	cis	rs62025270	0.593	rs62022926	ENSG00000259295.5	CSPG4P12	-4.83	1.81e-06	0.000218	-0.38	-0.22	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85191438~85213905:+
THCA	cis	rs4245128	0.717	rs2361225	ENSG00000247416.2	RP11-629G13.1	4.83	1.81e-06	0.000218	0.22	0.22	Life satisfaction;	chr11:112943884	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.775	rs2361226	ENSG00000247416.2	RP11-629G13.1	4.83	1.81e-06	0.000218	0.22	0.22	Life satisfaction;	chr11:112943885	chr11:112959279~112963460:-
THCA	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	4.83	1.81e-06	0.000218	0.27	0.22	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
THCA	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	4.83	1.81e-06	0.000218	0.27	0.22	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
THCA	cis	rs748404	0.626	rs35992154	ENSG00000205771.5	CATSPER2P1	-4.83	1.81e-06	0.000218	-0.27	-0.22	Lung cancer;	chr15:43345669	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs17780417	ENSG00000205771.5	CATSPER2P1	-4.83	1.81e-06	0.000218	-0.27	-0.22	Lung cancer;	chr15:43347264	chr15:43726918~43747094:-
THCA	cis	rs748404	0.666	rs7181634	ENSG00000205771.5	CATSPER2P1	-4.83	1.81e-06	0.000218	-0.27	-0.22	Lung cancer;	chr15:43351703	chr15:43726918~43747094:-
THCA	cis	rs748404	0.63	rs35278805	ENSG00000205771.5	CATSPER2P1	-4.83	1.81e-06	0.000218	-0.27	-0.22	Lung cancer;	chr15:43361124	chr15:43726918~43747094:-
THCA	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-4.83	1.81e-06	0.000218	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
THCA	cis	rs6545883	0.894	rs778148	ENSG00000270820.4	RP11-355B11.2	-4.83	1.81e-06	0.000218	-0.18	-0.22	Tuberculosis;	chr2:61379731	chr2:61471188~61484130:+
THCA	cis	rs3738814	0.529	rs761422	ENSG00000186301.8	MST1P2	4.83	1.81e-06	0.000218	0.18	0.22	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Height;	chr1:16975285	chr1:16645622~16650289:+
THCA	cis	rs393155	0.517	rs330050	ENSG00000253981.4	ALG1L13P	-4.83	1.81e-06	0.000218	-0.21	-0.22	Neuroticism;	chr8:9230169	chr8:8236003~8244667:-
THCA	cis	rs453301	0.571	rs330054	ENSG00000253981.4	ALG1L13P	-4.83	1.81e-06	0.000218	-0.21	-0.22	Joint mobility (Beighton score);	chr8:9230781	chr8:8236003~8244667:-
THCA	cis	rs4448343	1	rs16909919	ENSG00000271155.1	RP11-435O5.5	4.83	1.81e-06	0.000218	0.22	0.22	Height;	chr9:95503498	chr9:95506235~95507636:+
THCA	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-4.83	1.81e-06	0.000218	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
THCA	cis	rs9634489	0.511	rs9516673	ENSG00000247400.3	DNAJC3-AS1	-4.83	1.81e-06	0.000218	-0.14	-0.22	Body mass index;	chr13:96385335	chr13:95648733~95676925:-
THCA	cis	rs7914558	0.646	rs7909286	ENSG00000236937.2	PTGES3P4	4.83	1.81e-06	0.000218	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899235	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.646	rs7909591	ENSG00000236937.2	PTGES3P4	4.83	1.81e-06	0.000218	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899261	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.621	rs10786722	ENSG00000236937.2	PTGES3P4	4.83	1.81e-06	0.000218	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900311	chr10:102845595~102845950:+
THCA	cis	rs13160562	0.527	rs25862	ENSG00000248734.2	CTD-2260A17.1	4.83	1.81e-06	0.000218	0.22	0.22	Alcohol dependence;	chr5:96769131	chr5:96784777~96785999:+
THCA	cis	rs13113518	0.966	rs13108409	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55520278	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11726198	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55523835	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs11133396	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55524246	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs7675109	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55525589	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs4865005	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55525781	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13108499	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55526514	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13116194	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55531150	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13117836	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55531218	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs7668429	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55531811	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13113518	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55533481	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13152173	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55534788	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13141049	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55535489	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.967	rs12507722	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55536421	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.967	rs7696832	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55537080	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs34648901	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55541259	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.902	rs12505266	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55546002	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs56154935	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55546378	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs7662966	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55548261	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13115828	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55551447	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs13136282	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55551845	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11934897	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55553396	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.934	rs11932293	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55554025	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs4865011	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55554456	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs4865013	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55559957	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs13144598	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55570311	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs11942472	ENSG00000273257.1	RP11-177J6.1	4.83	1.81e-06	0.000218	0.28	0.22	Height;	chr4:55574959	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs4865007	ENSG00000273257.1	RP11-177J6.1	-4.83	1.81e-06	0.000218	-0.28	-0.22	Height;	chr4:55537550	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs4864548	ENSG00000273257.1	RP11-177J6.1	-4.83	1.81e-06	0.000218	-0.28	-0.22	Height;	chr4:55547636	chr4:55387949~55388271:+
THCA	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-4.83	1.81e-06	0.000218	-0.26	-0.22	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
THCA	cis	rs972578	0.791	rs5759042	ENSG00000274717.1	RP1-47A17.1	-4.83	1.81e-06	0.000218	-0.22	-0.22	Mean platelet volume;	chr22:42928177	chr22:42791814~42794313:-
THCA	cis	rs12908161	1	rs12911736	ENSG00000188388.10	GOLGA6L3	4.83	1.81e-06	0.000218	0.29	0.22	Schizophrenia;	chr15:84696777	chr15:85240472~85247170:+
THCA	cis	rs12908161	0.959	rs12908699	ENSG00000188388.10	GOLGA6L3	4.83	1.81e-06	0.000218	0.29	0.22	Schizophrenia;	chr15:84697172	chr15:85240472~85247170:+
THCA	cis	rs10090774	0.965	rs11785430	ENSG00000279766.1	RP11-642A1.2	-4.83	1.81e-06	0.000218	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140999428	chr8:140572142~140572812:-
THCA	cis	rs1005277	0.602	rs1831315	ENSG00000275858.1	RP11-291L22.8	4.83	1.81e-06	0.000218	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780130	ENSG00000275858.1	RP11-291L22.8	4.83	1.81e-06	0.000218	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38450738~38451069:-
THCA	cis	rs2617170	0.922	rs11838084	ENSG00000245648.1	RP11-277P12.20	-4.83	1.81e-06	0.000218	-0.23	-0.22	Behcet's disease;	chr12:10427704	chr12:10363769~10398506:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000164669.11	INTS4P1	4.83	1.81e-06	0.000218	0.27	0.22	Aortic root size;	chr7:65950660	chr7:65141225~65234216:+
THCA	cis	rs2692947	0.667	rs4144055	ENSG00000232931.4	LINC00342	4.83	1.81e-06	0.000219	0.17	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95982108	chr2:95807118~95816215:-
THCA	cis	rs12908161	0.515	rs12907646	ENSG00000225151.9	GOLGA2P7	-4.83	1.81e-06	0.000219	-0.33	-0.22	Schizophrenia;	chr15:84860265	chr15:84199311~84230136:-
THCA	cis	rs12554020	0.582	rs76849659	ENSG00000227603.1	RP11-165J3.6	4.83	1.81e-06	0.000219	0.43	0.22	Schizophrenia;	chr9:93685420	chr9:93435332~93437121:-
THCA	cis	rs7577696	0.889	rs455060	ENSG00000276334.1	AL133243.1	4.83	1.81e-06	0.000219	0.23	0.22	Inflammatory biomarkers;	chr2:32250040	chr2:32521927~32523547:+
THCA	cis	rs6973609	0.554	rs1600016	ENSG00000271122.1	RP11-379H18.1	4.83	1.82e-06	0.000219	0.15	0.22	Obesity-related traits;	chr7:35566102	chr7:35695214~35699413:+
THCA	cis	rs7267979	0.932	rs4280527	ENSG00000274973.1	RP13-401N8.7	-4.83	1.82e-06	0.000219	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25845497~25845862:+
THCA	cis	rs2436845	1	rs2513921	ENSG00000253669.3	KB-1732A1.1	-4.83	1.82e-06	0.000219	-0.22	-0.22	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102818167	chr8:102805517~102809971:+
THCA	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-4.83	1.82e-06	0.000219	-0.25	-0.22	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
THCA	cis	rs7577696	0.889	rs212737	ENSG00000276334.1	AL133243.1	4.83	1.82e-06	0.000219	0.23	0.22	Inflammatory biomarkers;	chr2:32249222	chr2:32521927~32523547:+
THCA	cis	rs17826219	0.585	rs8064302	ENSG00000266490.1	CTD-2349P21.9	-4.83	1.82e-06	0.000219	-0.3	-0.22	Body mass index;	chr17:30397920	chr17:30792372~30792833:+
THCA	cis	rs9925964	0.933	rs11150604	ENSG00000260911.2	RP11-196G11.2	-4.83	1.82e-06	0.000219	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31025699	chr16:31043150~31049868:+
THCA	cis	rs12476592	0.516	rs7558796	ENSG00000242412.1	DBIL5P2	4.83	1.82e-06	0.000219	0.28	0.22	Childhood ear infection;	chr2:63369973	chr2:63117851~63119542:-
THCA	cis	rs6088580	0.634	rs6058073	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.82e-06	0.000219	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34528678	chr20:33985617~33988989:-
THCA	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	4.83	1.82e-06	0.000219	0.21	0.22	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
THCA	cis	rs10895275	0.961	rs3858420	ENSG00000277459.1	RP11-732A21.3	-4.83	1.82e-06	0.000219	-0.17	-0.22	Migraine;	chr11:102227623	chr11:102109827~102110457:-
THCA	cis	rs12935229	1	rs12925274	ENSG00000260922.1	RP11-538I12.3	4.83	1.82e-06	0.000219	0.36	0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77286618	chr16:77234877~77290934:+
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000273796.1	LL21NC02-21A1.1	-4.83	1.82e-06	0.000219	-0.22	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45403809~45404369:-
THCA	cis	rs17772222	0.597	rs17700521	ENSG00000222990.1	RNU4-22P	4.83	1.82e-06	0.000219	0.29	0.22	Coronary artery calcification;	chr14:88849531	chr14:88513498~88513663:+
THCA	cis	rs2734839	0.964	rs7122246	ENSG00000270179.1	RP11-159N11.4	-4.83	1.82e-06	0.000219	-0.23	-0.22	Information processing speed;	chr11:113433735	chr11:113368478~113369117:+
THCA	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-4.83	1.82e-06	0.000219	-0.24	-0.22	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
THCA	cis	rs17767392	0.748	rs57204407	ENSG00000259146.3	RP1-261D10.2	4.83	1.82e-06	0.000219	0.29	0.22	Mitral valve prolapse;	chr14:71237544	chr14:71292729~71321814:-
THCA	cis	rs6490294	0.528	rs12422941	ENSG00000226469.1	ADAM1B	-4.83	1.82e-06	0.00022	-0.35	-0.22	Mean platelet volume;	chr12:112099934	chr12:111927018~111929017:+
THCA	cis	rs7474896	0.583	rs10764144	ENSG00000263064.2	RP11-291L22.7	4.83	1.82e-06	0.00022	0.29	0.22	Obesity (extreme);	chr10:37686804	chr10:38448689~38448949:+
THCA	cis	rs5758511	0.508	rs2854827	ENSG00000237037.8	NDUFA6-AS1	-4.83	1.82e-06	0.00022	-0.23	-0.22	Birth weight;	chr22:42065914	chr22:42090931~42137742:+
THCA	cis	rs17801127	1	rs848226	ENSG00000231969.1	AC144449.1	-4.83	1.82e-06	0.00022	-0.35	-0.22	Liver enzyme levels (alanine transaminase);	chr2:149700260	chr2:149587196~149848233:+
THCA	cis	rs4650994	0.593	rs7552110	ENSG00000273384.1	RP5-1098D14.1	-4.83	1.82e-06	0.00022	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178573019	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.509	rs7519794	ENSG00000273384.1	RP5-1098D14.1	-4.83	1.82e-06	0.00022	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178573255	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.55	rs12047530	ENSG00000273384.1	RP5-1098D14.1	-4.83	1.82e-06	0.00022	-0.29	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178574272	chr1:178651706~178652282:+
THCA	cis	rs228614	0.51	rs223452	ENSG00000248971.2	KRT8P46	-4.83	1.83e-06	0.00022	-0.27	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102728746~102730171:-
THCA	cis	rs11894081	1	rs11894081	ENSG00000232835.1	AC107057.1	4.83	1.83e-06	0.00022	0.22	0.22	Crohn's disease;	chr2:5523876	chr2:5549780~5556031:-
THCA	cis	rs16958440	0.708	rs62096462	ENSG00000267800.1	RP11-49K24.5	-4.83	1.83e-06	0.00022	-0.4	-0.22	Sitting height ratio;	chr18:47098808	chr18:47137018~47137290:+
THCA	cis	rs8028182	0.636	rs8036758	ENSG00000260274.1	RP11-817O13.8	4.83	1.83e-06	0.00022	0.16	0.22	Sudden cardiac arrest;	chr15:75525221	chr15:75368155~75369584:+
THCA	cis	rs17404153	0.599	rs6792616	ENSG00000248724.5	NPHP3-AS1	-4.83	1.83e-06	0.00022	-0.32	-0.22	LDL cholesterol;HDL cholesterol;	chr3:132430707	chr3:132721750~132874223:+
THCA	cis	rs9307551	1	rs7688923	ENSG00000250334.4	LINC00989	4.83	1.83e-06	0.00022	0.28	0.22	Refractive error;	chr4:79640877	chr4:79492416~79576460:+
THCA	cis	rs728616	0.558	rs2343302	ENSG00000242600.5	MBL1P	4.83	1.83e-06	0.00022	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80403430	chr10:79904898~79950336:+
THCA	cis	rs5758659	1	rs134873	ENSG00000281538.1	RP4-669P10.20	4.83	1.83e-06	0.00022	0.2	0.22	Cognitive function;	chr22:42261560	chr22:42138060~42139726:+
THCA	cis	rs35740288	0.822	rs17636864	ENSG00000259295.5	CSPG4P12	4.83	1.83e-06	0.00022	0.34	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85691358	chr15:85191438~85213905:+
THCA	cis	rs7572644	0.699	rs6731650	ENSG00000223522.1	AC093690.1	4.83	1.83e-06	0.00022	0.25	0.22	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28038296	chr2:28307691~28310459:-
THCA	cis	rs7208859	0.573	rs8078182	ENSG00000280069.1	CTD-2349P21.3	-4.83	1.83e-06	0.00022	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30738182~30740275:+
THCA	cis	rs12612619	0.732	rs13032059	ENSG00000229122.1	AGBL5-IT1	4.83	1.83e-06	0.00022	0.15	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010921	chr2:27061038~27061815:+
THCA	cis	rs12612619	0.732	rs13032100	ENSG00000229122.1	AGBL5-IT1	4.83	1.83e-06	0.00022	0.15	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010991	chr2:27061038~27061815:+
THCA	cis	rs9625935	0.957	rs9625919	ENSG00000279159.1	RP3-394A18.1	-4.83	1.83e-06	0.00022	-0.16	-0.22	Tonsillectomy;	chr22:30104969	chr22:29978950~30028236:-
THCA	cis	rs3820928	0.904	rs2195487	ENSG00000212391.1	SNORA48	-4.83	1.83e-06	0.00022	-0.25	-0.22	Pulmonary function;	chr2:226895004	chr2:226968989~226969122:-
THCA	cis	rs6600671	0.693	rs1853731	ENSG00000275585.1	CH17-118O6.3	-4.83	1.83e-06	0.00022	-0.27	-0.22	Hip geometry;	chr1:121510262	chr1:120985692~121052167:-
THCA	cis	rs755249	0.565	rs7539261	ENSG00000228060.1	RP11-69E11.8	4.83	1.83e-06	0.00022	0.2	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39565160~39573203:+
THCA	cis	rs9890032	0.542	rs35840638	ENSG00000266490.1	CTD-2349P21.9	4.83	1.83e-06	0.00022	0.23	0.22	Hip circumference adjusted for BMI;	chr17:30924623	chr17:30792372~30792833:+
THCA	cis	rs2235642	0.653	rs7197288	ENSG00000280231.1	LA16c-380F5.3	-4.83	1.83e-06	0.00022	-0.26	-0.22	Coronary artery disease;	chr16:1604752	chr16:1553655~1554130:-
THCA	cis	rs5752326	0.702	rs3752589	ENSG00000261188.1	CTA-445C9.14	4.83	1.83e-06	0.00022	0.29	0.22	Ischemic stroke;	chr22:26451620	chr22:26512537~26514568:+
THCA	cis	rs12760731	0.582	rs6676116	ENSG00000213057.5	C1orf220	4.83	1.83e-06	0.00022	0.25	0.22	Obesity-related traits;	chr1:178597643	chr1:178542752~178548889:+
THCA	cis	rs6430538	0.597	rs4954181	ENSG00000224043.6	CCNT2-AS1	-4.83	1.83e-06	0.000221	-0.23	-0.22	Parkinson's disease;	chr2:134812802	chr2:134735464~134918710:-
THCA	cis	rs3213758	0.643	rs78085561	ENSG00000275191.1	RP11-36I17.2	-4.83	1.83e-06	0.000221	-0.45	-0.22	Vitiligo (non-segmental);	chr16:53707076	chr16:53628256~53628816:-
THCA	cis	rs7554547	0.69	rs4846064	ENSG00000201801.1	RNU5E-4P	4.83	1.83e-06	0.000221	0.26	0.22	Nonsyndromic cleft lip with cleft palate;	chr1:11874785	chr1:11909808~11909927:-
THCA	cis	rs2803122	0.875	rs4625124	ENSG00000273226.1	RP11-513M16.8	-4.83	1.83e-06	0.000221	-0.2	-0.22	Pulse pressure;	chr9:19271341	chr9:19375451~19375996:+
THCA	cis	rs66887589	0.616	rs13113885	ENSG00000249244.1	RP11-548H18.2	4.83	1.83e-06	0.000221	0.23	0.22	Diastolic blood pressure;	chr4:119300021	chr4:119391831~119395335:-
THCA	cis	rs8020095	0.571	rs1950282	ENSG00000258561.1	RP11-72M17.1	4.83	1.83e-06	0.000221	0.29	0.22	Depression (quantitative trait);	chr14:67020912	chr14:66212810~66509394:-
THCA	cis	rs1150668	0.796	rs213236	ENSG00000176933.5	TOB2P1	-4.83	1.83e-06	0.000221	-0.23	-0.22	Pubertal anthropometrics;	chr6:28356620	chr6:28217643~28218634:-
THCA	cis	rs5015933	0.801	rs3104546	ENSG00000232630.1	PRPS1P2	-4.83	1.83e-06	0.000221	-0.15	-0.22	Body mass index;	chr9:125375390	chr9:125150653~125151589:+
THCA	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-4.83	1.83e-06	0.000221	-0.25	-0.22	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
THCA	cis	rs600231	0.542	rs11227198	ENSG00000245532.5	NEAT1	4.83	1.83e-06	0.000221	0.19	0.22	Bone mineral density;	chr11:65470503	chr11:65422774~65445540:+
THCA	cis	rs600231	0.542	rs11227199	ENSG00000245532.5	NEAT1	4.83	1.83e-06	0.000221	0.19	0.22	Bone mineral density;	chr11:65470650	chr11:65422774~65445540:+
THCA	cis	rs600231	0.542	rs12360896	ENSG00000245532.5	NEAT1	4.83	1.83e-06	0.000221	0.19	0.22	Bone mineral density;	chr11:65470835	chr11:65422774~65445540:+
THCA	cis	rs600231	0.542	rs34527830	ENSG00000245532.5	NEAT1	4.83	1.83e-06	0.000221	0.19	0.22	Bone mineral density;	chr11:65473392	chr11:65422774~65445540:+
THCA	cis	rs600231	0.577	rs35826299	ENSG00000245532.5	NEAT1	4.83	1.83e-06	0.000221	0.19	0.22	Bone mineral density;	chr11:65473493	chr11:65422774~65445540:+
THCA	cis	rs600231	0.508	rs11227202	ENSG00000245532.5	NEAT1	4.83	1.83e-06	0.000221	0.19	0.22	Bone mineral density;	chr11:65475246	chr11:65422774~65445540:+
THCA	cis	rs600231	0.542	rs10896010	ENSG00000245532.5	NEAT1	4.83	1.83e-06	0.000221	0.19	0.22	Bone mineral density;	chr11:65478749	chr11:65422774~65445540:+
THCA	cis	rs1048886	0.938	rs9455130	ENSG00000271967.1	RP11-134K13.4	-4.83	1.84e-06	0.000221	-0.22	-0.22	Type 2 diabetes;	chr6:70488940	chr6:70596438~70596980:+
THCA	cis	rs7914558	0.646	rs1046778	ENSG00000236937.2	PTGES3P4	4.83	1.84e-06	0.000221	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102901727	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.646	rs11191459	ENSG00000236937.2	PTGES3P4	4.83	1.84e-06	0.000221	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902361	chr10:102845595~102845950:+
THCA	cis	rs916888	0.531	rs183211	ENSG00000261575.2	RP11-259G18.1	4.83	1.84e-06	0.000221	0.26	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46267037~46268694:+
THCA	cis	rs2239547	0.522	rs2581815	ENSG00000242142.1	SERBP1P3	4.83	1.84e-06	0.000221	0.27	0.22	Schizophrenia;	chr3:52948143	chr3:53064283~53065091:-
THCA	cis	rs73198271	0.96	rs11776546	ENSG00000253893.2	FAM85B	4.83	1.84e-06	0.000221	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751671	chr8:8167819~8226614:-
THCA	cis	rs6088580	0.634	rs6059824	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.84e-06	0.000221	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34426737	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6058041	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.84e-06	0.000221	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34430202	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6058052	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.84e-06	0.000221	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34459279	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6088475	ENSG00000276073.1	RP5-1125A11.7	4.83	1.84e-06	0.000221	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34377181	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6142164	ENSG00000276073.1	RP5-1125A11.7	4.83	1.84e-06	0.000221	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34418791	chr20:33985617~33988989:-
THCA	cis	rs62246343	0.719	rs62246302	ENSG00000254485.4	RP11-380O24.1	4.83	1.84e-06	0.000221	0.29	0.22	Fibrinogen levels;	chr3:9411761	chr3:9292588~9363303:-
THCA	cis	rs9494145	0.526	rs62429816	ENSG00000232876.1	CTA-212D2.2	-4.83	1.84e-06	0.000221	-0.34	-0.22	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135164884	chr6:135055033~135060550:+
THCA	cis	rs7829975	0.667	rs1877119	ENSG00000233609.3	RP11-62H7.2	4.83	1.84e-06	0.000221	0.21	0.22	Mood instability;	chr8:8849687	chr8:8961200~8979025:+
THCA	cis	rs6951245	1	rs11764748	ENSG00000229043.2	AC091729.9	-4.83	1.84e-06	0.000221	-0.36	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054872	chr7:1160374~1165267:+
THCA	cis	rs1150668	0.796	rs1052215	ENSG00000273712.1	RP5-874C20.7	-4.83	1.84e-06	0.000221	-0.24	-0.22	Pubertal anthropometrics;	chr6:28380381	chr6:28315613~28315883:-
THCA	cis	rs4073582	0.595	rs801736	ENSG00000255320.1	RP11-755F10.1	-4.83	1.84e-06	0.000221	-0.27	-0.22	Gout;	chr11:66160959	chr11:66244840~66246239:-
THCA	cis	rs4073582	0.595	rs801734	ENSG00000255320.1	RP11-755F10.1	-4.83	1.84e-06	0.000221	-0.27	-0.22	Gout;	chr11:66163745	chr11:66244840~66246239:-
THCA	cis	rs34792	0.554	rs12933773	ENSG00000207425.1	Y_RNA	-4.83	1.84e-06	0.000221	-0.25	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:14915457~14915556:-
THCA	cis	rs6088580	0.634	rs6141465	ENSG00000276073.1	RP5-1125A11.7	4.83	1.84e-06	0.000221	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34379508	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6142157	ENSG00000276073.1	RP5-1125A11.7	4.83	1.84e-06	0.000221	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34396366	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6142159	ENSG00000276073.1	RP5-1125A11.7	4.83	1.84e-06	0.000221	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34405229	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6088502	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.84e-06	0.000221	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34449839	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6059856	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.84e-06	0.000221	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34470149	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6087588	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.84e-06	0.000221	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34478564	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs13041646	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.84e-06	0.000221	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34495076	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.602	rs6058064	ENSG00000276073.1	RP5-1125A11.7	-4.83	1.84e-06	0.000221	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34498817	chr20:33985617~33988989:-
THCA	cis	rs34792	0.554	rs12708796	ENSG00000207425.1	Y_RNA	-4.83	1.84e-06	0.000221	-0.25	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:14915457~14915556:-
THCA	cis	rs72945132	1	rs72945127	ENSG00000254604.1	AP000487.6	-4.83	1.84e-06	0.000221	-0.41	-0.22	Coronary artery disease;	chr11:70261544	chr11:70282367~70363368:-
THCA	cis	rs11671005	0.61	rs11669345	ENSG00000269600.1	AC016629.3	-4.83	1.84e-06	0.000221	-0.31	-0.22	Mean platelet volume;	chr19:58550892	chr19:58593896~58599355:-
THCA	cis	rs2361718	0.501	rs12944619	ENSG00000275479.1	RP11-334C17.6	4.83	1.84e-06	0.000221	0.21	0.22	Yeast infection;	chr17:80170310	chr17:80149627~80149798:+
THCA	cis	rs7403037	0.794	rs35985747	ENSG00000260760.1	PWRN3	4.83	1.84e-06	0.000221	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24513803	chr15:24441127~24447967:+
THCA	cis	rs4915077	1	rs17020149	ENSG00000226822.1	RP11-356N1.2	4.83	1.84e-06	0.000221	0.4	0.22	Hypothyroidism;	chr1:107832667	chr1:108071482~108074519:+
THCA	cis	rs2251381	0.808	rs7364112	ENSG00000176054.6	RPL23P2	4.83	1.84e-06	0.000221	0.19	0.22	Selective IgA deficiency;	chr21:29176647	chr21:28997613~28998033:-
THCA	cis	rs2735413	0.563	rs72800906	ENSG00000276007.1	RP11-358L22.3	4.83	1.84e-06	0.000221	0.25	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78012430	chr16:78123243~78124332:+
THCA	cis	rs2735413	0.563	rs72800907	ENSG00000276007.1	RP11-358L22.3	4.83	1.84e-06	0.000221	0.25	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78012475	chr16:78123243~78124332:+
THCA	cis	rs2735413	0.563	rs72800908	ENSG00000276007.1	RP11-358L22.3	4.83	1.84e-06	0.000221	0.25	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78012621	chr16:78123243~78124332:+
THCA	cis	rs12554020	0.582	rs12552323	ENSG00000227603.1	RP11-165J3.6	-4.83	1.84e-06	0.000221	-0.41	-0.22	Schizophrenia;	chr9:93680532	chr9:93435332~93437121:-
THCA	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	4.83	1.84e-06	0.000222	0.13	0.22	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
THCA	cis	rs3824488	0.834	rs79057214	ENSG00000237857.2	RP11-435O5.2	-4.83	1.84e-06	0.000222	-0.42	-0.22	Neuroticism;	chr9:95488392	chr9:95414834~95426796:-
THCA	cis	rs17270561	0.943	rs76703022	ENSG00000272462.2	U91328.19	-4.83	1.84e-06	0.000222	-0.21	-0.22	Iron status biomarkers;	chr6:25703301	chr6:25992662~26001775:+
THCA	cis	rs9402682	1	rs9402682	ENSG00000232876.1	CTA-212D2.2	-4.83	1.84e-06	0.000222	-0.3	-0.22	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135085045	chr6:135055033~135060550:+
THCA	cis	rs6545883	0.524	rs4599092	ENSG00000270820.4	RP11-355B11.2	-4.83	1.84e-06	0.000222	-0.19	-0.22	Tuberculosis;	chr2:61271833	chr2:61471188~61484130:+
THCA	cis	rs6088580	0.634	rs7271970	ENSG00000276073.1	RP5-1125A11.7	4.83	1.84e-06	0.000222	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34399860	chr20:33985617~33988989:-
THCA	cis	rs2236231	0.55	rs12897715	ENSG00000259502.1	RP11-643G16.3	-4.83	1.84e-06	0.000222	-0.25	-0.22	Plasma kynurenine levels in major depressive disorder;	chr14:67593117	chr14:67610986~67613864:+
THCA	cis	rs8046148	0.724	rs12930079	ENSG00000279356.1	RP11-429P3.8	4.83	1.84e-06	0.000222	0.26	0.22	Testicular germ cell tumor;	chr16:50092780	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs11642695	ENSG00000279356.1	RP11-429P3.8	4.83	1.84e-06	0.000222	0.26	0.22	Testicular germ cell tumor;	chr16:50093209	chr16:50072862~50074986:+
THCA	cis	rs7523875	0.572	rs76831274	ENSG00000153363.11	LINC00467	-4.83	1.84e-06	0.000222	-0.3	-0.22	Mean corpuscular volume;	chr1:211435104	chr1:211382803~211435333:+
THCA	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-4.83	1.84e-06	0.000222	-0.25	-0.22	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
THCA	cis	rs6012564	1	rs755587	ENSG00000227431.4	CSE1L-AS1	4.83	1.85e-06	0.000222	0.26	0.22	Anger;	chr20:49104420	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs11696870	ENSG00000227431.4	CSE1L-AS1	4.83	1.85e-06	0.000222	0.26	0.22	Anger;	chr20:49109070	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.963	rs6063355	ENSG00000227431.4	CSE1L-AS1	4.83	1.85e-06	0.000222	0.26	0.22	Anger;	chr20:49109592	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs6066968	ENSG00000227431.4	CSE1L-AS1	4.83	1.85e-06	0.000222	0.26	0.22	Anger;	chr20:49110804	chr20:49040463~49046044:-
THCA	cis	rs394563	0.601	rs431978	ENSG00000231760.4	RP11-350J20.5	-4.83	1.85e-06	0.000222	-0.3	-0.22	Dupuytren's disease;	chr6:149471864	chr6:149796151~149826294:-
THCA	cis	rs72843506	0.656	rs79406817	ENSG00000261033.1	RP11-209D14.2	4.83	1.85e-06	0.000222	0.42	0.22	Schizophrenia;	chr17:20011814	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs77090106	ENSG00000261033.1	RP11-209D14.2	4.83	1.85e-06	0.000222	0.42	0.22	Schizophrenia;	chr17:20044832	chr17:20008051~20009234:-
THCA	cis	rs860295	0.665	rs12028416	ENSG00000160766.13	GBAP1	-4.83	1.85e-06	0.000222	-0.25	-0.22	Body mass index;	chr1:155431370	chr1:155213821~155227422:-
THCA	cis	rs860295	0.629	rs12026638	ENSG00000160766.13	GBAP1	-4.83	1.85e-06	0.000222	-0.25	-0.22	Body mass index;	chr1:155431469	chr1:155213821~155227422:-
THCA	cis	rs3820928	0.874	rs10194663	ENSG00000212391.1	SNORA48	-4.83	1.85e-06	0.000222	-0.23	-0.22	Pulmonary function;	chr2:227010653	chr2:226968989~226969122:-
THCA	cis	rs295490	1	rs295490	ENSG00000272656.1	RP11-219D15.3	-4.83	1.85e-06	0.000222	-0.3	-0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139522529	chr3:139349024~139349371:-
THCA	cis	rs9890032	0.934	rs7225461	ENSG00000263531.1	RP13-753N3.1	4.83	1.85e-06	0.000222	0.29	0.22	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30863921~30864940:-
THCA	cis	rs6088580	0.634	rs62212172	ENSG00000276073.1	RP5-1125A11.7	4.83	1.85e-06	0.000222	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34399899	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs4142007	ENSG00000276073.1	RP5-1125A11.7	4.83	1.85e-06	0.000222	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34402244	chr20:33985617~33988989:-
THCA	cis	rs763121	0.853	rs5750621	ENSG00000228274.3	RP3-508I15.9	-4.83	1.85e-06	0.000222	-0.24	-0.22	Menopause (age at onset);	chr22:38560161	chr22:38667585~38681820:-
THCA	cis	rs763121	0.744	rs5757140	ENSG00000228274.3	RP3-508I15.9	-4.83	1.85e-06	0.000222	-0.24	-0.22	Menopause (age at onset);	chr22:38561008	chr22:38667585~38681820:-
THCA	cis	rs7614311	0.689	rs73122704	ENSG00000271843.1	RP11-245J9.5	-4.83	1.85e-06	0.000222	-0.4	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63855552	chr3:64008082~64008692:-
THCA	cis	rs72945132	0.66	rs7121703	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70294190	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7118156	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70296816	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7937984	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70298148	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs17160039	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70299383	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs12282678	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70306351	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.823	rs12292240	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70306506	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7945389	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70312770	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7116059	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70313584	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7116191	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70313675	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.714	rs57320340	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70313904	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.556	rs57172967	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70313954	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs67529561	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70315949	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs61260732	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000222	-0.4	-0.22	Coronary artery disease;	chr11:70316039	chr11:70282367~70363368:-
THCA	cis	rs4648045	0.828	rs3774936	ENSG00000246560.2	RP11-10L12.4	4.83	1.85e-06	0.000222	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102512980	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.861	rs3774937	ENSG00000246560.2	RP11-10L12.4	4.83	1.85e-06	0.000222	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102513096	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.828	rs62328542	ENSG00000246560.2	RP11-10L12.4	4.83	1.85e-06	0.000222	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102516430	chr4:102828055~102844075:+
THCA	cis	rs9527	0.501	rs12244388	ENSG00000213061.2	PFN1P11	4.83	1.85e-06	0.000222	0.27	0.22	Arsenic metabolism;	chr10:102880295	chr10:102838011~102845473:-
THCA	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	4.83	1.85e-06	0.000222	0.15	0.22	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
THCA	cis	rs8050907	0.744	rs7195782	ENSG00000278434.1	RP11-709D24.8	-4.83	1.85e-06	0.000222	-0.48	-0.22	Obesity-related traits;	chr16:4489860	chr16:4532216~4533670:-
THCA	cis	rs950880	0.71	rs12905	ENSG00000234389.1	AC007278.3	-4.83	1.85e-06	0.000222	-0.27	-0.22	Serum protein levels (sST2);	chr2:102343547	chr2:102438713~102440475:+
THCA	cis	rs2985684	1	rs7142457	ENSG00000278009.1	RP11-649E7.8	4.83	1.85e-06	0.000222	0.31	0.22	Carotid intima media thickness;	chr14:49631144	chr14:49601011~49601124:-
THCA	cis	rs2985684	0.901	rs2354448	ENSG00000278009.1	RP11-649E7.8	4.83	1.85e-06	0.000222	0.31	0.22	Carotid intima media thickness;	chr14:49631578	chr14:49601011~49601124:-
THCA	cis	rs2985684	1	rs1952012	ENSG00000278009.1	RP11-649E7.8	4.83	1.85e-06	0.000222	0.31	0.22	Carotid intima media thickness;	chr14:49632178	chr14:49601011~49601124:-
THCA	cis	rs9926296	0.656	rs4522419	ENSG00000260259.1	RP11-368I7.4	-4.83	1.85e-06	0.000222	-0.24	-0.22	Vitiligo;	chr16:89786899	chr16:89682620~89686569:-
THCA	cis	rs8028182	0.636	rs7495610	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75492100	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs12708519	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75510859	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs8029112	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75516631	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs4322627	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75518318	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs4886712	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75520547	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs8030802	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75520812	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.577	rs8023268	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75522331	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs8023815	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75522363	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs11636031	ENSG00000260274.1	RP11-817O13.8	4.83	1.85e-06	0.000222	0.16	0.22	Sudden cardiac arrest;	chr15:75523417	chr15:75368155~75369584:+
THCA	cis	rs9302635	0.745	rs35549608	ENSG00000260886.1	TAT-AS1	4.83	1.85e-06	0.000222	0.39	0.22	Blood protein levels;	chr16:72193499	chr16:71565789~71578187:+
THCA	cis	rs8113308	0.515	rs60581730	ENSG00000269483.1	AC006272.1	4.83	1.85e-06	0.000222	0.45	0.22	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51937883	chr19:51839924~51843324:-
THCA	cis	rs13434995	0.513	rs73236153	ENSG00000273257.1	RP11-177J6.1	-4.83	1.85e-06	0.000223	-0.33	-0.22	Adiponectin levels;	chr4:55585600	chr4:55387949~55388271:+
THCA	cis	rs3950186	0.794	rs6914007	ENSG00000215124.2	RP3-420J14.1	4.83	1.85e-06	0.000223	0.26	0.22	Anxiety and major depressive disorder;	chr6:11805176	chr6:11861626~11862970:-
THCA	cis	rs7598759	0.548	rs1823328	ENSG00000223198.1	RNU2-22P	-4.83	1.85e-06	0.000223	-0.28	-0.22	Noise-induced hearing loss;	chr2:231490473	chr2:231501990~231502201:-
THCA	cis	rs1979679	0.527	rs12825875	ENSG00000278733.1	RP11-425D17.1	4.83	1.85e-06	0.000223	0.25	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28147843	chr12:28185625~28186190:-
THCA	cis	rs2439831	1	rs690436	ENSG00000166763.7	STRCP1	4.83	1.85e-06	0.000223	0.29	0.22	Lung cancer in ever smokers;	chr15:43469007	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2264239	ENSG00000166763.7	STRCP1	4.83	1.85e-06	0.000223	0.29	0.22	Lung cancer in ever smokers;	chr15:43473335	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2439831	ENSG00000166763.7	STRCP1	4.83	1.85e-06	0.000223	0.29	0.22	Lung cancer in ever smokers;	chr15:43492277	chr15:43699488~43718184:-
THCA	cis	rs4915077	0.892	rs80353498	ENSG00000230489.1	VAV3-AS1	4.83	1.85e-06	0.000223	0.32	0.22	Hypothyroidism;	chr1:107804122	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs76804309	ENSG00000230489.1	VAV3-AS1	4.83	1.85e-06	0.000223	0.32	0.22	Hypothyroidism;	chr1:107804132	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs79729985	ENSG00000230489.1	VAV3-AS1	4.83	1.85e-06	0.000223	0.32	0.22	Hypothyroidism;	chr1:107804156	chr1:107964443~107994607:+
THCA	cis	rs6012564	0.928	rs6095396	ENSG00000227431.4	CSE1L-AS1	-4.83	1.85e-06	0.000223	-0.26	-0.22	Anger;	chr20:49010633	chr20:49040463~49046044:-
THCA	cis	rs7824557	0.679	rs7004362	ENSG00000154316.13	TDH	4.83	1.85e-06	0.000223	0.16	0.22	Retinal vascular caliber;	chr8:11278465	chr8:11339637~11368452:+
THCA	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-4.83	1.85e-06	0.000223	-0.27	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
THCA	cis	rs72945132	0.882	rs7941933	ENSG00000254604.1	AP000487.6	-4.83	1.85e-06	0.000223	-0.41	-0.22	Coronary artery disease;	chr11:70277245	chr11:70282367~70363368:-
THCA	cis	rs2235642	0.533	rs2667679	ENSG00000280231.1	LA16c-380F5.3	-4.83	1.85e-06	0.000223	-0.27	-0.22	Coronary artery disease;	chr16:1604945	chr16:1553655~1554130:-
THCA	cis	rs860295	0.665	rs11264367	ENSG00000160766.13	GBAP1	-4.83	1.85e-06	0.000223	-0.26	-0.22	Body mass index;	chr1:155367547	chr1:155213821~155227422:-
THCA	cis	rs3845817	0.868	rs702891	ENSG00000237979.1	AC007389.1	-4.83	1.85e-06	0.000223	-0.25	-0.22	Bipolar disorder;	chr2:65531316	chr2:65500993~65502138:-
THCA	cis	rs1962772	0.502	rs2720492	ENSG00000279903.1	RP11-349F21.5	-4.83	1.86e-06	0.000223	-0.26	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17526130	chr8:17500012~17500605:+
THCA	cis	rs911555	0.692	rs7146215	ENSG00000244691.1	RPL10AP1	4.83	1.86e-06	0.000223	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103412119~103412761:-
THCA	cis	rs3796352	1	rs7622420	ENSG00000242142.1	SERBP1P3	-4.83	1.86e-06	0.000223	-0.38	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53077053	chr3:53064283~53065091:-
THCA	cis	rs453301	0.571	rs2929453	ENSG00000248538.5	RP11-10A14.5	4.83	1.86e-06	0.000223	0.27	0.22	Joint mobility (Beighton score);	chr8:9226831	chr8:9189011~9202854:+
THCA	cis	rs11846409	0.521	rs10143547	ENSG00000211974.3	IGHV2-70	-4.83	1.86e-06	0.000223	-0.2	-0.22	Rheumatic heart disease;	chr14:106644638	chr14:106723574~106724093:-
THCA	cis	rs4660214	0.666	rs6698791	ENSG00000182109.6	RP11-69E11.4	-4.83	1.86e-06	0.000223	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39469104	chr1:39522280~39546187:-
THCA	cis	rs17594362	0.945	rs71425023	ENSG00000264190.1	MIR5006	4.83	1.86e-06	0.000223	0.36	0.22	Multiple sclerosis;	chr13:41571296	chr13:41568286~41568395:-
THCA	cis	rs711244	0.967	rs17496249	ENSG00000279519.1	RP11-288C18.1	4.83	1.86e-06	0.000223	0.18	0.22	Mean platelet volume;	chr2:36875106	chr2:36839922~36842539:-
THCA	cis	rs736408	0.648	rs3774355	ENSG00000243224.1	RP5-1157M23.2	-4.83	1.86e-06	0.000223	-0.24	-0.22	Bipolar disorder;	chr3:52783762	chr3:52239258~52241097:+
THCA	cis	rs12134133	1	rs28371597	ENSG00000237074.1	RP11-6J21.2	4.83	1.86e-06	0.000223	0.23	0.22	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207249067~207309121:+
THCA	cis	rs10090774	0.965	rs13250787	ENSG00000279766.1	RP11-642A1.2	4.83	1.86e-06	0.000224	0.27	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140906833	chr8:140572142~140572812:-
THCA	cis	rs6546886	0.625	rs12991192	ENSG00000257800.1	FNBP1P1	-4.83	1.86e-06	0.000224	-0.22	-0.22	Dialysis-related mortality;	chr2:74082539	chr2:74120680~74123218:+
THCA	cis	rs7773456	0.576	rs4140624	ENSG00000237404.1	RP3-471C18.2	4.83	1.86e-06	0.000224	0.28	0.22	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19689825~19753113:-
THCA	cis	rs10411161	0.752	rs9973239	ENSG00000275055.1	CTC-471J1.11	-4.83	1.86e-06	0.000224	-0.22	-0.22	Breast cancer;	chr19:51903526	chr19:52049007~52049754:+
THCA	cis	rs13113518	0.966	rs7677952	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55425312	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs1047354	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55429416	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs1056547	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55430596	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs1056545	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55430730	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs5863	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55430740	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs6828570	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55431595	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs3749474	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55434518	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs1474271	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55435912	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11937487	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55436576	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs3805146	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55436985	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11133378	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55439472	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11942279	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55439652	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs3805148	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55440643	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11133380	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55441110	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs12510110	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55441567	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs12510990	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55441907	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs3805149	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55442184	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11945370	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55442875	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.966	rs12647677	ENSG00000273257.1	RP11-177J6.1	4.83	1.86e-06	0.000224	0.28	0.22	Height;	chr4:55444253	chr4:55387949~55388271:+
THCA	cis	rs9487094	0.67	rs13199135	ENSG00000223537.2	RP5-919F19.5	-4.83	1.86e-06	0.000224	-0.22	-0.22	Height;	chr6:109588639	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs12193719	ENSG00000223537.2	RP5-919F19.5	-4.83	1.86e-06	0.000224	-0.22	-0.22	Height;	chr6:109589051	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.644	rs1960325	ENSG00000223537.2	RP5-919F19.5	-4.83	1.86e-06	0.000224	-0.22	-0.22	Height;	chr6:109592105	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs12528781	ENSG00000223537.2	RP5-919F19.5	-4.83	1.86e-06	0.000224	-0.22	-0.22	Height;	chr6:109608105	chr6:109487906~109506800:+
THCA	cis	rs17772222	1	rs17698817	ENSG00000222990.1	RNU4-22P	4.83	1.86e-06	0.000224	0.29	0.22	Coronary artery calcification;	chr14:88356632	chr14:88513498~88513663:+
THCA	cis	rs763121	0.853	rs3788545	ENSG00000235209.1	CTA-150C2.13	4.83	1.86e-06	0.000224	0.29	0.22	Menopause (age at onset);	chr22:38669167	chr22:38921227~38924708:+
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	4.83	1.87e-06	0.000224	0.27	0.22	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
THCA	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-4.83	1.87e-06	0.000224	-0.34	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
THCA	cis	rs2408955	0.522	rs6580650	ENSG00000273765.1	RP11-370I10.11	-4.83	1.87e-06	0.000224	-0.22	-0.22	Glycated hemoglobin levels;	chr12:48024773	chr12:48360920~48361377:+
THCA	cis	rs7924176	0.521	rs10824137	ENSG00000213731.2	RAB5CP1	4.83	1.87e-06	0.000224	0.27	0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:74423435~74424014:-
THCA	cis	rs73198271	0.96	rs73198290	ENSG00000253893.2	FAM85B	4.83	1.87e-06	0.000224	0.36	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758499	chr8:8167819~8226614:-
THCA	cis	rs4713118	0.869	rs6901520	ENSG00000226314.6	ZNF192P1	-4.83	1.87e-06	0.000224	-0.28	-0.22	Parkinson's disease;	chr6:27746796	chr6:28161781~28169594:+
THCA	cis	rs11671005	0.735	rs34188294	ENSG00000268912.1	CTD-2619J13.17	-4.83	1.87e-06	0.000224	-0.21	-0.22	Mean platelet volume;	chr19:58408190	chr19:58428632~58431148:-
THCA	cis	rs3738443	0.868	rs4351686	ENSG00000259865.1	RP11-488L18.10	4.83	1.87e-06	0.000224	0.23	0.22	Alcohol dependence;	chr1:247190028	chr1:247187281~247188526:-
THCA	cis	rs5015933	0.815	rs13291322	ENSG00000232630.1	PRPS1P2	-4.83	1.87e-06	0.000224	-0.15	-0.22	Body mass index;	chr9:125348076	chr9:125150653~125151589:+
THCA	cis	rs9380516	0.699	rs6911901	ENSG00000228559.1	RP3-340B19.3	-4.83	1.87e-06	0.000224	-0.29	-0.22	Hepatitis C induced liver fibrosis;	chr6:35561217	chr6:35544632~35545669:+
THCA	cis	rs4950322	0.542	rs3766519	ENSG00000271721.1	RP11-337C18.9	4.83	1.87e-06	0.000224	0.25	0.22	Protein quantitative trait loci;	chr1:147214802	chr1:147175602~147177740:+
THCA	cis	rs28374715	0.532	rs28463309	ENSG00000247556.5	OIP5-AS1	4.83	1.87e-06	0.000224	0.21	0.22	Ulcerative colitis;	chr15:41374518	chr15:41283990~41309737:+
THCA	cis	rs9875589	0.509	rs2168718	ENSG00000228242.5	AC093495.4	4.83	1.87e-06	0.000225	0.12	0.22	Ovarian reserve;	chr3:14042657	chr3:14144637~14165978:+
THCA	cis	rs2036707	1	rs2036707	ENSG00000274718.1	RP11-346C4.3	4.83	1.87e-06	0.000225	0.42	0.22	Obesity-related traits;	chr13:107832106	chr13:107870383~107873372:+
THCA	cis	rs763567	0.539	rs593479	ENSG00000271811.1	RP1-79C4.4	4.83	1.87e-06	0.000225	0.25	0.22	Tonsillectomy;	chr1:170673758	chr1:170667381~170669425:+
THCA	cis	rs7924176	0.601	rs10824091	ENSG00000213731.2	RAB5CP1	-4.83	1.87e-06	0.000225	-0.26	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74169750	chr10:74423435~74424014:-
THCA	cis	rs1167827	0.68	rs1167796	ENSG00000205583.12	STAG3L1	-4.83	1.87e-06	0.000225	-0.24	-0.22	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75359194~75395383:+
THCA	cis	rs7267979	1	rs4815420	ENSG00000274973.1	RP13-401N8.7	4.83	1.87e-06	0.000225	0.24	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25845497~25845862:+
THCA	cis	rs17826219	0.562	rs719600	ENSG00000263603.1	CTD-2349P21.5	4.83	1.87e-06	0.000225	0.37	0.22	Body mass index;	chr17:30404244	chr17:30729469~30731202:+
THCA	cis	rs375066	0.551	rs10408461	ENSG00000267058.1	RP11-15A1.3	4.83	1.87e-06	0.000225	0.19	0.22	Breast cancer;	chr19:43826620	chr19:43891804~43901805:-
THCA	cis	rs375066	0.551	rs11879541	ENSG00000267058.1	RP11-15A1.3	4.83	1.87e-06	0.000225	0.19	0.22	Breast cancer;	chr19:43827291	chr19:43891804~43901805:-
THCA	cis	rs375066	0.526	rs17712224	ENSG00000267058.1	RP11-15A1.3	4.83	1.87e-06	0.000225	0.19	0.22	Breast cancer;	chr19:43827442	chr19:43891804~43901805:-
THCA	cis	rs375066	0.551	rs10500286	ENSG00000267058.1	RP11-15A1.3	4.83	1.87e-06	0.000225	0.19	0.22	Breast cancer;	chr19:43827461	chr19:43891804~43901805:-
THCA	cis	rs7246657	0.551	rs10404069	ENSG00000226686.6	LINC01535	-4.83	1.87e-06	0.000225	-0.38	-0.22	Coronary artery calcification;	chr19:37147502	chr19:37251912~37265535:+
THCA	cis	rs2361718	0.5	rs8068856	ENSG00000275479.1	RP11-334C17.6	4.83	1.87e-06	0.000225	0.21	0.22	Yeast infection;	chr17:80126932	chr17:80149627~80149798:+
THCA	cis	rs11992162	1	rs11784499	ENSG00000206014.6	OR7E161P	-4.83	1.87e-06	0.000225	-0.26	-0.22	Monocyte count;	chr8:11977030	chr8:11928597~11929563:-
THCA	cis	rs1979679	0.918	rs11049529	ENSG00000247934.4	RP11-967K21.1	-4.83	1.87e-06	0.000225	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28318571	chr12:28163298~28190738:-
THCA	cis	rs13178541	0.81	rs4566785	ENSG00000250378.1	RP11-119J18.1	-4.83	1.87e-06	0.000225	-0.28	-0.22	IgG glycosylation;	chr5:135774028	chr5:135812667~135826582:+
THCA	cis	rs2179367	0.613	rs62426122	ENSG00000223701.3	RAET1E-AS1	4.83	1.88e-06	0.000225	0.3	0.22	Dupuytren's disease;	chr6:149427449	chr6:149884431~149919508:+
THCA	cis	rs9863	0.861	rs11057399	ENSG00000269997.1	RP11-214K3.21	-4.83	1.88e-06	0.000225	-0.27	-0.22	White blood cell count;	chr12:123940531	chr12:123966077~123966629:-
THCA	cis	rs3824435	0.783	rs4740814	ENSG00000272866.1	RP11-12D24.10	-4.83	1.88e-06	0.000225	-0.29	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5348622	chr9:5351796~5352410:-
THCA	cis	rs1387259	0.759	rs7960122	ENSG00000240399.1	RP1-228P16.1	-4.83	1.88e-06	0.000225	-0.23	-0.22	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48054813~48055591:-
THCA	cis	rs9925964	1	rs9925964	ENSG00000260911.2	RP11-196G11.2	-4.83	1.88e-06	0.000225	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118574	chr16:31043150~31049868:+
THCA	cis	rs9925964	0.967	rs4889620	ENSG00000260911.2	RP11-196G11.2	-4.83	1.88e-06	0.000225	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31119853	chr16:31043150~31049868:+
THCA	cis	rs739496	0.579	rs7975437	ENSG00000226469.1	ADAM1B	4.83	1.88e-06	0.000225	0.27	0.22	Platelet count;	chr12:111939145	chr12:111927018~111929017:+
THCA	cis	rs7727544	0.735	rs4705933	ENSG00000263597.1	MIR3936	4.83	1.88e-06	0.000225	0.21	0.22	Blood metabolite levels;	chr5:132342719	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.735	rs272867	ENSG00000263597.1	MIR3936	4.83	1.88e-06	0.000225	0.21	0.22	Blood metabolite levels;	chr5:132345364	chr5:132365490~132365599:-
THCA	cis	rs2281603	0.57	rs1470851	ENSG00000259116.1	RP11-973N13.4	-4.83	1.88e-06	0.000225	-0.19	-0.22	Lymphocyte counts;	chr14:64509402	chr14:64514154~64540368:-
THCA	cis	rs5742933	1	rs3791773	ENSG00000253559.1	OSGEPL1-AS1	-4.83	1.88e-06	0.000226	-0.27	-0.22	Ferritin levels;	chr2:189817906	chr2:189762704~189765556:+
THCA	cis	rs793571	0.554	rs12439231	ENSG00000245975.2	RP11-30K9.6	4.83	1.88e-06	0.000226	0.25	0.22	Schizophrenia;	chr15:58733396	chr15:58768072~58770974:-
THCA	cis	rs763121	0.853	rs5750626	ENSG00000235209.1	CTA-150C2.13	4.83	1.88e-06	0.000226	0.29	0.22	Menopause (age at onset);	chr22:38581885	chr22:38921227~38924708:+
THCA	cis	rs35740288	0.822	rs10520599	ENSG00000259295.5	CSPG4P12	4.83	1.88e-06	0.000226	0.34	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85679866	chr15:85191438~85213905:+
THCA	cis	rs8028182	0.636	rs28610581	ENSG00000260269.4	CTD-2323K18.1	-4.83	1.88e-06	0.000226	-0.32	-0.22	Sudden cardiac arrest;	chr15:75520133	chr15:75527150~75601205:-
THCA	cis	rs651907	0.557	rs3094296	ENSG00000244119.1	PDCL3P4	4.83	1.88e-06	0.000226	0.19	0.22	Colorectal cancer;	chr3:101681323	chr3:101712472~101713191:+
THCA	cis	rs964611	0.882	rs56308793	ENSG00000259488.2	RP11-154J22.1	-4.83	1.88e-06	0.000226	-0.2	-0.22	Metabolite levels (Pyroglutamine);	chr15:48350611	chr15:48312353~48331856:-
THCA	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-4.83	1.88e-06	0.000226	-0.31	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
THCA	cis	rs2243480	0.908	rs4718273	ENSG00000232559.3	GS1-124K5.12	-4.83	1.88e-06	0.000226	-0.32	-0.22	Diabetic kidney disease;	chr7:65751112	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs422164	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66121618	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs316313	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66128561	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs316312	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66131504	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs419603	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66132354	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs387676	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66133233	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66133553	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs431076	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66135333	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66136518	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs316334	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66137139	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs316330	ENSG00000164669.11	INTS4P1	4.83	1.88e-06	0.000226	0.42	0.22	Diabetic kidney disease;	chr7:66140385	chr7:65141225~65234216:+
THCA	cis	rs4144027	0.791	rs11160770	ENSG00000269958.1	RP11-73M18.8	4.83	1.88e-06	0.000226	0.19	0.22	Blood metabolite levels;	chr14:103895954	chr14:103696353~103697163:+
THCA	cis	rs72945132	0.882	rs60780459	ENSG00000254604.1	AP000487.6	-4.83	1.88e-06	0.000226	-0.4	-0.22	Coronary artery disease;	chr11:70316362	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs56176527	ENSG00000254604.1	AP000487.6	-4.83	1.88e-06	0.000226	-0.4	-0.22	Coronary artery disease;	chr11:70316407	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs17160777	ENSG00000254604.1	AP000487.6	-4.83	1.88e-06	0.000226	-0.4	-0.22	Coronary artery disease;	chr11:70317617	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7929271	ENSG00000254604.1	AP000487.6	-4.83	1.88e-06	0.000226	-0.4	-0.22	Coronary artery disease;	chr11:70319643	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7932431	ENSG00000254604.1	AP000487.6	-4.83	1.88e-06	0.000226	-0.4	-0.22	Coronary artery disease;	chr11:70319953	chr11:70282367~70363368:-
THCA	cis	rs4971059	0.654	rs10157801	ENSG00000236675.1	MTX1P1	-4.83	1.88e-06	0.000226	-0.2	-0.22	Breast cancer;	chr1:155147536	chr1:155230975~155234325:+
THCA	cis	rs7851660	0.809	rs7032114	ENSG00000214417.4	KRT18P13	-4.83	1.88e-06	0.000226	-0.19	-0.22	Strep throat;	chr9:97894177	chr9:97698922~97700734:+
THCA	cis	rs2255336	0.706	rs4415856	ENSG00000245648.1	RP11-277P12.20	-4.83	1.88e-06	0.000226	-0.25	-0.22	Blood protein levels;	chr12:10448069	chr12:10363769~10398506:+
THCA	cis	rs4578769	0.531	rs4616385	ENSG00000265939.1	UBE2CP2	4.83	1.88e-06	0.000226	0.25	0.22	Eosinophil percentage of white cells;	chr18:22895327	chr18:22900486~22900995:-
THCA	cis	rs12439619	0.921	rs4778672	ENSG00000255769.6	GOLGA2P10	4.83	1.88e-06	0.000226	0.29	0.22	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472993~82513950:-
THCA	cis	rs4578769	0.55	rs4800442	ENSG00000265939.1	UBE2CP2	4.83	1.88e-06	0.000226	0.25	0.22	Eosinophil percentage of white cells;	chr18:22958337	chr18:22900486~22900995:-
THCA	cis	rs12908161	1	rs58416181	ENSG00000188388.10	GOLGA6L3	4.83	1.89e-06	0.000226	0.29	0.22	Schizophrenia;	chr15:84721230	chr15:85240472~85247170:+
THCA	cis	rs7523875	0.744	rs61850982	ENSG00000153363.11	LINC00467	-4.83	1.89e-06	0.000226	-0.2	-0.22	Mean corpuscular volume;	chr1:211241590	chr1:211382803~211435333:+
THCA	cis	rs7523875	0.744	rs57331968	ENSG00000153363.11	LINC00467	-4.83	1.89e-06	0.000226	-0.2	-0.22	Mean corpuscular volume;	chr1:211242403	chr1:211382803~211435333:+
THCA	cis	rs763121	0.853	rs4821816	ENSG00000228274.3	RP3-508I15.9	-4.83	1.89e-06	0.000226	-0.24	-0.22	Menopause (age at onset);	chr22:38717129	chr22:38667585~38681820:-
THCA	cis	rs6951245	0.872	rs74360401	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1027767	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.935	rs118132455	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028596	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs78628466	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028817	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs11768761	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030171	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs76833820	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030642	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs28379681	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030903	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs28399710	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030995	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs28528096	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031276	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs74369356	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032075	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs77083167	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032187	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs74347384	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032804	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.872	rs75493422	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033254	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs118059236	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033566	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs113858334	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033840	chr7:1160374~1165267:+
THCA	cis	rs6951245	1	rs79765398	ENSG00000229043.2	AC091729.9	-4.83	1.89e-06	0.000226	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1034128	chr7:1160374~1165267:+
THCA	cis	rs1023500	0.505	rs134899	ENSG00000273366.1	CTA-989H11.1	-4.83	1.89e-06	0.000226	-0.27	-0.22	Schizophrenia;	chr22:42287024	chr22:42278188~42278846:+
THCA	cis	rs10888838	0.652	rs12410868	ENSG00000198711.5	SSBP3-AS1	4.83	1.89e-06	0.000226	0.27	0.22	Mitochondrial DNA levels;	chr1:54230646	chr1:54236440~54239063:+
THCA	cis	rs3743162	0.553	rs12915656	ENSG00000225151.9	GOLGA2P7	-4.83	1.89e-06	0.000226	-0.33	-0.22	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84199311~84230136:-
THCA	cis	rs62244186	0.541	rs9859879	ENSG00000214820.3	MPRIPP1	4.83	1.89e-06	0.000226	0.22	0.22	Depressive symptoms;	chr3:44798674	chr3:44579938~44581026:-
THCA	cis	rs6547741	0.743	rs7564625	ENSG00000234072.1	AC074117.10	-4.83	1.89e-06	0.000227	-0.17	-0.22	Oral cavity cancer;	chr2:27639530	chr2:27356246~27367622:+
THCA	cis	rs2236521	0.632	rs35265388	ENSG00000273619.1	RP5-908M14.9	-4.83	1.89e-06	0.000227	-0.18	-0.22	Pelvic organ prolapse;	chr20:62319222	chr20:62386303~62386970:-
THCA	cis	rs7432375	0.61	rs28458819	ENSG00000239213.4	NCK1-AS1	4.83	1.89e-06	0.000227	0.19	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136803472	chr3:136841726~136862054:-
THCA	cis	rs6832769	1	rs28448438	ENSG00000272969.1	RP11-528I4.2	-4.83	1.89e-06	0.000227	-0.25	-0.22	Personality dimensions;	chr4:55550498	chr4:55547112~55547889:+
THCA	cis	rs5758659	0.652	rs133358	ENSG00000270083.1	RP1-257I20.14	4.83	1.89e-06	0.000227	0.23	0.22	Cognitive function;	chr22:42046535	chr22:42089630~42090028:-
THCA	cis	rs7429990	1	rs7429990	ENSG00000228638.1	FCF1P2	-4.83	1.89e-06	0.000227	-0.22	-0.22	Educational attainment (years of education);	chr3:47860313	chr3:48290793~48291375:-
THCA	cis	rs6517329	0.585	rs726271	ENSG00000236830.5	CBR3-AS1	-4.83	1.89e-06	0.000227	-0.2	-0.22	Schizophrenia;	chr21:36153237	chr21:36131767~36175815:-
THCA	cis	rs13434995	0.513	rs7665286	ENSG00000273257.1	RP11-177J6.1	4.83	1.89e-06	0.000227	0.33	0.22	Adiponectin levels;	chr4:55578765	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs7683997	ENSG00000273257.1	RP11-177J6.1	4.83	1.89e-06	0.000227	0.33	0.22	Adiponectin levels;	chr4:55581272	chr4:55387949~55388271:+
THCA	cis	rs11671005	0.735	rs3826682	ENSG00000268912.1	CTD-2619J13.17	-4.83	1.89e-06	0.000227	-0.21	-0.22	Mean platelet volume;	chr19:58407381	chr19:58428632~58431148:-
THCA	cis	rs8002861	0.641	rs2325085	ENSG00000274001.1	RP11-5G9.5	4.83	1.89e-06	0.000227	0.25	0.22	Leprosy;	chr13:43835924	chr13:43877715~43878163:-
THCA	cis	rs7474896	1	rs61858629	ENSG00000263064.2	RP11-291L22.7	4.83	1.89e-06	0.000227	0.35	0.22	Obesity (extreme);	chr10:37725842	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs35258216	ENSG00000263064.2	RP11-291L22.7	4.83	1.89e-06	0.000227	0.35	0.22	Obesity (extreme);	chr10:37729292	chr10:38448689~38448949:+
THCA	cis	rs78487399	0.808	rs78108161	ENSG00000234936.1	AC010883.5	4.83	1.89e-06	0.000227	0.3	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43436709	chr2:43229573~43233394:+
THCA	cis	rs5015933	0.705	rs13288223	ENSG00000232630.1	PRPS1P2	-4.83	1.89e-06	0.000227	-0.15	-0.22	Body mass index;	chr9:125335388	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.815	rs12338077	ENSG00000232630.1	PRPS1P2	-4.83	1.89e-06	0.000227	-0.15	-0.22	Body mass index;	chr9:125345427	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.815	rs10986716	ENSG00000232630.1	PRPS1P2	-4.83	1.89e-06	0.000227	-0.15	-0.22	Body mass index;	chr9:125345606	chr9:125150653~125151589:+
THCA	cis	rs9625935	0.957	rs8135823	ENSG00000279159.1	RP3-394A18.1	4.83	1.89e-06	0.000227	0.17	0.22	Tonsillectomy;	chr22:30126470	chr22:29978950~30028236:-
THCA	cis	rs9925964	0.967	rs9936329	ENSG00000260911.2	RP11-196G11.2	-4.83	1.89e-06	0.000227	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31129478	chr16:31043150~31049868:+
THCA	cis	rs9925964	0.967	rs1549293	ENSG00000260911.2	RP11-196G11.2	-4.83	1.89e-06	0.000227	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31130672	chr16:31043150~31049868:+
THCA	cis	rs6600671	1	rs6600671	ENSG00000226067.5	CH17-118O6.2	-4.83	1.89e-06	0.000227	-0.22	-0.22	Hip geometry;	chr1:121458637	chr1:120913275~121009291:+
THCA	cis	rs13113518	1	rs13133579	ENSG00000273257.1	RP11-177J6.1	4.83	1.89e-06	0.000227	0.28	0.22	Height;	chr4:55459921	chr4:55387949~55388271:+
THCA	cis	rs4722166	0.645	rs1404006	ENSG00000225541.1	AC002480.5	-4.83	1.89e-06	0.000227	-0.27	-0.22	Lung cancer;	chr7:22755458	chr7:22571607~22661792:-
THCA	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	4.83	1.89e-06	0.000227	0.24	0.22	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
THCA	cis	rs7614311	0.954	rs2291533	ENSG00000271843.1	RP11-245J9.5	4.83	1.89e-06	0.000227	0.33	0.22	Lung function (FVC);Lung function (FEV1);	chr3:63831754	chr3:64008082~64008692:-
THCA	cis	rs9487094	0.67	rs11754340	ENSG00000223537.2	RP5-919F19.5	-4.83	1.89e-06	0.000227	-0.22	-0.22	Height;	chr6:109584789	chr6:109487906~109506800:+
THCA	cis	rs3760982	0.565	rs3786956	ENSG00000267058.1	RP11-15A1.3	-4.83	1.9e-06	0.000227	-0.2	-0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782677	chr19:43891804~43901805:-
THCA	cis	rs5742933	1	rs1898560	ENSG00000273240.1	RP11-455J20.3	-4.82	1.9e-06	0.000227	-0.24	-0.22	Ferritin levels;	chr2:189747601	chr2:189763859~189764456:-
THCA	cis	rs11671005	0.735	rs3764529	ENSG00000268912.1	CTD-2619J13.17	-4.82	1.9e-06	0.000227	-0.21	-0.22	Mean platelet volume;	chr19:58433722	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs1122955	ENSG00000268912.1	CTD-2619J13.17	-4.82	1.9e-06	0.000227	-0.21	-0.22	Mean platelet volume;	chr19:58434836	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs11668814	ENSG00000268912.1	CTD-2619J13.17	-4.82	1.9e-06	0.000227	-0.21	-0.22	Mean platelet volume;	chr19:58435466	chr19:58428632~58431148:-
THCA	cis	rs9487094	0.67	rs12194061	ENSG00000223537.2	RP5-919F19.5	-4.82	1.9e-06	0.000227	-0.22	-0.22	Height;	chr6:109546439	chr6:109487906~109506800:+
THCA	cis	rs6920372	0.731	rs2357124	ENSG00000223537.2	RP5-919F19.5	-4.82	1.9e-06	0.000227	-0.22	-0.22	Height;	chr6:109551060	chr6:109487906~109506800:+
THCA	cis	rs13178541	0.873	rs11749405	ENSG00000250378.1	RP11-119J18.1	-4.82	1.9e-06	0.000227	-0.28	-0.22	IgG glycosylation;	chr5:135804386	chr5:135812667~135826582:+
THCA	cis	rs2790457	0.958	rs2807754	ENSG00000254635.4	WAC-AS1	-4.82	1.9e-06	0.000227	-0.21	-0.22	Multiple myeloma;	chr10:28598263	chr10:28522652~28532743:-
THCA	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-4.82	1.9e-06	0.000227	-0.21	-0.22	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
THCA	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-4.82	1.9e-06	0.000227	-0.21	-0.22	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
THCA	cis	rs2790457	0.958	rs2772433	ENSG00000254635.4	WAC-AS1	4.82	1.9e-06	0.000227	0.21	0.22	Multiple myeloma;	chr10:28607017	chr10:28522652~28532743:-
THCA	cis	rs7598759	0.548	rs11686485	ENSG00000223198.1	RNU2-22P	-4.82	1.9e-06	0.000227	-0.28	-0.22	Noise-induced hearing loss;	chr2:231495986	chr2:231501990~231502201:-
THCA	cis	rs6477918	0.551	rs12335450	ENSG00000230185.4	C9orf147	4.82	1.9e-06	0.000227	0.23	0.22	Obstetric antiphospholipid syndrome;	chr9:112505097	chr9:112433816~112487204:-
THCA	cis	rs4787951	0.58	rs1805010	ENSG00000259940.2	CTD-3203P2.1	-4.82	1.9e-06	0.000228	-0.23	-0.22	Eosinophil percentage of white cells;	chr16:27344882	chr16:27213308~27214993:-
THCA	cis	rs7432375	0.58	rs4678441	ENSG00000239213.4	NCK1-AS1	4.82	1.9e-06	0.000228	0.19	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136813986	chr3:136841726~136862054:-
THCA	cis	rs7432375	0.58	rs4678442	ENSG00000239213.4	NCK1-AS1	4.82	1.9e-06	0.000228	0.19	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136814129	chr3:136841726~136862054:-
THCA	cis	rs7267979	0.932	rs417130	ENSG00000274973.1	RP13-401N8.7	-4.82	1.9e-06	0.000228	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.932	rs372678	ENSG00000274973.1	RP13-401N8.7	-4.82	1.9e-06	0.000228	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25845497~25845862:+
THCA	cis	rs11902236	0.544	rs5018439	ENSG00000188525.3	AC010969.1	-4.82	1.9e-06	0.000228	-0.27	-0.22	Prostate cancer;	chr2:9998424	chr2:10003158~10006030:-
THCA	cis	rs3820928	0.904	rs2217359	ENSG00000212391.1	SNORA48	-4.82	1.9e-06	0.000228	-0.24	-0.22	Pulmonary function;	chr2:226895176	chr2:226968989~226969122:-
THCA	cis	rs7005380	0.785	rs7814294	ENSG00000245330.4	KB-1471A8.1	-4.82	1.9e-06	0.000228	-0.21	-0.22	Interstitial lung disease;	chr8:119927196	chr8:119867419~119874488:-
THCA	cis	rs911555	0.723	rs7149767	ENSG00000244691.1	RPL10AP1	4.82	1.9e-06	0.000228	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103412119~103412761:-
THCA	cis	rs911555	0.692	rs7145753	ENSG00000244691.1	RPL10AP1	4.82	1.9e-06	0.000228	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103412119~103412761:-
THCA	cis	rs3824435	0.783	rs4742083	ENSG00000272866.1	RP11-12D24.10	-4.82	1.9e-06	0.000228	-0.29	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5348393	chr9:5351796~5352410:-
THCA	cis	rs17270561	0.609	rs1892246	ENSG00000272462.2	U91328.19	-4.82	1.9e-06	0.000228	-0.18	-0.22	Iron status biomarkers;	chr6:25764180	chr6:25992662~26001775:+
THCA	cis	rs736408	0.54	rs4687637	ENSG00000243224.1	RP5-1157M23.2	-4.82	1.9e-06	0.000228	-0.23	-0.22	Bipolar disorder;	chr3:52600076	chr3:52239258~52241097:+
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000232559.3	GS1-124K5.12	4.82	1.9e-06	0.000228	0.33	0.22	Diabetic kidney disease;	chr7:65966800	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs906134	ENSG00000232559.3	GS1-124K5.12	4.82	1.9e-06	0.000228	0.33	0.22	Diabetic kidney disease;	chr7:65979301	chr7:66554588~66576923:-
THCA	cis	rs7394190	0.748	rs11000728	ENSG00000271816.1	BMS1P4	-4.82	1.9e-06	0.000228	-0.26	-0.22	Incident atrial fibrillation;	chr10:73644542	chr10:73699151~73730487:-
THCA	cis	rs71636778	0.722	rs71636784	ENSG00000260063.1	RP5-968P14.2	-4.82	1.9e-06	0.000228	-0.29	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26842709	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.722	rs35650645	ENSG00000260063.1	RP5-968P14.2	-4.82	1.9e-06	0.000228	-0.29	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26842993	chr1:26692132~26694131:-
THCA	cis	rs153734	0.657	rs12497268	ENSG00000280620.1	SCAANT1	-4.82	1.9e-06	0.000228	-0.34	-0.22	Folate pathway vitamin levels;	chr3:64104687	chr3:63911518~63911772:-
THCA	cis	rs45509595	0.822	rs200484	ENSG00000280107.1	AL022393.9	-4.82	1.9e-06	0.000228	-0.33	-0.22	Breast cancer;	chr6:27807896	chr6:28170845~28172521:+
THCA	cis	rs1185460	1	rs1185460	ENSG00000272186.1	RP11-110I1.13	4.82	1.9e-06	0.000228	0.21	0.22	Coronary artery disease;	chr11:119072723	chr11:119067374~119067698:-
THCA	cis	rs1003719	0.68	rs2187577	ENSG00000230366.8	DSCR9	4.82	1.9e-06	0.000228	0.22	0.22	Eye color traits;	chr21:37161039	chr21:37208503~37221736:+
THCA	cis	rs734999	0.967	rs10797433	ENSG00000225931.3	RP3-395M20.7	4.82	1.9e-06	0.000228	0.26	0.22	Ulcerative colitis;	chr1:2570571	chr1:2566410~2569888:+
THCA	cis	rs72843506	0.656	rs73984573	ENSG00000231258.2	ZSWIM5P2	4.82	1.9e-06	0.000228	0.32	0.22	Schizophrenia;	chr17:20082027	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs78408002	ENSG00000231258.2	ZSWIM5P2	4.82	1.9e-06	0.000228	0.32	0.22	Schizophrenia;	chr17:20082601	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs7210439	ENSG00000231258.2	ZSWIM5P2	4.82	1.9e-06	0.000228	0.32	0.22	Schizophrenia;	chr17:20082728	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs7225605	ENSG00000231258.2	ZSWIM5P2	4.82	1.9e-06	0.000228	0.32	0.22	Schizophrenia;	chr17:20083136	chr17:20583758~20591180:-
THCA	cis	rs72945132	0.882	rs67244582	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70275903	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.825	rs12287883	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70276263	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.66	rs12292191	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70276320	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs55905028	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70281644	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs56770826	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70282768	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs61177215	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70283428	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs12279046	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70284282	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs17160753	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70285356	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs72945168	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70285365	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs12295111	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70285776	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs12289915	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70285850	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs12274436	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70286098	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs4261311	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70286796	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7943547	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70287176	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs12278125	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70287910	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs7928686	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70288422	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs59398290	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70288713	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs12278741	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70289636	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.769	rs11235754	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70289986	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.882	rs11235755	ENSG00000254604.1	AP000487.6	-4.82	1.9e-06	0.000228	-0.4	-0.22	Coronary artery disease;	chr11:70290217	chr11:70282367~70363368:-
THCA	cis	rs9388451	0.839	rs11154331	ENSG00000226409.1	RP11-735G4.1	-4.82	1.9e-06	0.000228	-0.26	-0.22	Brugada syndrome;	chr6:125790283	chr6:125370211~125374324:-
THCA	cis	rs317689	0.819	rs317667	ENSG00000274979.1	RP11-1143G9.5	-4.82	1.9e-06	0.000228	-0.25	-0.22	Response to diuretic therapy;	chr12:69309974	chr12:69326574~69331882:-
THCA	cis	rs317689	0.819	rs317664	ENSG00000274979.1	RP11-1143G9.5	-4.82	1.9e-06	0.000228	-0.25	-0.22	Response to diuretic therapy;	chr12:69310967	chr12:69326574~69331882:-
THCA	cis	rs3820928	0.874	rs13393894	ENSG00000212391.1	SNORA48	-4.82	1.9e-06	0.000228	-0.24	-0.22	Pulmonary function;	chr2:227015827	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs13393902	ENSG00000212391.1	SNORA48	-4.82	1.9e-06	0.000228	-0.24	-0.22	Pulmonary function;	chr2:227015838	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.845	rs4234065	ENSG00000212391.1	SNORA48	-4.82	1.9e-06	0.000228	-0.24	-0.22	Pulmonary function;	chr2:227017290	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs4234066	ENSG00000212391.1	SNORA48	-4.82	1.9e-06	0.000228	-0.24	-0.22	Pulmonary function;	chr2:227017464	chr2:226968989~226969122:-
THCA	cis	rs944289	0.708	rs2899845	ENSG00000258844.1	RP11-259K15.2	4.82	1.91e-06	0.000228	0.2	0.22	Thyroid cancer;	chr14:36116632	chr14:36214607~36235608:+
THCA	cis	rs12755164	0.778	rs4650157	ENSG00000223479.3	RP4-788P17.1	4.82	1.91e-06	0.000228	0.24	0.22	Schizophrenia;	chr1:72853816	chr1:73635216~73715214:+
THCA	cis	rs4915077	1	rs17020141	ENSG00000226822.1	RP11-356N1.2	-4.82	1.91e-06	0.000228	-0.39	-0.22	Hypothyroidism;	chr1:107827250	chr1:108071482~108074519:+
THCA	cis	rs8105895	0.935	rs78646027	ENSG00000269345.1	VN1R85P	4.82	1.91e-06	0.000228	0.29	0.22	Body mass index (change over time);	chr19:22074608	chr19:22174766~22175191:-
THCA	cis	rs1048886	0.808	rs1739338	ENSG00000271967.1	RP11-134K13.4	-4.82	1.91e-06	0.000229	-0.22	-0.22	Type 2 diabetes;	chr6:70476653	chr6:70596438~70596980:+
THCA	cis	rs7829975	0.711	rs12682352	ENSG00000254340.1	RP11-10A14.3	4.82	1.91e-06	0.000229	0.24	0.22	Mood instability;	chr8:8788736	chr8:9141424~9145435:+
THCA	cis	rs5742933	1	rs5742933	ENSG00000253559.1	OSGEPL1-AS1	-4.82	1.91e-06	0.000229	-0.27	-0.22	Ferritin levels;	chr2:189784590	chr2:189762704~189765556:+
THCA	cis	rs250518	0.926	rs6896898	ENSG00000272081.1	CTD-2376I4.2	4.82	1.91e-06	0.000229	0.28	0.22	Mean corpuscular hemoglobin concentration;	chr5:72795174	chr5:72955206~72955699:-
THCA	cis	rs4886920	0.638	rs12912467	ENSG00000260776.4	RP11-114H24.2	4.82	1.91e-06	0.000229	0.26	0.22	Neuroticism;	chr15:77828111	chr15:77914217~77926846:-
THCA	cis	rs7824557	0.778	rs6601572	ENSG00000154316.13	TDH	4.82	1.91e-06	0.000229	0.15	0.22	Retinal vascular caliber;	chr8:11235828	chr8:11339637~11368452:+
THCA	cis	rs72843506	0.656	rs10459970	ENSG00000261033.1	RP11-209D14.2	4.82	1.91e-06	0.000229	0.41	0.22	Schizophrenia;	chr17:20034028	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs2385960	ENSG00000261033.1	RP11-209D14.2	4.82	1.91e-06	0.000229	0.41	0.22	Schizophrenia;	chr17:20034904	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs8073875	ENSG00000261033.1	RP11-209D14.2	4.82	1.91e-06	0.000229	0.41	0.22	Schizophrenia;	chr17:20035746	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs57040439	ENSG00000261033.1	RP11-209D14.2	4.82	1.91e-06	0.000229	0.41	0.22	Schizophrenia;	chr17:20036522	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs58313980	ENSG00000261033.1	RP11-209D14.2	4.82	1.91e-06	0.000229	0.41	0.22	Schizophrenia;	chr17:20036737	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs73984559	ENSG00000261033.1	RP11-209D14.2	4.82	1.91e-06	0.000229	0.41	0.22	Schizophrenia;	chr17:20043203	chr17:20008051~20009234:-
THCA	cis	rs7851660	0.809	rs7022148	ENSG00000214417.4	KRT18P13	-4.82	1.91e-06	0.000229	-0.19	-0.22	Strep throat;	chr9:97898542	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.775	rs7034336	ENSG00000214417.4	KRT18P13	-4.82	1.91e-06	0.000229	-0.19	-0.22	Strep throat;	chr9:97898818	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs10818241	ENSG00000214417.4	KRT18P13	-4.82	1.91e-06	0.000229	-0.19	-0.22	Strep throat;	chr9:97899690	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.839	rs7027221	ENSG00000214417.4	KRT18P13	-4.82	1.91e-06	0.000229	-0.19	-0.22	Strep throat;	chr9:97900097	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs10739526	ENSG00000214417.4	KRT18P13	-4.82	1.91e-06	0.000229	-0.19	-0.22	Strep throat;	chr9:97900389	chr9:97698922~97700734:+
THCA	cis	rs5015933	0.815	rs10124754	ENSG00000232630.1	PRPS1P2	-4.82	1.91e-06	0.000229	-0.15	-0.22	Body mass index;	chr9:125327479	chr9:125150653~125151589:+
THCA	cis	rs13434995	0.513	rs2101476	ENSG00000273257.1	RP11-177J6.1	-4.82	1.91e-06	0.000229	-0.33	-0.22	Adiponectin levels;	chr4:55578961	chr4:55387949~55388271:+
THCA	cis	rs4660214	0.789	rs1180375	ENSG00000182109.6	RP11-69E11.4	4.82	1.91e-06	0.000229	0.21	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415368	chr1:39522280~39546187:-
THCA	cis	rs453301	0.686	rs11785819	ENSG00000254153.1	CTA-398F10.2	4.82	1.91e-06	0.000229	0.24	0.22	Joint mobility (Beighton score);	chr8:9012868	chr8:8456909~8461337:-
THCA	cis	rs4713118	0.512	rs2622319	ENSG00000261839.1	RP1-265C24.8	4.82	1.91e-06	0.000229	0.23	0.22	Parkinson's disease;	chr6:28152623	chr6:28136849~28139678:+
THCA	cis	rs7674212	0.51	rs55715738	ENSG00000246560.2	RP11-10L12.4	4.82	1.91e-06	0.000229	0.26	0.22	Type 2 diabetes;	chr4:103209032	chr4:102828055~102844075:+
THCA	cis	rs6088580	0.634	rs6120650	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.91e-06	0.000229	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34452168	chr20:33985617~33988989:-
THCA	cis	rs853679	0.546	rs200995	ENSG00000280107.1	AL022393.9	4.82	1.91e-06	0.000229	0.33	0.22	Depression;	chr6:27845916	chr6:28170845~28172521:+
THCA	cis	rs9425766	0.679	rs7537517	ENSG00000227373.4	RP11-160H22.5	4.82	1.91e-06	0.000229	0.31	0.22	Life satisfaction;	chr1:174207225	chr1:174115300~174160004:-
THCA	cis	rs72945132	0.66	rs67433166	ENSG00000254604.1	AP000487.6	-4.82	1.91e-06	0.000229	-0.4	-0.22	Coronary artery disease;	chr11:70275498	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.607	rs67767222	ENSG00000254604.1	AP000487.6	-4.82	1.91e-06	0.000229	-0.4	-0.22	Coronary artery disease;	chr11:70275504	chr11:70282367~70363368:-
THCA	cis	rs1383484	0.575	rs6603008	ENSG00000225151.9	GOLGA2P7	4.82	1.91e-06	0.000229	0.28	0.22	Height;	chr15:83935421	chr15:84199311~84230136:-
THCA	cis	rs6545883	0.507	rs34668697	ENSG00000270820.4	RP11-355B11.2	-4.82	1.91e-06	0.000229	-0.18	-0.22	Tuberculosis;	chr2:61341214	chr2:61471188~61484130:+
THCA	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-4.82	1.91e-06	0.000229	-0.13	-0.22	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
THCA	cis	rs9925964	0.933	rs10871454	ENSG00000260911.2	RP11-196G11.2	-4.82	1.91e-06	0.000229	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036758	chr16:31043150~31049868:+
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000229886.1	RP5-1132H15.3	4.82	1.91e-06	0.000229	0.26	0.22	Corneal structure;	chr7:66894282	chr7:66025126~66031544:-
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000229886.1	RP5-1132H15.3	4.82	1.91e-06	0.000229	0.26	0.22	Corneal structure;	chr7:66896631	chr7:66025126~66031544:-
THCA	cis	rs3743162	0.553	rs4842994	ENSG00000259728.4	LINC00933	-4.82	1.91e-06	0.000229	-0.3	-0.22	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84570649~84580175:+
THCA	cis	rs2777491	0.507	rs11854081	ENSG00000247556.5	OIP5-AS1	4.82	1.91e-06	0.000229	0.21	0.22	Ulcerative colitis;	chr15:41354200	chr15:41283990~41309737:+
THCA	cis	rs4578769	0.524	rs9956919	ENSG00000265939.1	UBE2CP2	4.82	1.91e-06	0.000229	0.25	0.22	Eosinophil percentage of white cells;	chr18:22896538	chr18:22900486~22900995:-
THCA	cis	rs2282300	0.739	rs1222221	ENSG00000242353.1	RP4-710M3.1	-4.82	1.91e-06	0.000229	-0.2	-0.22	Morning vs. evening chronotype;	chr11:30321191	chr11:30368148~30368646:+
THCA	cis	rs853679	0.546	rs483143	ENSG00000226314.6	ZNF192P1	-4.82	1.91e-06	0.000229	-0.37	-0.22	Depression;	chr6:27878966	chr6:28161781~28169594:+
THCA	cis	rs9910055	0.659	rs186603	ENSG00000267080.4	ASB16-AS1	4.82	1.91e-06	0.000229	0.19	0.22	Total body bone mineral density;	chr17:44130516	chr17:44175973~44186717:-
THCA	cis	rs6545883	0.894	rs1186703	ENSG00000270820.4	RP11-355B11.2	4.82	1.91e-06	0.000229	0.19	0.22	Tuberculosis;	chr2:61445830	chr2:61471188~61484130:+
THCA	cis	rs330048	0.51	rs11784654	ENSG00000254340.1	RP11-10A14.3	-4.82	1.91e-06	0.000229	-0.24	-0.22	Systemic lupus erythematosus;	chr8:9112101	chr8:9141424~9145435:+
THCA	cis	rs4915077	1	rs77125988	ENSG00000226822.1	RP11-356N1.2	4.82	1.92e-06	0.000229	0.4	0.22	Hypothyroidism;	chr1:107822089	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs74614887	ENSG00000226822.1	RP11-356N1.2	4.82	1.92e-06	0.000229	0.4	0.22	Hypothyroidism;	chr1:107822173	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs10494079	ENSG00000226822.1	RP11-356N1.2	4.82	1.92e-06	0.000229	0.4	0.22	Hypothyroidism;	chr1:107832253	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs17020148	ENSG00000226822.1	RP11-356N1.2	4.82	1.92e-06	0.000229	0.4	0.22	Hypothyroidism;	chr1:107832388	chr1:108071482~108074519:+
THCA	cis	rs539096	0.54	rs37452	ENSG00000237950.1	RP11-7O11.3	4.82	1.92e-06	0.00023	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43831901	chr1:43944370~43946551:-
THCA	cis	rs539096	0.54	rs3011219	ENSG00000237950.1	RP11-7O11.3	4.82	1.92e-06	0.00023	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43840448	chr1:43944370~43946551:-
THCA	cis	rs494453	0.961	rs488200	ENSG00000227811.2	FAM212B-AS1	-4.82	1.92e-06	0.00023	-0.28	-0.22	Osteoporosis-related phenotypes;	chr1:111720204	chr1:111739841~111747798:+
THCA	cis	rs11779988	0.545	rs208759	ENSG00000253671.1	RP11-806O11.1	-4.82	1.92e-06	0.00023	-0.28	-0.22	Breast cancer;	chr8:17950420	chr8:17808941~17820868:+
THCA	cis	rs8014252	0.708	rs8014179	ENSG00000259158.2	ADAM20P1	-4.82	1.92e-06	0.00023	-0.24	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70397162	chr14:70468881~70483756:-
THCA	cis	rs12681287	1	rs7833786	ENSG00000254231.1	CTD-2284J15.1	-4.82	1.92e-06	0.00023	-0.24	-0.22	Caudate activity during reward;	chr8:86259145	chr8:86333274~86343314:-
THCA	cis	rs7208859	0.673	rs999797	ENSG00000280069.1	CTD-2349P21.3	-4.82	1.92e-06	0.00023	-0.35	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30738182~30740275:+
THCA	cis	rs10904908	0.733	rs359288	ENSG00000229124.5	VIM-AS1	-4.82	1.92e-06	0.00023	-0.2	-0.22	Cholesterol, total;Total cholesterol levels;	chr10:17288181	chr10:17214239~17229985:-
THCA	cis	rs5771242	0.518	rs67881086	ENSG00000273253.2	RP3-402G11.26	-4.82	1.92e-06	0.00023	-0.24	-0.22	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50235010	chr22:50199090~50200837:-
THCA	cis	rs613391	0.702	rs619960	ENSG00000224549.1	RP11-370B11.3	-4.82	1.92e-06	0.00023	-0.24	-0.22	Quantitative traits;	chr9:22697681	chr9:22767175~22768316:+
THCA	cis	rs613391	0.702	rs619906	ENSG00000224549.1	RP11-370B11.3	-4.82	1.92e-06	0.00023	-0.24	-0.22	Quantitative traits;	chr9:22697707	chr9:22767175~22768316:+
THCA	cis	rs274567	0.602	rs272853	ENSG00000237714.1	P4HA2-AS1	4.82	1.92e-06	0.00023	0.29	0.22	Blood metabolite levels;	chr5:132352868	chr5:132184876~132192808:+
THCA	cis	rs240993	0.812	rs455650	ENSG00000271789.1	RP5-1112D6.7	-4.82	1.92e-06	0.00023	-0.27	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111370320	chr6:111297126~111298510:+
THCA	cis	rs9987353	0.566	rs34389718	ENSG00000248538.5	RP11-10A14.5	4.82	1.92e-06	0.00023	0.29	0.22	Recombination measurement;	chr8:9208015	chr8:9189011~9202854:+
THCA	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-4.82	1.92e-06	0.00023	-0.25	-0.22	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
THCA	cis	rs4415084	0.716	rs6451772	ENSG00000272335.1	RP11-53O19.3	-4.82	1.92e-06	0.00023	-0.18	-0.22	Breast cancer;	chr5:44785661	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs7710952	ENSG00000272335.1	RP11-53O19.3	-4.82	1.92e-06	0.00023	-0.18	-0.22	Breast cancer;	chr5:44785689	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs7710978	ENSG00000272335.1	RP11-53O19.3	-4.82	1.92e-06	0.00023	-0.18	-0.22	Breast cancer;	chr5:44785762	chr5:44826076~44828592:+
THCA	cis	rs72945132	0.825	rs7950280	ENSG00000254604.1	AP000487.6	-4.82	1.92e-06	0.00023	-0.4	-0.22	Coronary artery disease;	chr11:70367349	chr11:70282367~70363368:-
THCA	cis	rs10923574	0.597	rs10923576	ENSG00000231365.4	RP11-418J17.1	-4.82	1.92e-06	0.00023	-0.22	-0.22	Breast cancer;Folding of antihelix;	chr1:118500269	chr1:119140396~119275973:+
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000176933.5	TOB2P1	-4.82	1.92e-06	0.00023	-0.24	-0.22	Pubertal anthropometrics;	chr6:28175232	chr6:28217643~28218634:-
THCA	cis	rs7308116	0.645	rs10861833	ENSG00000258072.1	RP11-554D14.2	4.82	1.92e-06	0.00023	0.25	0.22	Pelvic organ prolapse (moderate/severe);	chr12:107902358	chr12:107903270~107903948:-
THCA	cis	rs8028182	0.636	rs11636199	ENSG00000260274.1	RP11-817O13.8	4.82	1.92e-06	0.00023	0.16	0.22	Sudden cardiac arrest;	chr15:75532996	chr15:75368155~75369584:+
THCA	cis	rs2980439	0.558	rs2955584	ENSG00000254153.1	CTA-398F10.2	-4.82	1.92e-06	0.00023	-0.23	-0.22	Neuroticism;	chr8:8234652	chr8:8456909~8461337:-
THCA	cis	rs6728302	0.557	rs7600132	ENSG00000244280.1	ECEL1P2	4.82	1.92e-06	0.00023	0.43	0.22	Height;	chr2:232383488	chr2:232385750~232387457:-
THCA	cis	rs6728302	0.557	rs73002000	ENSG00000244280.1	ECEL1P2	4.82	1.92e-06	0.00023	0.43	0.22	Height;	chr2:232389342	chr2:232385750~232387457:-
THCA	cis	rs1979679	0.608	rs1355472	ENSG00000247934.4	RP11-967K21.1	-4.82	1.92e-06	0.00023	-0.22	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28568481	chr12:28163298~28190738:-
THCA	cis	rs875971	0.54	rs1723268	ENSG00000229886.1	RP5-1132H15.3	4.82	1.92e-06	0.00023	0.23	0.22	Aortic root size;	chr7:66008093	chr7:66025126~66031544:-
THCA	cis	rs919433	0.889	rs6711624	ENSG00000231621.1	AC013264.2	4.82	1.92e-06	0.00023	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197342883	chr2:197197991~197199273:+
THCA	cis	rs11673344	0.563	rs55825113	ENSG00000276846.1	CTD-3220F14.3	4.82	1.92e-06	0.00023	0.17	0.22	Obesity-related traits;	chr19:37191523	chr19:37314868~37315620:-
THCA	cis	rs800160	1	rs800160	ENSG00000199550.1	Y_RNA	-4.82	1.92e-06	0.00023	-0.32	-0.22	Bacteremia;	chr11:2358904	chr11:2372638~2372750:+
THCA	cis	rs7851660	0.809	rs3808893	ENSG00000214417.4	KRT18P13	-4.82	1.92e-06	0.00023	-0.19	-0.22	Strep throat;	chr9:97901463	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs10984253	ENSG00000214417.4	KRT18P13	-4.82	1.92e-06	0.00023	-0.19	-0.22	Strep throat;	chr9:97902192	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs7044799	ENSG00000214417.4	KRT18P13	-4.82	1.92e-06	0.00023	-0.19	-0.22	Strep throat;	chr9:97903111	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs7031386	ENSG00000214417.4	KRT18P13	-4.82	1.92e-06	0.00023	-0.19	-0.22	Strep throat;	chr9:97903387	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs7048255	ENSG00000214417.4	KRT18P13	-4.82	1.92e-06	0.00023	-0.19	-0.22	Strep throat;	chr9:97903416	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.809	rs9299258	ENSG00000214417.4	KRT18P13	-4.82	1.92e-06	0.00023	-0.19	-0.22	Strep throat;	chr9:97904261	chr9:97698922~97700734:+
THCA	cis	rs5771242	0.518	rs5771258	ENSG00000273253.2	RP3-402G11.26	-4.82	1.92e-06	0.00023	-0.26	-0.22	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50237219	chr22:50199090~50200837:-
THCA	cis	rs2051211	0.947	rs60479981	ENSG00000229589.1	ACVR2B-AS1	-4.82	1.92e-06	0.00023	-0.23	-0.22	QRS duration;	chr3:38527120	chr3:38451027~38454820:-
THCA	cis	rs2976388	0.556	rs10956985	ENSG00000253741.1	CTD-2292P10.4	4.82	1.92e-06	0.00023	0.3	0.22	Urinary tract infection frequency;	chr8:142737332	chr8:142702252~142726973:-
THCA	cis	rs897984	0.568	rs11862962	ENSG00000260911.2	RP11-196G11.2	4.82	1.92e-06	0.00023	0.2	0.22	Dementia with Lewy bodies;	chr16:30898385	chr16:31043150~31049868:+
THCA	cis	rs2439831	1	rs7173487	ENSG00000166763.7	STRCP1	4.82	1.92e-06	0.00023	0.32	0.22	Lung cancer in ever smokers;	chr15:43458041	chr15:43699488~43718184:-
THCA	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-4.82	1.92e-06	0.00023	-0.32	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
THCA	cis	rs79349575	0.749	rs1057902	ENSG00000270781.1	RP11-501C14.9	-4.82	1.92e-06	0.00023	-0.26	-0.22	Type 2 diabetes;	chr17:48928226	chr17:48899131~48899748:+
THCA	cis	rs9300255	0.602	rs2682434	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123210177	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs4372492	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123212810	chr12:123252030~123261483:-
THCA	cis	rs7980687	0.627	rs1727325	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Head circumference (infant);Educational attainment;Height;	chr12:123213785	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.51	rs1727323	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123214243	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1716160	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123215678	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.569	rs1727320	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123215929	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1790131	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123216463	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.544	rs1790130	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123216723	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs2682431	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123218679	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs2851450	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123218954	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.568	rs1790102	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123220343	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1626899	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123223516	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs10846486	ENSG00000235423.7	RP11-282O18.3	4.82	1.92e-06	0.000231	0.23	0.22	Neutrophil percentage of white cells;	chr12:123225380	chr12:123252030~123261483:-
THCA	cis	rs59918340	0.764	rs4961256	ENSG00000253307.1	RP11-10J21.4	4.82	1.93e-06	0.000231	0.3	0.22	Immature fraction of reticulocytes;	chr8:141219847	chr8:141252286~141253292:-
THCA	cis	rs526231	0.756	rs2561479	ENSG00000175749.11	EIF3KP1	4.82	1.93e-06	0.000231	0.27	0.22	Primary biliary cholangitis;	chr5:103286176	chr5:103032376~103033031:+
THCA	cis	rs6517329	0.509	rs4816522	ENSG00000236830.5	CBR3-AS1	-4.82	1.93e-06	0.000231	-0.2	-0.22	Schizophrenia;	chr21:36150882	chr21:36131767~36175815:-
THCA	cis	rs7219021	0.518	rs6504584	ENSG00000248278.1	SUMO2P17	-4.82	1.93e-06	0.000231	-0.26	-0.22	Schizophrenia or bipolar disorder;	chr17:48864057	chr17:48874860~48908983:-
THCA	cis	rs7394190	0.748	rs2075641	ENSG00000271816.1	BMS1P4	-4.82	1.93e-06	0.000231	-0.27	-0.22	Incident atrial fibrillation;	chr10:73802350	chr10:73699151~73730487:-
THCA	cis	rs172166	0.561	rs149971	ENSG00000273712.1	RP5-874C20.7	4.82	1.93e-06	0.000231	0.24	0.22	Cardiac Troponin-T levels;	chr6:28014374	chr6:28315613~28315883:-
THCA	cis	rs2243480	1	rs466983	ENSG00000164669.11	INTS4P1	4.82	1.93e-06	0.000231	0.43	0.22	Diabetic kidney disease;	chr7:66055509	chr7:65141225~65234216:+
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000176933.5	TOB2P1	4.82	1.93e-06	0.000231	0.24	0.22	Pubertal anthropometrics;	chr6:28255953	chr6:28217643~28218634:-
THCA	cis	rs6546886	0.625	rs76483403	ENSG00000257800.1	FNBP1P1	-4.82	1.93e-06	0.000231	-0.23	-0.22	Dialysis-related mortality;	chr2:74026281	chr2:74120680~74123218:+
THCA	cis	rs651907	0.535	rs11717638	ENSG00000244119.1	PDCL3P4	4.82	1.93e-06	0.000231	0.2	0.22	Colorectal cancer;	chr3:101786624	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs34263427	ENSG00000244119.1	PDCL3P4	4.82	1.93e-06	0.000231	0.2	0.22	Colorectal cancer;	chr3:101788961	chr3:101712472~101713191:+
THCA	cis	rs651907	0.514	rs11706494	ENSG00000244119.1	PDCL3P4	4.82	1.93e-06	0.000231	0.2	0.22	Colorectal cancer;	chr3:101790631	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs34063583	ENSG00000244119.1	PDCL3P4	4.82	1.93e-06	0.000231	0.2	0.22	Colorectal cancer;	chr3:101791104	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs34161138	ENSG00000244119.1	PDCL3P4	4.82	1.93e-06	0.000231	0.2	0.22	Colorectal cancer;	chr3:101791544	chr3:101712472~101713191:+
THCA	cis	rs6545883	0.894	rs10177303	ENSG00000270820.4	RP11-355B11.2	-4.82	1.93e-06	0.000231	-0.18	-0.22	Tuberculosis;	chr2:61367324	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.894	rs2694639	ENSG00000270820.4	RP11-355B11.2	-4.82	1.93e-06	0.000231	-0.18	-0.22	Tuberculosis;	chr2:61368156	chr2:61471188~61484130:+
THCA	cis	rs2337406	0.925	rs873534	ENSG00000211974.3	IGHV2-70	-4.82	1.93e-06	0.000231	-0.23	-0.22	Alzheimer's disease (late onset);	chr14:106667423	chr14:106723574~106724093:-
THCA	cis	rs1023500	0.505	rs134887	ENSG00000182057.4	OGFRP1	4.82	1.93e-06	0.000231	0.26	0.22	Schizophrenia;	chr22:42278233	chr22:42269753~42275196:+
THCA	cis	rs1417569	0.517	rs2994625	ENSG00000237135.1	DDX10P1	4.82	1.93e-06	0.000231	0.26	0.22	Tuberculosis;	chr10:30906390	chr10:30919012~30921235:-
THCA	cis	rs3820928	0.935	rs113195824	ENSG00000212391.1	SNORA48	-4.82	1.93e-06	0.000231	-0.25	-0.22	Pulmonary function;	chr2:226904423	chr2:226968989~226969122:-
THCA	cis	rs17767392	0.788	rs7492426	ENSG00000259146.3	RP1-261D10.2	4.82	1.93e-06	0.000231	0.29	0.22	Mitral valve prolapse;	chr14:71232422	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.788	rs57723945	ENSG00000259146.3	RP1-261D10.2	4.82	1.93e-06	0.000231	0.29	0.22	Mitral valve prolapse;	chr14:71232465	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.748	rs7159252	ENSG00000259146.3	RP1-261D10.2	4.82	1.93e-06	0.000231	0.29	0.22	Mitral valve prolapse;	chr14:71237299	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.748	rs58952176	ENSG00000259146.3	RP1-261D10.2	4.82	1.93e-06	0.000231	0.29	0.22	Mitral valve prolapse;	chr14:71237326	chr14:71292729~71321814:-
THCA	cis	rs6772849	0.896	rs4857859	ENSG00000242551.2	POU5F1P6	-4.82	1.93e-06	0.000231	-0.28	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:128674735~128677005:-
THCA	cis	rs763121	0.853	rs9622833	ENSG00000228274.3	RP3-508I15.9	-4.82	1.93e-06	0.000231	-0.24	-0.22	Menopause (age at onset);	chr22:38604392	chr22:38667585~38681820:-
THCA	cis	rs4748857	0.504	rs4636559	ENSG00000224215.1	RP11-371A19.2	-4.82	1.93e-06	0.000231	-0.24	-0.22	Systemic lupus erythematosus;	chr10:23371864	chr10:23343957~23345181:+
THCA	cis	rs72843506	0.722	rs3764436	ENSG00000231258.2	ZSWIM5P2	4.82	1.93e-06	0.000231	0.32	0.22	Schizophrenia;	chr17:20110489	chr17:20583758~20591180:-
THCA	cis	rs539096	0.5	rs2906457	ENSG00000237950.1	RP11-7O11.3	4.82	1.93e-06	0.000231	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43872903	chr1:43944370~43946551:-
THCA	cis	rs911555	0.617	rs7156036	ENSG00000244691.1	RPL10AP1	4.82	1.93e-06	0.000231	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103412119~103412761:-
THCA	cis	rs911555	0.723	rs6575991	ENSG00000244691.1	RPL10AP1	4.82	1.93e-06	0.000231	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103412119~103412761:-
THCA	cis	rs7429990	0.965	rs1060407	ENSG00000228638.1	FCF1P2	-4.82	1.93e-06	0.000231	-0.22	-0.22	Educational attainment (years of education);	chr3:47916547	chr3:48290793~48291375:-
THCA	cis	rs7914558	1	rs7077291	ENSG00000236937.2	PTGES3P4	4.82	1.93e-06	0.000231	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185994	chr10:102845595~102845950:+
THCA	cis	rs3796352	1	rs9874517	ENSG00000242142.1	SERBP1P3	-4.82	1.93e-06	0.000231	-0.39	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53094355	chr3:53064283~53065091:-
THCA	cis	rs763121	0.651	rs738249	ENSG00000228274.3	RP3-508I15.9	-4.82	1.93e-06	0.000232	-0.24	-0.22	Menopause (age at onset);	chr22:38641974	chr22:38667585~38681820:-
THCA	cis	rs7267979	1	rs6050598	ENSG00000274973.1	RP13-401N8.7	-4.82	1.93e-06	0.000232	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25845497~25845862:+
THCA	cis	rs6600671	0.902	rs2222371	ENSG00000226067.5	CH17-118O6.2	-4.82	1.94e-06	0.000232	-0.23	-0.22	Hip geometry;	chr1:121547320	chr1:120913275~121009291:+
THCA	cis	rs9601248	0.756	rs7997134	ENSG00000227354.5	RBM26-AS1	-4.82	1.94e-06	0.000232	-0.21	-0.22	Major depressive disorder;	chr13:79619594	chr13:79406309~79424328:+
THCA	cis	rs9368481	0.761	rs6918835	ENSG00000261353.1	CTA-14H9.5	4.82	1.94e-06	0.000232	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26527063~26527404:+
THCA	cis	rs7598759	0.527	rs4973417	ENSG00000223198.1	RNU2-22P	-4.82	1.94e-06	0.000232	-0.28	-0.22	Noise-induced hearing loss;	chr2:231484925	chr2:231501990~231502201:-
THCA	cis	rs10845170	1	rs10845170	ENSG00000256667.5	KLRAP1	-4.82	1.94e-06	0.000232	-0.14	-0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:10571818	chr12:10588063~10599669:-
THCA	cis	rs1417569	0.546	rs2994623	ENSG00000237135.1	DDX10P1	4.82	1.94e-06	0.000232	0.26	0.22	Tuberculosis;	chr10:30903264	chr10:30919012~30921235:-
THCA	cis	rs1417569	0.517	rs2934637	ENSG00000237135.1	DDX10P1	4.82	1.94e-06	0.000232	0.26	0.22	Tuberculosis;	chr10:30904410	chr10:30919012~30921235:-
THCA	cis	rs6088580	0.634	rs4911153	ENSG00000276073.1	RP5-1125A11.7	4.82	1.94e-06	0.000232	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34373741	chr20:33985617~33988989:-
THCA	cis	rs13113518	1	rs56362210	ENSG00000273257.1	RP11-177J6.1	4.82	1.94e-06	0.000232	0.28	0.22	Height;	chr4:55540972	chr4:55387949~55388271:+
THCA	cis	rs11710088	0.707	rs35551531	ENSG00000244503.1	RP11-278L15.6	4.82	1.94e-06	0.000232	0.26	0.22	QRS duration;	chr3:149489199	chr3:149494660~149495995:+
THCA	cis	rs5015933	0.815	rs16928051	ENSG00000232630.1	PRPS1P2	-4.82	1.94e-06	0.000232	-0.15	-0.22	Body mass index;	chr9:125308738	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.815	rs4991998	ENSG00000232630.1	PRPS1P2	-4.82	1.94e-06	0.000232	-0.15	-0.22	Body mass index;	chr9:125314702	chr9:125150653~125151589:+
THCA	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	4.82	1.94e-06	0.000232	0.15	0.22	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
THCA	cis	rs897984	0.52	rs12928081	ENSG00000279196.1	RP11-1072A3.3	-4.82	1.94e-06	0.000232	-0.24	-0.22	Dementia with Lewy bodies;	chr16:30873838	chr16:30984630~30988270:-
THCA	cis	rs1023500	0.551	rs133379	ENSG00000273366.1	CTA-989H11.1	-4.82	1.94e-06	0.000232	-0.28	-0.22	Schizophrenia;	chr22:42072531	chr22:42278188~42278846:+
THCA	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-4.82	1.94e-06	0.000232	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
THCA	cis	rs27524	0.734	rs27037	ENSG00000248734.2	CTD-2260A17.1	4.82	1.94e-06	0.000232	0.24	0.22	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96784777~96785999:+
THCA	cis	rs34286592	1	rs4788187	ENSG00000214725.6	CDIPT-AS1	4.82	1.94e-06	0.000232	0.38	0.22	Multiple sclerosis;	chr16:29834364	chr16:29863593~29868053:+
THCA	cis	rs12887734	0.546	rs66676135	ENSG00000269910.1	RP11-73M18.10	4.82	1.94e-06	0.000232	0.2	0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103694516~103695050:-
THCA	cis	rs72843506	0.722	rs78041331	ENSG00000231258.2	ZSWIM5P2	4.82	1.94e-06	0.000232	0.33	0.22	Schizophrenia;	chr17:20305533	chr17:20583758~20591180:-
THCA	cis	rs9863	0.828	rs7975482	ENSG00000269997.1	RP11-214K3.21	-4.82	1.94e-06	0.000232	-0.27	-0.22	White blood cell count;	chr12:123997143	chr12:123966077~123966629:-
THCA	cis	rs6832769	1	rs4865008	ENSG00000272969.1	RP11-528I4.2	-4.82	1.94e-06	0.000232	-0.25	-0.22	Personality dimensions;	chr4:55544688	chr4:55547112~55547889:+
THCA	cis	rs17689437	0.957	rs7194242	ENSG00000275383.1	RP11-615I2.6	4.82	1.94e-06	0.000232	0.34	0.22	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68573838	chr16:68591382~68594424:+
THCA	cis	rs3750082	0.889	rs6962267	ENSG00000231952.3	DPY19L1P2	4.82	1.94e-06	0.000232	0.27	0.22	Glomerular filtration rate (creatinine);	chr7:32900162	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs11766608	ENSG00000231952.3	DPY19L1P2	4.82	1.94e-06	0.000232	0.27	0.22	Glomerular filtration rate (creatinine);	chr7:32900474	chr7:32812757~32838570:+
THCA	cis	rs2440129	0.632	rs15966	ENSG00000262089.1	RP11-589P10.5	4.82	1.94e-06	0.000232	0.2	0.22	Tonsillectomy;	chr17:7002324	chr17:6994642~6995189:-
THCA	cis	rs11673344	0.523	rs10420330	ENSG00000276846.1	CTD-3220F14.3	4.82	1.94e-06	0.000232	0.16	0.22	Obesity-related traits;	chr19:37111269	chr19:37314868~37315620:-
THCA	cis	rs5015933	0.815	rs13291655	ENSG00000232630.1	PRPS1P2	-4.82	1.94e-06	0.000232	-0.15	-0.22	Body mass index;	chr9:125348274	chr9:125150653~125151589:+
THCA	cis	rs5742933	1	rs4667306	ENSG00000253559.1	OSGEPL1-AS1	-4.82	1.94e-06	0.000232	-0.27	-0.22	Ferritin levels;	chr2:189725630	chr2:189762704~189765556:+
THCA	cis	rs5742933	1	rs16831925	ENSG00000253559.1	OSGEPL1-AS1	-4.82	1.94e-06	0.000232	-0.27	-0.22	Ferritin levels;	chr2:189731178	chr2:189762704~189765556:+
THCA	cis	rs2058059	0.636	rs2022928	ENSG00000205578.5	POM121B	-4.82	1.94e-06	0.000233	-0.33	-0.22	Subcutaneous adipose tissue;	chr7:72707432	chr7:73293497~73301161:+
THCA	cis	rs2790457	0.792	rs1265845	ENSG00000254635.4	WAC-AS1	-4.82	1.94e-06	0.000233	-0.22	-0.22	Multiple myeloma;	chr10:28638294	chr10:28522652~28532743:-
THCA	cis	rs5758659	0.652	rs133303	ENSG00000227370.1	RP4-669P10.19	-4.82	1.94e-06	0.000233	-0.2	-0.22	Cognitive function;	chr22:41999238	chr22:42132543~42132998:+
THCA	cis	rs2993535	1	rs2993535	ENSG00000233626.2	RP11-565J7.1	4.82	1.94e-06	0.000233	0.58	0.22	Hip circumference adjusted for BMI;	chr1:211981850	chr1:211936249~211936634:+
THCA	cis	rs853679	1	rs6905391	ENSG00000220721.1	OR1F12	4.82	1.95e-06	0.000233	0.34	0.22	Depression;	chr6:28294909	chr6:28073316~28074233:+
THCA	cis	rs7474896	1	rs9417263	ENSG00000263064.2	RP11-291L22.7	4.82	1.95e-06	0.000233	0.35	0.22	Obesity (extreme);	chr10:37825762	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs9417264	ENSG00000263064.2	RP11-291L22.7	4.82	1.95e-06	0.000233	0.35	0.22	Obesity (extreme);	chr10:37828642	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.945	rs9417265	ENSG00000263064.2	RP11-291L22.7	4.82	1.95e-06	0.000233	0.35	0.22	Obesity (extreme);	chr10:37829973	chr10:38448689~38448949:+
THCA	cis	rs6012564	0.963	rs2075679	ENSG00000227431.4	CSE1L-AS1	4.82	1.95e-06	0.000233	0.27	0.22	Anger;	chr20:49085052	chr20:49040463~49046044:-
THCA	cis	rs990871	0.512	rs1194273	ENSG00000227207.2	RPL31P12	4.82	1.95e-06	0.000233	0.25	0.22	Subcutaneous adipose tissue;	chr1:72231244	chr1:72301472~72301829:+
THCA	cis	rs62158800	0.925	rs58069412	ENSG00000237880.1	AC096669.2	4.82	1.95e-06	0.000233	0.32	0.22	Facial morphology (factor 22);	chr2:107592297	chr2:107385632~107542649:-
THCA	cis	rs829880	0.558	rs249817	ENSG00000227825.4	SLC9A7P1	4.82	1.95e-06	0.000233	0.2	0.22	Colonoscopy-negative controls vs population controls;	chr12:98503132	chr12:98453835~98457145:-
THCA	cis	rs829880	0.558	rs249820	ENSG00000227825.4	SLC9A7P1	4.82	1.95e-06	0.000233	0.2	0.22	Colonoscopy-negative controls vs population controls;	chr12:98503695	chr12:98453835~98457145:-
THCA	cis	rs829880	0.558	rs249821	ENSG00000227825.4	SLC9A7P1	4.82	1.95e-06	0.000233	0.2	0.22	Colonoscopy-negative controls vs population controls;	chr12:98504033	chr12:98453835~98457145:-
THCA	cis	rs5749696	1	rs7349039	ENSG00000224086.5	LL22NC03-86G7.1	4.82	1.95e-06	0.000233	0.26	0.22	Schizophrenia;	chr22:21713850	chr22:21938293~21977632:+
THCA	cis	rs2742234	0.518	rs2505514	ENSG00000273008.1	RP11-351D16.3	-4.82	1.95e-06	0.000233	-0.2	-0.22	Hirschsprung disease;	chr10:43137800	chr10:43136824~43138334:-
THCA	cis	rs7208859	0.573	rs216443	ENSG00000280069.1	CTD-2349P21.3	-4.82	1.95e-06	0.000233	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30738182~30740275:+
THCA	cis	rs2235642	0.592	rs743963	ENSG00000280231.1	LA16c-380F5.3	-4.82	1.95e-06	0.000233	-0.27	-0.22	Coronary artery disease;	chr16:1607349	chr16:1553655~1554130:-
THCA	cis	rs8062405	0.755	rs7186573	ENSG00000261766.1	RP11-22P6.2	-4.82	1.95e-06	0.000233	-0.22	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28862166~28863340:-
THCA	cis	rs2129782	0.717	rs59255907	ENSG00000253553.4	RP11-586K2.1	4.82	1.95e-06	0.000233	0.38	0.22	Electrodermal activity;	chr8:88553735	chr8:88326836~88737134:+
THCA	cis	rs7914558	1	rs10748838	ENSG00000236937.2	PTGES3P4	4.82	1.95e-06	0.000233	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184229	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs3758543	ENSG00000236937.2	PTGES3P4	4.82	1.95e-06	0.000233	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184987	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs4917997	ENSG00000236937.2	PTGES3P4	4.82	1.95e-06	0.000233	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185456	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs7077097	ENSG00000236937.2	PTGES3P4	4.82	1.95e-06	0.000233	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185706	chr10:102845595~102845950:+
THCA	cis	rs2337406	0.587	rs2516889	ENSG00000211974.3	IGHV2-70	4.82	1.95e-06	0.000233	0.21	0.22	Alzheimer's disease (late onset);	chr14:106648903	chr14:106723574~106724093:-
THCA	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	4.82	1.95e-06	0.000233	0.18	0.22	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
THCA	cis	rs1150668	0.83	rs213240	ENSG00000176933.5	TOB2P1	-4.82	1.95e-06	0.000233	-0.24	-0.22	Pubertal anthropometrics;	chr6:28348098	chr6:28217643~28218634:-
THCA	cis	rs5771242	0.518	rs7290465	ENSG00000273253.2	RP3-402G11.26	4.82	1.95e-06	0.000233	0.24	0.22	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50241329	chr22:50199090~50200837:-
THCA	cis	rs2834188	0.662	rs7282780	ENSG00000272659.1	AP000295.10	-4.82	1.95e-06	0.000233	-0.28	-0.22	Narcolepsy;	chr21:33315049	chr21:33309491~33310181:+
THCA	cis	rs763121	0.925	rs4821797	ENSG00000228274.3	RP3-508I15.9	-4.82	1.95e-06	0.000233	-0.22	-0.22	Menopause (age at onset);	chr22:38620177	chr22:38667585~38681820:-
THCA	cis	rs1371614	0.566	rs11695406	ENSG00000229122.1	AGBL5-IT1	-4.82	1.95e-06	0.000233	-0.15	-0.22	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26955261	chr2:27061038~27061815:+
THCA	cis	rs4648045	0.861	rs2272676	ENSG00000246560.2	RP11-10L12.4	4.82	1.95e-06	0.000233	0.28	0.22	Lymphocyte percentage of white cells;	chr4:102502169	chr4:102828055~102844075:+
THCA	cis	rs72945132	0.882	rs12294540	ENSG00000254604.1	AP000487.6	-4.82	1.95e-06	0.000233	-0.4	-0.22	Coronary artery disease;	chr11:70272867	chr11:70282367~70363368:-
THCA	cis	rs3820928	0.874	rs4675137	ENSG00000212391.1	SNORA48	-4.82	1.95e-06	0.000233	-0.24	-0.22	Pulmonary function;	chr2:227019194	chr2:226968989~226969122:-
THCA	cis	rs7474896	0.583	rs11011346	ENSG00000263064.2	RP11-291L22.7	4.82	1.95e-06	0.000233	0.29	0.22	Obesity (extreme);	chr10:37720555	chr10:38448689~38448949:+
THCA	cis	rs829883	0.622	rs4762498	ENSG00000227825.4	SLC9A7P1	-4.82	1.95e-06	0.000233	-0.21	-0.22	Colorectal adenoma (advanced);	chr12:98570959	chr12:98453835~98457145:-
THCA	cis	rs4886920	0.574	rs71407228	ENSG00000260776.4	RP11-114H24.2	4.82	1.95e-06	0.000233	0.33	0.22	Neuroticism;	chr15:77850726	chr15:77914217~77926846:-
THCA	cis	rs3750082	0.889	rs6972006	ENSG00000231952.3	DPY19L1P2	4.82	1.95e-06	0.000233	0.27	0.22	Glomerular filtration rate (creatinine);	chr7:32898680	chr7:32812757~32838570:+
THCA	cis	rs7829975	0.684	rs546603	ENSG00000254153.1	CTA-398F10.2	4.82	1.95e-06	0.000234	0.22	0.22	Mood instability;	chr8:8738328	chr8:8456909~8461337:-
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000273712.1	RP5-874C20.7	4.82	1.95e-06	0.000234	0.24	0.22	Pubertal anthropometrics;	chr6:28230503	chr6:28315613~28315883:-
THCA	cis	rs6940116	1	rs6940116	ENSG00000226314.6	ZNF192P1	-4.82	1.95e-06	0.000234	-0.33	-0.22	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28161781~28169594:+
THCA	cis	rs812925	0.537	rs10865324	ENSG00000270820.4	RP11-355B11.2	-4.82	1.95e-06	0.000234	-0.18	-0.22	Immature fraction of reticulocytes;	chr2:61394172	chr2:61471188~61484130:+
THCA	cis	rs1707322	1	rs785490	ENSG00000281133.1	AL355480.3	4.82	1.96e-06	0.000234	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs785493	ENSG00000281133.1	AL355480.3	4.82	1.96e-06	0.000234	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.964	rs785496	ENSG00000281133.1	AL355480.3	4.82	1.96e-06	0.000234	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs785497	ENSG00000281133.1	AL355480.3	4.82	1.96e-06	0.000234	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.964	rs785499	ENSG00000281133.1	AL355480.3	4.82	1.96e-06	0.000234	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45580892~45580996:-
THCA	cis	rs7474896	0.583	rs34185758	ENSG00000263064.2	RP11-291L22.7	4.82	1.96e-06	0.000234	0.3	0.22	Obesity (extreme);	chr10:37701926	chr10:38448689~38448949:+
THCA	cis	rs972578	0.765	rs2017874	ENSG00000274717.1	RP1-47A17.1	4.82	1.96e-06	0.000234	0.22	0.22	Mean platelet volume;	chr22:42907681	chr22:42791814~42794313:-
THCA	cis	rs1371614	0.588	rs11126784	ENSG00000229122.1	AGBL5-IT1	4.82	1.96e-06	0.000234	0.15	0.22	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946974	chr2:27061038~27061815:+
THCA	cis	rs7429990	0.932	rs7630685	ENSG00000228638.1	FCF1P2	4.82	1.96e-06	0.000234	0.22	0.22	Educational attainment (years of education);	chr3:48089680	chr3:48290793~48291375:-
THCA	cis	rs736408	0.522	rs11130310	ENSG00000243224.1	RP5-1157M23.2	-4.82	1.96e-06	0.000234	-0.23	-0.22	Bipolar disorder;	chr3:52640651	chr3:52239258~52241097:+
THCA	cis	rs6951245	1	rs80094748	ENSG00000229043.2	AC091729.9	-4.82	1.96e-06	0.000234	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1160374~1165267:+
THCA	cis	rs4950322	0.57	rs17356492	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147296089	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72691093	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147297977	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs76236344	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147297989	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72691095	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147298305	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72691097	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147299711	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72691098	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147300142	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72691102	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147301189	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692904	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147301437	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692905	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147301560	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692907	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147301921	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692914	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147302946	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692917	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147304389	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692920	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147308501	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs66580541	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147308828	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs945742	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147313437	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.543	rs4950318	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147316240	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.543	rs4950319	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147316250	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.543	rs4453096	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147316574	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.571	rs4373796	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147316747	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.543	rs4568882	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147316885	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.543	rs2883323	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147316995	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.543	rs2883324	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147317157	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.542	rs72692942	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147318467	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs4950399	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147319302	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs4950403	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147319723	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.517	rs116479391	ENSG00000271721.1	RP11-337C18.9	4.82	1.96e-06	0.000234	0.25	0.22	Protein quantitative trait loci;	chr1:147320940	chr1:147175602~147177740:+
THCA	cis	rs6490294	0.571	rs7965087	ENSG00000226469.1	ADAM1B	4.82	1.96e-06	0.000234	0.32	0.22	Mean platelet volume;	chr12:112110758	chr12:111927018~111929017:+
THCA	cis	rs17767392	0.633	rs7160587	ENSG00000259146.3	RP1-261D10.2	4.82	1.96e-06	0.000234	0.29	0.22	Mitral valve prolapse;	chr14:71237967	chr14:71292729~71321814:-
THCA	cis	rs9425766	0.679	rs9787001	ENSG00000227373.4	RP11-160H22.5	4.82	1.96e-06	0.000234	0.3	0.22	Life satisfaction;	chr1:174222556	chr1:174115300~174160004:-
THCA	cis	rs9425766	0.679	rs972361	ENSG00000227373.4	RP11-160H22.5	4.82	1.96e-06	0.000234	0.3	0.22	Life satisfaction;	chr1:174228270	chr1:174115300~174160004:-
THCA	cis	rs875971	0.522	rs7784623	ENSG00000229886.1	RP5-1132H15.3	4.82	1.96e-06	0.000234	0.22	0.22	Aortic root size;	chr7:65930047	chr7:66025126~66031544:-
THCA	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-4.82	1.96e-06	0.000234	-0.26	-0.22	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
THCA	cis	rs9625935	0.957	rs36594	ENSG00000279159.1	RP3-394A18.1	4.82	1.96e-06	0.000234	0.17	0.22	Tonsillectomy;	chr22:29938393	chr22:29978950~30028236:-
THCA	cis	rs1048886	0.808	rs16869340	ENSG00000271967.1	RP11-134K13.4	-4.82	1.96e-06	0.000234	-0.22	-0.22	Type 2 diabetes;	chr6:70540063	chr6:70596438~70596980:+
THCA	cis	rs4660456	0.504	rs570671	ENSG00000272145.1	NFYC-AS1	-4.82	1.96e-06	0.000234	-0.16	-0.22	Platelet count;	chr1:40625455	chr1:40690380~40692066:-
THCA	cis	rs972578	0.715	rs13433641	ENSG00000274717.1	RP1-47A17.1	-4.82	1.96e-06	0.000234	-0.22	-0.22	Mean platelet volume;	chr22:42872003	chr22:42791814~42794313:-
THCA	cis	rs651907	0.535	rs11714444	ENSG00000244119.1	PDCL3P4	4.82	1.96e-06	0.000234	0.2	0.22	Colorectal cancer;	chr3:101794838	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs12631513	ENSG00000244119.1	PDCL3P4	4.82	1.96e-06	0.000234	0.2	0.22	Colorectal cancer;	chr3:101798632	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs13094911	ENSG00000244119.1	PDCL3P4	4.82	1.96e-06	0.000234	0.2	0.22	Colorectal cancer;	chr3:101800177	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs11712309	ENSG00000244119.1	PDCL3P4	4.82	1.96e-06	0.000234	0.2	0.22	Colorectal cancer;	chr3:101800253	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs35799195	ENSG00000244119.1	PDCL3P4	4.82	1.96e-06	0.000234	0.2	0.22	Colorectal cancer;	chr3:101803083	chr3:101712472~101713191:+
THCA	cis	rs1005277	0.579	rs1614236	ENSG00000272983.1	RP11-508N22.12	4.82	1.96e-06	0.000235	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2749616	ENSG00000272983.1	RP11-508N22.12	4.82	1.96e-06	0.000235	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780146	ENSG00000272983.1	RP11-508N22.12	4.82	1.96e-06	0.000235	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38137337~38144399:+
THCA	cis	rs9625935	0.957	rs9625878	ENSG00000279159.1	RP3-394A18.1	-4.82	1.96e-06	0.000235	-0.17	-0.22	Tonsillectomy;	chr22:29897514	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs3887275	ENSG00000279159.1	RP3-394A18.1	-4.82	1.96e-06	0.000235	-0.17	-0.22	Tonsillectomy;	chr22:29904123	chr22:29978950~30028236:-
THCA	cis	rs748404	0.736	rs542036	ENSG00000166763.7	STRCP1	-4.82	1.96e-06	0.000235	-0.25	-0.22	Lung cancer;	chr15:43248941	chr15:43699488~43718184:-
THCA	cis	rs4660214	0.627	rs16837533	ENSG00000228060.1	RP11-69E11.8	-4.82	1.96e-06	0.000235	-0.26	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39238175	chr1:39565160~39573203:+
THCA	cis	rs797680	0.836	rs2391256	ENSG00000223745.6	RP4-717I23.3	4.82	1.96e-06	0.000235	0.13	0.22	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93401378	chr1:93262186~93346025:-
THCA	cis	rs1003719	0.68	rs767998	ENSG00000230366.8	DSCR9	4.82	1.96e-06	0.000235	0.22	0.22	Eye color traits;	chr21:37153352	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.582	rs2835634	ENSG00000230366.8	DSCR9	4.82	1.96e-06	0.000235	0.22	0.22	Eye color traits;	chr21:37155969	chr21:37208503~37221736:+
THCA	cis	rs317689	0.819	rs317677	ENSG00000274979.1	RP11-1143G9.5	-4.82	1.96e-06	0.000235	-0.25	-0.22	Response to diuretic therapy;	chr12:69298026	chr12:69326574~69331882:-
THCA	cis	rs317689	0.788	rs317679	ENSG00000274979.1	RP11-1143G9.5	-4.82	1.96e-06	0.000235	-0.25	-0.22	Response to diuretic therapy;	chr12:69299392	chr12:69326574~69331882:-
THCA	cis	rs9880211	0.606	rs28576629	ENSG00000273486.1	RP11-731C17.2	4.82	1.96e-06	0.000235	0.23	0.22	Height;Body mass index;	chr3:136054819	chr3:136837338~136839021:-
THCA	cis	rs6088580	0.634	rs6059850	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.96e-06	0.000235	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34456979	chr20:33985617~33988989:-
THCA	cis	rs453301	0.571	rs330057	ENSG00000248538.5	RP11-10A14.5	4.82	1.97e-06	0.000235	0.27	0.22	Joint mobility (Beighton score);	chr8:9232283	chr8:9189011~9202854:+
THCA	cis	rs919433	0.889	rs12693816	ENSG00000231621.1	AC013264.2	4.82	1.97e-06	0.000235	0.23	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343696	chr2:197197991~197199273:+
THCA	cis	rs7429990	0.93	rs13075457	ENSG00000228638.1	FCF1P2	4.82	1.97e-06	0.000235	0.21	0.22	Educational attainment (years of education);	chr3:48013063	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.93	rs11130152	ENSG00000228638.1	FCF1P2	4.82	1.97e-06	0.000235	0.21	0.22	Educational attainment (years of education);	chr3:48014919	chr3:48290793~48291375:-
THCA	cis	rs10510102	0.872	rs7907815	ENSG00000226864.1	ATE1-AS1	4.82	1.97e-06	0.000235	0.35	0.22	Breast cancer;	chr10:121965951	chr10:121928312~121951965:+
THCA	cis	rs250518	0.926	rs3846650	ENSG00000272081.1	CTD-2376I4.2	4.82	1.97e-06	0.000235	0.28	0.22	Mean corpuscular hemoglobin concentration;	chr5:72768560	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs3916445	ENSG00000272081.1	CTD-2376I4.2	4.82	1.97e-06	0.000235	0.28	0.22	Mean corpuscular hemoglobin concentration;	chr5:72773821	chr5:72955206~72955699:-
THCA	cis	rs875971	0.558	rs4433015	ENSG00000229886.1	RP5-1132H15.3	-4.82	1.97e-06	0.000235	-0.22	-0.22	Aortic root size;	chr7:66174736	chr7:66025126~66031544:-
THCA	cis	rs4218	0.597	rs12438208	ENSG00000259732.1	RP11-59H7.3	-4.82	1.97e-06	0.000235	-0.3	-0.22	Social communication problems;	chr15:59057715	chr15:59121034~59133250:+
THCA	cis	rs736408	0.608	rs35004449	ENSG00000242142.1	SERBP1P3	4.82	1.97e-06	0.000235	0.28	0.22	Bipolar disorder;	chr3:52818881	chr3:53064283~53065091:-
THCA	cis	rs12428035	0.881	rs76030156	ENSG00000247400.3	DNAJC3-AS1	-4.82	1.97e-06	0.000235	-0.22	-0.22	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95654576	chr13:95648733~95676925:-
THCA	cis	rs72843506	0.656	rs77314146	ENSG00000231258.2	ZSWIM5P2	4.82	1.97e-06	0.000235	0.34	0.22	Schizophrenia;	chr17:20003827	chr17:20583758~20591180:-
THCA	cis	rs875971	0.577	rs34888281	ENSG00000229886.1	RP5-1132H15.3	-4.82	1.97e-06	0.000235	-0.22	-0.22	Aortic root size;	chr7:66120784	chr7:66025126~66031544:-
THCA	cis	rs7819412	0.618	rs10105377	ENSG00000206014.6	OR7E161P	4.82	1.97e-06	0.000235	0.26	0.22	Triglycerides;	chr8:11118223	chr8:11928597~11929563:-
THCA	cis	rs9719620	0.967	rs4506137	ENSG00000236753.4	MKLN1-AS	-4.82	1.97e-06	0.000235	-0.21	-0.22	Male-pattern baldness;	chr7:131310020	chr7:131309744~131328222:-
THCA	cis	rs793571	0.554	rs7163939	ENSG00000245975.2	RP11-30K9.6	4.82	1.97e-06	0.000235	0.25	0.22	Schizophrenia;	chr15:58707956	chr15:58768072~58770974:-
THCA	cis	rs11089937	0.524	rs2877021	ENSG00000211639.2	IGLV4-60	4.82	1.97e-06	0.000235	0.15	0.22	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22162199~22162681:+
THCA	cis	rs13113518	0.902	rs3805150	ENSG00000273257.1	RP11-177J6.1	4.82	1.97e-06	0.000235	0.28	0.22	Height;	chr4:55446869	chr4:55387949~55388271:+
THCA	cis	rs897984	0.806	rs9319588	ENSG00000260911.2	RP11-196G11.2	-4.82	1.97e-06	0.000235	-0.18	-0.22	Dementia with Lewy bodies;	chr16:30919662	chr16:31043150~31049868:+
THCA	cis	rs897984	0.77	rs12930657	ENSG00000260911.2	RP11-196G11.2	-4.82	1.97e-06	0.000235	-0.18	-0.22	Dementia with Lewy bodies;	chr16:30920647	chr16:31043150~31049868:+
THCA	cis	rs897984	0.77	rs3813020	ENSG00000260911.2	RP11-196G11.2	-4.82	1.97e-06	0.000235	-0.18	-0.22	Dementia with Lewy bodies;	chr16:30922754	chr16:31043150~31049868:+
THCA	cis	rs972578	0.668	rs875629	ENSG00000274717.1	RP1-47A17.1	-4.82	1.97e-06	0.000236	-0.23	-0.22	Mean platelet volume;	chr22:42899262	chr22:42791814~42794313:-
THCA	cis	rs7267979	0.727	rs2474765	ENSG00000125804.12	FAM182A	-4.82	1.97e-06	0.000236	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.764	rs2474767	ENSG00000125804.12	FAM182A	-4.82	1.97e-06	0.000236	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:26054655~26086917:+
THCA	cis	rs3950186	0.834	rs1883325	ENSG00000215124.2	RP3-420J14.1	4.82	1.97e-06	0.000236	0.26	0.22	Anxiety and major depressive disorder;	chr6:11805843	chr6:11861626~11862970:-
THCA	cis	rs7211079	0.581	rs66994322	ENSG00000275479.1	RP11-334C17.6	4.82	1.97e-06	0.000236	0.25	0.22	Myocardial infarction;	chr17:80157441	chr17:80149627~80149798:+
THCA	cis	rs2985684	1	rs17121651	ENSG00000278009.1	RP11-649E7.8	4.82	1.97e-06	0.000236	0.31	0.22	Carotid intima media thickness;	chr14:49630454	chr14:49601011~49601124:-
THCA	cis	rs72843506	0.722	rs16942325	ENSG00000231258.2	ZSWIM5P2	4.82	1.97e-06	0.000236	0.34	0.22	Schizophrenia;	chr17:20123750	chr17:20583758~20591180:-
THCA	cis	rs847845	0.535	rs3734261	ENSG00000272288.4	RP11-140K17.3	4.82	1.97e-06	0.000236	0.26	0.22	Non-small cell lung cancer;	chr6:34872621	chr6:34696317~34697470:+
THCA	cis	rs763121	0.853	rs5750622	ENSG00000228274.3	RP3-508I15.9	-4.82	1.97e-06	0.000236	-0.24	-0.22	Menopause (age at onset);	chr22:38560459	chr22:38667585~38681820:-
THCA	cis	rs1889642	0.669	rs1335279	ENSG00000227354.5	RBM26-AS1	-4.82	1.97e-06	0.000236	-0.21	-0.22	Colonoscopy-negative controls vs population controls;	chr13:79825815	chr13:79406309~79424328:+
THCA	cis	rs8020095	0.571	rs17248252	ENSG00000258561.1	RP11-72M17.1	-4.82	1.97e-06	0.000236	-0.28	-0.22	Depression (quantitative trait);	chr14:67096212	chr14:66212810~66509394:-
THCA	cis	rs1003719	0.68	rs2835629	ENSG00000230366.8	DSCR9	4.82	1.97e-06	0.000236	0.22	0.22	Eye color traits;	chr21:37149360	chr21:37208503~37221736:+
THCA	cis	rs11089937	0.616	rs66651705	ENSG00000211639.2	IGLV4-60	4.82	1.98e-06	0.000236	0.16	0.22	Periodontitis (PAL4Q3);	chr22:22179973	chr22:22162199~22162681:+
THCA	cis	rs13113518	1	rs7691799	ENSG00000273257.1	RP11-177J6.1	4.82	1.98e-06	0.000236	0.28	0.22	Height;	chr4:55545574	chr4:55387949~55388271:+
THCA	cis	rs12681288	0.676	rs2701927	ENSG00000260721.1	AF067845.1	4.82	1.98e-06	0.000236	0.27	0.22	Schizophrenia;	chr8:1045886	chr8:1368642~1369833:-
THCA	cis	rs1003719	0.679	rs1133001	ENSG00000230366.8	DSCR9	4.82	1.98e-06	0.000236	0.22	0.22	Eye color traits;	chr21:37140656	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.654	rs764175	ENSG00000230366.8	DSCR9	4.82	1.98e-06	0.000236	0.22	0.22	Eye color traits;	chr21:37144758	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.641	rs13046844	ENSG00000230366.8	DSCR9	4.82	1.98e-06	0.000236	0.22	0.22	Eye color traits;	chr21:37145303	chr21:37208503~37221736:+
THCA	cis	rs3743162	0.553	rs12900463	ENSG00000225151.9	GOLGA2P7	-4.82	1.98e-06	0.000236	-0.33	-0.22	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84199311~84230136:-
THCA	cis	rs9393777	0.92	rs13212562	ENSG00000280107.1	AL022393.9	-4.82	1.98e-06	0.000236	-0.31	-0.22	Intelligence (multi-trait analysis);	chr6:27332531	chr6:28170845~28172521:+
THCA	cis	rs72843506	0.52	rs78178505	ENSG00000261033.1	RP11-209D14.2	4.82	1.98e-06	0.000236	0.43	0.22	Schizophrenia;	chr17:19984410	chr17:20008051~20009234:-
THCA	cis	rs160451	0.811	rs2735886	ENSG00000251136.7	RP11-37B2.1	4.82	1.98e-06	0.000236	0.2	0.22	Leprosy;	chr8:89639406	chr8:89609409~89757727:-
THCA	cis	rs8062405	0.755	rs12447461	ENSG00000261766.1	RP11-22P6.2	-4.82	1.98e-06	0.000236	-0.22	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28862166~28863340:-
THCA	cis	rs17818399	0.962	rs7565274	ENSG00000279254.1	RP11-536C12.1	-4.82	1.98e-06	0.000236	-0.23	-0.22	Height;	chr2:46614722	chr2:46668870~46670778:+
THCA	cis	rs7849973	0.637	rs12349560	ENSG00000234840.1	LINC01239	-4.82	1.98e-06	0.000236	-0.28	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22763159	chr9:22646200~22824213:+
THCA	cis	rs478304	0.903	rs61895677	ENSG00000214659.4	KRT8P26	-4.82	1.98e-06	0.000236	-0.18	-0.22	Acne (severe);	chr11:65781944	chr11:65726939~65728214:+
THCA	cis	rs478304	0.934	rs12801731	ENSG00000214659.4	KRT8P26	-4.82	1.98e-06	0.000236	-0.18	-0.22	Acne (severe);	chr11:65782135	chr11:65726939~65728214:+
THCA	cis	rs2447820	0.588	rs55746012	ENSG00000249996.1	RP11-359P5.1	4.82	1.98e-06	0.000236	0.26	0.22	Migraine;	chr5:123059150	chr5:123036271~123054667:+
THCA	cis	rs957448	1	rs72674843	ENSG00000253175.1	RP11-267M23.6	4.82	1.98e-06	0.000236	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94565036~94565715:+
THCA	cis	rs5742933	1	rs1966729	ENSG00000253559.1	OSGEPL1-AS1	-4.82	1.98e-06	0.000236	-0.26	-0.22	Ferritin levels;	chr2:189721105	chr2:189762704~189765556:+
THCA	cis	rs9816784	0.596	rs11185511	ENSG00000273009.1	RP11-352G9.1	-4.82	1.98e-06	0.000236	-0.25	-0.22	Mean corpuscular hemoglobin;	chr3:196108388	chr3:195913078~195913683:-
THCA	cis	rs9311474	0.607	rs11711421	ENSG00000243224.1	RP5-1157M23.2	-4.82	1.98e-06	0.000236	-0.23	-0.22	Electroencephalogram traits;	chr3:52527763	chr3:52239258~52241097:+
THCA	cis	rs874628	0.659	rs4808770	ENSG00000268650.3	AC068499.10	4.82	1.98e-06	0.000236	0.25	0.22	Multiple sclerosis;	chr19:18247095	chr19:18204730~18220480:+
THCA	cis	rs793571	0.505	rs12591290	ENSG00000245975.2	RP11-30K9.6	4.82	1.98e-06	0.000236	0.26	0.22	Schizophrenia;	chr15:58603305	chr15:58768072~58770974:-
THCA	cis	rs2692947	0.637	rs72492201	ENSG00000232931.4	LINC00342	4.82	1.98e-06	0.000237	0.17	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95964453	chr2:95807118~95816215:-
THCA	cis	rs11648785	0.747	rs3743826	ENSG00000222019.6	URAHP	4.82	1.98e-06	0.000237	0.19	0.22	Tanning;	chr16:90027806	chr16:90039761~90047773:-
THCA	cis	rs7702057	0.53	rs17138866	ENSG00000272265.1	CTD-2287O16.4	4.82	1.98e-06	0.000237	0.4	0.22	Amyotrophic lateral sclerosis;	chr5:116088914	chr5:116078110~116078570:-
THCA	cis	rs7702057	0.53	rs59429923	ENSG00000272265.1	CTD-2287O16.4	4.82	1.98e-06	0.000237	0.4	0.22	Amyotrophic lateral sclerosis;	chr5:116089241	chr5:116078110~116078570:-
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000273796.1	LL21NC02-21A1.1	-4.82	1.98e-06	0.000237	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45403809~45404369:-
THCA	cis	rs3743162	0.553	rs12915656	ENSG00000259728.4	LINC00933	4.82	1.98e-06	0.000237	0.3	0.22	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84570649~84580175:+
THCA	cis	rs804280	0.662	rs11784764	ENSG00000255046.1	RP11-297N6.4	4.82	1.98e-06	0.000237	0.26	0.22	Myopia (pathological);	chr8:11753365	chr8:11797928~11802568:-
THCA	cis	rs5015933	0.815	rs10819044	ENSG00000232630.1	PRPS1P2	-4.82	1.98e-06	0.000237	-0.14	-0.22	Body mass index;	chr9:125278750	chr9:125150653~125151589:+
THCA	cis	rs6012564	1	rs3091529	ENSG00000227431.4	CSE1L-AS1	-4.82	1.98e-06	0.000237	-0.26	-0.22	Anger;	chr20:49030531	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs1022687	ENSG00000227431.4	CSE1L-AS1	-4.82	1.98e-06	0.000237	-0.26	-0.22	Anger;	chr20:49032317	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.964	rs3092302	ENSG00000227431.4	CSE1L-AS1	-4.82	1.98e-06	0.000237	-0.26	-0.22	Anger;	chr20:49037721	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.964	rs73266241	ENSG00000227431.4	CSE1L-AS1	4.82	1.98e-06	0.000237	0.26	0.22	Anger;	chr20:49043748	chr20:49040463~49046044:-
THCA	cis	rs950169	0.58	rs2271431	ENSG00000188388.10	GOLGA6L3	4.82	1.98e-06	0.000237	0.29	0.22	Schizophrenia;	chr15:84646233	chr15:85240472~85247170:+
THCA	cis	rs2243480	1	rs383402	ENSG00000164669.11	INTS4P1	-4.82	1.98e-06	0.000237	-0.41	-0.22	Diabetic kidney disease;	chr7:66121666	chr7:65141225~65234216:+
THCA	cis	rs7772486	0.806	rs7740785	ENSG00000270638.1	RP3-466P17.1	4.82	1.98e-06	0.000237	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145735570~145737218:+
THCA	cis	rs7005380	0.733	rs2037346	ENSG00000245330.4	KB-1471A8.1	4.82	1.98e-06	0.000237	0.21	0.22	Interstitial lung disease;	chr8:119923212	chr8:119867419~119874488:-
THCA	cis	rs2303319	0.504	rs2084543	ENSG00000227403.1	AC009299.3	4.82	1.98e-06	0.000237	0.53	0.22	Cognitive function;	chr2:161839904	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187740	ENSG00000227403.1	AC009299.3	4.82	1.98e-06	0.000237	0.53	0.22	Cognitive function;	chr2:161841976	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs62187741	ENSG00000227403.1	AC009299.3	4.82	1.98e-06	0.000237	0.53	0.22	Cognitive function;	chr2:161842014	chr2:161244739~161249050:+
THCA	cis	rs2303319	0.504	rs72879275	ENSG00000227403.1	AC009299.3	4.82	1.98e-06	0.000237	0.53	0.22	Cognitive function;	chr2:161842313	chr2:161244739~161249050:+
THCA	cis	rs9388451	0.874	rs9398787	ENSG00000226409.1	RP11-735G4.1	-4.82	1.98e-06	0.000237	-0.25	-0.22	Brugada syndrome;	chr6:125769462	chr6:125370211~125374324:-
THCA	cis	rs317865	0.529	rs57811439	ENSG00000263327.5	TAPT1-AS1	-4.82	1.98e-06	0.000237	-0.33	-0.22	Kidney disease (early stage) in type 1 diabetes;	chr4:16193044	chr4:16226685~16320140:+
THCA	cis	rs7614311	0.681	rs73130565	ENSG00000271843.1	RP11-245J9.5	-4.82	1.98e-06	0.000237	-0.38	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63901459	chr3:64008082~64008692:-
THCA	cis	rs7829975	0.567	rs6601273	ENSG00000253981.4	ALG1L13P	-4.82	1.98e-06	0.000237	-0.21	-0.22	Mood instability;	chr8:8939009	chr8:8236003~8244667:-
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000273712.1	RP5-874C20.7	4.82	1.99e-06	0.000237	0.24	0.22	Pubertal anthropometrics;	chr6:28219323	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.515	rs1558205	ENSG00000273712.1	RP5-874C20.7	-4.82	1.99e-06	0.000237	-0.24	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28315613~28315883:-
THCA	cis	rs62025270	0.632	rs62022919	ENSG00000259295.5	CSPG4P12	-4.82	1.99e-06	0.000237	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85191438~85213905:+
THCA	cis	rs7772486	0.754	rs6570708	ENSG00000270638.1	RP3-466P17.1	-4.82	1.99e-06	0.000237	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145735570~145737218:+
THCA	cis	rs758324	0.572	rs247294	ENSG00000237714.1	P4HA2-AS1	-4.82	1.99e-06	0.000237	-0.3	-0.22	Alzheimer's disease in APOE e4- carriers;	chr5:132121335	chr5:132184876~132192808:+
THCA	cis	rs860295	0.702	rs5005770	ENSG00000160766.13	GBAP1	4.82	1.99e-06	0.000237	0.25	0.22	Body mass index;	chr1:155375252	chr1:155213821~155227422:-
THCA	cis	rs7911264	0.967	rs2497318	ENSG00000236493.2	EIF2S2P3	-4.82	1.99e-06	0.000237	-0.23	-0.22	Inflammatory bowel disease;	chr10:92672243	chr10:92668745~92669743:-
THCA	cis	rs2742234	0.541	rs2742235	ENSG00000273008.1	RP11-351D16.3	-4.82	1.99e-06	0.000237	-0.2	-0.22	Hirschsprung disease;	chr10:43120877	chr10:43136824~43138334:-
THCA	cis	rs6088580	0.634	rs2424992	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34424254	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6119497	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34424723	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6120642	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34424725	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.601	rs6059827	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34428552	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6059829	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34429268	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.602	rs6059834	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34431493	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6059835	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34432335	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6120644	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34436005	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.624	rs6120645	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34437366	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.602	rs6059840	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34442600	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs3736762	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34449531	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6058051	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34457057	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6087587	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34470823	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.601	rs6059872	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34494970	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.609	rs2378205	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.99e-06	0.000237	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34522998	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6088488	ENSG00000276073.1	RP5-1125A11.7	4.82	1.99e-06	0.000237	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34404825	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs4911418	ENSG00000276073.1	RP5-1125A11.7	4.82	1.99e-06	0.000237	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34406451	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6579165	ENSG00000276073.1	RP5-1125A11.7	4.82	1.99e-06	0.000237	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34406909	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs4911419	ENSG00000276073.1	RP5-1125A11.7	4.82	1.99e-06	0.000237	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34408067	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs4911421	ENSG00000276073.1	RP5-1125A11.7	4.82	1.99e-06	0.000237	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34411142	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs4911422	ENSG00000276073.1	RP5-1125A11.7	4.82	1.99e-06	0.000237	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34411539	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs2225837	ENSG00000276073.1	RP5-1125A11.7	4.82	1.99e-06	0.000237	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34417828	chr20:33985617~33988989:-
THCA	cis	rs7083	0.716	rs687740	ENSG00000254851.1	RP11-109L13.1	-4.82	1.99e-06	0.000237	-0.3	-0.22	Blood protein levels;	chr11:117306887	chr11:117135528~117138582:+
THCA	cis	rs2839186	0.632	rs17176110	ENSG00000215424.8	MCM3AP-AS1	4.81	1.99e-06	0.000237	0.13	0.22	Testicular germ cell tumor;	chr21:46286621	chr21:46229217~46259390:+
THCA	cis	rs8111500	0.793	rs8103121	ENSG00000232871.7	SEC1P	-4.81	1.99e-06	0.000237	-0.26	-0.22	Elevated serum carcinoembryonic antigen levels;	chr19:48654881	chr19:48638071~48682245:+
THCA	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	4.81	1.99e-06	0.000237	0.12	0.22	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	4.81	1.99e-06	0.000237	0.12	0.22	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	4.81	1.99e-06	0.000237	0.12	0.22	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
THCA	cis	rs8064024	0.619	rs9935080	ENSG00000267077.1	RP11-127I20.5	4.81	1.99e-06	0.000237	0.25	0.22	Cancer;	chr16:4852206	chr16:4795265~4796532:-
THCA	cis	rs2243480	0.522	rs1638736	ENSG00000228409.4	CCT6P1	4.81	1.99e-06	0.000237	0.32	0.22	Diabetic kidney disease;	chr7:66627321	chr7:65751142~65763354:+
THCA	cis	rs11634944	0.716	rs2052723	ENSG00000257151.1	PWAR6	4.81	1.99e-06	0.000238	0.16	0.22	Interleukin-8 levels;	chr15:24992745	chr15:25031873~25036490:+
THCA	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-4.81	1.99e-06	0.000238	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-4.81	1.99e-06	0.000238	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
THCA	cis	rs2282300	0.637	rs2065418	ENSG00000242353.1	RP4-710M3.1	-4.81	1.99e-06	0.000238	-0.18	-0.22	Morning vs. evening chronotype;	chr11:30400521	chr11:30368148~30368646:+
THCA	cis	rs481331	0.643	rs210285	ENSG00000215146.4	RP11-313J2.1	-4.81	1.99e-06	0.000238	-0.35	-0.22	Systemic juvenile idiopathic arthritis;	chr10:42583900	chr10:42331866~42367974:-
THCA	cis	rs922182	0.633	rs16947621	ENSG00000275785.1	RP11-111E14.2	4.81	1.99e-06	0.000238	0.24	0.22	Blood protein levels;	chr15:63979461	chr15:63890030~63890317:+
THCA	cis	rs860295	0.702	rs12039893	ENSG00000160766.13	GBAP1	-4.81	1.99e-06	0.000238	-0.26	-0.22	Body mass index;	chr1:155645024	chr1:155213821~155227422:-
THCA	cis	rs12549025	0.53	rs34297248	ENSG00000253390.1	CTC-756D1.2	-4.81	1.99e-06	0.000238	-0.33	-0.22	Reticulocyte fraction of red cells;	chr8:23506865	chr8:23458601~23484971:+
THCA	cis	rs4639966	0.836	rs10892282	ENSG00000255422.1	AP002954.4	-4.81	1.99e-06	0.000238	-0.26	-0.22	Systemic lupus erythematosus;	chr11:118757069	chr11:118704607~118750263:+
THCA	cis	rs4578769	0.55	rs11082182	ENSG00000265939.1	UBE2CP2	4.81	1.99e-06	0.000238	0.25	0.22	Eosinophil percentage of white cells;	chr18:22872136	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.531	rs11082183	ENSG00000265939.1	UBE2CP2	4.81	1.99e-06	0.000238	0.25	0.22	Eosinophil percentage of white cells;	chr18:22872137	chr18:22900486~22900995:-
THCA	cis	rs11779988	0.545	rs208058	ENSG00000253671.1	RP11-806O11.1	-4.81	1.99e-06	0.000238	-0.28	-0.22	Breast cancer;	chr8:17962924	chr8:17808941~17820868:+
THCA	cis	rs7493	0.901	rs11767787	ENSG00000233942.1	AC004012.1	4.81	1.99e-06	0.000238	0.33	0.22	Yu-Zhi constitution type in type 2 diabetes;	chr7:95397441	chr7:95471835~95473998:+
THCA	cis	rs9875589	0.509	rs2731332	ENSG00000228242.5	AC093495.4	4.81	1.99e-06	0.000238	0.12	0.22	Ovarian reserve;	chr3:14068583	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs2731330	ENSG00000228242.5	AC093495.4	4.81	1.99e-06	0.000238	0.12	0.22	Ovarian reserve;	chr3:14070088	chr3:14144637~14165978:+
THCA	cis	rs160451	0.811	rs160418	ENSG00000251136.7	RP11-37B2.1	4.81	2e-06	0.000238	0.2	0.22	Leprosy;	chr8:89631300	chr8:89609409~89757727:-
THCA	cis	rs651907	0.557	rs35850993	ENSG00000244119.1	PDCL3P4	4.81	2e-06	0.000238	0.2	0.22	Colorectal cancer;	chr3:101718589	chr3:101712472~101713191:+
THCA	cis	rs62025270	0.547	rs416916	ENSG00000202081.1	RNU6-1280P	-4.81	2e-06	0.000238	-0.3	-0.22	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85651522~85651628:-
THCA	cis	rs6870983	0.749	rs16903197	ENSG00000247828.6	TMEM161B-AS1	4.81	2e-06	0.000238	0.19	0.22	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88506327	chr5:88268895~88436685:+
THCA	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	4.81	2e-06	0.000238	0.12	0.22	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
THCA	cis	rs172166	0.516	rs2791333	ENSG00000273712.1	RP5-874C20.7	4.81	2e-06	0.000238	0.24	0.22	Cardiac Troponin-T levels;	chr6:28143336	chr6:28315613~28315883:-
THCA	cis	rs911555	0.706	rs10129426	ENSG00000269940.1	RP11-73M18.7	4.81	2e-06	0.000238	0.22	0.22	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103694560~103695170:+
THCA	cis	rs9368481	0.729	rs10946881	ENSG00000261353.1	CTA-14H9.5	-4.81	2e-06	0.000238	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26527063~26527404:+
THCA	cis	rs62402013	1	rs62402013	ENSG00000261353.1	CTA-14H9.5	-4.81	2e-06	0.000238	-0.23	-0.22	Schizophrenia;	chr6:26947221	chr6:26527063~26527404:+
THCA	cis	rs7772486	0.754	rs9373476	ENSG00000270638.1	RP3-466P17.1	4.81	2e-06	0.000238	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.727	rs11155442	ENSG00000270638.1	RP3-466P17.1	4.81	2e-06	0.000238	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145735570~145737218:+
THCA	cis	rs172166	0.694	rs1225716	ENSG00000261839.1	RP1-265C24.8	4.81	2e-06	0.000238	0.23	0.22	Cardiac Troponin-T levels;	chr6:28145968	chr6:28136849~28139678:+
THCA	cis	rs4660214	0.671	rs72637904	ENSG00000228060.1	RP11-69E11.8	-4.81	2e-06	0.000238	-0.26	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203010	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.671	rs17491275	ENSG00000228060.1	RP11-69E11.8	-4.81	2e-06	0.000238	-0.26	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39206873	chr1:39565160~39573203:+
THCA	cis	rs9487094	0.689	rs9480949	ENSG00000223537.2	RP5-919F19.5	-4.81	2e-06	0.000239	-0.22	-0.22	Height;	chr6:109407238	chr6:109487906~109506800:+
THCA	cis	rs654950	0.807	rs941970	ENSG00000230638.4	RP11-486B10.4	4.81	2e-06	0.000239	0.24	0.22	Airway imaging phenotypes;	chr1:41525196	chr1:41542069~41544310:+
THCA	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	4.81	2e-06	0.000239	0.26	0.22	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
THCA	cis	rs9875589	0.509	rs2733556	ENSG00000228242.5	AC093495.4	4.81	2e-06	0.000239	0.12	0.22	Ovarian reserve;	chr3:14058672	chr3:14144637~14165978:+
THCA	cis	rs2029362	1	rs11030064	ENSG00000245573.6	BDNF-AS	-4.81	2e-06	0.000239	-0.17	-0.22	Total body bone mineral density;	chr11:27596469	chr11:27506838~27698174:+
THCA	cis	rs270601	0.69	rs162907	ENSG00000224431.1	AC063976.7	-4.81	2e-06	0.000239	-0.19	-0.22	Acylcarnitine levels;	chr5:132244459	chr5:132199456~132203487:+
THCA	cis	rs270601	0.71	rs371709	ENSG00000224431.1	AC063976.7	4.81	2e-06	0.000239	0.19	0.22	Acylcarnitine levels;	chr5:132247547	chr5:132199456~132203487:+
THCA	cis	rs12935418	0.672	rs3784814	ENSG00000278985.1	RP11-303E16.9	4.81	2e-06	0.000239	0.24	0.22	Mean corpuscular volume;	chr16:81007652	chr16:80982319~80984094:-
THCA	cis	rs8067545	0.532	rs17759609	ENSG00000261033.1	RP11-209D14.2	-4.81	2e-06	0.000239	-0.31	-0.22	Schizophrenia;	chr17:20089201	chr17:20008051~20009234:-
THCA	cis	rs801193	0.967	rs2420827	ENSG00000224316.1	RP11-479O9.2	-4.81	2e-06	0.000239	-0.24	-0.22	Aortic root size;	chr7:66682114	chr7:65773620~65802067:+
THCA	cis	rs453301	0.571	rs2929454	ENSG00000253981.4	ALG1L13P	-4.81	2e-06	0.000239	-0.2	-0.22	Joint mobility (Beighton score);	chr8:9226344	chr8:8236003~8244667:-
THCA	cis	rs10946940	0.965	rs4713112	ENSG00000219392.1	RP1-265C24.5	4.81	2e-06	0.000239	0.25	0.22	Systemic lupus erythematosus;	chr6:27549054	chr6:28115628~28116551:+
THCA	cis	rs7851660	0.809	rs10984235	ENSG00000214417.4	KRT18P13	-4.81	2e-06	0.000239	-0.19	-0.22	Strep throat;	chr9:97898614	chr9:97698922~97700734:+
THCA	cis	rs7010876	0.537	rs1394514	ENSG00000253553.4	RP11-586K2.1	-4.81	2.01e-06	0.000239	-0.22	-0.22	Schizophrenia;	chr8:88401006	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.515	rs2134963	ENSG00000253553.4	RP11-586K2.1	4.81	2.01e-06	0.000239	0.22	0.22	Schizophrenia;	chr8:88395592	chr8:88326836~88737134:+
THCA	cis	rs1048886	0.882	rs2346889	ENSG00000271967.1	RP11-134K13.4	-4.81	2.01e-06	0.000239	-0.22	-0.22	Type 2 diabetes;	chr6:70406469	chr6:70596438~70596980:+
THCA	cis	rs763121	0.853	rs5757193	ENSG00000228274.3	RP3-508I15.9	4.81	2.01e-06	0.000239	0.24	0.22	Menopause (age at onset);	chr22:38638862	chr22:38667585~38681820:-
THCA	cis	rs7829975	0.573	rs7842359	ENSG00000254153.1	CTA-398F10.2	4.81	2.01e-06	0.000239	0.24	0.22	Mood instability;	chr8:8939568	chr8:8456909~8461337:-
THCA	cis	rs2243480	1	rs35820085	ENSG00000232559.3	GS1-124K5.12	4.81	2.01e-06	0.000239	0.33	0.22	Diabetic kidney disease;	chr7:65977771	chr7:66554588~66576923:-
THCA	cis	rs1707322	1	rs785484	ENSG00000281133.1	AL355480.3	4.81	2.01e-06	0.000239	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45580892~45580996:-
THCA	cis	rs11640436	0.607	rs9927552	ENSG00000260922.1	RP11-538I12.3	-4.81	2.01e-06	0.000239	-0.26	-0.22	Lobe attachment (rater-scored or self-reported);	chr16:77261933	chr16:77234877~77290934:+
THCA	cis	rs5742933	1	rs3791770	ENSG00000273240.1	RP11-455J20.3	-4.81	2.01e-06	0.000239	-0.24	-0.22	Ferritin levels;	chr2:189809109	chr2:189763859~189764456:-
THCA	cis	rs5742933	0.948	rs62184286	ENSG00000273240.1	RP11-455J20.3	-4.81	2.01e-06	0.000239	-0.24	-0.22	Ferritin levels;	chr2:189812147	chr2:189763859~189764456:-
THCA	cis	rs6088580	0.634	rs6059860	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.01e-06	0.000239	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34476025	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.57	rs6058057	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.01e-06	0.000239	-0.19	-0.22	Glomerular filtration rate (creatinine);	chr20:34477478	chr20:33985617~33988989:-
THCA	cis	rs6921919	0.525	rs11760133	ENSG00000280107.1	AL022393.9	-4.81	2.01e-06	0.000239	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28170845~28172521:+
THCA	cis	rs4245128	0.775	rs10789927	ENSG00000247416.2	RP11-629G13.1	4.81	2.01e-06	0.00024	0.21	0.22	Life satisfaction;	chr11:112938929	chr11:112959279~112963460:-
THCA	cis	rs897984	0.568	rs72799330	ENSG00000279196.1	RP11-1072A3.3	4.81	2.01e-06	0.00024	0.24	0.22	Dementia with Lewy bodies;	chr16:30882234	chr16:30984630~30988270:-
THCA	cis	rs13434995	0.513	rs4336288	ENSG00000273257.1	RP11-177J6.1	4.81	2.01e-06	0.00024	0.33	0.22	Adiponectin levels;	chr4:55584088	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs9993599	ENSG00000273257.1	RP11-177J6.1	4.81	2.01e-06	0.00024	0.33	0.22	Adiponectin levels;	chr4:55586798	chr4:55387949~55388271:+
THCA	cis	rs2688608	0.869	rs2250140	ENSG00000271816.1	BMS1P4	4.81	2.01e-06	0.00024	0.21	0.22	Inflammatory bowel disease;	chr10:73853123	chr10:73699151~73730487:-
THCA	cis	rs250518	0.926	rs34426717	ENSG00000272081.1	CTD-2376I4.2	4.81	2.01e-06	0.00024	0.28	0.22	Mean corpuscular hemoglobin concentration;	chr5:72752640	chr5:72955206~72955699:-
THCA	cis	rs2617170	0.961	rs1841958	ENSG00000245648.1	RP11-277P12.20	4.81	2.01e-06	0.00024	0.23	0.22	Behcet's disease;	chr12:10409490	chr12:10363769~10398506:+
THCA	cis	rs7403037	0.793	rs12917411	ENSG00000260760.1	PWRN3	4.81	2.01e-06	0.00024	0.25	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24386786	chr15:24441127~24447967:+
THCA	cis	rs9625935	0.748	rs41177	ENSG00000279159.1	RP3-394A18.1	-4.81	2.01e-06	0.00024	-0.15	-0.22	Tonsillectomy;	chr22:30042458	chr22:29978950~30028236:-
THCA	cis	rs7942368	0.941	rs1465900	ENSG00000261578.1	RP11-21L23.2	4.81	2.01e-06	0.00024	0.31	0.22	Endometriosis;	chr11:76762094	chr11:76800364~76804555:+
THCA	cis	rs7942368	1	rs10160660	ENSG00000261578.1	RP11-21L23.2	4.81	2.01e-06	0.00024	0.31	0.22	Endometriosis;	chr11:76763493	chr11:76800364~76804555:+
THCA	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-4.81	2.01e-06	0.00024	-0.13	-0.22	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
THCA	cis	rs10888838	0.756	rs11206307	ENSG00000198711.5	SSBP3-AS1	4.81	2.01e-06	0.00024	0.26	0.22	Mitochondrial DNA levels;	chr1:54224289	chr1:54236440~54239063:+
THCA	cis	rs6441961	0.586	rs7612940	ENSG00000223552.1	RP11-24F11.2	-4.81	2.01e-06	0.00024	-0.21	-0.22	Celiac disease;	chr3:46307797	chr3:46364955~46407059:-
THCA	cis	rs7829975	0.572	rs7005000	ENSG00000253981.4	ALG1L13P	-4.81	2.01e-06	0.00024	-0.21	-0.22	Mood instability;	chr8:8939092	chr8:8236003~8244667:-
THCA	cis	rs7085104	0.7	rs3740397	ENSG00000213061.2	PFN1P11	4.81	2.01e-06	0.00024	0.26	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102838011~102845473:-
THCA	cis	rs6686842	0.689	rs2885697	ENSG00000235358.1	RP11-399E6.1	-4.81	2.01e-06	0.00024	-0.29	-0.22	Height;	chr1:41078607	chr1:41242373~41284861:+
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000176933.5	TOB2P1	-4.81	2.01e-06	0.00024	-0.24	-0.22	Pubertal anthropometrics;	chr6:28259100	chr6:28217643~28218634:-
THCA	cis	rs12908161	1	rs62019469	ENSG00000275120.1	RP11-182J1.17	4.81	2.01e-06	0.00024	0.26	0.22	Schizophrenia;	chr15:84777989	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs12908549	ENSG00000275120.1	RP11-182J1.17	4.81	2.01e-06	0.00024	0.26	0.22	Schizophrenia;	chr15:84779120	chr15:84599434~84606463:-
THCA	cis	rs3750965	0.959	rs11228490	ENSG00000260895.1	RP11-554A11.7	-4.81	2.01e-06	0.00024	-0.29	-0.22	Hair color;	chr11:69093404	chr11:69103493~69109094:+
THCA	cis	rs964611	0.882	rs12909148	ENSG00000259488.2	RP11-154J22.1	4.81	2.01e-06	0.00024	0.2	0.22	Metabolite levels (Pyroglutamine);	chr15:48356800	chr15:48312353~48331856:-
THCA	cis	rs2439831	0.867	rs2255051	ENSG00000205771.5	CATSPER2P1	-4.81	2.01e-06	0.00024	-0.29	-0.22	Lung cancer in ever smokers;	chr15:43553963	chr15:43726918~43747094:-
THCA	cis	rs143663961	1	rs143663961	ENSG00000266490.1	CTD-2349P21.9	4.81	2.01e-06	0.00024	0.23	0.22	Invasive epithelial ovarian cancer;	chr17:30854207	chr17:30792372~30792833:+
THCA	cis	rs7572644	0.662	rs13402420	ENSG00000223522.1	AC093690.1	4.81	2.02e-06	0.00024	0.25	0.22	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28048568	chr2:28307691~28310459:-
THCA	cis	rs11673344	0.598	rs826326	ENSG00000276846.1	CTD-3220F14.3	4.81	2.02e-06	0.00024	0.17	0.22	Obesity-related traits;	chr19:37003863	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.542	rs826328	ENSG00000276846.1	CTD-3220F14.3	4.81	2.02e-06	0.00024	0.17	0.22	Obesity-related traits;	chr19:37004479	chr19:37314868~37315620:-
THCA	cis	rs11089937	0.559	rs2330014	ENSG00000211639.2	IGLV4-60	4.81	2.02e-06	0.00024	0.15	0.22	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22162199~22162681:+
THCA	cis	rs13434995	0.513	rs62309729	ENSG00000273257.1	RP11-177J6.1	-4.81	2.02e-06	0.00024	-0.33	-0.22	Adiponectin levels;	chr4:55536679	chr4:55387949~55388271:+
THCA	cis	rs4767841	0.935	rs2285595	ENSG00000248636.5	RP11-768F21.1	4.81	2.02e-06	0.00024	0.23	0.22	Urgency urinary incontinence;	chr12:119718603	chr12:119387987~119668079:-
THCA	cis	rs7246657	0.653	rs4805208	ENSG00000226686.6	LINC01535	-4.81	2.02e-06	0.00024	-0.39	-0.22	Coronary artery calcification;	chr19:37183357	chr19:37251912~37265535:+
THCA	cis	rs11671005	0.735	rs3826684	ENSG00000268912.1	CTD-2619J13.17	-4.81	2.02e-06	0.000241	-0.21	-0.22	Mean platelet volume;	chr19:58407338	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs3826683	ENSG00000268912.1	CTD-2619J13.17	-4.81	2.02e-06	0.000241	-0.21	-0.22	Mean platelet volume;	chr19:58407366	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.735	rs3826681	ENSG00000268912.1	CTD-2619J13.17	-4.81	2.02e-06	0.000241	-0.21	-0.22	Mean platelet volume;	chr19:58407397	chr19:58428632~58431148:-
THCA	cis	rs6058796	1	rs13036962	ENSG00000175730.8	BAK1P1	4.81	2.02e-06	0.000241	0.34	0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr20:32651208	chr20:32690180~32690815:-
THCA	cis	rs2692947	0.8	rs4332959	ENSG00000232931.4	LINC00342	4.81	2.02e-06	0.000241	0.18	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95883373	chr2:95807118~95816215:-
THCA	cis	rs972578	0.74	rs738384	ENSG00000274717.1	RP1-47A17.1	-4.81	2.02e-06	0.000241	-0.23	-0.22	Mean platelet volume;	chr22:42923152	chr22:42791814~42794313:-
THCA	cis	rs453301	0.658	rs3855900	ENSG00000254153.1	CTA-398F10.2	4.81	2.02e-06	0.000241	0.23	0.22	Joint mobility (Beighton score);	chr8:9044411	chr8:8456909~8461337:-
THCA	cis	rs5758659	0.569	rs133293	ENSG00000227370.1	RP4-669P10.19	-4.81	2.02e-06	0.000241	-0.2	-0.22	Cognitive function;	chr22:41986793	chr22:42132543~42132998:+
THCA	cis	rs172166	0.611	rs203882	ENSG00000261839.1	RP1-265C24.8	4.81	2.02e-06	0.000241	0.23	0.22	Cardiac Troponin-T levels;	chr6:28110724	chr6:28136849~28139678:+
THCA	cis	rs172166	0.694	rs1770131	ENSG00000261839.1	RP1-265C24.8	4.81	2.02e-06	0.000241	0.23	0.22	Cardiac Troponin-T levels;	chr6:28118635	chr6:28136849~28139678:+
THCA	cis	rs6012564	0.749	rs8120015	ENSG00000227431.4	CSE1L-AS1	4.81	2.02e-06	0.000241	0.26	0.22	Anger;	chr20:49128772	chr20:49040463~49046044:-
THCA	cis	rs9863	0.828	rs75989601	ENSG00000269997.1	RP11-214K3.21	-4.81	2.02e-06	0.000241	-0.27	-0.22	White blood cell count;	chr12:123982176	chr12:123966077~123966629:-
THCA	cis	rs9863	0.828	rs35099862	ENSG00000269997.1	RP11-214K3.21	-4.81	2.02e-06	0.000241	-0.27	-0.22	White blood cell count;	chr12:123982657	chr12:123966077~123966629:-
THCA	cis	rs6012564	0.929	rs4810898	ENSG00000227431.4	CSE1L-AS1	-4.81	2.02e-06	0.000241	-0.26	-0.22	Anger;	chr20:48937855	chr20:49040463~49046044:-
THCA	cis	rs10256972	0.732	rs1574108	ENSG00000225146.1	AC073957.15	4.81	2.02e-06	0.000241	0.23	0.22	Endometriosis;Longevity;	chr7:1066169	chr7:1029025~1043891:+
THCA	cis	rs7572644	0.603	rs7580274	ENSG00000223522.1	AC093690.1	4.81	2.02e-06	0.000241	0.25	0.22	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28043202	chr2:28307691~28310459:-
THCA	cis	rs1823874	0.584	rs9806196	ENSG00000182397.13	DNM1P46	-4.81	2.02e-06	0.000241	-0.24	-0.22	IgG glycosylation;	chr15:99842201	chr15:99790156~99806927:-
THCA	cis	rs922182	0.633	rs12904468	ENSG00000275785.1	RP11-111E14.2	-4.81	2.02e-06	0.000241	-0.24	-0.22	Blood protein levels;	chr15:63976691	chr15:63890030~63890317:+
THCA	cis	rs79349575	0.783	rs62078370	ENSG00000270781.1	RP11-501C14.9	-4.81	2.02e-06	0.000241	-0.26	-0.22	Type 2 diabetes;	chr17:48949474	chr17:48899131~48899748:+
THCA	cis	rs7635879	0.693	rs4687496	ENSG00000230102.6	RP11-407B7.1	4.81	2.03e-06	0.000241	0.17	0.22	Breastfeeding duration;	chr3:194011436	chr3:194005259~194070970:-
THCA	cis	rs7829975	0.606	rs6422352	ENSG00000253981.4	ALG1L13P	-4.81	2.03e-06	0.000241	-0.21	-0.22	Mood instability;	chr8:8936683	chr8:8236003~8244667:-
THCA	cis	rs7829975	0.606	rs891570	ENSG00000253981.4	ALG1L13P	-4.81	2.03e-06	0.000241	-0.21	-0.22	Mood instability;	chr8:8936944	chr8:8236003~8244667:-
THCA	cis	rs2243480	0.803	rs160649	ENSG00000232559.3	GS1-124K5.12	4.81	2.03e-06	0.000241	0.32	0.22	Diabetic kidney disease;	chr7:66078212	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs160648	ENSG00000232559.3	GS1-124K5.12	4.81	2.03e-06	0.000241	0.32	0.22	Diabetic kidney disease;	chr7:66078397	chr7:66554588~66576923:-
THCA	cis	rs6487679	0.526	rs7972426	ENSG00000111788.10	RP11-22B23.1	4.81	2.03e-06	0.000242	0.22	0.22	Non-alcoholic fatty liver disease histology (AST);	chr12:9228658	chr12:9277235~9313241:+
THCA	cis	rs7580717	0.785	rs10169399	ENSG00000224376.1	AC017104.6	4.81	2.03e-06	0.000242	0.24	0.22	Multiple myeloma;	chr2:231308398	chr2:231388976~231394991:+
THCA	cis	rs8028313	0.63	rs16951105	ENSG00000270964.1	RP11-502I4.3	-4.81	2.03e-06	0.000242	-0.19	-0.22	Obesity;	chr15:67673356	chr15:67541072~67542604:-
THCA	cis	rs10760706	0.537	rs12552646	ENSG00000234709.2	UPF3AP3	-4.81	2.03e-06	0.000242	-0.26	-0.22	Alopecia areata;	chr9:100106193	chr9:99998301~99999069:-
THCA	cis	rs6792584	0.637	rs9824745	ENSG00000241316.5	SUCLG2-AS1	-4.81	2.03e-06	0.000242	-0.23	-0.22	Corneal astigmatism;	chr3:67409068	chr3:67654697~67947713:+
THCA	cis	rs1552244	0.816	rs9847657	ENSG00000180385.7	EMC3-AS1	4.81	2.03e-06	0.000242	0.23	0.22	Alzheimer's disease;	chr3:10131808	chr3:9986893~10006990:+
THCA	cis	rs9487094	0.696	rs11153188	ENSG00000223537.2	RP5-919F19.5	-4.81	2.03e-06	0.000242	-0.22	-0.22	Height;	chr6:109558247	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs11752791	ENSG00000223537.2	RP5-919F19.5	-4.81	2.03e-06	0.000242	-0.22	-0.22	Height;	chr6:109564443	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs4490694	ENSG00000223537.2	RP5-919F19.5	-4.81	2.03e-06	0.000242	-0.22	-0.22	Height;	chr6:109571489	chr6:109487906~109506800:+
THCA	cis	rs1334894	0.901	rs72911380	ENSG00000228559.1	RP3-340B19.3	-4.81	2.03e-06	0.000242	-0.44	-0.22	Coronary artery disease;	chr6:35551706	chr6:35544632~35545669:+
THCA	cis	rs9625935	0.912	rs9620926	ENSG00000279159.1	RP3-394A18.1	-4.81	2.03e-06	0.000242	-0.17	-0.22	Tonsillectomy;	chr22:29879102	chr22:29978950~30028236:-
THCA	cis	rs11700536	1	rs2839636	ENSG00000236663.1	AP001631.9	4.81	2.03e-06	0.000242	0.29	0.22	Interleukin-18 levels;	chr21:43139085	chr21:43140523~43141092:-
THCA	cis	rs9880211	1	rs17200216	ENSG00000239213.4	NCK1-AS1	4.81	2.03e-06	0.000242	0.23	0.22	Height;Body mass index;	chr3:136348390	chr3:136841726~136862054:-
THCA	cis	rs9878978	0.964	rs17786885	ENSG00000237990.3	CNTN4-AS1	4.81	2.03e-06	0.000242	0.23	0.22	Blood pressure (smoking interaction);	chr3:2446983	chr3:3039033~3069242:-
THCA	cis	rs786425	0.77	rs7306549	ENSG00000270095.1	RP11-214K3.18	-4.81	2.03e-06	0.000242	-0.25	-0.22	Pubertal anthropometrics;	chr12:123672350	chr12:123971457~123971714:-
THCA	cis	rs7131987	0.903	rs1035604	ENSG00000275476.1	RP11-996F15.4	-4.81	2.03e-06	0.000242	-0.22	-0.22	QT interval;	chr12:29240169	chr12:29277397~29277882:-
THCA	cis	rs17801127	0.686	rs11693936	ENSG00000231969.1	AC144449.1	-4.81	2.03e-06	0.000242	-0.33	-0.22	Liver enzyme levels (alanine transaminase);	chr2:149698908	chr2:149587196~149848233:+
THCA	cis	rs752010	0.749	rs10749841	ENSG00000230638.4	RP11-486B10.4	-4.81	2.03e-06	0.000242	-0.24	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41646383	chr1:41542069~41544310:+
THCA	cis	rs1552244	0.554	rs6796411	ENSG00000180385.7	EMC3-AS1	4.81	2.04e-06	0.000242	0.21	0.22	Alzheimer's disease;	chr3:9968997	chr3:9986893~10006990:+
THCA	cis	rs5758659	0.714	rs2413668	ENSG00000182057.4	OGFRP1	-4.81	2.04e-06	0.000242	-0.25	-0.22	Cognitive function;	chr22:42109837	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.657	rs5758587	ENSG00000182057.4	OGFRP1	-4.81	2.04e-06	0.000242	-0.25	-0.22	Cognitive function;	chr22:42121632	chr22:42269753~42275196:+
THCA	cis	rs4443100	0.917	rs5996460	ENSG00000230701.2	FBXW4P1	4.81	2.04e-06	0.000242	0.27	0.22	Serum parathyroid hormone levels;	chr22:23050912	chr22:23262767~23265005:+
THCA	cis	rs8067545	0.604	rs55705283	ENSG00000270091.1	RP11-78O7.2	-4.81	2.04e-06	0.000242	-0.17	-0.22	Schizophrenia;	chr17:20123825	chr17:19896590~19897287:-
THCA	cis	rs4886920	0.672	rs4886926	ENSG00000260776.4	RP11-114H24.2	4.81	2.04e-06	0.000243	0.26	0.22	Neuroticism;	chr15:77829770	chr15:77914217~77926846:-
THCA	cis	rs62025270	0.632	rs62022918	ENSG00000259295.5	CSPG4P12	-4.81	2.04e-06	0.000243	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85191438~85213905:+
THCA	cis	rs62025270	0.632	rs111906684	ENSG00000259295.5	CSPG4P12	-4.81	2.04e-06	0.000243	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85191438~85213905:+
THCA	cis	rs453301	0.598	rs2921383	ENSG00000254153.1	CTA-398F10.2	-4.81	2.04e-06	0.000243	-0.22	-0.22	Joint mobility (Beighton score);	chr8:9034711	chr8:8456909~8461337:-
THCA	cis	rs1005277	0.579	rs1740737	ENSG00000275858.1	RP11-291L22.8	4.81	2.04e-06	0.000243	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38450738~38451069:-
THCA	cis	rs9487094	0.67	rs12214639	ENSG00000223537.2	RP5-919F19.5	-4.81	2.04e-06	0.000243	-0.22	-0.22	Height;	chr6:109576414	chr6:109487906~109506800:+
THCA	cis	rs7181230	0.885	rs28736699	ENSG00000275636.1	RP11-521C20.5	4.81	2.04e-06	0.000243	0.23	0.22	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40078892~40079347:+
THCA	cis	rs4578769	0.569	rs12966840	ENSG00000265939.1	UBE2CP2	-4.81	2.04e-06	0.000243	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22856911	chr18:22900486~22900995:-
THCA	cis	rs4915077	1	rs59093593	ENSG00000230489.1	VAV3-AS1	4.81	2.04e-06	0.000243	0.38	0.22	Hypothyroidism;	chr1:107806835	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs17020085	ENSG00000230489.1	VAV3-AS1	4.81	2.04e-06	0.000243	0.38	0.22	Hypothyroidism;	chr1:107809007	chr1:107964443~107994607:+
THCA	cis	rs7647973	0.58	rs4955432	ENSG00000229759.1	MRPS18AP1	4.81	2.04e-06	0.000243	0.28	0.22	Menarche (age at onset);	chr3:49229339	chr3:48256350~48256938:-
THCA	cis	rs6563199	0.522	rs7335775	ENSG00000214182.5	PTMAP5	4.81	2.04e-06	0.000243	0.19	0.22	Height;	chr13:80796054	chr13:81689911~81691072:+
THCA	cis	rs736408	0.609	rs1029871	ENSG00000243224.1	RP5-1157M23.2	-4.81	2.04e-06	0.000243	-0.24	-0.22	Bipolar disorder;	chr3:52763618	chr3:52239258~52241097:+
THCA	cis	rs270601	0.909	rs2569265	ENSG00000237714.1	P4HA2-AS1	-4.81	2.04e-06	0.000243	-0.29	-0.22	Acylcarnitine levels;	chr5:132368827	chr5:132184876~132192808:+
THCA	cis	rs8141529	0.748	rs6519766	ENSG00000226471.5	CTA-292E10.6	4.81	2.04e-06	0.000243	0.18	0.22	Lymphocyte counts;	chr22:28874003	chr22:28800683~28848559:+
THCA	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-4.81	2.04e-06	0.000243	-0.26	-0.22	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
THCA	cis	rs11722779	0.844	rs223345	ENSG00000248971.2	KRT8P46	-4.81	2.04e-06	0.000243	-0.26	-0.22	Schizophrenia;	chr4:102859366	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.873	rs223344	ENSG00000248971.2	KRT8P46	-4.81	2.04e-06	0.000243	-0.26	-0.22	Schizophrenia;	chr4:102859765	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.775	rs223341	ENSG00000248971.2	KRT8P46	-4.81	2.04e-06	0.000243	-0.26	-0.22	Schizophrenia;	chr4:102862343	chr4:102728746~102730171:-
THCA	cis	rs8046148	0.671	rs2160571	ENSG00000279356.1	RP11-429P3.8	4.81	2.04e-06	0.000243	0.25	0.22	Testicular germ cell tumor;	chr16:50080644	chr16:50072862~50074986:+
THCA	cis	rs17767392	0.813	rs8003478	ENSG00000259146.3	RP1-261D10.2	-4.81	2.04e-06	0.000243	-0.28	-0.22	Mitral valve prolapse;	chr14:71653646	chr14:71292729~71321814:-
THCA	cis	rs6088580	0.561	rs3761147	ENSG00000276073.1	RP5-1125A11.7	4.81	2.04e-06	0.000243	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34408883	chr20:33985617~33988989:-
THCA	cis	rs9549367	0.789	rs9549699	ENSG00000269125.1	RP11-98F14.11	-4.81	2.04e-06	0.000243	-0.25	-0.22	Platelet distribution width;	chr13:113223949	chr13:113165002~113165183:-
THCA	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-4.81	2.04e-06	0.000243	-0.29	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
THCA	cis	rs919433	0.713	rs55642934	ENSG00000231621.1	AC013264.2	-4.81	2.04e-06	0.000243	-0.23	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197626386	chr2:197197991~197199273:+
THCA	cis	rs7702057	0.53	rs17138848	ENSG00000272265.1	CTD-2287O16.4	4.81	2.05e-06	0.000244	0.38	0.22	Amyotrophic lateral sclerosis;	chr5:116083606	chr5:116078110~116078570:-
THCA	cis	rs3213758	0.588	rs10521294	ENSG00000275191.1	RP11-36I17.2	4.81	2.05e-06	0.000244	0.36	0.22	Vitiligo (non-segmental);	chr16:53528683	chr16:53628256~53628816:-
THCA	cis	rs7208859	0.623	rs3752019	ENSG00000280069.1	CTD-2349P21.3	-4.81	2.05e-06	0.000244	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs56146117	ENSG00000280069.1	CTD-2349P21.3	-4.81	2.05e-06	0.000244	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30738182~30740275:+
THCA	cis	rs72615157	0.634	rs74774557	ENSG00000242294.5	STAG3L5P	4.81	2.05e-06	0.000244	0.13	0.22	Lung function (FEV1/FVC);	chr7:100212802	chr7:100336079~100351900:+
THCA	cis	rs11853189	1	rs2867933	ENSG00000259562.2	RP11-762H8.2	-4.81	2.05e-06	0.000244	-0.2	-0.22	Red cell distribution width;	chr15:78282445	chr15:78290527~78291221:-
THCA	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	4.81	2.05e-06	0.000244	0.27	0.22	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
THCA	cis	rs6547741	0.844	rs9678851	ENSG00000234072.1	AC074117.10	-4.81	2.05e-06	0.000244	-0.17	-0.22	Oral cavity cancer;	chr2:27664167	chr2:27356246~27367622:+
THCA	cis	rs11634944	0.676	rs220027	ENSG00000257151.1	PWAR6	4.81	2.05e-06	0.000244	0.16	0.22	Interleukin-8 levels;	chr15:24951813	chr15:25031873~25036490:+
THCA	cis	rs1003719	0.715	rs2835639	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37164714	chr21:37208503~37221736:+
THCA	cis	rs6772849	0.93	rs68090762	ENSG00000242551.2	POU5F1P6	-4.81	2.05e-06	0.000244	-0.28	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128625064	chr3:128674735~128677005:-
THCA	cis	rs1003719	0.586	rs2298685	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37161088	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.679	rs2835638	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37162231	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.613	rs9978998	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37163546	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2835640	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37165078	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2835642	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37166764	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2156077	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37167055	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs1981433	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37169921	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2835644	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37173308	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2156078	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37174171	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2835646	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37174272	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2835647	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37174471	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.645	rs8131944	ENSG00000230366.8	DSCR9	4.81	2.05e-06	0.000244	0.22	0.22	Eye color traits;	chr21:37174913	chr21:37208503~37221736:+
THCA	cis	rs467650	0.553	rs469946	ENSG00000248489.1	CTD-2007H13.3	4.81	2.05e-06	0.000244	0.24	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98653345	chr5:98929171~98995013:+
THCA	cis	rs7208859	0.673	rs11652370	ENSG00000280069.1	CTD-2349P21.3	-4.81	2.05e-06	0.000244	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30738182~30740275:+
THCA	cis	rs2664588	1	rs2664588	ENSG00000276923.1	RP11-321P16.1	-4.81	2.05e-06	0.000244	-0.28	-0.22	Cerebrospinal fluid AB1-42 levels;	chr20:47951890	chr20:48073869~48074188:+
THCA	cis	rs270601	0.739	rs3900945	ENSG00000224431.1	AC063976.7	4.81	2.05e-06	0.000244	0.19	0.22	Acylcarnitine levels;	chr5:132257177	chr5:132199456~132203487:+
THCA	cis	rs2243480	1	rs431318	ENSG00000232559.3	GS1-124K5.12	4.81	2.05e-06	0.000244	0.32	0.22	Diabetic kidney disease;	chr7:66046610	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs313803	ENSG00000232559.3	GS1-124K5.12	4.81	2.05e-06	0.000244	0.32	0.22	Diabetic kidney disease;	chr7:66049744	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs313802	ENSG00000232559.3	GS1-124K5.12	4.81	2.05e-06	0.000244	0.32	0.22	Diabetic kidney disease;	chr7:66051386	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.803	rs403089	ENSG00000232559.3	GS1-124K5.12	4.81	2.05e-06	0.000244	0.32	0.22	Diabetic kidney disease;	chr7:66052736	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs458291	ENSG00000232559.3	GS1-124K5.12	4.81	2.05e-06	0.000244	0.32	0.22	Diabetic kidney disease;	chr7:66055492	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs464895	ENSG00000232559.3	GS1-124K5.12	4.81	2.05e-06	0.000244	0.32	0.22	Diabetic kidney disease;	chr7:66062119	chr7:66554588~66576923:-
THCA	cis	rs13113518	1	rs2279458	ENSG00000273257.1	RP11-177J6.1	4.81	2.05e-06	0.000244	0.28	0.22	Height;	chr4:55562653	chr4:55387949~55388271:+
THCA	cis	rs2839186	0.681	rs13047198	ENSG00000239415.1	AP001469.9	4.81	2.05e-06	0.000244	0.23	0.22	Testicular germ cell tumor;	chr21:46281921	chr21:46251549~46254133:-
THCA	cis	rs860295	0.702	rs34620961	ENSG00000160766.13	GBAP1	-4.81	2.05e-06	0.000244	-0.26	-0.22	Body mass index;	chr1:155680036	chr1:155213821~155227422:-
THCA	cis	rs4076555	0.517	rs10839784	ENSG00000251364.5	CTD-2516F10.2	-4.81	2.05e-06	0.000244	-0.26	-0.22	IgG glycosylation;	chr11:7446097	chr11:7427266~7512515:-
THCA	cis	rs13113518	1	rs13122619	ENSG00000273257.1	RP11-177J6.1	4.81	2.05e-06	0.000244	0.28	0.22	Height;	chr4:55479339	chr4:55387949~55388271:+
THCA	cis	rs4415084	0.745	rs12188871	ENSG00000272335.1	RP11-53O19.3	-4.81	2.05e-06	0.000244	-0.18	-0.22	Breast cancer;	chr5:44813902	chr5:44826076~44828592:+
THCA	cis	rs11992162	0.967	rs10108320	ENSG00000206014.6	OR7E161P	4.81	2.05e-06	0.000244	0.25	0.22	Monocyte count;	chr8:11974754	chr8:11928597~11929563:-
THCA	cis	rs2742234	0.59	rs2742237	ENSG00000273008.1	RP11-351D16.3	-4.81	2.06e-06	0.000245	-0.21	-0.22	Hirschsprung disease;	chr10:43125875	chr10:43136824~43138334:-
THCA	cis	rs1501911	0.611	rs7712408	ENSG00000248489.1	CTD-2007H13.3	-4.81	2.06e-06	0.000245	-0.23	-0.22	Lung function (FEV1/FVC);	chr5:99020633	chr5:98929171~98995013:+
THCA	cis	rs2251381	0.75	rs2251186	ENSG00000176054.6	RPL23P2	4.81	2.06e-06	0.000245	0.19	0.22	Selective IgA deficiency;	chr21:29156559	chr21:28997613~28998033:-
THCA	cis	rs6964833	0.935	rs34630792	ENSG00000278416.1	PMS2L2	4.81	2.06e-06	0.000245	0.34	0.22	Menarche (age at onset);	chr7:74646869	chr7:75344015~75359550:-
THCA	cis	rs6441961	0.501	rs36118141	ENSG00000223552.1	RP11-24F11.2	4.81	2.06e-06	0.000245	0.23	0.22	Celiac disease;	chr3:46247306	chr3:46364955~46407059:-
THCA	cis	rs13096142	0.574	rs13094085	ENSG00000223552.1	RP11-24F11.2	4.81	2.06e-06	0.000245	0.23	0.22	Celiac disease;	chr3:46252377	chr3:46364955~46407059:-
THCA	cis	rs7598759	0.548	rs11693738	ENSG00000223198.1	RNU2-22P	-4.81	2.06e-06	0.000245	-0.28	-0.22	Noise-induced hearing loss;	chr2:231495773	chr2:231501990~231502201:-
THCA	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	4.81	2.06e-06	0.000245	0.24	0.22	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
THCA	cis	rs10510102	0.872	rs11200269	ENSG00000226864.1	ATE1-AS1	4.81	2.06e-06	0.000245	0.35	0.22	Breast cancer;	chr10:121934021	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs11498944	ENSG00000226864.1	ATE1-AS1	4.81	2.06e-06	0.000245	0.35	0.22	Breast cancer;	chr10:121938748	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.81	rs12267347	ENSG00000226864.1	ATE1-AS1	4.81	2.06e-06	0.000245	0.35	0.22	Breast cancer;	chr10:121939110	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.808	rs12253007	ENSG00000226864.1	ATE1-AS1	4.81	2.06e-06	0.000245	0.35	0.22	Breast cancer;	chr10:121939360	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs79865971	ENSG00000226864.1	ATE1-AS1	4.81	2.06e-06	0.000245	0.35	0.22	Breast cancer;	chr10:121941208	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs74318512	ENSG00000226864.1	ATE1-AS1	4.81	2.06e-06	0.000245	0.35	0.22	Breast cancer;	chr10:121941465	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12257207	ENSG00000226864.1	ATE1-AS1	4.81	2.06e-06	0.000245	0.35	0.22	Breast cancer;	chr10:121941737	chr10:121928312~121951965:+
THCA	cis	rs12188164	0.515	rs11742006	ENSG00000225138.6	CTD-2228K2.7	4.81	2.06e-06	0.000245	0.23	0.22	Cystic fibrosis severity;	chr5:408414	chr5:473236~480884:+
THCA	cis	rs4950322	0.542	rs17159914	ENSG00000226015.2	CCT8P1	-4.81	2.06e-06	0.000245	-0.23	-0.22	Protein quantitative trait loci;	chr1:147183226	chr1:147203276~147204932:-
THCA	cis	rs6088580	0.634	rs11700221	ENSG00000276073.1	RP5-1125A11.7	4.81	2.06e-06	0.000245	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34352514	chr20:33985617~33988989:-
THCA	cis	rs17507216	1	rs3850610	ENSG00000255769.6	GOLGA2P10	4.81	2.06e-06	0.000245	0.3	0.22	Excessive daytime sleepiness;	chr15:82552642	chr15:82472993~82513950:-
THCA	cis	rs10923574	0.597	rs1146311	ENSG00000231365.4	RP11-418J17.1	4.81	2.06e-06	0.000245	0.22	0.22	Breast cancer;Folding of antihelix;	chr1:118484892	chr1:119140396~119275973:+
THCA	cis	rs12612619	0.732	rs1440044	ENSG00000229122.1	AGBL5-IT1	4.81	2.06e-06	0.000245	0.15	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004086	chr2:27061038~27061815:+
THCA	cis	rs12908161	1	rs12903134	ENSG00000275120.1	RP11-182J1.17	4.81	2.06e-06	0.000245	0.26	0.22	Schizophrenia;	chr15:84794468	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs35726233	ENSG00000275120.1	RP11-182J1.17	4.81	2.06e-06	0.000245	0.26	0.22	Schizophrenia;	chr15:84794569	chr15:84599434~84606463:-
THCA	cis	rs2120243	1	rs2120243	ENSG00000244515.1	KRT18P34	-4.81	2.06e-06	0.000245	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157429779	chr3:157162663~157163932:-
THCA	cis	rs2915864	0.512	rs252153	ENSG00000280047.1	CTC-463A16.1	-4.81	2.06e-06	0.000245	-0.3	-0.22	Facial morphology (factor 20);	chr5:142067295	chr5:142165767~142168387:+
THCA	cis	rs7618915	0.547	rs1561337	ENSG00000243224.1	RP5-1157M23.2	-4.81	2.06e-06	0.000245	-0.24	-0.22	Bipolar disorder;	chr3:52625947	chr3:52239258~52241097:+
THCA	cis	rs7647973	0.6	rs11920267	ENSG00000229759.1	MRPS18AP1	4.81	2.06e-06	0.000245	0.28	0.22	Menarche (age at onset);	chr3:49238531	chr3:48256350~48256938:-
THCA	cis	rs1275468	0.689	rs1795382	ENSG00000257497.2	RP11-585P4.5	-4.81	2.06e-06	0.000245	-0.34	-0.22	Polycystic ovary syndrome;	chr12:75586113	chr12:75483454~75489820:-
THCA	cis	rs911555	0.723	rs12894652	ENSG00000244691.1	RPL10AP1	4.81	2.06e-06	0.000245	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103412119~103412761:-
THCA	cis	rs9890032	0.581	rs62070592	ENSG00000264538.5	SUZ12P1	-4.81	2.06e-06	0.000245	-0.16	-0.22	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30709299~30790908:+
THCA	cis	rs8028182	0.636	rs8034317	ENSG00000260274.1	RP11-817O13.8	4.81	2.06e-06	0.000245	0.16	0.22	Sudden cardiac arrest;	chr15:75472002	chr15:75368155~75369584:+
THCA	cis	rs7005380	0.733	rs6469878	ENSG00000245330.4	KB-1471A8.1	-4.81	2.06e-06	0.000245	-0.21	-0.22	Interstitial lung disease;	chr8:119926208	chr8:119867419~119874488:-
THCA	cis	rs10916248	0.569	rs4654002	ENSG00000232628.4	RP11-365O16.3	4.81	2.06e-06	0.000245	0.24	0.22	QT interval (drug interaction);	chr1:224075680	chr1:224208747~224213279:-
THCA	cis	rs6472827	0.645	rs2977067	ENSG00000253983.2	RP1-16A9.1	4.81	2.06e-06	0.000246	0.31	0.22	Uterine fibroids;	chr8:74190596	chr8:74199396~74208441:+
THCA	cis	rs11157436	0.958	rs764160	ENSG00000211812.1	TRAV26-2	-4.81	2.06e-06	0.000246	-0.2	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22202583~22203368:+
THCA	cis	rs4654783	0.505	rs4655025	ENSG00000228397.1	RP1-224A6.3	4.81	2.06e-06	0.000246	0.31	0.22	Endometriosis;	chr1:22133261	chr1:22023994~22024968:-
THCA	cis	rs4713118	0.868	rs35069907	ENSG00000226314.6	ZNF192P1	-4.81	2.06e-06	0.000246	-0.29	-0.22	Parkinson's disease;	chr6:27778913	chr6:28161781~28169594:+
THCA	cis	rs8020912	0.504	rs3759577	ENSG00000244691.1	RPL10AP1	4.81	2.07e-06	0.000246	0.31	0.22	Granulocyte percentage of myeloid white cells;	chr14:103384626	chr14:103412119~103412761:-
THCA	cis	rs397969	0.502	rs62066352	ENSG00000261033.1	RP11-209D14.2	-4.81	2.07e-06	0.000246	-0.31	-0.22	Platelet count;	chr17:19998689	chr17:20008051~20009234:-
THCA	cis	rs7615952	0.688	rs7624806	ENSG00000248787.1	RP11-666A20.4	-4.81	2.07e-06	0.000246	-0.37	-0.22	Blood pressure (smoking interaction);	chr3:125880231	chr3:125908005~125910272:-
THCA	cis	rs10946940	0.965	rs6915266	ENSG00000219392.1	RP1-265C24.5	4.81	2.07e-06	0.000246	0.25	0.22	Systemic lupus erythematosus;	chr6:27560864	chr6:28115628~28116551:+
THCA	cis	rs5742933	1	rs5743032	ENSG00000273240.1	RP11-455J20.3	-4.81	2.07e-06	0.000246	-0.24	-0.22	Ferritin levels;	chr2:189814077	chr2:189763859~189764456:-
THCA	cis	rs7474896	1	rs12782327	ENSG00000263064.2	RP11-291L22.7	4.81	2.07e-06	0.000246	0.36	0.22	Obesity (extreme);	chr10:37803515	chr10:38448689~38448949:+
THCA	cis	rs2058059	0.636	rs3015935	ENSG00000205578.5	POM121B	-4.81	2.07e-06	0.000246	-0.33	-0.22	Subcutaneous adipose tissue;	chr7:72697290	chr7:73293497~73301161:+
THCA	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	4.81	2.07e-06	0.000246	0.25	0.22	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
THCA	cis	rs1005277	0.565	rs2474565	ENSG00000275858.1	RP11-291L22.8	4.81	2.07e-06	0.000246	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38450738~38451069:-
THCA	cis	rs2239547	0.618	rs3733047	ENSG00000242142.1	SERBP1P3	-4.81	2.07e-06	0.000246	-0.28	-0.22	Schizophrenia;	chr3:52837913	chr3:53064283~53065091:-
THCA	cis	rs7209700	0.547	rs7217214	ENSG00000228782.6	CTD-2026D20.3	-4.81	2.07e-06	0.000246	-0.26	-0.22	IgG glycosylation;	chr17:47277861	chr17:47450568~47492492:-
THCA	cis	rs6840258	0.831	rs3775226	ENSG00000251411.1	RP11-397E7.4	-4.81	2.07e-06	0.000246	-0.26	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87068313	chr4:86913266~86914817:-
THCA	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-4.81	2.07e-06	0.000246	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
THCA	cis	rs10895275	0.886	rs11605954	ENSG00000277459.1	RP11-732A21.3	4.81	2.07e-06	0.000246	0.17	0.22	Migraine;	chr11:102178490	chr11:102109827~102110457:-
THCA	cis	rs1334894	0.901	rs56353810	ENSG00000228559.1	RP3-340B19.3	-4.81	2.07e-06	0.000246	-0.44	-0.22	Coronary artery disease;	chr6:35553309	chr6:35544632~35545669:+
THCA	cis	rs1334894	0.901	rs56062505	ENSG00000228559.1	RP3-340B19.3	-4.81	2.07e-06	0.000246	-0.44	-0.22	Coronary artery disease;	chr6:35553405	chr6:35544632~35545669:+
THCA	cis	rs6745190	0.626	rs7562697	ENSG00000236153.1	AC104076.3	4.81	2.07e-06	0.000246	0.24	0.22	White blood cell count;	chr2:181054169	chr2:180979427~180980090:-
THCA	cis	rs3892630	0.824	rs34425841	ENSG00000267567.1	CTD-2538C1.3	4.81	2.07e-06	0.000246	0.35	0.22	Red blood cell traits;	chr19:32740713	chr19:32718298~32719595:-
THCA	cis	rs8059260	0.541	rs34361212	ENSG00000274038.1	RP11-66H6.4	-4.81	2.07e-06	0.000246	-0.41	-0.22	Alcohol consumption over the past year;	chr16:11145832	chr16:11056556~11057034:+
THCA	cis	rs1185460	1	rs1614264	ENSG00000272186.1	RP11-110I1.13	-4.81	2.07e-06	0.000246	-0.2	-0.22	Coronary artery disease;	chr11:119071928	chr11:119067374~119067698:-
THCA	cis	rs6479901	0.723	rs7088045	ENSG00000232075.1	MRPL35P2	-4.81	2.07e-06	0.000247	-0.3	-0.22	Intelligence (multi-trait analysis);	chr10:63319637	chr10:63634317~63634827:-
THCA	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	4.81	2.07e-06	0.000247	0.24	0.22	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
THCA	cis	rs10090774	0.87	rs10109378	ENSG00000279766.1	RP11-642A1.2	-4.81	2.07e-06	0.000247	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994574	chr8:140572142~140572812:-
THCA	cis	rs4650994	0.593	rs12735140	ENSG00000273384.1	RP5-1098D14.1	-4.81	2.07e-06	0.000247	-0.28	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178575083	chr1:178651706~178652282:+
THCA	cis	rs11157436	0.958	rs764161	ENSG00000211812.1	TRAV26-2	-4.81	2.07e-06	0.000247	-0.2	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22202583~22203368:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000228409.4	CCT6P1	-4.81	2.07e-06	0.000247	-0.18	-0.22	Aortic root size;	chr7:66622723	chr7:65751142~65763354:+
THCA	cis	rs950880	0.71	rs67723747	ENSG00000234389.1	AC007278.3	-4.81	2.08e-06	0.000247	-0.27	-0.22	Serum protein levels (sST2);	chr2:102353347	chr2:102438713~102440475:+
THCA	cis	rs950880	0.71	rs56386507	ENSG00000234389.1	AC007278.3	-4.81	2.08e-06	0.000247	-0.27	-0.22	Serum protein levels (sST2);	chr2:102354705	chr2:102438713~102440475:+
THCA	cis	rs240993	0.669	rs6935759	ENSG00000271789.1	RP5-1112D6.7	-4.81	2.08e-06	0.000247	-0.26	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111457517	chr6:111297126~111298510:+
THCA	cis	rs12755164	0.778	rs11210075	ENSG00000223479.3	RP4-788P17.1	4.81	2.08e-06	0.000247	0.24	0.22	Schizophrenia;	chr1:72856241	chr1:73635216~73715214:+
THCA	cis	rs2243480	1	rs316307	ENSG00000164669.11	INTS4P1	4.81	2.08e-06	0.000247	0.41	0.22	Diabetic kidney disease;	chr7:66105184	chr7:65141225~65234216:+
THCA	cis	rs6088580	0.634	rs6059875	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.08e-06	0.000247	-0.18	-0.22	Glomerular filtration rate (creatinine);	chr20:34498285	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6088512	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.08e-06	0.000247	-0.18	-0.22	Glomerular filtration rate (creatinine);	chr20:34508086	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6058070	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.08e-06	0.000247	-0.18	-0.22	Glomerular filtration rate (creatinine);	chr20:34515716	chr20:33985617~33988989:-
THCA	cis	rs8024893	1	rs8024893	ENSG00000270055.1	CTD-3092A11.2	4.81	2.08e-06	0.000247	0.28	0.22	Red cell distribution width;	chr15:31248786	chr15:30487963~30490313:+
THCA	cis	rs2742234	0.541	rs10899779	ENSG00000273008.1	RP11-351D16.3	4.81	2.08e-06	0.000247	0.2	0.22	Hirschsprung disease;	chr10:43228528	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.504	rs10899780	ENSG00000273008.1	RP11-351D16.3	4.81	2.08e-06	0.000247	0.2	0.22	Hirschsprung disease;	chr10:43230348	chr10:43136824~43138334:-
THCA	cis	rs1185460	0.904	rs1003081	ENSG00000272186.1	RP11-110I1.13	4.81	2.08e-06	0.000247	0.2	0.22	Coronary artery disease;	chr11:119043282	chr11:119067374~119067698:-
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000265443.1	CTD-2349P21.6	-4.81	2.08e-06	0.000247	-0.38	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30726305~30727564:-
THCA	cis	rs944289	0.708	rs6571736	ENSG00000258844.1	RP11-259K15.2	4.81	2.08e-06	0.000247	0.2	0.22	Thyroid cancer;	chr14:36111271	chr14:36214607~36235608:+
THCA	cis	rs944289	0.679	rs8016148	ENSG00000258844.1	RP11-259K15.2	4.81	2.08e-06	0.000247	0.2	0.22	Thyroid cancer;	chr14:36111688	chr14:36214607~36235608:+
THCA	cis	rs944289	0.708	rs2415315	ENSG00000258844.1	RP11-259K15.2	4.81	2.08e-06	0.000247	0.2	0.22	Thyroid cancer;	chr14:36115338	chr14:36214607~36235608:+
THCA	cis	rs944289	0.708	rs1475716	ENSG00000258844.1	RP11-259K15.2	4.81	2.08e-06	0.000247	0.2	0.22	Thyroid cancer;	chr14:36116033	chr14:36214607~36235608:+
THCA	cis	rs8062405	0.755	rs17640009	ENSG00000261766.1	RP11-22P6.2	-4.81	2.08e-06	0.000247	-0.22	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28862166~28863340:-
THCA	cis	rs17123764	0.605	rs73305098	ENSG00000257464.1	RP11-161H23.8	-4.81	2.08e-06	0.000247	-0.35	-0.22	Intelligence (multi-trait analysis);	chr12:49679214	chr12:49442424~49442652:-
THCA	cis	rs8067545	0.532	rs12449914	ENSG00000261033.1	RP11-209D14.2	-4.81	2.08e-06	0.000247	-0.31	-0.22	Schizophrenia;	chr17:20100656	chr17:20008051~20009234:-
THCA	cis	rs4578769	0.513	rs2034933	ENSG00000265939.1	UBE2CP2	4.81	2.08e-06	0.000247	0.24	0.22	Eosinophil percentage of white cells;	chr18:22918788	chr18:22900486~22900995:-
THCA	cis	rs7267979	0.933	rs11699203	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.933	rs6138571	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs416745	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs448396	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs447722	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs422424	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs422844	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs401166	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs404394	ENSG00000274973.1	RP13-401N8.7	-4.81	2.08e-06	0.000247	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25845497~25845862:+
THCA	cis	rs911555	0.723	rs4906324	ENSG00000244691.1	RPL10AP1	4.81	2.08e-06	0.000247	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103412119~103412761:-
THCA	cis	rs911555	0.723	rs2273701	ENSG00000244691.1	RPL10AP1	4.81	2.08e-06	0.000247	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103412119~103412761:-
THCA	cis	rs79243044	0.931	rs10742708	ENSG00000224295.2	AC087380.14	-4.81	2.08e-06	0.000247	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5533788	chr11:5518441~5524955:-
THCA	cis	rs375066	0.901	rs438517	ENSG00000278917.1	RP11-15A1.4	-4.81	2.08e-06	0.000247	-0.18	-0.22	Breast cancer;	chr19:43915506	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs446674	ENSG00000278917.1	RP11-15A1.4	-4.81	2.08e-06	0.000247	-0.18	-0.22	Breast cancer;	chr19:43916855	chr19:43891233~43895411:+
THCA	cis	rs4578769	0.55	rs12954377	ENSG00000265939.1	UBE2CP2	4.81	2.08e-06	0.000247	0.25	0.22	Eosinophil percentage of white cells;	chr18:22940862	chr18:22900486~22900995:-
THCA	cis	rs16846053	0.792	rs62190668	ENSG00000227403.1	AC009299.3	4.81	2.08e-06	0.000247	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161793422	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72877400	ENSG00000227403.1	AC009299.3	4.81	2.08e-06	0.000247	0.48	0.22	Blood osmolality (transformed sodium);	chr2:161820181	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs62187700	ENSG00000227403.1	AC009299.3	4.81	2.08e-06	0.000247	0.48	0.22	Blood osmolality (transformed sodium);	chr2:161821263	chr2:161244739~161249050:+
THCA	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	4.81	2.08e-06	0.000247	0.18	0.22	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
THCA	cis	rs7772486	0.754	rs6906258	ENSG00000270638.1	RP3-466P17.1	-4.81	2.08e-06	0.000247	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145735570~145737218:+
THCA	cis	rs7851660	0.844	rs13287360	ENSG00000214417.4	KRT18P13	-4.81	2.08e-06	0.000248	-0.19	-0.22	Strep throat;	chr9:97875399	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.844	rs4743139	ENSG00000214417.4	KRT18P13	-4.81	2.08e-06	0.000248	-0.19	-0.22	Strep throat;	chr9:97876138	chr9:97698922~97700734:+
THCA	cis	rs6750795	0.569	rs1667313	ENSG00000223198.1	RNU2-22P	-4.81	2.08e-06	0.000248	-0.27	-0.22	Height;	chr2:231543307	chr2:231501990~231502201:-
THCA	cis	rs539096	0.501	rs713191	ENSG00000237950.1	RP11-7O11.3	4.81	2.08e-06	0.000248	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43848881	chr1:43944370~43946551:-
THCA	cis	rs3011225	0.71	rs3011222	ENSG00000237950.1	RP11-7O11.3	4.81	2.08e-06	0.000248	0.19	0.22	Amyotrophic lateral sclerosis (age of onset);	chr1:43851873	chr1:43944370~43946551:-
THCA	cis	rs3011225	0.71	rs3011224	ENSG00000237950.1	RP11-7O11.3	4.81	2.08e-06	0.000248	0.19	0.22	Amyotrophic lateral sclerosis (age of onset);	chr1:43852811	chr1:43944370~43946551:-
THCA	cis	rs3011225	0.683	rs4660753	ENSG00000237950.1	RP11-7O11.3	4.81	2.08e-06	0.000248	0.19	0.22	Amyotrophic lateral sclerosis (age of onset);	chr1:43855372	chr1:43944370~43946551:-
THCA	cis	rs4660261	0.526	rs3011228	ENSG00000237950.1	RP11-7O11.3	4.81	2.08e-06	0.000248	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43860323	chr1:43944370~43946551:-
THCA	cis	rs17767392	0.958	rs55883127	ENSG00000259146.3	RP1-261D10.2	4.8	2.09e-06	0.000248	0.28	0.22	Mitral valve prolapse;	chr14:71513519	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs12892512	ENSG00000259146.3	RP1-261D10.2	4.8	2.09e-06	0.000248	0.28	0.22	Mitral valve prolapse;	chr14:71516579	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs35760654	ENSG00000259146.3	RP1-261D10.2	4.8	2.09e-06	0.000248	0.28	0.22	Mitral valve prolapse;	chr14:71517040	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.958	rs35231795	ENSG00000259146.3	RP1-261D10.2	4.8	2.09e-06	0.000248	0.28	0.22	Mitral valve prolapse;	chr14:71520657	chr14:71292729~71321814:-
THCA	cis	rs72615157	0.697	rs2056726	ENSG00000078319.8	PMS2P1	-4.8	2.09e-06	0.000248	-0.28	-0.22	Lung function (FEV1/FVC);	chr7:100182660	chr7:100320992~100341908:-
THCA	cis	rs5015933	0.815	rs10114168	ENSG00000232630.1	PRPS1P2	-4.8	2.09e-06	0.000248	-0.14	-0.22	Body mass index;	chr9:125273170	chr9:125150653~125151589:+
THCA	cis	rs7772486	0.754	rs864148	ENSG00000270638.1	RP3-466P17.1	-4.8	2.09e-06	0.000248	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145735570~145737218:+
THCA	cis	rs7537765	1	rs56190030	ENSG00000242349.4	NPPA-AS1	-4.8	2.09e-06	0.000248	-0.28	-0.22	QRS complex (12-leadsum);	chr1:11827325	chr1:11841017~11848079:+
THCA	cis	rs11779988	0.545	rs208764	ENSG00000253671.1	RP11-806O11.1	-4.8	2.09e-06	0.000248	-0.28	-0.22	Breast cancer;	chr8:17948761	chr8:17808941~17820868:+
THCA	cis	rs11779988	0.545	rs208763	ENSG00000253671.1	RP11-806O11.1	-4.8	2.09e-06	0.000248	-0.28	-0.22	Breast cancer;	chr8:17948973	chr8:17808941~17820868:+
THCA	cis	rs2803122	0.87	rs10738534	ENSG00000273226.1	RP11-513M16.8	-4.8	2.09e-06	0.000248	-0.19	-0.22	Pulse pressure;	chr9:19293780	chr9:19375451~19375996:+
THCA	cis	rs6044112	0.583	rs7352372	ENSG00000273998.1	RP4-777L9.2	4.8	2.09e-06	0.000248	0.31	0.22	Response to taxane treatment (docetaxel);	chr20:16531346	chr20:16576068~16579615:+
THCA	cis	rs9368481	0.678	rs62402024	ENSG00000261353.1	CTA-14H9.5	-4.8	2.09e-06	0.000248	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26527063~26527404:+
THCA	cis	rs752010	0.574	rs10890157	ENSG00000230638.4	RP11-486B10.4	-4.8	2.09e-06	0.000248	-0.24	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41652018	chr1:41542069~41544310:+
THCA	cis	rs752010	0.574	rs12130138	ENSG00000230638.4	RP11-486B10.4	-4.8	2.09e-06	0.000248	-0.24	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41652121	chr1:41542069~41544310:+
THCA	cis	rs427394	1	rs274672	ENSG00000248677.1	CTD-2044J15.1	4.8	2.09e-06	0.000248	0.2	0.22	Menopause (age at onset);	chr5:6744063	chr5:6686325~6707711:-
THCA	cis	rs481331	0.611	rs12264895	ENSG00000215146.4	RP11-313J2.1	4.8	2.09e-06	0.000248	0.35	0.22	Systemic juvenile idiopathic arthritis;	chr10:42695001	chr10:42331866~42367974:-
THCA	cis	rs7829975	0.846	rs1879957	ENSG00000254153.1	CTA-398F10.2	4.8	2.09e-06	0.000248	0.23	0.22	Mood instability;	chr8:8687298	chr8:8456909~8461337:-
THCA	cis	rs62184315	0.536	rs56324258	ENSG00000253559.1	OSGEPL1-AS1	-4.8	2.09e-06	0.000248	-0.31	-0.22	Alcohol dependence (age at onset);	chr2:189811589	chr2:189762704~189765556:+
THCA	cis	rs4722166	0.603	rs7801406	ENSG00000225541.1	AC002480.5	-4.8	2.09e-06	0.000248	-0.28	-0.22	Lung cancer;	chr7:22748655	chr7:22571607~22661792:-
THCA	cis	rs9487094	0.67	rs11755641	ENSG00000223537.2	RP5-919F19.5	-4.8	2.09e-06	0.000248	-0.22	-0.22	Height;	chr6:109586733	chr6:109487906~109506800:+
THCA	cis	rs7851660	0.809	rs7036589	ENSG00000214417.4	KRT18P13	4.8	2.09e-06	0.000248	0.19	0.22	Strep throat;	chr9:97895438	chr9:97698922~97700734:+
THCA	cis	rs10256972	0.706	rs4285396	ENSG00000225146.1	AC073957.15	4.8	2.09e-06	0.000248	0.24	0.22	Endometriosis;Longevity;	chr7:1084102	chr7:1029025~1043891:+
THCA	cis	rs1185460	0.804	rs13929	ENSG00000272186.1	RP11-110I1.13	-4.8	2.09e-06	0.000249	-0.2	-0.22	Coronary artery disease;	chr11:119045044	chr11:119067374~119067698:-
THCA	cis	rs12931792	0.712	rs56399904	ENSG00000273724.1	RP11-347C12.12	4.8	2.09e-06	0.000249	0.22	0.22	Tonsillectomy;	chr16:30154862	chr16:30336400~30343336:+
THCA	cis	rs11846409	0.932	rs28378201	ENSG00000274576.2	IGHV2-70	-4.8	2.09e-06	0.000249	-0.18	-0.22	Rheumatic heart disease;	chr14:106637262	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.86	rs74091720	ENSG00000274576.2	IGHV2-70	-4.8	2.09e-06	0.000249	-0.18	-0.22	Rheumatic heart disease;	chr14:106638192	chr14:106770577~106771020:-
THCA	cis	rs11673344	0.523	rs2562599	ENSG00000276846.1	CTD-3220F14.3	-4.8	2.09e-06	0.000249	-0.17	-0.22	Obesity-related traits;	chr19:37025472	chr19:37314868~37315620:-
THCA	cis	rs9307551	0.741	rs1971838	ENSG00000250334.4	LINC00989	-4.8	2.09e-06	0.000249	-0.28	-0.22	Refractive error;	chr4:79497477	chr4:79492416~79576460:+
THCA	cis	rs9880211	1	rs9837158	ENSG00000239213.4	NCK1-AS1	4.8	2.09e-06	0.000249	0.23	0.22	Height;Body mass index;	chr3:136354321	chr3:136841726~136862054:-
THCA	cis	rs2380220	0.574	rs7766765	ENSG00000261366.1	MANEA-AS1	-4.8	2.09e-06	0.000249	-0.21	-0.22	Behavioural disinhibition (generation interaction);	chr6:95549486	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.574	rs9400526	ENSG00000261366.1	MANEA-AS1	-4.8	2.09e-06	0.000249	-0.21	-0.22	Behavioural disinhibition (generation interaction);	chr6:95550565	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.574	rs9374322	ENSG00000261366.1	MANEA-AS1	-4.8	2.09e-06	0.000249	-0.21	-0.22	Behavioural disinhibition (generation interaction);	chr6:95551118	chr6:95575183~95577450:-
THCA	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	4.8	2.09e-06	0.000249	0.25	0.22	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
THCA	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	4.8	2.09e-06	0.000249	0.12	0.22	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
THCA	cis	rs62246343	0.605	rs17050395	ENSG00000254485.4	RP11-380O24.1	4.8	2.1e-06	0.000249	0.24	0.22	Fibrinogen levels;	chr3:9492290	chr3:9292588~9363303:-
THCA	cis	rs4578769	0.569	rs12958551	ENSG00000265939.1	UBE2CP2	4.8	2.1e-06	0.000249	0.25	0.22	Eosinophil percentage of white cells;	chr18:22897885	chr18:22900486~22900995:-
THCA	cis	rs930395	0.514	rs34501299	ENSG00000272335.1	RP11-53O19.3	4.8	2.1e-06	0.000249	0.18	0.22	Breast cancer;	chr5:44912977	chr5:44826076~44828592:+
THCA	cis	rs734999	0.572	rs4310388	ENSG00000225931.3	RP3-395M20.7	4.8	2.1e-06	0.000249	0.26	0.22	Ulcerative colitis;	chr1:2575976	chr1:2566410~2569888:+
THCA	cis	rs6832769	0.925	rs60992571	ENSG00000272969.1	RP11-528I4.2	-4.8	2.1e-06	0.000249	-0.25	-0.22	Personality dimensions;	chr4:55574645	chr4:55547112~55547889:+
THCA	cis	rs6954895	0.545	rs7794097	ENSG00000271122.1	RP11-379H18.1	4.8	2.1e-06	0.000249	0.14	0.22	Anger;	chr7:35549856	chr7:35695214~35699413:+
THCA	cis	rs7429990	0.965	rs7651237	ENSG00000228638.1	FCF1P2	4.8	2.1e-06	0.000249	0.22	0.22	Educational attainment (years of education);	chr3:48064038	chr3:48290793~48291375:-
THCA	cis	rs17666538	0.71	rs12716640	ENSG00000254207.1	RP11-43A14.1	4.8	2.1e-06	0.000249	0.44	0.22	IgG glycosylation;	chr8:695376	chr8:725188~725877:-
THCA	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	4.8	2.1e-06	0.000249	0.15	0.22	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
THCA	cis	rs2692947	0.537	rs11164049	ENSG00000235584.2	AC008268.1	-4.8	2.1e-06	0.000249	-0.22	-0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95679770	chr2:95666084~95668715:+
THCA	cis	rs12478296	0.901	rs59191623	ENSG00000261186.2	RP11-341N2.1	-4.8	2.1e-06	0.000249	-0.33	-0.22	Obesity-related traits;	chr2:242086444	chr2:242087351~242088457:-
THCA	cis	rs79243044	1	rs10838290	ENSG00000224295.2	AC087380.14	-4.8	2.1e-06	0.000249	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5538920	chr11:5518441~5524955:-
THCA	cis	rs79243044	0.965	rs10500649	ENSG00000224295.2	AC087380.14	-4.8	2.1e-06	0.000249	-0.22	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5539873	chr11:5518441~5524955:-
THCA	cis	rs17767392	0.881	rs12880188	ENSG00000259146.3	RP1-261D10.2	4.8	2.1e-06	0.00025	0.27	0.22	Mitral valve prolapse;	chr14:71543028	chr14:71292729~71321814:-
THCA	cis	rs6828666	1	rs6833533	ENSG00000271817.2	U3	4.8	2.1e-06	0.00025	0.26	0.22	Depression;	chr4:158855123	chr4:158700691~158700909:+
THCA	cis	rs1124769	0.7	rs35573737	ENSG00000259378.1	DCAF13P3	4.8	2.1e-06	0.00025	0.33	0.22	Cognitive performance;	chr15:50924623	chr15:50944663~50945996:+
THCA	cis	rs6908034	0.66	rs74795718	ENSG00000227116.1	RP3-471C18.1	-4.8	2.1e-06	0.00025	-0.41	-0.22	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782068	chr6:19730427~19734567:-
THCA	cis	rs1150668	0.799	rs853684	ENSG00000273712.1	RP5-874C20.7	4.8	2.1e-06	0.00025	0.24	0.22	Pubertal anthropometrics;	chr6:28326773	chr6:28315613~28315883:-
THCA	cis	rs4908768	0.501	rs2045820	ENSG00000232912.4	RP5-1115A15.1	4.8	2.1e-06	0.00025	0.21	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8424645~8434838:+
THCA	cis	rs16975963	0.644	rs73037036	ENSG00000226686.6	LINC01535	-4.8	2.1e-06	0.00025	-0.29	-0.22	Longevity;	chr19:37670169	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.644	rs111319455	ENSG00000226686.6	LINC01535	-4.8	2.1e-06	0.00025	-0.29	-0.22	Longevity;	chr19:37671746	chr19:37251912~37265535:+
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000176933.5	TOB2P1	-4.8	2.1e-06	0.00025	-0.24	-0.22	Pubertal anthropometrics;	chr6:28271903	chr6:28217643~28218634:-
THCA	cis	rs7403037	0.753	rs12899368	ENSG00000260760.1	PWRN3	4.8	2.1e-06	0.00025	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24248877	chr15:24441127~24447967:+
THCA	cis	rs7429990	0.901	rs9825114	ENSG00000228638.1	FCF1P2	4.8	2.1e-06	0.00025	0.21	0.22	Educational attainment (years of education);	chr3:48096592	chr3:48290793~48291375:-
THCA	cis	rs922182	0.633	rs12592702	ENSG00000275785.1	RP11-111E14.2	-4.8	2.1e-06	0.00025	-0.24	-0.22	Blood protein levels;	chr15:63979683	chr15:63890030~63890317:+
THCA	cis	rs17507216	0.591	rs7163848	ENSG00000255769.6	GOLGA2P10	-4.8	2.11e-06	0.00025	-0.33	-0.22	Excessive daytime sleepiness;	chr15:82729563	chr15:82472993~82513950:-
THCA	cis	rs7914558	1	rs4917996	ENSG00000236937.2	PTGES3P4	4.8	2.11e-06	0.00025	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103166072	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs6584540	ENSG00000236937.2	PTGES3P4	4.8	2.11e-06	0.00025	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103167877	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs7081075	ENSG00000236937.2	PTGES3P4	4.8	2.11e-06	0.00025	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103169434	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs10786740	ENSG00000236937.2	PTGES3P4	4.8	2.11e-06	0.00025	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103175836	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.901	rs35525740	ENSG00000236937.2	PTGES3P4	4.8	2.11e-06	0.00025	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181355	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.869	rs10883842	ENSG00000236937.2	PTGES3P4	4.8	2.11e-06	0.00025	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181832	chr10:102845595~102845950:+
THCA	cis	rs9973361	0.55	rs58562881	ENSG00000232411.1	AC009495.3	-4.8	2.11e-06	0.00025	-0.26	-0.22	Total body bone mineral density;	chr2:165838008	chr2:165833048~165839098:-
THCA	cis	rs13403656	1	rs13403656	ENSG00000240350.2	AC017002.1	4.8	2.11e-06	0.00025	0.39	0.22	Allergic disease (asthma, hay fever or eczema);	chr2:111511550	chr2:111491273~111570974:+
THCA	cis	rs13113518	1	rs4864990	ENSG00000273257.1	RP11-177J6.1	4.8	2.11e-06	0.00025	0.28	0.22	Height;	chr4:55447523	chr4:55387949~55388271:+
THCA	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	4.8	2.11e-06	0.00025	0.39	0.22	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
THCA	cis	rs9863	0.828	rs952632	ENSG00000269997.1	RP11-214K3.21	-4.8	2.11e-06	0.00025	-0.26	-0.22	White blood cell count;	chr12:123985191	chr12:123966077~123966629:-
THCA	cis	rs9863	0.694	rs11837287	ENSG00000269997.1	RP11-214K3.21	-4.8	2.11e-06	0.00025	-0.26	-0.22	White blood cell count;	chr12:123985512	chr12:123966077~123966629:-
THCA	cis	rs7192208	0.541	rs60275659	ENSG00000260922.1	RP11-538I12.3	4.8	2.11e-06	0.00025	0.34	0.22	White matter integrity;	chr16:77286815	chr16:77234877~77290934:+
THCA	cis	rs7267979	0.932	rs6107052	ENSG00000274973.1	RP13-401N8.7	-4.8	2.11e-06	0.00025	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25845497~25845862:+
THCA	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-4.8	2.11e-06	0.00025	-0.27	-0.22	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
THCA	cis	rs6908034	0.769	rs6916589	ENSG00000227116.1	RP3-471C18.1	-4.8	2.11e-06	0.00025	-0.36	-0.22	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761132	chr6:19730427~19734567:-
THCA	cis	rs9880211	0.718	rs56398805	ENSG00000273486.1	RP11-731C17.2	4.8	2.11e-06	0.00025	0.21	0.22	Height;Body mass index;	chr3:136213558	chr3:136837338~136839021:-
THCA	cis	rs1979679	0.578	rs1904387	ENSG00000278733.1	RP11-425D17.1	4.8	2.11e-06	0.00025	0.21	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28120723	chr12:28185625~28186190:-
THCA	cis	rs875971	0.522	rs6960048	ENSG00000223473.2	GS1-124K5.3	4.8	2.11e-06	0.00025	0.14	0.22	Aortic root size;	chr7:65943052	chr7:66491049~66493566:-
THCA	cis	rs494453	0.922	rs2477428	ENSG00000227811.2	FAM212B-AS1	-4.8	2.11e-06	0.00025	-0.27	-0.22	Osteoporosis-related phenotypes;	chr1:111671634	chr1:111739841~111747798:+
THCA	cis	rs494453	0.922	rs476515	ENSG00000227811.2	FAM212B-AS1	-4.8	2.11e-06	0.00025	-0.27	-0.22	Osteoporosis-related phenotypes;	chr1:111672454	chr1:111739841~111747798:+
THCA	cis	rs494453	0.883	rs1099800	ENSG00000227811.2	FAM212B-AS1	-4.8	2.11e-06	0.00025	-0.27	-0.22	Osteoporosis-related phenotypes;	chr1:111682961	chr1:111739841~111747798:+
THCA	cis	rs7267979	1	rs453329	ENSG00000274973.1	RP13-401N8.7	-4.8	2.11e-06	0.00025	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25845497~25845862:+
THCA	cis	rs922182	0.607	rs8030264	ENSG00000275785.1	RP11-111E14.2	-4.8	2.11e-06	0.00025	-0.24	-0.22	Blood protein levels;	chr15:63979297	chr15:63890030~63890317:+
THCA	cis	rs17695224	1	rs10422101	ENSG00000275055.1	CTC-471J1.11	4.8	2.11e-06	0.00025	0.17	0.22	HDL cholesterol;HDL cholesterol levels;	chr19:51816862	chr19:52049007~52049754:+
THCA	cis	rs2018683	0.834	rs733485	ENSG00000272568.4	CTB-113D17.1	4.8	2.11e-06	0.00025	0.21	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28979967~29013367:+
THCA	cis	rs453301	0.507	rs2929306	ENSG00000248538.5	RP11-10A14.5	4.8	2.11e-06	0.00025	0.27	0.22	Joint mobility (Beighton score);	chr8:9227399	chr8:9189011~9202854:+
THCA	cis	rs2243480	0.803	rs423187	ENSG00000164669.11	INTS4P1	4.8	2.11e-06	0.00025	0.42	0.22	Diabetic kidney disease;	chr7:66044512	chr7:65141225~65234216:+
THCA	cis	rs7267979	0.586	rs6050445	ENSG00000277938.1	RP5-965G21.3	4.8	2.11e-06	0.00025	0.18	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25229150~25231933:+
THCA	cis	rs10923574	0.597	rs1146308	ENSG00000231365.4	RP11-418J17.1	4.8	2.11e-06	0.000251	0.22	0.22	Breast cancer;Folding of antihelix;	chr1:118489101	chr1:119140396~119275973:+
THCA	cis	rs7474896	1	rs2738222	ENSG00000263064.2	RP11-291L22.7	-4.8	2.11e-06	0.000251	-0.36	-0.22	Obesity (extreme);	chr10:37894746	chr10:38448689~38448949:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000273796.1	LL21NC02-21A1.1	-4.8	2.11e-06	0.000251	-0.22	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45403809~45404369:-
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000273712.1	RP5-874C20.7	4.8	2.11e-06	0.000251	0.24	0.22	Pubertal anthropometrics;	chr6:28175232	chr6:28315613~28315883:-
THCA	cis	rs6490294	0.528	rs12423268	ENSG00000226469.1	ADAM1B	4.8	2.11e-06	0.000251	0.36	0.22	Mean platelet volume;	chr12:112203903	chr12:111927018~111929017:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000229886.1	RP5-1132H15.3	4.8	2.11e-06	0.000251	0.25	0.22	Corneal structure;	chr7:66925737	chr7:66025126~66031544:-
THCA	cis	rs2032366	0.592	rs12455039	ENSG00000267279.1	RP11-879F14.2	4.8	2.11e-06	0.000251	0.23	0.22	Obesity-related traits;	chr18:61583101	chr18:61585746~61606916:-
THCA	cis	rs812925	0.555	rs12616433	ENSG00000270820.4	RP11-355B11.2	4.8	2.11e-06	0.000251	0.18	0.22	Immature fraction of reticulocytes;	chr2:61469353	chr2:61471188~61484130:+
THCA	cis	rs7829975	0.811	rs7011229	ENSG00000254153.1	CTA-398F10.2	4.8	2.11e-06	0.000251	0.23	0.22	Mood instability;	chr8:8685814	chr8:8456909~8461337:-
THCA	cis	rs11673344	0.523	rs7245520	ENSG00000276846.1	CTD-3220F14.3	4.8	2.11e-06	0.000251	0.17	0.22	Obesity-related traits;	chr19:37036416	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs7256380	ENSG00000276846.1	CTD-3220F14.3	4.8	2.11e-06	0.000251	0.17	0.22	Obesity-related traits;	chr19:37041178	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs6510585	ENSG00000276846.1	CTD-3220F14.3	4.8	2.11e-06	0.000251	0.17	0.22	Obesity-related traits;	chr19:37063081	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs17206540	ENSG00000276846.1	CTD-3220F14.3	4.8	2.11e-06	0.000251	0.17	0.22	Obesity-related traits;	chr19:37069009	chr19:37314868~37315620:-
THCA	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-4.8	2.11e-06	0.000251	-0.21	-0.22	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
THCA	cis	rs2790457	0.917	rs2790462	ENSG00000254635.4	WAC-AS1	-4.8	2.11e-06	0.000251	-0.21	-0.22	Multiple myeloma;	chr10:28584273	chr10:28522652~28532743:-
THCA	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	4.8	2.11e-06	0.000251	0.24	0.22	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
THCA	cis	rs8105895	0.935	rs8111854	ENSG00000269345.1	VN1R85P	4.8	2.12e-06	0.000251	0.29	0.22	Body mass index (change over time);	chr19:22057411	chr19:22174766~22175191:-
THCA	cis	rs957448	1	rs1055797	ENSG00000253175.1	RP11-267M23.6	4.8	2.12e-06	0.000251	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94565036~94565715:+
THCA	cis	rs2179367	0.613	rs12207261	ENSG00000223701.3	RAET1E-AS1	4.8	2.12e-06	0.000251	0.3	0.22	Dupuytren's disease;	chr6:149423722	chr6:149884431~149919508:+
THCA	cis	rs858239	0.6	rs4409314	ENSG00000226816.2	AC005082.12	4.8	2.12e-06	0.000251	0.3	0.22	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23206013~23208045:+
THCA	cis	rs2734839	0.896	rs11608109	ENSG00000270179.1	RP11-159N11.4	-4.8	2.12e-06	0.000251	-0.23	-0.22	Information processing speed;	chr11:113432726	chr11:113368478~113369117:+
THCA	cis	rs6973609	0.524	rs343711	ENSG00000271122.1	RP11-379H18.1	4.8	2.12e-06	0.000251	0.14	0.22	Obesity-related traits;	chr7:35594740	chr7:35695214~35699413:+
THCA	cis	rs7829975	0.572	rs28446104	ENSG00000253981.4	ALG1L13P	-4.8	2.12e-06	0.000251	-0.21	-0.22	Mood instability;	chr8:8938391	chr8:8236003~8244667:-
THCA	cis	rs35160687	0.644	rs2367232	ENSG00000273080.1	RP11-301O19.1	-4.8	2.12e-06	0.000251	-0.23	-0.22	Night sleep phenotypes;	chr2:86314368	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.644	rs36079379	ENSG00000273080.1	RP11-301O19.1	-4.8	2.12e-06	0.000251	-0.23	-0.22	Night sleep phenotypes;	chr2:86318837	chr2:86195590~86196049:+
THCA	cis	rs172166	0.694	rs9295760	ENSG00000261839.1	RP1-265C24.8	4.8	2.12e-06	0.000251	0.23	0.22	Cardiac Troponin-T levels;	chr6:28179607	chr6:28136849~28139678:+
THCA	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	4.8	2.12e-06	0.000251	0.3	0.22	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
THCA	cis	rs9863	0.898	rs7301953	ENSG00000269997.1	RP11-214K3.21	-4.8	2.12e-06	0.000251	-0.27	-0.22	White blood cell count;	chr12:123921324	chr12:123966077~123966629:-
THCA	cis	rs17801127	0.818	rs1724817	ENSG00000231969.1	AC144449.1	-4.8	2.12e-06	0.000251	-0.35	-0.22	Liver enzyme levels (alanine transaminase);	chr2:149690198	chr2:149587196~149848233:+
THCA	cis	rs10090774	0.965	rs11781807	ENSG00000279766.1	RP11-642A1.2	-4.8	2.12e-06	0.000251	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140984294	chr8:140572142~140572812:-
THCA	cis	rs9992667	0.955	rs6855993	ENSG00000231160.8	KLF3-AS1	4.8	2.12e-06	0.000251	0.15	0.22	Eosinophil percentage of granulocytes;	chr4:38607291	chr4:38612701~38664883:-
THCA	cis	rs4824093	0.535	rs73441764	ENSG00000278869.1	CITF22-49E9.3	4.8	2.12e-06	0.000251	0.49	0.22	Amyotrophic lateral sclerosis (sporadic);	chr22:49861838	chr22:49933198~49934074:-
THCA	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	4.8	2.12e-06	0.000251	0.4	0.22	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
THCA	cis	rs9625935	0.778	rs715523	ENSG00000279159.1	RP3-394A18.1	4.8	2.12e-06	0.000252	0.17	0.22	Tonsillectomy;	chr22:29986807	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.843	rs2017677	ENSG00000279159.1	RP3-394A18.1	4.8	2.12e-06	0.000252	0.17	0.22	Tonsillectomy;	chr22:29987273	chr22:29978950~30028236:-
THCA	cis	rs6500550	0.851	rs11646287	ENSG00000276754.1	RP11-461A8.5	4.8	2.12e-06	0.000252	0.2	0.22	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3669343	chr16:3686998~3687380:+
THCA	cis	rs1048886	0.938	rs2639291	ENSG00000271967.1	RP11-134K13.4	-4.8	2.12e-06	0.000252	-0.22	-0.22	Type 2 diabetes;	chr6:70472310	chr6:70596438~70596980:+
THCA	cis	rs12962334	0.555	rs9959556	ENSG00000265939.1	UBE2CP2	4.8	2.12e-06	0.000252	0.24	0.22	Breast cancer;	chr18:23011982	chr18:22900486~22900995:-
THCA	cis	rs526231	0.756	rs35804	ENSG00000175749.11	EIF3KP1	4.8	2.12e-06	0.000252	0.27	0.22	Primary biliary cholangitis;	chr5:103289634	chr5:103032376~103033031:+
THCA	cis	rs860295	0.702	rs10752611	ENSG00000160766.13	GBAP1	-4.8	2.12e-06	0.000252	-0.25	-0.22	Body mass index;	chr1:155539316	chr1:155213821~155227422:-
THCA	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-4.8	2.12e-06	0.000252	-0.24	-0.22	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
THCA	cis	rs6430585	0.583	rs2304371	ENSG00000231890.6	DARS-AS1	-4.8	2.12e-06	0.000252	-0.24	-0.22	Corneal structure;	chr2:135803987	chr2:135985176~136022593:+
THCA	cis	rs9719620	0.9	rs4731788	ENSG00000236753.4	MKLN1-AS	-4.8	2.12e-06	0.000252	-0.21	-0.22	Male-pattern baldness;	chr7:131302207	chr7:131309744~131328222:-
THCA	cis	rs3020736	0.5	rs5996111	ENSG00000273366.1	CTA-989H11.1	4.8	2.12e-06	0.000252	0.28	0.22	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42278188~42278846:+
THCA	cis	rs438465	0.645	rs9406339	ENSG00000226194.4	RP1-137D17.1	4.8	2.12e-06	0.000252	0.35	0.22	Corneal astigmatism;	chr6:169398701	chr6:169369998~169388385:-
THCA	cis	rs2439831	0.867	rs2255440	ENSG00000205771.5	CATSPER2P1	-4.8	2.12e-06	0.000252	-0.29	-0.22	Lung cancer in ever smokers;	chr15:43538269	chr15:43726918~43747094:-
THCA	cis	rs860295	0.702	rs10796943	ENSG00000160766.13	GBAP1	-4.8	2.12e-06	0.000252	-0.25	-0.22	Body mass index;	chr1:155444938	chr1:155213821~155227422:-
THCA	cis	rs6728642	1	rs116171118	ENSG00000230606.9	AC159540.1	4.8	2.12e-06	0.000252	0.33	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97029299	chr2:97416165~97433527:-
THCA	cis	rs6728642	0.708	rs115507803	ENSG00000230606.9	AC159540.1	4.8	2.12e-06	0.000252	0.33	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97086317	chr2:97416165~97433527:-
THCA	cis	rs2834188	0.557	rs2834186	ENSG00000272659.1	AP000295.10	-4.8	2.13e-06	0.000252	-0.28	-0.22	Narcolepsy;	chr21:33314448	chr21:33309491~33310181:+
THCA	cis	rs916888	0.61	rs199453	ENSG00000261575.2	RP11-259G18.1	4.8	2.13e-06	0.000252	0.26	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46267037~46268694:+
THCA	cis	rs860295	0.529	rs11577179	ENSG00000225855.5	RUSC1-AS1	-4.8	2.13e-06	0.000252	-0.14	-0.22	Body mass index;	chr1:156013919	chr1:155316863~155324176:-
THCA	cis	rs6479874	1	rs7895755	ENSG00000223502.1	RP11-96B5.3	-4.8	2.13e-06	0.000252	-0.26	-0.22	Migraine;	chr10:51014288	chr10:51062579~51068553:-
THCA	cis	rs703842	1	rs8181644	ENSG00000270039.1	RP11-571M6.17	-4.8	2.13e-06	0.000252	-0.25	-0.22	Multiple sclerosis;	chr12:57779683	chr12:57803838~57804415:+
THCA	cis	rs7005380	0.733	rs10808505	ENSG00000245330.4	KB-1471A8.1	-4.8	2.13e-06	0.000252	-0.21	-0.22	Interstitial lung disease;	chr8:119927966	chr8:119867419~119874488:-
THCA	cis	rs7560272	0.723	rs13386124	ENSG00000163016.8	ALMS1P	4.8	2.13e-06	0.000252	0.28	0.22	Schizophrenia;	chr2:73544568	chr2:73644919~73685576:+
THCA	cis	rs9719620	0.834	rs4731786	ENSG00000236753.4	MKLN1-AS	-4.8	2.13e-06	0.000252	-0.21	-0.22	Male-pattern baldness;	chr7:131301579	chr7:131309744~131328222:-
THCA	cis	rs12188164	0.525	rs1114665	ENSG00000221990.4	EXOC3-AS1	-4.8	2.13e-06	0.000252	-0.17	-0.22	Cystic fibrosis severity;	chr5:452132	chr5:441498~443160:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000213640.3	EEF1DP4	-4.8	2.13e-06	0.000252	-0.25	-0.22	Calcium levels;	chr7:65853042	chr7:64862999~64864370:+
THCA	cis	rs17801127	0.515	rs35188572	ENSG00000231969.1	AC144449.1	4.8	2.13e-06	0.000253	0.44	0.22	Liver enzyme levels (alanine transaminase);	chr2:149891071	chr2:149587196~149848233:+
THCA	cis	rs763121	0.853	rs3827357	ENSG00000228274.3	RP3-508I15.9	-4.8	2.13e-06	0.000253	-0.24	-0.22	Menopause (age at onset);	chr22:38683408	chr22:38667585~38681820:-
THCA	cis	rs8062405	0.755	rs4788073	ENSG00000261766.1	RP11-22P6.2	-4.8	2.13e-06	0.000253	-0.22	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28862166~28863340:-
THCA	cis	rs73198271	1	rs11774744	ENSG00000253893.2	FAM85B	4.8	2.13e-06	0.000253	0.34	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750254	chr8:8167819~8226614:-
THCA	cis	rs6840258	0.831	rs3736668	ENSG00000251411.1	RP11-397E7.4	-4.8	2.13e-06	0.000253	-0.26	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87071058	chr4:86913266~86914817:-
THCA	cis	rs4415084	0.716	rs6451774	ENSG00000272335.1	RP11-53O19.3	-4.8	2.13e-06	0.000253	-0.18	-0.22	Breast cancer;	chr5:44793882	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs727305	ENSG00000272335.1	RP11-53O19.3	-4.8	2.13e-06	0.000253	-0.18	-0.22	Breast cancer;	chr5:44795940	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs2330619	ENSG00000272335.1	RP11-53O19.3	-4.8	2.13e-06	0.000253	-0.18	-0.22	Breast cancer;	chr5:44795960	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs727304	ENSG00000272335.1	RP11-53O19.3	-4.8	2.13e-06	0.000253	-0.18	-0.22	Breast cancer;	chr5:44796188	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs1438819	ENSG00000272335.1	RP11-53O19.3	-4.8	2.13e-06	0.000253	-0.18	-0.22	Breast cancer;	chr5:44797744	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.688	rs11741772	ENSG00000272335.1	RP11-53O19.3	-4.8	2.13e-06	0.000253	-0.18	-0.22	Breast cancer;	chr5:44814495	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs9637796	ENSG00000272335.1	RP11-53O19.3	-4.8	2.13e-06	0.000253	-0.18	-0.22	Breast cancer;	chr5:44817817	chr5:44826076~44828592:+
THCA	cis	rs2243480	1	rs35396113	ENSG00000232559.3	GS1-124K5.12	4.8	2.13e-06	0.000253	0.32	0.22	Diabetic kidney disease;	chr7:66030474	chr7:66554588~66576923:-
THCA	cis	rs8037818	1	rs4643284	ENSG00000261064.1	RP11-1000B6.3	-4.8	2.13e-06	0.000253	-0.18	-0.22	Obesity-related traits;	chr15:32639897	chr15:32536047~32587613:+
THCA	cis	rs8141529	0.956	rs469989	ENSG00000226471.5	CTA-292E10.6	4.8	2.13e-06	0.000253	0.18	0.22	Lymphocyte counts;	chr22:28907607	chr22:28800683~28848559:+
THCA	cis	rs9487094	0.626	rs12192776	ENSG00000223537.2	RP5-919F19.5	-4.8	2.13e-06	0.000253	-0.22	-0.22	Height;	chr6:109634150	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs12194157	ENSG00000223537.2	RP5-919F19.5	-4.8	2.13e-06	0.000253	-0.22	-0.22	Height;	chr6:109640141	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs12197950	ENSG00000223537.2	RP5-919F19.5	-4.8	2.13e-06	0.000253	-0.22	-0.22	Height;	chr6:109642186	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs7767525	ENSG00000223537.2	RP5-919F19.5	-4.8	2.13e-06	0.000253	-0.22	-0.22	Height;	chr6:109646187	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.504	rs71541003	ENSG00000223537.2	RP5-919F19.5	-4.8	2.13e-06	0.000253	-0.22	-0.22	Height;	chr6:109652694	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs3899233	ENSG00000223537.2	RP5-919F19.5	-4.8	2.13e-06	0.000253	-0.22	-0.22	Height;	chr6:109655791	chr6:109487906~109506800:+
THCA	cis	rs526231	0.756	rs556560	ENSG00000175749.11	EIF3KP1	-4.8	2.13e-06	0.000253	-0.27	-0.22	Primary biliary cholangitis;	chr5:103288223	chr5:103032376~103033031:+
THCA	cis	rs6714710	0.603	rs17489984	ENSG00000230606.9	AC159540.1	-4.8	2.13e-06	0.000253	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97804901	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.603	rs2044459	ENSG00000230606.9	AC159540.1	-4.8	2.13e-06	0.000253	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97830541	chr2:97416165~97433527:-
THCA	cis	rs6714710	0.557	rs17490429	ENSG00000230606.9	AC159540.1	-4.8	2.13e-06	0.000253	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97832561	chr2:97416165~97433527:-
THCA	cis	rs7727544	0.684	rs274561	ENSG00000263597.1	MIR3936	4.8	2.13e-06	0.000253	0.21	0.22	Blood metabolite levels;	chr5:132383536	chr5:132365490~132365599:-
THCA	cis	rs28374715	0.783	rs1866399	ENSG00000247556.5	OIP5-AS1	4.8	2.13e-06	0.000253	0.21	0.22	Ulcerative colitis;	chr15:41278941	chr15:41283990~41309737:+
THCA	cis	rs2243480	1	rs1039664	ENSG00000164669.11	INTS4P1	4.8	2.13e-06	0.000253	0.41	0.22	Diabetic kidney disease;	chr7:65984729	chr7:65141225~65234216:+
THCA	cis	rs11671005	0.735	rs12986387	ENSG00000268049.1	CTD-2619J13.9	-4.8	2.13e-06	0.000253	-0.33	-0.22	Mean platelet volume;	chr19:58415848	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs11667723	ENSG00000268049.1	CTD-2619J13.9	-4.8	2.13e-06	0.000253	-0.33	-0.22	Mean platelet volume;	chr19:58416122	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs11668789	ENSG00000268049.1	CTD-2619J13.9	-4.8	2.13e-06	0.000253	-0.33	-0.22	Mean platelet volume;	chr19:58416942	chr19:58357999~58359603:+
THCA	cis	rs4950322	0.57	rs3737855	ENSG00000180867.10	PDIA3P1	4.8	2.13e-06	0.000253	0.22	0.22	Protein quantitative trait loci;	chr1:147271257	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs4950316	ENSG00000180867.10	PDIA3P1	4.8	2.13e-06	0.000253	0.22	0.22	Protein quantitative trait loci;	chr1:147273712	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs2354428	ENSG00000180867.10	PDIA3P1	4.8	2.13e-06	0.000253	0.22	0.22	Protein quantitative trait loci;	chr1:147277512	chr1:147178113~147179622:+
THCA	cis	rs7665090	0.87	rs228615	ENSG00000251288.2	RP11-10L12.2	4.8	2.13e-06	0.000253	0.29	0.22	Primary biliary cholangitis;	chr4:102658303	chr4:102751401~102752641:+
THCA	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-4.8	2.13e-06	0.000253	-0.26	-0.22	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
THCA	cis	rs2439831	1	rs2253708	ENSG00000166763.7	STRCP1	4.8	2.13e-06	0.000253	0.29	0.22	Lung cancer in ever smokers;	chr15:43505075	chr15:43699488~43718184:-
THCA	cis	rs7942368	1	rs3758711	ENSG00000261578.1	RP11-21L23.2	4.8	2.13e-06	0.000253	0.31	0.22	Endometriosis;	chr11:76784516	chr11:76800364~76804555:+
THCA	cis	rs11955398	0.502	rs295524	ENSG00000272308.1	RP11-231G3.1	-4.8	2.14e-06	0.000253	-0.23	-0.22	Intelligence (multi-trait analysis);	chr5:61177224	chr5:60866457~60866935:-
THCA	cis	rs7580717	1	rs7580717	ENSG00000224376.1	AC017104.6	-4.8	2.14e-06	0.000253	-0.23	-0.22	Multiple myeloma;	chr2:231311828	chr2:231388976~231394991:+
THCA	cis	rs453301	0.658	rs9329175	ENSG00000254153.1	CTA-398F10.2	4.8	2.14e-06	0.000253	0.24	0.22	Joint mobility (Beighton score);	chr8:9009151	chr8:8456909~8461337:-
THCA	cis	rs5742933	1	rs1317751	ENSG00000273240.1	RP11-455J20.3	-4.8	2.14e-06	0.000253	-0.24	-0.22	Ferritin levels;	chr2:189807898	chr2:189763859~189764456:-
THCA	cis	rs9880211	0.848	rs71336069	ENSG00000239213.4	NCK1-AS1	4.8	2.14e-06	0.000253	0.24	0.22	Height;Body mass index;	chr3:136633024	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs28750366	ENSG00000239213.4	NCK1-AS1	4.8	2.14e-06	0.000253	0.24	0.22	Height;Body mass index;	chr3:136642213	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.846	rs73230043	ENSG00000239213.4	NCK1-AS1	4.8	2.14e-06	0.000253	0.24	0.22	Height;Body mass index;	chr3:136688317	chr3:136841726~136862054:-
THCA	cis	rs6671200	0.748	rs11589700	ENSG00000235501.4	RP4-639F20.1	-4.8	2.14e-06	0.000253	-0.42	-0.22	Stearic acid (18:0) levels;	chr1:95007885	chr1:94927566~94963270:+
THCA	cis	rs5742933	0.948	rs6434363	ENSG00000253559.1	OSGEPL1-AS1	-4.8	2.14e-06	0.000253	-0.26	-0.22	Ferritin levels;	chr2:189707565	chr2:189762704~189765556:+
THCA	cis	rs2447820	0.588	rs4333309	ENSG00000249996.1	RP11-359P5.1	-4.8	2.14e-06	0.000253	-0.25	-0.22	Migraine;	chr5:123062815	chr5:123036271~123054667:+
THCA	cis	rs10090774	1	rs10090774	ENSG00000279766.1	RP11-642A1.2	4.8	2.14e-06	0.000253	0.26	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140816640	chr8:140572142~140572812:-
THCA	cis	rs172166	0.611	rs203883	ENSG00000261839.1	RP1-265C24.8	4.8	2.14e-06	0.000253	0.23	0.22	Cardiac Troponin-T levels;	chr6:28110578	chr6:28136849~28139678:+
THCA	cis	rs250518	0.708	rs258893	ENSG00000272081.1	CTD-2376I4.2	4.8	2.14e-06	0.000254	0.26	0.22	Mean corpuscular hemoglobin concentration;	chr5:73009376	chr5:72955206~72955699:-
THCA	cis	rs4415084	0.652	rs4591754	ENSG00000272335.1	RP11-53O19.3	4.8	2.14e-06	0.000254	0.18	0.22	Breast cancer;	chr5:44894989	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs7356604	ENSG00000272335.1	RP11-53O19.3	4.8	2.14e-06	0.000254	0.18	0.22	Breast cancer;	chr5:44895097	chr5:44826076~44828592:+
THCA	cis	rs875971	0.597	rs11763224	ENSG00000228409.4	CCT6P1	-4.8	2.14e-06	0.000254	-0.19	-0.22	Aortic root size;	chr7:66518628	chr7:65751142~65763354:+
THCA	cis	rs2287838	0.967	rs12610468	ENSG00000267289.1	CTD-2623N2.11	-4.8	2.14e-06	0.000254	-0.25	-0.22	Sleep duration;	chr19:9878794	chr19:9834079~9835013:-
THCA	cis	rs7119	0.651	rs12902072	ENSG00000259362.2	RP11-307C19.1	-4.8	2.14e-06	0.000254	-0.32	-0.22	Type 2 diabetes;	chr15:77556390	chr15:77525540~77534110:+
THCA	cis	rs16846053	0.792	rs62187701	ENSG00000227403.1	AC009299.3	4.8	2.14e-06	0.000254	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161825821	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.792	rs72879215	ENSG00000227403.1	AC009299.3	4.8	2.14e-06	0.000254	0.49	0.22	Blood osmolality (transformed sodium);	chr2:161824713	chr2:161244739~161249050:+
THCA	cis	rs7493	0.755	rs13223537	ENSG00000233942.1	AC004012.1	-4.8	2.14e-06	0.000254	-0.35	-0.22	Yu-Zhi constitution type in type 2 diabetes;	chr7:95336855	chr7:95471835~95473998:+
THCA	cis	rs9487094	0.67	rs12197838	ENSG00000223537.2	RP5-919F19.5	-4.8	2.14e-06	0.000254	-0.22	-0.22	Height;	chr6:109672088	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs6911700	ENSG00000223537.2	RP5-919F19.5	-4.8	2.14e-06	0.000254	-0.22	-0.22	Height;	chr6:109676091	chr6:109487906~109506800:+
THCA	cis	rs10090774	0.932	rs11786859	ENSG00000279766.1	RP11-642A1.2	-4.8	2.14e-06	0.000254	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140974782	chr8:140572142~140572812:-
THCA	cis	rs1150668	0.799	rs7206	ENSG00000176933.5	TOB2P1	-4.8	2.14e-06	0.000254	-0.24	-0.22	Pubertal anthropometrics;	chr6:28233360	chr6:28217643~28218634:-
THCA	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-4.8	2.14e-06	0.000254	-0.3	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
THCA	cis	rs7088591	1	rs1029919	ENSG00000276818.1	AC026393.1	4.8	2.14e-06	0.000254	0.44	0.22	Blood pressure;	chr10:58015973	chr10:57095699~57095781:+
THCA	cis	rs72843506	0.722	rs9902683	ENSG00000231258.2	ZSWIM5P2	4.8	2.14e-06	0.000254	0.32	0.22	Schizophrenia;	chr17:20112115	chr17:20583758~20591180:-
THCA	cis	rs62246343	0.719	rs73115804	ENSG00000254485.4	RP11-380O24.1	4.8	2.14e-06	0.000254	0.29	0.22	Fibrinogen levels;	chr3:9399858	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.719	rs62246276	ENSG00000254485.4	RP11-380O24.1	4.8	2.14e-06	0.000254	0.29	0.22	Fibrinogen levels;	chr3:9403489	chr3:9292588~9363303:-
THCA	cis	rs1836229	0.558	rs10977314	ENSG00000225706.1	PTPRD-AS1	-4.8	2.14e-06	0.000254	-0.26	-0.22	Restless legs syndrome;	chr9:8833510	chr9:8858130~8862255:+
THCA	cis	rs7403037	0.837	rs2133278	ENSG00000260760.1	PWRN3	4.8	2.14e-06	0.000254	0.26	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24227131	chr15:24441127~24447967:+
THCA	cis	rs16976116	0.901	rs16976177	ENSG00000279145.1	RP11-547D13.1	4.8	2.14e-06	0.000254	0.25	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55217062	chr15:55171972~55178175:-
THCA	cis	rs9380516	0.853	rs4713879	ENSG00000228559.1	RP3-340B19.3	-4.8	2.14e-06	0.000254	-0.32	-0.22	Hepatitis C induced liver fibrosis;	chr6:35522461	chr6:35544632~35545669:+
THCA	cis	rs2067615	0.542	rs10861654	ENSG00000260329.1	RP11-412D9.4	-4.8	2.14e-06	0.000254	-0.2	-0.22	Heart rate;	chr12:106729118	chr12:106954029~106955497:-
THCA	cis	rs1979679	0.766	rs10843197	ENSG00000278733.1	RP11-425D17.1	-4.8	2.14e-06	0.000254	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28518308	chr12:28185625~28186190:-
THCA	cis	rs11723261	0.621	rs3829	ENSG00000211553.1	AC253576.2	-4.8	2.14e-06	0.000254	-0.32	-0.22	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:136461~136568:+
THCA	cis	rs11723261	0.621	rs57013142	ENSG00000211553.1	AC253576.2	-4.8	2.14e-06	0.000254	-0.32	-0.22	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:136461~136568:+
THCA	cis	rs6686842	0.56	rs17357905	ENSG00000235358.1	RP11-399E6.1	4.8	2.14e-06	0.000254	0.29	0.22	Height;	chr1:41018645	chr1:41242373~41284861:+
THCA	cis	rs11088226	1	rs2833889	ENSG00000186842.4	LINC00846	4.8	2.15e-06	0.000254	0.29	0.22	Gastritis;	chr21:32555458	chr21:32572238~32575881:-
THCA	cis	rs10090774	0.965	rs13258775	ENSG00000279766.1	RP11-642A1.2	-4.8	2.15e-06	0.000254	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140984141	chr8:140572142~140572812:-
THCA	cis	rs9625935	0.957	rs8136147	ENSG00000279159.1	RP3-394A18.1	-4.8	2.15e-06	0.000254	-0.17	-0.22	Tonsillectomy;	chr22:29908245	chr22:29978950~30028236:-
THCA	cis	rs10090774	0.932	rs7816620	ENSG00000279766.1	RP11-642A1.2	-4.8	2.15e-06	0.000254	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994015	chr8:140572142~140572812:-
THCA	cis	rs7647973	0.58	rs12637576	ENSG00000229759.1	MRPS18AP1	4.8	2.15e-06	0.000254	0.28	0.22	Menarche (age at onset);	chr3:49199901	chr3:48256350~48256938:-
THCA	cis	rs4415084	0.716	rs6451775	ENSG00000272335.1	RP11-53O19.3	4.8	2.15e-06	0.000254	0.18	0.22	Breast cancer;	chr5:44836686	chr5:44826076~44828592:+
THCA	cis	rs4948275	0.68	rs2650722	ENSG00000237233.2	TMEM26-AS1	-4.8	2.15e-06	0.000254	-0.29	-0.22	Night sleep phenotypes;	chr10:61545931	chr10:61452639~61481956:+
THCA	cis	rs28374715	0.532	rs11070328	ENSG00000247556.5	OIP5-AS1	4.8	2.15e-06	0.000254	0.21	0.22	Ulcerative colitis;	chr15:41359371	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.532	rs28535540	ENSG00000247556.5	OIP5-AS1	4.8	2.15e-06	0.000254	0.21	0.22	Ulcerative colitis;	chr15:41367079	chr15:41283990~41309737:+
THCA	cis	rs7914558	0.966	rs56946876	ENSG00000236937.2	PTGES3P4	4.8	2.15e-06	0.000254	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.933	rs12763665	ENSG00000236937.2	PTGES3P4	4.8	2.15e-06	0.000254	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs10786721	ENSG00000236937.2	PTGES3P4	4.8	2.15e-06	0.000254	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102845595~102845950:+
THCA	cis	rs17767392	0.834	rs55863348	ENSG00000259146.3	RP1-261D10.2	4.8	2.15e-06	0.000254	0.28	0.22	Mitral valve prolapse;	chr14:71257576	chr14:71292729~71321814:-
THCA	cis	rs8077577	0.747	rs11078415	ENSG00000273018.4	CTD-2303H24.2	-4.8	2.15e-06	0.000254	-0.31	-0.22	Obesity-related traits;	chr17:18352184	chr17:18511221~18551705:-
THCA	cis	rs11673344	0.523	rs36096221	ENSG00000276846.1	CTD-3220F14.3	4.8	2.15e-06	0.000254	0.17	0.22	Obesity-related traits;	chr19:37060838	chr19:37314868~37315620:-
THCA	cis	rs7614311	0.681	rs3774708	ENSG00000271843.1	RP11-245J9.5	-4.8	2.15e-06	0.000254	-0.37	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63895873	chr3:64008082~64008692:-
THCA	cis	rs930395	0.514	rs9791059	ENSG00000272335.1	RP11-53O19.3	4.8	2.15e-06	0.000255	0.18	0.22	Breast cancer;	chr5:44900345	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs4457088	ENSG00000272335.1	RP11-53O19.3	4.8	2.15e-06	0.000255	0.18	0.22	Breast cancer;	chr5:44900852	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs9791056	ENSG00000272335.1	RP11-53O19.3	4.8	2.15e-06	0.000255	0.18	0.22	Breast cancer;	chr5:44903789	chr5:44826076~44828592:+
THCA	cis	rs9925964	0.933	rs12448321	ENSG00000260911.2	RP11-196G11.2	-4.8	2.15e-06	0.000255	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036959	chr16:31043150~31049868:+
THCA	cis	rs4934494	0.573	rs67157720	ENSG00000232936.4	RP11-80H5.2	4.8	2.15e-06	0.000255	0.3	0.22	Red blood cell count;	chr10:89820415	chr10:89645282~89650667:+
THCA	cis	rs250518	0.926	rs11953054	ENSG00000272081.1	CTD-2376I4.2	4.8	2.15e-06	0.000255	0.28	0.22	Mean corpuscular hemoglobin concentration;	chr5:72746876	chr5:72955206~72955699:-
THCA	cis	rs7119	0.717	rs12916973	ENSG00000259362.2	RP11-307C19.1	4.8	2.15e-06	0.000255	0.31	0.22	Type 2 diabetes;	chr15:77515757	chr15:77525540~77534110:+
THCA	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	4.8	2.15e-06	0.000255	0.27	0.22	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
THCA	cis	rs2337406	0.587	rs2583291	ENSG00000211974.3	IGHV2-70	4.8	2.15e-06	0.000255	0.21	0.22	Alzheimer's disease (late onset);	chr14:106649293	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.587	rs2516886	ENSG00000211974.3	IGHV2-70	4.8	2.15e-06	0.000255	0.21	0.22	Alzheimer's disease (late onset);	chr14:106649674	chr14:106723574~106724093:-
THCA	cis	rs736408	0.609	rs2268025	ENSG00000243224.1	RP5-1157M23.2	-4.8	2.15e-06	0.000255	-0.24	-0.22	Bipolar disorder;	chr3:52761208	chr3:52239258~52241097:+
THCA	cis	rs3845817	0.801	rs2438102	ENSG00000237979.1	AC007389.1	4.8	2.15e-06	0.000255	0.25	0.22	Bipolar disorder;	chr2:65530223	chr2:65500993~65502138:-
THCA	cis	rs35740288	0.822	rs17637142	ENSG00000259295.5	CSPG4P12	4.8	2.15e-06	0.000255	0.34	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85697272	chr15:85191438~85213905:+
THCA	cis	rs2120243	0.504	rs114107407	ENSG00000241770.1	RP11-555M1.3	-4.8	2.15e-06	0.000255	-0.27	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157344846	chr3:157163452~157169133:+
THCA	cis	rs651907	0.535	rs13094753	ENSG00000244119.1	PDCL3P4	4.8	2.15e-06	0.000255	0.2	0.22	Colorectal cancer;	chr3:101806238	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs11716558	ENSG00000244119.1	PDCL3P4	4.8	2.15e-06	0.000255	0.2	0.22	Colorectal cancer;	chr3:101809637	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs12633089	ENSG00000244119.1	PDCL3P4	4.8	2.15e-06	0.000255	0.2	0.22	Colorectal cancer;	chr3:101809919	chr3:101712472~101713191:+
THCA	cis	rs8067545	0.532	rs12936794	ENSG00000261033.1	RP11-209D14.2	-4.8	2.15e-06	0.000255	-0.31	-0.22	Schizophrenia;	chr17:20009257	chr17:20008051~20009234:-
THCA	cis	rs875971	0.522	rs6960048	ENSG00000229886.1	RP5-1132H15.3	4.8	2.15e-06	0.000255	0.22	0.22	Aortic root size;	chr7:65943052	chr7:66025126~66031544:-
THCA	cis	rs4722166	0.695	rs56061963	ENSG00000225541.1	AC002480.5	-4.8	2.15e-06	0.000255	-0.27	-0.22	Lung cancer;	chr7:22760778	chr7:22571607~22661792:-
THCA	cis	rs2282300	0.637	rs10767841	ENSG00000242353.1	RP4-710M3.1	-4.8	2.15e-06	0.000255	-0.17	-0.22	Morning vs. evening chronotype;	chr11:30406728	chr11:30368148~30368646:+
THCA	cis	rs2282300	0.637	rs13642	ENSG00000242353.1	RP4-710M3.1	-4.8	2.15e-06	0.000255	-0.17	-0.22	Morning vs. evening chronotype;	chr11:30410673	chr11:30368148~30368646:+
THCA	cis	rs8062405	0.558	rs231976	ENSG00000278665.1	RP11-666O2.4	4.8	2.15e-06	0.000255	0.23	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28599241~28601881:-
THCA	cis	rs11992162	0.967	rs4840601	ENSG00000227888.4	FAM66A	4.8	2.15e-06	0.000255	0.28	0.22	Monocyte count;	chr8:11971221	chr8:12362019~12388296:+
THCA	cis	rs8028182	0.636	rs6495182	ENSG00000260269.4	CTD-2323K18.1	-4.8	2.15e-06	0.000255	-0.32	-0.22	Sudden cardiac arrest;	chr15:75522047	chr15:75527150~75601205:-
THCA	cis	rs7688540	0.76	rs28460123	ENSG00000250892.1	RP11-1365D11.1	4.8	2.16e-06	0.000255	0.3	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:201409~205009:-
THCA	cis	rs875971	0.54	rs4717275	ENSG00000229886.1	RP5-1132H15.3	-4.8	2.16e-06	0.000255	-0.22	-0.22	Aortic root size;	chr7:65800193	chr7:66025126~66031544:-
THCA	cis	rs17270561	0.609	rs2000351	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25759555	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4712968	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25760116	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs7769908	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25760311	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs7770037	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25760363	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9348695	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25762782	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs2000350	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25762926	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs1318016	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25764476	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs1892245	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25764605	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.583	rs6937800	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25765715	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs3778272	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25767433	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs2275905	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25767878	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs1892248	ENSG00000272462.2	U91328.19	-4.8	2.16e-06	0.000255	-0.18	-0.22	Iron status biomarkers;	chr6:25768686	chr6:25992662~26001775:+
THCA	cis	rs1559040	0.858	rs11695936	ENSG00000272156.1	RP11-477N3.1	-4.8	2.16e-06	0.000255	-0.34	-0.22	Sudden cardiac arrest;	chr2:54090135	chr2:54082554~54085066:+
THCA	cis	rs2797160	0.651	rs1269176	ENSG00000226409.1	RP11-735G4.1	-4.8	2.16e-06	0.000255	-0.26	-0.22	Endometrial cancer;	chr6:125708536	chr6:125370211~125374324:-
THCA	cis	rs12908161	1	rs3803405	ENSG00000275120.1	RP11-182J1.17	4.8	2.16e-06	0.000255	0.26	0.22	Schizophrenia;	chr15:84840409	chr15:84599434~84606463:-
THCA	cis	rs4722166	0.532	rs6963866	ENSG00000179428.2	AC073072.5	-4.8	2.16e-06	0.000255	-0.24	-0.22	Lung cancer;	chr7:22717722	chr7:22725395~22727620:-
THCA	cis	rs889398	0.935	rs1364063	ENSG00000226232.7	RP11-419C5.2	4.8	2.16e-06	0.000256	0.21	0.22	Body mass index;	chr16:69554669	chr16:69976388~69996188:-
THCA	cis	rs3764400	0.508	rs2240119	ENSG00000278765.1	RP5-890E16.5	-4.8	2.16e-06	0.000256	-0.39	-0.22	Body mass index;	chr17:48033806	chr17:48066704~48067293:-
THCA	cis	rs10483853	0.767	rs10136726	ENSG00000258695.2	RP3-414A15.2	4.8	2.16e-06	0.000256	0.3	0.22	Coronary artery calcification;	chr14:73345517	chr14:73522878~73530610:+
THCA	cis	rs734999	0.87	rs2147905	ENSG00000225931.3	RP3-395M20.7	-4.8	2.16e-06	0.000256	-0.26	-0.22	Ulcerative colitis;	chr1:2551482	chr1:2566410~2569888:+
THCA	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	4.8	2.16e-06	0.000256	0.24	0.22	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
THCA	cis	rs7493	0.851	rs11770903	ENSG00000233942.1	AC004012.1	4.8	2.16e-06	0.000256	0.32	0.22	Yu-Zhi constitution type in type 2 diabetes;	chr7:95397015	chr7:95471835~95473998:+
THCA	cis	rs5006884	0.715	rs7113385	ENSG00000167355.6	AC104389.28	-4.8	2.16e-06	0.000256	-0.34	-0.22	Fetal hemoglobin levels;	chr11:5366200	chr11:5304976~5505652:-
THCA	cis	rs12908161	0.853	rs11633788	ENSG00000259295.5	CSPG4P12	4.8	2.16e-06	0.000256	0.31	0.22	Schizophrenia;	chr15:84761911	chr15:85191438~85213905:+
THCA	cis	rs4415084	0.716	rs10462081	ENSG00000272335.1	RP11-53O19.3	-4.8	2.16e-06	0.000256	-0.18	-0.22	Breast cancer;	chr5:44800563	chr5:44826076~44828592:+
THCA	cis	rs202072	0.585	rs536208	ENSG00000272379.1	RP1-257A7.5	4.8	2.16e-06	0.000256	0.38	0.22	HIV-1 viral setpoint;	chr6:13256715	chr6:13290018~13290490:-
THCA	cis	rs11992162	0.967	rs7836456	ENSG00000206014.6	OR7E161P	-4.8	2.16e-06	0.000256	-0.25	-0.22	Monocyte count;	chr8:11971666	chr8:11928597~11929563:-
THCA	cis	rs1823913	0.614	rs12616167	ENSG00000280083.1	RP11-317J9.1	4.8	2.16e-06	0.000256	0.25	0.22	Obesity-related traits;	chr2:191311274	chr2:191154118~191156070:-
THCA	cis	rs2058059	0.636	rs2961005	ENSG00000205578.5	POM121B	4.8	2.16e-06	0.000256	0.33	0.22	Subcutaneous adipose tissue;	chr7:72675517	chr7:73293497~73301161:+
THCA	cis	rs8064024	0.59	rs7186142	ENSG00000267077.1	RP11-127I20.5	4.8	2.16e-06	0.000256	0.25	0.22	Cancer;	chr16:4850986	chr16:4795265~4796532:-
THCA	cis	rs13113518	1	rs4864542	ENSG00000273257.1	RP11-177J6.1	-4.8	2.16e-06	0.000256	-0.28	-0.22	Height;	chr4:55487920	chr4:55387949~55388271:+
THCA	cis	rs801193	0.742	rs9969300	ENSG00000229886.1	RP5-1132H15.3	-4.8	2.16e-06	0.000256	-0.22	-0.22	Aortic root size;	chr7:66316659	chr7:66025126~66031544:-
THCA	cis	rs3020736	0.5	rs4147641	ENSG00000273366.1	CTA-989H11.1	4.8	2.16e-06	0.000256	0.27	0.22	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs4147640	ENSG00000273366.1	CTA-989H11.1	4.8	2.16e-06	0.000256	0.27	0.22	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs1801311	ENSG00000273366.1	CTA-989H11.1	4.8	2.16e-06	0.000256	0.27	0.22	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42278188~42278846:+
THCA	cis	rs1023500	0.507	rs6002600	ENSG00000273366.1	CTA-989H11.1	4.8	2.16e-06	0.000256	0.27	0.22	Schizophrenia;	chr22:42092902	chr22:42278188~42278846:+
THCA	cis	rs7702057	0.53	rs3087831	ENSG00000272265.1	CTD-2287O16.4	4.8	2.16e-06	0.000256	0.38	0.22	Amyotrophic lateral sclerosis;	chr5:116084901	chr5:116078110~116078570:-
THCA	cis	rs7702057	0.53	rs3087832	ENSG00000272265.1	CTD-2287O16.4	4.8	2.16e-06	0.000256	0.38	0.22	Amyotrophic lateral sclerosis;	chr5:116084931	chr5:116078110~116078570:-
THCA	cis	rs7702057	0.53	rs73780832	ENSG00000272265.1	CTD-2287O16.4	4.8	2.16e-06	0.000256	0.38	0.22	Amyotrophic lateral sclerosis;	chr5:116085208	chr5:116078110~116078570:-
THCA	cis	rs34761973	0.569	rs7223411	ENSG00000272911.1	RP11-74E22.6	4.8	2.16e-06	0.000256	0.31	0.22	Depressive symptoms (multi-trait analysis);Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis);	chr17:2673883	chr17:2688473~2688960:+
THCA	cis	rs593531	0.513	rs7930193	ENSG00000212961.4	HNRNPA1P40	-4.8	2.16e-06	0.000256	-0.27	-0.22	Neuroticism;	chr11:74320512	chr11:74354443~74355720:+
THCA	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	4.8	2.16e-06	0.000256	0.31	0.22	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
THCA	cis	rs2221433	0.889	rs1394564	ENSG00000260310.1	RP11-27M24.2	4.8	2.16e-06	0.000256	0.28	0.22	Eating disorders;	chr16:10583324	chr16:10576499~10578183:-
THCA	cis	rs2243123	0.602	rs11927521	ENSG00000244040.4	IL12A-AS1	4.8	2.16e-06	0.000256	0.29	0.22	Multiple sclerosis;	chr3:159999298	chr3:159913400~160225299:-
THCA	cis	rs228614	0.51	rs223405	ENSG00000248971.2	KRT8P46	-4.8	2.17e-06	0.000256	-0.27	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102728746~102730171:-
THCA	cis	rs3770081	1	rs2278086	ENSG00000273080.1	RP11-301O19.1	-4.8	2.17e-06	0.000256	-0.48	-0.22	Facial emotion recognition (sad faces);	chr2:86054782	chr2:86195590~86196049:+
THCA	cis	rs4794202	0.534	rs6503875	ENSG00000264920.1	RP11-6N17.4	-4.8	2.17e-06	0.000257	-0.28	-0.22	Alzheimer's disease (cognitive decline);	chr17:47838029	chr17:47891255~47895812:-
THCA	cis	rs12134133	1	rs61822697	ENSG00000237074.1	RP11-6J21.2	4.8	2.17e-06	0.000257	0.23	0.22	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207249067~207309121:+
THCA	cis	rs13113518	1	rs9312661	ENSG00000273257.1	RP11-177J6.1	4.8	2.17e-06	0.000257	0.28	0.22	Height;	chr4:55476159	chr4:55387949~55388271:+
THCA	cis	rs8020095	0.571	rs7148044	ENSG00000258561.1	RP11-72M17.1	-4.8	2.17e-06	0.000257	-0.28	-0.22	Depression (quantitative trait);	chr14:67155853	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs7148425	ENSG00000258561.1	RP11-72M17.1	-4.8	2.17e-06	0.000257	-0.28	-0.22	Depression (quantitative trait);	chr14:67156099	chr14:66212810~66509394:-
THCA	cis	rs4535700	0.504	rs66528253	ENSG00000226278.1	PSPHP1	4.8	2.17e-06	0.000257	0.25	0.22	Macular telangiectasia type 2;	chr7:55929070	chr7:55764797~55773288:+
THCA	cis	rs4535700	0.501	rs11765577	ENSG00000226278.1	PSPHP1	4.8	2.17e-06	0.000257	0.25	0.22	Macular telangiectasia type 2;	chr7:55930245	chr7:55764797~55773288:+
THCA	cis	rs7829975	0.511	rs2980423	ENSG00000253981.4	ALG1L13P	4.8	2.17e-06	0.000257	0.21	0.22	Mood instability;	chr8:8285053	chr8:8236003~8244667:-
THCA	cis	rs2742234	0.59	rs741968	ENSG00000273008.1	RP11-351D16.3	-4.8	2.17e-06	0.000257	-0.2	-0.22	Hirschsprung disease;	chr10:43116260	chr10:43136824~43138334:-
THCA	cis	rs9283706	0.689	rs11956654	ENSG00000229666.1	MAST4-AS1	-4.8	2.17e-06	0.000257	-0.31	-0.22	Coronary artery disease;	chr5:67022368	chr5:67001383~67003953:-
THCA	cis	rs3750082	0.889	rs1817050	ENSG00000231952.3	DPY19L1P2	4.8	2.17e-06	0.000257	0.27	0.22	Glomerular filtration rate (creatinine);	chr7:32892294	chr7:32812757~32838570:+
THCA	cis	rs6472827	0.904	rs6986922	ENSG00000253983.2	RP1-16A9.1	4.8	2.17e-06	0.000257	0.39	0.22	Uterine fibroids;	chr8:74208158	chr8:74199396~74208441:+
THCA	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	4.8	2.17e-06	0.000257	0.15	0.22	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
THCA	cis	rs6479874	1	rs6479874	ENSG00000223502.1	RP11-96B5.3	4.8	2.17e-06	0.000257	0.24	0.22	Migraine;	chr10:51029595	chr10:51062579~51068553:-
THCA	cis	rs1150668	0.799	rs1150707	ENSG00000176933.5	TOB2P1	-4.8	2.17e-06	0.000257	-0.24	-0.22	Pubertal anthropometrics;	chr6:28229827	chr6:28217643~28218634:-
THCA	cis	rs3738443	0.904	rs61840000	ENSG00000259865.1	RP11-488L18.10	4.8	2.17e-06	0.000257	0.24	0.22	Alcohol dependence;	chr1:247199027	chr1:247187281~247188526:-
THCA	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	4.8	2.17e-06	0.000257	0.24	0.22	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
THCA	cis	rs5758659	0.714	rs5751216	ENSG00000182057.4	OGFRP1	-4.8	2.17e-06	0.000257	-0.25	-0.22	Cognitive function;	chr22:42112933	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.714	rs5758589	ENSG00000182057.4	OGFRP1	-4.8	2.17e-06	0.000257	-0.25	-0.22	Cognitive function;	chr22:42122378	chr22:42269753~42275196:+
THCA	cis	rs12962334	0.508	rs9966036	ENSG00000265939.1	UBE2CP2	4.8	2.17e-06	0.000257	0.25	0.22	Breast cancer;	chr18:22936105	chr18:22900486~22900995:-
THCA	cis	rs7647973	0.58	rs7652746	ENSG00000229759.1	MRPS18AP1	-4.8	2.17e-06	0.000257	-0.27	-0.22	Menarche (age at onset);	chr3:49224874	chr3:48256350~48256938:-
THCA	cis	rs9990333	0.762	rs6810239	ENSG00000231464.1	AC024937.4	-4.8	2.17e-06	0.000257	-0.26	-0.22	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085292	chr3:195996738~195998233:+
THCA	cis	rs5742933	1	rs3791770	ENSG00000253559.1	OSGEPL1-AS1	-4.8	2.17e-06	0.000257	-0.27	-0.22	Ferritin levels;	chr2:189809109	chr2:189762704~189765556:+
THCA	cis	rs5742933	0.948	rs62184286	ENSG00000253559.1	OSGEPL1-AS1	-4.8	2.17e-06	0.000257	-0.27	-0.22	Ferritin levels;	chr2:189812147	chr2:189762704~189765556:+
THCA	cis	rs2797160	0.904	rs1418637	ENSG00000237742.5	RP11-624M8.1	-4.8	2.17e-06	0.000257	-0.18	-0.22	Endometrial cancer;	chr6:125671407	chr6:125578558~125749190:-
THCA	cis	rs6921919	0.583	rs7759191	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs7764737	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs9461458	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.609	rs9468365	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs1361385	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs1416918	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs9468367	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs9461459	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs28360638	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs9468368	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs2041230	ENSG00000280107.1	AL022393.9	-4.8	2.17e-06	0.000257	-0.22	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28170845~28172521:+
THCA	cis	rs9393777	0.778	rs13212921	ENSG00000219392.1	RP1-265C24.5	-4.8	2.17e-06	0.000257	-0.41	-0.22	Intelligence (multi-trait analysis);	chr6:27237643	chr6:28115628~28116551:+
THCA	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-4.8	2.18e-06	0.000257	-0.22	-0.22	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
THCA	cis	rs30380	1	rs30379	ENSG00000272109.1	CTD-2260A17.3	-4.8	2.18e-06	0.000257	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96804353~96806105:+
THCA	cis	rs30380	1	rs30380	ENSG00000272109.1	CTD-2260A17.3	-4.8	2.18e-06	0.000257	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96804353~96806105:+
THCA	cis	rs9326248	0.516	rs6589577	ENSG00000280143.1	AP000892.6	4.8	2.18e-06	0.000257	0.36	0.22	Blood protein levels;	chr11:116879261	chr11:117204967~117210292:+
THCA	cis	rs748802	0.664	rs55726778	ENSG00000235387.1	LINC00961	-4.8	2.18e-06	0.000257	-0.24	-0.22	Resting heart rate;	chr9:35921306	chr9:35909483~35911686:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000164669.11	INTS4P1	4.8	2.18e-06	0.000257	0.27	0.22	Aortic root size;	chr7:66018255	chr7:65141225~65234216:+
THCA	cis	rs17767392	0.794	rs61989259	ENSG00000259146.3	RP1-261D10.2	4.8	2.18e-06	0.000258	0.29	0.22	Mitral valve prolapse;	chr14:71266789	chr14:71292729~71321814:-
THCA	cis	rs944289	0.708	rs7158599	ENSG00000258844.1	RP11-259K15.2	4.8	2.18e-06	0.000258	0.2	0.22	Thyroid cancer;	chr14:36111976	chr14:36214607~36235608:+
THCA	cis	rs4604234	0.614	rs11962441	ENSG00000272129.1	RP11-250B2.6	-4.8	2.18e-06	0.000258	-0.53	-0.22	Cancer;	chr6:80155705	chr6:80355424~80356859:+
THCA	cis	rs1635	0.655	rs9368532	ENSG00000216901.1	AL022393.7	4.8	2.18e-06	0.000258	0.49	0.22	Schizophrenia;	chr6:27814232	chr6:28176188~28176674:+
THCA	cis	rs7711186	0.708	rs10073925	ENSG00000252464.1	RN7SKP70	4.8	2.18e-06	0.000258	0.23	0.22	Urate levels in obese individuals;	chr5:178614911	chr5:178619728~178619998:-
THCA	cis	rs9625935	0.917	rs5763630	ENSG00000279159.1	RP3-394A18.1	4.8	2.18e-06	0.000258	0.17	0.22	Tonsillectomy;	chr22:29950367	chr22:29978950~30028236:-
THCA	cis	rs793571	0.505	rs28722857	ENSG00000245975.2	RP11-30K9.6	4.8	2.18e-06	0.000258	0.25	0.22	Schizophrenia;	chr15:58633876	chr15:58768072~58770974:-
THCA	cis	rs972578	0.765	rs4822208	ENSG00000274717.1	RP1-47A17.1	-4.8	2.18e-06	0.000258	-0.22	-0.22	Mean platelet volume;	chr22:42865217	chr22:42791814~42794313:-
THCA	cis	rs6142102	0.651	rs1015361	ENSG00000275784.1	RP5-1125A11.6	4.8	2.18e-06	0.000258	0.23	0.22	Skin pigmentation;	chr20:34150880	chr20:33989480~33991818:-
THCA	cis	rs8020095	0.571	rs7158228	ENSG00000258561.1	RP11-72M17.1	-4.8	2.18e-06	0.000258	-0.28	-0.22	Depression (quantitative trait);	chr14:67096006	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs7157394	ENSG00000258561.1	RP11-72M17.1	-4.8	2.18e-06	0.000258	-0.28	-0.22	Depression (quantitative trait);	chr14:67096052	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs7157418	ENSG00000258561.1	RP11-72M17.1	-4.8	2.18e-06	0.000258	-0.28	-0.22	Depression (quantitative trait);	chr14:67096098	chr14:66212810~66509394:-
THCA	cis	rs1707322	1	rs1707303	ENSG00000281133.1	AL355480.3	4.8	2.18e-06	0.000258	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45580892~45580996:-
THCA	cis	rs3820928	0.839	rs13404750	ENSG00000212391.1	SNORA48	-4.8	2.18e-06	0.000258	-0.23	-0.22	Pulmonary function;	chr2:227011413	chr2:226968989~226969122:-
THCA	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-4.8	2.18e-06	0.000258	-0.24	-0.22	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-4.8	2.18e-06	0.000258	-0.24	-0.22	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-4.8	2.18e-06	0.000258	-0.24	-0.22	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	4.8	2.18e-06	0.000258	0.24	0.22	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	4.8	2.18e-06	0.000258	0.24	0.22	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
THCA	cis	rs7474896	0.537	rs2505255	ENSG00000263064.2	RP11-291L22.7	4.8	2.18e-06	0.000258	0.29	0.22	Obesity (extreme);	chr10:38070714	chr10:38448689~38448949:+
THCA	cis	rs11955398	0.502	rs10471502	ENSG00000272308.1	RP11-231G3.1	-4.8	2.18e-06	0.000258	-0.23	-0.22	Intelligence (multi-trait analysis);	chr5:61073256	chr5:60866457~60866935:-
THCA	cis	rs8031584	0.958	rs7176569	ENSG00000178081.11	ULK4P3	-4.8	2.18e-06	0.000258	-0.28	-0.22	Huntington's disease progression;	chr15:30952292	chr15:30103720~30131757:+
THCA	cis	rs1048886	0.938	rs9294874	ENSG00000271967.1	RP11-134K13.4	-4.8	2.18e-06	0.000258	-0.22	-0.22	Type 2 diabetes;	chr6:70483110	chr6:70596438~70596980:+
THCA	cis	rs10833905	0.756	rs2303514	ENSG00000246225.5	RP11-17A1.3	-4.8	2.18e-06	0.000258	-0.32	-0.22	Sudden cardiac arrest;	chr11:22983988	chr11:22829380~22945393:+
THCA	cis	rs12935418	0.616	rs9936366	ENSG00000278985.1	RP11-303E16.9	4.8	2.18e-06	0.000258	0.24	0.22	Mean corpuscular volume;	chr16:81011657	chr16:80982319~80984094:-
THCA	cis	rs10090774	0.87	rs10093977	ENSG00000279766.1	RP11-642A1.2	-4.8	2.18e-06	0.000258	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141000585	chr8:140572142~140572812:-
THCA	cis	rs944289	0.74	rs12891345	ENSG00000258844.1	RP11-259K15.2	4.8	2.18e-06	0.000258	0.2	0.22	Thyroid cancer;	chr14:36126977	chr14:36214607~36235608:+
THCA	cis	rs539096	0.5	rs2527776	ENSG00000237950.1	RP11-7O11.3	4.8	2.19e-06	0.000258	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43879620	chr1:43944370~43946551:-
THCA	cis	rs539096	0.5	rs803678	ENSG00000237950.1	RP11-7O11.3	4.8	2.19e-06	0.000258	0.19	0.22	Intelligence (multi-trait analysis);	chr1:43885226	chr1:43944370~43946551:-
THCA	cis	rs62246343	0.719	rs6767213	ENSG00000254485.4	RP11-380O24.1	4.8	2.19e-06	0.000259	0.29	0.22	Fibrinogen levels;	chr3:9415588	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.719	rs62246305	ENSG00000254485.4	RP11-380O24.1	4.8	2.19e-06	0.000259	0.29	0.22	Fibrinogen levels;	chr3:9416565	chr3:9292588~9363303:-
THCA	cis	rs1536827	1	rs1536827	ENSG00000278518.1	RP11-108K14.12	4.8	2.19e-06	0.000259	0.45	0.22	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr10:133492654	chr10:133526259~133527513:-
THCA	cis	rs7010876	0.537	rs1504804	ENSG00000253553.4	RP11-586K2.1	4.8	2.19e-06	0.000259	0.22	0.22	Schizophrenia;	chr8:88401328	chr8:88326836~88737134:+
THCA	cis	rs17360053	1	rs7534624	ENSG00000218510.5	LINC00339	4.8	2.19e-06	0.000259	0.23	0.22	Obesity-related traits;	chr1:22168134	chr1:22025188~22031223:+
THCA	cis	rs6723108	0.654	rs520449	ENSG00000224043.6	CCNT2-AS1	-4.8	2.19e-06	0.000259	-0.26	-0.22	Type 2 diabetes;	chr2:134538048	chr2:134735464~134918710:-
THCA	cis	rs853679	0.546	rs200977	ENSG00000226314.6	ZNF192P1	-4.8	2.19e-06	0.000259	-0.37	-0.22	Depression;	chr6:27886523	chr6:28161781~28169594:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000213640.3	EEF1DP4	-4.79	2.19e-06	0.000259	-0.25	-0.22	Aortic root size;	chr7:65827018	chr7:64862999~64864370:+
THCA	cis	rs35934224	0.783	rs12106549	ENSG00000232926.1	AC000078.5	4.79	2.19e-06	0.000259	0.24	0.22	Glaucoma (primary open-angle);	chr22:19859464	chr22:19887289~19887970:+
THCA	cis	rs964611	0.882	rs4775754	ENSG00000259488.2	RP11-154J22.1	4.79	2.19e-06	0.000259	0.19	0.22	Metabolite levels (Pyroglutamine);	chr15:48369146	chr15:48312353~48331856:-
THCA	cis	rs3796352	1	rs34340609	ENSG00000242142.1	SERBP1P3	-4.79	2.19e-06	0.000259	-0.37	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53043260	chr3:53064283~53065091:-
THCA	cis	rs4950322	0.57	rs113498894	ENSG00000271721.1	RP11-337C18.9	4.79	2.19e-06	0.000259	0.25	0.22	Protein quantitative trait loci;	chr1:147318880	chr1:147175602~147177740:+
THCA	cis	rs3764400	0.508	rs72823519	ENSG00000278765.1	RP5-890E16.5	4.79	2.19e-06	0.000259	0.38	0.22	Body mass index;	chr17:47984519	chr17:48066704~48067293:-
THCA	cis	rs481331	0.799	rs7893674	ENSG00000215146.4	RP11-313J2.1	4.79	2.19e-06	0.000259	0.35	0.22	Systemic juvenile idiopathic arthritis;	chr10:42478995	chr10:42331866~42367974:-
THCA	cis	rs4535700	0.501	rs28828764	ENSG00000226278.1	PSPHP1	4.79	2.19e-06	0.000259	0.25	0.22	Macular telangiectasia type 2;	chr7:55920986	chr7:55764797~55773288:+
THCA	cis	rs4535700	0.501	rs2135116	ENSG00000226278.1	PSPHP1	4.79	2.19e-06	0.000259	0.25	0.22	Macular telangiectasia type 2;	chr7:55923451	chr7:55764797~55773288:+
THCA	cis	rs4535700	0.543	rs2174459	ENSG00000226278.1	PSPHP1	4.79	2.19e-06	0.000259	0.25	0.22	Macular telangiectasia type 2;	chr7:55923600	chr7:55764797~55773288:+
THCA	cis	rs2797160	0.904	rs2326292	ENSG00000237742.5	RP11-624M8.1	-4.79	2.19e-06	0.000259	-0.18	-0.22	Endometrial cancer;	chr6:125678528	chr6:125578558~125749190:-
THCA	cis	rs10833905	0.756	rs10833866	ENSG00000246225.5	RP11-17A1.3	-4.79	2.19e-06	0.000259	-0.31	-0.22	Sudden cardiac arrest;	chr11:22955270	chr11:22829380~22945393:+
THCA	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-4.79	2.19e-06	0.000259	-0.18	-0.22	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
THCA	cis	rs58605417	0.534	rs821116	ENSG00000253553.4	RP11-586K2.1	4.79	2.19e-06	0.000259	0.22	0.22	Schizophrenia;	chr8:88427224	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.534	rs1685546	ENSG00000253553.4	RP11-586K2.1	4.79	2.19e-06	0.000259	0.22	0.22	Schizophrenia;	chr8:88447287	chr8:88326836~88737134:+
THCA	cis	rs6012564	0.963	rs6063359	ENSG00000230758.1	SNAP23P	4.79	2.19e-06	0.000259	0.26	0.22	Anger;	chr20:49128547	chr20:49038357~49038602:-
THCA	cis	rs7618915	0.571	rs33964154	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.19e-06	0.000259	-0.24	-0.22	Bipolar disorder;	chr3:52562898	chr3:52239258~52241097:+
THCA	cis	rs375066	0.935	rs432454	ENSG00000278917.1	RP11-15A1.4	-4.79	2.19e-06	0.000259	-0.18	-0.22	Breast cancer;	chr19:43894679	chr19:43891233~43895411:+
THCA	cis	rs600231	0.542	rs10896008	ENSG00000245532.5	NEAT1	4.79	2.19e-06	0.000259	0.19	0.22	Bone mineral density;	chr11:65478433	chr11:65422774~65445540:+
THCA	cis	rs930395	0.514	rs4129642	ENSG00000272335.1	RP11-53O19.3	4.79	2.19e-06	0.000259	0.18	0.22	Breast cancer;	chr5:44898027	chr5:44826076~44828592:+
THCA	cis	rs9652601	0.691	rs11861236	ENSG00000274038.1	RP11-66H6.4	-4.79	2.19e-06	0.000259	-0.26	-0.22	Systemic lupus erythematosus;	chr16:11089769	chr16:11056556~11057034:+
THCA	cis	rs3796352	1	rs35507120	ENSG00000242142.1	SERBP1P3	-4.79	2.19e-06	0.000259	-0.42	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53019908	chr3:53064283~53065091:-
THCA	cis	rs1334894	0.818	rs72899794	ENSG00000228559.1	RP3-340B19.3	-4.79	2.19e-06	0.000259	-0.44	-0.22	Coronary artery disease;	chr6:35547457	chr6:35544632~35545669:+
THCA	cis	rs1334894	0.901	rs72899796	ENSG00000228559.1	RP3-340B19.3	-4.79	2.19e-06	0.000259	-0.44	-0.22	Coronary artery disease;	chr6:35547659	chr6:35544632~35545669:+
THCA	cis	rs2129782	0.702	rs79977096	ENSG00000253553.4	RP11-586K2.1	4.79	2.19e-06	0.000259	0.38	0.22	Electrodermal activity;	chr8:88538316	chr8:88326836~88737134:+
THCA	cis	rs6012564	1	rs6066975	ENSG00000230758.1	SNAP23P	-4.79	2.19e-06	0.000259	-0.26	-0.22	Anger;	chr20:49133840	chr20:49038357~49038602:-
THCA	cis	rs4950322	0.57	rs72691054	ENSG00000180867.10	PDIA3P1	4.79	2.2e-06	0.00026	0.22	0.22	Protein quantitative trait loci;	chr1:147277942	chr1:147178113~147179622:+
THCA	cis	rs13034020	0.522	rs12996059	ENSG00000271889.1	RP11-493E12.1	-4.79	2.2e-06	0.00026	-0.28	-0.22	Hodgkin's lymphoma;	chr2:61018416	chr2:61151433~61162105:-
THCA	cis	rs13034020	0.522	rs35217978	ENSG00000271889.1	RP11-493E12.1	-4.79	2.2e-06	0.00026	-0.28	-0.22	Hodgkin's lymphoma;	chr2:61019413	chr2:61151433~61162105:-
THCA	cis	rs13034020	0.522	rs13017457	ENSG00000271889.1	RP11-493E12.1	-4.79	2.2e-06	0.00026	-0.28	-0.22	Hodgkin's lymphoma;	chr2:61021510	chr2:61151433~61162105:-
THCA	cis	rs812925	0.519	rs1186706	ENSG00000270820.4	RP11-355B11.2	4.79	2.2e-06	0.00026	0.18	0.22	Immature fraction of reticulocytes;	chr2:61446259	chr2:61471188~61484130:+
THCA	cis	rs6921919	0.583	rs4254981	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.525	rs6929825	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs35599905	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs1124131	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs6899389	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs6922374	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs6899603	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs6922429	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs6922169	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.559	rs13210866	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.609	rs36018474	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs13201726	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs2027361	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs4642462	ENSG00000280107.1	AL022393.9	-4.79	2.2e-06	0.00026	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28170845~28172521:+
THCA	cis	rs7267979	0.727	rs4815431	ENSG00000125804.12	FAM182A	4.79	2.2e-06	0.00026	0.27	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26054655~26086917:+
THCA	cis	rs1707322	1	rs10890350	ENSG00000281133.1	AL355480.3	-4.79	2.2e-06	0.00026	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45580892~45580996:-
THCA	cis	rs728616	0.614	rs61859198	ENSG00000242600.5	MBL1P	4.79	2.2e-06	0.00026	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80354872	chr10:79904898~79950336:+
THCA	cis	rs6012564	1	rs2426106	ENSG00000227431.4	CSE1L-AS1	-4.79	2.2e-06	0.00026	-0.26	-0.22	Anger;	chr20:49022927	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs3092720	ENSG00000227431.4	CSE1L-AS1	-4.79	2.2e-06	0.00026	-0.26	-0.22	Anger;	chr20:49023929	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs3091866	ENSG00000227431.4	CSE1L-AS1	-4.79	2.2e-06	0.00026	-0.26	-0.22	Anger;	chr20:49031816	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs2252259	ENSG00000227431.4	CSE1L-AS1	-4.79	2.2e-06	0.00026	-0.26	-0.22	Anger;	chr20:49046286	chr20:49040463~49046044:-
THCA	cis	rs7474896	0.832	rs12570943	ENSG00000263064.2	RP11-291L22.7	4.79	2.2e-06	0.00026	0.35	0.22	Obesity (extreme);	chr10:37733541	chr10:38448689~38448949:+
THCA	cis	rs651907	0.535	rs17412601	ENSG00000244119.1	PDCL3P4	4.79	2.2e-06	0.00026	0.2	0.22	Colorectal cancer;	chr3:101780431	chr3:101712472~101713191:+
THCA	cis	rs11673344	0.542	rs2562598	ENSG00000276846.1	CTD-3220F14.3	4.79	2.2e-06	0.00026	0.16	0.22	Obesity-related traits;	chr19:37025318	chr19:37314868~37315620:-
THCA	cis	rs7833787	0.693	rs11204002	ENSG00000278886.1	RP11-108A14.1	-4.79	2.2e-06	0.00026	-0.28	-0.22	Obesity-related traits;	chr8:18842149	chr8:18864681~18865247:-
THCA	cis	rs9880211	0.563	rs1393787	ENSG00000273486.1	RP11-731C17.2	4.79	2.2e-06	0.00026	0.22	0.22	Height;Body mass index;	chr3:136135359	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.563	rs9881400	ENSG00000273486.1	RP11-731C17.2	4.79	2.2e-06	0.00026	0.22	0.22	Height;Body mass index;	chr3:136142824	chr3:136837338~136839021:-
THCA	cis	rs442309	0.532	rs10995301	ENSG00000238280.1	RP11-436D10.3	4.79	2.2e-06	0.00026	0.28	0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62747535	chr10:62793562~62805887:-
THCA	cis	rs2886497	0.947	rs7916466	ENSG00000224215.1	RP11-371A19.2	-4.79	2.2e-06	0.00026	-0.27	-0.22	Major depression and alcohol dependence;	chr10:23373179	chr10:23343957~23345181:+
THCA	cis	rs3820928	0.845	rs13415319	ENSG00000212391.1	SNORA48	-4.79	2.2e-06	0.00026	-0.23	-0.22	Pulmonary function;	chr2:227014220	chr2:226968989~226969122:-
THCA	cis	rs30380	1	rs27529	ENSG00000272109.1	CTD-2260A17.3	-4.79	2.2e-06	0.00026	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96804353~96806105:+
THCA	cis	rs1707322	0.964	rs785483	ENSG00000281133.1	AL355480.3	4.79	2.2e-06	0.00026	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.964	rs796773	ENSG00000281133.1	AL355480.3	4.79	2.2e-06	0.00026	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.896	rs785518	ENSG00000281133.1	AL355480.3	4.79	2.2e-06	0.00026	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs785519	ENSG00000281133.1	AL355480.3	4.79	2.2e-06	0.00026	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45580892~45580996:-
THCA	cis	rs11673344	0.504	rs2595555	ENSG00000276846.1	CTD-3220F14.3	4.79	2.2e-06	0.00026	0.16	0.22	Obesity-related traits;	chr19:37000219	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs1667377	ENSG00000276846.1	CTD-3220F14.3	4.79	2.2e-06	0.00026	0.16	0.22	Obesity-related traits;	chr19:37000966	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs1667379	ENSG00000276846.1	CTD-3220F14.3	4.79	2.2e-06	0.00026	0.16	0.22	Obesity-related traits;	chr19:37001192	chr19:37314868~37315620:-
THCA	cis	rs1150668	0.799	rs9301	ENSG00000273712.1	RP5-874C20.7	4.79	2.2e-06	0.00026	0.24	0.22	Pubertal anthropometrics;	chr6:28324929	chr6:28315613~28315883:-
THCA	cis	rs79243044	0.786	rs16932553	ENSG00000224295.2	AC087380.14	-4.79	2.2e-06	0.00026	-0.23	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5539736	chr11:5518441~5524955:-
THCA	cis	rs79243044	0.813	rs12421639	ENSG00000224295.2	AC087380.14	-4.79	2.2e-06	0.00026	-0.23	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5540330	chr11:5518441~5524955:-
THCA	cis	rs62025270	0.632	rs17636096	ENSG00000259295.5	CSPG4P12	-4.79	2.2e-06	0.00026	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85191438~85213905:+
THCA	cis	rs28476539	1	rs28476539	ENSG00000270480.1	RP11-57B24.1	4.79	2.2e-06	0.00026	0.34	0.22	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82631138	chr4:82691737~82692468:+
THCA	cis	rs7618915	0.524	rs35249778	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.2e-06	0.00026	-0.23	-0.22	Bipolar disorder;	chr3:52627624	chr3:52239258~52241097:+
THCA	cis	rs11096990	0.964	rs9998591	ENSG00000249685.1	RP11-360F5.3	4.79	2.2e-06	0.00026	0.28	0.22	Cognitive function;	chr4:39240491	chr4:39133913~39135608:+
THCA	cis	rs12908161	0.96	rs17599989	ENSG00000188388.10	GOLGA6L3	4.79	2.2e-06	0.00026	0.29	0.22	Schizophrenia;	chr15:84742305	chr15:85240472~85247170:+
THCA	cis	rs9880211	0.613	rs28535121	ENSG00000273486.1	RP11-731C17.2	4.79	2.2e-06	0.00026	0.22	0.22	Height;Body mass index;	chr3:136173956	chr3:136837338~136839021:-
THCA	cis	rs1005277	0.579	rs1780116	ENSG00000275858.1	RP11-291L22.8	4.79	2.2e-06	0.00026	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780121	ENSG00000275858.1	RP11-291L22.8	4.79	2.2e-06	0.00026	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780122	ENSG00000275858.1	RP11-291L22.8	4.79	2.2e-06	0.00026	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780145	ENSG00000275858.1	RP11-291L22.8	4.79	2.2e-06	0.00026	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38450738~38451069:-
THCA	cis	rs7618915	0.571	rs34954168	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.2e-06	0.00026	-0.24	-0.22	Bipolar disorder;	chr3:52578143	chr3:52239258~52241097:+
THCA	cis	rs17301013	0.932	rs1793297	ENSG00000227373.4	RP11-160H22.5	-4.79	2.21e-06	0.000261	-0.3	-0.22	Systemic lupus erythematosus;	chr1:174784411	chr1:174115300~174160004:-
THCA	cis	rs9880211	1	rs13071220	ENSG00000239213.4	NCK1-AS1	4.79	2.21e-06	0.000261	0.24	0.22	Height;Body mass index;	chr3:136595277	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.904	rs9857833	ENSG00000239213.4	NCK1-AS1	4.79	2.21e-06	0.000261	0.24	0.22	Height;Body mass index;	chr3:136685625	chr3:136841726~136862054:-
THCA	cis	rs12188164	0.812	rs10072668	ENSG00000221990.4	EXOC3-AS1	4.79	2.21e-06	0.000261	0.17	0.22	Cystic fibrosis severity;	chr5:422637	chr5:441498~443160:-
THCA	cis	rs4646450	0.945	rs12333760	ENSG00000244219.5	GS1-259H13.2	-4.79	2.21e-06	0.000261	-0.26	-0.22	Blood metabolite levels;	chr7:99587783	chr7:99598066~99610813:+
THCA	cis	rs8091660	0.624	rs907546	ENSG00000278983.1	RP11-426J5.3	4.79	2.21e-06	0.000261	0.31	0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48549919	chr18:48564795~48568342:+
THCA	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-4.79	2.21e-06	0.000261	-0.24	-0.22	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-4.79	2.21e-06	0.000261	-0.24	-0.22	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-4.79	2.21e-06	0.000261	-0.24	-0.22	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-4.79	2.21e-06	0.000261	-0.24	-0.22	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-4.79	2.21e-06	0.000261	-0.24	-0.22	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-4.79	2.21e-06	0.000261	-0.24	-0.22	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-4.79	2.21e-06	0.000261	-0.24	-0.22	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
THCA	cis	rs12935229	1	rs17712992	ENSG00000260922.1	RP11-538I12.3	-4.79	2.21e-06	0.000261	-0.35	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77292494	chr16:77234877~77290934:+
THCA	cis	rs9652601	0.691	rs12708717	ENSG00000274038.1	RP11-66H6.4	-4.79	2.21e-06	0.000261	-0.26	-0.22	Systemic lupus erythematosus;	chr16:11098522	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.608	rs8061826	ENSG00000274038.1	RP11-66H6.4	-4.79	2.21e-06	0.000261	-0.26	-0.22	Systemic lupus erythematosus;	chr16:11098930	chr16:11056556~11057034:+
THCA	cis	rs73108077	0.736	rs2376545	ENSG00000277112.2	RP11-755J8.1	-4.79	2.21e-06	0.000261	-0.35	-0.22	Red blood cell density in sickle cell anemia;	chr20:31293314	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs13433373	ENSG00000277112.2	RP11-755J8.1	-4.79	2.21e-06	0.000261	-0.35	-0.22	Red blood cell density in sickle cell anemia;	chr20:31296736	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.688	rs6061150	ENSG00000277112.2	RP11-755J8.1	-4.79	2.21e-06	0.000261	-0.35	-0.22	Red blood cell density in sickle cell anemia;	chr20:31301527	chr20:30681825~30723932:-
THCA	cis	rs8002861	0.905	rs11617551	ENSG00000274001.1	RP11-5G9.5	-4.79	2.21e-06	0.000261	-0.26	-0.22	Leprosy;	chr13:43869841	chr13:43877715~43878163:-
THCA	cis	rs7474896	0.583	rs1208770	ENSG00000226578.1	RP11-258F22.1	-4.79	2.21e-06	0.000261	-0.31	-0.22	Obesity (extreme);	chr10:37755755	chr10:37775371~37784131:-
THCA	cis	rs7474896	0.526	rs1742235	ENSG00000226578.1	RP11-258F22.1	-4.79	2.21e-06	0.000261	-0.31	-0.22	Obesity (extreme);	chr10:37763328	chr10:37775371~37784131:-
THCA	cis	rs7474896	0.559	rs1208779	ENSG00000226578.1	RP11-258F22.1	-4.79	2.21e-06	0.000261	-0.31	-0.22	Obesity (extreme);	chr10:37788801	chr10:37775371~37784131:-
THCA	cis	rs10761482	0.601	rs1954117	ENSG00000254271.1	RP11-131N11.4	4.79	2.21e-06	0.000261	0.3	0.22	Schizophrenia;	chr10:60450830	chr10:60734342~60741828:+
THCA	cis	rs6565653	0.967	rs9891253	ENSG00000262580.4	RP11-334C17.5	4.79	2.21e-06	0.000261	0.19	0.22	Ischemic stroke;	chr17:80226377	chr17:80200673~80205949:-
THCA	cis	rs1129187	0.755	rs3818554	ENSG00000272223.1	RP1-20C7.6	4.79	2.21e-06	0.000262	0.17	0.22	Alzheimer's disease in APOE e4+ carriers;	chr6:42966882	chr6:43033897~43034405:-
THCA	cis	rs6570726	0.967	rs441364	ENSG00000270638.1	RP3-466P17.1	4.79	2.21e-06	0.000262	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145532526	chr6:145735570~145737218:+
THCA	cis	rs9925964	0.9	rs9934438	ENSG00000260911.2	RP11-196G11.2	-4.79	2.21e-06	0.000262	-0.18	-0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093557	chr16:31043150~31049868:+
THCA	cis	rs4072705	0.615	rs4838189	ENSG00000224020.1	MIR181A2HG	-4.79	2.22e-06	0.000262	-0.2	-0.22	Menarche (age at onset);	chr9:124486647	chr9:124658467~124698631:+
THCA	cis	rs6860806	0.507	rs156322	ENSG00000224431.1	AC063976.7	4.79	2.22e-06	0.000262	0.19	0.22	Breast cancer;	chr5:132318232	chr5:132199456~132203487:+
THCA	cis	rs440932	0.717	rs330944	ENSG00000254340.1	RP11-10A14.3	4.79	2.22e-06	0.000262	0.24	0.22	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:9141424~9145435:+
THCA	cis	rs9925964	0.9	rs9934438	ENSG00000232748.3	RP11-196G11.6	4.79	2.22e-06	0.000262	0.25	0.22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093557	chr16:31056460~31062803:+
THCA	cis	rs288326	0.561	rs75139715	ENSG00000272800.1	RP11-438L19.1	4.79	2.22e-06	0.000262	0.39	0.22	Blood protein levels;	chr2:183025932	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs77426227	ENSG00000272800.1	RP11-438L19.1	4.79	2.22e-06	0.000262	0.39	0.22	Blood protein levels;	chr2:183025950	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs77227040	ENSG00000272800.1	RP11-438L19.1	4.79	2.22e-06	0.000262	0.39	0.22	Blood protein levels;	chr2:183029438	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs76829215	ENSG00000272800.1	RP11-438L19.1	4.79	2.22e-06	0.000262	0.39	0.22	Blood protein levels;	chr2:183029724	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs17703779	ENSG00000272800.1	RP11-438L19.1	4.79	2.22e-06	0.000262	0.39	0.22	Blood protein levels;	chr2:183031191	chr2:183214319~183215400:+
THCA	cis	rs1009077	0.68	rs2389870	ENSG00000245958.5	RP11-33B1.1	4.79	2.22e-06	0.000262	0.28	0.22	Endometriosis;	chr4:119600883	chr4:119454791~119552025:+
THCA	cis	rs5742933	1	rs12619808	ENSG00000273240.1	RP11-455J20.3	-4.79	2.22e-06	0.000262	-0.24	-0.22	Ferritin levels;	chr2:189776458	chr2:189763859~189764456:-
THCA	cis	rs4927850	1	rs7614767	ENSG00000185485.13	SDHAP1	4.79	2.22e-06	0.000262	0.19	0.22	Pancreatic cancer;	chr3:196026580	chr3:195959748~195990318:-
THCA	cis	rs172166	0.561	rs149973	ENSG00000176933.5	TOB2P1	-4.79	2.22e-06	0.000262	-0.23	-0.22	Cardiac Troponin-T levels;	chr6:28015835	chr6:28217643~28218634:-
THCA	cis	rs172166	0.561	rs149974	ENSG00000176933.5	TOB2P1	-4.79	2.22e-06	0.000262	-0.23	-0.22	Cardiac Troponin-T levels;	chr6:28017318	chr6:28217643~28218634:-
THCA	cis	rs17604090	0.628	rs875263	ENSG00000225264.3	ZNRF2P2	4.79	2.22e-06	0.000262	0.25	0.22	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29671450	chr7:29598795~29685255:-
THCA	cis	rs8067545	0.611	rs12942568	ENSG00000270091.1	RP11-78O7.2	4.79	2.22e-06	0.000262	0.16	0.22	Schizophrenia;	chr17:20214580	chr17:19896590~19897287:-
THCA	cis	rs172166	0.516	rs2791333	ENSG00000220721.1	OR1F12	4.79	2.22e-06	0.000262	0.24	0.22	Cardiac Troponin-T levels;	chr6:28143336	chr6:28073316~28074233:+
THCA	cis	rs2742234	0.541	rs11238483	ENSG00000273008.1	RP11-351D16.3	4.79	2.22e-06	0.000262	0.2	0.22	Hirschsprung disease;	chr10:43233332	chr10:43136824~43138334:-
THCA	cis	rs172166	0.538	rs1150686	ENSG00000273712.1	RP5-874C20.7	4.79	2.22e-06	0.000262	0.24	0.22	Cardiac Troponin-T levels;	chr6:28193493	chr6:28315613~28315883:-
THCA	cis	rs1150688	1	rs1150688	ENSG00000273712.1	RP5-874C20.7	4.79	2.22e-06	0.000262	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28315613~28315883:-
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000182586.6	LINC00334	-4.79	2.22e-06	0.000262	-0.23	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45234340~45258730:+
THCA	cis	rs6012564	1	rs6125540	ENSG00000227431.4	CSE1L-AS1	4.79	2.22e-06	0.000262	0.26	0.22	Anger;	chr20:49087502	chr20:49040463~49046044:-
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000232546.1	RP11-458F8.1	-4.79	2.22e-06	0.000262	-0.33	-0.22	Diabetic kidney disease;	chr7:66009932	chr7:66848496~66858136:+
THCA	cis	rs1371614	0.545	rs13035643	ENSG00000229122.1	AGBL5-IT1	-4.79	2.22e-06	0.000263	-0.15	-0.22	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950473	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.545	rs4665930	ENSG00000229122.1	AGBL5-IT1	-4.79	2.22e-06	0.000263	-0.15	-0.22	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950652	chr2:27061038~27061815:+
THCA	cis	rs4443100	0.77	rs6003472	ENSG00000230701.2	FBXW4P1	4.79	2.22e-06	0.000263	0.26	0.22	Serum parathyroid hormone levels;	chr22:23027658	chr22:23262767~23265005:+
THCA	cis	rs62158800	0.85	rs56721931	ENSG00000237880.1	AC096669.2	4.79	2.22e-06	0.000263	0.34	0.22	Facial morphology (factor 22);	chr2:107614359	chr2:107385632~107542649:-
THCA	cis	rs6728642	0.908	rs6731522	ENSG00000230606.9	AC159540.1	4.79	2.22e-06	0.000263	0.28	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96982260	chr2:97416165~97433527:-
THCA	cis	rs1979679	0.573	rs4930825	ENSG00000247934.4	RP11-967K21.1	4.79	2.22e-06	0.000263	0.21	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574174	chr12:28163298~28190738:-
THCA	cis	rs1823913	0.599	rs13020656	ENSG00000280083.1	RP11-317J9.1	-4.79	2.22e-06	0.000263	-0.26	-0.22	Obesity-related traits;	chr2:191314197	chr2:191154118~191156070:-
THCA	cis	rs875971	0.545	rs10261710	ENSG00000228409.4	CCT6P1	-4.79	2.22e-06	0.000263	-0.19	-0.22	Aortic root size;	chr7:66249202	chr7:65751142~65763354:+
THCA	cis	rs7618915	0.501	rs3852066	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52587823	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs2336146	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52592630	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs34754793	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52595161	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs9917834	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52600603	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs11130308	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52605241	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs3774366	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52607239	chr3:52239258~52241097:+
THCA	cis	rs736408	0.545	rs6445529	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52628706	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs7622694	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52629866	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs13085775	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52644354	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs62253740	ENSG00000243224.1	RP5-1157M23.2	-4.79	2.23e-06	0.000263	-0.23	-0.22	Bipolar disorder;	chr3:52650112	chr3:52239258~52241097:+
THCA	cis	rs9863	0.794	rs12310367	ENSG00000269997.1	RP11-214K3.21	-4.79	2.23e-06	0.000263	-0.26	-0.22	White blood cell count;	chr12:124002131	chr12:123966077~123966629:-
THCA	cis	rs7520050	0.933	rs12045165	ENSG00000234329.1	RP11-767N6.2	-4.79	2.23e-06	0.000263	-0.19	-0.22	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45651039~45651826:-
THCA	cis	rs8037818	1	rs11071856	ENSG00000261064.1	RP11-1000B6.3	-4.79	2.23e-06	0.000263	-0.19	-0.22	Obesity-related traits;	chr15:32633591	chr15:32536047~32587613:+
THCA	cis	rs656319	0.605	rs4840467	ENSG00000261451.1	RP11-981G7.1	4.79	2.23e-06	0.000263	0.3	0.22	Myopia (pathological);	chr8:10222127	chr8:10433672~10438312:+
THCA	cis	rs12893668	0.703	rs4906338	ENSG00000269958.1	RP11-73M18.8	4.79	2.23e-06	0.000263	0.21	0.22	Reticulocyte count;	chr14:103584020	chr14:103696353~103697163:+
THCA	cis	rs7432375	0.609	rs835637	ENSG00000239213.4	NCK1-AS1	4.79	2.23e-06	0.000263	0.19	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136954315	chr3:136841726~136862054:-
THCA	cis	rs911555	0.706	rs10129426	ENSG00000269910.1	RP11-73M18.10	4.79	2.23e-06	0.000263	0.19	0.22	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103694516~103695050:-
THCA	cis	rs12887734	0.524	rs4906363	ENSG00000269910.1	RP11-73M18.10	4.79	2.23e-06	0.000263	0.2	0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103694516~103695050:-
THCA	cis	rs6545883	0.524	rs778159	ENSG00000270820.4	RP11-355B11.2	-4.79	2.23e-06	0.000263	-0.18	-0.22	Tuberculosis;	chr2:61329609	chr2:61471188~61484130:+
THCA	cis	rs8020095	0.571	rs7156852	ENSG00000258561.1	RP11-72M17.1	-4.79	2.23e-06	0.000263	-0.29	-0.22	Depression (quantitative trait);	chr14:66873831	chr14:66212810~66509394:-
THCA	cis	rs4908760	0.827	rs10864360	ENSG00000232912.4	RP5-1115A15.1	4.79	2.23e-06	0.000264	0.21	0.22	Vitiligo;	chr1:8664463	chr1:8424645~8434838:+
THCA	cis	rs2838815	0.525	rs2071873	ENSG00000223768.1	LINC00205	-4.79	2.23e-06	0.000264	-0.21	-0.22	Pulmonary function;	chr21:45182918	chr21:45293285~45297354:+
THCA	cis	rs2839186	0.771	rs2839155	ENSG00000215424.8	MCM3AP-AS1	4.79	2.23e-06	0.000264	0.12	0.22	Testicular germ cell tumor;	chr21:46220078	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.771	rs13046451	ENSG00000215424.8	MCM3AP-AS1	-4.79	2.23e-06	0.000264	-0.12	-0.22	Testicular germ cell tumor;	chr21:46221459	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.771	rs2280959	ENSG00000215424.8	MCM3AP-AS1	4.79	2.23e-06	0.000264	0.12	0.22	Testicular germ cell tumor;	chr21:46222082	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.739	rs2280958	ENSG00000215424.8	MCM3AP-AS1	4.79	2.23e-06	0.000264	0.12	0.22	Testicular germ cell tumor;	chr21:46222102	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.77	rs2280956	ENSG00000215424.8	MCM3AP-AS1	-4.79	2.23e-06	0.000264	-0.12	-0.22	Testicular germ cell tumor;	chr21:46222409	chr21:46229217~46259390:+
THCA	cis	rs11673344	0.504	rs7258360	ENSG00000276846.1	CTD-3220F14.3	4.79	2.23e-06	0.000264	0.17	0.22	Obesity-related traits;	chr19:37115015	chr19:37314868~37315620:-
THCA	cis	rs7267979	0.844	rs6050477	ENSG00000274414.1	RP5-965G21.4	4.79	2.23e-06	0.000264	0.25	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:25239007~25245229:-
THCA	cis	rs11671005	0.735	rs11671591	ENSG00000268912.1	CTD-2619J13.17	4.79	2.23e-06	0.000264	0.2	0.22	Mean platelet volume;	chr19:58406970	chr19:58428632~58431148:-
THCA	cis	rs1707322	1	rs1612419	ENSG00000281133.1	AL355480.3	4.79	2.24e-06	0.000264	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45580892~45580996:-
THCA	cis	rs786425	0.77	rs7964443	ENSG00000270095.1	RP11-214K3.18	-4.79	2.24e-06	0.000264	-0.26	-0.22	Pubertal anthropometrics;	chr12:123681953	chr12:123971457~123971714:-
THCA	cis	rs375066	0.935	rs454559	ENSG00000278917.1	RP11-15A1.4	-4.79	2.24e-06	0.000264	-0.18	-0.22	Breast cancer;	chr19:43924968	chr19:43891233~43895411:+
THCA	cis	rs467650	1	rs467650	ENSG00000248489.1	CTD-2007H13.3	4.79	2.24e-06	0.000264	0.2	0.22	Venous thromboembolism (SNP x SNP interaction);	chr5:98633749	chr5:98929171~98995013:+
THCA	cis	rs7772486	0.754	rs6915718	ENSG00000270638.1	RP3-466P17.1	-4.79	2.24e-06	0.000264	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145735570~145737218:+
THCA	cis	rs997295	0.592	rs8026627	ENSG00000270964.1	RP11-502I4.3	4.79	2.24e-06	0.000264	0.18	0.22	Motion sickness;	chr15:67477968	chr15:67541072~67542604:-
THCA	cis	rs2243480	1	rs402418	ENSG00000232559.3	GS1-124K5.12	4.79	2.24e-06	0.000264	0.32	0.22	Diabetic kidney disease;	chr7:66044482	chr7:66554588~66576923:-
THCA	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-4.79	2.24e-06	0.000264	-0.25	-0.22	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
THCA	cis	rs10248839	0.518	rs1317741	ENSG00000225264.3	ZNRF2P2	4.79	2.24e-06	0.000264	0.25	0.22	Facial emotion recognition (angry faces);	chr7:29671533	chr7:29598795~29685255:-
THCA	cis	rs62158800	0.789	rs1913987	ENSG00000224568.1	AC096669.3	4.79	2.24e-06	0.000264	0.27	0.22	Facial morphology (factor 22);	chr2:107600164	chr2:107529487~107556326:+
THCA	cis	rs1003719	0.591	rs2018521	ENSG00000230366.8	DSCR9	4.79	2.24e-06	0.000264	0.23	0.22	Eye color traits;	chr21:37144964	chr21:37208503~37221736:+
THCA	cis	rs897984	0.644	rs73524556	ENSG00000279196.1	RP11-1072A3.3	4.79	2.24e-06	0.000264	0.21	0.22	Dementia with Lewy bodies;	chr16:30811841	chr16:30984630~30988270:-
THCA	cis	rs9467773	0.62	rs2504592	ENSG00000124549.13	BTN2A3P	4.79	2.24e-06	0.000264	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2504599	ENSG00000124549.13	BTN2A3P	4.79	2.24e-06	0.000264	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26421391~26432383:+
THCA	cis	rs6951245	0.882	rs11764817	ENSG00000229043.2	AC091729.9	-4.79	2.24e-06	0.000264	-0.33	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024974	chr7:1160374~1165267:+
THCA	cis	rs12681288	0.676	rs7459467	ENSG00000260721.1	AF067845.1	4.79	2.24e-06	0.000264	0.26	0.22	Schizophrenia;	chr8:1049359	chr8:1368642~1369833:-
THCA	cis	rs3824435	0.783	rs10481592	ENSG00000272866.1	RP11-12D24.10	-4.79	2.24e-06	0.000264	-0.29	-0.22	Risky sexual behaviors in alcohol dependence;	chr9:5342164	chr9:5351796~5352410:-
THCA	cis	rs172166	0.516	rs1150670	ENSG00000176933.5	TOB2P1	-4.79	2.24e-06	0.000264	-0.24	-0.22	Cardiac Troponin-T levels;	chr6:28162781	chr6:28217643~28218634:-
THCA	cis	rs989128	0.6	rs2240218	ENSG00000250286.1	RP11-94C24.8	-4.79	2.24e-06	0.000264	-0.21	-0.22	Type 2 diabetes;	chr17:50553219	chr17:50537294~50538754:-
THCA	cis	rs989128	0.572	rs6504674	ENSG00000250286.1	RP11-94C24.8	-4.79	2.24e-06	0.000264	-0.21	-0.22	Type 2 diabetes;	chr17:50553453	chr17:50537294~50538754:-
THCA	cis	rs989128	0.6	rs73338243	ENSG00000250286.1	RP11-94C24.8	-4.79	2.24e-06	0.000264	-0.21	-0.22	Type 2 diabetes;	chr17:50553963	chr17:50537294~50538754:-
THCA	cis	rs240993	0.715	rs4947122	ENSG00000271789.1	RP5-1112D6.7	-4.79	2.24e-06	0.000265	-0.25	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111548887	chr6:111297126~111298510:+
THCA	cis	rs2067615	0.579	rs4385986	ENSG00000260329.1	RP11-412D9.4	-4.79	2.24e-06	0.000265	-0.2	-0.22	Heart rate;	chr12:106739997	chr12:106954029~106955497:-
THCA	cis	rs10266483	0.739	rs12665990	ENSG00000227986.1	TRIM60P18	4.79	2.24e-06	0.000265	0.2	0.22	Response to statin therapy;	chr7:64404622	chr7:64355078~64356199:+
THCA	cis	rs6832769	1	rs6853192	ENSG00000272969.1	RP11-528I4.2	-4.79	2.24e-06	0.000265	-0.25	-0.22	Personality dimensions;	chr4:55543087	chr4:55547112~55547889:+
THCA	cis	rs786425	0.711	rs12819746	ENSG00000270095.1	RP11-214K3.18	-4.79	2.25e-06	0.000265	-0.25	-0.22	Pubertal anthropometrics;	chr12:123709027	chr12:123971457~123971714:-
THCA	cis	rs2742234	0.541	rs1317214	ENSG00000273008.1	RP11-351D16.3	4.79	2.25e-06	0.000265	0.2	0.22	Hirschsprung disease;	chr10:43238083	chr10:43136824~43138334:-
THCA	cis	rs4660214	0.666	rs10888788	ENSG00000182109.6	RP11-69E11.4	-4.79	2.25e-06	0.000265	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472024	chr1:39522280~39546187:-
THCA	cis	rs4915077	1	rs78326196	ENSG00000230489.1	VAV3-AS1	4.79	2.25e-06	0.000265	0.38	0.22	Hypothyroidism;	chr1:107834510	chr1:107964443~107994607:+
THCA	cis	rs4915077	1	rs2125747	ENSG00000230489.1	VAV3-AS1	4.79	2.25e-06	0.000265	0.38	0.22	Hypothyroidism;	chr1:107837911	chr1:107964443~107994607:+
THCA	cis	rs55702914	0.837	rs2195507	ENSG00000231621.1	AC013264.2	4.79	2.25e-06	0.000265	0.2	0.22	Major depression and alcohol dependence;	chr2:197307612	chr2:197197991~197199273:+
THCA	cis	rs6840360	0.642	rs2724577	ENSG00000270265.1	RP11-731D1.4	-4.79	2.25e-06	0.000265	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151333775~151353224:-
THCA	cis	rs5758659	0.967	rs5758670	ENSG00000227370.1	RP4-669P10.19	-4.79	2.25e-06	0.000265	-0.2	-0.22	Cognitive function;	chr22:42240681	chr22:42132543~42132998:+
THCA	cis	rs6997458	0.742	rs13269441	ENSG00000253549.4	RP11-317J10.2	4.79	2.25e-06	0.000265	0.21	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85418406	chr8:85441851~85464915:-
THCA	cis	rs2288884	0.559	rs6509611	ENSG00000269483.1	AC006272.1	4.79	2.25e-06	0.000265	0.24	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006953	chr19:51839924~51843324:-
THCA	cis	rs9467773	0.62	rs2504540	ENSG00000124549.13	BTN2A3P	4.79	2.25e-06	0.000265	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.596	rs2451750	ENSG00000124549.13	BTN2A3P	4.79	2.25e-06	0.000265	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.596	rs2451751	ENSG00000124549.13	BTN2A3P	4.79	2.25e-06	0.000265	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2504600	ENSG00000124549.13	BTN2A3P	4.79	2.25e-06	0.000265	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2130657	ENSG00000124549.13	BTN2A3P	4.79	2.25e-06	0.000265	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2498351	ENSG00000124549.13	BTN2A3P	4.79	2.25e-06	0.000265	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2504566	ENSG00000124549.13	BTN2A3P	4.79	2.25e-06	0.000265	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2494716	ENSG00000124549.13	BTN2A3P	4.79	2.25e-06	0.000265	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26421391~26432383:+
THCA	cis	rs7914558	0.646	rs7897654	ENSG00000236937.2	PTGES3P4	4.79	2.25e-06	0.000265	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902701	chr10:102845595~102845950:+
THCA	cis	rs17767392	0.788	rs7156194	ENSG00000259146.3	RP1-261D10.2	4.79	2.25e-06	0.000265	0.28	0.22	Mitral valve prolapse;	chr14:71231899	chr14:71292729~71321814:-
THCA	cis	rs2880765	0.506	rs719138	ENSG00000259630.2	CTD-2262B20.1	-4.79	2.25e-06	0.000265	-0.28	-0.22	Coronary artery disease;	chr15:85511831	chr15:85415228~85415633:+
THCA	cis	rs1009077	0.68	rs17358860	ENSG00000245958.5	RP11-33B1.1	-4.79	2.25e-06	0.000265	-0.27	-0.22	Endometriosis;	chr4:119596909	chr4:119454791~119552025:+
THCA	cis	rs1417569	0.517	rs3006596	ENSG00000237135.1	DDX10P1	4.79	2.25e-06	0.000266	0.26	0.22	Tuberculosis;	chr10:30892947	chr10:30919012~30921235:-
THCA	cis	rs274567	0.501	rs272856	ENSG00000237714.1	P4HA2-AS1	4.79	2.25e-06	0.000266	0.29	0.22	Blood metabolite levels;	chr5:132351388	chr5:132184876~132192808:+
THCA	cis	rs9880211	0.948	rs13316214	ENSG00000239213.4	NCK1-AS1	4.79	2.25e-06	0.000266	0.23	0.22	Height;Body mass index;	chr3:136439379	chr3:136841726~136862054:-
THCA	cis	rs9973361	0.531	rs9678548	ENSG00000232411.1	AC009495.3	-4.79	2.25e-06	0.000266	-0.27	-0.22	Total body bone mineral density;	chr2:165831318	chr2:165833048~165839098:-
THCA	cis	rs9329221	0.741	rs534523	ENSG00000248538.5	RP11-10A14.5	4.79	2.25e-06	0.000266	0.27	0.22	Neuroticism;	chr8:10027489	chr8:9189011~9202854:+
THCA	cis	rs6012564	1	rs6122763	ENSG00000230758.1	SNAP23P	-4.79	2.25e-06	0.000266	-0.26	-0.22	Anger;	chr20:49181116	chr20:49038357~49038602:-
THCA	cis	rs728616	0.558	rs35547640	ENSG00000242600.5	MBL1P	4.79	2.25e-06	0.000266	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80379394	chr10:79904898~79950336:+
THCA	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	4.79	2.25e-06	0.000266	0.25	0.22	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
THCA	cis	rs11157436	0.958	rs1041859	ENSG00000211812.1	TRAV26-2	-4.79	2.26e-06	0.000266	-0.2	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22202583~22203368:+
THCA	cis	rs11157436	0.958	rs1041860	ENSG00000211812.1	TRAV26-2	-4.79	2.26e-06	0.000266	-0.2	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22202583~22203368:+
THCA	cis	rs889398	0.874	rs2917677	ENSG00000226232.7	RP11-419C5.2	4.79	2.26e-06	0.000266	0.21	0.22	Body mass index;	chr16:69716946	chr16:69976388~69996188:-
THCA	cis	rs1040393	0.522	rs2049910	ENSG00000225171.2	DUTP6	-4.79	2.26e-06	0.000266	-0.32	-0.22	Schizophrenia;	chr1:166862888	chr1:166868748~166869209:+
THCA	cis	rs7404843	0.789	rs222907	ENSG00000263335.1	AF001548.5	4.79	2.26e-06	0.000266	0.34	0.22	Testicular germ cell tumor;	chr16:15404950	chr16:15726674~15732993:+
THCA	cis	rs786425	0.77	rs7138503	ENSG00000270095.1	RP11-214K3.18	-4.79	2.26e-06	0.000266	-0.26	-0.22	Pubertal anthropometrics;	chr12:123699280	chr12:123971457~123971714:-
THCA	cis	rs516805	0.961	rs510283	ENSG00000279114.1	RP3-425C14.5	-4.79	2.26e-06	0.000266	-0.21	-0.22	Lymphocyte counts;	chr6:122451547	chr6:122471923~122484161:+
THCA	cis	rs2835345	0.511	rs57583267	ENSG00000230479.1	AP000695.6	4.79	2.26e-06	0.000266	0.26	0.22	Pulmonary function;	chr21:36445230	chr21:36430360~36481070:+
THCA	cis	rs2742234	0.504	rs7093409	ENSG00000273008.1	RP11-351D16.3	4.79	2.26e-06	0.000266	0.19	0.22	Hirschsprung disease;	chr10:43244619	chr10:43136824~43138334:-
THCA	cis	rs7336933	0.808	rs9532963	ENSG00000278338.3	VWA8-AS1	4.79	2.26e-06	0.000266	0.37	0.22	Calcium levels;	chr13:42000720	chr13:41955808~41981565:+
THCA	cis	rs2018683	0.584	rs4722880	ENSG00000272568.4	CTB-113D17.1	4.79	2.26e-06	0.000266	0.2	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28979967~29013367:+
THCA	cis	rs10266483	0.739	rs2692104	ENSG00000228653.2	HNRNPCP7	-4.79	2.26e-06	0.000266	-0.19	-0.22	Response to statin therapy;	chr7:64300577	chr7:64500825~64501729:+
THCA	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-4.79	2.26e-06	0.000266	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
THCA	cis	rs2288884	0.559	rs11084130	ENSG00000269483.1	AC006272.1	4.79	2.26e-06	0.000267	0.25	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:51839924~51843324:-
THCA	cis	rs58605417	0.55	rs7817382	ENSG00000253553.4	RP11-586K2.1	-4.79	2.26e-06	0.000267	-0.24	-0.22	Schizophrenia;	chr8:88280074	chr8:88326836~88737134:+
THCA	cis	rs13160562	0.522	rs26502	ENSG00000248734.2	CTD-2260A17.1	4.79	2.26e-06	0.000267	0.21	0.22	Alcohol dependence;	chr5:96764254	chr5:96784777~96785999:+
THCA	cis	rs13160562	0.509	rs26501	ENSG00000248734.2	CTD-2260A17.1	4.79	2.26e-06	0.000267	0.21	0.22	Alcohol dependence;	chr5:96765060	chr5:96784777~96785999:+
THCA	cis	rs13160562	0.527	rs27525	ENSG00000248734.2	CTD-2260A17.1	4.79	2.26e-06	0.000267	0.21	0.22	Alcohol dependence;	chr5:96766255	chr5:96784777~96785999:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000229886.1	RP5-1132H15.3	-4.79	2.26e-06	0.000267	-0.22	-0.22	Aortic root size;	chr7:66039646	chr7:66025126~66031544:-
THCA	cis	rs3796352	1	rs34979715	ENSG00000242142.1	SERBP1P3	-4.79	2.26e-06	0.000267	-0.43	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:53014944	chr3:53064283~53065091:-
THCA	cis	rs8002861	0.619	rs1337203	ENSG00000274001.1	RP11-5G9.5	4.79	2.26e-06	0.000267	0.25	0.22	Leprosy;	chr13:43849485	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.664	rs1808097	ENSG00000274001.1	RP11-5G9.5	4.79	2.26e-06	0.000267	0.25	0.22	Leprosy;	chr13:43850630	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.664	rs2218497	ENSG00000274001.1	RP11-5G9.5	4.79	2.26e-06	0.000267	0.25	0.22	Leprosy;	chr13:43854657	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.664	rs9533662	ENSG00000274001.1	RP11-5G9.5	4.79	2.26e-06	0.000267	0.25	0.22	Leprosy;	chr13:43861852	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.619	rs9567289	ENSG00000274001.1	RP11-5G9.5	4.79	2.26e-06	0.000267	0.25	0.22	Leprosy;	chr13:43862968	chr13:43877715~43878163:-
THCA	cis	rs4948102	0.599	rs2230197	ENSG00000226278.1	PSPHP1	-4.79	2.26e-06	0.000267	-0.25	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55764797~55773288:+
THCA	cis	rs4948102	0.642	rs6593297	ENSG00000226278.1	PSPHP1	4.79	2.26e-06	0.000267	0.25	0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55764797~55773288:+
THCA	cis	rs3213758	1	rs12597881	ENSG00000275191.1	RP11-36I17.2	-4.79	2.26e-06	0.000267	-0.43	-0.22	Vitiligo (non-segmental);	chr16:53562454	chr16:53628256~53628816:-
THCA	cis	rs7192208	0.541	rs889705	ENSG00000260922.1	RP11-538I12.3	-4.79	2.26e-06	0.000267	-0.33	-0.22	White matter integrity;	chr16:77283500	chr16:77234877~77290934:+
THCA	cis	rs9283706	0.623	rs10055631	ENSG00000229666.1	MAST4-AS1	-4.79	2.26e-06	0.000267	-0.28	-0.22	Coronary artery disease;	chr5:67009610	chr5:67001383~67003953:-
THCA	cis	rs7838490	0.504	rs821120	ENSG00000253553.4	RP11-586K2.1	4.79	2.26e-06	0.000267	0.22	0.22	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88466030	chr8:88326836~88737134:+
THCA	cis	rs6479874	0.831	rs2660216	ENSG00000223502.1	RP11-96B5.3	-4.79	2.26e-06	0.000267	-0.26	-0.22	Migraine;	chr10:50992191	chr10:51062579~51068553:-
THCA	cis	rs6832769	0.961	rs7684810	ENSG00000272969.1	RP11-528I4.2	4.79	2.27e-06	0.000267	0.25	0.22	Personality dimensions;	chr4:55486627	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs13138697	ENSG00000272969.1	RP11-528I4.2	4.79	2.27e-06	0.000267	0.25	0.22	Personality dimensions;	chr4:55497142	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs6824057	ENSG00000272969.1	RP11-528I4.2	4.79	2.27e-06	0.000267	0.25	0.22	Personality dimensions;	chr4:55501111	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs12646078	ENSG00000272969.1	RP11-528I4.2	4.79	2.27e-06	0.000267	0.25	0.22	Personality dimensions;	chr4:55502037	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs6837710	ENSG00000272969.1	RP11-528I4.2	4.79	2.27e-06	0.000267	0.25	0.22	Personality dimensions;	chr4:55508288	chr4:55547112~55547889:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000223473.2	GS1-124K5.3	4.79	2.27e-06	0.000267	0.15	0.22	Aortic root size;	chr7:65963835	chr7:66491049~66493566:-
THCA	cis	rs752010	0.631	rs1073197	ENSG00000230638.4	RP11-486B10.4	4.79	2.27e-06	0.000267	0.26	0.22	Lupus nephritis in systemic lupus erythematosus;	chr1:41594151	chr1:41542069~41544310:+
THCA	cis	rs9467773	0.62	rs2451711	ENSG00000124549.13	BTN2A3P	4.79	2.27e-06	0.000267	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26421391~26432383:+
THCA	cis	rs897984	0.568	rs8050107	ENSG00000279196.1	RP11-1072A3.3	-4.79	2.27e-06	0.000267	-0.24	-0.22	Dementia with Lewy bodies;	chr16:30882130	chr16:30984630~30988270:-
THCA	cis	rs2735413	0.563	rs56214776	ENSG00000276007.1	RP11-358L22.3	4.79	2.27e-06	0.000267	0.24	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78011892	chr16:78123243~78124332:+
THCA	cis	rs2120243	0.533	rs1500921	ENSG00000241770.1	RP11-555M1.3	-4.79	2.27e-06	0.000267	-0.27	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157337638	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.533	rs62278578	ENSG00000241770.1	RP11-555M1.3	-4.79	2.27e-06	0.000267	-0.27	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338078	chr3:157163452~157169133:+
THCA	cis	rs73198271	0.96	rs12155530	ENSG00000253893.2	FAM85B	4.79	2.27e-06	0.000267	0.35	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8753454	chr8:8167819~8226614:-
THCA	cis	rs1185460	1	rs1784305	ENSG00000272186.1	RP11-110I1.13	-4.79	2.27e-06	0.000267	-0.2	-0.22	Coronary artery disease;	chr11:119071338	chr11:119067374~119067698:-
THCA	cis	rs3820928	1	rs10193404	ENSG00000212391.1	SNORA48	-4.79	2.27e-06	0.000267	-0.25	-0.22	Pulmonary function;	chr2:226913041	chr2:226968989~226969122:-
THCA	cis	rs11992162	0.967	rs4841661	ENSG00000206014.6	OR7E161P	-4.79	2.27e-06	0.000268	-0.25	-0.22	Monocyte count;	chr8:11975260	chr8:11928597~11929563:-
THCA	cis	rs11992162	1	rs11994417	ENSG00000206014.6	OR7E161P	-4.79	2.27e-06	0.000268	-0.25	-0.22	Monocyte count;	chr8:11975753	chr8:11928597~11929563:-
THCA	cis	rs1559040	0.929	rs72800729	ENSG00000272156.1	RP11-477N3.1	-4.79	2.27e-06	0.000268	-0.35	-0.22	Sudden cardiac arrest;	chr2:54088310	chr2:54082554~54085066:+
THCA	cis	rs4950322	0.748	rs17356680	ENSG00000226015.2	CCT8P1	4.79	2.27e-06	0.000268	0.25	0.22	Protein quantitative trait loci;	chr1:147354934	chr1:147203276~147204932:-
THCA	cis	rs10256972	0.706	rs12701969	ENSG00000225146.1	AC073957.15	4.79	2.27e-06	0.000268	0.24	0.22	Endometriosis;Longevity;	chr7:1082213	chr7:1029025~1043891:+
THCA	cis	rs9329221	0.65	rs657913	ENSG00000248538.5	RP11-10A14.5	4.79	2.27e-06	0.000268	0.27	0.22	Neuroticism;	chr8:10025065	chr8:9189011~9202854:+
THCA	cis	rs1979679	0.808	rs71452082	ENSG00000247934.4	RP11-967K21.1	-4.79	2.27e-06	0.000268	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28221647	chr12:28163298~28190738:-
THCA	cis	rs4061073	0.924	rs67060003	ENSG00000198711.5	SSBP3-AS1	-4.79	2.27e-06	0.000268	-0.2	-0.22	Body mass index;	chr1:54232568	chr1:54236440~54239063:+
THCA	cis	rs62025270	0.632	rs16943251	ENSG00000259295.5	CSPG4P12	-4.79	2.27e-06	0.000268	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85191438~85213905:+
THCA	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	4.79	2.27e-06	0.000268	0.12	0.22	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
THCA	cis	rs6545883	0.524	rs2694618	ENSG00000270820.4	RP11-355B11.2	4.79	2.27e-06	0.000268	0.18	0.22	Tuberculosis;	chr2:61309849	chr2:61471188~61484130:+
THCA	cis	rs9880211	1	rs28634226	ENSG00000239213.4	NCK1-AS1	4.79	2.28e-06	0.000268	0.23	0.22	Height;Body mass index;	chr3:136411040	chr3:136841726~136862054:-
THCA	cis	rs957448	1	rs16916881	ENSG00000253175.1	RP11-267M23.6	4.79	2.28e-06	0.000268	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94565036~94565715:+
THCA	cis	rs957448	1	rs28817653	ENSG00000253175.1	RP11-267M23.6	4.79	2.28e-06	0.000268	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94565036~94565715:+
THCA	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	4.79	2.28e-06	0.000268	0.24	0.22	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
THCA	cis	rs62246343	0.719	rs56782786	ENSG00000254485.4	RP11-380O24.1	4.79	2.28e-06	0.000268	0.29	0.22	Fibrinogen levels;	chr3:9425388	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.719	rs62246308	ENSG00000254485.4	RP11-380O24.1	4.79	2.28e-06	0.000268	0.29	0.22	Fibrinogen levels;	chr3:9427603	chr3:9292588~9363303:-
THCA	cis	rs7474896	0.616	rs2474561	ENSG00000276805.1	RP11-291L22.6	4.79	2.28e-06	0.000268	0.28	0.22	Obesity (extreme);	chr10:38084616	chr10:38451030~38451785:+
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000273796.1	LL21NC02-21A1.1	-4.79	2.28e-06	0.000268	-0.22	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45403809~45404369:-
THCA	cis	rs875971	0.545	rs6979636	ENSG00000228409.4	CCT6P1	-4.79	2.28e-06	0.000268	-0.18	-0.22	Aortic root size;	chr7:66276638	chr7:65751142~65763354:+
THCA	cis	rs4713118	0.591	rs2056924	ENSG00000216915.2	RP1-97D16.1	-4.79	2.28e-06	0.000268	-0.29	-0.22	Parkinson's disease;	chr6:27722395	chr6:27737000~27738494:-
THCA	cis	rs2617170	0.961	rs2734565	ENSG00000245648.1	RP11-277P12.20	4.79	2.28e-06	0.000268	0.23	0.22	Behcet's disease;	chr12:10407992	chr12:10363769~10398506:+
THCA	cis	rs8050907	0.744	rs17137053	ENSG00000278434.1	RP11-709D24.8	-4.79	2.28e-06	0.000269	-0.47	-0.22	Obesity-related traits;	chr16:4474154	chr16:4532216~4533670:-
THCA	cis	rs8050907	0.744	rs56235717	ENSG00000278434.1	RP11-709D24.8	-4.79	2.28e-06	0.000269	-0.47	-0.22	Obesity-related traits;	chr16:4474373	chr16:4532216~4533670:-
THCA	cis	rs8050907	0.744	rs55810554	ENSG00000278434.1	RP11-709D24.8	-4.79	2.28e-06	0.000269	-0.47	-0.22	Obesity-related traits;	chr16:4474391	chr16:4532216~4533670:-
THCA	cis	rs8050907	0.661	rs17137056	ENSG00000278434.1	RP11-709D24.8	-4.79	2.28e-06	0.000269	-0.47	-0.22	Obesity-related traits;	chr16:4474684	chr16:4532216~4533670:-
THCA	cis	rs8050907	0.744	rs13330957	ENSG00000278434.1	RP11-709D24.8	-4.79	2.28e-06	0.000269	-0.47	-0.22	Obesity-related traits;	chr16:4475329	chr16:4532216~4533670:-
THCA	cis	rs8050907	0.744	rs28629405	ENSG00000278434.1	RP11-709D24.8	-4.79	2.28e-06	0.000269	-0.47	-0.22	Obesity-related traits;	chr16:4475932	chr16:4532216~4533670:-
THCA	cis	rs8050907	0.744	rs17879291	ENSG00000278434.1	RP11-709D24.8	-4.79	2.28e-06	0.000269	-0.47	-0.22	Obesity-related traits;	chr16:4476103	chr16:4532216~4533670:-
THCA	cis	rs8050907	0.744	rs1362625	ENSG00000278434.1	RP11-709D24.8	-4.79	2.28e-06	0.000269	-0.47	-0.22	Obesity-related traits;	chr16:4476309	chr16:4532216~4533670:-
THCA	cis	rs1823913	0.637	rs4853584	ENSG00000280083.1	RP11-317J9.1	4.79	2.28e-06	0.000269	0.25	0.22	Obesity-related traits;	chr2:191310596	chr2:191154118~191156070:-
THCA	cis	rs1707322	0.964	rs785508	ENSG00000281133.1	AL355480.3	4.79	2.28e-06	0.000269	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.964	rs785509	ENSG00000281133.1	AL355480.3	4.79	2.28e-06	0.000269	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45580892~45580996:-
THCA	cis	rs11088226	1	rs2833888	ENSG00000186842.4	LINC00846	-4.79	2.28e-06	0.000269	-0.29	-0.22	Gastritis;	chr21:32555250	chr21:32572238~32575881:-
THCA	cis	rs9880211	0.821	rs9832813	ENSG00000273486.1	RP11-731C17.2	4.79	2.28e-06	0.000269	0.19	0.22	Height;Body mass index;	chr3:136346723	chr3:136837338~136839021:-
THCA	cis	rs7951911	1	rs4755957	ENSG00000254427.1	RP11-430H10.1	4.79	2.28e-06	0.000269	0.33	0.22	IgG glycosylation;	chr11:45079987	chr11:45355371~45366121:+
THCA	cis	rs6832769	0.961	rs13152650	ENSG00000272969.1	RP11-528I4.2	4.79	2.28e-06	0.000269	0.25	0.22	Personality dimensions;	chr4:55491691	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs1522110	ENSG00000272969.1	RP11-528I4.2	4.79	2.28e-06	0.000269	0.25	0.22	Personality dimensions;	chr4:55514116	chr4:55547112~55547889:+
THCA	cis	rs2067615	0.579	rs1073261	ENSG00000260329.1	RP11-412D9.4	-4.79	2.28e-06	0.000269	-0.2	-0.22	Heart rate;	chr12:106742164	chr12:106954029~106955497:-
THCA	cis	rs2243480	1	rs34702770	ENSG00000232559.3	GS1-124K5.12	4.79	2.28e-06	0.000269	0.32	0.22	Diabetic kidney disease;	chr7:65879836	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs34637256	ENSG00000232559.3	GS1-124K5.12	4.79	2.28e-06	0.000269	0.32	0.22	Diabetic kidney disease;	chr7:65895144	chr7:66554588~66576923:-
THCA	cis	rs12188164	0.543	rs890972	ENSG00000221990.4	EXOC3-AS1	-4.79	2.28e-06	0.000269	-0.17	-0.22	Cystic fibrosis severity;	chr5:462350	chr5:441498~443160:-
THCA	cis	rs12188164	0.543	rs2434694	ENSG00000221990.4	EXOC3-AS1	-4.79	2.28e-06	0.000269	-0.17	-0.22	Cystic fibrosis severity;	chr5:462619	chr5:441498~443160:-
THCA	cis	rs11723261	0.564	rs61792258	ENSG00000211553.1	AC253576.2	-4.79	2.28e-06	0.000269	-0.32	-0.22	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:136461~136568:+
THCA	cis	rs12893668	0.572	rs1606	ENSG00000269958.1	RP11-73M18.8	4.79	2.29e-06	0.000269	0.21	0.22	Reticulocyte count;	chr14:103694944	chr14:103696353~103697163:+
THCA	cis	rs79349575	0.87	rs12941262	ENSG00000270781.1	RP11-501C14.9	-4.79	2.29e-06	0.000269	-0.26	-0.22	Type 2 diabetes;	chr17:48889675	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.778	rs12950328	ENSG00000270781.1	RP11-501C14.9	-4.79	2.29e-06	0.000269	-0.26	-0.22	Type 2 diabetes;	chr17:48889699	chr17:48899131~48899748:+
THCA	cis	rs9959145	0.85	rs76780647	ENSG00000267108.1	RP11-861E21.1	4.79	2.29e-06	0.000269	0.27	0.22	Immune response to smallpox vaccine (IL-6);	chr18:12710821	chr18:12432897~12437635:+
THCA	cis	rs8067545	0.532	rs12943904	ENSG00000261033.1	RP11-209D14.2	-4.79	2.29e-06	0.000269	-0.31	-0.22	Schizophrenia;	chr17:20104254	chr17:20008051~20009234:-
THCA	cis	rs10833905	0.756	rs16910406	ENSG00000246225.5	RP11-17A1.3	4.79	2.29e-06	0.00027	0.32	0.22	Sudden cardiac arrest;	chr11:22984200	chr11:22829380~22945393:+
THCA	cis	rs853679	0.76	rs9393909	ENSG00000219392.1	RP1-265C24.5	4.79	2.29e-06	0.00027	0.35	0.22	Depression;	chr6:28239422	chr6:28115628~28116551:+
THCA	cis	rs7181230	0.885	rs2412478	ENSG00000275636.1	RP11-521C20.5	4.79	2.29e-06	0.00027	0.23	0.22	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40078892~40079347:+
THCA	cis	rs793571	0.505	rs2305421	ENSG00000245975.2	RP11-30K9.6	4.79	2.29e-06	0.00027	0.25	0.22	Schizophrenia;	chr15:58610884	chr15:58768072~58770974:-
THCA	cis	rs3892630	0.558	rs4588103	ENSG00000267567.1	CTD-2538C1.3	4.79	2.29e-06	0.00027	0.33	0.22	Red blood cell traits;	chr19:32861864	chr19:32718298~32719595:-
THCA	cis	rs8027521	0.64	rs8024617	ENSG00000280362.1	RP11-643A5.3	4.79	2.29e-06	0.00027	0.27	0.22	Circulating chemerin levels;	chr15:53976109	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.666	rs1478218	ENSG00000280362.1	RP11-643A5.3	4.79	2.29e-06	0.00027	0.27	0.22	Circulating chemerin levels;	chr15:53977255	chr15:53910769~53914712:+
THCA	cis	rs12887734	0.546	rs12886637	ENSG00000269910.1	RP11-73M18.10	-4.79	2.29e-06	0.00027	-0.2	-0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103694516~103695050:-
THCA	cis	rs6088580	0.634	rs6059779	ENSG00000276073.1	RP5-1125A11.7	4.79	2.29e-06	0.00027	0.19	0.22	Glomerular filtration rate (creatinine);	chr20:34362519	chr20:33985617~33988989:-
THCA	cis	rs2447820	0.5	rs165976	ENSG00000249996.1	RP11-359P5.1	4.79	2.29e-06	0.00027	0.25	0.22	Migraine;	chr5:122878151	chr5:123036271~123054667:+
THCA	cis	rs5758511	0.68	rs739146	ENSG00000281538.1	RP4-669P10.20	-4.79	2.29e-06	0.00027	-0.24	-0.22	Birth weight;	chr22:42264408	chr22:42138060~42139726:+
THCA	cis	rs12823128	0.766	rs12817361	ENSG00000256185.1	RP11-612B6.2	-4.79	2.29e-06	0.00027	-0.2	-0.22	Birth weight;	chr12:26734971	chr12:26335864~26336950:-
THCA	cis	rs6430538	0.621	rs12471304	ENSG00000224043.6	CCNT2-AS1	-4.79	2.29e-06	0.00027	-0.23	-0.22	Parkinson's disease;	chr2:134802950	chr2:134735464~134918710:-
THCA	cis	rs7829975	0.545	rs13261926	ENSG00000253893.2	FAM85B	4.79	2.29e-06	0.00027	0.3	0.22	Mood instability;	chr8:8694100	chr8:8167819~8226614:-
THCA	cis	rs6792584	0.743	rs4479607	ENSG00000241316.5	SUCLG2-AS1	4.79	2.29e-06	0.00027	0.21	0.22	Corneal astigmatism;	chr3:67461527	chr3:67654697~67947713:+
THCA	cis	rs72753537	0.766	rs114008430	ENSG00000214417.4	KRT18P13	4.79	2.29e-06	0.00027	0.24	0.22	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97847960	chr9:97698922~97700734:+
THCA	cis	rs13256369	0.826	rs12678414	ENSG00000254153.1	CTA-398F10.2	-4.79	2.29e-06	0.00027	-0.24	-0.22	Obesity-related traits;	chr8:8728506	chr8:8456909~8461337:-
THCA	cis	rs17123764	0.71	rs7296281	ENSG00000257464.1	RP11-161H23.8	-4.78	2.29e-06	0.00027	-0.34	-0.22	Intelligence (multi-trait analysis);	chr12:49570775	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs2005195	ENSG00000257464.1	RP11-161H23.8	-4.78	2.29e-06	0.00027	-0.34	-0.22	Intelligence (multi-trait analysis);	chr12:49589696	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs11169081	ENSG00000257464.1	RP11-161H23.8	-4.78	2.29e-06	0.00027	-0.34	-0.22	Intelligence (multi-trait analysis);	chr12:49591427	chr12:49442424~49442652:-
THCA	cis	rs72615157	0.634	rs2272343	ENSG00000078319.8	PMS2P1	-4.78	2.29e-06	0.00027	-0.28	-0.22	Lung function (FEV1/FVC);	chr7:100180662	chr7:100320992~100341908:-
THCA	cis	rs72615157	0.634	rs74742883	ENSG00000078319.8	PMS2P1	-4.78	2.29e-06	0.00027	-0.28	-0.22	Lung function (FEV1/FVC);	chr7:100188142	chr7:100320992~100341908:-
THCA	cis	rs11671005	0.735	rs12981875	ENSG00000268049.1	CTD-2619J13.9	-4.78	2.29e-06	0.00027	-0.33	-0.22	Mean platelet volume;	chr19:58423763	chr19:58357999~58359603:+
THCA	cis	rs12760731	0.582	rs35304375	ENSG00000213057.5	C1orf220	4.78	2.3e-06	0.00027	0.25	0.22	Obesity-related traits;	chr1:178570045	chr1:178542752~178548889:+
THCA	cis	rs12023718	0.545	rs12024886	ENSG00000213057.5	C1orf220	4.78	2.3e-06	0.00027	0.25	0.22	Obesity-related traits;	chr1:178578527	chr1:178542752~178548889:+
THCA	cis	rs7429990	0.965	rs35199727	ENSG00000228638.1	FCF1P2	-4.78	2.3e-06	0.00027	-0.22	-0.22	Educational attainment (years of education);	chr3:47905218	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs11707679	ENSG00000228638.1	FCF1P2	-4.78	2.3e-06	0.00027	-0.22	-0.22	Educational attainment (years of education);	chr3:47915016	chr3:48290793~48291375:-
THCA	cis	rs12188164	0.561	rs2721010	ENSG00000221990.4	EXOC3-AS1	-4.78	2.3e-06	0.00027	-0.17	-0.22	Cystic fibrosis severity;	chr5:456800	chr5:441498~443160:-
THCA	cis	rs7688540	0.8	rs1578898	ENSG00000250892.1	RP11-1365D11.1	4.78	2.3e-06	0.00027	0.3	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:201409~205009:-
THCA	cis	rs62025270	0.522	rs16943120	ENSG00000259295.5	CSPG4P12	-4.78	2.3e-06	0.00027	-0.37	-0.22	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85191438~85213905:+
THCA	cis	rs2236521	0.617	rs2236520	ENSG00000273619.1	RP5-908M14.9	-4.78	2.3e-06	0.00027	-0.17	-0.22	Pelvic organ prolapse;	chr20:62317116	chr20:62386303~62386970:-
THCA	cis	rs6832769	0.961	rs13128582	ENSG00000272969.1	RP11-528I4.2	4.78	2.3e-06	0.00027	0.25	0.22	Personality dimensions;	chr4:55462777	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.925	rs6817267	ENSG00000272969.1	RP11-528I4.2	4.78	2.3e-06	0.00027	0.25	0.22	Personality dimensions;	chr4:55472374	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs11931061	ENSG00000272969.1	RP11-528I4.2	4.78	2.3e-06	0.00027	0.25	0.22	Personality dimensions;	chr4:55472626	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs7668147	ENSG00000272969.1	RP11-528I4.2	4.78	2.3e-06	0.00027	0.25	0.22	Personality dimensions;	chr4:55473217	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs11947476	ENSG00000272969.1	RP11-528I4.2	4.78	2.3e-06	0.00027	0.25	0.22	Personality dimensions;	chr4:55473584	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs13102385	ENSG00000272969.1	RP11-528I4.2	4.78	2.3e-06	0.00027	0.25	0.22	Personality dimensions;	chr4:55479088	chr4:55547112~55547889:+
THCA	cis	rs58605417	0.534	rs1700138	ENSG00000253553.4	RP11-586K2.1	4.78	2.3e-06	0.00027	0.22	0.22	Schizophrenia;	chr8:88448795	chr8:88326836~88737134:+
THCA	cis	rs2446066	0.872	rs11170555	ENSG00000257379.1	RP11-793H13.8	4.78	2.3e-06	0.00027	0.33	0.22	Red blood cell count;	chr12:53430359	chr12:53441741~53467528:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000229886.1	RP5-1132H15.3	-4.78	2.3e-06	0.000271	-0.22	-0.22	Aortic root size;	chr7:65950660	chr7:66025126~66031544:-
THCA	cis	rs2243480	1	rs437889	ENSG00000232559.3	GS1-124K5.12	4.78	2.3e-06	0.000271	0.32	0.22	Diabetic kidney disease;	chr7:66044247	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs160655	ENSG00000232559.3	GS1-124K5.12	4.78	2.3e-06	0.000271	0.31	0.22	Diabetic kidney disease;	chr7:66068227	chr7:66554588~66576923:-
THCA	cis	rs17767392	0.958	rs4902942	ENSG00000259146.3	RP1-261D10.2	-4.78	2.3e-06	0.000271	-0.28	-0.22	Mitral valve prolapse;	chr14:71673942	chr14:71292729~71321814:-
THCA	cis	rs10984970	0.826	rs10984964	ENSG00000238181.2	AHCYP2	4.78	2.3e-06	0.000271	0.55	0.22	Lung cancer;	chr9:120597522	chr9:120720673~120721972:+
THCA	cis	rs867371	0.502	rs7176926	ENSG00000259429.4	UBE2Q2P2	-4.78	2.3e-06	0.000271	-0.17	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82355142~82420075:+
THCA	cis	rs9876781	1	rs9881491	ENSG00000244380.1	RP11-24C3.2	4.78	2.3e-06	0.000271	0.25	0.22	Longevity;	chr3:48446507	chr3:48440352~48446656:-
THCA	cis	rs6138458	1	rs2387361	ENSG00000274173.1	RP4-568C11.4	-4.78	2.3e-06	0.000271	-0.21	-0.22	Blood protein levels;	chr20:24919269	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs2387362	ENSG00000274173.1	RP4-568C11.4	-4.78	2.3e-06	0.000271	-0.21	-0.22	Blood protein levels;	chr20:24919270	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs1977540	ENSG00000274173.1	RP4-568C11.4	-4.78	2.3e-06	0.000271	-0.21	-0.22	Blood protein levels;	chr20:24919654	chr20:24931840~24932983:+
THCA	cis	rs10266483	0.774	rs56055804	ENSG00000227986.1	TRIM60P18	4.78	2.3e-06	0.000271	0.2	0.22	Response to statin therapy;	chr7:64410423	chr7:64355078~64356199:+
THCA	cis	rs853679	0.769	rs17720293	ENSG00000272009.1	RP1-313I6.12	-4.78	2.3e-06	0.000271	-0.37	-0.22	Depression;	chr6:28246920	chr6:28078792~28081130:-
THCA	cis	rs13434995	0.513	rs972446	ENSG00000273257.1	RP11-177J6.1	4.78	2.3e-06	0.000271	0.32	0.22	Adiponectin levels;	chr4:55569581	chr4:55387949~55388271:+
THCA	cis	rs13434995	0.513	rs11732481	ENSG00000273257.1	RP11-177J6.1	4.78	2.3e-06	0.000271	0.32	0.22	Adiponectin levels;	chr4:55570212	chr4:55387949~55388271:+
THCA	cis	rs4915077	1	rs9787296	ENSG00000230489.1	VAV3-AS1	4.78	2.3e-06	0.000271	0.38	0.22	Hypothyroidism;	chr1:107840205	chr1:107964443~107994607:+
THCA	cis	rs1371614	0.588	rs10181727	ENSG00000229122.1	AGBL5-IT1	-4.78	2.3e-06	0.000271	-0.15	-0.22	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26948377	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.545	rs1057115	ENSG00000229122.1	AGBL5-IT1	-4.78	2.3e-06	0.000271	-0.15	-0.22	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26949201	chr2:27061038~27061815:+
THCA	cis	rs2447820	0.541	rs171546	ENSG00000249996.1	RP11-359P5.1	4.78	2.3e-06	0.000271	0.25	0.22	Migraine;	chr5:122915059	chr5:123036271~123054667:+
THCA	cis	rs2447820	0.588	rs246304	ENSG00000249996.1	RP11-359P5.1	4.78	2.3e-06	0.000271	0.25	0.22	Migraine;	chr5:122916146	chr5:123036271~123054667:+
THCA	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	4.78	2.3e-06	0.000271	0.3	0.22	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
THCA	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-4.78	2.3e-06	0.000271	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
THCA	cis	rs2562456	0.876	rs2359144	ENSG00000268117.1	VN1R84P	4.78	2.3e-06	0.000271	0.34	0.22	Pain;	chr19:21407834	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.876	rs4638726	ENSG00000268117.1	VN1R84P	4.78	2.3e-06	0.000271	0.34	0.22	Pain;	chr19:21409710	chr19:21719801~21720035:-
THCA	cis	rs8141529	0.702	rs469991	ENSG00000272858.1	CTA-292E10.8	4.78	2.3e-06	0.000271	0.22	0.22	Lymphocyte counts;	chr22:28911871	chr22:28814914~28815662:+
THCA	cis	rs12188164	0.543	rs7728027	ENSG00000221990.4	EXOC3-AS1	-4.78	2.3e-06	0.000271	-0.17	-0.22	Cystic fibrosis severity;	chr5:459828	chr5:441498~443160:-
THCA	cis	rs1005277	0.579	rs1780137	ENSG00000272983.1	RP11-508N22.12	4.78	2.3e-06	0.000271	0.19	0.22	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38137337~38144399:+
THCA	cis	rs4915077	0.892	rs17020055	ENSG00000230489.1	VAV3-AS1	4.78	2.3e-06	0.000271	0.34	0.22	Hypothyroidism;	chr1:107793911	chr1:107964443~107994607:+
THCA	cis	rs494453	0.922	rs498787	ENSG00000227811.2	FAM212B-AS1	-4.78	2.3e-06	0.000271	-0.27	-0.22	Osteoporosis-related phenotypes;	chr1:111690722	chr1:111739841~111747798:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-4.78	2.31e-06	0.000271	-0.24	-0.22	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-4.78	2.31e-06	0.000271	-0.24	-0.22	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-4.78	2.31e-06	0.000271	-0.24	-0.22	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-4.78	2.31e-06	0.000271	-0.24	-0.22	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-4.78	2.31e-06	0.000271	-0.24	-0.22	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
THCA	cis	rs1009077	0.514	rs71614451	ENSG00000245958.5	RP11-33B1.1	4.78	2.31e-06	0.000271	0.29	0.22	Endometriosis;	chr4:119483305	chr4:119454791~119552025:+
THCA	cis	rs12887734	0.546	rs4900597	ENSG00000269910.1	RP11-73M18.10	-4.78	2.31e-06	0.000271	-0.2	-0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103800327	chr14:103694516~103695050:-
THCA	cis	rs12887734	0.569	rs66953418	ENSG00000269910.1	RP11-73M18.10	4.78	2.31e-06	0.000271	0.2	0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103694516~103695050:-
THCA	cis	rs6728642	0.614	rs113485946	ENSG00000230606.9	AC159540.1	4.78	2.31e-06	0.000271	0.33	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97200705	chr2:97416165~97433527:-
THCA	cis	rs6728642	0.808	rs114192053	ENSG00000230606.9	AC159540.1	4.78	2.31e-06	0.000271	0.33	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97206169	chr2:97416165~97433527:-
THCA	cis	rs7829975	0.572	rs28446104	ENSG00000254153.1	CTA-398F10.2	4.78	2.31e-06	0.000271	0.24	0.22	Mood instability;	chr8:8938391	chr8:8456909~8461337:-
THCA	cis	rs10510102	0.872	rs11200277	ENSG00000226864.1	ATE1-AS1	4.78	2.31e-06	0.000271	0.35	0.22	Breast cancer;	chr10:121944295	chr10:121928312~121951965:+
THCA	cis	rs7520050	0.807	rs3013594	ENSG00000234329.1	RP11-767N6.2	4.78	2.31e-06	0.000272	0.19	0.22	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000273796.1	LL21NC02-21A1.1	4.78	2.31e-06	0.000272	0.22	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45403809~45404369:-
THCA	cis	rs9634489	0.502	rs77248334	ENSG00000247400.3	DNAJC3-AS1	4.78	2.31e-06	0.000272	0.14	0.22	Body mass index;	chr13:96466908	chr13:95648733~95676925:-
THCA	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	4.78	2.31e-06	0.000272	0.26	0.22	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
THCA	cis	rs7005380	0.733	rs4871787	ENSG00000245330.4	KB-1471A8.1	-4.78	2.31e-06	0.000272	-0.21	-0.22	Interstitial lung disease;	chr8:119924178	chr8:119867419~119874488:-
THCA	cis	rs2281636	0.858	rs7068079	ENSG00000260475.1	RP11-85A1.3	-4.78	2.31e-06	0.000272	-0.2	-0.22	Obesity-related traits;	chr10:99607558	chr10:99621055~99621918:+
THCA	cis	rs3738443	0.817	rs6698690	ENSG00000259865.1	RP11-488L18.10	4.78	2.31e-06	0.000272	0.22	0.22	Alcohol dependence;	chr1:247199176	chr1:247187281~247188526:-
THCA	cis	rs4700393	0.52	rs6449484	ENSG00000251279.1	CTC-436P18.1	4.78	2.31e-06	0.000272	0.3	0.22	Intelligence (multi-trait analysis);	chr5:60699603	chr5:61162070~61232040:+
THCA	cis	rs6012564	1	rs11696396	ENSG00000230758.1	SNAP23P	4.78	2.31e-06	0.000272	0.26	0.22	Anger;	chr20:49136482	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs6066978	ENSG00000230758.1	SNAP23P	4.78	2.31e-06	0.000272	0.26	0.22	Anger;	chr20:49139205	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs6063361	ENSG00000230758.1	SNAP23P	4.78	2.31e-06	0.000272	0.26	0.22	Anger;	chr20:49141426	chr20:49038357~49038602:-
THCA	cis	rs9425766	0.679	rs12085290	ENSG00000227373.4	RP11-160H22.5	-4.78	2.31e-06	0.000272	-0.3	-0.22	Life satisfaction;	chr1:174124699	chr1:174115300~174160004:-
THCA	cis	rs7182621	0.509	rs12917012	ENSG00000182397.13	DNM1P46	4.78	2.31e-06	0.000272	0.24	0.22	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99790156~99806927:-
THCA	cis	rs7010876	0.561	rs1394519	ENSG00000253553.4	RP11-586K2.1	-4.78	2.31e-06	0.000272	-0.22	-0.22	Schizophrenia;	chr8:88388235	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs1394518	ENSG00000253553.4	RP11-586K2.1	-4.78	2.31e-06	0.000272	-0.22	-0.22	Schizophrenia;	chr8:88388297	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs1394517	ENSG00000253553.4	RP11-586K2.1	-4.78	2.31e-06	0.000272	-0.22	-0.22	Schizophrenia;	chr8:88388427	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs4961094	ENSG00000253553.4	RP11-586K2.1	-4.78	2.31e-06	0.000272	-0.22	-0.22	Schizophrenia;	chr8:88389036	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs4961096	ENSG00000253553.4	RP11-586K2.1	-4.78	2.31e-06	0.000272	-0.22	-0.22	Schizophrenia;	chr8:88389139	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs1875904	ENSG00000253553.4	RP11-586K2.1	-4.78	2.31e-06	0.000272	-0.22	-0.22	Schizophrenia;	chr8:88389498	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs12682164	ENSG00000253553.4	RP11-586K2.1	-4.78	2.31e-06	0.000272	-0.22	-0.22	Schizophrenia;	chr8:88390295	chr8:88326836~88737134:+
THCA	cis	rs875971	0.545	rs10261710	ENSG00000232546.1	RP11-458F8.1	4.78	2.31e-06	0.000272	0.21	0.22	Aortic root size;	chr7:66249202	chr7:66848496~66858136:+
THCA	cis	rs6674176	0.932	rs4660761	ENSG00000237950.1	RP11-7O11.3	4.78	2.31e-06	0.000272	0.22	0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43974474	chr1:43944370~43946551:-
THCA	cis	rs2803122	0.811	rs10811163	ENSG00000273226.1	RP11-513M16.8	-4.78	2.31e-06	0.000272	-0.2	-0.22	Pulse pressure;	chr9:19284150	chr9:19375451~19375996:+
THCA	cis	rs8105895	0.935	rs7253053	ENSG00000269345.1	VN1R85P	4.78	2.31e-06	0.000272	0.29	0.22	Body mass index (change over time);	chr19:22062883	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7247041	ENSG00000269345.1	VN1R85P	4.78	2.31e-06	0.000272	0.29	0.22	Body mass index (change over time);	chr19:22066988	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10420042	ENSG00000269345.1	VN1R85P	4.78	2.31e-06	0.000272	0.29	0.22	Body mass index (change over time);	chr19:22069124	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs2043315	ENSG00000269345.1	VN1R85P	4.78	2.31e-06	0.000272	0.29	0.22	Body mass index (change over time);	chr19:22070021	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10411275	ENSG00000269345.1	VN1R85P	4.78	2.31e-06	0.000272	0.29	0.22	Body mass index (change over time);	chr19:22076667	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10411943	ENSG00000269345.1	VN1R85P	4.78	2.31e-06	0.000272	0.29	0.22	Body mass index (change over time);	chr19:22076980	chr19:22174766~22175191:-
THCA	cis	rs651907	0.535	rs11707250	ENSG00000244119.1	PDCL3P4	-4.78	2.31e-06	0.000272	-0.2	-0.22	Colorectal cancer;	chr3:101790527	chr3:101712472~101713191:+
THCA	cis	rs72843506	0.591	rs74319100	ENSG00000231258.2	ZSWIM5P2	4.78	2.31e-06	0.000272	0.31	0.22	Schizophrenia;	chr17:20318079	chr17:20583758~20591180:-
THCA	cis	rs13434995	0.537	rs6554275	ENSG00000249700.7	SRD5A3-AS1	4.78	2.31e-06	0.000272	0.33	0.22	Adiponectin levels;	chr4:55362981	chr4:55363971~55395847:-
THCA	cis	rs6832769	1	rs7677526	ENSG00000272969.1	RP11-528I4.2	4.78	2.32e-06	0.000272	0.25	0.22	Personality dimensions;	chr4:55483741	chr4:55547112~55547889:+
THCA	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-4.78	2.32e-06	0.000272	-0.13	-0.22	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
THCA	cis	rs1865760	0.519	rs4360119	ENSG00000272462.2	U91328.19	-4.78	2.32e-06	0.000272	-0.18	-0.22	Height;	chr6:25814846	chr6:25992662~26001775:+
THCA	cis	rs202072	0.872	rs445714	ENSG00000272379.1	RP1-257A7.5	4.78	2.32e-06	0.000272	0.32	0.22	HIV-1 viral setpoint;	chr6:13280726	chr6:13290018~13290490:-
THCA	cis	rs9880211	1	rs12695649	ENSG00000239213.4	NCK1-AS1	4.78	2.32e-06	0.000273	0.23	0.22	Height;Body mass index;	chr3:136553074	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs6774964	ENSG00000239213.4	NCK1-AS1	4.78	2.32e-06	0.000273	0.23	0.22	Height;Body mass index;	chr3:136556740	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs6775314	ENSG00000239213.4	NCK1-AS1	4.78	2.32e-06	0.000273	0.23	0.22	Height;Body mass index;	chr3:136557106	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs28641809	ENSG00000239213.4	NCK1-AS1	4.78	2.32e-06	0.000273	0.23	0.22	Height;Body mass index;	chr3:136571647	chr3:136841726~136862054:-
THCA	cis	rs2287838	1	rs2303100	ENSG00000267289.1	CTD-2623N2.11	-4.78	2.32e-06	0.000273	-0.25	-0.22	Sleep duration;	chr19:9857758	chr19:9834079~9835013:-
THCA	cis	rs36093844	0.8	rs11826218	ENSG00000279742.1	RP11-700A24.1	-4.78	2.32e-06	0.000273	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85857479	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs2044390	ENSG00000279742.1	RP11-700A24.1	-4.78	2.32e-06	0.000273	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85858791	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs75639684	ENSG00000279742.1	RP11-700A24.1	-4.78	2.32e-06	0.000273	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85860533	chr11:85852557~85854943:-
THCA	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	4.78	2.32e-06	0.000273	0.12	0.22	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
THCA	cis	rs7772486	0.754	rs702306	ENSG00000270638.1	RP3-466P17.1	-4.78	2.32e-06	0.000273	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145735570~145737218:+
THCA	cis	rs9388451	0.839	rs9401845	ENSG00000226409.1	RP11-735G4.1	-4.78	2.32e-06	0.000273	-0.25	-0.22	Brugada syndrome;	chr6:125782972	chr6:125370211~125374324:-
THCA	cis	rs9388451	0.805	rs1028481	ENSG00000226409.1	RP11-735G4.1	-4.78	2.32e-06	0.000273	-0.25	-0.22	Brugada syndrome;	chr6:125785427	chr6:125370211~125374324:-
THCA	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-4.78	2.32e-06	0.000273	-0.33	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
THCA	cis	rs6088590	1	rs6088590	ENSG00000269202.1	RP4-614O4.12	-4.78	2.32e-06	0.000273	-0.19	-0.22	Coronary artery disease;	chr20:34725762	chr20:35201747~35203288:-
THCA	cis	rs6088590	1	rs6120705	ENSG00000269202.1	RP4-614O4.12	-4.78	2.32e-06	0.000273	-0.19	-0.22	Coronary artery disease;	chr20:34725936	chr20:35201747~35203288:-
THCA	cis	rs9880211	1	rs28718456	ENSG00000239213.4	NCK1-AS1	4.78	2.32e-06	0.000273	0.23	0.22	Height;Body mass index;	chr3:136485164	chr3:136841726~136862054:-
THCA	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	4.78	2.32e-06	0.000273	0.23	0.22	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
THCA	cis	rs12761761	1	rs7921418	ENSG00000279982.1	RP11-45A17.3	-4.78	2.32e-06	0.000273	-0.33	-0.22	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131961727	chr10:131996738~131999846:+
THCA	cis	rs10833905	0.701	rs11026873	ENSG00000246225.5	RP11-17A1.3	-4.78	2.32e-06	0.000273	-0.32	-0.22	Sudden cardiac arrest;	chr11:22983116	chr11:22829380~22945393:+
THCA	cis	rs1048886	0.938	rs6900840	ENSG00000271967.1	RP11-134K13.4	-4.78	2.32e-06	0.000273	-0.21	-0.22	Type 2 diabetes;	chr6:70472101	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs6911812	ENSG00000271967.1	RP11-134K13.4	-4.78	2.32e-06	0.000273	-0.21	-0.22	Type 2 diabetes;	chr6:70473512	chr6:70596438~70596980:+
THCA	cis	rs8141529	0.702	rs469992	ENSG00000272858.1	CTA-292E10.8	4.78	2.32e-06	0.000273	0.22	0.22	Lymphocyte counts;	chr22:28918911	chr22:28814914~28815662:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000164669.11	INTS4P1	4.78	2.32e-06	0.000273	0.31	0.22	Aortic root size;	chr7:66112359	chr7:65141225~65234216:+
THCA	cis	rs10510102	0.872	rs11200267	ENSG00000226864.1	ATE1-AS1	4.78	2.32e-06	0.000273	0.35	0.22	Breast cancer;	chr10:121929851	chr10:121928312~121951965:+
THCA	cis	rs9816784	0.901	rs56253832	ENSG00000273009.1	RP11-352G9.1	-4.78	2.32e-06	0.000273	-0.23	-0.22	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195913078~195913683:-
THCA	cis	rs10483853	0.767	rs12590879	ENSG00000258695.2	RP3-414A15.2	-4.78	2.33e-06	0.000273	-0.3	-0.22	Coronary artery calcification;	chr14:73338201	chr14:73522878~73530610:+
THCA	cis	rs7647973	0.769	rs7434187	ENSG00000228638.1	FCF1P2	-4.78	2.33e-06	0.000274	-0.27	-0.22	Menarche (age at onset);	chr3:48995534	chr3:48290793~48291375:-
THCA	cis	rs4648045	0.861	rs230523	ENSG00000246560.2	RP11-10L12.4	-4.78	2.33e-06	0.000274	-0.27	-0.22	Lymphocyte percentage of white cells;	chr4:102540881	chr4:102828055~102844075:+
THCA	cis	rs1823913	0.526	rs36028476	ENSG00000280083.1	RP11-317J9.1	-4.78	2.33e-06	0.000274	-0.25	-0.22	Obesity-related traits;	chr2:191300595	chr2:191154118~191156070:-
THCA	cis	rs7403037	0.617	rs35110243	ENSG00000259905.4	PWRN1	4.78	2.33e-06	0.000274	0.28	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24581421	chr15:24493137~24652130:+
THCA	cis	rs12449964	0.515	rs9899364	ENSG00000223979.2	SMCR2	4.78	2.33e-06	0.000274	0.23	0.22	Coronary artery disease or ischemic stroke;	chr17:17663798	chr17:17674026~17677688:-
THCA	cis	rs875971	0.545	rs73378304	ENSG00000232546.1	RP11-458F8.1	4.78	2.33e-06	0.000274	0.2	0.22	Aortic root size;	chr7:66175760	chr7:66848496~66858136:+
THCA	cis	rs919433	0.68	rs6434934	ENSG00000231621.1	AC013264.2	-4.78	2.33e-06	0.000274	-0.22	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197572662	chr2:197197991~197199273:+
THCA	cis	rs7141336	0.791	rs12883490	ENSG00000258884.1	CTD-3035D6.2	4.78	2.33e-06	0.000274	0.28	0.22	Anxiety disorder;	chr14:90729028	chr14:90822365~90828128:-
THCA	cis	rs10833905	0.756	rs11529712	ENSG00000246225.5	RP11-17A1.3	-4.78	2.33e-06	0.000274	-0.31	-0.22	Sudden cardiac arrest;	chr11:22964066	chr11:22829380~22945393:+
THCA	cis	rs1150668	0.699	rs1736895	ENSG00000176933.5	TOB2P1	-4.78	2.33e-06	0.000274	-0.24	-0.22	Pubertal anthropometrics;	chr6:28252048	chr6:28217643~28218634:-
THCA	cis	rs1552244	0.748	rs9862221	ENSG00000232901.1	CYCSP10	4.78	2.33e-06	0.000274	0.29	0.22	Alzheimer's disease;	chr3:10017974	chr3:10000647~10000940:-
THCA	cis	rs8113308	0.515	rs55866828	ENSG00000269483.1	AC006272.1	4.78	2.33e-06	0.000274	0.44	0.22	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938332	chr19:51839924~51843324:-
THCA	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-4.78	2.33e-06	0.000274	-0.21	-0.22	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
THCA	cis	rs9467773	0.549	rs9461273	ENSG00000261353.1	CTA-14H9.5	4.78	2.33e-06	0.000274	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26527063~26527404:+
THCA	cis	rs1371614	0.523	rs11904656	ENSG00000229122.1	AGBL5-IT1	4.78	2.33e-06	0.000274	0.15	0.22	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950381	chr2:27061038~27061815:+
THCA	cis	rs2904524	1	rs4761189	ENSG00000257815.4	RP11-611E13.2	-4.78	2.33e-06	0.000274	-0.2	-0.22	Amyotrophic lateral sclerosis (age of onset);	chr12:70247078	chr12:69904033~70243360:-
THCA	cis	rs860295	0.702	rs2025669	ENSG00000160766.13	GBAP1	-4.78	2.33e-06	0.000274	-0.25	-0.22	Body mass index;	chr1:155387818	chr1:155213821~155227422:-
THCA	cis	rs860295	0.702	rs12081067	ENSG00000160766.13	GBAP1	-4.78	2.33e-06	0.000274	-0.25	-0.22	Body mass index;	chr1:155389191	chr1:155213821~155227422:-
THCA	cis	rs860295	0.702	rs10908465	ENSG00000160766.13	GBAP1	-4.78	2.33e-06	0.000274	-0.25	-0.22	Body mass index;	chr1:155419897	chr1:155213821~155227422:-
THCA	cis	rs1322639	0.668	rs9766666	ENSG00000261039.2	RP11-417E7.2	-4.78	2.33e-06	0.000274	-0.25	-0.22	Pulse pressure;	chr6:169213446	chr6:169175304~169182740:-
THCA	cis	rs9880211	0.8	rs66509730	ENSG00000239213.4	NCK1-AS1	4.78	2.33e-06	0.000274	0.24	0.22	Height;Body mass index;	chr3:136785416	chr3:136841726~136862054:-
THCA	cis	rs2790457	0.795	rs7903703	ENSG00000254635.4	WAC-AS1	-4.78	2.33e-06	0.000274	-0.22	-0.22	Multiple myeloma;	chr10:28646220	chr10:28522652~28532743:-
THCA	cis	rs6787172	0.811	rs9810114	ENSG00000272087.1	RP11-379F4.7	4.78	2.33e-06	0.000274	0.19	0.22	Subjective well-being;	chr3:158494266	chr3:158693120~158693768:-
THCA	cis	rs950880	0.71	rs12469506	ENSG00000234389.1	AC007278.3	-4.78	2.33e-06	0.000274	-0.26	-0.22	Serum protein levels (sST2);	chr2:102349411	chr2:102438713~102440475:+
THCA	cis	rs3734266	0.702	rs2296362	ENSG00000272288.4	RP11-140K17.3	-4.78	2.34e-06	0.000275	-0.21	-0.22	Systemic lupus erythematosus;	chr6:34835222	chr6:34696317~34697470:+
THCA	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	4.78	2.34e-06	0.000275	0.29	0.22	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
THCA	cis	rs4767841	0.874	rs7294387	ENSG00000248636.5	RP11-768F21.1	-4.78	2.34e-06	0.000275	-0.23	-0.22	Urgency urinary incontinence;	chr12:119769607	chr12:119387987~119668079:-
THCA	cis	rs7394190	0.748	rs78985317	ENSG00000271848.1	RP11-464F9.21	-4.78	2.34e-06	0.000275	-0.3	-0.22	Incident atrial fibrillation;	chr10:73754707	chr10:73654039~73674719:+
THCA	cis	rs36715	0.909	rs152906	ENSG00000245937.6	LINC01184	4.78	2.34e-06	0.000275	0.24	0.22	Breast cancer;	chr5:128216148	chr5:127940426~128083172:-
THCA	cis	rs1979679	0.541	rs4931085	ENSG00000247934.4	RP11-967K21.1	4.78	2.34e-06	0.000275	0.21	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574577	chr12:28163298~28190738:-
THCA	cis	rs227275	0.554	rs223333	ENSG00000248971.2	KRT8P46	-4.78	2.34e-06	0.000275	-0.26	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223328	ENSG00000248971.2	KRT8P46	-4.78	2.34e-06	0.000275	-0.26	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102728746~102730171:-
THCA	cis	rs7615952	0.8	rs11915699	ENSG00000248787.1	RP11-666A20.4	-4.78	2.34e-06	0.000275	-0.36	-0.22	Blood pressure (smoking interaction);	chr3:125913841	chr3:125908005~125910272:-
THCA	cis	rs9625935	0.957	rs4337577	ENSG00000279159.1	RP3-394A18.1	-4.78	2.34e-06	0.000275	-0.16	-0.22	Tonsillectomy;	chr22:30116139	chr22:29978950~30028236:-
THCA	cis	rs9549367	0.789	rs7999579	ENSG00000269125.1	RP11-98F14.11	-4.78	2.34e-06	0.000275	-0.25	-0.22	Platelet distribution width;	chr13:113225043	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs6577035	ENSG00000269125.1	RP11-98F14.11	-4.78	2.34e-06	0.000275	-0.25	-0.22	Platelet distribution width;	chr13:113225683	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs12584981	ENSG00000269125.1	RP11-98F14.11	-4.78	2.34e-06	0.000275	-0.25	-0.22	Platelet distribution width;	chr13:113226871	chr13:113165002~113165183:-
THCA	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	4.78	2.34e-06	0.000275	0.18	0.22	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	4.78	2.34e-06	0.000275	0.18	0.22	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	4.78	2.34e-06	0.000275	0.18	0.22	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
THCA	cis	rs10090774	0.965	rs11990900	ENSG00000279766.1	RP11-642A1.2	-4.78	2.34e-06	0.000275	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140967821	chr8:140572142~140572812:-
THCA	cis	rs6750795	0.765	rs6742387	ENSG00000223198.1	RNU2-22P	-4.78	2.34e-06	0.000275	-0.28	-0.22	Height;	chr2:231490121	chr2:231501990~231502201:-
THCA	cis	rs6545883	0.794	rs778152	ENSG00000270820.4	RP11-355B11.2	-4.78	2.34e-06	0.000275	-0.18	-0.22	Tuberculosis;	chr2:61381405	chr2:61471188~61484130:+
THCA	cis	rs7537765	1	rs7537765	ENSG00000242349.4	NPPA-AS1	4.78	2.34e-06	0.000275	0.28	0.22	QRS complex (12-leadsum);	chr1:11827246	chr1:11841017~11848079:+
THCA	cis	rs9921338	0.632	rs80945	ENSG00000262703.1	RP11-485G7.6	-4.78	2.34e-06	0.000275	-0.3	-0.22	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249263	chr16:11348143~11349321:-
THCA	cis	rs9880211	1	rs9841529	ENSG00000239213.4	NCK1-AS1	4.78	2.34e-06	0.000275	0.23	0.22	Height;Body mass index;	chr3:136418441	chr3:136841726~136862054:-
THCA	cis	rs4950322	0.57	rs17356184	ENSG00000180867.10	PDIA3P1	4.78	2.34e-06	0.000275	0.22	0.22	Protein quantitative trait loci;	chr1:147262943	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs80270233	ENSG00000180867.10	PDIA3P1	4.78	2.34e-06	0.000275	0.22	0.22	Protein quantitative trait loci;	chr1:147263320	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs4950392	ENSG00000180867.10	PDIA3P1	4.78	2.34e-06	0.000275	0.22	0.22	Protein quantitative trait loci;	chr1:147264889	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs17356219	ENSG00000180867.10	PDIA3P1	4.78	2.34e-06	0.000275	0.22	0.22	Protein quantitative trait loci;	chr1:147265684	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72691041	ENSG00000180867.10	PDIA3P1	4.78	2.34e-06	0.000275	0.22	0.22	Protein quantitative trait loci;	chr1:147267084	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs17356233	ENSG00000180867.10	PDIA3P1	4.78	2.34e-06	0.000275	0.22	0.22	Protein quantitative trait loci;	chr1:147268843	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs17356240	ENSG00000180867.10	PDIA3P1	4.78	2.34e-06	0.000275	0.22	0.22	Protein quantitative trait loci;	chr1:147269877	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs1999820	ENSG00000180867.10	PDIA3P1	4.78	2.34e-06	0.000275	0.22	0.22	Protein quantitative trait loci;	chr1:147270329	chr1:147178113~147179622:+
THCA	cis	rs889398	0.935	rs244420	ENSG00000226232.7	RP11-419C5.2	4.78	2.34e-06	0.000275	0.21	0.22	Body mass index;	chr16:69624093	chr16:69976388~69996188:-
THCA	cis	rs7688540	0.8	rs10028482	ENSG00000250892.1	RP11-1365D11.1	4.78	2.35e-06	0.000276	0.3	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:201409~205009:-
THCA	cis	rs11902236	0.545	rs3791749	ENSG00000188525.3	AC010969.1	-4.78	2.35e-06	0.000276	-0.27	-0.22	Prostate cancer;	chr2:9999636	chr2:10003158~10006030:-
THCA	cis	rs733592	0.599	rs12819124	ENSG00000273765.1	RP11-370I10.11	4.78	2.35e-06	0.000276	0.2	0.22	Plateletcrit;	chr12:48015271	chr12:48360920~48361377:+
THCA	cis	rs7914558	0.621	rs7896290	ENSG00000236937.2	PTGES3P4	4.78	2.35e-06	0.000276	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102896258	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.621	rs12219346	ENSG00000236937.2	PTGES3P4	4.78	2.35e-06	0.000276	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102897543	chr10:102845595~102845950:+
THCA	cis	rs78487399	0.519	rs11124929	ENSG00000234936.1	AC010883.5	4.78	2.35e-06	0.000276	0.25	0.22	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43354964	chr2:43229573~43233394:+
THCA	cis	rs804280	0.703	rs745379	ENSG00000254948.1	OR7E158P	4.78	2.35e-06	0.000276	0.26	0.22	Myopia (pathological);	chr8:11758186	chr8:11919900~11920809:-
THCA	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-4.78	2.35e-06	0.000276	-0.25	-0.22	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
THCA	cis	rs9880211	0.635	rs9827662	ENSG00000273486.1	RP11-731C17.2	4.78	2.35e-06	0.000276	0.23	0.22	Height;Body mass index;	chr3:135991999	chr3:136837338~136839021:-
THCA	cis	rs12612619	0.659	rs12997235	ENSG00000229122.1	AGBL5-IT1	-4.78	2.35e-06	0.000276	-0.16	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006211	chr2:27061038~27061815:+
THCA	cis	rs7924176	0.58	rs7912162	ENSG00000213731.2	RAB5CP1	-4.78	2.35e-06	0.000276	-0.26	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74423435~74424014:-
THCA	cis	rs10090774	0.901	rs11781597	ENSG00000279766.1	RP11-642A1.2	-4.78	2.35e-06	0.000276	-0.27	-0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140995643	chr8:140572142~140572812:-
THCA	cis	rs911555	0.655	rs10141157	ENSG00000269958.1	RP11-73M18.8	4.78	2.35e-06	0.000276	0.2	0.22	Intelligence (multi-trait analysis);	chr14:103551768	chr14:103696353~103697163:+
THCA	cis	rs7615952	0.688	rs12638240	ENSG00000272840.1	RP11-379B18.6	4.78	2.35e-06	0.000276	0.33	0.22	Blood pressure (smoking interaction);	chr3:125822395	chr3:125774714~125797953:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-4.78	2.35e-06	0.000276	-0.24	-0.22	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-4.78	2.35e-06	0.000276	-0.24	-0.22	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
THCA	cis	rs12681288	0.644	rs2123058	ENSG00000260721.1	AF067845.1	4.78	2.35e-06	0.000276	0.26	0.22	Schizophrenia;	chr8:1050304	chr8:1368642~1369833:-
THCA	cis	rs2839186	0.732	rs8131458	ENSG00000215424.8	MCM3AP-AS1	4.78	2.35e-06	0.000276	0.13	0.22	Testicular germ cell tumor;	chr21:46274798	chr21:46229217~46259390:+
THCA	cis	rs3770081	1	rs111295372	ENSG00000273080.1	RP11-301O19.1	-4.78	2.35e-06	0.000276	-0.49	-0.22	Facial emotion recognition (sad faces);	chr2:86056234	chr2:86195590~86196049:+
THCA	cis	rs5742933	1	rs5743032	ENSG00000253559.1	OSGEPL1-AS1	-4.78	2.35e-06	0.000276	-0.27	-0.22	Ferritin levels;	chr2:189814077	chr2:189762704~189765556:+
THCA	cis	rs8028182	0.636	rs4564532	ENSG00000260274.1	RP11-817O13.8	4.78	2.35e-06	0.000276	0.15	0.22	Sudden cardiac arrest;	chr15:75413955	chr15:75368155~75369584:+
THCA	cis	rs1005277	0.563	rs2800550	ENSG00000275858.1	RP11-291L22.8	4.78	2.35e-06	0.000276	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38450738~38451069:-
THCA	cis	rs17095355	1	rs72828241	ENSG00000203876.8	ADD3-AS1	-4.78	2.35e-06	0.000276	-0.25	-0.22	Biliary atresia;	chr10:109984946	chr10:109940104~110008381:-
THCA	cis	rs9329221	0.683	rs658385	ENSG00000248538.5	RP11-10A14.5	4.78	2.35e-06	0.000277	0.27	0.22	Neuroticism;	chr8:10034667	chr8:9189011~9202854:+
THCA	cis	rs28386778	0.701	rs2727337	ENSG00000240280.5	TCAM1P	4.78	2.35e-06	0.000277	0.3	0.22	Prudent dietary pattern;	chr17:63914606	chr17:63849292~63864379:+
THCA	cis	rs4660214	0.639	rs6699928	ENSG00000182109.6	RP11-69E11.4	-4.78	2.36e-06	0.000277	-0.21	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39267827	chr1:39522280~39546187:-
THCA	cis	rs5758659	1	rs134869	ENSG00000227370.1	RP4-669P10.19	-4.78	2.36e-06	0.000277	-0.2	-0.22	Cognitive function;	chr22:42256068	chr22:42132543~42132998:+
THCA	cis	rs748404	0.666	rs35160541	ENSG00000205771.5	CATSPER2P1	-4.78	2.36e-06	0.000277	-0.27	-0.22	Lung cancer;	chr15:43365601	chr15:43726918~43747094:-
THCA	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	4.78	2.36e-06	0.000277	0.24	0.22	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
THCA	cis	rs860295	0.702	rs11264386	ENSG00000160766.13	GBAP1	-4.78	2.36e-06	0.000277	-0.26	-0.22	Body mass index;	chr1:155589379	chr1:155213821~155227422:-
THCA	cis	rs11992162	1	rs7460395	ENSG00000206014.6	OR7E161P	-4.78	2.36e-06	0.000277	-0.25	-0.22	Monocyte count;	chr8:11977866	chr8:11928597~11929563:-
THCA	cis	rs2070074	0.591	rs75039456	ENSG00000230074.1	RP11-195F19.9	-4.78	2.36e-06	0.000277	-0.5	-0.22	CTACK levels;	chr9:34612071	chr9:34665665~34681298:+
THCA	cis	rs6012564	1	rs4810909	ENSG00000230758.1	SNAP23P	-4.78	2.36e-06	0.000277	-0.26	-0.22	Anger;	chr20:49004835	chr20:49038357~49038602:-
THCA	cis	rs7829975	0.633	rs2979181	ENSG00000253981.4	ALG1L13P	4.78	2.36e-06	0.000277	0.21	0.22	Mood instability;	chr8:8465578	chr8:8236003~8244667:-
THCA	cis	rs7726839	0.54	rs72703078	ENSG00000225138.6	CTD-2228K2.7	4.78	2.36e-06	0.000277	0.27	0.22	Obesity-related traits;	chr5:594872	chr5:473236~480884:+
THCA	cis	rs10256972	0.616	rs7806746	ENSG00000225146.1	AC073957.15	4.78	2.36e-06	0.000277	0.21	0.22	Endometriosis;Longevity;	chr7:1035937	chr7:1029025~1043891:+
THCA	cis	rs911555	0.706	rs10129426	ENSG00000269958.1	RP11-73M18.8	4.78	2.36e-06	0.000277	0.2	0.22	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103696353~103697163:+
THCA	cis	rs9863	0.828	rs11057413	ENSG00000269997.1	RP11-214K3.21	-4.78	2.36e-06	0.000277	-0.26	-0.22	White blood cell count;	chr12:124004615	chr12:123966077~123966629:-
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000164669.11	INTS4P1	4.78	2.36e-06	0.000277	0.41	0.22	Diabetic kidney disease;	chr7:66136229	chr7:65141225~65234216:+
THCA	cis	rs2067615	0.56	rs4964485	ENSG00000260329.1	RP11-412D9.4	-4.78	2.36e-06	0.000277	-0.2	-0.22	Heart rate;	chr12:106728174	chr12:106954029~106955497:-
THCA	cis	rs2067615	0.579	rs6539283	ENSG00000260329.1	RP11-412D9.4	-4.78	2.36e-06	0.000277	-0.2	-0.22	Heart rate;	chr12:106829211	chr12:106954029~106955497:-
THCA	cis	rs7851660	0.805	rs7038998	ENSG00000214417.4	KRT18P13	-4.78	2.36e-06	0.000277	-0.19	-0.22	Strep throat;	chr9:97900114	chr9:97698922~97700734:+
THCA	cis	rs9300255	0.602	rs1790116	ENSG00000235423.7	RP11-282O18.3	4.78	2.36e-06	0.000277	0.22	0.22	Neutrophil percentage of white cells;	chr12:123133997	chr12:123252030~123261483:-
THCA	cis	rs10808739	0.614	rs62521095	ENSG00000254006.4	RP11-1D12.2	-4.78	2.36e-06	0.000277	-0.47	-0.22	HIV-1 susceptibility;	chr8:64718163	chr8:64801236~64817573:-
THCA	cis	rs1048886	0.938	rs6906592	ENSG00000271967.1	RP11-134K13.4	-4.78	2.36e-06	0.000277	-0.22	-0.22	Type 2 diabetes;	chr6:70472221	chr6:70596438~70596980:+
THCA	cis	rs7260598	0.539	rs11672512	ENSG00000268442.1	CTD-2027I19.2	4.78	2.36e-06	0.000277	0.31	0.22	Response to taxane treatment (placlitaxel);	chr19:23885948	chr19:24162370~24163425:-
THCA	cis	rs11668609	0.515	rs58278214	ENSG00000268442.1	CTD-2027I19.2	4.78	2.36e-06	0.000277	0.31	0.22	Response to taxane treatment (docetaxel);	chr19:23888887	chr19:24162370~24163425:-
THCA	cis	rs11668609	0.515	rs2195971	ENSG00000268442.1	CTD-2027I19.2	4.78	2.36e-06	0.000277	0.31	0.22	Response to taxane treatment (docetaxel);	chr19:23897191	chr19:24162370~24163425:-
THCA	cis	rs3782089	1	rs3782089	ENSG00000214659.4	KRT8P26	-4.78	2.36e-06	0.000277	-0.36	-0.22	Height;	chr11:65569348	chr11:65726939~65728214:+
THCA	cis	rs7618915	0.547	rs34017441	ENSG00000243224.1	RP5-1157M23.2	-4.78	2.36e-06	0.000278	-0.23	-0.22	Bipolar disorder;	chr3:52708397	chr3:52239258~52241097:+
THCA	cis	rs375066	0.551	rs11880651	ENSG00000267058.1	RP11-15A1.3	4.78	2.36e-06	0.000278	0.2	0.22	Breast cancer;	chr19:43827646	chr19:43891804~43901805:-
THCA	cis	rs9677476	0.779	rs72983683	ENSG00000224376.1	AC017104.6	4.78	2.36e-06	0.000278	0.27	0.22	Food antigen IgG levels;	chr2:231236257	chr2:231388976~231394991:+
THCA	cis	rs1005277	0.563	rs2505215	ENSG00000275858.1	RP11-291L22.8	4.78	2.36e-06	0.000278	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.563	rs2505216	ENSG00000275858.1	RP11-291L22.8	4.78	2.36e-06	0.000278	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2749612	ENSG00000275858.1	RP11-291L22.8	4.78	2.36e-06	0.000278	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38450738~38451069:-
THCA	cis	rs6477918	0.598	rs34442540	ENSG00000230185.4	C9orf147	-4.78	2.37e-06	0.000278	-0.23	-0.22	Obstetric antiphospholipid syndrome;	chr9:112455334	chr9:112433816~112487204:-
THCA	cis	rs9910055	0.659	rs227578	ENSG00000267080.4	ASB16-AS1	4.78	2.37e-06	0.000278	0.19	0.22	Total body bone mineral density;	chr17:44132821	chr17:44175973~44186717:-
THCA	cis	rs950880	0.71	rs3821204	ENSG00000234389.1	AC007278.3	-4.78	2.37e-06	0.000278	-0.26	-0.22	Serum protein levels (sST2);	chr2:102343821	chr2:102438713~102440475:+
THCA	cis	rs755249	0.517	rs66880209	ENSG00000228060.1	RP11-69E11.8	-4.78	2.37e-06	0.000278	-0.26	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39565160~39573203:+
THCA	cis	rs13434995	0.513	rs17721497	ENSG00000273257.1	RP11-177J6.1	4.78	2.37e-06	0.000278	0.33	0.22	Adiponectin levels;	chr4:55445081	chr4:55387949~55388271:+
THCA	cis	rs10851478	0.54	rs1904316	ENSG00000276593.1	RP11-295H24.5	-4.78	2.37e-06	0.000278	-0.23	-0.22	Oral cavity cancer;	chr15:49416513	chr15:49353485~49354034:+
THCA	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	4.78	2.37e-06	0.000278	0.27	0.22	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
THCA	cis	rs2058059	0.636	rs3015917	ENSG00000205578.5	POM121B	-4.78	2.37e-06	0.000278	-0.33	-0.22	Subcutaneous adipose tissue;	chr7:72679494	chr7:73293497~73301161:+
THCA	cis	rs7045881	0.877	rs62542156	ENSG00000254396.1	RP11-56F10.3	4.78	2.37e-06	0.000278	0.33	0.22	Schizophrenia;	chr9:26780640	chr9:27102630~27104728:+
THCA	cis	rs270601	0.683	rs81598	ENSG00000224431.1	AC063976.7	4.78	2.37e-06	0.000278	0.19	0.22	Acylcarnitine levels;	chr5:132252267	chr5:132199456~132203487:+
THCA	cis	rs4073582	0.595	rs801741	ENSG00000255320.1	RP11-755F10.1	-4.78	2.37e-06	0.000278	-0.27	-0.22	Gout;	chr11:66149613	chr11:66244840~66246239:-
THCA	cis	rs172166	0.516	rs2622322	ENSG00000273712.1	RP5-874C20.7	4.78	2.37e-06	0.000278	0.23	0.22	Cardiac Troponin-T levels;	chr6:28149665	chr6:28315613~28315883:-
THCA	cis	rs11955398	0.502	rs295559	ENSG00000272308.1	RP11-231G3.1	4.78	2.37e-06	0.000278	0.23	0.22	Intelligence (multi-trait analysis);	chr5:61105395	chr5:60866457~60866935:-
THCA	cis	rs7010876	0.537	rs4305946	ENSG00000253553.4	RP11-586K2.1	4.78	2.37e-06	0.000278	0.22	0.22	Schizophrenia;	chr8:88419537	chr8:88326836~88737134:+
THCA	cis	rs7577696	0.813	rs212723	ENSG00000276334.1	AL133243.1	4.78	2.37e-06	0.000279	0.23	0.22	Inflammatory biomarkers;	chr2:32242079	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.889	rs212731	ENSG00000276334.1	AL133243.1	4.78	2.37e-06	0.000279	0.23	0.22	Inflammatory biomarkers;	chr2:32247081	chr2:32521927~32523547:+
THCA	cis	rs250518	0.926	rs6875670	ENSG00000272081.1	CTD-2376I4.2	4.78	2.37e-06	0.000279	0.28	0.22	Mean corpuscular hemoglobin concentration;	chr5:72785943	chr5:72955206~72955699:-
THCA	cis	rs860295	0.702	rs11264387	ENSG00000160766.13	GBAP1	-4.78	2.37e-06	0.000279	-0.25	-0.22	Body mass index;	chr1:155593361	chr1:155213821~155227422:-
THCA	cis	rs7267979	1	rs4815417	ENSG00000274973.1	RP13-401N8.7	4.78	2.37e-06	0.000279	0.24	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25845497~25845862:+
THCA	cis	rs17095355	1	rs12244557	ENSG00000203876.8	ADD3-AS1	-4.78	2.37e-06	0.000279	-0.23	-0.22	Biliary atresia;	chr10:109986384	chr10:109940104~110008381:-
THCA	cis	rs7045881	0.877	rs111919934	ENSG00000254396.1	RP11-56F10.3	4.78	2.37e-06	0.000279	0.32	0.22	Schizophrenia;	chr9:26780390	chr9:27102630~27104728:+
THCA	cis	rs72843506	0.656	rs111249650	ENSG00000261033.1	RP11-209D14.2	4.78	2.37e-06	0.000279	0.41	0.22	Schizophrenia;	chr17:20008517	chr17:20008051~20009234:-
THCA	cis	rs7577696	0.889	rs212730	ENSG00000276334.1	AL133243.1	4.78	2.38e-06	0.000279	0.23	0.22	Inflammatory biomarkers;	chr2:32246604	chr2:32521927~32523547:+
THCA	cis	rs228614	0.536	rs223325	ENSG00000248971.2	KRT8P46	-4.78	2.38e-06	0.000279	-0.26	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102728746~102730171:-
THCA	cis	rs6802315	0.712	rs7615751	ENSG00000272087.1	RP11-379F4.7	4.78	2.38e-06	0.000279	0.19	0.22	Periodontitis (CDC/AAP);	chr3:158792041	chr3:158693120~158693768:-
THCA	cis	rs454422	1	rs236104	ENSG00000275632.1	RP5-967N21.11	4.78	2.38e-06	0.000279	0.21	0.22	HIV-1 viral setpoint;	chr20:5978314	chr20:6000418~6000941:+
THCA	cis	rs6860806	0.507	rs272854	ENSG00000237714.1	P4HA2-AS1	4.78	2.38e-06	0.000279	0.29	0.22	Breast cancer;	chr5:132352324	chr5:132184876~132192808:+
THCA	cis	rs9625935	0.957	rs36590	ENSG00000279159.1	RP3-394A18.1	4.78	2.38e-06	0.000279	0.17	0.22	Tonsillectomy;	chr22:29932081	chr22:29978950~30028236:-
THCA	cis	rs516805	0.847	rs520867	ENSG00000279114.1	RP3-425C14.5	-4.78	2.38e-06	0.000279	-0.22	-0.22	Lymphocyte counts;	chr6:122465501	chr6:122471923~122484161:+
THCA	cis	rs1979679	0.918	rs7977429	ENSG00000247934.4	RP11-967K21.1	-4.78	2.38e-06	0.000279	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28370376	chr12:28163298~28190738:-
THCA	cis	rs10208649	1	rs7594327	ENSG00000233266.1	HMGB1P31	4.78	2.38e-06	0.000279	0.51	0.22	Body mass index;	chr2:53830766	chr2:54051334~54051760:+
THCA	cis	rs804280	0.662	rs7826055	ENSG00000255046.1	RP11-297N6.4	4.78	2.38e-06	0.000279	0.24	0.22	Myopia (pathological);	chr8:11754214	chr8:11797928~11802568:-
THCA	cis	rs9652601	0.691	rs12922303	ENSG00000274038.1	RP11-66H6.4	-4.78	2.38e-06	0.000279	-0.26	-0.22	Systemic lupus erythematosus;	chr16:11099608	chr16:11056556~11057034:+
THCA	cis	rs56114371	0.777	rs200481	ENSG00000226314.6	ZNF192P1	-4.78	2.38e-06	0.000279	-0.34	-0.22	Breast cancer;	chr6:27806054	chr6:28161781~28169594:+
THCA	cis	rs2447820	0.5	rs246277	ENSG00000249996.1	RP11-359P5.1	-4.78	2.38e-06	0.000279	-0.25	-0.22	Migraine;	chr5:122904720	chr5:123036271~123054667:+
THCA	cis	rs11673344	0.504	rs10402907	ENSG00000276846.1	CTD-3220F14.3	4.78	2.38e-06	0.000279	0.16	0.22	Obesity-related traits;	chr19:37112874	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.563	rs4805199	ENSG00000276846.1	CTD-3220F14.3	4.78	2.38e-06	0.000279	0.16	0.22	Obesity-related traits;	chr19:37115527	chr19:37314868~37315620:-
THCA	cis	rs172166	0.538	rs149956	ENSG00000273712.1	RP5-874C20.7	4.78	2.38e-06	0.000279	0.23	0.22	Cardiac Troponin-T levels;	chr6:28068473	chr6:28315613~28315883:-
THCA	cis	rs9859260	0.616	rs9867473	ENSG00000273009.1	RP11-352G9.1	-4.78	2.38e-06	0.000279	-0.25	-0.22	Mean corpuscular volume;	chr3:196104227	chr3:195913078~195913683:-
THCA	cis	rs8141529	0.664	rs5762862	ENSG00000226471.5	CTA-292E10.6	-4.78	2.38e-06	0.000279	-0.19	-0.22	Lymphocyte counts;	chr22:28856744	chr22:28800683~28848559:+
THCA	cis	rs4950322	0.57	rs79810882	ENSG00000226015.2	CCT8P1	4.78	2.38e-06	0.000279	0.25	0.22	Protein quantitative trait loci;	chr1:147235575	chr1:147203276~147204932:-
THCA	cis	rs172166	0.56	rs203878	ENSG00000176933.5	TOB2P1	-4.78	2.38e-06	0.00028	-0.23	-0.22	Cardiac Troponin-T levels;	chr6:28081218	chr6:28217643~28218634:-
THCA	cis	rs11795343	0.503	rs7025666	ENSG00000232303.2	DFFBP1	-4.78	2.38e-06	0.00028	-0.27	-0.22	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32533831	chr9:32566148~32567126:-
THCA	cis	rs3820928	0.874	rs10210997	ENSG00000212391.1	SNORA48	-4.78	2.38e-06	0.00028	-0.23	-0.22	Pulmonary function;	chr2:226994392	chr2:226968989~226969122:-
THCA	cis	rs7403037	0.583	rs35463340	ENSG00000259905.4	PWRN1	4.78	2.38e-06	0.00028	0.28	0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24581313	chr15:24493137~24652130:+
THCA	cis	rs7580717	0.785	rs3731781	ENSG00000224376.1	AC017104.6	4.78	2.38e-06	0.00028	0.24	0.22	Multiple myeloma;	chr2:231294530	chr2:231388976~231394991:+
THCA	cis	rs853679	0.546	rs493161	ENSG00000226314.6	ZNF192P1	-4.78	2.38e-06	0.00028	-0.37	-0.22	Depression;	chr6:27882936	chr6:28161781~28169594:+
THCA	cis	rs4415084	1	rs10805686	ENSG00000272335.1	RP11-53O19.3	-4.78	2.39e-06	0.00028	-0.18	-0.22	Breast cancer;	chr5:44662026	chr5:44826076~44828592:+
THCA	cis	rs2777491	0.872	rs7163649	ENSG00000247556.5	OIP5-AS1	4.78	2.39e-06	0.00028	0.18	0.22	Ulcerative colitis;	chr15:41294600	chr15:41283990~41309737:+
THCA	cis	rs7914558	0.966	rs11191438	ENSG00000236937.2	PTGES3P4	4.78	2.39e-06	0.00028	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102845595~102845950:+
THCA	cis	rs1383484	0.575	rs1904866	ENSG00000225151.9	GOLGA2P7	4.78	2.39e-06	0.00028	0.28	0.22	Height;	chr15:83933434	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs17601029	ENSG00000275120.1	RP11-182J1.17	4.78	2.39e-06	0.00028	0.25	0.22	Schizophrenia;	chr15:84804478	chr15:84599434~84606463:-
THCA	cis	rs453301	0.658	rs9650616	ENSG00000254153.1	CTA-398F10.2	4.78	2.39e-06	0.00028	0.24	0.22	Joint mobility (Beighton score);	chr8:9011689	chr8:8456909~8461337:-
THCA	cis	rs5771225	0.563	rs738334	ENSG00000273253.2	RP3-402G11.26	-4.78	2.39e-06	0.00028	-0.25	-0.22	Late-onset Alzheimer's disease;	chr22:50249806	chr22:50199090~50200837:-
THCA	cis	rs11671005	0.735	rs35652377	ENSG00000268049.1	CTD-2619J13.9	-4.78	2.39e-06	0.00028	-0.33	-0.22	Mean platelet volume;	chr19:58417833	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs3764532	ENSG00000268049.1	CTD-2619J13.9	-4.78	2.39e-06	0.00028	-0.33	-0.22	Mean platelet volume;	chr19:58417855	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs3088284	ENSG00000268049.1	CTD-2619J13.9	-4.78	2.39e-06	0.00028	-0.33	-0.22	Mean platelet volume;	chr19:58418060	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs12981649	ENSG00000268049.1	CTD-2619J13.9	-4.78	2.39e-06	0.00028	-0.33	-0.22	Mean platelet volume;	chr19:58418676	chr19:58357999~58359603:+
THCA	cis	rs9291683	0.645	rs11557743	ENSG00000261490.1	RP11-448G15.3	-4.78	2.39e-06	0.00028	-0.14	-0.22	Bone mineral density;	chr4:10116753	chr4:10068089~10073019:-
THCA	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	4.78	2.39e-06	0.00028	0.25	0.22	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
THCA	cis	rs1005277	0.577	rs4934906	ENSG00000276805.1	RP11-291L22.6	4.78	2.39e-06	0.00028	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38451030~38451785:+
THCA	cis	rs1979679	0.842	rs1118097	ENSG00000247934.4	RP11-967K21.1	-4.78	2.39e-06	0.00028	-0.21	-0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28177156	chr12:28163298~28190738:-
THCA	cis	rs858239	0.601	rs28673077	ENSG00000226816.2	AC005082.12	4.78	2.39e-06	0.00028	0.31	0.22	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23206013~23208045:+
THCA	cis	rs11779988	0.545	rs454692	ENSG00000253671.1	RP11-806O11.1	-4.78	2.39e-06	0.00028	-0.28	-0.22	Breast cancer;	chr8:17931789	chr8:17808941~17820868:+
THCA	cis	rs2281603	0.57	rs11625265	ENSG00000259116.1	RP11-973N13.4	-4.78	2.39e-06	0.000281	-0.19	-0.22	Lymphocyte counts;	chr14:64510603	chr14:64514154~64540368:-
THCA	cis	rs7131987	0.834	rs12228468	ENSG00000275476.1	RP11-996F15.4	4.78	2.39e-06	0.000281	0.21	0.22	QT interval;	chr12:29300677	chr12:29277397~29277882:-
THCA	cis	rs6832769	0.89	rs1522107	ENSG00000272969.1	RP11-528I4.2	4.78	2.39e-06	0.000281	0.25	0.22	Personality dimensions;	chr4:55514606	chr4:55547112~55547889:+
THCA	cis	rs8064024	0.582	rs2660241	ENSG00000267077.1	RP11-127I20.5	4.78	2.39e-06	0.000281	0.25	0.22	Cancer;	chr16:4890022	chr16:4795265~4796532:-
THCA	cis	rs9527	0.571	rs7096249	ENSG00000213061.2	PFN1P11	4.78	2.39e-06	0.000281	0.26	0.22	Arsenic metabolism;	chr10:102858767	chr10:102838011~102845473:-
THCA	cis	rs9527	0.571	rs10786715	ENSG00000213061.2	PFN1P11	4.78	2.39e-06	0.000281	0.26	0.22	Arsenic metabolism;	chr10:102860978	chr10:102838011~102845473:-
THCA	cis	rs2034650	0.544	rs8034416	ENSG00000223313.1	RNU6-516P	4.78	2.39e-06	0.000281	0.24	0.22	Interstitial lung disease;	chr15:40411140	chr15:40529570~40529673:+
THCA	cis	rs9902453	1	rs60967688	ENSG00000263370.1	RP11-68I3.5	4.78	2.39e-06	0.000281	0.27	0.22	Coffee consumption (cups per day);	chr17:30110034	chr17:29639627~29640825:+
THCA	cis	rs72945132	0.882	rs56368270	ENSG00000254604.1	AP000487.6	-4.78	2.39e-06	0.000281	-0.41	-0.22	Coronary artery disease;	chr11:70316484	chr11:70282367~70363368:-
THCA	cis	rs7111546	0.625	rs79387090	ENSG00000246225.5	RP11-17A1.3	4.78	2.39e-06	0.000281	0.35	0.22	Dialysis-related mortality;	chr11:22889873	chr11:22829380~22945393:+
THCA	cis	rs6714710	0.603	rs34373359	ENSG00000230606.9	AC159540.1	-4.78	2.39e-06	0.000281	-0.25	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97825739	chr2:97416165~97433527:-
THCA	cis	rs7010876	0.537	rs1504805	ENSG00000253553.4	RP11-586K2.1	4.78	2.39e-06	0.000281	0.22	0.22	Schizophrenia;	chr8:88401627	chr8:88326836~88737134:+
THCA	cis	rs12760731	0.582	rs12048597	ENSG00000213057.5	C1orf220	4.78	2.39e-06	0.000281	0.25	0.22	Obesity-related traits;	chr1:178569181	chr1:178542752~178548889:+
THCA	cis	rs3820928	0.904	rs1835159	ENSG00000212391.1	SNORA48	-4.78	2.39e-06	0.000281	-0.24	-0.22	Pulmonary function;	chr2:226899341	chr2:226968989~226969122:-
THCA	cis	rs853679	1	rs853694	ENSG00000220721.1	OR1F12	4.78	2.39e-06	0.000281	0.33	0.22	Depression;	chr6:28311323	chr6:28073316~28074233:+
THCA	cis	rs10833905	0.756	rs11026868	ENSG00000246225.5	RP11-17A1.3	-4.78	2.39e-06	0.000281	-0.31	-0.22	Sudden cardiac arrest;	chr11:22971305	chr11:22829380~22945393:+
THCA	cis	rs16976116	0.53	rs2414399	ENSG00000279145.1	RP11-547D13.1	-4.78	2.4e-06	0.000281	-0.24	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55132229	chr15:55171972~55178175:-
THCA	cis	rs7267979	0.586	rs6083776	ENSG00000277938.1	RP5-965G21.3	4.78	2.4e-06	0.000281	0.18	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.586	rs1473695	ENSG00000277938.1	RP5-965G21.3	4.78	2.4e-06	0.000281	0.18	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25229150~25231933:+
THCA	cis	rs2243480	1	rs13247184	ENSG00000232559.3	GS1-124K5.12	4.78	2.4e-06	0.000281	0.32	0.22	Diabetic kidney disease;	chr7:65893941	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs35283677	ENSG00000232559.3	GS1-124K5.12	4.78	2.4e-06	0.000281	0.32	0.22	Diabetic kidney disease;	chr7:65894246	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs35421653	ENSG00000232559.3	GS1-124K5.12	4.78	2.4e-06	0.000281	0.32	0.22	Diabetic kidney disease;	chr7:65898442	chr7:66554588~66576923:-
THCA	cis	rs6445975	0.715	rs6769100	ENSG00000272360.1	RP11-359I18.5	4.78	2.4e-06	0.000281	0.22	0.22	Systemic lupus erythematosus;	chr3:58274272	chr3:58490830~58491291:-
THCA	cis	rs9487094	0.644	rs13201430	ENSG00000223537.2	RP5-919F19.5	-4.78	2.4e-06	0.000281	-0.21	-0.22	Height;	chr6:109634847	chr6:109487906~109506800:+
THCA	cis	rs9296095	0.656	rs547391	ENSG00000197251.3	LINC00336	-4.78	2.4e-06	0.000281	-0.25	-0.22	Platelet count;	chr6:33596136	chr6:33586106~33593338:-
THCA	cis	rs8062405	0.755	rs111693583	ENSG00000261766.1	RP11-22P6.2	-4.78	2.4e-06	0.000281	-0.21	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28862166~28863340:-
THCA	cis	rs6921919	0.583	rs11755942	ENSG00000280107.1	AL022393.9	-4.78	2.4e-06	0.000281	-0.21	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28170845~28172521:+
THCA	cis	rs3796352	0.667	rs34288509	ENSG00000242142.1	SERBP1P3	-4.78	2.4e-06	0.000281	-0.38	-0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52815477	chr3:53064283~53065091:-
THCA	cis	rs2692947	0.727	rs2692950	ENSG00000232931.4	LINC00342	4.78	2.4e-06	0.000281	0.17	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007776	chr2:95807118~95816215:-
THCA	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-4.78	2.4e-06	0.000282	-0.13	-0.22	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
THCA	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-4.78	2.4e-06	0.000282	-0.13	-0.22	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
THCA	cis	rs11858159	0.528	rs6576332	ENSG00000260760.1	PWRN3	-4.78	2.4e-06	0.000282	-0.22	-0.22	Platelet thrombus formation;	chr15:24549343	chr15:24441127~24447967:+
THCA	cis	rs4915077	0.892	rs17020064	ENSG00000230489.1	VAV3-AS1	4.78	2.4e-06	0.000282	0.37	0.22	Hypothyroidism;	chr1:107795178	chr1:107964443~107994607:+
THCA	cis	rs62158800	0.85	rs11897300	ENSG00000224568.1	AC096669.3	4.78	2.4e-06	0.000282	0.37	0.22	Facial morphology (factor 22);	chr2:107653102	chr2:107529487~107556326:+
THCA	cis	rs2797160	0.651	rs1268093	ENSG00000226409.1	RP11-735G4.1	4.78	2.4e-06	0.000282	0.26	0.22	Endometrial cancer;	chr6:125708089	chr6:125370211~125374324:-
THCA	cis	rs453301	0.686	rs17702602	ENSG00000254153.1	CTA-398F10.2	4.78	2.4e-06	0.000282	0.23	0.22	Joint mobility (Beighton score);	chr8:9051086	chr8:8456909~8461337:-
THCA	cis	rs2235642	0.75	rs2859310	ENSG00000280231.1	LA16c-380F5.3	4.78	2.4e-06	0.000282	0.25	0.22	Coronary artery disease;	chr16:1606764	chr16:1553655~1554130:-
THCA	cis	rs7141336	0.8	rs11624683	ENSG00000258884.1	CTD-3035D6.2	4.77	2.4e-06	0.000282	0.29	0.22	Anxiety disorder;	chr14:90822766	chr14:90822365~90828128:-
THCA	cis	rs7141336	0.77	rs12898117	ENSG00000258884.1	CTD-3035D6.2	4.77	2.4e-06	0.000282	0.29	0.22	Anxiety disorder;	chr14:90823136	chr14:90822365~90828128:-
THCA	cis	rs1005277	0.579	rs2505257	ENSG00000275858.1	RP11-291L22.8	4.77	2.41e-06	0.000282	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38450738~38451069:-
THCA	cis	rs10256972	0.721	rs10435145	ENSG00000225146.1	AC073957.15	4.77	2.41e-06	0.000282	0.22	0.22	Endometriosis;Longevity;	chr7:1026352	chr7:1029025~1043891:+
THCA	cis	rs4660456	0.504	rs587963	ENSG00000272145.1	NFYC-AS1	-4.77	2.41e-06	0.000282	-0.16	-0.22	Platelet count;	chr1:40640045	chr1:40690380~40692066:-
THCA	cis	rs5751901	0.614	rs6519520	ENSG00000215481.7	BCRP3	-4.77	2.41e-06	0.000282	-0.19	-0.22	Protein quantitative trait loci;	chr22:24595928	chr22:24632915~24653356:+
THCA	cis	rs7576126	0.515	rs1866050	ENSG00000237979.1	AC007389.1	4.77	2.41e-06	0.000282	0.28	0.22	Severe influenza A (H1N1) infection;	chr2:65450595	chr2:65500993~65502138:-
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000229886.1	RP5-1132H15.3	4.77	2.41e-06	0.000282	0.25	0.22	Corneal structure;	chr7:66938233	chr7:66025126~66031544:-
THCA	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	4.77	2.41e-06	0.000282	0.18	0.22	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
THCA	cis	rs3820928	0.874	rs10182307	ENSG00000212391.1	SNORA48	-4.77	2.41e-06	0.000282	-0.23	-0.22	Pulmonary function;	chr2:227010644	chr2:226968989~226969122:-
THCA	cis	rs3796352	1	rs10510761	ENSG00000242142.1	SERBP1P3	4.77	2.41e-06	0.000282	0.41	0.22	Immune reponse to smallpox (secreted IL-2);	chr3:52931239	chr3:53064283~53065091:-
THCA	cis	rs9368481	0.672	rs3931463	ENSG00000261353.1	CTA-14H9.5	-4.77	2.41e-06	0.000282	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26527063~26527404:+
THCA	cis	rs7819412	0.642	rs11250117	ENSG00000206014.6	OR7E161P	4.77	2.41e-06	0.000282	0.26	0.22	Triglycerides;	chr8:11115230	chr8:11928597~11929563:-
THCA	cis	rs2281603	0.57	rs1966865	ENSG00000259116.1	RP11-973N13.4	-4.77	2.41e-06	0.000283	-0.19	-0.22	Lymphocyte counts;	chr14:64509143	chr14:64514154~64540368:-
THCA	cis	rs989128	0.6	rs8082568	ENSG00000250286.1	RP11-94C24.8	-4.77	2.41e-06	0.000283	-0.21	-0.22	Type 2 diabetes;	chr17:50551951	chr17:50537294~50538754:-
THCA	cis	rs7537765	1	rs17037427	ENSG00000242349.4	NPPA-AS1	-4.77	2.41e-06	0.000283	-0.28	-0.22	QRS complex (12-leadsum);	chr1:11813359	chr1:11841017~11848079:+
THCA	cis	rs896854	1	rs896854	ENSG00000253528.2	RP11-347C18.4	4.77	2.41e-06	0.000283	0.24	0.22	Type 2 diabetes;	chr8:94948283	chr8:94974573~94974853:-
THCA	cis	rs896854	0.967	rs1320164	ENSG00000253528.2	RP11-347C18.4	4.77	2.41e-06	0.000283	0.24	0.22	Type 2 diabetes;	chr8:94948539	chr8:94974573~94974853:-
THCA	cis	rs896854	0.902	rs896852	ENSG00000253528.2	RP11-347C18.4	4.77	2.41e-06	0.000283	0.24	0.22	Type 2 diabetes;	chr8:94948658	chr8:94974573~94974853:-
THCA	cis	rs896854	1	rs7003387	ENSG00000253528.2	RP11-347C18.4	4.77	2.41e-06	0.000283	0.24	0.22	Type 2 diabetes;	chr8:94949751	chr8:94974573~94974853:-
THCA	cis	rs7829975	0.509	rs7838674	ENSG00000253981.4	ALG1L13P	-4.77	2.41e-06	0.000283	-0.21	-0.22	Mood instability;	chr8:8939563	chr8:8236003~8244667:-
THCA	cis	rs7702057	0.53	rs61672521	ENSG00000272265.1	CTD-2287O16.4	4.77	2.41e-06	0.000283	0.41	0.22	Amyotrophic lateral sclerosis;	chr5:116112548	chr5:116078110~116078570:-
THCA	cis	rs860295	0.529	rs17385065	ENSG00000225855.5	RUSC1-AS1	-4.77	2.41e-06	0.000283	-0.14	-0.22	Body mass index;	chr1:156006597	chr1:155316863~155324176:-
THCA	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	4.77	2.41e-06	0.000283	0.3	0.22	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
THCA	cis	rs17045328	1	rs2012296	ENSG00000274245.1	RP11-357P18.2	-4.77	2.41e-06	0.000283	-0.39	-0.22	Type 2 diabetes;	chr1:207193959	chr1:207372559~207373252:+
THCA	cis	rs12476592	0.516	rs1922421	ENSG00000242412.1	DBIL5P2	4.77	2.41e-06	0.000283	0.28	0.22	Childhood ear infection;	chr2:63365657	chr2:63117851~63119542:-
THCA	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-4.77	2.42e-06	0.000283	-0.25	-0.22	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
THCA	cis	rs12022452	0.822	rs7545012	ENSG00000237899.1	RP4-739H11.3	4.77	2.42e-06	0.000283	0.34	0.22	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40669089~40687588:-
THCA	cis	rs896854	0.738	rs481887	ENSG00000253528.2	RP11-347C18.4	-4.77	2.42e-06	0.000283	-0.26	-0.22	Type 2 diabetes;	chr8:94955610	chr8:94974573~94974853:-
THCA	cis	rs2243480	1	rs73150014	ENSG00000164669.11	INTS4P1	4.77	2.42e-06	0.000283	0.41	0.22	Diabetic kidney disease;	chr7:65985932	chr7:65141225~65234216:+
THCA	cis	rs4639966	0.836	rs4499035	ENSG00000255422.1	AP002954.4	4.77	2.42e-06	0.000283	0.26	0.22	Systemic lupus erythematosus;	chr11:118739754	chr11:118704607~118750263:+
THCA	cis	rs4639966	0.836	rs1893029	ENSG00000255422.1	AP002954.4	4.77	2.42e-06	0.000283	0.26	0.22	Systemic lupus erythematosus;	chr11:118740117	chr11:118704607~118750263:+
THCA	cis	rs972578	0.715	rs738535	ENSG00000274717.1	RP1-47A17.1	-4.77	2.42e-06	0.000283	-0.23	-0.22	Mean platelet volume;	chr22:42807131	chr22:42791814~42794313:-
THCA	cis	rs7914558	1	rs7094843	ENSG00000236937.2	PTGES3P4	4.77	2.42e-06	0.000283	0.28	0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103046897	chr10:102845595~102845950:+
THCA	cis	rs7829975	0.533	rs35900578	ENSG00000254153.1	CTA-398F10.2	-4.77	2.42e-06	0.000283	-0.24	-0.22	Mood instability;	chr8:8862003	chr8:8456909~8461337:-
THCA	cis	rs7141336	0.791	rs730043	ENSG00000258884.1	CTD-3035D6.2	4.77	2.42e-06	0.000283	0.29	0.22	Anxiety disorder;	chr14:90743271	chr14:90822365~90828128:-
THCA	cis	rs6088590	1	rs1998028	ENSG00000269202.1	RP4-614O4.12	-4.77	2.42e-06	0.000283	-0.19	-0.22	Coronary artery disease;	chr20:34756792	chr20:35201747~35203288:-
THCA	cis	rs7208859	0.673	rs2470251	ENSG00000280069.1	CTD-2349P21.3	-4.77	2.42e-06	0.000283	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30738182~30740275:+
THCA	cis	rs3950186	0.834	rs16871833	ENSG00000215124.2	RP3-420J14.1	4.77	2.42e-06	0.000283	0.26	0.22	Anxiety and major depressive disorder;	chr6:11803682	chr6:11861626~11862970:-
THCA	cis	rs2070074	0.591	rs2277202	ENSG00000230074.1	RP11-195F19.9	-4.77	2.42e-06	0.000283	-0.52	-0.22	CTACK levels;	chr9:34648023	chr9:34665665~34681298:+
THCA	cis	rs2070074	0.591	rs41274867	ENSG00000230074.1	RP11-195F19.9	-4.77	2.42e-06	0.000283	-0.52	-0.22	CTACK levels;	chr9:34648091	chr9:34665665~34681298:+
THCA	cis	rs7614311	0.681	rs2241822	ENSG00000271843.1	RP11-245J9.5	-4.77	2.42e-06	0.000283	-0.39	-0.22	Lung function (FVC);Lung function (FEV1);	chr3:63979628	chr3:64008082~64008692:-
THCA	cis	rs1885120	0.773	rs2425025	ENSG00000269202.1	RP4-614O4.12	4.77	2.42e-06	0.000284	0.39	0.22	Melanoma;	chr20:35259351	chr20:35201747~35203288:-
THCA	cis	rs9467773	0.572	rs62394558	ENSG00000124549.13	BTN2A3P	4.77	2.42e-06	0.000284	0.2	0.22	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26421391~26432383:+
THCA	cis	rs875971	0.666	rs13242072	ENSG00000229886.1	RP5-1132H15.3	-4.77	2.42e-06	0.000284	-0.22	-0.22	Aortic root size;	chr7:66301001	chr7:66025126~66031544:-
THCA	cis	rs11648785	0.661	rs870856	ENSG00000222019.6	URAHP	4.77	2.42e-06	0.000284	0.18	0.22	Tanning;	chr16:90023055	chr16:90039761~90047773:-
THCA	cis	rs2120243	0.967	rs7648322	ENSG00000244515.1	KRT18P34	-4.77	2.42e-06	0.000284	-0.25	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157425895	chr3:157162663~157163932:-
THCA	cis	rs11143230	0.964	rs62564009	ENSG00000225434.2	LINC01504	-4.77	2.42e-06	0.000284	-0.34	-0.22	Suicidal ideation;	chr9:72276536	chr9:72305430~72343210:+
THCA	cis	rs3820928	1	rs4675120	ENSG00000212391.1	SNORA48	-4.77	2.42e-06	0.000284	-0.24	-0.22	Pulmonary function;	chr2:226910172	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs7579961	ENSG00000212391.1	SNORA48	-4.77	2.42e-06	0.000284	-0.24	-0.22	Pulmonary function;	chr2:226912260	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs7592387	ENSG00000212391.1	SNORA48	-4.77	2.42e-06	0.000284	-0.24	-0.22	Pulmonary function;	chr2:226912379	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs11686072	ENSG00000212391.1	SNORA48	-4.77	2.42e-06	0.000284	-0.24	-0.22	Pulmonary function;	chr2:226912777	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs10167422	ENSG00000212391.1	SNORA48	-4.77	2.42e-06	0.000284	-0.24	-0.22	Pulmonary function;	chr2:226912838	chr2:226968989~226969122:-
THCA	cis	rs9880211	1	rs17364492	ENSG00000239213.4	NCK1-AS1	-4.77	2.42e-06	0.000284	-0.23	-0.22	Height;Body mass index;	chr3:136485595	chr3:136841726~136862054:-
THCA	cis	rs4934494	0.768	rs58163515	ENSG00000240996.1	RP11-80H5.7	-4.77	2.42e-06	0.000284	-0.25	-0.22	Red blood cell count;	chr10:89637807	chr10:89694295~89697928:-
THCA	cis	rs989128	0.517	rs1809284	ENSG00000250286.1	RP11-94C24.8	-4.77	2.42e-06	0.000284	-0.21	-0.22	Type 2 diabetes;	chr17:50554949	chr17:50537294~50538754:-
THCA	cis	rs9625935	0.957	rs9625931	ENSG00000279159.1	RP3-394A18.1	-4.77	2.42e-06	0.000284	-0.16	-0.22	Tonsillectomy;	chr22:30154941	chr22:29978950~30028236:-
THCA	cis	rs72843506	0.656	rs78325601	ENSG00000231258.2	ZSWIM5P2	4.77	2.42e-06	0.000284	0.34	0.22	Schizophrenia;	chr17:20018486	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs74648067	ENSG00000231258.2	ZSWIM5P2	4.77	2.42e-06	0.000284	0.34	0.22	Schizophrenia;	chr17:20022938	chr17:20583758~20591180:-
THCA	cis	rs8020095	0.571	rs10138865	ENSG00000258561.1	RP11-72M17.1	-4.77	2.42e-06	0.000284	-0.28	-0.22	Depression (quantitative trait);	chr14:67140085	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs1918483	ENSG00000258561.1	RP11-72M17.1	-4.77	2.42e-06	0.000284	-0.28	-0.22	Depression (quantitative trait);	chr14:67140906	chr14:66212810~66509394:-
THCA	cis	rs911555	0.755	rs7148567	ENSG00000244691.1	RPL10AP1	-4.77	2.42e-06	0.000284	-0.29	-0.22	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs10144051	ENSG00000244691.1	RPL10AP1	-4.77	2.42e-06	0.000284	-0.29	-0.22	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103412119~103412761:-
THCA	cis	rs1336149	0.901	rs822430	ENSG00000211581.1	MIR765	4.77	2.42e-06	0.000284	0.27	0.22	Chin dimples;	chr1:156932467	chr1:156936131~156936244:-
THCA	cis	rs7838490	0.504	rs4563940	ENSG00000253553.4	RP11-586K2.1	-4.77	2.42e-06	0.000284	-0.22	-0.22	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88481992	chr8:88326836~88737134:+
THCA	cis	rs10266483	0.739	rs679966	ENSG00000228653.2	HNRNPCP7	-4.77	2.42e-06	0.000284	-0.19	-0.22	Response to statin therapy;	chr7:64306688	chr7:64500825~64501729:+
THCA	cis	rs10760158	0.865	rs4836842	ENSG00000235865.2	GSN-AS1	4.77	2.42e-06	0.000284	0.18	0.22	Pulse pressure;	chr9:121251155	chr9:121280768~121285530:-
THCA	cis	rs13178541	0.81	rs4976389	ENSG00000250378.1	RP11-119J18.1	-4.77	2.43e-06	0.000284	-0.28	-0.22	IgG glycosylation;	chr5:135799469	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs10076529	ENSG00000250378.1	RP11-119J18.1	-4.77	2.43e-06	0.000284	-0.28	-0.22	IgG glycosylation;	chr5:135800916	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.639	rs6596264	ENSG00000250378.1	RP11-119J18.1	-4.77	2.43e-06	0.000284	-0.28	-0.22	IgG glycosylation;	chr5:135801128	chr5:135812667~135826582:+
THCA	cis	rs4950322	0.57	rs72691004	ENSG00000180867.10	PDIA3P1	4.77	2.43e-06	0.000284	0.21	0.22	Protein quantitative trait loci;	chr1:147234309	chr1:147178113~147179622:+
THCA	cis	rs2692947	0.666	rs7566050	ENSG00000232931.4	LINC00342	4.77	2.43e-06	0.000284	0.17	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95960282	chr2:95807118~95816215:-
THCA	cis	rs651907	0.535	rs61396602	ENSG00000244119.1	PDCL3P4	4.77	2.43e-06	0.000284	0.2	0.22	Colorectal cancer;	chr3:101790202	chr3:101712472~101713191:+
THCA	cis	rs4927850	1	rs7630875	ENSG00000185485.13	SDHAP1	4.77	2.43e-06	0.000284	0.18	0.22	Pancreatic cancer;	chr3:196026895	chr3:195959748~195990318:-
THCA	cis	rs950776	0.518	rs4887063	ENSG00000261762.1	RP11-650L12.2	-4.77	2.43e-06	0.000284	-0.27	-0.22	Sudden cardiac arrest;	chr15:78547373	chr15:78589123~78591276:-
THCA	cis	rs4698048	0.506	rs2080072	ENSG00000261490.1	RP11-448G15.3	-4.77	2.43e-06	0.000284	-0.14	-0.22	Skin aging (microtopography measurement);	chr4:10233998	chr4:10068089~10073019:-
THCA	cis	rs58605417	0.566	rs1504797	ENSG00000253553.4	RP11-586K2.1	4.77	2.43e-06	0.000284	0.22	0.22	Schizophrenia;	chr8:88422176	chr8:88326836~88737134:+
THCA	cis	rs793571	0.628	rs2013098	ENSG00000259250.1	RP11-50C13.1	-4.77	2.43e-06	0.000285	-0.23	-0.22	Schizophrenia;	chr15:58804600	chr15:58587507~58591676:+
THCA	cis	rs793571	0.628	rs28394222	ENSG00000259250.1	RP11-50C13.1	-4.77	2.43e-06	0.000285	-0.23	-0.22	Schizophrenia;	chr15:58804958	chr15:58587507~58591676:+
THCA	cis	rs12893668	0.703	rs7148456	ENSG00000269958.1	RP11-73M18.8	-4.77	2.43e-06	0.000285	-0.21	-0.22	Reticulocyte count;	chr14:103561933	chr14:103696353~103697163:+
THCA	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	4.77	2.43e-06	0.000285	0.27	0.22	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
THCA	cis	rs6442522	0.606	rs3773459	ENSG00000249786.6	EAF1-AS1	4.77	2.43e-06	0.000285	0.22	0.22	Uric acid levels;	chr3:15454137	chr3:15436171~15455940:-
THCA	cis	rs6442522	0.606	rs3773458	ENSG00000249786.6	EAF1-AS1	4.77	2.43e-06	0.000285	0.22	0.22	Uric acid levels;	chr3:15454147	chr3:15436171~15455940:-
THCA	cis	rs9987353	0.566	rs13260067	ENSG00000248538.5	RP11-10A14.5	4.77	2.43e-06	0.000285	0.29	0.22	Recombination measurement;	chr8:9213523	chr8:9189011~9202854:+
THCA	cis	rs9925964	0.9	rs56813533	ENSG00000260911.2	RP11-196G11.2	-4.77	2.43e-06	0.000285	-0.18	-0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31059160	chr16:31043150~31049868:+
THCA	cis	rs8002861	0.905	rs12428350	ENSG00000274001.1	RP11-5G9.5	-4.77	2.43e-06	0.000285	-0.26	-0.21	Leprosy;	chr13:43872025	chr13:43877715~43878163:-
THCA	cis	rs7429990	0.864	rs6777081	ENSG00000228638.1	FCF1P2	4.77	2.43e-06	0.000285	0.21	0.21	Educational attainment (years of education);	chr3:48114079	chr3:48290793~48291375:-
THCA	cis	rs11673344	0.523	rs2082010	ENSG00000276846.1	CTD-3220F14.3	4.77	2.43e-06	0.000285	0.16	0.21	Obesity-related traits;	chr19:37039874	chr19:37314868~37315620:-
THCA	cis	rs7474896	0.537	rs2505255	ENSG00000226578.1	RP11-258F22.1	-4.77	2.43e-06	0.000285	-0.3	-0.21	Obesity (extreme);	chr10:38070714	chr10:37775371~37784131:-
THCA	cis	rs1048886	0.872	rs4283855	ENSG00000271967.1	RP11-134K13.4	-4.77	2.43e-06	0.000285	-0.22	-0.21	Type 2 diabetes;	chr6:70515070	chr6:70596438~70596980:+
THCA	cis	rs642858	0.737	rs67762923	ENSG00000234147.1	RP3-460G2.2	4.77	2.43e-06	0.000285	0.27	0.21	Type 2 diabetes;	chr6:140362259	chr6:140845958~140852924:-
THCA	cis	rs3770081	1	rs73943909	ENSG00000272564.1	RP11-548P2.2	-4.77	2.43e-06	0.000285	-0.39	-0.21	Facial emotion recognition (sad faces);	chr2:85916255	chr2:85904279~85904727:+
THCA	cis	rs13434995	0.513	rs13133077	ENSG00000273257.1	RP11-177J6.1	4.77	2.43e-06	0.000285	0.33	0.21	Adiponectin levels;	chr4:55577642	chr4:55387949~55388271:+
THCA	cis	rs703842	0.616	rs4760332	ENSG00000270039.1	RP11-571M6.17	4.77	2.43e-06	0.000285	0.25	0.21	Multiple sclerosis;	chr12:57828889	chr12:57803838~57804415:+
THCA	cis	rs4578769	0.55	rs8092358	ENSG00000265939.1	UBE2CP2	4.77	2.43e-06	0.000285	0.24	0.21	Eosinophil percentage of white cells;	chr18:22911835	chr18:22900486~22900995:-
THCA	cis	rs763121	0.853	rs2072795	ENSG00000228274.3	RP3-508I15.9	4.77	2.43e-06	0.000285	0.23	0.21	Menopause (age at onset);	chr22:38668204	chr22:38667585~38681820:-
THCA	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	4.77	2.43e-06	0.000285	0.25	0.21	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
THCA	cis	rs8064024	0.65	rs8056889	ENSG00000267077.1	RP11-127I20.5	4.77	2.44e-06	0.000285	0.25	0.21	Cancer;	chr16:4853242	chr16:4795265~4796532:-
THCA	cis	rs755249	0.565	rs4660846	ENSG00000228060.1	RP11-69E11.8	4.77	2.44e-06	0.000285	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39565160~39573203:+
THCA	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	4.77	2.44e-06	0.000285	0.27	0.21	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
THCA	cis	rs911555	0.755	rs12436729	ENSG00000244691.1	RPL10AP1	4.77	2.44e-06	0.000285	0.29	0.21	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103412119~103412761:-
THCA	cis	rs6832769	1	rs7673908	ENSG00000272969.1	RP11-528I4.2	-4.77	2.44e-06	0.000285	-0.25	-0.21	Personality dimensions;	chr4:55528652	chr4:55547112~55547889:+
THCA	cis	rs1559040	1	rs72800741	ENSG00000272156.1	RP11-477N3.1	-4.77	2.44e-06	0.000285	-0.35	-0.21	Sudden cardiac arrest;	chr2:54106344	chr2:54082554~54085066:+
THCA	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	4.77	2.44e-06	0.000286	0.25	0.21	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
THCA	cis	rs7045881	0.877	rs17755607	ENSG00000254396.1	RP11-56F10.3	-4.77	2.44e-06	0.000286	-0.33	-0.21	Schizophrenia;	chr9:26785736	chr9:27102630~27104728:+
THCA	cis	rs12906542	0.516	rs76398134	ENSG00000260776.4	RP11-114H24.2	4.77	2.44e-06	0.000286	0.35	0.21	Breast cancer;	chr15:77996385	chr15:77914217~77926846:-
THCA	cis	rs6860806	0.531	rs270607	ENSG00000224431.1	AC063976.7	4.77	2.44e-06	0.000286	0.19	0.21	Breast cancer;	chr5:132313493	chr5:132199456~132203487:+
THCA	cis	rs9300255	0.537	rs1716182	ENSG00000235423.7	RP11-282O18.3	4.77	2.44e-06	0.000286	0.22	0.21	Neutrophil percentage of white cells;	chr12:123201580	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1402274	ENSG00000235423.7	RP11-282O18.3	4.77	2.44e-06	0.000286	0.22	0.21	Neutrophil percentage of white cells;	chr12:123201677	chr12:123252030~123261483:-
THCA	cis	rs67478160	0.595	rs2295146	ENSG00000258735.1	LINC00637	-4.77	2.44e-06	0.000286	-0.26	-0.21	Schizophrenia;	chr14:103733019	chr14:103847721~103858049:+
THCA	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-4.77	2.44e-06	0.000286	-0.25	-0.21	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
THCA	cis	rs4700393	0.542	rs4370226	ENSG00000251279.1	CTC-436P18.1	-4.77	2.44e-06	0.000286	-0.3	-0.21	Intelligence (multi-trait analysis);	chr5:60705295	chr5:61162070~61232040:+
THCA	cis	rs8031584	0.958	rs11637469	ENSG00000178081.11	ULK4P3	4.77	2.44e-06	0.000286	0.28	0.21	Huntington's disease progression;	chr15:30946580	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.958	rs8034856	ENSG00000178081.11	ULK4P3	4.77	2.44e-06	0.000286	0.28	0.21	Huntington's disease progression;	chr15:30948754	chr15:30103720~30131757:+
THCA	cis	rs6121246	0.609	rs6060627	ENSG00000230613.1	HM13-AS1	4.77	2.44e-06	0.000286	0.2	0.21	Mean corpuscular hemoglobin;	chr20:31674356	chr20:31567707~31573263:-
THCA	cis	rs9878978	0.754	rs6787085	ENSG00000237990.3	CNTN4-AS1	-4.77	2.44e-06	0.000286	-0.25	-0.21	Blood pressure (smoking interaction);	chr3:2394550	chr3:3039033~3069242:-
THCA	cis	rs7394190	0.748	rs2075641	ENSG00000271848.1	RP11-464F9.21	-4.77	2.44e-06	0.000286	-0.3	-0.21	Incident atrial fibrillation;	chr10:73802350	chr10:73654039~73674719:+
THCA	cis	rs459482	1	rs459498	ENSG00000228318.3	AP001610.5	-4.77	2.44e-06	0.000286	-0.25	-0.21	IgG glycosylation;	chr21:41423100	chr21:41441056~41445708:-
THCA	cis	rs7726839	0.507	rs72703100	ENSG00000225138.6	CTD-2228K2.7	4.77	2.45e-06	0.000286	0.27	0.21	Obesity-related traits;	chr5:614176	chr5:473236~480884:+
THCA	cis	rs7726839	0.574	rs72705014	ENSG00000225138.6	CTD-2228K2.7	4.77	2.45e-06	0.000286	0.27	0.21	Obesity-related traits;	chr5:619700	chr5:473236~480884:+
THCA	cis	rs801193	0.742	rs9969300	ENSG00000230295.1	RP11-458F8.2	4.77	2.45e-06	0.000286	0.17	0.21	Aortic root size;	chr7:66316659	chr7:66880708~66882981:+
THCA	cis	rs7727544	0.709	rs441969	ENSG00000263597.1	MIR3936	4.77	2.45e-06	0.000286	0.21	0.21	Blood metabolite levels;	chr5:132366428	chr5:132365490~132365599:-
THCA	cis	rs270601	0.69	rs162904	ENSG00000224431.1	AC063976.7	-4.77	2.45e-06	0.000286	-0.19	-0.21	Acylcarnitine levels;	chr5:132260091	chr5:132199456~132203487:+
THCA	cis	rs6570726	0.846	rs372904	ENSG00000270638.1	RP3-466P17.1	4.77	2.45e-06	0.000286	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs414297	ENSG00000270638.1	RP3-466P17.1	4.77	2.45e-06	0.000286	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145735570~145737218:+
THCA	cis	rs6832769	0.696	rs7660054	ENSG00000272969.1	RP11-528I4.2	4.77	2.45e-06	0.000287	0.25	0.21	Personality dimensions;	chr4:55402340	chr4:55547112~55547889:+
THCA	cis	rs7726839	0.54	rs72703087	ENSG00000225138.6	CTD-2228K2.7	4.77	2.45e-06	0.000287	0.27	0.21	Obesity-related traits;	chr5:597914	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs11750321	ENSG00000225138.6	CTD-2228K2.7	4.77	2.45e-06	0.000287	0.27	0.21	Obesity-related traits;	chr5:599081	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs72703092	ENSG00000225138.6	CTD-2228K2.7	4.77	2.45e-06	0.000287	0.27	0.21	Obesity-related traits;	chr5:599154	chr5:473236~480884:+
THCA	cis	rs11634944	0.772	rs2732029	ENSG00000257151.1	PWAR6	4.77	2.45e-06	0.000287	0.16	0.21	Interleukin-8 levels;	chr15:24990569	chr15:25031873~25036490:+
THCA	cis	rs2251381	0.722	rs2251278	ENSG00000176054.6	RPL23P2	4.77	2.45e-06	0.000287	0.19	0.21	Selective IgA deficiency;	chr21:29156913	chr21:28997613~28998033:-
THCA	cis	rs6445975	0.715	rs6809809	ENSG00000272360.1	RP11-359I18.5	-4.77	2.45e-06	0.000287	-0.23	-0.21	Systemic lupus erythematosus;	chr3:58282223	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.715	rs3773006	ENSG00000272360.1	RP11-359I18.5	-4.77	2.45e-06	0.000287	-0.23	-0.21	Systemic lupus erythematosus;	chr3:58283812	chr3:58490830~58491291:-
THCA	cis	rs6479874	0.688	rs2660217	ENSG00000223502.1	RP11-96B5.3	-4.77	2.45e-06	0.000287	-0.24	-0.21	Migraine;	chr10:50992200	chr10:51062579~51068553:-
THCA	cis	rs6479874	0.736	rs2660218	ENSG00000223502.1	RP11-96B5.3	-4.77	2.45e-06	0.000287	-0.24	-0.21	Migraine;	chr10:50992711	chr10:51062579~51068553:-
THCA	cis	rs6479874	0.736	rs2816834	ENSG00000223502.1	RP11-96B5.3	-4.77	2.45e-06	0.000287	-0.24	-0.21	Migraine;	chr10:50992971	chr10:51062579~51068553:-
THCA	cis	rs6479874	0.736	rs2816829	ENSG00000223502.1	RP11-96B5.3	-4.77	2.45e-06	0.000287	-0.24	-0.21	Migraine;	chr10:50993839	chr10:51062579~51068553:-
THCA	cis	rs6479874	0.736	rs2816828	ENSG00000223502.1	RP11-96B5.3	-4.77	2.45e-06	0.000287	-0.24	-0.21	Migraine;	chr10:50994003	chr10:51062579~51068553:-
THCA	cis	rs6479874	0.736	rs2816825	ENSG00000223502.1	RP11-96B5.3	-4.77	2.45e-06	0.000287	-0.24	-0.21	Migraine;	chr10:50994156	chr10:51062579~51068553:-
THCA	cis	rs6479874	0.736	rs2816836	ENSG00000223502.1	RP11-96B5.3	4.77	2.45e-06	0.000287	0.24	0.21	Migraine;	chr10:50992613	chr10:51062579~51068553:-
THCA	cis	rs2380220	0.606	rs4559095	ENSG00000261366.1	MANEA-AS1	-4.77	2.45e-06	0.000287	-0.2	-0.21	Behavioural disinhibition (generation interaction);	chr6:95546278	chr6:95575183~95577450:-
THCA	cis	rs13113518	1	rs4864546	ENSG00000273257.1	RP11-177J6.1	4.77	2.45e-06	0.000287	0.28	0.21	Height;	chr4:55537960	chr4:55387949~55388271:+
THCA	cis	rs2985684	0.894	rs2354439	ENSG00000278009.1	RP11-649E7.8	4.77	2.45e-06	0.000287	0.29	0.21	Carotid intima media thickness;	chr14:49552699	chr14:49601011~49601124:-
THCA	cis	rs7914558	1	rs8139	ENSG00000236937.2	PTGES3P4	4.77	2.45e-06	0.000287	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:102845595~102845950:+
THCA	cis	rs651907	0.535	rs58658478	ENSG00000244119.1	PDCL3P4	4.77	2.45e-06	0.000287	0.2	0.21	Colorectal cancer;	chr3:101792823	chr3:101712472~101713191:+
THCA	cis	rs2067615	0.579	rs12424114	ENSG00000260329.1	RP11-412D9.4	-4.77	2.45e-06	0.000287	-0.19	-0.21	Heart rate;	chr12:106750550	chr12:106954029~106955497:-
THCA	cis	rs4906332	0.811	rs2021965	ENSG00000244691.1	RPL10AP1	4.77	2.45e-06	0.000287	0.3	0.21	Coronary artery disease;	chr14:103530911	chr14:103412119~103412761:-
THCA	cis	rs4713118	0.662	rs149900	ENSG00000261839.1	RP1-265C24.8	4.77	2.45e-06	0.000287	0.24	0.21	Parkinson's disease;	chr6:28046819	chr6:28136849~28139678:+
THCA	cis	rs6832769	0.961	rs11947623	ENSG00000272969.1	RP11-528I4.2	4.77	2.45e-06	0.000287	0.25	0.21	Personality dimensions;	chr4:55483023	chr4:55547112~55547889:+
THCA	cis	rs6545883	0.859	rs35760550	ENSG00000270820.4	RP11-355B11.2	-4.77	2.45e-06	0.000287	-0.18	-0.21	Tuberculosis;	chr2:61376730	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.859	rs62149714	ENSG00000270820.4	RP11-355B11.2	-4.77	2.45e-06	0.000287	-0.18	-0.21	Tuberculosis;	chr2:61376734	chr2:61471188~61484130:+
THCA	cis	rs7914558	0.646	rs10883799	ENSG00000236937.2	PTGES3P4	4.77	2.45e-06	0.000287	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102903553	chr10:102845595~102845950:+
THCA	cis	rs7918232	0.882	rs788211	ENSG00000262412.1	RP11-85G18.6	-4.77	2.45e-06	0.000287	-0.33	-0.21	Breast cancer;	chr10:27190141	chr10:27243130~27250804:+
THCA	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-4.77	2.45e-06	0.000287	-0.31	-0.21	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
THCA	cis	rs9875589	0.509	rs2733555	ENSG00000228242.5	AC093495.4	4.77	2.45e-06	0.000287	0.12	0.21	Ovarian reserve;	chr3:14058149	chr3:14144637~14165978:+
THCA	cis	rs7429990	0.932	rs6766641	ENSG00000228638.1	FCF1P2	4.77	2.46e-06	0.000287	0.21	0.21	Educational attainment (years of education);	chr3:48103734	chr3:48290793~48291375:-
THCA	cis	rs6565180	0.926	rs12446288	ENSG00000274653.1	RP11-347C12.11	-4.77	2.46e-06	0.000287	-0.2	-0.21	Tonsillectomy;	chr16:30377388	chr16:30359825~30360336:+
THCA	cis	rs10266483	0.515	rs6948710	ENSG00000227986.1	TRIM60P18	4.77	2.46e-06	0.000287	0.2	0.21	Response to statin therapy;	chr7:64405625	chr7:64355078~64356199:+
THCA	cis	rs6479874	0.646	rs7083536	ENSG00000223502.1	RP11-96B5.3	-4.77	2.46e-06	0.000287	-0.24	-0.21	Migraine;	chr10:50995929	chr10:51062579~51068553:-
THCA	cis	rs4713118	0.628	rs12179134	ENSG00000280107.1	AL022393.9	-4.77	2.46e-06	0.000288	-0.29	-0.21	Parkinson's disease;	chr6:27707690	chr6:28170845~28172521:+
THCA	cis	rs9625935	0.957	rs9625933	ENSG00000279159.1	RP3-394A18.1	-4.77	2.46e-06	0.000288	-0.16	-0.21	Tonsillectomy;	chr22:30159227	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs8141765	ENSG00000279159.1	RP3-394A18.1	-4.77	2.46e-06	0.000288	-0.16	-0.21	Tonsillectomy;	chr22:30166250	chr22:29978950~30028236:-
THCA	cis	rs2905347	0.737	rs2905349	ENSG00000232949.1	AC002480.4	4.77	2.46e-06	0.000288	0.28	0.21	Major depression and alcohol dependence;	chr7:22589666	chr7:22589705~22591622:+
THCA	cis	rs6430585	0.591	rs75223002	ENSG00000231890.6	DARS-AS1	-4.77	2.46e-06	0.000288	-0.27	-0.21	Corneal structure;	chr2:135767739	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.702	rs2304601	ENSG00000231890.6	DARS-AS1	-4.77	2.46e-06	0.000288	-0.27	-0.21	Corneal structure;	chr2:135770464	chr2:135985176~136022593:+
THCA	cis	rs11143230	1	rs11143230	ENSG00000225434.2	LINC01504	4.77	2.46e-06	0.000288	0.33	0.21	Suicidal ideation;	chr9:72272787	chr9:72305430~72343210:+
THCA	cis	rs728616	0.614	rs3934643	ENSG00000242600.5	MBL1P	4.77	2.46e-06	0.000288	0.23	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79904898~79950336:+
THCA	cis	rs17767392	0.794	rs61989255	ENSG00000259146.3	RP1-261D10.2	4.77	2.46e-06	0.000288	0.28	0.21	Mitral valve prolapse;	chr14:71262940	chr14:71292729~71321814:-
THCA	cis	rs17767392	0.756	rs61989256	ENSG00000259146.3	RP1-261D10.2	4.77	2.46e-06	0.000288	0.28	0.21	Mitral valve prolapse;	chr14:71263247	chr14:71292729~71321814:-
THCA	cis	rs11779988	0.545	rs409217	ENSG00000253671.1	RP11-806O11.1	-4.77	2.46e-06	0.000288	-0.28	-0.21	Breast cancer;	chr8:17959088	chr8:17808941~17820868:+
THCA	cis	rs4578769	0.513	rs9953640	ENSG00000265939.1	UBE2CP2	4.77	2.46e-06	0.000288	0.25	0.21	Eosinophil percentage of white cells;	chr18:22947856	chr18:22900486~22900995:-
THCA	cis	rs9396146	0.609	rs3734672	ENSG00000272209.1	RP3-500L14.2	-4.77	2.46e-06	0.000288	-0.29	-0.21	Yeast infection;	chr6:13787346	chr6:13825432~13826574:+
THCA	cis	rs6442522	0.772	rs2278961	ENSG00000249786.6	EAF1-AS1	4.77	2.46e-06	0.000288	0.22	0.21	Uric acid levels;	chr3:15451300	chr3:15436171~15455940:-
THCA	cis	rs2243480	1	rs73142166	ENSG00000232559.3	GS1-124K5.12	4.77	2.46e-06	0.000288	0.32	0.21	Diabetic kidney disease;	chr7:65910845	chr7:66554588~66576923:-
THCA	cis	rs4852324	0.536	rs71418714	ENSG00000257800.1	FNBP1P1	4.77	2.46e-06	0.000288	0.37	0.21	Systemic lupus erythematosus;	chr2:73992759	chr2:74120680~74123218:+
THCA	cis	rs4852324	0.536	rs17009553	ENSG00000257800.1	FNBP1P1	-4.77	2.46e-06	0.000288	-0.37	-0.21	Systemic lupus erythematosus;	chr2:73992908	chr2:74120680~74123218:+
THCA	cis	rs4948102	0.642	rs4948104	ENSG00000226278.1	PSPHP1	-4.77	2.46e-06	0.000288	-0.25	-0.21	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55764797~55773288:+
THCA	cis	rs2281603	0.57	rs11848179	ENSG00000259116.1	RP11-973N13.4	-4.77	2.46e-06	0.000288	-0.19	-0.21	Lymphocyte counts;	chr14:64510335	chr14:64514154~64540368:-
THCA	cis	rs11673344	0.523	rs2891766	ENSG00000276846.1	CTD-3220F14.3	4.77	2.46e-06	0.000288	0.17	0.21	Obesity-related traits;	chr19:37037057	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.523	rs7245453	ENSG00000276846.1	CTD-3220F14.3	4.77	2.46e-06	0.000288	0.17	0.21	Obesity-related traits;	chr19:37043447	chr19:37314868~37315620:-
THCA	cis	rs736408	0.812	rs4687654	ENSG00000243224.1	RP5-1157M23.2	-4.77	2.46e-06	0.000288	-0.24	-0.21	Bipolar disorder;	chr3:52793550	chr3:52239258~52241097:+
THCA	cis	rs4950322	0.57	rs80070044	ENSG00000271721.1	RP11-337C18.9	4.77	2.46e-06	0.000288	0.25	0.21	Protein quantitative trait loci;	chr1:147330238	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692963	ENSG00000271721.1	RP11-337C18.9	4.77	2.46e-06	0.000288	0.25	0.21	Protein quantitative trait loci;	chr1:147331090	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.518	rs72692965	ENSG00000271721.1	RP11-337C18.9	4.77	2.46e-06	0.000288	0.25	0.21	Protein quantitative trait loci;	chr1:147332085	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.518	rs72692968	ENSG00000271721.1	RP11-337C18.9	4.77	2.46e-06	0.000288	0.25	0.21	Protein quantitative trait loci;	chr1:147332884	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.518	rs72692970	ENSG00000271721.1	RP11-337C18.9	4.77	2.46e-06	0.000288	0.25	0.21	Protein quantitative trait loci;	chr1:147332887	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692971	ENSG00000271721.1	RP11-337C18.9	4.77	2.46e-06	0.000288	0.25	0.21	Protein quantitative trait loci;	chr1:147333088	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692973	ENSG00000271721.1	RP11-337C18.9	4.77	2.46e-06	0.000288	0.25	0.21	Protein quantitative trait loci;	chr1:147333281	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692975	ENSG00000271721.1	RP11-337C18.9	4.77	2.46e-06	0.000288	0.25	0.21	Protein quantitative trait loci;	chr1:147333506	chr1:147175602~147177740:+
THCA	cis	rs28735056	0.609	rs4799099	ENSG00000261126.6	RP11-795F19.1	4.77	2.46e-06	0.000288	0.17	0.21	Schizophrenia;	chr18:79879585	chr18:80046900~80095482:+
THCA	cis	rs2439831	0.681	rs3742971	ENSG00000205771.5	CATSPER2P1	4.77	2.46e-06	0.000288	0.28	0.21	Lung cancer in ever smokers;	chr15:43330718	chr15:43726918~43747094:-
THCA	cis	rs10266483	0.739	rs55747800	ENSG00000227986.1	TRIM60P18	4.77	2.46e-06	0.000288	0.2	0.21	Response to statin therapy;	chr7:64410105	chr7:64355078~64356199:+
THCA	cis	rs12410462	0.636	rs2819511	ENSG00000227711.2	RP11-275O4.5	-4.77	2.46e-06	0.000288	-0.27	-0.21	Major depressive disorder;	chr1:227510773	chr1:227509028~227520477:-
THCA	cis	rs7614311	0.636	rs73117066	ENSG00000271843.1	RP11-245J9.5	-4.77	2.46e-06	0.000288	-0.38	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63940560	chr3:64008082~64008692:-
THCA	cis	rs651907	0.535	rs34648996	ENSG00000244119.1	PDCL3P4	4.77	2.47e-06	0.000288	0.2	0.21	Colorectal cancer;	chr3:101792358	chr3:101712472~101713191:+
THCA	cis	rs4948102	0.667	rs7811270	ENSG00000226278.1	PSPHP1	-4.77	2.47e-06	0.000289	-0.25	-0.21	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55764797~55773288:+
THCA	cis	rs7726839	0.555	rs7720419	ENSG00000225138.6	CTD-2228K2.7	4.77	2.47e-06	0.000289	0.21	0.21	Obesity-related traits;	chr5:589228	chr5:473236~480884:+
THCA	cis	rs2067615	0.542	rs7133161	ENSG00000260329.1	RP11-412D9.4	-4.77	2.47e-06	0.000289	-0.2	-0.21	Heart rate;	chr12:106745762	chr12:106954029~106955497:-
THCA	cis	rs7403037	0.804	rs28861743	ENSG00000260760.1	PWRN3	4.77	2.47e-06	0.000289	0.24	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24583566	chr15:24441127~24447967:+
THCA	cis	rs6832769	1	rs3805152	ENSG00000272969.1	RP11-528I4.2	4.77	2.47e-06	0.000289	0.25	0.21	Personality dimensions;	chr4:55493491	chr4:55547112~55547889:+
THCA	cis	rs4295623	0.559	rs4841600	ENSG00000255046.1	RP11-297N6.4	-4.77	2.47e-06	0.000289	-0.23	-0.21	Morning vs. evening chronotype;	chr8:11830639	chr8:11797928~11802568:-
THCA	cis	rs2732480	0.577	rs2634684	ENSG00000273765.1	RP11-370I10.11	-4.77	2.47e-06	0.000289	-0.22	-0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48360920~48361377:+
THCA	cis	rs9329221	0.683	rs4598253	ENSG00000248538.5	RP11-10A14.5	4.77	2.47e-06	0.000289	0.27	0.21	Neuroticism;	chr8:10032794	chr8:9189011~9202854:+
THCA	cis	rs375066	0.577	rs7508701	ENSG00000267058.1	RP11-15A1.3	4.77	2.47e-06	0.000289	0.2	0.21	Breast cancer;	chr19:43808710	chr19:43891804~43901805:-
THCA	cis	rs62025270	0.632	rs62022924	ENSG00000259295.5	CSPG4P12	-4.77	2.47e-06	0.000289	-0.37	-0.21	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85191438~85213905:+
THCA	cis	rs62025270	0.576	rs62022925	ENSG00000259295.5	CSPG4P12	-4.77	2.47e-06	0.000289	-0.37	-0.21	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85191438~85213905:+
THCA	cis	rs858239	0.509	rs6962213	ENSG00000226816.2	AC005082.12	4.77	2.47e-06	0.000289	0.31	0.21	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23206013~23208045:+
THCA	cis	rs786425	0.77	rs7960951	ENSG00000270095.1	RP11-214K3.18	-4.77	2.47e-06	0.000289	-0.26	-0.21	Pubertal anthropometrics;	chr12:123681282	chr12:123971457~123971714:-
THCA	cis	rs4535700	0.501	rs57251705	ENSG00000226278.1	PSPHP1	4.77	2.47e-06	0.000289	0.25	0.21	Macular telangiectasia type 2;	chr7:55913390	chr7:55764797~55773288:+
THCA	cis	rs11992162	0.967	rs10112888	ENSG00000206014.6	OR7E161P	-4.77	2.47e-06	0.000289	-0.25	-0.21	Monocyte count;	chr8:11972699	chr8:11928597~11929563:-
THCA	cis	rs7577696	0.889	rs6725184	ENSG00000276334.1	AL133243.1	-4.77	2.48e-06	0.000289	-0.23	-0.21	Inflammatory biomarkers;	chr2:32105816	chr2:32521927~32523547:+
THCA	cis	rs2985684	0.901	rs7146248	ENSG00000278009.1	RP11-649E7.8	4.77	2.48e-06	0.000289	0.31	0.21	Carotid intima media thickness;	chr14:49645349	chr14:49601011~49601124:-
THCA	cis	rs62158800	0.778	rs57500779	ENSG00000224568.1	AC096669.3	4.77	2.48e-06	0.000289	0.41	0.21	Facial morphology (factor 22);	chr2:107545088	chr2:107529487~107556326:+
THCA	cis	rs11148252	0.532	rs9536262	ENSG00000273784.3	RP11-78J21.7	4.77	2.48e-06	0.00029	0.24	0.21	Lewy body disease;	chr13:52728939	chr13:52600042~52642542:+
THCA	cis	rs6012564	1	rs2426109	ENSG00000227431.4	CSE1L-AS1	-4.77	2.48e-06	0.00029	-0.27	-0.21	Anger;	chr20:49046090	chr20:49040463~49046044:-
THCA	cis	rs3824488	0.92	rs28448271	ENSG00000237857.2	RP11-435O5.2	-4.77	2.48e-06	0.00029	-0.39	-0.21	Neuroticism;	chr9:95477448	chr9:95414834~95426796:-
THCA	cis	rs9625935	0.957	rs4239933	ENSG00000279159.1	RP3-394A18.1	-4.77	2.48e-06	0.00029	-0.16	-0.21	Tonsillectomy;	chr22:30116425	chr22:29978950~30028236:-
THCA	cis	rs10510102	0.872	rs12265369	ENSG00000226864.1	ATE1-AS1	4.77	2.48e-06	0.00029	0.35	0.21	Breast cancer;	chr10:121968455	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.872	rs12265542	ENSG00000226864.1	ATE1-AS1	4.77	2.48e-06	0.00029	0.35	0.21	Breast cancer;	chr10:121968740	chr10:121928312~121951965:+
THCA	cis	rs7403037	0.848	rs7403467	ENSG00000260760.1	PWRN3	4.77	2.48e-06	0.00029	0.25	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24595276	chr15:24441127~24447967:+
THCA	cis	rs7727544	0.684	rs272849	ENSG00000263597.1	MIR3936	4.77	2.48e-06	0.00029	0.21	0.21	Blood metabolite levels;	chr5:132354548	chr5:132365490~132365599:-
THCA	cis	rs12887734	0.524	rs722637	ENSG00000269910.1	RP11-73M18.10	-4.77	2.48e-06	0.00029	-0.19	-0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103694516~103695050:-
THCA	cis	rs17818399	0.962	rs2122715	ENSG00000279254.1	RP11-536C12.1	-4.77	2.48e-06	0.00029	-0.22	-0.21	Height;	chr2:46618710	chr2:46668870~46670778:+
THCA	cis	rs6570726	0.967	rs418662	ENSG00000270638.1	RP3-466P17.1	4.77	2.48e-06	0.00029	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145735570~145737218:+
THCA	cis	rs763121	0.752	rs6001190	ENSG00000235209.1	CTA-150C2.13	4.77	2.48e-06	0.00029	0.28	0.21	Menopause (age at onset);	chr22:38677806	chr22:38921227~38924708:+
THCA	cis	rs7726839	0.54	rs72703083	ENSG00000225138.6	CTD-2228K2.7	4.77	2.48e-06	0.00029	0.27	0.21	Obesity-related traits;	chr5:595250	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs58599998	ENSG00000225138.6	CTD-2228K2.7	4.77	2.48e-06	0.00029	0.27	0.21	Obesity-related traits;	chr5:595972	chr5:473236~480884:+
THCA	cis	rs7726839	0.507	rs56282020	ENSG00000225138.6	CTD-2228K2.7	4.77	2.48e-06	0.00029	0.27	0.21	Obesity-related traits;	chr5:596586	chr5:473236~480884:+
THCA	cis	rs7726839	0.507	rs60068988	ENSG00000225138.6	CTD-2228K2.7	4.77	2.48e-06	0.00029	0.27	0.21	Obesity-related traits;	chr5:597553	chr5:473236~480884:+
THCA	cis	rs57221529	0.709	rs72703090	ENSG00000225138.6	CTD-2228K2.7	4.77	2.48e-06	0.00029	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:598199	chr5:473236~480884:+
THCA	cis	rs2688608	0.836	rs2675668	ENSG00000271816.1	BMS1P4	4.77	2.48e-06	0.00029	0.21	0.21	Inflammatory bowel disease;	chr10:73876390	chr10:73699151~73730487:-
THCA	cis	rs28374715	0.783	rs11635269	ENSG00000247556.5	OIP5-AS1	4.77	2.48e-06	0.00029	0.2	0.21	Ulcerative colitis;	chr15:41278512	chr15:41283990~41309737:+
THCA	cis	rs642858	0.737	rs9373275	ENSG00000234147.1	RP3-460G2.2	4.77	2.48e-06	0.00029	0.27	0.21	Type 2 diabetes;	chr6:140342761	chr6:140845958~140852924:-
THCA	cis	rs642858	0.737	rs9376516	ENSG00000234147.1	RP3-460G2.2	4.77	2.48e-06	0.00029	0.27	0.21	Type 2 diabetes;	chr6:140347695	chr6:140845958~140852924:-
THCA	cis	rs3820928	0.874	rs4675138	ENSG00000212391.1	SNORA48	-4.77	2.48e-06	0.00029	-0.23	-0.21	Pulmonary function;	chr2:227019402	chr2:226968989~226969122:-
THCA	cis	rs172166	0.516	rs2021826	ENSG00000176933.5	TOB2P1	-4.77	2.48e-06	0.00029	-0.23	-0.21	Cardiac Troponin-T levels;	chr6:28164978	chr6:28217643~28218634:-
THCA	cis	rs7688540	0.515	rs28415975	ENSG00000275426.1	CH17-262A2.1	4.77	2.48e-06	0.00029	0.28	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:149738~150317:+
THCA	cis	rs4950322	0.542	rs17159924	ENSG00000226015.2	CCT8P1	4.77	2.48e-06	0.00029	0.25	0.21	Protein quantitative trait loci;	chr1:147199463	chr1:147203276~147204932:-
THCA	cis	rs7260598	0.539	rs57417281	ENSG00000268442.1	CTD-2027I19.2	4.77	2.48e-06	0.00029	0.32	0.21	Response to taxane treatment (placlitaxel);	chr19:23877968	chr19:24162370~24163425:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000229886.1	RP5-1132H15.3	4.77	2.49e-06	0.000291	0.22	0.21	Calcium levels;	chr7:65975383	chr7:66025126~66031544:-
THCA	cis	rs930395	0.514	rs10041518	ENSG00000272335.1	RP11-53O19.3	4.77	2.49e-06	0.000291	0.18	0.21	Breast cancer;	chr5:44927304	chr5:44826076~44828592:+
THCA	cis	rs35740288	0.822	rs4843092	ENSG00000259295.5	CSPG4P12	4.77	2.49e-06	0.000291	0.34	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85689949	chr15:85191438~85213905:+
THCA	cis	rs763121	0.886	rs1013339	ENSG00000228274.3	RP3-508I15.9	-4.77	2.49e-06	0.000291	-0.22	-0.21	Menopause (age at onset);	chr22:38578675	chr22:38667585~38681820:-
THCA	cis	rs6973609	1	rs6973609	ENSG00000271122.1	RP11-379H18.1	-4.77	2.49e-06	0.000291	-0.14	-0.21	Obesity-related traits;	chr7:35567623	chr7:35695214~35699413:+
THCA	cis	rs793571	0.554	rs17301954	ENSG00000245975.2	RP11-30K9.6	4.77	2.49e-06	0.000291	0.26	0.21	Schizophrenia;	chr15:58708232	chr15:58768072~58770974:-
THCA	cis	rs8020095	0.571	rs8010261	ENSG00000258561.1	RP11-72M17.1	-4.77	2.49e-06	0.000291	-0.28	-0.21	Depression (quantitative trait);	chr14:67141400	chr14:66212810~66509394:-
THCA	cis	rs3750082	0.855	rs6462430	ENSG00000231952.3	DPY19L1P2	4.77	2.49e-06	0.000291	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32882219	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs7781915	ENSG00000231952.3	DPY19L1P2	4.77	2.49e-06	0.000291	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32883547	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs12154586	ENSG00000231952.3	DPY19L1P2	4.77	2.49e-06	0.000291	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32883759	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs970673	ENSG00000231952.3	DPY19L1P2	4.77	2.49e-06	0.000291	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32888115	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs3750081	ENSG00000231952.3	DPY19L1P2	4.77	2.49e-06	0.000291	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32891264	chr7:32812757~32838570:+
THCA	cis	rs2302464	0.661	rs35914998	ENSG00000214846.4	RP11-115L11.1	4.77	2.49e-06	0.000291	0.51	0.21	Cerebrospinal fluid biomarker levels;	chr4:15745967	chr4:15730962~15731627:-
THCA	cis	rs7617773	0.817	rs745116	ENSG00000199476.1	Y_RNA	-4.77	2.49e-06	0.000291	-0.27	-0.21	Coronary artery disease;	chr3:48231046	chr3:48288587~48288694:+
THCA	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	4.77	2.49e-06	0.000291	0.23	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
THCA	cis	rs1003719	0.788	rs9981226	ENSG00000230366.8	DSCR9	-4.77	2.49e-06	0.000291	-0.22	-0.21	Eye color traits;	chr21:37079827	chr21:37208503~37221736:+
THCA	cis	rs4713118	0.955	rs9468206	ENSG00000220721.1	OR1F12	4.77	2.49e-06	0.000291	0.28	0.21	Parkinson's disease;	chr6:27722674	chr6:28073316~28074233:+
THCA	cis	rs72717009	0.825	rs7552317	ENSG00000225217.1	HSPA7	-4.77	2.49e-06	0.000291	-0.31	-0.21	Rheumatoid arthritis;	chr1:161509648	chr1:161606291~161608217:+
THCA	cis	rs6088590	1	rs10048849	ENSG00000269202.1	RP4-614O4.12	-4.77	2.49e-06	0.000291	-0.19	-0.21	Coronary artery disease;	chr20:34831877	chr20:35201747~35203288:-
THCA	cis	rs7267979	1	rs6132835	ENSG00000274973.1	RP13-401N8.7	-4.77	2.49e-06	0.000291	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25845497~25845862:+
THCA	cis	rs9863	0.861	rs12298484	ENSG00000269997.1	RP11-214K3.21	-4.77	2.49e-06	0.000291	-0.28	-0.21	White blood cell count;	chr12:123934127	chr12:123966077~123966629:-
THCA	cis	rs972578	0.715	rs2413722	ENSG00000274717.1	RP1-47A17.1	-4.77	2.49e-06	0.000291	-0.23	-0.21	Mean platelet volume;	chr22:42802928	chr22:42791814~42794313:-
THCA	cis	rs10875746	0.624	rs11168498	ENSG00000258234.1	RP11-370I10.2	4.77	2.49e-06	0.000291	0.25	0.21	Longevity (90 years and older);	chr12:48261305	chr12:48231098~48284210:-
THCA	cis	rs3750965	0.959	rs4930265	ENSG00000260895.1	RP11-554A11.7	4.77	2.49e-06	0.000291	0.29	0.21	Hair color;	chr11:69088486	chr11:69103493~69109094:+
THCA	cis	rs6545883	0.826	rs777591	ENSG00000270820.4	RP11-355B11.2	4.77	2.49e-06	0.000291	0.18	0.21	Tuberculosis;	chr2:61190482	chr2:61471188~61484130:+
THCA	cis	rs7760535	0.764	rs2343614	ENSG00000271789.1	RP5-1112D6.7	-4.77	2.49e-06	0.000291	-0.2	-0.21	Metabolic traits;	chr6:111383955	chr6:111297126~111298510:+
THCA	cis	rs9329221	0.525	rs4394398	ENSG00000261451.1	RP11-981G7.1	-4.77	2.49e-06	0.000291	-0.3	-0.21	Neuroticism;	chr8:10226884	chr8:10433672~10438312:+
THCA	cis	rs7403037	0.92	rs11161097	ENSG00000260760.1	PWRN3	4.77	2.5e-06	0.000292	0.25	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24486725	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.959	rs12914724	ENSG00000260760.1	PWRN3	4.77	2.5e-06	0.000292	0.25	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24500623	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.959	rs12910800	ENSG00000260760.1	PWRN3	4.77	2.5e-06	0.000292	0.25	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24500787	chr15:24441127~24447967:+
THCA	cis	rs526231	0.756	rs448086	ENSG00000175749.11	EIF3KP1	4.77	2.5e-06	0.000292	0.27	0.21	Primary biliary cholangitis;	chr5:103287880	chr5:103032376~103033031:+
THCA	cis	rs9840812	0.567	rs2655008	ENSG00000239213.4	NCK1-AS1	4.77	2.5e-06	0.000292	0.2	0.21	Fibrinogen levels;	chr3:136404933	chr3:136841726~136862054:-
THCA	cis	rs1003719	0.725	rs2187101	ENSG00000230366.8	DSCR9	-4.77	2.5e-06	0.000292	-0.22	-0.21	Eye color traits;	chr21:37080079	chr21:37208503~37221736:+
THCA	cis	rs752010	1	rs6664724	ENSG00000230638.4	RP11-486B10.4	-4.77	2.5e-06	0.000292	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41628150	chr1:41542069~41544310:+
THCA	cis	rs752010	1	rs6656183	ENSG00000230638.4	RP11-486B10.4	-4.77	2.5e-06	0.000292	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41628354	chr1:41542069~41544310:+
THCA	cis	rs17572109	0.666	rs11696005	ENSG00000237281.1	CATIP-AS2	-4.77	2.5e-06	0.000292	-0.25	-0.21	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218326889~218357966:-
THCA	cis	rs6012564	0.929	rs2426114	ENSG00000227431.4	CSE1L-AS1	-4.77	2.5e-06	0.000292	-0.26	-0.21	Anger;	chr20:49075855	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs2426116	ENSG00000227431.4	CSE1L-AS1	-4.77	2.5e-06	0.000292	-0.26	-0.21	Anger;	chr20:49076510	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs2024959	ENSG00000227431.4	CSE1L-AS1	4.77	2.5e-06	0.000292	0.26	0.21	Anger;	chr20:49078854	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs17632	ENSG00000227431.4	CSE1L-AS1	4.77	2.5e-06	0.000292	0.26	0.21	Anger;	chr20:49096526	chr20:49040463~49046044:-
THCA	cis	rs1559040	1	rs56374740	ENSG00000272156.1	RP11-477N3.1	-4.77	2.5e-06	0.000292	-0.34	-0.21	Sudden cardiac arrest;	chr2:54092380	chr2:54082554~54085066:+
THCA	cis	rs9311474	0.659	rs7638808	ENSG00000243224.1	RP5-1157M23.2	4.77	2.5e-06	0.000292	0.23	0.21	Electroencephalogram traits;	chr3:52538040	chr3:52239258~52241097:+
THCA	cis	rs9863	0.931	rs4930721	ENSG00000269997.1	RP11-214K3.21	-4.77	2.5e-06	0.000292	-0.27	-0.21	White blood cell count;	chr12:123933342	chr12:123966077~123966629:-
THCA	cis	rs642858	0.612	rs9399314	ENSG00000234147.1	RP3-460G2.2	4.77	2.5e-06	0.000292	0.27	0.21	Type 2 diabetes;	chr6:140358624	chr6:140845958~140852924:-
THCA	cis	rs858239	0.537	rs6942981	ENSG00000226816.2	AC005082.12	4.77	2.5e-06	0.000292	0.31	0.21	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23206013~23208045:+
THCA	cis	rs72843506	1	rs10459969	ENSG00000231258.2	ZSWIM5P2	4.77	2.5e-06	0.000292	0.27	0.21	Schizophrenia;	chr17:20032588	chr17:20583758~20591180:-
THCA	cis	rs72843506	1	rs72843506	ENSG00000231258.2	ZSWIM5P2	4.77	2.5e-06	0.000292	0.27	0.21	Schizophrenia;	chr17:20042974	chr17:20583758~20591180:-
THCA	cis	rs4512344	0.514	rs13255193	ENSG00000206014.6	OR7E161P	4.77	2.5e-06	0.000292	0.25	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11451683	chr8:11928597~11929563:-
THCA	cis	rs6121246	0.609	rs6060652	ENSG00000230613.1	HM13-AS1	4.77	2.5e-06	0.000292	0.2	0.21	Mean corpuscular hemoglobin;	chr20:31679042	chr20:31567707~31573263:-
THCA	cis	rs7829975	0.774	rs11249893	ENSG00000233609.3	RP11-62H7.2	4.77	2.5e-06	0.000292	0.22	0.21	Mood instability;	chr8:8843341	chr8:8961200~8979025:+
THCA	cis	rs12534093	0.662	rs7799435	ENSG00000234286.1	AC006026.13	-4.77	2.5e-06	0.000292	-0.34	-0.21	Infant length;Height;	chr7:23545083	chr7:23680195~23680786:-
THCA	cis	rs7005380	0.746	rs1464276	ENSG00000245330.4	KB-1471A8.1	-4.77	2.51e-06	0.000293	-0.21	-0.21	Interstitial lung disease;	chr8:119924801	chr8:119867419~119874488:-
THCA	cis	rs9467773	0.62	rs2504565	ENSG00000124549.13	BTN2A3P	4.77	2.51e-06	0.000293	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26421391~26432383:+
THCA	cis	rs6903823	0.508	rs1150726	ENSG00000273712.1	RP5-874C20.7	4.77	2.51e-06	0.000293	0.24	0.21	Pulmonary function;	chr6:28275265	chr6:28315613~28315883:-
THCA	cis	rs7688540	0.8	rs12510827	ENSG00000275426.1	CH17-262A2.1	4.77	2.51e-06	0.000293	0.27	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:149738~150317:+
THCA	cis	rs250518	0.926	rs7709640	ENSG00000272081.1	CTD-2376I4.2	4.77	2.51e-06	0.000293	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72791653	chr5:72955206~72955699:-
THCA	cis	rs8177876	0.749	rs2278025	ENSG00000261061.1	RP11-303E16.2	4.77	2.51e-06	0.000293	0.28	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045636	chr16:81030770~81031485:+
THCA	cis	rs4950322	0.57	rs17160051	ENSG00000226015.2	CCT8P1	4.77	2.51e-06	0.000293	0.25	0.21	Protein quantitative trait loci;	chr1:147255733	chr1:147203276~147204932:-
THCA	cis	rs7131987	0.903	rs1991114	ENSG00000275476.1	RP11-996F15.4	-4.77	2.51e-06	0.000293	-0.21	-0.21	QT interval;	chr12:29239149	chr12:29277397~29277882:-
THCA	cis	rs3820928	0.874	rs2177594	ENSG00000212391.1	SNORA48	-4.77	2.51e-06	0.000293	-0.24	-0.21	Pulmonary function;	chr2:226971523	chr2:226968989~226969122:-
THCA	cis	rs2446066	0.872	rs12368222	ENSG00000257379.1	RP11-793H13.8	4.77	2.51e-06	0.000293	0.32	0.21	Red blood cell count;	chr12:53430960	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.872	rs7309494	ENSG00000257379.1	RP11-793H13.8	4.77	2.51e-06	0.000293	0.32	0.21	Red blood cell count;	chr12:53432209	chr12:53441741~53467528:+
THCA	cis	rs11118620	0.853	rs11118622	ENSG00000257551.1	HLX-AS1	4.77	2.51e-06	0.000293	0.29	0.21	Heart failure;	chr1:220868833	chr1:220832763~220880140:-
THCA	cis	rs6545883	0.894	rs2600672	ENSG00000270820.4	RP11-355B11.2	4.77	2.51e-06	0.000293	0.18	0.21	Tuberculosis;	chr2:61309605	chr2:61471188~61484130:+
THCA	cis	rs6479874	0.646	rs7101068	ENSG00000223502.1	RP11-96B5.3	-4.77	2.51e-06	0.000293	-0.24	-0.21	Migraine;	chr10:50998744	chr10:51062579~51068553:-
THCA	cis	rs738144	0.593	rs4821828	ENSG00000235209.1	CTA-150C2.13	-4.77	2.51e-06	0.000293	-0.33	-0.21	IgG glycosylation;	chr22:38804638	chr22:38921227~38924708:+
THCA	cis	rs8062405	0.69	rs4787458	ENSG00000261766.1	RP11-22P6.2	-4.77	2.51e-06	0.000293	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28862166~28863340:-
THCA	cis	rs7432375	0.61	rs7621932	ENSG00000239213.4	NCK1-AS1	4.77	2.51e-06	0.000293	0.19	0.21	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136798174	chr3:136841726~136862054:-
THCA	cis	rs7432375	0.61	rs7633629	ENSG00000239213.4	NCK1-AS1	4.77	2.51e-06	0.000293	0.19	0.21	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136798186	chr3:136841726~136862054:-
THCA	cis	rs67478160	0.643	rs8005225	ENSG00000269910.1	RP11-73M18.10	-4.77	2.51e-06	0.000293	-0.18	-0.21	Schizophrenia;	chr14:103833814	chr14:103694516~103695050:-
THCA	cis	rs7914558	1	rs943036	ENSG00000236937.2	PTGES3P4	4.77	2.51e-06	0.000293	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103076290	chr10:102845595~102845950:+
THCA	cis	rs853679	1	rs2799077	ENSG00000272009.1	RP1-313I6.12	-4.77	2.51e-06	0.000293	-0.29	-0.21	Depression;	chr6:28266819	chr6:28078792~28081130:-
THCA	cis	rs7512898	0.5	rs10800724	ENSG00000260088.1	RP11-92G12.3	-4.77	2.51e-06	0.000293	-0.29	-0.21	Electrocardiographic conduction measures;	chr1:200709285	chr1:200669507~200694250:+
THCA	cis	rs7577696	0.962	rs2280967	ENSG00000276334.1	AL133243.1	-4.77	2.51e-06	0.000293	-0.22	-0.21	Inflammatory biomarkers;	chr2:32064677	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.962	rs34856365	ENSG00000276334.1	AL133243.1	-4.77	2.51e-06	0.000293	-0.22	-0.21	Inflammatory biomarkers;	chr2:32079931	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.962	rs6760105	ENSG00000276334.1	AL133243.1	-4.77	2.51e-06	0.000293	-0.22	-0.21	Inflammatory biomarkers;	chr2:32082317	chr2:32521927~32523547:+
THCA	cis	rs494453	0.922	rs484495	ENSG00000227811.2	FAM212B-AS1	-4.77	2.51e-06	0.000293	-0.27	-0.21	Osteoporosis-related phenotypes;	chr1:111693680	chr1:111739841~111747798:+
THCA	cis	rs494453	0.922	rs2473843	ENSG00000227811.2	FAM212B-AS1	-4.77	2.51e-06	0.000293	-0.27	-0.21	Osteoporosis-related phenotypes;	chr1:111698035	chr1:111739841~111747798:+
THCA	cis	rs494453	0.845	rs2477427	ENSG00000227811.2	FAM212B-AS1	-4.77	2.51e-06	0.000293	-0.27	-0.21	Osteoporosis-related phenotypes;	chr1:111698072	chr1:111739841~111747798:+
THCA	cis	rs9875589	0.509	rs2607757	ENSG00000228242.5	AC093495.4	-4.77	2.51e-06	0.000293	-0.12	-0.21	Ovarian reserve;	chr3:14040448	chr3:14144637~14165978:+
THCA	cis	rs10833905	0.756	rs11026869	ENSG00000246225.5	RP11-17A1.3	-4.77	2.51e-06	0.000294	-0.32	-0.21	Sudden cardiac arrest;	chr11:22973361	chr11:22829380~22945393:+
THCA	cis	rs8020095	0.528	rs8004488	ENSG00000258561.1	RP11-72M17.1	4.77	2.51e-06	0.000294	0.28	0.21	Depression (quantitative trait);	chr14:67200685	chr14:66212810~66509394:-
THCA	cis	rs11902236	0.57	rs1052835	ENSG00000188525.3	AC010969.1	-4.77	2.51e-06	0.000294	-0.27	-0.21	Prostate cancer;	chr2:10001945	chr2:10003158~10006030:-
THCA	cis	rs1040393	0.857	rs6678256	ENSG00000225171.2	DUTP6	4.77	2.52e-06	0.000294	0.31	0.21	Schizophrenia;	chr1:166958979	chr1:166868748~166869209:+
THCA	cis	rs11955398	0.502	rs34623	ENSG00000272308.1	RP11-231G3.1	-4.77	2.52e-06	0.000294	-0.23	-0.21	Intelligence (multi-trait analysis);	chr5:61166012	chr5:60866457~60866935:-
THCA	cis	rs763121	0.853	rs5757232	ENSG00000235209.1	CTA-150C2.13	4.77	2.52e-06	0.000294	0.28	0.21	Menopause (age at onset);	chr22:38675672	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs9306329	ENSG00000235209.1	CTA-150C2.13	4.77	2.52e-06	0.000294	0.28	0.21	Menopause (age at onset);	chr22:38676449	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5750662	ENSG00000235209.1	CTA-150C2.13	4.77	2.52e-06	0.000294	0.28	0.21	Menopause (age at onset);	chr22:38676467	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5750664	ENSG00000235209.1	CTA-150C2.13	4.77	2.52e-06	0.000294	0.28	0.21	Menopause (age at onset);	chr22:38676764	chr22:38921227~38924708:+
THCA	cis	rs763121	0.626	rs5757236	ENSG00000235209.1	CTA-150C2.13	4.77	2.52e-06	0.000294	0.28	0.21	Menopause (age at onset);	chr22:38677819	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs6001191	ENSG00000235209.1	CTA-150C2.13	4.77	2.52e-06	0.000294	0.28	0.21	Menopause (age at onset);	chr22:38678447	chr22:38921227~38924708:+
THCA	cis	rs12143943	0.966	rs898385	ENSG00000240219.1	RP11-430C7.5	4.77	2.52e-06	0.000294	0.19	0.21	Cognitive performance;	chr1:204610732	chr1:204626775~204629712:+
THCA	cis	rs739496	0.579	rs7956495	ENSG00000226469.1	ADAM1B	4.77	2.52e-06	0.000294	0.27	0.21	Platelet count;	chr12:111857889	chr12:111927018~111929017:+
THCA	cis	rs6088590	1	rs6087626	ENSG00000269202.1	RP4-614O4.12	-4.77	2.52e-06	0.000294	-0.19	-0.21	Coronary artery disease;	chr20:34759525	chr20:35201747~35203288:-
THCA	cis	rs6088590	1	rs2180276	ENSG00000269202.1	RP4-614O4.12	-4.77	2.52e-06	0.000294	-0.19	-0.21	Coronary artery disease;	chr20:34772982	chr20:35201747~35203288:-
THCA	cis	rs4660214	0.614	rs6688708	ENSG00000182109.6	RP11-69E11.4	-4.77	2.52e-06	0.000294	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39522280~39546187:-
THCA	cis	rs7838490	0.527	rs821121	ENSG00000253553.4	RP11-586K2.1	-4.77	2.52e-06	0.000294	-0.22	-0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88465856	chr8:88326836~88737134:+
THCA	cis	rs1979679	0.877	rs6487684	ENSG00000278733.1	RP11-425D17.1	-4.77	2.52e-06	0.000294	-0.22	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28490280	chr12:28185625~28186190:-
THCA	cis	rs2120243	0.874	rs2316706	ENSG00000244515.1	KRT18P34	-4.76	2.52e-06	0.000294	-0.25	-0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157442272	chr3:157162663~157163932:-
THCA	cis	rs7474896	1	rs61859667	ENSG00000263064.2	RP11-291L22.7	4.76	2.52e-06	0.000294	0.36	0.21	Obesity (extreme);	chr10:37727451	chr10:38448689~38448949:+
THCA	cis	rs703842	0.963	rs923829	ENSG00000270039.1	RP11-571M6.17	-4.76	2.52e-06	0.000294	-0.24	-0.21	Multiple sclerosis;	chr12:57780523	chr12:57803838~57804415:+
THCA	cis	rs1555322	0.932	rs6119593	ENSG00000126005.14	MMP24-AS1	-4.76	2.52e-06	0.000295	-0.29	-0.21	Attention deficit hyperactivity disorder;	chr20:35245926	chr20:35216462~35278131:-
THCA	cis	rs868036	0.634	rs8028313	ENSG00000270964.1	RP11-502I4.3	-4.76	2.52e-06	0.000295	-0.19	-0.21	Restless legs syndrome;	chr15:67750719	chr15:67541072~67542604:-
THCA	cis	rs2235642	0.75	rs1894649	ENSG00000280231.1	LA16c-380F5.3	-4.76	2.53e-06	0.000295	-0.25	-0.21	Coronary artery disease;	chr16:1607283	chr16:1553655~1554130:-
THCA	cis	rs78487399	0.808	rs17030946	ENSG00000234936.1	AC010883.5	4.76	2.53e-06	0.000295	0.3	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43506370	chr2:43229573~43233394:+
THCA	cis	rs875971	0.545	rs221986	ENSG00000164669.11	INTS4P1	4.76	2.53e-06	0.000295	0.31	0.21	Aortic root size;	chr7:66105323	chr7:65141225~65234216:+
THCA	cis	rs6430585	0.591	rs12466487	ENSG00000231890.6	DARS-AS1	4.76	2.53e-06	0.000295	0.26	0.21	Corneal structure;	chr2:135649508	chr2:135985176~136022593:+
THCA	cis	rs6088580	0.542	rs6059882	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.53e-06	0.000295	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34502362	chr20:33985617~33988989:-
THCA	cis	rs11157436	0.958	rs12433649	ENSG00000211812.1	TRAV26-2	-4.76	2.53e-06	0.000295	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22202583~22203368:+
THCA	cis	rs7772486	0.79	rs2253768	ENSG00000270638.1	RP3-466P17.1	4.76	2.53e-06	0.000295	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145735570~145737218:+
THCA	cis	rs7394190	0.748	rs78790589	ENSG00000271848.1	RP11-464F9.21	-4.76	2.53e-06	0.000295	-0.3	-0.21	Incident atrial fibrillation;	chr10:73779840	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs2292307	ENSG00000271848.1	RP11-464F9.21	-4.76	2.53e-06	0.000295	-0.3	-0.21	Incident atrial fibrillation;	chr10:73790158	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs11000780	ENSG00000271848.1	RP11-464F9.21	-4.76	2.53e-06	0.000295	-0.3	-0.21	Incident atrial fibrillation;	chr10:73799319	chr10:73654039~73674719:+
THCA	cis	rs28735056	0.584	rs35614280	ENSG00000261126.6	RP11-795F19.1	4.76	2.53e-06	0.000295	0.18	0.21	Schizophrenia;	chr18:79876679	chr18:80046900~80095482:+
THCA	cis	rs853679	1	rs1679709	ENSG00000272009.1	RP1-313I6.12	4.76	2.53e-06	0.000295	0.29	0.21	Depression;	chr6:28260564	chr6:28078792~28081130:-
THCA	cis	rs853679	1	rs1778511	ENSG00000272009.1	RP1-313I6.12	4.76	2.53e-06	0.000295	0.29	0.21	Depression;	chr6:28261633	chr6:28078792~28081130:-
THCA	cis	rs853679	1	rs11965538	ENSG00000272009.1	RP1-313I6.12	-4.76	2.53e-06	0.000295	-0.29	-0.21	Depression;	chr6:28272137	chr6:28078792~28081130:-
THCA	cis	rs853679	0.882	rs2743555	ENSG00000272009.1	RP1-313I6.12	-4.76	2.53e-06	0.000295	-0.29	-0.21	Depression;	chr6:28273304	chr6:28078792~28081130:-
THCA	cis	rs853679	1	rs1419183	ENSG00000272009.1	RP1-313I6.12	-4.76	2.53e-06	0.000295	-0.29	-0.21	Depression;	chr6:28275017	chr6:28078792~28081130:-
THCA	cis	rs853679	1	rs6901575	ENSG00000272009.1	RP1-313I6.12	-4.76	2.53e-06	0.000295	-0.29	-0.21	Depression;	chr6:28283207	chr6:28078792~28081130:-
THCA	cis	rs972578	0.715	rs9611914	ENSG00000274717.1	RP1-47A17.1	-4.76	2.53e-06	0.000295	-0.23	-0.21	Mean platelet volume;	chr22:42810581	chr22:42791814~42794313:-
THCA	cis	rs6921919	0.583	rs3800328	ENSG00000280107.1	AL022393.9	-4.76	2.53e-06	0.000295	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs740621	ENSG00000280107.1	AL022393.9	-4.76	2.53e-06	0.000295	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs740622	ENSG00000280107.1	AL022393.9	-4.76	2.53e-06	0.000295	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28170845~28172521:+
THCA	cis	rs12472274	0.817	rs12621791	ENSG00000279484.1	KLHL30-AS1	4.76	2.53e-06	0.000296	0.24	0.21	Phospholipid levels (plasma);	chr2:238195420	chr2:238152889~238155994:-
THCA	cis	rs12472274	0.941	rs4663861	ENSG00000279484.1	KLHL30-AS1	4.76	2.53e-06	0.000296	0.24	0.21	Phospholipid levels (plasma);	chr2:238196562	chr2:238152889~238155994:-
THCA	cis	rs3796352	1	rs35174175	ENSG00000242142.1	SERBP1P3	-4.76	2.53e-06	0.000296	-0.42	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:53007493	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs11713859	ENSG00000242142.1	SERBP1P3	-4.76	2.53e-06	0.000296	-0.42	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:53008064	chr3:53064283~53065091:-
THCA	cis	rs3796352	1	rs71617204	ENSG00000242142.1	SERBP1P3	-4.76	2.53e-06	0.000296	-0.42	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:53008935	chr3:53064283~53065091:-
THCA	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-4.76	2.53e-06	0.000296	-0.33	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
THCA	cis	rs9719620	0.967	rs13238585	ENSG00000236753.4	MKLN1-AS	-4.76	2.53e-06	0.000296	-0.21	-0.21	Male-pattern baldness;	chr7:131314288	chr7:131309744~131328222:-
THCA	cis	rs1577917	0.655	rs9342045	ENSG00000220563.1	PKMP3	4.76	2.53e-06	0.000296	0.16	0.21	Response to antipsychotic treatment;	chr6:85715430	chr6:85659892~85660606:-
THCA	cis	rs2466254	1	rs2466254	ENSG00000251468.2	RP11-369K16.1	4.76	2.53e-06	0.000296	0.31	0.21	Pneumonia;	chr8:12976853	chr8:12958387~12962200:+
THCA	cis	rs6088580	0.634	rs6059878	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.53e-06	0.000296	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34499361	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6120666	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.53e-06	0.000296	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34502913	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.601	rs6120668	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.53e-06	0.000296	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34511988	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6059887	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.53e-06	0.000296	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34513297	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6120669	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.53e-06	0.000296	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34517223	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6059892	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.53e-06	0.000296	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34517961	chr20:33985617~33988989:-
THCA	cis	rs5758659	1	rs134873	ENSG00000227370.1	RP4-669P10.19	-4.76	2.54e-06	0.000296	-0.2	-0.21	Cognitive function;	chr22:42261560	chr22:42132543~42132998:+
THCA	cis	rs11846409	0.932	rs61233250	ENSG00000211974.3	IGHV2-70	-4.76	2.54e-06	0.000296	-0.2	-0.21	Rheumatic heart disease;	chr14:106634072	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs60659763	ENSG00000211974.3	IGHV2-70	-4.76	2.54e-06	0.000296	-0.2	-0.21	Rheumatic heart disease;	chr14:106634172	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs57080270	ENSG00000211974.3	IGHV2-70	-4.76	2.54e-06	0.000296	-0.2	-0.21	Rheumatic heart disease;	chr14:106634215	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs60917084	ENSG00000211974.3	IGHV2-70	-4.76	2.54e-06	0.000296	-0.2	-0.21	Rheumatic heart disease;	chr14:106634621	chr14:106723574~106724093:-
THCA	cis	rs9307551	0.619	rs7670107	ENSG00000250334.4	LINC00989	-4.76	2.54e-06	0.000296	-0.26	-0.21	Refractive error;	chr4:79502861	chr4:79492416~79576460:+
THCA	cis	rs4908768	0.906	rs751790	ENSG00000232912.4	RP5-1115A15.1	4.76	2.54e-06	0.000296	0.27	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469081	chr1:8424645~8434838:+
THCA	cis	rs12036718	0.511	rs17104164	ENSG00000272491.1	RP5-1024N4.4	4.76	2.54e-06	0.000296	0.27	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr1:48115878	chr1:48227888~48229561:-
THCA	cis	rs2834188	0.557	rs1058867	ENSG00000272659.1	AP000295.10	4.76	2.54e-06	0.000296	0.27	0.21	Narcolepsy;	chr21:33297076	chr21:33309491~33310181:+
THCA	cis	rs9719620	0.967	rs4731789	ENSG00000236753.4	MKLN1-AS	-4.76	2.54e-06	0.000296	-0.21	-0.21	Male-pattern baldness;	chr7:131305094	chr7:131309744~131328222:-
THCA	cis	rs9719620	1	rs9719620	ENSG00000236753.4	MKLN1-AS	-4.76	2.54e-06	0.000296	-0.21	-0.21	Male-pattern baldness;	chr7:131309621	chr7:131309744~131328222:-
THCA	cis	rs34792	0.554	rs28393495	ENSG00000207425.1	Y_RNA	-4.76	2.54e-06	0.000296	-0.25	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15516406	chr16:14915457~14915556:-
THCA	cis	rs4639966	0.758	rs11217013	ENSG00000255422.1	AP002954.4	4.76	2.54e-06	0.000296	0.25	0.21	Systemic lupus erythematosus;	chr11:118754210	chr11:118704607~118750263:+
THCA	cis	rs467650	0.75	rs36766	ENSG00000248489.1	CTD-2007H13.3	4.76	2.54e-06	0.000296	0.2	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98612986	chr5:98929171~98995013:+
THCA	cis	rs7267979	1	rs4815411	ENSG00000274973.1	RP13-401N8.7	4.76	2.54e-06	0.000296	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25845497~25845862:+
THCA	cis	rs8067545	0.611	rs2703786	ENSG00000270091.1	RP11-78O7.2	4.76	2.54e-06	0.000296	0.16	0.21	Schizophrenia;	chr17:20253056	chr17:19896590~19897287:-
THCA	cis	rs1124769	0.719	rs1147138	ENSG00000259378.1	DCAF13P3	-4.76	2.54e-06	0.000296	-0.32	-0.21	Cognitive performance;	chr15:50885439	chr15:50944663~50945996:+
THCA	cis	rs9719620	0.967	rs10954315	ENSG00000236753.4	MKLN1-AS	-4.76	2.54e-06	0.000296	-0.21	-0.21	Male-pattern baldness;	chr7:131306850	chr7:131309744~131328222:-
THCA	cis	rs2361718	0.522	rs11867921	ENSG00000275479.1	RP11-334C17.6	4.76	2.54e-06	0.000296	0.21	0.21	Yeast infection;	chr17:80147371	chr17:80149627~80149798:+
THCA	cis	rs12908161	0.959	rs11637728	ENSG00000188388.10	GOLGA6L3	4.76	2.54e-06	0.000296	0.29	0.21	Schizophrenia;	chr15:84660161	chr15:85240472~85247170:+
THCA	cis	rs2886497	0.843	rs4297368	ENSG00000224215.1	RP11-371A19.2	-4.76	2.54e-06	0.000296	-0.27	-0.21	Major depression and alcohol dependence;	chr10:23373979	chr10:23343957~23345181:+
THCA	cis	rs793571	0.554	rs8033691	ENSG00000245975.2	RP11-30K9.6	4.76	2.54e-06	0.000296	0.25	0.21	Schizophrenia;	chr15:58711112	chr15:58768072~58770974:-
THCA	cis	rs9719620	0.868	rs13226691	ENSG00000236753.4	MKLN1-AS	-4.76	2.54e-06	0.000296	-0.21	-0.21	Male-pattern baldness;	chr7:131310803	chr7:131309744~131328222:-
THCA	cis	rs9719620	0.933	rs34281554	ENSG00000236753.4	MKLN1-AS	-4.76	2.54e-06	0.000296	-0.21	-0.21	Male-pattern baldness;	chr7:131311855	chr7:131309744~131328222:-
THCA	cis	rs9719620	0.9	rs11978923	ENSG00000236753.4	MKLN1-AS	-4.76	2.54e-06	0.000296	-0.21	-0.21	Male-pattern baldness;	chr7:131323684	chr7:131309744~131328222:-
THCA	cis	rs2115630	0.755	rs7169629	ENSG00000275120.1	RP11-182J1.17	4.76	2.54e-06	0.000296	0.22	0.21	P wave terminal force;	chr15:84648043	chr15:84599434~84606463:-
THCA	cis	rs4660261	0.526	rs2485997	ENSG00000237950.1	RP11-7O11.3	4.76	2.54e-06	0.000296	0.19	0.21	Intelligence (multi-trait analysis);	chr1:43880169	chr1:43944370~43946551:-
THCA	cis	rs440932	0.717	rs330944	ENSG00000253893.2	FAM85B	-4.76	2.54e-06	0.000297	-0.27	-0.21	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:8167819~8226614:-
THCA	cis	rs7246657	0.722	rs1291	ENSG00000276846.1	CTD-3220F14.3	-4.76	2.54e-06	0.000297	-0.21	-0.21	Coronary artery calcification;	chr19:37738477	chr19:37314868~37315620:-
THCA	cis	rs427394	0.802	rs200841	ENSG00000248677.1	CTD-2044J15.1	4.76	2.54e-06	0.000297	0.21	0.21	Menopause (age at onset);	chr5:6737021	chr5:6686325~6707711:-
THCA	cis	rs9719620	0.967	rs17815356	ENSG00000236753.4	MKLN1-AS	-4.76	2.54e-06	0.000297	-0.21	-0.21	Male-pattern baldness;	chr7:131324425	chr7:131309744~131328222:-
THCA	cis	rs2361718	0.521	rs2361724	ENSG00000275479.1	RP11-334C17.6	4.76	2.54e-06	0.000297	0.2	0.21	Yeast infection;	chr17:80125315	chr17:80149627~80149798:+
THCA	cis	rs7474896	1	rs2799495	ENSG00000263064.2	RP11-291L22.7	-4.76	2.54e-06	0.000297	-0.35	-0.21	Obesity (extreme);	chr10:37949056	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.895	rs650873	ENSG00000263064.2	RP11-291L22.7	-4.76	2.54e-06	0.000297	-0.35	-0.21	Obesity (extreme);	chr10:38035537	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.779	rs647617	ENSG00000263064.2	RP11-291L22.7	-4.76	2.54e-06	0.000297	-0.35	-0.21	Obesity (extreme);	chr10:38041377	chr10:38448689~38448949:+
THCA	cis	rs9329221	0.683	rs3105738	ENSG00000248538.5	RP11-10A14.5	4.76	2.55e-06	0.000297	0.27	0.21	Neuroticism;	chr8:10032404	chr8:9189011~9202854:+
THCA	cis	rs481331	0.799	rs1334053	ENSG00000215146.4	RP11-313J2.1	4.76	2.55e-06	0.000297	0.34	0.21	Systemic juvenile idiopathic arthritis;	chr10:42480283	chr10:42331866~42367974:-
THCA	cis	rs13113518	1	rs4864549	ENSG00000273257.1	RP11-177J6.1	4.76	2.55e-06	0.000297	0.28	0.21	Height;	chr4:55554380	chr4:55387949~55388271:+
THCA	cis	rs6973609	0.962	rs6462612	ENSG00000271122.1	RP11-379H18.1	4.76	2.55e-06	0.000297	0.14	0.21	Obesity-related traits;	chr7:35566864	chr7:35695214~35699413:+
THCA	cis	rs2337406	0.85	rs10131280	ENSG00000211974.3	IGHV2-70	-4.76	2.55e-06	0.000297	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106665591	chr14:106723574~106724093:-
THCA	cis	rs1040393	0.769	rs1543314	ENSG00000225171.2	DUTP6	4.76	2.55e-06	0.000297	0.31	0.21	Schizophrenia;	chr1:166874787	chr1:166868748~166869209:+
THCA	cis	rs62246343	0.719	rs1152314	ENSG00000254485.4	RP11-380O24.1	4.76	2.55e-06	0.000297	0.29	0.21	Fibrinogen levels;	chr3:9450656	chr3:9292588~9363303:-
THCA	cis	rs7587476	0.861	rs3768716	ENSG00000229267.2	AC072062.1	-4.76	2.55e-06	0.000297	-0.28	-0.21	Neuroblastoma;	chr2:214771070	chr2:214810229~214963274:+
THCA	cis	rs793571	0.554	rs28470809	ENSG00000245975.2	RP11-30K9.6	4.76	2.55e-06	0.000297	0.25	0.21	Schizophrenia;	chr15:58744059	chr15:58768072~58770974:-
THCA	cis	rs1003719	0.788	rs61701101	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000297	-0.22	-0.21	Eye color traits;	chr21:37078017	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs9977602	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000297	-0.22	-0.21	Eye color traits;	chr21:37078350	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs7276917	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000297	-0.22	-0.21	Eye color traits;	chr21:37079034	chr21:37208503~37221736:+
THCA	cis	rs9326248	0.53	rs473188	ENSG00000280143.1	AP000892.6	4.76	2.55e-06	0.000297	0.34	0.21	Blood protein levels;	chr11:116941313	chr11:117204967~117210292:+
THCA	cis	rs172166	0.516	rs1150670	ENSG00000273712.1	RP5-874C20.7	4.76	2.55e-06	0.000297	0.23	0.21	Cardiac Troponin-T levels;	chr6:28162781	chr6:28315613~28315883:-
THCA	cis	rs972578	0.765	rs4374465	ENSG00000274717.1	RP1-47A17.1	-4.76	2.55e-06	0.000297	-0.22	-0.21	Mean platelet volume;	chr22:42887256	chr22:42791814~42794313:-
THCA	cis	rs1823913	0.637	rs1378162	ENSG00000280083.1	RP11-317J9.1	-4.76	2.55e-06	0.000297	-0.25	-0.21	Obesity-related traits;	chr2:191298523	chr2:191154118~191156070:-
THCA	cis	rs6430538	0.597	rs4300887	ENSG00000224043.6	CCNT2-AS1	-4.76	2.55e-06	0.000297	-0.23	-0.21	Parkinson's disease;	chr2:134815240	chr2:134735464~134918710:-
THCA	cis	rs4915077	0.656	rs116617506	ENSG00000230489.1	VAV3-AS1	4.76	2.55e-06	0.000297	0.31	0.21	Hypothyroidism;	chr1:107811839	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.656	rs114087238	ENSG00000230489.1	VAV3-AS1	4.76	2.55e-06	0.000297	0.31	0.21	Hypothyroidism;	chr1:107811840	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.892	rs78484451	ENSG00000230489.1	VAV3-AS1	4.76	2.55e-06	0.000297	0.31	0.21	Hypothyroidism;	chr1:107811845	chr1:107964443~107994607:+
THCA	cis	rs2439831	0.717	rs2470132	ENSG00000205771.5	CATSPER2P1	-4.76	2.55e-06	0.000297	-0.29	-0.21	Lung cancer in ever smokers;	chr15:43543283	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-4.76	2.55e-06	0.000297	-0.29	-0.21	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
THCA	cis	rs4660214	0.666	rs11205828	ENSG00000182109.6	RP11-69E11.4	-4.76	2.55e-06	0.000297	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253674	chr1:39522280~39546187:-
THCA	cis	rs9393777	0.841	rs34332556	ENSG00000219392.1	RP1-265C24.5	-4.76	2.55e-06	0.000297	-0.42	-0.21	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28115628~28116551:+
THCA	cis	rs3820928	1	rs4675119	ENSG00000212391.1	SNORA48	-4.76	2.55e-06	0.000297	-0.24	-0.21	Pulmonary function;	chr2:226909919	chr2:226968989~226969122:-
THCA	cis	rs763121	0.853	rs5750668	ENSG00000228274.3	RP3-508I15.9	-4.76	2.55e-06	0.000298	-0.23	-0.21	Menopause (age at onset);	chr22:38683959	chr22:38667585~38681820:-
THCA	cis	rs375066	0.935	rs376032	ENSG00000278917.1	RP11-15A1.4	-4.76	2.55e-06	0.000298	-0.18	-0.21	Breast cancer;	chr19:43903412	chr19:43891233~43895411:+
THCA	cis	rs897984	0.568	rs67264578	ENSG00000260911.2	RP11-196G11.2	4.76	2.55e-06	0.000298	0.2	0.21	Dementia with Lewy bodies;	chr16:30868074	chr16:31043150~31049868:+
THCA	cis	rs897984	0.568	rs56083427	ENSG00000260911.2	RP11-196G11.2	4.76	2.55e-06	0.000298	0.2	0.21	Dementia with Lewy bodies;	chr16:30869977	chr16:31043150~31049868:+
THCA	cis	rs7554547	0.667	rs12065911	ENSG00000199347.1	RNU5E-1	-4.76	2.55e-06	0.000298	-0.29	-0.21	Nonsyndromic cleft lip with cleft palate;	chr1:11908323	chr1:11908152~11908271:+
THCA	cis	rs17404153	0.599	rs11713327	ENSG00000248724.5	NPHP3-AS1	-4.76	2.55e-06	0.000298	-0.32	-0.21	LDL cholesterol;HDL cholesterol;	chr3:132418415	chr3:132721750~132874223:+
THCA	cis	rs6832769	0.961	rs11939815	ENSG00000272969.1	RP11-528I4.2	4.76	2.55e-06	0.000298	0.25	0.21	Personality dimensions;	chr4:55492116	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.826	rs58894703	ENSG00000272969.1	RP11-528I4.2	4.76	2.55e-06	0.000298	0.25	0.21	Personality dimensions;	chr4:55492371	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs3805157	ENSG00000272969.1	RP11-528I4.2	4.76	2.55e-06	0.000298	0.25	0.21	Personality dimensions;	chr4:55497936	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs2177129	ENSG00000272969.1	RP11-528I4.2	4.76	2.55e-06	0.000298	0.25	0.21	Personality dimensions;	chr4:55499247	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.89	rs1980273	ENSG00000272969.1	RP11-528I4.2	4.76	2.55e-06	0.000298	0.25	0.21	Personality dimensions;	chr4:55501234	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs6819660	ENSG00000272969.1	RP11-528I4.2	4.76	2.55e-06	0.000298	0.25	0.21	Personality dimensions;	chr4:55508410	chr4:55547112~55547889:+
THCA	cis	rs9467773	0.62	rs2101581	ENSG00000124549.13	BTN2A3P	4.76	2.55e-06	0.000298	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26421391~26432383:+
THCA	cis	rs1003719	0.788	rs1155785	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000298	-0.22	-0.21	Eye color traits;	chr21:37075639	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs1155787	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000298	-0.22	-0.21	Eye color traits;	chr21:37075769	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs60447195	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000298	-0.22	-0.21	Eye color traits;	chr21:37076300	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.699	rs1015549	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000298	-0.22	-0.21	Eye color traits;	chr21:37076580	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs1015551	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000298	-0.22	-0.21	Eye color traits;	chr21:37077210	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.751	rs7280371	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000298	-0.22	-0.21	Eye color traits;	chr21:37077708	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs9975361	ENSG00000230366.8	DSCR9	-4.76	2.55e-06	0.000298	-0.22	-0.21	Eye color traits;	chr21:37077725	chr21:37208503~37221736:+
THCA	cis	rs6964833	1	rs4717906	ENSG00000278416.1	PMS2L2	4.76	2.55e-06	0.000298	0.33	0.21	Menarche (age at onset);	chr7:74671923	chr7:75344015~75359550:-
THCA	cis	rs801193	0.967	rs2420827	ENSG00000229886.1	RP5-1132H15.3	-4.76	2.55e-06	0.000298	-0.22	-0.21	Aortic root size;	chr7:66682114	chr7:66025126~66031544:-
THCA	cis	rs3820928	0.967	rs4675114	ENSG00000212391.1	SNORA48	-4.76	2.56e-06	0.000298	-0.24	-0.21	Pulmonary function;	chr2:226903646	chr2:226968989~226969122:-
THCA	cis	rs2921036	0.545	rs4840975	ENSG00000253981.4	ALG1L13P	-4.76	2.56e-06	0.000298	-0.24	-0.21	Neuroticism;	chr8:8505748	chr8:8236003~8244667:-
THCA	cis	rs8062405	0.824	rs4788084	ENSG00000261766.1	RP11-22P6.2	-4.76	2.56e-06	0.000298	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28862166~28863340:-
THCA	cis	rs4415084	0.716	rs9637783	ENSG00000272335.1	RP11-53O19.3	-4.76	2.56e-06	0.000298	-0.18	-0.21	Breast cancer;	chr5:44819544	chr5:44826076~44828592:+
THCA	cis	rs7914558	1	rs3740387	ENSG00000236937.2	PTGES3P4	4.76	2.56e-06	0.000298	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:102845595~102845950:+
THCA	cis	rs9863	0.896	rs12829951	ENSG00000269997.1	RP11-214K3.21	-4.76	2.56e-06	0.000298	-0.27	-0.21	White blood cell count;	chr12:123941294	chr12:123966077~123966629:-
THCA	cis	rs9863	0.861	rs7131882	ENSG00000269997.1	RP11-214K3.21	-4.76	2.56e-06	0.000298	-0.27	-0.21	White blood cell count;	chr12:123942189	chr12:123966077~123966629:-
THCA	cis	rs763121	0.719	rs138699	ENSG00000235209.1	CTA-150C2.13	4.76	2.56e-06	0.000298	0.31	0.21	Menopause (age at onset);	chr22:38733703	chr22:38921227~38924708:+
THCA	cis	rs957448	1	rs12543207	ENSG00000253175.1	RP11-267M23.6	4.76	2.56e-06	0.000299	0.28	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94565036~94565715:+
THCA	cis	rs7615952	0.558	rs17334039	ENSG00000272840.1	RP11-379B18.6	4.76	2.56e-06	0.000299	0.33	0.21	Blood pressure (smoking interaction);	chr3:125821465	chr3:125774714~125797953:+
THCA	cis	rs5758659	1	rs134882	ENSG00000281538.1	RP4-669P10.20	4.76	2.56e-06	0.000299	0.19	0.21	Cognitive function;	chr22:42274959	chr22:42138060~42139726:+
THCA	cis	rs270601	0.683	rs81598	ENSG00000237714.1	P4HA2-AS1	4.76	2.56e-06	0.000299	0.28	0.21	Acylcarnitine levels;	chr5:132252267	chr5:132184876~132192808:+
THCA	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-4.76	2.56e-06	0.000299	-0.27	-0.21	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
THCA	cis	rs1707322	1	rs785486	ENSG00000281133.1	AL355480.3	4.76	2.56e-06	0.000299	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.865	rs785501	ENSG00000281133.1	AL355480.3	4.76	2.56e-06	0.000299	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.929	rs785500	ENSG00000281133.1	AL355480.3	4.76	2.56e-06	0.000299	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45580892~45580996:-
THCA	cis	rs13113518	1	rs11133381	ENSG00000273257.1	RP11-177J6.1	4.76	2.56e-06	0.000299	0.28	0.21	Height;	chr4:55450812	chr4:55387949~55388271:+
THCA	cis	rs1005277	0.522	rs1208767	ENSG00000226578.1	RP11-258F22.1	-4.76	2.56e-06	0.000299	-0.25	-0.21	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:37775371~37784131:-
THCA	cis	rs7726839	0.54	rs72703095	ENSG00000225138.6	CTD-2228K2.7	4.76	2.57e-06	0.000299	0.27	0.21	Obesity-related traits;	chr5:601674	chr5:473236~480884:+
THCA	cis	rs1336900	0.544	rs10888386	ENSG00000231073.1	RP11-316M1.3	-4.76	2.57e-06	0.000299	-0.26	-0.21	Blood protein levels;	chr1:150639481	chr1:150973123~150975534:+
THCA	cis	rs17772222	0.917	rs77382318	ENSG00000222990.1	RNU4-22P	4.76	2.57e-06	0.000299	0.29	0.21	Coronary artery calcification;	chr14:88355785	chr14:88513498~88513663:+
THCA	cis	rs7394190	0.748	rs11000775	ENSG00000271848.1	RP11-464F9.21	-4.76	2.57e-06	0.000299	-0.29	-0.21	Incident atrial fibrillation;	chr10:73779252	chr10:73654039~73674719:+
THCA	cis	rs116248771	0.549	rs1548013	ENSG00000271778.1	RP11-379F4.8	4.76	2.57e-06	0.000299	0.29	0.21	diarrhoeal disease at age 2;	chr3:158713281	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.549	rs9825140	ENSG00000271778.1	RP11-379F4.8	4.76	2.57e-06	0.000299	0.29	0.21	diarrhoeal disease at age 2;	chr3:158717585	chr3:158782547~158783124:+
THCA	cis	rs7824557	0.606	rs2736270	ENSG00000154316.13	TDH	-4.76	2.57e-06	0.000299	-0.16	-0.21	Retinal vascular caliber;	chr8:11335084	chr8:11339637~11368452:+
THCA	cis	rs896854	0.818	rs13262110	ENSG00000253528.2	RP11-347C18.4	4.76	2.57e-06	0.000299	0.24	0.21	Type 2 diabetes;	chr8:94914662	chr8:94974573~94974853:-
THCA	cis	rs8031584	0.958	rs11293	ENSG00000178081.11	ULK4P3	4.76	2.57e-06	3e-04	0.28	0.21	Huntington's disease progression;	chr15:30942778	chr15:30103720~30131757:+
THCA	cis	rs10895275	0.851	rs12226331	ENSG00000277459.1	RP11-732A21.3	4.76	2.57e-06	3e-04	0.17	0.21	Migraine;	chr11:102200245	chr11:102109827~102110457:-
THCA	cis	rs11143230	1	rs17552729	ENSG00000225434.2	LINC01504	-4.76	2.57e-06	3e-04	-0.33	-0.21	Suicidal ideation;	chr9:72275265	chr9:72305430~72343210:+
THCA	cis	rs1577917	0.629	rs6927475	ENSG00000220563.1	PKMP3	4.76	2.57e-06	3e-04	0.16	0.21	Response to antipsychotic treatment;	chr6:85497055	chr6:85659892~85660606:-
THCA	cis	rs17798991	0.721	rs8099385	ENSG00000267674.1	RP11-813F20.2	-4.76	2.57e-06	3e-04	-0.23	-0.21	Obesity-related traits;	chr18:49600515	chr18:49739823~49742063:-
THCA	cis	rs4072705	0.586	rs7855247	ENSG00000224020.1	MIR181A2HG	4.76	2.57e-06	3e-04	0.2	0.21	Menarche (age at onset);	chr9:124484365	chr9:124658467~124698631:+
THCA	cis	rs4722166	0.695	rs35779989	ENSG00000225541.1	AC002480.5	-4.76	2.57e-06	3e-04	-0.26	-0.21	Lung cancer;	chr7:22760695	chr7:22571607~22661792:-
THCA	cis	rs12823128	1	rs12823128	ENSG00000256185.1	RP11-612B6.2	-4.76	2.57e-06	3e-04	-0.2	-0.21	Birth weight;	chr12:26719797	chr12:26335864~26336950:-
THCA	cis	rs13113518	0.507	rs4549456	ENSG00000249700.7	SRD5A3-AS1	4.76	2.57e-06	3e-04	0.27	0.21	Height;	chr4:55398586	chr4:55363971~55395847:-
THCA	cis	rs8028182	0.636	rs8036758	ENSG00000260269.4	CTD-2323K18.1	-4.76	2.57e-06	3e-04	-0.32	-0.21	Sudden cardiac arrest;	chr15:75525221	chr15:75527150~75601205:-
THCA	cis	rs6870983	0.749	rs60216969	ENSG00000247828.6	TMEM161B-AS1	4.76	2.57e-06	3e-04	0.19	0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88534272	chr5:88268895~88436685:+
THCA	cis	rs11779988	0.545	rs208752	ENSG00000253671.1	RP11-806O11.1	-4.76	2.58e-06	3e-04	-0.28	-0.21	Breast cancer;	chr8:17916749	chr8:17808941~17820868:+
THCA	cis	rs6964833	1	rs6964833	ENSG00000278416.1	PMS2L2	4.76	2.58e-06	3e-04	0.33	0.21	Menarche (age at onset);	chr7:74687575	chr7:75344015~75359550:-
THCA	cis	rs2348418	0.639	rs61301264	ENSG00000247934.4	RP11-967K21.1	-4.76	2.58e-06	3e-04	-0.18	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28112922	chr12:28163298~28190738:-
THCA	cis	rs763121	0.853	rs5757193	ENSG00000235209.1	CTA-150C2.13	-4.76	2.58e-06	3e-04	-0.28	-0.21	Menopause (age at onset);	chr22:38638862	chr22:38921227~38924708:+
THCA	cis	rs8062405	0.723	rs762633	ENSG00000261766.1	RP11-22P6.2	-4.76	2.58e-06	3e-04	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28862166~28863340:-
THCA	cis	rs11671005	0.695	rs8106061	ENSG00000268049.1	CTD-2619J13.9	-4.76	2.58e-06	3e-04	-0.33	-0.21	Mean platelet volume;	chr19:58406623	chr19:58357999~58359603:+
THCA	cis	rs703842	1	rs11172335	ENSG00000270039.1	RP11-571M6.17	-4.76	2.58e-06	3e-04	-0.25	-0.21	Multiple sclerosis;	chr12:57781418	chr12:57803838~57804415:+
THCA	cis	rs703842	0.964	rs2014886	ENSG00000270039.1	RP11-571M6.17	-4.76	2.58e-06	3e-04	-0.25	-0.21	Multiple sclerosis;	chr12:57783654	chr12:57803838~57804415:+
THCA	cis	rs703842	1	rs1599932	ENSG00000270039.1	RP11-571M6.17	-4.76	2.58e-06	3e-04	-0.25	-0.21	Multiple sclerosis;	chr12:57784160	chr12:57803838~57804415:+
THCA	cis	rs703842	1	rs11172342	ENSG00000270039.1	RP11-571M6.17	-4.76	2.58e-06	3e-04	-0.25	-0.21	Multiple sclerosis;	chr12:57793975	chr12:57803838~57804415:+
THCA	cis	rs703842	1	rs11172343	ENSG00000270039.1	RP11-571M6.17	-4.76	2.58e-06	3e-04	-0.25	-0.21	Multiple sclerosis;	chr12:57794374	chr12:57803838~57804415:+
THCA	cis	rs703842	1	rs1875124	ENSG00000270039.1	RP11-571M6.17	-4.76	2.58e-06	3e-04	-0.25	-0.21	Multiple sclerosis;	chr12:57803019	chr12:57803838~57804415:+
THCA	cis	rs8002861	0.905	rs12875768	ENSG00000274001.1	RP11-5G9.5	-4.76	2.58e-06	3e-04	-0.26	-0.21	Leprosy;	chr13:43854169	chr13:43877715~43878163:-
THCA	cis	rs9878978	0.66	rs62245707	ENSG00000237990.3	CNTN4-AS1	4.76	2.58e-06	3e-04	0.26	0.21	Blood pressure (smoking interaction);	chr3:2396500	chr3:3039033~3069242:-
THCA	cis	rs2692947	0.759	rs1917890	ENSG00000232931.4	LINC00342	4.76	2.58e-06	3e-04	0.17	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96006253	chr2:95807118~95816215:-
THCA	cis	rs75920871	0.61	rs888246	ENSG00000254851.1	RP11-109L13.1	-4.76	2.58e-06	0.000301	-0.48	-0.21	Subjective well-being;	chr11:116853516	chr11:117135528~117138582:+
THCA	cis	rs2692947	0.832	rs2579519	ENSG00000232931.4	LINC00342	4.76	2.58e-06	0.000301	0.17	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96009418	chr2:95807118~95816215:-
THCA	cis	rs2790457	0.833	rs1265847	ENSG00000254635.4	WAC-AS1	-4.76	2.58e-06	0.000301	-0.21	-0.21	Multiple myeloma;	chr10:28640757	chr10:28522652~28532743:-
THCA	cis	rs782590	0.607	rs2061032	ENSG00000272606.1	RP11-554J4.1	-4.76	2.58e-06	0.000301	-0.2	-0.21	Metabolic syndrome;	chr2:55452354	chr2:55617909~55618373:+
THCA	cis	rs4906332	0.811	rs2296487	ENSG00000244691.1	RPL10AP1	-4.76	2.58e-06	0.000301	-0.31	-0.21	Coronary artery disease;	chr14:103529868	chr14:103412119~103412761:-
THCA	cis	rs1552244	0.554	rs6768339	ENSG00000180385.7	EMC3-AS1	-4.76	2.58e-06	0.000301	-0.22	-0.21	Alzheimer's disease;	chr3:9964395	chr3:9986893~10006990:+
THCA	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-4.76	2.58e-06	0.000301	-0.19	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
THCA	cis	rs6545883	0.894	rs778143	ENSG00000270820.4	RP11-355B11.2	4.76	2.58e-06	0.000301	0.18	0.21	Tuberculosis;	chr2:61354755	chr2:61471188~61484130:+
THCA	cis	rs12234571	1	rs35005980	ENSG00000214293.7	APTR	-4.76	2.58e-06	0.000301	-0.28	-0.21	Obesity-related traits;	chr7:77955678	chr7:77657660~77696265:-
THCA	cis	rs2742234	0.541	rs1254958	ENSG00000273008.1	RP11-351D16.3	4.76	2.58e-06	0.000301	0.2	0.21	Hirschsprung disease;	chr10:43206695	chr10:43136824~43138334:-
THCA	cis	rs916888	0.61	rs142167	ENSG00000261575.2	RP11-259G18.1	-4.76	2.58e-06	0.000301	-0.26	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46267037~46268694:+
THCA	cis	rs62292953	1	rs62292953	ENSG00000248724.5	NPHP3-AS1	-4.76	2.58e-06	0.000301	-0.35	-0.21	Red cell distribution width;	chr3:132483605	chr3:132721750~132874223:+
THCA	cis	rs6686643	0.629	rs9333464	ENSG00000236206.1	RP11-306I1.2	4.76	2.58e-06	0.000301	0.34	0.21	Total ventricular volume;	chr1:165649480	chr1:165598463~165623331:+
THCA	cis	rs4987094	0.505	rs4938011	ENSG00000270179.1	RP11-159N11.4	4.76	2.59e-06	0.000301	0.27	0.21	Schizophrenia;	chr11:113376510	chr11:113368478~113369117:+
THCA	cis	rs7614311	1	rs2678352	ENSG00000271843.1	RP11-245J9.5	-4.76	2.59e-06	0.000301	-0.32	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63839964	chr3:64008082~64008692:-
THCA	cis	rs6430538	0.621	rs11900331	ENSG00000224043.6	CCNT2-AS1	-4.76	2.59e-06	0.000301	-0.23	-0.21	Parkinson's disease;	chr2:134814333	chr2:134735464~134918710:-
THCA	cis	rs375066	0.935	rs422457	ENSG00000278917.1	RP11-15A1.4	-4.76	2.59e-06	0.000301	-0.18	-0.21	Breast cancer;	chr19:43905259	chr19:43891233~43895411:+
THCA	cis	rs9467773	0.62	rs2451731	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs9295701	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2451741	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2494700	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.584	rs1021372	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.583	rs1021373	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2451744	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2494701	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs1027204	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2504567	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26421391~26432383:+
THCA	cis	rs3002131	0.604	rs1603742	ENSG00000272750.1	RP11-378J18.8	4.76	2.59e-06	0.000301	0.33	0.21	Interleukin-10 levels;	chr1:222571339	chr1:222658867~222661512:-
THCA	cis	rs9467773	0.62	rs2494696	ENSG00000124549.13	BTN2A3P	4.76	2.59e-06	0.000301	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26421391~26432383:+
THCA	cis	rs1023500	0.551	rs61665536	ENSG00000273366.1	CTA-989H11.1	4.76	2.59e-06	0.000301	0.27	0.21	Schizophrenia;	chr22:42116609	chr22:42278188~42278846:+
THCA	cis	rs1371614	0.502	rs4572551	ENSG00000229122.1	AGBL5-IT1	4.76	2.59e-06	0.000301	0.15	0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26971145	chr2:27061038~27061815:+
THCA	cis	rs10266483	0.739	rs682662	ENSG00000228653.2	HNRNPCP7	-4.76	2.59e-06	0.000302	-0.19	-0.21	Response to statin therapy;	chr7:64306107	chr7:64500825~64501729:+
THCA	cis	rs853679	0.527	rs213228	ENSG00000273712.1	RP5-874C20.7	4.76	2.59e-06	0.000302	0.24	0.21	Depression;	chr6:28363475	chr6:28315613~28315883:-
THCA	cis	rs7914558	0.966	rs3977751	ENSG00000236937.2	PTGES3P4	4.76	2.59e-06	0.000302	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:102845595~102845950:+
THCA	cis	rs1979679	0.837	rs2881860	ENSG00000247934.4	RP11-967K21.1	-4.76	2.59e-06	0.000302	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28363268	chr12:28163298~28190738:-
THCA	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	4.76	2.59e-06	0.000302	0.25	0.21	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
THCA	cis	rs4218	0.636	rs4775116	ENSG00000277144.1	RP11-59H7.4	4.76	2.59e-06	0.000302	0.3	0.21	Social communication problems;	chr15:59135608	chr15:59115547~59116089:-
THCA	cis	rs6012564	1	rs6125539	ENSG00000227431.4	CSE1L-AS1	4.76	2.59e-06	0.000302	0.27	0.21	Anger;	chr20:49087273	chr20:49040463~49046044:-
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000259295.5	CSPG4P12	4.76	2.59e-06	0.000302	0.29	0.21	P wave terminal force;	chr15:84655131	chr15:85191438~85213905:+
THCA	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-4.76	2.59e-06	0.000302	-0.32	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
THCA	cis	rs2787702	0.963	rs2254084	ENSG00000237233.2	TMEM26-AS1	-4.76	2.59e-06	0.000302	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61548636	chr10:61452639~61481956:+
THCA	cis	rs7824557	0.713	rs9286062	ENSG00000154316.13	TDH	4.76	2.59e-06	0.000302	0.15	0.21	Retinal vascular caliber;	chr8:11261018	chr8:11339637~11368452:+
THCA	cis	rs7336933	0.935	rs7333778	ENSG00000278338.3	VWA8-AS1	-4.76	2.59e-06	0.000302	-0.35	-0.21	Calcium levels;	chr13:41971938	chr13:41955808~41981565:+
THCA	cis	rs3820928	0.935	rs12151597	ENSG00000212391.1	SNORA48	-4.76	2.59e-06	0.000302	-0.23	-0.21	Pulmonary function;	chr2:226994508	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.839	rs12151848	ENSG00000212391.1	SNORA48	-4.76	2.59e-06	0.000302	-0.23	-0.21	Pulmonary function;	chr2:226994610	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10189579	ENSG00000212391.1	SNORA48	-4.76	2.59e-06	0.000302	-0.23	-0.21	Pulmonary function;	chr2:227000160	chr2:226968989~226969122:-
THCA	cis	rs4415084	0.966	rs16901937	ENSG00000272335.1	RP11-53O19.3	-4.76	2.59e-06	0.000302	-0.18	-0.21	Breast cancer;	chr5:44709039	chr5:44826076~44828592:+
THCA	cis	rs7267979	0.966	rs8123949	ENSG00000274973.1	RP13-401N8.7	4.76	2.59e-06	0.000302	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2184000	ENSG00000274973.1	RP13-401N8.7	4.76	2.59e-06	0.000302	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25845497~25845862:+
THCA	cis	rs10256972	0.732	rs12701856	ENSG00000225146.1	AC073957.15	4.76	2.59e-06	0.000302	0.22	0.21	Endometriosis;Longevity;	chr7:1068071	chr7:1029025~1043891:+
THCA	cis	rs4722166	0.695	rs4722177	ENSG00000225541.1	AC002480.5	-4.76	2.6e-06	0.000302	-0.26	-0.21	Lung cancer;	chr7:22758912	chr7:22571607~22661792:-
THCA	cis	rs7819412	0.775	rs34094119	ENSG00000206014.6	OR7E161P	4.76	2.6e-06	0.000302	0.24	0.21	Triglycerides;	chr8:11078388	chr8:11928597~11929563:-
THCA	cis	rs9990343	0.783	rs6441955	ENSG00000223552.1	RP11-24F11.2	-4.76	2.6e-06	0.000302	-0.19	-0.21	Brain structure;	chr3:46294844	chr3:46364955~46407059:-
THCA	cis	rs9990343	0.783	rs6441956	ENSG00000223552.1	RP11-24F11.2	-4.76	2.6e-06	0.000302	-0.19	-0.21	Brain structure;	chr3:46294910	chr3:46364955~46407059:-
THCA	cis	rs6860806	0.507	rs270606	ENSG00000237714.1	P4HA2-AS1	4.76	2.6e-06	0.000303	0.29	0.21	Breast cancer;	chr5:132315174	chr5:132184876~132192808:+
THCA	cis	rs2337406	0.85	rs11849578	ENSG00000211974.3	IGHV2-70	-4.76	2.6e-06	0.000303	-0.22	-0.21	Alzheimer's disease (late onset);	chr14:106670302	chr14:106723574~106724093:-
THCA	cis	rs60180747	0.865	rs11639144	ENSG00000261318.1	RP11-653J6.1	4.76	2.6e-06	0.000303	0.3	0.21	Testicular germ cell tumor;	chr15:66307758	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.865	rs11639073	ENSG00000261318.1	RP11-653J6.1	4.76	2.6e-06	0.000303	0.3	0.21	Testicular germ cell tumor;	chr15:66307759	chr15:66278498~66293357:-
THCA	cis	rs62158800	0.778	rs72823033	ENSG00000237880.1	AC096669.2	4.76	2.6e-06	0.000303	0.33	0.21	Facial morphology (factor 22);	chr2:107570342	chr2:107385632~107542649:-
THCA	cis	rs2051211	0.895	rs17037798	ENSG00000229589.1	ACVR2B-AS1	-4.76	2.6e-06	0.000303	-0.23	-0.21	QRS duration;	chr3:38513983	chr3:38451027~38454820:-
THCA	cis	rs916888	0.61	rs199452	ENSG00000261575.2	RP11-259G18.1	4.76	2.6e-06	0.000303	0.25	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46267037~46268694:+
THCA	cis	rs1046491	0.901	rs8085549	ENSG00000264964.1	RP11-888D10.3	4.76	2.6e-06	0.000303	0.36	0.21	Scarlet fever;	chr18:9190595	chr18:9315194~9334441:-
THCA	cis	rs11722779	0.873	rs223346	ENSG00000248971.2	KRT8P46	-4.76	2.6e-06	0.000303	-0.26	-0.21	Schizophrenia;	chr4:102859339	chr4:102728746~102730171:-
THCA	cis	rs11992162	0.551	rs35010200	ENSG00000206014.6	OR7E161P	4.76	2.6e-06	0.000303	0.25	0.21	Monocyte count;	chr8:11928146	chr8:11928597~11929563:-
THCA	cis	rs4950322	0.744	rs2353987	ENSG00000226015.2	CCT8P1	4.76	2.6e-06	0.000303	0.25	0.21	Protein quantitative trait loci;	chr1:147355845	chr1:147203276~147204932:-
THCA	cis	rs6887276	0.504	rs17764688	ENSG00000245937.6	LINC01184	-4.76	2.6e-06	0.000303	-0.21	-0.21	Height;	chr5:128011187	chr5:127940426~128083172:-
THCA	cis	rs317689	0.819	rs317660	ENSG00000274979.1	RP11-1143G9.5	-4.76	2.6e-06	0.000303	-0.24	-0.21	Response to diuretic therapy;	chr12:69292423	chr12:69326574~69331882:-
THCA	cis	rs5742933	0.948	rs2264018	ENSG00000253559.1	OSGEPL1-AS1	-4.76	2.6e-06	0.000303	-0.26	-0.21	Ferritin levels;	chr2:189712052	chr2:189762704~189765556:+
THCA	cis	rs12935418	0.672	rs9923948	ENSG00000278985.1	RP11-303E16.9	4.76	2.6e-06	0.000303	0.24	0.21	Mean corpuscular volume;	chr16:81013814	chr16:80982319~80984094:-
THCA	cis	rs8141529	0.748	rs132528	ENSG00000226471.5	CTA-292E10.6	4.76	2.6e-06	0.000303	0.18	0.21	Lymphocyte counts;	chr22:28899910	chr22:28800683~28848559:+
THCA	cis	rs7074356	0.569	rs7090863	ENSG00000242600.5	MBL1P	4.76	2.6e-06	0.000303	0.22	0.21	Borderline personality disorder;	chr10:80261637	chr10:79904898~79950336:+
THCA	cis	rs8105895	0.877	rs9973249	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22059358	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.877	rs2359833	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22059419	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.877	rs2163837	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22059434	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs2163835	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22059877	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs28857211	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22060302	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs28894669	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22060462	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10406551	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22061718	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10405613	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22061970	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10405673	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22062088	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10406485	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22062200	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10406119	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22062207	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.877	rs28822164	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22062306	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10408150	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22062423	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7251884	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22062728	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7252023	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22062844	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7252550	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22063215	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10413784	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22063389	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10407173	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22063861	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs8104144	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22064111	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs8103518	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22064150	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs8104630	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22064475	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs9653157	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22066688	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs9653142	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22066794	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7247147	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22067056	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7247228	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22067334	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.877	rs7248305	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22067469	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7250905	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22067941	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs2043317	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22068294	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs2043316	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22068402	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs8108651	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22068662	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs8108976	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22068899	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10420019	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22069103	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.778	rs10401922	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22070450	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10422289	ENSG00000269345.1	VN1R85P	4.76	2.6e-06	0.000303	0.28	0.21	Body mass index (change over time);	chr19:22073258	chr19:22174766~22175191:-
THCA	cis	rs4713118	0.868	rs7756968	ENSG00000226314.6	ZNF192P1	-4.76	2.6e-06	0.000303	-0.29	-0.21	Parkinson's disease;	chr6:27767175	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.826	rs2893929	ENSG00000226314.6	ZNF192P1	-4.76	2.6e-06	0.000303	-0.29	-0.21	Parkinson's disease;	chr6:27770953	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.666	rs4140646	ENSG00000226314.6	ZNF192P1	-4.76	2.6e-06	0.000303	-0.29	-0.21	Parkinson's disease;	chr6:27771022	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.666	rs2893930	ENSG00000226314.6	ZNF192P1	-4.76	2.6e-06	0.000303	-0.29	-0.21	Parkinson's disease;	chr6:27771027	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.868	rs742047	ENSG00000226314.6	ZNF192P1	-4.76	2.6e-06	0.000303	-0.29	-0.21	Parkinson's disease;	chr6:27771601	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.868	rs760587	ENSG00000226314.6	ZNF192P1	-4.76	2.6e-06	0.000303	-0.29	-0.21	Parkinson's disease;	chr6:27772521	chr6:28161781~28169594:+
THCA	cis	rs2562456	0.833	rs1781872	ENSG00000268117.1	VN1R84P	4.76	2.61e-06	0.000303	0.35	0.21	Pain;	chr19:21294601	chr19:21719801~21720035:-
THCA	cis	rs7010876	0.56	rs13275559	ENSG00000253553.4	RP11-586K2.1	4.76	2.61e-06	0.000303	0.22	0.21	Schizophrenia;	chr8:88406291	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.606	rs55758944	ENSG00000253553.4	RP11-586K2.1	4.76	2.61e-06	0.000303	0.22	0.21	Schizophrenia;	chr8:88410276	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.537	rs13277579	ENSG00000253553.4	RP11-586K2.1	4.76	2.61e-06	0.000303	0.22	0.21	Schizophrenia;	chr8:88411711	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.537	rs13251103	ENSG00000253553.4	RP11-586K2.1	4.76	2.61e-06	0.000303	0.22	0.21	Schizophrenia;	chr8:88415986	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.537	rs7838159	ENSG00000253553.4	RP11-586K2.1	4.76	2.61e-06	0.000303	0.22	0.21	Schizophrenia;	chr8:88417302	chr8:88326836~88737134:+
THCA	cis	rs35740288	0.721	rs17637276	ENSG00000259295.5	CSPG4P12	4.76	2.61e-06	0.000303	0.34	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700289	chr15:85191438~85213905:+
THCA	cis	rs7267979	1	rs6115153	ENSG00000274973.1	RP13-401N8.7	4.76	2.61e-06	0.000303	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs7268053	ENSG00000274973.1	RP13-401N8.7	4.76	2.61e-06	0.000303	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6083809	ENSG00000274973.1	RP13-401N8.7	4.76	2.61e-06	0.000303	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25845497~25845862:+
THCA	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	4.76	2.61e-06	0.000303	0.26	0.21	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
THCA	cis	rs8058578	0.775	rs8046391	ENSG00000279196.1	RP11-1072A3.3	4.76	2.61e-06	0.000303	0.22	0.21	Multiple myeloma;	chr16:30825327	chr16:30984630~30988270:-
THCA	cis	rs7181230	0.885	rs4497657	ENSG00000275636.1	RP11-521C20.5	4.76	2.61e-06	0.000304	0.23	0.21	Dehydroepiandrosterone sulphate levels;	chr15:40067232	chr15:40078892~40079347:+
THCA	cis	rs2243480	0.522	rs431168	ENSG00000228409.4	CCT6P1	4.76	2.61e-06	0.000304	0.29	0.21	Diabetic kidney disease;	chr7:66046617	chr7:65751142~65763354:+
THCA	cis	rs6832769	0.925	rs4865018	ENSG00000272969.1	RP11-528I4.2	-4.76	2.61e-06	0.000304	-0.25	-0.21	Personality dimensions;	chr4:55591024	chr4:55547112~55547889:+
THCA	cis	rs860295	0.702	rs10908471	ENSG00000160766.13	GBAP1	-4.76	2.61e-06	0.000304	-0.26	-0.21	Body mass index;	chr1:155573151	chr1:155213821~155227422:-
THCA	cis	rs860295	0.702	rs10908472	ENSG00000160766.13	GBAP1	-4.76	2.61e-06	0.000304	-0.26	-0.21	Body mass index;	chr1:155574465	chr1:155213821~155227422:-
THCA	cis	rs860295	0.702	rs11264383	ENSG00000160766.13	GBAP1	-4.76	2.61e-06	0.000304	-0.26	-0.21	Body mass index;	chr1:155575555	chr1:155213821~155227422:-
THCA	cis	rs7833787	0.827	rs12544633	ENSG00000278886.1	RP11-108A14.1	-4.76	2.61e-06	0.000304	-0.27	-0.21	Obesity-related traits;	chr8:18820792	chr8:18864681~18865247:-
THCA	cis	rs7833787	0.827	rs1022758	ENSG00000278886.1	RP11-108A14.1	-4.76	2.61e-06	0.000304	-0.27	-0.21	Obesity-related traits;	chr8:18821195	chr8:18864681~18865247:-
THCA	cis	rs3096299	0.563	rs4600467	ENSG00000261118.1	RP11-104N10.1	4.76	2.61e-06	0.000304	0.18	0.21	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89492017~89504460:-
THCA	cis	rs227275	0.554	rs223339	ENSG00000248971.2	KRT8P46	-4.76	2.61e-06	0.000304	-0.26	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102728746~102730171:-
THCA	cis	rs516805	0.961	rs483933	ENSG00000279114.1	RP3-425C14.5	-4.76	2.61e-06	0.000304	-0.21	-0.21	Lymphocyte counts;	chr6:122460377	chr6:122471923~122484161:+
THCA	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-4.76	2.61e-06	0.000304	-0.28	-0.21	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
THCA	cis	rs793571	0.505	rs9635351	ENSG00000245975.2	RP11-30K9.6	4.76	2.61e-06	0.000304	0.25	0.21	Schizophrenia;	chr15:58625762	chr15:58768072~58770974:-
THCA	cis	rs7914558	1	rs1926030	ENSG00000236937.2	PTGES3P4	4.76	2.61e-06	0.000304	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:102845595~102845950:+
THCA	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-4.76	2.61e-06	0.000304	-0.33	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
THCA	cis	rs202072	0.725	rs445590	ENSG00000272379.1	RP1-257A7.5	4.76	2.61e-06	0.000304	0.32	0.21	HIV-1 viral setpoint;	chr6:13280632	chr6:13290018~13290490:-
THCA	cis	rs202072	0.769	rs445591	ENSG00000272379.1	RP1-257A7.5	4.76	2.61e-06	0.000304	0.32	0.21	HIV-1 viral setpoint;	chr6:13280634	chr6:13290018~13290490:-
THCA	cis	rs12823128	0.783	rs2291261	ENSG00000256185.1	RP11-612B6.2	4.76	2.61e-06	0.000304	0.2	0.21	Birth weight;	chr12:26722632	chr12:26335864~26336950:-
THCA	cis	rs3750082	0.889	rs7785065	ENSG00000231952.3	DPY19L1P2	4.76	2.61e-06	0.000304	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32875592	chr7:32812757~32838570:+
THCA	cis	rs4950322	0.512	rs10736839	ENSG00000278811.3	LINC00624	-4.76	2.61e-06	0.000304	-0.23	-0.21	Protein quantitative trait loci;	chr1:147370431	chr1:147258885~147517875:-
THCA	cis	rs8020095	0.571	rs7493580	ENSG00000258561.1	RP11-72M17.1	-4.76	2.61e-06	0.000304	-0.28	-0.21	Depression (quantitative trait);	chr14:67113733	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.571	rs2039055	ENSG00000258561.1	RP11-72M17.1	-4.76	2.61e-06	0.000304	-0.28	-0.21	Depression (quantitative trait);	chr14:67114076	chr14:66212810~66509394:-
THCA	cis	rs2243480	1	rs4548056	ENSG00000232559.3	GS1-124K5.12	4.76	2.62e-06	0.000304	0.32	0.21	Diabetic kidney disease;	chr7:65833886	chr7:66554588~66576923:-
THCA	cis	rs116095464	0.558	rs113796397	ENSG00000248925.1	CTD-2083E4.6	4.76	2.62e-06	0.000304	0.31	0.21	Breast cancer;	chr5:246388	chr5:269858~271516:-
THCA	cis	rs9863	0.861	rs11057396	ENSG00000269997.1	RP11-214K3.21	-4.76	2.62e-06	0.000304	-0.27	-0.21	White blood cell count;	chr12:123934515	chr12:123966077~123966629:-
THCA	cis	rs8062405	0.755	rs55792032	ENSG00000261766.1	RP11-22P6.2	-4.76	2.62e-06	0.000304	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28862166~28863340:-
THCA	cis	rs9393777	0.92	rs35120058	ENSG00000219392.1	RP1-265C24.5	-4.76	2.62e-06	0.000304	-0.42	-0.21	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28115628~28116551:+
THCA	cis	rs11971779	1	rs75919582	ENSG00000252332.1	RNU6-911P	-4.76	2.62e-06	0.000304	-0.29	-0.21	Diisocyanate-induced asthma;	chr7:139370173	chr7:139448740~139448843:+
THCA	cis	rs3796352	1	rs4478072	ENSG00000242142.1	SERBP1P3	-4.76	2.62e-06	0.000304	-0.38	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:53072109	chr3:53064283~53065091:-
THCA	cis	rs4915077	1	rs79271996	ENSG00000230489.1	VAV3-AS1	4.76	2.62e-06	0.000304	0.33	0.21	Hypothyroidism;	chr1:107808148	chr1:107964443~107994607:+
THCA	cis	rs8028182	0.636	rs4886716	ENSG00000260274.1	RP11-817O13.8	4.76	2.62e-06	0.000304	0.16	0.21	Sudden cardiac arrest;	chr15:75563681	chr15:75368155~75369584:+
THCA	cis	rs12823128	0.819	rs2344500	ENSG00000256185.1	RP11-612B6.2	4.76	2.62e-06	0.000305	0.2	0.21	Birth weight;	chr12:26723687	chr12:26335864~26336950:-
THCA	cis	rs7618915	0.501	rs2289247	ENSG00000243224.1	RP5-1157M23.2	-4.76	2.62e-06	0.000305	-0.23	-0.21	Bipolar disorder;	chr3:52693241	chr3:52239258~52241097:+
THCA	cis	rs2976388	0.578	rs13263987	ENSG00000253741.1	CTD-2292P10.4	4.76	2.62e-06	0.000305	0.29	0.21	Urinary tract infection frequency;	chr8:142745969	chr8:142702252~142726973:-
THCA	cis	rs4915077	1	rs17020047	ENSG00000230489.1	VAV3-AS1	4.76	2.62e-06	0.000305	0.36	0.21	Hypothyroidism;	chr1:107789448	chr1:107964443~107994607:+
THCA	cis	rs2688608	0.904	rs2675669	ENSG00000271816.1	BMS1P4	4.76	2.62e-06	0.000305	0.21	0.21	Inflammatory bowel disease;	chr10:73894114	chr10:73699151~73730487:-
THCA	cis	rs7617773	0.815	rs9825637	ENSG00000199476.1	Y_RNA	-4.76	2.62e-06	0.000305	-0.28	-0.21	Coronary artery disease;	chr3:48330792	chr3:48288587~48288694:+
THCA	cis	rs412050	0.696	rs56226933	ENSG00000224086.5	LL22NC03-86G7.1	-4.76	2.62e-06	0.000305	-0.37	-0.21	Attention deficit hyperactivity disorder;	chr22:21985504	chr22:21938293~21977632:+
THCA	cis	rs17270561	0.666	rs4712976	ENSG00000272462.2	U91328.19	-4.76	2.62e-06	0.000305	-0.18	-0.21	Iron status biomarkers;	chr6:25841975	chr6:25992662~26001775:+
THCA	cis	rs2661868	0.788	rs2708631	ENSG00000232912.4	RP5-1115A15.1	-4.76	2.62e-06	0.000305	-0.24	-0.21	Life satisfaction;	chr1:8403450	chr1:8424645~8434838:+
THCA	cis	rs1046491	0.901	rs10502390	ENSG00000264964.1	RP11-888D10.3	4.76	2.62e-06	0.000305	0.37	0.21	Scarlet fever;	chr18:9113232	chr18:9315194~9334441:-
THCA	cis	rs801193	1	rs17566701	ENSG00000224316.1	RP11-479O9.2	4.76	2.62e-06	0.000305	0.24	0.21	Aortic root size;	chr7:66728196	chr7:65773620~65802067:+
THCA	cis	rs9314614	0.789	rs4841776	ENSG00000245857.2	GS1-24F4.2	4.76	2.62e-06	0.000305	0.27	0.21	White blood cell count (basophil);IgA nephropathy;	chr8:6854697	chr8:6835554~6885276:+
THCA	cis	rs9467773	0.62	rs2451737	ENSG00000124549.13	BTN2A3P	4.76	2.62e-06	0.000305	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.596	rs2494693	ENSG00000124549.13	BTN2A3P	4.76	2.62e-06	0.000305	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2494694	ENSG00000124549.13	BTN2A3P	4.76	2.62e-06	0.000305	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.595	rs2451736	ENSG00000124549.13	BTN2A3P	4.76	2.62e-06	0.000305	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26421391~26432383:+
THCA	cis	rs12931792	0.712	rs4787495	ENSG00000273724.1	RP11-347C12.12	-4.76	2.62e-06	0.000305	-0.22	-0.21	Tonsillectomy;	chr16:30154404	chr16:30336400~30343336:+
THCA	cis	rs7688540	0.8	rs6837796	ENSG00000275426.1	CH17-262A2.1	4.76	2.62e-06	0.000305	0.27	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:149738~150317:+
THCA	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-4.76	2.62e-06	0.000305	-0.32	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
THCA	cis	rs6545883	0.524	rs2694619	ENSG00000270820.4	RP11-355B11.2	-4.76	2.62e-06	0.000305	-0.18	-0.21	Tuberculosis;	chr2:61309766	chr2:61471188~61484130:+
THCA	cis	rs6787172	0.811	rs9865460	ENSG00000272087.1	RP11-379F4.7	4.76	2.62e-06	0.000305	0.19	0.21	Subjective well-being;	chr3:158494230	chr3:158693120~158693768:-
THCA	cis	rs4218	0.681	rs6494069	ENSG00000277144.1	RP11-59H7.4	-4.76	2.62e-06	0.000305	-0.29	-0.21	Social communication problems;	chr15:59094151	chr15:59115547~59116089:-
THCA	cis	rs9388451	0.839	rs4897157	ENSG00000226409.1	RP11-735G4.1	-4.76	2.62e-06	0.000305	-0.25	-0.21	Brugada syndrome;	chr6:125781835	chr6:125370211~125374324:-
THCA	cis	rs7267979	0.966	rs4815425	ENSG00000274973.1	RP13-401N8.7	4.76	2.62e-06	0.000305	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25845497~25845862:+
THCA	cis	rs2439831	0.541	rs12440854	ENSG00000205771.5	CATSPER2P1	-4.76	2.63e-06	0.000305	-0.32	-0.21	Lung cancer in ever smokers;	chr15:43318474	chr15:43726918~43747094:-
THCA	cis	rs4535700	0.501	rs9642405	ENSG00000226278.1	PSPHP1	4.76	2.63e-06	0.000305	0.25	0.21	Macular telangiectasia type 2;	chr7:55910473	chr7:55764797~55773288:+
THCA	cis	rs12554020	0.591	rs2989754	ENSG00000227603.1	RP11-165J3.6	-4.76	2.63e-06	0.000306	-0.25	-0.21	Schizophrenia;	chr9:93613875	chr9:93435332~93437121:-
THCA	cis	rs7746199	0.736	rs13195636	ENSG00000220721.1	OR1F12	4.76	2.63e-06	0.000306	0.49	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28073316~28074233:+
THCA	cis	rs11992162	0.591	rs34123222	ENSG00000254948.1	OR7E158P	4.76	2.63e-06	0.000306	0.27	0.21	Monocyte count;	chr8:11937840	chr8:11919900~11920809:-
THCA	cis	rs11846409	0.655	rs79296226	ENSG00000211974.3	IGHV2-70	4.76	2.63e-06	0.000306	0.21	0.21	Rheumatic heart disease;	chr14:106650436	chr14:106723574~106724093:-
THCA	cis	rs12893668	0.644	rs12890820	ENSG00000269958.1	RP11-73M18.8	4.76	2.63e-06	0.000306	0.21	0.21	Reticulocyte count;	chr14:103568512	chr14:103696353~103697163:+
THCA	cis	rs7617773	0.817	rs11710861	ENSG00000199476.1	Y_RNA	-4.76	2.63e-06	0.000306	-0.27	-0.21	Coronary artery disease;	chr3:48256070	chr3:48288587~48288694:+
THCA	cis	rs550448	0.841	rs78615563	ENSG00000234336.5	JAZF1-AS1	4.76	2.63e-06	0.000306	0.37	0.21	Type 1 diabetes;	chr7:28110093	chr7:28180322~28243917:+
THCA	cis	rs2836974	0.644	rs2836981	ENSG00000255568.3	BRWD1-AS2	-4.76	2.63e-06	0.000306	-0.17	-0.21	Cognitive function;	chr21:39316439	chr21:39313935~39314962:+
THCA	cis	rs17772222	0.63	rs1344747	ENSG00000222990.1	RNU4-22P	-4.76	2.63e-06	0.000306	-0.26	-0.21	Coronary artery calcification;	chr14:88548091	chr14:88513498~88513663:+
THCA	cis	rs6012564	0.89	rs6066976	ENSG00000230758.1	SNAP23P	4.76	2.63e-06	0.000306	0.25	0.21	Anger;	chr20:49134464	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs6066982	ENSG00000230758.1	SNAP23P	4.76	2.63e-06	0.000306	0.25	0.21	Anger;	chr20:49147021	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs7272164	ENSG00000230758.1	SNAP23P	4.76	2.63e-06	0.000306	0.25	0.21	Anger;	chr20:49149660	chr20:49038357~49038602:-
THCA	cis	rs7702057	0.53	rs17138850	ENSG00000272265.1	CTD-2287O16.4	4.76	2.63e-06	0.000306	0.38	0.21	Amyotrophic lateral sclerosis;	chr5:116085317	chr5:116078110~116078570:-
THCA	cis	rs7246657	0.598	rs28660259	ENSG00000226686.6	LINC01535	-4.76	2.63e-06	0.000306	-0.39	-0.21	Coronary artery calcification;	chr19:37167779	chr19:37251912~37265535:+
THCA	cis	rs11633886	0.569	rs4774812	ENSG00000273972.1	CTD-2306A12.1	-4.76	2.63e-06	0.000306	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45837853	chr15:45702640~45703183:+
THCA	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-4.76	2.63e-06	0.000306	-0.26	-0.21	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
THCA	cis	rs8062405	1	rs3888190	ENSG00000261766.1	RP11-22P6.2	-4.76	2.63e-06	0.000306	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28862166~28863340:-
THCA	cis	rs10483853	0.65	rs17126871	ENSG00000258695.2	RP3-414A15.2	-4.76	2.63e-06	0.000306	-0.3	-0.21	Coronary artery calcification;	chr14:73324614	chr14:73522878~73530610:+
THCA	cis	rs10923574	0.576	rs10923578	ENSG00000231365.4	RP11-418J17.1	-4.76	2.63e-06	0.000306	-0.21	-0.21	Breast cancer;Folding of antihelix;	chr1:118504538	chr1:119140396~119275973:+
THCA	cis	rs9910055	1	rs9895423	ENSG00000267080.4	ASB16-AS1	-4.76	2.63e-06	0.000306	-0.2	-0.21	Total body bone mineral density;	chr17:44208372	chr17:44175973~44186717:-
THCA	cis	rs4650994	0.593	rs2811297	ENSG00000273384.1	RP5-1098D14.1	-4.76	2.64e-06	0.000306	-0.28	-0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178582337	chr1:178651706~178652282:+
THCA	cis	rs9923856	0.542	rs11859698	ENSG00000274038.1	RP11-66H6.4	-4.76	2.64e-06	0.000306	-0.25	-0.21	Atopic dermatitis;Adult asthma;	chr16:11032878	chr16:11056556~11057034:+
THCA	cis	rs7914558	1	rs4917994	ENSG00000236937.2	PTGES3P4	4.76	2.64e-06	0.000306	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs2275271	ENSG00000236937.2	PTGES3P4	4.76	2.64e-06	0.000306	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs11191539	ENSG00000236937.2	PTGES3P4	4.76	2.64e-06	0.000306	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs943038	ENSG00000236937.2	PTGES3P4	4.76	2.64e-06	0.000306	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:102845595~102845950:+
THCA	cis	rs7819412	0.608	rs17780806	ENSG00000206014.6	OR7E161P	4.76	2.64e-06	0.000306	0.26	0.21	Triglycerides;	chr8:11118119	chr8:11928597~11929563:-
THCA	cis	rs801193	0.742	rs9969300	ENSG00000229180.5	GS1-124K5.11	-4.76	2.64e-06	0.000307	-0.15	-0.21	Aortic root size;	chr7:66316659	chr7:66526088~66542624:-
THCA	cis	rs2282300	0.637	rs10742240	ENSG00000242353.1	RP4-710M3.1	-4.76	2.64e-06	0.000307	-0.17	-0.21	Morning vs. evening chronotype;	chr11:30407891	chr11:30368148~30368646:+
THCA	cis	rs3820928	0.874	rs59630650	ENSG00000212391.1	SNORA48	-4.76	2.64e-06	0.000307	-0.23	-0.21	Pulmonary function;	chr2:226921798	chr2:226968989~226969122:-
THCA	cis	rs7181230	0.885	rs3923235	ENSG00000275636.1	RP11-521C20.5	4.76	2.64e-06	0.000307	0.23	0.21	Dehydroepiandrosterone sulphate levels;	chr15:40078920	chr15:40078892~40079347:+
THCA	cis	rs734999	0.611	rs10797431	ENSG00000225931.3	RP3-395M20.7	4.76	2.64e-06	0.000307	0.26	0.21	Ulcerative colitis;	chr1:2569783	chr1:2566410~2569888:+
THCA	cis	rs4767841	0.935	rs7299963	ENSG00000248636.5	RP11-768F21.1	-4.76	2.64e-06	0.000307	-0.22	-0.21	Urgency urinary incontinence;	chr12:119720398	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.935	rs3213625	ENSG00000248636.5	RP11-768F21.1	-4.76	2.64e-06	0.000307	-0.22	-0.21	Urgency urinary incontinence;	chr12:119720724	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.935	rs3213626	ENSG00000248636.5	RP11-768F21.1	-4.76	2.64e-06	0.000307	-0.22	-0.21	Urgency urinary incontinence;	chr12:119720736	chr12:119387987~119668079:-
THCA	cis	rs9926296	0.632	rs1800286	ENSG00000260259.1	RP11-368I7.4	-4.76	2.64e-06	0.000307	-0.24	-0.21	Vitiligo;	chr16:89803353	chr16:89682620~89686569:-
THCA	cis	rs683257	0.81	rs72990178	ENSG00000234147.1	RP3-460G2.2	-4.76	2.64e-06	0.000307	-0.37	-0.21	Facial emotion recognition (angry faces);	chr6:140888076	chr6:140845958~140852924:-
THCA	cis	rs1371614	0.545	rs12105356	ENSG00000229122.1	AGBL5-IT1	4.76	2.64e-06	0.000307	0.15	0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26952702	chr2:27061038~27061815:+
THCA	cis	rs4950322	0.57	rs72691012	ENSG00000180867.10	PDIA3P1	4.76	2.64e-06	0.000307	0.21	0.21	Protein quantitative trait loci;	chr1:147239751	chr1:147178113~147179622:+
THCA	cis	rs11168187	0.506	rs12812960	ENSG00000274902.1	RP1-197B17.4	4.76	2.64e-06	0.000307	0.29	0.21	Vertical cup-disc ratio;	chr12:47729395	chr12:47731908~47732351:+
THCA	cis	rs7474896	0.537	rs1208683	ENSG00000226578.1	RP11-258F22.1	4.75	2.64e-06	0.000307	0.3	0.21	Obesity (extreme);	chr10:37804795	chr10:37775371~37784131:-
THCA	cis	rs8064024	0.87	rs930854	ENSG00000267077.1	RP11-127I20.5	4.75	2.64e-06	0.000307	0.23	0.21	Cancer;	chr16:4814100	chr16:4795265~4796532:-
THCA	cis	rs1823874	0.542	rs1962946	ENSG00000182397.13	DNM1P46	-4.75	2.64e-06	0.000307	-0.24	-0.21	IgG glycosylation;	chr15:99834410	chr15:99790156~99806927:-
THCA	cis	rs250518	0.926	rs13157511	ENSG00000272081.1	CTD-2376I4.2	-4.75	2.64e-06	0.000307	-0.27	-0.21	Mean corpuscular hemoglobin concentration;	chr5:72775976	chr5:72955206~72955699:-
THCA	cis	rs8064024	0.62	rs9923349	ENSG00000267077.1	RP11-127I20.5	4.75	2.64e-06	0.000307	0.25	0.21	Cancer;	chr16:4855123	chr16:4795265~4796532:-
THCA	cis	rs3820928	0.874	rs10195072	ENSG00000212391.1	SNORA48	-4.75	2.64e-06	0.000307	-0.23	-0.21	Pulmonary function;	chr2:226929736	chr2:226968989~226969122:-
THCA	cis	rs9652601	0.959	rs12919083	ENSG00000274038.1	RP11-66H6.4	4.75	2.65e-06	0.000307	0.27	0.21	Systemic lupus erythematosus;	chr16:11095073	chr16:11056556~11057034:+
THCA	cis	rs1003719	0.788	rs2835602	ENSG00000230366.8	DSCR9	-4.75	2.65e-06	0.000307	-0.22	-0.21	Eye color traits;	chr21:37096769	chr21:37208503~37221736:+
THCA	cis	rs989128	0.6	rs739924	ENSG00000250286.1	RP11-94C24.8	-4.75	2.65e-06	0.000307	-0.21	-0.21	Type 2 diabetes;	chr17:50554246	chr17:50537294~50538754:-
THCA	cis	rs442309	0.574	rs7895364	ENSG00000238280.1	RP11-436D10.3	-4.75	2.65e-06	0.000308	-0.27	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62725053	chr10:62793562~62805887:-
THCA	cis	rs172166	0.516	rs2622322	ENSG00000176933.5	TOB2P1	-4.75	2.65e-06	0.000308	-0.23	-0.21	Cardiac Troponin-T levels;	chr6:28149665	chr6:28217643~28218634:-
THCA	cis	rs59918340	0.764	rs10107024	ENSG00000253307.1	RP11-10J21.4	4.75	2.65e-06	0.000308	0.29	0.21	Immature fraction of reticulocytes;	chr8:141217493	chr8:141252286~141253292:-
THCA	cis	rs1707322	0.638	rs1707302	ENSG00000280836.1	AL355480.1	4.75	2.65e-06	0.000308	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr1:45581219~45581321:-
THCA	cis	rs2734839	1	rs2734839	ENSG00000270179.1	RP11-159N11.4	-4.75	2.65e-06	0.000308	-0.22	-0.21	Information processing speed;	chr11:113415768	chr11:113368478~113369117:+
THCA	cis	rs2734839	0.927	rs2734837	ENSG00000270179.1	RP11-159N11.4	-4.75	2.65e-06	0.000308	-0.22	-0.21	Information processing speed;	chr11:113416107	chr11:113368478~113369117:+
THCA	cis	rs6728642	0.908	rs10207116	ENSG00000230606.9	AC159540.1	4.75	2.65e-06	0.000308	0.28	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97355418	chr2:97416165~97433527:-
THCA	cis	rs7577696	0.924	rs6747488	ENSG00000276334.1	AL133243.1	-4.75	2.65e-06	0.000308	-0.22	-0.21	Inflammatory biomarkers;	chr2:32086215	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.924	rs7561519	ENSG00000276334.1	AL133243.1	-4.75	2.65e-06	0.000308	-0.22	-0.21	Inflammatory biomarkers;	chr2:32087631	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.962	rs6738349	ENSG00000276334.1	AL133243.1	-4.75	2.65e-06	0.000308	-0.22	-0.21	Inflammatory biomarkers;	chr2:32089062	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.85	rs11124276	ENSG00000276334.1	AL133243.1	-4.75	2.65e-06	0.000308	-0.22	-0.21	Inflammatory biomarkers;	chr2:32093359	chr2:32521927~32523547:+
THCA	cis	rs10514928	1	rs10514928	ENSG00000228782.6	CTD-2026D20.3	-4.75	2.65e-06	0.000308	-0.44	-0.21	Left atrial antero-posterior diameter;	chr17:47426173	chr17:47450568~47492492:-
THCA	cis	rs1003719	0.715	rs2835613	ENSG00000230366.8	DSCR9	4.75	2.65e-06	0.000308	0.22	0.21	Eye color traits;	chr21:37124583	chr21:37208503~37221736:+
THCA	cis	rs9634489	0.502	rs17189979	ENSG00000247400.3	DNAJC3-AS1	4.75	2.65e-06	0.000308	0.14	0.21	Body mass index;	chr13:96468833	chr13:95648733~95676925:-
THCA	cis	rs8028182	0.636	rs7163907	ENSG00000260274.1	RP11-817O13.8	4.75	2.65e-06	0.000308	0.16	0.21	Sudden cardiac arrest;	chr15:75552756	chr15:75368155~75369584:+
THCA	cis	rs2742234	0.554	rs1270015	ENSG00000273008.1	RP11-351D16.3	4.75	2.65e-06	0.000308	0.2	0.21	Hirschsprung disease;	chr10:43202792	chr10:43136824~43138334:-
THCA	cis	rs5742933	0.696	rs17271246	ENSG00000253559.1	OSGEPL1-AS1	-4.75	2.65e-06	0.000308	-0.31	-0.21	Ferritin levels;	chr2:189781481	chr2:189762704~189765556:+
THCA	cis	rs12755164	0.778	rs11210081	ENSG00000223479.3	RP4-788P17.1	4.75	2.66e-06	0.000309	0.24	0.21	Schizophrenia;	chr1:72875571	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.778	rs12143796	ENSG00000223479.3	RP4-788P17.1	4.75	2.66e-06	0.000309	0.24	0.21	Schizophrenia;	chr1:72877705	chr1:73635216~73715214:+
THCA	cis	rs79349575	0.783	rs4255820	ENSG00000270781.1	RP11-501C14.9	-4.75	2.66e-06	0.000309	-0.26	-0.21	Type 2 diabetes;	chr17:48919221	chr17:48899131~48899748:+
THCA	cis	rs987724	0.515	rs4315647	ENSG00000240875.4	LINC00886	-4.75	2.66e-06	0.000309	-0.2	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156941199	chr3:156747346~156817062:-
THCA	cis	rs2051773	0.567	rs58047221	ENSG00000184669.7	OR7E14P	-4.75	2.66e-06	0.000309	-0.31	-0.21	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17035087	chr11:17013998~17053024:+
THCA	cis	rs6545883	0.501	rs935860	ENSG00000270820.4	RP11-355B11.2	4.75	2.66e-06	0.000309	0.18	0.21	Tuberculosis;	chr2:61179426	chr2:61471188~61484130:+
THCA	cis	rs3796352	0.527	rs11714793	ENSG00000242142.1	SERBP1P3	-4.75	2.66e-06	0.000309	-0.38	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:52890914	chr3:53064283~53065091:-
THCA	cis	rs2562456	0.876	rs10424079	ENSG00000268117.1	VN1R84P	4.75	2.66e-06	0.000309	0.34	0.21	Pain;	chr19:21406377	chr19:21719801~21720035:-
THCA	cis	rs4927850	0.521	rs4927679	ENSG00000207650.1	MIR570	-4.75	2.66e-06	0.000309	-0.21	-0.21	Pancreatic cancer;	chr3:195931489	chr3:195699401~195699497:+
THCA	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	4.75	2.66e-06	0.000309	0.23	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
THCA	cis	rs9393777	0.844	rs72839477	ENSG00000220721.1	OR1F12	4.75	2.66e-06	0.000309	0.49	0.21	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28073316~28074233:+
THCA	cis	rs8002861	0.664	rs4941474	ENSG00000274001.1	RP11-5G9.5	4.75	2.66e-06	0.00031	0.25	0.21	Leprosy;	chr13:43876153	chr13:43877715~43878163:-
THCA	cis	rs1876905	0.68	rs9384787	ENSG00000272356.1	RP5-1112D6.8	4.75	2.67e-06	0.00031	0.21	0.21	Mean corpuscular hemoglobin;	chr6:111113707	chr6:111309203~111313517:+
THCA	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	4.75	2.67e-06	0.00031	0.25	0.21	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
THCA	cis	rs9637599	0.967	rs7661312	ENSG00000246375.2	RP11-10L7.1	4.75	2.67e-06	0.00031	0.3	0.21	Metabolite levels (small molecules and protein measures);	chr4:88279855	chr4:88284942~88331421:+
THCA	cis	rs1150668	0.799	rs1150705	ENSG00000273712.1	RP5-874C20.7	4.75	2.67e-06	0.00031	0.23	0.21	Pubertal anthropometrics;	chr6:28226008	chr6:28315613~28315883:-
THCA	cis	rs1979679	0.918	rs1586868	ENSG00000247934.4	RP11-967K21.1	-4.75	2.67e-06	0.00031	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368176	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.918	rs1586867	ENSG00000247934.4	RP11-967K21.1	-4.75	2.67e-06	0.00031	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368345	chr12:28163298~28190738:-
THCA	cis	rs7838490	0.504	rs821119	ENSG00000253553.4	RP11-586K2.1	4.75	2.67e-06	0.00031	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88467008	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs2656312	ENSG00000253553.4	RP11-586K2.1	4.75	2.67e-06	0.00031	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88468751	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.527	rs1700150	ENSG00000253553.4	RP11-586K2.1	4.75	2.67e-06	0.00031	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88469258	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.527	rs1386767	ENSG00000253553.4	RP11-586K2.1	4.75	2.67e-06	0.00031	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88469446	chr8:88326836~88737134:+
THCA	cis	rs8062405	0.755	rs56209193	ENSG00000261766.1	RP11-22P6.2	-4.75	2.67e-06	0.00031	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28862166~28863340:-
THCA	cis	rs7829975	0.509	rs7838674	ENSG00000254153.1	CTA-398F10.2	4.75	2.67e-06	0.00031	0.23	0.21	Mood instability;	chr8:8939563	chr8:8456909~8461337:-
THCA	cis	rs3734266	0.702	rs11963234	ENSG00000272288.4	RP11-140K17.3	-4.75	2.67e-06	0.00031	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34754646	chr6:34696317~34697470:+
THCA	cis	rs2067615	0.524	rs754184	ENSG00000260329.1	RP11-412D9.4	-4.75	2.67e-06	0.00031	-0.2	-0.21	Heart rate;	chr12:106723743	chr12:106954029~106955497:-
THCA	cis	rs4693089	0.522	rs562957	ENSG00000213608.5	SLC25A14P1	-4.75	2.67e-06	0.00031	-0.25	-0.21	Menopause (age at onset);	chr4:83521862	chr4:83477524~83478424:+
THCA	cis	rs7614311	0.954	rs6762506	ENSG00000271843.1	RP11-245J9.5	-4.75	2.67e-06	0.00031	-0.34	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63808872	chr3:64008082~64008692:-
THCA	cis	rs8103278	0.507	rs2041975	ENSG00000267395.4	AC074212.6	-4.75	2.67e-06	0.00031	-0.14	-0.21	Coronary artery disease;	chr19:45735297	chr19:45767796~45772504:+
THCA	cis	rs2742234	0.541	rs12416428	ENSG00000273008.1	RP11-351D16.3	4.75	2.67e-06	0.000311	0.2	0.21	Hirschsprung disease;	chr10:43213550	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs11238476	ENSG00000273008.1	RP11-351D16.3	4.75	2.67e-06	0.000311	0.2	0.21	Hirschsprung disease;	chr10:43215988	chr10:43136824~43138334:-
THCA	cis	rs13434995	0.513	rs58476959	ENSG00000273257.1	RP11-177J6.1	-4.75	2.67e-06	0.000311	-0.32	-0.21	Adiponectin levels;	chr4:55496234	chr4:55387949~55388271:+
THCA	cis	rs274567	0.501	rs272855	ENSG00000237714.1	P4HA2-AS1	4.75	2.67e-06	0.000311	0.29	0.21	Blood metabolite levels;	chr5:132351482	chr5:132184876~132192808:+
THCA	cis	rs12497850	0.543	rs6446218	ENSG00000228638.1	FCF1P2	-4.75	2.67e-06	0.000311	-0.23	-0.21	Parkinson's disease;	chr3:49038080	chr3:48290793~48291375:-
THCA	cis	rs2243480	1	rs313814	ENSG00000232559.3	GS1-124K5.12	4.75	2.67e-06	0.000311	0.32	0.21	Diabetic kidney disease;	chr7:66038306	chr7:66554588~66576923:-
THCA	cis	rs7614311	0.636	rs3821902	ENSG00000271843.1	RP11-245J9.5	-4.75	2.68e-06	0.000311	-0.38	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63956021	chr3:64008082~64008692:-
THCA	cis	rs72843506	0.722	rs9897161	ENSG00000231258.2	ZSWIM5P2	4.75	2.68e-06	0.000311	0.31	0.21	Schizophrenia;	chr17:20130957	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.722	rs9897168	ENSG00000231258.2	ZSWIM5P2	4.75	2.68e-06	0.000311	0.31	0.21	Schizophrenia;	chr17:20130961	chr17:20583758~20591180:-
THCA	cis	rs5758659	1	rs5758659	ENSG00000227370.1	RP4-669P10.19	-4.75	2.68e-06	0.000311	-0.2	-0.21	Cognitive function;	chr22:42225997	chr22:42132543~42132998:+
THCA	cis	rs7726839	0.54	rs72703079	ENSG00000225138.6	CTD-2228K2.7	4.75	2.68e-06	0.000311	0.27	0.21	Obesity-related traits;	chr5:595058	chr5:473236~480884:+
THCA	cis	rs941408	0.515	rs1736193	ENSG00000261342.1	AC006538.1	4.75	2.68e-06	0.000311	0.24	0.21	Total cholesterol levels;	chr19:2785275	chr19:2727743~2729327:-
THCA	cis	rs7688540	0.76	rs7687833	ENSG00000250892.1	RP11-1365D11.1	4.75	2.68e-06	0.000311	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:201409~205009:-
THCA	cis	rs4639966	0.579	rs2186780	ENSG00000255239.1	AP002954.6	-4.75	2.68e-06	0.000311	-0.33	-0.21	Systemic lupus erythematosus;	chr11:118734742	chr11:118688039~118690600:-
THCA	cis	rs4639966	0.512	rs7926282	ENSG00000255239.1	AP002954.6	-4.75	2.68e-06	0.000311	-0.33	-0.21	Systemic lupus erythematosus;	chr11:118735205	chr11:118688039~118690600:-
THCA	cis	rs2562456	0.526	rs950504	ENSG00000268555.1	RP11-678G14.3	4.75	2.68e-06	0.000311	0.27	0.21	Pain;	chr19:21601193	chr19:21570822~21587322:-
THCA	cis	rs6973609	0.626	rs34206766	ENSG00000271122.1	RP11-379H18.1	4.75	2.68e-06	0.000311	0.15	0.21	Obesity-related traits;	chr7:35569083	chr7:35695214~35699413:+
THCA	cis	rs7577696	0.889	rs212735	ENSG00000276334.1	AL133243.1	4.75	2.68e-06	0.000311	0.23	0.21	Inflammatory biomarkers;	chr2:32248019	chr2:32521927~32523547:+
THCA	cis	rs9863	0.896	rs12824567	ENSG00000269997.1	RP11-214K3.21	-4.75	2.68e-06	0.000311	-0.26	-0.21	White blood cell count;	chr12:124010656	chr12:123966077~123966629:-
THCA	cis	rs13434995	0.513	rs2171617	ENSG00000273257.1	RP11-177J6.1	4.75	2.68e-06	0.000311	0.34	0.21	Adiponectin levels;	chr4:55591023	chr4:55387949~55388271:+
THCA	cis	rs12036718	0.511	rs12126234	ENSG00000272491.1	RP5-1024N4.4	4.75	2.68e-06	0.000311	0.27	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr1:48109546	chr1:48227888~48229561:-
THCA	cis	rs786425	0.77	rs7313032	ENSG00000270095.1	RP11-214K3.18	-4.75	2.68e-06	0.000311	-0.25	-0.21	Pubertal anthropometrics;	chr12:123688184	chr12:123971457~123971714:-
THCA	cis	rs7045881	0.935	rs62542152	ENSG00000254396.1	RP11-56F10.3	4.75	2.68e-06	0.000311	0.32	0.21	Schizophrenia;	chr9:26774499	chr9:27102630~27104728:+
THCA	cis	rs72945132	0.882	rs6592522	ENSG00000254604.1	AP000487.6	-4.75	2.68e-06	0.000311	-0.4	-0.21	Coronary artery disease;	chr11:70282165	chr11:70282367~70363368:-
THCA	cis	rs786425	0.77	rs7958693	ENSG00000270095.1	RP11-214K3.18	-4.75	2.68e-06	0.000311	-0.26	-0.21	Pubertal anthropometrics;	chr12:123678203	chr12:123971457~123971714:-
THCA	cis	rs6792584	0.637	rs7645948	ENSG00000241316.5	SUCLG2-AS1	4.75	2.68e-06	0.000311	0.23	0.21	Corneal astigmatism;	chr3:67408595	chr3:67654697~67947713:+
THCA	cis	rs12188164	0.525	rs2561665	ENSG00000221990.4	EXOC3-AS1	-4.75	2.69e-06	0.000312	-0.17	-0.21	Cystic fibrosis severity;	chr5:460020	chr5:441498~443160:-
THCA	cis	rs1005277	0.579	rs1614236	ENSG00000275858.1	RP11-291L22.8	4.75	2.69e-06	0.000312	0.26	0.21	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs2749616	ENSG00000275858.1	RP11-291L22.8	4.75	2.69e-06	0.000312	0.26	0.21	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.579	rs1780146	ENSG00000275858.1	RP11-291L22.8	4.75	2.69e-06	0.000312	0.26	0.21	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38450738~38451069:-
THCA	cis	rs786425	0.677	rs10846537	ENSG00000270095.1	RP11-214K3.18	-4.75	2.69e-06	0.000312	-0.25	-0.21	Pubertal anthropometrics;	chr12:123653799	chr12:123971457~123971714:-
THCA	cis	rs734999	0.967	rs6671426	ENSG00000225931.3	RP3-395M20.7	4.75	2.69e-06	0.000312	0.26	0.21	Ulcerative colitis;	chr1:2572795	chr1:2566410~2569888:+
THCA	cis	rs8031584	0.958	rs61997079	ENSG00000178081.11	ULK4P3	4.75	2.69e-06	0.000312	0.28	0.21	Huntington's disease progression;	chr15:30946068	chr15:30103720~30131757:+
THCA	cis	rs853679	1	rs7740487	ENSG00000220721.1	OR1F12	4.75	2.69e-06	0.000312	0.35	0.21	Depression;	chr6:28248708	chr6:28073316~28074233:+
THCA	cis	rs853679	1	rs68141011	ENSG00000220721.1	OR1F12	4.75	2.69e-06	0.000312	0.35	0.21	Depression;	chr6:28250019	chr6:28073316~28074233:+
THCA	cis	rs853679	1	rs13200462	ENSG00000220721.1	OR1F12	4.75	2.69e-06	0.000312	0.35	0.21	Depression;	chr6:28250421	chr6:28073316~28074233:+
THCA	cis	rs3738443	0.868	rs61840048	ENSG00000259865.1	RP11-488L18.10	4.75	2.69e-06	0.000312	0.23	0.21	Alcohol dependence;	chr1:247199829	chr1:247187281~247188526:-
THCA	cis	rs3824435	0.783	rs10481591	ENSG00000272866.1	RP11-12D24.10	-4.75	2.69e-06	0.000312	-0.29	-0.21	Risky sexual behaviors in alcohol dependence;	chr9:5342152	chr9:5351796~5352410:-
THCA	cis	rs6860806	0.507	rs273917	ENSG00000224431.1	AC063976.7	4.75	2.69e-06	0.000312	0.19	0.21	Breast cancer;	chr5:132323925	chr5:132199456~132203487:+
THCA	cis	rs270601	0.955	rs273911	ENSG00000224431.1	AC063976.7	4.75	2.69e-06	0.000312	0.19	0.21	Acylcarnitine levels;	chr5:132325833	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.507	rs272891	ENSG00000224431.1	AC063976.7	4.75	2.69e-06	0.000312	0.19	0.21	Breast cancer;	chr5:132328701	chr5:132199456~132203487:+
THCA	cis	rs11846409	0.932	rs28378201	ENSG00000211974.3	IGHV2-70	-4.75	2.69e-06	0.000312	-0.2	-0.21	Rheumatic heart disease;	chr14:106637262	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.86	rs74091720	ENSG00000211974.3	IGHV2-70	-4.75	2.69e-06	0.000312	-0.2	-0.21	Rheumatic heart disease;	chr14:106638192	chr14:106723574~106724093:-
THCA	cis	rs10090774	0.965	rs1375062	ENSG00000279766.1	RP11-642A1.2	-4.75	2.69e-06	0.000312	-0.27	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955682	chr8:140572142~140572812:-
THCA	cis	rs1005277	0.522	rs289649	ENSG00000226578.1	RP11-258F22.1	-4.75	2.69e-06	0.000312	-0.25	-0.21	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:37775371~37784131:-
THCA	cis	rs62158800	0.925	rs62158831	ENSG00000237880.1	AC096669.2	4.75	2.69e-06	0.000312	0.33	0.21	Facial morphology (factor 22);	chr2:107634732	chr2:107385632~107542649:-
THCA	cis	rs9388451	0.874	rs1159974	ENSG00000226409.1	RP11-735G4.1	4.75	2.69e-06	0.000312	0.25	0.21	Brugada syndrome;	chr6:125769131	chr6:125370211~125374324:-
THCA	cis	rs1003719	0.788	rs9975168	ENSG00000230366.8	DSCR9	4.75	2.69e-06	0.000313	0.22	0.21	Eye color traits;	chr21:37078257	chr21:37208503~37221736:+
THCA	cis	rs4908760	0.827	rs7556169	ENSG00000232912.4	RP5-1115A15.1	-4.75	2.69e-06	0.000313	-0.21	-0.21	Vitiligo;	chr1:8681342	chr1:8424645~8434838:+
THCA	cis	rs78487399	0.908	rs6544675	ENSG00000234936.1	AC010883.5	4.75	2.69e-06	0.000313	0.27	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43608813	chr2:43229573~43233394:+
THCA	cis	rs4742903	0.967	rs10820610	ENSG00000270332.1	SMC2-AS1	4.75	2.69e-06	0.000313	0.2	0.21	Breast cancer;High-grade serous ovarian cancer;	chr9:104145538	chr9:104080024~104093073:-
THCA	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-4.75	2.7e-06	0.000313	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
THCA	cis	rs12760731	0.582	rs74967269	ENSG00000213057.5	C1orf220	4.75	2.7e-06	0.000313	0.25	0.21	Obesity-related traits;	chr1:178602568	chr1:178542752~178548889:+
THCA	cis	rs12760731	0.582	rs2147031	ENSG00000213057.5	C1orf220	4.75	2.7e-06	0.000313	0.25	0.21	Obesity-related traits;	chr1:178603339	chr1:178542752~178548889:+
THCA	cis	rs6012564	1	rs6063360	ENSG00000230758.1	SNAP23P	4.75	2.7e-06	0.000313	0.25	0.21	Anger;	chr20:49131838	chr20:49038357~49038602:-
THCA	cis	rs17507216	0.628	rs8028130	ENSG00000255769.6	GOLGA2P10	-4.75	2.7e-06	0.000313	-0.33	-0.21	Excessive daytime sleepiness;	chr15:82734974	chr15:82472993~82513950:-
THCA	cis	rs9467773	0.62	rs9461276	ENSG00000261353.1	CTA-14H9.5	-4.75	2.7e-06	0.000313	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26527063~26527404:+
THCA	cis	rs4415084	1	rs6871484	ENSG00000272335.1	RP11-53O19.3	-4.75	2.7e-06	0.000313	-0.18	-0.21	Breast cancer;	chr5:44676203	chr5:44826076~44828592:+
THCA	cis	rs4415084	1	rs4419600	ENSG00000272335.1	RP11-53O19.3	-4.75	2.7e-06	0.000313	-0.18	-0.21	Breast cancer;	chr5:44678432	chr5:44826076~44828592:+
THCA	cis	rs481331	0.689	rs644175	ENSG00000215146.4	RP11-313J2.1	-4.75	2.7e-06	0.000313	-0.34	-0.21	Systemic juvenile idiopathic arthritis;	chr10:42703860	chr10:42331866~42367974:-
THCA	cis	rs4987094	0.505	rs7928201	ENSG00000270179.1	RP11-159N11.4	4.75	2.7e-06	0.000313	0.26	0.21	Schizophrenia;	chr11:113342347	chr11:113368478~113369117:+
THCA	cis	rs5758659	0.904	rs134877	ENSG00000281538.1	RP4-669P10.20	4.75	2.7e-06	0.000313	0.19	0.21	Cognitive function;	chr22:42266365	chr22:42138060~42139726:+
THCA	cis	rs3020736	0.5	rs6002601	ENSG00000273366.1	CTA-989H11.1	4.75	2.7e-06	0.000313	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42278188~42278846:+
THCA	cis	rs7429990	0.932	rs6803741	ENSG00000228638.1	FCF1P2	4.75	2.7e-06	0.000313	0.21	0.21	Educational attainment (years of education);	chr3:48082050	chr3:48290793~48291375:-
THCA	cis	rs13113518	1	rs4864994	ENSG00000273257.1	RP11-177J6.1	4.75	2.7e-06	0.000313	0.28	0.21	Height;	chr4:55451955	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs4864995	ENSG00000273257.1	RP11-177J6.1	4.75	2.7e-06	0.000313	0.28	0.21	Height;	chr4:55452853	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs12651640	ENSG00000273257.1	RP11-177J6.1	4.75	2.7e-06	0.000313	0.28	0.21	Height;	chr4:55454154	chr4:55387949~55388271:+
THCA	cis	rs911555	0.723	rs6575986	ENSG00000244691.1	RPL10AP1	-4.75	2.7e-06	0.000313	-0.29	-0.21	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103412119~103412761:-
THCA	cis	rs6832769	0.885	rs6815516	ENSG00000272969.1	RP11-528I4.2	-4.75	2.7e-06	0.000313	-0.25	-0.21	Personality dimensions;	chr4:55533017	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs17085889	ENSG00000272969.1	RP11-528I4.2	-4.75	2.7e-06	0.000313	-0.25	-0.21	Personality dimensions;	chr4:55535948	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs10005989	ENSG00000272969.1	RP11-528I4.2	-4.75	2.7e-06	0.000313	-0.25	-0.21	Personality dimensions;	chr4:55539039	chr4:55547112~55547889:+
THCA	cis	rs2361701	0.929	rs1467979	ENSG00000275479.1	RP11-334C17.6	-4.75	2.7e-06	0.000314	-0.23	-0.21	IgG glycosylation;	chr17:80086944	chr17:80149627~80149798:+
THCA	cis	rs79349575	0.783	rs1994970	ENSG00000270781.1	RP11-501C14.9	4.75	2.7e-06	0.000314	0.26	0.21	Type 2 diabetes;	chr17:48936765	chr17:48899131~48899748:+
THCA	cis	rs9840812	0.598	rs33999043	ENSG00000239213.4	NCK1-AS1	4.75	2.7e-06	0.000314	0.24	0.21	Fibrinogen levels;	chr3:136381198	chr3:136841726~136862054:-
THCA	cis	rs4925386	1	rs4925386	ENSG00000275437.1	RP5-908M14.10	4.75	2.7e-06	0.000314	0.2	0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62402236~62405935:-
THCA	cis	rs13256369	0.826	rs7846050	ENSG00000254153.1	CTA-398F10.2	-4.75	2.71e-06	0.000314	-0.24	-0.21	Obesity-related traits;	chr8:8718159	chr8:8456909~8461337:-
THCA	cis	rs3750082	0.889	rs13244998	ENSG00000231952.3	DPY19L1P2	4.75	2.71e-06	0.000314	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32873298	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs13230763	ENSG00000231952.3	DPY19L1P2	4.75	2.71e-06	0.000314	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32873353	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs9639669	ENSG00000231952.3	DPY19L1P2	4.75	2.71e-06	0.000314	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32873783	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.78	rs9638884	ENSG00000231952.3	DPY19L1P2	4.75	2.71e-06	0.000314	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32874000	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs4437549	ENSG00000231952.3	DPY19L1P2	4.75	2.71e-06	0.000314	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32875353	chr7:32812757~32838570:+
THCA	cis	rs7833787	0.759	rs4921964	ENSG00000278886.1	RP11-108A14.1	4.75	2.71e-06	0.000314	0.27	0.21	Obesity-related traits;	chr8:18822285	chr8:18864681~18865247:-
THCA	cis	rs17301013	0.932	rs3737651	ENSG00000227373.4	RP11-160H22.5	-4.75	2.71e-06	0.000314	-0.3	-0.21	Systemic lupus erythematosus;	chr1:174475414	chr1:174115300~174160004:-
THCA	cis	rs8031584	0.872	rs11634761	ENSG00000178081.11	ULK4P3	4.75	2.71e-06	0.000314	0.28	0.21	Huntington's disease progression;	chr15:30950970	chr15:30103720~30131757:+
THCA	cis	rs793571	0.628	rs12595057	ENSG00000259250.1	RP11-50C13.1	-4.75	2.71e-06	0.000314	-0.23	-0.21	Schizophrenia;	chr15:58830627	chr15:58587507~58591676:+
THCA	cis	rs2236521	0.659	rs73144993	ENSG00000273619.1	RP5-908M14.9	-4.75	2.71e-06	0.000314	-0.17	-0.21	Pelvic organ prolapse;	chr20:62318402	chr20:62386303~62386970:-
THCA	cis	rs412658	0.668	rs7253490	ENSG00000269345.1	VN1R85P	-4.75	2.71e-06	0.000314	-0.23	-0.21	Telomere length;	chr19:22110904	chr19:22174766~22175191:-
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000232559.3	GS1-124K5.12	4.75	2.71e-06	0.000314	0.31	0.21	Diabetic kidney disease;	chr7:65951319	chr7:66554588~66576923:-
THCA	cis	rs2742234	0.554	rs1254963	ENSG00000273008.1	RP11-351D16.3	4.75	2.71e-06	0.000314	0.2	0.21	Hirschsprung disease;	chr10:43200638	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.59	rs1254962	ENSG00000273008.1	RP11-351D16.3	4.75	2.71e-06	0.000314	0.2	0.21	Hirschsprung disease;	chr10:43201544	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.59	rs1254960	ENSG00000273008.1	RP11-351D16.3	4.75	2.71e-06	0.000314	0.2	0.21	Hirschsprung disease;	chr10:43204209	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs1254959	ENSG00000273008.1	RP11-351D16.3	4.75	2.71e-06	0.000314	0.2	0.21	Hirschsprung disease;	chr10:43205531	chr10:43136824~43138334:-
THCA	cis	rs7512898	0.522	rs7534184	ENSG00000260088.1	RP11-92G12.3	-4.75	2.71e-06	0.000314	-0.29	-0.21	Electrocardiographic conduction measures;	chr1:200708502	chr1:200669507~200694250:+
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000229886.1	RP5-1132H15.3	4.75	2.71e-06	0.000314	0.25	0.21	Corneal structure;	chr7:66902145	chr7:66025126~66031544:-
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000229886.1	RP5-1132H15.3	4.75	2.71e-06	0.000314	0.25	0.21	Corneal structure;	chr7:66904222	chr7:66025126~66031544:-
THCA	cis	rs453301	0.682	rs2929308	ENSG00000253981.4	ALG1L13P	-4.75	2.71e-06	0.000314	-0.2	-0.21	Joint mobility (Beighton score);	chr8:9226611	chr8:8236003~8244667:-
THCA	cis	rs1707322	0.964	rs1768802	ENSG00000281133.1	AL355480.3	4.75	2.71e-06	0.000314	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs1588663	ENSG00000281133.1	AL355480.3	4.75	2.71e-06	0.000314	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs1768801	ENSG00000281133.1	AL355480.3	4.75	2.71e-06	0.000314	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs1768800	ENSG00000281133.1	AL355480.3	4.75	2.71e-06	0.000314	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45580892~45580996:-
THCA	cis	rs427394	1	rs182135	ENSG00000248677.1	CTD-2044J15.1	4.75	2.71e-06	0.000314	0.2	0.21	Menopause (age at onset);	chr5:6747340	chr5:6686325~6707711:-
THCA	cis	rs58235267	0.591	rs4671457	ENSG00000242412.1	DBIL5P2	-4.75	2.71e-06	0.000314	-0.24	-0.21	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:63119221	chr2:63117851~63119542:-
THCA	cis	rs4578769	0.569	rs1379805	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22914589	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs1031652	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22916035	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs9967326	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22916787	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs9946660	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22917007	chr18:22900486~22900995:-
THCA	cis	rs12962334	0.568	rs2034932	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Breast cancer;	chr18:22918727	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs4800438	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22920482	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.55	rs721578	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22922719	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs7229422	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22923157	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs12960915	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22924013	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.589	rs9964726	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22925516	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs9958831	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22926050	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs11659166	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22926143	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs12957183	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000314	0.24	0.21	Eosinophil percentage of white cells;	chr18:22927124	chr18:22900486~22900995:-
THCA	cis	rs12612619	0.732	rs4665366	ENSG00000229122.1	AGBL5-IT1	-4.75	2.71e-06	0.000315	-0.15	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989728	chr2:27061038~27061815:+
THCA	cis	rs875971	0.522	rs1617484	ENSG00000229886.1	RP5-1132H15.3	4.75	2.71e-06	0.000315	0.22	0.21	Aortic root size;	chr7:65998108	chr7:66025126~66031544:-
THCA	cis	rs4578769	0.55	rs12958492	ENSG00000265939.1	UBE2CP2	4.75	2.71e-06	0.000315	0.24	0.21	Eosinophil percentage of white cells;	chr18:22988974	chr18:22900486~22900995:-
THCA	cis	rs2645424	0.602	rs3779663	ENSG00000255046.1	RP11-297N6.4	-4.75	2.72e-06	0.000315	-0.21	-0.21	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11813853	chr8:11797928~11802568:-
THCA	cis	rs5015933	0.815	rs937482	ENSG00000232630.1	PRPS1P2	-4.75	2.72e-06	0.000315	-0.15	-0.21	Body mass index;	chr9:125354538	chr9:125150653~125151589:+
THCA	cis	rs9990343	0.715	rs11922338	ENSG00000223552.1	RP11-24F11.2	-4.75	2.72e-06	0.000315	-0.19	-0.21	Brain structure;	chr3:46292869	chr3:46364955~46407059:-
THCA	cis	rs7665090	0.806	rs434644	ENSG00000251288.2	RP11-10L12.2	4.75	2.72e-06	0.000315	0.28	0.21	Primary biliary cholangitis;	chr4:102662032	chr4:102751401~102752641:+
THCA	cis	rs7577696	0.924	rs7601267	ENSG00000276334.1	AL133243.1	-4.75	2.72e-06	0.000315	-0.22	-0.21	Inflammatory biomarkers;	chr2:32047330	chr2:32521927~32523547:+
THCA	cis	rs3750965	1	rs7950657	ENSG00000260895.1	RP11-554A11.7	4.75	2.72e-06	0.000315	0.29	0.21	Hair color;	chr11:69067363	chr11:69103493~69109094:+
THCA	cis	rs3750965	1	rs61881024	ENSG00000260895.1	RP11-554A11.7	4.75	2.72e-06	0.000315	0.29	0.21	Hair color;	chr11:69070326	chr11:69103493~69109094:+
THCA	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-4.75	2.72e-06	0.000315	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
THCA	cis	rs7614311	0.639	rs73119035	ENSG00000271843.1	RP11-245J9.5	-4.75	2.72e-06	0.000315	-0.38	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:64008290	chr3:64008082~64008692:-
THCA	cis	rs10510102	0.566	rs885543	ENSG00000226864.1	ATE1-AS1	4.75	2.72e-06	0.000315	0.37	0.21	Breast cancer;	chr10:121973536	chr10:121928312~121951965:+
THCA	cis	rs4785204	0.558	rs6500280	ENSG00000279356.1	RP11-429P3.8	-4.75	2.72e-06	0.000315	-0.28	-0.21	Esophageal cancer (squamous cell);	chr16:50066363	chr16:50072862~50074986:+
THCA	cis	rs919433	0.963	rs12693815	ENSG00000231621.1	AC013264.2	4.75	2.72e-06	0.000315	0.22	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197303679	chr2:197197991~197199273:+
THCA	cis	rs9283706	0.607	rs13180020	ENSG00000229666.1	MAST4-AS1	-4.75	2.72e-06	0.000315	-0.3	-0.21	Coronary artery disease;	chr5:66998266	chr5:67001383~67003953:-
THCA	cis	rs3820928	0.967	rs2396435	ENSG00000212391.1	SNORA48	-4.75	2.72e-06	0.000315	-0.24	-0.21	Pulmonary function;	chr2:226913681	chr2:226968989~226969122:-
THCA	cis	rs11148252	0.574	rs3742297	ENSG00000273784.3	RP11-78J21.7	-4.75	2.72e-06	0.000315	-0.23	-0.21	Lewy body disease;	chr13:52703932	chr13:52600042~52642542:+
THCA	cis	rs11148252	0.574	rs9536247	ENSG00000273784.3	RP11-78J21.7	-4.75	2.72e-06	0.000315	-0.23	-0.21	Lewy body disease;	chr13:52705407	chr13:52600042~52642542:+
THCA	cis	rs481331	0.736	rs73253954	ENSG00000215146.4	RP11-313J2.1	4.75	2.72e-06	0.000315	0.35	0.21	Systemic juvenile idiopathic arthritis;	chr10:42472273	chr10:42331866~42367974:-
THCA	cis	rs9494145	0.526	rs55654242	ENSG00000232876.1	CTA-212D2.2	-4.75	2.72e-06	0.000315	-0.32	-0.21	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135156849	chr6:135055033~135060550:+
THCA	cis	rs12446956	0.527	rs8056162	ENSG00000280092.1	AC002044.3	4.75	2.72e-06	0.000315	0.32	0.21	Major depressive disorder;	chr16:73457670	chr16:73005601~73006141:-
THCA	cis	rs71636778	0.722	rs17162315	ENSG00000260063.1	RP5-968P14.2	-4.75	2.72e-06	0.000315	-0.29	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26849940	chr1:26692132~26694131:-
THCA	cis	rs9990343	0.783	rs4267678	ENSG00000223552.1	RP11-24F11.2	-4.75	2.72e-06	0.000315	-0.19	-0.21	Brain structure;	chr3:46294694	chr3:46364955~46407059:-
THCA	cis	rs7726839	0.574	rs12522955	ENSG00000225138.6	CTD-2228K2.7	4.75	2.72e-06	0.000315	0.26	0.21	Obesity-related traits;	chr5:639116	chr5:473236~480884:+
THCA	cis	rs728616	0.614	rs17678737	ENSG00000242600.5	MBL1P	4.75	2.72e-06	0.000315	0.28	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80374229	chr10:79904898~79950336:+
THCA	cis	rs728616	0.558	rs17616958	ENSG00000242600.5	MBL1P	4.75	2.72e-06	0.000315	0.28	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377705	chr10:79904898~79950336:+
THCA	cis	rs728616	0.558	rs17616964	ENSG00000242600.5	MBL1P	4.75	2.72e-06	0.000315	0.28	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377785	chr10:79904898~79950336:+
THCA	cis	rs27434	0.66	rs27043	ENSG00000272109.1	CTD-2260A17.3	4.75	2.72e-06	0.000315	0.34	0.21	Ankylosing spondylitis;	chr5:96781596	chr5:96804353~96806105:+
THCA	cis	rs9467773	0.62	rs1490488	ENSG00000124549.13	BTN2A3P	4.75	2.72e-06	0.000315	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs2494692	ENSG00000124549.13	BTN2A3P	4.75	2.72e-06	0.000315	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26421391~26432383:+
THCA	cis	rs8177876	0.749	rs804895	ENSG00000261838.4	RP11-303E16.6	-4.75	2.72e-06	0.000315	-0.37	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81066108	chr16:81069854~81076598:+
THCA	cis	rs13126694	0.778	rs7692254	ENSG00000248429.4	RP11-597D13.9	4.75	2.72e-06	0.000316	0.23	0.21	Blood osmolality (transformed sodium);	chr4:158134140	chr4:158170752~158202877:+
THCA	cis	rs9990343	0.748	rs11130087	ENSG00000223552.1	RP11-24F11.2	-4.75	2.72e-06	0.000316	-0.19	-0.21	Brain structure;	chr3:46293138	chr3:46364955~46407059:-
THCA	cis	rs4415084	1	rs10462079	ENSG00000272335.1	RP11-53O19.3	-4.75	2.72e-06	0.000316	-0.18	-0.21	Breast cancer;	chr5:44700008	chr5:44826076~44828592:+
THCA	cis	rs4415084	1	rs13179137	ENSG00000272335.1	RP11-53O19.3	-4.75	2.72e-06	0.000316	-0.18	-0.21	Breast cancer;	chr5:44702590	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.966	rs34762678	ENSG00000272335.1	RP11-53O19.3	-4.75	2.72e-06	0.000316	-0.18	-0.21	Breast cancer;	chr5:44705412	chr5:44826076~44828592:+
THCA	cis	rs13034020	0.522	rs72809436	ENSG00000271889.1	RP11-493E12.1	-4.75	2.72e-06	0.000316	-0.28	-0.21	Hodgkin's lymphoma;	chr2:61024010	chr2:61151433~61162105:-
THCA	cis	rs4448343	0.963	rs28457763	ENSG00000271155.1	RP11-435O5.5	-4.75	2.72e-06	0.000316	-0.22	-0.21	Height;	chr9:95498232	chr9:95506235~95507636:+
THCA	cis	rs4650994	0.593	rs2761459	ENSG00000273384.1	RP5-1098D14.1	-4.75	2.72e-06	0.000316	-0.28	-0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178582441	chr1:178651706~178652282:+
THCA	cis	rs7621331	0.926	rs1403766	ENSG00000273486.1	RP11-731C17.2	4.75	2.72e-06	0.000316	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:135949994	chr3:136837338~136839021:-
THCA	cis	rs10761482	0.601	rs7074460	ENSG00000254271.1	RP11-131N11.4	4.75	2.73e-06	0.000316	0.29	0.21	Schizophrenia;	chr10:60425085	chr10:60734342~60741828:+
THCA	cis	rs4713118	0.505	rs156740	ENSG00000280107.1	AL022393.9	-4.75	2.73e-06	0.000316	-0.21	-0.21	Parkinson's disease;	chr6:27992657	chr6:28170845~28172521:+
THCA	cis	rs3750965	1	rs1466222	ENSG00000260895.1	RP11-554A11.7	4.75	2.73e-06	0.000316	0.29	0.21	Hair color;	chr11:69065380	chr11:69103493~69109094:+
THCA	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	4.75	2.73e-06	0.000316	0.12	0.21	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
THCA	cis	rs7394190	0.748	rs4746151	ENSG00000271816.1	BMS1P4	-4.75	2.73e-06	0.000316	-0.27	-0.21	Incident atrial fibrillation;	chr10:73818962	chr10:73699151~73730487:-
THCA	cis	rs7394190	0.748	rs3843939	ENSG00000271816.1	BMS1P4	-4.75	2.73e-06	0.000316	-0.27	-0.21	Incident atrial fibrillation;	chr10:73819190	chr10:73699151~73730487:-
THCA	cis	rs7010876	0.561	rs4548227	ENSG00000253553.4	RP11-586K2.1	-4.75	2.73e-06	0.000316	-0.22	-0.21	Schizophrenia;	chr8:88340085	chr8:88326836~88737134:+
THCA	cis	rs7617773	0.817	rs9847953	ENSG00000199476.1	Y_RNA	-4.75	2.73e-06	0.000316	-0.27	-0.21	Coronary artery disease;	chr3:48241205	chr3:48288587~48288694:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000273712.1	RP5-874C20.7	4.75	2.73e-06	0.000316	0.23	0.21	Cardiac Troponin-T levels;	chr6:28164978	chr6:28315613~28315883:-
THCA	cis	rs7760535	0.656	rs7766190	ENSG00000255389.1	C6orf3	-4.75	2.73e-06	0.000316	-0.19	-0.21	Metabolic traits;	chr6:111583863	chr6:111599875~111602295:+
THCA	cis	rs12935418	0.616	rs62054238	ENSG00000278985.1	RP11-303E16.9	4.75	2.73e-06	0.000316	0.27	0.21	Mean corpuscular volume;	chr16:80965753	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.616	rs62054239	ENSG00000278985.1	RP11-303E16.9	4.75	2.73e-06	0.000316	0.27	0.21	Mean corpuscular volume;	chr16:80966287	chr16:80982319~80984094:-
THCA	cis	rs600231	0.508	rs17146964	ENSG00000245532.5	NEAT1	-4.75	2.73e-06	0.000316	-0.18	-0.21	Bone mineral density;	chr11:65481674	chr11:65422774~65445540:+
THCA	cis	rs2985684	1	rs2224949	ENSG00000278009.1	RP11-649E7.8	-4.75	2.73e-06	0.000316	-0.3	-0.21	Carotid intima media thickness;	chr14:49629842	chr14:49601011~49601124:-
THCA	cis	rs28735056	0.563	rs55642704	ENSG00000261126.6	RP11-795F19.1	-4.75	2.73e-06	0.000316	-0.18	-0.21	Schizophrenia;	chr18:79928124	chr18:80046900~80095482:+
THCA	cis	rs10090774	0.965	rs4440675	ENSG00000279766.1	RP11-642A1.2	-4.75	2.73e-06	0.000317	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140965358	chr8:140572142~140572812:-
THCA	cis	rs11633886	0.622	rs4774814	ENSG00000273972.1	CTD-2306A12.1	-4.75	2.73e-06	0.000317	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45837944	chr15:45702640~45703183:+
THCA	cis	rs2742234	0.541	rs7096500	ENSG00000273008.1	RP11-351D16.3	4.75	2.73e-06	0.000317	0.2	0.21	Hirschsprung disease;	chr10:43216647	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs4648313	ENSG00000273008.1	RP11-351D16.3	4.75	2.73e-06	0.000317	0.2	0.21	Hirschsprung disease;	chr10:43221291	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs10793424	ENSG00000273008.1	RP11-351D16.3	4.75	2.73e-06	0.000317	0.2	0.21	Hirschsprung disease;	chr10:43221668	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	4.75	2.73e-06	0.000317	0.2	0.21	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs61268333	ENSG00000273008.1	RP11-351D16.3	4.75	2.73e-06	0.000317	0.2	0.21	Hirschsprung disease;	chr10:43225922	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs60845448	ENSG00000273008.1	RP11-351D16.3	4.75	2.73e-06	0.000317	0.2	0.21	Hirschsprung disease;	chr10:43226014	chr10:43136824~43138334:-
THCA	cis	rs752010	0.967	rs10890151	ENSG00000230638.4	RP11-486B10.4	-4.75	2.73e-06	0.000317	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41636172	chr1:41542069~41544310:+
THCA	cis	rs62158800	0.778	rs62158794	ENSG00000237880.1	AC096669.2	4.75	2.73e-06	0.000317	0.33	0.21	Facial morphology (factor 22);	chr2:107575221	chr2:107385632~107542649:-
THCA	cis	rs2348418	0.67	rs10843098	ENSG00000247934.4	RP11-967K21.1	-4.75	2.73e-06	0.000317	-0.19	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28116709	chr12:28163298~28190738:-
THCA	cis	rs10090774	0.965	rs11780104	ENSG00000279766.1	RP11-642A1.2	-4.75	2.73e-06	0.000317	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992008	chr8:140572142~140572812:-
THCA	cis	rs72799341	1	rs72799341	ENSG00000279196.1	RP11-1072A3.3	4.75	2.73e-06	0.000317	0.24	0.21	Diastolic blood pressure;	chr16:30925422	chr16:30984630~30988270:-
THCA	cis	rs4722166	0.695	rs7793125	ENSG00000225541.1	AC002480.5	-4.75	2.73e-06	0.000317	-0.27	-0.21	Lung cancer;	chr7:22769541	chr7:22571607~22661792:-
THCA	cis	rs4722166	0.695	rs6946509	ENSG00000225541.1	AC002480.5	-4.75	2.73e-06	0.000317	-0.27	-0.21	Lung cancer;	chr7:22769871	chr7:22571607~22661792:-
THCA	cis	rs3750082	0.852	rs10260000	ENSG00000231952.3	DPY19L1P2	4.75	2.74e-06	0.000317	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32858622	chr7:32812757~32838570:+
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000259295.5	CSPG4P12	-4.75	2.74e-06	0.000317	-0.29	-0.21	P wave terminal force;	chr15:84654022	chr15:85191438~85213905:+
THCA	cis	rs4415084	0.688	rs67274820	ENSG00000272335.1	RP11-53O19.3	-4.75	2.74e-06	0.000317	-0.18	-0.21	Breast cancer;	chr5:44782193	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs16901963	ENSG00000272335.1	RP11-53O19.3	-4.75	2.74e-06	0.000317	-0.18	-0.21	Breast cancer;	chr5:44783000	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs16901965	ENSG00000272335.1	RP11-53O19.3	-4.75	2.74e-06	0.000317	-0.18	-0.21	Breast cancer;	chr5:44783256	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs6875933	ENSG00000272335.1	RP11-53O19.3	-4.75	2.74e-06	0.000317	-0.18	-0.21	Breast cancer;	chr5:44786594	chr5:44826076~44828592:+
THCA	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-4.75	2.74e-06	0.000317	-0.25	-0.21	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
THCA	cis	rs1048886	0.938	rs9455132	ENSG00000271967.1	RP11-134K13.4	-4.75	2.74e-06	0.000317	-0.22	-0.21	Type 2 diabetes;	chr6:70495768	chr6:70596438~70596980:+
THCA	cis	rs752010	0.749	rs12141084	ENSG00000230638.4	RP11-486B10.4	-4.75	2.74e-06	0.000317	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41652066	chr1:41542069~41544310:+
THCA	cis	rs453301	0.658	rs6983877	ENSG00000254153.1	CTA-398F10.2	4.75	2.74e-06	0.000317	0.23	0.21	Joint mobility (Beighton score);	chr8:9047129	chr8:8456909~8461337:-
THCA	cis	rs6142102	0.651	rs6059692	ENSG00000275784.1	RP5-1125A11.6	4.75	2.74e-06	0.000317	0.23	0.21	Skin pigmentation;	chr20:34158397	chr20:33989480~33991818:-
THCA	cis	rs3845817	0.868	rs702942	ENSG00000237979.1	AC007389.1	4.75	2.74e-06	0.000318	0.24	0.21	Bipolar disorder;	chr2:65529831	chr2:65500993~65502138:-
THCA	cis	rs756699	1	rs756699	ENSG00000279469.1	RP11-215P8.2	4.75	2.74e-06	0.000318	0.34	0.21	Multiple sclerosis;	chr5:134110884	chr5:134394360~134395008:-
THCA	cis	rs7010876	0.561	rs9656892	ENSG00000253553.4	RP11-586K2.1	-4.75	2.74e-06	0.000318	-0.22	-0.21	Schizophrenia;	chr8:88344351	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs7009149	ENSG00000253553.4	RP11-586K2.1	-4.75	2.74e-06	0.000318	-0.22	-0.21	Schizophrenia;	chr8:88344602	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.561	rs10955586	ENSG00000253553.4	RP11-586K2.1	-4.75	2.74e-06	0.000318	-0.22	-0.21	Schizophrenia;	chr8:88347369	chr8:88326836~88737134:+
THCA	cis	rs17711722	1	rs17711722	ENSG00000229886.1	RP5-1132H15.3	-4.75	2.74e-06	0.000318	-0.22	-0.21	Calcium levels;	chr7:65806210	chr7:66025126~66031544:-
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000229886.1	RP5-1132H15.3	-4.75	2.74e-06	0.000318	-0.22	-0.21	Calcium levels;	chr7:65808508	chr7:66025126~66031544:-
THCA	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	4.75	2.74e-06	0.000318	0.24	0.21	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
THCA	cis	rs7617773	0.78	rs6442111	ENSG00000199476.1	Y_RNA	-4.75	2.74e-06	0.000318	-0.27	-0.21	Coronary artery disease;	chr3:48270570	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs3937	ENSG00000199476.1	Y_RNA	-4.75	2.74e-06	0.000318	-0.27	-0.21	Coronary artery disease;	chr3:48270912	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.851	rs6775179	ENSG00000199476.1	Y_RNA	-4.75	2.74e-06	0.000318	-0.27	-0.21	Coronary artery disease;	chr3:48271928	chr3:48288587~48288694:+
THCA	cis	rs7829975	0.511	rs2980426	ENSG00000253981.4	ALG1L13P	4.75	2.74e-06	0.000318	0.21	0.21	Mood instability;	chr8:8288087	chr8:8236003~8244667:-
THCA	cis	rs12760731	0.582	rs4607830	ENSG00000213057.5	C1orf220	4.75	2.74e-06	0.000318	0.24	0.21	Obesity-related traits;	chr1:178566017	chr1:178542752~178548889:+
THCA	cis	rs11089937	0.616	rs12484482	ENSG00000211639.2	IGLV4-60	4.75	2.74e-06	0.000318	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22180158	chr22:22162199~22162681:+
THCA	cis	rs3820928	1	rs4675116	ENSG00000212391.1	SNORA48	-4.75	2.74e-06	0.000318	-0.24	-0.21	Pulmonary function;	chr2:226904891	chr2:226968989~226969122:-
THCA	cis	rs7474896	1	rs2738191	ENSG00000263064.2	RP11-291L22.7	4.75	2.74e-06	0.000318	0.35	0.21	Obesity (extreme);	chr10:37976858	chr10:38448689~38448949:+
THCA	cis	rs7731783	1	rs7731783	ENSG00000272459.1	RP11-1277A3.3	-4.75	2.74e-06	0.000318	-0.26	-0.21	Methadone dose in opioid dependence;	chr5:177633311	chr5:177554824~177555364:+
THCA	cis	rs73108077	0.92	rs10084487	ENSG00000277112.2	RP11-755J8.1	-4.75	2.75e-06	0.000318	-0.39	-0.21	Red blood cell density in sickle cell anemia;	chr20:31425330	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs10084488	ENSG00000277112.2	RP11-755J8.1	-4.75	2.75e-06	0.000318	-0.39	-0.21	Red blood cell density in sickle cell anemia;	chr20:31425366	chr20:30681825~30723932:-
THCA	cis	rs9634489	0.588	rs7986153	ENSG00000247400.3	DNAJC3-AS1	-4.75	2.75e-06	0.000318	-0.14	-0.21	Body mass index;	chr13:96273299	chr13:95648733~95676925:-
THCA	cis	rs1577917	0.883	rs1337854	ENSG00000220563.1	PKMP3	4.75	2.75e-06	0.000318	0.15	0.21	Response to antipsychotic treatment;	chr6:86014297	chr6:85659892~85660606:-
THCA	cis	rs2836950	0.501	rs35994303	ENSG00000238141.2	BRWD1-AS1	-4.75	2.75e-06	0.000318	-0.24	-0.21	Menarche (age at onset);	chr21:39314094	chr21:39315707~39323218:+
THCA	cis	rs7403037	0.848	rs28411795	ENSG00000260760.1	PWRN3	4.75	2.75e-06	0.000318	0.24	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24586810	chr15:24441127~24447967:+
THCA	cis	rs6088590	1	rs6119516	ENSG00000269202.1	RP4-614O4.12	-4.75	2.75e-06	0.000318	-0.19	-0.21	Coronary artery disease;	chr20:34740220	chr20:35201747~35203288:-
THCA	cis	rs11157436	0.871	rs8003190	ENSG00000211812.1	TRAV26-2	-4.75	2.75e-06	0.000318	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22202583~22203368:+
THCA	cis	rs7772486	0.719	rs702307	ENSG00000270638.1	RP3-466P17.1	-4.75	2.75e-06	0.000318	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145735570~145737218:+
THCA	cis	rs30380	1	rs27710	ENSG00000272109.1	CTD-2260A17.3	4.75	2.75e-06	0.000318	0.27	0.21	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96804353~96806105:+
THCA	cis	rs1048886	0.872	rs61223738	ENSG00000271967.1	RP11-134K13.4	-4.75	2.75e-06	0.000318	-0.21	-0.21	Type 2 diabetes;	chr6:70493385	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs7753355	ENSG00000271967.1	RP11-134K13.4	-4.75	2.75e-06	0.000318	-0.21	-0.21	Type 2 diabetes;	chr6:70507467	chr6:70596438~70596980:+
THCA	cis	rs11992162	0.597	rs6996342	ENSG00000206014.6	OR7E161P	4.75	2.75e-06	0.000318	0.25	0.21	Monocyte count;	chr8:11927032	chr8:11928597~11929563:-
THCA	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	4.75	2.75e-06	0.000318	0.15	0.21	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
THCA	cis	rs1371614	0.588	rs13017554	ENSG00000229122.1	AGBL5-IT1	4.75	2.75e-06	0.000318	0.15	0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26948114	chr2:27061038~27061815:+
THCA	cis	rs5742933	1	rs5743052	ENSG00000253559.1	OSGEPL1-AS1	-4.75	2.75e-06	0.000319	-0.26	-0.21	Ferritin levels;	chr2:189824558	chr2:189762704~189765556:+
THCA	cis	rs4950322	0.542	rs3766519	ENSG00000226015.2	CCT8P1	4.75	2.75e-06	0.000319	0.25	0.21	Protein quantitative trait loci;	chr1:147214802	chr1:147203276~147204932:-
THCA	cis	rs34845616	0.581	rs167915	ENSG00000280237.1	MIR4697HG	4.75	2.75e-06	0.000319	0.19	0.21	Hand grip strength;	chr11:133927686	chr11:133896438~133901601:-
THCA	cis	rs829883	0.659	rs11109528	ENSG00000227825.4	SLC9A7P1	-4.75	2.75e-06	0.000319	-0.21	-0.21	Colorectal adenoma (advanced);	chr12:98557584	chr12:98453835~98457145:-
THCA	cis	rs783540	0.5	rs7163840	ENSG00000278603.1	RP13-608F4.5	-4.75	2.76e-06	0.000319	-0.31	-0.21	Schizophrenia;	chr15:82729551	chr15:82472203~82472426:+
THCA	cis	rs12935418	0.672	rs12446810	ENSG00000278985.1	RP11-303E16.9	4.75	2.76e-06	0.000319	0.24	0.21	Mean corpuscular volume;	chr16:81009369	chr16:80982319~80984094:-
THCA	cis	rs7260598	0.539	rs11670271	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23883921	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs11670335	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23884108	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs11670289	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23884154	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs11672509	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23885967	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs13345286	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23886611	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs73525884	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23886899	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs73525888	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23887039	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs73525890	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23887109	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs73525891	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23887131	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs76305873	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23887151	chr19:24162370~24163425:-
THCA	cis	rs11668609	0.515	rs73525894	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (docetaxel);	chr19:23887976	chr19:24162370~24163425:-
THCA	cis	rs11668609	0.515	rs13346480	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (docetaxel);	chr19:23889271	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs1347177	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23896658	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs10412189	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23897536	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs7254143	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23897735	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs10418417	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23898005	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs10425498	ENSG00000268442.1	CTD-2027I19.2	4.75	2.76e-06	0.000319	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23898869	chr19:24162370~24163425:-
THCA	cis	rs10971721	0.822	rs12377078	ENSG00000281128.1	PTENP1-AS	-4.75	2.76e-06	0.000319	-0.5	-0.21	Body mass index;	chr9:33934823	chr9:33677268~33688011:+
THCA	cis	rs7131987	0.903	rs11050152	ENSG00000275476.1	RP11-996F15.4	-4.75	2.76e-06	0.000319	-0.21	-0.21	QT interval;	chr12:29251491	chr12:29277397~29277882:-
THCA	cis	rs989128	0.6	rs9913677	ENSG00000250286.1	RP11-94C24.8	-4.75	2.76e-06	0.000319	-0.21	-0.21	Type 2 diabetes;	chr17:50551220	chr17:50537294~50538754:-
THCA	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-4.75	2.76e-06	0.000319	-0.25	-0.21	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
THCA	cis	rs1334894	0.901	rs12526404	ENSG00000228559.1	RP3-340B19.3	-4.75	2.76e-06	0.000319	-0.43	-0.21	Coronary artery disease;	chr6:35533171	chr6:35544632~35545669:+
THCA	cis	rs786425	0.77	rs7308862	ENSG00000270095.1	RP11-214K3.18	-4.75	2.76e-06	0.00032	-0.25	-0.21	Pubertal anthropometrics;	chr12:123686604	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs7297576	ENSG00000270095.1	RP11-214K3.18	-4.75	2.76e-06	0.00032	-0.25	-0.21	Pubertal anthropometrics;	chr12:123686776	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs11609591	ENSG00000270095.1	RP11-214K3.18	-4.75	2.76e-06	0.00032	-0.25	-0.21	Pubertal anthropometrics;	chr12:123689518	chr12:123971457~123971714:-
THCA	cis	rs1023500	0.573	rs6002592	ENSG00000273366.1	CTA-989H11.1	4.75	2.76e-06	0.00032	0.27	0.21	Schizophrenia;	chr22:42080750	chr22:42278188~42278846:+
THCA	cis	rs10218795	1	rs10218795	ENSG00000233396.6	RP11-458D21.1	-4.75	2.76e-06	0.00032	-0.45	-0.21	Coronary heart disease (SNP X SNP interaction);	chr1:146018957	chr1:146052566~146061948:+
THCA	cis	rs7851660	0.772	rs6478471	ENSG00000214417.4	KRT18P13	-4.75	2.76e-06	0.00032	-0.19	-0.21	Strep throat;	chr9:97902100	chr9:97698922~97700734:+
THCA	cis	rs1836229	0.571	rs1972798	ENSG00000225706.1	PTPRD-AS1	-4.75	2.76e-06	0.00032	-0.25	-0.21	Restless legs syndrome;	chr9:8835579	chr9:8858130~8862255:+
THCA	cis	rs11992162	0.636	rs4841642	ENSG00000254948.1	OR7E158P	-4.75	2.76e-06	0.00032	-0.27	-0.21	Monocyte count;	chr8:11940825	chr8:11919900~11920809:-
THCA	cis	rs11992162	0.636	rs4841646	ENSG00000254948.1	OR7E158P	-4.75	2.76e-06	0.00032	-0.27	-0.21	Monocyte count;	chr8:11941198	chr8:11919900~11920809:-
THCA	cis	rs11671005	0.611	rs56026876	ENSG00000269473.1	CTD-2619J13.19	4.75	2.76e-06	0.00032	0.24	0.21	Mean platelet volume;	chr19:58494790	chr19:58440448~58445849:+
THCA	cis	rs6088580	0.634	rs4911420	ENSG00000276073.1	RP5-1125A11.7	4.75	2.76e-06	0.00032	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34410848	chr20:33985617~33988989:-
THCA	cis	rs453301	0.686	rs11787026	ENSG00000254153.1	CTA-398F10.2	-4.75	2.76e-06	0.00032	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9044861	chr8:8456909~8461337:-
THCA	cis	rs9595908	0.581	rs2032507	ENSG00000212293.1	SNORA16	4.75	2.76e-06	0.00032	0.24	0.21	Body mass index;	chr13:32779298	chr13:32420390~32420516:-
THCA	cis	rs10090774	0.965	rs10111363	ENSG00000279766.1	RP11-642A1.2	-4.75	2.76e-06	0.00032	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140918251	chr8:140572142~140572812:-
THCA	cis	rs2439831	0.681	rs956391	ENSG00000205771.5	CATSPER2P1	4.75	2.76e-06	0.00032	0.28	0.21	Lung cancer in ever smokers;	chr15:43325295	chr15:43726918~43747094:-
THCA	cis	rs6860806	0.507	rs272878	ENSG00000224431.1	AC063976.7	-4.75	2.77e-06	0.00032	-0.19	-0.21	Breast cancer;	chr5:132336076	chr5:132199456~132203487:+
THCA	cis	rs9863	0.896	rs7307053	ENSG00000269997.1	RP11-214K3.21	4.75	2.77e-06	0.00032	0.26	0.21	White blood cell count;	chr12:124009993	chr12:123966077~123966629:-
THCA	cis	rs7560272	0.588	rs4852965	ENSG00000163016.8	ALMS1P	-4.75	2.77e-06	0.00032	-0.26	-0.21	Schizophrenia;	chr2:73684042	chr2:73644919~73685576:+
THCA	cis	rs3892630	0.5	rs35170371	ENSG00000267567.1	CTD-2538C1.3	4.75	2.77e-06	0.00032	0.33	0.21	Red blood cell traits;	chr19:32864175	chr19:32718298~32719595:-
THCA	cis	rs7192208	0.541	rs3743749	ENSG00000260922.1	RP11-538I12.3	4.75	2.77e-06	0.00032	0.33	0.21	White matter integrity;	chr16:77289338	chr16:77234877~77290934:+
THCA	cis	rs250518	0.926	rs3846644	ENSG00000272081.1	CTD-2376I4.2	4.75	2.77e-06	0.00032	0.28	0.21	Mean corpuscular hemoglobin concentration;	chr5:72727276	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs4267846	ENSG00000272081.1	CTD-2376I4.2	4.75	2.77e-06	0.00032	0.28	0.21	Mean corpuscular hemoglobin concentration;	chr5:72735617	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs2338788	ENSG00000272081.1	CTD-2376I4.2	4.75	2.77e-06	0.00032	0.28	0.21	Mean corpuscular hemoglobin concentration;	chr5:72737690	chr5:72955206~72955699:-
THCA	cis	rs7577696	0.962	rs36014814	ENSG00000276334.1	AL133243.1	-4.75	2.77e-06	0.000321	-0.22	-0.21	Inflammatory biomarkers;	chr2:32079890	chr2:32521927~32523547:+
THCA	cis	rs7537765	1	rs17037429	ENSG00000242349.4	NPPA-AS1	4.75	2.77e-06	0.000321	0.28	0.21	QRS complex (12-leadsum);	chr1:11813730	chr1:11841017~11848079:+
THCA	cis	rs7537765	0.895	rs2236796	ENSG00000242349.4	NPPA-AS1	-4.75	2.77e-06	0.000321	-0.28	-0.21	QRS complex (12-leadsum);	chr1:11832558	chr1:11841017~11848079:+
THCA	cis	rs7537765	1	rs17037452	ENSG00000242349.4	NPPA-AS1	-4.75	2.77e-06	0.000321	-0.28	-0.21	QRS complex (12-leadsum);	chr1:11835618	chr1:11841017~11848079:+
THCA	cis	rs2239547	0.657	rs4687554	ENSG00000242142.1	SERBP1P3	4.75	2.77e-06	0.000321	0.27	0.21	Schizophrenia;	chr3:52830119	chr3:53064283~53065091:-
THCA	cis	rs7824557	0.606	rs1435277	ENSG00000154316.13	TDH	-4.75	2.77e-06	0.000321	-0.16	-0.21	Retinal vascular caliber;	chr8:11339461	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.606	rs2736273	ENSG00000154316.13	TDH	-4.75	2.77e-06	0.000321	-0.16	-0.21	Retinal vascular caliber;	chr8:11342429	chr8:11339637~11368452:+
THCA	cis	rs7312933	0.558	rs11181403	ENSG00000257225.1	RP11-328C8.4	-4.75	2.77e-06	0.000321	-0.22	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42289100	chr12:42459366~42466128:+
THCA	cis	rs4578769	0.569	rs12605806	ENSG00000265939.1	UBE2CP2	4.75	2.77e-06	0.000321	0.24	0.21	Eosinophil percentage of white cells;	chr18:22882093	chr18:22900486~22900995:-
THCA	cis	rs7403037	1	rs9788767	ENSG00000260760.1	PWRN3	4.74	2.77e-06	0.000321	0.25	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24516306	chr15:24441127~24447967:+
THCA	cis	rs10090774	0.965	rs10106750	ENSG00000279766.1	RP11-642A1.2	-4.74	2.77e-06	0.000321	-0.27	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994810	chr8:140572142~140572812:-
THCA	cis	rs1005277	0.54	rs4934907	ENSG00000226578.1	RP11-258F22.1	-4.74	2.77e-06	0.000321	-0.25	-0.21	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:37775371~37784131:-
THCA	cis	rs1005277	0.54	rs11011351	ENSG00000226578.1	RP11-258F22.1	-4.74	2.77e-06	0.000321	-0.25	-0.21	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:37775371~37784131:-
THCA	cis	rs73108077	1	rs73105971	ENSG00000277112.2	RP11-755J8.1	-4.74	2.77e-06	0.000321	-0.36	-0.21	Red blood cell density in sickle cell anemia;	chr20:31369934	chr20:30681825~30723932:-
THCA	cis	rs4578769	0.569	rs8094359	ENSG00000265939.1	UBE2CP2	4.74	2.77e-06	0.000321	0.24	0.21	Eosinophil percentage of white cells;	chr18:22907743	chr18:22900486~22900995:-
THCA	cis	rs9595908	0.785	rs4942804	ENSG00000212293.1	SNORA16	4.74	2.77e-06	0.000321	0.24	0.21	Body mass index;	chr13:32684365	chr13:32420390~32420516:-
THCA	cis	rs12472274	0.941	rs2880131	ENSG00000279484.1	KLHL30-AS1	4.74	2.77e-06	0.000321	0.24	0.21	Phospholipid levels (plasma);	chr2:238180510	chr2:238152889~238155994:-
THCA	cis	rs2787702	1	rs2787702	ENSG00000237233.2	TMEM26-AS1	-4.74	2.77e-06	0.000321	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61547717	chr10:61452639~61481956:+
THCA	cis	rs3750965	0.839	rs921670	ENSG00000260895.1	RP11-554A11.7	4.74	2.77e-06	0.000321	0.29	0.21	Hair color;	chr11:69104171	chr11:69103493~69109094:+
THCA	cis	rs12823128	0.766	rs35531611	ENSG00000256185.1	RP11-612B6.2	4.74	2.77e-06	0.000321	0.2	0.21	Birth weight;	chr12:26733501	chr12:26335864~26336950:-
THCA	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	4.74	2.77e-06	0.000321	0.28	0.21	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
THCA	cis	rs7111546	0.654	rs75397799	ENSG00000246225.5	RP11-17A1.3	4.74	2.78e-06	0.000321	0.38	0.21	Dialysis-related mortality;	chr11:22836864	chr11:22829380~22945393:+
THCA	cis	rs288326	0.561	rs78528869	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:182950774	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs17265866	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:182957646	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs41270217	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:182986149	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs17265894	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:182993440	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs74869113	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:182993578	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs77535302	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:183005317	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs74953433	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:183007937	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs75848966	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:183013365	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs77541378	ENSG00000272800.1	RP11-438L19.1	4.74	2.78e-06	0.000321	0.39	0.21	Blood protein levels;	chr2:183021543	chr2:183214319~183215400:+
THCA	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	4.74	2.78e-06	0.000321	0.3	0.21	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
THCA	cis	rs6973609	0.524	rs343709	ENSG00000271122.1	RP11-379H18.1	4.74	2.78e-06	0.000321	0.14	0.21	Obesity-related traits;	chr7:35595704	chr7:35695214~35699413:+
THCA	cis	rs4886920	0.638	rs4886919	ENSG00000260776.4	RP11-114H24.2	-4.74	2.78e-06	0.000322	-0.26	-0.21	Neuroticism;	chr15:77814822	chr15:77914217~77926846:-
THCA	cis	rs2797160	0.651	rs1268067	ENSG00000226409.1	RP11-735G4.1	4.74	2.78e-06	0.000322	0.27	0.21	Endometrial cancer;	chr6:125715475	chr6:125370211~125374324:-
THCA	cis	rs6500602	0.653	rs4786488	ENSG00000280063.1	RP11-295D4.3	4.74	2.78e-06	0.000322	0.13	0.21	Schizophrenia;	chr16:4392526	chr16:4346694~4348648:-
THCA	cis	rs30380	1	rs151964	ENSG00000272109.1	CTD-2260A17.3	-4.74	2.78e-06	0.000322	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96804353~96806105:+
THCA	cis	rs17331151	0.831	rs2240921	ENSG00000242142.1	SERBP1P3	-4.74	2.78e-06	0.000322	-0.38	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:52796748	chr3:53064283~53065091:-
THCA	cis	rs7727544	0.684	rs272869	ENSG00000263597.1	MIR3936	4.74	2.78e-06	0.000322	0.2	0.21	Blood metabolite levels;	chr5:132342304	chr5:132365490~132365599:-
THCA	cis	rs13118159	0.527	rs1250119	ENSG00000254094.1	AC078852.1	4.74	2.78e-06	0.000322	0.27	0.21	Longevity;	chr4:1267548	chr4:1356581~1358075:+
THCA	cis	rs6586163	0.527	rs3740286	ENSG00000261438.1	RP11-399O19.9	-4.74	2.78e-06	0.000322	-0.19	-0.21	Chronic lymphocytic leukemia;	chr10:88991583	chr10:89015836~89017059:+
THCA	cis	rs7429990	0.965	rs34750113	ENSG00000228638.1	FCF1P2	-4.74	2.78e-06	0.000322	-0.21	-0.21	Educational attainment (years of education);	chr3:47944902	chr3:48290793~48291375:-
THCA	cis	rs2439831	0.867	rs2245715	ENSG00000205771.5	CATSPER2P1	-4.74	2.78e-06	0.000322	-0.29	-0.21	Lung cancer in ever smokers;	chr15:43525854	chr15:43726918~43747094:-
THCA	cis	rs10510102	0.872	rs56108883	ENSG00000226864.1	ATE1-AS1	4.74	2.78e-06	0.000322	0.35	0.21	Breast cancer;	chr10:121825567	chr10:121928312~121951965:+
THCA	cis	rs763121	0.889	rs2267390	ENSG00000235209.1	CTA-150C2.13	4.74	2.78e-06	0.000322	0.28	0.21	Menopause (age at onset);	chr22:38493652	chr22:38921227~38924708:+
THCA	cis	rs9990333	0.87	rs58758084	ENSG00000231464.1	AC024937.4	-4.74	2.79e-06	0.000322	-0.25	-0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196086110	chr3:195996738~195998233:+
THCA	cis	rs3820928	0.934	rs1366756	ENSG00000212391.1	SNORA48	-4.74	2.79e-06	0.000322	-0.24	-0.21	Pulmonary function;	chr2:226907322	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs7561378	ENSG00000212391.1	SNORA48	-4.74	2.79e-06	0.000322	-0.24	-0.21	Pulmonary function;	chr2:226907532	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs2163041	ENSG00000212391.1	SNORA48	-4.74	2.79e-06	0.000322	-0.24	-0.21	Pulmonary function;	chr2:226907764	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs2396433	ENSG00000212391.1	SNORA48	-4.74	2.79e-06	0.000322	-0.24	-0.21	Pulmonary function;	chr2:226907786	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs3820928	ENSG00000212391.1	SNORA48	-4.74	2.79e-06	0.000322	-0.24	-0.21	Pulmonary function;	chr2:226908750	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs10204368	ENSG00000212391.1	SNORA48	-4.74	2.79e-06	0.000322	-0.24	-0.21	Pulmonary function;	chr2:226909528	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs10210763	ENSG00000212391.1	SNORA48	-4.74	2.79e-06	0.000322	-0.24	-0.21	Pulmonary function;	chr2:226911313	chr2:226968989~226969122:-
THCA	cis	rs1046896	0.538	rs3803771	ENSG00000263063.1	RP11-388C12.1	4.74	2.79e-06	0.000323	0.25	0.21	Glycated hemoglobin levels;	chr17:82729882	chr17:82713908~82716255:-
THCA	cis	rs7394190	0.748	rs2306327	ENSG00000271816.1	BMS1P4	-4.74	2.79e-06	0.000323	-0.27	-0.21	Incident atrial fibrillation;	chr10:73814020	chr10:73699151~73730487:-
THCA	cis	rs7618915	0.501	rs3733045	ENSG00000243224.1	RP5-1157M23.2	-4.74	2.79e-06	0.000323	-0.23	-0.21	Bipolar disorder;	chr3:52609291	chr3:52239258~52241097:+
THCA	cis	rs7746199	0.736	rs58616630	ENSG00000220721.1	OR1F12	4.74	2.79e-06	0.000323	0.47	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs34573979	ENSG00000220721.1	OR1F12	4.74	2.79e-06	0.000323	0.47	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28073316~28074233:+
THCA	cis	rs2439831	0.867	rs2412780	ENSG00000166763.7	STRCP1	4.74	2.79e-06	0.000323	0.29	0.21	Lung cancer in ever smokers;	chr15:43363596	chr15:43699488~43718184:-
THCA	cis	rs9875589	0.509	rs28865280	ENSG00000228242.5	AC093495.4	4.74	2.79e-06	0.000323	0.12	0.21	Ovarian reserve;	chr3:14023458	chr3:14144637~14165978:+
THCA	cis	rs3020736	0.519	rs5996116	ENSG00000273366.1	CTA-989H11.1	4.74	2.79e-06	0.000323	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42278188~42278846:+
THCA	cis	rs7403037	0.617	rs35149769	ENSG00000259905.4	PWRN1	4.74	2.79e-06	0.000323	0.28	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24591731	chr15:24493137~24652130:+
THCA	cis	rs8067545	0.611	rs2107565	ENSG00000270091.1	RP11-78O7.2	4.74	2.79e-06	0.000323	0.16	0.21	Schizophrenia;	chr17:20185179	chr17:19896590~19897287:-
THCA	cis	rs6012564	1	rs6125576	ENSG00000227431.4	CSE1L-AS1	4.74	2.79e-06	0.000323	0.27	0.21	Anger;	chr20:49160382	chr20:49040463~49046044:-
THCA	cis	rs6878727	0.526	rs2619951	ENSG00000253807.4	LINC01170	4.74	2.79e-06	0.000323	0.21	0.21	Breast cancer;	chr5:124309471	chr5:124059794~124405079:-
THCA	cis	rs62292953	0.79	rs2369801	ENSG00000248724.5	NPHP3-AS1	-4.74	2.79e-06	0.000323	-0.39	-0.21	Red cell distribution width;	chr3:132508836	chr3:132721750~132874223:+
THCA	cis	rs4578769	0.55	rs9945620	ENSG00000265939.1	UBE2CP2	4.74	2.79e-06	0.000323	0.24	0.21	Eosinophil percentage of white cells;	chr18:22997367	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.55	rs2305886	ENSG00000265939.1	UBE2CP2	4.74	2.79e-06	0.000323	0.24	0.21	Eosinophil percentage of white cells;	chr18:22997493	chr18:22900486~22900995:-
THCA	cis	rs2976388	0.556	rs4736323	ENSG00000253741.1	CTD-2292P10.4	4.74	2.79e-06	0.000323	0.29	0.21	Urinary tract infection frequency;	chr8:142748941	chr8:142702252~142726973:-
THCA	cis	rs7560272	0.538	rs4852976	ENSG00000163016.8	ALMS1P	-4.74	2.79e-06	0.000323	-0.27	-0.21	Schizophrenia;	chr2:73709195	chr2:73644919~73685576:+
THCA	cis	rs6988985	0.589	rs6471580	ENSG00000247317.3	RP11-273G15.2	-4.74	2.79e-06	0.000323	-0.23	-0.21	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905285	chr8:142981738~143018437:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000164669.11	INTS4P1	-4.74	2.8e-06	0.000323	-0.27	-0.21	Calcium levels;	chr7:65941231	chr7:65141225~65234216:+
THCA	cis	rs4578769	0.531	rs12969559	ENSG00000265939.1	UBE2CP2	4.74	2.8e-06	0.000323	0.24	0.21	Eosinophil percentage of white cells;	chr18:22913702	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs12326874	ENSG00000265939.1	UBE2CP2	4.74	2.8e-06	0.000323	0.24	0.21	Eosinophil percentage of white cells;	chr18:22926670	chr18:22900486~22900995:-
THCA	cis	rs9283706	0.562	rs6881240	ENSG00000229666.1	MAST4-AS1	-4.74	2.8e-06	0.000323	-0.32	-0.21	Coronary artery disease;	chr5:67035643	chr5:67001383~67003953:-
THCA	cis	rs2439831	0.85	rs3097773	ENSG00000166763.7	STRCP1	-4.74	2.8e-06	0.000323	-0.29	-0.21	Lung cancer in ever smokers;	chr15:43600874	chr15:43699488~43718184:-
THCA	cis	rs874628	0.659	rs2384987	ENSG00000268650.3	AC068499.10	4.74	2.8e-06	0.000324	0.24	0.21	Multiple sclerosis;	chr19:18246588	chr19:18204730~18220480:+
THCA	cis	rs7267979	0.966	rs6037097	ENSG00000274973.1	RP13-401N8.7	-4.74	2.8e-06	0.000324	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25845497~25845862:+
THCA	cis	rs1005277	0.505	rs7917943	ENSG00000226578.1	RP11-258F22.1	4.74	2.8e-06	0.000324	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:37775371~37784131:-
THCA	cis	rs9868809	0.772	rs12107418	ENSG00000270441.1	RP11-694I15.7	4.74	2.8e-06	0.000324	0.26	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48652354	chr3:49140086~49160851:-
THCA	cis	rs1577917	0.883	rs9450348	ENSG00000220563.1	PKMP3	-4.74	2.8e-06	0.000324	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85888318	chr6:85659892~85660606:-
THCA	cis	rs7474896	0.583	rs10827817	ENSG00000263064.2	RP11-291L22.7	4.74	2.8e-06	0.000324	0.28	0.21	Obesity (extreme);	chr10:37709046	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.54	rs2145487	ENSG00000226578.1	RP11-258F22.1	-4.74	2.8e-06	0.000324	-0.25	-0.21	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:37775371~37784131:-
THCA	cis	rs1023500	0.596	rs133350	ENSG00000237037.8	NDUFA6-AS1	-4.74	2.8e-06	0.000324	-0.18	-0.21	Schizophrenia;	chr22:42033045	chr22:42090931~42137742:+
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000229180.5	GS1-124K5.11	4.74	2.8e-06	0.000324	0.17	0.21	Corneal structure;	chr7:66902145	chr7:66526088~66542624:-
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000229180.5	GS1-124K5.11	4.74	2.8e-06	0.000324	0.17	0.21	Corneal structure;	chr7:66904222	chr7:66526088~66542624:-
THCA	cis	rs7119	0.717	rs12898656	ENSG00000259362.2	RP11-307C19.1	4.74	2.8e-06	0.000324	0.31	0.21	Type 2 diabetes;	chr15:77515653	chr15:77525540~77534110:+
THCA	cis	rs12478296	1	rs55742408	ENSG00000220804.7	AC093642.5	4.74	2.8e-06	0.000324	0.23	0.21	Obesity-related traits;	chr2:242098926	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs12469535	ENSG00000220804.7	AC093642.5	4.74	2.8e-06	0.000324	0.23	0.21	Obesity-related traits;	chr2:242101996	chr2:242088633~242160153:+
THCA	cis	rs9467773	0.595	rs7767847	ENSG00000261353.1	CTA-14H9.5	-4.74	2.8e-06	0.000324	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs3800303	ENSG00000261353.1	CTA-14H9.5	-4.74	2.8e-06	0.000324	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26527063~26527404:+
THCA	cis	rs16975963	0.644	rs2290999	ENSG00000226686.6	LINC01535	-4.74	2.8e-06	0.000324	-0.28	-0.21	Longevity;	chr19:37647986	chr19:37251912~37265535:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	4.74	2.8e-06	0.000324	0.24	0.21	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
THCA	cis	rs7924176	0.502	rs12784355	ENSG00000213731.2	RAB5CP1	-4.74	2.8e-06	0.000324	-0.25	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74423435~74424014:-
THCA	cis	rs7739264	0.583	rs6456264	ENSG00000237404.1	RP3-471C18.2	4.74	2.81e-06	0.000324	0.23	0.21	Endometriosis;	chr6:19786451	chr6:19689825~19753113:-
THCA	cis	rs1552244	1	rs17032295	ENSG00000180385.7	EMC3-AS1	4.74	2.81e-06	0.000324	0.24	0.21	Alzheimer's disease;	chr3:10044996	chr3:9986893~10006990:+
THCA	cis	rs9307551	0.619	rs13118924	ENSG00000250334.4	LINC00989	-4.74	2.81e-06	0.000325	-0.26	-0.21	Refractive error;	chr4:79502369	chr4:79492416~79576460:+
THCA	cis	rs6441961	0.628	rs6783993	ENSG00000223552.1	RP11-24F11.2	-4.74	2.81e-06	0.000325	-0.21	-0.21	Celiac disease;	chr3:46302202	chr3:46364955~46407059:-
THCA	cis	rs2549003	0.811	rs10072700	ENSG00000237714.1	P4HA2-AS1	-4.74	2.81e-06	0.000325	-0.32	-0.21	Asthma (sex interaction);	chr5:132481211	chr5:132184876~132192808:+
THCA	cis	rs4415084	1	rs10941677	ENSG00000272335.1	RP11-53O19.3	-4.74	2.81e-06	0.000325	-0.18	-0.21	Breast cancer;	chr5:44662297	chr5:44826076~44828592:+
THCA	cis	rs1979679	0.842	rs7138497	ENSG00000247934.4	RP11-967K21.1	-4.74	2.81e-06	0.000325	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28242918	chr12:28163298~28190738:-
THCA	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	4.74	2.81e-06	0.000325	0.23	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
THCA	cis	rs911555	0.723	rs56227024	ENSG00000244691.1	RPL10AP1	4.74	2.81e-06	0.000325	0.29	0.21	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103412119~103412761:-
THCA	cis	rs4906332	0.754	rs34235720	ENSG00000269910.1	RP11-73M18.10	4.74	2.81e-06	0.000325	0.21	0.21	Coronary artery disease;	chr14:103538631	chr14:103694516~103695050:-
THCA	cis	rs12755164	0.778	rs12735281	ENSG00000223479.3	RP4-788P17.1	4.74	2.81e-06	0.000325	0.24	0.21	Schizophrenia;	chr1:72852425	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.778	rs4649968	ENSG00000223479.3	RP4-788P17.1	4.74	2.81e-06	0.000325	0.24	0.21	Schizophrenia;	chr1:72853227	chr1:73635216~73715214:+
THCA	cis	rs12908161	1	rs4643294	ENSG00000188388.10	GOLGA6L3	4.74	2.81e-06	0.000325	0.29	0.21	Schizophrenia;	chr15:84707022	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs62021219	ENSG00000188388.10	GOLGA6L3	4.74	2.81e-06	0.000325	0.29	0.21	Schizophrenia;	chr15:84712928	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs34900908	ENSG00000188388.10	GOLGA6L3	4.74	2.81e-06	0.000325	0.29	0.21	Schizophrenia;	chr15:84714368	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs35524990	ENSG00000188388.10	GOLGA6L3	4.74	2.81e-06	0.000325	0.29	0.21	Schizophrenia;	chr15:84714972	chr15:85240472~85247170:+
THCA	cis	rs964611	0.882	rs4775749	ENSG00000259488.2	RP11-154J22.1	4.74	2.81e-06	0.000325	0.2	0.21	Metabolite levels (Pyroglutamine);	chr15:48350064	chr15:48312353~48331856:-
THCA	cis	rs3738443	1	rs74152976	ENSG00000259865.1	RP11-488L18.10	4.74	2.81e-06	0.000325	0.23	0.21	Alcohol dependence;	chr1:247183504	chr1:247187281~247188526:-
THCA	cis	rs62025270	0.593	rs7166540	ENSG00000259295.5	CSPG4P12	-4.74	2.81e-06	0.000325	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85191438~85213905:+
THCA	cis	rs7942368	0.941	rs11236936	ENSG00000261578.1	RP11-21L23.2	4.74	2.81e-06	0.000325	0.31	0.21	Endometriosis;	chr11:76789786	chr11:76800364~76804555:+
THCA	cis	rs1009077	0.561	rs13107334	ENSG00000245958.5	RP11-33B1.1	4.74	2.81e-06	0.000325	0.28	0.21	Endometriosis;	chr4:119503425	chr4:119454791~119552025:+
THCA	cis	rs3820928	0.874	rs13403281	ENSG00000212391.1	SNORA48	-4.74	2.81e-06	0.000325	-0.23	-0.21	Pulmonary function;	chr2:227016053	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.904	rs4439949	ENSG00000212391.1	SNORA48	-4.74	2.81e-06	0.000325	-0.24	-0.21	Pulmonary function;	chr2:226900238	chr2:226968989~226969122:-
THCA	cis	rs654950	0.841	rs676383	ENSG00000230638.4	RP11-486B10.4	4.74	2.81e-06	0.000325	0.24	0.21	Airway imaging phenotypes;	chr1:41528082	chr1:41542069~41544310:+
THCA	cis	rs7182948	0.874	rs3210227	ENSG00000259531.2	RP11-295H24.3	4.74	2.81e-06	0.000325	0.28	0.21	Lung adenocarcinoma;	chr15:49625144	chr15:49365124~49366685:-
THCA	cis	rs78487399	0.908	rs72868636	ENSG00000234936.1	AC010883.5	4.74	2.81e-06	0.000325	0.27	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43611377	chr2:43229573~43233394:+
THCA	cis	rs3820928	0.904	rs4129884	ENSG00000212391.1	SNORA48	-4.74	2.81e-06	0.000325	-0.23	-0.21	Pulmonary function;	chr2:226956227	chr2:226968989~226969122:-
THCA	cis	rs10923574	0.597	rs1951938	ENSG00000231365.4	RP11-418J17.1	-4.74	2.81e-06	0.000325	-0.21	-0.21	Breast cancer;Folding of antihelix;	chr1:118507115	chr1:119140396~119275973:+
THCA	cis	rs17801127	0.688	rs962097	ENSG00000231969.1	AC144449.1	-4.74	2.81e-06	0.000325	-0.33	-0.21	Liver enzyme levels (alanine transaminase);	chr2:149677380	chr2:149587196~149848233:+
THCA	cis	rs10761482	0.639	rs2067612	ENSG00000254271.1	RP11-131N11.4	4.74	2.81e-06	0.000325	0.29	0.21	Schizophrenia;	chr10:60452576	chr10:60734342~60741828:+
THCA	cis	rs7580717	0.785	rs62197352	ENSG00000224376.1	AC017104.6	4.74	2.82e-06	0.000326	0.24	0.21	Multiple myeloma;	chr2:231300520	chr2:231388976~231394991:+
THCA	cis	rs3820928	0.874	rs10167086	ENSG00000212391.1	SNORA48	4.74	2.82e-06	0.000326	0.23	0.21	Pulmonary function;	chr2:226928013	chr2:226968989~226969122:-
THCA	cis	rs62158800	0.85	rs62158798	ENSG00000237880.1	AC096669.2	4.74	2.82e-06	0.000326	0.33	0.21	Facial morphology (factor 22);	chr2:107584161	chr2:107385632~107542649:-
THCA	cis	rs12887734	0.524	rs4900599	ENSG00000269910.1	RP11-73M18.10	4.74	2.82e-06	0.000326	0.2	0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103694516~103695050:-
THCA	cis	rs858239	0.571	rs2390755	ENSG00000226816.2	AC005082.12	4.74	2.82e-06	0.000326	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23206013~23208045:+
THCA	cis	rs7726839	0.54	rs61580655	ENSG00000225138.6	CTD-2228K2.7	4.74	2.82e-06	0.000326	0.27	0.21	Obesity-related traits;	chr5:597449	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs57306627	ENSG00000225138.6	CTD-2228K2.7	4.74	2.82e-06	0.000326	0.27	0.21	Obesity-related traits;	chr5:597528	chr5:473236~480884:+
THCA	cis	rs8028182	0.636	rs4462560	ENSG00000260274.1	RP11-817O13.8	-4.74	2.82e-06	0.000326	-0.15	-0.21	Sudden cardiac arrest;	chr15:75355623	chr15:75368155~75369584:+
THCA	cis	rs1538970	0.781	rs11211139	ENSG00000234329.1	RP11-767N6.2	4.74	2.82e-06	0.000326	0.22	0.21	Platelet count;	chr1:45550079	chr1:45651039~45651826:-
THCA	cis	rs3820928	0.874	rs56324594	ENSG00000212391.1	SNORA48	-4.74	2.82e-06	0.000326	-0.23	-0.21	Pulmonary function;	chr2:227004138	chr2:226968989~226969122:-
THCA	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-4.74	2.82e-06	0.000326	-0.13	-0.21	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
THCA	cis	rs7493	0.901	rs17883318	ENSG00000233942.1	AC004012.1	4.74	2.82e-06	0.000326	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95329000	chr7:95471835~95473998:+
THCA	cis	rs28735056	0.572	rs4799100	ENSG00000261126.6	RP11-795F19.1	-4.74	2.82e-06	0.000326	-0.18	-0.21	Schizophrenia;	chr18:79880207	chr18:80046900~80095482:+
THCA	cis	rs3750082	0.889	rs6963831	ENSG00000231952.3	DPY19L1P2	4.74	2.82e-06	0.000326	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32895215	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs55647647	ENSG00000231952.3	DPY19L1P2	4.74	2.82e-06	0.000326	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32895408	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.815	rs6964458	ENSG00000231952.3	DPY19L1P2	4.74	2.82e-06	0.000326	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32895612	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs6462431	ENSG00000231952.3	DPY19L1P2	4.74	2.82e-06	0.000326	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32895827	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.889	rs12536400	ENSG00000231952.3	DPY19L1P2	4.74	2.82e-06	0.000326	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32896778	chr7:32812757~32838570:+
THCA	cis	rs453301	0.686	rs7017868	ENSG00000254153.1	CTA-398F10.2	4.74	2.83e-06	0.000327	0.23	0.21	Joint mobility (Beighton score);	chr8:9015783	chr8:8456909~8461337:-
THCA	cis	rs453301	0.686	rs3895823	ENSG00000254153.1	CTA-398F10.2	4.74	2.83e-06	0.000327	0.23	0.21	Joint mobility (Beighton score);	chr8:9016136	chr8:8456909~8461337:-
THCA	cis	rs6997458	0.713	rs703	ENSG00000253549.4	RP11-317J10.2	4.74	2.83e-06	0.000327	0.22	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85477174	chr8:85441851~85464915:-
THCA	cis	rs11633886	0.604	rs2413795	ENSG00000273972.1	CTD-2306A12.1	-4.74	2.83e-06	0.000327	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45816532	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.604	rs8029233	ENSG00000273972.1	CTD-2306A12.1	-4.74	2.83e-06	0.000327	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45817791	chr15:45702640~45703183:+
THCA	cis	rs763121	0.853	rs3788544	ENSG00000235209.1	CTA-150C2.13	4.74	2.83e-06	0.000327	0.28	0.21	Menopause (age at onset);	chr22:38668961	chr22:38921227~38924708:+
THCA	cis	rs6472827	0.645	rs2956024	ENSG00000253983.2	RP1-16A9.1	4.74	2.83e-06	0.000327	0.31	0.21	Uterine fibroids;	chr8:74191465	chr8:74199396~74208441:+
THCA	cis	rs2348418	0.639	rs41505151	ENSG00000247934.4	RP11-967K21.1	4.74	2.83e-06	0.000327	0.19	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28112651	chr12:28163298~28190738:-
THCA	cis	rs4415084	0.716	rs10057341	ENSG00000272335.1	RP11-53O19.3	4.74	2.83e-06	0.000327	0.18	0.21	Breast cancer;	chr5:44931738	chr5:44826076~44828592:+
THCA	cis	rs9925964	0.933	rs9923231	ENSG00000260911.2	RP11-196G11.2	-4.74	2.83e-06	0.000327	-0.18	-0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31096368	chr16:31043150~31049868:+
THCA	cis	rs7246657	0.653	rs10401525	ENSG00000226686.6	LINC01535	-4.74	2.83e-06	0.000327	-0.39	-0.21	Coronary artery calcification;	chr19:37168077	chr19:37251912~37265535:+
THCA	cis	rs858239	0.669	rs12539467	ENSG00000226816.2	AC005082.12	4.74	2.83e-06	0.000327	0.31	0.21	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23206013~23208045:+
THCA	cis	rs4915077	1	rs78288858	ENSG00000230489.1	VAV3-AS1	4.74	2.83e-06	0.000327	0.37	0.21	Hypothyroidism;	chr1:107819671	chr1:107964443~107994607:+
THCA	cis	rs2243480	0.522	rs431168	ENSG00000232546.1	RP11-458F8.1	-4.74	2.83e-06	0.000327	-0.33	-0.21	Diabetic kidney disease;	chr7:66046617	chr7:66848496~66858136:+
THCA	cis	rs2361718	0.5	rs12451697	ENSG00000275479.1	RP11-334C17.6	4.74	2.83e-06	0.000328	0.2	0.21	Yeast infection;	chr17:80126891	chr17:80149627~80149798:+
THCA	cis	rs453301	0.686	rs6601280	ENSG00000254153.1	CTA-398F10.2	-4.74	2.83e-06	0.000328	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9051726	chr8:8456909~8461337:-
THCA	cis	rs12908161	1	rs35960805	ENSG00000275120.1	RP11-182J1.17	4.74	2.84e-06	0.000328	0.25	0.21	Schizophrenia;	chr15:84800749	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs12912388	ENSG00000275120.1	RP11-182J1.17	4.74	2.84e-06	0.000328	0.25	0.21	Schizophrenia;	chr15:84801319	chr15:84599434~84606463:-
THCA	cis	rs1426063	0.858	rs10004802	ENSG00000260265.1	RP11-44F21.5	4.74	2.84e-06	0.000328	0.38	0.21	QT interval;	chr4:75084413	chr4:75081702~75084717:-
THCA	cis	rs5758659	0.714	rs5758578	ENSG00000182057.4	OGFRP1	-4.74	2.84e-06	0.000328	-0.24	-0.21	Cognitive function;	chr22:42094288	chr22:42269753~42275196:+
THCA	cis	rs8062405	0.723	rs62031562	ENSG00000261766.1	RP11-22P6.2	-4.74	2.84e-06	0.000328	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28862166~28863340:-
THCA	cis	rs8020095	0.571	rs2281676	ENSG00000258561.1	RP11-72M17.1	4.74	2.84e-06	0.000328	0.28	0.21	Depression (quantitative trait);	chr14:67171738	chr14:66212810~66509394:-
THCA	cis	rs6088580	0.634	rs6059897	ENSG00000276073.1	RP5-1125A11.7	-4.74	2.84e-06	0.000328	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34525419	chr20:33985617~33988989:-
THCA	cis	rs6586163	0.527	rs3824730	ENSG00000261438.1	RP11-399O19.9	-4.74	2.84e-06	0.000328	-0.19	-0.21	Chronic lymphocytic leukemia;	chr10:88992371	chr10:89015836~89017059:+
THCA	cis	rs6586163	0.546	rs12359362	ENSG00000261438.1	RP11-399O19.9	-4.74	2.84e-06	0.000328	-0.19	-0.21	Chronic lymphocytic leukemia;	chr10:88993388	chr10:89015836~89017059:+
THCA	cis	rs1005277	0.54	rs1814077	ENSG00000226578.1	RP11-258F22.1	-4.74	2.84e-06	0.000328	-0.25	-0.21	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:37775371~37784131:-
THCA	cis	rs6700559	0.643	rs1540683	ENSG00000260088.1	RP11-92G12.3	4.74	2.84e-06	0.000328	0.26	0.21	Coronary artery disease;	chr1:200693050	chr1:200669507~200694250:+
THCA	cis	rs17412738	0.607	rs10935011	ENSG00000248724.5	NPHP3-AS1	-4.74	2.84e-06	0.000328	-0.32	-0.21	Blood protein levels;	chr3:132449977	chr3:132721750~132874223:+
THCA	cis	rs6802315	0.74	rs9822005	ENSG00000272087.1	RP11-379F4.7	4.74	2.84e-06	0.000328	0.19	0.21	Periodontitis (CDC/AAP);	chr3:158794592	chr3:158693120~158693768:-
THCA	cis	rs12908161	1	rs12908161	ENSG00000188388.10	GOLGA6L3	4.74	2.84e-06	0.000328	0.29	0.21	Schizophrenia;	chr15:84664594	chr15:85240472~85247170:+
THCA	cis	rs4660456	0.504	rs491619	ENSG00000272145.1	NFYC-AS1	-4.74	2.84e-06	0.000329	-0.15	-0.21	Platelet count;	chr1:40641688	chr1:40690380~40692066:-
THCA	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-4.74	2.84e-06	0.000329	-0.12	-0.21	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
THCA	cis	rs2839186	0.77	rs2330353	ENSG00000215424.8	MCM3AP-AS1	4.74	2.84e-06	0.000329	0.12	0.21	Testicular germ cell tumor;	chr21:46249734	chr21:46229217~46259390:+
THCA	cis	rs889398	0.967	rs1437134	ENSG00000226232.7	RP11-419C5.2	-4.74	2.84e-06	0.000329	-0.21	-0.21	Body mass index;	chr16:69696523	chr16:69976388~69996188:-
THCA	cis	rs1766786	1	rs1766794	ENSG00000231365.4	RP11-418J17.1	-4.74	2.84e-06	0.000329	-0.29	-0.21	Chin dimples;	chr1:118923816	chr1:119140396~119275973:+
THCA	cis	rs7851660	0.809	rs1561957	ENSG00000214417.4	KRT18P13	-4.74	2.84e-06	0.000329	-0.19	-0.21	Strep throat;	chr9:97907990	chr9:97698922~97700734:+
THCA	cis	rs3750082	0.785	rs4720085	ENSG00000231952.3	DPY19L1P2	-4.74	2.85e-06	0.000329	-0.26	-0.21	Glomerular filtration rate (creatinine);	chr7:32928524	chr7:32812757~32838570:+
THCA	cis	rs7267979	0.932	rs2387891	ENSG00000274973.1	RP13-401N8.7	-4.74	2.85e-06	0.000329	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25845497~25845862:+
THCA	cis	rs4950322	0.542	rs3766520	ENSG00000226015.2	CCT8P1	4.74	2.85e-06	0.000329	0.25	0.21	Protein quantitative trait loci;	chr1:147214658	chr1:147203276~147204932:-
THCA	cis	rs73242632	0.881	rs73242633	ENSG00000269949.1	RP11-738E22.3	4.74	2.85e-06	0.000329	0.54	0.21	Congenital heart disease (maternal effect);	chr4:57053900	chr4:56960927~56961373:-
THCA	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-4.74	2.85e-06	0.000329	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
THCA	cis	rs8141529	0.748	rs715531	ENSG00000226471.5	CTA-292E10.6	-4.74	2.85e-06	0.000329	-0.18	-0.21	Lymphocyte counts;	chr22:28886691	chr22:28800683~28848559:+
THCA	cis	rs62158800	0.706	rs17034416	ENSG00000237880.1	AC096669.2	4.74	2.85e-06	0.000329	0.33	0.21	Facial morphology (factor 22);	chr2:107569777	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.568	rs62158774	ENSG00000237880.1	AC096669.2	4.74	2.85e-06	0.000329	0.33	0.21	Facial morphology (factor 22);	chr2:107573103	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.778	rs62158793	ENSG00000237880.1	AC096669.2	4.74	2.85e-06	0.000329	0.33	0.21	Facial morphology (factor 22);	chr2:107574814	chr2:107385632~107542649:-
THCA	cis	rs11992162	0.636	rs11250182	ENSG00000254948.1	OR7E158P	4.74	2.85e-06	0.000329	0.26	0.21	Monocyte count;	chr8:11950067	chr8:11919900~11920809:-
THCA	cis	rs2243480	1	rs958550	ENSG00000232546.1	RP11-458F8.1	4.74	2.85e-06	0.000329	0.28	0.21	Diabetic kidney disease;	chr7:66170692	chr7:66848496~66858136:+
THCA	cis	rs4908769	0.553	rs301792	ENSG00000232912.4	RP5-1115A15.1	4.74	2.85e-06	0.000329	0.23	0.21	Allergy;	chr1:8408218	chr1:8424645~8434838:+
THCA	cis	rs4908769	0.624	rs301790	ENSG00000232912.4	RP5-1115A15.1	4.74	2.85e-06	0.000329	0.23	0.21	Allergy;	chr1:8409224	chr1:8424645~8434838:+
THCA	cis	rs7429990	1	rs1665982	ENSG00000228638.1	FCF1P2	4.74	2.85e-06	0.000329	0.23	0.21	Educational attainment (years of education);	chr3:47863589	chr3:48290793~48291375:-
THCA	cis	rs930395	0.514	rs6880275	ENSG00000272335.1	RP11-53O19.3	4.74	2.85e-06	0.000329	0.18	0.21	Breast cancer;	chr5:44908833	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs6870136	ENSG00000272335.1	RP11-53O19.3	4.74	2.85e-06	0.000329	0.18	0.21	Breast cancer;	chr5:44910560	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs6881563	ENSG00000272335.1	RP11-53O19.3	4.74	2.85e-06	0.000329	0.18	0.21	Breast cancer;	chr5:44912751	chr5:44826076~44828592:+
THCA	cis	rs7336933	0.866	rs80199396	ENSG00000278338.3	VWA8-AS1	4.74	2.85e-06	0.000329	0.47	0.21	Calcium levels;	chr13:41913029	chr13:41955808~41981565:+
THCA	cis	rs453301	0.686	rs13252797	ENSG00000254153.1	CTA-398F10.2	-4.74	2.85e-06	0.000329	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9003920	chr8:8456909~8461337:-
THCA	cis	rs58235267	0.591	rs2162014	ENSG00000242412.1	DBIL5P2	-4.74	2.85e-06	0.000329	-0.24	-0.21	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:63118372	chr2:63117851~63119542:-
THCA	cis	rs13113518	1	rs1554483	ENSG00000273257.1	RP11-177J6.1	4.74	2.85e-06	0.000329	0.28	0.21	Height;	chr4:55455650	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs1464490	ENSG00000273257.1	RP11-177J6.1	4.74	2.85e-06	0.000329	0.28	0.21	Height;	chr4:55456620	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs10517346	ENSG00000273257.1	RP11-177J6.1	4.74	2.85e-06	0.000329	0.28	0.21	Height;	chr4:55457027	chr4:55387949~55388271:+
THCA	cis	rs13113518	1	rs11133384	ENSG00000273257.1	RP11-177J6.1	4.74	2.85e-06	0.000329	0.28	0.21	Height;	chr4:55457086	chr4:55387949~55388271:+
THCA	cis	rs9925964	0.967	rs889548	ENSG00000260911.2	RP11-196G11.2	4.74	2.85e-06	0.000329	0.18	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31126391	chr16:31043150~31049868:+
THCA	cis	rs111580313	0.534	rs4843169	ENSG00000270020.1	RP11-463O9.9	4.74	2.85e-06	0.000329	0.34	0.21	Systemic juvenile idiopathic arthritis;	chr16:86576206	chr16:86520383~86523897:-
THCA	cis	rs5742933	1	rs5742998	ENSG00000273240.1	RP11-455J20.3	-4.74	2.85e-06	0.000329	-0.24	-0.21	Ferritin levels;	chr2:189799626	chr2:189763859~189764456:-
THCA	cis	rs2447820	0.588	rs12055251	ENSG00000249996.1	RP11-359P5.1	4.74	2.85e-06	0.000329	0.25	0.21	Migraine;	chr5:123034581	chr5:123036271~123054667:+
THCA	cis	rs12681288	0.862	rs34510005	ENSG00000260721.1	AF067845.1	4.74	2.85e-06	0.000329	0.26	0.21	Schizophrenia;	chr8:1068943	chr8:1368642~1369833:-
THCA	cis	rs35160687	0.644	rs4832276	ENSG00000273080.1	RP11-301O19.1	4.74	2.85e-06	0.000329	0.23	0.21	Night sleep phenotypes;	chr2:86317895	chr2:86195590~86196049:+
THCA	cis	rs7394190	0.748	rs12573448	ENSG00000271848.1	RP11-464F9.21	-4.74	2.85e-06	0.000329	-0.3	-0.21	Incident atrial fibrillation;	chr10:73744754	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs12572278	ENSG00000271848.1	RP11-464F9.21	-4.74	2.85e-06	0.000329	-0.3	-0.21	Incident atrial fibrillation;	chr10:73744755	chr10:73654039~73674719:+
THCA	cis	rs442309	0.532	rs10995276	ENSG00000238280.1	RP11-436D10.3	4.74	2.85e-06	0.000329	0.28	0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62694301	chr10:62793562~62805887:-
THCA	cis	rs3020736	0.5	rs6002605	ENSG00000273366.1	CTA-989H11.1	4.74	2.85e-06	0.000329	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42278188~42278846:+
THCA	cis	rs7577696	0.962	rs7575139	ENSG00000276334.1	AL133243.1	-4.74	2.85e-06	0.00033	-0.22	-0.21	Inflammatory biomarkers;	chr2:32066265	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.962	rs6758024	ENSG00000276334.1	AL133243.1	-4.74	2.85e-06	0.00033	-0.22	-0.21	Inflammatory biomarkers;	chr2:32069417	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.962	rs10490360	ENSG00000276334.1	AL133243.1	-4.74	2.85e-06	0.00033	-0.22	-0.21	Inflammatory biomarkers;	chr2:32071199	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.853	rs56740303	ENSG00000276334.1	AL133243.1	-4.74	2.85e-06	0.00033	-0.22	-0.21	Inflammatory biomarkers;	chr2:32079587	chr2:32521927~32523547:+
THCA	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-4.74	2.85e-06	0.00033	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
THCA	cis	rs3820928	0.874	rs1320407	ENSG00000212391.1	SNORA48	-4.74	2.85e-06	0.00033	-0.23	-0.21	Pulmonary function;	chr2:227002669	chr2:226968989~226969122:-
THCA	cis	rs6840360	0.681	rs9968292	ENSG00000270265.1	RP11-731D1.4	-4.74	2.86e-06	0.00033	-0.2	-0.21	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151333775~151353224:-
THCA	cis	rs9987353	0.84	rs41436744	ENSG00000254153.1	CTA-398F10.2	4.74	2.86e-06	0.00033	0.25	0.21	Recombination measurement;	chr8:9265814	chr8:8456909~8461337:-
THCA	cis	rs957448	1	rs1023767	ENSG00000253175.1	RP11-267M23.6	4.74	2.86e-06	0.00033	0.27	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94565036~94565715:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000229886.1	RP5-1132H15.3	4.74	2.86e-06	0.00033	0.22	0.21	Aortic root size;	chr7:66008701	chr7:66025126~66031544:-
THCA	cis	rs9880211	0.8	rs34324561	ENSG00000239213.4	NCK1-AS1	4.74	2.86e-06	0.00033	0.23	0.21	Height;Body mass index;	chr3:136382400	chr3:136841726~136862054:-
THCA	cis	rs172166	0.516	rs1225710	ENSG00000176933.5	TOB2P1	4.74	2.86e-06	0.00033	0.23	0.21	Cardiac Troponin-T levels;	chr6:28132862	chr6:28217643~28218634:-
THCA	cis	rs8177876	0.822	rs8177959	ENSG00000261061.1	RP11-303E16.2	-4.74	2.86e-06	0.00033	-0.3	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81030770~81031485:+
THCA	cis	rs4950322	0.517	rs114823926	ENSG00000180867.10	PDIA3P1	4.74	2.86e-06	0.00033	0.21	0.21	Protein quantitative trait loci;	chr1:147281805	chr1:147178113~147179622:+
THCA	cis	rs4693089	0.564	rs971540	ENSG00000213608.5	SLC25A14P1	-4.74	2.86e-06	0.00033	-0.25	-0.21	Menopause (age at onset);	chr4:83512940	chr4:83477524~83478424:+
THCA	cis	rs4950322	0.547	rs6660507	ENSG00000226015.2	CCT8P1	4.74	2.86e-06	0.00033	0.23	0.21	Protein quantitative trait loci;	chr1:147148574	chr1:147203276~147204932:-
THCA	cis	rs62158800	0.778	rs62158769	ENSG00000224568.1	AC096669.3	4.74	2.86e-06	0.00033	0.43	0.21	Facial morphology (factor 22);	chr2:107544288	chr2:107529487~107556326:+
THCA	cis	rs2253762	0.507	rs10159582	ENSG00000226864.1	ATE1-AS1	4.74	2.86e-06	0.00033	0.34	0.21	Breast cancer;	chr10:121993110	chr10:121928312~121951965:+
THCA	cis	rs2253762	0.507	rs10159583	ENSG00000226864.1	ATE1-AS1	4.74	2.86e-06	0.00033	0.34	0.21	Breast cancer;	chr10:121993154	chr10:121928312~121951965:+
THCA	cis	rs72843506	0.722	rs5025290	ENSG00000261033.1	RP11-209D14.2	4.74	2.86e-06	0.00033	0.38	0.21	Schizophrenia;	chr17:20302504	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.722	rs9895177	ENSG00000261033.1	RP11-209D14.2	4.74	2.86e-06	0.00033	0.38	0.21	Schizophrenia;	chr17:20304281	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.722	rs9908418	ENSG00000261033.1	RP11-209D14.2	4.74	2.86e-06	0.00033	0.38	0.21	Schizophrenia;	chr17:20311252	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.591	rs75334890	ENSG00000261033.1	RP11-209D14.2	4.74	2.86e-06	0.00033	0.38	0.21	Schizophrenia;	chr17:20318087	chr17:20008051~20009234:-
THCA	cis	rs2115630	0.791	rs2008262	ENSG00000225151.9	GOLGA2P7	4.74	2.86e-06	0.00033	0.27	0.21	P wave terminal force;	chr15:84762039	chr15:84199311~84230136:-
THCA	cis	rs7615952	0.688	rs12638224	ENSG00000272840.1	RP11-379B18.6	4.74	2.86e-06	0.00033	0.33	0.21	Blood pressure (smoking interaction);	chr3:125822477	chr3:125774714~125797953:+
THCA	cis	rs858239	0.6	rs7776644	ENSG00000226816.2	AC005082.12	4.74	2.86e-06	0.00033	0.31	0.21	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23206013~23208045:+
THCA	cis	rs4700393	0.52	rs4515250	ENSG00000251279.1	CTC-436P18.1	-4.74	2.86e-06	0.00033	-0.3	-0.21	Intelligence (multi-trait analysis);	chr5:60646302	chr5:61162070~61232040:+
THCA	cis	rs9368481	0.7	rs6911401	ENSG00000261353.1	CTA-14H9.5	-4.74	2.86e-06	0.00033	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26527063~26527404:+
THCA	cis	rs10888838	0.618	rs15921	ENSG00000198711.5	SSBP3-AS1	4.74	2.86e-06	0.000331	0.2	0.21	Mitochondrial DNA levels;	chr1:54218183	chr1:54236440~54239063:+
THCA	cis	rs7620503	0.506	rs2242401	ENSG00000228561.2	RP11-114M1.1	4.74	2.86e-06	0.000331	0.24	0.21	Corneal structure;	chr3:177620492	chr3:177683627~177691250:+
THCA	cis	rs10510102	0.872	rs11200293	ENSG00000226864.1	ATE1-AS1	4.74	2.87e-06	0.000331	0.35	0.21	Breast cancer;	chr10:121969195	chr10:121928312~121951965:+
THCA	cis	rs1003719	0.788	rs1543748	ENSG00000230366.8	DSCR9	-4.74	2.87e-06	0.000331	-0.21	-0.21	Eye color traits;	chr21:37074281	chr21:37208503~37221736:+
THCA	cis	rs4763879	0.739	rs12582584	ENSG00000256673.1	RP11-599J14.2	4.74	2.87e-06	0.000331	0.26	0.21	Type 1 diabetes;	chr12:9671542	chr12:9398355~9414851:-
THCA	cis	rs72807343	0.661	rs72813734	ENSG00000245317.2	CTC-241N9.1	4.74	2.87e-06	0.000331	0.41	0.21	Alzheimer's disease (late onset);	chr5:179842193	chr5:179859013~179861283:+
THCA	cis	rs7674212	0.541	rs4699051	ENSG00000251288.2	RP11-10L12.2	-4.74	2.87e-06	0.000331	-0.27	-0.21	Type 2 diabetes;	chr4:103193237	chr4:102751401~102752641:+
THCA	cis	rs4591358	0.765	rs11884957	ENSG00000223466.1	AC064834.2	4.74	2.87e-06	0.000331	0.25	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195498120	chr2:195533035~195538681:+
THCA	cis	rs7010876	0.537	rs7822566	ENSG00000253553.4	RP11-586K2.1	4.74	2.87e-06	0.000331	0.21	0.21	Schizophrenia;	chr8:88406504	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.537	rs28445522	ENSG00000253553.4	RP11-586K2.1	4.74	2.87e-06	0.000331	0.21	0.21	Schizophrenia;	chr8:88407051	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.537	rs28671153	ENSG00000253553.4	RP11-586K2.1	4.74	2.87e-06	0.000331	0.21	0.21	Schizophrenia;	chr8:88410360	chr8:88326836~88737134:+
THCA	cis	rs6674176	0.932	rs12410334	ENSG00000237950.1	RP11-7O11.3	4.74	2.87e-06	0.000331	0.21	0.21	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43976849	chr1:43944370~43946551:-
THCA	cis	rs2243480	1	rs160639	ENSG00000164669.11	INTS4P1	4.74	2.87e-06	0.000331	0.4	0.21	Diabetic kidney disease;	chr7:66115000	chr7:65141225~65234216:+
THCA	cis	rs172166	0.516	rs2791333	ENSG00000176933.5	TOB2P1	-4.74	2.87e-06	0.000331	-0.23	-0.21	Cardiac Troponin-T levels;	chr6:28143336	chr6:28217643~28218634:-
THCA	cis	rs651907	0.535	rs17347156	ENSG00000244119.1	PDCL3P4	4.74	2.87e-06	0.000331	0.2	0.21	Colorectal cancer;	chr3:101785830	chr3:101712472~101713191:+
THCA	cis	rs3892630	0.878	rs2903759	ENSG00000267567.1	CTD-2538C1.3	4.74	2.87e-06	0.000332	0.32	0.21	Red blood cell traits;	chr19:32705041	chr19:32718298~32719595:-
THCA	cis	rs7429990	0.965	rs4858887	ENSG00000228638.1	FCF1P2	4.74	2.87e-06	0.000332	0.21	0.21	Educational attainment (years of education);	chr3:48050527	chr3:48290793~48291375:-
THCA	cis	rs9311474	0.632	rs6445528	ENSG00000243224.1	RP5-1157M23.2	4.74	2.87e-06	0.000332	0.23	0.21	Electroencephalogram traits;	chr3:52538431	chr3:52239258~52241097:+
THCA	cis	rs7617773	0.784	rs9850672	ENSG00000199476.1	Y_RNA	-4.74	2.88e-06	0.000332	-0.27	-0.21	Coronary artery disease;	chr3:48259682	chr3:48288587~48288694:+
THCA	cis	rs78487399	0.908	rs60868396	ENSG00000234936.1	AC010883.5	4.74	2.88e-06	0.000332	0.27	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43609738	chr2:43229573~43233394:+
THCA	cis	rs9467773	0.583	rs2498380	ENSG00000124549.13	BTN2A3P	-4.74	2.88e-06	0.000332	-0.2	-0.21	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26421391~26432383:+
THCA	cis	rs13113518	1	rs4864993	ENSG00000273257.1	RP11-177J6.1	4.74	2.88e-06	0.000332	0.28	0.21	Height;	chr4:55450662	chr4:55387949~55388271:+
THCA	cis	rs739496	0.579	rs7488629	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111835696	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.748	rs73422316	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Mean platelet volume;	chr12:111835870	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs73422318	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111838169	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7314870	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111838660	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs2879603	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111840221	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs3213628	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111842969	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7980569	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111843580	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7970847	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111843689	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs3782885	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111844779	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs11066046	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111846077	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs2158030	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111847787	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.799	rs7315642	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Mean platelet volume;	chr12:111848992	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs12302040	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111850375	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs12322899	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111850398	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs12307192	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111852542	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs12307365	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111852847	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs6489817	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111853438	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7296199	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111854040	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs12313385	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111854343	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7310605	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111854666	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7976557	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111862976	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs11066054	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111868361	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7297760	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111875884	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.799	rs12426566	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Mean platelet volume;	chr12:111877368	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs2097701	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111878970	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7294623	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111879292	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs16941703	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111880930	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs61440627	ENSG00000226469.1	ADAM1B	4.74	2.88e-06	0.000332	0.26	0.21	Platelet count;	chr12:111881193	chr12:111927018~111929017:+
THCA	cis	rs6012564	0.826	rs6012570	ENSG00000227431.4	CSE1L-AS1	-4.74	2.88e-06	0.000332	-0.27	-0.21	Anger;	chr20:48952121	chr20:49040463~49046044:-
THCA	cis	rs699371	0.525	rs7156302	ENSG00000259005.1	RP3-449M8.6	4.74	2.88e-06	0.000332	0.19	0.21	Height;	chr14:74428260	chr14:74474007~74474864:-
THCA	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-4.74	2.88e-06	0.000332	-0.13	-0.21	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-4.74	2.88e-06	0.000332	-0.13	-0.21	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
THCA	cis	rs8177876	0.822	rs804902	ENSG00000261061.1	RP11-303E16.2	-4.74	2.88e-06	0.000332	-0.27	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr16:81030770~81031485:+
THCA	cis	rs4415084	0.716	rs10038562	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44832124	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs6896350	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44832469	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.68	rs1371025	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44834131	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs2330620	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44839720	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs2083243	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44840045	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs729599	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44842158	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs16901990	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44842638	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.68	rs10072025	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44843392	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs1371024	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44843488	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.68	rs7715731	ENSG00000272335.1	RP11-53O19.3	4.74	2.88e-06	0.000332	0.18	0.21	Breast cancer;	chr5:44846742	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs12518851	ENSG00000272335.1	RP11-53O19.3	-4.74	2.88e-06	0.000332	-0.18	-0.21	Breast cancer;	chr5:44828129	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs13155698	ENSG00000272335.1	RP11-53O19.3	-4.74	2.88e-06	0.000332	-0.18	-0.21	Breast cancer;	chr5:44828579	chr5:44826076~44828592:+
THCA	cis	rs9307551	0.619	rs1440862	ENSG00000250334.4	LINC00989	-4.74	2.88e-06	0.000332	-0.26	-0.21	Refractive error;	chr4:79503116	chr4:79492416~79576460:+
THCA	cis	rs763121	0.853	rs138704	ENSG00000235209.1	CTA-150C2.13	4.74	2.88e-06	0.000332	0.29	0.21	Menopause (age at onset);	chr22:38737405	chr22:38921227~38924708:+
THCA	cis	rs7726839	0.574	rs72705017	ENSG00000225138.6	CTD-2228K2.7	4.74	2.88e-06	0.000332	0.27	0.21	Obesity-related traits;	chr5:623618	chr5:473236~480884:+
THCA	cis	rs11723261	0.621	rs11721745	ENSG00000211553.1	AC253576.2	-4.74	2.88e-06	0.000332	-0.31	-0.21	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:136461~136568:+
THCA	cis	rs6787172	0.811	rs1369562	ENSG00000272087.1	RP11-379F4.7	4.74	2.88e-06	0.000333	0.19	0.21	Subjective well-being;	chr3:158490771	chr3:158693120~158693768:-
THCA	cis	rs8020095	0.571	rs10138850	ENSG00000258561.1	RP11-72M17.1	4.74	2.88e-06	0.000333	0.28	0.21	Depression (quantitative trait);	chr14:67140051	chr14:66212810~66509394:-
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000164669.11	INTS4P1	4.74	2.89e-06	0.000333	0.41	0.21	Diabetic kidney disease;	chr7:65996588	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs1701750	ENSG00000164669.11	INTS4P1	4.74	2.89e-06	0.000333	0.41	0.21	Diabetic kidney disease;	chr7:66002158	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs1701758	ENSG00000164669.11	INTS4P1	4.74	2.89e-06	0.000333	0.41	0.21	Diabetic kidney disease;	chr7:66005214	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000164669.11	INTS4P1	4.74	2.89e-06	0.000333	0.41	0.21	Diabetic kidney disease;	chr7:66005945	chr7:65141225~65234216:+
THCA	cis	rs874628	0.659	rs4808120	ENSG00000268650.3	AC068499.10	4.74	2.89e-06	0.000333	0.24	0.21	Multiple sclerosis;	chr19:18247019	chr19:18204730~18220480:+
THCA	cis	rs8027521	0.905	rs1478219	ENSG00000280362.1	RP11-643A5.3	-4.74	2.89e-06	0.000333	-0.26	-0.21	Circulating chemerin levels;	chr15:53973421	chr15:53910769~53914712:+
THCA	cis	rs13118159	0.573	rs7664763	ENSG00000254094.1	AC078852.1	-4.74	2.89e-06	0.000333	-0.27	-0.21	Longevity;	chr4:1358517	chr4:1356581~1358075:+
THCA	cis	rs9902453	1	rs4581755	ENSG00000263370.1	RP11-68I3.5	4.74	2.89e-06	0.000333	0.28	0.21	Coffee consumption (cups per day);	chr17:30100880	chr17:29639627~29640825:+
THCA	cis	rs1371614	0.523	rs2891534	ENSG00000229122.1	AGBL5-IT1	4.74	2.89e-06	0.000334	0.15	0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26961578	chr2:27061038~27061815:+
THCA	cis	rs9959145	0.866	rs113413902	ENSG00000267108.1	RP11-861E21.1	4.74	2.89e-06	0.000334	0.26	0.21	Immune response to smallpox vaccine (IL-6);	chr18:12731558	chr18:12432897~12437635:+
THCA	cis	rs1023500	0.551	rs2859438	ENSG00000273366.1	CTA-989H11.1	-4.74	2.89e-06	0.000334	-0.27	-0.21	Schizophrenia;	chr22:42070976	chr22:42278188~42278846:+
THCA	cis	rs7914558	0.646	rs10883795	ENSG00000236937.2	PTGES3P4	4.74	2.89e-06	0.000334	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894820	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.646	rs10883796	ENSG00000236937.2	PTGES3P4	4.74	2.89e-06	0.000334	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895558	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.646	rs4363528	ENSG00000236937.2	PTGES3P4	4.74	2.89e-06	0.000334	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895758	chr10:102845595~102845950:+
THCA	cis	rs6433895	0.961	rs11891215	ENSG00000236153.1	AC104076.3	-4.74	2.89e-06	0.000334	-0.24	-0.21	Lymphocyte counts;	chr2:181145300	chr2:180979427~180980090:-
THCA	cis	rs763121	0.853	rs5750669	ENSG00000228274.3	RP3-508I15.9	-4.74	2.89e-06	0.000334	-0.23	-0.21	Menopause (age at onset);	chr22:38684633	chr22:38667585~38681820:-
THCA	cis	rs453301	0.571	rs2929453	ENSG00000253981.4	ALG1L13P	-4.74	2.89e-06	0.000334	-0.2	-0.21	Joint mobility (Beighton score);	chr8:9226831	chr8:8236003~8244667:-
THCA	cis	rs651907	0.535	rs4342086	ENSG00000244119.1	PDCL3P4	4.74	2.89e-06	0.000334	0.19	0.21	Colorectal cancer;	chr3:101784921	chr3:101712472~101713191:+
THCA	cis	rs35160687	0.623	rs4832263	ENSG00000273080.1	RP11-301O19.1	-4.74	2.89e-06	0.000334	-0.23	-0.21	Night sleep phenotypes;	chr2:86258034	chr2:86195590~86196049:+
THCA	cis	rs4415084	0.966	rs12516900	ENSG00000272335.1	RP11-53O19.3	-4.74	2.89e-06	0.000334	-0.17	-0.21	Breast cancer;	chr5:44644393	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.932	rs4321755	ENSG00000272335.1	RP11-53O19.3	-4.74	2.89e-06	0.000334	-0.17	-0.21	Breast cancer;	chr5:44646093	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.966	rs4492118	ENSG00000272335.1	RP11-53O19.3	-4.74	2.89e-06	0.000334	-0.17	-0.21	Breast cancer;	chr5:44646523	chr5:44826076~44828592:+
THCA	cis	rs4415084	1	rs6890556	ENSG00000272335.1	RP11-53O19.3	-4.74	2.89e-06	0.000334	-0.17	-0.21	Breast cancer;	chr5:44648564	chr5:44826076~44828592:+
THCA	cis	rs2243123	0.602	rs6441283	ENSG00000244040.4	IL12A-AS1	4.74	2.9e-06	0.000334	0.28	0.21	Multiple sclerosis;	chr3:160000113	chr3:159913400~160225299:-
THCA	cis	rs1003719	0.788	rs1543749	ENSG00000230366.8	DSCR9	-4.74	2.9e-06	0.000334	-0.21	-0.21	Eye color traits;	chr21:37074321	chr21:37208503~37221736:+
THCA	cis	rs4915077	1	rs17020146	ENSG00000226822.1	RP11-356N1.2	4.74	2.9e-06	0.000334	0.4	0.21	Hypothyroidism;	chr1:107832080	chr1:108071482~108074519:+
THCA	cis	rs4950322	0.57	rs72692979	ENSG00000271721.1	RP11-337C18.9	4.74	2.9e-06	0.000334	0.24	0.21	Protein quantitative trait loci;	chr1:147336094	chr1:147175602~147177740:+
THCA	cis	rs481331	0.799	rs3928822	ENSG00000215146.4	RP11-313J2.1	4.74	2.9e-06	0.000334	0.35	0.21	Systemic juvenile idiopathic arthritis;	chr10:42471984	chr10:42331866~42367974:-
THCA	cis	rs4915077	1	rs76590353	ENSG00000230489.1	VAV3-AS1	4.74	2.9e-06	0.000334	0.34	0.21	Hypothyroidism;	chr1:107800002	chr1:107964443~107994607:+
THCA	cis	rs250518	0.852	rs3846640	ENSG00000272081.1	CTD-2376I4.2	4.74	2.9e-06	0.000334	0.28	0.21	Mean corpuscular hemoglobin concentration;	chr5:72724139	chr5:72955206~72955699:-
THCA	cis	rs250518	0.888	rs6870112	ENSG00000272081.1	CTD-2376I4.2	4.74	2.9e-06	0.000334	0.28	0.21	Mean corpuscular hemoglobin concentration;	chr5:72725093	chr5:72955206~72955699:-
THCA	cis	rs3764021	1	rs7977720	ENSG00000256594.6	RP11-705C15.2	4.74	2.9e-06	0.000334	0.17	0.21	Type 1 diabetes;	chr12:9713753	chr12:9633419~9658412:+
THCA	cis	rs12413361	0.967	rs4749617	ENSG00000272914.1	RP11-330O11.3	-4.74	2.9e-06	0.000334	-0.19	-0.21	Height;	chr10:30824794	chr10:30831828~30833387:-
THCA	cis	rs2976388	0.578	rs34956412	ENSG00000253741.1	CTD-2292P10.4	4.74	2.9e-06	0.000334	0.3	0.21	Urinary tract infection frequency;	chr8:142740610	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.556	rs4736321	ENSG00000253741.1	CTD-2292P10.4	4.74	2.9e-06	0.000334	0.3	0.21	Urinary tract infection frequency;	chr8:142740776	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.578	rs13254358	ENSG00000253741.1	CTD-2292P10.4	4.74	2.9e-06	0.000334	0.3	0.21	Urinary tract infection frequency;	chr8:142742458	chr8:142702252~142726973:-
THCA	cis	rs9467773	0.62	rs2504571	ENSG00000124549.13	BTN2A3P	4.74	2.9e-06	0.000334	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26421391~26432383:+
THCA	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	4.74	2.9e-06	0.000334	0.18	0.21	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	4.74	2.9e-06	0.000334	0.18	0.21	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	4.74	2.9e-06	0.000334	0.18	0.21	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
THCA	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	4.74	2.9e-06	0.000334	0.18	0.21	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	4.74	2.9e-06	0.000334	0.18	0.21	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
THCA	cis	rs72843506	0.722	rs5025290	ENSG00000231258.2	ZSWIM5P2	4.74	2.9e-06	0.000334	0.31	0.21	Schizophrenia;	chr17:20302504	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.722	rs9895177	ENSG00000231258.2	ZSWIM5P2	4.74	2.9e-06	0.000334	0.31	0.21	Schizophrenia;	chr17:20304281	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.722	rs9908418	ENSG00000231258.2	ZSWIM5P2	4.74	2.9e-06	0.000334	0.31	0.21	Schizophrenia;	chr17:20311252	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.591	rs75334890	ENSG00000231258.2	ZSWIM5P2	4.74	2.9e-06	0.000334	0.31	0.21	Schizophrenia;	chr17:20318087	chr17:20583758~20591180:-
THCA	cis	rs651907	0.935	rs2929922	ENSG00000256628.3	ZBTB11-AS1	4.74	2.9e-06	0.000334	0.22	0.21	Colorectal cancer;	chr3:101869090	chr3:101676475~101679217:+
THCA	cis	rs2439831	0.85	rs28413881	ENSG00000166763.7	STRCP1	4.74	2.9e-06	0.000334	0.31	0.21	Lung cancer in ever smokers;	chr15:43881901	chr15:43699488~43718184:-
THCA	cis	rs6545883	0.524	rs12713435	ENSG00000270820.4	RP11-355B11.2	-4.74	2.9e-06	0.000334	-0.18	-0.21	Tuberculosis;	chr2:61272654	chr2:61471188~61484130:+
THCA	cis	rs12472274	0.941	rs6748440	ENSG00000279484.1	KLHL30-AS1	4.74	2.9e-06	0.000334	0.24	0.21	Phospholipid levels (plasma);	chr2:238191734	chr2:238152889~238155994:-
THCA	cis	rs7772486	0.72	rs6931553	ENSG00000270638.1	RP3-466P17.1	-4.74	2.9e-06	0.000335	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs6937661	ENSG00000270638.1	RP3-466P17.1	-4.74	2.9e-06	0.000335	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145735570~145737218:+
THCA	cis	rs17772222	1	rs17772288	ENSG00000222990.1	RNU4-22P	4.74	2.9e-06	0.000335	0.28	0.21	Coronary artery calcification;	chr14:88361022	chr14:88513498~88513663:+
THCA	cis	rs62355901	0.505	rs62356568	ENSG00000271828.1	CTD-2310F14.1	4.74	2.9e-06	0.000335	0.57	0.21	Breast cancer;	chr5:56955617	chr5:56927874~56929573:+
THCA	cis	rs4693089	0.522	rs9999564	ENSG00000213608.5	SLC25A14P1	-4.74	2.9e-06	0.000335	-0.25	-0.21	Menopause (age at onset);	chr4:83522944	chr4:83477524~83478424:+
THCA	cis	rs7005380	0.733	rs56864850	ENSG00000245330.4	KB-1471A8.1	-4.74	2.9e-06	0.000335	-0.21	-0.21	Interstitial lung disease;	chr8:119931204	chr8:119867419~119874488:-
THCA	cis	rs7005380	0.785	rs55892034	ENSG00000245330.4	KB-1471A8.1	-4.74	2.9e-06	0.000335	-0.21	-0.21	Interstitial lung disease;	chr8:119931267	chr8:119867419~119874488:-
THCA	cis	rs11089937	0.597	rs11704434	ENSG00000211639.2	IGLV4-60	4.74	2.9e-06	0.000335	0.16	0.21	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22162199~22162681:+
THCA	cis	rs1707322	1	rs7531911	ENSG00000281133.1	AL355480.3	-4.73	2.91e-06	0.000335	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45580892~45580996:-
THCA	cis	rs2439831	1	rs690316	ENSG00000166763.7	STRCP1	4.73	2.91e-06	0.000335	0.28	0.21	Lung cancer in ever smokers;	chr15:43445682	chr15:43699488~43718184:-
THCA	cis	rs897984	0.806	rs1046276	ENSG00000275263.1	RP11-1072A3.4	4.73	2.91e-06	0.000335	0.26	0.21	Dementia with Lewy bodies;	chr16:30903305	chr16:30956872~30957199:-
THCA	cis	rs4578769	0.55	rs9957690	ENSG00000265939.1	UBE2CP2	4.73	2.91e-06	0.000335	0.25	0.21	Eosinophil percentage of white cells;	chr18:22942697	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.55	rs12956837	ENSG00000265939.1	UBE2CP2	4.73	2.91e-06	0.000335	0.25	0.21	Eosinophil percentage of white cells;	chr18:22946865	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.55	rs9953479	ENSG00000265939.1	UBE2CP2	4.73	2.91e-06	0.000335	0.25	0.21	Eosinophil percentage of white cells;	chr18:22962644	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.55	rs12971230	ENSG00000265939.1	UBE2CP2	4.73	2.91e-06	0.000335	0.25	0.21	Eosinophil percentage of white cells;	chr18:22962987	chr18:22900486~22900995:-
THCA	cis	rs8177876	0.749	rs2278024	ENSG00000261838.4	RP11-303E16.6	4.73	2.91e-06	0.000335	0.38	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81069854~81076598:+
THCA	cis	rs13178541	0.745	rs11948578	ENSG00000250378.1	RP11-119J18.1	-4.73	2.91e-06	0.000335	-0.28	-0.21	IgG glycosylation;	chr5:135794511	chr5:135812667~135826582:+
THCA	cis	rs4415084	0.652	rs6883465	ENSG00000272335.1	RP11-53O19.3	4.73	2.91e-06	0.000335	0.18	0.21	Breast cancer;	chr5:44891518	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs7734331	ENSG00000272335.1	RP11-53O19.3	4.73	2.91e-06	0.000335	0.18	0.21	Breast cancer;	chr5:44895486	chr5:44826076~44828592:+
THCA	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	4.73	2.91e-06	0.000335	0.27	0.21	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
THCA	cis	rs6012564	1	rs2869716	ENSG00000227431.4	CSE1L-AS1	4.73	2.91e-06	0.000335	0.27	0.21	Anger;	chr20:49162803	chr20:49040463~49046044:-
THCA	cis	rs6441961	0.628	rs6441960	ENSG00000223552.1	RP11-24F11.2	4.73	2.91e-06	0.000335	0.21	0.21	Celiac disease;	chr3:46310383	chr3:46364955~46407059:-
THCA	cis	rs8062405	0.723	rs35175818	ENSG00000261766.1	RP11-22P6.2	-4.73	2.91e-06	0.000335	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28862166~28863340:-
THCA	cis	rs7141336	0.8	rs8016414	ENSG00000258884.1	CTD-3035D6.2	4.73	2.91e-06	0.000335	0.28	0.21	Anxiety disorder;	chr14:90822036	chr14:90822365~90828128:-
THCA	cis	rs7474896	0.515	rs594594	ENSG00000226578.1	RP11-258F22.1	4.73	2.91e-06	0.000335	0.3	0.21	Obesity (extreme);	chr10:38018795	chr10:37775371~37784131:-
THCA	cis	rs2439831	1	rs9920763	ENSG00000275601.1	AC011330.13	-4.73	2.91e-06	0.000335	-0.37	-0.21	Lung cancer in ever smokers;	chr15:43468310	chr15:43642389~43643023:-
THCA	cis	rs1023500	0.573	rs13057094	ENSG00000273366.1	CTA-989H11.1	-4.73	2.91e-06	0.000335	-0.28	-0.21	Schizophrenia;	chr22:42074313	chr22:42278188~42278846:+
THCA	cis	rs752010	0.967	rs10890153	ENSG00000230638.4	RP11-486B10.4	-4.73	2.91e-06	0.000335	-0.24	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41636389	chr1:41542069~41544310:+
THCA	cis	rs30380	1	rs26510	ENSG00000272109.1	CTD-2260A17.3	-4.73	2.91e-06	0.000335	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96804353~96806105:+
THCA	cis	rs11153306	0.515	rs3213575	ENSG00000231889.6	TRAF3IP2-AS1	4.73	2.91e-06	0.000336	0.19	0.21	Tonsillectomy;	chr6:111598068	chr6:111483511~111598302:+
THCA	cis	rs11992162	0.56	rs13276386	ENSG00000254948.1	OR7E158P	-4.73	2.91e-06	0.000336	-0.27	-0.21	Monocyte count;	chr8:11939912	chr8:11919900~11920809:-
THCA	cis	rs11992162	0.621	rs13268810	ENSG00000254948.1	OR7E158P	-4.73	2.91e-06	0.000336	-0.27	-0.21	Monocyte count;	chr8:11939921	chr8:11919900~11920809:-
THCA	cis	rs11992162	0.636	rs13265816	ENSG00000254948.1	OR7E158P	-4.73	2.91e-06	0.000336	-0.27	-0.21	Monocyte count;	chr8:11939976	chr8:11919900~11920809:-
THCA	cis	rs34792	0.525	rs12923446	ENSG00000207425.1	Y_RNA	4.73	2.91e-06	0.000336	0.24	0.21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15509723	chr16:14915457~14915556:-
THCA	cis	rs10208649	0.803	rs6739630	ENSG00000233266.1	HMGB1P31	4.73	2.91e-06	0.000336	0.52	0.21	Body mass index;	chr2:53753668	chr2:54051334~54051760:+
THCA	cis	rs911119	0.955	rs7270413	ENSG00000270001.1	RP11-218C14.8	-4.73	2.91e-06	0.000336	-0.32	-0.21	Chronic kidney disease;	chr20:23613184	chr20:23631826~23632316:-
THCA	cis	rs7665090	0.87	rs228614	ENSG00000251288.2	RP11-10L12.2	4.73	2.91e-06	0.000336	0.28	0.21	Primary biliary cholangitis;	chr4:102657480	chr4:102751401~102752641:+
THCA	cis	rs1836229	0.594	rs1434258	ENSG00000225706.1	PTPRD-AS1	4.73	2.91e-06	0.000336	0.25	0.21	Restless legs syndrome;	chr9:8830857	chr9:8858130~8862255:+
THCA	cis	rs919433	0.713	rs6719729	ENSG00000231621.1	AC013264.2	-4.73	2.91e-06	0.000336	-0.22	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197615348	chr2:197197991~197199273:+
THCA	cis	rs7520050	0.751	rs592214	ENSG00000234329.1	RP11-767N6.2	-4.73	2.92e-06	0.000336	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45558833	chr1:45651039~45651826:-
THCA	cis	rs2665103	0.632	rs3902959	ENSG00000259429.4	UBE2Q2P2	-4.73	2.92e-06	0.000336	-0.17	-0.21	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82355142~82420075:+
THCA	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	4.73	2.92e-06	0.000336	0.13	0.21	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
THCA	cis	rs6787172	0.811	rs1978779	ENSG00000272087.1	RP11-379F4.7	4.73	2.92e-06	0.000336	0.19	0.21	Subjective well-being;	chr3:158493502	chr3:158693120~158693768:-
THCA	cis	rs12612619	0.704	rs11680633	ENSG00000229122.1	AGBL5-IT1	4.73	2.92e-06	0.000336	0.15	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27001341	chr2:27061038~27061815:+
THCA	cis	rs17801127	0.818	rs9679510	ENSG00000231969.1	AC144449.1	4.73	2.92e-06	0.000336	0.44	0.21	Liver enzyme levels (alanine transaminase);	chr2:149844964	chr2:149587196~149848233:+
THCA	cis	rs6012564	0.928	rs2038509	ENSG00000227431.4	CSE1L-AS1	4.73	2.92e-06	0.000336	0.26	0.21	Anger;	chr20:49191533	chr20:49040463~49046044:-
THCA	cis	rs651907	0.535	rs35810977	ENSG00000244119.1	PDCL3P4	4.73	2.92e-06	0.000336	0.19	0.21	Colorectal cancer;	chr3:101812536	chr3:101712472~101713191:+
THCA	cis	rs3020736	0.5	rs6002616	ENSG00000273366.1	CTA-989H11.1	4.73	2.92e-06	0.000336	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs7364293	ENSG00000273366.1	CTA-989H11.1	4.73	2.92e-06	0.000336	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42278188~42278846:+
THCA	cis	rs17301013	0.932	rs2987869	ENSG00000227373.4	RP11-160H22.5	-4.73	2.92e-06	0.000336	-0.3	-0.21	Systemic lupus erythematosus;	chr1:174820269	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.827	rs1793309	ENSG00000227373.4	RP11-160H22.5	-4.73	2.92e-06	0.000336	-0.3	-0.21	Systemic lupus erythematosus;	chr1:174826199	chr1:174115300~174160004:-
THCA	cis	rs6088580	0.634	rs6059896	ENSG00000276073.1	RP5-1125A11.7	-4.73	2.92e-06	0.000336	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34523978	chr20:33985617~33988989:-
THCA	cis	rs4072705	0.586	rs7869042	ENSG00000224020.1	MIR181A2HG	4.73	2.92e-06	0.000336	0.2	0.21	Menarche (age at onset);	chr9:124484472	chr9:124658467~124698631:+
THCA	cis	rs9868809	0.772	rs9836462	ENSG00000270441.1	RP11-694I15.7	-4.73	2.92e-06	0.000337	-0.26	-0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48675358	chr3:49140086~49160851:-
THCA	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-4.73	2.92e-06	0.000337	-0.13	-0.21	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
THCA	cis	rs7702057	0.53	rs74583480	ENSG00000272265.1	CTD-2287O16.4	4.73	2.92e-06	0.000337	0.38	0.21	Amyotrophic lateral sclerosis;	chr5:116085200	chr5:116078110~116078570:-
THCA	cis	rs35740288	0.787	rs35250181	ENSG00000259295.5	CSPG4P12	4.73	2.92e-06	0.000337	0.33	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85699431	chr15:85191438~85213905:+
THCA	cis	rs2439831	0.867	rs8039638	ENSG00000166763.7	STRCP1	4.73	2.92e-06	0.000337	0.29	0.21	Lung cancer in ever smokers;	chr15:43342207	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs28415933	ENSG00000166763.7	STRCP1	4.73	2.92e-06	0.000337	0.29	0.21	Lung cancer in ever smokers;	chr15:43343602	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs12324572	ENSG00000166763.7	STRCP1	4.73	2.92e-06	0.000337	0.29	0.21	Lung cancer in ever smokers;	chr15:43344002	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2412779	ENSG00000166763.7	STRCP1	4.73	2.92e-06	0.000337	0.29	0.21	Lung cancer in ever smokers;	chr15:43363729	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.867	rs2899082	ENSG00000166763.7	STRCP1	4.73	2.92e-06	0.000337	0.29	0.21	Lung cancer in ever smokers;	chr15:43363845	chr15:43699488~43718184:-
THCA	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-4.73	2.92e-06	0.000337	-0.24	-0.21	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
THCA	cis	rs9300255	0.602	rs1790126	ENSG00000235423.7	RP11-282O18.3	4.73	2.92e-06	0.000337	0.22	0.21	Neutrophil percentage of white cells;	chr12:123199016	chr12:123252030~123261483:-
THCA	cis	rs9652601	0.665	rs17805769	ENSG00000274038.1	RP11-66H6.4	-4.73	2.92e-06	0.000337	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11092016	chr16:11056556~11057034:+
THCA	cis	rs8067545	0.611	rs2526477	ENSG00000270091.1	RP11-78O7.2	4.73	2.92e-06	0.000337	0.16	0.21	Schizophrenia;	chr17:20227880	chr17:19896590~19897287:-
THCA	cis	rs34286592	1	rs13331733	ENSG00000214725.6	CDIPT-AS1	-4.73	2.93e-06	0.000337	-0.4	-0.21	Multiple sclerosis;	chr16:29837096	chr16:29863593~29868053:+
THCA	cis	rs9307551	0.619	rs1074134	ENSG00000250334.4	LINC00989	-4.73	2.93e-06	0.000337	-0.26	-0.21	Refractive error;	chr4:79503752	chr4:79492416~79576460:+
THCA	cis	rs79349575	0.594	rs1985785	ENSG00000270781.1	RP11-501C14.9	-4.73	2.93e-06	0.000337	-0.26	-0.21	Type 2 diabetes;	chr17:48890426	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.685	rs1124829	ENSG00000270781.1	RP11-501C14.9	-4.73	2.93e-06	0.000337	-0.26	-0.21	Type 2 diabetes;	chr17:48890435	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.721	rs1008834	ENSG00000270781.1	RP11-501C14.9	-4.73	2.93e-06	0.000337	-0.26	-0.21	Type 2 diabetes;	chr17:48890646	chr17:48899131~48899748:+
THCA	cis	rs4767841	0.935	rs7131914	ENSG00000248636.5	RP11-768F21.1	-4.73	2.93e-06	0.000337	-0.22	-0.21	Urgency urinary incontinence;	chr12:119717772	chr12:119387987~119668079:-
THCA	cis	rs763121	0.853	rs3788544	ENSG00000228274.3	RP3-508I15.9	-4.73	2.93e-06	0.000337	-0.23	-0.21	Menopause (age at onset);	chr22:38668961	chr22:38667585~38681820:-
THCA	cis	rs752010	0.746	rs11210499	ENSG00000230638.4	RP11-486B10.4	4.73	2.93e-06	0.000337	0.23	0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41624032	chr1:41542069~41544310:+
THCA	cis	rs10208649	0.536	rs12613353	ENSG00000233266.1	HMGB1P31	4.73	2.93e-06	0.000337	0.32	0.21	Body mass index;	chr2:53747086	chr2:54051334~54051760:+
THCA	cis	rs7166081	0.738	rs28399271	ENSG00000270964.1	RP11-502I4.3	-4.73	2.93e-06	0.000337	-0.19	-0.21	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67417673	chr15:67541072~67542604:-
THCA	cis	rs10411161	0.702	rs10414472	ENSG00000275055.1	CTC-471J1.11	-4.73	2.93e-06	0.000337	-0.21	-0.21	Breast cancer;	chr19:51895344	chr19:52049007~52049754:+
THCA	cis	rs2287838	0.967	rs11669872	ENSG00000267289.1	CTD-2623N2.11	-4.73	2.93e-06	0.000337	-0.25	-0.21	Sleep duration;	chr19:9875848	chr19:9834079~9835013:-
THCA	cis	rs62025270	0.632	rs62022920	ENSG00000259295.5	CSPG4P12	-4.73	2.93e-06	0.000338	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85191438~85213905:+
THCA	cis	rs4415084	1	rs7735881	ENSG00000272335.1	RP11-53O19.3	-4.73	2.93e-06	0.000338	-0.17	-0.21	Breast cancer;	chr5:44650074	chr5:44826076~44828592:+
THCA	cis	rs11846409	0.86	rs1858692	ENSG00000274576.2	IGHV2-70	4.73	2.93e-06	0.000338	0.19	0.21	Rheumatic heart disease;	chr14:106622776	chr14:106770577~106771020:-
THCA	cis	rs9625935	0.917	rs5752993	ENSG00000279159.1	RP3-394A18.1	4.73	2.93e-06	0.000338	0.17	0.21	Tonsillectomy;	chr22:29991171	chr22:29978950~30028236:-
THCA	cis	rs972578	0.601	rs4820498	ENSG00000274717.1	RP1-47A17.1	-4.73	2.93e-06	0.000338	-0.22	-0.21	Mean platelet volume;	chr22:42931575	chr22:42791814~42794313:-
THCA	cis	rs9876781	1	rs1109227	ENSG00000244380.1	RP11-24C3.2	4.73	2.93e-06	0.000338	0.25	0.21	Longevity;	chr3:48437797	chr3:48440352~48446656:-
THCA	cis	rs2948294	0.566	rs13261997	ENSG00000254153.1	CTA-398F10.2	-4.73	2.93e-06	0.000338	-0.23	-0.21	Red cell distribution width;	chr8:8254773	chr8:8456909~8461337:-
THCA	cis	rs6806253	0.555	rs4857853	ENSG00000239405.1	TMED10P2	4.73	2.93e-06	0.000338	0.31	0.21	Pit-and-Fissure caries;	chr3:128526638	chr3:128538020~128538631:+
THCA	cis	rs4915077	1	rs78287223	ENSG00000230489.1	VAV3-AS1	4.73	2.93e-06	0.000338	0.36	0.21	Hypothyroidism;	chr1:107780024	chr1:107964443~107994607:+
THCA	cis	rs9902453	0.765	rs3115087	ENSG00000263370.1	RP11-68I3.5	4.73	2.93e-06	0.000338	0.28	0.21	Coffee consumption (cups per day);	chr17:29703249	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.817	rs3115089	ENSG00000263370.1	RP11-68I3.5	4.73	2.93e-06	0.000338	0.28	0.21	Coffee consumption (cups per day);	chr17:29704863	chr17:29639627~29640825:+
THCA	cis	rs1030877	0.515	rs1020064	ENSG00000235319.1	AC012360.4	-4.73	2.93e-06	0.000338	-0.27	-0.21	Obesity-related traits;	chr2:105281283	chr2:105324210~105330529:+
THCA	cis	rs1030877	0.515	rs2576741	ENSG00000235319.1	AC012360.4	-4.73	2.93e-06	0.000338	-0.27	-0.21	Obesity-related traits;	chr2:105281507	chr2:105324210~105330529:+
THCA	cis	rs6005807	0.543	rs6005868	ENSG00000226471.5	CTA-292E10.6	-4.73	2.93e-06	0.000338	-0.26	-0.21	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28769778	chr22:28800683~28848559:+
THCA	cis	rs7474896	0.537	rs1208591	ENSG00000120555.12	SEPT7P9	4.73	2.94e-06	0.000338	0.28	0.21	Obesity (extreme);	chr10:37923574	chr10:38383069~38402916:-
THCA	cis	rs1048886	0.938	rs9446252	ENSG00000271967.1	RP11-134K13.4	-4.73	2.94e-06	0.000338	-0.21	-0.21	Type 2 diabetes;	chr6:70444171	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs6918393	ENSG00000271967.1	RP11-134K13.4	-4.73	2.94e-06	0.000338	-0.21	-0.21	Type 2 diabetes;	chr6:70451613	chr6:70596438~70596980:+
THCA	cis	rs6570726	0.905	rs377143	ENSG00000270638.1	RP3-466P17.1	4.73	2.94e-06	0.000338	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145735570~145737218:+
THCA	cis	rs1003719	0.788	rs1543750	ENSG00000230366.8	DSCR9	-4.73	2.94e-06	0.000338	-0.21	-0.21	Eye color traits;	chr21:37074618	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs4817843	ENSG00000230366.8	DSCR9	-4.73	2.94e-06	0.000338	-0.21	-0.21	Eye color traits;	chr21:37074740	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs4817845	ENSG00000230366.8	DSCR9	-4.73	2.94e-06	0.000338	-0.21	-0.21	Eye color traits;	chr21:37074832	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs6517402	ENSG00000230366.8	DSCR9	-4.73	2.94e-06	0.000338	-0.21	-0.21	Eye color traits;	chr21:37075123	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs8133549	ENSG00000230366.8	DSCR9	-4.73	2.94e-06	0.000338	-0.21	-0.21	Eye color traits;	chr21:37075189	chr21:37208503~37221736:+
THCA	cis	rs11633886	0.63	rs8040587	ENSG00000273972.1	CTD-2306A12.1	-4.73	2.94e-06	0.000338	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45822724	chr15:45702640~45703183:+
THCA	cis	rs7577696	0.962	rs13022197	ENSG00000276334.1	AL133243.1	-4.73	2.94e-06	0.000338	-0.22	-0.21	Inflammatory biomarkers;	chr2:32118098	chr2:32521927~32523547:+
THCA	cis	rs9634489	0.588	rs4773948	ENSG00000247400.3	DNAJC3-AS1	-4.73	2.94e-06	0.000338	-0.14	-0.21	Body mass index;	chr13:96277719	chr13:95648733~95676925:-
THCA	cis	rs7829975	0.533	rs35900578	ENSG00000233609.3	RP11-62H7.2	4.73	2.94e-06	0.000338	0.21	0.21	Mood instability;	chr8:8862003	chr8:8961200~8979025:+
THCA	cis	rs10256972	0.758	rs7799391	ENSG00000225146.1	AC073957.15	4.73	2.94e-06	0.000338	0.22	0.21	Endometriosis;Longevity;	chr7:1042930	chr7:1029025~1043891:+
THCA	cis	rs7620503	0.516	rs1566409	ENSG00000228561.2	RP11-114M1.1	4.73	2.94e-06	0.000338	0.24	0.21	Corneal structure;	chr3:177616400	chr3:177683627~177691250:+
THCA	cis	rs12030196	0.827	rs932773	ENSG00000230812.4	LINC01358	-4.73	2.94e-06	0.000338	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58967949	chr1:59020387~59044614:+
THCA	cis	rs6490294	0.528	rs12582100	ENSG00000226469.1	ADAM1B	4.73	2.94e-06	0.000339	0.35	0.21	Mean platelet volume;	chr12:111941105	chr12:111927018~111929017:+
THCA	cis	rs6860806	0.507	rs273912	ENSG00000224431.1	AC063976.7	-4.73	2.94e-06	0.000339	-0.19	-0.21	Breast cancer;	chr5:132325656	chr5:132199456~132203487:+
THCA	cis	rs9475752	0.723	rs16888222	ENSG00000231441.1	RP11-472M19.2	4.73	2.94e-06	0.000339	0.23	0.21	Menarche (age at onset);	chr6:56902360	chr6:56844002~56864078:+
THCA	cis	rs9959145	0.866	rs78596711	ENSG00000267108.1	RP11-861E21.1	4.73	2.94e-06	0.000339	0.26	0.21	Immune response to smallpox vaccine (IL-6);	chr18:12732779	chr18:12432897~12437635:+
THCA	cis	rs7772486	0.72	rs6901888	ENSG00000270638.1	RP3-466P17.1	-4.73	2.94e-06	0.000339	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs4896841	ENSG00000270638.1	RP3-466P17.1	-4.73	2.94e-06	0.000339	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145735570~145737218:+
THCA	cis	rs17801127	0.818	rs73003921	ENSG00000231969.1	AC144449.1	4.73	2.94e-06	0.000339	0.44	0.21	Liver enzyme levels (alanine transaminase);	chr2:149844297	chr2:149587196~149848233:+
THCA	cis	rs7615952	0.546	rs2979333	ENSG00000171084.14	FAM86JP	4.73	2.94e-06	0.000339	0.28	0.21	Blood pressure (smoking interaction);	chr3:125641499	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.546	rs111812401	ENSG00000171084.14	FAM86JP	4.73	2.94e-06	0.000339	0.28	0.21	Blood pressure (smoking interaction);	chr3:125642651	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.546	rs2979350	ENSG00000171084.14	FAM86JP	4.73	2.94e-06	0.000339	0.28	0.21	Blood pressure (smoking interaction);	chr3:125643371	chr3:125916620~125930024:+
THCA	cis	rs748404	0.706	rs57728767	ENSG00000205771.5	CATSPER2P1	-4.73	2.94e-06	0.000339	-0.28	-0.21	Lung cancer;	chr15:43473639	chr15:43726918~43747094:-
THCA	cis	rs10090774	0.965	rs11786709	ENSG00000279766.1	RP11-642A1.2	-4.73	2.94e-06	0.000339	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140991849	chr8:140572142~140572812:-
THCA	cis	rs6951245	1	rs78308415	ENSG00000229043.2	AC091729.9	-4.73	2.94e-06	0.000339	-0.37	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032998	chr7:1160374~1165267:+
THCA	cis	rs7560272	0.538	rs12233112	ENSG00000163016.8	ALMS1P	-4.73	2.95e-06	0.000339	-0.27	-0.21	Schizophrenia;	chr2:73704637	chr2:73644919~73685576:+
THCA	cis	rs7412746	0.658	rs12405726	ENSG00000231073.1	RP11-316M1.3	4.73	2.95e-06	0.000339	0.26	0.21	Melanoma;	chr1:150983652	chr1:150973123~150975534:+
THCA	cis	rs763121	0.853	rs4820345	ENSG00000228274.3	RP3-508I15.9	-4.73	2.95e-06	0.000339	-0.24	-0.21	Menopause (age at onset);	chr22:38695146	chr22:38667585~38681820:-
THCA	cis	rs1923243	0.587	rs12127282	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.000339	0.24	0.21	Migraine;	chr1:72930949	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs4650165	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.000339	0.24	0.21	Migraine;	chr1:72931049	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs12760667	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.000339	0.24	0.21	Migraine;	chr1:72933201	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs4650167	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.000339	0.24	0.21	Migraine;	chr1:72940533	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.617	rs12724056	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.000339	0.24	0.21	Migraine;	chr1:72941967	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs12745861	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.000339	0.24	0.21	Migraine;	chr1:72949331	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.559	rs6682845	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.000339	0.24	0.21	Migraine;	chr1:72950162	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs11210095	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.000339	0.24	0.21	Migraine;	chr1:72952773	chr1:73635216~73715214:+
THCA	cis	rs17767392	0.813	rs11848785	ENSG00000259146.3	RP1-261D10.2	-4.73	2.95e-06	0.000339	-0.27	-0.21	Mitral valve prolapse;	chr14:71590638	chr14:71292729~71321814:-
THCA	cis	rs7131987	0.903	rs10843367	ENSG00000275476.1	RP11-996F15.4	-4.73	2.95e-06	0.000339	-0.21	-0.21	QT interval;	chr12:29255447	chr12:29277397~29277882:-
THCA	cis	rs793571	0.518	rs12912327	ENSG00000245975.2	RP11-30K9.6	4.73	2.95e-06	0.000339	0.25	0.21	Schizophrenia;	chr15:58693935	chr15:58768072~58770974:-
THCA	cis	rs2980439	0.783	rs2948305	ENSG00000254153.1	CTA-398F10.2	-4.73	2.95e-06	0.00034	-0.23	-0.21	Neuroticism;	chr8:8241055	chr8:8456909~8461337:-
THCA	cis	rs793571	0.554	rs12906714	ENSG00000245975.2	RP11-30K9.6	4.73	2.95e-06	0.00034	0.25	0.21	Schizophrenia;	chr15:58632821	chr15:58768072~58770974:-
THCA	cis	rs10946940	0.93	rs10807029	ENSG00000219392.1	RP1-265C24.5	4.73	2.95e-06	0.00034	0.25	0.21	Systemic lupus erythematosus;	chr6:27605684	chr6:28115628~28116551:+
THCA	cis	rs7404843	0.733	rs153003	ENSG00000263335.1	AF001548.5	4.73	2.95e-06	0.00034	0.33	0.21	Testicular germ cell tumor;	chr16:15397543	chr16:15726674~15732993:+
THCA	cis	rs12755164	0.724	rs1852232	ENSG00000223479.3	RP4-788P17.1	4.73	2.95e-06	0.00034	0.24	0.21	Schizophrenia;	chr1:72867836	chr1:73635216~73715214:+
THCA	cis	rs7537765	0.947	rs13306561	ENSG00000242349.4	NPPA-AS1	-4.73	2.95e-06	0.00034	-0.28	-0.21	QRS complex (12-leadsum);	chr1:11805747	chr1:11841017~11848079:+
THCA	cis	rs72717009	0.756	rs10494359	ENSG00000225217.1	HSPA7	-4.73	2.95e-06	0.00034	-0.33	-0.21	Rheumatoid arthritis;	chr1:161494086	chr1:161606291~161608217:+
THCA	cis	rs78487399	0.908	rs75664918	ENSG00000234936.1	AC010883.5	4.73	2.95e-06	0.00034	0.27	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43611951	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs10186307	ENSG00000234936.1	AC010883.5	4.73	2.95e-06	0.00034	0.27	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43612757	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs10186441	ENSG00000234936.1	AC010883.5	4.73	2.95e-06	0.00034	0.27	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43612909	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs7602701	ENSG00000234936.1	AC010883.5	4.73	2.95e-06	0.00034	0.27	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43613980	chr2:43229573~43233394:+
THCA	cis	rs7618915	0.501	rs10865974	ENSG00000243224.1	RP5-1157M23.2	4.73	2.95e-06	0.00034	0.23	0.21	Bipolar disorder;	chr3:52684264	chr3:52239258~52241097:+
THCA	cis	rs227275	0.524	rs223337	ENSG00000248971.2	KRT8P46	-4.73	2.96e-06	0.00034	-0.26	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102728746~102730171:-
THCA	cis	rs7942368	1	rs1440979	ENSG00000261578.1	RP11-21L23.2	4.73	2.96e-06	0.00034	0.31	0.21	Endometriosis;	chr11:76784085	chr11:76800364~76804555:+
THCA	cis	rs11073619	0.803	rs7180895	ENSG00000230373.7	GOLGA6L5P	4.73	2.96e-06	0.00034	0.31	0.21	Positive affect;	chr15:84614489	chr15:84507885~84516814:-
THCA	cis	rs13113518	0.702	rs78829811	ENSG00000273257.1	RP11-177J6.1	4.73	2.96e-06	0.00034	0.29	0.21	Height;	chr4:55558258	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.702	rs75801206	ENSG00000273257.1	RP11-177J6.1	4.73	2.96e-06	0.00034	0.29	0.21	Height;	chr4:55558259	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.702	rs34658078	ENSG00000273257.1	RP11-177J6.1	4.73	2.96e-06	0.00034	0.29	0.21	Height;	chr4:55558261	chr4:55387949~55388271:+
THCA	cis	rs9527	0.525	rs12770034	ENSG00000213061.2	PFN1P11	4.73	2.96e-06	0.00034	0.26	0.21	Arsenic metabolism;	chr10:102875838	chr10:102838011~102845473:-
THCA	cis	rs9634489	0.588	rs7331395	ENSG00000247400.3	DNAJC3-AS1	-4.73	2.96e-06	0.00034	-0.14	-0.21	Body mass index;	chr13:96284021	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.588	rs7336212	ENSG00000247400.3	DNAJC3-AS1	-4.73	2.96e-06	0.00034	-0.14	-0.21	Body mass index;	chr13:96284215	chr13:95648733~95676925:-
THCA	cis	rs7637701	0.773	rs4098	ENSG00000240875.4	LINC00886	-4.73	2.96e-06	0.00034	-0.16	-0.21	Breast cancer;	chr3:156783274	chr3:156747346~156817062:-
THCA	cis	rs2018683	0.523	rs1499224	ENSG00000272568.4	CTB-113D17.1	4.73	2.96e-06	0.00034	0.22	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28989852	chr7:28979967~29013367:+
THCA	cis	rs288326	0.561	rs77024950	ENSG00000272800.1	RP11-438L19.1	4.73	2.96e-06	0.00034	0.39	0.21	Blood protein levels;	chr2:182932499	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs79096460	ENSG00000272800.1	RP11-438L19.1	4.73	2.96e-06	0.00034	0.39	0.21	Blood protein levels;	chr2:182933949	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs77184695	ENSG00000272800.1	RP11-438L19.1	4.73	2.96e-06	0.00034	0.39	0.21	Blood protein levels;	chr2:182937845	chr2:183214319~183215400:+
THCA	cis	rs1003719	0.788	rs2835582	ENSG00000230366.8	DSCR9	-4.73	2.96e-06	0.00034	-0.21	-0.21	Eye color traits;	chr21:37086473	chr21:37208503~37221736:+
THCA	cis	rs72945132	0.882	rs11235739	ENSG00000254604.1	AP000487.6	-4.73	2.96e-06	0.00034	-0.39	-0.21	Coronary artery disease;	chr11:70286674	chr11:70282367~70363368:-
THCA	cis	rs800160	0.925	rs2097686	ENSG00000199550.1	Y_RNA	4.73	2.96e-06	0.00034	0.31	0.21	Bacteremia;	chr11:2362171	chr11:2372638~2372750:+
THCA	cis	rs427394	0.735	rs416689	ENSG00000248677.1	CTD-2044J15.1	4.73	2.96e-06	0.000341	0.2	0.21	Menopause (age at onset);	chr5:6740742	chr5:6686325~6707711:-
THCA	cis	rs73198271	0.729	rs66564323	ENSG00000253893.2	FAM85B	4.73	2.96e-06	0.000341	0.34	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747486	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.729	rs67653033	ENSG00000253893.2	FAM85B	4.73	2.96e-06	0.000341	0.34	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747534	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.729	rs67000451	ENSG00000253893.2	FAM85B	4.73	2.96e-06	0.000341	0.34	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8747573	chr8:8167819~8226614:-
THCA	cis	rs1876905	0.539	rs240969	ENSG00000255389.1	C6orf3	-4.73	2.96e-06	0.000341	-0.26	-0.21	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111599875~111602295:+
THCA	cis	rs1048886	0.872	rs7773794	ENSG00000271967.1	RP11-134K13.4	-4.73	2.96e-06	0.000341	-0.22	-0.21	Type 2 diabetes;	chr6:70516647	chr6:70596438~70596980:+
THCA	cis	rs11157436	0.958	rs17183308	ENSG00000211812.1	TRAV26-2	-4.73	2.96e-06	0.000341	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22202583~22203368:+
THCA	cis	rs2562456	0.833	rs1626404	ENSG00000268117.1	VN1R84P	4.73	2.96e-06	0.000341	0.35	0.21	Pain;	chr19:21300986	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs1781867	ENSG00000268117.1	VN1R84P	4.73	2.96e-06	0.000341	0.35	0.21	Pain;	chr19:21304368	chr19:21719801~21720035:-
THCA	cis	rs4415084	1	rs6874055	ENSG00000272335.1	RP11-53O19.3	-4.73	2.96e-06	0.000341	-0.17	-0.21	Breast cancer;	chr5:44666863	chr5:44826076~44828592:+
THCA	cis	rs6973609	0.554	rs17616342	ENSG00000271122.1	RP11-379H18.1	4.73	2.96e-06	0.000341	0.15	0.21	Obesity-related traits;	chr7:35567112	chr7:35695214~35699413:+
THCA	cis	rs453301	0.507	rs2929306	ENSG00000253981.4	ALG1L13P	-4.73	2.96e-06	0.000341	-0.2	-0.21	Joint mobility (Beighton score);	chr8:9227399	chr8:8236003~8244667:-
THCA	cis	rs8027521	0.666	rs7175118	ENSG00000280362.1	RP11-643A5.3	4.73	2.96e-06	0.000341	0.27	0.21	Circulating chemerin levels;	chr15:53977642	chr15:53910769~53914712:+
THCA	cis	rs12755164	0.778	rs12752778	ENSG00000223479.3	RP4-788P17.1	4.73	2.96e-06	0.000341	0.24	0.21	Schizophrenia;	chr1:72883731	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.778	rs1525981	ENSG00000223479.3	RP4-788P17.1	4.73	2.96e-06	0.000341	0.24	0.21	Schizophrenia;	chr1:72889045	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.724	rs61774086	ENSG00000223479.3	RP4-788P17.1	4.73	2.96e-06	0.000341	0.24	0.21	Schizophrenia;	chr1:72891143	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.778	rs12136682	ENSG00000223479.3	RP4-788P17.1	4.73	2.96e-06	0.000341	0.24	0.21	Schizophrenia;	chr1:72895510	chr1:73635216~73715214:+
THCA	cis	rs9990333	0.562	rs12632706	ENSG00000273009.1	RP11-352G9.1	-4.73	2.96e-06	0.000341	-0.24	-0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195913078~195913683:-
THCA	cis	rs13287066	0.669	rs10992728	ENSG00000227603.1	RP11-165J3.6	4.73	2.97e-06	0.000341	0.22	0.21	Intelligence (multi-trait analysis);	chr9:93416386	chr9:93435332~93437121:-
THCA	cis	rs8141529	0.702	rs469991	ENSG00000226471.5	CTA-292E10.6	4.73	2.97e-06	0.000341	0.18	0.21	Lymphocyte counts;	chr22:28911871	chr22:28800683~28848559:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-4.73	2.97e-06	0.000341	-0.24	-0.21	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
THCA	cis	rs9307551	0.584	rs12510243	ENSG00000250334.4	LINC00989	-4.73	2.97e-06	0.000342	-0.25	-0.21	Refractive error;	chr4:79551905	chr4:79492416~79576460:+
THCA	cis	rs7914558	0.901	rs1926034	ENSG00000236937.2	PTGES3P4	4.73	2.97e-06	0.000342	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103069345	chr10:102845595~102845950:+
THCA	cis	rs2412819	0.571	rs2729494	ENSG00000166763.7	STRCP1	-4.73	2.97e-06	0.000342	-0.28	-0.21	Lung cancer;	chr15:43837395	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs528764	ENSG00000166763.7	STRCP1	-4.73	2.97e-06	0.000342	-0.28	-0.21	Lung cancer;	chr15:43838650	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs495880	ENSG00000166763.7	STRCP1	-4.73	2.97e-06	0.000342	-0.28	-0.21	Lung cancer;	chr15:43855067	chr15:43699488~43718184:-
THCA	cis	rs2018683	0.624	rs1006521	ENSG00000272568.4	CTB-113D17.1	4.73	2.97e-06	0.000342	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28979967~29013367:+
THCA	cis	rs6832769	0.961	rs1011095	ENSG00000272969.1	RP11-528I4.2	4.73	2.97e-06	0.000342	0.25	0.21	Personality dimensions;	chr4:55398774	chr4:55547112~55547889:+
THCA	cis	rs875971	0.545	rs12670811	ENSG00000232546.1	RP11-458F8.1	4.73	2.97e-06	0.000342	0.2	0.21	Aortic root size;	chr7:66358032	chr7:66848496~66858136:+
THCA	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	4.73	2.97e-06	0.000342	0.21	0.21	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
THCA	cis	rs7617480	0.648	rs9882443	ENSG00000229759.1	MRPS18AP1	4.73	2.97e-06	0.000342	0.33	0.21	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48711631	chr3:48256350~48256938:-
THCA	cis	rs7191700	0.511	rs243330	ENSG00000263080.1	RP11-485G7.5	4.73	2.97e-06	0.000342	0.24	0.21	Multiple sclerosis;	chr16:11257134	chr16:11341809~11345211:-
THCA	cis	rs17826219	0.568	rs59858012	ENSG00000280069.1	CTD-2349P21.3	-4.73	2.97e-06	0.000342	-0.36	-0.21	Body mass index;	chr17:30751564	chr17:30738182~30740275:+
THCA	cis	rs7267979	0.932	rs928121	ENSG00000274973.1	RP13-401N8.7	-4.73	2.97e-06	0.000342	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25845497~25845862:+
THCA	cis	rs796395	0.664	rs2993047	ENSG00000232480.1	TGFB2-AS1	-4.73	2.98e-06	0.000342	-0.24	-0.21	Post bronchodilator FEV1/FVC ratio;	chr1:218511713	chr1:218344196~218345678:-
THCA	cis	rs8050907	0.744	rs8063084	ENSG00000278434.1	RP11-709D24.8	-4.73	2.98e-06	0.000342	-0.47	-0.21	Obesity-related traits;	chr16:4486554	chr16:4532216~4533670:-
THCA	cis	rs944289	0.966	rs1169146	ENSG00000258844.1	RP11-259K15.2	4.73	2.98e-06	0.000342	0.2	0.21	Thyroid cancer;	chr14:36163563	chr14:36214607~36235608:+
THCA	cis	rs71636778	0.543	rs113002196	ENSG00000260063.1	RP5-968P14.2	-4.73	2.98e-06	0.000342	-0.3	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26873665	chr1:26692132~26694131:-
THCA	cis	rs321358	0.731	rs516110	ENSG00000271584.1	RP11-89C3.4	4.73	2.98e-06	0.000342	0.34	0.21	Body mass index;	chr11:111166525	chr11:111091932~111097357:-
THCA	cis	rs5751614	1	rs1004040	ENSG00000230701.2	FBXW4P1	4.73	2.98e-06	0.000342	0.21	0.21	Height;	chr22:23242945	chr22:23262767~23265005:+
THCA	cis	rs902774	0.53	rs11834907	ENSG00000278185.1	RP11-153F5.7	4.73	2.98e-06	0.000342	0.34	0.21	Prostate cancer;	chr12:52957201	chr12:52946614~52947125:-
THCA	cis	rs7824557	0.688	rs2572397	ENSG00000154316.13	TDH	-4.73	2.98e-06	0.000342	-0.16	-0.21	Retinal vascular caliber;	chr8:11318894	chr8:11339637~11368452:+
THCA	cis	rs9283706	0.594	rs1428405	ENSG00000229666.1	MAST4-AS1	-4.73	2.98e-06	0.000342	-0.31	-0.21	Coronary artery disease;	chr5:67031365	chr5:67001383~67003953:-
THCA	cis	rs12049671	0.858	rs932837	ENSG00000227076.1	RP11-4C20.4	4.73	2.98e-06	0.000343	0.24	0.21	Response to amphetamines;	chr10:127938213	chr10:127934698~127936167:+
THCA	cis	rs587080	0.624	rs512715	ENSG00000254614.2	AP003068.23	-4.73	2.98e-06	0.000343	-0.29	-0.21	Plateletcrit;	chr11:65423737	chr11:65177606~65181834:-
THCA	cis	rs6921919	0.638	rs7772827	ENSG00000273712.1	RP5-874C20.7	4.73	2.98e-06	0.000343	0.25	0.21	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28315613~28315883:-
THCA	cis	rs8028182	0.636	rs7175852	ENSG00000260274.1	RP11-817O13.8	4.73	2.98e-06	0.000343	0.15	0.21	Sudden cardiac arrest;	chr15:75402194	chr15:75368155~75369584:+
THCA	cis	rs78487399	0.71	rs17030798	ENSG00000234936.1	AC010883.5	-4.73	2.98e-06	0.000343	-0.3	-0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43443044	chr2:43229573~43233394:+
THCA	cis	rs8141529	0.843	rs1065497	ENSG00000226471.5	CTA-292E10.6	-4.73	2.98e-06	0.000343	-0.18	-0.21	Lymphocyte counts;	chr22:28884003	chr22:28800683~28848559:+
THCA	cis	rs9880211	1	rs35899944	ENSG00000239213.4	NCK1-AS1	4.73	2.98e-06	0.000343	0.23	0.21	Height;Body mass index;	chr3:136510215	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs9878078	ENSG00000239213.4	NCK1-AS1	4.73	2.98e-06	0.000343	0.23	0.21	Height;Body mass index;	chr3:136518731	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs28811905	ENSG00000239213.4	NCK1-AS1	4.73	2.98e-06	0.000343	0.23	0.21	Height;Body mass index;	chr3:136533210	chr3:136841726~136862054:-
THCA	cis	rs427394	0.802	rs274712	ENSG00000248677.1	CTD-2044J15.1	4.73	2.98e-06	0.000343	0.2	0.21	Menopause (age at onset);	chr5:6723837	chr5:6686325~6707711:-
THCA	cis	rs427394	0.802	rs274698	ENSG00000248677.1	CTD-2044J15.1	4.73	2.98e-06	0.000343	0.2	0.21	Menopause (age at onset);	chr5:6730844	chr5:6686325~6707711:-
THCA	cis	rs427394	0.802	rs274694	ENSG00000248677.1	CTD-2044J15.1	4.73	2.98e-06	0.000343	0.2	0.21	Menopause (age at onset);	chr5:6733966	chr5:6686325~6707711:-
THCA	cis	rs427394	0.772	rs274689	ENSG00000248677.1	CTD-2044J15.1	4.73	2.98e-06	0.000343	0.2	0.21	Menopause (age at onset);	chr5:6736102	chr5:6686325~6707711:-
THCA	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-4.73	2.98e-06	0.000343	-0.24	-0.21	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
THCA	cis	rs12823128	0.819	rs7957289	ENSG00000256185.1	RP11-612B6.2	4.73	2.98e-06	0.000343	0.2	0.21	Birth weight;	chr12:26716300	chr12:26335864~26336950:-
THCA	cis	rs10208649	1	rs17045242	ENSG00000233266.1	HMGB1P31	4.73	2.98e-06	0.000343	0.5	0.21	Body mass index;	chr2:53806326	chr2:54051334~54051760:+
THCA	cis	rs6600671	0.899	rs11249432	ENSG00000275585.1	CH17-118O6.3	-4.73	2.98e-06	0.000343	-0.26	-0.21	Hip geometry;	chr1:121541678	chr1:120985692~121052167:-
THCA	cis	rs2985684	0.948	rs12897941	ENSG00000278009.1	RP11-649E7.8	4.73	2.99e-06	0.000343	0.29	0.21	Carotid intima media thickness;	chr14:49549983	chr14:49601011~49601124:-
THCA	cis	rs9625935	0.778	rs4820822	ENSG00000279159.1	RP3-394A18.1	4.73	2.99e-06	0.000343	0.17	0.21	Tonsillectomy;	chr22:29849171	chr22:29978950~30028236:-
THCA	cis	rs7688540	0.8	rs6857106	ENSG00000275426.1	CH17-262A2.1	-4.73	2.99e-06	0.000343	-0.26	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:149738~150317:+
THCA	cis	rs1048886	0.938	rs7752409	ENSG00000271967.1	RP11-134K13.4	-4.73	2.99e-06	0.000343	-0.21	-0.21	Type 2 diabetes;	chr6:70476578	chr6:70596438~70596980:+
THCA	cis	rs3845817	0.838	rs697150	ENSG00000237979.1	AC007389.1	4.73	2.99e-06	0.000343	0.24	0.21	Bipolar disorder;	chr2:65522950	chr2:65500993~65502138:-
THCA	cis	rs4713118	0.505	rs156740	ENSG00000220721.1	OR1F12	4.73	2.99e-06	0.000344	0.23	0.21	Parkinson's disease;	chr6:27992657	chr6:28073316~28074233:+
THCA	cis	rs5742933	1	rs16831939	ENSG00000253559.1	OSGEPL1-AS1	-4.73	2.99e-06	0.000344	-0.26	-0.21	Ferritin levels;	chr2:189739282	chr2:189762704~189765556:+
THCA	cis	rs763121	0.889	rs1837988	ENSG00000235209.1	CTA-150C2.13	4.73	2.99e-06	0.000344	0.28	0.21	Menopause (age at onset);	chr22:38505089	chr22:38921227~38924708:+
THCA	cis	rs6860806	0.507	rs156322	ENSG00000237714.1	P4HA2-AS1	4.73	2.99e-06	0.000344	0.28	0.21	Breast cancer;	chr5:132318232	chr5:132184876~132192808:+
THCA	cis	rs10760158	0.865	rs7865779	ENSG00000235865.2	GSN-AS1	4.73	2.99e-06	0.000344	0.18	0.21	Pulse pressure;	chr9:121240519	chr9:121280768~121285530:-
THCA	cis	rs7246657	0.551	rs28462002	ENSG00000276846.1	CTD-3220F14.3	4.73	2.99e-06	0.000344	0.26	0.21	Coronary artery calcification;	chr19:37143560	chr19:37314868~37315620:-
THCA	cis	rs10510102	0.808	rs11200296	ENSG00000226864.1	ATE1-AS1	4.73	2.99e-06	0.000344	0.35	0.21	Breast cancer;	chr10:121971956	chr10:121928312~121951965:+
THCA	cis	rs10208649	0.611	rs3929001	ENSG00000233266.1	HMGB1P31	-4.73	2.99e-06	0.000344	-0.39	-0.21	Body mass index;	chr2:54055750	chr2:54051334~54051760:+
THCA	cis	rs7403037	0.617	rs4073701	ENSG00000259905.4	PWRN1	4.73	2.99e-06	0.000344	0.27	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24599765	chr15:24493137~24652130:+
THCA	cis	rs1032466	0.783	rs6572681	ENSG00000270062.1	RP11-248J18.3	-4.73	2.99e-06	0.000344	-0.25	-0.21	Dupuytren's disease;	chr14:50650341	chr14:50723777~50724272:-
THCA	cis	rs6860806	0.507	rs2631371	ENSG00000237714.1	P4HA2-AS1	-4.73	2.99e-06	0.000344	-0.29	-0.21	Breast cancer;	chr5:132367999	chr5:132184876~132192808:+
THCA	cis	rs13113518	0.934	rs11133397	ENSG00000273257.1	RP11-177J6.1	4.73	2.99e-06	0.000344	0.28	0.21	Height;	chr4:55534166	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.934	rs11133398	ENSG00000273257.1	RP11-177J6.1	4.73	2.99e-06	0.000344	0.28	0.21	Height;	chr4:55534180	chr4:55387949~55388271:+
THCA	cis	rs1124769	0.671	rs36004063	ENSG00000259378.1	DCAF13P3	4.73	2.99e-06	0.000344	0.33	0.21	Cognitive performance;	chr15:50938637	chr15:50944663~50945996:+
THCA	cis	rs459482	0.576	rs461448	ENSG00000228318.3	AP001610.5	-4.73	2.99e-06	0.000344	-0.26	-0.21	IgG glycosylation;	chr21:41428996	chr21:41441056~41445708:-
THCA	cis	rs4927850	1	rs6799572	ENSG00000185485.13	SDHAP1	4.73	2.99e-06	0.000344	0.18	0.21	Pancreatic cancer;	chr3:196013537	chr3:195959748~195990318:-
THCA	cis	rs7614311	0.681	rs73117083	ENSG00000271843.1	RP11-245J9.5	-4.73	2.99e-06	0.000344	-0.38	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63962779	chr3:64008082~64008692:-
THCA	cis	rs2447820	0.5	rs246278	ENSG00000249996.1	RP11-359P5.1	4.73	2.99e-06	0.000344	0.25	0.21	Migraine;	chr5:122905343	chr5:123036271~123054667:+
THCA	cis	rs9880211	1	rs9809988	ENSG00000239213.4	NCK1-AS1	4.73	2.99e-06	0.000344	0.23	0.21	Height;Body mass index;	chr3:136803379	chr3:136841726~136862054:-
THCA	cis	rs7838490	0.553	rs1601820	ENSG00000253553.4	RP11-586K2.1	4.73	2.99e-06	0.000344	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88471289	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs1601819	ENSG00000253553.4	RP11-586K2.1	4.73	2.99e-06	0.000344	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88471418	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs1685553	ENSG00000253553.4	RP11-586K2.1	4.73	2.99e-06	0.000344	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88471819	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs1685552	ENSG00000253553.4	RP11-586K2.1	4.73	2.99e-06	0.000344	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88471942	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs1700154	ENSG00000253553.4	RP11-586K2.1	4.73	2.99e-06	0.000344	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88471943	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.609	rs1685551	ENSG00000253553.4	RP11-586K2.1	4.73	2.99e-06	0.000344	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88473588	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs1617649	ENSG00000253553.4	RP11-586K2.1	4.73	2.99e-06	0.000344	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88473698	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs1685549	ENSG00000253553.4	RP11-586K2.1	4.73	2.99e-06	0.000344	0.22	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88474284	chr8:88326836~88737134:+
THCA	cis	rs10504861	0.502	rs821108	ENSG00000253553.4	RP11-586K2.1	-4.73	2.99e-06	0.000344	-0.22	-0.21	Migraine without aura;	chr8:88487868	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs821107	ENSG00000253553.4	RP11-586K2.1	-4.73	2.99e-06	0.000344	-0.22	-0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88488434	chr8:88326836~88737134:+
THCA	cis	rs3845817	0.832	rs702945	ENSG00000237979.1	AC007389.1	4.73	2.99e-06	0.000344	0.24	0.21	Bipolar disorder;	chr2:65534098	chr2:65500993~65502138:-
THCA	cis	rs6545883	0.507	rs2442025	ENSG00000270820.4	RP11-355B11.2	-4.73	3e-06	0.000344	-0.18	-0.21	Tuberculosis;	chr2:61344310	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.524	rs2593631	ENSG00000270820.4	RP11-355B11.2	-4.73	3e-06	0.000344	-0.18	-0.21	Tuberculosis;	chr2:61345151	chr2:61471188~61484130:+
THCA	cis	rs6545883	0.542	rs2593628	ENSG00000270820.4	RP11-355B11.2	-4.73	3e-06	0.000344	-0.18	-0.21	Tuberculosis;	chr2:61346152	chr2:61471188~61484130:+
THCA	cis	rs7665090	0.806	rs413967	ENSG00000251288.2	RP11-10L12.2	4.73	3e-06	0.000344	0.28	0.21	Primary biliary cholangitis;	chr4:102662039	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.806	rs404574	ENSG00000251288.2	RP11-10L12.2	4.73	3e-06	0.000344	0.28	0.21	Primary biliary cholangitis;	chr4:102662051	chr4:102751401~102752641:+
THCA	cis	rs31251	0.903	rs11746464	ENSG00000224431.1	AC063976.7	4.73	3e-06	0.000344	0.18	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr5:131522034	chr5:132199456~132203487:+
THCA	cis	rs7914558	1	rs10883824	ENSG00000236937.2	PTGES3P4	4.73	3e-06	0.000344	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103053140	chr10:102845595~102845950:+
THCA	cis	rs12022452	0.822	rs11208390	ENSG00000237899.1	RP4-739H11.3	-4.73	3e-06	0.000345	-0.33	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40669089~40687588:-
THCA	cis	rs756699	0.908	rs30494	ENSG00000279469.1	RP11-215P8.2	-4.73	3e-06	0.000345	-0.32	-0.21	Multiple sclerosis;	chr5:134108259	chr5:134394360~134395008:-
THCA	cis	rs8141529	0.748	rs6005936	ENSG00000226471.5	CTA-292E10.6	-4.73	3e-06	0.000345	-0.18	-0.21	Lymphocyte counts;	chr22:28893262	chr22:28800683~28848559:+
THCA	cis	rs972578	0.715	rs12166809	ENSG00000274717.1	RP1-47A17.1	-4.73	3e-06	0.000345	-0.22	-0.21	Mean platelet volume;	chr22:42891284	chr22:42791814~42794313:-
THCA	cis	rs12554020	0.551	rs2989751	ENSG00000227603.1	RP11-165J3.6	-4.73	3e-06	0.000345	-0.24	-0.21	Schizophrenia;	chr9:93604365	chr9:93435332~93437121:-
THCA	cis	rs6714710	0.535	rs3192177	ENSG00000230606.9	AC159540.1	-4.73	3e-06	0.000345	-0.26	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97738048	chr2:97416165~97433527:-
THCA	cis	rs12823128	0.766	rs7316382	ENSG00000256185.1	RP11-612B6.2	4.73	3e-06	0.000345	0.2	0.21	Birth weight;	chr12:26771495	chr12:26335864~26336950:-
THCA	cis	rs6441961	0.501	rs41502550	ENSG00000223552.1	RP11-24F11.2	4.73	3e-06	0.000345	0.22	0.21	Celiac disease;	chr3:46238732	chr3:46364955~46407059:-
THCA	cis	rs6600671	0.966	rs6600664	ENSG00000275585.1	CH17-118O6.3	-4.73	3e-06	0.000345	-0.26	-0.21	Hip geometry;	chr1:121480638	chr1:120985692~121052167:-
THCA	cis	rs6600671	0.932	rs6600663	ENSG00000275585.1	CH17-118O6.3	-4.73	3e-06	0.000345	-0.26	-0.21	Hip geometry;	chr1:121480639	chr1:120985692~121052167:-
THCA	cis	rs7141336	0.728	rs11621422	ENSG00000258884.1	CTD-3035D6.2	4.73	3e-06	0.000345	0.29	0.21	Anxiety disorder;	chr14:90771254	chr14:90822365~90828128:-
THCA	cis	rs72945132	0.882	rs17160762	ENSG00000254604.1	AP000487.6	4.73	3e-06	0.000345	0.4	0.21	Coronary artery disease;	chr11:70288660	chr11:70282367~70363368:-
THCA	cis	rs9393777	0.844	rs28360634	ENSG00000280107.1	AL022393.9	-4.73	3e-06	0.000345	-0.4	-0.21	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28170845~28172521:+
THCA	cis	rs858239	0.539	rs870476	ENSG00000226816.2	AC005082.12	4.73	3e-06	0.000345	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23206013~23208045:+
THCA	cis	rs7851660	0.839	rs10818213	ENSG00000214417.4	KRT18P13	-4.73	3e-06	0.000345	-0.19	-0.21	Strep throat;	chr9:97886349	chr9:97698922~97700734:+
THCA	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-4.73	3e-06	0.000345	-0.24	-0.21	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-4.73	3e-06	0.000345	-0.24	-0.21	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-4.73	3e-06	0.000345	-0.24	-0.21	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
THCA	cis	rs2135507	1	rs2135507	ENSG00000270480.1	RP11-57B24.1	4.73	3e-06	0.000345	0.3	0.21	Juvenile osteochondritis dissecans;	chr4:82665518	chr4:82691737~82692468:+
THCA	cis	rs8177376	0.727	rs601985	ENSG00000254905.1	RP11-712L6.7	4.73	3e-06	0.000345	0.3	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327662	chr11:126292922~126294254:-
THCA	cis	rs4415084	1	rs13155752	ENSG00000272335.1	RP11-53O19.3	-4.73	3e-06	0.000345	-0.17	-0.21	Breast cancer;	chr5:44680585	chr5:44826076~44828592:+
THCA	cis	rs4908760	0.759	rs6577514	ENSG00000232912.4	RP5-1115A15.1	4.73	3.01e-06	0.000345	0.21	0.21	Vitiligo;	chr1:8652684	chr1:8424645~8434838:+
THCA	cis	rs10090774	0.965	rs11775023	ENSG00000279766.1	RP11-642A1.2	-4.73	3.01e-06	0.000345	-0.27	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959246	chr8:140572142~140572812:-
THCA	cis	rs138880	0.542	rs9616215	ENSG00000260613.1	RP3-522J7.6	-4.73	3.01e-06	0.000346	-0.37	-0.21	Schizophrenia;	chr22:49925186	chr22:49832616~49837786:-
THCA	cis	rs7851660	0.809	rs10115216	ENSG00000214417.4	KRT18P13	4.73	3.01e-06	0.000346	0.19	0.21	Strep throat;	chr9:97894837	chr9:97698922~97700734:+
THCA	cis	rs763121	0.853	rs3747172	ENSG00000235209.1	CTA-150C2.13	4.73	3.01e-06	0.000346	0.28	0.21	Menopause (age at onset);	chr22:38671519	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5750659	ENSG00000235209.1	CTA-150C2.13	4.73	3.01e-06	0.000346	0.28	0.21	Menopause (age at onset);	chr22:38672784	chr22:38921227~38924708:+
THCA	cis	rs763121	0.819	rs3747173	ENSG00000235209.1	CTA-150C2.13	4.73	3.01e-06	0.000346	0.28	0.21	Menopause (age at onset);	chr22:38673040	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs3747174	ENSG00000235209.1	CTA-150C2.13	4.73	3.01e-06	0.000346	0.28	0.21	Menopause (age at onset);	chr22:38673176	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs1065201	ENSG00000235209.1	CTA-150C2.13	4.73	3.01e-06	0.000346	0.28	0.21	Menopause (age at onset);	chr22:38673505	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5757226	ENSG00000235209.1	CTA-150C2.13	4.73	3.01e-06	0.000346	0.28	0.21	Menopause (age at onset);	chr22:38674545	chr22:38921227~38924708:+
THCA	cis	rs1003719	0.715	rs9974494	ENSG00000230366.8	DSCR9	4.73	3.01e-06	0.000346	0.22	0.21	Eye color traits;	chr21:37194265	chr21:37208503~37221736:+
THCA	cis	rs7914558	0.966	rs12571568	ENSG00000236937.2	PTGES3P4	4.73	3.01e-06	0.000346	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs12766205	ENSG00000236937.2	PTGES3P4	4.73	3.01e-06	0.000346	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs10883837	ENSG00000236937.2	PTGES3P4	4.73	3.01e-06	0.000346	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs746293	ENSG00000236937.2	PTGES3P4	4.73	3.01e-06	0.000346	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs11191577	ENSG00000236937.2	PTGES3P4	4.73	3.01e-06	0.000346	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:102845595~102845950:+
THCA	cis	rs11089937	0.825	rs5757012	ENSG00000211639.2	IGLV4-60	4.73	3.01e-06	0.000346	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22162199~22162681:+
THCA	cis	rs1003719	0.715	rs2835659	ENSG00000230366.8	DSCR9	4.73	3.01e-06	0.000346	0.22	0.21	Eye color traits;	chr21:37195601	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs7280251	ENSG00000230366.8	DSCR9	4.73	3.01e-06	0.000346	0.22	0.21	Eye color traits;	chr21:37195610	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs6579	ENSG00000230366.8	DSCR9	4.73	3.01e-06	0.000346	0.22	0.21	Eye color traits;	chr21:37196007	chr21:37208503~37221736:+
THCA	cis	rs250518	0.926	rs34919293	ENSG00000272081.1	CTD-2376I4.2	4.73	3.01e-06	0.000346	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72756687	chr5:72955206~72955699:-
THCA	cis	rs9326248	0.53	rs6589576	ENSG00000280143.1	AP000892.6	-4.73	3.01e-06	0.000346	-0.34	-0.21	Blood protein levels;	chr11:116865072	chr11:117204967~117210292:+
THCA	cis	rs4767841	0.904	rs278110	ENSG00000248636.5	RP11-768F21.1	-4.73	3.01e-06	0.000346	-0.22	-0.21	Urgency urinary incontinence;	chr12:119734722	chr12:119387987~119668079:-
THCA	cis	rs6044112	0.607	rs6044083	ENSG00000273998.1	RP4-777L9.2	4.73	3.01e-06	0.000346	0.3	0.21	Response to taxane treatment (docetaxel);	chr20:16534666	chr20:16576068~16579615:+
THCA	cis	rs5758659	0.904	rs134877	ENSG00000227370.1	RP4-669P10.19	-4.73	3.01e-06	0.000346	-0.19	-0.21	Cognitive function;	chr22:42266365	chr22:42132543~42132998:+
THCA	cis	rs2243480	1	rs781142	ENSG00000232559.3	GS1-124K5.12	4.73	3.01e-06	0.000346	0.31	0.21	Diabetic kidney disease;	chr7:65973791	chr7:66554588~66576923:-
THCA	cis	rs6044112	0.784	rs6075067	ENSG00000273998.1	RP4-777L9.2	4.73	3.01e-06	0.000346	0.32	0.21	Response to taxane treatment (docetaxel);	chr20:16535179	chr20:16576068~16579615:+
THCA	cis	rs427394	0.802	rs274692	ENSG00000248677.1	CTD-2044J15.1	4.73	3.02e-06	0.000346	0.2	0.21	Menopause (age at onset);	chr5:6734512	chr5:6686325~6707711:-
THCA	cis	rs12554020	0.681	rs75519210	ENSG00000227603.1	RP11-165J3.6	4.73	3.02e-06	0.000347	0.44	0.21	Schizophrenia;	chr9:93661448	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs112401922	ENSG00000227603.1	RP11-165J3.6	4.73	3.02e-06	0.000347	0.44	0.21	Schizophrenia;	chr9:93661517	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.504	rs74369348	ENSG00000227603.1	RP11-165J3.6	4.73	3.02e-06	0.000347	0.44	0.21	Schizophrenia;	chr9:93664902	chr9:93435332~93437121:-
THCA	cis	rs804280	0.662	rs804283	ENSG00000255046.1	RP11-297N6.4	-4.73	3.02e-06	0.000347	-0.25	-0.21	Myopia (pathological);	chr8:11753534	chr8:11797928~11802568:-
THCA	cis	rs7976269	0.609	rs4931141	ENSG00000275476.1	RP11-996F15.4	-4.73	3.02e-06	0.000347	-0.21	-0.21	Male-pattern baldness;	chr12:29057763	chr12:29277397~29277882:-
THCA	cis	rs3213758	0.881	rs75744751	ENSG00000275191.1	RP11-36I17.2	-4.73	3.02e-06	0.000347	-0.44	-0.21	Vitiligo (non-segmental);	chr16:53530489	chr16:53628256~53628816:-
THCA	cis	rs7403037	0.848	rs6576353	ENSG00000260760.1	PWRN3	4.73	3.02e-06	0.000347	0.24	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24593378	chr15:24441127~24447967:+
THCA	cis	rs72843506	0.656	rs79773274	ENSG00000231258.2	ZSWIM5P2	4.73	3.02e-06	0.000347	0.34	0.21	Schizophrenia;	chr17:20002618	chr17:20583758~20591180:-
THCA	cis	rs1371614	0.501	rs4992933	ENSG00000229122.1	AGBL5-IT1	4.73	3.02e-06	0.000347	0.15	0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956104	chr2:27061038~27061815:+
THCA	cis	rs17597773	0.674	rs10863568	ENSG00000238078.1	LINC01352	-4.73	3.02e-06	0.000347	-0.3	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220844737	chr1:220829255~220832429:+
THCA	cis	rs17594362	1	rs12867333	ENSG00000264190.1	MIR5006	4.73	3.02e-06	0.000347	0.34	0.21	Multiple sclerosis;	chr13:41564029	chr13:41568286~41568395:-
THCA	cis	rs7942368	0.941	rs10899283	ENSG00000261578.1	RP11-21L23.2	4.73	3.02e-06	0.000347	0.31	0.21	Endometriosis;	chr11:76794158	chr11:76800364~76804555:+
THCA	cis	rs6517329	0.509	rs11910763	ENSG00000236830.5	CBR3-AS1	-4.73	3.02e-06	0.000347	-0.2	-0.21	Schizophrenia;	chr21:36139329	chr21:36131767~36175815:-
THCA	cis	rs317689	0.959	rs317688	ENSG00000274979.1	RP11-1143G9.5	-4.73	3.02e-06	0.000347	-0.27	-0.21	Response to diuretic therapy;	chr12:69333070	chr12:69326574~69331882:-
THCA	cis	rs73108077	0.736	rs6058637	ENSG00000277112.2	RP11-755J8.1	-4.73	3.02e-06	0.000347	-0.35	-0.21	Red blood cell density in sickle cell anemia;	chr20:31325430	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs6057561	ENSG00000277112.2	RP11-755J8.1	-4.73	3.02e-06	0.000347	-0.35	-0.21	Red blood cell density in sickle cell anemia;	chr20:31327238	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs6119830	ENSG00000277112.2	RP11-755J8.1	-4.73	3.02e-06	0.000347	-0.35	-0.21	Red blood cell density in sickle cell anemia;	chr20:31327636	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs6119831	ENSG00000277112.2	RP11-755J8.1	-4.73	3.02e-06	0.000347	-0.35	-0.21	Red blood cell density in sickle cell anemia;	chr20:31328473	chr20:30681825~30723932:-
THCA	cis	rs8064024	0.65	rs3813749	ENSG00000267077.1	RP11-127I20.5	4.73	3.02e-06	0.000347	0.24	0.21	Cancer;	chr16:4869126	chr16:4795265~4796532:-
THCA	cis	rs7554547	0.69	rs4846066	ENSG00000201801.1	RNU5E-4P	4.73	3.03e-06	0.000347	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr1:11877993	chr1:11909808~11909927:-
THCA	cis	rs62158800	0.85	rs62158796	ENSG00000237880.1	AC096669.2	4.73	3.03e-06	0.000347	0.33	0.21	Facial morphology (factor 22);	chr2:107581616	chr2:107385632~107542649:-
THCA	cis	rs4915077	0.892	rs78499451	ENSG00000226822.1	RP11-356N1.2	4.73	3.03e-06	0.000347	0.4	0.21	Hypothyroidism;	chr1:107817167	chr1:108071482~108074519:+
THCA	cis	rs858239	0.601	rs1034963	ENSG00000226816.2	AC005082.12	4.73	3.03e-06	0.000347	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23206013~23208045:+
THCA	cis	rs12143943	0.802	rs12117054	ENSG00000240219.1	RP11-430C7.5	4.73	3.03e-06	0.000348	0.19	0.21	Cognitive performance;	chr1:204485613	chr1:204626775~204629712:+
THCA	cis	rs9527	0.571	rs12219246	ENSG00000213061.2	PFN1P11	4.73	3.03e-06	0.000348	0.26	0.21	Arsenic metabolism;	chr10:102853598	chr10:102838011~102845473:-
THCA	cis	rs6496044	0.507	rs62022863	ENSG00000259295.5	CSPG4P12	-4.73	3.03e-06	0.000348	-0.29	-0.21	Interstitial lung disease;	chr15:85618822	chr15:85191438~85213905:+
THCA	cis	rs4415084	0.68	rs12652026	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44798507	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.661	rs10462080	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44798950	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.646	rs13183209	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44803647	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.646	rs969679	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44803950	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs7717459	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44804423	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.688	rs10462083	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44806635	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs3761648	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44807977	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.662	rs3761649	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44808062	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs3761650	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44808254	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs3747479	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44809060	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs1866406	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44809843	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs11746506	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44812464	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs2165008	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44821577	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs4457089	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44821634	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs13189120	ENSG00000272335.1	RP11-53O19.3	-4.73	3.03e-06	0.000348	-0.18	-0.21	Breast cancer;	chr5:44822181	chr5:44826076~44828592:+
THCA	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-4.73	3.03e-06	0.000348	-0.24	-0.21	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-4.73	3.03e-06	0.000348	-0.24	-0.21	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
THCA	cis	rs758324	0.648	rs31473	ENSG00000237714.1	P4HA2-AS1	-4.73	3.03e-06	0.000348	-0.29	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132068753	chr5:132184876~132192808:+
THCA	cis	rs1476587	1	rs1476587	ENSG00000224046.1	AC005076.5	4.73	3.03e-06	0.000348	0.24	0.21	Brachial circumference;	chr7:87067398	chr7:87151423~87152420:-
THCA	cis	rs7727544	0.684	rs274546	ENSG00000263597.1	MIR3936	4.73	3.03e-06	0.000348	0.2	0.21	Blood metabolite levels;	chr5:132364175	chr5:132365490~132365599:-
THCA	cis	rs2067615	0.524	rs10778504	ENSG00000260329.1	RP11-412D9.4	-4.73	3.03e-06	0.000348	-0.2	-0.21	Heart rate;	chr12:106726646	chr12:106954029~106955497:-
THCA	cis	rs6012564	0.927	rs932451	ENSG00000227431.4	CSE1L-AS1	-4.73	3.03e-06	0.000348	-0.26	-0.21	Anger;	chr20:48957061	chr20:49040463~49046044:-
THCA	cis	rs6430585	0.528	rs309159	ENSG00000231890.6	DARS-AS1	-4.73	3.03e-06	0.000348	-0.25	-0.21	Corneal structure;	chr2:135927370	chr2:135985176~136022593:+
THCA	cis	rs9987353	0.518	rs4841110	ENSG00000248538.5	RP11-10A14.5	-4.73	3.03e-06	0.000348	-0.27	-0.21	Recombination measurement;	chr8:9228513	chr8:9189011~9202854:+
THCA	cis	rs7726839	0.54	rs11739847	ENSG00000225138.6	CTD-2228K2.7	4.73	3.04e-06	0.000348	0.27	0.21	Obesity-related traits;	chr5:609546	chr5:473236~480884:+
THCA	cis	rs7674212	0.507	rs223317	ENSG00000248971.2	KRT8P46	-4.73	3.04e-06	0.000349	-0.26	-0.21	Type 2 diabetes;	chr4:102881667	chr4:102728746~102730171:-
THCA	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-4.73	3.04e-06	0.000349	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
THCA	cis	rs4578769	0.531	rs9957103	ENSG00000265939.1	UBE2CP2	4.73	3.04e-06	0.000349	0.24	0.21	Eosinophil percentage of white cells;	chr18:22870172	chr18:22900486~22900995:-
THCA	cis	rs17767392	0.834	rs61989252	ENSG00000259146.3	RP1-261D10.2	4.73	3.04e-06	0.000349	0.28	0.21	Mitral valve prolapse;	chr14:71261197	chr14:71292729~71321814:-
THCA	cis	rs4245128	0.745	rs10750015	ENSG00000247416.2	RP11-629G13.1	4.73	3.04e-06	0.000349	0.21	0.21	Life satisfaction;	chr11:112938984	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.775	rs6589346	ENSG00000247416.2	RP11-629G13.1	4.73	3.04e-06	0.000349	0.21	0.21	Life satisfaction;	chr11:112940139	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.775	rs12282765	ENSG00000247416.2	RP11-629G13.1	4.73	3.04e-06	0.000349	0.21	0.21	Life satisfaction;	chr11:112940451	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.775	rs10488743	ENSG00000247416.2	RP11-629G13.1	4.73	3.04e-06	0.000349	0.21	0.21	Life satisfaction;	chr11:112942396	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.775	rs1447457	ENSG00000247416.2	RP11-629G13.1	4.73	3.04e-06	0.000349	0.21	0.21	Life satisfaction;	chr11:112946003	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.775	rs10891478	ENSG00000247416.2	RP11-629G13.1	4.73	3.04e-06	0.000349	0.21	0.21	Life satisfaction;	chr11:112946354	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.745	rs1838992	ENSG00000247416.2	RP11-629G13.1	4.73	3.04e-06	0.000349	0.21	0.21	Life satisfaction;	chr11:112947379	chr11:112959279~112963460:-
THCA	cis	rs55661361	0.679	rs12287365	ENSG00000254941.1	RP11-677M14.5	4.73	3.04e-06	0.000349	0.19	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742814	chr11:124807822~124808269:-
THCA	cis	rs181553	0.504	rs7237062	ENSG00000266696.1	RP11-30L3.2	4.73	3.04e-06	0.000349	0.3	0.21	Hip circumference adjusted for BMI;	chr18:49200883	chr18:49205912~49208781:+
THCA	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-4.73	3.04e-06	0.000349	-0.12	-0.21	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
THCA	cis	rs831574	0.614	rs6806547	ENSG00000280620.1	SCAANT1	4.73	3.04e-06	0.000349	0.32	0.21	Metabolite levels (Dihydroxy docosatrienoic acid);	chr3:63907801	chr3:63911518~63911772:-
THCA	cis	rs4925386	0.802	rs6142735	ENSG00000273619.1	RP5-908M14.9	-4.73	3.04e-06	0.000349	-0.18	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62386303~62386970:-
THCA	cis	rs8067545	0.611	rs2526486	ENSG00000270091.1	RP11-78O7.2	4.73	3.04e-06	0.000349	0.16	0.21	Schizophrenia;	chr17:20198313	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs2703775	ENSG00000270091.1	RP11-78O7.2	4.73	3.04e-06	0.000349	0.16	0.21	Schizophrenia;	chr17:20231153	chr17:19896590~19897287:-
THCA	cis	rs6088590	1	rs6087632	ENSG00000269202.1	RP4-614O4.12	-4.73	3.04e-06	0.000349	-0.19	-0.21	Coronary artery disease;	chr20:34819901	chr20:35201747~35203288:-
THCA	cis	rs6088590	0.931	rs6088617	ENSG00000269202.1	RP4-614O4.12	-4.73	3.04e-06	0.000349	-0.19	-0.21	Coronary artery disease;	chr20:34820233	chr20:35201747~35203288:-
THCA	cis	rs5758511	0.637	rs5751244	ENSG00000281538.1	RP4-669P10.20	-4.73	3.04e-06	0.000349	-0.24	-0.21	Birth weight;	chr22:42221405	chr22:42138060~42139726:+
THCA	cis	rs11846409	1	rs11846409	ENSG00000211974.3	IGHV2-70	-4.73	3.04e-06	0.000349	-0.2	-0.21	Rheumatic heart disease;	chr14:106645692	chr14:106723574~106724093:-
THCA	cis	rs12935418	0.616	rs8045512	ENSG00000278985.1	RP11-303E16.9	4.73	3.04e-06	0.000349	0.27	0.21	Mean corpuscular volume;	chr16:80952410	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.616	rs718954	ENSG00000278985.1	RP11-303E16.9	4.73	3.04e-06	0.000349	0.27	0.21	Mean corpuscular volume;	chr16:80953219	chr16:80982319~80984094:-
THCA	cis	rs526231	0.857	rs2569013	ENSG00000175749.11	EIF3KP1	4.73	3.04e-06	0.000349	0.28	0.21	Primary biliary cholangitis;	chr5:103305870	chr5:103032376~103033031:+
THCA	cis	rs953301	0.793	rs73019349	ENSG00000229808.1	RP11-456P18.2	-4.73	3.04e-06	0.000349	-0.57	-0.21	Left atrial antero-posterior diameter;	chr1:161898478	chr1:161890833~161892196:+
THCA	cis	rs953301	0.655	rs73019352	ENSG00000229808.1	RP11-456P18.2	-4.73	3.04e-06	0.000349	-0.57	-0.21	Left atrial antero-posterior diameter;	chr1:161904044	chr1:161890833~161892196:+
THCA	cis	rs11673344	0.523	rs7255724	ENSG00000276846.1	CTD-3220F14.3	4.73	3.04e-06	0.000349	0.17	0.21	Obesity-related traits;	chr19:37158675	chr19:37314868~37315620:-
THCA	cis	rs4950322	0.542	rs56080828	ENSG00000180867.10	PDIA3P1	4.73	3.04e-06	0.000349	0.21	0.21	Protein quantitative trait loci;	chr1:147183447	chr1:147178113~147179622:+
THCA	cis	rs6772849	0.804	rs4857920	ENSG00000242551.2	POU5F1P6	-4.73	3.04e-06	0.000349	-0.28	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128688780	chr3:128674735~128677005:-
THCA	cis	rs11700536	1	rs11700536	ENSG00000236663.1	AP001631.9	-4.72	3.04e-06	0.000349	-0.28	-0.21	Interleukin-18 levels;	chr21:43138577	chr21:43140523~43141092:-
THCA	cis	rs11096990	0.892	rs3733288	ENSG00000249685.1	RP11-360F5.3	-4.72	3.05e-06	0.00035	-0.28	-0.21	Cognitive function;	chr4:39216949	chr4:39133913~39135608:+
THCA	cis	rs4817775	0.546	rs9305577	ENSG00000236830.5	CBR3-AS1	-4.72	3.05e-06	0.00035	-0.2	-0.21	Bone mineral density;	chr21:36138814	chr21:36131767~36175815:-
THCA	cis	rs10090774	0.965	rs7843337	ENSG00000279766.1	RP11-642A1.2	4.72	3.05e-06	0.00035	0.26	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140952543	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13255947	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140901346	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10089610	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140911514	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13254151	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140915211	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13273095	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140916839	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11778436	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140920047	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11785722	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140923414	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10103265	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140924839	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.841	rs11781072	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140928040	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs11786423	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140929471	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11784127	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140931408	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.813	rs11774672	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140931433	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13279233	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140936375	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs11775547	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140938349	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs11777476	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140940276	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11774024	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140940435	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11167010	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140944111	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs10102796	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140945576	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10093049	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140947405	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs2166869	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140950479	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13269453	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140951078	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10088980	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140953591	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10092810	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955055	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11992645	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955298	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs55827446	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959173	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11775885	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959895	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10089966	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140962443	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13265704	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140963053	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs727944	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140965089	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.901	rs9324538	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140966639	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10104187	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140968361	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.87	rs10087115	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140968731	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13278775	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140971830	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.87	rs10099696	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140980411	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11990541	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140987915	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11167017	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140989972	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10110937	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992419	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs1397380	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992955	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11167018	ENSG00000279766.1	RP11-642A1.2	-4.72	3.05e-06	0.00035	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140993212	chr8:140572142~140572812:-
THCA	cis	rs3743162	0.553	rs12915656	ENSG00000275120.1	RP11-182J1.17	4.72	3.05e-06	0.00035	0.26	0.21	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84599434~84606463:-
THCA	cis	rs712039	1	rs712039	ENSG00000276054.1	RP11-378E13.3	4.72	3.05e-06	0.00035	0.3	0.21	Tuberculosis;	chr17:37490447	chr17:37386886~37387926:+
THCA	cis	rs6490294	0.851	rs56814171	ENSG00000226469.1	ADAM1B	4.72	3.05e-06	0.00035	0.26	0.21	Mean platelet volume;	chr12:111965146	chr12:111927018~111929017:+
THCA	cis	rs10851478	0.515	rs28375625	ENSG00000276593.1	RP11-295H24.5	-4.72	3.05e-06	0.00035	-0.23	-0.21	Oral cavity cancer;	chr15:49450297	chr15:49353485~49354034:+
THCA	cis	rs7267979	1	rs6050565	ENSG00000274973.1	RP13-401N8.7	4.72	3.05e-06	0.00035	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25845497~25845862:+
THCA	cis	rs6832769	1	rs13121235	ENSG00000272969.1	RP11-528I4.2	4.72	3.05e-06	0.00035	0.25	0.21	Personality dimensions;	chr4:55445780	chr4:55547112~55547889:+
THCA	cis	rs4295623	0.559	rs2409836	ENSG00000255046.1	RP11-297N6.4	-4.72	3.05e-06	0.00035	-0.23	-0.21	Morning vs. evening chronotype;	chr8:11831719	chr8:11797928~11802568:-
THCA	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-4.72	3.05e-06	0.00035	-0.24	-0.21	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
THCA	cis	rs4713118	0.911	rs9295746	ENSG00000220721.1	OR1F12	4.72	3.05e-06	0.00035	0.29	0.21	Parkinson's disease;	chr6:27762285	chr6:28073316~28074233:+
THCA	cis	rs4908768	0.501	rs12030885	ENSG00000232912.4	RP5-1115A15.1	4.72	3.05e-06	0.00035	0.2	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8721337	chr1:8424645~8434838:+
THCA	cis	rs250518	0.926	rs1509131	ENSG00000272081.1	CTD-2376I4.2	4.72	3.05e-06	0.00035	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72797651	chr5:72955206~72955699:-
THCA	cis	rs7141336	0.8	rs10136977	ENSG00000258884.1	CTD-3035D6.2	4.72	3.05e-06	0.00035	0.28	0.21	Anxiety disorder;	chr14:90822467	chr14:90822365~90828128:-
THCA	cis	rs8027521	0.666	rs2414277	ENSG00000280362.1	RP11-643A5.3	4.72	3.05e-06	0.00035	0.27	0.21	Circulating chemerin levels;	chr15:53978596	chr15:53910769~53914712:+
THCA	cis	rs9625935	0.917	rs5763675	ENSG00000279159.1	RP3-394A18.1	4.72	3.05e-06	0.00035	0.17	0.21	Tonsillectomy;	chr22:29990396	chr22:29978950~30028236:-
THCA	cis	rs6547741	0.844	rs55826602	ENSG00000234072.1	AC074117.10	-4.72	3.05e-06	0.00035	-0.16	-0.21	Oral cavity cancer;	chr2:27640585	chr2:27356246~27367622:+
THCA	cis	rs13118159	0.505	rs1250128	ENSG00000254094.1	AC078852.1	4.72	3.05e-06	0.00035	0.27	0.21	Longevity;	chr4:1263523	chr4:1356581~1358075:+
THCA	cis	rs739496	0.579	rs9971746	ENSG00000226469.1	ADAM1B	-4.72	3.06e-06	0.000351	-0.26	-0.21	Platelet count;	chr12:111899558	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs12296574	ENSG00000226469.1	ADAM1B	4.72	3.06e-06	0.000351	0.26	0.21	Platelet count;	chr12:111884973	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs1981517	ENSG00000226469.1	ADAM1B	4.72	3.06e-06	0.000351	0.26	0.21	Platelet count;	chr12:111885778	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs2269801	ENSG00000226469.1	ADAM1B	4.72	3.06e-06	0.000351	0.26	0.21	Platelet count;	chr12:111888319	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.748	rs2269802	ENSG00000226469.1	ADAM1B	4.72	3.06e-06	0.000351	0.26	0.21	Mean platelet volume;	chr12:111888334	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.799	rs73424286	ENSG00000226469.1	ADAM1B	4.72	3.06e-06	0.000351	0.26	0.21	Mean platelet volume;	chr12:111889338	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7974772	ENSG00000226469.1	ADAM1B	4.72	3.06e-06	0.000351	0.26	0.21	Platelet count;	chr12:111894479	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs10849981	ENSG00000226469.1	ADAM1B	4.72	3.06e-06	0.000351	0.26	0.21	Platelet count;	chr12:111897413	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs10849982	ENSG00000226469.1	ADAM1B	4.72	3.06e-06	0.000351	0.26	0.21	Platelet count;	chr12:111897735	chr12:111927018~111929017:+
THCA	cis	rs73108077	0.736	rs6058546	ENSG00000277112.2	RP11-755J8.1	-4.72	3.06e-06	0.000351	-0.35	-0.21	Red blood cell density in sickle cell anemia;	chr20:31314582	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs1997741	ENSG00000277112.2	RP11-755J8.1	-4.72	3.06e-06	0.000351	-0.35	-0.21	Red blood cell density in sickle cell anemia;	chr20:31323198	chr20:30681825~30723932:-
THCA	cis	rs7688540	0.76	rs12506250	ENSG00000250892.1	RP11-1365D11.1	4.72	3.06e-06	0.000351	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:201409~205009:-
THCA	cis	rs7688540	0.76	rs2883229	ENSG00000250892.1	RP11-1365D11.1	4.72	3.06e-06	0.000351	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:201409~205009:-
THCA	cis	rs7688540	0.76	rs4510422	ENSG00000250892.1	RP11-1365D11.1	4.72	3.06e-06	0.000351	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:201409~205009:-
THCA	cis	rs6012564	0.928	rs1043357	ENSG00000230758.1	SNAP23P	4.72	3.06e-06	0.000351	0.26	0.21	Anger;	chr20:49114691	chr20:49038357~49038602:-
THCA	cis	rs763121	0.853	rs5757162	ENSG00000228274.3	RP3-508I15.9	-4.72	3.06e-06	0.000351	-0.23	-0.21	Menopause (age at onset);	chr22:38597365	chr22:38667585~38681820:-
THCA	cis	rs6088590	0.687	rs6088582	ENSG00000269202.1	RP4-614O4.12	-4.72	3.06e-06	0.000351	-0.18	-0.21	Coronary artery disease;	chr20:34698994	chr20:35201747~35203288:-
THCA	cis	rs9326248	0.52	rs2735183	ENSG00000280143.1	AP000892.6	4.72	3.06e-06	0.000351	0.26	0.21	Blood protein levels;	chr11:117144479	chr11:117204967~117210292:+
THCA	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-4.72	3.06e-06	0.000351	-0.33	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
THCA	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-4.72	3.06e-06	0.000351	-0.33	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
THCA	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-4.72	3.06e-06	0.000351	-0.33	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
THCA	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-4.72	3.06e-06	0.000351	-0.33	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
THCA	cis	rs6840360	0.642	rs2724577	ENSG00000251611.1	RP11-610P16.1	-4.72	3.06e-06	0.000352	-0.18	-0.21	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151407551~151408835:-
THCA	cis	rs2337406	0.866	rs4280141	ENSG00000211974.3	IGHV2-70	4.72	3.07e-06	0.000352	0.2	0.21	Alzheimer's disease (late onset);	chr14:106780476	chr14:106723574~106724093:-
THCA	cis	rs2395909	1	rs2395909	ENSG00000238832.1	snoU109	4.72	3.07e-06	0.000352	0.23	0.21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr7:107652218	chr7:107603363~107603507:+
THCA	cis	rs1552244	0.816	rs9847657	ENSG00000232901.1	CYCSP10	4.72	3.07e-06	0.000352	0.27	0.21	Alzheimer's disease;	chr3:10131808	chr3:10000647~10000940:-
THCA	cis	rs11992162	0.613	rs6998690	ENSG00000254948.1	OR7E158P	-4.72	3.07e-06	0.000352	-0.27	-0.21	Monocyte count;	chr8:11941287	chr8:11919900~11920809:-
THCA	cis	rs6430585	0.528	rs56064699	ENSG00000231890.6	DARS-AS1	-4.72	3.07e-06	0.000352	-0.26	-0.21	Corneal structure;	chr2:135838136	chr2:135985176~136022593:+
THCA	cis	rs4915077	1	rs17020139	ENSG00000226822.1	RP11-356N1.2	4.72	3.07e-06	0.000352	0.4	0.21	Hypothyroidism;	chr1:107826861	chr1:108071482~108074519:+
THCA	cis	rs6772849	0.775	rs67105978	ENSG00000242551.2	POU5F1P6	-4.72	3.07e-06	0.000352	-0.29	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128696337	chr3:128674735~128677005:-
THCA	cis	rs1023500	0.573	rs2269524	ENSG00000273366.1	CTA-989H11.1	4.72	3.07e-06	0.000352	0.27	0.21	Schizophrenia;	chr22:42079699	chr22:42278188~42278846:+
THCA	cis	rs516805	0.961	rs693669	ENSG00000279114.1	RP3-425C14.5	-4.72	3.07e-06	0.000352	-0.21	-0.21	Lymphocyte counts;	chr6:122465690	chr6:122471923~122484161:+
THCA	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-4.72	3.07e-06	0.000352	-0.24	-0.21	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-4.72	3.07e-06	0.000352	-0.24	-0.21	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-4.72	3.07e-06	0.000352	-0.24	-0.21	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
THCA	cis	rs10510102	0.872	rs12247367	ENSG00000226864.1	ATE1-AS1	4.72	3.07e-06	0.000352	0.35	0.21	Breast cancer;	chr10:121961556	chr10:121928312~121951965:+
THCA	cis	rs6547741	0.844	rs7586655	ENSG00000234072.1	AC074117.10	-4.72	3.07e-06	0.000352	-0.16	-0.21	Oral cavity cancer;	chr2:27692792	chr2:27356246~27367622:+
THCA	cis	rs12908161	1	rs35316992	ENSG00000188388.10	GOLGA6L3	4.72	3.07e-06	0.000352	0.29	0.21	Schizophrenia;	chr15:84704902	chr15:85240472~85247170:+
THCA	cis	rs227275	0.554	rs6810668	ENSG00000248971.2	KRT8P46	-4.72	3.07e-06	0.000352	-0.26	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102728746~102730171:-
THCA	cis	rs4415084	1	rs13176502	ENSG00000272335.1	RP11-53O19.3	-4.72	3.07e-06	0.000352	-0.17	-0.21	Breast cancer;	chr5:44697806	chr5:44826076~44828592:+
THCA	cis	rs2439831	1	rs690316	ENSG00000205771.5	CATSPER2P1	-4.72	3.07e-06	0.000352	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43445682	chr15:43726918~43747094:-
THCA	cis	rs2554380	0.628	rs4473150	ENSG00000176700.18	SCAND2P	-4.72	3.07e-06	0.000352	-0.16	-0.21	Height;	chr15:83814079	chr15:84631451~84647478:+
THCA	cis	rs2447820	0.588	rs1866107	ENSG00000249996.1	RP11-359P5.1	4.72	3.07e-06	0.000352	0.25	0.21	Migraine;	chr5:123026441	chr5:123036271~123054667:+
THCA	cis	rs739496	0.579	rs57427612	ENSG00000226469.1	ADAM1B	4.72	3.07e-06	0.000352	0.26	0.21	Platelet count;	chr12:111856192	chr12:111927018~111929017:+
THCA	cis	rs1009077	0.68	rs13103899	ENSG00000245958.5	RP11-33B1.1	4.72	3.07e-06	0.000352	0.28	0.21	Endometriosis;	chr4:119517147	chr4:119454791~119552025:+
THCA	cis	rs4591358	0.765	rs16836629	ENSG00000223466.1	AC064834.2	4.72	3.07e-06	0.000352	0.25	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195499385	chr2:195533035~195538681:+
THCA	cis	rs6832769	1	rs28670674	ENSG00000272969.1	RP11-528I4.2	-4.72	3.07e-06	0.000352	-0.25	-0.21	Personality dimensions;	chr4:55540936	chr4:55547112~55547889:+
THCA	cis	rs651907	0.535	rs11711903	ENSG00000244119.1	PDCL3P4	4.72	3.07e-06	0.000352	0.19	0.21	Colorectal cancer;	chr3:101781904	chr3:101712472~101713191:+
THCA	cis	rs9875589	0.509	rs7648345	ENSG00000228242.5	AC093495.4	4.72	3.07e-06	0.000352	0.12	0.21	Ovarian reserve;	chr3:13998401	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs12330714	ENSG00000228242.5	AC093495.4	4.72	3.07e-06	0.000352	0.12	0.21	Ovarian reserve;	chr3:13998842	chr3:14144637~14165978:+
THCA	cis	rs3845817	0.808	rs702895	ENSG00000237979.1	AC007389.1	4.72	3.07e-06	0.000353	0.24	0.21	Bipolar disorder;	chr2:65534933	chr2:65500993~65502138:-
THCA	cis	rs3845817	0.868	rs702896	ENSG00000237979.1	AC007389.1	4.72	3.07e-06	0.000353	0.24	0.21	Bipolar disorder;	chr2:65535089	chr2:65500993~65502138:-
THCA	cis	rs9532669	0.926	rs9532691	ENSG00000229473.2	RGS17P1	-4.72	3.07e-06	0.000353	-0.26	-0.21	Cervical cancer;	chr13:40969358	chr13:40992779~40993331:-
THCA	cis	rs60180747	0.909	rs11639266	ENSG00000261318.1	RP11-653J6.1	4.72	3.08e-06	0.000353	0.3	0.21	Testicular germ cell tumor;	chr15:66308079	chr15:66278498~66293357:-
THCA	cis	rs8002861	0.875	rs12869697	ENSG00000274001.1	RP11-5G9.5	-4.72	3.08e-06	0.000353	-0.26	-0.21	Leprosy;	chr13:43865033	chr13:43877715~43878163:-
THCA	cis	rs3812049	0.506	rs36694	ENSG00000245937.6	LINC01184	4.72	3.08e-06	0.000353	0.24	0.21	Lymphocyte counts;Red cell distribution width;	chr5:128213263	chr5:127940426~128083172:-
THCA	cis	rs427394	1	rs427394	ENSG00000248677.1	CTD-2044J15.1	4.72	3.08e-06	0.000353	0.2	0.21	Menopause (age at onset);	chr5:6745762	chr5:6686325~6707711:-
THCA	cis	rs1979679	0.918	rs10843187	ENSG00000247934.4	RP11-967K21.1	4.72	3.08e-06	0.000353	0.21	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28483586	chr12:28163298~28190738:-
THCA	cis	rs4908768	0.52	rs11121216	ENSG00000232912.4	RP5-1115A15.1	4.72	3.08e-06	0.000353	0.21	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678885	chr1:8424645~8434838:+
THCA	cis	rs72945132	0.941	rs66803755	ENSG00000254604.1	AP000487.6	-4.72	3.08e-06	0.000353	-0.39	-0.21	Coronary artery disease;	chr11:70271367	chr11:70282367~70363368:-
THCA	cis	rs8028182	0.636	rs4299117	ENSG00000260269.4	CTD-2323K18.1	-4.72	3.08e-06	0.000353	-0.32	-0.21	Sudden cardiac arrest;	chr15:75497103	chr15:75527150~75601205:-
THCA	cis	rs9925964	0.933	rs2303222	ENSG00000232748.3	RP11-196G11.6	4.72	3.08e-06	0.000353	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:31056460~31062803:+
THCA	cis	rs3770081	1	rs60479377	ENSG00000273080.1	RP11-301O19.1	-4.72	3.08e-06	0.000353	-0.48	-0.21	Facial emotion recognition (sad faces);	chr2:86056825	chr2:86195590~86196049:+
THCA	cis	rs3770081	0.793	rs60719866	ENSG00000273080.1	RP11-301O19.1	-4.72	3.08e-06	0.000353	-0.48	-0.21	Facial emotion recognition (sad faces);	chr2:86057255	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs76081054	ENSG00000273080.1	RP11-301O19.1	-4.72	3.08e-06	0.000353	-0.48	-0.21	Facial emotion recognition (sad faces);	chr2:86057914	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs59947468	ENSG00000273080.1	RP11-301O19.1	-4.72	3.08e-06	0.000353	-0.48	-0.21	Facial emotion recognition (sad faces);	chr2:86062313	chr2:86195590~86196049:+
THCA	cis	rs875971	0.66	rs2013222	ENSG00000224316.1	RP11-479O9.2	-4.72	3.08e-06	0.000353	-0.24	-0.21	Aortic root size;	chr7:66570949	chr7:65773620~65802067:+
THCA	cis	rs12022452	0.822	rs6600343	ENSG00000237899.1	RP4-739H11.3	-4.72	3.08e-06	0.000353	-0.33	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40669089~40687588:-
THCA	cis	rs6012564	0.855	rs6095394	ENSG00000227431.4	CSE1L-AS1	-4.72	3.08e-06	0.000353	-0.26	-0.21	Anger;	chr20:49009007	chr20:49040463~49046044:-
THCA	cis	rs73108077	0.764	rs75475053	ENSG00000277112.2	RP11-755J8.1	-4.72	3.08e-06	0.000353	-0.43	-0.21	Red blood cell density in sickle cell anemia;	chr20:31217143	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.621	rs7261582	ENSG00000277112.2	RP11-755J8.1	-4.72	3.08e-06	0.000353	-0.43	-0.21	Red blood cell density in sickle cell anemia;	chr20:31226977	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.57	rs73119526	ENSG00000277112.2	RP11-755J8.1	-4.72	3.08e-06	0.000353	-0.43	-0.21	Red blood cell density in sickle cell anemia;	chr20:31252117	chr20:30681825~30723932:-
THCA	cis	rs2886497	0.894	rs7898036	ENSG00000224215.1	RP11-371A19.2	-4.72	3.08e-06	0.000353	-0.28	-0.21	Major depression and alcohol dependence;	chr10:23399520	chr10:23343957~23345181:+
THCA	cis	rs6921919	0.583	rs6907950	ENSG00000280107.1	AL022393.9	-4.72	3.09e-06	0.000354	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28170845~28172521:+
THCA	cis	rs997295	0.618	rs3784698	ENSG00000270964.1	RP11-502I4.3	4.72	3.09e-06	0.000354	0.18	0.21	Motion sickness;	chr15:67715244	chr15:67541072~67542604:-
THCA	cis	rs442309	0.875	rs224146	ENSG00000238280.1	RP11-436D10.3	-4.72	3.09e-06	0.000354	-0.25	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62723179	chr10:62793562~62805887:-
THCA	cis	rs1577917	0.883	rs1415749	ENSG00000220563.1	PKMP3	4.72	3.09e-06	0.000354	0.15	0.21	Response to antipsychotic treatment;	chr6:86069366	chr6:85659892~85660606:-
THCA	cis	rs4646450	0.735	rs10155966	ENSG00000244219.5	GS1-259H13.2	-4.72	3.09e-06	0.000354	-0.28	-0.21	Blood metabolite levels;	chr7:99383610	chr7:99598066~99610813:+
THCA	cis	rs6973609	0.626	rs6973640	ENSG00000271122.1	RP11-379H18.1	4.72	3.09e-06	0.000354	0.15	0.21	Obesity-related traits;	chr7:35567769	chr7:35695214~35699413:+
THCA	cis	rs1003719	0.762	rs2835598	ENSG00000230366.8	DSCR9	-4.72	3.09e-06	0.000354	-0.21	-0.21	Eye color traits;	chr21:37094369	chr21:37208503~37221736:+
THCA	cis	rs8024893	0.764	rs8035110	ENSG00000270055.1	CTD-3092A11.2	4.72	3.09e-06	0.000354	0.28	0.21	Red cell distribution width;	chr15:31241884	chr15:30487963~30490313:+
THCA	cis	rs8024893	0.764	rs8036245	ENSG00000270055.1	CTD-3092A11.2	4.72	3.09e-06	0.000354	0.28	0.21	Red cell distribution width;	chr15:31242211	chr15:30487963~30490313:+
THCA	cis	rs5758659	0.714	rs5758574	ENSG00000182057.4	OGFRP1	-4.72	3.09e-06	0.000354	-0.24	-0.21	Cognitive function;	chr22:42085396	chr22:42269753~42275196:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-4.72	3.09e-06	0.000354	-0.26	-0.21	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000164669.11	INTS4P1	-4.72	3.09e-06	0.000354	-0.26	-0.21	Aortic root size;	chr7:65951183	chr7:65141225~65234216:+
THCA	cis	rs8002861	0.905	rs6561149	ENSG00000274001.1	RP11-5G9.5	-4.72	3.09e-06	0.000354	-0.26	-0.21	Leprosy;	chr13:43882646	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.875	rs11616803	ENSG00000274001.1	RP11-5G9.5	-4.72	3.09e-06	0.000354	-0.26	-0.21	Leprosy;	chr13:43882973	chr13:43877715~43878163:-
THCA	cis	rs6728642	1	rs73959416	ENSG00000230606.9	AC159540.1	4.72	3.09e-06	0.000354	0.29	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96938781	chr2:97416165~97433527:-
THCA	cis	rs2237234	1	rs2237234	ENSG00000124549.13	BTN2A3P	-4.72	3.09e-06	0.000354	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26391166	chr6:26421391~26432383:+
THCA	cis	rs2447820	0.5	rs42394	ENSG00000249996.1	RP11-359P5.1	4.72	3.09e-06	0.000354	0.25	0.21	Migraine;	chr5:122968815	chr5:123036271~123054667:+
THCA	cis	rs288326	0.561	rs78745965	ENSG00000272800.1	RP11-438L19.1	4.72	3.09e-06	0.000354	0.39	0.21	Blood protein levels;	chr2:182983747	chr2:183214319~183215400:+
THCA	cis	rs10761482	0.566	rs4505011	ENSG00000254271.1	RP11-131N11.4	4.72	3.09e-06	0.000355	0.29	0.21	Schizophrenia;	chr10:60440550	chr10:60734342~60741828:+
THCA	cis	rs17270561	0.609	rs1937127	ENSG00000272462.2	U91328.19	4.72	3.1e-06	0.000355	0.18	0.21	Iron status biomarkers;	chr6:25769644	chr6:25992662~26001775:+
THCA	cis	rs11858159	0.545	rs6576303	ENSG00000260760.1	PWRN3	-4.72	3.1e-06	0.000355	-0.22	-0.21	Platelet thrombus formation;	chr15:24396134	chr15:24441127~24447967:+
THCA	cis	rs1211375	0.606	rs1203977	ENSG00000206168.1	Z69890.1	4.72	3.1e-06	0.000355	0.22	0.21	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:231134~231472:+
THCA	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	4.72	3.1e-06	0.000355	0.18	0.21	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	4.72	3.1e-06	0.000355	0.18	0.21	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	4.72	3.1e-06	0.000355	0.18	0.21	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000176933.5	TOB2P1	-4.72	3.1e-06	0.000355	-0.23	-0.21	Pubertal anthropometrics;	chr6:28219323	chr6:28217643~28218634:-
THCA	cis	rs812925	0.502	rs2053750	ENSG00000270820.4	RP11-355B11.2	-4.72	3.1e-06	0.000355	-0.18	-0.21	Immature fraction of reticulocytes;	chr2:61429138	chr2:61471188~61484130:+
THCA	cis	rs972578	0.668	rs8569	ENSG00000274717.1	RP1-47A17.1	-4.72	3.1e-06	0.000355	-0.22	-0.21	Mean platelet volume;	chr22:42870768	chr22:42791814~42794313:-
THCA	cis	rs9467773	0.62	rs2451732	ENSG00000124549.13	BTN2A3P	-4.72	3.1e-06	0.000355	-0.2	-0.21	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26421391~26432383:+
THCA	cis	rs6012564	0.963	rs2075679	ENSG00000230758.1	SNAP23P	4.72	3.1e-06	0.000355	0.26	0.21	Anger;	chr20:49085052	chr20:49038357~49038602:-
THCA	cis	rs440932	0.747	rs330946	ENSG00000253893.2	FAM85B	-4.72	3.1e-06	0.000355	-0.27	-0.21	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8167819~8226614:-
THCA	cis	rs3824435	0.783	rs4740812	ENSG00000272866.1	RP11-12D24.10	-4.72	3.1e-06	0.000355	-0.29	-0.21	Risky sexual behaviors in alcohol dependence;	chr9:5348031	chr9:5351796~5352410:-
THCA	cis	rs793571	0.628	rs12595057	ENSG00000245975.2	RP11-30K9.6	4.72	3.1e-06	0.000355	0.24	0.21	Schizophrenia;	chr15:58830627	chr15:58768072~58770974:-
THCA	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	4.72	3.1e-06	0.000355	0.21	0.21	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
THCA	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	4.72	3.1e-06	0.000355	0.21	0.21	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
THCA	cis	rs1023500	0.573	rs4822088	ENSG00000273366.1	CTA-989H11.1	-4.72	3.1e-06	0.000355	-0.27	-0.21	Schizophrenia;	chr22:42074585	chr22:42278188~42278846:+
THCA	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	4.72	3.1e-06	0.000355	0.22	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
THCA	cis	rs9326248	0.501	rs4938351	ENSG00000280143.1	AP000892.6	4.72	3.1e-06	0.000355	0.26	0.21	Blood protein levels;	chr11:117151636	chr11:117204967~117210292:+
THCA	cis	rs454422	0.857	rs236106	ENSG00000275632.1	RP5-967N21.11	4.72	3.1e-06	0.000355	0.21	0.21	HIV-1 viral setpoint;	chr20:5980045	chr20:6000418~6000941:+
THCA	cis	rs8067545	0.611	rs2013443	ENSG00000270091.1	RP11-78O7.2	-4.72	3.1e-06	0.000355	-0.16	-0.21	Schizophrenia;	chr17:20119796	chr17:19896590~19897287:-
THCA	cis	rs3796352	1	rs33999310	ENSG00000242142.1	SERBP1P3	-4.72	3.1e-06	0.000356	-0.4	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:52849316	chr3:53064283~53065091:-
THCA	cis	rs728616	0.558	rs2880599	ENSG00000242600.5	MBL1P	4.72	3.1e-06	0.000356	0.27	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80404679	chr10:79904898~79950336:+
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000189316.3	RP11-797H7.5	-4.72	3.1e-06	0.000356	-0.24	-0.21	Calcium levels;	chr7:65829495	chr7:64888527~64890100:-
THCA	cis	rs12761761	1	rs7921305	ENSG00000279982.1	RP11-45A17.3	-4.72	3.1e-06	0.000356	-0.33	-0.21	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131961692	chr10:131996738~131999846:+
THCA	cis	rs9533799	0.559	rs9533796	ENSG00000227258.4	SMIM2-AS1	-4.72	3.11e-06	0.000356	-0.24	-0.21	Amyotrophic lateral sclerosis;	chr13:44216310	chr13:44110451~44240517:+
THCA	cis	rs7615952	0.605	rs11708269	ENSG00000243429.1	OR7E29P	4.72	3.11e-06	0.000356	0.38	0.21	Blood pressure (smoking interaction);	chr3:125613306	chr3:125712139~125713045:+
THCA	cis	rs7577696	0.85	rs11676938	ENSG00000276334.1	AL133243.1	-4.72	3.11e-06	0.000356	-0.22	-0.21	Inflammatory biomarkers;	chr2:32090954	chr2:32521927~32523547:+
THCA	cis	rs858239	0.601	rs6461702	ENSG00000226816.2	AC005082.12	4.72	3.11e-06	0.000356	0.31	0.21	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23206013~23208045:+
THCA	cis	rs911555	0.755	rs11627446	ENSG00000244691.1	RPL10AP1	-4.72	3.11e-06	0.000356	-0.29	-0.21	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103412119~103412761:-
THCA	cis	rs763121	0.853	rs5757141	ENSG00000228274.3	RP3-508I15.9	-4.72	3.11e-06	0.000356	-0.23	-0.21	Menopause (age at onset);	chr22:38561478	chr22:38667585~38681820:-
THCA	cis	rs6973609	0.962	rs10230265	ENSG00000271122.1	RP11-379H18.1	4.72	3.11e-06	0.000356	0.14	0.21	Obesity-related traits;	chr7:35567404	chr7:35695214~35699413:+
THCA	cis	rs8062405	0.508	rs9929088	ENSG00000261766.1	RP11-22P6.2	4.72	3.11e-06	0.000356	0.22	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28990139	chr16:28862166~28863340:-
THCA	cis	rs2179367	0.537	rs6911411	ENSG00000216906.2	RP11-350J20.9	4.72	3.11e-06	0.000356	0.29	0.21	Dupuytren's disease;	chr6:149366954	chr6:149904243~149906418:+
THCA	cis	rs3892630	0.817	rs35408716	ENSG00000267567.1	CTD-2538C1.3	4.72	3.11e-06	0.000357	0.32	0.21	Red blood cell traits;	chr19:32697055	chr19:32718298~32719595:-
THCA	cis	rs3892630	0.878	rs66788054	ENSG00000267567.1	CTD-2538C1.3	4.72	3.11e-06	0.000357	0.32	0.21	Red blood cell traits;	chr19:32699240	chr19:32718298~32719595:-
THCA	cis	rs3892630	0.878	rs8112955	ENSG00000267567.1	CTD-2538C1.3	4.72	3.11e-06	0.000357	0.32	0.21	Red blood cell traits;	chr19:32700286	chr19:32718298~32719595:-
THCA	cis	rs7520050	0.966	rs785471	ENSG00000234329.1	RP11-767N6.2	-4.72	3.11e-06	0.000357	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45651039~45651826:-
THCA	cis	rs8141529	0.702	rs5762870	ENSG00000272858.1	CTA-292E10.8	-4.72	3.11e-06	0.000357	-0.22	-0.21	Lymphocyte counts;	chr22:28865171	chr22:28814914~28815662:+
THCA	cis	rs8046148	0.724	rs12922541	ENSG00000279356.1	RP11-429P3.8	4.72	3.11e-06	0.000357	0.25	0.21	Testicular germ cell tumor;	chr16:50045479	chr16:50072862~50074986:+
THCA	cis	rs1707322	0.963	rs11211202	ENSG00000281133.1	AL355480.3	-4.72	3.12e-06	0.000357	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45580892~45580996:-
THCA	cis	rs6860806	0.507	rs270601	ENSG00000224431.1	AC063976.7	4.72	3.12e-06	0.000357	0.19	0.21	Breast cancer;	chr5:132321304	chr5:132199456~132203487:+
THCA	cis	rs36093844	0.752	rs79734467	ENSG00000279742.1	RP11-700A24.1	-4.72	3.12e-06	0.000357	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85860910	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs57534090	ENSG00000279742.1	RP11-700A24.1	-4.72	3.12e-06	0.000357	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85861977	chr11:85852557~85854943:-
THCA	cis	rs172166	0.538	rs1150686	ENSG00000176933.5	TOB2P1	-4.72	3.12e-06	0.000357	-0.23	-0.21	Cardiac Troponin-T levels;	chr6:28193493	chr6:28217643~28218634:-
THCA	cis	rs1150688	1	rs1150688	ENSG00000176933.5	TOB2P1	-4.72	3.12e-06	0.000357	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28217643~28218634:-
THCA	cis	rs4664293	0.51	rs2042776	ENSG00000224152.1	AC009506.1	4.72	3.12e-06	0.000357	0.22	0.21	Monocyte percentage of white cells;	chr2:159653793	chr2:159615296~159617082:+
THCA	cis	rs16852403	0.548	rs316280	ENSG00000224687.1	RASAL2-AS1	4.72	3.12e-06	0.000357	0.31	0.21	Childhood ear infection;	chr1:178188950	chr1:178091508~178093984:-
THCA	cis	rs972578	0.715	rs8141676	ENSG00000274717.1	RP1-47A17.1	-4.72	3.12e-06	0.000357	-0.22	-0.21	Mean platelet volume;	chr22:42879962	chr22:42791814~42794313:-
THCA	cis	rs2051211	1	rs2051211	ENSG00000229589.1	ACVR2B-AS1	-4.72	3.12e-06	0.000357	-0.22	-0.21	QRS duration;	chr3:38518258	chr3:38451027~38454820:-
THCA	cis	rs3750082	0.855	rs12536402	ENSG00000231952.3	DPY19L1P2	-4.72	3.12e-06	0.000357	-0.27	-0.21	Glomerular filtration rate (creatinine);	chr7:32896807	chr7:32812757~32838570:+
THCA	cis	rs10761482	0.906	rs7093702	ENSG00000254271.1	RP11-131N11.4	4.72	3.12e-06	0.000357	0.29	0.21	Schizophrenia;	chr10:60333951	chr10:60734342~60741828:+
THCA	cis	rs11902236	0.545	rs13031952	ENSG00000188525.3	AC010969.1	-4.72	3.12e-06	0.000357	-0.26	-0.21	Prostate cancer;	chr2:9994269	chr2:10003158~10006030:-
THCA	cis	rs172166	0.516	rs1225618	ENSG00000273712.1	RP5-874C20.7	4.72	3.12e-06	0.000357	0.23	0.21	Cardiac Troponin-T levels;	chr6:28161935	chr6:28315613~28315883:-
THCA	cis	rs6570726	0.837	rs636894	ENSG00000270638.1	RP3-466P17.1	4.72	3.12e-06	0.000357	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs382910	ENSG00000270638.1	RP3-466P17.1	4.72	3.12e-06	0.000357	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs2485632	ENSG00000270638.1	RP3-466P17.1	4.72	3.12e-06	0.000357	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs2253307	ENSG00000270638.1	RP3-466P17.1	4.72	3.12e-06	0.000357	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145735570~145737218:+
THCA	cis	rs8014252	1	rs77867352	ENSG00000259158.2	ADAM20P1	-4.72	3.12e-06	0.000358	-0.25	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70427904	chr14:70468881~70483756:-
THCA	cis	rs8014252	1	rs12436464	ENSG00000259158.2	ADAM20P1	-4.72	3.12e-06	0.000358	-0.25	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70449684	chr14:70468881~70483756:-
THCA	cis	rs8058578	1	rs6565197	ENSG00000279196.1	RP11-1072A3.3	4.72	3.12e-06	0.000358	0.22	0.21	Multiple myeloma;	chr16:30695156	chr16:30984630~30988270:-
THCA	cis	rs17572109	0.666	rs4674297	ENSG00000237281.1	CATIP-AS2	4.72	3.12e-06	0.000358	0.24	0.21	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218326889~218357966:-
THCA	cis	rs6728642	1	rs7580504	ENSG00000230606.9	AC159540.1	4.72	3.12e-06	0.000358	0.31	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96939860	chr2:97416165~97433527:-
THCA	cis	rs4415084	1	rs920329	ENSG00000272335.1	RP11-53O19.3	-4.72	3.12e-06	0.000358	-0.17	-0.21	Breast cancer;	chr5:44702405	chr5:44826076~44828592:+
THCA	cis	rs4639966	0.579	rs2186780	ENSG00000255422.1	AP002954.4	4.72	3.12e-06	0.000358	0.27	0.21	Systemic lupus erythematosus;	chr11:118734742	chr11:118704607~118750263:+
THCA	cis	rs4639966	0.512	rs7926282	ENSG00000255422.1	AP002954.4	4.72	3.12e-06	0.000358	0.27	0.21	Systemic lupus erythematosus;	chr11:118735205	chr11:118704607~118750263:+
THCA	cis	rs2742234	0.541	rs10793422	ENSG00000273008.1	RP11-351D16.3	4.72	3.12e-06	0.000358	0.2	0.21	Hirschsprung disease;	chr10:43208426	chr10:43136824~43138334:-
THCA	cis	rs8049040	0.524	rs34538886	ENSG00000260886.1	TAT-AS1	4.72	3.12e-06	0.000358	0.31	0.21	Blood protein levels;	chr16:71389584	chr16:71565789~71578187:+
THCA	cis	rs11846409	0.932	rs2015469	ENSG00000211974.3	IGHV2-70	-4.72	3.12e-06	0.000358	-0.2	-0.21	Rheumatic heart disease;	chr14:106631857	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs56167903	ENSG00000211974.3	IGHV2-70	-4.72	3.12e-06	0.000358	-0.2	-0.21	Rheumatic heart disease;	chr14:106632070	chr14:106723574~106724093:-
THCA	cis	rs7560272	0.512	rs12998980	ENSG00000163016.8	ALMS1P	-4.72	3.13e-06	0.000358	-0.26	-0.21	Schizophrenia;	chr2:73703599	chr2:73644919~73685576:+
THCA	cis	rs8105895	0.935	rs28635943	ENSG00000269345.1	VN1R85P	4.72	3.13e-06	0.000358	0.28	0.21	Body mass index (change over time);	chr19:22085910	chr19:22174766~22175191:-
THCA	cis	rs317865	0.529	rs28487914	ENSG00000263327.5	TAPT1-AS1	-4.72	3.13e-06	0.000358	-0.33	-0.21	Kidney disease (early stage) in type 1 diabetes;	chr4:16189680	chr4:16226685~16320140:+
THCA	cis	rs4950322	0.802	rs72694705	ENSG00000226015.2	CCT8P1	4.72	3.13e-06	0.000358	0.25	0.21	Protein quantitative trait loci;	chr1:147362313	chr1:147203276~147204932:-
THCA	cis	rs7520050	0.807	rs4353138	ENSG00000234329.1	RP11-767N6.2	-4.72	3.13e-06	0.000358	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45754131	chr1:45651039~45651826:-
THCA	cis	rs34286592	1	rs34127220	ENSG00000214725.6	CDIPT-AS1	-4.72	3.13e-06	0.000358	-0.39	-0.21	Multiple sclerosis;	chr16:29831570	chr16:29863593~29868053:+
THCA	cis	rs2243480	1	rs2257790	ENSG00000164669.11	INTS4P1	4.72	3.13e-06	0.000358	0.41	0.21	Diabetic kidney disease;	chr7:66135463	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs316332	ENSG00000164669.11	INTS4P1	4.72	3.13e-06	0.000358	0.41	0.21	Diabetic kidney disease;	chr7:66139312	chr7:65141225~65234216:+
THCA	cis	rs5758511	0.68	rs5751243	ENSG00000281538.1	RP4-669P10.20	-4.72	3.13e-06	0.000359	-0.24	-0.21	Birth weight;	chr22:42221171	chr22:42138060~42139726:+
THCA	cis	rs6487679	0.526	rs972111	ENSG00000111788.10	RP11-22B23.1	4.72	3.13e-06	0.000359	0.22	0.21	Non-alcoholic fatty liver disease histology (AST);	chr12:9221777	chr12:9277235~9313241:+
THCA	cis	rs3213758	0.643	rs79627900	ENSG00000275191.1	RP11-36I17.2	-4.72	3.13e-06	0.000359	-0.44	-0.21	Vitiligo (non-segmental);	chr16:53706668	chr16:53628256~53628816:-
THCA	cis	rs8077577	0.689	rs2273029	ENSG00000273018.4	CTD-2303H24.2	-4.72	3.13e-06	0.000359	-0.31	-0.21	Obesity-related traits;	chr17:18333025	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.689	rs62072543	ENSG00000273018.4	CTD-2303H24.2	-4.72	3.13e-06	0.000359	-0.31	-0.21	Obesity-related traits;	chr17:18340558	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.747	rs62072544	ENSG00000273018.4	CTD-2303H24.2	-4.72	3.13e-06	0.000359	-0.31	-0.21	Obesity-related traits;	chr17:18340559	chr17:18511221~18551705:-
THCA	cis	rs2288884	0.505	rs17835435	ENSG00000269483.1	AC006272.1	4.72	3.13e-06	0.000359	0.32	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51931453	chr19:51839924~51843324:-
THCA	cis	rs2255336	0.81	rs10743886	ENSG00000245648.1	RP11-277P12.20	4.72	3.13e-06	0.000359	0.3	0.21	Blood protein levels;	chr12:10359063	chr12:10363769~10398506:+
THCA	cis	rs6088590	0.542	rs6059956	ENSG00000276073.1	RP5-1125A11.7	-4.72	3.14e-06	0.000359	-0.18	-0.21	Coronary artery disease;	chr20:34632266	chr20:33985617~33988989:-
THCA	cis	rs5758659	0.714	rs2284087	ENSG00000182057.4	OGFRP1	-4.72	3.14e-06	0.000359	-0.24	-0.21	Cognitive function;	chr22:42089667	chr22:42269753~42275196:+
THCA	cis	rs160451	0.811	rs216986	ENSG00000251136.7	RP11-37B2.1	4.72	3.14e-06	0.000359	0.2	0.21	Leprosy;	chr8:89642601	chr8:89609409~89757727:-
THCA	cis	rs9878978	1	rs62233806	ENSG00000237990.3	CNTN4-AS1	4.72	3.14e-06	0.000359	0.23	0.21	Blood pressure (smoking interaction);	chr3:2433794	chr3:3039033~3069242:-
THCA	cis	rs6490294	0.528	rs7980579	ENSG00000226469.1	ADAM1B	4.72	3.14e-06	0.000359	0.31	0.21	Mean platelet volume;	chr12:112009556	chr12:111927018~111929017:+
THCA	cis	rs10129255	0.833	rs61997797	ENSG00000211974.3	IGHV2-70	4.72	3.14e-06	0.000359	0.17	0.21	Kawasaki disease;	chr14:106815190	chr14:106723574~106724093:-
THCA	cis	rs10129255	0.833	rs7156689	ENSG00000211974.3	IGHV2-70	4.72	3.14e-06	0.000359	0.17	0.21	Kawasaki disease;	chr14:106816039	chr14:106723574~106724093:-
THCA	cis	rs6012564	1	rs911411	ENSG00000227431.4	CSE1L-AS1	4.72	3.14e-06	0.000359	0.26	0.21	Anger;	chr20:49101894	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs6063352	ENSG00000227431.4	CSE1L-AS1	4.72	3.14e-06	0.000359	0.26	0.21	Anger;	chr20:49102057	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs6063353	ENSG00000227431.4	CSE1L-AS1	4.72	3.14e-06	0.000359	0.26	0.21	Anger;	chr20:49103273	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs6063354	ENSG00000227431.4	CSE1L-AS1	4.72	3.14e-06	0.000359	0.26	0.21	Anger;	chr20:49103412	chr20:49040463~49046044:-
THCA	cis	rs6445975	0.667	rs2037123	ENSG00000272360.1	RP11-359I18.5	-4.72	3.14e-06	0.000359	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58253466	chr3:58490830~58491291:-
THCA	cis	rs412050	0.502	rs8136405	ENSG00000224086.5	LL22NC03-86G7.1	-4.72	3.14e-06	0.00036	-0.39	-0.21	Attention deficit hyperactivity disorder;	chr22:21793732	chr22:21938293~21977632:+
THCA	cis	rs62158800	0.85	rs62158795	ENSG00000237880.1	AC096669.2	4.72	3.14e-06	0.00036	0.33	0.21	Facial morphology (factor 22);	chr2:107578487	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.85	rs6755089	ENSG00000237880.1	AC096669.2	4.72	3.14e-06	0.00036	0.33	0.21	Facial morphology (factor 22);	chr2:107578947	chr2:107385632~107542649:-
THCA	cis	rs9532669	0.926	rs9532693	ENSG00000229473.2	RGS17P1	4.72	3.14e-06	0.00036	0.26	0.21	Cervical cancer;	chr13:40980557	chr13:40992779~40993331:-
THCA	cis	rs7267979	1	rs3761117	ENSG00000274973.1	RP13-401N8.7	4.72	3.14e-06	0.00036	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25845497~25845862:+
THCA	cis	rs7746199	0.736	rs17749927	ENSG00000220721.1	OR1F12	4.72	3.14e-06	0.00036	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs13192965	ENSG00000220721.1	OR1F12	4.72	3.14e-06	0.00036	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28073316~28074233:+
THCA	cis	rs1707322	1	rs4298677	ENSG00000281133.1	AL355480.3	-4.72	3.14e-06	0.00036	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45580892~45580996:-
THCA	cis	rs7824557	0.724	rs2572398	ENSG00000154316.13	TDH	-4.72	3.15e-06	0.00036	-0.16	-0.21	Retinal vascular caliber;	chr8:11320584	chr8:11339637~11368452:+
THCA	cis	rs4767841	0.625	rs2240310	ENSG00000248636.5	RP11-768F21.1	-4.72	3.15e-06	0.00036	-0.22	-0.21	Urgency urinary incontinence;	chr12:119783832	chr12:119387987~119668079:-
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000273796.1	LL21NC02-21A1.1	-4.72	3.15e-06	0.00036	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45403809~45404369:-
THCA	cis	rs3892630	0.878	rs6510277	ENSG00000267567.1	CTD-2538C1.3	4.72	3.15e-06	0.00036	0.32	0.21	Red blood cell traits;	chr19:32692763	chr19:32718298~32719595:-
THCA	cis	rs3892630	0.817	rs12609866	ENSG00000267567.1	CTD-2538C1.3	4.72	3.15e-06	0.00036	0.32	0.21	Red blood cell traits;	chr19:32693506	chr19:32718298~32719595:-
THCA	cis	rs7617773	0.817	rs6801801	ENSG00000199476.1	Y_RNA	-4.72	3.15e-06	0.00036	-0.27	-0.21	Coronary artery disease;	chr3:48284943	chr3:48288587~48288694:+
THCA	cis	rs11756659	0.505	rs16891142	ENSG00000272462.2	U91328.19	4.72	3.15e-06	0.00036	0.19	0.21	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25898911	chr6:25992662~26001775:+
THCA	cis	rs1048886	0.938	rs4707802	ENSG00000271967.1	RP11-134K13.4	4.72	3.15e-06	0.000361	0.22	0.21	Type 2 diabetes;	chr6:70387887	chr6:70596438~70596980:+
THCA	cis	rs7942368	1	rs1440978	ENSG00000261578.1	RP11-21L23.2	4.72	3.15e-06	0.000361	0.31	0.21	Endometriosis;	chr11:76765236	chr11:76800364~76804555:+
THCA	cis	rs10266483	0.656	rs670966	ENSG00000228653.2	HNRNPCP7	-4.72	3.15e-06	0.000361	-0.19	-0.21	Response to statin therapy;	chr7:64302521	chr7:64500825~64501729:+
THCA	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-4.72	3.15e-06	0.000361	-0.24	-0.21	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
THCA	cis	rs7914558	1	rs11191541	ENSG00000236937.2	PTGES3P4	4.72	3.16e-06	0.000361	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102845595~102845950:+
THCA	cis	rs11779988	0.545	rs208762	ENSG00000253671.1	RP11-806O11.1	-4.72	3.16e-06	0.000361	-0.27	-0.21	Breast cancer;	chr8:17949225	chr8:17808941~17820868:+
THCA	cis	rs651907	0.557	rs34947019	ENSG00000244119.1	PDCL3P4	4.72	3.16e-06	0.000361	0.19	0.21	Colorectal cancer;	chr3:101813391	chr3:101712472~101713191:+
THCA	cis	rs651907	0.535	rs34743741	ENSG00000244119.1	PDCL3P4	4.72	3.16e-06	0.000361	0.19	0.21	Colorectal cancer;	chr3:101813604	chr3:101712472~101713191:+
THCA	cis	rs7577696	0.924	rs6749336	ENSG00000276334.1	AL133243.1	-4.72	3.16e-06	0.000361	-0.22	-0.21	Inflammatory biomarkers;	chr2:32046641	chr2:32521927~32523547:+
THCA	cis	rs7403037	0.617	rs11161118	ENSG00000259905.4	PWRN1	4.72	3.16e-06	0.000361	0.28	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24596584	chr15:24493137~24652130:+
THCA	cis	rs8046148	0.724	rs1420689	ENSG00000279356.1	RP11-429P3.8	4.72	3.16e-06	0.000361	0.25	0.21	Testicular germ cell tumor;	chr16:50041365	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs4619403	ENSG00000279356.1	RP11-429P3.8	4.72	3.16e-06	0.000361	0.25	0.21	Testicular germ cell tumor;	chr16:50041637	chr16:50072862~50074986:+
THCA	cis	rs9880211	1	rs9818056	ENSG00000239213.4	NCK1-AS1	4.72	3.16e-06	0.000361	0.23	0.21	Height;Body mass index;	chr3:136491232	chr3:136841726~136862054:-
THCA	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-4.72	3.16e-06	0.000362	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
THCA	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-4.72	3.16e-06	0.000362	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000273712.1	RP5-874C20.7	4.72	3.16e-06	0.000362	0.23	0.21	Cardiac Troponin-T levels;	chr6:28200255	chr6:28315613~28315883:-
THCA	cis	rs793571	0.628	rs28733370	ENSG00000245975.2	RP11-30K9.6	4.72	3.16e-06	0.000362	0.24	0.21	Schizophrenia;	chr15:58779385	chr15:58768072~58770974:-
THCA	cis	rs793571	0.628	rs7165019	ENSG00000245975.2	RP11-30K9.6	4.72	3.16e-06	0.000362	0.24	0.21	Schizophrenia;	chr15:58780098	chr15:58768072~58770974:-
THCA	cis	rs7336933	0.935	rs7326697	ENSG00000278338.3	VWA8-AS1	-4.72	3.16e-06	0.000362	-0.35	-0.21	Calcium levels;	chr13:41962265	chr13:41955808~41981565:+
THCA	cis	rs9973361	0.531	rs13427965	ENSG00000232411.1	AC009495.3	-4.72	3.16e-06	0.000362	-0.27	-0.21	Total body bone mineral density;	chr2:165820420	chr2:165833048~165839098:-
THCA	cis	rs28510890	0.547	rs12443027	ENSG00000258676.4	RP11-386M24.3	4.72	3.17e-06	0.000362	0.25	0.21	Lung cancer in ever smokers;	chr15:92612013	chr15:92580829~92600545:+
THCA	cis	rs8030605	0.704	rs76730249	ENSG00000277245.1	RP11-48G14.3	4.72	3.17e-06	0.000362	0.37	0.21	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56336865	chr15:56447120~56447697:+
THCA	cis	rs1005277	0.505	rs200931	ENSG00000276805.1	RP11-291L22.6	4.72	3.17e-06	0.000362	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:38451030~38451785:+
THCA	cis	rs703842	1	rs10431505	ENSG00000270039.1	RP11-571M6.17	-4.72	3.17e-06	0.000362	-0.24	-0.21	Multiple sclerosis;	chr12:57784806	chr12:57803838~57804415:+
THCA	cis	rs7989336	0.664	rs12560495	ENSG00000247400.3	DNAJC3-AS1	-4.72	3.17e-06	0.000362	-0.13	-0.21	Obesity;	chr13:96326663	chr13:95648733~95676925:-
THCA	cis	rs7989336	0.663	rs976322	ENSG00000247400.3	DNAJC3-AS1	-4.72	3.17e-06	0.000362	-0.13	-0.21	Obesity;	chr13:96334035	chr13:95648733~95676925:-
THCA	cis	rs17826219	0.585	rs8064302	ENSG00000263603.1	CTD-2349P21.5	4.72	3.17e-06	0.000362	0.37	0.21	Body mass index;	chr17:30397920	chr17:30729469~30731202:+
THCA	cis	rs4950322	0.748	rs17360812	ENSG00000226015.2	CCT8P1	-4.72	3.17e-06	0.000362	-0.25	-0.21	Protein quantitative trait loci;	chr1:147355010	chr1:147203276~147204932:-
THCA	cis	rs7824557	0.527	rs11785394	ENSG00000206014.6	OR7E161P	4.72	3.17e-06	0.000362	0.25	0.21	Retinal vascular caliber;	chr8:11380520	chr8:11928597~11929563:-
THCA	cis	rs4218	0.681	rs2121236	ENSG00000277144.1	RP11-59H7.4	-4.72	3.17e-06	0.000363	-0.29	-0.21	Social communication problems;	chr15:59091923	chr15:59115547~59116089:-
THCA	cis	rs9878978	1	rs17194392	ENSG00000237990.3	CNTN4-AS1	4.72	3.17e-06	0.000363	0.23	0.21	Blood pressure (smoking interaction);	chr3:2445591	chr3:3039033~3069242:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000164669.11	INTS4P1	-4.72	3.17e-06	0.000363	-0.26	-0.21	Aortic root size;	chr7:65964026	chr7:65141225~65234216:+
THCA	cis	rs10208649	0.522	rs1001296	ENSG00000233266.1	HMGB1P31	-4.72	3.17e-06	0.000363	-0.57	-0.21	Body mass index;	chr2:54172496	chr2:54051334~54051760:+
THCA	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	4.72	3.17e-06	0.000363	0.19	0.21	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
THCA	cis	rs58605417	0.566	rs16882450	ENSG00000253553.4	RP11-586K2.1	4.72	3.17e-06	0.000363	0.22	0.21	Schizophrenia;	chr8:88423246	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.565	rs821114	ENSG00000253553.4	RP11-586K2.1	4.72	3.17e-06	0.000363	0.22	0.21	Schizophrenia;	chr8:88428103	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.534	rs821111	ENSG00000253553.4	RP11-586K2.1	4.72	3.17e-06	0.000363	0.22	0.21	Schizophrenia;	chr8:88431163	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.513	rs1094206	ENSG00000253553.4	RP11-586K2.1	4.72	3.17e-06	0.000363	0.22	0.21	Schizophrenia;	chr8:88434311	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.534	rs2134962	ENSG00000253553.4	RP11-586K2.1	4.72	3.17e-06	0.000363	0.22	0.21	Schizophrenia;	chr8:88434802	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.534	rs821096	ENSG00000253553.4	RP11-586K2.1	4.72	3.17e-06	0.000363	0.22	0.21	Schizophrenia;	chr8:88442131	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.535	rs821093	ENSG00000253553.4	RP11-586K2.1	4.72	3.17e-06	0.000363	0.22	0.21	Schizophrenia;	chr8:88443703	chr8:88326836~88737134:+
THCA	cis	rs35740288	0.822	rs17574774	ENSG00000259295.5	CSPG4P12	-4.72	3.17e-06	0.000363	-0.33	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85690139	chr15:85191438~85213905:+
THCA	cis	rs6787172	0.811	rs12637678	ENSG00000272087.1	RP11-379F4.7	4.72	3.18e-06	0.000363	0.19	0.21	Subjective well-being;	chr3:158530833	chr3:158693120~158693768:-
THCA	cis	rs4794202	0.891	rs59715174	ENSG00000264920.1	RP11-6N17.4	-4.72	3.18e-06	0.000363	-0.25	-0.21	Alzheimer's disease (cognitive decline);	chr17:47854047	chr17:47891255~47895812:-
THCA	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	4.72	3.18e-06	0.000363	0.23	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
THCA	cis	rs1023500	0.573	rs133377	ENSG00000273366.1	CTA-989H11.1	-4.72	3.18e-06	0.000363	-0.27	-0.21	Schizophrenia;	chr22:42070946	chr22:42278188~42278846:+
THCA	cis	rs12893668	0.673	rs2296482	ENSG00000269958.1	RP11-73M18.8	4.72	3.18e-06	0.000363	0.21	0.21	Reticulocyte count;	chr14:103563482	chr14:103696353~103697163:+
THCA	cis	rs4693089	0.604	rs12499395	ENSG00000213608.5	SLC25A14P1	4.72	3.18e-06	0.000363	0.25	0.21	Menopause (age at onset);	chr4:83466004	chr4:83477524~83478424:+
THCA	cis	rs7209700	0.547	rs55845779	ENSG00000228782.6	CTD-2026D20.3	-4.72	3.18e-06	0.000363	-0.25	-0.21	IgG glycosylation;	chr17:47277385	chr17:47450568~47492492:-
THCA	cis	rs2243480	1	rs2243480	ENSG00000230295.1	RP11-458F8.2	-4.72	3.18e-06	0.000363	-0.25	-0.21	Diabetic kidney disease;	chr7:66134209	chr7:66880708~66882981:+
THCA	cis	rs6832769	0.961	rs2412646	ENSG00000272969.1	RP11-528I4.2	4.72	3.18e-06	0.000364	0.25	0.21	Personality dimensions;	chr4:55452605	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs11733864	ENSG00000272969.1	RP11-528I4.2	4.72	3.18e-06	0.000364	0.25	0.21	Personality dimensions;	chr4:55455363	chr4:55547112~55547889:+
THCA	cis	rs11448612	1	rs11448612	ENSG00000214293.7	APTR	-4.72	3.18e-06	0.000364	-0.16	-0.21	Facial morphology (factor 23);	chr7:77633271	chr7:77657660~77696265:-
THCA	cis	rs4639966	0.836	rs7130875	ENSG00000255422.1	AP002954.4	4.72	3.18e-06	0.000364	0.25	0.21	Systemic lupus erythematosus;	chr11:118742965	chr11:118704607~118750263:+
THCA	cis	rs7829975	0.567	rs6601273	ENSG00000254153.1	CTA-398F10.2	4.72	3.18e-06	0.000364	0.23	0.21	Mood instability;	chr8:8939009	chr8:8456909~8461337:-
THCA	cis	rs2135507	0.948	rs2174631	ENSG00000270480.1	RP11-57B24.1	4.72	3.18e-06	0.000364	0.3	0.21	Juvenile osteochondritis dissecans;	chr4:82665267	chr4:82691737~82692468:+
THCA	cis	rs2135507	0.948	rs2174632	ENSG00000270480.1	RP11-57B24.1	4.72	3.18e-06	0.000364	0.3	0.21	Juvenile osteochondritis dissecans;	chr4:82665324	chr4:82691737~82692468:+
THCA	cis	rs6490294	0.571	rs11066117	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:111994905	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs11066118	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:111996348	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs11066120	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:111998391	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7312472	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112000966	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs57439171	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112001483	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7316650	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112001860	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7313773	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112003884	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs12423960	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112004612	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs10849992	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112005213	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7310545	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112006156	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7296841	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112006305	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs11066127	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112008551	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7952986	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112010358	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7132863	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112011079	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs12300496	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112012629	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs11066128	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112012950	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7316563	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112015831	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs58368428	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112024471	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7295294	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112027089	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs6489824	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112030613	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs12312538	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112051717	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.571	rs7959011	ENSG00000226469.1	ADAM1B	4.72	3.18e-06	0.000364	0.31	0.21	Mean platelet volume;	chr12:112063433	chr12:111927018~111929017:+
THCA	cis	rs7267979	1	rs2856	ENSG00000274973.1	RP13-401N8.7	-4.72	3.18e-06	0.000364	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25845497~25845862:+
THCA	cis	rs1823874	0.71	rs8042933	ENSG00000182397.13	DNM1P46	4.72	3.18e-06	0.000364	0.25	0.21	IgG glycosylation;	chr15:99824641	chr15:99790156~99806927:-
THCA	cis	rs10090774	0.901	rs13280609	ENSG00000279766.1	RP11-642A1.2	-4.72	3.18e-06	0.000364	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140961641	chr8:140572142~140572812:-
THCA	cis	rs2742234	0.541	rs10899778	ENSG00000273008.1	RP11-351D16.3	4.72	3.18e-06	0.000364	0.2	0.21	Hirschsprung disease;	chr10:43223061	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs11238481	ENSG00000273008.1	RP11-351D16.3	4.72	3.18e-06	0.000364	0.2	0.21	Hirschsprung disease;	chr10:43223838	chr10:43136824~43138334:-
THCA	cis	rs2549003	0.811	rs10035166	ENSG00000233006.5	AC034220.3	4.72	3.19e-06	0.000364	0.18	0.21	Asthma (sex interaction);	chr5:132488235	chr5:132311285~132369916:-
THCA	cis	rs4934494	0.768	rs12771413	ENSG00000240996.1	RP11-80H5.7	4.72	3.19e-06	0.000364	0.25	0.21	Red blood cell count;	chr10:89633010	chr10:89694295~89697928:-
THCA	cis	rs5742933	1	rs1550388	ENSG00000273240.1	RP11-455J20.3	4.72	3.19e-06	0.000364	0.24	0.21	Ferritin levels;	chr2:189739054	chr2:189763859~189764456:-
THCA	cis	rs12143943	0.934	rs1870551	ENSG00000240219.1	RP11-430C7.5	4.72	3.19e-06	0.000364	0.19	0.21	Cognitive performance;	chr1:204611886	chr1:204626775~204629712:+
THCA	cis	rs440932	0.757	rs330945	ENSG00000254340.1	RP11-10A14.3	4.72	3.19e-06	0.000364	0.23	0.21	High light scatter reticulocyte percentage of red cells;	chr8:9164423	chr8:9141424~9145435:+
THCA	cis	rs9595908	0.709	rs3752476	ENSG00000212293.1	SNORA16	-4.72	3.19e-06	0.000364	-0.24	-0.21	Body mass index;	chr13:32770965	chr13:32420390~32420516:-
THCA	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	4.72	3.19e-06	0.000364	0.23	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
THCA	cis	rs9300255	0.739	rs1980252	ENSG00000235423.7	RP11-282O18.3	4.72	3.19e-06	0.000364	0.22	0.21	Neutrophil percentage of white cells;	chr12:123260631	chr12:123252030~123261483:-
THCA	cis	rs4915077	1	rs75700031	ENSG00000226822.1	RP11-356N1.2	4.72	3.19e-06	0.000364	0.4	0.21	Hypothyroidism;	chr1:107814381	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs4915076	ENSG00000226822.1	RP11-356N1.2	4.72	3.19e-06	0.000364	0.4	0.21	Hypothyroidism;	chr1:107816883	chr1:108071482~108074519:+
THCA	cis	rs28829049	0.536	rs12405382	ENSG00000270728.1	RP4-657E11.10	-4.72	3.19e-06	0.000365	-0.17	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19222487	chr1:19297080~19297903:+
THCA	cis	rs4639966	0.836	rs7124498	ENSG00000255422.1	AP002954.4	4.72	3.19e-06	0.000365	0.25	0.21	Systemic lupus erythematosus;	chr11:118745544	chr11:118704607~118750263:+
THCA	cis	rs1979679	0.918	rs2348234	ENSG00000247934.4	RP11-967K21.1	-4.72	3.19e-06	0.000365	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28354126	chr12:28163298~28190738:-
THCA	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-4.72	3.19e-06	0.000365	-0.22	-0.21	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
THCA	cis	rs2282300	0.637	rs1765131	ENSG00000242353.1	RP4-710M3.1	-4.71	3.19e-06	0.000365	-0.18	-0.21	Morning vs. evening chronotype;	chr11:30382991	chr11:30368148~30368646:+
THCA	cis	rs172166	0.585	rs149963	ENSG00000273712.1	RP5-874C20.7	4.71	3.19e-06	0.000365	0.23	0.21	Cardiac Troponin-T levels;	chr6:28049354	chr6:28315613~28315883:-
THCA	cis	rs28374715	0.532	rs28477406	ENSG00000247556.5	OIP5-AS1	4.71	3.19e-06	0.000365	0.21	0.21	Ulcerative colitis;	chr15:41349838	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.681	rs7162231	ENSG00000247556.5	OIP5-AS1	4.71	3.19e-06	0.000365	0.2	0.21	Ulcerative colitis;	chr15:41299661	chr15:41283990~41309737:+
THCA	cis	rs6787172	0.811	rs7620927	ENSG00000272087.1	RP11-379F4.7	4.71	3.19e-06	0.000365	0.19	0.21	Subjective well-being;	chr3:158528094	chr3:158693120~158693768:-
THCA	cis	rs17767392	0.958	rs10873246	ENSG00000259146.3	RP1-261D10.2	-4.71	3.2e-06	0.000365	-0.28	-0.21	Mitral valve prolapse;	chr14:71686976	chr14:71292729~71321814:-
THCA	cis	rs2280018	0.526	rs1510148	ENSG00000263335.1	AF001548.5	-4.71	3.2e-06	0.000365	-0.26	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15726674~15732993:+
THCA	cis	rs4660214	0.666	rs10493087	ENSG00000182109.6	RP11-69E11.4	-4.71	3.2e-06	0.000365	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251584	chr1:39522280~39546187:-
THCA	cis	rs8028182	0.636	rs10152155	ENSG00000260274.1	RP11-817O13.8	4.71	3.2e-06	0.000365	0.15	0.21	Sudden cardiac arrest;	chr15:75409213	chr15:75368155~75369584:+
THCA	cis	rs2243480	1	rs427044	ENSG00000164669.11	INTS4P1	4.71	3.2e-06	0.000365	0.41	0.21	Diabetic kidney disease;	chr7:66043558	chr7:65141225~65234216:+
THCA	cis	rs6445975	0.639	rs2037125	ENSG00000272360.1	RP11-359I18.5	-4.71	3.2e-06	0.000365	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58255504	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.575	rs7614726	ENSG00000272360.1	RP11-359I18.5	-4.71	3.2e-06	0.000365	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58257562	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.667	rs34532954	ENSG00000272360.1	RP11-359I18.5	-4.71	3.2e-06	0.000365	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58257867	chr3:58490830~58491291:-
THCA	cis	rs7632954	0.596	rs9858072	ENSG00000227110.5	LMCD1-AS1	4.71	3.2e-06	0.000365	0.26	0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8466829	chr3:7952805~8611924:-
THCA	cis	rs853679	1	rs853676	ENSG00000220721.1	OR1F12	4.71	3.2e-06	0.000366	0.34	0.21	Depression;	chr6:28331910	chr6:28073316~28074233:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000099984.9	GSTT2	-4.71	3.2e-06	0.000366	-0.29	-0.21	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23980123~23983911:+
THCA	cis	rs10266483	0.921	rs687547	ENSG00000228653.2	HNRNPCP7	-4.71	3.2e-06	0.000366	-0.18	-0.21	Response to statin therapy;	chr7:64284551	chr7:64500825~64501729:+
THCA	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-4.71	3.2e-06	0.000366	-0.24	-0.21	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
THCA	cis	rs7267979	1	rs6076345	ENSG00000274973.1	RP13-401N8.7	4.71	3.2e-06	0.000366	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4815418	ENSG00000274973.1	RP13-401N8.7	4.71	3.2e-06	0.000366	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4813566	ENSG00000274973.1	RP13-401N8.7	4.71	3.2e-06	0.000366	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4815421	ENSG00000274973.1	RP13-401N8.7	4.71	3.2e-06	0.000366	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25845497~25845862:+
THCA	cis	rs2386661	0.523	rs7896088	ENSG00000231483.1	RP11-336A10.5	4.71	3.2e-06	0.000366	0.22	0.21	Breast cancer;	chr10:5610323	chr10:5608475~5610793:-
THCA	cis	rs6430538	0.621	rs749017	ENSG00000224043.6	CCNT2-AS1	-4.71	3.2e-06	0.000366	-0.23	-0.21	Parkinson's disease;	chr2:134816089	chr2:134735464~134918710:-
THCA	cis	rs2243480	1	rs160634	ENSG00000164669.11	INTS4P1	-4.71	3.2e-06	0.000366	-0.4	-0.21	Diabetic kidney disease;	chr7:66063677	chr7:65141225~65234216:+
THCA	cis	rs7267979	1	rs6050590	ENSG00000274973.1	RP13-401N8.7	4.71	3.21e-06	0.000366	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25845497~25845862:+
THCA	cis	rs7474896	1	rs11011339	ENSG00000263064.2	RP11-291L22.7	4.71	3.21e-06	0.000366	0.33	0.21	Obesity (extreme);	chr10:37707418	chr10:38448689~38448949:+
THCA	cis	rs58605417	0.522	rs1910731	ENSG00000253553.4	RP11-586K2.1	4.71	3.21e-06	0.000366	0.22	0.21	Schizophrenia;	chr8:88465427	chr8:88326836~88737134:+
THCA	cis	rs6012564	1	rs2426112	ENSG00000227431.4	CSE1L-AS1	-4.71	3.21e-06	0.000366	-0.26	-0.21	Anger;	chr20:49073602	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs2426113	ENSG00000227431.4	CSE1L-AS1	-4.71	3.21e-06	0.000366	-0.26	-0.21	Anger;	chr20:49073652	chr20:49040463~49046044:-
THCA	cis	rs6012564	1	rs3092411	ENSG00000227431.4	CSE1L-AS1	-4.71	3.21e-06	0.000366	-0.26	-0.21	Anger;	chr20:49074054	chr20:49040463~49046044:-
THCA	cis	rs7819412	0.775	rs4841489	ENSG00000206014.6	OR7E161P	4.71	3.21e-06	0.000366	0.24	0.21	Triglycerides;	chr8:11079301	chr8:11928597~11929563:-
THCA	cis	rs7520050	0.966	rs7556615	ENSG00000234329.1	RP11-767N6.2	-4.71	3.21e-06	0.000366	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45651039~45651826:-
THCA	cis	rs17092148	0.697	rs13037664	ENSG00000276073.1	RP5-1125A11.7	-4.71	3.21e-06	0.000366	-0.23	-0.21	Neuroticism;	chr20:34709184	chr20:33985617~33988989:-
THCA	cis	rs72843506	0.656	rs9913018	ENSG00000231258.2	ZSWIM5P2	4.71	3.21e-06	0.000367	0.31	0.21	Schizophrenia;	chr17:20160759	chr17:20583758~20591180:-
THCA	cis	rs8064024	0.681	rs1395602	ENSG00000267077.1	RP11-127I20.5	4.71	3.21e-06	0.000367	0.24	0.21	Cancer;	chr16:4861238	chr16:4795265~4796532:-
THCA	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-4.71	3.21e-06	0.000367	-0.24	-0.21	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
THCA	cis	rs6832769	0.925	rs1965467	ENSG00000272969.1	RP11-528I4.2	4.71	3.21e-06	0.000367	0.25	0.21	Personality dimensions;	chr4:55456573	chr4:55547112~55547889:+
THCA	cis	rs7267979	1	rs6050561	ENSG00000274973.1	RP13-401N8.7	4.71	3.21e-06	0.000367	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6083813	ENSG00000274973.1	RP13-401N8.7	4.71	3.21e-06	0.000367	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4815406	ENSG00000274973.1	RP13-401N8.7	4.71	3.21e-06	0.000367	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs6083817	ENSG00000274973.1	RP13-401N8.7	4.71	3.21e-06	0.000367	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050564	ENSG00000274973.1	RP13-401N8.7	4.71	3.21e-06	0.000367	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25845497~25845862:+
THCA	cis	rs7560272	0.538	rs17350056	ENSG00000163016.8	ALMS1P	-4.71	3.21e-06	0.000367	-0.27	-0.21	Schizophrenia;	chr2:73695750	chr2:73644919~73685576:+
THCA	cis	rs6866614	0.605	rs5029422	ENSG00000233006.5	AC034220.3	4.71	3.21e-06	0.000367	0.18	0.21	Perceived unattractiveness to mosquitoes;	chr5:132054921	chr5:132311285~132369916:-
THCA	cis	rs4950322	0.57	rs72691012	ENSG00000226015.2	CCT8P1	4.71	3.21e-06	0.000367	0.24	0.21	Protein quantitative trait loci;	chr1:147239751	chr1:147203276~147204932:-
THCA	cis	rs2790457	0.958	rs2790454	ENSG00000254635.4	WAC-AS1	-4.71	3.21e-06	0.000367	-0.21	-0.21	Multiple myeloma;	chr10:28553103	chr10:28522652~28532743:-
THCA	cis	rs12554020	0.582	rs76863038	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93666143	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs56310424	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93666313	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.504	rs12551694	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93666619	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs12555927	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93666800	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs3829059	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93668874	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs76499753	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93670155	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs1963	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93670315	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs76244171	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93673473	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs74921118	ENSG00000227603.1	RP11-165J3.6	4.71	3.21e-06	0.000367	0.44	0.21	Schizophrenia;	chr9:93675241	chr9:93435332~93437121:-
THCA	cis	rs4722585	0.513	rs11760917	ENSG00000273237.1	CTB-119C2.1	-4.71	3.21e-06	0.000367	-0.21	-0.21	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26168405	chr7:26173533~26174945:-
THCA	cis	rs1823913	0.66	rs1454752	ENSG00000280083.1	RP11-317J9.1	4.71	3.21e-06	0.000367	0.25	0.21	Obesity-related traits;	chr2:191298668	chr2:191154118~191156070:-
THCA	cis	rs4787951	0.56	rs3916997	ENSG00000259940.2	CTD-3203P2.1	-4.71	3.21e-06	0.000367	-0.22	-0.21	Eosinophil percentage of white cells;	chr16:27333793	chr16:27213308~27214993:-
THCA	cis	rs7394190	0.748	rs11000771	ENSG00000271848.1	RP11-464F9.21	-4.71	3.21e-06	0.000367	-0.29	-0.21	Incident atrial fibrillation;	chr10:73764700	chr10:73654039~73674719:+
THCA	cis	rs4646450	0.735	rs10243678	ENSG00000244219.5	GS1-259H13.2	-4.71	3.21e-06	0.000367	-0.28	-0.21	Blood metabolite levels;	chr7:99394321	chr7:99598066~99610813:+
THCA	cis	rs6445975	0.688	rs2271633	ENSG00000272360.1	RP11-359I18.5	-4.71	3.21e-06	0.000367	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58274346	chr3:58490830~58491291:-
THCA	cis	rs270601	0.913	rs273916	ENSG00000237714.1	P4HA2-AS1	4.71	3.21e-06	0.000367	0.28	0.21	Acylcarnitine levels;	chr5:132324137	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.507	rs273915	ENSG00000237714.1	P4HA2-AS1	4.71	3.21e-06	0.000367	0.28	0.21	Breast cancer;	chr5:132324426	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.507	rs272892	ENSG00000237714.1	P4HA2-AS1	4.71	3.21e-06	0.000367	0.28	0.21	Breast cancer;	chr5:132328656	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.531	rs272888	ENSG00000237714.1	P4HA2-AS1	4.71	3.21e-06	0.000367	0.28	0.21	Breast cancer;	chr5:132329730	chr5:132184876~132192808:+
THCA	cis	rs6921919	0.583	rs9468355	ENSG00000219392.1	RP1-265C24.5	-4.71	3.21e-06	0.000367	-0.26	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28115628~28116551:+
THCA	cis	rs1150668	0.796	rs213237	ENSG00000280107.1	AL022393.9	-4.71	3.22e-06	0.000367	-0.2	-0.21	Pubertal anthropometrics;	chr6:28356161	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs35560946	ENSG00000280107.1	AL022393.9	-4.71	3.22e-06	0.000367	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28170845~28172521:+
THCA	cis	rs8028182	0.636	rs12909863	ENSG00000260274.1	RP11-817O13.8	4.71	3.22e-06	0.000367	0.15	0.21	Sudden cardiac arrest;	chr15:75533481	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs12708520	ENSG00000260274.1	RP11-817O13.8	4.71	3.22e-06	0.000367	0.15	0.21	Sudden cardiac arrest;	chr15:75538198	chr15:75368155~75369584:+
THCA	cis	rs9601248	0.627	rs2146593	ENSG00000227676.3	LINC01068	4.71	3.22e-06	0.000367	0.27	0.21	Major depressive disorder;	chr13:79605977	chr13:79566727~79571436:+
THCA	cis	rs7942368	1	rs10899280	ENSG00000261578.1	RP11-21L23.2	4.71	3.22e-06	0.000367	0.31	0.21	Endometriosis;	chr11:76785693	chr11:76800364~76804555:+
THCA	cis	rs7608910	0.832	rs10191548	ENSG00000271889.1	RP11-493E12.1	4.71	3.22e-06	0.000368	0.23	0.21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60970260	chr2:61151433~61162105:-
THCA	cis	rs9970896	1	rs10927074	ENSG00000237845.1	RP5-940F7.2	-4.71	3.22e-06	0.000368	-0.41	-0.21	Monocyte percentage of white cells;	chr1:235940665	chr1:235942553~235943805:-
THCA	cis	rs2348418	0.579	rs2126896	ENSG00000247934.4	RP11-967K21.1	-4.71	3.22e-06	0.000368	-0.18	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28239701	chr12:28163298~28190738:-
THCA	cis	rs2243480	1	rs34970380	ENSG00000164669.11	INTS4P1	4.71	3.22e-06	0.000368	0.41	0.21	Diabetic kidney disease;	chr7:65966506	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000164669.11	INTS4P1	4.71	3.22e-06	0.000368	0.41	0.21	Diabetic kidney disease;	chr7:66004843	chr7:65141225~65234216:+
THCA	cis	rs651907	0.967	rs694936	ENSG00000256628.3	ZBTB11-AS1	4.71	3.22e-06	0.000368	0.22	0.21	Colorectal cancer;	chr3:101868949	chr3:101676475~101679217:+
THCA	cis	rs7617773	0.817	rs9837228	ENSG00000199476.1	Y_RNA	4.71	3.22e-06	0.000368	0.27	0.21	Coronary artery disease;	chr3:48282976	chr3:48288587~48288694:+
THCA	cis	rs7618915	0.547	rs33967311	ENSG00000243224.1	RP5-1157M23.2	-4.71	3.22e-06	0.000368	-0.23	-0.21	Bipolar disorder;	chr3:52649848	chr3:52239258~52241097:+
THCA	cis	rs2236231	0.55	rs2038490	ENSG00000259502.1	RP11-643G16.3	-4.71	3.22e-06	0.000368	-0.25	-0.21	Plasma kynurenine levels in major depressive disorder;	chr14:67593658	chr14:67610986~67613864:+
THCA	cis	rs9875589	0.509	rs6768383	ENSG00000228242.5	AC093495.4	4.71	3.22e-06	0.000368	0.12	0.21	Ovarian reserve;	chr3:14035452	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs6770928	ENSG00000228242.5	AC093495.4	4.71	3.22e-06	0.000368	0.12	0.21	Ovarian reserve;	chr3:14035689	chr3:14144637~14165978:+
THCA	cis	rs77637988	0.553	rs10169629	ENSG00000202227.1	RNU6-282P	4.71	3.22e-06	0.000368	0.22	0.21	Joint mobility (Beighton score);	chr2:48397905	chr2:48501922~48502024:-
THCA	cis	rs6570726	0.764	rs9403731	ENSG00000270638.1	RP3-466P17.1	4.71	3.22e-06	0.000368	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145735570~145737218:+
THCA	cis	rs728616	0.764	rs11201025	ENSG00000242600.5	MBL1P	4.71	3.22e-06	0.000368	0.23	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79904898~79950336:+
THCA	cis	rs7474896	0.515	rs675628	ENSG00000226578.1	RP11-258F22.1	4.71	3.22e-06	0.000368	0.3	0.21	Obesity (extreme);	chr10:38016403	chr10:37775371~37784131:-
THCA	cis	rs860295	0.5	rs34995046	ENSG00000225855.5	RUSC1-AS1	-4.71	3.22e-06	0.000368	-0.14	-0.21	Body mass index;	chr1:156018694	chr1:155316863~155324176:-
THCA	cis	rs11846409	0.932	rs28617526	ENSG00000274576.2	IGHV2-70	-4.71	3.22e-06	0.000368	-0.18	-0.21	Rheumatic heart disease;	chr14:106637322	chr14:106770577~106771020:-
THCA	cis	rs2288884	0.559	rs8111873	ENSG00000269483.1	AC006272.1	4.71	3.22e-06	0.000368	0.25	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:51839924~51843324:-
THCA	cis	rs6787172	0.811	rs6780010	ENSG00000272087.1	RP11-379F4.7	4.71	3.22e-06	0.000368	0.19	0.21	Subjective well-being;	chr3:158517627	chr3:158693120~158693768:-
THCA	cis	rs6441961	0.628	rs4683211	ENSG00000223552.1	RP11-24F11.2	-4.71	3.22e-06	0.000368	-0.21	-0.21	Celiac disease;	chr3:46303922	chr3:46364955~46407059:-
THCA	cis	rs8020095	1	rs1884066	ENSG00000258561.1	RP11-72M17.1	-4.71	3.23e-06	0.000368	-0.28	-0.21	Depression (quantitative trait);	chr14:66986117	chr14:66212810~66509394:-
THCA	cis	rs8050907	0.744	rs8055559	ENSG00000278434.1	RP11-709D24.8	-4.71	3.23e-06	0.000368	-0.47	-0.21	Obesity-related traits;	chr16:4490226	chr16:4532216~4533670:-
THCA	cis	rs9876781	1	rs2362452	ENSG00000244380.1	RP11-24C3.2	-4.71	3.23e-06	0.000368	-0.25	-0.21	Longevity;	chr3:48376724	chr3:48440352~48446656:-
THCA	cis	rs9487094	0.626	rs2025148	ENSG00000223537.2	RP5-919F19.5	-4.71	3.23e-06	0.000368	-0.21	-0.21	Height;	chr6:109706740	chr6:109487906~109506800:+
THCA	cis	rs7824557	0.569	rs35418978	ENSG00000154316.13	TDH	-4.71	3.23e-06	0.000369	-0.16	-0.21	Retinal vascular caliber;	chr8:11328944	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.606	rs2736264	ENSG00000154316.13	TDH	-4.71	3.23e-06	0.000369	-0.16	-0.21	Retinal vascular caliber;	chr8:11329130	chr8:11339637~11368452:+
THCA	cis	rs72843506	0.722	rs74255387	ENSG00000231258.2	ZSWIM5P2	4.71	3.23e-06	0.000369	0.33	0.21	Schizophrenia;	chr17:20198070	chr17:20583758~20591180:-
THCA	cis	rs972578	0.691	rs4822200	ENSG00000274717.1	RP1-47A17.1	-4.71	3.23e-06	0.000369	-0.23	-0.21	Mean platelet volume;	chr22:42805204	chr22:42791814~42794313:-
THCA	cis	rs8046148	0.694	rs6500282	ENSG00000279356.1	RP11-429P3.8	4.71	3.23e-06	0.000369	0.25	0.21	Testicular germ cell tumor;	chr16:50104189	chr16:50072862~50074986:+
THCA	cis	rs16975963	0.644	rs73035164	ENSG00000226686.6	LINC01535	-4.71	3.23e-06	0.000369	-0.28	-0.21	Longevity;	chr19:37655819	chr19:37251912~37265535:+
THCA	cis	rs9863	0.861	rs10846580	ENSG00000269997.1	RP11-214K3.21	-4.71	3.23e-06	0.000369	-0.26	-0.21	White blood cell count;	chr12:123930906	chr12:123966077~123966629:-
THCA	cis	rs10090774	0.965	rs11777839	ENSG00000279766.1	RP11-642A1.2	-4.71	3.23e-06	0.000369	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140907795	chr8:140572142~140572812:-
THCA	cis	rs1048886	0.938	rs56351105	ENSG00000271967.1	RP11-134K13.4	-4.71	3.23e-06	0.000369	-0.22	-0.21	Type 2 diabetes;	chr6:70396394	chr6:70596438~70596980:+
THCA	cis	rs7045881	0.8	rs62544434	ENSG00000254396.1	RP11-56F10.3	4.71	3.23e-06	0.000369	0.39	0.21	Schizophrenia;	chr9:26895827	chr9:27102630~27104728:+
THCA	cis	rs17767392	0.846	rs12884929	ENSG00000259146.3	RP1-261D10.2	4.71	3.24e-06	0.000369	0.27	0.21	Mitral valve prolapse;	chr14:71322229	chr14:71292729~71321814:-
THCA	cis	rs2239547	0.522	rs9865094	ENSG00000242142.1	SERBP1P3	-4.71	3.24e-06	0.000369	-0.26	-0.21	Schizophrenia;	chr3:52951303	chr3:53064283~53065091:-
THCA	cis	rs30380	1	rs246454	ENSG00000272109.1	CTD-2260A17.3	-4.71	3.24e-06	0.00037	-0.26	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96804353~96806105:+
THCA	cis	rs30380	0.922	rs246453	ENSG00000272109.1	CTD-2260A17.3	-4.71	3.24e-06	0.00037	-0.26	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96804353~96806105:+
THCA	cis	rs30380	1	rs30187	ENSG00000272109.1	CTD-2260A17.3	-4.71	3.24e-06	0.00037	-0.26	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96804353~96806105:+
THCA	cis	rs8002861	0.765	rs12868462	ENSG00000274001.1	RP11-5G9.5	-4.71	3.24e-06	0.00037	-0.26	-0.21	Leprosy;	chr13:43879344	chr13:43877715~43878163:-
THCA	cis	rs9309473	0.519	rs7606947	ENSG00000163016.8	ALMS1P	4.71	3.24e-06	0.00037	0.27	0.21	Metabolite levels;	chr2:73682691	chr2:73644919~73685576:+
THCA	cis	rs240993	0.812	rs6929024	ENSG00000271789.1	RP5-1112D6.7	4.71	3.24e-06	0.00037	0.26	0.21	Inflammatory skin disease;Psoriasis;	chr6:111545104	chr6:111297126~111298510:+
THCA	cis	rs1923243	0.71	rs12059553	ENSG00000223479.3	RP4-788P17.1	-4.71	3.24e-06	0.00037	-0.23	-0.21	Migraine;	chr1:73175403	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.558	rs12037338	ENSG00000223479.3	RP4-788P17.1	-4.71	3.24e-06	0.00037	-0.23	-0.21	Migraine;	chr1:73175846	chr1:73635216~73715214:+
THCA	cis	rs4784934	0.531	rs2042402	ENSG00000260186.4	RP11-481J2.2	4.71	3.24e-06	0.00037	0.28	0.21	QT interval;	chr16:58430011	chr16:58421326~58462470:+
THCA	cis	rs875971	0.522	rs709604	ENSG00000229886.1	RP5-1132H15.3	-4.71	3.24e-06	0.00037	-0.22	-0.21	Aortic root size;	chr7:66032447	chr7:66025126~66031544:-
THCA	cis	rs5752326	0.51	rs6005053	ENSG00000261188.1	CTA-445C9.14	4.71	3.24e-06	0.00037	0.21	0.21	Ischemic stroke;	chr22:26461633	chr22:26512537~26514568:+
THCA	cis	rs9863	0.896	rs7311233	ENSG00000269997.1	RP11-214K3.21	4.71	3.24e-06	0.00037	0.26	0.21	White blood cell count;	chr12:123991393	chr12:123966077~123966629:-
THCA	cis	rs6787172	0.677	rs6441206	ENSG00000272087.1	RP11-379F4.7	4.71	3.24e-06	0.00037	0.19	0.21	Subjective well-being;	chr3:158523282	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.748	rs7639678	ENSG00000272087.1	RP11-379F4.7	4.71	3.24e-06	0.00037	0.19	0.21	Subjective well-being;	chr3:158523664	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.811	rs1595029	ENSG00000272087.1	RP11-379F4.7	4.71	3.24e-06	0.00037	0.19	0.21	Subjective well-being;	chr3:158523978	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.777	rs1595028	ENSG00000272087.1	RP11-379F4.7	4.71	3.24e-06	0.00037	0.19	0.21	Subjective well-being;	chr3:158524109	chr3:158693120~158693768:-
THCA	cis	rs2239547	0.562	rs35380116	ENSG00000242142.1	SERBP1P3	-4.71	3.24e-06	0.00037	-0.26	-0.21	Schizophrenia;	chr3:52945162	chr3:53064283~53065091:-
THCA	cis	rs4578769	0.531	rs12964304	ENSG00000265939.1	UBE2CP2	4.71	3.24e-06	0.00037	0.24	0.21	Eosinophil percentage of white cells;	chr18:22928641	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.531	rs12968784	ENSG00000265939.1	UBE2CP2	4.71	3.24e-06	0.00037	0.24	0.21	Eosinophil percentage of white cells;	chr18:22928645	chr18:22900486~22900995:-
THCA	cis	rs36116061	1	rs36116061	ENSG00000253553.4	RP11-586K2.1	4.71	3.24e-06	0.00037	0.26	0.21	Cerebral amyloid deposition (PET imaging);	chr8:88361098	chr8:88326836~88737134:+
THCA	cis	rs11671005	0.695	rs8106061	ENSG00000268912.1	CTD-2619J13.17	-4.71	3.24e-06	0.00037	-0.2	-0.21	Mean platelet volume;	chr19:58406623	chr19:58428632~58431148:-
THCA	cis	rs739496	0.579	rs12582302	ENSG00000226469.1	ADAM1B	4.71	3.24e-06	0.00037	0.26	0.21	Platelet count;	chr12:111907830	chr12:111927018~111929017:+
THCA	cis	rs227275	0.527	rs223338	ENSG00000248971.2	KRT8P46	-4.71	3.24e-06	0.00037	-0.26	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102728746~102730171:-
THCA	cis	rs690037	0.641	rs538525	ENSG00000271964.1	RP11-415F23.2	4.71	3.24e-06	0.00037	0.19	0.21	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334772	chr3:16314439~16314987:+
THCA	cis	rs2018683	1	rs160837	ENSG00000272568.4	CTB-113D17.1	4.71	3.25e-06	0.00037	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28973116	chr7:28979967~29013367:+
THCA	cis	rs274567	0.55	rs272885	ENSG00000237714.1	P4HA2-AS1	4.71	3.25e-06	0.00037	0.28	0.21	Blood metabolite levels;	chr5:132332043	chr5:132184876~132192808:+
THCA	cis	rs72945132	0.714	rs117232799	ENSG00000254604.1	AP000487.6	-4.71	3.25e-06	0.00037	-0.41	-0.21	Coronary artery disease;	chr11:70311076	chr11:70282367~70363368:-
THCA	cis	rs2442825	0.54	rs35728233	ENSG00000206573.7	THUMPD3-AS1	-4.71	3.25e-06	0.000371	-0.15	-0.21	Cerebrospinal fluid clusterin levels;	chr3:9387510	chr3:9349689~9398579:-
THCA	cis	rs7267979	0.966	rs6083818	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4815409	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs6107031	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6115159	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4813562	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6037099	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs4815414	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6083825	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs34645895	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6115168	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6037105	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2387880	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2387882	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2387884	ENSG00000274973.1	RP13-401N8.7	4.71	3.25e-06	0.000371	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25845497~25845862:+
THCA	cis	rs10888838	0.756	rs11589005	ENSG00000198711.5	SSBP3-AS1	4.71	3.25e-06	0.000371	0.27	0.21	Mitochondrial DNA levels;	chr1:54227752	chr1:54236440~54239063:+
THCA	cis	rs853679	0.513	rs13437444	ENSG00000261839.1	RP1-265C24.8	4.71	3.25e-06	0.000371	0.28	0.21	Depression;	chr6:28103220	chr6:28136849~28139678:+
THCA	cis	rs11846409	0.86	rs59055020	ENSG00000211974.3	IGHV2-70	-4.71	3.25e-06	0.000371	-0.2	-0.21	Rheumatic heart disease;	chr14:106631573	chr14:106723574~106724093:-
THCA	cis	rs3796352	1	rs11718834	ENSG00000242142.1	SERBP1P3	-4.71	3.25e-06	0.000371	-0.4	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:52929652	chr3:53064283~53065091:-
THCA	cis	rs62184315	0.58	rs62185872	ENSG00000253559.1	OSGEPL1-AS1	-4.71	3.25e-06	0.000371	-0.29	-0.21	Alcohol dependence (age at onset);	chr2:189690033	chr2:189762704~189765556:+
THCA	cis	rs3734266	0.702	rs7743949	ENSG00000272288.4	RP11-140K17.3	-4.71	3.25e-06	0.000371	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34836738	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs13213604	ENSG00000272288.4	RP11-140K17.3	-4.71	3.25e-06	0.000371	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34844764	chr6:34696317~34697470:+
THCA	cis	rs2436845	1	rs972142	ENSG00000253669.3	KB-1732A1.1	-4.71	3.25e-06	0.000371	-0.22	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102824025	chr8:102805517~102809971:+
THCA	cis	rs7773456	0.74	rs6917179	ENSG00000227116.1	RP3-471C18.1	4.71	3.25e-06	0.000371	0.24	0.21	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19730427~19734567:-
THCA	cis	rs3770081	1	rs74607112	ENSG00000273080.1	RP11-301O19.1	-4.71	3.25e-06	0.000371	-0.46	-0.21	Facial emotion recognition (sad faces);	chr2:86078411	chr2:86195590~86196049:+
THCA	cis	rs1979679	0.842	rs1841964	ENSG00000247934.4	RP11-967K21.1	4.71	3.25e-06	0.000371	0.21	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28190100	chr12:28163298~28190738:-
THCA	cis	rs7647973	0.6	rs35174559	ENSG00000229759.1	MRPS18AP1	4.71	3.25e-06	0.000371	0.27	0.21	Menarche (age at onset);	chr3:49250326	chr3:48256350~48256938:-
THCA	cis	rs9875589	0.509	rs1844108	ENSG00000228242.5	AC093495.4	4.71	3.25e-06	0.000371	0.12	0.21	Ovarian reserve;	chr3:13982828	chr3:14144637~14165978:+
THCA	cis	rs5742933	1	rs55792400	ENSG00000273240.1	RP11-455J20.3	-4.71	3.25e-06	0.000371	-0.24	-0.21	Ferritin levels;	chr2:189686708	chr2:189763859~189764456:-
THCA	cis	rs5742933	0.947	rs62185871	ENSG00000273240.1	RP11-455J20.3	-4.71	3.25e-06	0.000371	-0.24	-0.21	Ferritin levels;	chr2:189686980	chr2:189763859~189764456:-
THCA	cis	rs7181230	0.885	rs4924413	ENSG00000275636.1	RP11-521C20.5	4.71	3.26e-06	0.000371	0.23	0.21	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40078892~40079347:+
THCA	cis	rs4763879	0.778	rs1044771	ENSG00000256673.1	RP11-599J14.2	4.71	3.26e-06	0.000371	0.26	0.21	Type 1 diabetes;	chr12:9699333	chr12:9398355~9414851:-
THCA	cis	rs858239	0.539	rs6976957	ENSG00000226816.2	AC005082.12	4.71	3.26e-06	0.000372	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23206013~23208045:+
THCA	cis	rs427943	0.766	rs372766	ENSG00000223768.1	LINC00205	-4.71	3.26e-06	0.000372	-0.19	-0.21	Body mass index;	chr21:45165565	chr21:45293285~45297354:+
THCA	cis	rs7924176	0.564	rs34868542	ENSG00000213731.2	RAB5CP1	-4.71	3.26e-06	0.000372	-0.26	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226399	chr10:74423435~74424014:-
THCA	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-4.71	3.26e-06	0.000372	-0.19	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
THCA	cis	rs804292	1	rs804292	ENSG00000255046.1	RP11-297N6.4	-4.71	3.26e-06	0.000372	-0.26	-0.21	Nicotine use;Alcohol dependence;	chr8:11786406	chr8:11797928~11802568:-
THCA	cis	rs1048886	0.938	rs7742044	ENSG00000271967.1	RP11-134K13.4	-4.71	3.26e-06	0.000372	-0.21	-0.21	Type 2 diabetes;	chr6:70422491	chr6:70596438~70596980:+
THCA	cis	rs7554547	0.6	rs2273290	ENSG00000199347.1	RNU5E-1	-4.71	3.26e-06	0.000372	-0.3	-0.21	Nonsyndromic cleft lip with cleft palate;	chr1:11958321	chr1:11908152~11908271:+
THCA	cis	rs6832769	0.925	rs4371676	ENSG00000272969.1	RP11-528I4.2	4.71	3.26e-06	0.000372	0.25	0.21	Personality dimensions;	chr4:55462841	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs4864998	ENSG00000272969.1	RP11-528I4.2	4.71	3.26e-06	0.000372	0.25	0.21	Personality dimensions;	chr4:55466439	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs2140077	ENSG00000272969.1	RP11-528I4.2	4.71	3.26e-06	0.000372	0.25	0.21	Personality dimensions;	chr4:55472786	chr4:55547112~55547889:+
THCA	cis	rs2836974	0.568	rs2183573	ENSG00000255568.3	BRWD1-AS2	-4.71	3.26e-06	0.000372	-0.17	-0.21	Cognitive function;	chr21:39202379	chr21:39313935~39314962:+
THCA	cis	rs9925964	0.933	rs56314408	ENSG00000260911.2	RP11-196G11.2	4.71	3.26e-06	0.000372	0.17	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106068	chr16:31043150~31049868:+
THCA	cis	rs465969	0.793	rs34288099	ENSG00000272356.1	RP5-1112D6.8	4.71	3.26e-06	0.000372	0.28	0.21	Psoriasis;	chr6:111424034	chr6:111309203~111313517:+
THCA	cis	rs10256972	0.786	rs3735686	ENSG00000225146.1	AC073957.15	4.71	3.26e-06	0.000372	0.22	0.21	Endometriosis;Longevity;	chr7:1022891	chr7:1029025~1043891:+
THCA	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-4.71	3.26e-06	0.000372	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
THCA	cis	rs6012564	0.927	rs6019553	ENSG00000227431.4	CSE1L-AS1	-4.71	3.26e-06	0.000372	-0.27	-0.21	Anger;	chr20:48955014	chr20:49040463~49046044:-
THCA	cis	rs9475752	0.744	rs17685235	ENSG00000231441.1	RP11-472M19.2	4.71	3.26e-06	0.000372	0.24	0.21	Menarche (age at onset);	chr6:56939607	chr6:56844002~56864078:+
THCA	cis	rs7726839	0.54	rs28364691	ENSG00000225138.6	CTD-2228K2.7	4.71	3.26e-06	0.000372	0.26	0.21	Obesity-related traits;	chr5:663969	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs72707016	ENSG00000225138.6	CTD-2228K2.7	4.71	3.26e-06	0.000372	0.26	0.21	Obesity-related traits;	chr5:665033	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs61731455	ENSG00000225138.6	CTD-2228K2.7	4.71	3.26e-06	0.000372	0.26	0.21	Obesity-related traits;	chr5:665180	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs74553517	ENSG00000225138.6	CTD-2228K2.7	4.71	3.26e-06	0.000372	0.26	0.21	Obesity-related traits;	chr5:665556	chr5:473236~480884:+
THCA	cis	rs6787172	0.755	rs9819134	ENSG00000272087.1	RP11-379F4.7	4.71	3.26e-06	0.000372	0.19	0.21	Subjective well-being;	chr3:158510483	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.811	rs9857535	ENSG00000272087.1	RP11-379F4.7	4.71	3.26e-06	0.000372	0.19	0.21	Subjective well-being;	chr3:158511008	chr3:158693120~158693768:-
THCA	cis	rs9311474	0.508	rs11718420	ENSG00000243224.1	RP5-1157M23.2	-4.71	3.26e-06	0.000372	-0.23	-0.21	Electroencephalogram traits;	chr3:52577397	chr3:52239258~52241097:+
THCA	cis	rs763121	0.853	rs2179142	ENSG00000273076.1	RP3-508I15.22	4.71	3.26e-06	0.000372	0.21	0.21	Menopause (age at onset);	chr22:38641949	chr22:38743495~38743910:+
THCA	cis	rs9876781	1	rs9883759	ENSG00000244380.1	RP11-24C3.2	4.71	3.26e-06	0.000372	0.25	0.21	Longevity;	chr3:48422209	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs6442120	ENSG00000244380.1	RP11-24C3.2	4.71	3.26e-06	0.000372	0.25	0.21	Longevity;	chr3:48423094	chr3:48440352~48446656:-
THCA	cis	rs7429990	0.864	rs319693	ENSG00000228638.1	FCF1P2	-4.71	3.27e-06	0.000373	-0.21	-0.21	Educational attainment (years of education);	chr3:47845090	chr3:48290793~48291375:-
THCA	cis	rs8177876	0.658	rs2278022	ENSG00000261838.4	RP11-303E16.6	4.71	3.27e-06	0.000373	0.38	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81069854~81076598:+
THCA	cis	rs2803122	0.934	rs1329730	ENSG00000273226.1	RP11-513M16.8	-4.71	3.27e-06	0.000373	-0.19	-0.21	Pulse pressure;	chr9:19277322	chr9:19375451~19375996:+
THCA	cis	rs2803122	0.869	rs10757046	ENSG00000273226.1	RP11-513M16.8	-4.71	3.27e-06	0.000373	-0.19	-0.21	Pulse pressure;	chr9:19278996	chr9:19375451~19375996:+
THCA	cis	rs2803122	0.934	rs10811161	ENSG00000273226.1	RP11-513M16.8	-4.71	3.27e-06	0.000373	-0.19	-0.21	Pulse pressure;	chr9:19279855	chr9:19375451~19375996:+
THCA	cis	rs317689	0.69	rs570256	ENSG00000274979.1	RP11-1143G9.5	-4.71	3.27e-06	0.000373	-0.24	-0.21	Response to diuretic therapy;	chr12:69269149	chr12:69326574~69331882:-
THCA	cis	rs317689	0.69	rs547827	ENSG00000274979.1	RP11-1143G9.5	-4.71	3.27e-06	0.000373	-0.24	-0.21	Response to diuretic therapy;	chr12:69275923	chr12:69326574~69331882:-
THCA	cis	rs317689	0.69	rs604168	ENSG00000274979.1	RP11-1143G9.5	-4.71	3.27e-06	0.000373	-0.24	-0.21	Response to diuretic therapy;	chr12:69277378	chr12:69326574~69331882:-
THCA	cis	rs12134133	1	rs6673333	ENSG00000237074.1	RP11-6J21.2	4.71	3.27e-06	0.000373	0.22	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207249067~207309121:+
THCA	cis	rs6012564	0.793	rs6067007	ENSG00000227431.4	CSE1L-AS1	4.71	3.27e-06	0.000373	0.27	0.21	Anger;	chr20:49204492	chr20:49040463~49046044:-
THCA	cis	rs9634489	0.502	rs1328048	ENSG00000247400.3	DNAJC3-AS1	4.71	3.27e-06	0.000373	0.14	0.21	Body mass index;	chr13:96467274	chr13:95648733~95676925:-
THCA	cis	rs12472274	0.941	rs36066920	ENSG00000279484.1	KLHL30-AS1	4.71	3.27e-06	0.000373	0.23	0.21	Phospholipid levels (plasma);	chr2:238165839	chr2:238152889~238155994:-
THCA	cis	rs7474896	1	rs61858625	ENSG00000263064.2	RP11-291L22.7	4.71	3.27e-06	0.000374	0.36	0.21	Obesity (extreme);	chr10:37713114	chr10:38448689~38448949:+
THCA	cis	rs11846409	0.799	rs10467899	ENSG00000211974.3	IGHV2-70	-4.71	3.28e-06	0.000374	-0.2	-0.21	Rheumatic heart disease;	chr14:106644012	chr14:106723574~106724093:-
THCA	cis	rs8177876	0.822	rs4889231	ENSG00000261061.1	RP11-303E16.2	4.71	3.28e-06	0.000374	0.29	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81030770~81031485:+
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000259295.5	CSPG4P12	-4.71	3.28e-06	0.000374	-0.29	-0.21	P wave terminal force;	chr15:84632519	chr15:85191438~85213905:+
THCA	cis	rs12681963	0.688	rs67240919	ENSG00000272375.1	RP11-51J9.6	4.71	3.28e-06	0.000374	0.31	0.21	Migraine;	chr8:30171039	chr8:30197404~30198048:+
THCA	cis	rs427394	0.802	rs274721	ENSG00000248677.1	CTD-2044J15.1	4.71	3.28e-06	0.000374	0.2	0.21	Menopause (age at onset);	chr5:6719051	chr5:6686325~6707711:-
THCA	cis	rs427394	0.802	rs274720	ENSG00000248677.1	CTD-2044J15.1	4.71	3.28e-06	0.000374	0.2	0.21	Menopause (age at onset);	chr5:6719820	chr5:6686325~6707711:-
THCA	cis	rs3820928	0.874	rs10176882	ENSG00000212391.1	SNORA48	-4.71	3.28e-06	0.000374	-0.23	-0.21	Pulmonary function;	chr2:227031716	chr2:226968989~226969122:-
THCA	cis	rs10916248	0.569	rs7528528	ENSG00000232628.4	RP11-365O16.3	-4.71	3.28e-06	0.000374	-0.24	-0.21	QT interval (drug interaction);	chr1:224077615	chr1:224208747~224213279:-
THCA	cis	rs12681963	0.688	rs73242322	ENSG00000272375.1	RP11-51J9.6	4.71	3.28e-06	0.000374	0.3	0.21	Migraine;	chr8:30177573	chr8:30197404~30198048:+
THCA	cis	rs6860806	0.507	rs2631362	ENSG00000224431.1	AC063976.7	-4.71	3.28e-06	0.000374	-0.19	-0.21	Breast cancer;	chr5:132371601	chr5:132199456~132203487:+
THCA	cis	rs2835345	0.511	rs2835356	ENSG00000230479.1	AP000695.6	4.71	3.28e-06	0.000374	0.25	0.21	Pulmonary function;	chr21:36444900	chr21:36430360~36481070:+
THCA	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-4.71	3.28e-06	0.000374	-0.12	-0.21	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000229886.1	RP5-1132H15.3	4.71	3.28e-06	0.000374	0.22	0.21	Calcium levels;	chr7:65903721	chr7:66025126~66031544:-
THCA	cis	rs7772486	0.764	rs7745696	ENSG00000270638.1	RP3-466P17.1	4.71	3.28e-06	0.000374	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs9403750	ENSG00000270638.1	RP3-466P17.1	4.71	3.28e-06	0.000374	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145735570~145737218:+
THCA	cis	rs922182	0.633	rs4776700	ENSG00000275785.1	RP11-111E14.2	-4.71	3.28e-06	0.000374	-0.23	-0.21	Blood protein levels;	chr15:63978662	chr15:63890030~63890317:+
THCA	cis	rs3198697	0.617	rs11075253	ENSG00000207425.1	Y_RNA	4.71	3.28e-06	0.000374	0.26	0.21	Triglycerides;	chr16:15054789	chr16:14915457~14915556:-
THCA	cis	rs9878978	0.964	rs34966409	ENSG00000237990.3	CNTN4-AS1	4.71	3.28e-06	0.000374	0.23	0.21	Blood pressure (smoking interaction);	chr3:2447205	chr3:3039033~3069242:-
THCA	cis	rs6787172	0.783	rs12489496	ENSG00000272087.1	RP11-379F4.7	4.71	3.28e-06	0.000374	0.19	0.21	Subjective well-being;	chr3:158518455	chr3:158693120~158693768:-
THCA	cis	rs9863	0.931	rs4575361	ENSG00000269997.1	RP11-214K3.21	-4.71	3.28e-06	0.000374	-0.27	-0.21	White blood cell count;	chr12:123925982	chr12:123966077~123966629:-
THCA	cis	rs2336384	0.593	rs2295281	ENSG00000199347.1	RNU5E-1	4.71	3.28e-06	0.000375	0.27	0.21	Platelet count;	chr1:11999355	chr1:11908152~11908271:+
THCA	cis	rs930395	0.514	rs10057521	ENSG00000272335.1	RP11-53O19.3	4.71	3.28e-06	0.000375	0.18	0.21	Breast cancer;	chr5:44865884	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs11958451	ENSG00000272335.1	RP11-53O19.3	4.71	3.28e-06	0.000375	0.18	0.21	Breast cancer;	chr5:44866800	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs4866920	ENSG00000272335.1	RP11-53O19.3	4.71	3.28e-06	0.000375	0.18	0.21	Breast cancer;	chr5:44879044	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs10040488	ENSG00000272335.1	RP11-53O19.3	4.71	3.28e-06	0.000375	0.18	0.21	Breast cancer;	chr5:44880186	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs13157608	ENSG00000272335.1	RP11-53O19.3	4.71	3.28e-06	0.000375	0.18	0.21	Breast cancer;	chr5:44881402	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs13168400	ENSG00000272335.1	RP11-53O19.3	4.71	3.28e-06	0.000375	0.18	0.21	Breast cancer;	chr5:44883434	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs4642377	ENSG00000272335.1	RP11-53O19.3	4.71	3.28e-06	0.000375	0.18	0.21	Breast cancer;	chr5:44885138	chr5:44826076~44828592:+
THCA	cis	rs1318937	0.915	rs3732728	ENSG00000224660.1	SH3BP5-AS1	-4.71	3.29e-06	0.000375	-0.13	-0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15256447	chr3:15254184~15264493:+
THCA	cis	rs7989336	0.69	rs1925113	ENSG00000247400.3	DNAJC3-AS1	-4.71	3.29e-06	0.000375	-0.13	-0.21	Obesity;	chr13:96325441	chr13:95648733~95676925:-
THCA	cis	rs795484	0.926	rs353893	ENSG00000275409.1	RP11-131L12.4	-4.71	3.29e-06	0.000375	-0.18	-0.21	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118193960	chr12:118430147~118430699:+
THCA	cis	rs2033711	0.622	rs975947	ENSG00000269054.1	CTD-2619J13.3	-4.71	3.29e-06	0.000375	-0.17	-0.21	Uric acid clearance;	chr19:58386826	chr19:58362585~58366591:+
THCA	cis	rs6921919	0.583	rs7740351	ENSG00000280107.1	AL022393.9	-4.71	3.29e-06	0.000375	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs16894108	ENSG00000280107.1	AL022393.9	-4.71	3.29e-06	0.000375	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28170845~28172521:+
THCA	cis	rs2439831	0.867	rs28729853	ENSG00000205771.5	CATSPER2P1	-4.71	3.29e-06	0.000375	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43381482	chr15:43726918~43747094:-
THCA	cis	rs7474896	0.945	rs615718	ENSG00000263064.2	RP11-291L22.7	-4.71	3.29e-06	0.000375	-0.35	-0.21	Obesity (extreme);	chr10:38022937	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.836	rs633029	ENSG00000263064.2	RP11-291L22.7	-4.71	3.29e-06	0.000375	-0.35	-0.21	Obesity (extreme);	chr10:38029325	chr10:38448689~38448949:+
THCA	cis	rs763121	0.853	rs6519119	ENSG00000228274.3	RP3-508I15.9	-4.71	3.29e-06	0.000375	-0.23	-0.21	Menopause (age at onset);	chr22:38593002	chr22:38667585~38681820:-
THCA	cis	rs5742933	1	rs3762545	ENSG00000273240.1	RP11-455J20.3	-4.71	3.29e-06	0.000375	-0.24	-0.21	Ferritin levels;	chr2:189790835	chr2:189763859~189764456:-
THCA	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-4.71	3.29e-06	0.000375	-0.18	-0.21	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
THCA	cis	rs7598759	0.527	rs12987949	ENSG00000223198.1	RNU2-22P	-4.71	3.29e-06	0.000375	-0.27	-0.21	Noise-induced hearing loss;	chr2:231502800	chr2:231501990~231502201:-
THCA	cis	rs7772486	0.79	rs2253880	ENSG00000270638.1	RP3-466P17.1	4.71	3.29e-06	0.000375	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs2814879	ENSG00000270638.1	RP3-466P17.1	4.71	3.29e-06	0.000375	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145735570~145737218:+
THCA	cis	rs4578769	0.569	rs9948922	ENSG00000265939.1	UBE2CP2	4.71	3.29e-06	0.000375	0.24	0.21	Eosinophil percentage of white cells;	chr18:22930198	chr18:22900486~22900995:-
THCA	cis	rs2243480	1	rs12698509	ENSG00000232559.3	GS1-124K5.12	4.71	3.29e-06	0.000375	0.31	0.21	Diabetic kidney disease;	chr7:65953889	chr7:66554588~66576923:-
THCA	cis	rs4950322	0.57	rs72691032	ENSG00000180867.10	PDIA3P1	4.71	3.29e-06	0.000375	0.21	0.21	Protein quantitative trait loci;	chr1:147261120	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72691033	ENSG00000180867.10	PDIA3P1	4.71	3.29e-06	0.000375	0.21	0.21	Protein quantitative trait loci;	chr1:147261267	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs111370771	ENSG00000180867.10	PDIA3P1	4.71	3.29e-06	0.000375	0.21	0.21	Protein quantitative trait loci;	chr1:147261420	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs4301678	ENSG00000180867.10	PDIA3P1	4.71	3.29e-06	0.000375	0.21	0.21	Protein quantitative trait loci;	chr1:147261907	chr1:147178113~147179622:+
THCA	cis	rs62158800	0.789	rs62158805	ENSG00000237880.1	AC096669.2	4.71	3.3e-06	0.000376	0.35	0.21	Facial morphology (factor 22);	chr2:107598151	chr2:107385632~107542649:-
THCA	cis	rs11955398	0.502	rs34591	ENSG00000272308.1	RP11-231G3.1	-4.71	3.3e-06	0.000376	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61034039	chr5:60866457~60866935:-
THCA	cis	rs4415084	1	rs12522626	ENSG00000272335.1	RP11-53O19.3	-4.71	3.3e-06	0.000376	-0.18	-0.21	Breast cancer;	chr5:44685596	chr5:44826076~44828592:+
THCA	cis	rs875971	0.545	rs1638735	ENSG00000228409.4	CCT6P1	-4.71	3.3e-06	0.000376	-0.18	-0.21	Aortic root size;	chr7:66630751	chr7:65751142~65763354:+
THCA	cis	rs6490294	0.748	rs111752063	ENSG00000226469.1	ADAM1B	4.71	3.3e-06	0.000376	0.26	0.21	Mean platelet volume;	chr12:111859646	chr12:111927018~111929017:+
THCA	cis	rs15676	0.947	rs7854319	ENSG00000234771.3	SLC25A25-AS1	-4.71	3.3e-06	0.000376	-0.18	-0.21	Blood metabolite levels;	chr9:128805716	chr9:128108581~128118693:-
THCA	cis	rs5997397	0.934	rs6005863	ENSG00000272858.1	CTA-292E10.8	-4.71	3.3e-06	0.000376	-0.21	-0.21	Red cell distribution width;	chr22:28760460	chr22:28814914~28815662:+
THCA	cis	rs713587	0.935	rs4430895	ENSG00000224165.4	DNAJC27-AS1	-4.71	3.3e-06	0.000376	-0.12	-0.21	Body mass index in non-asthmatics;	chr2:24938517	chr2:24971390~25039694:+
THCA	cis	rs36093844	0.752	rs74404559	ENSG00000279742.1	RP11-700A24.1	-4.71	3.3e-06	0.000376	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85854626	chr11:85852557~85854943:-
THCA	cis	rs1150668	0.796	rs213237	ENSG00000176933.5	TOB2P1	-4.71	3.3e-06	0.000376	-0.23	-0.21	Pubertal anthropometrics;	chr6:28356161	chr6:28217643~28218634:-
THCA	cis	rs539096	0.5	rs2367804	ENSG00000237950.1	RP11-7O11.3	4.71	3.3e-06	0.000376	0.19	0.21	Intelligence (multi-trait analysis);	chr1:43848594	chr1:43944370~43946551:-
THCA	cis	rs10760158	0.865	rs2239696	ENSG00000235865.2	GSN-AS1	4.71	3.3e-06	0.000376	0.18	0.21	Pulse pressure;	chr9:121266877	chr9:121280768~121285530:-
THCA	cis	rs763121	0.853	rs5757253	ENSG00000228274.3	RP3-508I15.9	-4.71	3.3e-06	0.000376	-0.23	-0.21	Menopause (age at onset);	chr22:38708315	chr22:38667585~38681820:-
THCA	cis	rs59918340	0.692	rs6983780	ENSG00000253307.1	RP11-10J21.4	4.71	3.3e-06	0.000376	0.29	0.21	Immature fraction of reticulocytes;	chr8:141221845	chr8:141252286~141253292:-
THCA	cis	rs59918340	0.728	rs4961340	ENSG00000253307.1	RP11-10J21.4	4.71	3.3e-06	0.000376	0.29	0.21	Immature fraction of reticulocytes;	chr8:141221903	chr8:141252286~141253292:-
THCA	cis	rs9311474	0.508	rs11714565	ENSG00000243224.1	RP5-1157M23.2	-4.71	3.3e-06	0.000376	-0.23	-0.21	Electroencephalogram traits;	chr3:52572276	chr3:52239258~52241097:+
THCA	cis	rs453301	0.653	rs7853	ENSG00000254340.1	RP11-10A14.3	4.71	3.3e-06	0.000376	0.23	0.21	Joint mobility (Beighton score);	chr8:9033304	chr8:9141424~9145435:+
THCA	cis	rs7402982	0.625	rs4966011	ENSG00000278022.1	RP11-35O15.2	-4.71	3.3e-06	0.000376	-0.22	-0.21	Birth weight;	chr15:98660777	chr15:98660210~98660668:+
THCA	cis	rs3734266	0.702	rs6904996	ENSG00000272288.4	RP11-140K17.3	-4.71	3.3e-06	0.000376	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34852743	chr6:34696317~34697470:+
THCA	cis	rs375066	0.551	rs349032	ENSG00000267058.1	RP11-15A1.3	-4.71	3.3e-06	0.000377	-0.19	-0.21	Breast cancer;	chr19:43813208	chr19:43891804~43901805:-
THCA	cis	rs4908769	0.624	rs6678140	ENSG00000232912.4	RP5-1115A15.1	-4.71	3.3e-06	0.000377	-0.23	-0.21	Allergy;	chr1:8376742	chr1:8424645~8434838:+
THCA	cis	rs1707322	1	rs10890359	ENSG00000281133.1	AL355480.3	-4.71	3.3e-06	0.000377	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45580892~45580996:-
THCA	cis	rs7911264	0.905	rs7918084	ENSG00000236493.2	EIF2S2P3	4.71	3.31e-06	0.000377	0.23	0.21	Inflammatory bowel disease;	chr10:92669710	chr10:92668745~92669743:-
THCA	cis	rs11723261	0.509	rs61792240	ENSG00000211553.1	AC253576.2	-4.71	3.31e-06	0.000377	-0.31	-0.21	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:136461~136568:+
THCA	cis	rs288326	0.561	rs74942055	ENSG00000272800.1	RP11-438L19.1	4.71	3.31e-06	0.000377	0.39	0.21	Blood protein levels;	chr2:182928925	chr2:183214319~183215400:+
THCA	cis	rs853679	0.766	rs9368561	ENSG00000220721.1	OR1F12	4.71	3.31e-06	0.000377	0.37	0.21	Depression;	chr6:28200565	chr6:28073316~28074233:+
THCA	cis	rs12823128	0.766	rs35781849	ENSG00000256185.1	RP11-612B6.2	4.71	3.31e-06	0.000377	0.2	0.21	Birth weight;	chr12:26773264	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs34606914	ENSG00000256185.1	RP11-612B6.2	4.71	3.31e-06	0.000377	0.2	0.21	Birth weight;	chr12:26774121	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs11611508	ENSG00000256185.1	RP11-612B6.2	4.71	3.31e-06	0.000377	0.2	0.21	Birth weight;	chr12:26774495	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs11611531	ENSG00000256185.1	RP11-612B6.2	4.71	3.31e-06	0.000377	0.2	0.21	Birth weight;	chr12:26774632	chr12:26335864~26336950:-
THCA	cis	rs7487075	0.78	rs12307969	ENSG00000257261.4	RP11-96H19.1	4.71	3.31e-06	0.000377	0.16	0.21	Itch intensity from mosquito bite;	chr12:46365274	chr12:46383679~46876159:+
THCA	cis	rs2439831	0.867	rs3213991	ENSG00000205771.5	CATSPER2P1	-4.71	3.31e-06	0.000377	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43378082	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs7163245	ENSG00000205771.5	CATSPER2P1	-4.71	3.31e-06	0.000377	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43379096	chr15:43726918~43747094:-
THCA	cis	rs8046148	0.694	rs2041920	ENSG00000279356.1	RP11-429P3.8	4.71	3.31e-06	0.000377	0.25	0.21	Testicular germ cell tumor;	chr16:50034511	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.724	rs2160568	ENSG00000279356.1	RP11-429P3.8	4.71	3.31e-06	0.000377	0.25	0.21	Testicular germ cell tumor;	chr16:50034534	chr16:50072862~50074986:+
THCA	cis	rs9300255	0.602	rs1727316	ENSG00000235423.7	RP11-282O18.3	4.71	3.31e-06	0.000377	0.22	0.21	Neutrophil percentage of white cells;	chr12:123134056	chr12:123252030~123261483:-
THCA	cis	rs950169	0.526	rs698620	ENSG00000259728.4	LINC00933	-4.71	3.31e-06	0.000377	-0.25	-0.21	Schizophrenia;	chr15:84633977	chr15:84570649~84580175:+
THCA	cis	rs4908768	0.535	rs2784738	ENSG00000232912.4	RP5-1115A15.1	-4.71	3.31e-06	0.000377	-0.24	-0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406157	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.535	rs2748456	ENSG00000232912.4	RP5-1115A15.1	-4.71	3.31e-06	0.000377	-0.24	-0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406690	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.535	rs2661868	ENSG00000232912.4	RP5-1115A15.1	-4.71	3.31e-06	0.000377	-0.24	-0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8409729	chr1:8424645~8434838:+
THCA	cis	rs911119	0.955	rs7265178	ENSG00000270001.1	RP11-218C14.8	-4.71	3.31e-06	0.000377	-0.31	-0.21	Chronic kidney disease;	chr20:23622745	chr20:23631826~23632316:-
THCA	cis	rs7160336	0.738	rs35579176	ENSG00000259065.1	RP5-1021I20.1	4.71	3.31e-06	0.000377	0.25	0.21	Blood protein levels;	chr14:74013601	chr14:73787360~73803270:+
THCA	cis	rs9816784	0.525	rs3326	ENSG00000273009.1	RP11-352G9.1	-4.71	3.31e-06	0.000377	-0.25	-0.21	Mean corpuscular hemoglobin;	chr3:196054635	chr3:195913078~195913683:-
THCA	cis	rs9863	0.861	rs3802999	ENSG00000269997.1	RP11-214K3.21	-4.71	3.31e-06	0.000377	-0.27	-0.21	White blood cell count;	chr12:123929551	chr12:123966077~123966629:-
THCA	cis	rs9925964	0.933	rs2359612	ENSG00000232748.3	RP11-196G11.6	-4.71	3.31e-06	0.000377	-0.25	-0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31092475	chr16:31056460~31062803:+
THCA	cis	rs10090774	0.687	rs11774679	ENSG00000279766.1	RP11-642A1.2	-4.71	3.32e-06	0.000378	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140907557	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11167007	ENSG00000279766.1	RP11-642A1.2	-4.71	3.32e-06	0.000378	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140908082	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13264974	ENSG00000279766.1	RP11-642A1.2	-4.71	3.32e-06	0.000378	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140908621	chr8:140572142~140572812:-
THCA	cis	rs2235642	0.507	rs2235645	ENSG00000280231.1	LA16c-380F5.3	-4.71	3.32e-06	0.000378	-0.29	-0.21	Coronary artery disease;	chr16:1547923	chr16:1553655~1554130:-
THCA	cis	rs36093844	0.8	rs59179556	ENSG00000279742.1	RP11-700A24.1	-4.71	3.32e-06	0.000378	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85862854	chr11:85852557~85854943:-
THCA	cis	rs17301013	0.861	rs1894200	ENSG00000227373.4	RP11-160H22.5	-4.71	3.32e-06	0.000378	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174842039	chr1:174115300~174160004:-
THCA	cis	rs10186029	0.657	rs11689895	ENSG00000270659.1	RP11-105N14.1	-4.71	3.32e-06	0.000378	-0.17	-0.21	Systemic sclerosis;	chr2:213073829	chr2:213152970~213153659:+
THCA	cis	rs6787172	0.811	rs28375539	ENSG00000272087.1	RP11-379F4.7	4.71	3.32e-06	0.000378	0.19	0.21	Subjective well-being;	chr3:158527108	chr3:158693120~158693768:-
THCA	cis	rs58605417	0.534	rs3105409	ENSG00000253553.4	RP11-586K2.1	4.71	3.32e-06	0.000378	0.22	0.21	Schizophrenia;	chr8:88436182	chr8:88326836~88737134:+
THCA	cis	rs11673344	0.542	rs1667380	ENSG00000276846.1	CTD-3220F14.3	4.71	3.32e-06	0.000378	0.16	0.21	Obesity-related traits;	chr19:37001848	chr19:37314868~37315620:-
THCA	cis	rs35160687	0.644	rs4832274	ENSG00000273080.1	RP11-301O19.1	-4.71	3.32e-06	0.000378	-0.23	-0.21	Night sleep phenotypes;	chr2:86301961	chr2:86195590~86196049:+
THCA	cis	rs453301	0.571	rs2929452	ENSG00000253981.4	ALG1L13P	-4.71	3.32e-06	0.000378	-0.2	-0.21	Joint mobility (Beighton score);	chr8:9226955	chr8:8236003~8244667:-
THCA	cis	rs4908768	0.52	rs4908507	ENSG00000232912.4	RP5-1115A15.1	4.71	3.32e-06	0.000378	0.21	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678878	chr1:8424645~8434838:+
THCA	cis	rs8027521	0.738	rs72736943	ENSG00000280362.1	RP11-643A5.3	4.71	3.32e-06	0.000378	0.27	0.21	Circulating chemerin levels;	chr15:53962277	chr15:53910769~53914712:+
THCA	cis	rs12234571	1	rs58908923	ENSG00000214293.7	APTR	4.71	3.32e-06	0.000378	0.3	0.21	Obesity-related traits;	chr7:77931349	chr7:77657660~77696265:-
THCA	cis	rs7267979	1	rs6083828	ENSG00000274973.1	RP13-401N8.7	4.71	3.32e-06	0.000379	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25845497~25845862:+
THCA	cis	rs453301	0.686	rs28482034	ENSG00000254153.1	CTA-398F10.2	4.71	3.32e-06	0.000379	0.23	0.21	Joint mobility (Beighton score);	chr8:9012154	chr8:8456909~8461337:-
THCA	cis	rs11633886	0.604	rs34042928	ENSG00000273972.1	CTD-2306A12.1	-4.71	3.32e-06	0.000379	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45813179	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.553	rs35116416	ENSG00000273972.1	CTD-2306A12.1	-4.71	3.32e-06	0.000379	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45813559	chr15:45702640~45703183:+
THCA	cis	rs1005277	0.54	rs2474598	ENSG00000275858.1	RP11-291L22.8	-4.71	3.33e-06	0.000379	-0.26	-0.21	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38450738~38451069:-
THCA	cis	rs8028182	0.636	rs7495610	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75492100	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs12708519	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75510859	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs8029112	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75516631	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs4322627	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75518318	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs4886712	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75520547	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs8030802	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75520812	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.577	rs8023268	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75522331	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs8023815	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75522363	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs11636031	ENSG00000260269.4	CTD-2323K18.1	-4.71	3.33e-06	0.000379	-0.32	-0.21	Sudden cardiac arrest;	chr15:75523417	chr15:75527150~75601205:-
THCA	cis	rs17095355	0.901	rs12240333	ENSG00000203876.8	ADD3-AS1	-4.71	3.33e-06	0.000379	-0.23	-0.21	Biliary atresia;	chr10:109984214	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs12263915	ENSG00000203876.8	ADD3-AS1	-4.71	3.33e-06	0.000379	-0.23	-0.21	Biliary atresia;	chr10:109984906	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs11194941	ENSG00000203876.8	ADD3-AS1	-4.71	3.33e-06	0.000379	-0.23	-0.21	Biliary atresia;	chr10:109985052	chr10:109940104~110008381:-
THCA	cis	rs46522	0.585	rs79049364	ENSG00000270781.1	RP11-501C14.9	-4.71	3.33e-06	0.000379	-0.26	-0.21	Coronary heart disease;	chr17:48937629	chr17:48899131~48899748:+
THCA	cis	rs79349575	0.811	rs80032154	ENSG00000270781.1	RP11-501C14.9	-4.71	3.33e-06	0.000379	-0.26	-0.21	Type 2 diabetes;	chr17:48937630	chr17:48899131~48899748:+
THCA	cis	rs10411161	0.702	rs6509591	ENSG00000275055.1	CTC-471J1.11	-4.71	3.33e-06	0.000379	-0.2	-0.21	Breast cancer;	chr19:51888687	chr19:52049007~52049754:+
THCA	cis	rs8067545	0.611	rs2189709	ENSG00000270091.1	RP11-78O7.2	4.71	3.33e-06	0.000379	0.16	0.21	Schizophrenia;	chr17:20179913	chr17:19896590~19897287:-
THCA	cis	rs2120243	0.533	rs1392798	ENSG00000241770.1	RP11-555M1.3	4.71	3.33e-06	0.00038	0.26	0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338498	chr3:157163452~157169133:+
THCA	cis	rs2304003	0.528	rs79761933	ENSG00000235192.1	AC009495.2	-4.71	3.33e-06	0.00038	-0.41	-0.21	Social communication problems;	chr2:165853729	chr2:165794851~165810010:+
THCA	cis	rs6500602	0.653	rs3747579	ENSG00000280063.1	RP11-295D4.3	-4.71	3.33e-06	0.00038	-0.12	-0.21	Schizophrenia;	chr16:4395326	chr16:4346694~4348648:-
THCA	cis	rs7914558	0.902	rs7092200	ENSG00000272912.1	RP11-724N1.1	-4.71	3.34e-06	0.00038	-0.24	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103085115	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs7896547	ENSG00000236937.2	PTGES3P4	4.71	3.34e-06	0.00038	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.933	rs2066323	ENSG00000236937.2	PTGES3P4	4.71	3.34e-06	0.00038	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:102845595~102845950:+
THCA	cis	rs7914558	1	rs7899084	ENSG00000236937.2	PTGES3P4	4.71	3.34e-06	0.00038	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:102845595~102845950:+
THCA	cis	rs453301	0.686	rs28665409	ENSG00000254153.1	CTA-398F10.2	4.71	3.34e-06	0.00038	0.23	0.21	Joint mobility (Beighton score);	chr8:9011767	chr8:8456909~8461337:-
THCA	cis	rs8002861	0.664	rs2325089	ENSG00000274001.1	RP11-5G9.5	-4.71	3.34e-06	0.00038	-0.25	-0.21	Leprosy;	chr13:43876086	chr13:43877715~43878163:-
THCA	cis	rs4950322	0.515	rs72691016	ENSG00000226015.2	CCT8P1	4.71	3.34e-06	0.00038	0.24	0.21	Protein quantitative trait loci;	chr1:147245375	chr1:147203276~147204932:-
THCA	cis	rs10483853	0.806	rs66498577	ENSG00000258695.2	RP3-414A15.2	-4.71	3.34e-06	0.00038	-0.3	-0.21	Coronary artery calcification;	chr14:73292012	chr14:73522878~73530610:+
THCA	cis	rs17801127	0.818	rs35875583	ENSG00000231969.1	AC144449.1	4.71	3.34e-06	0.00038	0.44	0.21	Liver enzyme levels (alanine transaminase);	chr2:149845854	chr2:149587196~149848233:+
THCA	cis	rs7208859	0.614	rs216474	ENSG00000266490.1	CTD-2349P21.9	-4.71	3.34e-06	0.00038	-0.28	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30792372~30792833:+
THCA	cis	rs6445975	0.667	rs2292676	ENSG00000272360.1	RP11-359I18.5	-4.71	3.34e-06	0.00038	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58250201	chr3:58490830~58491291:-
THCA	cis	rs8062405	0.558	rs151228	ENSG00000278665.1	RP11-666O2.4	4.71	3.34e-06	0.00038	0.22	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28599241~28601881:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000229886.1	RP5-1132H15.3	4.71	3.34e-06	0.00038	0.22	0.21	Calcium levels;	chr7:65853042	chr7:66025126~66031544:-
THCA	cis	rs875971	0.516	rs6945322	ENSG00000229886.1	RP5-1132H15.3	4.71	3.34e-06	0.00038	0.22	0.21	Aortic root size;	chr7:65871069	chr7:66025126~66031544:-
THCA	cis	rs8002861	0.664	rs9567292	ENSG00000274001.1	RP11-5G9.5	4.71	3.34e-06	0.000381	0.25	0.21	Leprosy;	chr13:43870680	chr13:43877715~43878163:-
THCA	cis	rs9863	0.861	rs77020228	ENSG00000269997.1	RP11-214K3.21	-4.71	3.34e-06	0.000381	-0.27	-0.21	White blood cell count;	chr12:123933925	chr12:123966077~123966629:-
THCA	cis	rs12541437	0.958	rs3020171	ENSG00000253327.2	RAD21-AS1	4.7	3.34e-06	0.000381	0.24	0.21	Gut microbiome composition (winter);	chr8:116921713	chr8:116874424~116876868:+
THCA	cis	rs172166	0.694	rs188105	ENSG00000261839.1	RP1-265C24.8	4.7	3.34e-06	0.000381	0.23	0.21	Cardiac Troponin-T levels;	chr6:28103615	chr6:28136849~28139678:+
THCA	cis	rs7726839	0.54	rs55929359	ENSG00000225138.6	CTD-2228K2.7	4.7	3.34e-06	0.000381	0.27	0.21	Obesity-related traits;	chr5:595841	chr5:473236~480884:+
THCA	cis	rs9868809	0.772	rs9841602	ENSG00000270441.1	RP11-694I15.7	4.7	3.34e-06	0.000381	0.26	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48676137	chr3:49140086~49160851:-
THCA	cis	rs8077577	0.708	rs9913139	ENSG00000273018.4	CTD-2303H24.2	-4.7	3.34e-06	0.000381	-0.31	-0.21	Obesity-related traits;	chr17:18250501	chr17:18511221~18551705:-
THCA	cis	rs288326	0.561	rs77460513	ENSG00000272800.1	RP11-438L19.1	4.7	3.34e-06	0.000381	0.37	0.21	Blood protein levels;	chr2:182954897	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs7595898	ENSG00000272800.1	RP11-438L19.1	4.7	3.34e-06	0.000381	0.37	0.21	Blood protein levels;	chr2:182955164	chr2:183214319~183215400:+
THCA	cis	rs453301	0.653	rs1045529	ENSG00000254340.1	RP11-10A14.3	-4.7	3.34e-06	0.000381	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9032588	chr8:9141424~9145435:+
THCA	cis	rs67478160	0.572	rs8016014	ENSG00000269910.1	RP11-73M18.10	4.7	3.35e-06	0.000381	0.18	0.21	Schizophrenia;	chr14:103827461	chr14:103694516~103695050:-
THCA	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-4.7	3.35e-06	0.000381	-0.13	-0.21	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-4.7	3.35e-06	0.000381	-0.13	-0.21	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
THCA	cis	rs13113518	1	rs11724094	ENSG00000273257.1	RP11-177J6.1	4.7	3.35e-06	0.000381	0.28	0.21	Height;	chr4:55501479	chr4:55387949~55388271:+
THCA	cis	rs1577917	0.883	rs2166664	ENSG00000220563.1	PKMP3	-4.7	3.35e-06	0.000381	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85886904	chr6:85659892~85660606:-
THCA	cis	rs11148252	0.553	rs2147692	ENSG00000273784.3	RP11-78J21.7	-4.7	3.35e-06	0.000381	-0.23	-0.21	Lewy body disease;	chr13:52712888	chr13:52600042~52642542:+
THCA	cis	rs7520050	0.966	rs785479	ENSG00000234329.1	RP11-767N6.2	-4.7	3.35e-06	0.000381	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45651039~45651826:-
THCA	cis	rs829883	0.659	rs10860342	ENSG00000227825.4	SLC9A7P1	4.7	3.35e-06	0.000381	0.21	0.21	Colorectal adenoma (advanced);	chr12:98547445	chr12:98453835~98457145:-
THCA	cis	rs2243480	1	rs56016656	ENSG00000164669.11	INTS4P1	4.7	3.35e-06	0.000381	0.41	0.21	Diabetic kidney disease;	chr7:65918494	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs56291018	ENSG00000164669.11	INTS4P1	4.7	3.35e-06	0.000381	0.41	0.21	Diabetic kidney disease;	chr7:65925352	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs36033484	ENSG00000164669.11	INTS4P1	4.7	3.35e-06	0.000381	0.41	0.21	Diabetic kidney disease;	chr7:65925571	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs34560516	ENSG00000164669.11	INTS4P1	4.7	3.35e-06	0.000381	0.41	0.21	Diabetic kidney disease;	chr7:65939105	chr7:65141225~65234216:+
THCA	cis	rs35740288	0.689	rs11630688	ENSG00000259295.5	CSPG4P12	4.7	3.35e-06	0.000381	0.33	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85710048	chr15:85191438~85213905:+
THCA	cis	rs6413860	0.637	rs12035469	ENSG00000260855.1	RP11-439E19.10	4.7	3.35e-06	0.000381	0.24	0.21	Gut microbiome composition (summer);	chr1:246695229	chr1:246772301~246775772:+
THCA	cis	rs2834188	0.521	rs9984454	ENSG00000272659.1	AP000295.10	-4.7	3.35e-06	0.000381	-0.27	-0.21	Narcolepsy;	chr21:33312229	chr21:33309491~33310181:+
THCA	cis	rs890448	1	rs1863569	ENSG00000254531.1	FLJ20021	-4.7	3.35e-06	0.000381	-0.19	-0.21	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101511385	chr4:101347780~101348883:+
THCA	cis	rs10760158	0.8	rs4556152	ENSG00000235865.2	GSN-AS1	4.7	3.35e-06	0.000381	0.18	0.21	Pulse pressure;	chr9:121254631	chr9:121280768~121285530:-
THCA	cis	rs270601	0.913	rs273916	ENSG00000224431.1	AC063976.7	4.7	3.35e-06	0.000381	0.19	0.21	Acylcarnitine levels;	chr5:132324137	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.507	rs273915	ENSG00000224431.1	AC063976.7	4.7	3.35e-06	0.000381	0.19	0.21	Breast cancer;	chr5:132324426	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.507	rs272892	ENSG00000224431.1	AC063976.7	4.7	3.35e-06	0.000381	0.19	0.21	Breast cancer;	chr5:132328656	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.531	rs272888	ENSG00000224431.1	AC063976.7	4.7	3.35e-06	0.000381	0.19	0.21	Breast cancer;	chr5:132329730	chr5:132199456~132203487:+
THCA	cis	rs9307551	0.522	rs13111877	ENSG00000250334.4	LINC00989	-4.7	3.35e-06	0.000381	-0.25	-0.21	Refractive error;	chr4:79506745	chr4:79492416~79576460:+
THCA	cis	rs12893668	0.703	rs2403197	ENSG00000269958.1	RP11-73M18.8	4.7	3.35e-06	0.000381	0.21	0.21	Reticulocyte count;	chr14:103587427	chr14:103696353~103697163:+
THCA	cis	rs7621025	0.69	rs11715257	ENSG00000239213.4	NCK1-AS1	4.7	3.35e-06	0.000382	0.2	0.21	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136463211	chr3:136841726~136862054:-
THCA	cis	rs12887734	0.524	rs12588797	ENSG00000269910.1	RP11-73M18.10	-4.7	3.35e-06	0.000382	-0.19	-0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103694516~103695050:-
THCA	cis	rs73108077	0.736	rs6058479	ENSG00000277112.2	RP11-755J8.1	-4.7	3.35e-06	0.000382	-0.34	-0.21	Red blood cell density in sickle cell anemia;	chr20:31282419	chr20:30681825~30723932:-
THCA	cis	rs656319	0.559	rs17689289	ENSG00000261451.1	RP11-981G7.1	4.7	3.35e-06	0.000382	0.26	0.21	Myopia (pathological);	chr8:10120470	chr8:10433672~10438312:+
THCA	cis	rs7141336	0.864	rs7148903	ENSG00000258884.1	CTD-3035D6.2	4.7	3.35e-06	0.000382	0.28	0.21	Anxiety disorder;	chr14:90821483	chr14:90822365~90828128:-
THCA	cis	rs67478160	0.643	rs2887282	ENSG00000269910.1	RP11-73M18.10	4.7	3.35e-06	0.000382	0.18	0.21	Schizophrenia;	chr14:103814397	chr14:103694516~103695050:-
THCA	cis	rs925946	0.666	rs11030102	ENSG00000245573.6	BDNF-AS	4.7	3.35e-06	0.000382	0.22	0.21	Weight;Body mass index;	chr11:27660049	chr11:27506838~27698174:+
THCA	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-4.7	3.36e-06	0.000382	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
THCA	cis	rs7577696	0.752	rs212721	ENSG00000276334.1	AL133243.1	4.7	3.36e-06	0.000382	0.23	0.21	Inflammatory biomarkers;	chr2:32240960	chr2:32521927~32523547:+
THCA	cis	rs4950322	0.57	rs4593887	ENSG00000180867.10	PDIA3P1	4.7	3.36e-06	0.000382	0.2	0.21	Protein quantitative trait loci;	chr1:147234246	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.542	rs28381210	ENSG00000226015.2	CCT8P1	4.7	3.36e-06	0.000382	0.25	0.21	Protein quantitative trait loci;	chr1:147201925	chr1:147203276~147204932:-
THCA	cis	rs4660456	0.504	rs2744805	ENSG00000272145.1	NFYC-AS1	-4.7	3.36e-06	0.000382	-0.16	-0.21	Platelet count;	chr1:40654827	chr1:40690380~40692066:-
THCA	cis	rs13113518	0.934	rs11935823	ENSG00000273257.1	RP11-177J6.1	4.7	3.36e-06	0.000382	0.28	0.21	Height;	chr4:55589624	chr4:55387949~55388271:+
THCA	cis	rs6993270	1	rs1519810	ENSG00000245330.4	KB-1471A8.1	-4.7	3.36e-06	0.000382	-0.27	-0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119923937	chr8:119867419~119874488:-
THCA	cis	rs2235642	0.533	rs2076436	ENSG00000280231.1	LA16c-380F5.3	-4.7	3.36e-06	0.000382	-0.28	-0.21	Coronary artery disease;	chr16:1558081	chr16:1553655~1554130:-
THCA	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-4.7	3.36e-06	0.000382	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
THCA	cis	rs4578769	0.55	rs8087501	ENSG00000265939.1	UBE2CP2	4.7	3.36e-06	0.000382	0.24	0.21	Eosinophil percentage of white cells;	chr18:22970711	chr18:22900486~22900995:-
THCA	cis	rs1003719	0.788	rs4572679	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37080927	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.751	rs10154032	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37081159	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs11701556	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37082853	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835574	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37083024	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835575	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37083636	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835576	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37085093	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835577	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37085157	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835578	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37085371	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835579	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37085665	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.751	rs2835585	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37088188	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835586	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37089026	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.737	rs2835587	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37089495	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835588	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37090416	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs3787782	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37090609	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs3787783	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37090659	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835589	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37091042	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs2835590	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37091106	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs3787786	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37091136	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs3787787	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37091152	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835592	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37092087	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs13050757	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37093045	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835593	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37093573	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.713	rs2835594	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37093764	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835595	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37093903	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835597	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37094239	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2006941	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37095316	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835600	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37096658	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs7277657	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37097223	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs4817849	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37097496	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs11911508	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37098204	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs34273703	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37102719	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs59637309	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37103098	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.762	rs11088381	ENSG00000230366.8	DSCR9	-4.7	3.36e-06	0.000382	-0.21	-0.21	Eye color traits;	chr21:37106129	chr21:37208503~37221736:+
THCA	cis	rs36093844	0.752	rs7121363	ENSG00000279742.1	RP11-700A24.1	-4.7	3.36e-06	0.000382	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85864067	chr11:85852557~85854943:-
THCA	cis	rs4950322	0.57	rs4950401	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147319571	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs4950402	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147319684	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs4950404	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147319834	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692946	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147319966	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692948	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147320298	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692951	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147320551	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs77118461	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147320718	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs78681047	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147321013	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.57	rs72692953	ENSG00000271721.1	RP11-337C18.9	4.7	3.36e-06	0.000383	0.24	0.21	Protein quantitative trait loci;	chr1:147321416	chr1:147175602~147177740:+
THCA	cis	rs8020095	1	rs8020095	ENSG00000258561.1	RP11-72M17.1	-4.7	3.36e-06	0.000383	-0.28	-0.21	Depression (quantitative trait);	chr14:66987141	chr14:66212810~66509394:-
THCA	cis	rs9329221	0.935	rs3750311	ENSG00000261451.1	RP11-981G7.1	-4.7	3.36e-06	0.000383	-0.27	-0.21	Neuroticism;	chr8:10426092	chr8:10433672~10438312:+
THCA	cis	rs9467773	0.62	rs2451738	ENSG00000124549.13	BTN2A3P	-4.7	3.36e-06	0.000383	-0.2	-0.21	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26421391~26432383:+
THCA	cis	rs957448	1	rs1055800	ENSG00000253175.1	RP11-267M23.6	-4.7	3.36e-06	0.000383	-0.27	-0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94565036~94565715:+
THCA	cis	rs72634501	0.642	rs67452844	ENSG00000228060.1	RP11-69E11.8	-4.7	3.36e-06	0.000383	-0.22	-0.21	HDL cholesterol;	chr1:39150610	chr1:39565160~39573203:+
THCA	cis	rs2439831	1	rs9920763	ENSG00000166763.7	STRCP1	4.7	3.36e-06	0.000383	0.33	0.21	Lung cancer in ever smokers;	chr15:43468310	chr15:43699488~43718184:-
THCA	cis	rs7829975	0.517	rs12542733	ENSG00000254340.1	RP11-10A14.3	-4.7	3.36e-06	0.000383	-0.23	-0.21	Mood instability;	chr8:8967348	chr8:9141424~9145435:+
THCA	cis	rs763121	0.853	rs2179142	ENSG00000228274.3	RP3-508I15.9	-4.7	3.37e-06	0.000383	-0.23	-0.21	Menopause (age at onset);	chr22:38641949	chr22:38667585~38681820:-
THCA	cis	rs897984	0.806	rs8052245	ENSG00000260911.2	RP11-196G11.2	-4.7	3.37e-06	0.000383	-0.18	-0.21	Dementia with Lewy bodies;	chr16:30905109	chr16:31043150~31049868:+
THCA	cis	rs4906332	0.811	rs2756138	ENSG00000252469.1	RNU7-160P	-4.7	3.37e-06	0.000383	-0.25	-0.21	Coronary artery disease;	chr14:103530396	chr14:103550345~103550406:+
THCA	cis	rs6121246	0.559	rs6060599	ENSG00000230613.1	HM13-AS1	4.7	3.37e-06	0.000383	0.2	0.21	Mean corpuscular hemoglobin;	chr20:31669951	chr20:31567707~31573263:-
THCA	cis	rs3020736	0.5	rs6002604	ENSG00000273366.1	CTA-989H11.1	4.7	3.37e-06	0.000383	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs5996109	ENSG00000273366.1	CTA-989H11.1	4.7	3.37e-06	0.000383	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs5996110	ENSG00000273366.1	CTA-989H11.1	4.7	3.37e-06	0.000383	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs9620026	ENSG00000273366.1	CTA-989H11.1	4.7	3.37e-06	0.000383	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs28791586	ENSG00000273366.1	CTA-989H11.1	4.7	3.37e-06	0.000383	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs2839708	ENSG00000273366.1	CTA-989H11.1	4.7	3.37e-06	0.000383	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs6519306	ENSG00000273366.1	CTA-989H11.1	4.7	3.37e-06	0.000383	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42278188~42278846:+
THCA	cis	rs4591358	0.684	rs35306440	ENSG00000223466.1	AC064834.2	4.7	3.37e-06	0.000383	0.25	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195507507	chr2:195533035~195538681:+
THCA	cis	rs6860806	0.507	rs582490	ENSG00000237714.1	P4HA2-AS1	-4.7	3.37e-06	0.000383	-0.29	-0.21	Breast cancer;	chr5:132374403	chr5:132184876~132192808:+
THCA	cis	rs274567	0.501	rs581968	ENSG00000237714.1	P4HA2-AS1	-4.7	3.37e-06	0.000383	-0.29	-0.21	Blood metabolite levels;	chr5:132374510	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.507	rs274572	ENSG00000237714.1	P4HA2-AS1	-4.7	3.37e-06	0.000383	-0.29	-0.21	Breast cancer;	chr5:132375225	chr5:132184876~132192808:+
THCA	cis	rs274567	0.501	rs274571	ENSG00000237714.1	P4HA2-AS1	-4.7	3.37e-06	0.000383	-0.29	-0.21	Blood metabolite levels;	chr5:132376433	chr5:132184876~132192808:+
THCA	cis	rs6441961	0.628	rs7635588	ENSG00000223552.1	RP11-24F11.2	-4.7	3.37e-06	0.000383	-0.21	-0.21	Celiac disease;	chr3:46303996	chr3:46364955~46407059:-
THCA	cis	rs2836974	0.666	rs4818015	ENSG00000255568.3	BRWD1-AS2	4.7	3.37e-06	0.000383	0.17	0.21	Cognitive function;	chr21:39303567	chr21:39313935~39314962:+
THCA	cis	rs8062405	0.757	rs2411453	ENSG00000278665.1	RP11-666O2.4	-4.7	3.37e-06	0.000383	-0.23	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28599241~28601881:-
THCA	cis	rs8113308	0.752	rs8113758	ENSG00000275055.1	CTC-471J1.11	-4.7	3.37e-06	0.000383	-0.21	-0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51990054	chr19:52049007~52049754:+
THCA	cis	rs1707322	0.928	rs7527244	ENSG00000281133.1	AL355480.3	-4.7	3.37e-06	0.000383	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45580892~45580996:-
THCA	cis	rs7577696	0.85	rs3769606	ENSG00000276334.1	AL133243.1	-4.7	3.37e-06	0.000383	-0.22	-0.21	Inflammatory biomarkers;	chr2:32092481	chr2:32521927~32523547:+
THCA	cis	rs4915077	1	rs78495697	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107813097	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs75382989	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107814313	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs17020122	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107814769	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs17020123	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107814951	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs74678088	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107815175	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs17020124	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107815389	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs77436627	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107815486	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs75778624	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107817168	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs112590700	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107820073	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs75125154	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107820904	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs79451333	ENSG00000226822.1	RP11-356N1.2	4.7	3.37e-06	0.000383	0.4	0.21	Hypothyroidism;	chr1:107821014	chr1:108071482~108074519:+
THCA	cis	rs12291225	0.585	rs11023194	ENSG00000251991.1	RNU7-49P	4.7	3.37e-06	0.000383	0.24	0.21	Sense of smell;	chr11:14348223	chr11:14478892~14478953:+
THCA	cis	rs4648045	0.822	rs72696109	ENSG00000246560.2	RP11-10L12.4	4.7	3.37e-06	0.000383	0.27	0.21	Lymphocyte percentage of white cells;	chr4:102491188	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.796	rs12661231	ENSG00000220563.1	PKMP3	-4.7	3.37e-06	0.000383	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85834753	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.839	rs1596990	ENSG00000220563.1	PKMP3	-4.7	3.37e-06	0.000383	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85840974	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.916	rs12661611	ENSG00000220563.1	PKMP3	-4.7	3.37e-06	0.000383	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85844117	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.637	rs1838957	ENSG00000220563.1	PKMP3	-4.7	3.37e-06	0.000383	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85855338	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.839	rs1838956	ENSG00000220563.1	PKMP3	-4.7	3.37e-06	0.000383	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85855545	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.839	rs12216103	ENSG00000220563.1	PKMP3	-4.7	3.37e-06	0.000383	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85861410	chr6:85659892~85660606:-
THCA	cis	rs6688613	0.685	rs4657613	ENSG00000225171.2	DUTP6	-4.7	3.37e-06	0.000383	-0.29	-0.21	Refractive astigmatism;	chr1:166901641	chr1:166868748~166869209:+
THCA	cis	rs801193	1	rs7782320	ENSG00000229886.1	RP5-1132H15.3	4.7	3.37e-06	0.000384	0.22	0.21	Aortic root size;	chr7:66712111	chr7:66025126~66031544:-
THCA	cis	rs10266483	0.739	rs2692099	ENSG00000271550.1	BNIP3P11	4.7	3.37e-06	0.000384	0.27	0.21	Response to statin therapy;	chr7:64307384	chr7:64678954~64687393:-
THCA	cis	rs11633886	0.604	rs11638402	ENSG00000273972.1	CTD-2306A12.1	-4.7	3.37e-06	0.000384	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45834686	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.604	rs11638436	ENSG00000273972.1	CTD-2306A12.1	-4.7	3.37e-06	0.000384	-0.24	-0.21	Diisocyanate-induced asthma;	chr15:45834750	chr15:45702640~45703183:+
THCA	cis	rs12908161	0.959	rs17598603	ENSG00000188388.10	GOLGA6L3	-4.7	3.37e-06	0.000384	-0.29	-0.21	Schizophrenia;	chr15:84656980	chr15:85240472~85247170:+
THCA	cis	rs72945132	1	rs72945132	ENSG00000254604.1	AP000487.6	-4.7	3.38e-06	0.000384	-0.4	-0.21	Coronary artery disease;	chr11:70267795	chr11:70282367~70363368:-
THCA	cis	rs2688608	0.901	rs2664280	ENSG00000271816.1	BMS1P4	-4.7	3.38e-06	0.000384	-0.21	-0.21	Inflammatory bowel disease;	chr10:73857586	chr10:73699151~73730487:-
THCA	cis	rs9634489	0.502	rs12431147	ENSG00000247400.3	DNAJC3-AS1	4.7	3.38e-06	0.000384	0.14	0.21	Body mass index;	chr13:96460344	chr13:95648733~95676925:-
THCA	cis	rs6012564	0.964	rs6125577	ENSG00000230758.1	SNAP23P	4.7	3.38e-06	0.000384	0.25	0.21	Anger;	chr20:49166558	chr20:49038357~49038602:-
THCA	cis	rs4535700	0.501	rs6943341	ENSG00000226278.1	PSPHP1	4.7	3.38e-06	0.000384	0.25	0.21	Macular telangiectasia type 2;	chr7:55907489	chr7:55764797~55773288:+
THCA	cis	rs853679	0.506	rs1150711	ENSG00000176933.5	TOB2P1	-4.7	3.38e-06	0.000384	-0.24	-0.21	Depression;	chr6:28240757	chr6:28217643~28218634:-
THCA	cis	rs7045881	0.935	rs12000467	ENSG00000254396.1	RP11-56F10.3	4.7	3.38e-06	0.000384	0.32	0.21	Schizophrenia;	chr9:26808070	chr9:27102630~27104728:+
THCA	cis	rs11603691	1	rs77319221	ENSG00000254662.1	RP11-872D17.4	-4.7	3.38e-06	0.000384	-0.39	-0.21	Low high density lipoprotein cholesterol levels;	chr11:57143790	chr11:57325603~57327958:+
THCA	cis	rs17123764	0.818	rs13066	ENSG00000257464.1	RP11-161H23.8	-4.7	3.38e-06	0.000384	-0.34	-0.21	Intelligence (multi-trait analysis);	chr12:49566768	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs11169076	ENSG00000257464.1	RP11-161H23.8	-4.7	3.38e-06	0.000384	-0.34	-0.21	Intelligence (multi-trait analysis);	chr12:49581625	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs17123808	ENSG00000257464.1	RP11-161H23.8	-4.7	3.38e-06	0.000384	-0.34	-0.21	Intelligence (multi-trait analysis);	chr12:49585630	chr12:49442424~49442652:-
THCA	cis	rs4578769	0.55	rs9951410	ENSG00000265939.1	UBE2CP2	4.7	3.38e-06	0.000384	0.24	0.21	Eosinophil percentage of white cells;	chr18:22964944	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.505	rs9951982	ENSG00000265939.1	UBE2CP2	4.7	3.38e-06	0.000384	0.24	0.21	Eosinophil percentage of white cells;	chr18:22965607	chr18:22900486~22900995:-
THCA	cis	rs7665090	0.87	rs228613	ENSG00000251288.2	RP11-10L12.2	4.7	3.38e-06	0.000384	0.28	0.21	Primary biliary cholangitis;	chr4:102656308	chr4:102751401~102752641:+
THCA	cis	rs9487094	0.67	rs12199154	ENSG00000223537.2	RP5-919F19.5	4.7	3.38e-06	0.000384	0.21	0.21	Height;	chr6:109501793	chr6:109487906~109506800:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000229886.1	RP5-1132H15.3	4.7	3.38e-06	0.000384	0.22	0.21	Aortic root size;	chr7:65827018	chr7:66025126~66031544:-
THCA	cis	rs6973609	0.568	rs12701435	ENSG00000271122.1	RP11-379H18.1	4.7	3.38e-06	0.000384	0.16	0.21	Obesity-related traits;	chr7:35562331	chr7:35695214~35699413:+
THCA	cis	rs763121	0.853	rs5750668	ENSG00000235209.1	CTA-150C2.13	4.7	3.38e-06	0.000385	0.28	0.21	Menopause (age at onset);	chr22:38683959	chr22:38921227~38924708:+
THCA	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	4.7	3.38e-06	0.000385	0.25	0.21	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
THCA	cis	rs4660456	0.542	rs850009	ENSG00000272145.1	NFYC-AS1	-4.7	3.39e-06	0.000385	-0.15	-0.21	Platelet count;	chr1:40643593	chr1:40690380~40692066:-
THCA	cis	rs6012564	0.928	rs1043357	ENSG00000227431.4	CSE1L-AS1	4.7	3.39e-06	0.000385	0.26	0.21	Anger;	chr20:49114691	chr20:49040463~49046044:-
THCA	cis	rs1707322	1	rs34444543	ENSG00000281133.1	AL355480.3	-4.7	3.39e-06	0.000385	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45580892~45580996:-
THCA	cis	rs7429990	0.76	rs319694	ENSG00000228638.1	FCF1P2	-4.7	3.39e-06	0.000385	-0.2	-0.21	Educational attainment (years of education);	chr3:47843463	chr3:48290793~48291375:-
THCA	cis	rs12760731	0.622	rs71628291	ENSG00000213057.5	C1orf220	4.7	3.39e-06	0.000385	0.25	0.21	Obesity-related traits;	chr1:178604608	chr1:178542752~178548889:+
THCA	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-4.7	3.39e-06	0.000385	-0.25	-0.21	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
THCA	cis	rs6832769	0.961	rs11133379	ENSG00000272969.1	RP11-528I4.2	4.7	3.39e-06	0.000385	0.25	0.21	Personality dimensions;	chr4:55439944	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs3736545	ENSG00000272969.1	RP11-528I4.2	4.7	3.39e-06	0.000385	0.25	0.21	Personality dimensions;	chr4:55444176	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs12643926	ENSG00000272969.1	RP11-528I4.2	4.7	3.39e-06	0.000385	0.25	0.21	Personality dimensions;	chr4:55444454	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs12647034	ENSG00000272969.1	RP11-528I4.2	4.7	3.39e-06	0.000385	0.25	0.21	Personality dimensions;	chr4:55444455	chr4:55547112~55547889:+
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000164669.11	INTS4P1	-4.7	3.39e-06	0.000385	-0.26	-0.21	Calcium levels;	chr7:65967580	chr7:65141225~65234216:+
THCA	cis	rs3743162	0.553	rs12900463	ENSG00000275120.1	RP11-182J1.17	4.7	3.39e-06	0.000385	0.26	0.21	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84599434~84606463:-
THCA	cis	rs1185460	1	rs7938944	ENSG00000272186.1	RP11-110I1.13	-4.7	3.39e-06	0.000385	-0.2	-0.21	Coronary artery disease;	chr11:119083356	chr11:119067374~119067698:-
THCA	cis	rs17412738	0.564	rs60074228	ENSG00000248724.5	NPHP3-AS1	-4.7	3.39e-06	0.000385	-0.32	-0.21	Blood protein levels;	chr3:132408416	chr3:132721750~132874223:+
THCA	cis	rs17404153	0.527	rs16839219	ENSG00000248724.5	NPHP3-AS1	-4.7	3.39e-06	0.000385	-0.32	-0.21	LDL cholesterol;HDL cholesterol;	chr3:132408616	chr3:132721750~132874223:+
THCA	cis	rs4767841	0.935	rs2936831	ENSG00000248636.5	RP11-768F21.1	-4.7	3.39e-06	0.000385	-0.22	-0.21	Urgency urinary incontinence;	chr12:119726459	chr12:119387987~119668079:-
THCA	cis	rs12906542	0.544	rs35472584	ENSG00000260776.4	RP11-114H24.2	4.7	3.39e-06	0.000385	0.31	0.21	Breast cancer;	chr15:77974385	chr15:77914217~77926846:-
THCA	cis	rs2386661	0.523	rs61832677	ENSG00000231483.1	RP11-336A10.5	4.7	3.39e-06	0.000386	0.22	0.21	Breast cancer;	chr10:5610514	chr10:5608475~5610793:-
THCA	cis	rs9558942	0.924	rs1927750	ENSG00000277863.1	RP11-282A11.4	-4.7	3.39e-06	0.000386	-0.28	-0.21	Obesity-related traits;	chr13:107055544	chr13:106903150~106904099:-
THCA	cis	rs6088580	0.609	rs6059845	ENSG00000276073.1	RP5-1125A11.7	-4.7	3.39e-06	0.000386	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34448695	chr20:33985617~33988989:-
THCA	cis	rs9926296	0.586	rs1800359	ENSG00000260259.1	RP11-368I7.4	-4.7	3.39e-06	0.000386	-0.24	-0.21	Vitiligo;	chr16:89738853	chr16:89682620~89686569:-
THCA	cis	rs75920871	0.61	rs11216169	ENSG00000254851.1	RP11-109L13.1	-4.7	3.39e-06	0.000386	-0.48	-0.21	Subjective well-being;	chr11:116873673	chr11:117135528~117138582:+
THCA	cis	rs4448343	1	rs28629854	ENSG00000271155.1	RP11-435O5.5	-4.7	3.4e-06	0.000386	-0.22	-0.21	Height;	chr9:95500551	chr9:95506235~95507636:+
THCA	cis	rs67478160	0.619	rs12886363	ENSG00000269910.1	RP11-73M18.10	4.7	3.4e-06	0.000386	0.19	0.21	Schizophrenia;	chr14:103807449	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs12880821	ENSG00000269910.1	RP11-73M18.10	4.7	3.4e-06	0.000386	0.19	0.21	Schizophrenia;	chr14:103809712	chr14:103694516~103695050:-
THCA	cis	rs6545883	0.507	rs12617371	ENSG00000270820.4	RP11-355B11.2	-4.7	3.4e-06	0.000386	-0.18	-0.21	Tuberculosis;	chr2:61341999	chr2:61471188~61484130:+
THCA	cis	rs752010	0.902	rs60743712	ENSG00000230638.4	RP11-486B10.4	-4.7	3.4e-06	0.000386	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41610958	chr1:41542069~41544310:+
THCA	cis	rs12908161	0.92	rs12904605	ENSG00000188388.10	GOLGA6L3	4.7	3.4e-06	0.000386	0.28	0.21	Schizophrenia;	chr15:84658188	chr15:85240472~85247170:+
THCA	cis	rs9634489	0.588	rs1927795	ENSG00000247400.3	DNAJC3-AS1	-4.7	3.4e-06	0.000386	-0.14	-0.21	Body mass index;	chr13:96268496	chr13:95648733~95676925:-
THCA	cis	rs8002861	0.905	rs12875052	ENSG00000274001.1	RP11-5G9.5	-4.7	3.4e-06	0.000386	-0.26	-0.21	Leprosy;	chr13:43875232	chr13:43877715~43878163:-
THCA	cis	rs1790761	0.52	rs4930461	ENSG00000255318.1	RP11-655M14.13	4.7	3.4e-06	0.000386	0.25	0.21	Mean corpuscular volume;	chr11:67627424	chr11:67618279~67627304:-
THCA	cis	rs7711186	0.708	rs1472457	ENSG00000252464.1	RN7SKP70	4.7	3.4e-06	0.000386	0.22	0.21	Urate levels in obese individuals;	chr5:178606263	chr5:178619728~178619998:-
THCA	cis	rs9652601	0.691	rs3893660	ENSG00000274038.1	RP11-66H6.4	-4.7	3.4e-06	0.000386	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11100073	chr16:11056556~11057034:+
THCA	cis	rs2439831	0.681	rs2242067	ENSG00000166763.7	STRCP1	4.7	3.4e-06	0.000386	0.32	0.21	Lung cancer in ever smokers;	chr15:43407105	chr15:43699488~43718184:-
THCA	cis	rs8141529	0.748	rs5997412	ENSG00000226471.5	CTA-292E10.6	-4.7	3.4e-06	0.000386	-0.17	-0.21	Lymphocyte counts;	chr22:28880759	chr22:28800683~28848559:+
THCA	cis	rs1707322	1	rs6675222	ENSG00000281133.1	AL355480.3	-4.7	3.4e-06	0.000386	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4660895	ENSG00000281133.1	AL355480.3	-4.7	3.4e-06	0.000386	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4660318	ENSG00000281133.1	AL355480.3	-4.7	3.4e-06	0.000386	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45580892~45580996:-
THCA	cis	rs12935418	0.634	rs9934940	ENSG00000278985.1	RP11-303E16.9	4.7	3.4e-06	0.000386	0.23	0.21	Mean corpuscular volume;	chr16:81016021	chr16:80982319~80984094:-
THCA	cis	rs7267979	0.586	rs11087505	ENSG00000277938.1	RP5-965G21.3	4.7	3.4e-06	0.000387	0.18	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:25229150~25231933:+
THCA	cis	rs17594362	1	rs12429256	ENSG00000264190.1	MIR5006	-4.7	3.4e-06	0.000387	-0.34	-0.21	Multiple sclerosis;	chr13:41562247	chr13:41568286~41568395:-
THCA	cis	rs2028299	0.879	rs8034631	ENSG00000259677.1	RP11-493E3.1	4.7	3.4e-06	0.000387	0.28	0.21	Type 2 diabetes;	chr15:89879433	chr15:89876540~89877285:+
THCA	cis	rs7617773	0.817	rs11928691	ENSG00000199476.1	Y_RNA	-4.7	3.4e-06	0.000387	-0.27	-0.21	Coronary artery disease;	chr3:48245275	chr3:48288587~48288694:+
THCA	cis	rs7617773	0.817	rs9311421	ENSG00000199476.1	Y_RNA	-4.7	3.4e-06	0.000387	-0.27	-0.21	Coronary artery disease;	chr3:48251588	chr3:48288587~48288694:+
THCA	cis	rs6547705	1	rs6547705	ENSG00000231259.4	AC125232.1	-4.7	3.4e-06	0.000387	-0.29	-0.21	Progressive supranuclear palsy;	chr2:86817193	chr2:87031815~87053069:-
THCA	cis	rs7554547	0.667	rs11121839	ENSG00000199347.1	RNU5E-1	-4.7	3.41e-06	0.000387	-0.29	-0.21	Nonsyndromic cleft lip with cleft palate;	chr1:11908280	chr1:11908152~11908271:+
THCA	cis	rs9880211	0.752	rs67145204	ENSG00000239213.4	NCK1-AS1	4.7	3.41e-06	0.000387	0.24	0.21	Height;Body mass index;	chr3:136609823	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.752	rs9820717	ENSG00000239213.4	NCK1-AS1	4.7	3.41e-06	0.000387	0.24	0.21	Height;Body mass index;	chr3:136627771	chr3:136841726~136862054:-
THCA	cis	rs12893668	0.543	rs12147645	ENSG00000269958.1	RP11-73M18.8	4.7	3.41e-06	0.000387	0.2	0.21	Reticulocyte count;	chr14:103633871	chr14:103696353~103697163:+
THCA	cis	rs6860806	0.507	rs272868	ENSG00000237714.1	P4HA2-AS1	4.7	3.41e-06	0.000387	0.28	0.21	Breast cancer;	chr5:132345058	chr5:132184876~132192808:+
THCA	cis	rs4970988	0.556	rs6681426	ENSG00000231073.1	RP11-316M1.3	-4.7	3.41e-06	0.000387	-0.26	-0.21	Urate levels;	chr1:150614495	chr1:150973123~150975534:+
THCA	cis	rs972578	0.74	rs7287792	ENSG00000274717.1	RP1-47A17.1	-4.7	3.41e-06	0.000387	-0.22	-0.21	Mean platelet volume;	chr22:42998483	chr22:42791814~42794313:-
THCA	cis	rs9902453	1	rs56280226	ENSG00000263370.1	RP11-68I3.5	4.7	3.41e-06	0.000387	0.28	0.21	Coffee consumption (cups per day);	chr17:30102557	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs8082175	ENSG00000263370.1	RP11-68I3.5	4.7	3.41e-06	0.000387	0.28	0.21	Coffee consumption (cups per day);	chr17:30103285	chr17:29639627~29640825:+
THCA	cis	rs703842	1	rs2072052	ENSG00000270039.1	RP11-571M6.17	-4.7	3.41e-06	0.000387	-0.25	-0.21	Multiple sclerosis;	chr12:57752936	chr12:57803838~57804415:+
THCA	cis	rs2032447	0.613	rs6456708	ENSG00000272462.2	U91328.19	-4.7	3.41e-06	0.000387	-0.16	-0.21	Intelligence (multi-trait analysis);	chr6:26032619	chr6:25992662~26001775:+
THCA	cis	rs972578	0.765	rs7285844	ENSG00000274717.1	RP1-47A17.1	-4.7	3.41e-06	0.000387	-0.22	-0.21	Mean platelet volume;	chr22:42901674	chr22:42791814~42794313:-
THCA	cis	rs2803122	0.846	rs7851656	ENSG00000273226.1	RP11-513M16.8	-4.7	3.41e-06	0.000387	-0.19	-0.21	Pulse pressure;	chr9:19213962	chr9:19375451~19375996:+
THCA	cis	rs763121	0.853	rs6519120	ENSG00000235209.1	CTA-150C2.13	-4.7	3.41e-06	0.000387	-0.28	-0.21	Menopause (age at onset);	chr22:38595388	chr22:38921227~38924708:+
THCA	cis	rs1823913	0.637	rs12992372	ENSG00000280083.1	RP11-317J9.1	-4.7	3.41e-06	0.000387	-0.24	-0.21	Obesity-related traits;	chr2:191289251	chr2:191154118~191156070:-
THCA	cis	rs8002861	0.846	rs12867732	ENSG00000274001.1	RP11-5G9.5	-4.7	3.41e-06	0.000388	-0.26	-0.21	Leprosy;	chr13:43908948	chr13:43877715~43878163:-
THCA	cis	rs4443100	0.958	rs9608066	ENSG00000230701.2	FBXW4P1	4.7	3.41e-06	0.000388	0.26	0.21	Serum parathyroid hormone levels;	chr22:23044992	chr22:23262767~23265005:+
THCA	cis	rs4443100	0.917	rs725984	ENSG00000230701.2	FBXW4P1	4.7	3.41e-06	0.000388	0.26	0.21	Serum parathyroid hormone levels;	chr22:23045462	chr22:23262767~23265005:+
THCA	cis	rs1823874	0.584	rs1823872	ENSG00000182397.13	DNM1P46	-4.7	3.41e-06	0.000388	-0.24	-0.21	IgG glycosylation;	chr15:99839246	chr15:99790156~99806927:-
THCA	cis	rs911555	0.723	rs12436956	ENSG00000244691.1	RPL10AP1	4.7	3.41e-06	0.000388	0.29	0.21	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103412119~103412761:-
THCA	cis	rs2120243	1	rs10936090	ENSG00000244515.1	KRT18P34	-4.7	3.41e-06	0.000388	-0.25	-0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157424965	chr3:157162663~157163932:-
THCA	cis	rs79243044	0.695	rs7131665	ENSG00000224295.2	AC087380.14	-4.7	3.41e-06	0.000388	-0.21	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5518440	chr11:5518441~5524955:-
THCA	cis	rs9890032	0.581	rs62070592	ENSG00000263603.1	CTD-2349P21.5	-4.7	3.41e-06	0.000388	-0.27	-0.21	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30729469~30731202:+
THCA	cis	rs4650994	0.593	rs2811302	ENSG00000273384.1	RP5-1098D14.1	-4.7	3.41e-06	0.000388	-0.28	-0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178583740	chr1:178651706~178652282:+
THCA	cis	rs7577696	0.853	rs212698	ENSG00000276334.1	AL133243.1	4.7	3.41e-06	0.000388	0.23	0.21	Inflammatory biomarkers;	chr2:32217928	chr2:32521927~32523547:+
THCA	cis	rs7665090	0.87	rs228623	ENSG00000251288.2	RP11-10L12.2	4.7	3.42e-06	0.000388	0.28	0.21	Primary biliary cholangitis;	chr4:102651163	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.837	rs228624	ENSG00000251288.2	RP11-10L12.2	4.7	3.42e-06	0.000388	0.28	0.21	Primary biliary cholangitis;	chr4:102651283	chr4:102751401~102752641:+
THCA	cis	rs9813712	0.953	rs6439222	ENSG00000253540.4	FAM86HP	4.7	3.42e-06	0.000388	0.26	0.21	Response to amphetamines;	chr3:130256298	chr3:130099092~130111472:-
THCA	cis	rs2790457	0.958	rs2790444	ENSG00000254635.4	WAC-AS1	-4.7	3.42e-06	0.000388	-0.21	-0.21	Multiple myeloma;	chr10:28536760	chr10:28522652~28532743:-
THCA	cis	rs5742933	0.948	rs6434365	ENSG00000253559.1	OSGEPL1-AS1	-4.7	3.42e-06	0.000388	-0.26	-0.21	Ferritin levels;	chr2:189707695	chr2:189762704~189765556:+
THCA	cis	rs6860806	0.531	rs274556	ENSG00000224431.1	AC063976.7	-4.7	3.42e-06	0.000388	-0.19	-0.21	Breast cancer;	chr5:132386383	chr5:132199456~132203487:+
THCA	cis	rs7188861	0.626	rs7193871	ENSG00000262703.1	RP11-485G7.6	4.7	3.42e-06	0.000388	0.24	0.21	HDL cholesterol;	chr16:11361749	chr16:11348143~11349321:-
THCA	cis	rs2732480	0.577	rs2634693	ENSG00000273765.1	RP11-370I10.11	4.7	3.42e-06	0.000388	0.22	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.577	rs2634691	ENSG00000273765.1	RP11-370I10.11	4.7	3.42e-06	0.000388	0.22	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48360920~48361377:+
THCA	cis	rs7552393	0.636	rs12144970	ENSG00000233008.4	RP11-475O6.1	-4.7	3.42e-06	0.000388	-0.25	-0.21	Select biomarker traits;	chr1:83794943	chr1:83575776~83861023:-
THCA	cis	rs9625935	0.957	rs17648725	ENSG00000279159.1	RP3-394A18.1	-4.7	3.42e-06	0.000388	-0.16	-0.21	Tonsillectomy;	chr22:30122839	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs11090598	ENSG00000279159.1	RP3-394A18.1	-4.7	3.42e-06	0.000388	-0.16	-0.21	Tonsillectomy;	chr22:30125781	chr22:29978950~30028236:-
THCA	cis	rs7618915	1	rs59565798	ENSG00000243224.1	RP5-1157M23.2	-4.7	3.42e-06	0.000388	-0.22	-0.21	Bipolar disorder;	chr3:52273153	chr3:52239258~52241097:+
THCA	cis	rs62158800	0.733	rs10199917	ENSG00000237880.1	AC096669.2	4.7	3.42e-06	0.000388	0.33	0.21	Facial morphology (factor 22);	chr2:107636523	chr2:107385632~107542649:-
THCA	cis	rs4072705	0.615	rs6478666	ENSG00000224020.1	MIR181A2HG	4.7	3.42e-06	0.000388	0.2	0.21	Menarche (age at onset);	chr9:124487064	chr9:124658467~124698631:+
THCA	cis	rs526231	0.644	rs386352	ENSG00000175749.11	EIF3KP1	4.7	3.42e-06	0.000389	0.27	0.21	Primary biliary cholangitis;	chr5:103280006	chr5:103032376~103033031:+
THCA	cis	rs34929064	0.881	rs7802442	ENSG00000179428.2	AC073072.5	-4.7	3.42e-06	0.000389	-0.23	-0.21	Major depression and alcohol dependence;	chr7:22696827	chr7:22725395~22727620:-
THCA	cis	rs12755164	0.742	rs11210076	ENSG00000223479.3	RP4-788P17.1	4.7	3.42e-06	0.000389	0.24	0.21	Schizophrenia;	chr1:72857948	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.778	rs4650158	ENSG00000223479.3	RP4-788P17.1	4.7	3.42e-06	0.000389	0.24	0.21	Schizophrenia;	chr1:72860296	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.778	rs12126853	ENSG00000223479.3	RP4-788P17.1	4.7	3.42e-06	0.000389	0.24	0.21	Schizophrenia;	chr1:72861620	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.778	rs6670128	ENSG00000223479.3	RP4-788P17.1	4.7	3.42e-06	0.000389	0.24	0.21	Schizophrenia;	chr1:72863093	chr1:73635216~73715214:+
THCA	cis	rs2018683	0.621	rs10261556	ENSG00000272568.4	CTB-113D17.1	4.7	3.42e-06	0.000389	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28937019	chr7:28979967~29013367:+
THCA	cis	rs5752326	0.51	rs739291	ENSG00000261188.1	CTA-445C9.14	4.7	3.42e-06	0.000389	0.2	0.21	Ischemic stroke;	chr22:26481573	chr22:26512537~26514568:+
THCA	cis	rs9329221	0.935	rs3750310	ENSG00000261451.1	RP11-981G7.1	-4.7	3.42e-06	0.000389	-0.27	-0.21	Neuroticism;	chr8:10425916	chr8:10433672~10438312:+
THCA	cis	rs72615157	0.634	rs74774557	ENSG00000078319.8	PMS2P1	-4.7	3.42e-06	0.000389	-0.28	-0.21	Lung function (FEV1/FVC);	chr7:100212802	chr7:100320992~100341908:-
THCA	cis	rs2742234	0.656	rs1864400	ENSG00000273008.1	RP11-351D16.3	-4.7	3.42e-06	0.000389	-0.2	-0.21	Hirschsprung disease;	chr10:43114918	chr10:43136824~43138334:-
THCA	cis	rs11051970	0.553	rs325419	ENSG00000274964.1	RP11-817I4.1	-4.7	3.43e-06	0.000389	-0.22	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32419526	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.594	rs325418	ENSG00000274964.1	RP11-817I4.1	-4.7	3.43e-06	0.000389	-0.22	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32419583	chr12:32339368~32340724:+
THCA	cis	rs6012564	1	rs755589	ENSG00000227431.4	CSE1L-AS1	4.7	3.43e-06	0.000389	0.26	0.21	Anger;	chr20:49104848	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.793	rs1043361	ENSG00000227431.4	CSE1L-AS1	4.7	3.43e-06	0.000389	0.26	0.21	Anger;	chr20:49114621	chr20:49040463~49046044:-
THCA	cis	rs9487094	0.666	rs13219952	ENSG00000223537.2	RP5-919F19.5	-4.7	3.43e-06	0.000389	-0.21	-0.21	Height;	chr6:109391084	chr6:109487906~109506800:+
THCA	cis	rs34792	0.528	rs153793	ENSG00000255277.3	ABCC6P2	4.7	3.43e-06	0.000389	0.22	0.21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15448342	chr16:14820792~14824702:-
THCA	cis	rs8064024	0.68	rs2063101	ENSG00000267077.1	RP11-127I20.5	4.7	3.43e-06	0.000389	0.24	0.21	Cancer;	chr16:4866347	chr16:4795265~4796532:-
THCA	cis	rs10043228	1	rs62384237	ENSG00000248445.4	SEMA6A-AS1	-4.7	3.43e-06	0.000389	-0.29	-0.21	Asthma or chronic obstructive pulmonary disease;	chr5:116204525	chr5:116447547~116508276:+
THCA	cis	rs12476592	0.516	rs6546002	ENSG00000242412.1	DBIL5P2	4.7	3.43e-06	0.000389	0.27	0.21	Childhood ear infection;	chr2:63366694	chr2:63117851~63119542:-
THCA	cis	rs3734266	0.702	rs13205210	ENSG00000272288.4	RP11-140K17.3	-4.7	3.43e-06	0.000389	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34864079	chr6:34696317~34697470:+
THCA	cis	rs228614	0.51	rs223438	ENSG00000248971.2	KRT8P46	4.7	3.43e-06	0.000389	0.26	0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102728746~102730171:-
THCA	cis	rs10090774	0.932	rs9644449	ENSG00000279766.1	RP11-642A1.2	-4.7	3.43e-06	0.000389	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140937186	chr8:140572142~140572812:-
THCA	cis	rs5758511	0.68	rs5758698	ENSG00000237037.8	NDUFA6-AS1	-4.7	3.43e-06	0.000389	-0.2	-0.21	Birth weight;	chr22:42288812	chr22:42090931~42137742:+
THCA	cis	rs9987353	0.566	rs6998368	ENSG00000248538.5	RP11-10A14.5	4.7	3.43e-06	0.00039	0.29	0.21	Recombination measurement;	chr8:9212778	chr8:9189011~9202854:+
THCA	cis	rs7141336	0.77	rs12890577	ENSG00000258884.1	CTD-3035D6.2	4.7	3.43e-06	0.00039	0.28	0.21	Anxiety disorder;	chr14:90827103	chr14:90822365~90828128:-
THCA	cis	rs2243480	1	rs781156	ENSG00000164669.11	INTS4P1	4.7	3.43e-06	0.00039	0.41	0.21	Diabetic kidney disease;	chr7:66014154	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs451396	ENSG00000164669.11	INTS4P1	4.7	3.43e-06	0.00039	0.41	0.21	Diabetic kidney disease;	chr7:66019087	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs1715235	ENSG00000164669.11	INTS4P1	4.7	3.43e-06	0.00039	0.41	0.21	Diabetic kidney disease;	chr7:66023407	chr7:65141225~65234216:+
THCA	cis	rs250518	0.926	rs6452683	ENSG00000272081.1	CTD-2376I4.2	4.7	3.43e-06	0.00039	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72787076	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs6875887	ENSG00000272081.1	CTD-2376I4.2	4.7	3.43e-06	0.00039	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72795067	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs6876549	ENSG00000272081.1	CTD-2376I4.2	4.7	3.43e-06	0.00039	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72795463	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs6897422	ENSG00000272081.1	CTD-2376I4.2	4.7	3.43e-06	0.00039	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72795532	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs6452687	ENSG00000272081.1	CTD-2376I4.2	4.7	3.43e-06	0.00039	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72795688	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs6452690	ENSG00000272081.1	CTD-2376I4.2	4.7	3.43e-06	0.00039	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72795785	chr5:72955206~72955699:-
THCA	cis	rs58605417	0.534	rs1700137	ENSG00000253553.4	RP11-586K2.1	4.7	3.43e-06	0.00039	0.22	0.21	Schizophrenia;	chr8:88449380	chr8:88326836~88737134:+
THCA	cis	rs11088226	1	rs11701627	ENSG00000186842.4	LINC00846	-4.7	3.43e-06	0.00039	-0.29	-0.21	Gastritis;	chr21:32555484	chr21:32572238~32575881:-
THCA	cis	rs12681288	0.748	rs7000148	ENSG00000260721.1	AF067845.1	4.7	3.43e-06	0.00039	0.25	0.21	Schizophrenia;	chr8:1066383	chr8:1368642~1369833:-
THCA	cis	rs2904967	0.537	rs7116674	ENSG00000255200.1	AP003068.18	4.7	3.43e-06	0.00039	0.44	0.21	Mean corpuscular volume;	chr11:65195487	chr11:65174117~65176470:-
THCA	cis	rs656319	0.513	rs3885723	ENSG00000261451.1	RP11-981G7.1	-4.7	3.43e-06	0.00039	-0.26	-0.21	Myopia (pathological);	chr8:10134151	chr8:10433672~10438312:+
THCA	cis	rs875971	0.545	rs313828	ENSG00000164669.11	INTS4P1	4.7	3.43e-06	0.00039	0.31	0.21	Aortic root size;	chr7:66087627	chr7:65141225~65234216:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000164669.11	INTS4P1	4.7	3.43e-06	0.00039	0.31	0.21	Aortic root size;	chr7:66089365	chr7:65141225~65234216:+
THCA	cis	rs79243044	1	rs7944109	ENSG00000224295.2	AC087380.14	-4.7	3.44e-06	0.00039	-0.22	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5543689	chr11:5518441~5524955:-
THCA	cis	rs1005277	0.603	rs1998062	ENSG00000275858.1	RP11-291L22.8	4.7	3.44e-06	0.00039	0.26	0.21	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38450738~38451069:-
THCA	cis	rs6441961	0.501	rs41418050	ENSG00000223552.1	RP11-24F11.2	4.7	3.44e-06	0.00039	0.22	0.21	Celiac disease;	chr3:46238755	chr3:46364955~46407059:-
THCA	cis	rs13108904	0.935	rs4974575	ENSG00000254094.1	AC078852.1	-4.7	3.44e-06	0.00039	-0.24	-0.21	Obesity-related traits;	chr4:1258240	chr4:1356581~1358075:+
THCA	cis	rs12049671	0.72	rs7900735	ENSG00000227076.1	RP11-4C20.4	4.7	3.44e-06	0.00039	0.24	0.21	Response to amphetamines;	chr10:127950639	chr10:127934698~127936167:+
THCA	cis	rs2018683	0.649	rs221171	ENSG00000228421.2	AC005013.5	-4.7	3.44e-06	0.00039	-0.25	-0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28966523	chr7:28957667~28959345:+
THCA	cis	rs7772486	0.806	rs2253648	ENSG00000270638.1	RP3-466P17.1	4.7	3.44e-06	0.00039	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145735570~145737218:+
THCA	cis	rs972578	0.715	rs4822211	ENSG00000274717.1	RP1-47A17.1	-4.7	3.44e-06	0.00039	-0.22	-0.21	Mean platelet volume;	chr22:42871825	chr22:42791814~42794313:-
THCA	cis	rs4646450	0.735	rs11762273	ENSG00000244219.5	GS1-259H13.2	-4.7	3.44e-06	0.00039	-0.28	-0.21	Blood metabolite levels;	chr7:99379564	chr7:99598066~99610813:+
THCA	cis	rs6088580	0.634	rs4911151	ENSG00000276073.1	RP5-1125A11.7	4.7	3.44e-06	0.00039	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34344467	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6088471	ENSG00000276073.1	RP5-1125A11.7	4.7	3.44e-06	0.00039	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34344837	chr20:33985617~33988989:-
THCA	cis	rs10761482	0.601	rs10733764	ENSG00000254271.1	RP11-131N11.4	4.7	3.44e-06	0.00039	0.29	0.21	Schizophrenia;	chr10:60450587	chr10:60734342~60741828:+
THCA	cis	rs8067545	0.935	rs7209734	ENSG00000270091.1	RP11-78O7.2	-4.7	3.44e-06	0.00039	-0.16	-0.21	Schizophrenia;	chr17:20085230	chr17:19896590~19897287:-
THCA	cis	rs172166	0.61	rs276369	ENSG00000273712.1	RP5-874C20.7	4.7	3.44e-06	0.00039	0.23	0.21	Cardiac Troponin-T levels;	chr6:27951465	chr6:28315613~28315883:-
THCA	cis	rs35160687	0.644	rs11680025	ENSG00000273080.1	RP11-301O19.1	-4.7	3.44e-06	0.000391	-0.23	-0.21	Night sleep phenotypes;	chr2:86318215	chr2:86195590~86196049:+
THCA	cis	rs6001482	0.638	rs5757574	ENSG00000272779.1	LL22NC03-80A10.6	-4.7	3.44e-06	0.000391	-0.24	-0.21	Diastolic blood pressure;	chr22:22231597	chr22:22303224~22310401:+
THCA	cis	rs7267979	0.932	rs6115214	ENSG00000274973.1	RP13-401N8.7	4.7	3.44e-06	0.000391	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25845497~25845862:+
THCA	cis	rs12681288	0.862	rs4735981	ENSG00000260721.1	AF067845.1	4.7	3.45e-06	0.000391	0.25	0.21	Schizophrenia;	chr8:1068437	chr8:1368642~1369833:-
THCA	cis	rs6600671	0.692	rs11249430	ENSG00000275585.1	CH17-118O6.3	-4.7	3.45e-06	0.000391	-0.27	-0.21	Hip geometry;	chr1:121547115	chr1:120985692~121052167:-
THCA	cis	rs228614	0.543	rs223330	ENSG00000248971.2	KRT8P46	-4.7	3.45e-06	0.000391	-0.26	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223329	ENSG00000248971.2	KRT8P46	-4.7	3.45e-06	0.000391	-0.26	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102728746~102730171:-
THCA	cis	rs228614	0.536	rs223327	ENSG00000248971.2	KRT8P46	-4.7	3.45e-06	0.000391	-0.26	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223326	ENSG00000248971.2	KRT8P46	-4.7	3.45e-06	0.000391	-0.26	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs223324	ENSG00000248971.2	KRT8P46	-4.7	3.45e-06	0.000391	-0.26	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102728746~102730171:-
THCA	cis	rs4950322	0.57	rs79810882	ENSG00000180867.10	PDIA3P1	4.7	3.45e-06	0.000391	0.21	0.21	Protein quantitative trait loci;	chr1:147235575	chr1:147178113~147179622:+
THCA	cis	rs2688608	0.901	rs2664282	ENSG00000271816.1	BMS1P4	4.7	3.45e-06	0.000391	0.21	0.21	Inflammatory bowel disease;	chr10:73860999	chr10:73699151~73730487:-
THCA	cis	rs2243480	1	rs958550	ENSG00000230295.1	RP11-458F8.2	4.7	3.45e-06	0.000391	0.26	0.21	Diabetic kidney disease;	chr7:66170692	chr7:66880708~66882981:+
THCA	cis	rs858239	0.539	rs10280815	ENSG00000226816.2	AC005082.12	4.7	3.45e-06	0.000392	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs10225608	ENSG00000226816.2	AC005082.12	4.7	3.45e-06	0.000392	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs28624974	ENSG00000226816.2	AC005082.12	4.7	3.45e-06	0.000392	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23206013~23208045:+
THCA	cis	rs5850	0.557	rs10270788	ENSG00000226816.2	AC005082.12	4.7	3.45e-06	0.000392	0.3	0.21	Blood protein levels;	chr7:23149381	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs28716381	ENSG00000226816.2	AC005082.12	4.7	3.45e-06	0.000392	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs1358442	ENSG00000226816.2	AC005082.12	4.7	3.45e-06	0.000392	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23206013~23208045:+
THCA	cis	rs4648045	0.828	rs62328541	ENSG00000246560.2	RP11-10L12.4	4.7	3.45e-06	0.000392	0.27	0.21	Lymphocyte percentage of white cells;	chr4:102512189	chr4:102828055~102844075:+
THCA	cis	rs3020736	0.5	rs6002614	ENSG00000273366.1	CTA-989H11.1	4.7	3.45e-06	0.000392	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs2413669	ENSG00000273366.1	CTA-989H11.1	4.7	3.45e-06	0.000392	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs6002618	ENSG00000273366.1	CTA-989H11.1	4.7	3.45e-06	0.000392	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs2413672	ENSG00000273366.1	CTA-989H11.1	4.7	3.45e-06	0.000392	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs6002623	ENSG00000273366.1	CTA-989H11.1	4.7	3.45e-06	0.000392	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs11090076	ENSG00000273366.1	CTA-989H11.1	4.7	3.45e-06	0.000392	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42278188~42278846:+
THCA	cis	rs3020736	0.5	rs764481	ENSG00000273366.1	CTA-989H11.1	4.7	3.45e-06	0.000392	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42278188~42278846:+
THCA	cis	rs4915077	1	rs11588186	ENSG00000230489.1	VAV3-AS1	4.7	3.45e-06	0.000392	0.37	0.21	Hypothyroidism;	chr1:107763935	chr1:107964443~107994607:+
THCA	cis	rs2015599	0.623	rs7358667	ENSG00000273680.1	RP11-996F15.6	-4.7	3.45e-06	0.000392	-0.3	-0.21	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29332733~29333383:-
THCA	cis	rs1005277	0.522	rs1208681	ENSG00000276805.1	RP11-291L22.6	4.7	3.45e-06	0.000392	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38451030~38451785:+
THCA	cis	rs796395	0.967	rs623356	ENSG00000228208.5	C1orf143	4.7	3.45e-06	0.000392	0.25	0.21	Post bronchodilator FEV1/FVC ratio;	chr1:218474044	chr1:218510096~218525978:+
THCA	cis	rs2287838	0.967	rs3786694	ENSG00000267289.1	CTD-2623N2.11	-4.7	3.45e-06	0.000392	-0.25	-0.21	Sleep duration;	chr19:9844665	chr19:9834079~9835013:-
THCA	cis	rs7394190	0.748	rs4082339	ENSG00000271816.1	BMS1P4	4.7	3.45e-06	0.000392	0.26	0.21	Incident atrial fibrillation;	chr10:73780054	chr10:73699151~73730487:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000232559.3	GS1-124K5.12	4.7	3.45e-06	0.000392	0.31	0.21	Diabetic kidney disease;	chr7:65924743	chr7:66554588~66576923:-
THCA	cis	rs12541437	1	rs3020161	ENSG00000253327.2	RAD21-AS1	4.7	3.45e-06	0.000392	0.23	0.21	Gut microbiome composition (winter);	chr8:116912414	chr8:116874424~116876868:+
THCA	cis	rs2239547	0.522	rs9831409	ENSG00000242142.1	SERBP1P3	-4.7	3.46e-06	0.000392	-0.26	-0.21	Schizophrenia;	chr3:52951695	chr3:53064283~53065091:-
THCA	cis	rs2239547	0.522	rs9311485	ENSG00000242142.1	SERBP1P3	-4.7	3.46e-06	0.000392	-0.26	-0.21	Schizophrenia;	chr3:52953629	chr3:53064283~53065091:-
THCA	cis	rs240993	0.812	rs6942129	ENSG00000271789.1	RP5-1112D6.7	-4.7	3.46e-06	0.000392	-0.26	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111442417	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs9487644	ENSG00000271789.1	RP5-1112D6.7	-4.7	3.46e-06	0.000392	-0.26	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111443064	chr6:111297126~111298510:+
THCA	cis	rs240993	0.761	rs9487645	ENSG00000271789.1	RP5-1112D6.7	-4.7	3.46e-06	0.000392	-0.26	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111443065	chr6:111297126~111298510:+
THCA	cis	rs7614311	0.681	rs6796317	ENSG00000271843.1	RP11-245J9.5	-4.7	3.46e-06	0.000392	-0.37	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63942063	chr3:64008082~64008692:-
THCA	cis	rs6973609	0.597	rs17171523	ENSG00000271122.1	RP11-379H18.1	4.7	3.46e-06	0.000392	0.16	0.21	Obesity-related traits;	chr7:35559907	chr7:35695214~35699413:+
THCA	cis	rs11157436	0.958	rs61972231	ENSG00000211812.1	TRAV26-2	-4.7	3.46e-06	0.000392	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22202583~22203368:+
THCA	cis	rs763121	0.853	rs4821811	ENSG00000273076.1	RP3-508I15.22	4.7	3.46e-06	0.000393	0.22	0.21	Menopause (age at onset);	chr22:38679140	chr22:38743495~38743910:+
THCA	cis	rs7209700	0.547	rs11649785	ENSG00000228782.6	CTD-2026D20.3	-4.7	3.46e-06	0.000393	-0.25	-0.21	IgG glycosylation;	chr17:47278354	chr17:47450568~47492492:-
THCA	cis	rs17095355	1	rs11194917	ENSG00000203876.8	ADD3-AS1	-4.7	3.46e-06	0.000393	-0.23	-0.21	Biliary atresia;	chr10:109932794	chr10:109940104~110008381:-
THCA	cis	rs890448	1	rs1863568	ENSG00000254531.1	FLJ20021	-4.7	3.46e-06	0.000393	-0.19	-0.21	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101511390	chr4:101347780~101348883:+
THCA	cis	rs7267979	0.546	rs8115804	ENSG00000274973.1	RP13-401N8.7	4.7	3.46e-06	0.000393	0.26	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25458147	chr20:25845497~25845862:+
THCA	cis	rs7260598	0.539	rs57061964	ENSG00000268442.1	CTD-2027I19.2	4.7	3.46e-06	0.000393	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23883476	chr19:24162370~24163425:-
THCA	cis	rs1923539	0.549	rs2250360	ENSG00000242600.5	MBL1P	-4.7	3.46e-06	0.000393	-0.19	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79905258	chr10:79904898~79950336:+
THCA	cis	rs3750082	0.817	rs2060731	ENSG00000231952.3	DPY19L1P2	-4.7	3.46e-06	0.000393	-0.26	-0.21	Glomerular filtration rate (creatinine);	chr7:32928734	chr7:32812757~32838570:+
THCA	cis	rs3820928	0.967	rs4675118	ENSG00000212391.1	SNORA48	-4.7	3.46e-06	0.000393	-0.24	-0.21	Pulmonary function;	chr2:226908441	chr2:226968989~226969122:-
THCA	cis	rs11148252	0.595	rs4885117	ENSG00000273784.3	RP11-78J21.7	-4.7	3.47e-06	0.000393	-0.23	-0.21	Lewy body disease;	chr13:52578892	chr13:52600042~52642542:+
THCA	cis	rs77637988	0.603	rs72820445	ENSG00000202227.1	RNU6-282P	4.7	3.47e-06	0.000393	0.22	0.21	Joint mobility (Beighton score);	chr2:48380717	chr2:48501922~48502024:-
THCA	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	4.7	3.47e-06	0.000393	0.26	0.21	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
THCA	cis	rs7809615	0.892	rs58964157	ENSG00000244219.5	GS1-259H13.2	-4.7	3.47e-06	0.000393	-0.38	-0.21	Blood metabolite ratios;	chr7:99436432	chr7:99598066~99610813:+
THCA	cis	rs58605417	0.522	rs1094202	ENSG00000253553.4	RP11-586K2.1	4.7	3.47e-06	0.000393	0.22	0.21	Schizophrenia;	chr8:88454523	chr8:88326836~88737134:+
THCA	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-4.7	3.47e-06	0.000394	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
THCA	cis	rs5760842	0.51	rs733117	ENSG00000279110.1	CTA-243E7.1	-4.7	3.47e-06	0.000394	-0.25	-0.21	Recurrent major depressive disorder;	chr22:25099860	chr22:25052122~25065241:-
THCA	cis	rs2732480	0.557	rs923397	ENSG00000273765.1	RP11-370I10.11	4.7	3.47e-06	0.000394	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48360920~48361377:+
THCA	cis	rs8067545	0.611	rs733794	ENSG00000270091.1	RP11-78O7.2	4.7	3.47e-06	0.000394	0.16	0.21	Schizophrenia;	chr17:20254644	chr17:19896590~19897287:-
THCA	cis	rs703842	0.585	rs10877022	ENSG00000270039.1	RP11-571M6.17	-4.7	3.47e-06	0.000394	-0.24	-0.21	Multiple sclerosis;	chr12:57830154	chr12:57803838~57804415:+
THCA	cis	rs10090774	0.965	rs13270490	ENSG00000279766.1	RP11-642A1.2	-4.7	3.47e-06	0.000394	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140951080	chr8:140572142~140572812:-
THCA	cis	rs9813712	1	rs57804141	ENSG00000253540.4	FAM86HP	4.7	3.47e-06	0.000394	0.26	0.21	Response to amphetamines;	chr3:130243669	chr3:130099092~130111472:-
THCA	cis	rs4713118	0.786	rs200502	ENSG00000220721.1	OR1F12	4.7	3.47e-06	0.000394	0.28	0.21	Parkinson's disease;	chr6:27820284	chr6:28073316~28074233:+
THCA	cis	rs4950322	0.542	rs28381210	ENSG00000271721.1	RP11-337C18.9	4.7	3.47e-06	0.000394	0.24	0.21	Protein quantitative trait loci;	chr1:147201925	chr1:147175602~147177740:+
THCA	cis	rs8028182	0.636	rs11637586	ENSG00000260269.4	CTD-2323K18.1	-4.7	3.47e-06	0.000394	-0.32	-0.21	Sudden cardiac arrest;	chr15:75498771	chr15:75527150~75601205:-
THCA	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-4.7	3.47e-06	0.000394	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
THCA	cis	rs763121	0.853	rs9610986	ENSG00000235209.1	CTA-150C2.13	4.7	3.47e-06	0.000394	0.27	0.21	Menopause (age at onset);	chr22:38629272	chr22:38921227~38924708:+
THCA	cis	rs930395	0.514	rs4391175	ENSG00000272335.1	RP11-53O19.3	4.7	3.48e-06	0.000394	0.18	0.21	Breast cancer;	chr5:44889954	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs7718354	ENSG00000272335.1	RP11-53O19.3	4.7	3.48e-06	0.000394	0.18	0.21	Breast cancer;	chr5:44890912	chr5:44826076~44828592:+
THCA	cis	rs2806561	0.704	rs7532266	ENSG00000249087.5	ZNF436-AS1	4.7	3.48e-06	0.000394	0.14	0.21	Height;	chr1:23225130	chr1:23368997~23371839:+
THCA	cis	rs7829975	0.606	rs6422352	ENSG00000254153.1	CTA-398F10.2	4.7	3.48e-06	0.000394	0.23	0.21	Mood instability;	chr8:8936683	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.606	rs891570	ENSG00000254153.1	CTA-398F10.2	4.7	3.48e-06	0.000394	0.23	0.21	Mood instability;	chr8:8936944	chr8:8456909~8461337:-
THCA	cis	rs8105895	0.935	rs62110990	ENSG00000269345.1	VN1R85P	4.7	3.48e-06	0.000394	0.28	0.21	Body mass index (change over time);	chr19:22077639	chr19:22174766~22175191:-
THCA	cis	rs11143230	1	rs17628494	ENSG00000225434.2	LINC01504	-4.7	3.48e-06	0.000394	-0.33	-0.21	Suicidal ideation;	chr9:72274251	chr9:72305430~72343210:+
THCA	cis	rs4415084	0.966	rs1898701	ENSG00000272335.1	RP11-53O19.3	-4.7	3.48e-06	0.000394	-0.17	-0.21	Breast cancer;	chr5:44695327	chr5:44826076~44828592:+
THCA	cis	rs4415084	1	rs1821936	ENSG00000272335.1	RP11-53O19.3	-4.7	3.48e-06	0.000394	-0.17	-0.21	Breast cancer;	chr5:44699380	chr5:44826076~44828592:+
THCA	cis	rs4415084	1	rs1371027	ENSG00000272335.1	RP11-53O19.3	-4.7	3.48e-06	0.000394	-0.17	-0.21	Breast cancer;	chr5:44699755	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.966	rs714130	ENSG00000272335.1	RP11-53O19.3	-4.7	3.48e-06	0.000394	-0.17	-0.21	Breast cancer;	chr5:44701316	chr5:44826076~44828592:+
THCA	cis	rs4415084	1	rs2165010	ENSG00000272335.1	RP11-53O19.3	-4.7	3.48e-06	0.000394	-0.17	-0.21	Breast cancer;	chr5:44706678	chr5:44826076~44828592:+
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000275400.1	RP4-756H11.5	-4.7	3.48e-06	0.000394	-0.23	-0.21	Corneal structure;	chr7:66835665	chr7:66553805~66554199:-
THCA	cis	rs642858	0.615	rs1856754	ENSG00000234147.1	RP3-460G2.2	-4.7	3.48e-06	0.000395	-0.26	-0.21	Type 2 diabetes;	chr6:140404256	chr6:140845958~140852924:-
THCA	cis	rs6973609	1	rs10279722	ENSG00000271122.1	RP11-379H18.1	4.7	3.48e-06	0.000395	0.14	0.21	Obesity-related traits;	chr7:35568463	chr7:35695214~35699413:+
THCA	cis	rs2777491	0.872	rs61037359	ENSG00000247556.5	OIP5-AS1	4.7	3.48e-06	0.000395	0.17	0.21	Ulcerative colitis;	chr15:41293728	chr15:41283990~41309737:+
THCA	cis	rs6840360	0.582	rs2724553	ENSG00000251611.1	RP11-610P16.1	-4.7	3.48e-06	0.000395	-0.16	-0.21	Intelligence (multi-trait analysis);	chr4:151400729	chr4:151407551~151408835:-
THCA	cis	rs1979679	0.76	rs16932640	ENSG00000247934.4	RP11-967K21.1	-4.7	3.48e-06	0.000395	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28142034	chr12:28163298~28190738:-
THCA	cis	rs12911832	0.727	rs682619	ENSG00000245975.2	RP11-30K9.6	4.7	3.48e-06	0.000395	0.2	0.21	Schizophrenia;	chr15:58806574	chr15:58768072~58770974:-
THCA	cis	rs651907	0.535	rs13084113	ENSG00000244119.1	PDCL3P4	4.7	3.48e-06	0.000395	0.19	0.21	Colorectal cancer;	chr3:101815195	chr3:101712472~101713191:+
THCA	cis	rs1707322	1	rs4660889	ENSG00000281133.1	AL355480.3	-4.7	3.48e-06	0.000395	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs10890355	ENSG00000281133.1	AL355480.3	-4.7	3.48e-06	0.000395	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211204	ENSG00000281133.1	AL355480.3	-4.7	3.48e-06	0.000395	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45580892~45580996:-
THCA	cis	rs11648785	0.777	rs3785183	ENSG00000222019.6	URAHP	4.7	3.48e-06	0.000395	0.18	0.21	Tanning;	chr16:90029153	chr16:90039761~90047773:-
THCA	cis	rs1836229	0.594	rs10758998	ENSG00000225706.1	PTPRD-AS1	-4.7	3.48e-06	0.000395	-0.25	-0.21	Restless legs syndrome;	chr9:8833943	chr9:8858130~8862255:+
THCA	cis	rs9875589	0.509	rs6778884	ENSG00000228242.5	AC093495.4	4.7	3.48e-06	0.000395	0.12	0.21	Ovarian reserve;	chr3:14003181	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs6775534	ENSG00000228242.5	AC093495.4	4.7	3.48e-06	0.000395	0.12	0.21	Ovarian reserve;	chr3:14009501	chr3:14144637~14165978:+
THCA	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-4.7	3.48e-06	0.000395	-0.3	-0.21	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
THCA	cis	rs12823128	0.729	rs12579514	ENSG00000256185.1	RP11-612B6.2	4.7	3.48e-06	0.000395	0.2	0.21	Birth weight;	chr12:26776901	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs12582081	ENSG00000256185.1	RP11-612B6.2	4.7	3.48e-06	0.000395	0.2	0.21	Birth weight;	chr12:26776980	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs12581140	ENSG00000256185.1	RP11-612B6.2	4.7	3.48e-06	0.000395	0.2	0.21	Birth weight;	chr12:26777121	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.729	rs34699075	ENSG00000256185.1	RP11-612B6.2	4.7	3.48e-06	0.000395	0.2	0.21	Birth weight;	chr12:26777567	chr12:26335864~26336950:-
THCA	cis	rs5758659	0.652	rs133349	ENSG00000273366.1	CTA-989H11.1	-4.7	3.48e-06	0.000395	-0.26	-0.21	Cognitive function;	chr22:42032723	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.652	rs5758553	ENSG00000273366.1	CTA-989H11.1	-4.7	3.48e-06	0.000395	-0.26	-0.21	Cognitive function;	chr22:42035425	chr22:42278188~42278846:+
THCA	cis	rs1880529	0.83	rs6818968	ENSG00000206820.1	RNU1-138P	-4.7	3.48e-06	0.000395	-0.25	-0.21	White matter integrity (bipolar disorder risk interaction);	chr4:113449960	chr4:113420323~113420486:+
THCA	cis	rs8020095	0.571	rs8009087	ENSG00000258561.1	RP11-72M17.1	4.7	3.49e-06	0.000395	0.28	0.21	Depression (quantitative trait);	chr14:67097493	chr14:66212810~66509394:-
THCA	cis	rs642803	0.569	rs44205	ENSG00000255120.4	OVOL1-AS1	4.7	3.49e-06	0.000395	0.28	0.21	Urate levels;	chr11:65797315	chr11:65789051~65790868:-
THCA	cis	rs12755164	0.724	rs12129026	ENSG00000223479.3	RP4-788P17.1	-4.7	3.49e-06	0.000395	-0.23	-0.21	Schizophrenia;	chr1:72850233	chr1:73635216~73715214:+
THCA	cis	rs4578769	0.513	rs34623893	ENSG00000265939.1	UBE2CP2	4.7	3.49e-06	0.000395	0.24	0.21	Eosinophil percentage of white cells;	chr18:22967224	chr18:22900486~22900995:-
THCA	cis	rs9393813	0.626	rs2393926	ENSG00000204789.4	ZNF204P	4.7	3.49e-06	0.000395	0.17	0.21	Bipolar disorder;	chr6:27352965	chr6:27357825~27360221:-
THCA	cis	rs79243044	1	rs7120668	ENSG00000224295.2	AC087380.14	-4.7	3.49e-06	0.000395	-0.22	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5546624	chr11:5518441~5524955:-
THCA	cis	rs2243480	1	rs313832	ENSG00000164669.11	INTS4P1	4.7	3.49e-06	0.000395	0.4	0.21	Diabetic kidney disease;	chr7:66085904	chr7:65141225~65234216:+
THCA	cis	rs763121	0.853	rs1043441	ENSG00000273076.1	RP3-508I15.22	4.7	3.49e-06	0.000395	0.22	0.21	Menopause (age at onset);	chr22:38734959	chr22:38743495~38743910:+
THCA	cis	rs7615952	0.8	rs2062773	ENSG00000248787.1	RP11-666A20.4	-4.7	3.49e-06	0.000396	-0.36	-0.21	Blood pressure (smoking interaction);	chr3:125920805	chr3:125908005~125910272:-
THCA	cis	rs4794202	1	rs4794202	ENSG00000264920.1	RP11-6N17.4	-4.7	3.49e-06	0.000396	-0.25	-0.21	Alzheimer's disease (cognitive decline);	chr17:47853173	chr17:47891255~47895812:-
THCA	cis	rs758324	0.661	rs156036	ENSG00000237714.1	P4HA2-AS1	-4.7	3.49e-06	0.000396	-0.3	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132187319	chr5:132184876~132192808:+
THCA	cis	rs7166081	0.672	rs3865018	ENSG00000270964.1	RP11-502I4.3	4.7	3.49e-06	0.000396	0.17	0.21	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67600428	chr15:67541072~67542604:-
THCA	cis	rs11853189	0.938	rs16969710	ENSG00000259562.2	RP11-762H8.2	-4.7	3.49e-06	0.000396	-0.21	-0.21	Red cell distribution width;	chr15:78314020	chr15:78290527~78291221:-
THCA	cis	rs7554547	0.69	rs7364817	ENSG00000201801.1	RNU5E-4P	4.7	3.49e-06	0.000396	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr1:11877060	chr1:11909808~11909927:-
THCA	cis	rs2439831	0.681	rs2278858	ENSG00000205771.5	CATSPER2P1	-4.7	3.49e-06	0.000396	-0.31	-0.21	Lung cancer in ever smokers;	chr15:43340557	chr15:43726918~43747094:-
THCA	cis	rs7615952	0.546	rs11718647	ENSG00000171084.14	FAM86JP	4.7	3.49e-06	0.000396	0.28	0.21	Blood pressure (smoking interaction);	chr3:125633178	chr3:125916620~125930024:+
THCA	cis	rs4787951	0.56	rs3024548	ENSG00000259940.2	CTD-3203P2.1	-4.7	3.49e-06	0.000396	-0.22	-0.21	Eosinophil percentage of white cells;	chr16:27343210	chr16:27213308~27214993:-
THCA	cis	rs703842	1	rs10877015	ENSG00000270039.1	RP11-571M6.17	-4.7	3.49e-06	0.000396	-0.24	-0.21	Multiple sclerosis;	chr12:57774005	chr12:57803838~57804415:+
THCA	cis	rs61160187	0.582	rs17332824	ENSG00000215032.2	GNL3LP1	-4.7	3.49e-06	0.000396	-0.26	-0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60870360	chr5:60891935~60893577:-
THCA	cis	rs2287838	1	rs2287838	ENSG00000267289.1	CTD-2623N2.11	-4.7	3.49e-06	0.000396	-0.25	-0.21	Sleep duration;	chr19:9848338	chr19:9834079~9835013:-
THCA	cis	rs6860806	0.507	rs273912	ENSG00000237714.1	P4HA2-AS1	-4.7	3.49e-06	0.000396	-0.28	-0.21	Breast cancer;	chr5:132325656	chr5:132184876~132192808:+
THCA	cis	rs9634489	0.502	rs986968	ENSG00000247400.3	DNAJC3-AS1	-4.7	3.5e-06	0.000396	-0.14	-0.21	Body mass index;	chr13:96451033	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.502	rs472010	ENSG00000247400.3	DNAJC3-AS1	-4.7	3.5e-06	0.000396	-0.14	-0.21	Body mass index;	chr13:96451724	chr13:95648733~95676925:-
THCA	cis	rs375066	0.901	rs12977303	ENSG00000278917.1	RP11-15A1.4	-4.7	3.5e-06	0.000396	-0.17	-0.21	Breast cancer;	chr19:43873517	chr19:43891233~43895411:+
THCA	cis	rs8028182	0.636	rs4886707	ENSG00000260274.1	RP11-817O13.8	4.7	3.5e-06	0.000396	0.15	0.21	Sudden cardiac arrest;	chr15:75463126	chr15:75368155~75369584:+
THCA	cis	rs589448	0.535	rs12423794	ENSG00000274979.1	RP11-1143G9.5	-4.7	3.5e-06	0.000396	-0.22	-0.21	Cerebrospinal fluid biomarker levels;	chr12:69319238	chr12:69326574~69331882:-
THCA	cis	rs2732480	0.557	rs2409004	ENSG00000273765.1	RP11-370I10.11	4.7	3.5e-06	0.000396	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.577	rs2450994	ENSG00000273765.1	RP11-370I10.11	4.7	3.5e-06	0.000396	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48360920~48361377:+
THCA	cis	rs6545883	0.524	rs2463101	ENSG00000270820.4	RP11-355B11.2	-4.7	3.5e-06	0.000397	-0.18	-0.21	Tuberculosis;	chr2:61347287	chr2:61471188~61484130:+
THCA	cis	rs7937	0.693	rs7254192	ENSG00000279108.1	CTC-490E21.11	-4.7	3.5e-06	0.000397	-0.22	-0.21	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40767794	chr19:40840159~40842039:+
THCA	cis	rs67478160	0.529	rs12880413	ENSG00000269910.1	RP11-73M18.10	4.7	3.5e-06	0.000397	0.18	0.21	Schizophrenia;	chr14:103801070	chr14:103694516~103695050:-
THCA	cis	rs7914558	0.646	rs12768205	ENSG00000236937.2	PTGES3P4	4.7	3.5e-06	0.000397	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102888092	chr10:102845595~102845950:+
THCA	cis	rs227275	0.554	rs223334	ENSG00000248971.2	KRT8P46	4.7	3.5e-06	0.000397	0.25	0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102728746~102730171:-
THCA	cis	rs7010876	0.537	rs13269593	ENSG00000253553.4	RP11-586K2.1	4.7	3.5e-06	0.000397	0.21	0.21	Schizophrenia;	chr8:88402241	chr8:88326836~88737134:+
THCA	cis	rs1048886	0.938	rs2747702	ENSG00000271967.1	RP11-134K13.4	-4.7	3.5e-06	0.000397	-0.22	-0.21	Type 2 diabetes;	chr6:70433465	chr6:70596438~70596980:+
THCA	cis	rs13108904	0.935	rs3755920	ENSG00000254094.1	AC078852.1	-4.7	3.5e-06	0.000397	-0.24	-0.21	Obesity-related traits;	chr4:1249829	chr4:1356581~1358075:+
THCA	cis	rs9990343	0.543	rs11574433	ENSG00000223552.1	RP11-24F11.2	4.7	3.5e-06	0.000397	0.19	0.21	Brain structure;	chr3:46406413	chr3:46364955~46407059:-
THCA	cis	rs9494145	0.526	rs9494154	ENSG00000232876.1	CTA-212D2.2	4.7	3.5e-06	0.000397	0.31	0.21	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135146867	chr6:135055033~135060550:+
THCA	cis	rs5758659	0.622	rs6519298	ENSG00000227370.1	RP4-669P10.19	-4.7	3.5e-06	0.000397	-0.2	-0.21	Cognitive function;	chr22:41968993	chr22:42132543~42132998:+
THCA	cis	rs1979679	0.879	rs980920	ENSG00000247934.4	RP11-967K21.1	-4.7	3.5e-06	0.000397	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28316178	chr12:28163298~28190738:-
THCA	cis	rs4604234	0.522	rs73479968	ENSG00000272129.1	RP11-250B2.6	-4.7	3.5e-06	0.000397	-0.51	-0.21	Cancer;	chr6:80190753	chr6:80355424~80356859:+
THCA	cis	rs2015599	0.623	rs7964831	ENSG00000273680.1	RP11-996F15.6	4.7	3.5e-06	0.000397	0.3	0.21	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29332733~29333383:-
THCA	cis	rs7976269	0.609	rs1344855	ENSG00000275476.1	RP11-996F15.4	4.69	3.5e-06	0.000397	0.21	0.21	Male-pattern baldness;	chr12:29065605	chr12:29277397~29277882:-
THCA	cis	rs17772222	0.63	rs7146241	ENSG00000222990.1	RNU4-22P	-4.69	3.5e-06	0.000397	-0.26	-0.21	Coronary artery calcification;	chr14:88551622	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.63	rs930181	ENSG00000222990.1	RNU4-22P	-4.69	3.5e-06	0.000397	-0.26	-0.21	Coronary artery calcification;	chr14:88552364	chr14:88513498~88513663:+
THCA	cis	rs4915077	0.892	rs17020104	ENSG00000230489.1	VAV3-AS1	4.69	3.51e-06	0.000397	0.31	0.21	Hypothyroidism;	chr1:107811048	chr1:107964443~107994607:+
THCA	cis	rs72843506	0.722	rs74658636	ENSG00000231258.2	ZSWIM5P2	4.69	3.51e-06	0.000397	0.32	0.21	Schizophrenia;	chr17:20294669	chr17:20583758~20591180:-
THCA	cis	rs3820928	0.904	rs6735069	ENSG00000212391.1	SNORA48	-4.69	3.51e-06	0.000397	-0.23	-0.21	Pulmonary function;	chr2:227028944	chr2:226968989~226969122:-
THCA	cis	rs13178541	0.81	rs11242264	ENSG00000250378.1	RP11-119J18.1	-4.69	3.51e-06	0.000397	-0.28	-0.21	IgG glycosylation;	chr5:135762546	chr5:135812667~135826582:+
THCA	cis	rs1023500	0.551	rs133355	ENSG00000273366.1	CTA-989H11.1	-4.69	3.51e-06	0.000397	-0.27	-0.21	Schizophrenia;	chr22:42044281	chr22:42278188~42278846:+
THCA	cis	rs12908161	0.92	rs35758837	ENSG00000275120.1	RP11-182J1.17	4.69	3.51e-06	0.000397	0.25	0.21	Schizophrenia;	chr15:84768151	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs17600551	ENSG00000275120.1	RP11-182J1.17	4.69	3.51e-06	0.000397	0.25	0.21	Schizophrenia;	chr15:84776027	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs36033486	ENSG00000275120.1	RP11-182J1.17	4.69	3.51e-06	0.000397	0.25	0.21	Schizophrenia;	chr15:84776461	chr15:84599434~84606463:-
THCA	cis	rs11110077	0.512	rs10860563	ENSG00000238105.6	GOLGA2P5	4.69	3.51e-06	0.000398	0.16	0.21	Response to antipsychotic treatment in schizophrenia (working memory);	chr12:100186043	chr12:100156357~100173659:-
THCA	cis	rs2288884	0.596	rs12459638	ENSG00000269483.1	AC006272.1	4.69	3.51e-06	0.000398	0.31	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51998549	chr19:51839924~51843324:-
THCA	cis	rs1003719	0.591	rs2040125	ENSG00000230366.8	DSCR9	-4.69	3.51e-06	0.000398	-0.23	-0.21	Eye color traits;	chr21:37176934	chr21:37208503~37221736:+
THCA	cis	rs11971779	1	rs11971779	ENSG00000252332.1	RNU6-911P	4.69	3.51e-06	0.000398	0.28	0.21	Diisocyanate-induced asthma;	chr7:139355512	chr7:139448740~139448843:+
THCA	cis	rs5758659	1	rs134882	ENSG00000273366.1	CTA-989H11.1	-4.69	3.51e-06	0.000398	-0.25	-0.21	Cognitive function;	chr22:42274959	chr22:42278188~42278846:+
THCA	cis	rs7829975	0.572	rs7005000	ENSG00000254153.1	CTA-398F10.2	4.69	3.51e-06	0.000398	0.23	0.21	Mood instability;	chr8:8939092	chr8:8456909~8461337:-
THCA	cis	rs6012564	0.559	rs61418814	ENSG00000230758.1	SNAP23P	4.69	3.51e-06	0.000398	0.26	0.21	Anger;	chr20:49153301	chr20:49038357~49038602:-
THCA	cis	rs7809615	0.748	rs35183025	ENSG00000244219.5	GS1-259H13.2	-4.69	3.51e-06	0.000398	-0.38	-0.21	Blood metabolite ratios;	chr7:99433159	chr7:99598066~99610813:+
THCA	cis	rs4915077	1	rs17014208	ENSG00000230489.1	VAV3-AS1	4.69	3.51e-06	0.000398	0.38	0.21	Hypothyroidism;	chr1:107795876	chr1:107964443~107994607:+
THCA	cis	rs752010	0.746	rs10890146	ENSG00000230638.4	RP11-486B10.4	-4.69	3.51e-06	0.000398	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41623718	chr1:41542069~41544310:+
THCA	cis	rs7394190	0.748	rs3740293	ENSG00000271816.1	BMS1P4	-4.69	3.51e-06	0.000398	-0.25	-0.21	Incident atrial fibrillation;	chr10:73646383	chr10:73699151~73730487:-
THCA	cis	rs7403037	0.958	rs61994700	ENSG00000260760.1	PWRN3	4.69	3.51e-06	0.000398	0.26	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24335185	chr15:24441127~24447967:+
THCA	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-4.69	3.51e-06	0.000398	-0.18	-0.21	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
THCA	cis	rs79349575	0.811	rs1057897	ENSG00000270781.1	RP11-501C14.9	-4.69	3.51e-06	0.000398	-0.26	-0.21	Type 2 diabetes;	chr17:48928147	chr17:48899131~48899748:+
THCA	cis	rs10090774	0.901	rs10106406	ENSG00000279766.1	RP11-642A1.2	-4.69	3.51e-06	0.000398	-0.27	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140996099	chr8:140572142~140572812:-
THCA	cis	rs1003719	0.715	rs58008706	ENSG00000230366.8	DSCR9	4.69	3.51e-06	0.000398	0.22	0.21	Eye color traits;	chr21:37168204	chr21:37208503~37221736:+
THCA	cis	rs7267979	0.899	rs6115213	ENSG00000274973.1	RP13-401N8.7	-4.69	3.52e-06	0.000398	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25845497~25845862:+
THCA	cis	rs9652601	0.691	rs12928726	ENSG00000274038.1	RP11-66H6.4	-4.69	3.52e-06	0.000399	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11097715	chr16:11056556~11057034:+
THCA	cis	rs9902453	0.845	rs7501472	ENSG00000263370.1	RP11-68I3.5	4.69	3.52e-06	0.000399	0.28	0.21	Coffee consumption (cups per day);	chr17:29683610	chr17:29639627~29640825:+
THCA	cis	rs12908161	0.96	rs34452033	ENSG00000275120.1	RP11-182J1.17	4.69	3.52e-06	0.000399	0.25	0.21	Schizophrenia;	chr15:84678762	chr15:84599434~84606463:-
THCA	cis	rs9625935	0.957	rs5763674	ENSG00000279159.1	RP3-394A18.1	4.69	3.52e-06	0.000399	0.17	0.21	Tonsillectomy;	chr22:29990369	chr22:29978950~30028236:-
THCA	cis	rs41313321	0.512	rs2240958	ENSG00000273186.1	RP11-339B21.10	4.69	3.52e-06	0.000399	0.3	0.21	Coenzyme Q10 levels;	chr9:128282905	chr9:128431598~128432006:+
THCA	cis	rs1864400	0.69	rs2565200	ENSG00000273008.1	RP11-351D16.3	-4.69	3.52e-06	0.000399	-0.2	-0.21	Hirschsprung disease;	chr10:43127485	chr10:43136824~43138334:-
THCA	cis	rs76382185	0.808	rs36106538	ENSG00000233184.5	RP11-421L21.3	4.69	3.52e-06	0.000399	0.32	0.21	Lymphocyte counts;	chr1:101135606	chr1:101025878~101087268:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000229180.5	GS1-124K5.11	4.69	3.52e-06	0.000399	0.17	0.21	Corneal structure;	chr7:66911108	chr7:66526088~66542624:-
THCA	cis	rs17508449	0.819	rs4589108	ENSG00000232450.1	RP4-730K3.3	-4.69	3.52e-06	0.000399	-0.34	-0.21	Leprosy;	chr1:113717003	chr1:113698884~113699631:-
THCA	cis	rs12823128	0.729	rs2100209	ENSG00000256185.1	RP11-612B6.2	4.69	3.52e-06	0.000399	0.2	0.21	Birth weight;	chr12:26780454	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs7134992	ENSG00000256185.1	RP11-612B6.2	4.69	3.52e-06	0.000399	0.2	0.21	Birth weight;	chr12:26781200	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs12581907	ENSG00000256185.1	RP11-612B6.2	4.69	3.52e-06	0.000399	0.2	0.21	Birth weight;	chr12:26781483	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs7298744	ENSG00000256185.1	RP11-612B6.2	4.69	3.52e-06	0.000399	0.2	0.21	Birth weight;	chr12:26783675	chr12:26335864~26336950:-
THCA	cis	rs12823128	0.766	rs7315217	ENSG00000256185.1	RP11-612B6.2	4.69	3.52e-06	0.000399	0.2	0.21	Birth weight;	chr12:26783831	chr12:26335864~26336950:-
THCA	cis	rs728616	0.51	rs35671072	ENSG00000242600.5	MBL1P	4.69	3.53e-06	0.000399	0.26	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80412499	chr10:79904898~79950336:+
THCA	cis	rs6477918	0.598	rs10981412	ENSG00000230185.4	C9orf147	4.69	3.53e-06	0.000399	0.23	0.21	Obstetric antiphospholipid syndrome;	chr9:112452844	chr9:112433816~112487204:-
THCA	cis	rs75422866	0.764	rs73104177	ENSG00000276691.1	RP5-1057I20.5	4.69	3.53e-06	0.000399	0.39	0.21	Pneumonia;	chr12:47713550	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.764	rs73104184	ENSG00000276691.1	RP5-1057I20.5	4.69	3.53e-06	0.000399	0.39	0.21	Pneumonia;	chr12:47715623	chr12:47788426~47788971:+
THCA	cis	rs10090774	0.687	rs11784281	ENSG00000280303.2	ERICD	-4.69	3.53e-06	0.000399	-0.2	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655911	chr8:140636281~140638283:+
THCA	cis	rs4722166	0.573	rs35436671	ENSG00000225541.1	AC002480.5	-4.69	3.53e-06	0.000399	-0.27	-0.21	Lung cancer;	chr7:22735889	chr7:22571607~22661792:-
THCA	cis	rs1923539	0.571	rs911887	ENSG00000225484.5	NUTM2B-AS1	4.69	3.53e-06	0.000399	0.23	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79941767	chr10:79663088~79826594:-
THCA	cis	rs7010876	0.515	rs2174367	ENSG00000253553.4	RP11-586K2.1	4.69	3.53e-06	0.000399	0.21	0.21	Schizophrenia;	chr8:88395967	chr8:88326836~88737134:+
THCA	cis	rs6997458	0.785	rs7016369	ENSG00000253549.4	RP11-317J10.2	-4.69	3.53e-06	0.000399	-0.22	-0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85456040	chr8:85441851~85464915:-
THCA	cis	rs7647973	0.58	rs12629759	ENSG00000229759.1	MRPS18AP1	4.69	3.53e-06	4e-04	0.27	0.21	Menarche (age at onset);	chr3:49199961	chr3:48256350~48256938:-
THCA	cis	rs2386661	0.712	rs11259544	ENSG00000231483.1	RP11-336A10.5	4.69	3.53e-06	4e-04	0.22	0.21	Breast cancer;	chr10:5604745	chr10:5608475~5610793:-
THCA	cis	rs8031584	0.958	rs3512	ENSG00000178081.11	ULK4P3	4.69	3.53e-06	4e-04	0.28	0.21	Huntington's disease progression;	chr15:30942802	chr15:30103720~30131757:+
THCA	cis	rs7577696	0.752	rs212714	ENSG00000276334.1	AL133243.1	4.69	3.53e-06	4e-04	0.23	0.21	Inflammatory biomarkers;	chr2:32235279	chr2:32521927~32523547:+
THCA	cis	rs12908161	0.959	rs12906348	ENSG00000275120.1	RP11-182J1.17	4.69	3.53e-06	4e-04	0.25	0.21	Schizophrenia;	chr15:84786190	chr15:84599434~84606463:-
THCA	cis	rs12908161	0.959	rs34342559	ENSG00000275120.1	RP11-182J1.17	4.69	3.53e-06	4e-04	0.25	0.21	Schizophrenia;	chr15:84788040	chr15:84599434~84606463:-
THCA	cis	rs12908161	0.959	rs62019472	ENSG00000275120.1	RP11-182J1.17	4.69	3.53e-06	4e-04	0.25	0.21	Schizophrenia;	chr15:84788262	chr15:84599434~84606463:-
THCA	cis	rs12908161	0.959	rs35557864	ENSG00000275120.1	RP11-182J1.17	4.69	3.53e-06	4e-04	0.25	0.21	Schizophrenia;	chr15:84788398	chr15:84599434~84606463:-
THCA	cis	rs8062405	0.792	rs12446550	ENSG00000261766.1	RP11-22P6.2	-4.69	3.53e-06	4e-04	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28862166~28863340:-
THCA	cis	rs2302464	0.661	rs6822515	ENSG00000214846.4	RP11-115L11.1	4.69	3.53e-06	4e-04	0.5	0.21	Cerebrospinal fluid biomarker levels;	chr4:15741571	chr4:15730962~15731627:-
THCA	cis	rs7598759	0.527	rs7571691	ENSG00000223198.1	RNU2-22P	-4.69	3.53e-06	4e-04	-0.27	-0.21	Noise-induced hearing loss;	chr2:231504690	chr2:231501990~231502201:-
THCA	cis	rs8067545	0.586	rs2526459	ENSG00000270091.1	RP11-78O7.2	4.69	3.53e-06	4e-04	0.16	0.21	Schizophrenia;	chr17:20186729	chr17:19896590~19897287:-
THCA	cis	rs9307551	0.584	rs2119419	ENSG00000250334.4	LINC00989	-4.69	3.53e-06	4e-04	-0.25	-0.21	Refractive error;	chr4:79515828	chr4:79492416~79576460:+
THCA	cis	rs4443100	0.631	rs13054904	ENSG00000230701.2	FBXW4P1	-4.69	3.53e-06	4e-04	-0.25	-0.21	Serum parathyroid hormone levels;	chr22:23068739	chr22:23262767~23265005:+
THCA	cis	rs972578	0.715	rs4820494	ENSG00000274717.1	RP1-47A17.1	4.69	3.53e-06	4e-04	0.22	0.21	Mean platelet volume;	chr22:42909855	chr22:42791814~42794313:-
THCA	cis	rs28374715	0.681	rs28687846	ENSG00000247556.5	OIP5-AS1	4.69	3.53e-06	4e-04	0.2	0.21	Ulcerative colitis;	chr15:41307704	chr15:41283990~41309737:+
THCA	cis	rs7403037	0.602	rs2677389	ENSG00000259905.4	PWRN1	4.69	3.53e-06	4e-04	0.21	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24191053	chr15:24493137~24652130:+
THCA	cis	rs67478160	0.583	rs12879612	ENSG00000269910.1	RP11-73M18.10	4.69	3.54e-06	4e-04	0.18	0.21	Schizophrenia;	chr14:103767281	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs4900594	ENSG00000269910.1	RP11-73M18.10	4.69	3.54e-06	4e-04	0.18	0.21	Schizophrenia;	chr14:103784669	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs3742369	ENSG00000269910.1	RP11-73M18.10	4.69	3.54e-06	4e-04	0.18	0.21	Schizophrenia;	chr14:103784939	chr14:103694516~103695050:-
THCA	cis	rs172166	0.694	rs203876	ENSG00000261839.1	RP1-265C24.8	4.69	3.54e-06	4e-04	0.23	0.21	Cardiac Troponin-T levels;	chr6:28078895	chr6:28136849~28139678:+
THCA	cis	rs172166	0.694	rs203877	ENSG00000261839.1	RP1-265C24.8	4.69	3.54e-06	4e-04	0.23	0.21	Cardiac Troponin-T levels;	chr6:28080846	chr6:28136849~28139678:+
THCA	cis	rs172166	0.652	rs476167	ENSG00000261839.1	RP1-265C24.8	4.69	3.54e-06	4e-04	0.23	0.21	Cardiac Troponin-T levels;	chr6:28098110	chr6:28136849~28139678:+
THCA	cis	rs172166	0.694	rs203892	ENSG00000261839.1	RP1-265C24.8	4.69	3.54e-06	4e-04	0.23	0.21	Cardiac Troponin-T levels;	chr6:28099418	chr6:28136849~28139678:+
THCA	cis	rs1003719	0.688	rs2000416	ENSG00000230366.8	DSCR9	4.69	3.54e-06	4e-04	0.22	0.21	Eye color traits;	chr21:37167787	chr21:37208503~37221736:+
THCA	cis	rs1371614	0.566	rs1440042	ENSG00000229122.1	AGBL5-IT1	4.69	3.54e-06	4e-04	0.15	0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26964946	chr2:27061038~27061815:+
THCA	cis	rs8024893	0.764	rs7182721	ENSG00000270055.1	CTD-3092A11.2	4.69	3.54e-06	4e-04	0.28	0.21	Red cell distribution width;	chr15:31239730	chr15:30487963~30490313:+
THCA	cis	rs6012564	1	rs6066977	ENSG00000230758.1	SNAP23P	4.69	3.54e-06	4e-04	0.25	0.21	Anger;	chr20:49138538	chr20:49038357~49038602:-
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000220721.1	OR1F12	4.69	3.54e-06	0.000401	0.23	0.21	Pubertal anthropometrics;	chr6:28175232	chr6:28073316~28074233:+
THCA	cis	rs2742234	0.518	rs1254967	ENSG00000273008.1	RP11-351D16.3	4.69	3.54e-06	0.000401	0.2	0.21	Hirschsprung disease;	chr10:43194943	chr10:43136824~43138334:-
THCA	cis	rs2058059	0.636	rs2960968	ENSG00000205578.5	POM121B	-4.69	3.54e-06	0.000401	-0.33	-0.21	Subcutaneous adipose tissue;	chr7:72702378	chr7:73293497~73301161:+
THCA	cis	rs7980687	0.628	rs2851443	ENSG00000256092.2	RP13-942N8.1	4.69	3.54e-06	0.000401	0.16	0.21	Head circumference (infant);Educational attainment;Height;	chr12:123209703	chr12:123363868~123366113:+
THCA	cis	rs7980687	0.596	rs1727319	ENSG00000256092.2	RP13-942N8.1	4.69	3.54e-06	0.000401	0.16	0.21	Head circumference (infant);Educational attainment;Height;	chr12:123216806	chr12:123363868~123366113:+
THCA	cis	rs11671005	0.693	rs11669665	ENSG00000268049.1	CTD-2619J13.9	-4.69	3.54e-06	0.000401	-0.33	-0.21	Mean platelet volume;	chr19:58420518	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.693	rs11084542	ENSG00000268049.1	CTD-2619J13.9	-4.69	3.54e-06	0.000401	-0.33	-0.21	Mean platelet volume;	chr19:58420732	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs11084543	ENSG00000268049.1	CTD-2619J13.9	-4.69	3.54e-06	0.000401	-0.33	-0.21	Mean platelet volume;	chr19:58421334	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs11881000	ENSG00000268049.1	CTD-2619J13.9	-4.69	3.54e-06	0.000401	-0.33	-0.21	Mean platelet volume;	chr19:58421421	chr19:58357999~58359603:+
THCA	cis	rs9625935	0.957	rs17643918	ENSG00000279159.1	RP3-394A18.1	-4.69	3.54e-06	0.000401	-0.17	-0.21	Tonsillectomy;	chr22:29877736	chr22:29978950~30028236:-
THCA	cis	rs3796352	0.667	rs34860124	ENSG00000242142.1	SERBP1P3	-4.69	3.54e-06	0.000401	-0.37	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:52823762	chr3:53064283~53065091:-
THCA	cis	rs9992667	0.955	rs922334	ENSG00000231160.8	KLF3-AS1	4.69	3.54e-06	0.000401	0.15	0.21	Eosinophil percentage of granulocytes;	chr4:38615137	chr4:38612701~38664883:-
THCA	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	4.69	3.54e-06	0.000401	0.25	0.21	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
THCA	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-4.69	3.54e-06	0.000401	-0.33	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
THCA	cis	rs786425	0.77	rs7974279	ENSG00000270095.1	RP11-214K3.18	-4.69	3.54e-06	0.000401	-0.25	-0.21	Pubertal anthropometrics;	chr12:123681864	chr12:123971457~123971714:-
THCA	cis	rs7474896	0.515	rs688608	ENSG00000263064.2	RP11-291L22.7	-4.69	3.54e-06	0.000401	-0.3	-0.21	Obesity (extreme);	chr10:38042696	chr10:38448689~38448949:+
THCA	cis	rs2302464	1	rs16892263	ENSG00000214846.4	RP11-115L11.1	-4.69	3.54e-06	0.000401	-0.53	-0.21	Cerebrospinal fluid biomarker levels;	chr4:15714254	chr4:15730962~15731627:-
THCA	cis	rs6745190	0.557	rs13011738	ENSG00000236153.1	AC104076.3	-4.69	3.54e-06	0.000401	-0.27	-0.21	White blood cell count;	chr2:181121015	chr2:180979427~180980090:-
THCA	cis	rs8067545	0.611	rs12603372	ENSG00000270091.1	RP11-78O7.2	-4.69	3.54e-06	0.000401	-0.16	-0.21	Schizophrenia;	chr17:20278253	chr17:19896590~19897287:-
THCA	cis	rs1707322	1	rs34694458	ENSG00000281133.1	AL355480.3	-4.69	3.55e-06	0.000401	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45580892~45580996:-
THCA	cis	rs829883	0.621	rs11109516	ENSG00000227825.4	SLC9A7P1	-4.69	3.55e-06	0.000401	-0.21	-0.21	Colorectal adenoma (advanced);	chr12:98527257	chr12:98453835~98457145:-
THCA	cis	rs2439831	0.85	rs558656	ENSG00000166763.7	STRCP1	4.69	3.55e-06	0.000401	0.28	0.21	Lung cancer in ever smokers;	chr15:43431316	chr15:43699488~43718184:-
THCA	cis	rs9595908	0.802	rs2010997	ENSG00000212293.1	SNORA16	4.69	3.55e-06	0.000401	0.25	0.21	Body mass index;	chr13:32496369	chr13:32420390~32420516:-
THCA	cis	rs3738443	0.868	rs7546908	ENSG00000259865.1	RP11-488L18.10	-4.69	3.55e-06	0.000401	-0.22	-0.21	Alcohol dependence;	chr1:247200531	chr1:247187281~247188526:-
THCA	cis	rs10248839	0.518	rs34011864	ENSG00000225264.3	ZNRF2P2	4.69	3.55e-06	0.000401	0.24	0.21	Facial emotion recognition (angry faces);	chr7:29658883	chr7:29598795~29685255:-
THCA	cis	rs11668609	0.515	rs61308481	ENSG00000268442.1	CTD-2027I19.2	4.69	3.55e-06	0.000401	0.31	0.21	Response to taxane treatment (docetaxel);	chr19:23882545	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs59175483	ENSG00000268442.1	CTD-2027I19.2	4.69	3.55e-06	0.000401	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23882740	chr19:24162370~24163425:-
THCA	cis	rs73198271	0.613	rs11249892	ENSG00000253893.2	FAM85B	4.69	3.55e-06	0.000401	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799730	chr8:8167819~8226614:-
THCA	cis	rs72843506	1	rs7223910	ENSG00000231258.2	ZSWIM5P2	4.69	3.55e-06	0.000402	0.26	0.21	Schizophrenia;	chr17:20079455	chr17:20583758~20591180:-
THCA	cis	rs57221529	0.766	rs12521051	ENSG00000225138.6	CTD-2228K2.7	-4.69	3.55e-06	0.000402	-0.27	-0.21	Lung disease severity in cystic fibrosis;	chr5:560325	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs12522303	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:555449	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs12521988	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:556306	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs17497684	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:558192	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs72706606	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:558494	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs12519763	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:559030	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs72706608	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:559088	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs72706610	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:560996	chr5:473236~480884:+
THCA	cis	rs57221529	0.709	rs72706611	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:561031	chr5:473236~480884:+
THCA	cis	rs57221529	0.709	rs72706612	ENSG00000225138.6	CTD-2228K2.7	4.69	3.55e-06	0.000402	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:561083	chr5:473236~480884:+
THCA	cis	rs875971	0.545	rs6950988	ENSG00000273142.1	RP11-458F8.4	4.69	3.55e-06	0.000402	0.2	0.21	Aortic root size;	chr7:66511428	chr7:66902857~66906297:+
THCA	cis	rs9925964	0.933	rs749671	ENSG00000232748.3	RP11-196G11.6	4.69	3.55e-06	0.000402	0.25	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077026	chr16:31056460~31062803:+
THCA	cis	rs1003719	0.688	rs2000413	ENSG00000230366.8	DSCR9	4.69	3.55e-06	0.000402	0.22	0.21	Eye color traits;	chr21:37167416	chr21:37208503~37221736:+
THCA	cis	rs8064024	0.62	rs8048709	ENSG00000267077.1	RP11-127I20.5	4.69	3.55e-06	0.000402	0.24	0.21	Cancer;	chr16:4863760	chr16:4795265~4796532:-
THCA	cis	rs7824557	0.564	rs11781637	ENSG00000154316.13	TDH	4.69	3.55e-06	0.000402	0.15	0.21	Retinal vascular caliber;	chr8:11357463	chr8:11339637~11368452:+
THCA	cis	rs4415084	0.68	rs10042455	ENSG00000272335.1	RP11-53O19.3	4.69	3.55e-06	0.000402	0.18	0.21	Breast cancer;	chr5:44924916	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs10039866	ENSG00000272335.1	RP11-53O19.3	4.69	3.55e-06	0.000402	0.18	0.21	Breast cancer;	chr5:44924959	chr5:44826076~44828592:+
THCA	cis	rs66887589	0.87	rs10518336	ENSG00000249244.1	RP11-548H18.2	4.69	3.55e-06	0.000402	0.22	0.21	Diastolic blood pressure;	chr4:119601779	chr4:119391831~119395335:-
THCA	cis	rs739496	0.579	rs3741998	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111902039	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs12319165	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111902930	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs73426310	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111904606	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs12427012	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111905570	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs12316525	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111906315	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs73426314	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111907252	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs11066077	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111908857	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs10849984	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111909924	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs10849985	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111909950	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs7136469	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111910387	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.799	rs11066082	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Mean platelet volume;	chr12:111913544	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs61612992	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111920260	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs7300320	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111922364	chr12:111927018~111929017:+
THCA	cis	rs739496	0.527	rs11066089	ENSG00000226469.1	ADAM1B	4.69	3.55e-06	0.000402	0.26	0.21	Platelet count;	chr12:111925463	chr12:111927018~111929017:+
THCA	cis	rs801193	0.935	rs11772264	ENSG00000229886.1	RP5-1132H15.3	4.69	3.55e-06	0.000402	0.22	0.21	Aortic root size;	chr7:66711400	chr7:66025126~66031544:-
THCA	cis	rs1005277	0.579	rs932538	ENSG00000272983.1	RP11-508N22.12	4.69	3.56e-06	0.000402	0.18	0.21	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.541	rs2472177	ENSG00000272983.1	RP11-508N22.12	4.69	3.56e-06	0.000402	0.18	0.21	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2472178	ENSG00000272983.1	RP11-508N22.12	4.69	3.56e-06	0.000402	0.18	0.21	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2474572	ENSG00000272983.1	RP11-508N22.12	4.69	3.56e-06	0.000402	0.18	0.21	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs2505198	ENSG00000272983.1	RP11-508N22.12	4.69	3.56e-06	0.000402	0.18	0.21	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38137337~38144399:+
THCA	cis	rs4915077	0.892	rs78435278	ENSG00000230489.1	VAV3-AS1	4.69	3.56e-06	0.000402	0.37	0.21	Hypothyroidism;	chr1:107804125	chr1:107964443~107994607:+
THCA	cis	rs2787702	1	rs2787704	ENSG00000237233.2	TMEM26-AS1	-4.69	3.56e-06	0.000402	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61553245	chr10:61452639~61481956:+
THCA	cis	rs6671200	1	rs60929805	ENSG00000235501.4	RP4-639F20.1	-4.69	3.56e-06	0.000403	-0.44	-0.21	Stearic acid (18:0) levels;	chr1:95180830	chr1:94927566~94963270:+
THCA	cis	rs6671200	1	rs76064624	ENSG00000235501.4	RP4-639F20.1	-4.69	3.56e-06	0.000403	-0.44	-0.21	Stearic acid (18:0) levels;	chr1:95195477	chr1:94927566~94963270:+
THCA	cis	rs6671200	1	rs71654417	ENSG00000235501.4	RP4-639F20.1	-4.69	3.56e-06	0.000403	-0.44	-0.21	Stearic acid (18:0) levels;	chr1:95195644	chr1:94927566~94963270:+
THCA	cis	rs959260	1	rs4789189	ENSG00000263843.1	RP11-649A18.12	4.69	3.56e-06	0.000403	0.22	0.21	Systemic lupus erythematosus;	chr17:75401904	chr17:75271369~75273895:+
THCA	cis	rs7246657	0.598	rs10417545	ENSG00000226686.6	LINC01535	-4.69	3.56e-06	0.000403	-0.39	-0.21	Coronary artery calcification;	chr19:37163361	chr19:37251912~37265535:+
THCA	cis	rs7474896	1	rs2144845	ENSG00000263064.2	RP11-291L22.7	-4.69	3.56e-06	0.000403	-0.35	-0.21	Obesity (extreme);	chr10:37932591	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2799505	ENSG00000263064.2	RP11-291L22.7	-4.69	3.56e-06	0.000403	-0.35	-0.21	Obesity (extreme);	chr10:37934086	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs1007133	ENSG00000263064.2	RP11-291L22.7	-4.69	3.56e-06	0.000403	-0.35	-0.21	Obesity (extreme);	chr10:37936365	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.945	rs2799506	ENSG00000263064.2	RP11-291L22.7	-4.69	3.56e-06	0.000403	-0.35	-0.21	Obesity (extreme);	chr10:37936431	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2799507	ENSG00000263064.2	RP11-291L22.7	-4.69	3.56e-06	0.000403	-0.35	-0.21	Obesity (extreme);	chr10:37938136	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.945	rs2092993	ENSG00000263064.2	RP11-291L22.7	-4.69	3.56e-06	0.000403	-0.35	-0.21	Obesity (extreme);	chr10:37939207	chr10:38448689~38448949:+
THCA	cis	rs7688540	0.8	rs61794998	ENSG00000250892.1	RP11-1365D11.1	4.69	3.56e-06	0.000403	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:201409~205009:-
THCA	cis	rs2562456	0.641	rs62107468	ENSG00000268117.1	VN1R84P	4.69	3.56e-06	0.000403	0.33	0.21	Pain;	chr19:21307177	chr19:21719801~21720035:-
THCA	cis	rs4824093	0.535	rs73443931	ENSG00000278869.1	CITF22-49E9.3	4.69	3.56e-06	0.000403	0.41	0.21	Amyotrophic lateral sclerosis (sporadic);	chr22:49897955	chr22:49933198~49934074:-
THCA	cis	rs72843506	0.586	rs59890010	ENSG00000261033.1	RP11-209D14.2	4.69	3.56e-06	0.000403	0.4	0.21	Schizophrenia;	chr17:19960360	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.586	rs73980762	ENSG00000261033.1	RP11-209D14.2	4.69	3.56e-06	0.000403	0.4	0.21	Schizophrenia;	chr17:19966113	chr17:20008051~20009234:-
THCA	cis	rs1979679	0.879	rs1581630	ENSG00000278733.1	RP11-425D17.1	-4.69	3.56e-06	0.000403	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28466378	chr12:28185625~28186190:-
THCA	cis	rs9475752	0.744	rs58604217	ENSG00000231441.1	RP11-472M19.2	4.69	3.56e-06	0.000403	0.23	0.21	Menarche (age at onset);	chr6:56938777	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.744	rs59797084	ENSG00000231441.1	RP11-472M19.2	4.69	3.56e-06	0.000403	0.23	0.21	Menarche (age at onset);	chr6:56938843	chr6:56844002~56864078:+
THCA	cis	rs62025270	0.688	rs17577869	ENSG00000259295.5	CSPG4P12	-4.69	3.56e-06	0.000403	-0.34	-0.21	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85191438~85213905:+
THCA	cis	rs6433895	0.71	rs56692685	ENSG00000236153.1	AC104076.3	-4.69	3.57e-06	0.000403	-0.26	-0.21	Lymphocyte counts;	chr2:181147366	chr2:180979427~180980090:-
THCA	cis	rs8067545	0.75	rs3862152	ENSG00000270091.1	RP11-78O7.2	-4.69	3.57e-06	0.000403	-0.16	-0.21	Schizophrenia;	chr17:20056380	chr17:19896590~19897287:-
THCA	cis	rs2787702	1	rs2787716	ENSG00000237233.2	TMEM26-AS1	4.69	3.57e-06	0.000403	0.26	0.21	Response to taxane treatment (placlitaxel);	chr10:61563595	chr10:61452639~61481956:+
THCA	cis	rs13178541	0.683	rs9800300	ENSG00000250378.1	RP11-119J18.1	-4.69	3.57e-06	0.000403	-0.28	-0.21	IgG glycosylation;	chr5:135760622	chr5:135812667~135826582:+
THCA	cis	rs6088580	0.634	rs6059880	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.57e-06	0.000403	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34500864	chr20:33985617~33988989:-
THCA	cis	rs6545883	0.524	rs811871	ENSG00000270820.4	RP11-355B11.2	-4.69	3.57e-06	0.000404	-0.18	-0.21	Tuberculosis;	chr2:61350814	chr2:61471188~61484130:+
THCA	cis	rs919433	1	rs1560277	ENSG00000231621.1	AC013264.2	-4.69	3.57e-06	0.000404	-0.22	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197323179	chr2:197197991~197199273:+
THCA	cis	rs2243480	1	rs13247184	ENSG00000164669.11	INTS4P1	4.69	3.57e-06	0.000404	0.41	0.21	Diabetic kidney disease;	chr7:65893941	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs35283677	ENSG00000164669.11	INTS4P1	4.69	3.57e-06	0.000404	0.41	0.21	Diabetic kidney disease;	chr7:65894246	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs35421653	ENSG00000164669.11	INTS4P1	4.69	3.57e-06	0.000404	0.41	0.21	Diabetic kidney disease;	chr7:65898442	chr7:65141225~65234216:+
THCA	cis	rs11853189	0.671	rs11853191	ENSG00000259562.2	RP11-762H8.2	4.69	3.57e-06	0.000404	0.18	0.21	Red cell distribution width;	chr15:78273499	chr15:78290527~78291221:-
THCA	cis	rs2836326	0.954	rs2836315	ENSG00000226012.1	AP001434.2	4.69	3.57e-06	0.000404	0.31	0.21	Metabolite levels (HVA);	chr21:38343205	chr21:38237217~38238201:-
THCA	cis	rs755249	0.529	rs3768299	ENSG00000228060.1	RP11-69E11.8	-4.69	3.57e-06	0.000404	-0.22	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39565160~39573203:+
THCA	cis	rs7474896	1	rs2799501	ENSG00000263064.2	RP11-291L22.7	-4.69	3.57e-06	0.000404	-0.35	-0.21	Obesity (extreme);	chr10:37878110	chr10:38448689~38448949:+
THCA	cis	rs2976388	0.533	rs12543368	ENSG00000253741.1	CTD-2292P10.4	4.69	3.57e-06	0.000404	0.3	0.21	Urinary tract infection frequency;	chr8:142738032	chr8:142702252~142726973:-
THCA	cis	rs4535700	0.501	rs28678267	ENSG00000226278.1	PSPHP1	4.69	3.58e-06	0.000404	0.25	0.21	Macular telangiectasia type 2;	chr7:55941797	chr7:55764797~55773288:+
THCA	cis	rs4535700	0.501	rs11765531	ENSG00000226278.1	PSPHP1	4.69	3.58e-06	0.000404	0.25	0.21	Macular telangiectasia type 2;	chr7:55942594	chr7:55764797~55773288:+
THCA	cis	rs240993	0.715	rs6920798	ENSG00000271789.1	RP5-1112D6.7	4.69	3.58e-06	0.000404	0.24	0.21	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111297126~111298510:+
THCA	cis	rs7942368	1	rs1837680	ENSG00000261578.1	RP11-21L23.2	4.69	3.58e-06	0.000404	0.31	0.21	Endometriosis;	chr11:76790407	chr11:76800364~76804555:+
THCA	cis	rs6750795	0.746	rs1667301	ENSG00000223198.1	RNU2-22P	-4.69	3.58e-06	0.000405	-0.27	-0.21	Height;	chr2:231559006	chr2:231501990~231502201:-
THCA	cis	rs853679	0.825	rs8180562	ENSG00000220721.1	OR1F12	4.69	3.58e-06	0.000405	0.37	0.21	Depression;	chr6:28173682	chr6:28073316~28074233:+
THCA	cis	rs853679	0.882	rs9380064	ENSG00000220721.1	OR1F12	4.69	3.58e-06	0.000405	0.37	0.21	Depression;	chr6:28175340	chr6:28073316~28074233:+
THCA	cis	rs1880529	0.797	rs13129686	ENSG00000206820.1	RNU1-138P	4.69	3.58e-06	0.000405	0.25	0.21	White matter integrity (bipolar disorder risk interaction);	chr4:113431993	chr4:113420323~113420486:+
THCA	cis	rs17301013	0.861	rs7538650	ENSG00000227373.4	RP11-160H22.5	-4.69	3.58e-06	0.000405	-0.3	-0.21	Systemic lupus erythematosus;	chr1:174788821	chr1:174115300~174160004:-
THCA	cis	rs6671200	1	rs71654418	ENSG00000235501.4	RP4-639F20.1	-4.69	3.58e-06	0.000405	-0.44	-0.21	Stearic acid (18:0) levels;	chr1:95197102	chr1:94927566~94963270:+
THCA	cis	rs62025270	0.632	rs55981798	ENSG00000259295.5	CSPG4P12	-4.69	3.58e-06	0.000405	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85191438~85213905:+
THCA	cis	rs62025270	0.576	rs17633959	ENSG00000259295.5	CSPG4P12	-4.69	3.58e-06	0.000405	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85191438~85213905:+
THCA	cis	rs72843506	0.722	rs117096120	ENSG00000231258.2	ZSWIM5P2	4.69	3.58e-06	0.000405	0.32	0.21	Schizophrenia;	chr17:20264380	chr17:20583758~20591180:-
THCA	cis	rs1031391	0.716	rs10772416	ENSG00000270863.1	DDX55P1	-4.69	3.58e-06	0.000405	-0.33	-0.21	Bitter taste perception;	chr12:11017488	chr12:11512723~11514136:+
THCA	cis	rs7914558	1	rs11191542	ENSG00000236937.2	PTGES3P4	4.69	3.58e-06	0.000405	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064567	chr10:102845595~102845950:+
THCA	cis	rs2412819	0.571	rs11070411	ENSG00000166763.7	STRCP1	-4.69	3.58e-06	0.000405	-0.28	-0.21	Lung cancer;	chr15:43766436	chr15:43699488~43718184:-
THCA	cis	rs2732480	0.577	rs2634678	ENSG00000273765.1	RP11-370I10.11	4.69	3.58e-06	0.000405	0.22	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48360920~48361377:+
THCA	cis	rs2243480	1	rs34193460	ENSG00000232559.3	GS1-124K5.12	4.69	3.58e-06	0.000405	0.32	0.21	Diabetic kidney disease;	chr7:65928123	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs57057549	ENSG00000232559.3	GS1-124K5.12	4.69	3.58e-06	0.000405	0.32	0.21	Diabetic kidney disease;	chr7:65940751	chr7:66554588~66576923:-
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000273024.4	INTS4P2	-4.69	3.58e-06	0.000405	-0.23	-0.21	Calcium levels;	chr7:65829754	chr7:65647864~65715661:+
THCA	cis	rs9902453	0.845	rs2617865	ENSG00000263370.1	RP11-68I3.5	-4.69	3.58e-06	0.000405	-0.28	-0.21	Coffee consumption (cups per day);	chr17:29722786	chr17:29639627~29640825:+
THCA	cis	rs654950	0.776	rs2759254	ENSG00000230638.4	RP11-486B10.4	4.69	3.58e-06	0.000405	0.25	0.21	Airway imaging phenotypes;	chr1:41570012	chr1:41542069~41544310:+
THCA	cis	rs7851660	0.844	rs993501	ENSG00000214417.4	KRT18P13	4.69	3.59e-06	0.000405	0.19	0.21	Strep throat;	chr9:97861095	chr9:97698922~97700734:+
THCA	cis	rs7403037	0.517	rs71461546	ENSG00000259905.4	PWRN1	4.69	3.59e-06	0.000405	0.28	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24552148	chr15:24493137~24652130:+
THCA	cis	rs9467773	0.583	rs2498380	ENSG00000261353.1	CTA-14H9.5	4.69	3.59e-06	0.000405	0.22	0.21	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26527063~26527404:+
THCA	cis	rs9902453	0.845	rs3115101	ENSG00000263370.1	RP11-68I3.5	4.69	3.59e-06	0.000406	0.28	0.21	Coffee consumption (cups per day);	chr17:29714609	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs3102556	ENSG00000263370.1	RP11-68I3.5	4.69	3.59e-06	0.000406	0.28	0.21	Coffee consumption (cups per day);	chr17:29715524	chr17:29639627~29640825:+
THCA	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	4.69	3.59e-06	0.000406	0.27	0.21	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
THCA	cis	rs2337406	0.778	rs56658355	ENSG00000211974.3	IGHV2-70	-4.69	3.59e-06	0.000406	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106662151	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.925	rs10131226	ENSG00000211974.3	IGHV2-70	-4.69	3.59e-06	0.000406	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106665764	chr14:106723574~106724093:-
THCA	cis	rs10256972	0.706	rs12701970	ENSG00000225146.1	AC073957.15	4.69	3.59e-06	0.000406	0.23	0.21	Endometriosis;Longevity;	chr7:1082322	chr7:1029025~1043891:+
THCA	cis	rs1003719	0.762	rs4399800	ENSG00000230366.8	DSCR9	-4.69	3.59e-06	0.000406	-0.21	-0.21	Eye color traits;	chr21:37117178	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2040341	ENSG00000230366.8	DSCR9	-4.69	3.59e-06	0.000406	-0.21	-0.21	Eye color traits;	chr21:37117453	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.713	rs7277150	ENSG00000230366.8	DSCR9	-4.69	3.59e-06	0.000406	-0.21	-0.21	Eye color traits;	chr21:37117706	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835605	ENSG00000230366.8	DSCR9	-4.69	3.59e-06	0.000406	-0.21	-0.21	Eye color traits;	chr21:37118434	chr21:37208503~37221736:+
THCA	cis	rs4950322	0.857	rs55790545	ENSG00000226015.2	CCT8P1	4.69	3.59e-06	0.000406	0.25	0.21	Protein quantitative trait loci;	chr1:147366649	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.857	rs7522219	ENSG00000226015.2	CCT8P1	4.69	3.59e-06	0.000406	0.25	0.21	Protein quantitative trait loci;	chr1:147366904	chr1:147203276~147204932:-
THCA	cis	rs874628	0.659	rs11667487	ENSG00000268650.3	AC068499.10	-4.69	3.59e-06	0.000406	-0.24	-0.21	Multiple sclerosis;	chr19:18240397	chr19:18204730~18220480:+
THCA	cis	rs7618915	0.547	rs12487591	ENSG00000243224.1	RP5-1157M23.2	-4.69	3.59e-06	0.000406	-0.23	-0.21	Bipolar disorder;	chr3:52608920	chr3:52239258~52241097:+
THCA	cis	rs875971	0.52	rs160645	ENSG00000164669.11	INTS4P1	4.69	3.59e-06	0.000406	0.31	0.21	Aortic root size;	chr7:66091320	chr7:65141225~65234216:+
THCA	cis	rs2562456	0.833	rs2154302	ENSG00000268117.1	VN1R84P	4.69	3.59e-06	0.000406	0.33	0.21	Pain;	chr19:21307609	chr19:21719801~21720035:-
THCA	cis	rs3820928	0.904	rs2396431	ENSG00000212391.1	SNORA48	-4.69	3.59e-06	0.000406	-0.24	-0.21	Pulmonary function;	chr2:226900772	chr2:226968989~226969122:-
THCA	cis	rs6693017	1	rs6693017	ENSG00000272823.1	RP11-295M18.6	-4.69	3.59e-06	0.000406	-0.32	-0.21	Monocyte early outgrowth colony forming units;	chr1:220803991	chr1:220828676~220829211:-
THCA	cis	rs17597773	0.674	rs10863569	ENSG00000238078.1	LINC01352	-4.69	3.59e-06	0.000406	-0.31	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220845598	chr1:220829255~220832429:+
THCA	cis	rs7772486	0.754	rs9373475	ENSG00000270638.1	RP3-466P17.1	4.69	3.59e-06	0.000406	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145735570~145737218:+
THCA	cis	rs911119	0.955	rs1555355	ENSG00000270001.1	RP11-218C14.8	-4.69	3.59e-06	0.000406	-0.31	-0.21	Chronic kidney disease;	chr20:23613943	chr20:23631826~23632316:-
THCA	cis	rs28374715	0.532	rs1899	ENSG00000247556.5	OIP5-AS1	4.69	3.59e-06	0.000406	0.2	0.21	Ulcerative colitis;	chr15:41397034	chr15:41283990~41309737:+
THCA	cis	rs11089937	0.895	rs5756985	ENSG00000211639.2	IGLV4-60	4.69	3.59e-06	0.000406	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22131847	chr22:22162199~22162681:+
THCA	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	4.69	3.59e-06	0.000406	0.24	0.21	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
THCA	cis	rs9425766	0.566	rs10912773	ENSG00000227373.4	RP11-160H22.5	4.69	3.6e-06	0.000406	0.3	0.21	Life satisfaction;	chr1:174374567	chr1:174115300~174160004:-
THCA	cis	rs2439831	0.867	rs935901	ENSG00000275601.1	AC011330.13	-4.69	3.6e-06	0.000406	-0.37	-0.21	Lung cancer in ever smokers;	chr15:43359058	chr15:43642389~43643023:-
THCA	cis	rs10510102	0.516	rs10887034	ENSG00000226864.1	ATE1-AS1	4.69	3.6e-06	0.000407	0.37	0.21	Breast cancer;	chr10:121973996	chr10:121928312~121951965:+
THCA	cis	rs7520050	0.778	rs3014238	ENSG00000234329.1	RP11-767N6.2	-4.69	3.6e-06	0.000407	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45651039~45651826:-
THCA	cis	rs453301	0.571	rs2929456	ENSG00000253981.4	ALG1L13P	-4.69	3.6e-06	0.000407	-0.2	-0.21	Joint mobility (Beighton score);	chr8:9225906	chr8:8236003~8244667:-
THCA	cis	rs6772849	0.775	rs12486377	ENSG00000242551.2	POU5F1P6	-4.69	3.6e-06	0.000407	-0.29	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128696010	chr3:128674735~128677005:-
THCA	cis	rs10090774	0.664	rs11774042	ENSG00000280303.2	ERICD	-4.69	3.6e-06	0.000407	-0.2	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140657279	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.71	rs7460	ENSG00000280303.2	ERICD	-4.69	3.6e-06	0.000407	-0.2	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140658761	chr8:140636281~140638283:+
THCA	cis	rs8141529	0.719	rs9625619	ENSG00000226471.5	CTA-292E10.6	-4.69	3.6e-06	0.000407	-0.17	-0.21	Lymphocyte counts;	chr22:28876340	chr22:28800683~28848559:+
THCA	cis	rs72945132	1	rs7938912	ENSG00000254604.1	AP000487.6	-4.69	3.6e-06	0.000407	-0.39	-0.21	Coronary artery disease;	chr11:70268779	chr11:70282367~70363368:-
THCA	cis	rs7617773	0.743	rs6804986	ENSG00000199476.1	Y_RNA	-4.69	3.6e-06	0.000407	-0.27	-0.21	Coronary artery disease;	chr3:48322105	chr3:48288587~48288694:+
THCA	cis	rs2243480	1	rs34815098	ENSG00000232559.3	GS1-124K5.12	4.69	3.6e-06	0.000407	0.31	0.21	Diabetic kidney disease;	chr7:65827267	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs35735127	ENSG00000232559.3	GS1-124K5.12	4.69	3.6e-06	0.000407	0.31	0.21	Diabetic kidney disease;	chr7:65835436	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs35256305	ENSG00000232559.3	GS1-124K5.12	4.69	3.6e-06	0.000407	0.31	0.21	Diabetic kidney disease;	chr7:65841418	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.803	rs34004500	ENSG00000232559.3	GS1-124K5.12	4.69	3.6e-06	0.000407	0.31	0.21	Diabetic kidney disease;	chr7:65847191	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs35825738	ENSG00000232559.3	GS1-124K5.12	4.69	3.6e-06	0.000407	0.31	0.21	Diabetic kidney disease;	chr7:65853040	chr7:66554588~66576923:-
THCA	cis	rs1336149	0.901	rs822438	ENSG00000211581.1	MIR765	-4.69	3.6e-06	0.000407	-0.27	-0.21	Chin dimples;	chr1:156924214	chr1:156936131~156936244:-
THCA	cis	rs17095355	1	rs3862006	ENSG00000203876.8	ADD3-AS1	4.69	3.6e-06	0.000407	0.23	0.21	Biliary atresia;	chr10:109991006	chr10:109940104~110008381:-
THCA	cis	rs2742234	0.59	rs2505506	ENSG00000273008.1	RP11-351D16.3	-4.69	3.6e-06	0.000407	-0.2	-0.21	Hirschsprung disease;	chr10:43150406	chr10:43136824~43138334:-
THCA	cis	rs6866614	0.639	rs1858074	ENSG00000233006.5	AC034220.3	4.69	3.6e-06	0.000407	0.18	0.21	Perceived unattractiveness to mosquitoes;	chr5:132036306	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.508	rs11739935	ENSG00000233006.5	AC034220.3	4.69	3.6e-06	0.000407	0.18	0.21	Blood metabolite levels;	chr5:132044965	chr5:132311285~132369916:-
THCA	cis	rs2033711	0.622	rs975947	ENSG00000268049.1	CTD-2619J13.9	-4.69	3.6e-06	0.000407	-0.27	-0.21	Uric acid clearance;	chr19:58386826	chr19:58357999~58359603:+
THCA	cis	rs875971	0.522	rs709604	ENSG00000164669.11	INTS4P1	4.69	3.6e-06	0.000407	0.26	0.21	Aortic root size;	chr7:66032447	chr7:65141225~65234216:+
THCA	cis	rs427394	0.664	rs274701	ENSG00000248677.1	CTD-2044J15.1	4.69	3.6e-06	0.000407	0.2	0.21	Menopause (age at onset);	chr5:6728594	chr5:6686325~6707711:-
THCA	cis	rs427394	0.664	rs274697	ENSG00000248677.1	CTD-2044J15.1	4.69	3.6e-06	0.000407	0.2	0.21	Menopause (age at onset);	chr5:6731364	chr5:6686325~6707711:-
THCA	cis	rs427394	0.664	rs274696	ENSG00000248677.1	CTD-2044J15.1	4.69	3.6e-06	0.000407	0.2	0.21	Menopause (age at onset);	chr5:6732100	chr5:6686325~6707711:-
THCA	cis	rs9902453	1	rs6505158	ENSG00000263370.1	RP11-68I3.5	-4.69	3.61e-06	0.000407	-0.28	-0.21	Coffee consumption (cups per day);	chr17:30076330	chr17:29639627~29640825:+
THCA	cis	rs4925386	0.84	rs6143036	ENSG00000273619.1	RP5-908M14.9	-4.69	3.61e-06	0.000408	-0.18	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62386303~62386970:-
THCA	cis	rs2742234	0.578	rs2742241	ENSG00000273008.1	RP11-351D16.3	-4.69	3.61e-06	0.000408	-0.2	-0.21	Hirschsprung disease;	chr10:43129775	chr10:43136824~43138334:-
THCA	cis	rs8002861	0.905	rs12853286	ENSG00000274001.1	RP11-5G9.5	-4.69	3.61e-06	0.000408	-0.26	-0.21	Leprosy;	chr13:43872681	chr13:43877715~43878163:-
THCA	cis	rs7618915	0.501	rs1866268	ENSG00000243224.1	RP5-1157M23.2	-4.69	3.61e-06	0.000408	-0.23	-0.21	Bipolar disorder;	chr3:52685382	chr3:52239258~52241097:+
THCA	cis	rs10266483	0.739	rs679966	ENSG00000271550.1	BNIP3P11	4.69	3.61e-06	0.000408	0.27	0.21	Response to statin therapy;	chr7:64306688	chr7:64678954~64687393:-
THCA	cis	rs3213758	0.541	rs17838423	ENSG00000275191.1	RP11-36I17.2	-4.69	3.61e-06	0.000408	-0.34	-0.21	Vitiligo (non-segmental);	chr16:53525818	chr16:53628256~53628816:-
THCA	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-4.69	3.61e-06	0.000408	-0.24	-0.21	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
THCA	cis	rs4237845	0.586	rs4760174	ENSG00000257159.1	RP11-58A17.3	4.69	3.61e-06	0.000408	0.27	0.21	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57967058~57968399:+
THCA	cis	rs6870983	0.749	rs6452795	ENSG00000247828.6	TMEM161B-AS1	-4.69	3.61e-06	0.000408	-0.19	-0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88535216	chr5:88268895~88436685:+
THCA	cis	rs10050311	1	rs10050311	ENSG00000251411.1	RP11-397E7.4	-4.69	3.61e-06	0.000408	-0.26	-0.21	Insulin-related traits;	chr4:86833266	chr4:86913266~86914817:-
THCA	cis	rs1009077	0.68	rs3775850	ENSG00000245958.5	RP11-33B1.1	4.69	3.61e-06	0.000408	0.28	0.21	Endometriosis;	chr4:119529863	chr4:119454791~119552025:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000229886.1	RP5-1132H15.3	4.69	3.61e-06	0.000408	0.22	0.21	Aortic root size;	chr7:65931217	chr7:66025126~66031544:-
THCA	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	4.69	3.61e-06	0.000408	0.18	0.21	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	4.69	3.61e-06	0.000408	0.18	0.21	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
THCA	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	4.69	3.61e-06	0.000408	0.18	0.21	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	4.69	3.61e-06	0.000408	0.18	0.21	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	4.69	3.61e-06	0.000408	0.18	0.21	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	4.69	3.61e-06	0.000408	0.18	0.21	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	4.69	3.61e-06	0.000408	0.18	0.21	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
THCA	cis	rs6441961	0.501	rs6810232	ENSG00000223552.1	RP11-24F11.2	-4.69	3.61e-06	0.000408	-0.22	-0.21	Celiac disease;	chr3:46285113	chr3:46364955~46407059:-
THCA	cis	rs2447820	0.588	rs12055256	ENSG00000249996.1	RP11-359P5.1	-4.69	3.61e-06	0.000408	-0.25	-0.21	Migraine;	chr5:123034951	chr5:123036271~123054667:+
THCA	cis	rs2742234	0.59	rs1254965	ENSG00000273008.1	RP11-351D16.3	4.69	3.62e-06	0.000408	0.2	0.21	Hirschsprung disease;	chr10:43194405	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.59	rs2115817	ENSG00000273008.1	RP11-351D16.3	-4.69	3.62e-06	0.000408	-0.2	-0.21	Hirschsprung disease;	chr10:43191104	chr10:43136824~43138334:-
THCA	cis	rs11148252	0.557	rs9536223	ENSG00000273784.3	RP11-78J21.7	-4.69	3.62e-06	0.000408	-0.23	-0.21	Lewy body disease;	chr13:52659059	chr13:52600042~52642542:+
THCA	cis	rs13178541	0.683	rs7378856	ENSG00000250378.1	RP11-119J18.1	-4.69	3.62e-06	0.000409	-0.27	-0.21	IgG glycosylation;	chr5:135751404	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.683	rs4036630	ENSG00000250378.1	RP11-119J18.1	-4.69	3.62e-06	0.000409	-0.27	-0.21	IgG glycosylation;	chr5:135752980	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.748	rs7379672	ENSG00000250378.1	RP11-119J18.1	-4.69	3.62e-06	0.000409	-0.27	-0.21	IgG glycosylation;	chr5:135754136	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs11950793	ENSG00000250378.1	RP11-119J18.1	-4.69	3.62e-06	0.000409	-0.27	-0.21	IgG glycosylation;	chr5:135754394	chr5:135812667~135826582:+
THCA	cis	rs875971	0.619	rs2302918	ENSG00000229886.1	RP5-1132H15.3	4.69	3.62e-06	0.000409	0.21	0.21	Aortic root size;	chr7:66535945	chr7:66025126~66031544:-
THCA	cis	rs12130871	0.63	rs11265544	ENSG00000232879.2	RP11-544M22.3	-4.69	3.62e-06	0.000409	-0.24	-0.21	Night sleep phenotypes;	chr1:161036229	chr1:161034834~161035006:+
THCA	cis	rs17095355	1	rs17095355	ENSG00000203876.8	ADD3-AS1	-4.69	3.62e-06	0.000409	-0.23	-0.21	Biliary atresia;	chr10:109975992	chr10:109940104~110008381:-
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000182586.6	LINC00334	-4.69	3.62e-06	0.000409	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45234340~45258730:+
THCA	cis	rs6570726	0.791	rs9373464	ENSG00000270638.1	RP3-466P17.1	4.69	3.62e-06	0.000409	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145735570~145737218:+
THCA	cis	rs1005277	0.522	rs11011343	ENSG00000276805.1	RP11-291L22.6	4.69	3.62e-06	0.000409	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38451030~38451785:+
THCA	cis	rs9467773	0.596	rs62396201	ENSG00000261353.1	CTA-14H9.5	-4.69	3.62e-06	0.000409	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26527063~26527404:+
THCA	cis	rs11955398	0.502	rs34592	ENSG00000272308.1	RP11-231G3.1	-4.69	3.62e-06	0.000409	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61033797	chr5:60866457~60866935:-
THCA	cis	rs11157436	0.958	rs2075494	ENSG00000211812.1	TRAV26-2	-4.69	3.62e-06	0.000409	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22202583~22203368:+
THCA	cis	rs11157436	0.958	rs2242542	ENSG00000211812.1	TRAV26-2	-4.69	3.62e-06	0.000409	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22202583~22203368:+
THCA	cis	rs11157436	0.958	rs17255537	ENSG00000211812.1	TRAV26-2	-4.69	3.62e-06	0.000409	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22202583~22203368:+
THCA	cis	rs1003719	0.743	rs2835615	ENSG00000230366.8	DSCR9	4.69	3.62e-06	0.000409	0.22	0.21	Eye color traits;	chr21:37125003	chr21:37208503~37221736:+
THCA	cis	rs9307551	0.741	rs1440863	ENSG00000250334.4	LINC00989	-4.69	3.62e-06	0.000409	-0.28	-0.21	Refractive error;	chr4:79503061	chr4:79492416~79576460:+
THCA	cis	rs9875589	0.509	rs9836573	ENSG00000228242.5	AC093495.4	4.69	3.62e-06	0.000409	0.12	0.21	Ovarian reserve;	chr3:14023739	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs1844107	ENSG00000228242.5	AC093495.4	4.69	3.62e-06	0.000409	0.12	0.21	Ovarian reserve;	chr3:14023819	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs1601868	ENSG00000228242.5	AC093495.4	4.69	3.62e-06	0.000409	0.12	0.21	Ovarian reserve;	chr3:14023950	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs4685062	ENSG00000228242.5	AC093495.4	4.69	3.62e-06	0.000409	0.12	0.21	Ovarian reserve;	chr3:14024909	chr3:14144637~14165978:+
THCA	cis	rs1876905	0.539	rs457497	ENSG00000255389.1	C6orf3	-4.69	3.63e-06	0.000409	-0.25	-0.21	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111599875~111602295:+
THCA	cis	rs930395	0.514	rs34325259	ENSG00000272335.1	RP11-53O19.3	-4.69	3.63e-06	0.000409	-0.18	-0.21	Breast cancer;	chr5:44936758	chr5:44826076~44828592:+
THCA	cis	rs9925964	0.967	rs749767	ENSG00000232748.3	RP11-196G11.6	-4.69	3.63e-06	0.000409	-0.25	-0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31113086	chr16:31056460~31062803:+
THCA	cis	rs6921919	0.583	rs16894060	ENSG00000280107.1	AL022393.9	-4.69	3.63e-06	0.00041	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28170845~28172521:+
THCA	cis	rs8064024	0.676	rs9938805	ENSG00000267077.1	RP11-127I20.5	-4.69	3.63e-06	0.00041	-0.24	-0.21	Cancer;	chr16:4827552	chr16:4795265~4796532:-
THCA	cis	rs17767392	0.958	rs7148679	ENSG00000259146.3	RP1-261D10.2	-4.69	3.63e-06	0.00041	-0.28	-0.21	Mitral valve prolapse;	chr14:71693604	chr14:71292729~71321814:-
THCA	cis	rs4927850	1	rs7627706	ENSG00000185485.13	SDHAP1	4.69	3.63e-06	0.00041	0.18	0.21	Pancreatic cancer;	chr3:196026482	chr3:195959748~195990318:-
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000185485.13	SDHAP1	4.69	3.63e-06	0.00041	0.18	0.21	Pancreatic cancer;	chr3:196026530	chr3:195959748~195990318:-
THCA	cis	rs4927850	1	rs7627868	ENSG00000185485.13	SDHAP1	4.69	3.63e-06	0.00041	0.18	0.21	Pancreatic cancer;	chr3:196026602	chr3:195959748~195990318:-
THCA	cis	rs8141529	0.748	rs5762874	ENSG00000226471.5	CTA-292E10.6	-4.69	3.63e-06	0.00041	-0.17	-0.21	Lymphocyte counts;	chr22:28873670	chr22:28800683~28848559:+
THCA	cis	rs9425766	0.591	rs2049991	ENSG00000227373.4	RP11-160H22.5	4.69	3.63e-06	0.00041	0.3	0.21	Life satisfaction;	chr1:174356428	chr1:174115300~174160004:-
THCA	cis	rs11756659	0.505	rs62394320	ENSG00000272462.2	U91328.19	4.69	3.63e-06	0.00041	0.19	0.21	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25891952	chr6:25992662~26001775:+
THCA	cis	rs2447820	0.588	rs246284	ENSG00000249996.1	RP11-359P5.1	4.69	3.63e-06	0.00041	0.25	0.21	Migraine;	chr5:122907173	chr5:123036271~123054667:+
THCA	cis	rs7267979	0.932	rs6132848	ENSG00000274973.1	RP13-401N8.7	-4.69	3.63e-06	0.00041	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25845497~25845862:+
THCA	cis	rs7942368	1	rs4309181	ENSG00000261578.1	RP11-21L23.2	4.69	3.63e-06	0.00041	0.31	0.21	Endometriosis;	chr11:76790661	chr11:76800364~76804555:+
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000230295.1	RP11-458F8.2	-4.69	3.63e-06	0.00041	-0.17	-0.21	Corneal structure;	chr7:66925268	chr7:66880708~66882981:+
THCA	cis	rs7833787	0.86	rs6981676	ENSG00000278886.1	RP11-108A14.1	-4.69	3.63e-06	0.00041	-0.27	-0.21	Obesity-related traits;	chr8:18821604	chr8:18864681~18865247:-
THCA	cis	rs9652601	0.622	rs6498143	ENSG00000274038.1	RP11-66H6.4	-4.69	3.63e-06	0.00041	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11001179	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.622	rs7194305	ENSG00000274038.1	RP11-66H6.4	-4.69	3.63e-06	0.00041	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11005850	chr16:11056556~11057034:+
THCA	cis	rs288326	0.561	rs74564500	ENSG00000272800.1	RP11-438L19.1	4.69	3.63e-06	0.00041	0.38	0.21	Blood protein levels;	chr2:182921692	chr2:183214319~183215400:+
THCA	cis	rs829883	0.659	rs12366275	ENSG00000227825.4	SLC9A7P1	-4.69	3.63e-06	0.00041	-0.21	-0.21	Colorectal adenoma (advanced);	chr12:98526498	chr12:98453835~98457145:-
THCA	cis	rs2439831	0.867	rs4583210	ENSG00000166763.7	STRCP1	4.69	3.63e-06	0.00041	0.29	0.21	Lung cancer in ever smokers;	chr15:43368727	chr15:43699488~43718184:-
THCA	cis	rs752010	0.967	rs752011	ENSG00000230638.4	RP11-486B10.4	-4.69	3.64e-06	0.00041	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41627258	chr1:41542069~41544310:+
THCA	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-4.69	3.64e-06	0.00041	-0.25	-0.21	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-4.69	3.64e-06	0.00041	-0.25	-0.21	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
THCA	cis	rs9910055	0.639	rs11656871	ENSG00000267080.4	ASB16-AS1	-4.69	3.64e-06	0.000411	-0.19	-0.21	Total body bone mineral density;	chr17:44191773	chr17:44175973~44186717:-
THCA	cis	rs8002861	0.875	rs12867890	ENSG00000274001.1	RP11-5G9.5	-4.69	3.64e-06	0.000411	-0.26	-0.21	Leprosy;	chr13:43848952	chr13:43877715~43878163:-
THCA	cis	rs2985684	0.894	rs4900927	ENSG00000278009.1	RP11-649E7.8	4.69	3.64e-06	0.000411	0.29	0.21	Carotid intima media thickness;	chr14:49552023	chr14:49601011~49601124:-
THCA	cis	rs6832769	0.89	rs564762	ENSG00000272969.1	RP11-528I4.2	4.69	3.64e-06	0.000411	0.24	0.21	Personality dimensions;	chr4:55418464	chr4:55547112~55547889:+
THCA	cis	rs9311474	0.508	rs12629701	ENSG00000243224.1	RP5-1157M23.2	-4.69	3.64e-06	0.000411	-0.23	-0.21	Electroencephalogram traits;	chr3:52585820	chr3:52239258~52241097:+
THCA	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000411	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000411	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000411	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000411	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000411	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000411	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000411	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-4.69	3.64e-06	0.000411	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
THCA	cis	rs2787702	0.929	rs2814032	ENSG00000237233.2	TMEM26-AS1	-4.69	3.64e-06	0.000411	-0.25	-0.21	Response to taxane treatment (placlitaxel);	chr10:61576925	chr10:61452639~61481956:+
THCA	cis	rs7621331	1	rs6810223	ENSG00000273486.1	RP11-731C17.2	4.69	3.64e-06	0.000411	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:135975662	chr3:136837338~136839021:-
THCA	cis	rs1048886	0.816	rs16869170	ENSG00000271967.1	RP11-134K13.4	-4.69	3.64e-06	0.000411	-0.22	-0.21	Type 2 diabetes;	chr6:70406048	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.882	rs1075263	ENSG00000271967.1	RP11-134K13.4	-4.69	3.64e-06	0.000411	-0.22	-0.21	Type 2 diabetes;	chr6:70407858	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.882	rs58144467	ENSG00000271967.1	RP11-134K13.4	-4.69	3.64e-06	0.000411	-0.22	-0.21	Type 2 diabetes;	chr6:70408604	chr6:70596438~70596980:+
THCA	cis	rs931127	0.719	rs2127507	ENSG00000214659.4	KRT8P26	4.69	3.64e-06	0.000411	0.18	0.21	Systemic lupus erythematosus;	chr11:65686959	chr11:65726939~65728214:+
THCA	cis	rs17594362	1	rs17594362	ENSG00000264190.1	MIR5006	4.69	3.64e-06	0.000411	0.34	0.21	Multiple sclerosis;	chr13:41565109	chr13:41568286~41568395:-
THCA	cis	rs9990333	0.6	rs6793116	ENSG00000231464.1	AC024937.4	-4.69	3.64e-06	0.000411	-0.25	-0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085217	chr3:195996738~195998233:+
THCA	cis	rs2836974	0.533	rs4817999	ENSG00000255568.3	BRWD1-AS2	-4.69	3.64e-06	0.000411	-0.17	-0.21	Cognitive function;	chr21:39182429	chr21:39313935~39314962:+
THCA	cis	rs728616	0.614	rs55768100	ENSG00000242600.5	MBL1P	4.69	3.64e-06	0.000411	0.23	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:79904898~79950336:+
THCA	cis	rs9302635	0.688	rs763665	ENSG00000260886.1	TAT-AS1	4.69	3.64e-06	0.000411	0.37	0.21	Blood protein levels;	chr16:72044144	chr16:71565789~71578187:+
THCA	cis	rs5771225	0.544	rs909688	ENSG00000273253.2	RP3-402G11.26	-4.69	3.65e-06	0.000411	-0.25	-0.21	Late-onset Alzheimer's disease;	chr22:50250601	chr22:50199090~50200837:-
THCA	cis	rs2749592	0.513	rs1208708	ENSG00000120555.12	SEPT7P9	4.69	3.65e-06	0.000412	0.23	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38383069~38402916:-
THCA	cis	rs7403037	0.848	rs12917173	ENSG00000260760.1	PWRN3	4.69	3.65e-06	0.000412	0.24	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24592422	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.848	rs11629872	ENSG00000260760.1	PWRN3	4.69	3.65e-06	0.000412	0.24	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24593777	chr15:24441127~24447967:+
THCA	cis	rs7914558	0.966	rs10748837	ENSG00000236937.2	PTGES3P4	4.69	3.65e-06	0.000412	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:102845595~102845950:+
THCA	cis	rs6012564	0.783	rs6125575	ENSG00000230758.1	SNAP23P	4.69	3.65e-06	0.000412	0.25	0.21	Anger;	chr20:49159159	chr20:49038357~49038602:-
THCA	cis	rs2058059	0.593	rs2960944	ENSG00000205578.5	POM121B	-4.69	3.65e-06	0.000412	-0.32	-0.21	Subcutaneous adipose tissue;	chr7:72680285	chr7:73293497~73301161:+
THCA	cis	rs931127	0.719	rs7949980	ENSG00000214659.4	KRT8P26	4.69	3.65e-06	0.000412	0.19	0.21	Systemic lupus erythematosus;	chr11:65678479	chr11:65726939~65728214:+
THCA	cis	rs35771425	0.572	rs34552796	ENSG00000153363.11	LINC00467	-4.69	3.65e-06	0.000412	-0.18	-0.21	Educational attainment (years of education);	chr1:211248887	chr1:211382803~211435333:+
THCA	cis	rs651907	0.967	rs641432	ENSG00000256628.3	ZBTB11-AS1	4.69	3.65e-06	0.000412	0.22	0.21	Colorectal cancer;	chr3:101868722	chr3:101676475~101679217:+
THCA	cis	rs736408	0.812	rs2071507	ENSG00000243224.1	RP5-1157M23.2	-4.69	3.65e-06	0.000412	-0.23	-0.21	Bipolar disorder;	chr3:52792691	chr3:52239258~52241097:+
THCA	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	4.69	3.65e-06	0.000412	0.24	0.21	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	4.69	3.65e-06	0.000412	0.24	0.21	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	4.69	3.65e-06	0.000412	0.24	0.21	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	4.69	3.65e-06	0.000412	0.24	0.21	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	4.69	3.65e-06	0.000412	0.24	0.21	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	4.69	3.65e-06	0.000412	0.24	0.21	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	4.69	3.65e-06	0.000412	0.24	0.21	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
THCA	cis	rs9876781	1	rs3774808	ENSG00000244380.1	RP11-24C3.2	4.69	3.65e-06	0.000412	0.25	0.21	Longevity;	chr3:48440237	chr3:48440352~48446656:-
THCA	cis	rs711244	0.783	rs2110944	ENSG00000279519.1	RP11-288C18.1	-4.69	3.65e-06	0.000412	-0.18	-0.21	Mean platelet volume;	chr2:36863090	chr2:36839922~36842539:-
THCA	cis	rs5742933	0.842	rs1225101	ENSG00000253559.1	OSGEPL1-AS1	-4.69	3.65e-06	0.000412	-0.25	-0.21	Ferritin levels;	chr2:189740695	chr2:189762704~189765556:+
THCA	cis	rs11846409	0.932	rs10151046	ENSG00000274576.2	IGHV2-70	-4.69	3.65e-06	0.000412	-0.18	-0.21	Rheumatic heart disease;	chr14:106633095	chr14:106770577~106771020:-
THCA	cis	rs2281603	0.521	rs10142879	ENSG00000259116.1	RP11-973N13.4	-4.69	3.65e-06	0.000412	-0.19	-0.21	Lymphocyte counts;	chr14:64499124	chr14:64514154~64540368:-
THCA	cis	rs3820928	0.967	rs4675113	ENSG00000212391.1	SNORA48	-4.69	3.65e-06	0.000412	-0.24	-0.21	Pulmonary function;	chr2:226901623	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs6752707	ENSG00000212391.1	SNORA48	-4.69	3.65e-06	0.000412	-0.24	-0.21	Pulmonary function;	chr2:226902106	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.933	rs1429267	ENSG00000212391.1	SNORA48	-4.69	3.65e-06	0.000412	-0.24	-0.21	Pulmonary function;	chr2:226902877	chr2:226968989~226969122:-
THCA	cis	rs6012564	0.559	rs61418814	ENSG00000227431.4	CSE1L-AS1	4.69	3.65e-06	0.000412	0.26	0.21	Anger;	chr20:49153301	chr20:49040463~49046044:-
THCA	cis	rs8067545	0.586	rs2703819	ENSG00000270091.1	RP11-78O7.2	4.69	3.65e-06	0.000412	0.16	0.21	Schizophrenia;	chr17:20218088	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs2703781	ENSG00000270091.1	RP11-78O7.2	4.69	3.65e-06	0.000412	0.16	0.21	Schizophrenia;	chr17:20241401	chr17:19896590~19897287:-
THCA	cis	rs9467773	0.62	rs9461275	ENSG00000124549.13	BTN2A3P	4.69	3.66e-06	0.000412	0.19	0.21	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26421391~26432383:+
THCA	cis	rs739496	0.615	rs59905228	ENSG00000226469.1	ADAM1B	4.69	3.66e-06	0.000412	0.27	0.21	Platelet count;	chr12:111743422	chr12:111927018~111929017:+
THCA	cis	rs2373226	1	rs2373226	ENSG00000223552.1	RP11-24F11.2	4.69	3.66e-06	0.000412	0.2	0.21	Itch intensity from mosquito bite;	chr3:46362672	chr3:46364955~46407059:-
THCA	cis	rs3820928	0.804	rs4144327	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226925546	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs7582251	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226926987	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10207404	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226929704	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.869	rs2396436	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226930748	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10169717	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226932195	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs1917125	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226934265	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.839	rs4673174	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226936600	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.804	rs4675125	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226937783	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs55743026	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226938097	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs67513858	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226940103	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs55959848	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226940710	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs7562776	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226941834	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10933163	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226950570	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs4234062	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226954334	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs10210963	ENSG00000212391.1	SNORA48	-4.69	3.66e-06	0.000412	-0.23	-0.21	Pulmonary function;	chr2:226957129	chr2:226968989~226969122:-
THCA	cis	rs7015630	1	rs7015630	ENSG00000251136.7	RP11-37B2.1	-4.69	3.66e-06	0.000413	-0.2	-0.21	Inflammatory bowel disease;Crohn's disease;	chr8:89863690	chr8:89609409~89757727:-
THCA	cis	rs6490294	0.528	rs12579851	ENSG00000226469.1	ADAM1B	4.69	3.66e-06	0.000413	0.36	0.21	Mean platelet volume;	chr12:112230951	chr12:111927018~111929017:+
THCA	cis	rs10923574	0.618	rs1146313	ENSG00000231365.4	RP11-418J17.1	4.69	3.66e-06	0.000413	0.22	0.21	Breast cancer;Folding of antihelix;	chr1:118483467	chr1:119140396~119275973:+
THCA	cis	rs2253762	0.54	rs79547192	ENSG00000226864.1	ATE1-AS1	4.69	3.66e-06	0.000413	0.34	0.21	Breast cancer;	chr10:121998664	chr10:121928312~121951965:+
THCA	cis	rs17801127	0.636	rs7566540	ENSG00000231969.1	AC144449.1	-4.69	3.66e-06	0.000413	-0.34	-0.21	Liver enzyme levels (alanine transaminase);	chr2:149664861	chr2:149587196~149848233:+
THCA	cis	rs2243480	1	rs313831	ENSG00000164669.11	INTS4P1	4.69	3.66e-06	0.000413	0.4	0.21	Diabetic kidney disease;	chr7:66086239	chr7:65141225~65234216:+
THCA	cis	rs9902453	0.845	rs3115099	ENSG00000263370.1	RP11-68I3.5	4.69	3.66e-06	0.000413	0.28	0.21	Coffee consumption (cups per day);	chr17:29692275	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs58606097	ENSG00000263370.1	RP11-68I3.5	4.69	3.66e-06	0.000413	0.28	0.21	Coffee consumption (cups per day);	chr17:29693361	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs3102559	ENSG00000263370.1	RP11-68I3.5	4.69	3.66e-06	0.000413	0.28	0.21	Coffee consumption (cups per day);	chr17:29702705	chr17:29639627~29640825:+
THCA	cis	rs875971	0.545	rs12671152	ENSG00000228409.4	CCT6P1	-4.69	3.66e-06	0.000413	-0.19	-0.21	Aortic root size;	chr7:66311140	chr7:65751142~65763354:+
THCA	cis	rs6860806	0.531	rs272887	ENSG00000224431.1	AC063976.7	4.69	3.66e-06	0.000413	0.19	0.21	Breast cancer;	chr5:132330020	chr5:132199456~132203487:+
THCA	cis	rs12823128	0.628	rs17401663	ENSG00000256185.1	RP11-612B6.2	-4.69	3.66e-06	0.000413	-0.2	-0.21	Birth weight;	chr12:26706086	chr12:26335864~26336950:-
THCA	cis	rs6496044	0.507	rs2467096	ENSG00000259407.1	RP11-158M2.3	4.69	3.66e-06	0.000413	0.22	0.21	Interstitial lung disease;	chr15:85667447	chr15:85744109~85750281:-
THCA	cis	rs4925386	1	rs1889201	ENSG00000275437.1	RP5-908M14.10	-4.69	3.66e-06	0.000413	-0.2	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62402236~62405935:-
THCA	cis	rs73108077	0.736	rs6058492	ENSG00000277112.2	RP11-755J8.1	-4.69	3.66e-06	0.000413	-0.34	-0.21	Red blood cell density in sickle cell anemia;	chr20:31286965	chr20:30681825~30723932:-
THCA	cis	rs11634944	0.869	rs2554429	ENSG00000257151.1	PWAR6	4.69	3.67e-06	0.000413	0.16	0.21	Interleukin-8 levels;	chr15:24970650	chr15:25031873~25036490:+
THCA	cis	rs7474896	0.731	rs2749577	ENSG00000263064.2	RP11-291L22.7	-4.69	3.67e-06	0.000413	-0.35	-0.21	Obesity (extreme);	chr10:37991957	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.945	rs2749575	ENSG00000263064.2	RP11-291L22.7	-4.69	3.67e-06	0.000413	-0.35	-0.21	Obesity (extreme);	chr10:37993647	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2474550	ENSG00000263064.2	RP11-291L22.7	-4.69	3.67e-06	0.000413	-0.35	-0.21	Obesity (extreme);	chr10:38001842	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2474549	ENSG00000263064.2	RP11-291L22.7	-4.69	3.67e-06	0.000413	-0.35	-0.21	Obesity (extreme);	chr10:38001844	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2738209	ENSG00000263064.2	RP11-291L22.7	-4.69	3.67e-06	0.000413	-0.35	-0.21	Obesity (extreme);	chr10:38018286	chr10:38448689~38448949:+
THCA	cis	rs172166	0.561	rs149976	ENSG00000176933.5	TOB2P1	4.69	3.67e-06	0.000414	0.23	0.21	Cardiac Troponin-T levels;	chr6:28019998	chr6:28217643~28218634:-
THCA	cis	rs12823128	0.901	rs1349231	ENSG00000256185.1	RP11-612B6.2	4.69	3.67e-06	0.000414	0.2	0.21	Birth weight;	chr12:26727419	chr12:26335864~26336950:-
THCA	cis	rs9307551	0.697	rs7691021	ENSG00000250334.4	LINC00989	-4.69	3.67e-06	0.000414	-0.28	-0.21	Refractive error;	chr4:79502775	chr4:79492416~79576460:+
THCA	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	4.69	3.67e-06	0.000414	0.22	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
THCA	cis	rs2742234	0.59	rs2505553	ENSG00000273008.1	RP11-351D16.3	-4.69	3.67e-06	0.000414	-0.2	-0.21	Hirschsprung disease;	chr10:43185803	chr10:43136824~43138334:-
THCA	cis	rs12893668	0.645	rs35229468	ENSG00000269958.1	RP11-73M18.8	4.69	3.67e-06	0.000414	0.21	0.21	Reticulocyte count;	chr14:103585720	chr14:103696353~103697163:+
THCA	cis	rs17772222	0.63	rs12437422	ENSG00000222990.1	RNU4-22P	-4.69	3.67e-06	0.000414	-0.26	-0.21	Coronary artery calcification;	chr14:88529621	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.605	rs4899955	ENSG00000222990.1	RNU4-22P	-4.69	3.67e-06	0.000414	-0.26	-0.21	Coronary artery calcification;	chr14:88530381	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.63	rs4904454	ENSG00000222990.1	RNU4-22P	-4.69	3.67e-06	0.000414	-0.26	-0.21	Coronary artery calcification;	chr14:88537777	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.63	rs2033418	ENSG00000222990.1	RNU4-22P	-4.69	3.67e-06	0.000414	-0.26	-0.21	Coronary artery calcification;	chr14:88539331	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.63	rs10873392	ENSG00000222990.1	RNU4-22P	-4.69	3.67e-06	0.000414	-0.26	-0.21	Coronary artery calcification;	chr14:88545124	chr14:88513498~88513663:+
THCA	cis	rs9625935	0.957	rs36607	ENSG00000279159.1	RP3-394A18.1	4.69	3.67e-06	0.000414	0.17	0.21	Tonsillectomy;	chr22:29945271	chr22:29978950~30028236:-
THCA	cis	rs916888	0.61	rs199454	ENSG00000261575.2	RP11-259G18.1	-4.68	3.67e-06	0.000414	-0.25	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46267037~46268694:+
THCA	cis	rs7621025	0.664	rs6439657	ENSG00000239213.4	NCK1-AS1	-4.68	3.67e-06	0.000414	-0.21	-0.21	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136775797	chr3:136841726~136862054:-
THCA	cis	rs587080	0.624	rs674485	ENSG00000254614.2	AP003068.23	-4.68	3.67e-06	0.000414	-0.29	-0.21	Plateletcrit;	chr11:65429922	chr11:65177606~65181834:-
THCA	cis	rs11846409	0.932	rs2583329	ENSG00000211974.3	IGHV2-70	4.68	3.67e-06	0.000414	0.2	0.21	Rheumatic heart disease;	chr14:106632971	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.86	rs10150951	ENSG00000211974.3	IGHV2-70	-4.68	3.67e-06	0.000414	-0.2	-0.21	Rheumatic heart disease;	chr14:106632988	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.86	rs17112419	ENSG00000211974.3	IGHV2-70	-4.68	3.67e-06	0.000414	-0.2	-0.21	Rheumatic heart disease;	chr14:106633260	chr14:106723574~106724093:-
THCA	cis	rs11080107	0.542	rs894606	ENSG00000264007.1	RP11-68I3.10	4.68	3.67e-06	0.000414	0.25	0.21	Coronary artery disease;	chr17:29582334	chr17:29621617~29622254:-
THCA	cis	rs2524276	1	rs2524276	ENSG00000229836.1	XXbac-BPG248L24.10	-4.68	3.67e-06	0.000414	-0.48	-0.21	Capecitabine sensitivity;	chr6:31440488	chr6:31307815~31308549:-
THCA	cis	rs3770081	1	rs78297976	ENSG00000272564.1	RP11-548P2.2	-4.68	3.67e-06	0.000414	-0.38	-0.21	Facial emotion recognition (sad faces);	chr2:85917118	chr2:85904279~85904727:+
THCA	cis	rs2115630	0.936	rs11073663	ENSG00000275120.1	RP11-182J1.17	-4.68	3.67e-06	0.000414	-0.22	-0.21	P wave terminal force;	chr15:84717037	chr15:84599434~84606463:-
THCA	cis	rs30380	1	rs30378	ENSG00000248734.2	CTD-2260A17.1	4.68	3.67e-06	0.000414	0.22	0.21	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96784777~96785999:+
THCA	cis	rs911119	0.955	rs6048930	ENSG00000270001.1	RP11-218C14.8	-4.68	3.68e-06	0.000414	-0.31	-0.21	Chronic kidney disease;	chr20:23611855	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs17751897	ENSG00000270001.1	RP11-218C14.8	-4.68	3.68e-06	0.000414	-0.31	-0.21	Chronic kidney disease;	chr20:23612077	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs67997662	ENSG00000270001.1	RP11-218C14.8	-4.68	3.68e-06	0.000414	-0.31	-0.21	Chronic kidney disease;	chr20:23612227	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs2067488	ENSG00000270001.1	RP11-218C14.8	-4.68	3.68e-06	0.000414	-0.31	-0.21	Chronic kidney disease;	chr20:23613694	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs61035931	ENSG00000270001.1	RP11-218C14.8	-4.68	3.68e-06	0.000414	-0.31	-0.21	Chronic kidney disease;	chr20:23615077	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs55897275	ENSG00000270001.1	RP11-218C14.8	-4.68	3.68e-06	0.000414	-0.31	-0.21	Chronic kidney disease;	chr20:23615316	chr20:23631826~23632316:-
THCA	cis	rs911119	0.908	rs6048949	ENSG00000270001.1	RP11-218C14.8	-4.68	3.68e-06	0.000414	-0.31	-0.21	Chronic kidney disease;	chr20:23622562	chr20:23631826~23632316:-
THCA	cis	rs911119	0.908	rs6048950	ENSG00000270001.1	RP11-218C14.8	-4.68	3.68e-06	0.000414	-0.31	-0.21	Chronic kidney disease;	chr20:23622615	chr20:23631826~23632316:-
THCA	cis	rs8058578	0.832	rs3812999	ENSG00000279196.1	RP11-1072A3.3	4.68	3.68e-06	0.000414	0.22	0.21	Multiple myeloma;	chr16:30762284	chr16:30984630~30988270:-
THCA	cis	rs62246343	0.516	rs2728934	ENSG00000254485.4	RP11-380O24.1	-4.68	3.68e-06	0.000415	-0.22	-0.21	Fibrinogen levels;	chr3:9421778	chr3:9292588~9363303:-
THCA	cis	rs17680741	0.542	rs35521186	ENSG00000225484.5	NUTM2B-AS1	-4.68	3.68e-06	0.000415	-0.3	-0.21	Coronary artery disease;	chr10:80484325	chr10:79663088~79826594:-
THCA	cis	rs4970988	0.526	rs6655975	ENSG00000231073.1	RP11-316M1.3	-4.68	3.68e-06	0.000415	-0.27	-0.21	Urate levels;	chr1:150569652	chr1:150973123~150975534:+
THCA	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-4.68	3.68e-06	0.000415	-0.32	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
THCA	cis	rs13034020	0.522	rs12464096	ENSG00000271889.1	RP11-493E12.1	-4.68	3.68e-06	0.000415	-0.28	-0.21	Hodgkin's lymphoma;	chr2:61012197	chr2:61151433~61162105:-
THCA	cis	rs13034020	0.522	rs12998880	ENSG00000271889.1	RP11-493E12.1	-4.68	3.68e-06	0.000415	-0.28	-0.21	Hodgkin's lymphoma;	chr2:61013747	chr2:61151433~61162105:-
THCA	cis	rs13034020	0.522	rs13005116	ENSG00000271889.1	RP11-493E12.1	-4.68	3.68e-06	0.000415	-0.28	-0.21	Hodgkin's lymphoma;	chr2:61014432	chr2:61151433~61162105:-
THCA	cis	rs13034020	0.522	rs35976602	ENSG00000271889.1	RP11-493E12.1	-4.68	3.68e-06	0.000415	-0.28	-0.21	Hodgkin's lymphoma;	chr2:61014447	chr2:61151433~61162105:-
THCA	cis	rs8067545	0.611	rs12949481	ENSG00000270091.1	RP11-78O7.2	4.68	3.68e-06	0.000415	0.16	0.21	Schizophrenia;	chr17:20287661	chr17:19896590~19897287:-
THCA	cis	rs7474896	1	rs11598044	ENSG00000263064.2	RP11-291L22.7	4.68	3.68e-06	0.000415	0.35	0.21	Obesity (extreme);	chr10:38053765	chr10:38448689~38448949:+
THCA	cis	rs3204270	1	rs3204270	ENSG00000262049.1	RP13-1032I1.7	4.68	3.68e-06	0.000415	0.24	0.21	Dental caries;	chr17:81715021	chr17:81701324~81703300:-
THCA	cis	rs453301	0.653	rs7016139	ENSG00000254153.1	CTA-398F10.2	4.68	3.68e-06	0.000415	0.22	0.21	Joint mobility (Beighton score);	chr8:9037960	chr8:8456909~8461337:-
THCA	cis	rs6860806	0.507	rs272883	ENSG00000237714.1	P4HA2-AS1	4.68	3.68e-06	0.000415	0.28	0.21	Breast cancer;	chr5:132333005	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.507	rs272882	ENSG00000237714.1	P4HA2-AS1	4.68	3.68e-06	0.000415	0.28	0.21	Breast cancer;	chr5:132333468	chr5:132184876~132192808:+
THCA	cis	rs6583331	0.837	rs9868705	ENSG00000232065.1	LINC01063	-4.68	3.68e-06	0.000415	-0.24	-0.21	Vitiligo;	chr3:196610326	chr3:196631498~196632587:-
THCA	cis	rs17597773	0.527	rs2484698	ENSG00000238078.1	LINC01352	4.68	3.68e-06	0.000415	0.26	0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220912723	chr1:220829255~220832429:+
THCA	cis	rs6860806	0.507	rs270606	ENSG00000224431.1	AC063976.7	4.68	3.68e-06	0.000415	0.19	0.21	Breast cancer;	chr5:132315174	chr5:132199456~132203487:+
THCA	cis	rs1555322	0.53	rs2425053	ENSG00000279253.1	RP4-614O4.13	-4.68	3.68e-06	0.000415	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35262727~35264187:-
THCA	cis	rs4713118	0.911	rs9461406	ENSG00000220721.1	OR1F12	-4.68	3.68e-06	0.000415	-0.29	-0.21	Parkinson's disease;	chr6:27751985	chr6:28073316~28074233:+
THCA	cis	rs11673344	0.543	rs12980849	ENSG00000276846.1	CTD-3220F14.3	4.68	3.68e-06	0.000415	0.16	0.21	Obesity-related traits;	chr19:37160812	chr19:37314868~37315620:-
THCA	cis	rs10208649	0.901	rs10180492	ENSG00000233266.1	HMGB1P31	4.68	3.68e-06	0.000415	0.5	0.21	Body mass index;	chr2:53829003	chr2:54051334~54051760:+
THCA	cis	rs2255336	0.671	rs7301582	ENSG00000245648.1	RP11-277P12.20	-4.68	3.68e-06	0.000415	-0.24	-0.21	Blood protein levels;	chr12:10449091	chr12:10363769~10398506:+
THCA	cis	rs2787702	1	rs2257189	ENSG00000237233.2	TMEM26-AS1	4.68	3.68e-06	0.000415	0.26	0.21	Response to taxane treatment (placlitaxel);	chr10:61558261	chr10:61452639~61481956:+
THCA	cis	rs17798991	0.721	rs11082765	ENSG00000267674.1	RP11-813F20.2	-4.68	3.68e-06	0.000415	-0.22	-0.21	Obesity-related traits;	chr18:49601903	chr18:49739823~49742063:-
THCA	cis	rs9902453	0.967	rs56129908	ENSG00000263370.1	RP11-68I3.5	4.68	3.68e-06	0.000415	0.28	0.21	Coffee consumption (cups per day);	chr17:30094364	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs4350617	ENSG00000263370.1	RP11-68I3.5	4.68	3.68e-06	0.000415	0.28	0.21	Coffee consumption (cups per day);	chr17:30096070	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs55971458	ENSG00000263370.1	RP11-68I3.5	4.68	3.68e-06	0.000415	0.28	0.21	Coffee consumption (cups per day);	chr17:30099998	chr17:29639627~29640825:+
THCA	cis	rs9925964	0.933	rs9923231	ENSG00000232748.3	RP11-196G11.6	4.68	3.68e-06	0.000415	0.25	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31096368	chr16:31056460~31062803:+
THCA	cis	rs172166	0.516	rs1225710	ENSG00000273712.1	RP5-874C20.7	-4.68	3.68e-06	0.000415	-0.23	-0.21	Cardiac Troponin-T levels;	chr6:28132862	chr6:28315613~28315883:-
THCA	cis	rs9467773	0.62	rs6925087	ENSG00000124549.13	BTN2A3P	4.68	3.68e-06	0.000415	0.19	0.21	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs4368798	ENSG00000124549.13	BTN2A3P	4.68	3.68e-06	0.000415	0.19	0.21	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26421391~26432383:+
THCA	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	4.68	3.68e-06	0.000415	0.27	0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
THCA	cis	rs2762353	0.524	rs9467596	ENSG00000272462.2	U91328.19	4.68	3.68e-06	0.000415	0.17	0.21	Blood metabolite levels;	chr6:25782794	chr6:25992662~26001775:+
THCA	cis	rs3820928	0.874	rs4423583	ENSG00000212391.1	SNORA48	4.68	3.69e-06	0.000415	0.23	0.21	Pulmonary function;	chr2:227010241	chr2:226968989~226969122:-
THCA	cis	rs4886920	0.672	rs11852322	ENSG00000260776.4	RP11-114H24.2	4.68	3.69e-06	0.000415	0.26	0.21	Neuroticism;	chr15:77829145	chr15:77914217~77926846:-
THCA	cis	rs9307551	0.697	rs7356151	ENSG00000250334.4	LINC00989	-4.68	3.69e-06	0.000416	-0.26	-0.21	Refractive error;	chr4:79539532	chr4:79492416~79576460:+
THCA	cis	rs9925964	0.687	rs12917722	ENSG00000232748.3	RP11-196G11.6	4.68	3.69e-06	0.000416	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30937076	chr16:31056460~31062803:+
THCA	cis	rs11640436	0.518	rs7192818	ENSG00000260922.1	RP11-538I12.3	-4.68	3.69e-06	0.000416	-0.25	-0.21	Lobe attachment (rater-scored or self-reported);	chr16:77266005	chr16:77234877~77290934:+
THCA	cis	rs6517329	0.509	rs2105749	ENSG00000236830.5	CBR3-AS1	-4.68	3.69e-06	0.000416	-0.2	-0.21	Schizophrenia;	chr21:36136716	chr21:36131767~36175815:-
THCA	cis	rs7618915	0.501	rs2336149	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.69e-06	0.000416	-0.23	-0.21	Bipolar disorder;	chr3:52658108	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs7611731	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.69e-06	0.000416	-0.23	-0.21	Bipolar disorder;	chr3:52658705	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs6804145	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.69e-06	0.000416	-0.23	-0.21	Bipolar disorder;	chr3:52660182	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs34157897	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.69e-06	0.000416	-0.23	-0.21	Bipolar disorder;	chr3:52682921	chr3:52239258~52241097:+
THCA	cis	rs736408	0.507	rs6445531	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.69e-06	0.000416	-0.23	-0.21	Bipolar disorder;	chr3:52683266	chr3:52239258~52241097:+
THCA	cis	rs7637701	0.713	rs9818780	ENSG00000240875.4	LINC00886	-4.68	3.69e-06	0.000416	-0.16	-0.21	Breast cancer;	chr3:156774969	chr3:156747346~156817062:-
THCA	cis	rs7637701	0.713	rs9878566	ENSG00000240875.4	LINC00886	-4.68	3.69e-06	0.000416	-0.16	-0.21	Breast cancer;	chr3:156775424	chr3:156747346~156817062:-
THCA	cis	rs58605417	0.566	rs55674305	ENSG00000253553.4	RP11-586K2.1	4.68	3.69e-06	0.000416	0.22	0.21	Schizophrenia;	chr8:88423639	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.566	rs56084092	ENSG00000253553.4	RP11-586K2.1	4.68	3.69e-06	0.000416	0.22	0.21	Schizophrenia;	chr8:88423648	chr8:88326836~88737134:+
THCA	cis	rs7617773	0.78	rs34523942	ENSG00000199476.1	Y_RNA	-4.68	3.69e-06	0.000416	-0.27	-0.21	Coronary artery disease;	chr3:48301179	chr3:48288587~48288694:+
THCA	cis	rs2303759	0.507	rs35042238	ENSG00000268686.1	AC010524.2	-4.68	3.69e-06	0.000416	-0.39	-0.21	Multiple sclerosis;	chr19:49369684	chr19:49368705~49388081:-
THCA	cis	rs6490294	0.528	rs12579336	ENSG00000226469.1	ADAM1B	4.68	3.69e-06	0.000416	0.35	0.21	Mean platelet volume;	chr12:112177734	chr12:111927018~111929017:+
THCA	cis	rs1395	0.925	rs2580754	ENSG00000234072.1	AC074117.10	-4.68	3.69e-06	0.000416	-0.17	-0.21	Blood metabolite levels;	chr2:27175328	chr2:27356246~27367622:+
THCA	cis	rs75504410	0.649	rs73232901	ENSG00000231160.8	KLF3-AS1	-4.68	3.69e-06	0.000416	-0.2	-0.21	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38692303	chr4:38612701~38664883:-
THCA	cis	rs75504410	0.649	rs3821998	ENSG00000231160.8	KLF3-AS1	-4.68	3.69e-06	0.000416	-0.2	-0.21	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38692945	chr4:38612701~38664883:-
THCA	cis	rs7849973	0.595	rs7469568	ENSG00000234840.1	LINC01239	-4.68	3.69e-06	0.000416	-0.28	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22767768	chr9:22646200~22824213:+
THCA	cis	rs930395	0.514	rs6874167	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44916572	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs4866921	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44917035	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs6451783	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44918191	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs6871820	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44919455	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs7736092	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44920893	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs10941687	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44921081	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs7708506	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44922602	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs7708686	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44922736	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs13153556	ENSG00000272335.1	RP11-53O19.3	4.68	3.7e-06	0.000416	0.18	0.21	Breast cancer;	chr5:44927999	chr5:44826076~44828592:+
THCA	cis	rs240993	0.812	rs4945881	ENSG00000271789.1	RP5-1112D6.7	4.68	3.7e-06	0.000417	0.25	0.21	Inflammatory skin disease;Psoriasis;	chr6:111470260	chr6:111297126~111298510:+
THCA	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-4.68	3.7e-06	0.000417	-0.3	-0.21	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
THCA	cis	rs2243480	0.522	rs431168	ENSG00000229886.1	RP5-1132H15.3	4.68	3.7e-06	0.000417	0.4	0.21	Diabetic kidney disease;	chr7:66046617	chr7:66025126~66031544:-
THCA	cis	rs3820928	0.904	rs60906902	ENSG00000212391.1	SNORA48	-4.68	3.7e-06	0.000417	-0.24	-0.21	Pulmonary function;	chr2:226895318	chr2:226968989~226969122:-
THCA	cis	rs4852324	0.536	rs6721042	ENSG00000257800.1	FNBP1P1	4.68	3.7e-06	0.000417	0.35	0.21	Systemic lupus erythematosus;	chr2:73990156	chr2:74120680~74123218:+
THCA	cis	rs1048886	0.938	rs79492893	ENSG00000271967.1	RP11-134K13.4	-4.68	3.7e-06	0.000417	-0.22	-0.21	Type 2 diabetes;	chr6:70399410	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs73474910	ENSG00000271967.1	RP11-134K13.4	-4.68	3.7e-06	0.000417	-0.22	-0.21	Type 2 diabetes;	chr6:70399683	chr6:70596438~70596980:+
THCA	cis	rs9875589	0.533	rs12490233	ENSG00000228242.5	AC093495.4	4.68	3.7e-06	0.000417	0.12	0.21	Ovarian reserve;	chr3:13935867	chr3:14144637~14165978:+
THCA	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	4.68	3.7e-06	0.000417	0.26	0.21	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
THCA	cis	rs875971	0.545	rs313830	ENSG00000164669.11	INTS4P1	4.68	3.7e-06	0.000417	0.31	0.21	Aortic root size;	chr7:66086944	chr7:65141225~65234216:+
THCA	cis	rs7520050	0.966	rs4073846	ENSG00000234329.1	RP11-767N6.2	4.68	3.7e-06	0.000417	0.19	0.21	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45651039~45651826:-
THCA	cis	rs12612619	0.732	rs11680032	ENSG00000229122.1	AGBL5-IT1	4.68	3.7e-06	0.000417	0.15	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26975280	chr2:27061038~27061815:+
THCA	cis	rs853679	1	rs853685	ENSG00000220721.1	OR1F12	4.68	3.7e-06	0.000417	0.33	0.21	Depression;	chr6:28321008	chr6:28073316~28074233:+
THCA	cis	rs4803480	0.554	rs12462194	ENSG00000267107.5	PCAT19	4.68	3.7e-06	0.000417	0.21	0.21	Schizophrenia;	chr19:41565931	chr19:41454169~41500649:-
THCA	cis	rs10461617	0.541	rs7715822	ENSG00000271828.1	CTD-2310F14.1	4.68	3.7e-06	0.000417	0.4	0.21	Type 2 diabetes;	chr5:56747773	chr5:56927874~56929573:+
THCA	cis	rs7809615	0.901	rs10273424	ENSG00000244219.5	GS1-259H13.2	-4.68	3.7e-06	0.000417	-0.39	-0.21	Blood metabolite ratios;	chr7:99598450	chr7:99598066~99610813:+
THCA	cis	rs11846409	0.932	rs28617526	ENSG00000211974.3	IGHV2-70	-4.68	3.7e-06	0.000417	-0.2	-0.21	Rheumatic heart disease;	chr14:106637322	chr14:106723574~106724093:-
THCA	cis	rs9487094	0.626	rs3799845	ENSG00000223537.2	RP5-919F19.5	-4.68	3.71e-06	0.000417	-0.21	-0.21	Height;	chr6:109706514	chr6:109487906~109506800:+
THCA	cis	rs453301	0.624	rs330049	ENSG00000253981.4	ALG1L13P	4.68	3.71e-06	0.000417	0.2	0.21	Joint mobility (Beighton score);	chr8:9229789	chr8:8236003~8244667:-
THCA	cis	rs11763147	1	rs11763147	ENSG00000272831.1	RP11-792A8.4	-4.68	3.71e-06	0.000418	-0.13	-0.21	Corneal structure;	chr7:65861834	chr7:66739829~66740385:-
THCA	cis	rs795484	0.89	rs61945179	ENSG00000275409.1	RP11-131L12.4	-4.68	3.71e-06	0.000418	-0.18	-0.21	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118215171	chr12:118430147~118430699:+
THCA	cis	rs4819052	0.851	rs2838866	ENSG00000273796.1	LL21NC02-21A1.1	-4.68	3.71e-06	0.000418	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45403809~45404369:-
THCA	cis	rs11992162	0.597	rs7016320	ENSG00000206014.6	OR7E161P	4.68	3.71e-06	0.000418	0.25	0.21	Monocyte count;	chr8:11923543	chr8:11928597~11929563:-
THCA	cis	rs10483853	0.747	rs17126867	ENSG00000258695.2	RP3-414A15.2	-4.68	3.71e-06	0.000418	-0.29	-0.21	Coronary artery calcification;	chr14:73324563	chr14:73522878~73530610:+
THCA	cis	rs13113518	1	rs55699500	ENSG00000273257.1	RP11-177J6.1	4.68	3.71e-06	0.000418	0.28	0.21	Height;	chr4:55540912	chr4:55387949~55388271:+
THCA	cis	rs2439831	0.85	rs558656	ENSG00000205771.5	CATSPER2P1	-4.68	3.71e-06	0.000418	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43431316	chr15:43726918~43747094:-
THCA	cis	rs8002861	0.641	rs4942252	ENSG00000274001.1	RP11-5G9.5	4.68	3.71e-06	0.000418	0.25	0.21	Leprosy;	chr13:43868903	chr13:43877715~43878163:-
THCA	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-4.68	3.71e-06	0.000418	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
THCA	cis	rs11118620	0.853	rs12037861	ENSG00000257551.1	HLX-AS1	4.68	3.71e-06	0.000418	0.29	0.21	Heart failure;	chr1:220864835	chr1:220832763~220880140:-
THCA	cis	rs4950322	0.57	rs6703892	ENSG00000180867.10	PDIA3P1	4.68	3.71e-06	0.000418	0.21	0.21	Protein quantitative trait loci;	chr1:147287627	chr1:147178113~147179622:+
THCA	cis	rs7829975	0.606	rs7819827	ENSG00000253981.4	ALG1L13P	-4.68	3.71e-06	0.000418	-0.2	-0.21	Mood instability;	chr8:8939545	chr8:8236003~8244667:-
THCA	cis	rs13287066	0.74	rs4744238	ENSG00000227603.1	RP11-165J3.6	4.68	3.71e-06	0.000418	0.22	0.21	Intelligence (multi-trait analysis);	chr9:93401702	chr9:93435332~93437121:-
THCA	cis	rs7202877	0.561	rs7202083	ENSG00000261783.1	RP11-252K23.2	-4.68	3.72e-06	0.000419	-0.44	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75349829	chr16:75379818~75381260:-
THCA	cis	rs2239547	0.522	rs2336162	ENSG00000242142.1	SERBP1P3	-4.68	3.72e-06	0.000419	-0.27	-0.21	Schizophrenia;	chr3:52917503	chr3:53064283~53065091:-
THCA	cis	rs12549025	0.53	rs11135740	ENSG00000253390.1	CTC-756D1.2	4.68	3.72e-06	0.000419	0.32	0.21	Reticulocyte fraction of red cells;	chr8:23510244	chr8:23458601~23484971:+
THCA	cis	rs6860806	0.507	rs274570	ENSG00000237714.1	P4HA2-AS1	-4.68	3.72e-06	0.000419	-0.28	-0.21	Breast cancer;	chr5:132377534	chr5:132184876~132192808:+
THCA	cis	rs7267979	0.903	rs6050482	ENSG00000277938.1	RP5-965G21.3	4.68	3.72e-06	0.000419	0.17	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.706	rs6037069	ENSG00000277938.1	RP5-965G21.3	4.68	3.72e-06	0.000419	0.17	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25229150~25231933:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000164669.11	INTS4P1	4.68	3.72e-06	0.000419	0.26	0.21	Aortic root size;	chr7:66039646	chr7:65141225~65234216:+
THCA	cis	rs2447820	0.52	rs12055325	ENSG00000249996.1	RP11-359P5.1	4.68	3.72e-06	0.000419	0.25	0.21	Migraine;	chr5:123033043	chr5:123036271~123054667:+
THCA	cis	rs2286503	1	rs2286498	ENSG00000226329.2	AC005682.6	-4.68	3.72e-06	0.000419	-0.25	-0.21	Fibrinogen;	chr7:22817885	chr7:22863874~22881350:-
THCA	cis	rs6860806	0.507	rs270601	ENSG00000237714.1	P4HA2-AS1	4.68	3.72e-06	0.000419	0.28	0.21	Breast cancer;	chr5:132321304	chr5:132184876~132192808:+
THCA	cis	rs12291225	0.585	rs34171876	ENSG00000251991.1	RNU7-49P	4.68	3.72e-06	0.000419	0.24	0.21	Sense of smell;	chr11:14332411	chr11:14478892~14478953:+
THCA	cis	rs6728642	0.831	rs10496325	ENSG00000230606.9	AC159540.1	-4.68	3.72e-06	0.000419	-0.27	-0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97017592	chr2:97416165~97433527:-
THCA	cis	rs73198271	0.653	rs10087742	ENSG00000253893.2	FAM85B	4.68	3.72e-06	0.000419	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8167819~8226614:-
THCA	cis	rs17695224	1	rs28873836	ENSG00000275055.1	CTC-471J1.11	-4.68	3.72e-06	0.000419	-0.17	-0.21	HDL cholesterol;HDL cholesterol levels;	chr19:51811402	chr19:52049007~52049754:+
THCA	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	4.68	3.72e-06	0.000419	0.24	0.21	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
THCA	cis	rs9880211	1	rs4038586	ENSG00000239213.4	NCK1-AS1	4.68	3.72e-06	0.000419	0.23	0.21	Height;Body mass index;	chr3:136644449	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs6767889	ENSG00000239213.4	NCK1-AS1	4.68	3.72e-06	0.000419	0.23	0.21	Height;Body mass index;	chr3:136646613	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.898	rs35304385	ENSG00000239213.4	NCK1-AS1	4.68	3.72e-06	0.000419	0.23	0.21	Height;Body mass index;	chr3:136667411	chr3:136841726~136862054:-
THCA	cis	rs6012564	1	rs3091497	ENSG00000227431.4	CSE1L-AS1	-4.68	3.72e-06	0.000419	-0.26	-0.21	Anger;	chr20:49028890	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.858	rs3091427	ENSG00000227431.4	CSE1L-AS1	-4.68	3.72e-06	0.000419	-0.26	-0.21	Anger;	chr20:49046845	chr20:49040463~49046044:-
THCA	cis	rs17095355	1	rs57440982	ENSG00000203876.8	ADD3-AS1	-4.68	3.73e-06	0.00042	-0.23	-0.21	Biliary atresia;	chr10:109976014	chr10:109940104~110008381:-
THCA	cis	rs8062405	0.755	rs17707300	ENSG00000261766.1	RP11-22P6.2	-4.68	3.73e-06	0.00042	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28862166~28863340:-
THCA	cis	rs2153535	0.585	rs2208540	ENSG00000230939.1	RP11-314C16.1	-4.68	3.73e-06	0.00042	-0.22	-0.21	Motion sickness;	chr6:8627147	chr6:8784178~8785445:+
THCA	cis	rs2447820	0.588	rs11241669	ENSG00000249996.1	RP11-359P5.1	-4.68	3.73e-06	0.00042	-0.25	-0.21	Migraine;	chr5:123033068	chr5:123036271~123054667:+
THCA	cis	rs8054556	0.692	rs7201384	ENSG00000183604.13	SMG1P5	-4.68	3.73e-06	0.00042	-0.2	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29913584	chr16:30267553~30335374:-
THCA	cis	rs2742234	0.59	rs2503848	ENSG00000273008.1	RP11-351D16.3	-4.68	3.73e-06	0.00042	-0.2	-0.21	Hirschsprung disease;	chr10:43177337	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.59	rs2435383	ENSG00000273008.1	RP11-351D16.3	-4.68	3.73e-06	0.00042	-0.2	-0.21	Hirschsprung disease;	chr10:43180223	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.541	rs1059484	ENSG00000273008.1	RP11-351D16.3	-4.68	3.73e-06	0.00042	-0.2	-0.21	Hirschsprung disease;	chr10:43184352	chr10:43136824~43138334:-
THCA	cis	rs6988985	0.56	rs5301	ENSG00000247317.3	RP11-273G15.2	-4.68	3.73e-06	0.00042	-0.23	-0.21	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142873857	chr8:142981738~143018437:-
THCA	cis	rs4074961	0.527	rs10908356	ENSG00000233621.1	LINC01137	-4.68	3.73e-06	0.00042	-0.22	-0.21	Axial length;	chr1:37572787	chr1:37454879~37474411:-
THCA	cis	rs8028182	0.636	rs4886707	ENSG00000260269.4	CTD-2323K18.1	-4.68	3.73e-06	0.00042	-0.32	-0.21	Sudden cardiac arrest;	chr15:75463126	chr15:75527150~75601205:-
THCA	cis	rs9875589	0.509	rs9824910	ENSG00000228242.5	AC093495.4	4.68	3.73e-06	0.00042	0.12	0.21	Ovarian reserve;	chr3:13998636	chr3:14144637~14165978:+
THCA	cis	rs12681288	0.862	rs2600487	ENSG00000260721.1	AF067845.1	4.68	3.73e-06	0.00042	0.26	0.21	Schizophrenia;	chr8:1066903	chr8:1368642~1369833:-
THCA	cis	rs4648045	0.756	rs72696114	ENSG00000246560.2	RP11-10L12.4	4.68	3.73e-06	0.00042	0.27	0.21	Lymphocyte percentage of white cells;	chr4:102495959	chr4:102828055~102844075:+
THCA	cis	rs10090774	0.71	rs13274713	ENSG00000280303.2	ERICD	-4.68	3.74e-06	0.000421	-0.2	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655098	chr8:140636281~140638283:+
THCA	cis	rs8062405	1	rs1987472	ENSG00000261766.1	RP11-22P6.2	-4.68	3.74e-06	0.000421	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28862166~28863340:-
THCA	cis	rs3820928	1	rs1346618	ENSG00000212391.1	SNORA48	4.68	3.74e-06	0.000421	0.24	0.21	Pulmonary function;	chr2:226907272	chr2:226968989~226969122:-
THCA	cis	rs6840360	0.87	rs1372978	ENSG00000270265.1	RP11-731D1.4	-4.68	3.74e-06	0.000421	-0.2	-0.21	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151333775~151353224:-
THCA	cis	rs6430538	0.646	rs6734820	ENSG00000224043.6	CCNT2-AS1	-4.68	3.74e-06	0.000421	-0.22	-0.21	Parkinson's disease;	chr2:134779238	chr2:134735464~134918710:-
THCA	cis	rs964611	0.882	rs11629707	ENSG00000259488.2	RP11-154J22.1	4.68	3.74e-06	0.000421	0.2	0.21	Metabolite levels (Pyroglutamine);	chr15:48348148	chr15:48312353~48331856:-
THCA	cis	rs11175834	0.655	rs12311233	ENSG00000213344.2	PCNPP3	-4.68	3.74e-06	0.000421	-0.35	-0.21	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65607333	chr12:65645992~65646462:-
THCA	cis	rs1050631	0.527	rs592261	ENSG00000260552.1	RP11-49I11.1	4.68	3.74e-06	0.000421	0.27	0.21	Esophageal squamous cell cancer (length of survival);	chr18:36172281	chr18:36179996~36187448:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	4.68	3.74e-06	0.000421	0.26	0.21	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
THCA	cis	rs12541437	0.958	rs2921729	ENSG00000253327.2	RAD21-AS1	4.68	3.74e-06	0.000421	0.24	0.21	Gut microbiome composition (winter);	chr8:116924606	chr8:116874424~116876868:+
THCA	cis	rs8028182	0.636	rs12909863	ENSG00000260269.4	CTD-2323K18.1	-4.68	3.74e-06	0.000421	-0.31	-0.21	Sudden cardiac arrest;	chr15:75533481	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs12708520	ENSG00000260269.4	CTD-2323K18.1	-4.68	3.74e-06	0.000421	-0.31	-0.21	Sudden cardiac arrest;	chr15:75538198	chr15:75527150~75601205:-
THCA	cis	rs4934494	0.768	rs34663515	ENSG00000240996.1	RP11-80H5.7	-4.68	3.74e-06	0.000421	-0.24	-0.21	Red blood cell count;	chr10:89632786	chr10:89694295~89697928:-
THCA	cis	rs4722166	0.63	rs13311155	ENSG00000225541.1	AC002480.5	-4.68	3.74e-06	0.000421	-0.27	-0.21	Lung cancer;	chr7:22750170	chr7:22571607~22661792:-
THCA	cis	rs4722166	0.63	rs13311199	ENSG00000225541.1	AC002480.5	-4.68	3.74e-06	0.000421	-0.27	-0.21	Lung cancer;	chr7:22750174	chr7:22571607~22661792:-
THCA	cis	rs3892630	1	rs3892630	ENSG00000267567.1	CTD-2538C1.3	-4.68	3.74e-06	0.000421	-0.32	-0.21	Red blood cell traits;	chr19:32690578	chr19:32718298~32719595:-
THCA	cis	rs6496044	0.507	rs1471455	ENSG00000259295.5	CSPG4P12	-4.68	3.74e-06	0.000421	-0.28	-0.21	Interstitial lung disease;	chr15:85611496	chr15:85191438~85213905:+
THCA	cis	rs7551222	0.714	rs930947	ENSG00000240219.1	RP11-430C7.5	4.68	3.74e-06	0.000421	0.22	0.21	Schizophrenia;	chr1:204572069	chr1:204626775~204629712:+
THCA	cis	rs3002131	0.604	rs2936038	ENSG00000272750.1	RP11-378J18.8	4.68	3.74e-06	0.000421	0.32	0.21	Interleukin-10 levels;	chr1:222572449	chr1:222658867~222661512:-
THCA	cis	rs7141336	0.77	rs36039295	ENSG00000258884.1	CTD-3035D6.2	4.68	3.74e-06	0.000421	0.28	0.21	Anxiety disorder;	chr14:90826986	chr14:90822365~90828128:-
THCA	cis	rs7141336	0.77	rs36118153	ENSG00000258884.1	CTD-3035D6.2	4.68	3.74e-06	0.000421	0.28	0.21	Anxiety disorder;	chr14:90826989	chr14:90822365~90828128:-
THCA	cis	rs2412819	0.571	rs678084	ENSG00000166763.7	STRCP1	-4.68	3.74e-06	0.000421	-0.28	-0.21	Lung cancer;	chr15:43828361	chr15:43699488~43718184:-
THCA	cis	rs17404153	0.599	rs10490863	ENSG00000248724.5	NPHP3-AS1	-4.68	3.74e-06	0.000421	-0.31	-0.21	LDL cholesterol;HDL cholesterol;	chr3:132412118	chr3:132721750~132874223:+
THCA	cis	rs1707322	1	rs10890353	ENSG00000281133.1	AL355480.3	-4.68	3.74e-06	0.000421	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45580892~45580996:-
THCA	cis	rs4713118	0.629	rs203887	ENSG00000272009.1	RP1-313I6.12	-4.68	3.75e-06	0.000422	-0.26	-0.21	Parkinson's disease;	chr6:28053491	chr6:28078792~28081130:-
THCA	cis	rs9487094	0.67	rs729888	ENSG00000223537.2	RP5-919F19.5	4.68	3.75e-06	0.000422	0.22	0.21	Height;	chr6:109636120	chr6:109487906~109506800:+
THCA	cis	rs8028182	0.636	rs8034317	ENSG00000260269.4	CTD-2323K18.1	-4.68	3.75e-06	0.000422	-0.31	-0.21	Sudden cardiac arrest;	chr15:75472002	chr15:75527150~75601205:-
THCA	cis	rs9634489	0.502	rs4456362	ENSG00000247400.3	DNAJC3-AS1	4.68	3.75e-06	0.000422	0.14	0.21	Body mass index;	chr13:96454604	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.502	rs10508028	ENSG00000247400.3	DNAJC3-AS1	4.68	3.75e-06	0.000422	0.14	0.21	Body mass index;	chr13:96456986	chr13:95648733~95676925:-
THCA	cis	rs30380	1	rs30378	ENSG00000272109.1	CTD-2260A17.3	-4.68	3.75e-06	0.000422	-0.26	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96804353~96806105:+
THCA	cis	rs6012564	0.826	rs34778847	ENSG00000230758.1	SNAP23P	4.68	3.75e-06	0.000422	0.25	0.21	Anger;	chr20:49121421	chr20:49038357~49038602:-
THCA	cis	rs2732480	0.577	rs2732481	ENSG00000273765.1	RP11-370I10.11	4.68	3.75e-06	0.000422	0.22	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.557	rs2732484	ENSG00000273765.1	RP11-370I10.11	4.68	3.75e-06	0.000422	0.22	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.577	rs2732486	ENSG00000273765.1	RP11-370I10.11	4.68	3.75e-06	0.000422	0.22	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.517	rs2634676	ENSG00000273765.1	RP11-370I10.11	4.68	3.75e-06	0.000422	0.22	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48360920~48361377:+
THCA	cis	rs7432375	0.61	rs56163507	ENSG00000239213.4	NCK1-AS1	4.68	3.75e-06	0.000422	0.18	0.21	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136797214	chr3:136841726~136862054:-
THCA	cis	rs1003719	0.715	rs2835657	ENSG00000230366.8	DSCR9	4.68	3.75e-06	0.000422	0.22	0.21	Eye color traits;	chr21:37192763	chr21:37208503~37221736:+
THCA	cis	rs1876905	0.539	rs240962	ENSG00000255389.1	C6orf3	-4.68	3.75e-06	0.000422	-0.26	-0.21	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111599875~111602295:+
THCA	cis	rs931127	0.719	rs2170082	ENSG00000214659.4	KRT8P26	4.68	3.75e-06	0.000422	0.19	0.21	Systemic lupus erythematosus;	chr11:65687324	chr11:65726939~65728214:+
THCA	cis	rs4927850	0.501	rs9881504	ENSG00000242086.7	LINC00969	4.68	3.75e-06	0.000422	0.21	0.21	Pancreatic cancer;	chr3:195929743	chr3:195658062~195739964:+
THCA	cis	rs4434138	0.683	rs13063160	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.75e-06	0.000423	-0.23	-0.21	Intelligence (multi-trait analysis);	chr3:52568258	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs6786043	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.75e-06	0.000423	-0.23	-0.21	Electroencephalogram traits;	chr3:52570845	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs7625743	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.75e-06	0.000423	-0.23	-0.21	Electroencephalogram traits;	chr3:52572350	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs6805156	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.75e-06	0.000423	-0.23	-0.21	Electroencephalogram traits;	chr3:52575346	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs7652191	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.75e-06	0.000423	-0.23	-0.21	Electroencephalogram traits;	chr3:52576399	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs4687629	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.75e-06	0.000423	-0.23	-0.21	Electroencephalogram traits;	chr3:52581211	chr3:52239258~52241097:+
THCA	cis	rs7614311	0.636	rs73130576	ENSG00000271843.1	RP11-245J9.5	-4.68	3.75e-06	0.000423	-0.37	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63905199	chr3:64008082~64008692:-
THCA	cis	rs375066	0.935	rs407731	ENSG00000278917.1	RP11-15A1.4	4.68	3.76e-06	0.000423	0.18	0.21	Breast cancer;	chr19:43913925	chr19:43891233~43895411:+
THCA	cis	rs4787951	0.826	rs2074572	ENSG00000259940.2	CTD-3203P2.1	-4.68	3.76e-06	0.000423	-0.24	-0.21	Eosinophil percentage of white cells;	chr16:27345038	chr16:27213308~27214993:-
THCA	cis	rs10510102	0.872	rs12244199	ENSG00000226864.1	ATE1-AS1	4.68	3.76e-06	0.000423	0.34	0.21	Breast cancer;	chr10:121965117	chr10:121928312~121951965:+
THCA	cis	rs2239547	0.522	rs9844736	ENSG00000242142.1	SERBP1P3	-4.68	3.76e-06	0.000423	-0.27	-0.21	Schizophrenia;	chr3:52897955	chr3:53064283~53065091:-
THCA	cis	rs703842	1	rs10747783	ENSG00000270039.1	RP11-571M6.17	-4.68	3.76e-06	0.000423	-0.25	-0.21	Multiple sclerosis;	chr12:57782831	chr12:57803838~57804415:+
THCA	cis	rs703842	0.964	rs10431552	ENSG00000270039.1	RP11-571M6.17	-4.68	3.76e-06	0.000423	-0.25	-0.21	Multiple sclerosis;	chr12:57784365	chr12:57803838~57804415:+
THCA	cis	rs1003719	0.715	rs2835658	ENSG00000230366.8	DSCR9	4.68	3.76e-06	0.000423	0.22	0.21	Eye color traits;	chr21:37192900	chr21:37208503~37221736:+
THCA	cis	rs6860806	0.507	rs274570	ENSG00000224431.1	AC063976.7	-4.68	3.76e-06	0.000423	-0.19	-0.21	Breast cancer;	chr5:132377534	chr5:132199456~132203487:+
THCA	cis	rs2287838	1	rs11667192	ENSG00000267289.1	CTD-2623N2.11	-4.68	3.76e-06	0.000423	-0.24	-0.21	Sleep duration;	chr19:9865294	chr19:9834079~9835013:-
THCA	cis	rs763121	0.853	rs5750668	ENSG00000273076.1	RP3-508I15.22	4.68	3.76e-06	0.000423	0.21	0.21	Menopause (age at onset);	chr22:38683959	chr22:38743495~38743910:+
THCA	cis	rs172166	0.61	rs156737	ENSG00000273712.1	RP5-874C20.7	4.68	3.76e-06	0.000423	0.23	0.21	Cardiac Troponin-T levels;	chr6:27927435	chr6:28315613~28315883:-
THCA	cis	rs8077577	0.708	rs11867855	ENSG00000273018.4	CTD-2303H24.2	-4.68	3.76e-06	0.000423	-0.31	-0.21	Obesity-related traits;	chr17:18359270	chr17:18511221~18551705:-
THCA	cis	rs1538970	0.816	rs868351	ENSG00000234329.1	RP11-767N6.2	4.68	3.76e-06	0.000423	0.21	0.21	Platelet count;	chr1:45544146	chr1:45651039~45651826:-
THCA	cis	rs3750082	0.889	rs6462432	ENSG00000231952.3	DPY19L1P2	4.68	3.76e-06	0.000423	0.27	0.21	Glomerular filtration rate (creatinine);	chr7:32895912	chr7:32812757~32838570:+
THCA	cis	rs8105895	0.799	rs10426159	ENSG00000269345.1	VN1R85P	4.68	3.76e-06	0.000423	0.28	0.21	Body mass index (change over time);	chr19:22084522	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.932	rs28600030	ENSG00000269345.1	VN1R85P	4.68	3.76e-06	0.000423	0.28	0.21	Body mass index (change over time);	chr19:22085641	chr19:22174766~22175191:-
THCA	cis	rs2239547	0.618	rs1573815	ENSG00000242142.1	SERBP1P3	-4.68	3.76e-06	0.000423	-0.27	-0.21	Schizophrenia;	chr3:52836116	chr3:53064283~53065091:-
THCA	cis	rs10760158	0.832	rs10739593	ENSG00000235865.2	GSN-AS1	4.68	3.76e-06	0.000423	0.18	0.21	Pulse pressure;	chr9:121258747	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.865	rs10760165	ENSG00000235865.2	GSN-AS1	4.68	3.76e-06	0.000423	0.18	0.21	Pulse pressure;	chr9:121258976	chr9:121280768~121285530:-
THCA	cis	rs375066	0.586	rs2356401	ENSG00000267058.1	RP11-15A1.3	-4.68	3.76e-06	0.000423	-0.19	-0.21	Breast cancer;	chr19:43817697	chr19:43891804~43901805:-
THCA	cis	rs9652601	0.691	rs3893661	ENSG00000274038.1	RP11-66H6.4	-4.68	3.76e-06	0.000424	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11100023	chr16:11056556~11057034:+
THCA	cis	rs6921919	0.515	rs1339898	ENSG00000273712.1	RP5-874C20.7	4.68	3.76e-06	0.000424	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28315613~28315883:-
THCA	cis	rs7267979	0.903	rs2474766	ENSG00000274973.1	RP13-401N8.7	-4.68	3.76e-06	0.000424	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25845497~25845862:+
THCA	cis	rs4578769	0.55	rs12966925	ENSG00000265939.1	UBE2CP2	4.68	3.76e-06	0.000424	0.24	0.21	Eosinophil percentage of white cells;	chr18:22953734	chr18:22900486~22900995:-
THCA	cis	rs1336900	0.641	rs6587756	ENSG00000231073.1	RP11-316M1.3	-4.68	3.77e-06	0.000424	-0.26	-0.21	Blood protein levels;	chr1:150574389	chr1:150973123~150975534:+
THCA	cis	rs1336900	0.637	rs35967040	ENSG00000231073.1	RP11-316M1.3	-4.68	3.77e-06	0.000424	-0.26	-0.21	Blood protein levels;	chr1:150583112	chr1:150973123~150975534:+
THCA	cis	rs12911832	1	rs12911832	ENSG00000245975.2	RP11-30K9.6	4.68	3.77e-06	0.000424	0.21	0.21	Schizophrenia;	chr15:58693705	chr15:58768072~58770974:-
THCA	cis	rs4144027	0.904	rs55696130	ENSG00000269940.1	RP11-73M18.7	-4.68	3.77e-06	0.000424	-0.22	-0.21	Blood metabolite levels;	chr14:103875527	chr14:103694560~103695170:+
THCA	cis	rs889398	0.869	rs862320	ENSG00000226232.7	RP11-419C5.2	4.68	3.77e-06	0.000424	0.21	0.21	Body mass index;	chr16:69617963	chr16:69976388~69996188:-
THCA	cis	rs7614311	0.731	rs73117087	ENSG00000271843.1	RP11-245J9.5	-4.68	3.77e-06	0.000424	-0.38	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63963020	chr3:64008082~64008692:-
THCA	cis	rs12476592	0.516	rs11883730	ENSG00000242412.1	DBIL5P2	-4.68	3.77e-06	0.000424	-0.27	-0.21	Childhood ear infection;	chr2:63365095	chr2:63117851~63119542:-
THCA	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-4.68	3.77e-06	0.000424	-0.24	-0.21	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
THCA	cis	rs7267979	0.932	rs6115215	ENSG00000274973.1	RP13-401N8.7	-4.68	3.77e-06	0.000424	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25845497~25845862:+
THCA	cis	rs8020095	0.571	rs8003929	ENSG00000258561.1	RP11-72M17.1	-4.68	3.77e-06	0.000424	-0.28	-0.21	Depression (quantitative trait);	chr14:67066556	chr14:66212810~66509394:-
THCA	cis	rs6012564	1	rs2869716	ENSG00000230758.1	SNAP23P	4.68	3.77e-06	0.000424	0.26	0.21	Anger;	chr20:49162803	chr20:49038357~49038602:-
THCA	cis	rs11671005	0.735	rs45617039	ENSG00000268912.1	CTD-2619J13.17	-4.68	3.77e-06	0.000424	-0.2	-0.21	Mean platelet volume;	chr19:58439729	chr19:58428632~58431148:-
THCA	cis	rs763121	0.819	rs5757237	ENSG00000235209.1	CTA-150C2.13	4.68	3.77e-06	0.000425	0.28	0.21	Menopause (age at onset);	chr22:38677830	chr22:38921227~38924708:+
THCA	cis	rs6477918	0.55	rs10981402	ENSG00000230185.4	C9orf147	-4.68	3.77e-06	0.000425	-0.23	-0.21	Obstetric antiphospholipid syndrome;	chr9:112428367	chr9:112433816~112487204:-
THCA	cis	rs970548	0.954	rs11239549	ENSG00000230869.1	CTGLF10P	4.68	3.77e-06	0.000425	0.26	0.21	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45523383	chr10:45678692~45700532:+
THCA	cis	rs4443100	0.874	rs5996454	ENSG00000230701.2	FBXW4P1	4.68	3.77e-06	0.000425	0.24	0.21	Serum parathyroid hormone levels;	chr22:23037029	chr22:23262767~23265005:+
THCA	cis	rs7980687	0.628	rs2102949	ENSG00000256092.2	RP13-942N8.1	4.68	3.78e-06	0.000425	0.16	0.21	Head circumference (infant);Educational attainment;Height;	chr12:123192216	chr12:123363868~123366113:+
THCA	cis	rs9300255	0.596	rs4460848	ENSG00000256092.2	RP13-942N8.1	4.68	3.78e-06	0.000425	0.16	0.21	Neutrophil percentage of white cells;	chr12:123193263	chr12:123363868~123366113:+
THCA	cis	rs10483853	0.767	rs60274183	ENSG00000258695.2	RP3-414A15.2	-4.68	3.78e-06	0.000425	-0.3	-0.21	Coronary artery calcification;	chr14:73445698	chr14:73522878~73530610:+
THCA	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	4.68	3.78e-06	0.000425	0.27	0.21	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
THCA	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	4.68	3.78e-06	0.000425	0.27	0.21	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
THCA	cis	rs972578	0.791	rs3091382	ENSG00000274717.1	RP1-47A17.1	-4.68	3.78e-06	0.000425	-0.22	-0.21	Mean platelet volume;	chr22:42895089	chr22:42791814~42794313:-
THCA	cis	rs34467563	0.626	rs2678336	ENSG00000253105.4	KB-1448A5.1	4.68	3.78e-06	0.000425	0.25	0.21	Lobe attachment (rater-scored or self-reported);	chr8:96367211	chr8:96371865~96387438:-
THCA	cis	rs526231	0.786	rs171695	ENSG00000175749.11	EIF3KP1	4.68	3.78e-06	0.000425	0.27	0.21	Primary biliary cholangitis;	chr5:103296339	chr5:103032376~103033031:+
THCA	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	4.68	3.78e-06	0.000425	0.18	0.21	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	4.68	3.78e-06	0.000425	0.18	0.21	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
THCA	cis	rs11671005	0.61	rs3816329	ENSG00000269600.1	AC016629.3	-4.68	3.78e-06	0.000425	-0.3	-0.21	Mean platelet volume;	chr19:58547326	chr19:58593896~58599355:-
THCA	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-4.68	3.78e-06	0.000425	-0.24	-0.21	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
THCA	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	4.68	3.78e-06	0.000425	0.18	0.21	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
THCA	cis	rs4705952	0.775	rs72797340	ENSG00000233006.5	AC034220.3	-4.68	3.78e-06	0.000425	-0.2	-0.21	C-reactive protein levels;	chr5:132531873	chr5:132311285~132369916:-
THCA	cis	rs7772486	0.692	rs1577916	ENSG00000270638.1	RP3-466P17.1	-4.68	3.78e-06	0.000425	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.72	rs7752286	ENSG00000270638.1	RP3-466P17.1	-4.68	3.78e-06	0.000425	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145735570~145737218:+
THCA	cis	rs28386778	0.7	rs12449555	ENSG00000240280.5	TCAM1P	4.68	3.78e-06	0.000426	0.29	0.21	Prudent dietary pattern;	chr17:63926622	chr17:63849292~63864379:+
THCA	cis	rs8067545	0.611	rs2703795	ENSG00000270091.1	RP11-78O7.2	4.68	3.78e-06	0.000426	0.16	0.21	Schizophrenia;	chr17:20173828	chr17:19896590~19897287:-
THCA	cis	rs1552244	1	rs17032299	ENSG00000232901.1	CYCSP10	4.68	3.78e-06	0.000426	0.28	0.21	Alzheimer's disease;	chr3:10045954	chr3:10000647~10000940:-
THCA	cis	rs2749592	0.531	rs1208559	ENSG00000226578.1	RP11-258F22.1	4.68	3.78e-06	0.000426	0.25	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:37775371~37784131:-
THCA	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-4.68	3.78e-06	0.000426	-0.13	-0.21	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
THCA	cis	rs71636778	0.631	rs34924059	ENSG00000260063.1	RP5-968P14.2	-4.68	3.79e-06	0.000426	-0.29	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26832353	chr1:26692132~26694131:-
THCA	cis	rs9863	0.828	rs11057409	ENSG00000270061.1	RP11-214K3.19	4.68	3.79e-06	0.000426	0.28	0.21	White blood cell count;	chr12:123994784	chr12:123969990~123970344:-
THCA	cis	rs4650994	0.593	rs10753180	ENSG00000273384.1	RP5-1098D14.1	-4.68	3.79e-06	0.000426	-0.28	-0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178551518	chr1:178651706~178652282:+
THCA	cis	rs6088590	0.687	rs6088580	ENSG00000269202.1	RP4-614O4.12	-4.68	3.79e-06	0.000426	-0.18	-0.21	Coronary artery disease;	chr20:34697249	chr20:35201747~35203288:-
THCA	cis	rs6088590	0.813	rs1884668	ENSG00000269202.1	RP4-614O4.12	-4.68	3.79e-06	0.000426	-0.18	-0.21	Coronary artery disease;	chr20:34697710	chr20:35201747~35203288:-
THCA	cis	rs34929064	0.672	rs2961298	ENSG00000179428.2	AC073072.5	4.68	3.79e-06	0.000426	0.24	0.21	Major depression and alcohol dependence;	chr7:22668472	chr7:22725395~22727620:-
THCA	cis	rs7914558	0.646	rs7100709	ENSG00000236937.2	PTGES3P4	4.68	3.79e-06	0.000426	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102889972	chr10:102845595~102845950:+
THCA	cis	rs7267979	1	rs4815424	ENSG00000274973.1	RP13-401N8.7	4.68	3.79e-06	0.000426	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25845497~25845862:+
THCA	cis	rs9625935	0.957	rs5763634	ENSG00000279159.1	RP3-394A18.1	4.68	3.79e-06	0.000426	0.16	0.21	Tonsillectomy;	chr22:29954543	chr22:29978950~30028236:-
THCA	cis	rs375066	0.868	rs370190	ENSG00000278917.1	RP11-15A1.4	-4.68	3.79e-06	0.000426	-0.18	-0.21	Breast cancer;	chr19:43920102	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs413093	ENSG00000278917.1	RP11-15A1.4	-4.68	3.79e-06	0.000426	-0.18	-0.21	Breast cancer;	chr19:43922113	chr19:43891233~43895411:+
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000272831.1	RP11-792A8.4	4.68	3.79e-06	0.000426	0.13	0.21	Calcium levels;	chr7:65967580	chr7:66739829~66740385:-
THCA	cis	rs7010876	0.56	rs1112164	ENSG00000253553.4	RP11-586K2.1	4.68	3.79e-06	0.000426	0.21	0.21	Schizophrenia;	chr8:88413215	chr8:88326836~88737134:+
THCA	cis	rs34792	0.525	rs12708795	ENSG00000207425.1	Y_RNA	-4.68	3.79e-06	0.000426	-0.24	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:14915457~14915556:-
THCA	cis	rs10090774	0.71	rs13273096	ENSG00000280303.2	ERICD	-4.68	3.79e-06	0.000426	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140665832	chr8:140636281~140638283:+
THCA	cis	rs79243044	1	rs10838299	ENSG00000224295.2	AC087380.14	-4.68	3.79e-06	0.000426	-0.22	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5545600	chr11:5518441~5524955:-
THCA	cis	rs6012564	0.964	rs6125547	ENSG00000227431.4	CSE1L-AS1	4.68	3.79e-06	0.000426	0.26	0.21	Anger;	chr20:49100868	chr20:49040463~49046044:-
THCA	cis	rs763121	0.853	rs8140617	ENSG00000235209.1	CTA-150C2.13	-4.68	3.79e-06	0.000427	-0.28	-0.21	Menopause (age at onset);	chr22:38574434	chr22:38921227~38924708:+
THCA	cis	rs11634944	1	rs220030	ENSG00000257151.1	PWAR6	4.68	3.79e-06	0.000427	0.16	0.21	Interleukin-8 levels;	chr15:24954621	chr15:25031873~25036490:+
THCA	cis	rs7141336	1	rs6575154	ENSG00000258884.1	CTD-3035D6.2	4.68	3.79e-06	0.000427	0.28	0.21	Anxiety disorder;	chr14:90818361	chr14:90822365~90828128:-
THCA	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-4.68	3.79e-06	0.000427	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
THCA	cis	rs7914558	0.932	rs4307650	ENSG00000236937.2	PTGES3P4	4.68	3.79e-06	0.000427	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:102845595~102845950:+
THCA	cis	rs10090774	0.664	rs10282830	ENSG00000280303.2	ERICD	-4.68	3.8e-06	0.000427	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140661435	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.71	rs10283164	ENSG00000280303.2	ERICD	-4.68	3.8e-06	0.000427	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140661530	chr8:140636281~140638283:+
THCA	cis	rs8141529	0.702	rs469990	ENSG00000226471.5	CTA-292E10.6	-4.68	3.8e-06	0.000427	-0.17	-0.21	Lymphocyte counts;	chr22:28908212	chr22:28800683~28848559:+
THCA	cis	rs7554547	0.644	rs57077193	ENSG00000201801.1	RNU5E-4P	4.68	3.8e-06	0.000427	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr1:11878154	chr1:11909808~11909927:-
THCA	cis	rs1979679	0.573	rs7316056	ENSG00000247934.4	RP11-967K21.1	4.68	3.8e-06	0.000427	0.21	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28575743	chr12:28163298~28190738:-
THCA	cis	rs5758511	0.773	rs9623482	ENSG00000281538.1	RP4-669P10.20	-4.68	3.8e-06	0.000427	-0.25	-0.21	Birth weight;	chr22:41964570	chr22:42138060~42139726:+
THCA	cis	rs6870983	0.697	rs6884773	ENSG00000247828.6	TMEM161B-AS1	4.68	3.8e-06	0.000427	0.19	0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88419648	chr5:88268895~88436685:+
THCA	cis	rs6445975	0.715	rs4681835	ENSG00000272360.1	RP11-359I18.5	-4.68	3.8e-06	0.000427	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58277624	chr3:58490830~58491291:-
THCA	cis	rs58605417	0.534	rs821095	ENSG00000253553.4	RP11-586K2.1	4.68	3.8e-06	0.000427	0.21	0.21	Schizophrenia;	chr8:88442603	chr8:88326836~88737134:+
THCA	cis	rs4535700	0.501	rs10227764	ENSG00000226278.1	PSPHP1	4.68	3.8e-06	0.000427	0.25	0.21	Macular telangiectasia type 2;	chr7:55944729	chr7:55764797~55773288:+
THCA	cis	rs4535700	0.501	rs60517461	ENSG00000226278.1	PSPHP1	4.68	3.8e-06	0.000427	0.25	0.21	Macular telangiectasia type 2;	chr7:55949952	chr7:55764797~55773288:+
THCA	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-4.68	3.8e-06	0.000427	-0.26	-0.21	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
THCA	cis	rs3750965	0.92	rs11828017	ENSG00000260895.1	RP11-554A11.7	4.68	3.8e-06	0.000427	0.28	0.21	Hair color;	chr11:69051149	chr11:69103493~69109094:+
THCA	cis	rs321358	0.79	rs4635115	ENSG00000271584.1	RP11-89C3.4	4.68	3.8e-06	0.000427	0.35	0.21	Body mass index;	chr11:111076352	chr11:111091932~111097357:-
THCA	cis	rs793571	0.628	rs28733370	ENSG00000259250.1	RP11-50C13.1	-4.68	3.8e-06	0.000427	-0.22	-0.21	Schizophrenia;	chr15:58779385	chr15:58587507~58591676:+
THCA	cis	rs793571	0.628	rs7165019	ENSG00000259250.1	RP11-50C13.1	-4.68	3.8e-06	0.000427	-0.22	-0.21	Schizophrenia;	chr15:58780098	chr15:58587507~58591676:+
THCA	cis	rs7772486	0.719	rs702317	ENSG00000270638.1	RP3-466P17.1	-4.68	3.8e-06	0.000427	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.72	rs4896837	ENSG00000270638.1	RP3-466P17.1	-4.68	3.8e-06	0.000427	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145735570~145737218:+
THCA	cis	rs9876781	1	rs7636782	ENSG00000244380.1	RP11-24C3.2	4.68	3.8e-06	0.000428	0.24	0.21	Longevity;	chr3:48379897	chr3:48440352~48446656:-
THCA	cis	rs7824557	0.724	rs2251473	ENSG00000154316.13	TDH	-4.68	3.8e-06	0.000428	-0.16	-0.21	Retinal vascular caliber;	chr8:11319617	chr8:11339637~11368452:+
THCA	cis	rs7851660	0.844	rs907581	ENSG00000214417.4	KRT18P13	-4.68	3.8e-06	0.000428	-0.19	-0.21	Strep throat;	chr9:97859907	chr9:97698922~97700734:+
THCA	cis	rs7647973	0.58	rs11716334	ENSG00000229759.1	MRPS18AP1	4.68	3.8e-06	0.000428	0.27	0.21	Menarche (age at onset);	chr3:49192663	chr3:48256350~48256938:-
THCA	cis	rs6835098	0.509	rs2332655	ENSG00000245213.5	RP11-10K16.1	4.68	3.81e-06	0.000428	0.17	0.21	Dementia and core Alzheimer's disease neuropathologic changes;	chr4:173171851	chr4:173131928~173169652:-
THCA	cis	rs17301013	0.507	rs11810824	ENSG00000227373.4	RP11-160H22.5	-4.68	3.81e-06	0.000428	-0.31	-0.21	Systemic lupus erythematosus;	chr1:174408223	chr1:174115300~174160004:-
THCA	cis	rs911119	0.818	rs12625182	ENSG00000270001.1	RP11-218C14.8	-4.68	3.81e-06	0.000428	-0.31	-0.21	Chronic kidney disease;	chr20:23623386	chr20:23631826~23632316:-
THCA	cis	rs7688540	0.8	rs6857106	ENSG00000250892.1	RP11-1365D11.1	-4.68	3.81e-06	0.000428	-0.29	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:201409~205009:-
THCA	cis	rs7528684	0.546	rs2778009	ENSG00000236731.1	RP4-801G22.2	4.68	3.81e-06	0.000428	0.22	0.21	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157652045	chr1:157629939~157630728:-
THCA	cis	rs7577696	0.853	rs212734	ENSG00000276334.1	AL133243.1	4.68	3.81e-06	0.000428	0.23	0.21	Inflammatory biomarkers;	chr2:32247684	chr2:32521927~32523547:+
THCA	cis	rs911119	0.913	rs6048929	ENSG00000270001.1	RP11-218C14.8	-4.68	3.81e-06	0.000428	-0.31	-0.21	Chronic kidney disease;	chr20:23608218	chr20:23631826~23632316:-
THCA	cis	rs2617170	0.922	rs2617149	ENSG00000245648.1	RP11-277P12.20	-4.68	3.81e-06	0.000428	-0.22	-0.21	Behcet's disease;	chr12:10375734	chr12:10363769~10398506:+
THCA	cis	rs9467773	0.62	rs2451732	ENSG00000261353.1	CTA-14H9.5	4.68	3.81e-06	0.000429	0.22	0.21	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26527063~26527404:+
THCA	cis	rs9992667	0.577	rs10021686	ENSG00000231160.8	KLF3-AS1	4.68	3.82e-06	0.000429	0.17	0.21	Eosinophil percentage of granulocytes;	chr4:38703636	chr4:38612701~38664883:-
THCA	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	4.68	3.82e-06	0.000429	0.25	0.21	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
THCA	cis	rs2337406	0.925	rs873533	ENSG00000274576.2	IGHV2-70	-4.68	3.82e-06	0.000429	-0.19	-0.21	Alzheimer's disease (late onset);	chr14:106667442	chr14:106770577~106771020:-
THCA	cis	rs11148252	0.595	rs4885325	ENSG00000273784.3	RP11-78J21.7	-4.68	3.82e-06	0.000429	-0.23	-0.21	Lewy body disease;	chr13:52597182	chr13:52600042~52642542:+
THCA	cis	rs9300255	0.568	rs3018098	ENSG00000235423.7	RP11-282O18.3	4.68	3.82e-06	0.000429	0.22	0.21	Neutrophil percentage of white cells;	chr12:123170265	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.544	rs1790100	ENSG00000235423.7	RP11-282O18.3	4.68	3.82e-06	0.000429	0.22	0.21	Neutrophil percentage of white cells;	chr12:123172178	chr12:123252030~123261483:-
THCA	cis	rs990871	0.53	rs1026566	ENSG00000227207.2	RPL31P12	4.68	3.82e-06	0.000429	0.24	0.21	Subcutaneous adipose tissue;	chr1:72243359	chr1:72301472~72301829:+
THCA	cis	rs9880211	1	rs9869630	ENSG00000239213.4	NCK1-AS1	4.68	3.82e-06	0.000429	0.23	0.21	Height;Body mass index;	chr3:136529177	chr3:136841726~136862054:-
THCA	cis	rs59918340	0.728	rs10875467	ENSG00000253307.1	RP11-10J21.4	-4.68	3.82e-06	0.000429	-0.29	-0.21	Immature fraction of reticulocytes;	chr8:141223297	chr8:141252286~141253292:-
THCA	cis	rs8028182	0.666	rs4886708	ENSG00000260274.1	RP11-817O13.8	4.68	3.83e-06	0.00043	0.15	0.21	Sudden cardiac arrest;	chr15:75470267	chr15:75368155~75369584:+
THCA	cis	rs1577917	0.883	rs13212415	ENSG00000220563.1	PKMP3	-4.68	3.83e-06	0.00043	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85898365	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.839	rs1447159	ENSG00000220563.1	PKMP3	-4.68	3.83e-06	0.00043	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85899531	chr6:85659892~85660606:-
THCA	cis	rs9910055	0.636	rs7089	ENSG00000267080.4	ASB16-AS1	-4.68	3.83e-06	0.00043	-0.19	-0.21	Total body bone mineral density;	chr17:44191649	chr17:44175973~44186717:-
THCA	cis	rs2243480	1	rs160646	ENSG00000164669.11	INTS4P1	4.68	3.83e-06	0.00043	0.4	0.21	Diabetic kidney disease;	chr7:66091293	chr7:65141225~65234216:+
THCA	cis	rs6088580	0.634	rs1205334	ENSG00000276073.1	RP5-1125A11.7	4.68	3.83e-06	0.00043	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34342563	chr20:33985617~33988989:-
THCA	cis	rs6973609	1	rs6973837	ENSG00000271122.1	RP11-379H18.1	4.68	3.83e-06	0.00043	0.14	0.21	Obesity-related traits;	chr7:35567864	chr7:35695214~35699413:+
THCA	cis	rs3930017	0.513	rs3930018	ENSG00000265479.4	DTX2P1-UPK3BP1-PMS2P11	4.68	3.83e-06	0.00043	0.26	0.21	Body mass index;	chr7:77091318	chr7:76980949~77043775:+
THCA	cis	rs8105895	0.825	rs62112369	ENSG00000269345.1	VN1R85P	4.68	3.83e-06	0.00043	0.27	0.21	Body mass index (change over time);	chr19:22131099	chr19:22174766~22175191:-
THCA	cis	rs7294478	1	rs7294478	ENSG00000256967.1	RP11-273B20.1	4.68	3.83e-06	0.00043	0.16	0.21	Neuritic plaque;	chr12:7114209	chr12:7129079~7131198:-
THCA	cis	rs2834188	0.737	rs2834185	ENSG00000272659.1	AP000295.10	-4.68	3.83e-06	0.00043	-0.28	-0.21	Narcolepsy;	chr21:33313599	chr21:33309491~33310181:+
THCA	cis	rs13434995	0.537	rs7340797	ENSG00000249700.7	SRD5A3-AS1	4.68	3.83e-06	0.00043	0.32	0.21	Adiponectin levels;	chr4:55363681	chr4:55363971~55395847:-
THCA	cis	rs1876905	0.539	rs240956	ENSG00000255389.1	C6orf3	-4.68	3.83e-06	0.00043	-0.26	-0.21	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111599875~111602295:+
THCA	cis	rs12030196	0.871	rs12080311	ENSG00000230812.4	LINC01358	-4.68	3.83e-06	0.00043	-0.27	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58987662	chr1:59020387~59044614:+
THCA	cis	rs11723261	0.582	rs61792238	ENSG00000211553.1	AC253576.2	-4.68	3.83e-06	0.00043	-0.31	-0.21	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:136461~136568:+
THCA	cis	rs7267979	0.934	rs4815423	ENSG00000274973.1	RP13-401N8.7	4.68	3.83e-06	0.00043	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25845497~25845862:+
THCA	cis	rs7746199	0.736	rs34965299	ENSG00000272009.1	RP1-313I6.12	-4.68	3.83e-06	0.00043	-0.4	-0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28078792~28081130:-
THCA	cis	rs35491132	1	rs35491132	ENSG00000272009.1	RP1-313I6.12	-4.68	3.83e-06	0.00043	-0.4	-0.21	Urinary tract infection frequency;	chr6:27559449	chr6:28078792~28081130:-
THCA	cis	rs11148252	0.904	rs9526927	ENSG00000273784.3	RP11-78J21.7	-4.68	3.83e-06	0.00043	-0.22	-0.21	Lewy body disease;	chr13:52477492	chr13:52600042~52642542:+
THCA	cis	rs6870983	0.857	rs7444298	ENSG00000247828.6	TMEM161B-AS1	4.68	3.83e-06	0.00043	0.19	0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88434210	chr5:88268895~88436685:+
THCA	cis	rs31251	0.903	rs11746464	ENSG00000237714.1	P4HA2-AS1	4.68	3.83e-06	0.000431	0.26	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr5:131522034	chr5:132184876~132192808:+
THCA	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	4.68	3.83e-06	0.000431	0.24	0.21	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
THCA	cis	rs9902453	0.791	rs3115090	ENSG00000263370.1	RP11-68I3.5	4.68	3.83e-06	0.000431	0.27	0.21	Coffee consumption (cups per day);	chr17:29707996	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.726	rs3115092	ENSG00000263370.1	RP11-68I3.5	4.68	3.83e-06	0.000431	0.27	0.21	Coffee consumption (cups per day);	chr17:29709332	chr17:29639627~29640825:+
THCA	cis	rs11673344	0.504	rs4239587	ENSG00000276846.1	CTD-3220F14.3	4.68	3.83e-06	0.000431	0.16	0.21	Obesity-related traits;	chr19:37136211	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs4805202	ENSG00000276846.1	CTD-3220F14.3	4.68	3.83e-06	0.000431	0.16	0.21	Obesity-related traits;	chr19:37136499	chr19:37314868~37315620:-
THCA	cis	rs11673344	0.504	rs4805203	ENSG00000276846.1	CTD-3220F14.3	4.68	3.83e-06	0.000431	0.16	0.21	Obesity-related traits;	chr19:37136586	chr19:37314868~37315620:-
THCA	cis	rs11955398	0.502	rs295561	ENSG00000272308.1	RP11-231G3.1	-4.68	3.84e-06	0.000431	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61104390	chr5:60866457~60866935:-
THCA	cis	rs8028182	0.636	rs11634863	ENSG00000260269.4	CTD-2323K18.1	-4.68	3.84e-06	0.000431	-0.31	-0.21	Sudden cardiac arrest;	chr15:75474331	chr15:75527150~75601205:-
THCA	cis	rs28510890	0.547	rs11853339	ENSG00000258676.4	RP11-386M24.3	4.68	3.84e-06	0.000431	0.23	0.21	Lung cancer in ever smokers;	chr15:92605654	chr15:92580829~92600545:+
THCA	cis	rs2239547	0.607	rs9836178	ENSG00000242142.1	SERBP1P3	-4.68	3.84e-06	0.000432	-0.27	-0.21	Schizophrenia;	chr3:52891387	chr3:53064283~53065091:-
THCA	cis	rs4819052	0.851	rs2255774	ENSG00000273796.1	LL21NC02-21A1.1	-4.68	3.84e-06	0.000432	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45403809~45404369:-
THCA	cis	rs8028182	0.636	rs7184046	ENSG00000260269.4	CTD-2323K18.1	-4.68	3.84e-06	0.000432	-0.32	-0.21	Sudden cardiac arrest;	chr15:75573809	chr15:75527150~75601205:-
THCA	cis	rs4578769	0.55	rs930909	ENSG00000265939.1	UBE2CP2	4.68	3.84e-06	0.000432	0.24	0.21	Eosinophil percentage of white cells;	chr18:22976361	chr18:22900486~22900995:-
THCA	cis	rs1005277	0.522	rs11011343	ENSG00000226578.1	RP11-258F22.1	-4.68	3.84e-06	0.000432	-0.24	-0.21	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:37775371~37784131:-
THCA	cis	rs10800713	0.779	rs2815289	ENSG00000260088.1	RP11-92G12.3	4.68	3.85e-06	0.000432	0.34	0.21	Tandem gait;	chr1:200610628	chr1:200669507~200694250:+
THCA	cis	rs2439831	1	rs2444032	ENSG00000205771.5	CATSPER2P1	-4.68	3.85e-06	0.000432	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43463148	chr15:43726918~43747094:-
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000275400.1	RP4-756H11.5	-4.68	3.85e-06	0.000432	-0.23	-0.21	Corneal structure;	chr7:66824628	chr7:66553805~66554199:-
THCA	cis	rs3177980	0.564	rs10919246	ENSG00000239494.2	RN7SL333P	4.67	3.85e-06	0.000432	0.19	0.21	Amyotrophic lateral sclerosis;	chr1:169795911	chr1:169859756~169860052:+
THCA	cis	rs9719620	0.967	rs11763660	ENSG00000236753.4	MKLN1-AS	-4.67	3.85e-06	0.000432	-0.21	-0.21	Male-pattern baldness;	chr7:131313238	chr7:131309744~131328222:-
THCA	cis	rs2439831	0.867	rs4583210	ENSG00000205771.5	CATSPER2P1	-4.67	3.85e-06	0.000432	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43368727	chr15:43726918~43747094:-
THCA	cis	rs12823128	0.967	rs12579808	ENSG00000256185.1	RP11-612B6.2	4.67	3.85e-06	0.000432	0.2	0.21	Birth weight;	chr12:26714067	chr12:26335864~26336950:-
THCA	cis	rs1563304	1	rs1563304	ENSG00000232300.1	FAM215B	4.67	3.85e-06	0.000432	0.42	0.21	Neuroticism;	chr17:46797087	chr17:46558830~46562795:-
THCA	cis	rs17801127	0.818	rs35536703	ENSG00000231969.1	AC144449.1	4.67	3.85e-06	0.000432	0.43	0.21	Liver enzyme levels (alanine transaminase);	chr2:149840947	chr2:149587196~149848233:+
THCA	cis	rs12497850	0.897	rs6781790	ENSG00000228638.1	FCF1P2	-4.67	3.85e-06	0.000432	-0.23	-0.21	Parkinson's disease;	chr3:49007334	chr3:48290793~48291375:-
THCA	cis	rs6088590	1	rs2295353	ENSG00000276073.1	RP5-1125A11.7	-4.67	3.85e-06	0.000432	-0.2	-0.21	Coronary artery disease;	chr20:34768708	chr20:33985617~33988989:-
THCA	cis	rs6088590	1	rs2295354	ENSG00000276073.1	RP5-1125A11.7	-4.67	3.85e-06	0.000432	-0.2	-0.21	Coronary artery disease;	chr20:34768738	chr20:33985617~33988989:-
THCA	cis	rs17680741	0.657	rs12246432	ENSG00000225484.5	NUTM2B-AS1	-4.67	3.85e-06	0.000432	-0.3	-0.21	Coronary artery disease;	chr10:80510462	chr10:79663088~79826594:-
THCA	cis	rs1979679	0.918	rs11049562	ENSG00000247934.4	RP11-967K21.1	-4.67	3.85e-06	0.000433	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28375576	chr12:28163298~28190738:-
THCA	cis	rs10090774	0.71	rs10283368	ENSG00000280303.2	ERICD	4.67	3.85e-06	0.000433	0.2	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140669718	chr8:140636281~140638283:+
THCA	cis	rs10888838	0.617	rs4927071	ENSG00000198711.5	SSBP3-AS1	4.67	3.85e-06	0.000433	0.2	0.21	Mitochondrial DNA levels;	chr1:54214239	chr1:54236440~54239063:+
THCA	cis	rs7267979	1	rs6050599	ENSG00000274973.1	RP13-401N8.7	4.67	3.85e-06	0.000433	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050602	ENSG00000274973.1	RP13-401N8.7	4.67	3.85e-06	0.000433	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs6083855	ENSG00000274973.1	RP13-401N8.7	4.67	3.85e-06	0.000433	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4815426	ENSG00000274973.1	RP13-401N8.7	4.67	3.85e-06	0.000433	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25845497~25845862:+
THCA	cis	rs2243480	1	rs781157	ENSG00000164669.11	INTS4P1	4.67	3.86e-06	0.000433	0.41	0.21	Diabetic kidney disease;	chr7:66013324	chr7:65141225~65234216:+
THCA	cis	rs6479874	0.736	rs2816835	ENSG00000223502.1	RP11-96B5.3	4.67	3.86e-06	0.000433	0.23	0.21	Migraine;	chr10:50992874	chr10:51062579~51068553:-
THCA	cis	rs7621025	0.617	rs12637102	ENSG00000239213.4	NCK1-AS1	4.67	3.86e-06	0.000433	0.2	0.21	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136493118	chr3:136841726~136862054:-
THCA	cis	rs10186029	0.719	rs10932460	ENSG00000270659.1	RP11-105N14.1	4.67	3.86e-06	0.000433	0.17	0.21	Systemic sclerosis;	chr2:213035748	chr2:213152970~213153659:+
THCA	cis	rs7160336	0.738	rs7145427	ENSG00000259065.1	RP5-1021I20.1	4.67	3.86e-06	0.000433	0.24	0.21	Blood protein levels;	chr14:74016745	chr14:73787360~73803270:+
THCA	cis	rs7160336	0.738	rs66941731	ENSG00000259065.1	RP5-1021I20.1	4.67	3.86e-06	0.000433	0.24	0.21	Blood protein levels;	chr14:74026538	chr14:73787360~73803270:+
THCA	cis	rs6832769	0.922	rs6825994	ENSG00000272969.1	RP11-528I4.2	-4.67	3.86e-06	0.000433	-0.25	-0.21	Personality dimensions;	chr4:55524244	chr4:55547112~55547889:+
THCA	cis	rs1707322	1	rs10890360	ENSG00000281133.1	AL355480.3	-4.67	3.86e-06	0.000433	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs6682683	ENSG00000281133.1	AL355480.3	-4.67	3.86e-06	0.000433	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45580892~45580996:-
THCA	cis	rs7141336	0.965	rs12884258	ENSG00000258884.1	CTD-3035D6.2	4.67	3.86e-06	0.000433	0.28	0.21	Anxiety disorder;	chr14:90817368	chr14:90822365~90828128:-
THCA	cis	rs4415084	1	rs4415084	ENSG00000272335.1	RP11-53O19.3	-4.67	3.86e-06	0.000433	-0.17	-0.21	Breast cancer;	chr5:44662413	chr5:44826076~44828592:+
THCA	cis	rs9880211	0.718	rs35320690	ENSG00000273486.1	RP11-731C17.2	-4.67	3.86e-06	0.000433	-0.21	-0.21	Height;Body mass index;	chr3:136213652	chr3:136837338~136839021:-
THCA	cis	rs9719620	0.967	rs4728218	ENSG00000236753.4	MKLN1-AS	-4.67	3.86e-06	0.000433	-0.21	-0.21	Male-pattern baldness;	chr7:131304576	chr7:131309744~131328222:-
THCA	cis	rs55661361	0.651	rs12293621	ENSG00000254941.1	RP11-677M14.5	4.67	3.86e-06	0.000433	0.19	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742932	chr11:124807822~124808269:-
THCA	cis	rs55661361	0.651	rs12293624	ENSG00000254941.1	RP11-677M14.5	4.67	3.86e-06	0.000433	0.19	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742937	chr11:124807822~124808269:-
THCA	cis	rs7191700	0.583	rs243314	ENSG00000263080.1	RP11-485G7.5	4.67	3.86e-06	0.000434	0.24	0.21	Multiple sclerosis;	chr16:11291247	chr16:11341809~11345211:-
THCA	cis	rs911555	0.723	rs6575986	ENSG00000269910.1	RP11-73M18.10	4.67	3.86e-06	0.000434	0.19	0.21	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103694516~103695050:-
THCA	cis	rs2742234	0.59	rs2257767	ENSG00000273008.1	RP11-351D16.3	-4.67	3.86e-06	0.000434	-0.2	-0.21	Hirschsprung disease;	chr10:43162363	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.59	rs2505557	ENSG00000273008.1	RP11-351D16.3	-4.67	3.86e-06	0.000434	-0.2	-0.21	Hirschsprung disease;	chr10:43170568	chr10:43136824~43138334:-
THCA	cis	rs9816784	0.525	rs41301371	ENSG00000273009.1	RP11-352G9.1	-4.67	3.86e-06	0.000434	-0.24	-0.21	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195913078~195913683:-
THCA	cis	rs11951515	0.509	rs12521249	ENSG00000248240.1	RP11-159F24.5	4.67	3.87e-06	0.000434	0.23	0.21	Metabolite levels  (X-11787);	chr5:43558527	chr5:43515274~43525310:+
THCA	cis	rs10129255	0.576	rs2157616	ENSG00000211970.3	IGHV4-61	-4.67	3.87e-06	0.000434	-0.12	-0.21	Kawasaki disease;	chr14:106767802	chr14:106639119~106639657:-
THCA	cis	rs7851660	0.844	rs6478445	ENSG00000214417.4	KRT18P13	-4.67	3.87e-06	0.000434	-0.19	-0.21	Strep throat;	chr9:97862017	chr9:97698922~97700734:+
THCA	cis	rs7851660	0.839	rs10113884	ENSG00000214417.4	KRT18P13	-4.67	3.87e-06	0.000434	-0.19	-0.21	Strep throat;	chr9:97862340	chr9:97698922~97700734:+
THCA	cis	rs889398	0.967	rs244417	ENSG00000226232.7	RP11-419C5.2	4.67	3.87e-06	0.000434	0.21	0.21	Body mass index;	chr16:69629616	chr16:69976388~69996188:-
THCA	cis	rs17301013	0.861	rs10912824	ENSG00000227373.4	RP11-160H22.5	4.67	3.87e-06	0.000434	0.3	0.21	Systemic lupus erythematosus;	chr1:174625846	chr1:174115300~174160004:-
THCA	cis	rs2239547	0.618	rs4687658	ENSG00000242142.1	SERBP1P3	4.67	3.87e-06	0.000434	0.27	0.21	Schizophrenia;	chr3:52826350	chr3:53064283~53065091:-
THCA	cis	rs2239547	0.657	rs2276817	ENSG00000242142.1	SERBP1P3	4.67	3.87e-06	0.000434	0.27	0.21	Schizophrenia;	chr3:52826920	chr3:53064283~53065091:-
THCA	cis	rs2239547	0.657	rs13072536	ENSG00000242142.1	SERBP1P3	4.67	3.87e-06	0.000434	0.27	0.21	Schizophrenia;	chr3:52827195	chr3:53064283~53065091:-
THCA	cis	rs2239547	0.657	rs12488303	ENSG00000242142.1	SERBP1P3	4.67	3.87e-06	0.000434	0.27	0.21	Schizophrenia;	chr3:52827987	chr3:53064283~53065091:-
THCA	cis	rs2239547	0.657	rs2072391	ENSG00000242142.1	SERBP1P3	4.67	3.87e-06	0.000434	0.27	0.21	Schizophrenia;	chr3:52828184	chr3:53064283~53065091:-
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000164669.11	INTS4P1	4.67	3.87e-06	0.000434	0.41	0.21	Diabetic kidney disease;	chr7:65924813	chr7:65141225~65234216:+
THCA	cis	rs6860806	0.507	rs2631364	ENSG00000237714.1	P4HA2-AS1	-4.67	3.87e-06	0.000434	-0.29	-0.21	Breast cancer;	chr5:132371222	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.531	rs2631359	ENSG00000237714.1	P4HA2-AS1	-4.67	3.87e-06	0.000434	-0.29	-0.21	Breast cancer;	chr5:132372200	chr5:132184876~132192808:+
THCA	cis	rs9878978	0.722	rs35000138	ENSG00000237990.3	CNTN4-AS1	4.67	3.87e-06	0.000434	0.26	0.21	Blood pressure (smoking interaction);	chr3:2395549	chr3:3039033~3069242:-
THCA	cis	rs1836229	0.594	rs4372066	ENSG00000225706.1	PTPRD-AS1	-4.67	3.87e-06	0.000434	-0.25	-0.21	Restless legs syndrome;	chr9:8829149	chr9:8858130~8862255:+
THCA	cis	rs3096299	0.658	rs4291902	ENSG00000261118.1	RP11-104N10.1	4.67	3.87e-06	0.000434	0.18	0.21	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89492017~89504460:-
THCA	cis	rs7648466	0.592	rs2087726	ENSG00000223552.1	RP11-24F11.2	4.67	3.87e-06	0.000434	0.19	0.21	Eotaxin levels;	chr3:46166818	chr3:46364955~46407059:-
THCA	cis	rs7648466	0.544	rs2172247	ENSG00000223552.1	RP11-24F11.2	4.67	3.87e-06	0.000434	0.19	0.21	Eotaxin levels;	chr3:46173178	chr3:46364955~46407059:-
THCA	cis	rs11671005	0.61	rs2305122	ENSG00000269600.1	AC016629.3	-4.67	3.87e-06	0.000434	-0.3	-0.21	Mean platelet volume;	chr19:58545385	chr19:58593896~58599355:-
THCA	cis	rs12931792	0.712	rs2887799	ENSG00000273724.1	RP11-347C12.12	4.67	3.87e-06	0.000434	0.21	0.21	Tonsillectomy;	chr16:30152512	chr16:30336400~30343336:+
THCA	cis	rs3128341	1	rs11581447	ENSG00000227207.2	RPL31P12	4.67	3.87e-06	0.000434	0.32	0.21	Intelligence (multi-trait analysis);	chr1:72364000	chr1:72301472~72301829:+
THCA	cis	rs6547741	0.563	rs10196039	ENSG00000234072.1	AC074117.10	-4.67	3.87e-06	0.000434	-0.16	-0.21	Oral cavity cancer;	chr2:27748328	chr2:27356246~27367622:+
THCA	cis	rs2676071	0.862	rs12148576	ENSG00000259721.1	RP11-758N13.1	4.67	3.87e-06	0.000435	0.26	0.21	Periodontitis (Mean PAL);	chr15:33309108	chr15:32717270~32719007:-
THCA	cis	rs7849973	0.524	rs10118643	ENSG00000224549.1	RP11-370B11.3	4.67	3.87e-06	0.000435	0.24	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22807219	chr9:22767175~22768316:+
THCA	cis	rs7394190	0.63	rs78845904	ENSG00000271848.1	RP11-464F9.21	-4.67	3.87e-06	0.000435	-0.29	-0.21	Incident atrial fibrillation;	chr10:73757491	chr10:73654039~73674719:+
THCA	cis	rs4950322	0.857	rs72693002	ENSG00000226015.2	CCT8P1	4.67	3.87e-06	0.000435	0.25	0.21	Protein quantitative trait loci;	chr1:147357593	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.857	rs72694703	ENSG00000226015.2	CCT8P1	4.67	3.87e-06	0.000435	0.25	0.21	Protein quantitative trait loci;	chr1:147358427	chr1:147203276~147204932:-
THCA	cis	rs7267979	0.966	rs2424715	ENSG00000274973.1	RP13-401N8.7	-4.67	3.87e-06	0.000435	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25845497~25845862:+
THCA	cis	rs11992162	0.613	rs56094399	ENSG00000254948.1	OR7E158P	4.67	3.87e-06	0.000435	0.27	0.21	Monocyte count;	chr8:11939961	chr8:11919900~11920809:-
THCA	cis	rs34286592	1	rs4788188	ENSG00000214725.6	CDIPT-AS1	-4.67	3.87e-06	0.000435	-0.37	-0.21	Multiple sclerosis;	chr16:29849542	chr16:29863593~29868053:+
THCA	cis	rs526231	0.819	rs2288788	ENSG00000175749.11	EIF3KP1	4.67	3.88e-06	0.000435	0.29	0.21	Primary biliary cholangitis;	chr5:103264868	chr5:103032376~103033031:+
THCA	cis	rs427394	0.664	rs274722	ENSG00000248677.1	CTD-2044J15.1	4.67	3.88e-06	0.000435	0.2	0.21	Menopause (age at onset);	chr5:6718555	chr5:6686325~6707711:-
THCA	cis	rs853679	0.882	rs3757188	ENSG00000220721.1	OR1F12	4.67	3.88e-06	0.000435	0.37	0.21	Depression;	chr6:28139579	chr6:28073316~28074233:+
THCA	cis	rs4908768	0.535	rs2708628	ENSG00000232912.4	RP5-1115A15.1	-4.67	3.88e-06	0.000435	-0.24	-0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8390388	chr1:8424645~8434838:+
THCA	cis	rs786425	0.707	rs1051793	ENSG00000270095.1	RP11-214K3.18	-4.67	3.88e-06	0.000435	-0.25	-0.21	Pubertal anthropometrics;	chr12:123659848	chr12:123971457~123971714:-
THCA	cis	rs786425	0.676	rs4930708	ENSG00000270095.1	RP11-214K3.18	-4.67	3.88e-06	0.000435	-0.25	-0.21	Pubertal anthropometrics;	chr12:123661150	chr12:123971457~123971714:-
THCA	cis	rs812925	0.519	rs1186696	ENSG00000270820.4	RP11-355B11.2	4.67	3.88e-06	0.000435	0.18	0.21	Immature fraction of reticulocytes;	chr2:61433348	chr2:61471188~61484130:+
THCA	cis	rs2688608	1	rs2688608	ENSG00000271816.1	BMS1P4	4.67	3.88e-06	0.000435	0.2	0.21	Inflammatory bowel disease;	chr10:73898591	chr10:73699151~73730487:-
THCA	cis	rs9880211	1	rs9880211	ENSG00000239213.4	NCK1-AS1	4.67	3.88e-06	0.000435	0.23	0.21	Height;Body mass index;	chr3:136388707	chr3:136841726~136862054:-
THCA	cis	rs6449502	0.764	rs12696975	ENSG00000251279.1	CTC-436P18.1	4.67	3.88e-06	0.000435	0.35	0.21	Mean platelet volume;	chr5:60772528	chr5:61162070~61232040:+
THCA	cis	rs8031584	0.918	rs34331396	ENSG00000178081.11	ULK4P3	4.67	3.88e-06	0.000435	0.27	0.21	Huntington's disease progression;	chr15:30956533	chr15:30103720~30131757:+
THCA	cis	rs79243044	0.862	rs10160561	ENSG00000224295.2	AC087380.14	4.67	3.88e-06	0.000435	0.21	0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5525579	chr11:5518441~5524955:-
THCA	cis	rs10938353	0.638	rs11732880	ENSG00000273369.1	RP11-700J17.1	-4.67	3.88e-06	0.000436	-0.25	-0.21	Body mass index;	chr4:44673497	chr4:44693946~44694386:-
THCA	cis	rs7119	0.651	rs12917431	ENSG00000259362.2	RP11-307C19.1	-4.67	3.88e-06	0.000436	-0.3	-0.21	Type 2 diabetes;	chr15:77557842	chr15:77525540~77534110:+
THCA	cis	rs62184315	0.536	rs5742985	ENSG00000253559.1	OSGEPL1-AS1	-4.67	3.88e-06	0.000436	-0.3	-0.21	Alcohol dependence (age at onset);	chr2:189796383	chr2:189762704~189765556:+
THCA	cis	rs17301013	0.932	rs1754355	ENSG00000227373.4	RP11-160H22.5	-4.67	3.88e-06	0.000436	-0.3	-0.21	Systemic lupus erythematosus;	chr1:174807407	chr1:174115300~174160004:-
THCA	cis	rs6517329	0.504	rs8133052	ENSG00000236830.5	CBR3-AS1	-4.67	3.88e-06	0.000436	-0.2	-0.21	Schizophrenia;	chr21:36135203	chr21:36131767~36175815:-
THCA	cis	rs6600671	0.934	rs12131379	ENSG00000275585.1	CH17-118O6.3	-4.67	3.89e-06	0.000436	-0.25	-0.21	Hip geometry;	chr1:121551639	chr1:120985692~121052167:-
THCA	cis	rs9516	1	rs9516	ENSG00000254974.1	RP11-702H23.2	-4.67	3.89e-06	0.000436	-0.23	-0.21	Facial morphology (factor 15, philtrum width);	chr11:74455233	chr11:74485580~74486051:-
THCA	cis	rs8077577	0.747	rs57490980	ENSG00000273018.4	CTD-2303H24.2	-4.67	3.89e-06	0.000436	-0.31	-0.21	Obesity-related traits;	chr17:18257439	chr17:18511221~18551705:-
THCA	cis	rs7267979	0.932	rs449370	ENSG00000274973.1	RP13-401N8.7	4.67	3.89e-06	0.000436	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25845497~25845862:+
THCA	cis	rs5771242	0.518	rs6010216	ENSG00000273253.2	RP3-402G11.26	-4.67	3.89e-06	0.000436	-0.24	-0.21	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50241042	chr22:50199090~50200837:-
THCA	cis	rs12449964	0.515	rs7225141	ENSG00000223979.2	SMCR2	4.67	3.89e-06	0.000436	0.22	0.21	Coronary artery disease or ischemic stroke;	chr17:17667513	chr17:17674026~17677688:-
THCA	cis	rs6787172	0.811	rs6795376	ENSG00000272087.1	RP11-379F4.7	4.67	3.89e-06	0.000437	0.19	0.21	Subjective well-being;	chr3:158496682	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.811	rs6762860	ENSG00000272087.1	RP11-379F4.7	4.67	3.89e-06	0.000437	0.19	0.21	Subjective well-being;	chr3:158497753	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.783	rs12638438	ENSG00000272087.1	RP11-379F4.7	4.67	3.89e-06	0.000437	0.19	0.21	Subjective well-being;	chr3:158502045	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.811	rs9810887	ENSG00000272087.1	RP11-379F4.7	4.67	3.89e-06	0.000437	0.19	0.21	Subjective well-being;	chr3:158503921	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.811	rs7623732	ENSG00000272087.1	RP11-379F4.7	4.67	3.89e-06	0.000437	0.19	0.21	Subjective well-being;	chr3:158504647	chr3:158693120~158693768:-
THCA	cis	rs6832769	1	rs28463765	ENSG00000272969.1	RP11-528I4.2	-4.67	3.89e-06	0.000437	-0.25	-0.21	Personality dimensions;	chr4:55546267	chr4:55547112~55547889:+
THCA	cis	rs2439831	0.867	rs3809481	ENSG00000205771.5	CATSPER2P1	-4.67	3.9e-06	0.000437	-0.29	-0.21	Lung cancer in ever smokers;	chr15:43370631	chr15:43726918~43747094:-
THCA	cis	rs7267979	0.866	rs6138609	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000437	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25845497~25845862:+
THCA	cis	rs362272	0.525	rs1313768	ENSG00000249673.5	NOP14-AS1	4.67	3.9e-06	0.000437	0.18	0.21	Serum sulfate level;	chr4:3052290	chr4:2934899~2961738:+
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000182586.6	LINC00334	-4.67	3.9e-06	0.000437	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45234340~45258730:+
THCA	cis	rs28374715	0.733	rs7167706	ENSG00000247556.5	OIP5-AS1	4.67	3.9e-06	0.000437	0.21	0.21	Ulcerative colitis;	chr15:41277446	chr15:41283990~41309737:+
THCA	cis	rs911119	0.818	rs56077567	ENSG00000270001.1	RP11-218C14.8	-4.67	3.9e-06	0.000437	-0.31	-0.21	Chronic kidney disease;	chr20:23610450	chr20:23631826~23632316:-
THCA	cis	rs75920871	0.61	rs74341458	ENSG00000254851.1	RP11-109L13.1	-4.67	3.9e-06	0.000437	-0.47	-0.21	Subjective well-being;	chr11:116880833	chr11:117135528~117138582:+
THCA	cis	rs6442522	0.809	rs972685	ENSG00000249786.6	EAF1-AS1	4.67	3.9e-06	0.000437	0.22	0.21	Uric acid levels;	chr3:15442762	chr3:15436171~15455940:-
THCA	cis	rs8062405	0.964	rs11860513	ENSG00000261766.1	RP11-22P6.2	-4.67	3.9e-06	0.000437	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28862166~28863340:-
THCA	cis	rs3743266	0.507	rs62005026	ENSG00000245534.5	RORA-AS1	-4.67	3.9e-06	0.000437	-0.28	-0.21	Menarche (age at onset);	chr15:60406255	chr15:60479178~60630637:+
THCA	cis	rs4074961	0.527	rs2294875	ENSG00000233621.1	LINC01137	-4.67	3.9e-06	0.000438	-0.22	-0.21	Axial length;	chr1:37586844	chr1:37454879~37474411:-
THCA	cis	rs12030196	1	rs11207368	ENSG00000230812.4	LINC01358	4.67	3.9e-06	0.000438	0.27	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59019388	chr1:59020387~59044614:+
THCA	cis	rs2886497	0.894	rs7916749	ENSG00000224215.1	RP11-371A19.2	-4.67	3.9e-06	0.000438	-0.27	-0.21	Major depression and alcohol dependence;	chr10:23394656	chr10:23343957~23345181:+
THCA	cis	rs7551222	0.714	rs4951404	ENSG00000240219.1	RP11-430C7.5	4.67	3.9e-06	0.000438	0.22	0.21	Schizophrenia;	chr1:204572214	chr1:204626775~204629712:+
THCA	cis	rs4648045	0.536	rs12648696	ENSG00000246560.2	RP11-10L12.4	4.67	3.9e-06	0.000438	0.26	0.21	Lymphocyte percentage of white cells;	chr4:102625739	chr4:102828055~102844075:+
THCA	cis	rs7267979	1	rs6050609	ENSG00000274973.1	RP13-401N8.7	4.67	3.9e-06	0.000438	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2424712	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2424714	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050617	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.933	rs2387887	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050626	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6037121	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs1047171	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050629	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050630	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050632	ENSG00000274973.1	RP13-401N8.7	-4.67	3.9e-06	0.000438	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25845497~25845862:+
THCA	cis	rs2427345	0.628	rs6089374	ENSG00000233017.2	RP5-908M14.5	-4.67	3.9e-06	0.000438	-0.23	-0.21	Prostate cancer;Post bronchodilator FEV1/FVC ratio;	chr20:62441942	chr20:62427827~62447621:+
THCA	cis	rs7403037	0.617	rs7172269	ENSG00000259905.4	PWRN1	4.67	3.9e-06	0.000438	0.27	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24598940	chr15:24493137~24652130:+
THCA	cis	rs6517329	0.538	rs1028997	ENSG00000236830.5	CBR3-AS1	4.67	3.9e-06	0.000438	0.2	0.21	Schizophrenia;	chr21:36159924	chr21:36131767~36175815:-
THCA	cis	rs4950322	0.57	rs7554833	ENSG00000271721.1	RP11-337C18.9	-4.67	3.91e-06	0.000438	-0.24	-0.21	Protein quantitative trait loci;	chr1:147289362	chr1:147175602~147177740:+
THCA	cis	rs2732480	0.577	rs2732479	ENSG00000273765.1	RP11-370I10.11	4.67	3.91e-06	0.000438	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.537	rs1061986	ENSG00000273765.1	RP11-370I10.11	4.67	3.91e-06	0.000438	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48360920~48361377:+
THCA	cis	rs801193	1	rs2659915	ENSG00000229886.1	RP5-1132H15.3	4.67	3.91e-06	0.000438	0.21	0.21	Aortic root size;	chr7:66688114	chr7:66025126~66031544:-
THCA	cis	rs2288884	0.541	rs7508746	ENSG00000269483.1	AC006272.1	4.67	3.91e-06	0.000438	0.31	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51990246	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.634	rs74476955	ENSG00000269483.1	AC006272.1	4.67	3.91e-06	0.000438	0.31	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997806	chr19:51839924~51843324:-
THCA	cis	rs10090774	0.965	rs9324540	ENSG00000279766.1	RP11-642A1.2	-4.67	3.91e-06	0.000438	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140980322	chr8:140572142~140572812:-
THCA	cis	rs62355901	0.505	rs62355912	ENSG00000271828.1	CTD-2310F14.1	4.67	3.91e-06	0.000438	0.53	0.21	Breast cancer;	chr5:56788004	chr5:56927874~56929573:+
THCA	cis	rs1046491	0.667	rs6506641	ENSG00000264964.1	RP11-888D10.3	4.67	3.91e-06	0.000439	0.36	0.21	Scarlet fever;	chr18:9111440	chr18:9315194~9334441:-
THCA	cis	rs12887734	0.546	rs12885509	ENSG00000269910.1	RP11-73M18.10	4.67	3.91e-06	0.000439	0.19	0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103694516~103695050:-
THCA	cis	rs755249	0.583	rs61779328	ENSG00000228060.1	RP11-69E11.8	-4.67	3.91e-06	0.000439	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39565160~39573203:+
THCA	cis	rs961831	0.539	rs2671622	ENSG00000224549.1	RP11-370B11.3	4.67	3.91e-06	0.000439	0.38	0.21	Personality dimensions;	chr9:22446752	chr9:22767175~22768316:+
THCA	cis	rs739496	0.579	rs16941759	ENSG00000226469.1	ADAM1B	-4.67	3.91e-06	0.000439	-0.26	-0.21	Platelet count;	chr12:111930117	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs3752630	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Platelet count;	chr12:111938186	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs3752631	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Platelet count;	chr12:111938353	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7959619	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Platelet count;	chr12:111938793	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs11066095	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Platelet count;	chr12:111939733	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7133881	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Platelet count;	chr12:111940964	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.748	rs7295665	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111941467	chr12:111927018~111929017:+
THCA	cis	rs739496	0.614	rs7137889	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Platelet count;	chr12:111941783	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs7973309	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Platelet count;	chr12:111944447	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs12579298	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111956218	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs12306814	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111966009	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs12423061	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111967091	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs112426410	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111969634	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs9971871	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111970572	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs1016078	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111972273	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs60217649	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111973116	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs11066111	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111977375	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs11066112	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111978782	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs2339908	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111980692	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.95	rs7313892	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111983548	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs73426401	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111985482	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.904	rs7956483	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111986766	chr12:111927018~111929017:+
THCA	cis	rs6490294	0.898	rs57646770	ENSG00000226469.1	ADAM1B	4.67	3.91e-06	0.000439	0.26	0.21	Mean platelet volume;	chr12:111993408	chr12:111927018~111929017:+
THCA	cis	rs6565180	1	rs12930787	ENSG00000274653.1	RP11-347C12.11	4.67	3.91e-06	0.000439	0.2	0.21	Tonsillectomy;	chr16:30369982	chr16:30359825~30360336:+
THCA	cis	rs2436845	1	rs1434235	ENSG00000253669.3	KB-1732A1.1	-4.67	3.91e-06	0.000439	-0.22	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102830804	chr8:102805517~102809971:+
THCA	cis	rs2436845	1	rs34655485	ENSG00000253669.3	KB-1732A1.1	-4.67	3.91e-06	0.000439	-0.22	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102832474	chr8:102805517~102809971:+
THCA	cis	rs7267979	0.933	rs2258728	ENSG00000274973.1	RP13-401N8.7	-4.67	3.92e-06	0.000439	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25845497~25845862:+
THCA	cis	rs7520050	0.966	rs6661910	ENSG00000234329.1	RP11-767N6.2	-4.67	3.92e-06	0.000439	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45651039~45651826:-
THCA	cis	rs7131987	0.903	rs7302129	ENSG00000275476.1	RP11-996F15.4	-4.67	3.92e-06	0.000439	-0.21	-0.21	QT interval;	chr12:29262347	chr12:29277397~29277882:-
THCA	cis	rs7474896	0.943	rs2799496	ENSG00000263064.2	RP11-291L22.7	-4.67	3.92e-06	0.000439	-0.35	-0.21	Obesity (extreme);	chr10:37954871	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2103936	ENSG00000263064.2	RP11-291L22.7	-4.67	3.92e-06	0.000439	-0.35	-0.21	Obesity (extreme);	chr10:37964405	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.945	rs2092995	ENSG00000263064.2	RP11-291L22.7	-4.67	3.92e-06	0.000439	-0.35	-0.21	Obesity (extreme);	chr10:37964646	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.945	rs2749593	ENSG00000263064.2	RP11-291L22.7	-4.67	3.92e-06	0.000439	-0.35	-0.21	Obesity (extreme);	chr10:37965179	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2738186	ENSG00000263064.2	RP11-291L22.7	-4.67	3.92e-06	0.000439	-0.35	-0.21	Obesity (extreme);	chr10:37967061	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs2738187	ENSG00000263064.2	RP11-291L22.7	-4.67	3.92e-06	0.000439	-0.35	-0.21	Obesity (extreme);	chr10:37971377	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.895	rs2245081	ENSG00000263064.2	RP11-291L22.7	-4.67	3.92e-06	0.000439	-0.35	-0.21	Obesity (extreme);	chr10:37971479	chr10:38448689~38448949:+
THCA	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	4.67	3.92e-06	0.000439	0.18	0.21	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
THCA	cis	rs4639966	0.723	rs11217022	ENSG00000255422.1	AP002954.4	4.67	3.92e-06	0.000439	0.25	0.21	Systemic lupus erythematosus;	chr11:118770897	chr11:118704607~118750263:+
THCA	cis	rs4767841	0.935	rs2936830	ENSG00000248636.5	RP11-768F21.1	-4.67	3.92e-06	0.000439	-0.22	-0.21	Urgency urinary incontinence;	chr12:119729350	chr12:119387987~119668079:-
THCA	cis	rs62025270	0.632	rs7163838	ENSG00000259295.5	CSPG4P12	-4.67	3.92e-06	0.000439	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85191438~85213905:+
THCA	cis	rs9283706	0.595	rs1115252	ENSG00000229666.1	MAST4-AS1	-4.67	3.92e-06	0.000439	-0.29	-0.21	Coronary artery disease;	chr5:67026913	chr5:67001383~67003953:-
THCA	cis	rs1005277	0.522	rs9418276	ENSG00000276805.1	RP11-291L22.6	4.67	3.92e-06	0.000439	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.522	rs7072977	ENSG00000276805.1	RP11-291L22.6	4.67	3.92e-06	0.000439	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38451030~38451785:+
THCA	cis	rs2483058	0.767	rs4127124	ENSG00000261000.1	RP11-534L20.5	4.67	3.92e-06	0.00044	0.23	0.21	Cholesterol and Triglycerides;	chr1:206451019	chr1:206503948~206504456:+
THCA	cis	rs2439831	0.764	rs12324584	ENSG00000205771.5	CATSPER2P1	-4.67	3.92e-06	0.00044	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43391248	chr15:43726918~43747094:-
THCA	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	4.67	3.92e-06	0.00044	0.28	0.21	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
THCA	cis	rs9393777	0.668	rs7746199	ENSG00000219392.1	RP1-265C24.5	4.67	3.93e-06	0.00044	0.29	0.21	Intelligence (multi-trait analysis);	chr6:27293545	chr6:28115628~28116551:+
THCA	cis	rs2562152	0.786	rs216594	ENSG00000226942.2	IL9RP3	-4.67	3.93e-06	0.00044	-0.28	-0.21	Glioblastoma;	chr16:53009	chr16:29336~38321:-
THCA	cis	rs1707322	0.964	rs7546237	ENSG00000281133.1	AL355480.3	-4.67	3.93e-06	0.00044	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211200	ENSG00000281133.1	AL355480.3	-4.67	3.93e-06	0.00044	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs7553924	ENSG00000281133.1	AL355480.3	-4.67	3.93e-06	0.00044	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4641257	ENSG00000281133.1	AL355480.3	-4.67	3.93e-06	0.00044	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs6693336	ENSG00000281133.1	AL355480.3	-4.67	3.93e-06	0.00044	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4539075	ENSG00000281133.1	AL355480.3	-4.67	3.93e-06	0.00044	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211219	ENSG00000281133.1	AL355480.3	-4.67	3.93e-06	0.00044	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211222	ENSG00000281133.1	AL355480.3	-4.67	3.93e-06	0.00044	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45580892~45580996:-
THCA	cis	rs8017455	0.523	rs10149807	ENSG00000259167.2	NMNAT1P1	4.67	3.93e-06	0.00044	0.31	0.21	Hair morphology;	chr14:81097516	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs10149739	ENSG00000259167.2	NMNAT1P1	4.67	3.93e-06	0.00044	0.31	0.21	Hair morphology;	chr14:81097527	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs10149992	ENSG00000259167.2	NMNAT1P1	4.67	3.93e-06	0.00044	0.31	0.21	Hair morphology;	chr14:81097556	chr14:81032529~81033404:+
THCA	cis	rs62025270	0.632	rs17637411	ENSG00000259295.5	CSPG4P12	-4.67	3.93e-06	0.00044	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85703216	chr15:85191438~85213905:+
THCA	cis	rs62025270	0.58	rs62022938	ENSG00000259295.5	CSPG4P12	-4.67	3.93e-06	0.00044	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85704764	chr15:85191438~85213905:+
THCA	cis	rs9309473	0.5	rs13022837	ENSG00000163016.8	ALMS1P	-4.67	3.93e-06	0.00044	-0.26	-0.21	Metabolite levels;	chr2:73685440	chr2:73644919~73685576:+
THCA	cis	rs9880211	1	rs13092193	ENSG00000239213.4	NCK1-AS1	4.67	3.93e-06	0.00044	0.23	0.21	Height;Body mass index;	chr3:136521524	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs6771002	ENSG00000239213.4	NCK1-AS1	4.67	3.93e-06	0.00044	0.23	0.21	Height;Body mass index;	chr3:136522186	chr3:136841726~136862054:-
THCA	cis	rs4639966	0.836	rs11217016	ENSG00000255422.1	AP002954.4	4.67	3.93e-06	0.00044	0.25	0.21	Systemic lupus erythematosus;	chr11:118756440	chr11:118704607~118750263:+
THCA	cis	rs7474896	0.559	rs1208645	ENSG00000226578.1	RP11-258F22.1	4.67	3.93e-06	0.00044	0.29	0.21	Obesity (extreme);	chr10:37843159	chr10:37775371~37784131:-
THCA	cis	rs6545883	0.811	rs778753	ENSG00000271889.1	RP11-493E12.1	4.67	3.93e-06	0.000441	0.2	0.21	Tuberculosis;	chr2:61553065	chr2:61151433~61162105:-
THCA	cis	rs739496	0.579	rs12321677	ENSG00000226469.1	ADAM1B	-4.67	3.93e-06	0.000441	-0.26	-0.21	Platelet count;	chr12:111901211	chr12:111927018~111929017:+
THCA	cis	rs7267979	1	rs2387881	ENSG00000274973.1	RP13-401N8.7	4.67	3.93e-06	0.000441	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25845497~25845862:+
THCA	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-4.67	3.93e-06	0.000441	-0.12	-0.21	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
THCA	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-4.67	3.93e-06	0.000441	-0.3	-0.21	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
THCA	cis	rs7618915	0.547	rs62255371	ENSG00000243224.1	RP5-1157M23.2	-4.67	3.94e-06	0.000441	-0.23	-0.21	Bipolar disorder;	chr3:52713305	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.57	rs11714088	ENSG00000243224.1	RP5-1157M23.2	-4.67	3.94e-06	0.000441	-0.23	-0.21	Bipolar disorder;	chr3:52724926	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs34610878	ENSG00000243224.1	RP5-1157M23.2	-4.67	3.94e-06	0.000441	-0.23	-0.21	Bipolar disorder;	chr3:52725153	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs11130323	ENSG00000243224.1	RP5-1157M23.2	-4.67	3.94e-06	0.000441	-0.23	-0.21	Bipolar disorder;	chr3:52736261	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.547	rs2268026	ENSG00000243224.1	RP5-1157M23.2	-4.67	3.94e-06	0.000441	-0.23	-0.21	Bipolar disorder;	chr3:52744331	chr3:52239258~52241097:+
THCA	cis	rs5742933	1	rs3762545	ENSG00000253559.1	OSGEPL1-AS1	-4.67	3.94e-06	0.000441	-0.26	-0.21	Ferritin levels;	chr2:189790835	chr2:189762704~189765556:+
THCA	cis	rs10761482	0.566	rs7092863	ENSG00000254271.1	RP11-131N11.4	4.67	3.94e-06	0.000441	0.29	0.21	Schizophrenia;	chr10:60421124	chr10:60734342~60741828:+
THCA	cis	rs9300255	0.602	rs1790095	ENSG00000235423.7	RP11-282O18.3	4.67	3.94e-06	0.000441	0.22	0.21	Neutrophil percentage of white cells;	chr12:123196675	chr12:123252030~123261483:-
THCA	cis	rs7989336	0.605	rs9516661	ENSG00000247400.3	DNAJC3-AS1	4.67	3.94e-06	0.000441	0.14	0.21	Obesity;	chr13:96322777	chr13:95648733~95676925:-
THCA	cis	rs10510102	1	rs11200181	ENSG00000226864.1	ATE1-AS1	4.67	3.94e-06	0.000441	0.33	0.21	Breast cancer;	chr10:121828528	chr10:121928312~121951965:+
THCA	cis	rs4415084	0.652	rs11747159	ENSG00000272335.1	RP11-53O19.3	-4.67	3.94e-06	0.000441	-0.18	-0.21	Breast cancer;	chr5:44737608	chr5:44826076~44828592:+
THCA	cis	rs11719291	0.833	rs13074318	ENSG00000270441.1	RP11-694I15.7	4.67	3.94e-06	0.000441	0.31	0.21	Cognitive function;	chr3:48779292	chr3:49140086~49160851:-
THCA	cis	rs7914558	1	rs7920251	ENSG00000236937.2	PTGES3P4	4.67	3.94e-06	0.000441	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:102845595~102845950:+
THCA	cis	rs4218	0.859	rs1486878	ENSG00000259732.1	RP11-59H7.3	-4.67	3.94e-06	0.000441	-0.28	-0.21	Social communication problems;	chr15:59123268	chr15:59121034~59133250:+
THCA	cis	rs12534093	0.701	rs67056093	ENSG00000234286.1	AC006026.13	-4.67	3.94e-06	0.000442	-0.33	-0.21	Infant length;Height;	chr7:23486450	chr7:23680195~23680786:-
THCA	cis	rs922182	0.538	rs16947599	ENSG00000275785.1	RP11-111E14.2	-4.67	3.94e-06	0.000442	-0.24	-0.21	Blood protein levels;	chr15:63968745	chr15:63890030~63890317:+
THCA	cis	rs1552244	0.688	rs9875667	ENSG00000180385.7	EMC3-AS1	4.67	3.94e-06	0.000442	0.23	0.21	Alzheimer's disease;	chr3:10138357	chr3:9986893~10006990:+
THCA	cis	rs2665103	0.589	rs3858953	ENSG00000259429.4	UBE2Q2P2	-4.67	3.94e-06	0.000442	-0.17	-0.21	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82355142~82420075:+
THCA	cis	rs9813712	0.672	rs73210789	ENSG00000253540.4	FAM86HP	4.67	3.95e-06	0.000442	0.26	0.21	Response to amphetamines;	chr3:130243418	chr3:130099092~130111472:-
THCA	cis	rs7267979	1	rs6115182	ENSG00000274973.1	RP13-401N8.7	4.67	3.95e-06	0.000442	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25845497~25845862:+
THCA	cis	rs4245128	0.736	rs7938406	ENSG00000247416.2	RP11-629G13.1	-4.67	3.95e-06	0.000442	-0.2	-0.21	Life satisfaction;	chr11:112952072	chr11:112959279~112963460:-
THCA	cis	rs10129255	0.872	rs10133674	ENSG00000211970.3	IGHV4-61	-4.67	3.95e-06	0.000442	-0.13	-0.21	Kawasaki disease;	chr14:106692788	chr14:106639119~106639657:-
THCA	cis	rs9300255	0.739	rs1969354	ENSG00000235423.7	RP11-282O18.3	4.67	3.95e-06	0.000442	0.22	0.21	Neutrophil percentage of white cells;	chr12:123257229	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.739	rs1533703	ENSG00000235423.7	RP11-282O18.3	4.67	3.95e-06	0.000442	0.22	0.21	Neutrophil percentage of white cells;	chr12:123257546	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.739	rs4759371	ENSG00000235423.7	RP11-282O18.3	4.67	3.95e-06	0.000442	0.22	0.21	Neutrophil percentage of white cells;	chr12:123258016	chr12:123252030~123261483:-
THCA	cis	rs63406760	1	rs63406760	ENSG00000235423.7	RP11-282O18.3	4.67	3.95e-06	0.000442	0.22	0.21	Allergic disease (asthma, hay fever or eczema);	chr12:123258146	chr12:123252030~123261483:-
THCA	cis	rs2191566	0.96	rs11083732	ENSG00000266921.1	RP11-15A1.7	-4.67	3.95e-06	0.000443	-0.2	-0.21	Acute lymphoblastic leukemia (childhood);	chr19:44016591	chr19:43996896~44002836:-
THCA	cis	rs2742234	0.59	rs2503863	ENSG00000273008.1	RP11-351D16.3	-4.67	3.95e-06	0.000443	-0.2	-0.21	Hirschsprung disease;	chr10:43171950	chr10:43136824~43138334:-
THCA	cis	rs7829975	0.572	rs28730413	ENSG00000253981.4	ALG1L13P	-4.67	3.95e-06	0.000443	-0.21	-0.21	Mood instability;	chr8:8937937	chr8:8236003~8244667:-
THCA	cis	rs10911902	0.56	rs76317001	ENSG00000229739.2	RP11-295K2.3	-4.67	3.95e-06	0.000443	-0.34	-0.21	Schizophrenia;	chr1:186303357	chr1:186435161~186470291:+
THCA	cis	rs6500550	0.599	rs2379220	ENSG00000276754.1	RP11-461A8.5	-4.67	3.95e-06	0.000443	-0.19	-0.21	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3644298	chr16:3686998~3687380:+
THCA	cis	rs71007656	1	rs71007656	ENSG00000276805.1	RP11-291L22.6	4.67	3.95e-06	0.000443	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38451030~38451785:+
THCA	cis	rs1005277	0.522	rs289648	ENSG00000276805.1	RP11-291L22.6	4.67	3.95e-06	0.000443	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38451030~38451785:+
THCA	cis	rs2243480	1	rs781156	ENSG00000232559.3	GS1-124K5.12	4.67	3.95e-06	0.000443	0.31	0.21	Diabetic kidney disease;	chr7:66014154	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs451396	ENSG00000232559.3	GS1-124K5.12	4.67	3.95e-06	0.000443	0.31	0.21	Diabetic kidney disease;	chr7:66019087	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1715235	ENSG00000232559.3	GS1-124K5.12	4.67	3.95e-06	0.000443	0.31	0.21	Diabetic kidney disease;	chr7:66023407	chr7:66554588~66576923:-
THCA	cis	rs734999	1	rs734999	ENSG00000225931.3	RP3-395M20.7	4.67	3.96e-06	0.000443	0.25	0.21	Ulcerative colitis;	chr1:2581777	chr1:2566410~2569888:+
THCA	cis	rs734999	1	rs2016366	ENSG00000225931.3	RP3-395M20.7	4.67	3.96e-06	0.000443	0.25	0.21	Ulcerative colitis;	chr1:2582239	chr1:2566410~2569888:+
THCA	cis	rs7520050	0.966	rs12409773	ENSG00000234329.1	RP11-767N6.2	-4.67	3.96e-06	0.000443	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs313809	ENSG00000164669.11	INTS4P1	4.67	3.96e-06	0.000443	0.41	0.21	Diabetic kidney disease;	chr7:66034996	chr7:65141225~65234216:+
THCA	cis	rs35771425	0.642	rs11586974	ENSG00000153363.11	LINC00467	4.67	3.96e-06	0.000443	0.17	0.21	Educational attainment (years of education);	chr1:211290773	chr1:211382803~211435333:+
THCA	cis	rs35771425	0.619	rs7529900	ENSG00000153363.11	LINC00467	-4.67	3.96e-06	0.000443	-0.17	-0.21	Educational attainment (years of education);	chr1:211269319	chr1:211382803~211435333:+
THCA	cis	rs35771425	0.642	rs3767380	ENSG00000153363.11	LINC00467	-4.67	3.96e-06	0.000443	-0.17	-0.21	Educational attainment (years of education);	chr1:211279503	chr1:211382803~211435333:+
THCA	cis	rs4443100	0.77	rs9612214	ENSG00000230701.2	FBXW4P1	4.67	3.96e-06	0.000443	0.25	0.21	Serum parathyroid hormone levels;	chr22:23025318	chr22:23262767~23265005:+
THCA	cis	rs654950	0.806	rs941971	ENSG00000230638.4	RP11-486B10.4	4.67	3.96e-06	0.000443	0.25	0.21	Airway imaging phenotypes;	chr1:41575222	chr1:41542069~41544310:+
THCA	cis	rs2898290	0.622	rs1478890	ENSG00000227888.4	FAM66A	-4.67	3.96e-06	0.000443	-0.27	-0.21	Systolic blood pressure;	chr8:11498093	chr8:12362019~12388296:+
THCA	cis	rs758324	0.681	rs25879	ENSG00000224431.1	AC063976.7	-4.67	3.96e-06	0.000443	-0.19	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132071351	chr5:132199456~132203487:+
THCA	cis	rs17666538	0.642	rs7821983	ENSG00000254207.1	RP11-43A14.1	4.67	3.96e-06	0.000443	0.44	0.21	IgG glycosylation;	chr8:693696	chr8:725188~725877:-
THCA	cis	rs7537765	1	rs41275472	ENSG00000242349.4	NPPA-AS1	-4.67	3.96e-06	0.000443	-0.28	-0.21	QRS complex (12-leadsum);	chr1:11816243	chr1:11841017~11848079:+
THCA	cis	rs7537765	1	rs2050265	ENSG00000242349.4	NPPA-AS1	-4.67	3.96e-06	0.000443	-0.28	-0.21	QRS complex (12-leadsum);	chr1:11819642	chr1:11841017~11848079:+
THCA	cis	rs9650657	0.504	rs6601565	ENSG00000206014.6	OR7E161P	4.67	3.96e-06	0.000443	0.25	0.21	Neuroticism;	chr8:11174719	chr8:11928597~11929563:-
THCA	cis	rs7819412	0.775	rs11773990	ENSG00000206014.6	OR7E161P	4.67	3.96e-06	0.000444	0.24	0.21	Triglycerides;	chr8:11077572	chr8:11928597~11929563:-
THCA	cis	rs7819412	0.775	rs4545055	ENSG00000206014.6	OR7E161P	4.67	3.96e-06	0.000444	0.24	0.21	Triglycerides;	chr8:11077856	chr8:11928597~11929563:-
THCA	cis	rs7819412	0.775	rs2898257	ENSG00000206014.6	OR7E161P	4.67	3.96e-06	0.000444	0.24	0.21	Triglycerides;	chr8:11077858	chr8:11928597~11929563:-
THCA	cis	rs2360027	0.599	rs1408586	ENSG00000231365.4	RP11-418J17.1	4.67	3.96e-06	0.000444	0.21	0.21	Tonsillectomy;	chr1:118537029	chr1:119140396~119275973:+
THCA	cis	rs972578	0.645	rs5751388	ENSG00000274717.1	RP1-47A17.1	-4.67	3.96e-06	0.000444	-0.22	-0.21	Mean platelet volume;	chr22:42854608	chr22:42791814~42794313:-
THCA	cis	rs651907	0.935	rs2926538	ENSG00000256628.3	ZBTB11-AS1	4.67	3.96e-06	0.000444	0.22	0.21	Colorectal cancer;	chr3:101868741	chr3:101676475~101679217:+
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000273796.1	LL21NC02-21A1.1	-4.67	3.96e-06	0.000444	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45403809~45404369:-
THCA	cis	rs7260598	0.539	rs61693040	ENSG00000268442.1	CTD-2027I19.2	4.67	3.96e-06	0.000444	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23883370	chr19:24162370~24163425:-
THCA	cis	rs516805	0.52	rs487098	ENSG00000279453.1	RP3-425C14.4	-4.67	3.96e-06	0.000444	-0.17	-0.21	Lymphocyte counts;	chr6:122444760	chr6:122436789~122439223:-
THCA	cis	rs4789693	0.518	rs6502117	ENSG00000260011.2	RP13-20L14.1	-4.67	3.97e-06	0.000444	-0.21	-0.21	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82381110~82382690:-
THCA	cis	rs7264396	0.836	rs224396	ENSG00000088340.14	FER1L4	4.67	3.97e-06	0.000444	0.19	0.21	Total cholesterol levels;	chr20:35524033	chr20:35558737~35607562:-
THCA	cis	rs7131987	0.903	rs2194518	ENSG00000275476.1	RP11-996F15.4	-4.67	3.97e-06	0.000444	-0.21	-0.21	QT interval;	chr12:29266527	chr12:29277397~29277882:-
THCA	cis	rs440932	1	rs365309	ENSG00000254340.1	RP11-10A14.3	-4.67	3.97e-06	0.000444	-0.23	-0.21	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9141424~9145435:+
THCA	cis	rs481331	0.866	rs522701	ENSG00000215146.4	RP11-313J2.1	4.67	3.97e-06	0.000444	0.34	0.21	Systemic juvenile idiopathic arthritis;	chr10:42674624	chr10:42331866~42367974:-
THCA	cis	rs5758659	0.622	rs5758527	ENSG00000227370.1	RP4-669P10.19	-4.67	3.97e-06	0.000444	-0.2	-0.21	Cognitive function;	chr22:41979757	chr22:42132543~42132998:+
THCA	cis	rs7824557	0.564	rs7828263	ENSG00000206014.6	OR7E161P	4.67	3.97e-06	0.000444	0.25	0.21	Retinal vascular caliber;	chr8:11374377	chr8:11928597~11929563:-
THCA	cis	rs4267450	0.649	rs12151045	ENSG00000261770.1	CTC-459F4.1	-4.67	3.97e-06	0.000444	-0.37	-0.21	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28316162	chr19:27757184~27760849:-
THCA	cis	rs899997	0.773	rs11072783	ENSG00000261143.1	ADAMTS7P3	4.67	3.97e-06	0.000444	0.31	0.21	Coronary artery disease or large artery stroke;	chr15:78673624	chr15:77976042~77993057:+
THCA	cis	rs714027	0.525	rs6006274	ENSG00000279699.1	RP1-102K2.9	4.67	3.97e-06	0.000444	0.22	0.21	Lymphocyte counts;	chr22:29836854	chr22:30275215~30276951:-
THCA	cis	rs4950322	0.512	rs2353974	ENSG00000271721.1	RP11-337C18.9	-4.67	3.97e-06	0.000445	-0.21	-0.21	Protein quantitative trait loci;	chr1:147384534	chr1:147175602~147177740:+
THCA	cis	rs7403037	0.656	rs1846362	ENSG00000260760.1	PWRN3	4.67	3.97e-06	0.000445	0.22	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24323759	chr15:24441127~24447967:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000229886.1	RP5-1132H15.3	-4.67	3.97e-06	0.000445	-0.22	-0.21	Aortic root size;	chr7:66589419	chr7:66025126~66031544:-
THCA	cis	rs7176527	0.519	rs12148368	ENSG00000188388.10	GOLGA6L3	4.67	3.97e-06	0.000445	0.27	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85240472~85247170:+
THCA	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-4.67	3.97e-06	0.000445	-0.25	-0.21	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
THCA	cis	rs793571	0.628	rs12591310	ENSG00000259250.1	RP11-50C13.1	-4.67	3.97e-06	0.000445	-0.22	-0.21	Schizophrenia;	chr15:58792069	chr15:58587507~58591676:+
THCA	cis	rs8141529	0.748	rs132531	ENSG00000226471.5	CTA-292E10.6	4.67	3.97e-06	0.000445	0.17	0.21	Lymphocyte counts;	chr22:28901377	chr22:28800683~28848559:+
THCA	cis	rs7403037	0.959	rs35600665	ENSG00000260760.1	PWRN3	4.67	3.97e-06	0.000445	0.25	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24496144	chr15:24441127~24447967:+
THCA	cis	rs375066	1	rs375066	ENSG00000278917.1	RP11-15A1.4	-4.67	3.97e-06	0.000445	-0.18	-0.21	Breast cancer;	chr19:43919418	chr19:43891233~43895411:+
THCA	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-4.67	3.98e-06	0.000445	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
THCA	cis	rs12410462	0.591	rs2819508	ENSG00000227711.2	RP11-275O4.5	-4.67	3.98e-06	0.000445	-0.26	-0.21	Major depressive disorder;	chr1:227516483	chr1:227509028~227520477:-
THCA	cis	rs17767392	0.834	rs11626886	ENSG00000259146.3	RP1-261D10.2	4.67	3.98e-06	0.000445	0.28	0.21	Mitral valve prolapse;	chr14:71260438	chr14:71292729~71321814:-
THCA	cis	rs8049040	0.586	rs8060176	ENSG00000260886.1	TAT-AS1	4.67	3.98e-06	0.000445	0.29	0.21	Blood protein levels;	chr16:71422854	chr16:71565789~71578187:+
THCA	cis	rs17597773	0.527	rs2484698	ENSG00000272823.1	RP11-295M18.6	4.67	3.98e-06	0.000445	0.25	0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220912723	chr1:220828676~220829211:-
THCA	cis	rs172166	0.694	rs203893	ENSG00000261839.1	RP1-265C24.8	4.67	3.98e-06	0.000445	0.23	0.21	Cardiac Troponin-T levels;	chr6:28094288	chr6:28136849~28139678:+
THCA	cis	rs11148252	0.595	rs4884522	ENSG00000273784.3	RP11-78J21.7	-4.67	3.98e-06	0.000445	-0.23	-0.21	Lewy body disease;	chr13:52479633	chr13:52600042~52642542:+
THCA	cis	rs1923243	0.71	rs11210174	ENSG00000223479.3	RP4-788P17.1	-4.67	3.98e-06	0.000446	-0.23	-0.21	Migraine;	chr1:73181389	chr1:73635216~73715214:+
THCA	cis	rs728616	0.558	rs723192	ENSG00000242600.5	MBL1P	4.67	3.98e-06	0.000446	0.22	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948257	chr10:79904898~79950336:+
THCA	cis	rs72945132	0.882	rs59681006	ENSG00000254604.1	AP000487.6	-4.67	3.98e-06	0.000446	-0.39	-0.21	Coronary artery disease;	chr11:70333295	chr11:70282367~70363368:-
THCA	cis	rs9549367	0.789	rs9549698	ENSG00000269125.1	RP11-98F14.11	-4.67	3.98e-06	0.000446	-0.25	-0.21	Platelet distribution width;	chr13:113223387	chr13:113165002~113165183:-
THCA	cis	rs6940638	0.637	rs13217239	ENSG00000216901.1	AL022393.7	4.67	3.98e-06	0.000446	0.26	0.21	Intelligence (multi-trait analysis);	chr6:27287188	chr6:28176188~28176674:+
THCA	cis	rs36093844	0.752	rs17744606	ENSG00000279742.1	RP11-700A24.1	-4.67	3.98e-06	0.000446	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85854407	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs75203358	ENSG00000279742.1	RP11-700A24.1	-4.67	3.98e-06	0.000446	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85856347	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs79349553	ENSG00000279742.1	RP11-700A24.1	-4.67	3.98e-06	0.000446	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85856793	chr11:85852557~85854943:-
THCA	cis	rs897984	0.568	rs72799330	ENSG00000260911.2	RP11-196G11.2	4.67	3.98e-06	0.000446	0.2	0.21	Dementia with Lewy bodies;	chr16:30882234	chr16:31043150~31049868:+
THCA	cis	rs7432375	0.901	rs7648531	ENSG00000273455.1	RP11-305O4.3	-4.67	3.99e-06	0.000446	-0.28	-0.21	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136743381	chr3:136087475~136087913:-
THCA	cis	rs738144	0.612	rs760485	ENSG00000235209.1	CTA-150C2.13	-4.67	3.99e-06	0.000446	-0.32	-0.21	IgG glycosylation;	chr22:38817512	chr22:38921227~38924708:+
THCA	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	4.67	3.99e-06	0.000446	0.23	0.21	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
THCA	cis	rs4934494	0.727	rs12572012	ENSG00000240996.1	RP11-80H5.7	-4.67	3.99e-06	0.000446	-0.24	-0.21	Red blood cell count;	chr10:89727892	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.727	rs3758388	ENSG00000240996.1	RP11-80H5.7	-4.67	3.99e-06	0.000446	-0.24	-0.21	Red blood cell count;	chr10:89729222	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.727	rs12783582	ENSG00000240996.1	RP11-80H5.7	-4.67	3.99e-06	0.000446	-0.24	-0.21	Red blood cell count;	chr10:89735210	chr10:89694295~89697928:-
THCA	cis	rs7809950	0.768	rs2701678	ENSG00000238832.1	snoU109	4.67	3.99e-06	0.000446	0.24	0.21	Coronary artery disease;	chr7:107643266	chr7:107603363~107603507:+
THCA	cis	rs7809950	0.817	rs2701679	ENSG00000238832.1	snoU109	4.67	3.99e-06	0.000446	0.24	0.21	Coronary artery disease;	chr7:107643463	chr7:107603363~107603507:+
THCA	cis	rs274567	0.55	rs272885	ENSG00000224431.1	AC063976.7	4.67	3.99e-06	0.000446	0.19	0.21	Blood metabolite levels;	chr5:132332043	chr5:132199456~132203487:+
THCA	cis	rs1555322	0.53	rs8122819	ENSG00000279253.1	RP4-614O4.13	-4.67	3.99e-06	0.000446	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35262727~35264187:-
THCA	cis	rs9467773	0.62	rs2101582	ENSG00000124549.13	BTN2A3P	4.67	3.99e-06	0.000447	0.19	0.21	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26421391~26432383:+
THCA	cis	rs17292804	0.506	rs71417868	ENSG00000269958.1	RP11-73M18.8	4.67	3.99e-06	0.000447	0.2	0.21	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103696353~103697163:+
THCA	cis	rs28510890	0.547	rs12441705	ENSG00000258676.4	RP11-386M24.3	4.67	3.99e-06	0.000447	0.24	0.21	Lung cancer in ever smokers;	chr15:92609319	chr15:92580829~92600545:+
THCA	cis	rs1555322	0.932	rs2425018	ENSG00000126005.14	MMP24-AS1	-4.67	3.99e-06	0.000447	-0.29	-0.21	Attention deficit hyperactivity disorder;	chr20:35230963	chr20:35216462~35278131:-
THCA	cis	rs4415084	1	rs1438825	ENSG00000272335.1	RP11-53O19.3	-4.67	3.99e-06	0.000447	-0.17	-0.21	Breast cancer;	chr5:44706829	chr5:44826076~44828592:+
THCA	cis	rs13126694	0.805	rs7692698	ENSG00000248429.4	RP11-597D13.9	4.67	3.99e-06	0.000447	0.23	0.21	Blood osmolality (transformed sodium);	chr4:157945200	chr4:158170752~158202877:+
THCA	cis	rs1371614	0.523	rs893789	ENSG00000229122.1	AGBL5-IT1	4.67	3.99e-06	0.000447	0.15	0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26961102	chr2:27061038~27061815:+
THCA	cis	rs1923243	0.71	rs6703953	ENSG00000223479.3	RP4-788P17.1	-4.67	3.99e-06	0.000447	-0.23	-0.21	Migraine;	chr1:73180183	chr1:73635216~73715214:+
THCA	cis	rs829883	0.622	rs7302630	ENSG00000227825.4	SLC9A7P1	-4.67	3.99e-06	0.000447	-0.2	-0.21	Colorectal adenoma (advanced);	chr12:98565799	chr12:98453835~98457145:-
THCA	cis	rs4906332	1	rs4900574	ENSG00000269910.1	RP11-73M18.10	-4.67	3.99e-06	0.000447	-0.18	-0.21	Coronary artery disease;	chr14:103412687	chr14:103694516~103695050:-
THCA	cis	rs6870983	0.749	rs7737179	ENSG00000247828.6	TMEM161B-AS1	-4.67	3.99e-06	0.000447	-0.18	-0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88499708	chr5:88268895~88436685:+
THCA	cis	rs703842	1	rs3825079	ENSG00000270039.1	RP11-571M6.17	-4.67	3.99e-06	0.000447	-0.24	-0.21	Multiple sclerosis;	chr12:57809571	chr12:57803838~57804415:+
THCA	cis	rs4767841	0.935	rs4766946	ENSG00000248636.5	RP11-768F21.1	-4.67	4e-06	0.000447	-0.22	-0.21	Urgency urinary incontinence;	chr12:119723516	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.935	rs4767840	ENSG00000248636.5	RP11-768F21.1	-4.67	4e-06	0.000447	-0.22	-0.21	Urgency urinary incontinence;	chr12:119724393	chr12:119387987~119668079:-
THCA	cis	rs1979679	0.842	rs7316299	ENSG00000247934.4	RP11-967K21.1	-4.67	4e-06	0.000447	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28179757	chr12:28163298~28190738:-
THCA	cis	rs6964833	1	rs34324835	ENSG00000278416.1	PMS2L2	4.67	4e-06	0.000447	0.33	0.21	Menarche (age at onset);	chr7:74717986	chr7:75344015~75359550:-
THCA	cis	rs8028182	0.636	rs11636199	ENSG00000260269.4	CTD-2323K18.1	-4.67	4e-06	0.000447	-0.31	-0.21	Sudden cardiac arrest;	chr15:75532996	chr15:75527150~75601205:-
THCA	cis	rs67478160	0.619	rs8018062	ENSG00000269910.1	RP11-73M18.10	4.67	4e-06	0.000447	0.18	0.21	Schizophrenia;	chr14:103815617	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs2223937	ENSG00000269910.1	RP11-73M18.10	4.67	4e-06	0.000447	0.18	0.21	Schizophrenia;	chr14:103820043	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs4900600	ENSG00000269910.1	RP11-73M18.10	4.67	4e-06	0.000447	0.18	0.21	Schizophrenia;	chr14:103825502	chr14:103694516~103695050:-
THCA	cis	rs7555523	0.778	rs4233408	ENSG00000224358.1	RP11-466F5.8	-4.67	4e-06	0.000447	-0.32	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165743723	chr1:165768929~165775176:+
THCA	cis	rs3734266	0.702	rs7764126	ENSG00000272288.4	RP11-140K17.3	-4.67	4e-06	0.000447	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34821285	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs71567467	ENSG00000272288.4	RP11-140K17.3	-4.67	4e-06	0.000447	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34822832	chr6:34696317~34697470:+
THCA	cis	rs718433	0.584	rs7158042	ENSG00000211778.2	TRAV4	4.67	4e-06	0.000448	0.16	0.21	Intraocular pressure;	chr14:21752794	chr14:21736152~21736982:+
THCA	cis	rs7551222	0.681	rs4245739	ENSG00000240219.1	RP11-430C7.5	4.67	4e-06	0.000448	0.22	0.21	Schizophrenia;	chr1:204549714	chr1:204626775~204629712:+
THCA	cis	rs1790761	0.658	rs684928	ENSG00000255318.1	RP11-655M14.13	4.67	4e-06	0.000448	0.24	0.21	Mean corpuscular volume;	chr11:67562271	chr11:67618279~67627304:-
THCA	cis	rs7615952	0.799	rs13315434	ENSG00000248787.1	RP11-666A20.4	-4.67	4e-06	0.000448	-0.35	-0.21	Blood pressure (smoking interaction);	chr3:125922551	chr3:125908005~125910272:-
THCA	cis	rs9925964	0.622	rs8046707	ENSG00000232748.3	RP11-196G11.6	4.67	4e-06	0.000448	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30904912	chr16:31056460~31062803:+
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000275400.1	RP4-756H11.5	-4.67	4e-06	0.000448	-0.23	-0.21	Corneal structure;	chr7:66790251	chr7:66553805~66554199:-
THCA	cis	rs925946	0.666	rs10835211	ENSG00000245573.6	BDNF-AS	-4.67	4e-06	0.000448	-0.23	-0.21	Weight;Body mass index;	chr11:27679818	chr11:27506838~27698174:+
THCA	cis	rs5742933	1	rs7557519	ENSG00000253559.1	OSGEPL1-AS1	-4.67	4e-06	0.000448	-0.26	-0.21	Ferritin levels;	chr2:189718461	chr2:189762704~189765556:+
THCA	cis	rs9925964	0.804	rs4889606	ENSG00000232748.3	RP11-196G11.6	-4.67	4e-06	0.000448	-0.25	-0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30999862	chr16:31056460~31062803:+
THCA	cis	rs2948294	0.588	rs12544596	ENSG00000253981.4	ALG1L13P	4.67	4e-06	0.000448	0.2	0.21	Red cell distribution width;	chr8:8258824	chr8:8236003~8244667:-
THCA	cis	rs7264396	1	rs224415	ENSG00000088340.14	FER1L4	4.67	4.01e-06	0.000448	0.2	0.21	Total cholesterol levels;	chr20:35547876	chr20:35558737~35607562:-
THCA	cis	rs12761761	1	rs12411375	ENSG00000279982.1	RP11-45A17.3	-4.67	4.01e-06	0.000448	-0.33	-0.21	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131962329	chr10:131996738~131999846:+
THCA	cis	rs748404	0.601	rs489964	ENSG00000166763.7	STRCP1	-4.67	4.01e-06	0.000448	-0.22	-0.21	Lung cancer;	chr15:43225356	chr15:43699488~43718184:-
THCA	cis	rs3845817	0.832	rs702950	ENSG00000237979.1	AC007389.1	4.67	4.01e-06	0.000448	0.24	0.21	Bipolar disorder;	chr2:65537776	chr2:65500993~65502138:-
THCA	cis	rs34929064	0.836	rs2961301	ENSG00000179428.2	AC073072.5	4.67	4.01e-06	0.000448	0.24	0.21	Major depression and alcohol dependence;	chr7:22669410	chr7:22725395~22727620:-
THCA	cis	rs9880211	0.699	rs9809269	ENSG00000239213.4	NCK1-AS1	4.67	4.01e-06	0.000448	0.25	0.21	Height;Body mass index;	chr3:136711064	chr3:136841726~136862054:-
THCA	cis	rs1790761	0.559	rs10896190	ENSG00000255318.1	RP11-655M14.13	4.67	4.01e-06	0.000449	0.24	0.21	Mean corpuscular volume;	chr11:67638652	chr11:67618279~67627304:-
THCA	cis	rs7520050	0.933	rs11211203	ENSG00000234329.1	RP11-767N6.2	-4.67	4.01e-06	0.000449	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs4660317	ENSG00000234329.1	RP11-767N6.2	-4.67	4.01e-06	0.000449	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs10749860	ENSG00000234329.1	RP11-767N6.2	-4.67	4.01e-06	0.000449	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs6688365	ENSG00000234329.1	RP11-767N6.2	-4.67	4.01e-06	0.000449	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6656992	ENSG00000234329.1	RP11-767N6.2	-4.67	4.01e-06	0.000449	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs61783220	ENSG00000234329.1	RP11-767N6.2	-4.67	4.01e-06	0.000449	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45651039~45651826:-
THCA	cis	rs34792	0.554	rs4597346	ENSG00000207425.1	Y_RNA	-4.67	4.01e-06	0.000449	-0.24	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:14915457~14915556:-
THCA	cis	rs1923243	0.71	rs12087611	ENSG00000223479.3	RP4-788P17.1	-4.67	4.01e-06	0.000449	-0.23	-0.21	Migraine;	chr1:73181022	chr1:73635216~73715214:+
THCA	cis	rs911119	0.955	rs8116859	ENSG00000270001.1	RP11-218C14.8	-4.67	4.01e-06	0.000449	-0.31	-0.21	Chronic kidney disease;	chr20:23610066	chr20:23631826~23632316:-
THCA	cis	rs10888838	0.652	rs11577661	ENSG00000198711.5	SSBP3-AS1	4.67	4.01e-06	0.000449	0.26	0.21	Mitochondrial DNA levels;	chr1:54227863	chr1:54236440~54239063:+
THCA	cis	rs7829975	0.564	rs2921057	ENSG00000253981.4	ALG1L13P	4.67	4.01e-06	0.000449	0.21	0.21	Mood instability;	chr8:8461157	chr8:8236003~8244667:-
THCA	cis	rs7402982	0.647	rs34038360	ENSG00000278022.1	RP11-35O15.2	-4.67	4.01e-06	0.000449	-0.22	-0.21	Birth weight;	chr15:98658344	chr15:98660210~98660668:+
THCA	cis	rs62158800	0.789	rs62158808	ENSG00000237880.1	AC096669.2	4.67	4.01e-06	0.000449	0.34	0.21	Facial morphology (factor 22);	chr2:107607292	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.925	rs62158810	ENSG00000237880.1	AC096669.2	4.67	4.01e-06	0.000449	0.34	0.21	Facial morphology (factor 22);	chr2:107612391	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.789	rs56158390	ENSG00000237880.1	AC096669.2	4.67	4.01e-06	0.000449	0.34	0.21	Facial morphology (factor 22);	chr2:107618616	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.925	rs62158827	ENSG00000237880.1	AC096669.2	4.67	4.01e-06	0.000449	0.34	0.21	Facial morphology (factor 22);	chr2:107624823	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.925	rs72823069	ENSG00000237880.1	AC096669.2	4.67	4.01e-06	0.000449	0.34	0.21	Facial morphology (factor 22);	chr2:107627392	chr2:107385632~107542649:-
THCA	cis	rs1577917	0.883	rs9450375	ENSG00000220563.1	PKMP3	4.67	4.01e-06	0.000449	0.15	0.21	Response to antipsychotic treatment;	chr6:86046911	chr6:85659892~85660606:-
THCA	cis	rs2380220	0.872	rs115871915	ENSG00000261366.1	MANEA-AS1	4.67	4.01e-06	0.000449	0.24	0.21	Behavioural disinhibition (generation interaction);	chr6:95486304	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs72922390	ENSG00000261366.1	MANEA-AS1	4.67	4.01e-06	0.000449	0.24	0.21	Behavioural disinhibition (generation interaction);	chr6:95486441	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.81	rs877096	ENSG00000261366.1	MANEA-AS1	4.67	4.01e-06	0.000449	0.24	0.21	Behavioural disinhibition (generation interaction);	chr6:95489170	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.872	rs2613529	ENSG00000261366.1	MANEA-AS1	4.67	4.01e-06	0.000449	0.24	0.21	Behavioural disinhibition (generation interaction);	chr6:95497160	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.872	rs67846436	ENSG00000261366.1	MANEA-AS1	4.67	4.01e-06	0.000449	0.24	0.21	Behavioural disinhibition (generation interaction);	chr6:95503645	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.872	rs66723559	ENSG00000261366.1	MANEA-AS1	4.67	4.01e-06	0.000449	0.24	0.21	Behavioural disinhibition (generation interaction);	chr6:95508462	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.81	rs66524640	ENSG00000261366.1	MANEA-AS1	4.67	4.01e-06	0.000449	0.24	0.21	Behavioural disinhibition (generation interaction);	chr6:95508690	chr6:95575183~95577450:-
THCA	cis	rs7819412	0.775	rs4841490	ENSG00000206014.6	OR7E161P	4.67	4.01e-06	0.000449	0.24	0.21	Triglycerides;	chr8:11079381	chr8:11928597~11929563:-
THCA	cis	rs11858159	0.565	rs8038318	ENSG00000260760.1	PWRN3	-4.67	4.01e-06	0.000449	-0.21	-0.21	Platelet thrombus formation;	chr15:24561913	chr15:24441127~24447967:+
THCA	cis	rs756699	0.822	rs244656	ENSG00000279469.1	RP11-215P8.2	-4.67	4.02e-06	0.000449	-0.33	-0.21	Multiple sclerosis;	chr5:134114136	chr5:134394360~134395008:-
THCA	cis	rs1048886	0.872	rs2639297	ENSG00000271967.1	RP11-134K13.4	4.67	4.02e-06	0.000449	0.22	0.21	Type 2 diabetes;	chr6:70509354	chr6:70596438~70596980:+
THCA	cis	rs6088590	0.735	rs6088618	ENSG00000269202.1	RP4-614O4.12	-4.67	4.02e-06	0.000449	-0.18	-0.21	Coronary artery disease;	chr20:34821547	chr20:35201747~35203288:-
THCA	cis	rs6860806	0.531	rs272887	ENSG00000237714.1	P4HA2-AS1	4.67	4.02e-06	0.000449	0.28	0.21	Breast cancer;	chr5:132330020	chr5:132184876~132192808:+
THCA	cis	rs9300255	0.602	rs1716168	ENSG00000235423.7	RP11-282O18.3	-4.67	4.02e-06	0.000449	-0.22	-0.21	Neutrophil percentage of white cells;	chr12:123167419	chr12:123252030~123261483:-
THCA	cis	rs7731390	0.51	rs28435738	ENSG00000233006.5	AC034220.3	4.67	4.02e-06	0.000449	0.27	0.21	IgG glycosylation;	chr5:132423947	chr5:132311285~132369916:-
THCA	cis	rs11846409	0.818	rs2516909	ENSG00000274576.2	IGHV2-70	4.67	4.02e-06	0.000449	0.18	0.21	Rheumatic heart disease;	chr14:106630317	chr14:106770577~106771020:-
THCA	cis	rs829883	0.659	rs11109521	ENSG00000227825.4	SLC9A7P1	-4.67	4.02e-06	0.00045	-0.21	-0.21	Colorectal adenoma (advanced);	chr12:98537031	chr12:98453835~98457145:-
THCA	cis	rs829883	0.659	rs11109522	ENSG00000227825.4	SLC9A7P1	-4.67	4.02e-06	0.00045	-0.21	-0.21	Colorectal adenoma (advanced);	chr12:98537186	chr12:98453835~98457145:-
THCA	cis	rs829883	0.646	rs4762494	ENSG00000227825.4	SLC9A7P1	-4.67	4.02e-06	0.00045	-0.21	-0.21	Colorectal adenoma (advanced);	chr12:98540056	chr12:98453835~98457145:-
THCA	cis	rs829883	0.659	rs4762495	ENSG00000227825.4	SLC9A7P1	-4.67	4.02e-06	0.00045	-0.21	-0.21	Colorectal adenoma (advanced);	chr12:98540327	chr12:98453835~98457145:-
THCA	cis	rs4713118	0.786	rs200503	ENSG00000220721.1	OR1F12	4.67	4.02e-06	0.00045	0.28	0.21	Parkinson's disease;	chr6:27818104	chr6:28073316~28074233:+
THCA	cis	rs12291225	0.546	rs12291662	ENSG00000251991.1	RNU7-49P	4.67	4.02e-06	0.00045	0.24	0.21	Sense of smell;	chr11:14321403	chr11:14478892~14478953:+
THCA	cis	rs12291225	0.545	rs11023187	ENSG00000251991.1	RNU7-49P	4.67	4.02e-06	0.00045	0.24	0.21	Sense of smell;	chr11:14324013	chr11:14478892~14478953:+
THCA	cis	rs12291225	0.585	rs10832242	ENSG00000251991.1	RNU7-49P	-4.67	4.02e-06	0.00045	-0.24	-0.21	Sense of smell;	chr11:14318958	chr11:14478892~14478953:+
THCA	cis	rs73108077	0.736	rs17325435	ENSG00000277112.2	RP11-755J8.1	-4.67	4.02e-06	0.00045	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31259887	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs73119535	ENSG00000277112.2	RP11-755J8.1	-4.67	4.02e-06	0.00045	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31260483	chr20:30681825~30723932:-
THCA	cis	rs9329221	0.678	rs560638	ENSG00000248538.5	RP11-10A14.5	4.67	4.02e-06	0.00045	0.26	0.21	Neuroticism;	chr8:10025257	chr8:9189011~9202854:+
THCA	cis	rs2742234	0.59	rs2435377	ENSG00000273008.1	RP11-351D16.3	4.67	4.02e-06	0.00045	0.2	0.21	Hirschsprung disease;	chr10:43188152	chr10:43136824~43138334:-
THCA	cis	rs7208859	0.614	rs7216394	ENSG00000266490.1	CTD-2349P21.9	-4.67	4.02e-06	0.00045	-0.27	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30792372~30792833:+
THCA	cis	rs7178572	0.598	rs907373	ENSG00000259362.2	RP11-307C19.1	-4.67	4.02e-06	0.00045	-0.26	-0.21	Type 2 diabetes;	chr15:77552212	chr15:77525540~77534110:+
THCA	cis	rs11089937	0.626	rs4820337	ENSG00000211638.2	IGLV8-61	4.67	4.02e-06	0.00045	0.17	0.21	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22098700~22099212:+
THCA	cis	rs6496932	0.635	rs11074191	ENSG00000259630.2	CTD-2262B20.1	-4.67	4.02e-06	0.00045	-0.26	-0.21	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85415228~85415633:+
THCA	cis	rs447735	0.537	rs7190341	ENSG00000260259.1	RP11-368I7.4	-4.67	4.02e-06	0.00045	-0.24	-0.21	Hemoglobin concentration;	chr16:89851129	chr16:89682620~89686569:-
THCA	cis	rs7520050	0.966	rs7539932	ENSG00000234329.1	RP11-767N6.2	-4.67	4.02e-06	0.00045	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs61783200	ENSG00000234329.1	RP11-767N6.2	-4.67	4.02e-06	0.00045	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6680380	ENSG00000234329.1	RP11-767N6.2	-4.67	4.02e-06	0.00045	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs10890354	ENSG00000234329.1	RP11-767N6.2	-4.67	4.02e-06	0.00045	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs6697557	ENSG00000234329.1	RP11-767N6.2	-4.67	4.02e-06	0.00045	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6701614	ENSG00000234329.1	RP11-767N6.2	-4.67	4.02e-06	0.00045	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45651039~45651826:-
THCA	cis	rs757110	0.59	rs7484027	ENSG00000260196.1	RP1-239B22.5	-4.67	4.02e-06	0.00045	-0.21	-0.21	Type 2 diabetes;	chr11:17346834	chr11:17380649~17383531:+
THCA	cis	rs6545883	0.894	rs2167566	ENSG00000270820.4	RP11-355B11.2	4.67	4.03e-06	0.00045	0.17	0.21	Tuberculosis;	chr2:61292273	chr2:61471188~61484130:+
THCA	cis	rs2688482	0.512	rs3103954	ENSG00000185485.13	SDHAP1	4.67	4.03e-06	0.00045	0.23	0.21	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195959748~195990318:-
THCA	cis	rs9910055	0.659	rs8079310	ENSG00000267080.4	ASB16-AS1	-4.67	4.03e-06	0.00045	-0.19	-0.21	Total body bone mineral density;	chr17:44192923	chr17:44175973~44186717:-
THCA	cis	rs2694917	0.669	rs774211	ENSG00000257576.1	RP11-153M3.1	4.67	4.03e-06	0.00045	0.35	0.21	Blood metabolite ratios;	chr12:56527155	chr12:56511002~56512703:+
THCA	cis	rs1003719	0.523	rs1063949	ENSG00000230366.8	DSCR9	4.67	4.03e-06	0.000451	0.22	0.21	Eye color traits;	chr21:37202374	chr21:37208503~37221736:+
THCA	cis	rs2360027	0.599	rs10923589	ENSG00000231365.4	RP11-418J17.1	-4.66	4.03e-06	0.000451	-0.22	-0.21	Tonsillectomy;	chr1:118531333	chr1:119140396~119275973:+
THCA	cis	rs5751901	0.575	rs2154611	ENSG00000215481.7	BCRP3	-4.66	4.03e-06	0.000451	-0.19	-0.21	Protein quantitative trait loci;	chr22:24593953	chr22:24632915~24653356:+
THCA	cis	rs6433895	0.883	rs11684463	ENSG00000236153.1	AC104076.3	-4.66	4.03e-06	0.000451	-0.24	-0.21	Lymphocyte counts;	chr2:181212808	chr2:180979427~180980090:-
THCA	cis	rs6433895	0.845	rs34366526	ENSG00000236153.1	AC104076.3	-4.66	4.03e-06	0.000451	-0.24	-0.21	Lymphocyte counts;	chr2:181217966	chr2:180979427~180980090:-
THCA	cis	rs4578769	0.55	rs11082225	ENSG00000265939.1	UBE2CP2	4.66	4.03e-06	0.000451	0.24	0.21	Eosinophil percentage of white cells;	chr18:22963794	chr18:22900486~22900995:-
THCA	cis	rs2439831	1	rs2467743	ENSG00000205771.5	CATSPER2P1	-4.66	4.03e-06	0.000451	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43458148	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2245176	ENSG00000205771.5	CATSPER2P1	-4.66	4.03e-06	0.000451	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43458564	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2245054	ENSG00000205771.5	CATSPER2P1	-4.66	4.03e-06	0.000451	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43459711	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2264876	ENSG00000205771.5	CATSPER2P1	-4.66	4.03e-06	0.000451	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43465221	chr15:43726918~43747094:-
THCA	cis	rs3734266	0.702	rs35940001	ENSG00000272288.4	RP11-140K17.3	-4.66	4.03e-06	0.000451	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34838763	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs11966100	ENSG00000272288.4	RP11-140K17.3	-4.66	4.03e-06	0.000451	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34839740	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs34480956	ENSG00000272288.4	RP11-140K17.3	-4.66	4.03e-06	0.000451	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34840324	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs13196785	ENSG00000272288.4	RP11-140K17.3	-4.66	4.03e-06	0.000451	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34841044	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs13213288	ENSG00000272288.4	RP11-140K17.3	-4.66	4.03e-06	0.000451	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34844683	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs34840245	ENSG00000272288.4	RP11-140K17.3	-4.66	4.03e-06	0.000451	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34844924	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs34355573	ENSG00000272288.4	RP11-140K17.3	-4.66	4.03e-06	0.000451	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34849619	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs35203657	ENSG00000272288.4	RP11-140K17.3	-4.66	4.03e-06	0.000451	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34853513	chr6:34696317~34697470:+
THCA	cis	rs1150668	0.745	rs213238	ENSG00000176933.5	TOB2P1	-4.66	4.03e-06	0.000451	-0.23	-0.21	Pubertal anthropometrics;	chr6:28354216	chr6:28217643~28218634:-
THCA	cis	rs2886497	0.894	rs12358180	ENSG00000224215.1	RP11-371A19.2	-4.66	4.03e-06	0.000451	-0.27	-0.21	Major depression and alcohol dependence;	chr10:23398399	chr10:23343957~23345181:+
THCA	cis	rs2018683	1	rs4719962	ENSG00000272568.4	CTB-113D17.1	4.66	4.03e-06	0.000451	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959621	chr7:28979967~29013367:+
THCA	cis	rs412050	0.793	rs238782	ENSG00000224086.5	LL22NC03-86G7.1	-4.66	4.04e-06	0.000451	-0.36	-0.21	Attention deficit hyperactivity disorder;	chr22:21987595	chr22:21938293~21977632:+
THCA	cis	rs494453	0.922	rs531692	ENSG00000227811.2	FAM212B-AS1	-4.66	4.04e-06	0.000451	-0.26	-0.21	Osteoporosis-related phenotypes;	chr1:111691954	chr1:111739841~111747798:+
THCA	cis	rs56313388	0.522	rs2060680	ENSG00000246379.5	RP11-461O7.1	-4.66	4.04e-06	0.000451	-0.22	-0.21	Pulse pressure;	chr16:56121550	chr16:56092987~56191094:-
THCA	cis	rs1005277	0.54	rs1814077	ENSG00000276805.1	RP11-291L22.6	4.66	4.04e-06	0.000451	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38451030~38451785:+
THCA	cis	rs4639966	0.836	rs7110526	ENSG00000255422.1	AP002954.4	4.66	4.04e-06	0.000451	0.25	0.21	Systemic lupus erythematosus;	chr11:118762824	chr11:118704607~118750263:+
THCA	cis	rs4639966	0.836	rs11217018	ENSG00000255422.1	AP002954.4	4.66	4.04e-06	0.000451	0.25	0.21	Systemic lupus erythematosus;	chr11:118764656	chr11:118704607~118750263:+
THCA	cis	rs4639966	0.797	rs11217021	ENSG00000255422.1	AP002954.4	4.66	4.04e-06	0.000451	0.25	0.21	Systemic lupus erythematosus;	chr11:118770119	chr11:118704607~118750263:+
THCA	cis	rs5758659	0.504	rs133367	ENSG00000227370.1	RP4-669P10.19	4.66	4.04e-06	0.000451	0.19	0.21	Cognitive function;	chr22:42067362	chr22:42132543~42132998:+
THCA	cis	rs2286503	0.65	rs1990279	ENSG00000226329.2	AC005682.6	4.66	4.04e-06	0.000451	0.26	0.21	Fibrinogen;	chr7:22851123	chr7:22863874~22881350:-
THCA	cis	rs930395	0.514	rs6868779	ENSG00000272335.1	RP11-53O19.3	4.66	4.04e-06	0.000452	0.18	0.21	Breast cancer;	chr5:44885898	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.652	rs10045264	ENSG00000272335.1	RP11-53O19.3	4.66	4.04e-06	0.000452	0.18	0.21	Breast cancer;	chr5:44886330	chr5:44826076~44828592:+
THCA	cis	rs8062405	0.964	rs62036614	ENSG00000261766.1	RP11-22P6.2	-4.66	4.04e-06	0.000452	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28862166~28863340:-
THCA	cis	rs7618915	0.571	rs6762457	ENSG00000243224.1	RP5-1157M23.2	-4.66	4.04e-06	0.000452	-0.23	-0.21	Bipolar disorder;	chr3:52575141	chr3:52239258~52241097:+
THCA	cis	rs748404	0.666	rs66629206	ENSG00000205771.5	CATSPER2P1	-4.66	4.04e-06	0.000452	-0.27	-0.21	Lung cancer;	chr15:43458804	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.681	rs524527	ENSG00000205771.5	CATSPER2P1	4.66	4.04e-06	0.000452	0.27	0.21	Lung cancer in ever smokers;	chr15:43306918	chr15:43726918~43747094:-
THCA	cis	rs10090774	0.965	rs10105905	ENSG00000279766.1	RP11-642A1.2	-4.66	4.04e-06	0.000452	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140850796	chr8:140572142~140572812:-
THCA	cis	rs6088580	0.634	rs6088484	ENSG00000276073.1	RP5-1125A11.7	4.66	4.04e-06	0.000452	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34398155	chr20:33985617~33988989:-
THCA	cis	rs1396485	0.607	rs17138861	ENSG00000248445.4	SEMA6A-AS1	-4.66	4.05e-06	0.000452	-0.21	-0.21	Inflammatory biomarkers;	chr5:116088173	chr5:116447547~116508276:+
THCA	cis	rs1396485	0.556	rs57552008	ENSG00000248445.4	SEMA6A-AS1	-4.66	4.05e-06	0.000452	-0.21	-0.21	Inflammatory biomarkers;	chr5:116088287	chr5:116447547~116508276:+
THCA	cis	rs1396485	0.607	rs59583434	ENSG00000248445.4	SEMA6A-AS1	-4.66	4.05e-06	0.000452	-0.21	-0.21	Inflammatory biomarkers;	chr5:116088288	chr5:116447547~116508276:+
THCA	cis	rs362272	0.502	rs2857839	ENSG00000249673.5	NOP14-AS1	4.66	4.05e-06	0.000452	0.17	0.21	Serum sulfate level;	chr4:3034903	chr4:2934899~2961738:+
THCA	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-4.66	4.05e-06	0.000452	-0.26	-0.21	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
THCA	cis	rs362272	0.502	rs2798298	ENSG00000249673.5	NOP14-AS1	4.66	4.05e-06	0.000452	0.17	0.21	Serum sulfate level;	chr4:3034875	chr4:2934899~2961738:+
THCA	cis	rs9300255	0.602	rs1716177	ENSG00000235423.7	RP11-282O18.3	4.66	4.05e-06	0.000452	0.22	0.21	Neutrophil percentage of white cells;	chr12:123170910	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.508	rs1716176	ENSG00000235423.7	RP11-282O18.3	4.66	4.05e-06	0.000452	0.22	0.21	Neutrophil percentage of white cells;	chr12:123170920	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1790098	ENSG00000235423.7	RP11-282O18.3	4.66	4.05e-06	0.000452	0.22	0.21	Neutrophil percentage of white cells;	chr12:123170934	chr12:123252030~123261483:-
THCA	cis	rs7772486	0.754	rs9390358	ENSG00000270638.1	RP3-466P17.1	4.66	4.05e-06	0.000452	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145735570~145737218:+
THCA	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-4.66	4.05e-06	0.000453	-0.28	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
THCA	cis	rs10266483	0.739	rs682662	ENSG00000271550.1	BNIP3P11	4.66	4.05e-06	0.000453	0.26	0.21	Response to statin therapy;	chr7:64306107	chr7:64678954~64687393:-
THCA	cis	rs9880211	0.948	rs9872178	ENSG00000239213.4	NCK1-AS1	4.66	4.05e-06	0.000453	0.23	0.21	Height;Body mass index;	chr3:136267596	chr3:136841726~136862054:-
THCA	cis	rs9527	0.571	rs3740400	ENSG00000213061.2	PFN1P11	4.66	4.05e-06	0.000453	0.26	0.21	Arsenic metabolism;	chr10:102869708	chr10:102838011~102845473:-
THCA	cis	rs9527	0.571	rs7904113	ENSG00000213061.2	PFN1P11	4.66	4.05e-06	0.000453	0.26	0.21	Arsenic metabolism;	chr10:102873357	chr10:102838011~102845473:-
THCA	cis	rs7851660	0.844	rs10759975	ENSG00000214417.4	KRT18P13	4.66	4.05e-06	0.000453	0.19	0.21	Strep throat;	chr9:97862911	chr9:97698922~97700734:+
THCA	cis	rs796395	0.65	rs675763	ENSG00000232480.1	TGFB2-AS1	-4.66	4.05e-06	0.000453	-0.23	-0.21	Post bronchodilator FEV1/FVC ratio;	chr1:218508777	chr1:218344196~218345678:-
THCA	cis	rs2980439	0.729	rs2955586	ENSG00000254153.1	CTA-398F10.2	-4.66	4.05e-06	0.000453	-0.22	-0.21	Neuroticism;	chr8:8236445	chr8:8456909~8461337:-
THCA	cis	rs2243480	1	rs465359	ENSG00000164669.11	INTS4P1	4.66	4.05e-06	0.000453	0.4	0.21	Diabetic kidney disease;	chr7:66093177	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs462853	ENSG00000164669.11	INTS4P1	4.66	4.05e-06	0.000453	0.4	0.21	Diabetic kidney disease;	chr7:66093180	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs160642	ENSG00000164669.11	INTS4P1	4.66	4.05e-06	0.000453	0.4	0.21	Diabetic kidney disease;	chr7:66093386	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000164669.11	INTS4P1	4.66	4.05e-06	0.000453	0.4	0.21	Diabetic kidney disease;	chr7:66100154	chr7:65141225~65234216:+
THCA	cis	rs1003719	0.68	rs2154537	ENSG00000230366.8	DSCR9	4.66	4.06e-06	0.000453	0.22	0.21	Eye color traits;	chr21:37129712	chr21:37208503~37221736:+
THCA	cis	rs703842	0.928	rs724834	ENSG00000270039.1	RP11-571M6.17	-4.66	4.06e-06	0.000453	-0.24	-0.21	Multiple sclerosis;	chr12:57786633	chr12:57803838~57804415:+
THCA	cis	rs6012564	0.927	rs6019570	ENSG00000227431.4	CSE1L-AS1	-4.66	4.06e-06	0.000453	-0.26	-0.21	Anger;	chr20:48983153	chr20:49040463~49046044:-
THCA	cis	rs7246760	0.867	rs61580479	ENSG00000267106.4	ZNF561-AS1	4.66	4.06e-06	0.000453	0.41	0.21	Pursuit maintenance gain;	chr19:9672264	chr19:9621291~9645896:+
THCA	cis	rs1707322	0.613	rs1473840	ENSG00000280836.1	AL355480.1	4.66	4.06e-06	0.000453	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr1:45581219~45581321:-
THCA	cis	rs34864796	0.547	rs200476	ENSG00000280107.1	AL022393.9	-4.66	4.06e-06	0.000453	-0.26	-0.21	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28170845~28172521:+
THCA	cis	rs28374715	0.681	rs7165396	ENSG00000247556.5	OIP5-AS1	4.66	4.06e-06	0.000454	0.2	0.21	Ulcerative colitis;	chr15:41294749	chr15:41283990~41309737:+
THCA	cis	rs172166	0.694	rs2791332	ENSG00000261839.1	RP1-265C24.8	4.66	4.06e-06	0.000454	0.23	0.21	Cardiac Troponin-T levels;	chr6:28141010	chr6:28136849~28139678:+
THCA	cis	rs8049040	0.967	rs8044168	ENSG00000260886.1	TAT-AS1	4.66	4.06e-06	0.000454	0.27	0.21	Blood protein levels;	chr16:71473080	chr16:71565789~71578187:+
THCA	cis	rs6600671	0.899	rs6674392	ENSG00000275585.1	CH17-118O6.3	-4.66	4.06e-06	0.000454	-0.25	-0.21	Hip geometry;	chr1:121518864	chr1:120985692~121052167:-
THCA	cis	rs12478296	0.901	rs6731775	ENSG00000220804.7	AC093642.5	4.66	4.06e-06	0.000454	0.23	0.21	Obesity-related traits;	chr2:242057292	chr2:242088633~242160153:+
THCA	cis	rs250518	0.735	rs26575	ENSG00000272081.1	CTD-2376I4.2	-4.66	4.06e-06	0.000454	-0.26	-0.21	Mean corpuscular hemoglobin concentration;	chr5:72998631	chr5:72955206~72955699:-
THCA	cis	rs7829975	0.684	rs488904	ENSG00000254153.1	CTA-398F10.2	4.66	4.06e-06	0.000454	0.22	0.21	Mood instability;	chr8:8730061	chr8:8456909~8461337:-
THCA	cis	rs58605417	0.522	rs3105405	ENSG00000253553.4	RP11-586K2.1	4.66	4.06e-06	0.000454	0.22	0.21	Schizophrenia;	chr8:88464791	chr8:88326836~88737134:+
THCA	cis	rs494453	0.922	rs480578	ENSG00000227811.2	FAM212B-AS1	-4.66	4.06e-06	0.000454	-0.26	-0.21	Osteoporosis-related phenotypes;	chr1:111709839	chr1:111739841~111747798:+
THCA	cis	rs1876905	0.539	rs240987	ENSG00000271789.1	RP5-1112D6.7	-4.66	4.06e-06	0.000454	-0.28	-0.21	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111297126~111298510:+
THCA	cis	rs752010	0.967	rs6675999	ENSG00000230638.4	RP11-486B10.4	-4.66	4.07e-06	0.000454	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41633353	chr1:41542069~41544310:+
THCA	cis	rs6479901	0.512	rs4746244	ENSG00000232075.1	MRPL35P2	-4.66	4.07e-06	0.000454	-0.39	-0.21	Intelligence (multi-trait analysis);	chr10:63599941	chr10:63634317~63634827:-
THCA	cis	rs1371614	0.523	rs12991124	ENSG00000229122.1	AGBL5-IT1	-4.66	4.07e-06	0.000454	-0.15	-0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956624	chr2:27061038~27061815:+
THCA	cis	rs11700536	1	rs4919965	ENSG00000236663.1	AP001631.9	-4.66	4.07e-06	0.000454	-0.27	-0.21	Interleukin-18 levels;	chr21:43137961	chr21:43140523~43141092:-
THCA	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-4.66	4.07e-06	0.000455	-0.13	-0.21	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
THCA	cis	rs17533156	0.557	rs16969683	ENSG00000222808.1	RNU4-47P	-4.66	4.07e-06	0.000455	-0.26	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:77132113	chr17:77152561~77152674:-
THCA	cis	rs8141529	0.673	rs132548	ENSG00000226471.5	CTA-292E10.6	4.66	4.07e-06	0.000455	0.17	0.21	Lymphocyte counts;	chr22:28921571	chr22:28800683~28848559:+
THCA	cis	rs911555	0.755	rs11620897	ENSG00000244691.1	RPL10AP1	-4.66	4.07e-06	0.000455	-0.29	-0.21	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103412119~103412761:-
THCA	cis	rs1923539	0.549	rs1923542	ENSG00000242600.5	MBL1P	-4.66	4.07e-06	0.000455	-0.19	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79909470	chr10:79904898~79950336:+
THCA	cis	rs5753037	0.809	rs2057882	ENSG00000279699.1	RP1-102K2.9	4.66	4.07e-06	0.000455	0.21	0.21	Type 1 diabetes;	chr22:29821838	chr22:30275215~30276951:-
THCA	cis	rs1577917	0.839	rs6929514	ENSG00000220563.1	PKMP3	-4.66	4.07e-06	0.000455	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85816050	chr6:85659892~85660606:-
THCA	cis	rs4916588	0.636	rs7615073	ENSG00000270170.1	NCBP2-AS2	4.66	4.07e-06	0.000455	0.17	0.21	Night sleep phenotypes;	chr3:196877691	chr3:196942623~196943540:+
THCA	cis	rs763121	0.819	rs138700	ENSG00000235209.1	CTA-150C2.13	4.66	4.07e-06	0.000455	0.29	0.21	Menopause (age at onset);	chr22:38733994	chr22:38921227~38924708:+
THCA	cis	rs5762430	0.576	rs5762481	ENSG00000235954.5	TTC28-AS1	4.66	4.08e-06	0.000455	0.2	0.21	Obesity;	chr22:28114249	chr22:27919376~28008581:+
THCA	cis	rs758324	0.577	rs652189	ENSG00000237714.1	P4HA2-AS1	-4.66	4.08e-06	0.000455	-0.29	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132123173	chr5:132184876~132192808:+
THCA	cis	rs6088580	0.634	rs2184836	ENSG00000276073.1	RP5-1125A11.7	4.66	4.08e-06	0.000455	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34375563	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.609	rs945674	ENSG00000276073.1	RP5-1125A11.7	4.66	4.08e-06	0.000455	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34376441	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.609	rs6058029	ENSG00000276073.1	RP5-1125A11.7	4.66	4.08e-06	0.000455	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34381837	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6088478	ENSG00000276073.1	RP5-1125A11.7	4.66	4.08e-06	0.000455	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34383913	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.608	rs2105109	ENSG00000276073.1	RP5-1125A11.7	4.66	4.08e-06	0.000455	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34384126	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6088483	ENSG00000276073.1	RP5-1125A11.7	4.66	4.08e-06	0.000455	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34396908	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs4911423	ENSG00000276073.1	RP5-1125A11.7	4.66	4.08e-06	0.000455	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34411580	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6141471	ENSG00000276073.1	RP5-1125A11.7	4.66	4.08e-06	0.000455	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34418924	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6059851	ENSG00000276073.1	RP5-1125A11.7	-4.66	4.08e-06	0.000455	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34460140	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.502	rs6059861	ENSG00000276073.1	RP5-1125A11.7	-4.66	4.08e-06	0.000455	-0.18	-0.21	Coronary artery disease;	chr20:34480758	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.634	rs6059868	ENSG00000276073.1	RP5-1125A11.7	-4.66	4.08e-06	0.000455	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34491655	chr20:33985617~33988989:-
THCA	cis	rs763121	0.853	rs2281021	ENSG00000235209.1	CTA-150C2.13	4.66	4.08e-06	0.000455	0.28	0.21	Menopause (age at onset);	chr22:38668662	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs5995610	ENSG00000235209.1	CTA-150C2.13	4.66	4.08e-06	0.000455	0.28	0.21	Menopause (age at onset);	chr22:38668676	chr22:38921227~38924708:+
THCA	cis	rs12908161	0.959	rs3748376	ENSG00000275120.1	RP11-182J1.17	4.66	4.08e-06	0.000456	0.25	0.21	Schizophrenia;	chr15:84785121	chr15:84599434~84606463:-
THCA	cis	rs7746199	0.736	rs13209332	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs34105070	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.673	rs72845046	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs67652222	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs13212093	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs34038546	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28073316~28074233:+
THCA	cis	rs141342723	1	rs141342723	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs34543938	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs56405707	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs13210634	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs13215275	ENSG00000220721.1	OR1F12	4.66	4.08e-06	0.000456	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	4.66	4.08e-06	0.000456	0.28	0.21	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
THCA	cis	rs7520050	0.966	rs11579634	ENSG00000234329.1	RP11-767N6.2	4.66	4.08e-06	0.000456	0.19	0.21	Reticulocyte count;Red blood cell count;	chr1:46000719	chr1:45651039~45651826:-
THCA	cis	rs270601	0.633	rs733300	ENSG00000224431.1	AC063976.7	4.66	4.08e-06	0.000456	0.18	0.21	Acylcarnitine levels;	chr5:132236550	chr5:132199456~132203487:+
THCA	cis	rs270601	0.633	rs4535443	ENSG00000224431.1	AC063976.7	4.66	4.08e-06	0.000456	0.18	0.21	Acylcarnitine levels;	chr5:132236868	chr5:132199456~132203487:+
THCA	cis	rs651907	0.557	rs11924013	ENSG00000244119.1	PDCL3P4	4.66	4.08e-06	0.000456	0.19	0.21	Colorectal cancer;	chr3:101647854	chr3:101712472~101713191:+
THCA	cis	rs4763879	0.739	rs2895988	ENSG00000256673.1	RP11-599J14.2	4.66	4.08e-06	0.000456	0.26	0.21	Type 1 diabetes;	chr12:9675831	chr12:9398355~9414851:-
THCA	cis	rs11175834	0.655	rs12311233	ENSG00000256915.1	RP11-221N13.4	-4.66	4.08e-06	0.000456	-0.36	-0.21	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65607333	chr12:65644334~65663299:+
THCA	cis	rs9307551	0.584	rs1371996	ENSG00000250334.4	LINC00989	-4.66	4.08e-06	0.000456	-0.25	-0.21	Refractive error;	chr4:79532718	chr4:79492416~79576460:+
THCA	cis	rs17772222	0.682	rs28482235	ENSG00000222990.1	RNU4-22P	4.66	4.09e-06	0.000456	0.25	0.21	Coronary artery calcification;	chr14:88472857	chr14:88513498~88513663:+
THCA	cis	rs6969780	0.841	rs10246712	ENSG00000233429.8	HOTAIRM1	4.66	4.09e-06	0.000456	0.27	0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27159241	chr7:27095647~27100265:+
THCA	cis	rs7989336	0.676	rs9556569	ENSG00000247400.3	DNAJC3-AS1	-4.66	4.09e-06	0.000456	-0.13	-0.21	Obesity;	chr13:96338777	chr13:95648733~95676925:-
THCA	cis	rs10129255	0.957	rs8009638	ENSG00000211970.3	IGHV4-61	-4.66	4.09e-06	0.000456	-0.13	-0.21	Kawasaki disease;	chr14:106777570	chr14:106639119~106639657:-
THCA	cis	rs8077577	0.747	rs11868708	ENSG00000273018.4	CTD-2303H24.2	-4.66	4.09e-06	0.000456	-0.31	-0.21	Obesity-related traits;	chr17:18341299	chr17:18511221~18551705:-
THCA	cis	rs467650	0.853	rs154205	ENSG00000246763.5	RGMB-AS1	4.66	4.09e-06	0.000456	0.22	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98649598	chr5:98769618~98773469:-
THCA	cis	rs17095355	1	rs12570423	ENSG00000203876.8	ADD3-AS1	-4.66	4.09e-06	0.000456	-0.23	-0.21	Biliary atresia;	chr10:109931184	chr10:109940104~110008381:-
THCA	cis	rs10208649	1	rs6545369	ENSG00000233266.1	HMGB1P31	4.66	4.09e-06	0.000456	0.5	0.21	Body mass index;	chr2:53828006	chr2:54051334~54051760:+
THCA	cis	rs6832769	0.925	rs6554292	ENSG00000272969.1	RP11-528I4.2	-4.66	4.09e-06	0.000457	-0.24	-0.21	Personality dimensions;	chr4:55584943	chr4:55547112~55547889:+
THCA	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-4.66	4.09e-06	0.000457	-0.21	-0.21	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
THCA	cis	rs6545883	0.507	rs4672427	ENSG00000270820.4	RP11-355B11.2	-4.66	4.09e-06	0.000457	-0.18	-0.21	Tuberculosis;	chr2:61242115	chr2:61471188~61484130:+
THCA	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-4.66	4.09e-06	0.000457	-0.24	-0.21	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
THCA	cis	rs481331	0.689	rs210220	ENSG00000215146.4	RP11-313J2.1	-4.66	4.09e-06	0.000457	-0.33	-0.21	Systemic juvenile idiopathic arthritis;	chr10:42560213	chr10:42331866~42367974:-
THCA	cis	rs7493	0.901	rs13226149	ENSG00000233942.1	AC004012.1	4.66	4.09e-06	0.000457	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95396288	chr7:95471835~95473998:+
THCA	cis	rs72843506	0.656	rs79406817	ENSG00000231258.2	ZSWIM5P2	4.66	4.09e-06	0.000457	0.33	0.21	Schizophrenia;	chr17:20011814	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs77090106	ENSG00000231258.2	ZSWIM5P2	4.66	4.09e-06	0.000457	0.33	0.21	Schizophrenia;	chr17:20044832	chr17:20583758~20591180:-
THCA	cis	rs6012564	1	rs3818262	ENSG00000230758.1	SNAP23P	4.66	4.1e-06	0.000457	0.25	0.21	Anger;	chr20:49125019	chr20:49038357~49038602:-
THCA	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	4.66	4.1e-06	0.000457	0.27	0.21	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
THCA	cis	rs9487094	0.67	rs1476388	ENSG00000223537.2	RP5-919F19.5	-4.66	4.1e-06	0.000458	-0.21	-0.21	Height;	chr6:109518783	chr6:109487906~109506800:+
THCA	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	4.66	4.1e-06	0.000458	0.33	0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
THCA	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-4.66	4.1e-06	0.000458	-0.33	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
THCA	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-4.66	4.1e-06	0.000458	-0.33	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
THCA	cis	rs79349575	0.655	rs62078384	ENSG00000270781.1	RP11-501C14.9	-4.66	4.1e-06	0.000458	-0.25	-0.21	Type 2 diabetes;	chr17:48967101	chr17:48899131~48899748:+
THCA	cis	rs736408	0.609	rs13061423	ENSG00000243224.1	RP5-1157M23.2	-4.66	4.1e-06	0.000458	-0.23	-0.21	Bipolar disorder;	chr3:52756197	chr3:52239258~52241097:+
THCA	cis	rs75920871	0.589	rs7941150	ENSG00000254851.1	RP11-109L13.1	-4.66	4.1e-06	0.000458	-0.39	-0.21	Subjective well-being;	chr11:117221105	chr11:117135528~117138582:+
THCA	cis	rs737008	0.821	rs28671554	ENSG00000263080.1	RP11-485G7.5	4.66	4.1e-06	0.000458	0.25	0.21	Obesity-related traits;	chr16:11309896	chr16:11341809~11345211:-
THCA	cis	rs7267979	0.966	rs6050567	ENSG00000274973.1	RP13-401N8.7	4.66	4.1e-06	0.000458	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25845497~25845862:+
THCA	cis	rs6570726	0.738	rs4495284	ENSG00000270638.1	RP3-466P17.1	4.66	4.1e-06	0.000458	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145735570~145737218:+
THCA	cis	rs6870983	0.802	rs7717613	ENSG00000247828.6	TMEM161B-AS1	4.66	4.11e-06	0.000458	0.19	0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88444606	chr5:88268895~88436685:+
THCA	cis	rs7267979	0.668	rs2387977	ENSG00000274414.1	RP5-965G21.4	4.66	4.11e-06	0.000458	0.26	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:25239007~25245229:-
THCA	cis	rs8064024	0.599	rs1876359	ENSG00000267077.1	RP11-127I20.5	4.66	4.11e-06	0.000458	0.25	0.21	Cancer;	chr16:4880099	chr16:4795265~4796532:-
THCA	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-4.66	4.11e-06	0.000458	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
THCA	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-4.66	4.11e-06	0.000458	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
THCA	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-4.66	4.11e-06	0.000458	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
THCA	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-4.66	4.11e-06	0.000458	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
THCA	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-4.66	4.11e-06	0.000458	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
THCA	cis	rs7618915	0.501	rs12635140	ENSG00000243224.1	RP5-1157M23.2	4.66	4.11e-06	0.000458	0.23	0.21	Bipolar disorder;	chr3:52704149	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs6617	ENSG00000243224.1	RP5-1157M23.2	-4.66	4.11e-06	0.000458	-0.23	-0.21	Bipolar disorder;	chr3:52706166	chr3:52239258~52241097:+
THCA	cis	rs7772486	0.754	rs9497419	ENSG00000270638.1	RP3-466P17.1	4.66	4.11e-06	0.000459	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs6921073	ENSG00000270638.1	RP3-466P17.1	4.66	4.11e-06	0.000459	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.727	rs12190966	ENSG00000270638.1	RP3-466P17.1	4.66	4.11e-06	0.000459	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145735570~145737218:+
THCA	cis	rs13108904	0.935	rs13148614	ENSG00000254094.1	AC078852.1	-4.66	4.11e-06	0.000459	-0.23	-0.21	Obesity-related traits;	chr4:1254569	chr4:1356581~1358075:+
THCA	cis	rs7637701	0.713	rs9867857	ENSG00000240875.4	LINC00886	-4.66	4.11e-06	0.000459	-0.16	-0.21	Breast cancer;	chr3:156773371	chr3:156747346~156817062:-
THCA	cis	rs10483853	0.806	rs10141031	ENSG00000258695.2	RP3-414A15.2	-4.66	4.11e-06	0.000459	-0.29	-0.21	Coronary artery calcification;	chr14:73306901	chr14:73522878~73530610:+
THCA	cis	rs3824488	0.599	rs16909859	ENSG00000271384.1	RP11-435O5.7	-4.66	4.11e-06	0.000459	-0.29	-0.21	Neuroticism;	chr9:95442510	chr9:95406990~95407662:-
THCA	cis	rs7914558	0.966	rs10786745	ENSG00000236937.2	PTGES3P4	4.66	4.11e-06	0.000459	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:102845595~102845950:+
THCA	cis	rs1383484	0.575	rs7182462	ENSG00000225151.9	GOLGA2P7	4.66	4.11e-06	0.000459	0.27	0.21	Height;	chr15:83937457	chr15:84199311~84230136:-
THCA	cis	rs763121	1	rs763121	ENSG00000273076.1	RP3-508I15.22	-4.66	4.11e-06	0.000459	-0.2	-0.21	Menopause (age at onset);	chr22:38483935	chr22:38743495~38743910:+
THCA	cis	rs6586163	0.527	rs12775501	ENSG00000261438.1	RP11-399O19.9	-4.66	4.12e-06	0.000459	-0.18	-0.21	Chronic lymphocytic leukemia;	chr10:88991152	chr10:89015836~89017059:+
THCA	cis	rs7010876	0.512	rs1604920	ENSG00000253553.4	RP11-586K2.1	4.66	4.12e-06	0.000459	0.21	0.21	Schizophrenia;	chr8:88450780	chr8:88326836~88737134:+
THCA	cis	rs763121	0.819	rs5757161	ENSG00000228274.3	RP3-508I15.9	-4.66	4.12e-06	0.000459	-0.22	-0.21	Menopause (age at onset);	chr22:38594657	chr22:38667585~38681820:-
THCA	cis	rs930395	0.514	rs10073945	ENSG00000272335.1	RP11-53O19.3	4.66	4.12e-06	0.000459	0.18	0.21	Breast cancer;	chr5:44932032	chr5:44826076~44828592:+
THCA	cis	rs5742933	1	rs5742998	ENSG00000253559.1	OSGEPL1-AS1	-4.66	4.12e-06	0.000459	-0.26	-0.21	Ferritin levels;	chr2:189799626	chr2:189762704~189765556:+
THCA	cis	rs7520050	0.966	rs4545281	ENSG00000234329.1	RP11-767N6.2	-4.66	4.12e-06	0.000459	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45894382	chr1:45651039~45651826:-
THCA	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	4.66	4.12e-06	0.000459	0.23	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
THCA	cis	rs9990333	0.544	rs11915082	ENSG00000273009.1	RP11-352G9.1	-4.66	4.12e-06	0.000459	-0.24	-0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195913078~195913683:-
THCA	cis	rs2015599	0.563	rs11050168	ENSG00000273680.1	RP11-996F15.6	-4.66	4.12e-06	0.00046	-0.3	-0.21	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29332733~29333383:-
THCA	cis	rs10266483	0.739	rs12538943	ENSG00000227986.1	TRIM60P18	4.66	4.12e-06	0.00046	0.2	0.21	Response to statin therapy;	chr7:64395990	chr7:64355078~64356199:+
THCA	cis	rs755249	0.883	rs12035330	ENSG00000228060.1	RP11-69E11.8	-4.66	4.12e-06	0.00046	-0.21	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39565160~39573203:+
THCA	cis	rs453301	0.682	rs2929451	ENSG00000253981.4	ALG1L13P	4.66	4.12e-06	0.00046	0.2	0.21	Joint mobility (Beighton score);	chr8:9227785	chr8:8236003~8244667:-
THCA	cis	rs6952407	1	rs6952407	ENSG00000229886.1	RP5-1132H15.3	-4.66	4.12e-06	0.00046	-0.21	-0.21	Cotinine glucuronidation;	chr7:66580525	chr7:66025126~66031544:-
THCA	cis	rs1979679	0.918	rs78500430	ENSG00000247934.4	RP11-967K21.1	-4.66	4.12e-06	0.00046	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28369828	chr12:28163298~28190738:-
THCA	cis	rs6671200	1	rs71654419	ENSG00000235501.4	RP4-639F20.1	-4.66	4.12e-06	0.00046	-0.43	-0.21	Stearic acid (18:0) levels;	chr1:95198941	chr1:94927566~94963270:+
THCA	cis	rs9902453	1	rs4465650	ENSG00000263370.1	RP11-68I3.5	4.66	4.12e-06	0.00046	0.28	0.21	Coffee consumption (cups per day);	chr17:30069703	chr17:29639627~29640825:+
THCA	cis	rs1880529	0.832	rs9307391	ENSG00000206820.1	RNU1-138P	-4.66	4.12e-06	0.00046	-0.25	-0.21	White matter integrity (bipolar disorder risk interaction);	chr4:113473518	chr4:113420323~113420486:+
THCA	cis	rs7394190	0.748	rs11000766	ENSG00000271848.1	RP11-464F9.21	-4.66	4.12e-06	0.00046	-0.29	-0.21	Incident atrial fibrillation;	chr10:73753194	chr10:73654039~73674719:+
THCA	cis	rs5742933	1	rs5742933	ENSG00000273240.1	RP11-455J20.3	-4.66	4.13e-06	0.00046	-0.24	-0.21	Ferritin levels;	chr2:189784590	chr2:189763859~189764456:-
THCA	cis	rs889398	0.9	rs4783722	ENSG00000226232.7	RP11-419C5.2	4.66	4.13e-06	0.00046	0.2	0.21	Body mass index;	chr16:69548009	chr16:69976388~69996188:-
THCA	cis	rs9925964	0.804	rs9926533	ENSG00000232748.3	RP11-196G11.6	4.66	4.13e-06	0.000461	0.25	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31002858	chr16:31056460~31062803:+
THCA	cis	rs7829975	0.573	rs7842359	ENSG00000253981.4	ALG1L13P	-4.66	4.13e-06	0.000461	-0.2	-0.21	Mood instability;	chr8:8939568	chr8:8236003~8244667:-
THCA	cis	rs1555322	0.789	rs10211823	ENSG00000269202.1	RP4-614O4.12	-4.66	4.13e-06	0.000461	-0.26	-0.21	Attention deficit hyperactivity disorder;	chr20:35220467	chr20:35201747~35203288:-
THCA	cis	rs2288884	0.559	rs73052102	ENSG00000269483.1	AC006272.1	4.66	4.13e-06	0.000461	0.24	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:51839924~51843324:-
THCA	cis	rs34286592	0.929	rs1057451	ENSG00000214725.6	CDIPT-AS1	-4.66	4.13e-06	0.000461	-0.37	-0.21	Multiple sclerosis;	chr16:29822167	chr16:29863593~29868053:+
THCA	cis	rs317689	0.658	rs479971	ENSG00000274979.1	RP11-1143G9.5	-4.66	4.13e-06	0.000461	-0.24	-0.21	Response to diuretic therapy;	chr12:69278691	chr12:69326574~69331882:-
THCA	cis	rs317689	0.608	rs650198	ENSG00000274979.1	RP11-1143G9.5	-4.66	4.13e-06	0.000461	-0.24	-0.21	Response to diuretic therapy;	chr12:69280815	chr12:69326574~69331882:-
THCA	cis	rs9494145	0.638	rs6934903	ENSG00000232876.1	CTA-212D2.2	4.66	4.13e-06	0.000461	0.33	0.21	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135130426	chr6:135055033~135060550:+
THCA	cis	rs9973361	1	rs9973899	ENSG00000232411.1	AC009495.3	-4.66	4.14e-06	0.000461	-0.27	-0.21	Total body bone mineral density;	chr2:165861072	chr2:165833048~165839098:-
THCA	cis	rs13113518	1	rs4864546	ENSG00000249700.7	SRD5A3-AS1	4.66	4.14e-06	0.000461	0.26	0.21	Height;	chr4:55537960	chr4:55363971~55395847:-
THCA	cis	rs7520050	0.778	rs2088102	ENSG00000234329.1	RP11-767N6.2	-4.66	4.14e-06	0.000461	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45651039~45651826:-
THCA	cis	rs9487094	0.626	rs11153213	ENSG00000223537.2	RP5-919F19.5	-4.66	4.14e-06	0.000461	-0.21	-0.21	Height;	chr6:109693890	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs12201356	ENSG00000223537.2	RP5-919F19.5	-4.66	4.14e-06	0.000461	-0.21	-0.21	Height;	chr6:109694672	chr6:109487906~109506800:+
THCA	cis	rs1707322	1	rs10158032	ENSG00000281133.1	AL355480.3	-4.66	4.14e-06	0.000461	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45580892~45580996:-
THCA	cis	rs7726839	0.794	rs10053310	ENSG00000225138.6	CTD-2228K2.7	4.66	4.14e-06	0.000461	0.24	0.21	Obesity-related traits;	chr5:595546	chr5:473236~480884:+
THCA	cis	rs7726839	0.718	rs6887972	ENSG00000225138.6	CTD-2228K2.7	4.66	4.14e-06	0.000461	0.24	0.21	Obesity-related traits;	chr5:597159	chr5:473236~480884:+
THCA	cis	rs61270009	0.955	rs415449	ENSG00000247828.6	TMEM161B-AS1	-4.66	4.14e-06	0.000462	-0.18	-0.21	Depressive symptoms;	chr5:88231533	chr5:88268895~88436685:+
THCA	cis	rs7520050	0.808	rs11211195	ENSG00000234329.1	RP11-767N6.2	-4.66	4.14e-06	0.000462	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.808	rs11211196	ENSG00000234329.1	RP11-767N6.2	-4.66	4.14e-06	0.000462	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45651039~45651826:-
THCA	cis	rs711244	0.901	rs3770776	ENSG00000279519.1	RP11-288C18.1	4.66	4.14e-06	0.000462	0.17	0.21	Mean platelet volume;	chr2:36923650	chr2:36839922~36842539:-
THCA	cis	rs6479874	0.915	rs4935212	ENSG00000223502.1	RP11-96B5.3	4.66	4.14e-06	0.000462	0.24	0.21	Migraine;	chr10:51012717	chr10:51062579~51068553:-
THCA	cis	rs7819412	0.805	rs4333549	ENSG00000206014.6	OR7E161P	4.66	4.14e-06	0.000462	0.24	0.21	Triglycerides;	chr8:11122051	chr8:11928597~11929563:-
THCA	cis	rs829883	0.659	rs11109517	ENSG00000227825.4	SLC9A7P1	4.66	4.14e-06	0.000462	0.21	0.21	Colorectal adenoma (advanced);	chr12:98527796	chr12:98453835~98457145:-
THCA	cis	rs829883	0.659	rs11109520	ENSG00000227825.4	SLC9A7P1	4.66	4.14e-06	0.000462	0.21	0.21	Colorectal adenoma (advanced);	chr12:98534868	chr12:98453835~98457145:-
THCA	cis	rs7621331	1	rs6807242	ENSG00000273486.1	RP11-731C17.2	4.66	4.14e-06	0.000462	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:135975101	chr3:136837338~136839021:-
THCA	cis	rs860295	0.702	rs10908470	ENSG00000160766.13	GBAP1	-4.66	4.14e-06	0.000462	-0.25	-0.21	Body mass index;	chr1:155557222	chr1:155213821~155227422:-
THCA	cis	rs6044112	0.784	rs6080293	ENSG00000273998.1	RP4-777L9.2	4.66	4.14e-06	0.000462	0.32	0.21	Response to taxane treatment (docetaxel);	chr20:16536269	chr20:16576068~16579615:+
THCA	cis	rs11089937	0.626	rs10483106	ENSG00000211638.2	IGLV8-61	-4.66	4.14e-06	0.000462	-0.19	-0.21	Periodontitis (PAL4Q3);	chr22:22149240	chr22:22098700~22099212:+
THCA	cis	rs9467773	0.572	rs13213953	ENSG00000124549.13	BTN2A3P	4.66	4.14e-06	0.000462	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26421391~26432383:+
THCA	cis	rs6570726	0.935	rs388394	ENSG00000270638.1	RP3-466P17.1	4.66	4.14e-06	0.000462	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145735570~145737218:+
THCA	cis	rs9307551	0.619	rs998437	ENSG00000250334.4	LINC00989	-4.66	4.15e-06	0.000462	-0.25	-0.21	Refractive error;	chr4:79508616	chr4:79492416~79576460:+
THCA	cis	rs7614311	0.731	rs3774719	ENSG00000271843.1	RP11-245J9.5	-4.66	4.15e-06	0.000462	-0.38	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63964662	chr3:64008082~64008692:-
THCA	cis	rs7520050	0.966	rs12139630	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs12144263	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6668284	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs4660321	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs11211189	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs12411269	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs11211198	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs10890352	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6700597	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6695809	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs11211199	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs4376778	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6672898	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45651039~45651826:-
THCA	cis	rs988712	0.705	rs11030099	ENSG00000245573.6	BDNF-AS	-4.66	4.15e-06	0.000463	-0.21	-0.21	Obesity;	chr11:27656036	chr11:27506838~27698174:+
THCA	cis	rs28476539	0.64	rs72658996	ENSG00000270480.1	RP11-57B24.1	4.66	4.15e-06	0.000463	0.33	0.21	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82631211	chr4:82691737~82692468:+
THCA	cis	rs7520050	0.933	rs6680211	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45651039~45651826:-
THCA	cis	rs375066	0.935	rs423765	ENSG00000278917.1	RP11-15A1.4	-4.66	4.15e-06	0.000463	-0.17	-0.21	Breast cancer;	chr19:43912047	chr19:43891233~43895411:+
THCA	cis	rs7520050	0.933	rs12565042	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs10789475	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.933	rs6666743	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.933	rs9787208	ENSG00000234329.1	RP11-767N6.2	-4.66	4.15e-06	0.000463	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45651039~45651826:-
THCA	cis	rs2694917	0.669	rs2694919	ENSG00000257576.1	RP11-153M3.1	4.66	4.15e-06	0.000463	0.36	0.21	Blood metabolite ratios;	chr12:56523606	chr12:56511002~56512703:+
THCA	cis	rs6570726	0.791	rs7765687	ENSG00000270638.1	RP3-466P17.1	4.66	4.15e-06	0.000463	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145735570~145737218:+
THCA	cis	rs10090774	0.71	rs13262271	ENSG00000280303.2	ERICD	-4.66	4.15e-06	0.000463	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140677795	chr8:140636281~140638283:+
THCA	cis	rs9326248	0.53	rs7124741	ENSG00000280143.1	AP000892.6	4.66	4.15e-06	0.000463	0.34	0.21	Blood protein levels;	chr11:116881503	chr11:117204967~117210292:+
THCA	cis	rs4484658	1	rs4484658	ENSG00000253773.2	C8orf37-AS1	4.66	4.15e-06	0.000463	0.39	0.21	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:95196498	chr8:95204456~95810136:+
THCA	cis	rs7674212	0.865	rs1481279	ENSG00000230069.3	LRRC37A15P	4.66	4.15e-06	0.000463	0.22	0.21	Type 2 diabetes;	chr4:103056781	chr4:102727274~102730721:-
THCA	cis	rs6787172	0.755	rs58733163	ENSG00000272087.1	RP11-379F4.7	4.66	4.16e-06	0.000463	0.19	0.21	Subjective well-being;	chr3:158526407	chr3:158693120~158693768:-
THCA	cis	rs3096299	0.504	rs4785574	ENSG00000261118.1	RP11-104N10.1	4.66	4.16e-06	0.000463	0.18	0.21	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89492017~89504460:-
THCA	cis	rs2288884	0.634	rs80309583	ENSG00000269483.1	AC006272.1	4.66	4.16e-06	0.000463	0.3	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51996949	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.634	rs17835649	ENSG00000269483.1	AC006272.1	4.66	4.16e-06	0.000463	0.3	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997362	chr19:51839924~51843324:-
THCA	cis	rs4970988	0.527	rs12067556	ENSG00000231073.1	RP11-316M1.3	4.66	4.16e-06	0.000463	0.26	0.21	Urate levels;	chr1:150642059	chr1:150973123~150975534:+
THCA	cis	rs9902453	0.791	rs3115086	ENSG00000263370.1	RP11-68I3.5	4.66	4.16e-06	0.000463	0.27	0.21	Coffee consumption (cups per day);	chr17:29698931	chr17:29639627~29640825:+
THCA	cis	rs1979679	0.918	rs10771429	ENSG00000278733.1	RP11-425D17.1	-4.66	4.16e-06	0.000464	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28468573	chr12:28185625~28186190:-
THCA	cis	rs9987353	0.566	rs34491841	ENSG00000253893.2	FAM85B	4.66	4.16e-06	0.000464	0.29	0.21	Recombination measurement;	chr8:9208000	chr8:8167819~8226614:-
THCA	cis	rs3002131	0.604	rs1319392	ENSG00000272750.1	RP11-378J18.8	4.66	4.16e-06	0.000464	0.31	0.21	Interleukin-10 levels;	chr1:222567271	chr1:222658867~222661512:-
THCA	cis	rs5742933	1	rs16831939	ENSG00000273240.1	RP11-455J20.3	-4.66	4.16e-06	0.000464	-0.23	-0.21	Ferritin levels;	chr2:189739282	chr2:189763859~189764456:-
THCA	cis	rs4415084	0.716	rs7712949	ENSG00000272335.1	RP11-53O19.3	-4.66	4.16e-06	0.000464	-0.18	-0.21	Breast cancer;	chr5:44770243	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs13154781	ENSG00000272335.1	RP11-53O19.3	-4.66	4.16e-06	0.000464	-0.18	-0.21	Breast cancer;	chr5:44774925	chr5:44826076~44828592:+
THCA	cis	rs9910055	0.639	rs227583	ENSG00000267080.4	ASB16-AS1	-4.66	4.16e-06	0.000464	-0.19	-0.21	Total body bone mineral density;	chr17:44154330	chr17:44175973~44186717:-
THCA	cis	rs899997	0.773	rs11072784	ENSG00000261143.1	ADAMTS7P3	4.66	4.16e-06	0.000464	0.31	0.21	Coronary artery disease or large artery stroke;	chr15:78673716	chr15:77976042~77993057:+
THCA	cis	rs9625935	0.957	rs62226366	ENSG00000279159.1	RP3-394A18.1	-4.66	4.16e-06	0.000464	-0.16	-0.21	Tonsillectomy;	chr22:30065270	chr22:29978950~30028236:-
THCA	cis	rs8002861	0.846	rs12428314	ENSG00000274001.1	RP11-5G9.5	-4.66	4.16e-06	0.000464	-0.26	-0.21	Leprosy;	chr13:43901875	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.846	rs12869521	ENSG00000274001.1	RP11-5G9.5	-4.66	4.16e-06	0.000464	-0.26	-0.21	Leprosy;	chr13:43904210	chr13:43877715~43878163:-
THCA	cis	rs10851478	0.515	rs12439429	ENSG00000276593.1	RP11-295H24.5	-4.66	4.16e-06	0.000464	-0.22	-0.21	Oral cavity cancer;	chr15:49442437	chr15:49353485~49354034:+
THCA	cis	rs11671005	0.735	rs34188294	ENSG00000268049.1	CTD-2619J13.9	-4.66	4.16e-06	0.000464	-0.33	-0.21	Mean platelet volume;	chr19:58408190	chr19:58357999~58359603:+
THCA	cis	rs2446066	0.872	rs111939932	ENSG00000257379.1	RP11-793H13.8	4.66	4.16e-06	0.000464	0.3	0.21	Red blood cell count;	chr12:53449987	chr12:53441741~53467528:+
THCA	cis	rs3845817	0.798	rs702952	ENSG00000237979.1	AC007389.1	4.66	4.16e-06	0.000464	0.24	0.21	Bipolar disorder;	chr2:65537915	chr2:65500993~65502138:-
THCA	cis	rs9875589	0.509	rs2129888	ENSG00000228242.5	AC093495.4	4.66	4.17e-06	0.000464	0.12	0.21	Ovarian reserve;	chr3:13972326	chr3:14144637~14165978:+
THCA	cis	rs3002131	0.522	rs2378583	ENSG00000272750.1	RP11-378J18.8	4.66	4.17e-06	0.000464	0.33	0.21	Interleukin-10 levels;	chr1:222565958	chr1:222658867~222661512:-
THCA	cis	rs2257011	0.733	rs1896796	ENSG00000274128.1	RP11-342A23.2	-4.66	4.17e-06	0.000465	-0.25	-0.21	Height;	chr15:83606228	chr15:83962176~83962583:+
THCA	cis	rs703842	0.616	rs4760171	ENSG00000270039.1	RP11-571M6.17	-4.66	4.17e-06	0.000465	-0.24	-0.21	Multiple sclerosis;	chr12:57832121	chr12:57803838~57804415:+
THCA	cis	rs9311474	0.508	rs11720159	ENSG00000243224.1	RP5-1157M23.2	-4.66	4.17e-06	0.000465	-0.23	-0.21	Electroencephalogram traits;	chr3:52583786	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs11720243	ENSG00000243224.1	RP5-1157M23.2	-4.66	4.17e-06	0.000465	-0.23	-0.21	Electroencephalogram traits;	chr3:52584002	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs7614498	ENSG00000243224.1	RP5-1157M23.2	-4.66	4.17e-06	0.000465	-0.23	-0.21	Electroencephalogram traits;	chr3:52584925	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs12637627	ENSG00000243224.1	RP5-1157M23.2	-4.66	4.17e-06	0.000465	-0.23	-0.21	Electroencephalogram traits;	chr3:52585946	chr3:52239258~52241097:+
THCA	cis	rs911555	0.673	rs7144271	ENSG00000244691.1	RPL10AP1	-4.66	4.17e-06	0.000465	-0.29	-0.21	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs10148970	ENSG00000244691.1	RPL10AP1	-4.66	4.17e-06	0.000465	-0.29	-0.21	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103412119~103412761:-
THCA	cis	rs1577917	0.839	rs12055653	ENSG00000220563.1	PKMP3	-4.66	4.17e-06	0.000465	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85836945	chr6:85659892~85660606:-
THCA	cis	rs6728642	0.808	rs113319086	ENSG00000230606.9	AC159540.1	4.66	4.17e-06	0.000465	0.32	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96967530	chr2:97416165~97433527:-
THCA	cis	rs78487399	0.71	rs76675804	ENSG00000234936.1	AC010883.5	4.66	4.17e-06	0.000465	0.32	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43384744	chr2:43229573~43233394:+
THCA	cis	rs1979679	0.918	rs1257741	ENSG00000247934.4	RP11-967K21.1	-4.66	4.17e-06	0.000465	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28381636	chr12:28163298~28190738:-
THCA	cis	rs7131987	0.644	rs6487817	ENSG00000275476.1	RP11-996F15.4	4.66	4.17e-06	0.000465	0.21	0.21	QT interval;	chr12:29395277	chr12:29277397~29277882:-
THCA	cis	rs8067545	0.611	rs2703788	ENSG00000270091.1	RP11-78O7.2	4.66	4.17e-06	0.000465	0.16	0.21	Schizophrenia;	chr17:20256373	chr17:19896590~19897287:-
THCA	cis	rs6728642	0.908	rs9973669	ENSG00000230606.9	AC159540.1	4.66	4.17e-06	0.000465	0.28	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97013357	chr2:97416165~97433527:-
THCA	cis	rs6671200	0.92	rs7555236	ENSG00000235501.4	RP4-639F20.1	-4.66	4.17e-06	0.000465	-0.44	-0.21	Stearic acid (18:0) levels;	chr1:95165758	chr1:94927566~94963270:+
THCA	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	4.66	4.18e-06	0.000466	0.26	0.21	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
THCA	cis	rs172166	0.516	rs2622322	ENSG00000220721.1	OR1F12	4.66	4.18e-06	0.000466	0.23	0.21	Cardiac Troponin-T levels;	chr6:28149665	chr6:28073316~28074233:+
THCA	cis	rs2787702	1	rs2787709	ENSG00000237233.2	TMEM26-AS1	-4.66	4.18e-06	0.000466	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61556663	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2606118	ENSG00000237233.2	TMEM26-AS1	-4.66	4.18e-06	0.000466	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61557048	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2124586	ENSG00000237233.2	TMEM26-AS1	-4.66	4.18e-06	0.000466	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61557412	chr10:61452639~61481956:+
THCA	cis	rs739496	0.579	rs12423041	ENSG00000226469.1	ADAM1B	4.66	4.18e-06	0.000466	0.26	0.21	Platelet count;	chr12:111887042	chr12:111927018~111929017:+
THCA	cis	rs4906332	0.782	rs2236281	ENSG00000244691.1	RPL10AP1	-4.66	4.18e-06	0.000466	-0.3	-0.21	Coronary artery disease;	chr14:103534181	chr14:103412119~103412761:-
THCA	cis	rs896854	0.738	rs509594	ENSG00000253528.2	RP11-347C18.4	-4.66	4.18e-06	0.000466	-0.25	-0.21	Type 2 diabetes;	chr8:94954928	chr8:94974573~94974853:-
THCA	cis	rs739496	0.579	rs80017658	ENSG00000226469.1	ADAM1B	4.66	4.18e-06	0.000466	0.26	0.21	Platelet count;	chr12:111942568	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs73426362	ENSG00000226469.1	ADAM1B	4.66	4.18e-06	0.000466	0.26	0.21	Platelet count;	chr12:111942666	chr12:111927018~111929017:+
THCA	cis	rs7246657	0.551	rs4806414	ENSG00000276846.1	CTD-3220F14.3	4.66	4.18e-06	0.000466	0.26	0.21	Coronary artery calcification;	chr19:37147886	chr19:37314868~37315620:-
THCA	cis	rs17772222	0.675	rs1099698	ENSG00000222990.1	RNU4-22P	-4.66	4.19e-06	0.000467	-0.25	-0.21	Coronary artery calcification;	chr14:88414904	chr14:88513498~88513663:+
THCA	cis	rs2980439	0.729	rs2955585	ENSG00000254153.1	CTA-398F10.2	-4.66	4.19e-06	0.000467	-0.22	-0.21	Neuroticism;	chr8:8235989	chr8:8456909~8461337:-
THCA	cis	rs2135507	0.894	rs6535369	ENSG00000270480.1	RP11-57B24.1	4.66	4.19e-06	0.000467	0.3	0.21	Juvenile osteochondritis dissecans;	chr4:82665826	chr4:82691737~82692468:+
THCA	cis	rs7617773	0.817	rs9830016	ENSG00000199476.1	Y_RNA	-4.66	4.19e-06	0.000467	-0.27	-0.21	Coronary artery disease;	chr3:48241004	chr3:48288587~48288694:+
THCA	cis	rs10129255	0.879	rs7160512	ENSG00000211970.3	IGHV4-61	-4.66	4.19e-06	0.000467	-0.12	-0.21	Kawasaki disease;	chr14:106694574	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.879	rs7159157	ENSG00000211970.3	IGHV4-61	-4.66	4.19e-06	0.000467	-0.12	-0.21	Kawasaki disease;	chr14:106694578	chr14:106639119~106639657:-
THCA	cis	rs72945132	0.882	rs67927691	ENSG00000254604.1	AP000487.6	-4.66	4.19e-06	0.000467	-0.39	-0.21	Coronary artery disease;	chr11:70282680	chr11:70282367~70363368:-
THCA	cis	rs11088226	0.75	rs2833885	ENSG00000186842.4	LINC00846	-4.66	4.19e-06	0.000467	-0.29	-0.21	Gastritis;	chr21:32550851	chr21:32572238~32575881:-
THCA	cis	rs2015599	0.623	rs1006410	ENSG00000273680.1	RP11-996F15.6	-4.66	4.19e-06	0.000467	-0.3	-0.21	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29332733~29333383:-
THCA	cis	rs10090774	0.965	rs11778798	ENSG00000279766.1	RP11-642A1.2	4.66	4.19e-06	0.000467	0.26	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140908781	chr8:140572142~140572812:-
THCA	cis	rs75422866	0.867	rs73104163	ENSG00000276691.1	RP5-1057I20.5	4.66	4.19e-06	0.000467	0.38	0.21	Pneumonia;	chr12:47706187	chr12:47788426~47788971:+
THCA	cis	rs75422866	1	rs12423045	ENSG00000276691.1	RP5-1057I20.5	4.66	4.19e-06	0.000467	0.38	0.21	Pneumonia;	chr12:47706275	chr12:47788426~47788971:+
THCA	cis	rs1009077	0.68	rs61747388	ENSG00000245958.5	RP11-33B1.1	4.66	4.19e-06	0.000467	0.27	0.21	Endometriosis;	chr4:119512860	chr4:119454791~119552025:+
THCA	cis	rs6088590	0.687	rs8115656	ENSG00000269202.1	RP4-614O4.12	-4.66	4.19e-06	0.000467	-0.18	-0.21	Coronary artery disease;	chr20:34694976	chr20:35201747~35203288:-
THCA	cis	rs7403037	1	rs17831583	ENSG00000260760.1	PWRN3	4.66	4.2e-06	0.000467	0.24	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24352075	chr15:24441127~24447967:+
THCA	cis	rs62025270	0.632	rs62022915	ENSG00000259295.5	CSPG4P12	-4.66	4.2e-06	0.000467	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85191438~85213905:+
THCA	cis	rs1790761	0.692	rs10444362	ENSG00000255318.1	RP11-655M14.13	4.66	4.2e-06	0.000467	0.23	0.21	Mean corpuscular volume;	chr11:67565619	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.692	rs638140	ENSG00000255318.1	RP11-655M14.13	4.66	4.2e-06	0.000467	0.23	0.21	Mean corpuscular volume;	chr11:67566387	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.692	rs1269981	ENSG00000255318.1	RP11-655M14.13	4.66	4.2e-06	0.000467	0.23	0.21	Mean corpuscular volume;	chr11:67567488	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.658	rs666328	ENSG00000255318.1	RP11-655M14.13	4.66	4.2e-06	0.000467	0.23	0.21	Mean corpuscular volume;	chr11:67568067	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.667	rs11227837	ENSG00000255318.1	RP11-655M14.13	4.66	4.2e-06	0.000467	0.23	0.21	Mean corpuscular volume;	chr11:67568953	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.667	rs658768	ENSG00000255318.1	RP11-655M14.13	4.66	4.2e-06	0.000467	0.23	0.21	Mean corpuscular volume;	chr11:67570337	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.667	rs591434	ENSG00000255318.1	RP11-655M14.13	4.66	4.2e-06	0.000467	0.23	0.21	Mean corpuscular volume;	chr11:67570343	chr11:67618279~67627304:-
THCA	cis	rs9910055	1	rs2071167	ENSG00000267080.4	ASB16-AS1	4.66	4.2e-06	0.000467	0.19	0.21	Total body bone mineral density;	chr17:44210151	chr17:44175973~44186717:-
THCA	cis	rs9487094	0.626	rs12204548	ENSG00000223537.2	RP5-919F19.5	-4.66	4.2e-06	0.000467	-0.21	-0.21	Height;	chr6:109715504	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.626	rs3799849	ENSG00000223537.2	RP5-919F19.5	-4.66	4.2e-06	0.000467	-0.21	-0.21	Height;	chr6:109715560	chr6:109487906~109506800:+
THCA	cis	rs7647973	0.58	rs35218722	ENSG00000229759.1	MRPS18AP1	4.66	4.2e-06	0.000468	0.27	0.21	Menarche (age at onset);	chr3:49238372	chr3:48256350~48256938:-
THCA	cis	rs41313321	0.512	rs12335613	ENSG00000273186.1	RP11-339B21.10	4.66	4.2e-06	0.000468	0.3	0.21	Coenzyme Q10 levels;	chr9:128277982	chr9:128431598~128432006:+
THCA	cis	rs9475752	0.744	rs1451705	ENSG00000231441.1	RP11-472M19.2	4.66	4.2e-06	0.000468	0.23	0.21	Menarche (age at onset);	chr6:56936976	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.744	rs1451706	ENSG00000231441.1	RP11-472M19.2	4.66	4.2e-06	0.000468	0.23	0.21	Menarche (age at onset);	chr6:56937029	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.744	rs61273855	ENSG00000231441.1	RP11-472M19.2	4.66	4.2e-06	0.000468	0.23	0.21	Menarche (age at onset);	chr6:56937692	chr6:56844002~56864078:+
THCA	cis	rs7726839	0.54	rs72705030	ENSG00000225138.6	CTD-2228K2.7	4.66	4.2e-06	0.000468	0.26	0.21	Obesity-related traits;	chr5:645447	chr5:473236~480884:+
THCA	cis	rs1005277	0.522	rs7090858	ENSG00000226578.1	RP11-258F22.1	4.66	4.2e-06	0.000468	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:37775371~37784131:-
THCA	cis	rs6860806	0.507	rs272880	ENSG00000224431.1	AC063976.7	4.66	4.2e-06	0.000468	0.19	0.21	Breast cancer;	chr5:132334485	chr5:132199456~132203487:+
THCA	cis	rs9813712	0.818	rs11718381	ENSG00000253540.4	FAM86HP	4.66	4.2e-06	0.000468	0.26	0.21	Response to amphetamines;	chr3:130222660	chr3:130099092~130111472:-
THCA	cis	rs12887734	0.524	rs4906364	ENSG00000269910.1	RP11-73M18.10	4.66	4.2e-06	0.000468	0.19	0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103694516~103695050:-
THCA	cis	rs375066	0.935	rs425217	ENSG00000278917.1	RP11-15A1.4	-4.66	4.2e-06	0.000468	-0.17	-0.21	Breast cancer;	chr19:43889823	chr19:43891233~43895411:+
THCA	cis	rs11671005	0.651	rs55716128	ENSG00000269600.1	AC016629.3	-4.66	4.21e-06	0.000469	-0.3	-0.21	Mean platelet volume;	chr19:58537387	chr19:58593896~58599355:-
THCA	cis	rs73108077	0.79	rs73104050	ENSG00000277112.2	RP11-755J8.1	-4.66	4.21e-06	0.000469	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31289961	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.79	rs73104055	ENSG00000277112.2	RP11-755J8.1	-4.66	4.21e-06	0.000469	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31293082	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.79	rs73104064	ENSG00000277112.2	RP11-755J8.1	-4.66	4.21e-06	0.000469	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31297920	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.79	rs73104067	ENSG00000277112.2	RP11-755J8.1	-4.66	4.21e-06	0.000469	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31298693	chr20:30681825~30723932:-
THCA	cis	rs1979679	0.879	rs2638950	ENSG00000247934.4	RP11-967K21.1	-4.66	4.21e-06	0.000469	-0.2	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28398634	chr12:28163298~28190738:-
THCA	cis	rs1003719	0.553	rs1063948	ENSG00000230366.8	DSCR9	4.66	4.21e-06	0.000469	0.22	0.21	Eye color traits;	chr21:37202373	chr21:37208503~37221736:+
THCA	cis	rs465969	1	rs9400478	ENSG00000272356.1	RP5-1112D6.8	-4.66	4.22e-06	0.000469	-0.33	-0.21	Psoriasis;	chr6:111478441	chr6:111309203~111313517:+
THCA	cis	rs2361718	0.564	rs2304844	ENSG00000275479.1	RP11-334C17.6	4.66	4.22e-06	0.000469	0.19	0.21	Yeast infection;	chr17:80110708	chr17:80149627~80149798:+
THCA	cis	rs7773456	0.74	rs4140625	ENSG00000227116.1	RP3-471C18.1	4.66	4.22e-06	0.00047	0.23	0.21	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19730427~19734567:-
THCA	cis	rs6993270	1	rs6993270	ENSG00000245330.4	KB-1471A8.1	4.66	4.22e-06	0.00047	0.26	0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119929476	chr8:119867419~119874488:-
THCA	cis	rs4388249	0.578	rs427691	ENSG00000271849.1	CTC-332L22.1	-4.66	4.22e-06	0.00047	-0.28	-0.21	Schizophrenia;	chr5:109678809	chr5:109687802~109688329:-
THCA	cis	rs6012564	0.826	rs2869715	ENSG00000230758.1	SNAP23P	4.66	4.22e-06	0.00047	0.25	0.21	Anger;	chr20:49143463	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.793	rs6066979	ENSG00000230758.1	SNAP23P	4.66	4.22e-06	0.00047	0.25	0.21	Anger;	chr20:49144319	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.762	rs6066980	ENSG00000230758.1	SNAP23P	4.66	4.22e-06	0.00047	0.25	0.21	Anger;	chr20:49144320	chr20:49038357~49038602:-
THCA	cis	rs11088226	1	rs2833890	ENSG00000186842.4	LINC00846	4.66	4.22e-06	0.00047	0.28	0.21	Gastritis;	chr21:32555576	chr21:32572238~32575881:-
THCA	cis	rs9910055	0.593	rs2905983	ENSG00000267080.4	ASB16-AS1	4.66	4.22e-06	0.00047	0.19	0.21	Total body bone mineral density;	chr17:44135061	chr17:44175973~44186717:-
THCA	cis	rs7394190	0.748	rs3781216	ENSG00000271848.1	RP11-464F9.21	-4.66	4.22e-06	0.00047	-0.29	-0.21	Incident atrial fibrillation;	chr10:73762646	chr10:73654039~73674719:+
THCA	cis	rs9910055	0.708	rs2631298	ENSG00000267080.4	ASB16-AS1	-4.66	4.22e-06	0.00047	-0.19	-0.21	Total body bone mineral density;	chr17:44142464	chr17:44175973~44186717:-
THCA	cis	rs7560272	0.501	rs2421674	ENSG00000273245.1	RP11-434P11.2	-4.65	4.22e-06	0.00047	-0.24	-0.21	Schizophrenia;	chr2:73728305	chr2:73750256~73750786:-
THCA	cis	rs2886497	0.624	rs7918621	ENSG00000224215.1	RP11-371A19.2	-4.65	4.22e-06	0.00047	-0.24	-0.21	Major depression and alcohol dependence;	chr10:23399757	chr10:23343957~23345181:+
THCA	cis	rs972578	0.651	rs5759002	ENSG00000274717.1	RP1-47A17.1	4.65	4.22e-06	0.00047	0.22	0.21	Mean platelet volume;	chr22:42867426	chr22:42791814~42794313:-
THCA	cis	rs7829975	0.846	rs11779061	ENSG00000254153.1	CTA-398F10.2	4.65	4.23e-06	0.00047	0.23	0.21	Mood instability;	chr8:8691922	chr8:8456909~8461337:-
THCA	cis	rs7403037	0.794	rs72703490	ENSG00000260760.1	PWRN3	4.65	4.23e-06	0.00047	0.25	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24250413	chr15:24441127~24447967:+
THCA	cis	rs7829975	0.617	rs4841071	ENSG00000254153.1	CTA-398F10.2	-4.65	4.23e-06	0.00047	-0.23	-0.21	Mood instability;	chr8:8933634	chr8:8456909~8461337:-
THCA	cis	rs2787702	1	rs1869926	ENSG00000237233.2	TMEM26-AS1	-4.65	4.23e-06	0.000471	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61554533	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs1869927	ENSG00000237233.2	TMEM26-AS1	-4.65	4.23e-06	0.000471	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61554714	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2787706	ENSG00000237233.2	TMEM26-AS1	-4.65	4.23e-06	0.000471	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61554930	chr10:61452639~61481956:+
THCA	cis	rs2288884	0.559	rs61287503	ENSG00000269483.1	AC006272.1	4.65	4.23e-06	0.000471	0.24	0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:51839924~51843324:-
THCA	cis	rs10090774	0.965	rs13250232	ENSG00000279766.1	RP11-642A1.2	-4.65	4.23e-06	0.000471	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140927107	chr8:140572142~140572812:-
THCA	cis	rs2120243	0.539	rs988587	ENSG00000241770.1	RP11-555M1.3	-4.65	4.23e-06	0.000471	-0.27	-0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157336482	chr3:157163452~157169133:+
THCA	cis	rs1707322	0.964	rs6697830	ENSG00000281133.1	AL355480.3	-4.65	4.23e-06	0.000471	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs12060274	ENSG00000281133.1	AL355480.3	-4.65	4.23e-06	0.000471	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45580892~45580996:-
THCA	cis	rs6993270	1	rs73705828	ENSG00000245330.4	KB-1471A8.1	-4.65	4.23e-06	0.000471	-0.26	-0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119926509	chr8:119867419~119874488:-
THCA	cis	rs6993270	0.895	rs7465212	ENSG00000245330.4	KB-1471A8.1	-4.65	4.23e-06	0.000471	-0.26	-0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119926553	chr8:119867419~119874488:-
THCA	cis	rs6993270	1	rs1034527	ENSG00000245330.4	KB-1471A8.1	-4.65	4.23e-06	0.000471	-0.26	-0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119926885	chr8:119867419~119874488:-
THCA	cis	rs6993270	1	rs56658648	ENSG00000245330.4	KB-1471A8.1	-4.65	4.23e-06	0.000471	-0.26	-0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119927398	chr8:119867419~119874488:-
THCA	cis	rs3820928	0.874	rs2272198	ENSG00000212391.1	SNORA48	4.65	4.23e-06	0.000471	0.23	0.21	Pulmonary function;	chr2:227028301	chr2:226968989~226969122:-
THCA	cis	rs12476592	0.516	rs6717060	ENSG00000242412.1	DBIL5P2	4.65	4.23e-06	0.000471	0.26	0.21	Childhood ear infection;	chr2:63341473	chr2:63117851~63119542:-
THCA	cis	rs8141529	0.748	rs132529	ENSG00000226471.5	CTA-292E10.6	4.65	4.23e-06	0.000471	0.18	0.21	Lymphocyte counts;	chr22:28900664	chr22:28800683~28848559:+
THCA	cis	rs2028299	1	rs1371135	ENSG00000259677.1	RP11-493E3.1	4.65	4.23e-06	0.000471	0.27	0.21	Type 2 diabetes;	chr15:89848038	chr15:89876540~89877285:+
THCA	cis	rs858239	0.539	rs6945510	ENSG00000226816.2	AC005082.12	4.65	4.23e-06	0.000471	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs6949363	ENSG00000226816.2	AC005082.12	4.65	4.23e-06	0.000471	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23206013~23208045:+
THCA	cis	rs9652601	0.691	rs3862468	ENSG00000274038.1	RP11-66H6.4	4.65	4.23e-06	0.000471	0.25	0.21	Systemic lupus erythematosus;	chr16:11100161	chr16:11056556~11057034:+
THCA	cis	rs7809950	0.637	rs2701685	ENSG00000238832.1	snoU109	4.65	4.23e-06	0.000471	0.23	0.21	Coronary artery disease;	chr7:107659139	chr7:107603363~107603507:+
THCA	cis	rs6477918	0.598	rs10817345	ENSG00000230185.4	C9orf147	-4.65	4.23e-06	0.000471	-0.23	-0.21	Obstetric antiphospholipid syndrome;	chr9:112447028	chr9:112433816~112487204:-
THCA	cis	rs13178541	0.81	rs6891354	ENSG00000250378.1	RP11-119J18.1	-4.65	4.23e-06	0.000471	-0.27	-0.21	IgG glycosylation;	chr5:135798986	chr5:135812667~135826582:+
THCA	cis	rs1122401	0.515	rs2564981	ENSG00000280159.1	CTD-2591A1.1	4.65	4.23e-06	0.000471	0.3	0.21	Smoking initiation;	chr5:54575075	chr5:54643557~54645987:+
THCA	cis	rs8042680	0.542	rs12440774	ENSG00000214432.8	AC068831.10	-4.65	4.24e-06	0.000471	-0.22	-0.21	Type 2 diabetes;	chr15:90939705	chr15:91022619~91036611:+
THCA	cis	rs4761702	0.922	rs7960229	ENSG00000257322.4	RP11-511B23.2	-4.65	4.24e-06	0.000471	-0.28	-0.21	Immature fraction of reticulocytes;	chr12:93323943	chr12:93003415~93215679:-
THCA	cis	rs172166	0.61	rs276369	ENSG00000280107.1	AL022393.9	-4.65	4.24e-06	0.000472	-0.2	-0.21	Cardiac Troponin-T levels;	chr6:27951465	chr6:28170845~28172521:+
THCA	cis	rs9652601	0.691	rs9921287	ENSG00000274038.1	RP11-66H6.4	-4.65	4.24e-06	0.000472	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11115882	chr16:11056556~11057034:+
THCA	cis	rs703842	1	rs3782130	ENSG00000270039.1	RP11-571M6.17	-4.65	4.24e-06	0.000472	-0.24	-0.21	Multiple sclerosis;	chr12:57768115	chr12:57803838~57804415:+
THCA	cis	rs2439831	0.867	rs28461955	ENSG00000205771.5	CATSPER2P1	-4.65	4.24e-06	0.000472	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43369261	chr15:43726918~43747094:-
THCA	cis	rs6088590	0.965	rs6120730	ENSG00000276073.1	RP5-1125A11.7	-4.65	4.24e-06	0.000472	-0.2	-0.21	Coronary artery disease;	chr20:34797299	chr20:33985617~33988989:-
THCA	cis	rs11846409	0.872	rs2956482	ENSG00000211974.3	IGHV2-70	4.65	4.24e-06	0.000472	0.2	0.21	Rheumatic heart disease;	chr14:106630013	chr14:106723574~106724093:-
THCA	cis	rs10932679	0.543	rs2014998	ENSG00000229352.1	AC007563.3	4.65	4.24e-06	0.000472	0.31	0.21	Pulse pressure;	chr2:216817238	chr2:216799608~216805335:+
THCA	cis	rs9380516	0.853	rs2050162	ENSG00000228559.1	RP3-340B19.3	-4.65	4.24e-06	0.000472	-0.31	-0.21	Hepatitis C induced liver fibrosis;	chr6:35514745	chr6:35544632~35545669:+
THCA	cis	rs11853189	1	rs11856774	ENSG00000259562.2	RP11-762H8.2	4.65	4.24e-06	0.000472	0.2	0.21	Red cell distribution width;	chr15:78273697	chr15:78290527~78291221:-
THCA	cis	rs9393813	0.626	rs2235232	ENSG00000204789.4	ZNF204P	4.65	4.24e-06	0.000472	0.17	0.21	Bipolar disorder;	chr6:27359084	chr6:27357825~27360221:-
THCA	cis	rs6993270	1	rs6469877	ENSG00000245330.4	KB-1471A8.1	-4.65	4.24e-06	0.000472	-0.26	-0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119924281	chr8:119867419~119874488:-
THCA	cis	rs5752326	0.558	rs1023494	ENSG00000261188.1	CTA-445C9.14	4.65	4.24e-06	0.000472	0.2	0.21	Ischemic stroke;	chr22:26469074	chr22:26512537~26514568:+
THCA	cis	rs2439831	1	rs690002	ENSG00000205771.5	CATSPER2P1	-4.65	4.24e-06	0.000472	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43437151	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs537115	ENSG00000205771.5	CATSPER2P1	-4.65	4.24e-06	0.000472	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43437750	chr15:43726918~43747094:-
THCA	cis	rs4245128	0.736	rs10891477	ENSG00000247416.2	RP11-629G13.1	4.65	4.24e-06	0.000472	0.2	0.21	Life satisfaction;	chr11:112942584	chr11:112959279~112963460:-
THCA	cis	rs2762353	0.524	rs3923	ENSG00000272462.2	U91328.19	4.65	4.24e-06	0.000472	0.17	0.21	Blood metabolite levels;	chr6:25783087	chr6:25992662~26001775:+
THCA	cis	rs2483058	0.767	rs61817176	ENSG00000261000.1	RP11-534L20.5	4.65	4.24e-06	0.000472	0.23	0.21	Cholesterol and Triglycerides;	chr1:206447682	chr1:206503948~206504456:+
THCA	cis	rs2985684	1	rs2985696	ENSG00000278009.1	RP11-649E7.8	4.65	4.25e-06	0.000472	0.3	0.21	Carotid intima media thickness;	chr14:49628195	chr14:49601011~49601124:-
THCA	cis	rs2657294	0.796	rs2804535	ENSG00000226051.5	ZNF503-AS1	4.65	4.25e-06	0.000473	0.29	0.21	Pneumonia;	chr10:75212086	chr10:75269819~75373500:+
THCA	cis	rs9876781	1	rs13091785	ENSG00000244380.1	RP11-24C3.2	4.65	4.25e-06	0.000473	0.25	0.21	Longevity;	chr3:48452692	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs6776700	ENSG00000244380.1	RP11-24C3.2	4.65	4.25e-06	0.000473	0.25	0.21	Longevity;	chr3:48455358	chr3:48440352~48446656:-
THCA	cis	rs893818	1	rs893816	ENSG00000261801.4	LOXL1-AS1	4.65	4.25e-06	0.000473	0.24	0.21	Exfoliation glaucoma or exfoliation syndrome;	chr15:73936123	chr15:73908071~73928248:-
THCA	cis	rs62158800	0.85	rs62158797	ENSG00000237880.1	AC096669.2	4.65	4.25e-06	0.000473	0.33	0.21	Facial morphology (factor 22);	chr2:107583129	chr2:107385632~107542649:-
THCA	cis	rs12682352	0.602	rs11783966	ENSG00000254153.1	CTA-398F10.2	4.65	4.25e-06	0.000473	0.23	0.21	Neuroticism;	chr8:8807637	chr8:8456909~8461337:-
THCA	cis	rs4650994	0.593	rs16853043	ENSG00000273384.1	RP5-1098D14.1	-4.65	4.25e-06	0.000473	-0.28	-0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178576791	chr1:178651706~178652282:+
THCA	cis	rs756699	0.749	rs244690	ENSG00000279469.1	RP11-215P8.2	-4.65	4.25e-06	0.000473	-0.31	-0.21	Multiple sclerosis;	chr5:134086053	chr5:134394360~134395008:-
THCA	cis	rs6496044	0.507	rs8034676	ENSG00000259407.1	RP11-158M2.3	-4.65	4.25e-06	0.000473	-0.22	-0.21	Interstitial lung disease;	chr15:85616031	chr15:85744109~85750281:-
THCA	cis	rs57221529	0.664	rs72704802	ENSG00000225138.6	CTD-2228K2.7	4.65	4.25e-06	0.000473	0.29	0.21	Lung disease severity in cystic fibrosis;	chr5:554096	chr5:473236~480884:+
THCA	cis	rs914615	0.552	rs12752585	ENSG00000236675.1	MTX1P1	-4.65	4.25e-06	0.000473	-0.2	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155162930	chr1:155230975~155234325:+
THCA	cis	rs2015599	0.623	rs1072724	ENSG00000273680.1	RP11-996F15.6	-4.65	4.26e-06	0.000473	-0.3	-0.21	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29332733~29333383:-
THCA	cis	rs8077577	0.747	rs12451698	ENSG00000273018.4	CTD-2303H24.2	-4.65	4.26e-06	0.000473	-0.3	-0.21	Obesity-related traits;	chr17:18333802	chr17:18511221~18551705:-
THCA	cis	rs1979679	0.879	rs2061759	ENSG00000247934.4	RP11-967K21.1	-4.65	4.26e-06	0.000474	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28310394	chr12:28163298~28190738:-
THCA	cis	rs4415084	1	rs12515012	ENSG00000272335.1	RP11-53O19.3	-4.65	4.26e-06	0.000474	-0.17	-0.21	Breast cancer;	chr5:44694433	chr5:44826076~44828592:+
THCA	cis	rs1395	0.925	rs1659676	ENSG00000234072.1	AC074117.10	4.65	4.26e-06	0.000474	0.17	0.21	Blood metabolite levels;	chr2:27176426	chr2:27356246~27367622:+
THCA	cis	rs4934494	0.681	rs12572928	ENSG00000240996.1	RP11-80H5.7	-4.65	4.26e-06	0.000474	-0.24	-0.21	Red blood cell count;	chr10:89793792	chr10:89694295~89697928:-
THCA	cis	rs9880211	0.563	rs6769762	ENSG00000273486.1	RP11-731C17.2	4.65	4.26e-06	0.000474	0.21	0.21	Height;Body mass index;	chr3:136189336	chr3:136837338~136839021:-
THCA	cis	rs3026101	0.507	rs2285748	ENSG00000234327.6	AC012146.7	-4.65	4.26e-06	0.000474	-0.2	-0.21	Body mass index;	chr17:5391681	chr17:5111468~5115004:+
THCA	cis	rs7474896	0.895	rs2749587	ENSG00000263064.2	RP11-291L22.7	-4.65	4.26e-06	0.000474	-0.34	-0.21	Obesity (extreme);	chr10:37980609	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs7086833	ENSG00000263064.2	RP11-291L22.7	-4.65	4.26e-06	0.000474	-0.34	-0.21	Obesity (extreme);	chr10:37988097	chr10:38448689~38448949:+
THCA	cis	rs6449502	0.92	rs158916	ENSG00000251279.1	CTC-436P18.1	4.65	4.26e-06	0.000474	0.34	0.21	Mean platelet volume;	chr5:60949318	chr5:61162070~61232040:+
THCA	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	4.65	4.26e-06	0.000474	0.2	0.21	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
THCA	cis	rs4650994	0.593	rs2761472	ENSG00000273384.1	RP5-1098D14.1	4.65	4.26e-06	0.000474	0.27	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178640221	chr1:178651706~178652282:+
THCA	cis	rs57502260	0.79	rs7129320	ENSG00000212093.1	AP000807.1	4.65	4.26e-06	0.000474	0.27	0.21	Total body bone mineral density (age 45-60);	chr11:68620752	chr11:68506083~68506166:-
THCA	cis	rs858239	0.632	rs6952947	ENSG00000226816.2	AC005082.12	-4.65	4.26e-06	0.000474	-0.3	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23206013~23208045:+
THCA	cis	rs2562456	0.526	rs950504	ENSG00000268119.4	CTD-2561J22.5	4.65	4.26e-06	0.000474	0.23	0.21	Pain;	chr19:21601193	chr19:21444241~21463908:-
THCA	cis	rs6967414	0.605	rs7786706	ENSG00000187953.9	PMS2CL	-4.65	4.26e-06	0.000474	-0.26	-0.21	Hematocrit;Hemoglobin concentration;	chr7:6707636	chr7:6710128~6753862:+
THCA	cis	rs7394190	0.748	rs4082339	ENSG00000271848.1	RP11-464F9.21	4.65	4.26e-06	0.000474	0.29	0.21	Incident atrial fibrillation;	chr10:73780054	chr10:73654039~73674719:+
THCA	cis	rs11992162	0.591	rs4240678	ENSG00000206014.6	OR7E161P	4.65	4.26e-06	0.000474	0.25	0.21	Monocyte count;	chr8:11944917	chr8:11928597~11929563:-
THCA	cis	rs7621331	1	rs67039922	ENSG00000273486.1	RP11-731C17.2	4.65	4.26e-06	0.000474	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136049390	chr3:136837338~136839021:-
THCA	cis	rs6445975	0.667	rs4681672	ENSG00000272360.1	RP11-359I18.5	-4.65	4.26e-06	0.000474	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58244709	chr3:58490830~58491291:-
THCA	cis	rs2412819	0.571	rs12443084	ENSG00000166763.7	STRCP1	-4.65	4.26e-06	0.000474	-0.27	-0.21	Lung cancer;	chr15:43748767	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs10163069	ENSG00000166763.7	STRCP1	-4.65	4.26e-06	0.000474	-0.27	-0.21	Lung cancer;	chr15:43755372	chr15:43699488~43718184:-
THCA	cis	rs2929278	0.617	rs3986209	ENSG00000166763.7	STRCP1	-4.65	4.26e-06	0.000474	-0.27	-0.21	Schizophrenia;	chr15:43758675	chr15:43699488~43718184:-
THCA	cis	rs4415084	0.662	rs12109710	ENSG00000272335.1	RP11-53O19.3	4.65	4.26e-06	0.000474	0.18	0.21	Breast cancer;	chr5:44929826	chr5:44826076~44828592:+
THCA	cis	rs4908760	0.792	rs10864361	ENSG00000232912.4	RP5-1115A15.1	-4.65	4.26e-06	0.000474	-0.21	-0.21	Vitiligo;	chr1:8666662	chr1:8424645~8434838:+
THCA	cis	rs7520050	0.966	rs7556436	ENSG00000234329.1	RP11-767N6.2	4.65	4.26e-06	0.000474	0.19	0.21	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45651039~45651826:-
THCA	cis	rs2797160	0.651	rs6939969	ENSG00000226409.1	RP11-735G4.1	4.65	4.26e-06	0.000474	0.26	0.21	Endometrial cancer;	chr6:125713417	chr6:125370211~125374324:-
THCA	cis	rs9300255	0.602	rs1727315	ENSG00000235423.7	RP11-282O18.3	-4.65	4.26e-06	0.000474	-0.22	-0.21	Neutrophil percentage of white cells;	chr12:123154383	chr12:123252030~123261483:-
THCA	cis	rs718433	0.584	rs4982495	ENSG00000211778.2	TRAV4	-4.65	4.26e-06	0.000474	-0.16	-0.21	Intraocular pressure;	chr14:21752285	chr14:21736152~21736982:+
THCA	cis	rs718433	0.584	rs4982496	ENSG00000211778.2	TRAV4	-4.65	4.26e-06	0.000474	-0.16	-0.21	Intraocular pressure;	chr14:21752353	chr14:21736152~21736982:+
THCA	cis	rs12410462	0.591	rs2819507	ENSG00000227711.2	RP11-275O4.5	-4.65	4.26e-06	0.000474	-0.26	-0.21	Major depressive disorder;	chr1:227519833	chr1:227509028~227520477:-
THCA	cis	rs7520050	0.933	rs6694340	ENSG00000234329.1	RP11-767N6.2	-4.65	4.27e-06	0.000474	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45651039~45651826:-
THCA	cis	rs2777491	0.872	rs7176588	ENSG00000247556.5	OIP5-AS1	4.65	4.27e-06	0.000474	0.17	0.21	Ulcerative colitis;	chr15:41296674	chr15:41283990~41309737:+
THCA	cis	rs10483853	0.806	rs7141241	ENSG00000258695.2	RP3-414A15.2	-4.65	4.27e-06	0.000475	-0.29	-0.21	Coronary artery calcification;	chr14:73342096	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.806	rs10142258	ENSG00000258695.2	RP3-414A15.2	-4.65	4.27e-06	0.000475	-0.29	-0.21	Coronary artery calcification;	chr14:73343509	chr14:73522878~73530610:+
THCA	cis	rs858239	0.539	rs4294098	ENSG00000226816.2	AC005082.12	4.65	4.27e-06	0.000475	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs4504540	ENSG00000226816.2	AC005082.12	4.65	4.27e-06	0.000475	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23206013~23208045:+
THCA	cis	rs858239	0.509	rs6975524	ENSG00000226816.2	AC005082.12	4.65	4.27e-06	0.000475	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs6955726	ENSG00000226816.2	AC005082.12	4.65	4.27e-06	0.000475	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs6955969	ENSG00000226816.2	AC005082.12	4.65	4.27e-06	0.000475	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs6956828	ENSG00000226816.2	AC005082.12	4.65	4.27e-06	0.000475	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23206013~23208045:+
THCA	cis	rs13126694	0.778	rs10013448	ENSG00000248429.4	RP11-597D13.9	4.65	4.27e-06	0.000475	0.22	0.21	Blood osmolality (transformed sodium);	chr4:158116101	chr4:158170752~158202877:+
THCA	cis	rs7179456	0.545	rs2250583	ENSG00000245975.2	RP11-30K9.6	-4.65	4.27e-06	0.000475	-0.2	-0.21	Asperger disorder;	chr15:58758183	chr15:58768072~58770974:-
THCA	cis	rs3740713	1	rs73440637	ENSG00000256464.1	YWHABP2	4.65	4.27e-06	0.000475	0.38	0.21	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr11:18490243~18490955:-
THCA	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-4.65	4.27e-06	0.000475	-0.2	-0.21	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
THCA	cis	rs1979679	0.842	rs10459090	ENSG00000247934.4	RP11-967K21.1	-4.65	4.27e-06	0.000475	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188207	chr12:28163298~28190738:-
THCA	cis	rs6496044	0.507	rs62022863	ENSG00000259407.1	RP11-158M2.3	4.65	4.27e-06	0.000475	0.22	0.21	Interstitial lung disease;	chr15:85618822	chr15:85744109~85750281:-
THCA	cis	rs62025270	0.649	rs12148610	ENSG00000259295.5	CSPG4P12	-4.65	4.27e-06	0.000475	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85191438~85213905:+
THCA	cis	rs8177876	0.841	rs117310590	ENSG00000261061.1	RP11-303E16.2	-4.65	4.27e-06	0.000475	-0.37	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094790	chr16:81030770~81031485:+
THCA	cis	rs6433895	1	rs34601234	ENSG00000236153.1	AC104076.3	-4.65	4.27e-06	0.000475	-0.24	-0.21	Lymphocyte counts;	chr2:181148393	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs7592486	ENSG00000236153.1	AC104076.3	-4.65	4.27e-06	0.000475	-0.24	-0.21	Lymphocyte counts;	chr2:181148536	chr2:180979427~180980090:-
THCA	cis	rs6433895	1	rs7566256	ENSG00000236153.1	AC104076.3	-4.65	4.27e-06	0.000475	-0.24	-0.21	Lymphocyte counts;	chr2:181148547	chr2:180979427~180980090:-
THCA	cis	rs6433895	0.961	rs7566434	ENSG00000236153.1	AC104076.3	-4.65	4.27e-06	0.000475	-0.24	-0.21	Lymphocyte counts;	chr2:181148888	chr2:180979427~180980090:-
THCA	cis	rs899997	0.773	rs8032156	ENSG00000261143.1	ADAMTS7P3	4.65	4.28e-06	0.000475	0.31	0.21	Coronary artery disease or large artery stroke;	chr15:78672156	chr15:77976042~77993057:+
THCA	cis	rs11992162	0.636	rs4841644	ENSG00000254948.1	OR7E158P	-4.65	4.28e-06	0.000475	-0.26	-0.21	Monocyte count;	chr8:11940924	chr8:11919900~11920809:-
THCA	cis	rs5769765	0.954	rs5770709	ENSG00000260613.1	RP3-522J7.6	4.65	4.28e-06	0.000476	0.25	0.21	Schizophrenia;	chr22:49851548	chr22:49832616~49837786:-
THCA	cis	rs9300255	0.739	rs11057210	ENSG00000235423.7	RP11-282O18.3	4.65	4.28e-06	0.000476	0.22	0.21	Neutrophil percentage of white cells;	chr12:123249252	chr12:123252030~123261483:-
THCA	cis	rs9601248	0.627	rs2876741	ENSG00000227676.3	LINC01068	-4.65	4.28e-06	0.000476	-0.27	-0.21	Major depressive disorder;	chr13:79612577	chr13:79566727~79571436:+
THCA	cis	rs9307551	0.619	rs1899232	ENSG00000250334.4	LINC00989	-4.65	4.28e-06	0.000476	-0.25	-0.21	Refractive error;	chr4:79501789	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.619	rs7684683	ENSG00000250334.4	LINC00989	-4.65	4.28e-06	0.000476	-0.25	-0.21	Refractive error;	chr4:79501867	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.584	rs7663844	ENSG00000250334.4	LINC00989	-4.65	4.28e-06	0.000476	-0.25	-0.21	Refractive error;	chr4:79502053	chr4:79492416~79576460:+
THCA	cis	rs7520050	0.966	rs7515491	ENSG00000234329.1	RP11-767N6.2	-4.65	4.28e-06	0.000476	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45889407	chr1:45651039~45651826:-
THCA	cis	rs7914558	0.966	rs1591915	ENSG00000236937.2	PTGES3P4	4.65	4.28e-06	0.000476	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102845595~102845950:+
THCA	cis	rs2797160	0.522	rs6925158	ENSG00000237742.5	RP11-624M8.1	-4.65	4.28e-06	0.000476	-0.19	-0.21	Endometrial cancer;	chr6:125619042	chr6:125578558~125749190:-
THCA	cis	rs9990333	0.622	rs57783901	ENSG00000207650.1	MIR570	4.65	4.28e-06	0.000476	0.22	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195699401~195699497:+
THCA	cis	rs2657294	0.929	rs6480771	ENSG00000226051.5	ZNF503-AS1	-4.65	4.28e-06	0.000476	-0.29	-0.21	Pneumonia;	chr10:75101922	chr10:75269819~75373500:+
THCA	cis	rs1923243	0.71	rs4233101	ENSG00000223479.3	RP4-788P17.1	-4.65	4.28e-06	0.000476	-0.24	-0.21	Migraine;	chr1:73113572	chr1:73635216~73715214:+
THCA	cis	rs2337406	0.778	rs56965016	ENSG00000211974.3	IGHV2-70	-4.65	4.28e-06	0.000476	-0.21	-0.21	Alzheimer's disease (late onset);	chr14:106656649	chr14:106723574~106724093:-
THCA	cis	rs4578769	0.55	rs9953702	ENSG00000265939.1	UBE2CP2	4.65	4.28e-06	0.000476	0.24	0.21	Eosinophil percentage of white cells;	chr18:22971001	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.569	rs9951157	ENSG00000265939.1	UBE2CP2	4.65	4.28e-06	0.000476	0.24	0.21	Eosinophil percentage of white cells;	chr18:22974173	chr18:22900486~22900995:-
THCA	cis	rs7772486	0.701	rs11155438	ENSG00000270638.1	RP3-466P17.1	4.65	4.29e-06	0.000476	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145735570~145737218:+
THCA	cis	rs9970896	1	rs6701752	ENSG00000237845.1	RP5-940F7.2	-4.65	4.29e-06	0.000477	-0.4	-0.21	Monocyte percentage of white cells;	chr1:235939586	chr1:235942553~235943805:-
THCA	cis	rs728616	0.51	rs12768957	ENSG00000278616.1	BEND3P3	4.65	4.29e-06	0.000477	0.21	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80427537	chr10:79682997~79685436:+
THCA	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-4.65	4.29e-06	0.000477	-0.32	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-4.65	4.29e-06	0.000477	-0.32	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
THCA	cis	rs62025270	0.632	rs6496109	ENSG00000259295.5	CSPG4P12	-4.65	4.29e-06	0.000477	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85191438~85213905:+
THCA	cis	rs4950322	0.57	rs72691090	ENSG00000180867.10	PDIA3P1	4.65	4.29e-06	0.000477	0.21	0.21	Protein quantitative trait loci;	chr1:147297884	chr1:147178113~147179622:+
THCA	cis	rs1707322	1	rs11211217	ENSG00000281133.1	AL355480.3	-4.65	4.29e-06	0.000477	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45580892~45580996:-
THCA	cis	rs2243480	1	rs34970380	ENSG00000232559.3	GS1-124K5.12	4.65	4.29e-06	0.000477	0.31	0.21	Diabetic kidney disease;	chr7:65966506	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1723270	ENSG00000232559.3	GS1-124K5.12	4.65	4.29e-06	0.000477	0.31	0.21	Diabetic kidney disease;	chr7:66004843	chr7:66554588~66576923:-
THCA	cis	rs7191700	0.511	rs12923756	ENSG00000263080.1	RP11-485G7.5	-4.65	4.29e-06	0.000477	-0.24	-0.21	Multiple sclerosis;	chr16:11265818	chr16:11341809~11345211:-
THCA	cis	rs2980439	0.807	rs2980438	ENSG00000253981.4	ALG1L13P	4.65	4.29e-06	0.000477	0.2	0.21	Neuroticism;	chr8:8237303	chr8:8236003~8244667:-
THCA	cis	rs2018683	1	rs740252	ENSG00000272568.4	CTB-113D17.1	4.65	4.3e-06	0.000477	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28958149	chr7:28979967~29013367:+
THCA	cis	rs1790761	0.504	rs61894496	ENSG00000184224.3	C11orf72	4.65	4.3e-06	0.000478	0.28	0.21	Mean corpuscular volume;	chr11:67624436	chr11:67602880~67606706:-
THCA	cis	rs13434995	0.513	rs17722979	ENSG00000273257.1	RP11-177J6.1	-4.65	4.3e-06	0.000478	-0.31	-0.21	Adiponectin levels;	chr4:55480244	chr4:55387949~55388271:+
THCA	cis	rs758324	0.681	rs25879	ENSG00000237714.1	P4HA2-AS1	-4.65	4.3e-06	0.000478	-0.29	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132071351	chr5:132184876~132192808:+
THCA	cis	rs67478160	0.572	rs8015603	ENSG00000269910.1	RP11-73M18.10	4.65	4.3e-06	0.000478	0.18	0.21	Schizophrenia;	chr14:103827341	chr14:103694516~103695050:-
THCA	cis	rs77637988	0.578	rs12328506	ENSG00000202227.1	RNU6-282P	4.65	4.3e-06	0.000478	0.22	0.21	Joint mobility (Beighton score);	chr2:48396045	chr2:48501922~48502024:-
THCA	cis	rs11673344	0.523	rs7248948	ENSG00000276846.1	CTD-3220F14.3	4.65	4.3e-06	0.000478	0.16	0.21	Obesity-related traits;	chr19:37056317	chr19:37314868~37315620:-
THCA	cis	rs2013441	0.508	rs34756775	ENSG00000261033.1	RP11-209D14.2	-4.65	4.3e-06	0.000478	-0.28	-0.21	Obesity-related traits;	chr17:20079525	chr17:20008051~20009234:-
THCA	cis	rs9818758	0.607	rs71324929	ENSG00000270441.1	RP11-694I15.7	4.65	4.3e-06	0.000478	0.31	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49007280	chr3:49140086~49160851:-
THCA	cis	rs10090774	0.71	rs10103745	ENSG00000280303.2	ERICD	-4.65	4.3e-06	0.000478	-0.2	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140680544	chr8:140636281~140638283:+
THCA	cis	rs4915077	1	rs76134821	ENSG00000226822.1	RP11-356N1.2	4.65	4.3e-06	0.000478	0.39	0.21	Hypothyroidism;	chr1:107815121	chr1:108071482~108074519:+
THCA	cis	rs6088590	1	rs6120747	ENSG00000276073.1	RP5-1125A11.7	-4.65	4.3e-06	0.000478	-0.2	-0.21	Coronary artery disease;	chr20:34861966	chr20:33985617~33988989:-
THCA	cis	rs494453	0.845	rs523650	ENSG00000227811.2	FAM212B-AS1	-4.65	4.3e-06	0.000478	-0.26	-0.21	Osteoporosis-related phenotypes;	chr1:111699642	chr1:111739841~111747798:+
THCA	cis	rs67478160	0.571	rs1155751	ENSG00000269910.1	RP11-73M18.10	4.65	4.31e-06	0.000479	0.18	0.21	Schizophrenia;	chr14:103820210	chr14:103694516~103695050:-
THCA	cis	rs7560272	0.538	rs4852975	ENSG00000163016.8	ALMS1P	-4.65	4.31e-06	0.000479	-0.26	-0.21	Schizophrenia;	chr2:73705338	chr2:73644919~73685576:+
THCA	cis	rs7267979	1	rs2424704	ENSG00000274973.1	RP13-401N8.7	-4.65	4.31e-06	0.000479	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25845497~25845862:+
THCA	cis	rs62292953	0.858	rs62292896	ENSG00000248724.5	NPHP3-AS1	-4.65	4.31e-06	0.000479	-0.35	-0.21	Red cell distribution width;	chr3:132467343	chr3:132721750~132874223:+
THCA	cis	rs3743162	0.553	rs4842994	ENSG00000275120.1	RP11-182J1.17	-4.65	4.31e-06	0.000479	-0.25	-0.21	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84599434~84606463:-
THCA	cis	rs9863	0.896	rs2130382	ENSG00000269997.1	RP11-214K3.21	-4.65	4.31e-06	0.000479	-0.26	-0.21	White blood cell count;	chr12:124000096	chr12:123966077~123966629:-
THCA	cis	rs6993270	1	rs7008908	ENSG00000245330.4	KB-1471A8.1	-4.65	4.31e-06	0.000479	-0.26	-0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119924650	chr8:119867419~119874488:-
THCA	cis	rs617791	0.508	rs10896074	ENSG00000255320.1	RP11-755F10.1	4.65	4.31e-06	0.000479	0.27	0.21	Breast cancer;	chr11:66008833	chr11:66244840~66246239:-
THCA	cis	rs13178541	0.81	rs13170007	ENSG00000250378.1	RP11-119J18.1	-4.65	4.31e-06	0.000479	-0.25	-0.21	IgG glycosylation;	chr5:135740893	chr5:135812667~135826582:+
THCA	cis	rs7618915	0.501	rs2164885	ENSG00000243224.1	RP5-1157M23.2	-4.65	4.31e-06	0.000479	-0.22	-0.21	Bipolar disorder;	chr3:52697253	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs3733041	ENSG00000243224.1	RP5-1157M23.2	-4.65	4.31e-06	0.000479	-0.22	-0.21	Bipolar disorder;	chr3:52697582	chr3:52239258~52241097:+
THCA	cis	rs763121	0.925	rs5757165	ENSG00000228274.3	RP3-508I15.9	-4.65	4.31e-06	0.000479	-0.21	-0.21	Menopause (age at onset);	chr22:38598572	chr22:38667585~38681820:-
THCA	cis	rs11089937	0.616	rs5750675	ENSG00000211639.2	IGLV4-60	4.65	4.32e-06	0.00048	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22179233	chr22:22162199~22162681:+
THCA	cis	rs987724	0.501	rs9851913	ENSG00000240875.4	LINC00886	-4.65	4.32e-06	0.00048	-0.2	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156883165	chr3:156747346~156817062:-
THCA	cis	rs2299587	0.607	rs2237848	ENSG00000253671.1	RP11-806O11.1	-4.65	4.32e-06	0.00048	-0.24	-0.21	Economic and political preferences;	chr8:18017095	chr8:17808941~17820868:+
THCA	cis	rs79243044	0.965	rs10838302	ENSG00000224295.2	AC087380.14	-4.65	4.32e-06	0.00048	-0.22	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5546479	chr11:5518441~5524955:-
THCA	cis	rs79243044	1	rs7131305	ENSG00000224295.2	AC087380.14	-4.65	4.32e-06	0.00048	-0.22	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5546505	chr11:5518441~5524955:-
THCA	cis	rs752010	0.714	rs7515948	ENSG00000230638.4	RP11-486B10.4	-4.65	4.32e-06	0.00048	-0.22	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41613375	chr1:41542069~41544310:+
THCA	cis	rs7403037	0.563	rs2677387	ENSG00000259905.4	PWRN1	4.65	4.32e-06	0.00048	0.21	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24187648	chr15:24493137~24652130:+
THCA	cis	rs3770081	1	rs73945535	ENSG00000272564.1	RP11-548P2.2	-4.65	4.32e-06	0.00048	-0.37	-0.21	Facial emotion recognition (sad faces);	chr2:85897750	chr2:85904279~85904727:+
THCA	cis	rs868036	0.609	rs3784707	ENSG00000270964.1	RP11-502I4.3	-4.65	4.32e-06	0.00048	-0.2	-0.21	Restless legs syndrome;	chr15:67751540	chr15:67541072~67542604:-
THCA	cis	rs6860806	0.507	rs273917	ENSG00000237714.1	P4HA2-AS1	4.65	4.32e-06	0.00048	0.28	0.21	Breast cancer;	chr5:132323925	chr5:132184876~132192808:+
THCA	cis	rs270601	0.955	rs273911	ENSG00000237714.1	P4HA2-AS1	4.65	4.32e-06	0.00048	0.28	0.21	Acylcarnitine levels;	chr5:132325833	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.507	rs272891	ENSG00000237714.1	P4HA2-AS1	4.65	4.32e-06	0.00048	0.28	0.21	Breast cancer;	chr5:132328701	chr5:132184876~132192808:+
THCA	cis	rs9532669	0.926	rs7799	ENSG00000229473.2	RGS17P1	4.65	4.32e-06	0.00048	0.26	0.21	Cervical cancer;	chr13:40958916	chr13:40992779~40993331:-
THCA	cis	rs990871	0.53	rs1675356	ENSG00000227207.2	RPL31P12	4.65	4.32e-06	0.00048	0.24	0.21	Subcutaneous adipose tissue;	chr1:72217543	chr1:72301472~72301829:+
THCA	cis	rs897984	0.568	rs8063565	ENSG00000260911.2	RP11-196G11.2	-4.65	4.32e-06	0.00048	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30872644	chr16:31043150~31049868:+
THCA	cis	rs4061073	0.961	rs9012	ENSG00000198711.5	SSBP3-AS1	-4.65	4.32e-06	0.00048	-0.19	-0.21	Body mass index;	chr1:54225792	chr1:54236440~54239063:+
THCA	cis	rs893818	1	rs1992314	ENSG00000261801.4	LOXL1-AS1	-4.65	4.32e-06	0.00048	-0.24	-0.21	Exfoliation glaucoma or exfoliation syndrome;	chr15:73931426	chr15:73908071~73928248:-
THCA	cis	rs7520050	0.966	rs7540325	ENSG00000234329.1	RP11-767N6.2	-4.65	4.32e-06	0.00048	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45651039~45651826:-
THCA	cis	rs7520050	1	rs7540699	ENSG00000234329.1	RP11-767N6.2	-4.65	4.32e-06	0.00048	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs4660319	ENSG00000234329.1	RP11-767N6.2	-4.65	4.32e-06	0.00048	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs11211213	ENSG00000234329.1	RP11-767N6.2	-4.65	4.32e-06	0.00048	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45651039~45651826:-
THCA	cis	rs7735319	0.533	rs2331146	ENSG00000249572.1	CTD-2203K17.1	-4.65	4.33e-06	0.000481	-0.25	-0.21	Systolic blood pressure;	chr5:33052415	chr5:33424025~33440619:-
THCA	cis	rs526231	0.67	rs253756	ENSG00000175749.11	EIF3KP1	4.65	4.33e-06	0.000481	0.27	0.21	Primary biliary cholangitis;	chr5:103284771	chr5:103032376~103033031:+
THCA	cis	rs2235642	0.75	rs763152	ENSG00000280231.1	LA16c-380F5.3	-4.65	4.33e-06	0.000481	-0.25	-0.21	Coronary artery disease;	chr16:1608055	chr16:1553655~1554130:-
THCA	cis	rs2235642	0.717	rs9937922	ENSG00000280231.1	LA16c-380F5.3	-4.65	4.33e-06	0.000481	-0.25	-0.21	Coronary artery disease;	chr16:1608153	chr16:1553655~1554130:-
THCA	cis	rs2562456	0.833	rs2650801	ENSG00000268081.1	RP11-678G14.2	4.65	4.33e-06	0.000481	0.33	0.21	Pain;	chr19:21452553	chr19:21554640~21569237:-
THCA	cis	rs9467773	0.901	rs1407045	ENSG00000261353.1	CTA-14H9.5	-4.65	4.33e-06	0.000481	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26475927	chr6:26527063~26527404:+
THCA	cis	rs11143230	1	rs17628566	ENSG00000225434.2	LINC01504	-4.65	4.33e-06	0.000481	-0.33	-0.21	Suicidal ideation;	chr9:72275885	chr9:72305430~72343210:+
THCA	cis	rs3002131	0.604	rs2133185	ENSG00000272750.1	RP11-378J18.8	4.65	4.33e-06	0.000481	0.31	0.21	Interleukin-10 levels;	chr1:222565628	chr1:222658867~222661512:-
THCA	cis	rs9467773	0.62	rs9461276	ENSG00000124549.13	BTN2A3P	4.65	4.33e-06	0.000481	0.19	0.21	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26421391~26432383:+
THCA	cis	rs9813712	0.595	rs12490957	ENSG00000249846.5	RP11-77P16.4	4.65	4.33e-06	0.000481	0.22	0.21	Response to amphetamines;	chr3:130287851	chr3:130112550~130120579:+
THCA	cis	rs375066	0.935	rs429027	ENSG00000278917.1	RP11-15A1.4	-4.65	4.33e-06	0.000481	-0.17	-0.21	Breast cancer;	chr19:43891337	chr19:43891233~43895411:+
THCA	cis	rs6490294	0.904	rs12423126	ENSG00000226469.1	ADAM1B	4.65	4.33e-06	0.000482	0.26	0.21	Mean platelet volume;	chr12:111991665	chr12:111927018~111929017:+
THCA	cis	rs8067545	0.611	rs757494	ENSG00000270091.1	RP11-78O7.2	4.65	4.34e-06	0.000482	0.16	0.21	Schizophrenia;	chr17:20247027	chr17:19896590~19897287:-
THCA	cis	rs748802	0.675	rs4878635	ENSG00000235387.1	LINC00961	-4.65	4.34e-06	0.000482	-0.24	-0.21	Resting heart rate;	chr9:35941930	chr9:35909483~35911686:+
THCA	cis	rs9987353	0.784	rs330014	ENSG00000254153.1	CTA-398F10.2	4.65	4.34e-06	0.000482	0.24	0.21	Recombination measurement;	chr8:9271334	chr8:8456909~8461337:-
THCA	cis	rs172166	0.516	rs1225618	ENSG00000176933.5	TOB2P1	-4.65	4.34e-06	0.000482	-0.23	-0.21	Cardiac Troponin-T levels;	chr6:28161935	chr6:28217643~28218634:-
THCA	cis	rs6964833	0.873	rs4717905	ENSG00000278416.1	PMS2L2	4.65	4.34e-06	0.000482	0.33	0.21	Menarche (age at onset);	chr7:74668903	chr7:75344015~75359550:-
THCA	cis	rs9875589	0.509	rs6783645	ENSG00000228242.5	AC093495.4	4.65	4.34e-06	0.000482	0.12	0.21	Ovarian reserve;	chr3:13983042	chr3:14144637~14165978:+
THCA	cis	rs6449502	0.841	rs34595	ENSG00000251279.1	CTC-436P18.1	4.65	4.34e-06	0.000482	0.35	0.21	Mean platelet volume;	chr5:61030884	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.841	rs248679	ENSG00000251279.1	CTC-436P18.1	4.65	4.34e-06	0.000482	0.35	0.21	Mean platelet volume;	chr5:61040652	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.841	rs248678	ENSG00000251279.1	CTC-436P18.1	4.65	4.34e-06	0.000482	0.35	0.21	Mean platelet volume;	chr5:61042031	chr5:61162070~61232040:+
THCA	cis	rs6806253	1	rs6806253	ENSG00000239405.1	TMED10P2	-4.65	4.34e-06	0.000482	-0.31	-0.21	Pit-and-Fissure caries;	chr3:128563854	chr3:128538020~128538631:+
THCA	cis	rs7772486	0.743	rs9403742	ENSG00000270638.1	RP3-466P17.1	4.65	4.34e-06	0.000482	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145735570~145737218:+
THCA	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	4.65	4.34e-06	0.000482	0.15	0.21	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
THCA	cis	rs2243480	1	rs3885839	ENSG00000164669.11	INTS4P1	4.65	4.34e-06	0.000482	0.41	0.21	Diabetic kidney disease;	chr7:65825416	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs73142122	ENSG00000164669.11	INTS4P1	4.65	4.34e-06	0.000482	0.41	0.21	Diabetic kidney disease;	chr7:65846311	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.901	rs73142137	ENSG00000164669.11	INTS4P1	4.65	4.34e-06	0.000482	0.41	0.21	Diabetic kidney disease;	chr7:65878455	chr7:65141225~65234216:+
THCA	cis	rs6449502	0.92	rs34641	ENSG00000251279.1	CTC-436P18.1	4.65	4.35e-06	0.000483	0.35	0.21	Mean platelet volume;	chr5:61051745	chr5:61162070~61232040:+
THCA	cis	rs9487094	0.517	rs3778474	ENSG00000223537.2	RP5-919F19.5	-4.65	4.35e-06	0.000483	-0.21	-0.21	Height;	chr6:109374782	chr6:109487906~109506800:+
THCA	cis	rs11673344	0.504	rs12984458	ENSG00000276846.1	CTD-3220F14.3	-4.65	4.35e-06	0.000483	-0.16	-0.21	Obesity-related traits;	chr19:37138189	chr19:37314868~37315620:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000272009.1	RP1-313I6.12	-4.65	4.35e-06	0.000483	-0.2	-0.21	Cardiac Troponin-T levels;	chr6:28200255	chr6:28078792~28081130:-
THCA	cis	rs7772486	0.754	rs9399561	ENSG00000270638.1	RP3-466P17.1	4.65	4.35e-06	0.000483	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145735570~145737218:+
THCA	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-4.65	4.35e-06	0.000483	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
THCA	cis	rs4713118	0.568	rs9468213	ENSG00000216915.2	RP1-97D16.1	-4.65	4.35e-06	0.000483	-0.29	-0.21	Parkinson's disease;	chr6:27738401	chr6:27737000~27738494:-
THCA	cis	rs35740288	0.787	rs11635418	ENSG00000259295.5	CSPG4P12	4.65	4.35e-06	0.000483	0.33	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700947	chr15:85191438~85213905:+
THCA	cis	rs7614311	0.681	rs73117042	ENSG00000271843.1	RP11-245J9.5	-4.65	4.35e-06	0.000484	-0.37	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63910867	chr3:64008082~64008692:-
THCA	cis	rs7614311	0.681	rs6809100	ENSG00000271843.1	RP11-245J9.5	-4.65	4.35e-06	0.000484	-0.37	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63915504	chr3:64008082~64008692:-
THCA	cis	rs6496044	0.507	rs7175731	ENSG00000259295.5	CSPG4P12	-4.65	4.36e-06	0.000484	-0.28	-0.21	Interstitial lung disease;	chr15:85611115	chr15:85191438~85213905:+
THCA	cis	rs62158800	0.925	rs7567243	ENSG00000224568.1	AC096669.3	4.65	4.36e-06	0.000484	0.38	0.21	Facial morphology (factor 22);	chr2:107588632	chr2:107529487~107556326:+
THCA	cis	rs2280018	0.526	rs2941257	ENSG00000263335.1	AF001548.5	-4.65	4.36e-06	0.000484	-0.25	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15726674~15732993:+
THCA	cis	rs160451	0.782	rs160410	ENSG00000251136.7	RP11-37B2.1	-4.65	4.36e-06	0.000484	-0.19	-0.21	Leprosy;	chr8:89636500	chr8:89609409~89757727:-
THCA	cis	rs516805	0.502	rs508468	ENSG00000279453.1	RP3-425C14.4	-4.65	4.36e-06	0.000484	-0.17	-0.21	Lymphocyte counts;	chr6:122441902	chr6:122436789~122439223:-
THCA	cis	rs516805	0.52	rs508012	ENSG00000279453.1	RP3-425C14.4	-4.65	4.36e-06	0.000484	-0.17	-0.21	Lymphocyte counts;	chr6:122442594	chr6:122436789~122439223:-
THCA	cis	rs516805	0.501	rs535954	ENSG00000279453.1	RP3-425C14.4	-4.65	4.36e-06	0.000484	-0.17	-0.21	Lymphocyte counts;	chr6:122442622	chr6:122436789~122439223:-
THCA	cis	rs9878978	0.722	rs35775662	ENSG00000237990.3	CNTN4-AS1	4.65	4.36e-06	0.000484	0.25	0.21	Blood pressure (smoking interaction);	chr3:2395539	chr3:3039033~3069242:-
THCA	cis	rs7829975	0.522	rs6601689	ENSG00000253981.4	ALG1L13P	4.65	4.36e-06	0.000485	0.21	0.21	Mood instability;	chr8:8314761	chr8:8236003~8244667:-
THCA	cis	rs911119	0.955	rs8121283	ENSG00000270001.1	RP11-218C14.8	-4.65	4.36e-06	0.000485	-0.3	-0.21	Chronic kidney disease;	chr20:23624365	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs8115417	ENSG00000270001.1	RP11-218C14.8	-4.65	4.36e-06	0.000485	-0.3	-0.21	Chronic kidney disease;	chr20:23624586	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs8121405	ENSG00000270001.1	RP11-218C14.8	-4.65	4.36e-06	0.000485	-0.3	-0.21	Chronic kidney disease;	chr20:23624589	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs8115423	ENSG00000270001.1	RP11-218C14.8	-4.65	4.36e-06	0.000485	-0.3	-0.21	Chronic kidney disease;	chr20:23624616	chr20:23631826~23632316:-
THCA	cis	rs11700536	0.656	rs9978825	ENSG00000236663.1	AP001631.9	4.65	4.36e-06	0.000485	0.28	0.21	Interleukin-18 levels;	chr21:43149043	chr21:43140523~43141092:-
THCA	cis	rs6496932	0.503	rs7170370	ENSG00000259630.2	CTD-2262B20.1	-4.65	4.37e-06	0.000485	-0.26	-0.21	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85415228~85415633:+
THCA	cis	rs6840360	0.901	rs1946999	ENSG00000270265.1	RP11-731D1.4	-4.65	4.37e-06	0.000485	-0.2	-0.21	Intelligence (multi-trait analysis);	chr4:151534187	chr4:151333775~151353224:-
THCA	cis	rs858239	0.509	rs57611130	ENSG00000226816.2	AC005082.12	4.65	4.37e-06	0.000485	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23206013~23208045:+
THCA	cis	rs59868192	0.925	rs72726027	ENSG00000246740.2	PLA2G4E-AS1	4.65	4.37e-06	0.000485	0.4	0.21	White blood cell count;	chr15:41956628	chr15:41972763~41999094:+
THCA	cis	rs1979679	0.918	rs10771427	ENSG00000278733.1	RP11-425D17.1	4.65	4.37e-06	0.000485	0.21	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28452493	chr12:28185625~28186190:-
THCA	cis	rs7746199	0.736	rs10484399	ENSG00000272009.1	RP1-313I6.12	-4.65	4.37e-06	0.000485	-0.39	-0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28078792~28081130:-
THCA	cis	rs7394190	0.748	rs2242254	ENSG00000271848.1	RP11-464F9.21	-4.65	4.37e-06	0.000485	-0.29	-0.21	Incident atrial fibrillation;	chr10:73825549	chr10:73654039~73674719:+
THCA	cis	rs3824488	0.599	rs16909856	ENSG00000271384.1	RP11-435O5.7	-4.65	4.37e-06	0.000485	-0.3	-0.21	Neuroticism;	chr9:95442211	chr9:95406990~95407662:-
THCA	cis	rs7618915	0.501	rs12486554	ENSG00000243224.1	RP5-1157M23.2	-4.65	4.37e-06	0.000485	-0.22	-0.21	Bipolar disorder;	chr3:52708521	chr3:52239258~52241097:+
THCA	cis	rs6088590	1	rs6119530	ENSG00000276073.1	RP5-1125A11.7	-4.65	4.37e-06	0.000485	-0.2	-0.21	Coronary artery disease;	chr20:34816127	chr20:33985617~33988989:-
THCA	cis	rs4218	0.689	rs11853828	ENSG00000259732.1	RP11-59H7.3	-4.65	4.37e-06	0.000485	-0.29	-0.21	Social communication problems;	chr15:59136031	chr15:59121034~59133250:+
THCA	cis	rs2348418	0.639	rs10459087	ENSG00000247934.4	RP11-967K21.1	4.65	4.37e-06	0.000485	0.18	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28115904	chr12:28163298~28190738:-
THCA	cis	rs4144027	0.904	rs35551424	ENSG00000269940.1	RP11-73M18.7	-4.65	4.37e-06	0.000485	-0.22	-0.21	Blood metabolite levels;	chr14:103875332	chr14:103694560~103695170:+
THCA	cis	rs17818399	0.815	rs17768132	ENSG00000279254.1	RP11-536C12.1	4.65	4.38e-06	0.000486	0.22	0.21	Height;	chr2:46636110	chr2:46668870~46670778:+
THCA	cis	rs8067545	0.611	rs2703803	ENSG00000270091.1	RP11-78O7.2	4.65	4.38e-06	0.000486	0.16	0.21	Schizophrenia;	chr17:20203756	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs2526482	ENSG00000270091.1	RP11-78O7.2	4.65	4.38e-06	0.000486	0.16	0.21	Schizophrenia;	chr17:20215820	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs7219615	ENSG00000270091.1	RP11-78O7.2	4.65	4.38e-06	0.000486	0.16	0.21	Schizophrenia;	chr17:20229245	chr17:19896590~19897287:-
THCA	cis	rs9902453	0.791	rs6505141	ENSG00000263370.1	RP11-68I3.5	4.65	4.38e-06	0.000486	0.27	0.21	Coffee consumption (cups per day);	chr17:29671169	chr17:29639627~29640825:+
THCA	cis	rs12823128	0.967	rs2291262	ENSG00000256185.1	RP11-612B6.2	4.65	4.38e-06	0.000486	0.2	0.21	Birth weight;	chr12:26722302	chr12:26335864~26336950:-
THCA	cis	rs2028299	0.959	rs12912009	ENSG00000259677.1	RP11-493E3.1	4.65	4.38e-06	0.000486	0.28	0.21	Type 2 diabetes;	chr15:89885916	chr15:89876540~89877285:+
THCA	cis	rs7429990	0.833	rs869508	ENSG00000228638.1	FCF1P2	-4.65	4.38e-06	0.000486	-0.21	-0.21	Educational attainment (years of education);	chr3:47571812	chr3:48290793~48291375:-
THCA	cis	rs889398	0.933	rs244418	ENSG00000226232.7	RP11-419C5.2	4.65	4.38e-06	0.000486	0.21	0.21	Body mass index;	chr16:69588859	chr16:69976388~69996188:-
THCA	cis	rs4908768	1	rs11121203	ENSG00000232912.4	RP5-1115A15.1	-4.65	4.38e-06	0.000486	-0.25	-0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8588181	chr1:8424645~8434838:+
THCA	cis	rs9990333	0.622	rs57783901	ENSG00000273009.1	RP11-352G9.1	-4.65	4.38e-06	0.000486	-0.23	-0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195913078~195913683:-
THCA	cis	rs6545883	0.542	rs7584500	ENSG00000270820.4	RP11-355B11.2	4.65	4.39e-06	0.000487	0.17	0.21	Tuberculosis;	chr2:61464980	chr2:61471188~61484130:+
THCA	cis	rs13126694	0.776	rs721604	ENSG00000248429.4	RP11-597D13.9	4.65	4.39e-06	0.000487	0.23	0.21	Blood osmolality (transformed sodium);	chr4:157945787	chr4:158170752~158202877:+
THCA	cis	rs7264396	1	rs224418	ENSG00000088340.14	FER1L4	4.65	4.39e-06	0.000487	0.19	0.21	Total cholesterol levels;	chr20:35554756	chr20:35558737~35607562:-
THCA	cis	rs738144	0.578	rs5750683	ENSG00000235209.1	CTA-150C2.13	4.65	4.39e-06	0.000487	0.31	0.21	IgG glycosylation;	chr22:38818141	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs4821811	ENSG00000228274.3	RP3-508I15.9	-4.65	4.39e-06	0.000487	-0.23	-0.21	Menopause (age at onset);	chr22:38679140	chr22:38667585~38681820:-
THCA	cis	rs516805	0.52	rs12524	ENSG00000279453.1	RP3-425C14.4	-4.65	4.39e-06	0.000487	-0.17	-0.21	Lymphocyte counts;	chr6:122444803	chr6:122436789~122439223:-
THCA	cis	rs8049040	0.967	rs8053993	ENSG00000260886.1	TAT-AS1	4.65	4.39e-06	0.000487	0.27	0.21	Blood protein levels;	chr16:71471593	chr16:71565789~71578187:+
THCA	cis	rs919433	0.963	rs10153881	ENSG00000231621.1	AC013264.2	4.65	4.39e-06	0.000487	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306374	chr2:197197991~197199273:+
THCA	cis	rs1383484	0.506	rs4414460	ENSG00000230373.7	GOLGA6L5P	-4.65	4.39e-06	0.000487	-0.21	-0.21	Height;	chr15:83893988	chr15:84507885~84516814:-
THCA	cis	rs9876781	1	rs7635522	ENSG00000244380.1	RP11-24C3.2	4.65	4.39e-06	0.000487	0.25	0.21	Longevity;	chr3:48382166	chr3:48440352~48446656:-
THCA	cis	rs763121	0.853	rs11704021	ENSG00000235209.1	CTA-150C2.13	4.65	4.39e-06	0.000487	0.28	0.21	Menopause (age at onset);	chr22:38678711	chr22:38921227~38924708:+
THCA	cis	rs9878978	1	rs1542901	ENSG00000237990.3	CNTN4-AS1	4.65	4.39e-06	0.000487	0.23	0.21	Blood pressure (smoking interaction);	chr3:2432328	chr3:3039033~3069242:-
THCA	cis	rs1979679	0.918	rs3858544	ENSG00000247934.4	RP11-967K21.1	4.65	4.39e-06	0.000487	0.2	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28442911	chr12:28163298~28190738:-
THCA	cis	rs7088591	0.867	rs7920373	ENSG00000276818.1	AC026393.1	4.65	4.39e-06	0.000487	0.39	0.21	Blood pressure;	chr10:58029757	chr10:57095699~57095781:+
THCA	cis	rs9532669	0.926	rs9532690	ENSG00000229473.2	RGS17P1	4.65	4.39e-06	0.000487	0.25	0.21	Cervical cancer;	chr13:40968654	chr13:40992779~40993331:-
THCA	cis	rs6997458	0.716	rs1845253	ENSG00000253549.4	RP11-317J10.2	4.65	4.39e-06	0.000487	0.21	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85489967	chr8:85441851~85464915:-
THCA	cis	rs1040393	0.953	rs926265	ENSG00000225171.2	DUTP6	4.65	4.39e-06	0.000487	0.31	0.21	Schizophrenia;	chr1:166933803	chr1:166868748~166869209:+
THCA	cis	rs801193	1	rs3778909	ENSG00000229886.1	RP5-1132H15.3	4.65	4.39e-06	0.000487	0.21	0.21	Aortic root size;	chr7:66790659	chr7:66025126~66031544:-
THCA	cis	rs6832769	0.925	rs2899037	ENSG00000272969.1	RP11-528I4.2	-4.65	4.39e-06	0.000487	-0.24	-0.21	Personality dimensions;	chr4:55591180	chr4:55547112~55547889:+
THCA	cis	rs4693089	0.522	rs576707	ENSG00000213608.5	SLC25A14P1	-4.65	4.39e-06	0.000488	-0.24	-0.21	Menopause (age at onset);	chr4:83526263	chr4:83477524~83478424:+
THCA	cis	rs4693089	0.522	rs547872	ENSG00000213608.5	SLC25A14P1	-4.65	4.39e-06	0.000488	-0.24	-0.21	Menopause (age at onset);	chr4:83527236	chr4:83477524~83478424:+
THCA	cis	rs4693089	0.522	rs509506	ENSG00000213608.5	SLC25A14P1	-4.65	4.39e-06	0.000488	-0.24	-0.21	Menopause (age at onset);	chr4:83528360	chr4:83477524~83478424:+
THCA	cis	rs2439831	0.681	rs2278858	ENSG00000275601.1	AC011330.13	-4.65	4.4e-06	0.000488	-0.35	-0.21	Lung cancer in ever smokers;	chr15:43340557	chr15:43642389~43643023:-
THCA	cis	rs9890032	0.509	rs11656986	ENSG00000263603.1	CTD-2349P21.5	-4.65	4.4e-06	0.000488	-0.27	-0.21	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30729469~30731202:+
THCA	cis	rs227275	0.525	rs223332	ENSG00000248971.2	KRT8P46	-4.65	4.4e-06	0.000488	-0.26	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102728746~102730171:-
THCA	cis	rs6964833	0.786	rs35633336	ENSG00000278416.1	PMS2L2	4.65	4.4e-06	0.000488	0.33	0.21	Menarche (age at onset);	chr7:74643961	chr7:75344015~75359550:-
THCA	cis	rs6964833	0.935	rs35735900	ENSG00000278416.1	PMS2L2	4.65	4.4e-06	0.000488	0.33	0.21	Menarche (age at onset);	chr7:74651887	chr7:75344015~75359550:-
THCA	cis	rs13118159	0.55	rs2878607	ENSG00000254094.1	AC078852.1	-4.65	4.4e-06	0.000488	-0.26	-0.21	Longevity;	chr4:1359522	chr4:1356581~1358075:+
THCA	cis	rs6921919	0.583	rs2071965	ENSG00000280107.1	AL022393.9	-4.65	4.4e-06	0.000488	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28170845~28172521:+
THCA	cis	rs2797160	0.547	rs9388442	ENSG00000237742.5	RP11-624M8.1	-4.65	4.4e-06	0.000488	-0.19	-0.21	Endometrial cancer;	chr6:125651462	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.515	rs9375409	ENSG00000237742.5	RP11-624M8.1	-4.65	4.4e-06	0.000488	-0.19	-0.21	Endometrial cancer;	chr6:125651652	chr6:125578558~125749190:-
THCA	cis	rs6671200	1	rs35143903	ENSG00000235501.4	RP4-639F20.1	-4.65	4.4e-06	0.000488	-0.44	-0.21	Stearic acid (18:0) levels;	chr1:95156971	chr1:94927566~94963270:+
THCA	cis	rs9863	0.828	rs4765127	ENSG00000270061.1	RP11-214K3.19	-4.65	4.4e-06	0.000488	-0.28	-0.21	White blood cell count;	chr12:123975620	chr12:123969990~123970344:-
THCA	cis	rs6012564	1	rs4810909	ENSG00000227431.4	CSE1L-AS1	-4.65	4.4e-06	0.000488	-0.26	-0.21	Anger;	chr20:49004835	chr20:49040463~49046044:-
THCA	cis	rs10090774	0.932	rs13259836	ENSG00000279766.1	RP11-642A1.2	-4.65	4.4e-06	0.000489	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955789	chr8:140572142~140572812:-
THCA	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-4.65	4.4e-06	0.000489	-0.26	-0.21	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
THCA	cis	rs4295623	0.556	rs10903343	ENSG00000255046.1	RP11-297N6.4	-4.65	4.4e-06	0.000489	-0.22	-0.21	Morning vs. evening chronotype;	chr8:11838363	chr8:11797928~11802568:-
THCA	cis	rs2665103	0.589	rs2134046	ENSG00000259429.4	UBE2Q2P2	-4.65	4.4e-06	0.000489	-0.17	-0.21	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82355142~82420075:+
THCA	cis	rs5753037	0.809	rs5997530	ENSG00000279699.1	RP1-102K2.9	4.65	4.41e-06	0.000489	0.21	0.21	Type 1 diabetes;	chr22:29807610	chr22:30275215~30276951:-
THCA	cis	rs80033912	0.64	rs6785832	ENSG00000229759.1	MRPS18AP1	4.65	4.41e-06	0.000489	0.26	0.21	Intelligence (multi-trait analysis);	chr3:49186883	chr3:48256350~48256938:-
THCA	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	4.65	4.41e-06	0.000489	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
THCA	cis	rs7621331	1	rs9877082	ENSG00000273486.1	RP11-731C17.2	4.65	4.41e-06	0.000489	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136032494	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs6771224	ENSG00000273486.1	RP11-731C17.2	4.65	4.41e-06	0.000489	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136041892	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs7643661	ENSG00000273486.1	RP11-731C17.2	4.65	4.41e-06	0.000489	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136043056	chr3:136837338~136839021:-
THCA	cis	rs7621331	0.963	rs7621425	ENSG00000273486.1	RP11-731C17.2	4.65	4.41e-06	0.000489	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136043175	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs9812561	ENSG00000273486.1	RP11-731C17.2	4.65	4.41e-06	0.000489	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136043668	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs9875328	ENSG00000273486.1	RP11-731C17.2	4.65	4.41e-06	0.000489	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136046348	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs9880721	ENSG00000273486.1	RP11-731C17.2	4.65	4.41e-06	0.000489	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136047322	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.8	rs28390205	ENSG00000239213.4	NCK1-AS1	4.65	4.41e-06	0.000489	0.23	0.21	Height;Body mass index;	chr3:136646008	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.752	rs35428413	ENSG00000239213.4	NCK1-AS1	4.65	4.41e-06	0.000489	0.23	0.21	Height;Body mass index;	chr3:136661856	chr3:136841726~136862054:-
THCA	cis	rs2921036	0.505	rs35190619	ENSG00000253981.4	ALG1L13P	-4.65	4.41e-06	0.000489	-0.23	-0.21	Neuroticism;	chr8:8504313	chr8:8236003~8244667:-
THCA	cis	rs2439831	1	rs2256764	ENSG00000205771.5	CATSPER2P1	-4.65	4.41e-06	0.000489	-0.3	-0.21	Lung cancer in ever smokers;	chr15:43443565	chr15:43726918~43747094:-
THCA	cis	rs1005277	0.522	rs289649	ENSG00000276805.1	RP11-291L22.6	4.65	4.41e-06	0.000489	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38451030~38451785:+
THCA	cis	rs8064024	0.599	rs2456779	ENSG00000267077.1	RP11-127I20.5	4.65	4.41e-06	0.000489	0.25	0.21	Cancer;	chr16:4875816	chr16:4795265~4796532:-
THCA	cis	rs3734266	0.639	rs11968972	ENSG00000272288.4	RP11-140K17.3	-4.65	4.41e-06	0.00049	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34773317	chr6:34696317~34697470:+
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000229180.5	GS1-124K5.11	4.65	4.41e-06	0.00049	0.17	0.21	Corneal structure;	chr7:66913899	chr7:66526088~66542624:-
THCA	cis	rs12823128	0.967	rs1900941	ENSG00000256185.1	RP11-612B6.2	4.65	4.42e-06	0.00049	0.2	0.21	Birth weight;	chr12:26715389	chr12:26335864~26336950:-
THCA	cis	rs800160	0.844	rs1088992	ENSG00000199550.1	Y_RNA	4.65	4.42e-06	0.00049	0.31	0.21	Bacteremia;	chr11:2361287	chr11:2372638~2372750:+
THCA	cis	rs1185460	1	rs4614	ENSG00000272186.1	RP11-110I1.13	-4.65	4.42e-06	0.00049	-0.21	-0.21	Coronary artery disease;	chr11:119081661	chr11:119067374~119067698:-
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000273024.4	INTS4P2	-4.65	4.42e-06	0.00049	-0.24	-0.21	Calcium levels;	chr7:65977808	chr7:65647864~65715661:+
THCA	cis	rs3820928	0.874	rs10178731	ENSG00000212391.1	SNORA48	-4.65	4.42e-06	0.00049	-0.22	-0.21	Pulmonary function;	chr2:227009516	chr2:226968989~226969122:-
THCA	cis	rs7208859	0.614	rs4794874	ENSG00000266490.1	CTD-2349P21.9	-4.64	4.42e-06	0.00049	-0.27	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30792372~30792833:+
THCA	cis	rs11634944	0.869	rs2554428	ENSG00000257151.1	PWAR6	4.64	4.42e-06	0.00049	0.16	0.21	Interleukin-8 levels;	chr15:24971011	chr15:25031873~25036490:+
THCA	cis	rs11634944	0.869	rs2732026	ENSG00000257151.1	PWAR6	4.64	4.42e-06	0.00049	0.16	0.21	Interleukin-8 levels;	chr15:24971341	chr15:25031873~25036490:+
THCA	cis	rs11673344	0.504	rs7252940	ENSG00000276846.1	CTD-3220F14.3	4.64	4.42e-06	0.00049	0.16	0.21	Obesity-related traits;	chr19:37138589	chr19:37314868~37315620:-
THCA	cis	rs2412819	0.571	rs4923965	ENSG00000166763.7	STRCP1	-4.64	4.42e-06	0.00049	-0.28	-0.21	Lung cancer;	chr15:43790232	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs4644832	ENSG00000166763.7	STRCP1	-4.64	4.42e-06	0.00049	-0.28	-0.21	Lung cancer;	chr15:43792507	chr15:43699488~43718184:-
THCA	cis	rs62158800	0.852	rs62161277	ENSG00000237880.1	AC096669.2	4.64	4.42e-06	0.00049	0.33	0.21	Facial morphology (factor 22);	chr2:107679728	chr2:107385632~107542649:-
THCA	cis	rs911119	0.913	rs13038990	ENSG00000270001.1	RP11-218C14.8	-4.64	4.42e-06	0.00049	-0.3	-0.21	Chronic kidney disease;	chr20:23608416	chr20:23631826~23632316:-
THCA	cis	rs4578769	0.55	rs7237400	ENSG00000265939.1	UBE2CP2	4.64	4.42e-06	0.00049	0.23	0.21	Eosinophil percentage of white cells;	chr18:22986533	chr18:22900486~22900995:-
THCA	cis	rs8028182	0.636	rs7163451	ENSG00000260269.4	CTD-2323K18.1	-4.64	4.42e-06	0.00049	-0.31	-0.21	Sudden cardiac arrest;	chr15:75568735	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs8036884	ENSG00000260269.4	CTD-2323K18.1	-4.64	4.42e-06	0.00049	-0.31	-0.21	Sudden cardiac arrest;	chr15:75570552	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.636	rs4075522	ENSG00000260269.4	CTD-2323K18.1	-4.64	4.42e-06	0.00049	-0.31	-0.21	Sudden cardiac arrest;	chr15:75571994	chr15:75527150~75601205:-
THCA	cis	rs804280	0.638	rs36038176	ENSG00000255046.1	RP11-297N6.4	4.64	4.42e-06	0.00049	0.26	0.21	Myopia (pathological);	chr8:11752486	chr8:11797928~11802568:-
THCA	cis	rs642858	0.615	rs1856757	ENSG00000234147.1	RP3-460G2.2	-4.64	4.42e-06	0.00049	-0.26	-0.21	Type 2 diabetes;	chr6:140412718	chr6:140845958~140852924:-
THCA	cis	rs4916588	0.748	rs75352101	ENSG00000270170.1	NCBP2-AS2	4.64	4.42e-06	0.00049	0.19	0.21	Night sleep phenotypes;	chr3:196891433	chr3:196942623~196943540:+
THCA	cis	rs67478160	0.619	rs11160759	ENSG00000269910.1	RP11-73M18.10	4.64	4.42e-06	0.00049	0.18	0.21	Schizophrenia;	chr14:103765205	chr14:103694516~103695050:-
THCA	cis	rs6088580	0.634	rs9789792	ENSG00000276073.1	RP5-1125A11.7	4.64	4.42e-06	0.000491	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34369903	chr20:33985617~33988989:-
THCA	cis	rs12681288	0.755	rs2123056	ENSG00000260721.1	AF067845.1	4.64	4.43e-06	0.000491	0.26	0.21	Schizophrenia;	chr8:1083366	chr8:1368642~1369833:-
THCA	cis	rs6012564	1	rs2075678	ENSG00000227431.4	CSE1L-AS1	4.64	4.43e-06	0.000491	0.26	0.21	Anger;	chr20:49084802	chr20:49040463~49046044:-
THCA	cis	rs1707322	0.896	rs809774	ENSG00000281133.1	AL355480.3	4.64	4.43e-06	0.000491	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45580892~45580996:-
THCA	cis	rs7824557	0.606	rs1047950	ENSG00000154316.13	TDH	-4.64	4.43e-06	0.000491	-0.16	-0.21	Retinal vascular caliber;	chr8:11327587	chr8:11339637~11368452:+
THCA	cis	rs11640436	0.607	rs4888615	ENSG00000260922.1	RP11-538I12.3	-4.64	4.43e-06	0.000491	-0.25	-0.21	Lobe attachment (rater-scored or self-reported);	chr16:77270822	chr16:77234877~77290934:+
THCA	cis	rs2120243	0.533	rs34263112	ENSG00000241770.1	RP11-555M1.3	-4.64	4.43e-06	0.000491	-0.26	-0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338259	chr3:157163452~157169133:+
THCA	cis	rs6832769	1	rs1522106	ENSG00000272969.1	RP11-528I4.2	-4.64	4.43e-06	0.000491	-0.25	-0.21	Personality dimensions;	chr4:55441047	chr4:55547112~55547889:+
THCA	cis	rs9527	0.571	rs12765337	ENSG00000213061.2	PFN1P11	4.64	4.43e-06	0.000491	0.26	0.21	Arsenic metabolism;	chr10:102875587	chr10:102838011~102845473:-
THCA	cis	rs6751744	0.855	rs35019796	ENSG00000226266.5	AC009961.3	-4.64	4.43e-06	0.000491	-0.26	-0.21	Dysphagia;	chr2:159510644	chr2:159670708~159712435:-
THCA	cis	rs6445975	0.715	rs4681836	ENSG00000272360.1	RP11-359I18.5	-4.64	4.43e-06	0.000491	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58281560	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.715	rs17059125	ENSG00000272360.1	RP11-359I18.5	-4.64	4.43e-06	0.000491	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58283023	chr3:58490830~58491291:-
THCA	cis	rs6445975	0.667	rs3773004	ENSG00000272360.1	RP11-359I18.5	-4.64	4.43e-06	0.000491	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58283724	chr3:58490830~58491291:-
THCA	cis	rs1040393	0.903	rs4657611	ENSG00000225171.2	DUTP6	4.64	4.43e-06	0.000491	0.31	0.21	Schizophrenia;	chr1:166880307	chr1:166868748~166869209:+
THCA	cis	rs36715	0.868	rs251387	ENSG00000245937.6	LINC01184	4.64	4.43e-06	0.000491	0.23	0.21	Breast cancer;	chr5:128211488	chr5:127940426~128083172:-
THCA	cis	rs748404	0.626	rs57938858	ENSG00000205771.5	CATSPER2P1	-4.64	4.43e-06	0.000491	-0.28	-0.21	Lung cancer;	chr15:43520259	chr15:43726918~43747094:-
THCA	cis	rs17270561	0.666	rs1141034	ENSG00000272462.2	U91328.19	-4.64	4.43e-06	0.000491	-0.18	-0.21	Iron status biomarkers;	chr6:25780104	chr6:25992662~26001775:+
THCA	cis	rs8177876	1	rs8177876	ENSG00000261061.1	RP11-303E16.2	-4.64	4.43e-06	0.000491	-0.37	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81030770~81031485:+
THCA	cis	rs7394190	0.748	rs11000777	ENSG00000271848.1	RP11-464F9.21	-4.64	4.44e-06	0.000492	-0.29	-0.21	Incident atrial fibrillation;	chr10:73785305	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs79936644	ENSG00000271848.1	RP11-464F9.21	-4.64	4.44e-06	0.000492	-0.29	-0.21	Incident atrial fibrillation;	chr10:73785359	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs4114992	ENSG00000271848.1	RP11-464F9.21	-4.64	4.44e-06	0.000492	-0.29	-0.21	Incident atrial fibrillation;	chr10:73807071	chr10:73654039~73674719:+
THCA	cis	rs7015630	1	rs2338883	ENSG00000251136.7	RP11-37B2.1	-4.64	4.44e-06	0.000492	-0.2	-0.21	Inflammatory bowel disease;Crohn's disease;	chr8:89865318	chr8:89609409~89757727:-
THCA	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-4.64	4.44e-06	0.000492	-0.25	-0.21	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
THCA	cis	rs12549025	0.53	rs28656888	ENSG00000253390.1	CTC-756D1.2	-4.64	4.44e-06	0.000492	-0.3	-0.21	Reticulocyte fraction of red cells;	chr8:23408696	chr8:23458601~23484971:+
THCA	cis	rs8014252	1	rs78093131	ENSG00000259158.2	ADAM20P1	-4.64	4.44e-06	0.000492	-0.24	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70454665	chr14:70468881~70483756:-
THCA	cis	rs172166	0.637	rs1233708	ENSG00000220721.1	OR1F12	4.64	4.44e-06	0.000492	0.25	0.21	Cardiac Troponin-T levels;	chr6:28205441	chr6:28073316~28074233:+
THCA	cis	rs12410462	0.591	rs2644162	ENSG00000227711.2	RP11-275O4.5	-4.64	4.44e-06	0.000492	-0.26	-0.21	Major depressive disorder;	chr1:227515696	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.636	rs2644154	ENSG00000227711.2	RP11-275O4.5	-4.64	4.44e-06	0.000492	-0.26	-0.21	Major depressive disorder;	chr1:227516187	chr1:227509028~227520477:-
THCA	cis	rs763121	0.853	rs9607566	ENSG00000273076.1	RP3-508I15.22	4.64	4.44e-06	0.000492	0.21	0.21	Menopause (age at onset);	chr22:38679429	chr22:38743495~38743910:+
THCA	cis	rs4415084	1	rs58144701	ENSG00000272335.1	RP11-53O19.3	-4.64	4.44e-06	0.000492	-0.17	-0.21	Breast cancer;	chr5:44676095	chr5:44826076~44828592:+
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000164669.11	INTS4P1	4.64	4.44e-06	0.000493	0.41	0.21	Diabetic kidney disease;	chr7:65999249	chr7:65141225~65234216:+
THCA	cis	rs150025731	1	rs150025731	ENSG00000261801.4	LOXL1-AS1	4.64	4.45e-06	0.000493	0.24	0.21	Joint mobility (Beighton score);	chr15:73931167	chr15:73908071~73928248:-
THCA	cis	rs8067545	0.611	rs7212500	ENSG00000270091.1	RP11-78O7.2	-4.64	4.45e-06	0.000493	-0.16	-0.21	Schizophrenia;	chr17:20142345	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs4925090	ENSG00000270091.1	RP11-78O7.2	-4.64	4.45e-06	0.000493	-0.16	-0.21	Schizophrenia;	chr17:20163318	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs9907516	ENSG00000270091.1	RP11-78O7.2	-4.64	4.45e-06	0.000493	-0.16	-0.21	Schizophrenia;	chr17:20167177	chr17:19896590~19897287:-
THCA	cis	rs16958440	0.708	rs57468764	ENSG00000267800.1	RP11-49K24.5	-4.64	4.45e-06	0.000493	-0.38	-0.21	Sitting height ratio;	chr18:47098485	chr18:47137018~47137290:+
THCA	cis	rs1046491	0.901	rs11663949	ENSG00000264964.1	RP11-888D10.3	4.64	4.45e-06	0.000493	0.36	0.21	Scarlet fever;	chr18:9189252	chr18:9315194~9334441:-
THCA	cis	rs375066	0.901	rs376069	ENSG00000278917.1	RP11-15A1.4	-4.64	4.45e-06	0.000493	-0.17	-0.21	Breast cancer;	chr19:43913143	chr19:43891233~43895411:+
THCA	cis	rs9878978	1	rs35941126	ENSG00000237990.3	CNTN4-AS1	4.64	4.45e-06	0.000493	0.23	0.21	Blood pressure (smoking interaction);	chr3:2435698	chr3:3039033~3069242:-
THCA	cis	rs829883	0.934	rs1641642	ENSG00000227825.4	SLC9A7P1	4.64	4.45e-06	0.000493	0.19	0.21	Colorectal adenoma (advanced);	chr12:98504948	chr12:98453835~98457145:-
THCA	cis	rs4824093	0.61	rs4824113	ENSG00000278869.1	CITF22-49E9.3	4.64	4.45e-06	0.000493	0.4	0.21	Amyotrophic lateral sclerosis (sporadic);	chr22:49891326	chr22:49933198~49934074:-
THCA	cis	rs4824093	0.61	rs58671506	ENSG00000278869.1	CITF22-49E9.3	4.64	4.45e-06	0.000493	0.4	0.21	Amyotrophic lateral sclerosis (sporadic);	chr22:49895335	chr22:49933198~49934074:-
THCA	cis	rs8177876	0.554	rs56286107	ENSG00000261061.1	RP11-303E16.2	-4.64	4.45e-06	0.000493	-0.38	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084227	chr16:81030770~81031485:+
THCA	cis	rs7181230	0.922	rs4924410	ENSG00000275636.1	RP11-521C20.5	-4.64	4.45e-06	0.000493	-0.23	-0.21	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40078892~40079347:+
THCA	cis	rs28386778	0.7	rs11079515	ENSG00000240280.5	TCAM1P	4.64	4.45e-06	0.000493	0.29	0.21	Prudent dietary pattern;	chr17:63928285	chr17:63849292~63864379:+
THCA	cis	rs6750795	0.746	rs2916579	ENSG00000223198.1	RNU2-22P	-4.64	4.45e-06	0.000493	-0.27	-0.21	Height;	chr2:231556448	chr2:231501990~231502201:-
THCA	cis	rs12126655	0.857	rs4460667	ENSG00000230489.1	VAV3-AS1	4.64	4.45e-06	0.000493	0.2	0.21	Plasma thyroid-stimulating hormone levels;	chr1:107836421	chr1:107964443~107994607:+
THCA	cis	rs7474896	0.515	rs675628	ENSG00000263064.2	RP11-291L22.7	-4.64	4.45e-06	0.000493	-0.28	-0.21	Obesity (extreme);	chr10:38016403	chr10:38448689~38448949:+
THCA	cis	rs72843506	0.591	rs75925580	ENSG00000231258.2	ZSWIM5P2	4.64	4.45e-06	0.000493	0.31	0.21	Schizophrenia;	chr17:20211700	chr17:20583758~20591180:-
THCA	cis	rs8031584	0.958	rs35256769	ENSG00000178081.11	ULK4P3	4.64	4.45e-06	0.000493	0.27	0.21	Huntington's disease progression;	chr15:30945573	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.958	rs11629793	ENSG00000178081.11	ULK4P3	4.64	4.45e-06	0.000493	0.27	0.21	Huntington's disease progression;	chr15:30946220	chr15:30103720~30131757:+
THCA	cis	rs11640436	0.544	rs12921392	ENSG00000260922.1	RP11-538I12.3	-4.64	4.45e-06	0.000493	-0.24	-0.21	Lobe attachment (rater-scored or self-reported);	chr16:77286708	chr16:77234877~77290934:+
THCA	cis	rs793571	0.628	rs11071397	ENSG00000245975.2	RP11-30K9.6	4.64	4.46e-06	0.000494	0.24	0.21	Schizophrenia;	chr15:58815298	chr15:58768072~58770974:-
THCA	cis	rs1880529	0.931	rs1964212	ENSG00000206820.1	RNU1-138P	-4.64	4.46e-06	0.000494	-0.24	-0.21	White matter integrity (bipolar disorder risk interaction);	chr4:113466090	chr4:113420323~113420486:+
THCA	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	4.64	4.46e-06	0.000494	0.15	0.21	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
THCA	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	4.64	4.46e-06	0.000494	0.15	0.21	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000185485.13	SDHAP1	4.64	4.46e-06	0.000494	0.18	0.21	Pancreatic cancer;	chr3:196024982	chr3:195959748~195990318:-
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000185485.13	SDHAP1	4.64	4.46e-06	0.000494	0.18	0.21	Pancreatic cancer;	chr3:196025389	chr3:195959748~195990318:-
THCA	cis	rs4927850	1	rs10881563	ENSG00000185485.13	SDHAP1	4.64	4.46e-06	0.000494	0.18	0.21	Pancreatic cancer;	chr3:196023354	chr3:195959748~195990318:-
THCA	cis	rs6545883	0.718	rs2694624	ENSG00000270820.4	RP11-355B11.2	4.64	4.46e-06	0.000494	0.18	0.21	Tuberculosis;	chr2:61445178	chr2:61471188~61484130:+
THCA	cis	rs1559040	0.932	rs72800719	ENSG00000272156.1	RP11-477N3.1	-4.64	4.46e-06	0.000494	-0.34	-0.21	Sudden cardiac arrest;	chr2:54053058	chr2:54082554~54085066:+
THCA	cis	rs858239	0.6	rs7776649	ENSG00000226816.2	AC005082.12	4.64	4.46e-06	0.000494	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23206013~23208045:+
THCA	cis	rs12893668	0.667	rs8017628	ENSG00000269958.1	RP11-73M18.8	4.64	4.47e-06	0.000495	0.2	0.21	Reticulocyte count;	chr14:103581091	chr14:103696353~103697163:+
THCA	cis	rs4718428	0.705	rs11028	ENSG00000229180.5	GS1-124K5.11	4.64	4.47e-06	0.000495	0.16	0.21	Corneal structure;	chr7:66811230	chr7:66526088~66542624:-
THCA	cis	rs2439831	0.681	rs28653441	ENSG00000166763.7	STRCP1	4.64	4.47e-06	0.000495	0.28	0.21	Lung cancer in ever smokers;	chr15:43385064	chr15:43699488~43718184:-
THCA	cis	rs930395	0.514	rs4360054	ENSG00000272335.1	RP11-53O19.3	4.64	4.47e-06	0.000495	0.18	0.21	Breast cancer;	chr5:44928902	chr5:44826076~44828592:+
THCA	cis	rs3750965	1	rs4930643	ENSG00000260895.1	RP11-554A11.7	4.64	4.47e-06	0.000495	0.29	0.21	Hair color;	chr11:69051468	chr11:69103493~69109094:+
THCA	cis	rs703842	0.616	rs10877024	ENSG00000270039.1	RP11-571M6.17	-4.64	4.47e-06	0.000495	-0.24	-0.21	Multiple sclerosis;	chr12:57832926	chr12:57803838~57804415:+
THCA	cis	rs4934494	0.727	rs67827533	ENSG00000240996.1	RP11-80H5.7	-4.64	4.47e-06	0.000495	-0.24	-0.21	Red blood cell count;	chr10:89745626	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs1926139	ENSG00000240996.1	RP11-80H5.7	-4.64	4.47e-06	0.000495	-0.24	-0.21	Red blood cell count;	chr10:89753395	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.727	rs55823491	ENSG00000240996.1	RP11-80H5.7	-4.64	4.47e-06	0.000495	-0.24	-0.21	Red blood cell count;	chr10:89757598	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.727	rs12570750	ENSG00000240996.1	RP11-80H5.7	-4.64	4.47e-06	0.000495	-0.24	-0.21	Red blood cell count;	chr10:89761273	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.723	rs17127001	ENSG00000240996.1	RP11-80H5.7	-4.64	4.47e-06	0.000495	-0.24	-0.21	Red blood cell count;	chr10:89762932	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.727	rs36019294	ENSG00000240996.1	RP11-80H5.7	-4.64	4.47e-06	0.000495	-0.24	-0.21	Red blood cell count;	chr10:89777822	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.636	rs34408087	ENSG00000240996.1	RP11-80H5.7	-4.64	4.47e-06	0.000495	-0.24	-0.21	Red blood cell count;	chr10:89783794	chr10:89694295~89697928:-
THCA	cis	rs13113518	0.966	rs7677952	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55425312	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs1047354	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55429416	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs1056547	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55430596	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs1056545	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55430730	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs5863	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55430740	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs6828570	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55431595	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs3749474	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55434518	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs1474271	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55435912	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11937487	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55436576	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs3805146	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55436985	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11133378	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55439472	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11942279	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55439652	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs3805148	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55440643	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11133380	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55441110	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs12510110	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55441567	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs12510990	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55441907	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs3805149	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55442184	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11945370	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55442875	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs12647677	ENSG00000249700.7	SRD5A3-AS1	4.64	4.47e-06	0.000495	0.26	0.21	Height;	chr4:55444253	chr4:55363971~55395847:-
THCA	cis	rs72843506	0.591	rs74319100	ENSG00000261033.1	RP11-209D14.2	4.64	4.47e-06	0.000496	0.37	0.21	Schizophrenia;	chr17:20318079	chr17:20008051~20009234:-
THCA	cis	rs7716600	0.501	rs1438827	ENSG00000272335.1	RP11-53O19.3	-4.64	4.48e-06	0.000496	-0.18	-0.21	Breast cancer;	chr5:44751854	chr5:44826076~44828592:+
THCA	cis	rs9467773	0.935	rs11752946	ENSG00000261353.1	CTA-14H9.5	-4.64	4.48e-06	0.000496	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26527063~26527404:+
THCA	cis	rs2677744	1	rs1266489	ENSG00000214432.8	AC068831.10	-4.64	4.48e-06	0.000496	-0.21	-0.21	Attention deficit hyperactivity disorder;	chr15:90915255	chr15:91022619~91036611:+
THCA	cis	rs736408	0.609	rs62255396	ENSG00000243224.1	RP5-1157M23.2	-4.64	4.48e-06	0.000496	-0.23	-0.21	Bipolar disorder;	chr3:52748823	chr3:52239258~52241097:+
THCA	cis	rs736408	0.609	rs13082960	ENSG00000243224.1	RP5-1157M23.2	-4.64	4.48e-06	0.000496	-0.23	-0.21	Bipolar disorder;	chr3:52751152	chr3:52239258~52241097:+
THCA	cis	rs736408	0.609	rs2336545	ENSG00000243224.1	RP5-1157M23.2	4.64	4.48e-06	0.000496	0.23	0.21	Bipolar disorder;	chr3:52753587	chr3:52239258~52241097:+
THCA	cis	rs12681963	0.688	rs55810013	ENSG00000272375.1	RP11-51J9.6	4.64	4.48e-06	0.000497	0.3	0.21	Migraine;	chr8:30181507	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs61621868	ENSG00000272375.1	RP11-51J9.6	4.64	4.48e-06	0.000497	0.3	0.21	Migraine;	chr8:30182621	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.541	rs56302321	ENSG00000272375.1	RP11-51J9.6	4.64	4.48e-06	0.000497	0.3	0.21	Migraine;	chr8:30183018	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs12548744	ENSG00000272375.1	RP11-51J9.6	4.64	4.48e-06	0.000497	0.3	0.21	Migraine;	chr8:30184400	chr8:30197404~30198048:+
THCA	cis	rs7429990	0.864	rs11712464	ENSG00000228638.1	FCF1P2	-4.64	4.49e-06	0.000497	-0.21	-0.21	Educational attainment (years of education);	chr3:47724057	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs56376646	ENSG00000228638.1	FCF1P2	-4.64	4.49e-06	0.000497	-0.21	-0.21	Educational attainment (years of education);	chr3:47732588	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs11927129	ENSG00000228638.1	FCF1P2	-4.64	4.49e-06	0.000497	-0.21	-0.21	Educational attainment (years of education);	chr3:47745413	chr3:48290793~48291375:-
THCA	cis	rs2436845	1	rs2513919	ENSG00000253669.3	KB-1732A1.1	-4.64	4.49e-06	0.000497	-0.22	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102819526	chr8:102805517~102809971:+
THCA	cis	rs752010	0.543	rs7545381	ENSG00000230638.4	RP11-486B10.4	-4.64	4.49e-06	0.000497	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41578512	chr1:41542069~41544310:+
THCA	cis	rs6012564	1	rs2295028	ENSG00000227431.4	CSE1L-AS1	-4.64	4.49e-06	0.000497	-0.25	-0.21	Anger;	chr20:48966421	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.806	rs4810903	ENSG00000227431.4	CSE1L-AS1	-4.64	4.49e-06	0.000497	-0.25	-0.21	Anger;	chr20:48982668	chr20:49040463~49046044:-
THCA	cis	rs8062405	1	rs4788102	ENSG00000261766.1	RP11-22P6.2	-4.64	4.49e-06	0.000497	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28862166~28863340:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000229886.1	RP5-1132H15.3	4.64	4.49e-06	0.000497	0.22	0.21	Aortic root size;	chr7:65966699	chr7:66025126~66031544:-
THCA	cis	rs12234571	1	rs60432998	ENSG00000214293.7	APTR	4.64	4.49e-06	0.000497	0.27	0.21	Obesity-related traits;	chr7:77917449	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs17159450	ENSG00000214293.7	APTR	4.64	4.49e-06	0.000497	0.27	0.21	Obesity-related traits;	chr7:77919029	chr7:77657660~77696265:-
THCA	cis	rs494453	0.807	rs2786966	ENSG00000227811.2	FAM212B-AS1	4.64	4.49e-06	0.000497	0.26	0.21	Osteoporosis-related phenotypes;	chr1:111638035	chr1:111739841~111747798:+
THCA	cis	rs6832769	1	rs6811520	ENSG00000272969.1	RP11-528I4.2	4.64	4.49e-06	0.000497	0.25	0.21	Personality dimensions;	chr4:55449011	chr4:55547112~55547889:+
THCA	cis	rs12410462	0.636	rs2814085	ENSG00000227711.2	RP11-275O4.5	-4.64	4.49e-06	0.000497	-0.26	-0.21	Major depressive disorder;	chr1:227517775	chr1:227509028~227520477:-
THCA	cis	rs1923243	0.678	rs10890011	ENSG00000223479.3	RP4-788P17.1	-4.64	4.49e-06	0.000497	-0.23	-0.21	Migraine;	chr1:73172011	chr1:73635216~73715214:+
THCA	cis	rs5742933	1	rs62184283	ENSG00000273240.1	RP11-455J20.3	-4.64	4.49e-06	0.000497	-0.24	-0.21	Ferritin levels;	chr2:189801179	chr2:189763859~189764456:-
THCA	cis	rs17095355	1	rs11194924	ENSG00000203876.8	ADD3-AS1	-4.64	4.49e-06	0.000498	-0.23	-0.21	Biliary atresia;	chr10:109936015	chr10:109940104~110008381:-
THCA	cis	rs72945132	1	rs72945129	ENSG00000254604.1	AP000487.6	-4.64	4.49e-06	0.000498	-0.4	-0.21	Coronary artery disease;	chr11:70264702	chr11:70282367~70363368:-
THCA	cis	rs7474896	0.583	rs11011341	ENSG00000226578.1	RP11-258F22.1	-4.64	4.5e-06	0.000498	-0.29	-0.21	Obesity (extreme);	chr10:37709572	chr10:37775371~37784131:-
THCA	cis	rs1005277	0.522	rs1208684	ENSG00000226578.1	RP11-258F22.1	-4.64	4.5e-06	0.000498	-0.24	-0.21	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:37775371~37784131:-
THCA	cis	rs8067545	1	rs2108980	ENSG00000270091.1	RP11-78O7.2	-4.64	4.5e-06	0.000498	-0.16	-0.21	Schizophrenia;	chr17:20017205	chr17:19896590~19897287:-
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000259295.5	CSPG4P12	-4.64	4.5e-06	0.000498	-0.28	-0.21	P wave terminal force;	chr15:84631400	chr15:85191438~85213905:+
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000259295.5	CSPG4P12	-4.64	4.5e-06	0.000498	-0.28	-0.21	P wave terminal force;	chr15:84631524	chr15:85191438~85213905:+
THCA	cis	rs8062405	1	rs12325113	ENSG00000261766.1	RP11-22P6.2	-4.64	4.5e-06	0.000498	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28862166~28863340:-
THCA	cis	rs56163509	1	rs56163509	ENSG00000261766.1	RP11-22P6.2	-4.64	4.5e-06	0.000498	-0.2	-0.21	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62037369	ENSG00000261766.1	RP11-22P6.2	-4.64	4.5e-06	0.000498	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.965	rs7359397	ENSG00000261766.1	RP11-22P6.2	-4.64	4.5e-06	0.000498	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28862166~28863340:-
THCA	cis	rs11671005	0.737	rs11671033	ENSG00000268912.1	CTD-2619J13.17	-4.64	4.5e-06	0.000498	-0.21	-0.21	Mean platelet volume;	chr19:58452302	chr19:58428632~58431148:-
THCA	cis	rs516805	0.52	rs554482	ENSG00000279453.1	RP3-425C14.4	-4.64	4.5e-06	0.000498	-0.17	-0.21	Lymphocyte counts;	chr6:122419645	chr6:122436789~122439223:-
THCA	cis	rs516805	0.502	rs578868	ENSG00000279453.1	RP3-425C14.4	-4.64	4.5e-06	0.000498	-0.17	-0.21	Lymphocyte counts;	chr6:122421230	chr6:122436789~122439223:-
THCA	cis	rs516805	0.52	rs576247	ENSG00000279453.1	RP3-425C14.4	-4.64	4.5e-06	0.000498	-0.17	-0.21	Lymphocyte counts;	chr6:122425793	chr6:122436789~122439223:-
THCA	cis	rs10833905	1	rs10833895	ENSG00000246225.5	RP11-17A1.3	-4.64	4.5e-06	0.000498	-0.3	-0.21	Sudden cardiac arrest;	chr11:23006951	chr11:22829380~22945393:+
THCA	cis	rs793571	0.628	rs12439632	ENSG00000245975.2	RP11-30K9.6	4.64	4.51e-06	0.000499	0.24	0.21	Schizophrenia;	chr15:58811764	chr15:58768072~58770974:-
THCA	cis	rs250518	0.926	rs7720803	ENSG00000272081.1	CTD-2376I4.2	4.64	4.51e-06	0.000499	0.27	0.21	Mean corpuscular hemoglobin concentration;	chr5:72762870	chr5:72955206~72955699:-
THCA	cis	rs8031584	0.958	rs1043742	ENSG00000178081.11	ULK4P3	4.64	4.51e-06	0.000499	0.27	0.21	Huntington's disease progression;	chr15:30940378	chr15:30103720~30131757:+
THCA	cis	rs2688608	0.901	rs2633312	ENSG00000271816.1	BMS1P4	4.64	4.51e-06	0.000499	0.21	0.21	Inflammatory bowel disease;	chr10:73871997	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.868	rs2688625	ENSG00000271816.1	BMS1P4	4.64	4.51e-06	0.000499	0.21	0.21	Inflammatory bowel disease;	chr10:73871790	chr10:73699151~73730487:-
THCA	cis	rs2439831	0.702	rs3784275	ENSG00000275601.1	AC011330.13	-4.64	4.51e-06	5e-04	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43799188	chr15:43642389~43643023:-
THCA	cis	rs8062405	0.754	rs62034323	ENSG00000261766.1	RP11-22P6.2	-4.64	4.52e-06	5e-04	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.824	rs62034324	ENSG00000261766.1	RP11-22P6.2	-4.64	4.52e-06	5e-04	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.824	rs62034326	ENSG00000261766.1	RP11-22P6.2	-4.64	4.52e-06	5e-04	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28862166~28863340:-
THCA	cis	rs7493	0.901	rs17882539	ENSG00000233942.1	AC004012.1	4.64	4.52e-06	5e-04	0.32	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95397096	chr7:95471835~95473998:+
THCA	cis	rs5769765	0.954	rs5770707	ENSG00000260613.1	RP3-522J7.6	4.64	4.52e-06	5e-04	0.25	0.21	Schizophrenia;	chr22:49850885	chr22:49832616~49837786:-
THCA	cis	rs763121	0.853	rs6001204	ENSG00000228274.3	RP3-508I15.9	-4.64	4.52e-06	5e-04	-0.23	-0.21	Menopause (age at onset);	chr22:38704234	chr22:38667585~38681820:-
THCA	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-4.64	4.52e-06	5e-04	-0.27	-0.21	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
THCA	cis	rs12472274	1	rs12472274	ENSG00000279484.1	KLHL30-AS1	4.64	4.52e-06	5e-04	0.23	0.21	Phospholipid levels (plasma);	chr2:238186781	chr2:238152889~238155994:-
THCA	cis	rs737008	0.96	rs11640295	ENSG00000263080.1	RP11-485G7.5	4.64	4.52e-06	5e-04	0.26	0.21	Obesity-related traits;	chr16:11296871	chr16:11341809~11345211:-
THCA	cis	rs8028182	0.636	rs4886716	ENSG00000260269.4	CTD-2323K18.1	-4.64	4.52e-06	5e-04	-0.32	-0.21	Sudden cardiac arrest;	chr15:75563681	chr15:75527150~75601205:-
THCA	cis	rs13108904	0.901	rs66987549	ENSG00000254094.1	AC078852.1	-4.64	4.52e-06	5e-04	-0.23	-0.21	Obesity-related traits;	chr4:1278829	chr4:1356581~1358075:+
THCA	cis	rs4074961	0.527	rs6704190	ENSG00000233621.1	LINC01137	-4.64	4.53e-06	0.000501	-0.22	-0.21	Axial length;	chr1:37545150	chr1:37454879~37474411:-
THCA	cis	rs7819412	0.608	rs28417109	ENSG00000206014.6	OR7E161P	4.64	4.53e-06	0.000501	0.25	0.21	Triglycerides;	chr8:11117571	chr8:11928597~11929563:-
THCA	cis	rs7141336	0.791	rs8010860	ENSG00000258884.1	CTD-3035D6.2	4.64	4.53e-06	0.000501	0.29	0.21	Anxiety disorder;	chr14:90741946	chr14:90822365~90828128:-
THCA	cis	rs13113518	0.902	rs3805150	ENSG00000249700.7	SRD5A3-AS1	4.64	4.53e-06	0.000501	0.26	0.21	Height;	chr4:55446869	chr4:55363971~55395847:-
THCA	cis	rs12428035	0.686	rs4347496	ENSG00000247400.3	DNAJC3-AS1	4.64	4.53e-06	0.000501	0.19	0.21	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95865120	chr13:95648733~95676925:-
THCA	cis	rs2439831	0.681	rs7175434	ENSG00000205771.5	CATSPER2P1	-4.64	4.53e-06	0.000501	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43336344	chr15:43726918~43747094:-
THCA	cis	rs7045881	0.825	rs77716663	ENSG00000254396.1	RP11-56F10.3	4.64	4.53e-06	0.000501	0.31	0.21	Schizophrenia;	chr9:26775020	chr9:27102630~27104728:+
THCA	cis	rs10761482	0.906	rs10740023	ENSG00000254271.1	RP11-131N11.4	4.64	4.53e-06	0.000501	0.28	0.21	Schizophrenia;	chr10:60328508	chr10:60734342~60741828:+
THCA	cis	rs516805	0.961	rs1267942	ENSG00000279114.1	RP3-425C14.5	-4.64	4.53e-06	0.000502	-0.21	-0.21	Lymphocyte counts;	chr6:122472375	chr6:122471923~122484161:+
THCA	cis	rs516805	0.961	rs471620	ENSG00000279114.1	RP3-425C14.5	-4.64	4.53e-06	0.000502	-0.21	-0.21	Lymphocyte counts;	chr6:122473532	chr6:122471923~122484161:+
THCA	cis	rs1707322	1	rs1613296	ENSG00000281133.1	AL355480.3	4.64	4.54e-06	0.000502	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45580892~45580996:-
THCA	cis	rs9300255	0.602	rs1716164	ENSG00000235423.7	RP11-282O18.3	4.64	4.54e-06	0.000502	0.22	0.21	Neutrophil percentage of white cells;	chr12:123179113	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.568	rs1727300	ENSG00000235423.7	RP11-282O18.3	4.64	4.54e-06	0.000502	0.22	0.21	Neutrophil percentage of white cells;	chr12:123179658	chr12:123252030~123261483:-
THCA	cis	rs11175834	1	rs11175834	ENSG00000250748.5	RP11-230G5.2	4.64	4.54e-06	0.000502	0.34	0.21	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65598856	chr12:65466820~65642372:-
THCA	cis	rs7520050	0.966	rs10890363	ENSG00000234329.1	RP11-767N6.2	4.64	4.54e-06	0.000502	0.19	0.21	Reticulocyte count;Red blood cell count;	chr1:45890476	chr1:45651039~45651826:-
THCA	cis	rs3020736	0.5	rs8138678	ENSG00000273366.1	CTA-989H11.1	4.64	4.54e-06	0.000502	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42278188~42278846:+
THCA	cis	rs728616	0.681	rs12413174	ENSG00000242600.5	MBL1P	4.64	4.54e-06	0.000502	0.27	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80302648	chr10:79904898~79950336:+
THCA	cis	rs2302464	1	rs2302464	ENSG00000214846.4	RP11-115L11.1	-4.64	4.54e-06	0.000502	-0.53	-0.21	Cerebrospinal fluid biomarker levels;	chr4:15707629	chr4:15730962~15731627:-
THCA	cis	rs8105895	0.935	rs6511321	ENSG00000269345.1	VN1R85P	4.64	4.54e-06	0.000502	0.28	0.21	Body mass index (change over time);	chr19:22087266	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.877	rs8100768	ENSG00000269345.1	VN1R85P	4.64	4.54e-06	0.000502	0.28	0.21	Body mass index (change over time);	chr19:22087666	chr19:22174766~22175191:-
THCA	cis	rs9902453	1	rs11080114	ENSG00000263370.1	RP11-68I3.5	-4.64	4.54e-06	0.000502	-0.28	-0.21	Coffee consumption (cups per day);	chr17:30080269	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs7221743	ENSG00000263370.1	RP11-68I3.5	-4.64	4.54e-06	0.000502	-0.28	-0.21	Coffee consumption (cups per day);	chr17:30080858	chr17:29639627~29640825:+
THCA	cis	rs600231	0.542	rs11227205	ENSG00000245532.5	NEAT1	4.64	4.54e-06	0.000502	0.19	0.21	Bone mineral density;	chr11:65488693	chr11:65422774~65445540:+
THCA	cis	rs931127	0.547	rs3886859	ENSG00000214659.4	KRT8P26	4.64	4.54e-06	0.000502	0.18	0.21	Systemic lupus erythematosus;	chr11:65690839	chr11:65726939~65728214:+
THCA	cis	rs3796352	1	rs11712653	ENSG00000242142.1	SERBP1P3	4.64	4.54e-06	0.000502	0.38	0.21	Immune reponse to smallpox (secreted IL-2);	chr3:53036859	chr3:53064283~53065091:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-4.64	4.54e-06	0.000503	-0.26	-0.21	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
THCA	cis	rs758324	0.661	rs368443	ENSG00000237714.1	P4HA2-AS1	-4.64	4.54e-06	0.000503	-0.29	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132116730	chr5:132184876~132192808:+
THCA	cis	rs8105895	0.935	rs10417916	ENSG00000269345.1	VN1R85P	4.64	4.54e-06	0.000503	0.28	0.21	Body mass index (change over time);	chr19:22089813	chr19:22174766~22175191:-
THCA	cis	rs2271316	0.587	rs11078659	ENSG00000262089.1	RP11-589P10.5	4.64	4.54e-06	0.000503	0.2	0.21	Blood metabolite levels;	chr17:7000625	chr17:6994642~6995189:-
THCA	cis	rs8062405	0.789	rs240704	ENSG00000261766.1	RP11-22P6.2	-4.64	4.55e-06	0.000503	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28862166~28863340:-
THCA	cis	rs7838490	0.673	rs16884419	ENSG00000253553.4	RP11-586K2.1	-4.64	4.55e-06	0.000503	-0.22	-0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88567420	chr8:88326836~88737134:+
THCA	cis	rs7474896	0.848	rs2738193	ENSG00000263064.2	RP11-291L22.7	-4.64	4.55e-06	0.000503	-0.34	-0.21	Obesity (extreme);	chr10:37978834	chr10:38448689~38448949:+
THCA	cis	rs8067545	0.67	rs918227	ENSG00000270091.1	RP11-78O7.2	-4.64	4.55e-06	0.000503	-0.16	-0.21	Schizophrenia;	chr17:20098851	chr17:19896590~19897287:-
THCA	cis	rs931127	0.666	rs7932857	ENSG00000214659.4	KRT8P26	4.64	4.55e-06	0.000503	0.18	0.21	Systemic lupus erythematosus;	chr11:65690022	chr11:65726939~65728214:+
THCA	cis	rs62158800	1	rs62158800	ENSG00000224568.1	AC096669.3	4.64	4.55e-06	0.000503	0.38	0.21	Facial morphology (factor 22);	chr2:107585523	chr2:107529487~107556326:+
THCA	cis	rs741738	1	rs10398	ENSG00000254910.1	RP11-326C3.7	-4.64	4.55e-06	0.000503	-0.26	-0.21	Granulocyte percentage of myeloid white cells;	chr11:308180	chr11:310139~311141:-
THCA	cis	rs240993	0.812	rs458806	ENSG00000271789.1	RP5-1112D6.7	-4.64	4.55e-06	0.000503	-0.26	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111354825	chr6:111297126~111298510:+
THCA	cis	rs12612619	0.732	rs11688708	ENSG00000229122.1	AGBL5-IT1	4.64	4.55e-06	0.000503	0.15	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976740	chr2:27061038~27061815:+
THCA	cis	rs922182	0.599	rs34409256	ENSG00000275785.1	RP11-111E14.2	-4.64	4.55e-06	0.000503	-0.23	-0.21	Blood protein levels;	chr15:63978115	chr15:63890030~63890317:+
THCA	cis	rs4578769	0.788	rs12962334	ENSG00000265939.1	UBE2CP2	4.64	4.55e-06	0.000503	0.24	0.21	Eosinophil percentage of white cells;	chr18:22897971	chr18:22900486~22900995:-
THCA	cis	rs516805	0.52	rs1267947	ENSG00000279453.1	RP3-425C14.4	-4.64	4.55e-06	0.000503	-0.17	-0.21	Lymphocyte counts;	chr6:122450892	chr6:122436789~122439223:-
THCA	cis	rs516805	0.545	rs1267948	ENSG00000279453.1	RP3-425C14.4	-4.64	4.55e-06	0.000503	-0.17	-0.21	Lymphocyte counts;	chr6:122452490	chr6:122436789~122439223:-
THCA	cis	rs7580717	0.962	rs7590204	ENSG00000224376.1	AC017104.6	4.64	4.55e-06	0.000503	0.22	0.21	Multiple myeloma;	chr2:231319258	chr2:231388976~231394991:+
THCA	cis	rs2439831	0.867	rs28461955	ENSG00000166763.7	STRCP1	4.64	4.55e-06	0.000504	0.29	0.21	Lung cancer in ever smokers;	chr15:43369261	chr15:43699488~43718184:-
THCA	cis	rs5742933	1	rs12052909	ENSG00000273240.1	RP11-455J20.3	-4.64	4.55e-06	0.000504	-0.23	-0.21	Ferritin levels;	chr2:189742484	chr2:189763859~189764456:-
THCA	cis	rs5742933	1	rs16831955	ENSG00000273240.1	RP11-455J20.3	-4.64	4.55e-06	0.000504	-0.23	-0.21	Ferritin levels;	chr2:189745811	chr2:189763859~189764456:-
THCA	cis	rs2281603	0.521	rs6573559	ENSG00000259116.1	RP11-973N13.4	-4.64	4.55e-06	0.000504	-0.17	-0.21	Lymphocyte counts;	chr14:64456448	chr14:64514154~64540368:-
THCA	cis	rs67478160	0.619	rs12878682	ENSG00000269910.1	RP11-73M18.10	4.64	4.56e-06	0.000504	0.18	0.21	Schizophrenia;	chr14:103767290	chr14:103694516~103695050:-
THCA	cis	rs61270009	0.955	rs454693	ENSG00000247828.6	TMEM161B-AS1	4.64	4.56e-06	0.000504	0.18	0.21	Depressive symptoms;	chr5:88248396	chr5:88268895~88436685:+
THCA	cis	rs2243480	1	rs431318	ENSG00000164669.11	INTS4P1	4.64	4.56e-06	0.000504	0.41	0.21	Diabetic kidney disease;	chr7:66046610	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs313803	ENSG00000164669.11	INTS4P1	4.64	4.56e-06	0.000504	0.41	0.21	Diabetic kidney disease;	chr7:66049744	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs313802	ENSG00000164669.11	INTS4P1	4.64	4.56e-06	0.000504	0.41	0.21	Diabetic kidney disease;	chr7:66051386	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000164669.11	INTS4P1	4.64	4.56e-06	0.000504	0.41	0.21	Diabetic kidney disease;	chr7:66052736	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs458291	ENSG00000164669.11	INTS4P1	4.64	4.56e-06	0.000504	0.41	0.21	Diabetic kidney disease;	chr7:66055492	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs464895	ENSG00000164669.11	INTS4P1	4.64	4.56e-06	0.000504	0.41	0.21	Diabetic kidney disease;	chr7:66062119	chr7:65141225~65234216:+
THCA	cis	rs10090774	0.71	rs11166991	ENSG00000280303.2	ERICD	-4.64	4.56e-06	0.000504	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140656314	chr8:140636281~140638283:+
THCA	cis	rs8028182	0.636	rs4886715	ENSG00000260274.1	RP11-817O13.8	4.64	4.56e-06	0.000504	0.15	0.21	Sudden cardiac arrest;	chr15:75539108	chr15:75368155~75369584:+
THCA	cis	rs8067545	0.611	rs1974745	ENSG00000270091.1	RP11-78O7.2	-4.64	4.56e-06	0.000504	-0.16	-0.21	Schizophrenia;	chr17:20156511	chr17:19896590~19897287:-
THCA	cis	rs4906332	0.782	rs2236281	ENSG00000252469.1	RNU7-160P	4.64	4.56e-06	0.000504	0.26	0.21	Coronary artery disease;	chr14:103534181	chr14:103550345~103550406:+
THCA	cis	rs9929218	0.501	rs12448999	ENSG00000260459.2	FTLP14	4.64	4.56e-06	0.000504	0.24	0.21	Colorectal cancer;	chr16:68781646	chr16:68822587~68823070:+
THCA	cis	rs1476587	0.92	rs56347838	ENSG00000224046.1	AC005076.5	4.64	4.56e-06	0.000504	0.23	0.21	Brachial circumference;	chr7:87066710	chr7:87151423~87152420:-
THCA	cis	rs8022179	0.58	rs6575977	ENSG00000244691.1	RPL10AP1	4.64	4.56e-06	0.000504	0.3	0.21	Monocyte count;	chr14:103357011	chr14:103412119~103412761:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000229886.1	RP5-1132H15.3	4.64	4.56e-06	0.000504	0.22	0.21	Calcium levels;	chr7:65974892	chr7:66025126~66031544:-
THCA	cis	rs7942368	0.941	rs737185	ENSG00000261578.1	RP11-21L23.2	4.64	4.56e-06	0.000504	0.3	0.21	Endometriosis;	chr11:76774314	chr11:76800364~76804555:+
THCA	cis	rs6920965	0.583	rs9388456	ENSG00000237742.5	RP11-624M8.1	-4.64	4.56e-06	0.000505	-0.18	-0.21	High light scatter reticulocyte count;	chr6:125826051	chr6:125578558~125749190:-
THCA	cis	rs795484	0.926	rs191626	ENSG00000275409.1	RP11-131L12.4	-4.64	4.56e-06	0.000505	-0.18	-0.21	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118191665	chr12:118430147~118430699:+
THCA	cis	rs930395	0.514	rs10063172	ENSG00000272335.1	RP11-53O19.3	4.64	4.56e-06	0.000505	0.18	0.21	Breast cancer;	chr5:44930607	chr5:44826076~44828592:+
THCA	cis	rs8177876	0.822	rs4324141	ENSG00000261061.1	RP11-303E16.2	4.64	4.56e-06	0.000505	0.29	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81030770~81031485:+
THCA	cis	rs6442522	0.606	rs2345105	ENSG00000249786.6	EAF1-AS1	4.64	4.57e-06	0.000505	0.22	0.21	Uric acid levels;	chr3:15454257	chr3:15436171~15455940:-
THCA	cis	rs6714710	0.603	rs11690687	ENSG00000230606.9	AC159540.1	-4.64	4.57e-06	0.000505	-0.23	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845358	chr2:97416165~97433527:-
THCA	cis	rs3750082	0.817	rs3750078	ENSG00000231952.3	DPY19L1P2	-4.64	4.57e-06	0.000505	-0.25	-0.21	Glomerular filtration rate (creatinine);	chr7:32929877	chr7:32812757~32838570:+
THCA	cis	rs9902453	0.904	rs8078638	ENSG00000263370.1	RP11-68I3.5	4.64	4.57e-06	0.000505	0.27	0.21	Coffee consumption (cups per day);	chr17:29963340	chr17:29639627~29640825:+
THCA	cis	rs9925964	0.869	rs749670	ENSG00000232748.3	RP11-196G11.6	4.64	4.57e-06	0.000505	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077304	chr16:31056460~31062803:+
THCA	cis	rs9625935	0.957	rs41179	ENSG00000279159.1	RP3-394A18.1	-4.64	4.57e-06	0.000506	-0.16	-0.21	Tonsillectomy;	chr22:30045688	chr22:29978950~30028236:-
THCA	cis	rs12681288	0.782	rs2600499	ENSG00000260721.1	AF067845.1	4.64	4.57e-06	0.000506	0.26	0.21	Schizophrenia;	chr8:1076619	chr8:1368642~1369833:-
THCA	cis	rs1046896	0.521	rs3848403	ENSG00000263063.1	RP11-388C12.1	-4.64	4.57e-06	0.000506	-0.25	-0.21	Glycated hemoglobin levels;	chr17:82736023	chr17:82713908~82716255:-
THCA	cis	rs7267979	0.586	rs1007707	ENSG00000277938.1	RP5-965G21.3	4.64	4.57e-06	0.000506	0.18	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25229150~25231933:+
THCA	cis	rs1577917	0.839	rs6454492	ENSG00000220563.1	PKMP3	-4.64	4.58e-06	0.000506	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85773496	chr6:85659892~85660606:-
THCA	cis	rs1790761	0.632	rs625978	ENSG00000255318.1	RP11-655M14.13	4.64	4.58e-06	0.000506	0.23	0.21	Mean corpuscular volume;	chr11:67577193	chr11:67618279~67627304:-
THCA	cis	rs654950	0.875	rs600109	ENSG00000230638.4	RP11-486B10.4	4.64	4.58e-06	0.000506	0.24	0.21	Airway imaging phenotypes;	chr1:41532575	chr1:41542069~41544310:+
THCA	cis	rs1150668	0.835	rs203869	ENSG00000176933.5	TOB2P1	-4.64	4.58e-06	0.000506	-0.23	-0.21	Pubertal anthropometrics;	chr6:28073041	chr6:28217643~28218634:-
THCA	cis	rs12091564	1	rs12091564	ENSG00000233396.6	RP11-458D21.1	4.64	4.58e-06	0.000506	0.44	0.21	Coronary heart disease (SNP X SNP interaction);	chr1:146039391	chr1:146052566~146061948:+
THCA	cis	rs72843506	0.722	rs79590067	ENSG00000231258.2	ZSWIM5P2	4.64	4.58e-06	0.000506	0.3	0.21	Schizophrenia;	chr17:20204101	chr17:20583758~20591180:-
THCA	cis	rs2412819	0.571	rs6493090	ENSG00000166763.7	STRCP1	-4.64	4.58e-06	0.000506	-0.27	-0.21	Lung cancer;	chr15:43792084	chr15:43699488~43718184:-
THCA	cis	rs2408955	0.542	rs7975632	ENSG00000273765.1	RP11-370I10.11	4.64	4.58e-06	0.000506	0.21	0.21	Glycated hemoglobin levels;	chr12:48049265	chr12:48360920~48361377:+
THCA	cis	rs12906542	0.516	rs76398134	ENSG00000259792.1	RP11-114H24.6	-4.64	4.58e-06	0.000506	-0.32	-0.21	Breast cancer;	chr15:77996385	chr15:77993405~77995289:+
THCA	cis	rs7608910	1	rs13003464	ENSG00000271889.1	RP11-493E12.1	4.64	4.58e-06	0.000506	0.21	0.21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60959694	chr2:61151433~61162105:-
THCA	cis	rs2348418	0.648	rs11049730	ENSG00000247934.4	RP11-967K21.1	4.64	4.58e-06	0.000506	0.18	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28586912	chr12:28163298~28190738:-
THCA	cis	rs4072705	0.615	rs7869829	ENSG00000224020.1	MIR181A2HG	4.64	4.58e-06	0.000506	0.19	0.21	Menarche (age at onset);	chr9:124484898	chr9:124658467~124698631:+
THCA	cis	rs2288884	0.579	rs6509603	ENSG00000260160.1	CTC-471J1.2	-4.64	4.58e-06	0.000506	-0.22	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51960977	chr19:52058490~52063703:-
THCA	cis	rs4072705	0.585	rs7852843	ENSG00000224020.1	MIR181A2HG	4.64	4.58e-06	0.000506	0.19	0.21	Menarche (age at onset);	chr9:124471544	chr9:124658467~124698631:+
THCA	cis	rs59918340	0.764	rs2304282	ENSG00000253307.1	RP11-10J21.4	4.64	4.58e-06	0.000506	0.29	0.21	Immature fraction of reticulocytes;	chr8:141219444	chr8:141252286~141253292:-
THCA	cis	rs2657294	0.796	rs2804534	ENSG00000226051.5	ZNF503-AS1	4.64	4.58e-06	0.000506	0.29	0.21	Pneumonia;	chr10:75208023	chr10:75269819~75373500:+
THCA	cis	rs9625935	0.957	rs7510705	ENSG00000279159.1	RP3-394A18.1	-4.64	4.58e-06	0.000506	-0.16	-0.21	Tonsillectomy;	chr22:30097929	chr22:29978950~30028236:-
THCA	cis	rs1003719	0.788	rs2156076	ENSG00000230366.8	DSCR9	-4.64	4.58e-06	0.000506	-0.21	-0.21	Eye color traits;	chr21:37080334	chr21:37208503~37221736:+
THCA	cis	rs564343	0.688	rs539046	ENSG00000255320.1	RP11-755F10.1	-4.64	4.58e-06	0.000506	-0.26	-0.21	Obesity (early onset extreme);	chr11:66076307	chr11:66244840~66246239:-
THCA	cis	rs9634489	0.588	rs1927786	ENSG00000247400.3	DNAJC3-AS1	-4.64	4.58e-06	0.000506	-0.13	-0.21	Body mass index;	chr13:96275915	chr13:95648733~95676925:-
THCA	cis	rs7621331	0.857	rs1523597	ENSG00000273486.1	RP11-731C17.2	4.64	4.58e-06	0.000506	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136020880	chr3:136837338~136839021:-
THCA	cis	rs7621331	0.963	rs1523596	ENSG00000273486.1	RP11-731C17.2	4.64	4.58e-06	0.000506	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136020965	chr3:136837338~136839021:-
THCA	cis	rs7621331	0.927	rs4073308	ENSG00000273486.1	RP11-731C17.2	4.64	4.58e-06	0.000506	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136021627	chr3:136837338~136839021:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-4.64	4.58e-06	0.000506	-0.23	-0.21	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
THCA	cis	rs2915864	0.861	rs2906053	ENSG00000280047.1	CTC-463A16.1	-4.64	4.58e-06	0.000506	-0.35	-0.21	Facial morphology (factor 20);	chr5:142214650	chr5:142165767~142168387:+
THCA	cis	rs2439831	0.867	rs2412780	ENSG00000205771.5	CATSPER2P1	-4.64	4.58e-06	0.000506	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43363596	chr15:43726918~43747094:-
THCA	cis	rs801193	1	rs4717319	ENSG00000229886.1	RP5-1132H15.3	4.64	4.58e-06	0.000507	0.21	0.21	Aortic root size;	chr7:66777606	chr7:66025126~66031544:-
THCA	cis	rs801193	0.904	rs4718403	ENSG00000229886.1	RP5-1132H15.3	4.64	4.58e-06	0.000507	0.21	0.21	Aortic root size;	chr7:66777742	chr7:66025126~66031544:-
THCA	cis	rs55704346	0.74	rs11943612	ENSG00000281501.1	SEPSECS-AS1	-4.64	4.58e-06	0.000507	-0.23	-0.21	Tonsillectomy;	chr4:25119696	chr4:25160641~25201440:+
THCA	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	4.64	4.59e-06	0.000507	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
THCA	cis	rs2803122	0.745	rs10123714	ENSG00000273226.1	RP11-513M16.8	-4.64	4.59e-06	0.000507	-0.19	-0.21	Pulse pressure;	chr9:19231645	chr9:19375451~19375996:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000223473.2	GS1-124K5.3	4.64	4.59e-06	0.000507	0.14	0.21	Aortic root size;	chr7:65960907	chr7:66491049~66493566:-
THCA	cis	rs1707322	1	rs11211190	ENSG00000281133.1	AL355480.3	-4.64	4.59e-06	0.000507	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs6429580	ENSG00000281133.1	AL355480.3	-4.64	4.59e-06	0.000507	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45580892~45580996:-
THCA	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-4.64	4.59e-06	0.000507	-0.12	-0.21	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
THCA	cis	rs1889642	0.669	rs1360814	ENSG00000227354.5	RBM26-AS1	-4.64	4.59e-06	0.000507	-0.2	-0.21	Colonoscopy-negative controls vs population controls;	chr13:79829782	chr13:79406309~79424328:+
THCA	cis	rs6088590	1	rs6087625	ENSG00000276073.1	RP5-1125A11.7	4.64	4.59e-06	0.000507	0.19	0.21	Coronary artery disease;	chr20:34754674	chr20:33985617~33988989:-
THCA	cis	rs72843506	0.656	rs77314146	ENSG00000261033.1	RP11-209D14.2	4.64	4.59e-06	0.000507	0.41	0.21	Schizophrenia;	chr17:20003827	chr17:20008051~20009234:-
THCA	cis	rs9393813	0.626	rs7772739	ENSG00000204789.4	ZNF204P	4.64	4.59e-06	0.000507	0.17	0.21	Bipolar disorder;	chr6:27351069	chr6:27357825~27360221:-
THCA	cis	rs12761761	1	rs11813081	ENSG00000279982.1	RP11-45A17.3	-4.64	4.59e-06	0.000507	-0.33	-0.21	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131944937	chr10:131996738~131999846:+
THCA	cis	rs526231	0.764	rs2569014	ENSG00000175749.11	EIF3KP1	4.64	4.59e-06	0.000507	0.27	0.21	Primary biliary cholangitis;	chr5:103302398	chr5:103032376~103033031:+
THCA	cis	rs7824557	0.806	rs34171564	ENSG00000154316.13	TDH	4.64	4.59e-06	0.000508	0.15	0.21	Retinal vascular caliber;	chr8:11237837	chr8:11339637~11368452:+
THCA	cis	rs7614311	0.689	rs73120898	ENSG00000271843.1	RP11-245J9.5	-4.64	4.59e-06	0.000508	-0.38	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63843104	chr3:64008082~64008692:-
THCA	cis	rs6545883	0.507	rs12478192	ENSG00000270820.4	RP11-355B11.2	-4.64	4.6e-06	0.000508	-0.18	-0.21	Tuberculosis;	chr2:61364040	chr2:61471188~61484130:+
THCA	cis	rs6012564	1	rs6125576	ENSG00000230758.1	SNAP23P	4.64	4.6e-06	0.000508	0.26	0.21	Anger;	chr20:49160382	chr20:49038357~49038602:-
THCA	cis	rs1790761	0.52	rs7124513	ENSG00000255318.1	RP11-655M14.13	-4.64	4.6e-06	0.000508	-0.25	-0.21	Mean corpuscular volume;	chr11:67628243	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.52	rs1551884	ENSG00000255318.1	RP11-655M14.13	-4.64	4.6e-06	0.000508	-0.25	-0.21	Mean corpuscular volume;	chr11:67632130	chr11:67618279~67627304:-
THCA	cis	rs9987353	0.519	rs2929465	ENSG00000253893.2	FAM85B	4.64	4.6e-06	0.000508	0.27	0.21	Recombination measurement;	chr8:9206492	chr8:8167819~8226614:-
THCA	cis	rs7429990	0.864	rs883662	ENSG00000228638.1	FCF1P2	-4.64	4.6e-06	0.000508	-0.21	-0.21	Educational attainment (years of education);	chr3:47619342	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.828	rs11712152	ENSG00000228638.1	FCF1P2	-4.64	4.6e-06	0.000508	-0.21	-0.21	Educational attainment (years of education);	chr3:47655314	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs12635438	ENSG00000228638.1	FCF1P2	-4.64	4.6e-06	0.000508	-0.21	-0.21	Educational attainment (years of education);	chr3:47693210	chr3:48290793~48291375:-
THCA	cis	rs2948294	0.524	rs13270062	ENSG00000254153.1	CTA-398F10.2	-4.64	4.6e-06	0.000508	-0.23	-0.21	Red cell distribution width;	chr8:8255128	chr8:8456909~8461337:-
THCA	cis	rs9595908	0.785	rs9315173	ENSG00000212293.1	SNORA16	4.64	4.6e-06	0.000508	0.24	0.21	Body mass index;	chr13:32645674	chr13:32420390~32420516:-
THCA	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-4.64	4.6e-06	0.000508	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
THCA	cis	rs62246343	0.541	rs17050396	ENSG00000254485.4	RP11-380O24.1	4.64	4.6e-06	0.000508	0.24	0.21	Fibrinogen levels;	chr3:9492652	chr3:9292588~9363303:-
THCA	cis	rs7572644	0.64	rs6547820	ENSG00000223522.1	AC093690.1	4.64	4.6e-06	0.000508	0.24	0.21	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28058678	chr2:28307691~28310459:-
THCA	cis	rs17507216	0.958	rs72751643	ENSG00000255769.6	GOLGA2P10	-4.64	4.6e-06	0.000508	-0.3	-0.21	Excessive daytime sleepiness;	chr15:82559444	chr15:82472993~82513950:-
THCA	cis	rs2018683	0.834	rs2012754	ENSG00000272568.4	CTB-113D17.1	4.64	4.6e-06	0.000509	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28979967~29013367:+
THCA	cis	rs7176527	0.579	rs366717	ENSG00000225151.9	GOLGA2P7	4.64	4.6e-06	0.000509	0.32	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84199311~84230136:-
THCA	cis	rs1790761	0.607	rs656652	ENSG00000255318.1	RP11-655M14.13	4.64	4.61e-06	0.000509	0.23	0.21	Mean corpuscular volume;	chr11:67576486	chr11:67618279~67627304:-
THCA	cis	rs703842	0.616	rs10877023	ENSG00000270039.1	RP11-571M6.17	-4.64	4.61e-06	0.000509	-0.24	-0.21	Multiple sclerosis;	chr12:57830416	chr12:57803838~57804415:+
THCA	cis	rs6088765	0.583	rs6058209	ENSG00000269202.1	RP4-614O4.12	-4.64	4.61e-06	0.000509	-0.2	-0.21	Ulcerative colitis;	chr20:35233774	chr20:35201747~35203288:-
THCA	cis	rs7474896	0.609	rs1830612	ENSG00000226578.1	RP11-258F22.1	-4.64	4.61e-06	0.000509	-0.29	-0.21	Obesity (extreme);	chr10:37710955	chr10:37775371~37784131:-
THCA	cis	rs12410462	0.591	rs2453682	ENSG00000227711.2	RP11-275O4.5	-4.64	4.61e-06	0.000509	-0.26	-0.21	Major depressive disorder;	chr1:227522680	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.591	rs1495851	ENSG00000227711.2	RP11-275O4.5	-4.64	4.61e-06	0.000509	-0.26	-0.21	Major depressive disorder;	chr1:227523372	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.551	rs2819503	ENSG00000227711.2	RP11-275O4.5	-4.64	4.61e-06	0.000509	-0.26	-0.21	Major depressive disorder;	chr1:227524787	chr1:227509028~227520477:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000272831.1	RP11-792A8.4	4.64	4.61e-06	0.000509	0.13	0.21	Aortic root size;	chr7:65964026	chr7:66739829~66740385:-
THCA	cis	rs7621331	1	rs35257855	ENSG00000273486.1	RP11-731C17.2	4.64	4.61e-06	0.000509	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:135988919	chr3:136837338~136839021:-
THCA	cis	rs1023500	0.596	rs133352	ENSG00000273366.1	CTA-989H11.1	-4.64	4.61e-06	0.000509	-0.27	-0.21	Schizophrenia;	chr22:42038018	chr22:42278188~42278846:+
THCA	cis	rs6832769	1	rs11133399	ENSG00000272969.1	RP11-528I4.2	-4.64	4.61e-06	0.00051	-0.25	-0.21	Personality dimensions;	chr4:55547664	chr4:55547112~55547889:+
THCA	cis	rs2115630	0.754	rs12595321	ENSG00000225151.9	GOLGA2P7	4.64	4.62e-06	0.00051	0.26	0.21	P wave terminal force;	chr15:84788038	chr15:84199311~84230136:-
THCA	cis	rs442309	1	rs224139	ENSG00000238280.1	RP11-436D10.3	-4.64	4.62e-06	0.00051	-0.25	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62713956	chr10:62793562~62805887:-
THCA	cis	rs4713118	0.866	rs9468217	ENSG00000220721.1	OR1F12	4.64	4.62e-06	0.00051	0.28	0.21	Parkinson's disease;	chr6:27758688	chr6:28073316~28074233:+
THCA	cis	rs7267979	0.966	rs3827014	ENSG00000274973.1	RP13-401N8.7	4.64	4.62e-06	0.00051	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25845497~25845862:+
THCA	cis	rs2688608	0.901	rs2459446	ENSG00000271816.1	BMS1P4	-4.64	4.62e-06	0.00051	-0.2	-0.21	Inflammatory bowel disease;	chr10:73841838	chr10:73699151~73730487:-
THCA	cis	rs3096299	0.685	rs4329923	ENSG00000261118.1	RP11-104N10.1	4.64	4.62e-06	0.00051	0.18	0.21	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89492017~89504460:-
THCA	cis	rs683257	0.81	rs1879508	ENSG00000234147.1	RP3-460G2.2	-4.64	4.62e-06	0.00051	-0.36	-0.21	Facial emotion recognition (angry faces);	chr6:140879471	chr6:140845958~140852924:-
THCA	cis	rs2985684	0.894	rs2883436	ENSG00000278009.1	RP11-649E7.8	4.64	4.62e-06	0.00051	0.29	0.21	Carotid intima media thickness;	chr14:49547104	chr14:49601011~49601124:-
THCA	cis	rs6088590	0.603	rs6579186	ENSG00000269202.1	RP4-614O4.12	-4.64	4.62e-06	0.00051	-0.18	-0.21	Coronary artery disease;	chr20:34694394	chr20:35201747~35203288:-
THCA	cis	rs2839186	0.709	rs2839176	ENSG00000215424.8	MCM3AP-AS1	4.64	4.62e-06	0.00051	0.12	0.21	Testicular germ cell tumor;	chr21:46258259	chr21:46229217~46259390:+
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000164669.11	INTS4P1	4.64	4.62e-06	0.000511	0.41	0.21	Diabetic kidney disease;	chr7:65914813	chr7:65141225~65234216:+
THCA	cis	rs13434995	0.513	rs1979605	ENSG00000273257.1	RP11-177J6.1	4.64	4.62e-06	0.000511	0.31	0.21	Adiponectin levels;	chr4:55552706	chr4:55387949~55388271:+
THCA	cis	rs7989336	0.663	rs8000148	ENSG00000247400.3	DNAJC3-AS1	-4.64	4.63e-06	0.000511	-0.13	-0.21	Obesity;	chr13:96323314	chr13:95648733~95676925:-
THCA	cis	rs972578	0.677	rs5751371	ENSG00000274717.1	RP1-47A17.1	-4.64	4.63e-06	0.000511	-0.23	-0.21	Mean platelet volume;	chr22:42792605	chr22:42791814~42794313:-
THCA	cis	rs4415084	0.966	rs36068815	ENSG00000272335.1	RP11-53O19.3	-4.64	4.63e-06	0.000511	-0.17	-0.21	Breast cancer;	chr5:44645896	chr5:44826076~44828592:+
THCA	cis	rs7937	0.693	rs2279011	ENSG00000279108.1	CTC-490E21.11	-4.64	4.63e-06	0.000511	-0.22	-0.21	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40763383	chr19:40840159~40842039:+
THCA	cis	rs858239	0.6	rs2003555	ENSG00000226816.2	AC005082.12	4.64	4.63e-06	0.000511	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs7784929	ENSG00000226816.2	AC005082.12	4.64	4.63e-06	0.000511	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs7799422	ENSG00000226816.2	AC005082.12	4.64	4.63e-06	0.000511	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs28483572	ENSG00000226816.2	AC005082.12	4.64	4.63e-06	0.000511	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs6961406	ENSG00000226816.2	AC005082.12	4.64	4.63e-06	0.000511	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs6461690	ENSG00000226816.2	AC005082.12	4.64	4.63e-06	0.000511	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs6967419	ENSG00000226816.2	AC005082.12	4.64	4.63e-06	0.000511	0.3	0.21	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23206013~23208045:+
THCA	cis	rs210138	1	rs210138	ENSG00000197251.3	LINC00336	-4.64	4.63e-06	0.000511	-0.27	-0.21	Testicular germ cell tumor;	chr6:33574761	chr6:33586106~33593338:-
THCA	cis	rs10904908	0.763	rs359284	ENSG00000229124.5	VIM-AS1	4.64	4.63e-06	0.000511	0.2	0.21	Cholesterol, total;Total cholesterol levels;	chr10:17284757	chr10:17214239~17229985:-
THCA	cis	rs10904908	0.703	rs359287	ENSG00000229124.5	VIM-AS1	4.64	4.63e-06	0.000511	0.2	0.21	Cholesterol, total;Total cholesterol levels;	chr10:17285792	chr10:17214239~17229985:-
THCA	cis	rs736408	1	rs4687552	ENSG00000243224.1	RP5-1157M23.2	-4.64	4.63e-06	0.000511	-0.23	-0.21	Bipolar disorder;	chr3:52804386	chr3:52239258~52241097:+
THCA	cis	rs4865169	0.811	rs6841086	ENSG00000269949.1	RP11-738E22.3	4.64	4.63e-06	0.000511	0.24	0.21	Breast cancer;	chr4:57037102	chr4:56960927~56961373:-
THCA	cis	rs1046491	0.523	rs11876120	ENSG00000264964.1	RP11-888D10.3	4.64	4.63e-06	0.000511	0.38	0.21	Scarlet fever;	chr18:9303513	chr18:9315194~9334441:-
THCA	cis	rs62025270	0.632	rs1807309	ENSG00000259295.5	CSPG4P12	-4.63	4.63e-06	0.000511	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85191438~85213905:+
THCA	cis	rs8062405	0.824	rs4788083	ENSG00000261766.1	RP11-22P6.2	-4.63	4.63e-06	0.000512	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28862166~28863340:-
THCA	cis	rs2732480	0.557	rs2732441	ENSG00000273765.1	RP11-370I10.11	4.63	4.63e-06	0.000512	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.577	rs2732448	ENSG00000273765.1	RP11-370I10.11	4.63	4.63e-06	0.000512	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.577	rs2732466	ENSG00000273765.1	RP11-370I10.11	4.63	4.63e-06	0.000512	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.557	rs2634682	ENSG00000273765.1	RP11-370I10.11	4.63	4.63e-06	0.000512	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48360920~48361377:+
THCA	cis	rs62246343	0.605	rs34665459	ENSG00000254485.4	RP11-380O24.1	4.63	4.63e-06	0.000512	0.23	0.21	Fibrinogen levels;	chr3:9423041	chr3:9292588~9363303:-
THCA	cis	rs9902453	0.765	rs3102560	ENSG00000263370.1	RP11-68I3.5	4.63	4.63e-06	0.000512	0.27	0.21	Coffee consumption (cups per day);	chr17:29702920	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.726	rs3115088	ENSG00000263370.1	RP11-68I3.5	4.63	4.63e-06	0.000512	0.27	0.21	Coffee consumption (cups per day);	chr17:29704257	chr17:29639627~29640825:+
THCA	cis	rs9393777	0.778	rs13219354	ENSG00000219392.1	RP1-265C24.5	-4.63	4.64e-06	0.000512	-0.4	-0.21	Intelligence (multi-trait analysis);	chr6:27217885	chr6:28115628~28116551:+
THCA	cis	rs9393777	0.778	rs67457459	ENSG00000219392.1	RP1-265C24.5	-4.63	4.64e-06	0.000512	-0.4	-0.21	Intelligence (multi-trait analysis);	chr6:27230564	chr6:28115628~28116551:+
THCA	cis	rs7849973	0.551	rs10117155	ENSG00000224549.1	RP11-370B11.3	4.63	4.64e-06	0.000512	0.24	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22809464	chr9:22767175~22768316:+
THCA	cis	rs6496932	0.635	rs11632761	ENSG00000259630.2	CTD-2262B20.1	-4.63	4.64e-06	0.000512	-0.26	-0.21	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85415228~85415633:+
THCA	cis	rs6496932	0.635	rs67659163	ENSG00000259630.2	CTD-2262B20.1	-4.63	4.64e-06	0.000512	-0.26	-0.21	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85415228~85415633:+
THCA	cis	rs1707322	1	rs11211205	ENSG00000281133.1	AL355480.3	-4.63	4.64e-06	0.000512	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45580892~45580996:-
THCA	cis	rs172166	0.694	rs1631552	ENSG00000261839.1	RP1-265C24.8	4.63	4.64e-06	0.000512	0.23	0.21	Cardiac Troponin-T levels;	chr6:28121921	chr6:28136849~28139678:+
THCA	cis	rs62184315	0.832	rs12466395	ENSG00000253559.1	OSGEPL1-AS1	-4.63	4.64e-06	0.000512	-0.25	-0.21	Alcohol dependence (age at onset);	chr2:189915972	chr2:189762704~189765556:+
THCA	cis	rs708224	0.508	rs1239576	ENSG00000274964.1	RP11-817I4.1	4.63	4.64e-06	0.000512	0.23	0.21	Pancreatic cancer;	chr12:32296665	chr12:32339368~32340724:+
THCA	cis	rs5742933	1	rs2289404	ENSG00000253559.1	OSGEPL1-AS1	-4.63	4.64e-06	0.000512	-0.26	-0.21	Ferritin levels;	chr2:189771288	chr2:189762704~189765556:+
THCA	cis	rs9307551	0.584	rs2119420	ENSG00000250334.4	LINC00989	-4.63	4.64e-06	0.000512	-0.25	-0.21	Refractive error;	chr4:79515963	chr4:79492416~79576460:+
THCA	cis	rs4578769	0.55	rs6507452	ENSG00000265939.1	UBE2CP2	4.63	4.64e-06	0.000512	0.24	0.21	Eosinophil percentage of white cells;	chr18:23032275	chr18:22900486~22900995:-
THCA	cis	rs62025270	0.632	rs13379832	ENSG00000259295.5	CSPG4P12	-4.63	4.64e-06	0.000512	-0.35	-0.21	Idiopathic pulmonary fibrosis;	chr15:85572669	chr15:85191438~85213905:+
THCA	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	4.63	4.64e-06	0.000512	0.23	0.21	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
THCA	cis	rs6570726	0.791	rs1935612	ENSG00000270638.1	RP3-466P17.1	4.63	4.64e-06	0.000512	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145735570~145737218:+
THCA	cis	rs8020095	0.8	rs10140569	ENSG00000258561.1	RP11-72M17.1	-4.63	4.64e-06	0.000512	-0.28	-0.21	Depression (quantitative trait);	chr14:66990753	chr14:66212810~66509394:-
THCA	cis	rs8020095	0.848	rs6573742	ENSG00000258561.1	RP11-72M17.1	-4.63	4.64e-06	0.000512	-0.28	-0.21	Depression (quantitative trait);	chr14:66992837	chr14:66212810~66509394:-
THCA	cis	rs72807343	0.661	rs72813738	ENSG00000245317.2	CTC-241N9.1	4.63	4.64e-06	0.000512	0.39	0.21	Alzheimer's disease (late onset);	chr5:179847328	chr5:179859013~179861283:+
THCA	cis	rs5742933	1	rs12619808	ENSG00000253559.1	OSGEPL1-AS1	-4.63	4.64e-06	0.000512	-0.26	-0.21	Ferritin levels;	chr2:189776458	chr2:189762704~189765556:+
THCA	cis	rs17508449	0.547	rs3195954	ENSG00000232450.1	RP4-730K3.3	-4.63	4.64e-06	0.000513	-0.3	-0.21	Leprosy;	chr1:113812032	chr1:113698884~113699631:-
THCA	cis	rs893818	1	rs2028387	ENSG00000261801.4	LOXL1-AS1	4.63	4.65e-06	0.000513	0.24	0.21	Exfoliation glaucoma or exfoliation syndrome;	chr15:73934696	chr15:73908071~73928248:-
THCA	cis	rs17301013	0.861	rs12568655	ENSG00000227373.4	RP11-160H22.5	4.63	4.65e-06	0.000513	0.3	0.21	Systemic lupus erythematosus;	chr1:174465194	chr1:174115300~174160004:-
THCA	cis	rs12612619	0.732	rs13020526	ENSG00000229122.1	AGBL5-IT1	4.63	4.65e-06	0.000513	0.15	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26981782	chr2:27061038~27061815:+
THCA	cis	rs9326248	0.52	rs6589602	ENSG00000280143.1	AP000892.6	4.63	4.65e-06	0.000513	0.26	0.21	Blood protein levels;	chr11:117166349	chr11:117204967~117210292:+
THCA	cis	rs4722166	0.532	rs6963591	ENSG00000179428.2	AC073072.5	4.63	4.65e-06	0.000513	0.23	0.21	Lung cancer;	chr7:22717651	chr7:22725395~22727620:-
THCA	cis	rs4819052	0.918	rs34886433	ENSG00000182586.6	LINC00334	-4.63	4.65e-06	0.000513	-0.26	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45234340~45258730:+
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000229180.5	GS1-124K5.11	4.63	4.65e-06	0.000513	0.16	0.21	Corneal structure;	chr7:66798563	chr7:66526088~66542624:-
THCA	cis	rs5758659	0.652	rs133347	ENSG00000273366.1	CTA-989H11.1	-4.63	4.65e-06	0.000513	-0.25	-0.21	Cognitive function;	chr22:42027641	chr22:42278188~42278846:+
THCA	cis	rs1876905	0.68	rs193281	ENSG00000272356.1	RP5-1112D6.8	4.63	4.65e-06	0.000513	0.21	0.21	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111309203~111313517:+
THCA	cis	rs7308116	0.676	rs10861832	ENSG00000258072.1	RP11-554D14.2	4.63	4.65e-06	0.000513	0.24	0.21	Pelvic organ prolapse (moderate/severe);	chr12:107901658	chr12:107903270~107903948:-
THCA	cis	rs990871	0.512	rs12137231	ENSG00000227207.2	RPL31P12	4.63	4.65e-06	0.000514	0.25	0.21	Subcutaneous adipose tissue;	chr1:72269775	chr1:72301472~72301829:+
THCA	cis	rs8062405	0.728	rs8056890	ENSG00000278665.1	RP11-666O2.4	4.63	4.65e-06	0.000514	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28599241~28601881:-
THCA	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-4.63	4.65e-06	0.000514	-0.22	-0.21	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
THCA	cis	rs72843506	0.722	rs16964352	ENSG00000261033.1	RP11-209D14.2	4.63	4.65e-06	0.000514	0.37	0.21	Schizophrenia;	chr17:20245095	chr17:20008051~20009234:-
THCA	cis	rs793571	0.554	rs12908261	ENSG00000245975.2	RP11-30K9.6	4.63	4.65e-06	0.000514	0.25	0.21	Schizophrenia;	chr15:58701582	chr15:58768072~58770974:-
THCA	cis	rs1048886	0.938	rs6934660	ENSG00000271967.1	RP11-134K13.4	-4.63	4.66e-06	0.000514	-0.22	-0.21	Type 2 diabetes;	chr6:70397722	chr6:70596438~70596980:+
THCA	cis	rs7621331	0.963	rs9842840	ENSG00000273486.1	RP11-731C17.2	4.63	4.66e-06	0.000514	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136017380	chr3:136837338~136839021:-
THCA	cis	rs317689	0.69	rs317656	ENSG00000274979.1	RP11-1143G9.5	-4.63	4.66e-06	0.000514	-0.24	-0.21	Response to diuretic therapy;	chr12:69287321	chr12:69326574~69331882:-
THCA	cis	rs10829156	0.629	rs7069955	ENSG00000240291.1	RP11-499P20.2	4.63	4.66e-06	0.000514	0.19	0.21	Sudden cardiac arrest;	chr10:18688210	chr10:18513115~18545651:-
THCA	cis	rs9880211	0.718	rs28631273	ENSG00000273486.1	RP11-731C17.2	4.63	4.66e-06	0.000514	0.21	0.21	Height;Body mass index;	chr3:136215869	chr3:136837338~136839021:-
THCA	cis	rs1577917	0.959	rs2816822	ENSG00000220563.1	PKMP3	-4.63	4.66e-06	0.000514	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85948574	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.804	rs2786854	ENSG00000220563.1	PKMP3	-4.63	4.66e-06	0.000514	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85959022	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.883	rs2660575	ENSG00000220563.1	PKMP3	-4.63	4.66e-06	0.000514	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85975277	chr6:85659892~85660606:-
THCA	cis	rs12760731	0.582	rs12046110	ENSG00000213057.5	C1orf220	-4.63	4.66e-06	0.000514	-0.24	-0.21	Obesity-related traits;	chr1:178561982	chr1:178542752~178548889:+
THCA	cis	rs12931792	0.846	rs9924308	ENSG00000273724.1	RP11-347C12.12	-4.63	4.66e-06	0.000514	-0.22	-0.21	Tonsillectomy;	chr16:30143419	chr16:30336400~30343336:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000272831.1	RP11-792A8.4	4.63	4.66e-06	0.000514	0.13	0.21	Aortic root size;	chr7:65832759	chr7:66739829~66740385:-
THCA	cis	rs875971	0.522	rs10807697	ENSG00000272831.1	RP11-792A8.4	4.63	4.66e-06	0.000514	0.13	0.21	Aortic root size;	chr7:65951183	chr7:66739829~66740385:-
THCA	cis	rs4218	0.871	rs2414621	ENSG00000277144.1	RP11-59H7.4	-4.63	4.66e-06	0.000514	-0.29	-0.21	Social communication problems;	chr15:59142129	chr15:59115547~59116089:-
THCA	cis	rs516805	0.52	rs474440	ENSG00000279453.1	RP3-425C14.4	-4.63	4.66e-06	0.000514	-0.17	-0.21	Lymphocyte counts;	chr6:122457954	chr6:122436789~122439223:-
THCA	cis	rs516805	0.52	rs4945703	ENSG00000279453.1	RP3-425C14.4	-4.63	4.66e-06	0.000514	-0.17	-0.21	Lymphocyte counts;	chr6:122460520	chr6:122436789~122439223:-
THCA	cis	rs2033711	0.755	rs4801587	ENSG00000269054.1	CTD-2619J13.3	-4.63	4.66e-06	0.000515	-0.17	-0.21	Uric acid clearance;	chr19:58425312	chr19:58362585~58366591:+
THCA	cis	rs17301013	0.829	rs2006197	ENSG00000227373.4	RP11-160H22.5	4.63	4.67e-06	0.000515	0.3	0.21	Systemic lupus erythematosus;	chr1:174432825	chr1:174115300~174160004:-
THCA	cis	rs1923539	0.549	rs2250135	ENSG00000242600.5	MBL1P	-4.63	4.67e-06	0.000515	-0.19	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79907567	chr10:79904898~79950336:+
THCA	cis	rs13178541	0.81	rs11743994	ENSG00000250378.1	RP11-119J18.1	-4.63	4.67e-06	0.000515	-0.25	-0.21	IgG glycosylation;	chr5:135741104	chr5:135812667~135826582:+
THCA	cis	rs2439831	0.681	rs11858152	ENSG00000205771.5	CATSPER2P1	-4.63	4.67e-06	0.000515	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43341998	chr15:43726918~43747094:-
THCA	cis	rs6012564	1	rs2295714	ENSG00000230758.1	SNAP23P	4.63	4.67e-06	0.000515	0.25	0.21	Anger;	chr20:49123277	chr20:49038357~49038602:-
THCA	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	4.63	4.67e-06	0.000515	0.26	0.21	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
THCA	cis	rs34929064	0.624	rs2905326	ENSG00000179428.2	AC073072.5	4.63	4.67e-06	0.000515	0.24	0.21	Major depression and alcohol dependence;	chr7:22674338	chr7:22725395~22727620:-
THCA	cis	rs7474896	0.515	rs2738203	ENSG00000263064.2	RP11-291L22.7	-4.63	4.67e-06	0.000516	-0.29	-0.21	Obesity (extreme);	chr10:37988668	chr10:38448689~38448949:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-4.63	4.67e-06	0.000516	-0.24	-0.21	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-4.63	4.67e-06	0.000516	-0.24	-0.21	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
THCA	cis	rs12541437	1	rs3020159	ENSG00000253327.2	RAD21-AS1	-4.63	4.68e-06	0.000516	-0.22	-0.21	Gut microbiome composition (winter);	chr8:116909416	chr8:116874424~116876868:+
THCA	cis	rs793571	0.628	rs28412567	ENSG00000259250.1	RP11-50C13.1	-4.63	4.68e-06	0.000516	-0.22	-0.21	Schizophrenia;	chr15:58810014	chr15:58587507~58591676:+
THCA	cis	rs793571	0.628	rs28876251	ENSG00000259250.1	RP11-50C13.1	-4.63	4.68e-06	0.000516	-0.22	-0.21	Schizophrenia;	chr15:58819121	chr15:58587507~58591676:+
THCA	cis	rs4950322	0.542	rs28381210	ENSG00000180867.10	PDIA3P1	4.63	4.68e-06	0.000516	0.21	0.21	Protein quantitative trait loci;	chr1:147201925	chr1:147178113~147179622:+
THCA	cis	rs7141336	0.791	rs17721241	ENSG00000258884.1	CTD-3035D6.2	4.63	4.68e-06	0.000516	0.28	0.21	Anxiety disorder;	chr14:90733600	chr14:90822365~90828128:-
THCA	cis	rs58235267	0.553	rs1025132	ENSG00000242412.1	DBIL5P2	-4.63	4.68e-06	0.000516	-0.23	-0.21	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:63133504	chr2:63117851~63119542:-
THCA	cis	rs67478160	0.643	rs12878868	ENSG00000269910.1	RP11-73M18.10	4.63	4.68e-06	0.000516	0.18	0.21	Schizophrenia;	chr14:103767388	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs11626377	ENSG00000269910.1	RP11-73M18.10	4.63	4.68e-06	0.000516	0.18	0.21	Schizophrenia;	chr14:103768020	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs876002	ENSG00000269910.1	RP11-73M18.10	4.63	4.68e-06	0.000516	0.18	0.21	Schizophrenia;	chr14:103773360	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.619	rs11628481	ENSG00000269910.1	RP11-73M18.10	4.63	4.68e-06	0.000516	0.18	0.21	Schizophrenia;	chr14:103775162	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.595	rs8022783	ENSG00000269910.1	RP11-73M18.10	4.63	4.68e-06	0.000516	0.18	0.21	Schizophrenia;	chr14:103779236	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.608	rs11160760	ENSG00000269910.1	RP11-73M18.10	4.63	4.68e-06	0.000516	0.18	0.21	Schizophrenia;	chr14:103782601	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.619	rs11160761	ENSG00000269910.1	RP11-73M18.10	4.63	4.68e-06	0.000516	0.18	0.21	Schizophrenia;	chr14:103788519	chr14:103694516~103695050:-
THCA	cis	rs763121	0.853	rs6519119	ENSG00000235209.1	CTA-150C2.13	4.63	4.68e-06	0.000516	0.28	0.21	Menopause (age at onset);	chr22:38593002	chr22:38921227~38924708:+
THCA	cis	rs7621331	0.963	rs1523595	ENSG00000273486.1	RP11-731C17.2	4.63	4.68e-06	0.000516	0.2	0.21	Waist circumference adjusted for body mass index;	chr3:136021305	chr3:136837338~136839021:-
THCA	cis	rs7572644	0.782	rs10175826	ENSG00000223522.1	AC093690.1	4.63	4.68e-06	0.000516	0.25	0.21	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28038517	chr2:28307691~28310459:-
THCA	cis	rs7551222	0.68	rs2125855	ENSG00000240219.1	RP11-430C7.5	4.63	4.68e-06	0.000516	0.22	0.21	Schizophrenia;	chr1:204577819	chr1:204626775~204629712:+
THCA	cis	rs7179456	0.547	rs6494035	ENSG00000245975.2	RP11-30K9.6	4.63	4.68e-06	0.000516	0.2	0.21	Asperger disorder;	chr15:58723689	chr15:58768072~58770974:-
THCA	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	4.63	4.68e-06	0.000516	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
THCA	cis	rs950169	0.734	rs67119537	ENSG00000259570.1	RP11-671M22.4	4.63	4.68e-06	0.000517	0.27	0.21	Schizophrenia;	chr15:84395671	chr15:84394512~84395514:+
THCA	cis	rs7208859	0.614	rs216474	ENSG00000263603.1	CTD-2349P21.5	4.63	4.68e-06	0.000517	0.36	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30729469~30731202:+
THCA	cis	rs12755164	0.771	rs12401308	ENSG00000223479.3	RP4-788P17.1	4.63	4.69e-06	0.000517	0.23	0.21	Schizophrenia;	chr1:72869984	chr1:73635216~73715214:+
THCA	cis	rs6988985	0.589	rs57219141	ENSG00000247317.3	RP11-273G15.2	-4.63	4.69e-06	0.000517	-0.23	-0.21	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142906203	chr8:142981738~143018437:-
THCA	cis	rs9875589	0.509	rs1906538	ENSG00000228242.5	AC093495.4	4.63	4.69e-06	0.000517	0.12	0.21	Ovarian reserve;	chr3:13972669	chr3:14144637~14165978:+
THCA	cis	rs2803122	0.871	rs10811164	ENSG00000273226.1	RP11-513M16.8	-4.63	4.69e-06	0.000517	-0.19	-0.21	Pulse pressure;	chr9:19284910	chr9:19375451~19375996:+
THCA	cis	rs801193	1	rs10252765	ENSG00000273142.1	RP11-458F8.4	-4.63	4.69e-06	0.000517	-0.17	-0.21	Aortic root size;	chr7:66763745	chr7:66902857~66906297:+
THCA	cis	rs17711722	0.701	rs781143	ENSG00000272831.1	RP11-792A8.4	4.63	4.69e-06	0.000517	0.13	0.21	Calcium levels;	chr7:65974892	chr7:66739829~66740385:-
THCA	cis	rs11148252	0.904	rs7321964	ENSG00000273784.3	RP11-78J21.7	-4.63	4.69e-06	0.000517	-0.22	-0.21	Lewy body disease;	chr13:52466687	chr13:52600042~52642542:+
THCA	cis	rs800160	1	rs800142	ENSG00000199550.1	Y_RNA	4.63	4.69e-06	0.000517	0.31	0.21	Bacteremia;	chr11:2363841	chr11:2372638~2372750:+
THCA	cis	rs67478160	0.643	rs11628332	ENSG00000269910.1	RP11-73M18.10	4.63	4.69e-06	0.000517	0.18	0.21	Schizophrenia;	chr14:103774804	chr14:103694516~103695050:-
THCA	cis	rs2243480	1	rs1723267	ENSG00000232559.3	GS1-124K5.12	4.63	4.69e-06	0.000518	0.31	0.21	Diabetic kidney disease;	chr7:66008327	chr7:66554588~66576923:-
THCA	cis	rs6832769	1	rs6851838	ENSG00000272969.1	RP11-528I4.2	-4.63	4.69e-06	0.000518	-0.24	-0.21	Personality dimensions;	chr4:55554580	chr4:55547112~55547889:+
THCA	cis	rs6832769	1	rs10034433	ENSG00000272969.1	RP11-528I4.2	-4.63	4.69e-06	0.000518	-0.24	-0.21	Personality dimensions;	chr4:55555009	chr4:55547112~55547889:+
THCA	cis	rs62025270	0.547	rs338540	ENSG00000259295.5	CSPG4P12	4.63	4.69e-06	0.000518	0.3	0.21	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85191438~85213905:+
THCA	cis	rs79040073	0.516	rs4338740	ENSG00000259531.2	RP11-295H24.3	4.63	4.7e-06	0.000518	0.26	0.21	Lung cancer in ever smokers;	chr15:49443100	chr15:49365124~49366685:-
THCA	cis	rs11992162	0.905	rs7836953	ENSG00000206014.6	OR7E161P	-4.63	4.7e-06	0.000518	-0.23	-0.21	Monocyte count;	chr8:11978203	chr8:11928597~11929563:-
THCA	cis	rs7394190	0.748	rs2306327	ENSG00000271848.1	RP11-464F9.21	-4.63	4.7e-06	0.000518	-0.29	-0.21	Incident atrial fibrillation;	chr10:73814020	chr10:73654039~73674719:+
THCA	cis	rs6009824	0.545	rs5770659	ENSG00000188511.11	C22orf34	4.63	4.7e-06	0.000518	0.26	0.21	Natriuretic peptide levels;	chr22:49690204	chr22:49414524~49657542:-
THCA	cis	rs12612619	0.732	rs893790	ENSG00000229122.1	AGBL5-IT1	-4.63	4.7e-06	0.000518	-0.15	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26978989	chr2:27061038~27061815:+
THCA	cis	rs2439831	1	rs2467739	ENSG00000166763.7	STRCP1	4.63	4.7e-06	0.000518	0.28	0.21	Lung cancer in ever smokers;	chr15:43447998	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs28666488	ENSG00000166763.7	STRCP1	4.63	4.7e-06	0.000518	0.28	0.21	Lung cancer in ever smokers;	chr15:43448892	chr15:43699488~43718184:-
THCA	cis	rs2439831	1	rs2245790	ENSG00000166763.7	STRCP1	4.63	4.7e-06	0.000518	0.28	0.21	Lung cancer in ever smokers;	chr15:43452259	chr15:43699488~43718184:-
THCA	cis	rs4948275	0.693	rs2814027	ENSG00000237233.2	TMEM26-AS1	4.63	4.7e-06	0.000518	0.27	0.21	Night sleep phenotypes;	chr10:61582354	chr10:61452639~61481956:+
THCA	cis	rs800160	0.777	rs962903	ENSG00000199550.1	Y_RNA	4.63	4.7e-06	0.000518	0.33	0.21	Bacteremia;	chr11:2331111	chr11:2372638~2372750:+
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000232559.3	GS1-124K5.12	4.63	4.7e-06	0.000518	0.31	0.21	Diabetic kidney disease;	chr7:65892097	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs35391607	ENSG00000232559.3	GS1-124K5.12	4.63	4.7e-06	0.000518	0.31	0.21	Diabetic kidney disease;	chr7:65895842	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs13220979	ENSG00000232559.3	GS1-124K5.12	4.63	4.7e-06	0.000518	0.31	0.21	Diabetic kidney disease;	chr7:65898217	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs34974928	ENSG00000232559.3	GS1-124K5.12	4.63	4.7e-06	0.000518	0.31	0.21	Diabetic kidney disease;	chr7:65899019	chr7:66554588~66576923:-
THCA	cis	rs7818382	1	rs7818382	ENSG00000253528.2	RP11-347C18.4	4.63	4.7e-06	0.000518	0.23	0.21	Alzheimer's disease (late onset);	chr8:95041772	chr8:94974573~94974853:-
THCA	cis	rs2732480	0.577	rs1489109	ENSG00000273765.1	RP11-370I10.11	4.63	4.7e-06	0.000518	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.577	rs1489108	ENSG00000273765.1	RP11-370I10.11	4.63	4.7e-06	0.000518	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48360920~48361377:+
THCA	cis	rs9818758	0.607	rs80170003	ENSG00000270441.1	RP11-694I15.7	4.63	4.7e-06	0.000518	0.31	0.21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48914207	chr3:49140086~49160851:-
THCA	cis	rs7520050	0.966	rs12049588	ENSG00000234329.1	RP11-767N6.2	-4.63	4.7e-06	0.000518	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs12021587	ENSG00000234329.1	RP11-767N6.2	-4.63	4.7e-06	0.000518	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45651039~45651826:-
THCA	cis	rs7824557	0.933	rs6601576	ENSG00000154316.13	TDH	4.63	4.7e-06	0.000519	0.15	0.21	Retinal vascular caliber;	chr8:11242766	chr8:11339637~11368452:+
THCA	cis	rs35740288	0.77	rs17635450	ENSG00000259295.5	CSPG4P12	-4.63	4.7e-06	0.000519	-0.33	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85655818	chr15:85191438~85213905:+
THCA	cis	rs7617480	0.648	rs6806356	ENSG00000228638.1	FCF1P2	-4.63	4.71e-06	0.000519	-0.26	-0.21	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48690203	chr3:48290793~48291375:-
THCA	cis	rs1003719	0.688	rs2835660	ENSG00000230366.8	DSCR9	4.63	4.71e-06	0.000519	0.22	0.21	Eye color traits;	chr21:37196581	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.688	rs2835662	ENSG00000230366.8	DSCR9	4.63	4.71e-06	0.000519	0.22	0.21	Eye color traits;	chr21:37196666	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs1034357	ENSG00000230366.8	DSCR9	4.63	4.71e-06	0.000519	0.22	0.21	Eye color traits;	chr21:37199181	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs2835664	ENSG00000230366.8	DSCR9	4.63	4.71e-06	0.000519	0.22	0.21	Eye color traits;	chr21:37201128	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.646	rs2032063	ENSG00000230366.8	DSCR9	4.63	4.71e-06	0.000519	0.22	0.21	Eye color traits;	chr21:37204356	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.646	rs7276711	ENSG00000230366.8	DSCR9	4.63	4.71e-06	0.000519	0.22	0.21	Eye color traits;	chr21:37205888	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs7276569	ENSG00000230366.8	DSCR9	4.63	4.71e-06	0.000519	0.22	0.21	Eye color traits;	chr21:37205906	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2212742	ENSG00000230366.8	DSCR9	4.63	4.71e-06	0.000519	0.22	0.21	Eye color traits;	chr21:37206384	chr21:37208503~37221736:+
THCA	cis	rs587080	0.654	rs595366	ENSG00000254614.2	AP003068.23	-4.63	4.71e-06	0.000519	-0.29	-0.21	Plateletcrit;	chr11:65429460	chr11:65177606~65181834:-
THCA	cis	rs2243480	1	rs437889	ENSG00000164669.11	INTS4P1	4.63	4.71e-06	0.000519	0.41	0.21	Diabetic kidney disease;	chr7:66044247	chr7:65141225~65234216:+
THCA	cis	rs9880211	0.613	rs9834966	ENSG00000273486.1	RP11-731C17.2	4.63	4.71e-06	0.000519	0.21	0.21	Height;Body mass index;	chr3:136089778	chr3:136837338~136839021:-
THCA	cis	rs7772486	0.764	rs7762562	ENSG00000270638.1	RP3-466P17.1	4.63	4.71e-06	0.000519	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145735570~145737218:+
THCA	cis	rs2742234	0.666	rs715106	ENSG00000273008.1	RP11-351D16.3	-4.63	4.71e-06	0.000519	-0.2	-0.21	Hirschsprung disease;	chr10:43121303	chr10:43136824~43138334:-
THCA	cis	rs7520050	0.966	rs11810993	ENSG00000234329.1	RP11-767N6.2	-4.63	4.71e-06	0.000519	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.898	rs34175029	ENSG00000234329.1	RP11-767N6.2	-4.63	4.71e-06	0.000519	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs2275426	ENSG00000234329.1	RP11-767N6.2	-4.63	4.71e-06	0.000519	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45651039~45651826:-
THCA	cis	rs115344852	0.575	rs2531820	ENSG00000216901.1	AL022393.7	4.63	4.71e-06	0.000519	0.3	0.21	Epithelial ovarian cancer;	chr6:28488942	chr6:28176188~28176674:+
THCA	cis	rs12681288	0.821	rs12547181	ENSG00000260721.1	AF067845.1	4.63	4.71e-06	0.000519	0.27	0.21	Schizophrenia;	chr8:1085601	chr8:1368642~1369833:-
THCA	cis	rs2975734	1	rs2975734	ENSG00000261451.1	RP11-981G7.1	-4.63	4.71e-06	0.000519	-0.26	-0.21	Chronotype;Morning vs. evening chronotype;	chr8:10232587	chr8:10433672~10438312:+
THCA	cis	rs7520050	1	rs12143096	ENSG00000234329.1	RP11-767N6.2	-4.63	4.71e-06	0.00052	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:45651039~45651826:-
THCA	cis	rs8031584	0.958	rs7168641	ENSG00000178081.11	ULK4P3	4.63	4.71e-06	0.00052	0.27	0.21	Huntington's disease progression;	chr15:30943249	chr15:30103720~30131757:+
THCA	cis	rs5758659	0.904	rs5758653	ENSG00000227370.1	RP4-669P10.19	-4.63	4.71e-06	0.00052	-0.19	-0.21	Cognitive function;	chr22:42217479	chr22:42132543~42132998:+
THCA	cis	rs494453	0.885	rs496296	ENSG00000227811.2	FAM212B-AS1	-4.63	4.72e-06	0.00052	-0.26	-0.21	Osteoporosis-related phenotypes;	chr1:111682034	chr1:111739841~111747798:+
THCA	cis	rs1923243	0.71	rs10789358	ENSG00000223479.3	RP4-788P17.1	-4.63	4.72e-06	0.00052	-0.23	-0.21	Migraine;	chr1:73178151	chr1:73635216~73715214:+
THCA	cis	rs78487399	0.808	rs13413856	ENSG00000234936.1	AC010883.5	4.63	4.72e-06	0.00052	0.29	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43537686	chr2:43229573~43233394:+
THCA	cis	rs10761482	1	rs1340652	ENSG00000254271.1	RP11-131N11.4	-4.63	4.72e-06	0.00052	-0.28	-0.21	Schizophrenia;	chr10:60318445	chr10:60734342~60741828:+
THCA	cis	rs12446956	0.568	rs9788947	ENSG00000280092.1	AC002044.3	4.63	4.72e-06	0.00052	0.31	0.21	Major depressive disorder;	chr16:73443226	chr16:73005601~73006141:-
THCA	cis	rs8062405	0.824	rs28698667	ENSG00000261766.1	RP11-22P6.2	-4.63	4.72e-06	0.00052	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28862166~28863340:-
THCA	cis	rs7614311	0.555	rs3774715	ENSG00000271843.1	RP11-245J9.5	-4.63	4.72e-06	0.00052	-0.37	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63934200	chr3:64008082~64008692:-
THCA	cis	rs7809615	0.901	rs11555142	ENSG00000244219.5	GS1-259H13.2	-4.63	4.72e-06	0.00052	-0.38	-0.21	Blood metabolite ratios;	chr7:99434970	chr7:99598066~99610813:+
THCA	cis	rs763121	0.853	rs35565791	ENSG00000235209.1	CTA-150C2.13	4.63	4.72e-06	0.00052	0.27	0.21	Menopause (age at onset);	chr22:38667006	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs35522482	ENSG00000235209.1	CTA-150C2.13	4.63	4.72e-06	0.00052	0.27	0.21	Menopause (age at onset);	chr22:38667010	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2072796	ENSG00000235209.1	CTA-150C2.13	4.63	4.72e-06	0.00052	0.27	0.21	Menopause (age at onset);	chr22:38668225	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2281019	ENSG00000235209.1	CTA-150C2.13	4.63	4.72e-06	0.00052	0.27	0.21	Menopause (age at onset);	chr22:38668373	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2281020	ENSG00000235209.1	CTA-150C2.13	4.63	4.72e-06	0.00052	0.27	0.21	Menopause (age at onset);	chr22:38668401	chr22:38921227~38924708:+
THCA	cis	rs7264396	0.943	rs6060448	ENSG00000088340.14	FER1L4	-4.63	4.72e-06	0.00052	-0.19	-0.21	Total cholesterol levels;	chr20:35524364	chr20:35558737~35607562:-
THCA	cis	rs17095355	1	rs7068482	ENSG00000203876.8	ADD3-AS1	-4.63	4.72e-06	0.00052	-0.23	-0.21	Biliary atresia;	chr10:109969745	chr10:109940104~110008381:-
THCA	cis	rs7520050	0.897	rs4440807	ENSG00000234329.1	RP11-767N6.2	-4.63	4.72e-06	0.00052	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:45651039~45651826:-
THCA	cis	rs9863	0.828	rs11057409	ENSG00000269997.1	RP11-214K3.21	4.63	4.72e-06	0.00052	0.26	0.21	White blood cell count;	chr12:123994784	chr12:123966077~123966629:-
THCA	cis	rs10911902	0.561	rs1919199	ENSG00000229739.2	RP11-295K2.3	-4.63	4.72e-06	0.00052	-0.34	-0.21	Schizophrenia;	chr1:186300752	chr1:186435161~186470291:+
THCA	cis	rs3742264	0.925	rs1087	ENSG00000235903.6	CPB2-AS1	4.63	4.72e-06	0.00052	0.27	0.21	Blood protein levels;	chr13:46053304	chr13:46052806~46113332:+
THCA	cis	rs11992162	0.967	rs4840601	ENSG00000254948.1	OR7E158P	-4.63	4.72e-06	0.00052	-0.26	-0.21	Monocyte count;	chr8:11971221	chr8:11919900~11920809:-
THCA	cis	rs11722228	1	rs6825187	ENSG00000261490.1	RP11-448G15.3	-4.63	4.72e-06	0.00052	-0.14	-0.21	Urate levels;Serum uric acid levels;Gout;	chr4:9913701	chr4:10068089~10073019:-
THCA	cis	rs7208859	0.673	rs56846352	ENSG00000280069.1	CTD-2349P21.3	-4.63	4.72e-06	0.00052	-0.3	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30738182~30740275:+
THCA	cis	rs7829975	0.593	rs2979241	ENSG00000233609.3	RP11-62H7.2	4.63	4.72e-06	0.000521	0.2	0.21	Mood instability;	chr8:8445843	chr8:8961200~8979025:+
THCA	cis	rs4639966	0.836	rs11217014	ENSG00000255422.1	AP002954.4	4.63	4.72e-06	0.000521	0.25	0.21	Systemic lupus erythematosus;	chr11:118755577	chr11:118704607~118750263:+
THCA	cis	rs72843506	0.722	rs9908032	ENSG00000231258.2	ZSWIM5P2	4.63	4.73e-06	0.000521	0.3	0.21	Schizophrenia;	chr17:20204871	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.722	rs12051550	ENSG00000231258.2	ZSWIM5P2	4.63	4.73e-06	0.000521	0.3	0.21	Schizophrenia;	chr17:20226233	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.722	rs75226250	ENSG00000231258.2	ZSWIM5P2	4.63	4.73e-06	0.000521	0.3	0.21	Schizophrenia;	chr17:20229004	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.722	rs9901484	ENSG00000231258.2	ZSWIM5P2	4.63	4.73e-06	0.000521	0.3	0.21	Schizophrenia;	chr17:20229581	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.722	rs78477504	ENSG00000231258.2	ZSWIM5P2	4.63	4.73e-06	0.000521	0.3	0.21	Schizophrenia;	chr17:20235034	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.656	rs16959946	ENSG00000231258.2	ZSWIM5P2	4.63	4.73e-06	0.000521	0.3	0.21	Schizophrenia;	chr17:20269134	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.722	rs76309839	ENSG00000231258.2	ZSWIM5P2	4.63	4.73e-06	0.000521	0.3	0.21	Schizophrenia;	chr17:20272147	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.652	rs28550747	ENSG00000231258.2	ZSWIM5P2	4.63	4.73e-06	0.000521	0.3	0.21	Schizophrenia;	chr17:20274999	chr17:20583758~20591180:-
THCA	cis	rs2787702	1	rs2787714	ENSG00000237233.2	TMEM26-AS1	-4.63	4.73e-06	0.000521	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61560071	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2606091	ENSG00000237233.2	TMEM26-AS1	-4.63	4.73e-06	0.000521	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61560316	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs1378885	ENSG00000237233.2	TMEM26-AS1	-4.63	4.73e-06	0.000521	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61560617	chr10:61452639~61481956:+
THCA	cis	rs2787702	0.963	rs1378886	ENSG00000237233.2	TMEM26-AS1	-4.63	4.73e-06	0.000521	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61561543	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2606093	ENSG00000237233.2	TMEM26-AS1	-4.63	4.73e-06	0.000521	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61561850	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2650733	ENSG00000237233.2	TMEM26-AS1	-4.63	4.73e-06	0.000521	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr10:61562517	chr10:61452639~61481956:+
THCA	cis	rs6728642	0.908	rs7588921	ENSG00000230606.9	AC159540.1	4.63	4.73e-06	0.000521	0.28	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97352698	chr2:97416165~97433527:-
THCA	cis	rs988712	0.672	rs12419948	ENSG00000245573.6	BDNF-AS	-4.63	4.73e-06	0.000521	-0.21	-0.21	Obesity;	chr11:27645437	chr11:27506838~27698174:+
THCA	cis	rs988712	0.672	rs925947	ENSG00000245573.6	BDNF-AS	-4.63	4.73e-06	0.000521	-0.21	-0.21	Obesity;	chr11:27645820	chr11:27506838~27698174:+
THCA	cis	rs988712	0.705	rs16917204	ENSG00000245573.6	BDNF-AS	-4.63	4.73e-06	0.000521	-0.21	-0.21	Obesity;	chr11:27646808	chr11:27506838~27698174:+
THCA	cis	rs988712	0.705	rs10501087	ENSG00000245573.6	BDNF-AS	4.63	4.73e-06	0.000521	0.21	0.21	Obesity;	chr11:27648561	chr11:27506838~27698174:+
THCA	cis	rs988712	0.705	rs4923463	ENSG00000245573.6	BDNF-AS	-4.63	4.73e-06	0.000521	-0.21	-0.21	Obesity;	chr11:27650953	chr11:27506838~27698174:+
THCA	cis	rs17404153	0.599	rs72990500	ENSG00000248724.5	NPHP3-AS1	-4.63	4.73e-06	0.000521	-0.31	-0.21	LDL cholesterol;HDL cholesterol;	chr3:132434768	chr3:132721750~132874223:+
THCA	cis	rs9307551	0.697	rs4975052	ENSG00000250334.4	LINC00989	-4.63	4.73e-06	0.000521	-0.28	-0.21	Refractive error;	chr4:79505054	chr4:79492416~79576460:+
THCA	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	4.63	4.74e-06	0.000522	0.17	0.21	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
THCA	cis	rs2243480	1	rs160644	ENSG00000164669.11	INTS4P1	4.63	4.74e-06	0.000522	0.39	0.21	Diabetic kidney disease;	chr7:66093199	chr7:65141225~65234216:+
THCA	cis	rs6088580	0.609	rs6059844	ENSG00000276073.1	RP5-1125A11.7	-4.63	4.74e-06	0.000522	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34448677	chr20:33985617~33988989:-
THCA	cis	rs1030877	0.515	rs2576742	ENSG00000235319.1	AC012360.4	-4.63	4.74e-06	0.000522	-0.27	-0.21	Obesity-related traits;	chr2:105282365	chr2:105324210~105330529:+
THCA	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	4.63	4.74e-06	0.000522	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
THCA	cis	rs654950	1	rs621680	ENSG00000230638.4	RP11-486B10.4	4.63	4.74e-06	0.000522	0.23	0.21	Airway imaging phenotypes;	chr1:41518913	chr1:41542069~41544310:+
THCA	cis	rs6750795	0.507	rs1667320	ENSG00000223198.1	RNU2-22P	-4.63	4.74e-06	0.000522	-0.26	-0.21	Height;	chr2:231553603	chr2:231501990~231502201:-
THCA	cis	rs6570726	0.934	rs9484995	ENSG00000270638.1	RP3-466P17.1	-4.63	4.74e-06	0.000522	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145459978	chr6:145735570~145737218:+
THCA	cis	rs6860806	0.531	rs274556	ENSG00000237714.1	P4HA2-AS1	-4.63	4.74e-06	0.000522	-0.29	-0.21	Breast cancer;	chr5:132386383	chr5:132184876~132192808:+
THCA	cis	rs3820928	0.874	rs2177593	ENSG00000212391.1	SNORA48	-4.63	4.74e-06	0.000522	-0.23	-0.21	Pulmonary function;	chr2:226969153	chr2:226968989~226969122:-
THCA	cis	rs7403037	0.617	rs13329120	ENSG00000259905.4	PWRN1	4.63	4.74e-06	0.000522	0.27	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24597526	chr15:24493137~24652130:+
THCA	cis	rs7914558	0.966	rs943035	ENSG00000236937.2	PTGES3P4	4.63	4.74e-06	0.000522	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103079395	chr10:102845595~102845950:+
THCA	cis	rs7914558	0.966	rs7921574	ENSG00000236937.2	PTGES3P4	4.63	4.74e-06	0.000522	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103081213	chr10:102845595~102845950:+
THCA	cis	rs6832769	0.961	rs10026692	ENSG00000272969.1	RP11-528I4.2	-4.63	4.74e-06	0.000522	-0.24	-0.21	Personality dimensions;	chr4:55586539	chr4:55547112~55547889:+
THCA	cis	rs9902453	0.791	rs3115100	ENSG00000263370.1	RP11-68I3.5	4.63	4.74e-06	0.000522	0.27	0.21	Coffee consumption (cups per day);	chr17:29718726	chr17:29639627~29640825:+
THCA	cis	rs1979679	0.918	rs11049513	ENSG00000247934.4	RP11-967K21.1	-4.63	4.74e-06	0.000522	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28297218	chr12:28163298~28190738:-
THCA	cis	rs440932	0.747	rs330946	ENSG00000248538.5	RP11-10A14.5	-4.63	4.74e-06	0.000523	-0.26	-0.21	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:9189011~9202854:+
THCA	cis	rs2239547	0.522	rs2581797	ENSG00000242142.1	SERBP1P3	-4.63	4.75e-06	0.000523	-0.26	-0.21	Schizophrenia;	chr3:52938452	chr3:53064283~53065091:-
THCA	cis	rs375066	0.935	rs406968	ENSG00000278917.1	RP11-15A1.4	-4.63	4.75e-06	0.000523	-0.17	-0.21	Breast cancer;	chr19:43914191	chr19:43891233~43895411:+
THCA	cis	rs442309	0.687	rs10822057	ENSG00000238280.1	RP11-436D10.3	-4.63	4.75e-06	0.000523	-0.26	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62760391	chr10:62793562~62805887:-
THCA	cis	rs4646450	0.735	rs28495024	ENSG00000244219.5	GS1-259H13.2	-4.63	4.75e-06	0.000523	-0.27	-0.21	Blood metabolite levels;	chr7:99419060	chr7:99598066~99610813:+
THCA	cis	rs9847710	0.967	rs2564934	ENSG00000242142.1	SERBP1P3	4.63	4.75e-06	0.000523	0.25	0.21	Ulcerative colitis;	chr3:52990564	chr3:53064283~53065091:-
THCA	cis	rs9847710	0.901	rs2564937	ENSG00000242142.1	SERBP1P3	4.63	4.75e-06	0.000523	0.25	0.21	Ulcerative colitis;	chr3:52991843	chr3:53064283~53065091:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000272831.1	RP11-792A8.4	4.63	4.75e-06	0.000523	0.13	0.21	Calcium levels;	chr7:65941231	chr7:66739829~66740385:-
THCA	cis	rs10256972	0.721	rs2030959	ENSG00000225146.1	AC073957.15	4.63	4.75e-06	0.000523	0.22	0.21	Endometriosis;Longevity;	chr7:1036270	chr7:1029025~1043891:+
THCA	cis	rs734999	0.967	rs7544646	ENSG00000225931.3	RP3-395M20.7	4.63	4.75e-06	0.000524	0.25	0.21	Ulcerative colitis;	chr1:2565210	chr1:2566410~2569888:+
THCA	cis	rs12935418	0.673	rs2549888	ENSG00000278985.1	RP11-303E16.9	-4.63	4.75e-06	0.000524	-0.23	-0.21	Mean corpuscular volume;	chr16:81028425	chr16:80982319~80984094:-
THCA	cis	rs1577917	0.816	rs1838952	ENSG00000220563.1	PKMP3	-4.63	4.75e-06	0.000524	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85891426	chr6:85659892~85660606:-
THCA	cis	rs7246760	0.867	rs7259075	ENSG00000267106.4	ZNF561-AS1	4.63	4.76e-06	0.000524	0.4	0.21	Pursuit maintenance gain;	chr19:9668100	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs35416342	ENSG00000267106.4	ZNF561-AS1	4.63	4.76e-06	0.000524	0.4	0.21	Pursuit maintenance gain;	chr19:9668382	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs12461215	ENSG00000267106.4	ZNF561-AS1	4.63	4.76e-06	0.000524	0.4	0.21	Pursuit maintenance gain;	chr19:9671785	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs1115825	ENSG00000267106.4	ZNF561-AS1	4.63	4.76e-06	0.000524	0.4	0.21	Pursuit maintenance gain;	chr19:9675445	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs59616842	ENSG00000267106.4	ZNF561-AS1	4.63	4.76e-06	0.000524	0.4	0.21	Pursuit maintenance gain;	chr19:9681569	chr19:9621291~9645896:+
THCA	cis	rs1866631	0.565	rs3769161	ENSG00000238133.5	MLK7-AS1	4.63	4.76e-06	0.000524	0.28	0.21	Lung cancer in ever smokers;	chr2:173201747	chr2:173166446~173282036:-
THCA	cis	rs6088590	1	rs3787222	ENSG00000269202.1	RP4-614O4.12	-4.63	4.76e-06	0.000524	-0.19	-0.21	Coronary artery disease;	chr20:34745236	chr20:35201747~35203288:-
THCA	cis	rs10208649	1	rs6545367	ENSG00000233266.1	HMGB1P31	4.63	4.76e-06	0.000524	0.49	0.21	Body mass index;	chr2:53810148	chr2:54051334~54051760:+
THCA	cis	rs17301013	0.861	rs1793319	ENSG00000227373.4	RP11-160H22.5	4.63	4.76e-06	0.000524	0.29	0.21	Systemic lupus erythematosus;	chr1:174795470	chr1:174115300~174160004:-
THCA	cis	rs12681288	0.748	rs2123054	ENSG00000260721.1	AF067845.1	4.63	4.76e-06	0.000524	0.26	0.21	Schizophrenia;	chr8:1078227	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.782	rs12549337	ENSG00000260721.1	AF067845.1	4.63	4.76e-06	0.000524	0.27	0.21	Schizophrenia;	chr8:1080187	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.782	rs6559213	ENSG00000260721.1	AF067845.1	4.63	4.76e-06	0.000524	0.27	0.21	Schizophrenia;	chr8:1080923	chr8:1368642~1369833:-
THCA	cis	rs4072705	0.615	rs7851737	ENSG00000224020.1	MIR181A2HG	4.63	4.76e-06	0.000525	0.19	0.21	Menarche (age at onset);	chr9:124485652	chr9:124658467~124698631:+
THCA	cis	rs4072705	0.586	rs7023736	ENSG00000224020.1	MIR181A2HG	-4.63	4.76e-06	0.000525	-0.19	-0.21	Menarche (age at onset);	chr9:124485667	chr9:124658467~124698631:+
THCA	cis	rs12935418	0.672	rs12446304	ENSG00000278985.1	RP11-303E16.9	4.63	4.77e-06	0.000525	0.23	0.21	Mean corpuscular volume;	chr16:81012730	chr16:80982319~80984094:-
THCA	cis	rs812925	0.519	rs967968	ENSG00000270820.4	RP11-355B11.2	-4.63	4.77e-06	0.000525	-0.18	-0.21	Immature fraction of reticulocytes;	chr2:61428921	chr2:61471188~61484130:+
THCA	cis	rs893818	1	rs893818	ENSG00000261801.4	LOXL1-AS1	4.63	4.77e-06	0.000525	0.24	0.21	Exfoliation glaucoma or exfoliation syndrome;	chr15:73936854	chr15:73908071~73928248:-
THCA	cis	rs893818	1	rs67173550	ENSG00000261801.4	LOXL1-AS1	4.63	4.77e-06	0.000525	0.24	0.21	Exfoliation glaucoma or exfoliation syndrome;	chr15:73937136	chr15:73908071~73928248:-
THCA	cis	rs897984	0.568	rs67456613	ENSG00000260911.2	RP11-196G11.2	4.63	4.77e-06	0.000525	0.19	0.21	Dementia with Lewy bodies;	chr16:30876974	chr16:31043150~31049868:+
THCA	cis	rs73198271	0.653	rs10087633	ENSG00000253893.2	FAM85B	4.63	4.77e-06	0.000525	0.28	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8167819~8226614:-
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000275400.1	RP4-756H11.5	-4.63	4.77e-06	0.000525	-0.23	-0.21	Corneal structure;	chr7:66830758	chr7:66553805~66554199:-
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000275400.1	RP4-756H11.5	-4.63	4.77e-06	0.000525	-0.23	-0.21	Corneal structure;	chr7:66845054	chr7:66553805~66554199:-
THCA	cis	rs752010	1	rs752010	ENSG00000230638.4	RP11-486B10.4	-4.63	4.77e-06	0.000525	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41627344	chr1:41542069~41544310:+
THCA	cis	rs4705952	0.832	rs2706391	ENSG00000233006.5	AC034220.3	-4.63	4.77e-06	0.000525	-0.2	-0.21	C-reactive protein levels;	chr5:132507614	chr5:132311285~132369916:-
THCA	cis	rs804280	0.662	rs810738	ENSG00000255046.1	RP11-297N6.4	-4.63	4.77e-06	0.000525	-0.25	-0.21	Myopia (pathological);	chr8:11753697	chr8:11797928~11802568:-
THCA	cis	rs4072705	0.646	rs915032	ENSG00000224020.1	MIR181A2HG	-4.63	4.77e-06	0.000525	-0.19	-0.21	Menarche (age at onset);	chr9:124483403	chr9:124658467~124698631:+
THCA	cis	rs8067545	0.562	rs2526481	ENSG00000270091.1	RP11-78O7.2	4.63	4.77e-06	0.000525	0.16	0.21	Schizophrenia;	chr17:20223705	chr17:19896590~19897287:-
THCA	cis	rs972578	0.715	rs9611904	ENSG00000274717.1	RP1-47A17.1	-4.63	4.77e-06	0.000526	-0.22	-0.21	Mean platelet volume;	chr22:42795362	chr22:42791814~42794313:-
THCA	cis	rs10510102	0.872	rs12248004	ENSG00000226864.1	ATE1-AS1	4.63	4.77e-06	0.000526	0.35	0.21	Breast cancer;	chr10:121972215	chr10:121928312~121951965:+
THCA	cis	rs13113518	1	rs4864990	ENSG00000249700.7	SRD5A3-AS1	4.63	4.78e-06	0.000526	0.26	0.21	Height;	chr4:55447523	chr4:55363971~55395847:-
THCA	cis	rs1232027	0.545	rs1650742	ENSG00000249655.1	CTC-325J23.2	4.63	4.78e-06	0.000526	0.24	0.21	Huntington's disease progression;	chr5:80695064	chr5:80630313~80631590:-
THCA	cis	rs712039	0.565	rs1714987	ENSG00000276054.1	RP11-378E13.3	4.63	4.78e-06	0.000526	0.32	0.21	Tuberculosis;	chr17:37386072	chr17:37386886~37387926:+
THCA	cis	rs7520050	0.966	rs12405451	ENSG00000234329.1	RP11-767N6.2	-4.63	4.78e-06	0.000526	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs11211224	ENSG00000234329.1	RP11-767N6.2	-4.63	4.78e-06	0.000526	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.933	rs6656022	ENSG00000234329.1	RP11-767N6.2	-4.63	4.78e-06	0.000526	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs4134386	ENSG00000234329.1	RP11-767N6.2	-4.63	4.78e-06	0.000526	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs12561806	ENSG00000234329.1	RP11-767N6.2	-4.63	4.78e-06	0.000526	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6669522	ENSG00000234329.1	RP11-767N6.2	-4.63	4.78e-06	0.000526	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45651039~45651826:-
THCA	cis	rs5742933	1	rs12052909	ENSG00000253559.1	OSGEPL1-AS1	-4.63	4.78e-06	0.000526	-0.26	-0.21	Ferritin levels;	chr2:189742484	chr2:189762704~189765556:+
THCA	cis	rs5742933	1	rs16831955	ENSG00000253559.1	OSGEPL1-AS1	-4.63	4.78e-06	0.000526	-0.26	-0.21	Ferritin levels;	chr2:189745811	chr2:189762704~189765556:+
THCA	cis	rs4639966	0.684	rs487177	ENSG00000255422.1	AP002954.4	4.63	4.78e-06	0.000526	0.25	0.21	Systemic lupus erythematosus;	chr11:118786588	chr11:118704607~118750263:+
THCA	cis	rs6088580	0.634	rs6059905	ENSG00000276073.1	RP5-1125A11.7	-4.63	4.78e-06	0.000526	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34539142	chr20:33985617~33988989:-
THCA	cis	rs8028182	0.636	rs4243034	ENSG00000260269.4	CTD-2323K18.1	-4.63	4.78e-06	0.000526	-0.31	-0.21	Sudden cardiac arrest;	chr15:75458628	chr15:75527150~75601205:-
THCA	cis	rs7746199	0.736	rs34965299	ENSG00000220721.1	OR1F12	4.63	4.78e-06	0.000526	0.47	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28073316~28074233:+
THCA	cis	rs35491132	1	rs35491132	ENSG00000220721.1	OR1F12	4.63	4.78e-06	0.000526	0.47	0.21	Urinary tract infection frequency;	chr6:27559449	chr6:28073316~28074233:+
THCA	cis	rs2018683	0.711	rs917213	ENSG00000272568.4	CTB-113D17.1	4.63	4.78e-06	0.000527	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928587	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.711	rs917214	ENSG00000272568.4	CTB-113D17.1	4.63	4.78e-06	0.000527	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928676	chr7:28979967~29013367:+
THCA	cis	rs9880211	0.613	rs34864445	ENSG00000273486.1	RP11-731C17.2	4.63	4.78e-06	0.000527	0.21	0.21	Height;Body mass index;	chr3:136104082	chr3:136837338~136839021:-
THCA	cis	rs447735	0.565	rs10852626	ENSG00000260259.1	RP11-368I7.4	-4.63	4.78e-06	0.000527	-0.23	-0.21	Hemoglobin concentration;	chr16:89848225	chr16:89682620~89686569:-
THCA	cis	rs4245128	0.775	rs2218618	ENSG00000247416.2	RP11-629G13.1	4.63	4.78e-06	0.000527	0.2	0.21	Life satisfaction;	chr11:112949746	chr11:112959279~112963460:-
THCA	cis	rs8077577	0.689	rs16961114	ENSG00000273018.4	CTD-2303H24.2	-4.63	4.79e-06	0.000527	-0.31	-0.21	Obesity-related traits;	chr17:18312025	chr17:18511221~18551705:-
THCA	cis	rs7849973	0.551	rs7850461	ENSG00000224549.1	RP11-370B11.3	-4.63	4.79e-06	0.000527	-0.24	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22809451	chr9:22767175~22768316:+
THCA	cis	rs79040073	0.911	rs11638981	ENSG00000259531.2	RP11-295H24.3	4.63	4.79e-06	0.000527	0.26	0.21	Lung cancer in ever smokers;	chr15:49029332	chr15:49365124~49366685:-
THCA	cis	rs959260	0.858	rs4788886	ENSG00000263843.1	RP11-649A18.12	4.63	4.79e-06	0.000527	0.23	0.21	Systemic lupus erythematosus;	chr17:75317245	chr17:75271369~75273895:+
THCA	cis	rs2657294	0.965	rs10824286	ENSG00000226051.5	ZNF503-AS1	-4.63	4.79e-06	0.000527	-0.28	-0.21	Pneumonia;	chr10:75172251	chr10:75269819~75373500:+
THCA	cis	rs1005277	0.505	rs10827835	ENSG00000226578.1	RP11-258F22.1	4.63	4.79e-06	0.000527	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:37775371~37784131:-
THCA	cis	rs793571	0.628	rs28510910	ENSG00000259250.1	RP11-50C13.1	-4.63	4.79e-06	0.000527	-0.22	-0.21	Schizophrenia;	chr15:58790188	chr15:58587507~58591676:+
THCA	cis	rs793571	0.628	rs28793354	ENSG00000259250.1	RP11-50C13.1	-4.63	4.79e-06	0.000527	-0.22	-0.21	Schizophrenia;	chr15:58792647	chr15:58587507~58591676:+
THCA	cis	rs12755164	0.724	rs6684318	ENSG00000223479.3	RP4-788P17.1	4.63	4.79e-06	0.000528	0.23	0.21	Schizophrenia;	chr1:72867482	chr1:73635216~73715214:+
THCA	cis	rs17604090	0.887	rs850013	ENSG00000227855.3	DPY19L2P3	4.63	4.79e-06	0.000528	0.24	0.21	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29626914	chr7:29650227~29742594:+
THCA	cis	rs9719620	0.967	rs4731794	ENSG00000236753.4	MKLN1-AS	4.63	4.8e-06	0.000528	0.2	0.21	Male-pattern baldness;	chr7:131323577	chr7:131309744~131328222:-
THCA	cis	rs9902453	0.765	rs2264303	ENSG00000263370.1	RP11-68I3.5	-4.63	4.8e-06	0.000528	-0.27	-0.21	Coffee consumption (cups per day);	chr17:29728330	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2264302	ENSG00000263370.1	RP11-68I3.5	-4.63	4.8e-06	0.000528	-0.27	-0.21	Coffee consumption (cups per day);	chr17:29730077	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2447935	ENSG00000263370.1	RP11-68I3.5	-4.63	4.8e-06	0.000528	-0.27	-0.21	Coffee consumption (cups per day);	chr17:29730506	chr17:29639627~29640825:+
THCA	cis	rs6433895	0.883	rs4432412	ENSG00000236153.1	AC104076.3	-4.63	4.8e-06	0.000528	-0.23	-0.21	Lymphocyte counts;	chr2:181204352	chr2:180979427~180980090:-
THCA	cis	rs7246657	0.551	rs62108899	ENSG00000226686.6	LINC01535	-4.63	4.8e-06	0.000528	-0.38	-0.21	Coronary artery calcification;	chr19:37104281	chr19:37251912~37265535:+
THCA	cis	rs1923243	0.587	rs12121441	ENSG00000223479.3	RP4-788P17.1	4.63	4.8e-06	0.000528	0.23	0.21	Migraine;	chr1:72907854	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs10493513	ENSG00000223479.3	RP4-788P17.1	4.63	4.8e-06	0.000528	0.23	0.21	Migraine;	chr1:72913906	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs10493514	ENSG00000223479.3	RP4-788P17.1	4.63	4.8e-06	0.000528	0.23	0.21	Migraine;	chr1:72914829	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.649	rs11210091	ENSG00000223479.3	RP4-788P17.1	4.63	4.8e-06	0.000528	0.23	0.21	Migraine;	chr1:72921022	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs11210092	ENSG00000223479.3	RP4-788P17.1	4.63	4.8e-06	0.000528	0.23	0.21	Migraine;	chr1:72923552	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.587	rs12128225	ENSG00000223479.3	RP4-788P17.1	4.63	4.8e-06	0.000528	0.23	0.21	Migraine;	chr1:72924648	chr1:73635216~73715214:+
THCA	cis	rs7914558	1	rs7067970	ENSG00000236937.2	PTGES3P4	4.63	4.8e-06	0.000528	0.27	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:102845595~102845950:+
THCA	cis	rs9925964	0.967	rs1978487	ENSG00000232748.3	RP11-196G11.6	-4.63	4.8e-06	0.000528	-0.24	-0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118621	chr16:31056460~31062803:+
THCA	cis	rs2067615	0.579	rs10861663	ENSG00000260329.1	RP11-412D9.4	-4.63	4.8e-06	0.000528	-0.19	-0.21	Heart rate;	chr12:106789811	chr12:106954029~106955497:-
THCA	cis	rs7772486	0.754	rs1415747	ENSG00000270638.1	RP3-466P17.1	4.63	4.8e-06	0.000528	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145735570~145737218:+
THCA	cis	rs1923243	0.71	rs10890016	ENSG00000223479.3	RP4-788P17.1	-4.63	4.8e-06	0.000528	-0.23	-0.21	Migraine;	chr1:73179214	chr1:73635216~73715214:+
THCA	cis	rs2439831	1	rs2444029	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43445286	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2467740	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43454594	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs561863	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43469154	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs689616	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43469703	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs689647	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43469998	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2251538	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43475011	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs2439832	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43487488	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2439850	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43492656	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2467736	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43492719	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2444250	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43492853	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs101094	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43495124	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs689781	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43499899	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2584725	ENSG00000205771.5	CATSPER2P1	-4.63	4.8e-06	0.000528	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43500937	chr15:43726918~43747094:-
THCA	cis	rs1707322	1	rs7526369	ENSG00000281133.1	AL355480.3	-4.63	4.8e-06	0.000528	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs10890371	ENSG00000281133.1	AL355480.3	-4.63	4.8e-06	0.000528	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45580892~45580996:-
THCA	cis	rs8067545	1	rs4925067	ENSG00000270091.1	RP11-78O7.2	-4.63	4.8e-06	0.000528	-0.16	-0.21	Schizophrenia;	chr17:20017909	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs2158472	ENSG00000270091.1	RP11-78O7.2	4.63	4.8e-06	0.000529	0.16	0.21	Schizophrenia;	chr17:20268211	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.586	rs3850779	ENSG00000270091.1	RP11-78O7.2	4.63	4.8e-06	0.000529	0.16	0.21	Schizophrenia;	chr17:20268559	chr17:19896590~19897287:-
THCA	cis	rs1046491	0.901	rs7229685	ENSG00000264964.1	RP11-888D10.3	4.63	4.81e-06	0.000529	0.35	0.21	Scarlet fever;	chr18:9194172	chr18:9315194~9334441:-
THCA	cis	rs8062405	0.755	rs4788074	ENSG00000261766.1	RP11-22P6.2	4.63	4.81e-06	0.000529	0.21	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28862166~28863340:-
THCA	cis	rs7617773	0.963	rs6800730	ENSG00000199476.1	Y_RNA	-4.63	4.81e-06	0.000529	-0.25	-0.21	Coronary artery disease;	chr3:48132720	chr3:48288587~48288694:+
THCA	cis	rs62158800	0.925	rs62158830	ENSG00000237880.1	AC096669.2	4.63	4.81e-06	0.000529	0.34	0.21	Facial morphology (factor 22);	chr2:107634350	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.925	rs62158832	ENSG00000237880.1	AC096669.2	4.63	4.81e-06	0.000529	0.34	0.21	Facial morphology (factor 22);	chr2:107635124	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.852	rs62158834	ENSG00000237880.1	AC096669.2	4.63	4.81e-06	0.000529	0.34	0.21	Facial morphology (factor 22);	chr2:107639879	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.703	rs55940013	ENSG00000237880.1	AC096669.2	4.63	4.81e-06	0.000529	0.34	0.21	Facial morphology (factor 22);	chr2:107642672	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.852	rs62158837	ENSG00000237880.1	AC096669.2	4.63	4.81e-06	0.000529	0.34	0.21	Facial morphology (factor 22);	chr2:107643102	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.852	rs62158838	ENSG00000237880.1	AC096669.2	4.63	4.81e-06	0.000529	0.34	0.21	Facial morphology (factor 22);	chr2:107644754	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.852	rs62158839	ENSG00000237880.1	AC096669.2	4.63	4.81e-06	0.000529	0.34	0.21	Facial morphology (factor 22);	chr2:107645837	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.852	rs17021579	ENSG00000237880.1	AC096669.2	4.63	4.81e-06	0.000529	0.34	0.21	Facial morphology (factor 22);	chr2:107650274	chr2:107385632~107542649:-
THCA	cis	rs9393777	0.92	rs67859638	ENSG00000220721.1	OR1F12	4.63	4.81e-06	0.000529	0.49	0.21	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28073316~28074233:+
THCA	cis	rs9467773	0.62	rs9461275	ENSG00000261353.1	CTA-14H9.5	-4.63	4.81e-06	0.000529	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26527063~26527404:+
THCA	cis	rs7403037	0.848	rs7495125	ENSG00000260760.1	PWRN3	4.63	4.81e-06	0.000529	0.24	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24588489	chr15:24441127~24447967:+
THCA	cis	rs4218	0.701	rs56375269	ENSG00000259732.1	RP11-59H7.3	-4.63	4.81e-06	0.000529	-0.28	-0.21	Social communication problems;	chr15:59137741	chr15:59121034~59133250:+
THCA	cis	rs2286503	1	rs1029740	ENSG00000226329.2	AC005682.6	4.63	4.81e-06	0.000529	0.25	0.21	Fibrinogen;	chr7:22833967	chr7:22863874~22881350:-
THCA	cis	rs8067545	0.611	rs2703805	ENSG00000270091.1	RP11-78O7.2	4.63	4.81e-06	0.000529	0.16	0.21	Schizophrenia;	chr17:20204460	chr17:19896590~19897287:-
THCA	cis	rs375066	0.586	rs59503823	ENSG00000267058.1	RP11-15A1.3	4.63	4.81e-06	0.000529	0.19	0.21	Breast cancer;	chr19:43822266	chr19:43891804~43901805:-
THCA	cis	rs2749592	0.918	rs4934590	ENSG00000263064.2	RP11-291L22.7	-4.63	4.81e-06	0.00053	-0.26	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr10:37588641	chr10:38448689~38448949:+
THCA	cis	rs4950322	0.57	rs4593887	ENSG00000226015.2	CCT8P1	4.63	4.82e-06	0.00053	0.24	0.21	Protein quantitative trait loci;	chr1:147234246	chr1:147203276~147204932:-
THCA	cis	rs2439831	0.681	rs1095386	ENSG00000205771.5	CATSPER2P1	-4.63	4.82e-06	0.00053	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43317311	chr15:43726918~43747094:-
THCA	cis	rs8062405	1	rs11861174	ENSG00000261766.1	RP11-22P6.2	-4.63	4.82e-06	0.00053	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62037367	ENSG00000261766.1	RP11-22P6.2	-4.63	4.82e-06	0.00053	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs7198606	ENSG00000261766.1	RP11-22P6.2	-4.63	4.82e-06	0.00053	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.929	rs11864750	ENSG00000261766.1	RP11-22P6.2	-4.63	4.82e-06	0.00053	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.964	rs7193733	ENSG00000261766.1	RP11-22P6.2	-4.63	4.82e-06	0.00053	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs8055982	ENSG00000261766.1	RP11-22P6.2	-4.63	4.82e-06	0.00053	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs7498665	ENSG00000261766.1	RP11-22P6.2	-4.63	4.82e-06	0.00053	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.964	rs11864107	ENSG00000261766.1	RP11-22P6.2	-4.63	4.82e-06	0.00053	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28862166~28863340:-
THCA	cis	rs2058059	0.636	rs3132428	ENSG00000205578.5	POM121B	-4.63	4.82e-06	0.00053	-0.32	-0.21	Subcutaneous adipose tissue;	chr7:72717018	chr7:73293497~73301161:+
THCA	cis	rs8054556	0.74	rs4609871	ENSG00000183604.13	SMG1P5	4.63	4.82e-06	0.00053	0.19	0.21	Autism spectrum disorder or schizophrenia;	chr16:29920743	chr16:30267553~30335374:-
THCA	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-4.63	4.82e-06	0.00053	-0.25	-0.21	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
THCA	cis	rs7551222	0.647	rs3014606	ENSG00000240219.1	RP11-430C7.5	-4.63	4.82e-06	0.00053	-0.22	-0.21	Schizophrenia;	chr1:204495022	chr1:204626775~204629712:+
THCA	cis	rs9902453	0.765	rs3102555	ENSG00000263370.1	RP11-68I3.5	4.63	4.82e-06	0.00053	0.27	0.21	Coffee consumption (cups per day);	chr17:29717083	chr17:29639627~29640825:+
THCA	cis	rs6088590	1	rs3787222	ENSG00000276073.1	RP5-1125A11.7	-4.63	4.82e-06	0.00053	-0.19	-0.21	Coronary artery disease;	chr20:34745236	chr20:33985617~33988989:-
THCA	cis	rs2790457	0.917	rs1265831	ENSG00000254635.4	WAC-AS1	-4.63	4.82e-06	0.00053	-0.21	-0.21	Multiple myeloma;	chr10:28623921	chr10:28522652~28532743:-
THCA	cis	rs13063635	0.764	rs7642229	ENSG00000226074.4	PRSS44	-4.63	4.82e-06	0.00053	-0.36	-0.21	Eosinophil percentage of granulocytes;	chr3:46049065	chr3:46809359~46812558:-
THCA	cis	rs736408	0.812	rs1075653	ENSG00000243224.1	RP5-1157M23.2	-4.63	4.82e-06	0.00053	-0.23	-0.21	Bipolar disorder;	chr3:52791512	chr3:52239258~52241097:+
THCA	cis	rs763121	0.925	rs4821815	ENSG00000228274.3	RP3-508I15.9	-4.63	4.82e-06	0.00053	-0.22	-0.21	Menopause (age at onset);	chr22:38709702	chr22:38667585~38681820:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-4.63	4.82e-06	0.00053	-0.23	-0.21	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
THCA	cis	rs12472274	0.941	rs12616232	ENSG00000279484.1	KLHL30-AS1	4.63	4.82e-06	0.00053	0.23	0.21	Phospholipid levels (plasma);	chr2:238171452	chr2:238152889~238155994:-
THCA	cis	rs4925386	1	rs4925382	ENSG00000275437.1	RP5-908M14.10	-4.63	4.82e-06	0.00053	-0.2	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62402236~62405935:-
THCA	cis	rs2070488	1	rs6772046	ENSG00000229589.1	ACVR2B-AS1	4.63	4.82e-06	0.00053	0.19	0.21	Electrocardiographic conduction measures;	chr3:38438169	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.965	rs7372386	ENSG00000229589.1	ACVR2B-AS1	4.63	4.82e-06	0.00053	0.19	0.21	Electrocardiographic conduction measures;	chr3:38442684	chr3:38451027~38454820:-
THCA	cis	rs11668609	0.506	rs8113480	ENSG00000268442.1	CTD-2027I19.2	-4.63	4.82e-06	0.000531	-0.31	-0.21	Response to taxane treatment (docetaxel);	chr19:23878217	chr19:24162370~24163425:-
THCA	cis	rs4916588	0.691	rs75135747	ENSG00000270170.1	NCBP2-AS2	4.63	4.83e-06	0.000531	0.18	0.21	Night sleep phenotypes;	chr3:196902707	chr3:196942623~196943540:+
THCA	cis	rs4660214	0.666	rs625384	ENSG00000182109.6	RP11-69E11.4	4.63	4.83e-06	0.000531	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39522280~39546187:-
THCA	cis	rs9847710	0.967	rs2564938	ENSG00000242142.1	SERBP1P3	4.63	4.83e-06	0.000531	0.25	0.21	Ulcerative colitis;	chr3:52992368	chr3:53064283~53065091:-
THCA	cis	rs10911902	0.602	rs1919200	ENSG00000229739.2	RP11-295K2.3	-4.63	4.83e-06	0.000531	-0.34	-0.21	Schizophrenia;	chr1:186300848	chr1:186435161~186470291:+
THCA	cis	rs12546962	0.639	rs17149817	ENSG00000254153.1	CTA-398F10.2	-4.63	4.83e-06	0.000531	-0.26	-0.21	Body mass index;	chr8:9337503	chr8:8456909~8461337:-
THCA	cis	rs763121	0.853	rs4821812	ENSG00000273076.1	RP3-508I15.22	4.63	4.83e-06	0.000531	0.21	0.21	Menopause (age at onset);	chr22:38679230	chr22:38743495~38743910:+
THCA	cis	rs6088590	0.93	rs6087618	ENSG00000269202.1	RP4-614O4.12	-4.63	4.83e-06	0.000531	-0.18	-0.21	Coronary artery disease;	chr20:34700603	chr20:35201747~35203288:-
THCA	cis	rs6088590	0.965	rs6087619	ENSG00000269202.1	RP4-614O4.12	-4.63	4.83e-06	0.000531	-0.18	-0.21	Coronary artery disease;	chr20:34700707	chr20:35201747~35203288:-
THCA	cis	rs7520050	0.966	rs6677007	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs4660898	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs11211230	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs35743647	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs7522601	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs10789487	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs34102169	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs4076006	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs11211234	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs11211241	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.902	rs4638056	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs11576305	ENSG00000234329.1	RP11-767N6.2	-4.63	4.83e-06	0.000531	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45651039~45651826:-
THCA	cis	rs2732480	0.577	rs2634680	ENSG00000273765.1	RP11-370I10.11	4.63	4.83e-06	0.000531	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48360920~48361377:+
THCA	cis	rs914615	0.507	rs4971085	ENSG00000236675.1	MTX1P1	-4.63	4.83e-06	0.000531	-0.19	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155165746	chr1:155230975~155234325:+
THCA	cis	rs7608910	0.77	rs10191951	ENSG00000271889.1	RP11-493E12.1	4.63	4.83e-06	0.000531	0.22	0.21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60970655	chr2:61151433~61162105:-
THCA	cis	rs12755164	0.778	rs12132492	ENSG00000223479.3	RP4-788P17.1	4.63	4.83e-06	0.000532	0.23	0.21	Schizophrenia;	chr1:72870906	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.778	rs6679710	ENSG00000223479.3	RP4-788P17.1	4.63	4.83e-06	0.000532	0.23	0.21	Schizophrenia;	chr1:72871235	chr1:73635216~73715214:+
THCA	cis	rs7267979	0.932	rs1541061	ENSG00000274973.1	RP13-401N8.7	-4.63	4.84e-06	0.000532	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.932	rs6138600	ENSG00000274973.1	RP13-401N8.7	-4.63	4.84e-06	0.000532	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.899	rs2104734	ENSG00000274973.1	RP13-401N8.7	-4.63	4.84e-06	0.000532	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25845497~25845862:+
THCA	cis	rs4415084	0.966	rs10805685	ENSG00000272335.1	RP11-53O19.3	-4.63	4.84e-06	0.000532	-0.17	-0.21	Breast cancer;	chr5:44661856	chr5:44826076~44828592:+
THCA	cis	rs4415084	1	rs7720551	ENSG00000272335.1	RP11-53O19.3	-4.63	4.84e-06	0.000532	-0.17	-0.21	Breast cancer;	chr5:44664375	chr5:44826076~44828592:+
THCA	cis	rs2948294	0.588	rs7011221	ENSG00000253981.4	ALG1L13P	4.63	4.84e-06	0.000532	0.2	0.21	Red cell distribution width;	chr8:8256724	chr8:8236003~8244667:-
THCA	cis	rs2948294	0.545	rs11776397	ENSG00000253981.4	ALG1L13P	4.63	4.84e-06	0.000532	0.2	0.21	Red cell distribution width;	chr8:8257639	chr8:8236003~8244667:-
THCA	cis	rs2742234	0.59	rs2435376	ENSG00000273008.1	RP11-351D16.3	-4.63	4.84e-06	0.000532	-0.19	-0.21	Hirschsprung disease;	chr10:43189515	chr10:43136824~43138334:-
THCA	cis	rs2742234	0.579	rs2503881	ENSG00000273008.1	RP11-351D16.3	-4.63	4.84e-06	0.000532	-0.19	-0.21	Hirschsprung disease;	chr10:43190578	chr10:43136824~43138334:-
THCA	cis	rs7403037	0.617	rs7496714	ENSG00000259905.4	PWRN1	4.63	4.84e-06	0.000532	0.27	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24601041	chr15:24493137~24652130:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000273142.1	RP11-458F8.4	4.63	4.84e-06	0.000532	0.17	0.21	Aortic root size;	chr7:66597493	chr7:66902857~66906297:+
THCA	cis	rs9990333	0.687	rs62285383	ENSG00000242086.7	LINC00969	4.63	4.84e-06	0.000532	0.2	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196087052	chr3:195658062~195739964:+
THCA	cis	rs793571	0.554	rs12441912	ENSG00000245975.2	RP11-30K9.6	4.63	4.84e-06	0.000532	0.25	0.21	Schizophrenia;	chr15:58701495	chr15:58768072~58770974:-
THCA	cis	rs13178541	0.81	rs11951836	ENSG00000250378.1	RP11-119J18.1	-4.63	4.84e-06	0.000532	-0.27	-0.21	IgG glycosylation;	chr5:135816068	chr5:135812667~135826582:+
THCA	cis	rs172166	0.61	rs156737	ENSG00000280107.1	AL022393.9	-4.63	4.84e-06	0.000532	-0.2	-0.21	Cardiac Troponin-T levels;	chr6:27927435	chr6:28170845~28172521:+
THCA	cis	rs73198271	0.653	rs10099808	ENSG00000253893.2	FAM85B	-4.63	4.84e-06	0.000533	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8167819~8226614:-
THCA	cis	rs6121246	0.909	rs6060633	ENSG00000230613.1	HM13-AS1	4.63	4.85e-06	0.000533	0.22	0.21	Mean corpuscular hemoglobin;	chr20:31675514	chr20:31567707~31573263:-
THCA	cis	rs8077577	0.747	rs16961153	ENSG00000273018.4	CTD-2303H24.2	4.63	4.85e-06	0.000533	0.3	0.21	Obesity-related traits;	chr17:18323787	chr17:18511221~18551705:-
THCA	cis	rs3738443	0.868	rs7551871	ENSG00000259865.1	RP11-488L18.10	4.62	4.85e-06	0.000533	0.22	0.21	Alcohol dependence;	chr1:247199888	chr1:247187281~247188526:-
THCA	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-4.62	4.85e-06	0.000533	-0.23	-0.21	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-4.62	4.85e-06	0.000533	-0.23	-0.21	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-4.62	4.85e-06	0.000533	-0.23	-0.21	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-4.62	4.85e-06	0.000533	-0.23	-0.21	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-4.62	4.85e-06	0.000533	-0.23	-0.21	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
THCA	cis	rs13126694	0.778	rs10000610	ENSG00000248429.4	RP11-597D13.9	4.62	4.85e-06	0.000533	0.22	0.21	Blood osmolality (transformed sodium);	chr4:158112023	chr4:158170752~158202877:+
THCA	cis	rs11955398	0.502	rs159371	ENSG00000272308.1	RP11-231G3.1	-4.62	4.85e-06	0.000533	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61148449	chr5:60866457~60866935:-
THCA	cis	rs829883	0.659	rs11109524	ENSG00000227825.4	SLC9A7P1	-4.62	4.85e-06	0.000533	-0.2	-0.21	Colorectal adenoma (advanced);	chr12:98545394	chr12:98453835~98457145:-
THCA	cis	rs7727544	0.735	rs272875	ENSG00000263597.1	MIR3936	4.62	4.85e-06	0.000533	0.2	0.21	Blood metabolite levels;	chr5:132339195	chr5:132365490~132365599:-
THCA	cis	rs8067545	0.611	rs8071274	ENSG00000270091.1	RP11-78O7.2	4.62	4.85e-06	0.000533	0.16	0.21	Schizophrenia;	chr17:20313615	chr17:19896590~19897287:-
THCA	cis	rs1923243	0.587	rs4233091	ENSG00000223479.3	RP4-788P17.1	4.62	4.85e-06	0.000533	0.23	0.21	Migraine;	chr1:72920165	chr1:73635216~73715214:+
THCA	cis	rs9326248	0.539	rs7120565	ENSG00000280143.1	AP000892.6	4.62	4.85e-06	0.000533	0.26	0.21	Blood protein levels;	chr11:117172233	chr11:117204967~117210292:+
THCA	cis	rs9368481	0.761	rs3931464	ENSG00000261353.1	CTA-14H9.5	-4.62	4.85e-06	0.000534	-0.22	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26527063~26527404:+
THCA	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	4.62	4.85e-06	0.000534	0.23	0.21	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
THCA	cis	rs752010	0.746	rs10749837	ENSG00000230638.4	RP11-486B10.4	-4.62	4.86e-06	0.000534	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41623800	chr1:41542069~41544310:+
THCA	cis	rs2985684	0.894	rs10147029	ENSG00000278009.1	RP11-649E7.8	-4.62	4.86e-06	0.000534	-0.29	-0.21	Carotid intima media thickness;	chr14:49553514	chr14:49601011~49601124:-
THCA	cis	rs8028182	0.636	rs28737338	ENSG00000260274.1	RP11-817O13.8	4.62	4.86e-06	0.000534	0.15	0.21	Sudden cardiac arrest;	chr15:75476338	chr15:75368155~75369584:+
THCA	cis	rs9487094	0.626	rs7773950	ENSG00000223537.2	RP5-919F19.5	-4.62	4.86e-06	0.000534	-0.21	-0.21	Height;	chr6:109494237	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs11153183	ENSG00000223537.2	RP5-919F19.5	-4.62	4.86e-06	0.000534	-0.21	-0.21	Height;	chr6:109496073	chr6:109487906~109506800:+
THCA	cis	rs1577917	0.883	rs2782263	ENSG00000220563.1	PKMP3	-4.62	4.86e-06	0.000534	-0.15	-0.21	Response to antipsychotic treatment;	chr6:86081589	chr6:85659892~85660606:-
THCA	cis	rs2447820	0.5	rs30025	ENSG00000249996.1	RP11-359P5.1	4.62	4.86e-06	0.000534	0.24	0.21	Migraine;	chr5:122949047	chr5:123036271~123054667:+
THCA	cis	rs801193	1	rs13239306	ENSG00000272831.1	RP11-792A8.4	-4.62	4.86e-06	0.000534	-0.13	-0.21	Aortic root size;	chr7:66671030	chr7:66739829~66740385:-
THCA	cis	rs7246657	0.509	rs10426093	ENSG00000276846.1	CTD-3220F14.3	4.62	4.86e-06	0.000534	0.25	0.21	Coronary artery calcification;	chr19:37124727	chr19:37314868~37315620:-
THCA	cis	rs516805	0.52	rs12662883	ENSG00000279453.1	RP3-425C14.4	-4.62	4.86e-06	0.000534	-0.17	-0.21	Lymphocyte counts;	chr6:122471463	chr6:122436789~122439223:-
THCA	cis	rs78487399	0.908	rs60735069	ENSG00000234936.1	AC010883.5	4.62	4.86e-06	0.000534	0.27	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43619088	chr2:43229573~43233394:+
THCA	cis	rs1577917	0.793	rs9362245	ENSG00000220563.1	PKMP3	-4.62	4.86e-06	0.000534	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85786602	chr6:85659892~85660606:-
THCA	cis	rs7141336	0.8	rs1570114	ENSG00000258884.1	CTD-3035D6.2	4.62	4.86e-06	0.000535	0.28	0.21	Anxiety disorder;	chr14:90821190	chr14:90822365~90828128:-
THCA	cis	rs8062405	0.824	rs62034319	ENSG00000261766.1	RP11-22P6.2	-4.62	4.87e-06	0.000535	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28862166~28863340:-
THCA	cis	rs8014252	1	rs12436902	ENSG00000259158.2	ADAM20P1	-4.62	4.87e-06	0.000535	-0.24	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70462379	chr14:70468881~70483756:-
THCA	cis	rs5753037	0.745	rs9306465	ENSG00000279699.1	RP1-102K2.9	4.62	4.87e-06	0.000535	0.21	0.21	Type 1 diabetes;	chr22:29825837	chr22:30275215~30276951:-
THCA	cis	rs7208859	0.573	rs73267873	ENSG00000280069.1	CTD-2349P21.3	-4.62	4.87e-06	0.000535	-0.29	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30738182~30740275:+
THCA	cis	rs17826219	0.561	rs4085382	ENSG00000280069.1	CTD-2349P21.3	-4.62	4.87e-06	0.000535	-0.29	-0.21	Body mass index;	chr17:30744184	chr17:30738182~30740275:+
THCA	cis	rs6430538	0.671	rs4954176	ENSG00000224043.6	CCNT2-AS1	-4.62	4.87e-06	0.000535	-0.22	-0.21	Parkinson's disease;	chr2:134786079	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.515	rs2156000	ENSG00000224043.6	CCNT2-AS1	-4.62	4.87e-06	0.000535	-0.22	-0.21	Type 2 diabetes;	chr2:134788860	chr2:134735464~134918710:-
THCA	cis	rs6772849	0.662	rs12494372	ENSG00000242551.2	POU5F1P6	-4.62	4.87e-06	0.000535	-0.28	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128682850	chr3:128674735~128677005:-
THCA	cis	rs253959	0.739	rs168826	ENSG00000272265.1	CTD-2287O16.4	-4.62	4.87e-06	0.000536	-0.24	-0.21	Bipolar disorder and schizophrenia;	chr5:116299083	chr5:116078110~116078570:-
THCA	cis	rs654950	0.776	rs2759252	ENSG00000230638.4	RP11-486B10.4	4.62	4.87e-06	0.000536	0.25	0.21	Airway imaging phenotypes;	chr1:41556183	chr1:41542069~41544310:+
THCA	cis	rs13113518	1	rs7660980	ENSG00000273257.1	RP11-177J6.1	-4.62	4.88e-06	0.000536	-0.28	-0.21	Height;	chr4:55542948	chr4:55387949~55388271:+
THCA	cis	rs7615952	0.546	rs2922194	ENSG00000171084.14	FAM86JP	4.62	4.88e-06	0.000536	0.29	0.21	Blood pressure (smoking interaction);	chr3:125613419	chr3:125916620~125930024:+
THCA	cis	rs4072705	0.614	rs7020027	ENSG00000224020.1	MIR181A2HG	4.62	4.88e-06	0.000536	0.19	0.21	Menarche (age at onset);	chr9:124479135	chr9:124658467~124698631:+
THCA	cis	rs12541437	0.958	rs2921730	ENSG00000253327.2	RAD21-AS1	4.62	4.88e-06	0.000536	0.23	0.21	Gut microbiome composition (winter);	chr8:116924447	chr8:116874424~116876868:+
THCA	cis	rs12541437	0.958	rs16889267	ENSG00000253327.2	RAD21-AS1	4.62	4.88e-06	0.000536	0.23	0.21	Gut microbiome composition (winter);	chr8:116925656	chr8:116874424~116876868:+
THCA	cis	rs7647973	0.58	rs11130184	ENSG00000229759.1	MRPS18AP1	4.62	4.88e-06	0.000536	0.27	0.21	Menarche (age at onset);	chr3:49192497	chr3:48256350~48256938:-
THCA	cis	rs7647973	0.58	rs2334958	ENSG00000229759.1	MRPS18AP1	4.62	4.88e-06	0.000536	0.27	0.21	Menarche (age at onset);	chr3:49214931	chr3:48256350~48256938:-
THCA	cis	rs1005277	0.522	rs200943	ENSG00000226578.1	RP11-258F22.1	-4.62	4.88e-06	0.000536	-0.24	-0.21	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:37775371~37784131:-
THCA	cis	rs1005277	0.505	rs719569	ENSG00000226578.1	RP11-258F22.1	4.62	4.88e-06	0.000536	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:37775371~37784131:-
THCA	cis	rs1005277	0.505	rs7099777	ENSG00000226578.1	RP11-258F22.1	4.62	4.88e-06	0.000536	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:37775371~37784131:-
THCA	cis	rs9816784	0.525	rs555412	ENSG00000273009.1	RP11-352G9.1	-4.62	4.88e-06	0.000536	-0.24	-0.21	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195913078~195913683:-
THCA	cis	rs9816784	0.525	rs422772	ENSG00000273009.1	RP11-352G9.1	-4.62	4.88e-06	0.000536	-0.24	-0.21	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195913078~195913683:-
THCA	cis	rs453301	0.598	rs2921383	ENSG00000254340.1	RP11-10A14.3	4.62	4.89e-06	0.000537	0.22	0.21	Joint mobility (Beighton score);	chr8:9034711	chr8:9141424~9145435:+
THCA	cis	rs9925964	0.933	rs4889530	ENSG00000232748.3	RP11-196G11.6	4.62	4.89e-06	0.000537	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31056460~31062803:+
THCA	cis	rs61270009	0.955	rs415302	ENSG00000247828.6	TMEM161B-AS1	-4.62	4.89e-06	0.000537	-0.18	-0.21	Depressive symptoms;	chr5:88231628	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs780398	ENSG00000247828.6	TMEM161B-AS1	-4.62	4.89e-06	0.000537	-0.18	-0.21	Depressive symptoms;	chr5:88234112	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs780399	ENSG00000247828.6	TMEM161B-AS1	-4.62	4.89e-06	0.000537	-0.18	-0.21	Depressive symptoms;	chr5:88237160	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.913	rs380670	ENSG00000247828.6	TMEM161B-AS1	-4.62	4.89e-06	0.000537	-0.18	-0.21	Depressive symptoms;	chr5:88243132	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs379430	ENSG00000247828.6	TMEM161B-AS1	-4.62	4.89e-06	0.000537	-0.18	-0.21	Depressive symptoms;	chr5:88243275	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs383385	ENSG00000247828.6	TMEM161B-AS1	-4.62	4.89e-06	0.000537	-0.18	-0.21	Depressive symptoms;	chr5:88246065	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs396702	ENSG00000247828.6	TMEM161B-AS1	-4.62	4.89e-06	0.000537	-0.18	-0.21	Depressive symptoms;	chr5:88247486	chr5:88268895~88436685:+
THCA	cis	rs5758511	0.508	rs28715885	ENSG00000281538.1	RP4-669P10.20	-4.62	4.89e-06	0.000537	-0.27	-0.21	Birth weight;	chr22:42045087	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.508	rs58099562	ENSG00000281538.1	RP4-669P10.20	-4.62	4.89e-06	0.000537	-0.27	-0.21	Birth weight;	chr22:42057768	chr22:42138060~42139726:+
THCA	cis	rs1979679	0.879	rs2638950	ENSG00000278733.1	RP11-425D17.1	4.62	4.89e-06	0.000537	0.21	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28398634	chr12:28185625~28186190:-
THCA	cis	rs4072705	0.615	rs7028021	ENSG00000224020.1	MIR181A2HG	-4.62	4.89e-06	0.000537	-0.19	-0.21	Menarche (age at onset);	chr9:124486743	chr9:124658467~124698631:+
THCA	cis	rs941408	0.515	rs759067	ENSG00000261342.1	AC006538.1	4.62	4.89e-06	0.000537	0.23	0.21	Total cholesterol levels;	chr19:2775670	chr19:2727743~2729327:-
THCA	cis	rs10208649	0.611	rs1974771	ENSG00000233266.1	HMGB1P31	4.62	4.89e-06	0.000537	0.4	0.21	Body mass index;	chr2:54051406	chr2:54051334~54051760:+
THCA	cis	rs2948294	0.524	rs13270062	ENSG00000253981.4	ALG1L13P	4.62	4.89e-06	0.000537	0.2	0.21	Red cell distribution width;	chr8:8255128	chr8:8236003~8244667:-
THCA	cis	rs8020095	0.848	rs8021044	ENSG00000258561.1	RP11-72M17.1	-4.62	4.9e-06	0.000538	-0.28	-0.21	Depression (quantitative trait);	chr14:66990413	chr14:66212810~66509394:-
THCA	cis	rs5742933	1	rs12622902	ENSG00000253559.1	OSGEPL1-AS1	-4.62	4.9e-06	0.000538	-0.26	-0.21	Ferritin levels;	chr2:189776263	chr2:189762704~189765556:+
THCA	cis	rs1048886	0.882	rs12528391	ENSG00000271967.1	RP11-134K13.4	-4.62	4.9e-06	0.000538	-0.22	-0.21	Type 2 diabetes;	chr6:70403365	chr6:70596438~70596980:+
THCA	cis	rs5753037	0.809	rs2074706	ENSG00000279699.1	RP1-102K2.9	4.62	4.9e-06	0.000538	0.21	0.21	Type 1 diabetes;	chr22:29804904	chr22:30275215~30276951:-
THCA	cis	rs4948275	0.631	rs1947520	ENSG00000237233.2	TMEM26-AS1	-4.62	4.9e-06	0.000538	-0.27	-0.21	Night sleep phenotypes;	chr10:61588334	chr10:61452639~61481956:+
THCA	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	4.62	4.9e-06	0.000538	0.27	0.21	Depression;	chr6:28314871	chr6:28943877~28944537:+
THCA	cis	rs58785573	0.504	rs9522	ENSG00000231160.8	KLF3-AS1	-4.62	4.9e-06	0.000538	-0.12	-0.21	Lymphocyte percentage of white cells;	chr4:38665351	chr4:38612701~38664883:-
THCA	cis	rs11858159	0.546	rs8036910	ENSG00000260760.1	PWRN3	-4.62	4.9e-06	0.000538	-0.21	-0.21	Platelet thrombus formation;	chr15:24568307	chr15:24441127~24447967:+
THCA	cis	rs8009147	1	rs8009147	ENSG00000269910.1	RP11-73M18.10	4.62	4.9e-06	0.000538	0.18	0.21	Autism spectrum disorder or schizophrenia;	chr14:103798325	chr14:103694516~103695050:-
THCA	cis	rs9467773	0.933	rs35355150	ENSG00000261353.1	CTA-14H9.5	-4.62	4.9e-06	0.000538	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26527063~26527404:+
THCA	cis	rs829883	1	rs2908843	ENSG00000227825.4	SLC9A7P1	-4.62	4.9e-06	0.000538	-0.19	-0.21	Colorectal adenoma (advanced);	chr12:98495554	chr12:98453835~98457145:-
THCA	cis	rs8062405	1	rs3088215	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs28403629	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs61737565	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs4788099	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs9972693	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.964	rs9972768	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.965	rs62037363	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs7205323	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs4788101	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62037364	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62037365	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.929	rs11150609	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.737	rs11861132	ENSG00000261766.1	RP11-22P6.2	-4.62	4.9e-06	0.000539	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28862166~28863340:-
THCA	cis	rs6441961	0.501	rs71327045	ENSG00000223552.1	RP11-24F11.2	4.62	4.9e-06	0.000539	0.21	0.21	Celiac disease;	chr3:46240087	chr3:46364955~46407059:-
THCA	cis	rs2980439	0.87	rs2945230	ENSG00000254153.1	CTA-398F10.2	-4.62	4.91e-06	0.000539	-0.22	-0.21	Neuroticism;	chr8:8252414	chr8:8456909~8461337:-
THCA	cis	rs9487094	0.689	rs9487069	ENSG00000223537.2	RP5-919F19.5	-4.62	4.91e-06	0.000539	-0.21	-0.21	Height;	chr6:109358652	chr6:109487906~109506800:+
THCA	cis	rs2439831	0.85	rs7181039	ENSG00000166763.7	STRCP1	4.62	4.91e-06	0.000539	0.31	0.21	Lung cancer in ever smokers;	chr15:43886914	chr15:43699488~43718184:-
THCA	cis	rs5753037	0.809	rs713657	ENSG00000279699.1	RP1-102K2.9	4.62	4.91e-06	0.000539	0.21	0.21	Type 1 diabetes;	chr22:29815887	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.809	rs5763512	ENSG00000279699.1	RP1-102K2.9	4.62	4.91e-06	0.000539	0.21	0.21	Type 1 diabetes;	chr22:29816377	chr22:30275215~30276951:-
THCA	cis	rs1350171	0.764	rs4631906	ENSG00000246523.6	RP11-736K20.6	-4.62	4.91e-06	0.000539	-0.31	-0.21	Hepatocellular carcinoma in hepatitis B infection;	chr11:86939240	chr11:86955619~87000959:+
THCA	cis	rs4794202	0.891	rs2074185	ENSG00000264920.1	RP11-6N17.4	-4.62	4.91e-06	0.000539	-0.24	-0.21	Alzheimer's disease (cognitive decline);	chr17:47853218	chr17:47891255~47895812:-
THCA	cis	rs564799	0.966	rs564976	ENSG00000244040.4	IL12A-AS1	4.62	4.91e-06	0.000539	0.27	0.21	Systemic lupus erythematosus;	chr3:160011272	chr3:159913400~160225299:-
THCA	cis	rs8058578	1	rs8058578	ENSG00000279196.1	RP11-1072A3.3	4.62	4.91e-06	0.000539	0.21	0.21	Multiple myeloma;	chr16:30714927	chr16:30984630~30988270:-
THCA	cis	rs7474896	0.537	rs1208683	ENSG00000263064.2	RP11-291L22.7	-4.62	4.91e-06	0.000539	-0.28	-0.21	Obesity (extreme);	chr10:37804795	chr10:38448689~38448949:+
THCA	cis	rs2412819	0.597	rs514311	ENSG00000166763.7	STRCP1	4.62	4.91e-06	0.000539	0.27	0.21	Lung cancer;	chr15:43869376	chr15:43699488~43718184:-
THCA	cis	rs9910055	0.659	rs112114764	ENSG00000267080.4	ASB16-AS1	4.62	4.91e-06	0.000539	0.19	0.21	Total body bone mineral density;	chr17:44123673	chr17:44175973~44186717:-
THCA	cis	rs4908760	0.792	rs11121215	ENSG00000232912.4	RP5-1115A15.1	4.62	4.91e-06	0.000539	0.2	0.21	Vitiligo;	chr1:8673069	chr1:8424645~8434838:+
THCA	cis	rs539096	0.566	rs3011220	ENSG00000237950.1	RP11-7O11.3	4.62	4.91e-06	0.000539	0.18	0.21	Intelligence (multi-trait analysis);	chr1:43843195	chr1:43944370~43946551:-
THCA	cis	rs9467773	0.62	rs9467810	ENSG00000261353.1	CTA-14H9.5	-4.62	4.91e-06	0.000539	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26527063~26527404:+
THCA	cis	rs911555	0.755	rs4143998	ENSG00000244691.1	RPL10AP1	-4.62	4.91e-06	0.00054	-0.28	-0.21	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs1138400	ENSG00000244691.1	RPL10AP1	-4.62	4.91e-06	0.00054	-0.28	-0.21	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs7147664	ENSG00000244691.1	RPL10AP1	-4.62	4.91e-06	0.00054	-0.28	-0.21	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103412119~103412761:-
THCA	cis	rs7772486	0.719	rs7753770	ENSG00000270638.1	RP3-466P17.1	-4.62	4.91e-06	0.00054	-0.16	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145735570~145737218:+
THCA	cis	rs7608910	1	rs7596362	ENSG00000271889.1	RP11-493E12.1	4.62	4.92e-06	0.00054	0.21	0.21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977553	chr2:61151433~61162105:-
THCA	cis	rs7520050	0.966	rs7524495	ENSG00000234329.1	RP11-767N6.2	-4.62	4.92e-06	0.00054	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45651039~45651826:-
THCA	cis	rs703842	0.963	rs2291617	ENSG00000270039.1	RP11-571M6.17	-4.62	4.92e-06	0.00054	-0.24	-0.21	Multiple sclerosis;	chr12:57772620	chr12:57803838~57804415:+
THCA	cis	rs7474896	0.887	rs34245730	ENSG00000263064.2	RP11-291L22.7	4.62	4.92e-06	0.00054	0.33	0.21	Obesity (extreme);	chr10:37658588	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011314	ENSG00000263064.2	RP11-291L22.7	4.62	4.92e-06	0.00054	0.33	0.21	Obesity (extreme);	chr10:37660987	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011315	ENSG00000263064.2	RP11-291L22.7	4.62	4.92e-06	0.00054	0.33	0.21	Obesity (extreme);	chr10:37661165	chr10:38448689~38448949:+
THCA	cis	rs6088590	1	rs2236270	ENSG00000276073.1	RP5-1125A11.7	-4.62	4.92e-06	0.00054	-0.19	-0.21	Coronary artery disease;	chr20:34935352	chr20:33985617~33988989:-
THCA	cis	rs3002131	0.604	rs3008641	ENSG00000272750.1	RP11-378J18.8	4.62	4.92e-06	0.00054	0.31	0.21	Interleukin-10 levels;	chr1:222566947	chr1:222658867~222661512:-
THCA	cis	rs10256972	0.681	rs6979076	ENSG00000225146.1	AC073957.15	-4.62	4.92e-06	0.00054	-0.23	-0.21	Endometriosis;Longevity;	chr7:1076611	chr7:1029025~1043891:+
THCA	cis	rs10090774	0.813	rs11787221	ENSG00000279766.1	RP11-642A1.2	-4.62	4.92e-06	0.00054	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708995	chr8:140572142~140572812:-
THCA	cis	rs7474896	1	rs36070619	ENSG00000263064.2	RP11-291L22.7	4.62	4.92e-06	0.00054	0.34	0.21	Obesity (extreme);	chr10:37664079	chr10:38448689~38448949:+
THCA	cis	rs988712	0.705	rs11030104	ENSG00000245573.6	BDNF-AS	4.62	4.92e-06	0.000541	0.21	0.21	Obesity;	chr11:27662970	chr11:27506838~27698174:+
THCA	cis	rs2439831	0.717	rs9806227	ENSG00000166763.7	STRCP1	4.62	4.92e-06	0.000541	0.28	0.21	Lung cancer in ever smokers;	chr15:43387917	chr15:43699488~43718184:-
THCA	cis	rs7179456	0.547	rs653765	ENSG00000245975.2	RP11-30K9.6	4.62	4.93e-06	0.000541	0.2	0.21	Asperger disorder;	chr15:58749813	chr15:58768072~58770974:-
THCA	cis	rs7267979	0.657	rs6107073	ENSG00000274414.1	RP5-965G21.4	-4.62	4.93e-06	0.000541	-0.25	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:25239007~25245229:-
THCA	cis	rs10090774	0.834	rs11997161	ENSG00000279766.1	RP11-642A1.2	-4.62	4.93e-06	0.000541	-0.25	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140728488	chr8:140572142~140572812:-
THCA	cis	rs2803122	0.871	rs3802333	ENSG00000273226.1	RP11-513M16.8	-4.62	4.93e-06	0.000541	-0.19	-0.21	Pulse pressure;	chr9:19232137	chr9:19375451~19375996:+
THCA	cis	rs9926296	0.609	rs4785710	ENSG00000260259.1	RP11-368I7.4	4.62	4.93e-06	0.000541	0.23	0.21	Vitiligo;	chr16:89730348	chr16:89682620~89686569:-
THCA	cis	rs7267979	0.586	rs6050439	ENSG00000277938.1	RP5-965G21.3	4.62	4.93e-06	0.000541	0.17	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25229150~25231933:+
THCA	cis	rs4950322	0.512	rs4625342	ENSG00000278811.3	LINC00624	-4.62	4.93e-06	0.000541	-0.22	-0.21	Protein quantitative trait loci;	chr1:147369887	chr1:147258885~147517875:-
THCA	cis	rs2153535	0.585	rs9378564	ENSG00000230939.1	RP11-314C16.1	-4.62	4.93e-06	0.000541	-0.22	-0.21	Motion sickness;	chr6:8639694	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs9379233	ENSG00000230939.1	RP11-314C16.1	-4.62	4.93e-06	0.000541	-0.22	-0.21	Motion sickness;	chr6:8639729	chr6:8784178~8785445:+
THCA	cis	rs9925964	0.967	rs1978487	ENSG00000260911.2	RP11-196G11.2	4.62	4.93e-06	0.000541	0.17	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118621	chr16:31043150~31049868:+
THCA	cis	rs763121	0.853	rs5757231	ENSG00000235209.1	CTA-150C2.13	-4.62	4.93e-06	0.000542	-0.27	-0.21	Menopause (age at onset);	chr22:38675653	chr22:38921227~38924708:+
THCA	cis	rs12681288	0.748	rs2701932	ENSG00000260721.1	AF067845.1	4.62	4.94e-06	0.000542	0.26	0.21	Schizophrenia;	chr8:1076946	chr8:1368642~1369833:-
THCA	cis	rs1009077	0.68	rs28540362	ENSG00000245958.5	RP11-33B1.1	4.62	4.94e-06	0.000542	0.24	0.21	Endometriosis;	chr4:119570722	chr4:119454791~119552025:+
THCA	cis	rs10090774	0.965	rs306951	ENSG00000279766.1	RP11-642A1.2	4.62	4.94e-06	0.000542	0.26	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141005549	chr8:140572142~140572812:-
THCA	cis	rs7760535	0.93	rs10872069	ENSG00000271789.1	RP5-1112D6.7	-4.62	4.94e-06	0.000542	-0.21	-0.21	Metabolic traits;	chr6:111540523	chr6:111297126~111298510:+
THCA	cis	rs4934494	0.681	rs1129777	ENSG00000240996.1	RP11-80H5.7	-4.62	4.94e-06	0.000542	-0.24	-0.21	Red blood cell count;	chr10:89709168	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.727	rs3824607	ENSG00000240996.1	RP11-80H5.7	-4.62	4.94e-06	0.000542	-0.24	-0.21	Red blood cell count;	chr10:89711258	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.681	rs3740035	ENSG00000240996.1	RP11-80H5.7	-4.62	4.94e-06	0.000542	-0.24	-0.21	Red blood cell count;	chr10:89716708	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.681	rs34591435	ENSG00000240996.1	RP11-80H5.7	-4.62	4.94e-06	0.000542	-0.24	-0.21	Red blood cell count;	chr10:89721691	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.727	rs12783845	ENSG00000240996.1	RP11-80H5.7	-4.62	4.94e-06	0.000542	-0.24	-0.21	Red blood cell count;	chr10:89722872	chr10:89694295~89697928:-
THCA	cis	rs4660214	0.666	rs11205839	ENSG00000182109.6	RP11-69E11.4	-4.62	4.94e-06	0.000542	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39522280~39546187:-
THCA	cis	rs7267979	0.586	rs1007708	ENSG00000277938.1	RP5-965G21.3	4.62	4.94e-06	0.000542	0.17	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25229150~25231933:+
THCA	cis	rs812925	0.502	rs6545868	ENSG00000270820.4	RP11-355B11.2	-4.62	4.94e-06	0.000542	-0.17	-0.21	Immature fraction of reticulocytes;	chr2:61428230	chr2:61471188~61484130:+
THCA	cis	rs7726839	0.574	rs11134148	ENSG00000225138.6	CTD-2228K2.7	4.62	4.94e-06	0.000543	0.26	0.21	Obesity-related traits;	chr5:636992	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs56325086	ENSG00000225138.6	CTD-2228K2.7	4.62	4.94e-06	0.000543	0.26	0.21	Obesity-related traits;	chr5:640613	chr5:473236~480884:+
THCA	cis	rs11992162	0.56	rs7846248	ENSG00000254948.1	OR7E158P	-4.62	4.94e-06	0.000543	-0.26	-0.21	Monocyte count;	chr8:11936540	chr8:11919900~11920809:-
THCA	cis	rs7914558	0.966	rs10883817	ENSG00000236937.2	PTGES3P4	4.62	4.94e-06	0.000543	0.26	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:102845595~102845950:+
THCA	cis	rs972578	0.653	rs5758951	ENSG00000274717.1	RP1-47A17.1	4.62	4.95e-06	0.000543	0.22	0.21	Mean platelet volume;	chr22:42801028	chr22:42791814~42794313:-
THCA	cis	rs8002861	0.87	rs9567293	ENSG00000274001.1	RP11-5G9.5	4.62	4.95e-06	0.000543	0.22	0.21	Leprosy;	chr13:43873107	chr13:43877715~43878163:-
THCA	cis	rs944289	0.74	rs414155	ENSG00000258844.1	RP11-259K15.2	-4.62	4.95e-06	0.000543	-0.18	-0.21	Thyroid cancer;	chr14:36076300	chr14:36214607~36235608:+
THCA	cis	rs9307551	0.619	rs723245	ENSG00000250334.4	LINC00989	-4.62	4.95e-06	0.000543	-0.25	-0.21	Refractive error;	chr4:79503913	chr4:79492416~79576460:+
THCA	cis	rs2067615	0.507	rs1922432	ENSG00000260329.1	RP11-412D9.4	-4.62	4.95e-06	0.000543	-0.2	-0.21	Heart rate;	chr12:106683454	chr12:106954029~106955497:-
THCA	cis	rs4662750	0.619	rs2244042	ENSG00000236682.1	AC068282.3	-4.62	4.95e-06	0.000543	-0.26	-0.21	Renal cell carcinoma;	chr2:127647423	chr2:127389130~127400580:+
THCA	cis	rs6088590	1	rs6087623	ENSG00000269202.1	RP4-614O4.12	-4.62	4.95e-06	0.000543	-0.19	-0.21	Coronary artery disease;	chr20:34729858	chr20:35201747~35203288:-
THCA	cis	rs2361710	0.668	rs4889830	ENSG00000279259.1	RP11-334C17.3	4.62	4.95e-06	0.000543	0.18	0.21	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80140729	chr17:80147250~80148596:+
THCA	cis	rs2015599	0.623	rs2288128	ENSG00000273680.1	RP11-996F15.6	-4.62	4.95e-06	0.000543	-0.3	-0.21	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29332733~29333383:-
THCA	cis	rs2015599	0.584	rs2288129	ENSG00000273680.1	RP11-996F15.6	-4.62	4.95e-06	0.000543	-0.3	-0.21	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29332733~29333383:-
THCA	cis	rs6860806	0.507	rs272880	ENSG00000237714.1	P4HA2-AS1	4.62	4.95e-06	0.000543	0.28	0.21	Breast cancer;	chr5:132334485	chr5:132184876~132192808:+
THCA	cis	rs9650657	0.504	rs6986032	ENSG00000206014.6	OR7E161P	4.62	4.95e-06	0.000544	0.24	0.21	Neuroticism;	chr8:11174731	chr8:11928597~11929563:-
THCA	cis	rs7191700	1	rs7191700	ENSG00000262703.1	RP11-485G7.6	4.62	4.96e-06	0.000544	0.27	0.21	Multiple sclerosis;	chr16:11312946	chr16:11348143~11349321:-
THCA	cis	rs7141336	0.791	rs8003239	ENSG00000258884.1	CTD-3035D6.2	-4.62	4.96e-06	0.000544	-0.27	-0.21	Anxiety disorder;	chr14:90753193	chr14:90822365~90828128:-
THCA	cis	rs13113518	1	rs11133381	ENSG00000249700.7	SRD5A3-AS1	4.62	4.96e-06	0.000544	0.26	0.21	Height;	chr4:55450812	chr4:55363971~55395847:-
THCA	cis	rs4654783	0.627	rs4655024	ENSG00000228397.1	RP1-224A6.3	4.62	4.96e-06	0.000544	0.3	0.21	Endometriosis;	chr1:22126221	chr1:22023994~22024968:-
THCA	cis	rs1185460	1	rs1799993	ENSG00000272186.1	RP11-110I1.13	4.62	4.96e-06	0.000544	0.2	0.21	Coronary artery disease;	chr11:119087417	chr11:119067374~119067698:-
THCA	cis	rs453301	0.653	rs7016139	ENSG00000254340.1	RP11-10A14.3	-4.62	4.96e-06	0.000544	-0.22	-0.21	Joint mobility (Beighton score);	chr8:9037960	chr8:9141424~9145435:+
THCA	cis	rs10483853	0.806	rs10149442	ENSG00000258695.2	RP3-414A15.2	-4.62	4.96e-06	0.000544	-0.29	-0.21	Coronary artery calcification;	chr14:73370343	chr14:73522878~73530610:+
THCA	cis	rs1923243	0.71	rs9633293	ENSG00000223479.3	RP4-788P17.1	-4.62	4.96e-06	0.000544	-0.23	-0.21	Migraine;	chr1:73156754	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs11210147	ENSG00000223479.3	RP4-788P17.1	-4.62	4.96e-06	0.000544	-0.23	-0.21	Migraine;	chr1:73157707	chr1:73635216~73715214:+
THCA	cis	rs9925964	0.933	rs56314408	ENSG00000232748.3	RP11-196G11.6	-4.62	4.96e-06	0.000544	-0.24	-0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106068	chr16:31056460~31062803:+
THCA	cis	rs17301013	0.794	rs1793293	ENSG00000227373.4	RP11-160H22.5	-4.62	4.96e-06	0.000544	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174774451	chr1:174115300~174160004:-
THCA	cis	rs858239	0.6	rs2072369	ENSG00000226816.2	AC005082.12	4.62	4.96e-06	0.000544	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23206013~23208045:+
THCA	cis	rs516805	0.501	rs564611	ENSG00000279453.1	RP3-425C14.4	-4.62	4.96e-06	0.000544	-0.17	-0.21	Lymphocyte counts;	chr6:122418178	chr6:122436789~122439223:-
THCA	cis	rs7772486	0.655	rs2142981	ENSG00000270638.1	RP3-466P17.1	-4.62	4.96e-06	0.000544	-0.16	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145735570~145737218:+
THCA	cis	rs1185460	1	rs7127212	ENSG00000272186.1	RP11-110I1.13	4.62	4.97e-06	0.000545	0.2	0.21	Coronary artery disease;	chr11:119082492	chr11:119067374~119067698:-
THCA	cis	rs2243480	1	rs427044	ENSG00000232559.3	GS1-124K5.12	4.62	4.97e-06	0.000545	0.31	0.21	Diabetic kidney disease;	chr7:66043558	chr7:66554588~66576923:-
THCA	cis	rs6121246	0.779	rs6060763	ENSG00000230613.1	HM13-AS1	4.62	4.97e-06	0.000545	0.22	0.21	Mean corpuscular hemoglobin;	chr20:31694420	chr20:31567707~31573263:-
THCA	cis	rs2243480	1	rs316315	ENSG00000164669.11	INTS4P1	-4.62	4.97e-06	0.000545	-0.35	-0.21	Diabetic kidney disease;	chr7:66126218	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs402418	ENSG00000164669.11	INTS4P1	4.62	4.97e-06	0.000545	0.4	0.21	Diabetic kidney disease;	chr7:66044482	chr7:65141225~65234216:+
THCA	cis	rs28374715	0.528	rs7178360	ENSG00000247556.5	OIP5-AS1	4.62	4.97e-06	0.000545	0.2	0.21	Ulcerative colitis;	chr15:41338977	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.578	rs7165914	ENSG00000247556.5	OIP5-AS1	4.62	4.97e-06	0.000545	0.2	0.21	Ulcerative colitis;	chr15:41340253	chr15:41283990~41309737:+
THCA	cis	rs7772486	0.701	rs697056	ENSG00000270638.1	RP3-466P17.1	-4.62	4.97e-06	0.000545	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145735570~145737218:+
THCA	cis	rs2483058	0.767	rs963894	ENSG00000261000.1	RP11-534L20.5	4.62	4.97e-06	0.000545	0.23	0.21	Cholesterol and Triglycerides;	chr1:206452085	chr1:206503948~206504456:+
THCA	cis	rs5742933	1	rs62184283	ENSG00000253559.1	OSGEPL1-AS1	-4.62	4.97e-06	0.000546	-0.26	-0.21	Ferritin levels;	chr2:189801179	chr2:189762704~189765556:+
THCA	cis	rs240993	0.812	rs9374262	ENSG00000271789.1	RP5-1112D6.7	4.62	4.98e-06	0.000546	0.26	0.21	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111297126~111298510:+
THCA	cis	rs2028299	1	rs4932148	ENSG00000259677.1	RP11-493E3.1	4.62	4.98e-06	0.000546	0.27	0.21	Type 2 diabetes;	chr15:89851124	chr15:89876540~89877285:+
THCA	cis	rs357894	1	rs357894	ENSG00000266696.1	RP11-30L3.2	4.62	4.98e-06	0.000546	0.23	0.21	Dental caries;	chr18:49053600	chr18:49205912~49208781:+
THCA	cis	rs7474896	1	rs34496143	ENSG00000263064.2	RP11-291L22.7	4.62	4.98e-06	0.000546	0.34	0.21	Obesity (extreme);	chr10:37703730	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs12357418	ENSG00000263064.2	RP11-291L22.7	4.62	4.98e-06	0.000546	0.34	0.21	Obesity (extreme);	chr10:37704932	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs72639533	ENSG00000263064.2	RP11-291L22.7	4.62	4.98e-06	0.000546	0.34	0.21	Obesity (extreme);	chr10:37708882	chr10:38448689~38448949:+
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000232559.3	GS1-124K5.12	4.62	4.98e-06	0.000546	0.31	0.21	Diabetic kidney disease;	chr7:65970805	chr7:66554588~66576923:-
THCA	cis	rs12612619	0.695	rs11126806	ENSG00000229122.1	AGBL5-IT1	-4.62	4.98e-06	0.000546	-0.15	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27002276	chr2:27061038~27061815:+
THCA	cis	rs1707322	0.638	rs1416706	ENSG00000280836.1	AL355480.1	4.62	4.98e-06	0.000546	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45581219~45581321:-
THCA	cis	rs2562456	0.839	rs2562411	ENSG00000268117.1	VN1R84P	4.62	4.98e-06	0.000546	0.33	0.21	Pain;	chr19:21419181	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.876	rs2562413	ENSG00000268117.1	VN1R84P	4.62	4.98e-06	0.000546	0.33	0.21	Pain;	chr19:21420084	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.916	rs1967182	ENSG00000268117.1	VN1R84P	4.62	4.98e-06	0.000546	0.33	0.21	Pain;	chr19:21420337	chr19:21719801~21720035:-
THCA	cis	rs9467773	0.62	rs6925087	ENSG00000261353.1	CTA-14H9.5	-4.62	4.98e-06	0.000546	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs4368798	ENSG00000261353.1	CTA-14H9.5	-4.62	4.98e-06	0.000546	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26527063~26527404:+
THCA	cis	rs2834188	0.538	rs2026253	ENSG00000272659.1	AP000295.10	-4.62	4.98e-06	0.000546	-0.26	-0.21	Narcolepsy;	chr21:33315661	chr21:33309491~33310181:+
THCA	cis	rs4218	0.731	rs11539756	ENSG00000259732.1	RP11-59H7.3	-4.62	4.98e-06	0.000547	-0.3	-0.21	Social communication problems;	chr15:59136912	chr15:59121034~59133250:+
THCA	cis	rs699371	0.525	rs7140692	ENSG00000259005.1	RP3-449M8.6	4.62	4.99e-06	0.000547	0.19	0.21	Height;	chr14:74434484	chr14:74474007~74474864:-
THCA	cis	rs73198271	0.653	rs3827811	ENSG00000253893.2	FAM85B	4.62	4.99e-06	0.000547	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8167819~8226614:-
THCA	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-4.62	4.99e-06	0.000547	-0.24	-0.21	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-4.62	4.99e-06	0.000547	-0.24	-0.21	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-4.62	4.99e-06	0.000547	-0.24	-0.21	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-4.62	4.99e-06	0.000547	-0.24	-0.21	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
THCA	cis	rs57221529	0.766	rs4081846	ENSG00000225138.6	CTD-2228K2.7	4.62	4.99e-06	0.000547	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:573904	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs4081847	ENSG00000225138.6	CTD-2228K2.7	4.62	4.99e-06	0.000547	0.27	0.21	Lung disease severity in cystic fibrosis;	chr5:573957	chr5:473236~480884:+
THCA	cis	rs2617170	0.922	rs1600128	ENSG00000245648.1	RP11-277P12.20	4.62	4.99e-06	0.000547	0.22	0.21	Behcet's disease;	chr12:10383559	chr12:10363769~10398506:+
THCA	cis	rs2617170	0.922	rs1904123	ENSG00000245648.1	RP11-277P12.20	4.62	4.99e-06	0.000547	0.22	0.21	Behcet's disease;	chr12:10385181	chr12:10363769~10398506:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000220721.1	OR1F12	4.62	4.99e-06	0.000547	0.23	0.21	Cardiac Troponin-T levels;	chr6:28164978	chr6:28073316~28074233:+
THCA	cis	rs654950	0.806	rs7550496	ENSG00000230638.4	RP11-486B10.4	-4.62	4.99e-06	0.000547	-0.24	-0.21	Airway imaging phenotypes;	chr1:41578163	chr1:41542069~41544310:+
THCA	cis	rs2243480	0.901	rs778732	ENSG00000232559.3	GS1-124K5.12	4.62	4.99e-06	0.000548	0.31	0.21	Diabetic kidney disease;	chr7:66357373	chr7:66554588~66576923:-
THCA	cis	rs858239	0.669	rs1006709	ENSG00000226816.2	AC005082.12	4.62	4.99e-06	0.000548	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23206013~23208045:+
THCA	cis	rs7111546	0.791	rs77245818	ENSG00000246225.5	RP11-17A1.3	4.62	5e-06	0.000548	0.36	0.21	Dialysis-related mortality;	chr11:22842303	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.791	rs7117614	ENSG00000246225.5	RP11-17A1.3	4.62	5e-06	0.000548	0.36	0.21	Dialysis-related mortality;	chr11:22842445	chr11:22829380~22945393:+
THCA	cis	rs9393813	0.626	rs9357038	ENSG00000204789.4	ZNF204P	4.62	5e-06	0.000548	0.17	0.21	Bipolar disorder;	chr6:27366794	chr6:27357825~27360221:-
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000229886.1	RP5-1132H15.3	4.62	5e-06	0.000548	0.39	0.21	Diabetic kidney disease;	chr7:66009932	chr7:66025126~66031544:-
THCA	cis	rs12761761	1	rs12764703	ENSG00000279982.1	RP11-45A17.3	-4.62	5e-06	0.000548	-0.31	-0.21	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131971832	chr10:131996738~131999846:+
THCA	cis	rs6840360	0.87	rs6814554	ENSG00000270265.1	RP11-731D1.4	-4.62	5e-06	0.000548	-0.2	-0.21	Intelligence (multi-trait analysis);	chr4:151533182	chr4:151333775~151353224:-
THCA	cis	rs7474896	1	rs2738225	ENSG00000263064.2	RP11-291L22.7	-4.62	5e-06	0.000548	-0.35	-0.21	Obesity (extreme);	chr10:37904201	chr10:38448689~38448949:+
THCA	cis	rs67478160	0.643	rs34813623	ENSG00000269910.1	RP11-73M18.10	4.62	5e-06	0.000548	0.18	0.21	Schizophrenia;	chr14:103796957	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.608	rs34066659	ENSG00000269910.1	RP11-73M18.10	4.62	5e-06	0.000548	0.18	0.21	Schizophrenia;	chr14:103797090	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs7147171	ENSG00000269910.1	RP11-73M18.10	4.62	5e-06	0.000548	0.18	0.21	Schizophrenia;	chr14:103798520	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.619	rs11623546	ENSG00000269910.1	RP11-73M18.10	4.62	5e-06	0.000548	0.18	0.21	Schizophrenia;	chr14:103802761	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.619	rs55824307	ENSG00000269910.1	RP11-73M18.10	4.62	5e-06	0.000548	0.18	0.21	Schizophrenia;	chr14:103804870	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.595	rs12879501	ENSG00000269910.1	RP11-73M18.10	4.62	5e-06	0.000548	0.18	0.21	Schizophrenia;	chr14:103806297	chr14:103694516~103695050:-
THCA	cis	rs9307551	0.619	rs723243	ENSG00000250334.4	LINC00989	-4.62	5e-06	0.000548	-0.25	-0.21	Refractive error;	chr4:79504189	chr4:79492416~79576460:+
THCA	cis	rs12497850	0.931	rs9840050	ENSG00000228638.1	FCF1P2	-4.62	5e-06	0.000548	-0.22	-0.21	Parkinson's disease;	chr3:49095877	chr3:48290793~48291375:-
THCA	cis	rs755249	0.701	rs1180342	ENSG00000182109.6	RP11-69E11.4	-4.62	5e-06	0.000548	-0.19	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39522280~39546187:-
THCA	cis	rs5742933	0.948	rs10195109	ENSG00000253559.1	OSGEPL1-AS1	4.62	5e-06	0.000549	0.26	0.21	Ferritin levels;	chr2:189704465	chr2:189762704~189765556:+
THCA	cis	rs4915077	0.773	rs17019773	ENSG00000230489.1	VAV3-AS1	4.62	5.01e-06	0.000549	0.34	0.21	Hypothyroidism;	chr1:107721390	chr1:107964443~107994607:+
THCA	cis	rs7520050	0.966	rs2486447	ENSG00000234329.1	RP11-767N6.2	-4.62	5.01e-06	0.000549	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs1085244	ENSG00000234329.1	RP11-767N6.2	-4.62	5.01e-06	0.000549	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6662641	ENSG00000234329.1	RP11-767N6.2	-4.62	5.01e-06	0.000549	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs1707335	ENSG00000234329.1	RP11-767N6.2	-4.62	5.01e-06	0.000549	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45651039~45651826:-
THCA	cis	rs11955398	0.502	rs6869073	ENSG00000272308.1	RP11-231G3.1	-4.62	5.01e-06	0.000549	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61117301	chr5:60866457~60866935:-
THCA	cis	rs11955398	0.542	rs295578	ENSG00000272308.1	RP11-231G3.1	-4.62	5.01e-06	0.000549	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61124955	chr5:60866457~60866935:-
THCA	cis	rs11955398	0.502	rs159375	ENSG00000272308.1	RP11-231G3.1	-4.62	5.01e-06	0.000549	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61137440	chr5:60866457~60866935:-
THCA	cis	rs11955398	0.502	rs159374	ENSG00000272308.1	RP11-231G3.1	-4.62	5.01e-06	0.000549	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61139117	chr5:60866457~60866935:-
THCA	cis	rs11955398	0.502	rs810884	ENSG00000272308.1	RP11-231G3.1	-4.62	5.01e-06	0.000549	-0.22	-0.21	Intelligence (multi-trait analysis);	chr5:61152449	chr5:60866457~60866935:-
THCA	cis	rs5742933	1	rs3791767	ENSG00000273240.1	RP11-455J20.3	4.62	5.01e-06	0.000549	0.23	0.21	Ferritin levels;	chr2:189775189	chr2:189763859~189764456:-
THCA	cis	rs11976180	0.517	rs6949375	ENSG00000228960.5	OR2A9P	-4.62	5.01e-06	0.000549	-0.37	-0.21	Obesity-related traits;	chr7:144076758	chr7:144294480~144300934:+
THCA	cis	rs17772222	0.63	rs12433739	ENSG00000258983.2	RP11-507K2.2	4.62	5.01e-06	0.000549	0.26	0.21	Coronary artery calcification;	chr14:88331704	chr14:88499334~88515502:+
THCA	cis	rs9890032	0.509	rs11656986	ENSG00000264538.5	SUZ12P1	-4.62	5.01e-06	0.000549	-0.16	-0.21	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30709299~30790908:+
THCA	cis	rs2380220	0.516	rs7748108	ENSG00000261366.1	MANEA-AS1	-4.62	5.01e-06	0.00055	-0.19	-0.21	Behavioural disinhibition (generation interaction);	chr6:95560206	chr6:95575183~95577450:-
THCA	cis	rs4908768	0.52	rs11121224	ENSG00000232912.4	RP5-1115A15.1	4.62	5.02e-06	0.00055	0.2	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8713456	chr1:8424645~8434838:+
THCA	cis	rs28386778	0.799	rs2665802	ENSG00000240280.5	TCAM1P	4.62	5.02e-06	0.00055	0.29	0.21	Prudent dietary pattern;	chr17:63917670	chr17:63849292~63864379:+
THCA	cis	rs972578	0.691	rs2179260	ENSG00000274717.1	RP1-47A17.1	4.62	5.02e-06	0.00055	0.22	0.21	Mean platelet volume;	chr22:42961066	chr22:42791814~42794313:-
THCA	cis	rs2439831	1	rs2584726	ENSG00000166763.7	STRCP1	4.62	5.02e-06	0.00055	0.28	0.21	Lung cancer in ever smokers;	chr15:43423184	chr15:43699488~43718184:-
THCA	cis	rs13113518	1	rs1554483	ENSG00000249700.7	SRD5A3-AS1	4.62	5.02e-06	0.00055	0.26	0.21	Height;	chr4:55455650	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs1464490	ENSG00000249700.7	SRD5A3-AS1	4.62	5.02e-06	0.00055	0.26	0.21	Height;	chr4:55456620	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs10517346	ENSG00000249700.7	SRD5A3-AS1	4.62	5.02e-06	0.00055	0.26	0.21	Height;	chr4:55457027	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11133384	ENSG00000249700.7	SRD5A3-AS1	4.62	5.02e-06	0.00055	0.26	0.21	Height;	chr4:55457086	chr4:55363971~55395847:-
THCA	cis	rs1488902	1	rs1488902	ENSG00000280367.1	RP11-121L10.2	-4.62	5.02e-06	0.00055	-0.19	-0.21	Amyotrophic lateral sclerosis;	chr11:89611857	chr11:90223153~90226538:+
THCA	cis	rs8062405	1	rs80275162	ENSG00000261766.1	RP11-22P6.2	-4.62	5.02e-06	0.00055	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28862166~28863340:-
THCA	cis	rs12681288	0.862	rs2701899	ENSG00000260721.1	AF067845.1	4.62	5.02e-06	0.00055	0.26	0.21	Schizophrenia;	chr8:1069581	chr8:1368642~1369833:-
THCA	cis	rs8077577	0.747	rs62072507	ENSG00000273018.4	CTD-2303H24.2	-4.62	5.02e-06	0.00055	-0.31	-0.21	Obesity-related traits;	chr17:18269021	chr17:18511221~18551705:-
THCA	cis	rs494453	0.744	rs2182016	ENSG00000227811.2	FAM212B-AS1	4.62	5.02e-06	0.00055	0.28	0.21	Osteoporosis-related phenotypes;	chr1:111641877	chr1:111739841~111747798:+
THCA	cis	rs11673344	0.504	rs11666786	ENSG00000276846.1	CTD-3220F14.3	4.62	5.02e-06	0.00055	0.16	0.21	Obesity-related traits;	chr19:37133947	chr19:37314868~37315620:-
THCA	cis	rs12291225	0.546	rs12795545	ENSG00000251991.1	RNU7-49P	4.62	5.02e-06	0.00055	0.24	0.21	Sense of smell;	chr11:14334018	chr11:14478892~14478953:+
THCA	cis	rs1864400	0.645	rs2249005	ENSG00000273008.1	RP11-351D16.3	-4.62	5.02e-06	0.00055	-0.2	-0.21	Hirschsprung disease;	chr10:43131832	chr10:43136824~43138334:-
THCA	cis	rs11148252	0.595	rs9526974	ENSG00000273784.3	RP11-78J21.7	-4.62	5.02e-06	0.00055	-0.23	-0.21	Lewy body disease;	chr13:52676905	chr13:52600042~52642542:+
THCA	cis	rs10483853	0.806	rs8009393	ENSG00000258695.2	RP3-414A15.2	-4.62	5.02e-06	0.000551	-0.29	-0.21	Coronary artery calcification;	chr14:73372872	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.806	rs12589279	ENSG00000258695.2	RP3-414A15.2	-4.62	5.02e-06	0.000551	-0.29	-0.21	Coronary artery calcification;	chr14:73386429	chr14:73522878~73530610:+
THCA	cis	rs2013441	0.513	rs62067488	ENSG00000261033.1	RP11-209D14.2	-4.62	5.03e-06	0.000551	-0.28	-0.21	Obesity-related traits;	chr17:20063968	chr17:20008051~20009234:-
THCA	cis	rs2617170	0.922	rs2617160	ENSG00000245648.1	RP11-277P12.20	4.62	5.03e-06	0.000551	0.22	0.21	Behcet's disease;	chr12:10392998	chr12:10363769~10398506:+
THCA	cis	rs17301013	0.861	rs61826916	ENSG00000227373.4	RP11-160H22.5	4.62	5.03e-06	0.000551	0.29	0.21	Systemic lupus erythematosus;	chr1:174616048	chr1:174115300~174160004:-
THCA	cis	rs6832769	1	rs726967	ENSG00000272969.1	RP11-528I4.2	-4.62	5.03e-06	0.000551	-0.25	-0.21	Personality dimensions;	chr4:55555546	chr4:55547112~55547889:+
THCA	cis	rs7267979	1	rs4815408	ENSG00000274973.1	RP13-401N8.7	4.62	5.03e-06	0.000551	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25845497~25845862:+
THCA	cis	rs17095355	1	rs12247564	ENSG00000203876.8	ADD3-AS1	-4.62	5.03e-06	0.000551	-0.22	-0.21	Biliary atresia;	chr10:109961642	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs12267704	ENSG00000203876.8	ADD3-AS1	-4.62	5.03e-06	0.000551	-0.22	-0.21	Biliary atresia;	chr10:109962250	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs12267714	ENSG00000203876.8	ADD3-AS1	-4.62	5.03e-06	0.000551	-0.22	-0.21	Biliary atresia;	chr10:109962294	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs12259261	ENSG00000203876.8	ADD3-AS1	-4.62	5.03e-06	0.000551	-0.22	-0.21	Biliary atresia;	chr10:109965387	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs12246851	ENSG00000203876.8	ADD3-AS1	-4.62	5.03e-06	0.000551	-0.22	-0.21	Biliary atresia;	chr10:109966582	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs12570820	ENSG00000203876.8	ADD3-AS1	-4.62	5.03e-06	0.000551	-0.22	-0.21	Biliary atresia;	chr10:109972749	chr10:109940104~110008381:-
THCA	cis	rs1707322	1	rs7538978	ENSG00000281133.1	AL355480.3	4.62	5.03e-06	0.000551	0.25	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45580892~45580996:-
THCA	cis	rs6787172	0.811	rs9883657	ENSG00000272087.1	RP11-379F4.7	-4.62	5.03e-06	0.000551	-0.18	-0.21	Subjective well-being;	chr3:158508210	chr3:158693120~158693768:-
THCA	cis	rs1046896	0.553	rs72634343	ENSG00000263063.1	RP11-388C12.1	-4.62	5.03e-06	0.000551	-0.27	-0.21	Glycated hemoglobin levels;	chr17:82869516	chr17:82713908~82716255:-
THCA	cis	rs875971	0.789	rs28815324	ENSG00000164669.11	INTS4P1	4.62	5.03e-06	0.000551	0.3	0.21	Aortic root size;	chr7:66100789	chr7:65141225~65234216:+
THCA	cis	rs11175834	0.655	rs11175829	ENSG00000250748.5	RP11-230G5.2	4.62	5.03e-06	0.000551	0.34	0.21	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65587275	chr12:65466820~65642372:-
THCA	cis	rs4950322	0.857	rs72693002	ENSG00000271721.1	RP11-337C18.9	4.62	5.03e-06	0.000551	0.24	0.21	Protein quantitative trait loci;	chr1:147357593	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.857	rs72694703	ENSG00000271721.1	RP11-337C18.9	4.62	5.03e-06	0.000551	0.24	0.21	Protein quantitative trait loci;	chr1:147358427	chr1:147175602~147177740:+
THCA	cis	rs4072705	0.646	rs2416933	ENSG00000224020.1	MIR181A2HG	4.62	5.03e-06	0.000551	0.19	0.21	Menarche (age at onset);	chr9:124483250	chr9:124658467~124698631:+
THCA	cis	rs12549025	0.559	rs721183	ENSG00000253390.1	CTC-756D1.2	-4.62	5.03e-06	0.000551	-0.32	-0.21	Reticulocyte fraction of red cells;	chr8:23528321	chr8:23458601~23484971:+
THCA	cis	rs7726839	0.794	rs6883536	ENSG00000225138.6	CTD-2228K2.7	4.62	5.03e-06	0.000551	0.23	0.21	Obesity-related traits;	chr5:599159	chr5:473236~480884:+
THCA	cis	rs730566	0.64	rs6442112	ENSG00000228638.1	FCF1P2	-4.62	5.03e-06	0.000551	-0.21	-0.21	Prion diseases;	chr3:48274544	chr3:48290793~48291375:-
THCA	cis	rs739496	0.501	rs441	ENSG00000226469.1	ADAM1B	4.62	5.03e-06	0.000551	0.26	0.21	Platelet count;	chr12:111791045	chr12:111927018~111929017:+
THCA	cis	rs2243480	1	rs937108	ENSG00000232559.3	GS1-124K5.12	4.62	5.03e-06	0.000551	0.31	0.21	Diabetic kidney disease;	chr7:65963465	chr7:66554588~66576923:-
THCA	cis	rs9625935	0.957	rs12168552	ENSG00000279159.1	RP3-394A18.1	-4.62	5.04e-06	0.000552	-0.16	-0.21	Tonsillectomy;	chr22:29863982	chr22:29978950~30028236:-
THCA	cis	rs2281603	0.762	rs10132794	ENSG00000259116.1	RP11-973N13.4	-4.62	5.04e-06	0.000552	-0.21	-0.21	Lymphocyte counts;	chr14:64581793	chr14:64514154~64540368:-
THCA	cis	rs736408	0.546	rs3733046	ENSG00000243224.1	RP5-1157M23.2	-4.62	5.04e-06	0.000552	-0.22	-0.21	Bipolar disorder;	chr3:52587611	chr3:52239258~52241097:+
THCA	cis	rs763121	0.853	rs5750671	ENSG00000228274.3	RP3-508I15.9	-4.62	5.04e-06	0.000552	-0.23	-0.21	Menopause (age at onset);	chr22:38698614	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs926299	ENSG00000228274.3	RP3-508I15.9	-4.62	5.04e-06	0.000552	-0.23	-0.21	Menopause (age at onset);	chr22:38699693	chr22:38667585~38681820:-
THCA	cis	rs763121	0.785	rs6001203	ENSG00000228274.3	RP3-508I15.9	-4.62	5.04e-06	0.000552	-0.23	-0.21	Menopause (age at onset);	chr22:38703597	chr22:38667585~38681820:-
THCA	cis	rs6121246	0.909	rs7272062	ENSG00000230613.1	HM13-AS1	4.62	5.04e-06	0.000552	0.22	0.21	Mean corpuscular hemoglobin;	chr20:31671342	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6119651	ENSG00000230613.1	HM13-AS1	4.62	5.04e-06	0.000552	0.22	0.21	Mean corpuscular hemoglobin;	chr20:31671443	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs2376992	ENSG00000230613.1	HM13-AS1	4.62	5.04e-06	0.000552	0.22	0.21	Mean corpuscular hemoglobin;	chr20:31675615	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6060644	ENSG00000230613.1	HM13-AS1	4.62	5.04e-06	0.000552	0.22	0.21	Mean corpuscular hemoglobin;	chr20:31677849	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6060679	ENSG00000230613.1	HM13-AS1	-4.62	5.04e-06	0.000552	-0.22	-0.21	Mean corpuscular hemoglobin;	chr20:31682969	chr20:31567707~31573263:-
THCA	cis	rs875971	0.66	rs10229345	ENSG00000229886.1	RP5-1132H15.3	4.62	5.04e-06	0.000552	0.22	0.21	Aortic root size;	chr7:66517181	chr7:66025126~66031544:-
THCA	cis	rs8067545	0.611	rs2703812	ENSG00000270091.1	RP11-78O7.2	4.62	5.04e-06	0.000552	0.16	0.21	Schizophrenia;	chr17:20211490	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs2703814	ENSG00000270091.1	RP11-78O7.2	4.62	5.04e-06	0.000552	0.16	0.21	Schizophrenia;	chr17:20213838	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.586	rs2526478	ENSG00000270091.1	RP11-78O7.2	-4.62	5.04e-06	0.000552	-0.16	-0.21	Schizophrenia;	chr17:20227139	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs2703776	ENSG00000270091.1	RP11-78O7.2	4.62	5.04e-06	0.000552	0.16	0.21	Schizophrenia;	chr17:20234396	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs2703777	ENSG00000270091.1	RP11-78O7.2	4.62	5.04e-06	0.000552	0.16	0.21	Schizophrenia;	chr17:20235578	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.586	rs11657161	ENSG00000270091.1	RP11-78O7.2	4.62	5.04e-06	0.000552	0.16	0.21	Schizophrenia;	chr17:20277402	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.563	rs3850780	ENSG00000270091.1	RP11-78O7.2	4.62	5.04e-06	0.000552	0.16	0.21	Schizophrenia;	chr17:20278589	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs11653630	ENSG00000270091.1	RP11-78O7.2	4.62	5.04e-06	0.000552	0.16	0.21	Schizophrenia;	chr17:20285733	chr17:19896590~19897287:-
THCA	cis	rs613391	0.742	rs637242	ENSG00000224549.1	RP11-370B11.3	-4.62	5.04e-06	0.000552	-0.23	-0.21	Quantitative traits;	chr9:22680771	chr9:22767175~22768316:+
THCA	cis	rs6445975	0.715	rs6790764	ENSG00000272360.1	RP11-359I18.5	-4.62	5.04e-06	0.000552	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58280223	chr3:58490830~58491291:-
THCA	cis	rs930395	0.514	rs4323241	ENSG00000272335.1	RP11-53O19.3	4.62	5.04e-06	0.000552	0.18	0.21	Breast cancer;	chr5:44929054	chr5:44826076~44828592:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000229180.5	GS1-124K5.11	4.62	5.04e-06	0.000552	0.17	0.21	Corneal structure;	chr7:66925737	chr7:66526088~66542624:-
THCA	cis	rs6772849	0.768	rs9820741	ENSG00000242551.2	POU5F1P6	-4.62	5.04e-06	0.000552	-0.28	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128697237	chr3:128674735~128677005:-
THCA	cis	rs2562456	0.793	rs73537884	ENSG00000268117.1	VN1R84P	4.62	5.04e-06	0.000552	0.33	0.21	Pain;	chr19:21321908	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs78467454	ENSG00000268117.1	VN1R84P	4.62	5.04e-06	0.000552	0.33	0.21	Pain;	chr19:21321930	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs55790393	ENSG00000268117.1	VN1R84P	4.62	5.04e-06	0.000552	0.33	0.21	Pain;	chr19:21323382	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs11672341	ENSG00000268117.1	VN1R84P	4.62	5.04e-06	0.000552	0.33	0.21	Pain;	chr19:21324502	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.754	rs11673234	ENSG00000268117.1	VN1R84P	4.62	5.04e-06	0.000552	0.33	0.21	Pain;	chr19:21324800	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.754	rs11673320	ENSG00000268117.1	VN1R84P	4.62	5.04e-06	0.000552	0.33	0.21	Pain;	chr19:21324801	chr19:21719801~21720035:-
THCA	cis	rs7474896	0.515	rs594594	ENSG00000263064.2	RP11-291L22.7	-4.62	5.04e-06	0.000552	-0.28	-0.21	Obesity (extreme);	chr10:38018795	chr10:38448689~38448949:+
THCA	cis	rs9475752	0.564	rs58721182	ENSG00000231441.1	RP11-472M19.2	4.62	5.05e-06	0.000553	0.23	0.21	Menarche (age at onset);	chr6:56902505	chr6:56844002~56864078:+
THCA	cis	rs763121	0.853	rs3747172	ENSG00000273076.1	RP3-508I15.22	4.62	5.05e-06	0.000553	0.21	0.21	Menopause (age at onset);	chr22:38671519	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5750659	ENSG00000273076.1	RP3-508I15.22	4.62	5.05e-06	0.000553	0.21	0.21	Menopause (age at onset);	chr22:38672784	chr22:38743495~38743910:+
THCA	cis	rs763121	0.819	rs3747173	ENSG00000273076.1	RP3-508I15.22	4.62	5.05e-06	0.000553	0.21	0.21	Menopause (age at onset);	chr22:38673040	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs3747174	ENSG00000273076.1	RP3-508I15.22	4.62	5.05e-06	0.000553	0.21	0.21	Menopause (age at onset);	chr22:38673176	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs1065201	ENSG00000273076.1	RP3-508I15.22	4.62	5.05e-06	0.000553	0.21	0.21	Menopause (age at onset);	chr22:38673505	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757226	ENSG00000273076.1	RP3-508I15.22	4.62	5.05e-06	0.000553	0.21	0.21	Menopause (age at onset);	chr22:38674545	chr22:38743495~38743910:+
THCA	cis	rs2904524	0.737	rs10506591	ENSG00000257815.4	RP11-611E13.2	-4.62	5.05e-06	0.000553	-0.3	-0.21	Amyotrophic lateral sclerosis (age of onset);	chr12:70355623	chr12:69904033~70243360:-
THCA	cis	rs11779988	0.528	rs208029	ENSG00000253671.1	RP11-806O11.1	-4.62	5.05e-06	0.000553	-0.27	-0.21	Breast cancer;	chr8:17983478	chr8:17808941~17820868:+
THCA	cis	rs9880211	0.8	rs35100027	ENSG00000239213.4	NCK1-AS1	4.62	5.05e-06	0.000553	0.23	0.21	Height;Body mass index;	chr3:136748719	chr3:136841726~136862054:-
THCA	cis	rs36093844	0.8	rs112468922	ENSG00000279742.1	RP11-700A24.1	-4.62	5.05e-06	0.000553	-0.3	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865651	chr11:85852557~85854943:-
THCA	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	4.62	5.05e-06	0.000553	0.23	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
THCA	cis	rs7429990	0.803	rs13319205	ENSG00000228638.1	FCF1P2	-4.62	5.05e-06	0.000553	-0.21	-0.21	Educational attainment (years of education);	chr3:47758726	chr3:48290793~48291375:-
THCA	cis	rs72843506	0.656	rs77540008	ENSG00000231258.2	ZSWIM5P2	4.62	5.05e-06	0.000553	0.31	0.21	Schizophrenia;	chr17:20069886	chr17:20583758~20591180:-
THCA	cis	rs11096990	0.855	rs2167494	ENSG00000249685.1	RP11-360F5.3	-4.62	5.05e-06	0.000553	-0.28	-0.21	Cognitive function;	chr4:39214601	chr4:39133913~39135608:+
THCA	cis	rs11122895	0.509	rs10174353	ENSG00000236307.2	EEF1E1P1	4.62	5.05e-06	0.000553	0.26	0.21	Allergic sensitization;	chr2:111690311	chr2:111887914~111888741:+
THCA	cis	rs6416877	0.704	rs11657524	ENSG00000277491.1	RP11-676J12.9	-4.62	5.06e-06	0.000554	-0.23	-0.21	Myeloid white cell count;	chr17:1454829	chr17:795306~795794:+
THCA	cis	rs6570726	0.935	rs398060	ENSG00000270638.1	RP3-466P17.1	-4.62	5.06e-06	0.000554	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145520379	chr6:145735570~145737218:+
THCA	cis	rs919433	0.617	rs4850807	ENSG00000231621.1	AC013264.2	4.62	5.06e-06	0.000554	0.22	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197711251	chr2:197197991~197199273:+
THCA	cis	rs875971	0.545	rs6961853	ENSG00000273142.1	RP11-458F8.4	4.62	5.06e-06	0.000554	0.19	0.21	Aortic root size;	chr7:66537035	chr7:66902857~66906297:+
THCA	cis	rs4648045	0.964	rs3774959	ENSG00000246560.2	RP11-10L12.4	-4.62	5.06e-06	0.000554	-0.26	-0.21	Lymphocyte percentage of white cells;	chr4:102589957	chr4:102828055~102844075:+
THCA	cis	rs7551222	0.646	rs2926536	ENSG00000240219.1	RP11-430C7.5	-4.62	5.06e-06	0.000554	-0.22	-0.21	Schizophrenia;	chr1:204487855	chr1:204626775~204629712:+
THCA	cis	rs11157436	0.958	rs17255510	ENSG00000211812.1	TRAV26-2	4.62	5.06e-06	0.000554	0.19	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22202583~22203368:+
THCA	cis	rs875971	1	rs1144895	ENSG00000222364.1	RNU6-96P	4.62	5.06e-06	0.000554	0.25	0.21	Aortic root size;	chr7:66076320	chr7:66395191~66395286:+
THCA	cis	rs11992186	0.597	rs11781841	ENSG00000254153.1	CTA-398F10.2	4.62	5.06e-06	0.000554	0.23	0.21	Neuroticism;	chr8:8737753	chr8:8456909~8461337:-
THCA	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-4.62	5.06e-06	0.000554	-0.33	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
THCA	cis	rs9595908	0.869	rs9595946	ENSG00000212293.1	SNORA16	4.62	5.06e-06	0.000554	0.24	0.21	Body mass index;	chr13:32628998	chr13:32420390~32420516:-
THCA	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	4.62	5.06e-06	0.000554	0.26	0.21	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
THCA	cis	rs7617480	0.617	rs7610519	ENSG00000229759.1	MRPS18AP1	4.62	5.06e-06	0.000554	0.32	0.21	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48708994	chr3:48256350~48256938:-
THCA	cis	rs4973397	0.774	rs12998237	ENSG00000224376.1	AC017104.6	4.62	5.06e-06	0.000554	0.24	0.21	Anti-saccade response;	chr2:231411940	chr2:231388976~231394991:+
THCA	cis	rs7824557	0.815	rs958648	ENSG00000154316.13	TDH	4.62	5.06e-06	0.000554	0.14	0.21	Retinal vascular caliber;	chr8:11246386	chr8:11339637~11368452:+
THCA	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	4.62	5.06e-06	0.000554	0.22	0.21	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
THCA	cis	rs2797160	0.547	rs10872298	ENSG00000237742.5	RP11-624M8.1	-4.62	5.06e-06	0.000554	-0.19	-0.21	Endometrial cancer;	chr6:125635202	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.547	rs9401836	ENSG00000237742.5	RP11-624M8.1	-4.62	5.06e-06	0.000554	-0.19	-0.21	Endometrial cancer;	chr6:125635590	chr6:125578558~125749190:-
THCA	cis	rs2797160	0.547	rs9401837	ENSG00000237742.5	RP11-624M8.1	-4.62	5.06e-06	0.000554	-0.19	-0.21	Endometrial cancer;	chr6:125635707	chr6:125578558~125749190:-
THCA	cis	rs240993	0.81	rs466765	ENSG00000271789.1	RP5-1112D6.7	-4.62	5.06e-06	0.000554	-0.26	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111347291	chr6:111297126~111298510:+
THCA	cis	rs752010	1	rs2077172	ENSG00000230638.4	RP11-486B10.4	-4.62	5.06e-06	0.000554	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41627669	chr1:41542069~41544310:+
THCA	cis	rs752010	1	rs4999015	ENSG00000230638.4	RP11-486B10.4	-4.62	5.06e-06	0.000554	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41627876	chr1:41542069~41544310:+
THCA	cis	rs7111546	0.791	rs77700609	ENSG00000246225.5	RP11-17A1.3	4.62	5.06e-06	0.000554	0.37	0.21	Dialysis-related mortality;	chr11:22856122	chr11:22829380~22945393:+
THCA	cis	rs73108077	0.736	rs6119276	ENSG00000277112.2	RP11-755J8.1	-4.62	5.07e-06	0.000555	-0.34	-0.21	Red blood cell density in sickle cell anemia;	chr20:31363733	chr20:30681825~30723932:-
THCA	cis	rs28374715	0.783	rs11630656	ENSG00000247556.5	OIP5-AS1	4.62	5.07e-06	0.000555	0.2	0.21	Ulcerative colitis;	chr15:41278711	chr15:41283990~41309737:+
THCA	cis	rs2797160	1	rs9491471	ENSG00000237742.5	RP11-624M8.1	-4.62	5.07e-06	0.000555	-0.18	-0.21	Endometrial cancer;	chr6:125670569	chr6:125578558~125749190:-
THCA	cis	rs3734266	0.702	rs13210470	ENSG00000272288.4	RP11-140K17.3	-4.62	5.07e-06	0.000555	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34834001	chr6:34696317~34697470:+
THCA	cis	rs793571	0.628	rs12439632	ENSG00000259250.1	RP11-50C13.1	-4.62	5.07e-06	0.000555	-0.22	-0.21	Schizophrenia;	chr15:58811764	chr15:58587507~58591676:+
THCA	cis	rs5758659	1	rs134900	ENSG00000273366.1	CTA-989H11.1	-4.62	5.07e-06	0.000555	-0.24	-0.21	Cognitive function;	chr22:42287337	chr22:42278188~42278846:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000273142.1	RP11-458F8.4	-4.62	5.07e-06	0.000555	-0.19	-0.21	Aortic root size;	chr7:66560286	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs73152714	ENSG00000273142.1	RP11-458F8.4	4.62	5.07e-06	0.000555	0.19	0.21	Aortic root size;	chr7:66534641	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000273142.1	RP11-458F8.4	4.62	5.07e-06	0.000555	0.19	0.21	Aortic root size;	chr7:66536353	chr7:66902857~66906297:+
THCA	cis	rs73198271	0.843	rs11775888	ENSG00000253893.2	FAM85B	4.62	5.07e-06	0.000555	0.33	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748188	chr8:8167819~8226614:-
THCA	cis	rs793571	0.628	rs7169205	ENSG00000259250.1	RP11-50C13.1	-4.62	5.07e-06	0.000555	-0.22	-0.21	Schizophrenia;	chr15:58788004	chr15:58587507~58591676:+
THCA	cis	rs8062405	1	rs8062405	ENSG00000261766.1	RP11-22P6.2	4.62	5.07e-06	0.000555	0.2	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28862166~28863340:-
THCA	cis	rs889398	0.967	rs244415	ENSG00000226232.7	RP11-419C5.2	4.62	5.07e-06	0.000555	0.2	0.21	Body mass index;	chr16:69632780	chr16:69976388~69996188:-
THCA	cis	rs35740288	0.929	rs11556865	ENSG00000259295.5	CSPG4P12	4.62	5.07e-06	0.000555	0.32	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85759949	chr15:85191438~85213905:+
THCA	cis	rs713477	0.524	rs4901560	ENSG00000258413.1	RP11-665C16.6	-4.62	5.07e-06	0.000556	-0.29	-0.21	Pediatric bone mineral content (femoral neck);	chr14:55421815	chr14:55262767~55272075:-
THCA	cis	rs4648045	0.647	rs230494	ENSG00000246560.2	RP11-10L12.4	-4.62	5.08e-06	0.000556	-0.25	-0.21	Lymphocyte percentage of white cells;	chr4:102565812	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.608	rs230495	ENSG00000246560.2	RP11-10L12.4	-4.62	5.08e-06	0.000556	-0.25	-0.21	Lymphocyte percentage of white cells;	chr4:102566143	chr4:102828055~102844075:+
THCA	cis	rs10829156	0.51	rs1490197	ENSG00000240291.1	RP11-499P20.2	4.62	5.08e-06	0.000556	0.17	0.21	Sudden cardiac arrest;	chr10:18696785	chr10:18513115~18545651:-
THCA	cis	rs17801127	0.748	rs16827313	ENSG00000231969.1	AC144449.1	4.62	5.08e-06	0.000556	0.35	0.21	Liver enzyme levels (alanine transaminase);	chr2:149669667	chr2:149587196~149848233:+
THCA	cis	rs2886497	0.947	rs4287250	ENSG00000224215.1	RP11-371A19.2	-4.62	5.08e-06	0.000556	-0.26	-0.21	Major depression and alcohol dependence;	chr10:23375462	chr10:23343957~23345181:+
THCA	cis	rs8058578	0.832	rs7500719	ENSG00000279196.1	RP11-1072A3.3	4.61	5.08e-06	0.000556	0.21	0.21	Multiple myeloma;	chr16:30829556	chr16:30984630~30988270:-
THCA	cis	rs12612619	0.732	rs920433	ENSG00000229122.1	AGBL5-IT1	4.61	5.08e-06	0.000556	0.15	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989658	chr2:27061038~27061815:+
THCA	cis	rs858239	0.539	rs4365988	ENSG00000226816.2	AC005082.12	4.61	5.08e-06	0.000556	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs10279194	ENSG00000226816.2	AC005082.12	4.61	5.08e-06	0.000556	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs3950345	ENSG00000226816.2	AC005082.12	4.61	5.08e-06	0.000556	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs2178140	ENSG00000226816.2	AC005082.12	4.61	5.08e-06	0.000556	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs2178139	ENSG00000226816.2	AC005082.12	4.61	5.08e-06	0.000556	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs2141306	ENSG00000226816.2	AC005082.12	4.61	5.08e-06	0.000556	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs2141305	ENSG00000226816.2	AC005082.12	4.61	5.08e-06	0.000556	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23206013~23208045:+
THCA	cis	rs7646881	0.544	rs73030851	ENSG00000240207.5	RP11-379F4.4	-4.61	5.08e-06	0.000556	-0.3	-0.21	Tetralogy of Fallot;	chr3:158699163	chr3:158732263~158784070:+
THCA	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	4.61	5.08e-06	0.000556	0.18	0.21	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
THCA	cis	rs1371614	0.566	rs10184824	ENSG00000229122.1	AGBL5-IT1	-4.61	5.08e-06	0.000556	-0.15	-0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26955084	chr2:27061038~27061815:+
THCA	cis	rs9311474	0.508	rs2878628	ENSG00000243224.1	RP5-1157M23.2	4.61	5.08e-06	0.000556	0.22	0.21	Electroencephalogram traits;	chr3:52550699	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs17052256	ENSG00000243224.1	RP5-1157M23.2	-4.61	5.08e-06	0.000556	-0.22	-0.21	Electroencephalogram traits;	chr3:52559103	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs17052259	ENSG00000243224.1	RP5-1157M23.2	-4.61	5.08e-06	0.000556	-0.22	-0.21	Electroencephalogram traits;	chr3:52559122	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs3796353	ENSG00000243224.1	RP5-1157M23.2	-4.61	5.08e-06	0.000556	-0.22	-0.21	Electroencephalogram traits;	chr3:52559214	chr3:52239258~52241097:+
THCA	cis	rs9329221	0.543	rs2952205	ENSG00000261451.1	RP11-981G7.1	4.61	5.08e-06	0.000556	0.25	0.21	Neuroticism;	chr8:10282355	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs35009431	ENSG00000206014.6	OR7E161P	4.61	5.08e-06	0.000556	0.24	0.21	Retinal vascular caliber;	chr8:11375279	chr8:11928597~11929563:-
THCA	cis	rs7394190	0.748	rs16930909	ENSG00000271848.1	RP11-464F9.21	-4.61	5.08e-06	0.000556	-0.29	-0.21	Incident atrial fibrillation;	chr10:73801824	chr10:73654039~73674719:+
THCA	cis	rs9902453	1	rs62070270	ENSG00000263370.1	RP11-68I3.5	4.61	5.08e-06	0.000557	0.27	0.21	Coffee consumption (cups per day);	chr17:29936962	chr17:29639627~29640825:+
THCA	cis	rs7474896	0.832	rs11596492	ENSG00000263064.2	RP11-291L22.7	4.61	5.08e-06	0.000557	0.34	0.21	Obesity (extreme);	chr10:37691541	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs7474896	ENSG00000263064.2	RP11-291L22.7	4.61	5.08e-06	0.000557	0.34	0.21	Obesity (extreme);	chr10:37693169	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs12772239	ENSG00000263064.2	RP11-291L22.7	4.61	5.08e-06	0.000557	0.34	0.21	Obesity (extreme);	chr10:37700016	chr10:38448689~38448949:+
THCA	cis	rs17270561	0.609	rs9358873	ENSG00000272462.2	U91328.19	-4.61	5.08e-06	0.000557	-0.18	-0.21	Iron status biomarkers;	chr6:25731555	chr6:25992662~26001775:+
THCA	cis	rs8105895	0.935	rs1968446	ENSG00000269345.1	VN1R85P	4.61	5.09e-06	0.000557	0.28	0.21	Body mass index (change over time);	chr19:22096245	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7256462	ENSG00000269345.1	VN1R85P	4.61	5.09e-06	0.000557	0.28	0.21	Body mass index (change over time);	chr19:22099191	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs10425828	ENSG00000269345.1	VN1R85P	4.61	5.09e-06	0.000557	0.28	0.21	Body mass index (change over time);	chr19:22100275	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs8103374	ENSG00000269345.1	VN1R85P	4.61	5.09e-06	0.000557	0.28	0.21	Body mass index (change over time);	chr19:22101517	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs8103279	ENSG00000269345.1	VN1R85P	4.61	5.09e-06	0.000557	0.28	0.21	Body mass index (change over time);	chr19:22101538	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.867	rs8106762	ENSG00000269345.1	VN1R85P	4.61	5.09e-06	0.000557	0.28	0.21	Body mass index (change over time);	chr19:22101934	chr19:22174766~22175191:-
THCA	cis	rs1880529	0.732	rs9307390	ENSG00000206820.1	RNU1-138P	-4.61	5.09e-06	0.000557	-0.24	-0.21	White matter integrity (bipolar disorder risk interaction);	chr4:113435007	chr4:113420323~113420486:+
THCA	cis	rs801193	0.935	rs3800820	ENSG00000229886.1	RP5-1132H15.3	-4.61	5.09e-06	0.000557	-0.21	-0.21	Aortic root size;	chr7:66682191	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs2003301	ENSG00000229886.1	RP5-1132H15.3	-4.61	5.09e-06	0.000557	-0.21	-0.21	Aortic root size;	chr7:66682669	chr7:66025126~66031544:-
THCA	cis	rs8062405	0.824	rs240702	ENSG00000261766.1	RP11-22P6.2	-4.61	5.09e-06	0.000557	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28862166~28863340:-
THCA	cis	rs2439831	1	rs689596	ENSG00000205771.5	CATSPER2P1	-4.61	5.09e-06	0.000557	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43469519	chr15:43726918~43747094:-
THCA	cis	rs2299587	0.775	rs10113677	ENSG00000253671.1	RP11-806O11.1	-4.61	5.09e-06	0.000557	-0.24	-0.21	Economic and political preferences;	chr8:17910175	chr8:17808941~17820868:+
THCA	cis	rs4660214	0.666	rs61783383	ENSG00000182109.6	RP11-69E11.4	-4.61	5.09e-06	0.000557	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341346	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs6704246	ENSG00000182109.6	RP11-69E11.4	-4.61	5.09e-06	0.000557	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39343612	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs596062	ENSG00000182109.6	RP11-69E11.4	4.61	5.09e-06	0.000557	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39360333	chr1:39522280~39546187:-
THCA	cis	rs7045881	0.8	rs12353269	ENSG00000254396.1	RP11-56F10.3	4.61	5.09e-06	0.000557	0.35	0.21	Schizophrenia;	chr9:26850611	chr9:27102630~27104728:+
THCA	cis	rs793571	0.628	rs28412567	ENSG00000245975.2	RP11-30K9.6	4.61	5.09e-06	0.000557	0.24	0.21	Schizophrenia;	chr15:58810014	chr15:58768072~58770974:-
THCA	cis	rs793571	0.628	rs28876251	ENSG00000245975.2	RP11-30K9.6	4.61	5.09e-06	0.000557	0.24	0.21	Schizophrenia;	chr15:58819121	chr15:58768072~58770974:-
THCA	cis	rs1707322	1	rs11211223	ENSG00000281133.1	AL355480.3	-4.61	5.1e-06	0.000558	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45580892~45580996:-
THCA	cis	rs7617480	0.648	rs4858830	ENSG00000228638.1	FCF1P2	-4.61	5.1e-06	0.000558	-0.25	-0.21	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48696569	chr3:48290793~48291375:-
THCA	cis	rs7617480	0.544	rs6442129	ENSG00000228638.1	FCF1P2	-4.61	5.1e-06	0.000558	-0.25	-0.21	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48697823	chr3:48290793~48291375:-
THCA	cis	rs755249	0.501	rs4660669	ENSG00000228060.1	RP11-69E11.8	4.61	5.1e-06	0.000558	0.21	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39565160~39573203:+
THCA	cis	rs9300255	0.679	rs10772998	ENSG00000235423.7	RP11-282O18.3	4.61	5.1e-06	0.000558	0.22	0.21	Neutrophil percentage of white cells;	chr12:123236630	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1727306	ENSG00000235423.7	RP11-282O18.3	4.61	5.1e-06	0.000558	0.22	0.21	Neutrophil percentage of white cells;	chr12:123181148	chr12:123252030~123261483:-
THCA	cis	rs7520050	0.966	rs785492	ENSG00000234329.1	RP11-767N6.2	-4.61	5.1e-06	0.000558	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45651039~45651826:-
THCA	cis	rs9902453	0.845	rs72823935	ENSG00000263370.1	RP11-68I3.5	4.61	5.1e-06	0.000558	0.27	0.21	Coffee consumption (cups per day);	chr17:29681577	chr17:29639627~29640825:+
THCA	cis	rs3213758	0.588	rs12448867	ENSG00000275191.1	RP11-36I17.2	-4.61	5.1e-06	0.000558	-0.35	-0.21	Vitiligo (non-segmental);	chr16:53525906	chr16:53628256~53628816:-
THCA	cis	rs758324	0.625	rs269899	ENSG00000237714.1	P4HA2-AS1	-4.61	5.1e-06	0.000558	-0.29	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132146406	chr5:132184876~132192808:+
THCA	cis	rs11009175	0.556	rs2093345	ENSG00000273038.2	RP11-479G22.8	-4.61	5.1e-06	0.000558	-0.24	-0.21	Depression (quantitative trait);	chr10:33037255	chr10:32887255~32889311:-
THCA	cis	rs17095355	1	rs12242642	ENSG00000203876.8	ADD3-AS1	-4.61	5.1e-06	0.000558	-0.22	-0.21	Biliary atresia;	chr10:109964455	chr10:109940104~110008381:-
THCA	cis	rs467650	0.963	rs154197	ENSG00000248489.1	CTD-2007H13.3	4.61	5.1e-06	0.000558	0.2	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98642639	chr5:98929171~98995013:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000164669.11	INTS4P1	4.61	5.1e-06	0.000558	0.26	0.21	Aortic root size;	chr7:65800193	chr7:65141225~65234216:+
THCA	cis	rs2483058	0.767	rs11809494	ENSG00000261000.1	RP11-534L20.5	4.61	5.1e-06	0.000558	0.23	0.21	Cholesterol and Triglycerides;	chr1:206450521	chr1:206503948~206504456:+
THCA	cis	rs2483058	0.739	rs3860302	ENSG00000261000.1	RP11-534L20.5	4.61	5.1e-06	0.000558	0.23	0.21	Cholesterol and Triglycerides;	chr1:206451299	chr1:206503948~206504456:+
THCA	cis	rs11846409	0.799	rs2583330	ENSG00000274576.2	IGHV2-70	4.61	5.1e-06	0.000558	0.18	0.21	Rheumatic heart disease;	chr14:106621051	chr14:106770577~106771020:-
THCA	cis	rs7429990	0.803	rs6776963	ENSG00000228638.1	FCF1P2	4.61	5.1e-06	0.000558	0.21	0.21	Educational attainment (years of education);	chr3:47789251	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs4858863	ENSG00000228638.1	FCF1P2	4.61	5.1e-06	0.000558	0.21	0.21	Educational attainment (years of education);	chr3:47814143	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs7629850	ENSG00000228638.1	FCF1P2	4.61	5.1e-06	0.000558	0.21	0.21	Educational attainment (years of education);	chr3:47815592	chr3:48290793~48291375:-
THCA	cis	rs1003719	0.715	rs4261789	ENSG00000230366.8	DSCR9	4.61	5.1e-06	0.000558	0.22	0.21	Eye color traits;	chr21:37131462	chr21:37208503~37221736:+
THCA	cis	rs703842	0.963	rs2069506	ENSG00000270039.1	RP11-571M6.17	-4.61	5.1e-06	0.000558	-0.24	-0.21	Multiple sclerosis;	chr12:57749071	chr12:57803838~57804415:+
THCA	cis	rs3824488	0.92	rs28418339	ENSG00000237857.2	RP11-435O5.2	-4.61	5.11e-06	0.000559	-0.38	-0.21	Neuroticism;	chr9:95491194	chr9:95414834~95426796:-
THCA	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	4.61	5.11e-06	0.000559	0.37	0.21	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
THCA	cis	rs11846409	0.932	rs73378155	ENSG00000211974.3	IGHV2-70	-4.61	5.11e-06	0.000559	-0.19	-0.21	Rheumatic heart disease;	chr14:106637840	chr14:106723574~106724093:-
THCA	cis	rs7394190	0.748	rs2306325	ENSG00000271848.1	RP11-464F9.21	-4.61	5.11e-06	0.000559	-0.29	-0.21	Incident atrial fibrillation;	chr10:73746916	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs11000764	ENSG00000271848.1	RP11-464F9.21	-4.61	5.11e-06	0.000559	-0.29	-0.21	Incident atrial fibrillation;	chr10:73747106	chr10:73654039~73674719:+
THCA	cis	rs9902453	0.74	rs2617867	ENSG00000263370.1	RP11-68I3.5	-4.61	5.11e-06	0.000559	-0.27	-0.21	Coffee consumption (cups per day);	chr17:29722381	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2628191	ENSG00000263370.1	RP11-68I3.5	-4.61	5.11e-06	0.000559	-0.27	-0.21	Coffee consumption (cups per day);	chr17:29724122	chr17:29639627~29640825:+
THCA	cis	rs7577696	0.889	rs212733	ENSG00000276334.1	AL133243.1	4.61	5.11e-06	0.000559	0.22	0.21	Inflammatory biomarkers;	chr2:32247571	chr2:32521927~32523547:+
THCA	cis	rs6445975	0.619	rs112015230	ENSG00000272360.1	RP11-359I18.5	-4.61	5.11e-06	0.000559	-0.22	-0.21	Systemic lupus erythematosus;	chr3:58276477	chr3:58490830~58491291:-
THCA	cis	rs72799341	1	rs7185007	ENSG00000279196.1	RP11-1072A3.3	4.61	5.11e-06	0.000559	0.24	0.21	Diastolic blood pressure;	chr16:30916188	chr16:30984630~30988270:-
THCA	cis	rs13034020	0.522	rs4564760	ENSG00000271889.1	RP11-493E12.1	-4.61	5.11e-06	0.000559	-0.26	-0.21	Hodgkin's lymphoma;	chr2:61021440	chr2:61151433~61162105:-
THCA	cis	rs7246657	0.551	rs12972146	ENSG00000276846.1	CTD-3220F14.3	4.61	5.12e-06	0.00056	0.25	0.21	Coronary artery calcification;	chr19:37135193	chr19:37314868~37315620:-
THCA	cis	rs5751614	0.537	rs5759681	ENSG00000240160.3	RN7SL263P	-4.61	5.12e-06	0.00056	-0.26	-0.21	Height;	chr22:23287365	chr22:23261782~23262071:-
THCA	cis	rs2562456	0.833	rs61035285	ENSG00000268117.1	VN1R84P	4.61	5.12e-06	0.00056	0.33	0.21	Pain;	chr19:21329475	chr19:21719801~21720035:-
THCA	cis	rs7111546	0.791	rs113593294	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22843378	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.791	rs112122189	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22848172	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.791	rs78131192	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22849056	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.791	rs76432525	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22849681	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.791	rs78969307	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22850803	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.791	rs80318330	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22851095	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.791	rs2191690	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22852659	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.734	rs56073540	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22854894	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.791	rs7108863	ENSG00000246225.5	RP11-17A1.3	4.61	5.12e-06	0.00056	0.36	0.21	Dialysis-related mortality;	chr11:22856829	chr11:22829380~22945393:+
THCA	cis	rs7520050	0.966	rs785495	ENSG00000234329.1	RP11-767N6.2	-4.61	5.12e-06	0.00056	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45651039~45651826:-
THCA	cis	rs6005807	0.543	rs6005866	ENSG00000226471.5	CTA-292E10.6	-4.61	5.12e-06	0.00056	-0.25	-0.21	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28766952	chr22:28800683~28848559:+
THCA	cis	rs56313388	0.522	rs12149791	ENSG00000246379.5	RP11-461O7.1	-4.61	5.12e-06	0.00056	-0.22	-0.21	Pulse pressure;	chr16:56172704	chr16:56092987~56191094:-
THCA	cis	rs73108077	0.704	rs73119542	ENSG00000277112.2	RP11-755J8.1	-4.61	5.12e-06	0.00056	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31268950	chr20:30681825~30723932:-
THCA	cis	rs2944755	0.919	rs2944753	ENSG00000279766.1	RP11-642A1.2	4.61	5.12e-06	0.00056	0.29	0.21	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140566264	chr8:140572142~140572812:-
THCA	cis	rs17818399	0.817	rs17767994	ENSG00000279254.1	RP11-536C12.1	4.61	5.12e-06	0.00056	0.22	0.21	Height;	chr2:46632940	chr2:46668870~46670778:+
THCA	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-4.61	5.13e-06	0.00056	-0.24	-0.21	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
THCA	cis	rs3738443	0.868	rs12569042	ENSG00000259865.1	RP11-488L18.10	4.61	5.13e-06	0.00056	0.22	0.21	Alcohol dependence;	chr1:247203078	chr1:247187281~247188526:-
THCA	cis	rs7520050	0.966	rs946529	ENSG00000234329.1	RP11-767N6.2	-4.61	5.13e-06	0.000561	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45651039~45651826:-
THCA	cis	rs9843304	0.616	rs34783865	ENSG00000244503.1	RP11-278L15.6	4.61	5.13e-06	0.000561	0.28	0.21	Gallstone disease;	chr3:149488005	chr3:149494660~149495995:+
THCA	cis	rs78487399	0.908	rs7576643	ENSG00000234936.1	AC010883.5	4.61	5.13e-06	0.000561	0.26	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43614130	chr2:43229573~43233394:+
THCA	cis	rs2439831	0.867	rs12323999	ENSG00000166763.7	STRCP1	4.61	5.13e-06	0.000561	0.28	0.21	Lung cancer in ever smokers;	chr15:43390917	chr15:43699488~43718184:-
THCA	cis	rs1707322	1	rs785498	ENSG00000281133.1	AL355480.3	4.61	5.13e-06	0.000561	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45580892~45580996:-
THCA	cis	rs12755164	0.724	rs1917882	ENSG00000223479.3	RP4-788P17.1	4.61	5.13e-06	0.000561	0.23	0.21	Schizophrenia;	chr1:72870424	chr1:73635216~73715214:+
THCA	cis	rs6860806	0.507	rs183898	ENSG00000237714.1	P4HA2-AS1	-4.61	5.13e-06	0.000561	-0.28	-0.21	Breast cancer;	chr5:132381210	chr5:132184876~132192808:+
THCA	cis	rs7829975	0.846	rs6601724	ENSG00000254153.1	CTA-398F10.2	4.61	5.13e-06	0.000561	0.22	0.21	Mood instability;	chr8:8687362	chr8:8456909~8461337:-
THCA	cis	rs6121246	0.559	rs6119650	ENSG00000230613.1	HM13-AS1	4.61	5.14e-06	0.000561	0.2	0.21	Mean corpuscular hemoglobin;	chr20:31670677	chr20:31567707~31573263:-
THCA	cis	rs11992186	0.597	rs77717027	ENSG00000254153.1	CTA-398F10.2	4.61	5.14e-06	0.000562	0.23	0.21	Neuroticism;	chr8:8734122	chr8:8456909~8461337:-
THCA	cis	rs2191566	0.96	rs8105571	ENSG00000266921.1	RP11-15A1.7	-4.61	5.14e-06	0.000562	-0.19	-0.21	Acute lymphoblastic leukemia (childhood);	chr19:44006189	chr19:43996896~44002836:-
THCA	cis	rs6832769	0.961	rs11133382	ENSG00000272969.1	RP11-528I4.2	4.61	5.14e-06	0.000562	0.24	0.21	Personality dimensions;	chr4:55450813	chr4:55547112~55547889:+
THCA	cis	rs9494145	0.526	rs7738935	ENSG00000232876.1	CTA-212D2.2	-4.61	5.14e-06	0.000562	-0.32	-0.21	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135152677	chr6:135055033~135060550:+
THCA	cis	rs13118159	0.55	rs13123016	ENSG00000254094.1	AC078852.1	-4.61	5.14e-06	0.000562	-0.26	-0.21	Longevity;	chr4:1347101	chr4:1356581~1358075:+
THCA	cis	rs412050	0.744	rs238781	ENSG00000224086.5	LL22NC03-86G7.1	-4.61	5.14e-06	0.000562	-0.36	-0.21	Attention deficit hyperactivity disorder;	chr22:21987474	chr22:21938293~21977632:+
THCA	cis	rs2153535	0.585	rs9328498	ENSG00000230939.1	RP11-314C16.1	-4.61	5.14e-06	0.000562	-0.22	-0.21	Motion sickness;	chr6:8623536	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs7750891	ENSG00000230939.1	RP11-314C16.1	-4.61	5.14e-06	0.000562	-0.22	-0.21	Motion sickness;	chr6:8624613	chr6:8784178~8785445:+
THCA	cis	rs17801127	0.748	rs6708998	ENSG00000231969.1	AC144449.1	4.61	5.14e-06	0.000562	0.35	0.21	Liver enzyme levels (alanine transaminase);	chr2:149656004	chr2:149587196~149848233:+
THCA	cis	rs10090774	0.965	rs1031262	ENSG00000279766.1	RP11-642A1.2	-4.61	5.14e-06	0.000562	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140975806	chr8:140572142~140572812:-
THCA	cis	rs875971	0.545	rs4441996	ENSG00000164669.11	INTS4P1	4.61	5.15e-06	0.000563	0.29	0.21	Aortic root size;	chr7:66123233	chr7:65141225~65234216:+
THCA	cis	rs160451	0.739	rs218904	ENSG00000251136.7	RP11-37B2.1	-4.61	5.15e-06	0.000563	-0.19	-0.21	Leprosy;	chr8:89722278	chr8:89609409~89757727:-
THCA	cis	rs2179367	0.6	rs58747890	ENSG00000216906.2	RP11-350J20.9	4.61	5.15e-06	0.000563	0.29	0.21	Dupuytren's disease;	chr6:149459369	chr6:149904243~149906418:+
THCA	cis	rs763121	0.853	rs5750626	ENSG00000228274.3	RP3-508I15.9	-4.61	5.15e-06	0.000563	-0.23	-0.21	Menopause (age at onset);	chr22:38581885	chr22:38667585~38681820:-
THCA	cis	rs8020095	0.571	rs8022657	ENSG00000258561.1	RP11-72M17.1	-4.61	5.15e-06	0.000563	-0.27	-0.21	Depression (quantitative trait);	chr14:66923782	chr14:66212810~66509394:-
THCA	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-4.61	5.15e-06	0.000563	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
THCA	cis	rs10090774	0.965	rs1397381	ENSG00000279766.1	RP11-642A1.2	-4.61	5.15e-06	0.000563	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992798	chr8:140572142~140572812:-
THCA	cis	rs13113518	0.902	rs12642716	ENSG00000249700.7	SRD5A3-AS1	4.61	5.15e-06	0.000563	0.26	0.21	Height;	chr4:55479996	chr4:55363971~55395847:-
THCA	cis	rs7829975	0.522	rs6601689	ENSG00000254153.1	CTA-398F10.2	-4.61	5.15e-06	0.000563	-0.23	-0.21	Mood instability;	chr8:8314761	chr8:8456909~8461337:-
THCA	cis	rs7583236	1	rs7567025	ENSG00000179818.12	PCBP1-AS1	4.61	5.15e-06	0.000563	0.21	0.21	Obesity-related traits;	chr2:69957976	chr2:69962263~70103220:-
THCA	cis	rs10904908	0.733	rs359299	ENSG00000229124.5	VIM-AS1	4.61	5.16e-06	0.000563	0.2	0.21	Cholesterol, total;Total cholesterol levels;	chr10:17292379	chr10:17214239~17229985:-
THCA	cis	rs9595908	0.709	rs7327412	ENSG00000212293.1	SNORA16	-4.61	5.16e-06	0.000563	-0.24	-0.21	Body mass index;	chr13:32774430	chr13:32420390~32420516:-
THCA	cis	rs2439831	1	rs689754	ENSG00000166763.7	STRCP1	4.61	5.16e-06	0.000564	0.28	0.21	Lung cancer in ever smokers;	chr15:43483697	chr15:43699488~43718184:-
THCA	cis	rs61160187	0.582	rs34619	ENSG00000215032.2	GNL3LP1	4.61	5.16e-06	0.000564	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60891935~60893577:-
THCA	cis	rs4950322	0.576	rs2353979	ENSG00000271721.1	RP11-337C18.9	-4.61	5.16e-06	0.000564	-0.21	-0.21	Protein quantitative trait loci;	chr1:147368185	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.576	rs2353980	ENSG00000271721.1	RP11-337C18.9	-4.61	5.16e-06	0.000564	-0.21	-0.21	Protein quantitative trait loci;	chr1:147368274	chr1:147175602~147177740:+
THCA	cis	rs62158800	0.778	rs62158794	ENSG00000224568.1	AC096669.3	4.61	5.16e-06	0.000564	0.39	0.21	Facial morphology (factor 22);	chr2:107575221	chr2:107529487~107556326:+
THCA	cis	rs6088580	0.634	rs6059890	ENSG00000276073.1	RP5-1125A11.7	-4.61	5.16e-06	0.000564	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34513848	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.66	rs6059893	ENSG00000276073.1	RP5-1125A11.7	-4.61	5.16e-06	0.000564	-0.18	-0.21	Glomerular filtration rate (creatinine);	chr20:34518092	chr20:33985617~33988989:-
THCA	cis	rs71391092	1	rs71391092	ENSG00000207525.1	Y_RNA	4.61	5.16e-06	0.000564	0.31	0.21	Schizophrenia;	chr16:74533177	chr16:74463888~74463988:-
THCA	cis	rs13126694	0.744	rs28477319	ENSG00000248429.4	RP11-597D13.9	4.61	5.16e-06	0.000564	0.22	0.21	Blood osmolality (transformed sodium);	chr4:158095785	chr4:158170752~158202877:+
THCA	cis	rs1876905	0.68	rs373526	ENSG00000272356.1	RP5-1112D6.8	4.61	5.17e-06	0.000565	0.21	0.21	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111309203~111313517:+
THCA	cis	rs7726839	0.574	rs12517345	ENSG00000225138.6	CTD-2228K2.7	4.61	5.17e-06	0.000565	0.26	0.21	Obesity-related traits;	chr5:628179	chr5:473236~480884:+
THCA	cis	rs8017455	0.523	rs10149740	ENSG00000259167.2	NMNAT1P1	4.61	5.17e-06	0.000565	0.31	0.21	Hair morphology;	chr14:81097487	chr14:81032529~81033404:+
THCA	cis	rs7942368	1	rs12282785	ENSG00000261578.1	RP11-21L23.2	4.61	5.17e-06	0.000565	0.3	0.21	Endometriosis;	chr11:76764986	chr11:76800364~76804555:+
THCA	cis	rs7520050	0.831	rs61783170	ENSG00000234329.1	RP11-767N6.2	-4.61	5.17e-06	0.000565	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45651039~45651826:-
THCA	cis	rs3820928	0.967	rs720501	ENSG00000212391.1	SNORA48	-4.61	5.17e-06	0.000565	-0.24	-0.21	Pulmonary function;	chr2:226913729	chr2:226968989~226969122:-
THCA	cis	rs1577917	0.92	rs1337842	ENSG00000220563.1	PKMP3	-4.61	5.17e-06	0.000565	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85965379	chr6:85659892~85660606:-
THCA	cis	rs1790761	0.52	rs12805884	ENSG00000255318.1	RP11-655M14.13	-4.61	5.17e-06	0.000565	-0.25	-0.21	Mean corpuscular volume;	chr11:67620506	chr11:67618279~67627304:-
THCA	cis	rs3820928	0.874	rs55748731	ENSG00000212391.1	SNORA48	-4.61	5.17e-06	0.000565	-0.23	-0.21	Pulmonary function;	chr2:226953913	chr2:226968989~226969122:-
THCA	cis	rs2742234	0.578	rs2435354	ENSG00000273008.1	RP11-351D16.3	-4.61	5.17e-06	0.000565	-0.19	-0.21	Hirschsprung disease;	chr10:43156997	chr10:43136824~43138334:-
THCA	cis	rs12681288	0.862	rs7814070	ENSG00000260721.1	AF067845.1	4.61	5.17e-06	0.000565	0.25	0.21	Schizophrenia;	chr8:1070991	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.862	rs7814231	ENSG00000260721.1	AF067845.1	4.61	5.17e-06	0.000565	0.25	0.21	Schizophrenia;	chr8:1071103	chr8:1368642~1369833:-
THCA	cis	rs2787702	1	rs2650752	ENSG00000237233.2	TMEM26-AS1	-4.61	5.17e-06	0.000565	-0.25	-0.21	Response to taxane treatment (placlitaxel);	chr10:61558690	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2650751	ENSG00000237233.2	TMEM26-AS1	-4.61	5.17e-06	0.000565	-0.25	-0.21	Response to taxane treatment (placlitaxel);	chr10:61558802	chr10:61452639~61481956:+
THCA	cis	rs2787702	0.963	rs2650747	ENSG00000237233.2	TMEM26-AS1	-4.61	5.17e-06	0.000565	-0.25	-0.21	Response to taxane treatment (placlitaxel);	chr10:61559115	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2650745	ENSG00000237233.2	TMEM26-AS1	-4.61	5.17e-06	0.000565	-0.25	-0.21	Response to taxane treatment (placlitaxel);	chr10:61559370	chr10:61452639~61481956:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000164669.11	INTS4P1	-4.61	5.17e-06	0.000565	-0.26	-0.21	Aortic root size;	chr7:65930047	chr7:65141225~65234216:+
THCA	cis	rs12887734	0.566	rs8548	ENSG00000269940.1	RP11-73M18.7	4.61	5.17e-06	0.000565	0.22	0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694560~103695170:+
THCA	cis	rs800160	1	rs1088993	ENSG00000199550.1	Y_RNA	4.61	5.17e-06	0.000565	0.31	0.21	Bacteremia;	chr11:2361401	chr11:2372638~2372750:+
THCA	cis	rs9990343	0.967	rs6782423	ENSG00000223552.1	RP11-24F11.2	-4.61	5.17e-06	0.000565	-0.19	-0.21	Brain structure;	chr3:46297882	chr3:46364955~46407059:-
THCA	cis	rs9652601	0.691	rs7198004	ENSG00000274038.1	RP11-66H6.4	-4.61	5.18e-06	0.000566	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11113760	chr16:11056556~11057034:+
THCA	cis	rs8040855	0.559	rs6496801	ENSG00000259630.2	CTD-2262B20.1	4.61	5.18e-06	0.000566	0.25	0.21	Bulimia nervosa;	chr15:85185168	chr15:85415228~85415633:+
THCA	cis	rs7267979	1	rs8125868	ENSG00000274973.1	RP13-401N8.7	4.61	5.18e-06	0.000566	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25845497~25845862:+
THCA	cis	rs2836974	0.644	rs4818017	ENSG00000255568.3	BRWD1-AS2	-4.61	5.18e-06	0.000566	-0.17	-0.21	Cognitive function;	chr21:39318635	chr21:39313935~39314962:+
THCA	cis	rs9880211	0.699	rs13433688	ENSG00000239213.4	NCK1-AS1	4.61	5.18e-06	0.000566	0.23	0.21	Height;Body mass index;	chr3:136690329	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.752	rs13062352	ENSG00000239213.4	NCK1-AS1	4.61	5.18e-06	0.000566	0.23	0.21	Height;Body mass index;	chr3:136745920	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs9845862	ENSG00000239213.4	NCK1-AS1	4.61	5.18e-06	0.000566	0.23	0.21	Height;Body mass index;	chr3:136753731	chr3:136841726~136862054:-
THCA	cis	rs7824557	0.527	rs2409756	ENSG00000206014.6	OR7E161P	4.61	5.18e-06	0.000566	0.24	0.21	Retinal vascular caliber;	chr8:11384516	chr8:11928597~11929563:-
THCA	cis	rs8028313	0.63	rs12900208	ENSG00000270964.1	RP11-502I4.3	-4.61	5.18e-06	0.000566	-0.18	-0.21	Obesity;	chr15:67670720	chr15:67541072~67542604:-
THCA	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	4.61	5.18e-06	0.000566	0.24	0.21	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
THCA	cis	rs11096990	0.855	rs1820939	ENSG00000249685.1	RP11-360F5.3	-4.61	5.18e-06	0.000566	-0.27	-0.21	Cognitive function;	chr4:39170115	chr4:39133913~39135608:+
THCA	cis	rs4852324	0.536	rs13387174	ENSG00000257800.1	FNBP1P1	4.61	5.18e-06	0.000566	0.36	0.21	Systemic lupus erythematosus;	chr2:73979558	chr2:74120680~74123218:+
THCA	cis	rs703842	1	rs10877012	ENSG00000270039.1	RP11-571M6.17	-4.61	5.18e-06	0.000566	-0.24	-0.21	Multiple sclerosis;	chr12:57768302	chr12:57803838~57804415:+
THCA	cis	rs8062405	0.69	rs762634	ENSG00000261766.1	RP11-22P6.2	-4.61	5.19e-06	0.000566	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28862166~28863340:-
THCA	cis	rs62034325	0.697	rs710410	ENSG00000261766.1	RP11-22P6.2	-4.61	5.19e-06	0.000566	-0.21	-0.21	Body mass index;	chr16:28592021	chr16:28862166~28863340:-
THCA	cis	rs12612619	0.732	rs1866655	ENSG00000229122.1	AGBL5-IT1	-4.61	5.19e-06	0.000566	-0.15	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26985999	chr2:27061038~27061815:+
THCA	cis	rs2013441	0.508	rs35191778	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20064449	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs35156798	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20064622	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs12453332	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20065984	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs1468953	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20067008	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs4471741	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20068240	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs35124809	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20070025	chr17:20008051~20009234:-
THCA	cis	rs10083830	0.628	rs35244101	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Immature fraction of reticulocytes;	chr17:20070140	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs35770292	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20070226	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs12947713	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20070689	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs35493088	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20070750	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs17685923	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20071291	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs11869931	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20071757	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs8081817	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20072153	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs8075343	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20072174	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs8068484	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20073081	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs4341795	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20073915	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs4346259	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20074101	chr17:20008051~20009234:-
THCA	cis	rs10083830	0.696	rs12949710	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Immature fraction of reticulocytes;	chr17:20074525	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.634	rs4925076	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20074979	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.508	rs4350625	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Obesity-related traits;	chr17:20077352	chr17:20008051~20009234:-
THCA	cis	rs10083830	0.566	rs7503407	ENSG00000261033.1	RP11-209D14.2	-4.61	5.19e-06	0.000567	-0.28	-0.21	Immature fraction of reticulocytes;	chr17:20077459	chr17:20008051~20009234:-
THCA	cis	rs2439831	0.681	rs1549523	ENSG00000205771.5	CATSPER2P1	-4.61	5.19e-06	0.000567	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43331991	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.681	rs1549525	ENSG00000205771.5	CATSPER2P1	-4.61	5.19e-06	0.000567	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43335657	chr15:43726918~43747094:-
THCA	cis	rs13113518	1	rs4864994	ENSG00000249700.7	SRD5A3-AS1	4.61	5.19e-06	0.000567	0.26	0.21	Height;	chr4:55451955	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs4864995	ENSG00000249700.7	SRD5A3-AS1	4.61	5.19e-06	0.000567	0.26	0.21	Height;	chr4:55452853	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs12651640	ENSG00000249700.7	SRD5A3-AS1	4.61	5.19e-06	0.000567	0.26	0.21	Height;	chr4:55454154	chr4:55363971~55395847:-
THCA	cis	rs4660214	0.666	rs2256614	ENSG00000182109.6	RP11-69E11.4	4.61	5.19e-06	0.000567	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39359046	chr1:39522280~39546187:-
THCA	cis	rs2590942	0.838	rs2815749	ENSG00000227207.2	RPL31P12	-4.61	5.19e-06	0.000567	-0.32	-0.21	Childhood body mass index;	chr1:72349100	chr1:72301472~72301829:+
THCA	cis	rs8059260	0.668	rs6498152	ENSG00000274038.1	RP11-66H6.4	-4.61	5.19e-06	0.000567	-0.29	-0.21	Alcohol consumption over the past year;	chr16:11030590	chr16:11056556~11057034:+
THCA	cis	rs6745190	0.575	rs35049898	ENSG00000236153.1	AC104076.3	-4.61	5.19e-06	0.000567	-0.23	-0.21	White blood cell count;	chr2:181117550	chr2:180979427~180980090:-
THCA	cis	rs2439831	0.85	rs524417	ENSG00000205771.5	CATSPER2P1	-4.61	5.19e-06	0.000567	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43480176	chr15:43726918~43747094:-
THCA	cis	rs6860806	0.507	rs272883	ENSG00000224431.1	AC063976.7	4.61	5.19e-06	0.000567	0.19	0.21	Breast cancer;	chr5:132333005	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.507	rs272882	ENSG00000224431.1	AC063976.7	4.61	5.19e-06	0.000567	0.19	0.21	Breast cancer;	chr5:132333468	chr5:132199456~132203487:+
THCA	cis	rs867186	1	rs73903017	ENSG00000126005.14	MMP24-AS1	-4.61	5.2e-06	0.000567	-0.33	-0.21	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35136955	chr20:35216462~35278131:-
THCA	cis	rs9650657	0.515	rs7820860	ENSG00000206014.6	OR7E161P	4.61	5.2e-06	0.000567	0.24	0.21	Neuroticism;	chr8:11092886	chr8:11928597~11929563:-
THCA	cis	rs9300255	0.537	rs2682429	ENSG00000235423.7	RP11-282O18.3	4.61	5.2e-06	0.000568	0.22	0.21	Neutrophil percentage of white cells;	chr12:123158408	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs2851438	ENSG00000235423.7	RP11-282O18.3	4.61	5.2e-06	0.000568	0.22	0.21	Neutrophil percentage of white cells;	chr12:123159142	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.568	rs1047158	ENSG00000235423.7	RP11-282O18.3	4.61	5.2e-06	0.000568	0.22	0.21	Neutrophil percentage of white cells;	chr12:123159509	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1051431	ENSG00000235423.7	RP11-282O18.3	4.61	5.2e-06	0.000568	0.22	0.21	Neutrophil percentage of white cells;	chr12:123161256	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1727296	ENSG00000235423.7	RP11-282O18.3	4.61	5.2e-06	0.000568	0.22	0.21	Neutrophil percentage of white cells;	chr12:123163178	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1716165	ENSG00000235423.7	RP11-282O18.3	4.61	5.2e-06	0.000568	0.22	0.21	Neutrophil percentage of white cells;	chr12:123164334	chr12:123252030~123261483:-
THCA	cis	rs890448	0.9	rs7673593	ENSG00000254531.1	FLJ20021	-4.61	5.2e-06	0.000568	-0.18	-0.21	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101522212	chr4:101347780~101348883:+
THCA	cis	rs2886497	0.894	rs7900459	ENSG00000224215.1	RP11-371A19.2	-4.61	5.2e-06	0.000568	-0.27	-0.21	Major depression and alcohol dependence;	chr10:23394594	chr10:23343957~23345181:+
THCA	cis	rs2821260	0.532	rs2821288	ENSG00000227207.2	RPL31P12	4.61	5.2e-06	0.000568	0.24	0.21	Intelligence (multi-trait analysis);	chr1:72195421	chr1:72301472~72301829:+
THCA	cis	rs61270009	0.955	rs13171573	ENSG00000247828.6	TMEM161B-AS1	4.61	5.2e-06	0.000568	0.18	0.21	Depressive symptoms;	chr5:88383625	chr5:88268895~88436685:+
THCA	cis	rs6088590	1	rs6119512	ENSG00000276073.1	RP5-1125A11.7	-4.61	5.2e-06	0.000568	-0.19	-0.21	Coronary artery disease;	chr20:34719100	chr20:33985617~33988989:-
THCA	cis	rs9326248	0.648	rs11216257	ENSG00000280143.1	AP000892.6	4.61	5.2e-06	0.000568	0.28	0.21	Blood protein levels;	chr11:117061845	chr11:117204967~117210292:+
THCA	cis	rs9878978	0.964	rs17194406	ENSG00000237990.3	CNTN4-AS1	4.61	5.2e-06	0.000568	0.23	0.21	Blood pressure (smoking interaction);	chr3:2446947	chr3:3039033~3069242:-
THCA	cis	rs13126694	0.744	rs10003459	ENSG00000248429.4	RP11-597D13.9	-4.61	5.2e-06	0.000568	-0.22	-0.21	Blood osmolality (transformed sodium);	chr4:158095602	chr4:158170752~158202877:+
THCA	cis	rs7772486	0.774	rs6930181	ENSG00000270638.1	RP3-466P17.1	-4.61	5.2e-06	0.000568	-0.16	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145735570~145737218:+
THCA	cis	rs9880211	0.644	rs6799320	ENSG00000273486.1	RP11-731C17.2	4.61	5.2e-06	0.000568	0.21	0.21	Height;Body mass index;	chr3:136083597	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.613	rs9653930	ENSG00000273486.1	RP11-731C17.2	4.61	5.2e-06	0.000568	0.21	0.21	Height;Body mass index;	chr3:136091472	chr3:136837338~136839021:-
THCA	cis	rs61270009	0.955	rs780401	ENSG00000247828.6	TMEM161B-AS1	-4.61	5.21e-06	0.000568	-0.18	-0.21	Depressive symptoms;	chr5:88244393	chr5:88268895~88436685:+
THCA	cis	rs2153535	0.585	rs9406183	ENSG00000230939.1	RP11-314C16.1	4.61	5.21e-06	0.000568	0.22	0.21	Motion sickness;	chr6:8639538	chr6:8784178~8785445:+
THCA	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-4.61	5.21e-06	0.000569	-0.24	-0.21	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
THCA	cis	rs728616	0.681	rs55838345	ENSG00000242600.5	MBL1P	4.61	5.21e-06	0.000569	0.27	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80325364	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs61859191	ENSG00000242600.5	MBL1P	4.61	5.21e-06	0.000569	0.27	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80331271	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs17678338	ENSG00000242600.5	MBL1P	4.61	5.21e-06	0.000569	0.27	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80338390	chr10:79904898~79950336:+
THCA	cis	rs11634944	0.689	rs2732040	ENSG00000257151.1	PWAR6	4.61	5.21e-06	0.000569	0.15	0.21	Interleukin-8 levels;	chr15:25024203	chr15:25031873~25036490:+
THCA	cis	rs875971	0.545	rs73136346	ENSG00000164669.11	INTS4P1	4.61	5.21e-06	0.000569	0.3	0.21	Aortic root size;	chr7:66101095	chr7:65141225~65234216:+
THCA	cis	rs9368481	0.761	rs12661756	ENSG00000261353.1	CTA-14H9.5	-4.61	5.21e-06	0.000569	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26527063~26527404:+
THCA	cis	rs4763879	0.729	rs10844472	ENSG00000256673.1	RP11-599J14.2	4.61	5.21e-06	0.000569	0.25	0.21	Type 1 diabetes;	chr12:9691137	chr12:9398355~9414851:-
THCA	cis	rs4916588	0.636	rs4916571	ENSG00000270170.1	NCBP2-AS2	4.61	5.21e-06	0.000569	0.16	0.21	Night sleep phenotypes;	chr3:196874193	chr3:196942623~196943540:+
THCA	cis	rs7403037	1	rs4992989	ENSG00000260760.1	PWRN3	4.61	5.21e-06	0.000569	0.25	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24576334	chr15:24441127~24447967:+
THCA	cis	rs394563	0.602	rs409111	ENSG00000231760.4	RP11-350J20.5	4.61	5.21e-06	0.000569	0.27	0.21	Dupuytren's disease;	chr6:149445724	chr6:149796151~149826294:-
THCA	cis	rs394563	0.602	rs409099	ENSG00000231760.4	RP11-350J20.5	4.61	5.21e-06	0.000569	0.27	0.21	Dupuytren's disease;	chr6:149445727	chr6:149796151~149826294:-
THCA	cis	rs889398	0.741	rs2362642	ENSG00000226232.7	RP11-419C5.2	-4.61	5.21e-06	0.000569	-0.21	-0.21	Body mass index;	chr16:69897555	chr16:69976388~69996188:-
THCA	cis	rs7267979	1	rs6050559	ENSG00000274973.1	RP13-401N8.7	-4.61	5.22e-06	0.000569	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25845497~25845862:+
THCA	cis	rs11976180	1	rs2961118	ENSG00000244198.4	RP4-545C24.1	-4.61	5.22e-06	0.000569	-0.2	-0.21	Obesity-related traits;	chr7:144058350	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2961119	ENSG00000244198.4	RP4-545C24.1	-4.61	5.22e-06	0.000569	-0.2	-0.21	Obesity-related traits;	chr7:144058759	chr7:144194858~144280547:+
THCA	cis	rs11671005	0.693	rs11668757	ENSG00000265272.2	RN7SL693P	4.61	5.22e-06	0.00057	0.29	0.21	Mean platelet volume;	chr19:58416932	chr19:58490797~58491075:+
THCA	cis	rs9876781	0.967	rs7618883	ENSG00000244380.1	RP11-24C3.2	4.61	5.22e-06	0.00057	0.25	0.21	Longevity;	chr3:48457056	chr3:48440352~48446656:-
THCA	cis	rs7726839	0.574	rs11739866	ENSG00000225138.6	CTD-2228K2.7	4.61	5.22e-06	0.00057	0.26	0.21	Obesity-related traits;	chr5:636184	chr5:473236~480884:+
THCA	cis	rs8077577	0.689	rs62072515	ENSG00000273018.4	CTD-2303H24.2	-4.61	5.22e-06	0.00057	-0.3	-0.21	Obesity-related traits;	chr17:18310121	chr17:18511221~18551705:-
THCA	cis	rs7773456	0.576	rs6924929	ENSG00000237404.1	RP3-471C18.2	4.61	5.22e-06	0.00057	0.27	0.21	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19689825~19753113:-
THCA	cis	rs6545883	0.507	rs59981505	ENSG00000270820.4	RP11-355B11.2	-4.61	5.22e-06	0.00057	-0.18	-0.21	Tuberculosis;	chr2:61353394	chr2:61471188~61484130:+
THCA	cis	rs7772486	0.79	rs1832362	ENSG00000270638.1	RP3-466P17.1	4.61	5.22e-06	0.00057	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145735570~145737218:+
THCA	cis	rs1555322	0.932	rs6119593	ENSG00000269202.1	RP4-614O4.12	-4.61	5.22e-06	0.00057	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35245926	chr20:35201747~35203288:-
THCA	cis	rs7267979	1	rs2257808	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2257809	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2424700	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs910997	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs1077889	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs3002702	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2257982	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2257985	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2257988	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2257432	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2258066	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2258135	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2258201	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2258563	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2258617	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2258769	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2258879	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2257496	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2258884	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2259837	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2259873	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs11100	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs1046073	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2259926	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2259928	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2259956	ENSG00000274973.1	RP13-401N8.7	-4.61	5.23e-06	0.00057	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2297496	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs7343481	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6115146	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.934	rs6037085	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs6050532	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6083804	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4815405	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050542	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6076336	ENSG00000274973.1	RP13-401N8.7	4.61	5.23e-06	0.00057	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25845497~25845862:+
THCA	cis	rs8059260	0.935	rs9928255	ENSG00000274038.1	RP11-66H6.4	-4.61	5.23e-06	0.00057	-0.29	-0.21	Alcohol consumption over the past year;	chr16:11027408	chr16:11056556~11057034:+
THCA	cis	rs2281603	0.762	rs61987034	ENSG00000259116.1	RP11-973N13.4	-4.61	5.23e-06	0.000571	-0.21	-0.21	Lymphocyte counts;	chr14:64567405	chr14:64514154~64540368:-
THCA	cis	rs2129782	0.764	rs7834743	ENSG00000253553.4	RP11-586K2.1	-4.61	5.23e-06	0.000571	-0.31	-0.21	Electrodermal activity;	chr8:88299556	chr8:88326836~88737134:+
THCA	cis	rs7688540	0.8	rs11723492	ENSG00000250892.1	RP11-1365D11.1	4.61	5.23e-06	0.000571	0.29	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:201409~205009:-
THCA	cis	rs4713118	0.513	rs149878	ENSG00000226314.6	ZNF192P1	-4.61	5.23e-06	0.000571	-0.24	-0.21	Parkinson's disease;	chr6:27910960	chr6:28161781~28169594:+
THCA	cis	rs2448490	0.642	rs535111	ENSG00000214659.4	KRT8P26	-4.61	5.23e-06	0.000571	-0.18	-0.21	Platelet count;	chr11:65717866	chr11:65726939~65728214:+
THCA	cis	rs61160187	0.555	rs34608	ENSG00000215032.2	GNL3LP1	4.61	5.24e-06	0.000571	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61161807	chr5:60891935~60893577:-
THCA	cis	rs758324	0.648	rs31474	ENSG00000237714.1	P4HA2-AS1	-4.61	5.24e-06	0.000571	-0.29	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132069334	chr5:132184876~132192808:+
THCA	cis	rs4415084	0.716	rs4373287	ENSG00000272335.1	RP11-53O19.3	4.61	5.24e-06	0.000571	0.18	0.21	Breast cancer;	chr5:44862782	chr5:44826076~44828592:+
THCA	cis	rs9847710	0.967	rs2244552	ENSG00000242142.1	SERBP1P3	4.61	5.24e-06	0.000572	0.24	0.21	Ulcerative colitis;	chr3:53021506	chr3:53064283~53065091:-
THCA	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	4.61	5.24e-06	0.000572	0.27	0.21	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
THCA	cis	rs7772486	0.754	rs6570718	ENSG00000270638.1	RP3-466P17.1	-4.61	5.24e-06	0.000572	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.654	rs6906402	ENSG00000270638.1	RP3-466P17.1	-4.61	5.24e-06	0.000572	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145735570~145737218:+
THCA	cis	rs1707322	0.964	rs10890358	ENSG00000281133.1	AL355480.3	-4.61	5.24e-06	0.000572	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45580892~45580996:-
THCA	cis	rs6570726	0.791	rs9497357	ENSG00000270638.1	RP3-466P17.1	4.61	5.25e-06	0.000572	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.764	rs4263604	ENSG00000270638.1	RP3-466P17.1	4.61	5.25e-06	0.000572	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145735570~145737218:+
THCA	cis	rs9652601	0.719	rs12103174	ENSG00000274038.1	RP11-66H6.4	-4.61	5.25e-06	0.000573	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11109873	chr16:11056556~11057034:+
THCA	cis	rs9652601	0.649	rs767448	ENSG00000274038.1	RP11-66H6.4	-4.61	5.25e-06	0.000573	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11110364	chr16:11056556~11057034:+
THCA	cis	rs7181230	0.885	rs8026641	ENSG00000275636.1	RP11-521C20.5	-4.61	5.25e-06	0.000573	-0.22	-0.21	Dehydroepiandrosterone sulphate levels;	chr15:40046660	chr15:40078892~40079347:+
THCA	cis	rs12291225	0.585	rs4517475	ENSG00000251991.1	RNU7-49P	4.61	5.25e-06	0.000573	0.24	0.21	Sense of smell;	chr11:14364599	chr11:14478892~14478953:+
THCA	cis	rs10256972	0.721	rs4720249	ENSG00000225146.1	AC073957.15	4.61	5.25e-06	0.000573	0.22	0.21	Endometriosis;Longevity;	chr7:1032927	chr7:1029025~1043891:+
THCA	cis	rs6088590	0.901	rs6087631	ENSG00000269202.1	RP4-614O4.12	-4.61	5.25e-06	0.000573	-0.19	-0.21	Coronary artery disease;	chr20:34815706	chr20:35201747~35203288:-
THCA	cis	rs7621331	0.963	rs9289503	ENSG00000273486.1	RP11-731C17.2	4.61	5.25e-06	0.000573	0.19	0.21	Waist circumference adjusted for body mass index;	chr3:136020499	chr3:136837338~136839021:-
THCA	cis	rs3734266	1	rs3734266	ENSG00000272288.4	RP11-140K17.3	-4.61	5.25e-06	0.000573	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34855410	chr6:34696317~34697470:+
THCA	cis	rs7396835	1	rs7396835	ENSG00000280143.1	AP000892.6	4.61	5.25e-06	0.000573	0.31	0.21	Quantitative traits;	chr11:116813312	chr11:117204967~117210292:+
THCA	cis	rs4245128	0.775	rs1155027	ENSG00000247416.2	RP11-629G13.1	4.61	5.25e-06	0.000573	0.2	0.21	Life satisfaction;	chr11:112944365	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.745	rs10789928	ENSG00000247416.2	RP11-629G13.1	4.61	5.25e-06	0.000573	0.2	0.21	Life satisfaction;	chr11:112945464	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.736	rs7105571	ENSG00000247416.2	RP11-629G13.1	4.61	5.25e-06	0.000573	0.2	0.21	Life satisfaction;	chr11:112946325	chr11:112959279~112963460:-
THCA	cis	rs4908769	0.66	rs172531	ENSG00000232912.4	RP5-1115A15.1	-4.61	5.26e-06	0.000573	-0.23	-0.21	Allergy;	chr1:8435530	chr1:8424645~8434838:+
THCA	cis	rs79040073	0.859	rs77468143	ENSG00000259531.2	RP11-295H24.3	4.61	5.26e-06	0.000573	0.27	0.21	Lung cancer in ever smokers;	chr15:49084427	chr15:49365124~49366685:-
THCA	cis	rs7577696	0.924	rs7370704	ENSG00000276334.1	AL133243.1	-4.61	5.26e-06	0.000574	-0.22	-0.21	Inflammatory biomarkers;	chr2:32032648	chr2:32521927~32523547:+
THCA	cis	rs17301013	0.897	rs1793291	ENSG00000227373.4	RP11-160H22.5	-4.61	5.26e-06	0.000574	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174822675	chr1:174115300~174160004:-
THCA	cis	rs7674212	0.581	rs11946020	ENSG00000248971.2	KRT8P46	-4.61	5.26e-06	0.000574	-0.26	-0.21	Type 2 diabetes;	chr4:103023585	chr4:102728746~102730171:-
THCA	cis	rs72717009	0.825	rs7529425	ENSG00000225217.1	HSPA7	-4.61	5.26e-06	0.000574	-0.32	-0.21	Rheumatoid arthritis;	chr1:161509809	chr1:161606291~161608217:+
THCA	cis	rs72717009	0.825	rs11810143	ENSG00000225217.1	HSPA7	-4.61	5.26e-06	0.000574	-0.32	-0.21	Rheumatoid arthritis;	chr1:161510859	chr1:161606291~161608217:+
THCA	cis	rs12410462	0.591	rs2644161	ENSG00000227711.2	RP11-275O4.5	4.61	5.26e-06	0.000574	0.26	0.21	Major depressive disorder;	chr1:227518618	chr1:227509028~227520477:-
THCA	cis	rs116248771	0.739	rs4679831	ENSG00000271778.1	RP11-379F4.8	4.61	5.26e-06	0.000574	0.28	0.21	diarrhoeal disease at age 2;	chr3:158603199	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs12629635	ENSG00000271778.1	RP11-379F4.8	4.61	5.26e-06	0.000574	0.28	0.21	diarrhoeal disease at age 2;	chr3:158604280	chr3:158782547~158783124:+
THCA	cis	rs73108077	0.736	rs2206384	ENSG00000277112.2	RP11-755J8.1	-4.61	5.26e-06	0.000574	-0.33	-0.21	Red blood cell density in sickle cell anemia;	chr20:31339363	chr20:30681825~30723932:-
THCA	cis	rs12478296	1	rs6717667	ENSG00000220804.7	AC093642.5	4.61	5.26e-06	0.000574	0.23	0.21	Obesity-related traits;	chr2:242055379	chr2:242088633~242160153:+
THCA	cis	rs17301013	0.861	rs333418	ENSG00000227373.4	RP11-160H22.5	4.61	5.26e-06	0.000574	0.29	0.21	Systemic lupus erythematosus;	chr1:174707294	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.828	rs332783	ENSG00000227373.4	RP11-160H22.5	4.61	5.26e-06	0.000574	0.29	0.21	Systemic lupus erythematosus;	chr1:174719260	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.861	rs170768	ENSG00000227373.4	RP11-160H22.5	4.61	5.26e-06	0.000574	0.29	0.21	Systemic lupus erythematosus;	chr1:174720787	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.861	rs332796	ENSG00000227373.4	RP11-160H22.5	4.61	5.26e-06	0.000574	0.29	0.21	Systemic lupus erythematosus;	chr1:174727142	chr1:174115300~174160004:-
THCA	cis	rs17301013	0.861	rs332799	ENSG00000227373.4	RP11-160H22.5	4.61	5.26e-06	0.000574	0.29	0.21	Systemic lupus erythematosus;	chr1:174731110	chr1:174115300~174160004:-
THCA	cis	rs6088580	0.608	rs8114616	ENSG00000276073.1	RP5-1125A11.7	4.61	5.26e-06	0.000574	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34381286	chr20:33985617~33988989:-
THCA	cis	rs17301013	0.932	rs4233195	ENSG00000227373.4	RP11-160H22.5	-4.61	5.26e-06	0.000574	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174806736	chr1:174115300~174160004:-
THCA	cis	rs564799	0.966	rs485789	ENSG00000244040.4	IL12A-AS1	4.61	5.26e-06	0.000574	0.27	0.21	Systemic lupus erythematosus;	chr3:160012361	chr3:159913400~160225299:-
THCA	cis	rs10186029	0.676	rs1025820	ENSG00000270659.1	RP11-105N14.1	-4.61	5.27e-06	0.000574	-0.17	-0.21	Systemic sclerosis;	chr2:213069054	chr2:213152970~213153659:+
THCA	cis	rs9652601	0.691	rs6498160	ENSG00000274038.1	RP11-66H6.4	-4.61	5.27e-06	0.000574	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11105590	chr16:11056556~11057034:+
THCA	cis	rs2179367	0.509	rs9485390	ENSG00000223701.3	RAET1E-AS1	4.61	5.27e-06	0.000574	0.29	0.21	Dupuytren's disease;	chr6:149421004	chr6:149884431~149919508:+
THCA	cis	rs7429990	0.828	rs55823596	ENSG00000228638.1	FCF1P2	-4.61	5.27e-06	0.000574	-0.21	-0.21	Educational attainment (years of education);	chr3:47758541	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.864	rs4858853	ENSG00000228638.1	FCF1P2	-4.61	5.27e-06	0.000574	-0.21	-0.21	Educational attainment (years of education);	chr3:47760605	chr3:48290793~48291375:-
THCA	cis	rs2191566	0.96	rs7255315	ENSG00000266921.1	RP11-15A1.7	-4.61	5.27e-06	0.000575	-0.19	-0.21	Acute lymphoblastic leukemia (childhood);	chr19:44006781	chr19:43996896~44002836:-
THCA	cis	rs739496	0.615	rs56884502	ENSG00000226469.1	ADAM1B	4.61	5.27e-06	0.000575	0.26	0.21	Platelet count;	chr12:111769496	chr12:111927018~111929017:+
THCA	cis	rs739496	0.642	rs74849450	ENSG00000226469.1	ADAM1B	4.61	5.27e-06	0.000575	0.26	0.21	Platelet count;	chr12:111771034	chr12:111927018~111929017:+
THCA	cis	rs427943	0.8	rs3788183	ENSG00000223768.1	LINC00205	-4.61	5.27e-06	0.000575	-0.19	-0.21	Body mass index;	chr21:45209549	chr21:45293285~45297354:+
THCA	cis	rs9902453	1	rs7207021	ENSG00000263370.1	RP11-68I3.5	-4.61	5.27e-06	0.000575	-0.27	-0.21	Coffee consumption (cups per day);	chr17:30073498	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs9897206	ENSG00000263370.1	RP11-68I3.5	-4.61	5.27e-06	0.000575	-0.27	-0.21	Coffee consumption (cups per day);	chr17:30079090	chr17:29639627~29640825:+
THCA	cis	rs9876781	1	rs6810060	ENSG00000244380.1	RP11-24C3.2	4.61	5.27e-06	0.000575	0.24	0.21	Longevity;	chr3:48393284	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs6770470	ENSG00000244380.1	RP11-24C3.2	4.61	5.27e-06	0.000575	0.24	0.21	Longevity;	chr3:48393659	chr3:48440352~48446656:-
THCA	cis	rs6496044	0.507	rs410522	ENSG00000259295.5	CSPG4P12	-4.61	5.27e-06	0.000575	-0.28	-0.21	Interstitial lung disease;	chr15:85663813	chr15:85191438~85213905:+
THCA	cis	rs8031584	0.918	rs34693097	ENSG00000178081.11	ULK4P3	4.61	5.27e-06	0.000575	0.27	0.21	Huntington's disease progression;	chr15:30961781	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.918	rs35784593	ENSG00000178081.11	ULK4P3	4.61	5.27e-06	0.000575	0.27	0.21	Huntington's disease progression;	chr15:30962385	chr15:30103720~30131757:+
THCA	cis	rs6570726	0.935	rs447818	ENSG00000270638.1	RP3-466P17.1	4.61	5.27e-06	0.000575	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145735570~145737218:+
THCA	cis	rs9300255	0.568	rs1790108	ENSG00000235423.7	RP11-282O18.3	4.61	5.28e-06	0.000575	0.22	0.21	Neutrophil percentage of white cells;	chr12:123152294	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.51	rs1790109	ENSG00000235423.7	RP11-282O18.3	4.61	5.28e-06	0.000575	0.22	0.21	Neutrophil percentage of white cells;	chr12:123153205	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.568	rs1627724	ENSG00000235423.7	RP11-282O18.3	4.61	5.28e-06	0.000575	0.22	0.21	Neutrophil percentage of white cells;	chr12:123154033	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1727314	ENSG00000235423.7	RP11-282O18.3	4.61	5.28e-06	0.000575	0.22	0.21	Neutrophil percentage of white cells;	chr12:123156117	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.537	rs1618679	ENSG00000235423.7	RP11-282O18.3	4.61	5.28e-06	0.000575	0.22	0.21	Neutrophil percentage of white cells;	chr12:123166167	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.568	rs1621194	ENSG00000235423.7	RP11-282O18.3	4.61	5.28e-06	0.000575	0.22	0.21	Neutrophil percentage of white cells;	chr12:123166471	chr12:123252030~123261483:-
THCA	cis	rs4950322	0.57	rs4950409	ENSG00000180867.10	PDIA3P1	4.61	5.28e-06	0.000575	0.21	0.21	Protein quantitative trait loci;	chr1:147335879	chr1:147178113~147179622:+
THCA	cis	rs7216064	0.734	rs11653507	ENSG00000278740.1	RP11-147L13.14	4.61	5.28e-06	0.000575	0.23	0.21	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67895948	chr17:68188547~68189165:+
THCA	cis	rs1979679	0.918	rs10843187	ENSG00000278733.1	RP11-425D17.1	-4.61	5.28e-06	0.000575	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28483586	chr12:28185625~28186190:-
THCA	cis	rs8062405	0.824	rs153106	ENSG00000261766.1	RP11-22P6.2	-4.61	5.28e-06	0.000575	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28862166~28863340:-
THCA	cis	rs17095355	1	rs7067604	ENSG00000203876.8	ADD3-AS1	-4.61	5.28e-06	0.000575	-0.24	-0.21	Biliary atresia;	chr10:109974907	chr10:109940104~110008381:-
THCA	cis	rs172166	0.516	rs1150670	ENSG00000220721.1	OR1F12	4.61	5.28e-06	0.000575	0.23	0.21	Cardiac Troponin-T levels;	chr6:28162781	chr6:28073316~28074233:+
THCA	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-4.61	5.28e-06	0.000576	-0.3	-0.21	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
THCA	cis	rs270601	0.77	rs10463891	ENSG00000237714.1	P4HA2-AS1	-4.61	5.28e-06	0.000576	-0.27	-0.21	Acylcarnitine levels;	chr5:132261699	chr5:132184876~132192808:+
THCA	cis	rs1046491	0.901	rs11663175	ENSG00000264964.1	RP11-888D10.3	4.61	5.28e-06	0.000576	0.35	0.21	Scarlet fever;	chr18:9175448	chr18:9315194~9334441:-
THCA	cis	rs1823874	0.71	rs2085087	ENSG00000182397.13	DNM1P46	-4.61	5.28e-06	0.000576	-0.24	-0.21	IgG glycosylation;	chr15:99819938	chr15:99790156~99806927:-
THCA	cis	rs4714902	0.571	rs5011271	ENSG00000231769.2	RP1-8B1.4	-4.61	5.28e-06	0.000576	-0.18	-0.21	Colonoscopy-negative controls vs population controls;	chr6:46174702	chr6:46097093~46129706:-
THCA	cis	rs4908769	0.624	rs2708630	ENSG00000232912.4	RP5-1115A15.1	-4.61	5.28e-06	0.000576	-0.22	-0.21	Allergy;	chr1:8387344	chr1:8424645~8434838:+
THCA	cis	rs13063635	0.85	rs7652478	ENSG00000226074.4	PRSS44	-4.61	5.28e-06	0.000576	-0.36	-0.21	Eosinophil percentage of granulocytes;	chr3:46048985	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs7642320	ENSG00000226074.4	PRSS44	-4.61	5.28e-06	0.000576	-0.36	-0.21	Eosinophil percentage of granulocytes;	chr3:46049130	chr3:46809359~46812558:-
THCA	cis	rs56313388	0.522	rs9929277	ENSG00000246379.5	RP11-461O7.1	-4.61	5.28e-06	0.000576	-0.22	-0.21	Pulse pressure;	chr16:56124806	chr16:56092987~56191094:-
THCA	cis	rs12612619	0.732	rs714513	ENSG00000229122.1	AGBL5-IT1	4.61	5.29e-06	0.000576	0.15	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26983606	chr2:27061038~27061815:+
THCA	cis	rs2742234	0.59	rs2503864	ENSG00000273008.1	RP11-351D16.3	-4.61	5.29e-06	0.000576	-0.19	-0.21	Hirschsprung disease;	chr10:43171319	chr10:43136824~43138334:-
THCA	cis	rs7554547	0.69	rs10864544	ENSG00000201801.1	RNU5E-4P	4.61	5.29e-06	0.000577	0.25	0.21	Nonsyndromic cleft lip with cleft palate;	chr1:11875666	chr1:11909808~11909927:-
THCA	cis	rs13256369	0.865	rs13282523	ENSG00000254153.1	CTA-398F10.2	-4.61	5.29e-06	0.000577	-0.23	-0.21	Obesity-related traits;	chr8:8719783	chr8:8456909~8461337:-
THCA	cis	rs7772486	0.72	rs6570713	ENSG00000270638.1	RP3-466P17.1	-4.61	5.29e-06	0.000577	-0.16	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145735570~145737218:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000273142.1	RP11-458F8.4	4.61	5.29e-06	0.000577	0.19	0.21	Aortic root size;	chr7:66622723	chr7:66902857~66906297:+
THCA	cis	rs9902453	0.765	rs9890747	ENSG00000263370.1	RP11-68I3.5	4.61	5.29e-06	0.000577	0.27	0.21	Coffee consumption (cups per day);	chr17:29680424	chr17:29639627~29640825:+
THCA	cis	rs8067545	0.611	rs77449863	ENSG00000270091.1	RP11-78O7.2	4.61	5.3e-06	0.000577	0.16	0.21	Schizophrenia;	chr17:20288547	chr17:19896590~19897287:-
THCA	cis	rs875971	0.619	rs10278371	ENSG00000229886.1	RP5-1132H15.3	-4.61	5.3e-06	0.000577	-0.21	-0.21	Aortic root size;	chr7:66586553	chr7:66025126~66031544:-
THCA	cis	rs8077577	0.747	rs62072540	ENSG00000273018.4	CTD-2303H24.2	-4.61	5.3e-06	0.000578	-0.3	-0.21	Obesity-related traits;	chr17:18321914	chr17:18511221~18551705:-
THCA	cis	rs7617773	0.779	rs11718329	ENSG00000199476.1	Y_RNA	-4.61	5.3e-06	0.000578	-0.26	-0.21	Coronary artery disease;	chr3:48268338	chr3:48288587~48288694:+
THCA	cis	rs17221829	0.965	rs10830363	ENSG00000280385.1	AP000648.5	-4.61	5.3e-06	0.000578	-0.2	-0.21	Anxiety in major depressive disorder;	chr11:89725300	chr11:90193614~90198120:+
THCA	cis	rs13118159	0.55	rs4974611	ENSG00000254094.1	AC078852.1	-4.61	5.3e-06	0.000578	-0.26	-0.21	Longevity;	chr4:1364661	chr4:1356581~1358075:+
THCA	cis	rs13118159	0.509	rs7688922	ENSG00000254094.1	AC078852.1	-4.61	5.3e-06	0.000578	-0.26	-0.21	Longevity;	chr4:1367223	chr4:1356581~1358075:+
THCA	cis	rs6496932	0.663	rs11074169	ENSG00000259630.2	CTD-2262B20.1	-4.61	5.3e-06	0.000578	-0.26	-0.21	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85415228~85415633:+
THCA	cis	rs3770081	1	rs78646493	ENSG00000273080.1	RP11-301O19.1	-4.61	5.3e-06	0.000578	-0.47	-0.21	Facial emotion recognition (sad faces);	chr2:86056072	chr2:86195590~86196049:+
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000275400.1	RP4-756H11.5	-4.61	5.3e-06	0.000578	-0.23	-0.21	Corneal structure;	chr7:66813271	chr7:66553805~66554199:-
THCA	cis	rs6860806	0.507	rs635620	ENSG00000237714.1	P4HA2-AS1	-4.61	5.3e-06	0.000578	-0.28	-0.21	Breast cancer;	chr5:132384571	chr5:132184876~132192808:+
THCA	cis	rs6860806	0.507	rs635619	ENSG00000237714.1	P4HA2-AS1	-4.61	5.3e-06	0.000578	-0.28	-0.21	Breast cancer;	chr5:132384573	chr5:132184876~132192808:+
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000227888.4	FAM66A	-4.61	5.3e-06	0.000578	-0.26	-0.21	Neuroticism;	chr8:11986249	chr8:12362019~12388296:+
THCA	cis	rs7731390	0.51	rs58395458	ENSG00000233006.5	AC034220.3	4.61	5.31e-06	0.000578	0.27	0.21	IgG glycosylation;	chr5:132465283	chr5:132311285~132369916:-
THCA	cis	rs6921919	0.583	rs6928773	ENSG00000280107.1	AL022393.9	-4.61	5.31e-06	0.000579	-0.2	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28170845~28172521:+
THCA	cis	rs9813712	0.78	rs7625942	ENSG00000253540.4	FAM86HP	4.61	5.31e-06	0.000579	0.26	0.21	Response to amphetamines;	chr3:130232611	chr3:130099092~130111472:-
THCA	cis	rs253959	0.663	rs56102010	ENSG00000272265.1	CTD-2287O16.4	-4.61	5.31e-06	0.000579	-0.26	-0.21	Bipolar disorder and schizophrenia;	chr5:116377318	chr5:116078110~116078570:-
THCA	cis	rs4693089	0.604	rs3775089	ENSG00000213608.5	SLC25A14P1	4.61	5.31e-06	0.000579	0.24	0.21	Menopause (age at onset);	chr4:83454644	chr4:83477524~83478424:+
THCA	cis	rs889398	0.967	rs35967356	ENSG00000226232.7	RP11-419C5.2	4.61	5.31e-06	0.000579	0.2	0.21	Body mass index;	chr16:69547451	chr16:69976388~69996188:-
THCA	cis	rs440932	0.747	rs330946	ENSG00000254340.1	RP11-10A14.3	4.61	5.31e-06	0.000579	0.23	0.21	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:9141424~9145435:+
THCA	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	-4.61	5.31e-06	0.000579	-0.22	-0.21	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
THCA	cis	rs5753037	0.809	rs5752964	ENSG00000279699.1	RP1-102K2.9	4.61	5.31e-06	0.000579	0.21	0.21	Type 1 diabetes;	chr22:29812619	chr22:30275215~30276951:-
THCA	cis	rs6856693	0.513	rs2280297	ENSG00000251139.2	RP11-701P16.2	-4.61	5.31e-06	0.000579	-0.24	-0.21	Menopause (age at onset);	chr4:184814959	chr4:184813619~184821300:+
THCA	cis	rs11976180	1	rs2371244	ENSG00000244198.4	RP4-545C24.1	-4.61	5.31e-06	0.000579	-0.2	-0.21	Obesity-related traits;	chr7:144060518	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs4726669	ENSG00000244198.4	RP4-545C24.1	-4.61	5.31e-06	0.000579	-0.2	-0.21	Obesity-related traits;	chr7:144061098	chr7:144194858~144280547:+
THCA	cis	rs10090774	0.93	rs9324539	ENSG00000279766.1	RP11-642A1.2	-4.61	5.32e-06	0.000579	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140966898	chr8:140572142~140572812:-
THCA	cis	rs4950322	0.57	rs17360443	ENSG00000180867.10	PDIA3P1	4.61	5.32e-06	0.000579	0.21	0.21	Protein quantitative trait loci;	chr1:147279737	chr1:147178113~147179622:+
THCA	cis	rs1823913	0.637	rs4613316	ENSG00000280083.1	RP11-317J9.1	-4.6	5.32e-06	0.000579	-0.24	-0.21	Obesity-related traits;	chr2:191326074	chr2:191154118~191156070:-
THCA	cis	rs2836974	0.666	rs11910705	ENSG00000255568.3	BRWD1-AS2	-4.6	5.32e-06	0.000579	-0.17	-0.21	Cognitive function;	chr21:39313678	chr21:39313935~39314962:+
THCA	cis	rs4660214	0.666	rs1180376	ENSG00000182109.6	RP11-69E11.4	4.6	5.32e-06	0.000579	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39522280~39546187:-
THCA	cis	rs2243480	1	rs4718270	ENSG00000164669.11	INTS4P1	4.6	5.32e-06	0.000579	0.4	0.21	Diabetic kidney disease;	chr7:65737415	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs4718269	ENSG00000164669.11	INTS4P1	-4.6	5.32e-06	0.000579	-0.4	-0.21	Diabetic kidney disease;	chr7:65735810	chr7:65141225~65234216:+
THCA	cis	rs5742933	1	rs1966729	ENSG00000273240.1	RP11-455J20.3	-4.6	5.32e-06	0.000579	-0.23	-0.21	Ferritin levels;	chr2:189721105	chr2:189763859~189764456:-
THCA	cis	rs10256972	0.758	rs11979275	ENSG00000225146.1	AC073957.15	4.6	5.32e-06	0.00058	0.22	0.21	Endometriosis;Longevity;	chr7:1029699	chr7:1029025~1043891:+
THCA	cis	rs10256972	0.758	rs11980081	ENSG00000225146.1	AC073957.15	4.6	5.32e-06	0.00058	0.22	0.21	Endometriosis;Longevity;	chr7:1029736	chr7:1029025~1043891:+
THCA	cis	rs11175834	1	rs11175834	ENSG00000213344.2	PCNPP3	4.6	5.32e-06	0.00058	0.35	0.21	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65598856	chr12:65645992~65646462:-
THCA	cis	rs13126694	1	rs13126694	ENSG00000248429.4	RP11-597D13.9	-4.6	5.32e-06	0.00058	-0.22	-0.21	Blood osmolality (transformed sodium);	chr4:158177632	chr4:158170752~158202877:+
THCA	cis	rs7688540	0.8	rs73793597	ENSG00000250892.1	RP11-1365D11.1	4.6	5.32e-06	0.00058	0.29	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:201409~205009:-
THCA	cis	rs875971	0.505	rs2462573	ENSG00000164669.11	INTS4P1	4.6	5.33e-06	0.00058	0.26	0.21	Aortic root size;	chr7:66042405	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000232559.3	GS1-124K5.12	4.6	5.33e-06	0.000581	0.28	0.21	Diabetic kidney disease;	chr7:65988305	chr7:66554588~66576923:-
THCA	cis	rs7520050	0.966	rs7550746	ENSG00000234329.1	RP11-767N6.2	-4.6	5.33e-06	0.000581	-0.18	-0.21	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45651039~45651826:-
THCA	cis	rs4950322	0.57	rs11800580	ENSG00000226015.2	CCT8P1	-4.6	5.33e-06	0.000581	-0.24	-0.21	Protein quantitative trait loci;	chr1:147261053	chr1:147203276~147204932:-
THCA	cis	rs4925386	0.921	rs11204472	ENSG00000275437.1	RP5-908M14.10	-4.6	5.34e-06	0.000581	-0.19	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62402236~62405935:-
THCA	cis	rs1979679	0.918	rs10771430	ENSG00000278733.1	RP11-425D17.1	-4.6	5.34e-06	0.000581	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28470505	chr12:28185625~28186190:-
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000229180.5	GS1-124K5.11	4.6	5.34e-06	0.000582	0.17	0.21	Corneal structure;	chr7:66790251	chr7:66526088~66542624:-
THCA	cis	rs1707322	1	rs4390216	ENSG00000281133.1	AL355480.3	-4.6	5.34e-06	0.000582	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.964	rs10437063	ENSG00000281133.1	AL355480.3	-4.6	5.34e-06	0.000582	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs6676982	ENSG00000281133.1	AL355480.3	-4.6	5.34e-06	0.000582	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.927	rs11211194	ENSG00000281133.1	AL355480.3	-4.6	5.34e-06	0.000582	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45580892~45580996:-
THCA	cis	rs8067545	0.611	rs2703771	ENSG00000270091.1	RP11-78O7.2	4.6	5.34e-06	0.000582	0.16	0.21	Schizophrenia;	chr17:20226841	chr17:19896590~19897287:-
THCA	cis	rs1334894	0.901	rs1977655	ENSG00000228559.1	RP3-340B19.3	-4.6	5.34e-06	0.000582	-0.42	-0.21	Coronary artery disease;	chr6:35553925	chr6:35544632~35545669:+
THCA	cis	rs10256972	0.758	rs4723649	ENSG00000225146.1	AC073957.15	4.6	5.34e-06	0.000582	0.22	0.21	Endometriosis;Longevity;	chr7:1032269	chr7:1029025~1043891:+
THCA	cis	rs73108077	0.79	rs73102048	ENSG00000277112.2	RP11-755J8.1	-4.6	5.34e-06	0.000582	-0.4	-0.21	Red blood cell density in sickle cell anemia;	chr20:31277508	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.704	rs7273922	ENSG00000277112.2	RP11-755J8.1	-4.6	5.34e-06	0.000582	-0.4	-0.21	Red blood cell density in sickle cell anemia;	chr20:31282601	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.79	rs73102082	ENSG00000277112.2	RP11-755J8.1	-4.6	5.34e-06	0.000582	-0.4	-0.21	Red blood cell density in sickle cell anemia;	chr20:31288687	chr20:30681825~30723932:-
THCA	cis	rs7829975	1	rs7829975	ENSG00000233609.3	RP11-62H7.2	-4.6	5.34e-06	0.000582	-0.2	-0.21	Mood instability;	chr8:8690607	chr8:8961200~8979025:+
THCA	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-4.6	5.35e-06	0.000582	-0.2	-0.21	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
THCA	cis	rs931127	0.692	rs7934517	ENSG00000214659.4	KRT8P26	4.6	5.35e-06	0.000582	0.18	0.21	Systemic lupus erythematosus;	chr11:65678202	chr11:65726939~65728214:+
THCA	cis	rs897984	0.52	rs12928081	ENSG00000260911.2	RP11-196G11.2	-4.6	5.35e-06	0.000582	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30873838	chr16:31043150~31049868:+
THCA	cis	rs2806561	0.704	rs2746560	ENSG00000249087.5	ZNF436-AS1	-4.6	5.35e-06	0.000583	-0.13	-0.21	Height;	chr1:23199786	chr1:23368997~23371839:+
THCA	cis	rs6442522	0.78	rs13068150	ENSG00000249786.6	EAF1-AS1	4.6	5.35e-06	0.000583	0.21	0.21	Uric acid levels;	chr3:15397434	chr3:15436171~15455940:-
THCA	cis	rs17095355	1	rs7079713	ENSG00000203876.8	ADD3-AS1	-4.6	5.35e-06	0.000583	-0.23	-0.21	Biliary atresia;	chr10:109995658	chr10:109940104~110008381:-
THCA	cis	rs1267303	0.642	rs1267301	ENSG00000232022.5	FAAHP1	-4.6	5.35e-06	0.000583	-0.25	-0.21	Monobrow;	chr1:46527181	chr1:46432129~46445521:+
THCA	cis	rs57502260	0.68	rs55654976	ENSG00000212093.1	AP000807.1	4.6	5.35e-06	0.000583	0.27	0.21	Total body bone mineral density (age 45-60);	chr11:68626073	chr11:68506083~68506166:-
THCA	cis	rs6088590	1	rs6120708	ENSG00000269202.1	RP4-614O4.12	-4.6	5.35e-06	0.000583	-0.18	-0.21	Coronary artery disease;	chr20:34747722	chr20:35201747~35203288:-
THCA	cis	rs17594362	0.943	rs60511964	ENSG00000264190.1	MIR5006	4.6	5.35e-06	0.000583	0.33	0.21	Multiple sclerosis;	chr13:41577891	chr13:41568286~41568395:-
THCA	cis	rs972578	0.715	rs5759032	ENSG00000274717.1	RP1-47A17.1	-4.6	5.36e-06	0.000583	-0.22	-0.21	Mean platelet volume;	chr22:42916919	chr22:42791814~42794313:-
THCA	cis	rs2787702	1	rs2650717	ENSG00000237233.2	TMEM26-AS1	4.6	5.36e-06	0.000583	0.26	0.21	Response to taxane treatment (placlitaxel);	chr10:61548311	chr10:61452639~61481956:+
THCA	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-4.6	5.36e-06	0.000583	-0.12	-0.21	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
THCA	cis	rs9307551	0.552	rs12506212	ENSG00000250334.4	LINC00989	-4.6	5.36e-06	0.000583	-0.24	-0.21	Refractive error;	chr4:79512944	chr4:79492416~79576460:+
THCA	cis	rs11976180	1	rs1919949	ENSG00000244198.4	RP4-545C24.1	-4.6	5.36e-06	0.000583	-0.21	-0.21	Obesity-related traits;	chr7:144070630	chr7:144194858~144280547:+
THCA	cis	rs4915077	1	rs17020127	ENSG00000226822.1	RP11-356N1.2	4.6	5.36e-06	0.000584	0.39	0.21	Hypothyroidism;	chr1:107815461	chr1:108071482~108074519:+
THCA	cis	rs2253762	0.507	rs75383663	ENSG00000226864.1	ATE1-AS1	4.6	5.36e-06	0.000584	0.33	0.21	Breast cancer;	chr10:121993340	chr10:121928312~121951965:+
THCA	cis	rs3785574	0.705	rs2665856	ENSG00000240280.5	TCAM1P	4.6	5.36e-06	0.000584	0.28	0.21	Height;	chr17:63905361	chr17:63849292~63864379:+
THCA	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-4.6	5.36e-06	0.000584	-0.12	-0.21	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-4.6	5.36e-06	0.000584	-0.12	-0.21	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-4.6	5.36e-06	0.000584	-0.12	-0.21	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-4.6	5.36e-06	0.000584	-0.12	-0.21	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-4.6	5.36e-06	0.000584	-0.12	-0.21	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	4.6	5.36e-06	0.000584	0.12	0.21	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
THCA	cis	rs2278702	1	rs2278702	ENSG00000259495.2	RP11-210M15.2	-4.6	5.36e-06	0.000584	-0.27	-0.21	Bipolar disorder;	chr15:80402580	chr15:80344853~80403575:-
THCA	cis	rs972578	0.691	rs738380	ENSG00000274717.1	RP1-47A17.1	-4.6	5.36e-06	0.000584	-0.22	-0.21	Mean platelet volume;	chr22:43004931	chr22:42791814~42794313:-
THCA	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-4.6	5.36e-06	0.000584	-0.12	-0.21	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
THCA	cis	rs12681288	0.862	rs2701898	ENSG00000260721.1	AF067845.1	4.6	5.36e-06	0.000584	0.25	0.21	Schizophrenia;	chr8:1070812	chr8:1368642~1369833:-
THCA	cis	rs1823874	0.677	rs2100446	ENSG00000182397.13	DNM1P46	-4.6	5.36e-06	0.000584	-0.24	-0.21	IgG glycosylation;	chr15:99820169	chr15:99790156~99806927:-
THCA	cis	rs1823874	0.677	rs2100447	ENSG00000182397.13	DNM1P46	-4.6	5.36e-06	0.000584	-0.24	-0.21	IgG glycosylation;	chr15:99820188	chr15:99790156~99806927:-
THCA	cis	rs4682868	0.581	rs6774801	ENSG00000273328.4	RP11-141M3.6	4.6	5.37e-06	0.000584	0.25	0.21	Monocyte percentage of white cells;	chr3:42882284	chr3:42809414~42908105:+
THCA	cis	rs6545883	0.507	rs4411680	ENSG00000270820.4	RP11-355B11.2	-4.6	5.37e-06	0.000584	-0.18	-0.21	Tuberculosis;	chr2:61356970	chr2:61471188~61484130:+
THCA	cis	rs4218	0.724	rs35168204	ENSG00000259732.1	RP11-59H7.3	-4.6	5.37e-06	0.000584	-0.29	-0.21	Social communication problems;	chr15:59121354	chr15:59121034~59133250:+
THCA	cis	rs7772486	0.79	rs2249147	ENSG00000270638.1	RP3-466P17.1	4.6	5.37e-06	0.000584	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145735570~145737218:+
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000229180.5	GS1-124K5.11	4.6	5.37e-06	0.000584	0.16	0.21	Corneal structure;	chr7:66938233	chr7:66526088~66542624:-
THCA	cis	rs3096299	0.503	rs9925045	ENSG00000261118.1	RP11-104N10.1	4.6	5.37e-06	0.000584	0.18	0.21	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89492017~89504460:-
THCA	cis	rs2439831	0.867	rs2278860	ENSG00000166763.7	STRCP1	-4.6	5.37e-06	0.000585	-0.28	-0.21	Lung cancer in ever smokers;	chr15:43366848	chr15:43699488~43718184:-
THCA	cis	rs8054556	0.74	rs4407079	ENSG00000183604.13	SMG1P5	-4.6	5.37e-06	0.000585	-0.19	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29920578	chr16:30267553~30335374:-
THCA	cis	rs875971	0.638	rs7793569	ENSG00000229886.1	RP5-1132H15.3	-4.6	5.37e-06	0.000585	-0.21	-0.21	Aortic root size;	chr7:66651646	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs6975195	ENSG00000229886.1	RP5-1132H15.3	-4.6	5.37e-06	0.000585	-0.21	-0.21	Aortic root size;	chr7:66659787	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs3857688	ENSG00000229886.1	RP5-1132H15.3	-4.6	5.37e-06	0.000585	-0.21	-0.21	Aortic root size;	chr7:66662819	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs2286684	ENSG00000229886.1	RP5-1132H15.3	-4.6	5.37e-06	0.000585	-0.21	-0.21	Aortic root size;	chr7:66664843	chr7:66025126~66031544:-
THCA	cis	rs801193	0.935	rs2286683	ENSG00000229886.1	RP5-1132H15.3	-4.6	5.37e-06	0.000585	-0.21	-0.21	Aortic root size;	chr7:66664856	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs10274773	ENSG00000229886.1	RP5-1132H15.3	-4.6	5.37e-06	0.000585	-0.21	-0.21	Aortic root size;	chr7:66668591	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs11773829	ENSG00000229886.1	RP5-1132H15.3	-4.6	5.37e-06	0.000585	-0.21	-0.21	Aortic root size;	chr7:66676087	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs7788576	ENSG00000229886.1	RP5-1132H15.3	-4.6	5.37e-06	0.000585	-0.21	-0.21	Aortic root size;	chr7:66683315	chr7:66025126~66031544:-
THCA	cis	rs801193	0.935	rs2659916	ENSG00000229886.1	RP5-1132H15.3	4.6	5.37e-06	0.000585	0.21	0.21	Aortic root size;	chr7:66686365	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs6958520	ENSG00000229886.1	RP5-1132H15.3	4.6	5.37e-06	0.000585	0.21	0.21	Aortic root size;	chr7:66686466	chr7:66025126~66031544:-
THCA	cis	rs801193	0.967	rs2707849	ENSG00000229886.1	RP5-1132H15.3	4.6	5.37e-06	0.000585	0.21	0.21	Aortic root size;	chr7:66687725	chr7:66025126~66031544:-
THCA	cis	rs6517329	0.513	rs62229302	ENSG00000236830.5	CBR3-AS1	4.6	5.37e-06	0.000585	0.2	0.21	Schizophrenia;	chr21:36156202	chr21:36131767~36175815:-
THCA	cis	rs6517329	0.513	rs61232790	ENSG00000236830.5	CBR3-AS1	4.6	5.37e-06	0.000585	0.2	0.21	Schizophrenia;	chr21:36156559	chr21:36131767~36175815:-
THCA	cis	rs9437689	0.508	rs1887094	ENSG00000235501.4	RP4-639F20.1	-4.6	5.37e-06	0.000585	-0.23	-0.21	Phospholipid levels (plasma);	chr1:94953146	chr1:94927566~94963270:+
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000272831.1	RP11-792A8.4	4.6	5.37e-06	0.000585	0.13	0.21	Calcium levels;	chr7:65903721	chr7:66739829~66740385:-
THCA	cis	rs17507216	0.56	rs28493687	ENSG00000255769.6	GOLGA2P10	-4.6	5.37e-06	0.000585	-0.25	-0.21	Excessive daytime sleepiness;	chr15:82560062	chr15:82472993~82513950:-
THCA	cis	rs7618915	0.501	rs13060048	ENSG00000243224.1	RP5-1157M23.2	-4.6	5.37e-06	0.000585	-0.22	-0.21	Bipolar disorder;	chr3:52564592	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs6786919	ENSG00000243224.1	RP5-1157M23.2	-4.6	5.37e-06	0.000585	-0.22	-0.21	Electroencephalogram traits;	chr3:52565773	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs6788887	ENSG00000243224.1	RP5-1157M23.2	-4.6	5.37e-06	0.000585	-0.22	-0.21	Electroencephalogram traits;	chr3:52570989	chr3:52239258~52241097:+
THCA	cis	rs9311474	0.508	rs4687546	ENSG00000243224.1	RP5-1157M23.2	-4.6	5.37e-06	0.000585	-0.22	-0.21	Electroencephalogram traits;	chr3:52571927	chr3:52239258~52241097:+
THCA	cis	rs2412819	0.597	rs541871	ENSG00000166763.7	STRCP1	4.6	5.38e-06	0.000585	0.27	0.21	Lung cancer;	chr15:43868656	chr15:43699488~43718184:-
THCA	cis	rs12478296	0.901	rs59191623	ENSG00000220804.7	AC093642.5	4.6	5.38e-06	0.000585	0.22	0.21	Obesity-related traits;	chr2:242086444	chr2:242088633~242160153:+
THCA	cis	rs2287838	0.967	rs11085425	ENSG00000267289.1	CTD-2623N2.11	-4.6	5.38e-06	0.000585	-0.24	-0.21	Sleep duration;	chr19:9867979	chr19:9834079~9835013:-
THCA	cis	rs1979679	0.918	rs10843176	ENSG00000247934.4	RP11-967K21.1	4.6	5.38e-06	0.000585	0.21	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28454984	chr12:28163298~28190738:-
THCA	cis	rs28374715	0.578	rs17730589	ENSG00000247556.5	OIP5-AS1	4.6	5.38e-06	0.000585	0.2	0.21	Ulcerative colitis;	chr15:41308680	chr15:41283990~41309737:+
THCA	cis	rs1790761	0.554	rs3758938	ENSG00000255318.1	RP11-655M14.13	-4.6	5.38e-06	0.000585	-0.26	-0.21	Mean corpuscular volume;	chr11:67634891	chr11:67618279~67627304:-
THCA	cis	rs812925	0.82	rs11692449	ENSG00000271889.1	RP11-493E12.1	4.6	5.38e-06	0.000585	0.21	0.21	Immature fraction of reticulocytes;	chr2:61477316	chr2:61151433~61162105:-
THCA	cis	rs7829975	0.606	rs10112585	ENSG00000254153.1	CTA-398F10.2	4.6	5.38e-06	0.000586	0.22	0.21	Mood instability;	chr8:8937520	chr8:8456909~8461337:-
THCA	cis	rs1707322	1	rs10789486	ENSG00000281133.1	AL355480.3	-4.6	5.38e-06	0.000586	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45580892~45580996:-
THCA	cis	rs1923243	0.681	rs12118352	ENSG00000223479.3	RP4-788P17.1	4.6	5.38e-06	0.000586	0.23	0.21	Migraine;	chr1:73017531	chr1:73635216~73715214:+
THCA	cis	rs467650	0.747	rs36768	ENSG00000248489.1	CTD-2007H13.3	4.6	5.38e-06	0.000586	0.2	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98614126	chr5:98929171~98995013:+
THCA	cis	rs72945132	1	rs56913804	ENSG00000254604.1	AP000487.6	-4.6	5.38e-06	0.000586	-0.39	-0.21	Coronary artery disease;	chr11:70268567	chr11:70282367~70363368:-
THCA	cis	rs2243480	0.908	rs4718273	ENSG00000164669.11	INTS4P1	-4.6	5.39e-06	0.000586	-0.4	-0.21	Diabetic kidney disease;	chr7:65751112	chr7:65141225~65234216:+
THCA	cis	rs7989336	0.568	rs9513130	ENSG00000247400.3	DNAJC3-AS1	4.6	5.39e-06	0.000586	0.14	0.21	Obesity;	chr13:96383463	chr13:95648733~95676925:-
THCA	cis	rs2058059	0.594	rs3015907	ENSG00000205578.5	POM121B	-4.6	5.39e-06	0.000586	-0.31	-0.21	Subcutaneous adipose tissue;	chr7:72670647	chr7:73293497~73301161:+
THCA	cis	rs332034	0.546	rs10094026	ENSG00000253893.2	FAM85B	4.6	5.39e-06	0.000586	0.38	0.21	Conduct disorder (maternal expressed emotions interaction);	chr8:8788928	chr8:8167819~8226614:-
THCA	cis	rs7819412	0.775	rs4840551	ENSG00000206014.6	OR7E161P	4.6	5.39e-06	0.000586	0.25	0.21	Triglycerides;	chr8:11171530	chr8:11928597~11929563:-
THCA	cis	rs17270561	0.609	rs7754296	ENSG00000272462.2	U91328.19	-4.6	5.39e-06	0.000586	-0.18	-0.21	Iron status biomarkers;	chr6:25744650	chr6:25992662~26001775:+
THCA	cis	rs75059851	0.756	rs11223661	ENSG00000280237.1	MIR4697HG	4.6	5.39e-06	0.000586	0.24	0.21	Schizophrenia;	chr11:133981517	chr11:133896438~133901601:-
THCA	cis	rs930395	0.533	rs11948636	ENSG00000272335.1	RP11-53O19.3	4.6	5.39e-06	0.000587	0.18	0.21	Breast cancer;	chr5:44881127	chr5:44826076~44828592:+
THCA	cis	rs7267979	1	rs11087520	ENSG00000274973.1	RP13-401N8.7	-4.6	5.4e-06	0.000587	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs398036	ENSG00000274973.1	RP13-401N8.7	-4.6	5.4e-06	0.000587	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs397119	ENSG00000274973.1	RP13-401N8.7	-4.6	5.4e-06	0.000587	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25845497~25845862:+
THCA	cis	rs9329221	0.683	rs658385	ENSG00000261451.1	RP11-981G7.1	-4.6	5.4e-06	0.000587	-0.25	-0.21	Neuroticism;	chr8:10034667	chr8:10433672~10438312:+
THCA	cis	rs2985684	1	rs11157696	ENSG00000278009.1	RP11-649E7.8	-4.6	5.4e-06	0.000587	-0.3	-0.21	Carotid intima media thickness;	chr14:49639028	chr14:49601011~49601124:-
THCA	cis	rs9902453	1	rs59274738	ENSG00000263370.1	RP11-68I3.5	4.6	5.4e-06	0.000587	0.27	0.21	Coffee consumption (cups per day);	chr17:30110617	chr17:29639627~29640825:+
THCA	cis	rs10266483	0.562	rs10949887	ENSG00000271550.1	BNIP3P11	4.6	5.4e-06	0.000587	0.3	0.21	Response to statin therapy;	chr7:64291702	chr7:64678954~64687393:-
THCA	cis	rs2412819	0.571	rs28410121	ENSG00000166763.7	STRCP1	-4.6	5.4e-06	0.000587	-0.27	-0.21	Lung cancer;	chr15:43777831	chr15:43699488~43718184:-
THCA	cis	rs801193	0.967	rs34356500	ENSG00000230295.1	RP11-458F8.2	-4.6	5.4e-06	0.000588	-0.16	-0.21	Aortic root size;	chr7:66771620	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000229180.5	GS1-124K5.11	4.6	5.4e-06	0.000588	0.17	0.21	Corneal structure;	chr7:66824628	chr7:66526088~66542624:-
THCA	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-4.6	5.4e-06	0.000588	-0.24	-0.21	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
THCA	cis	rs5742933	1	rs4666783	ENSG00000253559.1	OSGEPL1-AS1	-4.6	5.4e-06	0.000588	-0.25	-0.21	Ferritin levels;	chr2:189748254	chr2:189762704~189765556:+
THCA	cis	rs9910055	0.659	rs227584	ENSG00000267080.4	ASB16-AS1	-4.6	5.4e-06	0.000588	-0.19	-0.21	Total body bone mineral density;	chr17:44148179	chr17:44175973~44186717:-
THCA	cis	rs9910055	0.659	rs2246287	ENSG00000267080.4	ASB16-AS1	-4.6	5.4e-06	0.000588	-0.19	-0.21	Total body bone mineral density;	chr17:44155074	chr17:44175973~44186717:-
THCA	cis	rs9910055	0.659	rs6503488	ENSG00000267080.4	ASB16-AS1	-4.6	5.4e-06	0.000588	-0.19	-0.21	Total body bone mineral density;	chr17:44168790	chr17:44175973~44186717:-
THCA	cis	rs4415084	0.966	rs4571480	ENSG00000272335.1	RP11-53O19.3	4.6	5.4e-06	0.000588	0.17	0.21	Breast cancer;	chr5:44687086	chr5:44826076~44828592:+
THCA	cis	rs2115630	0.691	rs8040066	ENSG00000259728.4	LINC00933	-4.6	5.4e-06	0.000588	-0.24	-0.21	P wave terminal force;	chr15:84633234	chr15:84570649~84580175:+
THCA	cis	rs1334894	0.901	rs7768598	ENSG00000228559.1	RP3-340B19.3	4.6	5.4e-06	0.000588	0.41	0.21	Coronary artery disease;	chr6:35552874	chr6:35544632~35545669:+
THCA	cis	rs4950322	0.57	rs80070044	ENSG00000180867.10	PDIA3P1	4.6	5.41e-06	0.000588	0.21	0.21	Protein quantitative trait loci;	chr1:147330238	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692963	ENSG00000180867.10	PDIA3P1	4.6	5.41e-06	0.000588	0.21	0.21	Protein quantitative trait loci;	chr1:147331090	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.518	rs72692965	ENSG00000180867.10	PDIA3P1	4.6	5.41e-06	0.000588	0.21	0.21	Protein quantitative trait loci;	chr1:147332085	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.518	rs72692968	ENSG00000180867.10	PDIA3P1	4.6	5.41e-06	0.000588	0.21	0.21	Protein quantitative trait loci;	chr1:147332884	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.518	rs72692970	ENSG00000180867.10	PDIA3P1	4.6	5.41e-06	0.000588	0.21	0.21	Protein quantitative trait loci;	chr1:147332887	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692971	ENSG00000180867.10	PDIA3P1	4.6	5.41e-06	0.000588	0.21	0.21	Protein quantitative trait loci;	chr1:147333088	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692973	ENSG00000180867.10	PDIA3P1	4.6	5.41e-06	0.000588	0.21	0.21	Protein quantitative trait loci;	chr1:147333281	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692975	ENSG00000180867.10	PDIA3P1	4.6	5.41e-06	0.000588	0.21	0.21	Protein quantitative trait loci;	chr1:147333506	chr1:147178113~147179622:+
THCA	cis	rs10904908	0.733	rs191693	ENSG00000229124.5	VIM-AS1	4.6	5.41e-06	0.000588	0.2	0.21	Cholesterol, total;Total cholesterol levels;	chr10:17289116	chr10:17214239~17229985:-
THCA	cis	rs62025270	0.688	rs62022940	ENSG00000259295.5	CSPG4P12	-4.6	5.41e-06	0.000588	-0.35	-0.21	Idiopathic pulmonary fibrosis;	chr15:85709289	chr15:85191438~85213905:+
THCA	cis	rs10802047	0.573	rs2712253	ENSG00000231365.4	RP11-418J17.1	4.6	5.41e-06	0.000588	0.21	0.21	Relative hand skill in reading disability;	chr1:118736564	chr1:119140396~119275973:+
THCA	cis	rs10266483	0.921	rs683510	ENSG00000271550.1	BNIP3P11	4.6	5.41e-06	0.000588	0.26	0.21	Response to statin therapy;	chr7:64288983	chr7:64678954~64687393:-
THCA	cis	rs10266483	0.881	rs665452	ENSG00000271550.1	BNIP3P11	4.6	5.41e-06	0.000588	0.26	0.21	Response to statin therapy;	chr7:64289077	chr7:64678954~64687393:-
THCA	cis	rs875971	0.54	rs1723268	ENSG00000164669.11	INTS4P1	-4.6	5.41e-06	0.000588	-0.26	-0.21	Aortic root size;	chr7:66008093	chr7:65141225~65234216:+
THCA	cis	rs34286592	1	rs13332078	ENSG00000214725.6	CDIPT-AS1	-4.6	5.41e-06	0.000588	-0.38	-0.21	Multiple sclerosis;	chr16:29839384	chr16:29863593~29868053:+
THCA	cis	rs9876781	1	rs4858817	ENSG00000244380.1	RP11-24C3.2	-4.6	5.41e-06	0.000588	-0.25	-0.21	Longevity;	chr3:48375266	chr3:48440352~48446656:-
THCA	cis	rs11853189	1	rs78994386	ENSG00000259562.2	RP11-762H8.2	4.6	5.41e-06	0.000589	0.21	0.21	Red cell distribution width;	chr15:78278383	chr15:78290527~78291221:-
THCA	cis	rs11853189	0.938	rs75281351	ENSG00000259562.2	RP11-762H8.2	4.6	5.41e-06	0.000589	0.21	0.21	Red cell distribution width;	chr15:78287308	chr15:78290527~78291221:-
THCA	cis	rs17604090	0.529	rs10239226	ENSG00000225264.3	ZNRF2P2	4.6	5.41e-06	0.000589	0.24	0.21	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29676696	chr7:29598795~29685255:-
THCA	cis	rs17604090	0.557	rs10279965	ENSG00000225264.3	ZNRF2P2	4.6	5.41e-06	0.000589	0.24	0.21	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29677466	chr7:29598795~29685255:-
THCA	cis	rs8113308	0.81	rs17695737	ENSG00000269483.1	AC006272.1	4.6	5.41e-06	0.000589	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:51839924~51843324:-
THCA	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-4.6	5.41e-06	0.000589	-0.23	-0.21	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
THCA	cis	rs1923539	1	rs1923539	ENSG00000242600.5	MBL1P	-4.6	5.42e-06	0.000589	-0.2	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935194	chr10:79904898~79950336:+
THCA	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	4.6	5.42e-06	0.000589	0.24	0.21	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
THCA	cis	rs2677744	1	rs2677744	ENSG00000214432.8	AC068831.10	4.6	5.42e-06	0.00059	0.21	0.21	Attention deficit hyperactivity disorder;	chr15:90907211	chr15:91022619~91036611:+
THCA	cis	rs1371614	0.545	rs3769137	ENSG00000229122.1	AGBL5-IT1	-4.6	5.42e-06	0.00059	-0.14	-0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946622	chr2:27061038~27061815:+
THCA	cis	rs7191700	0.578	rs243324	ENSG00000263080.1	RP11-485G7.5	4.6	5.42e-06	0.00059	0.24	0.21	Multiple sclerosis;	chr16:11261113	chr16:11341809~11345211:-
THCA	cis	rs4789693	0.938	rs12952655	ENSG00000260011.2	RP13-20L14.1	4.6	5.43e-06	0.00059	0.21	0.21	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82381110~82382690:-
THCA	cis	rs4819052	0.851	rs875621	ENSG00000182586.6	LINC00334	-4.6	5.43e-06	0.00059	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45234340~45258730:+
THCA	cis	rs8062405	0.679	rs72793818	ENSG00000261766.1	RP11-22P6.2	-4.6	5.43e-06	0.00059	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28862166~28863340:-
THCA	cis	rs897984	0.568	rs8050107	ENSG00000260911.2	RP11-196G11.2	-4.6	5.43e-06	0.00059	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30882130	chr16:31043150~31049868:+
THCA	cis	rs1923243	0.71	rs10749816	ENSG00000223479.3	RP4-788P17.1	-4.6	5.43e-06	0.00059	-0.23	-0.21	Migraine;	chr1:73181538	chr1:73635216~73715214:+
THCA	cis	rs62244186	0.566	rs2135531	ENSG00000214820.3	MPRIPP1	4.6	5.43e-06	0.00059	0.21	0.21	Depressive symptoms;	chr3:44839666	chr3:44579938~44581026:-
THCA	cis	rs7336933	0.866	rs9532943	ENSG00000278338.3	VWA8-AS1	-4.6	5.43e-06	0.00059	-0.35	-0.21	Calcium levels;	chr13:41869219	chr13:41955808~41981565:+
THCA	cis	rs793571	0.628	rs7171482	ENSG00000245975.2	RP11-30K9.6	4.6	5.43e-06	0.000591	0.23	0.21	Schizophrenia;	chr15:58814296	chr15:58768072~58770974:-
THCA	cis	rs12908161	1	rs35630683	ENSG00000275120.1	RP11-182J1.17	4.6	5.43e-06	0.000591	0.25	0.21	Schizophrenia;	chr15:84806000	chr15:84599434~84606463:-
THCA	cis	rs35828350	1	rs35828350	ENSG00000275120.1	RP11-182J1.17	4.6	5.43e-06	0.000591	0.25	0.21	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84599434~84606463:-
THCA	cis	rs12908161	1	rs56864281	ENSG00000275120.1	RP11-182J1.17	4.6	5.43e-06	0.000591	0.25	0.21	Schizophrenia;	chr15:84814418	chr15:84599434~84606463:-
THCA	cis	rs6496932	0.663	rs2062238	ENSG00000259630.2	CTD-2262B20.1	-4.6	5.43e-06	0.000591	-0.26	-0.21	Central corneal thickness;Corneal structure;	chr15:85376002	chr15:85415228~85415633:+
THCA	cis	rs10090774	0.71	rs10088475	ENSG00000280303.2	ERICD	-4.6	5.43e-06	0.000591	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140660167	chr8:140636281~140638283:+
THCA	cis	rs763121	0.853	rs5757162	ENSG00000235209.1	CTA-150C2.13	4.6	5.43e-06	0.000591	0.27	0.21	Menopause (age at onset);	chr22:38597365	chr22:38921227~38924708:+
THCA	cis	rs78487399	0.908	rs12474102	ENSG00000234936.1	AC010883.5	4.6	5.43e-06	0.000591	0.26	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43608431	chr2:43229573~43233394:+
THCA	cis	rs2015599	0.623	rs3782505	ENSG00000273680.1	RP11-996F15.6	-4.6	5.44e-06	0.000591	-0.29	-0.21	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29332733~29333383:-
THCA	cis	rs2439831	0.867	rs28729853	ENSG00000166763.7	STRCP1	4.6	5.44e-06	0.000591	0.28	0.21	Lung cancer in ever smokers;	chr15:43381482	chr15:43699488~43718184:-
THCA	cis	rs7267979	0.966	rs454723	ENSG00000274973.1	RP13-401N8.7	-4.6	5.44e-06	0.000591	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25845497~25845862:+
THCA	cis	rs12935229	1	rs17712956	ENSG00000260922.1	RP11-538I12.3	-4.6	5.44e-06	0.000591	-0.35	-0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77288357	chr16:77234877~77290934:+
THCA	cis	rs8030605	0.704	rs55759746	ENSG00000277245.1	RP11-48G14.3	4.6	5.44e-06	0.000591	0.36	0.21	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56333954	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.704	rs72740574	ENSG00000277245.1	RP11-48G14.3	4.6	5.44e-06	0.000591	0.36	0.21	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56344809	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.778	rs72740578	ENSG00000277245.1	RP11-48G14.3	4.6	5.44e-06	0.000591	0.36	0.21	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56345898	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.778	rs72740579	ENSG00000277245.1	RP11-48G14.3	4.6	5.44e-06	0.000591	0.36	0.21	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56347840	chr15:56447120~56447697:+
THCA	cis	rs8067545	0.611	rs2703807	ENSG00000270091.1	RP11-78O7.2	4.6	5.44e-06	0.000591	0.16	0.21	Schizophrenia;	chr17:20205876	chr17:19896590~19897287:-
THCA	cis	rs4591358	0.651	rs66489016	ENSG00000223466.1	AC064834.2	4.6	5.44e-06	0.000592	0.24	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195431900	chr2:195533035~195538681:+
THCA	cis	rs12291225	0.585	rs11023197	ENSG00000251991.1	RNU7-49P	4.6	5.44e-06	0.000592	0.24	0.21	Sense of smell;	chr11:14359452	chr11:14478892~14478953:+
THCA	cis	rs8067545	0.518	rs7222987	ENSG00000270091.1	RP11-78O7.2	-4.6	5.44e-06	0.000592	-0.16	-0.21	Schizophrenia;	chr17:20152452	chr17:19896590~19897287:-
THCA	cis	rs7829975	0.667	rs1877119	ENSG00000254153.1	CTA-398F10.2	-4.6	5.44e-06	0.000592	-0.22	-0.21	Mood instability;	chr8:8849687	chr8:8456909~8461337:-
THCA	cis	rs9595908	0.785	rs6561500	ENSG00000212293.1	SNORA16	4.6	5.44e-06	0.000592	0.23	0.21	Body mass index;	chr13:32681234	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs3912038	ENSG00000212293.1	SNORA16	4.6	5.44e-06	0.000592	0.23	0.21	Body mass index;	chr13:32682061	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs3848085	ENSG00000212293.1	SNORA16	4.6	5.44e-06	0.000592	0.23	0.21	Body mass index;	chr13:32687527	chr13:32420390~32420516:-
THCA	cis	rs2212361	0.657	rs55873762	ENSG00000255893.1	RP11-685N10.1	-4.6	5.44e-06	0.000592	-0.26	-0.21	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94603156	chr11:94472908~94473570:-
THCA	cis	rs7621331	0.892	rs9868246	ENSG00000273486.1	RP11-731C17.2	4.6	5.45e-06	0.000592	0.19	0.21	Waist circumference adjusted for body mass index;	chr3:135960703	chr3:136837338~136839021:-
THCA	cis	rs7621331	0.963	rs9883808	ENSG00000273486.1	RP11-731C17.2	4.6	5.45e-06	0.000592	0.19	0.21	Waist circumference adjusted for body mass index;	chr3:135963372	chr3:136837338~136839021:-
THCA	cis	rs7621331	0.963	rs112781244	ENSG00000273486.1	RP11-731C17.2	4.6	5.45e-06	0.000592	0.19	0.21	Waist circumference adjusted for body mass index;	chr3:135966448	chr3:136837338~136839021:-
THCA	cis	rs12126655	0.771	rs6686757	ENSG00000230489.1	VAV3-AS1	4.6	5.45e-06	0.000592	0.22	0.21	Plasma thyroid-stimulating hormone levels;	chr1:107798348	chr1:107964443~107994607:+
THCA	cis	rs240993	0.812	rs9400476	ENSG00000271789.1	RP5-1112D6.7	4.6	5.45e-06	0.000592	0.25	0.21	Inflammatory skin disease;Psoriasis;	chr6:111463172	chr6:111297126~111298510:+
THCA	cis	rs2018683	0.649	rs221171	ENSG00000272568.4	CTB-113D17.1	-4.6	5.45e-06	0.000592	-0.21	-0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28966523	chr7:28979967~29013367:+
THCA	cis	rs9880211	0.8	rs9819856	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136773307	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs36109616	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136773561	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs35198484	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136773795	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs79876804	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136775308	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs75901823	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136775309	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.706	rs35716521	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136775828	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs35210994	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136777294	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs17365792	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136778550	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs1872239	ENSG00000239213.4	NCK1-AS1	4.6	5.45e-06	0.000593	0.23	0.21	Height;Body mass index;	chr3:136785069	chr3:136841726~136862054:-
THCA	cis	rs6012564	1	rs2273653	ENSG00000230758.1	SNAP23P	4.6	5.45e-06	0.000593	0.25	0.21	Anger;	chr20:49154219	chr20:49038357~49038602:-
THCA	cis	rs4908768	0.911	rs79769442	ENSG00000232912.4	RP5-1115A15.1	-4.6	5.45e-06	0.000593	-0.25	-0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598418	chr1:8424645~8434838:+
THCA	cis	rs7394190	0.63	rs113799665	ENSG00000271848.1	RP11-464F9.21	-4.6	5.45e-06	0.000593	-0.3	-0.21	Incident atrial fibrillation;	chr10:73815380	chr10:73654039~73674719:+
THCA	cis	rs1476587	0.92	rs13243613	ENSG00000224046.1	AC005076.5	4.6	5.45e-06	0.000593	0.23	0.21	Brachial circumference;	chr7:87061938	chr7:87151423~87152420:-
THCA	cis	rs6570726	0.967	rs413880	ENSG00000270638.1	RP3-466P17.1	4.6	5.45e-06	0.000593	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145735570~145737218:+
THCA	cis	rs2985684	0.901	rs57119148	ENSG00000278009.1	RP11-649E7.8	4.6	5.45e-06	0.000593	0.3	0.21	Carotid intima media thickness;	chr14:49630508	chr14:49601011~49601124:-
THCA	cis	rs4743820	0.503	rs4437763	ENSG00000230147.2	RP11-305L7.5	4.6	5.45e-06	0.000593	0.26	0.21	Ulcerative colitis;Inflammatory bowel disease;	chr9:91151297	chr9:91169585~91170045:-
THCA	cis	rs9925964	0.744	rs12716979	ENSG00000232748.3	RP11-196G11.6	4.6	5.46e-06	0.000594	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31000500	chr16:31056460~31062803:+
THCA	cis	rs875971	0.545	rs2707851	ENSG00000273142.1	RP11-458F8.4	-4.6	5.46e-06	0.000594	-0.19	-0.21	Aortic root size;	chr7:66624178	chr7:66902857~66906297:+
THCA	cis	rs1124769	0.692	rs3825797	ENSG00000259378.1	DCAF13P3	4.6	5.46e-06	0.000594	0.32	0.21	Cognitive performance;	chr15:50933486	chr15:50944663~50945996:+
THCA	cis	rs763121	0.706	rs3827356	ENSG00000228274.3	RP3-508I15.9	4.6	5.46e-06	0.000594	0.22	0.21	Menopause (age at onset);	chr22:38668801	chr22:38667585~38681820:-
THCA	cis	rs61160187	0.582	rs17444495	ENSG00000215032.2	GNL3LP1	4.6	5.46e-06	0.000594	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:60891935~60893577:-
THCA	cis	rs17685	0.753	rs7788763	ENSG00000230882.1	AC005077.14	-4.6	5.46e-06	0.000594	-0.2	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76022347	chr7:76071469~76074963:-
THCA	cis	rs9925964	0.967	rs12716981	ENSG00000232748.3	RP11-196G11.6	4.6	5.46e-06	0.000594	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106703	chr16:31056460~31062803:+
THCA	cis	rs496547	0.588	rs473298	ENSG00000255422.1	AP002954.4	-4.6	5.47e-06	0.000594	-0.22	-0.21	Hip minimal joint space width;	chr11:118808678	chr11:118704607~118750263:+
THCA	cis	rs7772486	0.79	rs9485024	ENSG00000270638.1	RP3-466P17.1	-4.6	5.47e-06	0.000594	-0.18	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145735570~145737218:+
THCA	cis	rs617791	0.508	rs10791837	ENSG00000255320.1	RP11-755F10.1	4.6	5.47e-06	0.000594	0.27	0.21	Breast cancer;	chr11:66007125	chr11:66244840~66246239:-
THCA	cis	rs617791	0.508	rs747526	ENSG00000255320.1	RP11-755F10.1	4.6	5.47e-06	0.000594	0.27	0.21	Breast cancer;	chr11:66008600	chr11:66244840~66246239:-
THCA	cis	rs8067545	0.611	rs8066143	ENSG00000270091.1	RP11-78O7.2	-4.6	5.47e-06	0.000594	-0.16	-0.21	Schizophrenia;	chr17:20145042	chr17:19896590~19897287:-
THCA	cis	rs6088590	0.965	rs6088620	ENSG00000269202.1	RP4-614O4.12	-4.6	5.47e-06	0.000594	-0.19	-0.21	Coronary artery disease;	chr20:34824219	chr20:35201747~35203288:-
THCA	cis	rs9300255	0.537	rs1727334	ENSG00000235423.7	RP11-282O18.3	4.6	5.47e-06	0.000594	0.22	0.21	Neutrophil percentage of white cells;	chr12:123229689	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.639	rs941306	ENSG00000235423.7	RP11-282O18.3	4.6	5.47e-06	0.000594	0.22	0.21	Neutrophil percentage of white cells;	chr12:123230566	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs941305	ENSG00000235423.7	RP11-282O18.3	4.6	5.47e-06	0.000594	0.22	0.21	Neutrophil percentage of white cells;	chr12:123230719	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.639	rs1716171	ENSG00000235423.7	RP11-282O18.3	4.6	5.47e-06	0.000594	0.22	0.21	Neutrophil percentage of white cells;	chr12:123231829	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.569	rs1716170	ENSG00000235423.7	RP11-282O18.3	4.6	5.47e-06	0.000594	0.22	0.21	Neutrophil percentage of white cells;	chr12:123231966	chr12:123252030~123261483:-
THCA	cis	rs8177876	0.658	rs2911158	ENSG00000261061.1	RP11-303E16.2	4.6	5.47e-06	0.000594	0.27	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057652	chr16:81030770~81031485:+
THCA	cis	rs6088580	0.634	rs4911152	ENSG00000276073.1	RP5-1125A11.7	4.6	5.47e-06	0.000594	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34367218	chr20:33985617~33988989:-
THCA	cis	rs9880211	0.66	rs9289514	ENSG00000239213.4	NCK1-AS1	4.6	5.47e-06	0.000594	0.23	0.21	Height;Body mass index;	chr3:136774361	chr3:136841726~136862054:-
THCA	cis	rs875971	0.522	rs9530	ENSG00000229886.1	RP5-1132H15.3	4.6	5.47e-06	0.000595	0.22	0.21	Aortic root size;	chr7:65960907	chr7:66025126~66031544:-
THCA	cis	rs526231	0.824	rs253753	ENSG00000175749.11	EIF3KP1	4.6	5.47e-06	0.000595	0.27	0.21	Primary biliary cholangitis;	chr5:103322120	chr5:103032376~103033031:+
THCA	cis	rs9558942	0.961	rs4771548	ENSG00000277863.1	RP11-282A11.4	-4.6	5.47e-06	0.000595	-0.27	-0.21	Obesity-related traits;	chr13:107045348	chr13:106903150~106904099:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000164669.11	INTS4P1	4.6	5.47e-06	0.000595	0.26	0.21	Aortic root size;	chr7:66048109	chr7:65141225~65234216:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000164669.11	INTS4P1	4.6	5.47e-06	0.000595	0.26	0.21	Aortic root size;	chr7:66048321	chr7:65141225~65234216:+
THCA	cis	rs17123764	0.71	rs12320556	ENSG00000257464.1	RP11-161H23.8	-4.6	5.48e-06	0.000595	-0.33	-0.21	Intelligence (multi-trait analysis);	chr12:49579228	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs876889	ENSG00000257464.1	RP11-161H23.8	-4.6	5.48e-06	0.000595	-0.33	-0.21	Intelligence (multi-trait analysis);	chr12:49589595	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs11169082	ENSG00000257464.1	RP11-161H23.8	-4.6	5.48e-06	0.000595	-0.33	-0.21	Intelligence (multi-trait analysis);	chr12:49591625	chr12:49442424~49442652:-
THCA	cis	rs6001482	0.679	rs5757568	ENSG00000272779.1	LL22NC03-80A10.6	-4.6	5.48e-06	0.000595	-0.23	-0.21	Diastolic blood pressure;	chr22:22229175	chr22:22303224~22310401:+
THCA	cis	rs613391	0.742	rs636398	ENSG00000224549.1	RP11-370B11.3	-4.6	5.48e-06	0.000595	-0.23	-0.21	Quantitative traits;	chr9:22680916	chr9:22767175~22768316:+
THCA	cis	rs80067372	0.625	rs4511593	ENSG00000233223.2	AC113189.5	-4.6	5.48e-06	0.000595	-0.18	-0.21	Chin dimples;	chr17:7552219	chr17:7581964~7584072:-
THCA	cis	rs2617170	0.845	rs1049174	ENSG00000245648.1	RP11-277P12.20	4.6	5.48e-06	0.000595	0.21	0.21	Behcet's disease;	chr12:10372766	chr12:10363769~10398506:+
THCA	cis	rs8077577	0.747	rs62072537	ENSG00000273018.4	CTD-2303H24.2	-4.6	5.48e-06	0.000595	-0.3	-0.21	Obesity-related traits;	chr17:18312786	chr17:18511221~18551705:-
THCA	cis	rs875971	0.545	rs4718348	ENSG00000232546.1	RP11-458F8.1	4.6	5.48e-06	0.000595	0.2	0.21	Aortic root size;	chr7:66441589	chr7:66848496~66858136:+
THCA	cis	rs6500550	0.599	rs73505446	ENSG00000276754.1	RP11-461A8.5	-4.6	5.48e-06	0.000596	-0.19	-0.21	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3644205	chr16:3686998~3687380:+
THCA	cis	rs8062405	1	rs62037371	ENSG00000261766.1	RP11-22P6.2	-4.6	5.48e-06	0.000596	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28862166~28863340:-
THCA	cis	rs28735056	0.592	rs12455965	ENSG00000261126.6	RP11-795F19.1	-4.6	5.48e-06	0.000596	-0.17	-0.21	Schizophrenia;	chr18:79928830	chr18:80046900~80095482:+
THCA	cis	rs4648045	0.608	rs230496	ENSG00000246560.2	RP11-10L12.4	-4.6	5.49e-06	0.000596	-0.25	-0.21	Lymphocyte percentage of white cells;	chr4:102567334	chr4:102828055~102844075:+
THCA	cis	rs416603	0.967	rs7191538	ENSG00000263080.1	RP11-485G7.5	-4.6	5.49e-06	0.000596	-0.24	-0.21	Type 1 diabetes;	chr16:11269532	chr16:11341809~11345211:-
THCA	cis	rs67478160	0.679	rs8011109	ENSG00000269910.1	RP11-73M18.10	4.6	5.49e-06	0.000596	0.18	0.21	Schizophrenia;	chr14:103813637	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.655	rs4900598	ENSG00000269910.1	RP11-73M18.10	4.6	5.49e-06	0.000596	0.18	0.21	Schizophrenia;	chr14:103815204	chr14:103694516~103695050:-
THCA	cis	rs253959	0.739	rs712572	ENSG00000272265.1	CTD-2287O16.4	-4.6	5.49e-06	0.000596	-0.23	-0.21	Bipolar disorder and schizophrenia;	chr5:116298430	chr5:116078110~116078570:-
THCA	cis	rs9880211	0.8	rs35422852	ENSG00000239213.4	NCK1-AS1	4.6	5.49e-06	0.000596	0.23	0.21	Height;Body mass index;	chr3:136787073	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs35880395	ENSG00000239213.4	NCK1-AS1	4.6	5.49e-06	0.000596	0.23	0.21	Height;Body mass index;	chr3:136788248	chr3:136841726~136862054:-
THCA	cis	rs853679	1	rs735765	ENSG00000272009.1	RP1-313I6.12	-4.6	5.49e-06	0.000596	-0.3	-0.21	Depression;	chr6:28202519	chr6:28078792~28081130:-
THCA	cis	rs8002861	0.846	rs12428112	ENSG00000274001.1	RP11-5G9.5	-4.6	5.49e-06	0.000596	-0.25	-0.21	Leprosy;	chr13:43901685	chr13:43877715~43878163:-
THCA	cis	rs763121	0.819	rs6001205	ENSG00000273076.1	RP3-508I15.22	4.6	5.49e-06	0.000596	0.21	0.21	Menopause (age at onset);	chr22:38704259	chr22:38743495~38743910:+
THCA	cis	rs6500550	0.63	rs8045058	ENSG00000276754.1	RP11-461A8.5	4.6	5.49e-06	0.000596	0.19	0.21	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3641654	chr16:3686998~3687380:+
THCA	cis	rs28374715	0.578	rs7169543	ENSG00000247556.5	OIP5-AS1	4.6	5.49e-06	0.000596	0.2	0.21	Ulcerative colitis;	chr15:41328207	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.528	rs7181982	ENSG00000247556.5	OIP5-AS1	4.6	5.49e-06	0.000596	0.2	0.21	Ulcerative colitis;	chr15:41330822	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.528	rs28492932	ENSG00000247556.5	OIP5-AS1	4.6	5.49e-06	0.000596	0.2	0.21	Ulcerative colitis;	chr15:41332199	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.578	rs13313520	ENSG00000247556.5	OIP5-AS1	4.6	5.49e-06	0.000596	0.2	0.21	Ulcerative colitis;	chr15:41336929	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.578	rs8036026	ENSG00000247556.5	OIP5-AS1	4.6	5.49e-06	0.000596	0.2	0.21	Ulcerative colitis;	chr15:41338301	chr15:41283990~41309737:+
THCA	cis	rs3734266	0.702	rs2296361	ENSG00000272288.4	RP11-140K17.3	4.6	5.49e-06	0.000596	0.21	0.21	Systemic lupus erythematosus;	chr6:34835590	chr6:34696317~34697470:+
THCA	cis	rs2467099	0.786	rs1135889	ENSG00000267801.1	RP11-552F3.9	4.6	5.49e-06	0.000596	0.28	0.21	Systolic blood pressure;	chr17:75930040	chr17:75876372~75879546:+
THCA	cis	rs2467099	0.679	rs59867239	ENSG00000267801.1	RP11-552F3.9	4.6	5.49e-06	0.000596	0.28	0.21	Systolic blood pressure;	chr17:75935706	chr17:75876372~75879546:+
THCA	cis	rs7141336	0.77	rs10135763	ENSG00000258884.1	CTD-3035D6.2	4.6	5.49e-06	0.000597	0.28	0.21	Anxiety disorder;	chr14:90827295	chr14:90822365~90828128:-
THCA	cis	rs28386778	0.669	rs12603821	ENSG00000240280.5	TCAM1P	4.6	5.49e-06	0.000597	0.29	0.21	Prudent dietary pattern;	chr17:63929072	chr17:63849292~63864379:+
THCA	cis	rs28386778	0.704	rs1051688	ENSG00000240280.5	TCAM1P	4.6	5.49e-06	0.000597	0.29	0.21	Prudent dietary pattern;	chr17:63929073	chr17:63849292~63864379:+
THCA	cis	rs734999	0.967	rs10752745	ENSG00000225931.3	RP3-395M20.7	4.6	5.49e-06	0.000597	0.25	0.21	Ulcerative colitis;	chr1:2576499	chr1:2566410~2569888:+
THCA	cis	rs1790761	0.692	rs674783	ENSG00000255318.1	RP11-655M14.13	4.6	5.49e-06	0.000597	0.23	0.21	Mean corpuscular volume;	chr11:67571605	chr11:67618279~67627304:-
THCA	cis	rs7474896	1	rs72639538	ENSG00000263064.2	RP11-291L22.7	4.6	5.49e-06	0.000597	0.34	0.21	Obesity (extreme);	chr10:38071588	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs61858886	ENSG00000263064.2	RP11-291L22.7	4.6	5.49e-06	0.000597	0.34	0.21	Obesity (extreme);	chr10:38071773	chr10:38448689~38448949:+
THCA	cis	rs13118159	0.55	rs2336081	ENSG00000254094.1	AC078852.1	4.6	5.5e-06	0.000597	0.26	0.21	Longevity;	chr4:1356534	chr4:1356581~1358075:+
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000232559.3	GS1-124K5.12	4.6	5.5e-06	0.000597	0.31	0.21	Diabetic kidney disease;	chr7:65914813	chr7:66554588~66576923:-
THCA	cis	rs890448	0.93	rs1426537	ENSG00000254531.1	FLJ20021	-4.6	5.5e-06	0.000598	-0.18	-0.21	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101511843	chr4:101347780~101348883:+
THCA	cis	rs1577917	0.839	rs9450333	ENSG00000220563.1	PKMP3	-4.6	5.5e-06	0.000598	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85810037	chr6:85659892~85660606:-
THCA	cis	rs10090774	0.965	rs13253989	ENSG00000279766.1	RP11-642A1.2	-4.6	5.5e-06	0.000598	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140922363	chr8:140572142~140572812:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000272831.1	RP11-792A8.4	4.6	5.5e-06	0.000598	0.13	0.21	Calcium levels;	chr7:65853042	chr7:66739829~66740385:-
THCA	cis	rs875971	0.516	rs6945322	ENSG00000272831.1	RP11-792A8.4	4.6	5.5e-06	0.000598	0.13	0.21	Aortic root size;	chr7:65871069	chr7:66739829~66740385:-
THCA	cis	rs9810089	0.835	rs6791611	ENSG00000273455.1	RP11-305O4.3	-4.6	5.5e-06	0.000598	-0.27	-0.21	Gestational age at birth (child effect);	chr3:136441748	chr3:136087475~136087913:-
THCA	cis	rs9875589	0.509	rs1586514	ENSG00000228242.5	AC093495.4	4.6	5.5e-06	0.000598	0.12	0.21	Ovarian reserve;	chr3:14008657	chr3:14144637~14165978:+
THCA	cis	rs4144027	0.967	rs12879686	ENSG00000269940.1	RP11-73M18.7	4.6	5.5e-06	0.000598	0.21	0.21	Blood metabolite levels;	chr14:103894404	chr14:103694560~103695170:+
THCA	cis	rs6840360	0.904	rs6825241	ENSG00000270265.1	RP11-731D1.4	-4.6	5.5e-06	0.000598	-0.19	-0.21	Intelligence (multi-trait analysis);	chr4:151622631	chr4:151333775~151353224:-
THCA	cis	rs7772486	0.79	rs2253764	ENSG00000270638.1	RP3-466P17.1	4.6	5.5e-06	0.000598	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145735570~145737218:+
THCA	cis	rs11220082	0.761	rs1044314	ENSG00000254671.2	STT3A-AS1	-4.6	5.5e-06	0.000598	-0.25	-0.21	Schizophrenia;	chr11:125431909	chr11:125570284~125592568:-
THCA	cis	rs12541437	1	rs2166483	ENSG00000253327.2	RAD21-AS1	-4.6	5.51e-06	0.000598	-0.22	-0.21	Gut microbiome composition (winter);	chr8:116912204	chr8:116874424~116876868:+
THCA	cis	rs10090774	0.965	rs7005021	ENSG00000279766.1	RP11-642A1.2	4.6	5.51e-06	0.000598	0.25	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140859797	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs1349081	ENSG00000279766.1	RP11-642A1.2	-4.6	5.51e-06	0.000598	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140933983	chr8:140572142~140572812:-
THCA	cis	rs2153535	0.585	rs9405403	ENSG00000230939.1	RP11-314C16.1	-4.6	5.51e-06	0.000598	-0.22	-0.21	Motion sickness;	chr6:8636061	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.56	rs7748421	ENSG00000230939.1	RP11-314C16.1	-4.6	5.51e-06	0.000598	-0.22	-0.21	Motion sickness;	chr6:8636271	chr6:8784178~8785445:+
THCA	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	4.6	5.51e-06	0.000598	0.24	0.21	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
THCA	cis	rs9625935	0.957	rs9625926	ENSG00000279159.1	RP3-394A18.1	-4.6	5.51e-06	0.000598	-0.15	-0.21	Tonsillectomy;	chr22:30143438	chr22:29978950~30028236:-
THCA	cis	rs3738443	1	rs3738443	ENSG00000259865.1	RP11-488L18.10	-4.6	5.51e-06	0.000598	-0.22	-0.21	Alcohol dependence;	chr1:247184887	chr1:247187281~247188526:-
THCA	cis	rs10811771	0.541	rs4338198	ENSG00000224549.1	RP11-370B11.3	-4.6	5.51e-06	0.000598	-0.23	-0.21	Response to antipsychotic therapy (extrapyramidal side effects);	chr9:22847737	chr9:22767175~22768316:+
THCA	cis	rs62184315	0.536	rs16831873	ENSG00000253559.1	OSGEPL1-AS1	-4.6	5.51e-06	0.000598	-0.29	-0.21	Alcohol dependence (age at onset);	chr2:189692172	chr2:189762704~189765556:+
THCA	cis	rs17095355	1	rs55717725	ENSG00000203876.8	ADD3-AS1	-4.6	5.51e-06	0.000599	-0.23	-0.21	Biliary atresia;	chr10:109906871	chr10:109940104~110008381:-
THCA	cis	rs4713118	0.513	rs149878	ENSG00000261839.1	RP1-265C24.8	4.6	5.51e-06	0.000599	0.22	0.21	Parkinson's disease;	chr6:27910960	chr6:28136849~28139678:+
THCA	cis	rs9813712	0.818	rs16845853	ENSG00000253540.4	FAM86HP	4.6	5.51e-06	0.000599	0.25	0.21	Response to amphetamines;	chr3:130229587	chr3:130099092~130111472:-
THCA	cis	rs2067615	0.579	rs9651957	ENSG00000260329.1	RP11-412D9.4	-4.6	5.52e-06	0.000599	-0.19	-0.21	Heart rate;	chr12:106776350	chr12:106954029~106955497:-
THCA	cis	rs227275	0.554	rs223319	ENSG00000248971.2	KRT8P46	-4.6	5.52e-06	0.000599	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102728746~102730171:-
THCA	cis	rs228614	0.509	rs223318	ENSG00000248971.2	KRT8P46	-4.6	5.52e-06	0.000599	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223315	ENSG00000248971.2	KRT8P46	-4.6	5.52e-06	0.000599	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102728746~102730171:-
THCA	cis	rs72843506	0.586	rs79634508	ENSG00000261033.1	RP11-209D14.2	4.6	5.52e-06	0.000599	0.4	0.21	Schizophrenia;	chr17:19933734	chr17:20008051~20009234:-
THCA	cis	rs6560517	0.957	rs13302654	ENSG00000234618.1	RPSAP9	-4.6	5.52e-06	0.000599	-0.22	-0.21	Dialysis-related mortality;	chr9:76374283	chr9:76398699~76399586:+
THCA	cis	rs7246657	0.551	rs4806414	ENSG00000226686.6	LINC01535	-4.6	5.52e-06	0.000599	-0.37	-0.21	Coronary artery calcification;	chr19:37147886	chr19:37251912~37265535:+
THCA	cis	rs8020095	0.571	rs6573752	ENSG00000258561.1	RP11-72M17.1	-4.6	5.52e-06	6e-04	-0.27	-0.21	Depression (quantitative trait);	chr14:67123075	chr14:66212810~66509394:-
THCA	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-4.6	5.52e-06	6e-04	-0.21	-0.21	Height;	chr5:37023796	chr5:36666214~36725195:-
THCA	cis	rs7085104	0.513	rs192569	ENSG00000213061.2	PFN1P11	-4.6	5.52e-06	6e-04	-0.24	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102838011~102845473:-
THCA	cis	rs1040393	0.953	rs2223222	ENSG00000225171.2	DUTP6	4.6	5.53e-06	6e-04	0.3	0.21	Schizophrenia;	chr1:166911293	chr1:166868748~166869209:+
THCA	cis	rs739496	0.579	rs2238152	ENSG00000226469.1	ADAM1B	4.6	5.53e-06	6e-04	0.26	0.21	Platelet count;	chr12:111776655	chr12:111927018~111929017:+
THCA	cis	rs2732480	0.557	rs2732454	ENSG00000273765.1	RP11-370I10.11	4.6	5.53e-06	6e-04	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48360920~48361377:+
THCA	cis	rs9368481	0.729	rs9379948	ENSG00000261353.1	CTA-14H9.5	-4.6	5.53e-06	0.000601	-0.22	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26527063~26527404:+
THCA	cis	rs72843506	0.586	rs56153261	ENSG00000261033.1	RP11-209D14.2	4.6	5.53e-06	0.000601	0.37	0.21	Schizophrenia;	chr17:19904200	chr17:20008051~20009234:-
THCA	cis	rs7246657	0.653	rs10406612	ENSG00000276846.1	CTD-3220F14.3	4.6	5.53e-06	0.000601	0.26	0.21	Coronary artery calcification;	chr19:37225709	chr19:37314868~37315620:-
THCA	cis	rs896854	0.738	rs2515226	ENSG00000253528.2	RP11-347C18.4	-4.6	5.53e-06	0.000601	-0.25	-0.21	Type 2 diabetes;	chr8:94953515	chr8:94974573~94974853:-
THCA	cis	rs240993	0.761	rs9400480	ENSG00000271789.1	RP5-1112D6.7	4.6	5.54e-06	0.000601	0.25	0.21	Inflammatory skin disease;Psoriasis;	chr6:111529394	chr6:111297126~111298510:+
THCA	cis	rs1560104	1	rs1560104	ENSG00000259876.1	CTD-3037G24.4	4.6	5.54e-06	0.000601	0.24	0.21	Obesity-related traits;	chr16:12614351	chr16:12556353~12557694:-
THCA	cis	rs72843506	0.722	rs16964352	ENSG00000231258.2	ZSWIM5P2	4.6	5.54e-06	0.000601	0.3	0.21	Schizophrenia;	chr17:20245095	chr17:20583758~20591180:-
THCA	cis	rs6728642	1	rs113863815	ENSG00000230606.9	AC159540.1	4.6	5.54e-06	0.000601	0.32	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96992076	chr2:97416165~97433527:-
THCA	cis	rs9625935	0.957	rs193473	ENSG00000279159.1	RP3-394A18.1	-4.6	5.54e-06	0.000601	-0.16	-0.21	Tonsillectomy;	chr22:30052410	chr22:29978950~30028236:-
THCA	cis	rs7637701	0.773	rs9859058	ENSG00000240875.4	LINC00886	-4.6	5.54e-06	0.000601	-0.16	-0.21	Breast cancer;	chr3:156795028	chr3:156747346~156817062:-
THCA	cis	rs7267979	0.789	rs6050472	ENSG00000274414.1	RP5-965G21.4	-4.6	5.54e-06	0.000601	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:25239007~25245229:-
THCA	cis	rs76382185	0.808	rs7538646	ENSG00000233184.5	RP11-421L21.3	4.6	5.54e-06	0.000601	0.31	0.21	Lymphocyte counts;	chr1:101136355	chr1:101025878~101087268:+
THCA	cis	rs6500602	0.584	rs11646063	ENSG00000280063.1	RP11-295D4.3	-4.6	5.54e-06	0.000602	-0.11	-0.21	Schizophrenia;	chr16:4389208	chr16:4346694~4348648:-
THCA	cis	rs714027	0.837	rs713875	ENSG00000279159.1	RP3-394A18.1	-4.6	5.54e-06	0.000602	-0.14	-0.21	Lymphocyte counts;	chr22:30196498	chr22:29978950~30028236:-
THCA	cis	rs1923243	0.71	rs10789359	ENSG00000223479.3	RP4-788P17.1	-4.6	5.55e-06	0.000602	-0.22	-0.21	Migraine;	chr1:73181704	chr1:73635216~73715214:+
THCA	cis	rs8105895	0.735	rs17554694	ENSG00000269345.1	VN1R85P	-4.6	5.55e-06	0.000602	-0.26	-0.21	Body mass index (change over time);	chr19:22134346	chr19:22174766~22175191:-
THCA	cis	rs6929812	0.967	rs35394453	ENSG00000271755.1	RP1-153G14.4	4.6	5.55e-06	0.000602	0.23	0.21	Neuroticism (multi-trait analysis);	chr6:27446052	chr6:27404010~27406964:-
THCA	cis	rs1979679	0.801	rs1965280	ENSG00000247934.4	RP11-967K21.1	-4.6	5.55e-06	0.000602	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143639	chr12:28163298~28190738:-
THCA	cis	rs60733400	0.644	rs28774982	ENSG00000225931.3	RP3-395M20.7	-4.6	5.55e-06	0.000602	-0.25	-0.21	Multiple sclerosis;	chr1:2689913	chr1:2566410~2569888:+
THCA	cis	rs11955398	0.502	rs34638	ENSG00000272308.1	RP11-231G3.1	4.6	5.55e-06	0.000602	0.22	0.21	Intelligence (multi-trait analysis);	chr5:61054660	chr5:60866457~60866935:-
THCA	cis	rs375066	0.935	rs388706	ENSG00000278917.1	RP11-15A1.4	-4.6	5.55e-06	0.000602	-0.17	-0.21	Breast cancer;	chr19:43914541	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs425221	ENSG00000278917.1	RP11-15A1.4	4.6	5.55e-06	0.000602	0.17	0.21	Breast cancer;	chr19:43914392	chr19:43891233~43895411:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000272831.1	RP11-792A8.4	4.6	5.55e-06	0.000602	0.13	0.21	Aortic root size;	chr7:65827018	chr7:66739829~66740385:-
THCA	cis	rs2590942	0.838	rs1460940	ENSG00000227207.2	RPL31P12	-4.6	5.55e-06	0.000602	-0.32	-0.21	Childhood body mass index;	chr1:72348934	chr1:72301472~72301829:+
THCA	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-4.6	5.55e-06	0.000603	-0.24	-0.21	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
THCA	cis	rs5758659	0.653	rs133383	ENSG00000281538.1	RP4-669P10.20	4.6	5.55e-06	0.000603	0.19	0.21	Cognitive function;	chr22:42077599	chr22:42138060~42139726:+
THCA	cis	rs1850744	0.51	rs4697905	ENSG00000250942.1	ENPP7P11	4.6	5.55e-06	0.000603	0.3	0.21	Economic and political preferences;	chr4:9887418	chr4:9677308~9677934:+
THCA	cis	rs752010	0.806	rs11210500	ENSG00000230638.4	RP11-486B10.4	-4.6	5.56e-06	0.000603	-0.22	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41624066	chr1:41542069~41544310:+
THCA	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-4.6	5.56e-06	0.000603	-0.31	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
THCA	cis	rs2836974	0.627	rs8127986	ENSG00000255568.3	BRWD1-AS2	-4.6	5.56e-06	0.000603	-0.17	-0.21	Cognitive function;	chr21:39315285	chr21:39313935~39314962:+
THCA	cis	rs56804039	1	rs7017341	ENSG00000254153.1	CTA-398F10.2	4.6	5.56e-06	0.000603	0.25	0.21	Cervical cancer;	chr8:8524154	chr8:8456909~8461337:-
THCA	cis	rs9843304	0.616	rs4681177	ENSG00000244503.1	RP11-278L15.6	4.6	5.56e-06	0.000603	0.27	0.21	Gallstone disease;	chr3:149485213	chr3:149494660~149495995:+
THCA	cis	rs1876905	0.569	rs354523	ENSG00000272356.1	RP5-1112D6.8	-4.6	5.56e-06	0.000603	-0.21	-0.21	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111309203~111313517:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	4.6	5.56e-06	0.000604	0.24	0.21	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
THCA	cis	rs61160187	0.582	rs1460961	ENSG00000215032.2	GNL3LP1	4.6	5.56e-06	0.000604	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60891935~60893577:-
THCA	cis	rs7537765	0.947	rs17037390	ENSG00000242349.4	NPPA-AS1	-4.6	5.56e-06	0.000604	-0.27	-0.21	QRS complex (12-leadsum);	chr1:11800786	chr1:11841017~11848079:+
THCA	cis	rs2281603	0.571	rs59577187	ENSG00000259116.1	RP11-973N13.4	-4.6	5.56e-06	0.000604	-0.18	-0.21	Lymphocyte counts;	chr14:64488953	chr14:64514154~64540368:-
THCA	cis	rs853679	0.546	rs483143	ENSG00000280107.1	AL022393.9	-4.6	5.56e-06	0.000604	-0.32	-0.21	Depression;	chr6:27878966	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs34477097	ENSG00000261839.1	RP1-265C24.8	4.6	5.57e-06	0.000604	0.24	0.21	Depression;	chr6:28229408	chr6:28136849~28139678:+
THCA	cis	rs7176527	1	rs7176527	ENSG00000225151.9	GOLGA2P7	4.59	5.57e-06	0.000604	0.34	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84199311~84230136:-
THCA	cis	rs2439831	1	rs690436	ENSG00000205771.5	CATSPER2P1	-4.59	5.57e-06	0.000604	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43469007	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2264239	ENSG00000205771.5	CATSPER2P1	-4.59	5.57e-06	0.000604	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43473335	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2439831	ENSG00000205771.5	CATSPER2P1	-4.59	5.57e-06	0.000604	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43492277	chr15:43726918~43747094:-
THCA	cis	rs62025270	0.576	rs55639123	ENSG00000259295.5	CSPG4P12	-4.59	5.57e-06	0.000605	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85191438~85213905:+
THCA	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-4.59	5.57e-06	0.000605	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
THCA	cis	rs10256972	0.758	rs9801444	ENSG00000225146.1	AC073957.15	-4.59	5.58e-06	0.000605	-0.22	-0.21	Endometriosis;Longevity;	chr7:1040808	chr7:1029025~1043891:+
THCA	cis	rs12681287	0.888	rs2976201	ENSG00000254231.1	CTD-2284J15.1	4.59	5.58e-06	0.000605	0.22	0.21	Caudate activity during reward;	chr8:86323708	chr8:86333274~86343314:-
THCA	cis	rs72717009	0.825	rs10494360	ENSG00000225217.1	HSPA7	-4.59	5.58e-06	0.000605	-0.32	-0.21	Rheumatoid arthritis;	chr1:161505960	chr1:161606291~161608217:+
THCA	cis	rs72717009	0.825	rs9427397	ENSG00000225217.1	HSPA7	-4.59	5.58e-06	0.000605	-0.32	-0.21	Rheumatoid arthritis;	chr1:161506414	chr1:161606291~161608217:+
THCA	cis	rs72717009	0.825	rs9427398	ENSG00000225217.1	HSPA7	-4.59	5.58e-06	0.000605	-0.32	-0.21	Rheumatoid arthritis;	chr1:161506415	chr1:161606291~161608217:+
THCA	cis	rs10946940	0.965	rs9393830	ENSG00000219392.1	RP1-265C24.5	-4.59	5.58e-06	0.000605	-0.24	-0.21	Systemic lupus erythematosus;	chr6:27619248	chr6:28115628~28116551:+
THCA	cis	rs55702914	0.71	rs1429419	ENSG00000231621.1	AC013264.2	4.59	5.58e-06	0.000605	0.2	0.21	Major depression and alcohol dependence;	chr2:197289823	chr2:197197991~197199273:+
THCA	cis	rs67478160	0.643	rs8003653	ENSG00000269910.1	RP11-73M18.10	4.59	5.58e-06	0.000605	0.18	0.21	Schizophrenia;	chr14:103832499	chr14:103694516~103695050:-
THCA	cis	rs911555	0.713	rs10162425	ENSG00000244691.1	RPL10AP1	-4.59	5.58e-06	0.000605	-0.28	-0.21	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103412119~103412761:-
THCA	cis	rs763121	0.853	rs5757181	ENSG00000228274.3	RP3-508I15.9	-4.59	5.58e-06	0.000605	-0.23	-0.21	Menopause (age at onset);	chr22:38617517	chr22:38667585~38681820:-
THCA	cis	rs643955	0.583	rs13250399	ENSG00000261451.1	RP11-981G7.1	-4.59	5.58e-06	0.000606	-0.27	-0.21	Systemic lupus erythematosus;	chr8:10015300	chr8:10433672~10438312:+
THCA	cis	rs911555	0.755	rs2273702	ENSG00000244691.1	RPL10AP1	4.59	5.58e-06	0.000606	0.28	0.21	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103412119~103412761:-
THCA	cis	rs6870983	0.697	rs35559400	ENSG00000247828.6	TMEM161B-AS1	-4.59	5.58e-06	0.000606	-0.17	-0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88146711	chr5:88268895~88436685:+
THCA	cis	rs893818	1	rs58270968	ENSG00000261801.4	LOXL1-AS1	4.59	5.58e-06	0.000606	0.23	0.21	Exfoliation glaucoma or exfoliation syndrome;	chr15:73933804	chr15:73908071~73928248:-
THCA	cis	rs12554020	0.582	rs7038310	ENSG00000227603.1	RP11-165J3.6	4.59	5.59e-06	0.000606	0.43	0.21	Schizophrenia;	chr9:93645638	chr9:93435332~93437121:-
THCA	cis	rs36093844	0.752	rs7127501	ENSG00000279742.1	RP11-700A24.1	-4.59	5.59e-06	0.000606	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85853262	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs17817254	ENSG00000279742.1	RP11-700A24.1	-4.59	5.59e-06	0.000606	-0.31	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85853783	chr11:85852557~85854943:-
THCA	cis	rs829883	0.573	rs73136486	ENSG00000227825.4	SLC9A7P1	-4.59	5.59e-06	0.000606	-0.2	-0.21	Colorectal adenoma (advanced);	chr12:98519949	chr12:98453835~98457145:-
THCA	cis	rs11540084	0.505	rs846866	ENSG00000279095.1	AC092066.1	-4.59	5.59e-06	0.000606	-0.28	-0.21	Mean platelet volume;	chr19:44630810	chr19:44664131~44666158:+
THCA	cis	rs9880211	0.635	rs10048942	ENSG00000273486.1	RP11-731C17.2	4.59	5.59e-06	0.000606	0.22	0.21	Height;Body mass index;	chr3:136066649	chr3:136837338~136839021:-
THCA	cis	rs7772486	0.719	rs2206141	ENSG00000270638.1	RP3-466P17.1	-4.59	5.59e-06	0.000606	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145735570~145737218:+
THCA	cis	rs7648466	0.592	rs4683184	ENSG00000223552.1	RP11-24F11.2	4.59	5.59e-06	0.000607	0.19	0.21	Eotaxin levels;	chr3:46146215	chr3:46364955~46407059:-
THCA	cis	rs2281603	0.762	rs10144661	ENSG00000259116.1	RP11-973N13.4	-4.59	5.59e-06	0.000607	-0.2	-0.21	Lymphocyte counts;	chr14:64569651	chr14:64514154~64540368:-
THCA	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-4.59	5.59e-06	0.000607	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
THCA	cis	rs2243480	1	rs781149	ENSG00000164669.11	INTS4P1	4.59	5.59e-06	0.000607	0.4	0.21	Diabetic kidney disease;	chr7:66016297	chr7:65141225~65234216:+
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000164669.11	INTS4P1	4.59	5.59e-06	0.000607	0.4	0.21	Diabetic kidney disease;	chr7:66021736	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs1167613	ENSG00000164669.11	INTS4P1	4.59	5.59e-06	0.000607	0.4	0.21	Diabetic kidney disease;	chr7:66022452	chr7:65141225~65234216:+
THCA	cis	rs2243480	1	rs313799	ENSG00000164669.11	INTS4P1	4.59	5.59e-06	0.000607	0.4	0.21	Diabetic kidney disease;	chr7:66029343	chr7:65141225~65234216:+
THCA	cis	rs7402982	0.625	rs7179841	ENSG00000278022.1	RP11-35O15.2	-4.59	5.59e-06	0.000607	-0.23	-0.21	Birth weight;	chr15:98661423	chr15:98660210~98660668:+
THCA	cis	rs2153535	0.585	rs4959494	ENSG00000230939.1	RP11-314C16.1	-4.59	5.59e-06	0.000607	-0.22	-0.21	Motion sickness;	chr6:8640935	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs4959495	ENSG00000230939.1	RP11-314C16.1	-4.59	5.59e-06	0.000607	-0.22	-0.21	Motion sickness;	chr6:8641186	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs11243264	ENSG00000230939.1	RP11-314C16.1	-4.59	5.59e-06	0.000607	-0.22	-0.21	Motion sickness;	chr6:8642912	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs11243265	ENSG00000230939.1	RP11-314C16.1	-4.59	5.59e-06	0.000607	-0.22	-0.21	Motion sickness;	chr6:8642925	chr6:8784178~8785445:+
THCA	cis	rs13178541	0.81	rs4457070	ENSG00000250378.1	RP11-119J18.1	4.59	5.59e-06	0.000607	0.26	0.21	IgG glycosylation;	chr5:135814396	chr5:135812667~135826582:+
THCA	cis	rs11079757	0.604	rs72823425	ENSG00000262879.4	RP11-156P1.3	4.59	5.6e-06	0.000607	0.23	0.21	Erythema nodosum in inflammatory bowel disease;	chr17:47111303	chr17:46984045~47100323:-
THCA	cis	rs8141529	0.748	rs5752826	ENSG00000226471.5	CTA-292E10.6	-4.59	5.6e-06	0.000607	-0.17	-0.21	Lymphocyte counts;	chr22:28873820	chr22:28800683~28848559:+
THCA	cis	rs988712	0.662	rs11030100	ENSG00000245573.6	BDNF-AS	-4.59	5.6e-06	0.000607	-0.2	-0.21	Obesity;	chr11:27656039	chr11:27506838~27698174:+
THCA	cis	rs13178541	0.626	rs4510575	ENSG00000250378.1	RP11-119J18.1	-4.59	5.6e-06	0.000607	-0.27	-0.21	IgG glycosylation;	chr5:135770111	chr5:135812667~135826582:+
THCA	cis	rs897984	0.52	rs4889622	ENSG00000279196.1	RP11-1072A3.3	-4.59	5.6e-06	0.000607	-0.22	-0.21	Dementia with Lewy bodies;	chr16:30859636	chr16:30984630~30988270:-
THCA	cis	rs67478160	0.595	rs1475007	ENSG00000269910.1	RP11-73M18.10	4.59	5.6e-06	0.000608	0.18	0.21	Schizophrenia;	chr14:103830810	chr14:103694516~103695050:-
THCA	cis	rs9902453	0.845	rs62068583	ENSG00000263370.1	RP11-68I3.5	4.59	5.6e-06	0.000608	0.27	0.21	Coffee consumption (cups per day);	chr17:29674464	chr17:29639627~29640825:+
THCA	cis	rs12554020	0.551	rs4744257	ENSG00000227603.1	RP11-165J3.6	-4.59	5.6e-06	0.000608	-0.24	-0.21	Schizophrenia;	chr9:93599204	chr9:93435332~93437121:-
THCA	cis	rs1048886	0.938	rs16869370	ENSG00000271967.1	RP11-134K13.4	4.59	5.6e-06	0.000608	0.21	0.21	Type 2 diabetes;	chr6:70557863	chr6:70596438~70596980:+
THCA	cis	rs6600671	0.719	rs9728991	ENSG00000275585.1	CH17-118O6.3	-4.59	5.61e-06	0.000608	-0.26	-0.21	Hip geometry;	chr1:121522281	chr1:120985692~121052167:-
THCA	cis	rs7520050	0.778	rs2991985	ENSG00000234329.1	RP11-767N6.2	-4.59	5.61e-06	0.000608	-0.18	-0.21	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45651039~45651826:-
THCA	cis	rs7141336	0.607	rs7149722	ENSG00000258884.1	CTD-3035D6.2	-4.59	5.61e-06	0.000608	-0.26	-0.21	Anxiety disorder;	chr14:90750945	chr14:90822365~90828128:-
THCA	cis	rs801193	0.742	rs9969300	ENSG00000223473.2	GS1-124K5.3	-4.59	5.61e-06	0.000608	-0.14	-0.21	Aortic root size;	chr7:66316659	chr7:66491049~66493566:-
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000273024.4	INTS4P2	4.59	5.61e-06	0.000608	0.23	0.21	Calcium levels;	chr7:65733651	chr7:65647864~65715661:+
THCA	cis	rs4639966	0.836	rs3825057	ENSG00000255422.1	AP002954.4	4.59	5.61e-06	0.000608	0.24	0.21	Systemic lupus erythematosus;	chr11:118752276	chr11:118704607~118750263:+
THCA	cis	rs4915077	0.773	rs4915069	ENSG00000230489.1	VAV3-AS1	4.59	5.61e-06	0.000608	0.33	0.21	Hypothyroidism;	chr1:107722714	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.773	rs17019787	ENSG00000230489.1	VAV3-AS1	4.59	5.61e-06	0.000608	0.33	0.21	Hypothyroidism;	chr1:107723344	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.773	rs17019790	ENSG00000230489.1	VAV3-AS1	4.59	5.61e-06	0.000608	0.33	0.21	Hypothyroidism;	chr1:107723977	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.773	rs17019798	ENSG00000230489.1	VAV3-AS1	4.59	5.61e-06	0.000608	0.33	0.21	Hypothyroidism;	chr1:107724593	chr1:107964443~107994607:+
THCA	cis	rs516805	0.52	rs1741820	ENSG00000279453.1	RP3-425C14.4	-4.59	5.61e-06	0.000608	-0.17	-0.21	Lymphocyte counts;	chr6:122400365	chr6:122436789~122439223:-
THCA	cis	rs8062405	1	rs8055138	ENSG00000261766.1	RP11-22P6.2	-4.59	5.61e-06	0.000608	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28862166~28863340:-
THCA	cis	rs1005277	0.54	rs289638	ENSG00000276805.1	RP11-291L22.6	4.59	5.61e-06	0.000608	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38451030~38451785:+
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000227888.4	FAM66A	4.59	5.61e-06	0.000608	0.26	0.21	Neuroticism;	chr8:11991324	chr8:12362019~12388296:+
THCA	cis	rs9549367	0.789	rs34448227	ENSG00000269125.1	RP11-98F14.11	-4.59	5.61e-06	0.000609	-0.24	-0.21	Platelet distribution width;	chr13:113230440	chr13:113165002~113165183:-
THCA	cis	rs2742234	0.59	rs2435337	ENSG00000273008.1	RP11-351D16.3	-4.59	5.61e-06	0.000609	-0.19	-0.21	Hirschsprung disease;	chr10:43166388	chr10:43136824~43138334:-
THCA	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	4.59	5.62e-06	0.000609	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
THCA	cis	rs2436845	1	rs974759	ENSG00000253669.3	KB-1732A1.1	-4.59	5.62e-06	0.000609	-0.21	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102825684	chr8:102805517~102809971:+
THCA	cis	rs2436845	0.934	rs2256440	ENSG00000253669.3	KB-1732A1.1	-4.59	5.62e-06	0.000609	-0.21	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102836035	chr8:102805517~102809971:+
THCA	cis	rs2436845	1	rs2436844	ENSG00000253669.3	KB-1732A1.1	-4.59	5.62e-06	0.000609	-0.21	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102837864	chr8:102805517~102809971:+
THCA	cis	rs2436845	0.966	rs2513898	ENSG00000253669.3	KB-1732A1.1	-4.59	5.62e-06	0.000609	-0.21	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102838004	chr8:102805517~102809971:+
THCA	cis	rs7394190	0.63	rs4746150	ENSG00000271816.1	BMS1P4	-4.59	5.62e-06	0.000609	-0.28	-0.21	Incident atrial fibrillation;	chr10:73806177	chr10:73699151~73730487:-
THCA	cis	rs2302464	1	rs10939631	ENSG00000214846.4	RP11-115L11.1	4.59	5.62e-06	0.000609	0.53	0.21	Cerebrospinal fluid biomarker levels;	chr4:15656946	chr4:15730962~15731627:-
THCA	cis	rs10129255	0.642	rs11624918	ENSG00000280411.1	IGHV1-69-2	-4.59	5.62e-06	0.000609	-0.14	-0.21	Kawasaki disease;	chr14:106664672	chr14:106762092~106762588:-
THCA	cis	rs6921919	0.638	rs2108926	ENSG00000219392.1	RP1-265C24.5	-4.59	5.62e-06	0.00061	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28115628~28116551:+
THCA	cis	rs10833905	0.756	rs76866579	ENSG00000246225.5	RP11-17A1.3	-4.59	5.62e-06	0.00061	-0.3	-0.21	Sudden cardiac arrest;	chr11:22977331	chr11:22829380~22945393:+
THCA	cis	rs2120243	0.539	rs4679793	ENSG00000241770.1	RP11-555M1.3	4.59	5.62e-06	0.00061	0.27	0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157404872	chr3:157163452~157169133:+
THCA	cis	rs9875589	0.509	rs1488377	ENSG00000228242.5	AC093495.4	4.59	5.63e-06	0.00061	0.12	0.21	Ovarian reserve;	chr3:14031678	chr3:14144637~14165978:+
THCA	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	4.59	5.63e-06	0.00061	0.24	0.21	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
THCA	cis	rs2446066	0.872	rs17099205	ENSG00000257379.1	RP11-793H13.8	4.59	5.63e-06	0.00061	0.31	0.21	Red blood cell count;	chr12:53430798	chr12:53441741~53467528:+
THCA	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	4.59	5.63e-06	0.00061	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
THCA	cis	rs496547	0.686	rs477014	ENSG00000255422.1	AP002954.4	-4.59	5.63e-06	0.00061	-0.22	-0.21	Hip minimal joint space width;	chr11:118808277	chr11:118704607~118750263:+
THCA	cis	rs496547	0.557	rs516719	ENSG00000255422.1	AP002954.4	-4.59	5.63e-06	0.00061	-0.22	-0.21	Hip minimal joint space width;	chr11:118808736	chr11:118704607~118750263:+
THCA	cis	rs7267979	1	rs6107033	ENSG00000274973.1	RP13-401N8.7	4.59	5.63e-06	0.00061	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25845497~25845862:+
THCA	cis	rs944289	0.708	rs1537426	ENSG00000258844.1	RP11-259K15.2	-4.59	5.63e-06	0.00061	-0.19	-0.21	Thyroid cancer;	chr14:36117961	chr14:36214607~36235608:+
THCA	cis	rs875971	0.522	rs781144	ENSG00000229886.1	RP5-1132H15.3	4.59	5.63e-06	0.00061	0.22	0.21	Aortic root size;	chr7:65975357	chr7:66025126~66031544:-
THCA	cis	rs10129255	0.701	rs2005643	ENSG00000280411.1	IGHV1-69-2	-4.59	5.63e-06	0.000611	-0.13	-0.21	Kawasaki disease;	chr14:106676288	chr14:106762092~106762588:-
THCA	cis	rs9875589	0.509	rs4047237	ENSG00000228242.5	AC093495.4	4.59	5.63e-06	0.000611	0.12	0.21	Ovarian reserve;	chr3:13971361	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs1488379	ENSG00000228242.5	AC093495.4	4.59	5.63e-06	0.000611	0.12	0.21	Ovarian reserve;	chr3:13973219	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs6442423	ENSG00000228242.5	AC093495.4	4.59	5.63e-06	0.000611	0.12	0.21	Ovarian reserve;	chr3:13974562	chr3:14144637~14165978:+
THCA	cis	rs10904908	0.862	rs359281	ENSG00000229124.5	VIM-AS1	4.59	5.64e-06	0.000611	0.2	0.21	Cholesterol, total;Total cholesterol levels;	chr10:17278145	chr10:17214239~17229985:-
THCA	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	4.59	5.64e-06	0.000611	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
THCA	cis	rs4415084	1	rs13156930	ENSG00000272335.1	RP11-53O19.3	-4.59	5.64e-06	0.000611	-0.17	-0.21	Breast cancer;	chr5:44697933	chr5:44826076~44828592:+
THCA	cis	rs2281636	0.754	rs4919364	ENSG00000260475.1	RP11-85A1.3	4.59	5.64e-06	0.000611	0.19	0.21	Obesity-related traits;	chr10:99604947	chr10:99621055~99621918:+
THCA	cis	rs11853189	0.938	rs78151008	ENSG00000259562.2	RP11-762H8.2	4.59	5.64e-06	0.000611	0.21	0.21	Red cell distribution width;	chr15:78300364	chr15:78290527~78291221:-
THCA	cis	rs11853189	0.938	rs2090679	ENSG00000259562.2	RP11-762H8.2	4.59	5.64e-06	0.000611	0.21	0.21	Red cell distribution width;	chr15:78304564	chr15:78290527~78291221:-
THCA	cis	rs11853189	0.938	rs74894101	ENSG00000259562.2	RP11-762H8.2	4.59	5.64e-06	0.000611	0.21	0.21	Red cell distribution width;	chr15:78305063	chr15:78290527~78291221:-
THCA	cis	rs11853189	0.938	rs75886457	ENSG00000259562.2	RP11-762H8.2	4.59	5.64e-06	0.000611	0.21	0.21	Red cell distribution width;	chr15:78305359	chr15:78290527~78291221:-
THCA	cis	rs11846409	0.932	rs2583329	ENSG00000274576.2	IGHV2-70	4.59	5.64e-06	0.000612	0.17	0.21	Rheumatic heart disease;	chr14:106632971	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.86	rs10150951	ENSG00000274576.2	IGHV2-70	-4.59	5.64e-06	0.000612	-0.17	-0.21	Rheumatic heart disease;	chr14:106632988	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.86	rs17112419	ENSG00000274576.2	IGHV2-70	-4.59	5.64e-06	0.000612	-0.17	-0.21	Rheumatic heart disease;	chr14:106633260	chr14:106770577~106771020:-
THCA	cis	rs4443100	0.958	rs9620213	ENSG00000230701.2	FBXW4P1	4.59	5.64e-06	0.000612	0.26	0.21	Serum parathyroid hormone levels;	chr22:23053233	chr22:23262767~23265005:+
THCA	cis	rs72843506	0.656	rs79773274	ENSG00000261033.1	RP11-209D14.2	4.59	5.64e-06	0.000612	0.4	0.21	Schizophrenia;	chr17:20002618	chr17:20008051~20009234:-
THCA	cis	rs7746199	0.736	rs35848276	ENSG00000220721.1	OR1F12	4.59	5.64e-06	0.000612	0.47	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28073316~28074233:+
THCA	cis	rs12935418	0.616	rs13332890	ENSG00000278985.1	RP11-303E16.9	4.59	5.64e-06	0.000612	0.23	0.21	Mean corpuscular volume;	chr16:80971836	chr16:80982319~80984094:-
THCA	cis	rs4785204	1	rs4785204	ENSG00000279356.1	RP11-429P3.8	-4.59	5.65e-06	0.000612	-0.38	-0.21	Esophageal cancer (squamous cell);	chr16:50069823	chr16:50072862~50074986:+
THCA	cis	rs9925964	0.967	rs889548	ENSG00000232748.3	RP11-196G11.6	-4.59	5.65e-06	0.000612	-0.24	-0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31126391	chr16:31056460~31062803:+
THCA	cis	rs2524005	1	rs2524005	ENSG00000272236.1	XXbac-BPG170G13.32	-4.59	5.65e-06	0.000612	-0.33	-0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29751965~29752207:-
THCA	cis	rs4916588	0.636	rs3964213	ENSG00000270170.1	NCBP2-AS2	4.59	5.65e-06	0.000612	0.16	0.21	Night sleep phenotypes;	chr3:196916045	chr3:196942623~196943540:+
THCA	cis	rs1003719	0.667	rs28666643	ENSG00000230366.8	DSCR9	-4.59	5.65e-06	0.000612	-0.22	-0.21	Eye color traits;	chr21:37083699	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.667	rs3753073	ENSG00000230366.8	DSCR9	-4.59	5.65e-06	0.000612	-0.22	-0.21	Eye color traits;	chr21:37094315	chr21:37208503~37221736:+
THCA	cis	rs67478160	0.619	rs12885018	ENSG00000269910.1	RP11-73M18.10	4.59	5.65e-06	0.000612	0.18	0.21	Schizophrenia;	chr14:103807475	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs12891175	ENSG00000269910.1	RP11-73M18.10	4.59	5.65e-06	0.000612	0.18	0.21	Schizophrenia;	chr14:103807829	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.595	rs12889993	ENSG00000269910.1	RP11-73M18.10	4.59	5.65e-06	0.000612	0.18	0.21	Schizophrenia;	chr14:103807957	chr14:103694516~103695050:-
THCA	cis	rs853679	0.882	rs9380069	ENSG00000272009.1	RP1-313I6.12	-4.59	5.65e-06	0.000612	-0.29	-0.21	Depression;	chr6:28235522	chr6:28078792~28081130:-
THCA	cis	rs12681288	0.782	rs2600500	ENSG00000260721.1	AF067845.1	4.59	5.65e-06	0.000613	0.26	0.21	Schizophrenia;	chr8:1079031	chr8:1368642~1369833:-
THCA	cis	rs7647973	0.58	rs2117938	ENSG00000229759.1	MRPS18AP1	-4.59	5.65e-06	0.000613	-0.26	-0.21	Menarche (age at onset);	chr3:49226417	chr3:48256350~48256938:-
THCA	cis	rs62158800	0.706	rs17034416	ENSG00000224568.1	AC096669.3	4.59	5.65e-06	0.000613	0.39	0.21	Facial morphology (factor 22);	chr2:107569777	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.568	rs62158774	ENSG00000224568.1	AC096669.3	4.59	5.65e-06	0.000613	0.39	0.21	Facial morphology (factor 22);	chr2:107573103	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.778	rs62158793	ENSG00000224568.1	AC096669.3	4.59	5.65e-06	0.000613	0.39	0.21	Facial morphology (factor 22);	chr2:107574814	chr2:107529487~107556326:+
THCA	cis	rs4824093	0.61	rs74371371	ENSG00000278869.1	CITF22-49E9.3	4.59	5.66e-06	0.000613	0.41	0.21	Amyotrophic lateral sclerosis (sporadic);	chr22:49920426	chr22:49933198~49934074:-
THCA	cis	rs4824093	0.61	rs73443974	ENSG00000278869.1	CITF22-49E9.3	4.59	5.66e-06	0.000613	0.41	0.21	Amyotrophic lateral sclerosis (sporadic);	chr22:49920668	chr22:49933198~49934074:-
THCA	cis	rs763121	0.853	rs138702	ENSG00000235209.1	CTA-150C2.13	-4.59	5.66e-06	0.000613	-0.27	-0.21	Menopause (age at onset);	chr22:38736596	chr22:38921227~38924708:+
THCA	cis	rs6723108	0.594	rs487404	ENSG00000224043.6	CCNT2-AS1	-4.59	5.66e-06	0.000614	-0.22	-0.21	Type 2 diabetes;	chr2:134543290	chr2:134735464~134918710:-
THCA	cis	rs7560272	0.538	rs2001436	ENSG00000163016.8	ALMS1P	-4.59	5.66e-06	0.000614	-0.25	-0.21	Schizophrenia;	chr2:73701838	chr2:73644919~73685576:+
THCA	cis	rs12935418	0.672	rs9938541	ENSG00000278985.1	RP11-303E16.9	4.59	5.66e-06	0.000614	0.23	0.21	Mean corpuscular volume;	chr16:81011623	chr16:80982319~80984094:-
THCA	cis	rs10266483	0.545	rs116760071	ENSG00000271550.1	BNIP3P11	-4.59	5.66e-06	0.000614	-0.3	-0.21	Response to statin therapy;	chr7:64289082	chr7:64678954~64687393:-
THCA	cis	rs13113518	0.841	rs11133400	ENSG00000249700.7	SRD5A3-AS1	4.59	5.67e-06	0.000614	0.26	0.21	Height;	chr4:55578787	chr4:55363971~55395847:-
THCA	cis	rs6442522	0.606	rs12633820	ENSG00000249786.6	EAF1-AS1	4.59	5.67e-06	0.000614	0.21	0.21	Uric acid levels;	chr3:15452495	chr3:15436171~15455940:-
THCA	cis	rs71537559	1	rs71537559	ENSG00000280107.1	AL022393.9	-4.59	5.67e-06	0.000614	-0.37	-0.21	Squamous cell lung carcinoma;	chr6:27342000	chr6:28170845~28172521:+
THCA	cis	rs7851660	0.809	rs10984230	ENSG00000214417.4	KRT18P13	-4.59	5.67e-06	0.000614	-0.19	-0.21	Strep throat;	chr9:97898002	chr9:97698922~97700734:+
THCA	cis	rs8105895	0.733	rs10423457	ENSG00000269345.1	VN1R85P	4.59	5.67e-06	0.000614	0.28	0.21	Body mass index (change over time);	chr19:22096465	chr19:22174766~22175191:-
THCA	cis	rs4925386	0.959	rs4925385	ENSG00000275437.1	RP5-908M14.10	-4.59	5.67e-06	0.000614	-0.19	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62402236~62405935:-
THCA	cis	rs12682352	0.715	rs332039	ENSG00000254153.1	CTA-398F10.2	-4.59	5.67e-06	0.000614	-0.23	-0.21	Neuroticism;	chr8:8866141	chr8:8456909~8461337:-
THCA	cis	rs8017455	0.523	rs10141582	ENSG00000259167.2	NMNAT1P1	4.59	5.67e-06	0.000614	0.31	0.21	Hair morphology;	chr14:81097841	chr14:81032529~81033404:+
THCA	cis	rs6121246	0.909	rs6060960	ENSG00000230613.1	HM13-AS1	-4.59	5.67e-06	0.000614	-0.22	-0.21	Mean corpuscular hemoglobin;	chr20:31806714	chr20:31567707~31573263:-
THCA	cis	rs1577917	0.839	rs12664634	ENSG00000220563.1	PKMP3	-4.59	5.67e-06	0.000614	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85869696	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.839	rs6454504	ENSG00000220563.1	PKMP3	-4.59	5.67e-06	0.000614	-0.15	-0.21	Response to antipsychotic treatment;	chr6:85870612	chr6:85659892~85660606:-
THCA	cis	rs4713118	0.699	rs573179	ENSG00000220721.1	OR1F12	4.59	5.67e-06	0.000615	0.28	0.21	Parkinson's disease;	chr6:27881898	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.699	rs200978	ENSG00000220721.1	OR1F12	4.59	5.67e-06	0.000615	0.28	0.21	Parkinson's disease;	chr6:27885390	chr6:28073316~28074233:+
THCA	cis	rs914615	0.552	rs4460629	ENSG00000236675.1	MTX1P1	-4.59	5.67e-06	0.000615	-0.19	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155162859	chr1:155230975~155234325:+
THCA	cis	rs6496044	0.507	rs1471455	ENSG00000259407.1	RP11-158M2.3	4.59	5.67e-06	0.000615	0.22	0.21	Interstitial lung disease;	chr15:85611496	chr15:85744109~85750281:-
THCA	cis	rs8067545	0.611	rs12938355	ENSG00000270091.1	RP11-78O7.2	4.59	5.68e-06	0.000615	0.16	0.21	Schizophrenia;	chr17:20291904	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.586	rs57837691	ENSG00000270091.1	RP11-78O7.2	4.59	5.68e-06	0.000615	0.16	0.21	Schizophrenia;	chr17:20299760	chr17:19896590~19897287:-
THCA	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-4.59	5.68e-06	0.000615	-0.12	-0.21	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
THCA	cis	rs11853189	0.873	rs117636273	ENSG00000259562.2	RP11-762H8.2	4.59	5.68e-06	0.000615	0.2	0.21	Red cell distribution width;	chr15:78264553	chr15:78290527~78291221:-
THCA	cis	rs67478160	0.643	rs11160762	ENSG00000269910.1	RP11-73M18.10	-4.59	5.68e-06	0.000615	-0.18	-0.21	Schizophrenia;	chr14:103788746	chr14:103694516~103695050:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000275400.1	RP4-756H11.5	-4.59	5.68e-06	0.000615	-0.2	-0.21	Aortic root size;	chr7:65975357	chr7:66553805~66554199:-
THCA	cis	rs1003719	0.667	rs2835606	ENSG00000230366.8	DSCR9	-4.59	5.68e-06	0.000615	-0.22	-0.21	Eye color traits;	chr21:37118551	chr21:37208503~37221736:+
THCA	cis	rs5769765	0.908	rs138880	ENSG00000260613.1	RP3-522J7.6	-4.59	5.68e-06	0.000615	-0.25	-0.21	Schizophrenia;	chr22:49824963	chr22:49832616~49837786:-
THCA	cis	rs6570726	1	rs374464	ENSG00000270638.1	RP3-466P17.1	4.59	5.68e-06	0.000615	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145735570~145737218:+
THCA	cis	rs6570726	1	rs450076	ENSG00000270638.1	RP3-466P17.1	4.59	5.68e-06	0.000615	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145735570~145737218:+
THCA	cis	rs7577696	0.853	rs212699	ENSG00000276334.1	AL133243.1	4.59	5.68e-06	0.000615	0.22	0.21	Inflammatory biomarkers;	chr2:32218450	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.853	rs212701	ENSG00000276334.1	AL133243.1	4.59	5.68e-06	0.000615	0.22	0.21	Inflammatory biomarkers;	chr2:32218985	chr2:32521927~32523547:+
THCA	cis	rs11976180	0.953	rs2951355	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144063469	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2951354	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144063908	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2951353	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144064023	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2961125	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144064677	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2961126	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144065643	chr7:144194858~144280547:+
THCA	cis	rs11976180	0.953	rs2961127	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144065644	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs1919948	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144065750	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2961128	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144066390	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2371247	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144067086	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2371248	ENSG00000244198.4	RP4-545C24.1	-4.59	5.68e-06	0.000615	-0.2	-0.21	Obesity-related traits;	chr7:144067096	chr7:144194858~144280547:+
THCA	cis	rs7474896	0.583	rs1208770	ENSG00000120555.12	SEPT7P9	4.59	5.68e-06	0.000615	0.28	0.21	Obesity (extreme);	chr10:37755755	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.526	rs1742235	ENSG00000120555.12	SEPT7P9	4.59	5.68e-06	0.000615	0.28	0.21	Obesity (extreme);	chr10:37763328	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.559	rs1208779	ENSG00000120555.12	SEPT7P9	4.59	5.68e-06	0.000615	0.28	0.21	Obesity (extreme);	chr10:37788801	chr10:38383069~38402916:-
THCA	cis	rs7085433	0.786	rs41306524	ENSG00000264204.2	AGAP7P	-4.59	5.68e-06	0.000615	-0.46	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr10:46012928	chr10:46109621~46131358:+
THCA	cis	rs889398	0.769	rs12927052	ENSG00000226232.7	RP11-419C5.2	4.59	5.68e-06	0.000616	0.2	0.21	Body mass index;	chr16:69823140	chr16:69976388~69996188:-
THCA	cis	rs72753537	0.752	rs4743137	ENSG00000214417.4	KRT18P13	4.59	5.68e-06	0.000616	0.24	0.21	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97851950	chr9:97698922~97700734:+
THCA	cis	rs36093844	0.752	rs17744675	ENSG00000279742.1	RP11-700A24.1	4.59	5.69e-06	0.000616	0.29	0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882863	chr11:85852557~85854943:-
THCA	cis	rs4908769	0.66	rs301801	ENSG00000232912.4	RP5-1115A15.1	4.59	5.69e-06	0.000616	0.23	0.21	Allergy;	chr1:8435885	chr1:8424645~8434838:+
THCA	cis	rs1876905	0.68	rs354547	ENSG00000272356.1	RP5-1112D6.8	4.59	5.69e-06	0.000616	0.21	0.21	Mean corpuscular hemoglobin;	chr6:111213919	chr6:111309203~111313517:+
THCA	cis	rs6560517	0.581	rs2501934	ENSG00000234618.1	RPSAP9	4.59	5.69e-06	0.000616	0.21	0.21	Dialysis-related mortality;	chr9:76375121	chr9:76398699~76399586:+
THCA	cis	rs12760731	0.545	rs34112873	ENSG00000213057.5	C1orf220	4.59	5.69e-06	0.000616	0.24	0.21	Obesity-related traits;	chr1:178550808	chr1:178542752~178548889:+
THCA	cis	rs10483853	0.806	rs7156451	ENSG00000258695.2	RP3-414A15.2	-4.59	5.69e-06	0.000616	-0.29	-0.21	Coronary artery calcification;	chr14:73393919	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.806	rs11159017	ENSG00000258695.2	RP3-414A15.2	-4.59	5.69e-06	0.000616	-0.29	-0.21	Coronary artery calcification;	chr14:73396220	chr14:73522878~73530610:+
THCA	cis	rs35762459	1	rs35762459	ENSG00000254860.4	TMEM9B-AS1	4.59	5.69e-06	0.000616	0.23	0.21	Immature fraction of reticulocytes;	chr11:8823106	chr11:8964675~8977527:+
THCA	cis	rs5753037	0.834	rs713656	ENSG00000279699.1	RP1-102K2.9	4.59	5.69e-06	0.000616	0.21	0.21	Type 1 diabetes;	chr22:29816205	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.809	rs17711377	ENSG00000279699.1	RP1-102K2.9	4.59	5.69e-06	0.000616	0.21	0.21	Type 1 diabetes;	chr22:29816997	chr22:30275215~30276951:-
THCA	cis	rs67478160	0.643	rs8005594	ENSG00000269910.1	RP11-73M18.10	4.59	5.69e-06	0.000616	0.18	0.21	Schizophrenia;	chr14:103813552	chr14:103694516~103695050:-
THCA	cis	rs899997	0.773	rs7178423	ENSG00000261143.1	ADAMTS7P3	4.59	5.69e-06	0.000617	0.31	0.21	Coronary artery disease or large artery stroke;	chr15:78672619	chr15:77976042~77993057:+
THCA	cis	rs7849973	0.5	rs10811788	ENSG00000224549.1	RP11-370B11.3	-4.59	5.7e-06	0.000617	-0.24	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22879357	chr9:22767175~22768316:+
THCA	cis	rs710913	0.738	rs1180347	ENSG00000182109.6	RP11-69E11.4	-4.59	5.7e-06	0.000617	-0.18	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39522280~39546187:-
THCA	cis	rs7851660	0.809	rs7032086	ENSG00000214417.4	KRT18P13	-4.59	5.7e-06	0.000617	-0.19	-0.21	Strep throat;	chr9:97894120	chr9:97698922~97700734:+
THCA	cis	rs2834188	0.557	rs7283095	ENSG00000272659.1	AP000295.10	-4.59	5.7e-06	0.000617	-0.26	-0.21	Narcolepsy;	chr21:33315195	chr21:33309491~33310181:+
THCA	cis	rs5758511	0.68	rs1107553	ENSG00000237037.8	NDUFA6-AS1	-4.59	5.7e-06	0.000617	-0.19	-0.21	Birth weight;	chr22:42271467	chr22:42090931~42137742:+
THCA	cis	rs8067545	0.611	rs10491107	ENSG00000270091.1	RP11-78O7.2	-4.59	5.7e-06	0.000617	-0.16	-0.21	Schizophrenia;	chr17:20284861	chr17:19896590~19897287:-
THCA	cis	rs6442522	0.606	rs13093164	ENSG00000249786.6	EAF1-AS1	4.59	5.7e-06	0.000617	0.22	0.21	Uric acid levels;	chr3:15452311	chr3:15436171~15455940:-
THCA	cis	rs3738443	0.868	rs56029850	ENSG00000259865.1	RP11-488L18.10	4.59	5.7e-06	0.000618	0.21	0.21	Alcohol dependence;	chr1:247201027	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.868	rs55643126	ENSG00000259865.1	RP11-488L18.10	4.59	5.7e-06	0.000618	0.21	0.21	Alcohol dependence;	chr1:247201042	chr1:247187281~247188526:-
THCA	cis	rs115769866	0.609	rs2191037	ENSG00000216901.1	AL022393.7	4.59	5.7e-06	0.000618	0.3	0.21	Bipolar disorder;	chr6:28499211	chr6:28176188~28176674:+
THCA	cis	rs115769866	0.569	rs2859358	ENSG00000216901.1	AL022393.7	4.59	5.7e-06	0.000618	0.3	0.21	Bipolar disorder;	chr6:28505044	chr6:28176188~28176674:+
THCA	cis	rs734999	0.967	rs6667605	ENSG00000225931.3	RP3-395M20.7	4.59	5.7e-06	0.000618	0.25	0.21	Ulcerative colitis;	chr1:2571341	chr1:2566410~2569888:+
THCA	cis	rs734999	0.967	rs6672381	ENSG00000225931.3	RP3-395M20.7	4.59	5.7e-06	0.000618	0.25	0.21	Ulcerative colitis;	chr1:2571395	chr1:2566410~2569888:+
THCA	cis	rs73198271	0.603	rs570364	ENSG00000253893.2	FAM85B	4.59	5.71e-06	0.000618	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736128	chr8:8167819~8226614:-
THCA	cis	rs8028182	0.636	rs7184046	ENSG00000260274.1	RP11-817O13.8	4.59	5.71e-06	0.000618	0.15	0.21	Sudden cardiac arrest;	chr15:75573809	chr15:75368155~75369584:+
THCA	cis	rs9595908	0.869	rs9595948	ENSG00000212293.1	SNORA16	4.59	5.71e-06	0.000618	0.24	0.21	Body mass index;	chr13:32629519	chr13:32420390~32420516:-
THCA	cis	rs6921919	0.583	rs1054372	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs9468354	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs7773051	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs12697938	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs13437294	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.609	rs9468357	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs34513104	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs9461456	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.525	rs9468360	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs16894021	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs11751693	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs7749736	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.525	rs9468361	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs7775132	ENSG00000280107.1	AL022393.9	-4.59	5.71e-06	0.000618	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28170845~28172521:+
THCA	cis	rs9925964	0.933	rs9929899	ENSG00000232748.3	RP11-196G11.6	4.59	5.71e-06	0.000618	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31056460~31062803:+
THCA	cis	rs2239547	0.562	rs2581810	ENSG00000242142.1	SERBP1P3	-4.59	5.71e-06	0.000618	-0.26	-0.21	Schizophrenia;	chr3:52926843	chr3:53064283~53065091:-
THCA	cis	rs972578	0.677	rs1807591	ENSG00000274717.1	RP1-47A17.1	-4.59	5.71e-06	0.000618	-0.22	-0.21	Mean platelet volume;	chr22:42798267	chr22:42791814~42794313:-
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000272831.1	RP11-792A8.4	4.59	5.71e-06	0.000618	0.13	0.21	Calcium levels;	chr7:65996954	chr7:66739829~66740385:-
THCA	cis	rs8177876	0.731	rs57606521	ENSG00000261061.1	RP11-303E16.2	-4.59	5.71e-06	0.000618	-0.37	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81103437	chr16:81030770~81031485:+
THCA	cis	rs2447820	0.588	rs982927	ENSG00000249996.1	RP11-359P5.1	-4.59	5.71e-06	0.000618	-0.24	-0.21	Migraine;	chr5:123019213	chr5:123036271~123054667:+
THCA	cis	rs9595908	0.694	rs9596233	ENSG00000212293.1	SNORA16	4.59	5.71e-06	0.000619	0.24	0.21	Body mass index;	chr13:32776878	chr13:32420390~32420516:-
THCA	cis	rs9880211	0.898	rs1052620	ENSG00000239213.4	NCK1-AS1	4.59	5.72e-06	0.000619	0.23	0.21	Height;Body mass index;	chr3:136855679	chr3:136841726~136862054:-
THCA	cis	rs2304003	1	rs2241462	ENSG00000235192.1	AC009495.2	4.59	5.72e-06	0.000619	0.29	0.21	Social communication problems;	chr2:165833126	chr2:165794851~165810010:+
THCA	cis	rs4950322	0.57	rs113498894	ENSG00000180867.10	PDIA3P1	4.59	5.72e-06	0.000619	0.21	0.21	Protein quantitative trait loci;	chr1:147318880	chr1:147178113~147179622:+
THCA	cis	rs9494145	0.526	rs7751525	ENSG00000232876.1	CTA-212D2.2	-4.59	5.72e-06	0.000619	-0.31	-0.21	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135142570	chr6:135055033~135060550:+
THCA	cis	rs8141529	0.732	rs2239815	ENSG00000272858.1	CTA-292E10.8	4.59	5.72e-06	0.000619	0.22	0.21	Lymphocyte counts;	chr22:28796682	chr22:28814914~28815662:+
THCA	cis	rs8062405	0.964	rs7187333	ENSG00000261766.1	RP11-22P6.2	-4.59	5.72e-06	0.000619	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs12446589	ENSG00000261766.1	RP11-22P6.2	-4.59	5.72e-06	0.000619	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28862166~28863340:-
THCA	cis	rs2281603	0.57	rs10136732	ENSG00000259116.1	RP11-973N13.4	-4.59	5.72e-06	0.00062	-0.18	-0.21	Lymphocyte counts;	chr14:64484255	chr14:64514154~64540368:-
THCA	cis	rs72843506	0.586	rs80289275	ENSG00000261033.1	RP11-209D14.2	4.59	5.72e-06	0.00062	0.4	0.21	Schizophrenia;	chr17:19914367	chr17:20008051~20009234:-
THCA	cis	rs11089937	0.616	rs12484472	ENSG00000211639.2	IGLV4-60	4.59	5.73e-06	0.00062	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22180136	chr22:22162199~22162681:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000272831.1	RP11-792A8.4	4.59	5.73e-06	0.00062	0.13	0.21	Aortic root size;	chr7:65931217	chr7:66739829~66740385:-
THCA	cis	rs875971	0.502	rs2946580	ENSG00000164669.11	INTS4P1	4.59	5.73e-06	0.00062	0.3	0.21	Aortic root size;	chr7:66066855	chr7:65141225~65234216:+
THCA	cis	rs875971	0.522	rs4718286	ENSG00000164669.11	INTS4P1	-4.59	5.73e-06	0.00062	-0.26	-0.21	Aortic root size;	chr7:65827777	chr7:65141225~65234216:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000164669.11	INTS4P1	-4.59	5.73e-06	0.00062	-0.26	-0.21	Calcium levels;	chr7:65837419	chr7:65141225~65234216:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000164669.11	INTS4P1	-4.59	5.73e-06	0.00062	-0.26	-0.21	Calcium levels;	chr7:65872915	chr7:65141225~65234216:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000275400.1	RP4-756H11.5	-4.59	5.73e-06	0.00062	-0.23	-0.21	Corneal structure;	chr7:66789303	chr7:66553805~66554199:-
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000232559.3	GS1-124K5.12	4.59	5.73e-06	0.00062	0.31	0.21	Diabetic kidney disease;	chr7:65924813	chr7:66554588~66576923:-
THCA	cis	rs12554020	0.582	rs79565493	ENSG00000227603.1	RP11-165J3.6	4.59	5.73e-06	0.00062	0.43	0.21	Schizophrenia;	chr9:93634820	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs74421510	ENSG00000227603.1	RP11-165J3.6	4.59	5.73e-06	0.00062	0.43	0.21	Schizophrenia;	chr9:93634872	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs55783552	ENSG00000227603.1	RP11-165J3.6	4.59	5.73e-06	0.00062	0.43	0.21	Schizophrenia;	chr9:93637205	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs80228675	ENSG00000227603.1	RP11-165J3.6	4.59	5.73e-06	0.00062	0.43	0.21	Schizophrenia;	chr9:93637918	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs79391190	ENSG00000227603.1	RP11-165J3.6	4.59	5.73e-06	0.00062	0.43	0.21	Schizophrenia;	chr9:93637992	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.681	rs76725109	ENSG00000227603.1	RP11-165J3.6	4.59	5.73e-06	0.00062	0.43	0.21	Schizophrenia;	chr9:93639802	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs7033532	ENSG00000227603.1	RP11-165J3.6	4.59	5.73e-06	0.00062	0.43	0.21	Schizophrenia;	chr9:93644962	chr9:93435332~93437121:-
THCA	cis	rs11264736	0.507	rs1832582	ENSG00000272030.1	RP1-178F15.4	4.59	5.73e-06	0.00062	0.23	0.21	Lentiform nucleus volume;	chr1:154053016	chr1:153631438~153634397:-
THCA	cis	rs11096990	0.855	rs6855008	ENSG00000249685.1	RP11-360F5.3	-4.59	5.73e-06	0.00062	-0.27	-0.21	Cognitive function;	chr4:39172006	chr4:39133913~39135608:+
THCA	cis	rs34779708	0.897	rs7900480	ENSG00000271335.4	RP11-324I22.4	-4.59	5.73e-06	0.00062	-0.2	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35314552~35336401:-
THCA	cis	rs7264396	0.832	rs224416	ENSG00000088340.14	FER1L4	4.59	5.73e-06	0.00062	0.2	0.21	Total cholesterol levels;	chr20:35550652	chr20:35558737~35607562:-
THCA	cis	rs34286592	0.929	rs1045968	ENSG00000214725.6	CDIPT-AS1	-4.59	5.73e-06	0.00062	-0.38	-0.21	Multiple sclerosis;	chr16:29815044	chr16:29863593~29868053:+
THCA	cis	rs58605417	0.522	rs1700155	ENSG00000253553.4	RP11-586K2.1	4.59	5.73e-06	0.00062	0.21	0.21	Schizophrenia;	chr8:88472273	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.522	rs1094209	ENSG00000253553.4	RP11-586K2.1	4.59	5.73e-06	0.00062	0.21	0.21	Schizophrenia;	chr8:88477595	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.522	rs10094691	ENSG00000253553.4	RP11-586K2.1	-4.59	5.73e-06	0.00062	-0.21	-0.21	Schizophrenia;	chr8:88484810	chr8:88326836~88737134:+
THCA	cis	rs4950322	0.57	rs72691004	ENSG00000226015.2	CCT8P1	4.59	5.73e-06	0.000621	0.24	0.21	Protein quantitative trait loci;	chr1:147234309	chr1:147203276~147204932:-
THCA	cis	rs763121	0.853	rs2413546	ENSG00000273076.1	RP3-508I15.22	4.59	5.73e-06	0.000621	0.21	0.21	Menopause (age at onset);	chr22:38710996	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2413547	ENSG00000273076.1	RP3-508I15.22	4.59	5.73e-06	0.000621	0.21	0.21	Menopause (age at onset);	chr22:38711333	chr22:38743495~38743910:+
THCA	cis	rs2806561	0.704	rs674386	ENSG00000249087.5	ZNF436-AS1	-4.59	5.74e-06	0.000621	-0.13	-0.21	Height;	chr1:23195342	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.704	rs663942	ENSG00000249087.5	ZNF436-AS1	-4.59	5.74e-06	0.000621	-0.13	-0.21	Height;	chr1:23195983	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.704	rs664301	ENSG00000249087.5	ZNF436-AS1	-4.59	5.74e-06	0.000621	-0.13	-0.21	Height;	chr1:23196029	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.704	rs636940	ENSG00000249087.5	ZNF436-AS1	-4.59	5.74e-06	0.000621	-0.13	-0.21	Height;	chr1:23196474	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.704	rs856510	ENSG00000249087.5	ZNF436-AS1	-4.59	5.74e-06	0.000621	-0.13	-0.21	Height;	chr1:23197914	chr1:23368997~23371839:+
THCA	cis	rs4144027	0.904	rs10438242	ENSG00000269910.1	RP11-73M18.10	-4.59	5.74e-06	0.000621	-0.18	-0.21	Blood metabolite levels;	chr14:103878738	chr14:103694516~103695050:-
THCA	cis	rs6442522	0.606	rs3274	ENSG00000249786.6	EAF1-AS1	4.59	5.74e-06	0.000621	0.22	0.21	Uric acid levels;	chr3:15450249	chr3:15436171~15455940:-
THCA	cis	rs7223535	1	rs7223535	ENSG00000263531.1	RP13-753N3.1	-4.59	5.74e-06	0.000621	-0.29	-0.21	Breast cancer;	chr17:30884649	chr17:30863921~30864940:-
THCA	cis	rs427943	0.639	rs2838820	ENSG00000223768.1	LINC00205	-4.59	5.74e-06	0.000621	-0.19	-0.21	Body mass index;	chr21:45226090	chr21:45293285~45297354:+
THCA	cis	rs11096990	0.855	rs56275407	ENSG00000249685.1	RP11-360F5.3	-4.59	5.74e-06	0.000621	-0.27	-0.21	Cognitive function;	chr4:39177224	chr4:39133913~39135608:+
THCA	cis	rs1962772	1	rs6997118	ENSG00000279903.1	RP11-349F21.5	-4.59	5.74e-06	0.000621	-0.26	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17513894	chr8:17500012~17500605:+
THCA	cis	rs7829975	0.582	rs6983150	ENSG00000254153.1	CTA-398F10.2	4.59	5.74e-06	0.000621	0.23	0.21	Mood instability;	chr8:8934916	chr8:8456909~8461337:-
THCA	cis	rs7614311	0.681	rs55917937	ENSG00000271843.1	RP11-245J9.5	-4.59	5.75e-06	0.000622	-0.31	-0.21	Lung function (FVC);Lung function (FEV1);	chr3:63909153	chr3:64008082~64008692:-
THCA	cis	rs6088590	0.965	rs6058108	ENSG00000276073.1	RP5-1125A11.7	-4.59	5.75e-06	0.000622	-0.19	-0.21	Coronary artery disease;	chr20:34700851	chr20:33985617~33988989:-
THCA	cis	rs734999	0.869	rs1555791	ENSG00000225931.3	RP3-395M20.7	4.59	5.75e-06	0.000622	0.25	0.21	Ulcerative colitis;	chr1:2567423	chr1:2566410~2569888:+
THCA	cis	rs6012564	1	rs3091497	ENSG00000230758.1	SNAP23P	-4.59	5.75e-06	0.000622	-0.25	-0.21	Anger;	chr20:49028890	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.858	rs3091427	ENSG00000230758.1	SNAP23P	-4.59	5.75e-06	0.000622	-0.25	-0.21	Anger;	chr20:49046845	chr20:49038357~49038602:-
THCA	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-4.59	5.75e-06	0.000622	-0.12	-0.21	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
THCA	cis	rs4925386	1	rs4925389	ENSG00000275437.1	RP5-908M14.10	-4.59	5.75e-06	0.000623	-0.19	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62402236~62405935:-
THCA	cis	rs6088590	1	rs6119530	ENSG00000269202.1	RP4-614O4.12	-4.59	5.75e-06	0.000623	-0.19	-0.21	Coronary artery disease;	chr20:34816127	chr20:35201747~35203288:-
THCA	cis	rs2836950	0.565	rs7279497	ENSG00000238141.2	BRWD1-AS1	4.59	5.75e-06	0.000623	0.23	0.21	Menarche (age at onset);	chr21:39159380	chr21:39315707~39323218:+
THCA	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-4.59	5.76e-06	0.000623	-0.12	-0.21	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
THCA	cis	rs7394190	0.748	rs1057410	ENSG00000271848.1	RP11-464F9.21	-4.59	5.76e-06	0.000623	-0.29	-0.21	Incident atrial fibrillation;	chr10:73814321	chr10:73654039~73674719:+
THCA	cis	rs6545883	0.542	rs10177225	ENSG00000270820.4	RP11-355B11.2	-4.59	5.76e-06	0.000623	-0.18	-0.21	Tuberculosis;	chr2:61367363	chr2:61471188~61484130:+
THCA	cis	rs7267979	1	rs6515651	ENSG00000274973.1	RP13-401N8.7	4.59	5.76e-06	0.000623	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2424716	ENSG00000274973.1	RP13-401N8.7	-4.59	5.76e-06	0.000623	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs761025	ENSG00000274973.1	RP13-401N8.7	-4.59	5.76e-06	0.000623	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25845497~25845862:+
THCA	cis	rs9487094	0.67	rs7755941	ENSG00000223537.2	RP5-919F19.5	-4.59	5.76e-06	0.000623	-0.21	-0.21	Height;	chr6:109494148	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.626	rs12195904	ENSG00000223537.2	RP5-919F19.5	-4.59	5.76e-06	0.000623	-0.21	-0.21	Height;	chr6:109494760	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs1406899	ENSG00000223537.2	RP5-919F19.5	-4.59	5.76e-06	0.000623	-0.21	-0.21	Height;	chr6:109495102	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs11754455	ENSG00000223537.2	RP5-919F19.5	-4.59	5.76e-06	0.000623	-0.21	-0.21	Height;	chr6:109496680	chr6:109487906~109506800:+
THCA	cis	rs2028299	0.959	rs2165069	ENSG00000259677.1	RP11-493E3.1	4.59	5.76e-06	0.000623	0.27	0.21	Type 2 diabetes;	chr15:89863887	chr15:89876540~89877285:+
THCA	cis	rs807029	0.577	rs701835	ENSG00000236662.1	RP11-108L7.4	4.59	5.76e-06	0.000623	0.22	0.21	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100980507~100985614:-
THCA	cis	rs5758659	0.504	rs133367	ENSG00000270083.1	RP1-257I20.14	-4.59	5.76e-06	0.000623	-0.22	-0.21	Cognitive function;	chr22:42067362	chr22:42089630~42090028:-
THCA	cis	rs7924176	0.601	rs7896660	ENSG00000213731.2	RAB5CP1	-4.59	5.76e-06	0.000623	-0.25	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74170399	chr10:74423435~74424014:-
THCA	cis	rs1559040	1	rs72800725	ENSG00000272156.1	RP11-477N3.1	-4.59	5.77e-06	0.000624	-0.33	-0.21	Sudden cardiac arrest;	chr2:54074000	chr2:54082554~54085066:+
THCA	cis	rs12908161	0.515	rs12907646	ENSG00000259728.4	LINC00933	4.59	5.77e-06	0.000624	0.29	0.21	Schizophrenia;	chr15:84860265	chr15:84570649~84580175:+
THCA	cis	rs2032366	0.592	rs59304542	ENSG00000267279.1	RP11-879F14.2	4.59	5.77e-06	0.000624	0.22	0.21	Obesity-related traits;	chr18:61581456	chr18:61585746~61606916:-
THCA	cis	rs1476587	0.688	rs35766334	ENSG00000224046.1	AC005076.5	4.59	5.77e-06	0.000624	0.22	0.21	Brachial circumference;	chr7:87078910	chr7:87151423~87152420:-
THCA	cis	rs7246657	0.551	rs10419174	ENSG00000276846.1	CTD-3220F14.3	4.59	5.77e-06	0.000624	0.25	0.21	Coronary artery calcification;	chr19:37114439	chr19:37314868~37315620:-
THCA	cis	rs4950322	0.802	rs72694705	ENSG00000271721.1	RP11-337C18.9	4.59	5.77e-06	0.000624	0.24	0.21	Protein quantitative trait loci;	chr1:147362313	chr1:147175602~147177740:+
THCA	cis	rs807029	0.72	rs701836	ENSG00000236662.1	RP11-108L7.4	4.59	5.77e-06	0.000624	0.21	0.21	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101007360	chr10:100980507~100985614:-
THCA	cis	rs7429990	0.864	rs13085978	ENSG00000228638.1	FCF1P2	-4.59	5.77e-06	0.000624	-0.2	-0.21	Educational attainment (years of education);	chr3:47608585	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.727	rs61675361	ENSG00000228638.1	FCF1P2	-4.59	5.77e-06	0.000624	-0.2	-0.21	Educational attainment (years of education);	chr3:47610630	chr3:48290793~48291375:-
THCA	cis	rs893818	1	rs4886776	ENSG00000261801.4	LOXL1-AS1	4.59	5.77e-06	0.000624	0.23	0.21	Exfoliation glaucoma or exfoliation syndrome;	chr15:73932655	chr15:73908071~73928248:-
THCA	cis	rs1880529	0.832	rs4833430	ENSG00000206820.1	RNU1-138P	-4.59	5.77e-06	0.000624	-0.25	-0.21	White matter integrity (bipolar disorder risk interaction);	chr4:113486838	chr4:113420323~113420486:+
THCA	cis	rs61270009	0.955	rs12657757	ENSG00000247828.6	TMEM161B-AS1	-4.59	5.78e-06	0.000625	-0.18	-0.21	Depressive symptoms;	chr5:88280952	chr5:88268895~88436685:+
THCA	cis	rs703842	1	rs6581155	ENSG00000270039.1	RP11-571M6.17	-4.59	5.78e-06	0.000625	-0.23	-0.21	Multiple sclerosis;	chr12:57784379	chr12:57803838~57804415:+
THCA	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	4.59	5.78e-06	0.000625	0.25	0.21	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
THCA	cis	rs79243044	0.76	rs16932551	ENSG00000224295.2	AC087380.14	-4.59	5.78e-06	0.000625	-0.22	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5539703	chr11:5518441~5524955:-
THCA	cis	rs9973361	0.531	rs13427949	ENSG00000232411.1	AC009495.3	-4.59	5.78e-06	0.000625	-0.25	-0.21	Total body bone mineral density;	chr2:165811465	chr2:165833048~165839098:-
THCA	cis	rs12134133	1	rs7526831	ENSG00000237074.1	RP11-6J21.2	4.59	5.78e-06	0.000625	0.22	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207249067~207309121:+
THCA	cis	rs62158800	0.925	rs884882	ENSG00000224568.1	AC096669.3	4.59	5.78e-06	0.000625	0.39	0.21	Facial morphology (factor 22);	chr2:107596156	chr2:107529487~107556326:+
THCA	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-4.59	5.78e-06	0.000625	-0.12	-0.21	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
THCA	cis	rs8062405	1	rs12443881	ENSG00000261766.1	RP11-22P6.2	-4.59	5.78e-06	0.000625	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28862166~28863340:-
THCA	cis	rs17818399	0.815	rs62136873	ENSG00000279254.1	RP11-536C12.1	-4.59	5.78e-06	0.000625	-0.22	-0.21	Height;	chr2:46634098	chr2:46668870~46670778:+
THCA	cis	rs172166	0.694	rs536704	ENSG00000261839.1	RP1-265C24.8	4.59	5.78e-06	0.000625	0.22	0.21	Cardiac Troponin-T levels;	chr6:28124825	chr6:28136849~28139678:+
THCA	cis	rs728616	0.614	rs58606426	ENSG00000242600.5	MBL1P	4.59	5.78e-06	0.000625	0.22	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs57966752	ENSG00000242600.5	MBL1P	4.59	5.78e-06	0.000625	0.22	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:79904898~79950336:+
THCA	cis	rs11096990	0.892	rs6531696	ENSG00000249685.1	RP11-360F5.3	-4.59	5.78e-06	0.000625	-0.27	-0.21	Cognitive function;	chr4:39190134	chr4:39133913~39135608:+
THCA	cis	rs12428035	0.772	rs4526890	ENSG00000247400.3	DNAJC3-AS1	4.59	5.79e-06	0.000626	0.19	0.21	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95862051	chr13:95648733~95676925:-
THCA	cis	rs9393813	0.605	rs12529458	ENSG00000204789.4	ZNF204P	-4.59	5.79e-06	0.000626	-0.17	-0.21	Bipolar disorder;	chr6:27393902	chr6:27357825~27360221:-
THCA	cis	rs11665867	0.761	rs76443752	ENSG00000279108.1	CTC-490E21.11	-4.59	5.79e-06	0.000626	-0.29	-0.21	Hematocrit;	chr19:40806707	chr19:40840159~40842039:+
THCA	cis	rs897984	0.553	rs2125293	ENSG00000279196.1	RP11-1072A3.3	-4.59	5.79e-06	0.000626	-0.23	-0.21	Dementia with Lewy bodies;	chr16:30852554	chr16:30984630~30988270:-
THCA	cis	rs897984	0.52	rs4889534	ENSG00000279196.1	RP11-1072A3.3	-4.59	5.79e-06	0.000626	-0.23	-0.21	Dementia with Lewy bodies;	chr16:30854119	chr16:30984630~30988270:-
THCA	cis	rs7577696	0.962	rs67157050	ENSG00000276334.1	AL133243.1	-4.59	5.79e-06	0.000626	-0.21	-0.21	Inflammatory biomarkers;	chr2:32046295	chr2:32521927~32523547:+
THCA	cis	rs17597773	0.674	rs1335919	ENSG00000238078.1	LINC01352	-4.59	5.79e-06	0.000626	-0.29	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220845043	chr1:220829255~220832429:+
THCA	cis	rs2562456	0.752	rs7258562	ENSG00000268117.1	VN1R84P	4.59	5.79e-06	0.000626	0.33	0.21	Pain;	chr19:21331762	chr19:21719801~21720035:-
THCA	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-4.59	5.79e-06	0.000626	-0.24	-0.21	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
THCA	cis	rs78487399	0.808	rs75321787	ENSG00000234936.1	AC010883.5	4.59	5.79e-06	0.000626	0.26	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43615932	chr2:43229573~43233394:+
THCA	cis	rs116248771	0.739	rs78151625	ENSG00000271778.1	RP11-379F4.8	4.59	5.79e-06	0.000626	0.28	0.21	diarrhoeal disease at age 2;	chr3:158598937	chr3:158782547~158783124:+
THCA	cis	rs9368481	0.761	rs4358615	ENSG00000261353.1	CTA-14H9.5	-4.59	5.79e-06	0.000626	-0.22	-0.21	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26527063~26527404:+
THCA	cis	rs3734266	0.702	rs6900426	ENSG00000272288.4	RP11-140K17.3	4.59	5.79e-06	0.000626	0.21	0.21	Systemic lupus erythematosus;	chr6:34656371	chr6:34696317~34697470:+
THCA	cis	rs7267979	0.932	rs6115200	ENSG00000274973.1	RP13-401N8.7	-4.59	5.79e-06	0.000626	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.932	rs6138588	ENSG00000274973.1	RP13-401N8.7	-4.59	5.79e-06	0.000626	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25845497~25845862:+
THCA	cis	rs4789693	0.938	rs8078595	ENSG00000260011.2	RP13-20L14.1	-4.59	5.79e-06	0.000626	-0.21	-0.21	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82381110~82382690:-
THCA	cis	rs67478160	0.619	rs1040813	ENSG00000269910.1	RP11-73M18.10	4.59	5.79e-06	0.000626	0.18	0.21	Schizophrenia;	chr14:103840359	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.619	rs1187416	ENSG00000269910.1	RP11-73M18.10	4.59	5.79e-06	0.000626	0.18	0.21	Schizophrenia;	chr14:103845128	chr14:103694516~103695050:-
THCA	cis	rs5758659	0.714	rs133376	ENSG00000281538.1	RP4-669P10.20	4.59	5.8e-06	0.000626	0.19	0.21	Cognitive function;	chr22:42070901	chr22:42138060~42139726:+
THCA	cis	rs2243480	1	rs313813	ENSG00000232559.3	GS1-124K5.12	4.59	5.8e-06	0.000626	0.31	0.21	Diabetic kidney disease;	chr7:66038513	chr7:66554588~66576923:-
THCA	cis	rs7520050	0.966	rs10890383	ENSG00000234329.1	RP11-767N6.2	-4.59	5.8e-06	0.000626	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:46122831	chr1:45651039~45651826:-
THCA	cis	rs738722	0.615	rs743184	ENSG00000272858.1	CTA-292E10.8	-4.59	5.8e-06	0.000627	-0.2	-0.21	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28706979	chr22:28814914~28815662:+
THCA	cis	rs867186	1	rs2295888	ENSG00000126005.14	MMP24-AS1	-4.59	5.8e-06	0.000627	-0.32	-0.21	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35135060	chr20:35216462~35278131:-
THCA	cis	rs2483058	0.739	rs963893	ENSG00000261000.1	RP11-534L20.5	4.59	5.8e-06	0.000627	0.22	0.21	Cholesterol and Triglycerides;	chr1:206452351	chr1:206503948~206504456:+
THCA	cis	rs6442522	0.606	rs3846128	ENSG00000249786.6	EAF1-AS1	4.59	5.8e-06	0.000627	0.22	0.21	Uric acid levels;	chr3:15450643	chr3:15436171~15455940:-
THCA	cis	rs367615	0.523	rs4330503	ENSG00000249476.1	CTD-2587M2.1	4.59	5.8e-06	0.000627	0.19	0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109519112	chr5:109237120~109326369:-
THCA	cis	rs6545883	0.86	rs777589	ENSG00000270820.4	RP11-355B11.2	4.59	5.8e-06	0.000627	0.17	0.21	Tuberculosis;	chr2:61198486	chr2:61471188~61484130:+
THCA	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-4.59	5.8e-06	0.000627	-0.24	-0.21	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
THCA	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-4.59	5.8e-06	0.000627	-0.24	-0.21	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-4.59	5.8e-06	0.000627	-0.24	-0.21	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-4.59	5.8e-06	0.000627	-0.24	-0.21	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-4.59	5.8e-06	0.000627	-0.24	-0.21	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
THCA	cis	rs10483853	0.806	rs11159015	ENSG00000258695.2	RP3-414A15.2	-4.59	5.81e-06	0.000627	-0.29	-0.21	Coronary artery calcification;	chr14:73364720	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.806	rs8015790	ENSG00000258695.2	RP3-414A15.2	-4.59	5.81e-06	0.000627	-0.29	-0.21	Coronary artery calcification;	chr14:73366297	chr14:73522878~73530610:+
THCA	cis	rs58605417	0.522	rs1094204	ENSG00000253553.4	RP11-586K2.1	4.59	5.81e-06	0.000628	0.21	0.21	Schizophrenia;	chr8:88452391	chr8:88326836~88737134:+
THCA	cis	rs4715166	0.736	rs6928740	ENSG00000272379.1	RP1-257A7.5	4.59	5.81e-06	0.000628	0.26	0.21	Hip geometry;	chr6:13232744	chr6:13290018~13290490:-
THCA	cis	rs5758659	1	rs5758660	ENSG00000227370.1	RP4-669P10.19	-4.59	5.81e-06	0.000628	-0.19	-0.21	Cognitive function;	chr22:42227712	chr22:42132543~42132998:+
THCA	cis	rs28476539	0.64	rs6837562	ENSG00000270480.1	RP11-57B24.1	-4.59	5.81e-06	0.000628	-0.32	-0.21	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82635255	chr4:82691737~82692468:+
THCA	cis	rs516805	0.961	rs527978	ENSG00000279114.1	RP3-425C14.5	-4.59	5.81e-06	0.000628	-0.21	-0.21	Lymphocyte counts;	chr6:122475225	chr6:122471923~122484161:+
THCA	cis	rs722599	0.748	rs17102884	ENSG00000279594.1	RP11-950C14.10	-4.59	5.81e-06	0.000628	-0.21	-0.21	IgG glycosylation;	chr14:74908196	chr14:75011269~75012851:-
THCA	cis	rs62025270	0.688	rs12148571	ENSG00000259295.5	CSPG4P12	-4.59	5.81e-06	0.000628	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85724162	chr15:85191438~85213905:+
THCA	cis	rs56114371	0.53	rs2056923	ENSG00000226314.6	ZNF192P1	-4.59	5.81e-06	0.000628	-0.31	-0.21	Breast cancer;	chr6:27722160	chr6:28161781~28169594:+
THCA	cis	rs6012564	0.89	rs6125591	ENSG00000230758.1	SNAP23P	4.59	5.81e-06	0.000628	0.26	0.21	Anger;	chr20:49204130	chr20:49038357~49038602:-
THCA	cis	rs10911902	0.643	rs7525634	ENSG00000229739.2	RP11-295K2.3	-4.59	5.81e-06	0.000628	-0.31	-0.21	Schizophrenia;	chr1:186411333	chr1:186435161~186470291:+
THCA	cis	rs6121246	0.559	rs12479491	ENSG00000230613.1	HM13-AS1	4.59	5.81e-06	0.000628	0.2	0.21	Mean corpuscular hemoglobin;	chr20:31677647	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6058352	ENSG00000230613.1	HM13-AS1	4.59	5.81e-06	0.000628	0.2	0.21	Mean corpuscular hemoglobin;	chr20:31681376	chr20:31567707~31573263:-
THCA	cis	rs6988985	0.589	rs6987382	ENSG00000247317.3	RP11-273G15.2	-4.59	5.81e-06	0.000628	-0.22	-0.21	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905775	chr8:142981738~143018437:-
THCA	cis	rs2839627	0.561	rs2839601	ENSG00000225218.1	AP001628.6	4.59	5.81e-06	0.000628	0.31	0.21	Information processing speed;	chr21:42897271	chr21:42831040~42836477:-
THCA	cis	rs9925964	0.869	rs2288004	ENSG00000232748.3	RP11-196G11.6	4.59	5.81e-06	0.000628	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31056460~31062803:+
THCA	cis	rs5758659	0.652	rs6519301	ENSG00000227370.1	RP4-669P10.19	-4.59	5.82e-06	0.000629	-0.19	-0.21	Cognitive function;	chr22:41989963	chr22:42132543~42132998:+
THCA	cis	rs9910055	0.571	rs28897216	ENSG00000267080.4	ASB16-AS1	-4.59	5.82e-06	0.000629	-0.19	-0.21	Total body bone mineral density;	chr17:44163456	chr17:44175973~44186717:-
THCA	cis	rs7045881	0.877	rs17693846	ENSG00000254396.1	RP11-56F10.3	4.59	5.82e-06	0.000629	0.32	0.21	Schizophrenia;	chr9:26785375	chr9:27102630~27104728:+
THCA	cis	rs7773456	0.576	rs12206194	ENSG00000237404.1	RP3-471C18.2	-4.59	5.82e-06	0.000629	-0.27	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19689825~19753113:-
THCA	cis	rs6449502	0.92	rs167912	ENSG00000251279.1	CTC-436P18.1	4.59	5.82e-06	0.000629	0.34	0.21	Mean platelet volume;	chr5:60989169	chr5:61162070~61232040:+
THCA	cis	rs59868192	0.925	rs1002774	ENSG00000246740.2	PLA2G4E-AS1	4.59	5.83e-06	0.000629	0.38	0.21	White blood cell count;	chr15:41969583	chr15:41972763~41999094:+
THCA	cis	rs4654783	0.627	rs66766977	ENSG00000228397.1	RP1-224A6.3	4.59	5.83e-06	0.00063	0.3	0.21	Endometriosis;	chr1:22104599	chr1:22023994~22024968:-
THCA	cis	rs5769765	0.865	rs3788730	ENSG00000260613.1	RP3-522J7.6	4.59	5.83e-06	0.00063	0.25	0.21	Schizophrenia;	chr22:49851047	chr22:49832616~49837786:-
THCA	cis	rs16846053	0.642	rs1449637	ENSG00000227403.1	AC009299.3	4.58	5.83e-06	0.00063	0.33	0.21	Blood osmolality (transformed sodium);	chr2:161819440	chr2:161244739~161249050:+
THCA	cis	rs62025270	0.747	rs17639314	ENSG00000259295.5	CSPG4P12	-4.58	5.83e-06	0.00063	-0.34	-0.21	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85191438~85213905:+
THCA	cis	rs12893668	0.703	rs34186780	ENSG00000252469.1	RNU7-160P	4.58	5.83e-06	0.00063	0.25	0.21	Reticulocyte count;	chr14:103561258	chr14:103550345~103550406:+
THCA	cis	rs9467773	0.595	rs7767847	ENSG00000124549.13	BTN2A3P	4.58	5.83e-06	0.00063	0.19	0.21	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26421391~26432383:+
THCA	cis	rs9467773	0.62	rs3800303	ENSG00000124549.13	BTN2A3P	4.58	5.83e-06	0.00063	0.19	0.21	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26421391~26432383:+
THCA	cis	rs12681288	0.676	rs2701910	ENSG00000260721.1	AF067845.1	4.58	5.83e-06	0.00063	0.25	0.21	Schizophrenia;	chr8:1051246	chr8:1368642~1369833:-
THCA	cis	rs7267979	1	rs6050631	ENSG00000274973.1	RP13-401N8.7	-4.58	5.83e-06	0.00063	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25845497~25845862:+
THCA	cis	rs7621331	1	rs13098245	ENSG00000273486.1	RP11-731C17.2	4.58	5.84e-06	0.00063	0.19	0.21	Waist circumference adjusted for body mass index;	chr3:135994792	chr3:136837338~136839021:-
THCA	cis	rs2721195	0.874	rs2721173	ENSG00000265393.1	CTD-2517M22.17	-4.58	5.84e-06	0.000631	-0.25	-0.21	Age at first birth;	chr8:144519045	chr8:144512567~144513672:+
THCA	cis	rs35740288	0.77	rs11631660	ENSG00000259295.5	CSPG4P12	-4.58	5.84e-06	0.000631	-0.32	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672181	chr15:85191438~85213905:+
THCA	cis	rs17818399	0.781	rs34449783	ENSG00000279254.1	RP11-536C12.1	-4.58	5.84e-06	0.000631	-0.22	-0.21	Height;	chr2:46636416	chr2:46668870~46670778:+
THCA	cis	rs17818399	0.815	rs17768138	ENSG00000279254.1	RP11-536C12.1	-4.58	5.84e-06	0.000631	-0.22	-0.21	Height;	chr2:46641078	chr2:46668870~46670778:+
THCA	cis	rs11779988	0.571	rs208053	ENSG00000253671.1	RP11-806O11.1	-4.58	5.84e-06	0.000631	-0.27	-0.21	Breast cancer;	chr8:17967818	chr8:17808941~17820868:+
THCA	cis	rs11779988	0.571	rs208052	ENSG00000253671.1	RP11-806O11.1	-4.58	5.84e-06	0.000631	-0.27	-0.21	Breast cancer;	chr8:17968050	chr8:17808941~17820868:+
THCA	cis	rs9863	0.861	rs4930725	ENSG00000270061.1	RP11-214K3.19	-4.58	5.84e-06	0.000631	-0.27	-0.21	White blood cell count;	chr12:123943615	chr12:123969990~123970344:-
THCA	cis	rs9880211	0.8	rs9865995	ENSG00000239213.4	NCK1-AS1	4.58	5.84e-06	0.000631	0.23	0.21	Height;Body mass index;	chr3:136794508	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs9871184	ENSG00000239213.4	NCK1-AS1	4.58	5.84e-06	0.000631	0.23	0.21	Height;Body mass index;	chr3:136795468	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs115050567	ENSG00000239213.4	NCK1-AS1	4.58	5.84e-06	0.000631	0.23	0.21	Height;Body mass index;	chr3:136796817	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs9858560	ENSG00000239213.4	NCK1-AS1	4.58	5.84e-06	0.000631	0.23	0.21	Height;Body mass index;	chr3:136798312	chr3:136841726~136862054:-
THCA	cis	rs6121246	0.609	rs2377317	ENSG00000230613.1	HM13-AS1	-4.58	5.84e-06	0.000631	-0.2	-0.21	Mean corpuscular hemoglobin;	chr20:31814699	chr20:31567707~31573263:-
THCA	cis	rs858239	0.6	rs1468592	ENSG00000226816.2	AC005082.12	-4.58	5.84e-06	0.000631	-0.29	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23206013~23208045:+
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000273796.1	LL21NC02-21A1.1	-4.58	5.84e-06	0.000631	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45403809~45404369:-
THCA	cis	rs8031584	0.958	rs34294266	ENSG00000178081.11	ULK4P3	4.58	5.85e-06	0.000631	0.27	0.21	Huntington's disease progression;	chr15:30954637	chr15:30103720~30131757:+
THCA	cis	rs1005277	0.579	rs2008449	ENSG00000272983.1	RP11-508N22.12	-4.58	5.85e-06	0.000632	-0.18	-0.21	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38137337~38144399:+
THCA	cis	rs8007846	0.9	rs8018379	ENSG00000276116.2	FUT8-AS1	4.58	5.85e-06	0.000632	0.21	0.21	Multiple sclerosis--Brain Glutamate Levels;	chr14:65795219	chr14:65411170~65412690:-
THCA	cis	rs12681288	0.821	rs35134698	ENSG00000260721.1	AF067845.1	4.58	5.85e-06	0.000632	0.26	0.21	Schizophrenia;	chr8:1085439	chr8:1368642~1369833:-
THCA	cis	rs6012564	1	rs6125539	ENSG00000230758.1	SNAP23P	4.58	5.85e-06	0.000632	0.26	0.21	Anger;	chr20:49087273	chr20:49038357~49038602:-
THCA	cis	rs6668108	1	rs6668108	ENSG00000224358.1	RP11-466F5.8	-4.58	5.85e-06	0.000632	-0.33	-0.21	Intraocular pressure;	chr1:165722083	chr1:165768929~165775176:+
THCA	cis	rs896854	0.714	rs572547	ENSG00000253528.2	RP11-347C18.4	-4.58	5.86e-06	0.000632	-0.25	-0.21	Type 2 diabetes;	chr8:94954058	chr8:94974573~94974853:-
THCA	cis	rs9813712	0.953	rs6804874	ENSG00000253540.4	FAM86HP	4.58	5.86e-06	0.000633	0.25	0.21	Response to amphetamines;	chr3:130257205	chr3:130099092~130111472:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000234585.5	CCT6P3	4.58	5.86e-06	0.000633	0.19	0.21	Calcium levels;	chr7:65892789	chr7:65038354~65074713:+
THCA	cis	rs4925386	1	rs6121990	ENSG00000275437.1	RP5-908M14.10	-4.58	5.86e-06	0.000633	-0.19	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62402236~62405935:-
THCA	cis	rs2985684	0.894	rs4900928	ENSG00000278009.1	RP11-649E7.8	4.58	5.86e-06	0.000633	0.28	0.21	Carotid intima media thickness;	chr14:49554099	chr14:49601011~49601124:-
THCA	cis	rs875971	0.522	rs1917563	ENSG00000272831.1	RP11-792A8.4	-4.58	5.86e-06	0.000633	-0.13	-0.21	Aortic root size;	chr7:65950660	chr7:66739829~66740385:-
THCA	cis	rs763121	0.853	rs5757232	ENSG00000273076.1	RP3-508I15.22	4.58	5.86e-06	0.000633	0.21	0.21	Menopause (age at onset);	chr22:38675672	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs9306329	ENSG00000273076.1	RP3-508I15.22	4.58	5.86e-06	0.000633	0.21	0.21	Menopause (age at onset);	chr22:38676449	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5750662	ENSG00000273076.1	RP3-508I15.22	4.58	5.86e-06	0.000633	0.21	0.21	Menopause (age at onset);	chr22:38676467	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5750664	ENSG00000273076.1	RP3-508I15.22	4.58	5.86e-06	0.000633	0.21	0.21	Menopause (age at onset);	chr22:38676764	chr22:38743495~38743910:+
THCA	cis	rs763121	0.626	rs5757236	ENSG00000273076.1	RP3-508I15.22	4.58	5.86e-06	0.000633	0.21	0.21	Menopause (age at onset);	chr22:38677819	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs6001191	ENSG00000273076.1	RP3-508I15.22	4.58	5.86e-06	0.000633	0.21	0.21	Menopause (age at onset);	chr22:38678447	chr22:38743495~38743910:+
THCA	cis	rs8177876	0.731	rs79546329	ENSG00000261061.1	RP11-303E16.2	-4.58	5.86e-06	0.000633	-0.37	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81103636	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.731	rs12448806	ENSG00000261061.1	RP11-303E16.2	-4.58	5.86e-06	0.000633	-0.37	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104597	chr16:81030770~81031485:+
THCA	cis	rs9880211	0.699	rs34804893	ENSG00000239213.4	NCK1-AS1	4.58	5.87e-06	0.000633	0.23	0.21	Height;Body mass index;	chr3:136621128	chr3:136841726~136862054:-
THCA	cis	rs17801127	0.818	rs848219	ENSG00000231969.1	AC144449.1	4.58	5.87e-06	0.000633	0.33	0.21	Liver enzyme levels (alanine transaminase);	chr2:149685494	chr2:149587196~149848233:+
THCA	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	4.58	5.87e-06	0.000634	0.21	0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
THCA	cis	rs6787172	0.811	rs9858318	ENSG00000272087.1	RP11-379F4.7	4.58	5.87e-06	0.000634	0.18	0.21	Subjective well-being;	chr3:158505502	chr3:158693120~158693768:-
THCA	cis	rs899997	0.862	rs8032552	ENSG00000261143.1	ADAMTS7P3	-4.58	5.87e-06	0.000634	-0.29	-0.21	Coronary artery disease or large artery stroke;	chr15:78678794	chr15:77976042~77993057:+
THCA	cis	rs2243480	1	rs160643	ENSG00000164669.11	INTS4P1	4.58	5.87e-06	0.000634	0.4	0.21	Diabetic kidney disease;	chr7:66093235	chr7:65141225~65234216:+
THCA	cis	rs4948275	0.666	rs2606089	ENSG00000237233.2	TMEM26-AS1	-4.58	5.87e-06	0.000634	-0.27	-0.21	Night sleep phenotypes;	chr10:61554047	chr10:61452639~61481956:+
THCA	cis	rs2243480	1	rs1404147	ENSG00000164669.11	INTS4P1	4.58	5.87e-06	0.000634	0.38	0.21	Diabetic kidney disease;	chr7:65799537	chr7:65141225~65234216:+
THCA	cis	rs2153535	0.585	rs9505505	ENSG00000230939.1	RP11-314C16.1	-4.58	5.87e-06	0.000634	-0.22	-0.21	Motion sickness;	chr6:8640246	chr6:8784178~8785445:+
THCA	cis	rs9396146	0.609	rs3800505	ENSG00000272209.1	RP3-500L14.2	-4.58	5.87e-06	0.000634	-0.28	-0.21	Yeast infection;	chr6:13787072	chr6:13825432~13826574:+
THCA	cis	rs7560272	0.512	rs4530394	ENSG00000163016.8	ALMS1P	-4.58	5.88e-06	0.000634	-0.26	-0.21	Schizophrenia;	chr2:73702523	chr2:73644919~73685576:+
THCA	cis	rs4819052	0.851	rs2838857	ENSG00000182586.6	LINC00334	-4.58	5.88e-06	0.000634	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45234340~45258730:+
THCA	cis	rs1923243	0.778	rs4268306	ENSG00000223479.3	RP4-788P17.1	-4.58	5.88e-06	0.000634	-0.23	-0.21	Migraine;	chr1:73146067	chr1:73635216~73715214:+
THCA	cis	rs2436845	1	rs2570942	ENSG00000253669.3	KB-1732A1.1	-4.58	5.88e-06	0.000635	-0.21	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848812	chr8:102805517~102809971:+
THCA	cis	rs829883	0.932	rs249840	ENSG00000227825.4	SLC9A7P1	4.58	5.88e-06	0.000635	0.19	0.21	Colorectal adenoma (advanced);	chr12:98478215	chr12:98453835~98457145:-
THCA	cis	rs829883	1	rs249839	ENSG00000227825.4	SLC9A7P1	4.58	5.88e-06	0.000635	0.19	0.21	Colorectal adenoma (advanced);	chr12:98478586	chr12:98453835~98457145:-
THCA	cis	rs941408	0.515	rs12610096	ENSG00000261342.1	AC006538.1	4.58	5.88e-06	0.000635	0.23	0.21	Total cholesterol levels;	chr19:2778131	chr19:2727743~2729327:-
THCA	cis	rs4660214	0.671	rs16826012	ENSG00000228060.1	RP11-69E11.8	4.58	5.88e-06	0.000635	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39565160~39573203:+
THCA	cis	rs6088580	0.634	rs3746455	ENSG00000276073.1	RP5-1125A11.7	4.58	5.88e-06	0.000635	0.18	0.21	Glomerular filtration rate (creatinine);	chr20:34369410	chr20:33985617~33988989:-
THCA	cis	rs9650657	0.53	rs6982381	ENSG00000206014.6	OR7E161P	4.58	5.88e-06	0.000635	0.24	0.21	Neuroticism;	chr8:11094990	chr8:11928597~11929563:-
THCA	cis	rs4660456	0.913	rs569159	ENSG00000272145.1	NFYC-AS1	4.58	5.88e-06	0.000635	0.15	0.21	Platelet count;	chr1:40701862	chr1:40690380~40692066:-
THCA	cis	rs2075824	0.715	rs3974759	ENSG00000267079.1	RP11-820I16.1	4.58	5.88e-06	0.000635	0.25	0.21	Obsessive-compulsive disorder or autism spectrum disorder;	chr18:11979295	chr18:11910634~11914344:-
THCA	cis	rs7246657	0.551	rs4806413	ENSG00000276846.1	CTD-3220F14.3	4.58	5.88e-06	0.000635	0.25	0.21	Coronary artery calcification;	chr19:37126814	chr19:37314868~37315620:-
THCA	cis	rs72843506	0.656	rs9901357	ENSG00000261033.1	RP11-209D14.2	4.58	5.88e-06	0.000635	0.38	0.21	Schizophrenia;	chr17:20105729	chr17:20008051~20009234:-
THCA	cis	rs12612619	0.732	rs12613822	ENSG00000229122.1	AGBL5-IT1	4.58	5.88e-06	0.000635	0.15	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26994234	chr2:27061038~27061815:+
THCA	cis	rs7267979	0.933	rs2261109	ENSG00000274973.1	RP13-401N8.7	-4.58	5.88e-06	0.000635	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2261698	ENSG00000274973.1	RP13-401N8.7	-4.58	5.88e-06	0.000635	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2261720	ENSG00000274973.1	RP13-401N8.7	-4.58	5.88e-06	0.000635	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2227890	ENSG00000274973.1	RP13-401N8.7	-4.58	5.88e-06	0.000635	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25845497~25845862:+
THCA	cis	rs1707322	1	rs4524994	ENSG00000281133.1	AL355480.3	-4.58	5.89e-06	0.000635	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs9787412	ENSG00000281133.1	AL355480.3	-4.58	5.89e-06	0.000635	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4660896	ENSG00000281133.1	AL355480.3	-4.58	5.89e-06	0.000635	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.928	rs10732844	ENSG00000281133.1	AL355480.3	-4.58	5.89e-06	0.000635	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs12133129	ENSG00000281133.1	AL355480.3	-4.58	5.89e-06	0.000635	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs4553121	ENSG00000281133.1	AL355480.3	-4.58	5.89e-06	0.000635	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs6690652	ENSG00000281133.1	AL355480.3	-4.58	5.89e-06	0.000635	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs6695421	ENSG00000281133.1	AL355480.3	-4.58	5.89e-06	0.000635	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45580892~45580996:-
THCA	cis	rs4950322	0.512	rs2883318	ENSG00000271721.1	RP11-337C18.9	4.58	5.89e-06	0.000636	0.21	0.21	Protein quantitative trait loci;	chr1:147377422	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.512	rs12409455	ENSG00000271721.1	RP11-337C18.9	4.58	5.89e-06	0.000636	0.21	0.21	Protein quantitative trait loci;	chr1:147378563	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.6	rs11240014	ENSG00000271721.1	RP11-337C18.9	4.58	5.89e-06	0.000636	0.21	0.21	Protein quantitative trait loci;	chr1:147380674	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.576	rs11240015	ENSG00000271721.1	RP11-337C18.9	4.58	5.89e-06	0.000636	0.21	0.21	Protein quantitative trait loci;	chr1:147380813	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.553	rs12093870	ENSG00000271721.1	RP11-337C18.9	4.58	5.89e-06	0.000636	0.21	0.21	Protein quantitative trait loci;	chr1:147380815	chr1:147175602~147177740:+
THCA	cis	rs4646450	0.735	rs2404323	ENSG00000244219.5	GS1-259H13.2	-4.58	5.89e-06	0.000636	-0.28	-0.21	Blood metabolite levels;	chr7:99387773	chr7:99598066~99610813:+
THCA	cis	rs9902453	1	rs62070312	ENSG00000263370.1	RP11-68I3.5	4.58	5.89e-06	0.000636	0.27	0.21	Coffee consumption (cups per day);	chr17:30111859	chr17:29639627~29640825:+
THCA	cis	rs7621331	1	rs34311570	ENSG00000273486.1	RP11-731C17.2	4.58	5.89e-06	0.000636	0.19	0.21	Waist circumference adjusted for body mass index;	chr3:135990140	chr3:136837338~136839021:-
THCA	cis	rs8105895	0.935	rs10418804	ENSG00000269345.1	VN1R85P	4.58	5.89e-06	0.000636	0.28	0.21	Body mass index (change over time);	chr19:22090213	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs2043319	ENSG00000269345.1	VN1R85P	4.58	5.89e-06	0.000636	0.28	0.21	Body mass index (change over time);	chr19:22091793	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs28374572	ENSG00000269345.1	VN1R85P	4.58	5.89e-06	0.000636	0.28	0.21	Body mass index (change over time);	chr19:22093676	chr19:22174766~22175191:-
THCA	cis	rs7115242	0.8	rs519794	ENSG00000280143.1	AP000892.6	4.58	5.89e-06	0.000636	0.32	0.21	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117204967~117210292:+
THCA	cis	rs3764021	0.527	rs2114870	ENSG00000214776.8	RP11-726G1.1	4.58	5.89e-06	0.000636	0.27	0.21	Type 1 diabetes;	chr12:9670544	chr12:9467552~9576275:+
THCA	cis	rs7824557	0.547	rs2736287	ENSG00000154316.13	TDH	4.58	5.9e-06	0.000636	0.16	0.21	Retinal vascular caliber;	chr8:11370497	chr8:11339637~11368452:+
THCA	cis	rs4819052	0.635	rs2838808	ENSG00000237664.1	LINC00316	-4.58	5.9e-06	0.000636	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45201191	chr21:45338590~45341990:-
THCA	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	4.58	5.9e-06	0.000637	0.23	0.21	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
THCA	cis	rs6657613	0.68	rs6690919	ENSG00000186301.8	MST1P2	4.58	5.9e-06	0.000637	0.17	0.21	Hip circumference adjusted for BMI;	chr1:17046710	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.621	rs9435749	ENSG00000186301.8	MST1P2	4.58	5.9e-06	0.000637	0.17	0.21	Hip circumference adjusted for BMI;	chr1:17047464	chr1:16645622~16650289:+
THCA	cis	rs2836950	0.565	rs2836926	ENSG00000238141.2	BRWD1-AS1	-4.58	5.9e-06	0.000637	-0.23	-0.21	Menarche (age at onset);	chr21:39164864	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.565	rs8131132	ENSG00000238141.2	BRWD1-AS1	-4.58	5.9e-06	0.000637	-0.23	-0.21	Menarche (age at onset);	chr21:39166330	chr21:39315707~39323218:+
THCA	cis	rs1923243	0.778	rs4564089	ENSG00000223479.3	RP4-788P17.1	-4.58	5.9e-06	0.000637	-0.23	-0.21	Migraine;	chr1:73143241	chr1:73635216~73715214:+
THCA	cis	rs4713118	0.699	rs200969	ENSG00000220721.1	OR1F12	4.58	5.9e-06	0.000637	0.28	0.21	Parkinson's disease;	chr6:27891675	chr6:28073316~28074233:+
THCA	cis	rs2067615	0.579	rs10861655	ENSG00000260329.1	RP11-412D9.4	4.58	5.9e-06	0.000637	0.19	0.21	Heart rate;	chr12:106735641	chr12:106954029~106955497:-
THCA	cis	rs889398	0.742	rs12446197	ENSG00000226232.7	RP11-419C5.2	4.58	5.91e-06	0.000637	0.2	0.21	Body mass index;	chr16:69820966	chr16:69976388~69996188:-
THCA	cis	rs987724	0.515	rs9876148	ENSG00000240875.4	LINC00886	-4.58	5.91e-06	0.000637	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156894349	chr3:156747346~156817062:-
THCA	cis	rs11976180	1	rs1533268	ENSG00000244198.4	RP4-545C24.1	-4.58	5.91e-06	0.000637	-0.2	-0.21	Obesity-related traits;	chr7:144069265	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs1533266	ENSG00000244198.4	RP4-545C24.1	-4.58	5.91e-06	0.000637	-0.2	-0.21	Obesity-related traits;	chr7:144069621	chr7:144194858~144280547:+
THCA	cis	rs3820928	0.904	rs10933161	ENSG00000212391.1	SNORA48	-4.58	5.91e-06	0.000637	-0.24	-0.21	Pulmonary function;	chr2:226900156	chr2:226968989~226969122:-
THCA	cis	rs853679	1	rs1778508	ENSG00000272009.1	RP1-313I6.12	4.58	5.91e-06	0.000637	0.28	0.21	Depression;	chr6:28262103	chr6:28078792~28081130:-
THCA	cis	rs763121	0.853	rs138704	ENSG00000228274.3	RP3-508I15.9	-4.58	5.91e-06	0.000637	-0.23	-0.21	Menopause (age at onset);	chr22:38737405	chr22:38667585~38681820:-
THCA	cis	rs6951245	0.938	rs112425403	ENSG00000229043.2	AC091729.9	-4.58	5.91e-06	0.000638	-0.36	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031895	chr7:1160374~1165267:+
THCA	cis	rs62025270	0.688	rs7182210	ENSG00000259295.5	CSPG4P12	-4.58	5.91e-06	0.000638	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85722551	chr15:85191438~85213905:+
THCA	cis	rs4915077	1	rs4915073	ENSG00000230489.1	VAV3-AS1	4.58	5.91e-06	0.000638	0.35	0.21	Hypothyroidism;	chr1:107783257	chr1:107964443~107994607:+
THCA	cis	rs8062405	1	rs72793811	ENSG00000261766.1	RP11-22P6.2	-4.58	5.91e-06	0.000638	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs72793812	ENSG00000261766.1	RP11-22P6.2	-4.58	5.91e-06	0.000638	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28862166~28863340:-
THCA	cis	rs2241024	0.509	rs12985675	ENSG00000281468.1	CTC-459F4.9	4.58	5.91e-06	0.000638	0.28	0.21	Testicular germ cell tumor;	chr19:27531795	chr19:27802838~27803472:+
THCA	cis	rs7618915	1	rs34569561	ENSG00000243224.1	RP5-1157M23.2	-4.58	5.92e-06	0.000638	-0.22	-0.21	Bipolar disorder;	chr3:52253277	chr3:52239258~52241097:+
THCA	cis	rs56804039	1	rs67180327	ENSG00000254153.1	CTA-398F10.2	4.58	5.92e-06	0.000638	0.25	0.21	Cervical cancer;	chr8:8523244	chr8:8456909~8461337:-
THCA	cis	rs56804039	1	rs67611618	ENSG00000254153.1	CTA-398F10.2	4.58	5.92e-06	0.000638	0.25	0.21	Cervical cancer;	chr8:8523429	chr8:8456909~8461337:-
THCA	cis	rs56804039	1	rs58361948	ENSG00000254153.1	CTA-398F10.2	4.58	5.92e-06	0.000638	0.25	0.21	Cervical cancer;	chr8:8523485	chr8:8456909~8461337:-
THCA	cis	rs56804039	1	rs56804039	ENSG00000254153.1	CTA-398F10.2	4.58	5.92e-06	0.000638	0.25	0.21	Cervical cancer;	chr8:8523519	chr8:8456909~8461337:-
THCA	cis	rs56804039	1	rs6986470	ENSG00000254153.1	CTA-398F10.2	4.58	5.92e-06	0.000638	0.25	0.21	Cervical cancer;	chr8:8523920	chr8:8456909~8461337:-
THCA	cis	rs10256972	0.713	rs10435026	ENSG00000225146.1	AC073957.15	4.58	5.92e-06	0.000638	0.22	0.21	Endometriosis;Longevity;	chr7:1026312	chr7:1029025~1043891:+
THCA	cis	rs1555322	0.932	rs6060321	ENSG00000126005.14	MMP24-AS1	-4.58	5.92e-06	0.000638	-0.27	-0.21	Attention deficit hyperactivity disorder;	chr20:35245978	chr20:35216462~35278131:-
THCA	cis	rs11098499	0.863	rs3736115	ENSG00000249244.1	RP11-548H18.2	-4.58	5.92e-06	0.000639	-0.25	-0.21	Corneal astigmatism;	chr4:119567548	chr4:119391831~119395335:-
THCA	cis	rs2657294	0.73	rs1259505	ENSG00000226051.5	ZNF503-AS1	-4.58	5.92e-06	0.000639	-0.29	-0.21	Pneumonia;	chr10:75237183	chr10:75269819~75373500:+
THCA	cis	rs17095355	1	rs55728195	ENSG00000203876.8	ADD3-AS1	-4.58	5.92e-06	0.000639	-0.22	-0.21	Biliary atresia;	chr10:109955841	chr10:109940104~110008381:-
THCA	cis	rs858239	0.6	rs4409314	ENSG00000230042.1	AK3P3	-4.58	5.92e-06	0.000639	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23129178~23129841:+
THCA	cis	rs1979679	1	rs1979679	ENSG00000247934.4	RP11-967K21.1	-4.58	5.93e-06	0.000639	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28253582	chr12:28163298~28190738:-
THCA	cis	rs2015599	0.623	rs7313552	ENSG00000273680.1	RP11-996F15.6	-4.58	5.93e-06	0.000639	-0.29	-0.21	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29332733~29333383:-
THCA	cis	rs2015599	0.584	rs7299283	ENSG00000273680.1	RP11-996F15.6	-4.58	5.93e-06	0.000639	-0.29	-0.21	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29332733~29333383:-
THCA	cis	rs453301	0.606	rs7462373	ENSG00000254153.1	CTA-398F10.2	4.58	5.93e-06	0.000639	0.22	0.21	Joint mobility (Beighton score);	chr8:9041808	chr8:8456909~8461337:-
THCA	cis	rs72843506	1	rs7223910	ENSG00000261033.1	RP11-209D14.2	4.58	5.93e-06	0.00064	0.31	0.21	Schizophrenia;	chr17:20079455	chr17:20008051~20009234:-
THCA	cis	rs13118159	0.509	rs4974554	ENSG00000254094.1	AC078852.1	-4.58	5.93e-06	0.00064	-0.26	-0.21	Longevity;	chr4:1363179	chr4:1356581~1358075:+
THCA	cis	rs2179367	0.568	rs9498358	ENSG00000216906.2	RP11-350J20.9	4.58	5.93e-06	0.00064	0.29	0.21	Dupuytren's disease;	chr6:149458529	chr6:149904243~149906418:+
THCA	cis	rs67478160	0.644	rs7159810	ENSG00000269910.1	RP11-73M18.10	4.58	5.93e-06	0.00064	0.18	0.21	Schizophrenia;	chr14:103827780	chr14:103694516~103695050:-
THCA	cis	rs57221529	0.709	rs4957056	ENSG00000225138.6	CTD-2228K2.7	4.58	5.93e-06	0.00064	0.26	0.21	Lung disease severity in cystic fibrosis;	chr5:569990	chr5:473236~480884:+
THCA	cis	rs2742234	0.541	rs1879310	ENSG00000273008.1	RP11-351D16.3	4.58	5.93e-06	0.00064	0.19	0.21	Hirschsprung disease;	chr10:43239327	chr10:43136824~43138334:-
THCA	cis	rs2304003	1	rs12473573	ENSG00000235192.1	AC009495.2	4.58	5.93e-06	0.00064	0.29	0.21	Social communication problems;	chr2:165832382	chr2:165794851~165810010:+
THCA	cis	rs1923243	0.778	rs10890008	ENSG00000223479.3	RP4-788P17.1	-4.58	5.93e-06	0.00064	-0.23	-0.21	Migraine;	chr1:73147323	chr1:73635216~73715214:+
THCA	cis	rs31251	1	rs32108	ENSG00000237714.1	P4HA2-AS1	4.58	5.93e-06	0.00064	0.26	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr5:131704859	chr5:132184876~132192808:+
THCA	cis	rs12439619	0.508	rs8032033	ENSG00000259429.4	UBE2Q2P2	-4.58	5.93e-06	0.00064	-0.17	-0.21	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82355142~82420075:+
THCA	cis	rs1267303	0.642	rs6670699	ENSG00000232022.5	FAAHP1	4.58	5.94e-06	0.00064	0.25	0.21	Monobrow;	chr1:46531598	chr1:46432129~46445521:+
THCA	cis	rs2281603	0.57	rs28766386	ENSG00000272909.1	CTD-2555O16.4	-4.58	5.94e-06	0.00064	-0.23	-0.21	Lymphocyte counts;	chr14:64479679	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs10133848	ENSG00000272909.1	CTD-2555O16.4	-4.58	5.94e-06	0.00064	-0.23	-0.21	Lymphocyte counts;	chr14:64481771	chr14:64440369~64442238:-
THCA	cis	rs62158800	0.598	rs1606984	ENSG00000224568.1	AC096669.3	4.58	5.94e-06	0.00064	0.26	0.21	Facial morphology (factor 22);	chr2:107675531	chr2:107529487~107556326:+
THCA	cis	rs36715	1	rs36697	ENSG00000245937.6	LINC01184	4.58	5.94e-06	0.000641	0.23	0.21	Breast cancer;	chr5:128213921	chr5:127940426~128083172:-
THCA	cis	rs36715	0.951	rs36698	ENSG00000245937.6	LINC01184	4.58	5.94e-06	0.000641	0.23	0.21	Breast cancer;	chr5:128214057	chr5:127940426~128083172:-
THCA	cis	rs10266483	0.843	rs667644	ENSG00000271550.1	BNIP3P11	4.58	5.94e-06	0.000641	0.26	0.21	Response to statin therapy;	chr7:64290180	chr7:64678954~64687393:-
THCA	cis	rs72843506	0.586	rs74433421	ENSG00000261033.1	RP11-209D14.2	4.58	5.94e-06	0.000641	0.4	0.21	Schizophrenia;	chr17:19914774	chr17:20008051~20009234:-
THCA	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	4.58	5.94e-06	0.000641	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000189316.3	RP11-797H7.5	-4.58	5.94e-06	0.000641	-0.23	-0.21	Calcium levels;	chr7:65825628	chr7:64888527~64890100:-
THCA	cis	rs2742234	0.59	rs2293020	ENSG00000273008.1	RP11-351D16.3	4.58	5.94e-06	0.000641	0.19	0.21	Hirschsprung disease;	chr10:43197439	chr10:43136824~43138334:-
THCA	cis	rs6012564	0.927	rs6019570	ENSG00000230758.1	SNAP23P	-4.58	5.94e-06	0.000641	-0.25	-0.21	Anger;	chr20:48983153	chr20:49038357~49038602:-
THCA	cis	rs941408	0.515	rs4624312	ENSG00000261342.1	AC006538.1	4.58	5.94e-06	0.000641	0.23	0.21	Total cholesterol levels;	chr19:2774462	chr19:2727743~2729327:-
THCA	cis	rs8062405	0.728	rs11642449	ENSG00000278665.1	RP11-666O2.4	4.58	5.95e-06	0.000641	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28599241~28601881:-
THCA	cis	rs4908769	0.624	rs894875	ENSG00000232912.4	RP5-1115A15.1	-4.58	5.95e-06	0.000641	-0.22	-0.21	Allergy;	chr1:8372076	chr1:8424645~8434838:+
THCA	cis	rs9880211	0.898	rs9870825	ENSG00000239213.4	NCK1-AS1	4.58	5.95e-06	0.000641	0.23	0.21	Height;Body mass index;	chr3:136346878	chr3:136841726~136862054:-
THCA	cis	rs2554380	0.628	rs7177929	ENSG00000176700.18	SCAND2P	-4.58	5.95e-06	0.000642	-0.15	-0.21	Height;	chr15:83809927	chr15:84631451~84647478:+
THCA	cis	rs61160187	0.582	rs62372103	ENSG00000215032.2	GNL3LP1	4.58	5.95e-06	0.000642	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60891935~60893577:-
THCA	cis	rs2239547	0.657	rs2071040	ENSG00000242142.1	SERBP1P3	4.58	5.95e-06	0.000642	0.27	0.21	Schizophrenia;	chr3:52830844	chr3:53064283~53065091:-
THCA	cis	rs7394190	0.748	rs4746147	ENSG00000271848.1	RP11-464F9.21	-4.58	5.96e-06	0.000642	-0.28	-0.21	Incident atrial fibrillation;	chr10:73767950	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs3088070	ENSG00000271848.1	RP11-464F9.21	-4.58	5.96e-06	0.000642	-0.28	-0.21	Incident atrial fibrillation;	chr10:73770255	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs11541237	ENSG00000271848.1	RP11-464F9.21	-4.58	5.96e-06	0.000642	-0.28	-0.21	Incident atrial fibrillation;	chr10:73771204	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs11000772	ENSG00000271848.1	RP11-464F9.21	-4.58	5.96e-06	0.000642	-0.28	-0.21	Incident atrial fibrillation;	chr10:73774230	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.748	rs11000773	ENSG00000271848.1	RP11-464F9.21	-4.58	5.96e-06	0.000642	-0.28	-0.21	Incident atrial fibrillation;	chr10:73774357	chr10:73654039~73674719:+
THCA	cis	rs7394190	0.688	rs76033784	ENSG00000271848.1	RP11-464F9.21	-4.58	5.96e-06	0.000642	-0.28	-0.21	Incident atrial fibrillation;	chr10:73776212	chr10:73654039~73674719:+
THCA	cis	rs34286592	0.929	rs10204	ENSG00000214725.6	CDIPT-AS1	-4.58	5.96e-06	0.000642	-0.36	-0.21	Multiple sclerosis;	chr16:29815217	chr16:29863593~29868053:+
THCA	cis	rs734999	0.588	rs876938	ENSG00000225931.3	RP3-395M20.7	4.58	5.96e-06	0.000642	0.25	0.21	Ulcerative colitis;	chr1:2591773	chr1:2566410~2569888:+
THCA	cis	rs8062405	0.965	rs56040780	ENSG00000261766.1	RP11-22P6.2	-4.58	5.96e-06	0.000643	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28862166~28863340:-
THCA	cis	rs763121	0.853	rs5750622	ENSG00000235209.1	CTA-150C2.13	4.58	5.96e-06	0.000643	0.27	0.21	Menopause (age at onset);	chr22:38560459	chr22:38921227~38924708:+
THCA	cis	rs526231	0.857	rs415657	ENSG00000175749.11	EIF3KP1	-4.58	5.96e-06	0.000643	-0.27	-0.21	Primary biliary cholangitis;	chr5:103329295	chr5:103032376~103033031:+
THCA	cis	rs3820928	0.874	rs4461255	ENSG00000212391.1	SNORA48	4.58	5.96e-06	0.000643	0.23	0.21	Pulmonary function;	chr2:226981808	chr2:226968989~226969122:-
THCA	cis	rs11621975	0.57	rs7143285	ENSG00000259088.1	CTD-2017C7.2	-4.58	5.97e-06	0.000643	-0.41	-0.21	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101771125	chr14:101796555~101810321:-
THCA	cis	rs453301	0.598	rs10104303	ENSG00000233609.3	RP11-62H7.2	4.58	5.97e-06	0.000643	0.2	0.21	Joint mobility (Beighton score);	chr8:8977018	chr8:8961200~8979025:+
THCA	cis	rs2281603	0.57	rs2123459	ENSG00000259116.1	RP11-973N13.4	-4.58	5.97e-06	0.000644	-0.18	-0.21	Lymphocyte counts;	chr14:64485585	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs11626222	ENSG00000259116.1	RP11-973N13.4	-4.58	5.97e-06	0.000644	-0.18	-0.21	Lymphocyte counts;	chr14:64486541	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs10132969	ENSG00000259116.1	RP11-973N13.4	-4.58	5.97e-06	0.000644	-0.18	-0.21	Lymphocyte counts;	chr14:64486862	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs10143839	ENSG00000259116.1	RP11-973N13.4	-4.58	5.97e-06	0.000644	-0.18	-0.21	Lymphocyte counts;	chr14:64486873	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs57525201	ENSG00000259116.1	RP11-973N13.4	-4.58	5.97e-06	0.000644	-0.18	-0.21	Lymphocyte counts;	chr14:64488974	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs10150781	ENSG00000259116.1	RP11-973N13.4	-4.58	5.97e-06	0.000644	-0.18	-0.21	Lymphocyte counts;	chr14:64489141	chr14:64514154~64540368:-
THCA	cis	rs4915077	1	rs10494075	ENSG00000230489.1	VAV3-AS1	4.58	5.97e-06	0.000644	0.35	0.21	Hypothyroidism;	chr1:107787734	chr1:107964443~107994607:+
THCA	cis	rs9902453	0.74	rs2254414	ENSG00000263370.1	RP11-68I3.5	-4.58	5.97e-06	0.000644	-0.27	-0.21	Coffee consumption (cups per day);	chr17:29734112	chr17:29639627~29640825:+
THCA	cis	rs10090774	0.93	rs9886378	ENSG00000279766.1	RP11-642A1.2	-4.58	5.97e-06	0.000644	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140910738	chr8:140572142~140572812:-
THCA	cis	rs481331	0.866	rs210298	ENSG00000215146.4	RP11-313J2.1	-4.58	5.97e-06	0.000644	-0.4	-0.21	Systemic juvenile idiopathic arthritis;	chr10:42642194	chr10:42331866~42367974:-
THCA	cis	rs73108077	0.736	rs6061028	ENSG00000277112.2	RP11-755J8.1	-4.58	5.97e-06	0.000644	-0.33	-0.21	Red blood cell density in sickle cell anemia;	chr20:31285774	chr20:30681825~30723932:-
THCA	cis	rs67478160	0.619	rs2368560	ENSG00000269910.1	RP11-73M18.10	4.58	5.97e-06	0.000644	0.18	0.21	Schizophrenia;	chr14:103806974	chr14:103694516~103695050:-
THCA	cis	rs8141529	0.956	rs132539	ENSG00000272858.1	CTA-292E10.8	-4.58	5.97e-06	0.000644	-0.22	-0.21	Lymphocyte counts;	chr22:28908265	chr22:28814914~28815662:+
THCA	cis	rs10504861	0.537	rs821103	ENSG00000253553.4	RP11-586K2.1	4.58	5.97e-06	0.000644	0.21	0.21	Migraine without aura;	chr8:88455252	chr8:88326836~88737134:+
THCA	cis	rs7851660	0.809	rs35324451	ENSG00000214417.4	KRT18P13	-4.58	5.98e-06	0.000644	-0.18	-0.21	Strep throat;	chr9:97897854	chr9:97698922~97700734:+
THCA	cis	rs8062405	0.755	rs4788076	ENSG00000261766.1	RP11-22P6.2	-4.58	5.98e-06	0.000644	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28862166~28863340:-
THCA	cis	rs2251381	0.64	rs2183568	ENSG00000176054.6	RPL23P2	-4.58	5.98e-06	0.000644	-0.19	-0.21	Selective IgA deficiency;	chr21:29112461	chr21:28997613~28998033:-
THCA	cis	rs763121	0.853	rs1056610	ENSG00000235209.1	CTA-150C2.13	-4.58	5.98e-06	0.000644	-0.27	-0.21	Menopause (age at onset);	chr22:38684073	chr22:38921227~38924708:+
THCA	cis	rs4950322	0.57	rs72692980	ENSG00000180867.10	PDIA3P1	4.58	5.98e-06	0.000645	0.21	0.21	Protein quantitative trait loci;	chr1:147337830	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.634	rs7542951	ENSG00000180867.10	PDIA3P1	4.58	5.98e-06	0.000645	0.21	0.21	Protein quantitative trait loci;	chr1:147340308	chr1:147178113~147179622:+
THCA	cis	rs7403037	0.583	rs60600106	ENSG00000260760.1	PWRN3	-4.58	5.98e-06	0.000645	-0.21	-0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24406033	chr15:24441127~24447967:+
THCA	cis	rs6517329	0.564	rs2835287	ENSG00000236830.5	CBR3-AS1	4.58	5.98e-06	0.000645	0.19	0.21	Schizophrenia;	chr21:36148980	chr21:36131767~36175815:-
THCA	cis	rs889398	0.802	rs12921407	ENSG00000226232.7	RP11-419C5.2	4.58	5.98e-06	0.000645	0.2	0.21	Body mass index;	chr16:69827030	chr16:69976388~69996188:-
THCA	cis	rs9878978	0.691	rs13064000	ENSG00000237990.3	CNTN4-AS1	4.58	5.98e-06	0.000645	0.25	0.21	Blood pressure (smoking interaction);	chr3:2398387	chr3:3039033~3069242:-
THCA	cis	rs7403037	0.55	rs34469274	ENSG00000259905.4	PWRN1	4.58	5.98e-06	0.000645	0.28	0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24362112	chr15:24493137~24652130:+
THCA	cis	rs1046491	0.803	rs11081459	ENSG00000264964.1	RP11-888D10.3	4.58	5.99e-06	0.000645	0.36	0.21	Scarlet fever;	chr18:9107817	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.614	rs12458095	ENSG00000264964.1	RP11-888D10.3	4.58	5.99e-06	0.000646	0.38	0.21	Scarlet fever;	chr18:9292291	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.614	rs12458179	ENSG00000264964.1	RP11-888D10.3	4.58	5.99e-06	0.000646	0.38	0.21	Scarlet fever;	chr18:9292626	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.522	rs2864544	ENSG00000264964.1	RP11-888D10.3	4.58	5.99e-06	0.000646	0.38	0.21	Scarlet fever;	chr18:9296151	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.522	rs35415521	ENSG00000264964.1	RP11-888D10.3	4.58	5.99e-06	0.000646	0.38	0.21	Scarlet fever;	chr18:9297330	chr18:9315194~9334441:-
THCA	cis	rs858239	0.6	rs7785842	ENSG00000226816.2	AC005082.12	4.58	5.99e-06	0.000646	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs7456915	ENSG00000226816.2	AC005082.12	4.58	5.99e-06	0.000646	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs13438179	ENSG00000226816.2	AC005082.12	4.58	5.99e-06	0.000646	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23206013~23208045:+
THCA	cis	rs116248771	0.739	rs114379619	ENSG00000271778.1	RP11-379F4.8	4.58	5.99e-06	0.000646	0.27	0.21	diarrhoeal disease at age 2;	chr3:158620992	chr3:158782547~158783124:+
THCA	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	4.58	5.99e-06	0.000646	0.26	0.21	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
THCA	cis	rs13113518	0.545	rs6810483	ENSG00000249700.7	SRD5A3-AS1	4.58	5.99e-06	0.000646	0.26	0.21	Height;	chr4:55424406	chr4:55363971~55395847:-
THCA	cis	rs4682868	0.581	rs4682869	ENSG00000273328.4	RP11-141M3.6	-4.58	5.99e-06	0.000646	-0.25	-0.21	Monocyte percentage of white cells;	chr3:42882472	chr3:42809414~42908105:+
THCA	cis	rs1707322	1	rs10890365	ENSG00000281133.1	AL355480.3	-4.58	5.99e-06	0.000646	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45580892~45580996:-
THCA	cis	rs11853189	0.938	rs75369292	ENSG00000259562.2	RP11-762H8.2	4.58	5.99e-06	0.000646	0.2	0.21	Red cell distribution width;	chr15:78263015	chr15:78290527~78291221:-
THCA	cis	rs11853189	0.938	rs77185764	ENSG00000259562.2	RP11-762H8.2	4.58	5.99e-06	0.000646	0.2	0.21	Red cell distribution width;	chr15:78263734	chr15:78290527~78291221:-
THCA	cis	rs11853189	0.882	rs78827644	ENSG00000259562.2	RP11-762H8.2	4.58	5.99e-06	0.000646	0.2	0.21	Red cell distribution width;	chr15:78263908	chr15:78290527~78291221:-
THCA	cis	rs11853189	0.882	rs79052265	ENSG00000259562.2	RP11-762H8.2	4.58	5.99e-06	0.000646	0.2	0.21	Red cell distribution width;	chr15:78263916	chr15:78290527~78291221:-
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000220721.1	OR1F12	4.58	6e-06	0.000646	0.23	0.21	Pubertal anthropometrics;	chr6:28294921	chr6:28073316~28074233:+
THCA	cis	rs34286592	0.929	rs8058824	ENSG00000214725.6	CDIPT-AS1	-4.58	6e-06	0.000646	-0.38	-0.21	Multiple sclerosis;	chr16:29817389	chr16:29863593~29868053:+
THCA	cis	rs34286592	0.929	rs35901559	ENSG00000214725.6	CDIPT-AS1	-4.58	6e-06	0.000646	-0.38	-0.21	Multiple sclerosis;	chr16:29818294	chr16:29863593~29868053:+
THCA	cis	rs34286592	0.929	rs11864180	ENSG00000214725.6	CDIPT-AS1	-4.58	6e-06	0.000646	-0.38	-0.21	Multiple sclerosis;	chr16:29819508	chr16:29863593~29868053:+
THCA	cis	rs34286592	0.929	rs9923649	ENSG00000214725.6	CDIPT-AS1	-4.58	6e-06	0.000646	-0.38	-0.21	Multiple sclerosis;	chr16:29820817	chr16:29863593~29868053:+
THCA	cis	rs13126694	0.678	rs4691452	ENSG00000248429.4	RP11-597D13.9	4.58	6e-06	0.000647	0.22	0.21	Blood osmolality (transformed sodium);	chr4:158080652	chr4:158170752~158202877:+
THCA	cis	rs13126694	0.744	rs11942932	ENSG00000248429.4	RP11-597D13.9	4.58	6e-06	0.000647	0.22	0.21	Blood osmolality (transformed sodium);	chr4:158081929	chr4:158170752~158202877:+
THCA	cis	rs270601	0.661	rs10036208	ENSG00000224431.1	AC063976.7	4.58	6e-06	0.000647	0.18	0.21	Acylcarnitine levels;	chr5:132235630	chr5:132199456~132203487:+
THCA	cis	rs6496044	0.507	rs2467096	ENSG00000259295.5	CSPG4P12	-4.58	6e-06	0.000647	-0.28	-0.21	Interstitial lung disease;	chr15:85667447	chr15:85191438~85213905:+
THCA	cis	rs2735413	0.564	rs4324138	ENSG00000276007.1	RP11-358L22.3	4.58	6e-06	0.000647	0.21	0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78067475	chr16:78123243~78124332:+
THCA	cis	rs72843506	0.722	rs78041331	ENSG00000261033.1	RP11-209D14.2	4.58	6e-06	0.000647	0.39	0.21	Schizophrenia;	chr17:20305533	chr17:20008051~20009234:-
THCA	cis	rs9847710	0.933	rs1529544	ENSG00000242142.1	SERBP1P3	-4.58	6e-06	0.000647	-0.24	-0.21	Ulcerative colitis;	chr3:53005439	chr3:53064283~53065091:-
THCA	cis	rs467650	1	rs469930	ENSG00000248489.1	CTD-2007H13.3	-4.58	6e-06	0.000647	-0.2	-0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98633416	chr5:98929171~98995013:+
THCA	cis	rs394563	0.591	rs237026	ENSG00000231760.4	RP11-350J20.5	4.58	6.01e-06	0.000647	0.26	0.21	Dupuytren's disease;	chr6:149399545	chr6:149796151~149826294:-
THCA	cis	rs4948275	0.693	rs2650729	ENSG00000237233.2	TMEM26-AS1	-4.58	6.01e-06	0.000647	-0.27	-0.21	Night sleep phenotypes;	chr10:61577411	chr10:61452639~61481956:+
THCA	cis	rs17270561	0.666	rs3923725	ENSG00000272462.2	U91328.19	-4.58	6.01e-06	0.000647	-0.18	-0.21	Iron status biomarkers;	chr6:25734692	chr6:25992662~26001775:+
THCA	cis	rs941408	0.515	rs878893	ENSG00000261342.1	AC006538.1	4.58	6.01e-06	0.000647	0.23	0.21	Total cholesterol levels;	chr19:2781327	chr19:2727743~2729327:-
THCA	cis	rs9650657	0.515	rs6601560	ENSG00000206014.6	OR7E161P	4.58	6.01e-06	0.000648	0.24	0.21	Neuroticism;	chr8:11093356	chr8:11928597~11929563:-
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000182586.6	LINC00334	-4.58	6.01e-06	0.000648	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000182586.6	LINC00334	-4.58	6.01e-06	0.000648	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000182586.6	LINC00334	-4.58	6.01e-06	0.000648	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000182586.6	LINC00334	-4.58	6.01e-06	0.000648	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000182586.6	LINC00334	-4.58	6.01e-06	0.000648	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000182586.6	LINC00334	-4.58	6.01e-06	0.000648	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45234340~45258730:+
THCA	cis	rs3764021	0.87	rs7970116	ENSG00000256594.6	RP11-705C15.2	-4.58	6.01e-06	0.000648	-0.16	-0.21	Type 1 diabetes;	chr12:9727518	chr12:9633419~9658412:+
THCA	cis	rs4245128	0.775	rs11214422	ENSG00000247416.2	RP11-629G13.1	4.58	6.01e-06	0.000648	0.2	0.21	Life satisfaction;	chr11:112932175	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.717	rs11214423	ENSG00000247416.2	RP11-629G13.1	4.58	6.01e-06	0.000648	0.2	0.21	Life satisfaction;	chr11:112932333	chr11:112959279~112963460:-
THCA	cis	rs795484	0.926	rs1726390	ENSG00000275409.1	RP11-131L12.4	-4.58	6.02e-06	0.000648	-0.17	-0.21	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118207579	chr12:118430147~118430699:+
THCA	cis	rs2574985	0.501	rs1011881	ENSG00000279863.1	RP11-521C22.2	4.58	6.02e-06	0.000648	0.23	0.21	Subjective well-being;	chr10:50487771	chr10:50334538~50336123:+
THCA	cis	rs4218	0.813	rs8036907	ENSG00000259732.1	RP11-59H7.3	-4.58	6.02e-06	0.000648	-0.29	-0.21	Social communication problems;	chr15:59121144	chr15:59121034~59133250:+
THCA	cis	rs9868809	0.772	rs2302295	ENSG00000270441.1	RP11-694I15.7	4.58	6.02e-06	0.000649	0.27	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48652677	chr3:49140086~49160851:-
THCA	cis	rs7264396	1	rs224424	ENSG00000088340.14	FER1L4	4.58	6.02e-06	0.000649	0.2	0.21	Total cholesterol levels;	chr20:35560231	chr20:35558737~35607562:-
THCA	cis	rs11648785	0.747	rs12920767	ENSG00000222019.6	URAHP	4.58	6.02e-06	0.000649	0.17	0.21	Tanning;	chr16:90028162	chr16:90039761~90047773:-
THCA	cis	rs71636778	0.631	rs12747620	ENSG00000260063.1	RP5-968P14.2	-4.58	6.03e-06	0.000649	-0.28	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26855770	chr1:26692132~26694131:-
THCA	cis	rs240993	0.812	rs9487668	ENSG00000271789.1	RP5-1112D6.7	4.58	6.03e-06	0.000649	0.26	0.21	Inflammatory skin disease;Psoriasis;	chr6:111553466	chr6:111297126~111298510:+
THCA	cis	rs2590942	0.578	rs34124399	ENSG00000227207.2	RPL31P12	4.58	6.03e-06	0.00065	0.37	0.21	Childhood body mass index;	chr1:72137817	chr1:72301472~72301829:+
THCA	cis	rs930395	0.514	rs10070037	ENSG00000272335.1	RP11-53O19.3	4.58	6.03e-06	0.00065	0.18	0.21	Breast cancer;	chr5:44870135	chr5:44826076~44828592:+
THCA	cis	rs8192917	0.511	rs12896130	ENSG00000258744.1	RP11-80A15.1	-4.58	6.04e-06	0.00065	-0.37	-0.21	Vitiligo;	chr14:24605976	chr14:24501594~24508688:+
THCA	cis	rs7260598	0.539	rs79838949	ENSG00000268442.1	CTD-2027I19.2	4.58	6.04e-06	0.00065	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23866311	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs10518280	ENSG00000268442.1	CTD-2027I19.2	4.58	6.04e-06	0.00065	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23872279	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs75695352	ENSG00000268442.1	CTD-2027I19.2	4.58	6.04e-06	0.00065	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23872302	chr19:24162370~24163425:-
THCA	cis	rs6442522	0.78	rs13095978	ENSG00000249786.6	EAF1-AS1	4.58	6.04e-06	0.00065	0.21	0.21	Uric acid levels;	chr3:15399603	chr3:15436171~15455940:-
THCA	cis	rs654950	0.901	rs1885654	ENSG00000230638.4	RP11-486B10.4	4.58	6.04e-06	0.000651	0.25	0.21	Airway imaging phenotypes;	chr1:41541517	chr1:41542069~41544310:+
THCA	cis	rs4915077	1	rs12563783	ENSG00000230489.1	VAV3-AS1	4.58	6.04e-06	0.000651	0.35	0.21	Hypothyroidism;	chr1:107769832	chr1:107964443~107994607:+
THCA	cis	rs6517329	0.585	rs8129035	ENSG00000236830.5	CBR3-AS1	-4.58	6.04e-06	0.000651	-0.19	-0.21	Schizophrenia;	chr21:36151725	chr21:36131767~36175815:-
THCA	cis	rs2836974	0.568	rs11910906	ENSG00000255568.3	BRWD1-AS2	-4.58	6.04e-06	0.000651	-0.17	-0.21	Cognitive function;	chr21:39313736	chr21:39313935~39314962:+
THCA	cis	rs990871	0.53	rs1194269	ENSG00000227207.2	RPL31P12	4.58	6.04e-06	0.000651	0.24	0.21	Subcutaneous adipose tissue;	chr1:72238177	chr1:72301472~72301829:+
THCA	cis	rs8054556	0.692	rs4424923	ENSG00000183604.13	SMG1P5	-4.58	6.04e-06	0.000651	-0.19	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29927972	chr16:30267553~30335374:-
THCA	cis	rs31251	0.835	rs2420148	ENSG00000224431.1	AC063976.7	-4.58	6.04e-06	0.000651	-0.17	-0.21	Itch intensity from mosquito bite adjusted by bite size;	chr5:131259715	chr5:132199456~132203487:+
THCA	cis	rs711244	0.935	rs2110942	ENSG00000279519.1	RP11-288C18.1	4.58	6.04e-06	0.000651	0.17	0.21	Mean platelet volume;	chr2:36869866	chr2:36839922~36842539:-
THCA	cis	rs2806561	0.704	rs2806570	ENSG00000249087.5	ZNF436-AS1	4.58	6.04e-06	0.000651	0.13	0.21	Height;	chr1:23200512	chr1:23368997~23371839:+
THCA	cis	rs2439831	0.618	rs8023508	ENSG00000166763.7	STRCP1	-4.58	6.05e-06	0.000651	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43883905	chr15:43699488~43718184:-
THCA	cis	rs1979679	0.879	rs55996833	ENSG00000247934.4	RP11-967K21.1	-4.58	6.05e-06	0.000651	-0.21	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28313303	chr12:28163298~28190738:-
THCA	cis	rs7829975	0.501	rs4840353	ENSG00000254153.1	CTA-398F10.2	4.58	6.05e-06	0.000651	0.23	0.21	Mood instability;	chr8:8723060	chr8:8456909~8461337:-
THCA	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	4.58	6.05e-06	0.000651	0.23	0.21	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
THCA	cis	rs6740462	0.959	rs268124	ENSG00000204929.10	AC074391.1	4.58	6.05e-06	0.000651	0.29	0.21	Inflammatory bowel disease;Crohn's disease;	chr2:65427230	chr2:65436711~66084639:+
THCA	cis	rs1003719	0.715	rs2251952	ENSG00000230366.8	DSCR9	4.58	6.05e-06	0.000651	0.21	0.21	Eye color traits;	chr21:37187410	chr21:37208503~37221736:+
THCA	cis	rs1005277	0.505	rs200931	ENSG00000226578.1	RP11-258F22.1	-4.58	6.05e-06	0.000651	-0.24	-0.21	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:37775371~37784131:-
THCA	cis	rs1046491	0.901	rs8085669	ENSG00000264964.1	RP11-888D10.3	4.58	6.05e-06	0.000651	0.35	0.21	Scarlet fever;	chr18:9190644	chr18:9315194~9334441:-
THCA	cis	rs8054556	0.692	rs12716972	ENSG00000183604.13	SMG1P5	-4.58	6.05e-06	0.000651	-0.19	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29925333	chr16:30267553~30335374:-
THCA	cis	rs1048886	0.872	rs6933337	ENSG00000271967.1	RP11-134K13.4	-4.58	6.05e-06	0.000652	-0.22	-0.21	Type 2 diabetes;	chr6:70402963	chr6:70596438~70596980:+
THCA	cis	rs9878978	0.722	rs2055481	ENSG00000237990.3	CNTN4-AS1	4.58	6.05e-06	0.000652	0.25	0.21	Blood pressure (smoking interaction);	chr3:2405241	chr3:3039033~3069242:-
THCA	cis	rs7577696	0.962	rs11124275	ENSG00000276334.1	AL133243.1	-4.58	6.05e-06	0.000652	-0.22	-0.21	Inflammatory biomarkers;	chr2:32078693	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.925	rs11683931	ENSG00000276334.1	AL133243.1	-4.58	6.05e-06	0.000652	-0.22	-0.21	Inflammatory biomarkers;	chr2:32078999	chr2:32521927~32523547:+
THCA	cis	rs2128382	0.53	rs4395866	ENSG00000253720.1	RP11-473O4.3	-4.58	6.05e-06	0.000652	-0.31	-0.21	Colorectal cancer;	chr8:129873282	chr8:129939856~129949394:+
THCA	cis	rs9300255	0.739	rs4759415	ENSG00000235423.7	RP11-282O18.3	-4.58	6.05e-06	0.000652	-0.21	-0.21	Neutrophil percentage of white cells;	chr12:123259127	chr12:123252030~123261483:-
THCA	cis	rs6832769	1	rs28582059	ENSG00000272969.1	RP11-528I4.2	-4.58	6.06e-06	0.000652	-0.24	-0.21	Personality dimensions;	chr4:55542237	chr4:55547112~55547889:+
THCA	cis	rs8028182	0.636	rs28783769	ENSG00000260274.1	RP11-817O13.8	4.58	6.06e-06	0.000652	0.15	0.21	Sudden cardiac arrest;	chr15:75556668	chr15:75368155~75369584:+
THCA	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-4.58	6.06e-06	0.000652	-0.27	-0.21	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
THCA	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-4.58	6.06e-06	0.000652	-0.27	-0.21	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
THCA	cis	rs1962772	0.74	rs2188022	ENSG00000279903.1	RP11-349F21.5	-4.58	6.06e-06	0.000652	-0.25	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17519884	chr8:17500012~17500605:+
THCA	cis	rs6547741	0.844	rs9941696	ENSG00000234072.1	AC074117.10	-4.58	6.06e-06	0.000652	-0.16	-0.21	Oral cavity cancer;	chr2:27697197	chr2:27356246~27367622:+
THCA	cis	rs202072	0.872	rs413120	ENSG00000272379.1	RP1-257A7.5	-4.58	6.06e-06	0.000652	-0.3	-0.21	HIV-1 viral setpoint;	chr6:13280409	chr6:13290018~13290490:-
THCA	cis	rs710865	0.541	rs2273046	ENSG00000270728.1	RP4-657E11.10	4.58	6.06e-06	0.000653	0.15	0.21	Brain structure;	chr1:19239802	chr1:19297080~19297903:+
THCA	cis	rs3177980	0.673	rs6694855	ENSG00000239494.2	RN7SL333P	-4.58	6.06e-06	0.000653	-0.2	-0.21	Amyotrophic lateral sclerosis;	chr1:169883710	chr1:169859756~169860052:+
THCA	cis	rs9300255	0.739	rs10846491	ENSG00000235423.7	RP11-282O18.3	4.58	6.06e-06	0.000653	0.21	0.21	Neutrophil percentage of white cells;	chr12:123268945	chr12:123252030~123261483:-
THCA	cis	rs875971	0.522	rs34973832	ENSG00000164669.11	INTS4P1	-4.58	6.06e-06	0.000653	-0.26	-0.21	Aortic root size;	chr7:65931217	chr7:65141225~65234216:+
THCA	cis	rs3824435	0.783	rs4740811	ENSG00000272866.1	RP11-12D24.10	4.58	6.06e-06	0.000653	0.28	0.21	Risky sexual behaviors in alcohol dependence;	chr9:5347702	chr9:5351796~5352410:-
THCA	cis	rs763121	0.853	rs3761454	ENSG00000235209.1	CTA-150C2.13	4.58	6.07e-06	0.000653	0.27	0.21	Menopause (age at onset);	chr22:38670815	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs3747170	ENSG00000235209.1	CTA-150C2.13	4.58	6.07e-06	0.000653	0.27	0.21	Menopause (age at onset);	chr22:38671326	chr22:38921227~38924708:+
THCA	cis	rs57221529	0.766	rs72703070	ENSG00000225138.6	CTD-2228K2.7	4.58	6.07e-06	0.000653	0.26	0.21	Lung disease severity in cystic fibrosis;	chr5:590343	chr5:473236~480884:+
THCA	cis	rs57221529	0.713	rs72703072	ENSG00000225138.6	CTD-2228K2.7	4.58	6.07e-06	0.000653	0.26	0.21	Lung disease severity in cystic fibrosis;	chr5:590511	chr5:473236~480884:+
THCA	cis	rs57221529	0.713	rs12522724	ENSG00000225138.6	CTD-2228K2.7	4.58	6.07e-06	0.000653	0.26	0.21	Lung disease severity in cystic fibrosis;	chr5:590627	chr5:473236~480884:+
THCA	cis	rs13113518	0.507	rs11943456	ENSG00000249700.7	SRD5A3-AS1	4.58	6.07e-06	0.000653	0.26	0.21	Height;	chr4:55410167	chr4:55363971~55395847:-
THCA	cis	rs780094	0.528	rs1728918	ENSG00000234072.1	AC074117.10	4.58	6.07e-06	0.000653	0.17	0.21	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27412596	chr2:27356246~27367622:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000229180.5	GS1-124K5.11	4.58	6.07e-06	0.000653	0.17	0.21	Corneal structure;	chr7:66789303	chr7:66526088~66542624:-
THCA	cis	rs9844666	0.512	rs9836374	ENSG00000273486.1	RP11-731C17.2	4.58	6.07e-06	0.000653	0.19	0.21	Height;	chr3:135989606	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs17250445	ENSG00000273486.1	RP11-731C17.2	4.58	6.07e-06	0.000653	0.19	0.21	Waist circumference adjusted for body mass index;	chr3:135990261	chr3:136837338~136839021:-
THCA	cis	rs7760951	0.722	rs9366890	ENSG00000228559.1	RP3-340B19.3	-4.58	6.07e-06	0.000653	-0.29	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr6:35595197	chr6:35544632~35545669:+
THCA	cis	rs62158800	0.85	rs62158795	ENSG00000224568.1	AC096669.3	4.58	6.07e-06	0.000654	0.39	0.21	Facial morphology (factor 22);	chr2:107578487	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.85	rs6755089	ENSG00000224568.1	AC096669.3	4.58	6.07e-06	0.000654	0.39	0.21	Facial morphology (factor 22);	chr2:107578947	chr2:107529487~107556326:+
THCA	cis	rs10090774	0.841	rs4562374	ENSG00000279766.1	RP11-642A1.2	-4.58	6.07e-06	0.000654	-0.25	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140722145	chr8:140572142~140572812:-
THCA	cis	rs2948294	0.566	rs13274039	ENSG00000254153.1	CTA-398F10.2	-4.58	6.07e-06	0.000654	-0.22	-0.21	Red cell distribution width;	chr8:8254137	chr8:8456909~8461337:-
THCA	cis	rs4886920	0.862	rs4486846	ENSG00000260776.4	RP11-114H24.2	-4.58	6.07e-06	0.000654	-0.24	-0.21	Neuroticism;	chr15:77846594	chr15:77914217~77926846:-
THCA	cis	rs427943	0.864	rs4819034	ENSG00000223768.1	LINC00205	-4.58	6.08e-06	0.000654	-0.19	-0.21	Body mass index;	chr21:45208676	chr21:45293285~45297354:+
THCA	cis	rs12887734	0.524	rs12888002	ENSG00000269940.1	RP11-73M18.7	4.58	6.08e-06	0.000654	0.22	0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103694560~103695170:+
THCA	cis	rs2797160	0.547	rs1418645	ENSG00000237742.5	RP11-624M8.1	-4.58	6.08e-06	0.000654	-0.19	-0.21	Endometrial cancer;	chr6:125625330	chr6:125578558~125749190:-
THCA	cis	rs1003719	0.715	rs8126941	ENSG00000230366.8	DSCR9	4.58	6.08e-06	0.000654	0.21	0.21	Eye color traits;	chr21:37179240	chr21:37208503~37221736:+
THCA	cis	rs7267979	1	rs2474777	ENSG00000274973.1	RP13-401N8.7	-4.58	6.08e-06	0.000654	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25845497~25845862:+
THCA	cis	rs1707322	1	rs7547189	ENSG00000281133.1	AL355480.3	-4.58	6.08e-06	0.000654	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs7547284	ENSG00000281133.1	AL355480.3	-4.58	6.08e-06	0.000654	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45580892~45580996:-
THCA	cis	rs9863	0.828	rs12303933	ENSG00000269997.1	RP11-214K3.21	-4.58	6.08e-06	0.000654	-0.25	-0.21	White blood cell count;	chr12:123997709	chr12:123966077~123966629:-
THCA	cis	rs11779988	0.545	rs421290	ENSG00000253671.1	RP11-806O11.1	-4.58	6.08e-06	0.000654	-0.27	-0.21	Breast cancer;	chr8:17908907	chr8:17808941~17820868:+
THCA	cis	rs9902453	0.817	rs880749	ENSG00000263370.1	RP11-68I3.5	-4.58	6.08e-06	0.000655	-0.27	-0.21	Coffee consumption (cups per day);	chr17:29732952	chr17:29639627~29640825:+
THCA	cis	rs4916588	0.79	rs4916448	ENSG00000270170.1	NCBP2-AS2	4.58	6.08e-06	0.000655	0.18	0.21	Night sleep phenotypes;	chr3:196894576	chr3:196942623~196943540:+
THCA	cis	rs17685	0.753	rs4732595	ENSG00000230882.1	AC005077.14	4.58	6.08e-06	0.000655	0.2	0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76125821	chr7:76071469~76074963:-
THCA	cis	rs12935418	0.616	rs11859567	ENSG00000278985.1	RP11-303E16.9	4.58	6.08e-06	0.000655	0.26	0.21	Mean corpuscular volume;	chr16:80935951	chr16:80982319~80984094:-
THCA	cis	rs8006682	0.541	rs2273486	ENSG00000259038.1	CTD-2325P2.4	4.58	6.08e-06	0.000655	0.26	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68626990	chr14:68627166~68628445:-
THCA	cis	rs7474896	0.583	rs10740950	ENSG00000226578.1	RP11-258F22.1	-4.58	6.08e-06	0.000655	-0.29	-0.21	Obesity (extreme);	chr10:37714568	chr10:37775371~37784131:-
THCA	cis	rs9902453	0.78	rs3115093	ENSG00000263370.1	RP11-68I3.5	4.58	6.08e-06	0.000655	0.27	0.21	Coffee consumption (cups per day);	chr17:29712737	chr17:29639627~29640825:+
THCA	cis	rs36715	0.953	rs2546146	ENSG00000245937.6	LINC01184	4.58	6.08e-06	0.000655	0.22	0.21	Breast cancer;	chr5:128210847	chr5:127940426~128083172:-
THCA	cis	rs9900062	0.586	rs11653958	ENSG00000270714.1	MINOS1P2	-4.58	6.09e-06	0.000655	-0.3	-0.21	QT interval;	chr17:64690612	chr17:64747264~64747492:-
THCA	cis	rs4713118	0.696	rs2394002	ENSG00000226314.6	ZNF192P1	-4.58	6.09e-06	0.000655	-0.27	-0.21	Parkinson's disease;	chr6:27780236	chr6:28161781~28169594:+
THCA	cis	rs944289	0.589	rs847514	ENSG00000258844.1	RP11-259K15.2	-4.58	6.09e-06	0.000655	-0.19	-0.21	Thyroid cancer;	chr14:36060904	chr14:36214607~36235608:+
THCA	cis	rs2836974	0.584	rs34436313	ENSG00000255568.3	BRWD1-AS2	-4.58	6.09e-06	0.000655	-0.17	-0.21	Cognitive function;	chr21:39313320	chr21:39313935~39314962:+
THCA	cis	rs6921919	0.583	rs3734563	ENSG00000280107.1	AL022393.9	-4.58	6.09e-06	0.000655	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28170845~28172521:+
THCA	cis	rs6921919	0.583	rs1591913	ENSG00000280107.1	AL022393.9	-4.58	6.09e-06	0.000655	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28170845~28172521:+
THCA	cis	rs2734839	0.964	rs4587762	ENSG00000270179.1	RP11-159N11.4	-4.58	6.09e-06	0.000655	-0.22	-0.21	Information processing speed;	chr11:113436171	chr11:113368478~113369117:+
THCA	cis	rs2562456	0.833	rs55920089	ENSG00000268117.1	VN1R84P	4.58	6.09e-06	0.000655	0.33	0.21	Pain;	chr19:21337891	chr19:21719801~21720035:-
THCA	cis	rs944289	0.74	rs398501	ENSG00000258844.1	RP11-259K15.2	4.58	6.09e-06	0.000655	0.18	0.21	Thyroid cancer;	chr14:36078452	chr14:36214607~36235608:+
THCA	cis	rs7615952	0.575	rs35949599	ENSG00000272840.1	RP11-379B18.6	4.58	6.09e-06	0.000656	0.32	0.21	Blood pressure (smoking interaction);	chr3:125825359	chr3:125774714~125797953:+
THCA	cis	rs800160	1	rs708152	ENSG00000199550.1	Y_RNA	4.58	6.09e-06	0.000656	0.31	0.21	Bacteremia;	chr11:2363118	chr11:2372638~2372750:+
THCA	cis	rs2243480	1	rs313813	ENSG00000164669.11	INTS4P1	4.58	6.09e-06	0.000656	0.4	0.21	Diabetic kidney disease;	chr7:66038513	chr7:65141225~65234216:+
THCA	cis	rs4415084	0.68	rs4495192	ENSG00000272335.1	RP11-53O19.3	4.58	6.09e-06	0.000656	0.18	0.21	Breast cancer;	chr5:44929075	chr5:44826076~44828592:+
THCA	cis	rs9902453	0.765	rs3102562	ENSG00000263370.1	RP11-68I3.5	4.58	6.09e-06	0.000656	0.27	0.21	Coffee consumption (cups per day);	chr17:29713385	chr17:29639627~29640825:+
THCA	cis	rs7851660	0.874	rs7847010	ENSG00000214417.4	KRT18P13	-4.58	6.1e-06	0.000656	-0.19	-0.21	Strep throat;	chr9:97868157	chr9:97698922~97700734:+
THCA	cis	rs8020095	1	rs7152001	ENSG00000258561.1	RP11-72M17.1	-4.58	6.1e-06	0.000656	-0.27	-0.21	Depression (quantitative trait);	chr14:66994631	chr14:66212810~66509394:-
THCA	cis	rs7618915	0.621	rs6788993	ENSG00000243224.1	RP5-1157M23.2	-4.58	6.1e-06	0.000656	-0.22	-0.21	Bipolar disorder;	chr3:52571120	chr3:52239258~52241097:+
THCA	cis	rs7647973	0.6	rs12631989	ENSG00000229759.1	MRPS18AP1	4.58	6.1e-06	0.000656	0.26	0.21	Menarche (age at onset);	chr3:49236563	chr3:48256350~48256938:-
THCA	cis	rs7647973	0.6	rs13064780	ENSG00000229759.1	MRPS18AP1	4.58	6.1e-06	0.000656	0.26	0.21	Menarche (age at onset);	chr3:49237393	chr3:48256350~48256938:-
THCA	cis	rs11722228	1	rs4697695	ENSG00000261490.1	RP11-448G15.3	4.58	6.1e-06	0.000656	0.14	0.21	Urate levels;Serum uric acid levels;Gout;	chr4:9914226	chr4:10068089~10073019:-
THCA	cis	rs9973361	0.531	rs13413443	ENSG00000232411.1	AC009495.3	-4.58	6.1e-06	0.000656	-0.26	-0.21	Total body bone mineral density;	chr2:165816439	chr2:165833048~165839098:-
THCA	cis	rs11148252	0.553	rs9536219	ENSG00000273784.3	RP11-78J21.7	-4.58	6.1e-06	0.000656	-0.23	-0.21	Lewy body disease;	chr13:52653166	chr13:52600042~52642542:+
THCA	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-4.58	6.1e-06	0.000656	-0.23	-0.21	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
THCA	cis	rs62158800	0.85	rs62158796	ENSG00000224568.1	AC096669.3	4.57	6.1e-06	0.000657	0.39	0.21	Facial morphology (factor 22);	chr2:107581616	chr2:107529487~107556326:+
THCA	cis	rs9847710	0.967	rs4687694	ENSG00000242142.1	SERBP1P3	4.57	6.1e-06	0.000657	0.24	0.21	Ulcerative colitis;	chr3:53015031	chr3:53064283~53065091:-
THCA	cis	rs5758511	0.68	rs5758687	ENSG00000227370.1	RP4-669P10.19	4.57	6.1e-06	0.000657	0.23	0.21	Birth weight;	chr22:42260582	chr22:42132543~42132998:+
THCA	cis	rs7665090	0.87	rs227361	ENSG00000248971.2	KRT8P46	-4.57	6.1e-06	0.000657	-0.24	-0.21	Primary biliary cholangitis;	chr4:102665820	chr4:102728746~102730171:-
THCA	cis	rs7829975	0.711	rs4481596	ENSG00000233609.3	RP11-62H7.2	4.57	6.11e-06	0.000657	0.2	0.21	Mood instability;	chr8:8846820	chr8:8961200~8979025:+
THCA	cis	rs807029	0.577	rs11190787	ENSG00000236662.1	RP11-108L7.4	4.57	6.11e-06	0.000657	0.22	0.21	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100980507~100985614:-
THCA	cis	rs13034020	0.522	rs62150978	ENSG00000271889.1	RP11-493E12.1	-4.57	6.11e-06	0.000657	-0.26	-0.21	Hodgkin's lymphoma;	chr2:61029087	chr2:61151433~61162105:-
THCA	cis	rs7618915	1	rs7618915	ENSG00000243224.1	RP5-1157M23.2	-4.57	6.11e-06	0.000657	-0.22	-0.21	Bipolar disorder;	chr3:52245578	chr3:52239258~52241097:+
THCA	cis	rs867186	1	rs60866116	ENSG00000126005.14	MMP24-AS1	-4.57	6.11e-06	0.000657	-0.32	-0.21	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35138347	chr20:35216462~35278131:-
THCA	cis	rs10875746	0.903	rs11168370	ENSG00000269514.1	RP11-370I10.12	4.57	6.11e-06	0.000657	0.18	0.21	Longevity (90 years and older);	chr12:48041497	chr12:48198387~48202031:+
THCA	cis	rs9910055	0.615	rs189049	ENSG00000267080.4	ASB16-AS1	4.57	6.11e-06	0.000657	0.19	0.21	Total body bone mineral density;	chr17:44119845	chr17:44175973~44186717:-
THCA	cis	rs12497850	0.931	rs6446205	ENSG00000228638.1	FCF1P2	-4.57	6.11e-06	0.000657	-0.22	-0.21	Parkinson's disease;	chr3:48997778	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.897	rs6795025	ENSG00000228638.1	FCF1P2	-4.57	6.11e-06	0.000657	-0.22	-0.21	Parkinson's disease;	chr3:49043814	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.897	rs7432989	ENSG00000228638.1	FCF1P2	-4.57	6.11e-06	0.000657	-0.22	-0.21	Parkinson's disease;	chr3:49067703	chr3:48290793~48291375:-
THCA	cis	rs1536827	0.748	rs1329153	ENSG00000278518.1	RP11-108K14.12	4.57	6.11e-06	0.000658	0.46	0.21	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr10:133492174	chr10:133526259~133527513:-
THCA	cis	rs8064024	0.599	rs882235	ENSG00000267077.1	RP11-127I20.5	4.57	6.11e-06	0.000658	0.24	0.21	Cancer;	chr16:4881650	chr16:4795265~4796532:-
THCA	cis	rs2070488	0.965	rs1984312	ENSG00000229589.1	ACVR2B-AS1	-4.57	6.11e-06	0.000658	-0.19	-0.21	Electrocardiographic conduction measures;	chr3:38496975	chr3:38451027~38454820:-
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000185485.13	SDHAP1	4.57	6.11e-06	0.000658	0.18	0.21	Pancreatic cancer;	chr3:196024568	chr3:195959748~195990318:-
THCA	cis	rs12478296	0.786	rs28802397	ENSG00000220804.7	AC093642.5	4.57	6.12e-06	0.000658	0.23	0.21	Obesity-related traits;	chr2:242107579	chr2:242088633~242160153:+
THCA	cis	rs6832769	1	rs1522108	ENSG00000272969.1	RP11-528I4.2	4.57	6.12e-06	0.000658	0.25	0.21	Personality dimensions;	chr4:55514566	chr4:55547112~55547889:+
THCA	cis	rs1046491	0.901	rs35002591	ENSG00000264964.1	RP11-888D10.3	4.57	6.12e-06	0.000658	0.36	0.21	Scarlet fever;	chr18:9103799	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs35587943	ENSG00000264964.1	RP11-888D10.3	4.57	6.12e-06	0.000658	0.36	0.21	Scarlet fever;	chr18:9105524	chr18:9315194~9334441:-
THCA	cis	rs10186029	0.676	rs12614406	ENSG00000270659.1	RP11-105N14.1	4.57	6.12e-06	0.000658	0.17	0.21	Systemic sclerosis;	chr2:213091079	chr2:213152970~213153659:+
THCA	cis	rs6845263	0.546	rs1426543	ENSG00000254531.1	FLJ20021	-4.57	6.12e-06	0.000658	-0.18	-0.21	Superior crus of antihelix expression;	chr4:101540871	chr4:101347780~101348883:+
THCA	cis	rs6517329	0.538	rs8126939	ENSG00000236830.5	CBR3-AS1	4.57	6.12e-06	0.000658	0.19	0.21	Schizophrenia;	chr21:36140649	chr21:36131767~36175815:-
THCA	cis	rs6517329	0.538	rs4817781	ENSG00000236830.5	CBR3-AS1	4.57	6.12e-06	0.000658	0.19	0.21	Schizophrenia;	chr21:36141298	chr21:36131767~36175815:-
THCA	cis	rs6517329	0.538	rs4817782	ENSG00000236830.5	CBR3-AS1	4.57	6.12e-06	0.000658	0.19	0.21	Schizophrenia;	chr21:36141449	chr21:36131767~36175815:-
THCA	cis	rs950776	0.616	rs3743077	ENSG00000261762.1	RP11-650L12.2	4.57	6.12e-06	0.000658	0.26	0.21	Sudden cardiac arrest;	chr15:78602554	chr15:78589123~78591276:-
THCA	cis	rs6732426	0.55	rs6544647	ENSG00000279873.2	LINC01126	4.57	6.12e-06	0.000658	0.16	0.21	Hair morphology;	chr2:43351280	chr2:43227210~43228855:+
THCA	cis	rs8028182	0.636	rs7163451	ENSG00000260274.1	RP11-817O13.8	4.57	6.12e-06	0.000659	0.15	0.21	Sudden cardiac arrest;	chr15:75568735	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs8036884	ENSG00000260274.1	RP11-817O13.8	4.57	6.12e-06	0.000659	0.15	0.21	Sudden cardiac arrest;	chr15:75570552	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.636	rs4075522	ENSG00000260274.1	RP11-817O13.8	4.57	6.12e-06	0.000659	0.15	0.21	Sudden cardiac arrest;	chr15:75571994	chr15:75368155~75369584:+
THCA	cis	rs2886497	0.895	rs67908826	ENSG00000224215.1	RP11-371A19.2	-4.57	6.12e-06	0.000659	-0.27	-0.21	Major depression and alcohol dependence;	chr10:23376874	chr10:23343957~23345181:+
THCA	cis	rs713477	0.505	rs9635232	ENSG00000258413.1	RP11-665C16.6	4.57	6.12e-06	0.000659	0.29	0.21	Pediatric bone mineral content (femoral neck);	chr14:55421162	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.79	rs7753833	ENSG00000270638.1	RP3-466P17.1	4.57	6.13e-06	0.000659	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145735570~145737218:+
THCA	cis	rs6908034	0.882	rs6456259	ENSG00000228412.5	RP4-625H18.2	4.57	6.13e-06	0.000659	0.34	0.21	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761487	chr6:19802164~19804752:-
THCA	cis	rs4714902	0.624	rs9472703	ENSG00000231769.2	RP1-8B1.4	-4.57	6.13e-06	0.000659	-0.18	-0.21	Colonoscopy-negative controls vs population controls;	chr6:46150227	chr6:46097093~46129706:-
THCA	cis	rs17772222	0.682	rs4904452	ENSG00000222990.1	RNU4-22P	-4.57	6.13e-06	0.000659	-0.25	-0.21	Coronary artery calcification;	chr14:88517329	chr14:88513498~88513663:+
THCA	cis	rs11096990	0.855	rs2566172	ENSG00000249685.1	RP11-360F5.3	-4.57	6.13e-06	0.00066	-0.27	-0.21	Cognitive function;	chr4:39150943	chr4:39133913~39135608:+
THCA	cis	rs796395	0.967	rs2798631	ENSG00000228208.5	C1orf143	4.57	6.13e-06	0.00066	0.25	0.21	Post bronchodilator FEV1/FVC ratio;	chr1:218438536	chr1:218510096~218525978:+
THCA	cis	rs2243480	0.708	rs781141	ENSG00000232559.3	GS1-124K5.12	4.57	6.13e-06	0.00066	0.3	0.21	Diabetic kidney disease;	chr7:65973566	chr7:66554588~66576923:-
THCA	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-4.57	6.13e-06	0.00066	-0.24	-0.21	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
THCA	cis	rs8049040	0.688	rs9940728	ENSG00000260886.1	TAT-AS1	4.57	6.14e-06	0.00066	0.25	0.21	Blood protein levels;	chr16:71381603	chr16:71565789~71578187:+
THCA	cis	rs9847710	0.967	rs2581824	ENSG00000242142.1	SERBP1P3	-4.57	6.14e-06	0.00066	-0.25	-0.21	Ulcerative colitis;	chr3:52988392	chr3:53064283~53065091:-
THCA	cis	rs4713118	0.539	rs200951	ENSG00000261839.1	RP1-265C24.8	4.57	6.14e-06	0.00066	0.22	0.21	Parkinson's disease;	chr6:27868152	chr6:28136849~28139678:+
THCA	cis	rs11633886	0.904	rs11636751	ENSG00000273972.1	CTD-2306A12.1	-4.57	6.14e-06	0.00066	-0.22	-0.21	Diisocyanate-induced asthma;	chr15:45811225	chr15:45702640~45703183:+
THCA	cis	rs12428035	0.686	rs4254181	ENSG00000247400.3	DNAJC3-AS1	4.57	6.14e-06	0.00066	0.19	0.21	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95881517	chr13:95648733~95676925:-
THCA	cis	rs67478160	0.643	rs11847468	ENSG00000269910.1	RP11-73M18.10	4.57	6.14e-06	0.000661	0.18	0.21	Schizophrenia;	chr14:103753958	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.595	rs67768834	ENSG00000269910.1	RP11-73M18.10	4.57	6.14e-06	0.000661	0.18	0.21	Schizophrenia;	chr14:103754748	chr14:103694516~103695050:-
THCA	cis	rs17095355	0.818	rs12268910	ENSG00000203876.8	ADD3-AS1	-4.57	6.15e-06	0.000661	-0.22	-0.21	Biliary atresia;	chr10:110118752	chr10:109940104~110008381:-
THCA	cis	rs7829975	0.66	rs10093926	ENSG00000254153.1	CTA-398F10.2	4.57	6.15e-06	0.000661	0.22	0.21	Mood instability;	chr8:8691510	chr8:8456909~8461337:-
THCA	cis	rs72615157	0.716	rs75779608	ENSG00000242294.5	STAG3L5P	4.57	6.15e-06	0.000661	0.13	0.21	Lung function (FEV1/FVC);	chr7:100171334	chr7:100336079~100351900:+
THCA	cis	rs2243480	0.706	rs6460257	ENSG00000232559.3	GS1-124K5.12	4.57	6.15e-06	0.000661	0.27	0.21	Diabetic kidney disease;	chr7:65731813	chr7:66554588~66576923:-
THCA	cis	rs73108077	0.736	rs73119530	ENSG00000277112.2	RP11-755J8.1	-4.57	6.15e-06	0.000661	-0.4	-0.21	Red blood cell density in sickle cell anemia;	chr20:31258810	chr20:30681825~30723932:-
THCA	cis	rs752010	0.967	rs4083593	ENSG00000230638.4	RP11-486B10.4	-4.57	6.15e-06	0.000661	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41633912	chr1:41542069~41544310:+
THCA	cis	rs7267979	1	rs2482911	ENSG00000274973.1	RP13-401N8.7	4.57	6.15e-06	0.000661	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25845497~25845862:+
THCA	cis	rs9532669	0.926	rs9532689	ENSG00000229473.2	RGS17P1	4.57	6.15e-06	0.000662	0.25	0.21	Cervical cancer;	chr13:40957990	chr13:40992779~40993331:-
THCA	cis	rs9437689	0.53	rs12137644	ENSG00000235501.4	RP4-639F20.1	-4.57	6.15e-06	0.000662	-0.23	-0.21	Phospholipid levels (plasma);	chr1:94953523	chr1:94927566~94963270:+
THCA	cis	rs6490294	0.651	rs440	ENSG00000226469.1	ADAM1B	4.57	6.15e-06	0.000662	0.26	0.21	Mean platelet volume;	chr12:111790910	chr12:111927018~111929017:+
THCA	cis	rs11308613	1	rs11308613	ENSG00000274317.1	RP11-93G5.1	-4.57	6.15e-06	0.000662	-0.27	-0.21	Mild influenza (H1N1) infection;	chr13:37983874	chr13:37934565~38048169:+
THCA	cis	rs9380516	0.627	rs2395633	ENSG00000228559.1	RP3-340B19.3	-4.57	6.16e-06	0.000662	-0.3	-0.21	Hepatitis C induced liver fibrosis;	chr6:35599887	chr6:35544632~35545669:+
THCA	cis	rs8064024	0.68	rs8056320	ENSG00000267077.1	RP11-127I20.5	4.57	6.16e-06	0.000662	0.23	0.21	Cancer;	chr16:4868016	chr16:4795265~4796532:-
THCA	cis	rs7819412	0.745	rs2898260	ENSG00000206014.6	OR7E161P	4.57	6.16e-06	0.000662	0.24	0.21	Triglycerides;	chr8:11081980	chr8:11928597~11929563:-
THCA	cis	rs829883	0.659	rs12366950	ENSG00000227825.4	SLC9A7P1	-4.57	6.16e-06	0.000662	-0.2	-0.21	Colorectal adenoma (advanced);	chr12:98554122	chr12:98453835~98457145:-
THCA	cis	rs8062405	0.723	rs12445744	ENSG00000261766.1	RP11-22P6.2	-4.57	6.16e-06	0.000662	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.755	rs4787455	ENSG00000261766.1	RP11-22P6.2	-4.57	6.16e-06	0.000662	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28862166~28863340:-
THCA	cis	rs28374715	0.578	rs17730888	ENSG00000247556.5	OIP5-AS1	4.57	6.16e-06	0.000662	0.2	0.21	Ulcerative colitis;	chr15:41345349	chr15:41283990~41309737:+
THCA	cis	rs4660214	0.666	rs597311	ENSG00000182109.6	RP11-69E11.4	4.57	6.16e-06	0.000663	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355254	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.615	rs597708	ENSG00000182109.6	RP11-69E11.4	4.57	6.16e-06	0.000663	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355291	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs636156	ENSG00000182109.6	RP11-69E11.4	4.57	6.16e-06	0.000663	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356065	chr1:39522280~39546187:-
THCA	cis	rs9652601	0.676	rs9926615	ENSG00000274038.1	RP11-66H6.4	-4.57	6.16e-06	0.000663	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11009303	chr16:11056556~11057034:+
THCA	cis	rs849141	0.524	rs849320	ENSG00000234336.5	JAZF1-AS1	-4.57	6.16e-06	0.000663	-0.34	-0.21	Height;Hip circumference adjusted for BMI;	chr7:28169217	chr7:28180322~28243917:+
THCA	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-4.57	6.17e-06	0.000663	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-4.57	6.17e-06	0.000663	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-4.57	6.17e-06	0.000663	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-4.57	6.17e-06	0.000663	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-4.57	6.17e-06	0.000663	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
THCA	cis	rs734999	0.545	rs6698817	ENSG00000225931.3	RP3-395M20.7	-4.57	6.17e-06	0.000663	-0.25	-0.21	Ulcerative colitis;	chr1:2632744	chr1:2566410~2569888:+
THCA	cis	rs734999	0.545	rs12752515	ENSG00000225931.3	RP3-395M20.7	-4.57	6.17e-06	0.000663	-0.25	-0.21	Ulcerative colitis;	chr1:2633026	chr1:2566410~2569888:+
THCA	cis	rs11634944	1	rs55816222	ENSG00000257151.1	PWAR6	4.57	6.17e-06	0.000663	0.16	0.21	Interleukin-8 levels;	chr15:24952044	chr15:25031873~25036490:+
THCA	cis	rs4568518	0.502	rs4543441	ENSG00000279048.1	RP11-511H23.2	4.57	6.17e-06	0.000663	0.13	0.21	Measles;	chr7:17943674	chr7:17940503~17942922:+
THCA	cis	rs10256972	0.641	rs12702017	ENSG00000225146.1	AC073957.15	4.57	6.17e-06	0.000663	0.22	0.21	Endometriosis;Longevity;	chr7:1089777	chr7:1029025~1043891:+
THCA	cis	rs5742933	0.51	rs10182631	ENSG00000273240.1	RP11-455J20.3	-4.57	6.17e-06	0.000663	-0.26	-0.21	Ferritin levels;	chr2:189635233	chr2:189763859~189764456:-
THCA	cis	rs11122895	0.509	rs55937046	ENSG00000236307.2	EEF1E1P1	4.57	6.17e-06	0.000663	0.26	0.21	Allergic sensitization;	chr2:111689719	chr2:111887914~111888741:+
THCA	cis	rs11992162	0.905	rs7836953	ENSG00000270154.1	RP11-419I17.1	4.57	6.17e-06	0.000663	0.25	0.21	Monocyte count;	chr8:11978203	chr8:12476462~12477122:+
THCA	cis	rs4950322	0.57	rs72692979	ENSG00000180867.10	PDIA3P1	4.57	6.17e-06	0.000663	0.21	0.21	Protein quantitative trait loci;	chr1:147336094	chr1:147178113~147179622:+
THCA	cis	rs8062405	1	rs55991577	ENSG00000261766.1	RP11-22P6.2	-4.57	6.17e-06	0.000663	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs56358680	ENSG00000261766.1	RP11-22P6.2	-4.57	6.17e-06	0.000663	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62036626	ENSG00000261766.1	RP11-22P6.2	-4.57	6.17e-06	0.000663	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62036657	ENSG00000261766.1	RP11-22P6.2	-4.57	6.17e-06	0.000663	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs12444171	ENSG00000261766.1	RP11-22P6.2	-4.57	6.17e-06	0.000663	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs56404918	ENSG00000261766.1	RP11-22P6.2	-4.57	6.17e-06	0.000663	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs55719896	ENSG00000261766.1	RP11-22P6.2	-4.57	6.17e-06	0.000663	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs55830740	ENSG00000261766.1	RP11-22P6.2	-4.57	6.17e-06	0.000663	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28862166~28863340:-
THCA	cis	rs481331	0.8	rs6593345	ENSG00000215146.4	RP11-313J2.1	4.57	6.17e-06	0.000663	0.32	0.21	Systemic juvenile idiopathic arthritis;	chr10:42485679	chr10:42331866~42367974:-
THCA	cis	rs9487094	0.67	rs2024852	ENSG00000223537.2	RP5-919F19.5	-4.57	6.17e-06	0.000663	-0.21	-0.21	Height;	chr6:109498586	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs13203587	ENSG00000223537.2	RP5-919F19.5	-4.57	6.17e-06	0.000663	-0.21	-0.21	Height;	chr6:109499759	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs12212476	ENSG00000223537.2	RP5-919F19.5	-4.57	6.17e-06	0.000663	-0.21	-0.21	Height;	chr6:109501402	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs12198938	ENSG00000223537.2	RP5-919F19.5	-4.57	6.17e-06	0.000663	-0.21	-0.21	Height;	chr6:109501429	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs13220915	ENSG00000223537.2	RP5-919F19.5	-4.57	6.17e-06	0.000663	-0.21	-0.21	Height;	chr6:109503623	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.626	rs10457192	ENSG00000223537.2	RP5-919F19.5	-4.57	6.17e-06	0.000663	-0.21	-0.21	Height;	chr6:109507271	chr6:109487906~109506800:+
THCA	cis	rs7772486	0.79	rs6570723	ENSG00000270638.1	RP3-466P17.1	4.57	6.17e-06	0.000663	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs6570724	ENSG00000270638.1	RP3-466P17.1	4.57	6.17e-06	0.000663	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs6917135	ENSG00000270638.1	RP3-466P17.1	4.57	6.17e-06	0.000663	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145735570~145737218:+
THCA	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	4.57	6.17e-06	0.000664	0.21	0.21	Height;	chr5:36887793	chr5:36666214~36725195:-
THCA	cis	rs72843506	0.527	rs76860197	ENSG00000261033.1	RP11-209D14.2	4.57	6.17e-06	0.000664	0.39	0.21	Schizophrenia;	chr17:19933383	chr17:20008051~20009234:-
THCA	cis	rs9475752	0.744	rs62411427	ENSG00000231441.1	RP11-472M19.2	4.57	6.18e-06	0.000664	0.23	0.21	Menarche (age at onset);	chr6:56936418	chr6:56844002~56864078:+
THCA	cis	rs2562456	0.833	rs7260065	ENSG00000268117.1	VN1R84P	4.57	6.18e-06	0.000664	0.33	0.21	Pain;	chr19:21334175	chr19:21719801~21720035:-
THCA	cis	rs7074356	0.523	rs7087728	ENSG00000242600.5	MBL1P	4.57	6.18e-06	0.000664	0.22	0.21	Borderline personality disorder;	chr10:80273714	chr10:79904898~79950336:+
THCA	cis	rs453301	0.571	rs2929305	ENSG00000253981.4	ALG1L13P	-4.57	6.18e-06	0.000664	-0.19	-0.21	Joint mobility (Beighton score);	chr8:9227707	chr8:8236003~8244667:-
THCA	cis	rs11846409	0.872	rs2516914	ENSG00000211974.3	IGHV2-70	4.57	6.18e-06	0.000664	0.19	0.21	Rheumatic heart disease;	chr14:106629835	chr14:106723574~106724093:-
THCA	cis	rs667920	0.557	rs35849216	ENSG00000273486.1	RP11-731C17.2	-4.57	6.18e-06	0.000664	-0.28	-0.21	Coronary artery disease;	chr3:136608727	chr3:136837338~136839021:-
THCA	cis	rs4948275	0.693	rs2787705	ENSG00000237233.2	TMEM26-AS1	-4.57	6.18e-06	0.000665	-0.27	-0.21	Night sleep phenotypes;	chr10:61554198	chr10:61452639~61481956:+
THCA	cis	rs1003719	0.762	rs8130846	ENSG00000230366.8	DSCR9	-4.57	6.19e-06	0.000665	-0.21	-0.21	Eye color traits;	chr21:37107942	chr21:37208503~37221736:+
THCA	cis	rs17801127	0.818	rs16827311	ENSG00000231969.1	AC144449.1	4.57	6.19e-06	0.000665	0.35	0.21	Liver enzyme levels (alanine transaminase);	chr2:149666306	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.748	rs79717439	ENSG00000231969.1	AC144449.1	4.57	6.19e-06	0.000665	0.35	0.21	Liver enzyme levels (alanine transaminase);	chr2:149668550	chr2:149587196~149848233:+
THCA	cis	rs172166	0.516	rs1225715	ENSG00000261839.1	RP1-265C24.8	-4.57	6.19e-06	0.000665	-0.2	-0.21	Cardiac Troponin-T levels;	chr6:28145595	chr6:28136849~28139678:+
THCA	cis	rs7809950	0.798	rs2701684	ENSG00000238832.1	snoU109	4.57	6.19e-06	0.000665	0.22	0.21	Coronary artery disease;	chr7:107659082	chr7:107603363~107603507:+
THCA	cis	rs2777491	0.957	rs1757454	ENSG00000247556.5	OIP5-AS1	4.57	6.19e-06	0.000665	0.17	0.21	Ulcerative colitis;	chr15:41485736	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.874	rs1655556	ENSG00000247556.5	OIP5-AS1	4.57	6.19e-06	0.000665	0.17	0.21	Ulcerative colitis;	chr15:41485737	chr15:41283990~41309737:+
THCA	cis	rs10761482	0.645	rs10761498	ENSG00000254271.1	RP11-131N11.4	4.57	6.19e-06	0.000665	0.28	0.21	Schizophrenia;	chr10:60423627	chr10:60734342~60741828:+
THCA	cis	rs146699004	1	rs146699004	ENSG00000263531.1	RP13-753N3.1	-4.57	6.19e-06	0.000665	-0.29	-0.21	Breast cancer;	chr17:30903504	chr17:30863921~30864940:-
THCA	cis	rs763121	0.819	rs138700	ENSG00000228274.3	RP3-508I15.9	-4.57	6.19e-06	0.000665	-0.23	-0.21	Menopause (age at onset);	chr22:38733994	chr22:38667585~38681820:-
THCA	cis	rs752010	0.714	rs7513753	ENSG00000230638.4	RP11-486B10.4	-4.57	6.19e-06	0.000666	-0.22	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41613561	chr1:41542069~41544310:+
THCA	cis	rs2281603	0.762	rs61987035	ENSG00000259116.1	RP11-973N13.4	-4.57	6.2e-06	0.000666	-0.2	-0.21	Lymphocyte counts;	chr14:64571149	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.762	rs10150987	ENSG00000259116.1	RP11-973N13.4	-4.57	6.2e-06	0.000666	-0.2	-0.21	Lymphocyte counts;	chr14:64571472	chr14:64514154~64540368:-
THCA	cis	rs2839186	0.771	rs13049175	ENSG00000215424.8	MCM3AP-AS1	-4.57	6.2e-06	0.000666	-0.12	-0.21	Testicular germ cell tumor;	chr21:46221412	chr21:46229217~46259390:+
THCA	cis	rs801193	0.967	rs3800823	ENSG00000229886.1	RP5-1132H15.3	-4.57	6.2e-06	0.000666	-0.21	-0.21	Aortic root size;	chr7:66682123	chr7:66025126~66031544:-
THCA	cis	rs172166	0.538	rs1150686	ENSG00000220721.1	OR1F12	4.57	6.2e-06	0.000666	0.23	0.21	Cardiac Troponin-T levels;	chr6:28193493	chr6:28073316~28074233:+
THCA	cis	rs1150688	1	rs1150688	ENSG00000220721.1	OR1F12	4.57	6.2e-06	0.000666	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28073316~28074233:+
THCA	cis	rs964611	0.882	rs10851465	ENSG00000259488.2	RP11-154J22.1	4.57	6.2e-06	0.000666	0.19	0.21	Metabolite levels (Pyroglutamine);	chr15:48337687	chr15:48312353~48331856:-
THCA	cis	rs9878978	0.754	rs6787193	ENSG00000237990.3	CNTN4-AS1	4.57	6.2e-06	0.000666	0.24	0.21	Blood pressure (smoking interaction);	chr3:2394450	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.754	rs6774579	ENSG00000237990.3	CNTN4-AS1	4.57	6.2e-06	0.000666	0.24	0.21	Blood pressure (smoking interaction);	chr3:2394578	chr3:3039033~3069242:-
THCA	cis	rs10911902	0.643	rs16825335	ENSG00000229739.2	RP11-295K2.3	-4.57	6.2e-06	0.000666	-0.31	-0.21	Schizophrenia;	chr1:186418612	chr1:186435161~186470291:+
THCA	cis	rs10483853	0.806	rs10151605	ENSG00000258695.2	RP3-414A15.2	-4.57	6.2e-06	0.000666	-0.29	-0.21	Coronary artery calcification;	chr14:73417109	chr14:73522878~73530610:+
THCA	cis	rs734999	0.588	rs2843404	ENSG00000225931.3	RP3-395M20.7	-4.57	6.21e-06	0.000667	-0.25	-0.21	Ulcerative colitis;	chr1:2599119	chr1:2566410~2569888:+
THCA	cis	rs734999	0.588	rs2764848	ENSG00000225931.3	RP3-395M20.7	-4.57	6.21e-06	0.000667	-0.25	-0.21	Ulcerative colitis;	chr1:2599255	chr1:2566410~2569888:+
THCA	cis	rs8062405	0.755	rs62034358	ENSG00000261766.1	RP11-22P6.2	-4.57	6.21e-06	0.000667	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.755	rs12445823	ENSG00000261766.1	RP11-22P6.2	-4.57	6.21e-06	0.000667	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28862166~28863340:-
THCA	cis	rs9878978	0.964	rs11718236	ENSG00000237990.3	CNTN4-AS1	4.57	6.21e-06	0.000667	0.23	0.21	Blood pressure (smoking interaction);	chr3:2436948	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.964	rs11707598	ENSG00000237990.3	CNTN4-AS1	4.57	6.21e-06	0.000667	0.23	0.21	Blood pressure (smoking interaction);	chr3:2437273	chr3:3039033~3069242:-
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000229180.5	GS1-124K5.11	4.57	6.21e-06	0.000667	0.17	0.21	Corneal structure;	chr7:66813271	chr7:66526088~66542624:-
THCA	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-4.57	6.21e-06	0.000667	-0.31	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
THCA	cis	rs9867325	1	rs9867325	ENSG00000239213.4	NCK1-AS1	4.57	6.21e-06	0.000667	0.23	0.21	Body mass index;	chr3:136900067	chr3:136841726~136862054:-
THCA	cis	rs9867325	1	rs9840500	ENSG00000239213.4	NCK1-AS1	4.57	6.21e-06	0.000667	0.23	0.21	Body mass index;	chr3:136902496	chr3:136841726~136862054:-
THCA	cis	rs10090774	0.71	rs13264524	ENSG00000280303.2	ERICD	-4.57	6.21e-06	0.000667	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140644559	chr8:140636281~140638283:+
THCA	cis	rs72717009	0.825	rs7529225	ENSG00000225217.1	HSPA7	-4.57	6.21e-06	0.000667	-0.32	-0.21	Rheumatoid arthritis;	chr1:161509562	chr1:161606291~161608217:+
THCA	cis	rs1046491	1	rs71362073	ENSG00000264964.1	RP11-888D10.3	4.57	6.21e-06	0.000667	0.35	0.21	Scarlet fever;	chr18:9208548	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs62085924	ENSG00000264964.1	RP11-888D10.3	4.57	6.21e-06	0.000667	0.35	0.21	Scarlet fever;	chr18:9209456	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs6506647	ENSG00000264964.1	RP11-888D10.3	4.57	6.21e-06	0.000667	0.35	0.21	Scarlet fever;	chr18:9240901	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs8086362	ENSG00000264964.1	RP11-888D10.3	4.57	6.21e-06	0.000667	0.35	0.21	Scarlet fever;	chr18:9243963	chr18:9315194~9334441:-
THCA	cis	rs7726839	0.794	rs10474792	ENSG00000225138.6	CTD-2228K2.7	4.57	6.22e-06	0.000668	0.23	0.21	Obesity-related traits;	chr5:599943	chr5:473236~480884:+
THCA	cis	rs7772486	0.79	rs9376968	ENSG00000270638.1	RP3-466P17.1	4.57	6.22e-06	0.000668	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145735570~145737218:+
THCA	cis	rs9300255	0.679	rs4759409	ENSG00000235423.7	RP11-282O18.3	4.57	6.22e-06	0.000668	0.22	0.21	Neutrophil percentage of white cells;	chr12:123235038	chr12:123252030~123261483:-
THCA	cis	rs1979679	0.842	rs4931730	ENSG00000247934.4	RP11-967K21.1	-4.57	6.22e-06	0.000668	-0.2	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146343	chr12:28163298~28190738:-
THCA	cis	rs4845875	0.504	rs198396	ENSG00000242349.4	NPPA-AS1	-4.57	6.22e-06	0.000668	-0.22	-0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11821263	chr1:11841017~11848079:+
THCA	cis	rs8067545	0.75	rs11871651	ENSG00000270091.1	RP11-78O7.2	-4.57	6.22e-06	0.000668	-0.15	-0.21	Schizophrenia;	chr17:20094112	chr17:19896590~19897287:-
THCA	cis	rs734999	0.967	rs10797434	ENSG00000225931.3	RP3-395M20.7	4.57	6.22e-06	0.000668	0.25	0.21	Ulcerative colitis;	chr1:2579841	chr1:2566410~2569888:+
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000229180.5	GS1-124K5.11	4.57	6.22e-06	0.000668	0.16	0.21	Corneal structure;	chr7:66894282	chr7:66526088~66542624:-
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000229180.5	GS1-124K5.11	4.57	6.22e-06	0.000668	0.16	0.21	Corneal structure;	chr7:66896631	chr7:66526088~66542624:-
THCA	cis	rs919433	0.617	rs4850436	ENSG00000231621.1	AC013264.2	4.57	6.23e-06	0.000669	0.22	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197676674	chr2:197197991~197199273:+
THCA	cis	rs763121	0.853	rs3827357	ENSG00000273076.1	RP3-508I15.22	4.57	6.23e-06	0.000669	0.21	0.21	Menopause (age at onset);	chr22:38683408	chr22:38743495~38743910:+
THCA	cis	rs11668609	0.515	rs11670600	ENSG00000268442.1	CTD-2027I19.2	4.57	6.23e-06	0.000669	0.31	0.21	Response to taxane treatment (docetaxel);	chr19:23782120	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs74612410	ENSG00000268442.1	CTD-2027I19.2	4.57	6.23e-06	0.000669	0.31	0.21	Response to taxane treatment (placlitaxel);	chr19:23785148	chr19:24162370~24163425:-
THCA	cis	rs642803	1	rs557675	ENSG00000255557.1	RP11-770G2.2	4.57	6.24e-06	0.000669	0.22	0.21	Urate levels;	chr11:65799248	chr11:65745729~65771585:+
THCA	cis	rs11853189	0.938	rs113594982	ENSG00000259562.2	RP11-762H8.2	4.57	6.24e-06	0.00067	0.2	0.21	Red cell distribution width;	chr15:78265050	chr15:78290527~78291221:-
THCA	cis	rs9875589	0.509	rs1873005	ENSG00000228242.5	AC093495.4	4.57	6.24e-06	0.00067	0.12	0.21	Ovarian reserve;	chr3:14018723	chr3:14144637~14165978:+
THCA	cis	rs9875589	0.509	rs7614591	ENSG00000228242.5	AC093495.4	4.57	6.24e-06	0.00067	0.12	0.21	Ovarian reserve;	chr3:14019618	chr3:14144637~14165978:+
THCA	cis	rs6921919	0.583	rs7764722	ENSG00000280107.1	AL022393.9	-4.57	6.24e-06	0.00067	-0.21	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28170845~28172521:+
THCA	cis	rs9380516	0.627	rs4401662	ENSG00000228559.1	RP3-340B19.3	-4.57	6.24e-06	0.00067	-0.29	-0.21	Hepatitis C induced liver fibrosis;	chr6:35616278	chr6:35544632~35545669:+
THCA	cis	rs7267979	0.702	rs449801	ENSG00000274414.1	RP5-965G21.4	-4.57	6.24e-06	0.00067	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:25239007~25245229:-
THCA	cis	rs2436845	1	rs2436845	ENSG00000253669.3	KB-1732A1.1	-4.57	6.24e-06	0.00067	-0.21	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102840179	chr8:102805517~102809971:+
THCA	cis	rs2436845	1	rs2436846	ENSG00000253669.3	KB-1732A1.1	-4.57	6.24e-06	0.00067	-0.21	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102840181	chr8:102805517~102809971:+
THCA	cis	rs2436845	1	rs2513913	ENSG00000253669.3	KB-1732A1.1	-4.57	6.24e-06	0.00067	-0.21	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102842878	chr8:102805517~102809971:+
THCA	cis	rs1979679	0.842	rs4931729	ENSG00000247934.4	RP11-967K21.1	-4.57	6.25e-06	0.00067	-0.2	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146306	chr12:28163298~28190738:-
THCA	cis	rs2842992	0.747	rs4709379	ENSG00000237927.1	RP3-393E18.2	-4.57	6.25e-06	0.000671	-0.33	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159806498	chr6:159586955~159589169:-
THCA	cis	rs6921919	0.583	rs6928771	ENSG00000280107.1	AL022393.9	-4.57	6.25e-06	0.000671	-0.2	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28170845~28172521:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000229886.1	RP5-1132H15.3	4.57	6.25e-06	0.000671	0.21	0.21	Calcium levels;	chr7:65996954	chr7:66025126~66031544:-
THCA	cis	rs9926296	0.581	rs12598477	ENSG00000260259.1	RP11-368I7.4	-4.57	6.25e-06	0.000671	-0.22	-0.21	Vitiligo;	chr16:89836074	chr16:89682620~89686569:-
THCA	cis	rs2562456	0.833	rs7246339	ENSG00000268117.1	VN1R84P	4.57	6.25e-06	0.000671	0.34	0.21	Pain;	chr19:21292495	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs55899865	ENSG00000268117.1	VN1R84P	4.57	6.25e-06	0.000671	0.34	0.21	Pain;	chr19:21298933	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs11667103	ENSG00000268117.1	VN1R84P	4.57	6.25e-06	0.000671	0.34	0.21	Pain;	chr19:21303839	chr19:21719801~21720035:-
THCA	cis	rs5758659	0.594	rs739292	ENSG00000227370.1	RP4-669P10.19	-4.57	6.25e-06	0.000671	-0.2	-0.21	Cognitive function;	chr22:41972853	chr22:42132543~42132998:+
THCA	cis	rs2011503	0.509	rs884480	ENSG00000271283.1	CTC-412M14.6	4.57	6.25e-06	0.000671	0.34	0.21	Bipolar disorder;	chr19:19663114	chr19:19699203~19699409:-
THCA	cis	rs2011503	0.509	rs73006705	ENSG00000271283.1	CTC-412M14.6	4.57	6.25e-06	0.000671	0.34	0.21	Bipolar disorder;	chr19:19671108	chr19:19699203~19699409:-
THCA	cis	rs3734266	0.536	rs6925175	ENSG00000272288.4	RP11-140K17.3	-4.57	6.25e-06	0.000671	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34864518	chr6:34696317~34697470:+
THCA	cis	rs9880211	0.948	rs1604793	ENSG00000239213.4	NCK1-AS1	4.57	6.25e-06	0.000671	0.23	0.21	Height;Body mass index;	chr3:136462228	chr3:136841726~136862054:-
THCA	cis	rs17772222	0.675	rs845758	ENSG00000258983.2	RP11-507K2.2	-4.57	6.26e-06	0.000671	-0.23	-0.21	Coronary artery calcification;	chr14:88433746	chr14:88499334~88515502:+
THCA	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-4.57	6.26e-06	0.000671	-0.32	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-4.57	6.26e-06	0.000671	-0.32	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
THCA	cis	rs270601	0.837	rs367805	ENSG00000224431.1	AC063976.7	4.57	6.26e-06	0.000671	0.18	0.21	Acylcarnitine levels;	chr5:132365587	chr5:132199456~132203487:+
THCA	cis	rs375066	0.934	rs411803	ENSG00000278917.1	RP11-15A1.4	4.57	6.26e-06	0.000671	0.17	0.21	Breast cancer;	chr19:43928688	chr19:43891233~43895411:+
THCA	cis	rs4950322	0.57	rs79810882	ENSG00000271721.1	RP11-337C18.9	4.57	6.26e-06	0.000672	0.23	0.21	Protein quantitative trait loci;	chr1:147235575	chr1:147175602~147177740:+
THCA	cis	rs1334894	1	rs72913427	ENSG00000228559.1	RP3-340B19.3	-4.57	6.26e-06	0.000672	-0.43	-0.21	Coronary artery disease;	chr6:35614026	chr6:35544632~35545669:+
THCA	cis	rs9902453	0.791	rs3098950	ENSG00000263370.1	RP11-68I3.5	4.57	6.26e-06	0.000672	0.26	0.21	Coffee consumption (cups per day);	chr17:29671367	chr17:29639627~29640825:+
THCA	cis	rs763121	0.853	rs4821808	ENSG00000235209.1	CTA-150C2.13	4.57	6.26e-06	0.000672	0.27	0.21	Menopause (age at onset);	chr22:38669734	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs4821809	ENSG00000235209.1	CTA-150C2.13	4.57	6.26e-06	0.000672	0.27	0.21	Menopause (age at onset);	chr22:38669738	chr22:38921227~38924708:+
THCA	cis	rs12541437	0.958	rs3020168	ENSG00000253327.2	RAD21-AS1	4.57	6.26e-06	0.000672	0.23	0.21	Gut microbiome composition (winter);	chr8:116918578	chr8:116874424~116876868:+
THCA	cis	rs12541437	0.958	rs2921733	ENSG00000253327.2	RAD21-AS1	4.57	6.26e-06	0.000672	0.23	0.21	Gut microbiome composition (winter);	chr8:116922600	chr8:116874424~116876868:+
THCA	cis	rs6569992	0.5	rs75623964	ENSG00000232876.1	CTA-212D2.2	-4.57	6.26e-06	0.000672	-0.31	-0.21	Red blood cell traits;	chr6:135147172	chr6:135055033~135060550:+
THCA	cis	rs17221829	0.627	rs1844202	ENSG00000280385.1	AP000648.5	-4.57	6.27e-06	0.000672	-0.2	-0.21	Anxiety in major depressive disorder;	chr11:89687001	chr11:90193614~90198120:+
THCA	cis	rs4925386	0.759	rs2427293	ENSG00000273619.1	RP5-908M14.9	4.57	6.27e-06	0.000672	0.18	0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62386303~62386970:-
THCA	cis	rs6477918	0.598	rs7866567	ENSG00000230185.4	C9orf147	-4.57	6.27e-06	0.000673	-0.22	-0.21	Obstetric antiphospholipid syndrome;	chr9:112437545	chr9:112433816~112487204:-
THCA	cis	rs4081724	0.63	rs17529595	ENSG00000267296.2	CEBPA-AS1	4.57	6.27e-06	0.000673	0.33	0.21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33315233	chr19:33302857~33305054:+
THCA	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-4.57	6.27e-06	0.000673	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
THCA	cis	rs7474896	0.583	rs12776092	ENSG00000226578.1	RP11-258F22.1	-4.57	6.27e-06	0.000673	-0.29	-0.21	Obesity (extreme);	chr10:37726867	chr10:37775371~37784131:-
THCA	cis	rs7474896	0.583	rs11011347	ENSG00000226578.1	RP11-258F22.1	-4.57	6.27e-06	0.000673	-0.29	-0.21	Obesity (extreme);	chr10:37730336	chr10:37775371~37784131:-
THCA	cis	rs925946	0.666	rs11030107	ENSG00000245573.6	BDNF-AS	-4.57	6.27e-06	0.000673	-0.22	-0.21	Weight;Body mass index;	chr11:27673288	chr11:27506838~27698174:+
THCA	cis	rs2835345	0.507	rs7280011	ENSG00000230479.1	AP000695.6	4.57	6.27e-06	0.000673	0.24	0.21	Pulmonary function;	chr21:36455256	chr21:36430360~36481070:+
THCA	cis	rs763121	0.889	rs9610971	ENSG00000235209.1	CTA-150C2.13	4.57	6.27e-06	0.000673	0.28	0.21	Menopause (age at onset);	chr22:38514805	chr22:38921227~38924708:+
THCA	cis	rs8062405	1	rs7498555	ENSG00000261766.1	RP11-22P6.2	-4.57	6.27e-06	0.000673	-0.2	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28862166~28863340:-
THCA	cis	rs990871	0.566	rs2126077	ENSG00000227207.2	RPL31P12	4.57	6.27e-06	0.000673	0.25	0.21	Subcutaneous adipose tissue;	chr1:72246924	chr1:72301472~72301829:+
THCA	cis	rs1396485	0.607	rs10477550	ENSG00000248445.4	SEMA6A-AS1	-4.57	6.28e-06	0.000673	-0.2	-0.21	Inflammatory biomarkers;	chr5:116094060	chr5:116447547~116508276:+
THCA	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	4.57	6.28e-06	0.000674	0.25	0.21	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
THCA	cis	rs2281603	0.762	rs10130241	ENSG00000259116.1	RP11-973N13.4	-4.57	6.28e-06	0.000674	-0.2	-0.21	Lymphocyte counts;	chr14:64577402	chr14:64514154~64540368:-
THCA	cis	rs6840258	0.831	rs3755980	ENSG00000251411.1	RP11-397E7.4	4.57	6.28e-06	0.000674	0.24	0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87121099	chr4:86913266~86914817:-
THCA	cis	rs10761482	0.861	rs9988785	ENSG00000254271.1	RP11-131N11.4	4.57	6.28e-06	0.000674	0.27	0.21	Schizophrenia;	chr10:60349234	chr10:60734342~60741828:+
THCA	cis	rs6496044	0.507	rs410522	ENSG00000259407.1	RP11-158M2.3	4.57	6.28e-06	0.000674	0.22	0.21	Interstitial lung disease;	chr15:85663813	chr15:85744109~85750281:-
THCA	cis	rs17597773	0.755	rs4431850	ENSG00000272823.1	RP11-295M18.6	-4.57	6.28e-06	0.000674	-0.29	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220847172	chr1:220828676~220829211:-
THCA	cis	rs9863	0.861	rs10846580	ENSG00000270061.1	RP11-214K3.19	-4.57	6.28e-06	0.000674	-0.28	-0.21	White blood cell count;	chr12:123930906	chr12:123969990~123970344:-
THCA	cis	rs56046484	0.789	rs896364	ENSG00000259295.5	CSPG4P12	4.57	6.28e-06	0.000674	0.35	0.21	Testicular germ cell tumor;	chr15:84976426	chr15:85191438~85213905:+
THCA	cis	rs617791	0.508	rs1047464	ENSG00000255320.1	RP11-755F10.1	4.57	6.29e-06	0.000674	0.27	0.21	Breast cancer;	chr11:66001985	chr11:66244840~66246239:-
THCA	cis	rs617791	0.508	rs2276132	ENSG00000255320.1	RP11-755F10.1	4.57	6.29e-06	0.000674	0.27	0.21	Breast cancer;	chr11:66003074	chr11:66244840~66246239:-
THCA	cis	rs6806253	0.878	rs2734046	ENSG00000239405.1	TMED10P2	-4.57	6.29e-06	0.000674	-0.35	-0.21	Pit-and-Fissure caries;	chr3:128573370	chr3:128538020~128538631:+
THCA	cis	rs10266483	0.656	rs670966	ENSG00000271550.1	BNIP3P11	4.57	6.29e-06	0.000675	0.26	0.21	Response to statin therapy;	chr7:64302521	chr7:64678954~64687393:-
THCA	cis	rs8028182	0.583	rs4886722	ENSG00000260274.1	RP11-817O13.8	4.57	6.29e-06	0.000675	0.15	0.21	Sudden cardiac arrest;	chr15:75629295	chr15:75368155~75369584:+
THCA	cis	rs73242632	0.881	rs17182939	ENSG00000269949.1	RP11-738E22.3	4.57	6.29e-06	0.000675	0.51	0.21	Congenital heart disease (maternal effect);	chr4:57060625	chr4:56960927~56961373:-
THCA	cis	rs1552244	0.766	rs34232505	ENSG00000180385.7	EMC3-AS1	4.57	6.29e-06	0.000675	0.23	0.21	Alzheimer's disease;	chr3:10144532	chr3:9986893~10006990:+
THCA	cis	rs6997458	0.813	rs3758078	ENSG00000253549.4	RP11-317J10.2	4.57	6.3e-06	0.000675	0.21	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85462435	chr8:85441851~85464915:-
THCA	cis	rs2948294	0.588	rs7011221	ENSG00000254153.1	CTA-398F10.2	-4.57	6.3e-06	0.000675	-0.23	-0.21	Red cell distribution width;	chr8:8256724	chr8:8456909~8461337:-
THCA	cis	rs2948294	0.545	rs11776397	ENSG00000254153.1	CTA-398F10.2	-4.57	6.3e-06	0.000675	-0.23	-0.21	Red cell distribution width;	chr8:8257639	chr8:8456909~8461337:-
THCA	cis	rs793571	0.628	rs2013098	ENSG00000245975.2	RP11-30K9.6	4.57	6.3e-06	0.000676	0.23	0.21	Schizophrenia;	chr15:58804600	chr15:58768072~58770974:-
THCA	cis	rs793571	0.628	rs28394222	ENSG00000245975.2	RP11-30K9.6	4.57	6.3e-06	0.000676	0.23	0.21	Schizophrenia;	chr15:58804958	chr15:58768072~58770974:-
THCA	cis	rs172166	0.516	rs1225618	ENSG00000220721.1	OR1F12	4.57	6.3e-06	0.000676	0.23	0.21	Cardiac Troponin-T levels;	chr6:28161935	chr6:28073316~28074233:+
THCA	cis	rs972578	0.677	rs9607949	ENSG00000274717.1	RP1-47A17.1	-4.57	6.31e-06	0.000676	-0.22	-0.21	Mean platelet volume;	chr22:42793826	chr22:42791814~42794313:-
THCA	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000676	-0.23	-0.21	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000676	-0.23	-0.21	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000676	-0.23	-0.21	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000676	-0.23	-0.21	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000676	-0.23	-0.21	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000676	-0.23	-0.21	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000676	-0.23	-0.21	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
THCA	cis	rs9863	0.828	rs12311848	ENSG00000270061.1	RP11-214K3.19	-4.57	6.31e-06	0.000677	-0.27	-0.21	White blood cell count;	chr12:124002304	chr12:123969990~123970344:-
THCA	cis	rs6969780	0.915	rs11983200	ENSG00000233429.8	HOTAIRM1	4.57	6.31e-06	0.000677	0.32	0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27146977	chr7:27095647~27100265:+
THCA	cis	rs9625935	0.957	rs36596	ENSG00000279159.1	RP3-394A18.1	4.57	6.31e-06	0.000677	0.16	0.21	Tonsillectomy;	chr22:29939280	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs36598	ENSG00000279159.1	RP3-394A18.1	4.57	6.31e-06	0.000677	0.16	0.21	Tonsillectomy;	chr22:29940417	chr22:29978950~30028236:-
THCA	cis	rs2692947	0.537	rs4907274	ENSG00000235584.2	AC008268.1	-4.57	6.31e-06	0.000677	-0.21	-0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95697934	chr2:95666084~95668715:+
THCA	cis	rs77637988	0.577	rs6705802	ENSG00000202227.1	RNU6-282P	4.57	6.31e-06	0.000677	0.21	0.21	Joint mobility (Beighton score);	chr2:48376344	chr2:48501922~48502024:-
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000265443.1	CTD-2349P21.6	-4.57	6.31e-06	0.000677	-0.36	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30726305~30727564:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	4.57	6.31e-06	0.000677	0.23	0.21	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	4.57	6.31e-06	0.000677	0.23	0.21	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000677	-0.23	-0.21	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000677	-0.23	-0.21	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-4.57	6.31e-06	0.000677	-0.23	-0.21	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
THCA	cis	rs3096299	0.509	rs4785691	ENSG00000261118.1	RP11-104N10.1	4.57	6.31e-06	0.000677	0.17	0.21	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89492017~89504460:-
THCA	cis	rs4715166	0.773	rs6458720	ENSG00000272379.1	RP1-257A7.5	-4.57	6.31e-06	0.000677	-0.26	-0.21	Hip geometry;	chr6:13224845	chr6:13290018~13290490:-
THCA	cis	rs6433895	0.883	rs6713632	ENSG00000236153.1	AC104076.3	-4.57	6.32e-06	0.000677	-0.23	-0.21	Lymphocyte counts;	chr2:181209271	chr2:180979427~180980090:-
THCA	cis	rs2287838	0.704	rs1862471	ENSG00000267289.1	CTD-2623N2.11	-4.57	6.32e-06	0.000677	-0.24	-0.21	Sleep duration;	chr19:9889646	chr19:9834079~9835013:-
THCA	cis	rs4415084	0.716	rs4596389	ENSG00000272335.1	RP11-53O19.3	-4.57	6.32e-06	0.000677	-0.17	-0.21	Breast cancer;	chr5:44836454	chr5:44826076~44828592:+
THCA	cis	rs3892630	0.5	rs6510301	ENSG00000267567.1	CTD-2538C1.3	4.57	6.32e-06	0.000677	0.31	0.21	Red blood cell traits;	chr19:32868885	chr19:32718298~32719595:-
THCA	cis	rs4824093	0.61	rs7410773	ENSG00000278869.1	CITF22-49E9.3	4.57	6.32e-06	0.000678	0.4	0.21	Amyotrophic lateral sclerosis (sporadic);	chr22:49920079	chr22:49933198~49934074:-
THCA	cis	rs2280018	0.963	rs12928424	ENSG00000263335.1	AF001548.5	-4.57	6.32e-06	0.000678	-0.22	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15726674~15732993:+
THCA	cis	rs41313321	0.541	rs2240956	ENSG00000273186.1	RP11-339B21.10	-4.57	6.32e-06	0.000678	-0.29	-0.21	Coenzyme Q10 levels;	chr9:128286481	chr9:128431598~128432006:+
THCA	cis	rs58235267	0.553	rs11890276	ENSG00000242412.1	DBIL5P2	-4.57	6.32e-06	0.000678	-0.23	-0.21	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:63139056	chr2:63117851~63119542:-
THCA	cis	rs1979679	0.918	rs786712	ENSG00000247934.4	RP11-967K21.1	-4.57	6.32e-06	0.000678	-0.2	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28399664	chr12:28163298~28190738:-
THCA	cis	rs1003719	0.68	rs2835630	ENSG00000230366.8	DSCR9	4.57	6.33e-06	0.000678	0.21	0.21	Eye color traits;	chr21:37149542	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs2257091	ENSG00000230366.8	DSCR9	4.57	6.33e-06	0.000678	0.21	0.21	Eye color traits;	chr21:37150318	chr21:37208503~37221736:+
THCA	cis	rs2985684	0.947	rs1952013	ENSG00000278009.1	RP11-649E7.8	4.57	6.33e-06	0.000678	0.3	0.21	Carotid intima media thickness;	chr14:49620639	chr14:49601011~49601124:-
THCA	cis	rs4948275	0.631	rs2606110	ENSG00000237233.2	TMEM26-AS1	-4.57	6.33e-06	0.000678	-0.27	-0.21	Night sleep phenotypes;	chr10:61587581	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.631	rs2606111	ENSG00000237233.2	TMEM26-AS1	-4.57	6.33e-06	0.000678	-0.27	-0.21	Night sleep phenotypes;	chr10:61588695	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.631	rs2787720	ENSG00000237233.2	TMEM26-AS1	-4.57	6.33e-06	0.000678	-0.27	-0.21	Night sleep phenotypes;	chr10:61588707	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.631	rs2606112	ENSG00000237233.2	TMEM26-AS1	-4.57	6.33e-06	0.000678	-0.27	-0.21	Night sleep phenotypes;	chr10:61588746	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.631	rs2650744	ENSG00000237233.2	TMEM26-AS1	-4.57	6.33e-06	0.000678	-0.27	-0.21	Night sleep phenotypes;	chr10:61588800	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.597	rs2606113	ENSG00000237233.2	TMEM26-AS1	-4.57	6.33e-06	0.000678	-0.27	-0.21	Night sleep phenotypes;	chr10:61589204	chr10:61452639~61481956:+
THCA	cis	rs67478160	0.654	rs1535097	ENSG00000269910.1	RP11-73M18.10	4.57	6.33e-06	0.000679	0.17	0.21	Schizophrenia;	chr14:103750312	chr14:103694516~103695050:-
THCA	cis	rs748404	0.556	rs10851414	ENSG00000249839.1	AC011330.5	4.57	6.33e-06	0.000679	0.24	0.21	Lung cancer;	chr15:43141734	chr15:43663654~43684339:-
THCA	cis	rs5753037	0.838	rs28749829	ENSG00000279699.1	RP1-102K2.9	4.57	6.33e-06	0.000679	0.21	0.21	Type 1 diabetes;	chr22:29823337	chr22:30275215~30276951:-
THCA	cis	rs758324	0.571	rs246840	ENSG00000237714.1	P4HA2-AS1	-4.57	6.33e-06	0.000679	-0.29	-0.21	Alzheimer's disease in APOE e4- carriers;	chr5:132128831	chr5:132184876~132192808:+
THCA	cis	rs2657294	0.796	rs2657290	ENSG00000226051.5	ZNF503-AS1	-4.57	6.33e-06	0.000679	-0.29	-0.21	Pneumonia;	chr10:75207404	chr10:75269819~75373500:+
THCA	cis	rs2657294	0.765	rs2804533	ENSG00000226051.5	ZNF503-AS1	-4.57	6.33e-06	0.000679	-0.29	-0.21	Pneumonia;	chr10:75207723	chr10:75269819~75373500:+
THCA	cis	rs11671005	0.735	rs11670871	ENSG00000268049.1	CTD-2619J13.9	4.57	6.34e-06	0.000679	0.32	0.21	Mean platelet volume;	chr19:58429147	chr19:58357999~58359603:+
THCA	cis	rs6137726	0.508	rs2424447	ENSG00000237396.1	LINC01384	4.57	6.34e-06	0.000679	0.18	0.21	Amyotrophic lateral sclerosis (sporadic);	chr20:22656380	chr20:22587522~22607517:-
THCA	cis	rs17685	0.712	rs10271413	ENSG00000230882.1	AC005077.14	4.57	6.34e-06	0.000679	0.2	0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76125540	chr7:76071469~76074963:-
THCA	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	4.57	6.34e-06	0.000679	0.23	0.21	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000243753.4	HLA-L	-4.57	6.34e-06	0.000679	-0.31	-0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30259584~30293014:+
THCA	cis	rs17711722	1	rs17711722	ENSG00000164669.11	INTS4P1	4.57	6.34e-06	0.00068	0.26	0.21	Calcium levels;	chr7:65806210	chr7:65141225~65234216:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000164669.11	INTS4P1	4.57	6.34e-06	0.00068	0.26	0.21	Calcium levels;	chr7:65808508	chr7:65141225~65234216:+
THCA	cis	rs9863	0.828	rs7307277	ENSG00000270061.1	RP11-214K3.19	-4.57	6.34e-06	0.00068	-0.27	-0.21	White blood cell count;	chr12:123990609	chr12:123969990~123970344:-
THCA	cis	rs9863	0.828	rs71458830	ENSG00000270061.1	RP11-214K3.19	-4.57	6.34e-06	0.00068	-0.27	-0.21	White blood cell count;	chr12:123992014	chr12:123969990~123970344:-
THCA	cis	rs9863	0.828	rs12809473	ENSG00000270061.1	RP11-214K3.19	-4.57	6.34e-06	0.00068	-0.27	-0.21	White blood cell count;	chr12:123992052	chr12:123969990~123970344:-
THCA	cis	rs9863	0.828	rs12827409	ENSG00000270061.1	RP11-214K3.19	-4.57	6.34e-06	0.00068	-0.27	-0.21	White blood cell count;	chr12:123992159	chr12:123969990~123970344:-
THCA	cis	rs9863	0.828	rs7135314	ENSG00000270061.1	RP11-214K3.19	-4.57	6.34e-06	0.00068	-0.27	-0.21	White blood cell count;	chr12:123994019	chr12:123969990~123970344:-
THCA	cis	rs9863	0.828	rs56041971	ENSG00000270061.1	RP11-214K3.19	-4.57	6.34e-06	0.00068	-0.27	-0.21	White blood cell count;	chr12:123996319	chr12:123969990~123970344:-
THCA	cis	rs2281603	0.762	rs11850291	ENSG00000259116.1	RP11-973N13.4	-4.57	6.34e-06	0.00068	-0.2	-0.21	Lymphocyte counts;	chr14:64582676	chr14:64514154~64540368:-
THCA	cis	rs8067545	0.578	rs9901336	ENSG00000270091.1	RP11-78O7.2	-4.57	6.34e-06	0.00068	-0.16	-0.21	Schizophrenia;	chr17:20160877	chr17:19896590~19897287:-
THCA	cis	rs5758511	0.68	rs5758686	ENSG00000227370.1	RP4-669P10.19	4.57	6.34e-06	0.00068	0.23	0.21	Birth weight;	chr22:42259371	chr22:42132543~42132998:+
THCA	cis	rs6921919	0.697	rs6942030	ENSG00000219392.1	RP1-265C24.5	-4.57	6.34e-06	0.00068	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28115628~28116551:+
THCA	cis	rs5742933	0.948	rs2264018	ENSG00000273240.1	RP11-455J20.3	-4.57	6.35e-06	0.00068	-0.23	-0.21	Ferritin levels;	chr2:189712052	chr2:189763859~189764456:-
THCA	cis	rs4660214	0.666	rs2275187	ENSG00000182109.6	RP11-69E11.4	-4.57	6.35e-06	0.00068	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297570	chr1:39522280~39546187:-
THCA	cis	rs7208859	0.623	rs58908911	ENSG00000280069.1	CTD-2349P21.3	-4.57	6.35e-06	0.00068	-0.34	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30738182~30740275:+
THCA	cis	rs2251188	0.565	rs2250356	ENSG00000187953.9	PMS2CL	-4.57	6.35e-06	0.00068	-0.22	-0.21	Sum basophil neutrophil counts;Neutrophil count;	chr7:6649491	chr7:6710128~6753862:+
THCA	cis	rs6701713	0.959	rs1408077	ENSG00000274245.1	RP11-357P18.2	-4.57	6.35e-06	0.00068	-0.24	-0.21	Alzheimer's disease (late onset);	chr1:207630796	chr1:207372559~207373252:+
THCA	cis	rs763121	1	rs763121	ENSG00000235209.1	CTA-150C2.13	-4.57	6.35e-06	0.00068	-0.26	-0.21	Menopause (age at onset);	chr22:38483935	chr22:38921227~38924708:+
THCA	cis	rs944289	0.708	rs2755194	ENSG00000258844.1	RP11-259K15.2	4.57	6.35e-06	0.00068	0.18	0.21	Thyroid cancer;	chr14:36079176	chr14:36214607~36235608:+
THCA	cis	rs944289	0.74	rs11156902	ENSG00000258844.1	RP11-259K15.2	4.57	6.35e-06	0.00068	0.18	0.21	Thyroid cancer;	chr14:36080016	chr14:36214607~36235608:+
THCA	cis	rs944289	0.712	rs35736442	ENSG00000258844.1	RP11-259K15.2	4.57	6.35e-06	0.00068	0.18	0.21	Thyroid cancer;	chr14:36081119	chr14:36214607~36235608:+
THCA	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-4.57	6.35e-06	0.00068	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-4.57	6.35e-06	0.00068	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-4.57	6.35e-06	0.00068	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-4.57	6.35e-06	0.00068	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-4.57	6.35e-06	0.00068	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-4.57	6.35e-06	0.00068	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
THCA	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	4.57	6.35e-06	0.000681	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
THCA	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	4.57	6.35e-06	0.000681	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
THCA	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	4.57	6.35e-06	0.000681	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
THCA	cis	rs897984	0.568	rs4889651	ENSG00000279196.1	RP11-1072A3.3	4.57	6.35e-06	0.000681	0.22	0.21	Dementia with Lewy bodies;	chr16:30884224	chr16:30984630~30988270:-
THCA	cis	rs7432375	0.61	rs4420814	ENSG00000239213.4	NCK1-AS1	4.57	6.35e-06	0.000681	0.18	0.21	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136794440	chr3:136841726~136862054:-
THCA	cis	rs858239	0.57	rs10235467	ENSG00000226816.2	AC005082.12	4.57	6.35e-06	0.000681	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23206013~23208045:+
THCA	cis	rs1707322	1	rs6687301	ENSG00000281133.1	AL355480.3	-4.57	6.35e-06	0.000681	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45580892~45580996:-
THCA	cis	rs7849973	0.595	rs1349151	ENSG00000234840.1	LINC01239	-4.57	6.35e-06	0.000681	-0.27	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22767237	chr9:22646200~22824213:+
THCA	cis	rs7181230	0.885	rs28444847	ENSG00000275636.1	RP11-521C20.5	4.57	6.36e-06	0.000681	0.22	0.21	Dehydroepiandrosterone sulphate levels;	chr15:40064403	chr15:40078892~40079347:+
THCA	cis	rs28374715	0.578	rs72739630	ENSG00000247556.5	OIP5-AS1	4.57	6.36e-06	0.000681	0.2	0.21	Ulcerative colitis;	chr15:41338866	chr15:41283990~41309737:+
THCA	cis	rs3820928	0.874	rs4144328	ENSG00000212391.1	SNORA48	-4.57	6.36e-06	0.000681	-0.22	-0.21	Pulmonary function;	chr2:226925471	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs11685983	ENSG00000212391.1	SNORA48	-4.57	6.36e-06	0.000681	-0.22	-0.21	Pulmonary function;	chr2:226935137	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.839	rs4675123	ENSG00000212391.1	SNORA48	-4.57	6.36e-06	0.000681	-0.22	-0.21	Pulmonary function;	chr2:226935489	chr2:226968989~226969122:-
THCA	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-4.57	6.36e-06	0.000681	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
THCA	cis	rs9863	0.828	rs7311969	ENSG00000270028.1	RP11-380L11.4	-4.57	6.36e-06	0.000681	-0.22	-0.21	White blood cell count;	chr12:123985786	chr12:123925461~123926083:-
THCA	cis	rs9880211	0.563	rs9848926	ENSG00000273486.1	RP11-731C17.2	4.57	6.36e-06	0.000681	0.21	0.21	Height;Body mass index;	chr3:136097460	chr3:136837338~136839021:-
THCA	cis	rs17597773	0.527	rs2484699	ENSG00000272823.1	RP11-295M18.6	-4.57	6.36e-06	0.000681	-0.25	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910410	chr1:220828676~220829211:-
THCA	cis	rs7267979	1	rs2482928	ENSG00000274973.1	RP13-401N8.7	4.57	6.36e-06	0.000681	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25845497~25845862:+
THCA	cis	rs8054556	0.74	rs8059619	ENSG00000183604.13	SMG1P5	-4.57	6.36e-06	0.000681	-0.19	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29914124	chr16:30267553~30335374:-
THCA	cis	rs4072705	0.616	rs915033	ENSG00000224020.1	MIR181A2HG	-4.57	6.36e-06	0.000682	-0.19	-0.21	Menarche (age at onset);	chr9:124483279	chr9:124658467~124698631:+
THCA	cis	rs4415084	1	rs2165009	ENSG00000272335.1	RP11-53O19.3	-4.57	6.36e-06	0.000682	-0.17	-0.21	Breast cancer;	chr5:44697814	chr5:44826076~44828592:+
THCA	cis	rs7493	0.95	rs11977702	ENSG00000233942.1	AC004012.1	4.57	6.36e-06	0.000682	0.32	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95400455	chr7:95471835~95473998:+
THCA	cis	rs8077577	0.747	rs2071242	ENSG00000273018.4	CTD-2303H24.2	-4.57	6.36e-06	0.000682	-0.3	-0.21	Obesity-related traits;	chr17:18251196	chr17:18511221~18551705:-
THCA	cis	rs793571	0.628	rs28510910	ENSG00000245975.2	RP11-30K9.6	4.57	6.36e-06	0.000682	0.24	0.21	Schizophrenia;	chr15:58790188	chr15:58768072~58770974:-
THCA	cis	rs793571	0.628	rs28793354	ENSG00000245975.2	RP11-30K9.6	4.57	6.36e-06	0.000682	0.24	0.21	Schizophrenia;	chr15:58792647	chr15:58768072~58770974:-
THCA	cis	rs4908769	0.66	rs159962	ENSG00000232912.4	RP5-1115A15.1	4.57	6.36e-06	0.000682	0.23	0.21	Allergy;	chr1:8430923	chr1:8424645~8434838:+
THCA	cis	rs7688540	0.74	rs28784663	ENSG00000250892.1	RP11-1365D11.1	4.57	6.37e-06	0.000682	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:201409~205009:-
THCA	cis	rs2239547	0.522	rs6773040	ENSG00000242142.1	SERBP1P3	-4.57	6.37e-06	0.000682	-0.27	-0.21	Schizophrenia;	chr3:52901412	chr3:53064283~53065091:-
THCA	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-4.57	6.37e-06	0.000682	-0.26	-0.21	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
THCA	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-4.57	6.37e-06	0.000682	-0.26	-0.21	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
THCA	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-4.57	6.37e-06	0.000682	-0.26	-0.21	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
THCA	cis	rs1728785	0.901	rs821169	ENSG00000274698.1	RP11-71L14.4	4.57	6.37e-06	0.000682	0.29	0.21	Ulcerative colitis;	chr16:68596281	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs1170420	ENSG00000274698.1	RP11-71L14.4	4.57	6.37e-06	0.000682	0.29	0.21	Ulcerative colitis;	chr16:68601974	chr16:68450283~68452318:+
THCA	cis	rs10090774	0.901	rs11986785	ENSG00000279766.1	RP11-642A1.2	-4.57	6.37e-06	0.000682	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140701852	chr8:140572142~140572812:-
THCA	cis	rs8113308	0.688	rs7259507	ENSG00000269483.1	AC006272.1	4.57	6.37e-06	0.000682	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942475	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs7259622	ENSG00000269483.1	AC006272.1	4.57	6.37e-06	0.000682	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942484	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs73582180	ENSG00000269483.1	AC006272.1	4.57	6.37e-06	0.000682	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943284	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs8105910	ENSG00000269483.1	AC006272.1	4.57	6.37e-06	0.000682	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943815	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs11880193	ENSG00000269483.1	AC006272.1	4.57	6.37e-06	0.000682	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51945416	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs16983256	ENSG00000269483.1	AC006272.1	4.57	6.37e-06	0.000682	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946228	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs8100521	ENSG00000269483.1	AC006272.1	4.57	6.37e-06	0.000682	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946390	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs8100541	ENSG00000269483.1	AC006272.1	4.57	6.37e-06	0.000682	0.34	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946442	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs11881650	ENSG00000269483.1	AC006272.1	-4.57	6.37e-06	0.000682	-0.34	-0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946886	chr19:51839924~51843324:-
THCA	cis	rs728616	0.614	rs61859199	ENSG00000242600.5	MBL1P	4.57	6.37e-06	0.000682	0.26	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs1538818	ENSG00000242600.5	MBL1P	4.57	6.37e-06	0.000682	0.26	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80363037	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs61859209	ENSG00000242600.5	MBL1P	4.57	6.37e-06	0.000682	0.26	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs61859210	ENSG00000242600.5	MBL1P	4.57	6.37e-06	0.000682	0.26	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80371712	chr10:79904898~79950336:+
THCA	cis	rs801193	1	rs4717310	ENSG00000229886.1	RP5-1132H15.3	4.57	6.37e-06	0.000682	0.21	0.21	Aortic root size;	chr7:66696020	chr7:66025126~66031544:-
THCA	cis	rs5751614	0.577	rs2330369	ENSG00000240160.3	RN7SL263P	4.57	6.37e-06	0.000682	0.25	0.21	Height;	chr22:23265255	chr22:23261782~23262071:-
THCA	cis	rs763121	0.819	rs5757237	ENSG00000273076.1	RP3-508I15.22	4.57	6.37e-06	0.000682	0.21	0.21	Menopause (age at onset);	chr22:38677830	chr22:38743495~38743910:+
THCA	cis	rs1559040	1	rs72800746	ENSG00000272156.1	RP11-477N3.1	-4.57	6.37e-06	0.000683	-0.34	-0.21	Sudden cardiac arrest;	chr2:54113543	chr2:54082554~54085066:+
THCA	cis	rs55726902	0.761	rs2544030	ENSG00000276691.1	RP5-1057I20.5	4.57	6.37e-06	0.000683	0.24	0.21	Allergic disease (asthma, hay fever or eczema);	chr12:47801668	chr12:47788426~47788971:+
THCA	cis	rs1962772	0.781	rs7822491	ENSG00000279903.1	RP11-349F21.5	-4.57	6.37e-06	0.000683	-0.25	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17519439	chr8:17500012~17500605:+
THCA	cis	rs1962772	0.781	rs2213906	ENSG00000279903.1	RP11-349F21.5	-4.57	6.37e-06	0.000683	-0.25	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17519548	chr8:17500012~17500605:+
THCA	cis	rs7829975	0.582	rs6982832	ENSG00000254153.1	CTA-398F10.2	4.57	6.37e-06	0.000683	0.23	0.21	Mood instability;	chr8:8934707	chr8:8456909~8461337:-
THCA	cis	rs7824557	0.806	rs7007394	ENSG00000154316.13	TDH	4.57	6.38e-06	0.000683	0.15	0.21	Retinal vascular caliber;	chr8:11237057	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.806	rs6601573	ENSG00000154316.13	TDH	4.57	6.38e-06	0.000683	0.15	0.21	Retinal vascular caliber;	chr8:11237242	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.806	rs6601574	ENSG00000154316.13	TDH	4.57	6.38e-06	0.000683	0.15	0.21	Retinal vascular caliber;	chr8:11237376	chr8:11339637~11368452:+
THCA	cis	rs7308116	0.645	rs10861834	ENSG00000258072.1	RP11-554D14.2	4.57	6.38e-06	0.000683	0.23	0.21	Pelvic organ prolapse (moderate/severe);	chr12:107903134	chr12:107903270~107903948:-
THCA	cis	rs8058578	0.943	rs7197770	ENSG00000279196.1	RP11-1072A3.3	4.57	6.38e-06	0.000683	0.21	0.21	Multiple myeloma;	chr16:30704587	chr16:30984630~30988270:-
THCA	cis	rs6088590	1	rs6087625	ENSG00000269202.1	RP4-614O4.12	4.57	6.38e-06	0.000683	0.18	0.21	Coronary artery disease;	chr20:34754674	chr20:35201747~35203288:-
THCA	cis	rs1005277	0.579	rs2800485	ENSG00000272983.1	RP11-508N22.12	4.57	6.38e-06	0.000683	0.18	0.21	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38137337~38144399:+
THCA	cis	rs7851660	0.844	rs10119853	ENSG00000214417.4	KRT18P13	-4.57	6.38e-06	0.000683	-0.19	-0.21	Strep throat;	chr9:97862699	chr9:97698922~97700734:+
THCA	cis	rs2018683	0.899	rs10269454	ENSG00000272568.4	CTB-113D17.1	4.57	6.38e-06	0.000683	0.2	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938783	chr7:28979967~29013367:+
THCA	cis	rs6121246	0.559	rs6119728	ENSG00000230613.1	HM13-AS1	4.57	6.38e-06	0.000684	0.19	0.21	Mean corpuscular hemoglobin;	chr20:31825318	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.609	rs2149281	ENSG00000230613.1	HM13-AS1	4.57	6.38e-06	0.000684	0.19	0.21	Mean corpuscular hemoglobin;	chr20:31830115	chr20:31567707~31573263:-
THCA	cis	rs8062405	0.69	rs7187604	ENSG00000261766.1	RP11-22P6.2	-4.57	6.38e-06	0.000684	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28862166~28863340:-
THCA	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-4.57	6.38e-06	0.000684	-0.21	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
THCA	cis	rs1023500	0.573	rs133381	ENSG00000273366.1	CTA-989H11.1	-4.57	6.38e-06	0.000684	-0.27	-0.21	Schizophrenia;	chr22:42074604	chr22:42278188~42278846:+
THCA	cis	rs2239547	0.618	rs2071041	ENSG00000242142.1	SERBP1P3	4.57	6.39e-06	0.000684	0.26	0.21	Schizophrenia;	chr3:52830677	chr3:53064283~53065091:-
THCA	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-4.56	6.39e-06	0.000684	-0.52	-0.21	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
THCA	cis	rs4927850	1	rs7625570	ENSG00000185485.13	SDHAP1	4.56	6.39e-06	0.000684	0.18	0.21	Pancreatic cancer;	chr3:196020527	chr3:195959748~195990318:-
THCA	cis	rs2281603	0.57	rs2123460	ENSG00000259116.1	RP11-973N13.4	-4.56	6.39e-06	0.000684	-0.17	-0.21	Lymphocyte counts;	chr14:64485507	chr14:64514154~64540368:-
THCA	cis	rs13126694	0.744	rs7656059	ENSG00000248429.4	RP11-597D13.9	4.56	6.39e-06	0.000684	0.22	0.21	Blood osmolality (transformed sodium);	chr4:158080386	chr4:158170752~158202877:+
THCA	cis	rs1019173	0.966	rs6971164	ENSG00000261455.1	LINC01003	4.56	6.39e-06	0.000684	0.19	0.21	Kidney function decline traits;	chr7:152011217	chr7:152463786~152465549:+
THCA	cis	rs17801127	0.901	rs13030023	ENSG00000231969.1	AC144449.1	4.56	6.39e-06	0.000684	0.35	0.21	Liver enzyme levels (alanine transaminase);	chr2:149653337	chr2:149587196~149848233:+
THCA	cis	rs1046896	0.576	rs8067360	ENSG00000263063.1	RP11-388C12.1	-4.56	6.39e-06	0.000685	-0.24	-0.21	Glycated hemoglobin levels;	chr17:82736950	chr17:82713908~82716255:-
THCA	cis	rs1979679	0.801	rs7977538	ENSG00000247934.4	RP11-967K21.1	-4.56	6.4e-06	0.000685	-0.2	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143503	chr12:28163298~28190738:-
THCA	cis	rs6517329	0.538	rs4816521	ENSG00000236830.5	CBR3-AS1	4.56	6.4e-06	0.000685	0.19	0.21	Schizophrenia;	chr21:36138440	chr21:36131767~36175815:-
THCA	cis	rs1979679	0.879	rs1002863	ENSG00000278733.1	RP11-425D17.1	-4.56	6.4e-06	0.000685	-0.2	-0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28500768	chr12:28185625~28186190:-
THCA	cis	rs9902453	0.765	rs2874505	ENSG00000263370.1	RP11-68I3.5	4.56	6.4e-06	0.000685	0.27	0.21	Coffee consumption (cups per day);	chr17:29710905	chr17:29639627~29640825:+
THCA	cis	rs6560517	0.581	rs2501933	ENSG00000234618.1	RPSAP9	4.56	6.4e-06	0.000685	0.21	0.21	Dialysis-related mortality;	chr9:76375259	chr9:76398699~76399586:+
THCA	cis	rs4950322	0.57	rs17356492	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147296089	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72691093	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147297977	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs76236344	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147297989	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72691095	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147298305	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72691097	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147299711	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72691098	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147300142	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72691102	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147301189	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692904	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147301437	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692905	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147301560	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692907	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147301921	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692914	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147302946	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692917	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147304389	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692920	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147308501	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs66580541	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147308828	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs945742	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147313437	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.543	rs4950318	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147316240	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.543	rs4950319	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147316250	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.543	rs4453096	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147316574	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.571	rs4373796	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147316747	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.543	rs4568882	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147316885	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.543	rs2883323	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147316995	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.543	rs2883324	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147317157	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.542	rs72692942	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147318467	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs4950399	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147319302	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs4950403	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147319723	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.517	rs116479391	ENSG00000180867.10	PDIA3P1	4.56	6.4e-06	0.000685	0.21	0.21	Protein quantitative trait loci;	chr1:147320940	chr1:147178113~147179622:+
THCA	cis	rs763121	0.853	rs11704021	ENSG00000273076.1	RP3-508I15.22	4.56	6.4e-06	0.000685	0.21	0.21	Menopause (age at onset);	chr22:38678711	chr22:38743495~38743910:+
THCA	cis	rs6969780	0.915	rs3807597	ENSG00000233429.8	HOTAIRM1	-4.56	6.4e-06	0.000685	-0.28	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149576	chr7:27095647~27100265:+
THCA	cis	rs6969780	0.915	rs12666919	ENSG00000233429.8	HOTAIRM1	-4.56	6.4e-06	0.000685	-0.28	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149879	chr7:27095647~27100265:+
THCA	cis	rs6969780	0.915	rs12666926	ENSG00000233429.8	HOTAIRM1	-4.56	6.4e-06	0.000685	-0.28	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149942	chr7:27095647~27100265:+
THCA	cis	rs6969780	0.915	rs886339	ENSG00000233429.8	HOTAIRM1	-4.56	6.4e-06	0.000685	-0.28	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27151051	chr7:27095647~27100265:+
THCA	cis	rs1479090	0.762	rs11100479	ENSG00000250027.1	RP11-563E2.2	-4.56	6.4e-06	0.000685	-0.21	-0.21	Lung cancer;	chr4:163091749	chr4:163108785~163119965:+
THCA	cis	rs11846409	0.86	rs61686131	ENSG00000274576.2	IGHV2-70	-4.56	6.41e-06	0.000686	-0.17	-0.21	Rheumatic heart disease;	chr14:106631568	chr14:106770577~106771020:-
THCA	cis	rs9925964	0.933	rs10871454	ENSG00000232748.3	RP11-196G11.6	4.56	6.41e-06	0.000686	0.24	0.21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036758	chr16:31056460~31062803:+
THCA	cis	rs67478160	0.643	rs6575999	ENSG00000269910.1	RP11-73M18.10	4.56	6.41e-06	0.000686	0.17	0.21	Schizophrenia;	chr14:103784272	chr14:103694516~103695050:-
THCA	cis	rs2836974	0.666	rs35182074	ENSG00000255568.3	BRWD1-AS2	-4.56	6.41e-06	0.000686	-0.17	-0.21	Cognitive function;	chr21:39313358	chr21:39313935~39314962:+
THCA	cis	rs1003719	0.788	rs2835584	ENSG00000230366.8	DSCR9	-4.56	6.41e-06	0.000687	-0.21	-0.21	Eye color traits;	chr21:37088038	chr21:37208503~37221736:+
THCA	cis	rs8028182	0.636	rs28623700	ENSG00000260274.1	RP11-817O13.8	4.56	6.41e-06	0.000687	0.15	0.21	Sudden cardiac arrest;	chr15:75557373	chr15:75368155~75369584:+
THCA	cis	rs8028182	0.577	rs28693593	ENSG00000260274.1	RP11-817O13.8	4.56	6.41e-06	0.000687	0.15	0.21	Sudden cardiac arrest;	chr15:75557435	chr15:75368155~75369584:+
THCA	cis	rs7111546	0.945	rs111566585	ENSG00000246225.5	RP11-17A1.3	4.56	6.41e-06	0.000687	0.38	0.21	Dialysis-related mortality;	chr11:22816267	chr11:22829380~22945393:+
THCA	cis	rs2921036	0.503	rs7817832	ENSG00000253893.2	FAM85B	-4.56	6.42e-06	0.000687	-0.32	-0.21	Neuroticism;	chr8:8523311	chr8:8167819~8226614:-
THCA	cis	rs73108077	0.736	rs73104095	ENSG00000277112.2	RP11-755J8.1	-4.56	6.42e-06	0.000687	-0.4	-0.21	Red blood cell density in sickle cell anemia;	chr20:31312074	chr20:30681825~30723932:-
THCA	cis	rs8054556	0.74	rs9936474	ENSG00000183604.13	SMG1P5	-4.56	6.42e-06	0.000687	-0.19	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29921370	chr16:30267553~30335374:-
THCA	cis	rs860295	0.812	rs12081192	ENSG00000160766.13	GBAP1	-4.56	6.42e-06	0.000687	-0.24	-0.21	Body mass index;	chr1:155768253	chr1:155213821~155227422:-
THCA	cis	rs801193	1	rs2707856	ENSG00000229886.1	RP5-1132H15.3	4.56	6.42e-06	0.000688	0.21	0.21	Aortic root size;	chr7:66746023	chr7:66025126~66031544:-
THCA	cis	rs2439831	0.867	rs3213991	ENSG00000166763.7	STRCP1	4.56	6.43e-06	0.000688	0.28	0.21	Lung cancer in ever smokers;	chr15:43378082	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.85	rs7163245	ENSG00000166763.7	STRCP1	4.56	6.43e-06	0.000688	0.28	0.21	Lung cancer in ever smokers;	chr15:43379096	chr15:43699488~43718184:-
THCA	cis	rs801193	1	rs2055682	ENSG00000229886.1	RP5-1132H15.3	4.56	6.43e-06	0.000688	0.21	0.21	Aortic root size;	chr7:66795302	chr7:66025126~66031544:-
THCA	cis	rs270601	0.909	rs2569265	ENSG00000224431.1	AC063976.7	-4.56	6.43e-06	0.000688	-0.18	-0.21	Acylcarnitine levels;	chr5:132368827	chr5:132199456~132203487:+
THCA	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-4.56	6.43e-06	0.000688	-0.27	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
THCA	cis	rs7829975	0.755	rs3789849	ENSG00000254153.1	CTA-398F10.2	-4.56	6.43e-06	0.000688	-0.22	-0.21	Mood instability;	chr8:8829544	chr8:8456909~8461337:-
THCA	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-4.56	6.43e-06	0.000688	-0.27	-0.21	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
THCA	cis	rs62184315	0.536	rs5742926	ENSG00000253559.1	OSGEPL1-AS1	-4.56	6.43e-06	0.000688	-0.3	-0.21	Alcohol dependence (age at onset);	chr2:189784079	chr2:189762704~189765556:+
THCA	cis	rs31251	1	rs31251	ENSG00000224431.1	AC063976.7	-4.56	6.43e-06	0.000688	-0.17	-0.21	Itch intensity from mosquito bite adjusted by bite size;	chr5:131498253	chr5:132199456~132203487:+
THCA	cis	rs2243480	0.522	rs778717	ENSG00000232546.1	RP11-458F8.1	-4.56	6.43e-06	0.000688	-0.34	-0.21	Diabetic kidney disease;	chr7:66383164	chr7:66848496~66858136:+
THCA	cis	rs4646450	0.735	rs10270459	ENSG00000244219.5	GS1-259H13.2	-4.56	6.43e-06	0.000688	-0.27	-0.21	Blood metabolite levels;	chr7:99381337	chr7:99598066~99610813:+
THCA	cis	rs987724	0.515	rs344073	ENSG00000240875.4	LINC00886	4.56	6.43e-06	0.000688	0.2	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156829224	chr3:156747346~156817062:-
THCA	cis	rs11853189	0.938	rs2277551	ENSG00000259562.2	RP11-762H8.2	4.56	6.43e-06	0.000689	0.2	0.21	Red cell distribution width;	chr15:78288139	chr15:78290527~78291221:-
THCA	cis	rs8141529	0.956	rs469989	ENSG00000272858.1	CTA-292E10.8	4.56	6.44e-06	0.000689	0.22	0.21	Lymphocyte counts;	chr22:28907607	chr22:28814914~28815662:+
THCA	cis	rs12908161	1	rs60957376	ENSG00000188388.10	GOLGA6L3	4.56	6.44e-06	0.000689	0.27	0.21	Schizophrenia;	chr15:84737561	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs11632465	ENSG00000188388.10	GOLGA6L3	4.56	6.44e-06	0.000689	0.27	0.21	Schizophrenia;	chr15:84738814	chr15:85240472~85247170:+
THCA	cis	rs9307551	0.741	rs6840265	ENSG00000250334.4	LINC00989	-4.56	6.44e-06	0.000689	-0.27	-0.21	Refractive error;	chr4:79521327	chr4:79492416~79576460:+
THCA	cis	rs10875746	0.551	rs1471998	ENSG00000226413.2	OR8T1P	4.56	6.44e-06	0.000689	0.29	0.21	Longevity (90 years and older);	chr12:48318219	chr12:48442030~48442947:-
THCA	cis	rs375066	0.516	rs7248807	ENSG00000267058.1	RP11-15A1.3	4.56	6.44e-06	0.000689	0.18	0.21	Breast cancer;	chr19:43825930	chr19:43891804~43901805:-
THCA	cis	rs78487399	0.908	rs75030714	ENSG00000234936.1	AC010883.5	4.56	6.44e-06	0.000689	0.26	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617733	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs75621188	ENSG00000234936.1	AC010883.5	4.56	6.44e-06	0.000689	0.26	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43619536	chr2:43229573~43233394:+
THCA	cis	rs17508449	0.547	rs3765598	ENSG00000232450.1	RP4-730K3.3	-4.56	6.45e-06	0.00069	-0.29	-0.21	Leprosy;	chr1:113851841	chr1:113698884~113699631:-
THCA	cis	rs2235642	0.785	rs1057983	ENSG00000280231.1	LA16c-380F5.3	-4.56	6.45e-06	0.00069	-0.24	-0.21	Coronary artery disease;	chr16:1610273	chr16:1553655~1554130:-
THCA	cis	rs7394190	0.63	rs113799665	ENSG00000271816.1	BMS1P4	-4.56	6.45e-06	0.00069	-0.26	-0.21	Incident atrial fibrillation;	chr10:73815380	chr10:73699151~73730487:-
THCA	cis	rs9487094	0.689	rs699700	ENSG00000223537.2	RP5-919F19.5	-4.56	6.45e-06	0.00069	-0.2	-0.21	Height;	chr6:109367528	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.689	rs11251	ENSG00000223537.2	RP5-919F19.5	-4.56	6.45e-06	0.00069	-0.2	-0.21	Height;	chr6:109368704	chr6:109487906~109506800:+
THCA	cis	rs7520050	0.966	rs12760175	ENSG00000234329.1	RP11-767N6.2	-4.56	6.45e-06	0.00069	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45982168	chr1:45651039~45651826:-
THCA	cis	rs9467773	0.62	rs2451711	ENSG00000261353.1	CTA-14H9.5	-4.56	6.45e-06	0.00069	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26527063~26527404:+
THCA	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-4.56	6.45e-06	0.00069	-0.26	-0.21	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
THCA	cis	rs1876905	0.68	rs1150082	ENSG00000272356.1	RP5-1112D6.8	-4.56	6.45e-06	0.000691	-0.21	-0.21	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111309203~111313517:+
THCA	cis	rs897984	0.553	rs2335013	ENSG00000279196.1	RP11-1072A3.3	-4.56	6.45e-06	0.000691	-0.22	-0.21	Dementia with Lewy bodies;	chr16:30866025	chr16:30984630~30988270:-
THCA	cis	rs2243480	0.522	rs1638736	ENSG00000232546.1	RP11-458F8.1	-4.56	6.46e-06	0.000691	-0.34	-0.21	Diabetic kidney disease;	chr7:66627321	chr7:66848496~66858136:+
THCA	cis	rs4950322	0.542	rs3766519	ENSG00000180867.10	PDIA3P1	4.56	6.46e-06	0.000691	0.21	0.21	Protein quantitative trait loci;	chr1:147214802	chr1:147178113~147179622:+
THCA	cis	rs5769765	0.954	rs6009900	ENSG00000260613.1	RP3-522J7.6	-4.56	6.46e-06	0.000691	-0.25	-0.21	Schizophrenia;	chr22:49842962	chr22:49832616~49837786:-
THCA	cis	rs7267979	0.899	rs2179459	ENSG00000274973.1	RP13-401N8.7	-4.56	6.46e-06	0.000691	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25845497~25845862:+
THCA	cis	rs17680741	0.697	rs12269333	ENSG00000225484.5	NUTM2B-AS1	-4.56	6.46e-06	0.000691	-0.29	-0.21	Coronary artery disease;	chr10:80507049	chr10:79663088~79826594:-
THCA	cis	rs755249	0.501	rs621807	ENSG00000228060.1	RP11-69E11.8	-4.56	6.46e-06	0.000691	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39565160~39573203:+
THCA	cis	rs8113308	0.81	rs56029016	ENSG00000269483.1	AC006272.1	4.56	6.46e-06	0.000691	0.33	0.21	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949209	chr19:51839924~51843324:-
THCA	cis	rs8062405	0.964	rs78613234	ENSG00000261766.1	RP11-22P6.2	-4.56	6.46e-06	0.000691	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62036624	ENSG00000261766.1	RP11-22P6.2	-4.56	6.46e-06	0.000691	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28862166~28863340:-
THCA	cis	rs10754283	0.557	rs1215511	ENSG00000231613.1	RP5-943J3.1	4.56	6.46e-06	0.000691	0.23	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89621984	chr1:89788914~89790492:+
THCA	cis	rs17095355	1	rs55781439	ENSG00000203876.8	ADD3-AS1	-4.56	6.46e-06	0.000691	-0.22	-0.21	Biliary atresia;	chr10:109910462	chr10:109940104~110008381:-
THCA	cis	rs7520050	0.743	rs61789988	ENSG00000234329.1	RP11-767N6.2	-4.56	6.46e-06	0.000691	-0.19	-0.21	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45651039~45651826:-
THCA	cis	rs7474896	0.537	rs1208591	ENSG00000263064.2	RP11-291L22.7	4.56	6.47e-06	0.000692	0.28	0.21	Obesity (extreme);	chr10:37923574	chr10:38448689~38448949:+
THCA	cis	rs8028182	0.636	rs62027181	ENSG00000260274.1	RP11-817O13.8	4.56	6.47e-06	0.000692	0.15	0.21	Sudden cardiac arrest;	chr15:75547611	chr15:75368155~75369584:+
THCA	cis	rs7520050	0.933	rs4504835	ENSG00000234329.1	RP11-767N6.2	-4.56	6.47e-06	0.000692	-0.18	-0.21	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45651039~45651826:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000234585.5	CCT6P3	4.56	6.47e-06	0.000692	0.19	0.21	Calcium levels;	chr7:65975383	chr7:65038354~65074713:+
THCA	cis	rs3177980	0.673	rs73026213	ENSG00000239494.2	RN7SL333P	-4.56	6.47e-06	0.000692	-0.2	-0.21	Amyotrophic lateral sclerosis;	chr1:169881233	chr1:169859756~169860052:+
THCA	cis	rs11976180	1	rs2951363	ENSG00000244198.4	RP4-545C24.1	-4.56	6.47e-06	0.000692	-0.2	-0.21	Obesity-related traits;	chr7:144057631	chr7:144194858~144280547:+
THCA	cis	rs7115242	0.8	rs7931770	ENSG00000280143.1	AP000892.6	4.56	6.47e-06	0.000692	0.32	0.21	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117204967~117210292:+
THCA	cis	rs62246343	0.605	rs3898760	ENSG00000254485.4	RP11-380O24.1	4.56	6.47e-06	0.000693	0.23	0.21	Fibrinogen levels;	chr3:9453435	chr3:9292588~9363303:-
THCA	cis	rs9876781	0.53	rs11708617	ENSG00000244380.1	RP11-24C3.2	4.56	6.47e-06	0.000693	0.26	0.21	Longevity;	chr3:48354819	chr3:48440352~48446656:-
THCA	cis	rs4950322	0.857	rs55790545	ENSG00000271721.1	RP11-337C18.9	4.56	6.48e-06	0.000693	0.24	0.21	Protein quantitative trait loci;	chr1:147366649	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.857	rs7522219	ENSG00000271721.1	RP11-337C18.9	4.56	6.48e-06	0.000693	0.24	0.21	Protein quantitative trait loci;	chr1:147366904	chr1:147175602~147177740:+
THCA	cis	rs7267979	1	rs6037095	ENSG00000274973.1	RP13-401N8.7	4.56	6.48e-06	0.000693	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6050562	ENSG00000274973.1	RP13-401N8.7	4.56	6.48e-06	0.000693	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4815407	ENSG00000274973.1	RP13-401N8.7	4.56	6.48e-06	0.000693	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25845497~25845862:+
THCA	cis	rs9283706	0.641	rs1990894	ENSG00000229666.1	MAST4-AS1	-4.56	6.48e-06	0.000693	-0.29	-0.21	Coronary artery disease;	chr5:67035857	chr5:67001383~67003953:-
THCA	cis	rs1913185	0.787	rs1449442	ENSG00000240032.1	RP11-274H2.3	-4.56	6.48e-06	0.000693	-0.32	-0.21	Obesity-related traits;	chr3:146082133	chr3:146066344~146069185:-
THCA	cis	rs6997458	0.785	rs931505	ENSG00000253549.4	RP11-317J10.2	4.56	6.48e-06	0.000693	0.21	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85436014	chr8:85441851~85464915:-
THCA	cis	rs11822910	0.654	rs2439450	ENSG00000265566.2	RN7SL605P	4.56	6.49e-06	0.000694	0.32	0.21	Platelet distribution width;	chr11:57445588	chr11:57528085~57528365:-
THCA	cis	rs79040073	0.637	rs73398264	ENSG00000259531.2	RP11-295H24.3	4.56	6.49e-06	0.000694	0.26	0.21	Lung cancer in ever smokers;	chr15:49414220	chr15:49365124~49366685:-
THCA	cis	rs4973397	0.81	rs12694890	ENSG00000224376.1	AC017104.6	-4.56	6.49e-06	0.000694	-0.23	-0.21	Anti-saccade response;	chr2:231411842	chr2:231388976~231394991:+
THCA	cis	rs875971	0.545	rs1638724	ENSG00000273142.1	RP11-458F8.4	-4.56	6.49e-06	0.000694	-0.19	-0.21	Aortic root size;	chr7:66575494	chr7:66902857~66906297:+
THCA	cis	rs8067545	0.75	rs4925080	ENSG00000270091.1	RP11-78O7.2	-4.56	6.49e-06	0.000694	-0.15	-0.21	Schizophrenia;	chr17:20088525	chr17:19896590~19897287:-
THCA	cis	rs17767294	0.611	rs66487884	ENSG00000219392.1	RP1-265C24.5	-4.56	6.49e-06	0.000694	-0.38	-0.21	Parkinson's disease;	chr6:28235134	chr6:28115628~28116551:+
THCA	cis	rs1023500	0.573	rs8135801	ENSG00000273366.1	CTA-989H11.1	4.56	6.49e-06	0.000694	0.26	0.21	Schizophrenia;	chr22:42079564	chr22:42278188~42278846:+
THCA	cis	rs990871	0.53	rs2821296	ENSG00000227207.2	RPL31P12	-4.56	6.49e-06	0.000694	-0.24	-0.21	Subcutaneous adipose tissue;	chr1:72164112	chr1:72301472~72301829:+
THCA	cis	rs990871	0.53	rs2630431	ENSG00000227207.2	RPL31P12	-4.56	6.49e-06	0.000694	-0.24	-0.21	Subcutaneous adipose tissue;	chr1:72169303	chr1:72301472~72301829:+
THCA	cis	rs990871	0.512	rs2821295	ENSG00000227207.2	RPL31P12	-4.56	6.49e-06	0.000694	-0.24	-0.21	Subcutaneous adipose tissue;	chr1:72174173	chr1:72301472~72301829:+
THCA	cis	rs990871	0.512	rs6699841	ENSG00000227207.2	RPL31P12	-4.56	6.49e-06	0.000694	-0.24	-0.21	Subcutaneous adipose tissue;	chr1:72180167	chr1:72301472~72301829:+
THCA	cis	rs8177876	0.584	rs2549899	ENSG00000261838.4	RP11-303E16.6	-4.56	6.49e-06	0.000694	-0.32	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81069854~81076598:+
THCA	cis	rs875971	0.66	rs10229345	ENSG00000236529.1	RP13-254B10.1	4.56	6.49e-06	0.000695	0.24	0.21	Aortic root size;	chr7:66517181	chr7:65840212~65840596:+
THCA	cis	rs7246657	0.551	rs11084873	ENSG00000276846.1	CTD-3220F14.3	4.56	6.5e-06	0.000695	0.25	0.21	Coronary artery calcification;	chr19:37093008	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.551	rs12978093	ENSG00000276846.1	CTD-3220F14.3	4.56	6.5e-06	0.000695	0.25	0.21	Coronary artery calcification;	chr19:37093514	chr19:37314868~37315620:-
THCA	cis	rs801193	1	rs62466794	ENSG00000229886.1	RP5-1132H15.3	4.56	6.5e-06	0.000695	0.21	0.21	Aortic root size;	chr7:66726592	chr7:66025126~66031544:-
THCA	cis	rs2777491	0.957	rs2015781	ENSG00000247556.5	OIP5-AS1	4.56	6.5e-06	0.000695	0.17	0.21	Ulcerative colitis;	chr15:41356769	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.957	rs919961	ENSG00000247556.5	OIP5-AS1	4.56	6.5e-06	0.000695	0.17	0.21	Ulcerative colitis;	chr15:41359523	chr15:41283990~41309737:+
THCA	cis	rs31251	1	rs32108	ENSG00000224431.1	AC063976.7	4.56	6.5e-06	0.000695	0.17	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr5:131704859	chr5:132199456~132203487:+
THCA	cis	rs45509595	0.556	rs34409918	ENSG00000220721.1	OR1F12	4.56	6.5e-06	0.000695	0.47	0.21	Breast cancer;	chr6:27717569	chr6:28073316~28074233:+
THCA	cis	rs4591358	0.734	rs11904194	ENSG00000223466.1	AC064834.2	4.56	6.51e-06	0.000696	0.24	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195495211	chr2:195533035~195538681:+
THCA	cis	rs6860806	0.507	rs270608	ENSG00000237714.1	P4HA2-AS1	4.56	6.51e-06	0.000696	0.28	0.21	Breast cancer;	chr5:132312713	chr5:132184876~132192808:+
THCA	cis	rs10761482	0.813	rs4948409	ENSG00000254271.1	RP11-131N11.4	4.56	6.51e-06	0.000696	0.27	0.21	Schizophrenia;	chr10:60356062	chr10:60734342~60741828:+
THCA	cis	rs34286592	1	rs62056375	ENSG00000214725.6	CDIPT-AS1	-4.56	6.51e-06	0.000696	-0.38	-0.21	Multiple sclerosis;	chr16:29846580	chr16:29863593~29868053:+
THCA	cis	rs12681288	0.748	rs2701935	ENSG00000260721.1	AF067845.1	4.56	6.51e-06	0.000696	0.26	0.21	Schizophrenia;	chr8:1078618	chr8:1368642~1369833:-
THCA	cis	rs1876905	0.68	rs402940	ENSG00000272356.1	RP5-1112D6.8	-4.56	6.51e-06	0.000696	-0.21	-0.21	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111309203~111313517:+
THCA	cis	rs1234598	1	rs1234598	ENSG00000272356.1	RP5-1112D6.8	-4.56	6.51e-06	0.000696	-0.21	-0.21	Mean corpuscular volume;	chr6:111208250	chr6:111309203~111313517:+
THCA	cis	rs1876905	0.68	rs354543	ENSG00000272356.1	RP5-1112D6.8	-4.56	6.51e-06	0.000696	-0.21	-0.21	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111309203~111313517:+
THCA	cis	rs9902453	1	rs8065059	ENSG00000263370.1	RP11-68I3.5	-4.56	6.51e-06	0.000696	-0.27	-0.21	Coffee consumption (cups per day);	chr17:30090358	chr17:29639627~29640825:+
THCA	cis	rs2787702	1	rs2787710	ENSG00000237233.2	TMEM26-AS1	-4.56	6.51e-06	0.000696	-0.25	-0.21	Response to taxane treatment (placlitaxel);	chr10:61556719	chr10:61452639~61481956:+
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000164669.11	INTS4P1	4.56	6.51e-06	0.000696	0.39	0.21	Diabetic kidney disease;	chr7:66100518	chr7:65141225~65234216:+
THCA	cis	rs763121	0.853	rs4821812	ENSG00000235209.1	CTA-150C2.13	4.56	6.51e-06	0.000696	0.27	0.21	Menopause (age at onset);	chr22:38679230	chr22:38921227~38924708:+
THCA	cis	rs453301	0.686	rs2409120	ENSG00000254153.1	CTA-398F10.2	4.56	6.51e-06	0.000696	0.22	0.21	Joint mobility (Beighton score);	chr8:9025061	chr8:8456909~8461337:-
THCA	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	4.56	6.51e-06	0.000696	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
THCA	cis	rs28829049	0.597	rs2296107	ENSG00000270728.1	RP4-657E11.10	-4.56	6.51e-06	0.000696	-0.15	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19150155	chr1:19297080~19297903:+
THCA	cis	rs2905347	1	rs2905347	ENSG00000232949.1	AC002480.4	4.56	6.52e-06	0.000697	0.26	0.21	Major depression and alcohol dependence;	chr7:22580700	chr7:22589705~22591622:+
THCA	cis	rs7394190	1	rs10824026	ENSG00000271848.1	RP11-464F9.21	-4.56	6.52e-06	0.000697	-0.25	-0.21	Incident atrial fibrillation;	chr10:73661450	chr10:73654039~73674719:+
THCA	cis	rs2281603	0.57	rs10134530	ENSG00000259116.1	RP11-973N13.4	4.56	6.52e-06	0.000697	0.17	0.21	Lymphocyte counts;	chr14:64484240	chr14:64514154~64540368:-
THCA	cis	rs6787172	0.811	rs9859129	ENSG00000272087.1	RP11-379F4.7	4.56	6.52e-06	0.000697	0.18	0.21	Subjective well-being;	chr3:158506005	chr3:158693120~158693768:-
THCA	cis	rs3892630	0.878	rs1061686	ENSG00000267567.1	CTD-2538C1.3	-4.56	6.52e-06	0.000697	-0.32	-0.21	Red blood cell traits;	chr19:32713638	chr19:32718298~32719595:-
THCA	cis	rs13178541	0.81	rs7379060	ENSG00000250378.1	RP11-119J18.1	-4.56	6.52e-06	0.000697	-0.25	-0.21	IgG glycosylation;	chr5:135745789	chr5:135812667~135826582:+
THCA	cis	rs9878978	1	rs62233805	ENSG00000237990.3	CNTN4-AS1	4.56	6.52e-06	0.000697	0.22	0.21	Blood pressure (smoking interaction);	chr3:2432701	chr3:3039033~3069242:-
THCA	cis	rs881375	0.678	rs7037195	ENSG00000270917.1	RP11-27I1.6	-4.56	6.52e-06	0.000697	-0.27	-0.21	Rheumatoid arthritis;	chr9:120921722	chr9:120812475~120812845:-
THCA	cis	rs62025270	0.632	rs7181796	ENSG00000259295.5	CSPG4P12	-4.56	6.53e-06	0.000698	-0.36	-0.21	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85191438~85213905:+
THCA	cis	rs17711722	0.701	rs781145	ENSG00000164669.11	INTS4P1	-4.56	6.53e-06	0.000698	-0.26	-0.21	Calcium levels;	chr7:65975383	chr7:65141225~65234216:+
THCA	cis	rs9926296	0.572	rs8047581	ENSG00000274627.1	RP11-104N10.2	-4.56	6.53e-06	0.000698	-0.2	-0.21	Vitiligo;	chr16:89818094	chr16:89516797~89522217:+
THCA	cis	rs7838490	0.504	rs1685554	ENSG00000253553.4	RP11-586K2.1	4.56	6.53e-06	0.000698	0.21	0.21	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88471762	chr8:88326836~88737134:+
THCA	cis	rs12893668	0.703	rs34896432	ENSG00000252469.1	RNU7-160P	4.56	6.53e-06	0.000698	0.25	0.21	Reticulocyte count;	chr14:103561658	chr14:103550345~103550406:+
THCA	cis	rs2436845	1	rs2164061	ENSG00000253669.3	KB-1732A1.1	4.56	6.54e-06	0.000699	0.21	0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102852245	chr8:102805517~102809971:+
THCA	cis	rs1923243	0.71	rs7523688	ENSG00000223479.3	RP4-788P17.1	-4.56	6.54e-06	0.000699	-0.22	-0.21	Migraine;	chr1:73160094	chr1:73635216~73715214:+
THCA	cis	rs8064024	0.56	rs741769	ENSG00000267077.1	RP11-127I20.5	4.56	6.54e-06	0.000699	0.24	0.21	Cancer;	chr16:4886204	chr16:4795265~4796532:-
THCA	cis	rs2836974	0.644	rs2410123	ENSG00000255568.3	BRWD1-AS2	-4.56	6.54e-06	0.000699	-0.17	-0.21	Cognitive function;	chr21:39328167	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.623	rs7280326	ENSG00000255568.3	BRWD1-AS2	-4.56	6.54e-06	0.000699	-0.17	-0.21	Cognitive function;	chr21:39328482	chr21:39313935~39314962:+
THCA	cis	rs4970988	0.556	rs6695123	ENSG00000231073.1	RP11-316M1.3	-4.56	6.54e-06	0.000699	-0.25	-0.21	Urate levels;	chr1:150591007	chr1:150973123~150975534:+
THCA	cis	rs763121	0.853	rs9622833	ENSG00000235209.1	CTA-150C2.13	4.56	6.54e-06	0.000699	0.27	0.21	Menopause (age at onset);	chr22:38604392	chr22:38921227~38924708:+
THCA	cis	rs829883	0.966	rs249818	ENSG00000227825.4	SLC9A7P1	4.56	6.54e-06	0.000699	0.19	0.21	Colorectal adenoma (advanced);	chr12:98503216	chr12:98453835~98457145:-
THCA	cis	rs8141529	0.702	rs5762870	ENSG00000226471.5	CTA-292E10.6	-4.56	6.54e-06	0.000699	-0.17	-0.21	Lymphocyte counts;	chr22:28865171	chr22:28800683~28848559:+
THCA	cis	rs274567	0.501	rs272855	ENSG00000224431.1	AC063976.7	4.56	6.54e-06	0.000699	0.19	0.21	Blood metabolite levels;	chr5:132351482	chr5:132199456~132203487:+
THCA	cis	rs9467773	0.62	rs2504592	ENSG00000261353.1	CTA-14H9.5	-4.56	6.54e-06	0.000699	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2504599	ENSG00000261353.1	CTA-14H9.5	-4.56	6.54e-06	0.000699	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26527063~26527404:+
THCA	cis	rs755249	0.565	rs3768320	ENSG00000228060.1	RP11-69E11.8	4.56	6.54e-06	0.000699	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39565160~39573203:+
THCA	cis	rs397969	0.596	rs35315252	ENSG00000261033.1	RP11-209D14.2	-4.56	6.54e-06	0.000699	-0.3	-0.21	Platelet count;	chr17:20002512	chr17:20008051~20009234:-
THCA	cis	rs2058059	0.636	rs3015906	ENSG00000205578.5	POM121B	-4.56	6.54e-06	0.000699	-0.32	-0.21	Subcutaneous adipose tissue;	chr7:72670552	chr7:73293497~73301161:+
THCA	cis	rs4927850	0.501	rs9881504	ENSG00000207650.1	MIR570	4.56	6.54e-06	0.000699	0.22	0.21	Pancreatic cancer;	chr3:195929743	chr3:195699401~195699497:+
THCA	cis	rs3820928	0.934	rs60141402	ENSG00000212391.1	SNORA48	-4.56	6.54e-06	0.000699	-0.23	-0.21	Pulmonary function;	chr2:226896729	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.934	rs16822890	ENSG00000212391.1	SNORA48	-4.56	6.54e-06	0.000699	-0.23	-0.21	Pulmonary function;	chr2:226896761	chr2:226968989~226969122:-
THCA	cis	rs3820928	1	rs9288617	ENSG00000212391.1	SNORA48	-4.56	6.54e-06	0.000699	-0.23	-0.21	Pulmonary function;	chr2:226898099	chr2:226968989~226969122:-
THCA	cis	rs829883	1	rs249837	ENSG00000227825.4	SLC9A7P1	4.56	6.54e-06	0.000699	0.19	0.21	Colorectal adenoma (advanced);	chr12:98482757	chr12:98453835~98457145:-
THCA	cis	rs829883	0.902	rs829884	ENSG00000227825.4	SLC9A7P1	4.56	6.54e-06	0.000699	0.19	0.21	Colorectal adenoma (advanced);	chr12:98485722	chr12:98453835~98457145:-
THCA	cis	rs829883	1	rs829883	ENSG00000227825.4	SLC9A7P1	4.56	6.54e-06	0.000699	0.19	0.21	Colorectal adenoma (advanced);	chr12:98485828	chr12:98453835~98457145:-
THCA	cis	rs6860806	0.507	rs272872	ENSG00000237714.1	P4HA2-AS1	-4.56	6.54e-06	0.000699	-0.28	-0.21	Breast cancer;	chr5:132340171	chr5:132184876~132192808:+
THCA	cis	rs1889642	0.626	rs9545219	ENSG00000227354.5	RBM26-AS1	4.56	6.54e-06	0.000699	0.2	0.21	Colonoscopy-negative controls vs population controls;	chr13:79833076	chr13:79406309~79424328:+
THCA	cis	rs1923243	0.743	rs11210170	ENSG00000223479.3	RP4-788P17.1	-4.56	6.54e-06	0.000699	-0.22	-0.21	Migraine;	chr1:73171763	chr1:73635216~73715214:+
THCA	cis	rs763121	0.853	rs3827357	ENSG00000235209.1	CTA-150C2.13	4.56	6.55e-06	0.000699	0.27	0.21	Menopause (age at onset);	chr22:38683408	chr22:38921227~38924708:+
THCA	cis	rs801193	0.935	rs2659899	ENSG00000229886.1	RP5-1132H15.3	4.56	6.55e-06	0.000699	0.21	0.21	Aortic root size;	chr7:66721734	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs1553609	ENSG00000229886.1	RP5-1132H15.3	4.56	6.55e-06	0.000699	0.21	0.21	Aortic root size;	chr7:66732152	chr7:66025126~66031544:-
THCA	cis	rs801193	0.967	rs2707853	ENSG00000229886.1	RP5-1132H15.3	4.56	6.55e-06	0.000699	0.21	0.21	Aortic root size;	chr7:66749023	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs2659889	ENSG00000229886.1	RP5-1132H15.3	4.56	6.55e-06	0.000699	0.21	0.21	Aortic root size;	chr7:66752125	chr7:66025126~66031544:-
THCA	cis	rs2253762	0.507	rs4752630	ENSG00000226864.1	ATE1-AS1	4.56	6.55e-06	0.000699	0.32	0.21	Breast cancer;	chr10:121991440	chr10:121928312~121951965:+
THCA	cis	rs6840360	0.901	rs1443094	ENSG00000270265.1	RP11-731D1.4	-4.56	6.55e-06	7e-04	-0.19	-0.21	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151333775~151353224:-
THCA	cis	rs1790761	0.52	rs12800028	ENSG00000255318.1	RP11-655M14.13	-4.56	6.55e-06	7e-04	-0.27	-0.21	Mean corpuscular volume;	chr11:67635814	chr11:67618279~67627304:-
THCA	cis	rs7267979	1	rs6050573	ENSG00000274973.1	RP13-401N8.7	-4.56	6.55e-06	7e-04	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25845497~25845862:+
THCA	cis	rs73108077	1	rs73108009	ENSG00000277112.2	RP11-755J8.1	-4.56	6.55e-06	7e-04	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31390409	chr20:30681825~30723932:-
THCA	cis	rs2985684	0.846	rs4476096	ENSG00000278009.1	RP11-649E7.8	4.56	6.55e-06	7e-04	0.28	0.21	Carotid intima media thickness;	chr14:49552673	chr14:49601011~49601124:-
THCA	cis	rs4950322	0.57	rs4950401	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147319571	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs4950402	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147319684	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs4950404	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147319834	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692946	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147319966	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692948	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147320298	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692951	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147320551	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs77118461	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147320718	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs78681047	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147321013	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.57	rs72692953	ENSG00000180867.10	PDIA3P1	4.56	6.55e-06	7e-04	0.21	0.21	Protein quantitative trait loci;	chr1:147321416	chr1:147178113~147179622:+
THCA	cis	rs6012564	1	rs56131635	ENSG00000230758.1	SNAP23P	4.56	6.55e-06	7e-04	0.24	0.21	Anger;	chr20:49157806	chr20:49038357~49038602:-
THCA	cis	rs7267979	1	rs10966	ENSG00000274973.1	RP13-401N8.7	-4.56	6.55e-06	7e-04	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25845497~25845862:+
THCA	cis	rs9307551	0.584	rs1978916	ENSG00000250334.4	LINC00989	-4.56	6.55e-06	7e-04	-0.25	-0.21	Refractive error;	chr4:79526106	chr4:79492416~79576460:+
THCA	cis	rs2836974	0.59	rs11911822	ENSG00000255568.3	BRWD1-AS2	-4.56	6.55e-06	7e-04	-0.17	-0.21	Cognitive function;	chr21:39235917	chr21:39313935~39314962:+
THCA	cis	rs481331	0.866	rs210221	ENSG00000215146.4	RP11-313J2.1	-4.56	6.55e-06	7e-04	-0.32	-0.21	Systemic juvenile idiopathic arthritis;	chr10:42561182	chr10:42331866~42367974:-
THCA	cis	rs2692947	0.537	rs11682182	ENSG00000235584.2	AC008268.1	-4.56	6.56e-06	7e-04	-0.2	-0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712462	chr2:95666084~95668715:+
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000229180.5	GS1-124K5.11	4.56	6.56e-06	7e-04	0.16	0.21	Corneal structure;	chr7:66830758	chr7:66526088~66542624:-
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000229180.5	GS1-124K5.11	4.56	6.56e-06	7e-04	0.16	0.21	Corneal structure;	chr7:66845054	chr7:66526088~66542624:-
THCA	cis	rs1823874	0.71	rs56160817	ENSG00000182397.13	DNM1P46	-4.56	6.56e-06	7e-04	-0.24	-0.21	IgG glycosylation;	chr15:99820472	chr15:99790156~99806927:-
THCA	cis	rs12554020	0.582	rs74842678	ENSG00000227603.1	RP11-165J3.6	4.56	6.56e-06	7e-04	0.43	0.21	Schizophrenia;	chr9:93658926	chr9:93435332~93437121:-
THCA	cis	rs1003719	0.715	rs1981432	ENSG00000230366.8	DSCR9	4.56	6.56e-06	0.000701	0.21	0.21	Eye color traits;	chr21:37169054	chr21:37208503~37221736:+
THCA	cis	rs10186029	0.676	rs4673720	ENSG00000270659.1	RP11-105N14.1	-4.56	6.56e-06	0.000701	-0.16	-0.21	Systemic sclerosis;	chr2:213076857	chr2:213152970~213153659:+
THCA	cis	rs3824488	0.92	rs28673156	ENSG00000237857.2	RP11-435O5.2	-4.56	6.56e-06	0.000701	-0.37	-0.21	Neuroticism;	chr9:95485508	chr9:95414834~95426796:-
THCA	cis	rs42648	0.869	rs42617	ENSG00000225498.1	AC002064.5	4.56	6.56e-06	0.000701	0.21	0.21	Homocysteine levels;	chr7:90322732	chr7:90312496~90322592:+
THCA	cis	rs875971	0.83	rs12673450	ENSG00000229886.1	RP5-1132H15.3	4.56	6.56e-06	0.000701	0.22	0.21	Aortic root size;	chr7:66544233	chr7:66025126~66031544:-
THCA	cis	rs8028182	0.636	rs4545784	ENSG00000260269.4	CTD-2323K18.1	-4.56	6.56e-06	0.000701	-0.31	-0.21	Sudden cardiac arrest;	chr15:75463310	chr15:75527150~75601205:-
THCA	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-4.56	6.56e-06	0.000701	-0.29	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
THCA	cis	rs59868192	0.925	rs16972296	ENSG00000246740.2	PLA2G4E-AS1	4.56	6.57e-06	0.000701	0.41	0.21	White blood cell count;	chr15:41936843	chr15:41972763~41999094:+
THCA	cis	rs7267979	0.903	rs2474769	ENSG00000274973.1	RP13-401N8.7	-4.56	6.57e-06	0.000701	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25845497~25845862:+
THCA	cis	rs4915077	1	rs78326196	ENSG00000226822.1	RP11-356N1.2	4.56	6.57e-06	0.000702	0.41	0.21	Hypothyroidism;	chr1:107834510	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs2125747	ENSG00000226822.1	RP11-356N1.2	4.56	6.57e-06	0.000702	0.41	0.21	Hypothyroidism;	chr1:107837911	chr1:108071482~108074519:+
THCA	cis	rs7577696	0.888	rs652978	ENSG00000276334.1	AL133243.1	-4.56	6.57e-06	0.000702	-0.22	-0.21	Inflammatory biomarkers;	chr2:32061342	chr2:32521927~32523547:+
THCA	cis	rs240993	0.812	rs28770304	ENSG00000271789.1	RP5-1112D6.7	4.56	6.58e-06	0.000702	0.25	0.21	Inflammatory skin disease;Psoriasis;	chr6:111461586	chr6:111297126~111298510:+
THCA	cis	rs240993	0.812	rs9387012	ENSG00000271789.1	RP5-1112D6.7	4.56	6.58e-06	0.000702	0.25	0.21	Inflammatory skin disease;Psoriasis;	chr6:111465824	chr6:111297126~111298510:+
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000164669.11	INTS4P1	-4.56	6.58e-06	0.000702	-0.26	-0.21	Calcium levels;	chr7:65903721	chr7:65141225~65234216:+
THCA	cis	rs2933343	0.951	rs9871612	ENSG00000261159.1	RP11-723O4.9	4.56	6.58e-06	0.000702	0.23	0.21	IgG glycosylation;	chr3:128851559	chr3:128859716~128860526:-
THCA	cis	rs2380205	0.651	rs1886057	ENSG00000232807.2	RP11-536K7.3	4.56	6.58e-06	0.000702	0.19	0.21	Breast cancer;	chr10:5883532	chr10:5934270~5945900:-
THCA	cis	rs2236231	0.55	rs61990080	ENSG00000259502.1	RP11-643G16.3	-4.56	6.58e-06	0.000703	-0.24	-0.21	Plasma kynurenine levels in major depressive disorder;	chr14:67595207	chr14:67610986~67613864:+
THCA	cis	rs2236231	0.55	rs61990081	ENSG00000259502.1	RP11-643G16.3	-4.56	6.58e-06	0.000703	-0.24	-0.21	Plasma kynurenine levels in major depressive disorder;	chr14:67595222	chr14:67610986~67613864:+
THCA	cis	rs875971	0.964	rs160635	ENSG00000222364.1	RNU6-96P	-4.56	6.58e-06	0.000703	-0.25	-0.21	Aortic root size;	chr7:66063931	chr7:66395191~66395286:+
THCA	cis	rs739496	0.615	rs4646778	ENSG00000226469.1	ADAM1B	4.56	6.58e-06	0.000703	0.26	0.21	Platelet count;	chr12:111797979	chr12:111927018~111929017:+
THCA	cis	rs301901	0.548	rs2366176	ENSG00000250155.1	CTD-2353F22.1	4.56	6.58e-06	0.000703	0.21	0.21	Height;	chr5:37439326	chr5:36666214~36725195:-
THCA	cis	rs2904524	0.609	rs57922961	ENSG00000257815.4	RP11-611E13.2	-4.56	6.59e-06	0.000703	-0.31	-0.21	Amyotrophic lateral sclerosis (age of onset);	chr12:70345617	chr12:69904033~70243360:-
THCA	cis	rs4578769	0.55	rs4471804	ENSG00000265939.1	UBE2CP2	-4.56	6.59e-06	0.000703	-0.23	-0.21	Eosinophil percentage of white cells;	chr18:22996218	chr18:22900486~22900995:-
THCA	cis	rs12143943	0.738	rs11240750	ENSG00000240219.1	RP11-430C7.5	4.56	6.59e-06	0.000704	0.18	0.21	Cognitive performance;	chr1:204490658	chr1:204626775~204629712:+
THCA	cis	rs115344852	0.557	rs2859351	ENSG00000216901.1	AL022393.7	4.56	6.59e-06	0.000704	0.3	0.21	Epithelial ovarian cancer;	chr6:28488418	chr6:28176188~28176674:+
THCA	cis	rs28829049	0.566	rs59681755	ENSG00000270728.1	RP4-657E11.10	-4.56	6.59e-06	0.000704	-0.15	-0.21	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19202491	chr1:19297080~19297903:+
THCA	cis	rs7617480	0.648	rs4858800	ENSG00000228638.1	FCF1P2	-4.56	6.59e-06	0.000704	-0.25	-0.21	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48718387	chr3:48290793~48291375:-
THCA	cis	rs7267979	1	rs6050566	ENSG00000274973.1	RP13-401N8.7	4.56	6.59e-06	0.000704	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs4813563	ENSG00000274973.1	RP13-401N8.7	4.56	6.59e-06	0.000704	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs6037103	ENSG00000274973.1	RP13-401N8.7	4.56	6.59e-06	0.000704	0.23	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25845497~25845862:+
THCA	cis	rs2898290	0.5	rs11998678	ENSG00000227888.4	FAM66A	-4.56	6.59e-06	0.000704	-0.26	-0.21	Systolic blood pressure;	chr8:11972641	chr8:12362019~12388296:+
THCA	cis	rs6954895	0.954	rs6972585	ENSG00000271122.1	RP11-379H18.1	4.56	6.59e-06	0.000704	0.15	0.21	Anger;	chr7:35546440	chr7:35695214~35699413:+
THCA	cis	rs4916588	0.636	rs4916566	ENSG00000270170.1	NCBP2-AS2	-4.56	6.59e-06	0.000704	-0.16	-0.21	Night sleep phenotypes;	chr3:196872053	chr3:196942623~196943540:+
THCA	cis	rs7141336	1	rs8019191	ENSG00000258884.1	CTD-3035D6.2	4.56	6.59e-06	0.000704	0.27	0.21	Anxiety disorder;	chr14:90819163	chr14:90822365~90828128:-
THCA	cis	rs73108077	1	rs73105976	ENSG00000277112.2	RP11-755J8.1	-4.56	6.59e-06	0.000704	-0.41	-0.21	Red blood cell density in sickle cell anemia;	chr20:31378130	chr20:30681825~30723932:-
THCA	cis	rs7314031	1	rs7314031	ENSG00000226469.1	ADAM1B	4.56	6.59e-06	0.000704	0.3	0.21	Reticulocyte count;Reticulocyte fraction of red cells;	chr12:112392775	chr12:111927018~111929017:+
THCA	cis	rs793571	0.628	rs12591310	ENSG00000245975.2	RP11-30K9.6	4.56	6.59e-06	0.000704	0.24	0.21	Schizophrenia;	chr15:58792069	chr15:58768072~58770974:-
THCA	cis	rs4908760	0.731	rs12075458	ENSG00000232912.4	RP5-1115A15.1	4.56	6.6e-06	0.000704	0.2	0.21	Vitiligo;	chr1:8698735	chr1:8424645~8434838:+
THCA	cis	rs9543976	1	rs9565177	ENSG00000261105.4	LMO7-AS1	-4.56	6.6e-06	0.000704	-0.31	-0.21	Diabetic retinopathy;	chr13:75621267	chr13:75604700~75635994:-
THCA	cis	rs1876905	0.524	rs1084639	ENSG00000272356.1	RP5-1112D6.8	-4.56	6.6e-06	0.000704	-0.21	-0.21	Mean corpuscular hemoglobin;	chr6:111165240	chr6:111309203~111313517:+
THCA	cis	rs17801127	0.591	rs10755045	ENSG00000231969.1	AC144449.1	-4.56	6.6e-06	0.000704	-0.33	-0.21	Liver enzyme levels (alanine transaminase);	chr2:149706334	chr2:149587196~149848233:+
THCA	cis	rs9880211	0.948	rs9820621	ENSG00000239213.4	NCK1-AS1	4.56	6.6e-06	0.000704	0.23	0.21	Height;Body mass index;	chr3:136391671	chr3:136841726~136862054:-
THCA	cis	rs8017455	0.523	rs28417017	ENSG00000259167.2	NMNAT1P1	4.56	6.6e-06	0.000705	0.31	0.21	Hair morphology;	chr14:81093942	chr14:81032529~81033404:+
THCA	cis	rs3796352	0.892	rs2581807	ENSG00000242142.1	SERBP1P3	4.56	6.6e-06	0.000705	0.35	0.21	Immune reponse to smallpox (secreted IL-2);	chr3:53054828	chr3:53064283~53065091:-
THCA	cis	rs1046491	1	rs62085927	ENSG00000264964.1	RP11-888D10.3	4.56	6.6e-06	0.000705	0.35	0.21	Scarlet fever;	chr18:9232564	chr18:9315194~9334441:-
THCA	cis	rs5758659	1	rs134873	ENSG00000273366.1	CTA-989H11.1	-4.56	6.6e-06	0.000705	-0.24	-0.21	Cognitive function;	chr22:42261560	chr22:42278188~42278846:+
THCA	cis	rs853679	1	rs10456362	ENSG00000272009.1	RP1-313I6.12	4.56	6.6e-06	0.000705	0.26	0.21	Depression;	chr6:28254038	chr6:28078792~28081130:-
THCA	cis	rs9902453	1	rs57411618	ENSG00000263370.1	RP11-68I3.5	4.56	6.61e-06	0.000705	0.27	0.21	Coffee consumption (cups per day);	chr17:29946034	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs7222308	ENSG00000263370.1	RP11-68I3.5	4.56	6.61e-06	0.000705	0.27	0.21	Coffee consumption (cups per day);	chr17:29950023	chr17:29639627~29640825:+
THCA	cis	rs9467773	0.62	rs2504540	ENSG00000261353.1	CTA-14H9.5	-4.56	6.61e-06	0.000705	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.596	rs2451750	ENSG00000261353.1	CTA-14H9.5	-4.56	6.61e-06	0.000705	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.596	rs2451751	ENSG00000261353.1	CTA-14H9.5	-4.56	6.61e-06	0.000705	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2504600	ENSG00000261353.1	CTA-14H9.5	-4.56	6.61e-06	0.000705	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2130657	ENSG00000261353.1	CTA-14H9.5	-4.56	6.61e-06	0.000705	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2498351	ENSG00000261353.1	CTA-14H9.5	-4.56	6.61e-06	0.000705	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2504566	ENSG00000261353.1	CTA-14H9.5	-4.56	6.61e-06	0.000705	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2494716	ENSG00000261353.1	CTA-14H9.5	-4.56	6.61e-06	0.000705	-0.21	-0.21	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26527063~26527404:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000164669.11	INTS4P1	-4.56	6.61e-06	0.000706	-0.26	-0.21	Aortic root size;	chr7:65827018	chr7:65141225~65234216:+
THCA	cis	rs9875589	0.509	rs4685051	ENSG00000228242.5	AC093495.4	4.56	6.61e-06	0.000706	0.12	0.21	Ovarian reserve;	chr3:13940260	chr3:14144637~14165978:+
THCA	cis	rs5742933	0.842	rs1225101	ENSG00000273240.1	RP11-455J20.3	-4.56	6.61e-06	0.000706	-0.23	-0.21	Ferritin levels;	chr2:189740695	chr2:189763859~189764456:-
THCA	cis	rs2948294	0.588	rs12544596	ENSG00000254340.1	RP11-10A14.3	4.56	6.61e-06	0.000706	0.23	0.21	Red cell distribution width;	chr8:8258824	chr8:9141424~9145435:+
THCA	cis	rs868036	0.718	rs8025790	ENSG00000270964.1	RP11-502I4.3	-4.56	6.61e-06	0.000706	-0.19	-0.21	Restless legs syndrome;	chr15:67784061	chr15:67541072~67542604:-
THCA	cis	rs875971	0.638	rs801205	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.62e-06	0.000706	-0.21	-0.21	Aortic root size;	chr7:66557157	chr7:66025126~66031544:-
THCA	cis	rs875971	0.617	rs810400	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.62e-06	0.000706	-0.21	-0.21	Aortic root size;	chr7:66557902	chr7:66025126~66031544:-
THCA	cis	rs875971	0.638	rs3898855	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.62e-06	0.000706	-0.21	-0.21	Aortic root size;	chr7:66571411	chr7:66025126~66031544:-
THCA	cis	rs875971	0.638	rs10278816	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.62e-06	0.000706	-0.21	-0.21	Aortic root size;	chr7:66572000	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs10281080	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.62e-06	0.000706	-0.21	-0.21	Aortic root size;	chr7:66577454	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs10950044	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.62e-06	0.000706	-0.21	-0.21	Aortic root size;	chr7:66577989	chr7:66025126~66031544:-
THCA	cis	rs875971	0.522	rs1968127	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.62e-06	0.000706	-0.21	-0.21	Aortic root size;	chr7:66591816	chr7:66025126~66031544:-
THCA	cis	rs5753037	0.702	rs249398	ENSG00000279699.1	RP1-102K2.9	4.56	6.62e-06	0.000706	0.2	0.21	Type 1 diabetes;	chr22:29818715	chr22:30275215~30276951:-
THCA	cis	rs782590	0.574	rs12991445	ENSG00000272606.1	RP11-554J4.1	-4.56	6.62e-06	0.000706	-0.19	-0.21	Metabolic syndrome;	chr2:55448803	chr2:55617909~55618373:+
THCA	cis	rs7267979	0.844	rs6107027	ENSG00000277938.1	RP5-965G21.3	4.56	6.62e-06	0.000706	0.17	0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25229150~25231933:+
THCA	cis	rs858239	0.6	rs10256524	ENSG00000226816.2	AC005082.12	4.56	6.62e-06	0.000707	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23206013~23208045:+
THCA	cis	rs67478160	0.654	rs11628240	ENSG00000269910.1	RP11-73M18.10	4.56	6.62e-06	0.000707	0.17	0.21	Schizophrenia;	chr14:103751798	chr14:103694516~103695050:-
THCA	cis	rs6545883	0.868	rs778755	ENSG00000271889.1	RP11-493E12.1	-4.56	6.62e-06	0.000707	-0.19	-0.21	Tuberculosis;	chr2:61553902	chr2:61151433~61162105:-
THCA	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-4.56	6.63e-06	0.000707	-0.24	-0.21	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
THCA	cis	rs6570726	0.905	rs442435	ENSG00000270638.1	RP3-466P17.1	4.56	6.63e-06	0.000707	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.905	rs396492	ENSG00000270638.1	RP3-466P17.1	4.56	6.63e-06	0.000707	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs7757387	ENSG00000270638.1	RP3-466P17.1	4.56	6.63e-06	0.000707	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145735570~145737218:+
THCA	cis	rs711244	0.656	rs79579364	ENSG00000279519.1	RP11-288C18.1	4.56	6.63e-06	0.000707	0.17	0.21	Mean platelet volume;	chr2:36906949	chr2:36839922~36842539:-
THCA	cis	rs1023500	0.573	rs133378	ENSG00000273366.1	CTA-989H11.1	-4.56	6.63e-06	0.000707	-0.26	-0.21	Schizophrenia;	chr22:42071691	chr22:42278188~42278846:+
THCA	cis	rs875971	1	rs1167411	ENSG00000222364.1	RNU6-96P	4.56	6.63e-06	0.000708	0.25	0.21	Aortic root size;	chr7:66074277	chr7:66395191~66395286:+
THCA	cis	rs6088813	0.961	rs2425062	ENSG00000279253.1	RP4-614O4.13	-4.56	6.63e-06	0.000708	-0.2	-0.21	Height;	chr20:35335763	chr20:35262727~35264187:-
THCA	cis	rs6560517	0.54	rs13294840	ENSG00000234618.1	RPSAP9	-4.56	6.63e-06	0.000708	-0.27	-0.21	Dialysis-related mortality;	chr9:76450159	chr9:76398699~76399586:+
THCA	cis	rs786425	0.77	rs7134074	ENSG00000270095.1	RP11-214K3.18	-4.56	6.63e-06	0.000708	-0.25	-0.21	Pubertal anthropometrics;	chr12:123675338	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs35158437	ENSG00000270095.1	RP11-214K3.18	-4.56	6.63e-06	0.000708	-0.25	-0.21	Pubertal anthropometrics;	chr12:123676217	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs7313261	ENSG00000270095.1	RP11-214K3.18	-4.56	6.63e-06	0.000708	-0.25	-0.21	Pubertal anthropometrics;	chr12:123682390	chr12:123971457~123971714:-
THCA	cis	rs5751614	0.537	rs3788358	ENSG00000240160.3	RN7SL263P	4.56	6.63e-06	0.000708	0.26	0.21	Height;	chr22:23274168	chr22:23261782~23262071:-
THCA	cis	rs1334894	0.584	rs7738975	ENSG00000228559.1	RP3-340B19.3	-4.56	6.63e-06	0.000708	-0.32	-0.21	Coronary artery disease;	chr6:35501946	chr6:35544632~35545669:+
THCA	cis	rs4819052	0.918	rs34886433	ENSG00000273796.1	LL21NC02-21A1.1	-4.56	6.64e-06	0.000708	-0.25	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45403809~45404369:-
THCA	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-4.56	6.64e-06	0.000708	-0.31	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
THCA	cis	rs6496932	0.755	rs6497021	ENSG00000259630.2	CTD-2262B20.1	-4.56	6.64e-06	0.000708	-0.25	-0.21	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85415228~85415633:+
THCA	cis	rs2721195	0.683	rs6989368	ENSG00000265393.1	CTD-2517M22.17	-4.56	6.64e-06	0.000708	-0.25	-0.21	Age at first birth;	chr8:144588073	chr8:144512567~144513672:+
THCA	cis	rs8141529	1	rs132534	ENSG00000226471.5	CTA-292E10.6	4.56	6.64e-06	0.000708	0.18	0.21	Lymphocyte counts;	chr22:28903818	chr22:28800683~28848559:+
THCA	cis	rs6845263	0.546	rs7682189	ENSG00000254531.1	FLJ20021	-4.56	6.64e-06	0.000709	-0.18	-0.21	Superior crus of antihelix expression;	chr4:101541398	chr4:101347780~101348883:+
THCA	cis	rs10090774	0.87	rs4563941	ENSG00000279766.1	RP11-642A1.2	-4.56	6.64e-06	0.000709	-0.25	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140722653	chr8:140572142~140572812:-
THCA	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-4.56	6.64e-06	0.000709	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
THCA	cis	rs990871	0.53	rs11209932	ENSG00000227207.2	RPL31P12	-4.56	6.64e-06	0.000709	-0.24	-0.21	Subcutaneous adipose tissue;	chr1:72177194	chr1:72301472~72301829:+
THCA	cis	rs990871	0.512	rs12036585	ENSG00000227207.2	RPL31P12	-4.56	6.64e-06	0.000709	-0.24	-0.21	Subcutaneous adipose tissue;	chr1:72178433	chr1:72301472~72301829:+
THCA	cis	rs4950322	0.518	rs55697094	ENSG00000226015.2	CCT8P1	4.56	6.64e-06	0.000709	0.24	0.21	Protein quantitative trait loci;	chr1:147121205	chr1:147203276~147204932:-
THCA	cis	rs10090774	0.87	rs7834669	ENSG00000279766.1	RP11-642A1.2	-4.56	6.64e-06	0.000709	-0.25	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140724287	chr8:140572142~140572812:-
THCA	cis	rs990871	0.53	rs2821293	ENSG00000227207.2	RPL31P12	-4.56	6.64e-06	0.000709	-0.24	-0.21	Subcutaneous adipose tissue;	chr1:72176967	chr1:72301472~72301829:+
THCA	cis	rs916888	0.61	rs199436	ENSG00000261575.2	RP11-259G18.1	-4.56	6.65e-06	0.000709	-0.25	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46267037~46268694:+
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000232559.3	GS1-124K5.12	4.56	6.65e-06	0.000709	0.3	0.21	Diabetic kidney disease;	chr7:65947955	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs59794892	ENSG00000232559.3	GS1-124K5.12	4.56	6.65e-06	0.000709	0.3	0.21	Diabetic kidney disease;	chr7:65950886	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000232559.3	GS1-124K5.12	4.56	6.65e-06	0.000709	0.3	0.21	Diabetic kidney disease;	chr7:65951525	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000232559.3	GS1-124K5.12	4.56	6.65e-06	0.000709	0.3	0.21	Diabetic kidney disease;	chr7:65951549	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs11538349	ENSG00000232559.3	GS1-124K5.12	4.56	6.65e-06	0.000709	0.3	0.21	Diabetic kidney disease;	chr7:65956884	chr7:66554588~66576923:-
THCA	cis	rs755249	0.51	rs599892	ENSG00000182109.6	RP11-69E11.4	4.56	6.65e-06	0.000709	0.2	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39522280~39546187:-
THCA	cis	rs1005277	0.54	rs7903942	ENSG00000276805.1	RP11-291L22.6	-4.56	6.65e-06	0.000709	-0.22	-0.21	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38451030~38451785:+
THCA	cis	rs17680741	0.697	rs2343550	ENSG00000225484.5	NUTM2B-AS1	-4.56	6.65e-06	0.000709	-0.29	-0.21	Coronary artery disease;	chr10:80504667	chr10:79663088~79826594:-
THCA	cis	rs858239	0.6	rs28646184	ENSG00000226816.2	AC005082.12	4.56	6.65e-06	0.00071	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23206013~23208045:+
THCA	cis	rs8067545	0.611	rs1859407	ENSG00000270091.1	RP11-78O7.2	4.56	6.65e-06	0.00071	0.16	0.21	Schizophrenia;	chr17:20174824	chr17:19896590~19897287:-
THCA	cis	rs6845263	0.546	rs2114366	ENSG00000254531.1	FLJ20021	-4.56	6.65e-06	0.00071	-0.18	-0.21	Superior crus of antihelix expression;	chr4:101538911	chr4:101347780~101348883:+
THCA	cis	rs6121246	0.512	rs6058384	ENSG00000230613.1	HM13-AS1	4.56	6.65e-06	0.00071	0.2	0.21	Mean corpuscular hemoglobin;	chr20:31688606	chr20:31567707~31573263:-
THCA	cis	rs56114371	0.53	rs169262	ENSG00000280107.1	AL022393.9	-4.56	6.66e-06	0.00071	-0.25	-0.21	Breast cancer;	chr6:27803112	chr6:28170845~28172521:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000229886.1	RP5-1132H15.3	4.56	6.66e-06	0.00071	0.21	0.21	Aortic root size;	chr7:66631041	chr7:66025126~66031544:-
THCA	cis	rs17095355	1	rs11194926	ENSG00000203876.8	ADD3-AS1	4.56	6.66e-06	0.00071	0.22	0.21	Biliary atresia;	chr10:109941164	chr10:109940104~110008381:-
THCA	cis	rs62158800	0.778	rs62158773	ENSG00000224568.1	AC096669.3	4.56	6.66e-06	0.000711	0.39	0.21	Facial morphology (factor 22);	chr2:107573089	chr2:107529487~107556326:+
THCA	cis	rs9393777	0.92	rs72839445	ENSG00000220721.1	OR1F12	4.56	6.67e-06	0.000711	0.48	0.21	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28073316~28074233:+
THCA	cis	rs1979679	0.801	rs6487686	ENSG00000247934.4	RP11-967K21.1	4.56	6.67e-06	0.000711	0.2	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28548362	chr12:28163298~28190738:-
THCA	cis	rs9863	0.828	rs4765127	ENSG00000269997.1	RP11-214K3.21	-4.56	6.67e-06	0.000711	-0.25	-0.21	White blood cell count;	chr12:123975620	chr12:123966077~123966629:-
THCA	cis	rs2439831	0.867	rs8039638	ENSG00000205771.5	CATSPER2P1	-4.56	6.67e-06	0.000711	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43342207	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs28415933	ENSG00000205771.5	CATSPER2P1	-4.56	6.67e-06	0.000711	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43343602	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs12324572	ENSG00000205771.5	CATSPER2P1	-4.56	6.67e-06	0.000711	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43344002	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2412779	ENSG00000205771.5	CATSPER2P1	-4.56	6.67e-06	0.000711	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43363729	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs2899082	ENSG00000205771.5	CATSPER2P1	-4.56	6.67e-06	0.000711	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43363845	chr15:43726918~43747094:-
THCA	cis	rs4763879	0.778	rs11052497	ENSG00000256673.1	RP11-599J14.2	4.56	6.67e-06	0.000711	0.25	0.21	Type 1 diabetes;	chr12:9696679	chr12:9398355~9414851:-
THCA	cis	rs4915077	1	rs9787296	ENSG00000226822.1	RP11-356N1.2	4.56	6.67e-06	0.000711	0.41	0.21	Hypothyroidism;	chr1:107840205	chr1:108071482~108074519:+
THCA	cis	rs17095355	1	rs17095350	ENSG00000203876.8	ADD3-AS1	-4.56	6.67e-06	0.000711	-0.22	-0.21	Biliary atresia;	chr10:109941950	chr10:109940104~110008381:-
THCA	cis	rs875971	0.522	rs7784623	ENSG00000234585.5	CCT6P3	4.56	6.67e-06	0.000711	0.18	0.21	Aortic root size;	chr7:65930047	chr7:65038354~65074713:+
THCA	cis	rs2787702	1	rs1378884	ENSG00000237233.2	TMEM26-AS1	4.56	6.67e-06	0.000711	0.26	0.21	Response to taxane treatment (placlitaxel);	chr10:61560174	chr10:61452639~61481956:+
THCA	cis	rs240993	0.627	rs174389	ENSG00000230177.1	RP5-1112D6.4	-4.56	6.67e-06	0.000711	-0.2	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111595190	chr6:111277932~111278742:+
THCA	cis	rs72615157	0.634	rs7789890	ENSG00000242294.5	STAG3L5P	4.56	6.67e-06	0.000711	0.13	0.21	Lung function (FEV1/FVC);	chr7:100202936	chr7:100336079~100351900:+
THCA	cis	rs72615157	0.634	rs79986079	ENSG00000242294.5	STAG3L5P	4.56	6.67e-06	0.000711	0.13	0.21	Lung function (FEV1/FVC);	chr7:100204421	chr7:100336079~100351900:+
THCA	cis	rs6570726	0.935	rs387965	ENSG00000270638.1	RP3-466P17.1	4.56	6.67e-06	0.000712	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145735570~145737218:+
THCA	cis	rs9880211	0.948	rs34913797	ENSG00000239213.4	NCK1-AS1	4.56	6.67e-06	0.000712	0.23	0.21	Height;Body mass index;	chr3:136408728	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs9812579	ENSG00000239213.4	NCK1-AS1	4.56	6.67e-06	0.000712	0.23	0.21	Height;Body mass index;	chr3:136432408	chr3:136841726~136862054:-
THCA	cis	rs6012564	1	rs6066975	ENSG00000227431.4	CSE1L-AS1	-4.56	6.67e-06	0.000712	-0.26	-0.21	Anger;	chr20:49133840	chr20:49040463~49046044:-
THCA	cis	rs17772222	0.74	rs10150986	ENSG00000222990.1	RNU4-22P	4.56	6.67e-06	0.000712	0.25	0.21	Coronary artery calcification;	chr14:88517326	chr14:88513498~88513663:+
THCA	cis	rs9625935	0.843	rs4239932	ENSG00000279159.1	RP3-394A18.1	4.56	6.67e-06	0.000712	0.16	0.21	Tonsillectomy;	chr22:29972395	chr22:29978950~30028236:-
THCA	cis	rs2243480	1	rs781157	ENSG00000232559.3	GS1-124K5.12	4.56	6.67e-06	0.000712	0.3	0.21	Diabetic kidney disease;	chr7:66013324	chr7:66554588~66576923:-
THCA	cis	rs2439831	0.867	rs2243434	ENSG00000166763.7	STRCP1	4.56	6.68e-06	0.000712	0.28	0.21	Lung cancer in ever smokers;	chr15:43397669	chr15:43699488~43718184:-
THCA	cis	rs8067545	1	rs8065337	ENSG00000270091.1	RP11-78O7.2	-4.56	6.68e-06	0.000712	-0.15	-0.21	Schizophrenia;	chr17:20038566	chr17:19896590~19897287:-
THCA	cis	rs8062405	0.895	rs56186137	ENSG00000261766.1	RP11-22P6.2	-4.56	6.68e-06	0.000712	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28862166~28863340:-
THCA	cis	rs332034	0.546	rs10091646	ENSG00000253893.2	FAM85B	4.56	6.68e-06	0.000713	0.39	0.21	Conduct disorder (maternal expressed emotions interaction);	chr8:8830249	chr8:8167819~8226614:-
THCA	cis	rs2281603	0.762	rs12588437	ENSG00000259116.1	RP11-973N13.4	-4.56	6.68e-06	0.000713	-0.2	-0.21	Lymphocyte counts;	chr14:64580366	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.762	rs12588509	ENSG00000259116.1	RP11-973N13.4	4.56	6.68e-06	0.000713	0.2	0.21	Lymphocyte counts;	chr14:64580554	chr14:64514154~64540368:-
THCA	cis	rs8049040	0.586	rs16972663	ENSG00000260886.1	TAT-AS1	4.56	6.68e-06	0.000713	0.29	0.21	Blood protein levels;	chr16:71426661	chr16:71565789~71578187:+
THCA	cis	rs911555	0.655	rs10149470	ENSG00000269910.1	RP11-73M18.10	4.56	6.68e-06	0.000713	0.18	0.21	Intelligence (multi-trait analysis);	chr14:103551616	chr14:103694516~103695050:-
THCA	cis	rs7511006	0.893	rs2038049	ENSG00000272836.1	RP3-402G11.27	-4.56	6.68e-06	0.000713	-0.17	-0.21	Obesity-related traits;	chr22:50216459	chr22:50205585~50206062:-
THCA	cis	rs2734839	0.964	rs11214605	ENSG00000270179.1	RP11-159N11.4	-4.55	6.69e-06	0.000713	-0.22	-0.21	Information processing speed;	chr11:113429879	chr11:113368478~113369117:+
THCA	cis	rs42648	0.869	rs10266179	ENSG00000225498.1	AC002064.5	4.55	6.69e-06	0.000713	0.21	0.21	Homocysteine levels;	chr7:90280668	chr7:90312496~90322592:+
THCA	cis	rs1046491	1	rs62085926	ENSG00000264964.1	RP11-888D10.3	4.55	6.69e-06	0.000713	0.35	0.21	Scarlet fever;	chr18:9212641	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs11661921	ENSG00000264964.1	RP11-888D10.3	4.55	6.69e-06	0.000713	0.35	0.21	Scarlet fever;	chr18:9214150	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs8089577	ENSG00000264964.1	RP11-888D10.3	4.55	6.69e-06	0.000713	0.35	0.21	Scarlet fever;	chr18:9217484	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs11872176	ENSG00000264964.1	RP11-888D10.3	4.55	6.69e-06	0.000713	0.35	0.21	Scarlet fever;	chr18:9218600	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs12454497	ENSG00000264964.1	RP11-888D10.3	4.55	6.69e-06	0.000713	0.35	0.21	Scarlet fever;	chr18:9224441	chr18:9315194~9334441:-
THCA	cis	rs11633886	0.835	rs7178907	ENSG00000273972.1	CTD-2306A12.1	-4.55	6.69e-06	0.000713	-0.22	-0.21	Diisocyanate-induced asthma;	chr15:45809159	chr15:45702640~45703183:+
THCA	cis	rs6840258	0.943	rs10029915	ENSG00000251411.1	RP11-397E7.4	-4.55	6.69e-06	0.000713	-0.24	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87138465	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.891	rs66477840	ENSG00000251411.1	RP11-397E7.4	-4.55	6.69e-06	0.000713	-0.24	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87142207	chr4:86913266~86914817:-
THCA	cis	rs1223245	0.74	rs360063	ENSG00000242861.1	RP11-285F7.2	4.55	6.69e-06	0.000713	0.17	0.21	Preschool internalizing problems;	chr1:225848608	chr1:225840883~225846522:-
THCA	cis	rs73198271	0.603	rs546606	ENSG00000253893.2	FAM85B	4.55	6.69e-06	0.000713	0.28	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8738333	chr8:8167819~8226614:-
THCA	cis	rs875971	0.66	rs12698534	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.000713	0.21	0.21	Aortic root size;	chr7:66521858	chr7:66025126~66031544:-
THCA	cis	rs62158800	0.778	rs72823033	ENSG00000224568.1	AC096669.3	4.55	6.69e-06	0.000713	0.39	0.21	Facial morphology (factor 22);	chr2:107570342	chr2:107529487~107556326:+
THCA	cis	rs7833787	0.668	rs2638631	ENSG00000278886.1	RP11-108A14.1	4.55	6.69e-06	0.000713	0.26	0.21	Obesity-related traits;	chr8:18820825	chr8:18864681~18865247:-
THCA	cis	rs2439831	0.867	rs2584702	ENSG00000166763.7	STRCP1	4.55	6.69e-06	0.000714	0.28	0.21	Lung cancer in ever smokers;	chr15:43392716	chr15:43699488~43718184:-
THCA	cis	rs12478296	1	rs12478296	ENSG00000220804.7	AC093642.5	-4.55	6.69e-06	0.000714	-0.23	-0.21	Obesity-related traits;	chr2:242106609	chr2:242088633~242160153:+
THCA	cis	rs13113518	1	rs7691799	ENSG00000249700.7	SRD5A3-AS1	4.55	6.69e-06	0.000714	0.25	0.21	Height;	chr4:55545574	chr4:55363971~55395847:-
THCA	cis	rs12143943	0.966	rs6669246	ENSG00000240219.1	RP11-430C7.5	4.55	6.69e-06	0.000714	0.18	0.21	Cognitive performance;	chr1:204588433	chr1:204626775~204629712:+
THCA	cis	rs6921919	0.697	rs758398	ENSG00000219392.1	RP1-265C24.5	-4.55	6.69e-06	0.000714	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28115628~28116551:+
THCA	cis	rs375066	0.539	rs7249057	ENSG00000267058.1	RP11-15A1.3	4.55	6.7e-06	0.000714	0.18	0.21	Breast cancer;	chr19:43826074	chr19:43891804~43901805:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000164669.11	INTS4P1	-4.55	6.7e-06	0.000714	-0.25	-0.21	Calcium levels;	chr7:65853042	chr7:65141225~65234216:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000164669.11	INTS4P1	-4.55	6.7e-06	0.000714	-0.25	-0.21	Aortic root size;	chr7:65871069	chr7:65141225~65234216:+
THCA	cis	rs548181	0.604	rs11608103	ENSG00000254671.2	STT3A-AS1	4.55	6.7e-06	0.000714	0.35	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125758022	chr11:125570284~125592568:-
THCA	cis	rs2018683	0.745	rs917217	ENSG00000272568.4	CTB-113D17.1	-4.55	6.7e-06	0.000714	-0.2	-0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935408	chr7:28979967~29013367:+
THCA	cis	rs11168351	0.926	rs10875719	ENSG00000273765.1	RP11-370I10.11	4.55	6.7e-06	0.000714	0.2	0.21	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48360920~48361377:+
THCA	cis	rs59918340	0.764	rs10101692	ENSG00000253307.1	RP11-10J21.4	4.55	6.7e-06	0.000714	0.28	0.21	Immature fraction of reticulocytes;	chr8:141220724	chr8:141252286~141253292:-
THCA	cis	rs12908161	0.515	rs12907646	ENSG00000275120.1	RP11-182J1.17	4.55	6.7e-06	0.000714	0.25	0.21	Schizophrenia;	chr15:84860265	chr15:84599434~84606463:-
THCA	cis	rs7554547	0.69	rs61402980	ENSG00000201801.1	RNU5E-4P	4.55	6.7e-06	0.000714	0.25	0.21	Nonsyndromic cleft lip with cleft palate;	chr1:11876432	chr1:11909808~11909927:-
THCA	cis	rs10090774	0.93	rs6982216	ENSG00000279766.1	RP11-642A1.2	-4.55	6.7e-06	0.000715	-0.26	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140838142	chr8:140572142~140572812:-
THCA	cis	rs189798	0.807	rs330909	ENSG00000253893.2	FAM85B	-4.55	6.7e-06	0.000715	-0.26	-0.21	Myopia (pathological);	chr8:9137877	chr8:8167819~8226614:-
THCA	cis	rs10760158	0.8	rs10818525	ENSG00000235865.2	GSN-AS1	4.55	6.7e-06	0.000715	0.18	0.21	Pulse pressure;	chr9:121289999	chr9:121280768~121285530:-
THCA	cis	rs2803122	0.934	rs4333703	ENSG00000273226.1	RP11-513M16.8	-4.55	6.71e-06	0.000715	-0.19	-0.21	Pulse pressure;	chr9:19287912	chr9:19375451~19375996:+
THCA	cis	rs8077577	0.747	rs12449313	ENSG00000273018.4	CTD-2303H24.2	-4.55	6.71e-06	0.000715	-0.3	-0.21	Obesity-related traits;	chr17:18317696	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.731	rs11869952	ENSG00000273018.4	CTD-2303H24.2	-4.55	6.71e-06	0.000715	-0.3	-0.21	Obesity-related traits;	chr17:18318399	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.689	rs16961133	ENSG00000273018.4	CTD-2303H24.2	-4.55	6.71e-06	0.000715	-0.3	-0.21	Obesity-related traits;	chr17:18320234	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.747	rs57697650	ENSG00000273018.4	CTD-2303H24.2	-4.55	6.71e-06	0.000715	-0.3	-0.21	Obesity-related traits;	chr17:18321381	chr17:18511221~18551705:-
THCA	cis	rs11633886	0.622	rs4774813	ENSG00000273972.1	CTD-2306A12.1	-4.55	6.71e-06	0.000715	-0.23	-0.21	Diisocyanate-induced asthma;	chr15:45837857	chr15:45702640~45703183:+
THCA	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-4.55	6.71e-06	0.000715	-0.31	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
THCA	cis	rs930395	0.514	rs11951760	ENSG00000272335.1	RP11-53O19.3	4.55	6.71e-06	0.000715	0.17	0.21	Breast cancer;	chr5:44872070	chr5:44826076~44828592:+
THCA	cis	rs858239	0.6	rs7787110	ENSG00000226816.2	AC005082.12	4.55	6.71e-06	0.000715	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23206013~23208045:+
THCA	cis	rs10487112	0.536	rs7779628	ENSG00000225498.1	AC002064.5	4.55	6.71e-06	0.000715	0.28	0.21	Perceived unattractiveness to mosquitoes;	chr7:90377944	chr7:90312496~90322592:+
THCA	cis	rs7772486	0.754	rs9399567	ENSG00000270638.1	RP3-466P17.1	4.55	6.71e-06	0.000715	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145735570~145737218:+
THCA	cis	rs1009077	0.61	rs2248236	ENSG00000245958.5	RP11-33B1.1	-4.55	6.71e-06	0.000715	-0.23	-0.21	Endometriosis;	chr4:119572782	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs2622499	ENSG00000245958.5	RP11-33B1.1	-4.55	6.71e-06	0.000715	-0.23	-0.21	Endometriosis;	chr4:119574695	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs2622500	ENSG00000245958.5	RP11-33B1.1	-4.55	6.71e-06	0.000715	-0.23	-0.21	Endometriosis;	chr4:119574951	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs12646525	ENSG00000245958.5	RP11-33B1.1	-4.55	6.71e-06	0.000715	-0.23	-0.21	Endometriosis;	chr4:119581306	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs12503853	ENSG00000245958.5	RP11-33B1.1	-4.55	6.71e-06	0.000715	-0.23	-0.21	Endometriosis;	chr4:119582008	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs12648259	ENSG00000245958.5	RP11-33B1.1	-4.55	6.71e-06	0.000715	-0.23	-0.21	Endometriosis;	chr4:119583024	chr4:119454791~119552025:+
THCA	cis	rs2072883	0.669	rs2038063	ENSG00000230319.1	AL022476.2	4.55	6.72e-06	0.000716	0.23	0.21	Schizophrenia;	chr22:43053502	chr22:43038585~43052366:+
THCA	cis	rs7760535	0.93	rs7742244	ENSG00000271789.1	RP5-1112D6.7	-4.55	6.72e-06	0.000716	-0.21	-0.21	Metabolic traits;	chr6:111531459	chr6:111297126~111298510:+
THCA	cis	rs1003719	0.667	rs13050226	ENSG00000230366.8	DSCR9	-4.55	6.72e-06	0.000716	-0.22	-0.21	Eye color traits;	chr21:37085408	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.667	rs73201942	ENSG00000230366.8	DSCR9	-4.55	6.72e-06	0.000716	-0.22	-0.21	Eye color traits;	chr21:37102864	chr21:37208503~37221736:+
THCA	cis	rs858239	0.539	rs4295546	ENSG00000226816.2	AC005082.12	4.55	6.72e-06	0.000716	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23206013~23208045:+
THCA	cis	rs9326248	0.769	rs499910	ENSG00000280143.1	AP000892.6	4.55	6.72e-06	0.000716	0.27	0.21	Blood protein levels;	chr11:116892318	chr11:117204967~117210292:+
THCA	cis	rs4660214	0.666	rs3116398	ENSG00000182109.6	RP11-69E11.4	-4.55	6.72e-06	0.000716	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39522280~39546187:-
THCA	cis	rs2985684	0.894	rs6572585	ENSG00000278009.1	RP11-649E7.8	4.55	6.72e-06	0.000716	0.29	0.21	Carotid intima media thickness;	chr14:49554357	chr14:49601011~49601124:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000229886.1	RP5-1132H15.3	4.55	6.72e-06	0.000716	0.21	0.21	Aortic root size;	chr7:66540165	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs13224319	ENSG00000229886.1	RP5-1132H15.3	4.55	6.72e-06	0.000716	0.21	0.21	Aortic root size;	chr7:66542376	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs801217	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.72e-06	0.000716	-0.21	-0.21	Aortic root size;	chr7:66545590	chr7:66025126~66031544:-
THCA	cis	rs875971	0.638	rs801216	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.72e-06	0.000716	-0.21	-0.21	Aortic root size;	chr7:66546680	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs801211	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.72e-06	0.000716	-0.21	-0.21	Aortic root size;	chr7:66550702	chr7:66025126~66031544:-
THCA	cis	rs8105895	0.799	rs6511327	ENSG00000269345.1	VN1R85P	4.55	6.72e-06	0.000716	0.28	0.21	Body mass index (change over time);	chr19:22104097	chr19:22174766~22175191:-
THCA	cis	rs72717009	0.825	rs6671753	ENSG00000225217.1	HSPA7	-4.55	6.72e-06	0.000717	-0.32	-0.21	Rheumatoid arthritis;	chr1:161508918	chr1:161606291~161608217:+
THCA	cis	rs972578	0.691	rs2006040	ENSG00000274717.1	RP1-47A17.1	-4.55	6.73e-06	0.000717	-0.22	-0.21	Mean platelet volume;	chr22:42802289	chr22:42791814~42794313:-
THCA	cis	rs9926296	0.581	rs1108064	ENSG00000260259.1	RP11-368I7.4	-4.55	6.73e-06	0.000717	-0.22	-0.21	Vitiligo;	chr16:89827742	chr16:89682620~89686569:-
THCA	cis	rs801193	1	rs2707836	ENSG00000229886.1	RP5-1132H15.3	4.55	6.73e-06	0.000717	0.21	0.21	Aortic root size;	chr7:66695448	chr7:66025126~66031544:-
THCA	cis	rs801193	0.844	rs7779971	ENSG00000229886.1	RP5-1132H15.3	4.55	6.73e-06	0.000717	0.21	0.21	Aortic root size;	chr7:66696803	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs2659906	ENSG00000229886.1	RP5-1132H15.3	4.55	6.73e-06	0.000717	0.21	0.21	Aortic root size;	chr7:66700323	chr7:66025126~66031544:-
THCA	cis	rs1150668	0.699	rs13408	ENSG00000176933.5	TOB2P1	-4.55	6.73e-06	0.000717	-0.23	-0.21	Pubertal anthropometrics;	chr6:28244970	chr6:28217643~28218634:-
THCA	cis	rs1555322	0.932	rs2425018	ENSG00000269202.1	RP4-614O4.12	-4.55	6.73e-06	0.000717	-0.25	-0.21	Attention deficit hyperactivity disorder;	chr20:35230963	chr20:35201747~35203288:-
THCA	cis	rs2439831	0.681	rs956391	ENSG00000275601.1	AC011330.13	4.55	6.73e-06	0.000717	0.31	0.21	Lung cancer in ever smokers;	chr15:43325295	chr15:43642389~43643023:-
THCA	cis	rs31251	0.782	rs2108450	ENSG00000224431.1	AC063976.7	4.55	6.73e-06	0.000717	0.17	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr5:131935329	chr5:132199456~132203487:+
THCA	cis	rs1020064	0.895	rs2250659	ENSG00000235319.1	AC012360.4	-4.55	6.73e-06	0.000717	-0.27	-0.21	AIDS;	chr2:105273227	chr2:105324210~105330529:+
THCA	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	4.55	6.73e-06	0.000717	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	4.55	6.73e-06	0.000717	0.29	0.21	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
THCA	cis	rs6163	0.727	rs284854	ENSG00000213061.2	PFN1P11	-4.55	6.73e-06	0.000717	-0.24	-0.21	Waist circumference;Hip circumference;	chr10:102814805	chr10:102838011~102845473:-
THCA	cis	rs7551222	0.714	rs2926534	ENSG00000240219.1	RP11-430C7.5	-4.55	6.73e-06	0.000717	-0.22	-0.21	Schizophrenia;	chr1:204495053	chr1:204626775~204629712:+
THCA	cis	rs72634501	0.716	rs2036465	ENSG00000228060.1	RP11-69E11.8	4.55	6.73e-06	0.000717	0.23	0.21	HDL cholesterol;	chr1:39110310	chr1:39565160~39573203:+
THCA	cis	rs2243480	1	rs2462569	ENSG00000164669.11	INTS4P1	-4.55	6.73e-06	0.000717	-0.39	-0.21	Diabetic kidney disease;	chr7:66009859	chr7:65141225~65234216:+
THCA	cis	rs1371614	0.632	rs12615423	ENSG00000272148.1	RP11-195B17.1	-4.55	6.73e-06	0.000718	-0.19	-0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26935755	chr2:27062428~27062907:-
THCA	cis	rs1866631	0.565	rs56151459	ENSG00000238133.5	MLK7-AS1	4.55	6.73e-06	0.000718	0.27	0.21	Lung cancer in ever smokers;	chr2:173168730	chr2:173166446~173282036:-
THCA	cis	rs1005277	1	rs1005277	ENSG00000276805.1	RP11-291L22.6	-4.55	6.74e-06	0.000718	-0.24	-0.21	Extrinsic epigenetic age acceleration;	chr10:37929331	chr10:38451030~38451785:+
THCA	cis	rs858239	0.6	rs10235786	ENSG00000230042.1	AK3P3	-4.55	6.74e-06	0.000718	-0.28	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23129178~23129841:+
THCA	cis	rs9843304	0.568	rs13062027	ENSG00000244503.1	RP11-278L15.6	4.55	6.74e-06	0.000718	0.28	0.21	Gallstone disease;	chr3:149494892	chr3:149494660~149495995:+
THCA	cis	rs3096299	0.685	rs4785568	ENSG00000261118.1	RP11-104N10.1	4.55	6.74e-06	0.000718	0.17	0.21	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89492017~89504460:-
THCA	cis	rs62025270	0.688	rs62022939	ENSG00000259295.5	CSPG4P12	-4.55	6.74e-06	0.000718	-0.35	-0.21	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85191438~85213905:+
THCA	cis	rs9900062	0.586	rs12600679	ENSG00000270714.1	MINOS1P2	-4.55	6.74e-06	0.000718	-0.28	-0.21	QT interval;	chr17:64691209	chr17:64747264~64747492:-
THCA	cis	rs375066	0.935	rs396973	ENSG00000278917.1	RP11-15A1.4	4.55	6.74e-06	0.000718	0.17	0.21	Breast cancer;	chr19:43895154	chr19:43891233~43895411:+
THCA	cis	rs56804039	1	rs11780966	ENSG00000254153.1	CTA-398F10.2	4.55	6.74e-06	0.000718	0.25	0.21	Cervical cancer;	chr8:8525886	chr8:8456909~8461337:-
THCA	cis	rs13126694	0.743	rs12512643	ENSG00000248429.4	RP11-597D13.9	4.55	6.74e-06	0.000718	0.22	0.21	Blood osmolality (transformed sodium);	chr4:158115588	chr4:158170752~158202877:+
THCA	cis	rs990871	0.53	rs11209933	ENSG00000227207.2	RPL31P12	-4.55	6.74e-06	0.000718	-0.24	-0.21	Subcutaneous adipose tissue;	chr1:72181760	chr1:72301472~72301829:+
THCA	cis	rs8031584	0.652	rs2691683	ENSG00000259845.1	HERC2P10	-4.55	6.74e-06	0.000718	-0.29	-0.21	Huntington's disease progression;	chr15:30842857	chr15:30815271~30844153:+
THCA	cis	rs734999	0.524	rs4648448	ENSG00000225931.3	RP3-395M20.7	4.55	6.74e-06	0.000718	0.24	0.21	Ulcerative colitis;	chr1:2779144	chr1:2566410~2569888:+
THCA	cis	rs739496	0.615	rs11609628	ENSG00000226469.1	ADAM1B	4.55	6.74e-06	0.000718	0.26	0.21	Platelet count;	chr12:111779404	chr12:111927018~111929017:+
THCA	cis	rs739496	0.615	rs4646777	ENSG00000226469.1	ADAM1B	4.55	6.74e-06	0.000718	0.26	0.21	Platelet count;	chr12:111792232	chr12:111927018~111929017:+
THCA	cis	rs4415084	1	rs6884702	ENSG00000272335.1	RP11-53O19.3	-4.55	6.75e-06	0.000719	-0.17	-0.21	Breast cancer;	chr5:44682487	chr5:44826076~44828592:+
THCA	cis	rs4415084	1	rs12187196	ENSG00000272335.1	RP11-53O19.3	-4.55	6.75e-06	0.000719	-0.17	-0.21	Breast cancer;	chr5:44683717	chr5:44826076~44828592:+
THCA	cis	rs17711722	0.701	rs781145	ENSG00000272831.1	RP11-792A8.4	4.55	6.75e-06	0.000719	0.13	0.21	Calcium levels;	chr7:65975383	chr7:66739829~66740385:-
THCA	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-4.55	6.75e-06	0.000719	-0.13	-0.21	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
THCA	cis	rs8031584	0.56	rs7171208	ENSG00000270015.1	RP11-540B6.6	4.55	6.75e-06	0.000719	0.15	0.21	Huntington's disease progression;	chr15:30906726	chr15:30926514~30928407:+
THCA	cis	rs17095355	1	rs12263484	ENSG00000203876.8	ADD3-AS1	-4.55	6.75e-06	0.000719	-0.23	-0.21	Biliary atresia;	chr10:109937497	chr10:109940104~110008381:-
THCA	cis	rs36093844	0.747	rs17817314	ENSG00000279742.1	RP11-700A24.1	-4.55	6.75e-06	0.000719	-0.3	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85883929	chr11:85852557~85854943:-
THCA	cis	rs5742933	1	rs4667306	ENSG00000273240.1	RP11-455J20.3	-4.55	6.75e-06	0.000719	-0.23	-0.21	Ferritin levels;	chr2:189725630	chr2:189763859~189764456:-
THCA	cis	rs5742933	1	rs16831925	ENSG00000273240.1	RP11-455J20.3	-4.55	6.75e-06	0.000719	-0.23	-0.21	Ferritin levels;	chr2:189731178	chr2:189763859~189764456:-
THCA	cis	rs7555523	0.83	rs6660601	ENSG00000224358.1	RP11-466F5.8	-4.55	6.75e-06	0.000719	-0.32	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165726618	chr1:165768929~165775176:+
THCA	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-4.55	6.76e-06	0.00072	-0.19	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
THCA	cis	rs3770081	1	rs58515922	ENSG00000272564.1	RP11-548P2.2	-4.55	6.76e-06	0.00072	-0.35	-0.21	Facial emotion recognition (sad faces);	chr2:85945914	chr2:85904279~85904727:+
THCA	cis	rs12497850	0.931	rs62262517	ENSG00000228638.1	FCF1P2	-4.55	6.76e-06	0.00072	-0.22	-0.21	Parkinson's disease;	chr3:49097481	chr3:48290793~48291375:-
THCA	cis	rs10090774	0.664	rs28605671	ENSG00000280303.2	ERICD	-4.55	6.76e-06	0.00072	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140645013	chr8:140636281~140638283:+
THCA	cis	rs11158026	0.526	rs3825610	ENSG00000258413.1	RP11-665C16.6	-4.55	6.76e-06	0.00072	-0.33	-0.21	Parkinson's disease;	chr14:54881198	chr14:55262767~55272075:-
THCA	cis	rs12534093	0.96	rs11769151	ENSG00000234286.1	AC006026.13	-4.55	6.76e-06	0.00072	-0.33	-0.21	Infant length;Height;	chr7:23464689	chr7:23680195~23680786:-
THCA	cis	rs9307551	0.584	rs1371995	ENSG00000250334.4	LINC00989	-4.55	6.76e-06	0.00072	-0.25	-0.21	Refractive error;	chr4:79523353	chr4:79492416~79576460:+
THCA	cis	rs734999	0.869	rs61054170	ENSG00000225931.3	RP3-395M20.7	4.55	6.76e-06	0.00072	0.25	0.21	Ulcerative colitis;	chr1:2566613	chr1:2566410~2569888:+
THCA	cis	rs5762752	0.647	rs9625533	ENSG00000272858.1	CTA-292E10.8	4.55	6.76e-06	0.00072	0.2	0.21	Optic disc area;	chr22:28692602	chr22:28814914~28815662:+
THCA	cis	rs2839186	0.709	rs2156117	ENSG00000215424.8	MCM3AP-AS1	4.55	6.76e-06	0.00072	0.12	0.21	Testicular germ cell tumor;	chr21:46249386	chr21:46229217~46259390:+
THCA	cis	rs1334894	1	rs747411	ENSG00000228559.1	RP3-340B19.3	-4.55	6.77e-06	0.000721	-0.43	-0.21	Coronary artery disease;	chr6:35618596	chr6:35544632~35545669:+
THCA	cis	rs4950322	0.542	rs3766520	ENSG00000180867.10	PDIA3P1	4.55	6.77e-06	0.000721	0.21	0.21	Protein quantitative trait loci;	chr1:147214658	chr1:147178113~147179622:+
THCA	cis	rs58605417	0.534	rs1601817	ENSG00000253553.4	RP11-586K2.1	-4.55	6.77e-06	0.000721	-0.21	-0.21	Schizophrenia;	chr8:88450092	chr8:88326836~88737134:+
THCA	cis	rs6751744	0.855	rs933794	ENSG00000226266.5	AC009961.3	-4.55	6.77e-06	0.000721	-0.26	-0.21	Dysphagia;	chr2:159524380	chr2:159670708~159712435:-
THCA	cis	rs849141	0.524	rs515013	ENSG00000234336.5	JAZF1-AS1	-4.55	6.77e-06	0.000721	-0.35	-0.21	Height;Hip circumference adjusted for BMI;	chr7:28176577	chr7:28180322~28243917:+
THCA	cis	rs12410462	0.591	rs6688145	ENSG00000227711.2	RP11-275O4.5	-4.55	6.77e-06	0.000721	-0.25	-0.21	Major depressive disorder;	chr1:227612459	chr1:227509028~227520477:-
THCA	cis	rs2985684	1	rs1957977	ENSG00000278009.1	RP11-649E7.8	4.55	6.77e-06	0.000721	0.29	0.21	Carotid intima media thickness;	chr14:49623885	chr14:49601011~49601124:-
THCA	cis	rs9307551	0.697	rs9993773	ENSG00000250334.4	LINC00989	-4.55	6.77e-06	0.000721	-0.27	-0.21	Refractive error;	chr4:79513450	chr4:79492416~79576460:+
THCA	cis	rs4906332	0.782	rs12891288	ENSG00000269910.1	RP11-73M18.10	4.55	6.77e-06	0.000721	0.2	0.21	Coronary artery disease;	chr14:103533413	chr14:103694516~103695050:-
THCA	cis	rs4794202	0.629	rs7212099	ENSG00000264920.1	RP11-6N17.4	-4.55	6.77e-06	0.000721	-0.27	-0.21	Alzheimer's disease (cognitive decline);	chr17:47848524	chr17:47891255~47895812:-
THCA	cis	rs6657613	0.68	rs9435747	ENSG00000186301.8	MST1P2	4.55	6.77e-06	0.000721	0.17	0.21	Hip circumference adjusted for BMI;	chr1:17045972	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs11582579	ENSG00000186301.8	MST1P2	4.55	6.77e-06	0.000721	0.17	0.21	Hip circumference adjusted for BMI;	chr1:17046016	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs6690934	ENSG00000186301.8	MST1P2	4.55	6.77e-06	0.000721	0.17	0.21	Hip circumference adjusted for BMI;	chr1:17046127	chr1:16645622~16650289:+
THCA	cis	rs17301013	0.861	rs2038025	ENSG00000227373.4	RP11-160H22.5	4.55	6.77e-06	0.000721	0.29	0.21	Systemic lupus erythematosus;	chr1:174574712	chr1:174115300~174160004:-
THCA	cis	rs6449502	0.92	rs158928	ENSG00000251279.1	CTC-436P18.1	-4.55	6.77e-06	0.000721	-0.34	-0.21	Mean platelet volume;	chr5:60932096	chr5:61162070~61232040:+
THCA	cis	rs736408	0.812	rs2071506	ENSG00000243224.1	RP5-1157M23.2	-4.55	6.77e-06	0.000721	-0.23	-0.21	Bipolar disorder;	chr3:52792260	chr3:52239258~52241097:+
THCA	cis	rs12935229	1	rs17769663	ENSG00000260922.1	RP11-538I12.3	-4.55	6.77e-06	0.000721	-0.35	-0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77284942	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs17712926	ENSG00000260922.1	RP11-538I12.3	-4.55	6.77e-06	0.000721	-0.35	-0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77285140	chr16:77234877~77290934:+
THCA	cis	rs3734266	0.584	rs12111129	ENSG00000272288.4	RP11-140K17.3	-4.55	6.77e-06	0.000721	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34806671	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs13213239	ENSG00000272288.4	RP11-140K17.3	-4.55	6.77e-06	0.000721	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34809715	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs7755354	ENSG00000272288.4	RP11-140K17.3	-4.55	6.77e-06	0.000721	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34814467	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs6910824	ENSG00000272288.4	RP11-140K17.3	-4.55	6.77e-06	0.000721	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34818729	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.646	rs912717	ENSG00000272288.4	RP11-140K17.3	-4.55	6.77e-06	0.000721	-0.21	-0.21	Systemic lupus erythematosus;	chr6:34820790	chr6:34696317~34697470:+
THCA	cis	rs2590942	0.838	rs2815757	ENSG00000227207.2	RPL31P12	-4.55	6.77e-06	0.000721	-0.33	-0.21	Childhood body mass index;	chr1:72298606	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.838	rs2568957	ENSG00000227207.2	RPL31P12	-4.55	6.77e-06	0.000721	-0.33	-0.21	Childhood body mass index;	chr1:72298747	chr1:72301472~72301829:+
THCA	cis	rs782212	0.527	rs2613499	ENSG00000227207.2	RPL31P12	4.55	6.77e-06	0.000721	0.33	0.21	Depression;	chr1:72285869	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.838	rs2613498	ENSG00000227207.2	RPL31P12	4.55	6.77e-06	0.000721	0.33	0.21	Childhood body mass index;	chr1:72287256	chr1:72301472~72301829:+
THCA	cis	rs875971	0.522	rs4718286	ENSG00000234585.5	CCT6P3	4.55	6.77e-06	0.000721	0.18	0.21	Aortic root size;	chr7:65827777	chr7:65038354~65074713:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000234585.5	CCT6P3	4.55	6.77e-06	0.000721	0.18	0.21	Calcium levels;	chr7:65837419	chr7:65038354~65074713:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000234585.5	CCT6P3	4.55	6.77e-06	0.000721	0.18	0.21	Calcium levels;	chr7:65872915	chr7:65038354~65074713:+
THCA	cis	rs858239	0.6	rs10233039	ENSG00000230042.1	AK3P3	-4.55	6.77e-06	0.000721	-0.28	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23129178~23129841:+
THCA	cis	rs6745190	0.575	rs6706696	ENSG00000236153.1	AC104076.3	-4.55	6.77e-06	0.000721	-0.23	-0.21	White blood cell count;	chr2:181116328	chr2:180979427~180980090:-
THCA	cis	rs6657613	0.649	rs9435746	ENSG00000186301.8	MST1P2	4.55	6.77e-06	0.000721	0.17	0.21	Hip circumference adjusted for BMI;	chr1:17045622	chr1:16645622~16650289:+
THCA	cis	rs8058578	1	rs56656810	ENSG00000279196.1	RP11-1072A3.3	4.55	6.78e-06	0.000722	0.21	0.21	Multiple myeloma;	chr16:30777438	chr16:30984630~30988270:-
THCA	cis	rs17767294	0.612	rs12332927	ENSG00000261839.1	RP1-265C24.8	4.55	6.78e-06	0.000722	0.31	0.21	Parkinson's disease;	chr6:27987337	chr6:28136849~28139678:+
THCA	cis	rs4879656	0.771	rs10971231	ENSG00000225693.1	LAGE3P1	-4.55	6.78e-06	0.000722	-0.24	-0.21	Menopause (age at onset);	chr9:32939760	chr9:33019682~33020165:-
THCA	cis	rs9902453	0.845	rs3102558	ENSG00000263370.1	RP11-68I3.5	4.55	6.78e-06	0.000722	0.27	0.21	Coffee consumption (cups per day);	chr17:29696124	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs2321331	ENSG00000263370.1	RP11-68I3.5	4.55	6.78e-06	0.000722	0.27	0.21	Coffee consumption (cups per day);	chr17:29698510	chr17:29639627~29640825:+
THCA	cis	rs2153535	0.553	rs6932565	ENSG00000230939.1	RP11-314C16.1	-4.55	6.78e-06	0.000722	-0.21	-0.21	Motion sickness;	chr6:8644926	chr6:8784178~8785445:+
THCA	cis	rs9878978	0.754	rs35669246	ENSG00000237990.3	CNTN4-AS1	4.55	6.78e-06	0.000722	0.24	0.21	Blood pressure (smoking interaction);	chr3:2395509	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.722	rs35472449	ENSG00000237990.3	CNTN4-AS1	4.55	6.78e-06	0.000722	0.24	0.21	Blood pressure (smoking interaction);	chr3:2395639	chr3:3039033~3069242:-
THCA	cis	rs4948275	0.667	rs2814030	ENSG00000237233.2	TMEM26-AS1	4.55	6.78e-06	0.000722	0.27	0.21	Night sleep phenotypes;	chr10:61578035	chr10:61452639~61481956:+
THCA	cis	rs71636778	0.631	rs71636787	ENSG00000260063.1	RP5-968P14.2	-4.55	6.79e-06	0.000722	-0.28	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26858624	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.631	rs71636788	ENSG00000260063.1	RP5-968P14.2	-4.55	6.79e-06	0.000722	-0.28	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26859994	chr1:26692132~26694131:-
THCA	cis	rs4660214	0.59	rs11205885	ENSG00000182109.6	RP11-69E11.4	-4.55	6.79e-06	0.000722	-0.2	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39306633	chr1:39522280~39546187:-
THCA	cis	rs7088591	0.85	rs75905559	ENSG00000276818.1	AC026393.1	4.55	6.79e-06	0.000723	0.45	0.21	Blood pressure;	chr10:57947551	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs117992850	ENSG00000276818.1	AC026393.1	4.55	6.79e-06	0.000723	0.45	0.21	Blood pressure;	chr10:57960331	chr10:57095699~57095781:+
THCA	cis	rs12534093	0.662	rs11767307	ENSG00000234286.1	AC006026.13	4.55	6.79e-06	0.000723	0.33	0.21	Infant length;Height;	chr7:23544877	chr7:23680195~23680786:-
THCA	cis	rs62244186	0.566	rs6766221	ENSG00000214820.3	MPRIPP1	4.55	6.79e-06	0.000723	0.21	0.21	Depressive symptoms;	chr3:44841292	chr3:44579938~44581026:-
THCA	cis	rs5751614	0.62	rs1811017	ENSG00000240160.3	RN7SL263P	4.55	6.79e-06	0.000723	0.25	0.21	Height;	chr22:23264771	chr22:23261782~23262071:-
THCA	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-4.55	6.79e-06	0.000723	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
THCA	cis	rs9843304	0.568	rs71304473	ENSG00000244503.1	RP11-278L15.6	4.55	6.79e-06	0.000723	0.28	0.21	Gallstone disease;	chr3:149499403	chr3:149494660~149495995:+
THCA	cis	rs1728785	1	rs1645936	ENSG00000274698.1	RP11-71L14.4	4.55	6.79e-06	0.000723	0.27	0.21	Ulcerative colitis;	chr16:68529840	chr16:68450283~68452318:+
THCA	cis	rs73108077	0.736	rs6060436	ENSG00000277112.2	RP11-755J8.1	-4.55	6.8e-06	0.000723	-0.33	-0.21	Red blood cell density in sickle cell anemia;	chr20:31258500	chr20:30681825~30723932:-
THCA	cis	rs453301	0.522	rs2929455	ENSG00000253981.4	ALG1L13P	-4.55	6.8e-06	0.000723	-0.19	-0.21	Joint mobility (Beighton score);	chr8:9225923	chr8:8236003~8244667:-
THCA	cis	rs7208859	0.673	rs28588622	ENSG00000280069.1	CTD-2349P21.3	-4.55	6.8e-06	0.000723	-0.33	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30738182~30740275:+
THCA	cis	rs889398	0.802	rs12919094	ENSG00000226232.7	RP11-419C5.2	4.55	6.8e-06	0.000724	0.2	0.21	Body mass index;	chr16:69809454	chr16:69976388~69996188:-
THCA	cis	rs987724	0.515	rs9870137	ENSG00000240875.4	LINC00886	-4.55	6.8e-06	0.000724	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898867	chr3:156747346~156817062:-
THCA	cis	rs4916588	0.636	rs75488116	ENSG00000270170.1	NCBP2-AS2	4.55	6.8e-06	0.000724	0.16	0.21	Night sleep phenotypes;	chr3:196892737	chr3:196942623~196943540:+
THCA	cis	rs4916588	0.636	rs6797560	ENSG00000270170.1	NCBP2-AS2	4.55	6.8e-06	0.000724	0.16	0.21	Night sleep phenotypes;	chr3:196893423	chr3:196942623~196943540:+
THCA	cis	rs4916588	0.559	rs6786938	ENSG00000270170.1	NCBP2-AS2	4.55	6.8e-06	0.000724	0.16	0.21	Night sleep phenotypes;	chr3:196893917	chr3:196942623~196943540:+
THCA	cis	rs4916588	0.636	rs60110595	ENSG00000270170.1	NCBP2-AS2	4.55	6.8e-06	0.000724	0.16	0.21	Night sleep phenotypes;	chr3:196894898	chr3:196942623~196943540:+
THCA	cis	rs4916588	0.608	rs4916581	ENSG00000270170.1	NCBP2-AS2	4.55	6.8e-06	0.000724	0.16	0.21	Night sleep phenotypes;	chr3:196909683	chr3:196942623~196943540:+
THCA	cis	rs4916588	0.639	rs4916583	ENSG00000270170.1	NCBP2-AS2	4.55	6.8e-06	0.000724	0.16	0.21	Night sleep phenotypes;	chr3:196911107	chr3:196942623~196943540:+
THCA	cis	rs4916588	0.636	rs11922178	ENSG00000270170.1	NCBP2-AS2	4.55	6.8e-06	0.000724	0.16	0.21	Night sleep phenotypes;	chr3:196913250	chr3:196942623~196943540:+
THCA	cis	rs17095355	1	rs72828245	ENSG00000203876.8	ADD3-AS1	-4.55	6.8e-06	0.000724	-0.22	-0.21	Biliary atresia;	chr10:109986838	chr10:109940104~110008381:-
THCA	cis	rs6570726	0.935	rs386344	ENSG00000270638.1	RP3-466P17.1	4.55	6.8e-06	0.000724	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145735570~145737218:+
THCA	cis	rs7181230	0.885	rs35781999	ENSG00000275636.1	RP11-521C20.5	4.55	6.8e-06	0.000724	0.22	0.21	Dehydroepiandrosterone sulphate levels;	chr15:40063205	chr15:40078892~40079347:+
THCA	cis	rs10090774	0.965	rs4246125	ENSG00000279766.1	RP11-642A1.2	4.55	6.8e-06	0.000724	0.25	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140778430	chr8:140572142~140572812:-
THCA	cis	rs6496932	0.635	rs12900455	ENSG00000259630.2	CTD-2262B20.1	-4.55	6.81e-06	0.000724	-0.25	-0.21	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85415228~85415633:+
THCA	cis	rs78487399	0.808	rs10168889	ENSG00000234936.1	AC010883.5	4.55	6.81e-06	0.000725	0.26	0.21	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43614578	chr2:43229573~43233394:+
THCA	cis	rs13178541	0.872	rs11242286	ENSG00000250378.1	RP11-119J18.1	-4.55	6.81e-06	0.000725	-0.24	-0.21	IgG glycosylation;	chr5:135790036	chr5:135812667~135826582:+
THCA	cis	rs250518	0.926	rs4321733	ENSG00000272081.1	CTD-2376I4.2	4.55	6.81e-06	0.000725	0.26	0.21	Mean corpuscular hemoglobin concentration;	chr5:72759145	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs4618410	ENSG00000272081.1	CTD-2376I4.2	4.55	6.81e-06	0.000725	0.26	0.21	Mean corpuscular hemoglobin concentration;	chr5:72759146	chr5:72955206~72955699:-
THCA	cis	rs7160336	0.738	rs11849883	ENSG00000259065.1	RP5-1021I20.1	4.55	6.81e-06	0.000725	0.24	0.21	Blood protein levels;	chr14:74010633	chr14:73787360~73803270:+
THCA	cis	rs7772486	0.754	rs9497401	ENSG00000270638.1	RP3-466P17.1	-4.55	6.81e-06	0.000725	-0.16	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145735570~145737218:+
THCA	cis	rs17095355	1	rs975442	ENSG00000203876.8	ADD3-AS1	-4.55	6.82e-06	0.000725	-0.22	-0.21	Biliary atresia;	chr10:109946137	chr10:109940104~110008381:-
THCA	cis	rs889398	0.967	rs12599391	ENSG00000226232.7	RP11-419C5.2	-4.55	6.82e-06	0.000725	-0.2	-0.21	Body mass index;	chr16:69571446	chr16:69976388~69996188:-
THCA	cis	rs9880211	0.613	rs12330335	ENSG00000273486.1	RP11-731C17.2	4.55	6.82e-06	0.000726	0.21	0.21	Height;Body mass index;	chr3:136134690	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.613	rs1393786	ENSG00000273486.1	RP11-731C17.2	4.55	6.82e-06	0.000726	0.21	0.21	Height;Body mass index;	chr3:136135193	chr3:136837338~136839021:-
THCA	cis	rs2281603	0.57	rs28766386	ENSG00000259116.1	RP11-973N13.4	-4.55	6.82e-06	0.000726	-0.17	-0.21	Lymphocyte counts;	chr14:64479679	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs10133848	ENSG00000259116.1	RP11-973N13.4	-4.55	6.82e-06	0.000726	-0.17	-0.21	Lymphocyte counts;	chr14:64481771	chr14:64514154~64540368:-
THCA	cis	rs1048886	0.938	rs16869156	ENSG00000271967.1	RP11-134K13.4	-4.55	6.82e-06	0.000726	-0.22	-0.21	Type 2 diabetes;	chr6:70399356	chr6:70596438~70596980:+
THCA	cis	rs67478160	0.643	rs4906369	ENSG00000269910.1	RP11-73M18.10	4.55	6.82e-06	0.000726	0.17	0.21	Schizophrenia;	chr14:103776121	chr14:103694516~103695050:-
THCA	cis	rs12188164	0.58	rs2672755	ENSG00000221990.4	EXOC3-AS1	-4.55	6.82e-06	0.000726	-0.16	-0.21	Cystic fibrosis severity;	chr5:457134	chr5:441498~443160:-
THCA	cis	rs72717009	0.825	rs9427399	ENSG00000225217.1	HSPA7	-4.55	6.83e-06	0.000726	-0.32	-0.21	Rheumatoid arthritis;	chr1:161506743	chr1:161606291~161608217:+
THCA	cis	rs72717009	0.825	rs7515174	ENSG00000225217.1	HSPA7	-4.55	6.83e-06	0.000726	-0.32	-0.21	Rheumatoid arthritis;	chr1:161507159	chr1:161606291~161608217:+
THCA	cis	rs72717009	0.825	rs7539468	ENSG00000225217.1	HSPA7	-4.55	6.83e-06	0.000726	-0.32	-0.21	Rheumatoid arthritis;	chr1:161507276	chr1:161606291~161608217:+
THCA	cis	rs72717009	0.778	rs9427400	ENSG00000225217.1	HSPA7	-4.55	6.83e-06	0.000726	-0.32	-0.21	Rheumatoid arthritis;	chr1:161507414	chr1:161606291~161608217:+
THCA	cis	rs8020095	0.571	rs8022328	ENSG00000258561.1	RP11-72M17.1	4.55	6.83e-06	0.000727	0.27	0.21	Depression (quantitative trait);	chr14:66786317	chr14:66212810~66509394:-
THCA	cis	rs11096990	0.855	rs11737290	ENSG00000249685.1	RP11-360F5.3	-4.55	6.83e-06	0.000727	-0.27	-0.21	Cognitive function;	chr4:39192318	chr4:39133913~39135608:+
THCA	cis	rs2361710	0.704	rs4889979	ENSG00000279259.1	RP11-334C17.3	4.55	6.83e-06	0.000727	0.17	0.21	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80147908	chr17:80147250~80148596:+
THCA	cis	rs3824435	0.706	rs4742085	ENSG00000272866.1	RP11-12D24.10	4.55	6.83e-06	0.000727	0.27	0.21	Risky sexual behaviors in alcohol dependence;	chr9:5350548	chr9:5351796~5352410:-
THCA	cis	rs1048886	0.816	rs61224912	ENSG00000271967.1	RP11-134K13.4	-4.55	6.83e-06	0.000727	-0.22	-0.21	Type 2 diabetes;	chr6:70409621	chr6:70596438~70596980:+
THCA	cis	rs752010	0.934	rs11210503	ENSG00000230638.4	RP11-486B10.4	-4.55	6.83e-06	0.000727	-0.23	-0.21	Lupus nephritis in systemic lupus erythematosus;	chr1:41635463	chr1:41542069~41544310:+
THCA	cis	rs10208649	1	rs75237140	ENSG00000233266.1	HMGB1P31	4.55	6.84e-06	0.000727	0.48	0.21	Body mass index;	chr2:53953570	chr2:54051334~54051760:+
THCA	cis	rs73198271	0.562	rs17698256	ENSG00000253893.2	FAM85B	4.55	6.84e-06	0.000727	0.35	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802103	chr8:8167819~8226614:-
THCA	cis	rs911555	0.723	rs11160751	ENSG00000244691.1	RPL10AP1	-4.55	6.84e-06	0.000727	-0.28	-0.21	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103412119~103412761:-
THCA	cis	rs853679	1	rs2799079	ENSG00000220721.1	OR1F12	4.55	6.84e-06	0.000727	0.33	0.21	Depression;	chr6:28267398	chr6:28073316~28074233:+
THCA	cis	rs6449502	0.92	rs162229	ENSG00000251279.1	CTC-436P18.1	4.55	6.84e-06	0.000727	0.34	0.21	Mean platelet volume;	chr5:61009200	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs162233	ENSG00000251279.1	CTC-436P18.1	4.55	6.84e-06	0.000727	0.34	0.21	Mean platelet volume;	chr5:61016378	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs162235	ENSG00000251279.1	CTC-436P18.1	4.55	6.84e-06	0.000727	0.34	0.21	Mean platelet volume;	chr5:61017188	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs158569	ENSG00000251279.1	CTC-436P18.1	4.55	6.84e-06	0.000727	0.34	0.21	Mean platelet volume;	chr5:61017370	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs158568	ENSG00000251279.1	CTC-436P18.1	4.55	6.84e-06	0.000727	0.34	0.21	Mean platelet volume;	chr5:61017728	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs158567	ENSG00000251279.1	CTC-436P18.1	4.55	6.84e-06	0.000727	0.34	0.21	Mean platelet volume;	chr5:61018572	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs158566	ENSG00000251279.1	CTC-436P18.1	4.55	6.84e-06	0.000727	0.34	0.21	Mean platelet volume;	chr5:61019156	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs158565	ENSG00000251279.1	CTC-436P18.1	4.55	6.84e-06	0.000727	0.34	0.21	Mean platelet volume;	chr5:61021100	chr5:61162070~61232040:+
THCA	cis	rs9329221	0.623	rs7825778	ENSG00000261451.1	RP11-981G7.1	-4.55	6.84e-06	0.000728	-0.25	-0.21	Neuroticism;	chr8:10403500	chr8:10433672~10438312:+
THCA	cis	rs896854	0.548	rs574183	ENSG00000253528.2	RP11-347C18.4	-4.55	6.84e-06	0.000728	-0.24	-0.21	Type 2 diabetes;	chr8:94961588	chr8:94974573~94974853:-
THCA	cis	rs2734839	0.964	rs2734831	ENSG00000270179.1	RP11-159N11.4	4.55	6.84e-06	0.000728	0.22	0.21	Information processing speed;	chr11:113422874	chr11:113368478~113369117:+
THCA	cis	rs2562456	0.876	rs2650844	ENSG00000268117.1	VN1R84P	4.55	6.84e-06	0.000728	0.33	0.21	Pain;	chr19:21419288	chr19:21719801~21720035:-
THCA	cis	rs6067053	0.533	rs6067019	ENSG00000227431.4	CSE1L-AS1	4.55	6.84e-06	0.000728	0.26	0.21	Intelligence (multi-trait analysis);	chr20:49211989	chr20:49040463~49046044:-
THCA	cis	rs9863	0.861	rs77020228	ENSG00000270061.1	RP11-214K3.19	-4.55	6.84e-06	0.000728	-0.28	-0.21	White blood cell count;	chr12:123933925	chr12:123969990~123970344:-
THCA	cis	rs4817775	0.531	rs7281243	ENSG00000236830.5	CBR3-AS1	-4.55	6.84e-06	0.000728	-0.19	-0.21	Bone mineral density;	chr21:36169700	chr21:36131767~36175815:-
THCA	cis	rs10256972	0.967	rs1881122	ENSG00000225146.1	AC073957.15	4.55	6.85e-06	0.000728	0.21	0.21	Endometriosis;Longevity;	chr7:1001310	chr7:1029025~1043891:+
THCA	cis	rs6121246	0.52	rs6060425	ENSG00000230613.1	HM13-AS1	4.55	6.85e-06	0.000729	0.24	0.21	Mean corpuscular hemoglobin;	chr20:31636552	chr20:31567707~31573263:-
THCA	cis	rs875971	0.861	rs801215	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.85e-06	0.000729	-0.22	-0.21	Aortic root size;	chr7:66546951	chr7:66025126~66031544:-
THCA	cis	rs8028182	0.636	rs28737338	ENSG00000260269.4	CTD-2323K18.1	-4.55	6.85e-06	0.000729	-0.31	-0.21	Sudden cardiac arrest;	chr15:75476338	chr15:75527150~75601205:-
THCA	cis	rs875971	0.798	rs12698522	ENSG00000229886.1	RP5-1132H15.3	4.55	6.85e-06	0.000729	0.22	0.21	Aortic root size;	chr7:66502354	chr7:66025126~66031544:-
THCA	cis	rs875971	0.83	rs28714531	ENSG00000229886.1	RP5-1132H15.3	4.55	6.85e-06	0.000729	0.22	0.21	Aortic root size;	chr7:66503250	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs12698526	ENSG00000229886.1	RP5-1132H15.3	4.55	6.85e-06	0.000729	0.22	0.21	Aortic root size;	chr7:66504118	chr7:66025126~66031544:-
THCA	cis	rs10932886	1	rs2054048	ENSG00000224819.1	AC093843.1	4.55	6.85e-06	0.000729	0.2	0.21	Brain imaging;	chr2:220849151	chr2:220791078~220797893:+
THCA	cis	rs807029	0.533	rs3824783	ENSG00000236662.1	RP11-108L7.4	4.55	6.85e-06	0.000729	0.22	0.21	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100980507~100985614:-
THCA	cis	rs12681963	0.688	rs6994064	ENSG00000248159.1	HSPA8P11	-4.55	6.86e-06	0.000729	-0.37	-0.21	Migraine;	chr8:30199673	chr8:30237382~30240997:+
THCA	cis	rs7267979	0.873	rs6037062	ENSG00000274973.1	RP13-401N8.7	-4.55	6.86e-06	0.000729	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25845497~25845862:+
THCA	cis	rs5770917	1	rs2269382	ENSG00000273272.1	CTA-384D8.34	4.55	6.86e-06	0.00073	0.32	0.21	Narcolepsy;	chr22:50580482	chr22:50542650~50543011:+
THCA	cis	rs2029362	0.536	rs12276167	ENSG00000245573.6	BDNF-AS	4.55	6.86e-06	0.00073	0.16	0.21	Total body bone mineral density;	chr11:27614024	chr11:27506838~27698174:+
THCA	cis	rs253959	0.739	rs1421842	ENSG00000272265.1	CTD-2287O16.4	-4.55	6.86e-06	0.00073	-0.23	-0.21	Bipolar disorder and schizophrenia;	chr5:116298593	chr5:116078110~116078570:-
THCA	cis	rs7141336	0.896	rs8009816	ENSG00000258884.1	CTD-3035D6.2	4.55	6.86e-06	0.00073	0.27	0.21	Anxiety disorder;	chr14:90820661	chr14:90822365~90828128:-
THCA	cis	rs801193	1	rs62466793	ENSG00000229886.1	RP5-1132H15.3	4.55	6.86e-06	0.00073	0.21	0.21	Aortic root size;	chr7:66726530	chr7:66025126~66031544:-
THCA	cis	rs990871	0.53	rs1194271	ENSG00000227207.2	RPL31P12	4.55	6.87e-06	0.00073	0.24	0.21	Subcutaneous adipose tissue;	chr1:72236282	chr1:72301472~72301829:+
THCA	cis	rs990871	0.548	rs1209251	ENSG00000227207.2	RPL31P12	4.55	6.87e-06	0.00073	0.24	0.21	Subcutaneous adipose tissue;	chr1:72236308	chr1:72301472~72301829:+
THCA	cis	rs990871	0.53	rs1194270	ENSG00000227207.2	RPL31P12	4.55	6.87e-06	0.00073	0.24	0.21	Subcutaneous adipose tissue;	chr1:72236630	chr1:72301472~72301829:+
THCA	cis	rs3820928	0.874	rs7576081	ENSG00000212391.1	SNORA48	-4.55	6.87e-06	0.00073	-0.23	-0.21	Pulmonary function;	chr2:226978918	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.839	rs35068645	ENSG00000212391.1	SNORA48	-4.55	6.87e-06	0.00073	-0.23	-0.21	Pulmonary function;	chr2:226979549	chr2:226968989~226969122:-
THCA	cis	rs4948275	0.693	rs2246190	ENSG00000237233.2	TMEM26-AS1	-4.55	6.87e-06	0.000731	-0.27	-0.21	Night sleep phenotypes;	chr10:61580354	chr10:61452639~61481956:+
THCA	cis	rs793571	0.628	rs7169205	ENSG00000245975.2	RP11-30K9.6	4.55	6.87e-06	0.000731	0.24	0.21	Schizophrenia;	chr15:58788004	chr15:58768072~58770974:-
THCA	cis	rs9880211	0.948	rs17298525	ENSG00000239213.4	NCK1-AS1	4.55	6.87e-06	0.000731	0.23	0.21	Height;Body mass index;	chr3:136474183	chr3:136841726~136862054:-
THCA	cis	rs2745572	0.752	rs7739648	ENSG00000272279.1	RP11-157J24.2	4.55	6.88e-06	0.000731	0.27	0.21	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1540248	chr6:1528364~1528911:-
THCA	cis	rs1962772	0.809	rs1557599	ENSG00000279903.1	RP11-349F21.5	-4.55	6.88e-06	0.000731	-0.26	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17514612	chr8:17500012~17500605:+
THCA	cis	rs1962772	0.847	rs2106031	ENSG00000279903.1	RP11-349F21.5	-4.55	6.88e-06	0.000731	-0.26	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17514700	chr8:17500012~17500605:+
THCA	cis	rs972578	0.691	rs8136156	ENSG00000274717.1	RP1-47A17.1	-4.55	6.88e-06	0.000731	-0.22	-0.21	Mean platelet volume;	chr22:42913503	chr22:42791814~42794313:-
THCA	cis	rs227275	0.527	rs223308	ENSG00000248971.2	KRT8P46	-4.55	6.88e-06	0.000731	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102728746~102730171:-
THCA	cis	rs2120243	0.539	rs9990136	ENSG00000241770.1	RP11-555M1.3	-4.55	6.88e-06	0.000732	-0.26	-0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157358045	chr3:157163452~157169133:+
THCA	cis	rs987724	0.515	rs6441101	ENSG00000240875.4	LINC00886	-4.55	6.88e-06	0.000732	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156875409	chr3:156747346~156817062:-
THCA	cis	rs36093844	0.752	rs56396016	ENSG00000279742.1	RP11-700A24.1	-4.55	6.88e-06	0.000732	-0.3	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85885347	chr11:85852557~85854943:-
THCA	cis	rs919433	0.926	rs12618567	ENSG00000231621.1	AC013264.2	4.55	6.88e-06	0.000732	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283467	chr2:197197991~197199273:+
THCA	cis	rs1005277	0.577	rs4934906	ENSG00000226578.1	RP11-258F22.1	-4.55	6.89e-06	0.000732	-0.24	-0.21	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:37775371~37784131:-
THCA	cis	rs7560272	0.538	rs17434634	ENSG00000163016.8	ALMS1P	-4.55	6.89e-06	0.000732	-0.25	-0.21	Schizophrenia;	chr2:73695799	chr2:73644919~73685576:+
THCA	cis	rs1861628	0.512	rs6435952	ENSG00000237930.1	AC007563.4	4.55	6.89e-06	0.000732	0.32	0.21	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216750007	chr2:216785774~216786144:-
THCA	cis	rs972578	0.715	rs9607948	ENSG00000274717.1	RP1-47A17.1	-4.55	6.89e-06	0.000733	-0.22	-0.21	Mean platelet volume;	chr22:42793074	chr22:42791814~42794313:-
THCA	cis	rs2412819	0.545	rs3862143	ENSG00000166763.7	STRCP1	-4.55	6.89e-06	0.000733	-0.27	-0.21	Lung cancer;	chr15:43779282	chr15:43699488~43718184:-
THCA	cis	rs79349575	0.756	rs62078385	ENSG00000270781.1	RP11-501C14.9	-4.55	6.89e-06	0.000733	-0.25	-0.21	Type 2 diabetes;	chr17:48967647	chr17:48899131~48899748:+
THCA	cis	rs7618915	0.501	rs3733039	ENSG00000243224.1	RP5-1157M23.2	-4.55	6.89e-06	0.000733	-0.22	-0.21	Bipolar disorder;	chr3:52685072	chr3:52239258~52241097:+
THCA	cis	rs62158800	0.925	rs62158828	ENSG00000237880.1	AC096669.2	4.55	6.9e-06	0.000733	0.33	0.21	Facial morphology (factor 22);	chr2:107628364	chr2:107385632~107542649:-
THCA	cis	rs7621331	1	rs9864247	ENSG00000273486.1	RP11-731C17.2	4.55	6.9e-06	0.000733	0.19	0.21	Waist circumference adjusted for body mass index;	chr3:135991334	chr3:136837338~136839021:-
THCA	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-4.55	6.9e-06	0.000733	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
THCA	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-4.55	6.9e-06	0.000733	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
THCA	cis	rs1334894	1	rs72921231	ENSG00000228559.1	RP3-340B19.3	-4.55	6.9e-06	0.000733	-0.44	-0.21	Coronary artery disease;	chr6:35621860	chr6:35544632~35545669:+
THCA	cis	rs1334894	1	rs7754668	ENSG00000228559.1	RP3-340B19.3	-4.55	6.9e-06	0.000733	-0.44	-0.21	Coronary artery disease;	chr6:35622315	chr6:35544632~35545669:+
THCA	cis	rs2436845	0.603	rs2679753	ENSG00000253320.4	KB-1507C5.2	-4.55	6.9e-06	0.000734	-0.18	-0.21	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855232	chr8:102864300~102977876:+
THCA	cis	rs2191566	0.821	rs62119173	ENSG00000266921.1	RP11-15A1.7	-4.55	6.9e-06	0.000734	-0.19	-0.21	Acute lymphoblastic leukemia (childhood);	chr19:44013921	chr19:43996896~44002836:-
THCA	cis	rs2191566	0.96	rs11083733	ENSG00000266921.1	RP11-15A1.7	-4.55	6.9e-06	0.000734	-0.19	-0.21	Acute lymphoblastic leukemia (childhood);	chr19:44016767	chr19:43996896~44002836:-
THCA	cis	rs72843506	0.586	rs73296067	ENSG00000261033.1	RP11-209D14.2	4.55	6.9e-06	0.000734	0.39	0.21	Schizophrenia;	chr17:19976988	chr17:20008051~20009234:-
THCA	cis	rs795484	0.926	rs353897	ENSG00000275409.1	RP11-131L12.4	-4.55	6.9e-06	0.000734	-0.18	-0.21	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118202036	chr12:118430147~118430699:+
THCA	cis	rs6806253	0.878	rs17344939	ENSG00000239405.1	TMED10P2	4.55	6.91e-06	0.000734	0.33	0.21	Pit-and-Fissure caries;	chr3:128566651	chr3:128538020~128538631:+
THCA	cis	rs4705962	0.837	rs4425499	ENSG00000230612.2	AC004237.1	4.55	6.91e-06	0.000734	0.25	0.21	Atopic dermatitis;	chr5:132713370	chr5:132688681~132723725:+
THCA	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-4.55	6.91e-06	0.000734	-0.24	-0.21	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
THCA	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-4.55	6.91e-06	0.000735	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
THCA	cis	rs9840812	0.522	rs711976	ENSG00000239213.4	NCK1-AS1	4.55	6.91e-06	0.000735	0.19	0.21	Fibrinogen levels;	chr3:136510180	chr3:136841726~136862054:-
THCA	cis	rs11902236	0.534	rs12614762	ENSG00000188525.3	AC010969.1	-4.55	6.91e-06	0.000735	-0.25	-0.21	Prostate cancer;	chr2:9978849	chr2:10003158~10006030:-
THCA	cis	rs17095355	0.636	rs3862007	ENSG00000203876.8	ADD3-AS1	4.55	6.91e-06	0.000735	0.22	0.21	Biliary atresia;	chr10:110003177	chr10:109940104~110008381:-
THCA	cis	rs4713118	0.539	rs200988	ENSG00000261839.1	RP1-265C24.8	4.55	6.91e-06	0.000735	0.22	0.21	Parkinson's disease;	chr6:27851575	chr6:28136849~28139678:+
THCA	cis	rs200986	1	rs200986	ENSG00000261839.1	RP1-265C24.8	4.55	6.91e-06	0.000735	0.22	0.21	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28136849~28139678:+
THCA	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-4.55	6.92e-06	0.000735	-0.23	-0.21	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
THCA	cis	rs875971	0.528	rs801213	ENSG00000273142.1	RP11-458F8.4	-4.55	6.92e-06	0.000735	-0.19	-0.21	Aortic root size;	chr7:66549931	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000273142.1	RP11-458F8.4	-4.55	6.92e-06	0.000735	-0.19	-0.21	Aortic root size;	chr7:66550643	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs1553610	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66732246	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs2707845	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66733811	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs2707850	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66738883	chr7:66025126~66031544:-
THCA	cis	rs801193	0.967	rs1110414	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66740595	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs7783924	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66744070	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs7789184	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66745208	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs2707854	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66747610	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs3800812	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66758474	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs4279493	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66761633	chr7:66025126~66031544:-
THCA	cis	rs801193	0.761	rs2659888	ENSG00000229886.1	RP5-1132H15.3	4.55	6.92e-06	0.000735	0.21	0.21	Aortic root size;	chr7:66765184	chr7:66025126~66031544:-
THCA	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-4.55	6.92e-06	0.000735	-0.24	-0.21	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
THCA	cis	rs17711722	0.523	rs313812	ENSG00000273024.4	INTS4P2	4.55	6.92e-06	0.000736	0.23	0.21	Calcium levels;	chr7:66040056	chr7:65647864~65715661:+
THCA	cis	rs8141529	0.509	rs6005927	ENSG00000226471.5	CTA-292E10.6	-4.55	6.92e-06	0.000736	-0.18	-0.21	Lymphocyte counts;	chr22:28859896	chr22:28800683~28848559:+
THCA	cis	rs919433	0.617	rs10931791	ENSG00000231621.1	AC013264.2	4.55	6.92e-06	0.000736	0.22	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197708888	chr2:197197991~197199273:+
THCA	cis	rs2483058	0.767	rs2336939	ENSG00000261000.1	RP11-534L20.5	4.55	6.93e-06	0.000736	0.22	0.21	Cholesterol and Triglycerides;	chr1:206446827	chr1:206503948~206504456:+
THCA	cis	rs2483058	0.767	rs11579993	ENSG00000261000.1	RP11-534L20.5	4.55	6.93e-06	0.000736	0.22	0.21	Cholesterol and Triglycerides;	chr1:206445529	chr1:206503948~206504456:+
THCA	cis	rs9876781	1	rs7653691	ENSG00000244380.1	RP11-24C3.2	-4.55	6.93e-06	0.000736	-0.24	-0.21	Longevity;	chr3:48378199	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs6442117	ENSG00000244380.1	RP11-24C3.2	-4.55	6.93e-06	0.000736	-0.24	-0.21	Longevity;	chr3:48378407	chr3:48440352~48446656:-
THCA	cis	rs7989336	0.69	rs7320184	ENSG00000247400.3	DNAJC3-AS1	-4.55	6.93e-06	0.000736	-0.13	-0.21	Obesity;	chr13:96324091	chr13:95648733~95676925:-
THCA	cis	rs950776	0.714	rs615470	ENSG00000261762.1	RP11-650L12.2	-4.55	6.93e-06	0.000736	-0.26	-0.21	Sudden cardiac arrest;	chr15:78593646	chr15:78589123~78591276:-
THCA	cis	rs285757	0.576	rs9972374	ENSG00000258741.3	RP11-386M24.4	-4.55	6.93e-06	0.000736	-0.22	-0.21	HIV-1 susceptibility;	chr15:92639192	chr15:92715710~92734195:-
THCA	cis	rs1876905	0.68	rs187130	ENSG00000272356.1	RP5-1112D6.8	-4.55	6.93e-06	0.000736	-0.21	-0.21	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111309203~111313517:+
THCA	cis	rs481331	0.866	rs210222	ENSG00000215146.4	RP11-313J2.1	4.55	6.93e-06	0.000736	0.32	0.21	Systemic juvenile idiopathic arthritis;	chr10:42561628	chr10:42331866~42367974:-
THCA	cis	rs1707322	1	rs12403666	ENSG00000281133.1	AL355480.3	-4.55	6.93e-06	0.000736	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45580892~45580996:-
THCA	cis	rs3096299	0.685	rs4785676	ENSG00000261118.1	RP11-104N10.1	4.55	6.93e-06	0.000737	0.17	0.21	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89492017~89504460:-
THCA	cis	rs4705962	0.878	rs4705965	ENSG00000230612.2	AC004237.1	4.55	6.94e-06	0.000737	0.25	0.21	Atopic dermatitis;	chr5:132719435	chr5:132688681~132723725:+
THCA	cis	rs9863	0.896	rs4930722	ENSG00000269997.1	RP11-214K3.21	-4.55	6.94e-06	0.000737	-0.26	-0.21	White blood cell count;	chr12:123938728	chr12:123966077~123966629:-
THCA	cis	rs6088813	0.961	rs981819	ENSG00000279253.1	RP4-614O4.13	-4.55	6.94e-06	0.000737	-0.2	-0.21	Height;	chr20:35336309	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.961	rs981818	ENSG00000279253.1	RP4-614O4.13	-4.55	6.94e-06	0.000737	-0.2	-0.21	Height;	chr20:35336327	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.961	rs2425063	ENSG00000279253.1	RP4-614O4.13	-4.55	6.94e-06	0.000737	-0.2	-0.21	Height;	chr20:35336470	chr20:35262727~35264187:-
THCA	cis	rs748404	0.556	rs574856	ENSG00000249839.1	AC011330.5	4.55	6.94e-06	0.000737	0.24	0.21	Lung cancer;	chr15:43168636	chr15:43663654~43684339:-
THCA	cis	rs12612619	0.732	rs7585410	ENSG00000229122.1	AGBL5-IT1	4.55	6.94e-06	0.000737	0.15	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26979252	chr2:27061038~27061815:+
THCA	cis	rs1964356	0.524	rs7839585	ENSG00000253893.2	FAM85B	4.55	6.94e-06	0.000737	0.26	0.21	Mean corpuscular volume;	chr8:8996725	chr8:8167819~8226614:-
THCA	cis	rs4948275	0.693	rs2254096	ENSG00000237233.2	TMEM26-AS1	-4.55	6.94e-06	0.000737	-0.27	-0.21	Night sleep phenotypes;	chr10:61548401	chr10:61452639~61481956:+
THCA	cis	rs9875589	0.509	rs4684174	ENSG00000228242.5	AC093495.4	4.55	6.94e-06	0.000738	0.12	0.21	Ovarian reserve;	chr3:14006875	chr3:14144637~14165978:+
THCA	cis	rs807029	0.577	rs750866	ENSG00000236662.1	RP11-108L7.4	4.55	6.94e-06	0.000738	0.22	0.21	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100980507~100985614:-
THCA	cis	rs73198271	0.565	rs575895	ENSG00000253893.2	FAM85B	4.55	6.94e-06	0.000738	0.28	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736737	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.565	rs575920	ENSG00000253893.2	FAM85B	4.55	6.94e-06	0.000738	0.28	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736744	chr8:8167819~8226614:-
THCA	cis	rs875971	0.522	rs1701760	ENSG00000164669.11	INTS4P1	-4.55	6.94e-06	0.000738	-0.26	-0.21	Aortic root size;	chr7:66008701	chr7:65141225~65234216:+
THCA	cis	rs7637701	0.773	rs7623691	ENSG00000240875.4	LINC00886	4.55	6.95e-06	0.000738	0.16	0.21	Breast cancer;	chr3:156790921	chr3:156747346~156817062:-
THCA	cis	rs17680741	0.697	rs11185829	ENSG00000225484.5	NUTM2B-AS1	-4.55	6.95e-06	0.000738	-0.29	-0.21	Coronary artery disease;	chr10:80508094	chr10:79663088~79826594:-
THCA	cis	rs453301	0.686	rs1045527	ENSG00000254153.1	CTA-398F10.2	4.55	6.95e-06	0.000738	0.22	0.21	Joint mobility (Beighton score);	chr8:9032531	chr8:8456909~8461337:-
THCA	cis	rs453301	0.682	rs2929308	ENSG00000248538.5	RP11-10A14.5	4.55	6.95e-06	0.000738	0.25	0.21	Joint mobility (Beighton score);	chr8:9226611	chr8:9189011~9202854:+
THCA	cis	rs6517329	0.538	rs4510305	ENSG00000236830.5	CBR3-AS1	4.55	6.95e-06	0.000738	0.19	0.21	Schizophrenia;	chr21:36148374	chr21:36131767~36175815:-
THCA	cis	rs3796352	0.667	rs13059141	ENSG00000242142.1	SERBP1P3	-4.55	6.95e-06	0.000738	-0.38	-0.21	Immune reponse to smallpox (secreted IL-2);	chr3:52807204	chr3:53064283~53065091:-
THCA	cis	rs11723261	0.621	rs61794960	ENSG00000211553.1	AC253576.2	-4.55	6.95e-06	0.000738	-0.3	-0.21	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:136461~136568:+
THCA	cis	rs9880211	0.898	rs73230099	ENSG00000239213.4	NCK1-AS1	4.55	6.95e-06	0.000739	0.23	0.21	Height;Body mass index;	chr3:136833785	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.898	rs73231903	ENSG00000239213.4	NCK1-AS1	4.55	6.95e-06	0.000739	0.23	0.21	Height;Body mass index;	chr3:136842783	chr3:136841726~136862054:-
THCA	cis	rs722599	0.748	rs17093914	ENSG00000279594.1	RP11-950C14.10	4.55	6.95e-06	0.000739	0.21	0.21	IgG glycosylation;	chr14:74896938	chr14:75011269~75012851:-
THCA	cis	rs713477	0.505	rs8019080	ENSG00000258413.1	RP11-665C16.6	4.55	6.95e-06	0.000739	0.29	0.21	Pediatric bone mineral content (femoral neck);	chr14:55424654	chr14:55262767~55272075:-
THCA	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-4.55	6.96e-06	0.000739	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
THCA	cis	rs3820928	0.874	rs7563644	ENSG00000212391.1	SNORA48	-4.55	6.96e-06	0.000739	-0.23	-0.21	Pulmonary function;	chr2:226982216	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs7605032	ENSG00000212391.1	SNORA48	-4.55	6.96e-06	0.000739	-0.23	-0.21	Pulmonary function;	chr2:226982914	chr2:226968989~226969122:-
THCA	cis	rs7394190	0.748	rs4746146	ENSG00000271848.1	RP11-464F9.21	-4.55	6.96e-06	0.000739	-0.28	-0.21	Incident atrial fibrillation;	chr10:73767439	chr10:73654039~73674719:+
THCA	cis	rs285757	0.532	rs11074092	ENSG00000258741.3	RP11-386M24.4	4.55	6.96e-06	0.000739	0.22	0.21	HIV-1 susceptibility;	chr15:92661075	chr15:92715710~92734195:-
THCA	cis	rs656319	0.629	rs10111315	ENSG00000261451.1	RP11-981G7.1	-4.55	6.96e-06	0.000739	-0.26	-0.21	Myopia (pathological);	chr8:10008078	chr8:10433672~10438312:+
THCA	cis	rs8020095	0.706	rs8006552	ENSG00000258561.1	RP11-72M17.1	-4.55	6.96e-06	0.000739	-0.26	-0.21	Depression (quantitative trait);	chr14:66827351	chr14:66212810~66509394:-
THCA	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	4.55	6.96e-06	0.000739	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
THCA	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	4.55	6.96e-06	0.000739	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
THCA	cis	rs9634489	0.588	rs1925121	ENSG00000247400.3	DNAJC3-AS1	-4.55	6.96e-06	0.000739	-0.13	-0.21	Body mass index;	chr13:96286526	chr13:95648733~95676925:-
THCA	cis	rs10090774	0.544	rs10097013	ENSG00000280303.2	ERICD	-4.55	6.96e-06	0.00074	-0.19	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140682362	chr8:140636281~140638283:+
THCA	cis	rs710913	0.717	rs1180349	ENSG00000182109.6	RP11-69E11.4	-4.55	6.96e-06	0.00074	-0.18	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39522280~39546187:-
THCA	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	4.55	6.96e-06	0.00074	0.21	0.21	Asthma;	chr2:102440033	chr2:102438713~102440475:+
THCA	cis	rs944289	0.74	rs1623766	ENSG00000258844.1	RP11-259K15.2	-4.55	6.96e-06	0.00074	-0.18	-0.21	Thyroid cancer;	chr14:36075632	chr14:36214607~36235608:+
THCA	cis	rs944289	0.74	rs416664	ENSG00000258844.1	RP11-259K15.2	-4.55	6.96e-06	0.00074	-0.18	-0.21	Thyroid cancer;	chr14:36076319	chr14:36214607~36235608:+
THCA	cis	rs944289	0.74	rs1617130	ENSG00000258844.1	RP11-259K15.2	-4.55	6.96e-06	0.00074	-0.18	-0.21	Thyroid cancer;	chr14:36077059	chr14:36214607~36235608:+
THCA	cis	rs953301	1	rs74125028	ENSG00000229808.1	RP11-456P18.2	-4.55	6.97e-06	0.00074	-0.56	-0.21	Left atrial antero-posterior diameter;	chr1:161871733	chr1:161890833~161892196:+
THCA	cis	rs953301	0.744	rs4532807	ENSG00000229808.1	RP11-456P18.2	-4.55	6.97e-06	0.00074	-0.56	-0.21	Left atrial antero-posterior diameter;	chr1:161887406	chr1:161890833~161892196:+
THCA	cis	rs35740288	0.77	rs11638278	ENSG00000259295.5	CSPG4P12	4.55	6.97e-06	0.00074	0.32	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85668173	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.688	rs12904047	ENSG00000259295.5	CSPG4P12	4.55	6.97e-06	0.00074	0.32	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85669635	chr15:85191438~85213905:+
THCA	cis	rs13287066	0.716	rs4744239	ENSG00000227603.1	RP11-165J3.6	4.55	6.97e-06	0.00074	0.21	0.21	Intelligence (multi-trait analysis);	chr9:93404100	chr9:93435332~93437121:-
THCA	cis	rs832540	0.564	rs33329	ENSG00000271828.1	CTD-2310F14.1	4.55	6.97e-06	0.00074	0.55	0.21	Coronary artery disease;	chr5:56849241	chr5:56927874~56929573:+
THCA	cis	rs6570726	0.935	rs400968	ENSG00000270638.1	RP3-466P17.1	4.55	6.97e-06	0.00074	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs391820	ENSG00000270638.1	RP3-466P17.1	4.55	6.97e-06	0.00074	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.875	rs1883407	ENSG00000270638.1	RP3-466P17.1	4.55	6.97e-06	0.00074	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs367612	ENSG00000270638.1	RP3-466P17.1	4.55	6.97e-06	0.00074	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.905	rs375692	ENSG00000270638.1	RP3-466P17.1	4.55	6.97e-06	0.00074	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145735570~145737218:+
THCA	cis	rs17508449	0.547	rs17463292	ENSG00000232450.1	RP4-730K3.3	-4.55	6.97e-06	0.00074	-0.29	-0.21	Leprosy;	chr1:113828618	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.547	rs3761935	ENSG00000232450.1	RP4-730K3.3	-4.55	6.97e-06	0.00074	-0.29	-0.21	Leprosy;	chr1:113829906	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.504	rs17509844	ENSG00000232450.1	RP4-730K3.3	-4.55	6.97e-06	0.00074	-0.29	-0.21	Leprosy;	chr1:113835147	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.547	rs6658523	ENSG00000232450.1	RP4-730K3.3	-4.55	6.97e-06	0.00074	-0.29	-0.21	Leprosy;	chr1:113843437	chr1:113698884~113699631:-
THCA	cis	rs8058578	0.943	rs3747486	ENSG00000279196.1	RP11-1072A3.3	4.55	6.97e-06	0.00074	0.21	0.21	Multiple myeloma;	chr16:30775606	chr16:30984630~30988270:-
THCA	cis	rs12478296	0.792	rs6740738	ENSG00000261186.2	RP11-341N2.1	-4.55	6.97e-06	0.00074	-0.32	-0.21	Obesity-related traits;	chr2:242065217	chr2:242087351~242088457:-
THCA	cis	rs7572644	0.664	rs10173848	ENSG00000223522.1	AC093690.1	4.55	6.97e-06	0.000741	0.24	0.21	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27920150	chr2:28307691~28310459:-
THCA	cis	rs11633886	0.835	rs2413793	ENSG00000273972.1	CTD-2306A12.1	-4.55	6.97e-06	0.000741	-0.22	-0.21	Diisocyanate-induced asthma;	chr15:45810619	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.835	rs2413794	ENSG00000273972.1	CTD-2306A12.1	-4.55	6.97e-06	0.000741	-0.22	-0.21	Diisocyanate-induced asthma;	chr15:45810812	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.835	rs11637752	ENSG00000273972.1	CTD-2306A12.1	-4.55	6.97e-06	0.000741	-0.22	-0.21	Diisocyanate-induced asthma;	chr15:45811375	chr15:45702640~45703183:+
THCA	cis	rs7829975	0.686	rs907180	ENSG00000233609.3	RP11-62H7.2	4.55	6.98e-06	0.000741	0.2	0.21	Mood instability;	chr8:8845317	chr8:8961200~8979025:+
THCA	cis	rs116248771	0.69	rs116470672	ENSG00000271778.1	RP11-379F4.8	4.55	6.98e-06	0.000741	0.27	0.21	diarrhoeal disease at age 2;	chr3:158619973	chr3:158782547~158783124:+
THCA	cis	rs6997458	0.785	rs713488	ENSG00000253549.4	RP11-317J10.2	4.55	6.98e-06	0.000741	0.21	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85429987	chr8:85441851~85464915:-
THCA	cis	rs6997458	0.785	rs713489	ENSG00000253549.4	RP11-317J10.2	4.55	6.98e-06	0.000741	0.21	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85430344	chr8:85441851~85464915:-
THCA	cis	rs6997458	0.651	rs2403105	ENSG00000253549.4	RP11-317J10.2	4.55	6.98e-06	0.000741	0.21	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85430904	chr8:85441851~85464915:-
THCA	cis	rs6997458	0.785	rs13255540	ENSG00000253549.4	RP11-317J10.2	4.55	6.98e-06	0.000741	0.21	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85431352	chr8:85441851~85464915:-
THCA	cis	rs8062405	0.824	rs4788085	ENSG00000261766.1	RP11-22P6.2	-4.55	6.98e-06	0.000741	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.824	rs28772958	ENSG00000261766.1	RP11-22P6.2	-4.55	6.98e-06	0.000741	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.789	rs2106480	ENSG00000261766.1	RP11-22P6.2	-4.55	6.98e-06	0.000741	-0.19	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28862166~28863340:-
THCA	cis	rs10090774	0.87	rs12234950	ENSG00000279766.1	RP11-642A1.2	4.55	6.98e-06	0.000741	0.25	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140746229	chr8:140572142~140572812:-
THCA	cis	rs7131987	0.801	rs962866	ENSG00000257176.2	RP11-996F15.2	-4.55	6.98e-06	0.000741	-0.2	-0.21	QT interval;	chr12:29281214	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.834	rs7139273	ENSG00000257176.2	RP11-996F15.2	-4.55	6.98e-06	0.000741	-0.2	-0.21	QT interval;	chr12:29281717	chr12:29280418~29317848:-
THCA	cis	rs7577696	0.853	rs212758	ENSG00000276334.1	AL133243.1	-4.55	6.98e-06	0.000741	-0.22	-0.21	Inflammatory biomarkers;	chr2:32200913	chr2:32521927~32523547:+
THCA	cis	rs1552244	0.706	rs279545	ENSG00000180385.7	EMC3-AS1	4.55	6.98e-06	0.000742	0.2	0.21	Alzheimer's disease;	chr3:9930809	chr3:9986893~10006990:+
THCA	cis	rs9388451	1	rs9388451	ENSG00000226409.1	RP11-735G4.1	-4.55	6.98e-06	0.000742	-0.24	-0.21	Brugada syndrome;	chr6:125769231	chr6:125370211~125374324:-
THCA	cis	rs10256972	0.552	rs2949192	ENSG00000225146.1	AC073957.15	4.55	6.98e-06	0.000742	0.22	0.21	Endometriosis;Longevity;	chr7:1164205	chr7:1029025~1043891:+
THCA	cis	rs427691	0.625	rs845733	ENSG00000271849.1	CTC-332L22.1	-4.55	6.98e-06	0.000742	-0.29	-0.21	Autism spectrum disorder or schizophrenia;	chr5:109687700	chr5:109687802~109688329:-
THCA	cis	rs7615952	0.688	rs9754526	ENSG00000272840.1	RP11-379B18.6	4.55	6.98e-06	0.000742	0.32	0.21	Blood pressure (smoking interaction);	chr3:125824023	chr3:125774714~125797953:+
THCA	cis	rs1707322	0.896	rs785512	ENSG00000281133.1	AL355480.3	4.55	6.99e-06	0.000742	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45580892~45580996:-
THCA	cis	rs6088590	1	rs55753039	ENSG00000269202.1	RP4-614O4.12	-4.55	6.99e-06	0.000742	-0.19	-0.21	Coronary artery disease;	chr20:34807137	chr20:35201747~35203288:-
THCA	cis	rs7429990	0.727	rs319695	ENSG00000228638.1	FCF1P2	4.55	6.99e-06	0.000742	0.2	0.21	Educational attainment (years of education);	chr3:47842749	chr3:48290793~48291375:-
THCA	cis	rs17095355	1	rs734164	ENSG00000203876.8	ADD3-AS1	-4.55	6.99e-06	0.000742	-0.22	-0.21	Biliary atresia;	chr10:109938402	chr10:109940104~110008381:-
THCA	cis	rs875971	0.66	rs801192	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.99e-06	0.000742	-0.21	-0.21	Aortic root size;	chr7:66566965	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs801190	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.99e-06	0.000742	-0.21	-0.21	Aortic root size;	chr7:66568046	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs3857686	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.99e-06	0.000742	-0.21	-0.21	Aortic root size;	chr7:66571204	chr7:66025126~66031544:-
THCA	cis	rs875971	0.638	rs6460305	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.99e-06	0.000742	-0.21	-0.21	Aortic root size;	chr7:66595421	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs10272357	ENSG00000229886.1	RP5-1132H15.3	-4.55	6.99e-06	0.000742	-0.21	-0.21	Aortic root size;	chr7:66598087	chr7:66025126~66031544:-
THCA	cis	rs12291225	0.585	rs4757250	ENSG00000251991.1	RNU7-49P	4.55	7e-06	0.000743	0.24	0.21	Sense of smell;	chr11:14354137	chr11:14478892~14478953:+
THCA	cis	rs8077577	0.747	rs35738574	ENSG00000273018.4	CTD-2303H24.2	-4.55	7e-06	0.000743	-0.3	-0.21	Obesity-related traits;	chr17:18248110	chr17:18511221~18551705:-
THCA	cis	rs8067545	0.75	rs6587215	ENSG00000270091.1	RP11-78O7.2	-4.54	7e-06	0.000743	-0.15	-0.21	Schizophrenia;	chr17:20077466	chr17:19896590~19897287:-
THCA	cis	rs9902453	0.868	rs7212162	ENSG00000263370.1	RP11-68I3.5	4.54	7e-06	0.000743	0.26	0.21	Coffee consumption (cups per day);	chr17:29994310	chr17:29639627~29640825:+
THCA	cis	rs763121	0.853	rs9607566	ENSG00000235209.1	CTA-150C2.13	4.54	7e-06	0.000743	0.27	0.21	Menopause (age at onset);	chr22:38679429	chr22:38921227~38924708:+
THCA	cis	rs642858	0.615	rs1856756	ENSG00000234147.1	RP3-460G2.2	-4.54	7e-06	0.000743	-0.25	-0.21	Type 2 diabetes;	chr6:140409647	chr6:140845958~140852924:-
THCA	cis	rs4948275	0.693	rs1902427	ENSG00000237233.2	TMEM26-AS1	-4.54	7e-06	0.000743	-0.27	-0.21	Night sleep phenotypes;	chr10:61550282	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs2787708	ENSG00000237233.2	TMEM26-AS1	-4.54	7e-06	0.000743	-0.27	-0.21	Night sleep phenotypes;	chr10:61556326	chr10:61452639~61481956:+
THCA	cis	rs2361710	0.704	rs12937349	ENSG00000279259.1	RP11-334C17.3	4.54	7.01e-06	0.000744	0.17	0.21	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80146521	chr17:80147250~80148596:+
THCA	cis	rs6430585	0.583	rs12373779	ENSG00000231890.6	DARS-AS1	-4.54	7.01e-06	0.000744	-0.25	-0.21	Corneal structure;	chr2:135829270	chr2:135985176~136022593:+
THCA	cis	rs829883	0.659	rs11109510	ENSG00000227825.4	SLC9A7P1	-4.54	7.01e-06	0.000744	-0.2	-0.21	Colorectal adenoma (advanced);	chr12:98517604	chr12:98453835~98457145:-
THCA	cis	rs253959	0.739	rs712573	ENSG00000272265.1	CTD-2287O16.4	-4.54	7.01e-06	0.000744	-0.23	-0.21	Bipolar disorder and schizophrenia;	chr5:116302121	chr5:116078110~116078570:-
THCA	cis	rs13063635	0.85	rs34386754	ENSG00000226074.4	PRSS44	-4.54	7.01e-06	0.000744	-0.35	-0.21	Eosinophil percentage of granulocytes;	chr3:46048521	chr3:46809359~46812558:-
THCA	cis	rs12478296	0.792	rs3924263	ENSG00000261186.2	RP11-341N2.1	-4.54	7.01e-06	0.000744	-0.31	-0.21	Obesity-related traits;	chr2:242063016	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs7420157	ENSG00000261186.2	RP11-341N2.1	-4.54	7.01e-06	0.000744	-0.31	-0.21	Obesity-related traits;	chr2:242063053	chr2:242087351~242088457:-
THCA	cis	rs11853189	0.938	rs16969703	ENSG00000259562.2	RP11-762H8.2	4.54	7.01e-06	0.000744	0.2	0.21	Red cell distribution width;	chr15:78299694	chr15:78290527~78291221:-
THCA	cis	rs4916588	0.58	rs73078422	ENSG00000270170.1	NCBP2-AS2	4.54	7.01e-06	0.000744	0.16	0.21	Night sleep phenotypes;	chr3:196889207	chr3:196942623~196943540:+
THCA	cis	rs7680126	0.536	rs3796841	ENSG00000261490.1	RP11-448G15.3	4.54	7.01e-06	0.000744	0.18	0.21	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10006280	chr4:10068089~10073019:-
THCA	cis	rs4578769	0.55	rs4474794	ENSG00000265939.1	UBE2CP2	4.54	7.01e-06	0.000744	0.23	0.21	Eosinophil percentage of white cells;	chr18:22987010	chr18:22900486~22900995:-
THCA	cis	rs10107145	0.509	rs4310166	ENSG00000280294.1	RP11-177H2.1	4.54	7.01e-06	0.000745	0.17	0.21	Systolic blood pressure;	chr8:10906226	chr8:10856085~10859436:-
THCA	cis	rs12935418	0.524	rs9933697	ENSG00000278985.1	RP11-303E16.9	4.54	7.02e-06	0.000745	0.21	0.21	Mean corpuscular volume;	chr16:80939637	chr16:80982319~80984094:-
THCA	cis	rs17270561	0.636	rs9348696	ENSG00000272462.2	U91328.19	-4.54	7.02e-06	0.000745	-0.17	-0.21	Iron status biomarkers;	chr6:25781710	chr6:25992662~26001775:+
THCA	cis	rs13178541	0.81	rs2304075	ENSG00000250378.1	RP11-119J18.1	-4.54	7.02e-06	0.000745	-0.26	-0.21	IgG glycosylation;	chr5:135842435	chr5:135812667~135826582:+
THCA	cis	rs7942368	0.941	rs10793195	ENSG00000261578.1	RP11-21L23.2	4.54	7.02e-06	0.000745	0.3	0.21	Endometriosis;	chr11:76793688	chr11:76800364~76804555:+
THCA	cis	rs17801127	0.748	rs1526282	ENSG00000231969.1	AC144449.1	4.54	7.02e-06	0.000745	0.35	0.21	Liver enzyme levels (alanine transaminase);	chr2:149658765	chr2:149587196~149848233:+
THCA	cis	rs7615952	0.512	rs34085484	ENSG00000272840.1	RP11-379B18.6	4.54	7.02e-06	0.000745	0.32	0.21	Blood pressure (smoking interaction);	chr3:125825343	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.608	rs35668111	ENSG00000272840.1	RP11-379B18.6	4.54	7.02e-06	0.000745	0.32	0.21	Blood pressure (smoking interaction);	chr3:125825792	chr3:125774714~125797953:+
THCA	cis	rs4072705	0.617	rs10283445	ENSG00000224020.1	MIR181A2HG	-4.54	7.02e-06	0.000745	-0.19	-0.21	Menarche (age at onset);	chr9:124481358	chr9:124658467~124698631:+
THCA	cis	rs1030877	0.515	rs1866038	ENSG00000235319.1	AC012360.4	-4.54	7.02e-06	0.000745	-0.27	-0.21	Obesity-related traits;	chr2:105262065	chr2:105324210~105330529:+
THCA	cis	rs2281603	0.57	rs11158542	ENSG00000272909.1	CTD-2555O16.4	4.54	7.02e-06	0.000745	0.23	0.21	Lymphocyte counts;	chr14:64462940	chr14:64440369~64442238:-
THCA	cis	rs10971721	0.822	rs10971739	ENSG00000281128.1	PTENP1-AS	4.54	7.03e-06	0.000746	0.44	0.21	Body mass index;	chr9:33855467	chr9:33677268~33688011:+
THCA	cis	rs12478296	0.901	rs6731775	ENSG00000261186.2	RP11-341N2.1	-4.54	7.03e-06	0.000746	-0.31	-0.21	Obesity-related traits;	chr2:242057292	chr2:242087351~242088457:-
THCA	cis	rs6832769	1	rs576779	ENSG00000272969.1	RP11-528I4.2	4.54	7.03e-06	0.000746	0.24	0.21	Personality dimensions;	chr4:55408140	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.961	rs480479	ENSG00000272969.1	RP11-528I4.2	4.54	7.03e-06	0.000746	0.24	0.21	Personality dimensions;	chr4:55408163	chr4:55547112~55547889:+
THCA	cis	rs4970988	0.556	rs2280078	ENSG00000231073.1	RP11-316M1.3	-4.54	7.03e-06	0.000746	-0.25	-0.21	Urate levels;	chr1:150627705	chr1:150973123~150975534:+
THCA	cis	rs4415084	0.716	rs6451781	ENSG00000272335.1	RP11-53O19.3	4.54	7.03e-06	0.000746	0.17	0.21	Breast cancer;	chr5:44860404	chr5:44826076~44828592:+
THCA	cis	rs4591358	0.626	rs7565624	ENSG00000223466.1	AC064834.2	4.54	7.03e-06	0.000746	0.24	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195431262	chr2:195533035~195538681:+
THCA	cis	rs7474896	0.583	rs1735621	ENSG00000120555.12	SEPT7P9	-4.54	7.03e-06	0.000746	-0.27	-0.21	Obesity (extreme);	chr10:37878795	chr10:38383069~38402916:-
THCA	cis	rs7085104	0.513	rs619824	ENSG00000236937.2	PTGES3P4	4.54	7.03e-06	0.000746	0.25	0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102845595~102845950:+
THCA	cis	rs6088590	1	rs6120750	ENSG00000276073.1	RP5-1125A11.7	-4.54	7.03e-06	0.000746	-0.19	-0.21	Coronary artery disease;	chr20:34877486	chr20:33985617~33988989:-
THCA	cis	rs111756027	0.783	rs2081254	ENSG00000260922.1	RP11-538I12.3	4.54	7.03e-06	0.000746	0.33	0.21	Bone mineral density (Ward's triangle area);	chr16:77282126	chr16:77234877~77290934:+
THCA	cis	rs11955398	0.502	rs295573	ENSG00000272308.1	RP11-231G3.1	-4.54	7.03e-06	0.000746	-0.21	-0.21	Intelligence (multi-trait analysis);	chr5:61130433	chr5:60866457~60866935:-
THCA	cis	rs12143943	0.934	rs4951406	ENSG00000240219.1	RP11-430C7.5	4.54	7.03e-06	0.000746	0.18	0.21	Cognitive performance;	chr1:204585475	chr1:204626775~204629712:+
THCA	cis	rs12143943	0.966	rs12135707	ENSG00000240219.1	RP11-430C7.5	4.54	7.03e-06	0.000746	0.18	0.21	Cognitive performance;	chr1:204587095	chr1:204626775~204629712:+
THCA	cis	rs17772222	0.516	rs1006259	ENSG00000258983.2	RP11-507K2.2	4.54	7.04e-06	0.000747	0.25	0.21	Coronary artery calcification;	chr14:88339759	chr14:88499334~88515502:+
THCA	cis	rs4767841	0.625	rs12300601	ENSG00000248636.5	RP11-768F21.1	-4.54	7.04e-06	0.000747	-0.21	-0.21	Urgency urinary incontinence;	chr12:119799987	chr12:119387987~119668079:-
THCA	cis	rs2836974	0.602	rs2037925	ENSG00000255568.3	BRWD1-AS2	-4.54	7.04e-06	0.000747	-0.17	-0.21	Cognitive function;	chr21:39328005	chr21:39313935~39314962:+
THCA	cis	rs12612619	0.732	rs11687536	ENSG00000229122.1	AGBL5-IT1	-4.54	7.04e-06	0.000747	-0.14	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976886	chr2:27061038~27061815:+
THCA	cis	rs7826238	0.509	rs2948288	ENSG00000253981.4	ALG1L13P	4.54	7.04e-06	0.000747	0.19	0.21	Systolic blood pressure;	chr8:8257782	chr8:8236003~8244667:-
THCA	cis	rs3820928	0.874	rs13385711	ENSG00000212391.1	SNORA48	-4.54	7.04e-06	0.000747	-0.23	-0.21	Pulmonary function;	chr2:226965698	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs6718057	ENSG00000212391.1	SNORA48	-4.54	7.04e-06	0.000747	-0.23	-0.21	Pulmonary function;	chr2:226969633	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs1917122	ENSG00000212391.1	SNORA48	-4.54	7.04e-06	0.000747	-0.23	-0.21	Pulmonary function;	chr2:226970965	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs7423610	ENSG00000212391.1	SNORA48	-4.54	7.04e-06	0.000747	-0.23	-0.21	Pulmonary function;	chr2:226971546	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.874	rs1996998	ENSG00000212391.1	SNORA48	-4.54	7.04e-06	0.000747	-0.23	-0.21	Pulmonary function;	chr2:226975578	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.845	rs1917126	ENSG00000212391.1	SNORA48	-4.54	7.04e-06	0.000747	-0.23	-0.21	Pulmonary function;	chr2:226976207	chr2:226968989~226969122:-
THCA	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	4.54	7.04e-06	0.000747	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
THCA	cis	rs67478160	0.643	rs2024667	ENSG00000269910.1	RP11-73M18.10	4.54	7.04e-06	0.000747	0.17	0.21	Schizophrenia;	chr14:103745192	chr14:103694516~103695050:-
THCA	cis	rs12470837	1	rs12470837	ENSG00000197927.11	C2orf27A	4.54	7.04e-06	0.000747	0.29	0.21	Cerebrospinal fluid clusterin levels in APOEe4+ carriers;Cerebrospinal fluid clusterin levels;	chr2:131824938	chr2:131722375~131767404:+
THCA	cis	rs9843304	0.568	rs11720325	ENSG00000244503.1	RP11-278L15.6	4.54	7.04e-06	0.000747	0.28	0.21	Gallstone disease;	chr3:149498524	chr3:149494660~149495995:+
THCA	cis	rs796395	0.641	rs3009935	ENSG00000232480.1	TGFB2-AS1	-4.54	7.05e-06	0.000747	-0.23	-0.21	Post bronchodilator FEV1/FVC ratio;	chr1:218489847	chr1:218344196~218345678:-
THCA	cis	rs9929218	0.52	rs1078621	ENSG00000260459.2	FTLP14	4.54	7.05e-06	0.000748	0.23	0.21	Colorectal cancer;	chr16:68745093	chr16:68822587~68823070:+
THCA	cis	rs1009077	0.61	rs3756154	ENSG00000245958.5	RP11-33B1.1	-4.54	7.05e-06	0.000748	-0.23	-0.21	Endometriosis;	chr4:119597174	chr4:119454791~119552025:+
THCA	cis	rs4538475	1	rs4273468	ENSG00000214846.4	RP11-115L11.1	-4.54	7.05e-06	0.000748	-0.3	-0.21	Parkinson's disease;	chr4:15736240	chr4:15730962~15731627:-
THCA	cis	rs17801127	0.901	rs16827293	ENSG00000231969.1	AC144449.1	-4.54	7.05e-06	0.000748	-0.35	-0.21	Liver enzyme levels (alanine transaminase);	chr2:149652818	chr2:149587196~149848233:+
THCA	cis	rs11671005	0.735	rs11667591	ENSG00000268049.1	CTD-2619J13.9	-4.54	7.05e-06	0.000748	-0.32	-0.21	Mean platelet volume;	chr19:58426270	chr19:58357999~58359603:+
THCA	cis	rs8058578	0.945	rs885107	ENSG00000279196.1	RP11-1072A3.3	4.54	7.05e-06	0.000748	0.21	0.21	Multiple myeloma;	chr16:30661398	chr16:30984630~30988270:-
THCA	cis	rs12554020	0.515	rs2254389	ENSG00000227603.1	RP11-165J3.6	-4.54	7.05e-06	0.000748	-0.23	-0.21	Schizophrenia;	chr9:93604133	chr9:93435332~93437121:-
THCA	cis	rs1979679	0.879	rs2061759	ENSG00000278733.1	RP11-425D17.1	4.54	7.05e-06	0.000748	0.21	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28310394	chr12:28185625~28186190:-
THCA	cis	rs28374715	0.578	rs10518717	ENSG00000247556.5	OIP5-AS1	4.54	7.06e-06	0.000748	0.2	0.21	Ulcerative colitis;	chr15:41331170	chr15:41283990~41309737:+
THCA	cis	rs867186	1	rs11906318	ENSG00000126005.14	MMP24-AS1	-4.54	7.06e-06	0.000749	-0.32	-0.21	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35141639	chr20:35216462~35278131:-
THCA	cis	rs786425	0.77	rs7313140	ENSG00000270095.1	RP11-214K3.18	-4.54	7.06e-06	0.000749	-0.24	-0.21	Pubertal anthropometrics;	chr12:123672641	chr12:123971457~123971714:-
THCA	cis	rs786425	0.77	rs7133199	ENSG00000270095.1	RP11-214K3.18	-4.54	7.06e-06	0.000749	-0.24	-0.21	Pubertal anthropometrics;	chr12:123674638	chr12:123971457~123971714:-
THCA	cis	rs7131987	0.868	rs737160	ENSG00000257176.2	RP11-996F15.2	-4.54	7.06e-06	0.000749	-0.2	-0.21	QT interval;	chr12:29276079	chr12:29280418~29317848:-
THCA	cis	rs67478160	0.619	rs12897150	ENSG00000269910.1	RP11-73M18.10	4.54	7.06e-06	0.000749	0.18	0.21	Schizophrenia;	chr14:103853193	chr14:103694516~103695050:-
THCA	cis	rs4819052	0.851	rs2838856	ENSG00000182586.6	LINC00334	-4.54	7.06e-06	0.000749	-0.22	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45234340~45258730:+
THCA	cis	rs138249	0.898	rs138232	ENSG00000273253.2	RP3-402G11.26	-4.54	7.06e-06	0.000749	-0.2	-0.21	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50121409	chr22:50199090~50200837:-
THCA	cis	rs5752326	0.558	rs5752329	ENSG00000261188.1	CTA-445C9.14	4.54	7.06e-06	0.000749	0.24	0.21	Ischemic stroke;	chr22:26450724	chr22:26512537~26514568:+
THCA	cis	rs6012564	1	rs2075678	ENSG00000230758.1	SNAP23P	4.54	7.06e-06	0.000749	0.25	0.21	Anger;	chr20:49084802	chr20:49038357~49038602:-
THCA	cis	rs17767294	1	rs17767294	ENSG00000261839.1	RP1-265C24.8	4.54	7.07e-06	0.000749	0.39	0.21	Parkinson's disease;	chr6:28086420	chr6:28136849~28139678:+
THCA	cis	rs73108077	0.607	rs6057566	ENSG00000277112.2	RP11-755J8.1	-4.54	7.07e-06	0.00075	-0.34	-0.21	Red blood cell density in sickle cell anemia;	chr20:31227621	chr20:30681825~30723932:-
THCA	cis	rs4971059	0.654	rs7364524	ENSG00000236675.1	MTX1P1	-4.54	7.07e-06	0.00075	-0.19	-0.21	Breast cancer;	chr1:155149446	chr1:155230975~155234325:+
THCA	cis	rs2839186	0.508	rs6518278	ENSG00000239415.1	AP001469.9	-4.54	7.07e-06	0.00075	-0.23	-0.21	Testicular germ cell tumor;	chr21:46220657	chr21:46251549~46254133:-
THCA	cis	rs2412819	0.571	rs2930531	ENSG00000166763.7	STRCP1	-4.54	7.07e-06	0.00075	-0.27	-0.21	Lung cancer;	chr15:43829372	chr15:43699488~43718184:-
THCA	cis	rs875971	0.619	rs12533585	ENSG00000229886.1	RP5-1132H15.3	4.54	7.07e-06	0.00075	0.21	0.21	Aortic root size;	chr7:66519618	chr7:66025126~66031544:-
THCA	cis	rs36715	1	rs251386	ENSG00000245937.6	LINC01184	4.54	7.07e-06	0.00075	0.23	0.21	Breast cancer;	chr5:128211606	chr5:127940426~128083172:-
THCA	cis	rs2665103	0.61	rs1972460	ENSG00000259429.4	UBE2Q2P2	-4.54	7.08e-06	0.00075	-0.16	-0.21	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82355142~82420075:+
THCA	cis	rs919433	0.617	rs4850809	ENSG00000231621.1	AC013264.2	4.54	7.08e-06	0.000751	0.22	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197718679	chr2:197197991~197199273:+
THCA	cis	rs453301	0.522	rs2929309	ENSG00000253981.4	ALG1L13P	-4.54	7.08e-06	0.000751	-0.19	-0.21	Joint mobility (Beighton score);	chr8:9226261	chr8:8236003~8244667:-
THCA	cis	rs2289700	1	rs3784540	ENSG00000252061.1	RNU6-415P	-4.54	7.08e-06	0.000751	-0.42	-0.21	Bipolar disorder;	chr15:78926990	chr15:78898840~78898936:-
THCA	cis	rs2289700	1	rs3825931	ENSG00000252061.1	RNU6-415P	-4.54	7.08e-06	0.000751	-0.42	-0.21	Bipolar disorder;	chr15:78927030	chr15:78898840~78898936:-
THCA	cis	rs6472235	0.586	rs62507386	ENSG00000272010.1	CTD-3025N20.3	-4.54	7.08e-06	0.000751	-0.22	-0.21	Plateletcrit;Myopia (pathological);	chr8:66012724	chr8:65591850~65592472:-
THCA	cis	rs11976180	1	rs7777389	ENSG00000244198.4	RP4-545C24.1	-4.54	7.08e-06	0.000751	-0.2	-0.21	Obesity-related traits;	chr7:144047709	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs67239267	ENSG00000244198.4	RP4-545C24.1	-4.54	7.08e-06	0.000751	-0.2	-0.21	Obesity-related traits;	chr7:144048023	chr7:144194858~144280547:+
THCA	cis	rs7267979	1	rs4815412	ENSG00000274973.1	RP13-401N8.7	-4.54	7.08e-06	0.000751	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25845497~25845862:+
THCA	cis	rs4819052	1	rs4819052	ENSG00000182586.6	LINC00334	-4.54	7.08e-06	0.000751	-0.24	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45234340~45258730:+
THCA	cis	rs7688540	0.515	rs28415975	ENSG00000250892.1	RP11-1365D11.1	4.54	7.08e-06	0.000751	0.3	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:201409~205009:-
THCA	cis	rs7583236	0.925	rs3821275	ENSG00000179818.12	PCBP1-AS1	-4.54	7.09e-06	0.000751	-0.21	-0.21	Obesity-related traits;	chr2:69959238	chr2:69962263~70103220:-
THCA	cis	rs1046896	0.519	rs9900369	ENSG00000263063.1	RP11-388C12.1	-4.54	7.09e-06	0.000751	-0.27	-0.21	Glycated hemoglobin levels;	chr17:82871931	chr17:82713908~82716255:-
THCA	cis	rs7200786	0.557	rs8057040	ENSG00000274038.1	RP11-66H6.4	-4.54	7.09e-06	0.000751	-0.25	-0.21	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10997502	chr16:11056556~11057034:+
THCA	cis	rs4713118	0.513	rs1225591	ENSG00000261839.1	RP1-265C24.8	4.54	7.09e-06	0.000752	0.22	0.21	Parkinson's disease;	chr6:28180974	chr6:28136849~28139678:+
THCA	cis	rs62025270	0.688	rs62022941	ENSG00000259295.5	CSPG4P12	-4.54	7.09e-06	0.000752	-0.35	-0.21	Idiopathic pulmonary fibrosis;	chr15:85712824	chr15:85191438~85213905:+
THCA	cis	rs2447820	0.5	rs26371	ENSG00000249996.1	RP11-359P5.1	4.54	7.09e-06	0.000752	0.24	0.21	Migraine;	chr5:122870830	chr5:123036271~123054667:+
THCA	cis	rs73198271	0.603	rs557892	ENSG00000253893.2	FAM85B	4.54	7.09e-06	0.000752	0.28	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8738538	chr8:8167819~8226614:-
THCA	cis	rs6840258	0.569	rs17012516	ENSG00000251411.1	RP11-397E7.4	4.54	7.09e-06	0.000752	0.23	0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87147991	chr4:86913266~86914817:-
THCA	cis	rs2985684	1	rs2147712	ENSG00000278009.1	RP11-649E7.8	4.54	7.09e-06	0.000752	0.29	0.21	Carotid intima media thickness;	chr14:49624966	chr14:49601011~49601124:-
THCA	cis	rs2985684	0.779	rs12160	ENSG00000278009.1	RP11-649E7.8	4.54	7.09e-06	0.000752	0.29	0.21	Carotid intima media thickness;	chr14:49625214	chr14:49601011~49601124:-
THCA	cis	rs77926410	0.604	rs11053801	ENSG00000245648.1	RP11-277P12.20	-4.54	7.09e-06	0.000752	-0.22	-0.21	Mean corpuscular volume;	chr12:10443518	chr12:10363769~10398506:+
THCA	cis	rs12681288	0.676	rs4565481	ENSG00000260721.1	AF067845.1	4.54	7.09e-06	0.000752	0.25	0.21	Schizophrenia;	chr8:1051944	chr8:1368642~1369833:-
THCA	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-4.54	7.1e-06	0.000752	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
THCA	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-4.54	7.1e-06	0.000752	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
THCA	cis	rs931127	0.658	rs7926512	ENSG00000214659.4	KRT8P26	4.54	7.1e-06	0.000752	0.18	0.21	Systemic lupus erythematosus;	chr11:65697016	chr11:65726939~65728214:+
THCA	cis	rs4144027	0.967	rs12879686	ENSG00000269910.1	RP11-73M18.10	4.54	7.1e-06	0.000753	0.19	0.21	Blood metabolite levels;	chr14:103894404	chr14:103694516~103695050:-
THCA	cis	rs17597773	0.527	rs1537806	ENSG00000272823.1	RP11-295M18.6	-4.54	7.1e-06	0.000753	-0.24	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910880	chr1:220828676~220829211:-
THCA	cis	rs987724	0.515	rs344079	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837783	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs344080	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837996	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs344082	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838290	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs344084	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838591	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs344087	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156842608	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs4680309	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156865807	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs2874488	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868027	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs6765353	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868755	chr3:156747346~156817062:-
THCA	cis	rs987724	0.515	rs7638330	ENSG00000240875.4	LINC00886	-4.54	7.1e-06	0.000753	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156869976	chr3:156747346~156817062:-
THCA	cis	rs4742903	0.868	rs4743684	ENSG00000270332.1	SMC2-AS1	4.54	7.1e-06	0.000753	0.19	0.21	Breast cancer;High-grade serous ovarian cancer;	chr9:104090104	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.967	rs7871759	ENSG00000270332.1	SMC2-AS1	4.54	7.1e-06	0.000753	0.19	0.21	Breast cancer;High-grade serous ovarian cancer;	chr9:104103157	chr9:104080024~104093073:-
THCA	cis	rs7267979	0.808	rs84816	ENSG00000274973.1	RP13-401N8.7	-4.54	7.1e-06	0.000753	-0.23	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25845497~25845862:+
THCA	cis	rs4218	0.689	rs35066133	ENSG00000277144.1	RP11-59H7.4	-4.54	7.1e-06	0.000753	-0.28	-0.21	Social communication problems;	chr15:59081917	chr15:59115547~59116089:-
THCA	cis	rs6570726	0.791	rs379040	ENSG00000270638.1	RP3-466P17.1	4.54	7.11e-06	0.000753	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs697054	ENSG00000270638.1	RP3-466P17.1	4.54	7.11e-06	0.000753	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145735570~145737218:+
THCA	cis	rs7826238	0.517	rs35144760	ENSG00000253981.4	ALG1L13P	-4.54	7.11e-06	0.000753	-0.23	-0.21	Systolic blood pressure;	chr8:8504213	chr8:8236003~8244667:-
THCA	cis	rs9902453	0.967	rs62070344	ENSG00000263370.1	RP11-68I3.5	4.54	7.11e-06	0.000753	0.27	0.21	Coffee consumption (cups per day);	chr17:30149979	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs4356528	ENSG00000263370.1	RP11-68I3.5	4.54	7.11e-06	0.000753	0.27	0.21	Coffee consumption (cups per day);	chr17:30162652	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.872	rs34698290	ENSG00000263370.1	RP11-68I3.5	4.54	7.11e-06	0.000753	0.27	0.21	Coffee consumption (cups per day);	chr17:30173447	chr17:29639627~29640825:+
THCA	cis	rs13098911	0.54	rs13069742	ENSG00000226074.4	PRSS44	-4.54	7.11e-06	0.000753	-0.37	-0.21	Celiac disease;	chr3:46072724	chr3:46809359~46812558:-
THCA	cis	rs875971	0.66	rs28698552	ENSG00000229886.1	RP5-1132H15.3	4.54	7.11e-06	0.000753	0.21	0.21	Aortic root size;	chr7:66540031	chr7:66025126~66031544:-
THCA	cis	rs2028299	1	rs12910992	ENSG00000259677.1	RP11-493E3.1	4.54	7.11e-06	0.000754	0.26	0.21	Type 2 diabetes;	chr15:89829233	chr15:89876540~89877285:+
THCA	cis	rs13118159	0.509	rs4974556	ENSG00000254094.1	AC078852.1	-4.54	7.11e-06	0.000754	-0.26	-0.21	Longevity;	chr4:1364353	chr4:1356581~1358075:+
THCA	cis	rs4916588	0.636	rs34533379	ENSG00000270170.1	NCBP2-AS2	4.54	7.11e-06	0.000754	0.16	0.21	Night sleep phenotypes;	chr3:196886204	chr3:196942623~196943540:+
THCA	cis	rs17801127	0.636	rs10933118	ENSG00000231969.1	AC144449.1	-4.54	7.11e-06	0.000754	-0.33	-0.21	Liver enzyme levels (alanine transaminase);	chr2:149704914	chr2:149587196~149848233:+
THCA	cis	rs4819052	0.851	rs9974891	ENSG00000182586.6	LINC00334	-4.54	7.11e-06	0.000754	-0.21	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45234340~45258730:+
THCA	cis	rs9902453	1	rs4533340	ENSG00000263370.1	RP11-68I3.5	4.54	7.11e-06	0.000754	0.27	0.21	Coffee consumption (cups per day);	chr17:29950933	chr17:29639627~29640825:+
THCA	cis	rs4743820	0.503	rs10820834	ENSG00000230147.2	RP11-305L7.5	4.54	7.11e-06	0.000754	0.26	0.21	Ulcerative colitis;Inflammatory bowel disease;	chr9:91155158	chr9:91169585~91170045:-
THCA	cis	rs2439831	0.702	rs495175	ENSG00000205771.5	CATSPER2P1	-4.54	7.12e-06	0.000754	-0.27	-0.21	Lung cancer in ever smokers;	chr15:43506486	chr15:43726918~43747094:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000273024.4	INTS4P2	-4.54	7.12e-06	0.000754	-0.22	-0.21	Calcium levels;	chr7:65800652	chr7:65647864~65715661:+
THCA	cis	rs1371614	0.523	rs12468761	ENSG00000229122.1	AGBL5-IT1	-4.54	7.12e-06	0.000755	-0.15	-0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26960925	chr2:27061038~27061815:+
THCA	cis	rs2806561	0.704	rs588387	ENSG00000249087.5	ZNF436-AS1	-4.54	7.12e-06	0.000755	-0.13	-0.21	Height;	chr1:23197196	chr1:23368997~23371839:+
THCA	cis	rs9863	0.861	rs7961449	ENSG00000270061.1	RP11-214K3.19	4.54	7.12e-06	0.000755	0.26	0.21	White blood cell count;	chr12:123952668	chr12:123969990~123970344:-
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000220721.1	OR1F12	4.54	7.12e-06	0.000755	0.23	0.21	Pubertal anthropometrics;	chr6:28298372	chr6:28073316~28074233:+
THCA	cis	rs7474896	0.537	rs2749586	ENSG00000226578.1	RP11-258F22.1	4.54	7.12e-06	0.000755	0.28	0.21	Obesity (extreme);	chr10:37981286	chr10:37775371~37784131:-
THCA	cis	rs7474896	0.515	rs2749582	ENSG00000226578.1	RP11-258F22.1	4.54	7.12e-06	0.000755	0.28	0.21	Obesity (extreme);	chr10:37986356	chr10:37775371~37784131:-
THCA	cis	rs1009077	0.579	rs10021460	ENSG00000245958.5	RP11-33B1.1	-4.54	7.12e-06	0.000755	-0.23	-0.21	Endometriosis;	chr4:119595464	chr4:119454791~119552025:+
THCA	cis	rs7824557	1	rs7824557	ENSG00000154316.13	TDH	4.54	7.12e-06	0.000755	0.15	0.21	Retinal vascular caliber;	chr8:11246602	chr8:11339637~11368452:+
THCA	cis	rs1003719	0.591	rs1053966	ENSG00000230366.8	DSCR9	4.54	7.13e-06	0.000755	0.22	0.21	Eye color traits;	chr21:37195708	chr21:37208503~37221736:+
THCA	cis	rs8077577	0.747	rs62072509	ENSG00000273018.4	CTD-2303H24.2	-4.54	7.13e-06	0.000755	-0.3	-0.21	Obesity-related traits;	chr17:18279079	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.747	rs8081155	ENSG00000273018.4	CTD-2303H24.2	-4.54	7.13e-06	0.000755	-0.3	-0.21	Obesity-related traits;	chr17:18288634	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.747	rs3817992	ENSG00000273018.4	CTD-2303H24.2	-4.54	7.13e-06	0.000755	-0.3	-0.21	Obesity-related traits;	chr17:18290697	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.747	rs2294913	ENSG00000273018.4	CTD-2303H24.2	-4.54	7.13e-06	0.000755	-0.3	-0.21	Obesity-related traits;	chr17:18299682	chr17:18511221~18551705:-
THCA	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-4.54	7.13e-06	0.000755	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
THCA	cis	rs1046896	0.553	rs56775875	ENSG00000263063.1	RP11-388C12.1	-4.54	7.13e-06	0.000755	-0.27	-0.21	Glycated hemoglobin levels;	chr17:82873415	chr17:82713908~82716255:-
THCA	cis	rs1046896	0.553	rs8073413	ENSG00000263063.1	RP11-388C12.1	-4.54	7.13e-06	0.000755	-0.27	-0.21	Glycated hemoglobin levels;	chr17:82878129	chr17:82713908~82716255:-
THCA	cis	rs9868809	0.772	rs9821797	ENSG00000270441.1	RP11-694I15.7	4.54	7.13e-06	0.000756	0.25	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48680820	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.772	rs9877794	ENSG00000270441.1	RP11-694I15.7	4.54	7.13e-06	0.000756	0.25	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48680955	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.772	rs9877501	ENSG00000270441.1	RP11-694I15.7	4.54	7.13e-06	0.000756	0.25	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48680957	chr3:49140086~49160851:-
THCA	cis	rs1046896	0.52	rs8074086	ENSG00000263063.1	RP11-388C12.1	-4.54	7.13e-06	0.000756	-0.27	-0.21	Glycated hemoglobin levels;	chr17:82860584	chr17:82713908~82716255:-
THCA	cis	rs4415084	0.716	rs1371022	ENSG00000272335.1	RP11-53O19.3	4.54	7.13e-06	0.000756	0.17	0.21	Breast cancer;	chr5:44847890	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs7726586	ENSG00000272335.1	RP11-53O19.3	4.54	7.13e-06	0.000756	0.17	0.21	Breast cancer;	chr5:44848720	chr5:44826076~44828592:+
THCA	cis	rs4713118	1	rs13215072	ENSG00000220721.1	OR1F12	4.54	7.13e-06	0.000756	0.26	0.21	Parkinson's disease;	chr6:27709949	chr6:28073316~28074233:+
THCA	cis	rs201673768	1	rs201673768	ENSG00000258273.1	RP11-370I10.4	-4.54	7.13e-06	0.000756	-0.25	-0.21	Platelet count;	chr12:48305834	chr12:48333755~48333901:-
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000185485.13	SDHAP1	4.54	7.13e-06	0.000756	0.18	0.21	Pancreatic cancer;	chr3:196021858	chr3:195959748~195990318:-
THCA	cis	rs4785204	0.618	rs55830064	ENSG00000279356.1	RP11-429P3.8	-4.54	7.13e-06	0.000756	-0.39	-0.21	Esophageal cancer (squamous cell);	chr16:49998730	chr16:50072862~50074986:+
THCA	cis	rs11648785	0.62	rs10153134	ENSG00000222019.6	URAHP	4.54	7.13e-06	0.000756	0.17	0.2	Tanning;	chr16:90024691	chr16:90039761~90047773:-
THCA	cis	rs1334894	1	rs12527893	ENSG00000228559.1	RP3-340B19.3	-4.54	7.13e-06	0.000756	-0.43	-0.2	Coronary artery disease;	chr6:35617322	chr6:35544632~35545669:+
THCA	cis	rs4934494	0.513	rs10881607	ENSG00000232936.4	RP11-80H5.2	4.54	7.13e-06	0.000756	0.26	0.2	Red blood cell count;	chr10:89614793	chr10:89645282~89650667:+
THCA	cis	rs7621331	1	rs7621331	ENSG00000273486.1	RP11-731C17.2	4.54	7.14e-06	0.000756	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:136043085	chr3:136837338~136839021:-
THCA	cis	rs3796352	0.892	rs9756317	ENSG00000242142.1	SERBP1P3	4.54	7.14e-06	0.000756	0.35	0.2	Immune reponse to smallpox (secreted IL-2);	chr3:53054799	chr3:53064283~53065091:-
THCA	cis	rs12497850	0.931	rs6446196	ENSG00000228638.1	FCF1P2	-4.54	7.14e-06	0.000756	-0.22	-0.2	Parkinson's disease;	chr3:48967290	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.805	rs6446198	ENSG00000228638.1	FCF1P2	-4.54	7.14e-06	0.000756	-0.22	-0.2	Parkinson's disease;	chr3:48970205	chr3:48290793~48291375:-
THCA	cis	rs7829975	0.658	rs907181	ENSG00000233609.3	RP11-62H7.2	4.54	7.14e-06	0.000757	0.2	0.2	Mood instability;	chr8:8845365	chr8:8961200~8979025:+
THCA	cis	rs863750	0.507	rs10846604	ENSG00000275389.1	RP11-214K3.24	-4.54	7.14e-06	0.000757	-0.29	-0.2	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124110948	chr12:124085761~124088598:+
THCA	cis	rs79243044	0.931	rs10742709	ENSG00000224295.2	AC087380.14	-4.54	7.14e-06	0.000757	-0.21	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5533813	chr11:5518441~5524955:-
THCA	cis	rs72615157	0.634	rs2272343	ENSG00000242294.5	STAG3L5P	4.54	7.14e-06	0.000757	0.13	0.2	Lung function (FEV1/FVC);	chr7:100180662	chr7:100336079~100351900:+
THCA	cis	rs72615157	0.634	rs74742883	ENSG00000242294.5	STAG3L5P	4.54	7.14e-06	0.000757	0.13	0.2	Lung function (FEV1/FVC);	chr7:100188142	chr7:100336079~100351900:+
THCA	cis	rs4965006	1	rs4965006	ENSG00000255992.1	RP11-417L19.4	-4.54	7.15e-06	0.000757	-0.33	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934988	chr12:131924736~131929351:-
THCA	cis	rs11853189	0.938	rs1879152	ENSG00000259562.2	RP11-762H8.2	4.54	7.15e-06	0.000757	0.2	0.2	Red cell distribution width;	chr15:78289498	chr15:78290527~78291221:-
THCA	cis	rs11853189	0.938	rs2280364	ENSG00000259562.2	RP11-762H8.2	4.54	7.15e-06	0.000757	0.2	0.2	Red cell distribution width;	chr15:78292764	chr15:78290527~78291221:-
THCA	cis	rs4722166	0.532	rs1404008	ENSG00000179428.2	AC073072.5	-4.54	7.15e-06	0.000757	-0.23	-0.2	Lung cancer;	chr7:22716381	chr7:22725395~22727620:-
THCA	cis	rs35740288	0.857	rs11630274	ENSG00000259295.5	CSPG4P12	4.54	7.15e-06	0.000757	0.32	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85745156	chr15:85191438~85213905:+
THCA	cis	rs12234571	1	rs73375848	ENSG00000214293.7	APTR	4.54	7.15e-06	0.000758	0.26	0.2	Obesity-related traits;	chr7:77885873	chr7:77657660~77696265:-
THCA	cis	rs5769765	1	rs2319458	ENSG00000260613.1	RP3-522J7.6	-4.54	7.15e-06	0.000758	-0.25	-0.2	Schizophrenia;	chr22:49842658	chr22:49832616~49837786:-
THCA	cis	rs4535700	0.501	rs57153841	ENSG00000226278.1	PSPHP1	4.54	7.15e-06	0.000758	0.24	0.2	Macular telangiectasia type 2;	chr7:55927400	chr7:55764797~55773288:+
THCA	cis	rs10760158	0.865	rs4836843	ENSG00000235865.2	GSN-AS1	4.54	7.15e-06	0.000758	0.17	0.2	Pulse pressure;	chr9:121279393	chr9:121280768~121285530:-
THCA	cis	rs6860806	0.507	rs2631364	ENSG00000224431.1	AC063976.7	-4.54	7.16e-06	0.000758	-0.19	-0.2	Breast cancer;	chr5:132371222	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.531	rs2631359	ENSG00000224431.1	AC063976.7	-4.54	7.16e-06	0.000758	-0.19	-0.2	Breast cancer;	chr5:132372200	chr5:132199456~132203487:+
THCA	cis	rs2921073	0.509	rs2976931	ENSG00000233609.3	RP11-62H7.2	4.54	7.16e-06	0.000758	0.19	0.2	Parkinson's disease;	chr8:8399807	chr8:8961200~8979025:+
THCA	cis	rs4763879	0.634	rs2012643	ENSG00000256673.1	RP11-599J14.2	4.54	7.16e-06	0.000758	0.25	0.2	Type 1 diabetes;	chr12:9707128	chr12:9398355~9414851:-
THCA	cis	rs2836974	0.644	rs11088471	ENSG00000255568.3	BRWD1-AS2	-4.54	7.16e-06	0.000758	-0.17	-0.2	Cognitive function;	chr21:39327387	chr21:39313935~39314962:+
THCA	cis	rs2029362	0.688	rs7938467	ENSG00000245573.6	BDNF-AS	-4.54	7.16e-06	0.000758	-0.16	-0.2	Total body bone mineral density;	chr11:27481128	chr11:27506838~27698174:+
THCA	cis	rs1728785	1	rs698728	ENSG00000274698.1	RP11-71L14.4	4.54	7.16e-06	0.000758	0.29	0.2	Ulcerative colitis;	chr16:68591350	chr16:68450283~68452318:+
THCA	cis	rs11992162	1	rs7460395	ENSG00000270154.1	RP11-419I17.1	4.54	7.16e-06	0.000759	0.26	0.2	Monocyte count;	chr8:11977866	chr8:12476462~12477122:+
THCA	cis	rs548181	1	rs548181	ENSG00000254671.2	STT3A-AS1	-4.54	7.16e-06	0.000759	-0.38	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125591814	chr11:125570284~125592568:-
THCA	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-4.54	7.16e-06	0.000759	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000229180.5	GS1-124K5.11	-4.54	7.16e-06	0.000759	-0.16	-0.2	Corneal structure;	chr7:66821880	chr7:66526088~66542624:-
THCA	cis	rs78487399	0.808	rs77852659	ENSG00000234936.1	AC010883.5	4.54	7.16e-06	0.000759	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534513	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.803	rs75275342	ENSG00000234936.1	AC010883.5	4.54	7.16e-06	0.000759	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43535746	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs113373412	ENSG00000234936.1	AC010883.5	4.54	7.16e-06	0.000759	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43535848	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs112387154	ENSG00000234936.1	AC010883.5	4.54	7.16e-06	0.000759	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536092	chr2:43229573~43233394:+
THCA	cis	rs2179367	0.613	rs62426122	ENSG00000216906.2	RP11-350J20.9	4.54	7.16e-06	0.000759	0.25	0.2	Dupuytren's disease;	chr6:149427449	chr6:149904243~149906418:+
THCA	cis	rs8017455	0.523	rs2075174	ENSG00000259167.2	NMNAT1P1	4.54	7.16e-06	0.000759	0.31	0.2	Hair morphology;	chr14:81092161	chr14:81032529~81033404:+
THCA	cis	rs797680	0.658	rs11164904	ENSG00000223745.6	RP4-717I23.3	4.54	7.16e-06	0.000759	0.12	0.2	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93315185	chr1:93262186~93346025:-
THCA	cis	rs453301	0.598	rs1025395	ENSG00000254153.1	CTA-398F10.2	-4.54	7.17e-06	0.000759	-0.21	-0.2	Joint mobility (Beighton score);	chr8:8979093	chr8:8456909~8461337:-
THCA	cis	rs959260	0.925	rs8072449	ENSG00000263843.1	RP11-649A18.12	4.54	7.17e-06	0.000759	0.23	0.2	Systemic lupus erythematosus;	chr17:75316103	chr17:75271369~75273895:+
THCA	cis	rs6430585	0.646	rs12476116	ENSG00000231890.6	DARS-AS1	-4.54	7.17e-06	0.00076	-0.26	-0.2	Corneal structure;	chr2:135739629	chr2:135985176~136022593:+
THCA	cis	rs59918340	0.764	rs4961258	ENSG00000253307.1	RP11-10J21.4	-4.54	7.17e-06	0.00076	-0.28	-0.2	Immature fraction of reticulocytes;	chr8:141222779	chr8:141252286~141253292:-
THCA	cis	rs1538970	0.781	rs713358	ENSG00000234329.1	RP11-767N6.2	4.54	7.17e-06	0.00076	0.21	0.2	Platelet count;	chr1:45522595	chr1:45651039~45651826:-
THCA	cis	rs4948275	0.605	rs2650746	ENSG00000237233.2	TMEM26-AS1	-4.54	7.17e-06	0.00076	-0.27	-0.2	Night sleep phenotypes;	chr10:61587436	chr10:61452639~61481956:+
THCA	cis	rs5771225	0.505	rs5771111	ENSG00000273253.2	RP3-402G11.26	-4.54	7.18e-06	0.00076	-0.25	-0.2	Late-onset Alzheimer's disease;	chr22:50257517	chr22:50199090~50200837:-
THCA	cis	rs8067545	0.75	rs4570919	ENSG00000270091.1	RP11-78O7.2	-4.54	7.18e-06	0.00076	-0.15	-0.2	Schizophrenia;	chr17:20097502	chr17:19896590~19897287:-
THCA	cis	rs858239	0.6	rs1115941	ENSG00000226816.2	AC005082.12	4.54	7.18e-06	0.00076	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23206013~23208045:+
THCA	cis	rs78487399	0.808	rs75126888	ENSG00000234936.1	AC010883.5	4.54	7.18e-06	0.000761	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43436868	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7575024	ENSG00000234936.1	AC010883.5	4.54	7.18e-06	0.000761	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43439852	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs28700209	ENSG00000234936.1	AC010883.5	4.54	7.18e-06	0.000761	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43440326	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7567535	ENSG00000234936.1	AC010883.5	4.54	7.18e-06	0.000761	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43441122	chr2:43229573~43233394:+
THCA	cis	rs7621331	1	rs13325914	ENSG00000273486.1	RP11-731C17.2	4.54	7.18e-06	0.000761	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135998375	chr3:136837338~136839021:-
THCA	cis	rs75422866	0.867	rs73111258	ENSG00000276691.1	RP5-1057I20.5	4.54	7.18e-06	0.000761	0.37	0.2	Pneumonia;	chr12:47597313	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs117388682	ENSG00000276691.1	RP5-1057I20.5	4.54	7.18e-06	0.000761	0.37	0.2	Pneumonia;	chr12:47599713	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs79113930	ENSG00000276691.1	RP5-1057I20.5	4.54	7.18e-06	0.000761	0.37	0.2	Pneumonia;	chr12:47600628	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs35044089	ENSG00000276691.1	RP5-1057I20.5	4.54	7.18e-06	0.000761	0.37	0.2	Pneumonia;	chr12:47610881	chr12:47788426~47788971:+
THCA	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-4.54	7.19e-06	0.000761	-0.32	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
THCA	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-4.54	7.19e-06	0.000761	-0.32	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
THCA	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-4.54	7.19e-06	0.000761	-0.32	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
THCA	cis	rs13113518	1	rs3762837	ENSG00000249700.7	SRD5A3-AS1	4.54	7.19e-06	0.000761	0.25	0.2	Height;	chr4:55511198	chr4:55363971~55395847:-
THCA	cis	rs2361718	0.5	rs8064429	ENSG00000275479.1	RP11-334C17.6	4.54	7.19e-06	0.000761	0.19	0.2	Yeast infection;	chr17:80122388	chr17:80149627~80149798:+
THCA	cis	rs2886497	0.947	rs1398023	ENSG00000224215.1	RP11-371A19.2	-4.54	7.19e-06	0.000761	-0.26	-0.2	Major depression and alcohol dependence;	chr10:23376613	chr10:23343957~23345181:+
THCA	cis	rs59868192	0.925	rs59114612	ENSG00000246740.2	PLA2G4E-AS1	4.54	7.19e-06	0.000761	0.4	0.2	White blood cell count;	chr15:41958317	chr15:41972763~41999094:+
THCA	cis	rs59868192	0.925	rs72726031	ENSG00000246740.2	PLA2G4E-AS1	4.54	7.19e-06	0.000761	0.4	0.2	White blood cell count;	chr15:41960142	chr15:41972763~41999094:+
THCA	cis	rs59868192	0.85	rs76177165	ENSG00000246740.2	PLA2G4E-AS1	4.54	7.19e-06	0.000761	0.4	0.2	White blood cell count;	chr15:41960290	chr15:41972763~41999094:+
THCA	cis	rs2836974	0.602	rs2836987	ENSG00000255568.3	BRWD1-AS2	-4.54	7.19e-06	0.000761	-0.17	-0.2	Cognitive function;	chr21:39334668	chr21:39313935~39314962:+
THCA	cis	rs890448	1	rs6532943	ENSG00000254531.1	FLJ20021	-4.54	7.19e-06	0.000761	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101512197	chr4:101347780~101348883:+
THCA	cis	rs28735056	0.563	rs12968139	ENSG00000261126.6	RP11-795F19.1	-4.54	7.19e-06	0.000762	-0.17	-0.2	Schizophrenia;	chr18:79925520	chr18:80046900~80095482:+
THCA	cis	rs9878978	0.722	rs13064421	ENSG00000237990.3	CNTN4-AS1	4.54	7.19e-06	0.000762	0.24	0.2	Blood pressure (smoking interaction);	chr3:2405841	chr3:3039033~3069242:-
THCA	cis	rs8062405	0.722	rs3785354	ENSG00000261766.1	RP11-22P6.2	-4.54	7.19e-06	0.000762	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28862166~28863340:-
THCA	cis	rs4660214	0.666	rs1984143	ENSG00000182109.6	RP11-69E11.4	-4.54	7.2e-06	0.000762	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs12025847	ENSG00000182109.6	RP11-69E11.4	-4.54	7.2e-06	0.000762	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39522280~39546187:-
THCA	cis	rs496547	0.719	rs598373	ENSG00000255422.1	AP002954.4	-4.54	7.2e-06	0.000762	-0.22	-0.2	Hip minimal joint space width;	chr11:118793668	chr11:118704607~118750263:+
THCA	cis	rs5758511	0.573	rs4501042	ENSG00000281538.1	RP4-669P10.20	4.54	7.2e-06	0.000762	0.2	0.2	Birth weight;	chr22:41849759	chr22:42138060~42139726:+
THCA	cis	rs12681288	0.676	rs35389636	ENSG00000260721.1	AF067845.1	4.54	7.2e-06	0.000762	0.26	0.2	Schizophrenia;	chr8:1060613	chr8:1368642~1369833:-
THCA	cis	rs61270009	0.955	rs17548339	ENSG00000247828.6	TMEM161B-AS1	4.54	7.2e-06	0.000762	0.18	0.2	Depressive symptoms;	chr5:88391761	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs16903122	ENSG00000247828.6	TMEM161B-AS1	4.54	7.2e-06	0.000762	0.18	0.2	Depressive symptoms;	chr5:88397744	chr5:88268895~88436685:+
THCA	cis	rs763121	0.752	rs6001190	ENSG00000273076.1	RP3-508I15.22	4.54	7.2e-06	0.000762	0.21	0.2	Menopause (age at onset);	chr22:38677806	chr22:38743495~38743910:+
THCA	cis	rs2281636	0.754	rs7092699	ENSG00000260475.1	RP11-85A1.3	4.54	7.2e-06	0.000762	0.19	0.2	Obesity-related traits;	chr10:99605545	chr10:99621055~99621918:+
THCA	cis	rs1949733	0.541	rs13139429	ENSG00000205959.3	RP11-689P11.2	4.54	7.2e-06	0.000763	0.17	0.2	Response to antineoplastic agents;	chr4:8532403	chr4:8482270~8512610:+
THCA	cis	rs17801127	0.748	rs6747199	ENSG00000231969.1	AC144449.1	4.54	7.2e-06	0.000763	0.35	0.2	Liver enzyme levels (alanine transaminase);	chr2:149676139	chr2:149587196~149848233:+
THCA	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	4.54	7.2e-06	0.000763	0.25	0.2	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
THCA	cis	rs2380220	0.872	rs7750757	ENSG00000261366.1	MANEA-AS1	-4.54	7.21e-06	0.000763	-0.22	-0.2	Behavioural disinhibition (generation interaction);	chr6:95549242	chr6:95575183~95577450:-
THCA	cis	rs7208859	0.673	rs9889755	ENSG00000280069.1	CTD-2349P21.3	4.54	7.21e-06	0.000763	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30738182~30740275:+
THCA	cis	rs12612619	0.732	rs12616092	ENSG00000229122.1	AGBL5-IT1	4.54	7.21e-06	0.000763	0.14	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26994360	chr2:27061038~27061815:+
THCA	cis	rs7403037	0.55	rs12185097	ENSG00000259905.4	PWRN1	4.54	7.21e-06	0.000763	0.28	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24404457	chr15:24493137~24652130:+
THCA	cis	rs7772486	0.754	rs1055212	ENSG00000270638.1	RP3-466P17.1	-4.54	7.21e-06	0.000763	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145735570~145737218:+
THCA	cis	rs2281558	0.876	rs2274890	ENSG00000125804.12	FAM182A	-4.54	7.22e-06	0.000764	-0.27	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:26054655~26086917:+
THCA	cis	rs1005277	0.505	rs200910	ENSG00000226578.1	RP11-258F22.1	-4.54	7.22e-06	0.000764	-0.24	-0.2	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:37775371~37784131:-
THCA	cis	rs7819412	0.805	rs2409710	ENSG00000206014.6	OR7E161P	4.54	7.22e-06	0.000764	0.24	0.2	Triglycerides;	chr8:11122311	chr8:11928597~11929563:-
THCA	cis	rs9326248	0.53	rs579890	ENSG00000280143.1	AP000892.6	4.54	7.22e-06	0.000764	0.34	0.2	Blood protein levels;	chr11:116928247	chr11:117204967~117210292:+
THCA	cis	rs734999	0.572	rs2985857	ENSG00000225931.3	RP3-395M20.7	-4.54	7.22e-06	0.000764	-0.25	-0.2	Ulcerative colitis;	chr1:2601185	chr1:2566410~2569888:+
THCA	cis	rs7267979	0.816	rs6115094	ENSG00000274973.1	RP13-401N8.7	-4.54	7.22e-06	0.000764	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25845497~25845862:+
THCA	cis	rs7520050	0.751	rs2991975	ENSG00000234329.1	RP11-767N6.2	-4.54	7.22e-06	0.000764	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45651039~45651826:-
THCA	cis	rs7267979	0.966	rs2151144	ENSG00000274973.1	RP13-401N8.7	4.54	7.22e-06	0.000764	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25845497~25845862:+
THCA	cis	rs17095355	1	rs7921609	ENSG00000203876.8	ADD3-AS1	-4.54	7.22e-06	0.000764	-0.23	-0.2	Biliary atresia;	chr10:109931841	chr10:109940104~110008381:-
THCA	cis	rs752010	0.967	rs6703597	ENSG00000230638.4	RP11-486B10.4	-4.54	7.22e-06	0.000764	-0.22	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41632233	chr1:41542069~41544310:+
THCA	cis	rs9543976	0.925	rs2876706	ENSG00000261105.4	LMO7-AS1	4.54	7.22e-06	0.000764	0.3	0.2	Diabetic retinopathy;	chr13:75612169	chr13:75604700~75635994:-
THCA	cis	rs6921919	0.945	rs61289879	ENSG00000219392.1	RP1-265C24.5	-4.54	7.23e-06	0.000765	-0.28	-0.2	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28115628~28116551:+
THCA	cis	rs12230172	0.653	rs1950103	ENSG00000258245.1	RP11-114H23.3	-4.54	7.23e-06	0.000765	-0.22	-0.2	Glioma;Non-glioblastoma glioma;	chr12:75821720	chr12:75688794~75689096:-
THCA	cis	rs12612619	0.732	rs722911	ENSG00000229122.1	AGBL5-IT1	4.54	7.23e-06	0.000765	0.14	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26988344	chr2:27061038~27061815:+
THCA	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	4.54	7.23e-06	0.000765	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
THCA	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-4.54	7.23e-06	0.000765	-0.22	-0.2	Monocyte count;	chr11:307036	chr11:318640~325631:+
THCA	cis	rs7577696	0.889	rs212759	ENSG00000276334.1	AL133243.1	4.54	7.23e-06	0.000765	0.22	0.2	Inflammatory biomarkers;	chr2:32201753	chr2:32521927~32523547:+
THCA	cis	rs849141	0.524	rs530649	ENSG00000234336.5	JAZF1-AS1	4.54	7.23e-06	0.000765	0.35	0.2	Height;Hip circumference adjusted for BMI;	chr7:28162811	chr7:28180322~28243917:+
THCA	cis	rs4218	0.734	rs12912071	ENSG00000259732.1	RP11-59H7.3	-4.54	7.23e-06	0.000765	-0.26	-0.2	Social communication problems;	chr15:59150951	chr15:59121034~59133250:+
THCA	cis	rs9652601	0.691	rs9939397	ENSG00000274038.1	RP11-66H6.4	-4.54	7.23e-06	0.000765	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11115907	chr16:11056556~11057034:+
THCA	cis	rs9902453	0.765	rs2628167	ENSG00000263370.1	RP11-68I3.5	-4.54	7.23e-06	0.000765	-0.26	-0.2	Coffee consumption (cups per day);	chr17:29737480	chr17:29639627~29640825:+
THCA	cis	rs930395	0.514	rs6871052	ENSG00000272335.1	RP11-53O19.3	4.54	7.23e-06	0.000765	0.17	0.2	Breast cancer;	chr5:44863215	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs6893319	ENSG00000272335.1	RP11-53O19.3	4.54	7.23e-06	0.000765	0.17	0.2	Breast cancer;	chr5:44863627	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.652	rs10053247	ENSG00000272335.1	RP11-53O19.3	4.54	7.23e-06	0.000765	0.17	0.2	Breast cancer;	chr5:44863857	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs10065638	ENSG00000272335.1	RP11-53O19.3	4.54	7.23e-06	0.000765	0.17	0.2	Breast cancer;	chr5:44866060	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs6894324	ENSG00000272335.1	RP11-53O19.3	4.54	7.23e-06	0.000765	0.17	0.2	Breast cancer;	chr5:44867234	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs10069220	ENSG00000272335.1	RP11-53O19.3	4.54	7.23e-06	0.000765	0.17	0.2	Breast cancer;	chr5:44881876	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs13187933	ENSG00000272335.1	RP11-53O19.3	4.54	7.23e-06	0.000765	0.17	0.2	Breast cancer;	chr5:44883141	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.652	rs11948387	ENSG00000272335.1	RP11-53O19.3	4.54	7.23e-06	0.000765	0.17	0.2	Breast cancer;	chr5:44884139	chr5:44826076~44828592:+
THCA	cis	rs7119	0.651	rs12917044	ENSG00000259362.2	RP11-307C19.1	4.54	7.23e-06	0.000766	0.29	0.2	Type 2 diabetes;	chr15:77557804	chr15:77525540~77534110:+
THCA	cis	rs1823913	0.562	rs17347499	ENSG00000280083.1	RP11-317J9.1	-4.54	7.23e-06	0.000766	-0.24	-0.2	Obesity-related traits;	chr2:191301116	chr2:191154118~191156070:-
THCA	cis	rs35740288	0.929	rs1978391	ENSG00000259295.5	CSPG4P12	-4.54	7.24e-06	0.000766	-0.32	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85768464	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.929	rs3858927	ENSG00000259295.5	CSPG4P12	4.54	7.24e-06	0.000766	0.32	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85758385	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.895	rs3743332	ENSG00000259295.5	CSPG4P12	4.54	7.24e-06	0.000766	0.32	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85760520	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.929	rs11635081	ENSG00000259295.5	CSPG4P12	4.54	7.24e-06	0.000766	0.32	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85761029	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.685	rs12899481	ENSG00000259295.5	CSPG4P12	4.54	7.24e-06	0.000766	0.32	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85765739	chr15:85191438~85213905:+
THCA	cis	rs10090774	0.93	rs11774305	ENSG00000279766.1	RP11-642A1.2	-4.54	7.24e-06	0.000766	-0.26	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140971098	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13253978	ENSG00000279766.1	RP11-642A1.2	-4.54	7.24e-06	0.000766	-0.26	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140971655	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.93	rs8180948	ENSG00000279766.1	RP11-642A1.2	-4.54	7.24e-06	0.000766	-0.26	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140972554	chr8:140572142~140572812:-
THCA	cis	rs807029	0.533	rs2295716	ENSG00000236662.1	RP11-108L7.4	4.54	7.24e-06	0.000766	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100980507~100985614:-
THCA	cis	rs807029	0.533	rs722435	ENSG00000236662.1	RP11-108L7.4	4.54	7.24e-06	0.000766	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100980507~100985614:-
THCA	cis	rs13126694	0.75	rs2346782	ENSG00000248429.4	RP11-597D13.9	4.54	7.24e-06	0.000766	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158170752~158202877:+
THCA	cis	rs2070488	0.813	rs3749387	ENSG00000229589.1	ACVR2B-AS1	4.54	7.24e-06	0.000766	0.2	0.2	Electrocardiographic conduction measures;	chr3:38454702	chr3:38451027~38454820:-
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000232559.3	GS1-124K5.12	-4.54	7.24e-06	0.000766	-0.3	-0.2	Diabetic kidney disease;	chr7:65928187	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs34136756	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65916269	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs34933526	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65918212	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6949812	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65922114	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs6970243	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65923503	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65925372	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs35058610	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65925938	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65940221	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs35046236	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65943626	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs36068983	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65944004	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs68189316	ENSG00000232559.3	GS1-124K5.12	4.54	7.24e-06	0.000766	0.3	0.2	Diabetic kidney disease;	chr7:65944182	chr7:66554588~66576923:-
THCA	cis	rs12134133	1	rs6660254	ENSG00000237074.1	RP11-6J21.2	4.54	7.24e-06	0.000766	0.22	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207249067~207309121:+
THCA	cis	rs7824557	0.815	rs2736372	ENSG00000154316.13	TDH	4.54	7.24e-06	0.000766	0.14	0.2	Retinal vascular caliber;	chr8:11248532	chr8:11339637~11368452:+
THCA	cis	rs12681288	0.782	rs2123055	ENSG00000260721.1	AF067845.1	4.54	7.25e-06	0.000767	0.26	0.2	Schizophrenia;	chr8:1079500	chr8:1368642~1369833:-
THCA	cis	rs4714902	0.655	rs1047153	ENSG00000231769.2	RP1-8B1.4	-4.54	7.25e-06	0.000767	-0.18	-0.2	Colonoscopy-negative controls vs population controls;	chr6:46161008	chr6:46097093~46129706:-
THCA	cis	rs7520050	0.645	rs1768809	ENSG00000281133.1	AL355480.3	4.54	7.25e-06	0.000767	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45580892~45580996:-
THCA	cis	rs2657294	0.796	rs2804535	ENSG00000233313.2	HMGA1P5	4.54	7.25e-06	0.000767	0.27	0.2	Pneumonia;	chr10:75212086	chr10:75276376~75276646:-
THCA	cis	rs338389	0.586	rs338387	ENSG00000260657.2	RP11-315D16.4	4.54	7.25e-06	0.000767	0.26	0.2	Survival in rectal cancer;	chr15:67968644	chr15:68267792~68277994:-
THCA	cis	rs7560272	0.538	rs6732812	ENSG00000163016.8	ALMS1P	-4.54	7.25e-06	0.000767	-0.25	-0.2	Schizophrenia;	chr2:73695348	chr2:73644919~73685576:+
THCA	cis	rs113835537	0.935	rs3867133	ENSG00000255517.5	CTD-3074O7.5	4.54	7.25e-06	0.000767	0.21	0.2	Airway imaging phenotypes;	chr11:66684491	chr11:66473490~66480233:-
THCA	cis	rs160451	0.774	rs4961159	ENSG00000251136.7	RP11-37B2.1	4.54	7.25e-06	0.000767	0.18	0.2	Leprosy;	chr8:89691677	chr8:89609409~89757727:-
THCA	cis	rs944289	0.74	rs884384	ENSG00000258844.1	RP11-259K15.2	4.54	7.26e-06	0.000767	0.18	0.2	Thyroid cancer;	chr14:36081801	chr14:36214607~36235608:+
THCA	cis	rs944289	0.74	rs884383	ENSG00000258844.1	RP11-259K15.2	4.54	7.26e-06	0.000767	0.18	0.2	Thyroid cancer;	chr14:36081936	chr14:36214607~36235608:+
THCA	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-4.54	7.26e-06	0.000768	-0.23	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
THCA	cis	rs7208859	0.725	rs9891656	ENSG00000280069.1	CTD-2349P21.3	-4.54	7.26e-06	0.000768	-0.3	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30738182~30740275:+
THCA	cis	rs2777491	0.874	rs11633799	ENSG00000247556.5	OIP5-AS1	4.54	7.26e-06	0.000768	0.17	0.2	Ulcerative colitis;	chr15:41284340	chr15:41283990~41309737:+
THCA	cis	rs12134133	1	rs1583090	ENSG00000237074.1	RP11-6J21.2	4.54	7.26e-06	0.000768	0.22	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207249067~207309121:+
THCA	cis	rs17597773	0.527	rs1537806	ENSG00000238078.1	LINC01352	-4.54	7.26e-06	0.000768	-0.26	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910880	chr1:220829255~220832429:+
THCA	cis	rs6517329	0.538	rs879893	ENSG00000236830.5	CBR3-AS1	4.54	7.26e-06	0.000768	0.19	0.2	Schizophrenia;	chr21:36136489	chr21:36131767~36175815:-
THCA	cis	rs72753537	0.817	rs10983920	ENSG00000214417.4	KRT18P13	4.54	7.26e-06	0.000768	0.23	0.2	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97840331	chr9:97698922~97700734:+
THCA	cis	rs1046491	0.614	rs8082834	ENSG00000264964.1	RP11-888D10.3	4.54	7.26e-06	0.000768	0.37	0.2	Scarlet fever;	chr18:9324485	chr18:9315194~9334441:-
THCA	cis	rs9329221	0.683	rs3105738	ENSG00000261451.1	RP11-981G7.1	-4.54	7.27e-06	0.000768	-0.25	-0.2	Neuroticism;	chr8:10032404	chr8:10433672~10438312:+
THCA	cis	rs654950	0.901	rs594656	ENSG00000230638.4	RP11-486B10.4	4.54	7.27e-06	0.000769	0.25	0.2	Airway imaging phenotypes;	chr1:41534202	chr1:41542069~41544310:+
THCA	cis	rs722599	0.748	rs3742783	ENSG00000279594.1	RP11-950C14.10	-4.54	7.27e-06	0.000769	-0.21	-0.2	IgG glycosylation;	chr14:74910305	chr14:75011269~75012851:-
THCA	cis	rs7829975	0.514	rs2976929	ENSG00000233609.3	RP11-62H7.2	4.54	7.27e-06	0.000769	0.19	0.2	Mood instability;	chr8:8401202	chr8:8961200~8979025:+
THCA	cis	rs2790457	0.833	rs1265846	ENSG00000254635.4	WAC-AS1	-4.54	7.27e-06	0.000769	-0.2	-0.2	Multiple myeloma;	chr10:28640168	chr10:28522652~28532743:-
THCA	cis	rs62025270	0.632	rs7177107	ENSG00000259295.5	CSPG4P12	-4.54	7.27e-06	0.000769	-0.35	-0.2	Idiopathic pulmonary fibrosis;	chr15:85580133	chr15:85191438~85213905:+
THCA	cis	rs7621331	0.963	rs9808979	ENSG00000273486.1	RP11-731C17.2	4.54	7.27e-06	0.000769	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:136000456	chr3:136837338~136839021:-
THCA	cis	rs7621331	1	rs9872542	ENSG00000273486.1	RP11-731C17.2	4.54	7.27e-06	0.000769	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:136001831	chr3:136837338~136839021:-
THCA	cis	rs13113518	0.966	rs11133387	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55475130	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs4864999	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55476736	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs12506788	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55477426	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs10517344	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55477545	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs10462032	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55479069	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs12501636	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55482317	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs6858803	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55484534	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13114841	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55485974	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs939823	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55487368	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs6838882	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55489310	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13146987	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55491628	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs7677085	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55495801	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs12510681	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55496737	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs12500162	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55496933	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.934	rs3805155	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55497842	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs7686261	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55500224	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11729220	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55501629	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11133390	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55501726	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11133391	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55501788	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs13133484	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55504176	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.934	rs13127906	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55504201	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs6849433	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55506498	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs12501327	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55507248	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11133392	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55507729	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs6838305	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55508587	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.902	rs12503578	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55509367	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs3828480	ENSG00000249700.7	SRD5A3-AS1	4.54	7.27e-06	0.000769	0.25	0.2	Height;	chr4:55510352	chr4:55363971~55395847:-
THCA	cis	rs9329221	0.682	rs11786677	ENSG00000261451.1	RP11-981G7.1	4.54	7.27e-06	0.000769	0.25	0.2	Neuroticism;	chr8:10406750	chr8:10433672~10438312:+
THCA	cis	rs990871	0.53	rs2797540	ENSG00000227207.2	RPL31P12	4.54	7.27e-06	0.000769	0.24	0.2	Subcutaneous adipose tissue;	chr1:72207511	chr1:72301472~72301829:+
THCA	cis	rs28476539	0.64	rs7672297	ENSG00000270480.1	RP11-57B24.1	4.54	7.27e-06	0.000769	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82633727	chr4:82691737~82692468:+
THCA	cis	rs2281603	0.57	rs3742606	ENSG00000272909.1	CTD-2555O16.4	-4.54	7.27e-06	0.000769	-0.23	-0.2	Lymphocyte counts;	chr14:64478371	chr14:64440369~64442238:-
THCA	cis	rs2243480	1	rs2462569	ENSG00000232559.3	GS1-124K5.12	-4.54	7.27e-06	0.000769	-0.3	-0.2	Diabetic kidney disease;	chr7:66009859	chr7:66554588~66576923:-
THCA	cis	rs2985684	0.894	rs7152110	ENSG00000278009.1	RP11-649E7.8	4.54	7.27e-06	0.000769	0.28	0.2	Carotid intima media thickness;	chr14:49551500	chr14:49601011~49601124:-
THCA	cis	rs7989336	0.605	rs7324999	ENSG00000247400.3	DNAJC3-AS1	4.54	7.28e-06	0.000769	0.13	0.2	Obesity;	chr13:96277274	chr13:95648733~95676925:-
THCA	cis	rs10090774	1	rs7001591	ENSG00000279766.1	RP11-642A1.2	4.54	7.28e-06	0.00077	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140823901	chr8:140572142~140572812:-
THCA	cis	rs854765	0.822	rs1889014	ENSG00000281749.1	Y_RNA	-4.54	7.28e-06	0.00077	-0.27	-0.2	Total body bone mineral density;	chr17:17863851	chr17:18001101~18001195:-
THCA	cis	rs4934494	0.813	rs12775783	ENSG00000240996.1	RP11-80H5.7	-4.54	7.28e-06	0.00077	-0.23	-0.2	Red blood cell count;	chr10:89646494	chr10:89694295~89697928:-
THCA	cis	rs10946940	0.965	rs6921256	ENSG00000216915.2	RP1-97D16.1	-4.54	7.28e-06	0.00077	-0.28	-0.2	Systemic lupus erythematosus;	chr6:27619739	chr6:27737000~27738494:-
THCA	cis	rs250518	0.692	rs10074296	ENSG00000272081.1	CTD-2376I4.2	4.54	7.29e-06	0.00077	0.26	0.2	Mean corpuscular hemoglobin concentration;	chr5:72791089	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs6873718	ENSG00000272081.1	CTD-2376I4.2	4.54	7.29e-06	0.00077	0.26	0.2	Mean corpuscular hemoglobin concentration;	chr5:72747581	chr5:72955206~72955699:-
THCA	cis	rs11148252	0.904	rs9568732	ENSG00000273784.3	RP11-78J21.7	4.54	7.29e-06	0.000771	0.22	0.2	Lewy body disease;	chr13:52419277	chr13:52600042~52642542:+
THCA	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-4.54	7.29e-06	0.000771	-0.24	-0.2	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
THCA	cis	rs11722779	0.935	rs11938650	ENSG00000248971.2	KRT8P46	-4.54	7.29e-06	0.000771	-0.25	-0.2	Schizophrenia;	chr4:103021639	chr4:102728746~102730171:-
THCA	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-4.54	7.29e-06	0.000771	-0.24	-0.2	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-4.54	7.29e-06	0.000771	-0.24	-0.2	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-4.54	7.29e-06	0.000771	-0.24	-0.2	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-4.54	7.29e-06	0.000771	-0.24	-0.2	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-4.54	7.29e-06	0.000771	-0.24	-0.2	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-4.54	7.29e-06	0.000771	-0.24	-0.2	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-4.54	7.29e-06	0.000771	-0.24	-0.2	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
THCA	cis	rs11846409	0.932	rs2015469	ENSG00000274576.2	IGHV2-70	-4.54	7.3e-06	0.000771	-0.17	-0.2	Rheumatic heart disease;	chr14:106631857	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs56167903	ENSG00000274576.2	IGHV2-70	-4.54	7.3e-06	0.000771	-0.17	-0.2	Rheumatic heart disease;	chr14:106632070	chr14:106770577~106771020:-
THCA	cis	rs1232027	0.547	rs857287	ENSG00000249655.1	CTC-325J23.2	-4.54	7.3e-06	0.000772	-0.24	-0.2	Huntington's disease progression;	chr5:80803138	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.555	rs857289	ENSG00000249655.1	CTC-325J23.2	-4.54	7.3e-06	0.000772	-0.24	-0.2	Huntington's disease progression;	chr5:80803236	chr5:80630313~80631590:-
THCA	cis	rs5758511	0.68	rs5751243	ENSG00000227370.1	RP4-669P10.19	4.54	7.3e-06	0.000772	0.23	0.2	Birth weight;	chr22:42221171	chr22:42132543~42132998:+
THCA	cis	rs8067545	0.611	rs2526476	ENSG00000270091.1	RP11-78O7.2	4.54	7.3e-06	0.000772	0.15	0.2	Schizophrenia;	chr17:20230976	chr17:19896590~19897287:-
THCA	cis	rs9494145	0.526	rs55875437	ENSG00000232876.1	CTA-212D2.2	-4.54	7.3e-06	0.000772	-0.3	-0.2	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135146050	chr6:135055033~135060550:+
THCA	cis	rs897984	0.52	rs4889536	ENSG00000279196.1	RP11-1072A3.3	-4.54	7.3e-06	0.000772	-0.22	-0.2	Dementia with Lewy bodies;	chr16:30860434	chr16:30984630~30988270:-
THCA	cis	rs7403037	0.602	rs1878504	ENSG00000259905.4	PWRN1	4.54	7.3e-06	0.000772	0.21	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24188801	chr15:24493137~24652130:+
THCA	cis	rs62158800	0.85	rs62158798	ENSG00000224568.1	AC096669.3	4.54	7.3e-06	0.000772	0.39	0.2	Facial morphology (factor 22);	chr2:107584161	chr2:107529487~107556326:+
THCA	cis	rs7824557	0.564	rs7839307	ENSG00000154316.13	TDH	-4.54	7.3e-06	0.000772	-0.15	-0.2	Retinal vascular caliber;	chr8:11341283	chr8:11339637~11368452:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000272831.1	RP11-792A8.4	4.54	7.3e-06	0.000772	0.13	0.2	Aortic root size;	chr7:66008093	chr7:66739829~66740385:-
THCA	cis	rs7267979	0.966	rs2500417	ENSG00000274973.1	RP13-401N8.7	4.54	7.3e-06	0.000772	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25845497~25845862:+
THCA	cis	rs12681963	0.688	rs4504591	ENSG00000248159.1	HSPA8P11	-4.54	7.31e-06	0.000772	-0.37	-0.2	Migraine;	chr8:30214868	chr8:30237382~30240997:+
THCA	cis	rs12234571	0.744	rs12234422	ENSG00000214293.7	APTR	4.54	7.31e-06	0.000772	0.28	0.2	Obesity-related traits;	chr7:77918197	chr7:77657660~77696265:-
THCA	cis	rs9487094	0.67	rs2024849	ENSG00000223537.2	RP5-919F19.5	-4.54	7.31e-06	0.000773	-0.21	-0.2	Height;	chr6:109497088	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs2024853	ENSG00000223537.2	RP5-919F19.5	-4.54	7.31e-06	0.000773	-0.21	-0.2	Height;	chr6:109498751	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.67	rs12197180	ENSG00000223537.2	RP5-919F19.5	-4.54	7.31e-06	0.000773	-0.21	-0.2	Height;	chr6:109500687	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.6	rs10457193	ENSG00000223537.2	RP5-919F19.5	-4.54	7.31e-06	0.000773	-0.21	-0.2	Height;	chr6:109507364	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.558	rs10457194	ENSG00000223537.2	RP5-919F19.5	-4.54	7.31e-06	0.000773	-0.21	-0.2	Height;	chr6:109507366	chr6:109487906~109506800:+
THCA	cis	rs317689	0.69	rs618470	ENSG00000274979.1	RP11-1143G9.5	-4.54	7.31e-06	0.000773	-0.23	-0.2	Response to diuretic therapy;	chr12:69278280	chr12:69326574~69331882:-
THCA	cis	rs11853189	0.938	rs77056929	ENSG00000259562.2	RP11-762H8.2	4.54	7.31e-06	0.000773	0.2	0.2	Red cell distribution width;	chr15:78296175	chr15:78290527~78291221:-
THCA	cis	rs6088590	1	rs11698977	ENSG00000276073.1	RP5-1125A11.7	-4.54	7.31e-06	0.000773	-0.19	-0.2	Coronary artery disease;	chr20:34861888	chr20:33985617~33988989:-
THCA	cis	rs12428035	0.772	rs3099363	ENSG00000247400.3	DNAJC3-AS1	4.54	7.31e-06	0.000773	0.19	0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95844604	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.772	rs3099362	ENSG00000247400.3	DNAJC3-AS1	4.54	7.31e-06	0.000773	0.19	0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95844816	chr13:95648733~95676925:-
THCA	cis	rs12291225	0.585	rs12270374	ENSG00000251991.1	RNU7-49P	4.54	7.31e-06	0.000773	0.24	0.2	Sense of smell;	chr11:14353533	chr11:14478892~14478953:+
THCA	cis	rs12291225	0.585	rs10832246	ENSG00000251991.1	RNU7-49P	4.54	7.31e-06	0.000773	0.24	0.2	Sense of smell;	chr11:14359282	chr11:14478892~14478953:+
THCA	cis	rs17221829	0.931	rs35892874	ENSG00000280385.1	AP000648.5	-4.54	7.31e-06	0.000773	-0.2	-0.2	Anxiety in major depressive disorder;	chr11:89719509	chr11:90193614~90198120:+
THCA	cis	rs8091660	0.624	rs9952398	ENSG00000278983.1	RP11-426J5.3	4.54	7.31e-06	0.000773	0.3	0.2	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550407	chr18:48564795~48568342:+
THCA	cis	rs4578769	0.569	rs3851822	ENSG00000265939.1	UBE2CP2	-4.54	7.31e-06	0.000773	-0.23	-0.2	Eosinophil percentage of white cells;	chr18:22882829	chr18:22900486~22900995:-
THCA	cis	rs2333194	0.739	rs61987083	ENSG00000258695.2	RP3-414A15.2	-4.54	7.31e-06	0.000773	-0.25	-0.2	Bipolar disorder with mood-incongruent psychosis;	chr14:73449154	chr14:73522878~73530610:+
THCA	cis	rs1371614	0.566	rs11887401	ENSG00000272148.1	RP11-195B17.1	4.54	7.32e-06	0.000773	0.18	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26958244	chr2:27062428~27062907:-
THCA	cis	rs9368481	0.761	rs7775041	ENSG00000261353.1	CTA-14H9.5	4.54	7.32e-06	0.000773	0.22	0.2	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26527063~26527404:+
THCA	cis	rs6840258	0.831	rs3775211	ENSG00000251411.1	RP11-397E7.4	-4.54	7.32e-06	0.000773	-0.24	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87117939	chr4:86913266~86914817:-
THCA	cis	rs736408	0.812	rs2071508	ENSG00000243224.1	RP5-1157M23.2	4.54	7.32e-06	0.000773	0.23	0.2	Bipolar disorder;	chr3:52792830	chr3:52239258~52241097:+
THCA	cis	rs7267979	0.744	rs6050463	ENSG00000274973.1	RP13-401N8.7	-4.54	7.32e-06	0.000773	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25845497~25845862:+
THCA	cis	rs5758511	0.689	rs11913578	ENSG00000281538.1	RP4-669P10.20	-4.54	7.32e-06	0.000773	-0.24	-0.2	Birth weight;	chr22:41951387	chr22:42138060~42139726:+
THCA	cis	rs2018683	0.711	rs2158788	ENSG00000272568.4	CTB-113D17.1	4.53	7.32e-06	0.000774	0.2	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932341	chr7:28979967~29013367:+
THCA	cis	rs7621025	0.505	rs61789642	ENSG00000273486.1	RP11-731C17.2	-4.53	7.32e-06	0.000774	-0.28	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390854	chr3:136837338~136839021:-
THCA	cis	rs7621025	0.505	rs61789643	ENSG00000273486.1	RP11-731C17.2	-4.53	7.32e-06	0.000774	-0.28	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136390910	chr3:136837338~136839021:-
THCA	cis	rs1876905	0.569	rs354542	ENSG00000272356.1	RP5-1112D6.8	-4.53	7.32e-06	0.000774	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111309203~111313517:+
THCA	cis	rs1876905	0.68	rs1216020	ENSG00000272356.1	RP5-1112D6.8	-4.53	7.32e-06	0.000774	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111309203~111313517:+
THCA	cis	rs1876905	0.569	rs354541	ENSG00000272356.1	RP5-1112D6.8	-4.53	7.32e-06	0.000774	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111309203~111313517:+
THCA	cis	rs1876905	0.68	rs354537	ENSG00000272356.1	RP5-1112D6.8	-4.53	7.32e-06	0.000774	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111309203~111313517:+
THCA	cis	rs1876905	0.68	rs354536	ENSG00000272356.1	RP5-1112D6.8	-4.53	7.32e-06	0.000774	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111309203~111313517:+
THCA	cis	rs1876905	0.68	rs1215848	ENSG00000272356.1	RP5-1112D6.8	-4.53	7.32e-06	0.000774	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111309203~111313517:+
THCA	cis	rs10984970	0.59	rs62577998	ENSG00000238181.2	AHCYP2	4.53	7.32e-06	0.000774	0.53	0.2	Lung cancer;	chr9:120535807	chr9:120720673~120721972:+
THCA	cis	rs7819412	0.838	rs3021494	ENSG00000206014.6	OR7E161P	4.53	7.32e-06	0.000774	0.24	0.2	Triglycerides;	chr8:11126024	chr8:11928597~11929563:-
THCA	cis	rs6860806	0.507	rs582490	ENSG00000224431.1	AC063976.7	-4.53	7.32e-06	0.000774	-0.18	-0.2	Breast cancer;	chr5:132374403	chr5:132199456~132203487:+
THCA	cis	rs274567	0.501	rs581968	ENSG00000224431.1	AC063976.7	-4.53	7.32e-06	0.000774	-0.18	-0.2	Blood metabolite levels;	chr5:132374510	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.507	rs274572	ENSG00000224431.1	AC063976.7	-4.53	7.32e-06	0.000774	-0.18	-0.2	Breast cancer;	chr5:132375225	chr5:132199456~132203487:+
THCA	cis	rs274567	0.501	rs274571	ENSG00000224431.1	AC063976.7	-4.53	7.32e-06	0.000774	-0.18	-0.2	Blood metabolite levels;	chr5:132376433	chr5:132199456~132203487:+
THCA	cis	rs181553	1	rs181553	ENSG00000266696.1	RP11-30L3.2	4.53	7.33e-06	0.000774	0.25	0.2	Hip circumference adjusted for BMI;	chr18:49035660	chr18:49205912~49208781:+
THCA	cis	rs9843304	0.616	rs4681174	ENSG00000244503.1	RP11-278L15.6	4.53	7.33e-06	0.000775	0.27	0.2	Gallstone disease;	chr3:149483839	chr3:149494660~149495995:+
THCA	cis	rs11976180	1	rs1533267	ENSG00000244198.4	RP4-545C24.1	-4.53	7.33e-06	0.000775	-0.2	-0.2	Obesity-related traits;	chr7:144069347	chr7:144194858~144280547:+
THCA	cis	rs8049040	0.5	rs7188475	ENSG00000260886.1	TAT-AS1	4.53	7.33e-06	0.000775	0.28	0.2	Blood protein levels;	chr16:71412455	chr16:71565789~71578187:+
THCA	cis	rs699371	0.525	rs10138386	ENSG00000259005.1	RP3-449M8.6	4.53	7.33e-06	0.000775	0.19	0.2	Height;	chr14:74434183	chr14:74474007~74474864:-
THCA	cis	rs7577696	0.962	rs17767988	ENSG00000276334.1	AL133243.1	-4.53	7.33e-06	0.000775	-0.21	-0.2	Inflammatory biomarkers;	chr2:32061757	chr2:32521927~32523547:+
THCA	cis	rs9634489	0.651	rs7983926	ENSG00000247400.3	DNAJC3-AS1	-4.53	7.33e-06	0.000775	-0.13	-0.2	Body mass index;	chr13:96336500	chr13:95648733~95676925:-
THCA	cis	rs4767841	0.552	rs12827937	ENSG00000252886.1	RN7SKP197	-4.53	7.34e-06	0.000775	-0.21	-0.2	Urgency urinary incontinence;	chr12:119612444	chr12:119631090~119631386:-
THCA	cis	rs752010	0.902	rs28635337	ENSG00000230638.4	RP11-486B10.4	-4.53	7.34e-06	0.000776	-0.22	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41635720	chr1:41542069~41544310:+
THCA	cis	rs4971059	0.654	rs4971076	ENSG00000236675.1	MTX1P1	-4.53	7.34e-06	0.000776	-0.19	-0.2	Breast cancer;	chr1:155152296	chr1:155230975~155234325:+
THCA	cis	rs4971059	0.654	rs4971052	ENSG00000236675.1	MTX1P1	-4.53	7.34e-06	0.000776	-0.19	-0.2	Breast cancer;	chr1:155153542	chr1:155230975~155234325:+
THCA	cis	rs2380220	0.751	rs117986000	ENSG00000261366.1	MANEA-AS1	4.53	7.34e-06	0.000776	0.23	0.2	Behavioural disinhibition (generation interaction);	chr6:95475578	chr6:95575183~95577450:-
THCA	cis	rs2281603	0.521	rs3742608	ENSG00000272909.1	CTD-2555O16.4	-4.53	7.34e-06	0.000776	-0.23	-0.2	Lymphocyte counts;	chr14:64470315	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs2045024	ENSG00000272909.1	CTD-2555O16.4	-4.53	7.34e-06	0.000776	-0.23	-0.2	Lymphocyte counts;	chr14:64470634	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs10131416	ENSG00000272909.1	CTD-2555O16.4	-4.53	7.34e-06	0.000776	-0.23	-0.2	Lymphocyte counts;	chr14:64477555	chr14:64440369~64442238:-
THCA	cis	rs9329221	0.741	rs13264066	ENSG00000248538.5	RP11-10A14.5	4.53	7.34e-06	0.000776	0.26	0.2	Neuroticism;	chr8:9946565	chr8:9189011~9202854:+
THCA	cis	rs9925964	0.9	rs56813533	ENSG00000232748.3	RP11-196G11.6	4.53	7.34e-06	0.000776	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31059160	chr16:31056460~31062803:+
THCA	cis	rs1962772	1	rs6997306	ENSG00000279903.1	RP11-349F21.5	-4.53	7.34e-06	0.000776	-0.26	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17514011	chr8:17500012~17500605:+
THCA	cis	rs4948275	0.693	rs2814031	ENSG00000237233.2	TMEM26-AS1	-4.53	7.34e-06	0.000776	-0.27	-0.2	Night sleep phenotypes;	chr10:61577762	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs2814028	ENSG00000237233.2	TMEM26-AS1	-4.53	7.34e-06	0.000776	-0.27	-0.2	Night sleep phenotypes;	chr10:61578535	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs2606103	ENSG00000237233.2	TMEM26-AS1	-4.53	7.34e-06	0.000776	-0.27	-0.2	Night sleep phenotypes;	chr10:61578805	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.658	rs1933444	ENSG00000237233.2	TMEM26-AS1	-4.53	7.34e-06	0.000776	-0.27	-0.2	Night sleep phenotypes;	chr10:61579286	chr10:61452639~61481956:+
THCA	cis	rs13063635	0.85	rs2088693	ENSG00000226074.4	PRSS44	4.53	7.34e-06	0.000776	0.35	0.2	Eosinophil percentage of granulocytes;	chr3:46035898	chr3:46809359~46812558:-
THCA	cis	rs12143943	0.966	rs12038102	ENSG00000240219.1	RP11-430C7.5	4.53	7.34e-06	0.000776	0.18	0.2	Cognitive performance;	chr1:204582279	chr1:204626775~204629712:+
THCA	cis	rs7772486	0.754	rs13214277	ENSG00000270638.1	RP3-466P17.1	4.53	7.35e-06	0.000776	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs9386132	ENSG00000270638.1	RP3-466P17.1	4.53	7.35e-06	0.000776	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145735570~145737218:+
THCA	cis	rs8062405	1	rs7187776	ENSG00000270424.1	RP11-1348G14.6	4.53	7.35e-06	0.000776	0.24	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28749959~28750595:-
THCA	cis	rs57221529	0.713	rs56328416	ENSG00000225138.6	CTD-2228K2.7	4.53	7.35e-06	0.000776	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:591023	chr5:473236~480884:+
THCA	cis	rs7942368	0.887	rs10899282	ENSG00000261578.1	RP11-21L23.2	4.53	7.35e-06	0.000776	0.3	0.2	Endometriosis;	chr11:76793654	chr11:76800364~76804555:+
THCA	cis	rs6939532	0.522	rs13218591	ENSG00000124549.13	BTN2A3P	-4.53	7.35e-06	0.000776	-0.22	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26376604	chr6:26421391~26432383:+
THCA	cis	rs71636778	0.631	rs1883660	ENSG00000260063.1	RP5-968P14.2	-4.53	7.35e-06	0.000776	-0.28	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26864920	chr1:26692132~26694131:-
THCA	cis	rs2554380	0.628	rs7175491	ENSG00000176700.18	SCAND2P	-4.53	7.35e-06	0.000777	-0.15	-0.2	Height;	chr15:83806187	chr15:84631451~84647478:+
THCA	cis	rs72717009	0.825	rs867624	ENSG00000225217.1	HSPA7	-4.53	7.35e-06	0.000777	-0.31	-0.2	Rheumatoid arthritis;	chr1:161498047	chr1:161606291~161608217:+
THCA	cis	rs13256369	0.708	rs10903310	ENSG00000254153.1	CTA-398F10.2	4.53	7.35e-06	0.000777	0.24	0.2	Obesity-related traits;	chr8:8732177	chr8:8456909~8461337:-
THCA	cis	rs919433	0.617	rs10931793	ENSG00000231621.1	AC013264.2	4.53	7.36e-06	0.000777	0.22	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197712861	chr2:197197991~197199273:+
THCA	cis	rs11662586	1	rs11662586	ENSG00000267251.2	AC139100.3	4.53	7.36e-06	0.000777	0.26	0.2	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79956171	chr18:80183680~80202992:+
THCA	cis	rs6560517	0.56	rs2490573	ENSG00000234618.1	RPSAP9	4.53	7.36e-06	0.000777	0.21	0.2	Dialysis-related mortality;	chr9:76374612	chr9:76398699~76399586:+
THCA	cis	rs228614	0.51	rs223311	ENSG00000248971.2	KRT8P46	-4.53	7.36e-06	0.000777	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102728746~102730171:-
THCA	cis	rs13113518	0.967	rs4340844	ENSG00000249700.7	SRD5A3-AS1	4.53	7.36e-06	0.000777	0.25	0.2	Height;	chr4:55462689	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs1522112	ENSG00000249700.7	SRD5A3-AS1	4.53	7.36e-06	0.000777	0.25	0.2	Height;	chr4:55463606	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs4864997	ENSG00000249700.7	SRD5A3-AS1	4.53	7.36e-06	0.000777	0.25	0.2	Height;	chr4:55466010	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs960152	ENSG00000249700.7	SRD5A3-AS1	4.53	7.36e-06	0.000777	0.25	0.2	Height;	chr4:55467308	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.967	rs12644948	ENSG00000249700.7	SRD5A3-AS1	4.53	7.36e-06	0.000777	0.25	0.2	Height;	chr4:55470266	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs3805151	ENSG00000249700.7	SRD5A3-AS1	4.53	7.36e-06	0.000777	0.25	0.2	Height;	chr4:55470874	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13118237	ENSG00000249700.7	SRD5A3-AS1	4.53	7.36e-06	0.000777	0.25	0.2	Height;	chr4:55474259	chr4:55363971~55395847:-
THCA	cis	rs9863	0.861	rs3802999	ENSG00000270061.1	RP11-214K3.19	-4.53	7.36e-06	0.000777	-0.28	-0.2	White blood cell count;	chr12:123929551	chr12:123969990~123970344:-
THCA	cis	rs9902453	1	rs12600855	ENSG00000263370.1	RP11-68I3.5	4.53	7.36e-06	0.000777	0.27	0.2	Coffee consumption (cups per day);	chr17:29952573	chr17:29639627~29640825:+
THCA	cis	rs28476539	0.567	rs17005922	ENSG00000270480.1	RP11-57B24.1	-4.53	7.36e-06	0.000777	-0.32	-0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82634663	chr4:82691737~82692468:+
THCA	cis	rs6908034	0.607	rs73378506	ENSG00000237404.1	RP3-471C18.2	-4.53	7.36e-06	0.000778	-0.35	-0.2	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819756	chr6:19689825~19753113:-
THCA	cis	rs10461617	0.541	rs832575	ENSG00000234553.1	AC022431.3	-4.53	7.36e-06	0.000778	-0.27	-0.2	Type 2 diabetes;	chr5:56865960	chr5:56536583~56537826:-
THCA	cis	rs858239	0.601	rs4599714	ENSG00000226816.2	AC005082.12	4.53	7.36e-06	0.000778	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23206013~23208045:+
THCA	cis	rs858239	0.601	rs10278776	ENSG00000226816.2	AC005082.12	4.53	7.36e-06	0.000778	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23206013~23208045:+
THCA	cis	rs858239	0.632	rs13438452	ENSG00000226816.2	AC005082.12	4.53	7.36e-06	0.000778	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23206013~23208045:+
THCA	cis	rs12500482	1	rs12500482	ENSG00000248399.1	RP11-503N18.4	-4.53	7.36e-06	0.000778	-0.18	-0.2	Cognitive function;	chr4:2428508	chr4:2463797~2464124:+
THCA	cis	rs4074961	0.527	rs10908355	ENSG00000233621.1	LINC01137	-4.53	7.36e-06	0.000778	-0.21	-0.2	Axial length;	chr1:37569685	chr1:37454879~37474411:-
THCA	cis	rs2303319	0.504	rs1996265	ENSG00000227403.1	AC009299.3	-4.53	7.36e-06	0.000778	-0.5	-0.2	Cognitive function;	chr2:161843066	chr2:161244739~161249050:+
THCA	cis	rs10490626	0.656	rs11556267	ENSG00000226856.4	AC093901.1	-4.53	7.36e-06	0.000778	-0.38	-0.2	LDL cholesterol;Cholesterol, total;	chr2:117918853	chr2:118132128~118186386:-
THCA	cis	rs6449502	0.92	rs6449508	ENSG00000251279.1	CTC-436P18.1	-4.53	7.37e-06	0.000778	-0.33	-0.2	Mean platelet volume;	chr5:60871193	chr5:61162070~61232040:+
THCA	cis	rs4713118	0.615	rs9348772	ENSG00000220721.1	OR1F12	4.53	7.37e-06	0.000778	0.23	0.2	Parkinson's disease;	chr6:27688311	chr6:28073316~28074233:+
THCA	cis	rs4845875	0.542	rs7537955	ENSG00000242349.4	NPPA-AS1	4.53	7.37e-06	0.000778	0.22	0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11797353	chr1:11841017~11848079:+
THCA	cis	rs4568518	0.53	rs4721672	ENSG00000279048.1	RP11-511H23.2	4.53	7.37e-06	0.000778	0.13	0.2	Measles;	chr7:17946475	chr7:17940503~17942922:+
THCA	cis	rs79243044	0.695	rs7104227	ENSG00000224295.2	AC087380.14	-4.53	7.37e-06	0.000778	-0.2	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5521954	chr11:5518441~5524955:-
THCA	cis	rs796395	0.967	rs1690789	ENSG00000232480.1	TGFB2-AS1	-4.53	7.37e-06	0.000778	-0.23	-0.2	Post bronchodilator FEV1/FVC ratio;	chr1:218524685	chr1:218344196~218345678:-
THCA	cis	rs801193	0.967	rs2707841	ENSG00000229886.1	RP5-1132H15.3	4.53	7.37e-06	0.000778	0.21	0.2	Aortic root size;	chr7:66692033	chr7:66025126~66031544:-
THCA	cis	rs801193	1	rs7785213	ENSG00000229886.1	RP5-1132H15.3	-4.53	7.37e-06	0.000778	-0.21	-0.2	Aortic root size;	chr7:66673991	chr7:66025126~66031544:-
THCA	cis	rs13178541	0.81	rs7379100	ENSG00000250378.1	RP11-119J18.1	-4.53	7.37e-06	0.000778	-0.26	-0.2	IgG glycosylation;	chr5:135773790	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs11959707	ENSG00000250378.1	RP11-119J18.1	-4.53	7.37e-06	0.000778	-0.26	-0.2	IgG glycosylation;	chr5:135775123	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.745	rs11950987	ENSG00000250378.1	RP11-119J18.1	-4.53	7.37e-06	0.000778	-0.26	-0.2	IgG glycosylation;	chr5:135776266	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.745	rs4513690	ENSG00000250378.1	RP11-119J18.1	-4.53	7.37e-06	0.000778	-0.26	-0.2	IgG glycosylation;	chr5:135776703	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs11242275	ENSG00000250378.1	RP11-119J18.1	-4.53	7.37e-06	0.000778	-0.26	-0.2	IgG glycosylation;	chr5:135777234	chr5:135812667~135826582:+
THCA	cis	rs7772486	0.754	rs2328709	ENSG00000270638.1	RP3-466P17.1	-4.53	7.37e-06	0.000779	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145735570~145737218:+
THCA	cis	rs7621331	1	rs17197552	ENSG00000273486.1	RP11-731C17.2	4.53	7.38e-06	0.000779	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:136003422	chr3:136837338~136839021:-
THCA	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-4.53	7.38e-06	0.000779	-0.29	-0.2	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-4.53	7.38e-06	0.000779	-0.29	-0.2	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
THCA	cis	rs875971	0.545	rs35459055	ENSG00000273142.1	RP11-458F8.4	4.53	7.38e-06	0.000779	0.19	0.2	Aortic root size;	chr7:66479399	chr7:66902857~66906297:+
THCA	cis	rs2590942	0.838	rs2815764	ENSG00000227207.2	RPL31P12	-4.53	7.38e-06	0.000779	-0.33	-0.2	Childhood body mass index;	chr1:72288440	chr1:72301472~72301829:+
THCA	cis	rs57221529	0.766	rs58015612	ENSG00000225138.6	CTD-2228K2.7	4.53	7.38e-06	0.000779	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:580550	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs12522140	ENSG00000225138.6	CTD-2228K2.7	4.53	7.38e-06	0.000779	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:587146	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs12518859	ENSG00000225138.6	CTD-2228K2.7	4.53	7.38e-06	0.000779	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:587317	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs72703064	ENSG00000225138.6	CTD-2228K2.7	4.53	7.38e-06	0.000779	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:587710	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs72703065	ENSG00000225138.6	CTD-2228K2.7	4.53	7.38e-06	0.000779	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:588008	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs1399381	ENSG00000225138.6	CTD-2228K2.7	4.53	7.38e-06	0.000779	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:589738	chr5:473236~480884:+
THCA	cis	rs6832769	0.925	rs6829182	ENSG00000272969.1	RP11-528I4.2	4.53	7.38e-06	0.000779	0.24	0.2	Personality dimensions;	chr4:55587989	chr4:55547112~55547889:+
THCA	cis	rs17496827	0.727	rs7581707	ENSG00000261428.2	RP11-16P6.1	4.53	7.38e-06	0.000779	0.2	0.2	Anorexia nervosa;	chr2:222496011	chr2:222566899~222569719:-
THCA	cis	rs12223324	0.654	rs10794338	ENSG00000255284.1	AP006621.5	-4.53	7.38e-06	0.00078	-0.18	-0.2	Fuchs's corneal dystrophy;	chr11:746992	chr11:777578~784297:+
THCA	cis	rs7829975	0.871	rs572307	ENSG00000254340.1	RP11-10A14.3	-4.53	7.38e-06	0.00078	-0.22	-0.2	Mood instability;	chr8:8721301	chr8:9141424~9145435:+
THCA	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-4.53	7.39e-06	0.00078	-0.25	-0.2	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
THCA	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-4.53	7.39e-06	0.00078	-0.25	-0.2	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
THCA	cis	rs12823128	0.967	rs12812999	ENSG00000256185.1	RP11-612B6.2	4.53	7.39e-06	0.00078	0.19	0.2	Birth weight;	chr12:26738092	chr12:26335864~26336950:-
THCA	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-4.53	7.39e-06	0.00078	-0.24	-0.2	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
THCA	cis	rs7614311	0.636	rs3846221	ENSG00000271843.1	RP11-245J9.5	-4.53	7.39e-06	0.00078	-0.37	-0.2	Lung function (FVC);Lung function (FEV1);	chr3:64022834	chr3:64008082~64008692:-
THCA	cis	rs6433895	0.677	rs11688120	ENSG00000236153.1	AC104076.3	-4.53	7.39e-06	0.00078	-0.26	-0.2	Lymphocyte counts;	chr2:181133223	chr2:180979427~180980090:-
THCA	cis	rs6433895	0.677	rs35725888	ENSG00000236153.1	AC104076.3	-4.53	7.39e-06	0.00078	-0.26	-0.2	Lymphocyte counts;	chr2:181133900	chr2:180979427~180980090:-
THCA	cis	rs6433895	0.677	rs35076700	ENSG00000236153.1	AC104076.3	-4.53	7.39e-06	0.00078	-0.26	-0.2	Lymphocyte counts;	chr2:181134597	chr2:180979427~180980090:-
THCA	cis	rs6433895	0.677	rs72887083	ENSG00000236153.1	AC104076.3	-4.53	7.39e-06	0.00078	-0.26	-0.2	Lymphocyte counts;	chr2:181134803	chr2:180979427~180980090:-
THCA	cis	rs6433895	0.677	rs34825850	ENSG00000236153.1	AC104076.3	-4.53	7.39e-06	0.00078	-0.26	-0.2	Lymphocyte counts;	chr2:181140599	chr2:180979427~180980090:-
THCA	cis	rs7824557	0.583	rs4448232	ENSG00000206014.6	OR7E161P	-4.53	7.39e-06	0.00078	-0.24	-0.2	Retinal vascular caliber;	chr8:11373845	chr8:11928597~11929563:-
THCA	cis	rs75422866	0.867	rs7303895	ENSG00000276691.1	RP5-1057I20.5	4.53	7.39e-06	0.00078	0.34	0.2	Pneumonia;	chr12:47683290	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs7304743	ENSG00000276691.1	RP5-1057I20.5	-4.53	7.39e-06	0.00078	-0.34	-0.2	Pneumonia;	chr12:47683658	chr12:47788426~47788971:+
THCA	cis	rs1962772	0.816	rs13279789	ENSG00000279903.1	RP11-349F21.5	-4.53	7.39e-06	0.00078	-0.26	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17518267	chr8:17500012~17500605:+
THCA	cis	rs2836974	0.666	rs1888487	ENSG00000255568.3	BRWD1-AS2	-4.53	7.39e-06	0.000781	-0.17	-0.2	Cognitive function;	chr21:39311333	chr21:39313935~39314962:+
THCA	cis	rs10208649	1	rs6759437	ENSG00000233266.1	HMGB1P31	4.53	7.4e-06	0.000781	0.5	0.2	Body mass index;	chr2:53821907	chr2:54051334~54051760:+
THCA	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-4.53	7.4e-06	0.000781	-0.24	-0.2	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
THCA	cis	rs9548119	1	rs9548119	ENSG00000223685.4	LINC00571	-4.53	7.4e-06	0.000781	-0.24	-0.2	Self-rated health;	chr13:37957444	chr13:38050817~38143232:-
THCA	cis	rs4650994	0.593	rs2811309	ENSG00000273384.1	RP5-1098D14.1	-4.53	7.4e-06	0.000781	-0.26	-0.2	HDL cholesterol;HDL cholesterol levels;	chr1:178638549	chr1:178651706~178652282:+
THCA	cis	rs4767841	0.562	rs10849683	ENSG00000252886.1	RN7SKP197	-4.53	7.4e-06	0.000781	-0.2	-0.2	Urgency urinary incontinence;	chr12:119624203	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.552	rs11064855	ENSG00000252886.1	RN7SKP197	-4.53	7.4e-06	0.000781	-0.2	-0.2	Urgency urinary incontinence;	chr12:119626986	chr12:119631090~119631386:-
THCA	cis	rs7829975	0.564	rs2921060	ENSG00000253981.4	ALG1L13P	-4.53	7.4e-06	0.000781	-0.2	-0.2	Mood instability;	chr8:8460307	chr8:8236003~8244667:-
THCA	cis	rs9876781	0.967	rs9876891	ENSG00000244380.1	RP11-24C3.2	4.53	7.4e-06	0.000781	0.24	0.2	Longevity;	chr3:48440024	chr3:48440352~48446656:-
THCA	cis	rs35740288	0.77	rs35348278	ENSG00000259295.5	CSPG4P12	4.53	7.4e-06	0.000781	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85657109	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs11630286	ENSG00000259295.5	CSPG4P12	4.53	7.4e-06	0.000781	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85659298	chr15:85191438~85213905:+
THCA	cis	rs7267979	1	rs6083844	ENSG00000274973.1	RP13-401N8.7	4.53	7.41e-06	0.000782	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25845497~25845862:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-4.53	7.41e-06	0.000782	-0.23	-0.2	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
THCA	cis	rs8064024	0.625	rs960006	ENSG00000267077.1	RP11-127I20.5	4.53	7.41e-06	0.000782	0.23	0.2	Cancer;	chr16:4861194	chr16:4795265~4796532:-
THCA	cis	rs36229146	1	rs36229146	ENSG00000225541.1	AC002480.5	-4.53	7.41e-06	0.000782	-0.26	-0.2	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22571607~22661792:-
THCA	cis	rs5751614	0.62	rs5759669	ENSG00000240160.3	RN7SL263P	4.53	7.41e-06	0.000782	0.24	0.2	Height;	chr22:23267313	chr22:23261782~23262071:-
THCA	cis	rs5751614	0.56	rs9612269	ENSG00000240160.3	RN7SL263P	4.53	7.41e-06	0.000782	0.24	0.2	Height;	chr22:23269170	chr22:23261782~23262071:-
THCA	cis	rs4971059	0.617	rs10908458	ENSG00000236675.1	MTX1P1	-4.53	7.41e-06	0.000782	-0.19	-0.2	Breast cancer;	chr1:155154472	chr1:155230975~155234325:+
THCA	cis	rs9902453	0.904	rs4567782	ENSG00000263370.1	RP11-68I3.5	4.53	7.41e-06	0.000782	0.26	0.2	Coffee consumption (cups per day);	chr17:29941782	chr17:29639627~29640825:+
THCA	cis	rs10129255	0.517	rs11625572	ENSG00000211974.3	IGHV2-70	4.53	7.41e-06	0.000782	0.16	0.2	Kawasaki disease;	chr14:106656426	chr14:106723574~106724093:-
THCA	cis	rs58605417	0.522	rs1685559	ENSG00000253553.4	RP11-586K2.1	4.53	7.41e-06	0.000782	0.21	0.2	Schizophrenia;	chr8:88467861	chr8:88326836~88737134:+
THCA	cis	rs10504861	0.537	rs866592	ENSG00000253553.4	RP11-586K2.1	4.53	7.41e-06	0.000782	0.21	0.2	Migraine without aura;	chr8:88468243	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.522	rs3105403	ENSG00000253553.4	RP11-586K2.1	4.53	7.41e-06	0.000782	0.21	0.2	Schizophrenia;	chr8:88468800	chr8:88326836~88737134:+
THCA	cis	rs7403037	1	rs9920830	ENSG00000260760.1	PWRN3	4.53	7.41e-06	0.000782	0.24	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24550769	chr15:24441127~24447967:+
THCA	cis	rs7403037	1	rs9920079	ENSG00000260760.1	PWRN3	4.53	7.41e-06	0.000782	0.24	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24550772	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.958	rs9920094	ENSG00000260760.1	PWRN3	4.53	7.41e-06	0.000782	0.24	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24550982	chr15:24441127~24447967:+
THCA	cis	rs988712	0.921	rs1013442	ENSG00000245573.6	BDNF-AS	-4.53	7.41e-06	0.000782	-0.19	-0.2	Obesity;	chr11:27557399	chr11:27506838~27698174:+
THCA	cis	rs9475752	0.744	rs17685218	ENSG00000231441.1	RP11-472M19.2	4.53	7.42e-06	0.000783	0.22	0.2	Menarche (age at onset);	chr6:56934357	chr6:56844002~56864078:+
THCA	cis	rs897984	0.52	rs4889614	ENSG00000279196.1	RP11-1072A3.3	-4.53	7.42e-06	0.000783	-0.22	-0.2	Dementia with Lewy bodies;	chr16:30850814	chr16:30984630~30988270:-
THCA	cis	rs6449502	0.764	rs13186761	ENSG00000251279.1	CTC-436P18.1	4.53	7.42e-06	0.000783	0.34	0.2	Mean platelet volume;	chr5:60765729	chr5:61162070~61232040:+
THCA	cis	rs11621975	0.57	rs61994022	ENSG00000259088.1	CTD-2017C7.2	-4.53	7.42e-06	0.000783	-0.4	-0.2	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101789505	chr14:101796555~101810321:-
THCA	cis	rs11955398	0.522	rs34643	ENSG00000272308.1	RP11-231G3.1	-4.53	7.42e-06	0.000783	-0.22	-0.2	Intelligence (multi-trait analysis);	chr5:61048750	chr5:60866457~60866935:-
THCA	cis	rs12911832	1	rs4774310	ENSG00000245975.2	RP11-30K9.6	4.53	7.42e-06	0.000783	0.2	0.2	Schizophrenia;	chr15:58692965	chr15:58768072~58770974:-
THCA	cis	rs763121	0.853	rs5750669	ENSG00000235209.1	CTA-150C2.13	4.53	7.42e-06	0.000783	0.27	0.2	Menopause (age at onset);	chr22:38684633	chr22:38921227~38924708:+
THCA	cis	rs10186029	0.648	rs13022006	ENSG00000270659.1	RP11-105N14.1	-4.53	7.42e-06	0.000783	-0.16	-0.2	Systemic sclerosis;	chr2:213075585	chr2:213152970~213153659:+
THCA	cis	rs62025270	0.632	rs62023935	ENSG00000259295.5	CSPG4P12	-4.53	7.42e-06	0.000783	-0.35	-0.2	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85191438~85213905:+
THCA	cis	rs9467773	0.596	rs3001369	ENSG00000124549.13	BTN2A3P	4.53	7.42e-06	0.000783	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26421391~26432383:+
THCA	cis	rs5753037	0.629	rs140138	ENSG00000279699.1	RP1-102K2.9	4.53	7.42e-06	0.000783	0.21	0.2	Type 1 diabetes;	chr22:29768639	chr22:30275215~30276951:-
THCA	cis	rs875971	0.756	rs4718328	ENSG00000229886.1	RP5-1132H15.3	-4.53	7.42e-06	0.000783	-0.21	-0.2	Aortic root size;	chr7:66228350	chr7:66025126~66031544:-
THCA	cis	rs73108077	0.736	rs732860	ENSG00000277112.2	RP11-755J8.1	-4.53	7.43e-06	0.000784	-0.33	-0.2	Red blood cell density in sickle cell anemia;	chr20:31269641	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs6121224	ENSG00000277112.2	RP11-755J8.1	-4.53	7.43e-06	0.000784	-0.33	-0.2	Red blood cell density in sickle cell anemia;	chr20:31272881	chr20:30681825~30723932:-
THCA	cis	rs6517329	0.538	rs1056892	ENSG00000236830.5	CBR3-AS1	4.53	7.43e-06	0.000784	0.19	0.2	Schizophrenia;	chr21:36146408	chr21:36131767~36175815:-
THCA	cis	rs8077577	0.747	rs62072541	ENSG00000273018.4	CTD-2303H24.2	-4.53	7.43e-06	0.000784	-0.3	-0.2	Obesity-related traits;	chr17:18323385	chr17:18511221~18551705:-
THCA	cis	rs8067545	0.611	rs2703800	ENSG00000270091.1	RP11-78O7.2	-4.53	7.44e-06	0.000785	-0.15	-0.2	Schizophrenia;	chr17:20183249	chr17:19896590~19897287:-
THCA	cis	rs17005891	0.517	rs11725437	ENSG00000270480.1	RP11-57B24.1	4.53	7.44e-06	0.000785	0.29	0.2	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82620238	chr4:82691737~82692468:+
THCA	cis	rs5742933	1	rs6717922	ENSG00000273240.1	RP11-455J20.3	-4.53	7.44e-06	0.000785	-0.23	-0.2	Ferritin levels;	chr2:189721497	chr2:189763859~189764456:-
THCA	cis	rs2980439	0.807	rs2980438	ENSG00000254153.1	CTA-398F10.2	-4.53	7.44e-06	0.000785	-0.22	-0.2	Neuroticism;	chr8:8237303	chr8:8456909~8461337:-
THCA	cis	rs9923856	0.653	rs9937309	ENSG00000263033.2	RP11-396B14.2	-4.53	7.44e-06	0.000785	-0.17	-0.2	Atopic dermatitis;Adult asthma;	chr16:11018255	chr16:11196177~11224969:+
THCA	cis	rs8077577	0.562	rs8081042	ENSG00000273018.4	CTD-2303H24.2	-4.53	7.44e-06	0.000785	-0.3	-0.2	Obesity-related traits;	chr17:18295753	chr17:18511221~18551705:-
THCA	cis	rs338389	0.542	rs338342	ENSG00000260657.2	RP11-315D16.4	4.53	7.44e-06	0.000785	0.26	0.2	Survival in rectal cancer;	chr15:67979714	chr15:68267792~68277994:-
THCA	cis	rs853679	0.599	rs202906	ENSG00000220721.1	OR1F12	-4.53	7.44e-06	0.000785	-0.32	-0.2	Depression;	chr6:28043874	chr6:28073316~28074233:+
THCA	cis	rs1035144	0.505	rs6574617	ENSG00000258915.1	BHLHB9P1	4.53	7.44e-06	0.000785	0.2	0.2	Male sexual orientation;	chr14:80991271	chr14:80981988~80983638:+
THCA	cis	rs1923243	0.749	rs12042085	ENSG00000223479.3	RP4-788P17.1	-4.53	7.45e-06	0.000785	-0.22	-0.2	Migraine;	chr1:73136562	chr1:73635216~73715214:+
THCA	cis	rs7621331	0.963	rs35188750	ENSG00000273486.1	RP11-731C17.2	4.53	7.45e-06	0.000786	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135953246	chr3:136837338~136839021:-
THCA	cis	rs990871	0.53	rs11209928	ENSG00000227207.2	RPL31P12	-4.53	7.45e-06	0.000786	-0.24	-0.2	Subcutaneous adipose tissue;	chr1:72161348	chr1:72301472~72301829:+
THCA	cis	rs1728785	0.688	rs698729	ENSG00000274698.1	RP11-71L14.4	4.53	7.45e-06	0.000786	0.29	0.2	Ulcerative colitis;	chr16:68590302	chr16:68450283~68452318:+
THCA	cis	rs67478160	0.643	rs7156697	ENSG00000269910.1	RP11-73M18.10	4.53	7.45e-06	0.000786	0.18	0.2	Schizophrenia;	chr14:103744799	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.679	rs7156834	ENSG00000269910.1	RP11-73M18.10	4.53	7.45e-06	0.000786	0.18	0.2	Schizophrenia;	chr14:103744843	chr14:103694516~103695050:-
THCA	cis	rs9475752	0.739	rs35605425	ENSG00000231441.1	RP11-472M19.2	4.53	7.45e-06	0.000786	0.28	0.2	Menarche (age at onset);	chr6:56995223	chr6:56844002~56864078:+
THCA	cis	rs4767841	0.552	rs10849682	ENSG00000252886.1	RN7SKP197	-4.53	7.45e-06	0.000786	-0.21	-0.2	Urgency urinary incontinence;	chr12:119622325	chr12:119631090~119631386:-
THCA	cis	rs1790761	0.554	rs12787511	ENSG00000255318.1	RP11-655M14.13	-4.53	7.45e-06	0.000786	-0.25	-0.2	Mean corpuscular volume;	chr11:67634164	chr11:67618279~67627304:-
THCA	cis	rs3764021	0.527	rs12227655	ENSG00000214776.8	RP11-726G1.1	4.53	7.45e-06	0.000786	0.27	0.2	Type 1 diabetes;	chr12:9715652	chr12:9467552~9576275:+
THCA	cis	rs3764021	0.506	rs12228641	ENSG00000214776.8	RP11-726G1.1	4.53	7.45e-06	0.000786	0.27	0.2	Type 1 diabetes;	chr12:9715680	chr12:9467552~9576275:+
THCA	cis	rs3824435	0.744	rs7854836	ENSG00000272866.1	RP11-12D24.10	-4.53	7.46e-06	0.000786	-0.28	-0.2	Risky sexual behaviors in alcohol dependence;	chr9:5345254	chr9:5351796~5352410:-
THCA	cis	rs1005277	0.505	rs1208689	ENSG00000226578.1	RP11-258F22.1	-4.53	7.46e-06	0.000786	-0.24	-0.2	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:37775371~37784131:-
THCA	cis	rs7176527	0.8	rs56747535	ENSG00000225151.9	GOLGA2P7	4.53	7.46e-06	0.000787	0.36	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:84199311~84230136:-
THCA	cis	rs9847710	0.967	rs2581778	ENSG00000242142.1	SERBP1P3	4.53	7.46e-06	0.000787	0.23	0.2	Ulcerative colitis;	chr3:53021295	chr3:53064283~53065091:-
THCA	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	4.53	7.46e-06	0.000787	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
THCA	cis	rs228614	0.51	rs223313	ENSG00000248971.2	KRT8P46	-4.53	7.46e-06	0.000787	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102728746~102730171:-
THCA	cis	rs6121246	0.609	rs1009453	ENSG00000230613.1	HM13-AS1	4.53	7.46e-06	0.000787	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31817037	chr20:31567707~31573263:-
THCA	cis	rs5758511	0.817	rs133291	ENSG00000281538.1	RP4-669P10.20	-4.53	7.46e-06	0.000787	-0.22	-0.2	Birth weight;	chr22:41873624	chr22:42138060~42139726:+
THCA	cis	rs11633886	0.835	rs3848111	ENSG00000273972.1	CTD-2306A12.1	-4.53	7.47e-06	0.000787	-0.22	-0.2	Diisocyanate-induced asthma;	chr15:45807349	chr15:45702640~45703183:+
THCA	cis	rs752010	0.714	rs10789403	ENSG00000230638.4	RP11-486B10.4	-4.53	7.47e-06	0.000788	-0.22	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41620198	chr1:41542069~41544310:+
THCA	cis	rs116248771	0.739	rs73156495	ENSG00000271778.1	RP11-379F4.8	4.53	7.47e-06	0.000788	0.27	0.2	diarrhoeal disease at age 2;	chr3:158702758	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs73156496	ENSG00000271778.1	RP11-379F4.8	4.53	7.47e-06	0.000788	0.27	0.2	diarrhoeal disease at age 2;	chr3:158703373	chr3:158782547~158783124:+
THCA	cis	rs858239	0.539	rs6965833	ENSG00000226816.2	AC005082.12	4.53	7.47e-06	0.000788	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23206013~23208045:+
THCA	cis	rs7621331	0.963	rs6771997	ENSG00000273486.1	RP11-731C17.2	-4.53	7.47e-06	0.000788	-0.19	-0.2	Waist circumference adjusted for body mass index;	chr3:136012472	chr3:136837338~136839021:-
THCA	cis	rs7617480	0.648	rs9864243	ENSG00000228638.1	FCF1P2	-4.53	7.47e-06	0.000788	-0.25	-0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48945299	chr3:48290793~48291375:-
THCA	cis	rs72634501	0.716	rs67637163	ENSG00000228060.1	RP11-69E11.8	-4.53	7.47e-06	0.000788	-0.23	-0.2	HDL cholesterol;	chr1:39110949	chr1:39565160~39573203:+
THCA	cis	rs453301	0.658	rs6986044	ENSG00000254153.1	CTA-398F10.2	4.53	7.48e-06	0.000788	0.22	0.2	Joint mobility (Beighton score);	chr8:9017276	chr8:8456909~8461337:-
THCA	cis	rs4878497	0.588	rs11795343	ENSG00000232303.2	DFFBP1	-4.53	7.48e-06	0.000789	-0.24	-0.2	Inflammatory skin disease;	chr9:32523739	chr9:32566148~32567126:-
THCA	cis	rs8062405	0.728	rs9931989	ENSG00000278665.1	RP11-666O2.4	-4.53	7.48e-06	0.000789	-0.23	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28599241~28601881:-
THCA	cis	rs7267979	0.966	rs2263204	ENSG00000274973.1	RP13-401N8.7	4.53	7.48e-06	0.000789	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25845497~25845862:+
THCA	cis	rs1876905	0.597	rs354538	ENSG00000272356.1	RP5-1112D6.8	-4.53	7.48e-06	0.000789	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111309203~111313517:+
THCA	cis	rs1876905	0.68	rs434034	ENSG00000272356.1	RP5-1112D6.8	-4.53	7.48e-06	0.000789	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111309203~111313517:+
THCA	cis	rs911555	0.673	rs7144271	ENSG00000269910.1	RP11-73M18.10	4.53	7.49e-06	0.000789	0.19	0.2	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs10148970	ENSG00000269910.1	RP11-73M18.10	4.53	7.49e-06	0.000789	0.19	0.2	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103694516~103695050:-
THCA	cis	rs7246657	0.551	rs12972146	ENSG00000226686.6	LINC01535	-4.53	7.49e-06	0.00079	-0.36	-0.2	Coronary artery calcification;	chr19:37135193	chr19:37251912~37265535:+
THCA	cis	rs71007656	1	rs71007656	ENSG00000226578.1	RP11-258F22.1	-4.53	7.49e-06	0.00079	-0.23	-0.2	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:37775371~37784131:-
THCA	cis	rs1005277	0.522	rs289648	ENSG00000226578.1	RP11-258F22.1	-4.53	7.49e-06	0.00079	-0.23	-0.2	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:37775371~37784131:-
THCA	cis	rs12143943	0.966	rs4951410	ENSG00000240219.1	RP11-430C7.5	4.53	7.49e-06	0.00079	0.18	0.2	Cognitive performance;	chr1:204594689	chr1:204626775~204629712:+
THCA	cis	rs12143943	0.966	rs2369246	ENSG00000240219.1	RP11-430C7.5	4.53	7.49e-06	0.00079	0.18	0.2	Cognitive performance;	chr1:204598634	chr1:204626775~204629712:+
THCA	cis	rs2011503	0.509	rs10403579	ENSG00000271283.1	CTC-412M14.6	4.53	7.49e-06	0.00079	0.34	0.2	Bipolar disorder;	chr19:19659520	chr19:19699203~19699409:-
THCA	cis	rs17095355	1	rs12570230	ENSG00000203876.8	ADD3-AS1	-4.53	7.49e-06	0.00079	-0.22	-0.2	Biliary atresia;	chr10:109931856	chr10:109940104~110008381:-
THCA	cis	rs758324	0.661	rs154727	ENSG00000237714.1	P4HA2-AS1	-4.53	7.5e-06	0.00079	-0.28	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132113064	chr5:132184876~132192808:+
THCA	cis	rs758324	0.661	rs633150	ENSG00000237714.1	P4HA2-AS1	-4.53	7.5e-06	0.00079	-0.28	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132114370	chr5:132184876~132192808:+
THCA	cis	rs5758511	0.637	rs5751244	ENSG00000227370.1	RP4-669P10.19	4.53	7.5e-06	0.00079	0.23	0.2	Birth weight;	chr22:42221405	chr22:42132543~42132998:+
THCA	cis	rs2836974	0.568	rs4816620	ENSG00000255568.3	BRWD1-AS2	-4.53	7.5e-06	0.00079	-0.17	-0.2	Cognitive function;	chr21:39241860	chr21:39313935~39314962:+
THCA	cis	rs17221829	1	rs17221829	ENSG00000280385.1	AP000648.5	4.53	7.5e-06	0.00079	0.2	0.2	Anxiety in major depressive disorder;	chr11:89733564	chr11:90193614~90198120:+
THCA	cis	rs8028182	0.583	rs9944207	ENSG00000260274.1	RP11-817O13.8	4.53	7.5e-06	0.00079	0.15	0.2	Sudden cardiac arrest;	chr15:75620548	chr15:75368155~75369584:+
THCA	cis	rs13126694	0.744	rs7691516	ENSG00000248429.4	RP11-597D13.9	4.53	7.5e-06	0.00079	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158073326	chr4:158170752~158202877:+
THCA	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	4.53	7.5e-06	0.000791	0.23	0.2	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
THCA	cis	rs7617480	0.648	rs10865953	ENSG00000228638.1	FCF1P2	-4.53	7.5e-06	0.000791	-0.25	-0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48722129	chr3:48290793~48291375:-
THCA	cis	rs250518	0.926	rs7723498	ENSG00000272081.1	CTD-2376I4.2	4.53	7.5e-06	0.000791	0.26	0.2	Mean corpuscular hemoglobin concentration;	chr5:72791470	chr5:72955206~72955699:-
THCA	cis	rs7809799	0.571	rs73163167	ENSG00000244219.5	GS1-259H13.2	-4.53	7.51e-06	0.000791	-0.45	-0.2	Ulcerative colitis;	chr7:99345463	chr7:99598066~99610813:+
THCA	cis	rs972578	0.765	rs7286299	ENSG00000274717.1	RP1-47A17.1	-4.53	7.51e-06	0.000791	-0.21	-0.2	Mean platelet volume;	chr22:42996850	chr22:42791814~42794313:-
THCA	cis	rs1538970	0.504	rs3790585	ENSG00000281133.1	AL355480.3	-4.53	7.51e-06	0.000792	-0.29	-0.2	Platelet count;	chr1:45557684	chr1:45580892~45580996:-
THCA	cis	rs7267979	1	rs7020	ENSG00000274973.1	RP13-401N8.7	-4.53	7.51e-06	0.000792	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25845497~25845862:+
THCA	cis	rs2483058	0.531	rs17433769	ENSG00000261000.1	RP11-534L20.5	-4.53	7.52e-06	0.000792	-0.23	-0.2	Cholesterol and Triglycerides;	chr1:206464459	chr1:206503948~206504456:+
THCA	cis	rs9307551	0.6	rs1440857	ENSG00000250334.4	LINC00989	-4.53	7.52e-06	0.000792	-0.23	-0.2	Refractive error;	chr4:79616866	chr4:79492416~79576460:+
THCA	cis	rs427691	0.625	rs372062	ENSG00000271849.1	CTC-332L22.1	-4.53	7.52e-06	0.000792	-0.29	-0.2	Autism spectrum disorder or schizophrenia;	chr5:109674826	chr5:109687802~109688329:-
THCA	cis	rs4388249	0.516	rs435494	ENSG00000271849.1	CTC-332L22.1	-4.53	7.52e-06	0.000792	-0.29	-0.2	Schizophrenia;	chr5:109674877	chr5:109687802~109688329:-
THCA	cis	rs13434995	0.635	rs1818461	ENSG00000273257.1	RP11-177J6.1	-4.53	7.52e-06	0.000793	-0.32	-0.2	Adiponectin levels;	chr4:55379156	chr4:55387949~55388271:+
THCA	cis	rs8062405	0.69	rs7187604	ENSG00000270424.1	RP11-1348G14.6	4.53	7.52e-06	0.000793	0.26	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28749959~28750595:-
THCA	cis	rs853679	0.55	rs34477097	ENSG00000272009.1	RP1-313I6.12	-4.53	7.52e-06	0.000793	-0.23	-0.2	Depression;	chr6:28229408	chr6:28078792~28081130:-
THCA	cis	rs6121246	0.954	rs6089093	ENSG00000224628.2	RP5-854E16.2	-4.53	7.52e-06	0.000793	-0.28	-0.2	Mean corpuscular hemoglobin;	chr20:31833656	chr20:31285317~31286835:-
THCA	cis	rs2018683	0.899	rs10479817	ENSG00000272568.4	CTB-113D17.1	4.53	7.53e-06	0.000793	0.2	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938531	chr7:28979967~29013367:+
THCA	cis	rs763121	0.853	rs6519120	ENSG00000228274.3	RP3-508I15.9	4.53	7.53e-06	0.000793	0.22	0.2	Menopause (age at onset);	chr22:38595388	chr22:38667585~38681820:-
THCA	cis	rs4415084	0.652	rs10070928	ENSG00000272335.1	RP11-53O19.3	4.53	7.53e-06	0.000793	0.17	0.2	Breast cancer;	chr5:44888455	chr5:44826076~44828592:+
THCA	cis	rs4763879	0.778	rs1056151	ENSG00000256673.1	RP11-599J14.2	4.53	7.53e-06	0.000793	0.25	0.2	Type 1 diabetes;	chr12:9698427	chr12:9398355~9414851:-
THCA	cis	rs875971	0.862	rs4718330	ENSG00000229886.1	RP5-1132H15.3	-4.53	7.54e-06	0.000794	-0.21	-0.2	Aortic root size;	chr7:66250256	chr7:66025126~66031544:-
THCA	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-4.53	7.54e-06	0.000794	-0.24	-0.2	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
THCA	cis	rs11671005	0.735	rs3764529	ENSG00000268049.1	CTD-2619J13.9	-4.53	7.54e-06	0.000794	-0.31	-0.2	Mean platelet volume;	chr19:58433722	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs1122955	ENSG00000268049.1	CTD-2619J13.9	-4.53	7.54e-06	0.000794	-0.31	-0.2	Mean platelet volume;	chr19:58434836	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.735	rs11668814	ENSG00000268049.1	CTD-2619J13.9	-4.53	7.54e-06	0.000794	-0.31	-0.2	Mean platelet volume;	chr19:58435466	chr19:58357999~58359603:+
THCA	cis	rs1823874	0.71	rs4246297	ENSG00000182397.13	DNM1P46	-4.53	7.54e-06	0.000794	-0.24	-0.2	IgG glycosylation;	chr15:99826723	chr15:99790156~99806927:-
THCA	cis	rs9900062	0.535	rs753917	ENSG00000270714.1	MINOS1P2	-4.53	7.54e-06	0.000794	-0.28	-0.2	QT interval;	chr17:64677018	chr17:64747264~64747492:-
THCA	cis	rs13256369	0.865	rs13277708	ENSG00000254153.1	CTA-398F10.2	-4.53	7.54e-06	0.000794	-0.22	-0.2	Obesity-related traits;	chr8:8716426	chr8:8456909~8461337:-
THCA	cis	rs9300255	0.699	rs11057204	ENSG00000235423.7	RP11-282O18.3	4.53	7.54e-06	0.000795	0.22	0.2	Neutrophil percentage of white cells;	chr12:123241280	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.62	rs7313483	ENSG00000235423.7	RP11-282O18.3	4.53	7.54e-06	0.000795	0.22	0.2	Neutrophil percentage of white cells;	chr12:123242287	chr12:123252030~123261483:-
THCA	cis	rs2153535	0.585	rs9393052	ENSG00000230939.1	RP11-314C16.1	-4.53	7.54e-06	0.000795	-0.21	-0.2	Motion sickness;	chr6:8644832	chr6:8784178~8785445:+
THCA	cis	rs853679	1	rs853676	ENSG00000272009.1	RP1-313I6.12	-4.53	7.54e-06	0.000795	-0.28	-0.2	Depression;	chr6:28331910	chr6:28078792~28081130:-
THCA	cis	rs9326248	0.53	rs2513095	ENSG00000280143.1	AP000892.6	4.53	7.54e-06	0.000795	0.33	0.2	Blood protein levels;	chr11:116935553	chr11:117204967~117210292:+
THCA	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	4.53	7.55e-06	0.000795	0.24	0.2	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
THCA	cis	rs738144	0.578	rs2142506	ENSG00000235209.1	CTA-150C2.13	-4.53	7.55e-06	0.000795	-0.31	-0.2	IgG glycosylation;	chr22:38816465	chr22:38921227~38924708:+
THCA	cis	rs5770917	1	rs2269381	ENSG00000273272.1	CTA-384D8.34	4.53	7.55e-06	0.000795	0.32	0.2	Narcolepsy;	chr22:50581640	chr22:50542650~50543011:+
THCA	cis	rs9973361	0.55	rs13411363	ENSG00000232411.1	AC009495.3	-4.53	7.55e-06	0.000795	-0.25	-0.2	Total body bone mineral density;	chr2:165810694	chr2:165833048~165839098:-
THCA	cis	rs394563	0.622	rs237024	ENSG00000231760.4	RP11-350J20.5	4.53	7.55e-06	0.000795	0.26	0.2	Dupuytren's disease;	chr6:149400829	chr6:149796151~149826294:-
THCA	cis	rs9467773	0.935	rs1056668	ENSG00000261353.1	CTA-14H9.5	-4.53	7.56e-06	0.000796	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26510377	chr6:26527063~26527404:+
THCA	cis	rs9733	0.596	rs7418501	ENSG00000231073.1	RP11-316M1.3	4.53	7.56e-06	0.000796	0.24	0.2	Tonsillectomy;	chr1:150739420	chr1:150973123~150975534:+
THCA	cis	rs2803122	0.869	rs10811150	ENSG00000273226.1	RP11-513M16.8	-4.53	7.56e-06	0.000796	-0.19	-0.2	Pulse pressure;	chr9:19253270	chr9:19375451~19375996:+
THCA	cis	rs899997	0.773	rs62010525	ENSG00000261143.1	ADAMTS7P3	-4.53	7.56e-06	0.000797	-0.31	-0.2	Coronary artery disease or large artery stroke;	chr15:78675968	chr15:77976042~77993057:+
THCA	cis	rs9863	0.861	rs4930723	ENSG00000270061.1	RP11-214K3.19	-4.53	7.57e-06	0.000797	-0.28	-0.2	White blood cell count;	chr12:123939053	chr12:123969990~123970344:-
THCA	cis	rs10510102	0.516	rs12244921	ENSG00000226864.1	ATE1-AS1	4.53	7.57e-06	0.000797	0.33	0.2	Breast cancer;	chr10:121990342	chr10:121928312~121951965:+
THCA	cis	rs76793172	0.623	rs2014377	ENSG00000267395.4	AC074212.6	-4.53	7.57e-06	0.000798	-0.18	-0.2	Eosinophil counts;	chr19:45766055	chr19:45767796~45772504:+
THCA	cis	rs72615157	0.634	rs11762932	ENSG00000242294.5	STAG3L5P	-4.53	7.58e-06	0.000798	-0.13	-0.2	Lung function (FEV1/FVC);	chr7:100195043	chr7:100336079~100351900:+
THCA	cis	rs7111546	0.945	rs77581416	ENSG00000246225.5	RP11-17A1.3	4.53	7.58e-06	0.000798	0.38	0.2	Dialysis-related mortality;	chr11:22825269	chr11:22829380~22945393:+
THCA	cis	rs7973683	0.541	rs57078519	ENSG00000270061.1	RP11-214K3.19	-4.53	7.58e-06	0.000798	-0.26	-0.2	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123904237	chr12:123969990~123970344:-
THCA	cis	rs2018683	0.711	rs1874977	ENSG00000272568.4	CTB-113D17.1	4.53	7.58e-06	0.000798	0.2	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928466	chr7:28979967~29013367:+
THCA	cis	rs8002861	0.875	rs12428432	ENSG00000274001.1	RP11-5G9.5	-4.53	7.58e-06	0.000798	-0.25	-0.2	Leprosy;	chr13:43889907	chr13:43877715~43878163:-
THCA	cis	rs5758511	0.68	rs5758687	ENSG00000281538.1	RP4-669P10.20	-4.53	7.58e-06	0.000798	-0.23	-0.2	Birth weight;	chr22:42260582	chr22:42138060~42139726:+
THCA	cis	rs17095355	1	rs59804002	ENSG00000203876.8	ADD3-AS1	-4.53	7.58e-06	0.000798	-0.23	-0.2	Biliary atresia;	chr10:109932285	chr10:109940104~110008381:-
THCA	cis	rs17221829	0.764	rs11605960	ENSG00000280385.1	AP000648.5	-4.53	7.58e-06	0.000798	-0.2	-0.2	Anxiety in major depressive disorder;	chr11:89685532	chr11:90193614~90198120:+
THCA	cis	rs1979679	0.625	rs10843148	ENSG00000278733.1	RP11-425D17.1	4.53	7.58e-06	0.000799	0.24	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28288131	chr12:28185625~28186190:-
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000185485.13	SDHAP1	4.53	7.58e-06	0.000799	0.18	0.2	Pancreatic cancer;	chr3:196009869	chr3:195959748~195990318:-
THCA	cis	rs4927850	1	rs4927704	ENSG00000185485.13	SDHAP1	4.53	7.58e-06	0.000799	0.18	0.2	Pancreatic cancer;	chr3:196011357	chr3:195959748~195990318:-
THCA	cis	rs4927850	1	rs4927848	ENSG00000185485.13	SDHAP1	4.53	7.58e-06	0.000799	0.18	0.2	Pancreatic cancer;	chr3:196011535	chr3:195959748~195990318:-
THCA	cis	rs7403037	0.617	rs8031555	ENSG00000259905.4	PWRN1	4.53	7.58e-06	0.000799	0.26	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24597593	chr15:24493137~24652130:+
THCA	cis	rs6860806	0.507	rs2631371	ENSG00000224431.1	AC063976.7	-4.53	7.59e-06	0.000799	-0.18	-0.2	Breast cancer;	chr5:132367999	chr5:132199456~132203487:+
THCA	cis	rs1075265	0.547	rs11125520	ENSG00000272156.1	RP11-477N3.1	4.53	7.59e-06	0.000799	0.2	0.2	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54082554~54085066:+
THCA	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	4.53	7.59e-06	0.000799	0.21	0.2	Height;	chr5:37025769	chr5:36666214~36725195:-
THCA	cis	rs756699	0.749	rs244658	ENSG00000279469.1	RP11-215P8.2	-4.53	7.59e-06	0.000799	-0.33	-0.2	Multiple sclerosis;	chr5:134096941	chr5:134394360~134395008:-
THCA	cis	rs795484	0.963	rs1277442	ENSG00000275409.1	RP11-131L12.4	4.53	7.59e-06	0.000799	0.18	0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118167766	chr12:118430147~118430699:+
THCA	cis	rs17095355	1	rs17126886	ENSG00000203876.8	ADD3-AS1	-4.53	7.59e-06	0.000799	-0.22	-0.2	Biliary atresia;	chr10:109935499	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs11194922	ENSG00000203876.8	ADD3-AS1	-4.53	7.59e-06	0.000799	-0.22	-0.2	Biliary atresia;	chr10:109935898	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs12570607	ENSG00000203876.8	ADD3-AS1	-4.53	7.59e-06	0.000799	-0.22	-0.2	Biliary atresia;	chr10:109936946	chr10:109940104~110008381:-
THCA	cis	rs6125597	0.516	rs6019537	ENSG00000230758.1	SNAP23P	-4.53	7.59e-06	0.000799	-0.24	-0.2	Intelligence (multi-trait analysis);	chr20:48927067	chr20:49038357~49038602:-
THCA	cis	rs944289	0.708	rs1958615	ENSG00000258844.1	RP11-259K15.2	4.53	7.59e-06	0.000799	0.18	0.2	Thyroid cancer;	chr14:36118282	chr14:36214607~36235608:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000234585.5	CCT6P3	4.53	7.59e-06	8e-04	0.18	0.2	Calcium levels;	chr7:65996954	chr7:65038354~65074713:+
THCA	cis	rs4245128	0.707	rs7102945	ENSG00000247416.2	RP11-629G13.1	4.53	7.59e-06	8e-04	0.2	0.2	Life satisfaction;	chr11:112934740	chr11:112959279~112963460:-
THCA	cis	rs10483853	0.806	rs2333135	ENSG00000258695.2	RP3-414A15.2	4.53	7.6e-06	8e-04	0.29	0.2	Coronary artery calcification;	chr14:73356374	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.747	rs56970276	ENSG00000258695.2	RP3-414A15.2	-4.53	7.6e-06	8e-04	-0.29	-0.2	Coronary artery calcification;	chr14:73352422	chr14:73522878~73530610:+
THCA	cis	rs4948275	0.631	rs2814024	ENSG00000237233.2	TMEM26-AS1	-4.53	7.6e-06	8e-04	-0.27	-0.2	Night sleep phenotypes;	chr10:61590868	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.598	rs2650742	ENSG00000237233.2	TMEM26-AS1	-4.53	7.6e-06	8e-04	-0.27	-0.2	Night sleep phenotypes;	chr10:61591188	chr10:61452639~61481956:+
THCA	cis	rs6840258	0.891	rs3775209	ENSG00000251411.1	RP11-397E7.4	-4.53	7.6e-06	8e-04	-0.24	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87125794	chr4:86913266~86914817:-
THCA	cis	rs516805	0.961	rs573709	ENSG00000279114.1	RP3-425C14.5	4.53	7.6e-06	8e-04	0.2	0.2	Lymphocyte counts;	chr6:122457673	chr6:122471923~122484161:+
THCA	cis	rs7267979	0.966	rs2261784	ENSG00000274973.1	RP13-401N8.7	-4.53	7.6e-06	8e-04	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2261785	ENSG00000274973.1	RP13-401N8.7	-4.53	7.6e-06	8e-04	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25845497~25845862:+
THCA	cis	rs7829975	0.617	rs4841072	ENSG00000254153.1	CTA-398F10.2	4.53	7.6e-06	0.000801	0.22	0.2	Mood instability;	chr8:8933743	chr8:8456909~8461337:-
THCA	cis	rs13401620	0.641	rs11123534	ENSG00000231013.1	AC013275.2	-4.53	7.6e-06	0.000801	-0.23	-0.2	Breast size;	chr2:119716230	chr2:119476448~119487346:+
THCA	cis	rs2692947	0.566	rs11676901	ENSG00000235584.2	AC008268.1	-4.53	7.61e-06	0.000801	-0.2	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95704823	chr2:95666084~95668715:+
THCA	cis	rs9902453	1	rs9890205	ENSG00000263370.1	RP11-68I3.5	-4.53	7.61e-06	0.000801	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30055686	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs4994355	ENSG00000263370.1	RP11-68I3.5	-4.53	7.61e-06	0.000801	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30059266	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs9890886	ENSG00000263370.1	RP11-68I3.5	-4.53	7.61e-06	0.000801	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30064058	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.935	rs9898424	ENSG00000263370.1	RP11-68I3.5	-4.53	7.61e-06	0.000801	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30065928	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs4465649	ENSG00000263370.1	RP11-68I3.5	-4.53	7.61e-06	0.000801	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30067729	chr17:29639627~29640825:+
THCA	cis	rs1365505	0.537	rs2052759	ENSG00000244879.4	GABPB1-AS1	-4.53	7.61e-06	0.000801	-0.21	-0.2	Blood metabolite ratios;	chr15:50183225	chr15:50354959~50372202:+
THCA	cis	rs7267979	1	rs2297497	ENSG00000274973.1	RP13-401N8.7	4.53	7.61e-06	0.000801	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25845497~25845862:+
THCA	cis	rs10946940	0.897	rs6456801	ENSG00000216915.2	RP1-97D16.1	-4.53	7.62e-06	0.000802	-0.27	-0.2	Systemic lupus erythematosus;	chr6:27657753	chr6:27737000~27738494:-
THCA	cis	rs11122895	0.509	rs6708131	ENSG00000236307.2	EEF1E1P1	4.53	7.62e-06	0.000802	0.26	0.2	Allergic sensitization;	chr2:111688082	chr2:111887914~111888741:+
THCA	cis	rs6560517	0.957	rs11144865	ENSG00000234618.1	RPSAP9	4.53	7.62e-06	0.000803	0.22	0.2	Dialysis-related mortality;	chr9:76382008	chr9:76398699~76399586:+
THCA	cis	rs56804039	0.895	rs11776995	ENSG00000254153.1	CTA-398F10.2	4.53	7.63e-06	0.000803	0.25	0.2	Cervical cancer;	chr8:8528037	chr8:8456909~8461337:-
THCA	cis	rs11148252	0.774	rs6561666	ENSG00000273784.3	RP11-78J21.7	-4.53	7.63e-06	0.000803	-0.22	-0.2	Lewy body disease;	chr13:52355910	chr13:52600042~52642542:+
THCA	cis	rs8062405	0.755	rs4787457	ENSG00000261766.1	RP11-22P6.2	-4.53	7.63e-06	0.000803	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.755	rs4788080	ENSG00000261766.1	RP11-22P6.2	-4.53	7.63e-06	0.000803	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.755	rs4787456	ENSG00000261766.1	RP11-22P6.2	-4.53	7.63e-06	0.000803	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.755	rs4788078	ENSG00000261766.1	RP11-22P6.2	-4.53	7.63e-06	0.000803	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28862166~28863340:-
THCA	cis	rs987724	0.515	rs1320011	ENSG00000240875.4	LINC00886	-4.53	7.63e-06	0.000803	-0.19	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156899993	chr3:156747346~156817062:-
THCA	cis	rs7674212	0.833	rs61075040	ENSG00000230069.3	LRRC37A15P	-4.53	7.63e-06	0.000803	-0.22	-0.2	Type 2 diabetes;	chr4:103052804	chr4:102727274~102730721:-
THCA	cis	rs11976180	1	rs11975942	ENSG00000244198.4	RP4-545C24.1	-4.53	7.63e-06	0.000803	-0.21	-0.2	Obesity-related traits;	chr7:144043487	chr7:144194858~144280547:+
THCA	cis	rs8058578	1	rs7187359	ENSG00000279196.1	RP11-1072A3.3	4.53	7.63e-06	0.000803	0.21	0.2	Multiple myeloma;	chr16:30691834	chr16:30984630~30988270:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000164669.11	INTS4P1	-4.53	7.63e-06	0.000803	-0.25	-0.2	Calcium levels;	chr7:65974892	chr7:65141225~65234216:+
THCA	cis	rs36093844	0.752	rs17817308	ENSG00000279742.1	RP11-700A24.1	-4.53	7.63e-06	0.000803	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882486	chr11:85852557~85854943:-
THCA	cis	rs4789693	0.518	rs6502117	ENSG00000279744.1	RP13-20L14.10	-4.53	7.63e-06	0.000803	-0.17	-0.2	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82462601~82464255:+
THCA	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	4.53	7.63e-06	0.000803	0.17	0.2	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
THCA	cis	rs890448	0.965	rs17031369	ENSG00000254531.1	FLJ20021	-4.53	7.63e-06	0.000804	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101510606	chr4:101347780~101348883:+
THCA	cis	rs890448	0.965	rs17031373	ENSG00000254531.1	FLJ20021	-4.53	7.63e-06	0.000804	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101510714	chr4:101347780~101348883:+
THCA	cis	rs4245128	0.775	rs2218617	ENSG00000247416.2	RP11-629G13.1	4.53	7.64e-06	0.000804	0.2	0.2	Life satisfaction;	chr11:112949270	chr11:112959279~112963460:-
THCA	cis	rs858239	0.601	rs764533	ENSG00000226816.2	AC005082.12	4.53	7.64e-06	0.000804	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23206013~23208045:+
THCA	cis	rs9467773	0.549	rs9467805	ENSG00000261353.1	CTA-14H9.5	-4.53	7.64e-06	0.000804	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26527063~26527404:+
THCA	cis	rs1003719	1	rs1003719	ENSG00000230366.8	DSCR9	-4.53	7.64e-06	0.000804	-0.21	-0.2	Eye color traits;	chr21:37118795	chr21:37208503~37221736:+
THCA	cis	rs12030196	0.827	rs6699576	ENSG00000230812.4	LINC01358	4.53	7.64e-06	0.000804	0.27	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58957154	chr1:59020387~59044614:+
THCA	cis	rs12893668	0.608	rs12889721	ENSG00000244691.1	RPL10AP1	-4.53	7.64e-06	0.000804	-0.29	-0.2	Reticulocyte count;	chr14:103568526	chr14:103412119~103412761:-
THCA	cis	rs7111546	0.945	rs11822698	ENSG00000246225.5	RP11-17A1.3	4.53	7.64e-06	0.000804	0.39	0.2	Dialysis-related mortality;	chr11:22831715	chr11:22829380~22945393:+
THCA	cis	rs911555	0.755	rs9671414	ENSG00000269910.1	RP11-73M18.10	-4.53	7.64e-06	0.000804	-0.19	-0.2	Intelligence (multi-trait analysis);	chr14:103500962	chr14:103694516~103695050:-
THCA	cis	rs7809799	0.571	rs66568021	ENSG00000244219.5	GS1-259H13.2	-4.53	7.64e-06	0.000804	-0.45	-0.2	Ulcerative colitis;	chr7:99345366	chr7:99598066~99610813:+
THCA	cis	rs7809799	0.571	rs67909852	ENSG00000244219.5	GS1-259H13.2	-4.53	7.64e-06	0.000804	-0.45	-0.2	Ulcerative colitis;	chr7:99347303	chr7:99598066~99610813:+
THCA	cis	rs9876781	1	rs9838618	ENSG00000244380.1	RP11-24C3.2	4.53	7.64e-06	0.000804	0.24	0.2	Longevity;	chr3:48445949	chr3:48440352~48446656:-
THCA	cis	rs7829975	0.84	rs572366	ENSG00000253981.4	ALG1L13P	4.53	7.65e-06	0.000805	0.2	0.2	Mood instability;	chr8:8721284	chr8:8236003~8244667:-
THCA	cis	rs17270561	0.666	rs9356987	ENSG00000272462.2	U91328.19	-4.53	7.65e-06	0.000805	-0.18	-0.2	Iron status biomarkers;	chr6:25738959	chr6:25992662~26001775:+
THCA	cis	rs2721195	0.549	rs2620666	ENSG00000265393.1	CTD-2517M22.17	-4.53	7.65e-06	0.000805	-0.25	-0.2	Age at first birth;	chr8:144478030	chr8:144512567~144513672:+
THCA	cis	rs9300255	0.507	rs1615350	ENSG00000256092.2	RP13-942N8.1	4.53	7.65e-06	0.000805	0.15	0.2	Neutrophil percentage of white cells;	chr12:123165788	chr12:123363868~123366113:+
THCA	cis	rs35740288	0.731	rs12898964	ENSG00000259295.5	CSPG4P12	4.53	7.65e-06	0.000805	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618046	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.731	rs2344440	ENSG00000259295.5	CSPG4P12	4.53	7.65e-06	0.000805	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618334	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs1157519	ENSG00000259295.5	CSPG4P12	4.53	7.65e-06	0.000805	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618427	chr15:85191438~85213905:+
THCA	cis	rs9990343	0.783	rs7643888	ENSG00000223552.1	RP11-24F11.2	-4.53	7.65e-06	0.000805	-0.18	-0.2	Brain structure;	chr3:46296961	chr3:46364955~46407059:-
THCA	cis	rs28735056	0.584	rs2364354	ENSG00000261126.6	RP11-795F19.1	4.53	7.65e-06	0.000805	0.18	0.2	Schizophrenia;	chr18:79891536	chr18:80046900~80095482:+
THCA	cis	rs2562456	0.833	rs11669790	ENSG00000268117.1	VN1R84P	4.53	7.65e-06	0.000805	0.33	0.2	Pain;	chr19:21328980	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62107534	ENSG00000268117.1	VN1R84P	4.53	7.65e-06	0.000805	0.33	0.2	Pain;	chr19:21329389	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs7258473	ENSG00000268117.1	VN1R84P	4.53	7.65e-06	0.000805	0.33	0.2	Pain;	chr19:21331795	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs2219839	ENSG00000268117.1	VN1R84P	4.53	7.65e-06	0.000805	0.33	0.2	Pain;	chr19:21333520	chr19:21719801~21720035:-
THCA	cis	rs5752326	0.51	rs2331252	ENSG00000261188.1	CTA-445C9.14	4.53	7.66e-06	0.000806	0.2	0.2	Ischemic stroke;	chr22:26475102	chr22:26512537~26514568:+
THCA	cis	rs5752326	0.51	rs4822723	ENSG00000261188.1	CTA-445C9.14	4.53	7.66e-06	0.000806	0.2	0.2	Ischemic stroke;	chr22:26477431	chr22:26512537~26514568:+
THCA	cis	rs5752326	0.51	rs3830172	ENSG00000261188.1	CTA-445C9.14	4.53	7.66e-06	0.000806	0.2	0.2	Ischemic stroke;	chr22:26477449	chr22:26512537~26514568:+
THCA	cis	rs7819412	0.669	rs35499486	ENSG00000206014.6	OR7E161P	4.53	7.66e-06	0.000806	0.24	0.2	Triglycerides;	chr8:11216527	chr8:11928597~11929563:-
THCA	cis	rs73108077	0.92	rs6057657	ENSG00000277112.2	RP11-755J8.1	4.53	7.66e-06	0.000806	0.34	0.2	Red blood cell density in sickle cell anemia;	chr20:31376027	chr20:30681825~30723932:-
THCA	cis	rs9868809	0.772	rs9809222	ENSG00000270441.1	RP11-694I15.7	4.53	7.66e-06	0.000806	0.25	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48676978	chr3:49140086~49160851:-
THCA	cis	rs28374715	0.681	rs28712264	ENSG00000247556.5	OIP5-AS1	4.52	7.66e-06	0.000806	0.2	0.2	Ulcerative colitis;	chr15:41296599	chr15:41283990~41309737:+
THCA	cis	rs375066	0.935	rs384329	ENSG00000278917.1	RP11-15A1.4	-4.52	7.66e-06	0.000806	-0.17	-0.2	Breast cancer;	chr19:43919829	chr19:43891233~43895411:+
THCA	cis	rs756699	0.749	rs244673	ENSG00000279469.1	RP11-215P8.2	-4.52	7.66e-06	0.000806	-0.3	-0.2	Multiple sclerosis;	chr5:134084952	chr5:134394360~134395008:-
THCA	cis	rs394563	0.517	rs377454	ENSG00000268592.3	RAET1E-AS1	4.52	7.67e-06	0.000806	0.29	0.2	Dupuytren's disease;	chr6:149469957	chr6:149863494~149919507:+
THCA	cis	rs1046491	0.522	rs2186914	ENSG00000264964.1	RP11-888D10.3	4.52	7.67e-06	0.000806	0.38	0.2	Scarlet fever;	chr18:9285724	chr18:9315194~9334441:-
THCA	cis	rs12893668	0.543	rs1799796	ENSG00000269958.1	RP11-73M18.8	4.52	7.67e-06	0.000807	0.2	0.2	Reticulocyte count;	chr14:103699590	chr14:103696353~103697163:+
THCA	cis	rs12893668	0.514	rs3212090	ENSG00000269958.1	RP11-73M18.8	4.52	7.67e-06	0.000807	0.2	0.2	Reticulocyte count;	chr14:103702526	chr14:103696353~103697163:+
THCA	cis	rs9302635	1	rs9302635	ENSG00000260886.1	TAT-AS1	4.52	7.67e-06	0.000807	0.32	0.2	Blood protein levels;	chr16:72110275	chr16:71565789~71578187:+
THCA	cis	rs1003719	1	rs2835607	ENSG00000230366.8	DSCR9	-4.52	7.67e-06	0.000807	-0.21	-0.2	Eye color traits;	chr21:37119673	chr21:37208503~37221736:+
THCA	cis	rs1003719	1	rs2154536	ENSG00000230366.8	DSCR9	-4.52	7.67e-06	0.000807	-0.21	-0.2	Eye color traits;	chr21:37119847	chr21:37208503~37221736:+
THCA	cis	rs1003719	1	rs2835608	ENSG00000230366.8	DSCR9	-4.52	7.67e-06	0.000807	-0.21	-0.2	Eye color traits;	chr21:37121155	chr21:37208503~37221736:+
THCA	cis	rs9878978	0.66	rs62245710	ENSG00000237990.3	CNTN4-AS1	4.52	7.67e-06	0.000807	0.25	0.2	Blood pressure (smoking interaction);	chr3:2410628	chr3:3039033~3069242:-
THCA	cis	rs1150668	0.796	rs1005125	ENSG00000176933.5	TOB2P1	-4.52	7.68e-06	0.000807	-0.22	-0.2	Pubertal anthropometrics;	chr6:28399578	chr6:28217643~28218634:-
THCA	cis	rs2028299	1	rs2351707	ENSG00000259677.1	RP11-493E3.1	4.52	7.68e-06	0.000808	0.26	0.2	Type 2 diabetes;	chr15:89840813	chr15:89876540~89877285:+
THCA	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-4.52	7.68e-06	0.000808	-0.24	-0.2	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-4.52	7.68e-06	0.000808	-0.24	-0.2	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
THCA	cis	rs6570726	0.764	rs9403726	ENSG00000270638.1	RP3-466P17.1	4.52	7.68e-06	0.000808	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145735570~145737218:+
THCA	cis	rs427691	0.625	rs845738	ENSG00000271849.1	CTC-332L22.1	-4.52	7.68e-06	0.000808	-0.29	-0.2	Autism spectrum disorder or schizophrenia;	chr5:109682414	chr5:109687802~109688329:-
THCA	cis	rs375066	0.935	rs408549	ENSG00000278917.1	RP11-15A1.4	-4.52	7.68e-06	0.000808	-0.17	-0.2	Breast cancer;	chr19:43921467	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs398388	ENSG00000278917.1	RP11-15A1.4	-4.52	7.68e-06	0.000808	-0.17	-0.2	Breast cancer;	chr19:43921530	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs403137	ENSG00000278917.1	RP11-15A1.4	-4.52	7.68e-06	0.000808	-0.17	-0.2	Breast cancer;	chr19:43923474	chr19:43891233~43895411:+
THCA	cis	rs375066	0.869	rs379785	ENSG00000278917.1	RP11-15A1.4	-4.52	7.68e-06	0.000808	-0.17	-0.2	Breast cancer;	chr19:43923949	chr19:43891233~43895411:+
THCA	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-4.52	7.68e-06	0.000808	-0.24	-0.2	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
THCA	cis	rs9902453	1	rs9902453	ENSG00000263370.1	RP11-68I3.5	-4.52	7.68e-06	0.000808	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30022077	chr17:29639627~29640825:+
THCA	cis	rs2337406	0.539	rs2583290	ENSG00000274576.2	IGHV2-70	4.52	7.68e-06	0.000808	0.17	0.2	Alzheimer's disease (late onset);	chr14:106650277	chr14:106770577~106771020:-
THCA	cis	rs9878978	1	rs11711499	ENSG00000237990.3	CNTN4-AS1	4.52	7.68e-06	0.000808	0.23	0.2	Blood pressure (smoking interaction);	chr3:2430661	chr3:3039033~3069242:-
THCA	cis	rs2836974	0.644	rs11088472	ENSG00000255568.3	BRWD1-AS2	-4.52	7.68e-06	0.000808	-0.17	-0.2	Cognitive function;	chr21:39327450	chr21:39313935~39314962:+
THCA	cis	rs5758511	0.573	rs5996074	ENSG00000230107.1	CTA-126B4.7	4.52	7.68e-06	0.000808	0.22	0.2	Birth weight;	chr22:41840333	chr22:42438023~42446195:+
THCA	cis	rs516805	0.52	rs13437168	ENSG00000279453.1	RP3-425C14.4	-4.52	7.69e-06	0.000808	-0.17	-0.2	Lymphocyte counts;	chr6:122465918	chr6:122436789~122439223:-
THCA	cis	rs9878978	1	rs13084976	ENSG00000237990.3	CNTN4-AS1	4.52	7.69e-06	0.000808	0.23	0.2	Blood pressure (smoking interaction);	chr3:2421168	chr3:3039033~3069242:-
THCA	cis	rs3782089	1	rs3782089	ENSG00000245532.5	NEAT1	4.52	7.69e-06	0.000809	0.26	0.2	Height;	chr11:65569348	chr11:65422774~65445540:+
THCA	cis	rs9863	0.861	rs11057399	ENSG00000270061.1	RP11-214K3.19	-4.52	7.69e-06	0.000809	-0.28	-0.2	White blood cell count;	chr12:123940531	chr12:123969990~123970344:-
THCA	cis	rs2554380	0.628	rs6602993	ENSG00000176700.18	SCAND2P	-4.52	7.69e-06	0.000809	-0.15	-0.2	Height;	chr15:83813610	chr15:84631451~84647478:+
THCA	cis	rs990871	0.53	rs2821285	ENSG00000227207.2	RPL31P12	4.52	7.69e-06	0.000809	0.24	0.2	Subcutaneous adipose tissue;	chr1:72201513	chr1:72301472~72301829:+
THCA	cis	rs990871	0.53	rs1858600	ENSG00000227207.2	RPL31P12	4.52	7.69e-06	0.000809	0.24	0.2	Subcutaneous adipose tissue;	chr1:72208806	chr1:72301472~72301829:+
THCA	cis	rs9878978	0.928	rs17786873	ENSG00000237990.3	CNTN4-AS1	4.52	7.69e-06	0.000809	0.22	0.2	Blood pressure (smoking interaction);	chr3:2444044	chr3:3039033~3069242:-
THCA	cis	rs2018683	0.899	rs10479816	ENSG00000272568.4	CTB-113D17.1	4.52	7.69e-06	0.000809	0.2	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938404	chr7:28979967~29013367:+
THCA	cis	rs875971	0.522	rs1880556	ENSG00000229886.1	RP5-1132H15.3	4.52	7.69e-06	0.000809	0.21	0.2	Aortic root size;	chr7:65967557	chr7:66025126~66031544:-
THCA	cis	rs7115242	0.8	rs4245168	ENSG00000280143.1	AP000892.6	4.52	7.69e-06	0.000809	0.32	0.2	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117204967~117210292:+
THCA	cis	rs7267979	0.934	rs2261753	ENSG00000274973.1	RP13-401N8.7	-4.52	7.7e-06	0.000809	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25845497~25845862:+
THCA	cis	rs11175834	0.655	rs10047609	ENSG00000250748.5	RP11-230G5.2	-4.52	7.7e-06	0.000809	-0.34	-0.2	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65582534	chr12:65466820~65642372:-
THCA	cis	rs2836950	0.545	rs2297256	ENSG00000238141.2	BRWD1-AS1	-4.52	7.7e-06	0.000809	-0.23	-0.2	Menarche (age at onset);	chr21:39186495	chr21:39315707~39323218:+
THCA	cis	rs1476587	0.92	rs2106954	ENSG00000224046.1	AC005076.5	4.52	7.7e-06	0.00081	0.21	0.2	Brachial circumference;	chr7:87111018	chr7:87151423~87152420:-
THCA	cis	rs5742933	1	rs1550388	ENSG00000253559.1	OSGEPL1-AS1	4.52	7.7e-06	0.00081	0.25	0.2	Ferritin levels;	chr2:189739054	chr2:189762704~189765556:+
THCA	cis	rs6517329	0.544	rs9305578	ENSG00000236830.5	CBR3-AS1	-4.52	7.71e-06	0.00081	-0.19	-0.2	Schizophrenia;	chr21:36141857	chr21:36131767~36175815:-
THCA	cis	rs6517329	0.585	rs2242803	ENSG00000236830.5	CBR3-AS1	-4.52	7.71e-06	0.00081	-0.19	-0.2	Schizophrenia;	chr21:36143725	chr21:36131767~36175815:-
THCA	cis	rs9307551	0.584	rs13113835	ENSG00000250334.4	LINC00989	-4.52	7.71e-06	0.000811	-0.25	-0.2	Refractive error;	chr4:79522945	chr4:79492416~79576460:+
THCA	cis	rs7474896	0.515	rs2738208	ENSG00000226578.1	RP11-258F22.1	4.52	7.71e-06	0.000811	0.28	0.2	Obesity (extreme);	chr10:38017200	chr10:37775371~37784131:-
THCA	cis	rs6088765	0.606	rs2425024	ENSG00000269202.1	RP4-614O4.12	4.52	7.71e-06	0.000811	0.19	0.2	Ulcerative colitis;	chr20:35257135	chr20:35201747~35203288:-
THCA	cis	rs758324	0.661	rs154728	ENSG00000237714.1	P4HA2-AS1	-4.52	7.71e-06	0.000811	-0.28	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132113336	chr5:132184876~132192808:+
THCA	cis	rs4742903	0.935	rs726203	ENSG00000270332.1	SMC2-AS1	4.52	7.72e-06	0.000811	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104144156	chr9:104080024~104093073:-
THCA	cis	rs6745190	0.512	rs35482602	ENSG00000236153.1	AC104076.3	-4.52	7.72e-06	0.000811	-0.26	-0.2	White blood cell count;	chr2:181130594	chr2:180979427~180980090:-
THCA	cis	rs12681288	0.821	rs2701944	ENSG00000260721.1	AF067845.1	4.52	7.72e-06	0.000811	0.26	0.2	Schizophrenia;	chr8:1084525	chr8:1368642~1369833:-
THCA	cis	rs4713118	0.869	rs9283881	ENSG00000226314.6	ZNF192P1	-4.52	7.72e-06	0.000812	-0.26	-0.2	Parkinson's disease;	chr6:27747476	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.869	rs9283882	ENSG00000226314.6	ZNF192P1	-4.52	7.72e-06	0.000812	-0.26	-0.2	Parkinson's disease;	chr6:27747479	chr6:28161781~28169594:+
THCA	cis	rs4948275	0.693	rs2253375	ENSG00000237233.2	TMEM26-AS1	-4.52	7.72e-06	0.000812	-0.27	-0.2	Night sleep phenotypes;	chr10:61565735	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs2650739	ENSG00000237233.2	TMEM26-AS1	-4.52	7.72e-06	0.000812	-0.27	-0.2	Night sleep phenotypes;	chr10:61567679	chr10:61452639~61481956:+
THCA	cis	rs5758659	0.935	rs134879	ENSG00000281538.1	RP4-669P10.20	4.52	7.72e-06	0.000812	0.18	0.2	Cognitive function;	chr22:42268195	chr22:42138060~42139726:+
THCA	cis	rs607541	1	rs674568	ENSG00000259520.4	CTD-2651B20.3	-4.52	7.72e-06	0.000812	-0.29	-0.2	Obesity-related traits;	chr15:45644389	chr15:45251580~45279251:-
THCA	cis	rs6545883	0.507	rs62149712	ENSG00000270820.4	RP11-355B11.2	-4.52	7.73e-06	0.000812	-0.17	-0.2	Tuberculosis;	chr2:61374137	chr2:61471188~61484130:+
THCA	cis	rs11992162	0.967	rs7836456	ENSG00000254948.1	OR7E158P	-4.52	7.73e-06	0.000812	-0.25	-0.2	Monocyte count;	chr8:11971666	chr8:11919900~11920809:-
THCA	cis	rs2590942	0.838	rs2613497	ENSG00000227207.2	RPL31P12	-4.52	7.73e-06	0.000813	-0.33	-0.2	Childhood body mass index;	chr1:72288142	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.838	rs2568953	ENSG00000227207.2	RPL31P12	-4.52	7.73e-06	0.000813	-0.33	-0.2	Childhood body mass index;	chr1:72288273	chr1:72301472~72301829:+
THCA	cis	rs11976180	1	rs2951308	ENSG00000244198.4	RP4-545C24.1	4.52	7.73e-06	0.000813	0.2	0.2	Obesity-related traits;	chr7:144070056	chr7:144194858~144280547:+
THCA	cis	rs9341808	0.529	rs4706840	ENSG00000260645.1	RP11-250B2.5	4.52	7.73e-06	0.000813	0.17	0.2	Sitting height ratio;	chr6:80348052	chr6:80466958~80469080:+
THCA	cis	rs9880211	1	rs12695645	ENSG00000239213.4	NCK1-AS1	4.52	7.73e-06	0.000813	0.23	0.2	Height;Body mass index;	chr3:136272039	chr3:136841726~136862054:-
THCA	cis	rs9341808	0.529	rs9350851	ENSG00000260645.1	RP11-250B2.5	4.52	7.73e-06	0.000813	0.17	0.2	Sitting height ratio;	chr6:80349471	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.529	rs9352826	ENSG00000260645.1	RP11-250B2.5	4.52	7.73e-06	0.000813	0.17	0.2	Sitting height ratio;	chr6:80349654	chr6:80466958~80469080:+
THCA	cis	rs1972460	0.506	rs62012050	ENSG00000259429.4	UBE2Q2P2	-4.52	7.73e-06	0.000813	-0.19	-0.2	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82355142~82420075:+
THCA	cis	rs302972	0.826	rs79229624	ENSG00000168405.13	CMAHP	4.52	7.74e-06	0.000813	0.44	0.2	Creatinine levels in ischemic stroke;	chr6:25074428	chr6:25081068~25166555:-
THCA	cis	rs1023500	0.573	rs133382	ENSG00000273366.1	CTA-989H11.1	-4.52	7.74e-06	0.000813	-0.26	-0.2	Schizophrenia;	chr22:42075770	chr22:42278188~42278846:+
THCA	cis	rs1023500	0.573	rs1807494	ENSG00000273366.1	CTA-989H11.1	4.52	7.74e-06	0.000813	0.26	0.2	Schizophrenia;	chr22:42078134	chr22:42278188~42278846:+
THCA	cis	rs875971	0.545	rs17138156	ENSG00000273142.1	RP11-458F8.4	4.52	7.74e-06	0.000814	0.19	0.2	Aortic root size;	chr7:66249708	chr7:66902857~66906297:+
THCA	cis	rs6860806	0.507	rs635620	ENSG00000224431.1	AC063976.7	-4.52	7.74e-06	0.000814	-0.18	-0.2	Breast cancer;	chr5:132384571	chr5:132199456~132203487:+
THCA	cis	rs6860806	0.507	rs635619	ENSG00000224431.1	AC063976.7	-4.52	7.74e-06	0.000814	-0.18	-0.2	Breast cancer;	chr5:132384573	chr5:132199456~132203487:+
THCA	cis	rs7615952	0.546	rs11717632	ENSG00000171084.14	FAM86JP	4.52	7.74e-06	0.000814	0.28	0.2	Blood pressure (smoking interaction);	chr3:125602286	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.546	rs2922197	ENSG00000171084.14	FAM86JP	4.52	7.74e-06	0.000814	0.28	0.2	Blood pressure (smoking interaction);	chr3:125603188	chr3:125916620~125930024:+
THCA	cis	rs6012564	0.927	rs932451	ENSG00000230758.1	SNAP23P	-4.52	7.75e-06	0.000814	-0.24	-0.2	Anger;	chr20:48957061	chr20:49038357~49038602:-
THCA	cis	rs667920	0.512	rs13069695	ENSG00000273486.1	RP11-731C17.2	-4.52	7.75e-06	0.000814	-0.28	-0.2	Coronary artery disease;	chr3:136572720	chr3:136837338~136839021:-
THCA	cis	rs116248771	0.739	rs6768636	ENSG00000271778.1	RP11-379F4.8	-4.52	7.75e-06	0.000814	-0.26	-0.2	diarrhoeal disease at age 2;	chr3:158629776	chr3:158782547~158783124:+
THCA	cis	rs911555	0.755	rs2273702	ENSG00000269910.1	RP11-73M18.10	-4.52	7.75e-06	0.000814	-0.19	-0.2	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103694516~103695050:-
THCA	cis	rs6121246	0.909	rs6060812	ENSG00000230613.1	HM13-AS1	4.52	7.75e-06	0.000814	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31705000	chr20:31567707~31573263:-
THCA	cis	rs6517329	0.538	rs12483755	ENSG00000236830.5	CBR3-AS1	4.52	7.75e-06	0.000814	0.19	0.2	Schizophrenia;	chr21:36136140	chr21:36131767~36175815:-
THCA	cis	rs12935229	1	rs17769754	ENSG00000260922.1	RP11-538I12.3	4.52	7.75e-06	0.000814	0.34	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77293964	chr16:77234877~77290934:+
THCA	cis	rs1383484	0.506	rs899927	ENSG00000230373.7	GOLGA6L5P	-4.52	7.75e-06	0.000815	-0.2	-0.2	Height;	chr15:83893127	chr15:84507885~84516814:-
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000182586.6	LINC00334	-4.52	7.75e-06	0.000815	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45234340~45258730:+
THCA	cis	rs734999	0.55	rs2985855	ENSG00000225931.3	RP3-395M20.7	-4.52	7.75e-06	0.000815	-0.25	-0.2	Ulcerative colitis;	chr1:2599933	chr1:2566410~2569888:+
THCA	cis	rs72615157	0.697	rs2056726	ENSG00000242294.5	STAG3L5P	4.52	7.75e-06	0.000815	0.13	0.2	Lung function (FEV1/FVC);	chr7:100182660	chr7:100336079~100351900:+
THCA	cis	rs9625935	0.879	rs36609	ENSG00000279159.1	RP3-394A18.1	4.52	7.75e-06	0.000815	0.16	0.2	Tonsillectomy;	chr22:29948468	chr22:29978950~30028236:-
THCA	cis	rs881375	0.9	rs2241003	ENSG00000270917.1	RP11-27I1.6	-4.52	7.75e-06	0.000815	-0.28	-0.2	Rheumatoid arthritis;	chr9:120904499	chr9:120812475~120812845:-
THCA	cis	rs12134133	1	rs11584921	ENSG00000237074.1	RP11-6J21.2	4.52	7.75e-06	0.000815	0.22	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207249067~207309121:+
THCA	cis	rs2839186	0.681	rs13047198	ENSG00000215424.8	MCM3AP-AS1	4.52	7.76e-06	0.000815	0.12	0.2	Testicular germ cell tumor;	chr21:46281921	chr21:46229217~46259390:+
THCA	cis	rs13178541	0.81	rs7379050	ENSG00000250378.1	RP11-119J18.1	-4.52	7.76e-06	0.000815	-0.24	-0.2	IgG glycosylation;	chr5:135745702	chr5:135812667~135826582:+
THCA	cis	rs11175834	0.655	rs11175839	ENSG00000256915.1	RP11-221N13.4	4.52	7.76e-06	0.000815	0.36	0.2	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65613113	chr12:65644334~65663299:+
THCA	cis	rs2120243	0.539	rs9857875	ENSG00000241770.1	RP11-555M1.3	-4.52	7.76e-06	0.000815	-0.26	-0.2	Hepatocellular carcinoma in hepatitis B infection;	chr3:157361108	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.565	rs1500919	ENSG00000241770.1	RP11-555M1.3	-4.52	7.76e-06	0.000815	-0.26	-0.2	Hepatocellular carcinoma in hepatitis B infection;	chr3:157361259	chr3:157163452~157169133:+
THCA	cis	rs11168351	1	rs11168351	ENSG00000273765.1	RP11-370I10.11	4.52	7.76e-06	0.000816	0.2	0.2	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48360920~48361377:+
THCA	cis	rs62244186	0.541	rs3804583	ENSG00000214820.3	MPRIPP1	4.52	7.76e-06	0.000816	0.21	0.2	Depressive symptoms;	chr3:44843155	chr3:44579938~44581026:-
THCA	cis	rs964611	0.882	rs3784621	ENSG00000259488.2	RP11-154J22.1	4.52	7.76e-06	0.000816	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48340895	chr15:48312353~48331856:-
THCA	cis	rs9880211	0.613	rs13079205	ENSG00000273486.1	RP11-731C17.2	4.52	7.76e-06	0.000816	0.21	0.2	Height;Body mass index;	chr3:136081851	chr3:136837338~136839021:-
THCA	cis	rs7141336	0.607	rs6575147	ENSG00000258884.1	CTD-3035D6.2	-4.52	7.76e-06	0.000816	-0.25	-0.2	Anxiety disorder;	chr14:90753254	chr14:90822365~90828128:-
THCA	cis	rs1538970	0.816	rs9727262	ENSG00000234329.1	RP11-767N6.2	4.52	7.76e-06	0.000816	0.21	0.2	Platelet count;	chr1:45532907	chr1:45651039~45651826:-
THCA	cis	rs2948294	0.588	rs7011221	ENSG00000254340.1	RP11-10A14.3	4.52	7.77e-06	0.000816	0.23	0.2	Red cell distribution width;	chr8:8256724	chr8:9141424~9145435:+
THCA	cis	rs2948294	0.545	rs11776397	ENSG00000254340.1	RP11-10A14.3	4.52	7.77e-06	0.000816	0.23	0.2	Red cell distribution width;	chr8:8257639	chr8:9141424~9145435:+
THCA	cis	rs116248771	0.739	rs7617983	ENSG00000271778.1	RP11-379F4.8	4.52	7.77e-06	0.000816	0.27	0.2	diarrhoeal disease at age 2;	chr3:158605927	chr3:158782547~158783124:+
THCA	cis	rs4713118	0.739	rs2893931	ENSG00000226314.6	ZNF192P1	-4.52	7.77e-06	0.000816	-0.26	-0.2	Parkinson's disease;	chr6:27780231	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.824	rs2092075	ENSG00000226314.6	ZNF192P1	-4.52	7.77e-06	0.000816	-0.26	-0.2	Parkinson's disease;	chr6:27781551	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.824	rs13211701	ENSG00000226314.6	ZNF192P1	-4.52	7.77e-06	0.000816	-0.26	-0.2	Parkinson's disease;	chr6:27782300	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.824	rs9468229	ENSG00000226314.6	ZNF192P1	-4.52	7.77e-06	0.000816	-0.26	-0.2	Parkinson's disease;	chr6:27782307	chr6:28161781~28169594:+
THCA	cis	rs2836950	0.545	rs1888489	ENSG00000238141.2	BRWD1-AS1	-4.52	7.77e-06	0.000816	-0.23	-0.2	Menarche (age at onset);	chr21:39161238	chr21:39315707~39323218:+
THCA	cis	rs9487094	0.67	rs2024850	ENSG00000223537.2	RP5-919F19.5	4.52	7.77e-06	0.000816	0.21	0.2	Height;	chr6:109497253	chr6:109487906~109506800:+
THCA	cis	rs1923243	0.71	rs4427361	ENSG00000223479.3	RP4-788P17.1	-4.52	7.77e-06	0.000816	-0.23	-0.2	Migraine;	chr1:73133596	chr1:73635216~73715214:+
THCA	cis	rs4648045	0.608	rs230512	ENSG00000246560.2	RP11-10L12.4	-4.52	7.77e-06	0.000816	-0.24	-0.2	Lymphocyte percentage of white cells;	chr4:102551728	chr4:102828055~102844075:+
THCA	cis	rs2904524	0.737	rs11544120	ENSG00000257815.4	RP11-611E13.2	-4.52	7.77e-06	0.000816	-0.3	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70242757	chr12:69904033~70243360:-
THCA	cis	rs7267979	0.966	rs2261790	ENSG00000274973.1	RP13-401N8.7	-4.52	7.77e-06	0.000817	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2261794	ENSG00000274973.1	RP13-401N8.7	-4.52	7.77e-06	0.000817	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2145126	ENSG00000274973.1	RP13-401N8.7	-4.52	7.77e-06	0.000817	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2257705	ENSG00000274973.1	RP13-401N8.7	-4.52	7.77e-06	0.000817	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2227892	ENSG00000274973.1	RP13-401N8.7	-4.52	7.77e-06	0.000817	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2257712	ENSG00000274973.1	RP13-401N8.7	-4.52	7.77e-06	0.000817	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2257461	ENSG00000274973.1	RP13-401N8.7	-4.52	7.77e-06	0.000817	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25845497~25845862:+
THCA	cis	rs8062405	0.895	rs62036658	ENSG00000261766.1	RP11-22P6.2	-4.52	7.77e-06	0.000817	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28862166~28863340:-
THCA	cis	rs801193	1	rs2659912	ENSG00000229886.1	RP5-1132H15.3	4.52	7.78e-06	0.000817	0.21	0.2	Aortic root size;	chr7:66693012	chr7:66025126~66031544:-
THCA	cis	rs17711722	1	rs17711722	ENSG00000272831.1	RP11-792A8.4	-4.52	7.78e-06	0.000817	-0.13	-0.2	Calcium levels;	chr7:65806210	chr7:66739829~66740385:-
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000272831.1	RP11-792A8.4	-4.52	7.78e-06	0.000817	-0.13	-0.2	Calcium levels;	chr7:65808508	chr7:66739829~66740385:-
THCA	cis	rs227275	0.554	rs223316	ENSG00000248971.2	KRT8P46	-4.52	7.78e-06	0.000817	-0.25	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs223314	ENSG00000248971.2	KRT8P46	-4.52	7.78e-06	0.000817	-0.25	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs7254	ENSG00000248971.2	KRT8P46	-4.52	7.78e-06	0.000817	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.566	rs6822658	ENSG00000248971.2	KRT8P46	-4.52	7.78e-06	0.000817	-0.25	-0.2	Schizophrenia;	chr4:102891964	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs6823625	ENSG00000248971.2	KRT8P46	-4.52	7.78e-06	0.000817	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs6846762	ENSG00000248971.2	KRT8P46	-4.52	7.78e-06	0.000817	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102728746~102730171:-
THCA	cis	rs228614	0.51	rs4699032	ENSG00000248971.2	KRT8P46	-4.52	7.78e-06	0.000817	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102728746~102730171:-
THCA	cis	rs4660456	0.619	rs753753	ENSG00000238287.1	RP11-656D10.3	-4.52	7.78e-06	0.000817	-0.24	-0.2	Platelet count;	chr1:40771716	chr1:40493157~40508661:-
THCA	cis	rs10911902	0.643	rs7556543	ENSG00000229739.2	RP11-295K2.3	-4.52	7.78e-06	0.000817	-0.32	-0.2	Schizophrenia;	chr1:186301287	chr1:186435161~186470291:+
THCA	cis	rs1979679	0.879	rs1002863	ENSG00000247934.4	RP11-967K21.1	4.52	7.78e-06	0.000817	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28500768	chr12:28163298~28190738:-
THCA	cis	rs2836974	0.602	rs8130854	ENSG00000255568.3	BRWD1-AS2	-4.52	7.78e-06	0.000818	-0.17	-0.2	Cognitive function;	chr21:39335115	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.605	rs2836988	ENSG00000255568.3	BRWD1-AS2	-4.52	7.78e-06	0.000818	-0.17	-0.2	Cognitive function;	chr21:39336049	chr21:39313935~39314962:+
THCA	cis	rs6570726	0.791	rs6914203	ENSG00000270638.1	RP3-466P17.1	4.52	7.78e-06	0.000818	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145735570~145737218:+
THCA	cis	rs5753037	0.809	rs2079338	ENSG00000279699.1	RP1-102K2.9	4.52	7.78e-06	0.000818	0.21	0.2	Type 1 diabetes;	chr22:29807853	chr22:30275215~30276951:-
THCA	cis	rs1979679	0.573	rs6487693	ENSG00000247934.4	RP11-967K21.1	4.52	7.78e-06	0.000818	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574158	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.573	rs6487694	ENSG00000247934.4	RP11-967K21.1	4.52	7.78e-06	0.000818	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574801	chr12:28163298~28190738:-
THCA	cis	rs76793172	0.588	rs8110017	ENSG00000267395.4	AC074212.6	-4.52	7.78e-06	0.000818	-0.18	-0.2	Eosinophil counts;	chr19:45786134	chr19:45767796~45772504:+
THCA	cis	rs13178541	0.81	rs11242278	ENSG00000250378.1	RP11-119J18.1	-4.52	7.79e-06	0.000818	-0.26	-0.2	IgG glycosylation;	chr5:135778043	chr5:135812667~135826582:+
THCA	cis	rs972578	0.967	rs5759082	ENSG00000230319.1	AL022476.2	4.52	7.79e-06	0.000818	0.21	0.2	Mean platelet volume;	chr22:43005073	chr22:43038585~43052366:+
THCA	cis	rs858239	0.6	rs7341483	ENSG00000226816.2	AC005082.12	-4.52	7.79e-06	0.000818	-0.29	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23206013~23208045:+
THCA	cis	rs4934494	0.768	rs11330	ENSG00000240996.1	RP11-80H5.7	4.52	7.79e-06	0.000818	0.23	0.2	Red blood cell count;	chr10:89634322	chr10:89694295~89697928:-
THCA	cis	rs17095355	1	rs4565840	ENSG00000203876.8	ADD3-AS1	-4.52	7.79e-06	0.000818	-0.22	-0.2	Biliary atresia;	chr10:109957382	chr10:109940104~110008381:-
THCA	cis	rs78487399	0.808	rs6752448	ENSG00000234936.1	AC010883.5	4.52	7.79e-06	0.000818	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43455457	chr2:43229573~43233394:+
THCA	cis	rs6088590	1	rs1998028	ENSG00000276073.1	RP5-1125A11.7	-4.52	7.79e-06	0.000818	-0.19	-0.2	Coronary artery disease;	chr20:34756792	chr20:33985617~33988989:-
THCA	cis	rs9475752	0.744	rs62411428	ENSG00000231441.1	RP11-472M19.2	4.52	7.79e-06	0.000818	0.22	0.2	Menarche (age at onset);	chr6:56936465	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.744	rs62411429	ENSG00000231441.1	RP11-472M19.2	4.52	7.79e-06	0.000818	0.22	0.2	Menarche (age at onset);	chr6:56936524	chr6:56844002~56864078:+
THCA	cis	rs9300255	0.544	rs2049114	ENSG00000235423.7	RP11-282O18.3	4.52	7.79e-06	0.000819	0.22	0.2	Neutrophil percentage of white cells;	chr12:123172791	chr12:123252030~123261483:-
THCA	cis	rs9467773	0.62	rs9467810	ENSG00000124549.13	BTN2A3P	4.52	7.79e-06	0.000819	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26421391~26432383:+
THCA	cis	rs738722	0.658	rs5762752	ENSG00000272858.1	CTA-292E10.8	-4.52	7.8e-06	0.000819	-0.2	-0.2	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28704989	chr22:28814914~28815662:+
THCA	cis	rs738722	0.681	rs5762753	ENSG00000272858.1	CTA-292E10.8	-4.52	7.8e-06	0.000819	-0.2	-0.2	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28704997	chr22:28814914~28815662:+
THCA	cis	rs7403037	0.617	rs34726019	ENSG00000259905.4	PWRN1	4.52	7.8e-06	0.000819	0.27	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24602083	chr15:24493137~24652130:+
THCA	cis	rs12234571	1	rs11984003	ENSG00000214293.7	APTR	4.52	7.8e-06	0.000819	0.25	0.2	Obesity-related traits;	chr7:77948442	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs12667313	ENSG00000214293.7	APTR	4.52	7.8e-06	0.000819	0.25	0.2	Obesity-related traits;	chr7:77950810	chr7:77657660~77696265:-
THCA	cis	rs889398	0.741	rs6499270	ENSG00000226232.7	RP11-419C5.2	4.52	7.8e-06	0.000819	0.2	0.2	Body mass index;	chr16:69883837	chr16:69976388~69996188:-
THCA	cis	rs2281636	0.929	rs7913190	ENSG00000233690.1	EBAG9P1	4.52	7.8e-06	0.00082	0.19	0.2	Obesity-related traits;	chr10:99738639	chr10:99697407~99697949:-
THCA	cis	rs919433	0.617	rs10460394	ENSG00000231621.1	AC013264.2	4.52	7.8e-06	0.00082	0.22	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197684017	chr2:197197991~197199273:+
THCA	cis	rs6997458	0.785	rs10907474	ENSG00000253549.4	RP11-317J10.2	4.52	7.8e-06	0.00082	0.21	0.2	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85450152	chr8:85441851~85464915:-
THCA	cis	rs6973609	0.513	rs6954895	ENSG00000271122.1	RP11-379H18.1	4.52	7.81e-06	0.00082	0.14	0.2	Obesity-related traits;	chr7:35546596	chr7:35695214~35699413:+
THCA	cis	rs9329221	0.741	rs9650622	ENSG00000248538.5	RP11-10A14.5	4.52	7.81e-06	0.00082	0.26	0.2	Neuroticism;	chr8:9946782	chr8:9189011~9202854:+
THCA	cis	rs9902453	0.904	rs12939344	ENSG00000263370.1	RP11-68I3.5	-4.52	7.81e-06	0.00082	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30001801	chr17:29639627~29640825:+
THCA	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	4.52	7.81e-06	0.00082	0.25	0.2	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000273024.4	INTS4P2	-4.52	7.81e-06	0.00082	-0.22	-0.2	Calcium levels;	chr7:65806798	chr7:65647864~65715661:+
THCA	cis	rs1046896	0.553	rs9893885	ENSG00000263063.1	RP11-388C12.1	-4.52	7.81e-06	0.00082	-0.27	-0.2	Glycated hemoglobin levels;	chr17:82879231	chr17:82713908~82716255:-
THCA	cis	rs1823874	0.605	rs1840300	ENSG00000182397.13	DNM1P46	-4.52	7.81e-06	0.000821	-0.22	-0.2	IgG glycosylation;	chr15:99826739	chr15:99790156~99806927:-
THCA	cis	rs6012564	0.893	rs6012579	ENSG00000227431.4	CSE1L-AS1	-4.52	7.81e-06	0.000821	-0.25	-0.2	Anger;	chr20:49006883	chr20:49040463~49046044:-
THCA	cis	rs713587	0.691	rs754536	ENSG00000224165.4	DNAJC27-AS1	4.52	7.81e-06	0.000821	0.11	0.2	Body mass index in non-asthmatics;	chr2:24953331	chr2:24971390~25039694:+
THCA	cis	rs713587	0.691	rs754537	ENSG00000224165.4	DNAJC27-AS1	4.52	7.81e-06	0.000821	0.11	0.2	Body mass index in non-asthmatics;	chr2:24953408	chr2:24971390~25039694:+
THCA	cis	rs7726839	0.574	rs72707007	ENSG00000225138.6	CTD-2228K2.7	4.52	7.82e-06	0.000821	0.25	0.2	Obesity-related traits;	chr5:661741	chr5:473236~480884:+
THCA	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	4.52	7.82e-06	0.000821	0.23	0.2	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	4.52	7.82e-06	0.000821	0.23	0.2	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	4.52	7.82e-06	0.000821	0.23	0.2	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
THCA	cis	rs1061377	0.513	rs2712000	ENSG00000249685.1	RP11-360F5.3	4.52	7.82e-06	0.000821	0.28	0.2	Uric acid levels;	chr4:39135462	chr4:39133913~39135608:+
THCA	cis	rs2886497	0.624	rs1398025	ENSG00000224215.1	RP11-371A19.2	-4.52	7.82e-06	0.000821	-0.23	-0.2	Major depression and alcohol dependence;	chr10:23391036	chr10:23343957~23345181:+
THCA	cis	rs9302635	0.55	rs35959677	ENSG00000260886.1	TAT-AS1	4.52	7.82e-06	0.000821	0.27	0.2	Blood protein levels;	chr16:72166902	chr16:71565789~71578187:+
THCA	cis	rs6121246	0.909	rs1994250	ENSG00000230613.1	HM13-AS1	4.52	7.82e-06	0.000821	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31699691	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs1994249	ENSG00000230613.1	HM13-AS1	4.52	7.82e-06	0.000821	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31699790	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.865	rs6058421	ENSG00000230613.1	HM13-AS1	4.52	7.82e-06	0.000821	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31707210	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6060870	ENSG00000230613.1	HM13-AS1	4.52	7.82e-06	0.000821	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31715496	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.821	rs3181073	ENSG00000230613.1	HM13-AS1	-4.52	7.82e-06	0.000821	-0.22	-0.2	Mean corpuscular hemoglobin;	chr20:31719396	chr20:31567707~31573263:-
THCA	cis	rs17685	0.712	rs7785025	ENSG00000230882.1	AC005077.14	-4.52	7.82e-06	0.000821	-0.2	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:75998783	chr7:76071469~76074963:-
THCA	cis	rs1200821	0.529	rs2475206	ENSG00000263064.2	RP11-291L22.7	-4.52	7.82e-06	0.000821	-0.23	-0.2	Hemostatic factors and hematological phenotypes;	chr10:37513604	chr10:38448689~38448949:+
THCA	cis	rs7726839	0.54	rs3792720	ENSG00000225138.6	CTD-2228K2.7	4.52	7.82e-06	0.000821	0.25	0.2	Obesity-related traits;	chr5:642913	chr5:473236~480884:+
THCA	cis	rs8062405	0.755	rs62034350	ENSG00000261766.1	RP11-22P6.2	-4.52	7.82e-06	0.000821	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28862166~28863340:-
THCA	cis	rs6840258	0.891	rs3755983	ENSG00000251411.1	RP11-397E7.4	-4.52	7.82e-06	0.000822	-0.24	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87116640	chr4:86913266~86914817:-
THCA	cis	rs8046148	0.724	rs2041918	ENSG00000279356.1	RP11-429P3.8	4.52	7.82e-06	0.000822	0.24	0.2	Testicular germ cell tumor;	chr16:50035401	chr16:50072862~50074986:+
THCA	cis	rs2439831	1	rs2253708	ENSG00000205771.5	CATSPER2P1	-4.52	7.83e-06	0.000822	-0.27	-0.2	Lung cancer in ever smokers;	chr15:43505075	chr15:43726918~43747094:-
THCA	cis	rs2836974	0.644	rs2836982	ENSG00000255568.3	BRWD1-AS2	-4.52	7.83e-06	0.000822	-0.17	-0.2	Cognitive function;	chr21:39317245	chr21:39313935~39314962:+
THCA	cis	rs807029	0.544	rs55646950	ENSG00000236662.1	RP11-108L7.4	4.52	7.83e-06	0.000822	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100980507~100985614:-
THCA	cis	rs17711722	0.523	rs365896	ENSG00000273024.4	INTS4P2	4.52	7.83e-06	0.000822	0.22	0.2	Calcium levels;	chr7:66045710	chr7:65647864~65715661:+
THCA	cis	rs987724	0.515	rs6762708	ENSG00000240875.4	LINC00886	4.52	7.83e-06	0.000823	0.19	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973815	chr3:156747346~156817062:-
THCA	cis	rs453301	0.538	rs7830804	ENSG00000233609.3	RP11-62H7.2	-4.52	7.83e-06	0.000823	-0.2	-0.2	Joint mobility (Beighton score);	chr8:9113252	chr8:8961200~8979025:+
THCA	cis	rs28714278	0.762	rs12050884	ENSG00000248508.5	SRP14-AS1	-4.52	7.84e-06	0.000823	-0.17	-0.2	Mean corpuscular hemoglobin;	chr15:40014133	chr15:40039311~40067290:+
THCA	cis	rs9650657	0.504	rs10109167	ENSG00000206014.6	OR7E161P	4.52	7.84e-06	0.000823	0.24	0.2	Neuroticism;	chr8:11176016	chr8:11928597~11929563:-
THCA	cis	rs57502260	0.704	rs60538784	ENSG00000212093.1	AP000807.1	4.52	7.84e-06	0.000823	0.27	0.2	Total body bone mineral density (age 45-60);	chr11:68619267	chr11:68506083~68506166:-
THCA	cis	rs35395347	0.702	rs4273407	ENSG00000229759.1	MRPS18AP1	4.52	7.84e-06	0.000823	0.5	0.2	Blood protein levels;	chr3:49240565	chr3:48256350~48256938:-
THCA	cis	rs6449502	0.92	rs329620	ENSG00000251279.1	CTC-436P18.1	4.52	7.84e-06	0.000824	0.34	0.2	Mean platelet volume;	chr5:60992700	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs329619	ENSG00000251279.1	CTC-436P18.1	4.52	7.84e-06	0.000824	0.34	0.2	Mean platelet volume;	chr5:60992880	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs290505	ENSG00000251279.1	CTC-436P18.1	4.52	7.84e-06	0.000824	0.34	0.2	Mean platelet volume;	chr5:61000729	chr5:61162070~61232040:+
THCA	cis	rs656319	0.647	rs13264668	ENSG00000261451.1	RP11-981G7.1	-4.52	7.84e-06	0.000824	-0.26	-0.2	Myopia (pathological);	chr8:10027367	chr8:10433672~10438312:+
THCA	cis	rs2467099	0.679	rs2608882	ENSG00000267801.1	RP11-552F3.9	4.52	7.85e-06	0.000824	0.27	0.2	Systolic blood pressure;	chr17:75938049	chr17:75876372~75879546:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000272831.1	RP11-792A8.4	-4.52	7.85e-06	0.000824	-0.13	-0.2	Aortic root size;	chr7:65800193	chr7:66739829~66740385:-
THCA	cis	rs4819052	0.851	rs1056101	ENSG00000273796.1	LL21NC02-21A1.1	-4.52	7.85e-06	0.000824	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45403809~45404369:-
THCA	cis	rs13063635	0.764	rs58552652	ENSG00000226074.4	PRSS44	-4.52	7.85e-06	0.000824	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46036800	chr3:46809359~46812558:-
THCA	cis	rs7772486	0.754	rs857881	ENSG00000270638.1	RP3-466P17.1	-4.52	7.86e-06	0.000825	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145735570~145737218:+
THCA	cis	rs6121246	0.559	rs6060716	ENSG00000230613.1	HM13-AS1	4.52	7.86e-06	0.000825	0.2	0.2	Mean corpuscular hemoglobin;	chr20:31687044	chr20:31567707~31573263:-
THCA	cis	rs2243480	1	rs56016656	ENSG00000232559.3	GS1-124K5.12	4.52	7.86e-06	0.000825	0.3	0.2	Diabetic kidney disease;	chr7:65918494	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs56291018	ENSG00000232559.3	GS1-124K5.12	4.52	7.86e-06	0.000825	0.3	0.2	Diabetic kidney disease;	chr7:65925352	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs36033484	ENSG00000232559.3	GS1-124K5.12	4.52	7.86e-06	0.000825	0.3	0.2	Diabetic kidney disease;	chr7:65925571	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs34560516	ENSG00000232559.3	GS1-124K5.12	4.52	7.86e-06	0.000825	0.3	0.2	Diabetic kidney disease;	chr7:65939105	chr7:66554588~66576923:-
THCA	cis	rs34421088	0.532	rs3808515	ENSG00000154316.13	TDH	-4.52	7.86e-06	0.000825	-0.15	-0.2	Neuroticism;	chr8:11298532	chr8:11339637~11368452:+
THCA	cis	rs375066	0.935	rs397913	ENSG00000278917.1	RP11-15A1.4	4.52	7.86e-06	0.000825	0.17	0.2	Breast cancer;	chr19:43894788	chr19:43891233~43895411:+
THCA	cis	rs78487399	0.908	rs78471316	ENSG00000234936.1	AC010883.5	4.52	7.86e-06	0.000825	0.26	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617309	chr2:43229573~43233394:+
THCA	cis	rs1538970	0.81	rs12067642	ENSG00000234329.1	RP11-767N6.2	4.52	7.87e-06	0.000826	0.21	0.2	Platelet count;	chr1:45461845	chr1:45651039~45651826:-
THCA	cis	rs748404	0.556	rs7166467	ENSG00000249839.1	AC011330.5	4.52	7.87e-06	0.000826	0.24	0.2	Lung cancer;	chr15:43148324	chr15:43663654~43684339:-
THCA	cis	rs911555	0.755	rs7148567	ENSG00000269910.1	RP11-73M18.10	4.52	7.87e-06	0.000826	0.19	0.2	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs10144051	ENSG00000269910.1	RP11-73M18.10	4.52	7.87e-06	0.000826	0.19	0.2	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103694516~103695050:-
THCA	cis	rs526231	0.764	rs599447	ENSG00000175749.11	EIF3KP1	4.52	7.87e-06	0.000826	0.26	0.2	Primary biliary cholangitis;	chr5:103302154	chr5:103032376~103033031:+
THCA	cis	rs7246760	0.867	rs66464474	ENSG00000267106.4	ZNF561-AS1	4.52	7.87e-06	0.000826	0.39	0.2	Pursuit maintenance gain;	chr19:9684473	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs55846005	ENSG00000267106.4	ZNF561-AS1	4.52	7.87e-06	0.000826	0.39	0.2	Pursuit maintenance gain;	chr19:9686033	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.737	rs60584926	ENSG00000267106.4	ZNF561-AS1	4.52	7.87e-06	0.000826	0.39	0.2	Pursuit maintenance gain;	chr19:9686338	chr19:9621291~9645896:+
THCA	cis	rs17270561	0.608	rs9358875	ENSG00000272462.2	U91328.19	-4.52	7.87e-06	0.000826	-0.18	-0.2	Iron status biomarkers;	chr6:25737780	chr6:25992662~26001775:+
THCA	cis	rs12444979	0.517	rs720173	ENSG00000261195.1	CTD-2380F24.1	-4.52	7.88e-06	0.000826	-0.34	-0.2	Body mass index;	chr16:19710484	chr16:19761172~19766099:-
THCA	cis	rs703842	1	rs10877013	ENSG00000270039.1	RP11-571M6.17	-4.52	7.88e-06	0.000827	-0.23	-0.2	Multiple sclerosis;	chr12:57771302	chr12:57803838~57804415:+
THCA	cis	rs9863	0.896	rs12829951	ENSG00000270061.1	RP11-214K3.19	-4.52	7.88e-06	0.000827	-0.28	-0.2	White blood cell count;	chr12:123941294	chr12:123969990~123970344:-
THCA	cis	rs9863	0.861	rs7131882	ENSG00000270061.1	RP11-214K3.19	-4.52	7.88e-06	0.000827	-0.28	-0.2	White blood cell count;	chr12:123942189	chr12:123969990~123970344:-
THCA	cis	rs7551222	0.646	rs4951382	ENSG00000240219.1	RP11-430C7.5	4.52	7.88e-06	0.000827	0.2	0.2	Schizophrenia;	chr1:204482367	chr1:204626775~204629712:+
THCA	cis	rs3820928	1	rs3820927	ENSG00000212391.1	SNORA48	-4.52	7.88e-06	0.000827	-0.23	-0.2	Pulmonary function;	chr2:226914475	chr2:226968989~226969122:-
THCA	cis	rs6001482	0.679	rs6001528	ENSG00000272779.1	LL22NC03-80A10.6	-4.52	7.88e-06	0.000827	-0.23	-0.2	Diastolic blood pressure;	chr22:22236511	chr22:22303224~22310401:+
THCA	cis	rs4817775	0.554	rs2835295	ENSG00000236830.5	CBR3-AS1	-4.52	7.88e-06	0.000827	-0.2	-0.2	Bone mineral density;	chr21:36173373	chr21:36131767~36175815:-
THCA	cis	rs17604090	0.938	rs73088374	ENSG00000227855.3	DPY19L2P3	4.52	7.88e-06	0.000827	0.27	0.2	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29615203	chr7:29650227~29742594:+
THCA	cis	rs683257	0.759	rs6937932	ENSG00000234147.1	RP3-460G2.2	-4.52	7.88e-06	0.000827	-0.35	-0.2	Facial emotion recognition (angry faces);	chr6:140884616	chr6:140845958~140852924:-
THCA	cis	rs2617170	0.883	rs1351111	ENSG00000245648.1	RP11-277P12.20	4.52	7.88e-06	0.000827	0.21	0.2	Behcet's disease;	chr12:10402849	chr12:10363769~10398506:+
THCA	cis	rs748404	0.666	rs10518812	ENSG00000205771.5	CATSPER2P1	4.52	7.88e-06	0.000827	0.26	0.2	Lung cancer;	chr15:43360739	chr15:43726918~43747094:-
THCA	cis	rs13063635	0.736	rs34805664	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46039616	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs35028116	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46039841	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs34610609	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46040215	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs13086534	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46041709	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs13064632	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46041865	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs34254987	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46042142	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs4683163	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Celiac disease;	chr3:46042880	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs4683164	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46042969	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.764	rs4234453	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46043457	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs12108042	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46044591	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs34867672	ENSG00000226074.4	PRSS44	-4.52	7.88e-06	0.000827	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46046790	chr3:46809359~46812558:-
THCA	cis	rs11153306	0.552	rs12196381	ENSG00000230177.1	RP5-1112D6.4	4.52	7.89e-06	0.000828	0.16	0.2	Tonsillectomy;	chr6:111618197	chr6:111277932~111278742:+
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000280107.1	AL022393.9	-4.52	7.89e-06	0.000828	-0.19	-0.2	Pubertal anthropometrics;	chr6:28411584	chr6:28170845~28172521:+
THCA	cis	rs7760535	1	rs7760535	ENSG00000271789.1	RP5-1112D6.7	4.52	7.89e-06	0.000828	0.21	0.2	Metabolic traits;	chr6:111425880	chr6:111297126~111298510:+
THCA	cis	rs1023500	0.573	rs133370	ENSG00000273366.1	CTA-989H11.1	-4.52	7.89e-06	0.000828	-0.26	-0.2	Schizophrenia;	chr22:42069256	chr22:42278188~42278846:+
THCA	cis	rs1023500	0.551	rs133371	ENSG00000273366.1	CTA-989H11.1	-4.52	7.89e-06	0.000828	-0.26	-0.2	Schizophrenia;	chr22:42069570	chr22:42278188~42278846:+
THCA	cis	rs1023500	0.573	rs133374	ENSG00000273366.1	CTA-989H11.1	-4.52	7.89e-06	0.000828	-0.26	-0.2	Schizophrenia;	chr22:42069937	chr22:42278188~42278846:+
THCA	cis	rs858239	0.601	rs11984129	ENSG00000226816.2	AC005082.12	4.52	7.89e-06	0.000828	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23206013~23208045:+
THCA	cis	rs8054556	0.74	rs8052502	ENSG00000183604.13	SMG1P5	-4.52	7.89e-06	0.000828	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29918407	chr16:30267553~30335374:-
THCA	cis	rs8031584	0.651	rs28664821	ENSG00000259845.1	HERC2P10	-4.52	7.89e-06	0.000828	-0.27	-0.2	Huntington's disease progression;	chr15:30880120	chr15:30815271~30844153:+
THCA	cis	rs12530	0.54	rs2294312	ENSG00000230736.2	RP1-149A16.3	-4.52	7.89e-06	0.000828	-0.24	-0.2	IgG glycosylation;	chr22:32397397	chr22:32376664~32384343:+
THCA	cis	rs2075824	0.715	rs1787989	ENSG00000267079.1	RP11-820I16.1	-4.52	7.89e-06	0.000828	-0.25	-0.2	Obsessive-compulsive disorder or autism spectrum disorder;	chr18:11974689	chr18:11910634~11914344:-
THCA	cis	rs7267979	0.934	rs2257464	ENSG00000274973.1	RP13-401N8.7	-4.52	7.89e-06	0.000828	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25845497~25845862:+
THCA	cis	rs875971	0.522	rs4718286	ENSG00000272831.1	RP11-792A8.4	4.52	7.9e-06	0.000828	0.13	0.2	Aortic root size;	chr7:65827777	chr7:66739829~66740385:-
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000272831.1	RP11-792A8.4	4.52	7.9e-06	0.000828	0.13	0.2	Calcium levels;	chr7:65837419	chr7:66739829~66740385:-
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000272831.1	RP11-792A8.4	4.52	7.9e-06	0.000828	0.13	0.2	Calcium levels;	chr7:65872915	chr7:66739829~66740385:-
THCA	cis	rs6570726	0.811	rs375873	ENSG00000270638.1	RP3-466P17.1	4.52	7.9e-06	0.000829	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145735570~145737218:+
THCA	cis	rs990871	0.543	rs1026567	ENSG00000227207.2	RPL31P12	4.52	7.9e-06	0.000829	0.24	0.2	Subcutaneous adipose tissue;	chr1:72242901	chr1:72301472~72301829:+
THCA	cis	rs4908769	0.66	rs302714	ENSG00000232912.4	RP5-1115A15.1	4.52	7.9e-06	0.000829	0.22	0.2	Allergy;	chr1:8426071	chr1:8424645~8434838:+
THCA	cis	rs189798	0.738	rs330911	ENSG00000253893.2	FAM85B	-4.52	7.9e-06	0.000829	-0.27	-0.2	Myopia (pathological);	chr8:9138763	chr8:8167819~8226614:-
THCA	cis	rs711244	0.756	rs28527412	ENSG00000279519.1	RP11-288C18.1	4.52	7.9e-06	0.000829	0.17	0.2	Mean platelet volume;	chr2:36913570	chr2:36839922~36842539:-
THCA	cis	rs11051970	0.589	rs325426	ENSG00000274964.1	RP11-817I4.1	-4.52	7.9e-06	0.000829	-0.22	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32382881	chr12:32339368~32340724:+
THCA	cis	rs6012564	0.964	rs6125547	ENSG00000230758.1	SNAP23P	4.52	7.9e-06	0.000829	0.25	0.2	Anger;	chr20:49100868	chr20:49038357~49038602:-
THCA	cis	rs7044106	0.537	rs10818474	ENSG00000270917.1	RP11-27I1.6	-4.52	7.9e-06	0.000829	-0.3	-0.2	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120812475~120812845:-
THCA	cis	rs17095355	1	rs72828232	ENSG00000203876.8	ADD3-AS1	-4.52	7.9e-06	0.000829	-0.23	-0.2	Biliary atresia;	chr10:109965540	chr10:109940104~110008381:-
THCA	cis	rs9307551	0.584	rs9994403	ENSG00000250334.4	LINC00989	-4.52	7.91e-06	0.000829	-0.24	-0.2	Refractive error;	chr4:79521324	chr4:79492416~79576460:+
THCA	cis	rs12681288	0.676	rs62488537	ENSG00000260721.1	AF067845.1	4.52	7.91e-06	0.00083	0.26	0.2	Schizophrenia;	chr8:1061962	chr8:1368642~1369833:-
THCA	cis	rs9847710	0.818	rs6445558	ENSG00000242142.1	SERBP1P3	-4.52	7.91e-06	0.00083	-0.23	-0.2	Ulcerative colitis;	chr3:53063644	chr3:53064283~53065091:-
THCA	cis	rs858239	0.6	rs6967475	ENSG00000226816.2	AC005082.12	4.52	7.91e-06	0.00083	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23206013~23208045:+
THCA	cis	rs2299587	0.573	rs6986123	ENSG00000253671.1	RP11-806O11.1	-4.52	7.91e-06	0.00083	-0.24	-0.2	Economic and political preferences;	chr8:18030564	chr8:17808941~17820868:+
THCA	cis	rs2440129	0.611	rs434473	ENSG00000262089.1	RP11-589P10.5	-4.52	7.91e-06	0.00083	-0.19	-0.2	Tonsillectomy;	chr17:7001615	chr17:6994642~6995189:-
THCA	cis	rs36093844	0.8	rs17817326	ENSG00000279742.1	RP11-700A24.1	-4.52	7.91e-06	0.00083	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884170	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs17817331	ENSG00000279742.1	RP11-700A24.1	4.52	7.91e-06	0.00083	0.29	0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884295	chr11:85852557~85854943:-
THCA	cis	rs9818758	0.607	rs73082362	ENSG00000270441.1	RP11-694I15.7	4.52	7.91e-06	0.00083	0.33	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076296	chr3:49140086~49160851:-
THCA	cis	rs17123764	0.818	rs3815832	ENSG00000257464.1	RP11-161H23.8	-4.52	7.92e-06	0.00083	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49554322	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs7970241	ENSG00000257464.1	RP11-161H23.8	-4.52	7.92e-06	0.00083	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49554976	chr12:49442424~49442652:-
THCA	cis	rs17123764	1	rs2241418	ENSG00000257464.1	RP11-161H23.8	-4.52	7.92e-06	0.00083	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49557449	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs12311839	ENSG00000257464.1	RP11-161H23.8	-4.52	7.92e-06	0.00083	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49569622	chr12:49442424~49442652:-
THCA	cis	rs17123764	1	rs11169069	ENSG00000257464.1	RP11-161H23.8	-4.52	7.92e-06	0.00083	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49572751	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.792	rs11169073	ENSG00000257464.1	RP11-161H23.8	-4.52	7.92e-06	0.00083	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49574643	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs7973389	ENSG00000257464.1	RP11-161H23.8	-4.52	7.92e-06	0.00083	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49586962	chr12:49442424~49442652:-
THCA	cis	rs10090774	0.965	rs11167015	ENSG00000279766.1	RP11-642A1.2	-4.52	7.92e-06	0.000831	-0.26	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140981341	chr8:140572142~140572812:-
THCA	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-4.52	7.92e-06	0.000831	-0.25	-0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
THCA	cis	rs9307551	0.584	rs13118848	ENSG00000250334.4	LINC00989	-4.52	7.92e-06	0.000831	-0.24	-0.2	Refractive error;	chr4:79525215	chr4:79492416~79576460:+
THCA	cis	rs4713118	0.868	rs2893928	ENSG00000272009.1	RP1-313I6.12	-4.52	7.92e-06	0.000831	-0.24	-0.2	Parkinson's disease;	chr6:27770651	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.673	rs35501037	ENSG00000272009.1	RP1-313I6.12	-4.52	7.92e-06	0.000831	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28078792~28081130:-
THCA	cis	rs61270009	0.955	rs34148755	ENSG00000247828.6	TMEM161B-AS1	4.52	7.93e-06	0.000831	0.18	0.2	Depressive symptoms;	chr5:88394130	chr5:88268895~88436685:+
THCA	cis	rs6441286	1	rs6441286	ENSG00000244040.4	IL12A-AS1	-4.52	7.93e-06	0.000831	-0.25	-0.2	Primary biliary cholangitis;	chr3:160011091	chr3:159913400~160225299:-
THCA	cis	rs6441286	1	rs9877910	ENSG00000244040.4	IL12A-AS1	-4.52	7.93e-06	0.000831	-0.25	-0.2	Primary biliary cholangitis;	chr3:160013032	chr3:159913400~160225299:-
THCA	cis	rs11846409	0.86	rs1974470	ENSG00000274576.2	IGHV2-70	-4.52	7.93e-06	0.000831	-0.18	-0.2	Rheumatic heart disease;	chr14:106621300	chr14:106770577~106771020:-
THCA	cis	rs62246343	0.541	rs2596937	ENSG00000254485.4	RP11-380O24.1	4.52	7.93e-06	0.000831	0.23	0.2	Fibrinogen levels;	chr3:9439222	chr3:9292588~9363303:-
THCA	cis	rs10090774	0.965	rs7839697	ENSG00000279766.1	RP11-642A1.2	4.52	7.93e-06	0.000832	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140804566	chr8:140572142~140572812:-
THCA	cis	rs5758511	0.68	rs5758699	ENSG00000227370.1	RP4-669P10.19	4.52	7.93e-06	0.000832	0.21	0.2	Birth weight;	chr22:42292028	chr22:42132543~42132998:+
THCA	cis	rs7246657	0.722	rs958305	ENSG00000267422.1	CTD-2554C21.1	4.52	7.93e-06	0.000832	0.22	0.2	Coronary artery calcification;	chr19:37698539	chr19:37779686~37792865:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000164669.11	INTS4P1	-4.52	7.93e-06	0.000832	-0.26	-0.2	Aortic root size;	chr7:65960907	chr7:65141225~65234216:+
THCA	cis	rs77637988	0.578	rs6718068	ENSG00000202227.1	RNU6-282P	4.52	7.94e-06	0.000832	0.21	0.2	Joint mobility (Beighton score);	chr2:48377839	chr2:48501922~48502024:-
THCA	cis	rs10090774	0.786	rs11776239	ENSG00000279766.1	RP11-642A1.2	-4.52	7.94e-06	0.000832	-0.25	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708602	chr8:140572142~140572812:-
THCA	cis	rs889398	0.677	rs68161338	ENSG00000226232.7	RP11-419C5.2	4.52	7.94e-06	0.000832	0.2	0.2	Body mass index;	chr16:69789875	chr16:69976388~69996188:-
THCA	cis	rs11332131	1	rs11332131	ENSG00000267302.4	RP11-178C3.2	4.52	7.94e-06	0.000832	0.24	0.2	Platelet distribution width;	chr17:59849031	chr17:59964832~59996972:+
THCA	cis	rs7267979	1	rs6076339	ENSG00000274973.1	RP13-401N8.7	4.52	7.94e-06	0.000832	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25845497~25845862:+
THCA	cis	rs2439831	0.681	rs2278859	ENSG00000166763.7	STRCP1	4.52	7.94e-06	0.000832	0.27	0.2	Lung cancer in ever smokers;	chr15:43340762	chr15:43699488~43718184:-
THCA	cis	rs2688608	1	rs2688610	ENSG00000271816.1	BMS1P4	-4.52	7.94e-06	0.000833	-0.19	-0.2	Inflammatory bowel disease;	chr10:73895173	chr10:73699151~73730487:-
THCA	cis	rs1046896	0.576	rs8082558	ENSG00000263063.1	RP11-388C12.1	-4.52	7.94e-06	0.000833	-0.24	-0.2	Glycated hemoglobin levels;	chr17:82737625	chr17:82713908~82716255:-
THCA	cis	rs9393777	0.92	rs13207689	ENSG00000220721.1	OR1F12	4.52	7.94e-06	0.000833	0.45	0.2	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28073316~28074233:+
THCA	cis	rs17095355	0.818	rs2501575	ENSG00000203876.8	ADD3-AS1	-4.52	7.94e-06	0.000833	-0.21	-0.2	Biliary atresia;	chr10:110090106	chr10:109940104~110008381:-
THCA	cis	rs12264252	0.623	rs12773636	ENSG00000225484.5	NUTM2B-AS1	-4.52	7.95e-06	0.000833	-0.31	-0.2	Coronary artery disease;	chr10:80502651	chr10:79663088~79826594:-
THCA	cis	rs11157436	0.914	rs7142794	ENSG00000211812.1	TRAV26-2	-4.52	7.95e-06	0.000833	-0.19	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22202583~22203368:+
THCA	cis	rs9326248	0.53	rs510988	ENSG00000280143.1	AP000892.6	4.52	7.95e-06	0.000834	0.33	0.2	Blood protein levels;	chr11:116943088	chr11:117204967~117210292:+
THCA	cis	rs9810089	0.749	rs664088	ENSG00000273455.1	RP11-305O4.3	4.52	7.96e-06	0.000834	0.27	0.2	Gestational age at birth (child effect);	chr3:136318144	chr3:136087475~136087913:-
THCA	cis	rs2412819	0.597	rs7181912	ENSG00000166763.7	STRCP1	-4.52	7.96e-06	0.000834	-0.27	-0.2	Lung cancer;	chr15:43770676	chr15:43699488~43718184:-
THCA	cis	rs11976180	1	rs11976037	ENSG00000244198.4	RP4-545C24.1	-4.52	7.96e-06	0.000834	-0.21	-0.2	Obesity-related traits;	chr7:144043931	chr7:144194858~144280547:+
THCA	cis	rs116248771	0.739	rs116045655	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000834	0.26	0.2	diarrhoeal disease at age 2;	chr3:158617579	chr3:158782547~158783124:+
THCA	cis	rs9902453	0.902	rs4075014	ENSG00000263370.1	RP11-68I3.5	4.52	7.96e-06	0.000834	0.27	0.2	Coffee consumption (cups per day);	chr17:29978656	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs12602258	ENSG00000263370.1	RP11-68I3.5	4.52	7.96e-06	0.000834	0.27	0.2	Coffee consumption (cups per day);	chr17:29990639	chr17:29639627~29640825:+
THCA	cis	rs10090774	1	rs4291312	ENSG00000279766.1	RP11-642A1.2	4.52	7.96e-06	0.000835	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140816039	chr8:140572142~140572812:-
THCA	cis	rs116248771	0.739	rs73156423	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158627839	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs76493374	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158627850	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs73156425	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158627888	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs73156426	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158628500	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs73156428	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158628682	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs12630515	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158628826	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs12639329	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158629356	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.793	rs6765967	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158629521	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs6801874	ENSG00000271778.1	RP11-379F4.8	4.52	7.96e-06	0.000835	0.26	0.2	diarrhoeal disease at age 2;	chr3:158629607	chr3:158782547~158783124:+
THCA	cis	rs911119	0.837	rs2208289	ENSG00000270001.1	RP11-218C14.8	4.52	7.97e-06	0.000835	0.3	0.2	Chronic kidney disease;	chr20:23598889	chr20:23631826~23632316:-
THCA	cis	rs4713118	0.955	rs9468204	ENSG00000220721.1	OR1F12	4.52	7.97e-06	0.000835	0.26	0.2	Parkinson's disease;	chr6:27721030	chr6:28073316~28074233:+
THCA	cis	rs2129782	0.85	rs12676132	ENSG00000253553.4	RP11-586K2.1	4.52	7.97e-06	0.000835	0.34	0.2	Electrodermal activity;	chr8:88550959	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.85	rs1487962	ENSG00000253553.4	RP11-586K2.1	4.52	7.97e-06	0.000835	0.34	0.2	Electrodermal activity;	chr8:88551591	chr8:88326836~88737134:+
THCA	cis	rs13034020	0.522	rs12988616	ENSG00000271889.1	RP11-493E12.1	-4.52	7.97e-06	0.000835	-0.26	-0.2	Hodgkin's lymphoma;	chr2:61017528	chr2:61151433~61162105:-
THCA	cis	rs6477918	0.598	rs7038491	ENSG00000230185.4	C9orf147	-4.52	7.97e-06	0.000835	-0.22	-0.2	Obstetric antiphospholipid syndrome;	chr9:112433834	chr9:112433816~112487204:-
THCA	cis	rs9863	0.931	rs4765335	ENSG00000269997.1	RP11-214K3.21	-4.52	7.97e-06	0.000836	-0.24	-0.2	White blood cell count;	chr12:123946265	chr12:123966077~123966629:-
THCA	cis	rs13178541	0.872	rs11950260	ENSG00000250378.1	RP11-119J18.1	-4.52	7.97e-06	0.000836	-0.24	-0.2	IgG glycosylation;	chr5:135809171	chr5:135812667~135826582:+
THCA	cis	rs2380220	0.51	rs9387562	ENSG00000261366.1	MANEA-AS1	-4.52	7.98e-06	0.000836	-0.2	-0.2	Behavioural disinhibition (generation interaction);	chr6:95609130	chr6:95575183~95577450:-
THCA	cis	rs8024893	1	rs6493544	ENSG00000270055.1	CTD-3092A11.2	4.52	7.98e-06	0.000836	0.26	0.2	Red cell distribution width;	chr15:31245356	chr15:30487963~30490313:+
THCA	cis	rs2243480	1	rs781149	ENSG00000232559.3	GS1-124K5.12	4.52	7.98e-06	0.000836	0.3	0.2	Diabetic kidney disease;	chr7:66016297	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000232559.3	GS1-124K5.12	4.52	7.98e-06	0.000836	0.3	0.2	Diabetic kidney disease;	chr7:66021736	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1167613	ENSG00000232559.3	GS1-124K5.12	4.52	7.98e-06	0.000836	0.3	0.2	Diabetic kidney disease;	chr7:66022452	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs313799	ENSG00000232559.3	GS1-124K5.12	4.52	7.98e-06	0.000836	0.3	0.2	Diabetic kidney disease;	chr7:66029343	chr7:66554588~66576923:-
THCA	cis	rs7914558	0.966	rs10786719	ENSG00000236937.2	PTGES3P4	-4.52	7.98e-06	0.000836	-0.26	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878235	chr10:102845595~102845950:+
THCA	cis	rs2466254	0.53	rs2280454	ENSG00000251468.2	RP11-369K16.1	-4.52	7.98e-06	0.000837	-0.3	-0.2	Pneumonia;	chr8:12979320	chr8:12958387~12962200:+
THCA	cis	rs453301	0.653	rs1562211	ENSG00000233609.3	RP11-62H7.2	-4.52	7.98e-06	0.000837	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9044914	chr8:8961200~8979025:+
THCA	cis	rs7520050	0.931	rs6698247	ENSG00000234329.1	RP11-767N6.2	-4.52	7.98e-06	0.000837	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs6675946	ENSG00000234329.1	RP11-767N6.2	-4.52	7.98e-06	0.000837	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs7526678	ENSG00000234329.1	RP11-767N6.2	-4.52	7.98e-06	0.000837	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.931	rs6686134	ENSG00000234329.1	RP11-767N6.2	-4.52	7.98e-06	0.000837	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.951	rs2228500	ENSG00000258273.1	RP11-370I10.4	-4.52	7.98e-06	0.000837	-0.29	-0.2	Longevity (90 years and older);	chr12:48132929	chr12:48333755~48333901:-
THCA	cis	rs13113518	0.902	rs11133386	ENSG00000249700.7	SRD5A3-AS1	4.52	7.98e-06	0.000837	0.25	0.2	Height;	chr4:55461320	chr4:55363971~55395847:-
THCA	cis	rs829880	0.558	rs249817	ENSG00000245017.2	RP11-181C3.1	4.52	7.98e-06	0.000837	0.26	0.2	Colonoscopy-negative controls vs population controls;	chr12:98503132	chr12:98485544~98503855:-
THCA	cis	rs829880	0.558	rs249820	ENSG00000245017.2	RP11-181C3.1	4.52	7.98e-06	0.000837	0.26	0.2	Colonoscopy-negative controls vs population controls;	chr12:98503695	chr12:98485544~98503855:-
THCA	cis	rs829880	0.558	rs249821	ENSG00000245017.2	RP11-181C3.1	4.52	7.98e-06	0.000837	0.26	0.2	Colonoscopy-negative controls vs population controls;	chr12:98504033	chr12:98485544~98503855:-
THCA	cis	rs1005277	0.522	rs289643	ENSG00000276805.1	RP11-291L22.6	4.52	7.99e-06	0.000837	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs34288524	ENSG00000263064.2	RP11-291L22.7	4.52	7.99e-06	0.000837	0.33	0.2	Obesity (extreme);	chr10:37655379	chr10:38448689~38448949:+
THCA	cis	rs375066	0.539	rs11878787	ENSG00000267058.1	RP11-15A1.3	4.52	7.99e-06	0.000837	0.19	0.2	Breast cancer;	chr19:43826088	chr19:43891804~43901805:-
THCA	cis	rs2617170	0.922	rs2250877	ENSG00000245648.1	RP11-277P12.20	4.52	7.99e-06	0.000837	0.22	0.2	Behcet's disease;	chr12:10393659	chr12:10363769~10398506:+
THCA	cis	rs2562456	0.834	rs2650848	ENSG00000268117.1	VN1R84P	4.52	7.99e-06	0.000837	0.32	0.2	Pain;	chr19:21403835	chr19:21719801~21720035:-
THCA	cis	rs17270561	0.585	rs9393663	ENSG00000272462.2	U91328.19	-4.52	7.99e-06	0.000837	-0.18	-0.2	Iron status biomarkers;	chr6:25740805	chr6:25992662~26001775:+
THCA	cis	rs4906332	0.782	rs2236281	ENSG00000269910.1	RP11-73M18.10	4.52	7.99e-06	0.000838	0.2	0.2	Coronary artery disease;	chr14:103534181	chr14:103694516~103695050:-
THCA	cis	rs7474896	0.559	rs1735629	ENSG00000226578.1	RP11-258F22.1	4.52	7.99e-06	0.000838	0.28	0.2	Obesity (extreme);	chr10:37889381	chr10:37775371~37784131:-
THCA	cis	rs5758511	0.68	rs5758657	ENSG00000227370.1	RP4-669P10.19	4.52	7.99e-06	0.000838	0.23	0.2	Birth weight;	chr22:42222663	chr22:42132543~42132998:+
THCA	cis	rs5758511	0.68	rs1033459	ENSG00000227370.1	RP4-669P10.19	4.52	7.99e-06	0.000838	0.23	0.2	Birth weight;	chr22:42223061	chr22:42132543~42132998:+
THCA	cis	rs7182948	0.914	rs74406736	ENSG00000259531.2	RP11-295H24.3	4.52	8e-06	0.000838	0.26	0.2	Lung adenocarcinoma;	chr15:49616880	chr15:49365124~49366685:-
THCA	cis	rs1005277	0.522	rs289645	ENSG00000276805.1	RP11-291L22.6	4.52	8e-06	0.000838	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:38451030~38451785:+
THCA	cis	rs7829975	0.806	rs2428	ENSG00000254340.1	RP11-10A14.3	4.52	8e-06	0.000838	0.22	0.2	Mood instability;	chr8:8783635	chr8:9141424~9145435:+
THCA	cis	rs887864	0.596	rs7184093	ENSG00000274038.1	RP11-66H6.4	-4.52	8e-06	0.000838	-0.25	-0.2	Allergic rhinitis;	chr16:11003992	chr16:11056556~11057034:+
THCA	cis	rs2467099	0.504	rs2608881	ENSG00000267801.1	RP11-552F3.9	4.52	8e-06	0.000838	0.25	0.2	Systolic blood pressure;	chr17:75940572	chr17:75876372~75879546:+
THCA	cis	rs2904524	1	rs7300901	ENSG00000257815.4	RP11-611E13.2	-4.52	8e-06	0.000838	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70323451	chr12:69904033~70243360:-
THCA	cis	rs4934494	0.768	rs1409357	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89669719	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs17125834	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89673405	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs12571918	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89674920	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs12776306	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89676300	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs7078321	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89678341	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs34379399	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89683526	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs17126269	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89694974	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs768805	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89695448	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs12571268	ENSG00000240996.1	RP11-80H5.7	-4.52	8e-06	0.000838	-0.23	-0.2	Red blood cell count;	chr10:89698830	chr10:89694295~89697928:-
THCA	cis	rs6840258	0.64	rs17012517	ENSG00000251411.1	RP11-397E7.4	-4.52	8e-06	0.000838	-0.24	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87149332	chr4:86913266~86914817:-
THCA	cis	rs6449502	0.764	rs13358053	ENSG00000251279.1	CTC-436P18.1	4.52	8e-06	0.000839	0.34	0.2	Mean platelet volume;	chr5:60753750	chr5:61162070~61232040:+
THCA	cis	rs36093844	0.8	rs78356210	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85870224	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.605	rs79719453	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85871174	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs113529766	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85872358	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs76464398	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85872855	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs116940726	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873009	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs1445505	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873679	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs1445504	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873836	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs1445503	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873968	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.698	rs79435802	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85874163	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs79814326	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85874530	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs75334800	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85875538	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs77497327	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85875898	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs79276445	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85876784	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs78681528	ENSG00000279742.1	RP11-700A24.1	-4.52	8e-06	0.000839	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85877113	chr11:85852557~85854943:-
THCA	cis	rs11846409	0.86	rs59055020	ENSG00000274576.2	IGHV2-70	-4.52	8.01e-06	0.000839	-0.17	-0.2	Rheumatic heart disease;	chr14:106631573	chr14:106770577~106771020:-
THCA	cis	rs2191566	0.922	rs7245749	ENSG00000266921.1	RP11-15A1.7	-4.52	8.01e-06	0.000839	-0.19	-0.2	Acute lymphoblastic leukemia (childhood);	chr19:44009780	chr19:43996896~44002836:-
THCA	cis	rs17772222	0.501	rs17124889	ENSG00000258983.2	RP11-507K2.2	4.52	8.01e-06	0.000839	0.23	0.2	Coronary artery calcification;	chr14:88834557	chr14:88499334~88515502:+
THCA	cis	rs3128341	1	rs3128341	ENSG00000227207.2	RPL31P12	-4.52	8.01e-06	0.000839	-0.31	-0.2	Intelligence (multi-trait analysis);	chr1:72284165	chr1:72301472~72301829:+
THCA	cis	rs8177376	0.834	rs12287976	ENSG00000254905.1	RP11-712L6.7	4.52	8.01e-06	0.000839	0.28	0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126302693	chr11:126292922~126294254:-
THCA	cis	rs4803480	0.786	rs4803479	ENSG00000267107.5	PCAT19	4.52	8.01e-06	0.000839	0.21	0.2	Schizophrenia;	chr19:41551234	chr19:41454169~41500649:-
THCA	cis	rs7537765	1	rs12567136	ENSG00000242349.4	NPPA-AS1	4.52	8.01e-06	0.000839	0.28	0.2	QRS complex (12-leadsum);	chr1:11823674	chr1:11841017~11848079:+
THCA	cis	rs9329221	0.65	rs657913	ENSG00000261451.1	RP11-981G7.1	-4.52	8.01e-06	0.00084	-0.25	-0.2	Neuroticism;	chr8:10025065	chr8:10433672~10438312:+
THCA	cis	rs7617480	0.648	rs9859473	ENSG00000228638.1	FCF1P2	-4.51	8.02e-06	0.00084	-0.24	-0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48799749	chr3:48290793~48291375:-
THCA	cis	rs42648	0.869	rs42609	ENSG00000225498.1	AC002064.5	4.51	8.02e-06	0.00084	0.21	0.2	Homocysteine levels;	chr7:90320541	chr7:90312496~90322592:+
THCA	cis	rs911555	0.713	rs10162425	ENSG00000269910.1	RP11-73M18.10	4.51	8.02e-06	0.00084	0.19	0.2	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103694516~103695050:-
THCA	cis	rs42648	0.869	rs1134956	ENSG00000225498.1	AC002064.5	4.51	8.02e-06	0.00084	0.21	0.2	Homocysteine levels;	chr7:90309366	chr7:90312496~90322592:+
THCA	cis	rs1003719	0.762	rs1155786	ENSG00000230366.8	DSCR9	-4.51	8.02e-06	0.00084	-0.21	-0.2	Eye color traits;	chr21:37075725	chr21:37208503~37221736:+
THCA	cis	rs11846409	0.652	rs10143549	ENSG00000274576.2	IGHV2-70	-4.51	8.02e-06	0.00084	-0.17	-0.2	Rheumatic heart disease;	chr14:106644643	chr14:106770577~106771020:-
THCA	cis	rs1923243	0.681	rs12126618	ENSG00000223479.3	RP4-788P17.1	4.51	8.02e-06	0.00084	0.22	0.2	Migraine;	chr1:73023722	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.619	rs11210105	ENSG00000223479.3	RP4-788P17.1	4.51	8.02e-06	0.00084	0.22	0.2	Migraine;	chr1:73032270	chr1:73635216~73715214:+
THCA	cis	rs656319	0.625	rs4526366	ENSG00000261451.1	RP11-981G7.1	-4.51	8.03e-06	0.000841	-0.27	-0.2	Myopia (pathological);	chr8:10032669	chr8:10433672~10438312:+
THCA	cis	rs10090774	0.965	rs10094003	ENSG00000279766.1	RP11-642A1.2	-4.51	8.03e-06	0.000841	-0.25	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140847055	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs4445273	ENSG00000279766.1	RP11-642A1.2	4.51	8.03e-06	0.000841	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140740574	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs4246123	ENSG00000279766.1	RP11-642A1.2	4.51	8.03e-06	0.000841	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140765069	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs7826800	ENSG00000279766.1	RP11-642A1.2	4.51	8.03e-06	0.000841	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140828313	chr8:140572142~140572812:-
THCA	cis	rs1479090	0.722	rs11941116	ENSG00000250027.1	RP11-563E2.2	-4.51	8.03e-06	0.000841	-0.21	-0.2	Lung cancer;	chr4:163092755	chr4:163108785~163119965:+
THCA	cis	rs1479090	0.762	rs1947794	ENSG00000250027.1	RP11-563E2.2	-4.51	8.03e-06	0.000841	-0.21	-0.2	Lung cancer;	chr4:163092815	chr4:163108785~163119965:+
THCA	cis	rs868036	0.681	rs4548812	ENSG00000270964.1	RP11-502I4.3	-4.51	8.03e-06	0.000841	-0.18	-0.2	Restless legs syndrome;	chr15:67768214	chr15:67541072~67542604:-
THCA	cis	rs9902453	0.904	rs12936302	ENSG00000263370.1	RP11-68I3.5	-4.51	8.03e-06	0.000841	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30022458	chr17:29639627~29640825:+
THCA	cis	rs3740713	1	rs35593189	ENSG00000256464.1	YWHABP2	4.51	8.04e-06	0.000842	0.36	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr11:18490243~18490955:-
THCA	cis	rs8054556	0.513	rs12596042	ENSG00000183604.13	SMG1P5	-4.51	8.04e-06	0.000842	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29923433	chr16:30267553~30335374:-
THCA	cis	rs7621331	1	rs6786769	ENSG00000273486.1	RP11-731C17.2	4.51	8.04e-06	0.000842	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135994927	chr3:136837338~136839021:-
THCA	cis	rs80067372	0.565	rs12452603	ENSG00000233223.2	AC113189.5	-4.51	8.04e-06	0.000842	-0.19	-0.2	Chin dimples;	chr17:7601659	chr17:7581964~7584072:-
THCA	cis	rs7726354	0.793	rs73756773	ENSG00000271828.1	CTD-2310F14.1	4.51	8.04e-06	0.000842	0.52	0.2	Breast cancer (early onset);	chr5:56707024	chr5:56927874~56929573:+
THCA	cis	rs7726354	0.793	rs57841600	ENSG00000271828.1	CTD-2310F14.1	4.51	8.04e-06	0.000842	0.52	0.2	Breast cancer (early onset);	chr5:56709238	chr5:56927874~56929573:+
THCA	cis	rs7726354	0.793	rs60588964	ENSG00000271828.1	CTD-2310F14.1	4.51	8.04e-06	0.000842	0.52	0.2	Breast cancer (early onset);	chr5:56710181	chr5:56927874~56929573:+
THCA	cis	rs2886497	0.894	rs11013455	ENSG00000224215.1	RP11-371A19.2	-4.51	8.04e-06	0.000842	-0.26	-0.2	Major depression and alcohol dependence;	chr10:23403608	chr10:23343957~23345181:+
THCA	cis	rs7772486	0.727	rs4896843	ENSG00000270638.1	RP3-466P17.1	-4.51	8.05e-06	0.000843	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145735570~145737218:+
THCA	cis	rs9329221	0.683	rs525726	ENSG00000261451.1	RP11-981G7.1	-4.51	8.05e-06	0.000843	-0.25	-0.2	Neuroticism;	chr8:10030287	chr8:10433672~10438312:+
THCA	cis	rs2015599	0.54	rs12301475	ENSG00000273680.1	RP11-996F15.6	-4.51	8.05e-06	0.000843	-0.29	-0.2	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29332733~29333383:-
THCA	cis	rs758324	0.704	rs31480	ENSG00000224431.1	AC063976.7	-4.51	8.05e-06	0.000843	-0.19	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132060639	chr5:132199456~132203487:+
THCA	cis	rs375066	0.935	rs387689	ENSG00000278917.1	RP11-15A1.4	-4.51	8.05e-06	0.000843	-0.17	-0.2	Breast cancer;	chr19:43915959	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs398193	ENSG00000278917.1	RP11-15A1.4	-4.51	8.05e-06	0.000843	-0.17	-0.2	Breast cancer;	chr19:43916268	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs450308	ENSG00000278917.1	RP11-15A1.4	-4.51	8.05e-06	0.000843	-0.17	-0.2	Breast cancer;	chr19:43918206	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs424729	ENSG00000278917.1	RP11-15A1.4	-4.51	8.05e-06	0.000843	-0.17	-0.2	Breast cancer;	chr19:43918650	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs423320	ENSG00000278917.1	RP11-15A1.4	-4.51	8.05e-06	0.000843	-0.17	-0.2	Breast cancer;	chr19:43918830	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs423752	ENSG00000278917.1	RP11-15A1.4	-4.51	8.05e-06	0.000843	-0.17	-0.2	Breast cancer;	chr19:43919043	chr19:43891233~43895411:+
THCA	cis	rs1979679	0.918	rs3858544	ENSG00000278733.1	RP11-425D17.1	-4.51	8.05e-06	0.000843	-0.2	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28442911	chr12:28185625~28186190:-
THCA	cis	rs8017455	0.523	rs10147011	ENSG00000259167.2	NMNAT1P1	4.51	8.05e-06	0.000843	0.3	0.2	Hair morphology;	chr14:81090935	chr14:81032529~81033404:+
THCA	cis	rs997295	0.592	rs12594849	ENSG00000270964.1	RP11-502I4.3	-4.51	8.05e-06	0.000843	-0.17	-0.2	Motion sickness;	chr15:67424234	chr15:67541072~67542604:-
THCA	cis	rs9880211	1	rs6768743	ENSG00000239213.4	NCK1-AS1	-4.51	8.05e-06	0.000843	-0.22	-0.2	Height;Body mass index;	chr3:136486165	chr3:136841726~136862054:-
THCA	cis	rs1552244	1	rs17032299	ENSG00000180385.7	EMC3-AS1	4.51	8.05e-06	0.000843	0.22	0.2	Alzheimer's disease;	chr3:10045954	chr3:9986893~10006990:+
THCA	cis	rs8067545	0.636	rs11204300	ENSG00000270091.1	RP11-78O7.2	4.51	8.05e-06	0.000843	0.15	0.2	Schizophrenia;	chr17:20292125	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs11653869	ENSG00000270091.1	RP11-78O7.2	4.51	8.05e-06	0.000843	0.15	0.2	Schizophrenia;	chr17:20294273	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs1373146	ENSG00000270091.1	RP11-78O7.2	4.51	8.05e-06	0.000843	0.15	0.2	Schizophrenia;	chr17:20303362	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.516	rs11869258	ENSG00000270091.1	RP11-78O7.2	4.51	8.05e-06	0.000843	0.15	0.2	Schizophrenia;	chr17:20303585	chr17:19896590~19897287:-
THCA	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-4.51	8.05e-06	0.000843	-0.23	-0.2	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
THCA	cis	rs807029	0.533	rs67813203	ENSG00000236662.1	RP11-108L7.4	4.51	8.06e-06	0.000844	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100980507~100985614:-
THCA	cis	rs7267979	0.789	rs2260197	ENSG00000274414.1	RP5-965G21.4	-4.51	8.06e-06	0.000844	-0.24	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:25239007~25245229:-
THCA	cis	rs11955398	0.502	rs42437	ENSG00000272308.1	RP11-231G3.1	-4.51	8.06e-06	0.000844	-0.21	-0.2	Intelligence (multi-trait analysis);	chr5:61052219	chr5:60866457~60866935:-
THCA	cis	rs1050288	0.525	rs10743608	ENSG00000256377.4	RP11-1060J15.4	-4.51	8.06e-06	0.000844	-0.3	-0.2	Pulse pressure;Resting heart rate;	chr12:27786422	chr12:27696388~27710770:-
THCA	cis	rs1728785	1	rs698719	ENSG00000274698.1	RP11-71L14.4	4.51	8.06e-06	0.000844	0.28	0.2	Ulcerative colitis;	chr16:68526222	chr16:68450283~68452318:+
THCA	cis	rs4650994	0.593	rs10798618	ENSG00000273384.1	RP5-1098D14.1	-4.51	8.06e-06	0.000844	-0.27	-0.2	HDL cholesterol;HDL cholesterol levels;	chr1:178549989	chr1:178651706~178652282:+
THCA	cis	rs16839793	1	rs16839793	ENSG00000248724.5	NPHP3-AS1	-4.51	8.06e-06	0.000844	-0.27	-0.2	Number of pregnancies;	chr3:132903813	chr3:132721750~132874223:+
THCA	cis	rs72843506	0.586	rs61749865	ENSG00000261033.1	RP11-209D14.2	4.51	8.06e-06	0.000844	0.39	0.2	Schizophrenia;	chr17:19931799	chr17:20008051~20009234:-
THCA	cis	rs807029	0.533	rs3740485	ENSG00000236662.1	RP11-108L7.4	4.51	8.06e-06	0.000844	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100980507~100985614:-
THCA	cis	rs807029	0.533	rs3740486	ENSG00000236662.1	RP11-108L7.4	4.51	8.06e-06	0.000844	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100980507~100985614:-
THCA	cis	rs807029	0.533	rs3740487	ENSG00000236662.1	RP11-108L7.4	4.51	8.06e-06	0.000844	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100980507~100985614:-
THCA	cis	rs1003719	0.715	rs2835667	ENSG00000230366.8	DSCR9	4.51	8.06e-06	0.000844	0.21	0.2	Eye color traits;	chr21:37207613	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs2835668	ENSG00000230366.8	DSCR9	4.51	8.06e-06	0.000844	0.21	0.2	Eye color traits;	chr21:37207850	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.68	rs2835670	ENSG00000230366.8	DSCR9	4.51	8.06e-06	0.000844	0.21	0.2	Eye color traits;	chr21:37208813	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.646	rs2835671	ENSG00000230366.8	DSCR9	4.51	8.06e-06	0.000844	0.21	0.2	Eye color traits;	chr21:37208824	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.646	rs2835672	ENSG00000230366.8	DSCR9	4.51	8.06e-06	0.000844	0.21	0.2	Eye color traits;	chr21:37208933	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.707	rs9976360	ENSG00000230366.8	DSCR9	4.51	8.06e-06	0.000844	0.21	0.2	Eye color traits;	chr21:37215559	chr21:37208503~37221736:+
THCA	cis	rs17597773	0.598	rs11118616	ENSG00000238078.1	LINC01352	-4.51	8.06e-06	0.000844	-0.29	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220832314	chr1:220829255~220832429:+
THCA	cis	rs5758511	0.68	rs1107554	ENSG00000230107.1	CTA-126B4.7	-4.51	8.07e-06	0.000845	-0.24	-0.2	Birth weight;	chr22:42271588	chr22:42438023~42446195:+
THCA	cis	rs7246657	0.551	rs10404069	ENSG00000276846.1	CTD-3220F14.3	4.51	8.07e-06	0.000845	0.25	0.2	Coronary artery calcification;	chr19:37147502	chr19:37314868~37315620:-
THCA	cis	rs12760731	0.582	rs6700741	ENSG00000213057.5	C1orf220	4.51	8.07e-06	0.000845	0.22	0.2	Obesity-related traits;	chr1:178597251	chr1:178542752~178548889:+
THCA	cis	rs75422866	0.867	rs73102188	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47662993	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102195	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47666309	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102201	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47669269	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104103	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47669604	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104104	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47671986	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104111	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47673994	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104115	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47684843	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104116	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47685023	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104138	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47692302	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.717	rs73104143	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47693449	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104144	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47694390	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104148	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47696732	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104152	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47699091	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73104155	ENSG00000276691.1	RP5-1057I20.5	4.51	8.07e-06	0.000845	0.36	0.2	Pneumonia;	chr12:47700790	chr12:47788426~47788971:+
THCA	cis	rs858239	0.6	rs6461692	ENSG00000226816.2	AC005082.12	4.51	8.07e-06	0.000845	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23206013~23208045:+
THCA	cis	rs10483853	0.806	rs10135747	ENSG00000258695.2	RP3-414A15.2	-4.51	8.07e-06	0.000845	-0.28	-0.2	Coronary artery calcification;	chr14:73422744	chr14:73522878~73530610:+
THCA	cis	rs2412819	0.571	rs4923964	ENSG00000166763.7	STRCP1	-4.51	8.07e-06	0.000845	-0.27	-0.2	Lung cancer;	chr15:43722882	chr15:43699488~43718184:-
THCA	cis	rs9543976	1	rs3818355	ENSG00000261105.4	LMO7-AS1	4.51	8.07e-06	0.000845	0.3	0.2	Diabetic retinopathy;	chr13:75622731	chr13:75604700~75635994:-
THCA	cis	rs8031584	0.679	rs34017474	ENSG00000215302.7	CTD-3092A11.1	-4.51	8.07e-06	0.000845	-0.23	-0.2	Huntington's disease progression;	chr15:30938408	chr15:30470779~30507623:+
THCA	cis	rs12497850	0.931	rs13064784	ENSG00000228638.1	FCF1P2	-4.51	8.07e-06	0.000845	-0.22	-0.2	Parkinson's disease;	chr3:49098528	chr3:48290793~48291375:-
THCA	cis	rs7824557	0.815	rs2572430	ENSG00000154316.13	TDH	-4.51	8.07e-06	0.000845	-0.14	-0.2	Retinal vascular caliber;	chr8:11247795	chr8:11339637~11368452:+
THCA	cis	rs9879311	0.966	rs775018	ENSG00000240288.6	GHRLOS	4.51	8.08e-06	0.000845	0.19	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358461	chr3:10285754~10293449:+
THCA	cis	rs2512987	0.76	rs2512988	ENSG00000254731.1	CTD-2005H7.1	-4.51	8.08e-06	0.000845	-0.24	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86702985	chr11:86703099~86714092:+
THCA	cis	rs7246760	0.867	rs67634928	ENSG00000267106.4	ZNF561-AS1	4.51	8.08e-06	0.000845	0.39	0.2	Pursuit maintenance gain;	chr19:9691721	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.737	rs73501268	ENSG00000267106.4	ZNF561-AS1	4.51	8.08e-06	0.000845	0.39	0.2	Pursuit maintenance gain;	chr19:9692405	chr19:9621291~9645896:+
THCA	cis	rs6121246	0.559	rs6119652	ENSG00000230613.1	HM13-AS1	4.51	8.08e-06	0.000845	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31671642	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6060621	ENSG00000230613.1	HM13-AS1	4.51	8.08e-06	0.000845	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31673759	chr20:31567707~31573263:-
THCA	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-4.51	8.08e-06	0.000845	-0.22	-0.2	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
THCA	cis	rs1046491	0.901	rs10853373	ENSG00000264964.1	RP11-888D10.3	4.51	8.08e-06	0.000846	0.34	0.2	Scarlet fever;	chr18:9149417	chr18:9315194~9334441:-
THCA	cis	rs858239	0.539	rs2390757	ENSG00000230042.1	AK3P3	-4.51	8.08e-06	0.000846	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23129178~23129841:+
THCA	cis	rs875971	0.522	rs6960048	ENSG00000234585.5	CCT6P3	4.51	8.08e-06	0.000846	0.18	0.2	Aortic root size;	chr7:65943052	chr7:65038354~65074713:+
THCA	cis	rs8396	0.883	rs17843929	ENSG00000271817.2	U3	4.51	8.08e-06	0.000846	0.24	0.2	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158715961	chr4:158700691~158700909:+
THCA	cis	rs11665867	0.887	rs11666504	ENSG00000279108.1	CTC-490E21.11	-4.51	8.08e-06	0.000846	-0.29	-0.2	Hematocrit;	chr19:40803335	chr19:40840159~40842039:+
THCA	cis	rs990871	0.53	rs1194284	ENSG00000227207.2	RPL31P12	4.51	8.09e-06	0.000846	0.24	0.2	Subcutaneous adipose tissue;	chr1:72246846	chr1:72301472~72301829:+
THCA	cis	rs6832769	0.961	rs28713343	ENSG00000272969.1	RP11-528I4.2	-4.51	8.09e-06	0.000846	-0.24	-0.2	Personality dimensions;	chr4:55590924	chr4:55547112~55547889:+
THCA	cis	rs35740288	0.77	rs11632750	ENSG00000259295.5	CSPG4P12	4.51	8.09e-06	0.000846	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672383	chr15:85191438~85213905:+
THCA	cis	rs72634501	0.622	rs4660416	ENSG00000228060.1	RP11-69E11.8	-4.51	8.09e-06	0.000847	-0.22	-0.2	HDL cholesterol;	chr1:39113314	chr1:39565160~39573203:+
THCA	cis	rs6012564	0.927	rs6019553	ENSG00000230758.1	SNAP23P	-4.51	8.09e-06	0.000847	-0.25	-0.2	Anger;	chr20:48955014	chr20:49038357~49038602:-
THCA	cis	rs41313321	0.512	rs2416981	ENSG00000273186.1	RP11-339B21.10	4.51	8.09e-06	0.000847	0.29	0.2	Coenzyme Q10 levels;	chr9:128279473	chr9:128431598~128432006:+
THCA	cis	rs10904908	0.733	rs359298	ENSG00000229124.5	VIM-AS1	4.51	8.09e-06	0.000847	0.19	0.2	Cholesterol, total;Total cholesterol levels;	chr10:17292177	chr10:17214239~17229985:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000275400.1	RP4-756H11.5	-4.51	8.09e-06	0.000847	-0.19	-0.2	Aortic root size;	chr7:65967557	chr7:66553805~66554199:-
THCA	cis	rs964611	0.882	rs11629725	ENSG00000259488.2	RP11-154J22.1	4.51	8.1e-06	0.000847	0.19	0.2	Metabolite levels (Pyroglutamine);	chr15:48347986	chr15:48312353~48331856:-
THCA	cis	rs9875589	0.509	rs1488375	ENSG00000228242.5	AC093495.4	4.51	8.1e-06	0.000848	0.12	0.2	Ovarian reserve;	chr3:14020063	chr3:14144637~14165978:+
THCA	cis	rs7819412	0.593	rs11778398	ENSG00000206014.6	OR7E161P	4.51	8.1e-06	0.000848	0.25	0.2	Triglycerides;	chr8:11116733	chr8:11928597~11929563:-
THCA	cis	rs11902236	0.545	rs744033	ENSG00000188525.3	AC010969.1	-4.51	8.1e-06	0.000848	-0.25	-0.2	Prostate cancer;	chr2:9984331	chr2:10003158~10006030:-
THCA	cis	rs1577917	0.559	rs2223788	ENSG00000220563.1	PKMP3	-4.51	8.1e-06	0.000848	-0.15	-0.2	Response to antipsychotic treatment;	chr6:86102202	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.523	rs1413724	ENSG00000220563.1	PKMP3	-4.51	8.1e-06	0.000848	-0.15	-0.2	Response to antipsychotic treatment;	chr6:86104831	chr6:85659892~85660606:-
THCA	cis	rs867186	1	rs8119827	ENSG00000126005.14	MMP24-AS1	-4.51	8.1e-06	0.000848	-0.33	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35139070	chr20:35216462~35278131:-
THCA	cis	rs5997397	0.934	rs6005864	ENSG00000272858.1	CTA-292E10.8	4.51	8.1e-06	0.000848	0.2	0.2	Red cell distribution width;	chr22:28761499	chr22:28814914~28815662:+
THCA	cis	rs12410462	0.551	rs6693348	ENSG00000227711.2	RP11-275O4.5	4.51	8.11e-06	0.000848	0.25	0.2	Major depressive disorder;	chr1:227531766	chr1:227509028~227520477:-
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000182586.6	LINC00334	4.51	8.11e-06	0.000848	0.21	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45234340~45258730:+
THCA	cis	rs62158800	0.852	rs60010278	ENSG00000224568.1	AC096669.3	4.51	8.11e-06	0.000849	0.39	0.2	Facial morphology (factor 22);	chr2:107653600	chr2:107529487~107556326:+
THCA	cis	rs13178541	0.81	rs11959218	ENSG00000250378.1	RP11-119J18.1	-4.51	8.11e-06	0.000849	-0.26	-0.2	IgG glycosylation;	chr5:135809526	chr5:135812667~135826582:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-4.51	8.11e-06	0.000849	-0.23	-0.2	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
THCA	cis	rs2018683	0.649	rs221193	ENSG00000272568.4	CTB-113D17.1	4.51	8.11e-06	0.000849	0.21	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28976168	chr7:28979967~29013367:+
THCA	cis	rs61160187	0.548	rs68104763	ENSG00000215032.2	GNL3LP1	4.51	8.11e-06	0.000849	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60891935~60893577:-
THCA	cis	rs9634489	0.619	rs9556562	ENSG00000247400.3	DNAJC3-AS1	-4.51	8.11e-06	0.000849	-0.13	-0.2	Body mass index;	chr13:96324995	chr13:95648733~95676925:-
THCA	cis	rs800160	1	rs2651807	ENSG00000199550.1	Y_RNA	4.51	8.11e-06	0.000849	0.3	0.2	Bacteremia;	chr11:2357610	chr11:2372638~2372750:+
THCA	cis	rs2281603	0.694	rs12385910	ENSG00000272909.1	CTD-2555O16.4	-4.51	8.11e-06	0.000849	-0.26	-0.2	Lymphocyte counts;	chr14:64533252	chr14:64440369~64442238:-
THCA	cis	rs9863	0.828	rs7975482	ENSG00000270061.1	RP11-214K3.19	-4.51	8.12e-06	0.000849	-0.27	-0.2	White blood cell count;	chr12:123997143	chr12:123969990~123970344:-
THCA	cis	rs875971	0.545	rs10950029	ENSG00000273142.1	RP11-458F8.4	4.51	8.12e-06	0.000849	0.19	0.2	Aortic root size;	chr7:66169334	chr7:66902857~66906297:+
THCA	cis	rs4722166	0.532	rs4719711	ENSG00000179428.2	AC073072.5	4.51	8.12e-06	0.00085	0.23	0.2	Lung cancer;	chr7:22716069	chr7:22725395~22727620:-
THCA	cis	rs4948275	0.693	rs1378889	ENSG00000237233.2	TMEM26-AS1	-4.51	8.12e-06	0.00085	-0.26	-0.2	Night sleep phenotypes;	chr10:61575134	chr10:61452639~61481956:+
THCA	cis	rs62246343	0.605	rs9842540	ENSG00000254485.4	RP11-380O24.1	4.51	8.12e-06	0.00085	0.24	0.2	Fibrinogen levels;	chr3:9399389	chr3:9292588~9363303:-
THCA	cis	rs858239	0.601	rs10224327	ENSG00000230042.1	AK3P3	-4.51	8.12e-06	0.00085	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23129178~23129841:+
THCA	cis	rs875971	0.862	rs10256544	ENSG00000229886.1	RP5-1132H15.3	4.51	8.12e-06	0.00085	0.21	0.2	Aortic root size;	chr7:66210141	chr7:66025126~66031544:-
THCA	cis	rs2120243	0.539	rs2047649	ENSG00000241770.1	RP11-555M1.3	-4.51	8.12e-06	0.00085	-0.26	-0.2	Hepatocellular carcinoma in hepatitis B infection;	chr3:157367816	chr3:157163452~157169133:+
THCA	cis	rs7542375	0.534	rs1580685	ENSG00000272823.1	RP11-295M18.6	-4.51	8.12e-06	0.00085	-0.29	-0.2	Obesity-related traits;	chr1:220849052	chr1:220828676~220829211:-
THCA	cis	rs7980687	0.657	rs2851447	ENSG00000256092.2	RP13-942N8.1	4.51	8.12e-06	0.00085	0.15	0.2	Head circumference (infant);Educational attainment;Height;	chr12:123180566	chr12:123363868~123366113:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
THCA	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
THCA	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
THCA	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-4.51	8.12e-06	0.00085	-0.23	-0.2	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
THCA	cis	rs7542375	0.534	rs56369151	ENSG00000238078.1	LINC01352	-4.51	8.13e-06	0.00085	-0.3	-0.2	Obesity-related traits;	chr1:220865711	chr1:220829255~220832429:+
THCA	cis	rs4908768	1	rs4908768	ENSG00000232912.4	RP5-1115A15.1	-4.51	8.13e-06	0.00085	-0.25	-0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594705	chr1:8424645~8434838:+
THCA	cis	rs4908768	1	rs12134896	ENSG00000232912.4	RP5-1115A15.1	-4.51	8.13e-06	0.00085	-0.25	-0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596168	chr1:8424645~8434838:+
THCA	cis	rs5751614	0.537	rs7292656	ENSG00000240160.3	RN7SL263P	4.51	8.13e-06	0.000851	0.26	0.2	Height;	chr22:23287415	chr22:23261782~23262071:-
THCA	cis	rs8031584	0.723	rs11632229	ENSG00000178081.11	ULK4P3	-4.51	8.13e-06	0.000851	-0.26	-0.2	Huntington's disease progression;	chr15:30887331	chr15:30103720~30131757:+
THCA	cis	rs9868809	0.772	rs9811318	ENSG00000270441.1	RP11-694I15.7	4.51	8.13e-06	0.000851	0.25	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48665173	chr3:49140086~49160851:-
THCA	cis	rs13256369	0.59	rs10113115	ENSG00000253893.2	FAM85B	-4.51	8.13e-06	0.000851	-0.27	-0.2	Obesity-related traits;	chr8:8702078	chr8:8167819~8226614:-
THCA	cis	rs9929218	0.559	rs12923775	ENSG00000260459.2	FTLP14	4.51	8.14e-06	0.000851	0.23	0.2	Colorectal cancer;	chr16:68722547	chr16:68822587~68823070:+
THCA	cis	rs4693089	0.604	rs13124479	ENSG00000213608.5	SLC25A14P1	4.51	8.14e-06	0.000851	0.24	0.2	Menopause (age at onset);	chr4:83483243	chr4:83477524~83478424:+
THCA	cis	rs1923243	0.648	rs34477433	ENSG00000223479.3	RP4-788P17.1	4.51	8.14e-06	0.000851	0.22	0.2	Migraine;	chr1:73005117	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.558	rs4344273	ENSG00000223479.3	RP4-788P17.1	4.51	8.14e-06	0.000851	0.22	0.2	Migraine;	chr1:73005950	chr1:73635216~73715214:+
THCA	cis	rs7474896	0.537	rs1208587	ENSG00000263064.2	RP11-291L22.7	-4.51	8.14e-06	0.000852	-0.27	-0.2	Obesity (extreme);	chr10:37918831	chr10:38448689~38448949:+
THCA	cis	rs4934494	0.768	rs12572608	ENSG00000240996.1	RP11-80H5.7	4.51	8.14e-06	0.000852	0.23	0.2	Red blood cell count;	chr10:89647170	chr10:89694295~89697928:-
THCA	cis	rs17221829	0.965	rs7927936	ENSG00000280385.1	AP000648.5	-4.51	8.15e-06	0.000853	-0.2	-0.2	Anxiety in major depressive disorder;	chr11:89727327	chr11:90193614~90198120:+
THCA	cis	rs11671005	0.695	rs8106061	ENSG00000268912.1	CTD-2619J13.17	-4.51	8.15e-06	0.000853	-0.17	-0.2	Mean platelet volume;	chr19:58406623	chr19:58428632~58431148:-
THCA	cis	rs9863	0.794	rs7978610	ENSG00000270061.1	RP11-214K3.19	4.51	8.16e-06	0.000853	0.27	0.2	White blood cell count;	chr12:123984025	chr12:123969990~123970344:-
THCA	cis	rs763121	0.853	rs5757231	ENSG00000273076.1	RP3-508I15.22	-4.51	8.16e-06	0.000853	-0.2	-0.2	Menopause (age at onset);	chr22:38675653	chr22:38743495~38743910:+
THCA	cis	rs10484434	0.818	rs11755492	ENSG00000272462.2	U91328.19	4.51	8.16e-06	0.000853	0.23	0.2	HIV-1 viral setpoint;	chr6:26045930	chr6:25992662~26001775:+
THCA	cis	rs2787702	1	rs2787712	ENSG00000237233.2	TMEM26-AS1	-4.51	8.16e-06	0.000853	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61557969	chr10:61452639~61481956:+
THCA	cis	rs9902453	0.967	rs8067576	ENSG00000263370.1	RP11-68I3.5	4.51	8.16e-06	0.000854	0.26	0.2	Coffee consumption (cups per day);	chr17:30117236	chr17:29639627~29640825:+
THCA	cis	rs654950	0.875	rs633297	ENSG00000230638.4	RP11-486B10.4	-4.51	8.16e-06	0.000854	-0.22	-0.2	Airway imaging phenotypes;	chr1:41519782	chr1:41542069~41544310:+
THCA	cis	rs5758511	0.773	rs7288749	ENSG00000281538.1	RP4-669P10.20	-4.51	8.17e-06	0.000854	-0.24	-0.2	Birth weight;	chr22:41960426	chr22:42138060~42139726:+
THCA	cis	rs7838490	0.504	rs821117	ENSG00000253553.4	RP11-586K2.1	4.51	8.17e-06	0.000854	0.21	0.2	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88467915	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.522	rs1601818	ENSG00000253553.4	RP11-586K2.1	4.51	8.17e-06	0.000854	0.21	0.2	Schizophrenia;	chr8:88471530	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.527	rs1103868	ENSG00000253553.4	RP11-586K2.1	4.51	8.17e-06	0.000854	0.21	0.2	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88476043	chr8:88326836~88737134:+
THCA	cis	rs58605417	0.522	rs2656311	ENSG00000253553.4	RP11-586K2.1	-4.51	8.17e-06	0.000854	-0.21	-0.2	Schizophrenia;	chr8:88485639	chr8:88326836~88737134:+
THCA	cis	rs4415084	0.652	rs10473376	ENSG00000272335.1	RP11-53O19.3	4.51	8.17e-06	0.000854	0.18	0.2	Breast cancer;	chr5:44931126	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs10473377	ENSG00000272335.1	RP11-53O19.3	4.51	8.17e-06	0.000854	0.18	0.2	Breast cancer;	chr5:44931144	chr5:44826076~44828592:+
THCA	cis	rs2562456	0.793	rs2562428	ENSG00000268278.1	RP11-420K14.1	-4.51	8.17e-06	0.000854	-0.25	-0.2	Pain;	chr19:21442652	chr19:21637974~21656300:+
THCA	cis	rs1866631	0.566	rs55913048	ENSG00000238133.5	MLK7-AS1	4.51	8.17e-06	0.000854	0.27	0.2	Lung cancer in ever smokers;	chr2:173189478	chr2:173166446~173282036:-
THCA	cis	rs4886920	0.519	rs75789686	ENSG00000260776.4	RP11-114H24.2	4.51	8.17e-06	0.000854	0.3	0.2	Neuroticism;	chr15:77821235	chr15:77914217~77926846:-
THCA	cis	rs35740288	0.77	rs4843085	ENSG00000259295.5	CSPG4P12	4.51	8.17e-06	0.000854	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85615268	chr15:85191438~85213905:+
THCA	cis	rs4713118	0.824	rs742046	ENSG00000226314.6	ZNF192P1	-4.51	8.17e-06	0.000855	-0.27	-0.2	Parkinson's disease;	chr6:27771475	chr6:28161781~28169594:+
THCA	cis	rs7141336	1	rs6575155	ENSG00000258884.1	CTD-3035D6.2	4.51	8.17e-06	0.000855	0.27	0.2	Anxiety disorder;	chr14:90818596	chr14:90822365~90828128:-
THCA	cis	rs10875746	0.551	rs2054904	ENSG00000226413.2	OR8T1P	4.51	8.17e-06	0.000855	0.29	0.2	Longevity (90 years and older);	chr12:48330571	chr12:48442030~48442947:-
THCA	cis	rs7246760	0.609	rs57889827	ENSG00000267106.4	ZNF561-AS1	4.51	8.17e-06	0.000855	0.4	0.2	Pursuit maintenance gain;	chr19:9666783	chr19:9621291~9645896:+
THCA	cis	rs883924	0.63	rs10993442	ENSG00000231107.1	LINC01508	4.51	8.18e-06	0.000855	0.24	0.2	Hepatitis C induced liver fibrosis;	chr9:90423909	chr9:90300902~90433505:-
THCA	cis	rs883924	0.63	rs10125952	ENSG00000231107.1	LINC01508	4.51	8.18e-06	0.000855	0.24	0.2	Hepatitis C induced liver fibrosis;	chr9:90427959	chr9:90300902~90433505:-
THCA	cis	rs7551222	0.646	rs4951384	ENSG00000240219.1	RP11-430C7.5	4.51	8.18e-06	0.000855	0.2	0.2	Schizophrenia;	chr1:204483386	chr1:204626775~204629712:+
THCA	cis	rs1035144	0.505	rs10145099	ENSG00000258915.1	BHLHB9P1	4.51	8.18e-06	0.000855	0.2	0.2	Male sexual orientation;	chr14:80990350	chr14:80981988~80983638:+
THCA	cis	rs9902453	1	rs12600993	ENSG00000263370.1	RP11-68I3.5	4.51	8.18e-06	0.000855	0.27	0.2	Coffee consumption (cups per day);	chr17:29964204	chr17:29639627~29640825:+
THCA	cis	rs2439831	0.85	rs3097773	ENSG00000205771.5	CATSPER2P1	4.51	8.18e-06	0.000855	0.27	0.2	Lung cancer in ever smokers;	chr15:43600874	chr15:43726918~43747094:-
THCA	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-4.51	8.18e-06	0.000855	-0.24	-0.2	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
THCA	cis	rs1923243	0.649	rs4233096	ENSG00000223479.3	RP4-788P17.1	4.51	8.18e-06	0.000855	0.22	0.2	Migraine;	chr1:72994742	chr1:73635216~73715214:+
THCA	cis	rs797680	0.681	rs4847406	ENSG00000223745.6	RP4-717I23.3	4.51	8.18e-06	0.000856	0.12	0.2	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93292893	chr1:93262186~93346025:-
THCA	cis	rs1790761	0.692	rs614080	ENSG00000255318.1	RP11-655M14.13	4.51	8.18e-06	0.000856	0.22	0.2	Mean corpuscular volume;	chr11:67579816	chr11:67618279~67627304:-
THCA	cis	rs6921919	0.609	rs9461455	ENSG00000273712.1	RP5-874C20.7	4.51	8.19e-06	0.000856	0.23	0.2	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28315613~28315883:-
THCA	cis	rs2304003	1	rs2060167	ENSG00000235192.1	AC009495.2	4.51	8.19e-06	0.000856	0.28	0.2	Social communication problems;	chr2:165832832	chr2:165794851~165810010:+
THCA	cis	rs9300255	0.544	rs1716175	ENSG00000235423.7	RP11-282O18.3	4.51	8.19e-06	0.000856	0.22	0.2	Neutrophil percentage of white cells;	chr12:123173841	chr12:123252030~123261483:-
THCA	cis	rs17095355	1	rs12570612	ENSG00000203876.8	ADD3-AS1	4.51	8.19e-06	0.000857	0.22	0.2	Biliary atresia;	chr10:109957927	chr10:109940104~110008381:-
THCA	cis	rs9788682	0.747	rs6495308	ENSG00000261143.1	ADAMTS7P3	-4.51	8.19e-06	0.000857	-0.27	-0.2	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615314	chr15:77976042~77993057:+
THCA	cis	rs4819052	0.851	rs1056100	ENSG00000273796.1	LL21NC02-21A1.1	-4.51	8.19e-06	0.000857	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45403809~45404369:-
THCA	cis	rs3764021	0.87	rs7970116	ENSG00000214776.8	RP11-726G1.1	-4.51	8.19e-06	0.000857	-0.25	-0.2	Type 1 diabetes;	chr12:9727518	chr12:9467552~9576275:+
THCA	cis	rs7746199	0.736	rs34064842	ENSG00000272009.1	RP1-313I6.12	-4.51	8.2e-06	0.000857	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28078792~28081130:-
THCA	cis	rs12439619	0.508	rs11856561	ENSG00000259429.4	UBE2Q2P2	-4.51	8.2e-06	0.000857	-0.17	-0.2	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82355142~82420075:+
THCA	cis	rs1005277	0.522	rs9418276	ENSG00000226578.1	RP11-258F22.1	-4.51	8.2e-06	0.000857	-0.23	-0.2	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:37775371~37784131:-
THCA	cis	rs1005277	0.522	rs7072977	ENSG00000226578.1	RP11-258F22.1	-4.51	8.2e-06	0.000857	-0.23	-0.2	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:37775371~37784131:-
THCA	cis	rs79040073	0.516	rs10519226	ENSG00000259531.2	RP11-295H24.3	4.51	8.2e-06	0.000857	0.27	0.2	Lung cancer in ever smokers;	chr15:49446036	chr15:49365124~49366685:-
THCA	cis	rs2115630	0.691	rs2292462	ENSG00000176700.18	SCAND2P	-4.51	8.2e-06	0.000857	-0.13	-0.2	P wave terminal force;	chr15:84657523	chr15:84631451~84647478:+
THCA	cis	rs1823874	0.677	rs8042705	ENSG00000182397.13	DNM1P46	-4.51	8.21e-06	0.000858	-0.24	-0.2	IgG glycosylation;	chr15:99824501	chr15:99790156~99806927:-
THCA	cis	rs3825942	0.568	rs9944214	ENSG00000261801.4	LOXL1-AS1	4.51	8.21e-06	0.000858	0.24	0.2	Glaucoma (exfoliation);	chr15:73939516	chr15:73908071~73928248:-
THCA	cis	rs8002861	0.664	rs1466005	ENSG00000274001.1	RP11-5G9.5	4.51	8.21e-06	0.000858	0.24	0.2	Leprosy;	chr13:43850074	chr13:43877715~43878163:-
THCA	cis	rs9467773	0.62	rs2494696	ENSG00000261353.1	CTA-14H9.5	-4.51	8.21e-06	0.000859	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26527063~26527404:+
THCA	cis	rs2028299	0.879	rs7163629	ENSG00000259677.1	RP11-493E3.1	4.51	8.21e-06	0.000859	0.27	0.2	Type 2 diabetes;	chr15:89873508	chr15:89876540~89877285:+
THCA	cis	rs2380220	0.576	rs7751219	ENSG00000261366.1	MANEA-AS1	-4.51	8.21e-06	0.000859	-0.2	-0.2	Behavioural disinhibition (generation interaction);	chr6:95571039	chr6:95575183~95577450:-
THCA	cis	rs3764021	0.527	rs10772062	ENSG00000214776.8	RP11-726G1.1	4.51	8.22e-06	0.000859	0.27	0.2	Type 1 diabetes;	chr12:9712561	chr12:9467552~9576275:+
THCA	cis	rs7942368	1	rs1837679	ENSG00000261578.1	RP11-21L23.2	4.51	8.22e-06	0.000859	0.3	0.2	Endometriosis;	chr11:76790513	chr11:76800364~76804555:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000272831.1	RP11-792A8.4	4.51	8.22e-06	0.000859	0.13	0.2	Aortic root size;	chr7:65930047	chr7:66739829~66740385:-
THCA	cis	rs2018683	0.87	rs13232487	ENSG00000272568.4	CTB-113D17.1	4.51	8.22e-06	0.000859	0.2	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945502	chr7:28979967~29013367:+
THCA	cis	rs1923243	0.59	rs12137741	ENSG00000223479.3	RP4-788P17.1	4.51	8.22e-06	0.000859	0.22	0.2	Migraine;	chr1:73000318	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.59	rs12118981	ENSG00000223479.3	RP4-788P17.1	4.51	8.22e-06	0.000859	0.22	0.2	Migraine;	chr1:73000321	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.648	rs4298682	ENSG00000223479.3	RP4-788P17.1	4.51	8.22e-06	0.000859	0.22	0.2	Migraine;	chr1:73001833	chr1:73635216~73715214:+
THCA	cis	rs11673344	0.504	rs4806407	ENSG00000276846.1	CTD-3220F14.3	-4.51	8.23e-06	0.00086	-0.16	-0.2	Obesity-related traits;	chr19:37097849	chr19:37314868~37315620:-
THCA	cis	rs9902453	1	rs4075623	ENSG00000263370.1	RP11-68I3.5	-4.51	8.23e-06	0.00086	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30059508	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs4795525	ENSG00000263370.1	RP11-68I3.5	-4.51	8.23e-06	0.00086	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30061469	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs4239227	ENSG00000263370.1	RP11-68I3.5	-4.51	8.23e-06	0.00086	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30062085	chr17:29639627~29640825:+
THCA	cis	rs12908161	0.959	rs17598603	ENSG00000275120.1	RP11-182J1.17	-4.51	8.23e-06	0.000861	-0.24	-0.2	Schizophrenia;	chr15:84656980	chr15:84599434~84606463:-
THCA	cis	rs12472274	0.817	rs34791859	ENSG00000279484.1	KLHL30-AS1	4.51	8.24e-06	0.000861	0.23	0.2	Phospholipid levels (plasma);	chr2:238162278	chr2:238152889~238155994:-
THCA	cis	rs4237845	0.611	rs7298370	ENSG00000257159.1	RP11-58A17.3	4.51	8.24e-06	0.000861	0.26	0.2	Intelligence (multi-trait analysis);	chr12:57925114	chr12:57967058~57968399:+
THCA	cis	rs9650657	0.504	rs10108347	ENSG00000206014.6	OR7E161P	4.51	8.24e-06	0.000861	0.24	0.2	Neuroticism;	chr8:11176008	chr8:11928597~11929563:-
THCA	cis	rs8014204	0.905	rs8014289	ENSG00000279594.1	RP11-950C14.10	-4.51	8.24e-06	0.000861	-0.2	-0.2	Caffeine consumption;	chr14:74910649	chr14:75011269~75012851:-
THCA	cis	rs4700393	0.52	rs6896680	ENSG00000251279.1	CTC-436P18.1	-4.51	8.24e-06	0.000861	-0.29	-0.2	Intelligence (multi-trait analysis);	chr5:60695704	chr5:61162070~61232040:+
THCA	cis	rs4916588	0.636	rs60109201	ENSG00000270170.1	NCBP2-AS2	4.51	8.24e-06	0.000861	0.16	0.2	Night sleep phenotypes;	chr3:196888119	chr3:196942623~196943540:+
THCA	cis	rs453301	0.653	rs7016139	ENSG00000233609.3	RP11-62H7.2	-4.51	8.25e-06	0.000862	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9037960	chr8:8961200~8979025:+
THCA	cis	rs8054556	0.765	rs11150574	ENSG00000183604.13	SMG1P5	-4.51	8.25e-06	0.000862	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29923498	chr16:30267553~30335374:-
THCA	cis	rs7924176	0.601	rs3750862	ENSG00000213731.2	RAB5CP1	-4.51	8.25e-06	0.000862	-0.25	-0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74091491	chr10:74423435~74424014:-
THCA	cis	rs2836974	0.563	rs997147	ENSG00000255568.3	BRWD1-AS2	-4.51	8.25e-06	0.000862	-0.17	-0.2	Cognitive function;	chr21:39323399	chr21:39313935~39314962:+
THCA	cis	rs28374715	0.629	rs2118740	ENSG00000247556.5	OIP5-AS1	4.51	8.25e-06	0.000862	0.2	0.2	Ulcerative colitis;	chr15:41285034	chr15:41283990~41309737:+
THCA	cis	rs12935229	1	rs67426384	ENSG00000260922.1	RP11-538I12.3	-4.51	8.25e-06	0.000862	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77292271	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs72801605	ENSG00000260922.1	RP11-538I12.3	-4.51	8.25e-06	0.000862	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77292618	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs35296483	ENSG00000260922.1	RP11-538I12.3	-4.51	8.25e-06	0.000862	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77293121	chr16:77234877~77290934:+
THCA	cis	rs7688540	0.511	rs11731927	ENSG00000211553.1	AC253576.2	-4.51	8.25e-06	0.000862	-0.32	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:136461~136568:+
THCA	cis	rs3740713	1	rs79199586	ENSG00000256464.1	YWHABP2	4.51	8.25e-06	0.000862	0.37	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr11:18490243~18490955:-
THCA	cis	rs8020095	0.571	rs10142059	ENSG00000258561.1	RP11-72M17.1	-4.51	8.25e-06	0.000862	-0.27	-0.2	Depression (quantitative trait);	chr14:67015912	chr14:66212810~66509394:-
THCA	cis	rs728616	0.681	rs12769764	ENSG00000272447.1	RP11-182L21.6	-4.51	8.26e-06	0.000863	-0.26	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80157357	chr10:79825902~79827602:+
THCA	cis	rs11633886	0.622	rs4774811	ENSG00000273972.1	CTD-2306A12.1	-4.51	8.26e-06	0.000863	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45837370	chr15:45702640~45703183:+
THCA	cis	rs2467099	0.504	rs2666005	ENSG00000267801.1	RP11-552F3.9	4.51	8.26e-06	0.000863	0.25	0.2	Systolic blood pressure;	chr17:75948515	chr17:75876372~75879546:+
THCA	cis	rs62025270	0.632	rs8029034	ENSG00000259295.5	CSPG4P12	-4.51	8.26e-06	0.000863	-0.35	-0.2	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85191438~85213905:+
THCA	cis	rs2380220	0.872	rs4546494	ENSG00000261366.1	MANEA-AS1	-4.51	8.26e-06	0.000863	-0.22	-0.2	Behavioural disinhibition (generation interaction);	chr6:95542750	chr6:95575183~95577450:-
THCA	cis	rs1580019	0.52	rs6945238	ENSG00000231952.3	DPY19L1P2	4.51	8.26e-06	0.000863	0.26	0.2	Cognitive ability;	chr7:32606484	chr7:32812757~32838570:+
THCA	cis	rs6988985	0.617	rs7016924	ENSG00000247317.3	RP11-273G15.2	4.51	8.27e-06	0.000863	0.22	0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142924657	chr8:142981738~143018437:-
THCA	cis	rs12681963	0.688	rs16876672	ENSG00000248159.1	HSPA8P11	4.51	8.27e-06	0.000864	0.37	0.2	Migraine;	chr8:30207450	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs7837611	ENSG00000248159.1	HSPA8P11	4.51	8.27e-06	0.000864	0.37	0.2	Migraine;	chr8:30210013	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs7014016	ENSG00000248159.1	HSPA8P11	4.51	8.27e-06	0.000864	0.37	0.2	Migraine;	chr8:30211271	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs73234786	ENSG00000248159.1	HSPA8P11	4.51	8.27e-06	0.000864	0.37	0.2	Migraine;	chr8:30212836	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs12680753	ENSG00000248159.1	HSPA8P11	4.51	8.27e-06	0.000864	0.37	0.2	Migraine;	chr8:30212963	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs55991127	ENSG00000248159.1	HSPA8P11	4.51	8.27e-06	0.000864	0.37	0.2	Migraine;	chr8:30213510	chr8:30237382~30240997:+
THCA	cis	rs5742933	1	rs55792400	ENSG00000253559.1	OSGEPL1-AS1	-4.51	8.27e-06	0.000864	-0.25	-0.2	Ferritin levels;	chr2:189686708	chr2:189762704~189765556:+
THCA	cis	rs5742933	0.947	rs62185871	ENSG00000253559.1	OSGEPL1-AS1	-4.51	8.27e-06	0.000864	-0.25	-0.2	Ferritin levels;	chr2:189686980	chr2:189762704~189765556:+
THCA	cis	rs4591358	0.765	rs2063838	ENSG00000223466.1	AC064834.2	4.51	8.27e-06	0.000864	0.24	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195493578	chr2:195533035~195538681:+
THCA	cis	rs12439619	1	rs12439619	ENSG00000276710.3	CSPG4P8	-4.51	8.27e-06	0.000864	-0.22	-0.2	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82459472~82477258:+
THCA	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-4.51	8.27e-06	0.000864	-0.23	-0.2	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
THCA	cis	rs7772486	0.754	rs697053	ENSG00000270638.1	RP3-466P17.1	-4.51	8.27e-06	0.000864	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145735570~145737218:+
THCA	cis	rs964611	0.882	rs11857977	ENSG00000259488.2	RP11-154J22.1	4.51	8.28e-06	0.000865	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48353478	chr15:48312353~48331856:-
THCA	cis	rs375066	0.935	rs428505	ENSG00000278917.1	RP11-15A1.4	-4.51	8.28e-06	0.000865	-0.17	-0.2	Breast cancer;	chr19:43924759	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs367741	ENSG00000278917.1	RP11-15A1.4	-4.51	8.28e-06	0.000865	-0.17	-0.2	Breast cancer;	chr19:43925028	chr19:43891233~43895411:+
THCA	cis	rs7989336	0.528	rs1927787	ENSG00000247400.3	DNAJC3-AS1	4.51	8.28e-06	0.000865	0.13	0.2	Obesity;	chr13:96275857	chr13:95648733~95676925:-
THCA	cis	rs7583236	0.929	rs3087933	ENSG00000179818.12	PCBP1-AS1	-4.51	8.28e-06	0.000865	-0.2	-0.2	Obesity-related traits;	chr2:69960406	chr2:69962263~70103220:-
THCA	cis	rs6500602	0.535	rs758044	ENSG00000280063.1	RP11-295D4.3	4.51	8.28e-06	0.000865	0.13	0.2	Schizophrenia;	chr16:4381201	chr16:4346694~4348648:-
THCA	cis	rs1979679	0.744	rs2348236	ENSG00000247934.4	RP11-967K21.1	4.51	8.28e-06	0.000865	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28441640	chr12:28163298~28190738:-
THCA	cis	rs3845817	0.966	rs13028180	ENSG00000237979.1	AC007389.1	-4.51	8.28e-06	0.000865	-0.23	-0.2	Bipolar disorder;	chr2:65536906	chr2:65500993~65502138:-
THCA	cis	rs10090774	0.965	rs4961291	ENSG00000279766.1	RP11-642A1.2	4.51	8.29e-06	0.000866	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140767676	chr8:140572142~140572812:-
THCA	cis	rs4722166	0.532	rs4719712	ENSG00000179428.2	AC073072.5	-4.51	8.29e-06	0.000866	-0.23	-0.2	Lung cancer;	chr7:22716188	chr7:22725395~22727620:-
THCA	cis	rs13113518	1	rs4864993	ENSG00000249700.7	SRD5A3-AS1	4.51	8.29e-06	0.000866	0.25	0.2	Height;	chr4:55450662	chr4:55363971~55395847:-
THCA	cis	rs11665867	0.941	rs73047100	ENSG00000279108.1	CTC-490E21.11	-4.51	8.29e-06	0.000866	-0.29	-0.2	Hematocrit;	chr19:40809766	chr19:40840159~40842039:+
THCA	cis	rs3734266	0.646	rs111567516	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34720937	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs34261333	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34721763	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs72910167	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34728388	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs77208116	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34729376	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs34377413	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34730524	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.646	rs35369977	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34731564	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.591	rs35744142	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34737265	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.639	rs66672772	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34738160	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs71542490	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34740699	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs11961041	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34742132	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs36026951	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34754984	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs6934741	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34762272	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.697	rs67895864	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34774996	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.639	rs11967912	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34790076	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.536	rs35143960	ENSG00000272288.4	RP11-140K17.3	-4.51	8.29e-06	0.000866	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34793898	chr6:34696317~34697470:+
THCA	cis	rs7267979	1	rs2257991	ENSG00000274973.1	RP13-401N8.7	4.51	8.3e-06	0.000867	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25845497~25845862:+
THCA	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-4.51	8.3e-06	0.000867	-0.11	-0.2	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
THCA	cis	rs6964833	1	rs17515241	ENSG00000278416.1	PMS2L2	-4.51	8.3e-06	0.000867	-0.32	-0.2	Menarche (age at onset);	chr7:74717695	chr7:75344015~75359550:-
THCA	cis	rs1979679	0.527	rs12809834	ENSG00000278733.1	RP11-425D17.1	4.51	8.3e-06	0.000867	0.24	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28180573	chr12:28185625~28186190:-
THCA	cis	rs736408	0.812	rs2239699	ENSG00000243224.1	RP5-1157M23.2	-4.51	8.3e-06	0.000867	-0.23	-0.2	Bipolar disorder;	chr3:52793899	chr3:52239258~52241097:+
THCA	cis	rs10510102	0.872	rs28586586	ENSG00000226864.1	ATE1-AS1	4.51	8.3e-06	0.000867	0.33	0.2	Breast cancer;	chr10:121950228	chr10:121928312~121951965:+
THCA	cis	rs2281603	1	rs2281603	ENSG00000259116.1	RP11-973N13.4	-4.51	8.3e-06	0.000867	-0.19	-0.2	Lymphocyte counts;	chr14:64459379	chr14:64514154~64540368:-
THCA	cis	rs4908768	0.859	rs55802878	ENSG00000232912.4	RP5-1115A15.1	-4.51	8.31e-06	0.000867	-0.24	-0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8606352	chr1:8424645~8434838:+
THCA	cis	rs75422866	0.867	rs78912815	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47612065	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73113117	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47617299	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73113139	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47622826	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73113143	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47623060	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.717	rs73113159	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47631318	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.717	rs73113161	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47632361	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs117022227	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47633282	chr12:47788426~47788971:+
THCA	cis	rs75422866	1	rs73102120	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47637280	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs12422974	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47644559	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102127	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47645341	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102140	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47647497	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102148	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47648013	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102151	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47648023	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs75568526	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47649718	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs116302411	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47649788	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102166	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47653769	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102168	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47654010	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs73102171	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47656077	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs76100981	ENSG00000276691.1	RP5-1057I20.5	4.51	8.31e-06	0.000867	0.36	0.2	Pneumonia;	chr12:47660092	chr12:47788426~47788971:+
THCA	cis	rs6840360	0.901	rs1561915	ENSG00000270265.1	RP11-731D1.4	-4.51	8.31e-06	0.000867	-0.19	-0.2	Intelligence (multi-trait analysis);	chr4:151558572	chr4:151333775~151353224:-
THCA	cis	rs6963495	0.818	rs711430	ENSG00000272604.1	RP11-251G23.5	4.51	8.31e-06	0.000867	0.25	0.2	Bipolar disorder (body mass index interaction);	chr7:105527522	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs818619	ENSG00000272604.1	RP11-251G23.5	4.51	8.31e-06	0.000867	0.25	0.2	Bipolar disorder (body mass index interaction);	chr7:105532058	chr7:105571083~105573660:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-4.51	8.31e-06	0.000867	-0.23	-0.2	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
THCA	cis	rs7726839	0.54	rs3749615	ENSG00000225138.6	CTD-2228K2.7	4.51	8.31e-06	0.000867	0.25	0.2	Obesity-related traits;	chr5:601370	chr5:473236~480884:+
THCA	cis	rs9467773	0.62	rs2101581	ENSG00000261353.1	CTA-14H9.5	-4.51	8.31e-06	0.000868	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26527063~26527404:+
THCA	cis	rs17270561	1	rs17270561	ENSG00000272462.2	U91328.19	4.51	8.31e-06	0.000868	0.2	0.2	Iron status biomarkers;	chr6:25820211	chr6:25992662~26001775:+
THCA	cis	rs2281603	0.57	rs73265640	ENSG00000259116.1	RP11-973N13.4	-4.51	8.31e-06	0.000868	-0.17	-0.2	Lymphocyte counts;	chr14:64483083	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs73265641	ENSG00000259116.1	RP11-973N13.4	-4.51	8.31e-06	0.000868	-0.17	-0.2	Lymphocyte counts;	chr14:64483146	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.521	rs35115595	ENSG00000259116.1	RP11-973N13.4	-4.51	8.31e-06	0.000868	-0.17	-0.2	Lymphocyte counts;	chr14:64483206	chr14:64514154~64540368:-
THCA	cis	rs718433	0.584	rs7142784	ENSG00000211778.2	TRAV4	-4.51	8.31e-06	0.000868	-0.16	-0.2	Intraocular pressure;	chr14:21745516	chr14:21736152~21736982:+
THCA	cis	rs6870983	0.857	rs10473915	ENSG00000247828.6	TMEM161B-AS1	4.51	8.31e-06	0.000868	0.18	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88449160	chr5:88268895~88436685:+
THCA	cis	rs7246760	0.867	rs12462694	ENSG00000267106.4	ZNF561-AS1	4.51	8.31e-06	0.000868	0.4	0.2	Pursuit maintenance gain;	chr19:9667356	chr19:9621291~9645896:+
THCA	cis	rs6832769	1	rs6832769	ENSG00000272969.1	RP11-528I4.2	4.51	8.31e-06	0.000868	0.24	0.2	Personality dimensions;	chr4:55432027	chr4:55547112~55547889:+
THCA	cis	rs734999	0.588	rs6689711	ENSG00000225931.3	RP3-395M20.7	-4.51	8.32e-06	0.000868	-0.24	-0.2	Ulcerative colitis;	chr1:2600028	chr1:2566410~2569888:+
THCA	cis	rs988712	0.576	rs6265	ENSG00000245573.6	BDNF-AS	-4.51	8.32e-06	0.000868	-0.21	-0.2	Obesity;	chr11:27658369	chr11:27506838~27698174:+
THCA	cis	rs9878978	0.722	rs35717117	ENSG00000237990.3	CNTN4-AS1	4.51	8.32e-06	0.000868	0.24	0.2	Blood pressure (smoking interaction);	chr3:2395266	chr3:3039033~3069242:-
THCA	cis	rs889398	0.771	rs1500337	ENSG00000226232.7	RP11-419C5.2	4.51	8.32e-06	0.000869	0.2	0.2	Body mass index;	chr16:69867981	chr16:69976388~69996188:-
THCA	cis	rs7474896	1	rs734512	ENSG00000263064.2	RP11-291L22.7	-4.51	8.32e-06	0.000869	-0.31	-0.2	Obesity (extreme);	chr10:37684144	chr10:38448689~38448949:+
THCA	cis	rs9467773	0.62	rs2451737	ENSG00000261353.1	CTA-14H9.5	-4.51	8.32e-06	0.000869	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.596	rs2494693	ENSG00000261353.1	CTA-14H9.5	-4.51	8.32e-06	0.000869	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2494694	ENSG00000261353.1	CTA-14H9.5	-4.51	8.32e-06	0.000869	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.595	rs2451736	ENSG00000261353.1	CTA-14H9.5	-4.51	8.32e-06	0.000869	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26527063~26527404:+
THCA	cis	rs11853189	0.938	rs16969707	ENSG00000259562.2	RP11-762H8.2	4.51	8.32e-06	0.000869	0.2	0.2	Red cell distribution width;	chr15:78301763	chr15:78290527~78291221:-
THCA	cis	rs10760158	0.865	rs10739594	ENSG00000235865.2	GSN-AS1	4.51	8.33e-06	0.000869	0.17	0.2	Pulse pressure;	chr9:121273102	chr9:121280768~121285530:-
THCA	cis	rs763121	0.853	rs5757187	ENSG00000235209.1	CTA-150C2.13	-4.51	8.33e-06	0.000869	-0.26	-0.2	Menopause (age at onset);	chr22:38625517	chr22:38921227~38924708:+
THCA	cis	rs8077577	0.747	rs1925	ENSG00000273018.4	CTD-2303H24.2	-4.51	8.33e-06	0.000869	-0.3	-0.2	Obesity-related traits;	chr17:18274401	chr17:18511221~18551705:-
THCA	cis	rs7621331	0.963	rs10212558	ENSG00000273486.1	RP11-731C17.2	4.51	8.33e-06	0.000869	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135953024	chr3:136837338~136839021:-
THCA	cis	rs4718428	0.705	rs11028	ENSG00000275400.1	RP4-756H11.5	-4.51	8.33e-06	0.00087	-0.22	-0.2	Corneal structure;	chr7:66811230	chr7:66553805~66554199:-
THCA	cis	rs10875746	0.859	rs12305511	ENSG00000258234.1	RP11-370I10.2	-4.51	8.33e-06	0.00087	-0.24	-0.2	Longevity (90 years and older);	chr12:48188933	chr12:48231098~48284210:-
THCA	cis	rs8031584	0.578	rs1088473	ENSG00000259845.1	HERC2P10	-4.51	8.34e-06	0.00087	-0.28	-0.2	Huntington's disease progression;	chr15:30847095	chr15:30815271~30844153:+
THCA	cis	rs8031584	0.678	rs4779496	ENSG00000259845.1	HERC2P10	4.51	8.34e-06	0.00087	0.28	0.2	Huntington's disease progression;	chr15:30858851	chr15:30815271~30844153:+
THCA	cis	rs8031584	0.678	rs4779497	ENSG00000259845.1	HERC2P10	4.51	8.34e-06	0.00087	0.28	0.2	Huntington's disease progression;	chr15:30859162	chr15:30815271~30844153:+
THCA	cis	rs8031584	0.678	rs8028173	ENSG00000259845.1	HERC2P10	4.51	8.34e-06	0.00087	0.28	0.2	Huntington's disease progression;	chr15:30863546	chr15:30815271~30844153:+
THCA	cis	rs8031584	0.706	rs2177670	ENSG00000259845.1	HERC2P10	4.51	8.34e-06	0.00087	0.28	0.2	Huntington's disease progression;	chr15:30865548	chr15:30815271~30844153:+
THCA	cis	rs8031584	0.678	rs36047941	ENSG00000259845.1	HERC2P10	4.51	8.34e-06	0.00087	0.28	0.2	Huntington's disease progression;	chr15:30867032	chr15:30815271~30844153:+
THCA	cis	rs8031584	0.678	rs4779790	ENSG00000259845.1	HERC2P10	4.51	8.34e-06	0.00087	0.28	0.2	Huntington's disease progression;	chr15:30872392	chr15:30815271~30844153:+
THCA	cis	rs8031584	0.678	rs8035703	ENSG00000259845.1	HERC2P10	4.51	8.34e-06	0.00087	0.28	0.2	Huntington's disease progression;	chr15:30876269	chr15:30815271~30844153:+
THCA	cis	rs4144027	0.875	rs6576010	ENSG00000269910.1	RP11-73M18.10	-4.51	8.34e-06	0.00087	-0.18	-0.2	Blood metabolite levels;	chr14:103883265	chr14:103694516~103695050:-
THCA	cis	rs7942368	1	rs1440980	ENSG00000261578.1	RP11-21L23.2	4.51	8.34e-06	0.00087	0.29	0.2	Endometriosis;	chr11:76784032	chr11:76800364~76804555:+
THCA	cis	rs8062405	1	rs8061590	ENSG00000261766.1	RP11-22P6.2	-4.51	8.34e-06	0.00087	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28862166~28863340:-
THCA	cis	rs7615952	0.546	rs2979340	ENSG00000171084.14	FAM86JP	4.51	8.34e-06	0.000871	0.28	0.2	Blood pressure (smoking interaction);	chr3:125622540	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.546	rs2979338	ENSG00000171084.14	FAM86JP	4.51	8.34e-06	0.000871	0.28	0.2	Blood pressure (smoking interaction);	chr3:125624282	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.546	rs2922171	ENSG00000171084.14	FAM86JP	4.51	8.34e-06	0.000871	0.28	0.2	Blood pressure (smoking interaction);	chr3:125624349	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.546	rs112919177	ENSG00000171084.14	FAM86JP	4.51	8.34e-06	0.000871	0.28	0.2	Blood pressure (smoking interaction);	chr3:125627226	chr3:125916620~125930024:+
THCA	cis	rs683257	0.929	rs9495849	ENSG00000234147.1	RP3-460G2.2	-4.51	8.34e-06	0.000871	-0.35	-0.2	Facial emotion recognition (angry faces);	chr6:140867341	chr6:140845958~140852924:-
THCA	cis	rs722599	0.748	rs731165	ENSG00000279594.1	RP11-950C14.10	-4.51	8.34e-06	0.000871	-0.21	-0.2	IgG glycosylation;	chr14:74885852	chr14:75011269~75012851:-
THCA	cis	rs7621331	1	rs9862264	ENSG00000273486.1	RP11-731C17.2	4.51	8.35e-06	0.000871	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135975654	chr3:136837338~136839021:-
THCA	cis	rs1707322	1	rs10890380	ENSG00000281133.1	AL355480.3	-4.51	8.35e-06	0.000871	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45580892~45580996:-
THCA	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-4.51	8.35e-06	0.000871	-0.26	-0.2	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
THCA	cis	rs6570726	0.791	rs398408	ENSG00000270638.1	RP3-466P17.1	4.51	8.35e-06	0.000871	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145735570~145737218:+
THCA	cis	rs16975963	0.545	rs12461753	ENSG00000226686.6	LINC01535	-4.51	8.35e-06	0.000871	-0.28	-0.2	Longevity;	chr19:37711614	chr19:37251912~37265535:+
THCA	cis	rs67517081	1	rs67517081	ENSG00000275263.1	RP11-1072A3.4	4.51	8.35e-06	0.000871	0.24	0.2	Mean corpuscular hemoglobin;	chr16:30976060	chr16:30956872~30957199:-
THCA	cis	rs9863	0.794	rs12310367	ENSG00000270061.1	RP11-214K3.19	-4.51	8.36e-06	0.000872	-0.27	-0.2	White blood cell count;	chr12:124002131	chr12:123969990~123970344:-
THCA	cis	rs7824557	0.603	rs11250130	ENSG00000154316.13	TDH	4.51	8.36e-06	0.000872	0.15	0.2	Retinal vascular caliber;	chr8:11356946	chr8:11339637~11368452:+
THCA	cis	rs448720	0.532	rs8033140	ENSG00000260657.2	RP11-315D16.4	4.51	8.36e-06	0.000872	0.29	0.2	Cognitive performance;	chr15:67906403	chr15:68267792~68277994:-
THCA	cis	rs12497850	0.931	rs7621015	ENSG00000228638.1	FCF1P2	-4.51	8.36e-06	0.000872	-0.22	-0.2	Parkinson's disease;	chr3:48978623	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs4072859	ENSG00000228638.1	FCF1P2	-4.51	8.36e-06	0.000872	-0.22	-0.2	Parkinson's disease;	chr3:48994772	chr3:48290793~48291375:-
THCA	cis	rs2562456	0.833	rs4334427	ENSG00000268117.1	VN1R84P	4.51	8.36e-06	0.000872	0.32	0.2	Pain;	chr19:21338090	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs4644962	ENSG00000268117.1	VN1R84P	4.51	8.36e-06	0.000872	0.32	0.2	Pain;	chr19:21338125	chr19:21719801~21720035:-
THCA	cis	rs2886497	0.894	rs2365888	ENSG00000224215.1	RP11-371A19.2	-4.51	8.36e-06	0.000872	-0.26	-0.2	Major depression and alcohol dependence;	chr10:23407426	chr10:23343957~23345181:+
THCA	cis	rs11633886	0.604	rs6493178	ENSG00000273972.1	CTD-2306A12.1	-4.51	8.36e-06	0.000872	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45812056	chr15:45702640~45703183:+
THCA	cis	rs990871	0.53	rs1194286	ENSG00000227207.2	RPL31P12	4.51	8.37e-06	0.000873	0.24	0.2	Subcutaneous adipose tissue;	chr1:72222820	chr1:72301472~72301829:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000234585.5	CCT6P3	-4.51	8.37e-06	0.000873	-0.18	-0.2	Aortic root size;	chr7:65800193	chr7:65038354~65074713:+
THCA	cis	rs4648045	0.647	rs230543	ENSG00000246560.2	RP11-10L12.4	-4.51	8.37e-06	0.000873	-0.24	-0.2	Lymphocyte percentage of white cells;	chr4:102579631	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.687	rs230544	ENSG00000246560.2	RP11-10L12.4	-4.51	8.37e-06	0.000873	-0.24	-0.2	Lymphocyte percentage of white cells;	chr4:102579718	chr4:102828055~102844075:+
THCA	cis	rs7267979	1	rs2500443	ENSG00000274973.1	RP13-401N8.7	4.51	8.38e-06	0.000874	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25845497~25845862:+
THCA	cis	rs11671005	0.735	rs34873624	ENSG00000268049.1	CTD-2619J13.9	-4.51	8.38e-06	0.000874	-0.31	-0.2	Mean platelet volume;	chr19:58432035	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.693	rs34230465	ENSG00000268049.1	CTD-2619J13.9	-4.51	8.38e-06	0.000874	-0.31	-0.2	Mean platelet volume;	chr19:58432209	chr19:58357999~58359603:+
THCA	cis	rs11853189	0.938	rs11854322	ENSG00000259562.2	RP11-762H8.2	4.51	8.38e-06	0.000874	0.2	0.2	Red cell distribution width;	chr15:78298072	chr15:78290527~78291221:-
THCA	cis	rs2836974	0.644	rs2836986	ENSG00000255568.3	BRWD1-AS2	-4.51	8.38e-06	0.000874	-0.17	-0.2	Cognitive function;	chr21:39330210	chr21:39313935~39314962:+
THCA	cis	rs1371614	0.523	rs4233714	ENSG00000229122.1	AGBL5-IT1	-4.51	8.38e-06	0.000874	-0.15	-0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26958586	chr2:27061038~27061815:+
THCA	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-4.51	8.38e-06	0.000874	-0.25	-0.2	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
THCA	cis	rs7267979	0.966	rs2257233	ENSG00000274973.1	RP13-401N8.7	4.51	8.38e-06	0.000874	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25845497~25845862:+
THCA	cis	rs10129255	0.5	rs4774189	ENSG00000211970.3	IGHV4-61	-4.51	8.38e-06	0.000874	-0.11	-0.2	Kawasaki disease;	chr14:106768275	chr14:106639119~106639657:-
THCA	cis	rs8067545	0.967	rs4924801	ENSG00000270091.1	RP11-78O7.2	-4.51	8.38e-06	0.000874	-0.15	-0.2	Schizophrenia;	chr17:20017757	chr17:19896590~19897287:-
THCA	cis	rs75422866	0.867	rs73102125	ENSG00000276691.1	RP5-1057I20.5	4.51	8.38e-06	0.000875	0.36	0.2	Pneumonia;	chr12:47637869	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs12426849	ENSG00000276691.1	RP5-1057I20.5	4.51	8.38e-06	0.000875	0.36	0.2	Pneumonia;	chr12:47638975	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs117950951	ENSG00000276691.1	RP5-1057I20.5	4.51	8.38e-06	0.000875	0.36	0.2	Pneumonia;	chr12:47639794	chr12:47788426~47788971:+
THCA	cis	rs75422866	0.867	rs7954764	ENSG00000276691.1	RP5-1057I20.5	4.51	8.38e-06	0.000875	0.36	0.2	Pneumonia;	chr12:47641136	chr12:47788426~47788971:+
THCA	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-4.5	8.39e-06	0.000875	-0.24	-0.2	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
THCA	cis	rs4713118	0.615	rs9295747	ENSG00000280107.1	AL022393.9	4.5	8.39e-06	0.000875	0.22	0.2	Parkinson's disease;	chr6:27769214	chr6:28170845~28172521:+
THCA	cis	rs8077577	0.747	rs3829956	ENSG00000273018.4	CTD-2303H24.2	-4.5	8.39e-06	0.000875	-0.29	-0.2	Obesity-related traits;	chr17:18316521	chr17:18511221~18551705:-
THCA	cis	rs5770917	1	rs5770911	ENSG00000273272.1	CTA-384D8.34	4.5	8.39e-06	0.000875	0.32	0.2	Narcolepsy;	chr22:50572812	chr22:50542650~50543011:+
THCA	cis	rs9863	0.898	rs7301953	ENSG00000270061.1	RP11-214K3.19	-4.5	8.39e-06	0.000875	-0.28	-0.2	White blood cell count;	chr12:123921324	chr12:123969990~123970344:-
THCA	cis	rs1552244	1	rs7626117	ENSG00000232901.1	CYCSP10	4.5	8.39e-06	0.000875	0.26	0.2	Alzheimer's disease;	chr3:10098987	chr3:10000647~10000940:-
THCA	cis	rs7772486	0.754	rs702304	ENSG00000270638.1	RP3-466P17.1	-4.5	8.39e-06	0.000875	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145735570~145737218:+
THCA	cis	rs6878727	0.517	rs11744118	ENSG00000253807.4	LINC01170	-4.5	8.39e-06	0.000875	-0.2	-0.2	Breast cancer;	chr5:124365753	chr5:124059794~124405079:-
THCA	cis	rs734999	0.967	rs10910089	ENSG00000225931.3	RP3-395M20.7	4.5	8.39e-06	0.000875	0.25	0.2	Ulcerative colitis;	chr1:2567179	chr1:2566410~2569888:+
THCA	cis	rs1577917	0.816	rs12664099	ENSG00000220563.1	PKMP3	-4.5	8.39e-06	0.000875	-0.15	-0.2	Response to antipsychotic treatment;	chr6:85938854	chr6:85659892~85660606:-
THCA	cis	rs2797160	0.651	rs6569437	ENSG00000226409.1	RP11-735G4.1	4.5	8.39e-06	0.000875	0.25	0.2	Endometrial cancer;	chr6:125713394	chr6:125370211~125374324:-
THCA	cis	rs2898290	0.622	rs7822109	ENSG00000227888.4	FAM66A	-4.5	8.4e-06	0.000876	-0.26	-0.2	Systolic blood pressure;	chr8:11491638	chr8:12362019~12388296:+
THCA	cis	rs4948275	0.693	rs2606106	ENSG00000237233.2	TMEM26-AS1	-4.5	8.4e-06	0.000876	-0.27	-0.2	Night sleep phenotypes;	chr10:61584791	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs1598574	ENSG00000237233.2	TMEM26-AS1	-4.5	8.4e-06	0.000876	-0.27	-0.2	Night sleep phenotypes;	chr10:61584954	chr10:61452639~61481956:+
THCA	cis	rs10090774	0.901	rs10112148	ENSG00000279766.1	RP11-642A1.2	-4.5	8.4e-06	0.000876	-0.26	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140699769	chr8:140572142~140572812:-
THCA	cis	rs2439831	0.85	rs67541383	ENSG00000166763.7	STRCP1	4.5	8.4e-06	0.000876	0.31	0.2	Lung cancer in ever smokers;	chr15:43880350	chr15:43699488~43718184:-
THCA	cis	rs829883	1	rs1347956	ENSG00000227825.4	SLC9A7P1	4.5	8.4e-06	0.000876	0.19	0.2	Colorectal adenoma (advanced);	chr12:98495786	chr12:98453835~98457145:-
THCA	cis	rs4819052	0.851	rs914218	ENSG00000182586.6	LINC00334	-4.5	8.4e-06	0.000876	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45234340~45258730:+
THCA	cis	rs111756027	0.539	rs8054228	ENSG00000260922.1	RP11-538I12.3	4.5	8.4e-06	0.000876	0.29	0.2	Bone mineral density (Ward's triangle area);	chr16:77261781	chr16:77234877~77290934:+
THCA	cis	rs12541437	0.958	rs2921738	ENSG00000253327.2	RAD21-AS1	4.5	8.4e-06	0.000876	0.22	0.2	Gut microbiome composition (winter);	chr8:116917435	chr8:116874424~116876868:+
THCA	cis	rs11633886	0.656	rs11638519	ENSG00000273972.1	CTD-2306A12.1	-4.5	8.4e-06	0.000876	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45834722	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.656	rs12900054	ENSG00000273972.1	CTD-2306A12.1	-4.5	8.4e-06	0.000876	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45836013	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.656	rs12900604	ENSG00000273972.1	CTD-2306A12.1	-4.5	8.4e-06	0.000876	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45836104	chr15:45702640~45703183:+
THCA	cis	rs829883	0.966	rs249815	ENSG00000227825.4	SLC9A7P1	4.5	8.41e-06	0.000876	0.19	0.2	Colorectal adenoma (advanced);	chr12:98499931	chr12:98453835~98457145:-
THCA	cis	rs829883	0.867	rs1641640	ENSG00000227825.4	SLC9A7P1	4.5	8.41e-06	0.000876	0.19	0.2	Colorectal adenoma (advanced);	chr12:98502239	chr12:98453835~98457145:-
THCA	cis	rs829883	0.872	rs1641641	ENSG00000227825.4	SLC9A7P1	4.5	8.41e-06	0.000876	0.19	0.2	Colorectal adenoma (advanced);	chr12:98502240	chr12:98453835~98457145:-
THCA	cis	rs7829975	0.514	rs2920991	ENSG00000233609.3	RP11-62H7.2	4.5	8.41e-06	0.000877	0.19	0.2	Mood instability;	chr8:8401607	chr8:8961200~8979025:+
THCA	cis	rs709400	0.643	rs11621777	ENSG00000258735.1	LINC00637	4.5	8.41e-06	0.000877	0.26	0.2	Body mass index;	chr14:103605753	chr14:103847721~103858049:+
THCA	cis	rs9467773	0.62	rs2451731	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs9295701	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2451741	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2494700	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.584	rs1021372	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.583	rs1021373	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2451744	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2494701	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs1027204	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2504567	ENSG00000261353.1	CTA-14H9.5	-4.5	8.41e-06	0.000877	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26527063~26527404:+
THCA	cis	rs875971	0.862	rs6952182	ENSG00000229886.1	RP5-1132H15.3	-4.5	8.41e-06	0.000877	-0.22	-0.2	Aortic root size;	chr7:66218330	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6964437	ENSG00000229886.1	RP5-1132H15.3	-4.5	8.41e-06	0.000877	-0.22	-0.2	Aortic root size;	chr7:66221457	chr7:66025126~66031544:-
THCA	cis	rs6517329	0.564	rs12626189	ENSG00000236830.5	CBR3-AS1	-4.5	8.41e-06	0.000877	-0.19	-0.2	Schizophrenia;	chr21:36137654	chr21:36131767~36175815:-
THCA	cis	rs703842	1	rs11172344	ENSG00000270039.1	RP11-571M6.17	-4.5	8.41e-06	0.000877	-0.23	-0.2	Multiple sclerosis;	chr12:57799665	chr12:57803838~57804415:+
THCA	cis	rs10860794	0.961	rs10778152	ENSG00000274560.1	RP11-285E23.2	-4.5	8.41e-06	0.000877	-0.13	-0.2	Blood protein levels;	chr12:101831973	chr12:101696002~101696450:-
THCA	cis	rs1046491	1	rs11660889	ENSG00000264964.1	RP11-888D10.3	4.5	8.41e-06	0.000877	0.34	0.2	Scarlet fever;	chr18:9177299	chr18:9315194~9334441:-
THCA	cis	rs7260598	0.539	rs76237579	ENSG00000268442.1	CTD-2027I19.2	4.5	8.41e-06	0.000877	0.3	0.2	Response to taxane treatment (placlitaxel);	chr19:23869921	chr19:24162370~24163425:-
THCA	cis	rs4934494	0.677	rs7905163	ENSG00000240996.1	RP11-80H5.7	-4.5	8.42e-06	0.000877	-0.24	-0.2	Red blood cell count;	chr10:89624173	chr10:89694295~89697928:-
THCA	cis	rs868036	0.609	rs2045960	ENSG00000270964.1	RP11-502I4.3	-4.5	8.42e-06	0.000878	-0.19	-0.2	Restless legs syndrome;	chr15:67799741	chr15:67541072~67542604:-
THCA	cis	rs7259376	0.967	rs808369	ENSG00000269345.1	VN1R85P	-4.5	8.42e-06	0.000878	-0.22	-0.2	Menopause (age at onset);	chr19:22291480	chr19:22174766~22175191:-
THCA	cis	rs758324	0.661	rs411219	ENSG00000237714.1	P4HA2-AS1	-4.5	8.42e-06	0.000878	-0.28	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132115940	chr5:132184876~132192808:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-4.5	8.42e-06	0.000878	-0.23	-0.2	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
THCA	cis	rs4819052	0.851	rs3673	ENSG00000182586.6	LINC00334	-4.5	8.42e-06	0.000878	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45234340~45258730:+
THCA	cis	rs17772222	0.651	rs865285	ENSG00000258983.2	RP11-507K2.2	-4.5	8.43e-06	0.000878	-0.23	-0.2	Coronary artery calcification;	chr14:88391138	chr14:88499334~88515502:+
THCA	cis	rs748802	0.55	rs10972619	ENSG00000235387.1	LINC00961	4.5	8.43e-06	0.000879	0.25	0.2	Resting heart rate;	chr9:35908491	chr9:35909483~35911686:+
THCA	cis	rs12935229	1	rs34371402	ENSG00000260922.1	RP11-538I12.3	-4.5	8.43e-06	0.000879	-0.33	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77282513	chr16:77234877~77290934:+
THCA	cis	rs2933343	0.716	rs9872706	ENSG00000261159.1	RP11-723O4.9	-4.5	8.43e-06	0.000879	-0.24	-0.2	IgG glycosylation;	chr3:128848262	chr3:128859716~128860526:-
THCA	cis	rs2013441	0.508	rs4925078	ENSG00000261033.1	RP11-209D14.2	4.5	8.43e-06	0.000879	0.27	0.2	Obesity-related traits;	chr17:20079160	chr17:20008051~20009234:-
THCA	cis	rs7178424	0.806	rs4587915	ENSG00000259251.2	RP11-643M14.1	4.5	8.43e-06	0.000879	0.21	0.2	Height;	chr15:61949763	chr15:62060503~62062434:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000272831.1	RP11-792A8.4	-4.5	8.43e-06	0.000879	-0.13	-0.2	Aortic root size;	chr7:66018255	chr7:66739829~66740385:-
THCA	cis	rs7267979	1	rs2500432	ENSG00000274973.1	RP13-401N8.7	-4.5	8.43e-06	0.000879	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25845497~25845862:+
THCA	cis	rs59868192	0.925	rs60772450	ENSG00000246740.2	PLA2G4E-AS1	4.5	8.44e-06	0.000879	0.39	0.2	White blood cell count;	chr15:41955274	chr15:41972763~41999094:+
THCA	cis	rs11722779	0.787	rs6533040	ENSG00000248971.2	KRT8P46	-4.5	8.44e-06	0.000879	-0.25	-0.2	Schizophrenia;	chr4:102951421	chr4:102728746~102730171:-
THCA	cis	rs2734839	0.964	rs12364051	ENSG00000270179.1	RP11-159N11.4	-4.5	8.44e-06	0.00088	-0.22	-0.2	Information processing speed;	chr11:113434592	chr11:113368478~113369117:+
THCA	cis	rs7621331	0.963	rs9862763	ENSG00000273486.1	RP11-731C17.2	4.5	8.44e-06	0.00088	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135968499	chr3:136837338~136839021:-
THCA	cis	rs1046491	0.901	rs7226632	ENSG00000264964.1	RP11-888D10.3	4.5	8.44e-06	0.00088	0.34	0.2	Scarlet fever;	chr18:9179151	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs11877843	ENSG00000264964.1	RP11-888D10.3	4.5	8.44e-06	0.00088	0.34	0.2	Scarlet fever;	chr18:9180217	chr18:9315194~9334441:-
THCA	cis	rs34286592	1	rs34286592	ENSG00000214725.6	CDIPT-AS1	-4.5	8.44e-06	0.00088	-0.38	-0.2	Multiple sclerosis;	chr16:29809159	chr16:29863593~29868053:+
THCA	cis	rs11710088	0.634	rs13095959	ENSG00000244503.1	RP11-278L15.6	4.5	8.45e-06	0.00088	0.25	0.2	QRS duration;	chr3:149489409	chr3:149494660~149495995:+
THCA	cis	rs2028299	0.92	rs2118847	ENSG00000259677.1	RP11-493E3.1	4.5	8.45e-06	0.000881	0.27	0.2	Type 2 diabetes;	chr15:89865615	chr15:89876540~89877285:+
THCA	cis	rs1707322	1	rs6661500	ENSG00000281133.1	AL355480.3	-4.5	8.45e-06	0.000881	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45580892~45580996:-
THCA	cis	rs7267979	1	rs6050544	ENSG00000274973.1	RP13-401N8.7	4.5	8.45e-06	0.000881	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25845497~25845862:+
THCA	cis	rs13063635	0.85	rs4683162	ENSG00000226074.4	PRSS44	-4.5	8.45e-06	0.000881	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46042449	chr3:46809359~46812558:-
THCA	cis	rs2880765	0.677	rs7181410	ENSG00000259630.2	CTD-2262B20.1	4.5	8.45e-06	0.000881	0.22	0.2	Coronary artery disease;	chr15:85463104	chr15:85415228~85415633:+
THCA	cis	rs17095355	0.579	rs72828224	ENSG00000203876.8	ADD3-AS1	-4.5	8.45e-06	0.000881	-0.22	-0.2	Biliary atresia;	chr10:109942289	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs1376111	ENSG00000203876.8	ADD3-AS1	-4.5	8.45e-06	0.000881	-0.22	-0.2	Biliary atresia;	chr10:109947497	chr10:109940104~110008381:-
THCA	cis	rs6496932	0.663	rs7183764	ENSG00000259630.2	CTD-2262B20.1	-4.5	8.45e-06	0.000881	-0.25	-0.2	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85415228~85415633:+
THCA	cis	rs6496932	0.663	rs4842878	ENSG00000259630.2	CTD-2262B20.1	-4.5	8.45e-06	0.000881	-0.25	-0.2	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85415228~85415633:+
THCA	cis	rs6496932	0.663	rs8040940	ENSG00000259630.2	CTD-2262B20.1	-4.5	8.45e-06	0.000881	-0.25	-0.2	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85415228~85415633:+
THCA	cis	rs847845	0.535	rs1201872	ENSG00000272288.4	RP11-140K17.3	4.5	8.45e-06	0.000881	0.24	0.2	Non-small cell lung cancer;	chr6:34587932	chr6:34696317~34697470:+
THCA	cis	rs3824488	0.92	rs28474857	ENSG00000237857.2	RP11-435O5.2	-4.5	8.45e-06	0.000881	-0.37	-0.2	Neuroticism;	chr9:95484922	chr9:95414834~95426796:-
THCA	cis	rs3096299	0.503	rs4785677	ENSG00000261118.1	RP11-104N10.1	4.5	8.46e-06	0.000881	0.17	0.2	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89492017~89504460:-
THCA	cis	rs736408	0.505	rs2083180	ENSG00000243224.1	RP5-1157M23.2	-4.5	8.46e-06	0.000881	-0.22	-0.2	Bipolar disorder;	chr3:52634103	chr3:52239258~52241097:+
THCA	cis	rs17095355	1	rs55897175	ENSG00000203876.8	ADD3-AS1	-4.5	8.46e-06	0.000881	-0.22	-0.2	Biliary atresia;	chr10:109939432	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs12254785	ENSG00000203876.8	ADD3-AS1	-4.5	8.46e-06	0.000881	-0.22	-0.2	Biliary atresia;	chr10:109939849	chr10:109940104~110008381:-
THCA	cis	rs1005277	0.505	rs200936	ENSG00000226578.1	RP11-258F22.1	-4.5	8.46e-06	0.000881	-0.24	-0.2	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:37775371~37784131:-
THCA	cis	rs1005277	0.505	rs200937	ENSG00000226578.1	RP11-258F22.1	-4.5	8.46e-06	0.000881	-0.24	-0.2	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:37775371~37784131:-
THCA	cis	rs2839186	0.708	rs17183123	ENSG00000215424.8	MCM3AP-AS1	4.5	8.46e-06	0.000881	0.12	0.2	Testicular germ cell tumor;	chr21:46252047	chr21:46229217~46259390:+
THCA	cis	rs9380516	0.627	rs7753746	ENSG00000228559.1	RP3-340B19.3	-4.5	8.46e-06	0.000881	-0.29	-0.2	Hepatitis C induced liver fibrosis;	chr6:35597645	chr6:35544632~35545669:+
THCA	cis	rs8031584	0.918	rs1425292	ENSG00000178081.11	ULK4P3	4.5	8.46e-06	0.000881	0.27	0.2	Huntington's disease progression;	chr15:30993219	chr15:30103720~30131757:+
THCA	cis	rs807029	0.577	rs3740488	ENSG00000236662.1	RP11-108L7.4	4.5	8.46e-06	0.000882	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100980507~100985614:-
THCA	cis	rs7200786	0.667	rs12448611	ENSG00000274038.1	RP11-66H6.4	4.5	8.46e-06	0.000882	0.25	0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10986594	chr16:11056556~11057034:+
THCA	cis	rs481331	0.736	rs115753346	ENSG00000215146.4	RP11-313J2.1	4.5	8.46e-06	0.000882	0.33	0.2	Systemic juvenile idiopathic arthritis;	chr10:42482108	chr10:42331866~42367974:-
THCA	cis	rs11673344	0.503	rs1667370	ENSG00000276846.1	CTD-3220F14.3	4.5	8.46e-06	0.000882	0.15	0.2	Obesity-related traits;	chr19:36999318	chr19:37314868~37315620:-
THCA	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-4.5	8.46e-06	0.000882	-0.23	-0.2	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
THCA	cis	rs593531	0.513	rs479968	ENSG00000255440.1	RP11-632K5.2	-4.5	8.47e-06	0.000882	-0.24	-0.2	Neuroticism;	chr11:74327229	chr11:74409060~74416379:+
THCA	cis	rs13325613	0.915	rs57115330	ENSG00000223552.1	RP11-24F11.2	-4.5	8.47e-06	0.000882	-0.3	-0.2	Monocyte count;	chr3:46213771	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34498313	ENSG00000223552.1	RP11-24F11.2	-4.5	8.47e-06	0.000882	-0.3	-0.2	Monocyte count;	chr3:46214305	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13088766	ENSG00000223552.1	RP11-24F11.2	-4.5	8.47e-06	0.000882	-0.3	-0.2	Monocyte count;	chr3:46216735	chr3:46364955~46407059:-
THCA	cis	rs12935418	0.616	rs8047785	ENSG00000278985.1	RP11-303E16.9	4.5	8.47e-06	0.000882	0.25	0.2	Mean corpuscular volume;	chr16:80935455	chr16:80982319~80984094:-
THCA	cis	rs12935418	0.616	rs11863536	ENSG00000278985.1	RP11-303E16.9	4.5	8.47e-06	0.000882	0.25	0.2	Mean corpuscular volume;	chr16:80935777	chr16:80982319~80984094:-
THCA	cis	rs2562456	0.754	rs58338799	ENSG00000268117.1	VN1R84P	4.5	8.47e-06	0.000883	0.32	0.2	Pain;	chr19:21339009	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs7259396	ENSG00000268117.1	VN1R84P	4.5	8.47e-06	0.000883	0.32	0.2	Pain;	chr19:21340661	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.678	rs7260140	ENSG00000268117.1	VN1R84P	4.5	8.47e-06	0.000883	0.32	0.2	Pain;	chr19:21340723	chr19:21719801~21720035:-
THCA	cis	rs4578769	0.55	rs4517887	ENSG00000265939.1	UBE2CP2	-4.5	8.47e-06	0.000883	-0.23	-0.2	Eosinophil percentage of white cells;	chr18:22994715	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.55	rs4635434	ENSG00000265939.1	UBE2CP2	-4.5	8.47e-06	0.000883	-0.23	-0.2	Eosinophil percentage of white cells;	chr18:22996032	chr18:22900486~22900995:-
THCA	cis	rs7572644	0.699	rs937812	ENSG00000223522.1	AC093690.1	4.5	8.47e-06	0.000883	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28032435	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.662	rs9309658	ENSG00000223522.1	AC093690.1	4.5	8.47e-06	0.000883	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28033964	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs7593127	ENSG00000223522.1	AC093690.1	4.5	8.47e-06	0.000883	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28035160	chr2:28307691~28310459:-
THCA	cis	rs867186	1	rs73903019	ENSG00000126005.14	MMP24-AS1	-4.5	8.48e-06	0.000883	-0.32	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35139976	chr20:35216462~35278131:-
THCA	cis	rs7746199	0.736	rs58616630	ENSG00000272009.1	RP1-313I6.12	-4.5	8.48e-06	0.000883	-0.38	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs34573979	ENSG00000272009.1	RP1-313I6.12	-4.5	8.48e-06	0.000883	-0.38	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28078792~28081130:-
THCA	cis	rs6545883	0.708	rs2518936	ENSG00000271889.1	RP11-493E12.1	4.5	8.48e-06	0.000883	0.19	0.2	Tuberculosis;	chr2:61565207	chr2:61151433~61162105:-
THCA	cis	rs4648045	0.647	rs230517	ENSG00000246560.2	RP11-10L12.4	-4.5	8.48e-06	0.000883	-0.24	-0.2	Lymphocyte percentage of white cells;	chr4:102549036	chr4:102828055~102844075:+
THCA	cis	rs7572644	0.699	rs10209126	ENSG00000223522.1	AC093690.1	4.5	8.48e-06	0.000884	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27986416	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs10175508	ENSG00000223522.1	AC093690.1	4.5	8.48e-06	0.000884	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27990557	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs1458398	ENSG00000223522.1	AC093690.1	4.5	8.48e-06	0.000884	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27997074	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.541	rs2839791	ENSG00000223522.1	AC093690.1	4.5	8.48e-06	0.000884	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28009412	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs7602328	ENSG00000223522.1	AC093690.1	4.5	8.48e-06	0.000884	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28012317	chr2:28307691~28310459:-
THCA	cis	rs9307551	0.711	rs11098774	ENSG00000249646.2	OR7E94P	4.5	8.48e-06	0.000884	0.27	0.2	Refractive error;	chr4:79615697	chr4:79587302~79588130:-
THCA	cis	rs7200786	0.667	rs9936979	ENSG00000274038.1	RP11-66H6.4	4.5	8.49e-06	0.000884	0.25	0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10986731	chr16:11056556~11057034:+
THCA	cis	rs6973609	0.597	rs17171522	ENSG00000271122.1	RP11-379H18.1	4.5	8.49e-06	0.000884	0.14	0.2	Obesity-related traits;	chr7:35559810	chr7:35695214~35699413:+
THCA	cis	rs1334894	1	rs72913423	ENSG00000228559.1	RP3-340B19.3	-4.5	8.49e-06	0.000884	-0.42	-0.2	Coronary artery disease;	chr6:35607930	chr6:35544632~35545669:+
THCA	cis	rs656319	0.669	rs56279061	ENSG00000248538.5	RP11-10A14.5	4.5	8.49e-06	0.000884	0.27	0.2	Myopia (pathological);	chr8:10016470	chr8:9189011~9202854:+
THCA	cis	rs2787702	0.929	rs2650728	ENSG00000237233.2	TMEM26-AS1	-4.5	8.49e-06	0.000884	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61576774	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2814029	ENSG00000237233.2	TMEM26-AS1	-4.5	8.49e-06	0.000884	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61578319	chr10:61452639~61481956:+
THCA	cis	rs2281603	0.57	rs3742606	ENSG00000259116.1	RP11-973N13.4	-4.5	8.49e-06	0.000885	-0.17	-0.2	Lymphocyte counts;	chr14:64478371	chr14:64514154~64540368:-
THCA	cis	rs2821260	0.53	rs6668604	ENSG00000227207.2	RPL31P12	-4.5	8.49e-06	0.000885	-0.24	-0.2	Intelligence (multi-trait analysis);	chr1:72185242	chr1:72301472~72301829:+
THCA	cis	rs964611	0.882	rs12903327	ENSG00000259488.2	RP11-154J22.1	4.5	8.49e-06	0.000885	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48355466	chr15:48312353~48331856:-
THCA	cis	rs12410462	0.591	rs12082414	ENSG00000227711.2	RP11-275O4.5	-4.5	8.49e-06	0.000885	-0.25	-0.2	Major depressive disorder;	chr1:227598556	chr1:227509028~227520477:-
THCA	cis	rs4824093	0.545	rs58876234	ENSG00000278869.1	CITF22-49E9.3	4.5	8.5e-06	0.000885	0.38	0.2	Amyotrophic lateral sclerosis (sporadic);	chr22:49865220	chr22:49933198~49934074:-
THCA	cis	rs4824093	0.61	rs60036544	ENSG00000278869.1	CITF22-49E9.3	4.5	8.5e-06	0.000885	0.38	0.2	Amyotrophic lateral sclerosis (sporadic);	chr22:49870371	chr22:49933198~49934074:-
THCA	cis	rs4824093	0.61	rs73441787	ENSG00000278869.1	CITF22-49E9.3	4.5	8.5e-06	0.000885	0.38	0.2	Amyotrophic lateral sclerosis (sporadic);	chr22:49875998	chr22:49933198~49934074:-
THCA	cis	rs4824093	0.61	rs73443906	ENSG00000278869.1	CITF22-49E9.3	4.5	8.5e-06	0.000885	0.38	0.2	Amyotrophic lateral sclerosis (sporadic);	chr22:49880645	chr22:49933198~49934074:-
THCA	cis	rs12691307	1	rs12691307	ENSG00000183604.13	SMG1P5	-4.5	8.5e-06	0.000885	-0.19	-0.2	Schizophrenia;	chr16:29928556	chr16:30267553~30335374:-
THCA	cis	rs11976180	1	rs2951372	ENSG00000244198.4	RP4-545C24.1	-4.5	8.5e-06	0.000885	-0.2	-0.2	Obesity-related traits;	chr7:144052410	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs1320894	ENSG00000244198.4	RP4-545C24.1	-4.5	8.5e-06	0.000885	-0.2	-0.2	Obesity-related traits;	chr7:144054709	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2951369	ENSG00000244198.4	RP4-545C24.1	-4.5	8.5e-06	0.000885	-0.2	-0.2	Obesity-related traits;	chr7:144055545	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2951368	ENSG00000244198.4	RP4-545C24.1	-4.5	8.5e-06	0.000885	-0.2	-0.2	Obesity-related traits;	chr7:144055728	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2961115	ENSG00000244198.4	RP4-545C24.1	-4.5	8.5e-06	0.000885	-0.2	-0.2	Obesity-related traits;	chr7:144056278	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2951364	ENSG00000244198.4	RP4-545C24.1	-4.5	8.5e-06	0.000885	-0.2	-0.2	Obesity-related traits;	chr7:144057390	chr7:144194858~144280547:+
THCA	cis	rs713477	0.524	rs7149317	ENSG00000258413.1	RP11-665C16.6	4.5	8.5e-06	0.000885	0.29	0.2	Pediatric bone mineral content (femoral neck);	chr14:55435824	chr14:55262767~55272075:-
THCA	cis	rs2067615	0.56	rs10861671	ENSG00000260329.1	RP11-412D9.4	-4.5	8.5e-06	0.000885	-0.19	-0.2	Heart rate;	chr12:106827149	chr12:106954029~106955497:-
THCA	cis	rs17345786	0.798	rs4257518	ENSG00000256628.3	ZBTB11-AS1	-4.5	8.5e-06	0.000885	-0.24	-0.2	Colonoscopy-negative controls vs population controls;	chr3:101562865	chr3:101676475~101679217:+
THCA	cis	rs12807809	1	rs12807809	ENSG00000254941.1	RP11-677M14.5	-4.5	8.5e-06	0.000885	-0.21	-0.2	Schizophrenia;	chr11:124736389	chr11:124807822~124808269:-
THCA	cis	rs36715	1	rs36693	ENSG00000245937.6	LINC01184	4.5	8.5e-06	0.000886	0.23	0.2	Breast cancer;	chr5:128213008	chr5:127940426~128083172:-
THCA	cis	rs4714902	0.655	rs9367235	ENSG00000231769.2	RP1-8B1.4	-4.5	8.5e-06	0.000886	-0.18	-0.2	Colonoscopy-negative controls vs population controls;	chr6:46142260	chr6:46097093~46129706:-
THCA	cis	rs55661361	0.708	rs7113041	ENSG00000254941.1	RP11-677M14.5	-4.5	8.5e-06	0.000886	-0.18	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742695	chr11:124807822~124808269:-
THCA	cis	rs13113518	1	rs13133579	ENSG00000249700.7	SRD5A3-AS1	4.5	8.5e-06	0.000886	0.25	0.2	Height;	chr4:55459921	chr4:55363971~55395847:-
THCA	cis	rs17221829	0.733	rs2200750	ENSG00000280385.1	AP000648.5	-4.5	8.51e-06	0.000886	-0.2	-0.2	Anxiety in major depressive disorder;	chr11:89682992	chr11:90193614~90198120:+
THCA	cis	rs11633886	0.835	rs4774769	ENSG00000273972.1	CTD-2306A12.1	-4.5	8.51e-06	0.000886	-0.22	-0.2	Diisocyanate-induced asthma;	chr15:45806495	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.835	rs4774770	ENSG00000273972.1	CTD-2306A12.1	-4.5	8.51e-06	0.000886	-0.22	-0.2	Diisocyanate-induced asthma;	chr15:45806692	chr15:45702640~45703183:+
THCA	cis	rs9990333	1	rs9990333	ENSG00000226155.1	AC124944.3	4.5	8.51e-06	0.000886	0.24	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195912049~195913986:+
THCA	cis	rs17154702	0.524	rs2664041	ENSG00000253893.2	FAM85B	4.5	8.51e-06	0.000886	0.28	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr8:8735634	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.632	rs570396	ENSG00000253893.2	FAM85B	4.5	8.51e-06	0.000886	0.28	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736142	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.603	rs571130	ENSG00000253893.2	FAM85B	4.5	8.51e-06	0.000886	0.28	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736181	chr8:8167819~8226614:-
THCA	cis	rs7819412	0.745	rs6601569	ENSG00000206014.6	OR7E161P	4.5	8.51e-06	0.000886	0.23	0.2	Triglycerides;	chr8:11216069	chr8:11928597~11929563:-
THCA	cis	rs2836950	0.565	rs8130320	ENSG00000238141.2	BRWD1-AS1	-4.5	8.51e-06	0.000886	-0.23	-0.2	Menarche (age at onset);	chr21:39208332	chr21:39315707~39323218:+
THCA	cis	rs3734266	0.646	rs2395605	ENSG00000272288.4	RP11-140K17.3	-4.5	8.51e-06	0.000886	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34810716	chr6:34696317~34697470:+
THCA	cis	rs17221829	0.829	rs11018737	ENSG00000280385.1	AP000648.5	-4.5	8.51e-06	0.000886	-0.2	-0.2	Anxiety in major depressive disorder;	chr11:89693964	chr11:90193614~90198120:+
THCA	cis	rs2439831	0.681	rs825739	ENSG00000166763.7	STRCP1	4.5	8.51e-06	0.000886	0.27	0.2	Lung cancer in ever smokers;	chr15:43300230	chr15:43699488~43718184:-
THCA	cis	rs9925964	0.967	rs14235	ENSG00000232748.3	RP11-196G11.6	4.5	8.51e-06	0.000886	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31110472	chr16:31056460~31062803:+
THCA	cis	rs7264396	1	rs224429	ENSG00000088340.14	FER1L4	4.5	8.51e-06	0.000886	0.19	0.2	Total cholesterol levels;	chr20:35564250	chr20:35558737~35607562:-
THCA	cis	rs4908769	0.624	rs2708633	ENSG00000232912.4	RP5-1115A15.1	-4.5	8.51e-06	0.000886	-0.22	-0.2	Allergy;	chr1:8379565	chr1:8424645~8434838:+
THCA	cis	rs1198872	0.503	rs1627163	ENSG00000272275.1	RP11-791G15.2	-4.5	8.51e-06	0.000887	-0.23	-0.2	Cardiac Troponin-T levels;	chr2:10814718	chr2:10767875~10770058:-
THCA	cis	rs6860806	0.507	rs183898	ENSG00000224431.1	AC063976.7	-4.5	8.51e-06	0.000887	-0.18	-0.2	Breast cancer;	chr5:132381210	chr5:132199456~132203487:+
THCA	cis	rs2153535	0.585	rs7766729	ENSG00000230939.1	RP11-314C16.1	-4.5	8.51e-06	0.000887	-0.22	-0.2	Motion sickness;	chr6:8627408	chr6:8784178~8785445:+
THCA	cis	rs6012564	0.893	rs6012579	ENSG00000230758.1	SNAP23P	-4.5	8.52e-06	0.000887	-0.24	-0.2	Anger;	chr20:49006883	chr20:49038357~49038602:-
THCA	cis	rs734999	0.588	rs3748818	ENSG00000225931.3	RP3-395M20.7	4.5	8.52e-06	0.000887	0.24	0.2	Ulcerative colitis;	chr1:2594221	chr1:2566410~2569888:+
THCA	cis	rs7267979	0.844	rs2257649	ENSG00000277938.1	RP5-965G21.3	4.5	8.52e-06	0.000887	0.17	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25229150~25231933:+
THCA	cis	rs6479874	0.736	rs2816837	ENSG00000223502.1	RP11-96B5.3	-4.5	8.52e-06	0.000887	-0.23	-0.2	Migraine;	chr10:50992404	chr10:51062579~51068553:-
THCA	cis	rs7615952	0.546	rs11711150	ENSG00000171084.14	FAM86JP	4.5	8.52e-06	0.000887	0.28	0.2	Blood pressure (smoking interaction);	chr3:125596819	chr3:125916620~125930024:+
THCA	cis	rs17428076	0.556	rs12692976	ENSG00000228389.1	AC068039.4	4.5	8.52e-06	0.000887	0.21	0.2	Myopia;	chr2:171827893	chr2:171773482~171775844:+
THCA	cis	rs758747	0.531	rs13332500	ENSG00000276754.1	RP11-461A8.5	-4.5	8.52e-06	0.000887	-0.18	-0.2	Body mass index;	chr16:3525270	chr16:3686998~3687380:+
THCA	cis	rs471756	0.523	rs663552	ENSG00000231808.2	LINC01388	-4.5	8.53e-06	0.000888	-0.23	-0.2	Mean platelet volume;	chr9:219896	chr9:112713~113754:-
THCA	cis	rs17507216	0.718	rs4779034	ENSG00000255769.6	GOLGA2P10	-4.5	8.53e-06	0.000888	-0.3	-0.2	Excessive daytime sleepiness;	chr15:82576799	chr15:82472993~82513950:-
THCA	cis	rs7688540	0.511	rs61794965	ENSG00000211553.1	AC253576.2	-4.5	8.53e-06	0.000888	-0.32	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:136461~136568:+
THCA	cis	rs548181	0.536	rs503288	ENSG00000254671.2	STT3A-AS1	4.5	8.53e-06	0.000888	0.34	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125591892	chr11:125570284~125592568:-
THCA	cis	rs67478160	0.643	rs12880167	ENSG00000269910.1	RP11-73M18.10	4.5	8.53e-06	0.000888	0.17	0.2	Schizophrenia;	chr14:103834492	chr14:103694516~103695050:-
THCA	cis	rs375066	0.935	rs426534	ENSG00000278917.1	RP11-15A1.4	-4.5	8.53e-06	0.000888	-0.17	-0.2	Breast cancer;	chr19:43908431	chr19:43891233~43895411:+
THCA	cis	rs1023500	0.596	rs133369	ENSG00000237037.8	NDUFA6-AS1	-4.5	8.53e-06	0.000888	-0.17	-0.2	Schizophrenia;	chr22:42067810	chr22:42090931~42137742:+
THCA	cis	rs7851660	0.594	rs28703314	ENSG00000214417.4	KRT18P13	-4.5	8.53e-06	0.000888	-0.18	-0.2	Strep throat;	chr9:97897863	chr9:97698922~97700734:+
THCA	cis	rs8054556	0.656	rs4420550	ENSG00000183604.13	SMG1P5	-4.5	8.53e-06	0.000888	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29927499	chr16:30267553~30335374:-
THCA	cis	rs61270009	0.955	rs4916898	ENSG00000247828.6	TMEM161B-AS1	4.5	8.53e-06	0.000888	0.17	0.2	Depressive symptoms;	chr5:88290245	chr5:88268895~88436685:+
THCA	cis	rs11723261	0.621	rs6599307	ENSG00000250892.1	RP11-1365D11.1	4.5	8.54e-06	0.000889	0.28	0.2	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:201409~205009:-
THCA	cis	rs9788682	0.747	rs7177514	ENSG00000261143.1	ADAMTS7P3	-4.5	8.54e-06	0.000889	-0.27	-0.2	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615064	chr15:77976042~77993057:+
THCA	cis	rs6963495	0.745	rs2392749	ENSG00000272604.1	RP11-251G23.5	4.5	8.54e-06	0.000889	0.25	0.2	Bipolar disorder (body mass index interaction);	chr7:105542158	chr7:105571083~105573660:+
THCA	cis	rs1030877	0.515	rs3828300	ENSG00000235319.1	AC012360.4	4.5	8.54e-06	0.000889	0.27	0.2	Obesity-related traits;	chr2:105284650	chr2:105324210~105330529:+
THCA	cis	rs11634944	0.901	rs34383778	ENSG00000257151.1	PWAR6	4.5	8.54e-06	0.000889	0.16	0.2	Interleukin-8 levels;	chr15:24951568	chr15:25031873~25036490:+
THCA	cis	rs9393777	0.844	rs35909544	ENSG00000219392.1	RP1-265C24.5	-4.5	8.54e-06	0.000889	-0.39	-0.2	Intelligence (multi-trait analysis);	chr6:27195677	chr6:28115628~28116551:+
THCA	cis	rs896854	0.738	rs527234	ENSG00000253528.2	RP11-347C18.4	-4.5	8.54e-06	0.000889	-0.24	-0.2	Type 2 diabetes;	chr8:94951570	chr8:94974573~94974853:-
THCA	cis	rs1113500	0.633	rs1777451	ENSG00000230489.1	VAV3-AS1	4.5	8.55e-06	0.00089	0.19	0.2	Growth-regulated protein alpha levels;	chr1:108035560	chr1:107964443~107994607:+
THCA	cis	rs181553	0.664	rs10775491	ENSG00000266696.1	RP11-30L3.2	-4.5	8.55e-06	0.00089	-0.24	-0.2	Hip circumference adjusted for BMI;	chr18:49162097	chr18:49205912~49208781:+
THCA	cis	rs6954895	0.545	rs918880	ENSG00000271122.1	RP11-379H18.1	4.5	8.55e-06	0.00089	0.13	0.2	Anger;	chr7:35550698	chr7:35695214~35699413:+
THCA	cis	rs2562456	0.833	rs62107540	ENSG00000268117.1	VN1R84P	4.5	8.55e-06	0.00089	0.33	0.2	Pain;	chr19:21335693	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62107541	ENSG00000268117.1	VN1R84P	4.5	8.55e-06	0.00089	0.33	0.2	Pain;	chr19:21335733	chr19:21719801~21720035:-
THCA	cis	rs853679	1	rs6905391	ENSG00000272009.1	RP1-313I6.12	-4.5	8.55e-06	0.00089	-0.27	-0.2	Depression;	chr6:28294909	chr6:28078792~28081130:-
THCA	cis	rs8017455	0.523	rs17111431	ENSG00000259167.2	NMNAT1P1	4.5	8.56e-06	0.00089	0.3	0.2	Hair morphology;	chr14:81093790	chr14:81032529~81033404:+
THCA	cis	rs526231	0.644	rs35797	ENSG00000175749.11	EIF3KP1	-4.5	8.56e-06	0.000891	-0.26	-0.2	Primary biliary cholangitis;	chr5:103278626	chr5:103032376~103033031:+
THCA	cis	rs9878978	0.691	rs34831690	ENSG00000237990.3	CNTN4-AS1	4.5	8.56e-06	0.000891	0.24	0.2	Blood pressure (smoking interaction);	chr3:2395959	chr3:3039033~3069242:-
THCA	cis	rs9878978	0.691	rs34078497	ENSG00000237990.3	CNTN4-AS1	4.5	8.56e-06	0.000891	0.24	0.2	Blood pressure (smoking interaction);	chr3:2395973	chr3:3039033~3069242:-
THCA	cis	rs4568518	0.53	rs10273476	ENSG00000279048.1	RP11-511H23.2	4.5	8.56e-06	0.000891	0.13	0.2	Measles;	chr7:17958795	chr7:17940503~17942922:+
THCA	cis	rs72634501	0.716	rs72660086	ENSG00000228060.1	RP11-69E11.8	-4.5	8.56e-06	0.000891	-0.22	-0.2	HDL cholesterol;	chr1:39106320	chr1:39565160~39573203:+
THCA	cis	rs7621331	0.963	rs1113211	ENSG00000273486.1	RP11-731C17.2	4.5	8.57e-06	0.000892	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135954635	chr3:136837338~136839021:-
THCA	cis	rs7824557	0.603	rs2250028	ENSG00000154316.13	TDH	-4.5	8.57e-06	0.000892	-0.15	-0.2	Retinal vascular caliber;	chr8:11356080	chr8:11339637~11368452:+
THCA	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-4.5	8.57e-06	0.000892	-0.32	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000275400.1	RP4-756H11.5	4.5	8.57e-06	0.000892	0.22	0.2	Corneal structure;	chr7:66821880	chr7:66553805~66554199:-
THCA	cis	rs7520050	0.966	rs61102033	ENSG00000234329.1	RP11-767N6.2	-4.5	8.57e-06	0.000892	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000273796.1	LL21NC02-21A1.1	-4.5	8.57e-06	0.000892	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45403809~45404369:-
THCA	cis	rs2880765	0.743	rs12906308	ENSG00000259630.2	CTD-2262B20.1	4.5	8.57e-06	0.000892	0.22	0.2	Coronary artery disease;	chr15:85464828	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.743	rs8039049	ENSG00000259630.2	CTD-2262B20.1	-4.5	8.57e-06	0.000892	-0.22	-0.2	Coronary artery disease;	chr15:85464398	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.743	rs8039631	ENSG00000259630.2	CTD-2262B20.1	-4.5	8.57e-06	0.000892	-0.22	-0.2	Coronary artery disease;	chr15:85464700	chr15:85415228~85415633:+
THCA	cis	rs1790761	0.667	rs598811	ENSG00000255318.1	RP11-655M14.13	4.5	8.58e-06	0.000892	0.22	0.2	Mean corpuscular volume;	chr11:67544205	chr11:67618279~67627304:-
THCA	cis	rs17270561	0.583	rs7749149	ENSG00000272462.2	U91328.19	-4.5	8.58e-06	0.000892	-0.17	-0.2	Iron status biomarkers;	chr6:25780911	chr6:25992662~26001775:+
THCA	cis	rs11633886	0.51	rs12594473	ENSG00000273972.1	CTD-2306A12.1	4.5	8.58e-06	0.000892	0.23	0.2	Diisocyanate-induced asthma;	chr15:45750399	chr15:45702640~45703183:+
THCA	cis	rs11096990	0.892	rs28639548	ENSG00000249685.1	RP11-360F5.3	-4.5	8.58e-06	0.000892	-0.26	-0.2	Cognitive function;	chr4:39185530	chr4:39133913~39135608:+
THCA	cis	rs7819412	0.806	rs2898256	ENSG00000206014.6	OR7E161P	4.5	8.58e-06	0.000892	0.24	0.2	Triglycerides;	chr8:11075185	chr8:11928597~11929563:-
THCA	cis	rs8058578	1	rs2289442	ENSG00000279196.1	RP11-1072A3.3	4.5	8.58e-06	0.000893	0.21	0.2	Multiple myeloma;	chr16:30728598	chr16:30984630~30988270:-
THCA	cis	rs4218	0.593	rs8040456	ENSG00000259732.1	RP11-59H7.3	-4.5	8.58e-06	0.000893	-0.28	-0.2	Social communication problems;	chr15:59063904	chr15:59121034~59133250:+
THCA	cis	rs9516	0.966	rs2887135	ENSG00000254974.1	RP11-702H23.2	4.5	8.59e-06	0.000893	0.23	0.2	Facial morphology (factor 15, philtrum width);	chr11:74452810	chr11:74485580~74486051:-
THCA	cis	rs9329221	0.683	rs4598253	ENSG00000261451.1	RP11-981G7.1	-4.5	8.59e-06	0.000893	-0.25	-0.2	Neuroticism;	chr8:10032794	chr8:10433672~10438312:+
THCA	cis	rs8113308	1	rs8113308	ENSG00000269483.1	AC006272.1	4.5	8.59e-06	0.000893	0.3	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942133	chr19:51839924~51843324:-
THCA	cis	rs2836974	0.644	rs719230	ENSG00000255568.3	BRWD1-AS2	-4.5	8.59e-06	0.000893	-0.17	-0.2	Cognitive function;	chr21:39304381	chr21:39313935~39314962:+
THCA	cis	rs9863	0.827	rs12823740	ENSG00000270028.1	RP11-380L11.4	4.5	8.59e-06	0.000893	0.21	0.2	White blood cell count;	chr12:123973455	chr12:123925461~123926083:-
THCA	cis	rs1023500	0.552	rs133368	ENSG00000237037.8	NDUFA6-AS1	-4.5	8.59e-06	0.000893	-0.17	-0.2	Schizophrenia;	chr22:42067685	chr22:42090931~42137742:+
THCA	cis	rs6747952	0.866	rs6726348	ENSG00000279484.1	KLHL30-AS1	4.5	8.59e-06	0.000894	0.19	0.2	Mean corpuscular hemoglobin concentration;	chr2:238175478	chr2:238152889~238155994:-
THCA	cis	rs7617480	0.648	rs4858830	ENSG00000229759.1	MRPS18AP1	4.5	8.59e-06	0.000894	0.31	0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48696569	chr3:48256350~48256938:-
THCA	cis	rs7617480	0.544	rs6442129	ENSG00000229759.1	MRPS18AP1	4.5	8.59e-06	0.000894	0.31	0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48697823	chr3:48256350~48256938:-
THCA	cis	rs17772222	0.606	rs449338	ENSG00000258983.2	RP11-507K2.2	-4.5	8.59e-06	0.000894	-0.23	-0.2	Coronary artery calcification;	chr14:88411690	chr14:88499334~88515502:+
THCA	cis	rs7726839	0.54	rs3749618	ENSG00000225138.6	CTD-2228K2.7	4.5	8.59e-06	0.000894	0.25	0.2	Obesity-related traits;	chr5:602535	chr5:473236~480884:+
THCA	cis	rs2904524	1	rs12309104	ENSG00000257815.4	RP11-611E13.2	-4.5	8.59e-06	0.000894	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70318084	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.881	rs940429	ENSG00000257815.4	RP11-611E13.2	-4.5	8.59e-06	0.000894	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70319028	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs12313398	ENSG00000257815.4	RP11-611E13.2	-4.5	8.59e-06	0.000894	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70320891	chr12:69904033~70243360:-
THCA	cis	rs2153535	0.561	rs9406184	ENSG00000230939.1	RP11-314C16.1	-4.5	8.59e-06	0.000894	-0.21	-0.2	Motion sickness;	chr6:8642681	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs11243263	ENSG00000230939.1	RP11-314C16.1	-4.5	8.59e-06	0.000894	-0.21	-0.2	Motion sickness;	chr6:8642880	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs9392233	ENSG00000230939.1	RP11-314C16.1	-4.5	8.59e-06	0.000894	-0.21	-0.2	Motion sickness;	chr6:8645042	chr6:8784178~8785445:+
THCA	cis	rs763121	0.853	rs1043441	ENSG00000228274.3	RP3-508I15.9	-4.5	8.59e-06	0.000894	-0.23	-0.2	Menopause (age at onset);	chr22:38734959	chr22:38667585~38681820:-
THCA	cis	rs28374715	0.532	rs11854632	ENSG00000247556.5	OIP5-AS1	-4.5	8.6e-06	0.000894	-0.19	-0.2	Ulcerative colitis;	chr15:41389896	chr15:41283990~41309737:+
THCA	cis	rs6416877	0.679	rs11078446	ENSG00000277491.1	RP11-676J12.9	-4.5	8.6e-06	0.000894	-0.22	-0.2	Myeloid white cell count;	chr17:1454240	chr17:795306~795794:+
THCA	cis	rs1766786	1	rs1766792	ENSG00000231365.4	RP11-418J17.1	-4.5	8.6e-06	0.000894	-0.27	-0.2	Chin dimples;	chr1:118923058	chr1:119140396~119275973:+
THCA	cis	rs3734266	0.702	rs1018622	ENSG00000272288.4	RP11-140K17.3	-4.5	8.6e-06	0.000894	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34820454	chr6:34696317~34697470:+
THCA	cis	rs4705952	0.832	rs17690122	ENSG00000233006.5	AC034220.3	-4.5	8.6e-06	0.000894	-0.19	-0.2	C-reactive protein levels;	chr5:132532143	chr5:132311285~132369916:-
THCA	cis	rs1667284	0.597	rs1667274	ENSG00000266521.1	RP11-650P15.1	4.5	8.6e-06	0.000894	0.26	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31632764	chr18:31496645~31497195:-
THCA	cis	rs172166	0.516	rs2622322	ENSG00000280107.1	AL022393.9	-4.5	8.6e-06	0.000895	-0.2	-0.2	Cardiac Troponin-T levels;	chr6:28149665	chr6:28170845~28172521:+
THCA	cis	rs11634944	0.506	rs765438	ENSG00000257151.1	PWAR6	4.5	8.61e-06	0.000895	0.15	0.2	Interleukin-8 levels;	chr15:24990981	chr15:25031873~25036490:+
THCA	cis	rs12935418	0.583	rs80181133	ENSG00000278985.1	RP11-303E16.9	4.5	8.61e-06	0.000895	0.26	0.2	Mean corpuscular volume;	chr16:80934053	chr16:80982319~80984094:-
THCA	cis	rs6456156	0.811	rs975822	ENSG00000235272.1	FAM103A2P	-4.5	8.61e-06	0.000896	-0.28	-0.2	Primary biliary cholangitis;	chr6:167102970	chr6:166586124~166586477:-
THCA	cis	rs3820928	1	rs1835158	ENSG00000212391.1	SNORA48	-4.5	8.61e-06	0.000896	-0.23	-0.2	Pulmonary function;	chr2:226899277	chr2:226968989~226969122:-
THCA	cis	rs11633886	0.622	rs4774224	ENSG00000273972.1	CTD-2306A12.1	-4.5	8.61e-06	0.000896	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45837808	chr15:45702640~45703183:+
THCA	cis	rs4906332	0.811	rs2296487	ENSG00000252469.1	RNU7-160P	4.5	8.61e-06	0.000896	0.25	0.2	Coronary artery disease;	chr14:103529868	chr14:103550345~103550406:+
THCA	cis	rs34421088	0.623	rs2572433	ENSG00000255046.1	RP11-297N6.4	-4.5	8.61e-06	0.000896	-0.23	-0.2	Neuroticism;	chr8:11243532	chr8:11797928~11802568:-
THCA	cis	rs1707322	1	rs10890378	ENSG00000281133.1	AL355480.3	4.5	8.61e-06	0.000896	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs785478	ENSG00000281133.1	AL355480.3	4.5	8.61e-06	0.000896	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs6657720	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs7519181	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs10890372	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.928	rs6681068	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211228	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs9803784	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs12022335	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs10890375	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs10890377	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs10789484	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs7527079	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs34446427	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs4660900	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4454479	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs7517560	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs12077546	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs12124291	ENSG00000281133.1	AL355480.3	-4.5	8.61e-06	0.000896	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45580892~45580996:-
THCA	cis	rs763121	0.853	rs4820345	ENSG00000235209.1	CTA-150C2.13	4.5	8.62e-06	0.000896	0.27	0.2	Menopause (age at onset);	chr22:38695146	chr22:38921227~38924708:+
THCA	cis	rs734999	0.967	rs4486391	ENSG00000225931.3	RP3-395M20.7	4.5	8.62e-06	0.000896	0.25	0.2	Ulcerative colitis;	chr1:2581616	chr1:2566410~2569888:+
THCA	cis	rs2028299	1	rs3960018	ENSG00000259677.1	RP11-493E3.1	4.5	8.62e-06	0.000896	0.26	0.2	Type 2 diabetes;	chr15:89840075	chr15:89876540~89877285:+
THCA	cis	rs2028299	1	rs2351706	ENSG00000259677.1	RP11-493E3.1	4.5	8.62e-06	0.000896	0.26	0.2	Type 2 diabetes;	chr15:89840883	chr15:89876540~89877285:+
THCA	cis	rs875971	0.862	rs880166	ENSG00000229886.1	RP5-1132H15.3	-4.5	8.62e-06	0.000896	-0.21	-0.2	Aortic root size;	chr7:66205775	chr7:66025126~66031544:-
THCA	cis	rs7119038	0.865	rs10892299	ENSG00000255239.1	AP002954.6	-4.5	8.62e-06	0.000897	-0.31	-0.2	Sjögren's syndrome;	chr11:118856134	chr11:118688039~118690600:-
THCA	cis	rs2302464	0.661	rs58156049	ENSG00000214846.4	RP11-115L11.1	4.5	8.62e-06	0.000897	0.5	0.2	Cerebrospinal fluid biomarker levels;	chr4:15745574	chr4:15730962~15731627:-
THCA	cis	rs4648045	0.647	rs230521	ENSG00000246560.2	RP11-10L12.4	-4.5	8.63e-06	0.000897	-0.24	-0.2	Lymphocyte percentage of white cells;	chr4:102542171	chr4:102828055~102844075:+
THCA	cis	rs4908768	0.581	rs2784740	ENSG00000232912.4	RP5-1115A15.1	-4.5	8.63e-06	0.000897	-0.23	-0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8440997	chr1:8424645~8434838:+
THCA	cis	rs8014252	0.803	rs17108107	ENSG00000259158.2	ADAM20P1	-4.5	8.63e-06	0.000897	-0.23	-0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70411054	chr14:70468881~70483756:-
THCA	cis	rs12681288	0.862	rs935821	ENSG00000260721.1	AF067845.1	4.5	8.63e-06	0.000897	0.24	0.2	Schizophrenia;	chr8:1072455	chr8:1368642~1369833:-
THCA	cis	rs6121246	0.909	rs6060979	ENSG00000230613.1	HM13-AS1	4.5	8.63e-06	0.000897	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31829719	chr20:31567707~31573263:-
THCA	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-4.5	8.63e-06	0.000897	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
THCA	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-4.5	8.63e-06	0.000897	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-4.5	8.63e-06	0.000897	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
THCA	cis	rs728616	0.614	rs1885552	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952336	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs1885551	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952597	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs12253608	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952727	chr10:79904898~79950336:+
THCA	cis	rs728616	0.764	rs1885549	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952794	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs12245076	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953675	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs10788319	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953754	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs11200859	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953805	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs10887229	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954018	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs10788321	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954039	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs61858839	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954162	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs61858841	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954420	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs61858842	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955283	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs10887233	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955596	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs10887234	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955666	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs2146192	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955982	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs2146191	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955998	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs10887243	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957339	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs10887244	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957352	chr10:79904898~79950336:+
THCA	cis	rs728616	0.541	rs61860401	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs61860413	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:79904898~79950336:+
THCA	cis	rs728616	0.614	rs61860414	ENSG00000242600.5	MBL1P	4.5	8.63e-06	0.000897	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:79904898~79950336:+
THCA	cis	rs3806843	0.518	rs2569191	ENSG00000202515.1	VTRNA1-3	4.5	8.63e-06	0.000898	0.23	0.2	Depressive symptoms (multi-trait analysis);	chr5:140634318	chr5:140726158~140726246:+
THCA	cis	rs875971	0.638	rs6960778	ENSG00000229886.1	RP5-1132H15.3	-4.5	8.63e-06	0.000898	-0.21	-0.2	Aortic root size;	chr7:66606610	chr7:66025126~66031544:-
THCA	cis	rs4218	0.859	rs755786	ENSG00000277144.1	RP11-59H7.4	-4.5	8.63e-06	0.000898	-0.28	-0.2	Social communication problems;	chr15:59118456	chr15:59115547~59116089:-
THCA	cis	rs11633886	0.835	rs11633914	ENSG00000273972.1	CTD-2306A12.1	-4.5	8.64e-06	0.000898	-0.22	-0.2	Diisocyanate-induced asthma;	chr15:45803324	chr15:45702640~45703183:+
THCA	cis	rs7674212	0.772	rs13113099	ENSG00000230069.3	LRRC37A15P	-4.5	8.64e-06	0.000898	-0.21	-0.2	Type 2 diabetes;	chr4:103052965	chr4:102727274~102730721:-
THCA	cis	rs2836950	0.545	rs2836952	ENSG00000238141.2	BRWD1-AS1	-4.5	8.64e-06	0.000898	-0.23	-0.2	Menarche (age at onset);	chr21:39244725	chr21:39315707~39323218:+
THCA	cis	rs1728785	0.901	rs2862781	ENSG00000274698.1	RP11-71L14.4	4.5	8.64e-06	0.000898	0.28	0.2	Ulcerative colitis;	chr16:68605331	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs7194664	ENSG00000274698.1	RP11-71L14.4	4.5	8.64e-06	0.000898	0.28	0.2	Ulcerative colitis;	chr16:68609410	chr16:68450283~68452318:+
THCA	cis	rs9494145	0.526	rs17064262	ENSG00000232876.1	CTA-212D2.2	-4.5	8.64e-06	0.000898	-0.31	-0.2	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135144336	chr6:135055033~135060550:+
THCA	cis	rs7520050	0.966	rs12564541	ENSG00000234329.1	RP11-767N6.2	-4.5	8.64e-06	0.000898	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45651039~45651826:-
THCA	cis	rs7474896	0.559	rs1735641	ENSG00000226578.1	RP11-258F22.1	4.5	8.64e-06	0.000898	0.28	0.2	Obesity (extreme);	chr10:37895924	chr10:37775371~37784131:-
THCA	cis	rs375066	0.935	rs373168	ENSG00000278917.1	RP11-15A1.4	-4.5	8.64e-06	0.000898	-0.17	-0.2	Breast cancer;	chr19:43926717	chr19:43891233~43895411:+
THCA	cis	rs11756659	0.505	rs16891146	ENSG00000272462.2	U91328.19	-4.5	8.64e-06	0.000898	-0.18	-0.2	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25903080	chr6:25992662~26001775:+
THCA	cis	rs4713118	0.786	rs200503	ENSG00000226314.6	ZNF192P1	-4.5	8.65e-06	0.000899	-0.26	-0.2	Parkinson's disease;	chr6:27818104	chr6:28161781~28169594:+
THCA	cis	rs2880765	0.743	rs11630410	ENSG00000259630.2	CTD-2262B20.1	-4.5	8.65e-06	0.000899	-0.22	-0.2	Coronary artery disease;	chr15:85461510	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.71	rs11630457	ENSG00000259630.2	CTD-2262B20.1	-4.5	8.65e-06	0.000899	-0.22	-0.2	Coronary artery disease;	chr15:85461570	chr15:85415228~85415633:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000272831.1	RP11-792A8.4	4.5	8.65e-06	0.000899	0.13	0.2	Aortic root size;	chr7:65963835	chr7:66739829~66740385:-
THCA	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-4.5	8.65e-06	0.000899	-0.24	-0.2	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
THCA	cis	rs3738443	0.644	rs2799177	ENSG00000259865.1	RP11-488L18.10	-4.5	8.65e-06	0.000899	-0.21	-0.2	Alcohol dependence;	chr1:247235898	chr1:247187281~247188526:-
THCA	cis	rs2281603	0.57	rs2123460	ENSG00000272909.1	CTD-2555O16.4	-4.5	8.65e-06	0.000899	-0.23	-0.2	Lymphocyte counts;	chr14:64485507	chr14:64440369~64442238:-
THCA	cis	rs2904524	0.737	rs3759156	ENSG00000257815.4	RP11-611E13.2	-4.5	8.65e-06	0.000899	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70241575	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs3759152	ENSG00000257815.4	RP11-611E13.2	-4.5	8.65e-06	0.000899	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70241817	chr12:69904033~70243360:-
THCA	cis	rs6430585	0.528	rs3099429	ENSG00000231890.6	DARS-AS1	-4.5	8.65e-06	0.000899	-0.24	-0.2	Corneal structure;	chr2:135898012	chr2:135985176~136022593:+
THCA	cis	rs9329221	0.712	rs1962073	ENSG00000261451.1	RP11-981G7.1	-4.5	8.65e-06	0.000899	-0.24	-0.2	Neuroticism;	chr8:10403043	chr8:10433672~10438312:+
THCA	cis	rs28476539	0.568	rs7691204	ENSG00000270480.1	RP11-57B24.1	4.5	8.65e-06	0.000899	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82632840	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.61	rs77589586	ENSG00000270480.1	RP11-57B24.1	4.5	8.65e-06	0.000899	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82633181	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.64	rs7655583	ENSG00000270480.1	RP11-57B24.1	4.5	8.65e-06	0.000899	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82633503	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.64	rs7672265	ENSG00000270480.1	RP11-57B24.1	4.5	8.65e-06	0.000899	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82633669	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.64	rs7656006	ENSG00000270480.1	RP11-57B24.1	4.5	8.65e-06	0.000899	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82633714	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.64	rs7672496	ENSG00000270480.1	RP11-57B24.1	4.5	8.65e-06	0.000899	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82633835	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.64	rs7698041	ENSG00000270480.1	RP11-57B24.1	4.5	8.65e-06	0.000899	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82633988	chr4:82691737~82692468:+
THCA	cis	rs2977993	1	rs2977993	ENSG00000234771.3	SLC25A25-AS1	4.5	8.65e-06	9e-04	0.17	0.2	Schizophrenia;	chr9:128846507	chr9:128108581~128118693:-
THCA	cis	rs4072705	0.646	rs10120967	ENSG00000224020.1	MIR181A2HG	-4.5	8.66e-06	9e-04	-0.19	-0.2	Menarche (age at onset);	chr9:124481855	chr9:124658467~124698631:+
THCA	cis	rs453301	0.658	rs12114954	ENSG00000233609.3	RP11-62H7.2	-4.5	8.66e-06	9e-04	-0.2	-0.2	Joint mobility (Beighton score);	chr8:9047352	chr8:8961200~8979025:+
THCA	cis	rs875971	0.767	rs12668005	ENSG00000229886.1	RP5-1132H15.3	4.5	8.66e-06	9e-04	0.21	0.2	Aortic root size;	chr7:66444034	chr7:66025126~66031544:-
THCA	cis	rs6445975	0.715	rs3773007	ENSG00000272360.1	RP11-359I18.5	-4.5	8.67e-06	0.000901	-0.22	-0.2	Systemic lupus erythematosus;	chr3:58283839	chr3:58490830~58491291:-
THCA	cis	rs858239	0.6	rs2014768	ENSG00000226816.2	AC005082.12	4.5	8.67e-06	0.000901	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs6978827	ENSG00000226816.2	AC005082.12	4.5	8.67e-06	0.000901	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs7790157	ENSG00000226816.2	AC005082.12	4.5	8.67e-06	0.000901	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs6960001	ENSG00000226816.2	AC005082.12	4.5	8.67e-06	0.000901	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs10237755	ENSG00000226816.2	AC005082.12	4.5	8.67e-06	0.000901	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs6961131	ENSG00000226816.2	AC005082.12	4.5	8.67e-06	0.000901	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23206013~23208045:+
THCA	cis	rs2880765	0.743	rs16940052	ENSG00000259630.2	CTD-2262B20.1	-4.5	8.67e-06	0.000901	-0.22	-0.2	Coronary artery disease;	chr15:85463443	chr15:85415228~85415633:+
THCA	cis	rs17095355	1	rs7906904	ENSG00000203876.8	ADD3-AS1	-4.5	8.68e-06	0.000902	-0.22	-0.2	Biliary atresia;	chr10:109948435	chr10:109940104~110008381:-
THCA	cis	rs56804039	1	rs11777086	ENSG00000254153.1	CTA-398F10.2	4.5	8.68e-06	0.000902	0.25	0.2	Cervical cancer;	chr8:8526969	chr8:8456909~8461337:-
THCA	cis	rs172166	0.561	rs149976	ENSG00000273712.1	RP5-874C20.7	-4.5	8.68e-06	0.000902	-0.22	-0.2	Cardiac Troponin-T levels;	chr6:28019998	chr6:28315613~28315883:-
THCA	cis	rs35740288	0.651	rs34257708	ENSG00000259295.5	CSPG4P12	4.5	8.68e-06	0.000902	0.35	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85641036	chr15:85191438~85213905:+
THCA	cis	rs10090774	0.965	rs306948	ENSG00000279766.1	RP11-642A1.2	4.5	8.68e-06	0.000902	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141006285	chr8:140572142~140572812:-
THCA	cis	rs4934494	0.768	rs2094214	ENSG00000240996.1	RP11-80H5.7	-4.5	8.68e-06	0.000902	-0.23	-0.2	Red blood cell count;	chr10:89649624	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.635	rs12572869	ENSG00000240996.1	RP11-80H5.7	-4.5	8.68e-06	0.000902	-0.23	-0.2	Red blood cell count;	chr10:89653611	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.768	rs67111731	ENSG00000240996.1	RP11-80H5.7	-4.5	8.68e-06	0.000902	-0.23	-0.2	Red blood cell count;	chr10:89659528	chr10:89694295~89697928:-
THCA	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-4.5	8.69e-06	0.000902	-0.28	-0.2	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
THCA	cis	rs8067545	0.611	rs2526465	ENSG00000270091.1	RP11-78O7.2	4.5	8.69e-06	0.000902	0.15	0.2	Schizophrenia;	chr17:20264298	chr17:19896590~19897287:-
THCA	cis	rs16846053	0.792	rs10200835	ENSG00000227403.1	AC009299.3	4.5	8.69e-06	0.000903	0.46	0.2	Blood osmolality (transformed sodium);	chr2:161831529	chr2:161244739~161249050:+
THCA	cis	rs1046896	0.586	rs9897951	ENSG00000263063.1	RP11-388C12.1	-4.5	8.69e-06	0.000903	-0.27	-0.2	Glycated hemoglobin levels;	chr17:82852786	chr17:82713908~82716255:-
THCA	cis	rs3820928	1	rs10197757	ENSG00000212391.1	SNORA48	-4.5	8.7e-06	0.000903	-0.23	-0.2	Pulmonary function;	chr2:226898528	chr2:226968989~226969122:-
THCA	cis	rs6657613	0.68	rs7545499	ENSG00000186301.8	MST1P2	-4.5	8.7e-06	0.000904	-0.17	-0.2	Hip circumference adjusted for BMI;	chr1:17048193	chr1:16645622~16650289:+
THCA	cis	rs11175834	0.655	rs11175829	ENSG00000213344.2	PCNPP3	4.5	8.7e-06	0.000904	0.35	0.2	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65587275	chr12:65645992~65646462:-
THCA	cis	rs7772486	0.754	rs12199362	ENSG00000270638.1	RP3-466P17.1	4.5	8.7e-06	0.000904	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145735570~145737218:+
THCA	cis	rs9878978	1	rs13074392	ENSG00000237990.3	CNTN4-AS1	4.5	8.7e-06	0.000904	0.22	0.2	Blood pressure (smoking interaction);	chr3:2444111	chr3:3039033~3069242:-
THCA	cis	rs12188164	0.515	rs11745246	ENSG00000225138.6	CTD-2228K2.7	4.5	8.7e-06	0.000904	0.21	0.2	Cystic fibrosis severity;	chr5:410828	chr5:473236~480884:+
THCA	cis	rs7674212	0.507	rs223322	ENSG00000248971.2	KRT8P46	-4.5	8.7e-06	0.000904	-0.25	-0.2	Type 2 diabetes;	chr4:102879037	chr4:102728746~102730171:-
THCA	cis	rs4654783	0.671	rs1474647	ENSG00000228397.1	RP1-224A6.3	4.5	8.7e-06	0.000904	0.29	0.2	Endometriosis;	chr1:22115372	chr1:22023994~22024968:-
THCA	cis	rs250518	0.926	rs10942402	ENSG00000272081.1	CTD-2376I4.2	-4.5	8.71e-06	0.000904	-0.26	-0.2	Mean corpuscular hemoglobin concentration;	chr5:72760272	chr5:72955206~72955699:-
THCA	cis	rs7989336	0.527	rs9525172	ENSG00000247400.3	DNAJC3-AS1	4.5	8.71e-06	0.000904	0.14	0.2	Obesity;	chr13:96256174	chr13:95648733~95676925:-
THCA	cis	rs875971	0.545	rs1267814	ENSG00000273142.1	RP11-458F8.4	-4.5	8.71e-06	0.000904	-0.19	-0.2	Aortic root size;	chr7:66579422	chr7:66902857~66906297:+
THCA	cis	rs62025270	0.547	rs8035496	ENSG00000259295.5	CSPG4P12	-4.5	8.71e-06	0.000905	-0.3	-0.2	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85191438~85213905:+
THCA	cis	rs13126694	0.744	rs10049927	ENSG00000248429.4	RP11-597D13.9	4.5	8.71e-06	0.000905	0.22	0.2	Blood osmolality (transformed sodium);	chr4:157998056	chr4:158170752~158202877:+
THCA	cis	rs13126694	0.71	rs13137826	ENSG00000248429.4	RP11-597D13.9	4.5	8.71e-06	0.000905	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158001354	chr4:158170752~158202877:+
THCA	cis	rs6901152	0.584	rs7748846	ENSG00000217648.1	RP1-95L4.4	-4.5	8.71e-06	0.000905	-0.21	-0.2	Acute lymphoblastic leukemia (childhood);	chr6:143243264	chr6:143342246~143343383:+
THCA	cis	rs7824557	0.564	rs13268126	ENSG00000206014.6	OR7E161P	4.5	8.71e-06	0.000905	0.24	0.2	Retinal vascular caliber;	chr8:11373065	chr8:11928597~11929563:-
THCA	cis	rs4950322	0.576	rs4950427	ENSG00000271721.1	RP11-337C18.9	-4.5	8.71e-06	0.000905	-0.2	-0.2	Protein quantitative trait loci;	chr1:147391175	chr1:147175602~147177740:+
THCA	cis	rs17604090	0.529	rs2392128	ENSG00000225264.3	ZNRF2P2	-4.5	8.71e-06	0.000905	-0.23	-0.2	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29671523	chr7:29598795~29685255:-
THCA	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	4.5	8.71e-06	0.000905	0.21	0.2	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
THCA	cis	rs138249	0.867	rs138226	ENSG00000273253.2	RP3-402G11.26	-4.5	8.71e-06	0.000905	-0.2	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50118358	chr22:50199090~50200837:-
THCA	cis	rs138249	0.898	rs138227	ENSG00000273253.2	RP3-402G11.26	-4.5	8.71e-06	0.000905	-0.2	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50118386	chr22:50199090~50200837:-
THCA	cis	rs2562456	0.833	rs62110071	ENSG00000268117.1	VN1R84P	4.5	8.72e-06	0.000905	0.33	0.2	Pain;	chr19:21288101	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs11667392	ENSG00000268117.1	VN1R84P	4.5	8.72e-06	0.000905	0.33	0.2	Pain;	chr19:21289806	chr19:21719801~21720035:-
THCA	cis	rs4824093	0.61	rs3761496	ENSG00000278869.1	CITF22-49E9.3	4.5	8.72e-06	0.000905	0.39	0.2	Amyotrophic lateral sclerosis (sporadic);	chr22:49852818	chr22:49933198~49934074:-
THCA	cis	rs9843304	0.568	rs13072639	ENSG00000244503.1	RP11-278L15.6	4.5	8.72e-06	0.000906	0.27	0.2	Gallstone disease;	chr3:149489241	chr3:149494660~149495995:+
THCA	cis	rs7267979	0.966	rs7270835	ENSG00000274973.1	RP13-401N8.7	-4.5	8.72e-06	0.000906	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6115191	ENSG00000274973.1	RP13-401N8.7	-4.5	8.72e-06	0.000906	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6107045	ENSG00000274973.1	RP13-401N8.7	-4.5	8.72e-06	0.000906	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6107046	ENSG00000274973.1	RP13-401N8.7	-4.5	8.72e-06	0.000906	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6107047	ENSG00000274973.1	RP13-401N8.7	-4.5	8.72e-06	0.000906	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25845497~25845862:+
THCA	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-4.5	8.72e-06	0.000906	-0.23	-0.2	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
THCA	cis	rs7824557	0.564	rs34389419	ENSG00000206014.6	OR7E161P	4.5	8.72e-06	0.000906	0.24	0.2	Retinal vascular caliber;	chr8:11371810	chr8:11928597~11929563:-
THCA	cis	rs7179456	0.547	rs6494036	ENSG00000245975.2	RP11-30K9.6	4.5	8.72e-06	0.000906	0.2	0.2	Asperger disorder;	chr15:58723762	chr15:58768072~58770974:-
THCA	cis	rs9392556	0.626	rs626080	ENSG00000272248.1	RP3-406P24.4	-4.5	8.73e-06	0.000906	-0.24	-0.2	Blood metabolite levels;	chr6:4101333	chr6:4018713~4019202:+
THCA	cis	rs9863	0.861	rs11057396	ENSG00000270061.1	RP11-214K3.19	-4.5	8.73e-06	0.000906	-0.28	-0.2	White blood cell count;	chr12:123934515	chr12:123969990~123970344:-
THCA	cis	rs2030746	0.899	rs2030745	ENSG00000237614.1	AC073257.2	-4.5	8.73e-06	0.000907	-0.24	-0.2	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120551706	chr2:120542909~120544326:-
THCA	cis	rs9902453	1	rs8065261	ENSG00000263370.1	RP11-68I3.5	-4.5	8.73e-06	0.000907	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30091023	chr17:29639627~29640825:+
THCA	cis	rs375066	0.935	rs397346	ENSG00000278917.1	RP11-15A1.4	-4.5	8.73e-06	0.000907	-0.17	-0.2	Breast cancer;	chr19:43894963	chr19:43891233~43895411:+
THCA	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-4.5	8.73e-06	0.000907	-0.11	-0.2	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-4.5	8.73e-06	0.000907	-0.11	-0.2	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
THCA	cis	rs860295	0.812	rs12407800	ENSG00000160766.13	GBAP1	-4.5	8.73e-06	0.000907	-0.24	-0.2	Body mass index;	chr1:155790951	chr1:155213821~155227422:-
THCA	cis	rs8031584	0.918	rs61997140	ENSG00000178081.11	ULK4P3	4.5	8.74e-06	0.000907	0.26	0.2	Huntington's disease progression;	chr15:30985109	chr15:30103720~30131757:+
THCA	cis	rs1061377	0.513	rs2566166	ENSG00000249685.1	RP11-360F5.3	-4.5	8.74e-06	0.000908	-0.27	-0.2	Uric acid levels;	chr4:39148404	chr4:39133913~39135608:+
THCA	cis	rs7216064	1	rs11079707	ENSG00000278740.1	RP11-147L13.14	-4.5	8.74e-06	0.000908	-0.23	-0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839501	chr17:68188547~68189165:+
THCA	cis	rs17123764	0.818	rs73305008	ENSG00000257464.1	RP11-161H23.8	-4.5	8.74e-06	0.000908	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49565128	chr12:49442424~49442652:-
THCA	cis	rs734999	0.588	rs2985859	ENSG00000225931.3	RP3-395M20.7	-4.5	8.74e-06	0.000908	-0.24	-0.2	Ulcerative colitis;	chr1:2600977	chr1:2566410~2569888:+
THCA	cis	rs734999	0.588	rs3001837	ENSG00000225931.3	RP3-395M20.7	-4.5	8.74e-06	0.000908	-0.24	-0.2	Ulcerative colitis;	chr1:2601067	chr1:2566410~2569888:+
THCA	cis	rs4713118	0.523	rs2179096	ENSG00000216915.2	RP1-97D16.1	-4.5	8.74e-06	0.000908	-0.27	-0.2	Parkinson's disease;	chr6:27698141	chr6:27737000~27738494:-
THCA	cis	rs931127	0.658	rs4930305	ENSG00000214659.4	KRT8P26	-4.5	8.74e-06	0.000908	-0.18	-0.2	Systemic lupus erythematosus;	chr11:65696529	chr11:65726939~65728214:+
THCA	cis	rs4629607	1	rs4629607	ENSG00000272335.1	RP11-53O19.3	4.5	8.74e-06	0.000908	0.17	0.2	Schizophrenia;	chr5:44857365	chr5:44826076~44828592:+
THCA	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	4.5	8.75e-06	0.000908	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
THCA	cis	rs9987353	0.519	rs13276350	ENSG00000248538.5	RP11-10A14.5	4.5	8.75e-06	0.000908	0.26	0.2	Recombination measurement;	chr8:9205647	chr8:9189011~9202854:+
THCA	cis	rs427943	0.864	rs9980766	ENSG00000223768.1	LINC00205	-4.5	8.75e-06	0.000909	-0.18	-0.2	Body mass index;	chr21:45199836	chr21:45293285~45297354:+
THCA	cis	rs75920871	0.764	rs74428560	ENSG00000254851.1	RP11-109L13.1	-4.5	8.75e-06	0.000909	-0.43	-0.2	Subjective well-being;	chr11:117119266	chr11:117135528~117138582:+
THCA	cis	rs7520050	1	rs12410070	ENSG00000234329.1	RP11-767N6.2	-4.5	8.75e-06	0.000909	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45651039~45651826:-
THCA	cis	rs7520050	0.966	rs12410071	ENSG00000234329.1	RP11-767N6.2	-4.5	8.75e-06	0.000909	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45651039~45651826:-
THCA	cis	rs79040073	0.516	rs17400427	ENSG00000259531.2	RP11-295H24.3	4.5	8.75e-06	0.000909	0.27	0.2	Lung cancer in ever smokers;	chr15:49448874	chr15:49365124~49366685:-
THCA	cis	rs13118159	0.509	rs1882098	ENSG00000254094.1	AC078852.1	-4.5	8.75e-06	0.000909	-0.25	-0.2	Longevity;	chr4:1358643	chr4:1356581~1358075:+
THCA	cis	rs138880	0.505	rs56248708	ENSG00000260613.1	RP3-522J7.6	-4.5	8.75e-06	0.000909	-0.33	-0.2	Schizophrenia;	chr22:49913321	chr22:49832616~49837786:-
THCA	cis	rs12472274	0.941	rs11677230	ENSG00000279484.1	KLHL30-AS1	4.5	8.75e-06	0.000909	0.22	0.2	Phospholipid levels (plasma);	chr2:238183413	chr2:238152889~238155994:-
THCA	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-4.5	8.76e-06	0.000909	-0.23	-0.2	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
THCA	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-4.5	8.76e-06	0.000909	-0.23	-0.2	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
THCA	cis	rs4356203	0.875	rs7125607	ENSG00000272034.1	SNORD14A	-4.5	8.76e-06	0.000909	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074603	chr11:17074654~17074744:-
THCA	cis	rs12500482	0.935	rs2239736	ENSG00000248399.1	RP11-503N18.4	-4.5	8.76e-06	0.00091	-0.18	-0.2	Cognitive function;	chr4:2437202	chr4:2463797~2464124:+
THCA	cis	rs1979679	0.918	rs10771430	ENSG00000247934.4	RP11-967K21.1	4.5	8.76e-06	0.00091	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28470505	chr12:28163298~28190738:-
THCA	cis	rs8002861	0.846	rs56408817	ENSG00000274001.1	RP11-5G9.5	-4.5	8.76e-06	0.00091	-0.25	-0.2	Leprosy;	chr13:43897847	chr13:43877715~43878163:-
THCA	cis	rs440932	1	rs365309	ENSG00000253893.2	FAM85B	4.5	8.76e-06	0.00091	0.25	0.2	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8167819~8226614:-
THCA	cis	rs739496	0.653	rs11613713	ENSG00000226469.1	ADAM1B	4.5	8.76e-06	0.00091	0.26	0.2	Platelet count;	chr12:111779334	chr12:111927018~111929017:+
THCA	cis	rs12931792	0.875	rs58175255	ENSG00000273724.1	RP11-347C12.12	4.5	8.76e-06	0.00091	0.21	0.2	Tonsillectomy;	chr16:30143969	chr16:30336400~30343336:+
THCA	cis	rs7772486	0.692	rs2265915	ENSG00000270638.1	RP3-466P17.1	4.5	8.77e-06	0.00091	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.713	rs1986729	ENSG00000270638.1	RP3-466P17.1	4.5	8.77e-06	0.00091	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145735570~145737218:+
THCA	cis	rs1003719	0.628	rs2252402	ENSG00000230366.8	DSCR9	-4.5	8.77e-06	0.00091	-0.21	-0.2	Eye color traits;	chr21:37148420	chr21:37208503~37221736:+
THCA	cis	rs9601248	0.756	rs9601251	ENSG00000227354.5	RBM26-AS1	-4.5	8.77e-06	0.000911	-0.2	-0.2	Major depressive disorder;	chr13:79615582	chr13:79406309~79424328:+
THCA	cis	rs8177876	0.749	rs2602407	ENSG00000261061.1	RP11-303E16.2	4.5	8.77e-06	0.000911	0.26	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059141	chr16:81030770~81031485:+
THCA	cis	rs375066	0.967	rs8104290	ENSG00000278917.1	RP11-15A1.4	-4.5	8.77e-06	0.000911	-0.17	-0.2	Breast cancer;	chr19:43863186	chr19:43891233~43895411:+
THCA	cis	rs375066	0.934	rs2191564	ENSG00000278917.1	RP11-15A1.4	-4.5	8.77e-06	0.000911	-0.17	-0.2	Breast cancer;	chr19:43863459	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs11673020	ENSG00000278917.1	RP11-15A1.4	-4.5	8.77e-06	0.000911	-0.17	-0.2	Breast cancer;	chr19:43870479	chr19:43891233~43895411:+
THCA	cis	rs7432375	0.61	rs6793936	ENSG00000239213.4	NCK1-AS1	4.5	8.77e-06	0.000911	0.18	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136790951	chr3:136841726~136862054:-
THCA	cis	rs6600671	0.934	rs11249429	ENSG00000275585.1	CH17-118O6.3	4.49	8.77e-06	0.000911	0.25	0.2	Hip geometry;	chr1:121549282	chr1:120985692~121052167:-
THCA	cis	rs7849973	0.552	rs9298841	ENSG00000224549.1	RP11-370B11.3	-4.49	8.77e-06	0.000911	-0.23	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22811337	chr9:22767175~22768316:+
THCA	cis	rs6745190	0.575	rs7566146	ENSG00000236153.1	AC104076.3	-4.49	8.78e-06	0.000911	-0.22	-0.2	White blood cell count;	chr2:181109359	chr2:180979427~180980090:-
THCA	cis	rs270601	0.77	rs932019	ENSG00000237714.1	P4HA2-AS1	4.49	8.78e-06	0.000911	0.26	0.2	Acylcarnitine levels;	chr5:132263677	chr5:132184876~132192808:+
THCA	cis	rs6442522	0.671	rs2305616	ENSG00000249786.6	EAF1-AS1	4.49	8.78e-06	0.000911	0.21	0.2	Uric acid levels;	chr3:15474188	chr3:15436171~15455940:-
THCA	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	4.49	8.78e-06	0.000911	0.19	0.2	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
THCA	cis	rs375066	0.901	rs372491	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43897641	chr19:43891233~43895411:+
THCA	cis	rs375066	0.868	rs453950	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43898903	chr19:43891233~43895411:+
THCA	cis	rs375066	0.934	rs440784	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43900190	chr19:43891233~43895411:+
THCA	cis	rs375066	0.901	rs374307	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43900246	chr19:43891233~43895411:+
THCA	cis	rs375066	0.967	rs441344	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43900530	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs398099	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43901129	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs385321	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43901135	chr19:43891233~43895411:+
THCA	cis	rs375066	0.967	rs376328	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43903335	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs365556	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43904047	chr19:43891233~43895411:+
THCA	cis	rs375066	0.901	rs451945	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43904601	chr19:43891233~43895411:+
THCA	cis	rs375066	0.934	rs454813	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43904821	chr19:43891233~43895411:+
THCA	cis	rs375066	0.967	rs417400	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43906694	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs439665	ENSG00000278917.1	RP11-15A1.4	-4.49	8.78e-06	0.000912	-0.17	-0.2	Breast cancer;	chr19:43910315	chr19:43891233~43895411:+
THCA	cis	rs990871	0.53	rs1194267	ENSG00000227207.2	RPL31P12	4.49	8.78e-06	0.000912	0.23	0.2	Subcutaneous adipose tissue;	chr1:72238843	chr1:72301472~72301829:+
THCA	cis	rs990871	0.53	rs1194265	ENSG00000227207.2	RPL31P12	4.49	8.78e-06	0.000912	0.23	0.2	Subcutaneous adipose tissue;	chr1:72241543	chr1:72301472~72301829:+
THCA	cis	rs4763879	0.593	rs7960328	ENSG00000256673.1	RP11-599J14.2	4.49	8.78e-06	0.000912	0.25	0.2	Type 1 diabetes;	chr12:9699584	chr12:9398355~9414851:-
THCA	cis	rs7085104	0.513	rs192569	ENSG00000236937.2	PTGES3P4	-4.49	8.78e-06	0.000912	-0.25	-0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102845595~102845950:+
THCA	cis	rs12143943	0.966	rs3789047	ENSG00000240219.1	RP11-430C7.5	4.49	8.78e-06	0.000912	0.18	0.2	Cognitive performance;	chr1:204617056	chr1:204626775~204629712:+
THCA	cis	rs10510102	0.516	rs10219133	ENSG00000226864.1	ATE1-AS1	4.49	8.78e-06	0.000912	0.34	0.2	Breast cancer;	chr10:121987898	chr10:121928312~121951965:+
THCA	cis	rs9905704	0.647	rs11652713	ENSG00000224738.1	AC099850.1	4.49	8.79e-06	0.000912	0.25	0.2	Testicular germ cell tumor;	chr17:59002381	chr17:59106598~59118267:+
THCA	cis	rs3785574	0.65	rs7406102	ENSG00000240280.5	TCAM1P	4.49	8.79e-06	0.000912	0.27	0.2	Height;	chr17:63927389	chr17:63849292~63864379:+
THCA	cis	rs2562456	0.833	rs56179986	ENSG00000268117.1	VN1R84P	4.49	8.79e-06	0.000912	0.33	0.2	Pain;	chr19:21337882	chr19:21719801~21720035:-
THCA	cis	rs990871	0.53	rs1205484	ENSG00000227207.2	RPL31P12	4.49	8.79e-06	0.000913	0.24	0.2	Subcutaneous adipose tissue;	chr1:72229864	chr1:72301472~72301829:+
THCA	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	4.49	8.79e-06	0.000913	0.23	0.2	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
THCA	cis	rs34929064	0.881	rs2961310	ENSG00000179428.2	AC073072.5	-4.49	8.8e-06	0.000913	-0.23	-0.2	Major depression and alcohol dependence;	chr7:22684788	chr7:22725395~22727620:-
THCA	cis	rs17221829	0.796	rs10830351	ENSG00000280385.1	AP000648.5	-4.49	8.8e-06	0.000913	-0.2	-0.2	Anxiety in major depressive disorder;	chr11:89697758	chr11:90193614~90198120:+
THCA	cis	rs734999	0.967	rs10910090	ENSG00000225931.3	RP3-395M20.7	4.49	8.8e-06	0.000913	0.25	0.2	Ulcerative colitis;	chr1:2564775	chr1:2566410~2569888:+
THCA	cis	rs7614311	0.636	rs77639204	ENSG00000271843.1	RP11-245J9.5	-4.49	8.8e-06	0.000913	-0.35	-0.2	Lung function (FVC);Lung function (FEV1);	chr3:64019776	chr3:64008082~64008692:-
THCA	cis	rs7555523	0.887	rs4657471	ENSG00000224358.1	RP11-466F5.8	-4.49	8.8e-06	0.000913	-0.32	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717636	chr1:165768929~165775176:+
THCA	cis	rs10132760	0.507	rs3899895	ENSG00000211778.2	TRAV4	-4.49	8.8e-06	0.000914	-0.15	-0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21776159	chr14:21736152~21736982:+
THCA	cis	rs11671005	0.735	rs11084544	ENSG00000268049.1	CTD-2619J13.9	-4.49	8.8e-06	0.000914	-0.31	-0.2	Mean platelet volume;	chr19:58428760	chr19:58357999~58359603:+
THCA	cis	rs2288884	0.505	rs17835435	ENSG00000260160.1	CTC-471J1.2	-4.49	8.8e-06	0.000914	-0.22	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51931453	chr19:52058490~52063703:-
THCA	cis	rs7615952	0.546	rs4428131	ENSG00000171084.14	FAM86JP	4.49	8.81e-06	0.000914	0.28	0.2	Blood pressure (smoking interaction);	chr3:125627635	chr3:125916620~125930024:+
THCA	cis	rs763121	0.853	rs5757181	ENSG00000235209.1	CTA-150C2.13	4.49	8.81e-06	0.000914	0.27	0.2	Menopause (age at onset);	chr22:38617517	chr22:38921227~38924708:+
THCA	cis	rs7577696	0.695	rs4952252	ENSG00000276334.1	AL133243.1	-4.49	8.81e-06	0.000914	-0.22	-0.2	Inflammatory biomarkers;	chr2:32157892	chr2:32521927~32523547:+
THCA	cis	rs9902453	1	rs4328498	ENSG00000263370.1	RP11-68I3.5	-4.49	8.81e-06	0.000915	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30017258	chr17:29639627~29640825:+
THCA	cis	rs2436845	1	rs2679755	ENSG00000253669.3	KB-1732A1.1	-4.49	8.81e-06	0.000915	-0.21	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102856682	chr8:102805517~102809971:+
THCA	cis	rs2436845	1	rs2679756	ENSG00000253669.3	KB-1732A1.1	-4.49	8.81e-06	0.000915	-0.21	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858241	chr8:102805517~102809971:+
THCA	cis	rs2436845	1	rs2679757	ENSG00000253669.3	KB-1732A1.1	-4.49	8.81e-06	0.000915	-0.21	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858590	chr8:102805517~102809971:+
THCA	cis	rs2904967	0.929	rs2904980	ENSG00000254614.2	AP003068.23	-4.49	8.81e-06	0.000915	-0.38	-0.2	Mean corpuscular volume;	chr11:65234208	chr11:65177606~65181834:-
THCA	cis	rs763121	0.853	rs5757141	ENSG00000235209.1	CTA-150C2.13	4.49	8.82e-06	0.000915	0.27	0.2	Menopause (age at onset);	chr22:38561478	chr22:38921227~38924708:+
THCA	cis	rs9847710	1	rs6770152	ENSG00000242142.1	SERBP1P3	4.49	8.82e-06	0.000915	0.24	0.2	Ulcerative colitis;	chr3:53066198	chr3:53064283~53065091:-
THCA	cis	rs11976180	1	rs13243677	ENSG00000244198.4	RP4-545C24.1	-4.49	8.82e-06	0.000915	-0.2	-0.2	Obesity-related traits;	chr7:144049479	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs13226728	ENSG00000244198.4	RP4-545C24.1	-4.49	8.82e-06	0.000915	-0.2	-0.2	Obesity-related traits;	chr7:144049485	chr7:144194858~144280547:+
THCA	cis	rs7577696	0.695	rs212743	ENSG00000276334.1	AL133243.1	4.49	8.82e-06	0.000915	0.22	0.2	Inflammatory biomarkers;	chr2:32185125	chr2:32521927~32523547:+
THCA	cis	rs2446066	0.799	rs11610326	ENSG00000257379.1	RP11-793H13.8	4.49	8.82e-06	0.000915	0.29	0.2	Red blood cell count;	chr12:53448070	chr12:53441741~53467528:+
THCA	cis	rs6806253	0.73	rs4431128	ENSG00000239405.1	TMED10P2	4.49	8.83e-06	0.000916	0.31	0.2	Pit-and-Fissure caries;	chr3:128532835	chr3:128538020~128538631:+
THCA	cis	rs2281603	0.521	rs3742608	ENSG00000259116.1	RP11-973N13.4	-4.49	8.83e-06	0.000916	-0.17	-0.2	Lymphocyte counts;	chr14:64470315	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs2045024	ENSG00000259116.1	RP11-973N13.4	-4.49	8.83e-06	0.000916	-0.17	-0.2	Lymphocyte counts;	chr14:64470634	chr14:64514154~64540368:-
THCA	cis	rs2281603	0.57	rs10131416	ENSG00000259116.1	RP11-973N13.4	-4.49	8.83e-06	0.000916	-0.17	-0.2	Lymphocyte counts;	chr14:64477555	chr14:64514154~64540368:-
THCA	cis	rs6860806	0.507	rs272868	ENSG00000224431.1	AC063976.7	4.49	8.83e-06	0.000917	0.18	0.2	Breast cancer;	chr5:132345058	chr5:132199456~132203487:+
THCA	cis	rs2436845	0.627	rs2916559	ENSG00000253320.4	KB-1507C5.2	-4.49	8.83e-06	0.000917	-0.18	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102814856	chr8:102864300~102977876:+
THCA	cis	rs2436845	0.627	rs2436849	ENSG00000253320.4	KB-1507C5.2	-4.49	8.83e-06	0.000917	-0.18	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102815320	chr8:102864300~102977876:+
THCA	cis	rs13063635	0.85	rs13087776	ENSG00000226074.4	PRSS44	-4.49	8.84e-06	0.000917	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46038379	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.85	rs13088143	ENSG00000226074.4	PRSS44	-4.49	8.84e-06	0.000917	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46038532	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.764	rs13068410	ENSG00000226074.4	PRSS44	-4.49	8.84e-06	0.000917	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46038684	chr3:46809359~46812558:-
THCA	cis	rs4591358	0.705	rs12994849	ENSG00000223466.1	AC064834.2	-4.49	8.84e-06	0.000917	-0.24	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195447620	chr2:195533035~195538681:+
THCA	cis	rs7772486	0.72	rs991507	ENSG00000270638.1	RP3-466P17.1	-4.49	8.84e-06	0.000917	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145735570~145737218:+
THCA	cis	rs11633886	0.835	rs8041150	ENSG00000273972.1	CTD-2306A12.1	-4.49	8.84e-06	0.000917	-0.22	-0.2	Diisocyanate-induced asthma;	chr15:45803848	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.869	rs8040361	ENSG00000273972.1	CTD-2306A12.1	-4.49	8.84e-06	0.000917	-0.22	-0.2	Diisocyanate-induced asthma;	chr15:45803893	chr15:45702640~45703183:+
THCA	cis	rs453301	0.631	rs11779804	ENSG00000254153.1	CTA-398F10.2	4.49	8.84e-06	0.000917	0.23	0.2	Joint mobility (Beighton score);	chr8:8940442	chr8:8456909~8461337:-
THCA	cis	rs2243480	1	rs709607	ENSG00000230295.1	RP11-458F8.2	4.49	8.84e-06	0.000918	0.25	0.2	Diabetic kidney disease;	chr7:65984554	chr7:66880708~66882981:+
THCA	cis	rs4568518	0.502	rs4544985	ENSG00000279048.1	RP11-511H23.2	4.49	8.85e-06	0.000918	0.13	0.2	Measles;	chr7:17944184	chr7:17940503~17942922:+
THCA	cis	rs853679	1	rs2799079	ENSG00000272009.1	RP1-313I6.12	-4.49	8.85e-06	0.000918	-0.27	-0.2	Depression;	chr6:28267398	chr6:28078792~28081130:-
THCA	cis	rs9307551	0.741	rs11936123	ENSG00000250334.4	LINC00989	-4.49	8.85e-06	0.000918	-0.27	-0.2	Refractive error;	chr4:79506113	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.741	rs1440860	ENSG00000250334.4	LINC00989	-4.49	8.85e-06	0.000918	-0.27	-0.2	Refractive error;	chr4:79509083	chr4:79492416~79576460:+
THCA	cis	rs7577696	0.962	rs13017189	ENSG00000276334.1	AL133243.1	-4.49	8.85e-06	0.000918	-0.21	-0.2	Inflammatory biomarkers;	chr2:32056211	chr2:32521927~32523547:+
THCA	cis	rs10090774	0.965	rs1868280	ENSG00000279766.1	RP11-642A1.2	4.49	8.86e-06	0.000919	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140886155	chr8:140572142~140572812:-
THCA	cis	rs11180559	0.925	rs56904707	ENSG00000257497.2	RP11-585P4.5	4.49	8.86e-06	0.000919	0.35	0.2	Daytime sleep phenotypes;	chr12:75528129	chr12:75483454~75489820:-
THCA	cis	rs2836950	0.565	rs2836934	ENSG00000238141.2	BRWD1-AS1	-4.49	8.87e-06	0.00092	-0.23	-0.2	Menarche (age at onset);	chr21:39192959	chr21:39315707~39323218:+
THCA	cis	rs875971	0.638	rs10249404	ENSG00000229886.1	RP5-1132H15.3	-4.49	8.87e-06	0.00092	-0.21	-0.2	Aortic root size;	chr7:66581737	chr7:66025126~66031544:-
THCA	cis	rs7942368	1	rs7107409	ENSG00000261578.1	RP11-21L23.2	4.49	8.87e-06	0.00092	0.29	0.2	Endometriosis;	chr11:76781151	chr11:76800364~76804555:+
THCA	cis	rs73108077	0.736	rs56047717	ENSG00000277112.2	RP11-755J8.1	-4.49	8.87e-06	0.00092	-0.33	-0.2	Red blood cell density in sickle cell anemia;	chr20:31279756	chr20:30681825~30723932:-
THCA	cis	rs6963495	0.818	rs1355614	ENSG00000272604.1	RP11-251G23.5	4.49	8.87e-06	0.00092	0.25	0.2	Bipolar disorder (body mass index interaction);	chr7:105538729	chr7:105571083~105573660:+
THCA	cis	rs12534093	1	rs35319316	ENSG00000234286.1	AC006026.13	-4.49	8.87e-06	0.00092	-0.32	-0.2	Infant length;Height;	chr7:23462137	chr7:23680195~23680786:-
THCA	cis	rs2436845	0.627	rs1991928	ENSG00000253320.4	KB-1507C5.2	-4.49	8.88e-06	0.000921	-0.18	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102860863	chr8:102864300~102977876:+
THCA	cis	rs4794202	0.7	rs11079797	ENSG00000264920.1	RP11-6N17.4	-4.49	8.88e-06	0.000921	-0.23	-0.2	Alzheimer's disease (cognitive decline);	chr17:47834936	chr17:47891255~47895812:-
THCA	cis	rs7829975	0.628	rs1109618	ENSG00000254153.1	CTA-398F10.2	4.49	8.88e-06	0.000921	0.23	0.2	Mood instability;	chr8:8713854	chr8:8456909~8461337:-
THCA	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-4.49	8.88e-06	0.000921	-0.11	-0.2	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
THCA	cis	rs8067545	0.75	rs4925072	ENSG00000270091.1	RP11-78O7.2	4.49	8.88e-06	0.000921	0.15	0.2	Schizophrenia;	chr17:20053586	chr17:19896590~19897287:-
THCA	cis	rs2028299	0.92	rs1866476	ENSG00000259677.1	RP11-493E3.1	4.49	8.88e-06	0.000921	0.27	0.2	Type 2 diabetes;	chr15:89885311	chr15:89876540~89877285:+
THCA	cis	rs7267979	0.966	rs6050611	ENSG00000276952.1	RP5-965G21.6	4.49	8.88e-06	0.000921	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25284915~25285588:-
THCA	cis	rs375066	0.935	rs10414702	ENSG00000278917.1	RP11-15A1.4	-4.49	8.89e-06	0.000922	-0.17	-0.2	Breast cancer;	chr19:43876384	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs10421518	ENSG00000278917.1	RP11-15A1.4	-4.49	8.89e-06	0.000922	-0.17	-0.2	Breast cancer;	chr19:43877134	chr19:43891233~43895411:+
THCA	cis	rs375066	0.87	rs7258418	ENSG00000278917.1	RP11-15A1.4	-4.49	8.89e-06	0.000922	-0.17	-0.2	Breast cancer;	chr19:43878931	chr19:43891233~43895411:+
THCA	cis	rs270601	0.77	rs4361510	ENSG00000237714.1	P4HA2-AS1	4.49	8.89e-06	0.000922	0.26	0.2	Acylcarnitine levels;	chr5:132263954	chr5:132184876~132192808:+
THCA	cis	rs270601	0.77	rs61352298	ENSG00000237714.1	P4HA2-AS1	4.49	8.89e-06	0.000922	0.26	0.2	Acylcarnitine levels;	chr5:132264896	chr5:132184876~132192808:+
THCA	cis	rs270601	0.739	rs1979981	ENSG00000237714.1	P4HA2-AS1	4.49	8.89e-06	0.000922	0.26	0.2	Acylcarnitine levels;	chr5:132266027	chr5:132184876~132192808:+
THCA	cis	rs270601	0.77	rs1007602	ENSG00000237714.1	P4HA2-AS1	4.49	8.89e-06	0.000922	0.26	0.2	Acylcarnitine levels;	chr5:132266473	chr5:132184876~132192808:+
THCA	cis	rs270601	0.71	rs4705852	ENSG00000237714.1	P4HA2-AS1	4.49	8.89e-06	0.000922	0.26	0.2	Acylcarnitine levels;	chr5:132267114	chr5:132184876~132192808:+
THCA	cis	rs1023500	0.551	rs2854837	ENSG00000273366.1	CTA-989H11.1	-4.49	8.89e-06	0.000922	-0.26	-0.2	Schizophrenia;	chr22:42062477	chr22:42278188~42278846:+
THCA	cis	rs1005277	0.522	rs289650	ENSG00000276805.1	RP11-291L22.6	4.49	8.89e-06	0.000922	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38451030~38451785:+
THCA	cis	rs713477	0.505	rs1953740	ENSG00000258413.1	RP11-665C16.6	4.49	8.89e-06	0.000922	0.29	0.2	Pediatric bone mineral content (femoral neck);	chr14:55419999	chr14:55262767~55272075:-
THCA	cis	rs3820928	0.874	rs4675130	ENSG00000212391.1	SNORA48	-4.49	8.89e-06	0.000922	-0.22	-0.2	Pulmonary function;	chr2:226963024	chr2:226968989~226969122:-
THCA	cis	rs8030605	0.704	rs11638872	ENSG00000277245.1	RP11-48G14.3	4.49	8.89e-06	0.000922	0.35	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56384620	chr15:56447120~56447697:+
THCA	cis	rs4660456	0.913	rs12743517	ENSG00000272145.1	NFYC-AS1	-4.49	8.89e-06	0.000922	-0.14	-0.2	Platelet count;	chr1:40759682	chr1:40690380~40692066:-
THCA	cis	rs6657613	0.68	rs2295059	ENSG00000186301.8	MST1P2	4.49	8.89e-06	0.000922	0.17	0.2	Hip circumference adjusted for BMI;	chr1:17050914	chr1:16645622~16650289:+
THCA	cis	rs7220401	0.521	rs2292973	ENSG00000264007.1	RP11-68I3.10	4.49	8.89e-06	0.000922	0.23	0.2	Coronary artery disease;	chr17:29565997	chr17:29621617~29622254:-
THCA	cis	rs683257	0.81	rs9484446	ENSG00000234147.1	RP3-460G2.2	-4.49	8.89e-06	0.000922	-0.35	-0.2	Facial emotion recognition (angry faces);	chr6:140861432	chr6:140845958~140852924:-
THCA	cis	rs683257	0.659	rs9495848	ENSG00000234147.1	RP3-460G2.2	-4.49	8.89e-06	0.000922	-0.35	-0.2	Facial emotion recognition (angry faces);	chr6:140863462	chr6:140845958~140852924:-
THCA	cis	rs28476539	0.64	rs35614535	ENSG00000270480.1	RP11-57B24.1	4.49	8.89e-06	0.000922	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82634373	chr4:82691737~82692468:+
THCA	cis	rs28476539	0.64	rs17005919	ENSG00000270480.1	RP11-57B24.1	4.49	8.89e-06	0.000922	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82634563	chr4:82691737~82692468:+
THCA	cis	rs6088580	0.634	rs6088508	ENSG00000276073.1	RP5-1125A11.7	-4.49	8.89e-06	0.000922	-0.17	-0.2	Glomerular filtration rate (creatinine);	chr20:34472276	chr20:33985617~33988989:-
THCA	cis	rs5758511	0.68	rs17002902	ENSG00000227370.1	RP4-669P10.19	4.49	8.89e-06	0.000922	0.23	0.2	Birth weight;	chr22:42229503	chr22:42132543~42132998:+
THCA	cis	rs8062405	1	rs62036617	ENSG00000261766.1	RP11-22P6.2	-4.49	8.9e-06	0.000922	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs4788095	ENSG00000261766.1	RP11-22P6.2	-4.49	8.9e-06	0.000922	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.964	rs72793809	ENSG00000261766.1	RP11-22P6.2	-4.49	8.9e-06	0.000922	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62036620	ENSG00000261766.1	RP11-22P6.2	-4.49	8.9e-06	0.000922	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28862166~28863340:-
THCA	cis	rs8062405	1	rs62036621	ENSG00000261766.1	RP11-22P6.2	-4.49	8.9e-06	0.000922	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28862166~28863340:-
THCA	cis	rs875971	0.545	rs75577046	ENSG00000273142.1	RP11-458F8.4	4.49	8.9e-06	0.000922	0.19	0.2	Aortic root size;	chr7:66493729	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000273142.1	RP11-458F8.4	4.49	8.9e-06	0.000922	0.19	0.2	Aortic root size;	chr7:66505541	chr7:66902857~66906297:+
THCA	cis	rs7267979	1	rs2500436	ENSG00000274973.1	RP13-401N8.7	4.49	8.9e-06	0.000923	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6083856	ENSG00000274973.1	RP13-401N8.7	4.49	8.9e-06	0.000923	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25845497~25845862:+
THCA	cis	rs6012564	0.749	rs8120015	ENSG00000230758.1	SNAP23P	4.49	8.9e-06	0.000923	0.24	0.2	Anger;	chr20:49128772	chr20:49038357~49038602:-
THCA	cis	rs9634489	0.872	rs912697	ENSG00000247400.3	DNAJC3-AS1	-4.49	8.9e-06	0.000923	-0.13	-0.2	Body mass index;	chr13:96396469	chr13:95648733~95676925:-
THCA	cis	rs2904524	0.737	rs76573214	ENSG00000257815.4	RP11-611E13.2	-4.49	8.91e-06	0.000923	-0.3	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70296410	chr12:69904033~70243360:-
THCA	cis	rs2018683	0.649	rs221193	ENSG00000228421.2	AC005013.5	4.49	8.91e-06	0.000923	0.24	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28976168	chr7:28957667~28959345:+
THCA	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
THCA	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
THCA	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
THCA	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-4.49	8.91e-06	0.000923	-0.23	-0.2	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
THCA	cis	rs2554380	0.628	rs7179507	ENSG00000176700.18	SCAND2P	-4.49	8.91e-06	0.000923	-0.15	-0.2	Height;	chr15:83804779	chr15:84631451~84647478:+
THCA	cis	rs6832769	0.922	rs11133376	ENSG00000272969.1	RP11-528I4.2	4.49	8.91e-06	0.000923	0.24	0.2	Personality dimensions;	chr4:55386866	chr4:55547112~55547889:+
THCA	cis	rs8077577	0.708	rs28364628	ENSG00000273018.4	CTD-2303H24.2	-4.49	8.91e-06	0.000924	-0.3	-0.2	Obesity-related traits;	chr17:18259948	chr17:18511221~18551705:-
THCA	cis	rs997295	0.556	rs10468041	ENSG00000270964.1	RP11-502I4.3	-4.49	8.91e-06	0.000924	-0.17	-0.2	Motion sickness;	chr15:67480865	chr15:67541072~67542604:-
THCA	cis	rs7959452	0.64	rs10878957	ENSG00000274979.1	RP11-1143G9.5	-4.49	8.92e-06	0.000924	-0.22	-0.2	Blood protein levels;	chr12:69305858	chr12:69326574~69331882:-
THCA	cis	rs2070488	1	rs1002675	ENSG00000229589.1	ACVR2B-AS1	4.49	8.92e-06	0.000924	0.19	0.2	Electrocardiographic conduction measures;	chr3:38403735	chr3:38451027~38454820:-
THCA	cis	rs9813712	0.855	rs10934930	ENSG00000253540.4	FAM86HP	4.49	8.92e-06	0.000924	0.25	0.2	Response to amphetamines;	chr3:130259564	chr3:130099092~130111472:-
THCA	cis	rs317689	0.69	rs7969559	ENSG00000274979.1	RP11-1143G9.5	-4.49	8.92e-06	0.000925	-0.22	-0.2	Response to diuretic therapy;	chr12:69261387	chr12:69326574~69331882:-
THCA	cis	rs73242632	1	rs41344750	ENSG00000269949.1	RP11-738E22.3	4.49	8.92e-06	0.000925	0.44	0.2	Congenital heart disease (maternal effect);	chr4:56964047	chr4:56960927~56961373:-
THCA	cis	rs9863	0.861	rs7973683	ENSG00000270028.1	RP11-380L11.4	4.49	8.92e-06	0.000925	0.21	0.2	White blood cell count;	chr12:123964676	chr12:123925461~123926083:-
THCA	cis	rs12612619	0.761	rs7606840	ENSG00000272148.1	RP11-195B17.1	4.49	8.92e-06	0.000925	0.19	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020496	chr2:27062428~27062907:-
THCA	cis	rs7615952	0.866	rs13063119	ENSG00000248787.1	RP11-666A20.4	-4.49	8.92e-06	0.000925	-0.35	-0.2	Blood pressure (smoking interaction);	chr3:125925004	chr3:125908005~125910272:-
THCA	cis	rs7621331	0.963	rs9826806	ENSG00000273486.1	RP11-731C17.2	4.49	8.92e-06	0.000925	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135956348	chr3:136837338~136839021:-
THCA	cis	rs7621331	0.963	rs9864514	ENSG00000273486.1	RP11-731C17.2	4.49	8.92e-06	0.000925	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135956645	chr3:136837338~136839021:-
THCA	cis	rs10208649	0.656	rs12623097	ENSG00000233266.1	HMGB1P31	4.49	8.93e-06	0.000925	0.39	0.2	Body mass index;	chr2:54071182	chr2:54051334~54051760:+
THCA	cis	rs2933343	0.716	rs9872706	ENSG00000231305.3	RP11-723O4.2	-4.49	8.93e-06	0.000925	-0.25	-0.2	IgG glycosylation;	chr3:128848262	chr3:128861313~128871540:-
THCA	cis	rs7182948	0.846	rs1354920	ENSG00000259531.2	RP11-295H24.3	-4.49	8.93e-06	0.000925	-0.24	-0.2	Lung adenocarcinoma;	chr15:49533326	chr15:49365124~49366685:-
THCA	cis	rs2562456	0.752	rs279809	ENSG00000268117.1	VN1R84P	4.49	8.93e-06	0.000925	0.33	0.2	Pain;	chr19:21284729	chr19:21719801~21720035:-
THCA	cis	rs67478160	0.704	rs12894254	ENSG00000269910.1	RP11-73M18.10	4.49	8.93e-06	0.000926	0.17	0.2	Schizophrenia;	chr14:103824612	chr14:103694516~103695050:-
THCA	cis	rs6088580	0.66	rs6087592	ENSG00000276073.1	RP5-1125A11.7	-4.49	8.94e-06	0.000926	-0.17	-0.2	Glomerular filtration rate (creatinine);	chr20:34526698	chr20:33985617~33988989:-
THCA	cis	rs7617480	0.648	rs4858800	ENSG00000229759.1	MRPS18AP1	4.49	8.94e-06	0.000926	0.31	0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48718387	chr3:48256350~48256938:-
THCA	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-4.49	8.94e-06	0.000927	-0.23	-0.2	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-4.49	8.94e-06	0.000927	-0.23	-0.2	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
THCA	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	4.49	8.94e-06	0.000927	0.23	0.2	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
THCA	cis	rs2036707	1	rs2036708	ENSG00000274718.1	RP11-346C4.3	4.49	8.94e-06	0.000927	0.4	0.2	Obesity-related traits;	chr13:107832890	chr13:107870383~107873372:+
THCA	cis	rs875971	0.522	rs6960048	ENSG00000164669.11	INTS4P1	-4.49	8.94e-06	0.000927	-0.25	-0.2	Aortic root size;	chr7:65943052	chr7:65141225~65234216:+
THCA	cis	rs12410462	0.551	rs66938123	ENSG00000227711.2	RP11-275O4.5	-4.49	8.94e-06	0.000927	-0.25	-0.2	Major depressive disorder;	chr1:227620530	chr1:227509028~227520477:-
THCA	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-4.49	8.95e-06	0.000927	-0.24	-0.2	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
THCA	cis	rs9380516	0.54	rs6926133	ENSG00000228559.1	RP3-340B19.3	-4.49	8.95e-06	0.000927	-0.28	-0.2	Hepatitis C induced liver fibrosis;	chr6:35611598	chr6:35544632~35545669:+
THCA	cis	rs2153535	0.585	rs1885203	ENSG00000230939.1	RP11-314C16.1	-4.49	8.95e-06	0.000927	-0.21	-0.2	Motion sickness;	chr6:8633646	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.537	rs9379232	ENSG00000230939.1	RP11-314C16.1	-4.49	8.95e-06	0.000927	-0.21	-0.2	Motion sickness;	chr6:8634176	chr6:8784178~8785445:+
THCA	cis	rs6121246	0.559	rs10439608	ENSG00000230613.1	HM13-AS1	4.49	8.95e-06	0.000927	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31671011	chr20:31567707~31573263:-
THCA	cis	rs1009077	0.68	rs13121569	ENSG00000245958.5	RP11-33B1.1	-4.49	8.95e-06	0.000928	-0.25	-0.2	Endometriosis;	chr4:119507249	chr4:119454791~119552025:+
THCA	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-4.49	8.96e-06	0.000929	-0.23	-0.2	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-4.49	8.96e-06	0.000929	-0.23	-0.2	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-4.49	8.96e-06	0.000929	-0.23	-0.2	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
THCA	cis	rs757978	0.585	rs34227388	ENSG00000223374.1	AC005104.3	4.49	8.96e-06	0.000929	0.22	0.2	Chronic lymphocytic leukemia;	chr2:241504414	chr2:241351340~241353104:-
THCA	cis	rs2163813	0.959	rs247773	ENSG00000271499.1	CTC-559E9.9	-4.49	8.96e-06	0.000929	-0.25	-0.2	Toenail selenium levels;	chr19:19735277	chr19:19750618~19752544:+
THCA	cis	rs10754283	0.557	rs1215508	ENSG00000231613.1	RP5-943J3.1	4.49	8.97e-06	0.000929	0.22	0.2	Amyotrophic lateral sclerosis (sporadic);	chr1:89623138	chr1:89788914~89790492:+
THCA	cis	rs58235267	0.544	rs12478556	ENSG00000242412.1	DBIL5P2	-4.49	8.97e-06	0.000929	-0.23	-0.2	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:63114576	chr2:63117851~63119542:-
THCA	cis	rs7111546	0.945	rs2286808	ENSG00000246225.5	RP11-17A1.3	4.49	8.97e-06	0.000929	0.38	0.2	Dialysis-related mortality;	chr11:22830178	chr11:22829380~22945393:+
THCA	cis	rs375066	0.868	rs378112	ENSG00000278917.1	RP11-15A1.4	-4.49	8.97e-06	0.000929	-0.17	-0.2	Breast cancer;	chr19:43917777	chr19:43891233~43895411:+
THCA	cis	rs375066	0.868	rs378109	ENSG00000278917.1	RP11-15A1.4	-4.49	8.97e-06	0.000929	-0.17	-0.2	Breast cancer;	chr19:43917785	chr19:43891233~43895411:+
THCA	cis	rs795484	0.89	rs811247	ENSG00000275409.1	RP11-131L12.4	-4.49	8.98e-06	0.00093	-0.17	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118185031	chr12:118430147~118430699:+
THCA	cis	rs62025270	0.688	rs56388190	ENSG00000259295.5	CSPG4P12	-4.49	8.98e-06	0.00093	-0.32	-0.2	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85191438~85213905:+
THCA	cis	rs2836950	0.565	rs4816617	ENSG00000238141.2	BRWD1-AS1	-4.49	8.98e-06	0.00093	-0.23	-0.2	Menarche (age at onset);	chr21:39168764	chr21:39315707~39323218:+
THCA	cis	rs11157436	1	rs11157436	ENSG00000211812.1	TRAV26-2	4.49	8.98e-06	0.00093	0.19	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22202583~22203368:+
THCA	cis	rs9601248	0.627	rs9545151	ENSG00000227676.3	LINC01068	-4.49	8.98e-06	0.00093	-0.26	-0.2	Major depressive disorder;	chr13:79608400	chr13:79566727~79571436:+
THCA	cis	rs752010	0.714	rs6658500	ENSG00000230638.4	RP11-486B10.4	4.49	8.98e-06	0.000931	0.22	0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41622673	chr1:41542069~41544310:+
THCA	cis	rs62246343	0.605	rs7650141	ENSG00000254485.4	RP11-380O24.1	4.49	8.99e-06	0.000931	0.23	0.2	Fibrinogen levels;	chr3:9407726	chr3:9292588~9363303:-
THCA	cis	rs7615952	0.8	rs11914298	ENSG00000248787.1	RP11-666A20.4	-4.49	8.99e-06	0.000932	-0.36	-0.2	Blood pressure (smoking interaction);	chr3:125924929	chr3:125908005~125910272:-
THCA	cis	rs6012564	0.964	rs6063371	ENSG00000227431.4	CSE1L-AS1	4.49	9e-06	0.000932	0.25	0.2	Anger;	chr20:49202768	chr20:49040463~49046044:-
THCA	cis	rs867371	0.614	rs1814739	ENSG00000259429.4	UBE2Q2P2	-4.49	9e-06	0.000932	-0.18	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82355142~82420075:+
THCA	cis	rs12887734	0.566	rs3742366	ENSG00000269940.1	RP11-73M18.7	4.49	9e-06	0.000932	0.21	0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103694560~103695170:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-4.49	9e-06	0.000932	-0.23	-0.2	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
THCA	cis	rs8058578	1	rs7198250	ENSG00000279196.1	RP11-1072A3.3	4.49	9e-06	0.000932	0.21	0.2	Multiple myeloma;	chr16:30735501	chr16:30984630~30988270:-
THCA	cis	rs8058578	1	rs6565201	ENSG00000279196.1	RP11-1072A3.3	4.49	9e-06	0.000932	0.21	0.2	Multiple myeloma;	chr16:30735870	chr16:30984630~30988270:-
THCA	cis	rs919433	0.617	rs2037590	ENSG00000231621.1	AC013264.2	4.49	9e-06	0.000933	0.22	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197720051	chr2:197197991~197199273:+
THCA	cis	rs2436845	1	rs2679754	ENSG00000253669.3	KB-1732A1.1	-4.49	9e-06	0.000933	-0.21	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855772	chr8:102805517~102809971:+
THCA	cis	rs7647973	0.516	rs4499638	ENSG00000229759.1	MRPS18AP1	4.49	9.01e-06	0.000933	0.26	0.2	Menarche (age at onset);	chr3:49165349	chr3:48256350~48256938:-
THCA	cis	rs1853665	1	rs1853665	ENSG00000218358.2	RAET1K	-4.49	9.01e-06	0.000933	-0.34	-0.2	Radiation response;	chr6:149977706	chr6:149998019~150005157:-
THCA	cis	rs7520050	0.778	rs3014216	ENSG00000280836.1	AL355480.1	-4.49	9.01e-06	0.000933	-0.25	-0.2	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45581219~45581321:-
THCA	cis	rs2948294	0.588	rs12544596	ENSG00000254153.1	CTA-398F10.2	-4.49	9.01e-06	0.000933	-0.22	-0.2	Red cell distribution width;	chr8:8258824	chr8:8456909~8461337:-
THCA	cis	rs4568518	0.53	rs11764965	ENSG00000279048.1	RP11-511H23.2	4.49	9.01e-06	0.000933	0.13	0.2	Measles;	chr7:17959127	chr7:17940503~17942922:+
THCA	cis	rs2657294	0.796	rs4746272	ENSG00000226051.5	ZNF503-AS1	-4.49	9.01e-06	0.000933	-0.28	-0.2	Pneumonia;	chr10:75203869	chr10:75269819~75373500:+
THCA	cis	rs728616	0.614	rs10887235	ENSG00000242600.5	MBL1P	4.49	9.01e-06	0.000933	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955890	chr10:79904898~79950336:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000275400.1	RP4-756H11.5	-4.49	9.01e-06	0.000933	-0.22	-0.2	Corneal structure;	chr7:66887678	chr7:66553805~66554199:-
THCA	cis	rs7809615	0.636	rs12538826	ENSG00000244219.5	GS1-259H13.2	-4.49	9.01e-06	0.000934	-0.26	-0.2	Blood metabolite ratios;	chr7:99432605	chr7:99598066~99610813:+
THCA	cis	rs116248771	0.739	rs73156415	ENSG00000271778.1	RP11-379F4.8	4.49	9.02e-06	0.000934	0.26	0.2	diarrhoeal disease at age 2;	chr3:158624906	chr3:158782547~158783124:+
THCA	cis	rs1476587	0.92	rs12704345	ENSG00000224046.1	AC005076.5	4.49	9.02e-06	0.000934	0.23	0.2	Brachial circumference;	chr7:87084708	chr7:87151423~87152420:-
THCA	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-4.49	9.02e-06	0.000934	-0.12	-0.2	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
THCA	cis	rs795484	0.816	rs2650175	ENSG00000275409.1	RP11-131L12.4	-4.49	9.02e-06	0.000934	-0.18	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118229615	chr12:118430147~118430699:+
THCA	cis	rs11723261	0.545	rs6812799	ENSG00000211553.1	AC253576.2	-4.49	9.02e-06	0.000934	-0.32	-0.2	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:136461~136568:+
THCA	cis	rs3734266	0.591	rs9469812	ENSG00000272288.4	RP11-140K17.3	-4.49	9.02e-06	0.000934	-0.22	-0.2	Systemic lupus erythematosus;	chr6:34599754	chr6:34696317~34697470:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000223473.2	GS1-124K5.3	4.49	9.02e-06	0.000934	0.14	0.2	Aortic root size;	chr7:66014585	chr7:66491049~66493566:-
THCA	cis	rs17711722	0.727	rs781151	ENSG00000223473.2	GS1-124K5.3	4.49	9.02e-06	0.000934	0.14	0.2	Calcium levels;	chr7:66014891	chr7:66491049~66493566:-
THCA	cis	rs9925964	0.933	rs12448321	ENSG00000232748.3	RP11-196G11.6	4.49	9.03e-06	0.000935	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036959	chr16:31056460~31062803:+
THCA	cis	rs858239	0.601	rs6969733	ENSG00000226816.2	AC005082.12	4.49	9.03e-06	0.000935	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23206013~23208045:+
THCA	cis	rs858239	0.601	rs4440529	ENSG00000226816.2	AC005082.12	4.49	9.03e-06	0.000935	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23206013~23208045:+
THCA	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	4.49	9.03e-06	0.000935	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
THCA	cis	rs2836950	0.585	rs1029004	ENSG00000238141.2	BRWD1-AS1	-4.49	9.03e-06	0.000935	-0.23	-0.2	Menarche (age at onset);	chr21:39243417	chr21:39315707~39323218:+
THCA	cis	rs11722779	0.903	rs13130741	ENSG00000248971.2	KRT8P46	-4.49	9.03e-06	0.000935	-0.25	-0.2	Schizophrenia;	chr4:103035799	chr4:102728746~102730171:-
THCA	cis	rs858239	0.601	rs3735228	ENSG00000226816.2	AC005082.12	4.49	9.03e-06	0.000935	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23206013~23208045:+
THCA	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-4.49	9.03e-06	0.000935	-0.25	-0.2	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
THCA	cis	rs2732480	0.577	rs2634681	ENSG00000273765.1	RP11-370I10.11	-4.49	9.03e-06	0.000935	-0.2	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48360920~48361377:+
THCA	cis	rs1559040	1	rs1559039	ENSG00000272156.1	RP11-477N3.1	-4.49	9.03e-06	0.000935	-0.32	-0.2	Sudden cardiac arrest;	chr2:54120695	chr2:54082554~54085066:+
THCA	cis	rs4713118	0.786	rs200502	ENSG00000226314.6	ZNF192P1	-4.49	9.03e-06	0.000935	-0.26	-0.2	Parkinson's disease;	chr6:27820284	chr6:28161781~28169594:+
THCA	cis	rs10090774	0.965	rs4507813	ENSG00000279766.1	RP11-642A1.2	4.49	9.03e-06	0.000935	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140786245	chr8:140572142~140572812:-
THCA	cis	rs7746199	0.736	rs13195636	ENSG00000272009.1	RP1-313I6.12	-4.49	9.04e-06	0.000936	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28078792~28081130:-
THCA	cis	rs711244	0.756	rs57747847	ENSG00000279519.1	RP11-288C18.1	4.49	9.04e-06	0.000936	0.17	0.2	Mean platelet volume;	chr2:36909617	chr2:36839922~36842539:-
THCA	cis	rs2163813	1	rs247772	ENSG00000271499.1	CTC-559E9.9	-4.49	9.04e-06	0.000936	-0.25	-0.2	Toenail selenium levels;	chr19:19735649	chr19:19750618~19752544:+
THCA	cis	rs36093844	0.752	rs17744699	ENSG00000279742.1	RP11-700A24.1	-4.49	9.04e-06	0.000936	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85886120	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs17817343	ENSG00000279742.1	RP11-700A24.1	-4.49	9.04e-06	0.000936	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85887269	chr11:85852557~85854943:-
THCA	cis	rs6963495	0.745	rs68153235	ENSG00000272604.1	RP11-251G23.5	4.49	9.05e-06	0.000936	0.25	0.2	Bipolar disorder (body mass index interaction);	chr7:105544385	chr7:105571083~105573660:+
THCA	cis	rs8062405	0.755	rs4149398	ENSG00000261766.1	RP11-22P6.2	-4.49	9.05e-06	0.000937	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28862166~28863340:-
THCA	cis	rs35740288	0.77	rs11631386	ENSG00000259295.5	CSPG4P12	4.49	9.05e-06	0.000937	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85648764	chr15:85191438~85213905:+
THCA	cis	rs61270009	0.955	rs10214154	ENSG00000247828.6	TMEM161B-AS1	-4.49	9.05e-06	0.000937	-0.17	-0.2	Depressive symptoms;	chr5:88249502	chr5:88268895~88436685:+
THCA	cis	rs6442522	1	rs6762167	ENSG00000249786.6	EAF1-AS1	-4.49	9.05e-06	0.000937	-0.21	-0.2	Uric acid levels;	chr3:15403530	chr3:15436171~15455940:-
THCA	cis	rs7122539	0.734	rs4930391	ENSG00000275484.1	CTC-1337H24.4	4.49	9.05e-06	0.000937	0.15	0.2	HIV-1 susceptibility;	chr11:66877783	chr11:67374416~67374932:+
THCA	cis	rs1150668	0.796	rs2247002	ENSG00000280107.1	AL022393.9	-4.49	9.06e-06	0.000937	-0.19	-0.2	Pubertal anthropometrics;	chr6:28430174	chr6:28170845~28172521:+
THCA	cis	rs526231	0.764	rs365975	ENSG00000175749.11	EIF3KP1	4.49	9.06e-06	0.000937	0.26	0.2	Primary biliary cholangitis;	chr5:103297657	chr5:103032376~103033031:+
THCA	cis	rs12410462	0.591	rs965942	ENSG00000227711.2	RP11-275O4.5	-4.49	9.06e-06	0.000937	-0.25	-0.2	Major depressive disorder;	chr1:227585273	chr1:227509028~227520477:-
THCA	cis	rs526231	0.67	rs444779	ENSG00000175749.11	EIF3KP1	4.49	9.06e-06	0.000938	0.26	0.2	Primary biliary cholangitis;	chr5:103288460	chr5:103032376~103033031:+
THCA	cis	rs858239	0.539	rs7791200	ENSG00000226816.2	AC005082.12	4.49	9.06e-06	0.000938	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs57864591	ENSG00000226816.2	AC005082.12	4.49	9.06e-06	0.000938	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23206013~23208045:+
THCA	cis	rs889512	0.731	rs8063014	ENSG00000261783.1	RP11-252K23.2	4.49	9.06e-06	0.000938	0.41	0.2	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75263775	chr16:75379818~75381260:-
THCA	cis	rs17695224	1	rs17695224	ENSG00000269483.1	AC006272.1	4.49	9.06e-06	0.000938	0.24	0.2	HDL cholesterol;HDL cholesterol levels;	chr19:51820963	chr19:51839924~51843324:-
THCA	cis	rs7688540	0.511	rs61794991	ENSG00000211553.1	AC253576.2	-4.49	9.06e-06	0.000938	-0.32	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:136461~136568:+
THCA	cis	rs4693089	0.604	rs34620667	ENSG00000213608.5	SLC25A14P1	4.49	9.07e-06	0.000938	0.24	0.2	Menopause (age at onset);	chr4:83483055	chr4:83477524~83478424:+
THCA	cis	rs2255336	0.81	rs10772267	ENSG00000245648.1	RP11-277P12.20	4.49	9.07e-06	0.000939	0.28	0.2	Blood protein levels;	chr12:10357969	chr12:10363769~10398506:+
THCA	cis	rs2380205	0.651	rs12357094	ENSG00000232807.2	RP11-536K7.3	4.49	9.07e-06	0.000939	0.19	0.2	Breast cancer;	chr10:5884340	chr10:5934270~5945900:-
THCA	cis	rs1048886	0.872	rs7743819	ENSG00000271967.1	RP11-134K13.4	-4.49	9.07e-06	0.000939	-0.2	-0.2	Type 2 diabetes;	chr6:70396954	chr6:70596438~70596980:+
THCA	cis	rs35740288	0.862	rs11637444	ENSG00000259295.5	CSPG4P12	4.49	9.07e-06	0.000939	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85767957	chr15:85191438~85213905:+
THCA	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-4.49	9.07e-06	0.000939	-0.11	-0.2	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-4.49	9.07e-06	0.000939	-0.11	-0.2	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
THCA	cis	rs9880211	0.8	rs13314357	ENSG00000239213.4	NCK1-AS1	4.49	9.07e-06	0.000939	0.23	0.2	Height;Body mass index;	chr3:136768717	chr3:136841726~136862054:-
THCA	cis	rs55661361	0.708	rs12278912	ENSG00000254941.1	RP11-677M14.5	4.49	9.07e-06	0.000939	0.19	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742263	chr11:124807822~124808269:-
THCA	cis	rs9558942	1	rs9558942	ENSG00000277863.1	RP11-282A11.4	-4.49	9.08e-06	0.000939	-0.26	-0.2	Obesity-related traits;	chr13:107047870	chr13:106903150~106904099:-
THCA	cis	rs8192917	0.573	rs10135076	ENSG00000258744.1	RP11-80A15.1	-4.49	9.08e-06	0.000939	-0.34	-0.2	Vitiligo;	chr14:24652763	chr14:24501594~24508688:+
THCA	cis	rs7336933	0.932	rs9532947	ENSG00000278338.3	VWA8-AS1	-4.49	9.08e-06	0.000939	-0.34	-0.2	Calcium levels;	chr13:41918079	chr13:41955808~41981565:+
THCA	cis	rs4915077	0.656	rs4440889	ENSG00000230489.1	VAV3-AS1	4.49	9.08e-06	0.000939	0.33	0.2	Hypothyroidism;	chr1:107717760	chr1:107964443~107994607:+
THCA	cis	rs2734839	0.964	rs12798900	ENSG00000270179.1	RP11-159N11.4	-4.49	9.08e-06	0.00094	-0.21	-0.2	Information processing speed;	chr11:113428274	chr11:113368478~113369117:+
THCA	cis	rs2120243	0.539	rs1568609	ENSG00000241770.1	RP11-555M1.3	-4.49	9.09e-06	0.00094	-0.26	-0.2	Hepatocellular carcinoma in hepatitis B infection;	chr3:157349050	chr3:157163452~157169133:+
THCA	cis	rs9634489	0.709	rs7491529	ENSG00000247400.3	DNAJC3-AS1	-4.49	9.09e-06	0.00094	-0.13	-0.2	Body mass index;	chr13:96368380	chr13:95648733~95676925:-
THCA	cis	rs1962772	0.781	rs2188021	ENSG00000279903.1	RP11-349F21.5	-4.49	9.09e-06	0.00094	-0.25	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17519733	chr8:17500012~17500605:+
THCA	cis	rs8067545	0.586	rs8080649	ENSG00000270091.1	RP11-78O7.2	-4.49	9.09e-06	0.00094	-0.15	-0.2	Schizophrenia;	chr17:20166364	chr17:19896590~19897287:-
THCA	cis	rs6490294	0.851	rs1016079	ENSG00000226469.1	ADAM1B	-4.49	9.09e-06	0.00094	-0.25	-0.2	Mean platelet volume;	chr12:111972382	chr12:111927018~111929017:+
THCA	cis	rs116248771	0.739	rs4679833	ENSG00000271778.1	RP11-379F4.8	4.49	9.09e-06	0.000941	0.26	0.2	diarrhoeal disease at age 2;	chr3:158622046	chr3:158782547~158783124:+
THCA	cis	rs1371614	0.523	rs12468721	ENSG00000229122.1	AGBL5-IT1	-4.49	9.09e-06	0.000941	-0.15	-0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26960883	chr2:27061038~27061815:+
THCA	cis	rs755249	0.73	rs3916164	ENSG00000228060.1	RP11-69E11.8	-4.49	9.09e-06	0.000941	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39604267	chr1:39565160~39573203:+
THCA	cis	rs1538970	0.816	rs61788356	ENSG00000234329.1	RP11-767N6.2	4.49	9.09e-06	0.000941	0.21	0.2	Platelet count;	chr1:45541003	chr1:45651039~45651826:-
THCA	cis	rs9959145	1	rs79692970	ENSG00000267108.1	RP11-861E21.1	4.49	9.09e-06	0.000941	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12580218	chr18:12432897~12437635:+
THCA	cis	rs2904524	0.737	rs79536434	ENSG00000257815.4	RP11-611E13.2	-4.49	9.1e-06	0.000941	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70258886	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs76944966	ENSG00000257815.4	RP11-611E13.2	-4.49	9.1e-06	0.000941	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70268886	chr12:69904033~70243360:-
THCA	cis	rs5751614	0.557	rs5759665	ENSG00000240160.3	RN7SL263P	4.49	9.1e-06	0.000941	0.28	0.2	Height;	chr22:23260033	chr22:23261782~23262071:-
THCA	cis	rs481331	0.866	rs1813564	ENSG00000215146.4	RP11-313J2.1	4.49	9.1e-06	0.000941	0.32	0.2	Systemic juvenile idiopathic arthritis;	chr10:42503316	chr10:42331866~42367974:-
THCA	cis	rs2436845	0.614	rs2436854	ENSG00000253320.4	KB-1507C5.2	-4.49	9.1e-06	0.000942	-0.17	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813809	chr8:102864300~102977876:+
THCA	cis	rs6088813	1	rs4911180	ENSG00000279253.1	RP4-614O4.13	4.49	9.1e-06	0.000942	0.2	0.2	Height;	chr20:35385145	chr20:35262727~35264187:-
THCA	cis	rs2303282	0.664	rs2440472	ENSG00000274031.1	RP11-413H22.3	-4.49	9.1e-06	0.000942	-0.24	-0.2	Breast cancer;	chr16:56402912	chr16:56465642~56466162:-
THCA	cis	rs2303282	0.664	rs2550310	ENSG00000274031.1	RP11-413H22.3	-4.49	9.1e-06	0.000942	-0.24	-0.2	Breast cancer;	chr16:56404198	chr16:56465642~56466162:-
THCA	cis	rs2303282	0.639	rs11644357	ENSG00000274031.1	RP11-413H22.3	-4.49	9.1e-06	0.000942	-0.24	-0.2	Breast cancer;	chr16:56411340	chr16:56465642~56466162:-
THCA	cis	rs889398	0.835	rs12925429	ENSG00000226232.7	RP11-419C5.2	4.49	9.1e-06	0.000942	0.2	0.2	Body mass index;	chr16:69767636	chr16:69976388~69996188:-
THCA	cis	rs718433	0.584	rs2204934	ENSG00000211778.2	TRAV4	-4.49	9.11e-06	0.000942	-0.16	-0.2	Intraocular pressure;	chr14:21744121	chr14:21736152~21736982:+
THCA	cis	rs8077577	0.747	rs62072511	ENSG00000273018.4	CTD-2303H24.2	-4.49	9.11e-06	0.000942	-0.3	-0.2	Obesity-related traits;	chr17:18289843	chr17:18511221~18551705:-
THCA	cis	rs875971	0.545	rs6460276	ENSG00000273142.1	RP11-458F8.4	4.49	9.11e-06	0.000942	0.19	0.2	Aortic root size;	chr7:66182290	chr7:66902857~66906297:+
THCA	cis	rs8017455	0.523	rs28701517	ENSG00000259167.2	NMNAT1P1	4.49	9.11e-06	0.000942	0.32	0.2	Hair morphology;	chr14:81090765	chr14:81032529~81033404:+
THCA	cis	rs202072	1	rs202053	ENSG00000272379.1	RP1-257A7.5	4.49	9.11e-06	0.000942	0.31	0.2	HIV-1 viral setpoint;	chr6:13273411	chr6:13290018~13290490:-
THCA	cis	rs8054556	0.74	rs10083738	ENSG00000183604.13	SMG1P5	-4.49	9.11e-06	0.000942	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29916381	chr16:30267553~30335374:-
THCA	cis	rs2836974	0.627	rs9981301	ENSG00000255568.3	BRWD1-AS2	-4.49	9.11e-06	0.000942	-0.17	-0.2	Cognitive function;	chr21:39314152	chr21:39313935~39314962:+
THCA	cis	rs6005807	0.92	rs16986509	ENSG00000226471.5	CTA-292E10.6	4.49	9.11e-06	0.000942	0.26	0.2	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28547489	chr22:28800683~28848559:+
THCA	cis	rs4948275	0.631	rs2814023	ENSG00000237233.2	TMEM26-AS1	-4.49	9.11e-06	0.000943	-0.26	-0.2	Night sleep phenotypes;	chr10:61593649	chr10:61452639~61481956:+
THCA	cis	rs2483058	0.767	rs2336938	ENSG00000261000.1	RP11-534L20.5	4.49	9.11e-06	0.000943	0.22	0.2	Cholesterol and Triglycerides;	chr1:206445453	chr1:206503948~206504456:+
THCA	cis	rs642858	0.615	rs13216392	ENSG00000234147.1	RP3-460G2.2	4.49	9.11e-06	0.000943	0.25	0.2	Type 2 diabetes;	chr6:140386445	chr6:140845958~140852924:-
THCA	cis	rs875971	0.508	rs10242423	ENSG00000229886.1	RP5-1132H15.3	-4.49	9.12e-06	0.000943	-0.2	-0.2	Aortic root size;	chr7:66594188	chr7:66025126~66031544:-
THCA	cis	rs875971	0.508	rs10253883	ENSG00000229886.1	RP5-1132H15.3	-4.49	9.12e-06	0.000943	-0.2	-0.2	Aortic root size;	chr7:66596151	chr7:66025126~66031544:-
THCA	cis	rs7615952	0.736	rs9866347	ENSG00000241288.6	RP11-379B18.5	-4.49	9.12e-06	0.000943	-0.28	-0.2	Blood pressure (smoking interaction);	chr3:125951082	chr3:125827238~125916384:-
THCA	cis	rs875971	0.862	rs10282433	ENSG00000229886.1	RP5-1132H15.3	-4.49	9.12e-06	0.000943	-0.21	-0.2	Aortic root size;	chr7:66256452	chr7:66025126~66031544:-
THCA	cis	rs5758511	0.68	rs5758662	ENSG00000227370.1	RP4-669P10.19	4.49	9.12e-06	0.000943	0.23	0.2	Birth weight;	chr22:42232082	chr22:42132543~42132998:+
THCA	cis	rs9926296	0.581	rs2108838	ENSG00000260259.1	RP11-368I7.4	-4.49	9.12e-06	0.000943	-0.22	-0.2	Vitiligo;	chr16:89838018	chr16:89682620~89686569:-
THCA	cis	rs1876905	0.68	rs557028	ENSG00000272356.1	RP5-1112D6.8	-4.49	9.12e-06	0.000944	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111309203~111313517:+
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000220721.1	OR1F12	4.49	9.12e-06	0.000944	0.22	0.2	Pubertal anthropometrics;	chr6:28230503	chr6:28073316~28074233:+
THCA	cis	rs2921073	0.604	rs2979140	ENSG00000254153.1	CTA-398F10.2	-4.49	9.12e-06	0.000944	-0.22	-0.2	Parkinson's disease;	chr8:8409692	chr8:8456909~8461337:-
THCA	cis	rs12143943	0.966	rs3789046	ENSG00000240219.1	RP11-430C7.5	4.49	9.13e-06	0.000944	0.18	0.2	Cognitive performance;	chr1:204617677	chr1:204626775~204629712:+
THCA	cis	rs12143943	0.966	rs3747632	ENSG00000240219.1	RP11-430C7.5	4.49	9.13e-06	0.000944	0.18	0.2	Cognitive performance;	chr1:204618112	chr1:204626775~204629712:+
THCA	cis	rs1046896	0.627	rs7225515	ENSG00000263063.1	RP11-388C12.1	-4.49	9.13e-06	0.000944	-0.27	-0.2	Glycated hemoglobin levels;	chr17:82837907	chr17:82713908~82716255:-
THCA	cis	rs2243480	1	rs1964692	ENSG00000232559.3	GS1-124K5.12	4.49	9.13e-06	0.000944	0.3	0.2	Diabetic kidney disease;	chr7:65989196	chr7:66554588~66576923:-
THCA	cis	rs61677309	0.809	rs3782042	ENSG00000280032.1	RP11-832A4.7	-4.49	9.13e-06	0.000944	-0.21	-0.2	Lung cancer in ever smokers;	chr11:118315204	chr11:118264593~118266817:+
THCA	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-4.49	9.13e-06	0.000944	-0.24	-0.2	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
THCA	cis	rs11976180	1	rs1919950	ENSG00000244198.4	RP4-545C24.1	-4.49	9.13e-06	0.000944	-0.2	-0.2	Obesity-related traits;	chr7:144070805	chr7:144194858~144280547:+
THCA	cis	rs7267979	1	rs2257420	ENSG00000274973.1	RP13-401N8.7	-4.49	9.13e-06	0.000945	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25845497~25845862:+
THCA	cis	rs9625935	0.957	rs2412963	ENSG00000279159.1	RP3-394A18.1	4.49	9.13e-06	0.000945	0.16	0.2	Tonsillectomy;	chr22:29995292	chr22:29978950~30028236:-
THCA	cis	rs9876781	1	rs6442118	ENSG00000244380.1	RP11-24C3.2	4.49	9.13e-06	0.000945	0.24	0.2	Longevity;	chr3:48398582	chr3:48440352~48446656:-
THCA	cis	rs7829975	0.514	rs2979151	ENSG00000233609.3	RP11-62H7.2	-4.49	9.14e-06	0.000945	-0.19	-0.2	Mood instability;	chr8:8400509	chr8:8961200~8979025:+
THCA	cis	rs875971	0.965	rs6971509	ENSG00000230189.5	GS1-124K5.2	-4.49	9.14e-06	0.000945	-0.13	-0.2	Aortic root size;	chr7:66249983	chr7:66409143~66490059:-
THCA	cis	rs4568518	0.502	rs10268632	ENSG00000279048.1	RP11-511H23.2	4.49	9.14e-06	0.000945	0.13	0.2	Measles;	chr7:17940658	chr7:17940503~17942922:+
THCA	cis	rs4971059	0.654	rs4971078	ENSG00000236675.1	MTX1P1	-4.49	9.14e-06	0.000945	-0.19	-0.2	Breast cancer;	chr1:155156547	chr1:155230975~155234325:+
THCA	cis	rs711244	0.721	rs13418962	ENSG00000279519.1	RP11-288C18.1	4.49	9.14e-06	0.000946	0.17	0.2	Mean platelet volume;	chr2:36909495	chr2:36839922~36842539:-
THCA	cis	rs11733284	0.963	rs98270	ENSG00000259959.1	RP11-121C2.2	4.49	9.14e-06	0.000946	0.17	0.2	Gout;Renal underexcretion gout;	chr4:48017306	chr4:47840122~47844339:-
THCA	cis	rs1707322	1	rs4660331	ENSG00000281133.1	AL355480.3	-4.49	9.14e-06	0.000946	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45580892~45580996:-
THCA	cis	rs16852403	0.506	rs519464	ENSG00000224687.1	RASAL2-AS1	-4.49	9.14e-06	0.000946	-0.29	-0.2	Childhood ear infection;	chr1:178252090	chr1:178091508~178093984:-
THCA	cis	rs453301	0.631	rs7843369	ENSG00000254153.1	CTA-398F10.2	4.49	9.15e-06	0.000946	0.23	0.2	Joint mobility (Beighton score);	chr8:8940276	chr8:8456909~8461337:-
THCA	cis	rs2839186	0.564	rs4819215	ENSG00000239415.1	AP001469.9	4.49	9.15e-06	0.000947	0.21	0.2	Testicular germ cell tumor;	chr21:46203659	chr21:46251549~46254133:-
THCA	cis	rs78487399	0.908	rs74854268	ENSG00000234936.1	AC010883.5	4.49	9.15e-06	0.000947	0.26	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43616940	chr2:43229573~43233394:+
THCA	cis	rs2191566	0.96	rs12232810	ENSG00000266921.1	RP11-15A1.7	-4.49	9.16e-06	0.000947	-0.19	-0.2	Acute lymphoblastic leukemia (childhood);	chr19:44020970	chr19:43996896~44002836:-
THCA	cis	rs2281603	0.57	rs73265639	ENSG00000272909.1	CTD-2555O16.4	-4.49	9.16e-06	0.000947	-0.23	-0.2	Lymphocyte counts;	chr14:64482973	chr14:64440369~64442238:-
THCA	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-4.49	9.16e-06	0.000947	-0.23	-0.2	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
THCA	cis	rs763121	0.853	rs2413545	ENSG00000228274.3	RP3-508I15.9	-4.49	9.16e-06	0.000947	-0.23	-0.2	Menopause (age at onset);	chr22:38696519	chr22:38667585~38681820:-
THCA	cis	rs4948275	0.693	rs753245	ENSG00000237233.2	TMEM26-AS1	-4.49	9.16e-06	0.000947	-0.27	-0.2	Night sleep phenotypes;	chr10:61582778	chr10:61452639~61481956:+
THCA	cis	rs4434138	0.568	rs6414569	ENSG00000243224.1	RP5-1157M23.2	-4.49	9.16e-06	0.000947	-0.22	-0.2	Intelligence (multi-trait analysis);	chr3:52674059	chr3:52239258~52241097:+
THCA	cis	rs2904524	0.737	rs74101499	ENSG00000257815.4	RP11-611E13.2	-4.49	9.16e-06	0.000947	-0.28	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70343610	chr12:69904033~70243360:-
THCA	cis	rs7829975	0.871	rs7829826	ENSG00000254340.1	RP11-10A14.3	-4.49	9.16e-06	0.000947	-0.22	-0.2	Mood instability;	chr8:8720610	chr8:9141424~9145435:+
THCA	cis	rs6449502	0.844	rs2928246	ENSG00000251279.1	CTC-436P18.1	4.49	9.16e-06	0.000947	0.33	0.2	Mean platelet volume;	chr5:61004082	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs162239	ENSG00000251279.1	CTC-436P18.1	4.49	9.16e-06	0.000947	0.33	0.2	Mean platelet volume;	chr5:61004808	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs290508	ENSG00000251279.1	CTC-436P18.1	4.49	9.16e-06	0.000947	0.33	0.2	Mean platelet volume;	chr5:61006972	chr5:61162070~61232040:+
THCA	cis	rs496547	0.686	rs540180	ENSG00000255422.1	AP002954.4	-4.49	9.16e-06	0.000947	-0.22	-0.2	Hip minimal joint space width;	chr11:118782920	chr11:118704607~118750263:+
THCA	cis	rs496547	0.686	rs2508916	ENSG00000255422.1	AP002954.4	-4.49	9.16e-06	0.000947	-0.22	-0.2	Hip minimal joint space width;	chr11:118783942	chr11:118704607~118750263:+
THCA	cis	rs2562456	0.833	rs62107539	ENSG00000268117.1	VN1R84P	4.49	9.16e-06	0.000947	0.33	0.2	Pain;	chr19:21334910	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs76646508	ENSG00000268117.1	VN1R84P	4.49	9.16e-06	0.000947	0.33	0.2	Pain;	chr19:21335247	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs77576302	ENSG00000268117.1	VN1R84P	4.49	9.16e-06	0.000947	0.33	0.2	Pain;	chr19:21335385	chr19:21719801~21720035:-
THCA	cis	rs9818758	0.607	rs73084135	ENSG00000270441.1	RP11-694I15.7	4.49	9.16e-06	0.000948	0.3	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49234785	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.607	rs56306491	ENSG00000270441.1	RP11-694I15.7	4.49	9.16e-06	0.000948	0.3	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49277527	chr3:49140086~49160851:-
THCA	cis	rs9329221	0.683	rs555200	ENSG00000261451.1	RP11-981G7.1	-4.49	9.17e-06	0.000948	-0.25	-0.2	Neuroticism;	chr8:10031219	chr8:10433672~10438312:+
THCA	cis	rs2836950	0.565	rs2836945	ENSG00000238141.2	BRWD1-AS1	-4.49	9.17e-06	0.000948	-0.23	-0.2	Menarche (age at onset);	chr21:39224831	chr21:39315707~39323218:+
THCA	cis	rs7560272	0.538	rs35767294	ENSG00000163016.8	ALMS1P	-4.49	9.17e-06	0.000948	-0.25	-0.2	Schizophrenia;	chr2:73695707	chr2:73644919~73685576:+
THCA	cis	rs5742933	0.948	rs6434363	ENSG00000273240.1	RP11-455J20.3	-4.49	9.17e-06	0.000948	-0.23	-0.2	Ferritin levels;	chr2:189707565	chr2:189763859~189764456:-
THCA	cis	rs593531	0.513	rs7120394	ENSG00000255440.1	RP11-632K5.2	-4.49	9.17e-06	0.000948	-0.24	-0.2	Neuroticism;	chr11:74323428	chr11:74409060~74416379:+
THCA	cis	rs2191566	0.96	rs6509133	ENSG00000266921.1	RP11-15A1.7	4.49	9.17e-06	0.000948	0.19	0.2	Acute lymphoblastic leukemia (childhood);	chr19:44018761	chr19:43996896~44002836:-
THCA	cis	rs61160187	0.549	rs12518404	ENSG00000215032.2	GNL3LP1	4.49	9.17e-06	0.000948	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60891935~60893577:-
THCA	cis	rs72843506	0.722	rs79590067	ENSG00000261033.1	RP11-209D14.2	4.49	9.18e-06	0.000949	0.36	0.2	Schizophrenia;	chr17:20204101	chr17:20008051~20009234:-
THCA	cis	rs453301	0.598	rs2921383	ENSG00000233609.3	RP11-62H7.2	4.48	9.18e-06	0.000949	0.19	0.2	Joint mobility (Beighton score);	chr8:9034711	chr8:8961200~8979025:+
THCA	cis	rs6657613	0.68	rs11203287	ENSG00000186301.8	MST1P2	4.48	9.18e-06	0.000949	0.17	0.2	Hip circumference adjusted for BMI;	chr1:17045902	chr1:16645622~16650289:+
THCA	cis	rs57221529	0.713	rs12521091	ENSG00000225138.6	CTD-2228K2.7	4.48	9.18e-06	0.000949	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:590595	chr5:473236~480884:+
THCA	cis	rs7621331	0.963	rs9846137	ENSG00000273486.1	RP11-731C17.2	4.48	9.18e-06	0.000949	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135956090	chr3:136837338~136839021:-
THCA	cis	rs6745190	0.575	rs62178846	ENSG00000236153.1	AC104076.3	-4.48	9.18e-06	0.000949	-0.22	-0.2	White blood cell count;	chr2:181108672	chr2:180979427~180980090:-
THCA	cis	rs2440129	0.591	rs312466	ENSG00000262089.1	RP11-589P10.5	-4.48	9.18e-06	0.000949	-0.19	-0.2	Tonsillectomy;	chr17:6995902	chr17:6994642~6995189:-
THCA	cis	rs2836950	0.509	rs11088466	ENSG00000238141.2	BRWD1-AS1	-4.48	9.18e-06	0.000949	-0.23	-0.2	Menarche (age at onset);	chr21:39208091	chr21:39315707~39323218:+
THCA	cis	rs338389	0.564	rs338393	ENSG00000260657.2	RP11-315D16.4	-4.48	9.18e-06	0.000949	-0.25	-0.2	Survival in rectal cancer;	chr15:67964657	chr15:68267792~68277994:-
THCA	cis	rs6546847	0.531	rs2567601	ENSG00000273245.1	RP11-434P11.2	4.48	9.19e-06	0.00095	0.35	0.2	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73750256~73750786:-
THCA	cis	rs9307551	0.552	rs4975089	ENSG00000250334.4	LINC00989	-4.48	9.19e-06	0.00095	-0.24	-0.2	Refractive error;	chr4:79490790	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.584	rs1115519	ENSG00000250334.4	LINC00989	-4.48	9.19e-06	0.00095	-0.24	-0.2	Refractive error;	chr4:79491857	chr4:79492416~79576460:+
THCA	cis	rs7819412	0.806	rs2409689	ENSG00000206014.6	OR7E161P	4.48	9.19e-06	0.00095	0.23	0.2	Triglycerides;	chr8:11075358	chr8:11928597~11929563:-
THCA	cis	rs17123764	0.818	rs7977389	ENSG00000257464.1	RP11-161H23.8	-4.48	9.19e-06	0.00095	-0.33	-0.2	Intelligence (multi-trait analysis);	chr12:49587939	chr12:49442424~49442652:-
THCA	cis	rs12497850	0.931	rs13315711	ENSG00000228638.1	FCF1P2	-4.48	9.19e-06	0.00095	-0.22	-0.2	Parkinson's disease;	chr3:48948966	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs7430198	ENSG00000228638.1	FCF1P2	-4.48	9.19e-06	0.00095	-0.22	-0.2	Parkinson's disease;	chr3:48951327	chr3:48290793~48291375:-
THCA	cis	rs4915077	0.881	rs11578263	ENSG00000230489.1	VAV3-AS1	-4.48	9.19e-06	0.00095	-0.34	-0.2	Hypothyroidism;	chr1:107782235	chr1:107964443~107994607:+
THCA	cis	rs1336149	0.901	rs865239	ENSG00000211581.1	MIR765	-4.48	9.19e-06	0.00095	-0.26	-0.2	Chin dimples;	chr1:156926372	chr1:156936131~156936244:-
THCA	cis	rs875971	0.545	rs17138149	ENSG00000273142.1	RP11-458F8.4	4.48	9.2e-06	0.00095	0.19	0.2	Aortic root size;	chr7:66228193	chr7:66902857~66906297:+
THCA	cis	rs7989336	0.568	rs9513127	ENSG00000247400.3	DNAJC3-AS1	4.48	9.2e-06	0.000951	0.13	0.2	Obesity;	chr13:96381508	chr13:95648733~95676925:-
THCA	cis	rs7989336	0.568	rs1925133	ENSG00000247400.3	DNAJC3-AS1	4.48	9.2e-06	0.000951	0.13	0.2	Obesity;	chr13:96382285	chr13:95648733~95676925:-
THCA	cis	rs7989336	0.568	rs9513131	ENSG00000247400.3	DNAJC3-AS1	4.48	9.2e-06	0.000951	0.13	0.2	Obesity;	chr13:96384619	chr13:95648733~95676925:-
THCA	cis	rs12699921	0.935	rs6461363	ENSG00000279048.1	RP11-511H23.2	4.48	9.2e-06	0.000951	0.13	0.2	Fibrinogen levels;	chr7:17952527	chr7:17940503~17942922:+
THCA	cis	rs911119	0.955	rs6048952	ENSG00000270001.1	RP11-218C14.8	-4.48	9.2e-06	0.000951	-0.29	-0.2	Chronic kidney disease;	chr20:23626620	chr20:23631826~23632316:-
THCA	cis	rs889398	0.802	rs2291959	ENSG00000226232.7	RP11-419C5.2	-4.48	9.2e-06	0.000951	-0.2	-0.2	Body mass index;	chr16:69840089	chr16:69976388~69996188:-
THCA	cis	rs889398	0.802	rs2937121	ENSG00000226232.7	RP11-419C5.2	4.48	9.2e-06	0.000951	0.2	0.2	Body mass index;	chr16:69836506	chr16:69976388~69996188:-
THCA	cis	rs6517329	0.7	rs11911678	ENSG00000230212.5	AP000688.14	-4.48	9.2e-06	0.000951	-0.26	-0.2	Schizophrenia;	chr21:36110704	chr21:36069642~36126640:-
THCA	cis	rs4763879	0.739	rs2114871	ENSG00000256673.1	RP11-599J14.2	4.48	9.21e-06	0.000951	0.25	0.2	Type 1 diabetes;	chr12:9676842	chr12:9398355~9414851:-
THCA	cis	rs55661361	0.708	rs12278912	ENSG00000255045.1	RP11-677M14.2	4.48	9.21e-06	0.000952	0.18	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742263	chr11:124744634~124746337:-
THCA	cis	rs738144	0.542	rs5757273	ENSG00000235209.1	CTA-150C2.13	-4.48	9.21e-06	0.000952	-0.35	-0.2	IgG glycosylation;	chr22:38761389	chr22:38921227~38924708:+
THCA	cis	rs10792665	0.778	rs10792667	ENSG00000255503.1	RP11-113K21.4	-4.48	9.21e-06	0.000952	-0.21	-0.2	Obesity-related traits;	chr11:82964536	chr11:83072402~83097196:-
THCA	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-4.48	9.21e-06	0.000952	-0.23	-0.2	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
THCA	cis	rs6840258	0.891	rs10023056	ENSG00000251411.1	RP11-397E7.4	-4.48	9.21e-06	0.000952	-0.24	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87143314	chr4:86913266~86914817:-
THCA	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	4.48	9.21e-06	0.000952	0.24	0.2	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
THCA	cis	rs4144027	0.967	rs4900601	ENSG00000269940.1	RP11-73M18.7	4.48	9.21e-06	0.000952	0.21	0.2	Blood metabolite levels;	chr14:103891739	chr14:103694560~103695170:+
THCA	cis	rs961831	0.539	rs693370	ENSG00000224549.1	RP11-370B11.3	-4.48	9.21e-06	0.000952	-0.36	-0.2	Personality dimensions;	chr9:22446298	chr9:22767175~22768316:+
THCA	cis	rs875971	0.767	rs1643394	ENSG00000229886.1	RP5-1132H15.3	4.48	9.22e-06	0.000953	0.21	0.2	Aortic root size;	chr7:66371107	chr7:66025126~66031544:-
THCA	cis	rs467650	0.853	rs456470	ENSG00000246763.5	RGMB-AS1	4.48	9.22e-06	0.000953	0.2	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98687777	chr5:98769618~98773469:-
THCA	cis	rs467650	0.853	rs457260	ENSG00000246763.5	RGMB-AS1	4.48	9.22e-06	0.000953	0.2	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98689031	chr5:98769618~98773469:-
THCA	cis	rs467650	0.853	rs294031	ENSG00000246763.5	RGMB-AS1	4.48	9.22e-06	0.000953	0.2	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98690903	chr5:98769618~98773469:-
THCA	cis	rs467650	0.747	rs382202	ENSG00000246763.5	RGMB-AS1	4.48	9.22e-06	0.000953	0.2	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98693015	chr5:98769618~98773469:-
THCA	cis	rs755249	0.501	rs1889830	ENSG00000228060.1	RP11-69E11.8	4.48	9.22e-06	0.000953	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39565160~39573203:+
THCA	cis	rs10510102	0.516	rs12242799	ENSG00000226864.1	ATE1-AS1	4.48	9.22e-06	0.000953	0.34	0.2	Breast cancer;	chr10:121980067	chr10:121928312~121951965:+
THCA	cis	rs4948275	0.693	rs2606104	ENSG00000237233.2	TMEM26-AS1	-4.48	9.22e-06	0.000953	-0.27	-0.2	Night sleep phenotypes;	chr10:61583103	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs2606105	ENSG00000237233.2	TMEM26-AS1	-4.48	9.22e-06	0.000953	-0.27	-0.2	Night sleep phenotypes;	chr10:61583174	chr10:61452639~61481956:+
THCA	cis	rs9880211	0.948	rs13321721	ENSG00000239213.4	NCK1-AS1	4.48	9.23e-06	0.000953	0.22	0.2	Height;Body mass index;	chr3:136490708	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs67949818	ENSG00000239213.4	NCK1-AS1	4.48	9.23e-06	0.000953	0.22	0.2	Height;Body mass index;	chr3:136494136	chr3:136841726~136862054:-
THCA	cis	rs12681963	0.688	rs4733444	ENSG00000248159.1	HSPA8P11	4.48	9.23e-06	0.000953	0.36	0.2	Migraine;	chr8:30218739	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs1566741	ENSG00000248159.1	HSPA8P11	4.48	9.23e-06	0.000953	0.36	0.2	Migraine;	chr8:30220913	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs1566738	ENSG00000248159.1	HSPA8P11	4.48	9.23e-06	0.000953	0.36	0.2	Migraine;	chr8:30221355	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs4733447	ENSG00000248159.1	HSPA8P11	4.48	9.23e-06	0.000953	0.36	0.2	Migraine;	chr8:30221526	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs4733451	ENSG00000248159.1	HSPA8P11	4.48	9.23e-06	0.000953	0.36	0.2	Migraine;	chr8:30221825	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.545	rs11994172	ENSG00000248159.1	HSPA8P11	4.48	9.23e-06	0.000953	0.36	0.2	Migraine;	chr8:30222043	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs11994173	ENSG00000248159.1	HSPA8P11	4.48	9.23e-06	0.000953	0.36	0.2	Migraine;	chr8:30222047	chr8:30237382~30240997:+
THCA	cis	rs6963495	0.818	rs56165465	ENSG00000272604.1	RP11-251G23.5	4.48	9.23e-06	0.000953	0.26	0.2	Bipolar disorder (body mass index interaction);	chr7:105539937	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs6961863	ENSG00000272604.1	RP11-251G23.5	4.48	9.23e-06	0.000953	0.26	0.2	Bipolar disorder (body mass index interaction);	chr7:105540506	chr7:105571083~105573660:+
THCA	cis	rs12497850	0.931	rs13316620	ENSG00000228638.1	FCF1P2	-4.48	9.23e-06	0.000953	-0.22	-0.2	Parkinson's disease;	chr3:49007922	chr3:48290793~48291375:-
THCA	cis	rs2120243	0.539	rs4680358	ENSG00000241770.1	RP11-555M1.3	-4.48	9.23e-06	0.000954	-0.26	-0.2	Hepatocellular carcinoma in hepatitis B infection;	chr3:157351486	chr3:157163452~157169133:+
THCA	cis	rs2287838	0.716	rs7245579	ENSG00000267289.1	CTD-2623N2.11	-4.48	9.23e-06	0.000954	-0.23	-0.2	Sleep duration;	chr19:9890200	chr19:9834079~9835013:-
THCA	cis	rs59868192	0.925	rs72726034	ENSG00000246740.2	PLA2G4E-AS1	4.48	9.23e-06	0.000954	0.38	0.2	White blood cell count;	chr15:41966756	chr15:41972763~41999094:+
THCA	cis	rs7542375	0.52	rs12141189	ENSG00000238078.1	LINC01352	-4.48	9.23e-06	0.000954	-0.29	-0.2	Obesity-related traits;	chr1:220880203	chr1:220829255~220832429:+
THCA	cis	rs6568686	0.732	rs6932122	ENSG00000255389.1	C6orf3	4.48	9.23e-06	0.000954	0.23	0.2	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111524367	chr6:111599875~111602295:+
THCA	cis	rs875971	0.638	rs6960778	ENSG00000272831.1	RP11-792A8.4	-4.48	9.23e-06	0.000954	-0.13	-0.2	Aortic root size;	chr7:66606610	chr7:66739829~66740385:-
THCA	cis	rs875971	0.545	rs1547529	ENSG00000273142.1	RP11-458F8.4	4.48	9.23e-06	0.000954	0.19	0.2	Aortic root size;	chr7:66258859	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000273142.1	RP11-458F8.4	4.48	9.23e-06	0.000954	0.19	0.2	Aortic root size;	chr7:66283366	chr7:66902857~66906297:+
THCA	cis	rs7621331	1	rs9834104	ENSG00000273486.1	RP11-731C17.2	4.48	9.24e-06	0.000954	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135973719	chr3:136837338~136839021:-
THCA	cis	rs1923243	0.71	rs7523754	ENSG00000223479.3	RP4-788P17.1	-4.48	9.24e-06	0.000954	-0.22	-0.2	Migraine;	chr1:73160130	chr1:73635216~73715214:+
THCA	cis	rs6416877	0.679	rs35316912	ENSG00000277491.1	RP11-676J12.9	-4.48	9.24e-06	0.000954	-0.22	-0.2	Myeloid white cell count;	chr17:1450641	chr17:795306~795794:+
THCA	cis	rs10090774	1	rs9650572	ENSG00000279766.1	RP11-642A1.2	4.48	9.25e-06	0.000955	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140821890	chr8:140572142~140572812:-
THCA	cis	rs4973397	0.81	rs12993290	ENSG00000224376.1	AC017104.6	4.48	9.25e-06	0.000955	0.23	0.2	Anti-saccade response;	chr2:231414976	chr2:231388976~231394991:+
THCA	cis	rs6545883	0.524	rs17482440	ENSG00000270820.4	RP11-355B11.2	-4.48	9.25e-06	0.000956	-0.17	-0.2	Tuberculosis;	chr2:61321722	chr2:61471188~61484130:+
THCA	cis	rs9880211	0.66	rs34645606	ENSG00000239213.4	NCK1-AS1	4.48	9.25e-06	0.000956	0.27	0.2	Height;Body mass index;	chr3:136811260	chr3:136841726~136862054:-
THCA	cis	rs17508449	0.547	rs79100402	ENSG00000232450.1	RP4-730K3.3	-4.48	9.25e-06	0.000956	-0.29	-0.2	Leprosy;	chr1:113803538	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.547	rs3789604	ENSG00000232450.1	RP4-730K3.3	-4.48	9.25e-06	0.000956	-0.29	-0.2	Leprosy;	chr1:113812320	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.547	rs55940960	ENSG00000232450.1	RP4-730K3.3	-4.48	9.25e-06	0.000956	-0.29	-0.2	Leprosy;	chr1:113813474	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.547	rs3811021	ENSG00000232450.1	RP4-730K3.3	-4.48	9.25e-06	0.000956	-0.29	-0.2	Leprosy;	chr1:113814041	chr1:113698884~113699631:-
THCA	cis	rs1979679	0.918	rs10771429	ENSG00000247934.4	RP11-967K21.1	4.48	9.25e-06	0.000956	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28468573	chr12:28163298~28190738:-
THCA	cis	rs4578769	0.55	rs11082258	ENSG00000265939.1	UBE2CP2	4.48	9.25e-06	0.000956	0.23	0.2	Eosinophil percentage of white cells;	chr18:23037401	chr18:22900486~22900995:-
THCA	cis	rs6787172	0.596	rs1714518	ENSG00000272087.1	RP11-379F4.7	-4.48	9.25e-06	0.000956	-0.18	-0.2	Subjective well-being;	chr3:158495634	chr3:158693120~158693768:-
THCA	cis	rs12935229	1	rs17769760	ENSG00000260922.1	RP11-538I12.3	-4.48	9.25e-06	0.000956	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77295503	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs17769766	ENSG00000260922.1	RP11-538I12.3	-4.48	9.25e-06	0.000956	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77295567	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs10459866	ENSG00000260922.1	RP11-538I12.3	-4.48	9.25e-06	0.000956	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77295681	chr16:77234877~77290934:+
THCA	cis	rs2280018	1	rs2280018	ENSG00000263335.1	AF001548.5	-4.48	9.25e-06	0.000956	-0.22	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15726674~15732993:+
THCA	cis	rs9863	0.828	rs4765541	ENSG00000270028.1	RP11-380L11.4	4.48	9.26e-06	0.000956	0.21	0.2	White blood cell count;	chr12:123981448	chr12:123925461~123926083:-
THCA	cis	rs1580019	0.665	rs34147895	ENSG00000231952.3	DPY19L1P2	-4.48	9.26e-06	0.000956	-0.26	-0.2	Cognitive ability;	chr7:32492184	chr7:32812757~32838570:+
THCA	cis	rs800160	0.777	rs2521288	ENSG00000199550.1	Y_RNA	4.48	9.26e-06	0.000956	0.31	0.2	Bacteremia;	chr11:2321533	chr11:2372638~2372750:+
THCA	cis	rs17801127	0.818	rs16827337	ENSG00000231969.1	AC144449.1	4.48	9.26e-06	0.000957	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149690094	chr2:149587196~149848233:+
THCA	cis	rs9300255	0.62	rs1716173	ENSG00000235423.7	RP11-282O18.3	4.48	9.26e-06	0.000957	0.22	0.2	Neutrophil percentage of white cells;	chr12:123176174	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.512	rs2851436	ENSG00000235423.7	RP11-282O18.3	4.48	9.26e-06	0.000957	0.22	0.2	Neutrophil percentage of white cells;	chr12:123182807	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.544	rs1716157	ENSG00000235423.7	RP11-282O18.3	4.48	9.26e-06	0.000957	0.22	0.2	Neutrophil percentage of white cells;	chr12:123185926	chr12:123252030~123261483:-
THCA	cis	rs17597773	0.635	rs1494368	ENSG00000238078.1	LINC01352	-4.48	9.27e-06	0.000957	-0.29	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220830826	chr1:220829255~220832429:+
THCA	cis	rs2439831	0.681	rs7168940	ENSG00000166763.7	STRCP1	4.48	9.27e-06	0.000957	0.27	0.2	Lung cancer in ever smokers;	chr15:43341136	chr15:43699488~43718184:-
THCA	cis	rs62158800	0.733	rs10199917	ENSG00000224568.1	AC096669.3	4.48	9.27e-06	0.000957	0.38	0.2	Facial morphology (factor 22);	chr2:107636523	chr2:107529487~107556326:+
THCA	cis	rs7267979	0.966	rs2482918	ENSG00000274973.1	RP13-401N8.7	4.48	9.27e-06	0.000957	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25845497~25845862:+
THCA	cis	rs9863	0.861	rs7312404	ENSG00000270061.1	RP11-214K3.19	-4.48	9.27e-06	0.000957	-0.27	-0.2	White blood cell count;	chr12:123962181	chr12:123969990~123970344:-
THCA	cis	rs9863	0.827	rs7134121	ENSG00000270061.1	RP11-214K3.19	-4.48	9.27e-06	0.000957	-0.27	-0.2	White blood cell count;	chr12:123962799	chr12:123969990~123970344:-
THCA	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-4.48	9.27e-06	0.000958	-0.23	-0.2	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
THCA	cis	rs4819052	0.808	rs2838862	ENSG00000273796.1	LL21NC02-21A1.1	-4.48	9.27e-06	0.000958	-0.2	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45266811	chr21:45403809~45404369:-
THCA	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-4.48	9.28e-06	0.000958	-0.23	-0.2	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
THCA	cis	rs9625935	0.957	rs2051764	ENSG00000279159.1	RP3-394A18.1	4.48	9.28e-06	0.000958	0.16	0.2	Tonsillectomy;	chr22:29965892	chr22:29978950~30028236:-
THCA	cis	rs2657294	0.726	rs4746275	ENSG00000233313.2	HMGA1P5	-4.48	9.28e-06	0.000958	-0.27	-0.2	Pneumonia;	chr10:75214940	chr10:75276376~75276646:-
THCA	cis	rs9910055	0.614	rs12944572	ENSG00000267080.4	ASB16-AS1	-4.48	9.28e-06	0.000958	-0.18	-0.2	Total body bone mineral density;	chr17:44167873	chr17:44175973~44186717:-
THCA	cis	rs7615952	0.688	rs17334074	ENSG00000272840.1	RP11-379B18.6	-4.48	9.28e-06	0.000958	-0.31	-0.2	Blood pressure (smoking interaction);	chr3:125821617	chr3:125774714~125797953:+
THCA	cis	rs875971	0.545	rs2460427	ENSG00000273142.1	RP11-458F8.4	-4.48	9.28e-06	0.000959	-0.19	-0.2	Aortic root size;	chr7:66154218	chr7:66902857~66906297:+
THCA	cis	rs860295	0.812	rs12131079	ENSG00000160766.13	GBAP1	4.48	9.28e-06	0.000959	0.22	0.2	Body mass index;	chr1:155349877	chr1:155213821~155227422:-
THCA	cis	rs17221829	0.733	rs11018728	ENSG00000280385.1	AP000648.5	-4.48	9.29e-06	0.000959	-0.2	-0.2	Anxiety in major depressive disorder;	chr11:89682774	chr11:90193614~90198120:+
THCA	cis	rs1046491	0.614	rs8092765	ENSG00000264964.1	RP11-888D10.3	4.48	9.29e-06	0.000959	0.36	0.2	Scarlet fever;	chr18:9299540	chr18:9315194~9334441:-
THCA	cis	rs4908769	0.624	rs301796	ENSG00000232912.4	RP5-1115A15.1	4.48	9.29e-06	0.000959	0.22	0.2	Allergy;	chr1:8406670	chr1:8424645~8434838:+
THCA	cis	rs4908769	0.587	rs301795	ENSG00000232912.4	RP5-1115A15.1	4.48	9.29e-06	0.000959	0.22	0.2	Allergy;	chr1:8407293	chr1:8424645~8434838:+
THCA	cis	rs4908769	0.624	rs301789	ENSG00000232912.4	RP5-1115A15.1	4.48	9.29e-06	0.000959	0.22	0.2	Allergy;	chr1:8409277	chr1:8424645~8434838:+
THCA	cis	rs9625935	0.917	rs737912	ENSG00000279159.1	RP3-394A18.1	4.48	9.3e-06	0.00096	0.15	0.2	Tonsillectomy;	chr22:30005667	chr22:29978950~30028236:-
THCA	cis	rs35740288	0.822	rs11629690	ENSG00000259295.5	CSPG4P12	4.48	9.3e-06	0.00096	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744493	chr15:85191438~85213905:+
THCA	cis	rs1962772	0.847	rs2157648	ENSG00000279903.1	RP11-349F21.5	-4.48	9.3e-06	0.00096	-0.25	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17514788	chr8:17500012~17500605:+
THCA	cis	rs8024893	0.764	rs7182545	ENSG00000215302.7	CTD-3092A11.1	-4.48	9.3e-06	0.00096	-0.32	-0.2	Red cell distribution width;	chr15:31239638	chr15:30470779~30507623:+
THCA	cis	rs1707322	1	rs10890370	ENSG00000281133.1	AL355480.3	-4.48	9.3e-06	0.000961	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45580892~45580996:-
THCA	cis	rs790006	0.958	rs17774651	ENSG00000243024.5	RPS11P6	-4.48	9.31e-06	0.000961	-0.25	-0.2	Response to cytidine analogues (gemcitabine);	chr12:64190087	chr12:64222337~64397065:+
THCA	cis	rs41307935	0.643	rs6658653	ENSG00000260063.1	RP5-968P14.2	-4.48	9.31e-06	0.000961	-0.42	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26999041	chr1:26692132~26694131:-
THCA	cis	rs2657294	0.965	rs2657291	ENSG00000226051.5	ZNF503-AS1	-4.48	9.31e-06	0.000961	-0.28	-0.2	Pneumonia;	chr10:75166945	chr10:75269819~75373500:+
THCA	cis	rs1577917	0.633	rs7770835	ENSG00000220563.1	PKMP3	-4.48	9.32e-06	0.000962	-0.15	-0.2	Response to antipsychotic treatment;	chr6:85899189	chr6:85659892~85660606:-
THCA	cis	rs10916248	0.55	rs7544572	ENSG00000232628.4	RP11-365O16.3	-4.48	9.32e-06	0.000962	-0.23	-0.2	QT interval (drug interaction);	chr1:224077515	chr1:224208747~224213279:-
THCA	cis	rs9543976	0.858	rs8192763	ENSG00000261105.4	LMO7-AS1	4.48	9.33e-06	0.000963	0.3	0.2	Diabetic retinopathy;	chr13:75605034	chr13:75604700~75635994:-
THCA	cis	rs9543976	1	rs1535724	ENSG00000261105.4	LMO7-AS1	4.48	9.33e-06	0.000963	0.3	0.2	Diabetic retinopathy;	chr13:75609137	chr13:75604700~75635994:-
THCA	cis	rs793571	0.666	rs544282	ENSG00000259250.1	RP11-50C13.1	-4.48	9.33e-06	0.000963	-0.2	-0.2	Schizophrenia;	chr15:58729903	chr15:58587507~58591676:+
THCA	cis	rs17597773	0.674	rs2378425	ENSG00000238078.1	LINC01352	-4.48	9.33e-06	0.000963	-0.28	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220842716	chr1:220829255~220832429:+
THCA	cis	rs10904908	0.763	rs10795469	ENSG00000229124.5	VIM-AS1	4.48	9.33e-06	0.000963	0.19	0.2	Cholesterol, total;Total cholesterol levels;	chr10:17292936	chr10:17214239~17229985:-
THCA	cis	rs2657294	0.965	rs2395140	ENSG00000226051.5	ZNF503-AS1	-4.48	9.33e-06	0.000963	-0.28	-0.2	Pneumonia;	chr10:75139253	chr10:75269819~75373500:+
THCA	cis	rs2657294	0.965	rs2997754	ENSG00000226051.5	ZNF503-AS1	-4.48	9.33e-06	0.000963	-0.28	-0.2	Pneumonia;	chr10:75144379	chr10:75269819~75373500:+
THCA	cis	rs2657294	0.965	rs10824285	ENSG00000226051.5	ZNF503-AS1	-4.48	9.33e-06	0.000963	-0.28	-0.2	Pneumonia;	chr10:75153271	chr10:75269819~75373500:+
THCA	cis	rs2657294	0.965	rs2047951	ENSG00000226051.5	ZNF503-AS1	-4.48	9.33e-06	0.000963	-0.28	-0.2	Pneumonia;	chr10:75161310	chr10:75269819~75373500:+
THCA	cis	rs2657294	0.965	rs2804523	ENSG00000226051.5	ZNF503-AS1	-4.48	9.33e-06	0.000963	-0.28	-0.2	Pneumonia;	chr10:75161584	chr10:75269819~75373500:+
THCA	cis	rs2657294	0.965	rs7899946	ENSG00000226051.5	ZNF503-AS1	-4.48	9.33e-06	0.000963	-0.28	-0.2	Pneumonia;	chr10:75166013	chr10:75269819~75373500:+
THCA	cis	rs7267979	0.966	rs910996	ENSG00000274973.1	RP13-401N8.7	-4.48	9.33e-06	0.000963	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25845497~25845862:+
THCA	cis	rs6973609	0.597	rs7794286	ENSG00000271122.1	RP11-379H18.1	4.48	9.33e-06	0.000963	0.13	0.2	Obesity-related traits;	chr7:35568805	chr7:35695214~35699413:+
THCA	cis	rs8192917	0.573	rs8010409	ENSG00000258744.1	RP11-80A15.1	-4.48	9.33e-06	0.000963	-0.37	-0.2	Vitiligo;	chr14:24611083	chr14:24501594~24508688:+
THCA	cis	rs6416877	0.655	rs10852857	ENSG00000277491.1	RP11-676J12.9	-4.48	9.33e-06	0.000963	-0.22	-0.2	Myeloid white cell count;	chr17:1452257	chr17:795306~795794:+
THCA	cis	rs6728642	0.901	rs10179966	ENSG00000230606.9	AC159540.1	4.48	9.33e-06	0.000963	0.26	0.2	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97179363	chr2:97416165~97433527:-
THCA	cis	rs7614311	0.681	rs6801346	ENSG00000271843.1	RP11-245J9.5	4.48	9.33e-06	0.000963	0.36	0.2	Lung function (FVC);Lung function (FEV1);	chr3:63961452	chr3:64008082~64008692:-
THCA	cis	rs4591358	0.705	rs2375526	ENSG00000223466.1	AC064834.2	-4.48	9.34e-06	0.000964	-0.24	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195496946	chr2:195533035~195538681:+
THCA	cis	rs9788682	0.747	rs8042059	ENSG00000261143.1	ADAMTS7P3	-4.48	9.34e-06	0.000964	-0.27	-0.2	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615517	chr15:77976042~77993057:+
THCA	cis	rs1030877	0.515	rs2576736	ENSG00000235319.1	AC012360.4	-4.48	9.34e-06	0.000964	-0.26	-0.2	Obesity-related traits;	chr2:105274514	chr2:105324210~105330529:+
THCA	cis	rs5997397	1	rs5997397	ENSG00000272858.1	CTA-292E10.8	-4.48	9.34e-06	0.000964	-0.2	-0.2	Red cell distribution width;	chr22:28758467	chr22:28814914~28815662:+
THCA	cis	rs6088590	1	rs6087632	ENSG00000276073.1	RP5-1125A11.7	-4.48	9.34e-06	0.000964	-0.19	-0.2	Coronary artery disease;	chr20:34819901	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.931	rs6088617	ENSG00000276073.1	RP5-1125A11.7	-4.48	9.34e-06	0.000964	-0.19	-0.2	Coronary artery disease;	chr20:34820233	chr20:33985617~33988989:-
THCA	cis	rs2483058	0.767	rs10779631	ENSG00000261000.1	RP11-534L20.5	4.48	9.34e-06	0.000964	0.22	0.2	Cholesterol and Triglycerides;	chr1:206448943	chr1:206503948~206504456:+
THCA	cis	rs5758511	0.68	rs5758681	ENSG00000227370.1	RP4-669P10.19	4.48	9.34e-06	0.000964	0.23	0.2	Birth weight;	chr22:42249085	chr22:42132543~42132998:+
THCA	cis	rs394563	0.601	rs367133	ENSG00000231760.4	RP11-350J20.5	4.48	9.34e-06	0.000964	0.27	0.2	Dupuytren's disease;	chr6:149476584	chr6:149796151~149826294:-
THCA	cis	rs11096990	0.855	rs75746161	ENSG00000249685.1	RP11-360F5.3	-4.48	9.34e-06	0.000964	-0.26	-0.2	Cognitive function;	chr4:39167481	chr4:39133913~39135608:+
THCA	cis	rs11992162	0.551	rs59191504	ENSG00000206014.6	OR7E161P	4.48	9.34e-06	0.000964	0.23	0.2	Monocyte count;	chr8:11927572	chr8:11928597~11929563:-
THCA	cis	rs752010	0.655	rs10890145	ENSG00000230638.4	RP11-486B10.4	-4.48	9.34e-06	0.000964	-0.22	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41620619	chr1:41542069~41544310:+
THCA	cis	rs752010	0.808	rs7529858	ENSG00000230638.4	RP11-486B10.4	-4.48	9.34e-06	0.000964	-0.22	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41620935	chr1:41542069~41544310:+
THCA	cis	rs752010	0.714	rs7552928	ENSG00000230638.4	RP11-486B10.4	-4.48	9.34e-06	0.000964	-0.22	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41620993	chr1:41542069~41544310:+
THCA	cis	rs7618915	0.773	rs10510760	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.35e-06	0.000964	-0.23	-0.2	Bipolar disorder;	chr3:52616332	chr3:52239258~52241097:+
THCA	cis	rs10256972	0.933	rs35696159	ENSG00000225146.1	AC073957.15	4.48	9.35e-06	0.000965	0.21	0.2	Endometriosis;Longevity;	chr7:1007558	chr7:1029025~1043891:+
THCA	cis	rs12530	0.54	rs737779	ENSG00000230736.2	RP1-149A16.3	-4.48	9.35e-06	0.000965	-0.24	-0.2	IgG glycosylation;	chr22:32400260	chr22:32376664~32384343:+
THCA	cis	rs9876781	1	rs9864371	ENSG00000244380.1	RP11-24C3.2	4.48	9.35e-06	0.000965	0.24	0.2	Longevity;	chr3:48385276	chr3:48440352~48446656:-
THCA	cis	rs2657294	0.965	rs4746264	ENSG00000226051.5	ZNF503-AS1	-4.48	9.35e-06	0.000965	-0.28	-0.2	Pneumonia;	chr10:75114194	chr10:75269819~75373500:+
THCA	cis	rs2657294	0.965	rs9299525	ENSG00000226051.5	ZNF503-AS1	-4.48	9.35e-06	0.000965	-0.28	-0.2	Pneumonia;	chr10:75118267	chr10:75269819~75373500:+
THCA	cis	rs2657294	0.965	rs10762658	ENSG00000226051.5	ZNF503-AS1	-4.48	9.35e-06	0.000965	-0.28	-0.2	Pneumonia;	chr10:75119804	chr10:75269819~75373500:+
THCA	cis	rs8027521	0.677	rs8030160	ENSG00000280362.1	RP11-643A5.3	4.48	9.35e-06	0.000965	0.26	0.2	Circulating chemerin levels;	chr15:53976457	chr15:53910769~53914712:+
THCA	cis	rs2886497	0.947	rs4590755	ENSG00000224215.1	RP11-371A19.2	-4.48	9.36e-06	0.000965	-0.26	-0.2	Major depression and alcohol dependence;	chr10:23375884	chr10:23343957~23345181:+
THCA	cis	rs2070488	1	rs2268758	ENSG00000229589.1	ACVR2B-AS1	4.48	9.36e-06	0.000965	0.19	0.2	Electrocardiographic conduction measures;	chr3:38472558	chr3:38451027~38454820:-
THCA	cis	rs1005277	0.579	rs176838	ENSG00000275858.1	RP11-291L22.8	-4.48	9.36e-06	0.000966	-0.24	-0.2	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38450738~38451069:-
THCA	cis	rs7267979	0.789	rs6076347	ENSG00000274414.1	RP5-965G21.4	4.48	9.36e-06	0.000966	0.24	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:25239007~25245229:-
THCA	cis	rs17221829	0.965	rs3871189	ENSG00000280385.1	AP000648.5	-4.48	9.36e-06	0.000966	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89718082	chr11:90193614~90198120:+
THCA	cis	rs7942368	0.878	rs1866843	ENSG00000261578.1	RP11-21L23.2	4.48	9.37e-06	0.000966	0.29	0.2	Endometriosis;	chr11:76778292	chr11:76800364~76804555:+
THCA	cis	rs4415084	0.716	rs4605791	ENSG00000272335.1	RP11-53O19.3	4.48	9.37e-06	0.000966	0.17	0.2	Breast cancer;	chr5:44855610	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.744	rs4604199	ENSG00000272335.1	RP11-53O19.3	4.48	9.37e-06	0.000966	0.17	0.2	Breast cancer;	chr5:44855614	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs4566804	ENSG00000272335.1	RP11-53O19.3	4.48	9.37e-06	0.000966	0.17	0.2	Breast cancer;	chr5:44855637	chr5:44826076~44828592:+
THCA	cis	rs172166	0.56	rs203878	ENSG00000220721.1	OR1F12	4.48	9.37e-06	0.000966	0.22	0.2	Cardiac Troponin-T levels;	chr6:28081218	chr6:28073316~28074233:+
THCA	cis	rs9625935	0.957	rs12171263	ENSG00000279159.1	RP3-394A18.1	-4.48	9.37e-06	0.000966	-0.16	-0.2	Tonsillectomy;	chr22:30161292	chr22:29978950~30028236:-
THCA	cis	rs71636778	0.631	rs74465889	ENSG00000260063.1	RP5-968P14.2	-4.48	9.37e-06	0.000967	-0.28	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26882948	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.631	rs113312820	ENSG00000260063.1	RP5-968P14.2	-4.48	9.37e-06	0.000967	-0.28	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26886588	chr1:26692132~26694131:-
THCA	cis	rs516805	0.847	rs520046	ENSG00000279114.1	RP3-425C14.5	-4.48	9.37e-06	0.000967	-0.2	-0.2	Lymphocyte counts;	chr6:122446048	chr6:122471923~122484161:+
THCA	cis	rs9329221	0.538	rs9650651	ENSG00000261451.1	RP11-981G7.1	4.48	9.37e-06	0.000967	0.24	0.2	Neuroticism;	chr8:10410030	chr8:10433672~10438312:+
THCA	cis	rs4794202	0.755	rs11651698	ENSG00000264920.1	RP11-6N17.4	-4.48	9.37e-06	0.000967	-0.24	-0.2	Alzheimer's disease (cognitive decline);	chr17:47854937	chr17:47891255~47895812:-
THCA	cis	rs2836974	0.644	rs61300849	ENSG00000255568.3	BRWD1-AS2	-4.48	9.37e-06	0.000967	-0.17	-0.2	Cognitive function;	chr21:39308268	chr21:39313935~39314962:+
THCA	cis	rs2657294	0.726	rs4746275	ENSG00000226051.5	ZNF503-AS1	-4.48	9.37e-06	0.000967	-0.28	-0.2	Pneumonia;	chr10:75214940	chr10:75269819~75373500:+
THCA	cis	rs9425766	0.541	rs4652274	ENSG00000227373.4	RP11-160H22.5	4.48	9.38e-06	0.000968	0.29	0.2	Life satisfaction;	chr1:174249434	chr1:174115300~174160004:-
THCA	cis	rs875971	0.895	rs7782806	ENSG00000229886.1	RP5-1132H15.3	-4.48	9.39e-06	0.000968	-0.21	-0.2	Aortic root size;	chr7:66192910	chr7:66025126~66031544:-
THCA	cis	rs930395	0.514	rs9292914	ENSG00000272335.1	RP11-53O19.3	4.48	9.39e-06	0.000968	0.17	0.2	Breast cancer;	chr5:44871279	chr5:44826076~44828592:+
THCA	cis	rs9307551	0.619	rs7690520	ENSG00000250334.4	LINC00989	-4.48	9.39e-06	0.000968	-0.24	-0.2	Refractive error;	chr4:79507806	chr4:79492416~79576460:+
THCA	cis	rs2839186	0.584	rs2032111	ENSG00000239415.1	AP001469.9	4.48	9.39e-06	0.000968	0.22	0.2	Testicular germ cell tumor;	chr21:46484656	chr21:46251549~46254133:-
THCA	cis	rs4713118	0.955	rs9468201	ENSG00000220721.1	OR1F12	4.48	9.39e-06	0.000968	0.26	0.2	Parkinson's disease;	chr6:27719256	chr6:28073316~28074233:+
THCA	cis	rs11157436	1	rs11157440	ENSG00000211812.1	TRAV26-2	-4.48	9.39e-06	0.000968	-0.19	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22202583~22203368:+
THCA	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-4.48	9.39e-06	0.000968	-0.11	-0.2	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-4.48	9.39e-06	0.000968	-0.11	-0.2	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
THCA	cis	rs2280018	1	rs2280017	ENSG00000263335.1	AF001548.5	4.48	9.39e-06	0.000968	0.22	0.2	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15726674~15732993:+
THCA	cis	rs6901004	0.565	rs6900341	ENSG00000271789.1	RP5-1112D6.7	-4.48	9.39e-06	0.000968	-0.2	-0.2	Blood metabolite levels;	chr6:111473206	chr6:111297126~111298510:+
THCA	cis	rs4927850	0.521	rs4927679	ENSG00000273009.1	RP11-352G9.1	4.48	9.39e-06	0.000969	0.2	0.2	Pancreatic cancer;	chr3:195931489	chr3:195913078~195913683:-
THCA	cis	rs9959145	0.929	rs113231666	ENSG00000267108.1	RP11-861E21.1	4.48	9.39e-06	0.000969	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12574011	chr18:12432897~12437635:+
THCA	cis	rs10129255	0.536	rs6576201	ENSG00000211970.3	IGHV4-61	4.48	9.39e-06	0.000969	0.11	0.2	Kawasaki disease;	chr14:106683696	chr14:106639119~106639657:-
THCA	cis	rs997295	0.592	rs7162320	ENSG00000270964.1	RP11-502I4.3	-4.48	9.39e-06	0.000969	-0.17	-0.2	Motion sickness;	chr15:67473700	chr15:67541072~67542604:-
THCA	cis	rs10208649	0.611	rs58851686	ENSG00000233266.1	HMGB1P31	4.48	9.4e-06	0.000969	0.37	0.2	Body mass index;	chr2:54057179	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.611	rs1363060	ENSG00000233266.1	HMGB1P31	4.48	9.4e-06	0.000969	0.37	0.2	Body mass index;	chr2:54057447	chr2:54051334~54051760:+
THCA	cis	rs9902453	0.808	rs1986555	ENSG00000263370.1	RP11-68I3.5	4.48	9.4e-06	0.000969	0.27	0.2	Coffee consumption (cups per day);	chr17:29687430	chr17:29639627~29640825:+
THCA	cis	rs62025270	0.688	rs7164373	ENSG00000259295.5	CSPG4P12	-4.48	9.4e-06	0.000969	-0.35	-0.2	Idiopathic pulmonary fibrosis;	chr15:85722432	chr15:85191438~85213905:+
THCA	cis	rs7246657	0.653	rs10414983	ENSG00000276846.1	CTD-3220F14.3	4.48	9.4e-06	0.00097	0.25	0.2	Coronary artery calcification;	chr19:37174830	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.598	rs10405372	ENSG00000276846.1	CTD-3220F14.3	4.48	9.4e-06	0.00097	0.25	0.2	Coronary artery calcification;	chr19:37177873	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.653	rs10425441	ENSG00000276846.1	CTD-3220F14.3	4.48	9.4e-06	0.00097	0.25	0.2	Coronary artery calcification;	chr19:37179746	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.653	rs4805207	ENSG00000276846.1	CTD-3220F14.3	4.48	9.4e-06	0.00097	0.25	0.2	Coronary artery calcification;	chr19:37182831	chr19:37314868~37315620:-
THCA	cis	rs7246657	0.653	rs28701616	ENSG00000276846.1	CTD-3220F14.3	4.48	9.4e-06	0.00097	0.25	0.2	Coronary artery calcification;	chr19:37190196	chr19:37314868~37315620:-
THCA	cis	rs9926296	0.593	rs6500456	ENSG00000260259.1	RP11-368I7.4	-4.48	9.4e-06	0.00097	-0.21	-0.2	Vitiligo;	chr16:89821933	chr16:89682620~89686569:-
THCA	cis	rs12478296	1	rs66612947	ENSG00000220804.7	AC093642.5	4.48	9.41e-06	0.00097	0.22	0.2	Obesity-related traits;	chr2:242093811	chr2:242088633~242160153:+
THCA	cis	rs1799922	0.708	rs339054	ENSG00000273270.1	RP11-212P7.2	4.48	9.41e-06	0.00097	0.22	0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128742457	chr7:128524016~128531069:-
THCA	cis	rs6840360	0.608	rs2724556	ENSG00000251611.1	RP11-610P16.1	-4.48	9.41e-06	0.000971	-0.15	-0.2	Intelligence (multi-trait analysis);	chr4:151420565	chr4:151407551~151408835:-
THCA	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-4.48	9.42e-06	0.000971	-0.25	-0.2	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
THCA	cis	rs8067545	0.578	rs4925087	ENSG00000270091.1	RP11-78O7.2	-4.48	9.42e-06	0.000971	-0.15	-0.2	Schizophrenia;	chr17:20121269	chr17:19896590~19897287:-
THCA	cis	rs9863	0.861	rs75321546	ENSG00000270061.1	RP11-214K3.19	-4.48	9.42e-06	0.000971	-0.27	-0.2	White blood cell count;	chr12:123962918	chr12:123969990~123970344:-
THCA	cis	rs9863	0.861	rs55990776	ENSG00000270061.1	RP11-214K3.19	-4.48	9.42e-06	0.000971	-0.27	-0.2	White blood cell count;	chr12:123962919	chr12:123969990~123970344:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000272831.1	RP11-792A8.4	4.48	9.42e-06	0.000971	0.13	0.2	Calcium levels;	chr7:65892789	chr7:66739829~66740385:-
THCA	cis	rs15676	0.853	rs2259043	ENSG00000234771.3	SLC25A25-AS1	4.48	9.42e-06	0.000971	0.17	0.2	Blood metabolite levels;	chr9:128845642	chr9:128108581~128118693:-
THCA	cis	rs7336933	0.877	rs9525554	ENSG00000278338.3	VWA8-AS1	-4.48	9.42e-06	0.000971	-0.34	-0.2	Calcium levels;	chr13:41931371	chr13:41955808~41981565:+
THCA	cis	rs7829975	0.508	rs1594437	ENSG00000254153.1	CTA-398F10.2	-4.48	9.42e-06	0.000971	-0.21	-0.2	Mood instability;	chr8:8968365	chr8:8456909~8461337:-
THCA	cis	rs375066	0.935	rs396874	ENSG00000278917.1	RP11-15A1.4	-4.48	9.42e-06	0.000972	-0.17	-0.2	Breast cancer;	chr19:43893073	chr19:43891233~43895411:+
THCA	cis	rs12478296	0.901	rs67423532	ENSG00000261186.2	RP11-341N2.1	-4.48	9.42e-06	0.000972	-0.31	-0.2	Obesity-related traits;	chr2:242062568	chr2:242087351~242088457:-
THCA	cis	rs12478296	0.901	rs67951957	ENSG00000261186.2	RP11-341N2.1	-4.48	9.42e-06	0.000972	-0.31	-0.2	Obesity-related traits;	chr2:242062750	chr2:242087351~242088457:-
THCA	cis	rs2904524	0.737	rs77477371	ENSG00000257815.4	RP11-611E13.2	-4.48	9.43e-06	0.000972	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70305388	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.618	rs75637384	ENSG00000257815.4	RP11-611E13.2	-4.48	9.43e-06	0.000972	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70315986	chr12:69904033~70243360:-
THCA	cis	rs4950322	0.57	rs7554833	ENSG00000180867.10	PDIA3P1	-4.48	9.43e-06	0.000972	-0.2	-0.2	Protein quantitative trait loci;	chr1:147289362	chr1:147178113~147179622:+
THCA	cis	rs75920871	0.609	rs11216180	ENSG00000254851.1	RP11-109L13.1	-4.48	9.43e-06	0.000972	-0.46	-0.2	Subjective well-being;	chr11:116902662	chr11:117135528~117138582:+
THCA	cis	rs4648045	0.687	rs1005819	ENSG00000246560.2	RP11-10L12.4	4.48	9.43e-06	0.000972	0.24	0.2	Lymphocyte percentage of white cells;	chr4:102583148	chr4:102828055~102844075:+
THCA	cis	rs6657613	0.68	rs7545518	ENSG00000186301.8	MST1P2	-4.48	9.43e-06	0.000972	-0.16	-0.2	Hip circumference adjusted for BMI;	chr1:17048247	chr1:16645622~16650289:+
THCA	cis	rs1923243	0.649	rs4330880	ENSG00000223479.3	RP4-788P17.1	-4.48	9.43e-06	0.000972	-0.22	-0.2	Migraine;	chr1:72922838	chr1:73635216~73715214:+
THCA	cis	rs6772849	0.93	rs1962040	ENSG00000242551.2	POU5F1P6	-4.48	9.43e-06	0.000972	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr3:128605318	chr3:128674735~128677005:-
THCA	cis	rs508487	0.537	rs5072	ENSG00000280143.1	AP000892.6	4.48	9.43e-06	0.000972	0.36	0.2	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117204967~117210292:+
THCA	cis	rs1046896	0.553	rs3744160	ENSG00000263063.1	RP11-388C12.1	-4.48	9.43e-06	0.000972	-0.26	-0.2	Glycated hemoglobin levels;	chr17:82870427	chr17:82713908~82716255:-
THCA	cis	rs4950322	0.57	rs4950400	ENSG00000271721.1	RP11-337C18.9	-4.48	9.43e-06	0.000972	-0.23	-0.2	Protein quantitative trait loci;	chr1:147319383	chr1:147175602~147177740:+
THCA	cis	rs59918340	0.728	rs10112337	ENSG00000253307.1	RP11-10J21.4	-4.48	9.43e-06	0.000972	-0.28	-0.2	Immature fraction of reticulocytes;	chr8:141223474	chr8:141252286~141253292:-
THCA	cis	rs800160	1	rs1088986	ENSG00000199550.1	Y_RNA	4.48	9.43e-06	0.000972	0.3	0.2	Bacteremia;	chr11:2356632	chr11:2372638~2372750:+
THCA	cis	rs62025270	0.632	rs80036674	ENSG00000259295.5	CSPG4P12	-4.48	9.43e-06	0.000972	-0.35	-0.2	Idiopathic pulmonary fibrosis;	chr15:85571217	chr15:85191438~85213905:+
THCA	cis	rs2067615	0.579	rs7297592	ENSG00000260329.1	RP11-412D9.4	-4.48	9.43e-06	0.000972	-0.19	-0.2	Heart rate;	chr12:106830191	chr12:106954029~106955497:-
THCA	cis	rs875971	1	rs6956179	ENSG00000230189.5	GS1-124K5.2	-4.48	9.43e-06	0.000973	-0.13	-0.2	Aortic root size;	chr7:66341672	chr7:66409143~66490059:-
THCA	cis	rs62246343	0.605	rs4328788	ENSG00000254485.4	RP11-380O24.1	4.48	9.44e-06	0.000973	0.23	0.2	Fibrinogen levels;	chr3:9415577	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.605	rs4308263	ENSG00000254485.4	RP11-380O24.1	4.48	9.44e-06	0.000973	0.23	0.2	Fibrinogen levels;	chr3:9415674	chr3:9292588~9363303:-
THCA	cis	rs7614311	0.594	rs1046025	ENSG00000271843.1	RP11-245J9.5	-4.48	9.44e-06	0.000973	-0.32	-0.2	Lung function (FVC);Lung function (FEV1);	chr3:64010586	chr3:64008082~64008692:-
THCA	cis	rs78487399	0.614	rs77101426	ENSG00000234936.1	AC010883.5	4.48	9.44e-06	0.000973	0.35	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43471614	chr2:43229573~43233394:+
THCA	cis	rs7216064	1	rs11870068	ENSG00000278740.1	RP11-147L13.14	4.48	9.44e-06	0.000973	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67948399	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs7223813	ENSG00000278740.1	RP11-147L13.14	4.48	9.44e-06	0.000973	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67949724	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.954	rs4790973	ENSG00000278740.1	RP11-147L13.14	4.48	9.44e-06	0.000973	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67955017	chr17:68188547~68189165:+
THCA	cis	rs35740288	0.77	rs55740125	ENSG00000259295.5	CSPG4P12	4.48	9.44e-06	0.000973	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612505	chr15:85191438~85213905:+
THCA	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-4.48	9.44e-06	0.000974	-0.23	-0.2	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
THCA	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-4.48	9.44e-06	0.000974	-0.23	-0.2	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
THCA	cis	rs4650994	0.623	rs2248666	ENSG00000273384.1	RP5-1098D14.1	-4.48	9.45e-06	0.000974	-0.26	-0.2	HDL cholesterol;HDL cholesterol levels;	chr1:178651466	chr1:178651706~178652282:+
THCA	cis	rs13434995	0.589	rs499110	ENSG00000249700.7	SRD5A3-AS1	-4.48	9.45e-06	0.000974	-0.29	-0.2	Adiponectin levels;	chr4:55381628	chr4:55363971~55395847:-
THCA	cis	rs709400	0.93	rs10134399	ENSG00000258735.1	LINC00637	4.48	9.45e-06	0.000974	0.26	0.2	Body mass index;	chr14:103617120	chr14:103847721~103858049:+
THCA	cis	rs9902453	0.765	rs2628185	ENSG00000263370.1	RP11-68I3.5	-4.48	9.45e-06	0.000974	-0.26	-0.2	Coffee consumption (cups per day);	chr17:29743089	chr17:29639627~29640825:+
THCA	cis	rs12216545	0.765	rs2272092	ENSG00000241134.3	BET1P1	-4.48	9.45e-06	0.000974	-0.24	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150567557	chr7:150749736~150750094:+
THCA	cis	rs9393777	0.668	rs3800318	ENSG00000219392.1	RP1-265C24.5	-4.48	9.45e-06	0.000974	-0.28	-0.2	Intelligence (multi-trait analysis);	chr6:27295862	chr6:28115628~28116551:+
THCA	cis	rs617791	0.53	rs10896073	ENSG00000255320.1	RP11-755F10.1	4.48	9.45e-06	0.000975	0.27	0.2	Breast cancer;	chr11:65995343	chr11:66244840~66246239:-
THCA	cis	rs4852324	0.536	rs13390332	ENSG00000257800.1	FNBP1P1	4.48	9.46e-06	0.000975	0.35	0.2	Systemic lupus erythematosus;	chr2:73980230	chr2:74120680~74123218:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000272831.1	RP11-792A8.4	4.48	9.46e-06	0.000975	0.13	0.2	Aortic root size;	chr7:65960907	chr7:66739829~66740385:-
THCA	cis	rs5752326	0.51	rs5761556	ENSG00000261188.1	CTA-445C9.14	4.48	9.46e-06	0.000975	0.19	0.2	Ischemic stroke;	chr22:26480915	chr22:26512537~26514568:+
THCA	cis	rs375066	0.901	rs376457	ENSG00000278917.1	RP11-15A1.4	-4.48	9.46e-06	0.000975	-0.17	-0.2	Breast cancer;	chr19:43908605	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs430667	ENSG00000278917.1	RP11-15A1.4	-4.48	9.46e-06	0.000975	-0.17	-0.2	Breast cancer;	chr19:43909101	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs398964	ENSG00000278917.1	RP11-15A1.4	-4.48	9.46e-06	0.000975	-0.17	-0.2	Breast cancer;	chr19:43909732	chr19:43891233~43895411:+
THCA	cis	rs6121246	0.609	rs6060948	ENSG00000230613.1	HM13-AS1	4.48	9.46e-06	0.000975	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31788590	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6060952	ENSG00000230613.1	HM13-AS1	4.48	9.46e-06	0.000975	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31794305	chr20:31567707~31573263:-
THCA	cis	rs2777491	0.915	rs8036498	ENSG00000247556.5	OIP5-AS1	4.48	9.46e-06	0.000975	0.17	0.2	Ulcerative colitis;	chr15:41311078	chr15:41283990~41309737:+
THCA	cis	rs734999	0.588	rs745368	ENSG00000225931.3	RP3-395M20.7	4.48	9.46e-06	0.000975	0.24	0.2	Ulcerative colitis;	chr1:2592766	chr1:2566410~2569888:+
THCA	cis	rs734999	0.566	rs10752747	ENSG00000225931.3	RP3-395M20.7	4.48	9.46e-06	0.000975	0.24	0.2	Ulcerative colitis;	chr1:2593476	chr1:2566410~2569888:+
THCA	cis	rs9311474	0.507	rs6787154	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.46e-06	0.000975	-0.22	-0.2	Electroencephalogram traits;	chr3:52750400	chr3:52239258~52241097:+
THCA	cis	rs1334894	1	rs12527329	ENSG00000228559.1	RP3-340B19.3	-4.48	9.46e-06	0.000975	-0.43	-0.2	Coronary artery disease;	chr6:35642974	chr6:35544632~35545669:+
THCA	cis	rs2905347	0.965	rs2961272	ENSG00000232949.1	AC002480.4	-4.48	9.47e-06	0.000975	-0.25	-0.2	Major depression and alcohol dependence;	chr7:22585117	chr7:22589705~22591622:+
THCA	cis	rs17270561	0.609	rs9358885	ENSG00000272462.2	U91328.19	-4.48	9.47e-06	0.000976	-0.17	-0.2	Iron status biomarkers;	chr6:25757796	chr6:25992662~26001775:+
THCA	cis	rs7141336	0.8	rs8016042	ENSG00000258884.1	CTD-3035D6.2	4.48	9.47e-06	0.000976	0.27	0.2	Anxiety disorder;	chr14:90821842	chr14:90822365~90828128:-
THCA	cis	rs10256972	0.721	rs6975972	ENSG00000225146.1	AC073957.15	4.48	9.47e-06	0.000976	0.21	0.2	Endometriosis;Longevity;	chr7:1030832	chr7:1029025~1043891:+
THCA	cis	rs1707322	1	rs6429588	ENSG00000281133.1	AL355480.3	-4.48	9.47e-06	0.000976	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs12097799	ENSG00000281133.1	AL355480.3	-4.48	9.47e-06	0.000976	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45580892~45580996:-
THCA	cis	rs9527	0.662	rs10786714	ENSG00000236937.2	PTGES3P4	4.48	9.47e-06	0.000976	0.28	0.2	Arsenic metabolism;	chr10:102838849	chr10:102845595~102845950:+
THCA	cis	rs8031584	0.723	rs711224	ENSG00000259845.1	HERC2P10	-4.48	9.48e-06	0.000977	-0.28	-0.2	Huntington's disease progression;	chr15:30835718	chr15:30815271~30844153:+
THCA	cis	rs1046491	0.901	rs12454936	ENSG00000264964.1	RP11-888D10.3	4.48	9.48e-06	0.000977	0.34	0.2	Scarlet fever;	chr18:9134440	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs8095601	ENSG00000264964.1	RP11-888D10.3	4.48	9.48e-06	0.000977	0.34	0.2	Scarlet fever;	chr18:9136157	chr18:9315194~9334441:-
THCA	cis	rs987724	0.515	rs1574980	ENSG00000240875.4	LINC00886	-4.48	9.48e-06	0.000977	-0.19	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156917639	chr3:156747346~156817062:-
THCA	cis	rs12439619	0.53	rs28883606	ENSG00000259429.4	UBE2Q2P2	-4.48	9.49e-06	0.000977	-0.16	-0.2	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82355142~82420075:+
THCA	cis	rs13178541	0.689	rs12521005	ENSG00000250378.1	RP11-119J18.1	-4.48	9.49e-06	0.000978	-0.26	-0.2	IgG glycosylation;	chr5:135823313	chr5:135812667~135826582:+
THCA	cis	rs1150668	0.83	rs2859365	ENSG00000280107.1	AL022393.9	4.48	9.49e-06	0.000978	0.19	0.2	Pubertal anthropometrics;	chr6:28423688	chr6:28170845~28172521:+
THCA	cis	rs7208859	0.614	rs216477	ENSG00000266490.1	CTD-2349P21.9	-4.48	9.49e-06	0.000978	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30792372~30792833:+
THCA	cis	rs7621331	0.963	rs9862743	ENSG00000273486.1	RP11-731C17.2	4.48	9.49e-06	0.000978	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:135968450	chr3:136837338~136839021:-
THCA	cis	rs2280018	0.963	rs11075255	ENSG00000263335.1	AF001548.5	-4.48	9.49e-06	0.000978	-0.22	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15726674~15732993:+
THCA	cis	rs9970896	1	rs1886654	ENSG00000237845.1	RP5-940F7.2	-4.48	9.5e-06	0.000978	-0.38	-0.2	Monocyte percentage of white cells;	chr1:235942610	chr1:235942553~235943805:-
THCA	cis	rs2886497	0.947	rs12414475	ENSG00000224215.1	RP11-371A19.2	4.48	9.5e-06	0.000978	0.25	0.2	Major depression and alcohol dependence;	chr10:23372362	chr10:23343957~23345181:+
THCA	cis	rs9393813	0.509	rs10946915	ENSG00000204789.4	ZNF204P	-4.48	9.5e-06	0.000978	-0.16	-0.2	Bipolar disorder;	chr6:27410051	chr6:27357825~27360221:-
THCA	cis	rs6560517	0.957	rs2377639	ENSG00000234618.1	RPSAP9	-4.48	9.5e-06	0.000979	-0.22	-0.2	Dialysis-related mortality;	chr9:76380337	chr9:76398699~76399586:+
THCA	cis	rs9902453	0.935	rs9905950	ENSG00000263370.1	RP11-68I3.5	4.48	9.5e-06	0.000979	0.26	0.2	Coffee consumption (cups per day);	chr17:30104180	chr17:29639627~29640825:+
THCA	cis	rs4443100	0.726	rs5996449	ENSG00000230701.2	FBXW4P1	4.48	9.5e-06	0.000979	0.24	0.2	Serum parathyroid hormone levels;	chr22:23023133	chr22:23262767~23265005:+
THCA	cis	rs7474896	0.583	rs10827818	ENSG00000226578.1	RP11-258F22.1	-4.48	9.5e-06	0.000979	-0.28	-0.2	Obesity (extreme);	chr10:37711928	chr10:37775371~37784131:-
THCA	cis	rs2562456	0.754	rs62107469	ENSG00000268117.1	VN1R84P	4.48	9.51e-06	0.000979	0.33	0.2	Pain;	chr19:21312699	chr19:21719801~21720035:-
THCA	cis	rs78487399	0.71	rs80100685	ENSG00000234936.1	AC010883.5	4.48	9.51e-06	0.000979	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43423274	chr2:43229573~43233394:+
THCA	cis	rs875971	0.862	rs6460282	ENSG00000229886.1	RP5-1132H15.3	-4.48	9.51e-06	0.000979	-0.21	-0.2	Aortic root size;	chr7:66226259	chr7:66025126~66031544:-
THCA	cis	rs6012564	1	rs755587	ENSG00000230758.1	SNAP23P	4.48	9.51e-06	0.000979	0.24	0.2	Anger;	chr20:49104420	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs11696870	ENSG00000230758.1	SNAP23P	4.48	9.51e-06	0.000979	0.24	0.2	Anger;	chr20:49109070	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.963	rs6063355	ENSG00000230758.1	SNAP23P	4.48	9.51e-06	0.000979	0.24	0.2	Anger;	chr20:49109592	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs6066968	ENSG00000230758.1	SNAP23P	4.48	9.51e-06	0.000979	0.24	0.2	Anger;	chr20:49110804	chr20:49038357~49038602:-
THCA	cis	rs919433	0.617	rs34632716	ENSG00000231621.1	AC013264.2	4.48	9.51e-06	0.00098	0.22	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197677895	chr2:197197991~197199273:+
THCA	cis	rs919433	0.617	rs12619333	ENSG00000231621.1	AC013264.2	4.48	9.51e-06	0.00098	0.22	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197702914	chr2:197197991~197199273:+
THCA	cis	rs2777491	0.915	rs28583065	ENSG00000247556.5	OIP5-AS1	4.48	9.51e-06	0.00098	0.17	0.2	Ulcerative colitis;	chr15:41316272	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.874	rs7161772	ENSG00000247556.5	OIP5-AS1	4.48	9.51e-06	0.00098	0.17	0.2	Ulcerative colitis;	chr15:41318868	chr15:41283990~41309737:+
THCA	cis	rs7648466	0.592	rs7616215	ENSG00000223552.1	RP11-24F11.2	-4.48	9.51e-06	0.00098	-0.18	-0.2	Eotaxin levels;	chr3:46164194	chr3:46364955~46407059:-
THCA	cis	rs7474896	0.559	rs1208560	ENSG00000226578.1	RP11-258F22.1	4.48	9.51e-06	0.00098	0.28	0.2	Obesity (extreme);	chr10:37932690	chr10:37775371~37784131:-
THCA	cis	rs2191566	1	rs390369	ENSG00000266921.1	RP11-15A1.7	4.48	9.51e-06	0.00098	0.19	0.2	Acute lymphoblastic leukemia (childhood);	chr19:44002832	chr19:43996896~44002836:-
THCA	cis	rs11096990	0.855	rs3796524	ENSG00000249685.1	RP11-360F5.3	-4.48	9.51e-06	0.00098	-0.26	-0.2	Cognitive function;	chr4:39194367	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.892	rs4974924	ENSG00000249685.1	RP11-360F5.3	-4.48	9.51e-06	0.00098	-0.26	-0.2	Cognitive function;	chr4:39196091	chr4:39133913~39135608:+
THCA	cis	rs7924176	0.601	rs10824071	ENSG00000213731.2	RAB5CP1	-4.48	9.51e-06	0.00098	-0.24	-0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74113881	chr10:74423435~74424014:-
THCA	cis	rs875971	0.545	rs10950036	ENSG00000273142.1	RP11-458F8.4	4.48	9.52e-06	0.00098	0.19	0.2	Aortic root size;	chr7:66353241	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000273142.1	RP11-458F8.4	4.48	9.52e-06	0.00098	0.19	0.2	Aortic root size;	chr7:66390342	chr7:66902857~66906297:+
THCA	cis	rs8062405	1	rs62036622	ENSG00000261766.1	RP11-22P6.2	-4.48	9.52e-06	0.00098	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28862166~28863340:-
THCA	cis	rs4415084	0.716	rs7708213	ENSG00000272335.1	RP11-53O19.3	4.48	9.52e-06	0.00098	0.17	0.2	Breast cancer;	chr5:44848299	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs4440370	ENSG00000272335.1	RP11-53O19.3	4.48	9.52e-06	0.00098	0.17	0.2	Breast cancer;	chr5:44853250	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.716	rs4492119	ENSG00000272335.1	RP11-53O19.3	4.48	9.52e-06	0.00098	0.17	0.2	Breast cancer;	chr5:44855512	chr5:44826076~44828592:+
THCA	cis	rs67478160	0.643	rs2295141	ENSG00000269910.1	RP11-73M18.10	4.48	9.52e-06	0.00098	0.17	0.2	Schizophrenia;	chr14:103746612	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.654	rs1997913	ENSG00000269910.1	RP11-73M18.10	4.48	9.52e-06	0.00098	0.17	0.2	Schizophrenia;	chr14:103747623	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs3818085	ENSG00000269910.1	RP11-73M18.10	4.48	9.52e-06	0.00098	0.17	0.2	Schizophrenia;	chr14:103749648	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.643	rs1535098	ENSG00000269910.1	RP11-73M18.10	4.48	9.52e-06	0.00098	0.17	0.2	Schizophrenia;	chr14:103750176	chr14:103694516~103695050:-
THCA	cis	rs564799	1	rs564799	ENSG00000244040.4	IL12A-AS1	4.48	9.52e-06	0.000981	0.26	0.2	Systemic lupus erythematosus;	chr3:160011200	chr3:159913400~160225299:-
THCA	cis	rs11157436	0.958	rs3811277	ENSG00000211812.1	TRAV26-2	-4.48	9.52e-06	0.000981	-0.19	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22202583~22203368:+
THCA	cis	rs7618915	0.501	rs1468638	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52714042	chr3:52239258~52241097:+
THCA	cis	rs736408	0.522	rs11716747	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52714841	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs35526119	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52715318	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs7624716	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52717518	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs2109634	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52718059	chr3:52239258~52241097:+
THCA	cis	rs2878628	0.596	rs57039206	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Intelligence (multi-trait analysis);	chr3:52724554	chr3:52239258~52241097:+
THCA	cis	rs2878628	0.65	rs56098033	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Intelligence (multi-trait analysis);	chr3:52724555	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs2079929	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52731630	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs34739010	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52732106	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs767418	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52733411	chr3:52239258~52241097:+
THCA	cis	rs736408	0.522	rs6445535	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52737452	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs2159644	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52740514	chr3:52239258~52241097:+
THCA	cis	rs736408	0.521	rs13074853	ENSG00000243224.1	RP5-1157M23.2	-4.48	9.53e-06	0.000981	-0.22	-0.2	Bipolar disorder;	chr3:52745785	chr3:52239258~52241097:+
THCA	cis	rs7191700	0.511	rs8058983	ENSG00000263080.1	RP11-485G7.5	-4.48	9.53e-06	0.000982	-0.23	-0.2	Multiple sclerosis;	chr16:11266992	chr16:11341809~11345211:-
THCA	cis	rs12962334	0.555	rs9954649	ENSG00000265939.1	UBE2CP2	4.48	9.54e-06	0.000982	0.23	0.2	Breast cancer;	chr18:23033307	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.505	rs9946743	ENSG00000265939.1	UBE2CP2	4.48	9.54e-06	0.000982	0.23	0.2	Eosinophil percentage of white cells;	chr18:23033394	chr18:22900486~22900995:-
THCA	cis	rs172166	0.538	rs149956	ENSG00000220721.1	OR1F12	4.48	9.54e-06	0.000982	0.22	0.2	Cardiac Troponin-T levels;	chr6:28068473	chr6:28073316~28074233:+
THCA	cis	rs858239	0.6	rs2072368	ENSG00000226816.2	AC005082.12	4.48	9.54e-06	0.000982	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23206013~23208045:+
THCA	cis	rs9810089	0.708	rs711977	ENSG00000273455.1	RP11-305O4.3	4.48	9.54e-06	0.000982	0.27	0.2	Gestational age at birth (child effect);	chr3:136508545	chr3:136087475~136087913:-
THCA	cis	rs17666538	0.71	rs7834337	ENSG00000254207.1	RP11-43A14.1	4.48	9.54e-06	0.000983	0.41	0.2	IgG glycosylation;	chr8:705828	chr8:725188~725877:-
THCA	cis	rs6496932	0.755	rs12905673	ENSG00000259630.2	CTD-2262B20.1	-4.48	9.54e-06	0.000983	-0.25	-0.2	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85415228~85415633:+
THCA	cis	rs9813712	0.953	rs12635811	ENSG00000253540.4	FAM86HP	-4.48	9.54e-06	0.000983	-0.25	-0.2	Response to amphetamines;	chr3:130262534	chr3:130099092~130111472:-
THCA	cis	rs7246760	0.867	rs2287843	ENSG00000267106.4	ZNF561-AS1	4.48	9.54e-06	0.000983	0.39	0.2	Pursuit maintenance gain;	chr19:9659237	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs66880218	ENSG00000267106.4	ZNF561-AS1	4.48	9.54e-06	0.000983	0.39	0.2	Pursuit maintenance gain;	chr19:9663479	chr19:9621291~9645896:+
THCA	cis	rs2299587	0.553	rs2299580	ENSG00000253671.1	RP11-806O11.1	-4.48	9.55e-06	0.000983	-0.23	-0.2	Economic and political preferences;	chr8:17877058	chr8:17808941~17820868:+
THCA	cis	rs7045881	0.735	rs16910895	ENSG00000254396.1	RP11-56F10.3	4.48	9.55e-06	0.000983	0.27	0.2	Schizophrenia;	chr9:26925658	chr9:27102630~27104728:+
THCA	cis	rs6963495	0.818	rs818621	ENSG00000272604.1	RP11-251G23.5	4.48	9.55e-06	0.000983	0.25	0.2	Bipolar disorder (body mass index interaction);	chr7:105532582	chr7:105571083~105573660:+
THCA	cis	rs858239	0.6	rs61292332	ENSG00000226816.2	AC005082.12	4.48	9.55e-06	0.000983	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23206013~23208045:+
THCA	cis	rs10875746	0.587	rs9788082	ENSG00000258234.1	RP11-370I10.2	4.48	9.55e-06	0.000984	0.25	0.2	Longevity (90 years and older);	chr12:48358273	chr12:48231098~48284210:-
THCA	cis	rs2290416	0.786	rs60401352	ENSG00000253931.1	RP11-909N17.2	4.48	9.55e-06	0.000984	0.39	0.2	Attention deficit hyperactivity disorder;	chr8:143590927	chr8:143412749~143417054:+
THCA	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-4.48	9.55e-06	0.000984	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-4.48	9.55e-06	0.000984	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-4.48	9.55e-06	0.000984	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000164669.11	INTS4P1	-4.48	9.56e-06	0.000984	-0.25	-0.2	Aortic root size;	chr7:65975357	chr7:65141225~65234216:+
THCA	cis	rs453301	0.624	rs4841083	ENSG00000254340.1	RP11-10A14.3	4.48	9.56e-06	0.000984	0.22	0.2	Joint mobility (Beighton score);	chr8:9012918	chr8:9141424~9145435:+
THCA	cis	rs17095355	1	rs9988702	ENSG00000203876.8	ADD3-AS1	-4.48	9.56e-06	0.000984	-0.22	-0.2	Biliary atresia;	chr10:109943631	chr10:109940104~110008381:-
THCA	cis	rs1150668	0.799	rs9301	ENSG00000220721.1	OR1F12	4.48	9.56e-06	0.000984	0.22	0.2	Pubertal anthropometrics;	chr6:28324929	chr6:28073316~28074233:+
THCA	cis	rs6138458	0.847	rs56312312	ENSG00000274173.1	RP4-568C11.4	4.48	9.56e-06	0.000984	0.2	0.2	Blood protein levels;	chr20:24978750	chr20:24931840~24932983:+
THCA	cis	rs9876781	1	rs11712561	ENSG00000244380.1	RP11-24C3.2	4.48	9.56e-06	0.000984	0.24	0.2	Longevity;	chr3:48393807	chr3:48440352~48446656:-
THCA	cis	rs7746199	0.736	rs17749927	ENSG00000272009.1	RP1-313I6.12	-4.48	9.56e-06	0.000984	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs13192965	ENSG00000272009.1	RP1-313I6.12	-4.48	9.56e-06	0.000984	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28078792~28081130:-
THCA	cis	rs858239	0.867	rs10250602	ENSG00000230042.1	AK3P3	-4.48	9.56e-06	0.000984	-0.28	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23129178~23129841:+
THCA	cis	rs9329221	0.617	rs483916	ENSG00000248538.5	RP11-10A14.5	4.48	9.56e-06	0.000984	0.26	0.2	Neuroticism;	chr8:9936091	chr8:9189011~9202854:+
THCA	cis	rs7267979	0.932	rs1985737	ENSG00000274973.1	RP13-401N8.7	-4.48	9.56e-06	0.000984	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25845497~25845862:+
THCA	cis	rs755249	0.753	rs72663529	ENSG00000182109.6	RP11-69E11.4	4.48	9.56e-06	0.000984	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39522280~39546187:-
THCA	cis	rs6657613	0.68	rs6698160	ENSG00000186301.8	MST1P2	4.48	9.56e-06	0.000984	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17049067	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs6701200	ENSG00000186301.8	MST1P2	4.48	9.56e-06	0.000984	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17049085	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs12122144	ENSG00000186301.8	MST1P2	4.48	9.56e-06	0.000984	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17049279	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs6700594	ENSG00000186301.8	MST1P2	4.48	9.56e-06	0.000984	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17050016	chr1:16645622~16650289:+
THCA	cis	rs890448	0.84	rs1426540	ENSG00000254531.1	FLJ20021	-4.48	9.57e-06	0.000985	-0.17	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101524619	chr4:101347780~101348883:+
THCA	cis	rs13113518	1	rs11724094	ENSG00000249700.7	SRD5A3-AS1	4.48	9.57e-06	0.000985	0.25	0.2	Height;	chr4:55501479	chr4:55363971~55395847:-
THCA	cis	rs9435732	0.62	rs12045097	ENSG00000268869.4	ESPNP	4.48	9.57e-06	0.000985	0.24	0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17019382	chr1:16687339~16720157:-
THCA	cis	rs453301	0.631	rs17700611	ENSG00000254153.1	CTA-398F10.2	4.48	9.57e-06	0.000985	0.23	0.2	Joint mobility (Beighton score);	chr8:8936144	chr8:8456909~8461337:-
THCA	cis	rs9880211	0.635	rs6775778	ENSG00000273486.1	RP11-731C17.2	-4.48	9.57e-06	0.000985	-0.21	-0.2	Height;Body mass index;	chr3:136007837	chr3:136837338~136839021:-
THCA	cis	rs6012564	1	rs911411	ENSG00000230758.1	SNAP23P	4.48	9.57e-06	0.000985	0.24	0.2	Anger;	chr20:49101894	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs6063352	ENSG00000230758.1	SNAP23P	4.48	9.57e-06	0.000985	0.24	0.2	Anger;	chr20:49102057	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs6063353	ENSG00000230758.1	SNAP23P	4.48	9.57e-06	0.000985	0.24	0.2	Anger;	chr20:49103273	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs6063354	ENSG00000230758.1	SNAP23P	4.48	9.57e-06	0.000985	0.24	0.2	Anger;	chr20:49103412	chr20:49038357~49038602:-
THCA	cis	rs5753037	0.809	rs2074707	ENSG00000279699.1	RP1-102K2.9	4.48	9.57e-06	0.000985	0.2	0.2	Type 1 diabetes;	chr22:29814367	chr22:30275215~30276951:-
THCA	cis	rs875971	0.83	rs6967708	ENSG00000229886.1	RP5-1132H15.3	-4.48	9.57e-06	0.000985	-0.21	-0.2	Aortic root size;	chr7:66192326	chr7:66025126~66031544:-
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000227888.4	FAM66A	4.48	9.58e-06	0.000986	0.25	0.2	Neuroticism;	chr8:11989569	chr8:12362019~12388296:+
THCA	cis	rs875971	0.895	rs6460278	ENSG00000229886.1	RP5-1132H15.3	-4.48	9.58e-06	0.000986	-0.21	-0.2	Aortic root size;	chr7:66197749	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6460279	ENSG00000229886.1	RP5-1132H15.3	-4.48	9.58e-06	0.000986	-0.21	-0.2	Aortic root size;	chr7:66197774	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs28491091	ENSG00000229886.1	RP5-1132H15.3	-4.48	9.58e-06	0.000986	-0.21	-0.2	Aortic root size;	chr7:66204077	chr7:66025126~66031544:-
THCA	cis	rs7647973	0.516	rs4536858	ENSG00000229759.1	MRPS18AP1	4.48	9.58e-06	0.000986	0.26	0.2	Menarche (age at onset);	chr3:49155648	chr3:48256350~48256938:-
THCA	cis	rs7647973	0.516	rs12490393	ENSG00000229759.1	MRPS18AP1	4.48	9.58e-06	0.000986	0.26	0.2	Menarche (age at onset);	chr3:49158699	chr3:48256350~48256938:-
THCA	cis	rs8077577	0.747	rs7215678	ENSG00000273018.4	CTD-2303H24.2	4.48	9.58e-06	0.000986	0.3	0.2	Obesity-related traits;	chr17:18236479	chr17:18511221~18551705:-
THCA	cis	rs28476539	0.568	rs6832564	ENSG00000270480.1	RP11-57B24.1	4.48	9.58e-06	0.000986	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82635346	chr4:82691737~82692468:+
THCA	cis	rs734999	0.545	rs4648356	ENSG00000225931.3	RP3-395M20.7	4.48	9.58e-06	0.000986	0.24	0.2	Ulcerative colitis;	chr1:2792599	chr1:2566410~2569888:+
THCA	cis	rs160451	0.782	rs160408	ENSG00000251136.7	RP11-37B2.1	4.48	9.59e-06	0.000986	0.18	0.2	Leprosy;	chr8:89634730	chr8:89609409~89757727:-
THCA	cis	rs11662586	0.574	rs55645353	ENSG00000267251.2	AC139100.3	4.48	9.59e-06	0.000986	0.28	0.2	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79995474	chr18:80183680~80202992:+
THCA	cis	rs8054556	0.692	rs12716973	ENSG00000183604.13	SMG1P5	-4.48	9.59e-06	0.000987	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29926331	chr16:30267553~30335374:-
THCA	cis	rs1023500	0.596	rs133352	ENSG00000237037.8	NDUFA6-AS1	-4.48	9.59e-06	0.000987	-0.17	-0.2	Schizophrenia;	chr22:42038018	chr22:42090931~42137742:+
THCA	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	4.48	9.59e-06	0.000987	0.12	0.2	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
THCA	cis	rs4906332	0.811	rs2296487	ENSG00000269910.1	RP11-73M18.10	4.48	9.6e-06	0.000987	0.2	0.2	Coronary artery disease;	chr14:103529868	chr14:103694516~103695050:-
THCA	cis	rs875971	0.723	rs28391294	ENSG00000229886.1	RP5-1132H15.3	-4.47	9.6e-06	0.000988	-0.21	-0.2	Aortic root size;	chr7:66189328	chr7:66025126~66031544:-
THCA	cis	rs2011503	0.509	rs11668721	ENSG00000271283.1	CTC-412M14.6	4.47	9.6e-06	0.000988	0.33	0.2	Bipolar disorder;	chr19:19650107	chr19:19699203~19699409:-
THCA	cis	rs8031584	0.918	rs61997138	ENSG00000178081.11	ULK4P3	4.47	9.6e-06	0.000988	0.26	0.2	Huntington's disease progression;	chr15:30978573	chr15:30103720~30131757:+
THCA	cis	rs6657613	0.649	rs2295060	ENSG00000186301.8	MST1P2	4.47	9.6e-06	0.000988	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17050295	chr1:16645622~16650289:+
THCA	cis	rs896854	0.738	rs1713669	ENSG00000253528.2	RP11-347C18.4	4.47	9.6e-06	0.000988	0.24	0.2	Type 2 diabetes;	chr8:94946409	chr8:94974573~94974853:-
THCA	cis	rs79040073	0.911	rs17393193	ENSG00000259531.2	RP11-295H24.3	4.47	9.6e-06	0.000988	0.26	0.2	Lung cancer in ever smokers;	chr15:49039882	chr15:49365124~49366685:-
THCA	cis	rs728616	0.614	rs59169164	ENSG00000242600.5	MBL1P	4.47	9.6e-06	0.000988	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952159	chr10:79904898~79950336:+
THCA	cis	rs2289700	1	rs2289697	ENSG00000252061.1	RNU6-415P	-4.47	9.6e-06	0.000988	-0.42	-0.2	Bipolar disorder;	chr15:78929565	chr15:78898840~78898936:-
THCA	cis	rs4074961	0.565	rs4415526	ENSG00000233621.1	LINC01137	-4.47	9.6e-06	0.000988	-0.21	-0.2	Axial length;	chr1:37606127	chr1:37454879~37474411:-
THCA	cis	rs2153535	0.561	rs9405404	ENSG00000230939.1	RP11-314C16.1	-4.47	9.61e-06	0.000988	-0.21	-0.2	Motion sickness;	chr6:8646583	chr6:8784178~8785445:+
THCA	cis	rs1823913	0.503	rs6706578	ENSG00000227542.1	AC092614.2	4.47	9.61e-06	0.000989	0.24	0.2	Obesity-related traits;	chr2:191346992	chr2:191229165~191246172:-
THCA	cis	rs2302464	1	rs75628417	ENSG00000214846.4	RP11-115L11.1	4.47	9.61e-06	0.000989	0.53	0.2	Cerebrospinal fluid biomarker levels;	chr4:15672941	chr4:15730962~15731627:-
THCA	cis	rs150992	0.574	rs2927655	ENSG00000246763.5	RGMB-AS1	4.47	9.61e-06	0.000989	0.21	0.2	Body mass index;	chr5:98839049	chr5:98769618~98773469:-
THCA	cis	rs4072705	0.614	rs1570581	ENSG00000224020.1	MIR181A2HG	-4.47	9.61e-06	0.000989	-0.19	-0.2	Menarche (age at onset);	chr9:124471780	chr9:124658467~124698631:+
THCA	cis	rs6951245	1	rs884977	ENSG00000229043.2	AC091729.9	-4.47	9.61e-06	0.000989	-0.33	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1026774	chr7:1160374~1165267:+
THCA	cis	rs7632954	0.596	rs7611030	ENSG00000227110.5	LMCD1-AS1	-4.47	9.61e-06	0.000989	-0.25	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8470235	chr3:7952805~8611924:-
THCA	cis	rs56114371	0.777	rs200481	ENSG00000280107.1	AL022393.9	-4.47	9.62e-06	0.000989	-0.29	-0.2	Breast cancer;	chr6:27806054	chr6:28170845~28172521:+
THCA	cis	rs1005277	0.54	rs289638	ENSG00000226578.1	RP11-258F22.1	-4.47	9.62e-06	0.000989	-0.23	-0.2	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:37775371~37784131:-
THCA	cis	rs56804039	1	rs34154295	ENSG00000254153.1	CTA-398F10.2	4.47	9.62e-06	0.00099	0.24	0.2	Cervical cancer;	chr8:8525967	chr8:8456909~8461337:-
THCA	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-4.47	9.62e-06	0.00099	-0.23	-0.2	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
THCA	cis	rs4824093	0.61	rs2208023	ENSG00000278869.1	CITF22-49E9.3	4.47	9.62e-06	0.00099	0.38	0.2	Amyotrophic lateral sclerosis (sporadic);	chr22:49856335	chr22:49933198~49934074:-
THCA	cis	rs8113308	0.81	rs11879040	ENSG00000269483.1	AC006272.1	4.47	9.62e-06	0.00099	0.33	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946856	chr19:51839924~51843324:-
THCA	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	4.47	9.62e-06	0.00099	0.21	0.2	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
THCA	cis	rs467650	1	rs469930	ENSG00000246763.5	RGMB-AS1	-4.47	9.62e-06	0.00099	-0.2	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98633416	chr5:98769618~98773469:-
THCA	cis	rs656319	0.669	rs56279061	ENSG00000261451.1	RP11-981G7.1	-4.47	9.62e-06	0.00099	-0.26	-0.2	Myopia (pathological);	chr8:10016470	chr8:10433672~10438312:+
THCA	cis	rs1150668	0.799	rs853684	ENSG00000220721.1	OR1F12	4.47	9.62e-06	0.00099	0.22	0.2	Pubertal anthropometrics;	chr6:28326773	chr6:28073316~28074233:+
THCA	cis	rs8077577	0.747	rs11872031	ENSG00000273018.4	CTD-2303H24.2	-4.47	9.63e-06	0.00099	-0.3	-0.2	Obesity-related traits;	chr17:18247500	chr17:18511221~18551705:-
THCA	cis	rs2153535	0.585	rs9393050	ENSG00000230939.1	RP11-314C16.1	-4.47	9.63e-06	0.00099	-0.21	-0.2	Motion sickness;	chr6:8635219	chr6:8784178~8785445:+
THCA	cis	rs338389	0.586	rs338402	ENSG00000260657.2	RP11-315D16.4	-4.47	9.63e-06	0.00099	-0.25	-0.2	Survival in rectal cancer;	chr15:67961613	chr15:68267792~68277994:-
THCA	cis	rs338389	0.586	rs338400	ENSG00000260657.2	RP11-315D16.4	-4.47	9.63e-06	0.00099	-0.25	-0.2	Survival in rectal cancer;	chr15:67961818	chr15:68267792~68277994:-
THCA	cis	rs7209700	0.547	rs7219925	ENSG00000228782.6	CTD-2026D20.3	-4.47	9.63e-06	0.00099	-0.22	-0.2	IgG glycosylation;	chr17:47264274	chr17:47450568~47492492:-
THCA	cis	rs3806843	0.518	rs2569188	ENSG00000202515.1	VTRNA1-3	4.47	9.63e-06	0.000991	0.23	0.2	Depressive symptoms (multi-trait analysis);	chr5:140628834	chr5:140726158~140726246:+
THCA	cis	rs7528684	0.565	rs2785661	ENSG00000236731.1	RP4-801G22.2	4.47	9.63e-06	0.000991	0.21	0.2	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157665444	chr1:157629939~157630728:-
THCA	cis	rs397969	0.596	rs17668529	ENSG00000261033.1	RP11-209D14.2	-4.47	9.63e-06	0.000991	-0.29	-0.2	Platelet count;	chr17:19996475	chr17:20008051~20009234:-
THCA	cis	rs397969	0.596	rs62066348	ENSG00000261033.1	RP11-209D14.2	-4.47	9.63e-06	0.000991	-0.29	-0.2	Platelet count;	chr17:19996600	chr17:20008051~20009234:-
THCA	cis	rs397969	0.57	rs62066349	ENSG00000261033.1	RP11-209D14.2	-4.47	9.63e-06	0.000991	-0.29	-0.2	Platelet count;	chr17:19996627	chr17:20008051~20009234:-
THCA	cis	rs397969	0.596	rs62066350	ENSG00000261033.1	RP11-209D14.2	-4.47	9.63e-06	0.000991	-0.29	-0.2	Platelet count;	chr17:19996729	chr17:20008051~20009234:-
THCA	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-4.47	9.63e-06	0.000991	-0.25	-0.2	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
THCA	cis	rs4865169	0.691	rs1056364	ENSG00000269949.1	RP11-738E22.3	-4.47	9.64e-06	0.000991	-0.24	-0.2	Breast cancer;	chr4:57023511	chr4:56960927~56961373:-
THCA	cis	rs9843304	0.568	rs10935763	ENSG00000244503.1	RP11-278L15.6	-4.47	9.64e-06	0.000991	-0.27	-0.2	Gallstone disease;	chr3:149501283	chr3:149494660~149495995:+
THCA	cis	rs362272	0.505	rs2857854	ENSG00000249673.5	NOP14-AS1	4.47	9.64e-06	0.000991	0.16	0.2	Serum sulfate level;	chr4:3041457	chr4:2934899~2961738:+
THCA	cis	rs7560272	0.502	rs13013228	ENSG00000163016.8	ALMS1P	-4.47	9.64e-06	0.000991	-0.25	-0.2	Schizophrenia;	chr2:73698089	chr2:73644919~73685576:+
THCA	cis	rs2797160	0.904	rs1739370	ENSG00000237742.5	RP11-624M8.1	4.47	9.64e-06	0.000991	0.17	0.2	Endometrial cancer;	chr6:125690085	chr6:125578558~125749190:-
THCA	cis	rs9467773	0.935	rs1884947	ENSG00000261353.1	CTA-14H9.5	-4.47	9.64e-06	0.000991	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26527063~26527404:+
THCA	cis	rs11722779	0.869	rs223323	ENSG00000248971.2	KRT8P46	-4.47	9.64e-06	0.000991	-0.25	-0.2	Schizophrenia;	chr4:102878412	chr4:102728746~102730171:-
THCA	cis	rs2412819	0.545	rs17795279	ENSG00000166763.7	STRCP1	-4.47	9.64e-06	0.000991	-0.28	-0.2	Lung cancer;	chr15:43637180	chr15:43699488~43718184:-
THCA	cis	rs11089937	0.616	rs5757258	ENSG00000211639.2	IGLV4-60	4.47	9.64e-06	0.000992	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22179648	chr22:22162199~22162681:+
THCA	cis	rs58605417	0.522	rs1601821	ENSG00000253553.4	RP11-586K2.1	4.47	9.64e-06	0.000992	0.21	0.2	Schizophrenia;	chr8:88471236	chr8:88326836~88737134:+
THCA	cis	rs9902453	0.967	rs4294864	ENSG00000263370.1	RP11-68I3.5	4.47	9.64e-06	0.000992	0.26	0.2	Coffee consumption (cups per day);	chr17:30113120	chr17:29639627~29640825:+
THCA	cis	rs12908161	0.96	rs62019463	ENSG00000188388.10	GOLGA6L3	4.47	9.65e-06	0.000992	0.27	0.2	Schizophrenia;	chr15:84744856	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs62019464	ENSG00000188388.10	GOLGA6L3	4.47	9.65e-06	0.000992	0.27	0.2	Schizophrenia;	chr15:84751238	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs11637142	ENSG00000188388.10	GOLGA6L3	4.47	9.65e-06	0.000992	0.27	0.2	Schizophrenia;	chr15:84752696	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs12910012	ENSG00000188388.10	GOLGA6L3	4.47	9.65e-06	0.000992	0.27	0.2	Schizophrenia;	chr15:84755431	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs12899981	ENSG00000188388.10	GOLGA6L3	4.47	9.65e-06	0.000992	0.27	0.2	Schizophrenia;	chr15:84759142	chr15:85240472~85247170:+
THCA	cis	rs7182948	0.958	rs10048065	ENSG00000259531.2	RP11-295H24.3	-4.47	9.65e-06	0.000992	-0.24	-0.2	Lung adenocarcinoma;	chr15:49458210	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.918	rs7178101	ENSG00000259531.2	RP11-295H24.3	-4.47	9.65e-06	0.000992	-0.24	-0.2	Lung adenocarcinoma;	chr15:49460497	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.918	rs2413958	ENSG00000259531.2	RP11-295H24.3	-4.47	9.65e-06	0.000992	-0.24	-0.2	Lung adenocarcinoma;	chr15:49468349	chr15:49365124~49366685:-
THCA	cis	rs12893668	0.703	rs34026011	ENSG00000269958.1	RP11-73M18.8	4.47	9.65e-06	0.000992	0.2	0.2	Reticulocyte count;	chr14:103584546	chr14:103696353~103697163:+
THCA	cis	rs703842	1	rs10877014	ENSG00000270039.1	RP11-571M6.17	-4.47	9.65e-06	0.000992	-0.23	-0.2	Multiple sclerosis;	chr12:57773878	chr12:57803838~57804415:+
THCA	cis	rs4227	0.883	rs4968214	ENSG00000233223.2	AC113189.5	4.47	9.65e-06	0.000992	0.18	0.2	IgA nephropathy;	chr17:7574159	chr17:7581964~7584072:-
THCA	cis	rs7617480	0.558	rs12715430	ENSG00000228638.1	FCF1P2	-4.47	9.65e-06	0.000993	-0.25	-0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48905422	chr3:48290793~48291375:-
THCA	cis	rs7688540	0.511	rs11731623	ENSG00000211553.1	AC253576.2	-4.47	9.65e-06	0.000993	-0.32	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:136461~136568:+
THCA	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-4.47	9.65e-06	0.000993	-0.24	-0.2	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
THCA	cis	rs10200159	1	rs3748955	ENSG00000272606.1	RP11-554J4.1	4.47	9.65e-06	0.000993	0.39	0.2	Vitiligo;	chr2:55626335	chr2:55617909~55618373:+
THCA	cis	rs4767841	0.874	rs6490269	ENSG00000248636.5	RP11-768F21.1	-4.47	9.66e-06	0.000993	-0.21	-0.2	Urgency urinary incontinence;	chr12:119769371	chr12:119387987~119668079:-
THCA	cis	rs9910055	0.659	rs3826412	ENSG00000267080.4	ASB16-AS1	-4.47	9.66e-06	0.000993	-0.18	-0.2	Total body bone mineral density;	chr17:44177729	chr17:44175973~44186717:-
THCA	cis	rs7267979	0.966	rs2261795	ENSG00000274973.1	RP13-401N8.7	-4.47	9.66e-06	0.000993	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25845497~25845862:+
THCA	cis	rs6787172	0.84	rs1656374	ENSG00000272087.1	RP11-379F4.7	4.47	9.66e-06	0.000994	0.18	0.2	Subjective well-being;	chr3:158565271	chr3:158693120~158693768:-
THCA	cis	rs829883	0.872	rs1641637	ENSG00000227825.4	SLC9A7P1	4.47	9.67e-06	0.000994	0.19	0.2	Colorectal adenoma (advanced);	chr12:98496786	chr12:98453835~98457145:-
THCA	cis	rs829883	0.902	rs1620317	ENSG00000227825.4	SLC9A7P1	4.47	9.67e-06	0.000994	0.19	0.2	Colorectal adenoma (advanced);	chr12:98496788	chr12:98453835~98457145:-
THCA	cis	rs829883	0.934	rs249814	ENSG00000227825.4	SLC9A7P1	4.47	9.67e-06	0.000994	0.19	0.2	Colorectal adenoma (advanced);	chr12:98499186	chr12:98453835~98457145:-
THCA	cis	rs9987353	0.544	rs2929470	ENSG00000248538.5	RP11-10A14.5	4.47	9.67e-06	0.000994	0.25	0.2	Recombination measurement;	chr8:9204980	chr8:9189011~9202854:+
THCA	cis	rs17095355	0.748	rs2501577	ENSG00000203876.8	ADD3-AS1	4.47	9.67e-06	0.000994	0.21	0.2	Biliary atresia;	chr10:110086929	chr10:109940104~110008381:-
THCA	cis	rs10256972	0.621	rs2363285	ENSG00000199023.2	MIR339	-4.47	9.68e-06	0.000995	-0.21	-0.2	Endometriosis;Longevity;	chr7:1052008	chr7:1022935~1023045:-
THCA	cis	rs13126694	0.744	rs11100148	ENSG00000248429.4	RP11-597D13.9	4.47	9.68e-06	0.000995	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158074688	chr4:158170752~158202877:+
THCA	cis	rs13126694	0.744	rs13121497	ENSG00000248429.4	RP11-597D13.9	4.47	9.68e-06	0.000995	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158076724	chr4:158170752~158202877:+
THCA	cis	rs9549367	0.789	rs2025247	ENSG00000269125.1	RP11-98F14.11	-4.47	9.68e-06	0.000995	-0.24	-0.2	Platelet distribution width;	chr13:113228250	chr13:113165002~113165183:-
THCA	cis	rs481331	0.866	rs11499092	ENSG00000215146.4	RP11-313J2.1	4.47	9.68e-06	0.000995	0.31	0.2	Systemic juvenile idiopathic arthritis;	chr10:42487197	chr10:42331866~42367974:-
THCA	cis	rs481331	0.866	rs11239615	ENSG00000215146.4	RP11-313J2.1	4.47	9.68e-06	0.000995	0.31	0.2	Systemic juvenile idiopathic arthritis;	chr10:42487207	chr10:42331866~42367974:-
THCA	cis	rs11665867	0.887	rs73047085	ENSG00000279108.1	CTC-490E21.11	-4.47	9.68e-06	0.000995	-0.28	-0.2	Hematocrit;	chr19:40802510	chr19:40840159~40842039:+
THCA	cis	rs11665867	0.887	rs76403165	ENSG00000279108.1	CTC-490E21.11	-4.47	9.68e-06	0.000995	-0.28	-0.2	Hematocrit;	chr19:40803078	chr19:40840159~40842039:+
THCA	cis	rs9307551	0.645	rs7655446	ENSG00000250334.4	LINC00989	-4.47	9.68e-06	0.000995	-0.27	-0.2	Refractive error;	chr4:79499947	chr4:79492416~79576460:+
THCA	cis	rs2836950	0.509	rs4816618	ENSG00000238141.2	BRWD1-AS1	-4.47	9.68e-06	0.000995	-0.23	-0.2	Menarche (age at onset);	chr21:39227603	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.527	rs2836948	ENSG00000238141.2	BRWD1-AS1	-4.47	9.68e-06	0.000995	-0.23	-0.2	Menarche (age at onset);	chr21:39227751	chr21:39315707~39323218:+
THCA	cis	rs4237845	0.636	rs11172371	ENSG00000270039.1	RP11-571M6.17	-4.47	9.69e-06	0.000996	-0.23	-0.2	Intelligence (multi-trait analysis);	chr12:57892405	chr12:57803838~57804415:+
THCA	cis	rs734999	0.967	rs7515633	ENSG00000225931.3	RP3-395M20.7	4.47	9.69e-06	0.000996	0.25	0.2	Ulcerative colitis;	chr1:2565214	chr1:2566410~2569888:+
THCA	cis	rs734999	0.967	rs2495365	ENSG00000225931.3	RP3-395M20.7	4.47	9.69e-06	0.000996	0.25	0.2	Ulcerative colitis;	chr1:2566588	chr1:2566410~2569888:+
THCA	cis	rs9329221	0.619	rs591346	ENSG00000261451.1	RP11-981G7.1	-4.47	9.7e-06	0.000997	-0.26	-0.2	Neuroticism;	chr8:9960555	chr8:10433672~10438312:+
THCA	cis	rs11976180	1	rs6464573	ENSG00000244198.4	RP4-545C24.1	4.47	9.7e-06	0.000997	0.2	0.2	Obesity-related traits;	chr7:144051005	chr7:144194858~144280547:+
THCA	cis	rs8028182	0.666	rs4886708	ENSG00000260269.4	CTD-2323K18.1	-4.47	9.71e-06	0.000998	-0.3	-0.2	Sudden cardiac arrest;	chr15:75470267	chr15:75527150~75601205:-
THCA	cis	rs59868192	0.925	rs72726032	ENSG00000246740.2	PLA2G4E-AS1	4.47	9.71e-06	0.000998	0.38	0.2	White blood cell count;	chr15:41966219	chr15:41972763~41999094:+
THCA	cis	rs72843506	1	rs10459969	ENSG00000261033.1	RP11-209D14.2	4.47	9.71e-06	0.000998	0.31	0.2	Schizophrenia;	chr17:20032588	chr17:20008051~20009234:-
THCA	cis	rs72843506	1	rs72843506	ENSG00000261033.1	RP11-209D14.2	4.47	9.71e-06	0.000998	0.31	0.2	Schizophrenia;	chr17:20042974	chr17:20008051~20009234:-
THCA	cis	rs9905704	0.624	rs34718875	ENSG00000224738.1	AC099850.1	4.47	9.71e-06	0.000998	0.25	0.2	Testicular germ cell tumor;	chr17:58995100	chr17:59106598~59118267:+
THCA	cis	rs6001482	0.656	rs1894237	ENSG00000272779.1	LL22NC03-80A10.6	-4.47	9.71e-06	0.000998	-0.23	-0.2	Diastolic blood pressure;	chr22:22235546	chr22:22303224~22310401:+
THCA	cis	rs7246657	0.551	rs4806413	ENSG00000226686.6	LINC01535	-4.47	9.71e-06	0.000998	-0.35	-0.2	Coronary artery calcification;	chr19:37126814	chr19:37251912~37265535:+
THCA	cis	rs78487399	0.808	rs116451849	ENSG00000234936.1	AC010883.5	4.47	9.71e-06	0.000998	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43435772	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs12104615	ENSG00000234936.1	AC010883.5	4.47	9.71e-06	0.000998	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43449799	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs12105399	ENSG00000234936.1	AC010883.5	4.47	9.71e-06	0.000998	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43449800	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6746610	ENSG00000234936.1	AC010883.5	4.47	9.71e-06	0.000998	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43450114	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs77527404	ENSG00000234936.1	AC010883.5	4.47	9.71e-06	0.000998	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451248	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7599781	ENSG00000234936.1	AC010883.5	4.47	9.71e-06	0.000998	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451587	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs17030818	ENSG00000234936.1	AC010883.5	4.47	9.71e-06	0.000998	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43453179	chr2:43229573~43233394:+
THCA	cis	rs375066	0.806	rs415168	ENSG00000278917.1	RP11-15A1.4	-4.47	9.71e-06	0.000998	-0.17	-0.2	Breast cancer;	chr19:43898422	chr19:43891233~43895411:+
THCA	cis	rs4742903	0.967	rs10820605	ENSG00000270332.1	SMC2-AS1	4.47	9.72e-06	0.000999	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104119121	chr9:104080024~104093073:-
THCA	cis	rs2070488	1	rs13058903	ENSG00000229589.1	ACVR2B-AS1	-4.47	9.72e-06	0.000999	-0.19	-0.2	Electrocardiographic conduction measures;	chr3:38471874	chr3:38451027~38454820:-
THCA	cis	rs1371614	0.545	rs3769138	ENSG00000229122.1	AGBL5-IT1	4.47	9.72e-06	0.000999	0.14	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946672	chr2:27061038~27061815:+
THCA	cis	rs17404153	0.599	rs17244458	ENSG00000248724.5	NPHP3-AS1	-4.47	9.72e-06	0.000999	-0.3	-0.2	LDL cholesterol;HDL cholesterol;	chr3:132410660	chr3:132721750~132874223:+
THCA	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-4.47	9.72e-06	0.000999	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-4.47	9.72e-06	0.000999	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
THCA	cis	rs1707322	0.963	rs11211229	ENSG00000281133.1	AL355480.3	-4.47	9.72e-06	0.000999	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45580892~45580996:-
THCA	cis	rs941408	0.515	rs56000942	ENSG00000261342.1	AC006538.1	4.47	9.73e-06	0.001	0.23	0.2	Total cholesterol levels;	chr19:2774106	chr19:2727743~2729327:-
THCA	cis	rs8058578	1	rs13338946	ENSG00000279196.1	RP11-1072A3.3	4.47	9.73e-06	0.001	0.21	0.2	Multiple myeloma;	chr16:30689537	chr16:30984630~30988270:-
THCA	cis	rs72799341	0.706	rs1060506	ENSG00000279196.1	RP11-1072A3.3	4.47	9.73e-06	0.001	0.21	0.2	Diastolic blood pressure;	chr16:31122128	chr16:30984630~30988270:-
THCA	cis	rs708224	0.966	rs261873	ENSG00000277342.1	RP11-843B15.4	4.47	9.74e-06	0.001	0.25	0.2	Pancreatic cancer;	chr12:32291358	chr12:32109076~32109602:+
THCA	cis	rs3892630	0.757	rs8109823	ENSG00000267567.1	CTD-2538C1.3	4.47	9.74e-06	0.001	0.31	0.2	Red blood cell traits;	chr19:32692410	chr19:32718298~32719595:-
THCA	cis	rs8064024	0.557	rs2251666	ENSG00000267077.1	RP11-127I20.5	4.47	9.74e-06	0.001	0.24	0.2	Cancer;	chr16:4873090	chr16:4795265~4796532:-
THCA	cis	rs4767841	1	rs2996027	ENSG00000252886.1	RN7SKP197	-4.47	9.74e-06	0.001	-0.2	-0.2	Urgency urinary incontinence;	chr12:119726478	chr12:119631090~119631386:-
THCA	cis	rs13126694	0.744	rs7673290	ENSG00000248429.4	RP11-597D13.9	4.47	9.74e-06	0.001	0.22	0.2	Blood osmolality (transformed sodium);	chr4:157998335	chr4:158170752~158202877:+
THCA	cis	rs7819412	0.775	rs4840551	ENSG00000261451.1	RP11-981G7.1	-4.47	9.74e-06	0.001	-0.26	-0.2	Triglycerides;	chr8:11171530	chr8:10433672~10438312:+
THCA	cis	rs16852403	0.531	rs494481	ENSG00000224687.1	RASAL2-AS1	-4.47	9.74e-06	0.001	-0.29	-0.2	Childhood ear infection;	chr1:178249688	chr1:178091508~178093984:-
THCA	cis	rs2613964	0.504	rs1903431	ENSG00000240057.4	RP11-572M11.4	-4.47	9.74e-06	0.001	-0.2	-0.2	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133810	chr3:113019532~113183301:+
THCA	cis	rs1023500	0.596	rs5751204	ENSG00000237037.8	NDUFA6-AS1	-4.47	9.75e-06	0.001	-0.17	-0.2	Schizophrenia;	chr22:42037797	chr22:42090931~42137742:+
THCA	cis	rs7474896	0.832	rs9418297	ENSG00000263064.2	RP11-291L22.7	4.47	9.75e-06	0.001	0.34	0.2	Obesity (extreme);	chr10:37847366	chr10:38448689~38448949:+
THCA	cis	rs4763879	0.778	rs7977940	ENSG00000256673.1	RP11-599J14.2	4.47	9.75e-06	0.001	0.24	0.2	Type 1 diabetes;	chr12:9686320	chr12:9398355~9414851:-
THCA	cis	rs4805272	1	rs4805276	ENSG00000267799.1	MAN1A2P1	4.47	9.75e-06	0.001	0.22	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28836987	chr19:28790812~28792871:-
THCA	cis	rs1850744	0.51	rs10805342	ENSG00000250942.1	ENPP7P11	4.47	9.75e-06	0.001	0.3	0.2	Economic and political preferences;	chr4:9885462	chr4:9677308~9677934:+
THCA	cis	rs17270561	0.609	rs4711097	ENSG00000272462.2	U91328.19	-4.47	9.75e-06	0.001	-0.17	-0.2	Iron status biomarkers;	chr6:25732086	chr6:25992662~26001775:+
THCA	cis	rs7141336	0.607	rs7158495	ENSG00000258884.1	CTD-3035D6.2	-4.47	9.75e-06	0.001	-0.26	-0.2	Anxiety disorder;	chr14:90745531	chr14:90822365~90828128:-
THCA	cis	rs1707322	1	rs946527	ENSG00000281133.1	AL355480.3	-4.47	9.75e-06	0.001	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45580892~45580996:-
THCA	cis	rs7179456	0.545	rs585192	ENSG00000245975.2	RP11-30K9.6	4.47	9.76e-06	0.001	0.19	0.2	Asperger disorder;	chr15:58760011	chr15:58768072~58770974:-
THCA	cis	rs7572644	0.739	rs6547815	ENSG00000223522.1	AC093690.1	4.47	9.76e-06	0.001	0.24	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27932328	chr2:28307691~28310459:-
THCA	cis	rs2281603	0.571	rs59577187	ENSG00000272909.1	CTD-2555O16.4	-4.47	9.76e-06	0.001	-0.23	-0.2	Lymphocyte counts;	chr14:64488953	chr14:64440369~64442238:-
THCA	cis	rs4713118	0.911	rs2394000	ENSG00000220721.1	OR1F12	4.47	9.76e-06	0.001	0.26	0.2	Parkinson's disease;	chr6:27719212	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.955	rs9393847	ENSG00000220721.1	OR1F12	4.47	9.76e-06	0.001	0.26	0.2	Parkinson's disease;	chr6:27720194	chr6:28073316~28074233:+
THCA	cis	rs2657294	0.796	rs1259501	ENSG00000226051.5	ZNF503-AS1	-4.47	9.76e-06	0.001	-0.28	-0.2	Pneumonia;	chr10:75230427	chr10:75269819~75373500:+
THCA	cis	rs1538970	0.851	rs61788285	ENSG00000234329.1	RP11-767N6.2	4.47	9.76e-06	0.001	0.2	0.2	Platelet count;	chr1:45453562	chr1:45651039~45651826:-
THCA	cis	rs72387598	1	rs72387598	ENSG00000234329.1	RP11-767N6.2	4.47	9.76e-06	0.001	0.2	0.2	Platelet distribution width;	chr1:45457307	chr1:45651039~45651826:-
THCA	cis	rs4908769	0.66	rs301803	ENSG00000232912.4	RP5-1115A15.1	4.47	9.77e-06	0.001	0.22	0.2	Allergy;	chr1:8438620	chr1:8424645~8434838:+
THCA	cis	rs61270009	0.955	rs12653830	ENSG00000247828.6	TMEM161B-AS1	4.47	9.77e-06	0.001	0.17	0.2	Depressive symptoms;	chr5:88353712	chr5:88268895~88436685:+
THCA	cis	rs496547	0.686	rs524590	ENSG00000255422.1	AP002954.4	-4.47	9.77e-06	0.001	-0.22	-0.2	Hip minimal joint space width;	chr11:118769354	chr11:118704607~118750263:+
THCA	cis	rs8058578	1	rs8048448	ENSG00000279196.1	RP11-1072A3.3	4.47	9.77e-06	0.001	0.21	0.2	Multiple myeloma;	chr16:30680887	chr16:30984630~30988270:-
THCA	cis	rs8058578	0.614	rs2878304	ENSG00000260911.2	RP11-196G11.2	-4.47	9.77e-06	0.001	-0.18	-0.2	Multiple myeloma;	chr16:30867045	chr16:31043150~31049868:+
THCA	cis	rs1979679	0.918	rs1533142	ENSG00000247934.4	RP11-967K21.1	4.47	9.77e-06	0.001	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28461206	chr12:28163298~28190738:-
THCA	cis	rs11902236	0.545	rs59715119	ENSG00000188525.3	AC010969.1	-4.47	9.77e-06	0.001	-0.25	-0.2	Prostate cancer;	chr2:9979488	chr2:10003158~10006030:-
THCA	cis	rs617791	0.53	rs735942	ENSG00000255320.1	RP11-755F10.1	4.47	9.78e-06	0.001	0.27	0.2	Breast cancer;	chr11:65981866	chr11:66244840~66246239:-
THCA	cis	rs875971	0.862	rs11765791	ENSG00000229886.1	RP5-1132H15.3	4.47	9.78e-06	0.001	0.21	0.2	Aortic root size;	chr7:66471587	chr7:66025126~66031544:-
THCA	cis	rs11088226	0.681	rs2833906	ENSG00000186842.4	LINC00846	-4.47	9.78e-06	0.00101	-0.3	-0.2	Gastritis;	chr21:32573211	chr21:32572238~32575881:-
THCA	cis	rs9283706	0.594	rs7735834	ENSG00000229666.1	MAST4-AS1	4.47	9.79e-06	0.00101	0.29	0.2	Coronary artery disease;	chr5:67041616	chr5:67001383~67003953:-
THCA	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	4.47	9.79e-06	0.00101	0.27	0.2	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
THCA	cis	rs6490294	0.528	rs16941724	ENSG00000226469.1	ADAM1B	4.47	9.79e-06	0.00101	0.33	0.2	Mean platelet volume;	chr12:111889253	chr12:111927018~111929017:+
THCA	cis	rs713587	0.719	rs58048722	ENSG00000224165.4	DNAJC27-AS1	4.47	9.79e-06	0.00101	0.11	0.2	Body mass index in non-asthmatics;	chr2:24964956	chr2:24971390~25039694:+
THCA	cis	rs394563	0.81	rs480870	ENSG00000231760.4	RP11-350J20.5	4.47	9.8e-06	0.00101	0.27	0.2	Dupuytren's disease;	chr6:149463682	chr6:149796151~149826294:-
THCA	cis	rs394563	0.775	rs420430	ENSG00000231760.4	RP11-350J20.5	4.47	9.8e-06	0.00101	0.27	0.2	Dupuytren's disease;	chr6:149464403	chr6:149796151~149826294:-
THCA	cis	rs394563	0.775	rs448420	ENSG00000231760.4	RP11-350J20.5	4.47	9.8e-06	0.00101	0.27	0.2	Dupuytren's disease;	chr6:149464666	chr6:149796151~149826294:-
THCA	cis	rs12935418	0.616	rs62054213	ENSG00000278985.1	RP11-303E16.9	4.47	9.8e-06	0.00101	0.25	0.2	Mean corpuscular volume;	chr16:80934306	chr16:80982319~80984094:-
THCA	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-4.47	9.8e-06	0.00101	-0.23	-0.2	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-4.47	9.8e-06	0.00101	-0.23	-0.2	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-4.47	9.8e-06	0.00101	-0.23	-0.2	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
THCA	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-4.47	9.8e-06	0.00101	-0.23	-0.2	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
THCA	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-4.47	9.8e-06	0.00101	-0.23	-0.2	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-4.47	9.8e-06	0.00101	-0.23	-0.2	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-4.47	9.8e-06	0.00101	-0.23	-0.2	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-4.47	9.8e-06	0.00101	-0.23	-0.2	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
THCA	cis	rs17508449	0.602	rs3789608	ENSG00000232450.1	RP4-730K3.3	-4.47	9.8e-06	0.00101	-0.29	-0.2	Leprosy;	chr1:113855166	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.547	rs55646484	ENSG00000232450.1	RP4-730K3.3	-4.47	9.8e-06	0.00101	-0.29	-0.2	Leprosy;	chr1:113856152	chr1:113698884~113699631:-
THCA	cis	rs17508449	0.547	rs35173468	ENSG00000232450.1	RP4-730K3.3	-4.47	9.8e-06	0.00101	-0.29	-0.2	Leprosy;	chr1:113856199	chr1:113698884~113699631:-
THCA	cis	rs453301	0.598	rs1025395	ENSG00000233609.3	RP11-62H7.2	4.47	9.8e-06	0.00101	0.19	0.2	Joint mobility (Beighton score);	chr8:8979093	chr8:8961200~8979025:+
THCA	cis	rs11673344	0.504	rs35579954	ENSG00000276846.1	CTD-3220F14.3	4.47	9.8e-06	0.00101	0.15	0.2	Obesity-related traits;	chr19:37139308	chr19:37314868~37315620:-
THCA	cis	rs2439831	0.681	rs3742969	ENSG00000205771.5	CATSPER2P1	-4.47	9.8e-06	0.00101	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43329749	chr15:43726918~43747094:-
THCA	cis	rs12234571	1	rs3815222	ENSG00000214293.7	APTR	4.47	9.8e-06	0.00101	0.25	0.2	Obesity-related traits;	chr7:77736095	chr7:77657660~77696265:-
THCA	cis	rs8067545	0.611	rs16960697	ENSG00000270091.1	RP11-78O7.2	-4.47	9.81e-06	0.00101	-0.15	-0.2	Schizophrenia;	chr17:20124405	chr17:19896590~19897287:-
THCA	cis	rs3845817	1	rs3845816	ENSG00000237979.1	AC007389.1	-4.47	9.81e-06	0.00101	-0.23	-0.2	Bipolar disorder;	chr2:65531221	chr2:65500993~65502138:-
THCA	cis	rs13113518	1	rs11133388	ENSG00000249700.7	SRD5A3-AS1	-4.47	9.81e-06	0.00101	-0.25	-0.2	Height;	chr4:55477866	chr4:55363971~55395847:-
THCA	cis	rs13063635	0.764	rs72901034	ENSG00000226074.4	PRSS44	-4.47	9.81e-06	0.00101	-0.35	-0.2	Eosinophil percentage of granulocytes;	chr3:46043829	chr3:46809359~46812558:-
THCA	cis	rs375066	0.935	rs367283	ENSG00000278917.1	RP11-15A1.4	-4.47	9.81e-06	0.00101	-0.17	-0.2	Breast cancer;	chr19:43901975	chr19:43891233~43895411:+
THCA	cis	rs375066	0.935	rs448823	ENSG00000278917.1	RP11-15A1.4	-4.47	9.81e-06	0.00101	-0.17	-0.2	Breast cancer;	chr19:43902139	chr19:43891233~43895411:+
THCA	cis	rs375066	0.868	rs448829	ENSG00000278917.1	RP11-15A1.4	-4.47	9.81e-06	0.00101	-0.17	-0.2	Breast cancer;	chr19:43902169	chr19:43891233~43895411:+
THCA	cis	rs13325613	0.915	rs35481399	ENSG00000223552.1	RP11-24F11.2	-4.47	9.81e-06	0.00101	-0.3	-0.2	Monocyte count;	chr3:46224089	chr3:46364955~46407059:-
THCA	cis	rs7267979	0.933	rs1130694	ENSG00000274973.1	RP13-401N8.7	-4.47	9.81e-06	0.00101	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25845497~25845862:+
THCA	cis	rs10149470	0.549	rs9652403	ENSG00000269910.1	RP11-73M18.10	4.47	9.81e-06	0.00101	0.18	0.2	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr14:103569687	chr14:103694516~103695050:-
THCA	cis	rs6442522	0.671	rs2305615	ENSG00000249786.6	EAF1-AS1	4.47	9.81e-06	0.00101	0.21	0.2	Uric acid levels;	chr3:15475518	chr3:15436171~15455940:-
THCA	cis	rs12935229	1	rs17769748	ENSG00000260922.1	RP11-538I12.3	-4.47	9.82e-06	0.00101	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77293520	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs35457602	ENSG00000260922.1	RP11-538I12.3	-4.47	9.82e-06	0.00101	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77293623	chr16:77234877~77290934:+
THCA	cis	rs2281603	0.57	rs10136732	ENSG00000272909.1	CTD-2555O16.4	-4.47	9.82e-06	0.00101	-0.23	-0.2	Lymphocyte counts;	chr14:64484255	chr14:64440369~64442238:-
THCA	cis	rs953301	0.793	rs61104653	ENSG00000229808.1	RP11-456P18.2	-4.47	9.82e-06	0.00101	-0.54	-0.2	Left atrial antero-posterior diameter;	chr1:161784654	chr1:161890833~161892196:+
THCA	cis	rs4144027	0.904	rs35551424	ENSG00000269958.1	RP11-73M18.8	-4.47	9.82e-06	0.00101	-0.19	-0.2	Blood metabolite levels;	chr14:103875332	chr14:103696353~103697163:+
THCA	cis	rs6747952	0.866	rs4663854	ENSG00000279484.1	KLHL30-AS1	-4.47	9.82e-06	0.00101	-0.19	-0.2	Mean corpuscular hemoglobin concentration;	chr2:238174526	chr2:238152889~238155994:-
THCA	cis	rs7141336	0.965	rs6575153	ENSG00000258884.1	CTD-3035D6.2	4.47	9.82e-06	0.00101	0.26	0.2	Anxiety disorder;	chr14:90813471	chr14:90822365~90828128:-
THCA	cis	rs2836974	0.644	rs1882779	ENSG00000255568.3	BRWD1-AS2	-4.47	9.82e-06	0.00101	-0.16	-0.2	Cognitive function;	chr21:39319012	chr21:39313935~39314962:+
THCA	cis	rs12541437	0.916	rs3020163	ENSG00000253327.2	RAD21-AS1	4.47	9.83e-06	0.00101	0.22	0.2	Gut microbiome composition (winter);	chr8:116914090	chr8:116874424~116876868:+
THCA	cis	rs12541437	0.958	rs3020164	ENSG00000253327.2	RAD21-AS1	4.47	9.83e-06	0.00101	0.22	0.2	Gut microbiome composition (winter);	chr8:116914536	chr8:116874424~116876868:+
THCA	cis	rs12541437	0.916	rs2921744	ENSG00000253327.2	RAD21-AS1	4.47	9.83e-06	0.00101	0.22	0.2	Gut microbiome composition (winter);	chr8:116914993	chr8:116874424~116876868:+
THCA	cis	rs13126694	0.744	rs4077776	ENSG00000248429.4	RP11-597D13.9	4.47	9.83e-06	0.00101	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158008446	chr4:158170752~158202877:+
THCA	cis	rs2688608	1	rs2675680	ENSG00000271816.1	BMS1P4	4.47	9.83e-06	0.00101	0.19	0.2	Inflammatory bowel disease;	chr10:73899106	chr10:73699151~73730487:-
THCA	cis	rs2839186	0.872	rs2250213	ENSG00000215424.8	MCM3AP-AS1	4.47	9.83e-06	0.00101	0.12	0.2	Testicular germ cell tumor;	chr21:46254361	chr21:46229217~46259390:+
THCA	cis	rs2015599	0.514	rs10843376	ENSG00000273680.1	RP11-996F15.6	-4.47	9.83e-06	0.00101	-0.28	-0.2	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29332733~29333383:-
THCA	cis	rs41307935	0.596	rs34204245	ENSG00000260063.1	RP5-968P14.2	-4.47	9.83e-06	0.00101	-0.28	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26877692	chr1:26692132~26694131:-
THCA	cis	rs1150668	0.796	rs213236	ENSG00000280107.1	AL022393.9	-4.47	9.83e-06	0.00101	-0.19	-0.2	Pubertal anthropometrics;	chr6:28356620	chr6:28170845~28172521:+
THCA	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	4.47	9.83e-06	0.00101	0.25	0.2	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
THCA	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	4.47	9.83e-06	0.00101	0.25	0.2	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
THCA	cis	rs17801127	0.748	rs57695743	ENSG00000231969.1	AC144449.1	4.47	9.84e-06	0.00101	0.36	0.2	Liver enzyme levels (alanine transaminase);	chr2:149705204	chr2:149587196~149848233:+
THCA	cis	rs9987353	0.519	rs2929465	ENSG00000248538.5	RP11-10A14.5	4.47	9.84e-06	0.00101	0.26	0.2	Recombination measurement;	chr8:9206492	chr8:9189011~9202854:+
THCA	cis	rs972578	0.74	rs9611968	ENSG00000274717.1	RP1-47A17.1	-4.47	9.84e-06	0.00101	-0.22	-0.2	Mean platelet volume;	chr22:42928756	chr22:42791814~42794313:-
THCA	cis	rs2836950	0.545	rs2836940	ENSG00000238141.2	BRWD1-AS1	-4.47	9.84e-06	0.00101	-0.23	-0.2	Menarche (age at onset);	chr21:39216770	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.565	rs2836942	ENSG00000238141.2	BRWD1-AS1	-4.47	9.84e-06	0.00101	-0.23	-0.2	Menarche (age at onset);	chr21:39219455	chr21:39315707~39323218:+
THCA	cis	rs77637988	0.533	rs13398791	ENSG00000202227.1	RNU6-282P	4.47	9.84e-06	0.00101	0.21	0.2	Joint mobility (Beighton score);	chr2:48395181	chr2:48501922~48502024:-
THCA	cis	rs758324	0.661	rs31477	ENSG00000224431.1	AC063976.7	-4.47	9.84e-06	0.00101	-0.19	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132086819	chr5:132199456~132203487:+
THCA	cis	rs2191566	1	rs369106	ENSG00000266921.1	RP11-15A1.7	4.47	9.84e-06	0.00101	0.19	0.2	Acute lymphoblastic leukemia (childhood);	chr19:44002778	chr19:43996896~44002836:-
THCA	cis	rs2836974	0.583	rs9636957	ENSG00000255568.3	BRWD1-AS2	-4.47	9.84e-06	0.00101	-0.16	-0.2	Cognitive function;	chr21:39333921	chr21:39313935~39314962:+
THCA	cis	rs4927850	1	rs10881564	ENSG00000185485.13	SDHAP1	4.47	9.84e-06	0.00101	0.17	0.2	Pancreatic cancer;	chr3:196023455	chr3:195959748~195990318:-
THCA	cis	rs8030605	0.704	rs72740592	ENSG00000277245.1	RP11-48G14.3	4.47	9.85e-06	0.00101	0.35	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56360613	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.704	rs117379966	ENSG00000277245.1	RP11-48G14.3	4.47	9.85e-06	0.00101	0.35	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56376460	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.704	rs72742607	ENSG00000277245.1	RP11-48G14.3	4.47	9.85e-06	0.00101	0.35	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56378061	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.704	rs72742619	ENSG00000277245.1	RP11-48G14.3	4.47	9.85e-06	0.00101	0.35	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56385765	chr15:56447120~56447697:+
THCA	cis	rs9863	0.861	rs11057397	ENSG00000270061.1	RP11-214K3.19	-4.47	9.85e-06	0.00101	-0.28	-0.2	White blood cell count;	chr12:123935181	chr12:123969990~123970344:-
THCA	cis	rs6600671	1	rs6600669	ENSG00000275585.1	CH17-118O6.3	-4.47	9.85e-06	0.00101	-0.24	-0.2	Hip geometry;	chr1:121471785	chr1:120985692~121052167:-
THCA	cis	rs1707322	1	rs4660334	ENSG00000281133.1	AL355480.3	-4.47	9.85e-06	0.00101	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45580892~45580996:-
THCA	cis	rs2980439	0.607	rs2980419	ENSG00000254153.1	CTA-398F10.2	-4.47	9.85e-06	0.00101	-0.22	-0.2	Neuroticism;	chr8:8256619	chr8:8456909~8461337:-
THCA	cis	rs3820928	0.874	rs4675133	ENSG00000212391.1	SNORA48	4.47	9.85e-06	0.00101	0.22	0.2	Pulmonary function;	chr2:226978294	chr2:226968989~226969122:-
THCA	cis	rs4072705	0.614	rs35929043	ENSG00000224020.1	MIR181A2HG	-4.47	9.85e-06	0.00101	-0.19	-0.2	Menarche (age at onset);	chr9:124472077	chr9:124658467~124698631:+
THCA	cis	rs2281603	0.674	rs74883409	ENSG00000259116.1	RP11-973N13.4	-4.47	9.85e-06	0.00101	-0.2	-0.2	Lymphocyte counts;	chr14:64594361	chr14:64514154~64540368:-
THCA	cis	rs11088226	0.681	rs2833911	ENSG00000186842.4	LINC00846	4.47	9.86e-06	0.00101	0.3	0.2	Gastritis;	chr21:32577319	chr21:32572238~32575881:-
THCA	cis	rs2880765	0.743	rs7168345	ENSG00000259630.2	CTD-2262B20.1	4.47	9.86e-06	0.00101	0.22	0.2	Coronary artery disease;	chr15:85470370	chr15:85415228~85415633:+
THCA	cis	rs17495987	0.63	rs17562406	ENSG00000219545.8	UMAD1	4.47	9.86e-06	0.00101	0.22	0.2	Tonsillectomy;	chr7:7868699	chr7:7640711~8004059:+
THCA	cis	rs2287838	0.668	rs12979274	ENSG00000267289.1	CTD-2623N2.11	4.47	9.86e-06	0.00101	0.23	0.2	Sleep duration;	chr19:9890249	chr19:9834079~9835013:-
THCA	cis	rs6832769	0.925	rs11133383	ENSG00000272969.1	RP11-528I4.2	-4.47	9.86e-06	0.00101	-0.24	-0.2	Personality dimensions;	chr4:55450878	chr4:55547112~55547889:+
THCA	cis	rs2286503	1	rs2286501	ENSG00000226329.2	AC005682.6	4.47	9.86e-06	0.00101	0.24	0.2	Fibrinogen;	chr7:22817166	chr7:22863874~22881350:-
THCA	cis	rs17604090	0.715	rs73088359	ENSG00000227855.3	DPY19L2P3	4.47	9.86e-06	0.00101	0.23	0.2	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29608062	chr7:29650227~29742594:+
THCA	cis	rs35740288	0.77	rs56092539	ENSG00000259295.5	CSPG4P12	4.47	9.86e-06	0.00101	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85639281	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs11636185	ENSG00000259295.5	CSPG4P12	4.47	9.86e-06	0.00101	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85639887	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs12898597	ENSG00000259295.5	CSPG4P12	4.47	9.86e-06	0.00101	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85646688	chr15:85191438~85213905:+
THCA	cis	rs793571	0.628	rs11071397	ENSG00000259250.1	RP11-50C13.1	-4.47	9.86e-06	0.00101	-0.21	-0.2	Schizophrenia;	chr15:58815298	chr15:58587507~58591676:+
THCA	cis	rs3770081	0.793	rs73945524	ENSG00000272564.1	RP11-548P2.2	-4.47	9.86e-06	0.00101	-0.34	-0.2	Facial emotion recognition (sad faces);	chr2:85854974	chr2:85904279~85904727:+
THCA	cis	rs3770081	1	rs57150081	ENSG00000272564.1	RP11-548P2.2	-4.47	9.86e-06	0.00101	-0.34	-0.2	Facial emotion recognition (sad faces);	chr2:85855359	chr2:85904279~85904727:+
THCA	cis	rs1061377	0.513	rs2711994	ENSG00000249685.1	RP11-360F5.3	-4.47	9.86e-06	0.00101	-0.27	-0.2	Uric acid levels;	chr4:39148121	chr4:39133913~39135608:+
THCA	cis	rs12681288	0.676	rs7011999	ENSG00000260721.1	AF067845.1	4.47	9.86e-06	0.00101	0.26	0.2	Schizophrenia;	chr8:1058446	chr8:1368642~1369833:-
THCA	cis	rs453301	0.652	rs2043129	ENSG00000254153.1	CTA-398F10.2	-4.47	9.87e-06	0.00101	-0.21	-0.2	Joint mobility (Beighton score);	chr8:8967994	chr8:8456909~8461337:-
THCA	cis	rs12216545	0.765	rs6464080	ENSG00000241134.3	BET1P1	-4.47	9.87e-06	0.00101	-0.24	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150563300	chr7:150749736~150750094:+
THCA	cis	rs12681288	0.823	rs2701903	ENSG00000260721.1	AF067845.1	-4.47	9.87e-06	0.00101	-0.23	-0.2	Schizophrenia;	chr8:1054029	chr8:1368642~1369833:-
THCA	cis	rs853679	1	rs1936365	ENSG00000272009.1	RP1-313I6.12	4.47	9.87e-06	0.00101	0.26	0.2	Depression;	chr6:28300675	chr6:28078792~28081130:-
THCA	cis	rs1876905	0.62	rs354525	ENSG00000272356.1	RP5-1112D6.8	-4.47	9.87e-06	0.00101	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111186193	chr6:111309203~111313517:+
THCA	cis	rs11779988	0.545	rs208753	ENSG00000253671.1	RP11-806O11.1	-4.47	9.87e-06	0.00101	-0.26	-0.2	Breast cancer;	chr8:17957406	chr8:17808941~17820868:+
THCA	cis	rs12410462	0.591	rs16847991	ENSG00000227711.2	RP11-275O4.5	-4.47	9.87e-06	0.00101	-0.25	-0.2	Major depressive disorder;	chr1:227603395	chr1:227509028~227520477:-
THCA	cis	rs7772486	0.754	rs10872580	ENSG00000270638.1	RP3-466P17.1	-4.47	9.87e-06	0.00101	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145735570~145737218:+
THCA	cis	rs516805	0.52	rs561470	ENSG00000279453.1	RP3-425C14.4	4.47	9.88e-06	0.00101	0.17	0.2	Lymphocyte counts;	chr6:122482967	chr6:122436789~122439223:-
THCA	cis	rs7572644	0.629	rs28662360	ENSG00000223522.1	AC093690.1	4.47	9.88e-06	0.00101	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27986053	chr2:28307691~28310459:-
THCA	cis	rs752010	0.806	rs6696511	ENSG00000230638.4	RP11-486B10.4	-4.47	9.88e-06	0.00101	-0.24	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41645217	chr1:41542069~41544310:+
THCA	cis	rs8062405	1	rs4451951	ENSG00000261766.1	RP11-22P6.2	-4.47	9.88e-06	0.00101	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28862166~28863340:-
THCA	cis	rs13113518	0.966	rs4864544	ENSG00000249700.7	SRD5A3-AS1	4.47	9.88e-06	0.00101	0.25	0.2	Height;	chr4:55515292	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs6847529	ENSG00000249700.7	SRD5A3-AS1	4.47	9.88e-06	0.00101	0.25	0.2	Height;	chr4:55518776	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs6822740	ENSG00000249700.7	SRD5A3-AS1	4.47	9.88e-06	0.00101	0.25	0.2	Height;	chr4:55518922	chr4:55363971~55395847:-
THCA	cis	rs17221829	0.932	rs7924841	ENSG00000280385.1	AP000648.5	-4.47	9.88e-06	0.00101	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89727116	chr11:90193614~90198120:+
THCA	cis	rs7618915	0.501	rs3755798	ENSG00000243224.1	RP5-1157M23.2	-4.47	9.88e-06	0.00101	-0.22	-0.2	Bipolar disorder;	chr3:52707144	chr3:52239258~52241097:+
THCA	cis	rs1040393	0.953	rs56407270	ENSG00000225171.2	DUTP6	4.47	9.89e-06	0.00101	0.29	0.2	Schizophrenia;	chr1:166932869	chr1:166868748~166869209:+
THCA	cis	rs10256972	0.681	rs12702016	ENSG00000225146.1	AC073957.15	4.47	9.89e-06	0.00101	0.22	0.2	Endometriosis;Longevity;	chr7:1089756	chr7:1029025~1043891:+
THCA	cis	rs853679	0.527	rs9461443	ENSG00000272009.1	RP1-313I6.12	-4.47	9.89e-06	0.00102	-0.23	-0.2	Depression;	chr6:28226851	chr6:28078792~28081130:-
THCA	cis	rs61270009	0.955	rs1367233	ENSG00000247828.6	TMEM161B-AS1	4.47	9.9e-06	0.00102	0.17	0.2	Depressive symptoms;	chr5:88301195	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs11740776	ENSG00000247828.6	TMEM161B-AS1	4.47	9.9e-06	0.00102	0.17	0.2	Depressive symptoms;	chr5:88303489	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs4916717	ENSG00000247828.6	TMEM161B-AS1	4.47	9.9e-06	0.00102	0.17	0.2	Depressive symptoms;	chr5:88305802	chr5:88268895~88436685:+
THCA	cis	rs2251381	0.606	rs8129515	ENSG00000176054.6	RPL23P2	4.47	9.9e-06	0.00102	0.18	0.2	Selective IgA deficiency;	chr21:29147846	chr21:28997613~28998033:-
THCA	cis	rs12908161	0.92	rs35738019	ENSG00000188388.10	GOLGA6L3	4.47	9.9e-06	0.00102	0.27	0.2	Schizophrenia;	chr15:84736979	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs34570071	ENSG00000188388.10	GOLGA6L3	4.47	9.9e-06	0.00102	0.27	0.2	Schizophrenia;	chr15:84736981	chr15:85240472~85247170:+
THCA	cis	rs11073619	0.558	rs12440039	ENSG00000259728.4	LINC00933	-4.47	9.9e-06	0.00102	-0.38	-0.2	Positive affect;	chr15:84144748	chr15:84570649~84580175:+
THCA	cis	rs736408	0.609	rs2230534	ENSG00000243224.1	RP5-1157M23.2	-4.47	9.9e-06	0.00102	-0.22	-0.2	Bipolar disorder;	chr3:52768386	chr3:52239258~52241097:+
THCA	cis	rs4819052	0.851	rs2838857	ENSG00000273796.1	LL21NC02-21A1.1	-4.47	9.91e-06	0.00102	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45403809~45404369:-
THCA	cis	rs7260598	0.605	rs61053953	ENSG00000268442.1	CTD-2027I19.2	4.47	9.91e-06	0.00102	0.3	0.2	Response to taxane treatment (placlitaxel);	chr19:23773846	chr19:24162370~24163425:-
THCA	cis	rs6545883	0.839	rs778764	ENSG00000271889.1	RP11-493E12.1	4.47	9.91e-06	0.00102	0.19	0.2	Tuberculosis;	chr2:61558545	chr2:61151433~61162105:-
THCA	cis	rs6751744	0.855	rs10206214	ENSG00000226266.5	AC009961.3	-4.47	9.91e-06	0.00102	-0.25	-0.2	Dysphagia;	chr2:159507781	chr2:159670708~159712435:-
THCA	cis	rs6751744	0.855	rs1425045	ENSG00000226266.5	AC009961.3	-4.47	9.91e-06	0.00102	-0.25	-0.2	Dysphagia;	chr2:159508236	chr2:159670708~159712435:-
THCA	cis	rs6067053	0.558	rs79274472	ENSG00000227431.4	CSE1L-AS1	4.47	9.91e-06	0.00102	0.25	0.2	Intelligence (multi-trait analysis);	chr20:49297643	chr20:49040463~49046044:-
THCA	cis	rs11722779	0.935	rs7676736	ENSG00000248971.2	KRT8P46	-4.47	9.91e-06	0.00102	-0.24	-0.2	Schizophrenia;	chr4:103016729	chr4:102728746~102730171:-
THCA	cis	rs73198271	0.632	rs57281209	ENSG00000253893.2	FAM85B	4.47	9.91e-06	0.00102	0.28	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8745285	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.632	rs57687880	ENSG00000253893.2	FAM85B	4.47	9.91e-06	0.00102	0.28	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8745400	chr8:8167819~8226614:-
THCA	cis	rs9307551	0.6	rs11098777	ENSG00000250334.4	LINC00989	-4.47	9.91e-06	0.00102	-0.23	-0.2	Refractive error;	chr4:79617698	chr4:79492416~79576460:+
THCA	cis	rs6449502	0.92	rs329614	ENSG00000251279.1	CTC-436P18.1	-4.47	9.91e-06	0.00102	-0.33	-0.2	Mean platelet volume;	chr5:61008344	chr5:61162070~61232040:+
THCA	cis	rs12760731	0.545	rs12032055	ENSG00000213057.5	C1orf220	4.47	9.92e-06	0.00102	0.22	0.2	Obesity-related traits;	chr1:178598799	chr1:178542752~178548889:+
THCA	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-4.47	9.92e-06	0.00102	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
THCA	cis	rs2281603	0.57	rs2123459	ENSG00000272909.1	CTD-2555O16.4	-4.47	9.92e-06	0.00102	-0.23	-0.2	Lymphocyte counts;	chr14:64485585	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs11626222	ENSG00000272909.1	CTD-2555O16.4	-4.47	9.92e-06	0.00102	-0.23	-0.2	Lymphocyte counts;	chr14:64486541	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs10132969	ENSG00000272909.1	CTD-2555O16.4	-4.47	9.92e-06	0.00102	-0.23	-0.2	Lymphocyte counts;	chr14:64486862	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs10143839	ENSG00000272909.1	CTD-2555O16.4	-4.47	9.92e-06	0.00102	-0.23	-0.2	Lymphocyte counts;	chr14:64486873	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs57525201	ENSG00000272909.1	CTD-2555O16.4	-4.47	9.92e-06	0.00102	-0.23	-0.2	Lymphocyte counts;	chr14:64488974	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs10150781	ENSG00000272909.1	CTD-2555O16.4	-4.47	9.92e-06	0.00102	-0.23	-0.2	Lymphocyte counts;	chr14:64489141	chr14:64440369~64442238:-
THCA	cis	rs7617480	0.648	rs6806356	ENSG00000229759.1	MRPS18AP1	4.47	9.92e-06	0.00102	0.31	0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48690203	chr3:48256350~48256938:-
THCA	cis	rs875971	0.825	rs6951503	ENSG00000229886.1	RP5-1132H15.3	-4.47	9.92e-06	0.00102	-0.21	-0.2	Aortic root size;	chr7:66253949	chr7:66025126~66031544:-
THCA	cis	rs858239	0.601	rs2141307	ENSG00000230042.1	AK3P3	-4.47	9.92e-06	0.00102	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23129178~23129841:+
THCA	cis	rs724818	0.661	rs80154434	ENSG00000251609.2	SETP12	-4.47	9.92e-06	0.00102	-0.51	-0.2	Monobrow thickness;	chr4:120785333	chr4:120895494~120897083:-
THCA	cis	rs4908760	0.795	rs6693009	ENSG00000232912.4	RP5-1115A15.1	4.47	9.92e-06	0.00102	0.2	0.2	Vitiligo;	chr1:8683651	chr1:8424645~8434838:+
THCA	cis	rs7179456	0.545	rs605928	ENSG00000245975.2	RP11-30K9.6	4.47	9.92e-06	0.00102	0.19	0.2	Asperger disorder;	chr15:58753964	chr15:58768072~58770974:-
THCA	cis	rs2033711	0.837	rs3764535	ENSG00000268049.1	CTD-2619J13.9	-4.47	9.93e-06	0.00102	-0.25	-0.2	Uric acid clearance;	chr19:58417685	chr19:58357999~58359603:+
THCA	cis	rs2839186	0.619	rs2187118	ENSG00000239415.1	AP001469.9	4.47	9.93e-06	0.00102	0.21	0.2	Testicular germ cell tumor;	chr21:46191396	chr21:46251549~46254133:-
THCA	cis	rs6121246	0.609	rs6089054	ENSG00000230613.1	HM13-AS1	4.47	9.93e-06	0.00102	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31735338	chr20:31567707~31573263:-
THCA	cis	rs6087771	0.851	rs6087775	ENSG00000230613.1	HM13-AS1	4.47	9.93e-06	0.00102	0.19	0.2	Putamen volume;Subcortical brain region volumes;	chr20:31737962	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.609	rs4453755	ENSG00000230613.1	HM13-AS1	4.47	9.93e-06	0.00102	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31743244	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.609	rs2376998	ENSG00000230613.1	HM13-AS1	4.47	9.93e-06	0.00102	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31752860	chr20:31567707~31573263:-
THCA	cis	rs9910055	0.659	rs721769	ENSG00000267080.4	ASB16-AS1	-4.47	9.93e-06	0.00102	-0.18	-0.2	Total body bone mineral density;	chr17:44184220	chr17:44175973~44186717:-
THCA	cis	rs3734266	0.702	rs6926373	ENSG00000272288.4	RP11-140K17.3	-4.47	9.93e-06	0.00102	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34833557	chr6:34696317~34697470:+
THCA	cis	rs7560272	0.512	rs13015885	ENSG00000163016.8	ALMS1P	-4.47	9.93e-06	0.00102	-0.25	-0.2	Schizophrenia;	chr2:73693355	chr2:73644919~73685576:+
THCA	cis	rs728616	0.614	rs2181204	ENSG00000242600.5	MBL1P	4.47	9.94e-06	0.00102	0.21	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79904898~79950336:+
THCA	cis	rs4415084	0.688	rs1837286	ENSG00000272335.1	RP11-53O19.3	4.47	9.94e-06	0.00102	0.17	0.2	Breast cancer;	chr5:44858639	chr5:44826076~44828592:+
THCA	cis	rs703842	1	rs10783848	ENSG00000270039.1	RP11-571M6.17	-4.47	9.94e-06	0.00102	-0.23	-0.2	Multiple sclerosis;	chr12:57802745	chr12:57803838~57804415:+
THCA	cis	rs3738443	0.817	rs61840053	ENSG00000259865.1	RP11-488L18.10	4.47	9.94e-06	0.00102	0.21	0.2	Alcohol dependence;	chr1:247204038	chr1:247187281~247188526:-
THCA	cis	rs4578769	0.55	rs4280358	ENSG00000265939.1	UBE2CP2	4.47	9.94e-06	0.00102	0.23	0.2	Eosinophil percentage of white cells;	chr18:23037844	chr18:22900486~22900995:-
THCA	cis	rs9902453	0.967	rs9913074	ENSG00000263370.1	RP11-68I3.5	4.47	9.94e-06	0.00102	0.25	0.2	Coffee consumption (cups per day);	chr17:30154181	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.934	rs7211246	ENSG00000263370.1	RP11-68I3.5	4.47	9.94e-06	0.00102	0.25	0.2	Coffee consumption (cups per day);	chr17:30158744	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.933	rs7216487	ENSG00000263370.1	RP11-68I3.5	4.47	9.94e-06	0.00102	0.25	0.2	Coffee consumption (cups per day);	chr17:30175624	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.933	rs7216494	ENSG00000263370.1	RP11-68I3.5	4.47	9.94e-06	0.00102	0.25	0.2	Coffee consumption (cups per day);	chr17:30175633	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.933	rs1532042	ENSG00000263370.1	RP11-68I3.5	4.47	9.94e-06	0.00102	0.25	0.2	Coffee consumption (cups per day);	chr17:30177371	chr17:29639627~29640825:+
THCA	cis	rs1538970	0.781	rs10890330	ENSG00000234329.1	RP11-767N6.2	4.47	9.94e-06	0.00102	0.2	0.2	Platelet count;	chr1:45454734	chr1:45651039~45651826:-
THCA	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-4.47	9.95e-06	0.00102	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-4.47	9.95e-06	0.00102	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-4.47	9.95e-06	0.00102	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
THCA	cis	rs6456156	0.846	rs9364891	ENSG00000235272.1	FAM103A2P	-4.47	9.95e-06	0.00102	-0.28	-0.2	Primary biliary cholangitis;	chr6:167102831	chr6:166586124~166586477:-
THCA	cis	rs972578	0.668	rs12106550	ENSG00000274717.1	RP1-47A17.1	-4.47	9.95e-06	0.00102	-0.22	-0.2	Mean platelet volume;	chr22:42940631	chr22:42791814~42794313:-
THCA	cis	rs972578	0.74	rs9611969	ENSG00000274717.1	RP1-47A17.1	-4.47	9.95e-06	0.00102	-0.22	-0.2	Mean platelet volume;	chr22:42940679	chr22:42791814~42794313:-
THCA	cis	rs2408955	0.522	rs4760612	ENSG00000273765.1	RP11-370I10.11	-4.47	9.95e-06	0.00102	-0.2	-0.2	Glycated hemoglobin levels;	chr12:48028073	chr12:48360920~48361377:+
THCA	cis	rs7141336	0.607	rs4904725	ENSG00000258884.1	CTD-3035D6.2	-4.47	9.95e-06	0.00102	-0.25	-0.2	Anxiety disorder;	chr14:90750428	chr14:90822365~90828128:-
THCA	cis	rs7474896	0.583	rs4934898	ENSG00000226578.1	RP11-258F22.1	-4.47	9.95e-06	0.00102	-0.28	-0.2	Obesity (extreme);	chr10:37701467	chr10:37775371~37784131:-
THCA	cis	rs2089222	0.655	rs11068070	ENSG00000196668.3	LINC00173	-4.47	9.95e-06	0.00102	-0.34	-0.2	Acute lymphoblastic leukemia (childhood);	chr12:116555110	chr12:116533422~116536518:+
THCA	cis	rs2797160	0.904	rs1612274	ENSG00000237742.5	RP11-624M8.1	4.47	9.95e-06	0.00102	0.17	0.2	Endometrial cancer;	chr6:125693761	chr6:125578558~125749190:-
THCA	cis	rs11098499	0.863	rs2306457	ENSG00000249244.1	RP11-548H18.2	4.47	9.95e-06	0.00102	0.24	0.2	Corneal astigmatism;	chr4:119551684	chr4:119391831~119395335:-
THCA	cis	rs7200786	0.584	rs4781030	ENSG00000274038.1	RP11-66H6.4	4.47	9.96e-06	0.00102	0.25	0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10988606	chr16:11056556~11057034:+
THCA	cis	rs30380	1	rs469758	ENSG00000248734.2	CTD-2260A17.1	4.47	9.96e-06	0.00102	0.21	0.2	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96784777~96785999:+
THCA	cis	rs7560272	0.501	rs12713798	ENSG00000273245.1	RP11-434P11.2	-4.47	9.96e-06	0.00102	-0.23	-0.2	Schizophrenia;	chr2:73759294	chr2:73750256~73750786:-
THCA	cis	rs4648045	0.687	rs4699030	ENSG00000246560.2	RP11-10L12.4	-4.47	9.96e-06	0.00102	-0.24	-0.2	Lymphocyte percentage of white cells;	chr4:102582667	chr4:102828055~102844075:+
THCA	cis	rs1538970	0.816	rs34673142	ENSG00000234329.1	RP11-767N6.2	4.47	9.96e-06	0.00102	0.2	0.2	Platelet count;	chr1:45519889	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.951	rs8804	ENSG00000258273.1	RP11-370I10.4	4.47	9.96e-06	0.00102	0.29	0.2	Longevity (90 years and older);	chr12:48147974	chr12:48333755~48333901:-
THCA	cis	rs5742933	0.948	rs6434365	ENSG00000273240.1	RP11-455J20.3	-4.47	9.96e-06	0.00102	-0.23	-0.2	Ferritin levels;	chr2:189707695	chr2:189763859~189764456:-
THCA	cis	rs57221529	0.766	rs56216231	ENSG00000225138.6	CTD-2228K2.7	4.47	9.96e-06	0.00102	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:581078	chr5:473236~480884:+
THCA	cis	rs57221529	0.766	rs56350081	ENSG00000225138.6	CTD-2228K2.7	4.47	9.96e-06	0.00102	0.26	0.2	Lung disease severity in cystic fibrosis;	chr5:583083	chr5:473236~480884:+
THCA	cis	rs763121	0.925	rs5750654	ENSG00000228274.3	RP3-508I15.9	-4.47	9.97e-06	0.00102	-0.21	-0.2	Menopause (age at onset);	chr22:38655423	chr22:38667585~38681820:-
THCA	cis	rs858239	0.601	rs987257	ENSG00000226816.2	AC005082.12	4.47	9.97e-06	0.00102	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23206013~23208045:+
THCA	cis	rs6657613	0.68	rs7536679	ENSG00000186301.8	MST1P2	-4.47	9.97e-06	0.00102	-0.16	-0.2	Hip circumference adjusted for BMI;	chr1:17048168	chr1:16645622~16650289:+
THCA	cis	rs7267979	0.833	rs6138556	ENSG00000274973.1	RP13-401N8.7	-4.47	9.97e-06	0.00102	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25845497~25845862:+
THCA	cis	rs7560272	0.501	rs2272178	ENSG00000273245.1	RP11-434P11.2	-4.47	9.98e-06	0.00102	-0.23	-0.2	Schizophrenia;	chr2:73750482	chr2:73750256~73750786:-
THCA	cis	rs7264396	1	rs224434	ENSG00000088340.14	FER1L4	4.47	9.98e-06	0.00102	0.19	0.2	Total cholesterol levels;	chr20:35565939	chr20:35558737~35607562:-
THCA	cis	rs2028299	0.92	rs12594774	ENSG00000259677.1	RP11-493E3.1	4.47	9.98e-06	0.00102	0.27	0.2	Type 2 diabetes;	chr15:89863652	chr15:89876540~89877285:+
THCA	cis	rs6121246	0.609	rs6060843	ENSG00000230613.1	HM13-AS1	4.47	9.98e-06	0.00102	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31709244	chr20:31567707~31573263:-
THCA	cis	rs4245128	0.689	rs10891474	ENSG00000247416.2	RP11-629G13.1	4.47	9.98e-06	0.00102	0.2	0.2	Life satisfaction;	chr11:112930167	chr11:112959279~112963460:-
THCA	cis	rs12612619	0.732	rs6547355	ENSG00000229122.1	AGBL5-IT1	4.47	9.98e-06	0.00102	0.14	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26987337	chr2:27061038~27061815:+
THCA	cis	rs1538970	0.851	rs2055145	ENSG00000234329.1	RP11-767N6.2	4.47	9.98e-06	0.00102	0.2	0.2	Platelet count;	chr1:45460823	chr1:45651039~45651826:-
THCA	cis	rs496547	0.686	rs487728	ENSG00000255422.1	AP002954.4	-4.47	9.99e-06	0.00102	-0.22	-0.2	Hip minimal joint space width;	chr11:118750785	chr11:118704607~118750263:+
THCA	cis	rs2836950	0.565	rs3171465	ENSG00000238141.2	BRWD1-AS1	-4.47	9.99e-06	0.00102	-0.23	-0.2	Menarche (age at onset);	chr21:39180381	chr21:39315707~39323218:+
THCA	cis	rs8192917	0.511	rs7153040	ENSG00000258744.1	RP11-80A15.1	-4.47	1e-05	0.00102	-0.34	-0.2	Vitiligo;	chr14:24604849	chr14:24501594~24508688:+
THCA	cis	rs867371	1	rs867370	ENSG00000255769.6	GOLGA2P10	4.47	1e-05	0.00102	0.23	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82472993~82513950:-
THCA	cis	rs867371	1	rs867371	ENSG00000255769.6	GOLGA2P10	4.47	1e-05	0.00102	0.23	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82472993~82513950:-
THCA	cis	rs12936587	0.568	rs4925062	ENSG00000223979.2	SMCR2	4.47	1e-05	0.00102	0.21	0.2	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17647452	chr17:17674026~17677688:-
THCA	cis	rs2797160	1	rs1739376	ENSG00000237742.5	RP11-624M8.1	4.47	1e-05	0.00102	0.17	0.2	Endometrial cancer;	chr6:125690938	chr6:125578558~125749190:-
THCA	cis	rs2836950	0.561	rs34705151	ENSG00000238141.2	BRWD1-AS1	-4.47	1e-05	0.00103	-0.23	-0.2	Menarche (age at onset);	chr21:39181418	chr21:39315707~39323218:+
THCA	cis	rs17005891	0.618	rs34156523	ENSG00000270480.1	RP11-57B24.1	4.47	1e-05	0.00103	0.27	0.2	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82627038	chr4:82691737~82692468:+
THCA	cis	rs6845263	0.546	rs9917916	ENSG00000254531.1	FLJ20021	-4.47	1e-05	0.00103	-0.17	-0.2	Superior crus of antihelix expression;	chr4:101534576	chr4:101347780~101348883:+
THCA	cis	rs36715	1	rs251213	ENSG00000245937.6	LINC01184	4.47	1e-05	0.00103	0.23	0.2	Breast cancer;	chr5:128209913	chr5:127940426~128083172:-
THCA	cis	rs36715	1	rs251212	ENSG00000245937.6	LINC01184	4.47	1e-05	0.00103	0.23	0.2	Breast cancer;	chr5:128210218	chr5:127940426~128083172:-
THCA	cis	rs36715	1	rs2617621	ENSG00000245937.6	LINC01184	4.47	1e-05	0.00103	0.23	0.2	Breast cancer;	chr5:128210574	chr5:127940426~128083172:-
THCA	cis	rs36715	1	rs181850	ENSG00000245937.6	LINC01184	4.47	1e-05	0.00103	0.23	0.2	Breast cancer;	chr5:128211795	chr5:127940426~128083172:-
THCA	cis	rs36715	0.953	rs185177	ENSG00000245937.6	LINC01184	4.47	1e-05	0.00103	0.23	0.2	Breast cancer;	chr5:128212118	chr5:127940426~128083172:-
THCA	cis	rs8058578	1	rs8051050	ENSG00000279196.1	RP11-1072A3.3	4.47	1e-05	0.00103	0.21	0.2	Multiple myeloma;	chr16:30676588	chr16:30984630~30988270:-
THCA	cis	rs740160	0.681	rs11974885	ENSG00000244219.5	GS1-259H13.2	-4.47	1e-05	0.00103	-0.34	-0.2	Dehydroepiandrosterone sulphate levels;	chr7:99293532	chr7:99598066~99610813:+
THCA	cis	rs1555322	0.818	rs2425022	ENSG00000126005.14	MMP24-AS1	-4.47	1e-05	0.00103	-0.26	-0.2	Attention deficit hyperactivity disorder;	chr20:35243384	chr20:35216462~35278131:-
THCA	cis	rs2836974	0.666	rs2836975	ENSG00000255568.3	BRWD1-AS2	-4.47	1e-05	0.00103	-0.17	-0.2	Cognitive function;	chr21:39291694	chr21:39313935~39314962:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000280107.1	AL022393.9	-4.47	1e-05	0.00103	-0.2	-0.2	Cardiac Troponin-T levels;	chr6:28164978	chr6:28170845~28172521:+
THCA	cis	rs7474896	0.583	rs7071147	ENSG00000226578.1	RP11-258F22.1	-4.47	1e-05	0.00103	-0.28	-0.2	Obesity (extreme);	chr10:37714448	chr10:37775371~37784131:-
THCA	cis	rs11158026	0.518	rs878944	ENSG00000258413.1	RP11-665C16.6	-4.47	1e-05	0.00103	-0.32	-0.2	Parkinson's disease;	chr14:54976884	chr14:55262767~55272075:-
THCA	cis	rs6121246	0.909	rs1994251	ENSG00000230613.1	HM13-AS1	4.47	1e-05	0.00103	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31699525	chr20:31567707~31573263:-
THCA	cis	rs36093844	0.8	rs75605851	ENSG00000279742.1	RP11-700A24.1	-4.47	1e-05	0.00103	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85868988	chr11:85852557~85854943:-
THCA	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-4.47	1e-05	0.00103	-0.23	-0.2	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
THCA	cis	rs7560272	0.538	rs2012574	ENSG00000163016.8	ALMS1P	-4.47	1e-05	0.00103	-0.25	-0.2	Schizophrenia;	chr2:73701239	chr2:73644919~73685576:+
THCA	cis	rs28374715	0.532	rs28703570	ENSG00000247556.5	OIP5-AS1	4.47	1e-05	0.00103	0.19	0.2	Ulcerative colitis;	chr15:41387294	chr15:41283990~41309737:+
THCA	cis	rs9487094	0.689	rs7754650	ENSG00000223537.2	RP5-919F19.5	-4.47	1e-05	0.00103	-0.2	-0.2	Height;	chr6:109405536	chr6:109487906~109506800:+
THCA	cis	rs76878669	0.917	rs10444359	ENSG00000255320.1	RP11-755F10.1	4.47	1e-05	0.00103	0.29	0.2	Educational attainment (years of education);	chr11:66335336	chr11:66244840~66246239:-
THCA	cis	rs9549367	0.804	rs9549704	ENSG00000269125.1	RP11-98F14.11	-4.47	1e-05	0.00103	-0.25	-0.2	Platelet distribution width;	chr13:113230873	chr13:113165002~113165183:-
THCA	cis	rs6088590	0.965	rs6120730	ENSG00000269202.1	RP4-614O4.12	-4.47	1e-05	0.00103	-0.18	-0.2	Coronary artery disease;	chr20:34797299	chr20:35201747~35203288:-
THCA	cis	rs138249	0.898	rs84504	ENSG00000273253.2	RP3-402G11.26	-4.47	1e-05	0.00103	-0.2	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50120818	chr22:50199090~50200837:-
THCA	cis	rs138249	0.934	rs138234	ENSG00000273253.2	RP3-402G11.26	-4.47	1e-05	0.00103	-0.2	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50121943	chr22:50199090~50200837:-
THCA	cis	rs6792584	0.637	rs4320072	ENSG00000241316.5	SUCLG2-AS1	4.47	1e-05	0.00103	0.22	0.2	Corneal astigmatism;	chr3:67408626	chr3:67654697~67947713:+
THCA	cis	rs875971	0.522	rs6960048	ENSG00000272831.1	RP11-792A8.4	4.47	1e-05	0.00103	0.13	0.2	Aortic root size;	chr7:65943052	chr7:66739829~66740385:-
THCA	cis	rs718433	0.616	rs2222916	ENSG00000211778.2	TRAV4	-4.47	1e-05	0.00103	-0.15	-0.2	Intraocular pressure;	chr14:21744319	chr14:21736152~21736982:+
THCA	cis	rs7119038	0.818	rs4936441	ENSG00000255239.1	AP002954.6	4.47	1e-05	0.00103	0.31	0.2	Sjögren's syndrome;	chr11:118854951	chr11:118688039~118690600:-
THCA	cis	rs858239	0.539	rs10247268	ENSG00000230042.1	AK3P3	-4.47	1e-05	0.00103	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs6461694	ENSG00000230042.1	AK3P3	-4.47	1e-05	0.00103	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23129178~23129841:+
THCA	cis	rs858239	0.508	rs7805071	ENSG00000230042.1	AK3P3	-4.47	1e-05	0.00103	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23129178~23129841:+
THCA	cis	rs858239	0.508	rs7805085	ENSG00000230042.1	AK3P3	-4.47	1e-05	0.00103	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23129178~23129841:+
THCA	cis	rs9878978	1	rs2174019	ENSG00000237990.3	CNTN4-AS1	4.47	1e-05	0.00103	0.22	0.2	Blood pressure (smoking interaction);	chr3:2430983	chr3:3039033~3069242:-
THCA	cis	rs6442522	0.56	rs7631005	ENSG00000249786.6	EAF1-AS1	4.47	1e-05	0.00103	0.21	0.2	Uric acid levels;	chr3:15473554	chr3:15436171~15455940:-
THCA	cis	rs12439619	0.508	rs17354842	ENSG00000259429.4	UBE2Q2P2	4.46	1e-05	0.00103	0.16	0.2	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82355142~82420075:+
THCA	cis	rs62025270	0.747	rs12324721	ENSG00000259295.5	CSPG4P12	-4.46	1e-05	0.00103	-0.33	-0.2	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85191438~85213905:+
THCA	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-4.46	1e-05	0.00103	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-4.46	1e-05	0.00103	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-4.46	1e-05	0.00103	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-4.46	1e-05	0.00103	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-4.46	1e-05	0.00103	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-4.46	1e-05	0.00103	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-4.46	1e-05	0.00103	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
THCA	cis	rs8067545	0.717	rs9907788	ENSG00000270091.1	RP11-78O7.2	-4.46	1e-05	0.00103	-0.15	-0.2	Schizophrenia;	chr17:20105590	chr17:19896590~19897287:-
THCA	cis	rs4705962	0.878	rs4266392	ENSG00000230612.2	AC004237.1	4.46	1e-05	0.00103	0.25	0.2	Atopic dermatitis;	chr5:132713563	chr5:132688681~132723725:+
THCA	cis	rs13178541	0.81	rs7378848	ENSG00000250378.1	RP11-119J18.1	4.46	1e-05	0.00103	0.24	0.2	IgG glycosylation;	chr5:135751336	chr5:135812667~135826582:+
THCA	cis	rs1046491	0.901	rs8090297	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9117290	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs41274300	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9119491	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs12454025	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9123494	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs12966444	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9123634	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs12966775	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9123862	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs12968060	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9123947	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs36125741	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9125539	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs12457429	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9125848	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs12457266	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9125853	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.901	rs35849084	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9127798	chr18:9315194~9334441:-
THCA	cis	rs1046491	0.803	rs11872481	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00103	0.34	0.2	Scarlet fever;	chr18:9128455	chr18:9315194~9334441:-
THCA	cis	rs7560272	0.538	rs13006448	ENSG00000163016.8	ALMS1P	-4.46	1.01e-05	0.00103	-0.25	-0.2	Schizophrenia;	chr2:73697297	chr2:73644919~73685576:+
THCA	cis	rs12935418	0.673	rs2549887	ENSG00000278985.1	RP11-303E16.9	-4.46	1.01e-05	0.00103	-0.23	-0.2	Mean corpuscular volume;	chr16:81028222	chr16:80982319~80984094:-
THCA	cis	rs8192917	0.573	rs34604102	ENSG00000258744.1	RP11-80A15.1	-4.46	1.01e-05	0.00103	-0.37	-0.2	Vitiligo;	chr14:24626169	chr14:24501594~24508688:+
THCA	cis	rs807029	0.577	rs11190786	ENSG00000236662.1	RP11-108L7.4	4.46	1.01e-05	0.00103	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100997685	chr10:100980507~100985614:-
THCA	cis	rs807029	0.577	rs7902510	ENSG00000236662.1	RP11-108L7.4	4.46	1.01e-05	0.00103	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998177	chr10:100980507~100985614:-
THCA	cis	rs807029	0.577	rs7903239	ENSG00000236662.1	RP11-108L7.4	4.46	1.01e-05	0.00103	0.22	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998580	chr10:100980507~100985614:-
THCA	cis	rs941408	0.515	rs759066	ENSG00000261342.1	AC006538.1	4.46	1.01e-05	0.00103	0.23	0.2	Total cholesterol levels;	chr19:2775339	chr19:2727743~2729327:-
THCA	cis	rs875971	0.619	rs10278371	ENSG00000223473.2	GS1-124K5.3	-4.46	1.01e-05	0.00103	-0.13	-0.2	Aortic root size;	chr7:66586553	chr7:66491049~66493566:-
THCA	cis	rs2836974	0.666	rs4624474	ENSG00000255568.3	BRWD1-AS2	-4.46	1.01e-05	0.00103	-0.17	-0.2	Cognitive function;	chr21:39314401	chr21:39313935~39314962:+
THCA	cis	rs4722166	0.532	rs4719713	ENSG00000179428.2	AC073072.5	-4.46	1.01e-05	0.00103	-0.23	-0.2	Lung cancer;	chr7:22719192	chr7:22725395~22727620:-
THCA	cis	rs4218	0.859	rs1809588	ENSG00000259732.1	RP11-59H7.3	-4.46	1.01e-05	0.00103	-0.27	-0.2	Social communication problems;	chr15:59121825	chr15:59121034~59133250:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-4.46	1.01e-05	0.00103	-0.23	-0.2	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
THCA	cis	rs332034	0.591	rs9650614	ENSG00000253893.2	FAM85B	4.46	1.01e-05	0.00103	0.39	0.2	Conduct disorder (maternal expressed emotions interaction);	chr8:8835876	chr8:8167819~8226614:-
THCA	cis	rs1167832	0.645	rs1167828	ENSG00000205583.12	STAG3L1	-4.46	1.01e-05	0.00103	-0.28	-0.2	Ankle injury;	chr7:75534076	chr7:75359194~75395383:+
THCA	cis	rs8054556	0.74	rs12716974	ENSG00000183604.13	SMG1P5	-4.46	1.01e-05	0.00103	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30267553~30335374:-
THCA	cis	rs875971	0.66	rs801193	ENSG00000229886.1	RP5-1132H15.3	-4.46	1.01e-05	0.00103	-0.21	-0.2	Aortic root size;	chr7:66565625	chr7:66025126~66031544:-
THCA	cis	rs875971	0.508	rs10258739	ENSG00000229886.1	RP5-1132H15.3	-4.46	1.01e-05	0.00103	-0.2	-0.2	Aortic root size;	chr7:66597948	chr7:66025126~66031544:-
THCA	cis	rs6723108	0.594	rs643796	ENSG00000224043.6	CCNT2-AS1	-4.46	1.01e-05	0.00103	-0.22	-0.2	Type 2 diabetes;	chr2:134543287	chr2:134735464~134918710:-
THCA	cis	rs709400	0.77	rs7142883	ENSG00000258735.1	LINC00637	4.46	1.01e-05	0.00103	0.26	0.2	Body mass index;	chr14:103600308	chr14:103847721~103858049:+
THCA	cis	rs710913	0.531	rs1180331	ENSG00000182109.6	RP11-69E11.4	-4.46	1.01e-05	0.00103	-0.18	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39522280~39546187:-
THCA	cis	rs427943	0.831	rs414715	ENSG00000223768.1	LINC00205	-4.46	1.01e-05	0.00103	-0.18	-0.2	Body mass index;	chr21:45164537	chr21:45293285~45297354:+
THCA	cis	rs61270009	0.955	rs454830	ENSG00000247828.6	TMEM161B-AS1	-4.46	1.01e-05	0.00103	-0.18	-0.2	Depressive symptoms;	chr5:88254678	chr5:88268895~88436685:+
THCA	cis	rs9625935	1	rs9625935	ENSG00000279159.1	RP3-394A18.1	-4.46	1.01e-05	0.00103	-0.15	-0.2	Tonsillectomy;	chr22:30185871	chr22:29978950~30028236:-
THCA	cis	rs6517329	0.649	rs7282480	ENSG00000236830.5	CBR3-AS1	4.46	1.01e-05	0.00103	0.19	0.2	Schizophrenia;	chr21:36119262	chr21:36131767~36175815:-
THCA	cis	rs1923243	0.647	rs10890013	ENSG00000223479.3	RP4-788P17.1	4.46	1.01e-05	0.00103	0.22	0.2	Migraine;	chr1:73174068	chr1:73635216~73715214:+
THCA	cis	rs11089937	0.616	rs12484496	ENSG00000211639.2	IGLV4-60	-4.46	1.01e-05	0.00103	-0.14	-0.2	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22162199~22162681:+
THCA	cis	rs4646450	0.735	rs2072181	ENSG00000244219.5	GS1-259H13.2	4.46	1.01e-05	0.00103	0.26	0.2	Blood metabolite levels;	chr7:99400848	chr7:99598066~99610813:+
THCA	cis	rs61270009	0.913	rs373845	ENSG00000247828.6	TMEM161B-AS1	-4.46	1.01e-05	0.00103	-0.18	-0.2	Depressive symptoms;	chr5:88253893	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs75214722	ENSG00000247828.6	TMEM161B-AS1	4.46	1.01e-05	0.00103	0.18	0.2	Depressive symptoms;	chr5:88269908	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs895295	ENSG00000247828.6	TMEM161B-AS1	4.46	1.01e-05	0.00103	0.18	0.2	Depressive symptoms;	chr5:88271529	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.913	rs16903040	ENSG00000247828.6	TMEM161B-AS1	4.46	1.01e-05	0.00103	0.18	0.2	Depressive symptoms;	chr5:88273220	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs12163987	ENSG00000247828.6	TMEM161B-AS1	4.46	1.01e-05	0.00103	0.18	0.2	Depressive symptoms;	chr5:88276209	chr5:88268895~88436685:+
THCA	cis	rs12497850	0.931	rs6414613	ENSG00000228638.1	FCF1P2	-4.46	1.01e-05	0.00103	-0.22	-0.2	Parkinson's disease;	chr3:48998452	chr3:48290793~48291375:-
THCA	cis	rs713477	0.505	rs8019209	ENSG00000258413.1	RP11-665C16.6	4.46	1.01e-05	0.00103	0.28	0.2	Pediatric bone mineral content (femoral neck);	chr14:55424611	chr14:55262767~55272075:-
THCA	cis	rs41313321	0.512	rs7850697	ENSG00000273186.1	RP11-339B21.10	4.46	1.01e-05	0.00103	0.31	0.2	Coenzyme Q10 levels;	chr9:128332833	chr9:128431598~128432006:+
THCA	cis	rs7914558	0.966	rs10748839	ENSG00000236937.2	PTGES3P4	4.46	1.01e-05	0.00103	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:102845595~102845950:+
THCA	cis	rs11133613	0.546	rs7730935	ENSG00000215246.5	RP11-43F13.3	4.46	1.01e-05	0.00103	0.38	0.2	Red cell distribution width;	chr5:891325	chr5:987180~997308:-
THCA	cis	rs10761482	0.566	rs10159663	ENSG00000254271.1	RP11-131N11.4	-4.46	1.01e-05	0.00103	-0.28	-0.2	Schizophrenia;	chr10:60448659	chr10:60734342~60741828:+
THCA	cis	rs11148252	0.574	rs7139495	ENSG00000273784.3	RP11-78J21.7	-4.46	1.01e-05	0.00103	-0.22	-0.2	Lewy body disease;	chr13:52709183	chr13:52600042~52642542:+
THCA	cis	rs890448	0.896	rs28465302	ENSG00000254531.1	FLJ20021	-4.46	1.01e-05	0.00103	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101483479	chr4:101347780~101348883:+
THCA	cis	rs890448	0.896	rs4540050	ENSG00000254531.1	FLJ20021	-4.46	1.01e-05	0.00103	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101486292	chr4:101347780~101348883:+
THCA	cis	rs260461	0.92	rs260455	ENSG00000268516.2	CTD-3138B18.5	-4.46	1.01e-05	0.00103	-0.28	-0.2	Attention deficit hyperactivity disorder;	chr19:58256126	chr19:58257270~58278808:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000272831.1	RP11-792A8.4	4.46	1.01e-05	0.00103	0.13	0.2	Aortic root size;	chr7:65966699	chr7:66739829~66740385:-
THCA	cis	rs863750	0.721	rs851132	ENSG00000275389.1	RP11-214K3.24	4.46	1.01e-05	0.00103	0.27	0.2	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124050277	chr12:124085761~124088598:+
THCA	cis	rs34286592	1	rs3976455	ENSG00000214725.6	CDIPT-AS1	-4.46	1.01e-05	0.00103	-0.37	-0.2	Multiple sclerosis;	chr16:29850126	chr16:29863593~29868053:+
THCA	cis	rs4948275	0.631	rs2650743	ENSG00000237233.2	TMEM26-AS1	-4.46	1.01e-05	0.00103	-0.26	-0.2	Night sleep phenotypes;	chr10:61590160	chr10:61452639~61481956:+
THCA	cis	rs78487399	0.808	rs75934770	ENSG00000234936.1	AC010883.5	4.46	1.01e-05	0.00103	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43432555	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs74365854	ENSG00000234936.1	AC010883.5	4.46	1.01e-05	0.00103	0.28	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43434343	chr2:43229573~43233394:+
THCA	cis	rs138857	0.515	rs9616375	ENSG00000260613.1	RP3-522J7.6	-4.46	1.01e-05	0.00103	-0.33	-0.2	Mean platelet volume;	chr22:49916952	chr22:49832616~49837786:-
THCA	cis	rs4415084	0.716	rs4395640	ENSG00000272335.1	RP11-53O19.3	4.46	1.01e-05	0.00104	0.17	0.2	Breast cancer;	chr5:44868998	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.652	rs10059086	ENSG00000272335.1	RP11-53O19.3	4.46	1.01e-05	0.00104	0.17	0.2	Breast cancer;	chr5:44871905	chr5:44826076~44828592:+
THCA	cis	rs930395	0.514	rs4866783	ENSG00000272335.1	RP11-53O19.3	4.46	1.01e-05	0.00104	0.17	0.2	Breast cancer;	chr5:44876405	chr5:44826076~44828592:+
THCA	cis	rs1046491	0.901	rs12454908	ENSG00000264964.1	RP11-888D10.3	4.46	1.01e-05	0.00104	0.34	0.2	Scarlet fever;	chr18:9134356	chr18:9315194~9334441:-
THCA	cis	rs9625935	0.957	rs8138286	ENSG00000279159.1	RP3-394A18.1	-4.46	1.01e-05	0.00104	-0.16	-0.2	Tonsillectomy;	chr22:30166998	chr22:29978950~30028236:-
THCA	cis	rs2243480	0.901	rs313808	ENSG00000232559.3	GS1-124K5.12	4.46	1.01e-05	0.00104	0.3	0.2	Diabetic kidney disease;	chr7:66034886	chr7:66554588~66576923:-
THCA	cis	rs1823874	0.71	rs2085086	ENSG00000182397.13	DNM1P46	-4.46	1.01e-05	0.00104	-0.23	-0.2	IgG glycosylation;	chr15:99819887	chr15:99790156~99806927:-
THCA	cis	rs2163813	1	rs247771	ENSG00000271499.1	CTC-559E9.9	-4.46	1.01e-05	0.00104	-0.25	-0.2	Toenail selenium levels;	chr19:19737073	chr19:19750618~19752544:+
THCA	cis	rs875971	0.545	rs11767262	ENSG00000273142.1	RP11-458F8.4	4.46	1.01e-05	0.00104	0.19	0.2	Aortic root size;	chr7:66302237	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000273142.1	RP11-458F8.4	4.46	1.01e-05	0.00104	0.19	0.2	Aortic root size;	chr7:66327797	chr7:66902857~66906297:+
THCA	cis	rs6001482	0.679	rs1475928	ENSG00000272779.1	LL22NC03-80A10.6	-4.46	1.01e-05	0.00104	-0.23	-0.2	Diastolic blood pressure;	chr22:22236137	chr22:22303224~22310401:+
THCA	cis	rs6088590	0.93	rs6120723	ENSG00000269202.1	RP4-614O4.12	-4.46	1.01e-05	0.00104	-0.18	-0.2	Coronary artery disease;	chr20:34776852	chr20:35201747~35203288:-
THCA	cis	rs6088590	1	rs6119524	ENSG00000269202.1	RP4-614O4.12	-4.46	1.01e-05	0.00104	-0.18	-0.2	Coronary artery disease;	chr20:34786010	chr20:35201747~35203288:-
THCA	cis	rs6088590	0.965	rs6120727	ENSG00000269202.1	RP4-614O4.12	-4.46	1.01e-05	0.00104	-0.18	-0.2	Coronary artery disease;	chr20:34786299	chr20:35201747~35203288:-
THCA	cis	rs6088590	1	rs28542147	ENSG00000269202.1	RP4-614O4.12	-4.46	1.01e-05	0.00104	-0.18	-0.2	Coronary artery disease;	chr20:34788520	chr20:35201747~35203288:-
THCA	cis	rs6088590	1	rs6088607	ENSG00000269202.1	RP4-614O4.12	-4.46	1.01e-05	0.00104	-0.18	-0.2	Coronary artery disease;	chr20:34790930	chr20:35201747~35203288:-
THCA	cis	rs6430538	0.671	rs6716734	ENSG00000224043.6	CCNT2-AS1	-4.46	1.01e-05	0.00104	-0.21	-0.2	Parkinson's disease;	chr2:134803571	chr2:134735464~134918710:-
THCA	cis	rs1876905	0.62	rs354530	ENSG00000272356.1	RP5-1112D6.8	-4.46	1.01e-05	0.00104	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111309203~111313517:+
THCA	cis	rs2886497	0.894	rs57858385	ENSG00000224215.1	RP11-371A19.2	-4.46	1.01e-05	0.00104	-0.26	-0.2	Major depression and alcohol dependence;	chr10:23407896	chr10:23343957~23345181:+
THCA	cis	rs8002861	0.905	rs6561150	ENSG00000274001.1	RP11-5G9.5	4.46	1.01e-05	0.00104	0.25	0.2	Leprosy;	chr13:43886334	chr13:43877715~43878163:-
THCA	cis	rs642858	0.615	rs6570396	ENSG00000234147.1	RP3-460G2.2	4.46	1.01e-05	0.00104	0.25	0.2	Type 2 diabetes;	chr6:140406369	chr6:140845958~140852924:-
THCA	cis	rs9467773	0.62	rs1490488	ENSG00000261353.1	CTA-14H9.5	-4.46	1.01e-05	0.00104	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26527063~26527404:+
THCA	cis	rs9467773	0.62	rs2494692	ENSG00000261353.1	CTA-14H9.5	-4.46	1.01e-05	0.00104	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26527063~26527404:+
THCA	cis	rs11671005	0.779	rs731259	ENSG00000265272.2	RN7SL693P	4.46	1.01e-05	0.00104	0.29	0.2	Mean platelet volume;	chr19:58478057	chr19:58490797~58491075:+
THCA	cis	rs6430585	0.583	rs58509842	ENSG00000231890.6	DARS-AS1	-4.46	1.01e-05	0.00104	-0.24	-0.2	Corneal structure;	chr2:135828457	chr2:135985176~136022593:+
THCA	cis	rs2657294	0.931	rs2804522	ENSG00000226051.5	ZNF503-AS1	-4.46	1.01e-05	0.00104	-0.28	-0.2	Pneumonia;	chr10:75159132	chr10:75269819~75373500:+
THCA	cis	rs1979679	1	rs11049487	ENSG00000247934.4	RP11-967K21.1	-4.46	1.01e-05	0.00104	-0.2	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28254157	chr12:28163298~28190738:-
THCA	cis	rs6012564	1	rs3091529	ENSG00000230758.1	SNAP23P	-4.46	1.01e-05	0.00104	-0.24	-0.2	Anger;	chr20:49030531	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs1022687	ENSG00000230758.1	SNAP23P	-4.46	1.01e-05	0.00104	-0.24	-0.2	Anger;	chr20:49032317	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.964	rs3092302	ENSG00000230758.1	SNAP23P	-4.46	1.01e-05	0.00104	-0.24	-0.2	Anger;	chr20:49037721	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.964	rs73266241	ENSG00000230758.1	SNAP23P	4.46	1.01e-05	0.00104	0.24	0.2	Anger;	chr20:49043748	chr20:49038357~49038602:-
THCA	cis	rs3738443	0.868	rs17269923	ENSG00000259865.1	RP11-488L18.10	4.46	1.01e-05	0.00104	0.21	0.2	Alcohol dependence;	chr1:247208861	chr1:247187281~247188526:-
THCA	cis	rs972578	0.715	rs4822246	ENSG00000274717.1	RP1-47A17.1	4.46	1.01e-05	0.00104	0.22	0.2	Mean platelet volume;	chr22:43007018	chr22:42791814~42794313:-
THCA	cis	rs2657294	0.965	rs2657285	ENSG00000226051.5	ZNF503-AS1	-4.46	1.01e-05	0.00104	-0.28	-0.2	Pneumonia;	chr10:75164166	chr10:75269819~75373500:+
THCA	cis	rs9863	0.861	rs11057397	ENSG00000269997.1	RP11-214K3.21	-4.46	1.01e-05	0.00104	-0.26	-0.2	White blood cell count;	chr12:123935181	chr12:123966077~123966629:-
THCA	cis	rs6921919	0.638	rs1416920	ENSG00000219392.1	RP1-265C24.5	-4.46	1.02e-05	0.00104	-0.24	-0.2	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.525	rs1361386	ENSG00000219392.1	RP1-265C24.5	-4.46	1.02e-05	0.00104	-0.24	-0.2	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28115628~28116551:+
THCA	cis	rs6921919	0.638	rs6456815	ENSG00000219392.1	RP1-265C24.5	-4.46	1.02e-05	0.00104	-0.24	-0.2	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28115628~28116551:+
THCA	cis	rs427394	0.802	rs274718	ENSG00000248677.1	CTD-2044J15.1	4.46	1.02e-05	0.00104	0.19	0.2	Menopause (age at onset);	chr5:6720875	chr5:6686325~6707711:-
THCA	cis	rs17685	0.753	rs4732542	ENSG00000230882.1	AC005077.14	4.46	1.02e-05	0.00104	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76033885	chr7:76071469~76074963:-
THCA	cis	rs9329221	0.683	rs688491	ENSG00000261451.1	RP11-981G7.1	-4.46	1.02e-05	0.00104	-0.25	-0.2	Neuroticism;	chr8:10027313	chr8:10433672~10438312:+
THCA	cis	rs10266483	0.739	rs2692104	ENSG00000271550.1	BNIP3P11	4.46	1.02e-05	0.00104	0.25	0.2	Response to statin therapy;	chr7:64300577	chr7:64678954~64687393:-
THCA	cis	rs2153535	0.585	rs9393053	ENSG00000230939.1	RP11-314C16.1	-4.46	1.02e-05	0.00104	-0.21	-0.2	Motion sickness;	chr6:8644947	chr6:8784178~8785445:+
THCA	cis	rs889398	0.802	rs9940315	ENSG00000226232.7	RP11-419C5.2	-4.46	1.02e-05	0.00104	-0.2	-0.2	Body mass index;	chr16:69842261	chr16:69976388~69996188:-
THCA	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-4.46	1.02e-05	0.00104	-0.11	-0.2	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
THCA	cis	rs7647973	0.577	rs6446247	ENSG00000228638.1	FCF1P2	-4.46	1.02e-05	0.00104	-0.25	-0.2	Menarche (age at onset);	chr3:49064568	chr3:48290793~48291375:-
THCA	cis	rs453301	0.686	rs4840389	ENSG00000254153.1	CTA-398F10.2	4.46	1.02e-05	0.00104	0.22	0.2	Joint mobility (Beighton score);	chr8:9026993	chr8:8456909~8461337:-
THCA	cis	rs453301	0.658	rs13271797	ENSG00000254153.1	CTA-398F10.2	4.46	1.02e-05	0.00104	0.22	0.2	Joint mobility (Beighton score);	chr8:9028444	chr8:8456909~8461337:-
THCA	cis	rs5758659	0.652	rs133300	ENSG00000205702.9	CYP2D7	4.46	1.02e-05	0.00104	0.15	0.2	Cognitive function;	chr22:41993835	chr22:42140203~42144577:-
THCA	cis	rs8028182	0.549	rs3809547	ENSG00000260274.1	RP11-817O13.8	-4.46	1.02e-05	0.00104	-0.14	-0.2	Sudden cardiac arrest;	chr15:75336500	chr15:75368155~75369584:+
THCA	cis	rs442309	0.687	rs10995294	ENSG00000238280.1	RP11-436D10.3	-4.46	1.02e-05	0.00104	-0.25	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62723157	chr10:62793562~62805887:-
THCA	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-4.46	1.02e-05	0.00104	-0.2	-0.2	Height;	chr5:37053881	chr5:36666214~36725195:-
THCA	cis	rs9283706	0.655	rs10069987	ENSG00000229666.1	MAST4-AS1	-4.46	1.02e-05	0.00104	-0.28	-0.2	Coronary artery disease;	chr5:66998599	chr5:67001383~67003953:-
THCA	cis	rs9928842	0.823	rs11149811	ENSG00000261783.1	RP11-252K23.2	4.46	1.02e-05	0.00104	0.39	0.2	Alcoholic chronic pancreatitis;	chr16:75266810	chr16:75379818~75381260:-
THCA	cis	rs1707322	1	rs4073847	ENSG00000281133.1	AL355480.3	4.46	1.02e-05	0.00104	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45580892~45580996:-
THCA	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-4.46	1.02e-05	0.00104	-0.11	-0.2	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-4.46	1.02e-05	0.00104	-0.11	-0.2	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-4.46	1.02e-05	0.00104	-0.11	-0.2	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-4.46	1.02e-05	0.00104	-0.11	-0.2	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
THCA	cis	rs7560272	0.538	rs2001436	ENSG00000273245.1	RP11-434P11.2	-4.46	1.02e-05	0.00104	-0.23	-0.2	Schizophrenia;	chr2:73701838	chr2:73750256~73750786:-
THCA	cis	rs4218	0.648	rs12442134	ENSG00000259732.1	RP11-59H7.3	-4.46	1.02e-05	0.00104	-0.28	-0.2	Social communication problems;	chr15:59074478	chr15:59121034~59133250:+
THCA	cis	rs1334894	1	rs55922240	ENSG00000228559.1	RP3-340B19.3	-4.46	1.02e-05	0.00104	-0.43	-0.2	Coronary artery disease;	chr6:35640319	chr6:35544632~35545669:+
THCA	cis	rs1334894	1	rs7756437	ENSG00000228559.1	RP3-340B19.3	-4.46	1.02e-05	0.00104	-0.43	-0.2	Coronary artery disease;	chr6:35642037	chr6:35544632~35545669:+
THCA	cis	rs875971	0.66	rs7807930	ENSG00000272831.1	RP11-792A8.4	-4.46	1.02e-05	0.00104	-0.13	-0.2	Aortic root size;	chr7:66622178	chr7:66739829~66740385:-
THCA	cis	rs710913	0.691	rs1180351	ENSG00000182109.6	RP11-69E11.4	-4.46	1.02e-05	0.00104	-0.18	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39522280~39546187:-
THCA	cis	rs710913	0.717	rs1180352	ENSG00000182109.6	RP11-69E11.4	-4.46	1.02e-05	0.00104	-0.18	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39522280~39546187:-
THCA	cis	rs72753537	0.817	rs12378536	ENSG00000214417.4	KRT18P13	4.46	1.02e-05	0.00104	0.23	0.2	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97846174	chr9:97698922~97700734:+
THCA	cis	rs2692947	0.537	rs11682182	ENSG00000235959.1	AC009237.17	-4.46	1.02e-05	0.00104	-0.22	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712462	chr2:95640181~95640604:-
THCA	cis	rs2735413	0.67	rs4522431	ENSG00000276007.1	RP11-358L22.3	4.46	1.02e-05	0.00104	0.19	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78077255	chr16:78123243~78124332:+
THCA	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-4.46	1.02e-05	0.00104	-0.23	-0.2	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
THCA	cis	rs8062405	1	rs62036616	ENSG00000261766.1	RP11-22P6.2	-4.46	1.02e-05	0.00104	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28862166~28863340:-
THCA	cis	rs6088590	0.901	rs6087631	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.02e-05	0.00104	-0.19	-0.2	Coronary artery disease;	chr20:34815706	chr20:33985617~33988989:-
THCA	cis	rs1200821	0.529	rs2505707	ENSG00000263064.2	RP11-291L22.7	4.46	1.02e-05	0.00104	0.22	0.2	Hemostatic factors and hematological phenotypes;	chr10:37512326	chr10:38448689~38448949:+
THCA	cis	rs2842992	0.747	rs4709378	ENSG00000237927.1	RP3-393E18.2	-4.46	1.02e-05	0.00104	-0.32	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159806403	chr6:159586955~159589169:-
THCA	cis	rs8067545	0.75	rs4924804	ENSG00000270091.1	RP11-78O7.2	-4.46	1.02e-05	0.00104	-0.15	-0.2	Schizophrenia;	chr17:20088526	chr17:19896590~19897287:-
THCA	cis	rs8067545	1	rs8067545	ENSG00000270091.1	RP11-78O7.2	-4.46	1.02e-05	0.00104	-0.15	-0.2	Schizophrenia;	chr17:20009397	chr17:19896590~19897287:-
THCA	cis	rs6570726	0.935	rs434298	ENSG00000270638.1	RP3-466P17.1	4.46	1.02e-05	0.00104	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145735570~145737218:+
THCA	cis	rs9902453	0.904	rs4461132	ENSG00000263370.1	RP11-68I3.5	4.46	1.02e-05	0.00104	0.26	0.2	Coffee consumption (cups per day);	chr17:30096412	chr17:29639627~29640825:+
THCA	cis	rs733592	0.504	rs2261608	ENSG00000258273.1	RP11-370I10.4	-4.46	1.02e-05	0.00104	-0.24	-0.2	Plateletcrit;	chr12:48327851	chr12:48333755~48333901:-
THCA	cis	rs2439831	1	rs2467739	ENSG00000205771.5	CATSPER2P1	-4.46	1.02e-05	0.00104	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43447998	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs28666488	ENSG00000205771.5	CATSPER2P1	-4.46	1.02e-05	0.00104	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43448892	chr15:43726918~43747094:-
THCA	cis	rs2439831	1	rs2245790	ENSG00000205771.5	CATSPER2P1	-4.46	1.02e-05	0.00104	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43452259	chr15:43726918~43747094:-
THCA	cis	rs728616	0.614	rs10887218	ENSG00000242600.5	MBL1P	4.46	1.02e-05	0.00104	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951268	chr10:79904898~79950336:+
THCA	cis	rs2734839	0.964	rs12800853	ENSG00000270179.1	RP11-159N11.4	-4.46	1.02e-05	0.00104	-0.21	-0.2	Information processing speed;	chr11:113431792	chr11:113368478~113369117:+
THCA	cis	rs9326248	0.53	rs11216171	ENSG00000280143.1	AP000892.6	4.46	1.02e-05	0.00104	0.27	0.2	Blood protein levels;	chr11:116878397	chr11:117204967~117210292:+
THCA	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-4.46	1.02e-05	0.00105	-0.11	-0.2	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
THCA	cis	rs6121246	0.559	rs6087771	ENSG00000230613.1	HM13-AS1	4.46	1.02e-05	0.00105	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31718921	chr20:31567707~31573263:-
THCA	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-4.46	1.02e-05	0.00105	-0.24	-0.2	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
THCA	cis	rs4578769	1	rs4578769	ENSG00000265939.1	UBE2CP2	4.46	1.02e-05	0.00105	0.25	0.2	Eosinophil percentage of white cells;	chr18:22815141	chr18:22900486~22900995:-
THCA	cis	rs2028299	0.92	rs4932261	ENSG00000259677.1	RP11-493E3.1	4.46	1.02e-05	0.00105	0.27	0.2	Type 2 diabetes;	chr15:89887164	chr15:89876540~89877285:+
THCA	cis	rs4682868	0.581	rs13068366	ENSG00000273328.4	RP11-141M3.6	-4.46	1.02e-05	0.00105	-0.24	-0.2	Monocyte percentage of white cells;	chr3:42880528	chr3:42809414~42908105:+
THCA	cis	rs2243480	1	rs67728539	ENSG00000232559.3	GS1-124K5.12	4.46	1.02e-05	0.00105	0.3	0.2	Diabetic kidney disease;	chr7:65913137	chr7:66554588~66576923:-
THCA	cis	rs4660456	0.576	rs2780948	ENSG00000238287.1	RP11-656D10.3	-4.46	1.02e-05	0.00105	-0.23	-0.2	Platelet count;	chr1:40776205	chr1:40493157~40508661:-
THCA	cis	rs10946940	0.864	rs13201411	ENSG00000219392.1	RP1-265C24.5	4.46	1.02e-05	0.00105	0.23	0.2	Systemic lupus erythematosus;	chr6:27530438	chr6:28115628~28116551:+
THCA	cis	rs987724	0.515	rs11914959	ENSG00000243926.1	TIPARP-AS1	4.46	1.02e-05	0.00105	0.26	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898616	chr3:156671862~156674378:-
THCA	cis	rs987724	0.501	rs4680313	ENSG00000243926.1	TIPARP-AS1	4.46	1.02e-05	0.00105	0.26	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901348	chr3:156671862~156674378:-
THCA	cis	rs714027	0.511	rs131274	ENSG00000279699.1	RP1-102K2.9	4.46	1.02e-05	0.00105	0.2	0.2	Lymphocyte counts;	chr22:29757875	chr22:30275215~30276951:-
THCA	cis	rs11992186	0.505	rs7845203	ENSG00000253981.4	ALG1L13P	4.46	1.02e-05	0.00105	0.19	0.2	Neuroticism;	chr8:8287918	chr8:8236003~8244667:-
THCA	cis	rs6088590	1	rs6119535	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.02e-05	0.00105	-0.19	-0.2	Coronary artery disease;	chr20:34854335	chr20:33985617~33988989:-
THCA	cis	rs4763879	0.634	rs61915473	ENSG00000256673.1	RP11-599J14.2	4.46	1.02e-05	0.00105	0.24	0.2	Type 1 diabetes;	chr12:9705282	chr12:9398355~9414851:-
THCA	cis	rs2787702	0.89	rs1350172	ENSG00000237233.2	TMEM26-AS1	-4.46	1.02e-05	0.00105	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61589009	chr10:61452639~61481956:+
THCA	cis	rs11976180	1	rs2961144	ENSG00000244198.4	RP4-545C24.1	4.46	1.02e-05	0.00105	0.2	0.2	Obesity-related traits;	chr7:144050777	chr7:144194858~144280547:+
THCA	cis	rs734999	0.588	rs2843401	ENSG00000225931.3	RP3-395M20.7	-4.46	1.02e-05	0.00105	-0.24	-0.2	Ulcerative colitis;	chr1:2596694	chr1:2566410~2569888:+
THCA	cis	rs734999	0.588	rs2843402	ENSG00000225931.3	RP3-395M20.7	-4.46	1.02e-05	0.00105	-0.24	-0.2	Ulcerative colitis;	chr1:2597243	chr1:2566410~2569888:+
THCA	cis	rs734999	0.588	rs2764842	ENSG00000225931.3	RP3-395M20.7	-4.46	1.02e-05	0.00105	-0.24	-0.2	Ulcerative colitis;	chr1:2597753	chr1:2566410~2569888:+
THCA	cis	rs115769866	0.609	rs974334	ENSG00000216901.1	AL022393.7	4.46	1.03e-05	0.00105	0.29	0.2	Bipolar disorder;	chr6:28506441	chr6:28176188~28176674:+
THCA	cis	rs7474896	1	rs11011321	ENSG00000263064.2	RP11-291L22.7	4.46	1.03e-05	0.00105	0.32	0.2	Obesity (extreme);	chr10:37673450	chr10:38448689~38448949:+
THCA	cis	rs2243480	1	rs958550	ENSG00000232559.3	GS1-124K5.12	-4.46	1.03e-05	0.00105	-0.3	-0.2	Diabetic kidney disease;	chr7:66170692	chr7:66554588~66576923:-
THCA	cis	rs4660214	0.666	rs7554206	ENSG00000182109.6	RP11-69E11.4	-4.46	1.03e-05	0.00105	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39522280~39546187:-
THCA	cis	rs7267979	0.868	rs6138546	ENSG00000274973.1	RP13-401N8.7	-4.46	1.03e-05	0.00105	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25845497~25845862:+
THCA	cis	rs228614	0.51	rs6830407	ENSG00000248971.2	KRT8P46	-4.46	1.03e-05	0.00105	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102728746~102730171:-
THCA	cis	rs9925964	1	rs9925964	ENSG00000232748.3	RP11-196G11.6	4.46	1.03e-05	0.00105	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118574	chr16:31056460~31062803:+
THCA	cis	rs9925964	0.967	rs4889620	ENSG00000232748.3	RP11-196G11.6	4.46	1.03e-05	0.00105	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31119853	chr16:31056460~31062803:+
THCA	cis	rs7432375	0.61	rs56695781	ENSG00000239213.4	NCK1-AS1	4.46	1.03e-05	0.00105	0.18	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136791759	chr3:136841726~136862054:-
THCA	cis	rs7942368	1	rs11236924	ENSG00000261578.1	RP11-21L23.2	4.46	1.03e-05	0.00105	0.3	0.2	Endometriosis;	chr11:76756303	chr11:76800364~76804555:+
THCA	cis	rs6504108	0.58	rs2924251	ENSG00000278765.1	RP5-890E16.5	4.46	1.03e-05	0.00105	0.23	0.2	Body mass index;	chr17:48261315	chr17:48066704~48067293:-
THCA	cis	rs12935229	1	rs17769712	ENSG00000260922.1	RP11-538I12.3	4.46	1.03e-05	0.00105	0.34	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77288602	chr16:77234877~77290934:+
THCA	cis	rs709400	0.894	rs56017123	ENSG00000258735.1	LINC00637	4.46	1.03e-05	0.00105	0.26	0.2	Body mass index;	chr14:103608940	chr14:103847721~103858049:+
THCA	cis	rs17221829	0.932	rs4753236	ENSG00000280385.1	AP000648.5	-4.46	1.03e-05	0.00105	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89714979	chr11:90193614~90198120:+
THCA	cis	rs4713118	0.591	rs2056924	ENSG00000280107.1	AL022393.9	-4.46	1.03e-05	0.00105	-0.21	-0.2	Parkinson's disease;	chr6:27722395	chr6:28170845~28172521:+
THCA	cis	rs6012564	0.928	rs8118105	ENSG00000230758.1	SNAP23P	4.46	1.03e-05	0.00105	0.24	0.2	Anger;	chr20:49182127	chr20:49038357~49038602:-
THCA	cis	rs2011503	0.509	rs76347963	ENSG00000271283.1	CTC-412M14.6	4.46	1.03e-05	0.00105	0.33	0.2	Bipolar disorder;	chr19:19669336	chr19:19699203~19699409:-
THCA	cis	rs6664467	1	rs6664467	ENSG00000249602.1	RP11-98D18.3	-4.46	1.03e-05	0.00105	-0.32	-0.2	Carotid plaque burden;	chr1:151765927	chr1:151763384~151769501:-
THCA	cis	rs10484434	0.901	rs62394550	ENSG00000272462.2	U91328.19	4.46	1.03e-05	0.00105	0.21	0.2	HIV-1 viral setpoint;	chr6:26034024	chr6:25992662~26001775:+
THCA	cis	rs1003719	0.762	rs3787780	ENSG00000230366.8	DSCR9	-4.46	1.03e-05	0.00105	-0.2	-0.2	Eye color traits;	chr21:37090314	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs2835599	ENSG00000230366.8	DSCR9	-4.46	1.03e-05	0.00105	-0.2	-0.2	Eye color traits;	chr21:37094637	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.788	rs9977314	ENSG00000230366.8	DSCR9	-4.46	1.03e-05	0.00105	-0.2	-0.2	Eye color traits;	chr21:37099663	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.737	rs9974374	ENSG00000230366.8	DSCR9	-4.46	1.03e-05	0.00105	-0.2	-0.2	Eye color traits;	chr21:37107585	chr21:37208503~37221736:+
THCA	cis	rs1923243	0.681	rs12119161	ENSG00000223479.3	RP4-788P17.1	4.46	1.03e-05	0.00105	0.22	0.2	Migraine;	chr1:73023813	chr1:73635216~73715214:+
THCA	cis	rs17685	0.593	rs56265719	ENSG00000230882.1	AC005077.14	4.46	1.03e-05	0.00105	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76166951	chr7:76071469~76074963:-
THCA	cis	rs2033711	0.84	rs3764533	ENSG00000268049.1	CTD-2619J13.9	-4.46	1.03e-05	0.00105	-0.25	-0.2	Uric acid clearance;	chr19:58417827	chr19:58357999~58359603:+
THCA	cis	rs10090774	0.965	rs4961234	ENSG00000279766.1	RP11-642A1.2	4.46	1.03e-05	0.00105	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830782	chr8:140572142~140572812:-
THCA	cis	rs3806843	0.576	rs251368	ENSG00000202515.1	VTRNA1-3	4.46	1.03e-05	0.00105	0.24	0.2	Depressive symptoms (multi-trait analysis);	chr5:140861442	chr5:140726158~140726246:+
THCA	cis	rs13126694	0.744	rs6821252	ENSG00000248429.4	RP11-597D13.9	4.46	1.03e-05	0.00105	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158076296	chr4:158170752~158202877:+
THCA	cis	rs752010	0.838	rs11210505	ENSG00000230638.4	RP11-486B10.4	-4.46	1.03e-05	0.00105	-0.22	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41639060	chr1:41542069~41544310:+
THCA	cis	rs138249	0.867	rs715616	ENSG00000273253.2	RP3-402G11.26	-4.46	1.03e-05	0.00105	-0.2	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50120076	chr22:50199090~50200837:-
THCA	cis	rs812925	0.537	rs2463097	ENSG00000270820.4	RP11-355B11.2	-4.46	1.03e-05	0.00105	-0.17	-0.2	Immature fraction of reticulocytes;	chr2:61387166	chr2:61471188~61484130:+
THCA	cis	rs2842992	0.958	rs2758318	ENSG00000237927.1	RP3-393E18.2	-4.46	1.03e-05	0.00105	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159648605	chr6:159586955~159589169:-
THCA	cis	rs2842992	1	rs2842992	ENSG00000237927.1	RP3-393E18.2	-4.46	1.03e-05	0.00105	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159650127	chr6:159586955~159589169:-
THCA	cis	rs890448	0.896	rs10433985	ENSG00000254531.1	FLJ20021	-4.46	1.03e-05	0.00105	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101481216	chr4:101347780~101348883:+
THCA	cis	rs890448	0.93	rs9307258	ENSG00000254531.1	FLJ20021	-4.46	1.03e-05	0.00105	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101490196	chr4:101347780~101348883:+
THCA	cis	rs11621975	0.655	rs72715638	ENSG00000259088.1	CTD-2017C7.2	-4.46	1.03e-05	0.00105	-0.4	-0.2	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101784513	chr14:101796555~101810321:-
THCA	cis	rs11621975	0.57	rs45482193	ENSG00000259088.1	CTD-2017C7.2	-4.46	1.03e-05	0.00105	-0.4	-0.2	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101785993	chr14:101796555~101810321:-
THCA	cis	rs7621331	0.963	rs6809006	ENSG00000273486.1	RP11-731C17.2	4.46	1.03e-05	0.00105	0.19	0.2	Waist circumference adjusted for body mass index;	chr3:136012398	chr3:136837338~136839021:-
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000182586.6	LINC00334	-4.46	1.03e-05	0.00105	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45234340~45258730:+
THCA	cis	rs875971	0.862	rs4236208	ENSG00000229886.1	RP5-1132H15.3	-4.46	1.03e-05	0.00105	-0.21	-0.2	Aortic root size;	chr7:66284091	chr7:66025126~66031544:-
THCA	cis	rs10090774	0.965	rs7461251	ENSG00000279766.1	RP11-642A1.2	-4.46	1.03e-05	0.00105	-0.25	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140711689	chr8:140572142~140572812:-
THCA	cis	rs453301	0.624	rs7014430	ENSG00000254153.1	CTA-398F10.2	-4.46	1.03e-05	0.00105	-0.22	-0.2	Joint mobility (Beighton score);	chr8:8970227	chr8:8456909~8461337:-
THCA	cis	rs7772486	0.754	rs9390356	ENSG00000270638.1	RP3-466P17.1	-4.46	1.03e-05	0.00105	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145735570~145737218:+
THCA	cis	rs1009077	0.578	rs6834347	ENSG00000245958.5	RP11-33B1.1	-4.46	1.03e-05	0.00105	-0.23	-0.2	Endometriosis;	chr4:119583524	chr4:119454791~119552025:+
THCA	cis	rs10208649	0.611	rs7583626	ENSG00000233266.1	HMGB1P31	4.46	1.03e-05	0.00105	0.38	0.2	Body mass index;	chr2:54063635	chr2:54051334~54051760:+
THCA	cis	rs5758659	0.714	rs6002626	ENSG00000281538.1	RP4-669P10.20	-4.46	1.03e-05	0.00105	-0.19	-0.2	Cognitive function;	chr22:42121985	chr22:42138060~42139726:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000272831.1	RP11-792A8.4	-4.46	1.03e-05	0.00105	-0.12	-0.2	Aortic root size;	chr7:66619753	chr7:66739829~66740385:-
THCA	cis	rs889398	0.741	rs3790075	ENSG00000226232.7	RP11-419C5.2	-4.46	1.03e-05	0.00105	-0.2	-0.2	Body mass index;	chr16:69873908	chr16:69976388~69996188:-
THCA	cis	rs889398	0.741	rs7190013	ENSG00000226232.7	RP11-419C5.2	-4.46	1.03e-05	0.00105	-0.2	-0.2	Body mass index;	chr16:69874345	chr16:69976388~69996188:-
THCA	cis	rs7520050	0.751	rs592214	ENSG00000281133.1	AL355480.3	4.46	1.03e-05	0.00105	0.23	0.2	Reticulocyte count;Red blood cell count;	chr1:45558833	chr1:45580892~45580996:-
THCA	cis	rs10946940	0.965	rs6456799	ENSG00000216915.2	RP1-97D16.1	4.46	1.03e-05	0.00105	0.27	0.2	Systemic lupus erythematosus;	chr6:27605757	chr6:27737000~27738494:-
THCA	cis	rs72681920	0.541	rs3114045	ENSG00000272777.1	RP11-571L19.8	-4.46	1.03e-05	0.00105	-0.21	-0.2	Alcohol dependence;	chr4:99331403	chr4:99067256~99068125:-
THCA	cis	rs1334894	1	rs72913417	ENSG00000228559.1	RP3-340B19.3	-4.46	1.03e-05	0.00105	-0.43	-0.2	Coronary artery disease;	chr6:35579089	chr6:35544632~35545669:+
THCA	cis	rs2243480	1	rs35542501	ENSG00000232559.3	GS1-124K5.12	4.46	1.03e-05	0.00105	0.29	0.2	Diabetic kidney disease;	chr7:65966228	chr7:66554588~66576923:-
THCA	cis	rs11089937	0.616	rs713644	ENSG00000211639.2	IGLV4-60	4.46	1.03e-05	0.00105	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs713624	ENSG00000211639.2	IGLV4-60	4.46	1.03e-05	0.00105	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22162199~22162681:+
THCA	cis	rs11671005	0.735	rs11668420	ENSG00000268049.1	CTD-2619J13.9	-4.46	1.03e-05	0.00105	-0.31	-0.2	Mean platelet volume;	chr19:58426469	chr19:58357999~58359603:+
THCA	cis	rs7924176	0.601	rs11000882	ENSG00000213731.2	RAB5CP1	-4.46	1.03e-05	0.00105	-0.24	-0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74130145	chr10:74423435~74424014:-
THCA	cis	rs1008126	0.642	rs2382689	ENSG00000234715.1	CTB-107G13.1	-4.46	1.03e-05	0.00105	-0.24	-0.2	Metabolite levels (Pyroglutamine);	chr7:103457010	chr7:103445207~103514007:+
THCA	cis	rs12682352	0.65	rs13265731	ENSG00000248538.5	RP11-10A14.5	-4.46	1.03e-05	0.00105	-0.26	-0.2	Neuroticism;	chr8:8815810	chr8:9189011~9202854:+
THCA	cis	rs728616	0.51	rs35671072	ENSG00000225484.5	NUTM2B-AS1	-4.46	1.03e-05	0.00105	-0.35	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80412499	chr10:79663088~79826594:-
THCA	cis	rs172166	0.516	rs1225710	ENSG00000280107.1	AL022393.9	4.46	1.03e-05	0.00105	0.2	0.2	Cardiac Troponin-T levels;	chr6:28132862	chr6:28170845~28172521:+
THCA	cis	rs6496044	0.568	rs12708554	ENSG00000259630.2	CTD-2262B20.1	-4.46	1.03e-05	0.00105	-0.22	-0.2	Interstitial lung disease;	chr15:85531066	chr15:85415228~85415633:+
THCA	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-4.46	1.03e-05	0.00105	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-4.46	1.03e-05	0.00105	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-4.46	1.03e-05	0.00105	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
THCA	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-4.46	1.03e-05	0.00105	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
THCA	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-4.46	1.03e-05	0.00105	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
THCA	cis	rs6088590	0.561	rs2295444	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.03e-05	0.00105	-0.17	-0.2	Coronary artery disease;	chr20:34586079	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.561	rs6059932	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.03e-05	0.00105	-0.17	-0.2	Coronary artery disease;	chr20:34587662	chr20:33985617~33988989:-
THCA	cis	rs2439831	0.681	rs28594657	ENSG00000205771.5	CATSPER2P1	-4.46	1.03e-05	0.00105	-0.31	-0.2	Lung cancer in ever smokers;	chr15:43296690	chr15:43726918~43747094:-
THCA	cis	rs496547	0.686	rs591756	ENSG00000255422.1	AP002954.4	-4.46	1.03e-05	0.00105	-0.21	-0.2	Hip minimal joint space width;	chr11:118808172	chr11:118704607~118750263:+
THCA	cis	rs250518	0.926	rs11747669	ENSG00000272081.1	CTD-2376I4.2	4.46	1.03e-05	0.00105	0.26	0.2	Mean corpuscular hemoglobin concentration;	chr5:72760354	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs6897924	ENSG00000272081.1	CTD-2376I4.2	4.46	1.03e-05	0.00105	0.26	0.2	Mean corpuscular hemoglobin concentration;	chr5:72765713	chr5:72955206~72955699:-
THCA	cis	rs250518	0.926	rs2338791	ENSG00000272081.1	CTD-2376I4.2	4.46	1.03e-05	0.00105	0.26	0.2	Mean corpuscular hemoglobin concentration;	chr5:72770970	chr5:72955206~72955699:-
THCA	cis	rs2905347	0.737	rs756879	ENSG00000232949.1	AC002480.4	-4.46	1.03e-05	0.00105	-0.26	-0.2	Major depression and alcohol dependence;	chr7:22594386	chr7:22589705~22591622:+
THCA	cis	rs6012564	0.964	rs6063371	ENSG00000230758.1	SNAP23P	4.46	1.03e-05	0.00105	0.25	0.2	Anger;	chr20:49202768	chr20:49038357~49038602:-
THCA	cis	rs2562456	0.793	rs61445561	ENSG00000268117.1	VN1R84P	4.46	1.03e-05	0.00105	0.33	0.2	Pain;	chr19:21321230	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs57299552	ENSG00000268117.1	VN1R84P	4.46	1.03e-05	0.00105	0.33	0.2	Pain;	chr19:21321326	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.754	rs76688173	ENSG00000268117.1	VN1R84P	4.46	1.03e-05	0.00105	0.33	0.2	Pain;	chr19:21321856	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs74711277	ENSG00000268117.1	VN1R84P	4.46	1.03e-05	0.00105	0.33	0.2	Pain;	chr19:21322641	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62107479	ENSG00000268117.1	VN1R84P	4.46	1.03e-05	0.00105	0.33	0.2	Pain;	chr19:21323962	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62107531	ENSG00000268117.1	VN1R84P	4.46	1.03e-05	0.00105	0.33	0.2	Pain;	chr19:21326263	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs55756795	ENSG00000268117.1	VN1R84P	4.46	1.03e-05	0.00105	0.33	0.2	Pain;	chr19:21327257	chr19:21719801~21720035:-
THCA	cis	rs763121	0.853	rs2267393	ENSG00000228274.3	RP3-508I15.9	-4.46	1.03e-05	0.00106	-0.22	-0.2	Menopause (age at onset);	chr22:38705614	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2267394	ENSG00000228274.3	RP3-508I15.9	-4.46	1.03e-05	0.00106	-0.22	-0.2	Menopause (age at onset);	chr22:38705628	chr22:38667585~38681820:-
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000234585.5	CCT6P3	4.46	1.03e-05	0.00106	0.18	0.2	Calcium levels;	chr7:65903721	chr7:65038354~65074713:+
THCA	cis	rs2018683	0.707	rs917219	ENSG00000272568.4	CTB-113D17.1	4.46	1.03e-05	0.00106	0.2	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935726	chr7:28979967~29013367:+
THCA	cis	rs13113518	1	rs7660980	ENSG00000249700.7	SRD5A3-AS1	-4.46	1.03e-05	0.00106	-0.25	-0.2	Height;	chr4:55542948	chr4:55363971~55395847:-
THCA	cis	rs6088590	0.523	rs6058084	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.03e-05	0.00106	-0.17	-0.2	Coronary artery disease;	chr20:34596000	chr20:33985617~33988989:-
THCA	cis	rs8067545	1	rs8071730	ENSG00000270091.1	RP11-78O7.2	-4.46	1.03e-05	0.00106	-0.15	-0.2	Schizophrenia;	chr17:20029418	chr17:19896590~19897287:-
THCA	cis	rs9487094	0.666	rs4946967	ENSG00000223537.2	RP5-919F19.5	-4.46	1.03e-05	0.00106	-0.2	-0.2	Height;	chr6:109357369	chr6:109487906~109506800:+
THCA	cis	rs6121246	0.559	rs6058462	ENSG00000230613.1	HM13-AS1	4.46	1.03e-05	0.00106	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31779871	chr20:31567707~31573263:-
THCA	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	4.46	1.03e-05	0.00106	0.23	0.2	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	4.46	1.03e-05	0.00106	0.23	0.2	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	4.46	1.03e-05	0.00106	0.23	0.2	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	4.46	1.03e-05	0.00106	0.23	0.2	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	4.46	1.03e-05	0.00106	0.23	0.2	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
THCA	cis	rs9494145	0.526	rs6924687	ENSG00000232876.1	CTA-212D2.2	-4.46	1.03e-05	0.00106	-0.3	-0.2	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135146383	chr6:135055033~135060550:+
THCA	cis	rs2337406	0.538	rs10141701	ENSG00000211974.3	IGHV2-70	-4.46	1.03e-05	0.00106	-0.18	-0.2	Alzheimer's disease (late onset);	chr14:106633467	chr14:106723574~106724093:-
THCA	cis	rs10435719	0.746	rs58007588	ENSG00000254948.1	OR7E158P	-4.46	1.03e-05	0.00106	-0.25	-0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:11919900~11920809:-
THCA	cis	rs7829975	0.591	rs12677543	ENSG00000253981.4	ALG1L13P	4.46	1.03e-05	0.00106	0.19	0.2	Mood instability;	chr8:8786764	chr8:8236003~8244667:-
THCA	cis	rs793571	0.503	rs1427281	ENSG00000245975.2	RP11-30K9.6	4.46	1.03e-05	0.00106	0.2	0.2	Schizophrenia;	chr15:58667074	chr15:58768072~58770974:-
THCA	cis	rs7267979	1	rs2482930	ENSG00000274973.1	RP13-401N8.7	4.46	1.03e-05	0.00106	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2500446	ENSG00000274973.1	RP13-401N8.7	4.46	1.03e-05	0.00106	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2482937	ENSG00000274973.1	RP13-401N8.7	4.46	1.03e-05	0.00106	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25845497~25845862:+
THCA	cis	rs9863	0.931	rs4930721	ENSG00000270061.1	RP11-214K3.19	-4.46	1.03e-05	0.00106	-0.28	-0.2	White blood cell count;	chr12:123933342	chr12:123969990~123970344:-
THCA	cis	rs5758659	0.714	rs5751220	ENSG00000281538.1	RP4-669P10.20	-4.46	1.03e-05	0.00106	-0.19	-0.2	Cognitive function;	chr22:42120201	chr22:42138060~42139726:+
THCA	cis	rs2070488	0.965	rs2366119	ENSG00000229589.1	ACVR2B-AS1	4.46	1.04e-05	0.00106	0.19	0.2	Electrocardiographic conduction measures;	chr3:38442962	chr3:38451027~38454820:-
THCA	cis	rs62025270	0.688	rs7179917	ENSG00000259295.5	CSPG4P12	-4.46	1.04e-05	0.00106	-0.35	-0.2	Idiopathic pulmonary fibrosis;	chr15:85722413	chr15:85191438~85213905:+
THCA	cis	rs1150668	0.796	rs728122	ENSG00000280107.1	AL022393.9	-4.46	1.04e-05	0.00106	-0.19	-0.2	Pubertal anthropometrics;	chr6:28431347	chr6:28170845~28172521:+
THCA	cis	rs2657294	0.761	rs1259498	ENSG00000226051.5	ZNF503-AS1	-4.46	1.04e-05	0.00106	-0.28	-0.2	Pneumonia;	chr10:75226983	chr10:75269819~75373500:+
THCA	cis	rs9595908	0.785	rs969703	ENSG00000212293.1	SNORA16	4.46	1.04e-05	0.00106	0.23	0.2	Body mass index;	chr13:32708264	chr13:32420390~32420516:-
THCA	cis	rs12410462	0.551	rs12092295	ENSG00000227711.2	RP11-275O4.5	-4.46	1.04e-05	0.00106	-0.24	-0.2	Major depressive disorder;	chr1:227648590	chr1:227509028~227520477:-
THCA	cis	rs2235642	0.505	rs56359342	ENSG00000280231.1	LA16c-380F5.3	-4.46	1.04e-05	0.00106	-0.25	-0.2	Coronary artery disease;	chr16:1604947	chr16:1553655~1554130:-
THCA	cis	rs6701713	0.959	rs1830763	ENSG00000274245.1	RP11-357P18.2	-4.46	1.04e-05	0.00106	-0.24	-0.2	Alzheimer's disease (late onset);	chr1:207627044	chr1:207372559~207373252:+
THCA	cis	rs6701713	0.959	rs1408078	ENSG00000274245.1	RP11-357P18.2	-4.46	1.04e-05	0.00106	-0.24	-0.2	Alzheimer's disease (late onset);	chr1:207627210	chr1:207372559~207373252:+
THCA	cis	rs6496044	0.507	rs7175731	ENSG00000259276.1	RP11-815J21.3	4.46	1.04e-05	0.00106	0.23	0.2	Interstitial lung disease;	chr15:85611115	chr15:85621264~85627689:-
THCA	cis	rs9309473	0.95	rs6726694	ENSG00000273245.1	RP11-434P11.2	4.46	1.04e-05	0.00106	0.27	0.2	Metabolite levels;	chr2:73620103	chr2:73750256~73750786:-
THCA	cis	rs9902453	0.933	rs7221154	ENSG00000263370.1	RP11-68I3.5	-4.46	1.04e-05	0.00106	-0.25	-0.2	Coffee consumption (cups per day);	chr17:30178006	chr17:29639627~29640825:+
THCA	cis	rs526231	0.736	rs6886092	ENSG00000175749.11	EIF3KP1	4.46	1.04e-05	0.00106	0.26	0.2	Primary biliary cholangitis;	chr5:103298328	chr5:103032376~103033031:+
THCA	cis	rs6416877	0.704	rs7208768	ENSG00000277491.1	RP11-676J12.9	-4.46	1.04e-05	0.00106	-0.22	-0.2	Myeloid white cell count;	chr17:1449407	chr17:795306~795794:+
THCA	cis	rs375066	0.935	rs417699	ENSG00000278917.1	RP11-15A1.4	-4.46	1.04e-05	0.00106	-0.17	-0.2	Breast cancer;	chr19:43913423	chr19:43891233~43895411:+
THCA	cis	rs2439831	1	rs689826	ENSG00000205771.5	CATSPER2P1	-4.46	1.04e-05	0.00106	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43457718	chr15:43726918~43747094:-
THCA	cis	rs4218	0.871	rs2414621	ENSG00000259732.1	RP11-59H7.3	-4.46	1.04e-05	0.00106	-0.28	-0.2	Social communication problems;	chr15:59142129	chr15:59121034~59133250:+
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000229886.1	RP5-1132H15.3	4.46	1.04e-05	0.00106	0.24	0.2	Corneal structure;	chr7:66950082	chr7:66025126~66031544:-
THCA	cis	rs4711890	1	rs4711890	ENSG00000270761.1	RP11-385F7.1	-4.46	1.04e-05	0.00106	-0.16	-0.2	Platelet count;	chr6:47638976	chr6:47477243~47477572:-
THCA	cis	rs13113518	1	rs9312661	ENSG00000249700.7	SRD5A3-AS1	4.46	1.04e-05	0.00106	0.25	0.2	Height;	chr4:55476159	chr4:55363971~55395847:-
THCA	cis	rs2281603	0.57	rs10134530	ENSG00000272909.1	CTD-2555O16.4	4.46	1.04e-05	0.00106	0.23	0.2	Lymphocyte counts;	chr14:64484240	chr14:64440369~64442238:-
THCA	cis	rs7511006	0.893	rs5771104	ENSG00000272836.1	RP3-402G11.27	-4.46	1.04e-05	0.00106	-0.16	-0.2	Obesity-related traits;	chr22:50213410	chr22:50205585~50206062:-
THCA	cis	rs7824557	0.544	rs1865521	ENSG00000206014.6	OR7E161P	-4.46	1.04e-05	0.00106	-0.23	-0.2	Retinal vascular caliber;	chr8:11373740	chr8:11928597~11929563:-
THCA	cis	rs734999	0.588	rs2260976	ENSG00000225931.3	RP3-395M20.7	-4.46	1.04e-05	0.00106	-0.24	-0.2	Ulcerative colitis;	chr1:2596239	chr1:2566410~2569888:+
THCA	cis	rs1728785	1	rs698717	ENSG00000274698.1	RP11-71L14.4	4.46	1.04e-05	0.00106	0.29	0.2	Ulcerative colitis;	chr16:68526296	chr16:68450283~68452318:+
THCA	cis	rs5758511	0.731	rs58302269	ENSG00000281538.1	RP4-669P10.20	-4.46	1.04e-05	0.00106	-0.24	-0.2	Birth weight;	chr22:41955305	chr22:42138060~42139726:+
THCA	cis	rs858239	0.539	rs4559148	ENSG00000230042.1	AK3P3	-4.46	1.04e-05	0.00106	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23129178~23129841:+
THCA	cis	rs858239	0.539	rs4377861	ENSG00000230042.1	AK3P3	-4.46	1.04e-05	0.00106	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23129178~23129841:+
THCA	cis	rs1124769	0.719	rs58137325	ENSG00000259378.1	DCAF13P3	4.46	1.04e-05	0.00106	0.31	0.2	Cognitive performance;	chr15:50922186	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs2663557	ENSG00000259378.1	DCAF13P3	-4.46	1.04e-05	0.00106	-0.31	-0.2	Cognitive performance;	chr15:50921427	chr15:50944663~50945996:+
THCA	cis	rs2281603	0.57	rs11627387	ENSG00000259116.1	RP11-973N13.4	-4.46	1.04e-05	0.00106	-0.17	-0.2	Lymphocyte counts;	chr14:64457259	chr14:64514154~64540368:-
THCA	cis	rs12681963	0.688	rs4733429	ENSG00000248159.1	HSPA8P11	4.46	1.04e-05	0.00106	0.37	0.2	Migraine;	chr8:30203643	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs4733431	ENSG00000248159.1	HSPA8P11	4.46	1.04e-05	0.00106	0.37	0.2	Migraine;	chr8:30203919	chr8:30237382~30240997:+
THCA	cis	rs4144027	0.904	rs55696130	ENSG00000269958.1	RP11-73M18.8	-4.46	1.04e-05	0.00106	-0.19	-0.2	Blood metabolite levels;	chr14:103875527	chr14:103696353~103697163:+
THCA	cis	rs4648045	0.687	rs1020760	ENSG00000246560.2	RP11-10L12.4	4.46	1.04e-05	0.00106	0.24	0.2	Lymphocyte percentage of white cells;	chr4:102593288	chr4:102828055~102844075:+
THCA	cis	rs9863	0.861	rs12301673	ENSG00000270061.1	RP11-214K3.19	-4.46	1.04e-05	0.00106	-0.26	-0.2	White blood cell count;	chr12:123971271	chr12:123969990~123970344:-
THCA	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-4.46	1.04e-05	0.00106	-0.26	-0.2	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
THCA	cis	rs11180559	1	rs11180559	ENSG00000257497.2	RP11-585P4.5	4.46	1.04e-05	0.00106	0.35	0.2	Daytime sleep phenotypes;	chr12:75526505	chr12:75483454~75489820:-
THCA	cis	rs6088590	0.93	rs6120723	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00106	-0.19	-0.2	Coronary artery disease;	chr20:34776852	chr20:33985617~33988989:-
THCA	cis	rs6088590	1	rs6119524	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00106	-0.19	-0.2	Coronary artery disease;	chr20:34786010	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.965	rs6120727	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00106	-0.19	-0.2	Coronary artery disease;	chr20:34786299	chr20:33985617~33988989:-
THCA	cis	rs6088590	1	rs28542147	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00106	-0.19	-0.2	Coronary artery disease;	chr20:34788520	chr20:33985617~33988989:-
THCA	cis	rs6088590	1	rs6088607	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00106	-0.19	-0.2	Coronary artery disease;	chr20:34790930	chr20:33985617~33988989:-
THCA	cis	rs2590942	0.583	rs2821235	ENSG00000227207.2	RPL31P12	4.46	1.04e-05	0.00106	0.35	0.2	Childhood body mass index;	chr1:72133487	chr1:72301472~72301829:+
THCA	cis	rs8192917	0.573	rs10139232	ENSG00000258744.1	RP11-80A15.1	-4.46	1.04e-05	0.00106	-0.34	-0.2	Vitiligo;	chr14:24654597	chr14:24501594~24508688:+
THCA	cis	rs6570726	0.791	rs9403734	ENSG00000270638.1	RP3-466P17.1	4.46	1.04e-05	0.00106	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145735570~145737218:+
THCA	cis	rs2562456	0.833	rs4321312	ENSG00000268117.1	VN1R84P	4.46	1.04e-05	0.00106	0.32	0.2	Pain;	chr19:21336614	chr19:21719801~21720035:-
THCA	cis	rs10090774	0.71	rs13278258	ENSG00000280303.2	ERICD	-4.46	1.04e-05	0.00106	-0.19	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140675675	chr8:140636281~140638283:+
THCA	cis	rs6121246	0.511	rs879982	ENSG00000230613.1	HM13-AS1	4.46	1.04e-05	0.00106	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31810707	chr20:31567707~31573263:-
THCA	cis	rs4722166	0.532	rs1880242	ENSG00000179428.2	AC073072.5	4.46	1.04e-05	0.00106	0.22	0.2	Lung cancer;	chr7:22719988	chr7:22725395~22727620:-
THCA	cis	rs9307551	0.817	rs13127970	ENSG00000249646.2	OR7E94P	-4.46	1.04e-05	0.00106	-0.26	-0.2	Refractive error;	chr4:79581236	chr4:79587302~79588130:-
THCA	cis	rs2135507	0.532	rs993380	ENSG00000270480.1	RP11-57B24.1	-4.46	1.04e-05	0.00106	-0.27	-0.2	Juvenile osteochondritis dissecans;	chr4:82663343	chr4:82691737~82692468:+
THCA	cis	rs76878669	0.917	rs10896110	ENSG00000255320.1	RP11-755F10.1	4.46	1.04e-05	0.00106	0.29	0.2	Educational attainment (years of education);	chr11:66334507	chr11:66244840~66246239:-
THCA	cis	rs4693089	0.604	rs13115704	ENSG00000213608.5	SLC25A14P1	4.46	1.04e-05	0.00106	0.23	0.2	Menopause (age at onset);	chr4:83466281	chr4:83477524~83478424:+
THCA	cis	rs13113518	1	rs4864547	ENSG00000249700.7	SRD5A3-AS1	4.46	1.04e-05	0.00106	0.25	0.2	Height;	chr4:55538228	chr4:55363971~55395847:-
THCA	cis	rs9329221	0.678	rs560638	ENSG00000261451.1	RP11-981G7.1	-4.46	1.04e-05	0.00106	-0.25	-0.2	Neuroticism;	chr8:10025257	chr8:10433672~10438312:+
THCA	cis	rs6449502	0.541	rs9291707	ENSG00000251279.1	CTC-436P18.1	4.46	1.04e-05	0.00106	0.37	0.2	Mean platelet volume;	chr5:61180399	chr5:61162070~61232040:+
THCA	cis	rs6745190	0.575	rs6706397	ENSG00000236153.1	AC104076.3	-4.46	1.04e-05	0.00106	-0.23	-0.2	White blood cell count;	chr2:181107073	chr2:180979427~180980090:-
THCA	cis	rs12478296	1	rs6732595	ENSG00000220804.7	AC093642.5	4.46	1.04e-05	0.00106	0.22	0.2	Obesity-related traits;	chr2:242093187	chr2:242088633~242160153:+
THCA	cis	rs17095355	1	rs61614979	ENSG00000203876.8	ADD3-AS1	-4.46	1.04e-05	0.00106	-0.21	-0.2	Biliary atresia;	chr10:109984236	chr10:109940104~110008381:-
THCA	cis	rs138453830	1	rs138453830	ENSG00000261485.1	PAN3-AS1	4.46	1.04e-05	0.00106	0.32	0.2	Hepcidin/transferrin saturation ratio;	chr13:28164927	chr13:28136843~28138193:-
THCA	cis	rs9309473	0.5	rs4852953	ENSG00000273245.1	RP11-434P11.2	-4.46	1.04e-05	0.00106	-0.24	-0.2	Metabolite levels;	chr2:73642781	chr2:73750256~73750786:-
THCA	cis	rs17095355	1	rs12265204	ENSG00000203876.8	ADD3-AS1	-4.46	1.04e-05	0.00106	-0.22	-0.2	Biliary atresia;	chr10:109992405	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs958086	ENSG00000203876.8	ADD3-AS1	-4.46	1.04e-05	0.00106	-0.22	-0.2	Biliary atresia;	chr10:109992790	chr10:109940104~110008381:-
THCA	cis	rs10761482	0.861	rs10994310	ENSG00000254271.1	RP11-131N11.4	-4.46	1.04e-05	0.00106	-0.27	-0.2	Schizophrenia;	chr10:60346411	chr10:60734342~60741828:+
THCA	cis	rs10484434	0.792	rs11961143	ENSG00000272462.2	U91328.19	4.46	1.04e-05	0.00106	0.21	0.2	HIV-1 viral setpoint;	chr6:26032645	chr6:25992662~26001775:+
THCA	cis	rs4713118	0.539	rs510987	ENSG00000261839.1	RP1-265C24.8	4.46	1.04e-05	0.00106	0.22	0.2	Parkinson's disease;	chr6:27879739	chr6:28136849~28139678:+
THCA	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	4.46	1.04e-05	0.00106	0.23	0.2	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	4.46	1.04e-05	0.00106	0.23	0.2	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	4.46	1.04e-05	0.00106	0.23	0.2	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
THCA	cis	rs73108077	0.736	rs6060596	ENSG00000277112.2	RP11-755J8.1	-4.46	1.04e-05	0.00107	-0.33	-0.2	Red blood cell density in sickle cell anemia;	chr20:31261457	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs6060617	ENSG00000277112.2	RP11-755J8.1	-4.46	1.04e-05	0.00107	-0.33	-0.2	Red blood cell density in sickle cell anemia;	chr20:31261849	chr20:30681825~30723932:-
THCA	cis	rs6088590	0.561	rs6088527	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00107	-0.17	-0.2	Coronary artery disease;	chr20:34568037	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.561	rs6087600	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00107	-0.17	-0.2	Coronary artery disease;	chr20:34569413	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.561	rs6059926	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00107	-0.17	-0.2	Coronary artery disease;	chr20:34577000	chr20:33985617~33988989:-
THCA	cis	rs6088580	0.713	rs1884669	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00107	-0.17	-0.2	Glomerular filtration rate (creatinine);	chr20:34583483	chr20:33985617~33988989:-
THCA	cis	rs79040073	1	rs79040073	ENSG00000259531.2	RP11-295H24.3	4.46	1.04e-05	0.00107	0.26	0.2	Lung cancer in ever smokers;	chr15:49038657	chr15:49365124~49366685:-
THCA	cis	rs4648045	0.687	rs230541	ENSG00000246560.2	RP11-10L12.4	-4.46	1.04e-05	0.00107	-0.24	-0.2	Lymphocyte percentage of white cells;	chr4:102576628	chr4:102828055~102844075:+
THCA	cis	rs11976180	1	rs11976180	ENSG00000244198.4	RP4-545C24.1	-4.46	1.04e-05	0.00107	-0.21	-0.2	Obesity-related traits;	chr7:144044487	chr7:144194858~144280547:+
THCA	cis	rs2787702	0.857	rs2245309	ENSG00000237233.2	TMEM26-AS1	-4.46	1.04e-05	0.00107	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61587934	chr10:61452639~61481956:+
THCA	cis	rs911555	0.723	rs11160751	ENSG00000269910.1	RP11-73M18.10	4.46	1.04e-05	0.00107	0.18	0.2	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103694516~103695050:-
THCA	cis	rs6088590	0.561	rs6087605	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00107	-0.17	-0.2	Coronary artery disease;	chr20:34592820	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.523	rs6088536	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.04e-05	0.00107	-0.17	-0.2	Coronary artery disease;	chr20:34601302	chr20:33985617~33988989:-
THCA	cis	rs722599	0.748	rs11623342	ENSG00000279594.1	RP11-950C14.10	-4.46	1.04e-05	0.00107	-0.21	-0.2	IgG glycosylation;	chr14:74881234	chr14:75011269~75012851:-
THCA	cis	rs7115242	0.669	rs1241658	ENSG00000280143.1	AP000892.6	4.46	1.04e-05	0.00107	0.33	0.2	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117204967~117210292:+
THCA	cis	rs11658311	0.85	rs9912678	ENSG00000232344.2	AC087163.2	4.46	1.04e-05	0.00107	0.26	0.2	Obsessive-compulsive symptoms;	chr17:17643398	chr17:18010643~18011822:+
THCA	cis	rs2284219	0.565	rs2284217	ENSG00000264520.1	RP4-777O23.2	-4.46	1.05e-05	0.00107	-0.2	-0.2	Type 2 diabetes;	chr7:30673992	chr7:30525731~30533613:+
THCA	cis	rs2787702	0.825	rs2606109	ENSG00000237233.2	TMEM26-AS1	-4.46	1.05e-05	0.00107	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61587101	chr10:61452639~61481956:+
THCA	cis	rs10043228	1	rs76292674	ENSG00000248445.4	SEMA6A-AS1	-4.46	1.05e-05	0.00107	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116289563	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs76414143	ENSG00000248445.4	SEMA6A-AS1	-4.46	1.05e-05	0.00107	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116289699	chr5:116447547~116508276:+
THCA	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-4.46	1.05e-05	0.00107	-0.23	-0.2	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
THCA	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-4.46	1.05e-05	0.00107	-0.23	-0.2	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-4.46	1.05e-05	0.00107	-0.23	-0.2	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-4.46	1.05e-05	0.00107	-0.23	-0.2	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
THCA	cis	rs4819052	0.851	rs2236445	ENSG00000273796.1	LL21NC02-21A1.1	-4.46	1.05e-05	0.00107	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45403809~45404369:-
THCA	cis	rs12546962	1	rs12546962	ENSG00000254153.1	CTA-398F10.2	-4.46	1.05e-05	0.00107	-0.24	-0.2	Body mass index;	chr8:9340675	chr8:8456909~8461337:-
THCA	cis	rs7560272	0.501	rs7210	ENSG00000273245.1	RP11-434P11.2	-4.46	1.05e-05	0.00107	-0.23	-0.2	Schizophrenia;	chr2:73729997	chr2:73750256~73750786:-
THCA	cis	rs4591358	0.654	rs6745113	ENSG00000223466.1	AC064834.2	-4.46	1.05e-05	0.00107	-0.24	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195505888	chr2:195533035~195538681:+
THCA	cis	rs6477918	0.598	rs10981407	ENSG00000230185.4	C9orf147	4.46	1.05e-05	0.00107	0.22	0.2	Obstetric antiphospholipid syndrome;	chr9:112444295	chr9:112433816~112487204:-
THCA	cis	rs8192917	0.573	rs55964774	ENSG00000258744.1	RP11-80A15.1	-4.46	1.05e-05	0.00107	-0.4	-0.2	Vitiligo;	chr14:24659508	chr14:24501594~24508688:+
THCA	cis	rs2717559	0.541	rs34497317	ENSG00000253741.1	CTD-2292P10.4	4.46	1.05e-05	0.00107	0.26	0.2	Urinary tract infection frequency;	chr8:142807637	chr8:142702252~142726973:-
THCA	cis	rs7246657	0.509	rs10426093	ENSG00000226686.6	LINC01535	-4.46	1.05e-05	0.00107	-0.35	-0.2	Coronary artery calcification;	chr19:37124727	chr19:37251912~37265535:+
THCA	cis	rs3734266	0.702	rs35141641	ENSG00000272288.4	RP11-140K17.3	-4.46	1.05e-05	0.00107	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34769175	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.639	rs9968782	ENSG00000272288.4	RP11-140K17.3	-4.46	1.05e-05	0.00107	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34769177	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs11968954	ENSG00000272288.4	RP11-140K17.3	-4.46	1.05e-05	0.00107	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34773397	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs35081279	ENSG00000272288.4	RP11-140K17.3	-4.46	1.05e-05	0.00107	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34776999	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs67622212	ENSG00000272288.4	RP11-140K17.3	-4.46	1.05e-05	0.00107	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34782255	chr6:34696317~34697470:+
THCA	cis	rs6845263	0.546	rs10018084	ENSG00000254531.1	FLJ20021	-4.46	1.05e-05	0.00107	-0.17	-0.2	Superior crus of antihelix expression;	chr4:101530682	chr4:101347780~101348883:+
THCA	cis	rs3796352	0.667	rs11720228	ENSG00000242142.1	SERBP1P3	-4.46	1.05e-05	0.00107	-0.36	-0.2	Immune reponse to smallpox (secreted IL-2);	chr3:52843254	chr3:53064283~53065091:-
THCA	cis	rs9902453	0.904	rs7208579	ENSG00000263370.1	RP11-68I3.5	4.46	1.05e-05	0.00107	0.26	0.2	Coffee consumption (cups per day);	chr17:29936049	chr17:29639627~29640825:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000272831.1	RP11-792A8.4	-4.46	1.05e-05	0.00107	-0.13	-0.2	Aortic root size;	chr7:66633495	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs1860470	ENSG00000272831.1	RP11-792A8.4	-4.46	1.05e-05	0.00107	-0.13	-0.2	Aortic root size;	chr7:66638707	chr7:66739829~66740385:-
THCA	cis	rs5751901	0.614	rs5760485	ENSG00000215481.7	BCRP3	-4.46	1.05e-05	0.00107	-0.18	-0.2	Protein quantitative trait loci;	chr22:24590505	chr22:24632915~24653356:+
THCA	cis	rs72843506	0.722	rs9908032	ENSG00000261033.1	RP11-209D14.2	4.46	1.05e-05	0.00107	0.36	0.2	Schizophrenia;	chr17:20204871	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.722	rs12051550	ENSG00000261033.1	RP11-209D14.2	4.46	1.05e-05	0.00107	0.36	0.2	Schizophrenia;	chr17:20226233	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.722	rs75226250	ENSG00000261033.1	RP11-209D14.2	4.46	1.05e-05	0.00107	0.36	0.2	Schizophrenia;	chr17:20229004	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.722	rs9901484	ENSG00000261033.1	RP11-209D14.2	4.46	1.05e-05	0.00107	0.36	0.2	Schizophrenia;	chr17:20229581	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.722	rs78477504	ENSG00000261033.1	RP11-209D14.2	4.46	1.05e-05	0.00107	0.36	0.2	Schizophrenia;	chr17:20235034	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.656	rs16959946	ENSG00000261033.1	RP11-209D14.2	4.46	1.05e-05	0.00107	0.36	0.2	Schizophrenia;	chr17:20269134	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.722	rs76309839	ENSG00000261033.1	RP11-209D14.2	4.46	1.05e-05	0.00107	0.36	0.2	Schizophrenia;	chr17:20272147	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.652	rs28550747	ENSG00000261033.1	RP11-209D14.2	4.46	1.05e-05	0.00107	0.36	0.2	Schizophrenia;	chr17:20274999	chr17:20008051~20009234:-
THCA	cis	rs1815787	1	rs1815787	ENSG00000280143.1	AP000892.6	4.46	1.05e-05	0.00107	0.32	0.2	Subjective well-being;	chr11:117050681	chr11:117204967~117210292:+
THCA	cis	rs2120243	0.539	rs12629552	ENSG00000241770.1	RP11-555M1.3	-4.46	1.05e-05	0.00107	-0.26	-0.2	Hepatocellular carcinoma in hepatitis B infection;	chr3:157368841	chr3:157163452~157169133:+
THCA	cis	rs301901	0.895	rs292172	ENSG00000250155.1	CTD-2353F22.1	-4.46	1.05e-05	0.00107	-0.2	-0.2	Height;	chr5:36817237	chr5:36666214~36725195:-
THCA	cis	rs7615952	0.609	rs13088451	ENSG00000272840.1	RP11-379B18.6	4.46	1.05e-05	0.00107	0.32	0.2	Blood pressure (smoking interaction);	chr3:125834656	chr3:125774714~125797953:+
THCA	cis	rs736408	0.609	rs2230535	ENSG00000243224.1	RP5-1157M23.2	-4.46	1.05e-05	0.00107	-0.22	-0.2	Bipolar disorder;	chr3:52766268	chr3:52239258~52241097:+
THCA	cis	rs9595908	0.785	rs4120131	ENSG00000212293.1	SNORA16	-4.46	1.05e-05	0.00107	-0.23	-0.2	Body mass index;	chr13:32702949	chr13:32420390~32420516:-
THCA	cis	rs1124769	0.57	rs2663552	ENSG00000259378.1	DCAF13P3	4.46	1.05e-05	0.00107	0.28	0.2	Cognitive performance;	chr15:50839973	chr15:50944663~50945996:+
THCA	cis	rs5742933	0.948	rs10195109	ENSG00000273240.1	RP11-455J20.3	4.46	1.05e-05	0.00107	0.23	0.2	Ferritin levels;	chr2:189704465	chr2:189763859~189764456:-
THCA	cis	rs6973609	0.597	rs34067996	ENSG00000271122.1	RP11-379H18.1	4.46	1.05e-05	0.00107	0.14	0.2	Obesity-related traits;	chr7:35569148	chr7:35695214~35699413:+
THCA	cis	rs2303282	0.664	rs4238787	ENSG00000274031.1	RP11-413H22.3	-4.46	1.05e-05	0.00107	-0.24	-0.2	Breast cancer;	chr16:56408154	chr16:56465642~56466162:-
THCA	cis	rs59868192	0.925	rs7183879	ENSG00000246740.2	PLA2G4E-AS1	4.46	1.05e-05	0.00107	0.38	0.2	White blood cell count;	chr15:41968258	chr15:41972763~41999094:+
THCA	cis	rs1707322	1	rs6671754	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs6666763	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4489497	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211235	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.893	rs9919275	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211236	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4660328	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.928	rs61785614	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs9793167	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211237	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs11211238	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4460583	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.963	rs4459051	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211239	ENSG00000281133.1	AL355480.3	-4.46	1.05e-05	0.00107	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45580892~45580996:-
THCA	cis	rs7746199	0.736	rs13209332	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs34105070	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.673	rs72845046	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs67652222	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs13212093	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs34038546	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28078792~28081130:-
THCA	cis	rs141342723	1	rs141342723	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs34543938	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs56405707	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs13210634	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs13215275	ENSG00000272009.1	RP1-313I6.12	-4.46	1.05e-05	0.00107	-0.39	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28078792~28081130:-
THCA	cis	rs9467773	0.935	rs4573	ENSG00000261353.1	CTA-14H9.5	-4.45	1.05e-05	0.00107	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26527063~26527404:+
THCA	cis	rs7560272	0.501	rs12713793	ENSG00000273245.1	RP11-434P11.2	-4.45	1.05e-05	0.00107	-0.23	-0.2	Schizophrenia;	chr2:73728987	chr2:73750256~73750786:-
THCA	cis	rs4788815	1	rs4788815	ENSG00000260886.1	TAT-AS1	4.45	1.05e-05	0.00107	0.26	0.2	Metabolite levels;	chr16:71600908	chr16:71565789~71578187:+
THCA	cis	rs17597773	0.674	rs12073837	ENSG00000238078.1	LINC01352	-4.45	1.05e-05	0.00107	-0.28	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220836863	chr1:220829255~220832429:+
THCA	cis	rs17597773	0.674	rs11118619	ENSG00000238078.1	LINC01352	-4.45	1.05e-05	0.00107	-0.28	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220838921	chr1:220829255~220832429:+
THCA	cis	rs858239	0.6	rs4321896	ENSG00000226816.2	AC005082.12	4.45	1.05e-05	0.00107	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs59073109	ENSG00000226816.2	AC005082.12	4.45	1.05e-05	0.00107	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs7788821	ENSG00000226816.2	AC005082.12	4.45	1.05e-05	0.00107	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs6956595	ENSG00000226816.2	AC005082.12	4.45	1.05e-05	0.00107	0.29	0.2	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23206013~23208045:+
THCA	cis	rs889398	1	rs889398	ENSG00000226232.7	RP11-419C5.2	4.45	1.05e-05	0.00107	0.2	0.2	Body mass index;	chr16:69522812	chr16:69976388~69996188:-
THCA	cis	rs9902453	0.845	rs7209622	ENSG00000263370.1	RP11-68I3.5	4.45	1.05e-05	0.00107	0.26	0.2	Coffee consumption (cups per day);	chr17:29929789	chr17:29639627~29640825:+
THCA	cis	rs467650	1	rs467650	ENSG00000246763.5	RGMB-AS1	4.45	1.05e-05	0.00107	0.2	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98633749	chr5:98769618~98773469:-
THCA	cis	rs11098499	0.863	rs1010739	ENSG00000249244.1	RP11-548H18.2	4.45	1.05e-05	0.00107	0.24	0.2	Corneal astigmatism;	chr4:119542316	chr4:119391831~119395335:-
THCA	cis	rs13325613	0.749	rs11929489	ENSG00000223552.1	RP11-24F11.2	-4.45	1.05e-05	0.00107	-0.29	-0.2	Monocyte count;	chr3:46218424	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34985947	ENSG00000223552.1	RP11-24F11.2	-4.45	1.05e-05	0.00107	-0.29	-0.2	Monocyte count;	chr3:46218517	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13062523	ENSG00000223552.1	RP11-24F11.2	-4.45	1.05e-05	0.00107	-0.29	-0.2	Monocyte count;	chr3:46219007	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.749	rs41537946	ENSG00000223552.1	RP11-24F11.2	-4.45	1.05e-05	0.00107	-0.29	-0.2	Monocyte count;	chr3:46219369	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35984988	ENSG00000223552.1	RP11-24F11.2	-4.45	1.05e-05	0.00107	-0.29	-0.2	Monocyte count;	chr3:46219765	chr3:46364955~46407059:-
THCA	cis	rs2839186	0.77	rs2839171	ENSG00000215424.8	MCM3AP-AS1	-4.45	1.05e-05	0.00107	-0.11	-0.2	Testicular germ cell tumor;	chr21:46253333	chr21:46229217~46259390:+
THCA	cis	rs7772486	0.738	rs2246334	ENSG00000270638.1	RP3-466P17.1	4.45	1.05e-05	0.00107	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145735570~145737218:+
THCA	cis	rs3770081	1	rs59968392	ENSG00000272564.1	RP11-548P2.2	-4.45	1.05e-05	0.00107	-0.35	-0.2	Facial emotion recognition (sad faces);	chr2:85907490	chr2:85904279~85904727:+
THCA	cis	rs76793172	0.623	rs8107744	ENSG00000267395.4	AC074212.6	-4.45	1.05e-05	0.00107	-0.18	-0.2	Eosinophil counts;	chr19:45797590	chr19:45767796~45772504:+
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000275400.1	RP4-756H11.5	4.45	1.05e-05	0.00107	0.22	0.2	Corneal structure;	chr7:66872661	chr7:66553805~66554199:-
THCA	cis	rs1048886	0.752	rs6923292	ENSG00000271967.1	RP11-134K13.4	-4.45	1.05e-05	0.00107	-0.2	-0.2	Type 2 diabetes;	chr6:70404966	chr6:70596438~70596980:+
THCA	cis	rs7396835	0.866	rs6589570	ENSG00000280143.1	AP000892.6	4.45	1.05e-05	0.00107	0.33	0.2	Quantitative traits;	chr11:116804578	chr11:117204967~117210292:+
THCA	cis	rs526231	0.857	rs13190417	ENSG00000175749.11	EIF3KP1	4.45	1.05e-05	0.00107	0.26	0.2	Primary biliary cholangitis;	chr5:103327625	chr5:103032376~103033031:+
THCA	cis	rs9392556	0.626	rs626080	ENSG00000230648.1	RP3-406P24.3	-4.45	1.05e-05	0.00107	-0.24	-0.2	Blood metabolite levels;	chr6:4101333	chr6:4018843~4021215:-
THCA	cis	rs10090774	0.93	rs4961289	ENSG00000279766.1	RP11-642A1.2	4.45	1.05e-05	0.00107	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140738166	chr8:140572142~140572812:-
THCA	cis	rs9878978	0.722	rs34953825	ENSG00000237990.3	CNTN4-AS1	4.45	1.05e-05	0.00107	0.24	0.2	Blood pressure (smoking interaction);	chr3:2395854	chr3:3039033~3069242:-
THCA	cis	rs7614311	0.636	rs73117041	ENSG00000271843.1	RP11-245J9.5	-4.45	1.05e-05	0.00107	-0.36	-0.2	Lung function (FVC);Lung function (FEV1);	chr3:63910590	chr3:64008082~64008692:-
THCA	cis	rs6657613	0.68	rs1546925	ENSG00000186301.8	MST1P2	4.45	1.05e-05	0.00107	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17049801	chr1:16645622~16650289:+
THCA	cis	rs10090774	0.71	rs13249806	ENSG00000280303.2	ERICD	-4.45	1.05e-05	0.00107	-0.19	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140675407	chr8:140636281~140638283:+
THCA	cis	rs73198271	0.603	rs777705	ENSG00000253893.2	FAM85B	4.45	1.05e-05	0.00107	0.28	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8729358	chr8:8167819~8226614:-
THCA	cis	rs559555	0.849	rs2208532	ENSG00000276517.1	AL133243.2	4.45	1.05e-05	0.00107	0.19	0.2	Blood metabolite ratios;Blood metabolite levels;	chr2:31563919	chr2:32526504~32529507:+
THCA	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	4.45	1.05e-05	0.00107	0.22	0.2	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
THCA	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-4.45	1.05e-05	0.00107	-0.22	-0.2	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
THCA	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-4.45	1.05e-05	0.00107	-0.22	-0.2	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
THCA	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-4.45	1.05e-05	0.00107	-0.22	-0.2	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
THCA	cis	rs9880211	0.706	rs9289513	ENSG00000239213.4	NCK1-AS1	4.45	1.05e-05	0.00107	0.23	0.2	Height;Body mass index;	chr3:136732904	chr3:136841726~136862054:-
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000182586.6	LINC00334	-4.45	1.05e-05	0.00107	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000182586.6	LINC00334	-4.45	1.05e-05	0.00107	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000182586.6	LINC00334	-4.45	1.05e-05	0.00107	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45234340~45258730:+
THCA	cis	rs1962772	0.811	rs10102203	ENSG00000279903.1	RP11-349F21.5	-4.45	1.05e-05	0.00107	-0.25	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17518860	chr8:17500012~17500605:+
THCA	cis	rs7474896	0.778	rs2753879	ENSG00000263064.2	RP11-291L22.7	-4.45	1.05e-05	0.00107	-0.35	-0.2	Obesity (extreme);	chr10:37884007	chr10:38448689~38448949:+
THCA	cis	rs9543976	0.858	rs9530447	ENSG00000261105.4	LMO7-AS1	4.45	1.05e-05	0.00107	0.3	0.2	Diabetic retinopathy;	chr13:75592666	chr13:75604700~75635994:-
THCA	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	4.45	1.05e-05	0.00107	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.548	rs17392014	ENSG00000215032.2	GNL3LP1	4.45	1.05e-05	0.00107	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60891935~60893577:-
THCA	cis	rs875971	0.642	rs35526611	ENSG00000272831.1	RP11-792A8.4	-4.45	1.05e-05	0.00107	-0.12	-0.2	Aortic root size;	chr7:66629021	chr7:66739829~66740385:-
THCA	cis	rs7474896	0.559	rs2738185	ENSG00000226578.1	RP11-258F22.1	4.45	1.05e-05	0.00107	0.28	0.2	Obesity (extreme);	chr10:37958808	chr10:37775371~37784131:-
THCA	cis	rs3738443	0.599	rs1934986	ENSG00000259865.1	RP11-488L18.10	4.45	1.05e-05	0.00107	0.21	0.2	Alcohol dependence;	chr1:247235696	chr1:247187281~247188526:-
THCA	cis	rs2549003	0.811	rs10072700	ENSG00000233006.5	AC034220.3	-4.45	1.05e-05	0.00107	-0.18	-0.2	Asthma (sex interaction);	chr5:132481211	chr5:132311285~132369916:-
THCA	cis	rs6121246	0.609	rs6089075	ENSG00000230613.1	HM13-AS1	4.45	1.05e-05	0.00107	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31805081	chr20:31567707~31573263:-
THCA	cis	rs2120243	0.539	rs988588	ENSG00000241770.1	RP11-555M1.3	-4.45	1.05e-05	0.00107	-0.26	-0.2	Hepatocellular carcinoma in hepatitis B infection;	chr3:157336227	chr3:157163452~157169133:+
THCA	cis	rs7216064	0.954	rs12602556	ENSG00000278740.1	RP11-147L13.14	4.45	1.05e-05	0.00107	0.24	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67830745	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs62084208	ENSG00000278740.1	RP11-147L13.14	4.45	1.05e-05	0.00107	0.24	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67831327	chr17:68188547~68189165:+
THCA	cis	rs5758511	0.573	rs2284082	ENSG00000281538.1	RP4-669P10.20	4.45	1.05e-05	0.00107	0.2	0.2	Birth weight;	chr22:41844793	chr22:42138060~42139726:+
THCA	cis	rs5751614	0.537	rs5759679	ENSG00000240160.3	RN7SL263P	4.45	1.05e-05	0.00107	0.25	0.2	Height;	chr22:23286826	chr22:23261782~23262071:-
THCA	cis	rs17095355	1	rs12569906	ENSG00000203876.8	ADD3-AS1	-4.45	1.05e-05	0.00108	-0.22	-0.2	Biliary atresia;	chr10:109947098	chr10:109940104~110008381:-
THCA	cis	rs11096990	0.855	rs4974986	ENSG00000249685.1	RP11-360F5.3	-4.45	1.06e-05	0.00108	-0.26	-0.2	Cognitive function;	chr4:39165308	chr4:39133913~39135608:+
THCA	cis	rs9902453	0.934	rs12453172	ENSG00000263370.1	RP11-68I3.5	4.45	1.06e-05	0.00108	0.26	0.2	Coffee consumption (cups per day);	chr17:30114572	chr17:29639627~29640825:+
THCA	cis	rs4664304	0.71	rs9636280	ENSG00000226266.5	AC009961.3	4.45	1.06e-05	0.00108	0.24	0.2	Crohn's disease;Inflammatory bowel disease;	chr2:159861341	chr2:159670708~159712435:-
THCA	cis	rs2380220	0.64	rs9320386	ENSG00000261366.1	MANEA-AS1	-4.45	1.06e-05	0.00108	-0.22	-0.2	Behavioural disinhibition (generation interaction);	chr6:95547079	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.935	rs7744491	ENSG00000261366.1	MANEA-AS1	-4.45	1.06e-05	0.00108	-0.22	-0.2	Behavioural disinhibition (generation interaction);	chr6:95547104	chr6:95575183~95577450:-
THCA	cis	rs740160	0.614	rs9969217	ENSG00000244219.5	GS1-259H13.2	-4.45	1.06e-05	0.00108	-0.32	-0.2	Dehydroepiandrosterone sulphate levels;	chr7:99293815	chr7:99598066~99610813:+
THCA	cis	rs2070488	0.965	rs7373828	ENSG00000229589.1	ACVR2B-AS1	4.45	1.06e-05	0.00108	0.18	0.2	Electrocardiographic conduction measures;	chr3:38482820	chr3:38451027~38454820:-
THCA	cis	rs11644601	1	rs11644601	ENSG00000207425.1	Y_RNA	4.45	1.06e-05	0.00108	0.24	0.2	Metabolite levels (lipid measures);	chr16:15078261	chr16:14915457~14915556:-
THCA	cis	rs7829975	0.777	rs486781	ENSG00000233609.3	RP11-62H7.2	-4.45	1.06e-05	0.00108	-0.19	-0.2	Mood instability;	chr8:8782230	chr8:8961200~8979025:+
THCA	cis	rs2886497	0.789	rs72771410	ENSG00000224215.1	RP11-371A19.2	-4.45	1.06e-05	0.00108	-0.26	-0.2	Major depression and alcohol dependence;	chr10:23402062	chr10:23343957~23345181:+
THCA	cis	rs11540084	0.505	rs28411142	ENSG00000279095.1	AC092066.1	4.45	1.06e-05	0.00108	0.27	0.2	Mean platelet volume;	chr19:44645671	chr19:44664131~44666158:+
THCA	cis	rs1962772	1	rs1962772	ENSG00000279903.1	RP11-349F21.5	4.45	1.06e-05	0.00108	0.25	0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17513267	chr8:17500012~17500605:+
THCA	cis	rs1962772	0.851	rs13252878	ENSG00000279903.1	RP11-349F21.5	-4.45	1.06e-05	0.00108	-0.25	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17518382	chr8:17500012~17500605:+
THCA	cis	rs2281603	0.57	rs73265639	ENSG00000259116.1	RP11-973N13.4	-4.45	1.06e-05	0.00108	-0.17	-0.2	Lymphocyte counts;	chr14:64482973	chr14:64514154~64540368:-
THCA	cis	rs75920871	0.764	rs80259223	ENSG00000254851.1	RP11-109L13.1	-4.45	1.06e-05	0.00108	-0.44	-0.2	Subjective well-being;	chr11:117053602	chr11:117135528~117138582:+
THCA	cis	rs1876905	0.68	rs783085	ENSG00000272356.1	RP5-1112D6.8	-4.45	1.06e-05	0.00108	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111155482	chr6:111309203~111313517:+
THCA	cis	rs3824488	0.92	rs80155616	ENSG00000237857.2	RP11-435O5.2	-4.45	1.06e-05	0.00108	-0.39	-0.2	Neuroticism;	chr9:95481586	chr9:95414834~95426796:-
THCA	cis	rs3824488	0.92	rs28510415	ENSG00000237857.2	RP11-435O5.2	-4.45	1.06e-05	0.00108	-0.39	-0.2	Neuroticism;	chr9:95482744	chr9:95414834~95426796:-
THCA	cis	rs1048886	0.872	rs9455177	ENSG00000271967.1	RP11-134K13.4	-4.45	1.06e-05	0.00108	-0.21	-0.2	Type 2 diabetes;	chr6:70591822	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9455182	ENSG00000271967.1	RP11-134K13.4	-4.45	1.06e-05	0.00108	-0.21	-0.2	Type 2 diabetes;	chr6:70593212	chr6:70596438~70596980:+
THCA	cis	rs2439831	0.681	rs825740	ENSG00000166763.7	STRCP1	4.45	1.06e-05	0.00108	0.27	0.2	Lung cancer in ever smokers;	chr15:43300210	chr15:43699488~43718184:-
THCA	cis	rs8077577	0.747	rs11867895	ENSG00000273018.4	CTD-2303H24.2	-4.45	1.06e-05	0.00108	-0.3	-0.2	Obesity-related traits;	chr17:18243407	chr17:18511221~18551705:-
THCA	cis	rs2787702	0.889	rs2606094	ENSG00000237233.2	TMEM26-AS1	-4.45	1.06e-05	0.00108	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61565089	chr10:61452639~61481956:+
THCA	cis	rs4819052	0.684	rs914216	ENSG00000182586.6	LINC00334	-4.45	1.06e-05	0.00108	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45234340~45258730:+
THCA	cis	rs987724	0.57	rs4680318	ENSG00000243926.1	TIPARP-AS1	4.45	1.06e-05	0.00108	0.26	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156953850	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs4234315	ENSG00000243926.1	TIPARP-AS1	4.45	1.06e-05	0.00108	0.26	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156955749	chr3:156671862~156674378:-
THCA	cis	rs7045881	0.736	rs12344894	ENSG00000254396.1	RP11-56F10.3	4.45	1.06e-05	0.00108	0.33	0.2	Schizophrenia;	chr9:26833143	chr9:27102630~27104728:+
THCA	cis	rs2439831	1	rs28628574	ENSG00000205771.5	CATSPER2P1	-4.45	1.06e-05	0.00108	-0.3	-0.2	Lung cancer in ever smokers;	chr15:43509840	chr15:43726918~43747094:-
THCA	cis	rs4714902	0.623	rs3734208	ENSG00000231769.2	RP1-8B1.4	-4.45	1.06e-05	0.00108	-0.18	-0.2	Colonoscopy-negative controls vs population controls;	chr6:46130021	chr6:46097093~46129706:-
THCA	cis	rs11846409	0.872	rs2516914	ENSG00000274576.2	IGHV2-70	4.45	1.06e-05	0.00108	0.16	0.2	Rheumatic heart disease;	chr14:106629835	chr14:106770577~106771020:-
THCA	cis	rs10895322	0.901	rs11225333	ENSG00000281655.1	RP11-817J15.3	-4.45	1.06e-05	0.00108	-0.28	-0.2	Neuroblastoma (11q deletion);	chr11:102583954	chr11:102681310~102683913:+
THCA	cis	rs1268083	0.546	rs9398785	ENSG00000226409.1	RP11-735G4.1	-4.45	1.06e-05	0.00108	-0.25	-0.2	Migraine;	chr6:125736602	chr6:125370211~125374324:-
THCA	cis	rs782212	0.592	rs782257	ENSG00000227207.2	RPL31P12	4.45	1.06e-05	0.00108	0.31	0.2	Depression;	chr1:72433376	chr1:72301472~72301829:+
THCA	cis	rs782212	0.592	rs992956	ENSG00000227207.2	RPL31P12	4.45	1.06e-05	0.00108	0.31	0.2	Depression;	chr1:72435458	chr1:72301472~72301829:+
THCA	cis	rs782212	0.559	rs1373914	ENSG00000227207.2	RPL31P12	4.45	1.06e-05	0.00108	0.31	0.2	Depression;	chr1:72435832	chr1:72301472~72301829:+
THCA	cis	rs7577696	0.72	rs212753	ENSG00000276334.1	AL133243.1	4.45	1.06e-05	0.00108	0.22	0.2	Inflammatory biomarkers;	chr2:32196286	chr2:32521927~32523547:+
THCA	cis	rs9341808	0.6	rs590641	ENSG00000272129.1	RP11-250B2.6	4.45	1.06e-05	0.00108	0.26	0.2	Sitting height ratio;	chr6:80256766	chr6:80355424~80356859:+
THCA	cis	rs12497850	0.897	rs9884022	ENSG00000228638.1	FCF1P2	-4.45	1.06e-05	0.00108	-0.22	-0.2	Parkinson's disease;	chr3:48919429	chr3:48290793~48291375:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000272831.1	RP11-792A8.4	-4.45	1.06e-05	0.00108	-0.12	-0.2	Aortic root size;	chr7:66603522	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs7807944	ENSG00000272831.1	RP11-792A8.4	-4.45	1.06e-05	0.00108	-0.12	-0.2	Aortic root size;	chr7:66622208	chr7:66739829~66740385:-
THCA	cis	rs875971	0.638	rs35986979	ENSG00000272831.1	RP11-792A8.4	-4.45	1.06e-05	0.00108	-0.12	-0.2	Aortic root size;	chr7:66624003	chr7:66739829~66740385:-
THCA	cis	rs8046148	0.724	rs11643164	ENSG00000279356.1	RP11-429P3.8	4.45	1.06e-05	0.00108	0.24	0.2	Testicular germ cell tumor;	chr16:50022643	chr16:50072862~50074986:+
THCA	cis	rs2898290	0.506	rs2736311	ENSG00000206014.6	OR7E161P	4.45	1.06e-05	0.00108	0.23	0.2	Systolic blood pressure;	chr8:11394661	chr8:11928597~11929563:-
THCA	cis	rs12681288	0.782	rs2600498	ENSG00000260721.1	AF067845.1	4.45	1.06e-05	0.00108	0.25	0.2	Schizophrenia;	chr8:1076520	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.782	rs12544713	ENSG00000260721.1	AF067845.1	4.45	1.06e-05	0.00108	0.25	0.2	Schizophrenia;	chr8:1076697	chr8:1368642~1369833:-
THCA	cis	rs4713118	1	rs4713118	ENSG00000220721.1	OR1F12	4.45	1.06e-05	0.00108	0.26	0.2	Parkinson's disease;	chr6:27709015	chr6:28073316~28074233:+
THCA	cis	rs394563	0.625	rs394526	ENSG00000231760.4	RP11-350J20.5	4.45	1.06e-05	0.00108	0.27	0.2	Dupuytren's disease;	chr6:149475839	chr6:149796151~149826294:-
THCA	cis	rs6676180	1	rs6676180	ENSG00000231365.4	RP11-418J17.1	-4.45	1.06e-05	0.00108	-0.2	-0.2	Monobrow;	chr1:119240600	chr1:119140396~119275973:+
THCA	cis	rs722599	0.748	rs2300599	ENSG00000279594.1	RP11-950C14.10	-4.45	1.06e-05	0.00108	-0.2	-0.2	IgG glycosylation;	chr14:74892738	chr14:75011269~75012851:-
THCA	cis	rs722599	0.748	rs61978948	ENSG00000279594.1	RP11-950C14.10	-4.45	1.06e-05	0.00108	-0.2	-0.2	IgG glycosylation;	chr14:74896666	chr14:75011269~75012851:-
THCA	cis	rs7772486	0.79	rs2253654	ENSG00000270638.1	RP3-466P17.1	4.45	1.06e-05	0.00108	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145735570~145737218:+
THCA	cis	rs4237845	0.611	rs4583019	ENSG00000257159.1	RP11-58A17.3	4.45	1.06e-05	0.00108	0.25	0.2	Intelligence (multi-trait analysis);	chr12:57922962	chr12:57967058~57968399:+
THCA	cis	rs867186	1	rs11908232	ENSG00000126005.14	MMP24-AS1	-4.45	1.06e-05	0.00108	-0.31	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35141674	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs11908100	ENSG00000126005.14	MMP24-AS1	-4.45	1.06e-05	0.00108	-0.31	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35141676	chr20:35216462~35278131:-
THCA	cis	rs8054556	0.74	rs11649612	ENSG00000183604.13	SMG1P5	-4.45	1.06e-05	0.00108	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30267553~30335374:-
THCA	cis	rs8054556	0.716	rs11642933	ENSG00000183604.13	SMG1P5	-4.45	1.06e-05	0.00108	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30267553~30335374:-
THCA	cis	rs9902453	0.904	rs4375718	ENSG00000263370.1	RP11-68I3.5	-4.45	1.06e-05	0.00108	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30036624	chr17:29639627~29640825:+
THCA	cis	rs7474896	1	rs3933229	ENSG00000263064.2	RP11-291L22.7	4.45	1.06e-05	0.00108	0.32	0.2	Obesity (extreme);	chr10:37651766	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.943	rs11011320	ENSG00000263064.2	RP11-291L22.7	4.45	1.06e-05	0.00108	0.32	0.2	Obesity (extreme);	chr10:37673084	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011322	ENSG00000263064.2	RP11-291L22.7	4.45	1.06e-05	0.00108	0.32	0.2	Obesity (extreme);	chr10:37675201	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs10827814	ENSG00000263064.2	RP11-291L22.7	4.45	1.06e-05	0.00108	0.32	0.2	Obesity (extreme);	chr10:37675462	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011330	ENSG00000263064.2	RP11-291L22.7	4.45	1.06e-05	0.00108	0.32	0.2	Obesity (extreme);	chr10:37679914	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011331	ENSG00000263064.2	RP11-291L22.7	4.45	1.06e-05	0.00108	0.32	0.2	Obesity (extreme);	chr10:37680010	chr10:38448689~38448949:+
THCA	cis	rs9548119	0.941	rs9576404	ENSG00000223685.4	LINC00571	-4.45	1.06e-05	0.00108	-0.23	-0.2	Self-rated health;	chr13:37953276	chr13:38050817~38143232:-
THCA	cis	rs1707322	1	rs11211248	ENSG00000281133.1	AL355480.3	-4.45	1.06e-05	0.00108	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs7532204	ENSG00000281133.1	AL355480.3	4.45	1.06e-05	0.00108	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.835	rs946525	ENSG00000281133.1	AL355480.3	4.45	1.06e-05	0.00108	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs946524	ENSG00000281133.1	AL355480.3	4.45	1.06e-05	0.00108	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4660336	ENSG00000281133.1	AL355480.3	4.45	1.06e-05	0.00108	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45580892~45580996:-
THCA	cis	rs12410462	0.551	rs66471275	ENSG00000227711.2	RP11-275O4.5	-4.45	1.06e-05	0.00108	-0.24	-0.2	Major depressive disorder;	chr1:227636611	chr1:227509028~227520477:-
THCA	cis	rs849141	0.524	rs79131915	ENSG00000234336.5	JAZF1-AS1	4.45	1.06e-05	0.00108	0.34	0.2	Height;Hip circumference adjusted for BMI;	chr7:28148427	chr7:28180322~28243917:+
THCA	cis	rs28735056	0.596	rs3744879	ENSG00000261126.6	RP11-795F19.1	-4.45	1.06e-05	0.00108	-0.16	-0.2	Schizophrenia;	chr18:79919006	chr18:80046900~80095482:+
THCA	cis	rs11671005	0.737	rs11671033	ENSG00000265272.2	RN7SL693P	4.45	1.06e-05	0.00108	0.29	0.2	Mean platelet volume;	chr19:58452302	chr19:58490797~58491075:+
THCA	cis	rs2191566	1	rs367499	ENSG00000266921.1	RP11-15A1.7	4.45	1.06e-05	0.00108	0.19	0.2	Acute lymphoblastic leukemia (childhood);	chr19:44000829	chr19:43996896~44002836:-
THCA	cis	rs172166	0.61	rs276369	ENSG00000220721.1	OR1F12	4.45	1.06e-05	0.00108	0.22	0.2	Cardiac Troponin-T levels;	chr6:27951465	chr6:28073316~28074233:+
THCA	cis	rs17597773	0.674	rs12089958	ENSG00000238078.1	LINC01352	-4.45	1.06e-05	0.00108	-0.28	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828021	chr1:220829255~220832429:+
THCA	cis	rs950880	0.71	rs11693204	ENSG00000234389.1	AC007278.3	-4.45	1.06e-05	0.00108	-0.24	-0.2	Serum protein levels (sST2);	chr2:102319514	chr2:102438713~102440475:+
THCA	cis	rs5751614	0.537	rs11090228	ENSG00000240160.3	RN7SL263P	4.45	1.06e-05	0.00108	0.26	0.2	Height;	chr22:23289452	chr22:23261782~23262071:-
THCA	cis	rs5751614	0.537	rs2227939	ENSG00000240160.3	RN7SL263P	4.45	1.06e-05	0.00108	0.26	0.2	Height;	chr22:23289614	chr22:23261782~23262071:-
THCA	cis	rs3764021	1	rs7977720	ENSG00000214776.8	RP11-726G1.1	4.45	1.06e-05	0.00108	0.24	0.2	Type 1 diabetes;	chr12:9713753	chr12:9467552~9576275:+
THCA	cis	rs2617170	0.885	rs7978962	ENSG00000245648.1	RP11-277P12.20	4.45	1.06e-05	0.00108	0.21	0.2	Behcet's disease;	chr12:10372225	chr12:10363769~10398506:+
THCA	cis	rs2777491	0.957	rs3743038	ENSG00000247556.5	OIP5-AS1	4.45	1.06e-05	0.00108	0.17	0.2	Ulcerative colitis;	chr15:41402545	chr15:41283990~41309737:+
THCA	cis	rs710913	0.745	rs1180334	ENSG00000182109.6	RP11-69E11.4	-4.45	1.06e-05	0.00108	-0.18	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39522280~39546187:-
THCA	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-4.45	1.06e-05	0.00108	-0.31	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
THCA	cis	rs526231	0.764	rs2116755	ENSG00000175749.11	EIF3KP1	4.45	1.06e-05	0.00108	0.26	0.2	Primary biliary cholangitis;	chr5:103314187	chr5:103032376~103033031:+
THCA	cis	rs526231	0.764	rs372564	ENSG00000175749.11	EIF3KP1	4.45	1.06e-05	0.00108	0.26	0.2	Primary biliary cholangitis;	chr5:103314823	chr5:103032376~103033031:+
THCA	cis	rs11822910	0.737	rs2584858	ENSG00000265566.2	RN7SL605P	4.45	1.06e-05	0.00108	0.32	0.2	Platelet distribution width;	chr11:57439604	chr11:57528085~57528365:-
THCA	cis	rs397969	0.569	rs62066351	ENSG00000261033.1	RP11-209D14.2	-4.45	1.06e-05	0.00108	-0.29	-0.2	Platelet count;	chr17:19997681	chr17:20008051~20009234:-
THCA	cis	rs397969	0.596	rs4925064	ENSG00000261033.1	RP11-209D14.2	-4.45	1.06e-05	0.00108	-0.29	-0.2	Platelet count;	chr17:19998092	chr17:20008051~20009234:-
THCA	cis	rs763121	0.853	rs5750669	ENSG00000273076.1	RP3-508I15.22	4.45	1.06e-05	0.00108	0.2	0.2	Menopause (age at onset);	chr22:38684633	chr22:38743495~38743910:+
THCA	cis	rs7074356	0.569	rs17102596	ENSG00000242600.5	MBL1P	4.45	1.06e-05	0.00108	0.21	0.2	Borderline personality disorder;	chr10:80275417	chr10:79904898~79950336:+
THCA	cis	rs863750	0.811	rs1716407	ENSG00000275389.1	RP11-214K3.24	4.45	1.06e-05	0.00108	0.27	0.2	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124030671	chr12:124085761~124088598:+
THCA	cis	rs17801127	0.748	rs6436389	ENSG00000231969.1	AC144449.1	-4.45	1.06e-05	0.00108	-0.33	-0.2	Liver enzyme levels (alanine transaminase);	chr2:149691760	chr2:149587196~149848233:+
THCA	cis	rs7824557	0.603	rs2249804	ENSG00000154316.13	TDH	-4.45	1.07e-05	0.00108	-0.15	-0.2	Retinal vascular caliber;	chr8:11358108	chr8:11339637~11368452:+
THCA	cis	rs7688540	0.511	rs4522818	ENSG00000211553.1	AC253576.2	-4.45	1.07e-05	0.00108	-0.31	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:136461~136568:+
THCA	cis	rs2904524	0.737	rs117771315	ENSG00000257815.4	RP11-611E13.2	-4.45	1.07e-05	0.00108	-0.28	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70183849	chr12:69904033~70243360:-
THCA	cis	rs6088590	1	rs2295353	ENSG00000269202.1	RP4-614O4.12	-4.45	1.07e-05	0.00108	-0.18	-0.2	Coronary artery disease;	chr20:34768708	chr20:35201747~35203288:-
THCA	cis	rs6088590	1	rs2295354	ENSG00000269202.1	RP4-614O4.12	-4.45	1.07e-05	0.00108	-0.18	-0.2	Coronary artery disease;	chr20:34768738	chr20:35201747~35203288:-
THCA	cis	rs1979679	0.918	rs786707	ENSG00000247934.4	RP11-967K21.1	-4.45	1.07e-05	0.00109	-0.2	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28420714	chr12:28163298~28190738:-
THCA	cis	rs17095355	1	rs17126890	ENSG00000203876.8	ADD3-AS1	-4.45	1.07e-05	0.00109	-0.22	-0.2	Biliary atresia;	chr10:109939411	chr10:109940104~110008381:-
THCA	cis	rs4824093	0.61	rs56810176	ENSG00000278869.1	CITF22-49E9.3	4.45	1.07e-05	0.00109	0.38	0.2	Amyotrophic lateral sclerosis (sporadic);	chr22:49909501	chr22:49933198~49934074:-
THCA	cis	rs7554547	0.6	rs2180180	ENSG00000199347.1	RNU5E-1	4.45	1.07e-05	0.00109	0.28	0.2	Nonsyndromic cleft lip with cleft palate;	chr1:11959312	chr1:11908152~11908271:+
THCA	cis	rs9326248	0.53	rs2000616	ENSG00000280143.1	AP000892.6	4.45	1.07e-05	0.00109	0.32	0.2	Blood protein levels;	chr11:117045813	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.53	rs10750100	ENSG00000280143.1	AP000892.6	4.45	1.07e-05	0.00109	0.32	0.2	Blood protein levels;	chr11:117046528	chr11:117204967~117210292:+
THCA	cis	rs8064024	0.65	rs12926178	ENSG00000267077.1	RP11-127I20.5	-4.45	1.07e-05	0.00109	-0.23	-0.2	Cancer;	chr16:4855914	chr16:4795265~4796532:-
THCA	cis	rs12681288	0.676	rs17668031	ENSG00000260721.1	AF067845.1	4.45	1.07e-05	0.00109	0.25	0.2	Schizophrenia;	chr8:1057176	chr8:1368642~1369833:-
THCA	cis	rs3796352	0.667	rs17331178	ENSG00000242142.1	SERBP1P3	-4.45	1.07e-05	0.00109	-0.38	-0.2	Immune reponse to smallpox (secreted IL-2);	chr3:52813528	chr3:53064283~53065091:-
THCA	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	4.45	1.07e-05	0.00109	0.2	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
THCA	cis	rs5758511	0.731	rs12158579	ENSG00000281538.1	RP4-669P10.20	-4.45	1.07e-05	0.00109	-0.23	-0.2	Birth weight;	chr22:41955285	chr22:42138060~42139726:+
THCA	cis	rs12264252	0.767	rs7902355	ENSG00000225484.5	NUTM2B-AS1	-4.45	1.07e-05	0.00109	-0.27	-0.2	Coronary artery disease;	chr10:80489352	chr10:79663088~79826594:-
THCA	cis	rs1889642	0.626	rs9545224	ENSG00000227354.5	RBM26-AS1	4.45	1.07e-05	0.00109	0.19	0.2	Colonoscopy-negative controls vs population controls;	chr13:79838326	chr13:79406309~79424328:+
THCA	cis	rs7031325	0.597	rs13289448	ENSG00000229611.1	RP11-390F4.10	-4.45	1.07e-05	0.00109	-0.23	-0.2	Systemic lupus erythematosus;	chr9:6666840	chr9:6704471~6707780:+
THCA	cis	rs9902453	0.967	rs9900911	ENSG00000263370.1	RP11-68I3.5	-4.45	1.07e-05	0.00109	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30003262	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.935	rs7220151	ENSG00000263370.1	RP11-68I3.5	-4.45	1.07e-05	0.00109	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30007692	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.838	rs7217638	ENSG00000263370.1	RP11-68I3.5	-4.45	1.07e-05	0.00109	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30009754	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs9912741	ENSG00000263370.1	RP11-68I3.5	-4.45	1.07e-05	0.00109	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30032493	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs9891871	ENSG00000263370.1	RP11-68I3.5	-4.45	1.07e-05	0.00109	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30043173	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs6505155	ENSG00000263370.1	RP11-68I3.5	-4.45	1.07e-05	0.00109	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30045765	chr17:29639627~29640825:+
THCA	cis	rs10129255	0.719	rs7156660	ENSG00000280411.1	IGHV1-69-2	-4.45	1.07e-05	0.00109	-0.13	-0.2	Kawasaki disease;	chr14:106673171	chr14:106762092~106762588:-
THCA	cis	rs12900463	0.813	rs186266	ENSG00000275120.1	RP11-182J1.17	4.45	1.07e-05	0.00109	0.23	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:84599434~84606463:-
THCA	cis	rs2732480	0.538	rs1387259	ENSG00000273765.1	RP11-370I10.11	-4.45	1.07e-05	0.00109	-0.2	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48360920~48361377:+
THCA	cis	rs9863	0.828	rs75989601	ENSG00000270061.1	RP11-214K3.19	-4.45	1.07e-05	0.00109	-0.27	-0.2	White blood cell count;	chr12:123982176	chr12:123969990~123970344:-
THCA	cis	rs9863	0.828	rs35099862	ENSG00000270061.1	RP11-214K3.19	-4.45	1.07e-05	0.00109	-0.27	-0.2	White blood cell count;	chr12:123982657	chr12:123969990~123970344:-
THCA	cis	rs2436845	0.934	rs2916564	ENSG00000253669.3	KB-1732A1.1	-4.45	1.07e-05	0.00109	-0.21	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102811112	chr8:102805517~102809971:+
THCA	cis	rs6012564	1	rs2295028	ENSG00000230758.1	SNAP23P	-4.45	1.07e-05	0.00109	-0.24	-0.2	Anger;	chr20:48966421	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.806	rs4810903	ENSG00000230758.1	SNAP23P	-4.45	1.07e-05	0.00109	-0.24	-0.2	Anger;	chr20:48982668	chr20:49038357~49038602:-
THCA	cis	rs10129255	0.5	rs988132	ENSG00000211970.3	IGHV4-61	-4.45	1.07e-05	0.00109	-0.11	-0.2	Kawasaki disease;	chr14:106776758	chr14:106639119~106639657:-
THCA	cis	rs2898290	0.622	rs7829381	ENSG00000251402.3	FAM90A25P	-4.45	1.07e-05	0.00109	-0.26	-0.2	Systolic blood pressure;	chr8:11487064	chr8:12415080~12418090:-
THCA	cis	rs2898290	0.622	rs11250140	ENSG00000251402.3	FAM90A25P	-4.45	1.07e-05	0.00109	-0.26	-0.2	Systolic blood pressure;	chr8:11489083	chr8:12415080~12418090:-
THCA	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-4.45	1.07e-05	0.00109	-0.23	-0.2	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
THCA	cis	rs1823874	0.71	rs2902472	ENSG00000182397.13	DNM1P46	-4.45	1.07e-05	0.00109	-0.23	-0.2	IgG glycosylation;	chr15:99824257	chr15:99790156~99806927:-
THCA	cis	rs17508449	0.547	rs11582409	ENSG00000232450.1	RP4-730K3.3	-4.45	1.07e-05	0.00109	-0.28	-0.2	Leprosy;	chr1:113856811	chr1:113698884~113699631:-
THCA	cis	rs2070488	0.965	rs2284820	ENSG00000229589.1	ACVR2B-AS1	-4.45	1.07e-05	0.00109	-0.19	-0.2	Electrocardiographic conduction measures;	chr3:38521088	chr3:38451027~38454820:-
THCA	cis	rs6012564	0.793	rs6125552	ENSG00000230758.1	SNAP23P	4.45	1.07e-05	0.00109	0.24	0.2	Anger;	chr20:49107788	chr20:49038357~49038602:-
THCA	cis	rs657075	0.595	rs35466090	ENSG00000237714.1	P4HA2-AS1	-4.45	1.07e-05	0.00109	-0.46	-0.2	Rheumatoid arthritis;	chr5:132287143	chr5:132184876~132192808:+
THCA	cis	rs73108077	0.79	rs73105930	ENSG00000277112.2	RP11-755J8.1	-4.45	1.07e-05	0.00109	-0.39	-0.2	Red blood cell density in sickle cell anemia;	chr20:31327265	chr20:30681825~30723932:-
THCA	cis	rs28476539	0.64	rs3733229	ENSG00000270480.1	RP11-57B24.1	4.45	1.07e-05	0.00109	0.32	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82631611	chr4:82691737~82692468:+
THCA	cis	rs496547	0.719	rs1790189	ENSG00000255422.1	AP002954.4	-4.45	1.07e-05	0.00109	-0.22	-0.2	Hip minimal joint space width;	chr11:118781617	chr11:118704607~118750263:+
THCA	cis	rs4906332	1	rs4900574	ENSG00000244691.1	RPL10AP1	4.45	1.07e-05	0.00109	0.25	0.2	Coronary artery disease;	chr14:103412687	chr14:103412119~103412761:-
THCA	cis	rs13126694	0.75	rs6833295	ENSG00000248429.4	RP11-597D13.9	4.45	1.07e-05	0.00109	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158143520	chr4:158170752~158202877:+
THCA	cis	rs2299587	0.637	rs7832527	ENSG00000253671.1	RP11-806O11.1	-4.45	1.07e-05	0.00109	-0.24	-0.2	Economic and political preferences;	chr8:18031834	chr8:17808941~17820868:+
THCA	cis	rs11096990	0.855	rs2566177	ENSG00000249685.1	RP11-360F5.3	-4.45	1.07e-05	0.00109	-0.26	-0.2	Cognitive function;	chr4:39154558	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2711934	ENSG00000249685.1	RP11-360F5.3	-4.45	1.07e-05	0.00109	-0.26	-0.2	Cognitive function;	chr4:39156254	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2711935	ENSG00000249685.1	RP11-360F5.3	-4.45	1.07e-05	0.00109	-0.26	-0.2	Cognitive function;	chr4:39160837	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2566183	ENSG00000249685.1	RP11-360F5.3	-4.45	1.07e-05	0.00109	-0.26	-0.2	Cognitive function;	chr4:39162288	chr4:39133913~39135608:+
THCA	cis	rs17221829	0.965	rs12292340	ENSG00000280385.1	AP000648.5	-4.45	1.07e-05	0.00109	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89728105	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.965	rs10830370	ENSG00000280385.1	AP000648.5	-4.45	1.07e-05	0.00109	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89728367	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.931	rs10160803	ENSG00000280385.1	AP000648.5	-4.45	1.07e-05	0.00109	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89728691	chr11:90193614~90198120:+
THCA	cis	rs3820928	0.839	rs10197773	ENSG00000212391.1	SNORA48	-4.45	1.07e-05	0.00109	-0.22	-0.2	Pulmonary function;	chr2:226960119	chr2:226968989~226969122:-
THCA	cis	rs375066	0.935	rs430308	ENSG00000278917.1	RP11-15A1.4	-4.45	1.07e-05	0.00109	-0.17	-0.2	Breast cancer;	chr19:43896223	chr19:43891233~43895411:+
THCA	cis	rs964611	0.882	rs16960809	ENSG00000259488.2	RP11-154J22.1	4.45	1.07e-05	0.00109	0.19	0.2	Metabolite levels (Pyroglutamine);	chr15:48354318	chr15:48312353~48331856:-
THCA	cis	rs35740288	0.929	rs11630585	ENSG00000259295.5	CSPG4P12	4.45	1.07e-05	0.00109	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762773	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.929	rs11636821	ENSG00000259295.5	CSPG4P12	4.45	1.07e-05	0.00109	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762774	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.929	rs11630684	ENSG00000259295.5	CSPG4P12	4.45	1.07e-05	0.00109	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85763025	chr15:85191438~85213905:+
THCA	cis	rs12497850	0.931	rs7636057	ENSG00000228638.1	FCF1P2	-4.45	1.07e-05	0.00109	-0.22	-0.2	Parkinson's disease;	chr3:48955149	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs7643368	ENSG00000228638.1	FCF1P2	-4.45	1.07e-05	0.00109	-0.22	-0.2	Parkinson's disease;	chr3:48955422	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.866	rs6791234	ENSG00000228638.1	FCF1P2	-4.45	1.07e-05	0.00109	-0.22	-0.2	Parkinson's disease;	chr3:48958704	chr3:48290793~48291375:-
THCA	cis	rs875971	0.545	rs6460298	ENSG00000273142.1	RP11-458F8.4	4.45	1.07e-05	0.00109	0.19	0.2	Aortic root size;	chr7:66442783	chr7:66902857~66906297:+
THCA	cis	rs6442522	0.606	rs3773462	ENSG00000249786.6	EAF1-AS1	4.45	1.07e-05	0.00109	0.21	0.2	Uric acid levels;	chr3:15452772	chr3:15436171~15455940:-
THCA	cis	rs11976180	1	rs2961132	ENSG00000244198.4	RP4-545C24.1	-4.45	1.07e-05	0.00109	-0.2	-0.2	Obesity-related traits;	chr7:144071035	chr7:144194858~144280547:+
THCA	cis	rs722599	0.748	rs741096	ENSG00000279594.1	RP11-950C14.10	-4.45	1.07e-05	0.00109	-0.2	-0.2	IgG glycosylation;	chr14:74884784	chr14:75011269~75012851:-
THCA	cis	rs722599	0.748	rs7145173	ENSG00000279594.1	RP11-950C14.10	-4.45	1.07e-05	0.00109	-0.2	-0.2	IgG glycosylation;	chr14:74884944	chr14:75011269~75012851:-
THCA	cis	rs801193	0.844	rs732465	ENSG00000229886.1	RP5-1132H15.3	4.45	1.07e-05	0.00109	0.2	0.2	Aortic root size;	chr7:66533463	chr7:66025126~66031544:-
THCA	cis	rs801193	0.773	rs801207	ENSG00000229886.1	RP5-1132H15.3	-4.45	1.07e-05	0.00109	-0.2	-0.2	Aortic root size;	chr7:66555603	chr7:66025126~66031544:-
THCA	cis	rs875971	0.543	rs801191	ENSG00000229886.1	RP5-1132H15.3	-4.45	1.07e-05	0.00109	-0.2	-0.2	Aortic root size;	chr7:66567968	chr7:66025126~66031544:-
THCA	cis	rs875971	0.508	rs6947808	ENSG00000229886.1	RP5-1132H15.3	-4.45	1.07e-05	0.00109	-0.2	-0.2	Aortic root size;	chr7:66580095	chr7:66025126~66031544:-
THCA	cis	rs3770081	1	rs58672934	ENSG00000272564.1	RP11-548P2.2	-4.45	1.07e-05	0.00109	-0.36	-0.2	Facial emotion recognition (sad faces);	chr2:85936113	chr2:85904279~85904727:+
THCA	cis	rs9925964	0.933	rs881929	ENSG00000232748.3	RP11-196G11.6	4.45	1.07e-05	0.00109	0.23	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31068050	chr16:31056460~31062803:+
THCA	cis	rs718433	0.556	rs1569287	ENSG00000211778.2	TRAV4	-4.45	1.08e-05	0.00109	-0.15	-0.2	Intraocular pressure;	chr14:21747309	chr14:21736152~21736982:+
THCA	cis	rs6730558	0.934	rs3856444	ENSG00000236008.1	AC011747.4	4.45	1.08e-05	0.00109	0.23	0.2	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8605868	chr2:8559833~8583792:-
THCA	cis	rs7188861	0.603	rs2113260	ENSG00000262636.1	CTD-3088G3.4	4.45	1.08e-05	0.0011	0.26	0.2	HDL cholesterol;	chr16:11362136	chr16:11380859~11381118:-
THCA	cis	rs17270561	0.609	rs9358876	ENSG00000272462.2	U91328.19	-4.45	1.08e-05	0.0011	-0.17	-0.2	Iron status biomarkers;	chr6:25738728	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.583	rs9393661	ENSG00000272462.2	U91328.19	-4.45	1.08e-05	0.0011	-0.17	-0.2	Iron status biomarkers;	chr6:25738852	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9356986	ENSG00000272462.2	U91328.19	-4.45	1.08e-05	0.0011	-0.17	-0.2	Iron status biomarkers;	chr6:25738891	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9358877	ENSG00000272462.2	U91328.19	-4.45	1.08e-05	0.0011	-0.17	-0.2	Iron status biomarkers;	chr6:25739000	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs12663099	ENSG00000272462.2	U91328.19	-4.45	1.08e-05	0.0011	-0.17	-0.2	Iron status biomarkers;	chr6:25739290	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9393662	ENSG00000272462.2	U91328.19	-4.45	1.08e-05	0.0011	-0.17	-0.2	Iron status biomarkers;	chr6:25739442	chr6:25992662~26001775:+
THCA	cis	rs9341808	0.556	rs10455370	ENSG00000260645.1	RP11-250B2.5	-4.45	1.08e-05	0.0011	-0.17	-0.2	Sitting height ratio;	chr6:80331150	chr6:80466958~80469080:+
THCA	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-4.45	1.08e-05	0.0011	-0.26	-0.2	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
THCA	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-4.45	1.08e-05	0.0011	-0.2	-0.2	Height;	chr5:36878678	chr5:36666214~36725195:-
THCA	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-4.45	1.08e-05	0.0011	-0.2	-0.2	Height;	chr5:36880769	chr5:36666214~36725195:-
THCA	cis	rs4578769	0.959	rs9947011	ENSG00000265939.1	UBE2CP2	-4.45	1.08e-05	0.0011	-0.24	-0.2	Eosinophil percentage of white cells;	chr18:22840446	chr18:22900486~22900995:-
THCA	cis	rs7829975	0.509	rs2945269	ENSG00000233609.3	RP11-62H7.2	4.45	1.08e-05	0.0011	0.19	0.2	Mood instability;	chr8:8258056	chr8:8961200~8979025:+
THCA	cis	rs442309	0.687	rs11815005	ENSG00000238280.1	RP11-436D10.3	-4.45	1.08e-05	0.0011	-0.25	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62696987	chr10:62793562~62805887:-
THCA	cis	rs7829975	0.5	rs7841082	ENSG00000254153.1	CTA-398F10.2	4.45	1.08e-05	0.0011	0.23	0.2	Mood instability;	chr8:8311465	chr8:8456909~8461337:-
THCA	cis	rs240993	0.812	rs9387013	ENSG00000271789.1	RP5-1112D6.7	4.45	1.08e-05	0.0011	0.24	0.2	Inflammatory skin disease;Psoriasis;	chr6:111512517	chr6:111297126~111298510:+
THCA	cis	rs9902453	0.9	rs12451122	ENSG00000263370.1	RP11-68I3.5	4.45	1.08e-05	0.0011	0.25	0.2	Coffee consumption (cups per day);	chr17:30159358	chr17:29639627~29640825:+
THCA	cis	rs2734839	0.929	rs7131627	ENSG00000270179.1	RP11-159N11.4	-4.45	1.08e-05	0.0011	-0.21	-0.2	Information processing speed;	chr11:113429107	chr11:113368478~113369117:+
THCA	cis	rs7829975	0.742	rs7832968	ENSG00000233609.3	RP11-62H7.2	4.45	1.08e-05	0.0011	0.19	0.2	Mood instability;	chr8:8795379	chr8:8961200~8979025:+
THCA	cis	rs9902453	0.904	rs9905638	ENSG00000263370.1	RP11-68I3.5	4.45	1.08e-05	0.0011	0.26	0.2	Coffee consumption (cups per day);	chr17:29934004	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.874	rs62070271	ENSG00000263370.1	RP11-68I3.5	4.45	1.08e-05	0.0011	0.26	0.2	Coffee consumption (cups per day);	chr17:29941340	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs9894893	ENSG00000263370.1	RP11-68I3.5	4.45	1.08e-05	0.0011	0.26	0.2	Coffee consumption (cups per day);	chr17:29943332	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.935	rs9909093	ENSG00000263370.1	RP11-68I3.5	4.45	1.08e-05	0.0011	0.26	0.2	Coffee consumption (cups per day);	chr17:29944189	chr17:29639627~29640825:+
THCA	cis	rs12612619	0.677	rs67100745	ENSG00000272148.1	RP11-195B17.1	4.45	1.08e-05	0.0011	0.19	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027882	chr2:27062428~27062907:-
THCA	cis	rs5758659	0.714	rs6002607	ENSG00000281538.1	RP4-669P10.20	-4.45	1.08e-05	0.0011	-0.18	-0.2	Cognitive function;	chr22:42100502	chr22:42138060~42139726:+
THCA	cis	rs12915845	0.603	rs11073783	ENSG00000271997.1	RP11-97O12.6	-4.45	1.08e-05	0.0011	-0.14	-0.2	Menarche (age at onset);	chr15:88500530	chr15:88501944~88505787:-
THCA	cis	rs9300255	0.569	rs1790115	ENSG00000235423.7	RP11-282O18.3	4.45	1.08e-05	0.0011	0.21	0.2	Neutrophil percentage of white cells;	chr12:123135723	chr12:123252030~123261483:-
THCA	cis	rs7521681	0.713	rs12033130	ENSG00000230489.1	VAV3-AS1	-4.45	1.08e-05	0.0011	-0.24	-0.2	Asthma and hay fever;	chr1:107794674	chr1:107964443~107994607:+
THCA	cis	rs6963495	0.818	rs73192125	ENSG00000272604.1	RP11-251G23.5	4.45	1.08e-05	0.0011	0.26	0.2	Bipolar disorder (body mass index interaction);	chr7:105534621	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.769	rs11556986	ENSG00000272604.1	RP11-251G23.5	4.45	1.08e-05	0.0011	0.26	0.2	Bipolar disorder (body mass index interaction);	chr7:105536594	chr7:105571083~105573660:+
THCA	cis	rs853679	0.505	rs200992	ENSG00000226314.6	ZNF192P1	-4.45	1.08e-05	0.0011	-0.34	-0.2	Depression;	chr6:27846899	chr6:28161781~28169594:+
THCA	cis	rs3738443	0.868	rs35229190	ENSG00000259865.1	RP11-488L18.10	4.45	1.08e-05	0.0011	0.21	0.2	Alcohol dependence;	chr1:247202339	chr1:247187281~247188526:-
THCA	cis	rs2028299	0.92	rs10852123	ENSG00000259677.1	RP11-493E3.1	4.45	1.08e-05	0.0011	0.27	0.2	Type 2 diabetes;	chr15:89885662	chr15:89876540~89877285:+
THCA	cis	rs1048886	0.882	rs6902773	ENSG00000271967.1	RP11-134K13.4	-4.45	1.08e-05	0.0011	-0.2	-0.2	Type 2 diabetes;	chr6:70405050	chr6:70596438~70596980:+
THCA	cis	rs4074961	0.509	rs4653300	ENSG00000233621.1	LINC01137	-4.45	1.08e-05	0.0011	-0.21	-0.2	Axial length;	chr1:37558453	chr1:37454879~37474411:-
THCA	cis	rs7474896	1	rs61857913	ENSG00000263064.2	RP11-291L22.7	4.45	1.08e-05	0.0011	0.32	0.2	Obesity (extreme);	chr10:37634777	chr10:38448689~38448949:+
THCA	cis	rs13113518	1	rs4865007	ENSG00000249700.7	SRD5A3-AS1	-4.45	1.08e-05	0.0011	-0.25	-0.2	Height;	chr4:55537550	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs4864548	ENSG00000249700.7	SRD5A3-AS1	-4.45	1.08e-05	0.0011	-0.25	-0.2	Height;	chr4:55547636	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs13108409	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55520278	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11726198	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55523835	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs11133396	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55524246	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs7675109	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55525589	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs4865005	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55525781	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13108499	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55526514	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13116194	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55531150	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13117836	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55531218	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs7668429	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55531811	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13113518	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55533481	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13152173	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55534788	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13141049	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55535489	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.967	rs12507722	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55536421	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.967	rs7696832	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55537080	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs34648901	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55541259	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.902	rs12505266	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55546002	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs56154935	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55546378	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs7662966	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55548261	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13115828	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55551447	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs13136282	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55551845	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs11934897	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55553396	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.934	rs11932293	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55554025	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs4865011	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55554456	chr4:55363971~55395847:-
THCA	cis	rs13113518	1	rs4865013	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55559957	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs13144598	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55570311	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.966	rs11942472	ENSG00000249700.7	SRD5A3-AS1	4.45	1.08e-05	0.0011	0.25	0.2	Height;	chr4:55574959	chr4:55363971~55395847:-
THCA	cis	rs67478160	0.619	rs10083370	ENSG00000269910.1	RP11-73M18.10	-4.45	1.08e-05	0.0011	-0.17	-0.2	Schizophrenia;	chr14:103847845	chr14:103694516~103695050:-
THCA	cis	rs67478160	0.619	rs10083367	ENSG00000269910.1	RP11-73M18.10	-4.45	1.08e-05	0.0011	-0.17	-0.2	Schizophrenia;	chr14:103847846	chr14:103694516~103695050:-
THCA	cis	rs189798	0.738	rs330908	ENSG00000253893.2	FAM85B	-4.45	1.08e-05	0.0011	-0.25	-0.2	Myopia (pathological);	chr8:9137656	chr8:8167819~8226614:-
THCA	cis	rs17345786	0.667	rs7622940	ENSG00000256628.3	ZBTB11-AS1	4.45	1.08e-05	0.0011	0.24	0.2	Colonoscopy-negative controls vs population controls;	chr3:101414311	chr3:101676475~101679217:+
THCA	cis	rs593531	0.592	rs3168173	ENSG00000255440.1	RP11-632K5.2	4.45	1.08e-05	0.0011	0.24	0.2	Neuroticism;	chr11:74331742	chr11:74409060~74416379:+
THCA	cis	rs2070488	1	rs2276540	ENSG00000229589.1	ACVR2B-AS1	4.45	1.08e-05	0.0011	0.19	0.2	Electrocardiographic conduction measures;	chr3:38471016	chr3:38451027~38454820:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000234585.5	CCT6P3	4.45	1.08e-05	0.0011	0.18	0.2	Calcium levels;	chr7:65974892	chr7:65038354~65074713:+
THCA	cis	rs875971	0.522	rs709604	ENSG00000272831.1	RP11-792A8.4	-4.45	1.08e-05	0.0011	-0.13	-0.2	Aortic root size;	chr7:66032447	chr7:66739829~66740385:-
THCA	cis	rs11148252	0.553	rs7999849	ENSG00000273784.3	RP11-78J21.7	-4.45	1.08e-05	0.0011	-0.22	-0.2	Lewy body disease;	chr13:52675279	chr13:52600042~52642542:+
THCA	cis	rs6088590	0.965	rs6088620	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.08e-05	0.0011	-0.19	-0.2	Coronary artery disease;	chr20:34824219	chr20:33985617~33988989:-
THCA	cis	rs2380220	0.541	rs9285413	ENSG00000261366.1	MANEA-AS1	-4.45	1.08e-05	0.0011	-0.2	-0.2	Behavioural disinhibition (generation interaction);	chr6:95575563	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.576	rs4368819	ENSG00000261366.1	MANEA-AS1	-4.45	1.08e-05	0.0011	-0.2	-0.2	Behavioural disinhibition (generation interaction);	chr6:95583233	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.576	rs4498363	ENSG00000261366.1	MANEA-AS1	-4.45	1.08e-05	0.0011	-0.2	-0.2	Behavioural disinhibition (generation interaction);	chr6:95594462	chr6:95575183~95577450:-
THCA	cis	rs1923243	0.778	rs6676166	ENSG00000223479.3	RP4-788P17.1	-4.45	1.08e-05	0.0011	-0.22	-0.2	Migraine;	chr1:73132400	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.778	rs6681999	ENSG00000223479.3	RP4-788P17.1	-4.45	1.08e-05	0.0011	-0.22	-0.2	Migraine;	chr1:73133100	chr1:73635216~73715214:+
THCA	cis	rs6439699	1	rs13096023	ENSG00000273486.1	RP11-731C17.2	4.45	1.08e-05	0.0011	0.22	0.2	Intelligence (multi-trait analysis);	chr3:137291845	chr3:136837338~136839021:-
THCA	cis	rs17604090	0.938	rs10276157	ENSG00000227855.3	DPY19L2P3	4.45	1.08e-05	0.0011	0.27	0.2	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29625400	chr7:29650227~29742594:+
THCA	cis	rs2289700	1	rs12441725	ENSG00000252061.1	RNU6-415P	-4.45	1.08e-05	0.0011	-0.41	-0.2	Bipolar disorder;	chr15:78926431	chr15:78898840~78898936:-
THCA	cis	rs2289700	1	rs3784537	ENSG00000252061.1	RNU6-415P	-4.45	1.08e-05	0.0011	-0.41	-0.2	Bipolar disorder;	chr15:78926652	chr15:78898840~78898936:-
THCA	cis	rs2289700	1	rs3784538	ENSG00000252061.1	RNU6-415P	-4.45	1.08e-05	0.0011	-0.41	-0.2	Bipolar disorder;	chr15:78926838	chr15:78898840~78898936:-
THCA	cis	rs2289700	0.803	rs8039683	ENSG00000252061.1	RNU6-415P	-4.45	1.08e-05	0.0011	-0.41	-0.2	Bipolar disorder;	chr15:78928003	chr15:78898840~78898936:-
THCA	cis	rs72928364	1	rs62275203	ENSG00000256628.3	ZBTB11-AS1	4.45	1.08e-05	0.0011	0.35	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100989103	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs66852780	ENSG00000256628.3	ZBTB11-AS1	4.45	1.08e-05	0.0011	0.35	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100990378	chr3:101676475~101679217:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000272831.1	RP11-792A8.4	4.45	1.08e-05	0.0011	0.13	0.2	Aortic root size;	chr7:66008701	chr7:66739829~66740385:-
THCA	cis	rs593531	0.513	rs7944333	ENSG00000255440.1	RP11-632K5.2	-4.45	1.08e-05	0.0011	-0.24	-0.2	Neuroticism;	chr11:74311384	chr11:74409060~74416379:+
THCA	cis	rs75920871	0.609	rs11216187	ENSG00000254851.1	RP11-109L13.1	-4.45	1.08e-05	0.0011	-0.42	-0.2	Subjective well-being;	chr11:116916432	chr11:117135528~117138582:+
THCA	cis	rs1876905	0.68	rs354540	ENSG00000272356.1	RP5-1112D6.8	-4.45	1.08e-05	0.0011	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111309203~111313517:+
THCA	cis	rs2303759	0.507	rs1465696	ENSG00000268686.1	AC010524.2	-4.45	1.08e-05	0.0011	-0.38	-0.2	Multiple sclerosis;	chr19:49334182	chr19:49368705~49388081:-
THCA	cis	rs7849973	0.579	rs10965453	ENSG00000234840.1	LINC01239	4.45	1.08e-05	0.0011	0.25	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22778493	chr9:22646200~22824213:+
THCA	cis	rs1790761	0.667	rs4147581	ENSG00000255318.1	RP11-655M14.13	4.45	1.08e-05	0.0011	0.22	0.2	Mean corpuscular volume;	chr11:67584114	chr11:67618279~67627304:-
THCA	cis	rs4144027	0.875	rs6576010	ENSG00000269958.1	RP11-73M18.8	-4.45	1.08e-05	0.0011	-0.19	-0.2	Blood metabolite levels;	chr14:103883265	chr14:103696353~103697163:+
THCA	cis	rs1783925	0.549	rs12797616	ENSG00000254671.2	STT3A-AS1	-4.45	1.08e-05	0.0011	-0.24	-0.2	Formal thought disorder in schizophrenia;	chr11:125444363	chr11:125570284~125592568:-
THCA	cis	rs9840812	0.61	rs34967300	ENSG00000239213.4	NCK1-AS1	-4.45	1.08e-05	0.0011	-0.21	-0.2	Fibrinogen levels;	chr3:136549976	chr3:136841726~136862054:-
THCA	cis	rs61270009	0.955	rs4916719	ENSG00000247828.6	TMEM161B-AS1	4.45	1.08e-05	0.0011	0.17	0.2	Depressive symptoms;	chr5:88327844	chr5:88268895~88436685:+
THCA	cis	rs9468199	0.505	rs72847381	ENSG00000280107.1	AL022393.9	-4.45	1.08e-05	0.0011	-0.43	-0.2	Parkinson's disease;	chr6:27906153	chr6:28170845~28172521:+
THCA	cis	rs17767294	0.708	rs72848752	ENSG00000280107.1	AL022393.9	-4.45	1.08e-05	0.0011	-0.43	-0.2	Parkinson's disease;	chr6:27910490	chr6:28170845~28172521:+
THCA	cis	rs55661361	0.679	rs12287365	ENSG00000245498.5	RP11-677M14.7	4.45	1.08e-05	0.0011	0.15	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742814	chr11:124800450~124834487:+
THCA	cis	rs6657613	0.628	rs761423	ENSG00000186301.8	MST1P2	-4.45	1.08e-05	0.0011	-0.16	-0.2	Hip circumference adjusted for BMI;	chr1:16975177	chr1:16645622~16650289:+
THCA	cis	rs875971	0.545	rs13311962	ENSG00000273142.1	RP11-458F8.4	-4.45	1.08e-05	0.0011	-0.19	-0.2	Aortic root size;	chr7:66603142	chr7:66902857~66906297:+
THCA	cis	rs62025270	0.848	rs62025269	ENSG00000259295.5	CSPG4P12	-4.45	1.08e-05	0.0011	-0.32	-0.2	Idiopathic pulmonary fibrosis;	chr15:85756859	chr15:85191438~85213905:+
THCA	cis	rs6442522	0.64	rs28632773	ENSG00000249786.6	EAF1-AS1	4.45	1.08e-05	0.0011	0.21	0.2	Uric acid levels;	chr3:15474411	chr3:15436171~15455940:-
THCA	cis	rs9380516	0.627	rs4713899	ENSG00000228559.1	RP3-340B19.3	4.45	1.08e-05	0.0011	0.29	0.2	Hepatitis C induced liver fibrosis;	chr6:35601504	chr6:35544632~35545669:+
THCA	cis	rs17221829	0.899	rs10160328	ENSG00000280385.1	AP000648.5	-4.45	1.08e-05	0.0011	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89728996	chr11:90193614~90198120:+
THCA	cis	rs4705952	0.832	rs72797338	ENSG00000233006.5	AC034220.3	-4.45	1.08e-05	0.0011	-0.18	-0.2	C-reactive protein levels;	chr5:132530716	chr5:132311285~132369916:-
THCA	cis	rs1962772	0.847	rs7007605	ENSG00000279903.1	RP11-349F21.5	-4.45	1.09e-05	0.0011	-0.25	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17515668	chr8:17500012~17500605:+
THCA	cis	rs12030196	1	rs932770	ENSG00000230812.4	LINC01358	4.45	1.09e-05	0.0011	0.26	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59017934	chr1:59020387~59044614:+
THCA	cis	rs2839186	0.588	rs2839140	ENSG00000239415.1	AP001469.9	-4.45	1.09e-05	0.0011	-0.21	-0.2	Testicular germ cell tumor;	chr21:46196166	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.647	rs9976233	ENSG00000239415.1	AP001469.9	-4.45	1.09e-05	0.0011	-0.21	-0.2	Testicular germ cell tumor;	chr21:46196999	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.588	rs7280110	ENSG00000239415.1	AP001469.9	-4.45	1.09e-05	0.0011	-0.21	-0.2	Testicular germ cell tumor;	chr21:46199125	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.616	rs4819213	ENSG00000239415.1	AP001469.9	-4.45	1.09e-05	0.0011	-0.21	-0.2	Testicular germ cell tumor;	chr21:46199386	chr21:46251549~46254133:-
THCA	cis	rs718433	0.584	rs2204935	ENSG00000211778.2	TRAV4	-4.45	1.09e-05	0.0011	-0.15	-0.2	Intraocular pressure;	chr14:21744180	chr14:21736152~21736982:+
THCA	cis	rs718433	0.584	rs4982492	ENSG00000211778.2	TRAV4	-4.45	1.09e-05	0.0011	-0.15	-0.2	Intraocular pressure;	chr14:21744535	chr14:21736152~21736982:+
THCA	cis	rs7267979	0.868	rs6138550	ENSG00000274973.1	RP13-401N8.7	-4.45	1.09e-05	0.0011	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.903	rs6050481	ENSG00000274973.1	RP13-401N8.7	-4.45	1.09e-05	0.0011	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.834	rs6115100	ENSG00000274973.1	RP13-401N8.7	-4.45	1.09e-05	0.0011	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25845497~25845862:+
THCA	cis	rs11771526	1	rs11770367	ENSG00000272905.1	RP11-265E18.1	4.45	1.09e-05	0.0011	0.29	0.2	Body mass index;	chr7:32314707	chr7:32845394~32846061:+
THCA	cis	rs11771526	1	rs62457533	ENSG00000272905.1	RP11-265E18.1	4.45	1.09e-05	0.0011	0.29	0.2	Body mass index;	chr7:32315722	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.892	rs62457534	ENSG00000272905.1	RP11-265E18.1	4.45	1.09e-05	0.0011	0.29	0.2	Body mass index;	chr7:32318040	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.681	rs62457535	ENSG00000272905.1	RP11-265E18.1	4.45	1.09e-05	0.0011	0.29	0.2	Body mass index;	chr7:32319098	chr7:32845394~32846061:+
THCA	cis	rs6005807	0.764	rs9620764	ENSG00000235954.5	TTC28-AS1	-4.45	1.09e-05	0.0011	-0.26	-0.2	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28045483	chr22:27919376~28008581:+
THCA	cis	rs6125597	0.533	rs6122778	ENSG00000227431.4	CSE1L-AS1	4.45	1.09e-05	0.0011	0.26	0.2	Intelligence (multi-trait analysis);	chr20:49267405	chr20:49040463~49046044:-
THCA	cis	rs1150668	0.83	rs213240	ENSG00000280107.1	AL022393.9	-4.45	1.09e-05	0.0011	-0.2	-0.2	Pubertal anthropometrics;	chr6:28348098	chr6:28170845~28172521:+
THCA	cis	rs654950	0.774	rs941972	ENSG00000230638.4	RP11-486B10.4	4.45	1.09e-05	0.0011	0.24	0.2	Airway imaging phenotypes;	chr1:41575069	chr1:41542069~41544310:+
THCA	cis	rs763121	0.853	rs2413545	ENSG00000235209.1	CTA-150C2.13	4.45	1.09e-05	0.0011	0.27	0.2	Menopause (age at onset);	chr22:38696519	chr22:38921227~38924708:+
THCA	cis	rs9309473	0.95	rs6705977	ENSG00000273245.1	RP11-434P11.2	4.45	1.09e-05	0.0011	0.28	0.2	Metabolite levels;	chr2:73622043	chr2:73750256~73750786:-
THCA	cis	rs59868192	0.925	rs72726037	ENSG00000246740.2	PLA2G4E-AS1	4.45	1.09e-05	0.0011	0.38	0.2	White blood cell count;	chr15:41971781	chr15:41972763~41999094:+
THCA	cis	rs1580019	0.52	rs13228793	ENSG00000231952.3	DPY19L1P2	-4.45	1.09e-05	0.0011	-0.26	-0.2	Cognitive ability;	chr7:32671853	chr7:32812757~32838570:+
THCA	cis	rs667920	0.512	rs13071085	ENSG00000273486.1	RP11-731C17.2	-4.45	1.09e-05	0.00111	-0.28	-0.2	Coronary artery disease;	chr3:136296081	chr3:136837338~136839021:-
THCA	cis	rs8067545	0.75	rs4925069	ENSG00000270091.1	RP11-78O7.2	-4.45	1.09e-05	0.00111	-0.15	-0.2	Schizophrenia;	chr17:20050218	chr17:19896590~19897287:-
THCA	cis	rs7824557	0.51	rs4841524	ENSG00000206014.6	OR7E161P	4.45	1.09e-05	0.00111	0.23	0.2	Retinal vascular caliber;	chr8:11385617	chr8:11928597~11929563:-
THCA	cis	rs9300255	0.507	rs1727302	ENSG00000256092.2	RP13-942N8.1	4.45	1.09e-05	0.00111	0.15	0.2	Neutrophil percentage of white cells;	chr12:123148383	chr12:123363868~123366113:+
THCA	cis	rs6840258	0.831	rs236676	ENSG00000251411.1	RP11-397E7.4	4.45	1.09e-05	0.00111	0.24	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87088468	chr4:86913266~86914817:-
THCA	cis	rs250518	0.926	rs10069567	ENSG00000272081.1	CTD-2376I4.2	4.45	1.09e-05	0.00111	0.26	0.2	Mean corpuscular hemoglobin concentration;	chr5:72771877	chr5:72955206~72955699:-
THCA	cis	rs9326248	0.53	rs511676	ENSG00000280143.1	AP000892.6	4.45	1.09e-05	0.00111	0.33	0.2	Blood protein levels;	chr11:116954168	chr11:117204967~117210292:+
THCA	cis	rs6832769	1	rs9997288	ENSG00000272969.1	RP11-528I4.2	4.45	1.09e-05	0.00111	0.24	0.2	Personality dimensions;	chr4:55481060	chr4:55547112~55547889:+
THCA	cis	rs1800795	0.599	rs1546762	ENSG00000179428.2	AC073072.5	-4.45	1.09e-05	0.00111	-0.22	-0.2	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22717884	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.532	rs1546763	ENSG00000179428.2	AC073072.5	-4.45	1.09e-05	0.00111	-0.22	-0.2	Lung cancer;	chr7:22718224	chr7:22725395~22727620:-
THCA	cis	rs734999	0.545	rs4648565	ENSG00000225931.3	RP3-395M20.7	-4.45	1.09e-05	0.00111	-0.24	-0.2	Ulcerative colitis;	chr1:2638584	chr1:2566410~2569888:+
THCA	cis	rs35771425	0.518	rs1055565	ENSG00000153363.11	LINC00467	-4.45	1.09e-05	0.00111	-0.15	-0.2	Educational attainment (years of education);	chr1:211432355	chr1:211382803~211435333:+
THCA	cis	rs2281603	0.57	rs10145013	ENSG00000259116.1	RP11-973N13.4	-4.45	1.09e-05	0.00111	-0.17	-0.2	Lymphocyte counts;	chr14:64474873	chr14:64514154~64540368:-
THCA	cis	rs7136259	0.779	rs11105377	ENSG00000258302.2	RP11-981P6.1	-4.45	1.09e-05	0.00111	-0.17	-0.2	Coronary heart disease;	chr12:89695052	chr12:89561129~89594878:+
THCA	cis	rs2590942	0.679	rs1385919	ENSG00000227207.2	RPL31P12	4.45	1.09e-05	0.00111	0.35	0.2	Childhood body mass index;	chr1:72140735	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.583	rs1545933	ENSG00000227207.2	RPL31P12	4.45	1.09e-05	0.00111	0.35	0.2	Childhood body mass index;	chr1:72146032	chr1:72301472~72301829:+
THCA	cis	rs260461	1	rs260461	ENSG00000268516.2	CTD-3138B18.5	-4.45	1.09e-05	0.00111	-0.28	-0.2	Attention deficit hyperactivity disorder;	chr19:58259517	chr19:58257270~58278808:-
THCA	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	4.45	1.09e-05	0.00111	0.23	0.2	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
THCA	cis	rs12406089	0.696	rs1009592	ENSG00000242349.4	NPPA-AS1	-4.45	1.09e-05	0.00111	-0.19	-0.2	N-terminal pro B-type natriuretic peptide levels;	chr1:11868657	chr1:11841017~11848079:+
THCA	cis	rs6433895	0.71	rs7581267	ENSG00000236153.1	AC104076.3	-4.45	1.09e-05	0.00111	-0.25	-0.2	Lymphocyte counts;	chr2:181143574	chr2:180979427~180980090:-
THCA	cis	rs9973361	0.531	rs62174851	ENSG00000232411.1	AC009495.3	-4.45	1.09e-05	0.00111	-0.25	-0.2	Total body bone mineral density;	chr2:165800811	chr2:165833048~165839098:-
THCA	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-4.45	1.09e-05	0.00111	-0.23	-0.2	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
THCA	cis	rs7772486	0.754	rs702319	ENSG00000270638.1	RP3-466P17.1	-4.45	1.09e-05	0.00111	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145735570~145737218:+
THCA	cis	rs7577696	0.886	rs6737500	ENSG00000276334.1	AL133243.1	-4.45	1.09e-05	0.00111	-0.21	-0.2	Inflammatory biomarkers;	chr2:32038018	chr2:32521927~32523547:+
THCA	cis	rs3785574	0.621	rs1051684	ENSG00000240280.5	TCAM1P	4.45	1.09e-05	0.00111	0.27	0.2	Height;	chr17:63929137	chr17:63849292~63864379:+
THCA	cis	rs9880211	0.948	rs9857966	ENSG00000239213.4	NCK1-AS1	4.45	1.09e-05	0.00111	0.22	0.2	Height;Body mass index;	chr3:136560548	chr3:136841726~136862054:-
THCA	cis	rs9300255	0.602	rs1106241	ENSG00000235423.7	RP11-282O18.3	4.45	1.09e-05	0.00111	0.21	0.2	Neutrophil percentage of white cells;	chr12:123142469	chr12:123252030~123261483:-
THCA	cis	rs8113308	1	rs7246064	ENSG00000269483.1	AC006272.1	4.45	1.09e-05	0.00111	0.3	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939009	chr19:51839924~51843324:-
THCA	cis	rs2028299	0.919	rs12440156	ENSG00000259677.1	RP11-493E3.1	4.45	1.09e-05	0.00111	0.26	0.2	Type 2 diabetes;	chr15:89877441	chr15:89876540~89877285:+
THCA	cis	rs858239	0.601	rs6980224	ENSG00000226816.2	AC005082.12	4.45	1.09e-05	0.00111	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23206013~23208045:+
THCA	cis	rs7111546	0.565	rs733296	ENSG00000246225.5	RP11-17A1.3	4.45	1.09e-05	0.00111	0.35	0.2	Dialysis-related mortality;	chr11:22915033	chr11:22829380~22945393:+
THCA	cis	rs1150668	0.799	rs1150707	ENSG00000220721.1	OR1F12	4.45	1.09e-05	0.00111	0.22	0.2	Pubertal anthropometrics;	chr6:28229827	chr6:28073316~28074233:+
THCA	cis	rs6730558	0.934	rs13007474	ENSG00000236008.1	AC011747.4	4.45	1.09e-05	0.00111	0.23	0.2	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8607783	chr2:8559833~8583792:-
THCA	cis	rs2243480	1	rs313814	ENSG00000164669.11	INTS4P1	4.45	1.09e-05	0.00111	0.39	0.2	Diabetic kidney disease;	chr7:66038306	chr7:65141225~65234216:+
THCA	cis	rs12541437	1	rs2921753	ENSG00000253327.2	RAD21-AS1	4.45	1.09e-05	0.00111	0.22	0.2	Gut microbiome composition (winter);	chr8:116906962	chr8:116874424~116876868:+
THCA	cis	rs2839186	0.558	rs2968	ENSG00000239415.1	AP001469.9	-4.45	1.09e-05	0.00111	-0.21	-0.2	Testicular germ cell tumor;	chr21:46188666	chr21:46251549~46254133:-
THCA	cis	rs9532669	0.926	rs9562254	ENSG00000229473.2	RGS17P1	-4.45	1.09e-05	0.00111	-0.25	-0.2	Cervical cancer;	chr13:40960902	chr13:40992779~40993331:-
THCA	cis	rs11673344	0.503	rs1667370	ENSG00000267260.1	CTD-2162K18.4	-4.45	1.09e-05	0.00111	-0.24	-0.2	Obesity-related traits;	chr19:36999318	chr19:36773153~36777078:+
THCA	cis	rs990871	0.512	rs6699731	ENSG00000227207.2	RPL31P12	-4.45	1.09e-05	0.00111	-0.24	-0.2	Subcutaneous adipose tissue;	chr1:72180051	chr1:72301472~72301829:+
THCA	cis	rs10860794	1	rs10745925	ENSG00000274560.1	RP11-285E23.2	-4.45	1.09e-05	0.00111	-0.13	-0.2	Blood protein levels;	chr12:101825121	chr12:101696002~101696450:-
THCA	cis	rs10860794	1	rs4764823	ENSG00000274560.1	RP11-285E23.2	-4.45	1.09e-05	0.00111	-0.13	-0.2	Blood protein levels;	chr12:101825988	chr12:101696002~101696450:-
THCA	cis	rs944289	0.708	rs1537424	ENSG00000258844.1	RP11-259K15.2	4.45	1.09e-05	0.00111	0.18	0.2	Thyroid cancer;	chr14:36104812	chr14:36214607~36235608:+
THCA	cis	rs1005277	0.579	rs1740732	ENSG00000272983.1	RP11-508N22.12	4.45	1.09e-05	0.00111	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38137337~38144399:+
THCA	cis	rs13126694	0.744	rs7682867	ENSG00000248429.4	RP11-597D13.9	4.45	1.09e-05	0.00111	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158026735	chr4:158170752~158202877:+
THCA	cis	rs13325613	0.915	rs7628489	ENSG00000223552.1	RP11-24F11.2	-4.45	1.09e-05	0.00111	-0.3	-0.2	Monocyte count;	chr3:46226384	chr3:46364955~46407059:-
THCA	cis	rs61270009	0.955	rs4916899	ENSG00000247828.6	TMEM161B-AS1	4.45	1.09e-05	0.00111	0.17	0.2	Depressive symptoms;	chr5:88292209	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs35300532	ENSG00000247828.6	TMEM161B-AS1	4.45	1.09e-05	0.00111	0.17	0.2	Depressive symptoms;	chr5:88293219	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs12659252	ENSG00000247828.6	TMEM161B-AS1	4.45	1.09e-05	0.00111	0.17	0.2	Depressive symptoms;	chr5:88297472	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs6872223	ENSG00000247828.6	TMEM161B-AS1	4.45	1.09e-05	0.00111	0.17	0.2	Depressive symptoms;	chr5:88306555	chr5:88268895~88436685:+
THCA	cis	rs7403037	1	rs7403037	ENSG00000260760.1	PWRN3	-4.45	1.09e-05	0.00111	-0.24	-0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24573350	chr15:24441127~24447967:+
THCA	cis	rs12546962	0.639	rs56731460	ENSG00000254153.1	CTA-398F10.2	-4.45	1.09e-05	0.00111	-0.25	-0.2	Body mass index;	chr8:9337160	chr8:8456909~8461337:-
THCA	cis	rs62025270	0.688	rs62025272	ENSG00000259295.5	CSPG4P12	-4.45	1.1e-05	0.00111	-0.32	-0.2	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85191438~85213905:+
THCA	cis	rs12410462	0.551	rs12096675	ENSG00000227711.2	RP11-275O4.5	-4.45	1.1e-05	0.00111	-0.24	-0.2	Major depressive disorder;	chr1:227651683	chr1:227509028~227520477:-
THCA	cis	rs964611	0.882	rs12441867	ENSG00000259488.2	RP11-154J22.1	4.45	1.1e-05	0.00111	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48343856	chr15:48312353~48331856:-
THCA	cis	rs8058578	1	rs67456513	ENSG00000279196.1	RP11-1072A3.3	4.45	1.1e-05	0.00111	0.2	0.2	Multiple myeloma;	chr16:30703507	chr16:30984630~30988270:-
THCA	cis	rs7246760	0.867	rs8112764	ENSG00000267106.4	ZNF561-AS1	4.45	1.1e-05	0.00111	0.39	0.2	Pursuit maintenance gain;	chr19:9638231	chr19:9621291~9645896:+
THCA	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	4.45	1.1e-05	0.00111	0.25	0.2	Depression;	chr6:28240757	chr6:28943877~28944537:+
THCA	cis	rs12462428	0.531	rs1544768	ENSG00000279748.1	CTD-3222D19.9	4.45	1.1e-05	0.00111	0.2	0.2	Educational attainment (years of education);	chr19:16547110	chr19:16586905~16589409:+
THCA	cis	rs9634489	0.588	rs9554335	ENSG00000247400.3	DNAJC3-AS1	-4.45	1.1e-05	0.00111	-0.13	-0.2	Body mass index;	chr13:96271405	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.588	rs1927789	ENSG00000247400.3	DNAJC3-AS1	-4.45	1.1e-05	0.00111	-0.13	-0.2	Body mass index;	chr13:96272077	chr13:95648733~95676925:-
THCA	cis	rs718433	0.584	rs10133988	ENSG00000211778.2	TRAV4	-4.45	1.1e-05	0.00111	-0.15	-0.2	Intraocular pressure;	chr14:21746376	chr14:21736152~21736982:+
THCA	cis	rs7246657	0.55	rs10411176	ENSG00000276846.1	CTD-3220F14.3	4.45	1.1e-05	0.00111	0.26	0.2	Coronary artery calcification;	chr19:37196051	chr19:37314868~37315620:-
THCA	cis	rs7178424	0.806	rs1425270	ENSG00000259251.2	RP11-643M14.1	4.45	1.1e-05	0.00111	0.2	0.2	Height;	chr15:61945511	chr15:62060503~62062434:+
THCA	cis	rs427394	0.743	rs274716	ENSG00000248677.1	CTD-2044J15.1	4.45	1.1e-05	0.00111	0.2	0.2	Menopause (age at onset);	chr5:6722176	chr5:6686325~6707711:-
THCA	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-4.45	1.1e-05	0.00111	-0.28	-0.2	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
THCA	cis	rs2439831	1	rs9920763	ENSG00000205771.5	CATSPER2P1	-4.45	1.1e-05	0.00111	-0.3	-0.2	Lung cancer in ever smokers;	chr15:43468310	chr15:43726918~43747094:-
THCA	cis	rs3738443	0.868	rs2892054	ENSG00000259865.1	RP11-488L18.10	4.45	1.1e-05	0.00111	0.21	0.2	Alcohol dependence;	chr1:247203803	chr1:247187281~247188526:-
THCA	cis	rs875971	0.825	rs1129531	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.1e-05	0.00111	-0.21	-0.2	Aortic root size;	chr7:66154117	chr7:66025126~66031544:-
THCA	cis	rs6517329	0.649	rs2242798	ENSG00000236830.5	CBR3-AS1	4.44	1.1e-05	0.00111	0.19	0.2	Schizophrenia;	chr21:36120583	chr21:36131767~36175815:-
THCA	cis	rs496547	0.719	rs472641	ENSG00000255422.1	AP002954.4	-4.44	1.1e-05	0.00112	-0.22	-0.2	Hip minimal joint space width;	chr11:118746835	chr11:118704607~118750263:+
THCA	cis	rs2033711	0.503	rs6510141	ENSG00000268230.4	CTD-2619J13.8	4.44	1.1e-05	0.00112	0.2	0.2	Uric acid clearance;	chr19:58374419	chr19:58346854~58362751:-
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000184274.3	LINC00315	-4.44	1.1e-05	0.00112	-0.27	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45300245~45305257:-
THCA	cis	rs2554380	0.628	rs4843158	ENSG00000176700.18	SCAND2P	-4.44	1.1e-05	0.00112	-0.15	-0.2	Height;	chr15:83802884	chr15:84631451~84647478:+
THCA	cis	rs6997458	0.785	rs2432083	ENSG00000253549.4	RP11-317J10.2	4.44	1.1e-05	0.00112	0.2	0.2	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85428379	chr8:85441851~85464915:-
THCA	cis	rs6496044	0.507	rs7175731	ENSG00000259407.1	RP11-158M2.3	4.44	1.1e-05	0.00112	0.22	0.2	Interstitial lung disease;	chr15:85611115	chr15:85744109~85750281:-
THCA	cis	rs7608910	0.896	rs1962449	ENSG00000271889.1	RP11-493E12.1	4.44	1.1e-05	0.00112	0.21	0.2	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60975414	chr2:61151433~61162105:-
THCA	cis	rs4650994	0.593	rs7540745	ENSG00000273384.1	RP5-1098D14.1	-4.44	1.1e-05	0.00112	-0.27	-0.2	HDL cholesterol;HDL cholesterol levels;	chr1:178560622	chr1:178651706~178652282:+
THCA	cis	rs17711722	1	rs17711722	ENSG00000234585.5	CCT6P3	-4.44	1.1e-05	0.00112	-0.18	-0.2	Calcium levels;	chr7:65806210	chr7:65038354~65074713:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000234585.5	CCT6P3	-4.44	1.1e-05	0.00112	-0.18	-0.2	Calcium levels;	chr7:65808508	chr7:65038354~65074713:+
THCA	cis	rs4906332	1	rs12896612	ENSG00000269910.1	RP11-73M18.10	4.44	1.1e-05	0.00112	0.17	0.2	Coronary artery disease;	chr14:103411531	chr14:103694516~103695050:-
THCA	cis	rs72843506	0.722	rs16942325	ENSG00000261033.1	RP11-209D14.2	4.44	1.1e-05	0.00112	0.38	0.2	Schizophrenia;	chr17:20123750	chr17:20008051~20009234:-
THCA	cis	rs890448	1	rs1346215	ENSG00000254531.1	FLJ20021	-4.44	1.1e-05	0.00112	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101516416	chr4:101347780~101348883:+
THCA	cis	rs9625935	0.957	rs3788423	ENSG00000279159.1	RP3-394A18.1	4.44	1.1e-05	0.00112	0.16	0.2	Tonsillectomy;	chr22:29995001	chr22:29978950~30028236:-
THCA	cis	rs3738443	0.817	rs61840052	ENSG00000259865.1	RP11-488L18.10	4.44	1.1e-05	0.00112	0.21	0.2	Alcohol dependence;	chr1:247204036	chr1:247187281~247188526:-
THCA	cis	rs7312933	0.558	rs2178753	ENSG00000257225.1	RP11-328C8.4	4.44	1.1e-05	0.00112	0.21	0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42339002	chr12:42459366~42466128:+
THCA	cis	rs2836950	0.52	rs2836966	ENSG00000238141.2	BRWD1-AS1	-4.44	1.1e-05	0.00112	-0.23	-0.2	Menarche (age at onset);	chr21:39265595	chr21:39315707~39323218:+
THCA	cis	rs791590	0.941	rs12722515	ENSG00000229664.1	RP11-536K7.5	-4.44	1.1e-05	0.00112	-0.33	-0.2	Soluble interleukin-2 receptor subunit alpha;	chr10:6039267	chr10:6025978~6036427:+
THCA	cis	rs17818399	0.815	rs17819022	ENSG00000279254.1	RP11-536C12.1	-4.44	1.1e-05	0.00112	-0.21	-0.2	Height;	chr2:46623432	chr2:46668870~46670778:+
THCA	cis	rs6449502	0.688	rs158920	ENSG00000251279.1	CTC-436P18.1	4.44	1.1e-05	0.00112	0.33	0.2	Mean platelet volume;	chr5:60945441	chr5:61162070~61232040:+
THCA	cis	rs914615	0.552	rs4276914	ENSG00000236675.1	MTX1P1	-4.44	1.1e-05	0.00112	-0.19	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155169753	chr1:155230975~155234325:+
THCA	cis	rs914615	0.552	rs4971088	ENSG00000236675.1	MTX1P1	-4.44	1.1e-05	0.00112	-0.19	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155170407	chr1:155230975~155234325:+
THCA	cis	rs914615	0.552	rs4971089	ENSG00000236675.1	MTX1P1	-4.44	1.1e-05	0.00112	-0.19	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155170451	chr1:155230975~155234325:+
THCA	cis	rs10860794	0.961	rs4764822	ENSG00000274560.1	RP11-285E23.2	-4.44	1.1e-05	0.00112	-0.13	-0.2	Blood protein levels;	chr12:101822895	chr12:101696002~101696450:-
THCA	cis	rs10860794	1	rs10860794	ENSG00000274560.1	RP11-285E23.2	-4.44	1.1e-05	0.00112	-0.13	-0.2	Blood protein levels;	chr12:101823942	chr12:101696002~101696450:-
THCA	cis	rs1913185	0.787	rs58874363	ENSG00000240032.1	RP11-274H2.3	-4.44	1.1e-05	0.00112	-0.31	-0.2	Obesity-related traits;	chr3:146126725	chr3:146066344~146069185:-
THCA	cis	rs4947019	0.688	rs9480937	ENSG00000223537.2	RP5-919F19.5	4.44	1.1e-05	0.00112	0.44	0.2	Hematological parameters;	chr6:109358629	chr6:109487906~109506800:+
THCA	cis	rs8062405	0.656	rs7189927	ENSG00000278665.1	RP11-666O2.4	-4.44	1.1e-05	0.00112	-0.23	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28599241~28601881:-
THCA	cis	rs931127	0.658	rs12787843	ENSG00000214659.4	KRT8P26	4.44	1.1e-05	0.00112	0.17	0.2	Systemic lupus erythematosus;	chr11:65709835	chr11:65726939~65728214:+
THCA	cis	rs12142240	0.698	rs79490411	ENSG00000232022.5	FAAHP1	-4.44	1.1e-05	0.00112	-0.24	-0.2	Menopause (age at onset);	chr1:46347896	chr1:46432129~46445521:+
THCA	cis	rs17301013	0.861	rs7521870	ENSG00000227373.4	RP11-160H22.5	-4.44	1.1e-05	0.00112	-0.29	-0.2	Systemic lupus erythematosus;	chr1:174497239	chr1:174115300~174160004:-
THCA	cis	rs3796352	0.667	rs3755805	ENSG00000242142.1	SERBP1P3	-4.44	1.1e-05	0.00112	-0.36	-0.2	Immune reponse to smallpox (secreted IL-2);	chr3:52832283	chr3:53064283~53065091:-
THCA	cis	rs1005277	0.557	rs2983338	ENSG00000272983.1	RP11-508N22.12	4.44	1.1e-05	0.00112	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38137337~38144399:+
THCA	cis	rs734999	0.549	rs60733400	ENSG00000225931.3	RP3-395M20.7	4.44	1.1e-05	0.00112	0.24	0.2	Ulcerative colitis;	chr1:2585342	chr1:2566410~2569888:+
THCA	cis	rs12887734	0.524	rs722637	ENSG00000269940.1	RP11-73M18.7	-4.44	1.1e-05	0.00112	-0.2	-0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103694560~103695170:+
THCA	cis	rs7647973	0.769	rs4974081	ENSG00000228638.1	FCF1P2	4.44	1.1e-05	0.00112	0.25	0.2	Menarche (age at onset);	chr3:49033066	chr3:48290793~48291375:-
THCA	cis	rs7554547	0.69	rs9661078	ENSG00000201801.1	RNU5E-4P	4.44	1.1e-05	0.00112	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr1:11876267	chr1:11909808~11909927:-
THCA	cis	rs7572644	0.699	rs7595986	ENSG00000223522.1	AC093690.1	4.44	1.1e-05	0.00112	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27862444	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs2337373	ENSG00000223522.1	AC093690.1	4.44	1.1e-05	0.00112	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27870055	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs13411592	ENSG00000223522.1	AC093690.1	4.44	1.1e-05	0.00112	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27875857	chr2:28307691~28310459:-
THCA	cis	rs9625935	0.957	rs34862234	ENSG00000279159.1	RP3-394A18.1	-4.44	1.1e-05	0.00112	-0.16	-0.2	Tonsillectomy;	chr22:29881077	chr22:29978950~30028236:-
THCA	cis	rs10266483	0.881	rs636242	ENSG00000271550.1	BNIP3P11	4.44	1.1e-05	0.00112	0.25	0.2	Response to statin therapy;	chr7:64284377	chr7:64678954~64687393:-
THCA	cis	rs10266483	0.921	rs653746	ENSG00000271550.1	BNIP3P11	4.44	1.1e-05	0.00112	0.25	0.2	Response to statin therapy;	chr7:64284399	chr7:64678954~64687393:-
THCA	cis	rs4927850	0.501	rs9881504	ENSG00000260261.1	RP11-480A16.1	-4.44	1.1e-05	0.00112	-0.13	-0.2	Pancreatic cancer;	chr3:195929743	chr3:195949188~195952695:-
THCA	cis	rs56313388	0.522	rs9931808	ENSG00000246379.5	RP11-461O7.1	-4.44	1.1e-05	0.00112	-0.21	-0.2	Pulse pressure;	chr16:56125259	chr16:56092987~56191094:-
THCA	cis	rs2836326	0.954	rs2836316	ENSG00000231123.1	SPATA20P1	4.44	1.1e-05	0.00112	0.28	0.2	Metabolite levels (HVA);	chr21:38343867	chr21:38238227~38238664:-
THCA	cis	rs394563	0.625	rs394526	ENSG00000268592.3	RAET1E-AS1	4.44	1.1e-05	0.00112	0.28	0.2	Dupuytren's disease;	chr6:149475839	chr6:149863494~149919507:+
THCA	cis	rs796395	0.641	rs519709	ENSG00000232480.1	TGFB2-AS1	-4.44	1.1e-05	0.00112	-0.23	-0.2	Post bronchodilator FEV1/FVC ratio;	chr1:218481392	chr1:218344196~218345678:-
THCA	cis	rs481331	0.866	rs209374	ENSG00000215146.4	RP11-313J2.1	-4.44	1.1e-05	0.00112	-0.39	-0.2	Systemic juvenile idiopathic arthritis;	chr10:42599114	chr10:42331866~42367974:-
THCA	cis	rs4072705	0.646	rs915034	ENSG00000224020.1	MIR181A2HG	-4.44	1.1e-05	0.00112	-0.18	-0.2	Menarche (age at onset);	chr9:124482676	chr9:124658467~124698631:+
THCA	cis	rs1766786	1	rs1766786	ENSG00000231365.4	RP11-418J17.1	-4.44	1.1e-05	0.00112	-0.28	-0.2	Chin dimples;	chr1:118909877	chr1:119140396~119275973:+
THCA	cis	rs1766786	0.925	rs1766787	ENSG00000231365.4	RP11-418J17.1	-4.44	1.1e-05	0.00112	-0.28	-0.2	Chin dimples;	chr1:118910135	chr1:119140396~119275973:+
THCA	cis	rs9543976	0.623	rs7317250	ENSG00000261105.4	LMO7-AS1	4.44	1.1e-05	0.00112	0.28	0.2	Diabetic retinopathy;	chr13:75593005	chr13:75604700~75635994:-
THCA	cis	rs62025270	0.688	rs10163064	ENSG00000259295.5	CSPG4P12	-4.44	1.1e-05	0.00112	-0.34	-0.2	Idiopathic pulmonary fibrosis;	chr15:85734289	chr15:85191438~85213905:+
THCA	cis	rs868036	0.718	rs8030456	ENSG00000270964.1	RP11-502I4.3	-4.44	1.11e-05	0.00112	-0.18	-0.2	Restless legs syndrome;	chr15:67784518	chr15:67541072~67542604:-
THCA	cis	rs868036	0.718	rs16951275	ENSG00000270964.1	RP11-502I4.3	-4.44	1.11e-05	0.00112	-0.18	-0.2	Restless legs syndrome;	chr15:67784830	chr15:67541072~67542604:-
THCA	cis	rs868036	0.672	rs7175517	ENSG00000270964.1	RP11-502I4.3	-4.44	1.11e-05	0.00112	-0.18	-0.2	Restless legs syndrome;	chr15:67785292	chr15:67541072~67542604:-
THCA	cis	rs868036	0.718	rs28463100	ENSG00000270964.1	RP11-502I4.3	-4.44	1.11e-05	0.00112	-0.18	-0.2	Restless legs syndrome;	chr15:67786431	chr15:67541072~67542604:-
THCA	cis	rs11723261	0.621	rs6599306	ENSG00000211553.1	AC253576.2	4.44	1.11e-05	0.00112	0.3	0.2	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:136461~136568:+
THCA	cis	rs4538475	1	rs4538475	ENSG00000214846.4	RP11-115L11.1	4.44	1.11e-05	0.00112	0.29	0.2	Parkinson's disease;	chr4:15736314	chr4:15730962~15731627:-
THCA	cis	rs13126694	0.744	rs28635553	ENSG00000248429.4	RP11-597D13.9	4.44	1.11e-05	0.00112	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158010962	chr4:158170752~158202877:+
THCA	cis	rs13126694	0.71	rs6847800	ENSG00000248429.4	RP11-597D13.9	4.44	1.11e-05	0.00112	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158011724	chr4:158170752~158202877:+
THCA	cis	rs6870983	0.802	rs62369123	ENSG00000247828.6	TMEM161B-AS1	4.44	1.11e-05	0.00112	0.18	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88459594	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.802	rs6452790	ENSG00000247828.6	TMEM161B-AS1	4.44	1.11e-05	0.00112	0.18	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88460891	chr5:88268895~88436685:+
THCA	cis	rs800160	1	rs1088987	ENSG00000199550.1	Y_RNA	4.44	1.11e-05	0.00112	0.3	0.2	Bacteremia;	chr11:2357966	chr11:2372638~2372750:+
THCA	cis	rs786425	0.655	rs7398298	ENSG00000270095.1	RP11-214K3.18	-4.44	1.11e-05	0.00112	-0.24	-0.2	Pubertal anthropometrics;	chr12:123708181	chr12:123971457~123971714:-
THCA	cis	rs786425	0.654	rs7305838	ENSG00000270095.1	RP11-214K3.18	-4.44	1.11e-05	0.00112	-0.24	-0.2	Pubertal anthropometrics;	chr12:123708924	chr12:123971457~123971714:-
THCA	cis	rs6430585	0.591	rs1374330	ENSG00000231890.6	DARS-AS1	-4.44	1.11e-05	0.00112	-0.24	-0.2	Corneal structure;	chr2:135663338	chr2:135985176~136022593:+
THCA	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	4.44	1.11e-05	0.00112	0.22	0.2	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000234585.5	CCT6P3	4.44	1.11e-05	0.00112	0.18	0.2	Aortic root size;	chr7:65827018	chr7:65038354~65074713:+
THCA	cis	rs447735	0.587	rs258336	ENSG00000260259.1	RP11-368I7.4	4.44	1.11e-05	0.00112	0.21	0.2	Hemoglobin concentration;	chr16:89654423	chr16:89682620~89686569:-
THCA	cis	rs1923243	0.778	rs7552761	ENSG00000223479.3	RP4-788P17.1	-4.44	1.11e-05	0.00112	-0.22	-0.2	Migraine;	chr1:73148398	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.778	rs10789355	ENSG00000223479.3	RP4-788P17.1	-4.44	1.11e-05	0.00112	-0.22	-0.2	Migraine;	chr1:73149444	chr1:73635216~73715214:+
THCA	cis	rs7829975	0.711	rs12682352	ENSG00000233609.3	RP11-62H7.2	4.44	1.11e-05	0.00112	0.2	0.2	Mood instability;	chr8:8788736	chr8:8961200~8979025:+
THCA	cis	rs13118159	0.55	rs4974612	ENSG00000254094.1	AC078852.1	-4.44	1.11e-05	0.00112	-0.25	-0.2	Longevity;	chr4:1370755	chr4:1356581~1358075:+
THCA	cis	rs9880211	0.948	rs34135127	ENSG00000239213.4	NCK1-AS1	4.44	1.11e-05	0.00112	0.22	0.2	Height;Body mass index;	chr3:136507656	chr3:136841726~136862054:-
THCA	cis	rs12935229	1	rs34504566	ENSG00000260922.1	RP11-538I12.3	-4.44	1.11e-05	0.00112	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77293740	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs12935229	ENSG00000260922.1	RP11-538I12.3	-4.44	1.11e-05	0.00112	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77294998	chr16:77234877~77290934:+
THCA	cis	rs7572644	0.699	rs1902966	ENSG00000223522.1	AC093690.1	4.44	1.11e-05	0.00112	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27966413	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs1841068	ENSG00000223522.1	AC093690.1	4.44	1.11e-05	0.00112	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27968762	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.662	rs12465103	ENSG00000223522.1	AC093690.1	4.44	1.11e-05	0.00112	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27976869	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs2337374	ENSG00000223522.1	AC093690.1	4.44	1.11e-05	0.00112	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27977285	chr2:28307691~28310459:-
THCA	cis	rs17270561	0.609	rs9358878	ENSG00000272462.2	U91328.19	-4.44	1.11e-05	0.00112	-0.17	-0.2	Iron status biomarkers;	chr6:25740045	chr6:25992662~26001775:+
THCA	cis	rs9532669	0.926	rs9525438	ENSG00000229473.2	RGS17P1	4.44	1.11e-05	0.00112	0.24	0.2	Cervical cancer;	chr13:40964123	chr13:40992779~40993331:-
THCA	cis	rs2028299	1	rs8031576	ENSG00000259677.1	RP11-493E3.1	4.44	1.11e-05	0.00112	0.26	0.2	Type 2 diabetes;	chr15:89836982	chr15:89876540~89877285:+
THCA	cis	rs227275	0.527	rs12500379	ENSG00000248971.2	KRT8P46	-4.44	1.11e-05	0.00112	-0.25	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102728746~102730171:-
THCA	cis	rs9925964	0.748	rs4889603	ENSG00000260911.2	RP11-196G11.2	4.44	1.11e-05	0.00112	0.16	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:31043150~31049868:+
THCA	cis	rs1396485	0.607	rs10076661	ENSG00000248445.4	SEMA6A-AS1	-4.44	1.11e-05	0.00112	-0.2	-0.2	Inflammatory biomarkers;	chr5:116093058	chr5:116447547~116508276:+
THCA	cis	rs7246760	0.867	rs66943818	ENSG00000267106.4	ZNF561-AS1	4.44	1.11e-05	0.00112	0.39	0.2	Pursuit maintenance gain;	chr19:9635691	chr19:9621291~9645896:+
THCA	cis	rs6067053	0.671	rs6067024	ENSG00000227431.4	CSE1L-AS1	4.44	1.11e-05	0.00112	0.25	0.2	Intelligence (multi-trait analysis);	chr20:49226609	chr20:49040463~49046044:-
THCA	cis	rs9926296	0.632	rs7206546	ENSG00000260259.1	RP11-368I7.4	4.44	1.11e-05	0.00113	0.22	0.2	Vitiligo;	chr16:89732671	chr16:89682620~89686569:-
THCA	cis	rs2115630	0.967	rs10438428	ENSG00000275120.1	RP11-182J1.17	-4.44	1.11e-05	0.00113	-0.2	-0.2	P wave terminal force;	chr15:84787514	chr15:84599434~84606463:-
THCA	cis	rs1942	1	rs1942	ENSG00000247556.5	OIP5-AS1	4.44	1.11e-05	0.00113	0.16	0.2	Eosinophil percentage of granulocytes;	chr15:41482225	chr15:41283990~41309737:+
THCA	cis	rs3813567	0.759	rs12594550	ENSG00000261143.1	ADAMTS7P3	4.44	1.11e-05	0.00113	0.31	0.2	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78666695	chr15:77976042~77993057:+
THCA	cis	rs12440869	1	rs6494640	ENSG00000270964.1	RP11-502I4.3	-4.44	1.11e-05	0.00113	-0.18	-0.2	Peak velocity of the mitral A-wave;	chr15:67247579	chr15:67541072~67542604:-
THCA	cis	rs72717009	0.825	rs12722986	ENSG00000225217.1	HSPA7	-4.44	1.11e-05	0.00113	-0.31	-0.2	Rheumatoid arthritis;	chr1:161495630	chr1:161606291~161608217:+
THCA	cis	rs2836950	0.52	rs11911087	ENSG00000238141.2	BRWD1-AS1	-4.44	1.11e-05	0.00113	-0.23	-0.2	Menarche (age at onset);	chr21:39293266	chr21:39315707~39323218:+
THCA	cis	rs62158800	0.925	rs62158826	ENSG00000224568.1	AC096669.3	4.44	1.11e-05	0.00113	0.4	0.2	Facial morphology (factor 22);	chr2:107620746	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.925	rs62158833	ENSG00000224568.1	AC096669.3	4.44	1.11e-05	0.00113	0.4	0.2	Facial morphology (factor 22);	chr2:107635171	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.85	rs72823078	ENSG00000224568.1	AC096669.3	4.44	1.11e-05	0.00113	0.4	0.2	Facial morphology (factor 22);	chr2:107663477	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.703	rs62161268	ENSG00000224568.1	AC096669.3	4.44	1.11e-05	0.00113	0.4	0.2	Facial morphology (factor 22);	chr2:107665854	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.852	rs62161269	ENSG00000224568.1	AC096669.3	4.44	1.11e-05	0.00113	0.4	0.2	Facial morphology (factor 22);	chr2:107667473	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.852	rs62161270	ENSG00000224568.1	AC096669.3	4.44	1.11e-05	0.00113	0.4	0.2	Facial morphology (factor 22);	chr2:107667735	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.777	rs62161274	ENSG00000224568.1	AC096669.3	4.44	1.11e-05	0.00113	0.4	0.2	Facial morphology (factor 22);	chr2:107670011	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.733	rs62161275	ENSG00000224568.1	AC096669.3	4.44	1.11e-05	0.00113	0.4	0.2	Facial morphology (factor 22);	chr2:107671292	chr2:107529487~107556326:+
THCA	cis	rs9314614	0.763	rs2977796	ENSG00000245857.2	GS1-24F4.2	4.44	1.11e-05	0.00113	0.26	0.2	White blood cell count (basophil);IgA nephropathy;	chr8:6852203	chr8:6835554~6885276:+
THCA	cis	rs10090774	0.93	rs4961293	ENSG00000279766.1	RP11-642A1.2	4.44	1.11e-05	0.00113	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140802275	chr8:140572142~140572812:-
THCA	cis	rs10744955	0.727	rs8035794	ENSG00000244879.4	GABPB1-AS1	-4.44	1.11e-05	0.00113	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50157506	chr15:50354959~50372202:+
THCA	cis	rs860295	0.702	rs2175391	ENSG00000160766.13	GBAP1	4.44	1.11e-05	0.00113	0.24	0.2	Body mass index;	chr1:155655811	chr1:155213821~155227422:-
THCA	cis	rs36093844	0.848	rs55836023	ENSG00000279742.1	RP11-700A24.1	-4.44	1.11e-05	0.00113	-0.28	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85855114	chr11:85852557~85854943:-
THCA	cis	rs7560272	0.538	rs4852972	ENSG00000163016.8	ALMS1P	-4.44	1.11e-05	0.00113	-0.25	-0.2	Schizophrenia;	chr2:73689545	chr2:73644919~73685576:+
THCA	cis	rs7088591	1	rs76647893	ENSG00000276818.1	AC026393.1	4.44	1.11e-05	0.00113	0.43	0.2	Blood pressure;	chr10:57958211	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs16911357	ENSG00000276818.1	AC026393.1	4.44	1.11e-05	0.00113	0.43	0.2	Blood pressure;	chr10:57961023	chr10:57095699~57095781:+
THCA	cis	rs875971	0.545	rs2420456	ENSG00000273142.1	RP11-458F8.4	4.44	1.11e-05	0.00113	0.18	0.2	Aortic root size;	chr7:66280619	chr7:66902857~66906297:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000234585.5	CCT6P3	4.44	1.11e-05	0.00113	0.18	0.2	Aortic root size;	chr7:65931217	chr7:65038354~65074713:+
THCA	cis	rs877529	0.967	rs139405	ENSG00000279833.1	RP4-742C19.13	-4.44	1.11e-05	0.00113	-0.13	-0.2	Multiple myeloma;	chr22:39153521	chr22:39133090~39136760:+
THCA	cis	rs2904524	0.737	rs74716826	ENSG00000257815.4	RP11-611E13.2	-4.44	1.11e-05	0.00113	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70215574	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs79581417	ENSG00000257815.4	RP11-611E13.2	-4.44	1.11e-05	0.00113	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70222308	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs17107832	ENSG00000257815.4	RP11-611E13.2	-4.44	1.11e-05	0.00113	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70222493	chr12:69904033~70243360:-
THCA	cis	rs931127	0.658	rs4244812	ENSG00000214659.4	KRT8P26	4.44	1.11e-05	0.00113	0.17	0.2	Systemic lupus erythematosus;	chr11:65713297	chr11:65726939~65728214:+
THCA	cis	rs1167832	0.645	rs1167829	ENSG00000205583.12	STAG3L1	-4.44	1.11e-05	0.00113	-0.28	-0.2	Ankle injury;	chr7:75535697	chr7:75359194~75395383:+
THCA	cis	rs228614	0.51	rs4699033	ENSG00000248971.2	KRT8P46	-4.44	1.11e-05	0.00113	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102728746~102730171:-
THCA	cis	rs6545883	0.524	rs12992614	ENSG00000270820.4	RP11-355B11.2	-4.44	1.11e-05	0.00113	-0.17	-0.2	Tuberculosis;	chr2:61365941	chr2:61471188~61484130:+
THCA	cis	rs17689437	0.918	rs11075685	ENSG00000275383.1	RP11-615I2.6	4.44	1.11e-05	0.00113	0.32	0.2	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68591532	chr16:68591382~68594424:+
THCA	cis	rs6772849	0.93	rs7639400	ENSG00000242551.2	POU5F1P6	-4.44	1.11e-05	0.00113	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr3:128604513	chr3:128674735~128677005:-
THCA	cis	rs875971	0.825	rs4587224	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.11e-05	0.00113	-0.21	-0.2	Aortic root size;	chr7:66271195	chr7:66025126~66031544:-
THCA	cis	rs875971	0.792	rs6971752	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.11e-05	0.00113	-0.21	-0.2	Aortic root size;	chr7:66272999	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs10950033	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.11e-05	0.00113	-0.21	-0.2	Aortic root size;	chr7:66274686	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs11760844	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.11e-05	0.00113	-0.21	-0.2	Aortic root size;	chr7:66274896	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs4149461	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.11e-05	0.00113	-0.21	-0.2	Aortic root size;	chr7:66279745	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs10261398	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.11e-05	0.00113	-0.21	-0.2	Aortic root size;	chr7:66285177	chr7:66025126~66031544:-
THCA	cis	rs7617480	0.549	rs9879978	ENSG00000228638.1	FCF1P2	-4.44	1.11e-05	0.00113	-0.24	-0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48809167	chr3:48290793~48291375:-
THCA	cis	rs28829049	0.597	rs1009806	ENSG00000270728.1	RP4-657E11.10	-4.44	1.11e-05	0.00113	-0.15	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19174057	chr1:19297080~19297903:+
THCA	cis	rs7829975	0.742	rs7832968	ENSG00000253981.4	ALG1L13P	4.44	1.11e-05	0.00113	0.19	0.2	Mood instability;	chr8:8795379	chr8:8236003~8244667:-
THCA	cis	rs9543976	1	rs7989568	ENSG00000261105.4	LMO7-AS1	4.44	1.11e-05	0.00113	0.3	0.2	Diabetic retinopathy;	chr13:75581428	chr13:75604700~75635994:-
THCA	cis	rs17772222	0.63	rs816069	ENSG00000222990.1	RNU4-22P	-4.44	1.11e-05	0.00113	-0.24	-0.2	Coronary artery calcification;	chr14:88500992	chr14:88513498~88513663:+
THCA	cis	rs1150668	0.799	rs7206	ENSG00000220721.1	OR1F12	4.44	1.11e-05	0.00113	0.22	0.2	Pubertal anthropometrics;	chr6:28233360	chr6:28073316~28074233:+
THCA	cis	rs11096990	0.892	rs11937540	ENSG00000249685.1	RP11-360F5.3	-4.44	1.11e-05	0.00113	-0.26	-0.2	Cognitive function;	chr4:39179897	chr4:39133913~39135608:+
THCA	cis	rs7182948	0.957	rs13329455	ENSG00000259531.2	RP11-295H24.3	4.44	1.11e-05	0.00113	0.26	0.2	Lung adenocarcinoma;	chr15:49620571	chr15:49365124~49366685:-
THCA	cis	rs7264396	1	rs224440	ENSG00000088340.14	FER1L4	4.44	1.11e-05	0.00113	0.19	0.2	Total cholesterol levels;	chr20:35571517	chr20:35558737~35607562:-
THCA	cis	rs12823128	0.967	rs2306547	ENSG00000256185.1	RP11-612B6.2	-4.44	1.11e-05	0.00113	-0.19	-0.2	Birth weight;	chr12:26724952	chr12:26335864~26336950:-
THCA	cis	rs496547	0.721	rs2508570	ENSG00000255422.1	AP002954.4	-4.44	1.11e-05	0.00113	-0.21	-0.2	Hip minimal joint space width;	chr11:118807900	chr11:118704607~118750263:+
THCA	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-4.44	1.11e-05	0.00113	-0.25	-0.2	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
THCA	cis	rs7572733	0.515	rs6752458	ENSG00000231621.1	AC013264.2	-4.44	1.11e-05	0.00113	-0.21	-0.2	Dermatomyositis;	chr2:197970382	chr2:197197991~197199273:+
THCA	cis	rs17507216	0.718	rs72753931	ENSG00000255769.6	GOLGA2P10	-4.44	1.11e-05	0.00113	-0.32	-0.2	Excessive daytime sleepiness;	chr15:82721485	chr15:82472993~82513950:-
THCA	cis	rs11634944	0.901	rs2855523	ENSG00000257151.1	PWAR6	4.44	1.11e-05	0.00113	0.15	0.2	Interleukin-8 levels;	chr15:24966466	chr15:25031873~25036490:+
THCA	cis	rs8177376	0.727	rs658614	ENSG00000254905.1	RP11-712L6.7	4.44	1.11e-05	0.00113	0.28	0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328096	chr11:126292922~126294254:-
THCA	cis	rs8177376	0.727	rs589442	ENSG00000254905.1	RP11-712L6.7	4.44	1.11e-05	0.00113	0.28	0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328101	chr11:126292922~126294254:-
THCA	cis	rs9595908	0.709	rs1929937	ENSG00000212293.1	SNORA16	4.44	1.11e-05	0.00113	0.23	0.2	Body mass index;	chr13:32722907	chr13:32420390~32420516:-
THCA	cis	rs875971	0.898	rs6977501	ENSG00000230189.5	GS1-124K5.2	-4.44	1.11e-05	0.00113	-0.13	-0.2	Aortic root size;	chr7:66228355	chr7:66409143~66490059:-
THCA	cis	rs6894268	0.751	rs11741546	ENSG00000250999.1	RP11-1379J22.5	4.44	1.11e-05	0.00113	0.25	0.2	Eating disorders;	chr5:179599908	chr5:179657762~179664432:+
THCA	cis	rs1150668	0.835	rs203869	ENSG00000220721.1	OR1F12	4.44	1.11e-05	0.00113	0.22	0.2	Pubertal anthropometrics;	chr6:28073041	chr6:28073316~28074233:+
THCA	cis	rs4660214	0.666	rs587404	ENSG00000182109.6	RP11-69E11.4	4.44	1.11e-05	0.00113	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39522280~39546187:-
THCA	cis	rs2070488	0.736	rs2070988	ENSG00000229589.1	ACVR2B-AS1	4.44	1.11e-05	0.00113	0.19	0.2	Electrocardiographic conduction measures;	chr3:38396344	chr3:38451027~38454820:-
THCA	cis	rs9925964	0.967	rs9936329	ENSG00000232748.3	RP11-196G11.6	4.44	1.12e-05	0.00113	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31129478	chr16:31056460~31062803:+
THCA	cis	rs9925964	0.967	rs1549293	ENSG00000232748.3	RP11-196G11.6	4.44	1.12e-05	0.00113	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31130672	chr16:31056460~31062803:+
THCA	cis	rs2904967	0.929	rs10750761	ENSG00000254614.2	AP003068.23	-4.44	1.12e-05	0.00113	-0.38	-0.2	Mean corpuscular volume;	chr11:65234620	chr11:65177606~65181834:-
THCA	cis	rs10761482	1	rs10821720	ENSG00000254271.1	RP11-131N11.4	4.44	1.12e-05	0.00113	0.27	0.2	Schizophrenia;	chr10:60317298	chr10:60734342~60741828:+
THCA	cis	rs718433	0.584	rs7160973	ENSG00000211778.2	TRAV4	-4.44	1.12e-05	0.00113	-0.15	-0.2	Intraocular pressure;	chr14:21748391	chr14:21736152~21736982:+
THCA	cis	rs718433	0.584	rs2075478	ENSG00000211778.2	TRAV4	-4.44	1.12e-05	0.00113	-0.15	-0.2	Intraocular pressure;	chr14:21749767	chr14:21736152~21736982:+
THCA	cis	rs718433	0.584	rs2874142	ENSG00000211778.2	TRAV4	-4.44	1.12e-05	0.00113	-0.15	-0.2	Intraocular pressure;	chr14:21750036	chr14:21736152~21736982:+
THCA	cis	rs9902453	0.967	rs7212741	ENSG00000263370.1	RP11-68I3.5	4.44	1.12e-05	0.00113	0.26	0.2	Coffee consumption (cups per day);	chr17:29995923	chr17:29639627~29640825:+
THCA	cis	rs1334894	1	rs10498734	ENSG00000228559.1	RP3-340B19.3	-4.44	1.12e-05	0.00113	-0.43	-0.2	Coronary artery disease;	chr6:35591996	chr6:35544632~35545669:+
THCA	cis	rs447735	0.587	rs258335	ENSG00000260259.1	RP11-368I7.4	4.44	1.12e-05	0.00113	0.21	0.2	Hemoglobin concentration;	chr16:89654536	chr16:89682620~89686569:-
THCA	cis	rs812925	0.537	rs10208769	ENSG00000270820.4	RP11-355B11.2	-4.44	1.12e-05	0.00113	-0.17	-0.2	Immature fraction of reticulocytes;	chr2:61378479	chr2:61471188~61484130:+
THCA	cis	rs3738443	0.953	rs61839997	ENSG00000259865.1	RP11-488L18.10	4.44	1.12e-05	0.00113	0.22	0.2	Alcohol dependence;	chr1:247197867	chr1:247187281~247188526:-
THCA	cis	rs9393777	0.623	rs13211166	ENSG00000219392.1	RP1-265C24.5	-4.44	1.12e-05	0.00113	-0.28	-0.2	Intelligence (multi-trait analysis);	chr6:27298161	chr6:28115628~28116551:+
THCA	cis	rs67478160	0.595	rs2295146	ENSG00000269910.1	RP11-73M18.10	4.44	1.12e-05	0.00113	0.17	0.2	Schizophrenia;	chr14:103733019	chr14:103694516~103695050:-
THCA	cis	rs10916248	0.569	rs7528514	ENSG00000232628.4	RP11-365O16.3	4.44	1.12e-05	0.00113	0.22	0.2	QT interval (drug interaction);	chr1:224077561	chr1:224208747~224213279:-
THCA	cis	rs472402	0.56	rs4702382	ENSG00000250056.4	LINC01018	-4.44	1.12e-05	0.00113	-0.25	-0.2	Response to amphetamines;	chr5:6665568	chr5:6582136~6588499:+
THCA	cis	rs7731390	0.541	rs7447266	ENSG00000233006.5	AC034220.3	4.44	1.12e-05	0.00113	0.27	0.2	IgG glycosylation;	chr5:132266840	chr5:132311285~132369916:-
THCA	cis	rs7520050	0.778	rs2934857	ENSG00000281133.1	AL355480.3	-4.44	1.12e-05	0.00113	-0.23	-0.2	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45580892~45580996:-
THCA	cis	rs6012564	0.963	rs6125590	ENSG00000230758.1	SNAP23P	4.44	1.12e-05	0.00113	0.25	0.2	Anger;	chr20:49204089	chr20:49038357~49038602:-
THCA	cis	rs2243480	1	rs73150014	ENSG00000232559.3	GS1-124K5.12	4.44	1.12e-05	0.00113	0.29	0.2	Diabetic kidney disease;	chr7:65985932	chr7:66554588~66576923:-
THCA	cis	rs9843304	0.5	rs34358037	ENSG00000244503.1	RP11-278L15.6	4.44	1.12e-05	0.00113	0.25	0.2	Gallstone disease;	chr3:149483497	chr3:149494660~149495995:+
THCA	cis	rs6088590	1	rs6119516	ENSG00000276073.1	RP5-1125A11.7	-4.44	1.12e-05	0.00113	-0.19	-0.2	Coronary artery disease;	chr20:34740220	chr20:33985617~33988989:-
THCA	cis	rs1538970	0.816	rs3790583	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00113	0.2	0.2	Platelet count;	chr1:45491156	chr1:45651039~45651826:-
THCA	cis	rs1538970	0.816	rs10789464	ENSG00000234329.1	RP11-767N6.2	4.44	1.12e-05	0.00113	0.2	0.2	Platelet count;	chr1:45493430	chr1:45651039~45651826:-
THCA	cis	rs8067545	0.586	rs2526463	ENSG00000270091.1	RP11-78O7.2	4.44	1.12e-05	0.00113	0.15	0.2	Schizophrenia;	chr17:20174984	chr17:19896590~19897287:-
THCA	cis	rs875971	0.756	rs2901210	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.12e-05	0.00113	-0.21	-0.2	Aortic root size;	chr7:66552518	chr7:66025126~66031544:-
THCA	cis	rs227275	0.556	rs4455413	ENSG00000248971.2	KRT8P46	-4.44	1.12e-05	0.00113	-0.25	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102728746~102730171:-
THCA	cis	rs6997458	0.785	rs1389245	ENSG00000253549.4	RP11-317J10.2	-4.44	1.12e-05	0.00113	-0.2	-0.2	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85440159	chr8:85441851~85464915:-
THCA	cis	rs6121246	0.821	rs6121209	ENSG00000230613.1	HM13-AS1	4.44	1.12e-05	0.00113	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31723455	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs57726761	ENSG00000230613.1	HM13-AS1	4.44	1.12e-05	0.00113	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31726243	chr20:31567707~31573263:-
THCA	cis	rs61270009	0.955	rs12514004	ENSG00000247828.6	TMEM161B-AS1	4.44	1.12e-05	0.00113	0.17	0.2	Depressive symptoms;	chr5:88269979	chr5:88268895~88436685:+
THCA	cis	rs3738443	1	rs61839991	ENSG00000259865.1	RP11-488L18.10	4.44	1.12e-05	0.00113	0.22	0.2	Alcohol dependence;	chr1:247186284	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.953	rs56065612	ENSG00000259865.1	RP11-488L18.10	4.44	1.12e-05	0.00113	0.22	0.2	Alcohol dependence;	chr1:247194812	chr1:247187281~247188526:-
THCA	cis	rs481331	0.676	rs210267	ENSG00000215146.4	RP11-313J2.1	-4.44	1.12e-05	0.00113	-0.31	-0.2	Systemic juvenile idiopathic arthritis;	chr10:42552510	chr10:42331866~42367974:-
THCA	cis	rs11633886	0.569	rs72719097	ENSG00000273972.1	CTD-2306A12.1	-4.44	1.12e-05	0.00113	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45836883	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.569	rs72719098	ENSG00000273972.1	CTD-2306A12.1	-4.44	1.12e-05	0.00113	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45836884	chr15:45702640~45703183:+
THCA	cis	rs853679	0.882	rs9468300	ENSG00000220721.1	OR1F12	4.44	1.12e-05	0.00113	0.35	0.2	Depression;	chr6:28159062	chr6:28073316~28074233:+
THCA	cis	rs6067053	0.646	rs3818066	ENSG00000227431.4	CSE1L-AS1	4.44	1.12e-05	0.00113	0.25	0.2	Intelligence (multi-trait analysis);	chr20:49278429	chr20:49040463~49046044:-
THCA	cis	rs6067053	0.671	rs6067035	ENSG00000227431.4	CSE1L-AS1	4.44	1.12e-05	0.00113	0.25	0.2	Intelligence (multi-trait analysis);	chr20:49291253	chr20:49040463~49046044:-
THCA	cis	rs7819412	0.806	rs6980856	ENSG00000206014.6	OR7E161P	-4.44	1.12e-05	0.00113	-0.23	-0.2	Triglycerides;	chr8:11080750	chr8:11928597~11929563:-
THCA	cis	rs79040073	0.576	rs17477923	ENSG00000259531.2	RP11-295H24.3	4.44	1.12e-05	0.00113	0.25	0.2	Lung cancer in ever smokers;	chr15:49418988	chr15:49365124~49366685:-
THCA	cis	rs12935418	0.561	rs2287991	ENSG00000278985.1	RP11-303E16.9	4.44	1.12e-05	0.00114	0.23	0.2	Mean corpuscular volume;	chr16:81006950	chr16:80982319~80984094:-
THCA	cis	rs10875746	0.551	rs1471997	ENSG00000226413.2	OR8T1P	4.44	1.12e-05	0.00114	0.28	0.2	Longevity (90 years and older);	chr12:48329812	chr12:48442030~48442947:-
THCA	cis	rs5758511	0.689	rs55906806	ENSG00000281538.1	RP4-669P10.20	-4.44	1.12e-05	0.00114	-0.27	-0.2	Birth weight;	chr22:42248465	chr22:42138060~42139726:+
THCA	cis	rs8105895	0.867	rs116220423	ENSG00000269345.1	VN1R85P	4.44	1.12e-05	0.00114	0.27	0.2	Body mass index (change over time);	chr19:22054239	chr19:22174766~22175191:-
THCA	cis	rs736408	0.608	rs6445534	ENSG00000243224.1	RP5-1157M23.2	-4.44	1.12e-05	0.00114	-0.22	-0.2	Bipolar disorder;	chr3:52709368	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs13079063	ENSG00000243224.1	RP5-1157M23.2	-4.44	1.12e-05	0.00114	-0.22	-0.2	Bipolar disorder;	chr3:52710444	chr3:52239258~52241097:+
THCA	cis	rs2439831	0.681	rs540031	ENSG00000166763.7	STRCP1	4.44	1.12e-05	0.00114	0.27	0.2	Lung cancer in ever smokers;	chr15:43316657	chr15:43699488~43718184:-
THCA	cis	rs6449502	0.764	rs158925	ENSG00000251279.1	CTC-436P18.1	4.44	1.12e-05	0.00114	0.33	0.2	Mean platelet volume;	chr5:60955977	chr5:61162070~61232040:+
THCA	cis	rs6730558	0.966	rs12993630	ENSG00000236008.1	AC011747.4	4.44	1.12e-05	0.00114	0.23	0.2	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8613139	chr2:8559833~8583792:-
THCA	cis	rs10090774	0.965	rs4246126	ENSG00000279766.1	RP11-642A1.2	4.44	1.12e-05	0.00114	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140780793	chr8:140572142~140572812:-
THCA	cis	rs7727544	0.545	rs4705915	ENSG00000233006.5	AC034220.3	4.44	1.12e-05	0.00114	0.17	0.2	Blood metabolite levels;	chr5:132055765	chr5:132311285~132369916:-
THCA	cis	rs17801127	0.748	rs13007543	ENSG00000231969.1	AC144449.1	4.44	1.12e-05	0.00114	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149682573	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.901	rs1017151	ENSG00000231969.1	AC144449.1	4.44	1.12e-05	0.00114	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149684159	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.901	rs6708629	ENSG00000231969.1	AC144449.1	4.44	1.12e-05	0.00114	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149685243	chr2:149587196~149848233:+
THCA	cis	rs812925	0.537	rs778153	ENSG00000270820.4	RP11-355B11.2	-4.44	1.12e-05	0.00114	-0.17	-0.2	Immature fraction of reticulocytes;	chr2:61381517	chr2:61471188~61484130:+
THCA	cis	rs442309	0.687	rs10995283	ENSG00000238280.1	RP11-436D10.3	-4.44	1.12e-05	0.00114	-0.25	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62714628	chr10:62793562~62805887:-
THCA	cis	rs442309	0.687	rs7084016	ENSG00000238280.1	RP11-436D10.3	-4.44	1.12e-05	0.00114	-0.25	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62720681	chr10:62793562~62805887:-
THCA	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	4.44	1.12e-05	0.00114	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
THCA	cis	rs1559040	0.86	rs7586592	ENSG00000272156.1	RP11-477N3.1	-4.44	1.12e-05	0.00114	-0.33	-0.2	Sudden cardiac arrest;	chr2:54145060	chr2:54082554~54085066:+
THCA	cis	rs867371	0.502	rs3759800	ENSG00000259429.4	UBE2Q2P2	4.44	1.12e-05	0.00114	0.16	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82355142~82420075:+
THCA	cis	rs10129255	0.957	rs61997760	ENSG00000211970.3	IGHV4-61	-4.44	1.12e-05	0.00114	-0.12	-0.2	Kawasaki disease;	chr14:106716993	chr14:106639119~106639657:-
THCA	cis	rs73108077	0.736	rs73104088	ENSG00000277112.2	RP11-755J8.1	-4.44	1.12e-05	0.00114	-0.41	-0.2	Red blood cell density in sickle cell anemia;	chr20:31311110	chr20:30681825~30723932:-
THCA	cis	rs9990333	0.562	rs12632706	ENSG00000207650.1	MIR570	4.44	1.12e-05	0.00114	0.22	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195699401~195699497:+
THCA	cis	rs78487399	0.908	rs77613902	ENSG00000234936.1	AC010883.5	4.44	1.12e-05	0.00114	0.26	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43616852	chr2:43229573~43233394:+
THCA	cis	rs12428035	1	rs12428035	ENSG00000247400.3	DNAJC3-AS1	4.44	1.12e-05	0.00114	0.19	0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95648618	chr13:95648733~95676925:-
THCA	cis	rs3096299	0.685	rs8050512	ENSG00000261118.1	RP11-104N10.1	4.44	1.12e-05	0.00114	0.17	0.2	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89492017~89504460:-
THCA	cis	rs9987353	0.62	rs34455383	ENSG00000253893.2	FAM85B	4.44	1.12e-05	0.00114	0.28	0.2	Recombination measurement;	chr8:9208948	chr8:8167819~8226614:-
THCA	cis	rs11976180	1	rs1919951	ENSG00000244198.4	RP4-545C24.1	-4.44	1.12e-05	0.00114	-0.2	-0.2	Obesity-related traits;	chr7:144071798	chr7:144194858~144280547:+
THCA	cis	rs3177980	0.596	rs12938	ENSG00000239494.2	RN7SL333P	-4.44	1.12e-05	0.00114	-0.19	-0.2	Amyotrophic lateral sclerosis;	chr1:169691640	chr1:169859756~169860052:+
THCA	cis	rs7637701	0.517	rs3851992	ENSG00000240875.4	LINC00886	-4.44	1.13e-05	0.00114	-0.15	-0.2	Breast cancer;	chr3:156681391	chr3:156747346~156817062:-
THCA	cis	rs875971	0.862	rs6460293	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00114	-0.21	-0.2	Aortic root size;	chr7:66345205	chr7:66025126~66031544:-
THCA	cis	rs8067545	0.75	rs4925085	ENSG00000270091.1	RP11-78O7.2	-4.44	1.13e-05	0.00114	-0.15	-0.2	Schizophrenia;	chr17:20096818	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs62067555	ENSG00000270091.1	RP11-78O7.2	-4.44	1.13e-05	0.00114	-0.15	-0.2	Schizophrenia;	chr17:20098189	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.717	rs7207625	ENSG00000270091.1	RP11-78O7.2	-4.44	1.13e-05	0.00114	-0.15	-0.2	Schizophrenia;	chr17:20098299	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs918228	ENSG00000270091.1	RP11-78O7.2	-4.44	1.13e-05	0.00114	-0.15	-0.2	Schizophrenia;	chr17:20098699	chr17:19896590~19897287:-
THCA	cis	rs6988985	0.589	rs13252628	ENSG00000247317.3	RP11-273G15.2	4.44	1.13e-05	0.00114	0.22	0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142913528	chr8:142981738~143018437:-
THCA	cis	rs10771431	0.782	rs10771415	ENSG00000256427.1	RP11-118B22.4	4.44	1.13e-05	0.00114	0.22	0.2	Breast size;	chr12:9205627	chr12:9246497~9257960:+
THCA	cis	rs854765	0.693	rs8079418	ENSG00000281749.1	Y_RNA	4.44	1.13e-05	0.00114	0.26	0.2	Total body bone mineral density;	chr17:18020746	chr17:18001101~18001195:-
THCA	cis	rs10090774	0.71	rs11166986	ENSG00000280303.2	ERICD	4.44	1.13e-05	0.00114	0.19	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140646056	chr8:140636281~140638283:+
THCA	cis	rs2243480	1	rs313807	ENSG00000232559.3	GS1-124K5.12	4.44	1.13e-05	0.00114	0.3	0.2	Diabetic kidney disease;	chr7:66034494	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs6960446	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00114	-0.21	-0.2	Aortic root size;	chr7:66268272	chr7:66025126~66031544:-
THCA	cis	rs875971	0.789	rs10260426	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00114	-0.21	-0.2	Aortic root size;	chr7:66271055	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs7796162	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00114	-0.21	-0.2	Aortic root size;	chr7:66280771	chr7:66025126~66031544:-
THCA	cis	rs7989336	0.605	rs7329346	ENSG00000247400.3	DNAJC3-AS1	4.44	1.13e-05	0.00114	0.13	0.2	Obesity;	chr13:96274742	chr13:95648733~95676925:-
THCA	cis	rs17095355	1	rs9630101	ENSG00000203876.8	ADD3-AS1	-4.44	1.13e-05	0.00114	-0.21	-0.2	Biliary atresia;	chr10:109978693	chr10:109940104~110008381:-
THCA	cis	rs7572644	0.699	rs12466717	ENSG00000223522.1	AC093690.1	4.44	1.13e-05	0.00114	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27873925	chr2:28307691~28310459:-
THCA	cis	rs6840360	0.901	rs6826799	ENSG00000270265.1	RP11-731D1.4	-4.44	1.13e-05	0.00114	-0.19	-0.2	Intelligence (multi-trait analysis);	chr4:151534548	chr4:151333775~151353224:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000234585.5	CCT6P3	4.44	1.13e-05	0.00114	0.18	0.2	Calcium levels;	chr7:65853042	chr7:65038354~65074713:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000234585.5	CCT6P3	4.44	1.13e-05	0.00114	0.18	0.2	Aortic root size;	chr7:65871069	chr7:65038354~65074713:+
THCA	cis	rs10802047	0.566	rs488423	ENSG00000231365.4	RP11-418J17.1	4.44	1.13e-05	0.00114	0.21	0.2	Relative hand skill in reading disability;	chr1:118709892	chr1:119140396~119275973:+
THCA	cis	rs7829975	0.627	rs876954	ENSG00000253981.4	ALG1L13P	4.44	1.13e-05	0.00114	0.2	0.2	Mood instability;	chr8:8453413	chr8:8236003~8244667:-
THCA	cis	rs1538970	0.816	rs4633317	ENSG00000234329.1	RP11-767N6.2	4.44	1.13e-05	0.00114	0.2	0.2	Platelet count;	chr1:45519485	chr1:45651039~45651826:-
THCA	cis	rs2625529	0.775	rs2723342	ENSG00000260037.4	CTD-2524L6.3	-4.44	1.13e-05	0.00114	-0.28	-0.2	Red blood cell count;	chr15:71815358	chr15:71818396~71823384:+
THCA	cis	rs9880211	0.613	rs6786582	ENSG00000273486.1	RP11-731C17.2	-4.44	1.13e-05	0.00114	-0.2	-0.2	Height;Body mass index;	chr3:136180142	chr3:136837338~136839021:-
THCA	cis	rs8177876	0.749	rs2549896	ENSG00000261061.1	RP11-303E16.2	4.44	1.13e-05	0.00114	0.27	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054334	chr16:81030770~81031485:+
THCA	cis	rs11157436	1	rs3811278	ENSG00000211812.1	TRAV26-2	-4.44	1.13e-05	0.00114	-0.19	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22202583~22203368:+
THCA	cis	rs6723108	0.668	rs613828	ENSG00000224043.6	CCNT2-AS1	-4.44	1.13e-05	0.00114	-0.22	-0.2	Type 2 diabetes;	chr2:134541142	chr2:134735464~134918710:-
THCA	cis	rs9863	0.828	rs4765562	ENSG00000270028.1	RP11-380L11.4	4.44	1.13e-05	0.00114	0.21	0.2	White blood cell count;	chr12:123988024	chr12:123925461~123926083:-
THCA	cis	rs6012564	0.819	rs1467417	ENSG00000227431.4	CSE1L-AS1	-4.44	1.13e-05	0.00114	-0.25	-0.2	Anger;	chr20:48917118	chr20:49040463~49046044:-
THCA	cis	rs6496932	0.663	rs7182814	ENSG00000259630.2	CTD-2262B20.1	-4.44	1.13e-05	0.00114	-0.24	-0.2	Central corneal thickness;Corneal structure;	chr15:85362840	chr15:85415228~85415633:+
THCA	cis	rs9863	0.861	rs34878139	ENSG00000270028.1	RP11-380L11.4	4.44	1.13e-05	0.00114	0.21	0.2	White blood cell count;	chr12:123961706	chr12:123925461~123926083:-
THCA	cis	rs9863	0.861	rs11833002	ENSG00000270028.1	RP11-380L11.4	4.44	1.13e-05	0.00114	0.21	0.2	White blood cell count;	chr12:123962069	chr12:123925461~123926083:-
THCA	cis	rs9925964	0.933	rs9939417	ENSG00000232748.3	RP11-196G11.6	4.44	1.13e-05	0.00114	0.23	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042146	chr16:31056460~31062803:+
THCA	cis	rs3824435	0.794	rs10815198	ENSG00000272866.1	RP11-12D24.10	-4.44	1.13e-05	0.00114	-0.28	-0.2	Risky sexual behaviors in alcohol dependence;	chr9:5375221	chr9:5351796~5352410:-
THCA	cis	rs9902453	0.904	rs55866125	ENSG00000263370.1	RP11-68I3.5	4.44	1.13e-05	0.00114	0.26	0.2	Coffee consumption (cups per day);	chr17:29985975	chr17:29639627~29640825:+
THCA	cis	rs4356203	0.875	rs11024136	ENSG00000272034.1	SNORD14A	-4.44	1.13e-05	0.00115	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17042850	chr11:17074654~17074744:-
THCA	cis	rs593531	0.513	rs3867268	ENSG00000255440.1	RP11-632K5.2	-4.44	1.13e-05	0.00115	-0.24	-0.2	Neuroticism;	chr11:74322332	chr11:74409060~74416379:+
THCA	cis	rs8067545	0.75	rs9944451	ENSG00000270091.1	RP11-78O7.2	-4.44	1.13e-05	0.00115	-0.15	-0.2	Schizophrenia;	chr17:20098003	chr17:19896590~19897287:-
THCA	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-4.44	1.13e-05	0.00115	-0.23	-0.2	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
THCA	cis	rs7555523	0.887	rs12691499	ENSG00000224358.1	RP11-466F5.8	-4.44	1.13e-05	0.00115	-0.31	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718428	chr1:165768929~165775176:+
THCA	cis	rs7555523	0.83	rs12691500	ENSG00000224358.1	RP11-466F5.8	-4.44	1.13e-05	0.00115	-0.31	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718524	chr1:165768929~165775176:+
THCA	cis	rs8054556	0.74	rs12444978	ENSG00000183604.13	SMG1P5	-4.44	1.13e-05	0.00115	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29913101	chr16:30267553~30335374:-
THCA	cis	rs4578769	0.531	rs768793	ENSG00000265939.1	UBE2CP2	4.44	1.13e-05	0.00115	0.23	0.2	Eosinophil percentage of white cells;	chr18:22976640	chr18:22900486~22900995:-
THCA	cis	rs9890032	0.542	rs35958868	ENSG00000263531.1	RP13-753N3.1	-4.44	1.13e-05	0.00115	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:30909727	chr17:30863921~30864940:-
THCA	cis	rs11633886	0.656	rs10153037	ENSG00000273972.1	CTD-2306A12.1	-4.44	1.13e-05	0.00115	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45832155	chr15:45702640~45703183:+
THCA	cis	rs12497850	0.931	rs9846123	ENSG00000228638.1	FCF1P2	4.44	1.13e-05	0.00115	0.22	0.2	Parkinson's disease;	chr3:49050679	chr3:48290793~48291375:-
THCA	cis	rs9863	0.827	rs6488913	ENSG00000270061.1	RP11-214K3.19	4.44	1.13e-05	0.00115	0.26	0.2	White blood cell count;	chr12:123961022	chr12:123969990~123970344:-
THCA	cis	rs2439831	0.681	rs28653441	ENSG00000205771.5	CATSPER2P1	-4.44	1.13e-05	0.00115	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43385064	chr15:43726918~43747094:-
THCA	cis	rs7772486	0.72	rs702320	ENSG00000270638.1	RP3-466P17.1	-4.44	1.13e-05	0.00115	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145735570~145737218:+
THCA	cis	rs7474896	0.943	rs11011326	ENSG00000263064.2	RP11-291L22.7	4.44	1.13e-05	0.00115	0.32	0.2	Obesity (extreme);	chr10:37677263	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.943	rs11011328	ENSG00000263064.2	RP11-291L22.7	4.44	1.13e-05	0.00115	0.32	0.2	Obesity (extreme);	chr10:37677419	chr10:38448689~38448949:+
THCA	cis	rs10090774	0.71	rs11780289	ENSG00000280303.2	ERICD	-4.44	1.13e-05	0.00115	-0.19	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140679315	chr8:140636281~140638283:+
THCA	cis	rs9543976	1	rs2328964	ENSG00000261105.4	LMO7-AS1	4.44	1.13e-05	0.00115	0.3	0.2	Diabetic retinopathy;	chr13:75564694	chr13:75604700~75635994:-
THCA	cis	rs1030877	0.515	rs2576735	ENSG00000235319.1	AC012360.4	-4.44	1.13e-05	0.00115	-0.26	-0.2	Obesity-related traits;	chr2:105272382	chr2:105324210~105330529:+
THCA	cis	rs7829975	0.777	rs560544	ENSG00000233609.3	RP11-62H7.2	-4.44	1.13e-05	0.00115	-0.19	-0.2	Mood instability;	chr8:8779919	chr8:8961200~8979025:+
THCA	cis	rs8020441	1	rs67186984	ENSG00000269906.1	RP11-248J18.2	4.44	1.13e-05	0.00115	0.28	0.2	Cognitive performance;	chr14:50702569	chr14:50662511~50663178:-
THCA	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-4.44	1.13e-05	0.00115	-0.2	-0.2	Height;	chr5:37019252	chr5:36666214~36725195:-
THCA	cis	rs2980439	0.517	rs712253	ENSG00000254153.1	CTA-398F10.2	4.44	1.13e-05	0.00115	0.22	0.2	Neuroticism;	chr8:8246260	chr8:8456909~8461337:-
THCA	cis	rs786425	0.689	rs2222060	ENSG00000270095.1	RP11-214K3.18	-4.44	1.13e-05	0.00115	-0.24	-0.2	Pubertal anthropometrics;	chr12:123709891	chr12:123971457~123971714:-
THCA	cis	rs11158026	0.526	rs72713477	ENSG00000258413.1	RP11-665C16.6	-4.44	1.13e-05	0.00115	-0.33	-0.2	Parkinson's disease;	chr14:54885323	chr14:55262767~55272075:-
THCA	cis	rs9527	0.614	rs4919691	ENSG00000213061.2	PFN1P11	4.44	1.13e-05	0.00115	0.25	0.2	Arsenic metabolism;	chr10:102864718	chr10:102838011~102845473:-
THCA	cis	rs875971	0.862	rs12537823	ENSG00000229886.1	RP5-1132H15.3	4.44	1.13e-05	0.00115	0.21	0.2	Aortic root size;	chr7:66255897	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs10276077	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00115	-0.21	-0.2	Aortic root size;	chr7:66263424	chr7:66025126~66031544:-
THCA	cis	rs875971	0.928	rs2036263	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00115	-0.21	-0.2	Aortic root size;	chr7:66335210	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs10240949	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00115	-0.21	-0.2	Aortic root size;	chr7:66339430	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs7782704	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00115	-0.21	-0.2	Aortic root size;	chr7:66340379	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6959268	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.13e-05	0.00115	-0.21	-0.2	Aortic root size;	chr7:66347979	chr7:66025126~66031544:-
THCA	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	4.44	1.13e-05	0.00115	0.24	0.2	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
THCA	cis	rs8046148	0.724	rs1362633	ENSG00000279356.1	RP11-429P3.8	-4.44	1.13e-05	0.00115	-0.24	-0.2	Testicular germ cell tumor;	chr16:50028661	chr16:50072862~50074986:+
THCA	cis	rs17801127	0.748	rs57536657	ENSG00000231969.1	AC144449.1	4.44	1.13e-05	0.00115	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149665638	chr2:149587196~149848233:+
THCA	cis	rs4589258	0.603	rs10830568	ENSG00000280367.1	RP11-121L10.2	4.44	1.13e-05	0.00115	0.19	0.2	Intelligence (multi-trait analysis);	chr11:90752129	chr11:90223153~90226538:+
THCA	cis	rs17095355	0.786	rs61624875	ENSG00000203876.8	ADD3-AS1	-4.44	1.14e-05	0.00115	-0.21	-0.2	Biliary atresia;	chr10:109962731	chr10:109940104~110008381:-
THCA	cis	rs17095355	1	rs11194933	ENSG00000203876.8	ADD3-AS1	-4.44	1.14e-05	0.00115	-0.21	-0.2	Biliary atresia;	chr10:109966104	chr10:109940104~110008381:-
THCA	cis	rs4144027	0.967	rs12879686	ENSG00000269958.1	RP11-73M18.8	4.44	1.14e-05	0.00115	0.19	0.2	Blood metabolite levels;	chr14:103894404	chr14:103696353~103697163:+
THCA	cis	rs12681963	0.61	rs75739606	ENSG00000248159.1	HSPA8P11	4.44	1.14e-05	0.00115	0.37	0.2	Migraine;	chr8:30178768	chr8:30237382~30240997:+
THCA	cis	rs6870983	0.802	rs10214175	ENSG00000247828.6	TMEM161B-AS1	4.44	1.14e-05	0.00115	0.18	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88468530	chr5:88268895~88436685:+
THCA	cis	rs2447820	0.5	rs28891	ENSG00000249996.1	RP11-359P5.1	-4.44	1.14e-05	0.00115	-0.23	-0.2	Migraine;	chr5:122947929	chr5:123036271~123054667:+
THCA	cis	rs8192917	0.524	rs7150217	ENSG00000258744.1	RP11-80A15.1	-4.44	1.14e-05	0.00115	-0.35	-0.2	Vitiligo;	chr14:24582905	chr14:24501594~24508688:+
THCA	cis	rs8192917	0.511	rs35240563	ENSG00000258744.1	RP11-80A15.1	-4.44	1.14e-05	0.00115	-0.35	-0.2	Vitiligo;	chr14:24593940	chr14:24501594~24508688:+
THCA	cis	rs8192917	0.511	rs7156640	ENSG00000258744.1	RP11-80A15.1	-4.44	1.14e-05	0.00115	-0.35	-0.2	Vitiligo;	chr14:24599747	chr14:24501594~24508688:+
THCA	cis	rs6433895	0.71	rs34467063	ENSG00000236153.1	AC104076.3	-4.44	1.14e-05	0.00115	-0.26	-0.2	Lymphocyte counts;	chr2:181149252	chr2:180979427~180980090:-
THCA	cis	rs4792901	0.918	rs67063813	ENSG00000267151.3	RP11-100E5.2	4.44	1.14e-05	0.00115	0.21	0.2	Dupuytren's disease;	chr17:43549360	chr17:43444707~43451200:+
THCA	cis	rs7688540	0.511	rs6841415	ENSG00000211553.1	AC253576.2	-4.44	1.14e-05	0.00115	-0.32	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:136461~136568:+
THCA	cis	rs4908768	0.581	rs2784739	ENSG00000232912.4	RP5-1115A15.1	-4.44	1.14e-05	0.00115	-0.23	-0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8437498	chr1:8424645~8434838:+
THCA	cis	rs17095355	1	rs7080576	ENSG00000203876.8	ADD3-AS1	4.44	1.14e-05	0.00115	0.21	0.2	Biliary atresia;	chr10:109951059	chr10:109940104~110008381:-
THCA	cis	rs375066	0.935	rs384522	ENSG00000278917.1	RP11-15A1.4	-4.44	1.14e-05	0.00115	-0.17	-0.2	Breast cancer;	chr19:43900892	chr19:43891233~43895411:+
THCA	cis	rs12034383	1	rs12041437	ENSG00000274245.1	RP11-357P18.2	-4.44	1.14e-05	0.00115	-0.18	-0.2	Erythrocyte sedimentation rate;	chr1:207629919	chr1:207372559~207373252:+
THCA	cis	rs12034383	1	rs12034383	ENSG00000274245.1	RP11-357P18.2	-4.44	1.14e-05	0.00115	-0.18	-0.2	Erythrocyte sedimentation rate;	chr1:207630250	chr1:207372559~207373252:+
THCA	cis	rs875971	0.545	rs73376394	ENSG00000232559.3	GS1-124K5.12	4.44	1.14e-05	0.00115	0.21	0.2	Aortic root size;	chr7:66172694	chr7:66554588~66576923:-
THCA	cis	rs7474896	0.537	rs2749589	ENSG00000226578.1	RP11-258F22.1	4.44	1.14e-05	0.00115	0.28	0.2	Obesity (extreme);	chr10:37977942	chr10:37775371~37784131:-
THCA	cis	rs2286503	1	rs2286503	ENSG00000226329.2	AC005682.6	4.44	1.14e-05	0.00115	0.24	0.2	Fibrinogen;	chr7:22816987	chr7:22863874~22881350:-
THCA	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	4.44	1.14e-05	0.00115	0.23	0.2	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
THCA	cis	rs607541	0.764	rs2470114	ENSG00000259520.4	CTD-2651B20.3	-4.44	1.14e-05	0.00115	-0.29	-0.2	Obesity-related traits;	chr15:45638524	chr15:45251580~45279251:-
THCA	cis	rs11758351	0.66	rs11753655	ENSG00000216331.1	HIST1H1PS1	4.44	1.14e-05	0.00115	0.32	0.2	Renal underexcretion gout;Gout;	chr6:26219881	chr6:26195566~26195771:+
THCA	cis	rs9880211	0.948	rs13326151	ENSG00000239213.4	NCK1-AS1	4.44	1.14e-05	0.00115	0.22	0.2	Height;Body mass index;	chr3:136542902	chr3:136841726~136862054:-
THCA	cis	rs17221829	0.965	rs11018745	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89710640	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.899	rs10830356	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89710771	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.965	rs3881252	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89712018	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.739	rs55812948	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89713164	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.965	rs1967075	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89714088	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.836	rs3931233	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89718420	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.692	rs2773236	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89721668	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.965	rs10830361	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89723105	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.965	rs12276507	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89723885	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.965	rs72952901	ENSG00000280385.1	AP000648.5	-4.44	1.14e-05	0.00115	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89724135	chr11:90193614~90198120:+
THCA	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-4.44	1.14e-05	0.00115	-0.24	-0.2	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
THCA	cis	rs4767841	0.935	rs3956827	ENSG00000252886.1	RN7SKP197	-4.44	1.14e-05	0.00115	-0.2	-0.2	Urgency urinary incontinence;	chr12:119751727	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.935	rs904655	ENSG00000252886.1	RN7SKP197	-4.44	1.14e-05	0.00115	-0.2	-0.2	Urgency urinary incontinence;	chr12:119752074	chr12:119631090~119631386:-
THCA	cis	rs12541437	1	rs2921747	ENSG00000253327.2	RAD21-AS1	4.44	1.14e-05	0.00115	0.22	0.2	Gut microbiome composition (winter);	chr8:116912681	chr8:116874424~116876868:+
THCA	cis	rs1707322	1	rs3922887	ENSG00000281133.1	AL355480.3	-4.44	1.14e-05	0.00115	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs3922886	ENSG00000281133.1	AL355480.3	-4.44	1.14e-05	0.00115	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45580892~45580996:-
THCA	cis	rs2777491	0.874	rs13379756	ENSG00000247556.5	OIP5-AS1	4.44	1.14e-05	0.00115	0.17	0.2	Ulcerative colitis;	chr15:41371698	chr15:41283990~41309737:+
THCA	cis	rs8020095	0.571	rs7141519	ENSG00000258561.1	RP11-72M17.1	-4.44	1.14e-05	0.00115	-0.27	-0.2	Depression (quantitative trait);	chr14:67057808	chr14:66212810~66509394:-
THCA	cis	rs722599	0.748	rs2537824	ENSG00000279594.1	RP11-950C14.10	-4.44	1.14e-05	0.00115	-0.2	-0.2	IgG glycosylation;	chr14:74900646	chr14:75011269~75012851:-
THCA	cis	rs722599	0.748	rs20578	ENSG00000279594.1	RP11-950C14.10	-4.44	1.14e-05	0.00115	-0.2	-0.2	IgG glycosylation;	chr14:74901104	chr14:75011269~75012851:-
THCA	cis	rs12893668	0.703	rs35498576	ENSG00000252469.1	RNU7-160P	4.44	1.14e-05	0.00115	0.24	0.2	Reticulocyte count;	chr14:103559556	chr14:103550345~103550406:+
THCA	cis	rs62392365	0.543	rs1665820	ENSG00000168405.13	CMAHP	4.44	1.14e-05	0.00115	0.42	0.2	Intelligence (multi-trait analysis);Schizophrenia;	chr6:25070610	chr6:25081068~25166555:-
THCA	cis	rs6449502	0.92	rs3797562	ENSG00000251279.1	CTC-436P18.1	4.44	1.14e-05	0.00115	0.33	0.2	Mean platelet volume;	chr5:60901273	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs12696976	ENSG00000251279.1	CTC-436P18.1	4.44	1.14e-05	0.00115	0.33	0.2	Mean platelet volume;	chr5:60907079	chr5:61162070~61232040:+
THCA	cis	rs7621331	1	rs6774289	ENSG00000273486.1	RP11-731C17.2	-4.44	1.14e-05	0.00115	-0.19	-0.2	Waist circumference adjusted for body mass index;	chr3:135995263	chr3:136837338~136839021:-
THCA	cis	rs4693089	0.545	rs4693627	ENSG00000213608.5	SLC25A14P1	4.44	1.14e-05	0.00115	0.23	0.2	Menopause (age at onset);	chr4:83474296	chr4:83477524~83478424:+
THCA	cis	rs56313388	0.505	rs11076146	ENSG00000246379.5	RP11-461O7.1	-4.44	1.14e-05	0.00115	-0.21	-0.2	Pulse pressure;	chr16:56227517	chr16:56092987~56191094:-
THCA	cis	rs481331	0.734	rs35917885	ENSG00000215146.4	RP11-313J2.1	4.44	1.14e-05	0.00115	0.31	0.2	Systemic juvenile idiopathic arthritis;	chr10:42483589	chr10:42331866~42367974:-
THCA	cis	rs2129782	0.702	rs12680992	ENSG00000253553.4	RP11-586K2.1	4.44	1.14e-05	0.00115	0.37	0.2	Electrodermal activity;	chr8:88586965	chr8:88326836~88737134:+
THCA	cis	rs858239	0.601	rs4140959	ENSG00000226816.2	AC005082.12	4.44	1.14e-05	0.00115	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23206013~23208045:+
THCA	cis	rs77972916	0.536	rs7589361	ENSG00000234936.1	AC010883.5	4.44	1.14e-05	0.00115	0.22	0.2	Granulocyte percentage of myeloid white cells;	chr2:43362189	chr2:43229573~43233394:+
THCA	cis	rs2836974	0.526	rs1888488	ENSG00000255568.3	BRWD1-AS2	-4.44	1.14e-05	0.00115	-0.16	-0.2	Cognitive function;	chr21:39314595	chr21:39313935~39314962:+
THCA	cis	rs11089937	0.616	rs4991798	ENSG00000211639.2	IGLV4-60	4.44	1.14e-05	0.00115	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22178915	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs4991799	ENSG00000211639.2	IGLV4-60	4.44	1.14e-05	0.00115	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22178938	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs4991800	ENSG00000211639.2	IGLV4-60	4.44	1.14e-05	0.00115	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22178942	chr22:22162199~22162681:+
THCA	cis	rs12682352	0.602	rs13260419	ENSG00000248538.5	RP11-10A14.5	-4.44	1.14e-05	0.00115	-0.26	-0.2	Neuroticism;	chr8:8817666	chr8:9189011~9202854:+
THCA	cis	rs2018683	1	rs2018683	ENSG00000272568.4	CTB-113D17.1	4.44	1.14e-05	0.00115	0.19	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28974579	chr7:28979967~29013367:+
THCA	cis	rs79243044	0.695	rs1391615	ENSG00000224295.2	AC087380.14	-4.44	1.14e-05	0.00115	-0.2	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5519949	chr11:5518441~5524955:-
THCA	cis	rs2657294	0.929	rs6480771	ENSG00000233313.2	HMGA1P5	-4.44	1.14e-05	0.00115	-0.27	-0.2	Pneumonia;	chr10:75101922	chr10:75276376~75276646:-
THCA	cis	rs75504410	0.579	rs337645	ENSG00000231160.8	KLF3-AS1	-4.44	1.14e-05	0.00116	-0.14	-0.2	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38613462	chr4:38612701~38664883:-
THCA	cis	rs9283706	0.595	rs6866433	ENSG00000229666.1	MAST4-AS1	-4.44	1.14e-05	0.00116	-0.27	-0.2	Coronary artery disease;	chr5:67028324	chr5:67001383~67003953:-
THCA	cis	rs4713118	0.869	rs9461405	ENSG00000220721.1	OR1F12	4.44	1.14e-05	0.00116	0.26	0.2	Parkinson's disease;	chr6:27751596	chr6:28073316~28074233:+
THCA	cis	rs4916588	0.697	rs11550120	ENSG00000270170.1	NCBP2-AS2	4.44	1.14e-05	0.00116	0.16	0.2	Night sleep phenotypes;	chr3:196936251	chr3:196942623~196943540:+
THCA	cis	rs4950322	0.547	rs17355509	ENSG00000271721.1	RP11-337C18.9	4.44	1.14e-05	0.00116	0.23	0.2	Protein quantitative trait loci;	chr1:147123139	chr1:147175602~147177740:+
THCA	cis	rs875971	0.862	rs13232191	ENSG00000229886.1	RP5-1132H15.3	4.44	1.14e-05	0.00116	0.21	0.2	Aortic root size;	chr7:66521661	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs10950043	ENSG00000229886.1	RP5-1132H15.3	4.44	1.14e-05	0.00116	0.21	0.2	Aortic root size;	chr7:66523623	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs17747530	ENSG00000229886.1	RP5-1132H15.3	4.44	1.14e-05	0.00116	0.21	0.2	Aortic root size;	chr7:66529742	chr7:66025126~66031544:-
THCA	cis	rs875971	0.767	rs61348003	ENSG00000229886.1	RP5-1132H15.3	4.44	1.14e-05	0.00116	0.21	0.2	Aortic root size;	chr7:66540947	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs13536	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.14e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66554203	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs801209	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.14e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66554403	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs801206	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.14e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66556979	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs801204	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.14e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66557934	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs801203	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.14e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66558025	chr7:66025126~66031544:-
THCA	cis	rs875971	0.825	rs801202	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.14e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66558942	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs801195	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.14e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66561128	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs801194	ENSG00000229886.1	RP5-1132H15.3	-4.44	1.14e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66563508	chr7:66025126~66031544:-
THCA	cis	rs7141336	0.791	rs17721217	ENSG00000258884.1	CTD-3035D6.2	4.44	1.14e-05	0.00116	0.27	0.2	Anxiety disorder;	chr14:90733123	chr14:90822365~90828128:-
THCA	cis	rs9300255	0.602	rs1616131	ENSG00000235423.7	RP11-282O18.3	4.44	1.14e-05	0.00116	0.21	0.2	Neutrophil percentage of white cells;	chr12:123135291	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs1616181	ENSG00000235423.7	RP11-282O18.3	4.44	1.14e-05	0.00116	0.21	0.2	Neutrophil percentage of white cells;	chr12:123135309	chr12:123252030~123261483:-
THCA	cis	rs9311474	0.569	rs7614981	ENSG00000243224.1	RP5-1157M23.2	-4.44	1.14e-05	0.00116	-0.21	-0.2	Electroencephalogram traits;	chr3:52532898	chr3:52239258~52241097:+
THCA	cis	rs2275848	0.932	rs13285107	ENSG00000203364.2	RP11-370F5.4	4.44	1.14e-05	0.00116	0.28	0.2	Obesity (early onset extreme);	chr9:93118772	chr9:93147040~93148556:+
THCA	cis	rs8067545	0.611	rs2526466	ENSG00000270091.1	RP11-78O7.2	4.44	1.14e-05	0.00116	0.15	0.2	Schizophrenia;	chr17:20261938	chr17:19896590~19897287:-
THCA	cis	rs9902453	0.757	rs12453308	ENSG00000263370.1	RP11-68I3.5	4.44	1.14e-05	0.00116	0.26	0.2	Coffee consumption (cups per day);	chr17:30114586	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs60176674	ENSG00000263370.1	RP11-68I3.5	4.44	1.14e-05	0.00116	0.26	0.2	Coffee consumption (cups per day);	chr17:30152836	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs61014003	ENSG00000263370.1	RP11-68I3.5	4.44	1.14e-05	0.00116	0.26	0.2	Coffee consumption (cups per day);	chr17:30158215	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs56326816	ENSG00000263370.1	RP11-68I3.5	4.44	1.14e-05	0.00116	0.26	0.2	Coffee consumption (cups per day);	chr17:30165787	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs4533341	ENSG00000263370.1	RP11-68I3.5	4.44	1.14e-05	0.00116	0.26	0.2	Coffee consumption (cups per day);	chr17:30168654	chr17:29639627~29640825:+
THCA	cis	rs7520050	0.865	rs785515	ENSG00000234329.1	RP11-767N6.2	-4.44	1.14e-05	0.00116	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:46096990	chr1:45651039~45651826:-
THCA	cis	rs654950	0.875	rs55865698	ENSG00000230638.4	RP11-486B10.4	4.44	1.14e-05	0.00116	0.22	0.2	Airway imaging phenotypes;	chr1:41521087	chr1:41542069~41544310:+
THCA	cis	rs4938303	0.633	rs17092638	ENSG00000254851.1	RP11-109L13.1	4.44	1.14e-05	0.00116	0.33	0.2	Triglycerides;	chr11:116685520	chr11:117135528~117138582:+
THCA	cis	rs7726839	0.54	rs12517638	ENSG00000225138.6	CTD-2228K2.7	4.44	1.14e-05	0.00116	0.24	0.2	Obesity-related traits;	chr5:645369	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs4957081	ENSG00000225138.6	CTD-2228K2.7	4.44	1.14e-05	0.00116	0.24	0.2	Obesity-related traits;	chr5:646303	chr5:473236~480884:+
THCA	cis	rs41313321	0.541	rs4637952	ENSG00000273186.1	RP11-339B21.10	4.44	1.14e-05	0.00116	0.29	0.2	Coenzyme Q10 levels;	chr9:128297978	chr9:128431598~128432006:+
THCA	cis	rs2904524	0.737	rs17108046	ENSG00000257815.4	RP11-611E13.2	-4.44	1.14e-05	0.00116	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70355084	chr12:69904033~70243360:-
THCA	cis	rs4948275	0.631	rs2606116	ENSG00000237233.2	TMEM26-AS1	-4.44	1.14e-05	0.00116	-0.26	-0.2	Night sleep phenotypes;	chr10:61591316	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.631	rs2606117	ENSG00000237233.2	TMEM26-AS1	-4.44	1.14e-05	0.00116	-0.26	-0.2	Night sleep phenotypes;	chr10:61592045	chr10:61452639~61481956:+
THCA	cis	rs9863	0.828	rs12303933	ENSG00000270061.1	RP11-214K3.19	-4.44	1.14e-05	0.00116	-0.26	-0.2	White blood cell count;	chr12:123997709	chr12:123969990~123970344:-
THCA	cis	rs10761482	0.861	rs10821730	ENSG00000254271.1	RP11-131N11.4	-4.44	1.14e-05	0.00116	-0.27	-0.2	Schizophrenia;	chr10:60339513	chr10:60734342~60741828:+
THCA	cis	rs4713118	0.513	rs6915987	ENSG00000219392.1	RP1-265C24.5	4.44	1.15e-05	0.00116	0.23	0.2	Parkinson's disease;	chr6:27547997	chr6:28115628~28116551:+
THCA	cis	rs17221829	0.965	rs28614109	ENSG00000280385.1	AP000648.5	-4.44	1.15e-05	0.00116	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89727775	chr11:90193614~90198120:+
THCA	cis	rs6832769	0.961	rs7660808	ENSG00000272969.1	RP11-528I4.2	-4.44	1.15e-05	0.00116	-0.23	-0.2	Personality dimensions;	chr4:55590505	chr4:55547112~55547889:+
THCA	cis	rs2135507	0.532	rs6817471	ENSG00000270480.1	RP11-57B24.1	-4.44	1.15e-05	0.00116	-0.27	-0.2	Juvenile osteochondritis dissecans;	chr4:82661928	chr4:82691737~82692468:+
THCA	cis	rs10744955	0.702	rs12591392	ENSG00000244879.4	GABPB1-AS1	-4.44	1.15e-05	0.00116	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50161192	chr15:50354959~50372202:+
THCA	cis	rs9634489	0.588	rs1930221	ENSG00000247400.3	DNAJC3-AS1	-4.44	1.15e-05	0.00116	-0.13	-0.2	Body mass index;	chr13:96278868	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.588	rs11841294	ENSG00000247400.3	DNAJC3-AS1	-4.44	1.15e-05	0.00116	-0.13	-0.2	Body mass index;	chr13:96279061	chr13:95648733~95676925:-
THCA	cis	rs61270009	0.863	rs6452782	ENSG00000247828.6	TMEM161B-AS1	4.44	1.15e-05	0.00116	0.17	0.2	Depressive symptoms;	chr5:88376887	chr5:88268895~88436685:+
THCA	cis	rs8064024	0.513	rs1049207	ENSG00000267077.1	RP11-127I20.5	-4.44	1.15e-05	0.00116	-0.23	-0.2	Cancer;	chr16:4884563	chr16:4795265~4796532:-
THCA	cis	rs8030605	0.778	rs11631618	ENSG00000277245.1	RP11-48G14.3	4.44	1.15e-05	0.00116	0.35	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56356495	chr15:56447120~56447697:+
THCA	cis	rs6121246	0.909	rs6058463	ENSG00000230613.1	HM13-AS1	4.44	1.15e-05	0.00116	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31797389	chr20:31567707~31573263:-
THCA	cis	rs7560272	0.501	rs6755500	ENSG00000273245.1	RP11-434P11.2	-4.44	1.15e-05	0.00116	-0.23	-0.2	Schizophrenia;	chr2:73715106	chr2:73750256~73750786:-
THCA	cis	rs1538970	0.774	rs67683090	ENSG00000234329.1	RP11-767N6.2	4.44	1.15e-05	0.00116	0.2	0.2	Platelet count;	chr1:45512131	chr1:45651039~45651826:-
THCA	cis	rs2880765	0.743	rs8032488	ENSG00000259630.2	CTD-2262B20.1	-4.44	1.15e-05	0.00116	-0.21	-0.2	Coronary artery disease;	chr15:85469537	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.743	rs8028240	ENSG00000259630.2	CTD-2262B20.1	-4.44	1.15e-05	0.00116	-0.21	-0.2	Coronary artery disease;	chr15:85470017	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.743	rs6497194	ENSG00000259630.2	CTD-2262B20.1	-4.44	1.15e-05	0.00116	-0.21	-0.2	Coronary artery disease;	chr15:85470885	chr15:85415228~85415633:+
THCA	cis	rs9929218	0.581	rs7203337	ENSG00000260459.2	FTLP14	4.44	1.15e-05	0.00116	0.22	0.2	Colorectal cancer;	chr16:68740897	chr16:68822587~68823070:+
THCA	cis	rs9878978	0.69	rs2874300	ENSG00000237990.3	CNTN4-AS1	4.44	1.15e-05	0.00116	0.24	0.2	Blood pressure (smoking interaction);	chr3:2406067	chr3:3039033~3069242:-
THCA	cis	rs7824557	0.547	rs4512344	ENSG00000254866.2	DEFB109P3	4.44	1.15e-05	0.00116	0.28	0.2	Retinal vascular caliber;	chr8:11221272	chr8:12150895~12151134:-
THCA	cis	rs13256369	1	rs13256369	ENSG00000254153.1	CTA-398F10.2	-4.44	1.15e-05	0.00116	-0.23	-0.2	Obesity-related traits;	chr8:8719869	chr8:8456909~8461337:-
THCA	cis	rs6745190	0.575	rs7569991	ENSG00000236153.1	AC104076.3	-4.44	1.15e-05	0.00116	-0.22	-0.2	White blood cell count;	chr2:181110525	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.575	rs11678264	ENSG00000236153.1	AC104076.3	-4.44	1.15e-05	0.00116	-0.22	-0.2	White blood cell count;	chr2:181111767	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.575	rs6711938	ENSG00000236153.1	AC104076.3	-4.44	1.15e-05	0.00116	-0.22	-0.2	White blood cell count;	chr2:181112301	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.575	rs7580796	ENSG00000236153.1	AC104076.3	-4.44	1.15e-05	0.00116	-0.22	-0.2	White blood cell count;	chr2:181113042	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.575	rs55664819	ENSG00000236153.1	AC104076.3	-4.44	1.15e-05	0.00116	-0.22	-0.2	White blood cell count;	chr2:181115342	chr2:180979427~180980090:-
THCA	cis	rs4950322	0.547	rs17355509	ENSG00000226015.2	CCT8P1	4.43	1.15e-05	0.00116	0.23	0.2	Protein quantitative trait loci;	chr1:147123139	chr1:147203276~147204932:-
THCA	cis	rs890448	1	rs11097750	ENSG00000254531.1	FLJ20021	-4.43	1.15e-05	0.00116	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101517153	chr4:101347780~101348883:+
THCA	cis	rs1003719	0.591	rs13046303	ENSG00000230366.8	DSCR9	4.43	1.15e-05	0.00116	0.21	0.2	Eye color traits;	chr21:37179674	chr21:37208503~37221736:+
THCA	cis	rs2842992	1	rs2758322	ENSG00000237927.1	RP3-393E18.2	-4.43	1.15e-05	0.00116	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159654156	chr6:159586955~159589169:-
THCA	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-4.43	1.15e-05	0.00116	-0.24	-0.2	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-4.43	1.15e-05	0.00116	-0.24	-0.2	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	4.43	1.15e-05	0.00116	0.24	0.2	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
THCA	cis	rs79243044	0.862	rs1560811	ENSG00000224295.2	AC087380.14	-4.43	1.15e-05	0.00116	-0.2	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5528301	chr11:5518441~5524955:-
THCA	cis	rs6696239	0.749	rs10916163	ENSG00000227711.2	RP11-275O4.5	4.43	1.15e-05	0.00116	0.27	0.2	Height;	chr1:227556013	chr1:227509028~227520477:-
THCA	cis	rs8031584	0.918	rs11639169	ENSG00000178081.11	ULK4P3	4.43	1.15e-05	0.00116	0.27	0.2	Huntington's disease progression;	chr15:30963235	chr15:30103720~30131757:+
THCA	cis	rs1124769	0.719	rs2291107	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50941615	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs1871460	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50943272	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs7176498	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50944641	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs3784304	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50945863	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs1955	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50945898	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs1876784	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50946758	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs12440387	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50966473	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.692	rs67889301	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50973842	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs12909839	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50991923	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs17646917	ENSG00000259378.1	DCAF13P3	4.43	1.15e-05	0.00116	0.3	0.2	Cognitive performance;	chr15:50993929	chr15:50944663~50945996:+
THCA	cis	rs5758511	0.773	rs62240999	ENSG00000281538.1	RP4-669P10.20	-4.43	1.15e-05	0.00116	-0.24	-0.2	Birth weight;	chr22:41959559	chr22:42138060~42139726:+
THCA	cis	rs8081395	0.741	rs1292055	ENSG00000267302.4	RP11-178C3.2	4.43	1.15e-05	0.00116	0.24	0.2	White blood cell count;	chr17:59881707	chr17:59964832~59996972:+
THCA	cis	rs889398	0.771	rs12927431	ENSG00000226232.7	RP11-419C5.2	4.43	1.15e-05	0.00116	0.19	0.2	Body mass index;	chr16:69823144	chr16:69976388~69996188:-
THCA	cis	rs7220401	0.542	rs55644350	ENSG00000263370.1	RP11-68I3.5	4.43	1.15e-05	0.00116	0.27	0.2	Coronary artery disease;	chr17:29586350	chr17:29639627~29640825:+
THCA	cis	rs57502260	0.915	rs7106320	ENSG00000212093.1	AP000807.1	4.43	1.15e-05	0.00116	0.26	0.2	Total body bone mineral density (age 45-60);	chr11:68442650	chr11:68506083~68506166:-
THCA	cis	rs149866169	1	rs149866169	ENSG00000220721.1	OR1F12	4.43	1.15e-05	0.00116	0.39	0.2	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28073316~28074233:+
THCA	cis	rs1150668	0.745	rs213238	ENSG00000273712.1	RP5-874C20.7	4.43	1.15e-05	0.00116	0.22	0.2	Pubertal anthropometrics;	chr6:28354216	chr6:28315613~28315883:-
THCA	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-4.43	1.15e-05	0.00116	-0.11	-0.2	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
THCA	cis	rs5015933	0.902	rs1874943	ENSG00000232630.1	PRPS1P2	-4.43	1.15e-05	0.00116	-0.14	-0.2	Body mass index;	chr9:125361055	chr9:125150653~125151589:+
THCA	cis	rs10256972	0.9	rs7812072	ENSG00000225146.1	AC073957.15	4.43	1.15e-05	0.00116	0.21	0.2	Endometriosis;Longevity;	chr7:1014226	chr7:1029025~1043891:+
THCA	cis	rs875971	0.862	rs1875057	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.15e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66266868	chr7:66025126~66031544:-
THCA	cis	rs875971	0.755	rs10228885	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.15e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66315542	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs3893216	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.15e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66325720	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6958294	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.15e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66329809	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs2088655	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.15e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66330724	chr7:66025126~66031544:-
THCA	cis	rs875971	0.895	rs10447522	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.15e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66331087	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs7783779	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.15e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66331639	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs2088653	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.15e-05	0.00116	-0.21	-0.2	Aortic root size;	chr7:66343621	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs778736	ENSG00000229886.1	RP5-1132H15.3	4.43	1.15e-05	0.00116	0.21	0.2	Aortic root size;	chr7:66348861	chr7:66025126~66031544:-
THCA	cis	rs17801127	1	rs848222	ENSG00000231969.1	AC144449.1	-4.43	1.15e-05	0.00116	-0.33	-0.2	Liver enzyme levels (alanine transaminase);	chr2:149693982	chr2:149587196~149848233:+
THCA	cis	rs9902453	1	rs6505152	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30004448	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs7223786	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30005089	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs8072664	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30006367	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.791	rs57719820	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30008070	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.935	rs9911794	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30022448	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs9896062	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30030029	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs9904336	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30030062	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs8071742	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30034651	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs4575590	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30034951	chr17:29639627~29640825:+
THCA	cis	rs9902453	1	rs4074170	ENSG00000263370.1	RP11-68I3.5	-4.43	1.15e-05	0.00116	-0.26	-0.2	Coffee consumption (cups per day);	chr17:30054123	chr17:29639627~29640825:+
THCA	cis	rs12234571	1	rs78146324	ENSG00000214293.7	APTR	4.43	1.15e-05	0.00116	0.25	0.2	Obesity-related traits;	chr7:77956639	chr7:77657660~77696265:-
THCA	cis	rs2446066	0.872	rs10876454	ENSG00000257379.1	RP11-793H13.8	4.43	1.15e-05	0.00117	0.31	0.2	Red blood cell count;	chr12:53427758	chr12:53441741~53467528:+
THCA	cis	rs201673768	1	rs201673768	ENSG00000269514.1	RP11-370I10.12	-4.43	1.15e-05	0.00117	-0.17	-0.2	Platelet count;	chr12:48305834	chr12:48198387~48202031:+
THCA	cis	rs62025270	0.806	rs62025266	ENSG00000259295.5	CSPG4P12	-4.43	1.15e-05	0.00117	-0.32	-0.2	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85191438~85213905:+
THCA	cis	rs801193	1	rs13239306	ENSG00000224316.1	RP11-479O9.2	-4.43	1.15e-05	0.00117	-0.23	-0.2	Aortic root size;	chr7:66671030	chr7:65773620~65802067:+
THCA	cis	rs7520050	0.778	rs2934857	ENSG00000280836.1	AL355480.1	-4.43	1.15e-05	0.00117	-0.24	-0.2	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45581219~45581321:-
THCA	cis	rs1580019	0.922	rs34545272	ENSG00000231952.3	DPY19L1P2	-4.43	1.15e-05	0.00117	-0.26	-0.2	Cognitive ability;	chr7:32421018	chr7:32812757~32838570:+
THCA	cis	rs481331	0.866	rs11499093	ENSG00000215146.4	RP11-313J2.1	-4.43	1.15e-05	0.00117	-0.31	-0.2	Systemic juvenile idiopathic arthritis;	chr10:42487342	chr10:42331866~42367974:-
THCA	cis	rs4237845	0.537	rs11172369	ENSG00000270039.1	RP11-571M6.17	-4.43	1.15e-05	0.00117	-0.23	-0.2	Intelligence (multi-trait analysis);	chr12:57886809	chr12:57803838~57804415:+
THCA	cis	rs736408	0.562	rs12497998	ENSG00000243224.1	RP5-1157M23.2	-4.43	1.15e-05	0.00117	-0.22	-0.2	Bipolar disorder;	chr3:52759586	chr3:52239258~52241097:+
THCA	cis	rs12435908	0.786	rs60919640	ENSG00000276116.2	FUT8-AS1	-4.43	1.15e-05	0.00117	-0.26	-0.2	Ischemic stroke;	chr14:65710332	chr14:65411170~65412690:-
THCA	cis	rs1414896	0.692	rs3767316	ENSG00000226026.4	RP11-57H12.3	-4.43	1.15e-05	0.00117	-0.19	-0.2	Non-alcoholic fatty liver disease histology (AST);	chr1:95239497	chr1:95163219~95233982:-
THCA	cis	rs7403037	0.876	rs61993152	ENSG00000260760.1	PWRN3	4.43	1.15e-05	0.00117	0.24	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24553782	chr15:24441127~24447967:+
THCA	cis	rs1005277	0.54	rs7903942	ENSG00000226578.1	RP11-258F22.1	4.43	1.15e-05	0.00117	0.23	0.2	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:37775371~37784131:-
THCA	cis	rs8062405	0.755	rs7193402	ENSG00000261766.1	RP11-22P6.2	-4.43	1.16e-05	0.00117	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28862166~28863340:-
THCA	cis	rs12030196	1	rs12023539	ENSG00000230812.4	LINC01358	-4.43	1.16e-05	0.00117	-0.26	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59005959	chr1:59020387~59044614:+
THCA	cis	rs7474896	0.559	rs1212108	ENSG00000120555.12	SEPT7P9	4.43	1.16e-05	0.00117	0.27	0.2	Obesity (extreme);	chr10:37805394	chr10:38383069~38402916:-
THCA	cis	rs11671005	0.693	rs11668821	ENSG00000268912.1	CTD-2619J13.17	-4.43	1.16e-05	0.00117	-0.19	-0.2	Mean platelet volume;	chr19:58444446	chr19:58428632~58431148:-
THCA	cis	rs11671005	0.616	rs12980907	ENSG00000268912.1	CTD-2619J13.17	-4.43	1.16e-05	0.00117	-0.19	-0.2	Mean platelet volume;	chr19:58444959	chr19:58428632~58431148:-
THCA	cis	rs8177876	0.631	rs2549895	ENSG00000261061.1	RP11-303E16.2	4.43	1.16e-05	0.00117	0.26	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81052415	chr16:81030770~81031485:+
THCA	cis	rs11710088	0.599	rs4681509	ENSG00000244503.1	RP11-278L15.6	4.43	1.16e-05	0.00117	0.25	0.2	QRS duration;	chr3:149483657	chr3:149494660~149495995:+
THCA	cis	rs10208649	0.572	rs7585466	ENSG00000233266.1	HMGB1P31	4.43	1.16e-05	0.00117	0.35	0.2	Body mass index;	chr2:54098988	chr2:54051334~54051760:+
THCA	cis	rs2790457	0.792	rs1265830	ENSG00000254635.4	WAC-AS1	4.43	1.16e-05	0.00117	0.2	0.2	Multiple myeloma;	chr10:28623294	chr10:28522652~28532743:-
THCA	cis	rs6479874	1	rs7080757	ENSG00000223502.1	RP11-96B5.3	-4.43	1.16e-05	0.00117	-0.24	-0.2	Migraine;	chr10:50999793	chr10:51062579~51068553:-
THCA	cis	rs2304003	1	rs10930182	ENSG00000235192.1	AC009495.2	4.43	1.16e-05	0.00117	0.27	0.2	Social communication problems;	chr2:165831678	chr2:165794851~165810010:+
THCA	cis	rs812925	0.537	rs2593620	ENSG00000270820.4	RP11-355B11.2	-4.43	1.16e-05	0.00117	-0.17	-0.2	Immature fraction of reticulocytes;	chr2:61386126	chr2:61471188~61484130:+
THCA	cis	rs9341808	0.529	rs2322765	ENSG00000260645.1	RP11-250B2.5	4.43	1.16e-05	0.00117	0.17	0.2	Sitting height ratio;	chr6:80354879	chr6:80466958~80469080:+
THCA	cis	rs6671200	1	rs12755552	ENSG00000235501.4	RP4-639F20.1	-4.43	1.16e-05	0.00117	-0.4	-0.2	Stearic acid (18:0) levels;	chr1:95219470	chr1:94927566~94963270:+
THCA	cis	rs7246657	0.551	rs10419174	ENSG00000226686.6	LINC01535	-4.43	1.16e-05	0.00117	-0.35	-0.2	Coronary artery calcification;	chr19:37114439	chr19:37251912~37265535:+
THCA	cis	rs11881751	0.655	rs10403949	ENSG00000267011.4	CTB-50L17.16	4.43	1.16e-05	0.00117	0.29	0.2	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr19:5035535	chr19:4457962~4471493:-
THCA	cis	rs59868192	0.925	rs72726038	ENSG00000246740.2	PLA2G4E-AS1	4.43	1.16e-05	0.00117	0.38	0.2	White blood cell count;	chr15:41973121	chr15:41972763~41999094:+
THCA	cis	rs59868192	0.925	rs72726040	ENSG00000246740.2	PLA2G4E-AS1	4.43	1.16e-05	0.00117	0.38	0.2	White blood cell count;	chr15:41973198	chr15:41972763~41999094:+
THCA	cis	rs807029	0.72	rs14177	ENSG00000236662.1	RP11-108L7.4	4.43	1.16e-05	0.00117	0.21	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101007398	chr10:100980507~100985614:-
THCA	cis	rs1572312	0.551	rs4023897	ENSG00000237928.4	NFIA-AS2	4.43	1.16e-05	0.00117	0.26	0.2	Maximal oxygen uptake response;	chr1:60957509	chr1:60940239~60970776:-
THCA	cis	rs8037818	1	rs8037102	ENSG00000261064.1	RP11-1000B6.3	-4.43	1.16e-05	0.00117	-0.17	-0.2	Obesity-related traits;	chr15:32640449	chr15:32536047~32587613:+
THCA	cis	rs7537765	0.947	rs17037388	ENSG00000242349.4	NPPA-AS1	-4.43	1.16e-05	0.00117	-0.26	-0.2	QRS complex (12-leadsum);	chr1:11797979	chr1:11841017~11848079:+
THCA	cis	rs172166	0.543	rs1150691	ENSG00000261839.1	RP1-265C24.8	4.43	1.16e-05	0.00117	0.19	0.2	Cardiac Troponin-T levels;	chr6:28200255	chr6:28136849~28139678:+
THCA	cis	rs9326248	0.581	rs7120515	ENSG00000280143.1	AP000892.6	4.43	1.16e-05	0.00117	0.24	0.2	Blood protein levels;	chr11:117121210	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.581	rs7106437	ENSG00000280143.1	AP000892.6	4.43	1.16e-05	0.00117	0.24	0.2	Blood protein levels;	chr11:117121360	chr11:117204967~117210292:+
THCA	cis	rs728616	0.51	rs35671072	ENSG00000278616.1	BEND3P3	4.43	1.16e-05	0.00117	0.2	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80412499	chr10:79682997~79685436:+
THCA	cis	rs2179367	0.509	rs9485390	ENSG00000216906.2	RP11-350J20.9	4.43	1.16e-05	0.00117	0.25	0.2	Dupuytren's disease;	chr6:149421004	chr6:149904243~149906418:+
THCA	cis	rs875971	0.66	rs1860468	ENSG00000272831.1	RP11-792A8.4	-4.43	1.16e-05	0.00117	-0.13	-0.2	Aortic root size;	chr7:66642265	chr7:66739829~66740385:-
THCA	cis	rs8028182	0.636	rs28783769	ENSG00000260269.4	CTD-2323K18.1	-4.43	1.16e-05	0.00117	-0.3	-0.2	Sudden cardiac arrest;	chr15:75556668	chr15:75527150~75601205:-
THCA	cis	rs6787172	0.811	rs11714869	ENSG00000272087.1	RP11-379F4.7	-4.43	1.16e-05	0.00117	-0.18	-0.2	Subjective well-being;	chr3:158476931	chr3:158693120~158693768:-
THCA	cis	rs5758511	0.68	rs58654759	ENSG00000237037.8	NDUFA6-AS1	-4.43	1.16e-05	0.00117	-0.19	-0.2	Birth weight;	chr22:42246570	chr22:42090931~42137742:+
THCA	cis	rs2243480	1	rs35396113	ENSG00000164669.11	INTS4P1	4.43	1.16e-05	0.00117	0.39	0.2	Diabetic kidney disease;	chr7:66030474	chr7:65141225~65234216:+
THCA	cis	rs703842	1	rs10783847	ENSG00000270039.1	RP11-571M6.17	-4.43	1.16e-05	0.00117	-0.23	-0.2	Multiple sclerosis;	chr12:57802664	chr12:57803838~57804415:+
THCA	cis	rs12439619	1	rs35152457	ENSG00000259429.4	UBE2Q2P2	-4.43	1.16e-05	0.00117	-0.18	-0.2	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82355142~82420075:+
THCA	cis	rs11658311	0.85	rs62066215	ENSG00000232344.2	AC087163.2	4.43	1.16e-05	0.00117	0.26	0.2	Obsessive-compulsive symptoms;	chr17:17636935	chr17:18010643~18011822:+
THCA	cis	rs453301	0.631	rs28572014	ENSG00000254153.1	CTA-398F10.2	4.43	1.16e-05	0.00117	0.23	0.2	Joint mobility (Beighton score);	chr8:8936097	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.606	rs11776838	ENSG00000254153.1	CTA-398F10.2	4.43	1.16e-05	0.00117	0.22	0.2	Mood instability;	chr8:8937291	chr8:8456909~8461337:-
THCA	cis	rs7216064	0.953	rs11079705	ENSG00000278740.1	RP11-147L13.14	4.43	1.16e-05	0.00117	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839336	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs11079706	ENSG00000278740.1	RP11-147L13.14	4.43	1.16e-05	0.00117	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839354	chr17:68188547~68189165:+
THCA	cis	rs1003719	0.591	rs2835618	ENSG00000230366.8	DSCR9	4.43	1.16e-05	0.00117	0.21	0.2	Eye color traits;	chr21:37130826	chr21:37208503~37221736:+
THCA	cis	rs8067545	0.611	rs7219908	ENSG00000270091.1	RP11-78O7.2	-4.43	1.16e-05	0.00117	-0.15	-0.2	Schizophrenia;	chr17:20139723	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs8078716	ENSG00000270091.1	RP11-78O7.2	-4.43	1.16e-05	0.00117	-0.15	-0.2	Schizophrenia;	chr17:20140978	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.578	rs62066870	ENSG00000270091.1	RP11-78O7.2	-4.43	1.16e-05	0.00117	-0.15	-0.2	Schizophrenia;	chr17:20160445	chr17:19896590~19897287:-
THCA	cis	rs11148252	0.774	rs9596649	ENSG00000273784.3	RP11-78J21.7	4.43	1.16e-05	0.00117	0.21	0.2	Lewy body disease;	chr13:52360475	chr13:52600042~52642542:+
THCA	cis	rs7989336	0.568	rs9300345	ENSG00000247400.3	DNAJC3-AS1	4.43	1.16e-05	0.00117	0.13	0.2	Obesity;	chr13:96386508	chr13:95648733~95676925:-
THCA	cis	rs6715284	0.786	rs6743951	ENSG00000183308.6	AC005037.3	4.43	1.16e-05	0.00117	0.5	0.2	Rheumatoid arthritis;	chr2:201493672	chr2:200963263~201009102:+
THCA	cis	rs6715284	0.786	rs13417718	ENSG00000183308.6	AC005037.3	4.43	1.16e-05	0.00117	0.5	0.2	Rheumatoid arthritis;	chr2:201504679	chr2:200963263~201009102:+
THCA	cis	rs6715284	0.681	rs58494612	ENSG00000183308.6	AC005037.3	4.43	1.16e-05	0.00117	0.5	0.2	Rheumatoid arthritis;	chr2:201507188	chr2:200963263~201009102:+
THCA	cis	rs6715284	0.786	rs7583945	ENSG00000183308.6	AC005037.3	4.43	1.16e-05	0.00117	0.5	0.2	Rheumatoid arthritis;	chr2:201512748	chr2:200963263~201009102:+
THCA	cis	rs914615	0.508	rs7535292	ENSG00000236675.1	MTX1P1	-4.43	1.16e-05	0.00117	-0.19	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155155273	chr1:155230975~155234325:+
THCA	cis	rs9634489	0.588	rs1927788	ENSG00000247400.3	DNAJC3-AS1	-4.43	1.16e-05	0.00117	-0.13	-0.2	Body mass index;	chr13:96275777	chr13:95648733~95676925:-
THCA	cis	rs4950322	0.512	rs2353981	ENSG00000278811.3	LINC00624	-4.43	1.16e-05	0.00117	-0.22	-0.2	Protein quantitative trait loci;	chr1:147368365	chr1:147258885~147517875:-
THCA	cis	rs7819412	0.745	rs7017567	ENSG00000206014.6	OR7E161P	4.43	1.16e-05	0.00117	0.23	0.2	Triglycerides;	chr8:11076189	chr8:11928597~11929563:-
THCA	cis	rs61270009	0.955	rs780404	ENSG00000247828.6	TMEM161B-AS1	-4.43	1.16e-05	0.00117	-0.17	-0.2	Depressive symptoms;	chr5:88256675	chr5:88268895~88436685:+
THCA	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-4.43	1.16e-05	0.00117	-0.23	-0.2	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-4.43	1.16e-05	0.00117	-0.23	-0.2	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
THCA	cis	rs9532669	0.927	rs9532670	ENSG00000229473.2	RGS17P1	-4.43	1.16e-05	0.00117	-0.25	-0.2	Cervical cancer;	chr13:40927691	chr13:40992779~40993331:-
THCA	cis	rs725613	0.512	rs4781033	ENSG00000274038.1	RP11-66H6.4	-4.43	1.16e-05	0.00117	-0.24	-0.2	Primary sclerosing cholangitis;	chr16:10993045	chr16:11056556~11057034:+
THCA	cis	rs9307551	0.857	rs2165387	ENSG00000249646.2	OR7E94P	-4.43	1.16e-05	0.00117	-0.26	-0.2	Refractive error;	chr4:79570666	chr4:79587302~79588130:-
THCA	cis	rs9393777	0.547	rs2893910	ENSG00000219392.1	RP1-265C24.5	-4.43	1.16e-05	0.00117	-0.28	-0.2	Intelligence (multi-trait analysis);	chr6:27315475	chr6:28115628~28116551:+
THCA	cis	rs2836974	0.583	rs2410124	ENSG00000255568.3	BRWD1-AS2	-4.43	1.16e-05	0.00117	-0.16	-0.2	Cognitive function;	chr21:39332834	chr21:39313935~39314962:+
THCA	cis	rs10911902	0.602	rs74370445	ENSG00000229739.2	RP11-295K2.3	-4.43	1.16e-05	0.00117	-0.31	-0.2	Schizophrenia;	chr1:186380327	chr1:186435161~186470291:+
THCA	cis	rs4948275	0.693	rs2787713	ENSG00000237233.2	TMEM26-AS1	4.43	1.16e-05	0.00117	0.26	0.2	Night sleep phenotypes;	chr10:61558446	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs2650732	ENSG00000237233.2	TMEM26-AS1	-4.43	1.16e-05	0.00117	-0.26	-0.2	Night sleep phenotypes;	chr10:61562549	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs1456284	ENSG00000237233.2	TMEM26-AS1	-4.43	1.16e-05	0.00117	-0.26	-0.2	Night sleep phenotypes;	chr10:61563057	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.667	rs2650727	ENSG00000237233.2	TMEM26-AS1	-4.43	1.16e-05	0.00117	-0.26	-0.2	Night sleep phenotypes;	chr10:61563814	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs12360246	ENSG00000237233.2	TMEM26-AS1	-4.43	1.16e-05	0.00117	-0.26	-0.2	Night sleep phenotypes;	chr10:61566059	chr10:61452639~61481956:+
THCA	cis	rs4948275	0.693	rs1824082	ENSG00000237233.2	TMEM26-AS1	-4.43	1.16e-05	0.00117	-0.26	-0.2	Night sleep phenotypes;	chr10:61566762	chr10:61452639~61481956:+
THCA	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-4.43	1.16e-05	0.00117	-0.3	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
THCA	cis	rs12022452	0.73	rs2297755	ENSG00000237899.1	RP4-739H11.3	-4.43	1.16e-05	0.00117	-0.33	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40669089~40687588:-
THCA	cis	rs2448490	0.642	rs573589	ENSG00000214659.4	KRT8P26	-4.43	1.16e-05	0.00118	-0.18	-0.2	Platelet count;	chr11:65716510	chr11:65726939~65728214:+
THCA	cis	rs1150668	0.796	rs2531832	ENSG00000280107.1	AL022393.9	-4.43	1.16e-05	0.00118	-0.2	-0.2	Pubertal anthropometrics;	chr6:28421445	chr6:28170845~28172521:+
THCA	cis	rs987724	0.501	rs2321293	ENSG00000240875.4	LINC00886	-4.43	1.16e-05	0.00118	-0.19	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156931311	chr3:156747346~156817062:-
THCA	cis	rs890448	1	rs890448	ENSG00000254531.1	FLJ20021	-4.43	1.16e-05	0.00118	-0.17	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101511545	chr4:101347780~101348883:+
THCA	cis	rs5771225	0.563	rs1129880	ENSG00000273253.2	RP3-402G11.26	-4.43	1.16e-05	0.00118	-0.24	-0.2	Late-onset Alzheimer's disease;	chr22:50255868	chr22:50199090~50200837:-
THCA	cis	rs875971	0.862	rs908915	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.16e-05	0.00118	-0.21	-0.2	Aortic root size;	chr7:66149664	chr7:66025126~66031544:-
THCA	cis	rs15676	0.947	rs2293966	ENSG00000234771.3	SLC25A25-AS1	4.43	1.16e-05	0.00118	0.17	0.2	Blood metabolite levels;	chr9:128829553	chr9:128108581~128118693:-
THCA	cis	rs61270009	0.955	rs11748768	ENSG00000247828.6	TMEM161B-AS1	4.43	1.16e-05	0.00118	0.17	0.2	Depressive symptoms;	chr5:88354818	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs11750391	ENSG00000247828.6	TMEM161B-AS1	4.43	1.16e-05	0.00118	0.17	0.2	Depressive symptoms;	chr5:88356255	chr5:88268895~88436685:+
THCA	cis	rs4443100	0.916	rs2330335	ENSG00000230701.2	FBXW4P1	4.43	1.16e-05	0.00118	0.24	0.2	Serum parathyroid hormone levels;	chr22:23040185	chr22:23262767~23265005:+
THCA	cis	rs964611	0.882	rs12148383	ENSG00000259488.2	RP11-154J22.1	4.43	1.17e-05	0.00118	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48368235	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs873661	ENSG00000259488.2	RP11-154J22.1	4.43	1.17e-05	0.00118	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48368914	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs4775753	ENSG00000259488.2	RP11-154J22.1	4.43	1.17e-05	0.00118	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48369022	chr15:48312353~48331856:-
THCA	cis	rs13256369	1	rs10098234	ENSG00000254153.1	CTA-398F10.2	-4.43	1.17e-05	0.00118	-0.22	-0.2	Obesity-related traits;	chr8:8719182	chr8:8456909~8461337:-
THCA	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	4.43	1.17e-05	0.00118	0.32	0.2	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
THCA	cis	rs6088590	1	rs6087623	ENSG00000276073.1	RP5-1125A11.7	-4.43	1.17e-05	0.00118	-0.18	-0.2	Coronary artery disease;	chr20:34729858	chr20:33985617~33988989:-
THCA	cis	rs13325613	0.915	rs7620586	ENSG00000223552.1	RP11-24F11.2	-4.43	1.17e-05	0.00118	-0.3	-0.2	Monocyte count;	chr3:46226246	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs71327043	ENSG00000223552.1	RP11-24F11.2	-4.43	1.17e-05	0.00118	-0.3	-0.2	Monocyte count;	chr3:46226851	chr3:46364955~46407059:-
THCA	cis	rs7474896	0.832	rs12768391	ENSG00000263064.2	RP11-291L22.7	4.43	1.17e-05	0.00118	0.35	0.2	Obesity (extreme);	chr10:37801716	chr10:38448689~38448949:+
THCA	cis	rs748404	0.706	rs35975365	ENSG00000205771.5	CATSPER2P1	-4.43	1.17e-05	0.00118	-0.28	-0.2	Lung cancer;	chr15:43379347	chr15:43726918~43747094:-
THCA	cis	rs60733400	0.5	rs72644697	ENSG00000225931.3	RP3-395M20.7	4.43	1.17e-05	0.00118	0.24	0.2	Multiple sclerosis;	chr1:2602166	chr1:2566410~2569888:+
THCA	cis	rs734999	0.588	rs11585048	ENSG00000225931.3	RP3-395M20.7	4.43	1.17e-05	0.00118	0.24	0.2	Ulcerative colitis;	chr1:2602648	chr1:2566410~2569888:+
THCA	cis	rs9847710	0.967	rs2564931	ENSG00000242142.1	SERBP1P3	4.43	1.17e-05	0.00118	0.24	0.2	Ulcerative colitis;	chr3:52986543	chr3:53064283~53065091:-
THCA	cis	rs9475752	0.744	rs746010	ENSG00000231441.1	RP11-472M19.2	4.43	1.17e-05	0.00118	0.21	0.2	Menarche (age at onset);	chr6:56935540	chr6:56844002~56864078:+
THCA	cis	rs7819412	0.594	rs17724226	ENSG00000206014.6	OR7E161P	4.43	1.17e-05	0.00118	0.24	0.2	Triglycerides;	chr8:11111416	chr8:11928597~11929563:-
THCA	cis	rs13126694	0.659	rs28514324	ENSG00000248429.4	RP11-597D13.9	4.43	1.17e-05	0.00118	0.22	0.2	Blood osmolality (transformed sodium);	chr4:158092778	chr4:158170752~158202877:+
THCA	cis	rs2191566	1	rs384544	ENSG00000266921.1	RP11-15A1.7	4.43	1.17e-05	0.00118	0.19	0.2	Acute lymphoblastic leukemia (childhood);	chr19:44001103	chr19:43996896~44002836:-
THCA	cis	rs11771526	1	rs17351142	ENSG00000272905.1	RP11-265E18.1	4.43	1.17e-05	0.00118	0.29	0.2	Body mass index;	chr7:32300231	chr7:32845394~32846061:+
THCA	cis	rs5770917	1	rs5770922	ENSG00000273272.1	CTA-384D8.34	4.43	1.17e-05	0.00118	0.32	0.2	Narcolepsy;	chr22:50584979	chr22:50542650~50543011:+
THCA	cis	rs12022452	0.818	rs11810978	ENSG00000237899.1	RP4-739H11.3	-4.43	1.17e-05	0.00118	-0.32	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40669089~40687588:-
THCA	cis	rs6088590	1	rs6120708	ENSG00000276073.1	RP5-1125A11.7	-4.43	1.17e-05	0.00118	-0.18	-0.2	Coronary artery disease;	chr20:34747722	chr20:33985617~33988989:-
THCA	cis	rs2360027	0.599	rs17257958	ENSG00000231365.4	RP11-418J17.1	-4.43	1.17e-05	0.00118	-0.2	-0.2	Tonsillectomy;	chr1:118537880	chr1:119140396~119275973:+
THCA	cis	rs4415084	0.716	rs6451778	ENSG00000272335.1	RP11-53O19.3	4.43	1.17e-05	0.00118	0.17	0.2	Breast cancer;	chr5:44857886	chr5:44826076~44828592:+
THCA	cis	rs5758659	0.935	rs134879	ENSG00000273366.1	CTA-989H11.1	-4.43	1.17e-05	0.00118	-0.24	-0.2	Cognitive function;	chr22:42268195	chr22:42278188~42278846:+
THCA	cis	rs9880211	1	rs9826454	ENSG00000239213.4	NCK1-AS1	4.43	1.17e-05	0.00118	0.22	0.2	Height;Body mass index;	chr3:136234378	chr3:136841726~136862054:-
THCA	cis	rs7772486	0.754	rs9386134	ENSG00000270638.1	RP3-466P17.1	4.43	1.17e-05	0.00118	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145735570~145737218:+
THCA	cis	rs71636778	0.631	rs77402838	ENSG00000260063.1	RP5-968P14.2	-4.43	1.17e-05	0.00118	-0.27	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26871242	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.631	rs12735407	ENSG00000260063.1	RP5-968P14.2	-4.43	1.17e-05	0.00118	-0.27	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26872446	chr1:26692132~26694131:-
THCA	cis	rs6745190	0.575	rs6433892	ENSG00000236153.1	AC104076.3	-4.43	1.17e-05	0.00118	-0.22	-0.2	White blood cell count;	chr2:181106510	chr2:180979427~180980090:-
THCA	cis	rs2898290	0.622	rs7822109	ENSG00000251402.3	FAM90A25P	-4.43	1.17e-05	0.00118	-0.26	-0.2	Systolic blood pressure;	chr8:11491638	chr8:12415080~12418090:-
THCA	cis	rs1150668	0.796	rs1124132	ENSG00000280107.1	AL022393.9	-4.43	1.17e-05	0.00118	-0.19	-0.2	Pubertal anthropometrics;	chr6:28412544	chr6:28170845~28172521:+
THCA	cis	rs9311474	0.629	rs9853056	ENSG00000243224.1	RP5-1157M23.2	-4.43	1.17e-05	0.00118	-0.22	-0.2	Electroencephalogram traits;	chr3:52521941	chr3:52239258~52241097:+
THCA	cis	rs10510102	0.516	rs10437506	ENSG00000226864.1	ATE1-AS1	4.43	1.17e-05	0.00118	0.33	0.2	Breast cancer;	chr10:121984011	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.516	rs74461504	ENSG00000226864.1	ATE1-AS1	4.43	1.17e-05	0.00118	0.33	0.2	Breast cancer;	chr10:121986077	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.516	rs61071865	ENSG00000226864.1	ATE1-AS1	4.43	1.17e-05	0.00118	0.33	0.2	Breast cancer;	chr10:121986236	chr10:121928312~121951965:+
THCA	cis	rs10510102	0.516	rs10159589	ENSG00000226864.1	ATE1-AS1	4.43	1.17e-05	0.00118	0.33	0.2	Breast cancer;	chr10:121986659	chr10:121928312~121951965:+
THCA	cis	rs72634501	0.716	rs4660165	ENSG00000228060.1	RP11-69E11.8	4.43	1.17e-05	0.00118	0.22	0.2	HDL cholesterol;	chr1:39112860	chr1:39565160~39573203:+
THCA	cis	rs4705952	0.832	rs763595	ENSG00000233006.5	AC034220.3	-4.43	1.17e-05	0.00118	-0.18	-0.2	C-reactive protein levels;	chr5:132527552	chr5:132311285~132369916:-
THCA	cis	rs858239	0.508	rs2390754	ENSG00000230042.1	AK3P3	-4.43	1.17e-05	0.00118	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23129178~23129841:+
THCA	cis	rs4906332	1	rs35862113	ENSG00000269910.1	RP11-73M18.10	4.43	1.17e-05	0.00118	0.17	0.2	Coronary artery disease;	chr14:103390892	chr14:103694516~103695050:-
THCA	cis	rs4906332	0.84	rs34161327	ENSG00000269910.1	RP11-73M18.10	4.43	1.17e-05	0.00118	0.17	0.2	Coronary artery disease;	chr14:103390988	chr14:103694516~103695050:-
THCA	cis	rs6921919	0.583	rs9468355	ENSG00000280107.1	AL022393.9	-4.43	1.17e-05	0.00118	-0.22	-0.2	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28170845~28172521:+
THCA	cis	rs10744955	0.679	rs4775867	ENSG00000244879.4	GABPB1-AS1	-4.43	1.17e-05	0.00118	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50165065	chr15:50354959~50372202:+
THCA	cis	rs10744955	0.727	rs6493413	ENSG00000244879.4	GABPB1-AS1	-4.43	1.17e-05	0.00118	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50165538	chr15:50354959~50372202:+
THCA	cis	rs10744955	0.727	rs2414032	ENSG00000244879.4	GABPB1-AS1	-4.43	1.17e-05	0.00118	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50166464	chr15:50354959~50372202:+
THCA	cis	rs6494488	0.5	rs67108203	ENSG00000259635.1	AC100830.3	-4.43	1.17e-05	0.00118	-0.49	-0.2	Coronary artery disease;	chr15:64713753	chr15:64701248~64719602:+
THCA	cis	rs2880765	0.714	rs6497187	ENSG00000259630.2	CTD-2262B20.1	-4.43	1.17e-05	0.00118	-0.21	-0.2	Coronary artery disease;	chr15:85468119	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.743	rs6497191	ENSG00000259630.2	CTD-2262B20.1	-4.43	1.17e-05	0.00118	-0.21	-0.2	Coronary artery disease;	chr15:85468270	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.743	rs6416598	ENSG00000259630.2	CTD-2262B20.1	-4.43	1.17e-05	0.00118	-0.21	-0.2	Coronary artery disease;	chr15:85468617	chr15:85415228~85415633:+
THCA	cis	rs13113518	1	rs2279458	ENSG00000249700.7	SRD5A3-AS1	4.43	1.17e-05	0.00118	0.25	0.2	Height;	chr4:55562653	chr4:55363971~55395847:-
THCA	cis	rs911186	0.812	rs3800316	ENSG00000216901.1	AL022393.7	4.43	1.17e-05	0.00118	0.26	0.2	Autism spectrum disorder or schizophrenia;	chr6:27288323	chr6:28176188~28176674:+
THCA	cis	rs7773456	1	rs7773456	ENSG00000237404.1	RP3-471C18.2	-4.43	1.17e-05	0.00118	-0.21	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr6:19823007	chr6:19689825~19753113:-
THCA	cis	rs9876781	1	rs725309	ENSG00000244380.1	RP11-24C3.2	-4.43	1.17e-05	0.00118	-0.23	-0.2	Longevity;	chr3:48377218	chr3:48440352~48446656:-
THCA	cis	rs10186029	0.676	rs35922168	ENSG00000270659.1	RP11-105N14.1	-4.43	1.17e-05	0.00118	-0.16	-0.2	Systemic sclerosis;	chr2:213084294	chr2:213152970~213153659:+
THCA	cis	rs6012564	0.963	rs6125590	ENSG00000227431.4	CSE1L-AS1	4.43	1.17e-05	0.00118	0.25	0.2	Anger;	chr20:49204089	chr20:49040463~49046044:-
THCA	cis	rs9527	0.551	rs28606370	ENSG00000213061.2	PFN1P11	4.43	1.17e-05	0.00118	0.25	0.2	Arsenic metabolism;	chr10:102911075	chr10:102838011~102845473:-
THCA	cis	rs4713118	0.513	rs6915987	ENSG00000216901.1	AL022393.7	-4.43	1.17e-05	0.00118	-0.24	-0.2	Parkinson's disease;	chr6:27547997	chr6:28176188~28176674:+
THCA	cis	rs7560272	0.538	rs13014700	ENSG00000273245.1	RP11-434P11.2	-4.43	1.17e-05	0.00118	-0.23	-0.2	Schizophrenia;	chr2:73692994	chr2:73750256~73750786:-
THCA	cis	rs7246657	0.551	rs62108899	ENSG00000276846.1	CTD-3220F14.3	4.43	1.17e-05	0.00118	0.26	0.2	Coronary artery calcification;	chr19:37104281	chr19:37314868~37315620:-
THCA	cis	rs763121	0.853	rs2072795	ENSG00000273076.1	RP3-508I15.22	-4.43	1.17e-05	0.00118	-0.2	-0.2	Menopause (age at onset);	chr22:38668204	chr22:38743495~38743910:+
THCA	cis	rs61270009	0.955	rs430943	ENSG00000247828.6	TMEM161B-AS1	-4.43	1.17e-05	0.00118	-0.18	-0.2	Depressive symptoms;	chr5:88251306	chr5:88268895~88436685:+
THCA	cis	rs1371614	0.632	rs12615423	ENSG00000229122.1	AGBL5-IT1	-4.43	1.17e-05	0.00118	-0.15	-0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26935755	chr2:27061038~27061815:+
THCA	cis	rs922182	0.547	rs12907026	ENSG00000275785.1	RP11-111E14.2	-4.43	1.17e-05	0.00118	-0.22	-0.2	Blood protein levels;	chr15:63979405	chr15:63890030~63890317:+
THCA	cis	rs17767294	0.708	rs17693877	ENSG00000219392.1	RP1-265C24.5	-4.43	1.17e-05	0.00118	-0.45	-0.2	Parkinson's disease;	chr6:27739267	chr6:28115628~28116551:+
THCA	cis	rs2135507	0.532	rs1848068	ENSG00000270480.1	RP11-57B24.1	-4.43	1.17e-05	0.00118	-0.27	-0.2	Juvenile osteochondritis dissecans;	chr4:82661393	chr4:82691737~82692468:+
THCA	cis	rs10875746	0.859	rs4760622	ENSG00000258234.1	RP11-370I10.2	4.43	1.17e-05	0.00118	0.24	0.2	Longevity (90 years and older);	chr12:48198177	chr12:48231098~48284210:-
THCA	cis	rs9987353	1	rs9987353	ENSG00000254153.1	CTA-398F10.2	4.43	1.17e-05	0.00118	0.24	0.2	Recombination measurement;	chr8:9258839	chr8:8456909~8461337:-
THCA	cis	rs867371	0.82	rs12443224	ENSG00000259429.4	UBE2Q2P2	-4.43	1.17e-05	0.00118	-0.16	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82355142~82420075:+
THCA	cis	rs6430585	0.583	rs3769008	ENSG00000231890.6	DARS-AS1	-4.43	1.17e-05	0.00118	-0.24	-0.2	Corneal structure;	chr2:135828613	chr2:135985176~136022593:+
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000182586.6	LINC00334	-4.43	1.17e-05	0.00118	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000182586.6	LINC00334	-4.43	1.17e-05	0.00118	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000182586.6	LINC00334	-4.43	1.17e-05	0.00118	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000182586.6	LINC00334	-4.43	1.17e-05	0.00118	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45234340~45258730:+
THCA	cis	rs1707322	1	rs4660905	ENSG00000281133.1	AL355480.3	4.43	1.17e-05	0.00118	0.24	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211243	ENSG00000281133.1	AL355480.3	-4.43	1.17e-05	0.00118	-0.24	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs11211244	ENSG00000281133.1	AL355480.3	-4.43	1.17e-05	0.00118	-0.24	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45580892~45580996:-
THCA	cis	rs1707322	1	rs4660903	ENSG00000281133.1	AL355480.3	-4.43	1.17e-05	0.00118	-0.24	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45580892~45580996:-
THCA	cis	rs11846409	0.629	rs76295389	ENSG00000211974.3	IGHV2-70	4.43	1.17e-05	0.00118	0.19	0.2	Rheumatic heart disease;	chr14:106650437	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.698	rs71419854	ENSG00000211974.3	IGHV2-70	4.43	1.17e-05	0.00118	0.19	0.2	Rheumatic heart disease;	chr14:106650440	chr14:106723574~106724093:-
THCA	cis	rs2337406	0.5	rs71419855	ENSG00000211974.3	IGHV2-70	4.43	1.17e-05	0.00118	0.19	0.2	Alzheimer's disease (late onset);	chr14:106650444	chr14:106723574~106724093:-
THCA	cis	rs6500602	0.592	rs8051780	ENSG00000280063.1	RP11-295D4.3	4.43	1.18e-05	0.00119	0.12	0.2	Schizophrenia;	chr16:4384373	chr16:4346694~4348648:-
THCA	cis	rs10484434	0.792	rs7757646	ENSG00000272810.1	U91328.22	4.43	1.18e-05	0.00119	0.21	0.2	HIV-1 viral setpoint;	chr6:26064151	chr6:26013241~26013757:+
THCA	cis	rs10484434	0.818	rs62394555	ENSG00000272810.1	U91328.22	4.43	1.18e-05	0.00119	0.21	0.2	HIV-1 viral setpoint;	chr6:26071861	chr6:26013241~26013757:+
THCA	cis	rs17270561	0.636	rs3922681	ENSG00000272462.2	U91328.19	-4.43	1.18e-05	0.00119	-0.18	-0.2	Iron status biomarkers;	chr6:25698253	chr6:25992662~26001775:+
THCA	cis	rs12612619	0.732	rs11126857	ENSG00000272148.1	RP11-195B17.1	-4.43	1.18e-05	0.00119	-0.19	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27074889	chr2:27062428~27062907:-
THCA	cis	rs2128382	0.53	rs59839253	ENSG00000253720.1	RP11-473O4.3	-4.43	1.18e-05	0.00119	-0.3	-0.2	Colorectal cancer;	chr8:129887082	chr8:129939856~129949394:+
THCA	cis	rs467650	0.963	rs154197	ENSG00000246763.5	RGMB-AS1	4.43	1.18e-05	0.00119	0.2	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98642639	chr5:98769618~98773469:-
THCA	cis	rs2299587	0.554	rs3853531	ENSG00000253671.1	RP11-806O11.1	4.43	1.18e-05	0.00119	0.23	0.2	Economic and political preferences;	chr8:17891411	chr8:17808941~17820868:+
THCA	cis	rs16966142	1	rs3890534	ENSG00000260259.1	RP11-368I7.4	4.43	1.18e-05	0.00119	0.29	0.2	Caffeine consumption;	chr16:89768881	chr16:89682620~89686569:-
THCA	cis	rs4713118	0.955	rs9468203	ENSG00000220721.1	OR1F12	4.43	1.18e-05	0.00119	0.26	0.2	Parkinson's disease;	chr6:27720888	chr6:28073316~28074233:+
THCA	cis	rs10090774	0.735	rs10108814	ENSG00000279766.1	RP11-642A1.2	-4.43	1.18e-05	0.00119	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708215	chr8:140572142~140572812:-
THCA	cis	rs11756659	0.697	rs7746105	ENSG00000272462.2	U91328.19	-4.43	1.18e-05	0.00119	-0.19	-0.2	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25944050	chr6:25992662~26001775:+
THCA	cis	rs17095355	1	rs7904096	ENSG00000203876.8	ADD3-AS1	-4.43	1.18e-05	0.00119	-0.22	-0.2	Biliary atresia;	chr10:109995561	chr10:109940104~110008381:-
THCA	cis	rs711244	0.721	rs7561572	ENSG00000279519.1	RP11-288C18.1	4.43	1.18e-05	0.00119	0.16	0.2	Mean platelet volume;	chr2:36914193	chr2:36839922~36842539:-
THCA	cis	rs3750082	0.754	rs35110377	ENSG00000231952.3	DPY19L1P2	-4.43	1.18e-05	0.00119	-0.24	-0.2	Glomerular filtration rate (creatinine);	chr7:32932158	chr7:32812757~32838570:+
THCA	cis	rs13256369	0.76	rs7816171	ENSG00000254153.1	CTA-398F10.2	-4.43	1.18e-05	0.00119	-0.23	-0.2	Obesity-related traits;	chr8:8718325	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.76	rs7839473	ENSG00000254153.1	CTA-398F10.2	-4.43	1.18e-05	0.00119	-0.23	-0.2	Obesity-related traits;	chr8:8718326	chr8:8456909~8461337:-
THCA	cis	rs10510102	0.516	rs79528809	ENSG00000226864.1	ATE1-AS1	4.43	1.18e-05	0.00119	0.33	0.2	Breast cancer;	chr10:121980309	chr10:121928312~121951965:+
THCA	cis	rs17270561	0.636	rs4360128	ENSG00000272462.2	U91328.19	-4.43	1.18e-05	0.00119	-0.17	-0.2	Iron status biomarkers;	chr6:25734330	chr6:25992662~26001775:+
THCA	cis	rs7216064	1	rs12602655	ENSG00000278740.1	RP11-147L13.14	4.43	1.18e-05	0.00119	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67913326	chr17:68188547~68189165:+
THCA	cis	rs12935229	1	rs12935394	ENSG00000260922.1	RP11-538I12.3	-4.43	1.18e-05	0.00119	-0.35	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77295093	chr16:77234877~77290934:+
THCA	cis	rs17772222	0.582	rs12050316	ENSG00000258983.2	RP11-507K2.2	4.43	1.18e-05	0.00119	0.23	0.2	Coronary artery calcification;	chr14:88522097	chr14:88499334~88515502:+
THCA	cis	rs4934494	0.677	rs11185806	ENSG00000240996.1	RP11-80H5.7	-4.43	1.18e-05	0.00119	-0.23	-0.2	Red blood cell count;	chr10:89620458	chr10:89694295~89697928:-
THCA	cis	rs6121246	0.738	rs2376996	ENSG00000230613.1	HM13-AS1	4.43	1.18e-05	0.00119	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31728864	chr20:31567707~31573263:-
THCA	cis	rs227275	0.556	rs4235407	ENSG00000248971.2	KRT8P46	-4.43	1.18e-05	0.00119	-0.25	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102728746~102730171:-
THCA	cis	rs875971	0.66	rs801193	ENSG00000223473.2	GS1-124K5.3	-4.43	1.18e-05	0.00119	-0.13	-0.2	Aortic root size;	chr7:66565625	chr7:66491049~66493566:-
THCA	cis	rs62244186	0.773	rs6809116	ENSG00000214820.3	MPRIPP1	4.43	1.18e-05	0.00119	0.21	0.2	Depressive symptoms;	chr3:44670605	chr3:44579938~44581026:-
THCA	cis	rs875971	1	rs2420820	ENSG00000230189.5	GS1-124K5.2	-4.43	1.18e-05	0.00119	-0.13	-0.2	Aortic root size;	chr7:66626920	chr7:66409143~66490059:-
THCA	cis	rs6600671	0.691	rs6600662	ENSG00000275585.1	CH17-118O6.3	-4.43	1.18e-05	0.00119	-0.25	-0.2	Hip geometry;	chr1:121488992	chr1:120985692~121052167:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.18e-05	0.00119	-0.2	-0.2	Aortic root size;	chr7:66603522	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs7807944	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.18e-05	0.00119	-0.2	-0.2	Aortic root size;	chr7:66622208	chr7:66025126~66031544:-
THCA	cis	rs875971	0.638	rs35986979	ENSG00000229886.1	RP5-1132H15.3	-4.43	1.18e-05	0.00119	-0.2	-0.2	Aortic root size;	chr7:66624003	chr7:66025126~66031544:-
THCA	cis	rs9326248	0.53	rs2513093	ENSG00000280143.1	AP000892.6	4.43	1.18e-05	0.00119	0.32	0.2	Blood protein levels;	chr11:116935971	chr11:117204967~117210292:+
THCA	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-4.43	1.18e-05	0.00119	-0.25	-0.2	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
THCA	cis	rs6442522	0.64	rs13095087	ENSG00000249786.6	EAF1-AS1	-4.43	1.18e-05	0.00119	-0.21	-0.2	Uric acid levels;	chr3:15477334	chr3:15436171~15455940:-
THCA	cis	rs944289	0.616	rs448145	ENSG00000258844.1	RP11-259K15.2	-4.43	1.18e-05	0.00119	-0.18	-0.2	Thyroid cancer;	chr14:36069722	chr14:36214607~36235608:+
THCA	cis	rs5753037	0.838	rs140149	ENSG00000279699.1	RP1-102K2.9	4.43	1.18e-05	0.00119	0.2	0.2	Type 1 diabetes;	chr22:29789624	chr22:30275215~30276951:-
THCA	cis	rs2153535	0.585	rs1328874	ENSG00000230939.1	RP11-314C16.1	-4.43	1.18e-05	0.00119	-0.21	-0.2	Motion sickness;	chr6:8621010	chr6:8784178~8785445:+
THCA	cis	rs6456156	0.846	rs10946211	ENSG00000235272.1	FAM103A2P	-4.43	1.18e-05	0.00119	-0.28	-0.2	Primary biliary cholangitis;	chr6:167102001	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.846	rs7749827	ENSG00000235272.1	FAM103A2P	-4.43	1.18e-05	0.00119	-0.28	-0.2	Primary biliary cholangitis;	chr6:167102136	chr6:166586124~166586477:-
THCA	cis	rs7045881	0.696	rs10511793	ENSG00000254396.1	RP11-56F10.3	4.43	1.18e-05	0.00119	0.26	0.2	Schizophrenia;	chr9:26924623	chr9:27102630~27104728:+
THCA	cis	rs911119	0.913	rs2405392	ENSG00000270001.1	RP11-218C14.8	-4.43	1.18e-05	0.00119	-0.3	-0.2	Chronic kidney disease;	chr20:23588549	chr20:23631826~23632316:-
THCA	cis	rs12439619	0.693	rs28665836	ENSG00000259429.4	UBE2Q2P2	-4.43	1.18e-05	0.00119	-0.16	-0.2	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82355142~82420075:+
THCA	cis	rs9902453	1	rs7212497	ENSG00000263370.1	RP11-68I3.5	-4.43	1.18e-05	0.00119	-0.27	-0.2	Coffee consumption (cups per day);	chr17:30008931	chr17:29639627~29640825:+
THCA	cis	rs447735	0.587	rs11647958	ENSG00000260259.1	RP11-368I7.4	4.43	1.18e-05	0.00119	0.22	0.2	Hemoglobin concentration;	chr16:89654501	chr16:89682620~89686569:-
THCA	cis	rs12410462	0.591	rs16847966	ENSG00000227711.2	RP11-275O4.5	-4.43	1.18e-05	0.00119	-0.25	-0.2	Major depressive disorder;	chr1:227583313	chr1:227509028~227520477:-
THCA	cis	rs2787702	0.929	rs2650741	ENSG00000237233.2	TMEM26-AS1	-4.43	1.18e-05	0.00119	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61572369	chr10:61452639~61481956:+
THCA	cis	rs6657613	0.68	rs10887994	ENSG00000186301.8	MST1P2	-4.43	1.18e-05	0.00119	-0.16	-0.2	Hip circumference adjusted for BMI;	chr1:17045260	chr1:16645622~16650289:+
THCA	cis	rs9300255	0.568	rs1790090	ENSG00000235423.7	RP11-282O18.3	4.43	1.18e-05	0.00119	0.21	0.2	Neutrophil percentage of white cells;	chr12:123148877	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs949142	ENSG00000235423.7	RP11-282O18.3	4.43	1.18e-05	0.00119	0.21	0.2	Neutrophil percentage of white cells;	chr12:123149496	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.602	rs884548	ENSG00000235423.7	RP11-282O18.3	4.43	1.18e-05	0.00119	0.21	0.2	Neutrophil percentage of white cells;	chr12:123149575	chr12:123252030~123261483:-
THCA	cis	rs858239	0.601	rs73272048	ENSG00000226816.2	AC005082.12	4.43	1.18e-05	0.00119	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23206013~23208045:+
THCA	cis	rs10256972	0.616	rs4585652	ENSG00000225146.1	AC073957.15	4.43	1.18e-05	0.00119	0.22	0.2	Endometriosis;Longevity;	chr7:1105760	chr7:1029025~1043891:+
THCA	cis	rs9863	0.861	rs4405410	ENSG00000270061.1	RP11-214K3.19	-4.43	1.18e-05	0.00119	-0.26	-0.2	White blood cell count;	chr12:123951241	chr12:123969990~123970344:-
THCA	cis	rs853679	0.599	rs149990	ENSG00000220721.1	OR1F12	4.43	1.18e-05	0.00119	0.32	0.2	Depression;	chr6:28030480	chr6:28073316~28074233:+
THCA	cis	rs12823128	0.967	rs34963777	ENSG00000256185.1	RP11-612B6.2	4.43	1.18e-05	0.00119	0.19	0.2	Birth weight;	chr12:26742418	chr12:26335864~26336950:-
THCA	cis	rs4713118	0.869	rs2056925	ENSG00000220721.1	OR1F12	4.43	1.18e-05	0.00119	0.26	0.2	Parkinson's disease;	chr6:27723126	chr6:28073316~28074233:+
THCA	cis	rs760794	0.577	rs17483277	ENSG00000237404.1	RP3-471C18.2	-4.43	1.18e-05	0.00119	-0.22	-0.2	Endometriosis;	chr6:19790340	chr6:19689825~19753113:-
THCA	cis	rs7726839	0.54	rs72705102	ENSG00000225138.6	CTD-2228K2.7	4.43	1.18e-05	0.00119	0.24	0.2	Obesity-related traits;	chr5:659322	chr5:473236~480884:+
THCA	cis	rs34286592	1	rs3815824	ENSG00000214725.6	CDIPT-AS1	-4.43	1.18e-05	0.00119	-0.36	-0.2	Multiple sclerosis;	chr16:29841539	chr16:29863593~29868053:+
THCA	cis	rs34286592	0.929	rs9939514	ENSG00000214725.6	CDIPT-AS1	-4.43	1.18e-05	0.00119	-0.36	-0.2	Multiple sclerosis;	chr16:29844410	chr16:29863593~29868053:+
THCA	cis	rs34286592	1	rs4787480	ENSG00000214725.6	CDIPT-AS1	-4.43	1.18e-05	0.00119	-0.36	-0.2	Multiple sclerosis;	chr16:29845995	chr16:29863593~29868053:+
THCA	cis	rs34286592	1	rs7201519	ENSG00000214725.6	CDIPT-AS1	-4.43	1.18e-05	0.00119	-0.36	-0.2	Multiple sclerosis;	chr16:29848656	chr16:29863593~29868053:+
THCA	cis	rs34286592	1	rs28599680	ENSG00000214725.6	CDIPT-AS1	-4.43	1.18e-05	0.00119	-0.36	-0.2	Multiple sclerosis;	chr16:29849364	chr16:29863593~29868053:+
THCA	cis	rs10911902	0.643	rs6678193	ENSG00000229739.2	RP11-295K2.3	-4.43	1.18e-05	0.00119	-0.32	-0.2	Schizophrenia;	chr1:186413607	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.602	rs79668124	ENSG00000229739.2	RP11-295K2.3	-4.43	1.18e-05	0.00119	-0.32	-0.2	Schizophrenia;	chr1:186415103	chr1:186435161~186470291:+
THCA	cis	rs9467773	0.62	rs2504565	ENSG00000261353.1	CTA-14H9.5	-4.43	1.18e-05	0.00119	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26527063~26527404:+
THCA	cis	rs2032447	0.613	rs6456708	ENSG00000272810.1	U91328.22	-4.43	1.18e-05	0.00119	-0.15	-0.2	Intelligence (multi-trait analysis);	chr6:26032619	chr6:26013241~26013757:+
THCA	cis	rs28829049	0.597	rs12566296	ENSG00000270728.1	RP4-657E11.10	-4.43	1.18e-05	0.00119	-0.15	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19171949	chr1:19297080~19297903:+
THCA	cis	rs10802047	0.505	rs2764475	ENSG00000231365.4	RP11-418J17.1	4.43	1.18e-05	0.00119	0.2	0.2	Relative hand skill in reading disability;	chr1:118746393	chr1:119140396~119275973:+
THCA	cis	rs172166	0.516	rs1225715	ENSG00000220721.1	OR1F12	-4.43	1.18e-05	0.00119	-0.23	-0.2	Cardiac Troponin-T levels;	chr6:28145595	chr6:28073316~28074233:+
THCA	cis	rs3930017	1	rs7783809	ENSG00000205482.8	AC007000.12	-4.43	1.18e-05	0.00119	-0.19	-0.2	Body mass index;	chr7:77090234	chr7:77052785~77059440:-
THCA	cis	rs12439619	1	rs12439619	ENSG00000259429.4	UBE2Q2P2	-4.43	1.18e-05	0.00119	-0.18	-0.2	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82355142~82420075:+
THCA	cis	rs763121	0.853	rs5750630	ENSG00000235209.1	CTA-150C2.13	4.43	1.19e-05	0.00119	0.26	0.2	Menopause (age at onset);	chr22:38589813	chr22:38921227~38924708:+
THCA	cis	rs2278702	0.943	rs57384130	ENSG00000259495.2	RP11-210M15.2	-4.43	1.19e-05	0.00119	-0.29	-0.2	Bipolar disorder;	chr15:80392604	chr15:80344853~80403575:-
THCA	cis	rs914615	0.552	rs11264339	ENSG00000236675.1	MTX1P1	4.43	1.19e-05	0.00119	0.19	0.2	Urinary albumin-to-creatinine ratio;	chr1:155168172	chr1:155230975~155234325:+
THCA	cis	rs172166	0.516	rs1150670	ENSG00000280107.1	AL022393.9	-4.43	1.19e-05	0.00119	-0.19	-0.2	Cardiac Troponin-T levels;	chr6:28162781	chr6:28170845~28172521:+
THCA	cis	rs6088580	0.634	rs4277599	ENSG00000276073.1	RP5-1125A11.7	4.43	1.19e-05	0.00119	0.17	0.2	Glomerular filtration rate (creatinine);	chr20:34421099	chr20:33985617~33988989:-
THCA	cis	rs6688613	0.685	rs742048	ENSG00000225171.2	DUTP6	4.43	1.19e-05	0.0012	0.29	0.2	Refractive astigmatism;	chr1:166940908	chr1:166868748~166869209:+
THCA	cis	rs1728785	1	rs1728785	ENSG00000274698.1	RP11-71L14.4	-4.43	1.19e-05	0.0012	-0.29	-0.2	Ulcerative colitis;	chr16:68557327	chr16:68450283~68452318:+
THCA	cis	rs755249	0.501	rs661316	ENSG00000228060.1	RP11-69E11.8	-4.43	1.19e-05	0.0012	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39565160~39573203:+
THCA	cis	rs17095355	1	rs17126883	ENSG00000203876.8	ADD3-AS1	-4.43	1.19e-05	0.0012	-0.23	-0.2	Biliary atresia;	chr10:109934938	chr10:109940104~110008381:-
THCA	cis	rs7089973	0.61	rs7097580	ENSG00000236799.1	RP11-383C6.2	-4.43	1.19e-05	0.0012	-0.24	-0.2	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114994743	chr10:114994657~114996593:+
THCA	cis	rs2028299	0.959	rs748508	ENSG00000259677.1	RP11-493E3.1	4.43	1.19e-05	0.0012	0.26	0.2	Type 2 diabetes;	chr15:89838026	chr15:89876540~89877285:+
THCA	cis	rs2028299	0.959	rs893617	ENSG00000259677.1	RP11-493E3.1	4.43	1.19e-05	0.0012	0.26	0.2	Type 2 diabetes;	chr15:89838046	chr15:89876540~89877285:+
THCA	cis	rs756699	0.749	rs244672	ENSG00000279469.1	RP11-215P8.2	-4.43	1.19e-05	0.0012	-0.3	-0.2	Multiple sclerosis;	chr5:134083592	chr5:134394360~134395008:-
THCA	cis	rs4819052	1	rs4818769	ENSG00000273796.1	LL21NC02-21A1.1	-4.43	1.19e-05	0.0012	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45403809~45404369:-
THCA	cis	rs7726839	0.561	rs4957050	ENSG00000225138.6	CTD-2228K2.7	4.43	1.19e-05	0.0012	0.23	0.2	Obesity-related traits;	chr5:578951	chr5:473236~480884:+
THCA	cis	rs7726839	0.561	rs4957049	ENSG00000225138.6	CTD-2228K2.7	4.43	1.19e-05	0.0012	0.23	0.2	Obesity-related traits;	chr5:578965	chr5:473236~480884:+
THCA	cis	rs7726839	0.561	rs72703044	ENSG00000225138.6	CTD-2228K2.7	4.43	1.19e-05	0.0012	0.23	0.2	Obesity-related traits;	chr5:579622	chr5:473236~480884:+
THCA	cis	rs13325613	0.834	rs35195804	ENSG00000223552.1	RP11-24F11.2	-4.43	1.19e-05	0.0012	-0.29	-0.2	Monocyte count;	chr3:46218704	chr3:46364955~46407059:-
THCA	cis	rs11779988	0.543	rs415226	ENSG00000253671.1	RP11-806O11.1	-4.43	1.19e-05	0.0012	-0.25	-0.2	Breast cancer;	chr8:18038629	chr8:17808941~17820868:+
THCA	cis	rs453301	0.653	rs7005133	ENSG00000233609.3	RP11-62H7.2	4.43	1.19e-05	0.0012	0.19	0.2	Joint mobility (Beighton score);	chr8:9043712	chr8:8961200~8979025:+
THCA	cis	rs7772486	0.774	rs2247571	ENSG00000270638.1	RP3-466P17.1	4.43	1.19e-05	0.0012	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145735570~145737218:+
THCA	cis	rs57502260	0.704	rs12286536	ENSG00000212093.1	AP000807.1	4.43	1.19e-05	0.0012	0.27	0.2	Total body bone mineral density (age 45-60);	chr11:68522766	chr11:68506083~68506166:-
THCA	cis	rs890448	0.895	rs4699221	ENSG00000254531.1	FLJ20021	-4.43	1.19e-05	0.0012	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101495663	chr4:101347780~101348883:+
THCA	cis	rs12935229	1	rs35924034	ENSG00000260922.1	RP11-538I12.3	-4.43	1.19e-05	0.0012	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77296415	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs35559419	ENSG00000260922.1	RP11-538I12.3	-4.43	1.19e-05	0.0012	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77296427	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs17713035	ENSG00000260922.1	RP11-538I12.3	-4.43	1.19e-05	0.0012	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77296526	chr16:77234877~77290934:+
THCA	cis	rs3177980	0.56	rs10919267	ENSG00000239494.2	RN7SL333P	-4.43	1.19e-05	0.0012	-0.19	-0.2	Amyotrophic lateral sclerosis;	chr1:169892071	chr1:169859756~169860052:+
THCA	cis	rs10744955	0.727	rs7179848	ENSG00000244879.4	GABPB1-AS1	-4.43	1.19e-05	0.0012	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50154851	chr15:50354959~50372202:+
THCA	cis	rs10744955	0.727	rs59983467	ENSG00000244879.4	GABPB1-AS1	-4.43	1.19e-05	0.0012	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50156817	chr15:50354959~50372202:+
THCA	cis	rs763121	0.819	rs5757133	ENSG00000228274.3	RP3-508I15.9	4.43	1.19e-05	0.0012	0.21	0.2	Menopause (age at onset);	chr22:38551830	chr22:38667585~38681820:-
THCA	cis	rs911555	0.755	rs9671414	ENSG00000244691.1	RPL10AP1	4.43	1.19e-05	0.0012	0.28	0.2	Intelligence (multi-trait analysis);	chr14:103500962	chr14:103412119~103412761:-
THCA	cis	rs6449502	0.92	rs2928243	ENSG00000251279.1	CTC-436P18.1	4.43	1.19e-05	0.0012	0.33	0.2	Mean platelet volume;	chr5:60966515	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs182351	ENSG00000251279.1	CTC-436P18.1	4.43	1.19e-05	0.0012	0.33	0.2	Mean platelet volume;	chr5:60968605	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs2619891	ENSG00000251279.1	CTC-436P18.1	4.43	1.19e-05	0.0012	0.33	0.2	Mean platelet volume;	chr5:60977972	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs2619892	ENSG00000251279.1	CTC-436P18.1	4.43	1.19e-05	0.0012	0.33	0.2	Mean platelet volume;	chr5:60978520	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs290504	ENSG00000251279.1	CTC-436P18.1	4.43	1.19e-05	0.0012	0.33	0.2	Mean platelet volume;	chr5:60999222	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs162250	ENSG00000251279.1	CTC-436P18.1	4.43	1.19e-05	0.0012	0.33	0.2	Mean platelet volume;	chr5:60999484	chr5:61162070~61232040:+
THCA	cis	rs7182948	0.957	rs28516445	ENSG00000259531.2	RP11-295H24.3	4.43	1.19e-05	0.0012	0.26	0.2	Lung adenocarcinoma;	chr15:49667937	chr15:49365124~49366685:-
THCA	cis	rs7829975	0.681	rs2271342	ENSG00000253981.4	ALG1L13P	4.43	1.19e-05	0.0012	0.19	0.2	Mood instability;	chr8:8786428	chr8:8236003~8244667:-
THCA	cis	rs8113308	0.689	rs8112515	ENSG00000275055.1	CTC-471J1.11	-4.43	1.19e-05	0.0012	-0.21	-0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987997	chr19:52049007~52049754:+
THCA	cis	rs9876781	1	rs9812647	ENSG00000244380.1	RP11-24C3.2	-4.43	1.19e-05	0.0012	-0.24	-0.2	Longevity;	chr3:48407507	chr3:48440352~48446656:-
THCA	cis	rs12911832	0.701	rs452698	ENSG00000245975.2	RP11-30K9.6	4.43	1.19e-05	0.0012	0.19	0.2	Schizophrenia;	chr15:58813372	chr15:58768072~58770974:-
THCA	cis	rs9902453	0.904	rs6505148	ENSG00000263370.1	RP11-68I3.5	4.43	1.19e-05	0.0012	0.26	0.2	Coffee consumption (cups per day);	chr17:29962800	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs4077465	ENSG00000263370.1	RP11-68I3.5	4.43	1.19e-05	0.0012	0.26	0.2	Coffee consumption (cups per day);	chr17:29973126	chr17:29639627~29640825:+
THCA	cis	rs301901	1	rs292184	ENSG00000250155.1	CTD-2353F22.1	-4.43	1.19e-05	0.0012	-0.2	-0.2	Height;	chr5:36963703	chr5:36666214~36725195:-
THCA	cis	rs41313321	0.541	rs7030121	ENSG00000273186.1	RP11-339B21.10	4.43	1.19e-05	0.0012	0.3	0.2	Coenzyme Q10 levels;	chr9:128339640	chr9:128431598~128432006:+
THCA	cis	rs2270204	0.574	rs7034056	ENSG00000273186.1	RP11-339B21.10	4.43	1.19e-05	0.0012	0.3	0.2	Body mass index;	chr9:128340498	chr9:128431598~128432006:+
THCA	cis	rs41313321	0.541	rs6478826	ENSG00000273186.1	RP11-339B21.10	4.43	1.19e-05	0.0012	0.3	0.2	Coenzyme Q10 levels;	chr9:128344246	chr9:128431598~128432006:+
THCA	cis	rs10266483	0.774	rs642909	ENSG00000234338.1	RP11-797H7.1	4.43	1.19e-05	0.0012	0.15	0.2	Response to statin therapy;	chr7:64309943	chr7:64835280~64836882:-
THCA	cis	rs10421328	0.848	rs7253821	ENSG00000271283.1	CTC-412M14.6	4.43	1.19e-05	0.0012	0.32	0.2	Parental longevity (combined parental age at death);	chr19:19674082	chr19:19699203~19699409:-
THCA	cis	rs7246760	0.867	rs1820114	ENSG00000267106.4	ZNF561-AS1	4.43	1.19e-05	0.0012	0.37	0.2	Pursuit maintenance gain;	chr19:9695016	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs66927855	ENSG00000267106.4	ZNF561-AS1	4.43	1.19e-05	0.0012	0.37	0.2	Pursuit maintenance gain;	chr19:9701052	chr19:9621291~9645896:+
THCA	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	4.43	1.19e-05	0.0012	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
THCA	cis	rs2836950	0.52	rs1980407	ENSG00000238141.2	BRWD1-AS1	-4.43	1.19e-05	0.0012	-0.23	-0.2	Menarche (age at onset);	chr21:39172035	chr21:39315707~39323218:+
THCA	cis	rs11122895	0.527	rs10186692	ENSG00000236307.2	EEF1E1P1	4.43	1.19e-05	0.0012	0.25	0.2	Allergic sensitization;	chr2:111686719	chr2:111887914~111888741:+
THCA	cis	rs4742903	0.967	rs2417485	ENSG00000270332.1	SMC2-AS1	4.43	1.19e-05	0.0012	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104104825	chr9:104080024~104093073:-
THCA	cis	rs13256369	1	rs9329166	ENSG00000254153.1	CTA-398F10.2	-4.43	1.19e-05	0.0012	-0.23	-0.2	Obesity-related traits;	chr8:8719145	chr8:8456909~8461337:-
THCA	cis	rs858239	0.601	rs10255228	ENSG00000226816.2	AC005082.12	4.43	1.19e-05	0.0012	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23206013~23208045:+
THCA	cis	rs7924176	0.564	rs2270551	ENSG00000213731.2	RAB5CP1	-4.43	1.19e-05	0.0012	-0.24	-0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74109307	chr10:74423435~74424014:-
THCA	cis	rs763121	0.853	rs5750621	ENSG00000235209.1	CTA-150C2.13	4.43	1.19e-05	0.0012	0.26	0.2	Menopause (age at onset);	chr22:38560161	chr22:38921227~38924708:+
THCA	cis	rs763121	0.744	rs5757140	ENSG00000235209.1	CTA-150C2.13	4.43	1.19e-05	0.0012	0.26	0.2	Menopause (age at onset);	chr22:38561008	chr22:38921227~38924708:+
THCA	cis	rs78487399	0.908	rs6731636	ENSG00000234936.1	AC010883.5	4.43	1.19e-05	0.0012	0.25	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43615907	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6705351	ENSG00000234936.1	AC010883.5	4.43	1.19e-05	0.0012	0.25	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43615998	chr2:43229573~43233394:+
THCA	cis	rs9880211	0.948	rs6806123	ENSG00000239213.4	NCK1-AS1	4.43	1.19e-05	0.0012	0.22	0.2	Height;Body mass index;	chr3:136586634	chr3:136841726~136862054:-
THCA	cis	rs9595908	0.709	rs7325016	ENSG00000212293.1	SNORA16	4.43	1.19e-05	0.0012	0.23	0.2	Body mass index;	chr13:32728681	chr13:32420390~32420516:-
THCA	cis	rs4713118	0.824	rs9366702	ENSG00000226314.6	ZNF192P1	-4.43	1.19e-05	0.0012	-0.26	-0.2	Parkinson's disease;	chr6:27766691	chr6:28161781~28169594:+
THCA	cis	rs11671005	0.735	rs45617039	ENSG00000268049.1	CTD-2619J13.9	-4.43	1.19e-05	0.0012	-0.31	-0.2	Mean platelet volume;	chr19:58439729	chr19:58357999~58359603:+
THCA	cis	rs10911902	0.561	rs78701198	ENSG00000229739.2	RP11-295K2.3	-4.43	1.19e-05	0.0012	-0.3	-0.2	Schizophrenia;	chr1:186380240	chr1:186435161~186470291:+
THCA	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-4.43	1.19e-05	0.0012	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-4.43	1.19e-05	0.0012	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-4.43	1.19e-05	0.0012	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
THCA	cis	rs427943	0.798	rs4818766	ENSG00000223768.1	LINC00205	-4.43	1.19e-05	0.0012	-0.18	-0.2	Body mass index;	chr21:45215436	chr21:45293285~45297354:+
THCA	cis	rs1979679	0.842	rs12049916	ENSG00000247934.4	RP11-967K21.1	-4.43	1.2e-05	0.0012	-0.21	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:28163298~28190738:-
THCA	cis	rs6745190	0.512	rs13026070	ENSG00000236153.1	AC104076.3	-4.43	1.2e-05	0.0012	-0.25	-0.2	White blood cell count;	chr2:181126695	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.557	rs13031518	ENSG00000236153.1	AC104076.3	-4.43	1.2e-05	0.0012	-0.25	-0.2	White blood cell count;	chr2:181127032	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.557	rs34504038	ENSG00000236153.1	AC104076.3	-4.43	1.2e-05	0.0012	-0.25	-0.2	White blood cell count;	chr2:181128227	chr2:180979427~180980090:-
THCA	cis	rs5753037	0.838	rs131293	ENSG00000279699.1	RP1-102K2.9	4.43	1.2e-05	0.0012	0.2	0.2	Type 1 diabetes;	chr22:29775042	chr22:30275215~30276951:-
THCA	cis	rs9291683	0.692	rs1558489	ENSG00000261490.1	RP11-448G15.3	-4.43	1.2e-05	0.0012	-0.13	-0.2	Bone mineral density;	chr4:10323865	chr4:10068089~10073019:-
THCA	cis	rs13201294	1	rs13201294	ENSG00000272009.1	RP1-313I6.12	-4.43	1.2e-05	0.0012	-0.31	-0.2	Squamous cell lung carcinoma;	chr6:27588362	chr6:28078792~28081130:-
THCA	cis	rs8030605	0.778	rs72740562	ENSG00000277245.1	RP11-48G14.3	4.43	1.2e-05	0.0012	0.35	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56331172	chr15:56447120~56447697:+
THCA	cis	rs722599	0.748	rs61978932	ENSG00000279594.1	RP11-950C14.10	-4.43	1.2e-05	0.0012	-0.2	-0.2	IgG glycosylation;	chr14:74876251	chr14:75011269~75012851:-
THCA	cis	rs6012564	0.89	rs6125591	ENSG00000227431.4	CSE1L-AS1	4.43	1.2e-05	0.0012	0.25	0.2	Anger;	chr20:49204130	chr20:49040463~49046044:-
THCA	cis	rs4713118	0.955	rs9380010	ENSG00000220721.1	OR1F12	4.43	1.2e-05	0.0012	0.26	0.2	Parkinson's disease;	chr6:27715793	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.955	rs9368528	ENSG00000220721.1	OR1F12	4.43	1.2e-05	0.0012	0.26	0.2	Parkinson's disease;	chr6:27716019	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.955	rs9380011	ENSG00000220721.1	OR1F12	4.43	1.2e-05	0.0012	0.26	0.2	Parkinson's disease;	chr6:27716145	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.955	rs9368529	ENSG00000220721.1	OR1F12	4.43	1.2e-05	0.0012	0.26	0.2	Parkinson's disease;	chr6:27716852	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.955	rs9380012	ENSG00000220721.1	OR1F12	4.43	1.2e-05	0.0012	0.26	0.2	Parkinson's disease;	chr6:27716875	chr6:28073316~28074233:+
THCA	cis	rs6920965	0.561	rs9401851	ENSG00000237742.5	RP11-624M8.1	-4.43	1.2e-05	0.0012	-0.18	-0.2	High light scatter reticulocyte count;	chr6:125860810	chr6:125578558~125749190:-
THCA	cis	rs7246657	0.507	rs8107654	ENSG00000226686.6	LINC01535	-4.43	1.2e-05	0.0012	-0.35	-0.2	Coronary artery calcification;	chr19:36962632	chr19:37251912~37265535:+
THCA	cis	rs997295	0.713	rs12904982	ENSG00000270964.1	RP11-502I4.3	-4.43	1.2e-05	0.0012	-0.17	-0.2	Motion sickness;	chr15:67713941	chr15:67541072~67542604:-
THCA	cis	rs13217239	0.511	rs3800314	ENSG00000219392.1	RP1-265C24.5	-4.43	1.2e-05	0.00121	-0.23	-0.2	Schizophrenia;	chr6:27268269	chr6:28115628~28116551:+
THCA	cis	rs1023500	0.529	rs133375	ENSG00000273366.1	CTA-989H11.1	-4.43	1.2e-05	0.00121	-0.25	-0.2	Schizophrenia;	chr22:42070505	chr22:42278188~42278846:+
THCA	cis	rs7760535	0.93	rs7742244	ENSG00000255389.1	C6orf3	-4.43	1.2e-05	0.00121	-0.19	-0.2	Metabolic traits;	chr6:111531459	chr6:111599875~111602295:+
THCA	cis	rs6951245	0.935	rs79067319	ENSG00000229043.2	AC091729.9	-4.43	1.2e-05	0.00121	-0.34	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025912	chr7:1160374~1165267:+
THCA	cis	rs6494488	0.5	rs59684202	ENSG00000259635.1	AC100830.3	-4.43	1.2e-05	0.00121	-0.48	-0.2	Coronary artery disease;	chr15:64726302	chr15:64701248~64719602:+
THCA	cis	rs893818	1	rs4886785	ENSG00000261801.4	LOXL1-AS1	4.43	1.2e-05	0.00121	0.23	0.2	Exfoliation glaucoma or exfoliation syndrome;	chr15:73937450	chr15:73908071~73928248:-
THCA	cis	rs10256972	0.567	rs7782651	ENSG00000225146.1	AC073957.15	4.43	1.2e-05	0.00121	0.22	0.2	Endometriosis;Longevity;	chr7:1120259	chr7:1029025~1043891:+
THCA	cis	rs4908769	0.624	rs2708632	ENSG00000232912.4	RP5-1115A15.1	-4.43	1.2e-05	0.00121	-0.22	-0.2	Allergy;	chr1:8404449	chr1:8424645~8434838:+
THCA	cis	rs6570726	0.935	rs366621	ENSG00000270638.1	RP3-466P17.1	4.43	1.2e-05	0.00121	0.15	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145735570~145737218:+
THCA	cis	rs2749592	0.513	rs1208708	ENSG00000226578.1	RP11-258F22.1	-4.43	1.2e-05	0.00121	-0.24	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:37775371~37784131:-
THCA	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	4.43	1.2e-05	0.00121	0.22	0.2	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
THCA	cis	rs7772486	0.72	rs1890171	ENSG00000270638.1	RP3-466P17.1	-4.43	1.2e-05	0.00121	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145735570~145737218:+
THCA	cis	rs8062405	0.755	rs4788074	ENSG00000270424.1	RP11-1348G14.6	-4.43	1.2e-05	0.00121	-0.25	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28749959~28750595:-
THCA	cis	rs4763879	0.634	rs917913	ENSG00000256673.1	RP11-599J14.2	4.43	1.2e-05	0.00121	0.24	0.2	Type 1 diabetes;	chr12:9707040	chr12:9398355~9414851:-
THCA	cis	rs467650	0.853	rs316511	ENSG00000246763.5	RGMB-AS1	4.43	1.2e-05	0.00121	0.2	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98673338	chr5:98769618~98773469:-
THCA	cis	rs467650	0.853	rs373773	ENSG00000246763.5	RGMB-AS1	4.43	1.2e-05	0.00121	0.2	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98684911	chr5:98769618~98773469:-
THCA	cis	rs6787172	0.811	rs9812624	ENSG00000272087.1	RP11-379F4.7	4.43	1.2e-05	0.00121	0.18	0.2	Subjective well-being;	chr3:158491861	chr3:158693120~158693768:-
THCA	cis	rs7074356	0.569	rs1832683	ENSG00000242600.5	MBL1P	4.42	1.2e-05	0.00121	0.21	0.2	Borderline personality disorder;	chr10:80272575	chr10:79904898~79950336:+
THCA	cis	rs2251188	0.565	rs2243544	ENSG00000187953.9	PMS2CL	4.42	1.2e-05	0.00121	0.22	0.2	Sum basophil neutrophil counts;Neutrophil count;	chr7:6650639	chr7:6710128~6753862:+
THCA	cis	rs9309473	0.558	rs11679042	ENSG00000273245.1	RP11-434P11.2	4.42	1.2e-05	0.00121	0.33	0.2	Metabolite levels;	chr2:73680184	chr2:73750256~73750786:-
THCA	cis	rs2836974	0.644	rs9978775	ENSG00000255568.3	BRWD1-AS2	-4.42	1.2e-05	0.00121	-0.16	-0.2	Cognitive function;	chr21:39322600	chr21:39313935~39314962:+
THCA	cis	rs6121246	0.909	rs6060793	ENSG00000230613.1	HM13-AS1	4.42	1.2e-05	0.00121	0.22	0.2	Mean corpuscular hemoglobin;	chr20:31701027	chr20:31567707~31573263:-
THCA	cis	rs6787172	0.811	rs1978781	ENSG00000272087.1	RP11-379F4.7	4.42	1.2e-05	0.00121	0.18	0.2	Subjective well-being;	chr3:158488994	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.782	rs4431160	ENSG00000272087.1	RP11-379F4.7	4.42	1.2e-05	0.00121	0.18	0.2	Subjective well-being;	chr3:158491277	chr3:158693120~158693768:-
THCA	cis	rs62025270	0.688	rs17575870	ENSG00000259295.5	CSPG4P12	-4.42	1.2e-05	0.00121	-0.35	-0.2	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85191438~85213905:+
THCA	cis	rs7772486	0.727	rs6941429	ENSG00000270638.1	RP3-466P17.1	4.42	1.2e-05	0.00121	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145735570~145737218:+
THCA	cis	rs12915845	0.545	rs12911061	ENSG00000271997.1	RP11-97O12.6	-4.42	1.2e-05	0.00121	-0.14	-0.2	Menarche (age at onset);	chr15:88523404	chr15:88501944~88505787:-
THCA	cis	rs2787702	1	rs2606101	ENSG00000237233.2	TMEM26-AS1	-4.42	1.2e-05	0.00121	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61575701	chr10:61452639~61481956:+
THCA	cis	rs2787702	1	rs2606102	ENSG00000237233.2	TMEM26-AS1	-4.42	1.2e-05	0.00121	-0.25	-0.2	Response to taxane treatment (placlitaxel);	chr10:61576265	chr10:61452639~61481956:+
THCA	cis	rs13113518	1	rs56362210	ENSG00000249700.7	SRD5A3-AS1	4.42	1.2e-05	0.00121	0.25	0.2	Height;	chr4:55540972	chr4:55363971~55395847:-
THCA	cis	rs763121	0.853	rs4821811	ENSG00000235209.1	CTA-150C2.13	4.42	1.2e-05	0.00121	0.27	0.2	Menopause (age at onset);	chr22:38679140	chr22:38921227~38924708:+
THCA	cis	rs1979679	0.918	rs786711	ENSG00000247934.4	RP11-967K21.1	-4.42	1.2e-05	0.00121	-0.2	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28406330	chr12:28163298~28190738:-
THCA	cis	rs2287838	0.716	rs7254559	ENSG00000267289.1	CTD-2623N2.11	-4.42	1.2e-05	0.00121	-0.23	-0.2	Sleep duration;	chr19:9892443	chr19:9834079~9835013:-
THCA	cis	rs12216545	0.765	rs1879865	ENSG00000241134.3	BET1P1	-4.42	1.2e-05	0.00121	-0.24	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150561335	chr7:150749736~150750094:+
THCA	cis	rs7772486	0.701	rs7772717	ENSG00000270638.1	RP3-466P17.1	4.42	1.2e-05	0.00121	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145735570~145737218:+
THCA	cis	rs801193	0.967	rs34356500	ENSG00000229886.1	RP5-1132H15.3	4.42	1.2e-05	0.00121	0.2	0.2	Aortic root size;	chr7:66771620	chr7:66025126~66031544:-
THCA	cis	rs7772486	0.754	rs2064185	ENSG00000270638.1	RP3-466P17.1	-4.42	1.2e-05	0.00121	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145735570~145737218:+
THCA	cis	rs964611	1	rs8037626	ENSG00000259488.2	RP11-154J22.1	-4.42	1.2e-05	0.00121	-0.21	-0.2	Metabolite levels (Pyroglutamine);	chr15:48314149	chr15:48312353~48331856:-
THCA	cis	rs7429990	0.931	rs62262084	ENSG00000228638.1	FCF1P2	-4.42	1.2e-05	0.00121	-0.21	-0.2	Educational attainment (years of education);	chr3:47612332	chr3:48290793~48291375:-
THCA	cis	rs5758511	0.68	rs5758651	ENSG00000227370.1	RP4-669P10.19	4.42	1.2e-05	0.00121	0.23	0.2	Birth weight;	chr22:42213142	chr22:42132543~42132998:+
THCA	cis	rs875971	0.642	rs35526611	ENSG00000229886.1	RP5-1132H15.3	-4.42	1.2e-05	0.00121	-0.2	-0.2	Aortic root size;	chr7:66629021	chr7:66025126~66031544:-
THCA	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	4.42	1.2e-05	0.00121	0.24	0.2	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
THCA	cis	rs1003719	0.591	rs9636914	ENSG00000230366.8	DSCR9	-4.42	1.2e-05	0.00121	-0.21	-0.2	Eye color traits;	chr21:37217431	chr21:37208503~37221736:+
THCA	cis	rs6570726	0.791	rs621382	ENSG00000270638.1	RP3-466P17.1	4.42	1.2e-05	0.00121	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs422099	ENSG00000270638.1	RP3-466P17.1	4.42	1.2e-05	0.00121	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145735570~145737218:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000229886.1	RP5-1132H15.3	-4.42	1.2e-05	0.00121	-0.2	-0.2	Aortic root size;	chr7:66619753	chr7:66025126~66031544:-
THCA	cis	rs57502260	0.704	rs17149179	ENSG00000212093.1	AP000807.1	4.42	1.2e-05	0.00121	0.27	0.2	Total body bone mineral density (age 45-60);	chr11:68584254	chr11:68506083~68506166:-
THCA	cis	rs9902453	0.904	rs9900112	ENSG00000263370.1	RP11-68I3.5	4.42	1.2e-05	0.00121	0.26	0.2	Coffee consumption (cups per day);	chr17:29955892	chr17:29639627~29640825:+
THCA	cis	rs642803	0.527	rs1647570	ENSG00000255120.4	OVOL1-AS1	4.42	1.2e-05	0.00121	0.27	0.2	Urate levels;	chr11:65800785	chr11:65789051~65790868:-
THCA	cis	rs9625935	0.871	rs3958025	ENSG00000279159.1	RP3-394A18.1	4.42	1.2e-05	0.00121	0.15	0.2	Tonsillectomy;	chr22:29833410	chr22:29978950~30028236:-
THCA	cis	rs889398	0.771	rs3790080	ENSG00000226232.7	RP11-419C5.2	-4.42	1.2e-05	0.00121	-0.2	-0.2	Body mass index;	chr16:69868236	chr16:69976388~69996188:-
THCA	cis	rs997295	0.713	rs10518739	ENSG00000270964.1	RP11-502I4.3	4.42	1.2e-05	0.00121	0.17	0.2	Motion sickness;	chr15:67722633	chr15:67541072~67542604:-
THCA	cis	rs11176749	0.543	rs10878621	ENSG00000256172.1	RP11-473M14.3	-4.42	1.21e-05	0.00121	-0.29	-0.2	Expressive vocabulary in infants;	chr12:67449313	chr12:67440998~67442559:-
THCA	cis	rs2980439	0.818	rs2948294	ENSG00000254153.1	CTA-398F10.2	-4.42	1.21e-05	0.00121	-0.21	-0.2	Neuroticism;	chr8:8237439	chr8:8456909~8461337:-
THCA	cis	rs6479874	1	rs7069183	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50996579	chr10:51062579~51068553:-
THCA	cis	rs6479874	1	rs6479840	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50997141	chr10:51062579~51068553:-
THCA	cis	rs6479874	1	rs7919300	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50997481	chr10:51062579~51068553:-
THCA	cis	rs6479874	1	rs7916094	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50997509	chr10:51062579~51068553:-
THCA	cis	rs6479874	1	rs2339688	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50998248	chr10:51062579~51068553:-
THCA	cis	rs6479874	1	rs10761662	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50998461	chr10:51062579~51068553:-
THCA	cis	rs6479874	1	rs4515917	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50999188	chr10:51062579~51068553:-
THCA	cis	rs6479874	0.85	rs7076470	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50999427	chr10:51062579~51068553:-
THCA	cis	rs6479874	1	rs7076631	ENSG00000223502.1	RP11-96B5.3	-4.42	1.21e-05	0.00121	-0.24	-0.2	Migraine;	chr10:50999563	chr10:51062579~51068553:-
THCA	cis	rs76878669	0.917	rs10219183	ENSG00000255320.1	RP11-755F10.1	-4.42	1.21e-05	0.00121	-0.28	-0.2	Educational attainment (years of education);	chr11:66322561	chr11:66244840~66246239:-
THCA	cis	rs9543976	0.92	rs9543972	ENSG00000261105.4	LMO7-AS1	4.42	1.21e-05	0.00121	0.29	0.2	Diabetic retinopathy;	chr13:75547539	chr13:75604700~75635994:-
THCA	cis	rs875971	0.965	rs697968	ENSG00000222364.1	RNU6-96P	4.42	1.21e-05	0.00121	0.24	0.2	Aortic root size;	chr7:66070046	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs1183245	ENSG00000222364.1	RNU6-96P	4.42	1.21e-05	0.00121	0.24	0.2	Aortic root size;	chr7:66076198	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs1144894	ENSG00000222364.1	RNU6-96P	4.42	1.21e-05	0.00121	0.24	0.2	Aortic root size;	chr7:66077907	chr7:66395191~66395286:+
THCA	cis	rs4789693	0.938	rs4789694	ENSG00000260011.2	RP13-20L14.1	4.42	1.21e-05	0.00121	0.2	0.2	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82381110~82382690:-
THCA	cis	rs6088590	0.707	rs67159833	ENSG00000269202.1	RP4-614O4.12	-4.42	1.21e-05	0.00121	-0.18	-0.2	Coronary artery disease;	chr20:34900276	chr20:35201747~35203288:-
THCA	cis	rs4947019	0.688	rs1476386	ENSG00000223537.2	RP5-919F19.5	-4.42	1.21e-05	0.00121	-0.44	-0.2	Hematological parameters;	chr6:109443201	chr6:109487906~109506800:+
THCA	cis	rs9878978	0.89	rs35104429	ENSG00000237990.3	CNTN4-AS1	4.42	1.21e-05	0.00121	0.22	0.2	Blood pressure (smoking interaction);	chr3:2439875	chr3:3039033~3069242:-
THCA	cis	rs9634489	0.502	rs431500	ENSG00000247400.3	DNAJC3-AS1	4.42	1.21e-05	0.00121	0.13	0.2	Body mass index;	chr13:96449749	chr13:95648733~95676925:-
THCA	cis	rs9863	0.861	rs7132655	ENSG00000270061.1	RP11-214K3.19	-4.42	1.21e-05	0.00121	-0.26	-0.2	White blood cell count;	chr12:123954426	chr12:123969990~123970344:-
THCA	cis	rs11148252	0.574	rs2038826	ENSG00000273784.3	RP11-78J21.7	-4.42	1.21e-05	0.00121	-0.22	-0.2	Lewy body disease;	chr13:52705878	chr13:52600042~52642542:+
THCA	cis	rs6088813	0.961	rs6060371	ENSG00000279253.1	RP4-614O4.13	-4.42	1.21e-05	0.00121	-0.19	-0.2	Height;	chr20:35325519	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.883	rs2425061	ENSG00000279253.1	RP4-614O4.13	-4.42	1.21e-05	0.00121	-0.19	-0.2	Height;	chr20:35327768	chr20:35262727~35264187:-
THCA	cis	rs9311474	0.539	rs12489828	ENSG00000243224.1	RP5-1157M23.2	-4.42	1.21e-05	0.00122	-0.21	-0.2	Electroencephalogram traits;	chr3:52532998	chr3:52239258~52241097:+
THCA	cis	rs13160562	0.666	rs26481	ENSG00000272109.1	CTD-2260A17.3	-4.42	1.21e-05	0.00122	-0.25	-0.2	Alcohol dependence;	chr5:96767648	chr5:96804353~96806105:+
THCA	cis	rs2980439	0.846	rs2980437	ENSG00000254153.1	CTA-398F10.2	4.42	1.21e-05	0.00122	0.21	0.2	Neuroticism;	chr8:8237241	chr8:8456909~8461337:-
THCA	cis	rs4938303	0.633	rs35681250	ENSG00000254851.1	RP11-109L13.1	4.42	1.21e-05	0.00122	0.34	0.2	Triglycerides;	chr11:116684670	chr11:117135528~117138582:+
THCA	cis	rs1552244	1	rs17032283	ENSG00000180385.7	EMC3-AS1	4.42	1.21e-05	0.00122	0.22	0.2	Alzheimer's disease;	chr3:10039861	chr3:9986893~10006990:+
THCA	cis	rs4950322	0.748	rs17356680	ENSG00000271721.1	RP11-337C18.9	4.42	1.21e-05	0.00122	0.23	0.2	Protein quantitative trait loci;	chr1:147354934	chr1:147175602~147177740:+
THCA	cis	rs9863	0.861	rs3789967	ENSG00000270028.1	RP11-380L11.4	4.42	1.21e-05	0.00122	0.21	0.2	White blood cell count;	chr12:123962792	chr12:123925461~123926083:-
THCA	cis	rs7220401	0.521	rs2278217	ENSG00000264007.1	RP11-68I3.10	4.42	1.21e-05	0.00122	0.23	0.2	Coronary artery disease;	chr17:29577599	chr17:29621617~29622254:-
THCA	cis	rs12134133	1	rs6540893	ENSG00000237074.1	RP11-6J21.2	4.42	1.21e-05	0.00122	0.21	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs61822674	ENSG00000237074.1	RP11-6J21.2	4.42	1.21e-05	0.00122	0.21	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs10442696	ENSG00000237074.1	RP11-6J21.2	4.42	1.21e-05	0.00122	0.21	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs7535532	ENSG00000237074.1	RP11-6J21.2	4.42	1.21e-05	0.00122	0.21	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs7543117	ENSG00000237074.1	RP11-6J21.2	4.42	1.21e-05	0.00122	0.21	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs6684804	ENSG00000237074.1	RP11-6J21.2	4.42	1.21e-05	0.00122	0.21	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs11582249	ENSG00000237074.1	RP11-6J21.2	4.42	1.21e-05	0.00122	0.21	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207249067~207309121:+
THCA	cis	rs454217	0.846	rs1661029	ENSG00000277851.1	RP11-756G20.1	4.42	1.21e-05	0.00122	0.2	0.2	Smoking quantity;	chr12:92324197	chr12:92247756~92363832:-
THCA	cis	rs35851103	0.506	rs4841659	ENSG00000270154.1	RP11-419I17.1	4.42	1.21e-05	0.00122	0.25	0.2	Neuroticism;	chr8:11970691	chr8:12476462~12477122:+
THCA	cis	rs42648	0.869	rs12704518	ENSG00000225498.1	AC002064.5	4.42	1.21e-05	0.00122	0.21	0.2	Homocysteine levels;	chr7:90285074	chr7:90312496~90322592:+
THCA	cis	rs6860806	0.507	rs272872	ENSG00000224431.1	AC063976.7	-4.42	1.21e-05	0.00122	-0.18	-0.2	Breast cancer;	chr5:132340171	chr5:132199456~132203487:+
THCA	cis	rs7216064	0.911	rs12449442	ENSG00000278740.1	RP11-147L13.14	4.42	1.21e-05	0.00122	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67951524	chr17:68188547~68189165:+
THCA	cis	rs6449502	0.92	rs35383830	ENSG00000251279.1	CTC-436P18.1	4.42	1.21e-05	0.00122	0.35	0.2	Mean platelet volume;	chr5:60915109	chr5:61162070~61232040:+
THCA	cis	rs9601248	0.756	rs9601252	ENSG00000227354.5	RBM26-AS1	-4.42	1.21e-05	0.00122	-0.2	-0.2	Major depressive disorder;	chr13:79615607	chr13:79406309~79424328:+
THCA	cis	rs4742903	0.791	rs6479226	ENSG00000270332.1	SMC2-AS1	4.42	1.21e-05	0.00122	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104210591	chr9:104080024~104093073:-
THCA	cis	rs7537765	1	rs55857306	ENSG00000242349.4	NPPA-AS1	-4.42	1.21e-05	0.00122	-0.27	-0.2	QRS complex (12-leadsum);	chr1:11835738	chr1:11841017~11848079:+
THCA	cis	rs189798	1	rs189798	ENSG00000233609.3	RP11-62H7.2	-4.42	1.21e-05	0.00122	-0.2	-0.2	Myopia (pathological);	chr8:9133067	chr8:8961200~8979025:+
THCA	cis	rs7045881	0.877	rs892571	ENSG00000254396.1	RP11-56F10.3	4.42	1.21e-05	0.00122	0.3	0.2	Schizophrenia;	chr9:26774038	chr9:27102630~27104728:+
THCA	cis	rs6993244	1	rs6993244	ENSG00000254340.1	RP11-10A14.3	4.42	1.21e-05	0.00122	0.21	0.2	Mean corpuscular hemoglobin;	chr8:9005549	chr8:9141424~9145435:+
THCA	cis	rs274567	0.501	rs272856	ENSG00000224431.1	AC063976.7	4.42	1.21e-05	0.00122	0.18	0.2	Blood metabolite levels;	chr5:132351388	chr5:132199456~132203487:+
THCA	cis	rs7474896	0.526	rs1208716	ENSG00000120555.12	SEPT7P9	4.42	1.21e-05	0.00122	0.27	0.2	Obesity (extreme);	chr10:37800345	chr10:38383069~38402916:-
THCA	cis	rs28735056	0.591	rs2277724	ENSG00000261126.6	RP11-795F19.1	-4.42	1.21e-05	0.00122	-0.16	-0.2	Schizophrenia;	chr18:79934294	chr18:80046900~80095482:+
THCA	cis	rs2549003	1	rs10068129	ENSG00000237714.1	P4HA2-AS1	4.42	1.21e-05	0.00122	0.25	0.2	Asthma (sex interaction);	chr5:132485554	chr5:132184876~132192808:+
THCA	cis	rs78487399	0.731	rs6722104	ENSG00000234936.1	AC010883.5	4.42	1.21e-05	0.00122	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43525207	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6751161	ENSG00000234936.1	AC010883.5	4.42	1.21e-05	0.00122	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43525409	chr2:43229573~43233394:+
THCA	cis	rs1124769	0.57	rs1903589	ENSG00000259378.1	DCAF13P3	-4.42	1.21e-05	0.00122	-0.28	-0.2	Cognitive performance;	chr15:50852087	chr15:50944663~50945996:+
THCA	cis	rs11623400	0.775	rs61978977	ENSG00000258744.1	RP11-80A15.1	-4.42	1.21e-05	0.00122	-0.33	-0.2	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);	chr14:24562392	chr14:24501594~24508688:+
THCA	cis	rs7312933	0.618	rs6582394	ENSG00000257225.1	RP11-328C8.4	-4.42	1.21e-05	0.00122	-0.21	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42292387	chr12:42459366~42466128:+
THCA	cis	rs2191566	1	rs2356549	ENSG00000266921.1	RP11-15A1.7	-4.42	1.21e-05	0.00122	-0.19	-0.2	Acute lymphoblastic leukemia (childhood);	chr19:44007050	chr19:43996896~44002836:-
THCA	cis	rs11915082	0.686	rs7349507	ENSG00000273009.1	RP11-352G9.1	-4.42	1.21e-05	0.00122	-0.23	-0.2	Mean corpuscular hemoglobin;	chr3:196059617	chr3:195913078~195913683:-
THCA	cis	rs10833905	1	rs77438393	ENSG00000246225.5	RP11-17A1.3	-4.42	1.21e-05	0.00122	-0.29	-0.2	Sudden cardiac arrest;	chr11:22991177	chr11:22829380~22945393:+
THCA	cis	rs6442522	0.867	rs12637268	ENSG00000249786.6	EAF1-AS1	4.42	1.21e-05	0.00122	0.21	0.2	Uric acid levels;	chr3:15458741	chr3:15436171~15455940:-
THCA	cis	rs17095355	1	rs11194920	ENSG00000203876.8	ADD3-AS1	-4.42	1.21e-05	0.00122	-0.22	-0.2	Biliary atresia;	chr10:109935654	chr10:109940104~110008381:-
THCA	cis	rs4845570	1	rs1054479	ENSG00000249602.1	RP11-98D18.3	-4.42	1.21e-05	0.00122	-0.3	-0.2	Coronary artery disease;	chr1:151773603	chr1:151763384~151769501:-
THCA	cis	rs4845570	1	rs6683364	ENSG00000249602.1	RP11-98D18.3	-4.42	1.21e-05	0.00122	-0.3	-0.2	Coronary artery disease;	chr1:151773726	chr1:151763384~151769501:-
THCA	cis	rs944289	0.74	rs379426	ENSG00000258844.1	RP11-259K15.2	-4.42	1.21e-05	0.00122	-0.18	-0.2	Thyroid cancer;	chr14:36075253	chr14:36214607~36235608:+
THCA	cis	rs72819454	0.522	rs17115934	ENSG00000280693.1	SH3PXD2A-AS1	-4.42	1.21e-05	0.00122	-0.36	-0.2	Interleukin-9 levels;	chr10:103769986	chr10:103745966~103755423:+
THCA	cis	rs72819454	0.522	rs911546	ENSG00000280693.1	SH3PXD2A-AS1	4.42	1.21e-05	0.00122	0.36	0.2	Interleukin-9 levels;	chr10:103771232	chr10:103745966~103755423:+
THCA	cis	rs4906332	0.966	rs12588705	ENSG00000269910.1	RP11-73M18.10	4.42	1.21e-05	0.00122	0.17	0.2	Coronary artery disease;	chr14:103399140	chr14:103694516~103695050:-
THCA	cis	rs4906332	0.966	rs59858038	ENSG00000269910.1	RP11-73M18.10	4.42	1.21e-05	0.00122	0.17	0.2	Coronary artery disease;	chr14:103400765	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs12889703	ENSG00000269910.1	RP11-73M18.10	4.42	1.21e-05	0.00122	0.17	0.2	Coronary artery disease;	chr14:103406614	chr14:103694516~103695050:-
THCA	cis	rs6490294	0.8	rs78783055	ENSG00000226469.1	ADAM1B	4.42	1.21e-05	0.00122	0.25	0.2	Mean platelet volume;	chr12:111795691	chr12:111927018~111929017:+
THCA	cis	rs8067545	0.611	rs9893832	ENSG00000270091.1	RP11-78O7.2	-4.42	1.21e-05	0.00122	-0.15	-0.2	Schizophrenia;	chr17:20134960	chr17:19896590~19897287:-
THCA	cis	rs6988985	0.53	rs57268571	ENSG00000247317.3	RP11-273G15.2	-4.42	1.21e-05	0.00122	-0.21	-0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142861186	chr8:142981738~143018437:-
THCA	cis	rs6988985	0.56	rs4418320	ENSG00000247317.3	RP11-273G15.2	-4.42	1.21e-05	0.00122	-0.21	-0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142862722	chr8:142981738~143018437:-
THCA	cis	rs2361710	0.668	rs2304855	ENSG00000279259.1	RP11-334C17.3	4.42	1.21e-05	0.00122	0.17	0.2	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80144467	chr17:80147250~80148596:+
THCA	cis	rs11148252	0.774	rs7334583	ENSG00000273784.3	RP11-78J21.7	4.42	1.21e-05	0.00122	0.21	0.2	Lewy body disease;	chr13:52356217	chr13:52600042~52642542:+
THCA	cis	rs11148252	0.595	rs9526968	ENSG00000273784.3	RP11-78J21.7	-4.42	1.21e-05	0.00122	-0.22	-0.2	Lewy body disease;	chr13:52666048	chr13:52600042~52642542:+
THCA	cis	rs9902453	0.934	rs7213902	ENSG00000263370.1	RP11-68I3.5	4.42	1.21e-05	0.00122	0.26	0.2	Coffee consumption (cups per day);	chr17:29995917	chr17:29639627~29640825:+
THCA	cis	rs4578769	0.531	rs768793	ENSG00000273232.1	RP11-370A5.2	4.42	1.21e-05	0.00122	0.27	0.2	Eosinophil percentage of white cells;	chr18:22976640	chr18:22882825~22883357:-
THCA	cis	rs1009077	0.563	rs10518335	ENSG00000245958.5	RP11-33B1.1	4.42	1.21e-05	0.00122	0.23	0.2	Endometriosis;	chr4:119601017	chr4:119454791~119552025:+
THCA	cis	rs709400	0.894	rs10143293	ENSG00000258735.1	LINC00637	4.42	1.21e-05	0.00122	0.26	0.2	Body mass index;	chr14:103596677	chr14:103847721~103858049:+
THCA	cis	rs61142792	1	rs75192957	ENSG00000272459.1	RP11-1277A3.3	4.42	1.22e-05	0.00122	0.47	0.2	Alzheimer disease and age of onset;	chr5:177551966	chr5:177554824~177555364:+
THCA	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	4.42	1.22e-05	0.00122	0.23	0.2	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	4.42	1.22e-05	0.00122	0.23	0.2	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
THCA	cis	rs8031584	0.958	rs61997076	ENSG00000178081.11	ULK4P3	4.42	1.22e-05	0.00122	0.27	0.2	Huntington's disease progression;	chr15:30924022	chr15:30103720~30131757:+
THCA	cis	rs35740288	0.77	rs11630968	ENSG00000259295.5	CSPG4P12	4.42	1.22e-05	0.00122	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85574770	chr15:85191438~85213905:+
THCA	cis	rs763121	0.889	rs9607557	ENSG00000228274.3	RP3-508I15.9	-4.42	1.22e-05	0.00122	-0.21	-0.2	Menopause (age at onset);	chr22:38644274	chr22:38667585~38681820:-
THCA	cis	rs919433	0.617	rs700638	ENSG00000231621.1	AC013264.2	-4.42	1.22e-05	0.00122	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197724226	chr2:197197991~197199273:+
THCA	cis	rs718433	0.584	rs8015812	ENSG00000211778.2	TRAV4	-4.42	1.22e-05	0.00122	-0.15	-0.2	Intraocular pressure;	chr14:21746791	chr14:21736152~21736982:+
THCA	cis	rs10860794	1	rs10128858	ENSG00000274560.1	RP11-285E23.2	-4.42	1.22e-05	0.00122	-0.13	-0.2	Blood protein levels;	chr12:101827588	chr12:101696002~101696450:-
THCA	cis	rs758324	0.716	rs27348	ENSG00000224431.1	AC063976.7	-4.42	1.22e-05	0.00122	-0.19	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132071446	chr5:132199456~132203487:+
THCA	cis	rs6479891	0.524	rs10740107	ENSG00000272767.1	JMJD1C-AS1	-4.42	1.22e-05	0.00122	-0.27	-0.2	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63465229~63466563:+
THCA	cis	rs12410462	0.591	rs12080590	ENSG00000227711.2	RP11-275O4.5	4.42	1.22e-05	0.00122	0.25	0.2	Major depressive disorder;	chr1:227572070	chr1:227509028~227520477:-
THCA	cis	rs9875589	0.509	rs7636901	ENSG00000228242.5	AC093495.4	4.42	1.22e-05	0.00122	0.11	0.2	Ovarian reserve;	chr3:13989458	chr3:14144637~14165978:+
THCA	cis	rs2562456	0.833	rs4429400	ENSG00000268117.1	VN1R84P	4.42	1.22e-05	0.00122	0.33	0.2	Pain;	chr19:21338163	chr19:21719801~21720035:-
THCA	cis	rs7136259	0.844	rs11105358	ENSG00000258302.2	RP11-981P6.1	-4.42	1.22e-05	0.00122	-0.17	-0.2	Coronary heart disease;	chr12:89648365	chr12:89561129~89594878:+
THCA	cis	rs738144	0.687	rs3761456	ENSG00000235209.1	CTA-150C2.13	4.42	1.22e-05	0.00122	0.31	0.2	IgG glycosylation;	chr22:38794460	chr22:38921227~38924708:+
THCA	cis	rs853679	0.527	rs213228	ENSG00000280107.1	AL022393.9	-4.42	1.22e-05	0.00122	-0.2	-0.2	Depression;	chr6:28363475	chr6:28170845~28172521:+
THCA	cis	rs35851103	0.506	rs4841659	ENSG00000227888.4	FAM66A	4.42	1.22e-05	0.00122	0.25	0.2	Neuroticism;	chr8:11970691	chr8:12362019~12388296:+
THCA	cis	rs13113518	1	rs4864542	ENSG00000249700.7	SRD5A3-AS1	-4.42	1.22e-05	0.00123	-0.25	-0.2	Height;	chr4:55487920	chr4:55363971~55395847:-
THCA	cis	rs1538970	0.924	rs4660858	ENSG00000234329.1	RP11-767N6.2	4.42	1.22e-05	0.00123	0.2	0.2	Platelet count;	chr1:45470679	chr1:45651039~45651826:-
THCA	cis	rs4763879	0.594	rs12427310	ENSG00000256673.1	RP11-599J14.2	4.42	1.22e-05	0.00123	0.24	0.2	Type 1 diabetes;	chr12:9707539	chr12:9398355~9414851:-
THCA	cis	rs7560272	0.538	rs7370393	ENSG00000163016.8	ALMS1P	-4.42	1.22e-05	0.00123	-0.25	-0.2	Schizophrenia;	chr2:73698509	chr2:73644919~73685576:+
THCA	cis	rs9467773	0.62	rs2451738	ENSG00000261353.1	CTA-14H9.5	4.42	1.22e-05	0.00123	0.21	0.2	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26527063~26527404:+
THCA	cis	rs2904524	0.737	rs79196039	ENSG00000257815.4	RP11-611E13.2	-4.42	1.22e-05	0.00123	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70324336	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs80215627	ENSG00000257815.4	RP11-611E13.2	-4.42	1.22e-05	0.00123	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70330630	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs10506589	ENSG00000257815.4	RP11-611E13.2	-4.42	1.22e-05	0.00123	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70333218	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs57020753	ENSG00000257815.4	RP11-611E13.2	-4.42	1.22e-05	0.00123	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70340648	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs77627803	ENSG00000257815.4	RP11-611E13.2	-4.42	1.22e-05	0.00123	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70345492	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs79637006	ENSG00000257815.4	RP11-611E13.2	-4.42	1.22e-05	0.00123	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70357844	chr12:69904033~70243360:-
THCA	cis	rs2657294	0.965	rs2657291	ENSG00000233313.2	HMGA1P5	-4.42	1.22e-05	0.00123	-0.27	-0.2	Pneumonia;	chr10:75166945	chr10:75276376~75276646:-
THCA	cis	rs2688482	0.512	rs3103953	ENSG00000185485.13	SDHAP1	-4.42	1.22e-05	0.00123	-0.21	-0.2	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195959748~195990318:-
THCA	cis	rs17092148	0.887	rs2889849	ENSG00000276073.1	RP5-1125A11.7	-4.42	1.22e-05	0.00123	-0.24	-0.2	Neuroticism;	chr20:34576473	chr20:33985617~33988989:-
THCA	cis	rs6121246	0.909	rs6089071	ENSG00000230613.1	HM13-AS1	4.42	1.22e-05	0.00123	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31790581	chr20:31567707~31573263:-
THCA	cis	rs593531	0.504	rs4944041	ENSG00000255440.1	RP11-632K5.2	-4.42	1.22e-05	0.00123	-0.24	-0.2	Neuroticism;	chr11:74318814	chr11:74409060~74416379:+
THCA	cis	rs593531	0.513	rs4944887	ENSG00000255440.1	RP11-632K5.2	-4.42	1.22e-05	0.00123	-0.24	-0.2	Neuroticism;	chr11:74318838	chr11:74409060~74416379:+
THCA	cis	rs1124769	0.719	rs1904430	ENSG00000259378.1	DCAF13P3	4.42	1.22e-05	0.00123	0.3	0.2	Cognitive performance;	chr15:50962822	chr15:50944663~50945996:+
THCA	cis	rs708224	0.845	rs792860	ENSG00000277342.1	RP11-843B15.4	4.42	1.22e-05	0.00123	0.26	0.2	Pancreatic cancer;	chr12:32276007	chr12:32109076~32109602:+
THCA	cis	rs2836950	0.501	rs2056844	ENSG00000238141.2	BRWD1-AS1	-4.42	1.22e-05	0.00123	-0.23	-0.2	Menarche (age at onset);	chr21:39298534	chr21:39315707~39323218:+
THCA	cis	rs7819412	0.539	rs11250131	ENSG00000206014.6	OR7E161P	4.42	1.22e-05	0.00123	0.22	0.2	Triglycerides;	chr8:11393666	chr8:11928597~11929563:-
THCA	cis	rs301801	0.803	rs2661863	ENSG00000232912.4	RP5-1115A15.1	-4.42	1.22e-05	0.00123	-0.22	-0.2	Optic cup area;Vertical cup-disc ratio;	chr1:8392665	chr1:8424645~8434838:+
THCA	cis	rs2070488	1	rs3792528	ENSG00000229589.1	ACVR2B-AS1	4.42	1.22e-05	0.00123	0.19	0.2	Electrocardiographic conduction measures;	chr3:38451812	chr3:38451027~38454820:-
THCA	cis	rs950776	0.752	rs7182583	ENSG00000261762.1	RP11-650L12.2	4.42	1.22e-05	0.00123	0.26	0.2	Sudden cardiac arrest;	chr15:78606868	chr15:78589123~78591276:-
THCA	cis	rs6416877	0.679	rs12946190	ENSG00000277491.1	RP11-676J12.9	-4.42	1.22e-05	0.00123	-0.22	-0.2	Myeloid white cell count;	chr17:1450528	chr17:795306~795794:+
THCA	cis	rs73108077	0.79	rs8122544	ENSG00000277112.2	RP11-755J8.1	-4.42	1.22e-05	0.00123	-0.39	-0.2	Red blood cell density in sickle cell anemia;	chr20:31346428	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.736	rs73105954	ENSG00000277112.2	RP11-755J8.1	-4.42	1.22e-05	0.00123	-0.39	-0.2	Red blood cell density in sickle cell anemia;	chr20:31355903	chr20:30681825~30723932:-
THCA	cis	rs62025270	0.688	rs17638180	ENSG00000259295.5	CSPG4P12	-4.42	1.22e-05	0.00123	-0.34	-0.2	Idiopathic pulmonary fibrosis;	chr15:85735164	chr15:85191438~85213905:+
THCA	cis	rs9959145	0.778	rs2186906	ENSG00000267108.1	RP11-861E21.1	4.42	1.22e-05	0.00123	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12572196	chr18:12432897~12437635:+
THCA	cis	rs62246343	0.605	rs9832810	ENSG00000254485.4	RP11-380O24.1	4.42	1.22e-05	0.00123	0.22	0.2	Fibrinogen levels;	chr3:9424095	chr3:9292588~9363303:-
THCA	cis	rs7267979	1	rs7267979	ENSG00000274973.1	RP13-401N8.7	-4.42	1.22e-05	0.00123	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25845497~25845862:+
THCA	cis	rs7403037	0.537	rs8028138	ENSG00000259905.4	PWRN1	4.42	1.22e-05	0.00123	0.21	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24183100	chr15:24493137~24652130:+
THCA	cis	rs9307551	0.697	rs1561638	ENSG00000250334.4	LINC00989	-4.42	1.23e-05	0.00123	-0.27	-0.2	Refractive error;	chr4:79499154	chr4:79492416~79576460:+
THCA	cis	rs8141529	0.719	rs132561	ENSG00000272858.1	CTA-292E10.8	4.42	1.23e-05	0.00123	0.2	0.2	Lymphocyte counts;	chr22:28955191	chr22:28814914~28815662:+
THCA	cis	rs7572733	0.534	rs700678	ENSG00000231621.1	AC013264.2	-4.42	1.23e-05	0.00123	-0.21	-0.2	Dermatomyositis;	chr2:197841096	chr2:197197991~197199273:+
THCA	cis	rs9863	0.862	rs6488912	ENSG00000270028.1	RP11-380L11.4	4.42	1.23e-05	0.00123	0.21	0.2	White blood cell count;	chr12:123958205	chr12:123925461~123926083:-
THCA	cis	rs9329221	0.507	rs12678938	ENSG00000248538.5	RP11-10A14.5	4.42	1.23e-05	0.00123	0.26	0.2	Neuroticism;	chr8:10159459	chr8:9189011~9202854:+
THCA	cis	rs7474896	0.537	rs2749588	ENSG00000226578.1	RP11-258F22.1	-4.42	1.23e-05	0.00123	-0.28	-0.2	Obesity (extreme);	chr10:37980529	chr10:37775371~37784131:-
THCA	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-4.42	1.23e-05	0.00123	-0.2	-0.2	Height;	chr5:37022673	chr5:36666214~36725195:-
THCA	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	4.42	1.23e-05	0.00123	0.2	0.2	Height;	chr5:37041491	chr5:36666214~36725195:-
THCA	cis	rs227275	0.525	rs4596243	ENSG00000248971.2	KRT8P46	-4.42	1.23e-05	0.00123	-0.25	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102728746~102730171:-
THCA	cis	rs1766786	0.925	rs1361207	ENSG00000231365.4	RP11-418J17.1	-4.42	1.23e-05	0.00123	-0.28	-0.2	Chin dimples;	chr1:118913608	chr1:119140396~119275973:+
THCA	cis	rs72843506	0.656	rs9913018	ENSG00000261033.1	RP11-209D14.2	4.42	1.23e-05	0.00123	0.36	0.2	Schizophrenia;	chr17:20160759	chr17:20008051~20009234:-
THCA	cis	rs1005277	0.638	rs1005278	ENSG00000276805.1	RP11-291L22.6	-4.42	1.23e-05	0.00123	-0.22	-0.2	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:38451030~38451785:+
THCA	cis	rs16852403	0.607	rs316249	ENSG00000224687.1	RASAL2-AS1	-4.42	1.23e-05	0.00123	-0.29	-0.2	Childhood ear infection;	chr1:178155461	chr1:178091508~178093984:-
THCA	cis	rs35740288	0.77	rs34048547	ENSG00000259295.5	CSPG4P12	4.42	1.23e-05	0.00123	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85637836	chr15:85191438~85213905:+
THCA	cis	rs6701713	0.804	rs4266886	ENSG00000274245.1	RP11-357P18.2	-4.42	1.23e-05	0.00123	-0.23	-0.2	Alzheimer's disease (late onset);	chr1:207512441	chr1:207372559~207373252:+
THCA	cis	rs9675999	1	rs9675999	ENSG00000265939.1	UBE2CP2	4.42	1.23e-05	0.00123	0.23	0.2	Breast cancer;	chr18:23047728	chr18:22900486~22900995:-
THCA	cis	rs4950322	0.58	rs2083720	ENSG00000226015.2	CCT8P1	4.42	1.23e-05	0.00123	0.23	0.2	Protein quantitative trait loci;	chr1:147122296	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.58	rs72706441	ENSG00000226015.2	CCT8P1	4.42	1.23e-05	0.00123	0.23	0.2	Protein quantitative trait loci;	chr1:147122601	chr1:147203276~147204932:-
THCA	cis	rs516805	0.52	rs7767237	ENSG00000279453.1	RP3-425C14.4	-4.42	1.23e-05	0.00123	-0.16	-0.2	Lymphocyte counts;	chr6:122488429	chr6:122436789~122439223:-
THCA	cis	rs516805	0.52	rs7767114	ENSG00000279453.1	RP3-425C14.4	-4.42	1.23e-05	0.00123	-0.16	-0.2	Lymphocyte counts;	chr6:122488454	chr6:122436789~122439223:-
THCA	cis	rs7264396	1	rs224409	ENSG00000088340.14	FER1L4	4.42	1.23e-05	0.00123	0.19	0.2	Total cholesterol levels;	chr20:35537096	chr20:35558737~35607562:-
THCA	cis	rs5769765	0.862	rs138897	ENSG00000260613.1	RP3-522J7.6	-4.42	1.23e-05	0.00123	-0.24	-0.2	Schizophrenia;	chr22:49837419	chr22:49832616~49837786:-
THCA	cis	rs79040073	0.911	rs34895054	ENSG00000259531.2	RP11-295H24.3	4.42	1.23e-05	0.00123	0.25	0.2	Lung cancer in ever smokers;	chr15:48992804	chr15:49365124~49366685:-
THCA	cis	rs2836950	0.52	rs8130240	ENSG00000238141.2	BRWD1-AS1	-4.42	1.23e-05	0.00123	-0.23	-0.2	Menarche (age at onset);	chr21:39166182	chr21:39315707~39323218:+
THCA	cis	rs6479891	1	rs6479899	ENSG00000272767.1	JMJD1C-AS1	-4.42	1.23e-05	0.00123	-0.28	-0.2	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63465229~63466563:+
THCA	cis	rs13126694	0.744	rs4521391	ENSG00000248429.4	RP11-597D13.9	4.42	1.23e-05	0.00123	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158017310	chr4:158170752~158202877:+
THCA	cis	rs7577696	0.853	rs430759	ENSG00000276334.1	AL133243.1	-4.42	1.23e-05	0.00123	-0.21	-0.2	Inflammatory biomarkers;	chr2:32222799	chr2:32521927~32523547:+
THCA	cis	rs6095360	0.625	rs2426132	ENSG00000227431.4	CSE1L-AS1	-4.42	1.23e-05	0.00123	-0.25	-0.2	Intelligence (multi-trait analysis);	chr20:49106590	chr20:49040463~49046044:-
THCA	cis	rs79243044	0.695	rs6578654	ENSG00000224295.2	AC087380.14	-4.42	1.23e-05	0.00123	-0.2	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5519383	chr11:5518441~5524955:-
THCA	cis	rs34286592	0.929	rs9932653	ENSG00000214725.6	CDIPT-AS1	-4.42	1.23e-05	0.00123	-0.37	-0.2	Multiple sclerosis;	chr16:29854352	chr16:29863593~29868053:+
THCA	cis	rs2033711	0.503	rs6510141	ENSG00000269473.1	CTD-2619J13.19	-4.42	1.23e-05	0.00123	-0.18	-0.2	Uric acid clearance;	chr19:58374419	chr19:58440448~58445849:+
THCA	cis	rs2028299	1	rs6496609	ENSG00000259677.1	RP11-493E3.1	4.42	1.23e-05	0.00123	0.26	0.2	Type 2 diabetes;	chr15:89836400	chr15:89876540~89877285:+
THCA	cis	rs11089937	0.522	rs5757259	ENSG00000211639.2	IGLV4-60	4.42	1.23e-05	0.00124	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22179649	chr22:22162199~22162681:+
THCA	cis	rs9890032	0.542	rs113934718	ENSG00000263531.1	RP13-753N3.1	-4.42	1.23e-05	0.00124	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:30887862	chr17:30863921~30864940:-
THCA	cis	rs807029	0.758	rs807025	ENSG00000236662.1	RP11-108L7.4	4.42	1.23e-05	0.00124	0.2	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101005064	chr10:100980507~100985614:-
THCA	cis	rs7577696	0.695	rs212744	ENSG00000276334.1	AL133243.1	4.42	1.23e-05	0.00124	0.22	0.2	Inflammatory biomarkers;	chr2:32186719	chr2:32521927~32523547:+
THCA	cis	rs7085104	0.513	rs619824	ENSG00000213061.2	PFN1P11	4.42	1.23e-05	0.00124	0.23	0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102838011~102845473:-
THCA	cis	rs1942	0.785	rs10851404	ENSG00000247556.5	OIP5-AS1	4.42	1.23e-05	0.00124	0.17	0.2	Eosinophil percentage of granulocytes;	chr15:41341872	chr15:41283990~41309737:+
THCA	cis	rs67478160	0.625	rs7141473	ENSG00000269910.1	RP11-73M18.10	-4.42	1.23e-05	0.00124	-0.17	-0.2	Schizophrenia;	chr14:103849718	chr14:103694516~103695050:-
THCA	cis	rs1979679	0.801	rs1463571	ENSG00000247934.4	RP11-967K21.1	-4.42	1.23e-05	0.00124	-0.2	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28144514	chr12:28163298~28190738:-
THCA	cis	rs7918232	0.891	rs10443987	ENSG00000262412.1	RP11-85G18.6	4.42	1.23e-05	0.00124	0.3	0.2	Breast cancer;	chr10:27086448	chr10:27243130~27250804:+
THCA	cis	rs6449502	0.92	rs4647108	ENSG00000251279.1	CTC-436P18.1	-4.42	1.23e-05	0.00124	-0.33	-0.2	Mean platelet volume;	chr5:60901888	chr5:61162070~61232040:+
THCA	cis	rs4906332	0.966	rs7401563	ENSG00000269910.1	RP11-73M18.10	4.42	1.23e-05	0.00124	0.17	0.2	Coronary artery disease;	chr14:103498088	chr14:103694516~103695050:-
THCA	cis	rs76793172	0.66	rs3760843	ENSG00000267395.4	AC074212.6	4.42	1.23e-05	0.00124	0.17	0.2	Eosinophil counts;	chr19:45785448	chr19:45767796~45772504:+
THCA	cis	rs17801127	0.748	rs12990272	ENSG00000231969.1	AC144449.1	4.42	1.23e-05	0.00124	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149670563	chr2:149587196~149848233:+
THCA	cis	rs950880	0.645	rs11679889	ENSG00000234389.1	AC007278.3	-4.42	1.23e-05	0.00124	-0.24	-0.2	Serum protein levels (sST2);	chr2:102324549	chr2:102438713~102440475:+
THCA	cis	rs972578	0.791	rs7290497	ENSG00000274717.1	RP1-47A17.1	-4.42	1.23e-05	0.00124	-0.21	-0.2	Mean platelet volume;	chr22:42928559	chr22:42791814~42794313:-
THCA	cis	rs28829049	0.597	rs2066002	ENSG00000270728.1	RP4-657E11.10	-4.42	1.23e-05	0.00124	-0.15	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19177806	chr1:19297080~19297903:+
THCA	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-4.42	1.23e-05	0.00124	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
THCA	cis	rs7829975	0.593	rs2921051	ENSG00000253981.4	ALG1L13P	4.42	1.23e-05	0.00124	0.19	0.2	Mood instability;	chr8:8462594	chr8:8236003~8244667:-
THCA	cis	rs9309473	0.898	rs10209517	ENSG00000273245.1	RP11-434P11.2	4.42	1.23e-05	0.00124	0.27	0.2	Metabolite levels;	chr2:73618265	chr2:73750256~73750786:-
THCA	cis	rs3748682	0.731	rs9729719	ENSG00000252448.1	SNORA63	-4.42	1.23e-05	0.00124	-0.25	-0.2	Hypothyroidism;	chr1:37832535	chr1:37884237~37884317:+
THCA	cis	rs516805	0.501	rs34157234	ENSG00000279453.1	RP3-425C14.4	-4.42	1.23e-05	0.00124	-0.16	-0.2	Lymphocyte counts;	chr6:122486870	chr6:122436789~122439223:-
THCA	cis	rs8062405	0.755	rs62034350	ENSG00000270424.1	RP11-1348G14.6	4.42	1.23e-05	0.00124	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28749959~28750595:-
THCA	cis	rs12935418	0.673	rs2602428	ENSG00000278985.1	RP11-303E16.9	-4.42	1.23e-05	0.00124	-0.22	-0.2	Mean corpuscular volume;	chr16:81028566	chr16:80982319~80984094:-
THCA	cis	rs17801127	0.818	rs34462373	ENSG00000231969.1	AC144449.1	4.42	1.23e-05	0.00124	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149674998	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.818	rs16825497	ENSG00000231969.1	AC144449.1	4.42	1.23e-05	0.00124	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149675672	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.818	rs34272267	ENSG00000231969.1	AC144449.1	4.42	1.23e-05	0.00124	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149679511	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.818	rs12233116	ENSG00000231969.1	AC144449.1	4.42	1.23e-05	0.00124	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149690652	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.818	rs12992502	ENSG00000231969.1	AC144449.1	4.42	1.23e-05	0.00124	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149691124	chr2:149587196~149848233:+
THCA	cis	rs1334894	1	rs755658	ENSG00000228559.1	RP3-340B19.3	4.42	1.23e-05	0.00124	0.4	0.2	Coronary artery disease;	chr6:35581893	chr6:35544632~35545669:+
THCA	cis	rs5758511	0.773	rs9680671	ENSG00000281538.1	RP4-669P10.20	-4.42	1.23e-05	0.00124	-0.22	-0.2	Birth weight;	chr22:41955473	chr22:42138060~42139726:+
THCA	cis	rs8002861	0.641	rs6561148	ENSG00000274001.1	RP11-5G9.5	4.42	1.23e-05	0.00124	0.23	0.2	Leprosy;	chr13:43852133	chr13:43877715~43878163:-
THCA	cis	rs801193	0.844	rs2244022	ENSG00000229886.1	RP5-1132H15.3	4.42	1.23e-05	0.00124	0.2	0.2	Aortic root size;	chr7:66737443	chr7:66025126~66031544:-
THCA	cis	rs7989336	0.568	rs9584362	ENSG00000247400.3	DNAJC3-AS1	4.42	1.23e-05	0.00124	0.13	0.2	Obesity;	chr13:96386437	chr13:95648733~95676925:-
THCA	cis	rs1538970	0.816	rs11211124	ENSG00000234329.1	RP11-767N6.2	4.42	1.23e-05	0.00124	0.2	0.2	Platelet count;	chr1:45496737	chr1:45651039~45651826:-
THCA	cis	rs1538970	0.816	rs12029322	ENSG00000234329.1	RP11-767N6.2	4.42	1.23e-05	0.00124	0.2	0.2	Platelet count;	chr1:45504774	chr1:45651039~45651826:-
THCA	cis	rs440932	0.565	rs19334	ENSG00000253893.2	FAM85B	-4.42	1.23e-05	0.00124	-0.26	-0.2	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:8167819~8226614:-
THCA	cis	rs12478296	0.792	rs6740738	ENSG00000220804.7	AC093642.5	4.42	1.23e-05	0.00124	0.21	0.2	Obesity-related traits;	chr2:242065217	chr2:242088633~242160153:+
THCA	cis	rs11633886	0.934	rs66526505	ENSG00000273972.1	CTD-2306A12.1	-4.42	1.23e-05	0.00124	-0.22	-0.2	Diisocyanate-induced asthma;	chr15:45797548	chr15:45702640~45703183:+
THCA	cis	rs2562456	0.833	rs1932087	ENSG00000268117.1	VN1R84P	4.42	1.23e-05	0.00124	0.33	0.2	Pain;	chr19:21338625	chr19:21719801~21720035:-
THCA	cis	rs60180747	1	rs11631625	ENSG00000261318.1	RP11-653J6.1	4.42	1.23e-05	0.00124	0.26	0.2	Testicular germ cell tumor;	chr15:66316393	chr15:66278498~66293357:-
THCA	cis	rs2692947	0.566	rs11676901	ENSG00000235959.1	AC009237.17	-4.42	1.23e-05	0.00124	-0.22	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95704823	chr2:95640181~95640604:-
THCA	cis	rs227275	0.525	rs2086499	ENSG00000248971.2	KRT8P46	-4.42	1.24e-05	0.00124	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102728746~102730171:-
THCA	cis	rs875971	0.83	rs778711	ENSG00000229886.1	RP5-1132H15.3	4.42	1.24e-05	0.00124	0.21	0.2	Aortic root size;	chr7:66386670	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs1083554	ENSG00000229886.1	RP5-1132H15.3	4.42	1.24e-05	0.00124	0.21	0.2	Aortic root size;	chr7:66387354	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs778707	ENSG00000229886.1	RP5-1132H15.3	4.42	1.24e-05	0.00124	0.21	0.2	Aortic root size;	chr7:66392040	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs778705	ENSG00000229886.1	RP5-1132H15.3	4.42	1.24e-05	0.00124	0.21	0.2	Aortic root size;	chr7:66396128	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs778697	ENSG00000229886.1	RP5-1132H15.3	4.42	1.24e-05	0.00124	0.21	0.2	Aortic root size;	chr7:66405439	chr7:66025126~66031544:-
THCA	cis	rs875971	0.798	rs7789615	ENSG00000229886.1	RP5-1132H15.3	4.42	1.24e-05	0.00124	0.21	0.2	Aortic root size;	chr7:66413674	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6978028	ENSG00000229886.1	RP5-1132H15.3	4.42	1.24e-05	0.00124	0.21	0.2	Aortic root size;	chr7:66421313	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6947339	ENSG00000229886.1	RP5-1132H15.3	4.42	1.24e-05	0.00124	0.21	0.2	Aortic root size;	chr7:66423483	chr7:66025126~66031544:-
THCA	cis	rs853679	0.599	rs149943	ENSG00000220721.1	OR1F12	4.42	1.24e-05	0.00124	0.32	0.2	Depression;	chr6:28034610	chr6:28073316~28074233:+
THCA	cis	rs889398	0.683	rs8047682	ENSG00000226232.7	RP11-419C5.2	-4.42	1.24e-05	0.00124	-0.2	-0.2	Body mass index;	chr16:69879543	chr16:69976388~69996188:-
THCA	cis	rs1559040	0.932	rs28368466	ENSG00000272156.1	RP11-477N3.1	-4.42	1.24e-05	0.00124	-0.32	-0.2	Sudden cardiac arrest;	chr2:54061824	chr2:54082554~54085066:+
THCA	cis	rs12428035	0.656	rs1854758	ENSG00000247400.3	DNAJC3-AS1	4.42	1.24e-05	0.00124	0.18	0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95889295	chr13:95648733~95676925:-
THCA	cis	rs3742264	0.731	rs7318648	ENSG00000235903.6	CPB2-AS1	-4.42	1.24e-05	0.00124	-0.27	-0.2	Blood protein levels;	chr13:46032497	chr13:46052806~46113332:+
THCA	cis	rs2299587	0.637	rs6586677	ENSG00000253671.1	RP11-806O11.1	-4.42	1.24e-05	0.00124	-0.23	-0.2	Economic and political preferences;	chr8:18033178	chr8:17808941~17820868:+
THCA	cis	rs4656958	0.538	rs12126310	ENSG00000233691.2	RP11-312J18.7	-4.42	1.24e-05	0.00124	-0.22	-0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160916773	chr1:160935537~160936126:+
THCA	cis	rs875971	0.545	rs1796217	ENSG00000273142.1	RP11-458F8.4	-4.42	1.24e-05	0.00124	-0.19	-0.2	Aortic root size;	chr7:66620931	chr7:66902857~66906297:+
THCA	cis	rs2732480	1	rs2732480	ENSG00000275228.1	RP11-370I10.10	4.42	1.24e-05	0.00124	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48327942~48328472:-
THCA	cis	rs11540084	0.505	rs3760624	ENSG00000279095.1	AC092066.1	4.42	1.24e-05	0.00124	0.26	0.2	Mean platelet volume;	chr19:44641449	chr19:44664131~44666158:+
THCA	cis	rs41313321	0.541	rs7867338	ENSG00000273186.1	RP11-339B21.10	4.42	1.24e-05	0.00124	0.3	0.2	Coenzyme Q10 levels;	chr9:128302043	chr9:128431598~128432006:+
THCA	cis	rs964611	0.882	rs11629805	ENSG00000259488.2	RP11-154J22.1	4.42	1.24e-05	0.00124	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48363267	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs12439526	ENSG00000259488.2	RP11-154J22.1	4.42	1.24e-05	0.00124	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48366050	chr15:48312353~48331856:-
THCA	cis	rs12893668	0.703	rs8017993	ENSG00000269958.1	RP11-73M18.8	4.42	1.24e-05	0.00124	0.19	0.2	Reticulocyte count;	chr14:103581397	chr14:103696353~103697163:+
THCA	cis	rs739496	0.579	rs3177647	ENSG00000226469.1	ADAM1B	4.42	1.24e-05	0.00124	0.25	0.2	Platelet count;	chr12:111839772	chr12:111927018~111929017:+
THCA	cis	rs31251	0.803	rs3756295	ENSG00000224431.1	AC063976.7	-4.42	1.24e-05	0.00124	-0.17	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr5:131357147	chr5:132199456~132203487:+
THCA	cis	rs6494488	0.5	rs67533952	ENSG00000259635.1	AC100830.3	-4.42	1.24e-05	0.00124	-0.48	-0.2	Coronary artery disease;	chr15:64732375	chr15:64701248~64719602:+
THCA	cis	rs7267979	0.586	rs6037057	ENSG00000277938.1	RP5-965G21.3	4.42	1.24e-05	0.00124	0.17	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25229150~25231933:+
THCA	cis	rs711244	0.783	rs2252032	ENSG00000279519.1	RP11-288C18.1	4.42	1.24e-05	0.00124	0.17	0.2	Mean platelet volume;	chr2:36872196	chr2:36839922~36842539:-
THCA	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
THCA	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
THCA	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
THCA	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
THCA	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00124	-0.23	-0.2	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
THCA	cis	rs1876905	0.68	rs354528	ENSG00000272356.1	RP5-1112D6.8	-4.42	1.24e-05	0.00124	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111184068	chr6:111309203~111313517:+
THCA	cis	rs2839186	0.807	rs2032226	ENSG00000215424.8	MCM3AP-AS1	4.42	1.24e-05	0.00124	0.12	0.2	Testicular germ cell tumor;	chr21:46260438	chr21:46229217~46259390:+
THCA	cis	rs61270009	0.955	rs10462472	ENSG00000247828.6	TMEM161B-AS1	4.42	1.24e-05	0.00124	0.18	0.2	Depressive symptoms;	chr5:88346652	chr5:88268895~88436685:+
THCA	cis	rs1048886	0.938	rs3846748	ENSG00000271967.1	RP11-134K13.4	4.42	1.24e-05	0.00124	0.2	0.2	Type 2 diabetes;	chr6:70397307	chr6:70596438~70596980:+
THCA	cis	rs7267979	0.668	rs4815398	ENSG00000274414.1	RP5-965G21.4	4.42	1.24e-05	0.00124	0.24	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:25239007~25245229:-
THCA	cis	rs4787951	0.56	rs2382720	ENSG00000259940.2	CTD-3203P2.1	-4.42	1.24e-05	0.00124	-0.21	-0.2	Eosinophil percentage of white cells;	chr16:27338691	chr16:27213308~27214993:-
THCA	cis	rs113835537	0.877	rs2229456	ENSG00000255517.5	CTD-3074O7.5	-4.42	1.24e-05	0.00124	-0.2	-0.2	Airway imaging phenotypes;	chr11:66561270	chr11:66473490~66480233:-
THCA	cis	rs7267979	1	rs13038834	ENSG00000274973.1	RP13-401N8.7	-4.42	1.24e-05	0.00124	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25845497~25845862:+
THCA	cis	rs997295	0.713	rs17243334	ENSG00000270964.1	RP11-502I4.3	-4.42	1.24e-05	0.00124	-0.17	-0.2	Motion sickness;	chr15:67720741	chr15:67541072~67542604:-
THCA	cis	rs722599	0.715	rs2300598	ENSG00000279594.1	RP11-950C14.10	-4.42	1.24e-05	0.00124	-0.2	-0.2	IgG glycosylation;	chr14:74892526	chr14:75011269~75012851:-
THCA	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-4.42	1.24e-05	0.00124	-0.11	-0.2	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
THCA	cis	rs7267979	0.903	rs2500400	ENSG00000274973.1	RP13-401N8.7	4.42	1.24e-05	0.00124	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25845497~25845862:+
THCA	cis	rs10984970	0.826	rs10984984	ENSG00000238181.2	AHCYP2	4.42	1.24e-05	0.00124	0.5	0.2	Lung cancer;	chr9:120701198	chr9:120720673~120721972:+
THCA	cis	rs5751614	0.537	rs9608093	ENSG00000240160.3	RN7SL263P	4.42	1.24e-05	0.00124	0.27	0.2	Height;	chr22:23271352	chr22:23261782~23262071:-
THCA	cis	rs1538970	0.739	rs4660863	ENSG00000234329.1	RP11-767N6.2	4.42	1.24e-05	0.00124	0.2	0.2	Platelet count;	chr1:45490196	chr1:45651039~45651826:-
THCA	cis	rs1346	0.552	rs10791821	ENSG00000245532.5	NEAT1	-4.42	1.24e-05	0.00125	-0.16	-0.2	Vertical cup-disc ratio;Optic cup area;	chr11:65600852	chr11:65422774~65445540:+
THCA	cis	rs7560272	0.538	rs2421575	ENSG00000273245.1	RP11-434P11.2	-4.42	1.24e-05	0.00125	-0.23	-0.2	Schizophrenia;	chr2:73692395	chr2:73750256~73750786:-
THCA	cis	rs8064024	0.599	rs3185547	ENSG00000267077.1	RP11-127I20.5	4.42	1.24e-05	0.00125	0.24	0.2	Cancer;	chr16:4881099	chr16:4795265~4796532:-
THCA	cis	rs2836950	0.565	rs2836930	ENSG00000238141.2	BRWD1-AS1	-4.42	1.24e-05	0.00125	-0.23	-0.2	Menarche (age at onset);	chr21:39173730	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.565	rs2836931	ENSG00000238141.2	BRWD1-AS1	-4.42	1.24e-05	0.00125	-0.23	-0.2	Menarche (age at onset);	chr21:39174643	chr21:39315707~39323218:+
THCA	cis	rs17801127	0.688	rs4667405	ENSG00000231969.1	AC144449.1	-4.42	1.24e-05	0.00125	-0.32	-0.2	Liver enzyme levels (alanine transaminase);	chr2:149703832	chr2:149587196~149848233:+
THCA	cis	rs4568518	0.53	rs4493811	ENSG00000279048.1	RP11-511H23.2	4.42	1.24e-05	0.00125	0.13	0.2	Measles;	chr7:17943746	chr7:17940503~17942922:+
THCA	cis	rs7924176	0.601	rs767809	ENSG00000213731.2	RAB5CP1	-4.42	1.24e-05	0.00125	-0.25	-0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74105307	chr10:74423435~74424014:-
THCA	cis	rs6860806	0.507	rs272854	ENSG00000224431.1	AC063976.7	4.42	1.24e-05	0.00125	0.18	0.2	Breast cancer;	chr5:132352324	chr5:132199456~132203487:+
THCA	cis	rs2842992	0.672	rs7738253	ENSG00000237927.1	RP3-393E18.2	-4.42	1.24e-05	0.00125	-0.3	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159772885	chr6:159586955~159589169:-
THCA	cis	rs453301	0.624	rs2915251	ENSG00000254340.1	RP11-10A14.3	4.42	1.24e-05	0.00125	0.22	0.2	Joint mobility (Beighton score);	chr8:9009901	chr8:9141424~9145435:+
THCA	cis	rs964611	0.882	rs8027003	ENSG00000259488.2	RP11-154J22.1	-4.42	1.24e-05	0.00125	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48355229	chr15:48312353~48331856:-
THCA	cis	rs6121246	0.954	rs6060978	ENSG00000230613.1	HM13-AS1	4.42	1.24e-05	0.00125	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31829090	chr20:31567707~31573263:-
THCA	cis	rs61270009	0.955	rs10514299	ENSG00000247828.6	TMEM161B-AS1	4.42	1.24e-05	0.00125	0.18	0.2	Depressive symptoms;	chr5:88367793	chr5:88268895~88436685:+
THCA	cis	rs7615952	0.546	rs2979307	ENSG00000171084.14	FAM86JP	-4.42	1.24e-05	0.00125	-0.27	-0.2	Blood pressure (smoking interaction);	chr3:125590730	chr3:125916620~125930024:+
THCA	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-4.42	1.24e-05	0.00125	-0.23	-0.2	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
THCA	cis	rs11671005	0.735	rs12977592	ENSG00000265272.2	RN7SL693P	4.42	1.24e-05	0.00125	0.26	0.2	Mean platelet volume;	chr19:58449689	chr19:58490797~58491075:+
THCA	cis	rs881375	0.678	rs1930782	ENSG00000270917.1	RP11-27I1.6	-4.42	1.24e-05	0.00125	-0.26	-0.2	Rheumatoid arthritis;	chr9:120925627	chr9:120812475~120812845:-
THCA	cis	rs1866631	0.565	rs13032010	ENSG00000238133.5	MLK7-AS1	4.42	1.24e-05	0.00125	0.26	0.2	Lung cancer in ever smokers;	chr2:173168965	chr2:173166446~173282036:-
THCA	cis	rs7176527	1	rs3762169	ENSG00000225151.9	GOLGA2P7	4.42	1.24e-05	0.00125	0.32	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84199311~84230136:-
THCA	cis	rs9863	0.828	rs952632	ENSG00000270061.1	RP11-214K3.19	-4.42	1.24e-05	0.00125	-0.26	-0.2	White blood cell count;	chr12:123985191	chr12:123969990~123970344:-
THCA	cis	rs9863	0.694	rs11837287	ENSG00000270061.1	RP11-214K3.19	-4.42	1.24e-05	0.00125	-0.26	-0.2	White blood cell count;	chr12:123985512	chr12:123969990~123970344:-
THCA	cis	rs8177876	0.822	rs4889225	ENSG00000261061.1	RP11-303E16.2	4.42	1.24e-05	0.00125	0.26	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr16:81030770~81031485:+
THCA	cis	rs17597773	0.754	rs1826647	ENSG00000238078.1	LINC01352	-4.42	1.24e-05	0.00125	-0.3	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220857612	chr1:220829255~220832429:+
THCA	cis	rs7542375	0.534	rs1587024	ENSG00000238078.1	LINC01352	-4.42	1.24e-05	0.00125	-0.3	-0.2	Obesity-related traits;	chr1:220857877	chr1:220829255~220832429:+
THCA	cis	rs12681963	0.688	rs6997926	ENSG00000248159.1	HSPA8P11	4.42	1.24e-05	0.00125	0.41	0.2	Migraine;	chr8:30197384	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs73234779	ENSG00000248159.1	HSPA8P11	4.42	1.24e-05	0.00125	0.41	0.2	Migraine;	chr8:30200997	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs16876663	ENSG00000248159.1	HSPA8P11	4.42	1.24e-05	0.00125	0.41	0.2	Migraine;	chr8:30202182	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs73234780	ENSG00000248159.1	HSPA8P11	4.42	1.24e-05	0.00125	0.41	0.2	Migraine;	chr8:30202239	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs73234781	ENSG00000248159.1	HSPA8P11	4.42	1.24e-05	0.00125	0.41	0.2	Migraine;	chr8:30202242	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs7001629	ENSG00000248159.1	HSPA8P11	4.42	1.24e-05	0.00125	0.41	0.2	Migraine;	chr8:30203273	chr8:30237382~30240997:+
THCA	cis	rs73108077	0.736	rs6060993	ENSG00000277112.2	RP11-755J8.1	-4.42	1.24e-05	0.00125	-0.33	-0.2	Red blood cell density in sickle cell anemia;	chr20:31278917	chr20:30681825~30723932:-
THCA	cis	rs6487679	0.543	rs7979115	ENSG00000111788.10	RP11-22B23.1	4.42	1.24e-05	0.00125	0.33	0.2	Non-alcoholic fatty liver disease histology (AST);	chr12:9212684	chr12:9277235~9313241:+
THCA	cis	rs481331	0.866	rs1889310	ENSG00000215146.4	RP11-313J2.1	4.42	1.24e-05	0.00125	0.31	0.2	Systemic juvenile idiopathic arthritis;	chr10:42486247	chr10:42331866~42367974:-
THCA	cis	rs3770081	1	rs79767540	ENSG00000272564.1	RP11-548P2.2	-4.42	1.24e-05	0.00125	-0.36	-0.2	Facial emotion recognition (sad faces);	chr2:85885539	chr2:85904279~85904727:+
THCA	cis	rs889398	0.741	rs7193038	ENSG00000226232.7	RP11-419C5.2	-4.42	1.24e-05	0.00125	-0.2	-0.2	Body mass index;	chr16:69892231	chr16:69976388~69996188:-
THCA	cis	rs889398	0.741	rs7192213	ENSG00000226232.7	RP11-419C5.2	-4.42	1.24e-05	0.00125	-0.2	-0.2	Body mass index;	chr16:69892377	chr16:69976388~69996188:-
THCA	cis	rs613391	0.561	rs575588	ENSG00000234840.1	LINC01239	4.42	1.24e-05	0.00125	0.23	0.2	Quantitative traits;	chr9:22717306	chr9:22646200~22824213:+
THCA	cis	rs790006	1	rs790006	ENSG00000243024.5	RPS11P6	4.42	1.24e-05	0.00125	0.23	0.2	Response to cytidine analogues (gemcitabine);	chr12:64212659	chr12:64222337~64397065:+
THCA	cis	rs9959145	1	rs28821540	ENSG00000267108.1	RP11-861E21.1	4.42	1.25e-05	0.00125	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12558309	chr18:12432897~12437635:+
THCA	cis	rs801193	0.904	rs4718405	ENSG00000275400.1	RP4-756H11.5	-4.42	1.25e-05	0.00125	-0.19	-0.2	Aortic root size;	chr7:66789659	chr7:66553805~66554199:-
THCA	cis	rs656319	0.647	rs13264668	ENSG00000248538.5	RP11-10A14.5	4.42	1.25e-05	0.00125	0.26	0.2	Myopia (pathological);	chr8:10027367	chr8:9189011~9202854:+
THCA	cis	rs12612619	0.704	rs3769139	ENSG00000272148.1	RP11-195B17.1	4.42	1.25e-05	0.00125	0.19	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092846	chr2:27062428~27062907:-
THCA	cis	rs17772222	0.682	rs28711639	ENSG00000222990.1	RNU4-22P	4.42	1.25e-05	0.00125	0.24	0.2	Coronary artery calcification;	chr14:88482277	chr14:88513498~88513663:+
THCA	cis	rs2386661	0.523	rs2386663	ENSG00000231483.1	RP11-336A10.5	4.42	1.25e-05	0.00125	0.2	0.2	Breast cancer;	chr10:5610776	chr10:5608475~5610793:-
THCA	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	4.42	1.25e-05	0.00125	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
THCA	cis	rs7267979	1	rs2500424	ENSG00000274973.1	RP13-401N8.7	4.42	1.25e-05	0.00125	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25845497~25845862:+
THCA	cis	rs875971	0.66	rs7807930	ENSG00000229886.1	RP5-1132H15.3	-4.42	1.25e-05	0.00125	-0.2	-0.2	Aortic root size;	chr7:66622178	chr7:66025126~66031544:-
THCA	cis	rs1003719	0.679	rs2835674	ENSG00000230366.8	DSCR9	4.42	1.25e-05	0.00125	0.21	0.2	Eye color traits;	chr21:37209221	chr21:37208503~37221736:+
THCA	cis	rs709400	0.894	rs61996721	ENSG00000258735.1	LINC00637	4.42	1.25e-05	0.00125	0.26	0.2	Body mass index;	chr14:103595015	chr14:103847721~103858049:+
THCA	cis	rs4763879	0.634	rs11052582	ENSG00000256673.1	RP11-599J14.2	4.42	1.25e-05	0.00125	0.24	0.2	Type 1 diabetes;	chr12:9706714	chr12:9398355~9414851:-
THCA	cis	rs8017455	0.523	rs6574625	ENSG00000259167.2	NMNAT1P1	4.42	1.25e-05	0.00125	0.31	0.2	Hair morphology;	chr14:81083189	chr14:81032529~81033404:+
THCA	cis	rs4715166	0.775	rs4715156	ENSG00000272379.1	RP1-257A7.5	4.42	1.25e-05	0.00125	0.26	0.2	Hip geometry;	chr6:13210698	chr6:13290018~13290490:-
THCA	cis	rs11758351	0.66	rs1997768	ENSG00000216331.1	HIST1H1PS1	-4.42	1.25e-05	0.00125	-0.32	-0.2	Renal underexcretion gout;Gout;	chr6:26217500	chr6:26195566~26195771:+
THCA	cis	rs375066	0.551	rs2099356	ENSG00000267058.1	RP11-15A1.3	4.42	1.25e-05	0.00125	0.18	0.2	Breast cancer;	chr19:43811044	chr19:43891804~43901805:-
THCA	cis	rs9283706	0.608	rs1991492	ENSG00000229666.1	MAST4-AS1	-4.42	1.25e-05	0.00125	-0.28	-0.2	Coronary artery disease;	chr5:67032481	chr5:67001383~67003953:-
THCA	cis	rs9283706	0.562	rs10471697	ENSG00000229666.1	MAST4-AS1	-4.42	1.25e-05	0.00125	-0.28	-0.2	Coronary artery disease;	chr5:67032727	chr5:67001383~67003953:-
THCA	cis	rs11633886	0.934	rs4774765	ENSG00000273972.1	CTD-2306A12.1	-4.42	1.25e-05	0.00125	-0.22	-0.2	Diisocyanate-induced asthma;	chr15:45796659	chr15:45702640~45703183:+
THCA	cis	rs7045881	0.8	rs7036055	ENSG00000254396.1	RP11-56F10.3	4.42	1.25e-05	0.00125	0.36	0.2	Schizophrenia;	chr9:26845128	chr9:27102630~27104728:+
THCA	cis	rs79243044	0.695	rs7945471	ENSG00000224295.2	AC087380.14	-4.42	1.25e-05	0.00125	-0.2	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5522573	chr11:5518441~5524955:-
THCA	cis	rs10911902	0.643	rs75008037	ENSG00000229739.2	RP11-295K2.3	-4.42	1.25e-05	0.00125	-0.32	-0.2	Schizophrenia;	chr1:186371380	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs76554103	ENSG00000229739.2	RP11-295K2.3	-4.42	1.25e-05	0.00125	-0.32	-0.2	Schizophrenia;	chr1:186371402	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs7514615	ENSG00000229739.2	RP11-295K2.3	-4.42	1.25e-05	0.00125	-0.32	-0.2	Schizophrenia;	chr1:186373191	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs6425027	ENSG00000229739.2	RP11-295K2.3	-4.42	1.25e-05	0.00125	-0.32	-0.2	Schizophrenia;	chr1:186376034	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs6425028	ENSG00000229739.2	RP11-295K2.3	-4.42	1.25e-05	0.00125	-0.32	-0.2	Schizophrenia;	chr1:186376149	chr1:186435161~186470291:+
THCA	cis	rs4767841	0.806	rs1122119	ENSG00000248636.5	RP11-768F21.1	-4.42	1.25e-05	0.00125	-0.21	-0.2	Urgency urinary incontinence;	chr12:119748903	chr12:119387987~119668079:-
THCA	cis	rs10860794	1	rs4764824	ENSG00000274560.1	RP11-285E23.2	-4.42	1.25e-05	0.00125	-0.13	-0.2	Blood protein levels;	chr12:101826225	chr12:101696002~101696450:-
THCA	cis	rs10860794	1	rs7964859	ENSG00000274560.1	RP11-285E23.2	-4.42	1.25e-05	0.00125	-0.13	-0.2	Blood protein levels;	chr12:101827005	chr12:101696002~101696450:-
THCA	cis	rs10860794	1	rs10128856	ENSG00000274560.1	RP11-285E23.2	-4.42	1.25e-05	0.00125	-0.13	-0.2	Blood protein levels;	chr12:101827259	chr12:101696002~101696450:-
THCA	cis	rs11096990	0.855	rs2566184	ENSG00000249685.1	RP11-360F5.3	-4.42	1.25e-05	0.00125	-0.26	-0.2	Cognitive function;	chr4:39162700	chr4:39133913~39135608:+
THCA	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	4.42	1.25e-05	0.00125	0.24	0.2	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
THCA	cis	rs897984	0.568	rs4889653	ENSG00000279196.1	RP11-1072A3.3	-4.42	1.25e-05	0.00125	-0.22	-0.2	Dementia with Lewy bodies;	chr16:30884392	chr16:30984630~30988270:-
THCA	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	4.42	1.25e-05	0.00125	0.22	0.2	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
THCA	cis	rs17095355	1	rs6584962	ENSG00000203876.8	ADD3-AS1	-4.42	1.25e-05	0.00125	-0.22	-0.2	Biliary atresia;	chr10:109930146	chr10:109940104~110008381:-
THCA	cis	rs875971	0.545	rs73376401	ENSG00000273142.1	RP11-458F8.4	4.42	1.25e-05	0.00125	0.18	0.2	Aortic root size;	chr7:66174841	chr7:66902857~66906297:+
THCA	cis	rs6088813	1	rs1540927	ENSG00000279253.1	RP4-614O4.13	4.42	1.25e-05	0.00125	0.2	0.2	Height;	chr20:35343541	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.922	rs6088800	ENSG00000279253.1	RP4-614O4.13	4.42	1.25e-05	0.00125	0.2	0.2	Height;	chr20:35346634	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.961	rs745931	ENSG00000279253.1	RP4-614O4.13	4.42	1.25e-05	0.00125	0.2	0.2	Height;	chr20:35368201	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs2425066	ENSG00000279253.1	RP4-614O4.13	-4.42	1.25e-05	0.00125	-0.2	-0.2	Height;	chr20:35339203	chr20:35262727~35264187:-
THCA	cis	rs453301	0.686	rs3989373	ENSG00000233609.3	RP11-62H7.2	-4.42	1.25e-05	0.00125	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9053798	chr8:8961200~8979025:+
THCA	cis	rs62025270	0.547	rs8035496	ENSG00000202081.1	RNU6-1280P	-4.42	1.25e-05	0.00125	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85651522~85651628:-
THCA	cis	rs7959452	0.64	rs12370042	ENSG00000274979.1	RP11-1143G9.5	-4.42	1.25e-05	0.00125	-0.21	-0.2	Blood protein levels;	chr12:69298640	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.605	rs12819406	ENSG00000274979.1	RP11-1143G9.5	-4.42	1.25e-05	0.00125	-0.21	-0.2	Blood protein levels;	chr12:69302620	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.64	rs4274230	ENSG00000274979.1	RP11-1143G9.5	-4.42	1.25e-05	0.00125	-0.21	-0.2	Blood protein levels;	chr12:69306992	chr12:69326574~69331882:-
THCA	cis	rs1334894	0.584	rs1883636	ENSG00000228559.1	RP3-340B19.3	-4.42	1.25e-05	0.00125	-0.31	-0.2	Coronary artery disease;	chr6:35500882	chr6:35544632~35545669:+
THCA	cis	rs4950322	0.57	rs17160051	ENSG00000180867.10	PDIA3P1	4.42	1.25e-05	0.00125	0.2	0.2	Protein quantitative trait loci;	chr1:147255733	chr1:147178113~147179622:+
THCA	cis	rs3002131	0.562	rs2173401	ENSG00000272750.1	RP11-378J18.8	4.42	1.25e-05	0.00125	0.31	0.2	Interleukin-10 levels;	chr1:222575992	chr1:222658867~222661512:-
THCA	cis	rs3002131	0.604	rs3008644	ENSG00000272750.1	RP11-378J18.8	4.42	1.25e-05	0.00125	0.31	0.2	Interleukin-10 levels;	chr1:222577402	chr1:222658867~222661512:-
THCA	cis	rs722599	0.715	rs2080086	ENSG00000279594.1	RP11-950C14.10	-4.42	1.25e-05	0.00125	-0.2	-0.2	IgG glycosylation;	chr14:74871705	chr14:75011269~75012851:-
THCA	cis	rs9818758	0.556	rs9813813	ENSG00000270441.1	RP11-694I15.7	4.42	1.25e-05	0.00125	0.29	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49169660	chr3:49140086~49160851:-
THCA	cis	rs12681963	0.688	rs7817838	ENSG00000248159.1	HSPA8P11	4.42	1.25e-05	0.00125	0.38	0.2	Migraine;	chr8:30205298	chr8:30237382~30240997:+
THCA	cis	rs3740713	1	rs73440625	ENSG00000256464.1	YWHABP2	4.42	1.25e-05	0.00125	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr11:18490243~18490955:-
THCA	cis	rs17092148	0.636	rs6058107	ENSG00000276073.1	RP5-1125A11.7	-4.42	1.25e-05	0.00125	-0.22	-0.2	Neuroticism;	chr20:34700742	chr20:33985617~33988989:-
THCA	cis	rs863750	0.507	rs10846601	ENSG00000275389.1	RP11-214K3.24	4.42	1.25e-05	0.00125	0.46	0.2	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124100606	chr12:124085761~124088598:+
THCA	cis	rs10744955	0.727	rs12913072	ENSG00000244879.4	GABPB1-AS1	-4.42	1.25e-05	0.00125	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50159293	chr15:50354959~50372202:+
THCA	cis	rs899997	0.773	rs12595461	ENSG00000261143.1	ADAMTS7P3	-4.42	1.25e-05	0.00126	-0.3	-0.2	Coronary artery disease or large artery stroke;	chr15:78676830	chr15:77976042~77993057:+
THCA	cis	rs7615952	0.736	rs13063122	ENSG00000248787.1	RP11-666A20.4	-4.42	1.25e-05	0.00126	-0.34	-0.2	Blood pressure (smoking interaction);	chr3:125925017	chr3:125908005~125910272:-
THCA	cis	rs7646881	0.544	rs16829273	ENSG00000240207.5	RP11-379F4.4	4.42	1.25e-05	0.00126	0.27	0.2	Tetralogy of Fallot;	chr3:158664831	chr3:158732263~158784070:+
THCA	cis	rs11088226	0.681	rs1015048	ENSG00000186842.4	LINC00846	-4.42	1.25e-05	0.00126	-0.29	-0.2	Gastritis;	chr21:32576996	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.681	rs9622	ENSG00000186842.4	LINC00846	-4.42	1.25e-05	0.00126	-0.29	-0.2	Gastritis;	chr21:32578758	chr21:32572238~32575881:-
THCA	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-4.42	1.25e-05	0.00126	-0.24	-0.2	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
THCA	cis	rs11621975	0.57	rs61993991	ENSG00000259088.1	CTD-2017C7.2	-4.42	1.25e-05	0.00126	-0.4	-0.2	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101781060	chr14:101796555~101810321:-
THCA	cis	rs2253762	0.54	rs7358186	ENSG00000226864.1	ATE1-AS1	4.41	1.25e-05	0.00126	0.32	0.2	Breast cancer;	chr10:122000816	chr10:121928312~121951965:+
THCA	cis	rs2243480	1	rs316331	ENSG00000164669.11	INTS4P1	-4.41	1.25e-05	0.00126	-0.38	-0.2	Diabetic kidney disease;	chr7:66139635	chr7:65141225~65234216:+
THCA	cis	rs7474896	0.526	rs1208633	ENSG00000120555.12	SEPT7P9	-4.41	1.25e-05	0.00126	-0.26	-0.2	Obesity (extreme);	chr10:37867945	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.559	rs1779075	ENSG00000120555.12	SEPT7P9	-4.41	1.25e-05	0.00126	-0.26	-0.2	Obesity (extreme);	chr10:37878602	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.559	rs2753880	ENSG00000120555.12	SEPT7P9	-4.41	1.25e-05	0.00126	-0.26	-0.2	Obesity (extreme);	chr10:37884410	chr10:38383069~38402916:-
THCA	cis	rs6449502	0.764	rs13153359	ENSG00000251279.1	CTC-436P18.1	4.41	1.25e-05	0.00126	0.33	0.2	Mean platelet volume;	chr5:60749420	chr5:61162070~61232040:+
THCA	cis	rs4915077	0.803	rs79748332	ENSG00000230489.1	VAV3-AS1	4.41	1.25e-05	0.00126	0.3	0.2	Hypothyroidism;	chr1:107754654	chr1:107964443~107994607:+
THCA	cis	rs9283706	0.608	rs1428407	ENSG00000229666.1	MAST4-AS1	-4.41	1.25e-05	0.00126	-0.29	-0.2	Coronary artery disease;	chr5:67034588	chr5:67001383~67003953:-
THCA	cis	rs875971	0.545	rs316316	ENSG00000273142.1	RP11-458F8.4	-4.41	1.26e-05	0.00126	-0.18	-0.2	Aortic root size;	chr7:66149270	chr7:66902857~66906297:+
THCA	cis	rs748404	0.601	rs502157	ENSG00000166763.7	STRCP1	-4.41	1.26e-05	0.00126	-0.21	-0.2	Lung cancer;	chr15:43236375	chr15:43699488~43718184:-
THCA	cis	rs875971	0.66	rs10229345	ENSG00000272831.1	RP11-792A8.4	4.41	1.26e-05	0.00126	0.13	0.2	Aortic root size;	chr7:66517181	chr7:66739829~66740385:-
THCA	cis	rs7474896	0.778	rs11011354	ENSG00000263064.2	RP11-291L22.7	4.41	1.26e-05	0.00126	0.35	0.2	Obesity (extreme);	chr10:37758955	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.832	rs12359608	ENSG00000263064.2	RP11-291L22.7	4.41	1.26e-05	0.00126	0.35	0.2	Obesity (extreme);	chr10:37789268	chr10:38448689~38448949:+
THCA	cis	rs7312933	0.618	rs7315968	ENSG00000257225.1	RP11-328C8.4	-4.41	1.26e-05	0.00126	-0.21	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42243284	chr12:42459366~42466128:+
THCA	cis	rs3734266	0.702	rs7775947	ENSG00000272288.4	RP11-140K17.3	-4.41	1.26e-05	0.00126	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34747380	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs7776439	ENSG00000272288.4	RP11-140K17.3	-4.41	1.26e-05	0.00126	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34747671	chr6:34696317~34697470:+
THCA	cis	rs11030122	1	rs4414209	ENSG00000230593.3	AC090804.1	-4.41	1.26e-05	0.00126	-0.26	-0.2	Mean platelet volume;Platelet distribution width;	chr11:3864281	chr11:3892398~3892887:-
THCA	cis	rs12497850	0.829	rs8926	ENSG00000228638.1	FCF1P2	-4.41	1.26e-05	0.00126	-0.21	-0.2	Parkinson's disease;	chr3:49015352	chr3:48290793~48291375:-
THCA	cis	rs6088590	0.561	rs6088528	ENSG00000276073.1	RP5-1125A11.7	-4.41	1.26e-05	0.00126	-0.17	-0.2	Coronary artery disease;	chr20:34568938	chr20:33985617~33988989:-
THCA	cis	rs61270009	0.955	rs2305104	ENSG00000247828.6	TMEM161B-AS1	-4.41	1.26e-05	0.00126	-0.17	-0.2	Depressive symptoms;	chr5:88324853	chr5:88268895~88436685:+
THCA	cis	rs7179456	0.557	rs446126	ENSG00000245975.2	RP11-30K9.6	4.41	1.26e-05	0.00126	0.19	0.2	Asperger disorder;	chr15:58820903	chr15:58768072~58770974:-
THCA	cis	rs2554380	0.628	rs919069	ENSG00000176700.18	SCAND2P	-4.41	1.26e-05	0.00126	-0.15	-0.2	Height;	chr15:83775776	chr15:84631451~84647478:+
THCA	cis	rs2905347	0.964	rs2961270	ENSG00000232949.1	AC002480.4	-4.41	1.26e-05	0.00126	-0.25	-0.2	Major depression and alcohol dependence;	chr7:22582519	chr7:22589705~22591622:+
THCA	cis	rs11148252	0.904	rs9536079	ENSG00000273784.3	RP11-78J21.7	-4.41	1.26e-05	0.00126	-0.21	-0.2	Lewy body disease;	chr13:52456430	chr13:52600042~52642542:+
THCA	cis	rs9516	1	rs2367995	ENSG00000254974.1	RP11-702H23.2	-4.41	1.26e-05	0.00126	-0.22	-0.2	Facial morphology (factor 15, philtrum width);	chr11:74452791	chr11:74485580~74486051:-
THCA	cis	rs9816784	0.525	rs714602	ENSG00000273009.1	RP11-352G9.1	-4.41	1.26e-05	0.00126	-0.23	-0.2	Mean corpuscular hemoglobin;	chr3:196067108	chr3:195913078~195913683:-
THCA	cis	rs9987353	0.519	rs11779181	ENSG00000248538.5	RP11-10A14.5	-4.41	1.26e-05	0.00126	-0.25	-0.2	Recombination measurement;	chr8:9205517	chr8:9189011~9202854:+
THCA	cis	rs2524005	1	rs2524005	ENSG00000235963.1	MCCD1P1	-4.41	1.26e-05	0.00126	-0.29	-0.2	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29907783~29908645:-
THCA	cis	rs7474896	0.559	rs10740949	ENSG00000226578.1	RP11-258F22.1	-4.41	1.26e-05	0.00126	-0.28	-0.2	Obesity (extreme);	chr10:37689507	chr10:37775371~37784131:-
THCA	cis	rs4803480	0.578	rs7252454	ENSG00000267107.5	PCAT19	4.41	1.26e-05	0.00126	0.23	0.2	Schizophrenia;	chr19:41527343	chr19:41454169~41500649:-
THCA	cis	rs4906332	0.899	rs12888042	ENSG00000269910.1	RP11-73M18.10	4.41	1.26e-05	0.00126	0.17	0.2	Coronary artery disease;	chr14:103425372	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs17617094	ENSG00000269910.1	RP11-73M18.10	4.41	1.26e-05	0.00126	0.17	0.2	Coronary artery disease;	chr14:103427091	chr14:103694516~103695050:-
THCA	cis	rs10904908	0.829	rs359282	ENSG00000229124.5	VIM-AS1	4.41	1.26e-05	0.00126	0.19	0.2	Cholesterol, total;Total cholesterol levels;	chr10:17283282	chr10:17214239~17229985:-
THCA	cis	rs17685	0.712	rs11770149	ENSG00000230882.1	AC005077.14	4.41	1.26e-05	0.00126	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76162326	chr7:76071469~76074963:-
THCA	cis	rs12554020	0.582	rs7038293	ENSG00000227603.1	RP11-165J3.6	4.41	1.26e-05	0.00126	0.41	0.2	Schizophrenia;	chr9:93646314	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs75018698	ENSG00000227603.1	RP11-165J3.6	4.41	1.26e-05	0.00126	0.41	0.2	Schizophrenia;	chr9:93647025	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.582	rs79049472	ENSG00000227603.1	RP11-165J3.6	4.41	1.26e-05	0.00126	0.41	0.2	Schizophrenia;	chr9:93647116	chr9:93435332~93437121:-
THCA	cis	rs2153535	0.536	rs78180822	ENSG00000230939.1	RP11-314C16.1	-4.41	1.26e-05	0.00126	-0.21	-0.2	Motion sickness;	chr6:8620941	chr6:8784178~8785445:+
THCA	cis	rs6432852	0.725	rs7564041	ENSG00000232411.1	AC009495.3	4.41	1.26e-05	0.00126	0.22	0.2	Diabetic kidney disease;	chr2:165878423	chr2:165833048~165839098:-
THCA	cis	rs890448	1	rs7695728	ENSG00000254531.1	FLJ20021	-4.41	1.26e-05	0.00126	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101513280	chr4:101347780~101348883:+
THCA	cis	rs2070488	0.965	rs6796845	ENSG00000229589.1	ACVR2B-AS1	-4.41	1.26e-05	0.00126	-0.18	-0.2	Electrocardiographic conduction measures;	chr3:38526280	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.965	rs3762791	ENSG00000229589.1	ACVR2B-AS1	-4.41	1.26e-05	0.00126	-0.18	-0.2	Electrocardiographic conduction measures;	chr3:38527337	chr3:38451027~38454820:-
THCA	cis	rs7560272	0.501	rs17350188	ENSG00000273245.1	RP11-434P11.2	4.41	1.26e-05	0.00126	0.23	0.2	Schizophrenia;	chr2:73737715	chr2:73750256~73750786:-
THCA	cis	rs8006682	0.541	rs17756615	ENSG00000259038.1	CTD-2325P2.4	4.41	1.26e-05	0.00126	0.25	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68623048	chr14:68627166~68628445:-
THCA	cis	rs8006682	0.541	rs12890235	ENSG00000259038.1	CTD-2325P2.4	4.41	1.26e-05	0.00126	0.25	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68623186	chr14:68627166~68628445:-
THCA	cis	rs752010	0.714	rs2148635	ENSG00000230638.4	RP11-486B10.4	4.41	1.26e-05	0.00126	0.21	0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41616781	chr1:41542069~41544310:+
THCA	cis	rs752010	0.714	rs2182606	ENSG00000230638.4	RP11-486B10.4	-4.41	1.26e-05	0.00126	-0.21	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41616704	chr1:41542069~41544310:+
THCA	cis	rs752010	0.714	rs6664708	ENSG00000230638.4	RP11-486B10.4	-4.41	1.26e-05	0.00126	-0.21	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41617399	chr1:41542069~41544310:+
THCA	cis	rs1003719	0.591	rs2835633	ENSG00000230366.8	DSCR9	4.41	1.26e-05	0.00126	0.2	0.2	Eye color traits;	chr21:37152719	chr21:37208503~37221736:+
THCA	cis	rs4925386	1	rs2151512	ENSG00000275437.1	RP5-908M14.10	-4.41	1.26e-05	0.00126	-0.19	-0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338439	chr20:62402236~62405935:-
THCA	cis	rs13256369	1	rs10088439	ENSG00000254153.1	CTA-398F10.2	-4.41	1.26e-05	0.00126	-0.22	-0.2	Obesity-related traits;	chr8:8719189	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs9329165	ENSG00000254153.1	CTA-398F10.2	4.41	1.26e-05	0.00126	0.22	0.2	Obesity-related traits;	chr8:8719132	chr8:8456909~8461337:-
THCA	cis	rs10129255	0.517	rs11625572	ENSG00000280411.1	IGHV1-69-2	-4.41	1.26e-05	0.00126	-0.13	-0.2	Kawasaki disease;	chr14:106656426	chr14:106762092~106762588:-
THCA	cis	rs7829975	0.514	rs2976926	ENSG00000233609.3	RP11-62H7.2	4.41	1.26e-05	0.00126	0.19	0.2	Mood instability;	chr8:8404114	chr8:8961200~8979025:+
THCA	cis	rs8046148	0.724	rs2058815	ENSG00000279356.1	RP11-429P3.8	4.41	1.26e-05	0.00126	0.24	0.2	Testicular germ cell tumor;	chr16:50024308	chr16:50072862~50074986:+
THCA	cis	rs4639966	0.756	rs61219050	ENSG00000255422.1	AP002954.4	4.41	1.26e-05	0.00126	0.24	0.2	Systemic lupus erythematosus;	chr11:118777915	chr11:118704607~118750263:+
THCA	cis	rs8177876	0.642	rs56375210	ENSG00000261061.1	RP11-303E16.2	-4.41	1.26e-05	0.00126	-0.38	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81110070	chr16:81030770~81031485:+
THCA	cis	rs34034104	0.501	rs16970660	ENSG00000223313.1	RNU6-516P	4.41	1.26e-05	0.00126	0.32	0.2	Itch intensity from mosquito bite;Itch intensity from mosquito bite adjusted by bite size;	chr15:40408568	chr15:40529570~40529673:+
THCA	cis	rs61270009	0.955	rs10514300	ENSG00000247828.6	TMEM161B-AS1	4.41	1.26e-05	0.00126	0.18	0.2	Depressive symptoms;	chr5:88409465	chr5:88268895~88436685:+
THCA	cis	rs9902453	0.904	rs7213076	ENSG00000263370.1	RP11-68I3.5	-4.41	1.26e-05	0.00126	-0.25	-0.2	Coffee consumption (cups per day);	chr17:30092410	chr17:29639627~29640825:+
THCA	cis	rs1876905	0.597	rs354551	ENSG00000272356.1	RP5-1112D6.8	-4.41	1.26e-05	0.00126	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111309203~111313517:+
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000273024.4	INTS4P2	-4.41	1.26e-05	0.00126	-0.22	-0.2	Calcium levels;	chr7:65751755	chr7:65647864~65715661:+
THCA	cis	rs12439619	1	rs35152457	ENSG00000276710.3	CSPG4P8	-4.41	1.26e-05	0.00126	-0.21	-0.2	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82459472~82477258:+
THCA	cis	rs12435908	1	rs11850163	ENSG00000276116.2	FUT8-AS1	-4.41	1.26e-05	0.00126	-0.31	-0.2	Ischemic stroke;	chr14:65381427	chr14:65411170~65412690:-
THCA	cis	rs12435908	1	rs58602070	ENSG00000276116.2	FUT8-AS1	-4.41	1.26e-05	0.00126	-0.31	-0.2	Ischemic stroke;	chr14:65382524	chr14:65411170~65412690:-
THCA	cis	rs7264396	0.943	rs224431	ENSG00000088340.14	FER1L4	4.41	1.26e-05	0.00127	0.19	0.2	Total cholesterol levels;	chr20:35565683	chr20:35558737~35607562:-
THCA	cis	rs7264396	1	rs224435	ENSG00000088340.14	FER1L4	4.41	1.26e-05	0.00127	0.19	0.2	Total cholesterol levels;	chr20:35566170	chr20:35558737~35607562:-
THCA	cis	rs7264396	1	rs224436	ENSG00000088340.14	FER1L4	4.41	1.26e-05	0.00127	0.19	0.2	Total cholesterol levels;	chr20:35566207	chr20:35558737~35607562:-
THCA	cis	rs12534093	0.772	rs34776209	ENSG00000234286.1	AC006026.13	-4.41	1.26e-05	0.00127	-0.31	-0.2	Infant length;Height;	chr7:23473474	chr7:23680195~23680786:-
THCA	cis	rs6787172	0.782	rs6780782	ENSG00000272087.1	RP11-379F4.7	4.41	1.26e-05	0.00127	0.18	0.2	Subjective well-being;	chr3:158468546	chr3:158693120~158693768:-
THCA	cis	rs953301	0.793	rs1394065	ENSG00000229808.1	RP11-456P18.2	4.41	1.26e-05	0.00127	0.52	0.2	Left atrial antero-posterior diameter;	chr1:161861106	chr1:161890833~161892196:+
THCA	cis	rs17270561	0.609	rs9358886	ENSG00000272462.2	U91328.19	-4.41	1.26e-05	0.00127	-0.17	-0.2	Iron status biomarkers;	chr6:25758025	chr6:25992662~26001775:+
THCA	cis	rs2836974	0.623	rs34240248	ENSG00000255568.3	BRWD1-AS2	-4.41	1.26e-05	0.00127	-0.16	-0.2	Cognitive function;	chr21:39313313	chr21:39313935~39314962:+
THCA	cis	rs4713118	0.662	rs149970	ENSG00000219891.2	ZSCAN12P1	4.41	1.27e-05	0.00127	0.26	0.2	Parkinson's disease;	chr6:28012442	chr6:28091154~28093664:+
THCA	cis	rs57221529	0.766	rs56278696	ENSG00000225138.6	CTD-2228K2.7	4.41	1.27e-05	0.00127	0.25	0.2	Lung disease severity in cystic fibrosis;	chr5:582554	chr5:473236~480884:+
THCA	cis	rs12962334	0.518	rs4800141	ENSG00000265939.1	UBE2CP2	4.41	1.27e-05	0.00127	0.22	0.2	Breast cancer;	chr18:22984312	chr18:22900486~22900995:-
THCA	cis	rs2797160	0.547	rs4144549	ENSG00000237742.5	RP11-624M8.1	4.41	1.27e-05	0.00127	0.19	0.2	Endometrial cancer;	chr6:125624105	chr6:125578558~125749190:-
THCA	cis	rs6442522	0.898	rs2219251	ENSG00000249786.6	EAF1-AS1	4.41	1.27e-05	0.00127	0.21	0.2	Uric acid levels;	chr3:15387661	chr3:15436171~15455940:-
THCA	cis	rs6442522	1	rs11918807	ENSG00000249786.6	EAF1-AS1	4.41	1.27e-05	0.00127	0.21	0.2	Uric acid levels;	chr3:15404770	chr3:15436171~15455940:-
THCA	cis	rs6012953	0.65	rs13045716	ENSG00000231715.1	COX6CP2	-4.41	1.27e-05	0.00127	-0.21	-0.2	Vitiligo;	chr20:50545704	chr20:50479767~50479991:+
THCA	cis	rs7772486	0.79	rs2249386	ENSG00000270638.1	RP3-466P17.1	4.41	1.27e-05	0.00127	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145735570~145737218:+
THCA	cis	rs2439831	0.867	rs935901	ENSG00000205771.5	CATSPER2P1	-4.41	1.27e-05	0.00127	-0.3	-0.2	Lung cancer in ever smokers;	chr15:43359058	chr15:43726918~43747094:-
THCA	cis	rs12936587	0.583	rs9783803	ENSG00000223979.2	SMCR2	4.41	1.27e-05	0.00127	0.21	0.2	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17649583	chr17:17674026~17677688:-
THCA	cis	rs6442522	1	rs6442522	ENSG00000249786.6	EAF1-AS1	4.41	1.27e-05	0.00127	0.21	0.2	Uric acid levels;	chr3:15399049	chr3:15436171~15455940:-
THCA	cis	rs11148252	0.904	rs3892337	ENSG00000273784.3	RP11-78J21.7	-4.41	1.27e-05	0.00127	-0.21	-0.2	Lewy body disease;	chr13:52455350	chr13:52600042~52642542:+
THCA	cis	rs10043228	1	rs62384189	ENSG00000248445.4	SEMA6A-AS1	-4.41	1.27e-05	0.00127	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116174694	chr5:116447547~116508276:+
THCA	cis	rs12681963	0.688	rs7009988	ENSG00000248159.1	HSPA8P11	4.41	1.27e-05	0.00127	0.36	0.2	Migraine;	chr8:30224947	chr8:30237382~30240997:+
THCA	cis	rs9880211	0.898	rs34031772	ENSG00000239213.4	NCK1-AS1	4.41	1.27e-05	0.00127	0.22	0.2	Height;Body mass index;	chr3:136299299	chr3:136841726~136862054:-
THCA	cis	rs11633886	0.656	rs11635738	ENSG00000273972.1	CTD-2306A12.1	-4.41	1.27e-05	0.00127	-0.23	-0.2	Diisocyanate-induced asthma;	chr15:45832805	chr15:45702640~45703183:+
THCA	cis	rs5758511	0.68	rs5758682	ENSG00000227370.1	RP4-669P10.19	4.41	1.27e-05	0.00127	0.23	0.2	Birth weight;	chr22:42249196	chr22:42132543~42132998:+
THCA	cis	rs5758511	0.68	rs34107327	ENSG00000227370.1	RP4-669P10.19	4.41	1.27e-05	0.00127	0.23	0.2	Birth weight;	chr22:42252347	chr22:42132543~42132998:+
THCA	cis	rs5758511	0.68	rs5758684	ENSG00000227370.1	RP4-669P10.19	4.41	1.27e-05	0.00127	0.23	0.2	Birth weight;	chr22:42253503	chr22:42132543~42132998:+
THCA	cis	rs6787172	0.811	rs1595030	ENSG00000272087.1	RP11-379F4.7	4.41	1.27e-05	0.00127	0.18	0.2	Subjective well-being;	chr3:158475878	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.811	rs6441203	ENSG00000272087.1	RP11-379F4.7	4.41	1.27e-05	0.00127	0.18	0.2	Subjective well-being;	chr3:158476351	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.811	rs11714821	ENSG00000272087.1	RP11-379F4.7	4.41	1.27e-05	0.00127	0.18	0.2	Subjective well-being;	chr3:158476896	chr3:158693120~158693768:-
THCA	cis	rs1124769	0.692	rs1147137	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50889686	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs2619689	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50892386	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs2619690	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50894018	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs1147134	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50896339	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs2663542	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50899224	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs1147132	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50900036	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs2663540	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50901062	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs1135397	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50907567	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs2614788	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50908084	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs2663531	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50912552	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs936482	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50918444	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs7170310	ENSG00000259378.1	DCAF13P3	-4.41	1.27e-05	0.00127	-0.3	-0.2	Cognitive performance;	chr15:50918934	chr15:50944663~50945996:+
THCA	cis	rs4742903	0.967	rs2274725	ENSG00000270332.1	SMC2-AS1	4.41	1.27e-05	0.00127	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104102289	chr9:104080024~104093073:-
THCA	cis	rs61160187	0.582	rs4647150	ENSG00000215032.2	GNL3LP1	4.41	1.27e-05	0.00127	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60891935~60893577:-
THCA	cis	rs375066	0.901	rs1050054	ENSG00000278917.1	RP11-15A1.4	-4.41	1.27e-05	0.00127	-0.16	-0.2	Breast cancer;	chr19:43872529	chr19:43891233~43895411:+
THCA	cis	rs9876781	1	rs13071337	ENSG00000244380.1	RP11-24C3.2	4.41	1.27e-05	0.00127	0.23	0.2	Longevity;	chr3:48396724	chr3:48440352~48446656:-
THCA	cis	rs116248771	0.739	rs16829122	ENSG00000271778.1	RP11-379F4.8	4.41	1.27e-05	0.00127	0.26	0.2	diarrhoeal disease at age 2;	chr3:158594878	chr3:158782547~158783124:+
THCA	cis	rs919433	0.617	rs700645	ENSG00000231621.1	AC013264.2	-4.41	1.27e-05	0.00127	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197740790	chr2:197197991~197199273:+
THCA	cis	rs4664293	0.718	rs4477859	ENSG00000230783.1	AC009961.2	4.41	1.27e-05	0.00127	0.25	0.2	Monocyte percentage of white cells;	chr2:159738616	chr2:159689217~159690291:-
THCA	cis	rs4742903	0.967	rs7048372	ENSG00000270332.1	SMC2-AS1	4.41	1.27e-05	0.00127	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104097457	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.967	rs10512325	ENSG00000270332.1	SMC2-AS1	4.41	1.27e-05	0.00127	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104098910	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs10820602	ENSG00000270332.1	SMC2-AS1	4.41	1.27e-05	0.00127	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104099001	chr9:104080024~104093073:-
THCA	cis	rs5758659	0.714	rs2284087	ENSG00000273366.1	CTA-989H11.1	4.41	1.27e-05	0.00127	0.24	0.2	Cognitive function;	chr22:42089667	chr22:42278188~42278846:+
THCA	cis	rs447735	0.566	rs258337	ENSG00000260259.1	RP11-368I7.4	4.41	1.27e-05	0.00127	0.21	0.2	Hemoglobin concentration;	chr16:89654302	chr16:89682620~89686569:-
THCA	cis	rs11779988	0.528	rs376771	ENSG00000253671.1	RP11-806O11.1	-4.41	1.27e-05	0.00127	-0.26	-0.2	Breast cancer;	chr8:18007476	chr8:17808941~17820868:+
THCA	cis	rs12681288	0.862	rs2004701	ENSG00000260721.1	AF067845.1	4.41	1.27e-05	0.00127	0.23	0.2	Schizophrenia;	chr8:1072287	chr8:1368642~1369833:-
THCA	cis	rs28599928	0.582	rs6003033	ENSG00000230319.1	AL022476.2	4.41	1.27e-05	0.00127	0.3	0.2	Breast cancer;	chr22:43070925	chr22:43038585~43052366:+
THCA	cis	rs6088813	1	rs6087705	ENSG00000279253.1	RP4-614O4.13	4.41	1.27e-05	0.00127	0.2	0.2	Height;	chr20:35413447	chr20:35262727~35264187:-
THCA	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-4.41	1.27e-05	0.00127	-0.35	-0.2	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
THCA	cis	rs72843506	0.52	rs78178505	ENSG00000231258.2	ZSWIM5P2	4.41	1.27e-05	0.00127	0.32	0.2	Schizophrenia;	chr17:19984410	chr17:20583758~20591180:-
THCA	cis	rs7726839	0.574	rs11134149	ENSG00000225138.6	CTD-2228K2.7	4.41	1.27e-05	0.00127	0.24	0.2	Obesity-related traits;	chr5:637162	chr5:473236~480884:+
THCA	cis	rs2120243	0.598	rs1500916	ENSG00000241770.1	RP11-555M1.3	-4.41	1.27e-05	0.00127	-0.26	-0.2	Hepatocellular carcinoma in hepatitis B infection;	chr3:157370253	chr3:157163452~157169133:+
THCA	cis	rs8014252	1	rs8014338	ENSG00000259158.2	ADAM20P1	-4.41	1.27e-05	0.00127	-0.23	-0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70461465	chr14:70468881~70483756:-
THCA	cis	rs7511006	1	rs17836662	ENSG00000272836.1	RP3-402G11.27	4.41	1.27e-05	0.00127	0.16	0.2	Obesity-related traits;	chr22:50233725	chr22:50205585~50206062:-
THCA	cis	rs2835345	0.596	rs2409817	ENSG00000230479.1	AP000695.6	4.41	1.27e-05	0.00127	0.24	0.2	Pulmonary function;	chr21:36455410	chr21:36430360~36481070:+
THCA	cis	rs4705952	0.832	rs2548989	ENSG00000233006.5	AC034220.3	-4.41	1.27e-05	0.00127	-0.18	-0.2	C-reactive protein levels;	chr5:132524013	chr5:132311285~132369916:-
THCA	cis	rs9925964	0.935	rs4527034	ENSG00000232748.3	RP11-196G11.6	-4.41	1.27e-05	0.00127	-0.23	-0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31120293	chr16:31056460~31062803:+
THCA	cis	rs1783925	0.549	rs11220082	ENSG00000254671.2	STT3A-AS1	-4.41	1.27e-05	0.00127	-0.24	-0.2	Formal thought disorder in schizophrenia;	chr11:125454069	chr11:125570284~125592568:-
THCA	cis	rs35740288	0.77	rs12906580	ENSG00000259295.5	CSPG4P12	-4.41	1.27e-05	0.00127	-0.31	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612056	chr15:85191438~85213905:+
THCA	cis	rs1923243	0.648	rs12127938	ENSG00000223479.3	RP4-788P17.1	4.41	1.27e-05	0.00127	0.22	0.2	Migraine;	chr1:73049511	chr1:73635216~73715214:+
THCA	cis	rs2179367	0.568	rs6932778	ENSG00000216906.2	RP11-350J20.9	4.41	1.27e-05	0.00127	0.27	0.2	Dupuytren's disease;	chr6:149328293	chr6:149904243~149906418:+
THCA	cis	rs7209700	0.547	rs10514919	ENSG00000228782.6	CTD-2026D20.3	-4.41	1.27e-05	0.00127	-0.22	-0.2	IgG glycosylation;	chr17:47264763	chr17:47450568~47492492:-
THCA	cis	rs10761482	0.769	rs1417380	ENSG00000254271.1	RP11-131N11.4	4.41	1.27e-05	0.00127	0.27	0.2	Schizophrenia;	chr10:60351528	chr10:60734342~60741828:+
THCA	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	4.41	1.27e-05	0.00127	0.23	0.2	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
THCA	cis	rs516805	0.52	rs509596	ENSG00000279453.1	RP3-425C14.4	-4.41	1.27e-05	0.00127	-0.16	-0.2	Lymphocyte counts;	chr6:122478396	chr6:122436789~122439223:-
THCA	cis	rs7772486	0.72	rs4896844	ENSG00000270638.1	RP3-466P17.1	-4.41	1.27e-05	0.00127	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145735570~145737218:+
THCA	cis	rs9309473	0.5	rs4852952	ENSG00000273245.1	RP11-434P11.2	-4.41	1.27e-05	0.00127	-0.24	-0.2	Metabolite levels;	chr2:73642780	chr2:73750256~73750786:-
THCA	cis	rs8077577	0.945	rs8065026	ENSG00000273018.4	CTD-2303H24.2	-4.41	1.27e-05	0.00127	-0.32	-0.2	Obesity-related traits;	chr17:18142976	chr17:18511221~18551705:-
THCA	cis	rs7219021	0.705	rs7207087	ENSG00000248278.1	SUMO2P17	4.41	1.27e-05	0.00127	0.26	0.2	Schizophrenia or bipolar disorder;	chr17:48840591	chr17:48874860~48908983:-
THCA	cis	rs875971	0.862	rs13226170	ENSG00000229886.1	RP5-1132H15.3	4.41	1.27e-05	0.00127	0.21	0.2	Aortic root size;	chr7:66534311	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs2420611	ENSG00000229886.1	RP5-1132H15.3	4.41	1.27e-05	0.00127	0.21	0.2	Aortic root size;	chr7:66534333	chr7:66025126~66031544:-
THCA	cis	rs925946	0.64	rs61888800	ENSG00000245573.6	BDNF-AS	-4.41	1.27e-05	0.00127	-0.22	-0.2	Weight;Body mass index;	chr11:27700731	chr11:27506838~27698174:+
THCA	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-4.41	1.27e-05	0.00127	-0.27	-0.2	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
THCA	cis	rs1023500	0.551	rs133355	ENSG00000237037.8	NDUFA6-AS1	-4.41	1.27e-05	0.00127	-0.17	-0.2	Schizophrenia;	chr22:42044281	chr22:42090931~42137742:+
THCA	cis	rs116248771	0.69	rs16847125	ENSG00000271778.1	RP11-379F4.8	4.41	1.27e-05	0.00127	0.26	0.2	diarrhoeal disease at age 2;	chr3:158699910	chr3:158782547~158783124:+
THCA	cis	rs4948275	0.693	rs2650731	ENSG00000237233.2	TMEM26-AS1	4.41	1.27e-05	0.00127	0.27	0.2	Night sleep phenotypes;	chr10:61579897	chr10:61452639~61481956:+
THCA	cis	rs1577917	0.74	rs9344542	ENSG00000220563.1	PKMP3	4.41	1.27e-05	0.00127	0.14	0.2	Response to antipsychotic treatment;	chr6:85684187	chr6:85659892~85660606:-
THCA	cis	rs4356203	0.905	rs11024148	ENSG00000272034.1	SNORD14A	-4.41	1.27e-05	0.00128	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074512	chr11:17074654~17074744:-
THCA	cis	rs2243480	1	rs313807	ENSG00000164669.11	INTS4P1	4.41	1.28e-05	0.00128	0.39	0.2	Diabetic kidney disease;	chr7:66034494	chr7:65141225~65234216:+
THCA	cis	rs340874	0.703	rs340835	ENSG00000274895.1	RP11-478J18.2	4.41	1.28e-05	0.00128	0.17	0.2	Type 2 diabetes;Fasting blood glucose;Homeostasis model assessment of beta-cell function;Fasting blood glucose (BMI interaction);	chr1:213990332	chr1:213983793~213986419:-
THCA	cis	rs12478296	1	rs73007140	ENSG00000220804.7	AC093642.5	4.41	1.28e-05	0.00128	0.21	0.2	Obesity-related traits;	chr2:242068605	chr2:242088633~242160153:+
THCA	cis	rs8077577	0.708	rs4450455	ENSG00000273018.4	CTD-2303H24.2	4.41	1.28e-05	0.00128	0.29	0.2	Obesity-related traits;	chr17:18237133	chr17:18511221~18551705:-
THCA	cis	rs11976180	0.569	rs12703565	ENSG00000228960.5	OR2A9P	-4.41	1.28e-05	0.00128	-0.35	-0.2	Obesity-related traits;	chr7:144057308	chr7:144294480~144300934:+
THCA	cis	rs453301	0.653	rs7853	ENSG00000233609.3	RP11-62H7.2	4.41	1.28e-05	0.00128	0.19	0.2	Joint mobility (Beighton score);	chr8:9033304	chr8:8961200~8979025:+
THCA	cis	rs7647973	0.566	rs57630346	ENSG00000228638.1	FCF1P2	-4.41	1.28e-05	0.00128	-0.24	-0.2	Menarche (age at onset);	chr3:49048782	chr3:48290793~48291375:-
THCA	cis	rs739496	0.615	rs4648328	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00128	0.26	0.2	Platelet count;	chr12:111784984	chr12:111927018~111929017:+
THCA	cis	rs7216064	1	rs12452511	ENSG00000278740.1	RP11-147L13.14	4.41	1.28e-05	0.00128	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836460	chr17:68188547~68189165:+
THCA	cis	rs9314614	0.899	rs2977802	ENSG00000245857.2	GS1-24F4.2	-4.41	1.28e-05	0.00128	-0.25	-0.2	White blood cell count (basophil);IgA nephropathy;	chr8:6837323	chr8:6835554~6885276:+
THCA	cis	rs4714902	0.655	rs7766019	ENSG00000231769.2	RP1-8B1.4	-4.41	1.28e-05	0.00128	-0.18	-0.2	Colonoscopy-negative controls vs population controls;	chr6:46115830	chr6:46097093~46129706:-
THCA	cis	rs3738443	0.577	rs1771936	ENSG00000259865.1	RP11-488L18.10	-4.41	1.28e-05	0.00128	-0.21	-0.2	Alcohol dependence;	chr1:247236534	chr1:247187281~247188526:-
THCA	cis	rs10090774	0.687	rs13267705	ENSG00000280303.2	ERICD	-4.41	1.28e-05	0.00128	-0.18	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655273	chr8:140636281~140638283:+
THCA	cis	rs10489167	0.85	rs7542349	ENSG00000237899.1	RP4-739H11.3	-4.41	1.28e-05	0.00128	-0.36	-0.2	Depressive and manic episodes in bipolar disorder;	chr1:40746498	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs7539902	ENSG00000237899.1	RP4-739H11.3	-4.41	1.28e-05	0.00128	-0.36	-0.2	Depressive and manic episodes in bipolar disorder;	chr1:40746499	chr1:40669089~40687588:-
THCA	cis	rs453301	0.658	rs6983877	ENSG00000233609.3	RP11-62H7.2	-4.41	1.28e-05	0.00128	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9047129	chr8:8961200~8979025:+
THCA	cis	rs9341808	0.644	rs62408577	ENSG00000272129.1	RP11-250B2.6	-4.41	1.28e-05	0.00128	-0.26	-0.2	Sitting height ratio;	chr6:80232307	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.644	rs76102095	ENSG00000272129.1	RP11-250B2.6	-4.41	1.28e-05	0.00128	-0.26	-0.2	Sitting height ratio;	chr6:80232309	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.644	rs59371711	ENSG00000272129.1	RP11-250B2.6	-4.41	1.28e-05	0.00128	-0.26	-0.2	Sitting height ratio;	chr6:80232310	chr6:80355424~80356859:+
THCA	cis	rs5758511	0.773	rs12167978	ENSG00000281538.1	RP4-669P10.20	-4.41	1.28e-05	0.00128	-0.24	-0.2	Birth weight;	chr22:41950471	chr22:42138060~42139726:+
THCA	cis	rs11884770	0.505	rs11886476	ENSG00000236432.6	AC097662.2	4.41	1.28e-05	0.00128	0.2	0.2	Advanced age-related macular degeneration;	chr2:227223633	chr2:227221052~227325201:-
THCA	cis	rs7474896	0.537	rs1208683	ENSG00000120555.12	SEPT7P9	-4.41	1.28e-05	0.00128	-0.26	-0.2	Obesity (extreme);	chr10:37804795	chr10:38383069~38402916:-
THCA	cis	rs642858	0.504	rs12530095	ENSG00000234147.1	RP3-460G2.2	4.41	1.28e-05	0.00128	0.25	0.2	Type 2 diabetes;	chr6:140417212	chr6:140845958~140852924:-
THCA	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-4.41	1.28e-05	0.00128	-0.22	-0.2	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
THCA	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-4.41	1.28e-05	0.00128	-0.22	-0.2	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
THCA	cis	rs67478160	0.619	rs3742365	ENSG00000269910.1	RP11-73M18.10	4.41	1.28e-05	0.00128	0.17	0.2	Schizophrenia;	chr14:103731914	chr14:103694516~103695050:-
THCA	cis	rs7572644	0.699	rs1506537	ENSG00000223522.1	AC093690.1	4.41	1.28e-05	0.00128	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27959034	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs12465000	ENSG00000223522.1	AC093690.1	4.41	1.28e-05	0.00128	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27976557	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs898032	ENSG00000223522.1	AC093690.1	4.41	1.28e-05	0.00128	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27980069	chr2:28307691~28310459:-
THCA	cis	rs2286503	0.839	rs4722188	ENSG00000226329.2	AC005682.6	4.41	1.28e-05	0.00128	0.24	0.2	Fibrinogen;	chr7:22820592	chr7:22863874~22881350:-
THCA	cis	rs4794202	0.836	rs11079798	ENSG00000264920.1	RP11-6N17.4	-4.41	1.28e-05	0.00128	-0.23	-0.2	Alzheimer's disease (cognitive decline);	chr17:47859521	chr17:47891255~47895812:-
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000229180.5	GS1-124K5.11	4.41	1.28e-05	0.00128	0.16	0.2	Corneal structure;	chr7:66835665	chr7:66526088~66542624:-
THCA	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-4.41	1.28e-05	0.00128	-0.12	-0.2	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
THCA	cis	rs1048886	0.938	rs2691493	ENSG00000271967.1	RP11-134K13.4	-4.41	1.28e-05	0.00128	-0.2	-0.2	Type 2 diabetes;	chr6:70580899	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.808	rs2691495	ENSG00000271967.1	RP11-134K13.4	-4.41	1.28e-05	0.00128	-0.2	-0.2	Type 2 diabetes;	chr6:70582169	chr6:70596438~70596980:+
THCA	cis	rs9863	0.862	rs6488912	ENSG00000269997.1	RP11-214K3.21	-4.41	1.28e-05	0.00128	-0.24	-0.2	White blood cell count;	chr12:123958205	chr12:123966077~123966629:-
THCA	cis	rs74233809	0.748	rs10786736	ENSG00000272912.1	RP11-724N1.1	-4.41	1.28e-05	0.00128	-0.33	-0.2	Birth weight;	chr10:103089359	chr10:102914585~102915404:+
THCA	cis	rs7031325	0.752	rs9785190	ENSG00000229611.1	RP11-390F4.10	-4.41	1.28e-05	0.00128	-0.23	-0.2	Systemic lupus erythematosus;	chr9:6665254	chr9:6704471~6707780:+
THCA	cis	rs911119	0.866	rs6048920	ENSG00000270001.1	RP11-218C14.8	-4.41	1.28e-05	0.00128	-0.3	-0.2	Chronic kidney disease;	chr20:23596207	chr20:23631826~23632316:-
THCA	cis	rs2214442	0.934	rs10215853	ENSG00000271133.4	CTA-293F17.1	4.41	1.28e-05	0.00128	0.2	0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20376621	chr7:20328299~20331747:-
THCA	cis	rs7111546	0.565	rs1981695	ENSG00000246225.5	RP11-17A1.3	4.41	1.28e-05	0.00128	0.36	0.2	Dialysis-related mortality;	chr11:22902458	chr11:22829380~22945393:+
THCA	cis	rs710865	0.541	rs2073104	ENSG00000270728.1	RP4-657E11.10	-4.41	1.28e-05	0.00128	-0.15	-0.2	Brain structure;	chr1:19238156	chr1:19297080~19297903:+
THCA	cis	rs739496	0.579	rs57046217	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00128	0.24	0.2	Platelet count;	chr12:111847312	chr12:111927018~111929017:+
THCA	cis	rs739496	0.579	rs75080921	ENSG00000226469.1	ADAM1B	4.41	1.28e-05	0.00128	0.24	0.2	Platelet count;	chr12:111861168	chr12:111927018~111929017:+
THCA	cis	rs2013441	0.508	rs4925075	ENSG00000261033.1	RP11-209D14.2	4.41	1.28e-05	0.00128	0.26	0.2	Obesity-related traits;	chr17:20066422	chr17:20008051~20009234:-
THCA	cis	rs7474896	0.515	rs624359	ENSG00000226578.1	RP11-258F22.1	4.41	1.28e-05	0.00128	0.28	0.2	Obesity (extreme);	chr10:38010204	chr10:37775371~37784131:-
THCA	cis	rs7474896	0.537	rs598857	ENSG00000226578.1	RP11-258F22.1	4.41	1.28e-05	0.00128	0.28	0.2	Obesity (extreme);	chr10:38013998	chr10:37775371~37784131:-
THCA	cis	rs728616	0.51	rs17679603	ENSG00000278616.1	BEND3P3	4.41	1.28e-05	0.00128	0.2	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80421678	chr10:79682997~79685436:+
THCA	cis	rs3764021	0.84	rs10743823	ENSG00000214776.8	RP11-726G1.1	4.41	1.28e-05	0.00128	0.24	0.2	Type 1 diabetes;	chr12:9728529	chr12:9467552~9576275:+
THCA	cis	rs17221829	0.965	rs10830362	ENSG00000280385.1	AP000648.5	-4.41	1.28e-05	0.00128	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89724740	chr11:90193614~90198120:+
THCA	cis	rs11096990	0.855	rs1597722	ENSG00000249685.1	RP11-360F5.3	4.41	1.28e-05	0.00128	0.26	0.2	Cognitive function;	chr4:39173255	chr4:39133913~39135608:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000229180.5	GS1-124K5.11	4.41	1.28e-05	0.00128	0.16	0.2	Corneal structure;	chr7:66887678	chr7:66526088~66542624:-
THCA	cis	rs5751614	0.62	rs1811018	ENSG00000240160.3	RN7SL263P	4.41	1.28e-05	0.00128	0.24	0.2	Height;	chr22:23264778	chr22:23261782~23262071:-
THCA	cis	rs9307551	0.584	rs12508756	ENSG00000250334.4	LINC00989	-4.41	1.28e-05	0.00128	-0.24	-0.2	Refractive error;	chr4:79486715	chr4:79492416~79576460:+
THCA	cis	rs1185460	0.967	rs1786690	ENSG00000272186.1	RP11-110I1.13	-4.41	1.28e-05	0.00128	-0.19	-0.2	Coronary artery disease;	chr11:119071357	chr11:119067374~119067698:-
THCA	cis	rs8028182	0.636	rs28623700	ENSG00000260269.4	CTD-2323K18.1	-4.41	1.28e-05	0.00128	-0.3	-0.2	Sudden cardiac arrest;	chr15:75557373	chr15:75527150~75601205:-
THCA	cis	rs8028182	0.577	rs28693593	ENSG00000260269.4	CTD-2323K18.1	-4.41	1.28e-05	0.00128	-0.3	-0.2	Sudden cardiac arrest;	chr15:75557435	chr15:75527150~75601205:-
THCA	cis	rs10851478	0.591	rs11634786	ENSG00000276593.1	RP11-295H24.5	-4.41	1.28e-05	0.00128	-0.22	-0.2	Oral cavity cancer;	chr15:49452370	chr15:49353485~49354034:+
THCA	cis	rs61270009	0.913	rs3733809	ENSG00000247828.6	TMEM161B-AS1	4.41	1.28e-05	0.00128	0.18	0.2	Depressive symptoms;	chr5:88410112	chr5:88268895~88436685:+
THCA	cis	rs60180747	1	rs17851970	ENSG00000261318.1	RP11-653J6.1	-4.41	1.28e-05	0.00128	-0.26	-0.2	Testicular germ cell tumor;	chr15:66320627	chr15:66278498~66293357:-
THCA	cis	rs6012564	0.963	rs6125551	ENSG00000230758.1	SNAP23P	-4.41	1.28e-05	0.00128	-0.24	-0.2	Anger;	chr20:49103849	chr20:49038357~49038602:-
THCA	cis	rs613391	0.885	rs578315	ENSG00000224549.1	RP11-370B11.3	-4.41	1.28e-05	0.00128	-0.24	-0.2	Quantitative traits;	chr9:22664214	chr9:22767175~22768316:+
THCA	cis	rs6728642	1	rs11900461	ENSG00000230606.9	AC159540.1	4.41	1.28e-05	0.00128	0.28	0.2	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96950256	chr2:97416165~97433527:-
THCA	cis	rs2281603	0.57	rs73265640	ENSG00000272909.1	CTD-2555O16.4	-4.41	1.28e-05	0.00128	-0.23	-0.2	Lymphocyte counts;	chr14:64483083	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs73265641	ENSG00000272909.1	CTD-2555O16.4	-4.41	1.28e-05	0.00128	-0.23	-0.2	Lymphocyte counts;	chr14:64483146	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.521	rs35115595	ENSG00000272909.1	CTD-2555O16.4	-4.41	1.28e-05	0.00128	-0.23	-0.2	Lymphocyte counts;	chr14:64483206	chr14:64440369~64442238:-
THCA	cis	rs7617480	0.648	rs6766238	ENSG00000228638.1	FCF1P2	-4.41	1.28e-05	0.00128	-0.24	-0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48764496	chr3:48290793~48291375:-
THCA	cis	rs35740288	0.742	rs4843087	ENSG00000259295.5	CSPG4P12	4.41	1.28e-05	0.00128	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85629624	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs62022867	ENSG00000259295.5	CSPG4P12	4.41	1.28e-05	0.00128	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630050	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.703	rs10520598	ENSG00000259295.5	CSPG4P12	4.41	1.28e-05	0.00128	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630150	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs11635587	ENSG00000259295.5	CSPG4P12	4.41	1.28e-05	0.00128	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630402	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs35447727	ENSG00000259295.5	CSPG4P12	4.41	1.28e-05	0.00128	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631168	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs34058174	ENSG00000259295.5	CSPG4P12	4.41	1.28e-05	0.00128	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631231	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.587	rs4843089	ENSG00000259295.5	CSPG4P12	4.41	1.28e-05	0.00128	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85632905	chr15:85191438~85213905:+
THCA	cis	rs8062405	0.755	rs62034325	ENSG00000270424.1	RP11-1348G14.6	4.41	1.29e-05	0.00128	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28749959~28750595:-
THCA	cis	rs10984970	0.826	rs62578020	ENSG00000238181.2	AHCYP2	4.41	1.29e-05	0.00128	0.5	0.2	Lung cancer;	chr9:120703241	chr9:120720673~120721972:+
THCA	cis	rs375066	0.935	rs4803662	ENSG00000278917.1	RP11-15A1.4	-4.41	1.29e-05	0.00128	-0.16	-0.2	Breast cancer;	chr19:43855412	chr19:43891233~43895411:+
THCA	cis	rs11089937	0.616	rs4991802	ENSG00000211639.2	IGLV4-60	4.41	1.29e-05	0.00128	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22179031	chr22:22162199~22162681:+
THCA	cis	rs875971	0.755	rs76288834	ENSG00000229886.1	RP5-1132H15.3	-4.41	1.29e-05	0.00129	-0.21	-0.2	Aortic root size;	chr7:66604815	chr7:66025126~66031544:-
THCA	cis	rs228614	0.514	rs59550147	ENSG00000248971.2	KRT8P46	-4.41	1.29e-05	0.00129	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102728746~102730171:-
THCA	cis	rs800160	0.844	rs2651784	ENSG00000199550.1	Y_RNA	4.41	1.29e-05	0.00129	0.31	0.2	Bacteremia;	chr11:2326319	chr11:2372638~2372750:+
THCA	cis	rs875971	1	rs1544549	ENSG00000230189.5	GS1-124K5.2	-4.41	1.29e-05	0.00129	-0.13	-0.2	Aortic root size;	chr7:66625676	chr7:66409143~66490059:-
THCA	cis	rs67478160	0.619	rs28698555	ENSG00000269910.1	RP11-73M18.10	-4.41	1.29e-05	0.00129	-0.17	-0.2	Schizophrenia;	chr14:103850149	chr14:103694516~103695050:-
THCA	cis	rs2688608	0.839	rs2633311	ENSG00000271816.1	BMS1P4	-4.41	1.29e-05	0.00129	-0.2	-0.2	Inflammatory bowel disease;	chr10:73838341	chr10:73699151~73730487:-
THCA	cis	rs6964833	1	rs4717907	ENSG00000184616.8	AC004166.6	4.41	1.29e-05	0.00129	0.29	0.2	Menarche (age at onset);	chr7:74672169	chr7:74906673~74913256:-
THCA	cis	rs6477918	0.55	rs10981397	ENSG00000230185.4	C9orf147	-4.41	1.29e-05	0.00129	-0.21	-0.2	Obstetric antiphospholipid syndrome;	chr9:112412368	chr9:112433816~112487204:-
THCA	cis	rs17767392	0.918	rs3784062	ENSG00000259146.3	RP1-261D10.2	-4.41	1.29e-05	0.00129	-0.27	-0.2	Mitral valve prolapse;	chr14:71623788	chr14:71292729~71321814:-
THCA	cis	rs2657294	0.796	rs1259501	ENSG00000233313.2	HMGA1P5	-4.41	1.29e-05	0.00129	-0.26	-0.2	Pneumonia;	chr10:75230427	chr10:75276376~75276646:-
THCA	cis	rs860295	0.812	rs11264363	ENSG00000160766.13	GBAP1	-4.41	1.29e-05	0.00129	-0.22	-0.2	Body mass index;	chr1:155348517	chr1:155213821~155227422:-
THCA	cis	rs2299587	0.527	rs7843715	ENSG00000253671.1	RP11-806O11.1	-4.41	1.29e-05	0.00129	-0.23	-0.2	Economic and political preferences;	chr8:17876017	chr8:17808941~17820868:+
THCA	cis	rs4434872	0.536	rs12039936	ENSG00000223599.1	RP11-216N14.7	-4.41	1.29e-05	0.00129	-0.38	-0.2	Conduct disorder (symptom count);	chr1:153881685	chr1:153852106~153853414:-
THCA	cis	rs7246657	0.653	rs4805208	ENSG00000276846.1	CTD-3220F14.3	4.41	1.29e-05	0.00129	0.25	0.2	Coronary artery calcification;	chr19:37183357	chr19:37314868~37315620:-
THCA	cis	rs6121246	0.609	rs6087783	ENSG00000230613.1	HM13-AS1	4.41	1.29e-05	0.00129	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31833421	chr20:31567707~31573263:-
THCA	cis	rs453301	0.624	rs2979256	ENSG00000254340.1	RP11-10A14.3	4.41	1.29e-05	0.00129	0.21	0.2	Joint mobility (Beighton score);	chr8:9014200	chr8:9141424~9145435:+
THCA	cis	rs9876781	1	rs11130170	ENSG00000244380.1	RP11-24C3.2	4.41	1.29e-05	0.00129	0.23	0.2	Longevity;	chr3:48408490	chr3:48440352~48446656:-
THCA	cis	rs6963495	0.745	rs818620	ENSG00000272604.1	RP11-251G23.5	4.41	1.29e-05	0.00129	0.25	0.2	Bipolar disorder (body mass index interaction);	chr7:105532238	chr7:105571083~105573660:+
THCA	cis	rs301901	0.965	rs3104057	ENSG00000250155.1	CTD-2353F22.1	-4.41	1.29e-05	0.00129	-0.2	-0.2	Height;	chr5:36982949	chr5:36666214~36725195:-
THCA	cis	rs301901	1	rs296962	ENSG00000250155.1	CTD-2353F22.1	-4.41	1.29e-05	0.00129	-0.2	-0.2	Height;	chr5:36990381	chr5:36666214~36725195:-
THCA	cis	rs8067545	0.75	rs1421174	ENSG00000270091.1	RP11-78O7.2	-4.41	1.29e-05	0.00129	-0.15	-0.2	Schizophrenia;	chr17:20046877	chr17:19896590~19897287:-
THCA	cis	rs17818399	0.926	rs35682608	ENSG00000279254.1	RP11-536C12.1	-4.41	1.29e-05	0.00129	-0.21	-0.2	Height;	chr2:46609403	chr2:46668870~46670778:+
THCA	cis	rs944289	1	rs944289	ENSG00000258844.1	RP11-259K15.2	4.41	1.29e-05	0.00129	0.19	0.2	Thyroid cancer;	chr14:36180040	chr14:36214607~36235608:+
THCA	cis	rs78487399	0.808	rs17039131	ENSG00000234936.1	AC010883.5	4.41	1.29e-05	0.00129	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43425259	chr2:43229573~43233394:+
THCA	cis	rs9863	0.828	rs12833624	ENSG00000270028.1	RP11-380L11.4	4.41	1.29e-05	0.00129	0.21	0.2	White blood cell count;	chr12:123992326	chr12:123925461~123926083:-
THCA	cis	rs9863	0.828	rs34114498	ENSG00000270028.1	RP11-380L11.4	4.41	1.29e-05	0.00129	0.21	0.2	White blood cell count;	chr12:123995826	chr12:123925461~123926083:-
THCA	cis	rs6088590	0.582	rs6059909	ENSG00000276073.1	RP5-1125A11.7	-4.41	1.29e-05	0.00129	-0.17	-0.2	Coronary artery disease;	chr20:34551887	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.561	rs11167239	ENSG00000276073.1	RP5-1125A11.7	-4.41	1.29e-05	0.00129	-0.17	-0.2	Coronary artery disease;	chr20:34552668	chr20:33985617~33988989:-
THCA	cis	rs12554020	0.582	rs77133953	ENSG00000227603.1	RP11-165J3.6	4.41	1.29e-05	0.00129	0.41	0.2	Schizophrenia;	chr9:93635287	chr9:93435332~93437121:-
THCA	cis	rs1005277	0.691	rs2474558	ENSG00000120555.12	SEPT7P9	-4.41	1.29e-05	0.00129	-0.23	-0.2	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38383069~38402916:-
THCA	cis	rs919433	0.653	rs700651	ENSG00000231621.1	AC013264.2	-4.41	1.29e-05	0.00129	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197766990	chr2:197197991~197199273:+
THCA	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-4.41	1.29e-05	0.00129	-0.23	-0.2	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-4.41	1.29e-05	0.00129	-0.23	-0.2	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
THCA	cis	rs3734266	0.702	rs4438945	ENSG00000272288.4	RP11-140K17.3	-4.41	1.29e-05	0.00129	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34722238	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs66926909	ENSG00000272288.4	RP11-140K17.3	-4.41	1.29e-05	0.00129	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34722933	chr6:34696317~34697470:+
THCA	cis	rs6442522	0.772	rs3890477	ENSG00000249786.6	EAF1-AS1	4.41	1.29e-05	0.00129	0.21	0.2	Uric acid levels;	chr3:15447816	chr3:15436171~15455940:-
THCA	cis	rs1150668	0.83	rs2023493	ENSG00000280107.1	AL022393.9	-4.41	1.29e-05	0.00129	-0.19	-0.2	Pubertal anthropometrics;	chr6:28432385	chr6:28170845~28172521:+
THCA	cis	rs6728302	0.557	rs73001973	ENSG00000244280.1	ECEL1P2	4.41	1.29e-05	0.00129	0.4	0.2	Height;	chr2:232376865	chr2:232385750~232387457:-
THCA	cis	rs7336933	1	rs7319447	ENSG00000278338.3	VWA8-AS1	-4.41	1.29e-05	0.00129	-0.34	-0.2	Calcium levels;	chr13:41977372	chr13:41955808~41981565:+
THCA	cis	rs72717009	0.825	rs61802846	ENSG00000225217.1	HSPA7	-4.41	1.29e-05	0.00129	-0.31	-0.2	Rheumatoid arthritis;	chr1:161504083	chr1:161606291~161608217:+
THCA	cis	rs9300255	0.602	rs1716167	ENSG00000235423.7	RP11-282O18.3	-4.41	1.29e-05	0.00129	-0.21	-0.2	Neutrophil percentage of white cells;	chr12:123166615	chr12:123252030~123261483:-
THCA	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-4.41	1.29e-05	0.00129	-0.2	-0.2	Height;	chr5:36911514	chr5:36666214~36725195:-
THCA	cis	rs17597773	0.674	rs2279638	ENSG00000238078.1	LINC01352	-4.41	1.29e-05	0.00129	-0.28	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828445	chr1:220829255~220832429:+
THCA	cis	rs73108077	0.736	rs77855283	ENSG00000277112.2	RP11-755J8.1	-4.41	1.29e-05	0.00129	-0.33	-0.2	Red blood cell density in sickle cell anemia;	chr20:31262576	chr20:30681825~30723932:-
THCA	cis	rs6787172	0.783	rs6441201	ENSG00000272087.1	RP11-379F4.7	4.41	1.29e-05	0.00129	0.18	0.2	Subjective well-being;	chr3:158460535	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.783	rs12496767	ENSG00000272087.1	RP11-379F4.7	4.41	1.29e-05	0.00129	0.18	0.2	Subjective well-being;	chr3:158461448	chr3:158693120~158693768:-
THCA	cis	rs2777491	0.915	rs7178634	ENSG00000247556.5	OIP5-AS1	4.41	1.29e-05	0.00129	0.16	0.2	Ulcerative colitis;	chr15:41342389	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.915	rs7178777	ENSG00000247556.5	OIP5-AS1	4.41	1.29e-05	0.00129	0.16	0.2	Ulcerative colitis;	chr15:41342390	chr15:41283990~41309737:+
THCA	cis	rs6840258	0.64	rs28734493	ENSG00000251411.1	RP11-397E7.4	-4.41	1.29e-05	0.00129	-0.23	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87151541	chr4:86913266~86914817:-
THCA	cis	rs2436845	0.627	rs1019976	ENSG00000253320.4	KB-1507C5.2	4.41	1.29e-05	0.00129	0.18	0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102852043	chr8:102864300~102977876:+
THCA	cis	rs4713118	0.866	rs2179094	ENSG00000226314.6	ZNF192P1	-4.41	1.29e-05	0.00129	-0.26	-0.2	Parkinson's disease;	chr6:27774046	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.824	rs2179095	ENSG00000226314.6	ZNF192P1	4.41	1.29e-05	0.00129	0.26	0.2	Parkinson's disease;	chr6:27783079	chr6:28161781~28169594:+
THCA	cis	rs6121246	0.909	rs6060821	ENSG00000230613.1	HM13-AS1	4.41	1.29e-05	0.00129	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31706231	chr20:31567707~31573263:-
THCA	cis	rs786425	0.682	rs7309528	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123687111	chr12:123971457~123971714:-
THCA	cis	rs786425	0.69	rs6488892	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123687279	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs6488893	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123687356	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs12829984	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123687760	chr12:123971457~123971714:-
THCA	cis	rs786425	0.654	rs7307343	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123689818	chr12:123971457~123971714:-
THCA	cis	rs786425	0.654	rs7310918	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123690109	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs11833604	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123691925	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs35946281	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123692469	chr12:123971457~123971714:-
THCA	cis	rs786425	0.655	rs12821242	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123693782	chr12:123971457~123971714:-
THCA	cis	rs786425	0.711	rs12831081	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123695192	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7298440	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123696502	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7979528	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123697273	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7968029	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123697573	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs11613632	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123699518	chr12:123971457~123971714:-
THCA	cis	rs786425	0.575	rs73219037	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123699935	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7398152	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123700092	chr12:123971457~123971714:-
THCA	cis	rs786425	0.655	rs7973155	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123701401	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs34586028	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123702535	chr12:123971457~123971714:-
THCA	cis	rs786425	0.655	rs11612030	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123703517	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs12827074	ENSG00000270095.1	RP11-214K3.18	-4.41	1.29e-05	0.00129	-0.24	-0.2	Pubertal anthropometrics;	chr12:123706289	chr12:123971457~123971714:-
THCA	cis	rs7220401	0.521	rs11080105	ENSG00000264007.1	RP11-68I3.10	4.41	1.29e-05	0.00129	0.23	0.2	Coronary artery disease;	chr17:29577693	chr17:29621617~29622254:-
THCA	cis	rs11637445	0.626	rs1878699	ENSG00000270964.1	RP11-502I4.3	-4.41	1.29e-05	0.00129	-0.18	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr15:67608545	chr15:67541072~67542604:-
THCA	cis	rs8177876	0.749	rs2911159	ENSG00000261061.1	RP11-303E16.2	4.41	1.29e-05	0.00129	0.26	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057653	chr16:81030770~81031485:+
THCA	cis	rs2439831	0.702	rs3784275	ENSG00000205771.5	CATSPER2P1	-4.41	1.29e-05	0.00129	-0.3	-0.2	Lung cancer in ever smokers;	chr15:43799188	chr15:43726918~43747094:-
THCA	cis	rs11773103	1	rs11769063	ENSG00000224046.1	AC005076.5	-4.41	1.29e-05	0.00129	-0.32	-0.2	Bipolar disorder or major depressive disorder (combined);	chr7:87289287	chr7:87151423~87152420:-
THCA	cis	rs453301	0.653	rs11784393	ENSG00000233609.3	RP11-62H7.2	4.41	1.29e-05	0.00129	0.19	0.2	Joint mobility (Beighton score);	chr8:9045624	chr8:8961200~8979025:+
THCA	cis	rs793571	0.536	rs7183336	ENSG00000245975.2	RP11-30K9.6	4.41	1.29e-05	0.00129	0.2	0.2	Schizophrenia;	chr15:58674037	chr15:58768072~58770974:-
THCA	cis	rs5751614	0.537	rs5759682	ENSG00000240160.3	RN7SL263P	4.41	1.29e-05	0.00129	0.25	0.2	Height;	chr22:23288992	chr22:23261782~23262071:-
THCA	cis	rs6723108	0.668	rs614356	ENSG00000224043.6	CCNT2-AS1	-4.41	1.29e-05	0.00129	-0.22	-0.2	Type 2 diabetes;	chr2:134541291	chr2:134735464~134918710:-
THCA	cis	rs10484434	0.901	rs62396160	ENSG00000272810.1	U91328.22	4.41	1.29e-05	0.00129	0.2	0.2	HIV-1 viral setpoint;	chr6:26075165	chr6:26013241~26013757:+
THCA	cis	rs11722779	0.838	rs4533776	ENSG00000248971.2	KRT8P46	-4.41	1.29e-05	0.00129	-0.24	-0.2	Schizophrenia;	chr4:102912732	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.838	rs6821247	ENSG00000248971.2	KRT8P46	-4.41	1.29e-05	0.00129	-0.24	-0.2	Schizophrenia;	chr4:102913483	chr4:102728746~102730171:-
THCA	cis	rs6723108	0.738	rs6751833	ENSG00000224043.6	CCNT2-AS1	-4.41	1.29e-05	0.00129	-0.21	-0.2	Type 2 diabetes;	chr2:134780328	chr2:134735464~134918710:-
THCA	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-4.41	1.29e-05	0.00129	-0.3	-0.2	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
THCA	cis	rs7267979	1	rs4815404	ENSG00000274973.1	RP13-401N8.7	4.41	1.29e-05	0.00129	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6083805	ENSG00000274973.1	RP13-401N8.7	4.41	1.29e-05	0.00129	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs7018	ENSG00000274973.1	RP13-401N8.7	-4.41	1.29e-05	0.00129	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25845497~25845862:+
THCA	cis	rs2886497	0.895	rs10828435	ENSG00000224215.1	RP11-371A19.2	-4.41	1.3e-05	0.00129	-0.24	-0.2	Major depression and alcohol dependence;	chr10:23371602	chr10:23343957~23345181:+
THCA	cis	rs6860806	0.507	rs200837	ENSG00000224431.1	AC063976.7	4.41	1.3e-05	0.00129	0.18	0.2	Breast cancer;	chr5:132364266	chr5:132199456~132203487:+
THCA	cis	rs13126694	0.839	rs66490968	ENSG00000248429.4	RP11-597D13.9	4.41	1.3e-05	0.00129	0.21	0.2	Blood osmolality (transformed sodium);	chr4:157994770	chr4:158170752~158202877:+
THCA	cis	rs17801127	0.748	rs12989809	ENSG00000231969.1	AC144449.1	4.41	1.3e-05	0.00129	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149670312	chr2:149587196~149848233:+
THCA	cis	rs4591358	0.677	rs7562869	ENSG00000223466.1	AC064834.2	4.41	1.3e-05	0.00129	0.23	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195425224	chr2:195533035~195538681:+
THCA	cis	rs4713118	0.868	rs10484401	ENSG00000220721.1	OR1F12	-4.41	1.3e-05	0.00129	-0.27	-0.2	Parkinson's disease;	chr6:27778811	chr6:28073316~28074233:+
THCA	cis	rs2657294	0.965	rs4746270	ENSG00000226051.5	ZNF503-AS1	-4.41	1.3e-05	0.00129	-0.27	-0.2	Pneumonia;	chr10:75185189	chr10:75269819~75373500:+
THCA	cis	rs61270009	0.955	rs410354	ENSG00000247828.6	TMEM161B-AS1	-4.41	1.3e-05	0.00129	-0.17	-0.2	Depressive symptoms;	chr5:88254467	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs375514	ENSG00000247828.6	TMEM161B-AS1	-4.41	1.3e-05	0.00129	-0.17	-0.2	Depressive symptoms;	chr5:88259477	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs377958	ENSG00000247828.6	TMEM161B-AS1	-4.41	1.3e-05	0.00129	-0.17	-0.2	Depressive symptoms;	chr5:88267571	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.913	rs402114	ENSG00000247828.6	TMEM161B-AS1	-4.41	1.3e-05	0.00129	-0.17	-0.2	Depressive symptoms;	chr5:88268106	chr5:88268895~88436685:+
THCA	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	4.41	1.3e-05	0.00129	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
THCA	cis	rs2985684	1	rs2985697	ENSG00000278009.1	RP11-649E7.8	4.41	1.3e-05	0.00129	0.29	0.2	Carotid intima media thickness;	chr14:49626184	chr14:49601011~49601124:-
THCA	cis	rs758324	0.797	rs247004	ENSG00000237714.1	P4HA2-AS1	4.41	1.3e-05	0.00129	0.3	0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132008665	chr5:132184876~132192808:+
THCA	cis	rs12234571	1	rs998537	ENSG00000214293.7	APTR	4.41	1.3e-05	0.0013	0.25	0.2	Obesity-related traits;	chr7:77860939	chr7:77657660~77696265:-
THCA	cis	rs1923243	0.71	rs4425940	ENSG00000223479.3	RP4-788P17.1	4.41	1.3e-05	0.0013	0.22	0.2	Migraine;	chr1:73112946	chr1:73635216~73715214:+
THCA	cis	rs6787172	0.84	rs1656376	ENSG00000272087.1	RP11-379F4.7	4.41	1.3e-05	0.0013	0.17	0.2	Subjective well-being;	chr3:158566892	chr3:158693120~158693768:-
THCA	cis	rs4819052	0.851	rs2236444	ENSG00000182586.6	LINC00334	-4.41	1.3e-05	0.0013	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45234340~45258730:+
THCA	cis	rs5758511	0.68	rs5758667	ENSG00000227370.1	RP4-669P10.19	4.41	1.3e-05	0.0013	0.23	0.2	Birth weight;	chr22:42237198	chr22:42132543~42132998:+
THCA	cis	rs478304	0.934	rs570954	ENSG00000255557.1	RP11-770G2.2	-4.41	1.3e-05	0.0013	-0.22	-0.2	Acne (severe);	chr11:65730790	chr11:65745729~65771585:+
THCA	cis	rs478304	0.934	rs669742	ENSG00000255557.1	RP11-770G2.2	-4.41	1.3e-05	0.0013	-0.22	-0.2	Acne (severe);	chr11:65733820	chr11:65745729~65771585:+
THCA	cis	rs478304	0.903	rs1151502	ENSG00000255557.1	RP11-770G2.2	-4.41	1.3e-05	0.0013	-0.22	-0.2	Acne (severe);	chr11:65736014	chr11:65745729~65771585:+
THCA	cis	rs478304	0.934	rs1193692	ENSG00000255557.1	RP11-770G2.2	-4.41	1.3e-05	0.0013	-0.22	-0.2	Acne (severe);	chr11:65736598	chr11:65745729~65771585:+
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000275400.1	RP4-756H11.5	-4.41	1.3e-05	0.0013	-0.21	-0.2	Corneal structure;	chr7:66798563	chr7:66553805~66554199:-
THCA	cis	rs17685	0.702	rs6960598	ENSG00000230882.1	AC005077.14	4.41	1.3e-05	0.0013	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76143673	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs10235738	ENSG00000230882.1	AC005077.14	4.41	1.3e-05	0.0013	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76144142	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs7794454	ENSG00000230882.1	AC005077.14	-4.41	1.3e-05	0.0013	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76146692	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs6953342	ENSG00000230882.1	AC005077.14	4.41	1.3e-05	0.0013	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76147435	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs10952842	ENSG00000230882.1	AC005077.14	4.41	1.3e-05	0.0013	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76151095	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs6464994	ENSG00000230882.1	AC005077.14	4.41	1.3e-05	0.0013	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76155350	chr7:76071469~76074963:-
THCA	cis	rs1383484	1	rs4357909	ENSG00000225151.9	GOLGA2P7	-4.41	1.3e-05	0.0013	-0.26	-0.2	Height;	chr15:83846823	chr15:84199311~84230136:-
THCA	cis	rs6870983	0.618	rs4916889	ENSG00000247828.6	TMEM161B-AS1	-4.41	1.3e-05	0.0013	-0.16	-0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88143874	chr5:88268895~88436685:+
THCA	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-4.41	1.3e-05	0.0013	-0.22	-0.2	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-4.41	1.3e-05	0.0013	-0.22	-0.2	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
THCA	cis	rs228769	1	rs12937692	ENSG00000267080.4	ASB16-AS1	-4.41	1.3e-05	0.0013	-0.19	-0.2	Bone mineral density (hip);Bone mineral density (spine);	chr17:44179062	chr17:44175973~44186717:-
THCA	cis	rs2439831	0.681	rs528517	ENSG00000166763.7	STRCP1	4.41	1.3e-05	0.0013	0.26	0.2	Lung cancer in ever smokers;	chr15:43320727	chr15:43699488~43718184:-
THCA	cis	rs56313388	0.541	rs7186005	ENSG00000246379.5	RP11-461O7.1	-4.41	1.3e-05	0.0013	-0.21	-0.2	Pulse pressure;	chr16:56171572	chr16:56092987~56191094:-
THCA	cis	rs9925964	0.591	rs11649653	ENSG00000232748.3	RP11-196G11.6	4.41	1.3e-05	0.0013	0.23	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30907166	chr16:31056460~31062803:+
THCA	cis	rs7511006	1	rs7364173	ENSG00000272836.1	RP3-402G11.27	4.41	1.3e-05	0.0013	0.16	0.2	Obesity-related traits;	chr22:50242600	chr22:50205585~50206062:-
THCA	cis	rs6430585	0.583	rs3769012	ENSG00000231890.6	DARS-AS1	-4.41	1.3e-05	0.0013	-0.24	-0.2	Corneal structure;	chr2:135798910	chr2:135985176~136022593:+
THCA	cis	rs4973397	0.81	rs12999051	ENSG00000224376.1	AC017104.6	4.41	1.3e-05	0.0013	0.23	0.2	Anti-saccade response;	chr2:231412281	chr2:231388976~231394991:+
THCA	cis	rs7267979	0.966	rs6037083	ENSG00000274973.1	RP13-401N8.7	4.41	1.3e-05	0.0013	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25845497~25845862:+
THCA	cis	rs911119	0.913	rs6036461	ENSG00000270001.1	RP11-218C14.8	-4.41	1.3e-05	0.0013	-0.3	-0.2	Chronic kidney disease;	chr20:23596117	chr20:23631826~23632316:-
THCA	cis	rs911119	0.866	rs4815223	ENSG00000270001.1	RP11-218C14.8	-4.41	1.3e-05	0.0013	-0.3	-0.2	Chronic kidney disease;	chr20:23596475	chr20:23631826~23632316:-
THCA	cis	rs911119	0.913	rs6048922	ENSG00000270001.1	RP11-218C14.8	-4.41	1.3e-05	0.0013	-0.3	-0.2	Chronic kidney disease;	chr20:23597479	chr20:23631826~23632316:-
THCA	cis	rs911119	0.955	rs6114201	ENSG00000270001.1	RP11-218C14.8	-4.41	1.3e-05	0.0013	-0.29	-0.2	Chronic kidney disease;	chr20:23626594	chr20:23631826~23632316:-
THCA	cis	rs67478160	0.643	rs8004408	ENSG00000269910.1	RP11-73M18.10	4.41	1.3e-05	0.0013	0.17	0.2	Schizophrenia;	chr14:103737601	chr14:103694516~103695050:-
THCA	cis	rs7045881	0.696	rs10812500	ENSG00000254396.1	RP11-56F10.3	4.41	1.3e-05	0.0013	0.26	0.2	Schizophrenia;	chr9:26946578	chr9:27102630~27104728:+
THCA	cis	rs8024893	1	rs7180114	ENSG00000270055.1	CTD-3092A11.2	4.41	1.3e-05	0.0013	0.26	0.2	Red cell distribution width;	chr15:31247976	chr15:30487963~30490313:+
THCA	cis	rs2221894	1	rs4732896	ENSG00000251191.6	LINC00589	-4.41	1.3e-05	0.0013	-0.24	-0.2	Obesity-related traits;	chr8:28967957	chr8:29673922~29748109:-
THCA	cis	rs8062405	0.723	rs4788079	ENSG00000261766.1	RP11-22P6.2	-4.41	1.3e-05	0.0013	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28862166~28863340:-
THCA	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	4.41	1.3e-05	0.0013	0.24	0.2	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
THCA	cis	rs875971	0.862	rs2909688	ENSG00000229886.1	RP5-1132H15.3	4.41	1.3e-05	0.0013	0.21	0.2	Aortic root size;	chr7:66376625	chr7:66025126~66031544:-
THCA	cis	rs72928364	1	rs34509910	ENSG00000256628.3	ZBTB11-AS1	4.41	1.3e-05	0.0013	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100998623	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.858	rs66512629	ENSG00000256628.3	ZBTB11-AS1	4.41	1.3e-05	0.0013	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101000713	chr3:101676475~101679217:+
THCA	cis	rs1499614	0.522	rs13247442	ENSG00000232546.1	RP11-458F8.1	-4.41	1.3e-05	0.0013	-0.34	-0.2	Gout;	chr7:66723871	chr7:66848496~66858136:+
THCA	cis	rs4722166	0.508	rs1474347	ENSG00000225541.1	AC002480.5	4.41	1.3e-05	0.0013	0.25	0.2	Lung cancer;	chr7:22728505	chr7:22571607~22661792:-
THCA	cis	rs9437689	0.541	rs1246351	ENSG00000235501.4	RP4-639F20.1	-4.41	1.3e-05	0.0013	-0.22	-0.2	Phospholipid levels (plasma);	chr1:94951185	chr1:94927566~94963270:+
THCA	cis	rs9959145	1	rs79998152	ENSG00000267108.1	RP11-861E21.1	4.41	1.3e-05	0.0013	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12567413	chr18:12432897~12437635:+
THCA	cis	rs9959145	0.778	rs77764901	ENSG00000267108.1	RP11-861E21.1	4.41	1.3e-05	0.0013	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12567459	chr18:12432897~12437635:+
THCA	cis	rs6787172	0.811	rs10936146	ENSG00000272087.1	RP11-379F4.7	4.41	1.3e-05	0.0013	0.18	0.2	Subjective well-being;	chr3:158485679	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.811	rs9835244	ENSG00000272087.1	RP11-379F4.7	4.41	1.3e-05	0.0013	0.18	0.2	Subjective well-being;	chr3:158486005	chr3:158693120~158693768:-
THCA	cis	rs4144027	0.791	rs67727470	ENSG00000269910.1	RP11-73M18.10	4.41	1.3e-05	0.0013	0.17	0.2	Blood metabolite levels;	chr14:103895659	chr14:103694516~103695050:-
THCA	cis	rs2251188	0.565	rs2246233	ENSG00000187953.9	PMS2CL	-4.41	1.3e-05	0.0013	-0.22	-0.2	Sum basophil neutrophil counts;Neutrophil count;	chr7:6661200	chr7:6710128~6753862:+
THCA	cis	rs274567	0.599	rs11242110	ENSG00000263597.1	MIR3936	-4.41	1.3e-05	0.0013	-0.18	-0.2	Blood metabolite levels;	chr5:132408085	chr5:132365490~132365599:-
THCA	cis	rs11088226	0.846	rs2833884	ENSG00000186842.4	LINC00846	-4.41	1.3e-05	0.0013	-0.26	-0.2	Gastritis;	chr21:32550765	chr21:32572238~32575881:-
THCA	cis	rs858239	0.601	rs1558313	ENSG00000226816.2	AC005082.12	4.41	1.3e-05	0.0013	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23206013~23208045:+
THCA	cis	rs6988985	0.56	rs7826809	ENSG00000247317.3	RP11-273G15.2	-4.41	1.3e-05	0.0013	-0.21	-0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142844193	chr8:142981738~143018437:-
THCA	cis	rs6988985	0.56	rs2078674	ENSG00000247317.3	RP11-273G15.2	-4.41	1.3e-05	0.0013	-0.21	-0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142846817	chr8:142981738~143018437:-
THCA	cis	rs2380205	0.62	rs12777477	ENSG00000232807.2	RP11-536K7.3	4.41	1.3e-05	0.0013	0.2	0.2	Breast cancer;	chr10:5870180	chr10:5934270~5945900:-
THCA	cis	rs1334894	1	rs58062737	ENSG00000228559.1	RP3-340B19.3	-4.41	1.3e-05	0.0013	-0.35	-0.2	Coronary artery disease;	chr6:35559780	chr6:35544632~35545669:+
THCA	cis	rs755249	0.501	rs2490945	ENSG00000228060.1	RP11-69E11.8	-4.41	1.3e-05	0.0013	-0.2	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39565160~39573203:+
THCA	cis	rs7819412	0.775	rs6601564	ENSG00000206014.6	OR7E161P	4.41	1.3e-05	0.0013	0.24	0.2	Triglycerides;	chr8:11124541	chr8:11928597~11929563:-
THCA	cis	rs7646881	0.544	rs6792976	ENSG00000240207.5	RP11-379F4.4	-4.41	1.3e-05	0.0013	-0.28	-0.2	Tetralogy of Fallot;	chr3:158608781	chr3:158732263~158784070:+
THCA	cis	rs13126694	0.744	rs9968557	ENSG00000248429.4	RP11-597D13.9	4.41	1.31e-05	0.0013	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158098673	chr4:158170752~158202877:+
THCA	cis	rs9890032	0.564	rs62070652	ENSG00000263531.1	RP13-753N3.1	-4.41	1.31e-05	0.0013	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:30894259	chr17:30863921~30864940:-
THCA	cis	rs2115630	0.653	rs61394864	ENSG00000176700.18	SCAND2P	-4.41	1.31e-05	0.0013	-0.13	-0.2	P wave terminal force;	chr15:84626943	chr15:84631451~84647478:+
THCA	cis	rs708547	0.581	rs6554400	ENSG00000269949.1	RP11-738E22.3	-4.41	1.31e-05	0.0013	-0.24	-0.2	Response to bleomycin (chromatid breaks);	chr4:56939140	chr4:56960927~56961373:-
THCA	cis	rs5758511	0.68	rs739147	ENSG00000237037.8	NDUFA6-AS1	-4.41	1.31e-05	0.0013	-0.19	-0.2	Birth weight;	chr22:42275060	chr22:42090931~42137742:+
THCA	cis	rs8058578	0.633	rs113448632	ENSG00000279196.1	RP11-1072A3.3	4.41	1.31e-05	0.0013	0.22	0.2	Multiple myeloma;	chr16:30886898	chr16:30984630~30988270:-
THCA	cis	rs890448	1	rs11097749	ENSG00000254531.1	FLJ20021	-4.41	1.31e-05	0.0013	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101515560	chr4:101347780~101348883:+
THCA	cis	rs890448	1	rs6831916	ENSG00000254531.1	FLJ20021	-4.41	1.31e-05	0.0013	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101515796	chr4:101347780~101348883:+
THCA	cis	rs10833905	0.756	rs4923046	ENSG00000246225.5	RP11-17A1.3	-4.41	1.31e-05	0.0013	-0.31	-0.2	Sudden cardiac arrest;	chr11:22969127	chr11:22829380~22945393:+
THCA	cis	rs2839186	0.619	rs2187118	ENSG00000228137.1	AP001469.7	4.41	1.31e-05	0.0013	0.2	0.2	Testicular germ cell tumor;	chr21:46191396	chr21:46246890~46247682:+
THCA	cis	rs4934494	0.727	rs12764076	ENSG00000240996.1	RP11-80H5.7	-4.41	1.31e-05	0.0013	-0.23	-0.2	Red blood cell count;	chr10:89630443	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.634	rs12762448	ENSG00000240996.1	RP11-80H5.7	-4.41	1.31e-05	0.0013	-0.23	-0.2	Red blood cell count;	chr10:89630483	chr10:89694295~89697928:-
THCA	cis	rs6088590	0.648	rs6059991	ENSG00000269202.1	RP4-614O4.12	-4.41	1.31e-05	0.0013	-0.17	-0.2	Coronary artery disease;	chr20:34693032	chr20:35201747~35203288:-
THCA	cis	rs7186908	0.711	rs9923344	ENSG00000260886.1	TAT-AS1	4.41	1.31e-05	0.0013	0.26	0.2	Liver enzyme levels (alkaline phosphatase);	chr16:72156754	chr16:71565789~71578187:+
THCA	cis	rs7608910	1	rs7608910	ENSG00000271889.1	RP11-493E12.1	-4.41	1.31e-05	0.0013	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977721	chr2:61151433~61162105:-
THCA	cis	rs453301	0.686	rs6601281	ENSG00000233609.3	RP11-62H7.2	-4.41	1.31e-05	0.0013	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9053494	chr8:8961200~8979025:+
THCA	cis	rs2549003	1	rs17848418	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132485496	chr5:132184876~132192808:+
THCA	cis	rs2549003	0.87	rs61175929	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132485856	chr5:132184876~132192808:+
THCA	cis	rs2549003	0.87	rs10053046	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132485866	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs2070726	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132486046	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs2070725	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132486096	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs10214312	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132486174	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs9282762	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132486363	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs2070724	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132486380	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs9282763	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132486441	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs9282761	ENSG00000237714.1	P4HA2-AS1	-4.41	1.31e-05	0.0013	-0.25	-0.2	Asthma (sex interaction);	chr5:132486532	chr5:132184876~132192808:+
THCA	cis	rs8062405	0.824	rs4788083	ENSG00000270424.1	RP11-1348G14.6	4.41	1.31e-05	0.0013	0.23	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28749959~28750595:-
THCA	cis	rs12216545	0.737	rs10238055	ENSG00000241134.3	BET1P1	-4.41	1.31e-05	0.0013	-0.24	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552641	chr7:150749736~150750094:+
THCA	cis	rs875971	0.522	rs1880556	ENSG00000272831.1	RP11-792A8.4	4.41	1.31e-05	0.0013	0.13	0.2	Aortic root size;	chr7:65967557	chr7:66739829~66740385:-
THCA	cis	rs7267979	0.844	rs2424703	ENSG00000277938.1	RP5-965G21.3	4.41	1.31e-05	0.0013	0.16	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.74	rs2259961	ENSG00000277938.1	RP5-965G21.3	4.41	1.31e-05	0.0013	0.16	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.844	rs2474780	ENSG00000277938.1	RP5-965G21.3	4.41	1.31e-05	0.0013	0.16	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.789	rs4815400	ENSG00000277938.1	RP5-965G21.3	-4.41	1.31e-05	0.0013	-0.16	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25229150~25231933:+
THCA	cis	rs654950	0.783	rs668359	ENSG00000230638.4	RP11-486B10.4	4.41	1.31e-05	0.0013	0.22	0.2	Airway imaging phenotypes;	chr1:41537754	chr1:41542069~41544310:+
THCA	cis	rs7826238	0.535	rs2979179	ENSG00000233609.3	RP11-62H7.2	4.41	1.31e-05	0.00131	0.19	0.2	Systolic blood pressure;	chr8:8462519	chr8:8961200~8979025:+
THCA	cis	rs9926296	0.535	rs36022917	ENSG00000260259.1	RP11-368I7.4	-4.41	1.31e-05	0.00131	-0.21	-0.2	Vitiligo;	chr16:89826830	chr16:89682620~89686569:-
THCA	cis	rs9926296	0.562	rs4785725	ENSG00000260259.1	RP11-368I7.4	-4.41	1.31e-05	0.00131	-0.21	-0.2	Vitiligo;	chr16:89826835	chr16:89682620~89686569:-
THCA	cis	rs1334894	1	rs2294807	ENSG00000228559.1	RP3-340B19.3	-4.41	1.31e-05	0.00131	-0.41	-0.2	Coronary artery disease;	chr6:35587333	chr6:35544632~35545669:+
THCA	cis	rs2898290	0.622	rs4840567	ENSG00000251402.3	FAM90A25P	-4.41	1.31e-05	0.00131	-0.26	-0.2	Systolic blood pressure;	chr8:11490116	chr8:12415080~12418090:-
THCA	cis	rs6806253	0.941	rs35972360	ENSG00000239405.1	TMED10P2	4.41	1.31e-05	0.00131	0.31	0.2	Pit-and-Fissure caries;	chr3:128565433	chr3:128538020~128538631:+
THCA	cis	rs12935229	1	rs34031278	ENSG00000260922.1	RP11-538I12.3	-4.41	1.31e-05	0.00131	-0.33	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77293895	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs12933721	ENSG00000260922.1	RP11-538I12.3	-4.41	1.31e-05	0.00131	-0.33	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77294742	chr16:77234877~77290934:+
THCA	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	4.41	1.31e-05	0.00131	0.22	0.2	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
THCA	cis	rs6686643	1	rs6686643	ENSG00000236206.1	RP11-306I1.2	4.41	1.31e-05	0.00131	0.27	0.2	Total ventricular volume;	chr1:165647351	chr1:165598463~165623331:+
THCA	cis	rs7829975	0.846	rs7005216	ENSG00000254153.1	CTA-398F10.2	4.41	1.31e-05	0.00131	0.21	0.2	Mood instability;	chr8:8689600	chr8:8456909~8461337:-
THCA	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	4.41	1.31e-05	0.00131	0.28	0.2	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
THCA	cis	rs7176527	0.5	rs895571	ENSG00000188388.10	GOLGA6L3	4.41	1.31e-05	0.00131	0.26	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:85240472~85247170:+
THCA	cis	rs9300255	0.537	rs2695482	ENSG00000235423.7	RP11-282O18.3	4.41	1.31e-05	0.00131	0.21	0.2	Neutrophil percentage of white cells;	chr12:123138627	chr12:123252030~123261483:-
THCA	cis	rs7474896	1	rs12778627	ENSG00000263064.2	RP11-291L22.7	4.41	1.31e-05	0.00131	0.32	0.2	Obesity (extreme);	chr10:37646474	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.945	rs35175108	ENSG00000263064.2	RP11-291L22.7	4.41	1.31e-05	0.00131	0.32	0.2	Obesity (extreme);	chr10:37647127	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011303	ENSG00000263064.2	RP11-291L22.7	4.41	1.31e-05	0.00131	0.32	0.2	Obesity (extreme);	chr10:37647715	chr10:38448689~38448949:+
THCA	cis	rs7474896	1	rs11011304	ENSG00000263064.2	RP11-291L22.7	4.41	1.31e-05	0.00131	0.32	0.2	Obesity (extreme);	chr10:37648023	chr10:38448689~38448949:+
THCA	cis	rs5758511	0.573	rs2267439	ENSG00000281538.1	RP4-669P10.20	4.41	1.31e-05	0.00131	0.19	0.2	Birth weight;	chr22:41841765	chr22:42138060~42139726:+
THCA	cis	rs7577696	0.695	rs212686	ENSG00000276334.1	AL133243.1	4.41	1.31e-05	0.00131	0.22	0.2	Inflammatory biomarkers;	chr2:32209800	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.695	rs212687	ENSG00000276334.1	AL133243.1	4.41	1.31e-05	0.00131	0.22	0.2	Inflammatory biomarkers;	chr2:32210107	chr2:32521927~32523547:+
THCA	cis	rs7182948	0.957	rs10519233	ENSG00000259531.2	RP11-295H24.3	4.4	1.31e-05	0.00131	0.26	0.2	Lung adenocarcinoma;	chr15:49614173	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.957	rs77846978	ENSG00000259531.2	RP11-295H24.3	4.4	1.31e-05	0.00131	0.26	0.2	Lung adenocarcinoma;	chr15:49614796	chr15:49365124~49366685:-
THCA	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	4.4	1.31e-05	0.00131	0.22	0.2	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
THCA	cis	rs657075	0.595	rs17693348	ENSG00000237714.1	P4HA2-AS1	-4.4	1.31e-05	0.00131	-0.45	-0.2	Rheumatoid arthritis;	chr5:132280515	chr5:132184876~132192808:+
THCA	cis	rs4906332	0.933	rs34606394	ENSG00000269910.1	RP11-73M18.10	4.4	1.31e-05	0.00131	0.17	0.2	Coronary artery disease;	chr14:103449299	chr14:103694516~103695050:-
THCA	cis	rs1991601	0.686	rs2358891	ENSG00000235655.3	H3F3AP4	4.4	1.31e-05	0.00131	0.28	0.2	QRS complex (12-leadsum);	chr2:174694076	chr2:174719908~174720318:+
THCA	cis	rs4308124	0.708	rs61358692	ENSG00000230499.1	AC108463.1	-4.4	1.31e-05	0.00131	-0.29	-0.2	Vitiligo;	chr2:111207582	chr2:111195963~111206494:+
THCA	cis	rs9510787	0.51	rs1034068	ENSG00000205861.10	C1QTNF9B-AS1	-4.4	1.31e-05	0.00131	-0.25	-0.2	Nasopharyngeal carcinoma;	chr13:23656672	chr13:23888889~23897263:+
THCA	cis	rs4948102	0.551	rs4275190	ENSG00000275875.1	RP11-613E4.5	-4.4	1.31e-05	0.00131	-0.24	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55741525~55741869:+
THCA	cis	rs11633886	0.528	rs2899383	ENSG00000273972.1	CTD-2306A12.1	4.4	1.31e-05	0.00131	0.22	0.2	Diisocyanate-induced asthma;	chr15:45804853	chr15:45702640~45703183:+
THCA	cis	rs12935229	0.756	rs17712821	ENSG00000260922.1	RP11-538I12.3	-4.4	1.31e-05	0.00131	-0.31	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77278863	chr16:77234877~77290934:+
THCA	cis	rs9987353	0.83	rs2126267	ENSG00000254153.1	CTA-398F10.2	4.4	1.31e-05	0.00131	0.24	0.2	Recombination measurement;	chr8:9250441	chr8:8456909~8461337:-
THCA	cis	rs7031325	0.719	rs10975724	ENSG00000229611.1	RP11-390F4.10	-4.4	1.31e-05	0.00131	-0.23	-0.2	Systemic lupus erythematosus;	chr9:6665469	chr9:6704471~6707780:+
THCA	cis	rs7031325	0.752	rs10975726	ENSG00000229611.1	RP11-390F4.10	-4.4	1.31e-05	0.00131	-0.23	-0.2	Systemic lupus erythematosus;	chr9:6665851	chr9:6704471~6707780:+
THCA	cis	rs6442522	0.809	rs6805196	ENSG00000249786.6	EAF1-AS1	4.4	1.31e-05	0.00131	0.21	0.2	Uric acid levels;	chr3:15410471	chr3:15436171~15455940:-
THCA	cis	rs79461387	1	rs79461387	ENSG00000263531.1	RP13-753N3.1	-4.4	1.31e-05	0.00131	-0.29	-0.2	Neutrophil percentage of white cells;	chr17:30841059	chr17:30863921~30864940:-
THCA	cis	rs79461387	1	rs75637630	ENSG00000263531.1	RP13-753N3.1	-4.4	1.31e-05	0.00131	-0.29	-0.2	Neutrophil percentage of white cells;	chr17:30841060	chr17:30863921~30864940:-
THCA	cis	rs79461387	1	rs76947600	ENSG00000263531.1	RP13-753N3.1	-4.4	1.31e-05	0.00131	-0.29	-0.2	Neutrophil percentage of white cells;	chr17:30841061	chr17:30863921~30864940:-
THCA	cis	rs79461387	1	rs117529210	ENSG00000263531.1	RP13-753N3.1	-4.4	1.31e-05	0.00131	-0.29	-0.2	Neutrophil percentage of white cells;	chr17:30841062	chr17:30863921~30864940:-
THCA	cis	rs12444979	0.517	rs720176	ENSG00000261195.1	CTD-2380F24.1	-4.4	1.31e-05	0.00131	-0.33	-0.2	Body mass index;	chr16:19710193	chr16:19761172~19766099:-
THCA	cis	rs2253762	0.507	rs11200310	ENSG00000226864.1	ATE1-AS1	4.4	1.31e-05	0.00131	0.32	0.2	Breast cancer;	chr10:121989944	chr10:121928312~121951965:+
THCA	cis	rs4845570	0.749	rs11586446	ENSG00000203288.3	RP11-98D18.9	-4.4	1.31e-05	0.00131	-0.25	-0.2	Coronary artery disease;	chr1:151740012	chr1:151790804~151794402:+
THCA	cis	rs7577696	0.962	rs12992743	ENSG00000276334.1	AL133243.1	-4.4	1.31e-05	0.00131	-0.21	-0.2	Inflammatory biomarkers;	chr2:32075500	chr2:32521927~32523547:+
THCA	cis	rs3770081	1	rs17584578	ENSG00000273080.1	RP11-301O19.1	4.4	1.31e-05	0.00131	0.44	0.2	Facial emotion recognition (sad faces);	chr2:86080501	chr2:86195590~86196049:+
THCA	cis	rs4950322	0.512	rs10736839	ENSG00000271721.1	RP11-337C18.9	-4.4	1.32e-05	0.00131	-0.2	-0.2	Protein quantitative trait loci;	chr1:147370431	chr1:147175602~147177740:+
THCA	cis	rs9309473	0.95	rs6711001	ENSG00000273245.1	RP11-434P11.2	4.4	1.32e-05	0.00131	0.28	0.2	Metabolite levels;	chr2:73623693	chr2:73750256~73750786:-
THCA	cis	rs7608910	1	rs67927699	ENSG00000271889.1	RP11-493E12.1	4.4	1.32e-05	0.00131	0.2	0.2	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60960280	chr2:61151433~61162105:-
THCA	cis	rs1823874	0.71	rs56186545	ENSG00000182397.13	DNM1P46	-4.4	1.32e-05	0.00131	-0.23	-0.2	IgG glycosylation;	chr15:99820554	chr15:99790156~99806927:-
THCA	cis	rs442309	0.687	rs11599754	ENSG00000238280.1	RP11-436D10.3	-4.4	1.32e-05	0.00131	-0.25	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62706891	chr10:62793562~62805887:-
THCA	cis	rs6496932	0.663	rs12915663	ENSG00000259630.2	CTD-2262B20.1	-4.4	1.32e-05	0.00131	-0.24	-0.2	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85415228~85415633:+
THCA	cis	rs10875746	0.859	rs4760695	ENSG00000258234.1	RP11-370I10.2	4.4	1.32e-05	0.00131	0.24	0.2	Longevity (90 years and older);	chr12:48198065	chr12:48231098~48284210:-
THCA	cis	rs2281636	1	rs11190263	ENSG00000233690.1	EBAG9P1	4.4	1.32e-05	0.00131	0.19	0.2	Obesity-related traits;	chr10:99746626	chr10:99697407~99697949:-
THCA	cis	rs801193	0.548	rs2659904	ENSG00000229886.1	RP5-1132H15.3	4.4	1.32e-05	0.00131	0.21	0.2	Aortic root size;	chr7:66713615	chr7:66025126~66031544:-
THCA	cis	rs807029	0.758	rs807027	ENSG00000236662.1	RP11-108L7.4	4.4	1.32e-05	0.00131	0.2	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101004850	chr10:100980507~100985614:-
THCA	cis	rs1873147	0.861	rs2899687	ENSG00000259672.1	RP11-69G7.1	4.4	1.32e-05	0.00131	0.23	0.2	Orofacial clefts;	chr15:63033349	chr15:63098870~63110403:+
THCA	cis	rs6088813	1	rs6088815	ENSG00000279253.1	RP4-614O4.13	4.4	1.32e-05	0.00131	0.19	0.2	Height;	chr20:35388671	chr20:35262727~35264187:-
THCA	cis	rs1876905	0.68	rs9400468	ENSG00000272356.1	RP5-1112D6.8	-4.4	1.32e-05	0.00131	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111138766	chr6:111309203~111313517:+
THCA	cis	rs3892630	0.818	rs80137870	ENSG00000267567.1	CTD-2538C1.3	4.4	1.32e-05	0.00131	0.3	0.2	Red blood cell traits;	chr19:32691844	chr19:32718298~32719595:-
THCA	cis	rs9926296	0.632	rs4785716	ENSG00000274627.1	RP11-104N10.2	-4.4	1.32e-05	0.00131	-0.21	-0.2	Vitiligo;	chr16:89734719	chr16:89516797~89522217:+
THCA	cis	rs61160187	0.582	rs1526896	ENSG00000215032.2	GNL3LP1	4.4	1.32e-05	0.00131	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60891935~60893577:-
THCA	cis	rs11148252	0.904	rs7990581	ENSG00000273784.3	RP11-78J21.7	-4.4	1.32e-05	0.00131	-0.21	-0.2	Lewy body disease;	chr13:52445298	chr13:52600042~52642542:+
THCA	cis	rs12755164	0.533	rs2259126	ENSG00000223479.3	RP4-788P17.1	-4.4	1.32e-05	0.00131	-0.22	-0.2	Schizophrenia;	chr1:72827677	chr1:73635216~73715214:+
THCA	cis	rs8031584	0.678	rs3122	ENSG00000178081.11	ULK4P3	-4.4	1.32e-05	0.00131	-0.27	-0.2	Huntington's disease progression;	chr15:30878087	chr15:30103720~30131757:+
THCA	cis	rs3177980	0.56	rs73026243	ENSG00000239494.2	RN7SL333P	-4.4	1.32e-05	0.00131	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr1:169910890	chr1:169859756~169860052:+
THCA	cis	rs1005277	0.505	rs200935	ENSG00000226578.1	RP11-258F22.1	-4.4	1.32e-05	0.00131	-0.23	-0.2	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:37775371~37784131:-
THCA	cis	rs1371614	0.632	rs6718978	ENSG00000272148.1	RP11-195B17.1	4.4	1.32e-05	0.00132	0.18	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26938723	chr2:27062428~27062907:-
THCA	cis	rs4886920	0.573	rs11854573	ENSG00000260776.4	RP11-114H24.2	4.4	1.32e-05	0.00132	0.26	0.2	Neuroticism;	chr15:77815770	chr15:77914217~77926846:-
THCA	cis	rs858239	0.57	rs10271613	ENSG00000226816.2	AC005082.12	4.4	1.32e-05	0.00132	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23206013~23208045:+
THCA	cis	rs858239	0.57	rs10242166	ENSG00000226816.2	AC005082.12	4.4	1.32e-05	0.00132	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23206013~23208045:+
THCA	cis	rs656319	0.607	rs35437983	ENSG00000261451.1	RP11-981G7.1	-4.4	1.32e-05	0.00132	-0.26	-0.2	Myopia (pathological);	chr8:10147543	chr8:10433672~10438312:+
THCA	cis	rs4789693	0.518	rs6502108	ENSG00000260011.2	RP13-20L14.1	4.4	1.32e-05	0.00132	0.2	0.2	Glucocorticoid-induced osteonecrosis;	chr17:82417023	chr17:82381110~82382690:-
THCA	cis	rs2290416	0.892	rs62523607	ENSG00000253931.1	RP11-909N17.2	4.4	1.32e-05	0.00132	0.4	0.2	Attention deficit hyperactivity disorder;	chr8:143585262	chr8:143412749~143417054:+
THCA	cis	rs61270009	0.955	rs11741675	ENSG00000247828.6	TMEM161B-AS1	4.4	1.32e-05	0.00132	0.17	0.2	Depressive symptoms;	chr5:88332984	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs4916904	ENSG00000247828.6	TMEM161B-AS1	4.4	1.32e-05	0.00132	0.17	0.2	Depressive symptoms;	chr5:88338780	chr5:88268895~88436685:+
THCA	cis	rs1003247	0.614	rs10247225	ENSG00000271122.1	RP11-379H18.1	4.4	1.32e-05	0.00132	0.13	0.2	Cognitive function;	chr7:35571560	chr7:35695214~35699413:+
THCA	cis	rs2590942	0.838	rs2613496	ENSG00000227207.2	RPL31P12	-4.4	1.32e-05	0.00132	-0.32	-0.2	Childhood body mass index;	chr1:72289105	chr1:72301472~72301829:+
THCA	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	4.4	1.32e-05	0.00132	0.22	0.2	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	4.4	1.32e-05	0.00132	0.22	0.2	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	4.4	1.32e-05	0.00132	0.22	0.2	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	4.4	1.32e-05	0.00132	0.22	0.2	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
THCA	cis	rs12819124	0.502	rs10875718	ENSG00000273765.1	RP11-370I10.11	4.4	1.32e-05	0.00132	0.2	0.2	Glycated hemoglobin levels;	chr12:48017319	chr12:48360920~48361377:+
THCA	cis	rs7829975	0.502	rs7820738	ENSG00000233609.3	RP11-62H7.2	-4.4	1.32e-05	0.00132	-0.19	-0.2	Mood instability;	chr8:8845097	chr8:8961200~8979025:+
THCA	cis	rs227275	0.525	rs3974608	ENSG00000248971.2	KRT8P46	-4.4	1.32e-05	0.00132	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102728746~102730171:-
THCA	cis	rs919433	0.617	rs700642	ENSG00000231621.1	AC013264.2	4.4	1.32e-05	0.00132	0.21	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197736006	chr2:197197991~197199273:+
THCA	cis	rs270601	0.739	rs3900945	ENSG00000237714.1	P4HA2-AS1	4.4	1.32e-05	0.00132	0.26	0.2	Acylcarnitine levels;	chr5:132257177	chr5:132184876~132192808:+
THCA	cis	rs12497850	0.931	rs7626445	ENSG00000228638.1	FCF1P2	-4.4	1.32e-05	0.00132	-0.21	-0.2	Parkinson's disease;	chr3:49077111	chr3:48290793~48291375:-
THCA	cis	rs11634944	0.676	rs220028	ENSG00000251896.1	SNORD116-27	-4.4	1.32e-05	0.00132	-0.22	-0.2	Interleukin-8 levels;	chr15:24955890	chr15:25101575~25101666:+
THCA	cis	rs11220082	0.627	rs35102191	ENSG00000254671.2	STT3A-AS1	-4.4	1.32e-05	0.00132	-0.24	-0.2	Schizophrenia;	chr11:125455250	chr11:125570284~125592568:-
THCA	cis	rs12893668	0.703	rs4906335	ENSG00000252469.1	RNU7-160P	4.4	1.32e-05	0.00132	0.24	0.2	Reticulocyte count;	chr14:103554804	chr14:103550345~103550406:+
THCA	cis	rs7726354	0.793	rs73756772	ENSG00000271828.1	CTD-2310F14.1	4.4	1.32e-05	0.00132	0.5	0.2	Breast cancer (early onset);	chr5:56706309	chr5:56927874~56929573:+
THCA	cis	rs394563	0.591	rs11155641	ENSG00000231760.4	RP11-350J20.5	-4.4	1.32e-05	0.00132	-0.25	-0.2	Dupuytren's disease;	chr6:149327459	chr6:149796151~149826294:-
THCA	cis	rs722599	0.748	rs731952	ENSG00000279594.1	RP11-950C14.10	4.4	1.32e-05	0.00132	0.2	0.2	IgG glycosylation;	chr14:74899744	chr14:75011269~75012851:-
THCA	cis	rs72799341	1	rs1458201	ENSG00000279196.1	RP11-1072A3.3	4.4	1.32e-05	0.00132	0.23	0.2	Diastolic blood pressure;	chr16:30904808	chr16:30984630~30988270:-
THCA	cis	rs883924	0.63	rs10115761	ENSG00000231107.1	LINC01508	4.4	1.32e-05	0.00132	0.23	0.2	Hepatitis C induced liver fibrosis;	chr9:90419898	chr9:90300902~90433505:-
THCA	cis	rs9309473	0.95	rs13427832	ENSG00000273245.1	RP11-434P11.2	4.4	1.32e-05	0.00132	0.27	0.2	Metabolite levels;	chr2:73617691	chr2:73750256~73750786:-
THCA	cis	rs962856	0.897	rs7579304	ENSG00000236780.4	AC078941.1	4.4	1.32e-05	0.00132	0.24	0.2	Pancreatic cancer;	chr2:67384118	chr2:67123357~67215319:-
THCA	cis	rs13325613	0.915	rs11926063	ENSG00000223552.1	RP11-24F11.2	-4.4	1.32e-05	0.00132	-0.3	-0.2	Monocyte count;	chr3:46222226	chr3:46364955~46407059:-
THCA	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-4.4	1.32e-05	0.00132	-0.22	-0.2	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	4.4	1.32e-05	0.00132	0.22	0.2	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
THCA	cis	rs17095355	1	rs13377046	ENSG00000203876.8	ADD3-AS1	-4.4	1.32e-05	0.00132	-0.21	-0.2	Biliary atresia;	chr10:109969470	chr10:109940104~110008381:-
THCA	cis	rs17270561	0.636	rs12194699	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25729001	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9379786	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25730027	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9393658	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25730210	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs12529272	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25731114	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9393659	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25731130	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs12203927	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25732462	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs12192077	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25732566	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4464787	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25733330	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4711098	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25734111	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs3922699	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25734741	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs6924782	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25735588	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs6924794	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25735646	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs3922842	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25736336	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs7754733	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25744821	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs7754814	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25745015	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs7775354	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25745038	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9379789	ENSG00000272462.2	U91328.19	-4.4	1.32e-05	0.00132	-0.17	-0.2	Iron status biomarkers;	chr6:25745351	chr6:25992662~26001775:+
THCA	cis	rs57502260	0.704	rs55975204	ENSG00000212093.1	AP000807.1	4.4	1.32e-05	0.00132	0.27	0.2	Total body bone mineral density (age 45-60);	chr11:68481656	chr11:68506083~68506166:-
THCA	cis	rs62292953	0.79	rs11925382	ENSG00000248724.5	NPHP3-AS1	-4.4	1.32e-05	0.00132	-0.33	-0.2	Red cell distribution width;	chr3:132500710	chr3:132721750~132874223:+
THCA	cis	rs454217	0.846	rs1948656	ENSG00000277851.1	RP11-756G20.1	4.4	1.33e-05	0.00132	0.2	0.2	Smoking quantity;	chr12:92337508	chr12:92247756~92363832:-
THCA	cis	rs11971779	0.938	rs28477480	ENSG00000252332.1	RNU6-911P	4.4	1.33e-05	0.00132	0.25	0.2	Diisocyanate-induced asthma;	chr7:139351312	chr7:139448740~139448843:+
THCA	cis	rs7560272	0.501	rs13003035	ENSG00000273245.1	RP11-434P11.2	-4.4	1.33e-05	0.00132	-0.23	-0.2	Schizophrenia;	chr2:73730100	chr2:73750256~73750786:-
THCA	cis	rs7560272	0.501	rs12992607	ENSG00000273245.1	RP11-434P11.2	-4.4	1.33e-05	0.00132	-0.23	-0.2	Schizophrenia;	chr2:73732833	chr2:73750256~73750786:-
THCA	cis	rs875971	0.79	rs10257911	ENSG00000229886.1	RP5-1132H15.3	-4.4	1.33e-05	0.00132	-0.21	-0.2	Aortic root size;	chr7:66278783	chr7:66025126~66031544:-
THCA	cis	rs763121	0.853	rs2267395	ENSG00000235209.1	CTA-150C2.13	4.4	1.33e-05	0.00132	0.27	0.2	Menopause (age at onset);	chr22:38717898	chr22:38921227~38924708:+
THCA	cis	rs6163	0.727	rs284854	ENSG00000236937.2	PTGES3P4	-4.4	1.33e-05	0.00132	-0.25	-0.2	Waist circumference;Hip circumference;	chr10:102814805	chr10:102845595~102845950:+
THCA	cis	rs7178572	0.625	rs907372	ENSG00000259362.2	RP11-307C19.1	-4.4	1.33e-05	0.00132	-0.24	-0.2	Type 2 diabetes;	chr15:77552174	chr15:77525540~77534110:+
THCA	cis	rs944289	0.74	rs7145145	ENSG00000258844.1	RP11-259K15.2	4.4	1.33e-05	0.00132	0.18	0.2	Thyroid cancer;	chr14:36110724	chr14:36214607~36235608:+
THCA	cis	rs944289	0.708	rs7145311	ENSG00000258844.1	RP11-259K15.2	4.4	1.33e-05	0.00132	0.18	0.2	Thyroid cancer;	chr14:36110738	chr14:36214607~36235608:+
THCA	cis	rs516805	0.52	rs9375150	ENSG00000279453.1	RP3-425C14.4	4.4	1.33e-05	0.00132	0.16	0.2	Lymphocyte counts;	chr6:122566410	chr6:122436789~122439223:-
THCA	cis	rs7216064	0.906	rs1976052	ENSG00000278740.1	RP11-147L13.14	4.4	1.33e-05	0.00132	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834462	chr17:68188547~68189165:+
THCA	cis	rs4415084	0.716	rs1438822	ENSG00000272335.1	RP11-53O19.3	4.4	1.33e-05	0.00132	0.17	0.2	Breast cancer;	chr5:44859070	chr5:44826076~44828592:+
THCA	cis	rs9876781	0.967	rs2885509	ENSG00000244380.1	RP11-24C3.2	-4.4	1.33e-05	0.00132	-0.23	-0.2	Longevity;	chr3:48376729	chr3:48440352~48446656:-
THCA	cis	rs2257011	0.733	rs1896796	ENSG00000230373.7	GOLGA6L5P	-4.4	1.33e-05	0.00132	-0.19	-0.2	Height;	chr15:83606228	chr15:84507885~84516814:-
THCA	cis	rs8067545	0.611	rs11868116	ENSG00000270091.1	RP11-78O7.2	-4.4	1.33e-05	0.00132	-0.15	-0.2	Schizophrenia;	chr17:20126280	chr17:19896590~19897287:-
THCA	cis	rs9311474	0.508	rs1570	ENSG00000243224.1	RP5-1157M23.2	-4.4	1.33e-05	0.00132	-0.21	-0.2	Electroencephalogram traits;	chr3:52552666	chr3:52239258~52241097:+
THCA	cis	rs55661361	0.708	rs7113041	ENSG00000245498.5	RP11-677M14.7	-4.4	1.33e-05	0.00132	-0.15	-0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742695	chr11:124800450~124834487:+
THCA	cis	rs2446066	0.872	rs8652	ENSG00000257379.1	RP11-793H13.8	4.4	1.33e-05	0.00132	0.27	0.2	Red blood cell count;	chr12:53446601	chr12:53441741~53467528:+
THCA	cis	rs1538970	0.816	rs11211123	ENSG00000234329.1	RP11-767N6.2	4.4	1.33e-05	0.00132	0.2	0.2	Platelet count;	chr1:45491937	chr1:45651039~45651826:-
THCA	cis	rs7647973	0.769	rs6772452	ENSG00000228638.1	FCF1P2	-4.4	1.33e-05	0.00132	-0.24	-0.2	Menarche (age at onset);	chr3:49003029	chr3:48290793~48291375:-
THCA	cis	rs172166	0.538	rs149956	ENSG00000280107.1	AL022393.9	-4.4	1.33e-05	0.00132	-0.19	-0.2	Cardiac Troponin-T levels;	chr6:28068473	chr6:28170845~28172521:+
THCA	cis	rs9890032	0.564	rs62070643	ENSG00000263531.1	RP13-753N3.1	-4.4	1.33e-05	0.00132	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:30839284	chr17:30863921~30864940:-
THCA	cis	rs13098911	0.54	rs9877748	ENSG00000226074.4	PRSS44	-4.4	1.33e-05	0.00132	-0.36	-0.2	Celiac disease;	chr3:46069589	chr3:46809359~46812558:-
THCA	cis	rs2028299	0.92	rs11638138	ENSG00000259677.1	RP11-493E3.1	-4.4	1.33e-05	0.00132	-0.26	-0.2	Type 2 diabetes;	chr15:89885523	chr15:89876540~89877285:+
THCA	cis	rs755249	0.508	rs624971	ENSG00000182109.6	RP11-69E11.4	4.4	1.33e-05	0.00132	0.2	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39522280~39546187:-
THCA	cis	rs914615	0.552	rs4421576	ENSG00000236675.1	MTX1P1	-4.4	1.33e-05	0.00132	-0.19	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155169734	chr1:155230975~155234325:+
THCA	cis	rs722599	0.748	rs59112602	ENSG00000279594.1	RP11-950C14.10	-4.4	1.33e-05	0.00132	-0.2	-0.2	IgG glycosylation;	chr14:74892114	chr14:75011269~75012851:-
THCA	cis	rs62158800	0.778	rs62158773	ENSG00000237880.1	AC096669.2	4.4	1.33e-05	0.00132	0.31	0.2	Facial morphology (factor 22);	chr2:107573089	chr2:107385632~107542649:-
THCA	cis	rs6088590	0.561	rs6059918	ENSG00000276073.1	RP5-1125A11.7	-4.4	1.33e-05	0.00132	-0.17	-0.2	Coronary artery disease;	chr20:34562699	chr20:33985617~33988989:-
THCA	cis	rs2904524	0.737	rs78139401	ENSG00000257815.4	RP11-611E13.2	-4.4	1.33e-05	0.00132	-0.28	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70175769	chr12:69904033~70243360:-
THCA	cis	rs1728785	0.901	rs698711	ENSG00000274698.1	RP11-71L14.4	4.4	1.33e-05	0.00133	0.27	0.2	Ulcerative colitis;	chr16:68528052	chr16:68450283~68452318:+
THCA	cis	rs739496	0.546	rs11066055	ENSG00000226469.1	ADAM1B	4.4	1.33e-05	0.00133	0.24	0.2	Platelet count;	chr12:111875412	chr12:111927018~111929017:+
THCA	cis	rs7824557	0.525	rs12682349	ENSG00000206014.6	OR7E161P	-4.4	1.33e-05	0.00133	-0.23	-0.2	Retinal vascular caliber;	chr8:11387794	chr8:11928597~11929563:-
THCA	cis	rs61160187	0.577	rs34741733	ENSG00000215032.2	GNL3LP1	4.4	1.33e-05	0.00133	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60891935~60893577:-
THCA	cis	rs375066	0.901	rs368316	ENSG00000278917.1	RP11-15A1.4	-4.4	1.33e-05	0.00133	-0.17	-0.2	Breast cancer;	chr19:43927742	chr19:43891233~43895411:+
THCA	cis	rs12534093	0.701	rs10950951	ENSG00000234286.1	AC006026.13	-4.4	1.33e-05	0.00133	-0.31	-0.2	Infant length;Height;	chr7:23484218	chr7:23680195~23680786:-
THCA	cis	rs59868192	0.925	rs113877402	ENSG00000246740.2	PLA2G4E-AS1	4.4	1.33e-05	0.00133	0.39	0.2	White blood cell count;	chr15:41952725	chr15:41972763~41999094:+
THCA	cis	rs2281603	0.52	rs61985663	ENSG00000272909.1	CTD-2555O16.4	-4.4	1.33e-05	0.00133	-0.23	-0.2	Lymphocyte counts;	chr14:64470986	chr14:64440369~64442238:-
THCA	cis	rs9890032	0.564	rs111305917	ENSG00000263531.1	RP13-753N3.1	-4.4	1.33e-05	0.00133	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:30887777	chr17:30863921~30864940:-
THCA	cis	rs2030746	0.899	rs3843846	ENSG00000237614.1	AC073257.2	4.4	1.33e-05	0.00133	0.24	0.2	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120554223	chr2:120542909~120544326:-
THCA	cis	rs7088591	0.867	rs16911664	ENSG00000276818.1	AC026393.1	4.4	1.33e-05	0.00133	0.42	0.2	Blood pressure;	chr10:58041571	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs58969693	ENSG00000276818.1	AC026393.1	4.4	1.33e-05	0.00133	0.42	0.2	Blood pressure;	chr10:58042008	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs16911666	ENSG00000276818.1	AC026393.1	4.4	1.33e-05	0.00133	0.42	0.2	Blood pressure;	chr10:58042699	chr10:57095699~57095781:+
THCA	cis	rs75920871	0.614	rs10892045	ENSG00000254851.1	RP11-109L13.1	-4.4	1.33e-05	0.00133	-0.42	-0.2	Subjective well-being;	chr11:116914108	chr11:117135528~117138582:+
THCA	cis	rs1962772	0.773	rs7843817	ENSG00000279903.1	RP11-349F21.5	-4.4	1.33e-05	0.00133	-0.25	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17519342	chr8:17500012~17500605:+
THCA	cis	rs755249	0.501	rs2455648	ENSG00000228060.1	RP11-69E11.8	-4.4	1.33e-05	0.00133	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39565160~39573203:+
THCA	cis	rs654950	0.806	rs10749832	ENSG00000230638.4	RP11-486B10.4	-4.4	1.33e-05	0.00133	-0.23	-0.2	Airway imaging phenotypes;	chr1:41576135	chr1:41542069~41544310:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000273142.1	RP11-458F8.4	4.4	1.33e-05	0.00133	0.18	0.2	Aortic root size;	chr7:66164012	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000273142.1	RP11-458F8.4	4.4	1.33e-05	0.00133	0.18	0.2	Aortic root size;	chr7:66166374	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000273142.1	RP11-458F8.4	4.4	1.33e-05	0.00133	0.18	0.2	Aortic root size;	chr7:66168318	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000273142.1	RP11-458F8.4	4.4	1.33e-05	0.00133	0.18	0.2	Aortic root size;	chr7:66169164	chr7:66902857~66906297:+
THCA	cis	rs10875746	0.556	rs4760619	ENSG00000258234.1	RP11-370I10.2	4.4	1.33e-05	0.00133	0.26	0.2	Longevity (90 years and older);	chr12:48106148	chr12:48231098~48284210:-
THCA	cis	rs6490294	0.571	rs12425329	ENSG00000226469.1	ADAM1B	4.4	1.33e-05	0.00133	0.29	0.2	Mean platelet volume;	chr12:112004628	chr12:111927018~111929017:+
THCA	cis	rs812925	0.537	rs778146	ENSG00000270820.4	RP11-355B11.2	-4.4	1.33e-05	0.00133	-0.17	-0.2	Immature fraction of reticulocytes;	chr2:61379340	chr2:61471188~61484130:+
THCA	cis	rs7772486	0.79	rs2265474	ENSG00000270638.1	RP3-466P17.1	4.4	1.33e-05	0.00133	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145735570~145737218:+
THCA	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-4.4	1.33e-05	0.00133	-0.23	-0.2	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-4.4	1.33e-05	0.00133	-0.23	-0.2	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
THCA	cis	rs2436845	0.627	rs2436861	ENSG00000253320.4	KB-1507C5.2	-4.4	1.33e-05	0.00133	-0.18	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102812625	chr8:102864300~102977876:+
THCA	cis	rs2436845	0.603	rs2513923	ENSG00000253320.4	KB-1507C5.2	-4.4	1.33e-05	0.00133	-0.18	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813207	chr8:102864300~102977876:+
THCA	cis	rs10484434	0.818	rs62394542	ENSG00000272462.2	U91328.19	4.4	1.33e-05	0.00133	0.21	0.2	HIV-1 viral setpoint;	chr6:25991007	chr6:25992662~26001775:+
THCA	cis	rs4648045	0.687	rs3821958	ENSG00000246560.2	RP11-10L12.4	4.4	1.34e-05	0.00133	0.23	0.2	Lymphocyte percentage of white cells;	chr4:102587667	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.687	rs1287	ENSG00000246560.2	RP11-10L12.4	4.4	1.34e-05	0.00133	0.23	0.2	Lymphocyte percentage of white cells;	chr4:102588279	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.687	rs1020759	ENSG00000246560.2	RP11-10L12.4	4.4	1.34e-05	0.00133	0.23	0.2	Lymphocyte percentage of white cells;	chr4:102589354	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.687	rs3774960	ENSG00000246560.2	RP11-10L12.4	4.4	1.34e-05	0.00133	0.23	0.2	Lymphocyte percentage of white cells;	chr4:102590173	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.687	rs4698858	ENSG00000246560.2	RP11-10L12.4	4.4	1.34e-05	0.00133	0.23	0.2	Lymphocyte percentage of white cells;	chr4:102591916	chr4:102828055~102844075:+
THCA	cis	rs3758785	0.565	rs598645	ENSG00000255893.1	RP11-685N10.1	4.4	1.34e-05	0.00133	0.21	0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94338579	chr11:94472908~94473570:-
THCA	cis	rs6137726	0.508	rs2424450	ENSG00000237396.1	LINC01384	4.4	1.34e-05	0.00133	0.18	0.2	Amyotrophic lateral sclerosis (sporadic);	chr20:22657348	chr20:22587522~22607517:-
THCA	cis	rs11951515	0.508	rs11958046	ENSG00000248240.1	RP11-159F24.5	-4.4	1.34e-05	0.00133	-0.21	-0.2	Metabolite levels  (X-11787);	chr5:43583287	chr5:43515274~43525310:+
THCA	cis	rs10027350	0.964	rs2302565	ENSG00000281501.1	SEPSECS-AS1	4.4	1.34e-05	0.00133	0.22	0.2	Childhood ear infection;	chr4:25144685	chr4:25160641~25201440:+
THCA	cis	rs7726354	0.793	rs73756771	ENSG00000271828.1	CTD-2310F14.1	4.4	1.34e-05	0.00133	0.52	0.2	Breast cancer (early onset);	chr5:56705175	chr5:56927874~56929573:+
THCA	cis	rs4763879	0.778	rs2895989	ENSG00000256673.1	RP11-599J14.2	4.4	1.34e-05	0.00133	0.24	0.2	Type 1 diabetes;	chr12:9688735	chr12:9398355~9414851:-
THCA	cis	rs1979679	0.918	rs7314502	ENSG00000278733.1	RP11-425D17.1	-4.4	1.34e-05	0.00133	-0.2	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28462300	chr12:28185625~28186190:-
THCA	cis	rs997295	0.713	rs8042567	ENSG00000270964.1	RP11-502I4.3	-4.4	1.34e-05	0.00133	-0.17	-0.2	Motion sickness;	chr15:67683261	chr15:67541072~67542604:-
THCA	cis	rs442309	0.967	rs224031	ENSG00000238280.1	RP11-436D10.3	-4.4	1.34e-05	0.00133	-0.23	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62761596	chr10:62793562~62805887:-
THCA	cis	rs9326248	0.53	rs2000614	ENSG00000280143.1	AP000892.6	4.4	1.34e-05	0.00133	0.31	0.2	Blood protein levels;	chr11:117045026	chr11:117204967~117210292:+
THCA	cis	rs889398	0.802	rs12598642	ENSG00000226232.7	RP11-419C5.2	4.4	1.34e-05	0.00133	0.2	0.2	Body mass index;	chr16:69814869	chr16:69976388~69996188:-
THCA	cis	rs12541437	0.958	rs3020165	ENSG00000253327.2	RAD21-AS1	4.4	1.34e-05	0.00133	0.22	0.2	Gut microbiome composition (winter);	chr8:116915112	chr8:116874424~116876868:+
THCA	cis	rs858239	0.601	rs6962526	ENSG00000226816.2	AC005082.12	4.4	1.34e-05	0.00133	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23206013~23208045:+
THCA	cis	rs858239	0.539	rs6971673	ENSG00000226816.2	AC005082.12	4.4	1.34e-05	0.00133	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23206013~23208045:+
THCA	cis	rs858239	0.601	rs10278700	ENSG00000226816.2	AC005082.12	4.4	1.34e-05	0.00133	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23206013~23208045:+
THCA	cis	rs858239	0.601	rs10263110	ENSG00000226816.2	AC005082.12	4.4	1.34e-05	0.00133	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23206013~23208045:+
THCA	cis	rs6802315	1	rs6802315	ENSG00000272087.1	RP11-379F4.7	4.4	1.34e-05	0.00133	0.18	0.2	Periodontitis (CDC/AAP);	chr3:158796571	chr3:158693120~158693768:-
THCA	cis	rs875971	1	rs7792762	ENSG00000229886.1	RP5-1132H15.3	4.4	1.34e-05	0.00133	0.21	0.2	Aortic root size;	chr7:66539151	chr7:66025126~66031544:-
THCA	cis	rs7587476	0.505	rs777323	ENSG00000229267.2	AC072062.1	4.4	1.34e-05	0.00133	0.24	0.2	Neuroblastoma;	chr2:214873761	chr2:214810229~214963274:+
THCA	cis	rs4245128	0.745	rs10750015	ENSG00000227487.3	NCAM1-AS1	4.4	1.34e-05	0.00133	0.2	0.2	Life satisfaction;	chr11:112938984	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.775	rs6589346	ENSG00000227487.3	NCAM1-AS1	4.4	1.34e-05	0.00133	0.2	0.2	Life satisfaction;	chr11:112940139	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.775	rs12282765	ENSG00000227487.3	NCAM1-AS1	4.4	1.34e-05	0.00133	0.2	0.2	Life satisfaction;	chr11:112940451	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.775	rs10488743	ENSG00000227487.3	NCAM1-AS1	4.4	1.34e-05	0.00133	0.2	0.2	Life satisfaction;	chr11:112942396	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.775	rs1447457	ENSG00000227487.3	NCAM1-AS1	4.4	1.34e-05	0.00133	0.2	0.2	Life satisfaction;	chr11:112946003	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.775	rs10891478	ENSG00000227487.3	NCAM1-AS1	4.4	1.34e-05	0.00133	0.2	0.2	Life satisfaction;	chr11:112946354	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.745	rs1838992	ENSG00000227487.3	NCAM1-AS1	4.4	1.34e-05	0.00133	0.2	0.2	Life satisfaction;	chr11:112947379	chr11:113269532~113273901:-
THCA	cis	rs7829975	0.777	rs486781	ENSG00000253981.4	ALG1L13P	-4.4	1.34e-05	0.00133	-0.19	-0.2	Mood instability;	chr8:8782230	chr8:8236003~8244667:-
THCA	cis	rs7829975	0.777	rs560544	ENSG00000253981.4	ALG1L13P	-4.4	1.34e-05	0.00133	-0.19	-0.2	Mood instability;	chr8:8779919	chr8:8236003~8244667:-
THCA	cis	rs1046896	0.594	rs4075209	ENSG00000263063.1	RP11-388C12.1	-4.4	1.34e-05	0.00133	-0.26	-0.2	Glycated hemoglobin levels;	chr17:82842151	chr17:82713908~82716255:-
THCA	cis	rs7474896	1	rs10827809	ENSG00000263064.2	RP11-291L22.7	-4.4	1.34e-05	0.00133	-0.32	-0.2	Obesity (extreme);	chr10:37642884	chr10:38448689~38448949:+
THCA	cis	rs10911902	0.643	rs75235608	ENSG00000229739.2	RP11-295K2.3	-4.4	1.34e-05	0.00133	-0.32	-0.2	Schizophrenia;	chr1:186303471	chr1:186435161~186470291:+
THCA	cis	rs11976180	1	rs2961120	ENSG00000244198.4	RP4-545C24.1	-4.4	1.34e-05	0.00133	-0.2	-0.2	Obesity-related traits;	chr7:144059492	chr7:144194858~144280547:+
THCA	cis	rs11976180	1	rs2951360	ENSG00000244198.4	RP4-545C24.1	-4.4	1.34e-05	0.00133	-0.2	-0.2	Obesity-related traits;	chr7:144060256	chr7:144194858~144280547:+
THCA	cis	rs3745672	0.744	rs279271	ENSG00000219665.7	CTD-2006C1.2	-4.4	1.34e-05	0.00133	-0.36	-0.2	Multiple sclerosis;	chr19:11958328	chr19:11987617~12046275:+
THCA	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-4.4	1.34e-05	0.00133	-0.11	-0.2	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
THCA	cis	rs7617480	0.617	rs7610519	ENSG00000228638.1	FCF1P2	-4.4	1.34e-05	0.00133	-0.25	-0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48708994	chr3:48290793~48291375:-
THCA	cis	rs831574	0.714	rs166229	ENSG00000280620.1	SCAANT1	-4.4	1.34e-05	0.00133	-0.25	-0.2	Metabolite levels (Dihydroxy docosatrienoic acid);	chr3:64035552	chr3:63911518~63911772:-
THCA	cis	rs804280	0.662	rs11784693	ENSG00000255046.1	RP11-297N6.4	4.4	1.34e-05	0.00133	0.23	0.2	Myopia (pathological);	chr8:11753165	chr8:11797928~11802568:-
THCA	cis	rs4742903	0.967	rs4742904	ENSG00000270332.1	SMC2-AS1	4.4	1.34e-05	0.00133	0.19	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104094671	chr9:104080024~104093073:-
THCA	cis	rs2436845	0.627	rs1897787	ENSG00000253320.4	KB-1507C5.2	4.4	1.34e-05	0.00133	0.18	0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102850195	chr8:102864300~102977876:+
THCA	cis	rs2554380	0.628	rs2081541	ENSG00000176700.18	SCAND2P	-4.4	1.34e-05	0.00133	-0.15	-0.2	Height;	chr15:83774934	chr15:84631451~84647478:+
THCA	cis	rs6894268	0.751	rs28410430	ENSG00000250999.1	RP11-1379J22.5	4.4	1.34e-05	0.00133	0.25	0.2	Eating disorders;	chr5:179595112	chr5:179657762~179664432:+
THCA	cis	rs448720	0.508	rs396174	ENSG00000260657.2	RP11-315D16.4	-4.4	1.34e-05	0.00133	-0.25	-0.2	Cognitive performance;	chr15:67928740	chr15:68267792~68277994:-
THCA	cis	rs12157904	1	rs12158264	ENSG00000279738.1	RP5-1014D13.2	-4.4	1.34e-05	0.00133	-0.34	-0.2	Response to anti-depressant treatment in major depressive disorder;	chr22:37605497	chr22:37876148~37895563:+
THCA	cis	rs9341808	0.667	rs2490239	ENSG00000272129.1	RP11-250B2.6	4.4	1.34e-05	0.00133	0.25	0.2	Sitting height ratio;	chr6:80116572	chr6:80355424~80356859:+
THCA	cis	rs786425	0.637	rs7308234	ENSG00000270095.1	RP11-214K3.18	-4.4	1.34e-05	0.00133	-0.24	-0.2	Pubertal anthropometrics;	chr12:123699257	chr12:123971457~123971714:-
THCA	cis	rs858239	0.539	rs6975852	ENSG00000230042.1	AK3P3	-4.4	1.34e-05	0.00133	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23129178~23129841:+
THCA	cis	rs6088813	0.961	rs878639	ENSG00000279253.1	RP4-614O4.13	-4.4	1.34e-05	0.00133	-0.2	-0.2	Height;	chr20:35306660	chr20:35262727~35264187:-
THCA	cis	rs172166	0.538	rs1150686	ENSG00000280107.1	AL022393.9	-4.4	1.34e-05	0.00133	-0.19	-0.2	Cardiac Troponin-T levels;	chr6:28193493	chr6:28170845~28172521:+
THCA	cis	rs1150688	1	rs1150688	ENSG00000280107.1	AL022393.9	-4.4	1.34e-05	0.00133	-0.19	-0.2	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28170845~28172521:+
THCA	cis	rs11719291	0.833	rs73080361	ENSG00000270441.1	RP11-694I15.7	4.4	1.34e-05	0.00133	0.31	0.2	Cognitive function;	chr3:48794713	chr3:49140086~49160851:-
THCA	cis	rs453301	0.592	rs4841084	ENSG00000233609.3	RP11-62H7.2	4.4	1.34e-05	0.00133	0.19	0.2	Joint mobility (Beighton score);	chr8:9026395	chr8:8961200~8979025:+
THCA	cis	rs453301	0.653	rs2956244	ENSG00000233609.3	RP11-62H7.2	4.4	1.34e-05	0.00133	0.19	0.2	Joint mobility (Beighton score);	chr8:9027656	chr8:8961200~8979025:+
THCA	cis	rs60180747	0.909	rs78136741	ENSG00000261318.1	RP11-653J6.1	4.4	1.34e-05	0.00133	0.28	0.2	Testicular germ cell tumor;	chr15:66435972	chr15:66278498~66293357:-
THCA	cis	rs7208859	0.673	rs999798	ENSG00000280069.1	CTD-2349P21.3	-4.4	1.34e-05	0.00133	-0.28	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30738182~30740275:+
THCA	cis	rs9876781	1	rs3214041	ENSG00000244380.1	RP11-24C3.2	4.4	1.34e-05	0.00133	0.23	0.2	Longevity;	chr3:48413059	chr3:48440352~48446656:-
THCA	cis	rs858239	0.601	rs1981665	ENSG00000226816.2	AC005082.12	4.4	1.34e-05	0.00133	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23206013~23208045:+
THCA	cis	rs9788682	0.747	rs8042374	ENSG00000261143.1	ADAMTS7P3	-4.4	1.34e-05	0.00133	-0.27	-0.2	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615690	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs8043009	ENSG00000261143.1	ADAMTS7P3	-4.4	1.34e-05	0.00133	-0.27	-0.2	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615812	chr15:77976042~77993057:+
THCA	cis	rs10484434	1	rs10484434	ENSG00000272462.2	U91328.19	-4.4	1.34e-05	0.00133	-0.22	-0.2	HIV-1 viral setpoint;	chr6:26031385	chr6:25992662~26001775:+
THCA	cis	rs10484434	0.818	rs62000984	ENSG00000272462.2	U91328.19	4.4	1.34e-05	0.00133	0.22	0.2	HIV-1 viral setpoint;	chr6:26017447	chr6:25992662~26001775:+
THCA	cis	rs7658584	1	rs7682757	ENSG00000246375.2	RP11-10L7.1	4.4	1.34e-05	0.00134	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175424	chr4:88284942~88331421:+
THCA	cis	rs7474896	1	rs11011334	ENSG00000263064.2	RP11-291L22.7	-4.4	1.34e-05	0.00134	-0.32	-0.2	Obesity (extreme);	chr10:37684223	chr10:38448689~38448949:+
THCA	cis	rs116248771	0.739	rs4334688	ENSG00000271778.1	RP11-379F4.8	4.4	1.34e-05	0.00134	0.26	0.2	diarrhoeal disease at age 2;	chr3:158640877	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.69	rs73156439	ENSG00000271778.1	RP11-379F4.8	4.4	1.34e-05	0.00134	0.26	0.2	diarrhoeal disease at age 2;	chr3:158641673	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs2082159	ENSG00000271778.1	RP11-379F4.8	4.4	1.34e-05	0.00134	0.26	0.2	diarrhoeal disease at age 2;	chr3:158641878	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs2082158	ENSG00000271778.1	RP11-379F4.8	4.4	1.34e-05	0.00134	0.26	0.2	diarrhoeal disease at age 2;	chr3:158642002	chr3:158782547~158783124:+
THCA	cis	rs2721173	0.619	rs997258	ENSG00000265393.1	CTD-2517M22.17	4.4	1.34e-05	0.00134	0.25	0.2	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr8:144677692	chr8:144512567~144513672:+
THCA	cis	rs7474896	0.559	rs1735629	ENSG00000120555.12	SEPT7P9	-4.4	1.34e-05	0.00134	-0.26	-0.2	Obesity (extreme);	chr10:37889381	chr10:38383069~38402916:-
THCA	cis	rs9959145	1	rs9946557	ENSG00000267108.1	RP11-861E21.1	4.4	1.34e-05	0.00134	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12563862	chr18:12432897~12437635:+
THCA	cis	rs72843506	0.722	rs3764436	ENSG00000261033.1	RP11-209D14.2	4.4	1.34e-05	0.00134	0.36	0.2	Schizophrenia;	chr17:20110489	chr17:20008051~20009234:-
THCA	cis	rs6449502	0.92	rs4647078	ENSG00000251279.1	CTC-436P18.1	-4.4	1.34e-05	0.00134	-0.33	-0.2	Mean platelet volume;	chr5:60921211	chr5:61162070~61232040:+
THCA	cis	rs863750	0.777	rs825456	ENSG00000275389.1	RP11-214K3.24	4.4	1.34e-05	0.00134	0.27	0.2	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124053028	chr12:124085761~124088598:+
THCA	cis	rs1267303	0.833	rs59914572	ENSG00000232022.5	FAAHP1	4.4	1.34e-05	0.00134	0.22	0.2	Monobrow;	chr1:46525193	chr1:46432129~46445521:+
THCA	cis	rs8067545	0.611	rs9902032	ENSG00000270091.1	RP11-78O7.2	-4.4	1.34e-05	0.00134	-0.15	-0.2	Schizophrenia;	chr17:20111865	chr17:19896590~19897287:-
THCA	cis	rs6832769	0.922	rs28665088	ENSG00000272969.1	RP11-528I4.2	4.4	1.34e-05	0.00134	0.23	0.2	Personality dimensions;	chr4:55384913	chr4:55547112~55547889:+
THCA	cis	rs6442522	0.809	rs2290537	ENSG00000249786.6	EAF1-AS1	4.4	1.34e-05	0.00134	0.21	0.2	Uric acid levels;	chr3:15414210	chr3:15436171~15455940:-
THCA	cis	rs9307551	0.636	rs1440861	ENSG00000250334.4	LINC00989	4.4	1.34e-05	0.00134	0.23	0.2	Refractive error;	chr4:79505470	chr4:79492416~79576460:+
THCA	cis	rs17095355	1	rs7905306	ENSG00000203876.8	ADD3-AS1	-4.4	1.34e-05	0.00134	-0.21	-0.2	Biliary atresia;	chr10:109953144	chr10:109940104~110008381:-
THCA	cis	rs1023500	0.552	rs133368	ENSG00000273366.1	CTA-989H11.1	-4.4	1.34e-05	0.00134	-0.25	-0.2	Schizophrenia;	chr22:42067685	chr22:42278188~42278846:+
THCA	cis	rs10090774	0.901	rs11166995	ENSG00000279766.1	RP11-642A1.2	4.4	1.34e-05	0.00134	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140709152	chr8:140572142~140572812:-
THCA	cis	rs526231	0.725	rs487937	ENSG00000175749.11	EIF3KP1	4.4	1.34e-05	0.00134	0.26	0.2	Primary biliary cholangitis;	chr5:103302541	chr5:103032376~103033031:+
THCA	cis	rs77637988	0.604	rs17855177	ENSG00000202227.1	RNU6-282P	4.4	1.34e-05	0.00134	0.21	0.2	Joint mobility (Beighton score);	chr2:48375113	chr2:48501922~48502024:-
THCA	cis	rs11976180	1	rs1540894	ENSG00000244198.4	RP4-545C24.1	-4.4	1.34e-05	0.00134	-0.2	-0.2	Obesity-related traits;	chr7:144070583	chr7:144194858~144280547:+
THCA	cis	rs10744955	0.727	rs57187078	ENSG00000244879.4	GABPB1-AS1	-4.4	1.34e-05	0.00134	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50157016	chr15:50354959~50372202:+
THCA	cis	rs4682868	0.552	rs6771233	ENSG00000273328.4	RP11-141M3.6	-4.4	1.34e-05	0.00134	-0.24	-0.2	Monocyte percentage of white cells;	chr3:42881205	chr3:42809414~42908105:+
THCA	cis	rs17801127	0.818	rs7600186	ENSG00000231969.1	AC144449.1	-4.4	1.35e-05	0.00134	-0.32	-0.2	Liver enzyme levels (alanine transaminase);	chr2:149707590	chr2:149587196~149848233:+
THCA	cis	rs11540084	0.505	rs35739046	ENSG00000279095.1	AC092066.1	4.4	1.35e-05	0.00134	0.27	0.2	Mean platelet volume;	chr19:44657255	chr19:44664131~44666158:+
THCA	cis	rs10911902	0.643	rs75906210	ENSG00000229739.2	RP11-295K2.3	-4.4	1.35e-05	0.00134	-0.31	-0.2	Schizophrenia;	chr1:186365092	chr1:186435161~186470291:+
THCA	cis	rs758324	0.741	rs10075660	ENSG00000237714.1	P4HA2-AS1	-4.4	1.35e-05	0.00134	-0.28	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:131905150	chr5:132184876~132192808:+
THCA	cis	rs76793172	0.66	rs4803852	ENSG00000267395.4	AC074212.6	-4.4	1.35e-05	0.00134	-0.17	-0.2	Eosinophil counts;	chr19:45735668	chr19:45767796~45772504:+
THCA	cis	rs78487399	0.808	rs7591387	ENSG00000234936.1	AC010883.5	4.4	1.35e-05	0.00134	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43528893	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs111783562	ENSG00000234936.1	AC010883.5	4.4	1.35e-05	0.00134	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43532242	chr2:43229573~43233394:+
THCA	cis	rs1048886	0.816	rs73474934	ENSG00000271967.1	RP11-134K13.4	-4.4	1.35e-05	0.00134	-0.21	-0.2	Type 2 diabetes;	chr6:70410360	chr6:70596438~70596980:+
THCA	cis	rs8030605	0.704	rs7163544	ENSG00000277245.1	RP11-48G14.3	-4.4	1.35e-05	0.00134	-0.34	-0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56386173	chr15:56447120~56447697:+
THCA	cis	rs496547	0.654	rs688161	ENSG00000255422.1	AP002954.4	-4.4	1.35e-05	0.00134	-0.21	-0.2	Hip minimal joint space width;	chr11:118807001	chr11:118704607~118750263:+
THCA	cis	rs11148252	0.904	rs9568734	ENSG00000273784.3	RP11-78J21.7	-4.4	1.35e-05	0.00134	-0.21	-0.2	Lewy body disease;	chr13:52430087	chr13:52600042~52642542:+
THCA	cis	rs3198697	0.663	rs12928099	ENSG00000207425.1	Y_RNA	4.4	1.35e-05	0.00134	0.24	0.2	Triglycerides;	chr16:15056648	chr16:14915457~14915556:-
THCA	cis	rs10875746	0.855	rs73102065	ENSG00000258273.1	RP11-370I10.4	4.4	1.35e-05	0.00134	0.29	0.2	Longevity (90 years and older);	chr12:48098824	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.855	rs73102067	ENSG00000258273.1	RP11-370I10.4	4.4	1.35e-05	0.00134	0.29	0.2	Longevity (90 years and older);	chr12:48100643	chr12:48333755~48333901:-
THCA	cis	rs1728785	1	rs12918861	ENSG00000274698.1	RP11-71L14.4	4.4	1.35e-05	0.00134	0.28	0.2	Ulcerative colitis;	chr16:68532605	chr16:68450283~68452318:+
THCA	cis	rs7829975	0.514	rs2945873	ENSG00000233609.3	RP11-62H7.2	4.4	1.35e-05	0.00134	0.19	0.2	Mood instability;	chr8:8402935	chr8:8961200~8979025:+
THCA	cis	rs4938303	0.633	rs12800436	ENSG00000254851.1	RP11-109L13.1	4.4	1.35e-05	0.00134	0.36	0.2	Triglycerides;	chr11:116688086	chr11:117135528~117138582:+
THCA	cis	rs3806843	0.521	rs192231	ENSG00000202515.1	VTRNA1-3	4.4	1.35e-05	0.00134	0.24	0.2	Depressive symptoms (multi-trait analysis);	chr5:140868954	chr5:140726158~140726246:+
THCA	cis	rs8017455	0.523	rs2075177	ENSG00000259167.2	NMNAT1P1	4.4	1.35e-05	0.00134	0.31	0.2	Hair morphology;	chr14:81092877	chr14:81032529~81033404:+
THCA	cis	rs738144	0.687	rs4821826	ENSG00000235209.1	CTA-150C2.13	-4.4	1.35e-05	0.00134	-0.31	-0.2	IgG glycosylation;	chr22:38796990	chr22:38921227~38924708:+
THCA	cis	rs4273100	0.79	rs60606605	ENSG00000263934.3	SNORD3A	4.4	1.35e-05	0.00134	0.3	0.2	Schizophrenia;	chr17:19373831	chr17:19188016~19188714:+
THCA	cis	rs12931792	0.782	rs6565176	ENSG00000273724.1	RP11-347C12.12	4.4	1.35e-05	0.00134	0.21	0.2	Tonsillectomy;	chr16:30163605	chr16:30336400~30343336:+
THCA	cis	rs12931792	0.72	rs12102320	ENSG00000273724.1	RP11-347C12.12	4.4	1.35e-05	0.00134	0.21	0.2	Tonsillectomy;	chr16:30167195	chr16:30336400~30343336:+
THCA	cis	rs453301	0.657	rs36056437	ENSG00000233609.3	RP11-62H7.2	-4.4	1.35e-05	0.00134	-0.21	-0.2	Joint mobility (Beighton score);	chr8:8935355	chr8:8961200~8979025:+
THCA	cis	rs7577696	0.695	rs12465351	ENSG00000276334.1	AL133243.1	-4.4	1.35e-05	0.00134	-0.21	-0.2	Inflammatory biomarkers;	chr2:32169836	chr2:32521927~32523547:+
THCA	cis	rs8067545	0.75	rs888423	ENSG00000270091.1	RP11-78O7.2	-4.4	1.35e-05	0.00134	-0.15	-0.2	Schizophrenia;	chr17:20096096	chr17:19896590~19897287:-
THCA	cis	rs73108077	1	rs73108077	ENSG00000277112.2	RP11-755J8.1	-4.4	1.35e-05	0.00134	-0.4	-0.2	Red blood cell density in sickle cell anemia;	chr20:31419056	chr20:30681825~30723932:-
THCA	cis	rs7829975	0.511	rs2980512	ENSG00000233609.3	RP11-62H7.2	4.4	1.35e-05	0.00134	0.19	0.2	Mood instability;	chr8:8283379	chr8:8961200~8979025:+
THCA	cis	rs6696239	0.956	rs1045407	ENSG00000227711.2	RP11-275O4.5	4.4	1.35e-05	0.00134	0.27	0.2	Height;	chr1:227659532	chr1:227509028~227520477:-
THCA	cis	rs2948294	0.588	rs4840913	ENSG00000254153.1	CTA-398F10.2	-4.4	1.35e-05	0.00134	-0.22	-0.2	Red cell distribution width;	chr8:8259384	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.514	rs2979139	ENSG00000233609.3	RP11-62H7.2	4.4	1.35e-05	0.00134	0.19	0.2	Mood instability;	chr8:8410803	chr8:8961200~8979025:+
THCA	cis	rs7577696	0.695	rs6717209	ENSG00000276334.1	AL133243.1	-4.4	1.35e-05	0.00134	-0.21	-0.2	Inflammatory biomarkers;	chr2:32168880	chr2:32521927~32523547:+
THCA	cis	rs160451	0.782	rs6999425	ENSG00000251136.7	RP11-37B2.1	4.4	1.35e-05	0.00134	0.18	0.2	Leprosy;	chr8:89694952	chr8:89609409~89757727:-
THCA	cis	rs6546847	0.531	rs2567603	ENSG00000273245.1	RP11-434P11.2	4.4	1.35e-05	0.00134	0.34	0.2	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73750256~73750786:-
THCA	cis	rs4759375	0.915	rs11057273	ENSG00000256092.2	RP13-942N8.1	4.4	1.35e-05	0.00134	0.22	0.2	HDL cholesterol;	chr12:123329919	chr12:123363868~123366113:+
THCA	cis	rs394563	0.839	rs584916	ENSG00000231760.4	RP11-350J20.5	4.4	1.35e-05	0.00134	0.26	0.2	Dupuytren's disease;	chr6:149469183	chr6:149796151~149826294:-
THCA	cis	rs793571	0.666	rs544282	ENSG00000245975.2	RP11-30K9.6	4.4	1.35e-05	0.00134	0.21	0.2	Schizophrenia;	chr15:58729903	chr15:58768072~58770974:-
THCA	cis	rs7989336	0.568	rs9516674	ENSG00000247400.3	DNAJC3-AS1	4.4	1.35e-05	0.00134	0.13	0.2	Obesity;	chr13:96385779	chr13:95648733~95676925:-
THCA	cis	rs4906332	1	rs55731474	ENSG00000269910.1	RP11-73M18.10	4.4	1.35e-05	0.00134	0.17	0.2	Coronary artery disease;	chr14:103412144	chr14:103694516~103695050:-
THCA	cis	rs6121246	0.909	rs6058460	ENSG00000230613.1	HM13-AS1	4.4	1.35e-05	0.00134	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31775268	chr20:31567707~31573263:-
THCA	cis	rs10484434	0.818	rs6925912	ENSG00000272810.1	U91328.22	4.4	1.35e-05	0.00134	0.19	0.2	HIV-1 viral setpoint;	chr6:25976699	chr6:26013241~26013757:+
THCA	cis	rs12234571	1	rs61283667	ENSG00000214293.7	APTR	4.4	1.35e-05	0.00134	0.26	0.2	Obesity-related traits;	chr7:77879771	chr7:77657660~77696265:-
THCA	cis	rs11051970	0.589	rs325425	ENSG00000274964.1	RP11-817I4.1	-4.4	1.35e-05	0.00134	-0.21	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32378278	chr12:32339368~32340724:+
THCA	cis	rs4879656	0.705	rs10813910	ENSG00000225693.1	LAGE3P1	-4.4	1.35e-05	0.00134	-0.23	-0.2	Menopause (age at onset);	chr9:32965209	chr9:33019682~33020165:-
THCA	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-4.4	1.35e-05	0.00134	-0.11	-0.2	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-4.4	1.35e-05	0.00134	-0.11	-0.2	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-4.4	1.35e-05	0.00134	-0.11	-0.2	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
THCA	cis	rs911119	0.913	rs6036465	ENSG00000270001.1	RP11-218C14.8	-4.4	1.35e-05	0.00134	-0.29	-0.2	Chronic kidney disease;	chr20:23607366	chr20:23631826~23632316:-
THCA	cis	rs12586722	1	rs12586722	ENSG00000259158.2	ADAM20P1	-4.4	1.35e-05	0.00134	-0.23	-0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70423423	chr14:70468881~70483756:-
THCA	cis	rs8014252	1	rs75971975	ENSG00000259158.2	ADAM20P1	-4.4	1.35e-05	0.00134	-0.23	-0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70436281	chr14:70468881~70483756:-
THCA	cis	rs8014252	1	rs12436808	ENSG00000259158.2	ADAM20P1	-4.4	1.35e-05	0.00134	-0.23	-0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70437890	chr14:70468881~70483756:-
THCA	cis	rs8014252	1	rs73291944	ENSG00000259158.2	ADAM20P1	-4.4	1.35e-05	0.00134	-0.23	-0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70438599	chr14:70468881~70483756:-
THCA	cis	rs8014252	1	rs73291972	ENSG00000259158.2	ADAM20P1	-4.4	1.35e-05	0.00134	-0.23	-0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70452813	chr14:70468881~70483756:-
THCA	cis	rs35740288	0.77	rs67253156	ENSG00000259295.5	CSPG4P12	4.4	1.35e-05	0.00134	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561814	chr15:85191438~85213905:+
THCA	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-4.4	1.35e-05	0.00134	-0.22	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
THCA	cis	rs138880	0.542	rs9616371	ENSG00000260613.1	RP3-522J7.6	-4.4	1.35e-05	0.00134	-0.32	-0.2	Schizophrenia;	chr22:49912690	chr22:49832616~49837786:-
THCA	cis	rs6088813	0.961	rs6060369	ENSG00000279253.1	RP4-614O4.13	-4.4	1.35e-05	0.00134	-0.19	-0.2	Height;	chr20:35319358	chr20:35262727~35264187:-
THCA	cis	rs890448	1	rs7673910	ENSG00000254531.1	FLJ20021	-4.4	1.35e-05	0.00134	-0.17	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101513367	chr4:101347780~101348883:+
THCA	cis	rs2243480	1	rs1039664	ENSG00000232559.3	GS1-124K5.12	4.4	1.35e-05	0.00134	0.29	0.2	Diabetic kidney disease;	chr7:65984729	chr7:66554588~66576923:-
THCA	cis	rs2070488	0.965	rs2366123	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38451662	chr3:38451027~38454820:-
THCA	cis	rs31251	0.782	rs2108450	ENSG00000237714.1	P4HA2-AS1	4.4	1.35e-05	0.00134	0.25	0.2	Itch intensity from mosquito bite adjusted by bite size;	chr5:131935329	chr5:132184876~132192808:+
THCA	cis	rs7312933	0.618	rs7954523	ENSG00000257225.1	RP11-328C8.4	-4.4	1.35e-05	0.00134	-0.21	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42287706	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.618	rs12366848	ENSG00000257225.1	RP11-328C8.4	-4.4	1.35e-05	0.00134	-0.21	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42288413	chr12:42459366~42466128:+
THCA	cis	rs6840258	0.64	rs4577539	ENSG00000251411.1	RP11-397E7.4	-4.4	1.35e-05	0.00134	-0.23	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87202806	chr4:86913266~86914817:-
THCA	cis	rs9283706	0.655	rs1008017	ENSG00000229666.1	MAST4-AS1	-4.4	1.35e-05	0.00134	-0.28	-0.2	Coronary artery disease;	chr5:66999561	chr5:67001383~67003953:-
THCA	cis	rs3820928	0.839	rs12470666	ENSG00000212391.1	SNORA48	-4.4	1.35e-05	0.00134	-0.22	-0.2	Pulmonary function;	chr2:227011809	chr2:226968989~226969122:-
THCA	cis	rs2070488	0.932	rs1841776	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38439236	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs1841777	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38443328	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs7373816	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38448952	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs13079757	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38449953	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs3792527	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38451721	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.965	rs3762788	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38452361	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs2268753	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38458698	chr3:38451027~38454820:-
THCA	cis	rs454217	0.846	rs337661	ENSG00000277851.1	RP11-756G20.1	4.4	1.35e-05	0.00134	0.2	0.2	Smoking quantity;	chr12:92310960	chr12:92247756~92363832:-
THCA	cis	rs883924	0.63	rs10993452	ENSG00000231107.1	LINC01508	4.4	1.35e-05	0.00134	0.23	0.2	Hepatitis C induced liver fibrosis;	chr9:90425047	chr9:90300902~90433505:-
THCA	cis	rs2070488	1	rs34258593	ENSG00000229589.1	ACVR2B-AS1	4.4	1.35e-05	0.00134	0.19	0.2	Electrocardiographic conduction measures;	chr3:38423074	chr3:38451027~38454820:-
THCA	cis	rs2657294	0.965	rs10824286	ENSG00000233313.2	HMGA1P5	-4.4	1.35e-05	0.00134	-0.26	-0.2	Pneumonia;	chr10:75172251	chr10:75276376~75276646:-
THCA	cis	rs4705962	0.878	rs2299009	ENSG00000230612.2	AC004237.1	4.4	1.35e-05	0.00134	0.25	0.2	Atopic dermatitis;	chr5:132707121	chr5:132688681~132723725:+
THCA	cis	rs889398	0.802	rs12925700	ENSG00000226232.7	RP11-419C5.2	4.4	1.35e-05	0.00134	0.2	0.2	Body mass index;	chr16:69759560	chr16:69976388~69996188:-
THCA	cis	rs35740288	1	rs35740288	ENSG00000259295.5	CSPG4P12	4.4	1.35e-05	0.00134	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85753854	chr15:85191438~85213905:+
THCA	cis	rs35740288	1	rs17577449	ENSG00000259295.5	CSPG4P12	4.4	1.35e-05	0.00134	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85753954	chr15:85191438~85213905:+
THCA	cis	rs6787172	0.728	rs7649463	ENSG00000272087.1	RP11-379F4.7	4.4	1.35e-05	0.00134	0.18	0.2	Subjective well-being;	chr3:158472524	chr3:158693120~158693768:-
THCA	cis	rs172166	0.561	rs149973	ENSG00000220721.1	OR1F12	4.4	1.35e-05	0.00135	0.22	0.2	Cardiac Troponin-T levels;	chr6:28015835	chr6:28073316~28074233:+
THCA	cis	rs172166	0.561	rs149974	ENSG00000220721.1	OR1F12	4.4	1.35e-05	0.00135	0.22	0.2	Cardiac Troponin-T levels;	chr6:28017318	chr6:28073316~28074233:+
THCA	cis	rs2735413	0.632	rs11864652	ENSG00000276007.1	RP11-358L22.3	4.4	1.35e-05	0.00135	0.19	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78060111	chr16:78123243~78124332:+
THCA	cis	rs8031584	0.736	rs11635775	ENSG00000259845.1	HERC2P10	4.4	1.35e-05	0.00135	0.28	0.2	Huntington's disease progression;	chr15:30868437	chr15:30815271~30844153:+
THCA	cis	rs73198271	0.562	rs75525911	ENSG00000253893.2	FAM85B	4.4	1.35e-05	0.00135	0.35	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801849	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.562	rs79296712	ENSG00000253893.2	FAM85B	4.4	1.35e-05	0.00135	0.35	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802468	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.562	rs76702427	ENSG00000253893.2	FAM85B	4.4	1.35e-05	0.00135	0.35	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802631	chr8:8167819~8226614:-
THCA	cis	rs10090774	0.71	rs9324533	ENSG00000280303.2	ERICD	-4.4	1.35e-05	0.00135	-0.19	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140681905	chr8:140636281~140638283:+
THCA	cis	rs8062405	0.755	rs4787457	ENSG00000270424.1	RP11-1348G14.6	4.4	1.35e-05	0.00135	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.755	rs4788080	ENSG00000270424.1	RP11-1348G14.6	4.4	1.35e-05	0.00135	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.755	rs4787456	ENSG00000270424.1	RP11-1348G14.6	4.4	1.35e-05	0.00135	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.755	rs4788078	ENSG00000270424.1	RP11-1348G14.6	4.4	1.35e-05	0.00135	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28749959~28750595:-
THCA	cis	rs2164273	0.565	rs2736387	ENSG00000154316.13	TDH	-4.4	1.35e-05	0.00135	-0.15	-0.2	Extraversion;	chr8:11299862	chr8:11339637~11368452:+
THCA	cis	rs2439831	0.681	rs1549523	ENSG00000166763.7	STRCP1	4.4	1.35e-05	0.00135	0.26	0.2	Lung cancer in ever smokers;	chr15:43331991	chr15:43699488~43718184:-
THCA	cis	rs2439831	0.681	rs1549525	ENSG00000166763.7	STRCP1	4.4	1.35e-05	0.00135	0.26	0.2	Lung cancer in ever smokers;	chr15:43335657	chr15:43699488~43718184:-
THCA	cis	rs4356203	0.905	rs7927240	ENSG00000272034.1	SNORD14A	-4.4	1.35e-05	0.00135	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17056681	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs7946165	ENSG00000272034.1	SNORD14A	-4.4	1.35e-05	0.00135	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17057080	chr11:17074654~17074744:-
THCA	cis	rs1061377	0.513	rs2566162	ENSG00000249685.1	RP11-360F5.3	4.4	1.35e-05	0.00135	0.28	0.2	Uric acid levels;	chr4:39126453	chr4:39133913~39135608:+
THCA	cis	rs2721195	0.614	rs12719778	ENSG00000265393.1	CTD-2517M22.17	-4.4	1.35e-05	0.00135	-0.25	-0.2	Age at first birth;	chr8:144654498	chr8:144512567~144513672:+
THCA	cis	rs10888838	0.756	rs11206309	ENSG00000198711.5	SSBP3-AS1	4.4	1.35e-05	0.00135	0.26	0.2	Mitochondrial DNA levels;	chr1:54228581	chr1:54236440~54239063:+
THCA	cis	rs6449502	0.841	rs1609041	ENSG00000251279.1	CTC-436P18.1	4.4	1.35e-05	0.00135	0.33	0.2	Mean platelet volume;	chr5:60966062	chr5:61162070~61232040:+
THCA	cis	rs11722779	0.658	rs6533044	ENSG00000248971.2	KRT8P46	-4.4	1.36e-05	0.00135	-0.24	-0.2	Schizophrenia;	chr4:102965261	chr4:102728746~102730171:-
THCA	cis	rs2303759	0.515	rs2334867	ENSG00000268686.1	AC010524.2	4.4	1.36e-05	0.00135	0.32	0.2	Multiple sclerosis;	chr19:49284948	chr19:49368705~49388081:-
THCA	cis	rs4948275	0.631	rs2606114	ENSG00000237233.2	TMEM26-AS1	-4.4	1.36e-05	0.00135	-0.26	-0.2	Night sleep phenotypes;	chr10:61589393	chr10:61452639~61481956:+
THCA	cis	rs6088813	1	rs4911492	ENSG00000279253.1	RP4-614O4.13	4.4	1.36e-05	0.00135	0.19	0.2	Height;	chr20:35363996	chr20:35262727~35264187:-
THCA	cis	rs7746199	0.736	rs72845070	ENSG00000272009.1	RP1-313I6.12	-4.4	1.36e-05	0.00135	-0.41	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28078792~28081130:-
THCA	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	4.4	1.36e-05	0.00135	0.22	0.2	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	4.4	1.36e-05	0.00135	0.22	0.2	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	4.4	1.36e-05	0.00135	0.22	0.2	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
THCA	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-4.4	1.36e-05	0.00135	-0.22	-0.2	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-4.4	1.36e-05	0.00135	-0.22	-0.2	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-4.4	1.36e-05	0.00135	-0.22	-0.2	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-4.4	1.36e-05	0.00135	-0.22	-0.2	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-4.4	1.36e-05	0.00135	-0.22	-0.2	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-4.4	1.36e-05	0.00135	-0.22	-0.2	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-4.4	1.36e-05	0.00135	-0.22	-0.2	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-4.4	1.36e-05	0.00135	-0.22	-0.2	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
THCA	cis	rs2072883	0.624	rs1040431	ENSG00000230319.1	AL022476.2	4.4	1.36e-05	0.00135	0.22	0.2	Schizophrenia;	chr22:43060677	chr22:43038585~43052366:+
THCA	cis	rs4654783	0.627	rs2092322	ENSG00000228397.1	RP1-224A6.3	-4.4	1.36e-05	0.00135	-0.28	-0.2	Endometriosis;	chr1:22109230	chr1:22023994~22024968:-
THCA	cis	rs1150668	0.764	rs9368565	ENSG00000176933.5	TOB2P1	4.4	1.36e-05	0.00135	0.22	0.2	Pubertal anthropometrics;	chr6:28377433	chr6:28217643~28218634:-
THCA	cis	rs2657294	0.796	rs2657290	ENSG00000233313.2	HMGA1P5	-4.4	1.36e-05	0.00135	-0.26	-0.2	Pneumonia;	chr10:75207404	chr10:75276376~75276646:-
THCA	cis	rs2657294	0.765	rs2804533	ENSG00000233313.2	HMGA1P5	-4.4	1.36e-05	0.00135	-0.26	-0.2	Pneumonia;	chr10:75207723	chr10:75276376~75276646:-
THCA	cis	rs271738	0.674	rs271762	ENSG00000231768.1	LINC01354	4.4	1.36e-05	0.00135	0.22	0.2	Bipolar disorder;	chr1:234534101	chr1:234527891~234531779:-
THCA	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-4.4	1.36e-05	0.00135	-0.11	-0.2	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-4.4	1.36e-05	0.00135	-0.11	-0.2	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
THCA	cis	rs763121	0.819	rs4560233	ENSG00000228274.3	RP3-508I15.9	-4.4	1.36e-05	0.00135	-0.22	-0.2	Menopause (age at onset);	chr22:38586437	chr22:38667585~38681820:-
THCA	cis	rs748404	0.601	rs502157	ENSG00000249839.1	AC011330.5	4.4	1.36e-05	0.00135	0.23	0.2	Lung cancer;	chr15:43236375	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.681	rs7175434	ENSG00000166763.7	STRCP1	4.4	1.36e-05	0.00135	0.26	0.2	Lung cancer in ever smokers;	chr15:43336344	chr15:43699488~43718184:-
THCA	cis	rs35176054	0.73	rs7093473	ENSG00000280693.1	SH3PXD2A-AS1	4.4	1.36e-05	0.00135	0.36	0.2	Atrial fibrillation;	chr10:103775573	chr10:103745966~103755423:+
THCA	cis	rs172166	0.61	rs156737	ENSG00000220721.1	OR1F12	4.4	1.36e-05	0.00135	0.22	0.2	Cardiac Troponin-T levels;	chr6:27927435	chr6:28073316~28074233:+
THCA	cis	rs4763879	0.593	rs2080206	ENSG00000256673.1	RP11-599J14.2	4.4	1.36e-05	0.00135	0.24	0.2	Type 1 diabetes;	chr12:9715370	chr12:9398355~9414851:-
THCA	cis	rs8177876	0.749	rs12927239	ENSG00000261061.1	RP11-303E16.2	-4.4	1.36e-05	0.00135	-0.27	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81053883	chr16:81030770~81031485:+
THCA	cis	rs791590	1	rs791590	ENSG00000229664.1	RP11-536K7.5	-4.4	1.36e-05	0.00135	-0.33	-0.2	Soluble interleukin-2 receptor subunit alpha;	chr10:6048359	chr10:6025978~6036427:+
THCA	cis	rs9863	0.861	rs4765219	ENSG00000270061.1	RP11-214K3.19	-4.4	1.36e-05	0.00135	-0.26	-0.2	White blood cell count;	chr12:123955563	chr12:123969990~123970344:-
THCA	cis	rs1923243	0.619	rs12131876	ENSG00000223479.3	RP4-788P17.1	4.4	1.36e-05	0.00135	0.22	0.2	Migraine;	chr1:73049654	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs4491023	ENSG00000223479.3	RP4-788P17.1	4.4	1.36e-05	0.00135	0.22	0.2	Migraine;	chr1:73053282	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.674	rs12409227	ENSG00000223479.3	RP4-788P17.1	4.4	1.36e-05	0.00135	0.22	0.2	Schizophrenia;	chr1:73059426	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs34631243	ENSG00000223479.3	RP4-788P17.1	4.4	1.36e-05	0.00135	0.22	0.2	Migraine;	chr1:73060239	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.749	rs11210115	ENSG00000223479.3	RP4-788P17.1	4.4	1.36e-05	0.00135	0.22	0.2	Migraine;	chr1:73062169	chr1:73635216~73715214:+
THCA	cis	rs2439831	1	rs2245908	ENSG00000205771.5	CATSPER2P1	-4.4	1.36e-05	0.00135	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43439256	chr15:43726918~43747094:-
THCA	cis	rs9625935	0.957	rs9625873	ENSG00000279159.1	RP3-394A18.1	-4.4	1.36e-05	0.00135	-0.16	-0.2	Tonsillectomy;	chr22:29892409	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs9625874	ENSG00000279159.1	RP3-394A18.1	-4.4	1.36e-05	0.00135	-0.16	-0.2	Tonsillectomy;	chr22:29892636	chr22:29978950~30028236:-
THCA	cis	rs79040073	0.954	rs79234094	ENSG00000259531.2	RP11-295H24.3	4.4	1.36e-05	0.00135	0.26	0.2	Lung cancer in ever smokers;	chr15:49117330	chr15:49365124~49366685:-
THCA	cis	rs17270561	0.609	rs4712964	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25740594	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9366629	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25740988	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.553	rs6456696	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741180	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs6456697	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741206	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs6456698	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741436	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.666	rs4711099	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741581	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4711100	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741726	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4711101	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741742	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4712965	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741794	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.608	rs4711102	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741847	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4711103	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25741996	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9379788	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25742531	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9358879	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25742690	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs9358880	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25742933	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4145216	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25743331	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4145217	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25743769	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9393665	ENSG00000272462.2	U91328.19	-4.4	1.36e-05	0.00135	-0.17	-0.2	Iron status biomarkers;	chr6:25744056	chr6:25992662~26001775:+
THCA	cis	rs875971	0.793	rs460678	ENSG00000222364.1	RNU6-96P	-4.4	1.36e-05	0.00135	-0.24	-0.2	Aortic root size;	chr7:66062213	chr7:66395191~66395286:+
THCA	cis	rs7520050	0.778	rs3014218	ENSG00000234329.1	RP11-767N6.2	-4.4	1.36e-05	0.00135	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45651039~45651826:-
THCA	cis	rs1790761	0.667	rs1254123	ENSG00000255318.1	RP11-655M14.13	4.4	1.36e-05	0.00135	0.22	0.2	Mean corpuscular volume;	chr11:67567341	chr11:67618279~67627304:-
THCA	cis	rs1003719	0.68	rs3737540	ENSG00000230366.8	DSCR9	4.4	1.36e-05	0.00135	0.2	0.2	Eye color traits;	chr21:37150966	chr21:37208503~37221736:+
THCA	cis	rs2281636	0.754	rs7087826	ENSG00000260475.1	RP11-85A1.3	4.4	1.36e-05	0.00135	0.18	0.2	Obesity-related traits;	chr10:99604588	chr10:99621055~99621918:+
THCA	cis	rs17221829	0.965	rs12278734	ENSG00000280385.1	AP000648.5	-4.4	1.36e-05	0.00135	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89728004	chr11:90193614~90198120:+
THCA	cis	rs1150668	0.796	rs1052215	ENSG00000176933.5	TOB2P1	4.4	1.36e-05	0.00135	0.22	0.2	Pubertal anthropometrics;	chr6:28380381	chr6:28217643~28218634:-
THCA	cis	rs4660214	0.724	rs2484751	ENSG00000228060.1	RP11-69E11.8	4.4	1.36e-05	0.00135	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39565160~39573203:+
THCA	cis	rs17221829	0.614	rs10765236	ENSG00000280385.1	AP000648.5	-4.4	1.36e-05	0.00135	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89716862	chr11:90193614~90198120:+
THCA	cis	rs7726839	0.561	rs72703046	ENSG00000225138.6	CTD-2228K2.7	4.4	1.36e-05	0.00135	0.23	0.2	Obesity-related traits;	chr5:580014	chr5:473236~480884:+
THCA	cis	rs12541437	0.958	rs2921739	ENSG00000253327.2	RAD21-AS1	-4.4	1.36e-05	0.00135	-0.22	-0.2	Gut microbiome composition (winter);	chr8:116917219	chr8:116874424~116876868:+
THCA	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	4.4	1.36e-05	0.00135	0.22	0.2	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
THCA	cis	rs36093844	0.752	rs80193798	ENSG00000279742.1	RP11-700A24.1	-4.4	1.36e-05	0.00135	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866486	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.615	rs77258124	ENSG00000279742.1	RP11-700A24.1	-4.4	1.36e-05	0.00135	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867038	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.8	rs76663264	ENSG00000279742.1	RP11-700A24.1	-4.4	1.36e-05	0.00135	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867412	chr11:85852557~85854943:-
THCA	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	4.4	1.36e-05	0.00135	0.25	0.2	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
THCA	cis	rs330048	0.525	rs10112237	ENSG00000254340.1	RP11-10A14.3	-4.4	1.36e-05	0.00135	-0.21	-0.2	Systemic lupus erythematosus;	chr8:9215219	chr8:9141424~9145435:+
THCA	cis	rs2014572	0.733	rs1019071	ENSG00000267871.4	CTC-444N24.6	4.4	1.36e-05	0.00135	0.18	0.2	Hyperactive-impulsive symptoms;	chr19:57248848	chr19:57267220~57280334:-
THCA	cis	rs6671200	1	rs34396223	ENSG00000235501.4	RP4-639F20.1	-4.4	1.36e-05	0.00135	-0.42	-0.2	Stearic acid (18:0) levels;	chr1:95232272	chr1:94927566~94963270:+
THCA	cis	rs6671200	1	rs62625008	ENSG00000235501.4	RP4-639F20.1	-4.4	1.36e-05	0.00135	-0.42	-0.2	Stearic acid (18:0) levels;	chr1:95237026	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.92	rs35403759	ENSG00000235501.4	RP4-639F20.1	-4.4	1.36e-05	0.00135	-0.42	-0.2	Stearic acid (18:0) levels;	chr1:95237334	chr1:94927566~94963270:+
THCA	cis	rs1124769	0.692	rs12595526	ENSG00000259378.1	DCAF13P3	4.4	1.36e-05	0.00135	0.3	0.2	Cognitive performance;	chr15:50932824	chr15:50944663~50945996:+
THCA	cis	rs10484434	0.901	rs41266783	ENSG00000272462.2	U91328.19	4.4	1.36e-05	0.00135	0.22	0.2	HIV-1 viral setpoint;	chr6:26032200	chr6:25992662~26001775:+
THCA	cis	rs5751614	0.62	rs5759670	ENSG00000240160.3	RN7SL263P	4.4	1.36e-05	0.00135	0.24	0.2	Height;	chr22:23272239	chr22:23261782~23262071:-
THCA	cis	rs7772486	0.686	rs1292334	ENSG00000270638.1	RP3-466P17.1	4.4	1.36e-05	0.00135	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145735570~145737218:+
THCA	cis	rs12446554	0.509	rs56100071	ENSG00000261195.1	CTD-2380F24.1	-4.4	1.36e-05	0.00135	-0.33	-0.2	Obesity;	chr16:19698429	chr16:19761172~19766099:-
THCA	cis	rs10875746	0.551	rs12322347	ENSG00000226413.2	OR8T1P	4.4	1.36e-05	0.00135	0.29	0.2	Longevity (90 years and older);	chr12:48313915	chr12:48442030~48442947:-
THCA	cis	rs10875746	0.551	rs12322348	ENSG00000226413.2	OR8T1P	4.4	1.36e-05	0.00135	0.29	0.2	Longevity (90 years and older);	chr12:48313916	chr12:48442030~48442947:-
THCA	cis	rs1728785	1	rs1645928	ENSG00000274698.1	RP11-71L14.4	4.4	1.37e-05	0.00136	0.29	0.2	Ulcerative colitis;	chr16:68556707	chr16:68450283~68452318:+
THCA	cis	rs736408	0.812	rs746694	ENSG00000243224.1	RP5-1157M23.2	-4.4	1.37e-05	0.00136	-0.22	-0.2	Bipolar disorder;	chr3:52792604	chr3:52239258~52241097:+
THCA	cis	rs6570726	0.875	rs368744	ENSG00000270638.1	RP3-466P17.1	4.4	1.37e-05	0.00136	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145735570~145737218:+
THCA	cis	rs2717559	0.515	rs55720963	ENSG00000253741.1	CTD-2292P10.4	4.4	1.37e-05	0.00136	0.26	0.2	Urinary tract infection frequency;	chr8:142814541	chr8:142702252~142726973:-
THCA	cis	rs227275	0.525	rs10028116	ENSG00000248971.2	KRT8P46	-4.4	1.37e-05	0.00136	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102728746~102730171:-
THCA	cis	rs227275	0.554	rs9307281	ENSG00000248971.2	KRT8P46	-4.4	1.37e-05	0.00136	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.903	rs6533037	ENSG00000248971.2	KRT8P46	-4.4	1.37e-05	0.00136	-0.24	-0.2	Schizophrenia;	chr4:102935865	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.903	rs4530634	ENSG00000248971.2	KRT8P46	-4.4	1.37e-05	0.00136	-0.24	-0.2	Schizophrenia;	chr4:102937924	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs7676943	ENSG00000248971.2	KRT8P46	-4.4	1.37e-05	0.00136	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs6419160	ENSG00000248971.2	KRT8P46	-4.4	1.37e-05	0.00136	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.901	rs28674656	ENSG00000248971.2	KRT8P46	-4.4	1.37e-05	0.00136	-0.24	-0.2	Schizophrenia;	chr4:102944396	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.838	rs3974494	ENSG00000248971.2	KRT8P46	-4.4	1.37e-05	0.00136	-0.24	-0.2	Schizophrenia;	chr4:102945323	chr4:102728746~102730171:-
THCA	cis	rs12497850	0.931	rs4974080	ENSG00000228638.1	FCF1P2	-4.4	1.37e-05	0.00136	-0.21	-0.2	Parkinson's disease;	chr3:48993395	chr3:48290793~48291375:-
THCA	cis	rs16846053	0.786	rs1227922	ENSG00000227403.1	AC009299.3	4.4	1.37e-05	0.00136	0.44	0.2	Blood osmolality (transformed sodium);	chr2:161835130	chr2:161244739~161249050:+
THCA	cis	rs964611	0.938	rs8032357	ENSG00000259488.2	RP11-154J22.1	-4.4	1.37e-05	0.00136	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48326622	chr15:48312353~48331856:-
THCA	cis	rs9380516	0.627	rs7748266	ENSG00000228559.1	RP3-340B19.3	-4.4	1.37e-05	0.00136	-0.29	-0.2	Hepatitis C induced liver fibrosis;	chr6:35624967	chr6:35544632~35545669:+
THCA	cis	rs1790761	0.692	rs10896179	ENSG00000255318.1	RP11-655M14.13	4.4	1.37e-05	0.00136	0.22	0.2	Mean corpuscular volume;	chr11:67549457	chr11:67618279~67627304:-
THCA	cis	rs9880211	0.898	rs28877020	ENSG00000239213.4	NCK1-AS1	4.4	1.37e-05	0.00136	0.22	0.2	Height;Body mass index;	chr3:136676874	chr3:136841726~136862054:-
THCA	cis	rs27434	0.605	rs12659825	ENSG00000272109.1	CTD-2260A17.3	4.4	1.37e-05	0.00136	0.32	0.2	Ankylosing spondylitis;	chr5:96852380	chr5:96804353~96806105:+
THCA	cis	rs734999	0.933	rs4648648	ENSG00000225931.3	RP3-395M20.7	4.4	1.37e-05	0.00136	0.24	0.2	Ulcerative colitis;	chr1:2581013	chr1:2566410~2569888:+
THCA	cis	rs7191700	0.836	rs28502009	ENSG00000262703.1	RP11-485G7.6	4.4	1.37e-05	0.00136	0.25	0.2	Multiple sclerosis;	chr16:11332684	chr16:11348143~11349321:-
THCA	cis	rs881375	0.526	rs1930785	ENSG00000270917.1	RP11-27I1.6	-4.4	1.37e-05	0.00136	-0.27	-0.2	Rheumatoid arthritis;	chr9:120928959	chr9:120812475~120812845:-
THCA	cis	rs9876781	1	rs28824259	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48384185	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs12487542	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48384586	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs73074358	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48385757	chr3:48440352~48446656:-
THCA	cis	rs9876781	0.967	rs34761139	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48386489	chr3:48440352~48446656:-
THCA	cis	rs9876781	0.868	rs9875280	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48387420	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs6796491	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48388977	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs6804774	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48389129	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs9826195	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48392157	chr3:48440352~48446656:-
THCA	cis	rs9876781	0.967	rs9864815	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48392588	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs9809843	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48392923	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs1563736	ENSG00000244380.1	RP11-24C3.2	4.4	1.37e-05	0.00136	0.23	0.2	Longevity;	chr3:48395329	chr3:48440352~48446656:-
THCA	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	4.4	1.37e-05	0.00136	0.22	0.2	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
THCA	cis	rs990871	0.53	rs1194263	ENSG00000227207.2	RPL31P12	-4.4	1.37e-05	0.00136	-0.23	-0.2	Subcutaneous adipose tissue;	chr1:72242471	chr1:72301472~72301829:+
THCA	cis	rs3892630	0.878	rs8108621	ENSG00000267567.1	CTD-2538C1.3	4.4	1.37e-05	0.00136	0.3	0.2	Red blood cell traits;	chr19:32692385	chr19:32718298~32719595:-
THCA	cis	rs5769765	0.908	rs138867	ENSG00000260613.1	RP3-522J7.6	4.4	1.37e-05	0.00136	0.24	0.2	Schizophrenia;	chr22:49814055	chr22:49832616~49837786:-
THCA	cis	rs6442522	1	rs6778562	ENSG00000249786.6	EAF1-AS1	4.4	1.37e-05	0.00136	0.21	0.2	Uric acid levels;	chr3:15441268	chr3:15436171~15455940:-
THCA	cis	rs9926296	0.643	rs2159114	ENSG00000260259.1	RP11-368I7.4	-4.4	1.37e-05	0.00136	-0.22	-0.2	Vitiligo;	chr16:89765433	chr16:89682620~89686569:-
THCA	cis	rs172166	0.516	rs2791333	ENSG00000280107.1	AL022393.9	-4.4	1.37e-05	0.00136	-0.19	-0.2	Cardiac Troponin-T levels;	chr6:28143336	chr6:28170845~28172521:+
THCA	cis	rs911119	0.866	rs6048925	ENSG00000270001.1	RP11-218C14.8	-4.4	1.37e-05	0.00136	-0.29	-0.2	Chronic kidney disease;	chr20:23598419	chr20:23631826~23632316:-
THCA	cis	rs911119	0.913	rs6048926	ENSG00000270001.1	RP11-218C14.8	-4.4	1.37e-05	0.00136	-0.29	-0.2	Chronic kidney disease;	chr20:23600350	chr20:23631826~23632316:-
THCA	cis	rs911119	0.913	rs6106685	ENSG00000270001.1	RP11-218C14.8	-4.4	1.37e-05	0.00136	-0.29	-0.2	Chronic kidney disease;	chr20:23600975	chr20:23631826~23632316:-
THCA	cis	rs1023500	0.596	rs133369	ENSG00000273366.1	CTA-989H11.1	-4.4	1.37e-05	0.00136	-0.25	-0.2	Schizophrenia;	chr22:42067810	chr22:42278188~42278846:+
THCA	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	4.4	1.37e-05	0.00136	0.22	0.2	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	4.4	1.37e-05	0.00136	0.22	0.2	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	4.4	1.37e-05	0.00136	0.22	0.2	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
THCA	cis	rs9928842	0.882	rs11641896	ENSG00000261783.1	RP11-252K23.2	4.4	1.37e-05	0.00136	0.39	0.2	Alcoholic chronic pancreatitis;	chr16:75266281	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	4.4	1.37e-05	0.00136	0.24	0.2	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
THCA	cis	rs67478160	0.572	rs8016014	ENSG00000269940.1	RP11-73M18.7	4.4	1.37e-05	0.00136	0.19	0.2	Schizophrenia;	chr14:103827461	chr14:103694560~103695170:+
THCA	cis	rs4713118	0.955	rs9468200	ENSG00000220721.1	OR1F12	4.4	1.37e-05	0.00136	0.26	0.2	Parkinson's disease;	chr6:27715284	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.955	rs34752872	ENSG00000220721.1	OR1F12	4.4	1.37e-05	0.00136	0.26	0.2	Parkinson's disease;	chr6:27715465	chr6:28073316~28074233:+
THCA	cis	rs9326248	0.53	rs6589589	ENSG00000280143.1	AP000892.6	4.4	1.37e-05	0.00136	0.32	0.2	Blood protein levels;	chr11:117061712	chr11:117204967~117210292:+
THCA	cis	rs332034	0.546	rs28581487	ENSG00000253893.2	FAM85B	4.39	1.37e-05	0.00136	0.38	0.2	Conduct disorder (maternal expressed emotions interaction);	chr8:8838832	chr8:8167819~8226614:-
THCA	cis	rs332034	0.546	rs28481744	ENSG00000253893.2	FAM85B	4.39	1.37e-05	0.00136	0.38	0.2	Conduct disorder (maternal expressed emotions interaction);	chr8:8838836	chr8:8167819~8226614:-
THCA	cis	rs72753537	0.817	rs72753507	ENSG00000214417.4	KRT18P13	4.39	1.37e-05	0.00136	0.23	0.2	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97851554	chr9:97698922~97700734:+
THCA	cis	rs72753537	0.689	rs72753509	ENSG00000214417.4	KRT18P13	4.39	1.37e-05	0.00136	0.23	0.2	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97852718	chr9:97698922~97700734:+
THCA	cis	rs2904524	1	rs7980085	ENSG00000257815.4	RP11-611E13.2	4.39	1.37e-05	0.00136	0.18	0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70293850	chr12:69904033~70243360:-
THCA	cis	rs4356203	0.875	rs7939614	ENSG00000272034.1	SNORD14A	-4.39	1.37e-05	0.00136	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058073	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs9919540	ENSG00000272034.1	SNORD14A	-4.39	1.37e-05	0.00136	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058786	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs17472886	ENSG00000272034.1	SNORD14A	-4.39	1.37e-05	0.00136	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17064620	chr11:17074654~17074744:-
THCA	cis	rs10761482	0.668	rs1002710	ENSG00000254271.1	RP11-131N11.4	4.39	1.37e-05	0.00136	0.24	0.2	Schizophrenia;	chr10:60362362	chr10:60734342~60741828:+
THCA	cis	rs7615952	0.8	rs12489350	ENSG00000248787.1	RP11-666A20.4	-4.39	1.37e-05	0.00136	-0.34	-0.2	Blood pressure (smoking interaction);	chr3:125925273	chr3:125908005~125910272:-
THCA	cis	rs4878497	0.544	rs3205166	ENSG00000232303.2	DFFBP1	4.39	1.37e-05	0.00136	0.23	0.2	Inflammatory skin disease;	chr9:32459452	chr9:32566148~32567126:-
THCA	cis	rs914615	0.529	rs11264338	ENSG00000236675.1	MTX1P1	-4.39	1.37e-05	0.00136	-0.18	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155166081	chr1:155230975~155234325:+
THCA	cis	rs910873	0.656	rs62213589	ENSG00000276073.1	RP5-1125A11.7	4.39	1.37e-05	0.00136	0.35	0.2	Melanoma;	chr20:34632031	chr20:33985617~33988989:-
THCA	cis	rs8081395	0.741	rs2645462	ENSG00000267302.4	RP11-178C3.2	4.39	1.37e-05	0.00136	0.23	0.2	White blood cell count;	chr17:59906198	chr17:59964832~59996972:+
THCA	cis	rs8081395	0.711	rs1292034	ENSG00000267302.4	RP11-178C3.2	4.39	1.37e-05	0.00136	0.23	0.2	White blood cell count;	chr17:59912499	chr17:59964832~59996972:+
THCA	cis	rs8081395	0.741	rs180532	ENSG00000267302.4	RP11-178C3.2	4.39	1.37e-05	0.00136	0.23	0.2	White blood cell count;	chr17:59925936	chr17:59964832~59996972:+
THCA	cis	rs8081395	0.741	rs180530	ENSG00000267302.4	RP11-178C3.2	4.39	1.37e-05	0.00136	0.23	0.2	White blood cell count;	chr17:59926233	chr17:59964832~59996972:+
THCA	cis	rs4654783	0.671	rs3765351	ENSG00000218510.5	LINC00339	-4.39	1.37e-05	0.00136	-0.21	-0.2	Endometriosis;	chr1:22119498	chr1:22025188~22031223:+
THCA	cis	rs9800506	0.609	rs3798346	ENSG00000271304.1	DPRXP2	4.39	1.37e-05	0.00136	0.26	0.2	Neutrophil percentage of granulocytes;	chr6:35594863	chr6:35989515~35990436:-
THCA	cis	rs62025270	0.632	rs56153788	ENSG00000259295.5	CSPG4P12	-4.39	1.37e-05	0.00136	-0.34	-0.2	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85191438~85213905:+
THCA	cis	rs427943	0.553	rs11701929	ENSG00000223768.1	LINC00205	-4.39	1.37e-05	0.00136	-0.18	-0.2	Body mass index;	chr21:45224820	chr21:45293285~45297354:+
THCA	cis	rs854765	0.686	rs8065497	ENSG00000281749.1	Y_RNA	-4.39	1.37e-05	0.00136	-0.26	-0.2	Total body bone mineral density;	chr17:17879335	chr17:18001101~18001195:-
THCA	cis	rs11722779	0.873	rs6533041	ENSG00000248971.2	KRT8P46	-4.39	1.37e-05	0.00136	-0.24	-0.2	Schizophrenia;	chr4:102951615	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs4699037	ENSG00000248971.2	KRT8P46	-4.39	1.37e-05	0.00136	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs3857198	ENSG00000248971.2	KRT8P46	-4.39	1.37e-05	0.00136	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.935	rs3857199	ENSG00000248971.2	KRT8P46	-4.39	1.37e-05	0.00136	-0.24	-0.2	Schizophrenia;	chr4:102957991	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs4699039	ENSG00000248971.2	KRT8P46	-4.39	1.37e-05	0.00136	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102728746~102730171:-
THCA	cis	rs4950322	0.748	rs56392137	ENSG00000271721.1	RP11-337C18.9	4.39	1.37e-05	0.00136	0.23	0.2	Protein quantitative trait loci;	chr1:147352450	chr1:147175602~147177740:+
THCA	cis	rs860295	0.702	rs10908479	ENSG00000160766.13	GBAP1	-4.39	1.37e-05	0.00136	-0.23	-0.2	Body mass index;	chr1:155673612	chr1:155213821~155227422:-
THCA	cis	rs763121	0.853	rs5750673	ENSG00000273076.1	RP3-508I15.22	4.39	1.37e-05	0.00136	0.2	0.2	Menopause (age at onset);	chr22:38714119	chr22:38743495~38743910:+
THCA	cis	rs2447820	1	rs371883	ENSG00000249996.1	RP11-359P5.1	-4.39	1.37e-05	0.00136	-0.25	-0.2	Migraine;	chr5:122928275	chr5:123036271~123054667:+
THCA	cis	rs35740288	0.822	rs11630179	ENSG00000259295.5	CSPG4P12	4.39	1.37e-05	0.00136	0.31	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85739703	chr15:85191438~85213905:+
THCA	cis	rs853679	1	rs853694	ENSG00000272009.1	RP1-313I6.12	-4.39	1.37e-05	0.00136	-0.26	-0.2	Depression;	chr6:28311323	chr6:28078792~28081130:-
THCA	cis	rs2070488	1	rs13072809	ENSG00000229589.1	ACVR2B-AS1	4.39	1.37e-05	0.00136	0.18	0.2	Electrocardiographic conduction measures;	chr3:38426680	chr3:38451027~38454820:-
THCA	cis	rs9475752	0.545	rs1044670	ENSG00000231441.1	RP11-472M19.2	-4.39	1.37e-05	0.00136	-0.28	-0.2	Menarche (age at onset);	chr6:57027181	chr6:56844002~56864078:+
THCA	cis	rs12681288	0.723	rs11784252	ENSG00000260721.1	AF067845.1	4.39	1.37e-05	0.00136	0.25	0.2	Schizophrenia;	chr8:1077964	chr8:1368642~1369833:-
THCA	cis	rs9880211	0.563	rs6793835	ENSG00000273486.1	RP11-731C17.2	-4.39	1.37e-05	0.00136	-0.2	-0.2	Height;Body mass index;	chr3:136101092	chr3:136837338~136839021:-
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000164669.11	INTS4P1	-4.39	1.37e-05	0.00136	-0.25	-0.2	Calcium levels;	chr7:65996954	chr7:65141225~65234216:+
THCA	cis	rs2836950	0.565	rs2150414	ENSG00000238141.2	BRWD1-AS1	-4.39	1.37e-05	0.00136	-0.23	-0.2	Menarche (age at onset);	chr21:39243062	chr21:39315707~39323218:+
THCA	cis	rs11902236	0.545	rs3791759	ENSG00000188525.3	AC010969.1	-4.39	1.38e-05	0.00136	-0.24	-0.2	Prostate cancer;	chr2:9979751	chr2:10003158~10006030:-
THCA	cis	rs72928364	0.858	rs34645172	ENSG00000256628.3	ZBTB11-AS1	4.39	1.38e-05	0.00136	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100990891	chr3:101676475~101679217:+
THCA	cis	rs2243480	0.522	rs778717	ENSG00000228409.4	CCT6P1	4.39	1.38e-05	0.00136	0.3	0.2	Diabetic kidney disease;	chr7:66383164	chr7:65751142~65763354:+
THCA	cis	rs6723108	0.515	rs4954179	ENSG00000224043.6	CCNT2-AS1	-4.39	1.38e-05	0.00136	-0.21	-0.2	Type 2 diabetes;	chr2:134800167	chr2:134735464~134918710:-
THCA	cis	rs7855088	0.789	rs7044744	ENSG00000236130.1	PTCSC2	-4.39	1.38e-05	0.00136	-0.16	-0.2	Serum thyroid-stimulating hormone levels;	chr9:98006994	chr9:97805935~97810008:-
THCA	cis	rs7577696	0.649	rs212762	ENSG00000276334.1	AL133243.1	4.39	1.38e-05	0.00136	0.21	0.2	Inflammatory biomarkers;	chr2:32204428	chr2:32521927~32523547:+
THCA	cis	rs11644601	1	rs11644601	ENSG00000263335.1	AF001548.5	-4.39	1.38e-05	0.00136	-0.25	-0.2	Metabolite levels (lipid measures);	chr16:15078261	chr16:15726674~15732993:+
THCA	cis	rs2657294	0.965	rs7079694	ENSG00000226051.5	ZNF503-AS1	-4.39	1.38e-05	0.00136	-0.27	-0.2	Pneumonia;	chr10:75136804	chr10:75269819~75373500:+
THCA	cis	rs4763879	0.634	rs61915472	ENSG00000256673.1	RP11-599J14.2	4.39	1.38e-05	0.00136	0.24	0.2	Type 1 diabetes;	chr12:9700995	chr12:9398355~9414851:-
THCA	cis	rs4948275	0.693	rs753246	ENSG00000237233.2	TMEM26-AS1	-4.39	1.38e-05	0.00137	-0.26	-0.2	Night sleep phenotypes;	chr10:61582729	chr10:61452639~61481956:+
THCA	cis	rs2191566	1	rs2191566	ENSG00000266921.1	RP11-15A1.7	4.39	1.38e-05	0.00137	0.19	0.2	Acute lymphoblastic leukemia (childhood);	chr19:44007237	chr19:43996896~44002836:-
THCA	cis	rs944289	0.616	rs410546	ENSG00000258844.1	RP11-259K15.2	-4.39	1.38e-05	0.00137	-0.18	-0.2	Thyroid cancer;	chr14:36071858	chr14:36214607~36235608:+
THCA	cis	rs10875746	0.624	rs7297298	ENSG00000258234.1	RP11-370I10.2	4.39	1.38e-05	0.00137	0.23	0.2	Longevity (90 years and older);	chr12:48278523	chr12:48231098~48284210:-
THCA	cis	rs2070488	0.965	rs13079145	ENSG00000229589.1	ACVR2B-AS1	4.39	1.38e-05	0.00137	0.19	0.2	Electrocardiographic conduction measures;	chr3:38476501	chr3:38451027~38454820:-
THCA	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-4.39	1.38e-05	0.00137	-0.24	-0.2	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
THCA	cis	rs791590	0.941	rs41294713	ENSG00000229664.1	RP11-536K7.5	-4.39	1.38e-05	0.00137	-0.33	-0.2	Soluble interleukin-2 receptor subunit alpha;	chr10:6038391	chr10:6025978~6036427:+
THCA	cis	rs4648045	0.647	rs230526	ENSG00000246560.2	RP11-10L12.4	-4.39	1.38e-05	0.00137	-0.23	-0.2	Lymphocyte percentage of white cells;	chr4:102537668	chr4:102828055~102844075:+
THCA	cis	rs5758511	0.68	rs5758652	ENSG00000227370.1	RP4-669P10.19	4.39	1.38e-05	0.00137	0.23	0.2	Birth weight;	chr22:42216402	chr22:42132543~42132998:+
THCA	cis	rs5758511	0.68	rs1033460	ENSG00000227370.1	RP4-669P10.19	4.39	1.38e-05	0.00137	0.23	0.2	Birth weight;	chr22:42223302	chr22:42132543~42132998:+
THCA	cis	rs5758511	0.679	rs55867855	ENSG00000227370.1	RP4-669P10.19	4.39	1.38e-05	0.00137	0.23	0.2	Birth weight;	chr22:42227252	chr22:42132543~42132998:+
THCA	cis	rs10510102	0.516	rs12256693	ENSG00000226864.1	ATE1-AS1	4.39	1.38e-05	0.00137	0.34	0.2	Breast cancer;	chr10:121976839	chr10:121928312~121951965:+
THCA	cis	rs1371614	0.566	rs10203050	ENSG00000229122.1	AGBL5-IT1	-4.39	1.38e-05	0.00137	-0.14	-0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26963693	chr2:27061038~27061815:+
THCA	cis	rs8067545	1	rs4925065	ENSG00000270091.1	RP11-78O7.2	-4.39	1.38e-05	0.00137	-0.15	-0.2	Schizophrenia;	chr17:20011233	chr17:19896590~19897287:-
THCA	cis	rs7658584	1	rs6837857	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88173724	chr4:88284942~88331421:+
THCA	cis	rs7658584	1	rs35839768	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88173895	chr4:88284942~88331421:+
THCA	cis	rs7658584	1	rs35537015	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88173914	chr4:88284942~88331421:+
THCA	cis	rs7658584	0.891	rs35229708	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88174587	chr4:88284942~88331421:+
THCA	cis	rs7658584	1	rs7699279	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175136	chr4:88284942~88331421:+
THCA	cis	rs7658584	1	rs7657531	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175228	chr4:88284942~88331421:+
THCA	cis	rs7658584	0.945	rs7658211	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175311	chr4:88284942~88331421:+
THCA	cis	rs7658584	0.945	rs7657757	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175328	chr4:88284942~88331421:+
THCA	cis	rs4144027	0.791	rs11160770	ENSG00000269910.1	RP11-73M18.10	4.39	1.38e-05	0.00137	0.17	0.2	Blood metabolite levels;	chr14:103895954	chr14:103694516~103695050:-
THCA	cis	rs3177980	0.56	rs16862745	ENSG00000239494.2	RN7SL333P	-4.39	1.38e-05	0.00137	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr1:169891058	chr1:169859756~169860052:+
THCA	cis	rs2904524	0.737	rs58905326	ENSG00000257815.4	RP11-611E13.2	-4.39	1.38e-05	0.00137	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70227601	chr12:69904033~70243360:-
THCA	cis	rs7216064	0.817	rs12603589	ENSG00000278740.1	RP11-147L13.14	4.39	1.38e-05	0.00137	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829132	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.817	rs12601921	ENSG00000278740.1	RP11-147L13.14	4.39	1.38e-05	0.00137	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829238	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.813	rs12601919	ENSG00000278740.1	RP11-147L13.14	4.39	1.38e-05	0.00137	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829258	chr17:68188547~68189165:+
THCA	cis	rs5758659	0.714	rs7245	ENSG00000281538.1	RP4-669P10.20	-4.39	1.38e-05	0.00137	-0.18	-0.2	Cognitive function;	chr22:42085845	chr22:42138060~42139726:+
THCA	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
THCA	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	4.39	1.38e-05	0.00137	0.22	0.2	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
THCA	cis	rs42648	0.777	rs4728878	ENSG00000225498.1	AC002064.5	4.39	1.38e-05	0.00137	0.21	0.2	Homocysteine levels;	chr7:90294918	chr7:90312496~90322592:+
THCA	cis	rs42648	0.837	rs13239439	ENSG00000225498.1	AC002064.5	4.39	1.38e-05	0.00137	0.21	0.2	Homocysteine levels;	chr7:90295086	chr7:90312496~90322592:+
THCA	cis	rs42648	0.837	rs7786771	ENSG00000225498.1	AC002064.5	4.39	1.38e-05	0.00137	0.21	0.2	Homocysteine levels;	chr7:90295453	chr7:90312496~90322592:+
THCA	cis	rs755249	0.583	rs61779328	ENSG00000237624.1	OXCT2P1	4.39	1.38e-05	0.00137	0.3	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39514956~39516490:+
THCA	cis	rs7674212	0.531	rs4698876	ENSG00000248971.2	KRT8P46	-4.39	1.38e-05	0.00137	-0.24	-0.2	Type 2 diabetes;	chr4:103012410	chr4:102728746~102730171:-
THCA	cis	rs7674212	0.531	rs7665026	ENSG00000248971.2	KRT8P46	-4.39	1.38e-05	0.00137	-0.24	-0.2	Type 2 diabetes;	chr4:103015491	chr4:102728746~102730171:-
THCA	cis	rs12428035	1	rs115779493	ENSG00000247400.3	DNAJC3-AS1	-4.39	1.38e-05	0.00137	-0.2	-0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95648194	chr13:95648733~95676925:-
THCA	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	4.39	1.38e-05	0.00137	0.28	0.2	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
THCA	cis	rs10744955	0.727	rs11637945	ENSG00000244879.4	GABPB1-AS1	-4.39	1.38e-05	0.00137	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50162489	chr15:50354959~50372202:+
THCA	cis	rs2898290	0.622	rs978804	ENSG00000251402.3	FAM90A25P	-4.39	1.38e-05	0.00137	-0.26	-0.2	Systolic blood pressure;	chr8:11486164	chr8:12415080~12418090:-
THCA	cis	rs7115242	0.8	rs493134	ENSG00000280143.1	AP000892.6	4.39	1.38e-05	0.00137	0.32	0.2	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117204967~117210292:+
THCA	cis	rs5758659	1	rs134869	ENSG00000273366.1	CTA-989H11.1	-4.39	1.38e-05	0.00137	-0.24	-0.2	Cognitive function;	chr22:42256068	chr22:42278188~42278846:+
THCA	cis	rs7918232	0.83	rs7915902	ENSG00000262412.1	RP11-85G18.6	4.39	1.38e-05	0.00137	0.31	0.2	Breast cancer;	chr10:27121805	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs10741128	ENSG00000262412.1	RP11-85G18.6	4.39	1.38e-05	0.00137	0.31	0.2	Breast cancer;	chr10:27122580	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs6482598	ENSG00000262412.1	RP11-85G18.6	4.39	1.38e-05	0.00137	0.31	0.2	Breast cancer;	chr10:27137446	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs10829195	ENSG00000262412.1	RP11-85G18.6	4.39	1.38e-05	0.00137	0.31	0.2	Breast cancer;	chr10:27142635	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.83	rs7911024	ENSG00000262412.1	RP11-85G18.6	4.39	1.38e-05	0.00137	0.31	0.2	Breast cancer;	chr10:27144707	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.782	rs7910168	ENSG00000262412.1	RP11-85G18.6	4.39	1.38e-05	0.00137	0.31	0.2	Breast cancer;	chr10:27176367	chr10:27243130~27250804:+
THCA	cis	rs7216064	0.953	rs12601759	ENSG00000278740.1	RP11-147L13.14	4.39	1.38e-05	0.00137	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67959168	chr17:68188547~68189165:+
THCA	cis	rs9816784	0.696	rs6778081	ENSG00000185485.13	SDHAP1	-4.39	1.38e-05	0.00137	-0.16	-0.2	Mean corpuscular hemoglobin;	chr3:196092334	chr3:195959748~195990318:-
THCA	cis	rs8067545	0.717	rs34401389	ENSG00000270091.1	RP11-78O7.2	-4.39	1.38e-05	0.00137	-0.15	-0.2	Schizophrenia;	chr17:20086123	chr17:19896590~19897287:-
THCA	cis	rs10266483	0.661	rs608769	ENSG00000228653.2	HNRNPCP7	-4.39	1.38e-05	0.00137	-0.17	-0.2	Response to statin therapy;	chr7:64292783	chr7:64500825~64501729:+
THCA	cis	rs786425	0.901	rs11057307	ENSG00000270095.1	RP11-214K3.18	-4.39	1.38e-05	0.00137	-0.23	-0.2	Pubertal anthropometrics;	chr12:123613666	chr12:123971457~123971714:-
THCA	cis	rs42648	0.869	rs12374728	ENSG00000225498.1	AC002064.5	4.39	1.38e-05	0.00137	0.21	0.2	Homocysteine levels;	chr7:90312570	chr7:90312496~90322592:+
THCA	cis	rs42648	0.869	rs42611	ENSG00000225498.1	AC002064.5	4.39	1.38e-05	0.00137	0.21	0.2	Homocysteine levels;	chr7:90320746	chr7:90312496~90322592:+
THCA	cis	rs2278702	0.943	rs3743408	ENSG00000259495.2	RP11-210M15.2	4.39	1.38e-05	0.00137	0.26	0.2	Bipolar disorder;	chr15:80397993	chr15:80344853~80403575:-
THCA	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-4.39	1.38e-05	0.00137	-0.12	-0.2	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
THCA	cis	rs11846409	0.932	rs73378158	ENSG00000274576.2	IGHV2-70	-4.39	1.38e-05	0.00137	-0.16	-0.2	Rheumatic heart disease;	chr14:106638433	chr14:106770577~106771020:-
THCA	cis	rs6494488	0.5	rs61117068	ENSG00000259635.1	AC100830.3	-4.39	1.38e-05	0.00137	-0.48	-0.2	Coronary artery disease;	chr15:64667435	chr15:64701248~64719602:+
THCA	cis	rs57502260	0.704	rs2186937	ENSG00000212093.1	AP000807.1	4.39	1.38e-05	0.00137	0.26	0.2	Total body bone mineral density (age 45-60);	chr11:68489379	chr11:68506083~68506166:-
THCA	cis	rs4906332	1	rs2065017	ENSG00000269910.1	RP11-73M18.10	4.39	1.38e-05	0.00137	0.17	0.2	Coronary artery disease;	chr14:103413242	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs12885762	ENSG00000269910.1	RP11-73M18.10	4.39	1.38e-05	0.00137	0.17	0.2	Coronary artery disease;	chr14:103415863	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs12892062	ENSG00000269910.1	RP11-73M18.10	4.39	1.38e-05	0.00137	0.17	0.2	Coronary artery disease;	chr14:103417175	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs7155980	ENSG00000269910.1	RP11-73M18.10	4.39	1.38e-05	0.00137	0.17	0.2	Coronary artery disease;	chr14:103456082	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs8012623	ENSG00000269910.1	RP11-73M18.10	4.39	1.38e-05	0.00137	0.17	0.2	Coronary artery disease;	chr14:103470749	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs34347076	ENSG00000269910.1	RP11-73M18.10	4.39	1.38e-05	0.00137	0.17	0.2	Coronary artery disease;	chr14:103488732	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs35344594	ENSG00000269910.1	RP11-73M18.10	4.39	1.38e-05	0.00137	0.17	0.2	Coronary artery disease;	chr14:103489455	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs2065018	ENSG00000269910.1	RP11-73M18.10	-4.39	1.38e-05	0.00137	-0.17	-0.2	Coronary artery disease;	chr14:103412850	chr14:103694516~103695050:-
THCA	cis	rs11846409	0.872	rs2956482	ENSG00000274576.2	IGHV2-70	4.39	1.38e-05	0.00137	0.16	0.2	Rheumatic heart disease;	chr14:106630013	chr14:106770577~106771020:-
THCA	cis	rs7658584	1	rs7657928	ENSG00000246375.2	RP11-10L7.1	4.39	1.38e-05	0.00137	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175428	chr4:88284942~88331421:+
THCA	cis	rs10411161	0.58	rs12151288	ENSG00000275055.1	CTC-471J1.11	-4.39	1.38e-05	0.00137	-0.16	-0.2	Breast cancer;	chr19:51878299	chr19:52049007~52049754:+
THCA	cis	rs11089937	0.626	rs4820337	ENSG00000211639.2	IGLV4-60	-4.39	1.38e-05	0.00137	-0.15	-0.2	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22162199~22162681:+
THCA	cis	rs9926296	0.632	rs4785717	ENSG00000274627.1	RP11-104N10.2	-4.39	1.38e-05	0.00137	-0.2	-0.2	Vitiligo;	chr16:89734725	chr16:89516797~89522217:+
THCA	cis	rs7520050	0.898	rs4660885	ENSG00000281133.1	AL355480.3	4.39	1.38e-05	0.00137	0.23	0.2	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45580892~45580996:-
THCA	cis	rs10411262	0.746	rs314660	ENSG00000245598.5	DACT3-AS1	-4.39	1.38e-05	0.00137	-0.24	-0.2	Tonsillectomy;	chr19:46669588	chr19:46660364~46677447:+
THCA	cis	rs1923243	0.587	rs4590631	ENSG00000223479.3	RP4-788P17.1	4.39	1.38e-05	0.00137	0.22	0.2	Migraine;	chr1:72956127	chr1:73635216~73715214:+
THCA	cis	rs6449502	0.541	rs10054247	ENSG00000251279.1	CTC-436P18.1	4.39	1.38e-05	0.00137	0.36	0.2	Mean platelet volume;	chr5:61131357	chr5:61162070~61232040:+
THCA	cis	rs7474896	0.559	rs1735641	ENSG00000120555.12	SEPT7P9	-4.39	1.38e-05	0.00137	-0.26	-0.2	Obesity (extreme);	chr10:37895924	chr10:38383069~38402916:-
THCA	cis	rs67478160	0.643	rs12434686	ENSG00000269910.1	RP11-73M18.10	-4.39	1.38e-05	0.00137	-0.17	-0.2	Schizophrenia;	chr14:103849696	chr14:103694516~103695050:-
THCA	cis	rs6449502	0.92	rs34599	ENSG00000251279.1	CTC-436P18.1	4.39	1.38e-05	0.00137	0.33	0.2	Mean platelet volume;	chr5:61059631	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs248680	ENSG00000251279.1	CTC-436P18.1	4.39	1.38e-05	0.00137	0.33	0.2	Mean platelet volume;	chr5:61065827	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs9291704	ENSG00000251279.1	CTC-436P18.1	4.39	1.38e-05	0.00137	0.33	0.2	Mean platelet volume;	chr5:61067086	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs34425764	ENSG00000251279.1	CTC-436P18.1	4.39	1.38e-05	0.00137	0.33	0.2	Mean platelet volume;	chr5:61069947	chr5:61162070~61232040:+
THCA	cis	rs6067053	0.671	rs1130146	ENSG00000227431.4	CSE1L-AS1	4.39	1.38e-05	0.00137	0.25	0.2	Intelligence (multi-trait analysis);	chr20:49242680	chr20:49040463~49046044:-
THCA	cis	rs4660214	0.666	rs950805	ENSG00000182109.6	RP11-69E11.4	-4.39	1.38e-05	0.00137	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39239786	chr1:39522280~39546187:-
THCA	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-4.39	1.39e-05	0.00137	-0.2	-0.2	Height;	chr5:37053874	chr5:36666214~36725195:-
THCA	cis	rs11051970	0.589	rs2931550	ENSG00000274964.1	RP11-817I4.1	-4.39	1.39e-05	0.00137	-0.21	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32389099	chr12:32339368~32340724:+
THCA	cis	rs17597773	0.638	rs10495152	ENSG00000272823.1	RP11-295M18.6	-4.39	1.39e-05	0.00137	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220817013	chr1:220828676~220829211:-
THCA	cis	rs12073837	0.784	rs6673877	ENSG00000272823.1	RP11-295M18.6	-4.39	1.39e-05	0.00137	-0.25	-0.2	F-cell distribution;	chr1:220817642	chr1:220828676~220829211:-
THCA	cis	rs9341808	0.559	rs7762895	ENSG00000260645.1	RP11-250B2.5	4.39	1.39e-05	0.00137	0.17	0.2	Sitting height ratio;	chr6:80351714	chr6:80466958~80469080:+
THCA	cis	rs7474896	0.515	rs662928	ENSG00000226578.1	RP11-258F22.1	4.39	1.39e-05	0.00137	0.28	0.2	Obesity (extreme);	chr10:38027288	chr10:37775371~37784131:-
THCA	cis	rs2070488	1	rs2070488	ENSG00000229589.1	ACVR2B-AS1	-4.39	1.39e-05	0.00137	-0.18	-0.2	Electrocardiographic conduction measures;	chr3:38400999	chr3:38451027~38454820:-
THCA	cis	rs7045881	0.867	rs4490929	ENSG00000254396.1	RP11-56F10.3	4.39	1.39e-05	0.00137	0.29	0.2	Schizophrenia;	chr9:26818167	chr9:27102630~27104728:+
THCA	cis	rs12497850	0.897	rs7373778	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48798959	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9876848	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48806626	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.805	rs11130176	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48806644	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9311430	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48807818	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9311432	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48813010	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9682444	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48815206	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9835307	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48820372	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9311433	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48826402	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9755490	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48834231	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs7430501	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48852686	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs10780033	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48853842	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9840684	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48856347	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.864	rs7431857	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48862914	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs4974079	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48869036	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.897	rs6446252	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48873692	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs4974087	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48881799	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs4974085	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48887467	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs28642807	ENSG00000228638.1	FCF1P2	-4.39	1.39e-05	0.00137	-0.21	-0.2	Parkinson's disease;	chr3:48889383	chr3:48290793~48291375:-
THCA	cis	rs1046896	0.503	rs2459703	ENSG00000263063.1	RP11-388C12.1	4.39	1.39e-05	0.00137	0.23	0.2	Glycated hemoglobin levels;	chr17:82732756	chr17:82713908~82716255:-
THCA	cis	rs227275	0.525	rs1080081	ENSG00000248971.2	KRT8P46	-4.39	1.39e-05	0.00137	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs4699049	ENSG00000248971.2	KRT8P46	-4.39	1.39e-05	0.00137	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102728746~102730171:-
THCA	cis	rs877529	0.932	rs139398	ENSG00000279833.1	RP4-742C19.13	-4.39	1.39e-05	0.00137	-0.13	-0.2	Multiple myeloma;	chr22:39148965	chr22:39133090~39136760:+
THCA	cis	rs3893377	0.848	rs11933202	ENSG00000214846.4	RP11-115L11.1	4.39	1.39e-05	0.00137	0.26	0.2	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15742905	chr4:15730962~15731627:-
THCA	cis	rs2692947	0.537	rs12478605	ENSG00000235584.2	AC008268.1	-4.39	1.39e-05	0.00137	-0.2	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95711330	chr2:95666084~95668715:+
THCA	cis	rs10090774	0.71	rs13266116	ENSG00000280303.2	ERICD	-4.39	1.39e-05	0.00137	-0.18	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140646656	chr8:140636281~140638283:+
THCA	cis	rs2904524	0.737	rs76849223	ENSG00000257815.4	RP11-611E13.2	-4.39	1.39e-05	0.00138	-0.28	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70188682	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs76313038	ENSG00000257815.4	RP11-611E13.2	-4.39	1.39e-05	0.00138	-0.28	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70191691	chr12:69904033~70243360:-
THCA	cis	rs2898290	0.622	rs1600250	ENSG00000251402.3	FAM90A25P	-4.39	1.39e-05	0.00138	-0.26	-0.2	Systolic blood pressure;	chr8:11487916	chr8:12415080~12418090:-
THCA	cis	rs2898290	0.593	rs1600252	ENSG00000251402.3	FAM90A25P	-4.39	1.39e-05	0.00138	-0.26	-0.2	Systolic blood pressure;	chr8:11488135	chr8:12415080~12418090:-
THCA	cis	rs250518	0.926	rs35132569	ENSG00000272081.1	CTD-2376I4.2	4.39	1.39e-05	0.00138	0.25	0.2	Mean corpuscular hemoglobin concentration;	chr5:72763914	chr5:72955206~72955699:-
THCA	cis	rs875971	0.66	rs3764903	ENSG00000223473.2	GS1-124K5.3	-4.39	1.39e-05	0.00138	-0.13	-0.2	Aortic root size;	chr7:66633495	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs1860470	ENSG00000223473.2	GS1-124K5.3	-4.39	1.39e-05	0.00138	-0.13	-0.2	Aortic root size;	chr7:66638707	chr7:66491049~66493566:-
THCA	cis	rs1018326	0.565	rs4508560	ENSG00000236153.1	AC104076.3	-4.39	1.39e-05	0.00138	-0.21	-0.2	Ankylosing spondylitis;	chr2:181002458	chr2:180979427~180980090:-
THCA	cis	rs17221829	0.965	rs10830355	ENSG00000280385.1	AP000648.5	-4.39	1.39e-05	0.00138	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89710261	chr11:90193614~90198120:+
THCA	cis	rs6088590	0.965	rs13040449	ENSG00000269202.1	RP4-614O4.12	-4.39	1.39e-05	0.00138	-0.18	-0.2	Coronary artery disease;	chr20:34771098	chr20:35201747~35203288:-
THCA	cis	rs62025270	0.688	rs17576534	ENSG00000259295.5	CSPG4P12	-4.39	1.39e-05	0.00138	-0.34	-0.2	Idiopathic pulmonary fibrosis;	chr15:85742509	chr15:85191438~85213905:+
THCA	cis	rs11671005	0.696	rs73066211	ENSG00000265272.2	RN7SL693P	4.39	1.39e-05	0.00138	0.29	0.2	Mean platelet volume;	chr19:58485712	chr19:58490797~58491075:+
THCA	cis	rs890448	1	rs4698960	ENSG00000254531.1	FLJ20021	-4.39	1.39e-05	0.00138	-0.17	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101520111	chr4:101347780~101348883:+
THCA	cis	rs7508	0.511	rs208056	ENSG00000253671.1	RP11-806O11.1	-4.39	1.39e-05	0.00138	-0.26	-0.2	Atrial fibrillation;	chr8:17965375	chr8:17808941~17820868:+
THCA	cis	rs8177876	0.915	rs1563072	ENSG00000261061.1	RP11-303E16.2	4.39	1.39e-05	0.00138	0.34	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095811	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.841	rs874437	ENSG00000261061.1	RP11-303E16.2	4.39	1.39e-05	0.00138	0.34	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095890	chr16:81030770~81031485:+
THCA	cis	rs12234571	1	rs9641306	ENSG00000214293.7	APTR	4.39	1.39e-05	0.00138	0.25	0.2	Obesity-related traits;	chr7:77934385	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs11978636	ENSG00000214293.7	APTR	4.39	1.39e-05	0.00138	0.25	0.2	Obesity-related traits;	chr7:77940879	chr7:77657660~77696265:-
THCA	cis	rs9902453	0.933	rs7225462	ENSG00000263370.1	RP11-68I3.5	4.39	1.39e-05	0.00138	0.25	0.2	Coffee consumption (cups per day);	chr17:29994208	chr17:29639627~29640825:+
THCA	cis	rs11671005	0.779	rs11670125	ENSG00000265272.2	RN7SL693P	4.39	1.39e-05	0.00138	0.28	0.2	Mean platelet volume;	chr19:58476023	chr19:58490797~58491075:+
THCA	cis	rs6845263	0.546	rs2114364	ENSG00000254531.1	FLJ20021	-4.39	1.39e-05	0.00138	-0.17	-0.2	Superior crus of antihelix expression;	chr4:101534196	chr4:101347780~101348883:+
THCA	cis	rs3733585	0.631	rs4697707	ENSG00000261490.1	RP11-448G15.3	-4.39	1.39e-05	0.00138	-0.13	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10118163	chr4:10068089~10073019:-
THCA	cis	rs9549367	0.762	rs9549694	ENSG00000269125.1	RP11-98F14.11	-4.39	1.39e-05	0.00138	-0.23	-0.2	Platelet distribution width;	chr13:113216196	chr13:113165002~113165183:-
THCA	cis	rs13256369	1	rs4841017	ENSG00000254153.1	CTA-398F10.2	-4.39	1.39e-05	0.00138	-0.22	-0.2	Obesity-related traits;	chr8:8719583	chr8:8456909~8461337:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000164669.11	INTS4P1	-4.39	1.39e-05	0.00138	-0.25	-0.2	Aortic root size;	chr7:65967557	chr7:65141225~65234216:+
THCA	cis	rs454217	0.846	rs428699	ENSG00000277851.1	RP11-756G20.1	4.39	1.39e-05	0.00138	0.2	0.2	Smoking quantity;	chr12:92334822	chr12:92247756~92363832:-
THCA	cis	rs564343	0.545	rs2241303	ENSG00000255320.1	RP11-755F10.1	-4.39	1.39e-05	0.00138	-0.25	-0.2	Obesity (early onset extreme);	chr11:66052190	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	4.39	1.39e-05	0.00138	0.23	0.2	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	4.39	1.39e-05	0.00138	0.23	0.2	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	4.39	1.39e-05	0.00138	0.23	0.2	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	4.39	1.39e-05	0.00138	0.23	0.2	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
THCA	cis	rs7312933	0.501	rs7296357	ENSG00000257225.1	RP11-328C8.4	4.39	1.39e-05	0.00138	0.2	0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42336089	chr12:42459366~42466128:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000223473.2	GS1-124K5.3	-4.39	1.39e-05	0.00138	-0.13	-0.2	Cotinine glucuronidation;	chr7:66580525	chr7:66491049~66493566:-
THCA	cis	rs782212	0.592	rs707444	ENSG00000227207.2	RPL31P12	-4.39	1.39e-05	0.00138	-0.31	-0.2	Depression;	chr1:72483607	chr1:72301472~72301829:+
THCA	cis	rs4934494	0.677	rs1409360	ENSG00000240996.1	RP11-80H5.7	-4.39	1.39e-05	0.00138	-0.23	-0.2	Red blood cell count;	chr10:89625547	chr10:89694295~89697928:-
THCA	cis	rs10090774	0.965	rs7815898	ENSG00000279766.1	RP11-642A1.2	4.39	1.39e-05	0.00138	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140866442	chr8:140572142~140572812:-
THCA	cis	rs4915077	0.773	rs17019795	ENSG00000230489.1	VAV3-AS1	-4.39	1.39e-05	0.00138	-0.31	-0.2	Hypothyroidism;	chr1:107724348	chr1:107964443~107994607:+
THCA	cis	rs7267979	0.565	rs4815432	ENSG00000274414.1	RP5-965G21.4	4.39	1.39e-05	0.00138	0.24	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.565	rs6076364	ENSG00000274414.1	RP5-965G21.4	4.39	1.39e-05	0.00138	0.24	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:25239007~25245229:-
THCA	cis	rs12755164	0.771	rs12565252	ENSG00000223479.3	RP4-788P17.1	-4.39	1.39e-05	0.00138	-0.22	-0.2	Schizophrenia;	chr1:72878472	chr1:73635216~73715214:+
THCA	cis	rs4218	0.597	rs12438111	ENSG00000259732.1	RP11-59H7.3	-4.39	1.39e-05	0.00138	-0.28	-0.2	Social communication problems;	chr15:59057540	chr15:59121034~59133250:+
THCA	cis	rs881375	0.678	rs1014530	ENSG00000270917.1	RP11-27I1.6	-4.39	1.4e-05	0.00138	-0.26	-0.2	Rheumatoid arthritis;	chr9:120922814	chr9:120812475~120812845:-
THCA	cis	rs4713118	0.738	rs200465	ENSG00000226314.6	ZNF192P1	-4.39	1.4e-05	0.00138	-0.26	-0.2	Parkinson's disease;	chr6:27789875	chr6:28161781~28169594:+
THCA	cis	rs1979679	0.673	rs12229872	ENSG00000247934.4	RP11-967K21.1	-4.39	1.4e-05	0.00138	-0.19	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28137845	chr12:28163298~28190738:-
THCA	cis	rs6988985	0.56	rs3753122	ENSG00000247317.3	RP11-273G15.2	-4.39	1.4e-05	0.00138	-0.21	-0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142845511	chr8:142981738~143018437:-
THCA	cis	rs13126694	0.71	rs6848159	ENSG00000248429.4	RP11-597D13.9	-4.39	1.4e-05	0.00138	-0.21	-0.2	Blood osmolality (transformed sodium);	chr4:158051130	chr4:158170752~158202877:+
THCA	cis	rs7855088	0.764	rs7874518	ENSG00000236130.1	PTCSC2	-4.39	1.4e-05	0.00138	-0.16	-0.2	Serum thyroid-stimulating hormone levels;	chr9:97997821	chr9:97805935~97810008:-
THCA	cis	rs7855088	0.789	rs1131641	ENSG00000236130.1	PTCSC2	-4.39	1.4e-05	0.00138	-0.16	-0.2	Serum thyroid-stimulating hormone levels;	chr9:98005248	chr9:97805935~97810008:-
THCA	cis	rs7855088	0.789	rs4743152	ENSG00000236130.1	PTCSC2	-4.39	1.4e-05	0.00138	-0.16	-0.2	Serum thyroid-stimulating hormone levels;	chr9:98006009	chr9:97805935~97810008:-
THCA	cis	rs9875589	0.509	rs1386932	ENSG00000228242.5	AC093495.4	4.39	1.4e-05	0.00138	0.11	0.2	Ovarian reserve;	chr3:14019869	chr3:14144637~14165978:+
THCA	cis	rs7267979	0.753	rs404148	ENSG00000274414.1	RP5-965G21.4	-4.39	1.4e-05	0.00138	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:25239007~25245229:-
THCA	cis	rs853679	0.76	rs9393909	ENSG00000280107.1	AL022393.9	4.39	1.4e-05	0.00138	0.29	0.2	Depression;	chr6:28239422	chr6:28170845~28172521:+
THCA	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-4.39	1.4e-05	0.00138	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
THCA	cis	rs7658584	1	rs7658584	ENSG00000246375.2	RP11-10L7.1	-4.39	1.4e-05	0.00138	-0.34	-0.2	Squamous cell lung carcinoma;	chr4:88175489	chr4:88284942~88331421:+
THCA	cis	rs7824557	0.564	rs6601584	ENSG00000154316.13	TDH	4.39	1.4e-05	0.00138	0.15	0.2	Retinal vascular caliber;	chr8:11374834	chr8:11339637~11368452:+
THCA	cis	rs2692947	0.673	rs4907279	ENSG00000232931.4	LINC00342	4.39	1.4e-05	0.00138	0.16	0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95734220	chr2:95807118~95816215:-
THCA	cis	rs62025270	0.688	rs79083718	ENSG00000259295.5	CSPG4P12	-4.39	1.4e-05	0.00139	-0.34	-0.2	Idiopathic pulmonary fibrosis;	chr15:85720298	chr15:85191438~85213905:+
THCA	cis	rs8113308	0.81	rs10411484	ENSG00000269483.1	AC006272.1	4.39	1.4e-05	0.00139	0.33	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940152	chr19:51839924~51843324:-
THCA	cis	rs4693089	0.604	rs1126971	ENSG00000213608.5	SLC25A14P1	4.39	1.4e-05	0.00139	0.23	0.2	Menopause (age at onset);	chr4:83461399	chr4:83477524~83478424:+
THCA	cis	rs4693089	0.604	rs12642536	ENSG00000213608.5	SLC25A14P1	4.39	1.4e-05	0.00139	0.23	0.2	Menopause (age at onset);	chr4:83462657	chr4:83477524~83478424:+
THCA	cis	rs4693089	0.604	rs868217	ENSG00000213608.5	SLC25A14P1	4.39	1.4e-05	0.00139	0.23	0.2	Menopause (age at onset);	chr4:83464303	chr4:83477524~83478424:+
THCA	cis	rs4693089	0.584	rs17355013	ENSG00000213608.5	SLC25A14P1	4.39	1.4e-05	0.00139	0.23	0.2	Menopause (age at onset);	chr4:83464931	chr4:83477524~83478424:+
THCA	cis	rs17221829	0.863	rs11018739	ENSG00000280385.1	AP000648.5	-4.39	1.4e-05	0.00139	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89694486	chr11:90193614~90198120:+
THCA	cis	rs1003719	0.614	rs1053808	ENSG00000230366.8	DSCR9	4.39	1.4e-05	0.00139	0.2	0.2	Eye color traits;	chr21:37153056	chr21:37208503~37221736:+
THCA	cis	rs5758511	0.773	rs73165164	ENSG00000281538.1	RP4-669P10.20	-4.39	1.4e-05	0.00139	-0.24	-0.2	Birth weight;	chr22:41959545	chr22:42138060~42139726:+
THCA	cis	rs56313388	0.505	rs899241	ENSG00000246379.5	RP11-461O7.1	-4.39	1.4e-05	0.00139	-0.21	-0.2	Pulse pressure;	chr16:56266089	chr16:56092987~56191094:-
THCA	cis	rs78487399	0.808	rs17030925	ENSG00000234936.1	AC010883.5	4.39	1.4e-05	0.00139	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43486669	chr2:43229573~43233394:+
THCA	cis	rs8062405	0.698	rs7188071	ENSG00000278665.1	RP11-666O2.4	-4.39	1.4e-05	0.00139	-0.23	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28599241~28601881:-
THCA	cis	rs656319	0.559	rs55683917	ENSG00000261451.1	RP11-981G7.1	-4.39	1.4e-05	0.00139	-0.24	-0.2	Myopia (pathological);	chr8:10118969	chr8:10433672~10438312:+
THCA	cis	rs7924176	0.601	rs17676126	ENSG00000213731.2	RAB5CP1	-4.39	1.4e-05	0.00139	-0.24	-0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74145440	chr10:74423435~74424014:-
THCA	cis	rs9876781	1	rs725310	ENSG00000244380.1	RP11-24C3.2	-4.39	1.4e-05	0.00139	-0.23	-0.2	Longevity;	chr3:48377081	chr3:48440352~48446656:-
THCA	cis	rs7577696	0.924	rs72862234	ENSG00000276334.1	AL133243.1	-4.39	1.4e-05	0.00139	-0.21	-0.2	Inflammatory biomarkers;	chr2:32045077	chr2:32521927~32523547:+
THCA	cis	rs13126694	0.744	rs10027000	ENSG00000248429.4	RP11-597D13.9	4.39	1.4e-05	0.00139	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158053401	chr4:158170752~158202877:+
THCA	cis	rs10761482	0.769	rs10761483	ENSG00000254271.1	RP11-131N11.4	4.39	1.4e-05	0.00139	0.27	0.2	Schizophrenia;	chr10:60338640	chr10:60734342~60741828:+
THCA	cis	rs35851103	0.507	rs6601649	ENSG00000206014.6	OR7E161P	4.39	1.4e-05	0.00139	0.24	0.2	Neuroticism;	chr8:11999808	chr8:11928597~11929563:-
THCA	cis	rs6121246	0.821	rs7265413	ENSG00000230613.1	HM13-AS1	4.39	1.4e-05	0.00139	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31730120	chr20:31567707~31573263:-
THCA	cis	rs9876781	1	rs2885510	ENSG00000244380.1	RP11-24C3.2	-4.39	1.4e-05	0.00139	-0.23	-0.2	Longevity;	chr3:48376736	chr3:48440352~48446656:-
THCA	cis	rs11723261	0.582	rs11248006	ENSG00000211553.1	AC253576.2	-4.39	1.4e-05	0.00139	-0.29	-0.2	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:136461~136568:+
THCA	cis	rs6570726	0.791	rs12208019	ENSG00000270638.1	RP3-466P17.1	4.39	1.4e-05	0.00139	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs11155435	ENSG00000270638.1	RP3-466P17.1	4.39	1.4e-05	0.00139	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145735570~145737218:+
THCA	cis	rs11633886	0.902	rs7167219	ENSG00000273972.1	CTD-2306A12.1	-4.39	1.4e-05	0.00139	-0.21	-0.2	Diisocyanate-induced asthma;	chr15:45793086	chr15:45702640~45703183:+
THCA	cis	rs61270009	0.908	rs780405	ENSG00000247828.6	TMEM161B-AS1	-4.39	1.4e-05	0.00139	-0.17	-0.2	Depressive symptoms;	chr5:88260522	chr5:88268895~88436685:+
THCA	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-4.39	1.4e-05	0.00139	-0.23	-0.2	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
THCA	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-4.39	1.4e-05	0.00139	-0.23	-0.2	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-4.39	1.4e-05	0.00139	-0.23	-0.2	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-4.39	1.4e-05	0.00139	-0.23	-0.2	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
THCA	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-4.39	1.4e-05	0.00139	-0.23	-0.2	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
THCA	cis	rs7429990	0.965	rs62260764	ENSG00000228638.1	FCF1P2	-4.39	1.4e-05	0.00139	-0.21	-0.2	Educational attainment (years of education);	chr3:47949010	chr3:48290793~48291375:-
THCA	cis	rs12935229	0.756	rs35076488	ENSG00000260922.1	RP11-538I12.3	-4.39	1.4e-05	0.00139	-0.32	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77278389	chr16:77234877~77290934:+
THCA	cis	rs807029	0.577	rs3740489	ENSG00000236662.1	RP11-108L7.4	4.39	1.4e-05	0.00139	0.21	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100980507~100985614:-
THCA	cis	rs807029	0.577	rs3740490	ENSG00000236662.1	RP11-108L7.4	4.39	1.4e-05	0.00139	0.21	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100996986	chr10:100980507~100985614:-
THCA	cis	rs7560272	0.502	rs4513320	ENSG00000273245.1	RP11-434P11.2	-4.39	1.4e-05	0.00139	-0.23	-0.2	Schizophrenia;	chr2:73693614	chr2:73750256~73750786:-
THCA	cis	rs17221829	0.965	rs10830368	ENSG00000280385.1	AP000648.5	-4.39	1.4e-05	0.00139	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89726538	chr11:90193614~90198120:+
THCA	cis	rs28829049	0.535	rs12565185	ENSG00000270728.1	RP4-657E11.10	-4.39	1.4e-05	0.00139	-0.15	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19171815	chr1:19297080~19297903:+
THCA	cis	rs6012564	1	rs6012564	ENSG00000230758.1	SNAP23P	4.39	1.41e-05	0.00139	0.24	0.2	Anger;	chr20:48925063	chr20:49038357~49038602:-
THCA	cis	rs6570726	0.791	rs2096201	ENSG00000270638.1	RP3-466P17.1	4.39	1.41e-05	0.00139	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145735570~145737218:+
THCA	cis	rs9543976	1	rs7339146	ENSG00000261105.4	LMO7-AS1	-4.39	1.41e-05	0.00139	-0.29	-0.2	Diabetic retinopathy;	chr13:75599583	chr13:75604700~75635994:-
THCA	cis	rs9543976	1	rs4885324	ENSG00000261105.4	LMO7-AS1	4.39	1.41e-05	0.00139	0.29	0.2	Diabetic retinopathy;	chr13:75599611	chr13:75604700~75635994:-
THCA	cis	rs9543976	0.92	rs9543992	ENSG00000261105.4	LMO7-AS1	4.39	1.41e-05	0.00139	0.29	0.2	Diabetic retinopathy;	chr13:75600938	chr13:75604700~75635994:-
THCA	cis	rs9543976	1	rs8192762	ENSG00000261105.4	LMO7-AS1	4.39	1.41e-05	0.00139	0.29	0.2	Diabetic retinopathy;	chr13:75602544	chr13:75604700~75635994:-
THCA	cis	rs2790457	0.792	rs1265841	ENSG00000254635.4	WAC-AS1	-4.39	1.41e-05	0.00139	-0.2	-0.2	Multiple myeloma;	chr10:28631772	chr10:28522652~28532743:-
THCA	cis	rs2287838	0.704	rs12979606	ENSG00000267289.1	CTD-2623N2.11	-4.39	1.41e-05	0.00139	-0.23	-0.2	Sleep duration;	chr19:9889322	chr19:9834079~9835013:-
THCA	cis	rs7560272	0.564	rs10496190	ENSG00000163016.8	ALMS1P	-4.39	1.41e-05	0.00139	-0.23	-0.2	Schizophrenia;	chr2:73411695	chr2:73644919~73685576:+
THCA	cis	rs6067053	0.633	rs7266044	ENSG00000227431.4	CSE1L-AS1	-4.39	1.41e-05	0.00139	-0.25	-0.2	Intelligence (multi-trait analysis);	chr20:49274119	chr20:49040463~49046044:-
THCA	cis	rs9818758	0.607	rs61729488	ENSG00000270441.1	RP11-694I15.7	4.39	1.41e-05	0.00139	0.29	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49030471	chr3:49140086~49160851:-
THCA	cis	rs7614311	0.636	rs17344090	ENSG00000271843.1	RP11-245J9.5	-4.39	1.41e-05	0.00139	-0.34	-0.2	Lung function (FVC);Lung function (FEV1);	chr3:64018425	chr3:64008082~64008692:-
THCA	cis	rs1728785	1	rs698716	ENSG00000274698.1	RP11-71L14.4	4.39	1.41e-05	0.00139	0.29	0.2	Ulcerative colitis;	chr16:68526393	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.892	rs4783562	ENSG00000274698.1	RP11-71L14.4	4.39	1.41e-05	0.00139	0.29	0.2	Ulcerative colitis;	chr16:68529060	chr16:68450283~68452318:+
THCA	cis	rs17095355	1	rs11194923	ENSG00000203876.8	ADD3-AS1	-4.39	1.41e-05	0.00139	-0.22	-0.2	Biliary atresia;	chr10:109936004	chr10:109940104~110008381:-
THCA	cis	rs858239	0.57	rs6968242	ENSG00000226816.2	AC005082.12	4.39	1.41e-05	0.00139	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23206013~23208045:+
THCA	cis	rs2777491	0.915	rs9302109	ENSG00000247556.5	OIP5-AS1	4.39	1.41e-05	0.00139	0.16	0.2	Ulcerative colitis;	chr15:41319982	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.915	rs7165675	ENSG00000247556.5	OIP5-AS1	4.39	1.41e-05	0.00139	0.16	0.2	Ulcerative colitis;	chr15:41322506	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.915	rs28526381	ENSG00000247556.5	OIP5-AS1	4.39	1.41e-05	0.00139	0.16	0.2	Ulcerative colitis;	chr15:41329644	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.915	rs28578057	ENSG00000247556.5	OIP5-AS1	4.39	1.41e-05	0.00139	0.16	0.2	Ulcerative colitis;	chr15:41329723	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.915	rs16971767	ENSG00000247556.5	OIP5-AS1	4.39	1.41e-05	0.00139	0.16	0.2	Ulcerative colitis;	chr15:41331110	chr15:41283990~41309737:+
THCA	cis	rs2070488	0.965	rs2300668	ENSG00000229589.1	ACVR2B-AS1	-4.39	1.41e-05	0.00139	-0.18	-0.2	Electrocardiographic conduction measures;	chr3:38499050	chr3:38451027~38454820:-
THCA	cis	rs889398	0.741	rs6499268	ENSG00000226232.7	RP11-419C5.2	-4.39	1.41e-05	0.00139	-0.2	-0.2	Body mass index;	chr16:69872626	chr16:69976388~69996188:-
THCA	cis	rs2904524	0.737	rs2033525	ENSG00000257815.4	RP11-611E13.2	-4.39	1.41e-05	0.00139	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70368939	chr12:69904033~70243360:-
THCA	cis	rs41313321	0.541	rs1468648	ENSG00000273186.1	RP11-339B21.10	-4.39	1.41e-05	0.00139	-0.28	-0.2	Coenzyme Q10 levels;	chr9:128295706	chr9:128431598~128432006:+
THCA	cis	rs2251381	0.75	rs2251087	ENSG00000176054.6	RPL23P2	4.39	1.41e-05	0.00139	0.17	0.2	Selective IgA deficiency;	chr21:29155678	chr21:28997613~28998033:-
THCA	cis	rs72615157	0.629	rs55839153	ENSG00000242294.5	STAG3L5P	4.39	1.41e-05	0.00139	0.13	0.2	Lung function (FEV1/FVC);	chr7:100154943	chr7:100336079~100351900:+
THCA	cis	rs35740288	0.857	rs11632034	ENSG00000259295.5	CSPG4P12	4.39	1.41e-05	0.00139	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85740841	chr15:85191438~85213905:+
THCA	cis	rs2439831	0.681	rs478104	ENSG00000166763.7	STRCP1	4.39	1.41e-05	0.00139	0.26	0.2	Lung cancer in ever smokers;	chr15:43302702	chr15:43699488~43718184:-
THCA	cis	rs75059851	0.756	rs11223648	ENSG00000280237.1	MIR4697HG	4.39	1.41e-05	0.00139	0.23	0.2	Schizophrenia;	chr11:133970517	chr11:133896438~133901601:-
THCA	cis	rs890448	0.93	rs28589339	ENSG00000254531.1	FLJ20021	-4.39	1.41e-05	0.0014	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101462946	chr4:101347780~101348883:+
THCA	cis	rs9300255	0.537	rs1619561	ENSG00000235423.7	RP11-282O18.3	4.39	1.41e-05	0.0014	0.21	0.2	Neutrophil percentage of white cells;	chr12:123135721	chr12:123252030~123261483:-
THCA	cis	rs227275	0.525	rs17215211	ENSG00000248971.2	KRT8P46	-4.39	1.41e-05	0.0014	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102728746~102730171:-
THCA	cis	rs2446066	0.872	rs11170558	ENSG00000257379.1	RP11-793H13.8	4.39	1.41e-05	0.0014	0.3	0.2	Red blood cell count;	chr12:53441251	chr12:53441741~53467528:+
THCA	cis	rs2898290	0.622	rs978804	ENSG00000227888.4	FAM66A	-4.39	1.41e-05	0.0014	-0.26	-0.2	Systolic blood pressure;	chr8:11486164	chr8:12362019~12388296:+
THCA	cis	rs4906332	1	rs10459573	ENSG00000269910.1	RP11-73M18.10	4.39	1.41e-05	0.0014	0.17	0.2	Coronary artery disease;	chr14:103459120	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs4906327	ENSG00000269910.1	RP11-73M18.10	4.39	1.41e-05	0.0014	0.17	0.2	Coronary artery disease;	chr14:103462702	chr14:103694516~103695050:-
THCA	cis	rs2467099	0.735	rs55793071	ENSG00000267801.1	RP11-552F3.9	4.39	1.41e-05	0.0014	0.27	0.2	Systolic blood pressure;	chr17:75913867	chr17:75876372~75879546:+
THCA	cis	rs10744955	0.727	rs8042657	ENSG00000244879.4	GABPB1-AS1	-4.39	1.41e-05	0.0014	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50160504	chr15:50354959~50372202:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000229886.1	RP5-1132H15.3	-4.39	1.41e-05	0.0014	-0.2	-0.2	Aortic root size;	chr7:66633495	chr7:66025126~66031544:-
THCA	cis	rs875971	0.66	rs1860470	ENSG00000229886.1	RP5-1132H15.3	-4.39	1.41e-05	0.0014	-0.2	-0.2	Aortic root size;	chr7:66638707	chr7:66025126~66031544:-
THCA	cis	rs734999	0.549	rs6667564	ENSG00000225931.3	RP3-395M20.7	4.39	1.41e-05	0.0014	0.24	0.2	Ulcerative colitis;	chr1:2588863	chr1:2566410~2569888:+
THCA	cis	rs734999	0.588	rs6701238	ENSG00000225931.3	RP3-395M20.7	4.39	1.41e-05	0.0014	0.24	0.2	Ulcerative colitis;	chr1:2589061	chr1:2566410~2569888:+
THCA	cis	rs734999	0.549	rs6670198	ENSG00000225931.3	RP3-395M20.7	4.39	1.41e-05	0.0014	0.24	0.2	Ulcerative colitis;	chr1:2589088	chr1:2566410~2569888:+
THCA	cis	rs13118159	0.55	rs11941200	ENSG00000254094.1	AC078852.1	-4.39	1.41e-05	0.0014	-0.25	-0.2	Longevity;	chr4:1375305	chr4:1356581~1358075:+
THCA	cis	rs13118159	0.55	rs11946956	ENSG00000254094.1	AC078852.1	-4.39	1.41e-05	0.0014	-0.25	-0.2	Longevity;	chr4:1375306	chr4:1356581~1358075:+
THCA	cis	rs30380	0.688	rs27524	ENSG00000272109.1	CTD-2260A17.3	-4.39	1.41e-05	0.0014	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr5:96766240	chr5:96804353~96806105:+
THCA	cis	rs964611	0.882	rs4775750	ENSG00000259488.2	RP11-154J22.1	4.39	1.41e-05	0.0014	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48360567	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs4775751	ENSG00000259488.2	RP11-154J22.1	4.39	1.41e-05	0.0014	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48360910	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs11070636	ENSG00000259488.2	RP11-154J22.1	4.39	1.41e-05	0.0014	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48364720	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs11070637	ENSG00000259488.2	RP11-154J22.1	4.39	1.41e-05	0.0014	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48364881	chr15:48312353~48331856:-
THCA	cis	rs12428035	1	rs12429254	ENSG00000247400.3	DNAJC3-AS1	-4.39	1.41e-05	0.0014	-0.2	-0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95647409	chr13:95648733~95676925:-
THCA	cis	rs56313388	0.522	rs4784642	ENSG00000246379.5	RP11-461O7.1	-4.39	1.41e-05	0.0014	-0.21	-0.2	Pulse pressure;	chr16:56189980	chr16:56092987~56191094:-
THCA	cis	rs997295	0.675	rs12902804	ENSG00000270964.1	RP11-502I4.3	-4.39	1.41e-05	0.0014	-0.16	-0.2	Motion sickness;	chr15:67696320	chr15:67541072~67542604:-
THCA	cis	rs2839627	0.598	rs9975526	ENSG00000225218.1	AP001628.6	4.39	1.41e-05	0.0014	0.29	0.2	Information processing speed;	chr21:42846463	chr21:42831040~42836477:-
THCA	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	4.39	1.41e-05	0.0014	0.2	0.2	Height;	chr5:36948260	chr5:36666214~36725195:-
THCA	cis	rs9283706	0.594	rs1366338	ENSG00000229666.1	MAST4-AS1	4.39	1.41e-05	0.0014	0.3	0.2	Coronary artery disease;	chr5:67048479	chr5:67001383~67003953:-
THCA	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	4.39	1.41e-05	0.0014	0.25	0.2	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
THCA	cis	rs10256972	0.63	rs13235747	ENSG00000225146.1	AC073957.15	4.39	1.41e-05	0.0014	0.22	0.2	Endometriosis;Longevity;	chr7:1089487	chr7:1029025~1043891:+
THCA	cis	rs657075	0.595	rs6865305	ENSG00000237714.1	P4HA2-AS1	-4.39	1.41e-05	0.0014	-0.43	-0.2	Rheumatoid arthritis;	chr5:132280980	chr5:132184876~132192808:+
THCA	cis	rs10911902	0.643	rs3820182	ENSG00000229739.2	RP11-295K2.3	4.39	1.41e-05	0.0014	0.3	0.2	Schizophrenia;	chr1:186321201	chr1:186435161~186470291:+
THCA	cis	rs17095355	1	rs13377169	ENSG00000203876.8	ADD3-AS1	-4.39	1.41e-05	0.0014	-0.21	-0.2	Biliary atresia;	chr10:109969656	chr10:109940104~110008381:-
THCA	cis	rs397969	0.596	rs17605101	ENSG00000261033.1	RP11-209D14.2	-4.39	1.41e-05	0.0014	-0.29	-0.2	Platelet count;	chr17:19974321	chr17:20008051~20009234:-
THCA	cis	rs740160	0.51	rs10267346	ENSG00000244219.5	GS1-259H13.2	-4.39	1.41e-05	0.0014	-0.26	-0.2	Dehydroepiandrosterone sulphate levels;	chr7:99301144	chr7:99598066~99610813:+
THCA	cis	rs9925964	0.935	rs12597511	ENSG00000232748.3	RP11-196G11.6	4.39	1.41e-05	0.0014	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31133898	chr16:31056460~31062803:+
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000182586.6	LINC00334	-4.39	1.41e-05	0.0014	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45234340~45258730:+
THCA	cis	rs11671005	0.779	rs3794970	ENSG00000265272.2	RN7SL693P	-4.39	1.41e-05	0.0014	-0.28	-0.2	Mean platelet volume;	chr19:58474893	chr19:58490797~58491075:+
THCA	cis	rs9652601	0.691	rs9941107	ENSG00000274038.1	RP11-66H6.4	-4.39	1.41e-05	0.0014	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11102184	chr16:11056556~11057034:+
THCA	cis	rs4654783	0.671	rs3765351	ENSG00000228397.1	RP1-224A6.3	4.39	1.41e-05	0.0014	0.28	0.2	Endometriosis;	chr1:22119498	chr1:22023994~22024968:-
THCA	cis	rs61160187	0.582	rs12653132	ENSG00000215032.2	GNL3LP1	4.39	1.41e-05	0.0014	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs56284222	ENSG00000215032.2	GNL3LP1	4.39	1.41e-05	0.0014	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60891935~60893577:-
THCA	cis	rs4144027	0.967	rs4900601	ENSG00000269910.1	RP11-73M18.10	4.39	1.41e-05	0.0014	0.18	0.2	Blood metabolite levels;	chr14:103891739	chr14:103694516~103695050:-
THCA	cis	rs8141529	0.702	rs132536	ENSG00000226471.5	CTA-292E10.6	4.39	1.42e-05	0.0014	0.16	0.2	Lymphocyte counts;	chr22:28906918	chr22:28800683~28848559:+
THCA	cis	rs10761482	1	rs10821722	ENSG00000254271.1	RP11-131N11.4	4.39	1.42e-05	0.0014	0.26	0.2	Schizophrenia;	chr10:60321327	chr10:60734342~60741828:+
THCA	cis	rs3806843	0.547	rs183679	ENSG00000202515.1	VTRNA1-3	4.39	1.42e-05	0.0014	0.24	0.2	Depressive symptoms (multi-trait analysis);	chr5:140891432	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs550475	ENSG00000202515.1	VTRNA1-3	-4.39	1.42e-05	0.0014	-0.24	-0.2	Depressive symptoms (multi-trait analysis);	chr5:140893943	chr5:140726158~140726246:+
THCA	cis	rs4713118	0.568	rs9468213	ENSG00000280107.1	AL022393.9	-4.39	1.42e-05	0.0014	-0.21	-0.2	Parkinson's disease;	chr6:27738401	chr6:28170845~28172521:+
THCA	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-4.39	1.42e-05	0.0014	-0.2	-0.2	Height;	chr5:37007527	chr5:36666214~36725195:-
THCA	cis	rs42648	0.869	rs1015402	ENSG00000225498.1	AC002064.5	4.39	1.42e-05	0.0014	0.21	0.2	Homocysteine levels;	chr7:90283955	chr7:90312496~90322592:+
THCA	cis	rs12931792	0.782	rs13331817	ENSG00000273724.1	RP11-347C12.12	4.39	1.42e-05	0.0014	0.22	0.2	Tonsillectomy;	chr16:30161306	chr16:30336400~30343336:+
THCA	cis	rs9438901	0.614	rs2375278	ENSG00000261349.1	RP3-465N24.5	4.39	1.42e-05	0.0014	0.28	0.2	Red cell distribution width;	chr1:25202547	chr1:25266102~25267136:-
THCA	cis	rs7726839	0.54	rs4957080	ENSG00000225138.6	CTD-2228K2.7	-4.39	1.42e-05	0.0014	-0.24	-0.2	Obesity-related traits;	chr5:644437	chr5:473236~480884:+
THCA	cis	rs116248771	0.739	rs73156488	ENSG00000271778.1	RP11-379F4.8	4.39	1.42e-05	0.0014	0.26	0.2	diarrhoeal disease at age 2;	chr3:158696153	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs73156489	ENSG00000271778.1	RP11-379F4.8	4.39	1.42e-05	0.0014	0.26	0.2	diarrhoeal disease at age 2;	chr3:158696237	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs1051109	ENSG00000271778.1	RP11-379F4.8	4.39	1.42e-05	0.0014	0.26	0.2	diarrhoeal disease at age 2;	chr3:158697555	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.696	rs16847123	ENSG00000271778.1	RP11-379F4.8	4.39	1.42e-05	0.0014	0.26	0.2	diarrhoeal disease at age 2;	chr3:158698348	chr3:158782547~158783124:+
THCA	cis	rs801193	0.613	rs2016325	ENSG00000232546.1	RP11-458F8.1	4.39	1.42e-05	0.0014	0.17	0.2	Aortic root size;	chr7:66858513	chr7:66848496~66858136:+
THCA	cis	rs1707322	1	rs4660906	ENSG00000281133.1	AL355480.3	-4.39	1.42e-05	0.0014	-0.24	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45580892~45580996:-
THCA	cis	rs11884770	0.522	rs11902088	ENSG00000236432.6	AC097662.2	4.39	1.42e-05	0.0014	0.2	0.2	Advanced age-related macular degeneration;	chr2:227223600	chr2:227221052~227325201:-
THCA	cis	rs1823874	0.677	rs56096943	ENSG00000182397.13	DNM1P46	-4.39	1.42e-05	0.0014	-0.23	-0.2	IgG glycosylation;	chr15:99820513	chr15:99790156~99806927:-
THCA	cis	rs9487094	0.626	rs12215077	ENSG00000223537.2	RP5-919F19.5	4.39	1.42e-05	0.0014	0.2	0.2	Height;	chr6:109731677	chr6:109487906~109506800:+
THCA	cis	rs227275	0.556	rs28367331	ENSG00000248971.2	KRT8P46	-4.39	1.42e-05	0.0014	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102728746~102730171:-
THCA	cis	rs2929282	1	rs2929282	ENSG00000166763.7	STRCP1	4.39	1.42e-05	0.0014	0.38	0.2	Triglycerides;Triglyceride levels;	chr15:43953733	chr15:43699488~43718184:-
THCA	cis	rs12935229	1	rs12923460	ENSG00000260922.1	RP11-538I12.3	-4.39	1.42e-05	0.0014	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77290431	chr16:77234877~77290934:+
THCA	cis	rs12935229	1	rs12927388	ENSG00000260922.1	RP11-538I12.3	-4.39	1.42e-05	0.0014	-0.34	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77290509	chr16:77234877~77290934:+
THCA	cis	rs17221829	0.965	rs11018753	ENSG00000280385.1	AP000648.5	-4.39	1.42e-05	0.0014	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89725896	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.965	rs10830365	ENSG00000280385.1	AP000648.5	-4.39	1.42e-05	0.0014	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89725897	chr11:90193614~90198120:+
THCA	cis	rs10946940	0.93	rs10807029	ENSG00000216915.2	RP1-97D16.1	4.39	1.42e-05	0.0014	0.27	0.2	Systemic lupus erythematosus;	chr6:27605684	chr6:27737000~27738494:-
THCA	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	4.39	1.42e-05	0.0014	0.19	0.2	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
THCA	cis	rs13256369	0.802	rs11249885	ENSG00000254153.1	CTA-398F10.2	-4.39	1.42e-05	0.0014	-0.22	-0.2	Obesity-related traits;	chr8:8704498	chr8:8456909~8461337:-
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000182586.6	LINC00334	-4.39	1.42e-05	0.0014	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45234340~45258730:+
THCA	cis	rs7474896	0.609	rs11011336	ENSG00000226578.1	RP11-258F22.1	-4.39	1.42e-05	0.0014	-0.28	-0.2	Obesity (extreme);	chr10:37696388	chr10:37775371~37784131:-
THCA	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-4.39	1.42e-05	0.0014	-0.18	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
THCA	cis	rs3733585	0.605	rs4235355	ENSG00000261490.1	RP11-448G15.3	-4.39	1.42e-05	0.0014	-0.13	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10121454	chr4:10068089~10073019:-
THCA	cis	rs642858	0.693	rs9385911	ENSG00000234147.1	RP3-460G2.2	4.39	1.42e-05	0.0014	0.25	0.2	Type 2 diabetes;	chr6:140376881	chr6:140845958~140852924:-
THCA	cis	rs2886497	0.947	rs67207208	ENSG00000224215.1	RP11-371A19.2	-4.39	1.42e-05	0.0014	-0.25	-0.2	Major depression and alcohol dependence;	chr10:23376985	chr10:23343957~23345181:+
THCA	cis	rs5742933	1	rs7557519	ENSG00000273240.1	RP11-455J20.3	-4.39	1.42e-05	0.0014	-0.22	-0.2	Ferritin levels;	chr2:189718461	chr2:189763859~189764456:-
THCA	cis	rs763121	0.524	rs760645	ENSG00000273076.1	RP3-508I15.22	4.39	1.42e-05	0.0014	0.2	0.2	Menopause (age at onset);	chr22:38636265	chr22:38743495~38743910:+
THCA	cis	rs752010	0.684	rs10789402	ENSG00000230638.4	RP11-486B10.4	-4.39	1.42e-05	0.0014	-0.21	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41618978	chr1:41542069~41544310:+
THCA	cis	rs12681963	0.565	rs4733393	ENSG00000248159.1	HSPA8P11	-4.39	1.42e-05	0.00141	-0.38	-0.2	Migraine;	chr8:30140438	chr8:30237382~30240997:+
THCA	cis	rs6496932	0.802	rs67928464	ENSG00000259630.2	CTD-2262B20.1	4.39	1.42e-05	0.00141	0.24	0.2	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85415228~85415633:+
THCA	cis	rs1150668	1	rs1150668	ENSG00000176933.5	TOB2P1	-4.39	1.42e-05	0.00141	-0.22	-0.2	Pubertal anthropometrics;	chr6:28162011	chr6:28217643~28218634:-
THCA	cis	rs9307551	0.857	rs2196978	ENSG00000249646.2	OR7E94P	4.39	1.42e-05	0.00141	0.26	0.2	Refractive error;	chr4:79614815	chr4:79587302~79588130:-
THCA	cis	rs964611	0.882	rs8025164	ENSG00000259488.2	RP11-154J22.1	4.39	1.42e-05	0.00141	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48346517	chr15:48312353~48331856:-
THCA	cis	rs4295623	0.585	rs34421088	ENSG00000270154.1	RP11-419I17.1	-4.39	1.42e-05	0.00141	-0.24	-0.2	Morning vs. evening chronotype;	chr8:11731533	chr8:12476462~12477122:+
THCA	cis	rs11633886	1	rs2413792	ENSG00000273972.1	CTD-2306A12.1	-4.39	1.42e-05	0.00141	-0.21	-0.2	Diisocyanate-induced asthma;	chr15:45801469	chr15:45702640~45703183:+
THCA	cis	rs8020441	0.945	rs67713610	ENSG00000269906.1	RP11-248J18.2	4.39	1.42e-05	0.00141	0.28	0.2	Cognitive performance;	chr14:50702112	chr14:50662511~50663178:-
THCA	cis	rs6840258	0.64	rs1552144	ENSG00000251411.1	RP11-397E7.4	4.39	1.42e-05	0.00141	0.23	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87173498	chr4:86913266~86914817:-
THCA	cis	rs5758511	0.773	rs1894714	ENSG00000281538.1	RP4-669P10.20	4.39	1.42e-05	0.00141	0.23	0.2	Birth weight;	chr22:41953130	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.731	rs5751186	ENSG00000281538.1	RP4-669P10.20	4.39	1.42e-05	0.00141	0.23	0.2	Birth weight;	chr22:41953706	chr22:42138060~42139726:+
THCA	cis	rs1414896	0.669	rs11165345	ENSG00000226026.4	RP11-57H12.3	4.39	1.42e-05	0.00141	0.19	0.2	Non-alcoholic fatty liver disease histology (AST);	chr1:95227082	chr1:95163219~95233982:-
THCA	cis	rs7246657	0.722	rs958305	ENSG00000276846.1	CTD-3220F14.3	-4.39	1.42e-05	0.00141	-0.19	-0.2	Coronary artery calcification;	chr19:37698539	chr19:37314868~37315620:-
THCA	cis	rs875971	0.545	rs12671152	ENSG00000232546.1	RP11-458F8.1	4.39	1.42e-05	0.00141	0.2	0.2	Aortic root size;	chr7:66311140	chr7:66848496~66858136:+
THCA	cis	rs17270561	0.609	rs6941933	ENSG00000272462.2	U91328.19	-4.39	1.42e-05	0.00141	-0.17	-0.2	Iron status biomarkers;	chr6:25745474	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs6923367	ENSG00000272462.2	U91328.19	-4.39	1.42e-05	0.00141	-0.17	-0.2	Iron status biomarkers;	chr6:25745624	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs6923839	ENSG00000272462.2	U91328.19	-4.39	1.42e-05	0.00141	-0.17	-0.2	Iron status biomarkers;	chr6:25745625	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs4145218	ENSG00000272462.2	U91328.19	-4.39	1.42e-05	0.00141	-0.17	-0.2	Iron status biomarkers;	chr6:25745855	chr6:25992662~26001775:+
THCA	cis	rs72843506	0.591	rs75925580	ENSG00000261033.1	RP11-209D14.2	4.39	1.42e-05	0.00141	0.35	0.2	Schizophrenia;	chr17:20211700	chr17:20008051~20009234:-
THCA	cis	rs854765	0.624	rs9899634	ENSG00000281749.1	Y_RNA	-4.39	1.42e-05	0.00141	-0.25	-0.2	Total body bone mineral density;	chr17:17824629	chr17:18001101~18001195:-
THCA	cis	rs11096990	0.855	rs2566170	ENSG00000249685.1	RP11-360F5.3	-4.39	1.42e-05	0.00141	-0.26	-0.2	Cognitive function;	chr4:39150757	chr4:39133913~39135608:+
THCA	cis	rs890448	0.965	rs17031366	ENSG00000254531.1	FLJ20021	-4.39	1.42e-05	0.00141	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101503642	chr4:101347780~101348883:+
THCA	cis	rs17685	0.712	rs1859792	ENSG00000230882.1	AC005077.14	4.39	1.42e-05	0.00141	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76159946	chr7:76071469~76074963:-
THCA	cis	rs35740288	0.77	rs745191	ENSG00000259295.5	CSPG4P12	4.39	1.42e-05	0.00141	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85579939	chr15:85191438~85213905:+
THCA	cis	rs4748857	0.502	rs7068798	ENSG00000224215.1	RP11-371A19.2	-4.39	1.42e-05	0.00141	-0.22	-0.2	Systemic lupus erythematosus;	chr10:23383258	chr10:23343957~23345181:+
THCA	cis	rs6929812	0.967	rs7509	ENSG00000271755.1	RP1-153G14.4	4.39	1.42e-05	0.00141	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27451068	chr6:27404010~27406964:-
THCA	cis	rs4788570	0.615	rs2052584	ENSG00000260185.1	RP11-432I5.6	4.39	1.42e-05	0.00141	0.36	0.2	Intelligence (multi-trait analysis);	chr16:71655074	chr16:71655027~71664212:+
THCA	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-4.39	1.42e-05	0.00141	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
THCA	cis	rs11668609	0.515	rs76035839	ENSG00000268442.1	CTD-2027I19.2	4.39	1.42e-05	0.00141	0.3	0.2	Response to taxane treatment (docetaxel);	chr19:23768434	chr19:24162370~24163425:-
THCA	cis	rs10200159	1	rs6712314	ENSG00000272606.1	RP11-554J4.1	4.39	1.42e-05	0.00141	0.38	0.2	Vitiligo;	chr2:55626901	chr2:55617909~55618373:+
THCA	cis	rs1267303	0.642	rs7542296	ENSG00000232022.5	FAAHP1	4.39	1.43e-05	0.00141	0.23	0.2	Monobrow;	chr1:46532337	chr1:46432129~46445521:+
THCA	cis	rs11822910	0.737	rs2729389	ENSG00000265566.2	RN7SL605P	-4.39	1.43e-05	0.00141	-0.31	-0.2	Platelet distribution width;	chr11:57444173	chr11:57528085~57528365:-
THCA	cis	rs16852403	0.583	rs1855174	ENSG00000224687.1	RASAL2-AS1	4.39	1.43e-05	0.00141	0.33	0.2	Childhood ear infection;	chr1:178093905	chr1:178091508~178093984:-
THCA	cis	rs6441286	1	rs4679868	ENSG00000244040.4	IL12A-AS1	4.39	1.43e-05	0.00141	0.25	0.2	Primary biliary cholangitis;	chr3:160006367	chr3:159913400~160225299:-
THCA	cis	rs2287838	0.901	rs5004102	ENSG00000267289.1	CTD-2623N2.11	-4.39	1.43e-05	0.00141	-0.23	-0.2	Sleep duration;	chr19:9871658	chr19:9834079~9835013:-
THCA	cis	rs5753037	0.702	rs140143	ENSG00000279699.1	RP1-102K2.9	4.39	1.43e-05	0.00141	0.2	0.2	Type 1 diabetes;	chr22:29777120	chr22:30275215~30276951:-
THCA	cis	rs9341808	0.667	rs2322632	ENSG00000272129.1	RP11-250B2.6	4.39	1.43e-05	0.00141	0.25	0.2	Sitting height ratio;	chr6:80135891	chr6:80355424~80356859:+
THCA	cis	rs919433	0.617	rs700643	ENSG00000231621.1	AC013264.2	-4.39	1.43e-05	0.00141	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197736646	chr2:197197991~197199273:+
THCA	cis	rs6449502	0.764	rs1824531	ENSG00000251279.1	CTC-436P18.1	4.39	1.43e-05	0.00141	0.34	0.2	Mean platelet volume;	chr5:60779366	chr5:61162070~61232040:+
THCA	cis	rs2243480	1	rs78803505	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65917585	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs34577383	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65920739	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs55895244	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65922691	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs7795242	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65925107	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs2177703	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65926730	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs35432774	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65928032	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs56985706	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65929575	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs60683927	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65929781	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs58062456	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65929865	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs34529418	ENSG00000232559.3	GS1-124K5.12	4.39	1.43e-05	0.00141	0.29	0.2	Diabetic kidney disease;	chr7:65938222	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs10950025	ENSG00000273142.1	RP11-458F8.4	4.39	1.43e-05	0.00141	0.18	0.2	Aortic root size;	chr7:66158946	chr7:66902857~66906297:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000273142.1	RP11-458F8.4	4.39	1.43e-05	0.00141	0.18	0.2	Aortic root size;	chr7:66160135	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000273142.1	RP11-458F8.4	4.39	1.43e-05	0.00141	0.18	0.2	Aortic root size;	chr7:66161064	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs316324	ENSG00000273142.1	RP11-458F8.4	-4.39	1.43e-05	0.00141	-0.18	-0.2	Aortic root size;	chr7:66145627	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000273142.1	RP11-458F8.4	-4.39	1.43e-05	0.00141	-0.18	-0.2	Aortic root size;	chr7:66146002	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000273142.1	RP11-458F8.4	-4.39	1.43e-05	0.00141	-0.18	-0.2	Aortic root size;	chr7:66152984	chr7:66902857~66906297:+
THCA	cis	rs1923243	0.749	rs11210167	ENSG00000223479.3	RP4-788P17.1	-4.39	1.43e-05	0.00141	-0.22	-0.2	Migraine;	chr1:73171006	chr1:73635216~73715214:+
THCA	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	4.39	1.43e-05	0.00141	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
THCA	cis	rs12410462	0.551	rs7539151	ENSG00000227711.2	RP11-275O4.5	-4.39	1.43e-05	0.00141	-0.24	-0.2	Major depressive disorder;	chr1:227654042	chr1:227509028~227520477:-
THCA	cis	rs4693089	0.564	rs12505955	ENSG00000213608.5	SLC25A14P1	4.39	1.43e-05	0.00141	0.23	0.2	Menopause (age at onset);	chr4:83459802	chr4:83477524~83478424:+
THCA	cis	rs7617480	0.648	rs10865953	ENSG00000229759.1	MRPS18AP1	4.39	1.43e-05	0.00141	0.31	0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48722129	chr3:48256350~48256938:-
THCA	cis	rs6487679	0.543	rs11612110	ENSG00000111788.10	RP11-22B23.1	-4.39	1.43e-05	0.00141	-0.34	-0.2	Non-alcoholic fatty liver disease histology (AST);	chr12:9200195	chr12:9277235~9313241:+
THCA	cis	rs4218	0.689	rs12440692	ENSG00000277144.1	RP11-59H7.4	-4.39	1.43e-05	0.00141	-0.28	-0.2	Social communication problems;	chr15:59090671	chr15:59115547~59116089:-
THCA	cis	rs67981189	0.892	rs221899	ENSG00000269927.1	RP6-91H8.3	4.39	1.43e-05	0.00141	0.22	0.2	Schizophrenia;	chr14:71138551	chr14:71141125~71143253:-
THCA	cis	rs6845263	0.624	rs13434873	ENSG00000254531.1	FLJ20021	-4.39	1.43e-05	0.00141	-0.17	-0.2	Superior crus of antihelix expression;	chr4:101529865	chr4:101347780~101348883:+
THCA	cis	rs72928364	1	rs35517882	ENSG00000256628.3	ZBTB11-AS1	4.39	1.43e-05	0.00141	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100978330	chr3:101676475~101679217:+
THCA	cis	rs35740288	0.857	rs3803506	ENSG00000259295.5	CSPG4P12	4.39	1.43e-05	0.00141	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85747709	chr15:85191438~85213905:+
THCA	cis	rs4934494	0.591	rs7476027	ENSG00000240996.1	RP11-80H5.7	-4.39	1.43e-05	0.00141	-0.23	-0.2	Red blood cell count;	chr10:89621164	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185808	ENSG00000240996.1	RP11-80H5.7	-4.39	1.43e-05	0.00141	-0.23	-0.2	Red blood cell count;	chr10:89621353	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185809	ENSG00000240996.1	RP11-80H5.7	-4.39	1.43e-05	0.00141	-0.23	-0.2	Red blood cell count;	chr10:89621474	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185810	ENSG00000240996.1	RP11-80H5.7	-4.39	1.43e-05	0.00141	-0.23	-0.2	Red blood cell count;	chr10:89621724	chr10:89694295~89697928:-
THCA	cis	rs10266483	0.639	rs6952592	ENSG00000228653.2	HNRNPCP7	-4.39	1.43e-05	0.00141	-0.17	-0.2	Response to statin therapy;	chr7:64293667	chr7:64500825~64501729:+
THCA	cis	rs10266483	0.705	rs660228	ENSG00000228653.2	HNRNPCP7	-4.39	1.43e-05	0.00141	-0.17	-0.2	Response to statin therapy;	chr7:64295867	chr7:64500825~64501729:+
THCA	cis	rs17095355	1	rs2122517	ENSG00000203876.8	ADD3-AS1	-4.39	1.43e-05	0.00141	-0.22	-0.2	Biliary atresia;	chr10:109995029	chr10:109940104~110008381:-
THCA	cis	rs60733400	0.818	rs10909839	ENSG00000225931.3	RP3-395M20.7	4.39	1.43e-05	0.00141	0.23	0.2	Multiple sclerosis;	chr1:2791865	chr1:2566410~2569888:+
THCA	cis	rs2562152	0.706	rs216598	ENSG00000226942.2	IL9RP3	-4.39	1.43e-05	0.00141	-0.26	-0.2	Glioblastoma;	chr16:58586	chr16:29336~38321:-
THCA	cis	rs950880	0.71	rs12470867	ENSG00000234389.1	AC007278.3	-4.39	1.43e-05	0.00141	-0.23	-0.2	Serum protein levels (sST2);	chr2:102309906	chr2:102438713~102440475:+
THCA	cis	rs8062405	0.722	rs3785354	ENSG00000270424.1	RP11-1348G14.6	4.39	1.43e-05	0.00141	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28749959~28750595:-
THCA	cis	rs1046491	1	rs11661901	ENSG00000264964.1	RP11-888D10.3	4.39	1.43e-05	0.00141	0.33	0.2	Scarlet fever;	chr18:9250377	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs11664929	ENSG00000264964.1	RP11-888D10.3	4.39	1.43e-05	0.00141	0.33	0.2	Scarlet fever;	chr18:9250538	chr18:9315194~9334441:-
THCA	cis	rs1046491	1	rs11081469	ENSG00000264964.1	RP11-888D10.3	4.39	1.43e-05	0.00141	0.33	0.2	Scarlet fever;	chr18:9276265	chr18:9315194~9334441:-
THCA	cis	rs972578	0.715	rs5759054	ENSG00000274717.1	RP1-47A17.1	-4.39	1.43e-05	0.00142	-0.21	-0.2	Mean platelet volume;	chr22:42952172	chr22:42791814~42794313:-
THCA	cis	rs1003719	0.628	rs2835635	ENSG00000230366.8	DSCR9	4.39	1.43e-05	0.00142	0.2	0.2	Eye color traits;	chr21:37156565	chr21:37208503~37221736:+
THCA	cis	rs10761482	0.861	rs7096250	ENSG00000254271.1	RP11-131N11.4	4.39	1.43e-05	0.00142	0.27	0.2	Schizophrenia;	chr10:60346561	chr10:60734342~60741828:+
THCA	cis	rs12188164	0.515	rs2672744	ENSG00000225138.6	CTD-2228K2.7	-4.39	1.43e-05	0.00142	-0.2	-0.2	Cystic fibrosis severity;	chr5:410932	chr5:473236~480884:+
THCA	cis	rs7246657	0.551	rs10407224	ENSG00000276846.1	CTD-3220F14.3	4.39	1.43e-05	0.00142	0.25	0.2	Coronary artery calcification;	chr19:37160568	chr19:37314868~37315620:-
THCA	cis	rs756699	0.749	rs244670	ENSG00000279469.1	RP11-215P8.2	-4.39	1.43e-05	0.00142	-0.3	-0.2	Multiple sclerosis;	chr5:134083048	chr5:134394360~134395008:-
THCA	cis	rs77637988	0.578	rs7577237	ENSG00000202227.1	RNU6-282P	-4.38	1.43e-05	0.00142	-0.21	-0.2	Joint mobility (Beighton score);	chr2:48374677	chr2:48501922~48502024:-
THCA	cis	rs9302635	0.513	rs13334151	ENSG00000260886.1	TAT-AS1	4.38	1.43e-05	0.00142	0.26	0.2	Blood protein levels;	chr16:72155828	chr16:71565789~71578187:+
THCA	cis	rs5758659	1	rs134902	ENSG00000281538.1	RP4-669P10.20	4.38	1.43e-05	0.00142	0.18	0.2	Cognitive function;	chr22:42287991	chr22:42138060~42139726:+
THCA	cis	rs4074961	0.585	rs10752600	ENSG00000233621.1	LINC01137	-4.38	1.43e-05	0.00142	-0.21	-0.2	Axial length;	chr1:37601951	chr1:37454879~37474411:-
THCA	cis	rs849141	0.524	rs849334	ENSG00000234336.5	JAZF1-AS1	-4.38	1.43e-05	0.00142	-0.34	-0.2	Height;Hip circumference adjusted for BMI;	chr7:28184223	chr7:28180322~28243917:+
THCA	cis	rs849141	0.553	rs565317	ENSG00000234336.5	JAZF1-AS1	-4.38	1.43e-05	0.00142	-0.34	-0.2	Height;Hip circumference adjusted for BMI;	chr7:28185895	chr7:28180322~28243917:+
THCA	cis	rs9875589	0.509	rs4685058	ENSG00000228242.5	AC093495.4	4.38	1.43e-05	0.00142	0.11	0.2	Ovarian reserve;	chr3:13988884	chr3:14144637~14165978:+
THCA	cis	rs6088590	1	rs10048849	ENSG00000276073.1	RP5-1125A11.7	-4.38	1.43e-05	0.00142	-0.18	-0.2	Coronary artery disease;	chr20:34831877	chr20:33985617~33988989:-
THCA	cis	rs6787172	0.582	rs1656377	ENSG00000272087.1	RP11-379F4.7	-4.38	1.43e-05	0.00142	-0.17	-0.2	Subjective well-being;	chr3:158567491	chr3:158693120~158693768:-
THCA	cis	rs5771225	0.544	rs1555048	ENSG00000273253.2	RP3-402G11.26	-4.38	1.43e-05	0.00142	-0.23	-0.2	Late-onset Alzheimer's disease;	chr22:50249919	chr22:50199090~50200837:-
THCA	cis	rs4713118	0.824	rs9468223	ENSG00000226314.6	ZNF192P1	-4.38	1.43e-05	0.00142	-0.26	-0.2	Parkinson's disease;	chr6:27772887	chr6:28161781~28169594:+
THCA	cis	rs2299587	0.554	rs9325823	ENSG00000253671.1	RP11-806O11.1	4.38	1.43e-05	0.00142	0.23	0.2	Economic and political preferences;	chr8:17878362	chr8:17808941~17820868:+
THCA	cis	rs8067545	0.611	rs7222984	ENSG00000270091.1	RP11-78O7.2	-4.38	1.43e-05	0.00142	-0.15	-0.2	Schizophrenia;	chr17:20116381	chr17:19896590~19897287:-
THCA	cis	rs7474896	0.559	rs1024202	ENSG00000226578.1	RP11-258F22.1	4.38	1.43e-05	0.00142	0.28	0.2	Obesity (extreme);	chr10:37990049	chr10:37775371~37784131:-
THCA	cis	rs7474896	0.537	rs1022449	ENSG00000226578.1	RP11-258F22.1	4.38	1.43e-05	0.00142	0.28	0.2	Obesity (extreme);	chr10:37990539	chr10:37775371~37784131:-
THCA	cis	rs4693089	0.604	rs4693625	ENSG00000213608.5	SLC25A14P1	4.38	1.43e-05	0.00142	0.23	0.2	Menopause (age at onset);	chr4:83445214	chr4:83477524~83478424:+
THCA	cis	rs9880211	0.948	rs9813691	ENSG00000239213.4	NCK1-AS1	4.38	1.43e-05	0.00142	0.22	0.2	Height;Body mass index;	chr3:136541880	chr3:136841726~136862054:-
THCA	cis	rs9880211	1	rs9883189	ENSG00000239213.4	NCK1-AS1	4.38	1.43e-05	0.00142	0.22	0.2	Height;Body mass index;	chr3:136570624	chr3:136841726~136862054:-
THCA	cis	rs1009077	0.61	rs7684899	ENSG00000245958.5	RP11-33B1.1	-4.38	1.44e-05	0.00142	-0.22	-0.2	Endometriosis;	chr4:119600474	chr4:119454791~119552025:+
THCA	cis	rs8067545	0.578	rs4925091	ENSG00000270091.1	RP11-78O7.2	-4.38	1.44e-05	0.00142	-0.15	-0.2	Schizophrenia;	chr17:20163675	chr17:19896590~19897287:-
THCA	cis	rs858239	0.601	rs6966776	ENSG00000226816.2	AC005082.12	4.38	1.44e-05	0.00142	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23206013~23208045:+
THCA	cis	rs12234571	1	rs12234571	ENSG00000214293.7	APTR	-4.38	1.44e-05	0.00142	-0.24	-0.2	Obesity-related traits;	chr7:77920589	chr7:77657660~77696265:-
THCA	cis	rs4819052	0.851	rs8126930	ENSG00000273796.1	LL21NC02-21A1.1	-4.38	1.44e-05	0.00142	-0.2	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45403809~45404369:-
THCA	cis	rs362272	0.525	rs2798286	ENSG00000249673.5	NOP14-AS1	4.38	1.44e-05	0.00142	0.16	0.2	Serum sulfate level;	chr4:3044446	chr4:2934899~2961738:+
THCA	cis	rs875971	0.545	rs75840613	ENSG00000273142.1	RP11-458F8.4	4.38	1.44e-05	0.00142	0.18	0.2	Aortic root size;	chr7:66376399	chr7:66902857~66906297:+
THCA	cis	rs9393777	0.92	rs13195040	ENSG00000220721.1	OR1F12	-4.38	1.44e-05	0.00142	-0.4	-0.2	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28073316~28074233:+
THCA	cis	rs28829049	0.597	rs72651403	ENSG00000270728.1	RP4-657E11.10	-4.38	1.44e-05	0.00142	-0.15	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19193393	chr1:19297080~19297903:+
THCA	cis	rs17270561	0.609	rs1937131	ENSG00000272462.2	U91328.19	4.38	1.44e-05	0.00142	0.17	0.2	Iron status biomarkers;	chr6:25744603	chr6:25992662~26001775:+
THCA	cis	rs2839186	0.585	rs2839154	ENSG00000223901.2	AP001469.5	-4.38	1.44e-05	0.00142	-0.21	-0.2	Testicular germ cell tumor;	chr21:46217846	chr21:46220269~46225364:+
THCA	cis	rs6517329	0.649	rs4817776	ENSG00000236830.5	CBR3-AS1	4.38	1.44e-05	0.00142	0.19	0.2	Schizophrenia;	chr21:36121124	chr21:36131767~36175815:-
THCA	cis	rs42648	0.869	rs1015403	ENSG00000225498.1	AC002064.5	4.38	1.44e-05	0.00142	0.2	0.2	Homocysteine levels;	chr7:90284388	chr7:90312496~90322592:+
THCA	cis	rs42648	0.869	rs1015404	ENSG00000225498.1	AC002064.5	4.38	1.44e-05	0.00142	0.2	0.2	Homocysteine levels;	chr7:90284632	chr7:90312496~90322592:+
THCA	cis	rs12935229	0.756	rs17701900	ENSG00000260922.1	RP11-538I12.3	-4.38	1.44e-05	0.00142	-0.32	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77277395	chr16:77234877~77290934:+
THCA	cis	rs8077577	0.638	rs4386179	ENSG00000273018.4	CTD-2303H24.2	4.38	1.44e-05	0.00142	0.3	0.2	Obesity-related traits;	chr17:18231460	chr17:18511221~18551705:-
THCA	cis	rs2070488	0.965	rs13093640	ENSG00000229589.1	ACVR2B-AS1	4.38	1.44e-05	0.00142	0.18	0.2	Electrocardiographic conduction measures;	chr3:38445685	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs762317	ENSG00000229589.1	ACVR2B-AS1	4.38	1.44e-05	0.00142	0.18	0.2	Electrocardiographic conduction measures;	chr3:38456168	chr3:38451027~38454820:-
THCA	cis	rs7474896	0.832	rs12783722	ENSG00000263064.2	RP11-291L22.7	4.38	1.44e-05	0.00142	0.35	0.2	Obesity (extreme);	chr10:37736156	chr10:38448689~38448949:+
THCA	cis	rs227584	0.663	rs2040810	ENSG00000267080.4	ASB16-AS1	4.38	1.44e-05	0.00142	0.17	0.2	Bone mineral density;Bone mineral density (hip);	chr17:44166403	chr17:44175973~44186717:-
THCA	cis	rs4443100	0.916	rs6003482	ENSG00000230701.2	FBXW4P1	4.38	1.44e-05	0.00142	0.23	0.2	Serum parathyroid hormone levels;	chr22:23037185	chr22:23262767~23265005:+
THCA	cis	rs1113500	0.73	rs1361829	ENSG00000230489.1	VAV3-AS1	4.38	1.44e-05	0.00142	0.18	0.2	Growth-regulated protein alpha levels;	chr1:108051273	chr1:107964443~107994607:+
THCA	cis	rs4713118	0.868	rs9468220	ENSG00000220721.1	OR1F12	-4.38	1.44e-05	0.00142	-0.28	-0.2	Parkinson's disease;	chr6:27765197	chr6:28073316~28074233:+
THCA	cis	rs55661361	0.651	rs12293621	ENSG00000245498.5	RP11-677M14.7	4.38	1.44e-05	0.00142	0.15	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742932	chr11:124800450~124834487:+
THCA	cis	rs55661361	0.651	rs12293624	ENSG00000245498.5	RP11-677M14.7	4.38	1.44e-05	0.00142	0.15	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742937	chr11:124800450~124834487:+
THCA	cis	rs1823874	0.71	rs55947799	ENSG00000182397.13	DNM1P46	-4.38	1.44e-05	0.00142	-0.23	-0.2	IgG glycosylation;	chr15:99820700	chr15:99790156~99806927:-
THCA	cis	rs1823874	0.71	rs4965543	ENSG00000182397.13	DNM1P46	-4.38	1.44e-05	0.00142	-0.23	-0.2	IgG glycosylation;	chr15:99821050	chr15:99790156~99806927:-
THCA	cis	rs1823874	0.71	rs3919790	ENSG00000182397.13	DNM1P46	-4.38	1.44e-05	0.00142	-0.23	-0.2	IgG glycosylation;	chr15:99821130	chr15:99790156~99806927:-
THCA	cis	rs9840812	0.522	rs699165	ENSG00000239213.4	NCK1-AS1	4.38	1.44e-05	0.00142	0.19	0.2	Fibrinogen levels;	chr3:136505855	chr3:136841726~136862054:-
THCA	cis	rs12134133	1	rs61822669	ENSG00000237074.1	RP11-6J21.2	4.38	1.44e-05	0.00142	0.21	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207249067~207309121:+
THCA	cis	rs3764021	0.743	rs7973535	ENSG00000214776.8	RP11-726G1.1	4.38	1.44e-05	0.00142	0.24	0.2	Type 1 diabetes;	chr12:9727801	chr12:9467552~9576275:+
THCA	cis	rs3764021	0.87	rs7973638	ENSG00000214776.8	RP11-726G1.1	4.38	1.44e-05	0.00142	0.24	0.2	Type 1 diabetes;	chr12:9727845	chr12:9467552~9576275:+
THCA	cis	rs4713118	0.669	rs200997	ENSG00000220721.1	OR1F12	4.38	1.44e-05	0.00142	0.24	0.2	Parkinson's disease;	chr6:27844037	chr6:28073316~28074233:+
THCA	cis	rs6430585	0.528	rs309172	ENSG00000231890.6	DARS-AS1	-4.38	1.44e-05	0.00142	-0.23	-0.2	Corneal structure;	chr2:135916458	chr2:135985176~136022593:+
THCA	cis	rs3770081	1	rs58686314	ENSG00000272564.1	RP11-548P2.2	-4.38	1.44e-05	0.00142	-0.35	-0.2	Facial emotion recognition (sad faces);	chr2:85896844	chr2:85904279~85904727:+
THCA	cis	rs9813712	0.83	rs9755184	ENSG00000253540.4	FAM86HP	-4.38	1.44e-05	0.00142	-0.24	-0.2	Response to amphetamines;	chr3:130262278	chr3:130099092~130111472:-
THCA	cis	rs911119	0.913	rs6048924	ENSG00000270001.1	RP11-218C14.8	-4.38	1.44e-05	0.00142	-0.29	-0.2	Chronic kidney disease;	chr20:23598359	chr20:23631826~23632316:-
THCA	cis	rs10256972	0.967	rs4723338	ENSG00000225146.1	AC073957.15	4.38	1.44e-05	0.00142	0.2	0.2	Endometriosis;Longevity;	chr7:996605	chr7:1029025~1043891:+
THCA	cis	rs4973397	0.765	rs13025087	ENSG00000224376.1	AC017104.6	-4.38	1.44e-05	0.00142	-0.22	-0.2	Anti-saccade response;	chr2:231400203	chr2:231388976~231394991:+
THCA	cis	rs10875746	0.951	rs11168433	ENSG00000258273.1	RP11-370I10.4	4.38	1.44e-05	0.00142	0.28	0.2	Longevity (90 years and older);	chr12:48164281	chr12:48333755~48333901:-
THCA	cis	rs6787172	0.87	rs1714524	ENSG00000272087.1	RP11-379F4.7	4.38	1.44e-05	0.00142	0.17	0.2	Subjective well-being;	chr3:158555307	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.837	rs1656373	ENSG00000272087.1	RP11-379F4.7	4.38	1.44e-05	0.00142	0.17	0.2	Subjective well-being;	chr3:158555732	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.806	rs1435641	ENSG00000272087.1	RP11-379F4.7	4.38	1.44e-05	0.00142	0.17	0.2	Subjective well-being;	chr3:158558132	chr3:158693120~158693768:-
THCA	cis	rs1005277	0.529	rs1780125	ENSG00000272983.1	RP11-508N22.12	4.38	1.44e-05	0.00142	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38137337~38144399:+
THCA	cis	rs4906332	0.868	rs4900578	ENSG00000269910.1	RP11-73M18.10	4.38	1.44e-05	0.00142	0.17	0.2	Coronary artery disease;	chr14:103459673	chr14:103694516~103695050:-
THCA	cis	rs890448	1	rs995313	ENSG00000254531.1	FLJ20021	-4.38	1.44e-05	0.00143	-0.17	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101512902	chr4:101347780~101348883:+
THCA	cis	rs875971	0.862	rs7786892	ENSG00000229886.1	RP5-1132H15.3	-4.38	1.44e-05	0.00143	-0.21	-0.2	Aortic root size;	chr7:66163889	chr7:66025126~66031544:-
THCA	cis	rs7959452	0.64	rs1598543	ENSG00000274979.1	RP11-1143G9.5	-4.38	1.44e-05	0.00143	-0.21	-0.2	Blood protein levels;	chr12:69294977	chr12:69326574~69331882:-
THCA	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	4.38	1.44e-05	0.00143	0.2	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
THCA	cis	rs8192917	0.524	rs56404718	ENSG00000258744.1	RP11-80A15.1	-4.38	1.44e-05	0.00143	-0.33	-0.2	Vitiligo;	chr14:24650565	chr14:24501594~24508688:+
THCA	cis	rs4743820	0.503	rs10820835	ENSG00000230147.2	RP11-305L7.5	-4.38	1.44e-05	0.00143	-0.25	-0.2	Ulcerative colitis;Inflammatory bowel disease;	chr9:91158945	chr9:91169585~91170045:-
THCA	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-4.38	1.44e-05	0.00143	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
THCA	cis	rs7572644	0.699	rs10194283	ENSG00000223522.1	AC093690.1	4.38	1.44e-05	0.00143	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27936212	chr2:28307691~28310459:-
THCA	cis	rs6430538	0.55	rs11902999	ENSG00000224043.6	CCNT2-AS1	-4.38	1.44e-05	0.00143	-0.21	-0.2	Parkinson's disease;	chr2:134809581	chr2:134735464~134918710:-
THCA	cis	rs2028299	0.919	rs3759831	ENSG00000259677.1	RP11-493E3.1	4.38	1.44e-05	0.00143	0.25	0.2	Type 2 diabetes;	chr15:89871410	chr15:89876540~89877285:+
THCA	cis	rs7267979	0.934	rs2261115	ENSG00000274973.1	RP13-401N8.7	-4.38	1.45e-05	0.00143	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2261747	ENSG00000274973.1	RP13-401N8.7	-4.38	1.45e-05	0.00143	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25845497~25845862:+
THCA	cis	rs997295	0.713	rs12905509	ENSG00000270964.1	RP11-502I4.3	-4.38	1.45e-05	0.00143	-0.16	-0.2	Motion sickness;	chr15:67701770	chr15:67541072~67542604:-
THCA	cis	rs10875746	0.903	rs2158516	ENSG00000258273.1	RP11-370I10.4	4.38	1.45e-05	0.00143	0.28	0.2	Longevity (90 years and older);	chr12:48097051	chr12:48333755~48333901:-
THCA	cis	rs8077577	0.708	rs2290502	ENSG00000273018.4	CTD-2303H24.2	4.38	1.45e-05	0.00143	0.29	0.2	Obesity-related traits;	chr17:18230181	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.708	rs3862147	ENSG00000273018.4	CTD-2303H24.2	4.38	1.45e-05	0.00143	0.29	0.2	Obesity-related traits;	chr17:18230399	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.708	rs3889544	ENSG00000273018.4	CTD-2303H24.2	4.38	1.45e-05	0.00143	0.29	0.2	Obesity-related traits;	chr17:18230474	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.708	rs4556848	ENSG00000273018.4	CTD-2303H24.2	4.38	1.45e-05	0.00143	0.29	0.2	Obesity-related traits;	chr17:18231553	chr17:18511221~18551705:-
THCA	cis	rs2033711	0.87	rs4801583	ENSG00000269054.1	CTD-2619J13.3	-4.38	1.45e-05	0.00143	-0.16	-0.2	Uric acid clearance;	chr19:58407038	chr19:58362585~58366591:+
THCA	cis	rs7208859	0.673	rs216424	ENSG00000280069.1	CTD-2349P21.3	-4.38	1.45e-05	0.00143	-0.28	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30738182~30740275:+
THCA	cis	rs72949976	0.864	rs62186566	ENSG00000270659.1	RP11-105N14.1	4.38	1.45e-05	0.00143	0.16	0.2	Squamous cell lung carcinoma;Lung cancer;	chr2:213159697	chr2:213152970~213153659:+
THCA	cis	rs7918232	0.943	rs6482593	ENSG00000262412.1	RP11-85G18.6	4.38	1.45e-05	0.00143	0.3	0.2	Breast cancer;	chr10:27082508	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.943	rs4747584	ENSG00000262412.1	RP11-85G18.6	4.38	1.45e-05	0.00143	0.3	0.2	Breast cancer;	chr10:27084404	chr10:27243130~27250804:+
THCA	cis	rs8031584	1	rs1474380	ENSG00000178081.11	ULK4P3	4.38	1.45e-05	0.00143	0.26	0.2	Huntington's disease progression;	chr15:30977032	chr15:30103720~30131757:+
THCA	cis	rs116248771	0.69	rs10936149	ENSG00000271778.1	RP11-379F4.8	4.38	1.45e-05	0.00143	0.26	0.2	diarrhoeal disease at age 2;	chr3:158576104	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.793	rs12494750	ENSG00000271778.1	RP11-379F4.8	4.38	1.45e-05	0.00143	0.26	0.2	diarrhoeal disease at age 2;	chr3:158580622	chr3:158782547~158783124:+
THCA	cis	rs2904967	0.526	rs171193	ENSG00000254614.2	AP003068.23	-4.38	1.45e-05	0.00143	-0.32	-0.2	Mean corpuscular volume;	chr11:65215128	chr11:65177606~65181834:-
THCA	cis	rs710865	0.541	rs12567768	ENSG00000270728.1	RP4-657E11.10	-4.38	1.45e-05	0.00143	-0.15	-0.2	Brain structure;	chr1:19242109	chr1:19297080~19297903:+
THCA	cis	rs7829975	0.577	rs7816329	ENSG00000254153.1	CTA-398F10.2	4.38	1.45e-05	0.00143	0.23	0.2	Mood instability;	chr8:8686333	chr8:8456909~8461337:-
THCA	cis	rs11992162	0.613	rs6601634	ENSG00000254948.1	OR7E158P	4.38	1.45e-05	0.00143	0.25	0.2	Monocyte count;	chr8:11948947	chr8:11919900~11920809:-
THCA	cis	rs17801127	0.818	rs16825494	ENSG00000231969.1	AC144449.1	4.38	1.45e-05	0.00143	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149675536	chr2:149587196~149848233:+
THCA	cis	rs1923243	0.589	rs6674333	ENSG00000223479.3	RP4-788P17.1	4.38	1.45e-05	0.00143	0.22	0.2	Migraine;	chr1:73165875	chr1:73635216~73715214:+
THCA	cis	rs227275	0.556	rs6815526	ENSG00000248971.2	KRT8P46	-4.38	1.45e-05	0.00143	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs6824070	ENSG00000248971.2	KRT8P46	-4.38	1.45e-05	0.00143	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.935	rs6856176	ENSG00000248971.2	KRT8P46	-4.38	1.45e-05	0.00143	-0.24	-0.2	Schizophrenia;	chr4:102902574	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs11722779	ENSG00000248971.2	KRT8P46	-4.38	1.45e-05	0.00143	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102728746~102730171:-
THCA	cis	rs9510787	0.538	rs1630	ENSG00000205861.10	C1QTNF9B-AS1	-4.38	1.45e-05	0.00143	-0.25	-0.2	Nasopharyngeal carcinoma;	chr13:23675708	chr13:23888889~23897263:+
THCA	cis	rs1048886	0.882	rs73474937	ENSG00000271967.1	RP11-134K13.4	-4.38	1.45e-05	0.00143	-0.21	-0.2	Type 2 diabetes;	chr6:70412509	chr6:70596438~70596980:+
THCA	cis	rs1538970	0.924	rs12037201	ENSG00000234329.1	RP11-767N6.2	4.38	1.45e-05	0.00143	0.2	0.2	Platelet count;	chr1:45475677	chr1:45651039~45651826:-
THCA	cis	rs12497850	0.865	rs13072911	ENSG00000228638.1	FCF1P2	-4.38	1.45e-05	0.00143	-0.21	-0.2	Parkinson's disease;	chr3:48924695	chr3:48290793~48291375:-
THCA	cis	rs240993	0.812	rs2025269	ENSG00000271789.1	RP5-1112D6.7	-4.38	1.45e-05	0.00143	-0.24	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111489237	chr6:111297126~111298510:+
THCA	cis	rs9810089	0.843	rs696081	ENSG00000273455.1	RP11-305O4.3	-4.38	1.45e-05	0.00143	-0.26	-0.2	Gestational age at birth (child effect);	chr3:136328347	chr3:136087475~136087913:-
THCA	cis	rs6001482	0.662	rs6001526	ENSG00000272779.1	LL22NC03-80A10.6	-4.38	1.45e-05	0.00143	-0.22	-0.2	Diastolic blood pressure;	chr22:22234518	chr22:22303224~22310401:+
THCA	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	4.38	1.45e-05	0.00143	0.24	0.2	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
THCA	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	4.38	1.45e-05	0.00143	0.24	0.2	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
THCA	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	4.38	1.45e-05	0.00143	0.24	0.2	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
THCA	cis	rs8177876	0.584	rs13185	ENSG00000261061.1	RP11-303E16.2	4.38	1.45e-05	0.00143	0.25	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046036	chr16:81030770~81031485:+
THCA	cis	rs227275	0.525	rs6533052	ENSG00000248971.2	KRT8P46	-4.38	1.45e-05	0.00143	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs13117110	ENSG00000248971.2	KRT8P46	-4.38	1.45e-05	0.00143	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs13144033	ENSG00000248971.2	KRT8P46	-4.38	1.45e-05	0.00143	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102728746~102730171:-
THCA	cis	rs972578	0.677	rs2056946	ENSG00000274717.1	RP1-47A17.1	-4.38	1.45e-05	0.00143	-0.21	-0.2	Mean platelet volume;	chr22:42954371	chr22:42791814~42794313:-
THCA	cis	rs9863	0.861	rs34878139	ENSG00000269997.1	RP11-214K3.21	-4.38	1.45e-05	0.00143	-0.24	-0.2	White blood cell count;	chr12:123961706	chr12:123966077~123966629:-
THCA	cis	rs9863	0.861	rs11833002	ENSG00000269997.1	RP11-214K3.21	-4.38	1.45e-05	0.00143	-0.24	-0.2	White blood cell count;	chr12:123962069	chr12:123966077~123966629:-
THCA	cis	rs911119	0.866	rs2405393	ENSG00000270001.1	RP11-218C14.8	-4.38	1.45e-05	0.00143	-0.29	-0.2	Chronic kidney disease;	chr20:23588755	chr20:23631826~23632316:-
THCA	cis	rs911119	0.866	rs4346460	ENSG00000270001.1	RP11-218C14.8	-4.38	1.45e-05	0.00143	-0.29	-0.2	Chronic kidney disease;	chr20:23588763	chr20:23631826~23632316:-
THCA	cis	rs911119	0.913	rs12710327	ENSG00000270001.1	RP11-218C14.8	-4.38	1.45e-05	0.00143	-0.29	-0.2	Chronic kidney disease;	chr20:23589052	chr20:23631826~23632316:-
THCA	cis	rs2734839	0.964	rs7131440	ENSG00000270179.1	RP11-159N11.4	4.38	1.45e-05	0.00143	0.21	0.2	Information processing speed;	chr11:113429188	chr11:113368478~113369117:+
THCA	cis	rs10256972	0.521	rs7457418	ENSG00000225146.1	AC073957.15	4.38	1.45e-05	0.00143	0.21	0.2	Endometriosis;Longevity;	chr7:1070619	chr7:1029025~1043891:+
THCA	cis	rs8028182	0.549	rs11072542	ENSG00000260274.1	RP11-817O13.8	-4.38	1.45e-05	0.00143	-0.14	-0.2	Sudden cardiac arrest;	chr15:75342258	chr15:75368155~75369584:+
THCA	cis	rs1707322	0.963	rs34907901	ENSG00000281133.1	AL355480.3	-4.38	1.45e-05	0.00143	-0.24	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45580892~45580996:-
THCA	cis	rs442309	0.687	rs10822053	ENSG00000238280.1	RP11-436D10.3	4.38	1.45e-05	0.00143	0.25	0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62701075	chr10:62793562~62805887:-
THCA	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	4.38	1.45e-05	0.00143	0.23	0.2	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
THCA	cis	rs6840258	0.891	rs17012512	ENSG00000251411.1	RP11-397E7.4	-4.38	1.45e-05	0.00143	-0.23	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87146352	chr4:86913266~86914817:-
THCA	cis	rs656319	0.625	rs34427895	ENSG00000261451.1	RP11-981G7.1	-4.38	1.45e-05	0.00143	-0.26	-0.2	Myopia (pathological);	chr8:10017711	chr8:10433672~10438312:+
THCA	cis	rs2904524	0.737	rs2030671	ENSG00000257815.4	RP11-611E13.2	-4.38	1.45e-05	0.00143	-0.29	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70250837	chr12:69904033~70243360:-
THCA	cis	rs17270561	0.609	rs1892255	ENSG00000272462.2	U91328.19	-4.38	1.45e-05	0.00143	-0.17	-0.2	Iron status biomarkers;	chr6:25750126	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs1892254	ENSG00000272462.2	U91328.19	-4.38	1.45e-05	0.00143	-0.17	-0.2	Iron status biomarkers;	chr6:25750302	chr6:25992662~26001775:+
THCA	cis	rs12478296	0.901	rs59477854	ENSG00000220804.7	AC093642.5	4.38	1.45e-05	0.00143	0.21	0.2	Obesity-related traits;	chr2:242073339	chr2:242088633~242160153:+
THCA	cis	rs1023500	0.552	rs5758566	ENSG00000273366.1	CTA-989H11.1	-4.38	1.45e-05	0.00143	-0.26	-0.2	Schizophrenia;	chr22:42058350	chr22:42278188~42278846:+
THCA	cis	rs6787172	0.811	rs7648618	ENSG00000272087.1	RP11-379F4.7	4.38	1.45e-05	0.00143	0.18	0.2	Subjective well-being;	chr3:158505049	chr3:158693120~158693768:-
THCA	cis	rs28829049	0.597	rs71645438	ENSG00000270728.1	RP4-657E11.10	-4.38	1.45e-05	0.00143	-0.15	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19175855	chr1:19297080~19297903:+
THCA	cis	rs738144	0.643	rs4638897	ENSG00000235209.1	CTA-150C2.13	-4.38	1.45e-05	0.00143	-0.31	-0.2	IgG glycosylation;	chr22:38789183	chr22:38921227~38924708:+
THCA	cis	rs12234571	1	rs75451541	ENSG00000214293.7	APTR	4.38	1.45e-05	0.00143	0.25	0.2	Obesity-related traits;	chr7:77930918	chr7:77657660~77696265:-
THCA	cis	rs12234571	0.793	rs79986314	ENSG00000214293.7	APTR	4.38	1.45e-05	0.00143	0.25	0.2	Obesity-related traits;	chr7:77931656	chr7:77657660~77696265:-
THCA	cis	rs2898290	0.5	rs11998678	ENSG00000206014.6	OR7E161P	4.38	1.45e-05	0.00143	0.23	0.2	Systolic blood pressure;	chr8:11972641	chr8:11928597~11929563:-
THCA	cis	rs6449502	0.777	rs6449507	ENSG00000251279.1	CTC-436P18.1	-4.38	1.46e-05	0.00144	-0.33	-0.2	Mean platelet volume;	chr5:60867843	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs4647168	ENSG00000251279.1	CTC-436P18.1	-4.38	1.46e-05	0.00144	-0.33	-0.2	Mean platelet volume;	chr5:60873287	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.777	rs7445953	ENSG00000251279.1	CTC-436P18.1	-4.38	1.46e-05	0.00144	-0.33	-0.2	Mean platelet volume;	chr5:60881162	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs6449510	ENSG00000251279.1	CTC-436P18.1	-4.38	1.46e-05	0.00144	-0.33	-0.2	Mean platelet volume;	chr5:60883491	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs2306350	ENSG00000251279.1	CTC-436P18.1	-4.38	1.46e-05	0.00144	-0.33	-0.2	Mean platelet volume;	chr5:60890791	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs2306351	ENSG00000251279.1	CTC-436P18.1	-4.38	1.46e-05	0.00144	-0.33	-0.2	Mean platelet volume;	chr5:60891148	chr5:61162070~61232040:+
THCA	cis	rs17095355	1	rs921348	ENSG00000203876.8	ADD3-AS1	-4.38	1.46e-05	0.00144	-0.21	-0.2	Biliary atresia;	chr10:109947740	chr10:109940104~110008381:-
THCA	cis	rs516805	0.52	rs155465	ENSG00000279453.1	RP3-425C14.4	-4.38	1.46e-05	0.00144	-0.16	-0.2	Lymphocyte counts;	chr6:122511027	chr6:122436789~122439223:-
THCA	cis	rs791590	0.941	rs12722527	ENSG00000229664.1	RP11-536K7.5	-4.38	1.46e-05	0.00144	-0.33	-0.2	Soluble interleukin-2 receptor subunit alpha;	chr10:6035365	chr10:6025978~6036427:+
THCA	cis	rs1923243	0.647	rs11210145	ENSG00000223479.3	RP4-788P17.1	4.38	1.46e-05	0.00144	0.22	0.2	Migraine;	chr1:73155986	chr1:73635216~73715214:+
THCA	cis	rs801193	1	rs17566701	ENSG00000272831.1	RP11-792A8.4	4.38	1.46e-05	0.00144	0.13	0.2	Aortic root size;	chr7:66728196	chr7:66739829~66740385:-
THCA	cis	rs4915077	0.892	rs41486546	ENSG00000230489.1	VAV3-AS1	4.38	1.46e-05	0.00144	0.32	0.2	Hypothyroidism;	chr1:107756357	chr1:107964443~107994607:+
THCA	cis	rs9921338	0.668	rs193779	ENSG00000262636.1	CTD-3088G3.4	-4.38	1.46e-05	0.00144	-0.29	-0.2	Vein graft stenosis in coronary artery bypass grafting;	chr16:11257108	chr16:11380859~11381118:-
THCA	cis	rs795484	1	rs795484	ENSG00000275409.1	RP11-131L12.4	-4.38	1.46e-05	0.00144	-0.17	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118152057	chr12:118430147~118430699:+
THCA	cis	rs1850744	0.51	rs4697901	ENSG00000250942.1	ENPP7P11	4.38	1.46e-05	0.00144	0.29	0.2	Economic and political preferences;	chr4:9862074	chr4:9677308~9677934:+
THCA	cis	rs17123764	0.818	rs3887728	ENSG00000257464.1	RP11-161H23.8	-4.38	1.46e-05	0.00144	-0.31	-0.2	Intelligence (multi-trait analysis);	chr12:49578549	chr12:49442424~49442652:-
THCA	cis	rs7474896	0.887	rs10827844	ENSG00000263064.2	RP11-291L22.7	4.38	1.46e-05	0.00144	0.33	0.2	Obesity (extreme);	chr10:38065366	chr10:38448689~38448949:+
THCA	cis	rs7657257	1	rs7657257	ENSG00000214846.4	RP11-115L11.1	4.38	1.46e-05	0.00144	0.51	0.2	Blood protein levels;	chr4:15645318	chr4:15730962~15731627:-
THCA	cis	rs792448	0.506	rs2275712	ENSG00000226251.4	RP11-15I11.3	-4.38	1.46e-05	0.00144	-0.25	-0.2	White blood cell count (basophil);	chr1:212444487	chr1:212225278~212238977:-
THCA	cis	rs1923243	0.647	rs12126688	ENSG00000223479.3	RP4-788P17.1	4.38	1.46e-05	0.00144	0.22	0.2	Migraine;	chr1:73176803	chr1:73635216~73715214:+
THCA	cis	rs7577696	0.695	rs7588883	ENSG00000276334.1	AL133243.1	-4.38	1.46e-05	0.00144	-0.21	-0.2	Inflammatory biomarkers;	chr2:32172198	chr2:32521927~32523547:+
THCA	cis	rs7209700	0.632	rs11657963	ENSG00000228782.6	CTD-2026D20.3	-4.38	1.46e-05	0.00144	-0.21	-0.2	IgG glycosylation;	chr17:47270167	chr17:47450568~47492492:-
THCA	cis	rs7209700	0.662	rs8074094	ENSG00000228782.6	CTD-2026D20.3	-4.38	1.46e-05	0.00144	-0.21	-0.2	IgG glycosylation;	chr17:47270655	chr17:47450568~47492492:-
THCA	cis	rs481331	0.866	rs11239614	ENSG00000215146.4	RP11-313J2.1	4.38	1.46e-05	0.00144	0.31	0.2	Systemic juvenile idiopathic arthritis;	chr10:42487070	chr10:42331866~42367974:-
THCA	cis	rs4713118	0.955	rs9393848	ENSG00000220721.1	OR1F12	4.38	1.46e-05	0.00144	0.26	0.2	Parkinson's disease;	chr6:27720590	chr6:28073316~28074233:+
THCA	cis	rs3740713	1	rs73436668	ENSG00000256464.1	YWHABP2	4.38	1.46e-05	0.00144	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr11:18490243~18490955:-
THCA	cis	rs9876781	1	rs7651407	ENSG00000244380.1	RP11-24C3.2	4.38	1.46e-05	0.00144	0.23	0.2	Longevity;	chr3:48402409	chr3:48440352~48446656:-
THCA	cis	rs12681963	0.688	rs7820490	ENSG00000248159.1	HSPA8P11	4.38	1.46e-05	0.00144	0.36	0.2	Migraine;	chr8:30213634	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs4507726	ENSG00000248159.1	HSPA8P11	4.38	1.46e-05	0.00144	0.36	0.2	Migraine;	chr8:30214491	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs4454242	ENSG00000248159.1	HSPA8P11	4.38	1.46e-05	0.00144	0.36	0.2	Migraine;	chr8:30214804	chr8:30237382~30240997:+
THCA	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	4.38	1.46e-05	0.00144	0.26	0.2	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000273712.1	RP5-874C20.7	4.38	1.46e-05	0.00144	0.22	0.2	Pubertal anthropometrics;	chr6:28271903	chr6:28315613~28315883:-
THCA	cis	rs6067053	0.621	rs11696801	ENSG00000227431.4	CSE1L-AS1	4.38	1.46e-05	0.00144	0.25	0.2	Intelligence (multi-trait analysis);	chr20:49251062	chr20:49040463~49046044:-
THCA	cis	rs6067053	0.671	rs6125600	ENSG00000227431.4	CSE1L-AS1	4.38	1.46e-05	0.00144	0.25	0.2	Intelligence (multi-trait analysis);	chr20:49256363	chr20:49040463~49046044:-
THCA	cis	rs10129255	0.642	rs11624918	ENSG00000211974.3	IGHV2-70	4.38	1.46e-05	0.00144	0.16	0.2	Kawasaki disease;	chr14:106664672	chr14:106723574~106724093:-
THCA	cis	rs1850744	0.51	rs10003673	ENSG00000250942.1	ENPP7P11	4.38	1.46e-05	0.00144	0.29	0.2	Economic and political preferences;	chr4:9860676	chr4:9677308~9677934:+
THCA	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	-4.38	1.46e-05	0.00144	-0.24	-0.2	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
THCA	cis	rs9990343	0.783	rs4683205	ENSG00000223552.1	RP11-24F11.2	4.38	1.46e-05	0.00144	0.18	0.2	Brain structure;	chr3:46293179	chr3:46364955~46407059:-
THCA	cis	rs17597773	0.638	rs6541161	ENSG00000272823.1	RP11-295M18.6	-4.38	1.46e-05	0.00144	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220820922	chr1:220828676~220829211:-
THCA	cis	rs12030196	1	rs12031587	ENSG00000230812.4	LINC01358	4.38	1.46e-05	0.00144	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59006381	chr1:59020387~59044614:+
THCA	cis	rs7577696	0.695	rs11124278	ENSG00000276334.1	AL133243.1	-4.38	1.46e-05	0.00144	-0.21	-0.2	Inflammatory biomarkers;	chr2:32173443	chr2:32521927~32523547:+
THCA	cis	rs227275	0.525	rs7672319	ENSG00000248971.2	KRT8P46	-4.38	1.46e-05	0.00144	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs6533051	ENSG00000248971.2	KRT8P46	-4.38	1.46e-05	0.00144	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102728746~102730171:-
THCA	cis	rs10911902	0.643	rs79080293	ENSG00000229739.2	RP11-295K2.3	-4.38	1.46e-05	0.00144	-0.32	-0.2	Schizophrenia;	chr1:186379546	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs3766699	ENSG00000229739.2	RP11-295K2.3	-4.38	1.46e-05	0.00144	-0.32	-0.2	Schizophrenia;	chr1:186381179	chr1:186435161~186470291:+
THCA	cis	rs7772486	0.754	rs6932863	ENSG00000270638.1	RP3-466P17.1	-4.38	1.46e-05	0.00144	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145735570~145737218:+
THCA	cis	rs911119	0.913	rs1158167	ENSG00000270001.1	RP11-218C14.8	4.38	1.46e-05	0.00144	0.29	0.2	Chronic kidney disease;	chr20:23597552	chr20:23631826~23632316:-
THCA	cis	rs911119	0.913	rs3004139	ENSG00000270001.1	RP11-218C14.8	4.38	1.46e-05	0.00144	0.29	0.2	Chronic kidney disease;	chr20:23598037	chr20:23631826~23632316:-
THCA	cis	rs8081395	0.801	rs2645479	ENSG00000267302.4	RP11-178C3.2	4.38	1.46e-05	0.00144	0.24	0.2	White blood cell count;	chr17:59843171	chr17:59964832~59996972:+
THCA	cis	rs9902453	0.967	rs61240589	ENSG00000263370.1	RP11-68I3.5	4.38	1.46e-05	0.00144	0.26	0.2	Coffee consumption (cups per day);	chr17:30122017	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs55748380	ENSG00000263370.1	RP11-68I3.5	4.38	1.46e-05	0.00144	0.26	0.2	Coffee consumption (cups per day);	chr17:30142764	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.933	rs60694493	ENSG00000263370.1	RP11-68I3.5	4.38	1.46e-05	0.00144	0.26	0.2	Coffee consumption (cups per day);	chr17:30146238	chr17:29639627~29640825:+
THCA	cis	rs394563	0.601	rs391875	ENSG00000268592.3	RAET1E-AS1	4.38	1.46e-05	0.00144	0.27	0.2	Dupuytren's disease;	chr6:149474000	chr6:149863494~149919507:+
THCA	cis	rs11250097	0.507	rs2409779	ENSG00000206014.6	OR7E161P	4.38	1.46e-05	0.00144	0.23	0.2	Neuroticism;	chr8:11453831	chr8:11928597~11929563:-
THCA	cis	rs6772849	0.93	rs12487604	ENSG00000242551.2	POU5F1P6	-4.38	1.46e-05	0.00144	-0.26	-0.2	Monocyte percentage of white cells;Monocyte count;	chr3:128618232	chr3:128674735~128677005:-
THCA	cis	rs875971	0.862	rs778686	ENSG00000229886.1	RP5-1132H15.3	4.38	1.46e-05	0.00144	0.2	0.2	Aortic root size;	chr7:66370923	chr7:66025126~66031544:-
THCA	cis	rs6586163	0.509	rs2031610	ENSG00000261438.1	RP11-399O19.9	-4.38	1.46e-05	0.00144	-0.17	-0.2	Chronic lymphocytic leukemia;	chr10:88994730	chr10:89015836~89017059:+
THCA	cis	rs617791	0.569	rs11227370	ENSG00000255320.1	RP11-755F10.1	4.38	1.46e-05	0.00144	0.26	0.2	Breast cancer;	chr11:65980222	chr11:66244840~66246239:-
THCA	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-4.38	1.46e-05	0.00144	-0.27	-0.2	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
THCA	cis	rs7772486	0.754	rs4896839	ENSG00000270638.1	RP3-466P17.1	-4.38	1.46e-05	0.00144	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145735570~145737218:+
THCA	cis	rs394563	0.601	rs367133	ENSG00000268592.3	RAET1E-AS1	4.38	1.46e-05	0.00144	0.27	0.2	Dupuytren's disease;	chr6:149476584	chr6:149863494~149919507:+
THCA	cis	rs1113500	0.565	rs11185226	ENSG00000226822.1	RP11-356N1.2	4.38	1.46e-05	0.00144	0.23	0.2	Growth-regulated protein alpha levels;	chr1:108005429	chr1:108071482~108074519:+
THCA	cis	rs964611	0.882	rs11631831	ENSG00000259488.2	RP11-154J22.1	4.38	1.46e-05	0.00144	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48361563	chr15:48312353~48331856:-
THCA	cis	rs867186	1	rs12105996	ENSG00000126005.14	MMP24-AS1	-4.38	1.46e-05	0.00144	-0.3	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35143207	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs57690120	ENSG00000126005.14	MMP24-AS1	-4.38	1.46e-05	0.00144	-0.3	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35143634	chr20:35216462~35278131:-
THCA	cis	rs62025270	0.632	rs62022943	ENSG00000259295.5	CSPG4P12	-4.38	1.46e-05	0.00144	-0.34	-0.2	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85191438~85213905:+
THCA	cis	rs2153535	0.585	rs7753781	ENSG00000230939.1	RP11-314C16.1	-4.38	1.47e-05	0.00144	-0.21	-0.2	Motion sickness;	chr6:8637268	chr6:8784178~8785445:+
THCA	cis	rs465969	1	rs7750803	ENSG00000272356.1	RP5-1112D6.8	-4.38	1.47e-05	0.00144	-0.3	-0.2	Psoriasis;	chr6:111478910	chr6:111309203~111313517:+
THCA	cis	rs17685	0.523	rs10246583	ENSG00000230882.1	AC005077.14	4.38	1.47e-05	0.00144	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76117349	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs55812043	ENSG00000230882.1	AC005077.14	4.38	1.47e-05	0.00144	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76117923	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs10264760	ENSG00000230882.1	AC005077.14	4.38	1.47e-05	0.00144	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76120376	chr7:76071469~76074963:-
THCA	cis	rs2446066	0.872	rs3741664	ENSG00000257379.1	RP11-793H13.8	4.38	1.47e-05	0.00144	0.3	0.2	Red blood cell count;	chr12:53428886	chr12:53441741~53467528:+
THCA	cis	rs711244	0.756	rs7573966	ENSG00000279519.1	RP11-288C18.1	4.38	1.47e-05	0.00144	0.16	0.2	Mean platelet volume;	chr2:36910903	chr2:36839922~36842539:-
THCA	cis	rs4906332	1	rs13987	ENSG00000269910.1	RP11-73M18.10	4.38	1.47e-05	0.00145	0.17	0.2	Coronary artery disease;	chr14:103503572	chr14:103694516~103695050:-
THCA	cis	rs10109025	0.701	rs10101292	ENSG00000206014.6	OR7E161P	4.38	1.47e-05	0.00145	0.23	0.2	Joint mobility (Beighton score);	chr8:10998964	chr8:11928597~11929563:-
THCA	cis	rs4648045	0.608	rs230505	ENSG00000246560.2	RP11-10L12.4	4.38	1.47e-05	0.00145	0.23	0.2	Lymphocyte percentage of white cells;	chr4:102560194	chr4:102828055~102844075:+
THCA	cis	rs1124769	0.671	rs11070822	ENSG00000259378.1	DCAF13P3	4.38	1.47e-05	0.00145	0.3	0.2	Cognitive performance;	chr15:50950585	chr15:50944663~50945996:+
THCA	cis	rs6517329	0.6	rs6517330	ENSG00000236830.5	CBR3-AS1	4.38	1.47e-05	0.00145	0.19	0.2	Schizophrenia;	chr21:36117163	chr21:36131767~36175815:-
THCA	cis	rs4824093	0.61	rs4141437	ENSG00000278869.1	CITF22-49E9.3	-4.38	1.47e-05	0.00145	-0.37	-0.2	Amyotrophic lateral sclerosis (sporadic);	chr22:49850071	chr22:49933198~49934074:-
THCA	cis	rs73198271	0.562	rs112717383	ENSG00000253893.2	FAM85B	4.38	1.47e-05	0.00145	0.35	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8805706	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.562	rs17631052	ENSG00000253893.2	FAM85B	4.38	1.47e-05	0.00145	0.35	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8806277	chr8:8167819~8226614:-
THCA	cis	rs6845263	0.571	rs1593545	ENSG00000254531.1	FLJ20021	-4.38	1.47e-05	0.00145	-0.17	-0.2	Superior crus of antihelix expression;	chr4:101536850	chr4:101347780~101348883:+
THCA	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	4.38	1.47e-05	0.00145	0.14	0.2	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
THCA	cis	rs1023500	0.505	rs134878	ENSG00000273366.1	CTA-989H11.1	-4.38	1.47e-05	0.00145	-0.25	-0.2	Schizophrenia;	chr22:42267868	chr22:42278188~42278846:+
THCA	cis	rs2574985	0.548	rs2339505	ENSG00000279863.1	RP11-521C22.2	4.38	1.47e-05	0.00145	0.22	0.2	Subjective well-being;	chr10:50498346	chr10:50334538~50336123:+
THCA	cis	rs12681963	0.688	rs4733159	ENSG00000248159.1	HSPA8P11	-4.38	1.47e-05	0.00145	-0.36	-0.2	Migraine;	chr8:30202344	chr8:30237382~30240997:+
THCA	cis	rs9300255	0.83	rs28413626	ENSG00000235423.7	RP11-282O18.3	-4.38	1.47e-05	0.00145	-0.21	-0.2	Neutrophil percentage of white cells;	chr12:123376905	chr12:123252030~123261483:-
THCA	cis	rs6728642	1	rs75297860	ENSG00000230606.9	AC159540.1	4.38	1.47e-05	0.00145	0.3	0.2	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96934341	chr2:97416165~97433527:-
THCA	cis	rs786425	0.627	rs35804181	ENSG00000270095.1	RP11-214K3.18	-4.38	1.47e-05	0.00145	-0.24	-0.2	Pubertal anthropometrics;	chr12:123677797	chr12:123971457~123971714:-
THCA	cis	rs7403037	0.536	rs34030559	ENSG00000260760.1	PWRN3	4.38	1.47e-05	0.00145	0.23	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24177898	chr15:24441127~24447967:+
THCA	cis	rs227275	0.525	rs6533050	ENSG00000248971.2	KRT8P46	-4.38	1.47e-05	0.00145	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102728746~102730171:-
THCA	cis	rs12935229	1	rs1060547	ENSG00000260922.1	RP11-538I12.3	-4.38	1.47e-05	0.00145	-0.33	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77282253	chr16:77234877~77290934:+
THCA	cis	rs6490294	0.528	rs11066126	ENSG00000226469.1	ADAM1B	4.38	1.47e-05	0.00145	0.29	0.2	Mean platelet volume;	chr12:112007087	chr12:111927018~111929017:+
THCA	cis	rs4715166	0.701	rs6458718	ENSG00000272379.1	RP1-257A7.5	4.38	1.47e-05	0.00145	0.25	0.2	Hip geometry;	chr6:13210225	chr6:13290018~13290490:-
THCA	cis	rs12900463	0.813	rs187316	ENSG00000275120.1	RP11-182J1.17	4.38	1.47e-05	0.00145	0.23	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862764	chr15:84599434~84606463:-
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000273712.1	RP5-874C20.7	-4.38	1.47e-05	0.00145	-0.22	-0.2	Pubertal anthropometrics;	chr6:28255953	chr6:28315613~28315883:-
THCA	cis	rs4776970	0.632	rs8030996	ENSG00000270964.1	RP11-502I4.3	-4.38	1.47e-05	0.00145	-0.16	-0.2	Body mass index;Waist circumference;	chr15:67739068	chr15:67541072~67542604:-
THCA	cis	rs12410462	0.551	rs2819502	ENSG00000227711.2	RP11-275O4.5	-4.38	1.47e-05	0.00145	-0.24	-0.2	Major depressive disorder;	chr1:227524951	chr1:227509028~227520477:-
THCA	cis	rs2337406	0.587	rs11624678	ENSG00000274576.2	IGHV2-70	4.38	1.47e-05	0.00145	0.17	0.2	Alzheimer's disease (late onset);	chr14:106650408	chr14:106770577~106771020:-
THCA	cis	rs709400	0.832	rs55864158	ENSG00000258735.1	LINC00637	4.38	1.47e-05	0.00145	0.26	0.2	Body mass index;	chr14:103602242	chr14:103847721~103858049:+
THCA	cis	rs13113518	1	rs13122619	ENSG00000249700.7	SRD5A3-AS1	4.38	1.47e-05	0.00145	0.24	0.2	Height;	chr4:55479339	chr4:55363971~55395847:-
THCA	cis	rs4948275	0.693	rs2650730	ENSG00000237233.2	TMEM26-AS1	-4.38	1.47e-05	0.00145	-0.26	-0.2	Night sleep phenotypes;	chr10:61579592	chr10:61452639~61481956:+
THCA	cis	rs3824488	0.92	rs10512249	ENSG00000237857.2	RP11-435O5.2	-4.38	1.47e-05	0.00145	-0.34	-0.2	Neuroticism;	chr9:95494027	chr9:95414834~95426796:-
THCA	cis	rs4819052	0.766	rs4819035	ENSG00000182586.6	LINC00334	-4.38	1.47e-05	0.00145	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45234340~45258730:+
THCA	cis	rs780094	0.5	rs4665987	ENSG00000234072.1	AC074117.10	4.38	1.47e-05	0.00145	0.16	0.2	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27532958	chr2:27356246~27367622:+
THCA	cis	rs496547	0.756	rs562059	ENSG00000255422.1	AP002954.4	-4.38	1.47e-05	0.00145	-0.22	-0.2	Hip minimal joint space width;	chr11:118731349	chr11:118704607~118750263:+
THCA	cis	rs617791	0.53	rs7952056	ENSG00000255320.1	RP11-755F10.1	4.38	1.47e-05	0.00145	0.26	0.2	Breast cancer;	chr11:65977126	chr11:66244840~66246239:-
THCA	cis	rs10043228	1	rs78362565	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.47e-05	0.00145	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116228596	chr5:116447547~116508276:+
THCA	cis	rs801193	0.569	rs7782587	ENSG00000229886.1	RP5-1132H15.3	4.38	1.47e-05	0.00145	0.21	0.2	Aortic root size;	chr7:66701485	chr7:66025126~66031544:-
THCA	cis	rs800160	0.588	rs800146	ENSG00000236264.4	RPL26P30	4.38	1.47e-05	0.00145	0.27	0.2	Bacteremia;	chr11:2347753	chr11:2335132~2335776:-
THCA	cis	rs2252521	0.583	rs320088	ENSG00000272568.4	CTB-113D17.1	4.38	1.47e-05	0.00145	0.22	0.2	Cognitive performance;	chr7:29043646	chr7:28979967~29013367:+
THCA	cis	rs2252521	0.614	rs317703	ENSG00000272568.4	CTB-113D17.1	4.38	1.47e-05	0.00145	0.22	0.2	Cognitive performance;	chr7:29047610	chr7:28979967~29013367:+
THCA	cis	rs2252521	0.526	rs317704	ENSG00000272568.4	CTB-113D17.1	4.38	1.47e-05	0.00145	0.22	0.2	Cognitive performance;	chr7:29047727	chr7:28979967~29013367:+
THCA	cis	rs703842	1	rs11172349	ENSG00000270039.1	RP11-571M6.17	-4.38	1.48e-05	0.00145	-0.23	-0.2	Multiple sclerosis;	chr12:57818745	chr12:57803838~57804415:+
THCA	cis	rs12681288	0.823	rs4735974	ENSG00000260721.1	AF067845.1	4.38	1.48e-05	0.00145	0.23	0.2	Schizophrenia;	chr8:1050218	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.754	rs4735975	ENSG00000260721.1	AF067845.1	4.38	1.48e-05	0.00145	0.23	0.2	Schizophrenia;	chr8:1050470	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.792	rs12678495	ENSG00000260721.1	AF067845.1	4.38	1.48e-05	0.00145	0.23	0.2	Schizophrenia;	chr8:1050858	chr8:1368642~1369833:-
THCA	cis	rs7560272	0.538	rs2012574	ENSG00000273245.1	RP11-434P11.2	-4.38	1.48e-05	0.00145	-0.23	-0.2	Schizophrenia;	chr2:73701239	chr2:73750256~73750786:-
THCA	cis	rs7924176	0.601	rs10824072	ENSG00000213731.2	RAB5CP1	-4.38	1.48e-05	0.00145	-0.23	-0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74114134	chr10:74423435~74424014:-
THCA	cis	rs35740288	0.77	rs11634707	ENSG00000259295.5	CSPG4P12	4.38	1.48e-05	0.00145	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85608636	chr15:85191438~85213905:+
THCA	cis	rs790006	1	rs790010	ENSG00000243024.5	RPS11P6	4.38	1.48e-05	0.00145	0.23	0.2	Response to cytidine analogues (gemcitabine);	chr12:64209967	chr12:64222337~64397065:+
THCA	cis	rs4356203	0.905	rs11024158	ENSG00000272034.1	SNORD14A	4.38	1.48e-05	0.00145	0.2	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17103621	chr11:17074654~17074744:-
THCA	cis	rs6087771	0.781	rs6089067	ENSG00000230613.1	HM13-AS1	4.38	1.48e-05	0.00145	0.19	0.2	Putamen volume;Subcortical brain region volumes;	chr20:31771091	chr20:31567707~31573263:-
THCA	cis	rs78487399	0.908	rs76450091	ENSG00000234936.1	AC010883.5	4.38	1.48e-05	0.00145	0.26	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43540050	chr2:43229573~43233394:+
THCA	cis	rs4805272	1	rs888828	ENSG00000267799.1	MAN1A2P1	4.38	1.48e-05	0.00145	0.22	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834150	chr19:28790812~28792871:-
THCA	cis	rs2439831	0.681	rs526450	ENSG00000205771.5	CATSPER2P1	-4.38	1.48e-05	0.00145	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43307127	chr15:43726918~43747094:-
THCA	cis	rs6546847	0.531	rs2567602	ENSG00000273245.1	RP11-434P11.2	4.38	1.48e-05	0.00145	0.34	0.2	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73750256~73750786:-
THCA	cis	rs11665867	1	rs11665867	ENSG00000279108.1	CTC-490E21.11	-4.38	1.48e-05	0.00145	-0.28	-0.2	Hematocrit;	chr19:40760574	chr19:40840159~40842039:+
THCA	cis	rs3770081	1	rs57178127	ENSG00000272564.1	RP11-548P2.2	-4.38	1.48e-05	0.00145	-0.35	-0.2	Facial emotion recognition (sad faces);	chr2:85871131	chr2:85904279~85904727:+
THCA	cis	rs55702914	1	rs56234206	ENSG00000231621.1	AC013264.2	-4.38	1.48e-05	0.00145	-0.19	-0.2	Major depression and alcohol dependence;	chr2:197351271	chr2:197197991~197199273:+
THCA	cis	rs12931792	0.687	rs8057425	ENSG00000273724.1	RP11-347C12.12	4.38	1.48e-05	0.00146	0.21	0.2	Tonsillectomy;	chr16:30171220	chr16:30336400~30343336:+
THCA	cis	rs6870983	0.895	rs2410763	ENSG00000247828.6	TMEM161B-AS1	-4.38	1.48e-05	0.00146	-0.19	-0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88370824	chr5:88268895~88436685:+
THCA	cis	rs10761482	0.535	rs4948419	ENSG00000254271.1	RP11-131N11.4	4.38	1.48e-05	0.00146	0.26	0.2	Schizophrenia;	chr10:60436098	chr10:60734342~60741828:+
THCA	cis	rs4218	0.638	rs12437587	ENSG00000277144.1	RP11-59H7.4	-4.38	1.48e-05	0.00146	-0.27	-0.2	Social communication problems;	chr15:59072785	chr15:59115547~59116089:-
THCA	cis	rs465969	0.546	rs7772141	ENSG00000272356.1	RP5-1112D6.8	-4.38	1.48e-05	0.00146	-0.3	-0.2	Psoriasis;	chr6:111472358	chr6:111309203~111313517:+
THCA	cis	rs465969	0.793	rs7776047	ENSG00000272356.1	RP5-1112D6.8	-4.38	1.48e-05	0.00146	-0.3	-0.2	Psoriasis;	chr6:111472391	chr6:111309203~111313517:+
THCA	cis	rs8105895	0.935	rs7252380	ENSG00000269345.1	VN1R85P	4.38	1.48e-05	0.00146	0.27	0.2	Body mass index (change over time);	chr19:22062913	chr19:22174766~22175191:-
THCA	cis	rs55702914	0.809	rs6738721	ENSG00000231621.1	AC013264.2	4.38	1.48e-05	0.00146	0.19	0.2	Major depression and alcohol dependence;	chr2:197317610	chr2:197197991~197199273:+
THCA	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	4.38	1.48e-05	0.00146	0.23	0.2	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	4.38	1.48e-05	0.00146	0.23	0.2	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	4.38	1.48e-05	0.00146	0.23	0.2	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	4.38	1.48e-05	0.00146	0.23	0.2	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
THCA	cis	rs7572644	0.699	rs7595847	ENSG00000223522.1	AC093690.1	4.38	1.48e-05	0.00146	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27950176	chr2:28307691~28310459:-
THCA	cis	rs3736594	0.607	rs7584462	ENSG00000223522.1	AC093690.1	4.38	1.48e-05	0.00146	0.23	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:27953189	chr2:28307691~28310459:-
THCA	cis	rs227275	0.525	rs5028609	ENSG00000248971.2	KRT8P46	-4.38	1.48e-05	0.00146	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs6815540	ENSG00000248971.2	KRT8P46	-4.38	1.48e-05	0.00146	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs4698867	ENSG00000248971.2	KRT8P46	-4.38	1.48e-05	0.00146	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs7663876	ENSG00000248971.2	KRT8P46	-4.38	1.48e-05	0.00146	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs6821173	ENSG00000248971.2	KRT8P46	-4.38	1.48e-05	0.00146	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102728746~102730171:-
THCA	cis	rs10946940	1	rs10946940	ENSG00000216915.2	RP1-97D16.1	4.38	1.48e-05	0.00146	0.27	0.2	Systemic lupus erythematosus;	chr6:27592808	chr6:27737000~27738494:-
THCA	cis	rs2549003	0.966	rs2070730	ENSG00000237714.1	P4HA2-AS1	-4.38	1.48e-05	0.00146	-0.25	-0.2	Asthma (sex interaction);	chr5:132484108	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs7701588	ENSG00000237714.1	P4HA2-AS1	-4.38	1.48e-05	0.00146	-0.25	-0.2	Asthma (sex interaction);	chr5:132484278	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs2070728	ENSG00000237714.1	P4HA2-AS1	-4.38	1.48e-05	0.00146	-0.25	-0.2	Asthma (sex interaction);	chr5:132484285	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs2070727	ENSG00000237714.1	P4HA2-AS1	-4.38	1.48e-05	0.00146	-0.25	-0.2	Asthma (sex interaction);	chr5:132484583	chr5:132184876~132192808:+
THCA	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	4.38	1.48e-05	0.00146	0.23	0.2	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
THCA	cis	rs6517329	0.538	rs879894	ENSG00000236830.5	CBR3-AS1	4.38	1.48e-05	0.00146	0.19	0.2	Schizophrenia;	chr21:36136345	chr21:36131767~36175815:-
THCA	cis	rs12755164	0.771	rs6689491	ENSG00000223479.3	RP4-788P17.1	-4.38	1.48e-05	0.00146	-0.21	-0.2	Schizophrenia;	chr1:72886346	chr1:73635216~73715214:+
THCA	cis	rs7312933	0.566	rs11181454	ENSG00000257225.1	RP11-328C8.4	4.38	1.48e-05	0.00146	0.2	0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42352684	chr12:42459366~42466128:+
THCA	cis	rs800160	0.858	rs800117	ENSG00000199550.1	Y_RNA	4.38	1.48e-05	0.00146	0.3	0.2	Bacteremia;	chr11:2341560	chr11:2372638~2372750:+
THCA	cis	rs9959145	1	rs9989546	ENSG00000267108.1	RP11-861E21.1	4.38	1.48e-05	0.00146	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12562538	chr18:12432897~12437635:+
THCA	cis	rs1124769	0.57	rs2614765	ENSG00000259378.1	DCAF13P3	-4.38	1.48e-05	0.00146	-0.27	-0.2	Cognitive performance;	chr15:50851805	chr15:50944663~50945996:+
THCA	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	4.38	1.48e-05	0.00146	0.22	0.2	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
THCA	cis	rs427943	0.735	rs1537121	ENSG00000223768.1	LINC00205	-4.38	1.48e-05	0.00146	-0.18	-0.2	Body mass index;	chr21:45178435	chr21:45293285~45297354:+
THCA	cis	rs6745190	0.575	rs6710650	ENSG00000236153.1	AC104076.3	-4.38	1.48e-05	0.00146	-0.22	-0.2	White blood cell count;	chr2:181108080	chr2:180979427~180980090:-
THCA	cis	rs7119	0.651	rs12902449	ENSG00000259362.2	RP11-307C19.1	-4.38	1.48e-05	0.00146	-0.28	-0.2	Type 2 diabetes;	chr15:77558584	chr15:77525540~77534110:+
THCA	cis	rs9902453	1	rs28664971	ENSG00000263370.1	RP11-68I3.5	4.38	1.48e-05	0.00146	0.25	0.2	Coffee consumption (cups per day);	chr17:30110392	chr17:29639627~29640825:+
THCA	cis	rs9487094	0.626	rs11153215	ENSG00000223537.2	RP5-919F19.5	-4.38	1.48e-05	0.00146	-0.2	-0.2	Height;	chr6:109732518	chr6:109487906~109506800:+
THCA	cis	rs28829049	0.597	rs12563386	ENSG00000270728.1	RP4-657E11.10	-4.38	1.48e-05	0.00146	-0.15	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19128711	chr1:19297080~19297903:+
THCA	cis	rs61270009	0.863	rs35339529	ENSG00000247828.6	TMEM161B-AS1	4.38	1.48e-05	0.00146	0.17	0.2	Depressive symptoms;	chr5:88360284	chr5:88268895~88436685:+
THCA	cis	rs116248771	0.739	rs4680448	ENSG00000271778.1	RP11-379F4.8	4.38	1.48e-05	0.00146	0.26	0.2	diarrhoeal disease at age 2;	chr3:158632189	chr3:158782547~158783124:+
THCA	cis	rs442309	0.64	rs11597299	ENSG00000238280.1	RP11-436D10.3	-4.38	1.48e-05	0.00146	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62706515	chr10:62793562~62805887:-
THCA	cis	rs875971	0.965	rs28682868	ENSG00000229886.1	RP5-1132H15.3	-4.38	1.48e-05	0.00146	-0.21	-0.2	Aortic root size;	chr7:66224822	chr7:66025126~66031544:-
THCA	cis	rs853679	1	rs853676	ENSG00000273712.1	RP5-874C20.7	4.38	1.48e-05	0.00146	0.31	0.2	Depression;	chr6:28331910	chr6:28315613~28315883:-
THCA	cis	rs13434995	0.589	rs861029	ENSG00000249700.7	SRD5A3-AS1	-4.38	1.48e-05	0.00146	-0.29	-0.2	Adiponectin levels;	chr4:55379470	chr4:55363971~55395847:-
THCA	cis	rs875971	0.545	rs12671152	ENSG00000232559.3	GS1-124K5.12	4.38	1.48e-05	0.00146	0.23	0.2	Aortic root size;	chr7:66311140	chr7:66554588~66576923:-
THCA	cis	rs7200786	0.692	rs1035089	ENSG00000274038.1	RP11-66H6.4	-4.38	1.48e-05	0.00146	-0.25	-0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10954493	chr16:11056556~11057034:+
THCA	cis	rs10043228	0.702	rs10051697	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116142873	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62385177	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116144783	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs4398671	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116222145	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs1382340	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116222464	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs1382339	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116222466	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs17139192	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116226013	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs17139193	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116226376	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12519989	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116226945	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs77564939	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116228597	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs10051240	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116234234	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12523347	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116236698	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12332489	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116243689	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12332585	ENSG00000248445.4	SEMA6A-AS1	-4.38	1.48e-05	0.00146	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116245698	chr5:116447547~116508276:+
THCA	cis	rs786425	0.717	rs12817757	ENSG00000270095.1	RP11-214K3.18	-4.38	1.48e-05	0.00146	-0.24	-0.2	Pubertal anthropometrics;	chr12:123671940	chr12:123971457~123971714:-
THCA	cis	rs3740713	1	rs75487138	ENSG00000256464.1	YWHABP2	4.38	1.48e-05	0.00146	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr11:18490243~18490955:-
THCA	cis	rs9307551	0.584	rs1115518	ENSG00000250334.4	LINC00989	-4.38	1.48e-05	0.00146	-0.24	-0.2	Refractive error;	chr4:79491423	chr4:79492416~79576460:+
THCA	cis	rs4742903	0.935	rs3818626	ENSG00000270332.1	SMC2-AS1	4.38	1.48e-05	0.00146	0.18	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104094352	chr9:104080024~104093073:-
THCA	cis	rs2436845	1	rs2679749	ENSG00000253669.3	KB-1732A1.1	-4.38	1.48e-05	0.00146	-0.21	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102846260	chr8:102805517~102809971:+
THCA	cis	rs6951245	1	rs6951245	ENSG00000229043.2	AC091729.9	-4.38	1.48e-05	0.00146	-0.33	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018557	chr7:1160374~1165267:+
THCA	cis	rs6951245	0.935	rs11763765	ENSG00000229043.2	AC091729.9	-4.38	1.48e-05	0.00146	-0.33	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020874	chr7:1160374~1165267:+
THCA	cis	rs2467099	1	rs2467099	ENSG00000267801.1	RP11-552F3.9	4.38	1.48e-05	0.00146	0.26	0.2	Systolic blood pressure;	chr17:75952964	chr17:75876372~75879546:+
THCA	cis	rs4693089	0.604	rs11731801	ENSG00000213608.5	SLC25A14P1	4.38	1.48e-05	0.00146	0.23	0.2	Menopause (age at onset);	chr4:83473383	chr4:83477524~83478424:+
THCA	cis	rs4693089	0.541	rs67855514	ENSG00000213608.5	SLC25A14P1	4.38	1.48e-05	0.00146	0.23	0.2	Menopause (age at onset);	chr4:83473794	chr4:83477524~83478424:+
THCA	cis	rs12440869	1	rs2414945	ENSG00000270964.1	RP11-502I4.3	4.38	1.48e-05	0.00146	0.17	0.2	Peak velocity of the mitral A-wave;	chr15:67275230	chr15:67541072~67542604:-
THCA	cis	rs801193	1	rs10234018	ENSG00000223473.2	GS1-124K5.3	-4.38	1.48e-05	0.00146	-0.13	-0.2	Aortic root size;	chr7:66681297	chr7:66491049~66493566:-
THCA	cis	rs12681963	0.764	rs4733391	ENSG00000248159.1	HSPA8P11	-4.38	1.48e-05	0.00146	-0.38	-0.2	Migraine;	chr8:30140084	chr8:30237382~30240997:+
THCA	cis	rs4835473	0.637	rs11932061	ENSG00000251600.4	RP11-673E1.1	4.38	1.48e-05	0.00146	0.24	0.2	Immature fraction of reticulocytes;	chr4:143768124	chr4:143912331~143982454:+
THCA	cis	rs7216064	0.953	rs80135947	ENSG00000278740.1	RP11-147L13.14	4.38	1.48e-05	0.00146	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839885	chr17:68188547~68189165:+
THCA	cis	rs7208859	0.524	rs8069400	ENSG00000265443.1	CTD-2349P21.6	-4.38	1.48e-05	0.00146	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30726305~30727564:-
THCA	cis	rs7973683	0.541	rs7976319	ENSG00000270061.1	RP11-214K3.19	-4.38	1.48e-05	0.00146	-0.25	-0.2	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123903964	chr12:123969990~123970344:-
THCA	cis	rs12439619	0.508	rs8023960	ENSG00000259429.4	UBE2Q2P2	-4.38	1.49e-05	0.00146	-0.16	-0.2	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82355142~82420075:+
THCA	cis	rs10875746	0.903	rs11168420	ENSG00000258234.1	RP11-370I10.2	4.38	1.49e-05	0.00146	0.24	0.2	Longevity (90 years and older);	chr12:48122113	chr12:48231098~48284210:-
THCA	cis	rs3770081	1	rs73945530	ENSG00000272564.1	RP11-548P2.2	-4.38	1.49e-05	0.00146	-0.35	-0.2	Facial emotion recognition (sad faces);	chr2:85872245	chr2:85904279~85904727:+
THCA	cis	rs9309473	0.797	rs6723247	ENSG00000273245.1	RP11-434P11.2	4.38	1.49e-05	0.00146	0.27	0.2	Metabolite levels;	chr2:73619622	chr2:73750256~73750786:-
THCA	cis	rs9487094	0.666	rs7748669	ENSG00000223537.2	RP5-919F19.5	-4.38	1.49e-05	0.00146	-0.2	-0.2	Height;	chr6:109424139	chr6:109487906~109506800:+
THCA	cis	rs2732480	0.967	rs2732469	ENSG00000273765.1	RP11-370I10.11	4.38	1.49e-05	0.00146	0.19	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48360920~48361377:+
THCA	cis	rs57502260	0.79	rs7128942	ENSG00000212093.1	AP000807.1	4.38	1.49e-05	0.00146	0.25	0.2	Total body bone mineral density (age 45-60);	chr11:68620516	chr11:68506083~68506166:-
THCA	cis	rs1371614	0.632	rs6718978	ENSG00000229122.1	AGBL5-IT1	4.38	1.49e-05	0.00146	0.14	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26938723	chr2:27061038~27061815:+
THCA	cis	rs7394190	0.748	rs2242254	ENSG00000271816.1	BMS1P4	-4.38	1.49e-05	0.00146	-0.25	-0.2	Incident atrial fibrillation;	chr10:73825549	chr10:73699151~73730487:-
THCA	cis	rs13113518	0.702	rs78829811	ENSG00000249700.7	SRD5A3-AS1	4.38	1.49e-05	0.00146	0.25	0.2	Height;	chr4:55558258	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.702	rs75801206	ENSG00000249700.7	SRD5A3-AS1	4.38	1.49e-05	0.00146	0.25	0.2	Height;	chr4:55558259	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.702	rs34658078	ENSG00000249700.7	SRD5A3-AS1	4.38	1.49e-05	0.00146	0.25	0.2	Height;	chr4:55558261	chr4:55363971~55395847:-
THCA	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	4.38	1.49e-05	0.00146	0.23	0.2	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	4.38	1.49e-05	0.00146	0.23	0.2	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
THCA	cis	rs4578769	0.959	rs9945114	ENSG00000265939.1	UBE2CP2	4.38	1.49e-05	0.00146	0.24	0.2	Eosinophil percentage of white cells;	chr18:22884044	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.918	rs8089471	ENSG00000265939.1	UBE2CP2	4.38	1.49e-05	0.00146	0.24	0.2	Eosinophil percentage of white cells;	chr18:22892994	chr18:22900486~22900995:-
THCA	cis	rs12681963	0.688	rs7012749	ENSG00000248159.1	HSPA8P11	-4.38	1.49e-05	0.00146	-0.37	-0.2	Migraine;	chr8:30156243	chr8:30237382~30240997:+
THCA	cis	rs9880211	0.571	rs13066401	ENSG00000239213.4	NCK1-AS1	4.38	1.49e-05	0.00146	0.27	0.2	Height;Body mass index;	chr3:136626977	chr3:136841726~136862054:-
THCA	cis	rs7674212	0.531	rs10006474	ENSG00000248971.2	KRT8P46	-4.38	1.49e-05	0.00146	-0.24	-0.2	Type 2 diabetes;	chr4:103006890	chr4:102728746~102730171:-
THCA	cis	rs6449502	0.92	rs34640	ENSG00000251279.1	CTC-436P18.1	4.38	1.49e-05	0.00146	0.34	0.2	Mean platelet volume;	chr5:61052888	chr5:61162070~61232040:+
THCA	cis	rs1908814	0.509	rs13282439	ENSG00000254948.1	OR7E158P	-4.38	1.49e-05	0.00146	-0.25	-0.2	Neuroticism;	chr8:11937392	chr8:11919900~11920809:-
THCA	cis	rs10256972	0.591	rs10229680	ENSG00000225146.1	AC073957.15	4.38	1.49e-05	0.00146	0.22	0.2	Endometriosis;Longevity;	chr7:1118929	chr7:1029025~1043891:+
THCA	cis	rs12681963	0.688	rs10954880	ENSG00000248159.1	HSPA8P11	-4.38	1.49e-05	0.00147	-0.36	-0.2	Migraine;	chr8:30151166	chr8:30237382~30240997:+
THCA	cis	rs2033711	0.84	rs3764533	ENSG00000269054.1	CTD-2619J13.3	-4.38	1.49e-05	0.00147	-0.16	-0.2	Uric acid clearance;	chr19:58417827	chr19:58362585~58366591:+
THCA	cis	rs9487094	0.626	rs1322124	ENSG00000223537.2	RP5-919F19.5	-4.38	1.49e-05	0.00147	-0.2	-0.2	Height;	chr6:109741670	chr6:109487906~109506800:+
THCA	cis	rs7646881	0.544	rs74821076	ENSG00000240207.5	RP11-379F4.4	-4.38	1.49e-05	0.00147	-0.3	-0.2	Tetralogy of Fallot;	chr3:158683377	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.589	rs17631016	ENSG00000240207.5	RP11-379F4.4	-4.38	1.49e-05	0.00147	-0.3	-0.2	Tetralogy of Fallot;	chr3:158685696	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.508	rs17631078	ENSG00000240207.5	RP11-379F4.4	-4.38	1.49e-05	0.00147	-0.3	-0.2	Tetralogy of Fallot;	chr3:158687916	chr3:158732263~158784070:+
THCA	cis	rs738722	1	rs1807609	ENSG00000272858.1	CTA-292E10.8	-4.38	1.49e-05	0.00147	-0.21	-0.2	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28735141	chr22:28814914~28815662:+
THCA	cis	rs9926296	0.656	rs11861084	ENSG00000260259.1	RP11-368I7.4	4.38	1.49e-05	0.00147	0.21	0.2	Vitiligo;	chr16:89809302	chr16:89682620~89686569:-
THCA	cis	rs9911578	0.835	rs9889419	ENSG00000224738.1	AC099850.1	4.38	1.49e-05	0.00147	0.23	0.2	Intelligence (multi-trait analysis);	chr17:58395898	chr17:59106598~59118267:+
THCA	cis	rs1923243	0.71	rs4233103	ENSG00000223479.3	RP4-788P17.1	4.38	1.49e-05	0.00147	0.22	0.2	Migraine;	chr1:73114116	chr1:73635216~73715214:+
THCA	cis	rs858239	0.601	rs6966776	ENSG00000230042.1	AK3P3	-4.38	1.49e-05	0.00147	-0.24	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23129178~23129841:+
THCA	cis	rs62025270	0.806	rs62025262	ENSG00000259295.5	CSPG4P12	-4.38	1.49e-05	0.00147	-0.32	-0.2	Idiopathic pulmonary fibrosis;	chr15:85750002	chr15:85191438~85213905:+
THCA	cis	rs17695224	1	rs10422101	ENSG00000269483.1	AC006272.1	-4.38	1.49e-05	0.00147	-0.23	-0.2	HDL cholesterol;HDL cholesterol levels;	chr19:51816862	chr19:51839924~51843324:-
THCA	cis	rs9905704	0.647	rs2108435	ENSG00000224738.1	AC099850.1	-4.38	1.49e-05	0.00147	-0.24	-0.2	Testicular germ cell tumor;	chr17:59024772	chr17:59106598~59118267:+
THCA	cis	rs76793172	0.623	rs10775546	ENSG00000267395.4	AC074212.6	-4.38	1.49e-05	0.00147	-0.17	-0.2	Eosinophil counts;	chr19:45764276	chr19:45767796~45772504:+
THCA	cis	rs12755164	0.771	rs11210084	ENSG00000223479.3	RP4-788P17.1	-4.38	1.49e-05	0.00147	-0.21	-0.2	Schizophrenia;	chr1:72896094	chr1:73635216~73715214:+
THCA	cis	rs792448	0.506	rs12567517	ENSG00000226251.4	RP11-15I11.3	4.38	1.49e-05	0.00147	0.25	0.2	White blood cell count (basophil);	chr1:212444081	chr1:212225278~212238977:-
THCA	cis	rs2033711	0.837	rs3764535	ENSG00000269054.1	CTD-2619J13.3	-4.38	1.49e-05	0.00147	-0.16	-0.2	Uric acid clearance;	chr19:58417685	chr19:58362585~58366591:+
THCA	cis	rs72819454	0.522	rs55909417	ENSG00000280693.1	SH3PXD2A-AS1	-4.38	1.49e-05	0.00147	-0.35	-0.2	Interleukin-9 levels;	chr10:103767403	chr10:103745966~103755423:+
THCA	cis	rs4415084	0.966	rs4479849	ENSG00000272335.1	RP11-53O19.3	4.38	1.49e-05	0.00147	0.16	0.2	Breast cancer;	chr5:44643904	chr5:44826076~44828592:+
THCA	cis	rs1923243	0.71	rs10399828	ENSG00000223479.3	RP4-788P17.1	-4.38	1.49e-05	0.00147	-0.22	-0.2	Migraine;	chr1:73153749	chr1:73635216~73715214:+
THCA	cis	rs1979679	0.918	rs7135922	ENSG00000247934.4	RP11-967K21.1	4.38	1.49e-05	0.00147	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28469148	chr12:28163298~28190738:-
THCA	cis	rs6920372	0.748	rs12190372	ENSG00000223537.2	RP5-919F19.5	-4.38	1.49e-05	0.00147	-0.2	-0.2	Height;	chr6:109763331	chr6:109487906~109506800:+
THCA	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	4.38	1.49e-05	0.00147	0.23	0.2	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
THCA	cis	rs12908161	0.96	rs34452033	ENSG00000188388.10	GOLGA6L3	4.38	1.49e-05	0.00147	0.26	0.2	Schizophrenia;	chr15:84678762	chr15:85240472~85247170:+
THCA	cis	rs11992162	0.967	rs11250185	ENSG00000270154.1	RP11-419I17.1	4.38	1.49e-05	0.00147	0.25	0.2	Monocyte count;	chr8:11975614	chr8:12476462~12477122:+
THCA	cis	rs1572312	0.792	rs2211469	ENSG00000237928.4	NFIA-AS2	4.38	1.49e-05	0.00147	0.26	0.2	Maximal oxygen uptake response;	chr1:60967070	chr1:60940239~60970776:-
THCA	cis	rs11026091	1	rs7104094	ENSG00000224513.2	AC109309.4	-4.38	1.49e-05	0.00147	-0.25	-0.2	Multiple sclerosis;	chr11:3239029	chr11:3226061~3232838:+
THCA	cis	rs5758659	0.714	rs133373	ENSG00000281538.1	RP4-669P10.20	4.38	1.49e-05	0.00147	0.18	0.2	Cognitive function;	chr22:42069784	chr22:42138060~42139726:+
THCA	cis	rs11540084	0.505	rs35385129	ENSG00000279095.1	AC092066.1	4.38	1.49e-05	0.00147	0.26	0.2	Mean platelet volume;	chr19:44658921	chr19:44664131~44666158:+
THCA	cis	rs2070488	0.965	rs7372849	ENSG00000229589.1	ACVR2B-AS1	4.38	1.49e-05	0.00147	0.18	0.2	Electrocardiographic conduction measures;	chr3:38482837	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.896	rs11914389	ENSG00000229589.1	ACVR2B-AS1	4.38	1.49e-05	0.00147	0.18	0.2	Electrocardiographic conduction measures;	chr3:38485724	chr3:38451027~38454820:-
THCA	cis	rs13126694	0.778	rs12503001	ENSG00000248429.4	RP11-597D13.9	4.38	1.49e-05	0.00147	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158100822	chr4:158170752~158202877:+
THCA	cis	rs7216064	0.817	rs28609796	ENSG00000278740.1	RP11-147L13.14	4.38	1.49e-05	0.00147	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67858988	chr17:68188547~68189165:+
THCA	cis	rs9880211	0.948	rs9844666	ENSG00000239213.4	NCK1-AS1	4.38	1.49e-05	0.00147	0.22	0.2	Height;Body mass index;	chr3:136255374	chr3:136841726~136862054:-
THCA	cis	rs4906332	1	rs55731474	ENSG00000244691.1	RPL10AP1	-4.38	1.49e-05	0.00147	-0.25	-0.2	Coronary artery disease;	chr14:103412144	chr14:103412119~103412761:-
THCA	cis	rs4763879	0.634	rs2098298	ENSG00000256673.1	RP11-599J14.2	4.38	1.49e-05	0.00147	0.24	0.2	Type 1 diabetes;	chr12:9707473	chr12:9398355~9414851:-
THCA	cis	rs9863	0.861	rs3789967	ENSG00000269997.1	RP11-214K3.21	-4.38	1.49e-05	0.00147	-0.24	-0.2	White blood cell count;	chr12:123962792	chr12:123966077~123966629:-
THCA	cis	rs7923609	1	rs7073746	ENSG00000232075.1	MRPL35P2	-4.38	1.49e-05	0.00147	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63144311	chr10:63634317~63634827:-
THCA	cis	rs17123764	1	rs7131915	ENSG00000257464.1	RP11-161H23.8	-4.38	1.49e-05	0.00147	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49573877	chr12:49442424~49442652:-
THCA	cis	rs28829049	0.597	rs34219832	ENSG00000270728.1	RP4-657E11.10	-4.38	1.49e-05	0.00147	-0.15	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19175938	chr1:19297080~19297903:+
THCA	cis	rs2853333	0.558	rs2284148	ENSG00000269553.1	U62631.5	-4.38	1.49e-05	0.00147	-0.22	-0.2	Red blood cell count;	chr19:35274521	chr19:35330843~35331920:+
THCA	cis	rs1200821	0.535	rs1208783	ENSG00000263064.2	RP11-291L22.7	4.38	1.5e-05	0.00147	0.22	0.2	Hemostatic factors and hematological phenotypes;	chr10:37478539	chr10:38448689~38448949:+
THCA	cis	rs550448	0.947	rs77181159	ENSG00000234336.5	JAZF1-AS1	4.38	1.5e-05	0.00147	0.34	0.2	Type 1 diabetes;	chr7:28132505	chr7:28180322~28243917:+
THCA	cis	rs7746199	0.736	rs13193542	ENSG00000220721.1	OR1F12	4.38	1.5e-05	0.00147	0.45	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs13193480	ENSG00000220721.1	OR1F12	4.38	1.5e-05	0.00147	0.45	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28073316~28074233:+
THCA	cis	rs17270561	0.636	rs10946793	ENSG00000272462.2	U91328.19	-4.38	1.5e-05	0.00147	-0.17	-0.2	Iron status biomarkers;	chr6:25699771	chr6:25992662~26001775:+
THCA	cis	rs35740288	0.77	rs36044792	ENSG00000259295.5	CSPG4P12	4.38	1.5e-05	0.00147	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85603320	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs11635190	ENSG00000259295.5	CSPG4P12	4.38	1.5e-05	0.00147	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605300	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs11631449	ENSG00000259295.5	CSPG4P12	4.38	1.5e-05	0.00147	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605422	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs1871285	ENSG00000259295.5	CSPG4P12	4.38	1.5e-05	0.00147	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609256	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs4843081	ENSG00000259295.5	CSPG4P12	4.38	1.5e-05	0.00147	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609813	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs4843082	ENSG00000259295.5	CSPG4P12	4.38	1.5e-05	0.00147	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85610159	chr15:85191438~85213905:+
THCA	cis	rs6121246	0.559	rs6121243	ENSG00000230613.1	HM13-AS1	4.38	1.5e-05	0.00147	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31827291	chr20:31567707~31573263:-
THCA	cis	rs807029	0.577	rs701834	ENSG00000236662.1	RP11-108L7.4	4.38	1.5e-05	0.00147	0.21	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100980507~100985614:-
THCA	cis	rs35740288	0.77	rs17570529	ENSG00000259295.5	CSPG4P12	4.38	1.5e-05	0.00147	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85582376	chr15:85191438~85213905:+
THCA	cis	rs6723108	0.515	rs55687393	ENSG00000224043.6	CCNT2-AS1	-4.38	1.5e-05	0.00147	-0.21	-0.2	Type 2 diabetes;	chr2:134782661	chr2:134735464~134918710:-
THCA	cis	rs6600671	1	rs7532615	ENSG00000270231.3	NBPF8P	-4.38	1.5e-05	0.00147	-0.18	-0.2	Hip geometry;	chr1:121430980	chr1:120436353~120467739:+
THCA	cis	rs12612619	0.732	rs11897106	ENSG00000272148.1	RP11-195B17.1	-4.38	1.5e-05	0.00147	-0.18	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26973431	chr2:27062428~27062907:-
THCA	cis	rs10435719	0.867	rs6999030	ENSG00000206014.6	OR7E161P	-4.38	1.5e-05	0.00147	-0.24	-0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.834	rs6985792	ENSG00000206014.6	OR7E161P	-4.38	1.5e-05	0.00147	-0.24	-0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:11928597~11929563:-
THCA	cis	rs12612619	0.704	rs6754356	ENSG00000272148.1	RP11-195B17.1	4.38	1.5e-05	0.00147	0.18	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092153	chr2:27062428~27062907:-
THCA	cis	rs12755164	0.771	rs6657082	ENSG00000223479.3	RP4-788P17.1	4.37	1.5e-05	0.00147	0.21	0.2	Schizophrenia;	chr1:72887645	chr1:73635216~73715214:+
THCA	cis	rs11250097	0.549	rs11778177	ENSG00000206014.6	OR7E161P	4.37	1.5e-05	0.00147	0.23	0.2	Neuroticism;	chr8:11452853	chr8:11928597~11929563:-
THCA	cis	rs11250097	0.549	rs11784897	ENSG00000206014.6	OR7E161P	4.37	1.5e-05	0.00147	0.23	0.2	Neuroticism;	chr8:11452933	chr8:11928597~11929563:-
THCA	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-4.37	1.5e-05	0.00147	-0.28	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
THCA	cis	rs890448	1	rs17031377	ENSG00000254531.1	FLJ20021	-4.37	1.5e-05	0.00147	-0.18	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101510783	chr4:101347780~101348883:+
THCA	cis	rs7560272	0.538	rs13006448	ENSG00000273245.1	RP11-434P11.2	-4.37	1.5e-05	0.00147	-0.23	-0.2	Schizophrenia;	chr2:73697297	chr2:73750256~73750786:-
THCA	cis	rs763121	0.719	rs138699	ENSG00000228274.3	RP3-508I15.9	-4.37	1.5e-05	0.00147	-0.23	-0.2	Menopause (age at onset);	chr22:38733703	chr22:38667585~38681820:-
THCA	cis	rs9309473	0.606	rs79234109	ENSG00000273245.1	RP11-434P11.2	4.37	1.5e-05	0.00147	0.34	0.2	Metabolite levels;	chr2:73621227	chr2:73750256~73750786:-
THCA	cis	rs7615952	0.605	rs11708269	ENSG00000272840.1	RP11-379B18.6	4.37	1.5e-05	0.00147	0.39	0.2	Blood pressure (smoking interaction);	chr3:125613306	chr3:125774714~125797953:+
THCA	cis	rs683257	0.81	rs6570429	ENSG00000234147.1	RP3-460G2.2	-4.37	1.5e-05	0.00147	-0.35	-0.2	Facial emotion recognition (angry faces);	chr6:140893165	chr6:140845958~140852924:-
THCA	cis	rs683257	0.81	rs6570430	ENSG00000234147.1	RP3-460G2.2	-4.37	1.5e-05	0.00147	-0.35	-0.2	Facial emotion recognition (angry faces);	chr6:140893167	chr6:140845958~140852924:-
THCA	cis	rs755249	0.51	rs582883	ENSG00000182109.6	RP11-69E11.4	4.37	1.5e-05	0.00147	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39522280~39546187:-
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	4.37	1.5e-05	0.00147	0.24	0.2	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
THCA	cis	rs8058578	0.945	rs8058961	ENSG00000279196.1	RP11-1072A3.3	4.37	1.5e-05	0.00147	0.2	0.2	Multiple myeloma;	chr16:30797742	chr16:30984630~30988270:-
THCA	cis	rs713587	0.776	rs3731623	ENSG00000224165.4	DNAJC27-AS1	-4.37	1.5e-05	0.00147	-0.11	-0.2	Body mass index in non-asthmatics;	chr2:24940914	chr2:24971390~25039694:+
THCA	cis	rs17666538	0.585	rs336444	ENSG00000254207.1	RP11-43A14.1	-4.37	1.5e-05	0.00147	-0.38	-0.2	IgG glycosylation;	chr8:683123	chr8:725188~725877:-
THCA	cis	rs6449502	0.764	rs16878397	ENSG00000251279.1	CTC-436P18.1	4.37	1.5e-05	0.00148	0.36	0.2	Mean platelet volume;	chr5:60769692	chr5:61162070~61232040:+
THCA	cis	rs4819052	0.851	rs1056099	ENSG00000182586.6	LINC00334	-4.37	1.5e-05	0.00148	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2236446	ENSG00000182586.6	LINC00334	-4.37	1.5e-05	0.00148	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45234340~45258730:+
THCA	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	4.37	1.5e-05	0.00148	0.24	0.2	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
THCA	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	4.37	1.5e-05	0.00148	0.24	0.2	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
THCA	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	4.37	1.5e-05	0.00148	0.24	0.2	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
THCA	cis	rs12410462	0.551	rs12095502	ENSG00000227711.2	RP11-275O4.5	-4.37	1.5e-05	0.00148	-0.24	-0.2	Major depressive disorder;	chr1:227668821	chr1:227509028~227520477:-
THCA	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-4.37	1.5e-05	0.00148	-0.23	-0.2	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
THCA	cis	rs962856	0.964	rs13415002	ENSG00000236780.4	AC078941.1	4.37	1.5e-05	0.00148	0.24	0.2	Pancreatic cancer;	chr2:67384691	chr2:67123357~67215319:-
THCA	cis	rs6088813	0.767	rs4911179	ENSG00000279253.1	RP4-614O4.13	4.37	1.5e-05	0.00148	0.19	0.2	Height;	chr20:35385096	chr20:35262727~35264187:-
THCA	cis	rs1150668	0.796	rs2531825	ENSG00000176933.5	TOB2P1	-4.37	1.5e-05	0.00148	-0.21	-0.2	Pubertal anthropometrics;	chr6:28381487	chr6:28217643~28218634:-
THCA	cis	rs4950322	0.744	rs2353987	ENSG00000271721.1	RP11-337C18.9	4.37	1.5e-05	0.00148	0.23	0.2	Protein quantitative trait loci;	chr1:147355845	chr1:147175602~147177740:+
THCA	cis	rs9902453	0.967	rs12602065	ENSG00000263370.1	RP11-68I3.5	4.37	1.5e-05	0.00148	0.25	0.2	Coffee consumption (cups per day);	chr17:30155470	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.934	rs4343336	ENSG00000263370.1	RP11-68I3.5	4.37	1.5e-05	0.00148	0.25	0.2	Coffee consumption (cups per day);	chr17:30161218	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.934	rs7223645	ENSG00000263370.1	RP11-68I3.5	4.37	1.5e-05	0.00148	0.25	0.2	Coffee consumption (cups per day);	chr17:30164011	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs12450441	ENSG00000263370.1	RP11-68I3.5	4.37	1.5e-05	0.00148	0.25	0.2	Coffee consumption (cups per day);	chr17:30168003	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs7222685	ENSG00000263370.1	RP11-68I3.5	4.37	1.5e-05	0.00148	0.25	0.2	Coffee consumption (cups per day);	chr17:30169412	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.934	rs34433787	ENSG00000263370.1	RP11-68I3.5	4.37	1.5e-05	0.00148	0.25	0.2	Coffee consumption (cups per day);	chr17:30169762	chr17:29639627~29640825:+
THCA	cis	rs1971762	0.545	rs10747675	ENSG00000270175.1	RP11-793H13.11	4.37	1.5e-05	0.00148	0.13	0.2	Height;	chr12:53606247	chr12:53500162~53500936:-
THCA	cis	rs7829975	0.509	rs2945269	ENSG00000254153.1	CTA-398F10.2	-4.37	1.5e-05	0.00148	-0.21	-0.2	Mood instability;	chr8:8258056	chr8:8456909~8461337:-
THCA	cis	rs711244	0.748	rs10193295	ENSG00000279519.1	RP11-288C18.1	4.37	1.5e-05	0.00148	0.16	0.2	Mean platelet volume;	chr2:36941906	chr2:36839922~36842539:-
THCA	cis	rs12410462	0.591	rs2132366	ENSG00000227711.2	RP11-275O4.5	-4.37	1.5e-05	0.00148	-0.25	-0.2	Major depressive disorder;	chr1:227599401	chr1:227509028~227520477:-
THCA	cis	rs6565653	0.967	rs6565652	ENSG00000262580.4	RP11-334C17.5	4.37	1.5e-05	0.00148	0.17	0.2	Ischemic stroke;	chr17:80227755	chr17:80200673~80205949:-
THCA	cis	rs10911902	0.602	rs6425025	ENSG00000229739.2	RP11-295K2.3	-4.37	1.5e-05	0.00148	-0.32	-0.2	Schizophrenia;	chr1:186305025	chr1:186435161~186470291:+
THCA	cis	rs10484434	0.818	rs66536062	ENSG00000272810.1	U91328.22	4.37	1.5e-05	0.00148	0.19	0.2	HIV-1 viral setpoint;	chr6:26012479	chr6:26013241~26013757:+
THCA	cis	rs4578769	0.55	rs9956087	ENSG00000265939.1	UBE2CP2	4.37	1.5e-05	0.00148	0.22	0.2	Eosinophil percentage of white cells;	chr18:23030538	chr18:22900486~22900995:-
THCA	cis	rs897984	0.52	rs4889614	ENSG00000260911.2	RP11-196G11.2	-4.37	1.5e-05	0.00148	-0.18	-0.2	Dementia with Lewy bodies;	chr16:30850814	chr16:31043150~31049868:+
THCA	cis	rs763121	0.853	rs1056610	ENSG00000228274.3	RP3-508I15.9	4.37	1.5e-05	0.00148	0.21	0.2	Menopause (age at onset);	chr22:38684073	chr22:38667585~38681820:-
THCA	cis	rs6929812	0.665	rs7744110	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27453525	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs2235252	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27454714	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs12199110	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27455789	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs2092121	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27456405	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs2092122	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27456532	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs764460	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27456595	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.594	rs764461	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27456664	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.629	rs10484398	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27457181	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs1883216	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27457406	chr6:27404010~27406964:-
THCA	cis	rs2064219	0.662	rs7761989	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Depressive symptoms;Depressive symptoms (multi-trait analysis);	chr6:27458055	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs7743465	ENSG00000271755.1	RP1-153G14.4	4.37	1.5e-05	0.00148	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27458938	chr6:27404010~27406964:-
THCA	cis	rs2179367	0.6	rs11155654	ENSG00000216906.2	RP11-350J20.9	4.37	1.5e-05	0.00148	0.27	0.2	Dupuytren's disease;	chr6:149442001	chr6:149904243~149906418:+
THCA	cis	rs2645424	0.525	rs17814426	ENSG00000255046.1	RP11-297N6.4	4.37	1.5e-05	0.00148	0.2	0.2	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856796	chr8:11797928~11802568:-
THCA	cis	rs6088590	1	rs2378256	ENSG00000269202.1	RP4-614O4.12	-4.37	1.5e-05	0.00148	-0.18	-0.2	Coronary artery disease;	chr20:34704323	chr20:35201747~35203288:-
THCA	cis	rs6088590	0.965	rs910869	ENSG00000269202.1	RP4-614O4.12	-4.37	1.5e-05	0.00148	-0.18	-0.2	Coronary artery disease;	chr20:34704973	chr20:35201747~35203288:-
THCA	cis	rs156299	0.513	rs156287	ENSG00000234286.1	AC006026.13	4.37	1.5e-05	0.00148	0.26	0.2	Vitamin D levels;	chr7:24198054	chr7:23680195~23680786:-
THCA	cis	rs1923539	0.662	rs2758557	ENSG00000225484.5	NUTM2B-AS1	4.37	1.5e-05	0.00148	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928848	chr10:79663088~79826594:-
THCA	cis	rs9925964	0.967	rs2032915	ENSG00000232748.3	RP11-196G11.6	4.37	1.5e-05	0.00148	0.23	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106092	chr16:31056460~31062803:+
THCA	cis	rs12681963	0.614	rs7013787	ENSG00000248159.1	HSPA8P11	4.37	1.5e-05	0.00148	0.36	0.2	Migraine;	chr8:30203272	chr8:30237382~30240997:+
THCA	cis	rs2153535	0.585	rs2224480	ENSG00000230939.1	RP11-314C16.1	-4.37	1.5e-05	0.00148	-0.21	-0.2	Motion sickness;	chr6:8647646	chr6:8784178~8785445:+
THCA	cis	rs7608910	0.896	rs55776317	ENSG00000271889.1	RP11-493E12.1	4.37	1.5e-05	0.00148	0.21	0.2	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60964860	chr2:61151433~61162105:-
THCA	cis	rs858239	0.6	rs10256359	ENSG00000226816.2	AC005082.12	4.37	1.5e-05	0.00148	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23206013~23208045:+
THCA	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-4.37	1.51e-05	0.00148	-0.28	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
THCA	cis	rs10911902	0.643	rs74842753	ENSG00000229739.2	RP11-295K2.3	-4.37	1.51e-05	0.00148	-0.32	-0.2	Schizophrenia;	chr1:186390059	chr1:186435161~186470291:+
THCA	cis	rs13126694	0.744	rs10005901	ENSG00000248429.4	RP11-597D13.9	4.37	1.51e-05	0.00148	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158041750	chr4:158170752~158202877:+
THCA	cis	rs13053505	0.779	rs7288826	ENSG00000235209.1	CTA-150C2.13	4.37	1.51e-05	0.00148	0.3	0.2	Menarche (age at onset);	chr22:38818769	chr22:38921227~38924708:+
THCA	cis	rs11771526	0.786	rs11768318	ENSG00000272905.1	RP11-265E18.1	4.37	1.51e-05	0.00148	0.28	0.2	Body mass index;	chr7:32333353	chr7:32845394~32846061:+
THCA	cis	rs172166	0.637	rs1233691	ENSG00000261839.1	RP1-265C24.8	4.37	1.51e-05	0.00148	0.21	0.2	Cardiac Troponin-T levels;	chr6:28186119	chr6:28136849~28139678:+
THCA	cis	rs6988985	0.56	rs4736346	ENSG00000247317.3	RP11-273G15.2	-4.37	1.51e-05	0.00148	-0.21	-0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142870433	chr8:142981738~143018437:-
THCA	cis	rs2460905	0.717	rs62487520	ENSG00000251468.2	RP11-369K16.1	-4.37	1.51e-05	0.00148	-0.35	-0.2	Post-traumatic stress disorder;	chr8:12920636	chr8:12958387~12962200:+
THCA	cis	rs7551222	0.681	rs2926533	ENSG00000240219.1	RP11-430C7.5	-4.37	1.51e-05	0.00148	-0.21	-0.2	Schizophrenia;	chr1:204511614	chr1:204626775~204629712:+
THCA	cis	rs454217	0.846	rs337663	ENSG00000277851.1	RP11-756G20.1	-4.37	1.51e-05	0.00148	-0.2	-0.2	Smoking quantity;	chr12:92311428	chr12:92247756~92363832:-
THCA	cis	rs1521470	1	rs1521470	ENSG00000272556.1	RP11-638I8.1	4.37	1.51e-05	0.00148	0.27	0.2	Schizophrenia;Bipolar disorder lithium response (continuous) or schizophrenia;	chr7:45607253	chr7:45814602~45815263:+
THCA	cis	rs734999	0.545	rs6666430	ENSG00000225931.3	RP3-395M20.7	4.37	1.51e-05	0.00148	0.23	0.2	Ulcerative colitis;	chr1:2782407	chr1:2566410~2569888:+
THCA	cis	rs858239	0.601	rs11982002	ENSG00000226816.2	AC005082.12	4.37	1.51e-05	0.00148	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23206013~23208045:+
THCA	cis	rs829883	0.724	rs11109508	ENSG00000227825.4	SLC9A7P1	-4.37	1.51e-05	0.00148	-0.19	-0.2	Colorectal adenoma (advanced);	chr12:98512207	chr12:98453835~98457145:-
THCA	cis	rs7824557	0.583	rs2263511	ENSG00000206014.6	OR7E161P	4.37	1.51e-05	0.00148	0.23	0.2	Retinal vascular caliber;	chr8:11375809	chr8:11928597~11929563:-
THCA	cis	rs7246657	0.653	rs10402050	ENSG00000276846.1	CTD-3220F14.3	4.37	1.51e-05	0.00148	0.25	0.2	Coronary artery calcification;	chr19:37198056	chr19:37314868~37315620:-
THCA	cis	rs4948275	0.693	rs2814033	ENSG00000237233.2	TMEM26-AS1	4.37	1.51e-05	0.00148	0.26	0.2	Night sleep phenotypes;	chr10:61571836	chr10:61452639~61481956:+
THCA	cis	rs962856	0.964	rs1552359	ENSG00000236780.4	AC078941.1	4.37	1.51e-05	0.00148	0.24	0.2	Pancreatic cancer;	chr2:67388297	chr2:67123357~67215319:-
THCA	cis	rs962856	0.964	rs5022017	ENSG00000236780.4	AC078941.1	4.37	1.51e-05	0.00148	0.24	0.2	Pancreatic cancer;	chr2:67392045	chr2:67123357~67215319:-
THCA	cis	rs889398	0.741	rs4146819	ENSG00000226232.7	RP11-419C5.2	-4.37	1.51e-05	0.00148	-0.2	-0.2	Body mass index;	chr16:69889660	chr16:69976388~69996188:-
THCA	cis	rs55702914	0.809	rs2376407	ENSG00000231621.1	AC013264.2	4.37	1.51e-05	0.00148	0.19	0.2	Major depression and alcohol dependence;	chr2:197318741	chr2:197197991~197199273:+
THCA	cis	rs10266483	0.705	rs1111649	ENSG00000228653.2	HNRNPCP7	-4.37	1.51e-05	0.00148	-0.17	-0.2	Response to statin therapy;	chr7:64296435	chr7:64500825~64501729:+
THCA	cis	rs516805	0.52	rs9388099	ENSG00000279453.1	RP3-425C14.4	4.37	1.51e-05	0.00148	0.16	0.2	Lymphocyte counts;	chr6:122566904	chr6:122436789~122439223:-
THCA	cis	rs62490346	0.528	rs7842443	ENSG00000261451.1	RP11-981G7.1	-4.37	1.51e-05	0.00148	-0.27	-0.2	Chickenpox;	chr8:10372534	chr8:10433672~10438312:+
THCA	cis	rs812925	0.502	rs778150	ENSG00000270820.4	RP11-355B11.2	-4.37	1.51e-05	0.00148	-0.17	-0.2	Immature fraction of reticulocytes;	chr2:61381237	chr2:61471188~61484130:+
THCA	cis	rs1913185	0.787	rs59384952	ENSG00000240032.1	RP11-274H2.3	-4.37	1.51e-05	0.00148	-0.31	-0.2	Obesity-related traits;	chr3:146060012	chr3:146066344~146069185:-
THCA	cis	rs734999	0.566	rs6664969	ENSG00000225931.3	RP3-395M20.7	4.37	1.51e-05	0.00149	0.23	0.2	Ulcerative colitis;	chr1:2603539	chr1:2566410~2569888:+
THCA	cis	rs10895322	1	rs5024119	ENSG00000281655.1	RP11-817J15.3	-4.37	1.51e-05	0.00149	-0.27	-0.2	Neuroblastoma (11q deletion);	chr11:102592628	chr11:102681310~102683913:+
THCA	cis	rs4934494	0.768	rs12570813	ENSG00000240996.1	RP11-80H5.7	-4.37	1.51e-05	0.00149	-0.23	-0.2	Red blood cell count;	chr10:89630974	chr10:89694295~89697928:-
THCA	cis	rs138249	1	rs138252	ENSG00000273253.2	RP3-402G11.26	-4.37	1.51e-05	0.00149	-0.19	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50132444	chr22:50199090~50200837:-
THCA	cis	rs4803480	0.935	rs9304595	ENSG00000270164.1	LINC01480	4.37	1.51e-05	0.00149	0.2	0.2	Schizophrenia;	chr19:41571639	chr19:41535183~41536904:+
THCA	cis	rs8031584	0.706	rs798084	ENSG00000178081.11	ULK4P3	4.37	1.51e-05	0.00149	0.26	0.2	Huntington's disease progression;	chr15:30834732	chr15:30103720~30131757:+
THCA	cis	rs1823874	0.72	rs1993296	ENSG00000254744.3	CTD-3076O17.1	-4.37	1.51e-05	0.00149	-0.21	-0.2	IgG glycosylation;	chr15:99823383	chr15:99970215~99974010:+
THCA	cis	rs9959145	1	rs28575715	ENSG00000267199.1	RP11-861E21.2	4.37	1.51e-05	0.00149	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12586349	chr18:12438890~12448205:+
THCA	cis	rs10043228	1	rs10478288	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116169924	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs4283834	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116185766	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384212	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116185970	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12522441	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116188108	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs7443669	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116191914	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384231	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116194607	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs10042278	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116197231	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384233	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116197900	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs10035646	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116199277	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.59	rs10040345	ENSG00000248445.4	SEMA6A-AS1	-4.37	1.51e-05	0.00149	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116199740	chr5:116447547~116508276:+
THCA	cis	rs62244186	0.748	rs6441861	ENSG00000214820.3	MPRIPP1	4.37	1.51e-05	0.00149	0.21	0.2	Depressive symptoms;	chr3:44610795	chr3:44579938~44581026:-
THCA	cis	rs6088813	0.961	rs6088791	ENSG00000279253.1	RP4-614O4.13	-4.37	1.51e-05	0.00149	-0.19	-0.2	Height;	chr20:35320106	chr20:35262727~35264187:-
THCA	cis	rs61270009	0.955	rs12515274	ENSG00000247828.6	TMEM161B-AS1	4.37	1.51e-05	0.00149	0.17	0.2	Depressive symptoms;	chr5:88359845	chr5:88268895~88436685:+
THCA	cis	rs180358	0.588	rs2542062	ENSG00000254851.1	RP11-109L13.1	-4.37	1.51e-05	0.00149	-0.33	-0.2	Multiple sclerosis (severity);	chr11:116809733	chr11:117135528~117138582:+
THCA	cis	rs2692947	0.537	rs1834135	ENSG00000235959.1	AC009237.17	-4.37	1.52e-05	0.00149	-0.22	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578477	chr2:95640181~95640604:-
THCA	cis	rs67478160	0.595	rs12433109	ENSG00000269910.1	RP11-73M18.10	4.37	1.52e-05	0.00149	0.17	0.2	Schizophrenia;	chr14:103730270	chr14:103694516~103695050:-
THCA	cis	rs8177876	0.915	rs73597252	ENSG00000261061.1	RP11-303E16.2	-4.37	1.52e-05	0.00149	-0.34	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81030770~81031485:+
THCA	cis	rs8105895	1	rs62112917	ENSG00000269345.1	VN1R85P	4.37	1.52e-05	0.00149	0.28	0.2	Body mass index (change over time);	chr19:22043778	chr19:22174766~22175191:-
THCA	cis	rs375066	0.868	rs368079	ENSG00000278917.1	RP11-15A1.4	-4.37	1.52e-05	0.00149	-0.16	-0.2	Breast cancer;	chr19:43889204	chr19:43891233~43895411:+
THCA	cis	rs6973609	0.575	rs7776612	ENSG00000271122.1	RP11-379H18.1	4.37	1.52e-05	0.00149	0.14	0.2	Obesity-related traits;	chr7:35549603	chr7:35695214~35699413:+
THCA	cis	rs12541437	1	rs2921750	ENSG00000253327.2	RAD21-AS1	4.37	1.52e-05	0.00149	0.21	0.2	Gut microbiome composition (winter);	chr8:116908843	chr8:116874424~116876868:+
THCA	cis	rs172166	0.516	rs1225710	ENSG00000220721.1	OR1F12	-4.37	1.52e-05	0.00149	-0.22	-0.2	Cardiac Troponin-T levels;	chr6:28132862	chr6:28073316~28074233:+
THCA	cis	rs4780355	1	rs4780355	ENSG00000263080.1	RP11-485G7.5	4.37	1.52e-05	0.00149	0.24	0.2	Crohn's disease and psoriasis;	chr16:11254001	chr16:11341809~11345211:-
THCA	cis	rs7474896	0.583	rs1735621	ENSG00000226578.1	RP11-258F22.1	4.37	1.52e-05	0.00149	0.28	0.2	Obesity (extreme);	chr10:37878795	chr10:37775371~37784131:-
THCA	cis	rs7829975	0.711	rs12682352	ENSG00000253981.4	ALG1L13P	4.37	1.52e-05	0.00149	0.19	0.2	Mood instability;	chr8:8788736	chr8:8236003~8244667:-
THCA	cis	rs3742264	0.768	rs3783200	ENSG00000235903.6	CPB2-AS1	-4.37	1.52e-05	0.00149	-0.27	-0.2	Blood protein levels;	chr13:46042327	chr13:46052806~46113332:+
THCA	cis	rs7208859	0.673	rs11653955	ENSG00000265443.1	CTD-2349P21.6	-4.37	1.52e-05	0.00149	-0.35	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30726305~30727564:-
THCA	cis	rs728616	0.51	rs17617406	ENSG00000278616.1	BEND3P3	-4.37	1.52e-05	0.00149	-0.2	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80414800	chr10:79682997~79685436:+
THCA	cis	rs9890032	0.542	rs62068770	ENSG00000263531.1	RP13-753N3.1	-4.37	1.52e-05	0.00149	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:30918357	chr17:30863921~30864940:-
THCA	cis	rs10090774	0.965	rs2665883	ENSG00000279766.1	RP11-642A1.2	4.37	1.52e-05	0.00149	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140995814	chr8:140572142~140572812:-
THCA	cis	rs67839313	0.748	rs961090	ENSG00000273855.1	RP11-133K1.12	-4.37	1.52e-05	0.00149	-0.23	-0.2	Type 2 diabetes;	chr15:40325213	chr15:40285468~40285909:-
THCA	cis	rs875971	0.545	rs4441996	ENSG00000273142.1	RP11-458F8.4	-4.37	1.52e-05	0.00149	-0.18	-0.2	Aortic root size;	chr7:66123233	chr7:66902857~66906297:+
THCA	cis	rs7989336	0.663	rs2147687	ENSG00000247400.3	DNAJC3-AS1	-4.37	1.52e-05	0.00149	-0.12	-0.2	Obesity;	chr13:96309130	chr13:95648733~95676925:-
THCA	cis	rs12216545	0.737	rs2103034	ENSG00000241134.3	BET1P1	-4.37	1.52e-05	0.00149	-0.24	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150540829	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs1522598	ENSG00000241134.3	BET1P1	-4.37	1.52e-05	0.00149	-0.24	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150542748	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs1916007	ENSG00000241134.3	BET1P1	-4.37	1.52e-05	0.00149	-0.24	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150543201	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs1916006	ENSG00000241134.3	BET1P1	-4.37	1.52e-05	0.00149	-0.24	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150543468	chr7:150749736~150750094:+
THCA	cis	rs7847628	0.666	rs2031974	ENSG00000270917.1	RP11-27I1.6	-4.37	1.52e-05	0.00149	-0.3	-0.2	Birth weight;	chr9:120765243	chr9:120812475~120812845:-
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000229180.5	GS1-124K5.11	4.37	1.52e-05	0.00149	0.16	0.2	Corneal structure;	chr7:66801919	chr7:66526088~66542624:-
THCA	cis	rs962856	0.964	rs6546303	ENSG00000236780.4	AC078941.1	4.37	1.52e-05	0.00149	0.24	0.2	Pancreatic cancer;	chr2:67385986	chr2:67123357~67215319:-
THCA	cis	rs2251381	0.75	rs2776250	ENSG00000176054.6	RPL23P2	4.37	1.52e-05	0.00149	0.17	0.2	Selective IgA deficiency;	chr21:29155773	chr21:28997613~28998033:-
THCA	cis	rs1923243	0.681	rs35449387	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73076857	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.648	rs55859451	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73081588	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.62	rs12138265	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73085578	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.652	rs7555449	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73087346	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs6424510	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73089031	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs6424512	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73089072	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs7516218	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73089470	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.648	rs4233100	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73091210	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.588	rs4295841	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73091588	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs12141350	ENSG00000223479.3	RP4-788P17.1	4.37	1.52e-05	0.00149	0.22	0.2	Migraine;	chr1:73094184	chr1:73635216~73715214:+
THCA	cis	rs7474896	1	rs35031837	ENSG00000263064.2	RP11-291L22.7	4.37	1.52e-05	0.00149	0.32	0.2	Obesity (extreme);	chr10:37645280	chr10:38448689~38448949:+
THCA	cis	rs2236521	0.617	rs113604626	ENSG00000273619.1	RP5-908M14.9	-4.37	1.52e-05	0.00149	-0.16	-0.2	Pelvic organ prolapse;	chr20:62318450	chr20:62386303~62386970:-
THCA	cis	rs72843506	0.722	rs9897161	ENSG00000261033.1	RP11-209D14.2	4.37	1.52e-05	0.00149	0.35	0.2	Schizophrenia;	chr17:20130957	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.722	rs9897168	ENSG00000261033.1	RP11-209D14.2	4.37	1.52e-05	0.00149	0.35	0.2	Schizophrenia;	chr17:20130961	chr17:20008051~20009234:-
THCA	cis	rs853679	1	rs853679	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.00149	-0.26	-0.2	Depression;	chr6:28329086	chr6:28078792~28081130:-
THCA	cis	rs853679	1	rs853678	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.00149	-0.26	-0.2	Depression;	chr6:28329536	chr6:28078792~28081130:-
THCA	cis	rs6570726	0.791	rs378937	ENSG00000270638.1	RP3-466P17.1	4.37	1.52e-05	0.00149	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145735570~145737218:+
THCA	cis	rs78487399	0.908	rs57066469	ENSG00000234936.1	AC010883.5	4.37	1.52e-05	0.00149	0.25	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43616674	chr2:43229573~43233394:+
THCA	cis	rs4578769	0.918	rs9957390	ENSG00000265939.1	UBE2CP2	4.37	1.52e-05	0.00149	0.24	0.2	Eosinophil percentage of white cells;	chr18:22840421	chr18:22900486~22900995:-
THCA	cis	rs516805	0.52	rs197678	ENSG00000279453.1	RP3-425C14.4	-4.37	1.52e-05	0.00149	-0.16	-0.2	Lymphocyte counts;	chr6:122534039	chr6:122436789~122439223:-
THCA	cis	rs7176527	0.848	rs72630463	ENSG00000225151.9	GOLGA2P7	4.37	1.52e-05	0.00149	0.37	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84750699	chr15:84199311~84230136:-
THCA	cis	rs11658311	0.655	rs115173716	ENSG00000232344.2	AC087163.2	4.37	1.52e-05	0.00149	0.29	0.2	Obsessive-compulsive symptoms;	chr17:17773111	chr17:18010643~18011822:+
THCA	cis	rs796395	0.579	rs612295	ENSG00000232480.1	TGFB2-AS1	-4.37	1.52e-05	0.00149	-0.22	-0.2	Post bronchodilator FEV1/FVC ratio;	chr1:218479648	chr1:218344196~218345678:-
THCA	cis	rs2980439	0.525	rs2945238	ENSG00000253981.4	ALG1L13P	4.37	1.52e-05	0.00149	0.19	0.2	Neuroticism;	chr8:8312614	chr8:8236003~8244667:-
THCA	cis	rs793571	0.522	rs11071398	ENSG00000245975.2	RP11-30K9.6	4.37	1.52e-05	0.00149	0.19	0.2	Schizophrenia;	chr15:58827878	chr15:58768072~58770974:-
THCA	cis	rs6449502	0.541	rs13186053	ENSG00000251279.1	CTC-436P18.1	4.37	1.52e-05	0.00149	0.36	0.2	Mean platelet volume;	chr5:61123275	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.541	rs13190305	ENSG00000251279.1	CTC-436P18.1	4.37	1.52e-05	0.00149	0.36	0.2	Mean platelet volume;	chr5:61123550	chr5:61162070~61232040:+
THCA	cis	rs2839627	0.561	rs9808758	ENSG00000225218.1	AP001628.6	4.37	1.52e-05	0.00149	0.29	0.2	Information processing speed;	chr21:42842280	chr21:42831040~42836477:-
THCA	cis	rs1560104	0.871	rs4479213	ENSG00000259876.1	CTD-3037G24.4	4.37	1.52e-05	0.0015	0.23	0.2	Obesity-related traits;	chr16:12618447	chr16:12556353~12557694:-
THCA	cis	rs853679	0.607	rs13194781	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.0015	-0.38	-0.2	Depression;	chr6:27847861	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs36116761	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.0015	-0.38	-0.2	Depression;	chr6:27850704	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs34194357	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.0015	-0.38	-0.2	Depression;	chr6:27850757	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13199772	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.0015	-0.38	-0.2	Depression;	chr6:27866307	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13199906	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.0015	-0.38	-0.2	Depression;	chr6:27866361	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs17763089	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.0015	-0.38	-0.2	Depression;	chr6:27867440	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs17695758	ENSG00000272009.1	RP1-313I6.12	-4.37	1.52e-05	0.0015	-0.38	-0.2	Depression;	chr6:27869405	chr6:28078792~28081130:-
THCA	cis	rs1113500	0.509	rs1619485	ENSG00000226822.1	RP11-356N1.2	-4.37	1.52e-05	0.0015	-0.21	-0.2	Growth-regulated protein alpha levels;	chr1:108065725	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.527	rs1777482	ENSG00000226822.1	RP11-356N1.2	-4.37	1.52e-05	0.0015	-0.21	-0.2	Growth-regulated protein alpha levels;	chr1:108068752	chr1:108071482~108074519:+
THCA	cis	rs375066	0.901	rs1978723	ENSG00000278917.1	RP11-15A1.4	4.37	1.52e-05	0.0015	0.17	0.2	Breast cancer;	chr19:43879648	chr19:43891233~43895411:+
THCA	cis	rs12755164	0.771	rs1405051	ENSG00000223479.3	RP4-788P17.1	-4.37	1.52e-05	0.0015	-0.21	-0.2	Schizophrenia;	chr1:72882801	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.771	rs6679116	ENSG00000223479.3	RP4-788P17.1	-4.37	1.52e-05	0.0015	-0.21	-0.2	Schizophrenia;	chr1:72883206	chr1:73635216~73715214:+
THCA	cis	rs7528684	0.546	rs2485066	ENSG00000236731.1	RP4-801G22.2	4.37	1.52e-05	0.0015	0.2	0.2	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157662711	chr1:157629939~157630728:-
THCA	cis	rs7528684	0.546	rs11264790	ENSG00000236731.1	RP4-801G22.2	4.37	1.52e-05	0.0015	0.2	0.2	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157666284	chr1:157629939~157630728:-
THCA	cis	rs6442522	0.768	rs3821638	ENSG00000249786.6	EAF1-AS1	4.37	1.52e-05	0.0015	0.21	0.2	Uric acid levels;	chr3:15469537	chr3:15436171~15455940:-
THCA	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-4.37	1.52e-05	0.0015	-0.3	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-4.37	1.52e-05	0.0015	-0.3	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
THCA	cis	rs1046896	0.552	rs12602280	ENSG00000263063.1	RP11-388C12.1	-4.37	1.52e-05	0.0015	-0.26	-0.2	Glycated hemoglobin levels;	chr17:82847545	chr17:82713908~82716255:-
THCA	cis	rs752010	0.967	rs6681441	ENSG00000230638.4	RP11-486B10.4	-4.37	1.52e-05	0.0015	-0.22	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr1:41632650	chr1:41542069~41544310:+
THCA	cis	rs7829975	0.591	rs12677543	ENSG00000233609.3	RP11-62H7.2	4.37	1.52e-05	0.0015	0.19	0.2	Mood instability;	chr8:8786764	chr8:8961200~8979025:+
THCA	cis	rs4950322	0.58	rs2083720	ENSG00000271721.1	RP11-337C18.9	4.37	1.52e-05	0.0015	0.22	0.2	Protein quantitative trait loci;	chr1:147122296	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.58	rs72706441	ENSG00000271721.1	RP11-337C18.9	4.37	1.52e-05	0.0015	0.22	0.2	Protein quantitative trait loci;	chr1:147122601	chr1:147175602~147177740:+
THCA	cis	rs9863	0.861	rs7958691	ENSG00000270028.1	RP11-380L11.4	4.37	1.53e-05	0.0015	0.2	0.2	White blood cell count;	chr12:123956196	chr12:123925461~123926083:-
THCA	cis	rs4835473	0.637	rs9993457	ENSG00000251600.4	RP11-673E1.1	4.37	1.53e-05	0.0015	0.24	0.2	Immature fraction of reticulocytes;	chr4:143752364	chr4:143912331~143982454:+
THCA	cis	rs9487094	0.626	rs4947016	ENSG00000223537.2	RP5-919F19.5	-4.37	1.53e-05	0.0015	-0.2	-0.2	Height;	chr6:109740895	chr6:109487906~109506800:+
THCA	cis	rs1728785	0.901	rs8050289	ENSG00000274698.1	RP11-71L14.4	4.37	1.53e-05	0.0015	0.27	0.2	Ulcerative colitis;	chr16:68533073	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1728780	ENSG00000274698.1	RP11-71L14.4	4.37	1.53e-05	0.0015	0.27	0.2	Ulcerative colitis;	chr16:68533739	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1749792	ENSG00000274698.1	RP11-71L14.4	4.37	1.53e-05	0.0015	0.27	0.2	Ulcerative colitis;	chr16:68535537	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.818	rs12926059	ENSG00000274698.1	RP11-71L14.4	4.37	1.53e-05	0.0015	0.27	0.2	Ulcerative colitis;	chr16:68535556	chr16:68450283~68452318:+
THCA	cis	rs6730558	1	rs3896594	ENSG00000236008.1	AC011747.4	-4.37	1.53e-05	0.0015	-0.23	-0.2	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8622284	chr2:8559833~8583792:-
THCA	cis	rs6570726	0.643	rs9403735	ENSG00000270638.1	RP3-466P17.1	4.37	1.53e-05	0.0015	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145735570~145737218:+
THCA	cis	rs881375	0.678	rs7021049	ENSG00000270917.1	RP11-27I1.6	-4.37	1.53e-05	0.0015	-0.27	-0.2	Rheumatoid arthritis;	chr9:120921704	chr9:120812475~120812845:-
THCA	cis	rs4763879	0.634	rs12424826	ENSG00000256673.1	RP11-599J14.2	4.37	1.53e-05	0.0015	0.24	0.2	Type 1 diabetes;	chr12:9701981	chr12:9398355~9414851:-
THCA	cis	rs763121	0.819	rs4560233	ENSG00000273076.1	RP3-508I15.22	4.37	1.53e-05	0.0015	0.2	0.2	Menopause (age at onset);	chr22:38586437	chr22:38743495~38743910:+
THCA	cis	rs5758511	0.773	rs11913631	ENSG00000281538.1	RP4-669P10.20	-4.37	1.53e-05	0.0015	-0.23	-0.2	Birth weight;	chr22:41951367	chr22:42138060~42139726:+
THCA	cis	rs2281636	0.898	rs7903514	ENSG00000233690.1	EBAG9P1	4.37	1.53e-05	0.0015	0.19	0.2	Obesity-related traits;	chr10:99705951	chr10:99697407~99697949:-
THCA	cis	rs801193	0.935	rs11772264	ENSG00000272831.1	RP11-792A8.4	4.37	1.53e-05	0.0015	0.12	0.2	Aortic root size;	chr7:66711400	chr7:66739829~66740385:-
THCA	cis	rs4144027	0.904	rs10438244	ENSG00000269910.1	RP11-73M18.10	-4.37	1.53e-05	0.0015	-0.18	-0.2	Blood metabolite levels;	chr14:103879848	chr14:103694516~103695050:-
THCA	cis	rs4660456	0.556	rs823674	ENSG00000272145.1	NFYC-AS1	4.37	1.53e-05	0.0015	0.12	0.2	Platelet count;	chr1:40774799	chr1:40690380~40692066:-
THCA	cis	rs17597773	0.527	rs2484699	ENSG00000238078.1	LINC01352	-4.37	1.53e-05	0.0015	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910410	chr1:220829255~220832429:+
THCA	cis	rs9532669	0.889	rs6560964	ENSG00000229473.2	RGS17P1	4.37	1.53e-05	0.0015	0.25	0.2	Cervical cancer;	chr13:40871132	chr13:40992779~40993331:-
THCA	cis	rs17270561	0.609	rs9379785	ENSG00000272462.2	U91328.19	-4.37	1.53e-05	0.0015	-0.17	-0.2	Iron status biomarkers;	chr6:25725985	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9358871	ENSG00000272462.2	U91328.19	-4.37	1.53e-05	0.0015	-0.17	-0.2	Iron status biomarkers;	chr6:25726447	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4711095	ENSG00000272462.2	U91328.19	-4.37	1.53e-05	0.0015	-0.17	-0.2	Iron status biomarkers;	chr6:25726546	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4712959	ENSG00000272462.2	U91328.19	-4.37	1.53e-05	0.0015	-0.17	-0.2	Iron status biomarkers;	chr6:25726829	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4712960	ENSG00000272462.2	U91328.19	-4.37	1.53e-05	0.0015	-0.17	-0.2	Iron status biomarkers;	chr6:25727037	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4712961	ENSG00000272462.2	U91328.19	-4.37	1.53e-05	0.0015	-0.17	-0.2	Iron status biomarkers;	chr6:25727106	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9358872	ENSG00000272462.2	U91328.19	-4.37	1.53e-05	0.0015	-0.17	-0.2	Iron status biomarkers;	chr6:25727289	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9356985	ENSG00000272462.2	U91328.19	-4.37	1.53e-05	0.0015	-0.17	-0.2	Iron status biomarkers;	chr6:25727870	chr6:25992662~26001775:+
THCA	cis	rs4685724	0.55	rs3925391	ENSG00000223727.5	AC026188.1	-4.37	1.53e-05	0.0015	-0.27	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:3980216	chr3:3250687~3627296:-
THCA	cis	rs7560272	0.538	rs12233112	ENSG00000273245.1	RP11-434P11.2	-4.37	1.53e-05	0.0015	-0.23	-0.2	Schizophrenia;	chr2:73704637	chr2:73750256~73750786:-
THCA	cis	rs858239	0.541	rs4624924	ENSG00000226816.2	AC005082.12	4.37	1.53e-05	0.0015	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23206013~23208045:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000223473.2	GS1-124K5.3	-4.37	1.53e-05	0.0015	-0.13	-0.2	Aortic root size;	chr7:66120784	chr7:66491049~66493566:-
THCA	cis	rs7166081	0.738	rs2286664	ENSG00000270964.1	RP11-502I4.3	-4.37	1.53e-05	0.0015	-0.17	-0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67409157	chr15:67541072~67542604:-
THCA	cis	rs253959	0.739	rs153613	ENSG00000272265.1	CTD-2287O16.4	-4.37	1.53e-05	0.0015	-0.22	-0.2	Bipolar disorder and schizophrenia;	chr5:116297777	chr5:116078110~116078570:-
THCA	cis	rs2243480	0.901	rs313808	ENSG00000164669.11	INTS4P1	4.37	1.53e-05	0.0015	0.38	0.2	Diabetic kidney disease;	chr7:66034886	chr7:65141225~65234216:+
THCA	cis	rs3820928	0.839	rs13398103	ENSG00000212391.1	SNORA48	-4.37	1.53e-05	0.0015	-0.22	-0.2	Pulmonary function;	chr2:226994977	chr2:226968989~226969122:-
THCA	cis	rs5758659	0.652	rs5758537	ENSG00000205702.9	CYP2D7	4.37	1.53e-05	0.0015	0.15	0.2	Cognitive function;	chr22:42001038	chr22:42140203~42144577:-
THCA	cis	rs13113518	1	rs4865004	ENSG00000249700.7	SRD5A3-AS1	4.37	1.53e-05	0.0015	0.24	0.2	Height;	chr4:55515118	chr4:55363971~55395847:-
THCA	cis	rs6921919	0.638	rs2108926	ENSG00000273712.1	RP5-874C20.7	4.37	1.53e-05	0.0015	0.23	0.2	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28315613~28315883:-
THCA	cis	rs61270009	0.955	rs13189889	ENSG00000247828.6	TMEM161B-AS1	4.37	1.53e-05	0.0015	0.18	0.2	Depressive symptoms;	chr5:88365589	chr5:88268895~88436685:+
THCA	cis	rs4906332	0.811	rs2021965	ENSG00000252469.1	RNU7-160P	-4.37	1.53e-05	0.0015	-0.24	-0.2	Coronary artery disease;	chr14:103530911	chr14:103550345~103550406:+
THCA	cis	rs17772222	0.651	rs12586714	ENSG00000258983.2	RP11-507K2.2	4.37	1.53e-05	0.0015	0.22	0.2	Coronary artery calcification;	chr14:88360497	chr14:88499334~88515502:+
THCA	cis	rs5758659	0.652	rs133305	ENSG00000205702.9	CYP2D7	4.37	1.53e-05	0.0015	0.15	0.2	Cognitive function;	chr22:41999956	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.682	rs133306	ENSG00000205702.9	CYP2D7	4.37	1.53e-05	0.0015	0.15	0.2	Cognitive function;	chr22:42000146	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.519	rs133307	ENSG00000205702.9	CYP2D7	4.37	1.53e-05	0.0015	0.15	0.2	Cognitive function;	chr22:42000564	chr22:42140203~42144577:-
THCA	cis	rs2337406	0.5	rs57619050	ENSG00000211974.3	IGHV2-70	-4.37	1.53e-05	0.0015	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106820074	chr14:106723574~106724093:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000223473.2	GS1-124K5.3	4.37	1.53e-05	0.0015	0.13	0.2	Aortic root size;	chr7:66540165	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs13224319	ENSG00000223473.2	GS1-124K5.3	4.37	1.53e-05	0.0015	0.13	0.2	Aortic root size;	chr7:66542376	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs801217	ENSG00000223473.2	GS1-124K5.3	-4.37	1.53e-05	0.0015	-0.13	-0.2	Aortic root size;	chr7:66545590	chr7:66491049~66493566:-
THCA	cis	rs875971	0.638	rs801216	ENSG00000223473.2	GS1-124K5.3	-4.37	1.53e-05	0.0015	-0.13	-0.2	Aortic root size;	chr7:66546680	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs801211	ENSG00000223473.2	GS1-124K5.3	-4.37	1.53e-05	0.0015	-0.13	-0.2	Aortic root size;	chr7:66550702	chr7:66491049~66493566:-
THCA	cis	rs867186	1	rs75648520	ENSG00000126005.14	MMP24-AS1	-4.37	1.53e-05	0.0015	-0.32	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35136418	chr20:35216462~35278131:-
THCA	cis	rs7267979	1	rs1888999	ENSG00000274973.1	RP13-401N8.7	-4.37	1.53e-05	0.0015	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25845497~25845862:+
THCA	cis	rs5758511	0.573	rs2267438	ENSG00000281538.1	RP4-669P10.20	4.37	1.53e-05	0.0015	0.19	0.2	Birth weight;	chr22:41841561	chr22:42138060~42139726:+
THCA	cis	rs9400467	0.545	rs9320366	ENSG00000255389.1	C6orf3	4.37	1.53e-05	0.0015	0.23	0.2	Amino acid levels;Blood metabolite levels;	chr6:111515841	chr6:111599875~111602295:+
THCA	cis	rs7520050	0.966	rs1707336	ENSG00000234329.1	RP11-767N6.2	-4.37	1.53e-05	0.0015	-0.18	-0.2	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45651039~45651826:-
THCA	cis	rs7403037	0.602	rs4778287	ENSG00000260760.1	PWRN3	4.37	1.53e-05	0.0015	0.23	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24191055	chr15:24441127~24447967:+
THCA	cis	rs78487399	0.808	rs7586101	ENSG00000234936.1	AC010883.5	-4.37	1.53e-05	0.0015	-0.26	-0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43442712	chr2:43229573~43233394:+
THCA	cis	rs875971	0.862	rs2420174	ENSG00000229886.1	RP5-1132H15.3	-4.37	1.53e-05	0.0015	-0.21	-0.2	Aortic root size;	chr7:66180374	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs2420173	ENSG00000229886.1	RP5-1132H15.3	-4.37	1.53e-05	0.0015	-0.21	-0.2	Aortic root size;	chr7:66180412	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs4718319	ENSG00000229886.1	RP5-1132H15.3	-4.37	1.53e-05	0.0015	-0.21	-0.2	Aortic root size;	chr7:66187797	chr7:66025126~66031544:-
THCA	cis	rs17095355	0.818	rs7086057	ENSG00000203876.8	ADD3-AS1	-4.37	1.53e-05	0.0015	-0.21	-0.2	Biliary atresia;	chr10:110107318	chr10:109940104~110008381:-
THCA	cis	rs4434872	0.536	rs61804837	ENSG00000223599.1	RP11-216N14.7	-4.37	1.53e-05	0.0015	-0.38	-0.2	Conduct disorder (symptom count);	chr1:153872997	chr1:153852106~153853414:-
THCA	cis	rs734999	0.545	rs3890745	ENSG00000225931.3	RP3-395M20.7	-4.37	1.53e-05	0.00151	-0.23	-0.2	Ulcerative colitis;	chr1:2622185	chr1:2566410~2569888:+
THCA	cis	rs13126694	0.778	rs13106004	ENSG00000248429.4	RP11-597D13.9	4.37	1.53e-05	0.00151	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158104532	chr4:158170752~158202877:+
THCA	cis	rs13126694	0.744	rs13106234	ENSG00000248429.4	RP11-597D13.9	4.37	1.53e-05	0.00151	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158104618	chr4:158170752~158202877:+
THCA	cis	rs7824557	0.583	rs2263512	ENSG00000206014.6	OR7E161P	4.37	1.53e-05	0.00151	0.23	0.2	Retinal vascular caliber;	chr8:11375910	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.583	rs6601585	ENSG00000206014.6	OR7E161P	4.37	1.53e-05	0.00151	0.23	0.2	Retinal vascular caliber;	chr8:11376150	chr8:11928597~11929563:-
THCA	cis	rs116248771	0.739	rs4680455	ENSG00000271778.1	RP11-379F4.8	4.37	1.53e-05	0.00151	0.26	0.2	diarrhoeal disease at age 2;	chr3:158667094	chr3:158782547~158783124:+
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000220721.1	OR1F12	4.37	1.53e-05	0.00151	0.22	0.2	Pubertal anthropometrics;	chr6:28271903	chr6:28073316~28074233:+
THCA	cis	rs9900062	0.546	rs2428352	ENSG00000270714.1	MINOS1P2	4.37	1.53e-05	0.00151	0.27	0.2	QT interval;	chr17:64698620	chr17:64747264~64747492:-
THCA	cis	rs453301	0.624	rs2979265	ENSG00000254340.1	RP11-10A14.3	4.37	1.53e-05	0.00151	0.21	0.2	Joint mobility (Beighton score);	chr8:9001207	chr8:9141424~9145435:+
THCA	cis	rs593531	0.55	rs537637	ENSG00000255440.1	RP11-632K5.2	-4.37	1.53e-05	0.00151	-0.23	-0.2	Neuroticism;	chr11:74436383	chr11:74409060~74416379:+
THCA	cis	rs8031584	1	rs35811129	ENSG00000178081.11	ULK4P3	4.37	1.54e-05	0.00151	0.27	0.2	Huntington's disease progression;	chr15:30949143	chr15:30103720~30131757:+
THCA	cis	rs7267979	1	rs2482943	ENSG00000274973.1	RP13-401N8.7	4.37	1.54e-05	0.00151	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2500418	ENSG00000274973.1	RP13-401N8.7	4.37	1.54e-05	0.00151	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25845497~25845862:+
THCA	cis	rs440932	0.757	rs330945	ENSG00000248538.5	RP11-10A14.5	-4.37	1.54e-05	0.00151	-0.24	-0.2	High light scatter reticulocyte percentage of red cells;	chr8:9164423	chr8:9189011~9202854:+
THCA	cis	rs17801127	0.748	rs12990176	ENSG00000231969.1	AC144449.1	-4.37	1.54e-05	0.00151	-0.39	-0.2	Liver enzyme levels (alanine transaminase);	chr2:149820562	chr2:149587196~149848233:+
THCA	cis	rs7833787	0.526	rs17468284	ENSG00000278886.1	RP11-108A14.1	4.37	1.54e-05	0.00151	0.29	0.2	Obesity-related traits;	chr8:18854813	chr8:18864681~18865247:-
THCA	cis	rs4803480	0.678	rs3745936	ENSG00000270164.1	LINC01480	-4.37	1.54e-05	0.00151	-0.18	-0.2	Schizophrenia;	chr19:41586462	chr19:41535183~41536904:+
THCA	cis	rs227275	0.525	rs4623004	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs11097796	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs11097797	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs4699046	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs4699047	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs28778380	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs10029073	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs4698874	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs724446	ENSG00000248971.2	KRT8P46	-4.37	1.54e-05	0.00151	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102728746~102730171:-
THCA	cis	rs4845570	1	rs7542898	ENSG00000249602.1	RP11-98D18.3	-4.37	1.54e-05	0.00151	-0.29	-0.2	Coronary artery disease;	chr1:151781146	chr1:151763384~151769501:-
THCA	cis	rs5758511	0.773	rs62240997	ENSG00000281538.1	RP4-669P10.20	-4.37	1.54e-05	0.00151	-0.23	-0.2	Birth weight;	chr22:41958563	chr22:42138060~42139726:+
THCA	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-4.37	1.54e-05	0.00151	-0.23	-0.2	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
THCA	cis	rs1823913	0.538	rs11892998	ENSG00000227542.1	AC092614.2	4.37	1.54e-05	0.00151	0.22	0.2	Obesity-related traits;	chr2:191340159	chr2:191229165~191246172:-
THCA	cis	rs7267979	1	rs2500443	ENSG00000276952.1	RP5-965G21.6	-4.37	1.54e-05	0.00151	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25284915~25285588:-
THCA	cis	rs4924544	1	rs4924544	ENSG00000247556.5	OIP5-AS1	4.37	1.54e-05	0.00151	0.16	0.2	Eosinophil percentage of white cells;	chr15:41401257	chr15:41283990~41309737:+
THCA	cis	rs9625935	0.957	rs12171250	ENSG00000279159.1	RP3-394A18.1	-4.37	1.54e-05	0.00151	-0.15	-0.2	Tonsillectomy;	chr22:30147514	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs9620953	ENSG00000279159.1	RP3-394A18.1	-4.37	1.54e-05	0.00151	-0.15	-0.2	Tonsillectomy;	chr22:30150256	chr22:29978950~30028236:-
THCA	cis	rs6546886	0.917	rs11884748	ENSG00000235499.1	AC073046.25	4.37	1.54e-05	0.00151	0.18	0.2	Dialysis-related mortality;	chr2:74021324	chr2:73985132~73986343:+
THCA	cis	rs6696239	0.956	rs903691	ENSG00000227711.2	RP11-275O4.5	4.37	1.54e-05	0.00151	0.28	0.2	Height;	chr1:227543361	chr1:227509028~227520477:-
THCA	cis	rs12893668	0.673	rs2296482	ENSG00000244691.1	RPL10AP1	-4.37	1.54e-05	0.00151	-0.28	-0.2	Reticulocyte count;	chr14:103563482	chr14:103412119~103412761:-
THCA	cis	rs17507216	0.628	rs28371837	ENSG00000255769.6	GOLGA2P10	-4.37	1.54e-05	0.00151	-0.3	-0.2	Excessive daytime sleepiness;	chr15:82714435	chr15:82472993~82513950:-
THCA	cis	rs7216064	1	rs3206817	ENSG00000278740.1	RP11-147L13.14	4.37	1.54e-05	0.00151	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896718	chr17:68188547~68189165:+
THCA	cis	rs6517329	0.649	rs2409758	ENSG00000236830.5	CBR3-AS1	4.37	1.54e-05	0.00151	0.19	0.2	Schizophrenia;	chr21:36118357	chr21:36131767~36175815:-
THCA	cis	rs2777491	0.574	rs11858812	ENSG00000247556.5	OIP5-AS1	4.37	1.54e-05	0.00151	0.19	0.2	Ulcerative colitis;	chr15:41439352	chr15:41283990~41309737:+
THCA	cis	rs7267979	1	rs2482928	ENSG00000276952.1	RP5-965G21.6	-4.37	1.54e-05	0.00151	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25284915~25285588:-
THCA	cis	rs5753037	0.702	rs36576	ENSG00000279699.1	RP1-102K2.9	4.37	1.54e-05	0.00151	0.19	0.2	Type 1 diabetes;	chr22:29810302	chr22:30275215~30276951:-
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000182586.6	LINC00334	-4.37	1.54e-05	0.00151	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45234340~45258730:+
THCA	cis	rs564799	0.966	rs485499	ENSG00000244040.4	IL12A-AS1	-4.37	1.54e-05	0.00151	-0.26	-0.2	Systemic lupus erythematosus;	chr3:160028076	chr3:159913400~160225299:-
THCA	cis	rs10256972	0.577	rs4999286	ENSG00000225146.1	AC073957.15	4.37	1.54e-05	0.00151	0.21	0.2	Endometriosis;Longevity;	chr7:1159870	chr7:1029025~1043891:+
THCA	cis	rs9368481	0.761	rs4713062	ENSG00000261353.1	CTA-14H9.5	4.37	1.54e-05	0.00151	0.21	0.2	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26527063~26527404:+
THCA	cis	rs728616	0.51	rs17679603	ENSG00000242600.5	MBL1P	4.37	1.54e-05	0.00151	0.25	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80421678	chr10:79904898~79950336:+
THCA	cis	rs4767841	0.868	rs1318272	ENSG00000248636.5	RP11-768F21.1	-4.37	1.54e-05	0.00151	-0.21	-0.2	Urgency urinary incontinence;	chr12:119751883	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.901	rs904654	ENSG00000248636.5	RP11-768F21.1	-4.37	1.54e-05	0.00151	-0.21	-0.2	Urgency urinary incontinence;	chr12:119752083	chr12:119387987~119668079:-
THCA	cis	rs2164273	0.523	rs1435279	ENSG00000154316.13	TDH	-4.37	1.54e-05	0.00151	-0.15	-0.2	Extraversion;	chr8:11300878	chr8:11339637~11368452:+
THCA	cis	rs875971	0.66	rs1860468	ENSG00000229886.1	RP5-1132H15.3	-4.37	1.54e-05	0.00151	-0.2	-0.2	Aortic root size;	chr7:66642265	chr7:66025126~66031544:-
THCA	cis	rs9341808	0.667	rs2505944	ENSG00000272129.1	RP11-250B2.6	4.37	1.54e-05	0.00151	0.25	0.2	Sitting height ratio;	chr6:80178693	chr6:80355424~80356859:+
THCA	cis	rs987724	0.515	rs453219	ENSG00000240875.4	LINC00886	-4.37	1.54e-05	0.00151	-0.19	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856463	chr3:156747346~156817062:-
THCA	cis	rs2033711	0.728	rs4801586	ENSG00000269054.1	CTD-2619J13.3	-4.37	1.54e-05	0.00151	-0.16	-0.2	Uric acid clearance;	chr19:58423161	chr19:58362585~58366591:+
THCA	cis	rs76793172	0.588	rs659444	ENSG00000267395.4	AC074212.6	-4.37	1.54e-05	0.00151	-0.18	-0.2	Eosinophil counts;	chr19:45781689	chr19:45767796~45772504:+
THCA	cis	rs875971	1	rs6963646	ENSG00000229886.1	RP5-1132H15.3	-4.37	1.54e-05	0.00151	-0.21	-0.2	Aortic root size;	chr7:66220780	chr7:66025126~66031544:-
THCA	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	4.37	1.54e-05	0.00151	0.21	0.2	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
THCA	cis	rs858239	0.601	rs73272053	ENSG00000230042.1	AK3P3	-4.37	1.54e-05	0.00151	-0.26	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23129178~23129841:+
THCA	cis	rs1728785	0.901	rs1728797	ENSG00000274698.1	RP11-71L14.4	4.37	1.54e-05	0.00151	0.27	0.2	Ulcerative colitis;	chr16:68537086	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1728801	ENSG00000274698.1	RP11-71L14.4	4.37	1.54e-05	0.00151	0.27	0.2	Ulcerative colitis;	chr16:68537554	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1645981	ENSG00000274698.1	RP11-71L14.4	4.37	1.54e-05	0.00151	0.27	0.2	Ulcerative colitis;	chr16:68537745	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1728764	ENSG00000274698.1	RP11-71L14.4	4.37	1.54e-05	0.00151	0.27	0.2	Ulcerative colitis;	chr16:68538389	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1749791	ENSG00000274698.1	RP11-71L14.4	4.37	1.54e-05	0.00151	0.27	0.2	Ulcerative colitis;	chr16:68538444	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1170445	ENSG00000274698.1	RP11-71L14.4	4.37	1.54e-05	0.00151	0.27	0.2	Ulcerative colitis;	chr16:68539161	chr16:68450283~68452318:+
THCA	cis	rs494453	0.922	rs569504	ENSG00000227811.2	FAM212B-AS1	-4.37	1.54e-05	0.00151	-0.25	-0.2	Osteoporosis-related phenotypes;	chr1:111669155	chr1:111739841~111747798:+
THCA	cis	rs6860806	0.507	rs270608	ENSG00000224431.1	AC063976.7	4.37	1.54e-05	0.00151	0.18	0.2	Breast cancer;	chr5:132312713	chr5:132199456~132203487:+
THCA	cis	rs763121	0.853	rs4821816	ENSG00000235209.1	CTA-150C2.13	4.37	1.54e-05	0.00151	0.27	0.2	Menopause (age at onset);	chr22:38717129	chr22:38921227~38924708:+
THCA	cis	rs4660214	0.666	rs597311	ENSG00000228060.1	RP11-69E11.8	-4.37	1.54e-05	0.00151	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355254	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.615	rs597708	ENSG00000228060.1	RP11-69E11.8	-4.37	1.54e-05	0.00151	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355291	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs636156	ENSG00000228060.1	RP11-69E11.8	-4.37	1.54e-05	0.00151	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356065	chr1:39565160~39573203:+
THCA	cis	rs613391	0.767	rs605204	ENSG00000224549.1	RP11-370B11.3	-4.37	1.55e-05	0.00151	-0.22	-0.2	Quantitative traits;	chr9:22682878	chr9:22767175~22768316:+
THCA	cis	rs4906332	1	rs35224956	ENSG00000269910.1	RP11-73M18.10	4.37	1.55e-05	0.00151	0.17	0.2	Coronary artery disease;	chr14:103434144	chr14:103694516~103695050:-
THCA	cis	rs2408955	0.521	rs1476607	ENSG00000273765.1	RP11-370I10.11	-4.37	1.55e-05	0.00151	-0.2	-0.2	Glycated hemoglobin levels;	chr12:48131021	chr12:48360920~48361377:+
THCA	cis	rs2806561	0.606	rs218341	ENSG00000249087.5	ZNF436-AS1	-4.37	1.55e-05	0.00152	-0.13	-0.2	Height;	chr1:22967660	chr1:23368997~23371839:+
THCA	cis	rs9863	0.898	rs11057400	ENSG00000270061.1	RP11-214K3.19	-4.37	1.55e-05	0.00152	-0.27	-0.2	White blood cell count;	chr12:123940602	chr12:123969990~123970344:-
THCA	cis	rs7474896	0.836	rs584630	ENSG00000263064.2	RP11-291L22.7	4.37	1.55e-05	0.00152	0.32	0.2	Obesity (extreme);	chr10:38049771	chr10:38448689~38448949:+
THCA	cis	rs2333194	0.772	rs12589739	ENSG00000258695.2	RP3-414A15.2	-4.37	1.55e-05	0.00152	-0.24	-0.2	Bipolar disorder with mood-incongruent psychosis;	chr14:73436348	chr14:73522878~73530610:+
THCA	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-4.37	1.55e-05	0.00152	-0.12	-0.2	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
THCA	cis	rs858239	0.899	rs5850	ENSG00000230042.1	AK3P3	-4.37	1.55e-05	0.00152	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23129178~23129841:+
THCA	cis	rs454217	0.846	rs1661024	ENSG00000277851.1	RP11-756G20.1	4.37	1.55e-05	0.00152	0.2	0.2	Smoking quantity;	chr12:92330771	chr12:92247756~92363832:-
THCA	cis	rs1923243	0.681	rs35312548	ENSG00000223479.3	RP4-788P17.1	4.37	1.55e-05	0.00152	0.22	0.2	Migraine;	chr1:73080569	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs34535929	ENSG00000223479.3	RP4-788P17.1	4.37	1.55e-05	0.00152	0.22	0.2	Migraine;	chr1:73081368	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs4650183	ENSG00000223479.3	RP4-788P17.1	4.37	1.55e-05	0.00152	0.22	0.2	Migraine;	chr1:73086551	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs7517842	ENSG00000223479.3	RP4-788P17.1	4.37	1.55e-05	0.00152	0.22	0.2	Migraine;	chr1:73092493	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs12127236	ENSG00000223479.3	RP4-788P17.1	4.37	1.55e-05	0.00152	0.22	0.2	Migraine;	chr1:73094285	chr1:73635216~73715214:+
THCA	cis	rs7855088	0.789	rs4742710	ENSG00000236130.1	PTCSC2	-4.37	1.55e-05	0.00152	-0.16	-0.2	Serum thyroid-stimulating hormone levels;	chr9:98018233	chr9:97805935~97810008:-
THCA	cis	rs8141529	0.702	rs469992	ENSG00000226471.5	CTA-292E10.6	4.37	1.55e-05	0.00152	0.16	0.2	Lymphocyte counts;	chr22:28918911	chr22:28800683~28848559:+
THCA	cis	rs4906332	1	rs1951389	ENSG00000269910.1	RP11-73M18.10	4.37	1.55e-05	0.00152	0.17	0.2	Coronary artery disease;	chr14:103432188	chr14:103694516~103695050:-
THCA	cis	rs4906332	0.901	rs4900575	ENSG00000269910.1	RP11-73M18.10	4.37	1.55e-05	0.00152	0.17	0.2	Coronary artery disease;	chr14:103432832	chr14:103694516~103695050:-
THCA	cis	rs16976116	0.901	rs28478777	ENSG00000279145.1	RP11-547D13.1	4.37	1.55e-05	0.00152	0.22	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55220548	chr15:55171972~55178175:-
THCA	cis	rs9368481	0.743	rs9368480	ENSG00000261353.1	CTA-14H9.5	-4.37	1.55e-05	0.00152	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26527063~26527404:+
THCA	cis	rs7577696	0.962	rs7608127	ENSG00000276334.1	AL133243.1	-4.37	1.55e-05	0.00152	-0.21	-0.2	Inflammatory biomarkers;	chr2:32054854	chr2:32521927~32523547:+
THCA	cis	rs793571	0.502	rs411007	ENSG00000245975.2	RP11-30K9.6	4.37	1.55e-05	0.00152	0.18	0.2	Schizophrenia;	chr15:58786303	chr15:58768072~58770974:-
THCA	cis	rs11153306	1	rs11153306	ENSG00000231889.6	TRAF3IP2-AS1	4.37	1.55e-05	0.00152	0.17	0.2	Tonsillectomy;	chr6:111629446	chr6:111483511~111598302:+
THCA	cis	rs2822388	0.59	rs2822387	ENSG00000228314.1	CYP4F29P	-4.37	1.55e-05	0.00152	-0.38	-0.2	Stroke;	chr21:14034842	chr21:13843133~13848364:-
THCA	cis	rs5758659	0.622	rs129856	ENSG00000205702.9	CYP2D7	4.37	1.55e-05	0.00152	0.15	0.2	Cognitive function;	chr22:42003392	chr22:42140203~42144577:-
THCA	cis	rs2067615	0.579	rs4964492	ENSG00000260329.1	RP11-412D9.4	-4.37	1.55e-05	0.00152	-0.18	-0.2	Heart rate;	chr12:106828996	chr12:106954029~106955497:-
THCA	cis	rs15676	0.947	rs2805103	ENSG00000234771.3	SLC25A25-AS1	4.37	1.55e-05	0.00152	0.16	0.2	Blood metabolite levels;	chr9:128836618	chr9:128108581~128118693:-
THCA	cis	rs15676	0.947	rs2759009	ENSG00000234771.3	SLC25A25-AS1	4.37	1.55e-05	0.00152	0.16	0.2	Blood metabolite levels;	chr9:128836729	chr9:128108581~128118693:-
THCA	cis	rs3785574	0.65	rs2005132	ENSG00000240280.5	TCAM1P	4.37	1.55e-05	0.00152	0.26	0.2	Height;	chr17:63930872	chr17:63849292~63864379:+
THCA	cis	rs3785574	0.65	rs8077653	ENSG00000240280.5	TCAM1P	4.37	1.55e-05	0.00152	0.26	0.2	Height;	chr17:63931605	chr17:63849292~63864379:+
THCA	cis	rs12216545	0.765	rs7785909	ENSG00000241134.3	BET1P1	-4.37	1.55e-05	0.00152	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150525142	chr7:150749736~150750094:+
THCA	cis	rs763121	0.962	rs5757135	ENSG00000228274.3	RP3-508I15.9	-4.37	1.55e-05	0.00152	-0.2	-0.2	Menopause (age at onset);	chr22:38556568	chr22:38667585~38681820:-
THCA	cis	rs10875746	0.903	rs4760681	ENSG00000258273.1	RP11-370I10.4	4.37	1.55e-05	0.00152	0.28	0.2	Longevity (90 years and older);	chr12:48111447	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs11168418	ENSG00000258273.1	RP11-370I10.4	4.37	1.55e-05	0.00152	0.28	0.2	Longevity (90 years and older);	chr12:48121971	chr12:48333755~48333901:-
THCA	cis	rs10090774	0.769	rs56352956	ENSG00000279766.1	RP11-642A1.2	4.37	1.55e-05	0.00152	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140730167	chr8:140572142~140572812:-
THCA	cis	rs6964833	0.786	rs35633336	ENSG00000184616.8	AC004166.6	4.37	1.55e-05	0.00152	0.31	0.2	Menarche (age at onset);	chr7:74643961	chr7:74906673~74913256:-
THCA	cis	rs6964833	0.935	rs35735900	ENSG00000184616.8	AC004166.6	4.37	1.55e-05	0.00152	0.31	0.2	Menarche (age at onset);	chr7:74651887	chr7:74906673~74913256:-
THCA	cis	rs11157436	1	rs75648426	ENSG00000211812.1	TRAV26-2	-4.37	1.55e-05	0.00152	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22202583~22203368:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000223473.2	GS1-124K5.3	4.37	1.55e-05	0.00152	0.13	0.2	Aortic root size;	chr7:66521858	chr7:66491049~66493566:-
THCA	cis	rs6517329	0.524	rs13047406	ENSG00000236830.5	CBR3-AS1	-4.37	1.55e-05	0.00152	-0.19	-0.2	Schizophrenia;	chr21:36132840	chr21:36131767~36175815:-
THCA	cis	rs10995505	0.589	rs1553789	ENSG00000232075.1	MRPL35P2	4.37	1.55e-05	0.00152	0.29	0.2	Intelligence (multi-trait analysis);	chr10:63119469	chr10:63634317~63634827:-
THCA	cis	rs3806843	0.606	rs251377	ENSG00000202515.1	VTRNA1-3	4.37	1.55e-05	0.00152	0.24	0.2	Depressive symptoms (multi-trait analysis);	chr5:140876207	chr5:140726158~140726246:+
THCA	cis	rs6477918	0.55	rs10981399	ENSG00000230185.4	C9orf147	-4.37	1.55e-05	0.00152	-0.21	-0.2	Obstetric antiphospholipid syndrome;	chr9:112413295	chr9:112433816~112487204:-
THCA	cis	rs9863	0.896	rs2130382	ENSG00000270061.1	RP11-214K3.19	-4.37	1.55e-05	0.00152	-0.26	-0.2	White blood cell count;	chr12:124000096	chr12:123969990~123970344:-
THCA	cis	rs9652601	0.691	rs7203150	ENSG00000274038.1	RP11-66H6.4	-4.37	1.55e-05	0.00152	-0.23	-0.2	Systemic lupus erythematosus;	chr16:11113865	chr16:11056556~11057034:+
THCA	cis	rs4356203	0.905	rs35933265	ENSG00000272034.1	SNORD14A	-4.37	1.55e-05	0.00152	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17093707	chr11:17074654~17074744:-
THCA	cis	rs3796352	1	rs11714876	ENSG00000242142.1	SERBP1P3	4.37	1.55e-05	0.00152	0.35	0.2	Immune reponse to smallpox (secreted IL-2);	chr3:53067624	chr3:53064283~53065091:-
THCA	cis	rs6088813	1	rs2425065	ENSG00000279253.1	RP4-614O4.13	-4.37	1.56e-05	0.00152	-0.19	-0.2	Height;	chr20:35338465	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6088799	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35346498	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs4911491	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35359482	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6087698	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35361116	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6141546	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35361479	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs4911178	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35364817	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6142359	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35372647	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.925	rs1540928	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35374042	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6141548	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35383282	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs4911494	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35384111	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6142370	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35385575	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6141549	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35386248	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6088812	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35386360	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6088813	ENSG00000279253.1	RP4-614O4.13	4.37	1.56e-05	0.00152	0.19	0.2	Height;	chr20:35387378	chr20:35262727~35264187:-
THCA	cis	rs875971	0.66	rs28698552	ENSG00000272831.1	RP11-792A8.4	4.37	1.56e-05	0.00152	0.12	0.2	Aortic root size;	chr7:66540031	chr7:66739829~66740385:-
THCA	cis	rs3806843	0.576	rs251376	ENSG00000202515.1	VTRNA1-3	4.37	1.56e-05	0.00152	0.24	0.2	Depressive symptoms (multi-trait analysis);	chr5:140874104	chr5:140726158~140726246:+
THCA	cis	rs7658584	1	rs13128241	ENSG00000246375.2	RP11-10L7.1	4.37	1.56e-05	0.00152	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175657	chr4:88284942~88331421:+
THCA	cis	rs7658584	1	rs13128083	ENSG00000246375.2	RP11-10L7.1	4.37	1.56e-05	0.00152	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175692	chr4:88284942~88331421:+
THCA	cis	rs7658584	1	rs55987521	ENSG00000246375.2	RP11-10L7.1	4.37	1.56e-05	0.00152	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175926	chr4:88284942~88331421:+
THCA	cis	rs7658584	1	rs1481014	ENSG00000246375.2	RP11-10L7.1	4.37	1.56e-05	0.00152	0.34	0.2	Squamous cell lung carcinoma;	chr4:88175999	chr4:88284942~88331421:+
THCA	cis	rs3806843	0.576	rs251373	ENSG00000202515.1	VTRNA1-3	4.37	1.56e-05	0.00153	0.24	0.2	Depressive symptoms (multi-trait analysis);	chr5:140873030	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.545	rs251375	ENSG00000202515.1	VTRNA1-3	4.37	1.56e-05	0.00153	0.24	0.2	Depressive symptoms (multi-trait analysis);	chr5:140873375	chr5:140726158~140726246:+
THCA	cis	rs11157436	1	rs61972228	ENSG00000211812.1	TRAV26-2	-4.37	1.56e-05	0.00153	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22202583~22203368:+
THCA	cis	rs11157436	1	rs12587157	ENSG00000211812.1	TRAV26-2	-4.37	1.56e-05	0.00153	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22202583~22203368:+
THCA	cis	rs11157436	0.915	rs11622938	ENSG00000211812.1	TRAV26-2	-4.37	1.56e-05	0.00153	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22202583~22203368:+
THCA	cis	rs4908769	0.624	rs301818	ENSG00000232912.4	RP5-1115A15.1	4.37	1.56e-05	0.00153	0.22	0.2	Allergy;	chr1:8443182	chr1:8424645~8434838:+
THCA	cis	rs763121	0.853	rs2413545	ENSG00000273076.1	RP3-508I15.22	4.37	1.56e-05	0.00153	0.2	0.2	Menopause (age at onset);	chr22:38696519	chr22:38743495~38743910:+
THCA	cis	rs6708331	0.517	rs12614547	ENSG00000179818.12	PCBP1-AS1	-4.37	1.56e-05	0.00153	-0.15	-0.2	Obesity-related traits;	chr2:70056839	chr2:69962263~70103220:-
THCA	cis	rs17723470	0.836	rs11038350	ENSG00000254427.1	RP11-430H10.1	4.37	1.56e-05	0.00153	0.22	0.2	Thyroid hormone levels;	chr11:45200412	chr11:45355371~45366121:+
THCA	cis	rs9309473	0.5	rs2421664	ENSG00000273245.1	RP11-434P11.2	-4.37	1.56e-05	0.00153	-0.23	-0.2	Metabolite levels;	chr2:73631754	chr2:73750256~73750786:-
THCA	cis	rs7809799	0.571	rs111251485	ENSG00000244219.5	GS1-259H13.2	-4.37	1.56e-05	0.00153	-0.44	-0.2	Ulcerative colitis;	chr7:99360607	chr7:99598066~99610813:+
THCA	cis	rs7403037	0.761	rs36096018	ENSG00000260760.1	PWRN3	4.37	1.56e-05	0.00153	0.24	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24375474	chr15:24441127~24447967:+
THCA	cis	rs6745190	0.626	rs4602187	ENSG00000236153.1	AC104076.3	4.37	1.56e-05	0.00153	0.21	0.2	White blood cell count;	chr2:180969291	chr2:180979427~180980090:-
THCA	cis	rs4693089	0.604	rs13142167	ENSG00000213608.5	SLC25A14P1	4.37	1.56e-05	0.00153	0.23	0.2	Menopause (age at onset);	chr4:83466087	chr4:83477524~83478424:+
THCA	cis	rs454217	0.846	rs381966	ENSG00000277851.1	RP11-756G20.1	4.37	1.56e-05	0.00153	0.2	0.2	Smoking quantity;	chr12:92335913	chr12:92247756~92363832:-
THCA	cis	rs17095355	0.786	rs58096078	ENSG00000203876.8	ADD3-AS1	-4.37	1.56e-05	0.00153	-0.21	-0.2	Biliary atresia;	chr10:109974528	chr10:109940104~110008381:-
THCA	cis	rs12906542	0.516	rs894301	ENSG00000259792.1	RP11-114H24.6	-4.37	1.56e-05	0.00153	-0.31	-0.2	Breast cancer;	chr15:78005183	chr15:77993405~77995289:+
THCA	cis	rs12906542	0.516	rs4886989	ENSG00000259792.1	RP11-114H24.6	-4.37	1.56e-05	0.00153	-0.31	-0.2	Breast cancer;	chr15:78011406	chr15:77993405~77995289:+
THCA	cis	rs12906542	0.516	rs56357772	ENSG00000259792.1	RP11-114H24.6	-4.37	1.56e-05	0.00153	-0.31	-0.2	Breast cancer;	chr15:78020699	chr15:77993405~77995289:+
THCA	cis	rs12906542	0.516	rs16969422	ENSG00000259792.1	RP11-114H24.6	-4.37	1.56e-05	0.00153	-0.31	-0.2	Breast cancer;	chr15:78033857	chr15:77993405~77995289:+
THCA	cis	rs5758511	0.633	rs5758690	ENSG00000227370.1	RP4-669P10.19	4.37	1.56e-05	0.00153	0.22	0.2	Birth weight;	chr22:42272289	chr22:42132543~42132998:+
THCA	cis	rs55702914	0.935	rs67735550	ENSG00000231621.1	AC013264.2	-4.37	1.56e-05	0.00153	-0.19	-0.2	Major depression and alcohol dependence;	chr2:197364729	chr2:197197991~197199273:+
THCA	cis	rs7726839	0.555	rs4541696	ENSG00000225138.6	CTD-2228K2.7	4.37	1.56e-05	0.00153	0.18	0.2	Obesity-related traits;	chr5:580938	chr5:473236~480884:+
THCA	cis	rs73198271	0.531	rs3827812	ENSG00000253893.2	FAM85B	4.37	1.56e-05	0.00153	0.34	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797388	chr8:8167819~8226614:-
THCA	cis	rs2033711	0.783	rs8113810	ENSG00000269054.1	CTD-2619J13.3	-4.37	1.56e-05	0.00153	-0.16	-0.2	Uric acid clearance;	chr19:58420739	chr19:58362585~58366591:+
THCA	cis	rs2033711	0.87	rs4801270	ENSG00000269054.1	CTD-2619J13.3	-4.37	1.56e-05	0.00153	-0.16	-0.2	Uric acid clearance;	chr19:58421395	chr19:58362585~58366591:+
THCA	cis	rs111756027	0.542	rs56821398	ENSG00000260922.1	RP11-538I12.3	4.37	1.56e-05	0.00153	0.28	0.2	Bone mineral density (Ward's triangle area);	chr16:77265858	chr16:77234877~77290934:+
THCA	cis	rs12478296	0.901	rs9653611	ENSG00000220804.7	AC093642.5	4.37	1.56e-05	0.00153	0.21	0.2	Obesity-related traits;	chr2:242064805	chr2:242088633~242160153:+
THCA	cis	rs12478296	0.818	rs57194240	ENSG00000220804.7	AC093642.5	4.37	1.56e-05	0.00153	0.21	0.2	Obesity-related traits;	chr2:242069394	chr2:242088633~242160153:+
THCA	cis	rs8006682	0.541	rs12882449	ENSG00000259038.1	CTD-2325P2.4	4.37	1.56e-05	0.00153	0.24	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68621688	chr14:68627166~68628445:-
THCA	cis	rs2039553	0.697	rs2802634	ENSG00000227354.5	RBM26-AS1	4.37	1.56e-05	0.00153	0.19	0.2	Pancreatic cancer;	chr13:79731722	chr13:79406309~79424328:+
THCA	cis	rs3782123	0.514	rs11246009	ENSG00000277290.1	RP11-326C3.16	-4.37	1.56e-05	0.00153	-0.26	-0.2	Red cell distribution width;Glycated hemoglobin levels;	chr11:223733	chr11:243099~243483:-
THCA	cis	rs17123764	0.818	rs7953911	ENSG00000257464.1	RP11-161H23.8	-4.37	1.56e-05	0.00153	-0.32	-0.2	Intelligence (multi-trait analysis);	chr12:49554717	chr12:49442424~49442652:-
THCA	cis	rs3764021	0.87	rs2401395	ENSG00000214776.8	RP11-726G1.1	4.37	1.56e-05	0.00153	0.24	0.2	Type 1 diabetes;	chr12:9726944	chr12:9467552~9576275:+
THCA	cis	rs9314614	0.934	rs2978893	ENSG00000245857.2	GS1-24F4.2	4.37	1.56e-05	0.00153	0.25	0.2	White blood cell count (basophil);IgA nephropathy;	chr8:6838495	chr8:6835554~6885276:+
THCA	cis	rs7045881	0.733	rs62544412	ENSG00000254396.1	RP11-56F10.3	4.37	1.56e-05	0.00153	0.36	0.2	Schizophrenia;	chr9:26885822	chr9:27102630~27104728:+
THCA	cis	rs34467563	0.626	rs2640818	ENSG00000253105.4	KB-1448A5.1	4.37	1.56e-05	0.00153	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96363849	chr8:96371865~96387438:-
THCA	cis	rs34467563	0.626	rs2640816	ENSG00000253105.4	KB-1448A5.1	4.37	1.56e-05	0.00153	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96364474	chr8:96371865~96387438:-
THCA	cis	rs34467563	0.626	rs2678332	ENSG00000253105.4	KB-1448A5.1	4.37	1.56e-05	0.00153	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96364752	chr8:96371865~96387438:-
THCA	cis	rs34467563	0.626	rs2678333	ENSG00000253105.4	KB-1448A5.1	4.37	1.56e-05	0.00153	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96364989	chr8:96371865~96387438:-
THCA	cis	rs34467563	0.626	rs2640815	ENSG00000253105.4	KB-1448A5.1	4.37	1.56e-05	0.00153	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96365017	chr8:96371865~96387438:-
THCA	cis	rs6878727	0.665	rs256851	ENSG00000253807.4	LINC01170	4.37	1.56e-05	0.00153	0.18	0.2	Breast cancer;	chr5:124326984	chr5:124059794~124405079:-
THCA	cis	rs6494488	0.5	rs7173216	ENSG00000259635.1	AC100830.3	-4.36	1.56e-05	0.00153	-0.47	-0.2	Coronary artery disease;	chr15:64730957	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744725	ENSG00000259635.1	AC100830.3	-4.36	1.56e-05	0.00153	-0.47	-0.2	Coronary artery disease;	chr15:64731754	chr15:64701248~64719602:+
THCA	cis	rs3733585	0.631	rs3822236	ENSG00000261490.1	RP11-448G15.3	-4.36	1.56e-05	0.00153	-0.13	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10118337	chr4:10068089~10073019:-
THCA	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	4.36	1.57e-05	0.00153	0.24	0.2	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
THCA	cis	rs79461387	1	rs79461387	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00153	0.21	0.2	Neutrophil percentage of white cells;	chr17:30841059	chr17:30792372~30792833:+
THCA	cis	rs79461387	1	rs75637630	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00153	0.21	0.2	Neutrophil percentage of white cells;	chr17:30841060	chr17:30792372~30792833:+
THCA	cis	rs79461387	1	rs76947600	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00153	0.21	0.2	Neutrophil percentage of white cells;	chr17:30841061	chr17:30792372~30792833:+
THCA	cis	rs79461387	1	rs117529210	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00153	0.21	0.2	Neutrophil percentage of white cells;	chr17:30841062	chr17:30792372~30792833:+
THCA	cis	rs3796352	1	rs17052727	ENSG00000242142.1	SERBP1P3	-4.36	1.57e-05	0.00153	-0.35	-0.2	Immune reponse to smallpox (secreted IL-2);	chr3:53036898	chr3:53064283~53065091:-
THCA	cis	rs10946940	0.965	rs6915266	ENSG00000216915.2	RP1-97D16.1	4.36	1.57e-05	0.00153	0.27	0.2	Systemic lupus erythematosus;	chr6:27560864	chr6:27737000~27738494:-
THCA	cis	rs6600671	1	rs11249351	ENSG00000270231.3	NBPF8P	4.36	1.57e-05	0.00153	0.17	0.2	Hip geometry;	chr1:121430082	chr1:120436353~120467739:+
THCA	cis	rs868036	0.609	rs2127163	ENSG00000270964.1	RP11-502I4.3	-4.36	1.57e-05	0.00153	-0.19	-0.2	Restless legs syndrome;	chr15:67798504	chr15:67541072~67542604:-
THCA	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	4.36	1.57e-05	0.00153	0.25	0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
THCA	cis	rs77637988	0.578	rs7576964	ENSG00000202227.1	RNU6-282P	4.36	1.57e-05	0.00153	0.21	0.2	Joint mobility (Beighton score);	chr2:48374309	chr2:48501922~48502024:-
THCA	cis	rs375066	0.935	rs108775	ENSG00000278917.1	RP11-15A1.4	-4.36	1.57e-05	0.00153	-0.17	-0.2	Breast cancer;	chr19:43901770	chr19:43891233~43895411:+
THCA	cis	rs2439831	0.681	rs511673	ENSG00000205771.5	CATSPER2P1	-4.36	1.57e-05	0.00154	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43326665	chr15:43726918~43747094:-
THCA	cis	rs564343	0.563	rs493320	ENSG00000255320.1	RP11-755F10.1	-4.36	1.57e-05	0.00154	-0.25	-0.2	Obesity (early onset extreme);	chr11:66064896	chr11:66244840~66246239:-
THCA	cis	rs1061377	0.513	rs2566163	ENSG00000249685.1	RP11-360F5.3	4.36	1.57e-05	0.00154	0.28	0.2	Uric acid levels;	chr4:39128345	chr4:39133913~39135608:+
THCA	cis	rs7474896	1	rs11011317	ENSG00000263064.2	RP11-291L22.7	4.36	1.57e-05	0.00154	0.32	0.2	Obesity (extreme);	chr10:37666861	chr10:38448689~38448949:+
THCA	cis	rs10090774	0.932	rs11998619	ENSG00000279766.1	RP11-642A1.2	-4.36	1.57e-05	0.00154	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140885597	chr8:140572142~140572812:-
THCA	cis	rs2281636	0.931	rs2300984	ENSG00000233690.1	EBAG9P1	4.36	1.57e-05	0.00154	0.19	0.2	Obesity-related traits;	chr10:99717100	chr10:99697407~99697949:-
THCA	cis	rs2281636	0.894	rs2300985	ENSG00000233690.1	EBAG9P1	4.36	1.57e-05	0.00154	0.19	0.2	Obesity-related traits;	chr10:99717148	chr10:99697407~99697949:-
THCA	cis	rs227275	0.525	rs9917919	ENSG00000248971.2	KRT8P46	-4.36	1.57e-05	0.00154	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102728746~102730171:-
THCA	cis	rs9341808	0.667	rs2490251	ENSG00000272129.1	RP11-250B2.6	4.36	1.57e-05	0.00154	0.25	0.2	Sitting height ratio;	chr6:80185447	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.628	rs2490245	ENSG00000272129.1	RP11-250B2.6	4.36	1.57e-05	0.00154	0.25	0.2	Sitting height ratio;	chr6:80182710	chr6:80355424~80356859:+
THCA	cis	rs8031584	0.872	rs11634761	ENSG00000270015.1	RP11-540B6.6	-4.36	1.57e-05	0.00154	-0.15	-0.2	Huntington's disease progression;	chr15:30950970	chr15:30926514~30928407:+
THCA	cis	rs911555	0.655	rs10149470	ENSG00000269958.1	RP11-73M18.8	4.36	1.57e-05	0.00154	0.18	0.2	Intelligence (multi-trait analysis);	chr14:103551616	chr14:103696353~103697163:+
THCA	cis	rs11153306	0.677	rs3777921	ENSG00000231889.6	TRAF3IP2-AS1	-4.36	1.57e-05	0.00154	-0.17	-0.2	Tonsillectomy;	chr6:111603207	chr6:111483511~111598302:+
THCA	cis	rs9863	0.861	rs9971695	ENSG00000270028.1	RP11-380L11.4	4.36	1.57e-05	0.00154	0.21	0.2	White blood cell count;	chr12:123928944	chr12:123925461~123926083:-
THCA	cis	rs9863	0.827	rs4930706	ENSG00000270028.1	RP11-380L11.4	4.36	1.57e-05	0.00154	0.21	0.2	White blood cell count;	chr12:123932791	chr12:123925461~123926083:-
THCA	cis	rs4722166	0.597	rs1554606	ENSG00000225541.1	AC002480.5	-4.36	1.57e-05	0.00154	-0.24	-0.2	Lung cancer;	chr7:22729088	chr7:22571607~22661792:-
THCA	cis	rs2286503	0.966	rs6949233	ENSG00000226329.2	AC005682.6	4.36	1.57e-05	0.00154	0.24	0.2	Fibrinogen;	chr7:22818572	chr7:22863874~22881350:-
THCA	cis	rs13126694	0.71	rs9995402	ENSG00000248429.4	RP11-597D13.9	4.36	1.57e-05	0.00154	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158105262	chr4:158170752~158202877:+
THCA	cis	rs13126694	0.71	rs34237515	ENSG00000248429.4	RP11-597D13.9	4.36	1.57e-05	0.00154	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158105607	chr4:158170752~158202877:+
THCA	cis	rs7260598	0.539	rs75624869	ENSG00000268442.1	CTD-2027I19.2	4.36	1.57e-05	0.00154	0.29	0.2	Response to taxane treatment (placlitaxel);	chr19:23788844	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.502	rs80285843	ENSG00000268442.1	CTD-2027I19.2	4.36	1.57e-05	0.00154	0.29	0.2	Response to taxane treatment (placlitaxel);	chr19:23791663	chr19:24162370~24163425:-
THCA	cis	rs274567	0.599	rs11242110	ENSG00000224431.1	AC063976.7	-4.36	1.57e-05	0.00154	-0.16	-0.2	Blood metabolite levels;	chr5:132408085	chr5:132199456~132203487:+
THCA	cis	rs9868809	0.505	rs28793701	ENSG00000270441.1	RP11-694I15.7	4.36	1.57e-05	0.00154	0.27	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48725250	chr3:49140086~49160851:-
THCA	cis	rs72928364	0.872	rs13064121	ENSG00000256628.3	ZBTB11-AS1	4.36	1.57e-05	0.00154	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100991869	chr3:101676475~101679217:+
THCA	cis	rs795484	0.963	rs1726392	ENSG00000275409.1	RP11-131L12.4	-4.36	1.57e-05	0.00154	-0.17	-0.2	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118161120	chr12:118430147~118430699:+
THCA	cis	rs7989336	0.663	rs3886692	ENSG00000247400.3	DNAJC3-AS1	-4.36	1.57e-05	0.00154	-0.12	-0.2	Obesity;	chr13:96317753	chr13:95648733~95676925:-
THCA	cis	rs27434	0.66	rs26493	ENSG00000272109.1	CTD-2260A17.3	-4.36	1.57e-05	0.00154	-0.33	-0.2	Ankylosing spondylitis;	chr5:96819615	chr5:96804353~96806105:+
THCA	cis	rs11633886	0.934	rs2413791	ENSG00000273972.1	CTD-2306A12.1	-4.36	1.57e-05	0.00154	-0.21	-0.2	Diisocyanate-induced asthma;	chr15:45801195	chr15:45702640~45703183:+
THCA	cis	rs453301	0.658	rs3855900	ENSG00000233609.3	RP11-62H7.2	-4.36	1.57e-05	0.00154	-0.19	-0.2	Joint mobility (Beighton score);	chr8:9044411	chr8:8961200~8979025:+
THCA	cis	rs9878978	0.963	rs62233814	ENSG00000237990.3	CNTN4-AS1	4.36	1.57e-05	0.00154	0.22	0.2	Blood pressure (smoking interaction);	chr3:2440094	chr3:3039033~3069242:-
THCA	cis	rs8177876	0.915	rs8059692	ENSG00000261061.1	RP11-303E16.2	-4.36	1.57e-05	0.00154	-0.33	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81030770~81031485:+
THCA	cis	rs62158800	0.925	rs62158804	ENSG00000224568.1	AC096669.3	4.36	1.57e-05	0.00154	0.4	0.2	Facial morphology (factor 22);	chr2:107594974	chr2:107529487~107556326:+
THCA	cis	rs7572733	0.515	rs1356542	ENSG00000231621.1	AC013264.2	-4.36	1.57e-05	0.00154	-0.21	-0.2	Dermatomyositis;	chr2:197970978	chr2:197197991~197199273:+
THCA	cis	rs5758659	0.652	rs133303	ENSG00000205702.9	CYP2D7	4.36	1.57e-05	0.00154	0.15	0.2	Cognitive function;	chr22:41999238	chr22:42140203~42144577:-
THCA	cis	rs1371614	0.632	rs7589627	ENSG00000272148.1	RP11-195B17.1	4.36	1.58e-05	0.00154	0.18	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26936918	chr2:27062428~27062907:-
THCA	cis	rs1204798	0.588	rs2228547	ENSG00000237021.2	RP3-486I3.7	-4.36	1.58e-05	0.00154	-0.28	-0.2	Dental caries;	chr6:116120483	chr6:116254207~116256743:+
THCA	cis	rs13434995	0.589	rs496055	ENSG00000249700.7	SRD5A3-AS1	-4.36	1.58e-05	0.00154	-0.29	-0.2	Adiponectin levels;	chr4:55383670	chr4:55363971~55395847:-
THCA	cis	rs4713118	0.868	rs7756968	ENSG00000220721.1	OR1F12	4.36	1.58e-05	0.00154	0.27	0.2	Parkinson's disease;	chr6:27767175	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.826	rs2893929	ENSG00000220721.1	OR1F12	4.36	1.58e-05	0.00154	0.27	0.2	Parkinson's disease;	chr6:27770953	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.666	rs4140646	ENSG00000220721.1	OR1F12	4.36	1.58e-05	0.00154	0.27	0.2	Parkinson's disease;	chr6:27771022	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.666	rs2893930	ENSG00000220721.1	OR1F12	4.36	1.58e-05	0.00154	0.27	0.2	Parkinson's disease;	chr6:27771027	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.868	rs742047	ENSG00000220721.1	OR1F12	4.36	1.58e-05	0.00154	0.27	0.2	Parkinson's disease;	chr6:27771601	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.868	rs760587	ENSG00000220721.1	OR1F12	4.36	1.58e-05	0.00154	0.27	0.2	Parkinson's disease;	chr6:27772521	chr6:28073316~28074233:+
THCA	cis	rs11157436	0.958	rs2204963	ENSG00000211812.1	TRAV26-2	-4.36	1.58e-05	0.00154	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22202583~22203368:+
THCA	cis	rs11157436	0.958	rs61972229	ENSG00000211812.1	TRAV26-2	-4.36	1.58e-05	0.00154	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22202583~22203368:+
THCA	cis	rs11157436	0.958	rs17183301	ENSG00000211812.1	TRAV26-2	-4.36	1.58e-05	0.00154	-0.18	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22202583~22203368:+
THCA	cis	rs807029	0.533	rs12571302	ENSG00000236662.1	RP11-108L7.4	4.36	1.58e-05	0.00154	0.21	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100980507~100985614:-
THCA	cis	rs807029	0.533	rs2863095	ENSG00000236662.1	RP11-108L7.4	4.36	1.58e-05	0.00154	0.21	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100980507~100985614:-
THCA	cis	rs227275	0.525	rs13150426	ENSG00000248971.2	KRT8P46	-4.36	1.58e-05	0.00154	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs28445579	ENSG00000248971.2	KRT8P46	-4.36	1.58e-05	0.00154	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102728746~102730171:-
THCA	cis	rs2302464	1	rs10011868	ENSG00000214846.4	RP11-115L11.1	4.36	1.58e-05	0.00154	0.51	0.2	Cerebrospinal fluid biomarker levels;	chr4:15659205	chr4:15730962~15731627:-
THCA	cis	rs6870983	0.895	rs7442885	ENSG00000247828.6	TMEM161B-AS1	4.36	1.58e-05	0.00154	0.19	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88387060	chr5:88268895~88436685:+
THCA	cis	rs9329221	0.683	rs814359	ENSG00000261451.1	RP11-981G7.1	-4.36	1.58e-05	0.00154	-0.24	-0.2	Neuroticism;	chr8:10025622	chr8:10433672~10438312:+
THCA	cis	rs9465539	0.597	rs9465523	ENSG00000228412.5	RP4-625H18.2	-4.36	1.58e-05	0.00154	-0.34	-0.2	Neuroticism;	chr6:19780725	chr6:19802164~19804752:-
THCA	cis	rs9926296	0.624	rs1110331	ENSG00000274627.1	RP11-104N10.2	4.36	1.58e-05	0.00154	0.19	0.2	Vitiligo;	chr16:89707988	chr16:89516797~89522217:+
THCA	cis	rs10043228	1	rs10079394	ENSG00000248445.4	SEMA6A-AS1	-4.36	1.58e-05	0.00154	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116265222	chr5:116447547~116508276:+
THCA	cis	rs9959145	0.706	rs28663159	ENSG00000267199.1	RP11-861E21.2	4.36	1.58e-05	0.00154	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12612441	chr18:12438890~12448205:+
THCA	cis	rs516805	0.683	rs502071	ENSG00000279114.1	RP3-425C14.5	-4.36	1.58e-05	0.00154	-0.27	-0.2	Lymphocyte counts;	chr6:122417917	chr6:122471923~122484161:+
THCA	cis	rs453301	0.686	rs10217044	ENSG00000254153.1	CTA-398F10.2	4.36	1.58e-05	0.00154	0.21	0.2	Joint mobility (Beighton score);	chr8:9037242	chr8:8456909~8461337:-
THCA	cis	rs1979679	0.879	rs1581630	ENSG00000247934.4	RP11-967K21.1	4.36	1.58e-05	0.00154	0.19	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28466378	chr12:28163298~28190738:-
THCA	cis	rs7178572	0.625	rs12904553	ENSG00000259362.2	RP11-307C19.1	-4.36	1.58e-05	0.00154	-0.24	-0.2	Type 2 diabetes;	chr15:77553617	chr15:77525540~77534110:+
THCA	cis	rs9890032	0.542	rs11867227	ENSG00000263531.1	RP13-753N3.1	-4.36	1.58e-05	0.00154	-0.28	-0.2	Hip circumference adjusted for BMI;	chr17:30923893	chr17:30863921~30864940:-
THCA	cis	rs6496932	0.676	rs7183651	ENSG00000259630.2	CTD-2262B20.1	-4.36	1.58e-05	0.00154	-0.24	-0.2	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85415228~85415633:+
THCA	cis	rs755249	0.508	rs586057	ENSG00000182109.6	RP11-69E11.4	4.36	1.58e-05	0.00155	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39522280~39546187:-
THCA	cis	rs454217	0.846	rs418571	ENSG00000277851.1	RP11-756G20.1	4.36	1.58e-05	0.00155	0.2	0.2	Smoking quantity;	chr12:92330380	chr12:92247756~92363832:-
THCA	cis	rs4705952	0.887	rs4705953	ENSG00000233006.5	AC034220.3	4.36	1.58e-05	0.00155	0.18	0.2	C-reactive protein levels;	chr5:132506483	chr5:132311285~132369916:-
THCA	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	4.36	1.58e-05	0.00155	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs67555188	ENSG00000215032.2	GNL3LP1	4.36	1.58e-05	0.00155	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs67858932	ENSG00000215032.2	GNL3LP1	4.36	1.58e-05	0.00155	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60891935~60893577:-
THCA	cis	rs1232027	0.666	rs1677666	ENSG00000249655.1	CTC-325J23.2	4.36	1.58e-05	0.00155	0.22	0.2	Huntington's disease progression;	chr5:80626006	chr5:80630313~80631590:-
THCA	cis	rs12149695	0.735	rs28456036	ENSG00000259940.2	CTD-3203P2.1	-4.36	1.58e-05	0.00155	-0.22	-0.2	Gut microbiota (bacterial taxa);	chr16:27233227	chr16:27213308~27214993:-
THCA	cis	rs6870983	0.947	rs2410767	ENSG00000247828.6	TMEM161B-AS1	4.36	1.58e-05	0.00155	0.19	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88409451	chr5:88268895~88436685:+
THCA	cis	rs10484434	0.901	rs1800758	ENSG00000272810.1	U91328.22	4.36	1.58e-05	0.00155	0.21	0.2	HIV-1 viral setpoint;	chr6:26093008	chr6:26013241~26013757:+
THCA	cis	rs416603	0.967	rs11644184	ENSG00000263080.1	RP11-485G7.5	-4.36	1.58e-05	0.00155	-0.23	-0.2	Type 1 diabetes;	chr16:11271247	chr16:11341809~11345211:-
THCA	cis	rs7209700	0.662	rs8066295	ENSG00000228782.6	CTD-2026D20.3	4.36	1.58e-05	0.00155	0.21	0.2	IgG glycosylation;	chr17:47270837	chr17:47450568~47492492:-
THCA	cis	rs1913185	0.787	rs67671074	ENSG00000240032.1	RP11-274H2.3	-4.36	1.58e-05	0.00155	-0.3	-0.2	Obesity-related traits;	chr3:146085476	chr3:146066344~146069185:-
THCA	cis	rs8028182	0.636	rs4886715	ENSG00000260269.4	CTD-2323K18.1	-4.36	1.58e-05	0.00155	-0.3	-0.2	Sudden cardiac arrest;	chr15:75539108	chr15:75527150~75601205:-
THCA	cis	rs4767841	0.565	rs203332	ENSG00000248636.5	RP11-768F21.1	4.36	1.58e-05	0.00155	0.2	0.2	Urgency urinary incontinence;	chr12:119772533	chr12:119387987~119668079:-
THCA	cis	rs875971	0.66	rs801192	ENSG00000272831.1	RP11-792A8.4	-4.36	1.58e-05	0.00155	-0.12	-0.2	Aortic root size;	chr7:66566965	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs801190	ENSG00000272831.1	RP11-792A8.4	-4.36	1.58e-05	0.00155	-0.12	-0.2	Aortic root size;	chr7:66568046	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs3857686	ENSG00000272831.1	RP11-792A8.4	-4.36	1.58e-05	0.00155	-0.12	-0.2	Aortic root size;	chr7:66571204	chr7:66739829~66740385:-
THCA	cis	rs875971	0.638	rs6460305	ENSG00000272831.1	RP11-792A8.4	-4.36	1.58e-05	0.00155	-0.12	-0.2	Aortic root size;	chr7:66595421	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs10272357	ENSG00000272831.1	RP11-792A8.4	-4.36	1.58e-05	0.00155	-0.12	-0.2	Aortic root size;	chr7:66598087	chr7:66739829~66740385:-
THCA	cis	rs2904524	1	rs1983437	ENSG00000257815.4	RP11-611E13.2	-4.36	1.58e-05	0.00155	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70329989	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs2272180	ENSG00000257815.4	RP11-611E13.2	-4.36	1.58e-05	0.00155	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70330227	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs7309116	ENSG00000257815.4	RP11-611E13.2	-4.36	1.58e-05	0.00155	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70341314	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs9804870	ENSG00000257815.4	RP11-611E13.2	-4.36	1.58e-05	0.00155	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70346955	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.881	rs12316184	ENSG00000257815.4	RP11-611E13.2	-4.36	1.58e-05	0.00155	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70348121	chr12:69904033~70243360:-
THCA	cis	rs10510102	0.516	rs3936070	ENSG00000226864.1	ATE1-AS1	4.36	1.58e-05	0.00155	0.34	0.2	Breast cancer;	chr10:121974440	chr10:121928312~121951965:+
THCA	cis	rs12541437	1	rs3020156	ENSG00000253327.2	RAD21-AS1	4.36	1.58e-05	0.00155	0.21	0.2	Gut microbiome composition (winter);	chr8:116909116	chr8:116874424~116876868:+
THCA	cis	rs6496932	0.663	rs4843051	ENSG00000259630.2	CTD-2262B20.1	-4.36	1.58e-05	0.00155	-0.24	-0.2	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85415228~85415633:+
THCA	cis	rs8031584	0.678	rs798086	ENSG00000259845.1	HERC2P10	-4.36	1.58e-05	0.00155	-0.28	-0.2	Huntington's disease progression;	chr15:30837008	chr15:30815271~30844153:+
THCA	cis	rs2129782	0.702	rs6982579	ENSG00000253553.4	RP11-586K2.1	4.36	1.59e-05	0.00155	0.36	0.2	Electrodermal activity;	chr8:88580424	chr8:88326836~88737134:+
THCA	cis	rs27434	0.51	rs27038	ENSG00000272109.1	CTD-2260A17.3	-4.36	1.59e-05	0.00155	-0.32	-0.2	Ankylosing spondylitis;	chr5:96777250	chr5:96804353~96806105:+
THCA	cis	rs6696239	1	rs10916160	ENSG00000227711.2	RP11-275O4.5	4.36	1.59e-05	0.00155	0.27	0.2	Height;	chr1:227540518	chr1:227509028~227520477:-
THCA	cis	rs17685	0.712	rs6976236	ENSG00000230882.1	AC005077.14	4.36	1.59e-05	0.00155	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76111769	chr7:76071469~76074963:-
THCA	cis	rs12478296	1	rs56136197	ENSG00000220804.7	AC093642.5	4.36	1.59e-05	0.00155	0.22	0.2	Obesity-related traits;	chr2:242101726	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs56387669	ENSG00000220804.7	AC093642.5	4.36	1.59e-05	0.00155	0.22	0.2	Obesity-related traits;	chr2:242101738	chr2:242088633~242160153:+
THCA	cis	rs4722166	0.597	rs2069845	ENSG00000225541.1	AC002480.5	-4.36	1.59e-05	0.00155	-0.24	-0.2	Lung cancer;	chr7:22730530	chr7:22571607~22661792:-
THCA	cis	rs875971	0.66	rs6460308	ENSG00000223473.2	GS1-124K5.3	-4.36	1.59e-05	0.00155	-0.13	-0.2	Aortic root size;	chr7:66619753	chr7:66491049~66493566:-
THCA	cis	rs9818758	0.556	rs11716614	ENSG00000270441.1	RP11-694I15.7	4.36	1.59e-05	0.00155	0.31	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48979775	chr3:49140086~49160851:-
THCA	cis	rs4819052	1	rs733739	ENSG00000273796.1	LL21NC02-21A1.1	-4.36	1.59e-05	0.00155	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45403809~45404369:-
THCA	cis	rs970548	0.954	rs2291429	ENSG00000230869.1	CTGLF10P	4.36	1.59e-05	0.00155	0.25	0.2	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45463433	chr10:45678692~45700532:+
THCA	cis	rs4759375	1	rs28532037	ENSG00000256092.2	RP13-942N8.1	4.36	1.59e-05	0.00155	0.23	0.2	HDL cholesterol;	chr12:123398859	chr12:123363868~123366113:+
THCA	cis	rs12216545	0.765	rs1851435	ENSG00000241134.3	BET1P1	-4.36	1.59e-05	0.00155	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150531697	chr7:150749736~150750094:+
THCA	cis	rs6442522	0.678	rs13085575	ENSG00000249786.6	EAF1-AS1	4.36	1.59e-05	0.00155	0.2	0.2	Uric acid levels;	chr3:15457823	chr3:15436171~15455940:-
THCA	cis	rs858239	0.899	rs7794684	ENSG00000230042.1	AK3P3	-4.36	1.59e-05	0.00155	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23129178~23129841:+
THCA	cis	rs12908161	0.959	rs12906348	ENSG00000188388.10	GOLGA6L3	4.36	1.59e-05	0.00155	0.26	0.2	Schizophrenia;	chr15:84786190	chr15:85240472~85247170:+
THCA	cis	rs12908161	0.959	rs34342559	ENSG00000188388.10	GOLGA6L3	4.36	1.59e-05	0.00155	0.26	0.2	Schizophrenia;	chr15:84788040	chr15:85240472~85247170:+
THCA	cis	rs12908161	0.959	rs62019472	ENSG00000188388.10	GOLGA6L3	4.36	1.59e-05	0.00155	0.26	0.2	Schizophrenia;	chr15:84788262	chr15:85240472~85247170:+
THCA	cis	rs12908161	0.959	rs35557864	ENSG00000188388.10	GOLGA6L3	4.36	1.59e-05	0.00155	0.26	0.2	Schizophrenia;	chr15:84788398	chr15:85240472~85247170:+
THCA	cis	rs17772222	0.682	rs10132554	ENSG00000222990.1	RNU4-22P	4.36	1.59e-05	0.00155	0.24	0.2	Coronary artery calcification;	chr14:88473090	chr14:88513498~88513663:+
THCA	cis	rs61270009	0.955	rs780397	ENSG00000247828.6	TMEM161B-AS1	-4.36	1.59e-05	0.00155	-0.18	-0.2	Depressive symptoms;	chr5:88233841	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.874	rs780403	ENSG00000247828.6	TMEM161B-AS1	-4.36	1.59e-05	0.00155	-0.18	-0.2	Depressive symptoms;	chr5:88244989	chr5:88268895~88436685:+
THCA	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	4.36	1.59e-05	0.00155	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
THCA	cis	rs77972916	0.536	rs6751209	ENSG00000234936.1	AC010883.5	4.36	1.59e-05	0.00155	0.22	0.2	Granulocyte percentage of myeloid white cells;	chr2:43361163	chr2:43229573~43233394:+
THCA	cis	rs868036	0.681	rs2241423	ENSG00000270964.1	RP11-502I4.3	-4.36	1.59e-05	0.00155	-0.18	-0.2	Restless legs syndrome;	chr15:67794500	chr15:67541072~67542604:-
THCA	cis	rs11722779	0.933	rs7695096	ENSG00000248971.2	KRT8P46	-4.36	1.59e-05	0.00155	-0.24	-0.2	Schizophrenia;	chr4:103011399	chr4:102728746~102730171:-
THCA	cis	rs2777491	0.872	rs11267024	ENSG00000247556.5	OIP5-AS1	4.36	1.59e-05	0.00155	0.17	0.2	Ulcerative colitis;	chr15:41284043	chr15:41283990~41309737:+
THCA	cis	rs12681963	0.688	rs55725858	ENSG00000248159.1	HSPA8P11	4.36	1.59e-05	0.00155	0.36	0.2	Migraine;	chr8:30194695	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.541	rs56339843	ENSG00000248159.1	HSPA8P11	4.36	1.59e-05	0.00155	0.36	0.2	Migraine;	chr8:30194766	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs73242337	ENSG00000248159.1	HSPA8P11	4.36	1.59e-05	0.00155	0.36	0.2	Migraine;	chr8:30200526	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs73242338	ENSG00000248159.1	HSPA8P11	4.36	1.59e-05	0.00155	0.36	0.2	Migraine;	chr8:30200574	chr8:30237382~30240997:+
THCA	cis	rs10043228	1	rs10055868	ENSG00000248445.4	SEMA6A-AS1	-4.36	1.59e-05	0.00155	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116135915	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12515466	ENSG00000248445.4	SEMA6A-AS1	-4.36	1.59e-05	0.00155	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116256180	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs10073364	ENSG00000248445.4	SEMA6A-AS1	-4.36	1.59e-05	0.00155	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116256885	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs10036292	ENSG00000248445.4	SEMA6A-AS1	-4.36	1.59e-05	0.00155	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116260174	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs10043228	ENSG00000248445.4	SEMA6A-AS1	-4.36	1.59e-05	0.00155	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116261351	chr5:116447547~116508276:+
THCA	cis	rs7191700	0.511	rs8043625	ENSG00000263080.1	RP11-485G7.5	-4.36	1.59e-05	0.00155	-0.23	-0.2	Multiple sclerosis;	chr16:11268038	chr16:11341809~11345211:-
THCA	cis	rs453301	0.686	rs6987107	ENSG00000254153.1	CTA-398F10.2	4.36	1.59e-05	0.00155	0.21	0.2	Joint mobility (Beighton score);	chr8:9036071	chr8:8456909~8461337:-
THCA	cis	rs7045881	0.877	rs12338262	ENSG00000254396.1	RP11-56F10.3	-4.36	1.59e-05	0.00155	-0.28	-0.2	Schizophrenia;	chr9:26800361	chr9:27102630~27104728:+
THCA	cis	rs734999	0.588	rs10910098	ENSG00000225931.3	RP3-395M20.7	4.36	1.59e-05	0.00155	0.23	0.2	Ulcerative colitis;	chr1:2601811	chr1:2566410~2569888:+
THCA	cis	rs734999	0.588	rs60520190	ENSG00000225931.3	RP3-395M20.7	4.36	1.59e-05	0.00155	0.23	0.2	Ulcerative colitis;	chr1:2602267	chr1:2566410~2569888:+
THCA	cis	rs734999	0.566	rs6424092	ENSG00000225931.3	RP3-395M20.7	-4.36	1.59e-05	0.00155	-0.23	-0.2	Ulcerative colitis;	chr1:2601460	chr1:2566410~2569888:+
THCA	cis	rs972578	0.691	rs5759057	ENSG00000274717.1	RP1-47A17.1	-4.36	1.59e-05	0.00155	-0.21	-0.2	Mean platelet volume;	chr22:42958124	chr22:42791814~42794313:-
THCA	cis	rs453301	0.624	rs6987558	ENSG00000254340.1	RP11-10A14.3	4.36	1.59e-05	0.00155	0.21	0.2	Joint mobility (Beighton score);	chr8:9005011	chr8:9141424~9145435:+
THCA	cis	rs752590	0.806	rs874898	ENSG00000227359.1	AC017074.2	4.36	1.59e-05	0.00155	0.24	0.2	Mucinous ovarian carcinoma;	chr2:113216619	chr2:113677702~113704078:-
THCA	cis	rs1055129	0.537	rs10852766	ENSG00000267801.1	RP11-552F3.9	-4.36	1.59e-05	0.00155	-0.23	-0.2	White matter hyperintensity burden;	chr17:75955783	chr17:75876372~75879546:+
THCA	cis	rs17221829	0.965	rs10830364	ENSG00000280385.1	AP000648.5	-4.36	1.59e-05	0.00155	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89725464	chr11:90193614~90198120:+
THCA	cis	rs860295	0.702	rs12041534	ENSG00000160766.13	GBAP1	4.36	1.59e-05	0.00155	0.22	0.2	Body mass index;	chr1:155437305	chr1:155213821~155227422:-
THCA	cis	rs61270009	0.955	rs11743103	ENSG00000247828.6	TMEM161B-AS1	-4.36	1.59e-05	0.00155	-0.17	-0.2	Depressive symptoms;	chr5:88380145	chr5:88268895~88436685:+
THCA	cis	rs801193	1	rs7782320	ENSG00000272831.1	RP11-792A8.4	4.36	1.59e-05	0.00155	0.12	0.2	Aortic root size;	chr7:66712111	chr7:66739829~66740385:-
THCA	cis	rs8105895	0.935	rs8110289	ENSG00000269345.1	VN1R85P	4.36	1.59e-05	0.00155	0.27	0.2	Body mass index (change over time);	chr19:22056915	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.736	rs2359835	ENSG00000269345.1	VN1R85P	4.36	1.59e-05	0.00155	0.27	0.2	Body mass index (change over time);	chr19:22059888	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.733	rs62110979	ENSG00000269345.1	VN1R85P	4.36	1.59e-05	0.00155	0.27	0.2	Body mass index (change over time);	chr19:22062350	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7252220	ENSG00000269345.1	VN1R85P	4.36	1.59e-05	0.00155	0.27	0.2	Body mass index (change over time);	chr19:22062762	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62110981	ENSG00000269345.1	VN1R85P	4.36	1.59e-05	0.00155	0.27	0.2	Body mass index (change over time);	chr19:22063211	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62110985	ENSG00000269345.1	VN1R85P	4.36	1.59e-05	0.00155	0.27	0.2	Body mass index (change over time);	chr19:22073275	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62110987	ENSG00000269345.1	VN1R85P	4.36	1.59e-05	0.00155	0.27	0.2	Body mass index (change over time);	chr19:22074493	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62110988	ENSG00000269345.1	VN1R85P	4.36	1.59e-05	0.00155	0.27	0.2	Body mass index (change over time);	chr19:22077154	chr19:22174766~22175191:-
THCA	cis	rs9573567	0.609	rs9573553	ENSG00000261553.4	RP11-29G8.3	-4.36	1.59e-05	0.00155	-0.38	-0.2	Red blood cell count;Mean corpuscular volume;	chr13:75465192	chr13:75549773~75807120:+
THCA	cis	rs875971	0.619	rs12533585	ENSG00000272831.1	RP11-792A8.4	4.36	1.59e-05	0.00155	0.12	0.2	Aortic root size;	chr7:66519618	chr7:66739829~66740385:-
THCA	cis	rs10995505	0.589	rs4601646	ENSG00000232075.1	MRPL35P2	-4.36	1.59e-05	0.00156	-0.29	-0.2	Intelligence (multi-trait analysis);	chr10:63120520	chr10:63634317~63634827:-
THCA	cis	rs9487094	0.626	rs4141930	ENSG00000223537.2	RP5-919F19.5	-4.36	1.59e-05	0.00156	-0.2	-0.2	Height;	chr6:109739615	chr6:109487906~109506800:+
THCA	cis	rs10483853	0.806	rs10137332	ENSG00000258695.2	RP3-414A15.2	-4.36	1.59e-05	0.00156	-0.27	-0.2	Coronary artery calcification;	chr14:73316246	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.806	rs10220341	ENSG00000258695.2	RP3-414A15.2	-4.36	1.59e-05	0.00156	-0.27	-0.2	Coronary artery calcification;	chr14:73317727	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.806	rs11625692	ENSG00000258695.2	RP3-414A15.2	-4.36	1.59e-05	0.00156	-0.27	-0.2	Coronary artery calcification;	chr14:73329557	chr14:73522878~73530610:+
THCA	cis	rs911119	0.913	rs4815222	ENSG00000270001.1	RP11-218C14.8	4.36	1.59e-05	0.00156	0.29	0.2	Chronic kidney disease;	chr20:23596327	chr20:23631826~23632316:-
THCA	cis	rs4218	0.681	rs10518996	ENSG00000277144.1	RP11-59H7.4	-4.36	1.59e-05	0.00156	-0.27	-0.2	Social communication problems;	chr15:59085247	chr15:59115547~59116089:-
THCA	cis	rs972578	0.967	rs2038058	ENSG00000230319.1	AL022476.2	4.36	1.59e-05	0.00156	0.21	0.2	Mean platelet volume;	chr22:42938289	chr22:43038585~43052366:+
THCA	cis	rs10833905	1	rs7932620	ENSG00000246225.5	RP11-17A1.3	-4.36	1.59e-05	0.00156	-0.28	-0.2	Sudden cardiac arrest;	chr11:23003174	chr11:22829380~22945393:+
THCA	cis	rs9926296	0.681	rs12923946	ENSG00000260259.1	RP11-368I7.4	-4.36	1.59e-05	0.00156	-0.22	-0.2	Vitiligo;	chr16:89754672	chr16:89682620~89686569:-
THCA	cis	rs17508449	0.505	rs78491726	ENSG00000232450.1	RP4-730K3.3	-4.36	1.59e-05	0.00156	-0.28	-0.2	Leprosy;	chr1:113784847	chr1:113698884~113699631:-
THCA	cis	rs4356203	0.905	rs7107283	ENSG00000272034.1	SNORD14A	4.36	1.59e-05	0.00156	0.19	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17067856	chr11:17074654~17074744:-
THCA	cis	rs72928364	1	rs62275204	ENSG00000256628.3	ZBTB11-AS1	4.36	1.59e-05	0.00156	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100995762	chr3:101676475~101679217:+
THCA	cis	rs7560272	0.538	rs4852972	ENSG00000273245.1	RP11-434P11.2	-4.36	1.59e-05	0.00156	-0.23	-0.2	Schizophrenia;	chr2:73689545	chr2:73750256~73750786:-
THCA	cis	rs4713118	0.615	rs9348772	ENSG00000261839.1	RP1-265C24.8	4.36	1.59e-05	0.00156	0.2	0.2	Parkinson's disease;	chr6:27688311	chr6:28136849~28139678:+
THCA	cis	rs128738	0.5	rs743563	ENSG00000237714.1	P4HA2-AS1	-4.36	1.59e-05	0.00156	-0.3	-0.2	Giant cell arteritis;	chr5:132233713	chr5:132184876~132192808:+
THCA	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-4.36	1.59e-05	0.00156	-0.24	-0.2	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
THCA	cis	rs13126694	0.71	rs4631100	ENSG00000248429.4	RP11-597D13.9	4.36	1.59e-05	0.00156	0.21	0.2	Blood osmolality (transformed sodium);	chr4:157991162	chr4:158170752~158202877:+
THCA	cis	rs1232027	0.7	rs1677633	ENSG00000249655.1	CTC-325J23.2	4.36	1.59e-05	0.00156	0.22	0.2	Huntington's disease progression;	chr5:80632405	chr5:80630313~80631590:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000223473.2	GS1-124K5.3	-4.36	1.59e-05	0.00156	-0.13	-0.2	Aortic root size;	chr7:66603522	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs7807944	ENSG00000223473.2	GS1-124K5.3	-4.36	1.59e-05	0.00156	-0.13	-0.2	Aortic root size;	chr7:66622208	chr7:66491049~66493566:-
THCA	cis	rs875971	0.638	rs35986979	ENSG00000223473.2	GS1-124K5.3	-4.36	1.59e-05	0.00156	-0.13	-0.2	Aortic root size;	chr7:66624003	chr7:66491049~66493566:-
THCA	cis	rs4845570	1	rs4845356	ENSG00000249602.1	RP11-98D18.3	4.36	1.59e-05	0.00156	0.28	0.2	Coronary artery disease;	chr1:151786747	chr1:151763384~151769501:-
THCA	cis	rs914615	0.552	rs11264337	ENSG00000236675.1	MTX1P1	-4.36	1.59e-05	0.00156	-0.18	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155165974	chr1:155230975~155234325:+
THCA	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-4.36	1.6e-05	0.00156	-0.24	-0.2	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
THCA	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-4.36	1.6e-05	0.00156	-0.24	-0.2	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
THCA	cis	rs2281603	0.57	rs10145013	ENSG00000272909.1	CTD-2555O16.4	-4.36	1.6e-05	0.00156	-0.22	-0.2	Lymphocyte counts;	chr14:64474873	chr14:64440369~64442238:-
THCA	cis	rs6696239	1	rs10916162	ENSG00000227711.2	RP11-275O4.5	-4.36	1.6e-05	0.00156	-0.27	-0.2	Height;	chr1:227550092	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.868	rs74579475	ENSG00000227711.2	RP11-275O4.5	-4.36	1.6e-05	0.00156	-0.27	-0.2	Height;	chr1:227551606	chr1:227509028~227520477:-
THCA	cis	rs782212	0.514	rs1664410	ENSG00000227207.2	RPL31P12	4.36	1.6e-05	0.00156	0.31	0.2	Depression;	chr1:72466633	chr1:72301472~72301829:+
THCA	cis	rs782212	0.592	rs796698	ENSG00000227207.2	RPL31P12	4.36	1.6e-05	0.00156	0.31	0.2	Depression;	chr1:72472812	chr1:72301472~72301829:+
THCA	cis	rs12497850	0.931	rs11924597	ENSG00000228638.1	FCF1P2	-4.36	1.6e-05	0.00156	-0.21	-0.2	Parkinson's disease;	chr3:48900357	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.897	rs9850134	ENSG00000228638.1	FCF1P2	-4.36	1.6e-05	0.00156	-0.21	-0.2	Parkinson's disease;	chr3:48919714	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs9867373	ENSG00000228638.1	FCF1P2	-4.36	1.6e-05	0.00156	-0.21	-0.2	Parkinson's disease;	chr3:48923505	chr3:48290793~48291375:-
THCA	cis	rs875971	0.895	rs4145009	ENSG00000229886.1	RP5-1132H15.3	-4.36	1.6e-05	0.00156	-0.21	-0.2	Aortic root size;	chr7:66261628	chr7:66025126~66031544:-
THCA	cis	rs12931792	0.748	rs11150585	ENSG00000273724.1	RP11-347C12.12	4.36	1.6e-05	0.00156	0.21	0.2	Tonsillectomy;	chr16:30172965	chr16:30336400~30343336:+
THCA	cis	rs4356203	0.905	rs11821773	ENSG00000272034.1	SNORD14A	-4.36	1.6e-05	0.00156	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17095807	chr11:17074654~17074744:-
THCA	cis	rs11088226	0.681	rs1015047	ENSG00000186842.4	LINC00846	-4.36	1.6e-05	0.00156	-0.29	-0.2	Gastritis;	chr21:32577113	chr21:32572238~32575881:-
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000182586.6	LINC00334	-4.36	1.6e-05	0.00156	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45234340~45258730:+
THCA	cis	rs478304	0.903	rs61895677	ENSG00000255557.1	RP11-770G2.2	-4.36	1.6e-05	0.00156	-0.21	-0.2	Acne (severe);	chr11:65781944	chr11:65745729~65771585:+
THCA	cis	rs478304	0.934	rs12801731	ENSG00000255557.1	RP11-770G2.2	-4.36	1.6e-05	0.00156	-0.21	-0.2	Acne (severe);	chr11:65782135	chr11:65745729~65771585:+
THCA	cis	rs8031584	0.781	rs4779498	ENSG00000178081.11	ULK4P3	4.36	1.6e-05	0.00156	0.26	0.2	Huntington's disease progression;	chr15:30885273	chr15:30103720~30131757:+
THCA	cis	rs683257	0.683	rs9495859	ENSG00000234147.1	RP3-460G2.2	-4.36	1.6e-05	0.00156	-0.35	-0.2	Facial emotion recognition (angry faces);	chr6:140894388	chr6:140845958~140852924:-
THCA	cis	rs8067545	0.75	rs9897653	ENSG00000270091.1	RP11-78O7.2	-4.36	1.6e-05	0.00156	-0.14	-0.2	Schizophrenia;	chr17:20084611	chr17:19896590~19897287:-
THCA	cis	rs13034020	0.79	rs72809405	ENSG00000271889.1	RP11-493E12.1	-4.36	1.6e-05	0.00156	-0.29	-0.2	Hodgkin's lymphoma;	chr2:60946247	chr2:61151433~61162105:-
THCA	cis	rs972578	0.691	rs56013521	ENSG00000274717.1	RP1-47A17.1	-4.36	1.6e-05	0.00156	-0.21	-0.2	Mean platelet volume;	chr22:42964675	chr22:42791814~42794313:-
THCA	cis	rs7182948	0.957	rs17402569	ENSG00000259531.2	RP11-295H24.3	4.36	1.6e-05	0.00156	0.25	0.2	Lung adenocarcinoma;	chr15:49623209	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.957	rs28568399	ENSG00000259531.2	RP11-295H24.3	4.36	1.6e-05	0.00156	0.25	0.2	Lung adenocarcinoma;	chr15:49634253	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.957	rs28671247	ENSG00000259531.2	RP11-295H24.3	4.36	1.6e-05	0.00156	0.25	0.2	Lung adenocarcinoma;	chr15:49634896	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.957	rs17481696	ENSG00000259531.2	RP11-295H24.3	4.36	1.6e-05	0.00156	0.25	0.2	Lung adenocarcinoma;	chr15:49646554	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.957	rs9920705	ENSG00000259531.2	RP11-295H24.3	4.36	1.6e-05	0.00156	0.25	0.2	Lung adenocarcinoma;	chr15:49648560	chr15:49365124~49366685:-
THCA	cis	rs9902453	0.9	rs56195309	ENSG00000263370.1	RP11-68I3.5	4.36	1.6e-05	0.00156	0.26	0.2	Coffee consumption (cups per day);	chr17:30126735	chr17:29639627~29640825:+
THCA	cis	rs875971	0.505	rs2462573	ENSG00000275400.1	RP4-756H11.5	4.36	1.6e-05	0.00156	0.19	0.2	Aortic root size;	chr7:66042405	chr7:66553805~66554199:-
THCA	cis	rs17495987	0.63	rs17496524	ENSG00000219545.8	UMAD1	4.36	1.6e-05	0.00156	0.21	0.2	Tonsillectomy;	chr7:7868543	chr7:7640711~8004059:+
THCA	cis	rs6840258	0.64	rs11946293	ENSG00000251411.1	RP11-397E7.4	4.36	1.6e-05	0.00156	0.23	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87191788	chr4:86913266~86914817:-
THCA	cis	rs5742933	1	rs6719224	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.6e-05	0.00156	-0.27	-0.2	Ferritin levels;	chr2:189769545	chr2:189762704~189765556:+
THCA	cis	rs703842	0.892	rs1021469	ENSG00000270039.1	RP11-571M6.17	-4.36	1.6e-05	0.00156	-0.23	-0.2	Multiple sclerosis;	chr12:57814381	chr12:57803838~57804415:+
THCA	cis	rs9309473	0.95	rs13391258	ENSG00000273245.1	RP11-434P11.2	4.36	1.6e-05	0.00156	0.27	0.2	Metabolite levels;	chr2:73621806	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.898	rs6546861	ENSG00000273245.1	RP11-434P11.2	4.36	1.6e-05	0.00156	0.27	0.2	Metabolite levels;	chr2:73622734	chr2:73750256~73750786:-
THCA	cis	rs12126655	0.732	rs17020110	ENSG00000230489.1	VAV3-AS1	4.36	1.6e-05	0.00156	0.21	0.2	Plasma thyroid-stimulating hormone levels;	chr1:107811534	chr1:107964443~107994607:+
THCA	cis	rs858239	0.601	rs15775	ENSG00000226816.2	AC005082.12	4.36	1.6e-05	0.00156	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23206013~23208045:+
THCA	cis	rs1048886	0.938	rs2691488	ENSG00000271967.1	RP11-134K13.4	-4.36	1.6e-05	0.00156	-0.21	-0.2	Type 2 diabetes;	chr6:70578512	chr6:70596438~70596980:+
THCA	cis	rs4722166	0.564	rs1800797	ENSG00000225541.1	AC002480.5	-4.36	1.6e-05	0.00156	-0.26	-0.2	Lung cancer;	chr7:22726602	chr7:22571607~22661792:-
THCA	cis	rs62158800	0.925	rs908436	ENSG00000224568.1	AC096669.3	4.36	1.6e-05	0.00156	0.4	0.2	Facial morphology (factor 22);	chr2:107595865	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.778	rs884883	ENSG00000224568.1	AC096669.3	4.36	1.6e-05	0.00156	0.4	0.2	Facial morphology (factor 22);	chr2:107596111	chr2:107529487~107556326:+
THCA	cis	rs427943	0.864	rs377902	ENSG00000223768.1	LINC00205	-4.36	1.6e-05	0.00156	-0.18	-0.2	Body mass index;	chr21:45168705	chr21:45293285~45297354:+
THCA	cis	rs8028182	0.549	rs7402293	ENSG00000260274.1	RP11-817O13.8	-4.36	1.6e-05	0.00156	-0.14	-0.2	Sudden cardiac arrest;	chr15:75343796	chr15:75368155~75369584:+
THCA	cis	rs2836950	0.545	rs8132424	ENSG00000238141.2	BRWD1-AS1	4.36	1.6e-05	0.00156	0.22	0.2	Menarche (age at onset);	chr21:39212486	chr21:39315707~39323218:+
THCA	cis	rs7219021	0.634	rs9905428	ENSG00000248278.1	SUMO2P17	-4.36	1.6e-05	0.00156	-0.26	-0.2	Schizophrenia or bipolar disorder;	chr17:48871347	chr17:48874860~48908983:-
THCA	cis	rs6894268	0.685	rs28685239	ENSG00000250999.1	RP11-1379J22.5	4.36	1.6e-05	0.00156	0.25	0.2	Eating disorders;	chr5:179594981	chr5:179657762~179664432:+
THCA	cis	rs786425	0.966	rs786422	ENSG00000270095.1	RP11-214K3.18	4.36	1.6e-05	0.00156	0.22	0.2	Pubertal anthropometrics;	chr12:123599015	chr12:123971457~123971714:-
THCA	cis	rs9532669	0.963	rs4600338	ENSG00000229473.2	RGS17P1	4.36	1.6e-05	0.00156	0.25	0.2	Cervical cancer;	chr13:40925175	chr13:40992779~40993331:-
THCA	cis	rs12541437	1	rs3020160	ENSG00000253327.2	RAD21-AS1	4.36	1.6e-05	0.00156	0.21	0.2	Gut microbiome composition (winter);	chr8:116911350	chr8:116874424~116876868:+
THCA	cis	rs9911578	0.835	rs9303398	ENSG00000224738.1	AC099850.1	-4.36	1.6e-05	0.00156	-0.23	-0.2	Intelligence (multi-trait analysis);	chr17:58406896	chr17:59106598~59118267:+
THCA	cis	rs1003719	0.788	rs4411798	ENSG00000230366.8	DSCR9	-4.36	1.6e-05	0.00156	-0.2	-0.2	Eye color traits;	chr21:37080883	chr21:37208503~37221736:+
THCA	cis	rs28374715	0.532	rs7168431	ENSG00000247556.5	OIP5-AS1	4.36	1.6e-05	0.00156	0.19	0.2	Ulcerative colitis;	chr15:41380186	chr15:41283990~41309737:+
THCA	cis	rs1501911	0.509	rs692759	ENSG00000248489.1	CTD-2007H13.3	-4.36	1.6e-05	0.00156	-0.18	-0.2	Lung function (FEV1/FVC);	chr5:98856841	chr5:98929171~98995013:+
THCA	cis	rs34286592	0.929	rs11863748	ENSG00000214725.6	CDIPT-AS1	-4.36	1.6e-05	0.00156	-0.36	-0.2	Multiple sclerosis;	chr16:29824267	chr16:29863593~29868053:+
THCA	cis	rs453301	0.538	rs7830804	ENSG00000254153.1	CTA-398F10.2	4.36	1.6e-05	0.00157	0.21	0.2	Joint mobility (Beighton score);	chr8:9113252	chr8:8456909~8461337:-
THCA	cis	rs1979679	0.918	rs7314502	ENSG00000247934.4	RP11-967K21.1	4.36	1.6e-05	0.00157	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28462300	chr12:28163298~28190738:-
THCA	cis	rs7809799	0.571	rs11977673	ENSG00000244219.5	GS1-259H13.2	4.36	1.6e-05	0.00157	0.41	0.2	Ulcerative colitis;	chr7:99296312	chr7:99598066~99610813:+
THCA	cis	rs9990333	0.862	rs6806599	ENSG00000226155.1	AC124944.3	4.36	1.6e-05	0.00157	0.23	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195912049~195913986:+
THCA	cis	rs6442522	0.678	rs12494919	ENSG00000249786.6	EAF1-AS1	4.36	1.6e-05	0.00157	0.2	0.2	Uric acid levels;	chr3:15456765	chr3:15436171~15455940:-
THCA	cis	rs4971059	0.617	rs12127609	ENSG00000236675.1	MTX1P1	-4.36	1.6e-05	0.00157	-0.18	-0.2	Breast cancer;	chr1:155161015	chr1:155230975~155234325:+
THCA	cis	rs4906332	0.966	rs35443927	ENSG00000269910.1	RP11-73M18.10	4.36	1.6e-05	0.00157	0.17	0.2	Coronary artery disease;	chr14:103383378	chr14:103694516~103695050:-
THCA	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-4.36	1.6e-05	0.00157	-0.22	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
THCA	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-4.36	1.6e-05	0.00157	-0.22	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
THCA	cis	rs3002142	0.908	rs3002139	ENSG00000272750.1	RP11-378J18.8	-4.36	1.6e-05	0.00157	-0.27	-0.2	LDL peak particle diameter (total fat intake interaction);	chr1:222611722	chr1:222658867~222661512:-
THCA	cis	rs6693017	1	rs17008835	ENSG00000272823.1	RP11-295M18.6	4.36	1.6e-05	0.00157	0.29	0.2	Monocyte early outgrowth colony forming units;	chr1:220806087	chr1:220828676~220829211:-
THCA	cis	rs8014204	0.819	rs2003490	ENSG00000279594.1	RP11-950C14.10	4.36	1.6e-05	0.00157	0.2	0.2	Caffeine consumption;	chr14:74910852	chr14:75011269~75012851:-
THCA	cis	rs17270561	0.609	rs4712963	ENSG00000272462.2	U91328.19	-4.36	1.6e-05	0.00157	-0.17	-0.2	Iron status biomarkers;	chr6:25740274	chr6:25992662~26001775:+
THCA	cis	rs2287838	0.704	rs12977419	ENSG00000267289.1	CTD-2623N2.11	-4.36	1.61e-05	0.00157	-0.23	-0.2	Sleep duration;	chr19:9889523	chr19:9834079~9835013:-
THCA	cis	rs1371614	0.632	rs7589627	ENSG00000229122.1	AGBL5-IT1	4.36	1.61e-05	0.00157	0.14	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26936918	chr2:27061038~27061815:+
THCA	cis	rs829883	0.724	rs11109507	ENSG00000227825.4	SLC9A7P1	4.36	1.61e-05	0.00157	0.19	0.2	Colorectal adenoma (advanced);	chr12:98510382	chr12:98453835~98457145:-
THCA	cis	rs829883	0.724	rs3168521	ENSG00000227825.4	SLC9A7P1	-4.36	1.61e-05	0.00157	-0.19	-0.2	Colorectal adenoma (advanced);	chr12:98514769	chr12:98453835~98457145:-
THCA	cis	rs17818399	0.89	rs34752561	ENSG00000279254.1	RP11-536C12.1	-4.36	1.61e-05	0.00157	-0.21	-0.2	Height;	chr2:46623011	chr2:46668870~46670778:+
THCA	cis	rs911119	0.955	rs1011226	ENSG00000270001.1	RP11-218C14.8	4.36	1.61e-05	0.00157	0.29	0.2	Chronic kidney disease;	chr20:23625196	chr20:23631826~23632316:-
THCA	cis	rs6929812	0.665	rs6456786	ENSG00000271755.1	RP1-153G14.4	4.36	1.61e-05	0.00157	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27448052	chr6:27404010~27406964:-
THCA	cis	rs4591358	0.734	rs16836256	ENSG00000223466.1	AC064834.2	4.36	1.61e-05	0.00157	0.23	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195470381	chr2:195533035~195538681:+
THCA	cis	rs17767294	0.541	rs733743	ENSG00000216901.1	AL022393.7	-4.36	1.61e-05	0.00157	-0.41	-0.2	Parkinson's disease;	chr6:28359594	chr6:28176188~28176674:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000230189.5	GS1-124K5.2	-4.36	1.61e-05	0.00157	-0.14	-0.2	Aortic root size;	chr7:66087510	chr7:66409143~66490059:-
THCA	cis	rs1577917	0.74	rs2475792	ENSG00000220563.1	PKMP3	4.36	1.61e-05	0.00157	0.14	0.2	Response to antipsychotic treatment;	chr6:85682384	chr6:85659892~85660606:-
THCA	cis	rs375066	0.967	rs436249	ENSG00000278917.1	RP11-15A1.4	-4.36	1.61e-05	0.00157	-0.16	-0.2	Breast cancer;	chr19:43895413	chr19:43891233~43895411:+
THCA	cis	rs7838490	0.504	rs1906449	ENSG00000253553.4	RP11-586K2.1	4.36	1.61e-05	0.00157	0.2	0.2	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88490410	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.639	rs11996834	ENSG00000253553.4	RP11-586K2.1	4.36	1.61e-05	0.00157	0.2	0.2	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88493090	chr8:88326836~88737134:+
THCA	cis	rs3930017	1	rs3930017	ENSG00000205482.8	AC007000.12	-4.36	1.61e-05	0.00157	-0.18	-0.2	Body mass index;	chr7:77091265	chr7:77052785~77059440:-
THCA	cis	rs11098499	0.863	rs1155576	ENSG00000249244.1	RP11-548H18.2	4.36	1.61e-05	0.00157	0.23	0.2	Corneal astigmatism;	chr4:119529004	chr4:119391831~119395335:-
THCA	cis	rs10833905	1	rs28776242	ENSG00000246225.5	RP11-17A1.3	-4.36	1.61e-05	0.00157	-0.28	-0.2	Sudden cardiac arrest;	chr11:22986516	chr11:22829380~22945393:+
THCA	cis	rs11955398	0.502	rs158938	ENSG00000272308.1	RP11-231G3.1	-4.36	1.61e-05	0.00157	-0.21	-0.2	Intelligence (multi-trait analysis);	chr5:60939413	chr5:60866457~60866935:-
THCA	cis	rs2135507	0.532	rs35061774	ENSG00000270480.1	RP11-57B24.1	-4.36	1.61e-05	0.00157	-0.26	-0.2	Juvenile osteochondritis dissecans;	chr4:82660460	chr4:82691737~82692468:+
THCA	cis	rs2135507	0.532	rs3733227	ENSG00000270480.1	RP11-57B24.1	-4.36	1.61e-05	0.00157	-0.26	-0.2	Juvenile osteochondritis dissecans;	chr4:82661058	chr4:82691737~82692468:+
THCA	cis	rs867371	0.614	rs7183805	ENSG00000259429.4	UBE2Q2P2	-4.36	1.61e-05	0.00157	-0.17	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82355142~82420075:+
THCA	cis	rs6929812	0.639	rs6456789	ENSG00000271755.1	RP1-153G14.4	4.36	1.61e-05	0.00157	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27458719	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.629	rs7743443	ENSG00000271755.1	RP1-153G14.4	4.36	1.61e-05	0.00157	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27458880	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs7748366	ENSG00000271755.1	RP1-153G14.4	4.36	1.61e-05	0.00157	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27459763	chr6:27404010~27406964:-
THCA	cis	rs10090774	0.87	rs6994744	ENSG00000279766.1	RP11-642A1.2	4.36	1.61e-05	0.00157	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140730769	chr8:140572142~140572812:-
THCA	cis	rs61270009	0.955	rs768705	ENSG00000247828.6	TMEM161B-AS1	4.36	1.61e-05	0.00157	0.17	0.2	Depressive symptoms;	chr5:88272893	chr5:88268895~88436685:+
THCA	cis	rs2446066	0.799	rs76805893	ENSG00000257379.1	RP11-793H13.8	4.36	1.61e-05	0.00157	0.29	0.2	Red blood cell count;	chr12:53436335	chr12:53441741~53467528:+
THCA	cis	rs875971	0.642	rs35526611	ENSG00000223473.2	GS1-124K5.3	-4.36	1.61e-05	0.00157	-0.13	-0.2	Aortic root size;	chr7:66629021	chr7:66491049~66493566:-
THCA	cis	rs7688540	0.547	rs11728864	ENSG00000211553.1	AC253576.2	-4.36	1.61e-05	0.00157	-0.31	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:136461~136568:+
THCA	cis	rs17818399	0.926	rs1824050	ENSG00000279254.1	RP11-536C12.1	-4.36	1.61e-05	0.00157	-0.21	-0.2	Height;	chr2:46612338	chr2:46668870~46670778:+
THCA	cis	rs17818399	0.926	rs1378764	ENSG00000279254.1	RP11-536C12.1	-4.36	1.61e-05	0.00157	-0.21	-0.2	Height;	chr2:46612542	chr2:46668870~46670778:+
THCA	cis	rs2129782	0.702	rs12675707	ENSG00000253553.4	RP11-586K2.1	4.36	1.61e-05	0.00157	0.37	0.2	Electrodermal activity;	chr8:88557319	chr8:88326836~88737134:+
THCA	cis	rs12612619	0.704	rs10185736	ENSG00000272148.1	RP11-195B17.1	-4.36	1.61e-05	0.00157	-0.19	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27098356	chr2:27062428~27062907:-
THCA	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	4.36	1.61e-05	0.00157	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
THCA	cis	rs28374715	0.532	rs28584379	ENSG00000247556.5	OIP5-AS1	4.36	1.61e-05	0.00157	0.19	0.2	Ulcerative colitis;	chr15:41378210	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.532	rs11854820	ENSG00000247556.5	OIP5-AS1	4.36	1.61e-05	0.00157	0.19	0.2	Ulcerative colitis;	chr15:41384328	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.532	rs3204853	ENSG00000247556.5	OIP5-AS1	4.36	1.61e-05	0.00157	0.19	0.2	Ulcerative colitis;	chr15:41396968	chr15:41283990~41309737:+
THCA	cis	rs321358	0.79	rs10502128	ENSG00000271584.1	RP11-89C3.4	4.36	1.61e-05	0.00157	0.33	0.2	Body mass index;	chr11:111076827	chr11:111091932~111097357:-
THCA	cis	rs321358	0.848	rs57168185	ENSG00000271584.1	RP11-89C3.4	4.36	1.61e-05	0.00157	0.33	0.2	Body mass index;	chr11:111078120	chr11:111091932~111097357:-
THCA	cis	rs9863	0.861	rs11835839	ENSG00000270028.1	RP11-380L11.4	4.36	1.61e-05	0.00157	0.2	0.2	White blood cell count;	chr12:123946502	chr12:123925461~123926083:-
THCA	cis	rs1232027	0.622	rs1628627	ENSG00000249655.1	CTC-325J23.2	4.36	1.61e-05	0.00157	0.22	0.2	Huntington's disease progression;	chr5:80671443	chr5:80630313~80631590:-
THCA	cis	rs950776	0.752	rs62010327	ENSG00000261762.1	RP11-650L12.2	4.36	1.61e-05	0.00157	0.26	0.2	Sudden cardiac arrest;	chr15:78600442	chr15:78589123~78591276:-
THCA	cis	rs1113500	0.73	rs1777457	ENSG00000230489.1	VAV3-AS1	4.36	1.61e-05	0.00157	0.18	0.2	Growth-regulated protein alpha levels;	chr1:108045573	chr1:107964443~107994607:+
THCA	cis	rs1113500	0.73	rs1777456	ENSG00000230489.1	VAV3-AS1	4.36	1.61e-05	0.00157	0.18	0.2	Growth-regulated protein alpha levels;	chr1:108045850	chr1:107964443~107994607:+
THCA	cis	rs1113500	0.73	rs1781077	ENSG00000230489.1	VAV3-AS1	4.36	1.61e-05	0.00157	0.18	0.2	Growth-regulated protein alpha levels;	chr1:108046967	chr1:107964443~107994607:+
THCA	cis	rs1113500	0.73	rs1618693	ENSG00000230489.1	VAV3-AS1	4.36	1.61e-05	0.00157	0.18	0.2	Growth-regulated protein alpha levels;	chr1:108048961	chr1:107964443~107994607:+
THCA	cis	rs1113500	0.698	rs1781078	ENSG00000230489.1	VAV3-AS1	4.36	1.61e-05	0.00157	0.18	0.2	Growth-regulated protein alpha levels;	chr1:108049020	chr1:107964443~107994607:+
THCA	cis	rs7572644	0.699	rs13416434	ENSG00000223522.1	AC093690.1	4.36	1.61e-05	0.00157	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27939407	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs10170872	ENSG00000223522.1	AC093690.1	4.36	1.61e-05	0.00157	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27941686	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs7577437	ENSG00000223522.1	AC093690.1	4.36	1.61e-05	0.00157	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27945548	chr2:28307691~28310459:-
THCA	cis	rs6929812	0.665	rs2235254	ENSG00000271755.1	RP1-153G14.4	4.36	1.61e-05	0.00158	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27455015	chr6:27404010~27406964:-
THCA	cis	rs9926296	0.632	rs2011925	ENSG00000260259.1	RP11-368I7.4	-4.36	1.61e-05	0.00158	-0.22	-0.2	Vitiligo;	chr16:89747656	chr16:89682620~89686569:-
THCA	cis	rs12935229	0.756	rs17712814	ENSG00000260922.1	RP11-538I12.3	-4.36	1.61e-05	0.00158	-0.31	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77278815	chr16:77234877~77290934:+
THCA	cis	rs2554380	0.628	rs2401130	ENSG00000176700.18	SCAND2P	-4.36	1.61e-05	0.00158	-0.14	-0.2	Height;	chr15:83801983	chr15:84631451~84647478:+
THCA	cis	rs2554380	0.628	rs2401131	ENSG00000176700.18	SCAND2P	-4.36	1.61e-05	0.00158	-0.14	-0.2	Height;	chr15:83802144	chr15:84631451~84647478:+
THCA	cis	rs7819412	0.775	rs2001329	ENSG00000261451.1	RP11-981G7.1	-4.36	1.61e-05	0.00158	-0.25	-0.2	Triglycerides;	chr8:11129349	chr8:10433672~10438312:+
THCA	cis	rs7176527	1	rs3762169	ENSG00000230373.7	GOLGA6L5P	4.36	1.62e-05	0.00158	0.24	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84507885~84516814:-
THCA	cis	rs6500602	0.563	rs3810818	ENSG00000280063.1	RP11-295D4.3	4.36	1.62e-05	0.00158	0.12	0.2	Schizophrenia;	chr16:4382028	chr16:4346694~4348648:-
THCA	cis	rs6600671	0.967	rs12069545	ENSG00000270231.3	NBPF8P	4.36	1.62e-05	0.00158	0.17	0.2	Hip geometry;	chr1:121430343	chr1:120436353~120467739:+
THCA	cis	rs6787172	0.905	rs1714507	ENSG00000272087.1	RP11-379F4.7	4.36	1.62e-05	0.00158	0.17	0.2	Subjective well-being;	chr3:158533643	chr3:158693120~158693768:-
THCA	cis	rs7577696	0.962	rs11691879	ENSG00000276334.1	AL133243.1	-4.36	1.62e-05	0.00158	-0.21	-0.2	Inflammatory biomarkers;	chr2:32049148	chr2:32521927~32523547:+
THCA	cis	rs4218	0.648	rs877269	ENSG00000259732.1	RP11-59H7.3	-4.36	1.62e-05	0.00158	-0.28	-0.2	Social communication problems;	chr15:59081595	chr15:59121034~59133250:+
THCA	cis	rs10510102	0.516	rs78586895	ENSG00000226864.1	ATE1-AS1	4.36	1.62e-05	0.00158	0.33	0.2	Breast cancer;	chr10:121977081	chr10:121928312~121951965:+
THCA	cis	rs11846409	0.629	rs76295389	ENSG00000274576.2	IGHV2-70	4.36	1.62e-05	0.00158	0.17	0.2	Rheumatic heart disease;	chr14:106650437	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.698	rs71419854	ENSG00000274576.2	IGHV2-70	4.36	1.62e-05	0.00158	0.17	0.2	Rheumatic heart disease;	chr14:106650440	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.5	rs71419855	ENSG00000274576.2	IGHV2-70	4.36	1.62e-05	0.00158	0.17	0.2	Alzheimer's disease (late onset);	chr14:106650444	chr14:106770577~106771020:-
THCA	cis	rs5758511	0.817	rs133291	ENSG00000230107.1	CTA-126B4.7	-4.36	1.62e-05	0.00158	-0.23	-0.2	Birth weight;	chr22:41873624	chr22:42438023~42446195:+
THCA	cis	rs868036	0.681	rs3784718	ENSG00000270964.1	RP11-502I4.3	-4.36	1.62e-05	0.00158	-0.18	-0.2	Restless legs syndrome;	chr15:67805666	chr15:67541072~67542604:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000272831.1	RP11-792A8.4	4.36	1.62e-05	0.00158	0.12	0.2	Aortic root size;	chr7:66540165	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs13224319	ENSG00000272831.1	RP11-792A8.4	4.36	1.62e-05	0.00158	0.12	0.2	Aortic root size;	chr7:66542376	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs801217	ENSG00000272831.1	RP11-792A8.4	-4.36	1.62e-05	0.00158	-0.12	-0.2	Aortic root size;	chr7:66545590	chr7:66739829~66740385:-
THCA	cis	rs875971	0.638	rs801216	ENSG00000272831.1	RP11-792A8.4	-4.36	1.62e-05	0.00158	-0.12	-0.2	Aortic root size;	chr7:66546680	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs801211	ENSG00000272831.1	RP11-792A8.4	-4.36	1.62e-05	0.00158	-0.12	-0.2	Aortic root size;	chr7:66550702	chr7:66739829~66740385:-
THCA	cis	rs6012564	1	rs3092374	ENSG00000230758.1	SNAP23P	-4.36	1.62e-05	0.00158	-0.24	-0.2	Anger;	chr20:49047407	chr20:49038357~49038602:-
THCA	cis	rs160451	0.782	rs7828553	ENSG00000251136.7	RP11-37B2.1	4.36	1.62e-05	0.00158	0.18	0.2	Leprosy;	chr8:89700193	chr8:89609409~89757727:-
THCA	cis	rs713587	0.571	rs2438679	ENSG00000224165.4	DNAJC27-AS1	4.36	1.62e-05	0.00158	0.11	0.2	Body mass index in non-asthmatics;	chr2:25094784	chr2:24971390~25039694:+
THCA	cis	rs6600671	0.934	rs7528274	ENSG00000275585.1	CH17-118O6.3	-4.36	1.62e-05	0.00158	-0.24	-0.2	Hip geometry;	chr1:121545103	chr1:120985692~121052167:-
THCA	cis	rs2787702	0.963	rs2814026	ENSG00000237233.2	TMEM26-AS1	-4.36	1.62e-05	0.00158	-0.24	-0.2	Response to taxane treatment (placlitaxel);	chr10:61583336	chr10:61452639~61481956:+
THCA	cis	rs2787702	0.963	rs1598575	ENSG00000237233.2	TMEM26-AS1	-4.36	1.62e-05	0.00158	-0.24	-0.2	Response to taxane treatment (placlitaxel);	chr10:61584982	chr10:61452639~61481956:+
THCA	cis	rs6860806	0.507	rs273901	ENSG00000224431.1	AC063976.7	4.36	1.62e-05	0.00158	0.18	0.2	Breast cancer;	chr5:132358667	chr5:132199456~132203487:+
THCA	cis	rs270601	0.913	rs273899	ENSG00000224431.1	AC063976.7	4.36	1.62e-05	0.00158	0.18	0.2	Acylcarnitine levels;	chr5:132359485	chr5:132199456~132203487:+
THCA	cis	rs9307551	0.6	rs11098778	ENSG00000250334.4	LINC00989	-4.36	1.62e-05	0.00158	-0.22	-0.2	Refractive error;	chr4:79617847	chr4:79492416~79576460:+
THCA	cis	rs113835537	1	rs113835537	ENSG00000255517.5	CTD-3074O7.5	-4.36	1.62e-05	0.00158	-0.2	-0.2	Airway imaging phenotypes;	chr11:66572168	chr11:66473490~66480233:-
THCA	cis	rs1979679	0.877	rs6487684	ENSG00000247934.4	RP11-967K21.1	4.36	1.62e-05	0.00158	0.2	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28490280	chr12:28163298~28190738:-
THCA	cis	rs7474896	0.537	rs2472149	ENSG00000120555.12	SEPT7P9	-4.36	1.62e-05	0.00158	-0.26	-0.2	Obesity (extreme);	chr10:37973268	chr10:38383069~38402916:-
THCA	cis	rs2275906	0.557	rs56392519	ENSG00000272462.2	U91328.19	4.36	1.62e-05	0.00158	0.18	0.2	Urate levels in lean individuals;	chr6:25885943	chr6:25992662~26001775:+
THCA	cis	rs4650994	0.623	rs35854525	ENSG00000273384.1	RP5-1098D14.1	-4.36	1.62e-05	0.00158	-0.25	-0.2	HDL cholesterol;HDL cholesterol levels;	chr1:178649469	chr1:178651706~178652282:+
THCA	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-4.36	1.62e-05	0.00158	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
THCA	cis	rs9634489	0.588	rs1925118	ENSG00000247400.3	DNAJC3-AS1	-4.36	1.62e-05	0.00158	-0.12	-0.2	Body mass index;	chr13:96291907	chr13:95648733~95676925:-
THCA	cis	rs7088591	0.867	rs79088358	ENSG00000276818.1	AC026393.1	4.36	1.62e-05	0.00158	0.42	0.2	Blood pressure;	chr10:58051765	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs78709800	ENSG00000276818.1	AC026393.1	4.36	1.62e-05	0.00158	0.42	0.2	Blood pressure;	chr10:58054264	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.571	rs76814247	ENSG00000276818.1	AC026393.1	4.36	1.62e-05	0.00158	0.42	0.2	Blood pressure;	chr10:58059390	chr10:57095699~57095781:+
THCA	cis	rs1962073	0.507	rs7460226	ENSG00000261451.1	RP11-981G7.1	4.36	1.62e-05	0.00158	0.25	0.2	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10340208	chr8:10433672~10438312:+
THCA	cis	rs12143943	0.966	rs4950953	ENSG00000240219.1	RP11-430C7.5	4.36	1.62e-05	0.00158	0.17	0.2	Cognitive performance;	chr1:204606353	chr1:204626775~204629712:+
THCA	cis	rs12935418	0.672	rs78895138	ENSG00000278985.1	RP11-303E16.9	4.36	1.62e-05	0.00158	0.22	0.2	Mean corpuscular volume;	chr16:81014820	chr16:80982319~80984094:-
THCA	cis	rs4906332	1	rs12147655	ENSG00000269910.1	RP11-73M18.10	4.36	1.62e-05	0.00158	0.17	0.2	Coronary artery disease;	chr14:103384569	chr14:103694516~103695050:-
THCA	cis	rs9625935	0.957	rs4993442	ENSG00000279159.1	RP3-394A18.1	4.36	1.62e-05	0.00158	0.16	0.2	Tonsillectomy;	chr22:29857267	chr22:29978950~30028236:-
THCA	cis	rs12755164	0.771	rs2901713	ENSG00000223479.3	RP4-788P17.1	-4.36	1.62e-05	0.00158	-0.21	-0.2	Schizophrenia;	chr1:72848790	chr1:73635216~73715214:+
THCA	cis	rs4742903	0.933	rs10820608	ENSG00000270332.1	SMC2-AS1	4.36	1.62e-05	0.00158	0.18	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104128559	chr9:104080024~104093073:-
THCA	cis	rs9818758	0.607	rs34823813	ENSG00000270441.1	RP11-694I15.7	4.36	1.62e-05	0.00158	0.29	0.2	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49712543	chr3:49140086~49160851:-
THCA	cis	rs427943	0.798	rs2225434	ENSG00000223768.1	LINC00205	-4.36	1.62e-05	0.00158	-0.18	-0.2	Body mass index;	chr21:45214231	chr21:45293285~45297354:+
THCA	cis	rs858239	0.899	rs28635122	ENSG00000230042.1	AK3P3	-4.36	1.62e-05	0.00158	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23129178~23129841:+
THCA	cis	rs3770081	1	rs17026701	ENSG00000272564.1	RP11-548P2.2	-4.36	1.62e-05	0.00158	-0.35	-0.2	Facial emotion recognition (sad faces);	chr2:85859732	chr2:85904279~85904727:+
THCA	cis	rs7560272	0.538	rs13014700	ENSG00000163016.8	ALMS1P	-4.36	1.62e-05	0.00158	-0.24	-0.2	Schizophrenia;	chr2:73692994	chr2:73644919~73685576:+
THCA	cis	rs853679	0.769	rs7752608	ENSG00000272009.1	RP1-313I6.12	-4.36	1.62e-05	0.00158	-0.34	-0.2	Depression;	chr6:28333418	chr6:28078792~28081130:-
THCA	cis	rs875971	0.545	rs1796222	ENSG00000273142.1	RP11-458F8.4	-4.36	1.62e-05	0.00158	-0.18	-0.2	Aortic root size;	chr7:66592167	chr7:66902857~66906297:+
THCA	cis	rs8002861	0.641	rs2028813	ENSG00000274001.1	RP11-5G9.5	4.36	1.62e-05	0.00158	0.23	0.2	Leprosy;	chr13:43847990	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.619	rs9562516	ENSG00000274001.1	RP11-5G9.5	4.36	1.62e-05	0.00158	0.23	0.2	Leprosy;	chr13:43857602	chr13:43877715~43878163:-
THCA	cis	rs4604234	0.803	rs11961389	ENSG00000272129.1	RP11-250B2.6	-4.36	1.62e-05	0.00158	-0.5	-0.2	Cancer;	chr6:80254174	chr6:80355424~80356859:+
THCA	cis	rs1842579	1	rs1842579	ENSG00000272691.1	RP11-290M5.4	4.36	1.62e-05	0.00158	0.2	0.2	Coronary artery aneurysm in Kawasaki disease;	chr1:85823399	chr1:85578500~85578742:-
THCA	cis	rs9549367	0.789	rs35569628	ENSG00000269125.1	RP11-98F14.11	-4.36	1.62e-05	0.00158	-0.23	-0.2	Platelet distribution width;	chr13:113218398	chr13:113165002~113165183:-
THCA	cis	rs12234571	1	rs35462861	ENSG00000214293.7	APTR	4.36	1.62e-05	0.00159	0.24	0.2	Obesity-related traits;	chr7:77941441	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs11971037	ENSG00000214293.7	APTR	4.36	1.62e-05	0.00159	0.24	0.2	Obesity-related traits;	chr7:77948368	chr7:77657660~77696265:-
THCA	cis	rs6490294	0.904	rs11066098	ENSG00000226469.1	ADAM1B	4.36	1.63e-05	0.00159	0.24	0.2	Mean platelet volume;	chr12:111950324	chr12:111927018~111929017:+
THCA	cis	rs11976180	0.517	rs6949375	ENSG00000244479.5	OR2A1-AS1	4.36	1.63e-05	0.00159	0.28	0.2	Obesity-related traits;	chr7:144076758	chr7:144251264~144356181:-
THCA	cis	rs332034	0.546	rs28870140	ENSG00000253893.2	FAM85B	4.36	1.63e-05	0.00159	0.37	0.2	Conduct disorder (maternal expressed emotions interaction);	chr8:8832260	chr8:8167819~8226614:-
THCA	cis	rs4759375	1	rs11057223	ENSG00000256092.2	RP13-942N8.1	-4.36	1.63e-05	0.00159	-0.22	-0.2	HDL cholesterol;	chr12:123270508	chr12:123363868~123366113:+
THCA	cis	rs4713118	0.662	rs469228	ENSG00000219891.2	ZSCAN12P1	4.36	1.63e-05	0.00159	0.26	0.2	Parkinson's disease;	chr6:28002926	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.54	rs469227	ENSG00000219891.2	ZSCAN12P1	4.36	1.63e-05	0.00159	0.26	0.2	Parkinson's disease;	chr6:28002927	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs149948	ENSG00000219891.2	ZSCAN12P1	4.36	1.63e-05	0.00159	0.26	0.2	Parkinson's disease;	chr6:28007039	chr6:28091154~28093664:+
THCA	cis	rs2289700	1	rs2289698	ENSG00000252061.1	RNU6-415P	-4.36	1.63e-05	0.00159	-0.41	-0.2	Bipolar disorder;	chr15:78931103	chr15:78898840~78898936:-
THCA	cis	rs786425	0.801	rs12813346	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.23	-0.2	Pubertal anthropometrics;	chr12:123716567	chr12:123971457~123971714:-
THCA	cis	rs2412819	0.571	rs514255	ENSG00000166763.7	STRCP1	4.36	1.63e-05	0.00159	0.26	0.2	Lung cancer;	chr15:43893134	chr15:43699488~43718184:-
THCA	cis	rs7829975	0.5	rs7841082	ENSG00000253981.4	ALG1L13P	-4.36	1.63e-05	0.00159	-0.2	-0.2	Mood instability;	chr8:8311465	chr8:8236003~8244667:-
THCA	cis	rs62458065	0.513	rs702831	ENSG00000231952.3	DPY19L1P2	4.36	1.63e-05	0.00159	0.33	0.2	Metabolite levels (HVA/MHPG ratio);	chr7:32540103	chr7:32812757~32838570:+
THCA	cis	rs875971	0.638	rs801205	ENSG00000223473.2	GS1-124K5.3	-4.36	1.63e-05	0.00159	-0.13	-0.2	Aortic root size;	chr7:66557157	chr7:66491049~66493566:-
THCA	cis	rs875971	0.617	rs810400	ENSG00000223473.2	GS1-124K5.3	-4.36	1.63e-05	0.00159	-0.13	-0.2	Aortic root size;	chr7:66557902	chr7:66491049~66493566:-
THCA	cis	rs875971	0.638	rs3898855	ENSG00000223473.2	GS1-124K5.3	-4.36	1.63e-05	0.00159	-0.13	-0.2	Aortic root size;	chr7:66571411	chr7:66491049~66493566:-
THCA	cis	rs875971	0.638	rs10278816	ENSG00000223473.2	GS1-124K5.3	-4.36	1.63e-05	0.00159	-0.13	-0.2	Aortic root size;	chr7:66572000	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs10281080	ENSG00000223473.2	GS1-124K5.3	-4.36	1.63e-05	0.00159	-0.13	-0.2	Aortic root size;	chr7:66577454	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs10950044	ENSG00000223473.2	GS1-124K5.3	-4.36	1.63e-05	0.00159	-0.13	-0.2	Aortic root size;	chr7:66577989	chr7:66491049~66493566:-
THCA	cis	rs875971	0.522	rs1968127	ENSG00000223473.2	GS1-124K5.3	-4.36	1.63e-05	0.00159	-0.13	-0.2	Aortic root size;	chr7:66591816	chr7:66491049~66493566:-
THCA	cis	rs10833905	1	rs1465521	ENSG00000246225.5	RP11-17A1.3	-4.36	1.63e-05	0.00159	-0.29	-0.2	Sudden cardiac arrest;	chr11:23010880	chr11:22829380~22945393:+
THCA	cis	rs4948275	0.606	rs2787719	ENSG00000237233.2	TMEM26-AS1	-4.36	1.63e-05	0.00159	-0.26	-0.2	Night sleep phenotypes;	chr10:61573465	chr10:61452639~61481956:+
THCA	cis	rs10875746	0.951	rs2286021	ENSG00000258273.1	RP11-370I10.4	4.36	1.63e-05	0.00159	0.28	0.2	Longevity (90 years and older);	chr12:48134437	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs11168427	ENSG00000258273.1	RP11-370I10.4	4.36	1.63e-05	0.00159	0.28	0.2	Longevity (90 years and older);	chr12:48145196	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.951	rs61918826	ENSG00000258273.1	RP11-370I10.4	4.36	1.63e-05	0.00159	0.28	0.2	Longevity (90 years and older);	chr12:48150195	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.904	rs10875750	ENSG00000258273.1	RP11-370I10.4	4.36	1.63e-05	0.00159	0.28	0.2	Longevity (90 years and older);	chr12:48151847	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.951	rs7485355	ENSG00000258273.1	RP11-370I10.4	4.36	1.63e-05	0.00159	0.28	0.2	Longevity (90 years and older);	chr12:48154559	chr12:48333755~48333901:-
THCA	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	4.36	1.63e-05	0.00159	0.22	0.2	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
THCA	cis	rs72753537	0.817	rs7043516	ENSG00000214417.4	KRT18P13	4.36	1.63e-05	0.00159	0.23	0.2	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97855151	chr9:97698922~97700734:+
THCA	cis	rs7243790	1	rs10502990	ENSG00000277324.1	RP11-850A17.1	4.36	1.63e-05	0.00159	0.21	0.2	Diastolic blood pressure;	chr18:54438168	chr18:54268346~54270028:-
THCA	cis	rs516805	0.961	rs544099	ENSG00000279114.1	RP3-425C14.5	4.36	1.63e-05	0.00159	0.2	0.2	Lymphocyte counts;	chr6:122479837	chr6:122471923~122484161:+
THCA	cis	rs734999	0.545	rs10752748	ENSG00000225931.3	RP3-395M20.7	4.36	1.63e-05	0.00159	0.23	0.2	Ulcerative colitis;	chr1:2613201	chr1:2566410~2569888:+
THCA	cis	rs734999	0.505	rs4648659	ENSG00000225931.3	RP3-395M20.7	-4.36	1.63e-05	0.00159	-0.23	-0.2	Ulcerative colitis;	chr1:2629464	chr1:2566410~2569888:+
THCA	cis	rs734999	0.545	rs28532547	ENSG00000225931.3	RP3-395M20.7	-4.36	1.63e-05	0.00159	-0.23	-0.2	Ulcerative colitis;	chr1:2629847	chr1:2566410~2569888:+
THCA	cis	rs12030196	1	rs12030196	ENSG00000230812.4	LINC01358	4.36	1.63e-05	0.00159	0.25	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59017648	chr1:59020387~59044614:+
THCA	cis	rs10043228	1	rs12332658	ENSG00000248445.4	SEMA6A-AS1	-4.36	1.63e-05	0.00159	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116209909	chr5:116447547~116508276:+
THCA	cis	rs4947019	0.609	rs9487099	ENSG00000223537.2	RP5-919F19.5	-4.36	1.63e-05	0.00159	-0.37	-0.2	Hematological parameters;	chr6:109423803	chr6:109487906~109506800:+
THCA	cis	rs2474937	0.592	rs7537930	ENSG00000231365.4	RP11-418J17.1	4.36	1.63e-05	0.00159	0.19	0.2	Congenital heart malformation;	chr1:118368009	chr1:119140396~119275973:+
THCA	cis	rs2777491	0.915	rs8032838	ENSG00000247556.5	OIP5-AS1	4.36	1.63e-05	0.00159	0.16	0.2	Ulcerative colitis;	chr15:41313434	chr15:41283990~41309737:+
THCA	cis	rs28735056	0.584	rs11664834	ENSG00000261126.6	RP11-795F19.1	4.36	1.63e-05	0.00159	0.17	0.2	Schizophrenia;	chr18:79884876	chr18:80046900~80095482:+
THCA	cis	rs1005277	0.505	rs200939	ENSG00000226578.1	RP11-258F22.1	-4.36	1.63e-05	0.00159	-0.23	-0.2	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:37775371~37784131:-
THCA	cis	rs11242704	0.632	rs4959568	ENSG00000272279.1	RP11-157J24.2	-4.36	1.63e-05	0.00159	-0.33	-0.2	Response to hepatitis C treatment;	chr6:1530194	chr6:1528364~1528911:-
THCA	cis	rs17801127	0.901	rs76041558	ENSG00000231969.1	AC144449.1	4.36	1.63e-05	0.00159	0.35	0.2	Liver enzyme levels (alanine transaminase);	chr2:149706333	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.901	rs13030540	ENSG00000231969.1	AC144449.1	4.36	1.63e-05	0.00159	0.35	0.2	Liver enzyme levels (alanine transaminase);	chr2:149707085	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.818	rs16827371	ENSG00000231969.1	AC144449.1	4.36	1.63e-05	0.00159	0.35	0.2	Liver enzyme levels (alanine transaminase);	chr2:149707661	chr2:149587196~149848233:+
THCA	cis	rs7572644	0.699	rs7426295	ENSG00000223522.1	AC093690.1	-4.36	1.63e-05	0.00159	-0.23	-0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27856127	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs4233719	ENSG00000223522.1	AC093690.1	-4.36	1.63e-05	0.00159	-0.23	-0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27856477	chr2:28307691~28310459:-
THCA	cis	rs116248771	0.739	rs73156437	ENSG00000271778.1	RP11-379F4.8	4.36	1.63e-05	0.00159	0.26	0.2	diarrhoeal disease at age 2;	chr3:158641495	chr3:158782547~158783124:+
THCA	cis	rs7829975	0.557	rs7816427	ENSG00000254153.1	CTA-398F10.2	4.36	1.63e-05	0.00159	0.23	0.2	Mood instability;	chr8:8688374	chr8:8456909~8461337:-
THCA	cis	rs2692947	0.537	rs11679899	ENSG00000235584.2	AC008268.1	-4.36	1.63e-05	0.00159	-0.19	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712414	chr2:95666084~95668715:+
THCA	cis	rs7551222	0.752	rs4252694	ENSG00000240219.1	RP11-430C7.5	4.36	1.63e-05	0.00159	0.18	0.2	Schizophrenia;	chr1:204529928	chr1:204626775~204629712:+
THCA	cis	rs2964991	1	rs2964991	ENSG00000232480.1	TGFB2-AS1	-4.36	1.63e-05	0.00159	-0.22	-0.2	Post bronchodilator FEV1/FVC ratio;	chr1:218511890	chr1:218344196~218345678:-
THCA	cis	rs9650657	0.515	rs6601560	ENSG00000254948.1	OR7E158P	4.36	1.63e-05	0.00159	0.24	0.2	Neuroticism;	chr8:11093356	chr8:11919900~11920809:-
THCA	cis	rs9863	0.896	rs4765148	ENSG00000270061.1	RP11-214K3.19	-4.36	1.63e-05	0.00159	-0.26	-0.2	White blood cell count;	chr12:123994090	chr12:123969990~123970344:-
THCA	cis	rs786425	0.682	rs7302649	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.24	-0.2	Pubertal anthropometrics;	chr12:123675219	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs34534928	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.24	-0.2	Pubertal anthropometrics;	chr12:123676287	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs12820195	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.24	-0.2	Pubertal anthropometrics;	chr12:123677500	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7973695	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.24	-0.2	Pubertal anthropometrics;	chr12:123677930	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7959553	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.24	-0.2	Pubertal anthropometrics;	chr12:123678158	chr12:123971457~123971714:-
THCA	cis	rs786425	0.711	rs66690784	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.24	-0.2	Pubertal anthropometrics;	chr12:123681130	chr12:123971457~123971714:-
THCA	cis	rs786425	0.711	rs7963968	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.24	-0.2	Pubertal anthropometrics;	chr12:123681494	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7302788	ENSG00000270095.1	RP11-214K3.18	-4.36	1.63e-05	0.00159	-0.24	-0.2	Pubertal anthropometrics;	chr12:123682474	chr12:123971457~123971714:-
THCA	cis	rs7267979	0.966	rs2263204	ENSG00000276952.1	RP5-965G21.6	-4.36	1.63e-05	0.00159	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25284915~25285588:-
THCA	cis	rs3738443	0.645	rs11811599	ENSG00000259865.1	RP11-488L18.10	4.36	1.63e-05	0.00159	0.17	0.2	Alcohol dependence;	chr1:247203133	chr1:247187281~247188526:-
THCA	cis	rs5769765	0.954	rs1569954	ENSG00000260613.1	RP3-522J7.6	4.36	1.63e-05	0.00159	0.24	0.2	Schizophrenia;	chr22:49850423	chr22:49832616~49837786:-
THCA	cis	rs1979679	0.573	rs7315906	ENSG00000247934.4	RP11-967K21.1	4.36	1.63e-05	0.00159	0.19	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28575612	chr12:28163298~28190738:-
THCA	cis	rs9376098	0.83	rs6913228	ENSG00000232876.1	CTA-212D2.2	-4.36	1.63e-05	0.00159	-0.24	-0.2	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135182912	chr6:135055033~135060550:+
THCA	cis	rs2298450	0.512	rs2245474	ENSG00000214867.3	SRSF9P1	-4.35	1.63e-05	0.00159	-0.26	-0.2	Schizophrenia;	chr21:36240109	chr21:36295173~36295702:-
THCA	cis	rs6442522	0.809	rs13081119	ENSG00000249786.6	EAF1-AS1	-4.35	1.64e-05	0.00159	-0.2	-0.2	Uric acid levels;	chr3:15409514	chr3:15436171~15455940:-
THCA	cis	rs9905704	0.624	rs8080071	ENSG00000224738.1	AC099850.1	-4.35	1.64e-05	0.00159	-0.24	-0.2	Testicular germ cell tumor;	chr17:59016464	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.647	rs12943705	ENSG00000224738.1	AC099850.1	-4.35	1.64e-05	0.00159	-0.24	-0.2	Testicular germ cell tumor;	chr17:59019686	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.647	rs9898048	ENSG00000224738.1	AC099850.1	4.35	1.64e-05	0.00159	0.24	0.2	Testicular germ cell tumor;	chr17:59031182	chr17:59106598~59118267:+
THCA	cis	rs5742933	1	rs1898560	ENSG00000253559.1	OSGEPL1-AS1	-4.35	1.64e-05	0.00159	-0.24	-0.2	Ferritin levels;	chr2:189747601	chr2:189762704~189765556:+
THCA	cis	rs713587	0.571	rs563590	ENSG00000224165.4	DNAJC27-AS1	4.35	1.64e-05	0.0016	0.11	0.2	Body mass index in non-asthmatics;	chr2:25108303	chr2:24971390~25039694:+
THCA	cis	rs72843506	0.722	rs9902683	ENSG00000261033.1	RP11-209D14.2	4.35	1.64e-05	0.0016	0.35	0.2	Schizophrenia;	chr17:20112115	chr17:20008051~20009234:-
THCA	cis	rs12034383	1	rs11803956	ENSG00000274245.1	RP11-357P18.2	4.35	1.64e-05	0.0016	0.18	0.2	Erythrocyte sedimentation rate;	chr1:207629676	chr1:207372559~207373252:+
THCA	cis	rs7336933	0.866	rs9566874	ENSG00000278338.3	VWA8-AS1	-4.35	1.64e-05	0.0016	-0.33	-0.2	Calcium levels;	chr13:41879958	chr13:41955808~41981565:+
THCA	cis	rs7336933	0.799	rs2225439	ENSG00000278338.3	VWA8-AS1	-4.35	1.64e-05	0.0016	-0.33	-0.2	Calcium levels;	chr13:41883671	chr13:41955808~41981565:+
THCA	cis	rs7336933	0.866	rs7328609	ENSG00000278338.3	VWA8-AS1	-4.35	1.64e-05	0.0016	-0.33	-0.2	Calcium levels;	chr13:41887053	chr13:41955808~41981565:+
THCA	cis	rs7336933	0.866	rs7318484	ENSG00000278338.3	VWA8-AS1	-4.35	1.64e-05	0.0016	-0.33	-0.2	Calcium levels;	chr13:41888874	chr13:41955808~41981565:+
THCA	cis	rs7336933	0.799	rs7318334	ENSG00000278338.3	VWA8-AS1	-4.35	1.64e-05	0.0016	-0.33	-0.2	Calcium levels;	chr13:41888891	chr13:41955808~41981565:+
THCA	cis	rs7336933	0.866	rs7332372	ENSG00000278338.3	VWA8-AS1	-4.35	1.64e-05	0.0016	-0.33	-0.2	Calcium levels;	chr13:41891354	chr13:41955808~41981565:+
THCA	cis	rs6088813	0.961	rs6060373	ENSG00000279253.1	RP4-614O4.13	4.35	1.64e-05	0.0016	0.19	0.2	Height;	chr20:35326405	chr20:35262727~35264187:-
THCA	cis	rs17666538	0.71	rs1703941	ENSG00000254207.1	RP11-43A14.1	4.35	1.64e-05	0.0016	0.4	0.2	IgG glycosylation;	chr8:708447	chr8:725188~725877:-
THCA	cis	rs2361710	0.669	rs12940486	ENSG00000279259.1	RP11-334C17.3	4.35	1.64e-05	0.0016	0.17	0.2	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80144770	chr17:80147250~80148596:+
THCA	cis	rs13178541	0.81	rs10070559	ENSG00000250378.1	RP11-119J18.1	-4.35	1.64e-05	0.0016	-0.25	-0.2	IgG glycosylation;	chr5:135822430	chr5:135812667~135826582:+
THCA	cis	rs9876781	1	rs7630741	ENSG00000244380.1	RP11-24C3.2	4.35	1.64e-05	0.0016	0.23	0.2	Longevity;	chr3:48378233	chr3:48440352~48446656:-
THCA	cis	rs4705962	0.878	rs2023823	ENSG00000230612.2	AC004237.1	4.35	1.64e-05	0.0016	0.24	0.2	Atopic dermatitis;	chr5:132697114	chr5:132688681~132723725:+
THCA	cis	rs62246343	0.63	rs60771966	ENSG00000254485.4	RP11-380O24.1	4.35	1.64e-05	0.0016	0.31	0.2	Fibrinogen levels;	chr3:9465573	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.63	rs59302296	ENSG00000254485.4	RP11-380O24.1	4.35	1.64e-05	0.0016	0.31	0.2	Fibrinogen levels;	chr3:9465630	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.63	rs62246320	ENSG00000254485.4	RP11-380O24.1	4.35	1.64e-05	0.0016	0.31	0.2	Fibrinogen levels;	chr3:9470291	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.63	rs11542009	ENSG00000254485.4	RP11-380O24.1	4.35	1.64e-05	0.0016	0.31	0.2	Fibrinogen levels;	chr3:9475685	chr3:9292588~9363303:-
THCA	cis	rs6449502	0.92	rs7714071	ENSG00000251279.1	CTC-436P18.1	-4.35	1.64e-05	0.0016	-0.33	-0.2	Mean platelet volume;	chr5:60844627	chr5:61162070~61232040:+
THCA	cis	rs5758511	0.689	rs55906806	ENSG00000205702.9	CYP2D7	4.35	1.64e-05	0.0016	0.22	0.2	Birth weight;	chr22:42248465	chr22:42140203~42144577:-
THCA	cis	rs7829975	0.774	rs11775523	ENSG00000233609.3	RP11-62H7.2	4.35	1.64e-05	0.0016	0.19	0.2	Mood instability;	chr8:8821666	chr8:8961200~8979025:+
THCA	cis	rs2803122	0.869	rs4977528	ENSG00000273226.1	RP11-513M16.8	-4.35	1.64e-05	0.0016	-0.18	-0.2	Pulse pressure;	chr9:19282454	chr9:19375451~19375996:+
THCA	cis	rs3740713	1	rs1848048	ENSG00000256464.1	YWHABP2	4.35	1.64e-05	0.0016	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs16935432	ENSG00000256464.1	YWHABP2	4.35	1.64e-05	0.0016	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs76599129	ENSG00000256464.1	YWHABP2	4.35	1.64e-05	0.0016	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr11:18490243~18490955:-
THCA	cis	rs890448	1	rs1426542	ENSG00000254531.1	FLJ20021	-4.35	1.64e-05	0.0016	-0.17	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101518313	chr4:101347780~101348883:+
THCA	cis	rs12908161	1	rs35808647	ENSG00000188388.10	GOLGA6L3	4.35	1.64e-05	0.0016	0.26	0.2	Schizophrenia;	chr15:84834210	chr15:85240472~85247170:+
THCA	cis	rs9926296	0.609	rs4785714	ENSG00000260259.1	RP11-368I7.4	4.35	1.64e-05	0.0016	0.21	0.2	Vitiligo;	chr16:89731996	chr16:89682620~89686569:-
THCA	cis	rs9326248	0.53	rs6589575	ENSG00000280143.1	AP000892.6	4.35	1.64e-05	0.0016	0.33	0.2	Blood protein levels;	chr11:116862594	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.53	rs718847	ENSG00000280143.1	AP000892.6	4.35	1.64e-05	0.0016	0.33	0.2	Blood protein levels;	chr11:116863430	chr11:117204967~117210292:+
THCA	cis	rs8077577	0.708	rs2290503	ENSG00000273018.4	CTD-2303H24.2	4.35	1.64e-05	0.0016	0.29	0.2	Obesity-related traits;	chr17:18232439	chr17:18511221~18551705:-
THCA	cis	rs2115630	0.641	rs11073613	ENSG00000229212.6	RP11-561C5.4	4.35	1.64e-05	0.0016	0.26	0.2	P wave terminal force;	chr15:84642662	chr15:85205440~85234795:-
THCA	cis	rs8058578	1	rs7204278	ENSG00000279196.1	RP11-1072A3.3	4.35	1.64e-05	0.0016	0.2	0.2	Multiple myeloma;	chr16:30718953	chr16:30984630~30988270:-
THCA	cis	rs13160562	0.666	rs28096	ENSG00000272109.1	CTD-2260A17.3	-4.35	1.64e-05	0.0016	-0.25	-0.2	Alcohol dependence;	chr5:96773540	chr5:96804353~96806105:+
THCA	cis	rs3743266	1	rs3743266	ENSG00000245534.5	RORA-AS1	-4.35	1.64e-05	0.0016	-0.23	-0.2	Menarche (age at onset);	chr15:60489314	chr15:60479178~60630637:+
THCA	cis	rs9467773	0.649	rs2145318	ENSG00000261353.1	CTA-14H9.5	-4.35	1.64e-05	0.0016	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:26496375	chr6:26527063~26527404:+
THCA	cis	rs9863	0.861	rs11835839	ENSG00000269997.1	RP11-214K3.21	-4.35	1.64e-05	0.0016	-0.23	-0.2	White blood cell count;	chr12:123946502	chr12:123966077~123966629:-
THCA	cis	rs7737355	0.685	rs257388	ENSG00000224431.1	AC063976.7	-4.35	1.64e-05	0.0016	-0.28	-0.2	Life satisfaction;	chr5:131410831	chr5:132199456~132203487:+
THCA	cis	rs9810089	0.9	rs11915629	ENSG00000273455.1	RP11-305O4.3	4.35	1.64e-05	0.0016	0.26	0.2	Gestational age at birth (child effect);	chr3:136420888	chr3:136087475~136087913:-
THCA	cis	rs3764021	0.527	rs11052423	ENSG00000214776.8	RP11-726G1.1	-4.35	1.64e-05	0.0016	-0.26	-0.2	Type 1 diabetes;	chr12:9687442	chr12:9467552~9576275:+
THCA	cis	rs875971	0.638	rs801205	ENSG00000272831.1	RP11-792A8.4	-4.35	1.64e-05	0.0016	-0.12	-0.2	Aortic root size;	chr7:66557157	chr7:66739829~66740385:-
THCA	cis	rs875971	0.617	rs810400	ENSG00000272831.1	RP11-792A8.4	-4.35	1.64e-05	0.0016	-0.12	-0.2	Aortic root size;	chr7:66557902	chr7:66739829~66740385:-
THCA	cis	rs875971	0.638	rs3898855	ENSG00000272831.1	RP11-792A8.4	-4.35	1.64e-05	0.0016	-0.12	-0.2	Aortic root size;	chr7:66571411	chr7:66739829~66740385:-
THCA	cis	rs875971	0.638	rs10278816	ENSG00000272831.1	RP11-792A8.4	-4.35	1.64e-05	0.0016	-0.12	-0.2	Aortic root size;	chr7:66572000	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs10281080	ENSG00000272831.1	RP11-792A8.4	-4.35	1.64e-05	0.0016	-0.12	-0.2	Aortic root size;	chr7:66577454	chr7:66739829~66740385:-
THCA	cis	rs875971	0.66	rs10950044	ENSG00000272831.1	RP11-792A8.4	-4.35	1.64e-05	0.0016	-0.12	-0.2	Aortic root size;	chr7:66577989	chr7:66739829~66740385:-
THCA	cis	rs875971	0.522	rs1968127	ENSG00000272831.1	RP11-792A8.4	-4.35	1.64e-05	0.0016	-0.12	-0.2	Aortic root size;	chr7:66591816	chr7:66739829~66740385:-
THCA	cis	rs1048886	0.882	rs16869168	ENSG00000271967.1	RP11-134K13.4	-4.35	1.64e-05	0.0016	-0.2	-0.2	Type 2 diabetes;	chr6:70406036	chr6:70596438~70596980:+
THCA	cis	rs1979679	0.682	rs4359252	ENSG00000278733.1	RP11-425D17.1	-4.35	1.64e-05	0.0016	-0.22	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28434298	chr12:28185625~28186190:-
THCA	cis	rs357618	1	rs165351	ENSG00000260581.1	CTB-113P19.4	4.35	1.64e-05	0.0016	0.26	0.2	Basophil percentage of white cells;	chr5:151475320	chr5:151652275~151655449:+
THCA	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-4.35	1.65e-05	0.0016	-0.23	-0.2	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
THCA	cis	rs6600671	1	rs1832558	ENSG00000270231.3	NBPF8P	4.35	1.65e-05	0.0016	0.17	0.2	Hip geometry;	chr1:121435521	chr1:120436353~120467739:+
THCA	cis	rs897984	0.52	rs4889536	ENSG00000260911.2	RP11-196G11.2	-4.35	1.65e-05	0.0016	-0.18	-0.2	Dementia with Lewy bodies;	chr16:30860434	chr16:31043150~31049868:+
THCA	cis	rs4660214	0.666	rs2490946	ENSG00000182109.6	RP11-69E11.4	4.35	1.65e-05	0.0016	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39522280~39546187:-
THCA	cis	rs755249	0.51	rs1184716	ENSG00000182109.6	RP11-69E11.4	4.35	1.65e-05	0.0016	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39522280~39546187:-
THCA	cis	rs9475752	0.545	rs75396144	ENSG00000231441.1	RP11-472M19.2	4.35	1.65e-05	0.0016	0.28	0.2	Menarche (age at onset);	chr6:57025285	chr6:56844002~56864078:+
THCA	cis	rs4650994	0.623	rs12121188	ENSG00000273384.1	RP5-1098D14.1	-4.35	1.65e-05	0.0016	-0.25	-0.2	HDL cholesterol;HDL cholesterol levels;	chr1:178653364	chr1:178651706~178652282:+
THCA	cis	rs868036	0.681	rs9920643	ENSG00000270964.1	RP11-502I4.3	-4.35	1.65e-05	0.0016	-0.18	-0.2	Restless legs syndrome;	chr15:67811976	chr15:67541072~67542604:-
THCA	cis	rs868036	0.681	rs4776977	ENSG00000270964.1	RP11-502I4.3	-4.35	1.65e-05	0.0016	-0.18	-0.2	Restless legs syndrome;	chr15:67815881	chr15:67541072~67542604:-
THCA	cis	rs868036	0.681	rs4776981	ENSG00000270964.1	RP11-502I4.3	-4.35	1.65e-05	0.0016	-0.18	-0.2	Restless legs syndrome;	chr15:67817136	chr15:67541072~67542604:-
THCA	cis	rs172166	0.637	rs1225592	ENSG00000261839.1	RP1-265C24.8	4.35	1.65e-05	0.0016	0.21	0.2	Cardiac Troponin-T levels;	chr6:28182464	chr6:28136849~28139678:+
THCA	cis	rs172166	0.637	rs1225595	ENSG00000261839.1	RP1-265C24.8	4.35	1.65e-05	0.0016	0.21	0.2	Cardiac Troponin-T levels;	chr6:28183562	chr6:28136849~28139678:+
THCA	cis	rs854765	0.856	rs2955382	ENSG00000281749.1	Y_RNA	-4.35	1.65e-05	0.0016	-0.26	-0.2	Total body bone mineral density;	chr17:18044396	chr17:18001101~18001195:-
THCA	cis	rs7267979	0.789	rs1983974	ENSG00000277938.1	RP5-965G21.3	-4.35	1.65e-05	0.0016	-0.16	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25229150~25231933:+
THCA	cis	rs12887734	0.546	rs66676135	ENSG00000269940.1	RP11-73M18.7	4.35	1.65e-05	0.0016	0.2	0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103694560~103695170:+
THCA	cis	rs7216064	1	rs7214758	ENSG00000278740.1	RP11-147L13.14	4.35	1.65e-05	0.0016	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67884422	chr17:68188547~68189165:+
THCA	cis	rs875971	0.862	rs6944374	ENSG00000229886.1	RP5-1132H15.3	-4.35	1.65e-05	0.0016	-0.21	-0.2	Aortic root size;	chr7:66221942	chr7:66025126~66031544:-
THCA	cis	rs12216545	0.765	rs1851434	ENSG00000241134.3	BET1P1	4.35	1.65e-05	0.0016	0.23	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532365	chr7:150749736~150750094:+
THCA	cis	rs12440869	0.92	rs8030142	ENSG00000270964.1	RP11-502I4.3	-4.35	1.65e-05	0.00161	-0.17	-0.2	Peak velocity of the mitral A-wave;	chr15:67357100	chr15:67541072~67542604:-
THCA	cis	rs12188164	0.515	rs17562461	ENSG00000225138.6	CTD-2228K2.7	4.35	1.65e-05	0.00161	0.21	0.2	Cystic fibrosis severity;	chr5:411246	chr5:473236~480884:+
THCA	cis	rs12216545	0.765	rs7792574	ENSG00000241134.3	BET1P1	-4.35	1.65e-05	0.00161	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150527118	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs7787639	ENSG00000241134.3	BET1P1	-4.35	1.65e-05	0.00161	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150529528	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs7788962	ENSG00000241134.3	BET1P1	-4.35	1.65e-05	0.00161	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150530139	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs4339548	ENSG00000241134.3	BET1P1	-4.35	1.65e-05	0.00161	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532227	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs4607525	ENSG00000241134.3	BET1P1	-4.35	1.65e-05	0.00161	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532262	chr7:150749736~150750094:+
THCA	cis	rs9468199	1	rs9468199	ENSG00000219392.1	RP1-265C24.5	-4.35	1.65e-05	0.00161	-0.28	-0.2	Parkinson's disease;	chr6:27713436	chr6:28115628~28116551:+
THCA	cis	rs12612619	0.69	rs6754371	ENSG00000272148.1	RP11-195B17.1	4.35	1.65e-05	0.00161	0.19	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092196	chr2:27062428~27062907:-
THCA	cis	rs6840258	0.582	rs10000784	ENSG00000251411.1	RP11-397E7.4	-4.35	1.65e-05	0.00161	-0.23	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87166331	chr4:86913266~86914817:-
THCA	cis	rs4443100	0.67	rs13056137	ENSG00000230701.2	FBXW4P1	4.35	1.65e-05	0.00161	0.24	0.2	Serum parathyroid hormone levels;	chr22:23065083	chr22:23262767~23265005:+
THCA	cis	rs6751744	0.855	rs6432534	ENSG00000226266.5	AC009961.3	-4.35	1.65e-05	0.00161	-0.25	-0.2	Dysphagia;	chr2:159521561	chr2:159670708~159712435:-
THCA	cis	rs12497850	0.897	rs9681717	ENSG00000228638.1	FCF1P2	-4.35	1.65e-05	0.00161	-0.21	-0.2	Parkinson's disease;	chr3:48835565	chr3:48290793~48291375:-
THCA	cis	rs8062405	0.728	rs9931989	ENSG00000261766.1	RP11-22P6.2	4.35	1.65e-05	0.00161	0.19	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28862166~28863340:-
THCA	cis	rs1150668	0.764	rs9368565	ENSG00000280107.1	AL022393.9	4.35	1.65e-05	0.00161	0.19	0.2	Pubertal anthropometrics;	chr6:28377433	chr6:28170845~28172521:+
THCA	cis	rs4908769	0.627	rs301798	ENSG00000232912.4	RP5-1115A15.1	4.35	1.65e-05	0.00161	0.22	0.2	Allergy;	chr1:8428505	chr1:8424645~8434838:+
THCA	cis	rs6012564	1	rs730543	ENSG00000230758.1	SNAP23P	-4.35	1.65e-05	0.00161	-0.23	-0.2	Anger;	chr20:49019178	chr20:49038357~49038602:-
THCA	cis	rs7088591	0.867	rs57811976	ENSG00000276818.1	AC026393.1	4.35	1.65e-05	0.00161	0.42	0.2	Blood pressure;	chr10:58044760	chr10:57095699~57095781:+
THCA	cis	rs8062405	0.723	rs12445744	ENSG00000270424.1	RP11-1348G14.6	4.35	1.65e-05	0.00161	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.755	rs4787455	ENSG00000270424.1	RP11-1348G14.6	4.35	1.65e-05	0.00161	0.25	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28749959~28750595:-
THCA	cis	rs2448490	0.642	rs507859	ENSG00000214659.4	KRT8P26	-4.35	1.65e-05	0.00161	-0.18	-0.2	Platelet count;	chr11:65704511	chr11:65726939~65728214:+
THCA	cis	rs595244	0.908	rs2118181	ENSG00000259705.1	RP11-227D13.1	-4.35	1.65e-05	0.00161	-0.28	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48623687	chr15:48645951~48652016:+
THCA	cis	rs7216064	1	rs56393562	ENSG00000278740.1	RP11-147L13.14	4.35	1.65e-05	0.00161	0.22	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67937802	chr17:68188547~68189165:+
THCA	cis	rs9840812	0.691	rs7621025	ENSG00000239213.4	NCK1-AS1	4.35	1.65e-05	0.00161	0.18	0.2	Fibrinogen levels;	chr3:136553404	chr3:136841726~136862054:-
THCA	cis	rs7216064	1	rs62084210	ENSG00000278740.1	RP11-147L13.14	4.35	1.65e-05	0.00161	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67832594	chr17:68188547~68189165:+
THCA	cis	rs9467773	0.62	rs2504571	ENSG00000261353.1	CTA-14H9.5	-4.35	1.65e-05	0.00161	-0.2	-0.2	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26527063~26527404:+
THCA	cis	rs62025270	0.848	rs2554	ENSG00000259295.5	CSPG4P12	-4.35	1.65e-05	0.00161	-0.32	-0.2	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85191438~85213905:+
THCA	cis	rs728616	0.51	rs12768957	ENSG00000242600.5	MBL1P	4.35	1.65e-05	0.00161	0.24	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80427537	chr10:79904898~79950336:+
THCA	cis	rs6747952	0.899	rs2880132	ENSG00000279484.1	KLHL30-AS1	4.35	1.65e-05	0.00161	0.19	0.2	Mean corpuscular hemoglobin concentration;	chr2:238174335	chr2:238152889~238155994:-
THCA	cis	rs875971	0.66	rs12698534	ENSG00000272831.1	RP11-792A8.4	4.35	1.65e-05	0.00161	0.12	0.2	Aortic root size;	chr7:66521858	chr7:66739829~66740385:-
THCA	cis	rs4819052	0.851	rs1056101	ENSG00000182586.6	LINC00334	-4.35	1.65e-05	0.00161	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45234340~45258730:+
THCA	cis	rs2018683	0.803	rs12700920	ENSG00000272568.4	CTB-113D17.1	4.35	1.65e-05	0.00161	0.19	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.933	rs12536127	ENSG00000272568.4	CTB-113D17.1	4.35	1.65e-05	0.00161	0.19	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28979967~29013367:+
THCA	cis	rs801193	0.967	rs34356500	ENSG00000232546.1	RP11-458F8.1	-4.35	1.65e-05	0.00161	-0.16	-0.2	Aortic root size;	chr7:66771620	chr7:66848496~66858136:+
THCA	cis	rs10911902	0.643	rs2297226	ENSG00000229739.2	RP11-295K2.3	-4.35	1.65e-05	0.00161	-0.3	-0.2	Schizophrenia;	chr1:186374627	chr1:186435161~186470291:+
THCA	cis	rs4776970	0.632	rs12592101	ENSG00000270964.1	RP11-502I4.3	-4.35	1.65e-05	0.00161	-0.16	-0.2	Body mass index;Waist circumference;	chr15:67737232	chr15:67541072~67542604:-
THCA	cis	rs35740288	0.77	rs11630112	ENSG00000259295.5	CSPG4P12	4.35	1.65e-05	0.00161	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85577015	chr15:85191438~85213905:+
THCA	cis	rs9840812	0.691	rs1070232	ENSG00000239213.4	NCK1-AS1	4.35	1.65e-05	0.00161	0.19	0.2	Fibrinogen levels;	chr3:136529245	chr3:136841726~136862054:-
THCA	cis	rs62158800	0.852	rs57399677	ENSG00000237880.1	AC096669.2	4.35	1.65e-05	0.00161	0.32	0.2	Facial morphology (factor 22);	chr2:107680504	chr2:107385632~107542649:-
THCA	cis	rs10484434	0.901	rs36125084	ENSG00000272462.2	U91328.19	4.35	1.65e-05	0.00161	0.21	0.2	HIV-1 viral setpoint;	chr6:25969884	chr6:25992662~26001775:+
THCA	cis	rs4938330	0.723	rs7931398	ENSG00000254851.1	RP11-109L13.1	4.35	1.65e-05	0.00161	0.28	0.2	Blood protein levels;	chr11:117008960	chr11:117135528~117138582:+
THCA	cis	rs914615	0.552	rs7556304	ENSG00000236675.1	MTX1P1	-4.35	1.65e-05	0.00161	-0.18	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155167033	chr1:155230975~155234325:+
THCA	cis	rs4648045	0.687	rs3774956	ENSG00000246560.2	RP11-10L12.4	4.35	1.65e-05	0.00161	0.23	0.2	Lymphocyte percentage of white cells;	chr4:102587369	chr4:102828055~102844075:+
THCA	cis	rs1046491	1	rs12455304	ENSG00000264964.1	RP11-888D10.3	4.35	1.65e-05	0.00161	0.33	0.2	Scarlet fever;	chr18:9200840	chr18:9315194~9334441:-
THCA	cis	rs9876781	0.539	rs9809695	ENSG00000244380.1	RP11-24C3.2	-4.35	1.66e-05	0.00161	-0.24	-0.2	Longevity;	chr3:48364654	chr3:48440352~48446656:-
THCA	cis	rs13178541	0.873	rs11745158	ENSG00000250378.1	RP11-119J18.1	-4.35	1.66e-05	0.00161	-0.23	-0.2	IgG glycosylation;	chr5:135794701	chr5:135812667~135826582:+
THCA	cis	rs962856	1	rs6710832	ENSG00000236780.4	AC078941.1	4.35	1.66e-05	0.00161	0.24	0.2	Pancreatic cancer;	chr2:67374810	chr2:67123357~67215319:-
THCA	cis	rs73198271	0.562	rs17631022	ENSG00000253893.2	FAM85B	4.35	1.66e-05	0.00161	0.34	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8804687	chr8:8167819~8226614:-
THCA	cis	rs1728785	0.688	rs698718	ENSG00000274698.1	RP11-71L14.4	4.35	1.66e-05	0.00161	0.27	0.2	Ulcerative colitis;	chr16:68526282	chr16:68450283~68452318:+
THCA	cis	rs9302635	0.513	rs12928732	ENSG00000260886.1	TAT-AS1	4.35	1.66e-05	0.00161	0.26	0.2	Blood protein levels;	chr16:72154784	chr16:71565789~71578187:+
THCA	cis	rs9863	0.861	rs4765305	ENSG00000270028.1	RP11-380L11.4	4.35	1.66e-05	0.00161	0.2	0.2	White blood cell count;	chr12:123946065	chr12:123925461~123926083:-
THCA	cis	rs6747952	0.899	rs2121404	ENSG00000279484.1	KLHL30-AS1	4.35	1.66e-05	0.00161	0.18	0.2	Mean corpuscular hemoglobin concentration;	chr2:238175185	chr2:238152889~238155994:-
THCA	cis	rs4714902	0.655	rs993632	ENSG00000231769.2	RP1-8B1.4	-4.35	1.66e-05	0.00161	-0.17	-0.2	Colonoscopy-negative controls vs population controls;	chr6:46118520	chr6:46097093~46129706:-
THCA	cis	rs12908161	1	rs12903134	ENSG00000188388.10	GOLGA6L3	4.35	1.66e-05	0.00161	0.26	0.2	Schizophrenia;	chr15:84794468	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs35726233	ENSG00000188388.10	GOLGA6L3	4.35	1.66e-05	0.00161	0.26	0.2	Schizophrenia;	chr15:84794569	chr15:85240472~85247170:+
THCA	cis	rs4835473	0.637	rs13110964	ENSG00000251600.4	RP11-673E1.1	4.35	1.66e-05	0.00161	0.24	0.2	Immature fraction of reticulocytes;	chr4:143765119	chr4:143912331~143982454:+
THCA	cis	rs7572644	0.782	rs10185472	ENSG00000223522.1	AC093690.1	4.35	1.66e-05	0.00161	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27928487	chr2:28307691~28310459:-
THCA	cis	rs7726839	0.794	rs11739663	ENSG00000225138.6	CTD-2228K2.7	4.35	1.66e-05	0.00161	0.22	0.2	Obesity-related traits;	chr5:593968	chr5:473236~480884:+
THCA	cis	rs17772222	0.545	rs1758846	ENSG00000222990.1	RNU4-22P	-4.35	1.66e-05	0.00161	-0.24	-0.2	Coronary artery calcification;	chr14:88449288	chr14:88513498~88513663:+
THCA	cis	rs4936099	0.646	rs4937514	ENSG00000175773.11	RP11-121M22.1	4.35	1.66e-05	0.00161	0.17	0.2	Optic cup area;Vertical cup-disc ratio;	chr11:130394620	chr11:130314993~130403657:+
THCA	cis	rs875971	1	rs1981798	ENSG00000230189.5	GS1-124K5.2	4.35	1.66e-05	0.00161	0.13	0.2	Aortic root size;	chr7:66489916	chr7:66409143~66490059:-
THCA	cis	rs7572644	0.782	rs4666030	ENSG00000223522.1	AC093690.1	-4.35	1.66e-05	0.00162	-0.23	-0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27874355	chr2:28307691~28310459:-
THCA	cis	rs7618915	0.679	rs6802320	ENSG00000243224.1	RP5-1157M23.2	-4.35	1.66e-05	0.00162	-0.21	-0.2	Bipolar disorder;	chr3:52207819	chr3:52239258~52241097:+
THCA	cis	rs8054556	0.73	rs4788190	ENSG00000183604.13	SMG1P5	-4.35	1.66e-05	0.00162	-0.18	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30267553~30335374:-
THCA	cis	rs1923243	0.71	rs12118367	ENSG00000223479.3	RP4-788P17.1	4.35	1.66e-05	0.00162	0.22	0.2	Migraine;	chr1:73135379	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.677	rs12137150	ENSG00000223479.3	RP4-788P17.1	4.35	1.66e-05	0.00162	0.22	0.2	Migraine;	chr1:73135616	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs28589838	ENSG00000223479.3	RP4-788P17.1	4.35	1.66e-05	0.00162	0.22	0.2	Migraine;	chr1:73135736	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs34459928	ENSG00000223479.3	RP4-788P17.1	4.35	1.66e-05	0.00162	0.22	0.2	Migraine;	chr1:73135789	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4582739	ENSG00000223479.3	RP4-788P17.1	4.35	1.66e-05	0.00162	0.22	0.2	Migraine;	chr1:73136698	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12138397	ENSG00000223479.3	RP4-788P17.1	4.35	1.66e-05	0.00162	0.22	0.2	Migraine;	chr1:73137182	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.678	rs12119633	ENSG00000223479.3	RP4-788P17.1	4.35	1.66e-05	0.00162	0.22	0.2	Migraine;	chr1:73137190	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12725886	ENSG00000223479.3	RP4-788P17.1	4.35	1.66e-05	0.00162	0.22	0.2	Migraine;	chr1:73137832	chr1:73635216~73715214:+
THCA	cis	rs4743820	0.503	rs10991791	ENSG00000230147.2	RP11-305L7.5	4.35	1.66e-05	0.00162	0.25	0.2	Ulcerative colitis;Inflammatory bowel disease;	chr9:91159223	chr9:91169585~91170045:-
THCA	cis	rs2880765	0.743	rs4551990	ENSG00000259630.2	CTD-2262B20.1	-4.35	1.66e-05	0.00162	-0.21	-0.2	Coronary artery disease;	chr15:85472056	chr15:85415228~85415633:+
THCA	cis	rs6088590	1	rs2076668	ENSG00000276073.1	RP5-1125A11.7	-4.35	1.66e-05	0.00162	-0.18	-0.2	Coronary artery disease;	chr20:34849818	chr20:33985617~33988989:-
THCA	cis	rs375066	0.935	rs10406290	ENSG00000278917.1	RP11-15A1.4	-4.35	1.66e-05	0.00162	-0.16	-0.2	Breast cancer;	chr19:43874725	chr19:43891233~43895411:+
THCA	cis	rs2412819	0.559	rs8040336	ENSG00000166763.7	STRCP1	4.35	1.66e-05	0.00162	0.2	0.2	Lung cancer;	chr15:43761419	chr15:43699488~43718184:-
THCA	cis	rs9467773	0.523	rs2498399	ENSG00000228223.2	HCG11	-4.35	1.66e-05	0.00162	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26523450~26526579:+
THCA	cis	rs1048886	0.872	rs16869373	ENSG00000271967.1	RP11-134K13.4	-4.35	1.66e-05	0.00162	-0.21	-0.2	Type 2 diabetes;	chr6:70559929	chr6:70596438~70596980:+
THCA	cis	rs1113500	0.73	rs1781080	ENSG00000230489.1	VAV3-AS1	4.35	1.66e-05	0.00162	0.18	0.2	Growth-regulated protein alpha levels;	chr1:108050793	chr1:107964443~107994607:+
THCA	cis	rs17270561	0.609	rs1937132	ENSG00000272462.2	U91328.19	-4.35	1.66e-05	0.00162	-0.17	-0.2	Iron status biomarkers;	chr6:25756789	chr6:25992662~26001775:+
THCA	cis	rs17685	0.753	rs1104879	ENSG00000230882.1	AC005077.14	4.35	1.66e-05	0.00162	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76056250	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs7804598	ENSG00000230882.1	AC005077.14	4.35	1.66e-05	0.00162	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76073260	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs59659102	ENSG00000230882.1	AC005077.14	4.35	1.66e-05	0.00162	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76080796	chr7:76071469~76074963:-
THCA	cis	rs17685	0.725	rs6467993	ENSG00000230882.1	AC005077.14	4.35	1.66e-05	0.00162	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76090032	chr7:76071469~76074963:-
THCA	cis	rs17685	0.725	rs7795291	ENSG00000230882.1	AC005077.14	4.35	1.66e-05	0.00162	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76095888	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs6954569	ENSG00000230882.1	AC005077.14	4.35	1.66e-05	0.00162	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76109567	chr7:76071469~76074963:-
THCA	cis	rs516805	0.501	rs11751662	ENSG00000279453.1	RP3-425C14.4	-4.35	1.66e-05	0.00162	-0.16	-0.2	Lymphocyte counts;	chr6:122491925	chr6:122436789~122439223:-
THCA	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-4.35	1.66e-05	0.00162	-0.25	-0.2	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
THCA	cis	rs9880211	0.615	rs66890203	ENSG00000239213.4	NCK1-AS1	4.35	1.66e-05	0.00162	0.27	0.2	Height;Body mass index;	chr3:136434703	chr3:136841726~136862054:-
THCA	cis	rs7617480	0.648	rs9848268	ENSG00000229759.1	MRPS18AP1	4.35	1.66e-05	0.00162	0.32	0.2	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48724838	chr3:48256350~48256938:-
THCA	cis	rs734999	0.588	rs10910099	ENSG00000225931.3	RP3-395M20.7	-4.35	1.66e-05	0.00162	-0.23	-0.2	Ulcerative colitis;	chr1:2602113	chr1:2566410~2569888:+
THCA	cis	rs1728785	1	rs1749793	ENSG00000274698.1	RP11-71L14.4	4.35	1.66e-05	0.00162	0.28	0.2	Ulcerative colitis;	chr16:68535409	chr16:68450283~68452318:+
THCA	cis	rs8067545	1	rs9891739	ENSG00000270091.1	RP11-78O7.2	-4.35	1.66e-05	0.00162	-0.15	-0.2	Schizophrenia;	chr17:20038864	chr17:19896590~19897287:-
THCA	cis	rs7829975	0.659	rs4382480	ENSG00000254340.1	RP11-10A14.3	4.35	1.66e-05	0.00162	0.22	0.2	Mood instability;	chr8:8863963	chr8:9141424~9145435:+
THCA	cis	rs4705952	0.832	rs2706394	ENSG00000233006.5	AC034220.3	-4.35	1.66e-05	0.00162	-0.19	-0.2	C-reactive protein levels;	chr5:132523819	chr5:132311285~132369916:-
THCA	cis	rs2380220	0.872	rs2613528	ENSG00000261366.1	MANEA-AS1	4.35	1.66e-05	0.00162	0.24	0.2	Behavioural disinhibition (generation interaction);	chr6:95491561	chr6:95575183~95577450:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000272831.1	RP11-792A8.4	4.35	1.66e-05	0.00162	0.12	0.2	Aortic root size;	chr7:65975357	chr7:66739829~66740385:-
THCA	cis	rs4434872	0.536	rs12045838	ENSG00000223599.1	RP11-216N14.7	-4.35	1.66e-05	0.00162	-0.37	-0.2	Conduct disorder (symptom count);	chr1:153887540	chr1:153852106~153853414:-
THCA	cis	rs10888838	0.756	rs59455983	ENSG00000198711.5	SSBP3-AS1	4.35	1.67e-05	0.00162	0.25	0.2	Mitochondrial DNA levels;	chr1:54229275	chr1:54236440~54239063:+
THCA	cis	rs4660214	0.614	rs11205802	ENSG00000182109.6	RP11-69E11.4	-4.35	1.67e-05	0.00162	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233442	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.614	rs10888715	ENSG00000182109.6	RP11-69E11.4	-4.35	1.67e-05	0.00162	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233572	chr1:39522280~39546187:-
THCA	cis	rs6940638	0.688	rs9379960	ENSG00000219392.1	RP1-265C24.5	-4.35	1.67e-05	0.00162	-0.23	-0.2	Intelligence (multi-trait analysis);	chr6:27153546	chr6:28115628~28116551:+
THCA	cis	rs728616	0.614	rs958865	ENSG00000242600.5	MBL1P	4.35	1.67e-05	0.00162	0.21	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948273	chr10:79904898~79950336:+
THCA	cis	rs1124769	0.599	rs57262951	ENSG00000259378.1	DCAF13P3	4.35	1.67e-05	0.00162	0.3	0.2	Cognitive performance;	chr15:50788541	chr15:50944663~50945996:+
THCA	cis	rs6940638	0.688	rs2022272	ENSG00000219392.1	RP1-265C24.5	-4.35	1.67e-05	0.00162	-0.23	-0.2	Intelligence (multi-trait analysis);	chr6:27135801	chr6:28115628~28116551:+
THCA	cis	rs10129255	0.834	rs10139893	ENSG00000211970.3	IGHV4-61	-4.35	1.67e-05	0.00162	-0.12	-0.2	Kawasaki disease;	chr14:106711377	chr14:106639119~106639657:-
THCA	cis	rs62025270	0.576	rs62022947	ENSG00000259295.5	CSPG4P12	-4.35	1.67e-05	0.00162	-0.33	-0.2	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85191438~85213905:+
THCA	cis	rs4950322	0.515	rs17160050	ENSG00000180867.10	PDIA3P1	4.35	1.67e-05	0.00162	0.19	0.2	Protein quantitative trait loci;	chr1:147255558	chr1:147178113~147179622:+
THCA	cis	rs763121	0.853	rs2281021	ENSG00000273076.1	RP3-508I15.22	4.35	1.67e-05	0.00162	0.2	0.2	Menopause (age at onset);	chr22:38668662	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5995610	ENSG00000273076.1	RP3-508I15.22	4.35	1.67e-05	0.00162	0.2	0.2	Menopause (age at onset);	chr22:38668676	chr22:38743495~38743910:+
THCA	cis	rs6163	0.727	rs284862	ENSG00000213061.2	PFN1P11	-4.35	1.67e-05	0.00162	-0.23	-0.2	Waist circumference;Hip circumference;	chr10:102812324	chr10:102838011~102845473:-
THCA	cis	rs11633886	0.528	rs2248207	ENSG00000273972.1	CTD-2306A12.1	4.35	1.67e-05	0.00162	0.22	0.2	Diisocyanate-induced asthma;	chr15:45809215	chr15:45702640~45703183:+
THCA	cis	rs2439831	0.681	rs511673	ENSG00000166763.7	STRCP1	4.35	1.67e-05	0.00162	0.26	0.2	Lung cancer in ever smokers;	chr15:43326665	chr15:43699488~43718184:-
THCA	cis	rs13118159	0.55	rs4974614	ENSG00000254094.1	AC078852.1	-4.35	1.67e-05	0.00162	-0.24	-0.2	Longevity;	chr4:1379701	chr4:1356581~1358075:+
THCA	cis	rs875971	0.508	rs10950045	ENSG00000229886.1	RP5-1132H15.3	-4.35	1.67e-05	0.00162	-0.2	-0.2	Aortic root size;	chr7:66601386	chr7:66025126~66031544:-
THCA	cis	rs801193	0.839	rs6968619	ENSG00000229886.1	RP5-1132H15.3	-4.35	1.67e-05	0.00162	-0.2	-0.2	Aortic root size;	chr7:66603880	chr7:66025126~66031544:-
THCA	cis	rs801193	0.805	rs12532355	ENSG00000229886.1	RP5-1132H15.3	-4.35	1.67e-05	0.00162	-0.2	-0.2	Aortic root size;	chr7:66605597	chr7:66025126~66031544:-
THCA	cis	rs7520050	0.778	rs2934857	ENSG00000234329.1	RP11-767N6.2	4.35	1.67e-05	0.00162	0.18	0.2	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45651039~45651826:-
THCA	cis	rs9911578	0.835	rs2301867	ENSG00000224738.1	AC099850.1	-4.35	1.67e-05	0.00162	-0.23	-0.2	Intelligence (multi-trait analysis);	chr17:58402713	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.835	rs723991	ENSG00000224738.1	AC099850.1	-4.35	1.67e-05	0.00162	-0.23	-0.2	Intelligence (multi-trait analysis);	chr17:58404678	chr17:59106598~59118267:+
THCA	cis	rs62246343	0.63	rs3774063	ENSG00000254485.4	RP11-380O24.1	4.35	1.67e-05	0.00162	0.32	0.2	Fibrinogen levels;	chr3:9470052	chr3:9292588~9363303:-
THCA	cis	rs8192917	0.573	rs66505306	ENSG00000258744.1	RP11-80A15.1	-4.35	1.67e-05	0.00162	-0.36	-0.2	Vitiligo;	chr14:24609404	chr14:24501594~24508688:+
THCA	cis	rs13126694	0.62	rs6844184	ENSG00000248429.4	RP11-597D13.9	4.35	1.67e-05	0.00162	0.21	0.2	Blood osmolality (transformed sodium);	chr4:158094156	chr4:158170752~158202877:+
THCA	cis	rs6439699	0.83	rs7626812	ENSG00000273486.1	RP11-731C17.2	4.35	1.67e-05	0.00162	0.2	0.2	Intelligence (multi-trait analysis);	chr3:137319218	chr3:136837338~136839021:-
THCA	cis	rs16852403	0.585	rs2815288	ENSG00000224687.1	RASAL2-AS1	-4.35	1.67e-05	0.00162	-0.29	-0.2	Childhood ear infection;	chr1:178250651	chr1:178091508~178093984:-
THCA	cis	rs1853665	0.58	rs6557201	ENSG00000231760.4	RP11-350J20.5	4.35	1.67e-05	0.00162	0.31	0.2	Radiation response;	chr6:149951431	chr6:149796151~149826294:-
THCA	cis	rs801193	0.839	rs12534943	ENSG00000229886.1	RP5-1132H15.3	-4.35	1.67e-05	0.00162	-0.2	-0.2	Aortic root size;	chr7:66605533	chr7:66025126~66031544:-
THCA	cis	rs897984	0.806	rs9319588	ENSG00000275263.1	RP11-1072A3.4	4.35	1.67e-05	0.00163	0.23	0.2	Dementia with Lewy bodies;	chr16:30919662	chr16:30956872~30957199:-
THCA	cis	rs897984	0.77	rs12930657	ENSG00000275263.1	RP11-1072A3.4	4.35	1.67e-05	0.00163	0.23	0.2	Dementia with Lewy bodies;	chr16:30920647	chr16:30956872~30957199:-
THCA	cis	rs897984	0.77	rs3813020	ENSG00000275263.1	RP11-1072A3.4	4.35	1.67e-05	0.00163	0.23	0.2	Dementia with Lewy bodies;	chr16:30922754	chr16:30956872~30957199:-
THCA	cis	rs4578769	0.531	rs9951973	ENSG00000265939.1	UBE2CP2	-4.35	1.67e-05	0.00163	-0.23	-0.2	Eosinophil percentage of white cells;	chr18:22974353	chr18:22900486~22900995:-
THCA	cis	rs12887734	0.546	rs12886637	ENSG00000269940.1	RP11-73M18.7	-4.35	1.67e-05	0.00163	-0.2	-0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103694560~103695170:+
THCA	cis	rs1371614	0.632	rs1992311	ENSG00000272148.1	RP11-195B17.1	4.35	1.67e-05	0.00163	0.18	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26936473	chr2:27062428~27062907:-
THCA	cis	rs2115630	0.967	rs8027779	ENSG00000275120.1	RP11-182J1.17	-4.35	1.67e-05	0.00163	-0.2	-0.2	P wave terminal force;	chr15:84712154	chr15:84599434~84606463:-
THCA	cis	rs11175834	0.655	rs10047609	ENSG00000213344.2	PCNPP3	-4.35	1.67e-05	0.00163	-0.34	-0.2	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65582534	chr12:65645992~65646462:-
THCA	cis	rs4705952	0.943	rs7736328	ENSG00000233006.5	AC034220.3	4.35	1.67e-05	0.00163	0.18	0.2	C-reactive protein levels;	chr5:132504704	chr5:132311285~132369916:-
THCA	cis	rs7267979	1	rs7019	ENSG00000274973.1	RP13-401N8.7	-4.35	1.67e-05	0.00163	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25845497~25845862:+
THCA	cis	rs10461617	0.541	rs7715822	ENSG00000234553.1	AC022431.3	-4.35	1.67e-05	0.00163	-0.28	-0.2	Type 2 diabetes;	chr5:56747773	chr5:56536583~56537826:-
THCA	cis	rs875971	0.66	rs28698552	ENSG00000223473.2	GS1-124K5.3	4.35	1.67e-05	0.00163	0.13	0.2	Aortic root size;	chr7:66540031	chr7:66491049~66493566:-
THCA	cis	rs12530	0.54	rs5998471	ENSG00000230736.2	RP1-149A16.3	-4.35	1.67e-05	0.00163	-0.23	-0.2	IgG glycosylation;	chr22:32390230	chr22:32376664~32384343:+
THCA	cis	rs1577917	0.545	rs9344548	ENSG00000220563.1	PKMP3	4.35	1.67e-05	0.00163	0.14	0.2	Response to antipsychotic treatment;	chr6:85777619	chr6:85659892~85660606:-
THCA	cis	rs4713118	0.662	rs464312	ENSG00000219891.2	ZSCAN12P1	4.35	1.67e-05	0.00163	0.26	0.2	Parkinson's disease;	chr6:27999813	chr6:28091154~28093664:+
THCA	cis	rs868036	0.609	rs16951304	ENSG00000270964.1	RP11-502I4.3	-4.35	1.67e-05	0.00163	-0.19	-0.2	Restless legs syndrome;	chr15:67797280	chr15:67541072~67542604:-
THCA	cis	rs34467563	0.605	rs7832352	ENSG00000253105.4	KB-1448A5.1	4.35	1.67e-05	0.00163	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96413067	chr8:96371865~96387438:-
THCA	cis	rs7806994	1	rs7806994	ENSG00000275875.1	RP11-613E4.5	-4.35	1.68e-05	0.00163	-0.31	-0.2	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55741525~55741869:+
THCA	cis	rs9902453	0.967	rs12450956	ENSG00000263370.1	RP11-68I3.5	4.35	1.68e-05	0.00163	0.25	0.2	Coffee consumption (cups per day);	chr17:30202007	chr17:29639627~29640825:+
THCA	cis	rs786425	0.77	rs66647364	ENSG00000270095.1	RP11-214K3.18	-4.35	1.68e-05	0.00163	-0.24	-0.2	Pubertal anthropometrics;	chr12:123712733	chr12:123971457~123971714:-
THCA	cis	rs7615952	0.512	rs4679430	ENSG00000272840.1	RP11-379B18.6	4.35	1.68e-05	0.00163	0.28	0.2	Blood pressure (smoking interaction);	chr3:125639049	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.512	rs34651730	ENSG00000272840.1	RP11-379B18.6	4.35	1.68e-05	0.00163	0.28	0.2	Blood pressure (smoking interaction);	chr3:125639796	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.512	rs2979334	ENSG00000272840.1	RP11-379B18.6	4.35	1.68e-05	0.00163	0.28	0.2	Blood pressure (smoking interaction);	chr3:125639980	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.512	rs11929125	ENSG00000272840.1	RP11-379B18.6	4.35	1.68e-05	0.00163	0.28	0.2	Blood pressure (smoking interaction);	chr3:125640599	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.512	rs11921452	ENSG00000272840.1	RP11-379B18.6	4.35	1.68e-05	0.00163	0.28	0.2	Blood pressure (smoking interaction);	chr3:125640906	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.512	rs2922175	ENSG00000272840.1	RP11-379B18.6	4.35	1.68e-05	0.00163	0.28	0.2	Blood pressure (smoking interaction);	chr3:125642516	chr3:125774714~125797953:+
THCA	cis	rs12440869	0.92	rs975944	ENSG00000270964.1	RP11-502I4.3	4.35	1.68e-05	0.00163	0.17	0.2	Peak velocity of the mitral A-wave;	chr15:67316352	chr15:67541072~67542604:-
THCA	cis	rs59868192	0.925	rs72726025	ENSG00000246740.2	PLA2G4E-AS1	4.35	1.68e-05	0.00163	0.38	0.2	White blood cell count;	chr15:41948583	chr15:41972763~41999094:+
THCA	cis	rs7555523	0.887	rs4657475	ENSG00000224358.1	RP11-466F5.8	-4.35	1.68e-05	0.00163	-0.31	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717938	chr1:165768929~165775176:+
THCA	cis	rs7555523	0.887	rs4656461	ENSG00000224358.1	RP11-466F5.8	-4.35	1.68e-05	0.00163	-0.31	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717968	chr1:165768929~165775176:+
THCA	cis	rs2836950	0.565	rs2150413	ENSG00000238141.2	BRWD1-AS1	-4.35	1.68e-05	0.00163	-0.22	-0.2	Menarche (age at onset);	chr21:39242952	chr21:39315707~39323218:+
THCA	cis	rs7474896	0.537	rs1208587	ENSG00000120555.12	SEPT7P9	-4.35	1.68e-05	0.00163	-0.26	-0.2	Obesity (extreme);	chr10:37918831	chr10:38383069~38402916:-
THCA	cis	rs957448	0.554	rs12682601	ENSG00000253175.1	RP11-267M23.6	4.35	1.68e-05	0.00163	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94565036~94565715:+
THCA	cis	rs113835537	0.808	rs10896128	ENSG00000255517.5	CTD-3074O7.5	-4.35	1.68e-05	0.00163	-0.2	-0.2	Airway imaging phenotypes;	chr11:66557058	chr11:66473490~66480233:-
THCA	cis	rs9516	1	rs10898990	ENSG00000254974.1	RP11-702H23.2	-4.35	1.68e-05	0.00163	-0.21	-0.2	Facial morphology (factor 15, philtrum width);	chr11:74454121	chr11:74485580~74486051:-
THCA	cis	rs9516	1	rs10898991	ENSG00000254974.1	RP11-702H23.2	-4.35	1.68e-05	0.00163	-0.21	-0.2	Facial morphology (factor 15, philtrum width);	chr11:74454148	chr11:74485580~74486051:-
THCA	cis	rs703842	1	rs4646536	ENSG00000270039.1	RP11-571M6.17	-4.35	1.68e-05	0.00163	-0.22	-0.2	Multiple sclerosis;	chr12:57764205	chr12:57803838~57804415:+
THCA	cis	rs10484434	0.892	rs62394556	ENSG00000272810.1	U91328.22	4.35	1.68e-05	0.00163	0.2	0.2	HIV-1 viral setpoint;	chr6:26072668	chr6:26013241~26013757:+
THCA	cis	rs12681287	1	rs12681287	ENSG00000254231.1	CTD-2284J15.1	-4.35	1.68e-05	0.00163	-0.22	-0.2	Caudate activity during reward;	chr8:86257307	chr8:86333274~86343314:-
THCA	cis	rs5769765	0.862	rs138856	ENSG00000260613.1	RP3-522J7.6	-4.35	1.68e-05	0.00163	-0.24	-0.2	Schizophrenia;	chr22:49805730	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.862	rs138857	ENSG00000260613.1	RP3-522J7.6	-4.35	1.68e-05	0.00163	-0.24	-0.2	Schizophrenia;	chr22:49805941	chr22:49832616~49837786:-
THCA	cis	rs1923243	0.681	rs4350157	ENSG00000223479.3	RP4-788P17.1	4.35	1.68e-05	0.00163	0.22	0.2	Migraine;	chr1:73093025	chr1:73635216~73715214:+
THCA	cis	rs9843304	0.526	rs9850213	ENSG00000243885.1	RP11-278L15.2	-4.35	1.68e-05	0.00163	-0.22	-0.2	Gallstone disease;	chr3:149484803	chr3:149384179~149385800:-
THCA	cis	rs890448	0.93	rs2433314	ENSG00000254531.1	FLJ20021	-4.35	1.68e-05	0.00163	-0.17	-0.2	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101468618	chr4:101347780~101348883:+
THCA	cis	rs9309473	0.95	rs6546860	ENSG00000273245.1	RP11-434P11.2	4.35	1.68e-05	0.00163	0.27	0.2	Metabolite levels;	chr2:73617122	chr2:73750256~73750786:-
THCA	cis	rs4693089	0.604	rs4693629	ENSG00000213608.5	SLC25A14P1	4.35	1.68e-05	0.00163	0.23	0.2	Menopause (age at onset);	chr4:83475577	chr4:83477524~83478424:+
THCA	cis	rs4693089	0.604	rs17352803	ENSG00000213608.5	SLC25A14P1	4.35	1.68e-05	0.00163	0.23	0.2	Menopause (age at onset);	chr4:83476437	chr4:83477524~83478424:+
THCA	cis	rs6832769	0.922	rs9993675	ENSG00000272969.1	RP11-528I4.2	4.35	1.68e-05	0.00163	0.23	0.2	Personality dimensions;	chr4:55377355	chr4:55547112~55547889:+
THCA	cis	rs9634489	0.677	rs7996639	ENSG00000247400.3	DNAJC3-AS1	-4.35	1.68e-05	0.00163	-0.13	-0.2	Body mass index;	chr13:96366836	chr13:95648733~95676925:-
THCA	cis	rs4568518	0.53	rs7802331	ENSG00000279048.1	RP11-511H23.2	4.35	1.68e-05	0.00163	0.12	0.2	Measles;	chr7:17955352	chr7:17940503~17942922:+
THCA	cis	rs9634489	0.559	rs7998759	ENSG00000247400.3	DNAJC3-AS1	-4.35	1.68e-05	0.00163	-0.12	-0.2	Body mass index;	chr13:96288030	chr13:95648733~95676925:-
THCA	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-4.35	1.68e-05	0.00163	-0.2	-0.2	Height;	chr5:36865567	chr5:36666214~36725195:-
THCA	cis	rs2467099	0.786	rs1463486	ENSG00000267801.1	RP11-552F3.9	4.35	1.68e-05	0.00163	0.26	0.2	Systolic blood pressure;	chr17:75947861	chr17:75876372~75879546:+
THCA	cis	rs17772222	0.651	rs1950280	ENSG00000258983.2	RP11-507K2.2	-4.35	1.68e-05	0.00163	-0.22	-0.2	Coronary artery calcification;	chr14:88366259	chr14:88499334~88515502:+
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000220721.1	OR1F12	4.35	1.68e-05	0.00163	0.22	0.2	Pubertal anthropometrics;	chr6:28219323	chr6:28073316~28074233:+
THCA	cis	rs8062405	1	rs2008514	ENSG00000261766.1	RP11-22P6.2	4.35	1.68e-05	0.00163	0.19	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28862166~28863340:-
THCA	cis	rs2898290	0.5	rs11998678	ENSG00000270154.1	RP11-419I17.1	-4.35	1.68e-05	0.00163	-0.24	-0.2	Systolic blood pressure;	chr8:11972641	chr8:12476462~12477122:+
THCA	cis	rs2439831	1	rs2439841	ENSG00000205771.5	CATSPER2P1	-4.35	1.68e-05	0.00163	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43442551	chr15:43726918~43747094:-
THCA	cis	rs9926296	0.581	rs6500457	ENSG00000260259.1	RP11-368I7.4	4.35	1.68e-05	0.00163	0.21	0.2	Vitiligo;	chr16:89832356	chr16:89682620~89686569:-
THCA	cis	rs13178541	0.63	rs6871355	ENSG00000250378.1	RP11-119J18.1	-4.35	1.68e-05	0.00163	-0.29	-0.2	IgG glycosylation;	chr5:135777444	chr5:135812667~135826582:+
THCA	cis	rs9341808	0.628	rs1892475	ENSG00000272129.1	RP11-250B2.6	4.35	1.68e-05	0.00163	0.25	0.2	Sitting height ratio;	chr6:80152496	chr6:80355424~80356859:+
THCA	cis	rs9283706	0.608	rs1428408	ENSG00000229666.1	MAST4-AS1	-4.35	1.68e-05	0.00163	-0.28	-0.2	Coronary artery disease;	chr5:67035375	chr5:67001383~67003953:-
THCA	cis	rs8054556	0.74	rs3924855	ENSG00000183604.13	SMG1P5	-4.35	1.68e-05	0.00163	-0.18	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29943634	chr16:30267553~30335374:-
THCA	cis	rs911119	0.913	rs3004145	ENSG00000270001.1	RP11-218C14.8	4.35	1.68e-05	0.00163	0.29	0.2	Chronic kidney disease;	chr20:23602239	chr20:23631826~23632316:-
THCA	cis	rs1853665	0.58	rs4242282	ENSG00000231760.4	RP11-350J20.5	4.35	1.68e-05	0.00163	0.31	0.2	Radiation response;	chr6:149952210	chr6:149796151~149826294:-
THCA	cis	rs4705952	0.832	rs4705863	ENSG00000233006.5	AC034220.3	4.35	1.68e-05	0.00163	0.18	0.2	C-reactive protein levels;	chr5:132506529	chr5:132311285~132369916:-
THCA	cis	rs868036	0.681	rs28376010	ENSG00000270964.1	RP11-502I4.3	-4.35	1.68e-05	0.00163	-0.19	-0.2	Restless legs syndrome;	chr15:67771401	chr15:67541072~67542604:-
THCA	cis	rs2803122	0.902	rs10811162	ENSG00000273226.1	RP11-513M16.8	-4.35	1.68e-05	0.00163	-0.18	-0.2	Pulse pressure;	chr9:19282310	chr9:19375451~19375996:+
THCA	cis	rs7560272	0.538	rs2421575	ENSG00000163016.8	ALMS1P	-4.35	1.68e-05	0.00164	-0.24	-0.2	Schizophrenia;	chr2:73692395	chr2:73644919~73685576:+
THCA	cis	rs6657613	0.873	rs926702	ENSG00000186301.8	MST1P2	4.35	1.68e-05	0.00164	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17010026	chr1:16645622~16650289:+
THCA	cis	rs6545883	0.558	rs7587389	ENSG00000270820.4	RP11-355B11.2	-4.35	1.68e-05	0.00164	-0.17	-0.2	Tuberculosis;	chr2:61422656	chr2:61471188~61484130:+
THCA	cis	rs2839186	0.721	rs3788252	ENSG00000215424.8	MCM3AP-AS1	4.35	1.68e-05	0.00164	0.12	0.2	Testicular germ cell tumor;	chr21:46241321	chr21:46229217~46259390:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000272831.1	RP11-792A8.4	4.35	1.68e-05	0.00164	0.12	0.2	Aortic root size;	chr7:66631041	chr7:66739829~66740385:-
THCA	cis	rs253959	0.739	rs37181	ENSG00000272265.1	CTD-2287O16.4	-4.35	1.68e-05	0.00164	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr5:116294307	chr5:116078110~116078570:-
THCA	cis	rs790006	0.958	rs11175274	ENSG00000243024.5	RPS11P6	-4.35	1.68e-05	0.00164	-0.25	-0.2	Response to cytidine analogues (gemcitabine);	chr12:64188871	chr12:64222337~64397065:+
THCA	cis	rs45509595	0.556	rs34409918	ENSG00000272009.1	RP1-313I6.12	-4.35	1.68e-05	0.00164	-0.38	-0.2	Breast cancer;	chr6:27717569	chr6:28078792~28081130:-
THCA	cis	rs2836950	0.501	rs13047518	ENSG00000238141.2	BRWD1-AS1	-4.35	1.68e-05	0.00164	-0.23	-0.2	Menarche (age at onset);	chr21:39335381	chr21:39315707~39323218:+
THCA	cis	rs10043228	1	rs12517508	ENSG00000248445.4	SEMA6A-AS1	-4.35	1.68e-05	0.00164	-0.26	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116087877	chr5:116447547~116508276:+
THCA	cis	rs2836950	0.502	rs12627205	ENSG00000238141.2	BRWD1-AS1	-4.35	1.68e-05	0.00164	-0.22	-0.2	Menarche (age at onset);	chr21:39258101	chr21:39315707~39323218:+
THCA	cis	rs34761973	1	rs34761973	ENSG00000272911.1	RP11-74E22.6	-4.35	1.68e-05	0.00164	-0.29	-0.2	Depressive symptoms (multi-trait analysis);Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis);	chr17:2614804	chr17:2688473~2688960:+
THCA	cis	rs5758659	0.714	rs2284087	ENSG00000281538.1	RP4-669P10.20	-4.35	1.68e-05	0.00164	-0.18	-0.2	Cognitive function;	chr22:42089667	chr22:42138060~42139726:+
THCA	cis	rs700651	0.754	rs1518367	ENSG00000231621.1	AC013264.2	-4.35	1.68e-05	0.00164	-0.21	-0.2	Intracranial aneurysm;	chr2:197942291	chr2:197197991~197199273:+
THCA	cis	rs1728785	1	rs12925177	ENSG00000274698.1	RP11-71L14.4	-4.35	1.69e-05	0.00164	-0.27	-0.2	Ulcerative colitis;	chr16:68535742	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1069288	ENSG00000274698.1	RP11-71L14.4	4.35	1.69e-05	0.00164	0.27	0.2	Ulcerative colitis;	chr16:68551382	chr16:68450283~68452318:+
THCA	cis	rs6088590	0.931	rs12625149	ENSG00000269202.1	RP4-614O4.12	4.35	1.69e-05	0.00164	0.18	0.2	Coronary artery disease;	chr20:34838009	chr20:35201747~35203288:-
THCA	cis	rs17270561	0.609	rs17267614	ENSG00000272462.2	U91328.19	-4.35	1.69e-05	0.00164	-0.17	-0.2	Iron status biomarkers;	chr6:25729799	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9348694	ENSG00000272462.2	U91328.19	-4.35	1.69e-05	0.00164	-0.17	-0.2	Iron status biomarkers;	chr6:25753412	chr6:25992662~26001775:+
THCA	cis	rs4742903	0.904	rs7028408	ENSG00000270332.1	SMC2-AS1	4.35	1.69e-05	0.00164	0.18	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104097530	chr9:104080024~104093073:-
THCA	cis	rs128738	0.5	rs28667882	ENSG00000237714.1	P4HA2-AS1	-4.35	1.69e-05	0.00164	-0.3	-0.2	Giant cell arteritis;	chr5:132232420	chr5:132184876~132192808:+
THCA	cis	rs6546886	0.625	rs13019449	ENSG00000257800.1	FNBP1P1	-4.35	1.69e-05	0.00164	-0.2	-0.2	Dialysis-related mortality;	chr2:74030758	chr2:74120680~74123218:+
THCA	cis	rs8067545	0.934	rs34848191	ENSG00000270091.1	RP11-78O7.2	-4.35	1.69e-05	0.00164	-0.15	-0.2	Schizophrenia;	chr17:20015313	chr17:19896590~19897287:-
THCA	cis	rs394563	0.601	rs376269	ENSG00000268592.3	RAET1E-AS1	4.35	1.69e-05	0.00164	0.27	0.2	Dupuytren's disease;	chr6:149474018	chr6:149863494~149919507:+
THCA	cis	rs1923243	0.71	rs9645298	ENSG00000223479.3	RP4-788P17.1	4.35	1.69e-05	0.00164	0.22	0.2	Migraine;	chr1:73112253	chr1:73635216~73715214:+
THCA	cis	rs11633886	0.528	rs3914852	ENSG00000273972.1	CTD-2306A12.1	4.35	1.69e-05	0.00164	0.22	0.2	Diisocyanate-induced asthma;	chr15:45808853	chr15:45702640~45703183:+
THCA	cis	rs2549003	1	rs6873426	ENSG00000237714.1	P4HA2-AS1	-4.35	1.69e-05	0.00164	-0.25	-0.2	Asthma (sex interaction);	chr5:132482939	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs6894655	ENSG00000237714.1	P4HA2-AS1	-4.35	1.69e-05	0.00164	-0.25	-0.2	Asthma (sex interaction);	chr5:132482957	chr5:132184876~132192808:+
THCA	cis	rs2549003	0.966	rs839	ENSG00000237714.1	P4HA2-AS1	-4.35	1.69e-05	0.00164	-0.25	-0.2	Asthma (sex interaction);	chr5:132483434	chr5:132184876~132192808:+
THCA	cis	rs12681288	0.894	rs66739903	ENSG00000260721.1	AF067845.1	4.35	1.69e-05	0.00164	0.24	0.2	Schizophrenia;	chr8:1060492	chr8:1368642~1369833:-
THCA	cis	rs9549367	0.529	rs55946737	ENSG00000269125.1	RP11-98F14.11	-4.35	1.69e-05	0.00164	-0.27	-0.2	Platelet distribution width;	chr13:113155700	chr13:113165002~113165183:-
THCA	cis	rs12234571	1	rs59033784	ENSG00000214293.7	APTR	4.35	1.69e-05	0.00164	0.25	0.2	Obesity-related traits;	chr7:77853158	chr7:77657660~77696265:-
THCA	cis	rs34929064	0.881	rs2067074	ENSG00000179428.2	AC073072.5	4.35	1.69e-05	0.00164	0.22	0.2	Major depression and alcohol dependence;	chr7:22681324	chr7:22725395~22727620:-
THCA	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	4.35	1.69e-05	0.00164	0.12	0.2	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
THCA	cis	rs889398	0.741	rs10852461	ENSG00000226232.7	RP11-419C5.2	-4.35	1.69e-05	0.00164	-0.2	-0.2	Body mass index;	chr16:69894943	chr16:69976388~69996188:-
THCA	cis	rs10744955	0.727	rs2414030	ENSG00000244879.4	GABPB1-AS1	-4.35	1.69e-05	0.00164	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr15:50164293	chr15:50354959~50372202:+
THCA	cis	rs11153306	0.677	rs10872070	ENSG00000231889.6	TRAF3IP2-AS1	4.35	1.69e-05	0.00164	0.17	0.2	Tonsillectomy;	chr6:111600601	chr6:111483511~111598302:+
THCA	cis	rs9880211	0.8	rs13433683	ENSG00000239213.4	NCK1-AS1	-4.35	1.69e-05	0.00164	-0.22	-0.2	Height;Body mass index;	chr3:136799828	chr3:136841726~136862054:-
THCA	cis	rs9834970	0.588	rs4441609	ENSG00000281100.1	RP11-640L9.2	-4.35	1.69e-05	0.00164	-0.21	-0.2	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36851226	chr3:36823151~36825158:-
THCA	cis	rs7200786	0.669	rs4781027	ENSG00000274038.1	RP11-66H6.4	4.35	1.69e-05	0.00164	0.25	0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10958591	chr16:11056556~11057034:+
THCA	cis	rs4819052	0.851	rs914214	ENSG00000182586.6	LINC00334	-4.35	1.69e-05	0.00164	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45234340~45258730:+
THCA	cis	rs62025270	0.632	rs10520594	ENSG00000259295.5	CSPG4P12	4.35	1.69e-05	0.00164	0.34	0.2	Idiopathic pulmonary fibrosis;	chr15:85585410	chr15:85191438~85213905:+
THCA	cis	rs10208649	0.706	rs75833613	ENSG00000233266.1	HMGB1P31	4.35	1.69e-05	0.00164	0.37	0.2	Body mass index;	chr2:54065224	chr2:54051334~54051760:+
THCA	cis	rs1124769	0.57	rs2574757	ENSG00000259378.1	DCAF13P3	4.35	1.69e-05	0.00164	0.28	0.2	Cognitive performance;	chr15:50846263	chr15:50944663~50945996:+
THCA	cis	rs10875746	0.68	rs4760610	ENSG00000258273.1	RP11-370I10.4	4.35	1.69e-05	0.00164	0.27	0.2	Longevity (90 years and older);	chr12:48024442	chr12:48333755~48333901:-
THCA	cis	rs9925964	0.933	rs2303223	ENSG00000232748.3	RP11-196G11.6	4.35	1.69e-05	0.00164	0.23	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31063854	chr16:31056460~31062803:+
THCA	cis	rs9425766	0.566	rs12079820	ENSG00000227373.4	RP11-160H22.5	4.35	1.69e-05	0.00164	0.28	0.2	Life satisfaction;	chr1:174240771	chr1:174115300~174160004:-
THCA	cis	rs867186	1	rs11908683	ENSG00000126005.14	MMP24-AS1	-4.35	1.69e-05	0.00164	-0.32	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35133117	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs75287019	ENSG00000126005.14	MMP24-AS1	-4.35	1.69e-05	0.00164	-0.32	-0.2	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35133458	chr20:35216462~35278131:-
THCA	cis	rs73108077	1	rs73108027	ENSG00000277112.2	RP11-755J8.1	-4.35	1.69e-05	0.00164	-0.39	-0.2	Red blood cell density in sickle cell anemia;	chr20:31398778	chr20:30681825~30723932:-
THCA	cis	rs1923243	0.617	rs4592217	ENSG00000223479.3	RP4-788P17.1	4.35	1.69e-05	0.00164	0.22	0.2	Migraine;	chr1:73033259	chr1:73635216~73715214:+
THCA	cis	rs997295	0.713	rs3784695	ENSG00000270964.1	RP11-502I4.3	-4.35	1.69e-05	0.00164	-0.17	-0.2	Motion sickness;	chr15:67710264	chr15:67541072~67542604:-
THCA	cis	rs7312933	0.558	rs4768399	ENSG00000257225.1	RP11-328C8.4	4.35	1.69e-05	0.00164	0.2	0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42348894	chr12:42459366~42466128:+
THCA	cis	rs10923574	0.576	rs1146315	ENSG00000231365.4	RP11-418J17.1	4.35	1.69e-05	0.00164	0.2	0.2	Breast cancer;Folding of antihelix;	chr1:118481780	chr1:119140396~119275973:+
THCA	cis	rs7577696	0.962	rs2365555	ENSG00000276334.1	AL133243.1	4.35	1.69e-05	0.00164	0.21	0.2	Inflammatory biomarkers;	chr2:32055630	chr2:32521927~32523547:+
THCA	cis	rs1046896	0.514	rs9894705	ENSG00000263063.1	RP11-388C12.1	4.35	1.69e-05	0.00164	0.25	0.2	Glycated hemoglobin levels;	chr17:82865882	chr17:82713908~82716255:-
THCA	cis	rs42648	0.869	rs6970376	ENSG00000225498.1	AC002064.5	-4.35	1.69e-05	0.00164	-0.2	-0.2	Homocysteine levels;	chr7:90308772	chr7:90312496~90322592:+
THCA	cis	rs10510102	0.516	rs10159759	ENSG00000226864.1	ATE1-AS1	4.35	1.69e-05	0.00164	0.33	0.2	Breast cancer;	chr10:121986533	chr10:121928312~121951965:+
THCA	cis	rs2072883	0.624	rs5759129	ENSG00000230319.1	AL022476.2	4.35	1.69e-05	0.00164	0.21	0.2	Schizophrenia;	chr22:43063020	chr22:43038585~43052366:+
THCA	cis	rs9902453	0.904	rs12952179	ENSG00000263370.1	RP11-68I3.5	-4.35	1.69e-05	0.00164	-0.25	-0.2	Coffee consumption (cups per day);	chr17:30085669	chr17:29639627~29640825:+
THCA	cis	rs12549025	0.623	rs11779446	ENSG00000253390.1	CTC-756D1.2	-4.35	1.69e-05	0.00164	-0.33	-0.2	Reticulocyte fraction of red cells;	chr8:23530813	chr8:23458601~23484971:+
THCA	cis	rs7560272	0.538	rs3980695	ENSG00000273245.1	RP11-434P11.2	-4.35	1.69e-05	0.00164	-0.22	-0.2	Schizophrenia;	chr2:73712425	chr2:73750256~73750786:-
THCA	cis	rs875971	0.83	rs4718358	ENSG00000230189.5	GS1-124K5.2	4.35	1.69e-05	0.00164	0.13	0.2	Aortic root size;	chr7:66508681	chr7:66409143~66490059:-
THCA	cis	rs10833905	0.775	rs10833889	ENSG00000246225.5	RP11-17A1.3	-4.35	1.69e-05	0.00164	-0.28	-0.2	Sudden cardiac arrest;	chr11:23001805	chr11:22829380~22945393:+
THCA	cis	rs801193	0.742	rs9969300	ENSG00000230189.5	GS1-124K5.2	-4.35	1.69e-05	0.00164	-0.13	-0.2	Aortic root size;	chr7:66316659	chr7:66409143~66490059:-
THCA	cis	rs7688540	0.511	rs76125013	ENSG00000211553.1	AC253576.2	-4.35	1.69e-05	0.00164	-0.31	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:136461~136568:+
THCA	cis	rs6496044	0.568	rs11636764	ENSG00000259630.2	CTD-2262B20.1	-4.35	1.69e-05	0.00165	-0.21	-0.2	Interstitial lung disease;	chr15:85536520	chr15:85415228~85415633:+
THCA	cis	rs6496044	0.591	rs979825	ENSG00000259630.2	CTD-2262B20.1	-4.35	1.69e-05	0.00165	-0.21	-0.2	Interstitial lung disease;	chr15:85537394	chr15:85415228~85415633:+
THCA	cis	rs6496044	0.547	rs8039929	ENSG00000259630.2	CTD-2262B20.1	-4.35	1.69e-05	0.00165	-0.21	-0.2	Interstitial lung disease;	chr15:85537731	chr15:85415228~85415633:+
THCA	cis	rs4591358	0.765	rs9288249	ENSG00000223466.1	AC064834.2	-4.35	1.69e-05	0.00165	-0.23	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195452555	chr2:195533035~195538681:+
THCA	cis	rs1124769	0.523	rs12595051	ENSG00000259378.1	DCAF13P3	4.35	1.69e-05	0.00165	0.28	0.2	Cognitive performance;	chr15:50808981	chr15:50944663~50945996:+
THCA	cis	rs4714902	0.655	rs9395156	ENSG00000231769.2	RP1-8B1.4	-4.35	1.69e-05	0.00165	-0.17	-0.2	Colonoscopy-negative controls vs population controls;	chr6:46116234	chr6:46097093~46129706:-
THCA	cis	rs1124769	0.719	rs2663536	ENSG00000259378.1	DCAF13P3	-4.35	1.69e-05	0.00165	-0.3	-0.2	Cognitive performance;	chr15:50902784	chr15:50944663~50945996:+
THCA	cis	rs2439831	0.85	rs28509275	ENSG00000205771.5	CATSPER2P1	-4.35	1.69e-05	0.00165	-0.31	-0.2	Lung cancer in ever smokers;	chr15:43805907	chr15:43726918~43747094:-
THCA	cis	rs11153306	1	rs17703931	ENSG00000231889.6	TRAF3IP2-AS1	-4.35	1.69e-05	0.00165	-0.17	-0.2	Tonsillectomy;	chr6:111629792	chr6:111483511~111598302:+
THCA	cis	rs72799341	0.706	rs59735493	ENSG00000279196.1	RP11-1072A3.3	4.35	1.7e-05	0.00165	0.2	0.2	Diastolic blood pressure;	chr16:31121779	chr16:30984630~30988270:-
THCA	cis	rs11671005	0.779	rs3794971	ENSG00000265272.2	RN7SL693P	4.35	1.7e-05	0.00165	0.28	0.2	Mean platelet volume;	chr19:58474499	chr19:58490797~58491075:+
THCA	cis	rs6951245	0.935	rs11766669	ENSG00000229043.2	AC091729.9	-4.35	1.7e-05	0.00165	-0.33	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1023957	chr7:1160374~1165267:+
THCA	cis	rs2281636	0.723	rs3740078	ENSG00000260475.1	RP11-85A1.3	4.35	1.7e-05	0.00165	0.2	0.2	Obesity-related traits;	chr10:99685834	chr10:99621055~99621918:+
THCA	cis	rs2281636	0.723	rs11190246	ENSG00000260475.1	RP11-85A1.3	4.35	1.7e-05	0.00165	0.2	0.2	Obesity-related traits;	chr10:99691854	chr10:99621055~99621918:+
THCA	cis	rs12216545	0.765	rs12538773	ENSG00000241134.3	BET1P1	-4.35	1.7e-05	0.00165	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552967	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs10254007	ENSG00000241134.3	BET1P1	-4.35	1.7e-05	0.00165	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150556293	chr7:150749736~150750094:+
THCA	cis	rs7136259	0.844	rs7313874	ENSG00000258302.2	RP11-981P6.1	4.35	1.7e-05	0.00165	0.17	0.2	Coronary heart disease;	chr12:89571272	chr12:89561129~89594878:+
THCA	cis	rs79349575	0.716	rs595767	ENSG00000270781.1	RP11-501C14.9	-4.35	1.7e-05	0.00165	-0.24	-0.2	Type 2 diabetes;	chr17:48880625	chr17:48899131~48899748:+
THCA	cis	rs6413860	0.571	rs11809795	ENSG00000260855.1	RP11-439E19.10	4.35	1.7e-05	0.00165	0.23	0.2	Gut microbiome composition (summer);	chr1:246684522	chr1:246772301~246775772:+
THCA	cis	rs7826238	0.564	rs2921053	ENSG00000233609.3	RP11-62H7.2	4.35	1.7e-05	0.00165	0.19	0.2	Systolic blood pressure;	chr8:8462453	chr8:8961200~8979025:+
THCA	cis	rs1923539	0.662	rs7893691	ENSG00000225484.5	NUTM2B-AS1	4.35	1.7e-05	0.00165	0.22	0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79931504	chr10:79663088~79826594:-
THCA	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-4.35	1.7e-05	0.00165	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
THCA	cis	rs875971	0.619	rs12533585	ENSG00000223473.2	GS1-124K5.3	4.35	1.7e-05	0.00165	0.13	0.2	Aortic root size;	chr7:66519618	chr7:66491049~66493566:-
THCA	cis	rs12410462	0.551	rs10916178	ENSG00000227711.2	RP11-275O4.5	-4.35	1.7e-05	0.00165	-0.24	-0.2	Major depressive disorder;	chr1:227629892	chr1:227509028~227520477:-
THCA	cis	rs4237845	0.537	rs10747786	ENSG00000270039.1	RP11-571M6.17	-4.35	1.7e-05	0.00165	-0.21	-0.2	Intelligence (multi-trait analysis);	chr12:57866818	chr12:57803838~57804415:+
THCA	cis	rs138249	1	rs138250	ENSG00000273253.2	RP3-402G11.26	-4.35	1.7e-05	0.00165	-0.19	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50131932	chr22:50199090~50200837:-
THCA	cis	rs755249	0.958	rs2068663	ENSG00000237624.1	OXCT2P1	4.35	1.7e-05	0.00165	0.27	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39514956~39516490:+
THCA	cis	rs10435719	0.753	rs9694940	ENSG00000254948.1	OR7E158P	-4.35	1.7e-05	0.00165	-0.25	-0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:11919900~11920809:-
THCA	cis	rs9880211	0.898	rs13434116	ENSG00000239213.4	NCK1-AS1	4.35	1.7e-05	0.00165	0.22	0.2	Height;Body mass index;	chr3:136634232	chr3:136841726~136862054:-
THCA	cis	rs10129255	0.833	rs61997797	ENSG00000280411.1	IGHV1-69-2	-4.35	1.7e-05	0.00165	-0.13	-0.2	Kawasaki disease;	chr14:106815190	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.833	rs7156689	ENSG00000280411.1	IGHV1-69-2	-4.35	1.7e-05	0.00165	-0.13	-0.2	Kawasaki disease;	chr14:106816039	chr14:106762092~106762588:-
THCA	cis	rs7219021	0.77	rs7217007	ENSG00000248278.1	SUMO2P17	4.35	1.7e-05	0.00165	0.24	0.2	Schizophrenia or bipolar disorder;	chr17:48767335	chr17:48874860~48908983:-
THCA	cis	rs6870983	0.636	rs12522676	ENSG00000247828.6	TMEM161B-AS1	-4.35	1.7e-05	0.00165	-0.16	-0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88149673	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.636	rs12521792	ENSG00000247828.6	TMEM161B-AS1	-4.35	1.7e-05	0.00165	-0.16	-0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88151870	chr5:88268895~88436685:+
THCA	cis	rs613391	0.522	rs555828	ENSG00000234840.1	LINC01239	4.35	1.7e-05	0.00165	0.23	0.2	Quantitative traits;	chr9:22733239	chr9:22646200~22824213:+
THCA	cis	rs6688613	0.685	rs10800276	ENSG00000225171.2	DUTP6	4.35	1.7e-05	0.00165	0.27	0.2	Refractive astigmatism;	chr1:166889704	chr1:166868748~166869209:+
THCA	cis	rs11633886	0.934	rs1554420	ENSG00000273972.1	CTD-2306A12.1	-4.35	1.7e-05	0.00165	-0.21	-0.2	Diisocyanate-induced asthma;	chr15:45784990	chr15:45702640~45703183:+
THCA	cis	rs2898290	0.622	rs4840567	ENSG00000227888.4	FAM66A	-4.35	1.7e-05	0.00165	-0.25	-0.2	Systolic blood pressure;	chr8:11490116	chr8:12362019~12388296:+
THCA	cis	rs3733585	0.605	rs4697710	ENSG00000261490.1	RP11-448G15.3	-4.35	1.7e-05	0.00165	-0.13	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10121025	chr4:10068089~10073019:-
THCA	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	4.35	1.7e-05	0.00165	0.24	0.2	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
THCA	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	4.35	1.7e-05	0.00165	0.25	0.2	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
THCA	cis	rs4705952	0.832	rs4705864	ENSG00000233006.5	AC034220.3	4.35	1.7e-05	0.00165	0.18	0.2	C-reactive protein levels;	chr5:132506635	chr5:132311285~132369916:-
THCA	cis	rs804280	0.662	rs11250164	ENSG00000255046.1	RP11-297N6.4	4.35	1.7e-05	0.00165	0.22	0.2	Myopia (pathological);	chr8:11753177	chr8:11797928~11802568:-
THCA	cis	rs10911902	0.643	rs16825185	ENSG00000229739.2	RP11-295K2.3	-4.35	1.7e-05	0.00165	-0.3	-0.2	Schizophrenia;	chr1:186337932	chr1:186435161~186470291:+
THCA	cis	rs11651753	1	rs11651753	ENSG00000264920.1	RP11-6N17.4	-4.35	1.7e-05	0.00165	-0.17	-0.2	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47951723	chr17:47891255~47895812:-
THCA	cis	rs4660214	0.666	rs7553009	ENSG00000182109.6	RP11-69E11.4	-4.35	1.7e-05	0.00165	-0.19	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39247441	chr1:39522280~39546187:-
THCA	cis	rs7136259	0.815	rs7297206	ENSG00000258302.2	RP11-981P6.1	-4.35	1.7e-05	0.00165	-0.17	-0.2	Coronary heart disease;	chr12:89625452	chr12:89561129~89594878:+
THCA	cis	rs6964833	0.935	rs13238996	ENSG00000184616.8	AC004166.6	4.35	1.7e-05	0.00165	0.32	0.2	Menarche (age at onset);	chr7:74655318	chr7:74906673~74913256:-
THCA	cis	rs8054556	0.74	rs12716975	ENSG00000183604.13	SMG1P5	-4.35	1.7e-05	0.00165	-0.18	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29939508	chr16:30267553~30335374:-
THCA	cis	rs76793172	0.557	rs6509234	ENSG00000267395.4	AC074212.6	-4.35	1.7e-05	0.00165	-0.17	-0.2	Eosinophil counts;	chr19:45726453	chr19:45767796~45772504:+
THCA	cis	rs7267979	1	rs2482930	ENSG00000276952.1	RP5-965G21.6	-4.35	1.7e-05	0.00165	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2500446	ENSG00000276952.1	RP5-965G21.6	-4.35	1.7e-05	0.00165	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2482937	ENSG00000276952.1	RP5-965G21.6	-4.35	1.7e-05	0.00165	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25284915~25285588:-
THCA	cis	rs4820294	0.926	rs62236671	ENSG00000233360.4	Z83844.1	4.35	1.7e-05	0.00165	0.24	0.2	Fat distribution (HIV);	chr22:37673298	chr22:37641832~37658377:-
THCA	cis	rs12216545	0.737	rs6464075	ENSG00000241134.3	BET1P1	-4.35	1.7e-05	0.00165	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150537453	chr7:150749736~150750094:+
THCA	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	4.35	1.7e-05	0.00165	0.14	0.2	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
THCA	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	4.35	1.7e-05	0.00165	0.14	0.2	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
THCA	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	4.35	1.7e-05	0.00165	0.14	0.2	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
THCA	cis	rs189798	0.845	rs330904	ENSG00000233609.3	RP11-62H7.2	-4.35	1.7e-05	0.00165	-0.2	-0.2	Myopia (pathological);	chr8:9134315	chr8:8961200~8979025:+
THCA	cis	rs4915077	0.803	rs76698933	ENSG00000230489.1	VAV3-AS1	4.35	1.7e-05	0.00165	0.29	0.2	Hypothyroidism;	chr1:107835331	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.803	rs77705025	ENSG00000230489.1	VAV3-AS1	4.35	1.7e-05	0.00165	0.29	0.2	Hypothyroidism;	chr1:107836350	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.803	rs74399981	ENSG00000230489.1	VAV3-AS1	4.35	1.7e-05	0.00165	0.29	0.2	Hypothyroidism;	chr1:107836535	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.803	rs4915080	ENSG00000230489.1	VAV3-AS1	4.35	1.7e-05	0.00165	0.29	0.2	Hypothyroidism;	chr1:107838145	chr1:107964443~107994607:+
THCA	cis	rs944289	0.966	rs2415317	ENSG00000258844.1	RP11-259K15.2	-4.35	1.7e-05	0.00165	-0.18	-0.2	Thyroid cancer;	chr14:36140472	chr14:36214607~36235608:+
THCA	cis	rs73108077	0.736	rs7273790	ENSG00000277112.2	RP11-755J8.1	4.35	1.7e-05	0.00165	0.38	0.2	Red blood cell density in sickle cell anemia;	chr20:31312478	chr20:30681825~30723932:-
THCA	cis	rs2898290	0.622	rs7829381	ENSG00000227888.4	FAM66A	-4.35	1.7e-05	0.00165	-0.26	-0.2	Systolic blood pressure;	chr8:11487064	chr8:12362019~12388296:+
THCA	cis	rs2898290	0.622	rs11250140	ENSG00000227888.4	FAM66A	-4.35	1.7e-05	0.00165	-0.26	-0.2	Systolic blood pressure;	chr8:11489083	chr8:12362019~12388296:+
THCA	cis	rs2380220	0.541	rs72928273	ENSG00000261366.1	MANEA-AS1	4.35	1.7e-05	0.00165	0.21	0.2	Behavioural disinhibition (generation interaction);	chr6:95631484	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.541	rs72928277	ENSG00000261366.1	MANEA-AS1	4.35	1.7e-05	0.00165	0.21	0.2	Behavioural disinhibition (generation interaction);	chr6:95631869	chr6:95575183~95577450:-
THCA	cis	rs34467563	0.626	rs938831	ENSG00000253105.4	KB-1448A5.1	-4.35	1.71e-05	0.00165	-0.24	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:96367052	chr8:96371865~96387438:-
THCA	cis	rs2070488	0.965	rs9829192	ENSG00000229589.1	ACVR2B-AS1	-4.35	1.71e-05	0.00166	-0.18	-0.2	Electrocardiographic conduction measures;	chr3:38527972	chr3:38451027~38454820:-
THCA	cis	rs2836950	0.565	rs2836943	ENSG00000238141.2	BRWD1-AS1	-4.35	1.71e-05	0.00166	-0.22	-0.2	Menarche (age at onset);	chr21:39220685	chr21:39315707~39323218:+
THCA	cis	rs4927850	0.521	rs4927679	ENSG00000242086.7	LINC00969	-4.35	1.71e-05	0.00166	-0.17	-0.2	Pancreatic cancer;	chr3:195931489	chr3:195658062~195739964:+
THCA	cis	rs4713118	0.669	rs200997	ENSG00000280107.1	AL022393.9	-4.35	1.71e-05	0.00166	-0.21	-0.2	Parkinson's disease;	chr6:27844037	chr6:28170845~28172521:+
THCA	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	4.35	1.71e-05	0.00166	0.28	0.2	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
THCA	cis	rs2070074	1	rs80317929	ENSG00000230074.1	RP11-195F19.9	-4.35	1.71e-05	0.00166	-0.36	-0.2	CTACK levels;	chr9:34598006	chr9:34665665~34681298:+
THCA	cis	rs4950322	0.748	rs17356680	ENSG00000180867.10	PDIA3P1	4.35	1.71e-05	0.00166	0.2	0.2	Protein quantitative trait loci;	chr1:147354934	chr1:147178113~147179622:+
THCA	cis	rs7131987	0.65	rs67146951	ENSG00000273680.1	RP11-996F15.6	4.35	1.71e-05	0.00166	0.28	0.2	QT interval;	chr12:29297620	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.65	rs10843382	ENSG00000273680.1	RP11-996F15.6	4.35	1.71e-05	0.00166	0.28	0.2	QT interval;	chr12:29298788	chr12:29332733~29333383:-
THCA	cis	rs9796	0.621	rs11858678	ENSG00000247556.5	OIP5-AS1	4.35	1.71e-05	0.00166	0.16	0.2	Menopause (age at onset);	chr15:41175734	chr15:41283990~41309737:+
THCA	cis	rs442309	1	rs224071	ENSG00000238280.1	RP11-436D10.3	4.35	1.71e-05	0.00166	0.23	0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62748715	chr10:62793562~62805887:-
THCA	cis	rs736408	0.562	rs1014969	ENSG00000243224.1	RP5-1157M23.2	-4.35	1.71e-05	0.00166	-0.22	-0.2	Bipolar disorder;	chr3:52774325	chr3:52239258~52241097:+
THCA	cis	rs2281603	1	rs11849530	ENSG00000259116.1	RP11-973N13.4	-4.35	1.71e-05	0.00166	-0.19	-0.2	Lymphocyte counts;	chr14:64451694	chr14:64514154~64540368:-
THCA	cis	rs1046896	0.594	rs67813226	ENSG00000263063.1	RP11-388C12.1	-4.34	1.71e-05	0.00166	-0.26	-0.2	Glycated hemoglobin levels;	chr17:82893258	chr17:82713908~82716255:-
THCA	cis	rs4948102	0.595	rs7793921	ENSG00000275875.1	RP11-613E4.5	-4.34	1.71e-05	0.00166	-0.23	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55741525~55741869:+
THCA	cis	rs4948102	0.595	rs10255049	ENSG00000275875.1	RP11-613E4.5	-4.34	1.71e-05	0.00166	-0.23	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55741525~55741869:+
THCA	cis	rs9302635	0.513	rs7198572	ENSG00000260886.1	TAT-AS1	4.34	1.71e-05	0.00166	0.26	0.2	Blood protein levels;	chr16:72149321	chr16:71565789~71578187:+
THCA	cis	rs7572644	0.739	rs10204488	ENSG00000223522.1	AC093690.1	4.34	1.71e-05	0.00166	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27909383	chr2:28307691~28310459:-
THCA	cis	rs12142240	0.738	rs41293275	ENSG00000232022.5	FAAHP1	-4.34	1.71e-05	0.00166	-0.22	-0.2	Menopause (age at onset);	chr1:46340757	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.738	rs17361749	ENSG00000232022.5	FAAHP1	-4.34	1.71e-05	0.00166	-0.22	-0.2	Menopause (age at onset);	chr1:46340808	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.738	rs41293277	ENSG00000232022.5	FAAHP1	-4.34	1.71e-05	0.00166	-0.22	-0.2	Menopause (age at onset);	chr1:46340878	chr1:46432129~46445521:+
THCA	cis	rs4434872	0.536	rs61804838	ENSG00000223599.1	RP11-216N14.7	-4.34	1.71e-05	0.00166	-0.37	-0.2	Conduct disorder (symptom count);	chr1:153873415	chr1:153852106~153853414:-
THCA	cis	rs4434872	0.536	rs33998934	ENSG00000223599.1	RP11-216N14.7	-4.34	1.71e-05	0.00166	-0.37	-0.2	Conduct disorder (symptom count);	chr1:153873589	chr1:153852106~153853414:-
THCA	cis	rs7824557	0.527	rs4634600	ENSG00000206014.6	OR7E161P	4.34	1.71e-05	0.00166	0.22	0.2	Retinal vascular caliber;	chr8:11381508	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.527	rs4631425	ENSG00000206014.6	OR7E161P	4.34	1.71e-05	0.00166	0.22	0.2	Retinal vascular caliber;	chr8:11381545	chr8:11928597~11929563:-
THCA	cis	rs3808502	0.585	rs4549730	ENSG00000206014.6	OR7E161P	4.34	1.71e-05	0.00166	0.22	0.2	Neuroticism;	chr8:11381569	chr8:11928597~11929563:-
THCA	cis	rs73108077	1	rs6059305	ENSG00000277112.2	RP11-755J8.1	-4.34	1.71e-05	0.00166	-0.39	-0.2	Red blood cell density in sickle cell anemia;	chr20:31432624	chr20:30681825~30723932:-
THCA	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-4.34	1.71e-05	0.00166	-0.2	-0.2	Height;	chr5:36882917	chr5:36666214~36725195:-
THCA	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	4.34	1.71e-05	0.00166	0.14	0.2	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
THCA	cis	rs708224	0.817	rs161978	ENSG00000277342.1	RP11-843B15.4	4.34	1.71e-05	0.00166	0.25	0.2	Pancreatic cancer;	chr12:32266939	chr12:32109076~32109602:+
THCA	cis	rs8030605	0.704	rs11632260	ENSG00000277245.1	RP11-48G14.3	4.34	1.71e-05	0.00166	0.34	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56309620	chr15:56447120~56447697:+
THCA	cis	rs711244	0.756	rs7588378	ENSG00000279519.1	RP11-288C18.1	4.34	1.71e-05	0.00166	0.16	0.2	Mean platelet volume;	chr2:36914352	chr2:36839922~36842539:-
THCA	cis	rs1414896	0.609	rs11165335	ENSG00000226026.4	RP11-57H12.3	4.34	1.71e-05	0.00166	0.19	0.2	Non-alcoholic fatty liver disease histology (AST);	chr1:95176216	chr1:95163219~95233982:-
THCA	cis	rs7141336	0.607	rs1885030	ENSG00000258884.1	CTD-3035D6.2	-4.34	1.71e-05	0.00166	-0.25	-0.2	Anxiety disorder;	chr14:90751788	chr14:90822365~90828128:-
THCA	cis	rs6088590	0.931	rs6088624	ENSG00000276073.1	RP5-1125A11.7	-4.34	1.71e-05	0.00166	-0.18	-0.2	Coronary artery disease;	chr20:34849049	chr20:33985617~33988989:-
THCA	cis	rs10875746	0.951	rs11168433	ENSG00000258234.1	RP11-370I10.2	4.34	1.71e-05	0.00166	0.23	0.2	Longevity (90 years and older);	chr12:48164281	chr12:48231098~48284210:-
THCA	cis	rs7572644	0.699	rs6708889	ENSG00000223522.1	AC093690.1	4.34	1.71e-05	0.00166	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27884825	chr2:28307691~28310459:-
THCA	cis	rs4664304	0.62	rs12692569	ENSG00000226266.5	AC009961.3	-4.34	1.71e-05	0.00166	-0.23	-0.2	Crohn's disease;Inflammatory bowel disease;	chr2:159867068	chr2:159670708~159712435:-
THCA	cis	rs7772486	0.764	rs2265471	ENSG00000270638.1	RP3-466P17.1	4.34	1.71e-05	0.00166	0.15	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145735570~145737218:+
THCA	cis	rs4237845	0.537	rs2002275	ENSG00000270039.1	RP11-571M6.17	-4.34	1.71e-05	0.00166	-0.22	-0.2	Intelligence (multi-trait analysis);	chr12:57889602	chr12:57803838~57804415:+
THCA	cis	rs7216064	1	rs62085993	ENSG00000278740.1	RP11-147L13.14	4.34	1.71e-05	0.00166	0.22	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67927036	chr17:68188547~68189165:+
THCA	cis	rs5758511	0.68	rs58654759	ENSG00000227370.1	RP4-669P10.19	4.34	1.71e-05	0.00166	0.23	0.2	Birth weight;	chr22:42246570	chr22:42132543~42132998:+
THCA	cis	rs6832769	0.922	rs28726308	ENSG00000272969.1	RP11-528I4.2	4.34	1.71e-05	0.00166	0.23	0.2	Personality dimensions;	chr4:55368239	chr4:55547112~55547889:+
THCA	cis	rs1923243	0.648	rs7551726	ENSG00000223479.3	RP4-788P17.1	4.34	1.71e-05	0.00166	0.22	0.2	Migraine;	chr1:73093026	chr1:73635216~73715214:+
THCA	cis	rs453301	0.624	rs2979265	ENSG00000233609.3	RP11-62H7.2	4.34	1.71e-05	0.00166	0.19	0.2	Joint mobility (Beighton score);	chr8:9001207	chr8:8961200~8979025:+
THCA	cis	rs1538970	0.924	rs11211117	ENSG00000234329.1	RP11-767N6.2	4.34	1.71e-05	0.00166	0.2	0.2	Platelet count;	chr1:45464574	chr1:45651039~45651826:-
THCA	cis	rs1538970	0.924	rs11211118	ENSG00000234329.1	RP11-767N6.2	4.34	1.71e-05	0.00166	0.2	0.2	Platelet count;	chr1:45464598	chr1:45651039~45651826:-
THCA	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	4.34	1.72e-05	0.00166	0.24	0.2	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
THCA	cis	rs6430538	0.671	rs6736792	ENSG00000224043.6	CCNT2-AS1	-4.34	1.72e-05	0.00166	-0.21	-0.2	Parkinson's disease;	chr2:134814520	chr2:134735464~134918710:-
THCA	cis	rs2657294	0.965	rs2657286	ENSG00000226051.5	ZNF503-AS1	4.34	1.72e-05	0.00166	0.27	0.2	Pneumonia;	chr10:75145940	chr10:75269819~75373500:+
THCA	cis	rs34467563	0.626	rs2640813	ENSG00000253105.4	KB-1448A5.1	4.34	1.72e-05	0.00166	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96365336	chr8:96371865~96387438:-
THCA	cis	rs7396835	0.551	rs10750098	ENSG00000280143.1	AP000892.6	4.34	1.72e-05	0.00166	0.34	0.2	Quantitative traits;	chr11:116834852	chr11:117204967~117210292:+
THCA	cis	rs868036	0.718	rs922494	ENSG00000270964.1	RP11-502I4.3	-4.34	1.72e-05	0.00167	-0.18	-0.2	Restless legs syndrome;	chr15:67828306	chr15:67541072~67542604:-
THCA	cis	rs944289	0.966	rs1169124	ENSG00000258844.1	RP11-259K15.2	4.34	1.72e-05	0.00167	0.18	0.2	Thyroid cancer;	chr14:36150082	chr14:36214607~36235608:+
THCA	cis	rs944289	0.899	rs1169125	ENSG00000258844.1	RP11-259K15.2	4.34	1.72e-05	0.00167	0.18	0.2	Thyroid cancer;	chr14:36150560	chr14:36214607~36235608:+
THCA	cis	rs944289	0.966	rs1169129	ENSG00000258844.1	RP11-259K15.2	4.34	1.72e-05	0.00167	0.18	0.2	Thyroid cancer;	chr14:36152619	chr14:36214607~36235608:+
THCA	cis	rs7141336	1	rs8005254	ENSG00000258884.1	CTD-3035D6.2	4.34	1.72e-05	0.00167	0.26	0.2	Anxiety disorder;	chr14:90820265	chr14:90822365~90828128:-
THCA	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	4.34	1.72e-05	0.00167	0.23	0.2	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
THCA	cis	rs941408	0.515	rs7253128	ENSG00000261342.1	AC006538.1	4.34	1.72e-05	0.00167	0.22	0.2	Total cholesterol levels;	chr19:2776984	chr19:2727743~2729327:-
THCA	cis	rs10875746	0.768	rs4760609	ENSG00000269514.1	RP11-370I10.12	-4.34	1.72e-05	0.00167	-0.19	-0.2	Longevity (90 years and older);	chr12:48021974	chr12:48198387~48202031:+
THCA	cis	rs8031584	0.736	rs11635775	ENSG00000178081.11	ULK4P3	4.34	1.72e-05	0.00167	0.26	0.2	Huntington's disease progression;	chr15:30868437	chr15:30103720~30131757:+
THCA	cis	rs791590	0.941	rs12722523	ENSG00000229664.1	RP11-536K7.5	-4.34	1.72e-05	0.00167	-0.33	-0.2	Soluble interleukin-2 receptor subunit alpha;	chr10:6036427	chr10:6025978~6036427:+
THCA	cis	rs654950	0.901	rs607586	ENSG00000230638.4	RP11-486B10.4	4.34	1.72e-05	0.00167	0.24	0.2	Airway imaging phenotypes;	chr1:41538708	chr1:41542069~41544310:+
THCA	cis	rs5758511	0.689	rs5758691	ENSG00000237037.8	NDUFA6-AS1	-4.34	1.72e-05	0.00167	-0.18	-0.2	Birth weight;	chr22:42272498	chr22:42090931~42137742:+
THCA	cis	rs5758511	0.68	rs1001586	ENSG00000237037.8	NDUFA6-AS1	-4.34	1.72e-05	0.00167	-0.18	-0.2	Birth weight;	chr22:42274287	chr22:42090931~42137742:+
THCA	cis	rs897984	0.762	rs1870293	ENSG00000275263.1	RP11-1072A3.4	4.34	1.72e-05	0.00167	0.23	0.2	Dementia with Lewy bodies;	chr16:30959620	chr16:30956872~30957199:-
THCA	cis	rs12935229	0.867	rs12930139	ENSG00000260922.1	RP11-538I12.3	-4.34	1.72e-05	0.00167	-0.31	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77279055	chr16:77234877~77290934:+
THCA	cis	rs2153535	0.585	rs9393048	ENSG00000230939.1	RP11-314C16.1	-4.34	1.72e-05	0.00167	-0.21	-0.2	Motion sickness;	chr6:8626321	chr6:8784178~8785445:+
THCA	cis	rs2033711	0.87	rs3764534	ENSG00000269054.1	CTD-2619J13.3	-4.34	1.72e-05	0.00167	-0.16	-0.2	Uric acid clearance;	chr19:58417769	chr19:58362585~58366591:+
THCA	cis	rs6121246	0.909	rs3203770	ENSG00000230613.1	HM13-AS1	4.34	1.72e-05	0.00167	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31794512	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6119725	ENSG00000230613.1	HM13-AS1	4.34	1.72e-05	0.00167	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31797754	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs1075698	ENSG00000230613.1	HM13-AS1	4.34	1.72e-05	0.00167	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31800189	chr20:31567707~31573263:-
THCA	cis	rs7088591	0.867	rs117214557	ENSG00000276818.1	AC026393.1	4.34	1.72e-05	0.00167	0.42	0.2	Blood pressure;	chr10:58045667	chr10:57095699~57095781:+
THCA	cis	rs7216064	1	rs11869819	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872553	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs55939964	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873181	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs12602912	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873957	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.953	rs12450907	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67874528	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs4569324	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67876634	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs62084248	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878425	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs12451511	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878745	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs62084249	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878882	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs35243555	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880361	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs58122682	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880799	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs62084251	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882620	chr17:68188547~68189165:+
THCA	cis	rs56313388	0.505	rs7203524	ENSG00000246379.5	RP11-461O7.1	-4.34	1.72e-05	0.00167	-0.21	-0.2	Pulse pressure;	chr16:56226367	chr16:56092987~56191094:-
THCA	cis	rs7267979	1	rs2482927	ENSG00000274973.1	RP13-401N8.7	4.34	1.72e-05	0.00167	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25845497~25845862:+
THCA	cis	rs6569038	0.522	rs1334922	ENSG00000253194.1	RP11-351A11.1	4.34	1.72e-05	0.00167	0.28	0.2	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119052007	chr6:118934785~119031541:+
THCA	cis	rs718433	0.556	rs2075477	ENSG00000211778.2	TRAV4	-4.34	1.72e-05	0.00167	-0.15	-0.2	Intraocular pressure;	chr14:21749072	chr14:21736152~21736982:+
THCA	cis	rs527616	0.793	rs675150	ENSG00000275805.1	RP11-349H17.2	4.34	1.72e-05	0.00167	0.25	0.2	Breast cancer;	chr18:26759755	chr18:26565723~26575626:-
THCA	cis	rs17412738	0.607	rs10512843	ENSG00000248724.5	NPHP3-AS1	-4.34	1.72e-05	0.00167	-0.29	-0.2	Blood protein levels;	chr3:132448983	chr3:132721750~132874223:+
THCA	cis	rs7577696	0.695	rs11676475	ENSG00000276334.1	AL133243.1	-4.34	1.72e-05	0.00167	-0.21	-0.2	Inflammatory biomarkers;	chr2:32164121	chr2:32521927~32523547:+
THCA	cis	rs2554380	0.628	rs963690	ENSG00000176700.18	SCAND2P	-4.34	1.72e-05	0.00167	-0.15	-0.2	Height;	chr15:83771068	chr15:84631451~84647478:+
THCA	cis	rs11633886	0.585	rs17636535	ENSG00000259200.1	RP11-718O11.1	4.34	1.72e-05	0.00167	0.24	0.2	Diisocyanate-induced asthma;	chr15:45786680	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.585	rs12915664	ENSG00000259200.1	RP11-718O11.1	4.34	1.72e-05	0.00167	0.24	0.2	Diisocyanate-induced asthma;	chr15:45787855	chr15:45705078~45931069:+
THCA	cis	rs7142002	0.536	rs10083330	ENSG00000272444.1	RP11-1017G21.6	-4.34	1.72e-05	0.00167	-0.35	-0.2	Autism;	chr14:102208211	chr14:101952416~101953063:+
THCA	cis	rs1842579	1	rs2297744	ENSG00000272691.1	RP11-290M5.4	-4.34	1.72e-05	0.00167	-0.2	-0.2	Coronary artery aneurysm in Kawasaki disease;	chr1:85840590	chr1:85578500~85578742:-
THCA	cis	rs7216064	1	rs8082512	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840943	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.953	rs8073510	ENSG00000278740.1	RP11-147L13.14	4.34	1.72e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67843094	chr17:68188547~68189165:+
THCA	cis	rs72843506	0.656	rs111249650	ENSG00000231258.2	ZSWIM5P2	4.34	1.72e-05	0.00167	0.3	0.2	Schizophrenia;	chr17:20008517	chr17:20583758~20591180:-
THCA	cis	rs9487094	0.626	rs2273752	ENSG00000223537.2	RP5-919F19.5	-4.34	1.72e-05	0.00167	-0.2	-0.2	Height;	chr6:109738307	chr6:109487906~109506800:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000223473.2	GS1-124K5.3	-4.34	1.72e-05	0.00167	-0.14	-0.2	Aortic root size;	chr7:66087510	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs778734	ENSG00000229886.1	RP5-1132H15.3	4.34	1.72e-05	0.00167	0.2	0.2	Aortic root size;	chr7:66349862	chr7:66025126~66031544:-
THCA	cis	rs7577696	0.671	rs212738	ENSG00000276334.1	AL133243.1	4.34	1.72e-05	0.00167	0.21	0.2	Inflammatory biomarkers;	chr2:32178253	chr2:32521927~32523547:+
THCA	cis	rs8067545	0.685	rs4479309	ENSG00000270091.1	RP11-78O7.2	-4.34	1.72e-05	0.00167	-0.15	-0.2	Schizophrenia;	chr17:20068270	chr17:19896590~19897287:-
THCA	cis	rs1334894	1	rs16878812	ENSG00000228559.1	RP3-340B19.3	-4.34	1.72e-05	0.00167	-0.35	-0.2	Coronary artery disease;	chr6:35601785	chr6:35544632~35545669:+
THCA	cis	rs1923243	0.681	rs12127301	ENSG00000223479.3	RP4-788P17.1	4.34	1.72e-05	0.00167	0.22	0.2	Migraine;	chr1:73094471	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.592	rs12120935	ENSG00000223479.3	RP4-788P17.1	4.34	1.72e-05	0.00167	0.22	0.2	Migraine;	chr1:73095915	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.648	rs12122055	ENSG00000223479.3	RP4-788P17.1	4.34	1.72e-05	0.00167	0.22	0.2	Migraine;	chr1:73097093	chr1:73635216~73715214:+
THCA	cis	rs4273100	0.85	rs11204306	ENSG00000263934.3	SNORD3A	4.34	1.73e-05	0.00167	0.29	0.2	Schizophrenia;	chr17:19364058	chr17:19188016~19188714:+
THCA	cis	rs4273100	0.79	rs2048230	ENSG00000263934.3	SNORD3A	4.34	1.73e-05	0.00167	0.29	0.2	Schizophrenia;	chr17:19372886	chr17:19188016~19188714:+
THCA	cis	rs4906332	1	rs17617307	ENSG00000269910.1	RP11-73M18.10	4.34	1.73e-05	0.00167	0.17	0.2	Coronary artery disease;	chr14:103438628	chr14:103694516~103695050:-
THCA	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	4.34	1.73e-05	0.00167	0.22	0.2	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
THCA	cis	rs11673344	0.573	rs73039109	ENSG00000267260.1	CTD-2162K18.4	-4.34	1.73e-05	0.00167	-0.27	-0.2	Obesity-related traits;	chr19:36891073	chr19:36773153~36777078:+
THCA	cis	rs875971	1	rs6979382	ENSG00000229886.1	RP5-1132H15.3	4.34	1.73e-05	0.00167	0.2	0.2	Aortic root size;	chr7:66421388	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs6961990	ENSG00000229886.1	RP5-1132H15.3	4.34	1.73e-05	0.00167	0.2	0.2	Aortic root size;	chr7:66423583	chr7:66025126~66031544:-
THCA	cis	rs911119	0.913	rs3810575	ENSG00000270001.1	RP11-218C14.8	-4.34	1.73e-05	0.00167	-0.29	-0.2	Chronic kidney disease;	chr20:23602755	chr20:23631826~23632316:-
THCA	cis	rs1979679	0.918	rs1533142	ENSG00000278733.1	RP11-425D17.1	-4.34	1.73e-05	0.00167	-0.2	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28461206	chr12:28185625~28186190:-
THCA	cis	rs7267979	1	rs6050555	ENSG00000274973.1	RP13-401N8.7	4.34	1.73e-05	0.00167	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25845497~25845862:+
THCA	cis	rs12073837	0.5	rs4143772	ENSG00000238078.1	LINC01352	-4.34	1.73e-05	0.00167	-0.24	-0.2	F-cell distribution;	chr1:220815004	chr1:220829255~220832429:+
THCA	cis	rs4356203	0.905	rs2052188	ENSG00000272034.1	SNORD14A	4.34	1.73e-05	0.00167	0.19	0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105123	chr11:17074654~17074744:-
THCA	cis	rs7829975	0.577	rs940032	ENSG00000254153.1	CTA-398F10.2	4.34	1.73e-05	0.00167	0.22	0.2	Mood instability;	chr8:8688833	chr8:8456909~8461337:-
THCA	cis	rs3020736	0.519	rs5996116	ENSG00000237037.8	NDUFA6-AS1	4.34	1.73e-05	0.00167	0.16	0.2	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42090931~42137742:+
THCA	cis	rs7216064	1	rs4318247	ENSG00000278740.1	RP11-147L13.14	4.34	1.73e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67886056	chr17:68188547~68189165:+
THCA	cis	rs1124769	0.57	rs1903588	ENSG00000259378.1	DCAF13P3	-4.34	1.73e-05	0.00167	-0.27	-0.2	Cognitive performance;	chr15:50851849	chr15:50944663~50945996:+
THCA	cis	rs7216064	0.906	rs78452260	ENSG00000278740.1	RP11-147L13.14	4.34	1.73e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852406	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs62084240	ENSG00000278740.1	RP11-147L13.14	4.34	1.73e-05	0.00167	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67863117	chr17:68188547~68189165:+
THCA	cis	rs7726354	1	rs73122135	ENSG00000271828.1	CTD-2310F14.1	4.34	1.73e-05	0.00167	0.53	0.2	Breast cancer (early onset);	chr5:56971481	chr5:56927874~56929573:+
THCA	cis	rs17221829	0.965	rs11018751	ENSG00000280385.1	AP000648.5	4.34	1.73e-05	0.00167	0.19	0.2	Anxiety in major depressive disorder;	chr11:89725741	chr11:90193614~90198120:+
THCA	cis	rs427943	0.766	rs446158	ENSG00000223768.1	LINC00205	-4.34	1.73e-05	0.00167	-0.18	-0.2	Body mass index;	chr21:45170038	chr21:45293285~45297354:+
THCA	cis	rs17270561	0.609	rs9358883	ENSG00000272462.2	U91328.19	-4.34	1.73e-05	0.00167	-0.17	-0.2	Iron status biomarkers;	chr6:25755287	chr6:25992662~26001775:+
THCA	cis	rs962856	0.964	rs600388	ENSG00000236780.4	AC078941.1	4.34	1.73e-05	0.00167	0.24	0.2	Pancreatic cancer;	chr2:67429677	chr2:67123357~67215319:-
THCA	cis	rs9287719	0.747	rs1534400	ENSG00000243819.4	RN7SL832P	4.34	1.73e-05	0.00167	0.15	0.2	Prostate cancer;	chr2:10556707	chr2:10690344~10692099:+
THCA	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	4.34	1.73e-05	0.00167	0.23	0.2	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
THCA	cis	rs9905704	0.647	rs8077332	ENSG00000224738.1	AC099850.1	4.34	1.73e-05	0.00167	0.24	0.2	Testicular germ cell tumor;	chr17:59027862	chr17:59106598~59118267:+
THCA	cis	rs12410462	0.591	rs72632830	ENSG00000227711.2	RP11-275O4.5	-4.34	1.73e-05	0.00167	-0.24	-0.2	Major depressive disorder;	chr1:227541196	chr1:227509028~227520477:-
THCA	cis	rs763121	0.819	rs6001205	ENSG00000235209.1	CTA-150C2.13	4.34	1.73e-05	0.00168	0.26	0.2	Menopause (age at onset);	chr22:38704259	chr22:38921227~38924708:+
THCA	cis	rs2153535	0.536	rs1328876	ENSG00000230939.1	RP11-314C16.1	-4.34	1.73e-05	0.00168	-0.21	-0.2	Motion sickness;	chr6:8620940	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs1328875	ENSG00000230939.1	RP11-314C16.1	-4.34	1.73e-05	0.00168	-0.21	-0.2	Motion sickness;	chr6:8620946	chr6:8784178~8785445:+
THCA	cis	rs274567	0.602	rs272853	ENSG00000224431.1	AC063976.7	4.34	1.73e-05	0.00168	0.17	0.2	Blood metabolite levels;	chr5:132352868	chr5:132199456~132203487:+
THCA	cis	rs3864261	0.895	rs2673911	ENSG00000249085.1	CTD-2631K10.1	-4.34	1.73e-05	0.00168	-0.29	-0.2	Discordance in emotional problems in monozygotic twins;	chr5:72761435	chr5:72794405~72816565:-
THCA	cis	rs1923243	0.714	rs12134234	ENSG00000223479.3	RP4-788P17.1	4.34	1.73e-05	0.00168	0.22	0.2	Migraine;	chr1:73048446	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs11210112	ENSG00000223479.3	RP4-788P17.1	4.34	1.73e-05	0.00168	0.22	0.2	Migraine;	chr1:73054505	chr1:73635216~73715214:+
THCA	cis	rs10946940	0.896	rs12208078	ENSG00000219392.1	RP1-265C24.5	4.34	1.73e-05	0.00168	0.23	0.2	Systemic lupus erythematosus;	chr6:27530802	chr6:28115628~28116551:+
THCA	cis	rs10946940	0.965	rs10946935	ENSG00000219392.1	RP1-265C24.5	4.34	1.73e-05	0.00168	0.23	0.2	Systemic lupus erythematosus;	chr6:27533566	chr6:28115628~28116551:+
THCA	cis	rs7711186	0.786	rs7702255	ENSG00000252464.1	RN7SKP70	4.34	1.73e-05	0.00168	0.24	0.2	Urate levels in obese individuals;	chr5:178659250	chr5:178619728~178619998:-
THCA	cis	rs6870983	0.895	rs1430204	ENSG00000247828.6	TMEM161B-AS1	4.34	1.73e-05	0.00168	0.18	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88382815	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.895	rs10043347	ENSG00000247828.6	TMEM161B-AS1	4.34	1.73e-05	0.00168	0.18	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88383508	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.895	rs13157159	ENSG00000247828.6	TMEM161B-AS1	-4.34	1.73e-05	0.00168	-0.18	-0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88366503	chr5:88268895~88436685:+
THCA	cis	rs472402	0.56	rs2288447	ENSG00000250056.4	LINC01018	-4.34	1.73e-05	0.00168	-0.24	-0.2	Response to amphetamines;	chr5:6625978	chr5:6582136~6588499:+
THCA	cis	rs7523875	0.678	rs12041498	ENSG00000153363.11	LINC00467	-4.34	1.73e-05	0.00168	-0.18	-0.2	Mean corpuscular volume;	chr1:211311718	chr1:211382803~211435333:+
THCA	cis	rs67478160	0.643	rs8005225	ENSG00000269940.1	RP11-73M18.7	-4.34	1.73e-05	0.00168	-0.19	-0.2	Schizophrenia;	chr14:103833814	chr14:103694560~103695170:+
THCA	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	4.34	1.73e-05	0.00168	0.24	0.2	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
THCA	cis	rs783540	0.542	rs62009945	ENSG00000278603.1	RP13-608F4.5	-4.34	1.73e-05	0.00168	-0.29	-0.2	Schizophrenia;	chr15:82631205	chr15:82472203~82472426:+
THCA	cis	rs41313321	0.541	rs4637952	ENSG00000272696.1	RP11-339B21.13	4.34	1.73e-05	0.00168	0.14	0.2	Coenzyme Q10 levels;	chr9:128297978	chr9:128316337~128316909:+
THCA	cis	rs6121246	0.559	rs6060950	ENSG00000230613.1	HM13-AS1	4.34	1.73e-05	0.00168	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31790228	chr20:31567707~31573263:-
THCA	cis	rs2688608	0.933	rs2633307	ENSG00000271816.1	BMS1P4	4.34	1.73e-05	0.00168	0.19	0.2	Inflammatory bowel disease;	chr10:73894123	chr10:73699151~73730487:-
THCA	cis	rs9902453	0.845	rs2259855	ENSG00000263370.1	RP11-68I3.5	-4.34	1.73e-05	0.00168	-0.26	-0.2	Coffee consumption (cups per day);	chr17:29770842	chr17:29639627~29640825:+
THCA	cis	rs2298450	0.555	rs2845756	ENSG00000214867.3	SRSF9P1	4.34	1.73e-05	0.00168	0.26	0.2	Schizophrenia;	chr21:36239594	chr21:36295173~36295702:-
THCA	cis	rs13256369	0.774	rs13248423	ENSG00000254153.1	CTA-398F10.2	-4.34	1.73e-05	0.00168	-0.22	-0.2	Obesity-related traits;	chr8:8720092	chr8:8456909~8461337:-
THCA	cis	rs6416877	0.679	rs16946807	ENSG00000277491.1	RP11-676J12.9	-4.34	1.73e-05	0.00168	-0.22	-0.2	Myeloid white cell count;	chr17:1453285	chr17:795306~795794:+
THCA	cis	rs7819412	0.837	rs17724467	ENSG00000206014.6	OR7E161P	4.34	1.73e-05	0.00168	0.23	0.2	Triglycerides;	chr8:11118172	chr8:11928597~11929563:-
THCA	cis	rs6715284	0.786	rs13423990	ENSG00000183308.6	AC005037.3	4.34	1.73e-05	0.00168	0.49	0.2	Rheumatoid arthritis;	chr2:201481567	chr2:200963263~201009102:+
THCA	cis	rs7267979	0.966	rs2500417	ENSG00000276952.1	RP5-965G21.6	-4.34	1.73e-05	0.00168	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25284915~25285588:-
THCA	cis	rs12234571	1	rs6953416	ENSG00000214293.7	APTR	4.34	1.73e-05	0.00168	0.25	0.2	Obesity-related traits;	chr7:77880608	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs11971380	ENSG00000214293.7	APTR	4.34	1.73e-05	0.00168	0.25	0.2	Obesity-related traits;	chr7:77887567	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs10953373	ENSG00000214293.7	APTR	4.34	1.73e-05	0.00168	0.25	0.2	Obesity-related traits;	chr7:77894387	chr7:77657660~77696265:-
THCA	cis	rs12887734	0.524	rs17791722	ENSG00000269940.1	RP11-73M18.7	4.34	1.73e-05	0.00168	0.2	0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103819873	chr14:103694560~103695170:+
THCA	cis	rs7760535	0.711	rs455834	ENSG00000230177.1	RP5-1112D6.4	-4.34	1.73e-05	0.00168	-0.17	-0.2	Metabolic traits;	chr6:111316902	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.711	rs240972	ENSG00000230177.1	RP5-1112D6.4	-4.34	1.73e-05	0.00168	-0.17	-0.2	Metabolic traits;	chr6:111317132	chr6:111277932~111278742:+
THCA	cis	rs17723470	1	rs11038357	ENSG00000254427.1	RP11-430H10.1	-4.34	1.73e-05	0.00168	-0.22	-0.2	Thyroid hormone levels;	chr11:45216307	chr11:45355371~45366121:+
THCA	cis	rs7537765	1	rs56153133	ENSG00000242349.4	NPPA-AS1	-4.34	1.74e-05	0.00168	-0.27	-0.2	QRS complex (12-leadsum);	chr1:11825590	chr1:11841017~11848079:+
THCA	cis	rs7179456	0.513	rs640704	ENSG00000245975.2	RP11-30K9.6	4.34	1.74e-05	0.00168	0.19	0.2	Asperger disorder;	chr15:58756822	chr15:58768072~58770974:-
THCA	cis	rs17122278	1	rs2277293	ENSG00000243431.1	RPL5P30	4.34	1.74e-05	0.00168	0.2	0.2	Total cholesterol levels;	chr11:118552153	chr11:118560690~118561580:+
THCA	cis	rs2380205	1	rs2380205	ENSG00000232807.2	RP11-536K7.3	4.34	1.74e-05	0.00168	0.18	0.2	Breast cancer;	chr10:5844771	chr10:5934270~5945900:-
THCA	cis	rs1371614	0.632	rs1992311	ENSG00000229122.1	AGBL5-IT1	4.34	1.74e-05	0.00168	0.14	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26936473	chr2:27061038~27061815:+
THCA	cis	rs713587	0.571	rs2917916	ENSG00000224165.4	DNAJC27-AS1	4.34	1.74e-05	0.00168	0.11	0.2	Body mass index in non-asthmatics;	chr2:25093467	chr2:24971390~25039694:+
THCA	cis	rs6840360	0.582	rs2724553	ENSG00000270265.1	RP11-731D1.4	-4.34	1.74e-05	0.00168	-0.18	-0.2	Intelligence (multi-trait analysis);	chr4:151400729	chr4:151333775~151353224:-
THCA	cis	rs116248771	0.739	rs12488447	ENSG00000271778.1	RP11-379F4.8	4.34	1.74e-05	0.00168	0.26	0.2	diarrhoeal disease at age 2;	chr3:158704035	chr3:158782547~158783124:+
THCA	cis	rs6546886	0.957	rs4371381	ENSG00000235499.1	AC073046.25	4.34	1.74e-05	0.00168	0.18	0.2	Dialysis-related mortality;	chr2:74019486	chr2:73985132~73986343:+
THCA	cis	rs4705952	0.832	rs2548991	ENSG00000233006.5	AC034220.3	4.34	1.74e-05	0.00168	0.18	0.2	C-reactive protein levels;	chr5:132526339	chr5:132311285~132369916:-
THCA	cis	rs2629751	0.537	rs2722200	ENSG00000214198.6	RP11-642P15.1	-4.34	1.74e-05	0.00168	-0.17	-0.2	Hepatitis C induced liver fibrosis;	chr12:103971344	chr12:103843749~103930211:-
THCA	cis	rs10208649	0.656	rs60191560	ENSG00000233266.1	HMGB1P31	4.34	1.74e-05	0.00168	0.36	0.2	Body mass index;	chr2:54058661	chr2:54051334~54051760:+
THCA	cis	rs301901	1	rs159755	ENSG00000250155.1	CTD-2353F22.1	-4.34	1.74e-05	0.00168	-0.2	-0.2	Height;	chr5:36995103	chr5:36666214~36725195:-
THCA	cis	rs1728785	0.591	rs10775305	ENSG00000274698.1	RP11-71L14.4	4.34	1.74e-05	0.00168	0.28	0.2	Ulcerative colitis;	chr16:68622557	chr16:68450283~68452318:+
THCA	cis	rs875971	0.505	rs1167386	ENSG00000275400.1	RP4-756H11.5	4.34	1.74e-05	0.00168	0.19	0.2	Aortic root size;	chr7:66048109	chr7:66553805~66554199:-
THCA	cis	rs875971	0.505	rs1167385	ENSG00000275400.1	RP4-756H11.5	4.34	1.74e-05	0.00168	0.19	0.2	Aortic root size;	chr7:66048321	chr7:66553805~66554199:-
THCA	cis	rs782212	0.501	rs2815775	ENSG00000227207.2	RPL31P12	-4.34	1.74e-05	0.00168	-0.31	-0.2	Depression;	chr1:72387726	chr1:72301472~72301829:+
THCA	cis	rs782212	0.592	rs1460939	ENSG00000227207.2	RPL31P12	-4.34	1.74e-05	0.00168	-0.31	-0.2	Depression;	chr1:72395884	chr1:72301472~72301829:+
THCA	cis	rs782212	0.592	rs2590943	ENSG00000227207.2	RPL31P12	-4.34	1.74e-05	0.00168	-0.31	-0.2	Depression;	chr1:72408773	chr1:72301472~72301829:+
THCA	cis	rs13401620	0.745	rs6542544	ENSG00000231013.1	AC013275.2	-4.34	1.74e-05	0.00168	-0.22	-0.2	Breast size;	chr2:119712064	chr2:119476448~119487346:+
THCA	cis	rs72928364	1	rs13072788	ENSG00000256628.3	ZBTB11-AS1	4.34	1.74e-05	0.00168	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101019368	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs62275773	ENSG00000256628.3	ZBTB11-AS1	4.34	1.74e-05	0.00168	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101021321	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs13091757	ENSG00000256628.3	ZBTB11-AS1	4.34	1.74e-05	0.00168	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101022780	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs13060166	ENSG00000256628.3	ZBTB11-AS1	4.34	1.74e-05	0.00168	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101023978	chr3:101676475~101679217:+
THCA	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-4.34	1.74e-05	0.00168	-0.23	-0.2	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
THCA	cis	rs11955398	0.502	rs158922	ENSG00000272308.1	RP11-231G3.1	-4.34	1.74e-05	0.00168	-0.21	-0.2	Intelligence (multi-trait analysis);	chr5:60945159	chr5:60866457~60866935:-
THCA	cis	rs853679	1	rs1778508	ENSG00000273712.1	RP5-874C20.7	-4.34	1.74e-05	0.00168	-0.31	-0.2	Depression;	chr6:28262103	chr6:28315613~28315883:-
THCA	cis	rs9863	0.794	rs7133378	ENSG00000269997.1	RP11-214K3.21	-4.34	1.74e-05	0.00168	-0.24	-0.2	White blood cell count;	chr12:123924955	chr12:123966077~123966629:-
THCA	cis	rs7918232	0.825	rs4749233	ENSG00000262412.1	RP11-85G18.6	4.34	1.74e-05	0.00169	0.31	0.2	Breast cancer;	chr10:27179038	chr10:27243130~27250804:+
THCA	cis	rs6087771	0.926	rs6058431	ENSG00000230613.1	HM13-AS1	4.34	1.74e-05	0.00169	0.19	0.2	Putamen volume;Subcortical brain region volumes;	chr20:31709330	chr20:31567707~31573263:-
THCA	cis	rs6570726	0.905	rs1355146	ENSG00000270638.1	RP3-466P17.1	-4.34	1.74e-05	0.00169	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145735570~145737218:+
THCA	cis	rs6449502	0.541	rs767634	ENSG00000251279.1	CTC-436P18.1	4.34	1.74e-05	0.00169	0.37	0.2	Mean platelet volume;	chr5:61048470	chr5:61162070~61232040:+
THCA	cis	rs4714902	0.655	rs995563	ENSG00000231769.2	RP1-8B1.4	-4.34	1.74e-05	0.00169	-0.17	-0.2	Colonoscopy-negative controls vs population controls;	chr6:46115200	chr6:46097093~46129706:-
THCA	cis	rs12478296	1	rs55777943	ENSG00000261186.2	RP11-341N2.1	-4.34	1.74e-05	0.00169	-0.32	-0.2	Obesity-related traits;	chr2:242098535	chr2:242087351~242088457:-
THCA	cis	rs79040073	0.637	rs1023683	ENSG00000259531.2	RP11-295H24.3	4.34	1.74e-05	0.00169	0.27	0.2	Lung cancer in ever smokers;	chr15:49415250	chr15:49365124~49366685:-
THCA	cis	rs79040073	0.637	rs11639423	ENSG00000259531.2	RP11-295H24.3	4.34	1.74e-05	0.00169	0.27	0.2	Lung cancer in ever smokers;	chr15:49415448	chr15:49365124~49366685:-
THCA	cis	rs7267979	0.966	rs2482918	ENSG00000276952.1	RP5-965G21.6	-4.34	1.74e-05	0.00169	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25284915~25285588:-
THCA	cis	rs804280	0.564	rs4639	ENSG00000255046.1	RP11-297N6.4	-4.34	1.74e-05	0.00169	-0.19	-0.2	Myopia (pathological);	chr8:11787242	chr8:11797928~11802568:-
THCA	cis	rs875971	0.66	rs7807930	ENSG00000223473.2	GS1-124K5.3	-4.34	1.74e-05	0.00169	-0.13	-0.2	Aortic root size;	chr7:66622178	chr7:66491049~66493566:-
THCA	cis	rs4845570	1	rs6673002	ENSG00000249602.1	RP11-98D18.3	4.34	1.74e-05	0.00169	0.29	0.2	Coronary artery disease;	chr1:151770799	chr1:151763384~151769501:-
THCA	cis	rs7918232	0.882	rs10829190	ENSG00000262412.1	RP11-85G18.6	4.34	1.74e-05	0.00169	0.3	0.2	Breast cancer;	chr10:27120626	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs4749230	ENSG00000262412.1	RP11-85G18.6	4.34	1.74e-05	0.00169	0.3	0.2	Breast cancer;	chr10:27152289	chr10:27243130~27250804:+
THCA	cis	rs12915845	0.584	rs7403482	ENSG00000271997.1	RP11-97O12.6	-4.34	1.75e-05	0.00169	-0.14	-0.2	Menarche (age at onset);	chr15:88519478	chr15:88501944~88505787:-
THCA	cis	rs12500482	0.935	rs12644638	ENSG00000248399.1	RP11-503N18.4	-4.34	1.75e-05	0.00169	-0.17	-0.2	Cognitive function;	chr4:2411734	chr4:2463797~2464124:+
THCA	cis	rs240993	0.812	rs9400481	ENSG00000271789.1	RP5-1112D6.7	4.34	1.75e-05	0.00169	0.25	0.2	Inflammatory skin disease;Psoriasis;	chr6:111529539	chr6:111297126~111298510:+
THCA	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-4.34	1.75e-05	0.00169	-0.27	-0.2	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
THCA	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-4.34	1.75e-05	0.00169	-0.27	-0.2	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
THCA	cis	rs116248771	0.69	rs16829314	ENSG00000271778.1	RP11-379F4.8	4.34	1.75e-05	0.00169	0.26	0.2	diarrhoeal disease at age 2;	chr3:158698620	chr3:158782547~158783124:+
THCA	cis	rs12073837	0.784	rs61830288	ENSG00000272823.1	RP11-295M18.6	-4.34	1.75e-05	0.00169	-0.25	-0.2	F-cell distribution;	chr1:220815399	chr1:220828676~220829211:-
THCA	cis	rs12073837	0.784	rs61830289	ENSG00000272823.1	RP11-295M18.6	-4.34	1.75e-05	0.00169	-0.25	-0.2	F-cell distribution;	chr1:220815400	chr1:220828676~220829211:-
THCA	cis	rs12073837	0.784	rs35730037	ENSG00000272823.1	RP11-295M18.6	-4.34	1.75e-05	0.00169	-0.25	-0.2	F-cell distribution;	chr1:220815403	chr1:220828676~220829211:-
THCA	cis	rs17597773	0.638	rs7530074	ENSG00000272823.1	RP11-295M18.6	-4.34	1.75e-05	0.00169	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815924	chr1:220828676~220829211:-
THCA	cis	rs17597773	0.638	rs7530176	ENSG00000272823.1	RP11-295M18.6	-4.34	1.75e-05	0.00169	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816040	chr1:220828676~220829211:-
THCA	cis	rs17597773	0.638	rs7553447	ENSG00000272823.1	RP11-295M18.6	-4.34	1.75e-05	0.00169	-0.25	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816192	chr1:220828676~220829211:-
THCA	cis	rs9863	0.931	rs11831913	ENSG00000270061.1	RP11-214K3.19	-4.34	1.75e-05	0.00169	-0.26	-0.2	White blood cell count;	chr12:123962351	chr12:123969990~123970344:-
THCA	cis	rs6496044	0.507	rs1471455	ENSG00000259276.1	RP11-815J21.3	4.34	1.75e-05	0.00169	0.23	0.2	Interstitial lung disease;	chr15:85611496	chr15:85621264~85627689:-
THCA	cis	rs73198271	0.531	rs17630714	ENSG00000253893.2	FAM85B	4.34	1.75e-05	0.00169	0.35	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8800171	chr8:8167819~8226614:-
THCA	cis	rs12216545	0.669	rs1879871	ENSG00000241134.3	BET1P1	-4.34	1.75e-05	0.00169	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150603305	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.662	rs1879872	ENSG00000241134.3	BET1P1	-4.34	1.75e-05	0.00169	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150603336	chr7:150749736~150750094:+
THCA	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	4.34	1.75e-05	0.00169	0.22	0.2	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
THCA	cis	rs2777491	0.915	rs7180418	ENSG00000247556.5	OIP5-AS1	4.34	1.75e-05	0.00169	0.16	0.2	Ulcerative colitis;	chr15:41337304	chr15:41283990~41309737:+
THCA	cis	rs2904524	0.737	rs7486625	ENSG00000257815.4	RP11-611E13.2	-4.34	1.75e-05	0.00169	-0.27	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70205252	chr12:69904033~70243360:-
THCA	cis	rs4780355	0.843	rs413024	ENSG00000263080.1	RP11-485G7.5	4.34	1.75e-05	0.00169	0.25	0.2	Crohn's disease and psoriasis;	chr16:11260234	chr16:11341809~11345211:-
THCA	cis	rs9341808	0.667	rs2476826	ENSG00000272129.1	RP11-250B2.6	4.34	1.75e-05	0.00169	0.25	0.2	Sitting height ratio;	chr6:80166347	chr6:80355424~80356859:+
THCA	cis	rs7772486	0.776	rs4316025	ENSG00000270638.1	RP3-466P17.1	-4.34	1.75e-05	0.00169	-0.15	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145735570~145737218:+
THCA	cis	rs13325613	0.915	rs35678191	ENSG00000223552.1	RP11-24F11.2	-4.34	1.75e-05	0.00169	-0.29	-0.2	Monocyte count;	chr3:46229908	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.833	rs71327044	ENSG00000223552.1	RP11-24F11.2	-4.34	1.75e-05	0.00169	-0.29	-0.2	Monocyte count;	chr3:46229963	chr3:46364955~46407059:-
THCA	cis	rs3177980	0.522	rs73026245	ENSG00000239494.2	RN7SL333P	-4.34	1.75e-05	0.00169	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr1:169912320	chr1:169859756~169860052:+
THCA	cis	rs3177980	0.56	rs11589247	ENSG00000239494.2	RN7SL333P	-4.34	1.75e-05	0.00169	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr1:169913769	chr1:169859756~169860052:+
THCA	cis	rs4819052	0.807	rs1075788	ENSG00000182586.6	LINC00334	-4.34	1.75e-05	0.00169	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45234340~45258730:+
THCA	cis	rs75059851	0.756	rs11223650	ENSG00000280237.1	MIR4697HG	4.34	1.75e-05	0.00169	0.22	0.2	Schizophrenia;	chr11:133970752	chr11:133896438~133901601:-
THCA	cis	rs75059851	0.756	rs55747998	ENSG00000280237.1	MIR4697HG	4.34	1.75e-05	0.00169	0.22	0.2	Schizophrenia;	chr11:133970898	chr11:133896438~133901601:-
THCA	cis	rs9880211	0.562	rs13068210	ENSG00000273486.1	RP11-731C17.2	4.34	1.75e-05	0.00169	0.2	0.2	Height;Body mass index;	chr3:136186704	chr3:136837338~136839021:-
THCA	cis	rs6929812	0.691	rs10807024	ENSG00000271755.1	RP1-153G14.4	4.34	1.75e-05	0.00169	0.22	0.2	Neuroticism (multi-trait analysis);	chr6:27460926	chr6:27404010~27406964:-
THCA	cis	rs2288884	0.649	rs11667001	ENSG00000260160.1	CTC-471J1.2	-4.34	1.75e-05	0.00169	-0.23	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049416	chr19:52058490~52063703:-
THCA	cis	rs7551222	0.714	rs4951401	ENSG00000240219.1	RP11-430C7.5	4.34	1.75e-05	0.0017	0.21	0.2	Schizophrenia;	chr1:204568520	chr1:204626775~204629712:+
THCA	cis	rs8105895	0.935	rs16998834	ENSG00000269345.1	VN1R85P	4.34	1.75e-05	0.0017	0.27	0.2	Body mass index (change over time);	chr19:22084235	chr19:22174766~22175191:-
THCA	cis	rs7576126	1	rs7576126	ENSG00000214533.3	KRT18P33	-4.34	1.75e-05	0.0017	-0.24	-0.2	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65666695~65667737:+
THCA	cis	rs1389724	0.632	rs11102167	ENSG00000259834.1	RP11-284N8.3	4.34	1.75e-05	0.0017	0.18	0.2	Schizophrenia;	chr1:110797380	chr1:110653560~110657040:-
THCA	cis	rs807029	0.533	rs67692077	ENSG00000236662.1	RP11-108L7.4	4.34	1.75e-05	0.0017	0.21	0.2	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100980507~100985614:-
THCA	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	4.34	1.75e-05	0.0017	0.21	0.2	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
THCA	cis	rs6840258	0.64	rs1481947	ENSG00000251411.1	RP11-397E7.4	-4.34	1.75e-05	0.0017	-0.23	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87159990	chr4:86913266~86914817:-
THCA	cis	rs6560517	0.581	rs2501935	ENSG00000234618.1	RPSAP9	-4.34	1.75e-05	0.0017	-0.2	-0.2	Dialysis-related mortality;	chr9:76374913	chr9:76398699~76399586:+
THCA	cis	rs4971059	0.654	rs12028043	ENSG00000236675.1	MTX1P1	-4.34	1.75e-05	0.0017	-0.18	-0.2	Breast cancer;	chr1:155160360	chr1:155230975~155234325:+
THCA	cis	rs2688608	0.933	rs2688614	ENSG00000271816.1	BMS1P4	4.34	1.75e-05	0.0017	0.19	0.2	Inflammatory bowel disease;	chr10:73893118	chr10:73699151~73730487:-
THCA	cis	rs4578769	0.55	rs4473296	ENSG00000265939.1	UBE2CP2	-4.34	1.75e-05	0.0017	-0.22	-0.2	Eosinophil percentage of white cells;	chr18:22986421	chr18:22900486~22900995:-
THCA	cis	rs2287641	0.677	rs58015041	ENSG00000272156.1	RP11-477N3.1	4.34	1.75e-05	0.0017	0.37	0.2	Cannabis dependence symptom count;	chr2:54037239	chr2:54082554~54085066:+
THCA	cis	rs17270561	0.609	rs9348692	ENSG00000272462.2	U91328.19	-4.34	1.76e-05	0.0017	-0.17	-0.2	Iron status biomarkers;	chr6:25720584	chr6:25992662~26001775:+
THCA	cis	rs2286503	0.901	rs2286505	ENSG00000226329.2	AC005682.6	4.34	1.76e-05	0.0017	0.24	0.2	Fibrinogen;	chr7:22815221	chr7:22863874~22881350:-
THCA	cis	rs2243480	1	rs410128	ENSG00000164669.11	INTS4P1	4.34	1.76e-05	0.0017	0.39	0.2	Diabetic kidney disease;	chr7:66138186	chr7:65141225~65234216:+
THCA	cis	rs10504861	0.559	rs55806463	ENSG00000253553.4	RP11-586K2.1	4.34	1.76e-05	0.0017	0.2	0.2	Migraine without aura;	chr8:88498476	chr8:88326836~88737134:+
THCA	cis	rs12428035	0.772	rs72636541	ENSG00000247400.3	DNAJC3-AS1	-4.34	1.76e-05	0.0017	-0.19	-0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95842510	chr13:95648733~95676925:-
THCA	cis	rs8064024	0.68	rs3747613	ENSG00000267077.1	RP11-127I20.5	-4.34	1.76e-05	0.0017	-0.22	-0.2	Cancer;	chr16:4858503	chr16:4795265~4796532:-
THCA	cis	rs858239	0.601	rs7805206	ENSG00000230042.1	AK3P3	-4.34	1.76e-05	0.0017	-0.26	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23129178~23129841:+
THCA	cis	rs9925964	0.933	rs11150604	ENSG00000232748.3	RP11-196G11.6	4.34	1.76e-05	0.0017	0.23	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31025699	chr16:31056460~31062803:+
THCA	cis	rs7487075	0.78	rs10785624	ENSG00000257261.4	RP11-96H19.1	4.34	1.76e-05	0.0017	0.15	0.2	Itch intensity from mosquito bite;	chr12:46373004	chr12:46383679~46876159:+
THCA	cis	rs7487075	0.78	rs2279559	ENSG00000257261.4	RP11-96H19.1	4.34	1.76e-05	0.0017	0.15	0.2	Itch intensity from mosquito bite;	chr12:46373392	chr12:46383679~46876159:+
THCA	cis	rs6832769	0.922	rs819271	ENSG00000272969.1	RP11-528I4.2	4.34	1.76e-05	0.0017	0.23	0.2	Personality dimensions;	chr4:55372680	chr4:55547112~55547889:+
THCA	cis	rs160451	0.811	rs218945	ENSG00000251136.7	RP11-37B2.1	-4.34	1.76e-05	0.0017	-0.17	-0.2	Leprosy;	chr8:89701884	chr8:89609409~89757727:-
THCA	cis	rs2692947	0.537	rs11677429	ENSG00000235959.1	AC009237.17	-4.34	1.76e-05	0.0017	-0.22	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95527313	chr2:95640181~95640604:-
THCA	cis	rs2692947	0.508	rs2216793	ENSG00000235959.1	AC009237.17	-4.34	1.76e-05	0.0017	-0.22	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95530574	chr2:95640181~95640604:-
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000184274.3	LINC00315	-4.34	1.76e-05	0.0017	-0.25	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45300245~45305257:-
THCA	cis	rs8105895	0.877	rs62112919	ENSG00000269345.1	VN1R85P	4.34	1.76e-05	0.0017	0.28	0.2	Body mass index (change over time);	chr19:22044343	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62112920	ENSG00000269345.1	VN1R85P	4.34	1.76e-05	0.0017	0.28	0.2	Body mass index (change over time);	chr19:22044347	chr19:22174766~22175191:-
THCA	cis	rs1923243	0.625	rs11210125	ENSG00000223479.3	RP4-788P17.1	4.34	1.76e-05	0.0017	0.22	0.2	Migraine;	chr1:73095920	chr1:73635216~73715214:+
THCA	cis	rs9863	0.861	rs4930726	ENSG00000269997.1	RP11-214K3.21	-4.34	1.76e-05	0.0017	-0.23	-0.2	White blood cell count;	chr12:123943784	chr12:123966077~123966629:-
THCA	cis	rs987724	0.515	rs6787457	ENSG00000243926.1	TIPARP-AS1	4.34	1.76e-05	0.0017	0.26	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156891157	chr3:156671862~156674378:-
THCA	cis	rs17723470	1	rs3758723	ENSG00000254427.1	RP11-430H10.1	-4.34	1.76e-05	0.0017	-0.22	-0.2	Thyroid hormone levels;	chr11:45221961	chr11:45355371~45366121:+
THCA	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-4.34	1.76e-05	0.0017	-0.23	-0.2	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
THCA	cis	rs7621331	0.963	rs13317459	ENSG00000273486.1	RP11-731C17.2	-4.34	1.76e-05	0.0017	-0.19	-0.2	Waist circumference adjusted for body mass index;	chr3:135951214	chr3:136837338~136839021:-
THCA	cis	rs7772486	0.776	rs2265467	ENSG00000270638.1	RP3-466P17.1	4.34	1.76e-05	0.0017	0.15	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145735570~145737218:+
THCA	cis	rs8020441	1	rs68157165	ENSG00000269906.1	RP11-248J18.2	4.34	1.76e-05	0.0017	0.28	0.2	Cognitive performance;	chr14:50702502	chr14:50662511~50663178:-
THCA	cis	rs7312933	0.669	rs7974476	ENSG00000257225.1	RP11-328C8.4	-4.34	1.76e-05	0.0017	-0.2	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42148682	chr12:42459366~42466128:+
THCA	cis	rs964611	0.882	rs79379792	ENSG00000259488.2	RP11-154J22.1	-4.34	1.76e-05	0.0017	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48351980	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs13380180	ENSG00000259488.2	RP11-154J22.1	-4.34	1.76e-05	0.0017	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48352572	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs13379705	ENSG00000259488.2	RP11-154J22.1	-4.34	1.76e-05	0.0017	-0.19	-0.2	Metabolite levels (Pyroglutamine);	chr15:48352611	chr15:48312353~48331856:-
THCA	cis	rs11633886	0.528	rs2248216	ENSG00000273972.1	CTD-2306A12.1	4.34	1.76e-05	0.0017	0.22	0.2	Diisocyanate-induced asthma;	chr15:45809383	chr15:45702640~45703183:+
THCA	cis	rs6121246	0.609	rs6060983	ENSG00000230613.1	HM13-AS1	4.34	1.76e-05	0.0017	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31833121	chr20:31567707~31573263:-
THCA	cis	rs12440869	1	rs8042340	ENSG00000270964.1	RP11-502I4.3	-4.34	1.76e-05	0.0017	-0.17	-0.2	Peak velocity of the mitral A-wave;	chr15:67251384	chr15:67541072~67542604:-
THCA	cis	rs713587	0.571	rs564667	ENSG00000224165.4	DNAJC27-AS1	4.34	1.76e-05	0.0017	0.11	0.2	Body mass index in non-asthmatics;	chr2:25087991	chr2:24971390~25039694:+
THCA	cis	rs713587	0.571	rs546217	ENSG00000224165.4	DNAJC27-AS1	4.34	1.76e-05	0.0017	0.11	0.2	Body mass index in non-asthmatics;	chr2:25088668	chr2:24971390~25039694:+
THCA	cis	rs801193	1	rs2420824	ENSG00000224316.1	RP11-479O9.2	-4.34	1.76e-05	0.0017	-0.22	-0.2	Aortic root size;	chr7:66666129	chr7:65773620~65802067:+
THCA	cis	rs17597773	0.674	rs1494372	ENSG00000238078.1	LINC01352	-4.34	1.76e-05	0.0017	-0.27	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841279	chr1:220829255~220832429:+
THCA	cis	rs7336933	0.866	rs2003064	ENSG00000278338.3	VWA8-AS1	-4.34	1.76e-05	0.0017	-0.33	-0.2	Calcium levels;	chr13:41907576	chr13:41955808~41981565:+
THCA	cis	rs7336933	0.866	rs9315872	ENSG00000278338.3	VWA8-AS1	-4.34	1.76e-05	0.0017	-0.33	-0.2	Calcium levels;	chr13:41915872	chr13:41955808~41981565:+
THCA	cis	rs786425	0.601	rs7138209	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123672505	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs12822546	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123672700	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7975119	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123673127	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7975233	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123673198	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7978447	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123673533	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7953596	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123673903	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7953599	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123673908	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7963498	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123673955	chr12:123971457~123971714:-
THCA	cis	rs786425	0.74	rs7133543	ENSG00000270095.1	RP11-214K3.18	-4.34	1.76e-05	0.0017	-0.24	-0.2	Pubertal anthropometrics;	chr12:123674864	chr12:123971457~123971714:-
THCA	cis	rs7209700	0.662	rs11656865	ENSG00000228782.6	CTD-2026D20.3	-4.34	1.76e-05	0.0017	-0.21	-0.2	IgG glycosylation;	chr17:47269123	chr17:47450568~47492492:-
THCA	cis	rs9810089	0.802	rs10935182	ENSG00000273455.1	RP11-305O4.3	4.34	1.76e-05	0.00171	0.26	0.2	Gestational age at birth (child effect);	chr3:136418580	chr3:136087475~136087913:-
THCA	cis	rs8020441	1	rs8018822	ENSG00000269906.1	RP11-248J18.2	4.34	1.76e-05	0.00171	0.28	0.2	Cognitive performance;	chr14:50703891	chr14:50662511~50663178:-
THCA	cis	rs1853665	0.831	rs7755447	ENSG00000231760.4	RP11-350J20.5	4.34	1.76e-05	0.00171	0.36	0.2	Radiation response;	chr6:149959287	chr6:149796151~149826294:-
THCA	cis	rs2281603	0.62	rs9323450	ENSG00000259116.1	RP11-973N13.4	-4.34	1.76e-05	0.00171	-0.16	-0.2	Lymphocyte counts;	chr14:64461249	chr14:64514154~64540368:-
THCA	cis	rs62158800	0.789	rs116799836	ENSG00000237880.1	AC096669.2	4.34	1.76e-05	0.00171	0.31	0.2	Facial morphology (factor 22);	chr2:107676150	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.789	rs2138473	ENSG00000237880.1	AC096669.2	4.34	1.76e-05	0.00171	0.31	0.2	Facial morphology (factor 22);	chr2:107678290	chr2:107385632~107542649:-
THCA	cis	rs7131987	0.585	rs2059362	ENSG00000275476.1	RP11-996F15.4	4.34	1.76e-05	0.00171	0.2	0.2	QT interval;	chr12:29243072	chr12:29277397~29277882:-
THCA	cis	rs128738	0.5	rs6875603	ENSG00000237714.1	P4HA2-AS1	-4.34	1.77e-05	0.00171	-0.3	-0.2	Giant cell arteritis;	chr5:132229697	chr5:132184876~132192808:+
THCA	cis	rs972578	0.668	rs11705627	ENSG00000274717.1	RP1-47A17.1	-4.34	1.77e-05	0.00171	-0.21	-0.2	Mean platelet volume;	chr22:42985644	chr22:42791814~42794313:-
THCA	cis	rs6570726	0.818	rs9390338	ENSG00000270638.1	RP3-466P17.1	4.34	1.77e-05	0.00171	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs6570693	ENSG00000270638.1	RP3-466P17.1	4.34	1.77e-05	0.00171	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs6570694	ENSG00000270638.1	RP3-466P17.1	4.34	1.77e-05	0.00171	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs6570695	ENSG00000270638.1	RP3-466P17.1	4.34	1.77e-05	0.00171	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.764	rs9386125	ENSG00000270638.1	RP3-466P17.1	4.34	1.77e-05	0.00171	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs9373466	ENSG00000270638.1	RP3-466P17.1	4.34	1.77e-05	0.00171	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145735570~145737218:+
THCA	cis	rs12142240	0.698	rs72677589	ENSG00000232022.5	FAAHP1	-4.34	1.77e-05	0.00171	-0.22	-0.2	Menopause (age at onset);	chr1:46352098	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72677592	ENSG00000232022.5	FAAHP1	-4.34	1.77e-05	0.00171	-0.22	-0.2	Menopause (age at onset);	chr1:46352616	chr1:46432129~46445521:+
THCA	cis	rs12497850	0.864	rs4521268	ENSG00000228638.1	FCF1P2	-4.34	1.77e-05	0.00171	-0.21	-0.2	Parkinson's disease;	chr3:49100471	chr3:48290793~48291375:-
THCA	cis	rs8177876	0.731	rs4889227	ENSG00000261838.4	RP11-303E16.6	-4.34	1.77e-05	0.00171	-0.34	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81069854~81076598:+
THCA	cis	rs11976180	0.517	rs6949375	ENSG00000204959.4	ARHGEF34P	4.34	1.77e-05	0.00171	0.29	0.2	Obesity-related traits;	chr7:144076758	chr7:144272445~144286966:-
THCA	cis	rs2692947	0.537	rs2320170	ENSG00000235959.1	AC009237.17	4.34	1.77e-05	0.00171	0.21	0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95574025	chr2:95640181~95640604:-
THCA	cis	rs9467773	0.596	rs62396201	ENSG00000124549.13	BTN2A3P	4.34	1.77e-05	0.00171	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26421391~26432383:+
THCA	cis	rs897984	0.553	rs2125293	ENSG00000260911.2	RP11-196G11.2	-4.34	1.77e-05	0.00171	-0.18	-0.2	Dementia with Lewy bodies;	chr16:30852554	chr16:31043150~31049868:+
THCA	cis	rs897984	0.52	rs4889534	ENSG00000260911.2	RP11-196G11.2	-4.34	1.77e-05	0.00171	-0.18	-0.2	Dementia with Lewy bodies;	chr16:30854119	chr16:31043150~31049868:+
THCA	cis	rs4705962	0.842	rs17690965	ENSG00000230612.2	AC004237.1	4.34	1.77e-05	0.00171	0.24	0.2	Atopic dermatitis;	chr5:132694975	chr5:132688681~132723725:+
THCA	cis	rs9532669	0.963	rs7989303	ENSG00000229473.2	RGS17P1	4.34	1.77e-05	0.00171	0.24	0.2	Cervical cancer;	chr13:40950087	chr13:40992779~40993331:-
THCA	cis	rs1728785	1	rs7192341	ENSG00000274698.1	RP11-71L14.4	4.34	1.77e-05	0.00171	0.28	0.2	Ulcerative colitis;	chr16:68535321	chr16:68450283~68452318:+
THCA	cis	rs801193	1	rs2659909	ENSG00000224316.1	RP11-479O9.2	4.34	1.77e-05	0.00171	0.22	0.2	Aortic root size;	chr7:66695292	chr7:65773620~65802067:+
THCA	cis	rs7142002	0.536	rs28626353	ENSG00000272444.1	RP11-1017G21.6	-4.34	1.77e-05	0.00171	-0.35	-0.2	Autism;	chr14:102217225	chr14:101952416~101953063:+
THCA	cis	rs868036	0.718	rs2241420	ENSG00000270964.1	RP11-502I4.3	-4.34	1.77e-05	0.00171	-0.18	-0.2	Restless legs syndrome;	chr15:67790478	chr15:67541072~67542604:-
THCA	cis	rs868036	0.681	rs4776375	ENSG00000270964.1	RP11-502I4.3	-4.34	1.77e-05	0.00171	-0.18	-0.2	Restless legs syndrome;	chr15:67793217	chr15:67541072~67542604:-
THCA	cis	rs1005277	0.579	rs1740735	ENSG00000272983.1	RP11-508N22.12	4.34	1.77e-05	0.00171	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38137337~38144399:+
THCA	cis	rs17685	0.753	rs2302438	ENSG00000230882.1	AC005077.14	4.34	1.77e-05	0.00171	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76047747	chr7:76071469~76074963:-
THCA	cis	rs5758659	0.652	rs133301	ENSG00000205702.9	CYP2D7	4.34	1.77e-05	0.00171	0.15	0.2	Cognitive function;	chr22:41994089	chr22:42140203~42144577:-
THCA	cis	rs972578	0.715	rs4820483	ENSG00000274717.1	RP1-47A17.1	-4.34	1.77e-05	0.00171	-0.21	-0.2	Mean platelet volume;	chr22:42792174	chr22:42791814~42794313:-
THCA	cis	rs2337406	0.714	rs115401799	ENSG00000211974.3	IGHV2-70	-4.34	1.77e-05	0.00171	-0.21	-0.2	Alzheimer's disease (late onset);	chr14:106813739	chr14:106723574~106724093:-
THCA	cis	rs9283706	0.594	rs10515036	ENSG00000229666.1	MAST4-AS1	4.34	1.77e-05	0.00171	0.29	0.2	Coronary artery disease;	chr5:67047959	chr5:67001383~67003953:-
THCA	cis	rs6751744	0.824	rs10205689	ENSG00000226266.5	AC009961.3	-4.34	1.77e-05	0.00171	-0.24	-0.2	Dysphagia;	chr2:159507158	chr2:159670708~159712435:-
THCA	cis	rs4713118	0.513	rs149954	ENSG00000261839.1	RP1-265C24.8	4.34	1.77e-05	0.00171	0.21	0.2	Parkinson's disease;	chr6:28067468	chr6:28136849~28139678:+
THCA	cis	rs7577696	0.962	rs7600173	ENSG00000276334.1	AL133243.1	-4.34	1.77e-05	0.00171	-0.2	-0.2	Inflammatory biomarkers;	chr2:32043341	chr2:32521927~32523547:+
THCA	cis	rs2439831	0.867	rs45585139	ENSG00000166763.7	STRCP1	4.34	1.77e-05	0.00171	0.31	0.2	Lung cancer in ever smokers;	chr15:43408229	chr15:43699488~43718184:-
THCA	cis	rs1005277	0.579	rs2103938	ENSG00000272983.1	RP11-508N22.12	4.34	1.77e-05	0.00171	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38137337~38144399:+
THCA	cis	rs7312933	0.558	rs7965743	ENSG00000257225.1	RP11-328C8.4	4.34	1.77e-05	0.00171	0.2	0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42343020	chr12:42459366~42466128:+
THCA	cis	rs763121	0.657	rs5995603	ENSG00000235209.1	CTA-150C2.13	4.34	1.77e-05	0.00171	0.27	0.2	Menopause (age at onset);	chr22:38644728	chr22:38921227~38924708:+
THCA	cis	rs7824557	0.564	rs12547100	ENSG00000206014.6	OR7E161P	4.34	1.77e-05	0.00171	0.23	0.2	Retinal vascular caliber;	chr8:11385123	chr8:11928597~11929563:-
THCA	cis	rs6012953	0.692	rs941798	ENSG00000231715.1	COX6CP2	-4.34	1.77e-05	0.00171	-0.21	-0.2	Vitiligo;	chr20:50546698	chr20:50479767~50479991:+
THCA	cis	rs12906542	0.516	rs4886992	ENSG00000259792.1	RP11-114H24.6	-4.34	1.77e-05	0.00171	-0.31	-0.2	Breast cancer;	chr15:78032887	chr15:77993405~77995289:+
THCA	cis	rs12908161	0.92	rs35758837	ENSG00000188388.10	GOLGA6L3	4.34	1.77e-05	0.00171	0.26	0.2	Schizophrenia;	chr15:84768151	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs17600551	ENSG00000188388.10	GOLGA6L3	4.34	1.77e-05	0.00171	0.26	0.2	Schizophrenia;	chr15:84776027	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs36033486	ENSG00000188388.10	GOLGA6L3	4.34	1.77e-05	0.00171	0.26	0.2	Schizophrenia;	chr15:84776461	chr15:85240472~85247170:+
THCA	cis	rs6591182	0.967	rs11227229	ENSG00000245532.5	NEAT1	-4.34	1.77e-05	0.00171	-0.12	-0.2	Non-alcoholic fatty liver disease histology (lobular);	chr11:65586679	chr11:65422774~65445540:+
THCA	cis	rs13034020	0.522	rs62150970	ENSG00000271889.1	RP11-493E12.1	-4.34	1.77e-05	0.00171	-0.25	-0.2	Hodgkin's lymphoma;	chr2:61017275	chr2:61151433~61162105:-
THCA	cis	rs7829975	1	rs7829975	ENSG00000254340.1	RP11-10A14.3	-4.34	1.77e-05	0.00172	-0.22	-0.2	Mood instability;	chr8:8690607	chr8:9141424~9145435:+
THCA	cis	rs34467563	0.59	rs2640812	ENSG00000253105.4	KB-1448A5.1	4.34	1.77e-05	0.00172	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96365766	chr8:96371865~96387438:-
THCA	cis	rs12216545	0.695	rs10276888	ENSG00000241134.3	BET1P1	-4.34	1.77e-05	0.00172	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150533238	chr7:150749736~150750094:+
THCA	cis	rs1559040	0.932	rs10208690	ENSG00000272156.1	RP11-477N3.1	4.34	1.77e-05	0.00172	0.3	0.2	Sudden cardiac arrest;	chr2:54066783	chr2:54082554~54085066:+
THCA	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-4.34	1.78e-05	0.00172	-0.21	-0.2	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
THCA	cis	rs3808502	0.527	rs2736374	ENSG00000261451.1	RP11-981G7.1	-4.34	1.78e-05	0.00172	-0.25	-0.2	Neuroticism;	chr8:11256319	chr8:10433672~10438312:+
THCA	cis	rs12915845	0.545	rs17197019	ENSG00000271997.1	RP11-97O12.6	4.34	1.78e-05	0.00172	0.13	0.2	Menarche (age at onset);	chr15:88536441	chr15:88501944~88505787:-
THCA	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-4.34	1.78e-05	0.00172	-0.21	-0.2	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
THCA	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-4.34	1.78e-05	0.00172	-0.21	-0.2	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
THCA	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-4.34	1.78e-05	0.00172	-0.21	-0.2	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
THCA	cis	rs6517329	0.6	rs2835279	ENSG00000236830.5	CBR3-AS1	4.34	1.78e-05	0.00172	0.19	0.2	Schizophrenia;	chr21:36112905	chr21:36131767~36175815:-
THCA	cis	rs9810089	0.843	rs650326	ENSG00000273455.1	RP11-305O4.3	4.34	1.78e-05	0.00172	0.26	0.2	Gestational age at birth (child effect);	chr3:136318865	chr3:136087475~136087913:-
THCA	cis	rs7989336	0.663	rs4773947	ENSG00000247400.3	DNAJC3-AS1	-4.34	1.78e-05	0.00172	-0.12	-0.2	Obesity;	chr13:96277571	chr13:95648733~95676925:-
THCA	cis	rs7726354	0.546	rs73756777	ENSG00000271828.1	CTD-2310F14.1	4.34	1.78e-05	0.00172	0.49	0.2	Breast cancer (early onset);	chr5:56715409	chr5:56927874~56929573:+
THCA	cis	rs7088591	0.867	rs75669474	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58019069	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs79222211	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58019331	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs76477258	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58019586	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs60861367	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58020977	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.702	rs1930485	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58022383	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs78984217	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58024639	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs78155896	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58026618	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs60842412	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58027741	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs117018639	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58028974	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs78685378	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58029008	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs61369006	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58031724	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs117304534	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58036018	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs78582893	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58039474	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs76196769	ENSG00000276818.1	AC026393.1	4.34	1.78e-05	0.00172	0.42	0.2	Blood pressure;	chr10:58039493	chr10:57095699~57095781:+
THCA	cis	rs4218	0.597	rs12438962	ENSG00000259732.1	RP11-59H7.3	-4.34	1.78e-05	0.00172	-0.27	-0.2	Social communication problems;	chr15:59065694	chr15:59121034~59133250:+
THCA	cis	rs4218	0.517	rs71480503	ENSG00000259732.1	RP11-59H7.3	-4.34	1.78e-05	0.00172	-0.28	-0.2	Social communication problems;	chr15:59098246	chr15:59121034~59133250:+
THCA	cis	rs31251	0.9	rs11953786	ENSG00000237714.1	P4HA2-AS1	4.34	1.78e-05	0.00172	0.24	0.2	Itch intensity from mosquito bite adjusted by bite size;	chr5:131735747	chr5:132184876~132192808:+
THCA	cis	rs7474896	0.832	rs2738207	ENSG00000263064.2	RP11-291L22.7	-4.34	1.78e-05	0.00172	-0.34	-0.2	Obesity (extreme);	chr10:38017151	chr10:38448689~38448949:+
THCA	cis	rs4805272	0.889	rs6509071	ENSG00000267799.1	MAN1A2P1	4.34	1.78e-05	0.00172	0.22	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28838744	chr19:28790812~28792871:-
THCA	cis	rs7577696	0.962	rs13000753	ENSG00000276334.1	AL133243.1	-4.34	1.78e-05	0.00172	-0.21	-0.2	Inflammatory biomarkers;	chr2:32057228	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.962	rs13024004	ENSG00000276334.1	AL133243.1	-4.34	1.78e-05	0.00172	-0.21	-0.2	Inflammatory biomarkers;	chr2:32057293	chr2:32521927~32523547:+
THCA	cis	rs301901	1	rs292182	ENSG00000250155.1	CTD-2353F22.1	-4.34	1.78e-05	0.00172	-0.2	-0.2	Height;	chr5:36954710	chr5:36666214~36725195:-
THCA	cis	rs6570726	0.791	rs11759979	ENSG00000270638.1	RP3-466P17.1	4.34	1.78e-05	0.00172	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145735570~145737218:+
THCA	cis	rs9863	0.931	rs11057401	ENSG00000270061.1	RP11-214K3.19	-4.34	1.78e-05	0.00172	-0.26	-0.2	White blood cell count;	chr12:123942759	chr12:123969990~123970344:-
THCA	cis	rs17095355	0.71	rs2481106	ENSG00000203876.8	ADD3-AS1	-4.34	1.78e-05	0.00172	-0.2	-0.2	Biliary atresia;	chr10:110072680	chr10:109940104~110008381:-
THCA	cis	rs2281603	0.57	rs1966865	ENSG00000272909.1	CTD-2555O16.4	-4.34	1.78e-05	0.00172	-0.23	-0.2	Lymphocyte counts;	chr14:64509143	chr14:64440369~64442238:-
THCA	cis	rs2436845	0.58	rs2436850	ENSG00000253320.4	KB-1507C5.2	-4.34	1.78e-05	0.00172	-0.17	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102815152	chr8:102864300~102977876:+
THCA	cis	rs2153535	0.585	rs1328873	ENSG00000230939.1	RP11-314C16.1	-4.34	1.78e-05	0.00172	-0.21	-0.2	Motion sickness;	chr6:8621171	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs9393047	ENSG00000230939.1	RP11-314C16.1	-4.34	1.78e-05	0.00172	-0.21	-0.2	Motion sickness;	chr6:8622373	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs9505495	ENSG00000230939.1	RP11-314C16.1	-4.34	1.78e-05	0.00172	-0.21	-0.2	Motion sickness;	chr6:8622963	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs9328499	ENSG00000230939.1	RP11-314C16.1	-4.34	1.78e-05	0.00172	-0.21	-0.2	Motion sickness;	chr6:8623546	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs4960448	ENSG00000230939.1	RP11-314C16.1	-4.34	1.78e-05	0.00172	-0.21	-0.2	Motion sickness;	chr6:8624438	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs4960449	ENSG00000230939.1	RP11-314C16.1	-4.34	1.78e-05	0.00172	-0.21	-0.2	Motion sickness;	chr6:8625762	chr6:8784178~8785445:+
THCA	cis	rs42648	0.869	rs6948139	ENSG00000225498.1	AC002064.5	4.34	1.78e-05	0.00172	0.2	0.2	Homocysteine levels;	chr7:90308467	chr7:90312496~90322592:+
THCA	cis	rs42648	0.837	rs6970750	ENSG00000225498.1	AC002064.5	4.34	1.78e-05	0.00172	0.2	0.2	Homocysteine levels;	chr7:90308877	chr7:90312496~90322592:+
THCA	cis	rs7855088	0.789	rs987142	ENSG00000236130.1	PTCSC2	4.34	1.78e-05	0.00172	0.16	0.2	Serum thyroid-stimulating hormone levels;	chr9:98012364	chr9:97805935~97810008:-
THCA	cis	rs7726839	0.54	rs72705097	ENSG00000225138.6	CTD-2228K2.7	4.34	1.78e-05	0.00172	0.24	0.2	Obesity-related traits;	chr5:654952	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs12520279	ENSG00000225138.6	CTD-2228K2.7	4.34	1.78e-05	0.00172	0.24	0.2	Obesity-related traits;	chr5:657176	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs4957083	ENSG00000225138.6	CTD-2228K2.7	4.34	1.78e-05	0.00172	0.24	0.2	Obesity-related traits;	chr5:659228	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs7558	ENSG00000225138.6	CTD-2228K2.7	4.34	1.78e-05	0.00172	0.24	0.2	Obesity-related traits;	chr5:660376	chr5:473236~480884:+
THCA	cis	rs1023500	0.573	rs133382	ENSG00000237037.8	NDUFA6-AS1	-4.34	1.78e-05	0.00172	-0.16	-0.2	Schizophrenia;	chr22:42075770	chr22:42090931~42137742:+
THCA	cis	rs1023500	0.573	rs1807494	ENSG00000237037.8	NDUFA6-AS1	4.34	1.78e-05	0.00172	0.16	0.2	Schizophrenia;	chr22:42078134	chr22:42090931~42137742:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000223473.2	GS1-124K5.3	-4.34	1.78e-05	0.00172	-0.13	-0.2	Aortic root size;	chr7:66566965	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs801190	ENSG00000223473.2	GS1-124K5.3	-4.34	1.78e-05	0.00172	-0.13	-0.2	Aortic root size;	chr7:66568046	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs3857686	ENSG00000223473.2	GS1-124K5.3	-4.34	1.78e-05	0.00172	-0.13	-0.2	Aortic root size;	chr7:66571204	chr7:66491049~66493566:-
THCA	cis	rs875971	0.638	rs6460305	ENSG00000223473.2	GS1-124K5.3	-4.34	1.78e-05	0.00172	-0.13	-0.2	Aortic root size;	chr7:66595421	chr7:66491049~66493566:-
THCA	cis	rs875971	0.66	rs10272357	ENSG00000223473.2	GS1-124K5.3	-4.34	1.78e-05	0.00172	-0.13	-0.2	Aortic root size;	chr7:66598087	chr7:66491049~66493566:-
THCA	cis	rs4934494	0.689	rs11185895	ENSG00000240996.1	RP11-80H5.7	4.34	1.78e-05	0.00172	0.21	0.2	Red blood cell count;	chr10:89817482	chr10:89694295~89697928:-
THCA	cis	rs12908161	0.959	rs17534709	ENSG00000188388.10	GOLGA6L3	4.34	1.78e-05	0.00172	0.27	0.2	Schizophrenia;	chr15:84771166	chr15:85240472~85247170:+
THCA	cis	rs919433	0.617	rs700646	ENSG00000231621.1	AC013264.2	-4.34	1.78e-05	0.00172	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197743787	chr2:197197991~197199273:+
THCA	cis	rs722599	0.748	rs1059326	ENSG00000279594.1	RP11-950C14.10	-4.34	1.78e-05	0.00172	-0.2	-0.2	IgG glycosylation;	chr14:74902682	chr14:75011269~75012851:-
THCA	cis	rs736408	0.527	rs2577831	ENSG00000243224.1	RP5-1157M23.2	-4.34	1.78e-05	0.00172	-0.2	-0.2	Bipolar disorder;	chr3:52594040	chr3:52239258~52241097:+
THCA	cis	rs782212	0.592	rs782245	ENSG00000227207.2	RPL31P12	4.34	1.78e-05	0.00172	0.3	0.2	Depression;	chr1:72450161	chr1:72301472~72301829:+
THCA	cis	rs782212	0.592	rs782242	ENSG00000227207.2	RPL31P12	4.34	1.78e-05	0.00172	0.3	0.2	Depression;	chr1:72450891	chr1:72301472~72301829:+
THCA	cis	rs782212	0.592	rs782221	ENSG00000227207.2	RPL31P12	4.34	1.78e-05	0.00172	0.3	0.2	Depression;	chr1:72458374	chr1:72301472~72301829:+
THCA	cis	rs782212	0.559	rs782218	ENSG00000227207.2	RPL31P12	4.34	1.78e-05	0.00172	0.3	0.2	Depression;	chr1:72459714	chr1:72301472~72301829:+
THCA	cis	rs17801127	0.901	rs16827376	ENSG00000231969.1	AC144449.1	4.34	1.78e-05	0.00172	0.35	0.2	Liver enzyme levels (alanine transaminase);	chr2:149708333	chr2:149587196~149848233:+
THCA	cis	rs10811771	0.527	rs4446815	ENSG00000224549.1	RP11-370B11.3	-4.34	1.78e-05	0.00172	-0.22	-0.2	Response to antipsychotic therapy (extrapyramidal side effects);	chr9:22847962	chr9:22767175~22768316:+
THCA	cis	rs42648	0.869	rs42613	ENSG00000225498.1	AC002064.5	4.34	1.78e-05	0.00172	0.2	0.2	Homocysteine levels;	chr7:90320989	chr7:90312496~90322592:+
THCA	cis	rs42648	0.837	rs42615	ENSG00000225498.1	AC002064.5	4.34	1.78e-05	0.00172	0.2	0.2	Homocysteine levels;	chr7:90321187	chr7:90312496~90322592:+
THCA	cis	rs7267979	0.966	rs2151144	ENSG00000276952.1	RP5-965G21.6	-4.34	1.78e-05	0.00172	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25284915~25285588:-
THCA	cis	rs7089973	0.61	rs12246008	ENSG00000236799.1	RP11-383C6.2	-4.34	1.78e-05	0.00172	-0.24	-0.2	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:115002010	chr10:114994657~114996593:+
THCA	cis	rs7833787	0.526	rs11782622	ENSG00000278886.1	RP11-108A14.1	4.34	1.78e-05	0.00172	0.27	0.2	Obesity-related traits;	chr8:18835943	chr8:18864681~18865247:-
THCA	cis	rs657075	0.595	rs7721296	ENSG00000237714.1	P4HA2-AS1	-4.34	1.78e-05	0.00172	-0.41	-0.2	Rheumatoid arthritis;	chr5:132280273	chr5:132184876~132192808:+
THCA	cis	rs61160187	0.582	rs3797559	ENSG00000215032.2	GNL3LP1	4.34	1.78e-05	0.00172	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:60891935~60893577:-
THCA	cis	rs10911902	0.643	rs76469621	ENSG00000229739.2	RP11-295K2.3	-4.34	1.78e-05	0.00172	-0.3	-0.2	Schizophrenia;	chr1:186363848	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs79081972	ENSG00000229739.2	RP11-295K2.3	-4.34	1.78e-05	0.00172	-0.3	-0.2	Schizophrenia;	chr1:186364669	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs75490185	ENSG00000229739.2	RP11-295K2.3	-4.34	1.78e-05	0.00172	-0.3	-0.2	Schizophrenia;	chr1:186366319	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs112738913	ENSG00000229739.2	RP11-295K2.3	-4.34	1.78e-05	0.00172	-0.3	-0.2	Schizophrenia;	chr1:186367231	chr1:186435161~186470291:+
THCA	cis	rs8067545	0.516	rs4925086	ENSG00000270091.1	RP11-78O7.2	-4.34	1.78e-05	0.00172	-0.15	-0.2	Schizophrenia;	chr17:20110146	chr17:19896590~19897287:-
THCA	cis	rs7267979	0.966	rs4813557	ENSG00000274973.1	RP13-401N8.7	4.34	1.78e-05	0.00172	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25845497~25845862:+
THCA	cis	rs1414896	0.646	rs12135093	ENSG00000226026.4	RP11-57H12.3	4.34	1.78e-05	0.00172	0.19	0.2	Non-alcoholic fatty liver disease histology (AST);	chr1:95208490	chr1:95163219~95233982:-
THCA	cis	rs703842	0.739	rs701008	ENSG00000270039.1	RP11-571M6.17	-4.33	1.78e-05	0.00172	-0.22	-0.2	Multiple sclerosis;	chr12:57723862	chr12:57803838~57804415:+
THCA	cis	rs34467563	0.626	rs2678331	ENSG00000253105.4	KB-1448A5.1	4.33	1.78e-05	0.00172	0.24	0.2	Lobe attachment (rater-scored or self-reported);	chr8:96363908	chr8:96371865~96387438:-
THCA	cis	rs253959	0.705	rs153590	ENSG00000272265.1	CTD-2287O16.4	-4.33	1.79e-05	0.00172	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr5:116304341	chr5:116078110~116078570:-
THCA	cis	rs7209700	0.547	rs16941776	ENSG00000228782.6	CTD-2026D20.3	-4.33	1.79e-05	0.00172	-0.22	-0.2	IgG glycosylation;	chr17:47265775	chr17:47450568~47492492:-
THCA	cis	rs7209700	0.547	rs16941780	ENSG00000228782.6	CTD-2026D20.3	-4.33	1.79e-05	0.00172	-0.22	-0.2	IgG glycosylation;	chr17:47265817	chr17:47450568~47492492:-
THCA	cis	rs875971	0.862	rs10224872	ENSG00000229886.1	RP5-1132H15.3	-4.33	1.79e-05	0.00172	-0.2	-0.2	Aortic root size;	chr7:66294786	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs949930	ENSG00000229886.1	RP5-1132H15.3	-4.33	1.79e-05	0.00172	-0.2	-0.2	Aortic root size;	chr7:66301835	chr7:66025126~66031544:-
THCA	cis	rs10895322	1	rs10895322	ENSG00000281655.1	RP11-817J15.3	4.33	1.79e-05	0.00172	0.27	0.2	Neuroblastoma (11q deletion);	chr11:102599525	chr11:102681310~102683913:+
THCA	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-4.33	1.79e-05	0.00172	-0.3	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
THCA	cis	rs4948275	0.693	rs2606115	ENSG00000237233.2	TMEM26-AS1	-4.33	1.79e-05	0.00172	-0.26	-0.2	Night sleep phenotypes;	chr10:61556771	chr10:61452639~61481956:+
THCA	cis	rs57502260	0.764	rs3867143	ENSG00000212093.1	AP000807.1	4.33	1.79e-05	0.00172	0.26	0.2	Total body bone mineral density (age 45-60);	chr11:68455606	chr11:68506083~68506166:-
THCA	cis	rs128738	0.672	rs159906	ENSG00000237714.1	P4HA2-AS1	-4.33	1.79e-05	0.00172	-0.27	-0.2	Giant cell arteritis;	chr5:132167502	chr5:132184876~132192808:+
THCA	cis	rs7726354	0.793	rs76482628	ENSG00000271828.1	CTD-2310F14.1	4.33	1.79e-05	0.00172	0.53	0.2	Breast cancer (early onset);	chr5:56729855	chr5:56927874~56929573:+
THCA	cis	rs11992162	1	rs11784499	ENSG00000270154.1	RP11-419I17.1	4.33	1.79e-05	0.00173	0.25	0.2	Monocyte count;	chr8:11977030	chr8:12476462~12477122:+
THCA	cis	rs9309473	0.653	rs6718843	ENSG00000273245.1	RP11-434P11.2	4.33	1.79e-05	0.00173	0.27	0.2	Metabolite levels;	chr2:73625378	chr2:73750256~73750786:-
THCA	cis	rs7819412	0.807	rs4840542	ENSG00000206014.6	OR7E161P	4.33	1.79e-05	0.00173	0.23	0.2	Triglycerides;	chr8:11087299	chr8:11928597~11929563:-
THCA	cis	rs442309	0.687	rs10822054	ENSG00000238280.1	RP11-436D10.3	-4.33	1.79e-05	0.00173	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62720492	chr10:62793562~62805887:-
THCA	cis	rs8006682	0.541	rs10483815	ENSG00000259038.1	CTD-2325P2.4	-4.33	1.79e-05	0.00173	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68622274	chr14:68627166~68628445:-
THCA	cis	rs703842	0.616	rs1875125	ENSG00000270039.1	RP11-571M6.17	-4.33	1.79e-05	0.00173	-0.23	-0.2	Multiple sclerosis;	chr12:57833458	chr12:57803838~57804415:+
THCA	cis	rs2467099	0.732	rs2168855	ENSG00000267801.1	RP11-552F3.9	4.33	1.79e-05	0.00173	0.26	0.2	Systolic blood pressure;	chr17:75947269	chr17:75876372~75879546:+
THCA	cis	rs10484434	0.71	rs34956419	ENSG00000272810.1	U91328.22	4.33	1.79e-05	0.00173	0.2	0.2	HIV-1 viral setpoint;	chr6:26077646	chr6:26013241~26013757:+
THCA	cis	rs7572644	0.699	rs1458396	ENSG00000223522.1	AC093690.1	4.33	1.79e-05	0.00173	0.22	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27913484	chr2:28307691~28310459:-
THCA	cis	rs61160187	0.582	rs976630	ENSG00000215032.2	GNL3LP1	4.33	1.79e-05	0.00173	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:60891935~60893577:-
THCA	cis	rs5758659	1	rs5751255	ENSG00000273366.1	CTA-989H11.1	-4.33	1.79e-05	0.00173	-0.24	-0.2	Cognitive function;	chr22:42252402	chr22:42278188~42278846:+
THCA	cis	rs13108904	0.901	rs4974594	ENSG00000254094.1	AC078852.1	4.33	1.79e-05	0.00173	0.23	0.2	Obesity-related traits;	chr4:1306692	chr4:1356581~1358075:+
THCA	cis	rs7819412	0.645	rs4841508	ENSG00000255495.1	AC145124.2	-4.33	1.79e-05	0.00173	-0.23	-0.2	Triglycerides;	chr8:11207494	chr8:12194467~12196280:+
THCA	cis	rs7826238	0.509	rs2948288	ENSG00000254153.1	CTA-398F10.2	-4.33	1.79e-05	0.00173	-0.21	-0.2	Systolic blood pressure;	chr8:8257782	chr8:8456909~8461337:-
THCA	cis	rs35851103	0.507	rs6601649	ENSG00000254866.2	DEFB109P3	4.33	1.79e-05	0.00173	0.28	0.2	Neuroticism;	chr8:11999808	chr8:12150895~12151134:-
THCA	cis	rs4819052	0.851	rs28442024	ENSG00000182586.6	LINC00334	-4.33	1.79e-05	0.00173	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45234340~45258730:+
THCA	cis	rs7474896	0.583	rs11011346	ENSG00000226578.1	RP11-258F22.1	-4.33	1.79e-05	0.00173	-0.28	-0.2	Obesity (extreme);	chr10:37720555	chr10:37775371~37784131:-
THCA	cis	rs2677744	0.814	rs4932379	ENSG00000214432.8	AC068831.10	-4.33	1.79e-05	0.00173	-0.2	-0.2	Attention deficit hyperactivity disorder;	chr15:90945446	chr15:91022619~91036611:+
THCA	cis	rs459571	0.959	rs416390	ENSG00000235106.7	LINC00094	-4.33	1.79e-05	0.00173	-0.17	-0.2	Platelet distribution width;	chr9:134043427	chr9:134025439~134034666:+
THCA	cis	rs459571	0.883	rs2520096	ENSG00000235106.7	LINC00094	4.33	1.79e-05	0.00173	0.17	0.2	Platelet distribution width;	chr9:134054294	chr9:134025439~134034666:+
THCA	cis	rs9625935	0.957	rs9625879	ENSG00000279159.1	RP3-394A18.1	-4.33	1.79e-05	0.00173	-0.16	-0.2	Tonsillectomy;	chr22:29897613	chr22:29978950~30028236:-
THCA	cis	rs7838490	0.504	rs1352320	ENSG00000253553.4	RP11-586K2.1	4.33	1.79e-05	0.00173	0.2	0.2	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88503878	chr8:88326836~88737134:+
THCA	cis	rs1005277	0.579	rs1621040	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780136	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780138	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780139	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.602	rs1780141	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.541	rs1740741	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.528	rs2057228	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1740742	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.602	rs1740743	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1740745	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1740747	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1740749	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.579	rs1780115	ENSG00000272983.1	RP11-508N22.12	4.33	1.79e-05	0.00173	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38137337~38144399:+
THCA	cis	rs17123764	1	rs73305012	ENSG00000257464.1	RP11-161H23.8	-4.33	1.79e-05	0.00173	-0.31	-0.2	Intelligence (multi-trait analysis);	chr12:49568854	chr12:49442424~49442652:-
THCA	cis	rs786425	0.682	rs7135660	ENSG00000270095.1	RP11-214K3.18	-4.33	1.79e-05	0.00173	-0.23	-0.2	Pubertal anthropometrics;	chr12:123689687	chr12:123971457~123971714:-
THCA	cis	rs9863	0.861	rs4765305	ENSG00000269997.1	RP11-214K3.21	-4.33	1.79e-05	0.00173	-0.23	-0.2	White blood cell count;	chr12:123946065	chr12:123966077~123966629:-
THCA	cis	rs62158800	0.85	rs62158797	ENSG00000224568.1	AC096669.3	4.33	1.79e-05	0.00173	0.37	0.2	Facial morphology (factor 22);	chr2:107583129	chr2:107529487~107556326:+
THCA	cis	rs1962772	0.774	rs28483692	ENSG00000279903.1	RP11-349F21.5	-4.33	1.79e-05	0.00173	-0.25	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17515215	chr8:17500012~17500605:+
THCA	cis	rs13178541	0.817	rs7449192	ENSG00000250378.1	RP11-119J18.1	-4.33	1.79e-05	0.00173	-0.23	-0.2	IgG glycosylation;	chr5:135793068	chr5:135812667~135826582:+
THCA	cis	rs718433	0.584	rs1569292	ENSG00000211778.2	TRAV4	-4.33	1.79e-05	0.00173	-0.15	-0.2	Intraocular pressure;	chr14:21748709	chr14:21736152~21736982:+
THCA	cis	rs7572644	0.699	rs2016616	ENSG00000223522.1	AC093690.1	4.33	1.79e-05	0.00173	0.22	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27911170	chr2:28307691~28310459:-
THCA	cis	rs9341808	0.667	rs2490244	ENSG00000272129.1	RP11-250B2.6	4.33	1.79e-05	0.00173	0.25	0.2	Sitting height ratio;	chr6:80181395	chr6:80355424~80356859:+
THCA	cis	rs875971	1	rs3981131	ENSG00000230189.5	GS1-124K5.2	4.33	1.79e-05	0.00173	0.13	0.2	Aortic root size;	chr7:66486690	chr7:66409143~66490059:-
THCA	cis	rs6560517	0.813	rs2501927	ENSG00000234618.1	RPSAP9	4.33	1.79e-05	0.00173	0.2	0.2	Dialysis-related mortality;	chr9:76386913	chr9:76398699~76399586:+
THCA	cis	rs3177980	0.529	rs648576	ENSG00000239494.2	RN7SL333P	4.33	1.79e-05	0.00173	0.19	0.2	Amyotrophic lateral sclerosis;	chr1:169930286	chr1:169859756~169860052:+
THCA	cis	rs12216545	0.765	rs6464082	ENSG00000241134.3	BET1P1	-4.33	1.79e-05	0.00173	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150563519	chr7:150749736~150750094:+
THCA	cis	rs6012564	1	rs2426106	ENSG00000230758.1	SNAP23P	-4.33	1.8e-05	0.00173	-0.23	-0.2	Anger;	chr20:49022927	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs3092720	ENSG00000230758.1	SNAP23P	-4.33	1.8e-05	0.00173	-0.23	-0.2	Anger;	chr20:49023929	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs3091866	ENSG00000230758.1	SNAP23P	-4.33	1.8e-05	0.00173	-0.23	-0.2	Anger;	chr20:49031816	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs2252259	ENSG00000230758.1	SNAP23P	-4.33	1.8e-05	0.00173	-0.23	-0.2	Anger;	chr20:49046286	chr20:49038357~49038602:-
THCA	cis	rs3734266	0.639	rs7761391	ENSG00000272288.4	RP11-140K17.3	4.33	1.8e-05	0.00173	0.19	0.2	Systemic lupus erythematosus;	chr6:34836427	chr6:34696317~34697470:+
THCA	cis	rs868036	0.718	rs28675295	ENSG00000270964.1	RP11-502I4.3	-4.33	1.8e-05	0.00173	-0.18	-0.2	Restless legs syndrome;	chr15:67824062	chr15:67541072~67542604:-
THCA	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs12498539	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119547215	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3822194	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119550493	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3822195	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119550505	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3775854	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119550816	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs6853998	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119554705	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs6858777	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119554811	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs11731756	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119557541	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs34308924	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119560276	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs2170276	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119564669	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	4.33	1.8e-05	0.00173	0.23	0.2	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
THCA	cis	rs1876905	0.62	rs377716	ENSG00000272356.1	RP5-1112D6.8	-4.33	1.8e-05	0.00173	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111181705	chr6:111309203~111313517:+
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000182586.6	LINC00334	4.33	1.8e-05	0.00173	0.21	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45234340~45258730:+
THCA	cis	rs997295	0.737	rs11631474	ENSG00000270964.1	RP11-502I4.3	4.33	1.8e-05	0.00173	0.16	0.2	Motion sickness;	chr15:67641829	chr15:67541072~67542604:-
THCA	cis	rs10483853	0.806	rs4539535	ENSG00000258695.2	RP3-414A15.2	-4.33	1.8e-05	0.00173	-0.27	-0.2	Coronary artery calcification;	chr14:73333325	chr14:73522878~73530610:+
THCA	cis	rs4767841	0.565	rs4766949	ENSG00000248636.5	RP11-768F21.1	-4.33	1.8e-05	0.00173	-0.2	-0.2	Urgency urinary incontinence;	chr12:119789194	chr12:119387987~119668079:-
THCA	cis	rs755249	1	rs61779359	ENSG00000237624.1	OXCT2P1	4.33	1.8e-05	0.00173	0.27	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39514956~39516490:+
THCA	cis	rs755249	0.959	rs61781363	ENSG00000237624.1	OXCT2P1	4.33	1.8e-05	0.00173	0.27	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39514956~39516490:+
THCA	cis	rs755249	1	rs4660808	ENSG00000237624.1	OXCT2P1	4.33	1.8e-05	0.00173	0.27	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39514956~39516490:+
THCA	cis	rs755249	1	rs61781364	ENSG00000237624.1	OXCT2P1	4.33	1.8e-05	0.00173	0.27	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39514956~39516490:+
THCA	cis	rs78487399	0.71	rs75514072	ENSG00000234936.1	AC010883.5	4.33	1.8e-05	0.00173	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43523085	chr2:43229573~43233394:+
THCA	cis	rs75059851	0.756	rs2000852	ENSG00000280237.1	MIR4697HG	4.33	1.8e-05	0.00173	0.22	0.2	Schizophrenia;	chr11:133968326	chr11:133896438~133901601:-
THCA	cis	rs2836950	0.565	rs8134214	ENSG00000238141.2	BRWD1-AS1	-4.33	1.8e-05	0.00173	-0.22	-0.2	Menarche (age at onset);	chr21:39170441	chr21:39315707~39323218:+
THCA	cis	rs4589258	0.564	rs10734135	ENSG00000280367.1	RP11-121L10.2	4.33	1.8e-05	0.00174	0.19	0.2	Intelligence (multi-trait analysis);	chr11:90739807	chr11:90223153~90226538:+
THCA	cis	rs1150668	0.699	rs1736895	ENSG00000273712.1	RP5-874C20.7	4.33	1.8e-05	0.00174	0.21	0.2	Pubertal anthropometrics;	chr6:28252048	chr6:28315613~28315883:-
THCA	cis	rs944289	0.617	rs11156905	ENSG00000258844.1	RP11-259K15.2	4.33	1.8e-05	0.00174	0.18	0.2	Thyroid cancer;	chr14:36100314	chr14:36214607~36235608:+
THCA	cis	rs17801127	0.748	rs35762145	ENSG00000231969.1	AC144449.1	4.33	1.8e-05	0.00174	0.4	0.2	Liver enzyme levels (alanine transaminase);	chr2:149822604	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.688	rs73003910	ENSG00000231969.1	AC144449.1	4.33	1.8e-05	0.00174	0.4	0.2	Liver enzyme levels (alanine transaminase);	chr2:149822905	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.818	rs35325983	ENSG00000231969.1	AC144449.1	4.33	1.8e-05	0.00174	0.4	0.2	Liver enzyme levels (alanine transaminase);	chr2:149823057	chr2:149587196~149848233:+
THCA	cis	rs6088813	1	rs1570004	ENSG00000279253.1	RP4-614O4.13	4.33	1.8e-05	0.00174	0.19	0.2	Height;	chr20:35370450	chr20:35262727~35264187:-
THCA	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	4.33	1.8e-05	0.00174	0.22	0.2	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
THCA	cis	rs6088813	0.961	rs3795159	ENSG00000279253.1	RP4-614O4.13	-4.33	1.8e-05	0.00174	-0.2	-0.2	Height;	chr20:35308459	chr20:35262727~35264187:-
THCA	cis	rs7619708	1	rs7619708	ENSG00000226155.1	AC124944.3	4.33	1.8e-05	0.00174	0.28	0.2	Red cell distribution width;	chr3:196083316	chr3:195912049~195913986:+
THCA	cis	rs1334894	1	rs113244441	ENSG00000228559.1	RP3-340B19.3	-4.33	1.8e-05	0.00174	-0.4	-0.2	Coronary artery disease;	chr6:35560913	chr6:35544632~35545669:+
THCA	cis	rs7178424	0.777	rs8033816	ENSG00000259251.2	RP11-643M14.1	-4.33	1.8e-05	0.00174	-0.2	-0.2	Height;	chr15:61940968	chr15:62060503~62062434:+
THCA	cis	rs7940646	1	rs7940646	ENSG00000254554.1	RP11-351I24.1	-4.33	1.8e-05	0.00174	-0.24	-0.2	Platelet aggregation;	chr11:10647681	chr11:10302657~10303704:-
THCA	cis	rs10454142	0.731	rs11680719	ENSG00000202227.1	RNU6-282P	4.33	1.8e-05	0.00174	0.21	0.2	Sex hormone-binding globulin levels;	chr2:48430704	chr2:48501922~48502024:-
THCA	cis	rs4705952	0.832	rs4143832	ENSG00000233006.5	AC034220.3	4.33	1.8e-05	0.00174	0.18	0.2	C-reactive protein levels;	chr5:132527285	chr5:132311285~132369916:-
THCA	cis	rs7702057	0.53	rs1567330	ENSG00000272265.1	CTD-2287O16.4	4.33	1.8e-05	0.00174	0.35	0.2	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116078110~116078570:-
THCA	cis	rs10744955	0.727	rs11070759	ENSG00000244879.4	GABPB1-AS1	4.33	1.8e-05	0.00174	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr15:50165661	chr15:50354959~50372202:+
THCA	cis	rs6012564	1	rs3092039	ENSG00000230758.1	SNAP23P	-4.33	1.8e-05	0.00174	-0.23	-0.2	Anger;	chr20:49062233	chr20:49038357~49038602:-
THCA	cis	rs12216545	0.737	rs1879866	ENSG00000241134.3	BET1P1	-4.33	1.8e-05	0.00174	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150561241	chr7:150749736~150750094:+
THCA	cis	rs41342147	0.66	rs77576057	ENSG00000223374.1	AC005104.3	4.33	1.8e-05	0.00174	0.17	0.2	Vitiligo;	chr2:241350428	chr2:241351340~241353104:-
THCA	cis	rs8062405	0.789	rs151174	ENSG00000270424.1	RP11-1348G14.6	4.33	1.8e-05	0.00174	0.23	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28749959~28750595:-
THCA	cis	rs667920	0.575	rs9861150	ENSG00000273486.1	RP11-731C17.2	4.33	1.8e-05	0.00174	0.2	0.2	Coronary artery disease;	chr3:136464478	chr3:136837338~136839021:-
THCA	cis	rs758747	0.546	rs740862	ENSG00000276754.1	RP11-461A8.5	-4.33	1.8e-05	0.00174	-0.18	-0.2	Body mass index;	chr16:3639677	chr16:3686998~3687380:+
THCA	cis	rs2018683	0.691	rs4722881	ENSG00000272568.4	CTB-113D17.1	-4.33	1.8e-05	0.00174	-0.2	-0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28961944	chr7:28979967~29013367:+
THCA	cis	rs4705952	0.832	rs2706390	ENSG00000233006.5	AC034220.3	-4.33	1.8e-05	0.00174	-0.18	-0.2	C-reactive protein levels;	chr5:132506588	chr5:132311285~132369916:-
THCA	cis	rs4218	0.648	rs12441973	ENSG00000259732.1	RP11-59H7.3	-4.33	1.8e-05	0.00174	-0.28	-0.2	Social communication problems;	chr15:59057016	chr15:59121034~59133250:+
THCA	cis	rs800160	0.925	rs800154	ENSG00000199550.1	Y_RNA	4.33	1.8e-05	0.00174	0.29	0.2	Bacteremia;	chr11:2352556	chr11:2372638~2372750:+
THCA	cis	rs2028299	0.959	rs12594808	ENSG00000259677.1	RP11-493E3.1	4.33	1.8e-05	0.00174	0.26	0.2	Type 2 diabetes;	chr15:89857652	chr15:89876540~89877285:+
THCA	cis	rs7809615	0.748	rs9632722	ENSG00000244219.5	GS1-259H13.2	-4.33	1.8e-05	0.00174	-0.33	-0.2	Blood metabolite ratios;	chr7:99517945	chr7:99598066~99610813:+
THCA	cis	rs7809615	0.748	rs12533251	ENSG00000244219.5	GS1-259H13.2	-4.33	1.8e-05	0.00174	-0.33	-0.2	Blood metabolite ratios;	chr7:99518054	chr7:99598066~99610813:+
THCA	cis	rs7772486	0.79	rs9403749	ENSG00000270638.1	RP3-466P17.1	4.33	1.8e-05	0.00174	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145735570~145737218:+
THCA	cis	rs6657613	0.649	rs11203286	ENSG00000186301.8	MST1P2	4.33	1.8e-05	0.00174	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17044302	chr1:16645622~16650289:+
THCA	cis	rs6477918	0.544	rs34651548	ENSG00000230185.4	C9orf147	-4.33	1.8e-05	0.00174	-0.22	-0.2	Obstetric antiphospholipid syndrome;	chr9:112480141	chr9:112433816~112487204:-
THCA	cis	rs1005277	0.579	rs1780133	ENSG00000272983.1	RP11-508N22.12	4.33	1.8e-05	0.00174	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38137337~38144399:+
THCA	cis	rs4218	0.635	rs10431792	ENSG00000259732.1	RP11-59H7.3	-4.33	1.8e-05	0.00174	-0.27	-0.2	Social communication problems;	chr15:59066181	chr15:59121034~59133250:+
THCA	cis	rs11992162	0.967	rs7461062	ENSG00000270154.1	RP11-419I17.1	4.33	1.81e-05	0.00174	0.24	0.2	Monocyte count;	chr8:11974439	chr8:12476462~12477122:+
THCA	cis	rs12428035	1	rs12429385	ENSG00000247400.3	DNAJC3-AS1	-4.33	1.81e-05	0.00174	-0.19	-0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95649682	chr13:95648733~95676925:-
THCA	cis	rs7474896	1	rs61858626	ENSG00000263064.2	RP11-291L22.7	4.33	1.81e-05	0.00174	0.35	0.2	Obesity (extreme);	chr10:37713499	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.778	rs35872666	ENSG00000263064.2	RP11-291L22.7	4.33	1.81e-05	0.00174	0.35	0.2	Obesity (extreme);	chr10:37713771	chr10:38448689~38448949:+
THCA	cis	rs11955398	0.502	rs290513	ENSG00000272308.1	RP11-231G3.1	-4.33	1.81e-05	0.00174	-0.2	-0.2	Intelligence (multi-trait analysis);	chr5:61014936	chr5:60866457~60866935:-
THCA	cis	rs11955398	0.502	rs248688	ENSG00000272308.1	RP11-231G3.1	-4.33	1.81e-05	0.00174	-0.2	-0.2	Intelligence (multi-trait analysis);	chr5:61021606	chr5:60866457~60866935:-
THCA	cis	rs2657294	0.931	rs2804522	ENSG00000233313.2	HMGA1P5	-4.33	1.81e-05	0.00174	-0.26	-0.2	Pneumonia;	chr10:75159132	chr10:75276376~75276646:-
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000232559.3	GS1-124K5.12	4.33	1.81e-05	0.00174	0.29	0.2	Diabetic kidney disease;	chr7:65996588	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1701750	ENSG00000232559.3	GS1-124K5.12	4.33	1.81e-05	0.00174	0.29	0.2	Diabetic kidney disease;	chr7:66002158	chr7:66554588~66576923:-
THCA	cis	rs2243480	1	rs1701758	ENSG00000232559.3	GS1-124K5.12	4.33	1.81e-05	0.00174	0.29	0.2	Diabetic kidney disease;	chr7:66005214	chr7:66554588~66576923:-
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000232559.3	GS1-124K5.12	4.33	1.81e-05	0.00174	0.29	0.2	Diabetic kidney disease;	chr7:66005945	chr7:66554588~66576923:-
THCA	cis	rs10435719	0.509	rs13248956	ENSG00000254948.1	OR7E158P	-4.33	1.81e-05	0.00174	-0.25	-0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932259	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.528	rs13250020	ENSG00000254948.1	OR7E158P	-4.33	1.81e-05	0.00174	-0.25	-0.2	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932260	chr8:11919900~11920809:-
THCA	cis	rs786425	0.628	rs118004082	ENSG00000270095.1	RP11-214K3.18	-4.33	1.81e-05	0.00174	-0.24	-0.2	Pubertal anthropometrics;	chr12:123684693	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs35416308	ENSG00000270095.1	RP11-214K3.18	-4.33	1.81e-05	0.00174	-0.24	-0.2	Pubertal anthropometrics;	chr12:123684914	chr12:123971457~123971714:-
THCA	cis	rs7772486	0.806	rs2247317	ENSG00000270638.1	RP3-466P17.1	4.33	1.81e-05	0.00174	0.15	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145735570~145737218:+
THCA	cis	rs7396835	0.866	rs6589571	ENSG00000280143.1	AP000892.6	4.33	1.81e-05	0.00174	0.31	0.2	Quantitative traits;	chr11:116809702	chr11:117204967~117210292:+
THCA	cis	rs1972460	0.506	rs62012050	ENSG00000276710.3	CSPG4P8	-4.33	1.81e-05	0.00174	-0.21	-0.2	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82459472~82477258:+
THCA	cis	rs7914558	0.902	rs3736922	ENSG00000272912.1	RP11-724N1.1	4.33	1.81e-05	0.00174	0.23	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102914585~102915404:+
THCA	cis	rs72928364	1	rs10511181	ENSG00000256628.3	ZBTB11-AS1	4.33	1.81e-05	0.00174	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100971018	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs17398684	ENSG00000256628.3	ZBTB11-AS1	4.33	1.81e-05	0.00174	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100976498	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs62275199	ENSG00000256628.3	ZBTB11-AS1	4.33	1.81e-05	0.00174	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100976569	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs62275200	ENSG00000256628.3	ZBTB11-AS1	4.33	1.81e-05	0.00174	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100977787	chr3:101676475~101679217:+
THCA	cis	rs55661361	0.651	rs12293621	ENSG00000255045.1	RP11-677M14.2	4.33	1.81e-05	0.00174	0.18	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742932	chr11:124744634~124746337:-
THCA	cis	rs55661361	0.651	rs12293624	ENSG00000255045.1	RP11-677M14.2	4.33	1.81e-05	0.00174	0.18	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742937	chr11:124744634~124746337:-
THCA	cis	rs240993	0.812	rs9481160	ENSG00000271789.1	RP5-1112D6.7	4.33	1.81e-05	0.00174	0.24	0.2	Inflammatory skin disease;Psoriasis;	chr6:111517317	chr6:111297126~111298510:+
THCA	cis	rs10090774	0.932	rs13256088	ENSG00000279766.1	RP11-642A1.2	-4.33	1.81e-05	0.00174	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844857	chr8:140572142~140572812:-
THCA	cis	rs763121	0.776	rs4820346	ENSG00000235209.1	CTA-150C2.13	-4.33	1.81e-05	0.00174	-0.26	-0.2	Menopause (age at onset);	chr22:38729069	chr22:38921227~38924708:+
THCA	cis	rs13178541	0.81	rs878068	ENSG00000250378.1	RP11-119J18.1	4.33	1.81e-05	0.00174	0.25	0.2	IgG glycosylation;	chr5:135826667	chr5:135812667~135826582:+
THCA	cis	rs7396835	0.741	rs7396851	ENSG00000280143.1	AP000892.6	-4.33	1.81e-05	0.00174	-0.29	-0.2	Quantitative traits;	chr11:116813448	chr11:117204967~117210292:+
THCA	cis	rs1823874	0.72	rs2003037	ENSG00000254744.3	CTD-3076O17.1	-4.33	1.81e-05	0.00174	-0.2	-0.2	IgG glycosylation;	chr15:99821757	chr15:99970215~99974010:+
THCA	cis	rs9987353	0.793	rs9329182	ENSG00000254153.1	CTA-398F10.2	4.33	1.81e-05	0.00174	0.23	0.2	Recombination measurement;	chr8:9253679	chr8:8456909~8461337:-
THCA	cis	rs7809615	0.581	rs11760993	ENSG00000244219.5	GS1-259H13.2	-4.33	1.81e-05	0.00174	-0.39	-0.2	Blood metabolite ratios;	chr7:99411391	chr7:99598066~99610813:+
THCA	cis	rs1371614	0.55	rs2384508	ENSG00000272148.1	RP11-195B17.1	4.33	1.81e-05	0.00174	0.18	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26920188	chr2:27062428~27062907:-
THCA	cis	rs7200786	0.619	rs9934231	ENSG00000274038.1	RP11-66H6.4	4.33	1.81e-05	0.00174	0.24	0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10999464	chr16:11056556~11057034:+
THCA	cis	rs3767627	0.505	rs12023748	ENSG00000203819.6	HIST2H2BC	4.33	1.81e-05	0.00174	0.25	0.2	Height;	chr1:149969301	chr1:149850193~149850772:-
THCA	cis	rs4805272	1	rs7258298	ENSG00000267799.1	MAN1A2P1	4.33	1.81e-05	0.00174	0.22	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832623	chr19:28790812~28792871:-
THCA	cis	rs3806843	0.576	rs251370	ENSG00000202515.1	VTRNA1-3	4.33	1.81e-05	0.00174	0.23	0.2	Depressive symptoms (multi-trait analysis);	chr5:140866702	chr5:140726158~140726246:+
THCA	cis	rs10911902	0.643	rs78088787	ENSG00000229739.2	RP11-295K2.3	-4.33	1.81e-05	0.00175	-0.29	-0.2	Schizophrenia;	chr1:186364550	chr1:186435161~186470291:+
THCA	cis	rs7216064	1	rs58551145	ENSG00000278740.1	RP11-147L13.14	4.33	1.81e-05	0.00175	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841119	chr17:68188547~68189165:+
THCA	cis	rs12893668	0.667	rs8017628	ENSG00000252469.1	RNU7-160P	4.33	1.81e-05	0.00175	0.23	0.2	Reticulocyte count;	chr14:103581091	chr14:103550345~103550406:+
THCA	cis	rs6870983	0.947	rs7445169	ENSG00000247828.6	TMEM161B-AS1	4.33	1.81e-05	0.00175	0.18	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88407282	chr5:88268895~88436685:+
THCA	cis	rs7267979	0.727	rs2474765	ENSG00000274973.1	RP13-401N8.7	-4.33	1.81e-05	0.00175	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.764	rs2474767	ENSG00000274973.1	RP13-401N8.7	-4.33	1.81e-05	0.00175	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25845497~25845862:+
THCA	cis	rs9928842	0.823	rs6564243	ENSG00000261783.1	RP11-252K23.2	4.33	1.81e-05	0.00175	0.37	0.2	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75379818~75381260:-
THCA	cis	rs962856	0.822	rs1944911	ENSG00000236780.4	AC078941.1	4.33	1.81e-05	0.00175	0.24	0.2	Pancreatic cancer;	chr2:67420029	chr2:67123357~67215319:-
THCA	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	4.33	1.81e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
THCA	cis	rs1541160	0.913	rs621437	ENSG00000239494.2	RN7SL333P	-4.33	1.81e-05	0.00175	-0.19	-0.2	Amyotrophic lateral sclerosis;	chr1:169955618	chr1:169859756~169860052:+
THCA	cis	rs763121	0.889	rs1837988	ENSG00000273076.1	RP3-508I15.22	4.33	1.81e-05	0.00175	0.2	0.2	Menopause (age at onset);	chr22:38505089	chr22:38743495~38743910:+
THCA	cis	rs301901	1	rs300065	ENSG00000250155.1	CTD-2353F22.1	-4.33	1.81e-05	0.00175	-0.2	-0.2	Height;	chr5:36997725	chr5:36666214~36725195:-
THCA	cis	rs12681963	0.688	rs10503864	ENSG00000248159.1	HSPA8P11	-4.33	1.81e-05	0.00175	-0.37	-0.2	Migraine;	chr8:30193697	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs16876622	ENSG00000248159.1	HSPA8P11	4.33	1.81e-05	0.00175	0.37	0.2	Migraine;	chr8:30178120	chr8:30237382~30240997:+
THCA	cis	rs5758511	0.68	rs56111723	ENSG00000227370.1	RP4-669P10.19	4.33	1.81e-05	0.00175	0.22	0.2	Birth weight;	chr22:42268877	chr22:42132543~42132998:+
THCA	cis	rs7560272	0.538	rs17434655	ENSG00000163016.8	ALMS1P	4.33	1.81e-05	0.00175	0.24	0.2	Schizophrenia;	chr2:73695962	chr2:73644919~73685576:+
THCA	cis	rs853679	1	rs2799079	ENSG00000273712.1	RP5-874C20.7	4.33	1.81e-05	0.00175	0.31	0.2	Depression;	chr6:28267398	chr6:28315613~28315883:-
THCA	cis	rs12681288	0.676	rs1562925	ENSG00000260721.1	AF067845.1	4.33	1.81e-05	0.00175	0.25	0.2	Schizophrenia;	chr8:1060894	chr8:1368642~1369833:-
THCA	cis	rs4308124	0.708	rs67816163	ENSG00000230499.1	AC108463.1	-4.33	1.81e-05	0.00175	-0.29	-0.2	Vitiligo;	chr2:111205733	chr2:111195963~111206494:+
THCA	cis	rs4308124	0.679	rs7600458	ENSG00000230499.1	AC108463.1	-4.33	1.81e-05	0.00175	-0.29	-0.2	Vitiligo;	chr2:111206013	chr2:111195963~111206494:+
THCA	cis	rs4308124	0.708	rs56693625	ENSG00000230499.1	AC108463.1	-4.33	1.81e-05	0.00175	-0.29	-0.2	Vitiligo;	chr2:111207578	chr2:111195963~111206494:+
THCA	cis	rs478304	0.593	rs12576766	ENSG00000255557.1	RP11-770G2.2	4.33	1.81e-05	0.00175	0.23	0.2	Acne (severe);	chr11:65721085	chr11:65745729~65771585:+
THCA	cis	rs6487679	0.543	rs972110	ENSG00000111788.10	RP11-22B23.1	4.33	1.81e-05	0.00175	0.32	0.2	Non-alcoholic fatty liver disease histology (AST);	chr12:9221750	chr12:9277235~9313241:+
THCA	cis	rs10875746	0.859	rs11558768	ENSG00000258234.1	RP11-370I10.2	4.33	1.81e-05	0.00175	0.23	0.2	Longevity (90 years and older);	chr12:48184006	chr12:48231098~48284210:-
THCA	cis	rs997295	0.638	rs11854197	ENSG00000270964.1	RP11-502I4.3	-4.33	1.81e-05	0.00175	-0.16	-0.2	Motion sickness;	chr15:67685046	chr15:67541072~67542604:-
THCA	cis	rs10916248	0.559	rs56023673	ENSG00000237101.1	RP11-365O16.6	-4.33	1.81e-05	0.00175	-0.2	-0.2	QT interval (drug interaction);	chr1:224180821	chr1:224219613~224228043:+
THCA	cis	rs755249	0.917	rs61779330	ENSG00000237624.1	OXCT2P1	4.33	1.81e-05	0.00175	0.27	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39514956~39516490:+
THCA	cis	rs755249	0.876	rs72662001	ENSG00000237624.1	OXCT2P1	4.33	1.81e-05	0.00175	0.27	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39514956~39516490:+
THCA	cis	rs2252790	0.64	rs10484838	ENSG00000237021.2	RP3-486I3.7	-4.33	1.81e-05	0.00175	-0.21	-0.2	Fast beta electroencephalogram;	chr6:116276561	chr6:116254207~116256743:+
THCA	cis	rs6442522	0.737	rs905640	ENSG00000249786.6	EAF1-AS1	4.33	1.81e-05	0.00175	0.2	0.2	Uric acid levels;	chr3:15454333	chr3:15436171~15455940:-
THCA	cis	rs4888671	0.908	rs2966034	ENSG00000261707.1	RP11-264M12.2	-4.33	1.81e-05	0.00175	-0.35	-0.2	Obesity-related traits;	chr16:77751203	chr16:77741468~77743000:-
THCA	cis	rs7608910	0.93	rs4560096	ENSG00000271889.1	RP11-493E12.1	4.33	1.82e-05	0.00175	0.2	0.2	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977782	chr2:61151433~61162105:-
THCA	cis	rs10911902	0.643	rs34585917	ENSG00000229739.2	RP11-295K2.3	-4.33	1.82e-05	0.00175	-0.3	-0.2	Schizophrenia;	chr1:186317650	chr1:186435161~186470291:+
THCA	cis	rs8177876	0.822	rs1563075	ENSG00000261838.4	RP11-303E16.6	4.33	1.82e-05	0.00175	0.34	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81069854~81076598:+
THCA	cis	rs7474896	0.515	rs624359	ENSG00000120555.12	SEPT7P9	-4.33	1.82e-05	0.00175	-0.26	-0.2	Obesity (extreme);	chr10:38010204	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.537	rs598857	ENSG00000120555.12	SEPT7P9	-4.33	1.82e-05	0.00175	-0.26	-0.2	Obesity (extreme);	chr10:38013998	chr10:38383069~38402916:-
THCA	cis	rs10090774	0.965	rs6578135	ENSG00000279766.1	RP11-642A1.2	4.33	1.82e-05	0.00175	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140768550	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs4554515	ENSG00000279766.1	RP11-642A1.2	4.33	1.82e-05	0.00175	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140768594	chr8:140572142~140572812:-
THCA	cis	rs2467099	0.504	rs55956362	ENSG00000267801.1	RP11-552F3.9	4.33	1.82e-05	0.00175	0.24	0.2	Systolic blood pressure;	chr17:75905213	chr17:75876372~75879546:+
THCA	cis	rs4788570	0.615	rs7188675	ENSG00000260185.1	RP11-432I5.6	-4.33	1.82e-05	0.00175	-0.36	-0.2	Intelligence (multi-trait analysis);	chr16:71646099	chr16:71655027~71664212:+
THCA	cis	rs2886497	0.57	rs2012456	ENSG00000224215.1	RP11-371A19.2	-4.33	1.82e-05	0.00175	-0.23	-0.2	Major depression and alcohol dependence;	chr10:23392833	chr10:23343957~23345181:+
THCA	cis	rs736408	0.562	rs2072390	ENSG00000243224.1	RP5-1157M23.2	-4.33	1.82e-05	0.00175	-0.21	-0.2	Bipolar disorder;	chr3:52746493	chr3:52239258~52241097:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000275400.1	RP4-756H11.5	-4.33	1.82e-05	0.00175	-0.21	-0.2	Corneal structure;	chr7:66925737	chr7:66553805~66554199:-
THCA	cis	rs734999	0.545	rs10797441	ENSG00000225931.3	RP3-395M20.7	4.33	1.82e-05	0.00175	0.23	0.2	Ulcerative colitis;	chr1:2620221	chr1:2566410~2569888:+
THCA	cis	rs4948275	0.596	rs2650716	ENSG00000237233.2	TMEM26-AS1	-4.33	1.82e-05	0.00175	-0.24	-0.2	Night sleep phenotypes;	chr10:61549420	chr10:61452639~61481956:+
THCA	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	4.33	1.82e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	4.33	1.82e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	4.33	1.82e-05	0.00175	0.22	0.2	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
THCA	cis	rs1232027	0.656	rs1677625	ENSG00000249655.1	CTC-325J23.2	4.33	1.82e-05	0.00175	0.22	0.2	Huntington's disease progression;	chr5:80664629	chr5:80630313~80631590:-
THCA	cis	rs5753037	0.809	rs140150	ENSG00000279699.1	RP1-102K2.9	4.33	1.82e-05	0.00175	0.19	0.2	Type 1 diabetes;	chr22:29789730	chr22:30275215~30276951:-
THCA	cis	rs11955398	0.502	rs290514	ENSG00000272308.1	RP11-231G3.1	-4.33	1.82e-05	0.00175	-0.21	-0.2	Intelligence (multi-trait analysis);	chr5:60934494	chr5:60866457~60866935:-
THCA	cis	rs7246657	0.508	rs10419845	ENSG00000226686.6	LINC01535	-4.33	1.82e-05	0.00175	-0.34	-0.2	Coronary artery calcification;	chr19:37000290	chr19:37251912~37265535:+
THCA	cis	rs12440869	1	rs12708494	ENSG00000270964.1	RP11-502I4.3	4.33	1.82e-05	0.00175	0.17	0.2	Peak velocity of the mitral A-wave;	chr15:67355230	chr15:67541072~67542604:-
THCA	cis	rs12478296	0.786	rs72620862	ENSG00000220804.7	AC093642.5	4.33	1.82e-05	0.00175	0.22	0.2	Obesity-related traits;	chr2:242102636	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs66466023	ENSG00000220804.7	AC093642.5	4.33	1.82e-05	0.00175	0.22	0.2	Obesity-related traits;	chr2:242104000	chr2:242088633~242160153:+
THCA	cis	rs12478296	0.901	rs56318767	ENSG00000220804.7	AC093642.5	4.33	1.82e-05	0.00175	0.22	0.2	Obesity-related traits;	chr2:242104440	chr2:242088633~242160153:+
THCA	cis	rs2839627	0.638	rs7276320	ENSG00000225218.1	AP001628.6	-4.33	1.82e-05	0.00175	-0.32	-0.2	Information processing speed;	chr21:42849478	chr21:42831040~42836477:-
THCA	cis	rs17801127	0.818	rs12995026	ENSG00000231969.1	AC144449.1	4.33	1.82e-05	0.00175	0.35	0.2	Liver enzyme levels (alanine transaminase);	chr2:149708526	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.818	rs16827383	ENSG00000231969.1	AC144449.1	4.33	1.82e-05	0.00175	0.35	0.2	Liver enzyme levels (alanine transaminase);	chr2:149709562	chr2:149587196~149848233:+
THCA	cis	rs454217	0.846	rs427600	ENSG00000277851.1	RP11-756G20.1	4.33	1.82e-05	0.00175	0.2	0.2	Smoking quantity;	chr12:92326886	chr12:92247756~92363832:-
THCA	cis	rs454217	0.818	rs1661031	ENSG00000277851.1	RP11-756G20.1	4.33	1.82e-05	0.00175	0.2	0.2	Smoking quantity;	chr12:92328010	chr12:92247756~92363832:-
THCA	cis	rs61270009	0.955	rs12655529	ENSG00000247828.6	TMEM161B-AS1	4.33	1.82e-05	0.00175	0.17	0.2	Depressive symptoms;	chr5:88280980	chr5:88268895~88436685:+
THCA	cis	rs71636778	0.631	rs76133297	ENSG00000260063.1	RP5-968P14.2	-4.33	1.82e-05	0.00175	-0.27	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26827979	chr1:26692132~26694131:-
THCA	cis	rs2836974	0.605	rs2836971	ENSG00000255568.3	BRWD1-AS2	-4.33	1.82e-05	0.00175	-0.16	-0.2	Cognitive function;	chr21:39280114	chr21:39313935~39314962:+
THCA	cis	rs6477918	0.598	rs7041981	ENSG00000230185.4	C9orf147	-4.33	1.82e-05	0.00175	-0.21	-0.2	Obstetric antiphospholipid syndrome;	chr9:112420435	chr9:112433816~112487204:-
THCA	cis	rs6477918	0.598	rs949904	ENSG00000230185.4	C9orf147	-4.33	1.82e-05	0.00175	-0.21	-0.2	Obstetric antiphospholipid syndrome;	chr9:112421656	chr9:112433816~112487204:-
THCA	cis	rs9532669	0.926	rs4942014	ENSG00000229473.2	RGS17P1	4.33	1.82e-05	0.00176	0.24	0.2	Cervical cancer;	chr13:40966366	chr13:40992779~40993331:-
THCA	cis	rs9283706	0.608	rs10060497	ENSG00000229666.1	MAST4-AS1	-4.33	1.82e-05	0.00176	-0.28	-0.2	Coronary artery disease;	chr5:67036578	chr5:67001383~67003953:-
THCA	cis	rs5758659	0.714	rs2413668	ENSG00000273366.1	CTA-989H11.1	4.33	1.82e-05	0.00176	0.23	0.2	Cognitive function;	chr22:42109837	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.657	rs5758587	ENSG00000273366.1	CTA-989H11.1	4.33	1.82e-05	0.00176	0.23	0.2	Cognitive function;	chr22:42121632	chr22:42278188~42278846:+
THCA	cis	rs10875746	0.951	rs10875756	ENSG00000258273.1	RP11-370I10.4	4.33	1.82e-05	0.00176	0.28	0.2	Longevity (90 years and older);	chr12:48168521	chr12:48333755~48333901:-
THCA	cis	rs4972806	0.814	rs2113560	ENSG00000226363.3	HAGLROS	-4.33	1.82e-05	0.00176	-0.23	-0.2	IgG glycosylation;	chr2:176166258	chr2:176177717~176179008:+
THCA	cis	rs11719291	0.831	rs11715177	ENSG00000270441.1	RP11-694I15.7	4.33	1.82e-05	0.00176	0.27	0.2	Cognitive function;	chr3:48726461	chr3:49140086~49160851:-
THCA	cis	rs9311474	0.598	rs1010554	ENSG00000243224.1	RP5-1157M23.2	4.33	1.82e-05	0.00176	0.21	0.2	Electroencephalogram traits;	chr3:52508903	chr3:52239258~52241097:+
THCA	cis	rs800160	0.545	rs2173887	ENSG00000236264.4	RPL26P30	4.33	1.82e-05	0.00176	0.27	0.2	Bacteremia;	chr11:2335898	chr11:2335132~2335776:-
THCA	cis	rs10090774	1	rs4961296	ENSG00000279766.1	RP11-642A1.2	4.33	1.82e-05	0.00176	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140815482	chr8:140572142~140572812:-
THCA	cis	rs10090774	1	rs11166999	ENSG00000279766.1	RP11-642A1.2	4.33	1.82e-05	0.00176	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140819711	chr8:140572142~140572812:-
THCA	cis	rs889398	0.77	rs8052225	ENSG00000226232.7	RP11-419C5.2	-4.33	1.82e-05	0.00176	-0.19	-0.2	Body mass index;	chr16:69849750	chr16:69976388~69996188:-
THCA	cis	rs7039377	0.658	rs7048582	ENSG00000273036.2	FAM95C	4.33	1.82e-05	0.00176	0.14	0.2	Obesity-related traits;	chr9:38670781	chr9:38540567~38545372:-
THCA	cis	rs10483853	0.806	rs8013402	ENSG00000258695.2	RP3-414A15.2	-4.33	1.82e-05	0.00176	-0.27	-0.2	Coronary artery calcification;	chr14:73281790	chr14:73522878~73530610:+
THCA	cis	rs2115630	0.691	rs61322921	ENSG00000176700.18	SCAND2P	-4.33	1.82e-05	0.00176	-0.13	-0.2	P wave terminal force;	chr15:84620407	chr15:84631451~84647478:+
THCA	cis	rs3760982	0.546	rs73048681	ENSG00000267058.1	RP11-15A1.3	-4.33	1.82e-05	0.00176	-0.18	-0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785793	chr19:43891804~43901805:-
THCA	cis	rs10484434	0.818	rs6925912	ENSG00000272462.2	U91328.19	4.33	1.82e-05	0.00176	0.2	0.2	HIV-1 viral setpoint;	chr6:25976699	chr6:25992662~26001775:+
THCA	cis	rs2243480	0.522	rs1638736	ENSG00000230295.1	RP11-458F8.2	-4.33	1.82e-05	0.00176	-0.3	-0.2	Diabetic kidney disease;	chr7:66627321	chr7:66880708~66882981:+
THCA	cis	rs61160187	0.61	rs4700399	ENSG00000215032.2	GNL3LP1	4.33	1.83e-05	0.00176	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60891935~60893577:-
THCA	cis	rs9863	0.861	rs7958691	ENSG00000269997.1	RP11-214K3.21	-4.33	1.83e-05	0.00176	-0.23	-0.2	White blood cell count;	chr12:123956196	chr12:123966077~123966629:-
THCA	cis	rs3824488	0.652	rs73529860	ENSG00000271155.1	RP11-435O5.5	-4.33	1.83e-05	0.00176	-0.28	-0.2	Neuroticism;	chr9:95537018	chr9:95506235~95507636:+
THCA	cis	rs801193	0.904	rs4718405	ENSG00000229180.5	GS1-124K5.11	4.33	1.83e-05	0.00176	0.14	0.2	Aortic root size;	chr7:66789659	chr7:66526088~66542624:-
THCA	cis	rs875971	0.54	rs781152	ENSG00000164669.11	INTS4P1	-4.33	1.83e-05	0.00176	-0.24	-0.2	Aortic root size;	chr7:66014585	chr7:65141225~65234216:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000164669.11	INTS4P1	-4.33	1.83e-05	0.00176	-0.24	-0.2	Calcium levels;	chr7:66014891	chr7:65141225~65234216:+
THCA	cis	rs9925964	0.748	rs11640961	ENSG00000260911.2	RP11-196G11.2	-4.33	1.83e-05	0.00176	-0.16	-0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30968497	chr16:31043150~31049868:+
THCA	cis	rs10043228	0.826	rs62384461	ENSG00000248445.4	SEMA6A-AS1	-4.33	1.83e-05	0.00176	-0.27	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116283659	chr5:116447547~116508276:+
THCA	cis	rs1150668	0.796	rs1052215	ENSG00000280107.1	AL022393.9	4.33	1.83e-05	0.00176	0.19	0.2	Pubertal anthropometrics;	chr6:28380381	chr6:28170845~28172521:+
THCA	cis	rs10090774	0.93	rs6578132	ENSG00000279766.1	RP11-642A1.2	4.33	1.83e-05	0.00176	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140752459	chr8:140572142~140572812:-
THCA	cis	rs61270009	0.955	rs78909929	ENSG00000247828.6	TMEM161B-AS1	4.33	1.83e-05	0.00176	0.17	0.2	Depressive symptoms;	chr5:88344154	chr5:88268895~88436685:+
THCA	cis	rs9393777	0.668	rs72839449	ENSG00000219392.1	RP1-265C24.5	-4.33	1.83e-05	0.00176	-0.28	-0.2	Intelligence (multi-trait analysis);	chr6:27293882	chr6:28115628~28116551:+
THCA	cis	rs12612619	0.732	rs2304681	ENSG00000272148.1	RP11-195B17.1	-4.33	1.83e-05	0.00176	-0.19	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092384	chr2:27062428~27062907:-
THCA	cis	rs875971	0.545	rs1909508	ENSG00000273142.1	RP11-458F8.4	4.33	1.83e-05	0.00176	0.18	0.2	Aortic root size;	chr7:66301366	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-4.33	1.83e-05	0.00176	-0.22	-0.2	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
THCA	cis	rs7188445	0.615	rs4340340	ENSG00000277954.1	RP11-679B19.1	-4.33	1.83e-05	0.00176	-0.22	-0.2	Urate levels;	chr16:79716720	chr16:79202624~79206739:-
THCA	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	4.33	1.83e-05	0.00176	0.26	0.2	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
THCA	cis	rs5760842	0.967	rs5760834	ENSG00000236641.1	CTA-221G9.7	-4.33	1.83e-05	0.00176	-0.21	-0.2	Recurrent major depressive disorder;	chr22:25083512	chr22:25212742~25213685:+
THCA	cis	rs4819052	0.851	rs2838856	ENSG00000273796.1	LL21NC02-21A1.1	-4.33	1.83e-05	0.00176	-0.2	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45403809~45404369:-
THCA	cis	rs2749592	0.55	rs4934881	ENSG00000226578.1	RP11-258F22.1	4.33	1.83e-05	0.00176	0.23	0.2	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:37775371~37784131:-
THCA	cis	rs7702057	0.53	rs3946989	ENSG00000272265.1	CTD-2287O16.4	4.33	1.83e-05	0.00176	0.35	0.2	Amyotrophic lateral sclerosis;	chr5:116078431	chr5:116078110~116078570:-
THCA	cis	rs7702057	0.53	rs1567331	ENSG00000272265.1	CTD-2287O16.4	4.33	1.83e-05	0.00176	0.35	0.2	Amyotrophic lateral sclerosis;	chr5:116078627	chr5:116078110~116078570:-
THCA	cis	rs7702057	0.53	rs1567332	ENSG00000272265.1	CTD-2287O16.4	4.33	1.83e-05	0.00176	0.35	0.2	Amyotrophic lateral sclerosis;	chr5:116078690	chr5:116078110~116078570:-
THCA	cis	rs138249	0.966	rs138238	ENSG00000273253.2	RP3-402G11.26	-4.33	1.83e-05	0.00176	-0.19	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50124711	chr22:50199090~50200837:-
THCA	cis	rs17221829	0.748	rs1825956	ENSG00000280385.1	AP000648.5	-4.33	1.83e-05	0.00176	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89730855	chr11:90193614~90198120:+
THCA	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	4.33	1.83e-05	0.00176	0.17	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
THCA	cis	rs9879311	1	rs9879311	ENSG00000240288.6	GHRLOS	4.33	1.83e-05	0.00176	0.17	0.2	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373659	chr3:10285754~10293449:+
THCA	cis	rs4805272	1	rs8106785	ENSG00000267799.1	MAN1A2P1	4.33	1.83e-05	0.00176	0.21	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28831805	chr19:28790812~28792871:-
THCA	cis	rs4682868	0.581	rs7630617	ENSG00000273328.4	RP11-141M3.6	-4.33	1.83e-05	0.00176	-0.23	-0.2	Monocyte percentage of white cells;	chr3:42880157	chr3:42809414~42908105:+
THCA	cis	rs9847710	1	rs4687697	ENSG00000242142.1	SERBP1P3	-4.33	1.83e-05	0.00176	-0.23	-0.2	Ulcerative colitis;	chr3:53056474	chr3:53064283~53065091:-
THCA	cis	rs10875746	0.904	rs11168422	ENSG00000258273.1	RP11-370I10.4	4.33	1.83e-05	0.00176	0.28	0.2	Longevity (90 years and older);	chr12:48125722	chr12:48333755~48333901:-
THCA	cis	rs1048886	0.816	rs6932470	ENSG00000271967.1	RP11-134K13.4	-4.33	1.83e-05	0.00177	-0.21	-0.2	Type 2 diabetes;	chr6:70411970	chr6:70596438~70596980:+
THCA	cis	rs860295	0.812	rs7556519	ENSG00000160766.13	GBAP1	-4.33	1.83e-05	0.00177	-0.23	-0.2	Body mass index;	chr1:155857755	chr1:155213821~155227422:-
THCA	cis	rs6441286	0.964	rs13096549	ENSG00000244040.4	IL12A-AS1	4.33	1.83e-05	0.00177	0.25	0.2	Primary biliary cholangitis;	chr3:160025126	chr3:159913400~160225299:-
THCA	cis	rs758324	0.797	rs644713	ENSG00000237714.1	P4HA2-AS1	4.33	1.83e-05	0.00177	0.29	0.2	Alzheimer's disease in APOE e4- carriers;	chr5:132003396	chr5:132184876~132192808:+
THCA	cis	rs9326248	0.53	rs10732856	ENSG00000280143.1	AP000892.6	4.33	1.83e-05	0.00177	0.31	0.2	Blood protein levels;	chr11:117036397	chr11:117204967~117210292:+
THCA	cis	rs2447820	0.5	rs35801915	ENSG00000249996.1	RP11-359P5.1	4.33	1.83e-05	0.00177	0.22	0.2	Migraine;	chr5:122796358	chr5:123036271~123054667:+
THCA	cis	rs853679	1	rs853685	ENSG00000272009.1	RP1-313I6.12	-4.33	1.83e-05	0.00177	-0.26	-0.2	Depression;	chr6:28321008	chr6:28078792~28081130:-
THCA	cis	rs9840812	0.728	rs6439646	ENSG00000239213.4	NCK1-AS1	4.33	1.83e-05	0.00177	0.18	0.2	Fibrinogen levels;	chr3:136554721	chr3:136841726~136862054:-
THCA	cis	rs1232027	0.656	rs1677650	ENSG00000249655.1	CTC-325J23.2	4.33	1.83e-05	0.00177	0.22	0.2	Huntington's disease progression;	chr5:80671345	chr5:80630313~80631590:-
THCA	cis	rs713587	0.571	rs2918630	ENSG00000224165.4	DNAJC27-AS1	4.33	1.83e-05	0.00177	0.11	0.2	Body mass index in non-asthmatics;	chr2:25091317	chr2:24971390~25039694:+
THCA	cis	rs4947019	1	rs11153170	ENSG00000223537.2	RP5-919F19.5	4.33	1.83e-05	0.00177	0.32	0.2	Hematological parameters;	chr6:109331325	chr6:109487906~109506800:+
THCA	cis	rs6730558	0.899	rs12692363	ENSG00000236008.1	AC011747.4	4.33	1.83e-05	0.00177	0.22	0.2	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8603346	chr2:8559833~8583792:-
THCA	cis	rs7520050	0.743	rs61789988	ENSG00000280836.1	AL355480.1	4.33	1.84e-05	0.00177	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45581219~45581321:-
THCA	cis	rs8141529	0.509	rs5762863	ENSG00000226471.5	CTA-292E10.6	-4.33	1.84e-05	0.00177	-0.17	-0.2	Lymphocyte counts;	chr22:28857347	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.509	rs5762864	ENSG00000226471.5	CTA-292E10.6	-4.33	1.84e-05	0.00177	-0.17	-0.2	Lymphocyte counts;	chr22:28857376	chr22:28800683~28848559:+
THCA	cis	rs9959145	1	rs111268621	ENSG00000267108.1	RP11-861E21.1	4.33	1.84e-05	0.00177	0.24	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12546290	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs9966118	ENSG00000267108.1	RP11-861E21.1	4.33	1.84e-05	0.00177	0.24	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12548859	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs77079191	ENSG00000267108.1	RP11-861E21.1	4.33	1.84e-05	0.00177	0.24	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12549379	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs1940973	ENSG00000267108.1	RP11-861E21.1	4.33	1.84e-05	0.00177	0.24	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12550748	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs79785672	ENSG00000267108.1	RP11-861E21.1	4.33	1.84e-05	0.00177	0.24	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12552110	chr18:12432897~12437635:+
THCA	cis	rs9959145	1	rs77321492	ENSG00000267108.1	RP11-861E21.1	4.33	1.84e-05	0.00177	0.24	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12552124	chr18:12432897~12437635:+
THCA	cis	rs8067545	0.75	rs4005937	ENSG00000270091.1	RP11-78O7.2	-4.33	1.84e-05	0.00177	-0.14	-0.2	Schizophrenia;	chr17:20056515	chr17:19896590~19897287:-
THCA	cis	rs4794202	0.629	rs916798	ENSG00000264920.1	RP11-6N17.4	-4.33	1.84e-05	0.00177	-0.26	-0.2	Alzheimer's disease (cognitive decline);	chr17:47818205	chr17:47891255~47895812:-
THCA	cis	rs10090774	0.965	rs13251663	ENSG00000279766.1	RP11-642A1.2	-4.33	1.84e-05	0.00177	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140831478	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11167001	ENSG00000279766.1	RP11-642A1.2	-4.33	1.84e-05	0.00177	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844303	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.932	rs11167002	ENSG00000279766.1	RP11-642A1.2	-4.33	1.84e-05	0.00177	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844410	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13256101	ENSG00000279766.1	RP11-642A1.2	-4.33	1.84e-05	0.00177	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844865	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.896	rs11787521	ENSG00000279766.1	RP11-642A1.2	-4.33	1.84e-05	0.00177	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844994	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10875458	ENSG00000279766.1	RP11-642A1.2	4.33	1.84e-05	0.00177	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140769727	chr8:140572142~140572812:-
THCA	cis	rs10090774	1	rs6578140	ENSG00000279766.1	RP11-642A1.2	4.33	1.84e-05	0.00177	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140824011	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs10088621	ENSG00000279766.1	RP11-642A1.2	4.33	1.84e-05	0.00177	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140828127	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs4961297	ENSG00000279766.1	RP11-642A1.2	4.33	1.84e-05	0.00177	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140829135	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs4434666	ENSG00000279766.1	RP11-642A1.2	4.33	1.84e-05	0.00177	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830069	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs4246128	ENSG00000279766.1	RP11-642A1.2	4.33	1.84e-05	0.00177	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830640	chr8:140572142~140572812:-
THCA	cis	rs9926296	0.557	rs11076618	ENSG00000260259.1	RP11-368I7.4	-4.33	1.84e-05	0.00177	-0.22	-0.2	Vitiligo;	chr16:89741297	chr16:89682620~89686569:-
THCA	cis	rs7267979	1	rs6138572	ENSG00000274973.1	RP13-401N8.7	-4.33	1.84e-05	0.00177	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6138575	ENSG00000274973.1	RP13-401N8.7	-4.33	1.84e-05	0.00177	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs11087521	ENSG00000274973.1	RP13-401N8.7	-4.33	1.84e-05	0.00177	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25845497~25845862:+
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000182586.6	LINC00334	-4.33	1.84e-05	0.00177	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45234340~45258730:+
THCA	cis	rs972578	0.668	rs5759013	ENSG00000274717.1	RP1-47A17.1	4.33	1.84e-05	0.00177	0.21	0.2	Mean platelet volume;	chr22:42893467	chr22:42791814~42794313:-
THCA	cis	rs950776	0.714	rs17408276	ENSG00000261762.1	RP11-650L12.2	4.33	1.84e-05	0.00177	0.26	0.2	Sudden cardiac arrest;	chr15:78589276	chr15:78589123~78591276:-
THCA	cis	rs9900062	0.586	rs2676307	ENSG00000270714.1	MINOS1P2	-4.33	1.84e-05	0.00177	-0.27	-0.2	QT interval;	chr17:64694595	chr17:64747264~64747492:-
THCA	cis	rs1204798	1	rs1204821	ENSG00000237021.2	RP3-486I3.7	-4.33	1.84e-05	0.00177	-0.21	-0.2	Dental caries;	chr6:116242100	chr6:116254207~116256743:+
THCA	cis	rs6600671	0.967	rs4844613	ENSG00000270231.3	NBPF8P	4.33	1.84e-05	0.00177	0.17	0.2	Hip geometry;	chr1:121431913	chr1:120436353~120467739:+
THCA	cis	rs2921036	0.545	rs4840975	ENSG00000254153.1	CTA-398F10.2	4.33	1.84e-05	0.00177	0.24	0.2	Neuroticism;	chr8:8505748	chr8:8456909~8461337:-
THCA	cis	rs4568518	0.53	rs7802064	ENSG00000279048.1	RP11-511H23.2	4.33	1.84e-05	0.00177	0.12	0.2	Measles;	chr7:17955230	chr7:17940503~17942922:+
THCA	cis	rs4218	0.531	rs1374156	ENSG00000277144.1	RP11-59H7.4	-4.33	1.84e-05	0.00177	-0.26	-0.2	Social communication problems;	chr15:59046746	chr15:59115547~59116089:-
THCA	cis	rs1075232	0.522	rs57924788	ENSG00000270055.1	CTD-3092A11.2	-4.33	1.84e-05	0.00177	-0.3	-0.2	Survival in colorectal cancer (non-distant metastatic);	chr15:31457519	chr15:30487963~30490313:+
THCA	cis	rs7267979	0.789	rs6083820	ENSG00000274414.1	RP5-965G21.4	4.33	1.84e-05	0.00177	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:25239007~25245229:-
THCA	cis	rs8030605	0.632	rs11639320	ENSG00000277245.1	RP11-48G14.3	4.33	1.84e-05	0.00177	0.34	0.2	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56460268	chr15:56447120~56447697:+
THCA	cis	rs7829975	0.774	rs1703982	ENSG00000254340.1	RP11-10A14.3	-4.33	1.84e-05	0.00177	-0.22	-0.2	Mood instability;	chr8:8740878	chr8:9141424~9145435:+
THCA	cis	rs7267979	1	rs2500436	ENSG00000276952.1	RP5-965G21.6	-4.33	1.84e-05	0.00177	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6083856	ENSG00000276952.1	RP5-965G21.6	-4.33	1.84e-05	0.00177	-0.21	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25284915~25285588:-
THCA	cis	rs6449502	0.541	rs11744226	ENSG00000251279.1	CTC-436P18.1	4.33	1.84e-05	0.00177	0.36	0.2	Mean platelet volume;	chr5:61115072	chr5:61162070~61232040:+
THCA	cis	rs7015630	1	rs2879287	ENSG00000251136.7	RP11-37B2.1	-4.33	1.84e-05	0.00177	-0.19	-0.2	Inflammatory bowel disease;Crohn's disease;	chr8:89865237	chr8:89609409~89757727:-
THCA	cis	rs78487399	0.808	rs6726643	ENSG00000234936.1	AC010883.5	4.33	1.84e-05	0.00177	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43526607	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6752964	ENSG00000234936.1	AC010883.5	4.33	1.84e-05	0.00177	0.27	0.2	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43527516	chr2:43229573~43233394:+
THCA	cis	rs10792320	0.619	rs1800008	ENSG00000279491.1	RP11-810P12.7	-4.33	1.84e-05	0.00177	-0.25	-0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61962711	chr11:61967794~61969490:+
THCA	cis	rs57024841	0.562	rs7862602	ENSG00000238268.2	RP11-229P13.19	4.33	1.84e-05	0.00177	0.21	0.2	Beta-trace protein levels;	chr9:136946019	chr9:136975094~136976981:+
THCA	cis	rs7824557	0.545	rs2572450	ENSG00000206014.6	OR7E161P	4.33	1.84e-05	0.00177	0.23	0.2	Retinal vascular caliber;	chr8:11372129	chr8:11928597~11929563:-
THCA	cis	rs9425766	0.566	rs4447042	ENSG00000227373.4	RP11-160H22.5	4.33	1.84e-05	0.00177	0.28	0.2	Life satisfaction;	chr1:174212747	chr1:174115300~174160004:-
THCA	cis	rs11089937	0.522	rs2005239	ENSG00000211639.2	IGLV4-60	4.33	1.84e-05	0.00177	0.13	0.2	Periodontitis (PAL4Q3);	chr22:22178083	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs743520	ENSG00000211639.2	IGLV4-60	4.33	1.84e-05	0.00177	0.13	0.2	Periodontitis (PAL4Q3);	chr22:22178249	chr22:22162199~22162681:+
THCA	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	4.33	1.84e-05	0.00177	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
THCA	cis	rs2154427	0.511	rs7279487	ENSG00000238197.4	PAXBP1-AS1	4.33	1.84e-05	0.00177	0.18	0.2	Bilirubin levels;	chr21:32629514	chr21:32728115~32743122:+
THCA	cis	rs4693089	0.604	rs10516689	ENSG00000213608.5	SLC25A14P1	-4.33	1.84e-05	0.00177	-0.22	-0.2	Menopause (age at onset);	chr4:83463842	chr4:83477524~83478424:+
THCA	cis	rs7577696	0.695	rs4952209	ENSG00000276334.1	AL133243.1	4.33	1.84e-05	0.00177	0.21	0.2	Inflammatory biomarkers;	chr2:32160964	chr2:32521927~32523547:+
THCA	cis	rs2006933	1	rs9914405	ENSG00000237575.4	PYY2	4.33	1.84e-05	0.00177	0.24	0.2	Amyotrophic lateral sclerosis;	chr17:28261333	chr17:28226563~28228065:+
THCA	cis	rs35740288	0.77	rs11635711	ENSG00000259295.5	CSPG4P12	4.33	1.84e-05	0.00177	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85583255	chr15:85191438~85213905:+
THCA	cis	rs10090774	0.932	rs1448226	ENSG00000279766.1	RP11-642A1.2	-4.33	1.84e-05	0.00177	-0.24	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140894289	chr8:140572142~140572812:-
THCA	cis	rs4656958	0.538	rs11265522	ENSG00000233691.2	RP11-312J18.7	-4.33	1.84e-05	0.00177	-0.22	-0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160920369	chr1:160935537~160936126:+
THCA	cis	rs71636778	0.722	rs34928032	ENSG00000260063.1	RP5-968P14.2	-4.33	1.84e-05	0.00177	-0.27	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26812738	chr1:26692132~26694131:-
THCA	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	4.33	1.84e-05	0.00177	0.22	0.2	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
THCA	cis	rs4356203	0.905	rs7930058	ENSG00000272034.1	SNORD14A	-4.33	1.84e-05	0.00177	-0.19	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17045071	chr11:17074654~17074744:-
THCA	cis	rs7111546	0.945	rs1019216	ENSG00000246225.5	RP11-17A1.3	4.33	1.84e-05	0.00178	0.35	0.2	Dialysis-related mortality;	chr11:22821674	chr11:22829380~22945393:+
THCA	cis	rs849141	0.524	rs550448	ENSG00000234336.5	JAZF1-AS1	4.33	1.84e-05	0.00178	0.32	0.2	Height;Hip circumference adjusted for BMI;	chr7:28189423	chr7:28180322~28243917:+
THCA	cis	rs13113518	1	rs55699500	ENSG00000249700.7	SRD5A3-AS1	4.33	1.84e-05	0.00178	0.24	0.2	Height;	chr4:55540912	chr4:55363971~55395847:-
THCA	cis	rs10911902	0.643	rs3766705	ENSG00000229739.2	RP11-295K2.3	-4.33	1.84e-05	0.00178	-0.31	-0.2	Schizophrenia;	chr1:186342680	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs16825201	ENSG00000229739.2	RP11-295K2.3	-4.33	1.84e-05	0.00178	-0.31	-0.2	Schizophrenia;	chr1:186344698	chr1:186435161~186470291:+
THCA	cis	rs4144027	0.935	rs881056	ENSG00000269958.1	RP11-73M18.8	-4.33	1.84e-05	0.00178	-0.18	-0.2	Blood metabolite levels;	chr14:103887888	chr14:103696353~103697163:+
THCA	cis	rs10484434	0.818	rs11759668	ENSG00000272462.2	U91328.19	4.33	1.84e-05	0.00178	0.2	0.2	HIV-1 viral setpoint;	chr6:26014261	chr6:25992662~26001775:+
THCA	cis	rs10484434	0.901	rs2230654	ENSG00000272462.2	U91328.19	-4.33	1.84e-05	0.00178	-0.2	-0.2	HIV-1 viral setpoint;	chr6:26033413	chr6:25992662~26001775:+
THCA	cis	rs2692947	0.568	rs57579941	ENSG00000235584.2	AC008268.1	-4.33	1.85e-05	0.00178	-0.19	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95670505	chr2:95666084~95668715:+
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000176700.18	SCAND2P	-4.33	1.85e-05	0.00178	-0.13	-0.2	P wave terminal force;	chr15:84631400	chr15:84631451~84647478:+
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000176700.18	SCAND2P	-4.33	1.85e-05	0.00178	-0.13	-0.2	P wave terminal force;	chr15:84631524	chr15:84631451~84647478:+
THCA	cis	rs12935418	0.832	rs79957369	ENSG00000261838.4	RP11-303E16.6	4.33	1.85e-05	0.00178	0.31	0.2	Mean corpuscular volume;	chr16:81025654	chr16:81069854~81076598:+
THCA	cis	rs6688613	0.685	rs61815130	ENSG00000225171.2	DUTP6	-4.33	1.85e-05	0.00178	-0.28	-0.2	Refractive astigmatism;	chr1:166941228	chr1:166868748~166869209:+
THCA	cis	rs654950	0.806	rs1815257	ENSG00000230638.4	RP11-486B10.4	4.33	1.85e-05	0.00178	0.23	0.2	Airway imaging phenotypes;	chr1:41575808	chr1:41542069~41544310:+
THCA	cis	rs654950	0.806	rs2759251	ENSG00000230638.4	RP11-486B10.4	4.33	1.85e-05	0.00178	0.23	0.2	Airway imaging phenotypes;	chr1:41576078	chr1:41542069~41544310:+
THCA	cis	rs9926296	0.632	rs9935559	ENSG00000274627.1	RP11-104N10.2	4.33	1.85e-05	0.00178	0.2	0.2	Vitiligo;	chr16:89734121	chr16:89516797~89522217:+
THCA	cis	rs453301	0.597	rs7001187	ENSG00000254153.1	CTA-398F10.2	4.33	1.85e-05	0.00178	0.23	0.2	Joint mobility (Beighton score);	chr8:8935272	chr8:8456909~8461337:-
THCA	cis	rs1204798	0.898	rs1204814	ENSG00000237021.2	RP3-486I3.7	-4.33	1.85e-05	0.00178	-0.21	-0.2	Dental caries;	chr6:116232411	chr6:116254207~116256743:+
THCA	cis	rs7474896	0.515	rs2505233	ENSG00000120555.12	SEPT7P9	4.33	1.85e-05	0.00178	0.26	0.2	Obesity (extreme);	chr10:38051337	chr10:38383069~38402916:-
THCA	cis	rs783540	0.5	rs783541	ENSG00000278603.1	RP13-608F4.5	-4.33	1.85e-05	0.00178	-0.29	-0.2	Schizophrenia;	chr15:82586310	chr15:82472203~82472426:+
THCA	cis	rs812925	0.502	rs13028833	ENSG00000270820.4	RP11-355B11.2	-4.33	1.85e-05	0.00178	-0.17	-0.2	Immature fraction of reticulocytes;	chr2:61417194	chr2:61471188~61484130:+
THCA	cis	rs7829975	0.582	rs448231	ENSG00000254153.1	CTA-398F10.2	4.33	1.85e-05	0.00178	0.22	0.2	Mood instability;	chr8:8932549	chr8:8456909~8461337:-
THCA	cis	rs6449502	0.841	rs10471503	ENSG00000251279.1	CTC-436P18.1	4.33	1.85e-05	0.00178	0.33	0.2	Mean platelet volume;	chr5:61074210	chr5:61162070~61232040:+
THCA	cis	rs734999	0.505	rs60687045	ENSG00000225931.3	RP3-395M20.7	4.33	1.85e-05	0.00178	0.23	0.2	Ulcerative colitis;	chr1:2608164	chr1:2566410~2569888:+
THCA	cis	rs7824557	0.564	rs12547100	ENSG00000154316.13	TDH	4.33	1.85e-05	0.00178	0.15	0.2	Retinal vascular caliber;	chr8:11385123	chr8:11339637~11368452:+
THCA	cis	rs72799341	0.706	rs11865499	ENSG00000279196.1	RP11-1072A3.3	4.33	1.85e-05	0.00178	0.2	0.2	Diastolic blood pressure;	chr16:31120929	chr16:30984630~30988270:-
THCA	cis	rs972578	0.791	rs713776	ENSG00000274717.1	RP1-47A17.1	-4.33	1.85e-05	0.00178	-0.2	-0.2	Mean platelet volume;	chr22:43000088	chr22:42791814~42794313:-
THCA	cis	rs61270009	0.955	rs4916897	ENSG00000247828.6	TMEM161B-AS1	4.33	1.85e-05	0.00178	0.17	0.2	Depressive symptoms;	chr5:88285771	chr5:88268895~88436685:+
THCA	cis	rs4578769	0.959	rs6507323	ENSG00000265939.1	UBE2CP2	-4.33	1.85e-05	0.00178	-0.24	-0.2	Eosinophil percentage of white cells;	chr18:22846715	chr18:22900486~22900995:-
THCA	cis	rs5752326	0.51	rs5761557	ENSG00000261188.1	CTA-445C9.14	-4.33	1.85e-05	0.00178	-0.21	-0.2	Ischemic stroke;	chr22:26482058	chr22:26512537~26514568:+
THCA	cis	rs7829975	0.774	rs11249893	ENSG00000254340.1	RP11-10A14.3	4.33	1.85e-05	0.00178	0.22	0.2	Mood instability;	chr8:8843341	chr8:9141424~9145435:+
THCA	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	4.33	1.85e-05	0.00178	0.16	0.2	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	4.33	1.85e-05	0.00178	0.16	0.2	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
THCA	cis	rs9902453	0.933	rs9898353	ENSG00000263370.1	RP11-68I3.5	4.33	1.85e-05	0.00178	0.25	0.2	Coffee consumption (cups per day);	chr17:30124847	chr17:29639627~29640825:+
THCA	cis	rs9425766	0.566	rs4442420	ENSG00000227373.4	RP11-160H22.5	4.33	1.85e-05	0.00178	0.28	0.2	Life satisfaction;	chr1:174199667	chr1:174115300~174160004:-
THCA	cis	rs62158800	0.852	rs62161277	ENSG00000224568.1	AC096669.3	4.33	1.85e-05	0.00178	0.37	0.2	Facial morphology (factor 22);	chr2:107679728	chr2:107529487~107556326:+
THCA	cis	rs17772222	0.682	rs2401751	ENSG00000222990.1	RNU4-22P	-4.33	1.85e-05	0.00178	-0.24	-0.2	Coronary artery calcification;	chr14:88480278	chr14:88513498~88513663:+
THCA	cis	rs4356203	0.905	rs615358	ENSG00000272034.1	SNORD14A	-4.33	1.85e-05	0.00178	-0.2	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17188885	chr11:17074654~17074744:-
THCA	cis	rs123509	0.874	rs339683	ENSG00000173811.9	CCDC13-AS1	4.33	1.85e-05	0.00178	0.22	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42747019	chr3:42732575~42746768:+
THCA	cis	rs113835537	0.935	rs75863187	ENSG00000255517.5	CTD-3074O7.5	-4.33	1.85e-05	0.00178	-0.21	-0.2	Airway imaging phenotypes;	chr11:66675990	chr11:66473490~66480233:-
THCA	cis	rs6121246	0.559	rs6121172	ENSG00000230613.1	HM13-AS1	4.33	1.85e-05	0.00178	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31708292	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6060857	ENSG00000230613.1	HM13-AS1	4.33	1.85e-05	0.00178	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31712419	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs1484994	ENSG00000230613.1	HM13-AS1	4.33	1.85e-05	0.00178	0.19	0.2	Mean corpuscular hemoglobin;	chr20:31718172	chr20:31567707~31573263:-
THCA	cis	rs10027350	0.964	rs10026230	ENSG00000281501.1	SEPSECS-AS1	4.33	1.85e-05	0.00178	0.22	0.2	Childhood ear infection;	chr4:25135784	chr4:25160641~25201440:+
THCA	cis	rs2777491	0.574	rs28700583	ENSG00000247556.5	OIP5-AS1	4.33	1.85e-05	0.00178	0.19	0.2	Ulcerative colitis;	chr15:41421874	chr15:41283990~41309737:+
THCA	cis	rs1371614	0.632	rs6759548	ENSG00000272148.1	RP11-195B17.1	4.33	1.85e-05	0.00178	0.18	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26938192	chr2:27062428~27062907:-
THCA	cis	rs4713118	1	rs1139226	ENSG00000220721.1	OR1F12	4.33	1.85e-05	0.00178	0.25	0.2	Parkinson's disease;	chr6:27707511	chr6:28073316~28074233:+
THCA	cis	rs4713118	1	rs9468195	ENSG00000220721.1	OR1F12	4.33	1.85e-05	0.00178	0.25	0.2	Parkinson's disease;	chr6:27708530	chr6:28073316~28074233:+
THCA	cis	rs7246760	0.867	rs56307296	ENSG00000267106.4	ZNF561-AS1	4.33	1.85e-05	0.00178	0.39	0.2	Pursuit maintenance gain;	chr19:9633423	chr19:9621291~9645896:+
THCA	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	4.33	1.85e-05	0.00178	0.23	0.2	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	4.33	1.85e-05	0.00178	0.23	0.2	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	4.33	1.85e-05	0.00178	0.23	0.2	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	4.33	1.85e-05	0.00178	0.23	0.2	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	4.33	1.85e-05	0.00178	0.23	0.2	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	4.33	1.85e-05	0.00178	0.23	0.2	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
THCA	cis	rs75920871	0.614	rs117287138	ENSG00000254851.1	RP11-109L13.1	-4.33	1.85e-05	0.00178	-0.44	-0.2	Subjective well-being;	chr11:116924163	chr11:117135528~117138582:+
THCA	cis	rs7746199	0.668	rs7749305	ENSG00000220721.1	OR1F12	4.33	1.85e-05	0.00178	0.38	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28073316~28074233:+
THCA	cis	rs2070488	1	rs36006749	ENSG00000229589.1	ACVR2B-AS1	4.33	1.85e-05	0.00178	0.18	0.2	Electrocardiographic conduction measures;	chr3:38401821	chr3:38451027~38454820:-
THCA	cis	rs7711186	0.881	rs7720343	ENSG00000252464.1	RN7SKP70	4.33	1.85e-05	0.00178	0.23	0.2	Urate levels in obese individuals;	chr5:178659187	chr5:178619728~178619998:-
THCA	cis	rs4218	0.681	rs1074701	ENSG00000277144.1	RP11-59H7.4	-4.33	1.85e-05	0.00178	-0.27	-0.2	Social communication problems;	chr15:59073862	chr15:59115547~59116089:-
THCA	cis	rs17507216	0.718	rs72751662	ENSG00000255769.6	GOLGA2P10	-4.33	1.85e-05	0.00178	-0.3	-0.2	Excessive daytime sleepiness;	chr15:82594705	chr15:82472993~82513950:-
THCA	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	4.33	1.85e-05	0.00178	0.22	0.2	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
THCA	cis	rs6479874	1	rs2879550	ENSG00000223502.1	RP11-96B5.3	-4.33	1.86e-05	0.00178	-0.23	-0.2	Migraine;	chr10:50995464	chr10:51062579~51068553:-
THCA	cis	rs1371614	0.588	rs11126784	ENSG00000272148.1	RP11-195B17.1	4.33	1.86e-05	0.00178	0.18	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946974	chr2:27062428~27062907:-
THCA	cis	rs9902453	0.967	rs28792710	ENSG00000263370.1	RP11-68I3.5	4.33	1.86e-05	0.00179	0.25	0.2	Coffee consumption (cups per day);	chr17:30122997	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.933	rs8074028	ENSG00000263370.1	RP11-68I3.5	4.33	1.86e-05	0.00179	0.25	0.2	Coffee consumption (cups per day);	chr17:30134669	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.933	rs9908901	ENSG00000263370.1	RP11-68I3.5	4.33	1.86e-05	0.00179	0.25	0.2	Coffee consumption (cups per day);	chr17:30142695	chr17:29639627~29640825:+
THCA	cis	rs6441286	1	rs2279741	ENSG00000244040.4	IL12A-AS1	-4.33	1.86e-05	0.00179	-0.24	-0.2	Primary biliary cholangitis;	chr3:160026474	chr3:159913400~160225299:-
THCA	cis	rs6580649	0.941	rs1859441	ENSG00000273765.1	RP11-370I10.11	-4.33	1.86e-05	0.00179	-0.22	-0.2	Lung cancer;	chr12:48029450	chr12:48360920~48361377:+
THCA	cis	rs4915077	0.892	rs78435278	ENSG00000226822.1	RP11-356N1.2	4.33	1.86e-05	0.00179	0.38	0.2	Hypothyroidism;	chr1:107804125	chr1:108071482~108074519:+
THCA	cis	rs9863	0.828	rs11057413	ENSG00000270061.1	RP11-214K3.19	-4.33	1.86e-05	0.00179	-0.26	-0.2	White blood cell count;	chr12:124004615	chr12:123969990~123970344:-
THCA	cis	rs13434995	0.589	rs62306207	ENSG00000249700.7	SRD5A3-AS1	-4.33	1.86e-05	0.00179	-0.28	-0.2	Adiponectin levels;	chr4:55384548	chr4:55363971~55395847:-
THCA	cis	rs12534093	0.883	rs10950942	ENSG00000234286.1	AC006026.13	-4.33	1.86e-05	0.00179	-0.31	-0.2	Infant length;Height;	chr7:23445083	chr7:23680195~23680786:-
THCA	cis	rs138249	1	rs138249	ENSG00000273253.2	RP3-402G11.26	-4.33	1.86e-05	0.00179	-0.19	-0.2	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50131361	chr22:50199090~50200837:-
THCA	cis	rs6449502	1	rs6889730	ENSG00000251279.1	CTC-436P18.1	-4.33	1.86e-05	0.00179	-0.33	-0.2	Mean platelet volume;	chr5:60825270	chr5:61162070~61232040:+
THCA	cis	rs4578769	0.959	rs3851816	ENSG00000265939.1	UBE2CP2	4.33	1.86e-05	0.00179	0.24	0.2	Eosinophil percentage of white cells;	chr18:22866880	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.842	rs8093152	ENSG00000265939.1	UBE2CP2	4.33	1.86e-05	0.00179	0.24	0.2	Eosinophil percentage of white cells;	chr18:22867925	chr18:22900486~22900995:-
THCA	cis	rs4971059	0.507	rs11264321	ENSG00000160766.13	GBAP1	-4.33	1.86e-05	0.00179	-0.21	-0.2	Breast cancer;	chr1:155113422	chr1:155213821~155227422:-
THCA	cis	rs7824557	0.524	rs7835318	ENSG00000206014.6	OR7E161P	4.33	1.86e-05	0.00179	0.23	0.2	Retinal vascular caliber;	chr8:11096364	chr8:11928597~11929563:-
THCA	cis	rs2191566	0.96	rs56171514	ENSG00000266921.1	RP11-15A1.7	-4.33	1.86e-05	0.00179	-0.18	-0.2	Acute lymphoblastic leukemia (childhood);	chr19:44001958	chr19:43996896~44002836:-
THCA	cis	rs6433895	0.677	rs72888919	ENSG00000236153.1	AC104076.3	-4.33	1.86e-05	0.00179	-0.24	-0.2	Lymphocyte counts;	chr2:181162274	chr2:180979427~180980090:-
THCA	cis	rs1476679	0.927	rs2405442	ENSG00000078319.8	PMS2P1	-4.33	1.86e-05	0.00179	-0.23	-0.2	Alzheimer's disease (late onset);	chr7:100373690	chr7:100320992~100341908:-
THCA	cis	rs250585	0.62	rs3096145	ENSG00000260136.4	CTD-2270L9.4	4.33	1.86e-05	0.00179	0.16	0.2	Egg allergy;	chr16:23601679	chr16:23452758~23457606:+
THCA	cis	rs4948102	0.642	rs4948104	ENSG00000275875.1	RP11-613E4.5	-4.33	1.86e-05	0.00179	-0.24	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55741525~55741869:+
THCA	cis	rs5758511	0.68	rs5758692	ENSG00000237037.8	NDUFA6-AS1	-4.33	1.86e-05	0.00179	-0.18	-0.2	Birth weight;	chr22:42273023	chr22:42090931~42137742:+
THCA	cis	rs7267979	1	rs2500448	ENSG00000274973.1	RP13-401N8.7	4.33	1.86e-05	0.00179	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.873	rs6083853	ENSG00000274973.1	RP13-401N8.7	4.33	1.86e-05	0.00179	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.934	rs2482913	ENSG00000274973.1	RP13-401N8.7	4.33	1.86e-05	0.00179	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25845497~25845862:+
THCA	cis	rs4434872	0.536	rs12726350	ENSG00000223599.1	RP11-216N14.7	-4.33	1.86e-05	0.00179	-0.38	-0.2	Conduct disorder (symptom count);	chr1:153862063	chr1:153852106~153853414:-
THCA	cis	rs2904524	1	rs7311497	ENSG00000257815.4	RP11-611E13.2	-4.33	1.86e-05	0.00179	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70343818	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs11178195	ENSG00000257815.4	RP11-611E13.2	-4.33	1.86e-05	0.00179	-0.18	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70345715	chr12:69904033~70243360:-
THCA	cis	rs8141529	1	rs132534	ENSG00000272858.1	CTA-292E10.8	4.33	1.86e-05	0.00179	0.21	0.2	Lymphocyte counts;	chr22:28903818	chr22:28814914~28815662:+
THCA	cis	rs4805272	0.962	rs1363325	ENSG00000267799.1	MAN1A2P1	4.33	1.86e-05	0.00179	0.21	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834759	chr19:28790812~28792871:-
THCA	cis	rs9341808	0.667	rs1408292	ENSG00000272129.1	RP11-250B2.6	4.33	1.86e-05	0.00179	0.25	0.2	Sitting height ratio;	chr6:80174189	chr6:80355424~80356859:+
THCA	cis	rs875971	0.502	rs1796227	ENSG00000273142.1	RP11-458F8.4	-4.33	1.86e-05	0.00179	-0.18	-0.2	Aortic root size;	chr7:66622032	chr7:66902857~66906297:+
THCA	cis	rs964611	0.938	rs12592330	ENSG00000259488.2	RP11-154J22.1	4.33	1.86e-05	0.00179	0.18	0.2	Metabolite levels (Pyroglutamine);	chr15:48353083	chr15:48312353~48331856:-
THCA	cis	rs4443100	0.77	rs6003467	ENSG00000230701.2	FBXW4P1	4.33	1.86e-05	0.00179	0.24	0.2	Serum parathyroid hormone levels;	chr22:23024155	chr22:23262767~23265005:+
THCA	cis	rs7572644	0.699	rs4390729	ENSG00000223522.1	AC093690.1	4.33	1.86e-05	0.00179	0.22	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27939994	chr2:28307691~28310459:-
THCA	cis	rs8050907	0.744	rs8044698	ENSG00000278434.1	RP11-709D24.8	4.33	1.86e-05	0.00179	0.45	0.2	Obesity-related traits;	chr16:4527068	chr16:4532216~4533670:-
THCA	cis	rs875971	0.862	rs2901152	ENSG00000229886.1	RP5-1132H15.3	-4.33	1.86e-05	0.00179	-0.21	-0.2	Aortic root size;	chr7:66300017	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs10263690	ENSG00000229886.1	RP5-1132H15.3	-4.33	1.86e-05	0.00179	-0.21	-0.2	Aortic root size;	chr7:66301466	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs10250544	ENSG00000229886.1	RP5-1132H15.3	-4.33	1.86e-05	0.00179	-0.21	-0.2	Aortic root size;	chr7:66301574	chr7:66025126~66031544:-
THCA	cis	rs997295	0.675	rs17242605	ENSG00000270964.1	RP11-502I4.3	-4.33	1.86e-05	0.00179	-0.16	-0.2	Motion sickness;	chr15:67671098	chr15:67541072~67542604:-
THCA	cis	rs997295	0.675	rs12912974	ENSG00000270964.1	RP11-502I4.3	-4.33	1.86e-05	0.00179	-0.16	-0.2	Motion sickness;	chr15:67682041	chr15:67541072~67542604:-
THCA	cis	rs111756027	0.635	rs68179431	ENSG00000260922.1	RP11-538I12.3	4.33	1.86e-05	0.00179	0.3	0.2	Bone mineral density (Ward's triangle area);	chr16:77253016	chr16:77234877~77290934:+
THCA	cis	rs6479891	1	rs10437345	ENSG00000272767.1	JMJD1C-AS1	-4.33	1.86e-05	0.00179	-0.27	-0.2	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63465229~63466563:+
THCA	cis	rs1538970	0.924	rs11211111	ENSG00000234329.1	RP11-767N6.2	4.33	1.86e-05	0.00179	0.2	0.2	Platelet count;	chr1:45443110	chr1:45651039~45651826:-
THCA	cis	rs1538970	0.924	rs1006216	ENSG00000234329.1	RP11-767N6.2	4.33	1.86e-05	0.00179	0.2	0.2	Platelet count;	chr1:45444322	chr1:45651039~45651826:-
THCA	cis	rs1538970	0.924	rs1007858	ENSG00000234329.1	RP11-767N6.2	4.33	1.86e-05	0.00179	0.2	0.2	Platelet count;	chr1:45446333	chr1:45651039~45651826:-
THCA	cis	rs9717605	1	rs9505897	ENSG00000226445.1	XXyac-YX65C7_A.2	4.32	1.86e-05	0.00179	0.24	0.2	Left atrial antero-posterior diameter;	chr6:169246656	chr6:169213254~169239565:+
THCA	cis	rs910873	1	rs56020497	ENSG00000276073.1	RP5-1125A11.7	4.32	1.86e-05	0.00179	0.37	0.2	Melanoma;	chr20:34578666	chr20:33985617~33988989:-
THCA	cis	rs910873	1	rs17305573	ENSG00000276073.1	RP5-1125A11.7	4.32	1.86e-05	0.00179	0.37	0.2	Melanoma;	chr20:34592348	chr20:33985617~33988989:-
THCA	cis	rs62025270	0.688	rs11073516	ENSG00000259295.5	CSPG4P12	-4.32	1.86e-05	0.00179	-0.33	-0.2	Idiopathic pulmonary fibrosis;	chr15:85741996	chr15:85191438~85213905:+
THCA	cis	rs7688540	0.511	rs75433628	ENSG00000211553.1	AC253576.2	-4.32	1.86e-05	0.00179	-0.3	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:136461~136568:+
THCA	cis	rs4742903	1	rs3780535	ENSG00000270332.1	SMC2-AS1	4.32	1.86e-05	0.00179	0.18	0.2	Breast cancer;High-grade serous ovarian cancer;	chr9:104131930	chr9:104080024~104093073:-
THCA	cis	rs10875746	0.951	rs2286021	ENSG00000258234.1	RP11-370I10.2	4.32	1.86e-05	0.00179	0.23	0.2	Longevity (90 years and older);	chr12:48134437	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs11168427	ENSG00000258234.1	RP11-370I10.2	4.32	1.86e-05	0.00179	0.23	0.2	Longevity (90 years and older);	chr12:48145196	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.951	rs61918826	ENSG00000258234.1	RP11-370I10.2	4.32	1.86e-05	0.00179	0.23	0.2	Longevity (90 years and older);	chr12:48150195	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.904	rs10875750	ENSG00000258234.1	RP11-370I10.2	4.32	1.86e-05	0.00179	0.23	0.2	Longevity (90 years and older);	chr12:48151847	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.951	rs7485355	ENSG00000258234.1	RP11-370I10.2	4.32	1.86e-05	0.00179	0.23	0.2	Longevity (90 years and older);	chr12:48154559	chr12:48231098~48284210:-
THCA	cis	rs71636778	0.631	rs60314236	ENSG00000260063.1	RP5-968P14.2	-4.32	1.87e-05	0.00179	-0.27	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26828675	chr1:26692132~26694131:-
THCA	cis	rs59972978	0.562	rs3810541	ENSG00000124097.7	HMGB1P1	4.32	1.87e-05	0.00179	0.26	0.2	Alcohol consumption;	chr20:57488263	chr20:57488392~57489027:-
THCA	cis	rs1499614	0.522	rs13247442	ENSG00000232559.3	GS1-124K5.12	4.32	1.87e-05	0.00179	0.38	0.2	Gout;	chr7:66723871	chr7:66554588~66576923:-
THCA	cis	rs7647973	0.516	rs4308307	ENSG00000229759.1	MRPS18AP1	4.32	1.87e-05	0.00179	0.25	0.2	Menarche (age at onset);	chr3:49155783	chr3:48256350~48256938:-
THCA	cis	rs760794	0.577	rs7752808	ENSG00000237404.1	RP3-471C18.2	-4.32	1.87e-05	0.00179	-0.22	-0.2	Endometriosis;	chr6:19792665	chr6:19689825~19753113:-
THCA	cis	rs4938303	0.633	rs77835865	ENSG00000254851.1	RP11-109L13.1	4.32	1.87e-05	0.00179	0.32	0.2	Triglycerides;	chr11:116684713	chr11:117135528~117138582:+
THCA	cis	rs2886497	0.947	rs1398024	ENSG00000224215.1	RP11-371A19.2	-4.32	1.87e-05	0.00179	-0.25	-0.2	Major depression and alcohol dependence;	chr10:23376509	chr10:23343957~23345181:+
THCA	cis	rs11971779	0.941	rs28395455	ENSG00000252332.1	RNU6-911P	-4.32	1.87e-05	0.0018	-0.25	-0.2	Diisocyanate-induced asthma;	chr7:139351240	chr7:139448740~139448843:+
THCA	cis	rs11992162	1	rs12334769	ENSG00000270154.1	RP11-419I17.1	4.32	1.87e-05	0.0018	0.24	0.2	Monocyte count;	chr8:11975652	chr8:12476462~12477122:+
THCA	cis	rs1414896	0.624	rs4949995	ENSG00000226026.4	RP11-57H12.3	4.32	1.87e-05	0.0018	0.19	0.2	Non-alcoholic fatty liver disease histology (AST);	chr1:95174640	chr1:95163219~95233982:-
THCA	cis	rs6929812	0.605	rs12526495	ENSG00000204789.4	ZNF204P	-4.32	1.87e-05	0.0018	-0.16	-0.2	Neuroticism (multi-trait analysis);	chr6:27426092	chr6:27357825~27360221:-
THCA	cis	rs5758659	0.622	rs5758527	ENSG00000273366.1	CTA-989H11.1	-4.32	1.87e-05	0.0018	-0.24	-0.2	Cognitive function;	chr22:41979757	chr22:42278188~42278846:+
THCA	cis	rs6657613	0.651	rs2295057	ENSG00000186301.8	MST1P2	4.32	1.87e-05	0.0018	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17051061	chr1:16645622~16650289:+
THCA	cis	rs919433	0.679	rs55656916	ENSG00000231621.1	AC013264.2	-4.32	1.87e-05	0.0018	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197654904	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs13394214	ENSG00000231621.1	AC013264.2	-4.32	1.87e-05	0.0018	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197662647	chr2:197197991~197199273:+
THCA	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-4.32	1.87e-05	0.0018	-0.22	-0.2	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
THCA	cis	rs8031584	0.678	rs798086	ENSG00000178081.11	ULK4P3	-4.32	1.87e-05	0.0018	-0.26	-0.2	Huntington's disease progression;	chr15:30837008	chr15:30103720~30131757:+
THCA	cis	rs62244186	0.748	rs2888410	ENSG00000214820.3	MPRIPP1	4.32	1.87e-05	0.0018	0.21	0.2	Depressive symptoms;	chr3:44613984	chr3:44579938~44581026:-
THCA	cis	rs3770081	0.826	rs1019591	ENSG00000273080.1	RP11-301O19.1	-4.32	1.87e-05	0.0018	-0.43	-0.2	Facial emotion recognition (sad faces);	chr2:86071476	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs6750765	ENSG00000273080.1	RP11-301O19.1	-4.32	1.87e-05	0.0018	-0.43	-0.2	Facial emotion recognition (sad faces);	chr2:86073185	chr2:86195590~86196049:+
THCA	cis	rs36093844	0.752	rs7943104	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85834137	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs80323143	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85835053	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.651	rs55978615	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85835348	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs79516304	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85836192	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs1445511	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837006	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.698	rs55951560	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837299	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs56036199	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837720	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs7931771	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85838845	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs7931698	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85838883	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs76407487	ENSG00000279742.1	RP11-700A24.1	-4.32	1.87e-05	0.0018	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85839589	chr11:85852557~85854943:-
THCA	cis	rs1728785	1	rs1182968	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68540042	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1170442	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68540161	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs864742	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68541406	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs864741	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68542674	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1094282	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68543357	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs7196104	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68545843	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1624718	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68546482	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs4783656	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68546819	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1645923	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68547148	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.818	rs1814299	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68547429	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs933713	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68547475	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs11642189	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68550087	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs8058145	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68550187	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs8058314	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68550248	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.818	rs1728772	ENSG00000274698.1	RP11-71L14.4	4.32	1.87e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68550623	chr16:68450283~68452318:+
THCA	cis	rs868036	0.681	rs13329567	ENSG00000270964.1	RP11-502I4.3	-4.32	1.87e-05	0.0018	-0.18	-0.2	Restless legs syndrome;	chr15:67812029	chr15:67541072~67542604:-
THCA	cis	rs1232027	0.666	rs1643637	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80633090	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs2560423	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80633355	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643638	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80634437	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1650717	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80634760	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1650715	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80634922	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1650712	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80639694	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643657	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80640598	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs966762	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80640980	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677692	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80641195	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677691	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80641209	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1650709	ENSG00000249655.1	CTC-325J23.2	4.32	1.87e-05	0.0018	0.22	0.2	Huntington's disease progression;	chr5:80641355	chr5:80630313~80631590:-
THCA	cis	rs889398	0.741	rs6499269	ENSG00000226232.7	RP11-419C5.2	-4.32	1.87e-05	0.0018	-0.2	-0.2	Body mass index;	chr16:69875015	chr16:69976388~69996188:-
THCA	cis	rs13126694	0.744	rs7657303	ENSG00000248429.4	RP11-597D13.9	-4.32	1.87e-05	0.0018	-0.21	-0.2	Blood osmolality (transformed sodium);	chr4:157992992	chr4:158170752~158202877:+
THCA	cis	rs12440869	1	rs9806386	ENSG00000270964.1	RP11-502I4.3	-4.32	1.87e-05	0.0018	-0.17	-0.2	Peak velocity of the mitral A-wave;	chr15:67319831	chr15:67541072~67542604:-
THCA	cis	rs10027350	1	rs10027350	ENSG00000281501.1	SEPSECS-AS1	4.32	1.87e-05	0.0018	0.22	0.2	Childhood ear infection;	chr4:25130872	chr4:25160641~25201440:+
THCA	cis	rs7551222	0.68	rs2169137	ENSG00000240219.1	RP11-430C7.5	4.32	1.87e-05	0.0018	0.21	0.2	Schizophrenia;	chr1:204528785	chr1:204626775~204629712:+
THCA	cis	rs12908161	0.959	rs3748376	ENSG00000188388.10	GOLGA6L3	4.32	1.87e-05	0.0018	0.26	0.2	Schizophrenia;	chr15:84785121	chr15:85240472~85247170:+
THCA	cis	rs9573567	0.609	rs9565164	ENSG00000261553.4	RP11-29G8.3	-4.32	1.87e-05	0.0018	-0.37	-0.2	Red blood cell count;Mean corpuscular volume;	chr13:75465240	chr13:75549773~75807120:+
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000265443.1	CTD-2349P21.6	-4.32	1.87e-05	0.0018	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000265443.1	CTD-2349P21.6	-4.32	1.87e-05	0.0018	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000265443.1	CTD-2349P21.6	-4.32	1.87e-05	0.0018	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000265443.1	CTD-2349P21.6	-4.32	1.87e-05	0.0018	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000265443.1	CTD-2349P21.6	-4.32	1.87e-05	0.0018	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000265443.1	CTD-2349P21.6	-4.32	1.87e-05	0.0018	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000265443.1	CTD-2349P21.6	-4.32	1.87e-05	0.0018	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30726305~30727564:-
THCA	cis	rs6570726	0.935	rs110289	ENSG00000270638.1	RP3-466P17.1	4.32	1.87e-05	0.0018	0.15	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145735570~145737218:+
THCA	cis	rs1923243	0.677	rs6690119	ENSG00000223479.3	RP4-788P17.1	4.32	1.87e-05	0.0018	0.22	0.2	Migraine;	chr1:73115281	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4469676	ENSG00000223479.3	RP4-788P17.1	4.32	1.87e-05	0.0018	0.22	0.2	Migraine;	chr1:73116240	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4355999	ENSG00000223479.3	RP4-788P17.1	4.32	1.87e-05	0.0018	0.22	0.2	Migraine;	chr1:73119107	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4263954	ENSG00000223479.3	RP4-788P17.1	4.32	1.87e-05	0.0018	0.22	0.2	Migraine;	chr1:73119155	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4543746	ENSG00000223479.3	RP4-788P17.1	4.32	1.87e-05	0.0018	0.22	0.2	Migraine;	chr1:73122357	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs61628231	ENSG00000223479.3	RP4-788P17.1	4.32	1.87e-05	0.0018	0.22	0.2	Migraine;	chr1:73123481	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs12130289	ENSG00000223479.3	RP4-788P17.1	4.32	1.87e-05	0.0018	0.22	0.2	Migraine;	chr1:73123868	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.743	rs4622015	ENSG00000223479.3	RP4-788P17.1	4.32	1.87e-05	0.0018	0.22	0.2	Migraine;	chr1:73124379	chr1:73635216~73715214:+
THCA	cis	rs2191566	0.821	rs59756444	ENSG00000266921.1	RP11-15A1.7	-4.32	1.87e-05	0.0018	-0.18	-0.2	Acute lymphoblastic leukemia (childhood);	chr19:44009504	chr19:43996896~44002836:-
THCA	cis	rs4693089	0.604	rs2279658	ENSG00000213608.5	SLC25A14P1	-4.32	1.87e-05	0.0018	-0.22	-0.2	Menopause (age at onset);	chr4:83456344	chr4:83477524~83478424:+
THCA	cis	rs12497850	0.864	rs3212	ENSG00000228638.1	FCF1P2	-4.32	1.87e-05	0.0018	-0.21	-0.2	Parkinson's disease;	chr3:49108308	chr3:48290793~48291375:-
THCA	cis	rs72634501	0.568	rs590214	ENSG00000228060.1	RP11-69E11.8	-4.32	1.87e-05	0.0018	-0.19	-0.2	HDL cholesterol;	chr1:39146821	chr1:39565160~39573203:+
THCA	cis	rs4713118	0.662	rs149901	ENSG00000219891.2	ZSCAN12P1	4.32	1.87e-05	0.0018	0.26	0.2	Parkinson's disease;	chr6:27997725	chr6:28091154~28093664:+
THCA	cis	rs12755164	0.771	rs7519251	ENSG00000223479.3	RP4-788P17.1	-4.32	1.87e-05	0.0018	-0.21	-0.2	Schizophrenia;	chr1:72856114	chr1:73635216~73715214:+
THCA	cis	rs11089937	0.584	rs5757245	ENSG00000211639.2	IGLV4-60	4.32	1.87e-05	0.0018	0.14	0.2	Periodontitis (PAL4Q3);	chr22:22176674	chr22:22162199~22162681:+
THCA	cis	rs227275	0.525	rs3974485	ENSG00000248971.2	KRT8P46	-4.32	1.87e-05	0.0018	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs2866417	ENSG00000248971.2	KRT8P46	-4.32	1.87e-05	0.0018	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102728746~102730171:-
THCA	cis	rs7829975	0.777	rs560544	ENSG00000254340.1	RP11-10A14.3	-4.32	1.87e-05	0.0018	-0.21	-0.2	Mood instability;	chr8:8779919	chr8:9141424~9145435:+
THCA	cis	rs713477	0.524	rs2341538	ENSG00000258413.1	RP11-665C16.6	-4.32	1.87e-05	0.0018	-0.28	-0.2	Pediatric bone mineral content (femoral neck);	chr14:55428456	chr14:55262767~55272075:-
THCA	cis	rs755249	0.727	rs12028034	ENSG00000237624.1	OXCT2P1	-4.32	1.88e-05	0.0018	-0.24	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39514956~39516490:+
THCA	cis	rs7688540	0.511	rs6845131	ENSG00000211553.1	AC253576.2	-4.32	1.88e-05	0.0018	-0.31	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:136461~136568:+
THCA	cis	rs181553	0.961	rs357909	ENSG00000266696.1	RP11-30L3.2	4.32	1.88e-05	0.0018	0.24	0.2	Hip circumference adjusted for BMI;	chr18:49033509	chr18:49205912~49208781:+
THCA	cis	rs76934034	0.522	rs117488236	ENSG00000264204.2	AGAP7P	-4.32	1.88e-05	0.0018	-0.39	-0.2	Prostate cancer;	chr10:45546587	chr10:46109621~46131358:+
THCA	cis	rs8177376	0.727	rs240537	ENSG00000254905.1	RP11-712L6.7	4.32	1.88e-05	0.0018	0.28	0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126343446	chr11:126292922~126294254:-
THCA	cis	rs6792584	0.861	rs9856294	ENSG00000241316.5	SUCLG2-AS1	4.32	1.88e-05	0.0018	0.19	0.2	Corneal astigmatism;	chr3:67477875	chr3:67654697~67947713:+
THCA	cis	rs76382185	0.74	rs7529431	ENSG00000233184.5	RP11-421L21.3	4.32	1.88e-05	0.0018	0.29	0.2	Lymphocyte counts;	chr1:101133683	chr1:101025878~101087268:+
THCA	cis	rs5769765	0.773	rs9616751	ENSG00000260613.1	RP3-522J7.6	-4.32	1.88e-05	0.0018	-0.24	-0.2	Schizophrenia;	chr22:49828588	chr22:49832616~49837786:-
THCA	cis	rs10484434	0.818	rs11756400	ENSG00000272462.2	U91328.19	4.32	1.88e-05	0.0018	0.2	0.2	HIV-1 viral setpoint;	chr6:26040625	chr6:25992662~26001775:+
THCA	cis	rs10484434	1	rs11751732	ENSG00000272462.2	U91328.19	4.32	1.88e-05	0.0018	0.2	0.2	HIV-1 viral setpoint;	chr6:26043836	chr6:25992662~26001775:+
THCA	cis	rs10484434	0.818	rs61289224	ENSG00000272462.2	U91328.19	4.32	1.88e-05	0.0018	0.2	0.2	HIV-1 viral setpoint;	chr6:26049068	chr6:25992662~26001775:+
THCA	cis	rs1043595	1	rs79829700	ENSG00000271553.1	RP11-274B21.10	-4.32	1.88e-05	0.0018	-0.2	-0.2	Intelligence (multi-trait analysis);	chr7:128743501	chr7:128667043~128668156:+
THCA	cis	rs55966801	0.68	rs6541	ENSG00000277290.1	RP11-326C3.16	-4.32	1.88e-05	0.0018	-0.25	-0.2	Plateletcrit;	chr11:252851	chr11:243099~243483:-
THCA	cis	rs11722779	0.935	rs3974481	ENSG00000248971.2	KRT8P46	-4.32	1.88e-05	0.0018	-0.24	-0.2	Schizophrenia;	chr4:102956834	chr4:102728746~102730171:-
THCA	cis	rs72843506	0.586	rs75128113	ENSG00000231258.2	ZSWIM5P2	4.32	1.88e-05	0.0018	0.31	0.2	Schizophrenia;	chr17:20000172	chr17:20583758~20591180:-
THCA	cis	rs9876781	1	rs10470686	ENSG00000244380.1	RP11-24C3.2	4.32	1.88e-05	0.0018	0.23	0.2	Longevity;	chr3:48408549	chr3:48440352~48446656:-
THCA	cis	rs1728785	1	rs7118	ENSG00000274698.1	RP11-71L14.4	4.32	1.88e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68566952	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs1631910	ENSG00000274698.1	RP11-71L14.4	4.32	1.88e-05	0.0018	0.27	0.2	Ulcerative colitis;	chr16:68569432	chr16:68450283~68452318:+
THCA	cis	rs922182	0.678	rs10163006	ENSG00000275785.1	RP11-111E14.2	4.32	1.88e-05	0.0018	0.22	0.2	Blood protein levels;	chr15:64009630	chr15:63890030~63890317:+
THCA	cis	rs4660214	0.666	rs663449	ENSG00000182109.6	RP11-69E11.4	4.32	1.88e-05	0.0018	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39522280~39546187:-
THCA	cis	rs711244	0.772	rs11124554	ENSG00000279519.1	RP11-288C18.1	4.32	1.88e-05	0.0018	0.16	0.2	Mean platelet volume;	chr2:36922355	chr2:36839922~36842539:-
THCA	cis	rs4568518	0.53	rs4721674	ENSG00000279048.1	RP11-511H23.2	4.32	1.88e-05	0.0018	0.12	0.2	Measles;	chr7:17953754	chr7:17940503~17942922:+
THCA	cis	rs7216064	1	rs12600941	ENSG00000278740.1	RP11-147L13.14	4.32	1.88e-05	0.0018	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67922691	chr17:68188547~68189165:+
THCA	cis	rs736408	0.812	rs9324	ENSG00000243224.1	RP5-1157M23.2	-4.32	1.88e-05	0.0018	-0.22	-0.2	Bipolar disorder;	chr3:52791569	chr3:52239258~52241097:+
THCA	cis	rs607541	1	rs607594	ENSG00000259520.4	CTD-2651B20.3	-4.32	1.88e-05	0.00181	-0.28	-0.2	Obesity-related traits;	chr15:45642642	chr15:45251580~45279251:-
THCA	cis	rs607541	1	rs607541	ENSG00000259520.4	CTD-2651B20.3	-4.32	1.88e-05	0.00181	-0.28	-0.2	Obesity-related traits;	chr15:45642671	chr15:45251580~45279251:-
THCA	cis	rs7829975	0.564	rs2976855	ENSG00000253981.4	ALG1L13P	4.32	1.88e-05	0.00181	0.18	0.2	Mood instability;	chr8:8444284	chr8:8236003~8244667:-
THCA	cis	rs7577696	0.785	rs3769602	ENSG00000276334.1	AL133243.1	-4.32	1.88e-05	0.00181	-0.21	-0.2	Inflammatory biomarkers;	chr2:32156760	chr2:32521927~32523547:+
THCA	cis	rs7182948	0.957	rs9920574	ENSG00000259531.2	RP11-295H24.3	4.32	1.88e-05	0.00181	0.25	0.2	Lung adenocarcinoma;	chr15:49594121	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.957	rs28843724	ENSG00000259531.2	RP11-295H24.3	4.32	1.88e-05	0.00181	0.25	0.2	Lung adenocarcinoma;	chr15:49600784	chr15:49365124~49366685:-
THCA	cis	rs875971	0.838	rs2173570	ENSG00000230189.5	GS1-124K5.2	-4.32	1.88e-05	0.00181	-0.13	-0.2	Aortic root size;	chr7:66297976	chr7:66409143~66490059:-
THCA	cis	rs17221829	0.932	rs10830358	ENSG00000280385.1	AP000648.5	-4.32	1.88e-05	0.00181	-0.18	-0.2	Anxiety in major depressive disorder;	chr11:89719775	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.72	rs10765237	ENSG00000280385.1	AP000648.5	-4.32	1.88e-05	0.00181	-0.18	-0.2	Anxiety in major depressive disorder;	chr11:89720430	chr11:90193614~90198120:+
THCA	cis	rs496547	0.719	rs476246	ENSG00000255422.1	AP002954.4	4.32	1.88e-05	0.00181	0.21	0.2	Hip minimal joint space width;	chr11:118747211	chr11:118704607~118750263:+
THCA	cis	rs1005277	0.522	rs289647	ENSG00000226578.1	RP11-258F22.1	-4.32	1.88e-05	0.00181	-0.22	-0.2	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:37775371~37784131:-
THCA	cis	rs10090774	0.965	rs306957	ENSG00000279766.1	RP11-642A1.2	4.32	1.88e-05	0.00181	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140999493	chr8:140572142~140572812:-
THCA	cis	rs16852403	0.583	rs6670912	ENSG00000224687.1	RASAL2-AS1	4.32	1.88e-05	0.00181	0.32	0.2	Childhood ear infection;	chr1:178113275	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.583	rs10798596	ENSG00000224687.1	RASAL2-AS1	4.32	1.88e-05	0.00181	0.32	0.2	Childhood ear infection;	chr1:178113507	chr1:178091508~178093984:-
THCA	cis	rs7829975	0.782	rs6990746	ENSG00000254153.1	CTA-398F10.2	4.32	1.88e-05	0.00181	0.21	0.2	Mood instability;	chr8:8690301	chr8:8456909~8461337:-
THCA	cis	rs2688482	0.557	rs3103952	ENSG00000207650.1	MIR570	4.32	1.88e-05	0.00181	0.26	0.2	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195699401~195699497:+
THCA	cis	rs4144027	0.875	rs6576010	ENSG00000269940.1	RP11-73M18.7	-4.32	1.88e-05	0.00181	-0.2	-0.2	Blood metabolite levels;	chr14:103883265	chr14:103694560~103695170:+
THCA	cis	rs375066	0.935	rs371875	ENSG00000278917.1	RP11-15A1.4	-4.32	1.88e-05	0.00181	-0.16	-0.2	Breast cancer;	chr19:43889105	chr19:43891233~43895411:+
THCA	cis	rs724818	0.661	rs3804170	ENSG00000251609.2	SETP12	-4.32	1.88e-05	0.00181	-0.49	-0.2	Monobrow thickness;	chr4:120783880	chr4:120895494~120897083:-
THCA	cis	rs5751614	0.577	rs6003600	ENSG00000240160.3	RN7SL263P	4.32	1.88e-05	0.00181	0.23	0.2	Height;	chr22:23275893	chr22:23261782~23262071:-
THCA	cis	rs5751614	0.577	rs5759675	ENSG00000240160.3	RN7SL263P	4.32	1.88e-05	0.00181	0.23	0.2	Height;	chr22:23278154	chr22:23261782~23262071:-
THCA	cis	rs860295	0.776	rs11264362	ENSG00000160766.13	GBAP1	4.32	1.88e-05	0.00181	0.22	0.2	Body mass index;	chr1:155345824	chr1:155213821~155227422:-
THCA	cis	rs13113518	0.841	rs11133400	ENSG00000272969.1	RP11-528I4.2	4.32	1.88e-05	0.00181	0.23	0.2	Height;	chr4:55578787	chr4:55547112~55547889:+
THCA	cis	rs7903456	0.569	rs12572491	ENSG00000236417.2	CTSLP1	-4.32	1.88e-05	0.00181	-0.3	-0.2	Gout;Renal underexcretion gout;	chr10:87034126	chr10:87386685~87390203:-
THCA	cis	rs9902453	0.967	rs1906451	ENSG00000263370.1	RP11-68I3.5	4.32	1.89e-05	0.00181	0.25	0.2	Coffee consumption (cups per day);	chr17:30188461	chr17:29639627~29640825:+
THCA	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-4.32	1.89e-05	0.00181	-0.27	-0.2	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
THCA	cis	rs4906332	1	rs7155822	ENSG00000269910.1	RP11-73M18.10	4.32	1.89e-05	0.00181	0.17	0.2	Coronary artery disease;	chr14:103456053	chr14:103694516~103695050:-
THCA	cis	rs17801127	0.901	rs16827290	ENSG00000231969.1	AC144449.1	4.32	1.89e-05	0.00181	0.34	0.2	Liver enzyme levels (alanine transaminase);	chr2:149652761	chr2:149587196~149848233:+
THCA	cis	rs9868809	0.881	rs7631574	ENSG00000270441.1	RP11-694I15.7	-4.32	1.89e-05	0.00181	-0.24	-0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48625613	chr3:49140086~49160851:-
THCA	cis	rs1023500	0.573	rs133378	ENSG00000237037.8	NDUFA6-AS1	-4.32	1.89e-05	0.00181	-0.16	-0.2	Schizophrenia;	chr22:42071691	chr22:42090931~42137742:+
THCA	cis	rs6121246	0.697	rs6060912	ENSG00000230613.1	HM13-AS1	4.32	1.89e-05	0.00181	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31737952	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6089058	ENSG00000230613.1	HM13-AS1	4.32	1.89e-05	0.00181	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31738535	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.821	rs6119718	ENSG00000230613.1	HM13-AS1	4.32	1.89e-05	0.00181	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31743271	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.821	rs6058448	ENSG00000230613.1	HM13-AS1	4.32	1.89e-05	0.00181	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31744593	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs8126355	ENSG00000230613.1	HM13-AS1	4.32	1.89e-05	0.00181	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31744857	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6060923	ENSG00000230613.1	HM13-AS1	4.32	1.89e-05	0.00181	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31748852	chr20:31567707~31573263:-
THCA	cis	rs1023500	0.573	rs8135801	ENSG00000237037.8	NDUFA6-AS1	4.32	1.89e-05	0.00181	0.16	0.2	Schizophrenia;	chr22:42079564	chr22:42090931~42137742:+
THCA	cis	rs12497850	0.931	rs7627404	ENSG00000228638.1	FCF1P2	-4.32	1.89e-05	0.00181	-0.21	-0.2	Parkinson's disease;	chr3:48782235	chr3:48290793~48291375:-
THCA	cis	rs6472827	1	rs6472827	ENSG00000253983.2	RP1-16A9.1	-4.32	1.89e-05	0.00181	-0.33	-0.2	Uterine fibroids;	chr8:74207107	chr8:74199396~74208441:+
THCA	cis	rs67478160	0.619	rs8018062	ENSG00000269940.1	RP11-73M18.7	4.32	1.89e-05	0.00181	0.19	0.2	Schizophrenia;	chr14:103815617	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs2223937	ENSG00000269940.1	RP11-73M18.7	4.32	1.89e-05	0.00181	0.19	0.2	Schizophrenia;	chr14:103820043	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs4900600	ENSG00000269940.1	RP11-73M18.7	4.32	1.89e-05	0.00181	0.19	0.2	Schizophrenia;	chr14:103825502	chr14:103694560~103695170:+
THCA	cis	rs11992162	0.933	rs10108075	ENSG00000270154.1	RP11-419I17.1	4.32	1.89e-05	0.00181	0.24	0.2	Monocyte count;	chr8:11974570	chr8:12476462~12477122:+
THCA	cis	rs4805272	1	rs888826	ENSG00000267799.1	MAN1A2P1	4.32	1.89e-05	0.00181	0.21	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834512	chr19:28790812~28792871:-
THCA	cis	rs690037	0.673	rs690573	ENSG00000271964.1	RP11-415F23.2	-4.32	1.89e-05	0.00181	-0.18	-0.2	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334933	chr3:16314439~16314987:+
THCA	cis	rs8141529	0.509	rs5762863	ENSG00000272858.1	CTA-292E10.8	-4.32	1.89e-05	0.00181	-0.21	-0.2	Lymphocyte counts;	chr22:28857347	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.509	rs5762864	ENSG00000272858.1	CTA-292E10.8	-4.32	1.89e-05	0.00181	-0.21	-0.2	Lymphocyte counts;	chr22:28857376	chr22:28814914~28815662:+
THCA	cis	rs7267979	0.789	rs4815429	ENSG00000277938.1	RP5-965G21.3	-4.32	1.89e-05	0.00181	-0.16	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25229150~25231933:+
THCA	cis	rs11658311	0.85	rs11653696	ENSG00000232344.2	AC087163.2	4.32	1.89e-05	0.00181	0.29	0.2	Obsessive-compulsive symptoms;	chr17:17730967	chr17:18010643~18011822:+
THCA	cis	rs1923243	0.649	rs12138334	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00181	0.22	0.2	Migraine;	chr1:73085824	chr1:73635216~73715214:+
THCA	cis	rs7829975	0.902	rs485107	ENSG00000254340.1	RP11-10A14.3	-4.32	1.89e-05	0.00181	-0.21	-0.2	Mood instability;	chr8:8723898	chr8:9141424~9145435:+
THCA	cis	rs2153535	0.585	rs9379237	ENSG00000230939.1	RP11-314C16.1	-4.32	1.89e-05	0.00181	-0.2	-0.2	Motion sickness;	chr6:8654330	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.609	rs1328864	ENSG00000230939.1	RP11-314C16.1	-4.32	1.89e-05	0.00181	-0.2	-0.2	Motion sickness;	chr6:8656048	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs7450731	ENSG00000230939.1	RP11-314C16.1	-4.32	1.89e-05	0.00181	-0.2	-0.2	Motion sickness;	chr6:8656501	chr6:8784178~8785445:+
THCA	cis	rs7572733	0.515	rs1401096	ENSG00000231621.1	AC013264.2	-4.32	1.89e-05	0.00182	-0.21	-0.2	Dermatomyositis;	chr2:197959104	chr2:197197991~197199273:+
THCA	cis	rs7923609	0.905	rs7088799	ENSG00000232075.1	MRPL35P2	-4.32	1.89e-05	0.00182	-0.26	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63256414	chr10:63634317~63634827:-
THCA	cis	rs6490294	0.904	rs76300790	ENSG00000226469.1	ADAM1B	4.32	1.89e-05	0.00182	0.26	0.2	Mean platelet volume;	chr12:111964865	chr12:111927018~111929017:+
THCA	cis	rs9510787	0.649	rs7991222	ENSG00000205861.10	C1QTNF9B-AS1	-4.32	1.89e-05	0.00182	-0.25	-0.2	Nasopharyngeal carcinoma;	chr13:23640518	chr13:23888889~23897263:+
THCA	cis	rs8081395	0.741	rs1292051	ENSG00000267302.4	RP11-178C3.2	4.32	1.89e-05	0.00182	0.23	0.2	White blood cell count;	chr17:59886562	chr17:59964832~59996972:+
THCA	cis	rs854765	0.583	rs6502625	ENSG00000281749.1	Y_RNA	4.32	1.89e-05	0.00182	0.26	0.2	Total body bone mineral density;	chr17:17944972	chr17:18001101~18001195:-
THCA	cis	rs711244	0.935	rs6752845	ENSG00000279519.1	RP11-288C18.1	4.32	1.89e-05	0.00182	0.16	0.2	Mean platelet volume;	chr2:36867996	chr2:36839922~36842539:-
THCA	cis	rs9510787	0.538	rs9507136	ENSG00000205861.10	C1QTNF9B-AS1	-4.32	1.89e-05	0.00182	-0.25	-0.2	Nasopharyngeal carcinoma;	chr13:23655214	chr13:23888889~23897263:+
THCA	cis	rs8177876	0.749	rs12927828	ENSG00000261061.1	RP11-303E16.2	-4.32	1.89e-05	0.00182	-0.25	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81030770~81031485:+
THCA	cis	rs1923243	0.647	rs4650195	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73171958	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs35133930	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73172640	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6695455	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73173151	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6695460	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73173157	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6658012	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73173327	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6683380	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73173509	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6698500	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73173633	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs10890012	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73173898	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs10890014	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73174136	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs10890015	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73174243	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs34719239	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73174997	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs4503305	ENSG00000223479.3	RP4-788P17.1	4.32	1.89e-05	0.00182	0.22	0.2	Migraine;	chr1:73179104	chr1:73635216~73715214:+
THCA	cis	rs2657294	0.796	rs2804534	ENSG00000233313.2	HMGA1P5	4.32	1.89e-05	0.00182	0.26	0.2	Pneumonia;	chr10:75208023	chr10:75276376~75276646:-
THCA	cis	rs4713118	0.615	rs9348772	ENSG00000280107.1	AL022393.9	-4.32	1.9e-05	0.00182	-0.2	-0.2	Parkinson's disease;	chr6:27688311	chr6:28170845~28172521:+
THCA	cis	rs875971	1	rs2220626	ENSG00000222364.1	RNU6-96P	4.32	1.9e-05	0.00182	0.23	0.2	Aortic root size;	chr7:66081075	chr7:66395191~66395286:+
THCA	cis	rs3740713	1	rs60376560	ENSG00000256464.1	YWHABP2	4.32	1.9e-05	0.00182	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr11:18490243~18490955:-
THCA	cis	rs1048886	0.872	rs6902986	ENSG00000271967.1	RP11-134K13.4	-4.32	1.9e-05	0.00182	-0.21	-0.2	Type 2 diabetes;	chr6:70391772	chr6:70596438~70596980:+
THCA	cis	rs17507216	0.718	rs72751657	ENSG00000255769.6	GOLGA2P10	-4.32	1.9e-05	0.00182	-0.3	-0.2	Excessive daytime sleepiness;	chr15:82581259	chr15:82472993~82513950:-
THCA	cis	rs6951245	1	rs11763020	ENSG00000229043.2	AC091729.9	-4.32	1.9e-05	0.00182	-0.33	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020652	chr7:1160374~1165267:+
THCA	cis	rs8113308	0.81	rs8104281	ENSG00000269483.1	AC006272.1	4.32	1.9e-05	0.00182	0.32	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939766	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs8104121	ENSG00000269483.1	AC006272.1	4.32	1.9e-05	0.00182	0.32	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939810	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs8104323	ENSG00000269483.1	AC006272.1	4.32	1.9e-05	0.00182	0.32	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939992	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs8108525	ENSG00000269483.1	AC006272.1	4.32	1.9e-05	0.00182	0.32	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940883	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs7258701	ENSG00000269483.1	AC006272.1	4.32	1.9e-05	0.00182	0.32	0.2	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51941816	chr19:51839924~51843324:-
THCA	cis	rs2886497	0.624	rs4748878	ENSG00000224215.1	RP11-371A19.2	-4.32	1.9e-05	0.00182	-0.22	-0.2	Major depression and alcohol dependence;	chr10:23388895	chr10:23343957~23345181:+
THCA	cis	rs7191700	0.836	rs12708722	ENSG00000262703.1	RP11-485G7.6	4.32	1.9e-05	0.00182	0.25	0.2	Multiple sclerosis;	chr16:11335048	chr16:11348143~11349321:-
THCA	cis	rs7191700	0.836	rs10163410	ENSG00000262703.1	RP11-485G7.6	4.32	1.9e-05	0.00182	0.25	0.2	Multiple sclerosis;	chr16:11336758	chr16:11348143~11349321:-
THCA	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	4.32	1.9e-05	0.00182	0.14	0.2	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
THCA	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	4.32	1.9e-05	0.00182	0.14	0.2	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
THCA	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	4.32	1.9e-05	0.00182	0.14	0.2	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
THCA	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	4.32	1.9e-05	0.00182	0.14	0.2	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
THCA	cis	rs10833905	1	rs10766991	ENSG00000246225.5	RP11-17A1.3	-4.32	1.9e-05	0.00182	-0.28	-0.2	Sudden cardiac arrest;	chr11:22987325	chr11:22829380~22945393:+
THCA	cis	rs10833905	1	rs10833877	ENSG00000246225.5	RP11-17A1.3	-4.32	1.9e-05	0.00182	-0.28	-0.2	Sudden cardiac arrest;	chr11:22988269	chr11:22829380~22945393:+
THCA	cis	rs6580649	0.941	rs7310579	ENSG00000273765.1	RP11-370I10.11	-4.32	1.9e-05	0.00182	-0.22	-0.2	Lung cancer;	chr12:48033740	chr12:48360920~48361377:+
THCA	cis	rs8105895	0.935	rs62111039	ENSG00000269345.1	VN1R85P	4.32	1.9e-05	0.00182	0.27	0.2	Body mass index (change over time);	chr19:22104534	chr19:22174766~22175191:-
THCA	cis	rs1538970	0.924	rs7528573	ENSG00000234329.1	RP11-767N6.2	4.32	1.9e-05	0.00182	0.2	0.2	Platelet count;	chr1:45448188	chr1:45651039~45651826:-
THCA	cis	rs9309473	0.519	rs13022145	ENSG00000273245.1	RP11-434P11.2	-4.32	1.9e-05	0.00182	-0.23	-0.2	Metabolite levels;	chr2:73636346	chr2:73750256~73750786:-
THCA	cis	rs9902453	0.967	rs55744550	ENSG00000263370.1	RP11-68I3.5	4.32	1.9e-05	0.00182	0.25	0.2	Coffee consumption (cups per day);	chr17:30148711	chr17:29639627~29640825:+
THCA	cis	rs10107145	0.509	rs73209953	ENSG00000280294.1	RP11-177H2.1	4.32	1.9e-05	0.00182	0.17	0.2	Systolic blood pressure;	chr8:10902602	chr8:10856085~10859436:-
THCA	cis	rs8002861	0.905	rs12873099	ENSG00000274001.1	RP11-5G9.5	-4.32	1.9e-05	0.00182	-0.24	-0.2	Leprosy;	chr13:43822111	chr13:43877715~43878163:-
THCA	cis	rs7216064	1	rs7216064	ENSG00000278740.1	RP11-147L13.14	4.32	1.9e-05	0.00182	0.22	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67902693	chr17:68188547~68189165:+
THCA	cis	rs2281603	0.762	rs10132794	ENSG00000272909.1	CTD-2555O16.4	-4.32	1.9e-05	0.00182	-0.27	-0.2	Lymphocyte counts;	chr14:64581793	chr14:64440369~64442238:-
THCA	cis	rs4950322	0.518	rs55697094	ENSG00000180867.10	PDIA3P1	4.32	1.9e-05	0.00182	0.19	0.2	Protein quantitative trait loci;	chr1:147121205	chr1:147178113~147179622:+
THCA	cis	rs288326	0.561	rs80099669	ENSG00000272800.1	RP11-438L19.1	4.32	1.9e-05	0.00182	0.35	0.2	Blood protein levels;	chr2:182912253	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs76304059	ENSG00000272800.1	RP11-438L19.1	4.32	1.9e-05	0.00182	0.35	0.2	Blood protein levels;	chr2:182914827	chr2:183214319~183215400:+
THCA	cis	rs10090774	0.965	rs6578133	ENSG00000279766.1	RP11-642A1.2	4.32	1.9e-05	0.00182	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140763753	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs4378011	ENSG00000279766.1	RP11-642A1.2	4.32	1.9e-05	0.00182	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140764477	chr8:140572142~140572812:-
THCA	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-4.32	1.9e-05	0.00182	-0.14	-0.2	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
THCA	cis	rs5769765	0.658	rs2157536	ENSG00000260613.1	RP3-522J7.6	-4.32	1.9e-05	0.00182	-0.24	-0.2	Schizophrenia;	chr22:49796532	chr22:49832616~49837786:-
THCA	cis	rs6845263	0.571	rs1834628	ENSG00000254531.1	FLJ20021	-4.32	1.9e-05	0.00182	-0.16	-0.2	Superior crus of antihelix expression;	chr4:101531406	chr4:101347780~101348883:+
THCA	cis	rs227275	0.525	rs10032234	ENSG00000248971.2	KRT8P46	-4.32	1.9e-05	0.00182	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs3886723	ENSG00000248971.2	KRT8P46	-4.32	1.9e-05	0.00182	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102728746~102730171:-
THCA	cis	rs228614	0.517	rs3886722	ENSG00000248971.2	KRT8P46	-4.32	1.9e-05	0.00182	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs11737544	ENSG00000248971.2	KRT8P46	-4.32	1.9e-05	0.00182	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102728746~102730171:-
THCA	cis	rs7511006	0.895	rs5771270	ENSG00000272836.1	RP3-402G11.27	-4.32	1.9e-05	0.00182	-0.16	-0.2	Obesity-related traits;	chr22:50244436	chr22:50205585~50206062:-
THCA	cis	rs6870983	1	rs6870983	ENSG00000247828.6	TMEM161B-AS1	4.32	1.9e-05	0.00182	0.18	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88401716	chr5:88268895~88436685:+
THCA	cis	rs56804039	1	rs59620654	ENSG00000254153.1	CTA-398F10.2	4.32	1.9e-05	0.00182	0.23	0.2	Cervical cancer;	chr8:8525122	chr8:8456909~8461337:-
THCA	cis	rs1728785	1	rs1728781	ENSG00000274698.1	RP11-71L14.4	4.32	1.9e-05	0.00183	0.27	0.2	Ulcerative colitis;	chr16:68533891	chr16:68450283~68452318:+
THCA	cis	rs7665090	0.87	rs228623	ENSG00000230069.3	LRRC37A15P	4.32	1.9e-05	0.00183	0.2	0.2	Primary biliary cholangitis;	chr4:102651163	chr4:102727274~102730721:-
THCA	cis	rs7665090	0.837	rs228624	ENSG00000230069.3	LRRC37A15P	4.32	1.9e-05	0.00183	0.2	0.2	Primary biliary cholangitis;	chr4:102651283	chr4:102727274~102730721:-
THCA	cis	rs2243480	0.522	rs1638736	ENSG00000232559.3	GS1-124K5.12	4.32	1.9e-05	0.00183	0.37	0.2	Diabetic kidney disease;	chr7:66627321	chr7:66554588~66576923:-
THCA	cis	rs9302635	0.625	rs34417180	ENSG00000260886.1	TAT-AS1	4.32	1.9e-05	0.00183	0.35	0.2	Blood protein levels;	chr16:72185857	chr16:71565789~71578187:+
THCA	cis	rs4443100	0.67	rs9612225	ENSG00000230701.2	FBXW4P1	4.32	1.9e-05	0.00183	0.24	0.2	Serum parathyroid hormone levels;	chr22:23064441	chr22:23262767~23265005:+
THCA	cis	rs4443100	0.67	rs13054331	ENSG00000230701.2	FBXW4P1	4.32	1.9e-05	0.00183	0.24	0.2	Serum parathyroid hormone levels;	chr22:23064885	chr22:23262767~23265005:+
THCA	cis	rs11955398	0.502	rs3101879	ENSG00000272308.1	RP11-231G3.1	-4.32	1.9e-05	0.00183	-0.2	-0.2	Intelligence (multi-trait analysis);	chr5:60971048	chr5:60866457~60866935:-
THCA	cis	rs2921073	0.605	rs2976933	ENSG00000254153.1	CTA-398F10.2	-4.32	1.9e-05	0.00183	-0.21	-0.2	Parkinson's disease;	chr8:8397365	chr8:8456909~8461337:-
THCA	cis	rs763121	0.853	rs1062687	ENSG00000228274.3	RP3-508I15.9	-4.32	1.9e-05	0.00183	-0.22	-0.2	Menopause (age at onset);	chr22:38738710	chr22:38667585~38681820:-
THCA	cis	rs4780355	1	rs1111186	ENSG00000263080.1	RP11-485G7.5	4.32	1.91e-05	0.00183	0.24	0.2	Crohn's disease and psoriasis;	chr16:11253191	chr16:11341809~11345211:-
THCA	cis	rs4308124	0.708	rs28766030	ENSG00000230499.1	AC108463.1	-4.32	1.91e-05	0.00183	-0.29	-0.2	Vitiligo;	chr2:111204852	chr2:111195963~111206494:+
THCA	cis	rs12908161	0.959	rs61074241	ENSG00000188388.10	GOLGA6L3	4.32	1.91e-05	0.00183	0.27	0.2	Schizophrenia;	chr15:84790165	chr15:85240472~85247170:+
THCA	cis	rs12446554	0.511	rs72769544	ENSG00000261195.1	CTD-2380F24.1	-4.32	1.91e-05	0.00183	-0.32	-0.2	Obesity;	chr16:19765915	chr16:19761172~19766099:-
THCA	cis	rs902774	0.53	rs12819597	ENSG00000278185.1	RP11-153F5.7	4.32	1.91e-05	0.00183	0.32	0.2	Prostate cancer;	chr12:52960172	chr12:52946614~52947125:-
THCA	cis	rs6701713	0.959	rs4844610	ENSG00000274245.1	RP11-357P18.2	-4.32	1.91e-05	0.00183	-0.25	-0.2	Alzheimer's disease (late onset);	chr1:207629207	chr1:207372559~207373252:+
THCA	cis	rs1923243	0.71	rs11210128	ENSG00000223479.3	RP4-788P17.1	4.32	1.91e-05	0.00183	0.22	0.2	Migraine;	chr1:73114504	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6662171	ENSG00000223479.3	RP4-788P17.1	4.32	1.91e-05	0.00183	0.22	0.2	Migraine;	chr1:73114764	chr1:73635216~73715214:+
THCA	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	4.32	1.91e-05	0.00183	0.22	0.2	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
THCA	cis	rs875971	0.965	rs6971509	ENSG00000229886.1	RP5-1132H15.3	-4.32	1.91e-05	0.00183	-0.2	-0.2	Aortic root size;	chr7:66249983	chr7:66025126~66031544:-
THCA	cis	rs4713118	0.868	rs35069907	ENSG00000220721.1	OR1F12	4.32	1.91e-05	0.00183	0.27	0.2	Parkinson's disease;	chr6:27778913	chr6:28073316~28074233:+
THCA	cis	rs734999	0.588	rs3748819	ENSG00000225931.3	RP3-395M20.7	4.32	1.91e-05	0.00183	0.23	0.2	Ulcerative colitis;	chr1:2593527	chr1:2566410~2569888:+
THCA	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-4.32	1.91e-05	0.00183	-0.23	-0.2	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
THCA	cis	rs1346	0.58	rs10791819	ENSG00000245532.5	NEAT1	4.32	1.91e-05	0.00183	0.15	0.2	Vertical cup-disc ratio;Optic cup area;	chr11:65596394	chr11:65422774~65445540:+
THCA	cis	rs10090774	0.965	rs7843014	ENSG00000279766.1	RP11-642A1.2	4.32	1.91e-05	0.00183	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140780382	chr8:140572142~140572812:-
THCA	cis	rs8028182	0.636	rs62027209	ENSG00000260274.1	RP11-817O13.8	4.32	1.91e-05	0.00183	0.14	0.2	Sudden cardiac arrest;	chr15:75579285	chr15:75368155~75369584:+
THCA	cis	rs8058578	1	rs67128646	ENSG00000279196.1	RP11-1072A3.3	4.32	1.91e-05	0.00183	0.2	0.2	Multiple myeloma;	chr16:30660776	chr16:30984630~30988270:-
THCA	cis	rs2749592	0.588	rs2504144	ENSG00000226578.1	RP11-258F22.1	-4.32	1.91e-05	0.00183	-0.24	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr10:38094597	chr10:37775371~37784131:-
THCA	cis	rs375066	0.935	rs368089	ENSG00000278917.1	RP11-15A1.4	-4.32	1.91e-05	0.00183	-0.16	-0.2	Breast cancer;	chr19:43894932	chr19:43891233~43895411:+
THCA	cis	rs7403037	0.583	rs8042000	ENSG00000260760.1	PWRN3	4.32	1.91e-05	0.00183	0.21	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24347476	chr15:24441127~24447967:+
THCA	cis	rs7973719	0.509	rs10161405	ENSG00000205885.6	C1RL-AS1	-4.32	1.91e-05	0.00183	-0.16	-0.2	IgG glycosylation;	chr12:7206050	chr12:7108052~7122501:+
THCA	cis	rs7973719	0.509	rs10161542	ENSG00000205885.6	C1RL-AS1	-4.32	1.91e-05	0.00183	-0.16	-0.2	IgG glycosylation;	chr12:7206088	chr12:7108052~7122501:+
THCA	cis	rs6687821	0.515	rs524515	ENSG00000261737.1	RP4-612B15.3	-4.32	1.91e-05	0.00183	-0.3	-0.2	Yeast infection;	chr1:86907736	chr1:86703502~86704462:-
THCA	cis	rs2439831	0.867	rs3213990	ENSG00000205771.5	CATSPER2P1	-4.32	1.91e-05	0.00183	-0.26	-0.2	Lung cancer in ever smokers;	chr15:43378028	chr15:43726918~43747094:-
THCA	cis	rs4237845	0.513	rs7134797	ENSG00000270039.1	RP11-571M6.17	-4.32	1.91e-05	0.00183	-0.22	-0.2	Intelligence (multi-trait analysis);	chr12:57870069	chr12:57803838~57804415:+
THCA	cis	rs2836950	0.545	rs11701805	ENSG00000238141.2	BRWD1-AS1	-4.32	1.91e-05	0.00183	-0.22	-0.2	Menarche (age at onset);	chr21:39246757	chr21:39315707~39323218:+
THCA	cis	rs12478296	0.901	rs9653611	ENSG00000261186.2	RP11-341N2.1	-4.32	1.91e-05	0.00183	-0.3	-0.2	Obesity-related traits;	chr2:242064805	chr2:242087351~242088457:-
THCA	cis	rs12478296	0.818	rs57194240	ENSG00000261186.2	RP11-341N2.1	-4.32	1.91e-05	0.00183	-0.3	-0.2	Obesity-related traits;	chr2:242069394	chr2:242087351~242088457:-
THCA	cis	rs7572733	0.534	rs1464211	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197933906	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs1607375	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197935663	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs4369854	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197935906	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs1983359	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197940374	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.515	rs11887138	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197941114	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs1518365	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197944686	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs1518363	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197945407	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs1518361	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197948150	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs1464209	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197949672	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs11890137	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197951938	chr2:197197991~197199273:+
THCA	cis	rs700651	0.786	rs58224025	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Intracranial aneurysm;	chr2:197957264	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.515	rs13408411	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Dermatomyositis;	chr2:197960738	chr2:197197991~197199273:+
THCA	cis	rs700651	0.752	rs1850631	ENSG00000231621.1	AC013264.2	-4.32	1.91e-05	0.00183	-0.21	-0.2	Intracranial aneurysm;	chr2:197964744	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.515	rs35730302	ENSG00000231621.1	AC013264.2	4.32	1.91e-05	0.00183	0.21	0.2	Dermatomyositis;	chr2:197953902	chr2:197197991~197199273:+
THCA	cis	rs5758659	0.714	rs5751216	ENSG00000281538.1	RP4-669P10.20	-4.32	1.91e-05	0.00183	-0.18	-0.2	Cognitive function;	chr22:42112933	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.714	rs5758589	ENSG00000281538.1	RP4-669P10.20	-4.32	1.91e-05	0.00183	-0.18	-0.2	Cognitive function;	chr22:42122378	chr22:42138060~42139726:+
THCA	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	4.32	1.91e-05	0.00183	0.16	0.2	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
THCA	cis	rs3764021	0.506	rs10844468	ENSG00000214776.8	RP11-726G1.1	4.32	1.91e-05	0.00183	0.25	0.2	Type 1 diabetes;	chr12:9690799	chr12:9467552~9576275:+
THCA	cis	rs7474896	1	rs11011294	ENSG00000263064.2	RP11-291L22.7	-4.32	1.91e-05	0.00183	-0.32	-0.2	Obesity (extreme);	chr10:37632142	chr10:38448689~38448949:+
THCA	cis	rs6472235	0.586	rs2357567	ENSG00000272010.1	CTD-3025N20.3	4.32	1.91e-05	0.00183	0.21	0.2	Plateletcrit;Myopia (pathological);	chr8:66003718	chr8:65591850~65592472:-
THCA	cis	rs2281603	0.57	rs11848179	ENSG00000272909.1	CTD-2555O16.4	-4.32	1.92e-05	0.00184	-0.23	-0.2	Lymphocyte counts;	chr14:64510335	chr14:64440369~64442238:-
THCA	cis	rs2919009	0.766	rs56102659	ENSG00000271670.1	RP11-95I16.4	4.32	1.92e-05	0.00184	0.22	0.2	Obesity-related traits;	chr10:120786205	chr10:120879256~120880667:-
THCA	cis	rs7267979	0.789	rs6083810	ENSG00000274414.1	RP5-965G21.4	4.32	1.92e-05	0.00184	0.23	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:25239007~25245229:-
THCA	cis	rs7560272	0.529	rs2421672	ENSG00000273245.1	RP11-434P11.2	-4.32	1.92e-05	0.00184	-0.22	-0.2	Schizophrenia;	chr2:73728413	chr2:73750256~73750786:-
THCA	cis	rs9368481	0.729	rs9379950	ENSG00000261353.1	CTA-14H9.5	4.32	1.92e-05	0.00184	0.21	0.2	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26527063~26527404:+
THCA	cis	rs9368481	1	rs9368481	ENSG00000261353.1	CTA-14H9.5	4.32	1.92e-05	0.00184	0.21	0.2	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26527063~26527404:+
THCA	cis	rs9368481	0.554	rs2754603	ENSG00000261353.1	CTA-14H9.5	4.32	1.92e-05	0.00184	0.21	0.2	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26527063~26527404:+
THCA	cis	rs9368481	0.761	rs9357028	ENSG00000261353.1	CTA-14H9.5	4.32	1.92e-05	0.00184	0.21	0.2	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26527063~26527404:+
THCA	cis	rs6088813	1	rs6142358	ENSG00000279253.1	RP4-614O4.13	-4.32	1.92e-05	0.00184	-0.19	-0.2	Height;	chr20:35372505	chr20:35262727~35264187:-
THCA	cis	rs62458065	0.513	rs7788809	ENSG00000231952.3	DPY19L1P2	4.32	1.92e-05	0.00184	0.33	0.2	Metabolite levels (HVA/MHPG ratio);	chr7:32513010	chr7:32812757~32838570:+
THCA	cis	rs3002131	0.604	rs3002151	ENSG00000272750.1	RP11-378J18.8	4.32	1.92e-05	0.00184	0.28	0.2	Interleukin-10 levels;	chr1:222573225	chr1:222658867~222661512:-
THCA	cis	rs1129187	0.967	rs11752813	ENSG00000272223.1	RP1-20C7.6	4.32	1.92e-05	0.00184	0.15	0.2	Alzheimer's disease in APOE e4+ carriers;	chr6:42960279	chr6:43033897~43034405:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000272831.1	RP11-792A8.4	-4.32	1.92e-05	0.00184	-0.12	-0.2	Aortic root size;	chr7:66048109	chr7:66739829~66740385:-
THCA	cis	rs875971	0.505	rs1167385	ENSG00000272831.1	RP11-792A8.4	-4.32	1.92e-05	0.00184	-0.12	-0.2	Aortic root size;	chr7:66048321	chr7:66739829~66740385:-
THCA	cis	rs6701713	0.919	rs6661489	ENSG00000274245.1	RP11-357P18.2	-4.32	1.92e-05	0.00184	-0.22	-0.2	Alzheimer's disease (late onset);	chr1:207524699	chr1:207372559~207373252:+
THCA	cis	rs10911902	0.643	rs78468398	ENSG00000229739.2	RP11-295K2.3	-4.32	1.92e-05	0.00184	-0.3	-0.2	Schizophrenia;	chr1:186315149	chr1:186435161~186470291:+
THCA	cis	rs17685	0.725	rs4476928	ENSG00000230882.1	AC005077.14	-4.32	1.92e-05	0.00184	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76012789	chr7:76071469~76074963:-
THCA	cis	rs10911902	0.643	rs1406294	ENSG00000229739.2	RP11-295K2.3	-4.32	1.92e-05	0.00184	-0.3	-0.2	Schizophrenia;	chr1:186314293	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs76559138	ENSG00000229739.2	RP11-295K2.3	-4.32	1.92e-05	0.00184	-0.3	-0.2	Schizophrenia;	chr1:186314891	chr1:186435161~186470291:+
THCA	cis	rs7711186	0.786	rs7723335	ENSG00000252464.1	RN7SKP70	4.32	1.92e-05	0.00184	0.23	0.2	Urate levels in obese individuals;	chr5:178656975	chr5:178619728~178619998:-
THCA	cis	rs12216545	0.644	rs62491782	ENSG00000241134.3	BET1P1	-4.32	1.92e-05	0.00184	-0.23	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150612325	chr7:150749736~150750094:+
THCA	cis	rs35740288	0.77	rs12907126	ENSG00000259295.5	CSPG4P12	4.32	1.92e-05	0.00184	0.3	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85628126	chr15:85191438~85213905:+
THCA	cis	rs17801127	0.818	rs16827301	ENSG00000231969.1	AC144449.1	4.32	1.92e-05	0.00184	0.33	0.2	Liver enzyme levels (alanine transaminase);	chr2:149654608	chr2:149587196~149848233:+
THCA	cis	rs2657294	0.965	rs7088974	ENSG00000226051.5	ZNF503-AS1	-4.32	1.92e-05	0.00184	-0.27	-0.2	Pneumonia;	chr10:75131338	chr10:75269819~75373500:+
THCA	cis	rs2033711	0.84	rs10423138	ENSG00000269054.1	CTD-2619J13.3	-4.32	1.92e-05	0.00184	-0.15	-0.2	Uric acid clearance;	chr19:58416935	chr19:58362585~58366591:+
THCA	cis	rs10760158	0.739	rs4837819	ENSG00000226752.6	PSMD5-AS1	-4.32	1.92e-05	0.00184	-0.24	-0.2	Pulse pressure;	chr9:121246156	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.739	rs10760163	ENSG00000226752.6	PSMD5-AS1	-4.32	1.92e-05	0.00184	-0.24	-0.2	Pulse pressure;	chr9:121246174	chr9:120824828~120854385:+
THCA	cis	rs10411161	0.702	rs6509592	ENSG00000275055.1	CTC-471J1.11	-4.32	1.92e-05	0.00184	-0.19	-0.2	Breast cancer;	chr19:51889897	chr19:52049007~52049754:+
THCA	cis	rs7646881	0.544	rs75227002	ENSG00000240207.5	RP11-379F4.4	-4.32	1.92e-05	0.00184	-0.3	-0.2	Tetralogy of Fallot;	chr3:158616384	chr3:158732263~158784070:+
THCA	cis	rs4074961	0.505	rs4653306	ENSG00000233621.1	LINC01137	-4.32	1.92e-05	0.00184	-0.2	-0.2	Axial length;	chr1:37599789	chr1:37454879~37474411:-
THCA	cis	rs8067545	0.611	rs7216599	ENSG00000270091.1	RP11-78O7.2	-4.32	1.92e-05	0.00184	-0.15	-0.2	Schizophrenia;	chr17:20112287	chr17:19896590~19897287:-
THCA	cis	rs2348418	0.67	rs4035202	ENSG00000247934.4	RP11-967K21.1	-4.32	1.92e-05	0.00184	-0.17	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28118015	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.67	rs1824919	ENSG00000247934.4	RP11-967K21.1	-4.32	1.92e-05	0.00184	-0.17	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28118449	chr12:28163298~28190738:-
THCA	cis	rs9863	0.896	rs77112003	ENSG00000270061.1	RP11-214K3.19	-4.32	1.92e-05	0.00184	-0.26	-0.2	White blood cell count;	chr12:124002996	chr12:123969990~123970344:-
THCA	cis	rs79243044	0.695	rs2010794	ENSG00000224295.2	AC087380.14	4.32	1.92e-05	0.00184	0.2	0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5524592	chr11:5518441~5524955:-
THCA	cis	rs2153535	0.585	rs9379236	ENSG00000230939.1	RP11-314C16.1	-4.32	1.92e-05	0.00184	-0.2	-0.2	Motion sickness;	chr6:8651792	chr6:8784178~8785445:+
THCA	cis	rs34975555	0.614	rs375017	ENSG00000253671.1	RP11-806O11.1	-4.32	1.92e-05	0.00184	-0.29	-0.2	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17994940	chr8:17808941~17820868:+
THCA	cis	rs9905704	0.647	rs33922512	ENSG00000224738.1	AC099850.1	-4.32	1.92e-05	0.00184	-0.24	-0.2	Testicular germ cell tumor;	chr17:59036787	chr17:59106598~59118267:+
THCA	cis	rs72717009	0.825	rs12746613	ENSG00000225217.1	HSPA7	4.32	1.92e-05	0.00184	0.3	0.2	Rheumatoid arthritis;	chr1:161497252	chr1:161606291~161608217:+
THCA	cis	rs7976269	0.609	rs4141946	ENSG00000275476.1	RP11-996F15.4	-4.32	1.92e-05	0.00184	-0.2	-0.2	Male-pattern baldness;	chr12:29066432	chr12:29277397~29277882:-
THCA	cis	rs8058578	0.832	rs35969813	ENSG00000279196.1	RP11-1072A3.3	4.32	1.92e-05	0.00184	0.2	0.2	Multiple myeloma;	chr16:30703096	chr16:30984630~30988270:-
THCA	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	4.32	1.92e-05	0.00184	0.22	0.2	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
THCA	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	4.32	1.92e-05	0.00184	0.22	0.2	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
THCA	cis	rs6569038	0.557	rs1342794	ENSG00000253194.1	RP11-351A11.1	4.32	1.92e-05	0.00184	0.28	0.2	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119055182	chr6:118934785~119031541:+
THCA	cis	rs10090774	0.965	rs3923115	ENSG00000279766.1	RP11-642A1.2	4.32	1.92e-05	0.00184	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140744352	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs35426024	ENSG00000279766.1	RP11-642A1.2	4.32	1.92e-05	0.00184	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140745211	chr8:140572142~140572812:-
THCA	cis	rs7267979	0.966	rs7270835	ENSG00000276952.1	RP5-965G21.6	4.32	1.92e-05	0.00184	0.21	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6115191	ENSG00000276952.1	RP5-965G21.6	4.32	1.92e-05	0.00184	0.21	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6107045	ENSG00000276952.1	RP5-965G21.6	4.32	1.92e-05	0.00184	0.21	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6107046	ENSG00000276952.1	RP5-965G21.6	4.32	1.92e-05	0.00184	0.21	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6107047	ENSG00000276952.1	RP5-965G21.6	4.32	1.92e-05	0.00184	0.21	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25284915~25285588:-
THCA	cis	rs3738443	0.83	rs6684181	ENSG00000259865.1	RP11-488L18.10	4.32	1.92e-05	0.00184	0.21	0.2	Alcohol dependence;	chr1:247184669	chr1:247187281~247188526:-
THCA	cis	rs10256972	0.685	rs10263665	ENSG00000199023.2	MIR339	-4.32	1.92e-05	0.00184	-0.2	-0.2	Endometriosis;Longevity;	chr7:1070992	chr7:1022935~1023045:-
THCA	cis	rs9810089	0.843	rs838202	ENSG00000273455.1	RP11-305O4.3	4.32	1.92e-05	0.00184	0.26	0.2	Gestational age at birth (child effect);	chr3:136316375	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.843	rs681783	ENSG00000273455.1	RP11-305O4.3	4.32	1.92e-05	0.00184	0.26	0.2	Gestational age at birth (child effect);	chr3:136316461	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.843	rs1279086	ENSG00000273455.1	RP11-305O4.3	4.32	1.92e-05	0.00184	0.26	0.2	Gestational age at birth (child effect);	chr3:136319732	chr3:136087475~136087913:-
THCA	cis	rs116248771	0.739	rs73156451	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158647660	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs73156455	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158649768	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs12633674	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158650428	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.793	rs73156465	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158656746	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs7648050	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158659681	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs4680454	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158660124	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs2291595	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158661058	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs16829290	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158674489	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.691	rs2363658	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158678077	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs4680456	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158680053	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.739	rs73156478	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158680927	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.69	rs4459938	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158688286	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.69	rs73156490	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158698695	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.69	rs73156491	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158698783	chr3:158782547~158783124:+
THCA	cis	rs116248771	0.69	rs73156492	ENSG00000271778.1	RP11-379F4.8	4.32	1.93e-05	0.00184	0.26	0.2	diarrhoeal disease at age 2;	chr3:158699010	chr3:158782547~158783124:+
THCA	cis	rs6430538	0.671	rs6740829	ENSG00000224043.6	CCNT2-AS1	-4.32	1.93e-05	0.00184	-0.21	-0.2	Parkinson's disease;	chr2:134815694	chr2:134735464~134918710:-
THCA	cis	rs9425766	0.541	rs12691474	ENSG00000227373.4	RP11-160H22.5	4.32	1.93e-05	0.00184	0.28	0.2	Life satisfaction;	chr1:174200867	chr1:174115300~174160004:-
THCA	cis	rs5758511	0.689	rs17478227	ENSG00000205702.9	CYP2D7	-4.32	1.93e-05	0.00185	-0.21	-0.2	Birth weight;	chr22:42258321	chr22:42140203~42144577:-
THCA	cis	rs17685	0.725	rs7807647	ENSG00000230882.1	AC005077.14	-4.32	1.93e-05	0.00185	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:75999351	chr7:76071469~76074963:-
THCA	cis	rs4218	0.648	rs12442086	ENSG00000259732.1	RP11-59H7.3	-4.32	1.93e-05	0.00185	-0.27	-0.2	Social communication problems;	chr15:59074364	chr15:59121034~59133250:+
THCA	cis	rs1048886	0.872	rs16869353	ENSG00000271967.1	RP11-134K13.4	-4.32	1.93e-05	0.00185	-0.21	-0.2	Type 2 diabetes;	chr6:70545730	chr6:70596438~70596980:+
THCA	cis	rs1124769	0.719	rs12916845	ENSG00000259378.1	DCAF13P3	4.32	1.93e-05	0.00185	0.29	0.2	Cognitive performance;	chr15:50936255	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs7176496	ENSG00000259378.1	DCAF13P3	4.32	1.93e-05	0.00185	0.29	0.2	Cognitive performance;	chr15:50944640	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.719	rs12593342	ENSG00000259378.1	DCAF13P3	4.32	1.93e-05	0.00185	0.29	0.2	Cognitive performance;	chr15:50971967	chr15:50944663~50945996:+
THCA	cis	rs1371614	0.545	rs3769136	ENSG00000229122.1	AGBL5-IT1	4.32	1.93e-05	0.00185	0.14	0.2	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26945875	chr2:27061038~27061815:+
THCA	cis	rs9634489	0.62	rs1927792	ENSG00000247400.3	DNAJC3-AS1	-4.32	1.93e-05	0.00185	-0.13	-0.2	Body mass index;	chr13:96269059	chr13:95648733~95676925:-
THCA	cis	rs9435732	0.54	rs9325647	ENSG00000268869.4	ESPNP	4.32	1.93e-05	0.00185	0.23	0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17039305	chr1:16687339~16720157:-
THCA	cis	rs9435732	0.504	rs9787230	ENSG00000268869.4	ESPNP	4.32	1.93e-05	0.00185	0.23	0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17044475	chr1:16687339~16720157:-
THCA	cis	rs9326248	0.53	rs7121347	ENSG00000280143.1	AP000892.6	4.32	1.93e-05	0.00185	0.31	0.2	Blood protein levels;	chr11:116996493	chr11:117204967~117210292:+
THCA	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	4.32	1.93e-05	0.00185	0.23	0.2	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
THCA	cis	rs6088813	1	rs6087702	ENSG00000279253.1	RP4-614O4.13	4.32	1.93e-05	0.00185	0.19	0.2	Height;	chr20:35408142	chr20:35262727~35264187:-
THCA	cis	rs4927850	1	rs4927850	ENSG00000185485.13	SDHAP1	-4.32	1.93e-05	0.00185	-0.17	-0.2	Pancreatic cancer;	chr3:196024759	chr3:195959748~195990318:-
THCA	cis	rs4819052	0.851	rs2236443	ENSG00000182586.6	LINC00334	-4.32	1.93e-05	0.00185	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45234340~45258730:+
THCA	cis	rs1055129	0.584	rs9895947	ENSG00000267801.1	RP11-552F3.9	4.32	1.93e-05	0.00185	0.23	0.2	White matter hyperintensity burden;	chr17:75912485	chr17:75876372~75879546:+
THCA	cis	rs4144027	0.818	rs881057	ENSG00000269958.1	RP11-73M18.8	-4.32	1.93e-05	0.00185	-0.18	-0.2	Blood metabolite levels;	chr14:103887921	chr14:103696353~103697163:+
THCA	cis	rs829883	0.724	rs1439774	ENSG00000227825.4	SLC9A7P1	-4.32	1.93e-05	0.00185	-0.19	-0.2	Colorectal adenoma (advanced);	chr12:98513914	chr12:98453835~98457145:-
THCA	cis	rs16852403	0.531	rs389563	ENSG00000224687.1	RASAL2-AS1	-4.32	1.93e-05	0.00185	-0.28	-0.2	Childhood ear infection;	chr1:178194009	chr1:178091508~178093984:-
THCA	cis	rs2836950	0.502	rs2150411	ENSG00000238141.2	BRWD1-AS1	-4.32	1.93e-05	0.00185	-0.22	-0.2	Menarche (age at onset);	chr21:39202626	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.545	rs4818001	ENSG00000238141.2	BRWD1-AS1	-4.32	1.93e-05	0.00185	-0.22	-0.2	Menarche (age at onset);	chr21:39203162	chr21:39315707~39323218:+
THCA	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-4.32	1.93e-05	0.00185	-0.22	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
THCA	cis	rs6657613	0.68	rs10887990	ENSG00000186301.8	MST1P2	4.32	1.93e-05	0.00185	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17032891	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs11579925	ENSG00000186301.8	MST1P2	4.32	1.93e-05	0.00185	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17036210	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs10788650	ENSG00000186301.8	MST1P2	4.32	1.93e-05	0.00185	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17036364	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.649	rs2179793	ENSG00000186301.8	MST1P2	4.32	1.93e-05	0.00185	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17039238	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs7517920	ENSG00000186301.8	MST1P2	4.32	1.93e-05	0.00185	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17042820	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs11203284	ENSG00000186301.8	MST1P2	4.32	1.93e-05	0.00185	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17043457	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs10887992	ENSG00000186301.8	MST1P2	4.32	1.93e-05	0.00185	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17043718	chr1:16645622~16650289:+
THCA	cis	rs6657613	0.68	rs10887993	ENSG00000186301.8	MST1P2	4.32	1.93e-05	0.00185	0.16	0.2	Hip circumference adjusted for BMI;	chr1:17043746	chr1:16645622~16650289:+
THCA	cis	rs7474896	0.559	rs1208560	ENSG00000120555.12	SEPT7P9	-4.32	1.93e-05	0.00185	-0.26	-0.2	Obesity (extreme);	chr10:37932690	chr10:38383069~38402916:-
THCA	cis	rs1923243	0.681	rs11210117	ENSG00000223479.3	RP4-788P17.1	4.32	1.93e-05	0.00185	0.22	0.2	Migraine;	chr1:73065515	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs11210118	ENSG00000223479.3	RP4-788P17.1	4.32	1.93e-05	0.00185	0.22	0.2	Migraine;	chr1:73065603	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs7528197	ENSG00000223479.3	RP4-788P17.1	4.32	1.93e-05	0.00185	0.22	0.2	Migraine;	chr1:73067631	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs11210120	ENSG00000223479.3	RP4-788P17.1	4.32	1.93e-05	0.00185	0.22	0.2	Migraine;	chr1:73068063	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs4649976	ENSG00000223479.3	RP4-788P17.1	4.32	1.93e-05	0.00185	0.22	0.2	Migraine;	chr1:73068195	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs35493511	ENSG00000223479.3	RP4-788P17.1	4.32	1.93e-05	0.00185	0.22	0.2	Migraine;	chr1:73076602	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs35967561	ENSG00000223479.3	RP4-788P17.1	4.32	1.93e-05	0.00185	0.22	0.2	Migraine;	chr1:73076726	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs12145800	ENSG00000223479.3	RP4-788P17.1	4.32	1.93e-05	0.00185	0.22	0.2	Migraine;	chr1:73086066	chr1:73635216~73715214:+
THCA	cis	rs740160	0.51	rs6958704	ENSG00000244219.5	GS1-259H13.2	-4.32	1.93e-05	0.00185	-0.29	-0.2	Dehydroepiandrosterone sulphate levels;	chr7:99300735	chr7:99598066~99610813:+
THCA	cis	rs7688540	0.511	rs10003260	ENSG00000211553.1	AC253576.2	-4.32	1.93e-05	0.00185	-0.3	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:136461~136568:+
THCA	cis	rs9425766	0.566	rs56188862	ENSG00000227373.4	RP11-160H22.5	4.32	1.93e-05	0.00185	0.28	0.2	Life satisfaction;	chr1:174220131	chr1:174115300~174160004:-
THCA	cis	rs2836950	0.565	rs7276046	ENSG00000238141.2	BRWD1-AS1	-4.32	1.93e-05	0.00185	-0.22	-0.2	Menarche (age at onset);	chr21:39209367	chr21:39315707~39323218:+
THCA	cis	rs10090774	0.965	rs4961288	ENSG00000279766.1	RP11-642A1.2	4.32	1.93e-05	0.00185	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140731369	chr8:140572142~140572812:-
THCA	cis	rs2208568	1	rs2208568	ENSG00000237845.1	RP5-940F7.2	-4.32	1.93e-05	0.00185	-0.38	-0.2	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;White blood cell count;	chr1:235926855	chr1:235942553~235943805:-
THCA	cis	rs8077577	0.945	rs62072496	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.93e-05	0.00185	-0.34	-0.2	Obesity-related traits;	chr17:18221429	chr17:18511221~18551705:-
THCA	cis	rs2799081	1	rs2799081	ENSG00000273712.1	RP5-874C20.7	4.32	1.93e-05	0.00185	0.23	0.2	Myopia;	chr6:28302807	chr6:28315613~28315883:-
THCA	cis	rs10256972	1	rs10256972	ENSG00000225146.1	AC073957.15	-4.32	1.93e-05	0.00185	-0.2	-0.2	Endometriosis;Longevity;	chr7:999367	chr7:1029025~1043891:+
THCA	cis	rs227275	0.525	rs13113923	ENSG00000248971.2	KRT8P46	-4.32	1.93e-05	0.00185	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102728746~102730171:-
THCA	cis	rs1962772	0.773	rs2016139	ENSG00000279903.1	RP11-349F21.5	-4.32	1.93e-05	0.00185	-0.25	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17516927	chr8:17500012~17500605:+
THCA	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-4.32	1.94e-05	0.00185	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
THCA	cis	rs7572644	0.76	rs10190494	ENSG00000223522.1	AC093690.1	4.32	1.94e-05	0.00185	0.23	0.2	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27908376	chr2:28307691~28310459:-
THCA	cis	rs7267979	0.546	rs8115804	ENSG00000125804.12	FAM182A	4.32	1.94e-05	0.00185	0.26	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25458147	chr20:26054655~26086917:+
THCA	cis	rs10484434	0.818	rs3799374	ENSG00000272810.1	U91328.22	4.32	1.94e-05	0.00185	0.2	0.2	HIV-1 viral setpoint;	chr6:26088179	chr6:26013241~26013757:+
THCA	cis	rs2070488	0.965	rs2051216	ENSG00000229589.1	ACVR2B-AS1	-4.32	1.94e-05	0.00185	-0.18	-0.2	Electrocardiographic conduction measures;	chr3:38520797	chr3:38451027~38454820:-
THCA	cis	rs4805272	1	rs7256812	ENSG00000267799.1	MAN1A2P1	4.32	1.94e-05	0.00185	0.22	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832523	chr19:28790812~28792871:-
THCA	cis	rs3740713	1	rs73438686	ENSG00000256464.1	YWHABP2	4.32	1.94e-05	0.00185	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr11:18490243~18490955:-
THCA	cis	rs62025270	0.547	rs416916	ENSG00000259295.5	CSPG4P12	-4.32	1.94e-05	0.00185	-0.28	-0.2	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85191438~85213905:+
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000176933.5	TOB2P1	-4.32	1.94e-05	0.00185	-0.21	-0.2	Pubertal anthropometrics;	chr6:28411584	chr6:28217643~28218634:-
THCA	cis	rs9388451	0.531	rs9321057	ENSG00000226409.1	RP11-735G4.1	-4.32	1.94e-05	0.00185	-0.24	-0.2	Brugada syndrome;	chr6:125835797	chr6:125370211~125374324:-
THCA	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-4.32	1.94e-05	0.00185	-0.2	-0.2	Height;	chr5:36904297	chr5:36666214~36725195:-
THCA	cis	rs2692947	0.732	rs56847058	ENSG00000232931.4	LINC00342	4.32	1.94e-05	0.00185	0.16	0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95741145	chr2:95807118~95816215:-
THCA	cis	rs7809799	0.571	rs11978582	ENSG00000244219.5	GS1-259H13.2	4.32	1.94e-05	0.00185	0.42	0.2	Ulcerative colitis;	chr7:99318335	chr7:99598066~99610813:+
THCA	cis	rs6088590	0.735	rs6060003	ENSG00000269202.1	RP4-614O4.12	-4.32	1.94e-05	0.00185	-0.16	-0.2	Coronary artery disease;	chr20:34707141	chr20:35201747~35203288:-
THCA	cis	rs12497850	0.931	rs13064911	ENSG00000228638.1	FCF1P2	-4.32	1.94e-05	0.00186	-0.21	-0.2	Parkinson's disease;	chr3:48914952	chr3:48290793~48291375:-
THCA	cis	rs4072705	0.646	rs7037254	ENSG00000224020.1	MIR181A2HG	4.32	1.94e-05	0.00186	0.18	0.2	Menarche (age at onset);	chr9:124483133	chr9:124658467~124698631:+
THCA	cis	rs853679	0.599	rs156743	ENSG00000220721.1	OR1F12	4.32	1.94e-05	0.00186	0.31	0.2	Depression;	chr6:27999311	chr6:28073316~28074233:+
THCA	cis	rs2348418	0.639	rs10459086	ENSG00000247934.4	RP11-967K21.1	-4.32	1.94e-05	0.00186	-0.17	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28115511	chr12:28163298~28190738:-
THCA	cis	rs12928939	0.517	rs71384782	ENSG00000260886.1	TAT-AS1	4.32	1.94e-05	0.00186	0.27	0.2	Post bronchodilator FEV1;	chr16:71944688	chr16:71565789~71578187:+
THCA	cis	rs9875589	0.509	rs1601870	ENSG00000228242.5	AC093495.4	4.32	1.94e-05	0.00186	0.11	0.2	Ovarian reserve;	chr3:13982662	chr3:14144637~14165978:+
THCA	cis	rs56313388	0.522	rs3909221	ENSG00000246379.5	RP11-461O7.1	-4.32	1.94e-05	0.00186	-0.21	-0.2	Pulse pressure;	chr16:56130631	chr16:56092987~56191094:-
THCA	cis	rs9959145	1	rs111384103	ENSG00000267199.1	RP11-861E21.2	4.32	1.94e-05	0.00186	0.25	0.2	Immune response to smallpox vaccine (IL-6);	chr18:12606483	chr18:12438890~12448205:+
THCA	cis	rs997295	0.713	rs9302246	ENSG00000270964.1	RP11-502I4.3	-4.32	1.94e-05	0.00186	-0.16	-0.2	Motion sickness;	chr15:67728942	chr15:67541072~67542604:-
THCA	cis	rs4785204	0.618	rs59952328	ENSG00000279356.1	RP11-429P3.8	-4.32	1.94e-05	0.00186	-0.37	-0.2	Esophageal cancer (squamous cell);	chr16:50007821	chr16:50072862~50074986:+
THCA	cis	rs28735056	0.935	rs537962	ENSG00000261126.6	RP11-795F19.1	4.32	1.94e-05	0.00186	0.16	0.2	Schizophrenia;	chr18:79832660	chr18:80046900~80095482:+
THCA	cis	rs7989336	0.501	rs1925107	ENSG00000247400.3	DNAJC3-AS1	4.32	1.94e-05	0.00186	0.13	0.2	Obesity;	chr13:96358413	chr13:95648733~95676925:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	4.32	1.94e-05	0.00186	0.23	0.2	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	4.32	1.94e-05	0.00186	0.23	0.2	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
THCA	cis	rs875971	0.505	rs2462573	ENSG00000272831.1	RP11-792A8.4	-4.32	1.94e-05	0.00186	-0.12	-0.2	Aortic root size;	chr7:66042405	chr7:66739829~66740385:-
THCA	cis	rs6600671	1	rs7532615	ENSG00000275585.1	CH17-118O6.3	4.32	1.94e-05	0.00186	0.24	0.2	Hip geometry;	chr1:121430980	chr1:120985692~121052167:-
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000182586.6	LINC00334	-4.32	1.94e-05	0.00186	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000182586.6	LINC00334	-4.32	1.94e-05	0.00186	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000182586.6	LINC00334	-4.32	1.94e-05	0.00186	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000182586.6	LINC00334	-4.32	1.94e-05	0.00186	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000182586.6	LINC00334	-4.32	1.94e-05	0.00186	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45234340~45258730:+
THCA	cis	rs755249	0.51	rs613511	ENSG00000182109.6	RP11-69E11.4	4.32	1.94e-05	0.00186	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs629093	ENSG00000182109.6	RP11-69E11.4	4.32	1.94e-05	0.00186	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs1180383	ENSG00000182109.6	RP11-69E11.4	4.32	1.94e-05	0.00186	0.19	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380595	chr1:39522280~39546187:-
THCA	cis	rs17801127	0.688	rs73003930	ENSG00000231969.1	AC144449.1	4.32	1.94e-05	0.00186	0.44	0.2	Liver enzyme levels (alanine transaminase);	chr2:149857101	chr2:149587196~149848233:+
THCA	cis	rs31251	0.967	rs2240525	ENSG00000237714.1	P4HA2-AS1	4.32	1.94e-05	0.00186	0.24	0.2	Itch intensity from mosquito bite adjusted by bite size;	chr5:131980191	chr5:132184876~132192808:+
THCA	cis	rs875971	0.964	rs160635	ENSG00000272831.1	RP11-792A8.4	4.32	1.94e-05	0.00186	0.13	0.2	Aortic root size;	chr7:66063931	chr7:66739829~66740385:-
THCA	cis	rs420259	0.516	rs120963	ENSG00000260136.4	CTD-2270L9.4	4.32	1.94e-05	0.00186	0.15	0.2	Bipolar disorder;	chr16:23596749	chr16:23452758~23457606:+
THCA	cis	rs860295	0.729	rs11264369	ENSG00000160766.13	GBAP1	4.32	1.94e-05	0.00186	0.23	0.2	Body mass index;	chr1:155390039	chr1:155213821~155227422:-
THCA	cis	rs12428035	0.505	rs9590328	ENSG00000247400.3	DNAJC3-AS1	-4.32	1.94e-05	0.00186	-0.17	-0.2	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95796129	chr13:95648733~95676925:-
THCA	cis	rs6479901	0.512	rs7082090	ENSG00000272767.1	JMJD1C-AS1	4.32	1.94e-05	0.00186	0.27	0.2	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63465229~63466563:+
THCA	cis	rs35771425	0.536	rs6656860	ENSG00000153363.11	LINC00467	-4.32	1.94e-05	0.00186	-0.14	-0.2	Educational attainment (years of education);	chr1:211447463	chr1:211382803~211435333:+
THCA	cis	rs1923243	0.778	rs11210166	ENSG00000223479.3	RP4-788P17.1	-4.32	1.94e-05	0.00186	-0.21	-0.2	Migraine;	chr1:73170900	chr1:73635216~73715214:+
THCA	cis	rs7267979	0.966	rs2387885	ENSG00000274973.1	RP13-401N8.7	4.32	1.94e-05	0.00186	0.22	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2424713	ENSG00000274973.1	RP13-401N8.7	-4.32	1.94e-05	0.00186	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25845497~25845862:+
THCA	cis	rs3740713	1	rs73440614	ENSG00000256464.1	YWHABP2	4.32	1.94e-05	0.00186	0.35	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr11:18490243~18490955:-
THCA	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	4.32	1.94e-05	0.00186	0.23	0.2	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
THCA	cis	rs613391	0.885	rs1098967	ENSG00000224549.1	RP11-370B11.3	-4.32	1.94e-05	0.00186	-0.24	-0.2	Quantitative traits;	chr9:22661811	chr9:22767175~22768316:+
THCA	cis	rs75504410	0.678	rs17428931	ENSG00000231160.8	KLF3-AS1	4.32	1.94e-05	0.00186	0.2	0.2	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38687421	chr4:38612701~38664883:-
THCA	cis	rs526231	0.764	rs183707	ENSG00000175749.11	EIF3KP1	4.32	1.94e-05	0.00186	0.25	0.2	Primary biliary cholangitis;	chr5:103305081	chr5:103032376~103033031:+
THCA	cis	rs11671005	0.779	rs731259	ENSG00000268049.1	CTD-2619J13.9	-4.32	1.95e-05	0.00186	-0.31	-0.2	Mean platelet volume;	chr19:58478057	chr19:58357999~58359603:+
THCA	cis	rs28829049	0.861	rs2147946	ENSG00000270728.1	RP4-657E11.10	-4.32	1.95e-05	0.00186	-0.14	-0.2	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19042393	chr1:19297080~19297903:+
THCA	cis	rs12541437	1	rs3020154	ENSG00000253327.2	RAD21-AS1	4.32	1.95e-05	0.00186	0.21	0.2	Gut microbiome composition (winter);	chr8:116905950	chr8:116874424~116876868:+
THCA	cis	rs6517329	0.933	rs12151967	ENSG00000236830.5	CBR3-AS1	4.32	1.95e-05	0.00186	0.18	0.2	Schizophrenia;	chr21:36111456	chr21:36131767~36175815:-
THCA	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	4.32	1.95e-05	0.00186	0.23	0.2	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
THCA	cis	rs9467773	0.62	rs2101582	ENSG00000261353.1	CTA-14H9.5	-4.32	1.95e-05	0.00186	-0.2	-0.2	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26527063~26527404:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000275400.1	RP4-756H11.5	4.32	1.95e-05	0.00186	0.19	0.2	Aortic root size;	chr7:66039646	chr7:66553805~66554199:-
THCA	cis	rs6416877	0.704	rs34490967	ENSG00000277491.1	RP11-676J12.9	-4.32	1.95e-05	0.00186	-0.22	-0.2	Myeloid white cell count;	chr17:1438957	chr17:795306~795794:+
THCA	cis	rs6416877	0.655	rs12938903	ENSG00000277491.1	RP11-676J12.9	-4.32	1.95e-05	0.00186	-0.22	-0.2	Myeloid white cell count;	chr17:1443369	chr17:795306~795794:+
THCA	cis	rs7209700	0.662	rs8080254	ENSG00000228782.6	CTD-2026D20.3	4.32	1.95e-05	0.00186	0.21	0.2	IgG glycosylation;	chr17:47270526	chr17:47450568~47492492:-
THCA	cis	rs10043228	1	rs13362043	ENSG00000248445.4	SEMA6A-AS1	-4.31	1.95e-05	0.00186	-0.26	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116260565	chr5:116447547~116508276:+
THCA	cis	rs17221829	0.965	rs10830359	ENSG00000280385.1	AP000648.5	-4.31	1.95e-05	0.00186	-0.19	-0.2	Anxiety in major depressive disorder;	chr11:89722276	chr11:90193614~90198120:+
THCA	cis	rs9595908	0.709	rs17516498	ENSG00000212293.1	SNORA16	4.31	1.95e-05	0.00186	0.23	0.2	Body mass index;	chr13:32750477	chr13:32420390~32420516:-
THCA	cis	rs6088590	1	rs6088590	ENSG00000276073.1	RP5-1125A11.7	-4.31	1.95e-05	0.00186	-0.18	-0.2	Coronary artery disease;	chr20:34725762	chr20:33985617~33988989:-
THCA	cis	rs6088590	1	rs6120705	ENSG00000276073.1	RP5-1125A11.7	-4.31	1.95e-05	0.00186	-0.18	-0.2	Coronary artery disease;	chr20:34725936	chr20:33985617~33988989:-
THCA	cis	rs875971	0.898	rs6977501	ENSG00000229886.1	RP5-1132H15.3	-4.31	1.95e-05	0.00186	-0.2	-0.2	Aortic root size;	chr7:66228355	chr7:66025126~66031544:-
THCA	cis	rs4648045	0.822	rs62328536	ENSG00000246560.2	RP11-10L12.4	4.31	1.95e-05	0.00186	0.25	0.2	Lymphocyte percentage of white cells;	chr4:102477892	chr4:102828055~102844075:+
THCA	cis	rs9625935	0.843	rs36580	ENSG00000279159.1	RP3-394A18.1	4.31	1.95e-05	0.00186	0.16	0.2	Tonsillectomy;	chr22:29923405	chr22:29978950~30028236:-
THCA	cis	rs6840360	0.692	rs1838043	ENSG00000251611.1	RP11-610P16.1	-4.31	1.95e-05	0.00186	-0.14	-0.2	Intelligence (multi-trait analysis);	chr4:151490310	chr4:151407551~151408835:-
THCA	cis	rs763121	0.853	rs35565791	ENSG00000273076.1	RP3-508I15.22	4.31	1.95e-05	0.00186	0.2	0.2	Menopause (age at onset);	chr22:38667006	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs35522482	ENSG00000273076.1	RP3-508I15.22	4.31	1.95e-05	0.00186	0.2	0.2	Menopause (age at onset);	chr22:38667010	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2072796	ENSG00000273076.1	RP3-508I15.22	4.31	1.95e-05	0.00186	0.2	0.2	Menopause (age at onset);	chr22:38668225	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2281019	ENSG00000273076.1	RP3-508I15.22	4.31	1.95e-05	0.00186	0.2	0.2	Menopause (age at onset);	chr22:38668373	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2281020	ENSG00000273076.1	RP3-508I15.22	4.31	1.95e-05	0.00186	0.2	0.2	Menopause (age at onset);	chr22:38668401	chr22:38743495~38743910:+
THCA	cis	rs4664304	0.714	rs66496937	ENSG00000226266.5	AC009961.3	4.31	1.95e-05	0.00187	0.24	0.2	Crohn's disease;Inflammatory bowel disease;	chr2:159881998	chr2:159670708~159712435:-
THCA	cis	rs800160	0.777	rs2651779	ENSG00000199550.1	Y_RNA	4.31	1.95e-05	0.00187	0.3	0.2	Bacteremia;	chr11:2323040	chr11:2372638~2372750:+
THCA	cis	rs800160	0.777	rs11022289	ENSG00000199550.1	Y_RNA	4.31	1.95e-05	0.00187	0.3	0.2	Bacteremia;	chr11:2324187	chr11:2372638~2372750:+
THCA	cis	rs12462428	0.531	rs731617	ENSG00000279748.1	CTD-3222D19.9	4.31	1.95e-05	0.00187	0.2	0.2	Educational attainment (years of education);	chr19:16555046	chr19:16586905~16589409:+
THCA	cis	rs711244	0.777	rs12476515	ENSG00000279519.1	RP11-288C18.1	-4.31	1.95e-05	0.00187	-0.16	-0.2	Mean platelet volume;	chr2:36875477	chr2:36839922~36842539:-
THCA	cis	rs3734266	0.702	rs72892286	ENSG00000272288.4	RP11-140K17.3	-4.31	1.95e-05	0.00187	-0.2	-0.2	Systemic lupus erythematosus;	chr6:34794400	chr6:34696317~34697470:+
THCA	cis	rs6088590	1	rs6087626	ENSG00000276073.1	RP5-1125A11.7	-4.31	1.95e-05	0.00187	-0.18	-0.2	Coronary artery disease;	chr20:34759525	chr20:33985617~33988989:-
THCA	cis	rs6088590	1	rs2180276	ENSG00000276073.1	RP5-1125A11.7	-4.31	1.95e-05	0.00187	-0.18	-0.2	Coronary artery disease;	chr20:34772982	chr20:33985617~33988989:-
THCA	cis	rs17685	0.753	rs10085567	ENSG00000230882.1	AC005077.14	4.31	1.95e-05	0.00187	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76104888	chr7:76071469~76074963:-
THCA	cis	rs3924048	0.559	rs4075304	ENSG00000276830.1	MIR6730	-4.31	1.95e-05	0.00187	-0.19	-0.2	Optic cup area;	chr1:12566774	chr1:12578957~12579023:-
THCA	cis	rs7646881	0.544	rs12637589	ENSG00000240207.5	RP11-379F4.4	-4.31	1.95e-05	0.00187	-0.3	-0.2	Tetralogy of Fallot;	chr3:158625546	chr3:158732263~158784070:+
THCA	cis	rs2286503	0.966	rs2286507	ENSG00000226329.2	AC005682.6	4.31	1.95e-05	0.00187	0.24	0.2	Fibrinogen;	chr7:22815141	chr7:22863874~22881350:-
THCA	cis	rs11722779	0.844	rs10003326	ENSG00000248971.2	KRT8P46	-4.31	1.95e-05	0.00187	-0.24	-0.2	Schizophrenia;	chr4:102948193	chr4:102728746~102730171:-
THCA	cis	rs10483853	0.806	rs66534540	ENSG00000258695.2	RP3-414A15.2	-4.31	1.95e-05	0.00187	-0.27	-0.2	Coronary artery calcification;	chr14:73333467	chr14:73522878~73530610:+
THCA	cis	rs2128382	0.556	rs11984804	ENSG00000253720.1	RP11-473O4.3	-4.31	1.95e-05	0.00187	-0.29	-0.2	Colorectal cancer;	chr8:129889159	chr8:129939856~129949394:+
THCA	cis	rs2128382	0.556	rs2086641	ENSG00000253720.1	RP11-473O4.3	-4.31	1.95e-05	0.00187	-0.29	-0.2	Colorectal cancer;	chr8:129889663	chr8:129939856~129949394:+
THCA	cis	rs453301	0.686	rs11785634	ENSG00000254153.1	CTA-398F10.2	4.31	1.95e-05	0.00187	0.21	0.2	Joint mobility (Beighton score);	chr8:9035087	chr8:8456909~8461337:-
THCA	cis	rs7176527	1	rs7176527	ENSG00000230373.7	GOLGA6L5P	4.31	1.95e-05	0.00187	0.24	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84507885~84516814:-
THCA	cis	rs4568518	0.501	rs12699920	ENSG00000279048.1	RP11-511H23.2	4.31	1.95e-05	0.00187	0.12	0.2	Measles;	chr7:17953326	chr7:17940503~17942922:+
THCA	cis	rs2337406	0.714	rs7152055	ENSG00000211974.3	IGHV2-70	-4.31	1.95e-05	0.00187	-0.2	-0.2	Alzheimer's disease (late onset);	chr14:106818996	chr14:106723574~106724093:-
THCA	cis	rs13098911	0.54	rs2102055	ENSG00000226074.4	PRSS44	-4.31	1.95e-05	0.00187	-0.35	-0.2	Celiac disease;	chr3:46031212	chr3:46809359~46812558:-
THCA	cis	rs10875746	0.517	rs12721420	ENSG00000258273.1	RP11-370I10.4	4.31	1.96e-05	0.00187	0.3	0.2	Longevity (90 years and older);	chr12:47965011	chr12:48333755~48333901:-
THCA	cis	rs72843506	0.591	rs117720402	ENSG00000231258.2	ZSWIM5P2	4.31	1.96e-05	0.00187	0.31	0.2	Schizophrenia;	chr17:20444298	chr17:20583758~20591180:-
THCA	cis	rs4218	0.648	rs35769647	ENSG00000259732.1	RP11-59H7.3	-4.31	1.96e-05	0.00187	-0.27	-0.2	Social communication problems;	chr15:59081670	chr15:59121034~59133250:+
THCA	cis	rs36093844	0.752	rs77197861	ENSG00000279742.1	RP11-700A24.1	-4.31	1.96e-05	0.00187	-0.29	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85836362	chr11:85852557~85854943:-
THCA	cis	rs8105895	0.935	rs62111030	ENSG00000269345.1	VN1R85P	4.31	1.96e-05	0.00187	0.27	0.2	Body mass index (change over time);	chr19:22096573	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62111032	ENSG00000269345.1	VN1R85P	4.31	1.96e-05	0.00187	0.27	0.2	Body mass index (change over time);	chr19:22098547	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs959908	ENSG00000269345.1	VN1R85P	4.31	1.96e-05	0.00187	0.27	0.2	Body mass index (change over time);	chr19:22099091	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.867	rs12151358	ENSG00000269345.1	VN1R85P	4.31	1.96e-05	0.00187	0.27	0.2	Body mass index (change over time);	chr19:22099806	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62111034	ENSG00000269345.1	VN1R85P	4.31	1.96e-05	0.00187	0.27	0.2	Body mass index (change over time);	chr19:22101918	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.867	rs62111037	ENSG00000269345.1	VN1R85P	4.31	1.96e-05	0.00187	0.27	0.2	Body mass index (change over time);	chr19:22103761	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs7254050	ENSG00000269345.1	VN1R85P	4.31	1.96e-05	0.00187	0.27	0.2	Body mass index (change over time);	chr19:22103939	chr19:22174766~22175191:-
THCA	cis	rs12887734	0.546	rs4900597	ENSG00000269940.1	RP11-73M18.7	-4.31	1.96e-05	0.00187	-0.2	-0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103800327	chr14:103694560~103695170:+
THCA	cis	rs12887734	0.569	rs66953418	ENSG00000269940.1	RP11-73M18.7	4.31	1.96e-05	0.00187	0.2	0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103694560~103695170:+
THCA	cis	rs849141	0.524	rs849328	ENSG00000234336.5	JAZF1-AS1	-4.31	1.96e-05	0.00187	-0.32	-0.2	Height;Hip circumference adjusted for BMI;	chr7:28193789	chr7:28180322~28243917:+
THCA	cis	rs10266483	0.705	rs599522	ENSG00000228653.2	HNRNPCP7	-4.31	1.96e-05	0.00187	-0.17	-0.2	Response to statin therapy;	chr7:64298104	chr7:64500825~64501729:+
THCA	cis	rs875971	0.619	rs10278371	ENSG00000272831.1	RP11-792A8.4	-4.31	1.96e-05	0.00187	-0.12	-0.2	Aortic root size;	chr7:66586553	chr7:66739829~66740385:-
THCA	cis	rs875971	0.825	rs1000464	ENSG00000229886.1	RP5-1132H15.3	-4.31	1.96e-05	0.00187	-0.2	-0.2	Aortic root size;	chr7:66312922	chr7:66025126~66031544:-
THCA	cis	rs8177876	0.642	rs12445303	ENSG00000261061.1	RP11-303E16.2	4.31	1.96e-05	0.00187	0.27	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81030770~81031485:+
THCA	cis	rs2334880	0.61	rs8051767	ENSG00000260593.1	RP11-432I5.2	-4.31	1.96e-05	0.00187	-0.31	-0.2	Malaria;	chr16:71697817	chr16:71623708~71626816:-
THCA	cis	rs9307551	0.741	rs4101007	ENSG00000250334.4	LINC00989	-4.31	1.96e-05	0.00187	-0.26	-0.2	Refractive error;	chr4:79490540	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.741	rs880988	ENSG00000250334.4	LINC00989	-4.31	1.96e-05	0.00187	-0.26	-0.2	Refractive error;	chr4:79494318	chr4:79492416~79576460:+
THCA	cis	rs3785574	0.65	rs2320125	ENSG00000240280.5	TCAM1P	4.31	1.96e-05	0.00187	0.26	0.2	Height;	chr17:63930958	chr17:63849292~63864379:+
THCA	cis	rs1124769	0.672	rs12909760	ENSG00000259378.1	DCAF13P3	4.31	1.96e-05	0.00187	0.29	0.2	Cognitive performance;	chr15:50870064	chr15:50944663~50945996:+
THCA	cis	rs804280	0.565	rs2645453	ENSG00000255046.1	RP11-297N6.4	-4.31	1.96e-05	0.00187	-0.2	-0.2	Myopia (pathological);	chr8:11764492	chr8:11797928~11802568:-
THCA	cis	rs17270561	0.609	rs4131670	ENSG00000272462.2	U91328.19	-4.31	1.96e-05	0.00187	-0.17	-0.2	Iron status biomarkers;	chr6:25738391	chr6:25992662~26001775:+
THCA	cis	rs2278702	0.943	rs77271632	ENSG00000259495.2	RP11-210M15.2	-4.31	1.96e-05	0.00187	-0.28	-0.2	Bipolar disorder;	chr15:80396735	chr15:80344853~80403575:-
THCA	cis	rs13325613	0.834	rs34759782	ENSG00000223552.1	RP11-24F11.2	-4.31	1.96e-05	0.00187	-0.29	-0.2	Monocyte count;	chr3:46218953	chr3:46364955~46407059:-
THCA	cis	rs5751614	0.62	rs6003598	ENSG00000240160.3	RN7SL263P	4.31	1.96e-05	0.00187	0.23	0.2	Height;	chr22:23274529	chr22:23261782~23262071:-
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000273796.1	LL21NC02-21A1.1	-4.31	1.96e-05	0.00187	-0.22	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000182586.6	LINC00334	-4.31	1.96e-05	0.00187	-0.21	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45234340~45258730:+
THCA	cis	rs2562152	0.744	rs216597	ENSG00000226942.2	IL9RP3	-4.31	1.96e-05	0.00187	-0.26	-0.2	Glioblastoma;	chr16:56777	chr16:29336~38321:-
THCA	cis	rs1923243	0.71	rs4650188	ENSG00000223479.3	RP4-788P17.1	4.31	1.96e-05	0.00187	0.22	0.2	Migraine;	chr1:73114407	chr1:73635216~73715214:+
THCA	cis	rs10911902	0.643	rs17491733	ENSG00000229739.2	RP11-295K2.3	-4.31	1.96e-05	0.00187	-0.31	-0.2	Schizophrenia;	chr1:186402168	chr1:186435161~186470291:+
THCA	cis	rs5751614	0.537	rs9608100	ENSG00000240160.3	RN7SL263P	4.31	1.96e-05	0.00187	0.25	0.2	Height;	chr22:23290070	chr22:23261782~23262071:-
THCA	cis	rs7267979	0.718	rs2983489	ENSG00000274973.1	RP13-401N8.7	-4.31	1.96e-05	0.00187	-0.22	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25845497~25845862:+
THCA	cis	rs8067545	0.611	rs12936443	ENSG00000270091.1	RP11-78O7.2	-4.31	1.96e-05	0.00188	-0.15	-0.2	Schizophrenia;	chr17:20130133	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.611	rs6587219	ENSG00000270091.1	RP11-78O7.2	-4.31	1.96e-05	0.00188	-0.15	-0.2	Schizophrenia;	chr17:20131218	chr17:19896590~19897287:-
THCA	cis	rs12915845	0.545	rs4407042	ENSG00000271997.1	RP11-97O12.6	-4.31	1.96e-05	0.00188	-0.13	-0.2	Menarche (age at onset);	chr15:88534654	chr15:88501944~88505787:-
THCA	cis	rs73193808	0.614	rs2832251	ENSG00000176054.6	RPL23P2	4.31	1.96e-05	0.00188	0.18	0.2	Coronary artery disease;	chr21:29187231	chr21:28997613~28998033:-
THCA	cis	rs1046896	0.739	rs2379358	ENSG00000263063.1	RP11-388C12.1	-4.31	1.96e-05	0.00188	-0.25	-0.2	Glycated hemoglobin levels;	chr17:82783736	chr17:82713908~82716255:-
THCA	cis	rs72843506	0.722	rs74658636	ENSG00000261033.1	RP11-209D14.2	4.31	1.96e-05	0.00188	0.36	0.2	Schizophrenia;	chr17:20294669	chr17:20008051~20009234:-
THCA	cis	rs7665090	0.87	rs228614	ENSG00000248971.2	KRT8P46	4.31	1.96e-05	0.00188	0.24	0.2	Primary biliary cholangitis;	chr4:102657480	chr4:102728746~102730171:-
THCA	cis	rs5760092	0.572	rs738806	ENSG00000244425.3	RN7SL268P	-4.31	1.96e-05	0.00188	-0.19	-0.2	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23879493~23879790:-
THCA	cis	rs11722779	0.844	rs3974602	ENSG00000248971.2	KRT8P46	-4.31	1.96e-05	0.00188	-0.24	-0.2	Schizophrenia;	chr4:102928840	chr4:102728746~102730171:-
THCA	cis	rs2153535	0.518	rs9285977	ENSG00000230939.1	RP11-314C16.1	-4.31	1.96e-05	0.00188	-0.21	-0.2	Motion sickness;	chr6:8572052	chr6:8784178~8785445:+
THCA	cis	rs2304003	1	rs980231	ENSG00000235192.1	AC009495.2	4.31	1.97e-05	0.00188	0.27	0.2	Social communication problems;	chr2:165824612	chr2:165794851~165810010:+
THCA	cis	rs4792901	0.759	rs34409913	ENSG00000267151.3	RP11-100E5.2	4.31	1.97e-05	0.00188	0.21	0.2	Dupuytren's disease;	chr17:43486925	chr17:43444707~43451200:+
THCA	cis	rs1150668	0.83	rs2859365	ENSG00000176933.5	TOB2P1	4.31	1.97e-05	0.00188	0.21	0.2	Pubertal anthropometrics;	chr6:28423688	chr6:28217643~28218634:-
THCA	cis	rs889122	1	rs73018016	ENSG00000267289.1	CTD-2623N2.11	4.31	1.97e-05	0.00188	0.25	0.2	Menarche (age at onset);	chr19:9886685	chr19:9834079~9835013:-
THCA	cis	rs919433	0.679	rs10497806	ENSG00000231621.1	AC013264.2	-4.31	1.97e-05	0.00188	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197644227	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs10166328	ENSG00000231621.1	AC013264.2	-4.31	1.97e-05	0.00188	-0.21	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197647193	chr2:197197991~197199273:+
THCA	cis	rs1005277	0.502	rs2800484	ENSG00000272983.1	RP11-508N22.12	4.31	1.97e-05	0.00188	0.17	0.2	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38137337~38144399:+
THCA	cis	rs7772486	0.754	rs2328707	ENSG00000270638.1	RP3-466P17.1	-4.31	1.97e-05	0.00188	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145735570~145737218:+
THCA	cis	rs8059260	0.866	rs12922318	ENSG00000274038.1	RP11-66H6.4	-4.31	1.97e-05	0.00188	-0.27	-0.2	Alcohol consumption over the past year;	chr16:10946769	chr16:11056556~11057034:+
THCA	cis	rs4915077	0.803	rs12566129	ENSG00000230489.1	VAV3-AS1	4.31	1.97e-05	0.00188	0.3	0.2	Hypothyroidism;	chr1:107754587	chr1:107964443~107994607:+
THCA	cis	rs31251	0.9	rs11953786	ENSG00000224431.1	AC063976.7	4.31	1.97e-05	0.00188	0.16	0.2	Itch intensity from mosquito bite adjusted by bite size;	chr5:131735747	chr5:132199456~132203487:+
THCA	cis	rs11030122	0.959	rs10835236	ENSG00000230593.3	AC090804.1	4.31	1.97e-05	0.00188	0.26	0.2	Mean platelet volume;Platelet distribution width;	chr11:3884282	chr11:3892398~3892887:-
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000176700.18	SCAND2P	-4.31	1.97e-05	0.00188	-0.13	-0.2	P wave terminal force;	chr15:84632519	chr15:84631451~84647478:+
THCA	cis	rs4906332	1	rs28711288	ENSG00000269910.1	RP11-73M18.10	4.31	1.97e-05	0.00188	0.17	0.2	Coronary artery disease;	chr14:103439789	chr14:103694516~103695050:-
THCA	cis	rs875971	0.505	rs1723275	ENSG00000272831.1	RP11-792A8.4	-4.31	1.97e-05	0.00188	-0.12	-0.2	Aortic root size;	chr7:66039646	chr7:66739829~66740385:-
THCA	cis	rs758324	0.773	rs6870930	ENSG00000237714.1	P4HA2-AS1	-4.31	1.97e-05	0.00188	-0.27	-0.2	Alzheimer's disease in APOE e4- carriers;	chr5:131774432	chr5:132184876~132192808:+
THCA	cis	rs9900062	0.586	rs6504249	ENSG00000270714.1	MINOS1P2	-4.31	1.97e-05	0.00188	-0.27	-0.2	QT interval;	chr17:64680031	chr17:64747264~64747492:-
THCA	cis	rs10911902	0.643	rs16825150	ENSG00000229739.2	RP11-295K2.3	-4.31	1.97e-05	0.00188	-0.3	-0.2	Schizophrenia;	chr1:186306628	chr1:186435161~186470291:+
THCA	cis	rs72928364	1	rs62275198	ENSG00000256628.3	ZBTB11-AS1	4.31	1.97e-05	0.00188	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100969129	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs13088524	ENSG00000256628.3	ZBTB11-AS1	4.31	1.97e-05	0.00188	0.34	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100969238	chr3:101676475~101679217:+
THCA	cis	rs6472827	0.794	rs4439117	ENSG00000253983.2	RP1-16A9.1	4.31	1.97e-05	0.00188	0.32	0.2	Uterine fibroids;	chr8:74207475	chr8:74199396~74208441:+
THCA	cis	rs1923243	0.647	rs6657881	ENSG00000223479.3	RP4-788P17.1	4.31	1.97e-05	0.00188	0.22	0.2	Migraine;	chr1:73176944	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6657885	ENSG00000223479.3	RP4-788P17.1	4.31	1.97e-05	0.00188	0.22	0.2	Migraine;	chr1:73176947	chr1:73635216~73715214:+
THCA	cis	rs4948275	0.641	rs1378887	ENSG00000237233.2	TMEM26-AS1	-4.31	1.97e-05	0.00188	-0.25	-0.2	Night sleep phenotypes;	chr10:61561613	chr10:61452639~61481956:+
THCA	cis	rs5751901	0.614	rs5760489	ENSG00000215481.7	BCRP3	-4.31	1.97e-05	0.00188	-0.17	-0.2	Protein quantitative trait loci;	chr22:24594679	chr22:24632915~24653356:+
THCA	cis	rs7216064	0.953	rs75231441	ENSG00000278740.1	RP11-147L13.14	4.31	1.97e-05	0.00188	0.23	0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889369	chr17:68188547~68189165:+
THCA	cis	rs172166	0.516	rs1225618	ENSG00000280107.1	AL022393.9	-4.31	1.97e-05	0.00188	-0.19	-0.2	Cardiac Troponin-T levels;	chr6:28161935	chr6:28170845~28172521:+
THCA	cis	rs9925964	0.967	rs2855475	ENSG00000232748.3	RP11-196G11.6	-4.31	1.97e-05	0.00188	-0.23	-0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31136227	chr16:31056460~31062803:+
THCA	cis	rs9595908	0.568	rs61945198	ENSG00000212293.1	SNORA16	4.31	1.97e-05	0.00188	0.23	0.2	Body mass index;	chr13:32797780	chr13:32420390~32420516:-
THCA	cis	rs7829975	0.807	rs519019	ENSG00000254340.1	RP11-10A14.3	-4.31	1.97e-05	0.00188	-0.21	-0.2	Mood instability;	chr8:8737594	chr8:9141424~9145435:+
THCA	cis	rs11671005	0.779	rs3794971	ENSG00000268049.1	CTD-2619J13.9	-4.31	1.97e-05	0.00188	-0.3	-0.2	Mean platelet volume;	chr19:58474499	chr19:58357999~58359603:+
THCA	cis	rs3796352	1	rs11707780	ENSG00000242142.1	SERBP1P3	4.31	1.97e-05	0.00188	0.33	0.2	Immune reponse to smallpox (secreted IL-2);	chr3:53050310	chr3:53064283~53065091:-
THCA	cis	rs7216064	0.953	rs10445361	ENSG00000265055.1	AC145343.2	-4.31	1.97e-05	0.00188	-0.28	-0.2	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67966122	chr17:68096046~68101474:-
THCA	cis	rs7359257	0.576	rs11638507	ENSG00000270964.1	RP11-502I4.3	-4.31	1.97e-05	0.00188	-0.18	-0.2	Menarche (age at onset);	chr15:67581707	chr15:67541072~67542604:-
THCA	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	4.31	1.97e-05	0.00188	0.13	0.2	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
THCA	cis	rs9880211	0.898	rs6770476	ENSG00000239213.4	NCK1-AS1	4.31	1.97e-05	0.00188	0.18	0.2	Height;Body mass index;	chr3:136355078	chr3:136841726~136862054:-
THCA	cis	rs427691	0.545	rs25914	ENSG00000271849.1	CTC-332L22.1	-4.31	1.97e-05	0.00188	-0.27	-0.2	Autism spectrum disorder or schizophrenia;	chr5:109657320	chr5:109687802~109688329:-
THCA	cis	rs9549367	0.577	rs513479	ENSG00000269125.1	RP11-98F14.11	-4.31	1.97e-05	0.00188	-0.27	-0.2	Platelet distribution width;	chr13:113160886	chr13:113165002~113165183:-
THCA	cis	rs6921919	0.638	rs7772827	ENSG00000219392.1	RP1-265C24.5	-4.31	1.97e-05	0.00189	-0.22	-0.2	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28115628~28116551:+
THCA	cis	rs12681288	0.862	rs11996703	ENSG00000260721.1	AF067845.1	4.31	1.97e-05	0.00189	0.23	0.2	Schizophrenia;	chr8:1059093	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.832	rs2123060	ENSG00000260721.1	AF067845.1	4.31	1.97e-05	0.00189	0.23	0.2	Schizophrenia;	chr8:1059313	chr8:1368642~1369833:-
THCA	cis	rs2015599	0.549	rs7134796	ENSG00000273680.1	RP11-996F15.6	-4.31	1.97e-05	0.00189	-0.28	-0.2	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29332733~29333383:-
THCA	cis	rs227275	0.525	rs1383733	ENSG00000248971.2	KRT8P46	-4.31	1.97e-05	0.00189	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102728746~102730171:-
THCA	cis	rs4218	0.648	rs34407560	ENSG00000259732.1	RP11-59H7.3	-4.31	1.97e-05	0.00189	-0.27	-0.2	Social communication problems;	chr15:59073397	chr15:59121034~59133250:+
THCA	cis	rs9905704	0.624	rs4932691	ENSG00000224738.1	AC099850.1	-4.31	1.97e-05	0.00189	-0.24	-0.2	Testicular germ cell tumor;	chr17:59017256	chr17:59106598~59118267:+
THCA	cis	rs1728785	0.818	rs1069289	ENSG00000274698.1	RP11-71L14.4	4.31	1.97e-05	0.00189	0.28	0.2	Ulcerative colitis;	chr16:68551414	chr16:68450283~68452318:+
THCA	cis	rs4908768	0.906	rs11121182	ENSG00000232912.4	RP5-1115A15.1	-4.31	1.97e-05	0.00189	-0.24	-0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8462493	chr1:8424645~8434838:+
THCA	cis	rs7560272	0.538	rs4852975	ENSG00000273245.1	RP11-434P11.2	-4.31	1.98e-05	0.00189	-0.23	-0.2	Schizophrenia;	chr2:73705338	chr2:73750256~73750786:-
THCA	cis	rs138880	0.58	rs28562884	ENSG00000260613.1	RP3-522J7.6	-4.31	1.98e-05	0.00189	-0.32	-0.2	Schizophrenia;	chr22:49919221	chr22:49832616~49837786:-
THCA	cis	rs6840258	0.582	rs28670747	ENSG00000251411.1	RP11-397E7.4	-4.31	1.98e-05	0.00189	-0.23	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87157327	chr4:86913266~86914817:-
THCA	cis	rs6570726	0.791	rs440477	ENSG00000270638.1	RP3-466P17.1	4.31	1.98e-05	0.00189	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs385729	ENSG00000270638.1	RP3-466P17.1	4.31	1.98e-05	0.00189	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs7755253	ENSG00000270638.1	RP3-466P17.1	4.31	1.98e-05	0.00189	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.764	rs376257	ENSG00000270638.1	RP3-466P17.1	4.31	1.98e-05	0.00189	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.693	rs450921	ENSG00000270638.1	RP3-466P17.1	4.31	1.98e-05	0.00189	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs365747	ENSG00000270638.1	RP3-466P17.1	4.31	1.98e-05	0.00189	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145735570~145737218:+
THCA	cis	rs7829975	0.871	rs572307	ENSG00000253981.4	ALG1L13P	-4.31	1.98e-05	0.00189	-0.18	-0.2	Mood instability;	chr8:8721301	chr8:8236003~8244667:-
THCA	cis	rs6570726	0.791	rs370112	ENSG00000270638.1	RP3-466P17.1	4.31	1.98e-05	0.00189	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs427128	ENSG00000270638.1	RP3-466P17.1	4.31	1.98e-05	0.00189	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145735570~145737218:+
THCA	cis	rs2839186	0.77	rs2839984	ENSG00000215424.8	MCM3AP-AS1	4.31	1.98e-05	0.00189	0.11	0.2	Testicular germ cell tumor;	chr21:46251776	chr21:46229217~46259390:+
THCA	cis	rs5758511	0.773	rs8140869	ENSG00000281538.1	RP4-669P10.20	4.31	1.98e-05	0.00189	0.23	0.2	Birth weight;	chr22:41948293	chr22:42138060~42139726:+
THCA	cis	rs8105895	0.935	rs62111028	ENSG00000269345.1	VN1R85P	4.31	1.98e-05	0.00189	0.27	0.2	Body mass index (change over time);	chr19:22089595	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.733	rs62111029	ENSG00000269345.1	VN1R85P	4.31	1.98e-05	0.00189	0.27	0.2	Body mass index (change over time);	chr19:22093799	chr19:22174766~22175191:-
THCA	cis	rs10090774	0.965	rs4246124	ENSG00000279766.1	RP11-642A1.2	4.31	1.98e-05	0.00189	0.24	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140765238	chr8:140572142~140572812:-
THCA	cis	rs1728785	1	rs1170439	ENSG00000274698.1	RP11-71L14.4	4.31	1.98e-05	0.00189	0.28	0.2	Ulcerative colitis;	chr16:68574608	chr16:68450283~68452318:+
THCA	cis	rs9987353	0.518	rs4841110	ENSG00000253981.4	ALG1L13P	4.31	1.98e-05	0.00189	0.19	0.2	Recombination measurement;	chr8:9228513	chr8:8236003~8244667:-
THCA	cis	rs6472827	0.953	rs4455819	ENSG00000253983.2	RP1-16A9.1	-4.31	1.98e-05	0.00189	-0.33	-0.2	Uterine fibroids;	chr8:74210566	chr8:74199396~74208441:+
THCA	cis	rs12478296	0.901	rs7603560	ENSG00000261186.2	RP11-341N2.1	-4.31	1.98e-05	0.00189	-0.32	-0.2	Obesity-related traits;	chr2:242101105	chr2:242087351~242088457:-
THCA	cis	rs868036	0.718	rs3784710	ENSG00000270964.1	RP11-502I4.3	-4.31	1.98e-05	0.00189	-0.18	-0.2	Restless legs syndrome;	chr15:67780120	chr15:67541072~67542604:-
THCA	cis	rs6121246	0.909	rs6058450	ENSG00000230613.1	HM13-AS1	4.31	1.98e-05	0.00189	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31756108	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6060929	ENSG00000230613.1	HM13-AS1	4.31	1.98e-05	0.00189	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31758111	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6119720	ENSG00000230613.1	HM13-AS1	4.31	1.98e-05	0.00189	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31759765	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.909	rs6087778	ENSG00000230613.1	HM13-AS1	4.31	1.98e-05	0.00189	0.21	0.2	Mean corpuscular hemoglobin;	chr20:31766339	chr20:31567707~31573263:-
THCA	cis	rs911555	0.755	rs6575988	ENSG00000269910.1	RP11-73M18.10	-4.31	1.98e-05	0.00189	-0.18	-0.2	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103694516~103695050:-
THCA	cis	rs17685	0.753	rs1637039	ENSG00000230882.1	AC005077.14	4.31	1.98e-05	0.00189	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76063691	chr7:76071469~76074963:-
THCA	cis	rs4767841	0.625	rs574155	ENSG00000248636.5	RP11-768F21.1	-4.31	1.98e-05	0.00189	-0.2	-0.2	Urgency urinary incontinence;	chr12:119790006	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.537	rs574142	ENSG00000248636.5	RP11-768F21.1	-4.31	1.98e-05	0.00189	-0.2	-0.2	Urgency urinary incontinence;	chr12:119790010	chr12:119387987~119668079:-
THCA	cis	rs189218934	1	rs189218934	ENSG00000261143.1	ADAMTS7P3	4.31	1.98e-05	0.00189	0.27	0.2	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78611645	chr15:77976042~77993057:+
THCA	cis	rs8050907	0.744	rs12446765	ENSG00000278434.1	RP11-709D24.8	-4.31	1.98e-05	0.00189	-0.44	-0.2	Obesity-related traits;	chr16:4519624	chr16:4532216~4533670:-
THCA	cis	rs3096299	0.642	rs12934829	ENSG00000261118.1	RP11-104N10.1	4.31	1.98e-05	0.00189	0.16	0.2	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89492017~89504460:-
THCA	cis	rs7200786	0.692	rs8054758	ENSG00000274038.1	RP11-66H6.4	-4.31	1.98e-05	0.00189	-0.24	-0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10997269	chr16:11056556~11057034:+
THCA	cis	rs1414896	0.692	rs67380262	ENSG00000226026.4	RP11-57H12.3	4.31	1.98e-05	0.00189	0.18	0.2	Non-alcoholic fatty liver disease histology (AST);	chr1:95241661	chr1:95163219~95233982:-
THCA	cis	rs57502260	0.573	rs11228294	ENSG00000212093.1	AP000807.1	4.31	1.98e-05	0.00189	0.22	0.2	Total body bone mineral density (age 45-60);	chr11:68621099	chr11:68506083~68506166:-
THCA	cis	rs4578769	0.959	rs12964817	ENSG00000265939.1	UBE2CP2	4.31	1.98e-05	0.00189	0.24	0.2	Eosinophil percentage of white cells;	chr18:22876657	chr18:22900486~22900995:-
THCA	cis	rs2380220	0.808	rs2716074	ENSG00000261366.1	MANEA-AS1	4.31	1.98e-05	0.00189	0.23	0.2	Behavioural disinhibition (generation interaction);	chr6:95459786	chr6:95575183~95577450:-
THCA	cis	rs28735056	0.967	rs4799092	ENSG00000261126.6	RP11-795F19.1	-4.31	1.98e-05	0.00189	-0.16	-0.2	Schizophrenia;	chr18:79848203	chr18:80046900~80095482:+
THCA	cis	rs7586085	0.868	rs13430211	ENSG00000232411.1	AC009495.3	-4.31	1.98e-05	0.00189	-0.21	-0.2	Total body bone mineral density;	chr2:165766088	chr2:165833048~165839098:-
THCA	cis	rs10484434	0.818	rs6906460	ENSG00000272810.1	U91328.22	4.31	1.98e-05	0.00189	0.19	0.2	HIV-1 viral setpoint;	chr6:25977133	chr6:26013241~26013757:+
THCA	cis	rs1129187	1	rs1129187	ENSG00000272223.1	RP1-20C7.6	4.31	1.98e-05	0.00189	0.15	0.2	Alzheimer's disease in APOE e4+ carriers;	chr6:42964462	chr6:43033897~43034405:-
THCA	cis	rs9863	0.861	rs10846579	ENSG00000270028.1	RP11-380L11.4	4.31	1.98e-05	0.00189	0.21	0.2	White blood cell count;	chr12:123922856	chr12:123925461~123926083:-
THCA	cis	rs9863	0.861	rs11057394	ENSG00000270028.1	RP11-380L11.4	4.31	1.98e-05	0.00189	0.21	0.2	White blood cell count;	chr12:123923129	chr12:123925461~123926083:-
THCA	cis	rs9863	0.861	rs12809125	ENSG00000270028.1	RP11-380L11.4	4.31	1.98e-05	0.00189	0.21	0.2	White blood cell count;	chr12:123923444	chr12:123925461~123926083:-
THCA	cis	rs6908034	0.6	rs6901079	ENSG00000228412.5	RP4-625H18.2	4.31	1.98e-05	0.00189	0.27	0.2	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19776428	chr6:19802164~19804752:-
THCA	cis	rs10875746	0.951	rs10875747	ENSG00000258273.1	RP11-370I10.4	4.31	1.98e-05	0.00189	0.28	0.2	Longevity (90 years and older);	chr12:48132078	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.951	rs10875748	ENSG00000258273.1	RP11-370I10.4	4.31	1.98e-05	0.00189	0.28	0.2	Longevity (90 years and older);	chr12:48132577	chr12:48333755~48333901:-
THCA	cis	rs1232027	0.7	rs1677626	ENSG00000249655.1	CTC-325J23.2	-4.31	1.98e-05	0.00189	-0.22	-0.2	Huntington's disease progression;	chr5:80653626	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs2560424	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80629486	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs2618372	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80629791	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1623489	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80630296	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1677636	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80630307	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.632	rs60244599	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80630608	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677634	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80632505	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643636	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80632948	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.632	rs1650718	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80634457	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.632	rs1677706	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80634484	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.632	rs1677701	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80635513	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677700	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80635600	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs67837398	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80636677	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs71578847	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80636685	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643662	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80637416	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643661	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80637757	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643660	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80638208	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643659	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80639017	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677696	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80639198	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1650710	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80640342	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643658	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80640522	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677687	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80642517	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1677686	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80642709	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643647	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80642749	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643648	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80642796	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1677685	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80643122	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643649	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80643630	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643650	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80644324	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs58490646	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80644715	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs865647	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80646457	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs34965641	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80646557	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs844370	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80647183	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs836822	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80647957	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs865645	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80648285	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1650701	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80648612	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1650700	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80648613	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs836818	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80652137	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.632	rs863215	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80652186	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs861373	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80652243	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1643646	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80652822	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677670	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80652835	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1478834	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80653756	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1478835	ENSG00000249655.1	CTC-325J23.2	4.31	1.98e-05	0.00189	0.22	0.2	Huntington's disease progression;	chr5:80653781	chr5:80630313~80631590:-
THCA	cis	rs1682859	0.601	rs329672	ENSG00000280237.1	MIR4697HG	4.31	1.98e-05	0.00189	0.17	0.2	Obesity-related traits;	chr11:133929237	chr11:133896438~133901601:-
THCA	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	4.31	1.98e-05	0.00189	0.23	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
THCA	cis	rs227275	0.525	rs7685399	ENSG00000248971.2	KRT8P46	-4.31	1.98e-05	0.00189	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102728746~102730171:-
THCA	cis	rs227275	0.525	rs7688940	ENSG00000248971.2	KRT8P46	-4.31	1.98e-05	0.00189	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102728746~102730171:-
THCA	cis	rs4578769	0.569	rs9955139	ENSG00000265939.1	UBE2CP2	4.31	1.98e-05	0.00189	0.23	0.2	Eosinophil percentage of white cells;	chr18:23048189	chr18:22900486~22900995:-
THCA	cis	rs2898290	0.622	rs978803	ENSG00000251402.3	FAM90A25P	4.31	1.98e-05	0.00189	0.25	0.2	Systolic blood pressure;	chr8:11485966	chr8:12415080~12418090:-
THCA	cis	rs4748857	0.502	rs6482272	ENSG00000224215.1	RP11-371A19.2	-4.31	1.98e-05	0.00189	-0.22	-0.2	Systemic lupus erythematosus;	chr10:23386909	chr10:23343957~23345181:+
THCA	cis	rs7182948	0.874	rs17404262	ENSG00000259531.2	RP11-295H24.3	4.31	1.98e-05	0.00189	0.26	0.2	Lung adenocarcinoma;	chr15:49675422	chr15:49365124~49366685:-
THCA	cis	rs9532669	0.963	rs4942012	ENSG00000229473.2	RGS17P1	4.31	1.98e-05	0.00189	0.24	0.2	Cervical cancer;	chr13:40939112	chr13:40992779~40993331:-
THCA	cis	rs61270009	0.913	rs396676	ENSG00000247828.6	TMEM161B-AS1	-4.31	1.98e-05	0.00189	-0.17	-0.2	Depressive symptoms;	chr5:88220002	chr5:88268895~88436685:+
THCA	cis	rs6430585	0.527	rs1900306	ENSG00000231890.6	DARS-AS1	-4.31	1.98e-05	0.00189	-0.23	-0.2	Corneal structure;	chr2:135658963	chr2:135985176~136022593:+
THCA	cis	rs7429990	0.965	rs17785248	ENSG00000228638.1	FCF1P2	-4.31	1.98e-05	0.00189	-0.21	-0.2	Educational attainment (years of education);	chr3:47631425	chr3:48290793~48291375:-
THCA	cis	rs2342371	0.848	rs5016648	ENSG00000273013.1	CTD-2002J20.1	4.31	1.98e-05	0.00189	0.19	0.2	Fat distribution (HIV);	chr3:196481118	chr3:196474801~196475394:+
THCA	cis	rs2342371	0.848	rs9864836	ENSG00000273013.1	CTD-2002J20.1	-4.31	1.98e-05	0.00189	-0.19	-0.2	Fat distribution (HIV);	chr3:196473866	chr3:196474801~196475394:+
THCA	cis	rs7845219	0.51	rs10113282	ENSG00000253528.2	RP11-347C18.4	4.31	1.98e-05	0.00189	0.22	0.2	Type 2 diabetes;	chr8:95026024	chr8:94974573~94974853:-
THCA	cis	rs17801127	0.748	rs78209888	ENSG00000231969.1	AC144449.1	4.31	1.98e-05	0.00189	0.33	0.2	Liver enzyme levels (alanine transaminase);	chr2:149668565	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.818	rs16827316	ENSG00000231969.1	AC144449.1	4.31	1.98e-05	0.00189	0.33	0.2	Liver enzyme levels (alanine transaminase);	chr2:149674565	chr2:149587196~149848233:+
THCA	cis	rs7674212	0.556	rs6533039	ENSG00000248971.2	KRT8P46	-4.31	1.99e-05	0.0019	-0.24	-0.2	Type 2 diabetes;	chr4:102938381	chr4:102728746~102730171:-
THCA	cis	rs7809799	0.571	rs67546174	ENSG00000244219.5	GS1-259H13.2	-4.31	1.99e-05	0.0019	-0.43	-0.2	Ulcerative colitis;	chr7:99340631	chr7:99598066~99610813:+
THCA	cis	rs2692947	0.537	rs1345917	ENSG00000235959.1	AC009237.17	-4.31	1.99e-05	0.0019	-0.22	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95534855	chr2:95640181~95640604:-
THCA	cis	rs7924176	0.564	rs12572820	ENSG00000213731.2	RAB5CP1	-4.31	1.99e-05	0.0019	-0.23	-0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74117387	chr10:74423435~74424014:-
THCA	cis	rs7973683	0.541	rs6488910	ENSG00000270061.1	RP11-214K3.19	-4.31	1.99e-05	0.0019	-0.24	-0.19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123909150	chr12:123969990~123970344:-
THCA	cis	rs7267979	0.844	rs6083845	ENSG00000277938.1	RP5-965G21.3	-4.31	1.99e-05	0.0019	-0.16	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25229150~25231933:+
THCA	cis	rs2898290	0.622	rs13272061	ENSG00000227888.4	FAM66A	-4.31	1.99e-05	0.0019	-0.25	-0.19	Systolic blood pressure;	chr8:11494752	chr8:12362019~12388296:+
THCA	cis	rs8113308	0.81	rs55810059	ENSG00000269483.1	AC006272.1	4.31	1.99e-05	0.0019	0.33	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51947475	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs7255377	ENSG00000269483.1	AC006272.1	4.31	1.99e-05	0.0019	0.33	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948085	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.81	rs7254930	ENSG00000269483.1	AC006272.1	4.31	1.99e-05	0.0019	0.33	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948274	chr19:51839924~51843324:-
THCA	cis	rs713587	0.571	rs475868	ENSG00000224165.4	DNAJC27-AS1	4.31	1.99e-05	0.0019	0.11	0.19	Body mass index in non-asthmatics;	chr2:25095190	chr2:24971390~25039694:+
THCA	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-4.31	1.99e-05	0.0019	-0.25	-0.19	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
THCA	cis	rs3785574	0.65	rs2070776	ENSG00000240280.5	TCAM1P	4.31	1.99e-05	0.0019	0.26	0.19	Height;	chr17:63930138	chr17:63849292~63864379:+
THCA	cis	rs4705962	0.878	rs7734673	ENSG00000230612.2	AC004237.1	4.31	1.99e-05	0.0019	0.24	0.19	Atopic dermatitis;	chr5:132722774	chr5:132688681~132723725:+
THCA	cis	rs7572733	0.515	rs1518368	ENSG00000231621.1	AC013264.2	-4.31	1.99e-05	0.0019	-0.21	-0.19	Dermatomyositis;	chr2:197974421	chr2:197197991~197199273:+
THCA	cis	rs10510102	0.516	rs11200301	ENSG00000226864.1	ATE1-AS1	4.31	1.99e-05	0.0019	0.32	0.19	Breast cancer;	chr10:121977976	chr10:121928312~121951965:+
THCA	cis	rs734999	0.545	rs41300092	ENSG00000225931.3	RP3-395M20.7	4.31	1.99e-05	0.0019	0.23	0.19	Ulcerative colitis;	chr1:2606399	chr1:2566410~2569888:+
THCA	cis	rs734999	0.545	rs10910105	ENSG00000225931.3	RP3-395M20.7	4.31	1.99e-05	0.0019	0.23	0.19	Ulcerative colitis;	chr1:2606770	chr1:2566410~2569888:+
THCA	cis	rs734999	0.545	rs10797436	ENSG00000225931.3	RP3-395M20.7	4.31	1.99e-05	0.0019	0.23	0.19	Ulcerative colitis;	chr1:2606910	chr1:2566410~2569888:+
THCA	cis	rs734999	0.545	rs10910106	ENSG00000225931.3	RP3-395M20.7	4.31	1.99e-05	0.0019	0.23	0.19	Ulcerative colitis;	chr1:2607447	chr1:2566410~2569888:+
THCA	cis	rs9532669	0.963	rs3736953	ENSG00000229473.2	RGS17P1	4.31	1.99e-05	0.0019	0.24	0.19	Cervical cancer;	chr13:40951450	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7322399	ENSG00000229473.2	RGS17P1	4.31	1.99e-05	0.0019	0.24	0.19	Cervical cancer;	chr13:40952511	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7322097	ENSG00000229473.2	RGS17P1	4.31	1.99e-05	0.0019	0.24	0.19	Cervical cancer;	chr13:40952513	chr13:40992779~40993331:-
THCA	cis	rs7829975	0.577	rs940030	ENSG00000254153.1	CTA-398F10.2	4.31	1.99e-05	0.0019	0.22	0.19	Mood instability;	chr8:8689418	chr8:8456909~8461337:-
THCA	cis	rs853679	0.882	rs4713140	ENSG00000273712.1	RP5-874C20.7	4.31	1.99e-05	0.0019	0.33	0.19	Depression;	chr6:28129415	chr6:28315613~28315883:-
THCA	cis	rs2235642	1	rs2235642	ENSG00000260989.1	LA16c-395F10.2	-4.31	1.99e-05	0.0019	-0.2	-0.19	Coronary artery disease;	chr16:1534865	chr16:1580527~1610328:+
THCA	cis	rs28735056	1	rs56376220	ENSG00000261126.6	RP11-795F19.1	-4.31	1.99e-05	0.0019	-0.16	-0.19	Schizophrenia;	chr18:79849462	chr18:80046900~80095482:+
THCA	cis	rs11157436	1	rs12587166	ENSG00000211812.1	TRAV26-2	-4.31	1.99e-05	0.0019	-0.18	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22202583~22203368:+
THCA	cis	rs111756027	0.732	rs67583150	ENSG00000260922.1	RP11-538I12.3	4.31	1.99e-05	0.0019	0.28	0.19	Bone mineral density (Ward's triangle area);	chr16:77270040	chr16:77234877~77290934:+
THCA	cis	rs7045881	0.8	rs62544406	ENSG00000254396.1	RP11-56F10.3	4.31	1.99e-05	0.0019	0.34	0.19	Schizophrenia;	chr9:26872767	chr9:27102630~27104728:+
THCA	cis	rs2836974	0.666	rs12626405	ENSG00000255568.3	BRWD1-AS2	-4.31	1.99e-05	0.0019	-0.16	-0.19	Cognitive function;	chr21:39291195	chr21:39313935~39314962:+
THCA	cis	rs7586085	0.903	rs12692777	ENSG00000232411.1	AC009495.3	-4.31	1.99e-05	0.0019	-0.22	-0.19	Total body bone mineral density;	chr2:165766678	chr2:165833048~165839098:-
THCA	cis	rs67478160	0.572	rs8015603	ENSG00000269940.1	RP11-73M18.7	4.31	1.99e-05	0.0019	0.19	0.19	Schizophrenia;	chr14:103827341	chr14:103694560~103695170:+
THCA	cis	rs7688540	0.511	rs61794969	ENSG00000211553.1	AC253576.2	-4.31	2e-05	0.0019	-0.3	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:136461~136568:+
THCA	cis	rs17095355	1	rs12571674	ENSG00000203876.8	ADD3-AS1	4.31	2e-05	0.0019	0.22	0.19	Biliary atresia;	chr10:109957850	chr10:109940104~110008381:-
THCA	cis	rs60180747	0.909	rs17200912	ENSG00000261318.1	RP11-653J6.1	4.31	2e-05	0.0019	0.27	0.19	Testicular germ cell tumor;	chr15:66437969	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.909	rs17200970	ENSG00000261318.1	RP11-653J6.1	4.31	2e-05	0.0019	0.27	0.19	Testicular germ cell tumor;	chr15:66438707	chr15:66278498~66293357:-
THCA	cis	rs9828933	0.701	rs7621544	ENSG00000224479.4	AC136289.1	4.31	2e-05	0.0019	0.28	0.19	Type 2 diabetes;	chr3:63943005	chr3:63742293~63827445:-
THCA	cis	rs875971	0.545	rs316306	ENSG00000273142.1	RP11-458F8.4	-4.31	2e-05	0.0019	-0.18	-0.19	Aortic root size;	chr7:66153687	chr7:66902857~66906297:+
THCA	cis	rs7899106	1	rs116841464	ENSG00000270002.1	RP11-93H12.4	4.31	2e-05	0.0019	0.34	0.19	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85607805	chr10:85644073~85648066:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000275400.1	RP4-756H11.5	-4.31	2e-05	0.0019	-0.21	-0.19	Corneal structure;	chr7:66911108	chr7:66553805~66554199:-
THCA	cis	rs7246657	0.551	rs10407224	ENSG00000226686.6	LINC01535	-4.31	2e-05	0.0019	-0.35	-0.19	Coronary artery calcification;	chr19:37160568	chr19:37251912~37265535:+
THCA	cis	rs1124769	0.57	rs7181593	ENSG00000259378.1	DCAF13P3	-4.31	2e-05	0.0019	-0.27	-0.19	Cognitive performance;	chr15:50853917	chr15:50944663~50945996:+
THCA	cis	rs9368222	1	rs9368222	ENSG00000280989.1	LINC00581	4.31	2e-05	0.0019	0.27	0.19	Body mass index;Peak insulin response;Acute insulin response;	chr6:20686765	chr6:21486061~21511895:-
THCA	cis	rs17428076	0.514	rs3821095	ENSG00000228389.1	AC068039.4	4.31	2e-05	0.0019	0.2	0.19	Myopia;	chr2:171827496	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.791	rs9322029	ENSG00000270638.1	RP3-466P17.1	4.31	2e-05	0.00191	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs9403730	ENSG00000270638.1	RP3-466P17.1	4.31	2e-05	0.00191	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145735570~145737218:+
THCA	cis	rs9928842	0.77	rs4888364	ENSG00000261783.1	RP11-252K23.2	4.31	2e-05	0.00191	0.37	0.19	Alcoholic chronic pancreatitis;	chr16:75245612	chr16:75379818~75381260:-
THCA	cis	rs6088590	0.561	rs764597	ENSG00000276073.1	RP5-1125A11.7	-4.31	2e-05	0.00191	-0.17	-0.19	Coronary artery disease;	chr20:34573421	chr20:33985617~33988989:-
THCA	cis	rs55702914	0.935	rs17405525	ENSG00000231621.1	AC013264.2	4.31	2e-05	0.00191	0.19	0.19	Major depression and alcohol dependence;	chr2:197349459	chr2:197197991~197199273:+
THCA	cis	rs734999	0.545	rs897628	ENSG00000225931.3	RP3-395M20.7	4.31	2e-05	0.00191	0.24	0.19	Ulcerative colitis;	chr1:2800059	chr1:2566410~2569888:+
THCA	cis	rs7918232	1	rs7918232	ENSG00000262412.1	RP11-85G18.6	4.31	2e-05	0.00191	0.28	0.19	Breast cancer;	chr10:27080233	chr10:27243130~27250804:+
THCA	cis	rs10510102	0.516	rs11200300	ENSG00000226864.1	ATE1-AS1	4.31	2e-05	0.00191	0.33	0.19	Breast cancer;	chr10:121977489	chr10:121928312~121951965:+
THCA	cis	rs1232027	0.656	rs1677703	ENSG00000249655.1	CTC-325J23.2	4.31	2e-05	0.00191	0.22	0.19	Huntington's disease progression;	chr5:80661918	chr5:80630313~80631590:-
THCA	cis	rs9510787	0.538	rs9783554	ENSG00000205861.10	C1QTNF9B-AS1	-4.31	2e-05	0.00191	-0.26	-0.19	Nasopharyngeal carcinoma;	chr13:23649965	chr13:23888889~23897263:+
THCA	cis	rs9510787	0.538	rs993737	ENSG00000205861.10	C1QTNF9B-AS1	-4.31	2e-05	0.00191	-0.26	-0.19	Nasopharyngeal carcinoma;	chr13:23652543	chr13:23888889~23897263:+
THCA	cis	rs2898290	0.622	rs978802	ENSG00000251402.3	FAM90A25P	-4.31	2e-05	0.00191	-0.25	-0.19	Systolic blood pressure;	chr8:11485769	chr8:12415080~12418090:-
THCA	cis	rs11242704	0.632	rs57995235	ENSG00000272279.1	RP11-157J24.2	-4.31	2e-05	0.00191	-0.32	-0.19	Response to hepatitis C treatment;	chr6:1530716	chr6:1528364~1528911:-
THCA	cis	rs7614311	0.636	rs3733126	ENSG00000271843.1	RP11-245J9.5	-4.31	2e-05	0.00191	-0.3	-0.19	Lung function (FVC);Lung function (FEV1);	chr3:64002495	chr3:64008082~64008692:-
THCA	cis	rs10932886	1	rs10932886	ENSG00000224819.1	AC093843.1	4.31	2e-05	0.00191	0.19	0.19	Brain imaging;	chr2:220855368	chr2:220791078~220797893:+
THCA	cis	rs2153535	1	rs11243251	ENSG00000230939.1	RP11-314C16.1	4.31	2e-05	0.00191	0.21	0.19	Motion sickness;	chr6:8367974	chr6:8784178~8785445:+
THCA	cis	rs2749592	0.725	rs9417245	ENSG00000263064.2	RP11-291L22.7	-4.31	2e-05	0.00191	-0.24	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37537394	chr10:38448689~38448949:+
THCA	cis	rs6479901	0.557	rs12773283	ENSG00000272767.1	JMJD1C-AS1	-4.31	2e-05	0.00191	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63465229~63466563:+
THCA	cis	rs12022452	0.908	rs4660423	ENSG00000237899.1	RP4-739H11.3	-4.31	2e-05	0.00191	-0.32	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40669089~40687588:-
THCA	cis	rs2278702	0.943	rs17315116	ENSG00000259495.2	RP11-210M15.2	-4.31	2e-05	0.00191	-0.28	-0.19	Bipolar disorder;	chr15:80396263	chr15:80344853~80403575:-
THCA	cis	rs6683071	0.689	rs12063226	ENSG00000225265.1	TAF1A-AS1	4.31	2e-05	0.00191	0.24	0.19	Cognitive performance;	chr1:222753913	chr1:222589825~222593032:+
THCA	cis	rs6088813	1	rs56306402	ENSG00000279253.1	RP4-614O4.13	4.31	2e-05	0.00191	0.19	0.19	Height;	chr20:35349901	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.885	rs6142353	ENSG00000279253.1	RP4-614O4.13	4.31	2e-05	0.00191	0.19	0.19	Height;	chr20:35354882	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs735531	ENSG00000279253.1	RP4-614O4.13	4.31	2e-05	0.00191	0.19	0.19	Height;	chr20:35359927	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs62211529	ENSG00000279253.1	RP4-614O4.13	4.31	2e-05	0.00191	0.19	0.19	Height;	chr20:35371512	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6142369	ENSG00000279253.1	RP4-614O4.13	4.31	2e-05	0.00191	0.19	0.19	Height;	chr20:35385512	chr20:35262727~35264187:-
THCA	cis	rs10256972	0.552	rs7805591	ENSG00000225146.1	AC073957.15	4.31	2e-05	0.00191	0.21	0.19	Endometriosis;Longevity;	chr7:1171109	chr7:1029025~1043891:+
THCA	cis	rs7474896	0.515	rs594594	ENSG00000120555.12	SEPT7P9	-4.31	2e-05	0.00191	-0.26	-0.19	Obesity (extreme);	chr10:38018795	chr10:38383069~38402916:-
THCA	cis	rs12216545	0.765	rs2204129	ENSG00000241134.3	BET1P1	-4.31	2e-05	0.00191	-0.23	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150554351	chr7:150749736~150750094:+
THCA	cis	rs4845570	1	rs3790514	ENSG00000249602.1	RP11-98D18.3	-4.31	2e-05	0.00191	-0.29	-0.19	Coronary artery disease;	chr1:151771692	chr1:151763384~151769501:-
THCA	cis	rs875971	0.862	rs1968126	ENSG00000229886.1	RP5-1132H15.3	-4.31	2e-05	0.00191	-0.2	-0.19	Aortic root size;	chr7:66592017	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6460306	ENSG00000229886.1	RP5-1132H15.3	-4.31	2e-05	0.00191	-0.2	-0.19	Aortic root size;	chr7:66595806	chr7:66025126~66031544:-
THCA	cis	rs3764021	0.87	rs10772085	ENSG00000256594.6	RP11-705C15.2	4.31	2e-05	0.00191	0.15	0.19	Type 1 diabetes;	chr12:9724281	chr12:9633419~9658412:+
THCA	cis	rs1979679	0.842	rs4931727	ENSG00000247934.4	RP11-967K21.1	-4.31	2e-05	0.00191	-0.19	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146186	chr12:28163298~28190738:-
THCA	cis	rs11148252	0.508	rs11148260	ENSG00000273784.3	RP11-78J21.7	-4.31	2e-05	0.00191	-0.2	-0.19	Lewy body disease;	chr13:52588508	chr13:52600042~52642542:+
THCA	cis	rs2886497	0.947	rs1995980	ENSG00000224215.1	RP11-371A19.2	4.31	2e-05	0.00191	0.25	0.19	Major depression and alcohol dependence;	chr10:23378666	chr10:23343957~23345181:+
THCA	cis	rs2554380	0.628	rs6602990	ENSG00000176700.18	SCAND2P	-4.31	2e-05	0.00191	-0.14	-0.19	Height;	chr15:83783470	chr15:84631451~84647478:+
THCA	cis	rs957448	0.687	rs10104041	ENSG00000253175.1	RP11-267M23.6	4.31	2e-05	0.00191	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94565036~94565715:+
THCA	cis	rs2933343	0.553	rs35076317	ENSG00000261159.1	RP11-723O4.9	4.31	2e-05	0.00191	0.2	0.19	IgG glycosylation;	chr3:128996692	chr3:128859716~128860526:-
THCA	cis	rs962856	0.964	rs4671183	ENSG00000236780.4	AC078941.1	4.31	2e-05	0.00191	0.24	0.19	Pancreatic cancer;	chr2:67416545	chr2:67123357~67215319:-
THCA	cis	rs2281603	0.52	rs61985663	ENSG00000259116.1	RP11-973N13.4	-4.31	2e-05	0.00191	-0.17	-0.19	Lymphocyte counts;	chr14:64470986	chr14:64514154~64540368:-
THCA	cis	rs1046491	1	rs34322928	ENSG00000264964.1	RP11-888D10.3	4.31	2e-05	0.00191	0.33	0.19	Scarlet fever;	chr18:9259396	chr18:9315194~9334441:-
THCA	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	4.31	2.01e-05	0.00191	0.24	0.19	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
THCA	cis	rs1150668	0.796	rs2531832	ENSG00000176933.5	TOB2P1	-4.31	2.01e-05	0.00191	-0.21	-0.19	Pubertal anthropometrics;	chr6:28421445	chr6:28217643~28218634:-
THCA	cis	rs791590	0.941	rs12722489	ENSG00000229664.1	RP11-536K7.5	-4.31	2.01e-05	0.00191	-0.33	-0.19	Soluble interleukin-2 receptor subunit alpha;	chr10:6060049	chr10:6025978~6036427:+
THCA	cis	rs10484434	0.818	rs6935470	ENSG00000272810.1	U91328.22	4.31	2.01e-05	0.00191	0.19	0.19	HIV-1 viral setpoint;	chr6:25990590	chr6:26013241~26013757:+
THCA	cis	rs10484434	0.818	rs2051538	ENSG00000272810.1	U91328.22	4.31	2.01e-05	0.00191	0.19	0.19	HIV-1 viral setpoint;	chr6:25991392	chr6:26013241~26013757:+
THCA	cis	rs679515	1	rs679515	ENSG00000274245.1	RP11-357P18.2	-4.31	2.01e-05	0.00191	-0.25	-0.19	Alzheimer's disease in APOE e4+ carriers;	chr1:207577223	chr1:207372559~207373252:+
THCA	cis	rs465969	1	rs1407644	ENSG00000272356.1	RP5-1112D6.8	-4.31	2.01e-05	0.00191	-0.29	-0.19	Psoriasis;	chr6:111480895	chr6:111309203~111313517:+
THCA	cis	rs28510890	0.547	rs11853583	ENSG00000258676.4	RP11-386M24.3	4.31	2.01e-05	0.00191	0.22	0.19	Lung cancer in ever smokers;	chr15:92605846	chr15:92580829~92600545:+
THCA	cis	rs9625935	0.957	rs10048885	ENSG00000279159.1	RP3-394A18.1	-4.31	2.01e-05	0.00191	-0.15	-0.19	Tonsillectomy;	chr22:30184263	chr22:29978950~30028236:-
THCA	cis	rs6416877	0.731	rs12936625	ENSG00000277491.1	RP11-676J12.9	-4.31	2.01e-05	0.00191	-0.21	-0.19	Myeloid white cell count;	chr17:1434769	chr17:795306~795794:+
THCA	cis	rs9283706	0.607	rs11749164	ENSG00000229666.1	MAST4-AS1	-4.31	2.01e-05	0.00191	-0.27	-0.19	Coronary artery disease;	chr5:66998374	chr5:67001383~67003953:-
THCA	cis	rs8081395	0.775	rs2645482	ENSG00000267302.4	RP11-178C3.2	4.31	2.01e-05	0.00191	0.23	0.19	White blood cell count;	chr17:59865754	chr17:59964832~59996972:+
THCA	cis	rs8081395	0.805	rs2645485	ENSG00000267302.4	RP11-178C3.2	4.31	2.01e-05	0.00191	0.23	0.19	White blood cell count;	chr17:59866920	chr17:59964832~59996972:+
THCA	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-4.31	2.01e-05	0.00191	-0.23	-0.19	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
THCA	cis	rs607541	0.85	rs9672672	ENSG00000259520.4	CTD-2651B20.3	-4.31	2.01e-05	0.00191	-0.38	-0.19	Obesity-related traits;	chr15:45636853	chr15:45251580~45279251:-
THCA	cis	rs1930961	0.85	rs5996945	ENSG00000272942.1	CTA-246H3.12	4.31	2.01e-05	0.00192	0.32	0.19	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25434324~25435070:-
THCA	cis	rs2836974	0.59	rs9974757	ENSG00000255568.3	BRWD1-AS2	-4.31	2.01e-05	0.00192	-0.16	-0.19	Cognitive function;	chr21:39245318	chr21:39313935~39314962:+
THCA	cis	rs8024893	1	rs8038787	ENSG00000270055.1	CTD-3092A11.2	4.31	2.01e-05	0.00192	0.25	0.19	Red cell distribution width;	chr15:31246171	chr15:30487963~30490313:+
THCA	cis	rs78487399	0.808	rs17030998	ENSG00000234936.1	AC010883.5	4.31	2.01e-05	0.00192	0.27	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43531060	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs17031000	ENSG00000234936.1	AC010883.5	4.31	2.01e-05	0.00192	0.27	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43531486	chr2:43229573~43233394:+
THCA	cis	rs7560272	0.538	rs7599453	ENSG00000273245.1	RP11-434P11.2	-4.31	2.01e-05	0.00192	-0.22	-0.19	Schizophrenia;	chr2:73710774	chr2:73750256~73750786:-
THCA	cis	rs10875746	0.951	rs10875747	ENSG00000258234.1	RP11-370I10.2	4.31	2.01e-05	0.00192	0.23	0.19	Longevity (90 years and older);	chr12:48132078	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.951	rs10875748	ENSG00000258234.1	RP11-370I10.2	4.31	2.01e-05	0.00192	0.23	0.19	Longevity (90 years and older);	chr12:48132577	chr12:48231098~48284210:-
THCA	cis	rs459571	0.959	rs2520099	ENSG00000235106.7	LINC00094	4.31	2.01e-05	0.00192	0.17	0.19	Platelet distribution width;	chr9:134053017	chr9:134025439~134034666:+
THCA	cis	rs793571	0.502	rs395601	ENSG00000245975.2	RP11-30K9.6	4.31	2.01e-05	0.00192	0.18	0.19	Schizophrenia;	chr15:58770997	chr15:58768072~58770974:-
THCA	cis	rs227275	0.525	rs28845922	ENSG00000248971.2	KRT8P46	-4.31	2.01e-05	0.00192	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102728746~102730171:-
THCA	cis	rs763121	0.853	rs2413546	ENSG00000235209.1	CTA-150C2.13	4.31	2.01e-05	0.00192	0.26	0.19	Menopause (age at onset);	chr22:38710996	chr22:38921227~38924708:+
THCA	cis	rs763121	0.853	rs2413547	ENSG00000235209.1	CTA-150C2.13	4.31	2.01e-05	0.00192	0.26	0.19	Menopause (age at onset);	chr22:38711333	chr22:38921227~38924708:+
THCA	cis	rs4648045	0.647	rs230529	ENSG00000246560.2	RP11-10L12.4	4.31	2.01e-05	0.00192	0.23	0.19	Lymphocyte percentage of white cells;	chr4:102536261	chr4:102828055~102844075:+
THCA	cis	rs728616	0.51	rs34782759	ENSG00000225484.5	NUTM2B-AS1	-4.31	2.01e-05	0.00192	-0.34	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80435463	chr10:79663088~79826594:-
THCA	cis	rs7586673	0.578	rs6723840	ENSG00000235724.7	AC009299.2	-4.31	2.01e-05	0.00192	-0.22	-0.19	Intelligence (multi-trait analysis);	chr2:161023104	chr2:161222785~161308303:-
THCA	cis	rs7586673	0.578	rs6723841	ENSG00000235724.7	AC009299.2	-4.31	2.01e-05	0.00192	-0.22	-0.19	Intelligence (multi-trait analysis);	chr2:161023105	chr2:161222785~161308303:-
THCA	cis	rs6472827	0.904	rs2956031	ENSG00000253983.2	RP1-16A9.1	4.31	2.01e-05	0.00192	0.32	0.19	Uterine fibroids;	chr8:74203074	chr8:74199396~74208441:+
THCA	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-4.31	2.01e-05	0.00192	-0.22	-0.19	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
THCA	cis	rs11098499	0.863	rs6858592	ENSG00000249244.1	RP11-548H18.2	4.31	2.01e-05	0.00192	0.23	0.19	Corneal astigmatism;	chr4:119537537	chr4:119391831~119395335:-
THCA	cis	rs3764021	0.87	rs10844597	ENSG00000256594.6	RP11-705C15.2	4.31	2.01e-05	0.00192	0.15	0.19	Type 1 diabetes;	chr12:9722303	chr12:9633419~9658412:+
THCA	cis	rs55661361	0.679	rs12287365	ENSG00000255045.1	RP11-677M14.2	4.31	2.01e-05	0.00192	0.18	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742814	chr11:124744634~124746337:-
THCA	cis	rs7089973	0.61	rs11197023	ENSG00000236799.1	RP11-383C6.2	-4.31	2.01e-05	0.00192	-0.24	-0.19	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114996467	chr10:114994657~114996593:+
THCA	cis	rs71636778	0.584	rs36042864	ENSG00000260063.1	RP5-968P14.2	-4.31	2.01e-05	0.00192	-0.27	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26820453	chr1:26692132~26694131:-
THCA	cis	rs7665090	0.846	rs4496586	ENSG00000251288.2	RP11-10L12.2	-4.31	2.01e-05	0.00192	-0.25	-0.19	Primary biliary cholangitis;	chr4:102636154	chr4:102751401~102752641:+
THCA	cis	rs853679	0.599	rs149949	ENSG00000220721.1	OR1F12	4.31	2.02e-05	0.00192	0.31	0.19	Depression;	chr6:28043738	chr6:28073316~28074233:+
THCA	cis	rs11771526	1	rs11771526	ENSG00000272905.1	RP11-265E18.1	4.31	2.02e-05	0.00192	0.27	0.19	Body mass index;	chr7:32303006	chr7:32845394~32846061:+
THCA	cis	rs2120243	0.539	rs6801110	ENSG00000241770.1	RP11-555M1.3	-4.31	2.02e-05	0.00192	-0.26	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157366942	chr3:157163452~157169133:+
THCA	cis	rs74233809	1	rs12219304	ENSG00000272912.1	RP11-724N1.1	-4.31	2.02e-05	0.00192	-0.36	-0.19	Birth weight;	chr10:103171827	chr10:102914585~102915404:+
THCA	cis	rs2797160	0.547	rs10872298	ENSG00000226409.1	RP11-735G4.1	-4.31	2.02e-05	0.00192	-0.25	-0.19	Endometrial cancer;	chr6:125635202	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.547	rs9401836	ENSG00000226409.1	RP11-735G4.1	-4.31	2.02e-05	0.00192	-0.25	-0.19	Endometrial cancer;	chr6:125635590	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.547	rs9401837	ENSG00000226409.1	RP11-735G4.1	-4.31	2.02e-05	0.00192	-0.25	-0.19	Endometrial cancer;	chr6:125635707	chr6:125370211~125374324:-
THCA	cis	rs4803480	1	rs11882144	ENSG00000270164.1	LINC01480	-4.31	2.02e-05	0.00192	-0.2	-0.19	Schizophrenia;	chr19:41566244	chr19:41535183~41536904:+
THCA	cis	rs62158800	0.598	rs57147583	ENSG00000224568.1	AC096669.3	4.31	2.02e-05	0.00192	0.24	0.19	Facial morphology (factor 22);	chr2:107668603	chr2:107529487~107556326:+
THCA	cis	rs2554380	0.628	rs4843156	ENSG00000176700.18	SCAND2P	-4.31	2.02e-05	0.00192	-0.15	-0.19	Height;	chr15:83788593	chr15:84631451~84647478:+
THCA	cis	rs13325613	0.915	rs7651539	ENSG00000223552.1	RP11-24F11.2	4.31	2.02e-05	0.00192	0.29	0.19	Monocyte count;	chr3:46226588	chr3:46364955~46407059:-
THCA	cis	rs867186	0.925	rs6120844	ENSG00000126005.14	MMP24-AS1	-4.31	2.02e-05	0.00192	-0.25	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35132437	chr20:35216462~35278131:-
THCA	cis	rs2281636	1	rs10786569	ENSG00000233690.1	EBAG9P1	4.31	2.02e-05	0.00192	0.19	0.19	Obesity-related traits;	chr10:99753828	chr10:99697407~99697949:-
THCA	cis	rs3177980	0.529	rs549002	ENSG00000239494.2	RN7SL333P	-4.31	2.02e-05	0.00192	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr1:169920900	chr1:169859756~169860052:+
THCA	cis	rs4295623	0.559	rs4841600	ENSG00000270154.1	RP11-419I17.1	4.31	2.02e-05	0.00192	0.24	0.19	Morning vs. evening chronotype;	chr8:11830639	chr8:12476462~12477122:+
THCA	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-4.31	2.02e-05	0.00192	-0.22	-0.19	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
THCA	cis	rs8031584	0.958	rs61997079	ENSG00000270015.1	RP11-540B6.6	-4.31	2.02e-05	0.00192	-0.15	-0.19	Huntington's disease progression;	chr15:30946068	chr15:30926514~30928407:+
THCA	cis	rs11634944	1	rs4906940	ENSG00000257151.1	PWAR6	4.31	2.02e-05	0.00192	0.15	0.19	Interleukin-8 levels;	chr15:24956512	chr15:25031873~25036490:+
THCA	cis	rs62458065	0.513	rs787216	ENSG00000231952.3	DPY19L1P2	4.31	2.02e-05	0.00192	0.33	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32539279	chr7:32812757~32838570:+
THCA	cis	rs62458065	0.513	rs787220	ENSG00000231952.3	DPY19L1P2	4.31	2.02e-05	0.00192	0.33	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32541527	chr7:32812757~32838570:+
THCA	cis	rs9902453	0.765	rs34585141	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30009414	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs4528633	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30029118	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs7225686	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30029726	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs4547389	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30037750	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs55633288	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30041178	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.874	rs7220004	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30042530	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs11654983	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30043024	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs7218113	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30045112	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs7219456	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30047094	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.874	rs11653805	ENSG00000263370.1	RP11-68I3.5	-4.31	2.02e-05	0.00192	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30051258	chr17:29639627~29640825:+
THCA	cis	rs4792901	0.918	rs34012717	ENSG00000267151.3	RP11-100E5.2	4.31	2.02e-05	0.00192	0.2	0.19	Dupuytren's disease;	chr17:43557213	chr17:43444707~43451200:+
THCA	cis	rs181553	1	rs833521	ENSG00000266696.1	RP11-30L3.2	4.31	2.02e-05	0.00192	0.24	0.19	Hip circumference adjusted for BMI;	chr18:49041382	chr18:49205912~49208781:+
THCA	cis	rs55702914	0.746	rs4850425	ENSG00000231621.1	AC013264.2	4.31	2.02e-05	0.00193	0.19	0.19	Major depression and alcohol dependence;	chr2:197288062	chr2:197197991~197199273:+
THCA	cis	rs2380220	0.808	rs2380224	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95447677	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2386669	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95454245	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2263180	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95454433	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2716072	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95461897	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2613547	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95462435	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2613548	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95462683	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2716070	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95464499	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2716069	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95465100	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2613551	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95466864	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2613553	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95468828	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.808	rs2613554	ENSG00000261366.1	MANEA-AS1	4.31	2.02e-05	0.00193	0.22	0.19	Behavioural disinhibition (generation interaction);	chr6:95468906	chr6:95575183~95577450:-
THCA	cis	rs9863	0.861	rs12317176	ENSG00000270028.1	RP11-380L11.4	4.31	2.02e-05	0.00193	0.21	0.19	White blood cell count;	chr12:123920171	chr12:123925461~123926083:-
THCA	cis	rs12439619	0.739	rs4778988	ENSG00000259429.4	UBE2Q2P2	-4.31	2.02e-05	0.00193	-0.18	-0.19	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82355142~82420075:+
THCA	cis	rs35740288	0.77	rs62023931	ENSG00000259295.5	CSPG4P12	4.31	2.02e-05	0.00193	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85589521	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs11631018	ENSG00000259295.5	CSPG4P12	4.31	2.02e-05	0.00193	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85597303	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs1382534	ENSG00000259295.5	CSPG4P12	4.31	2.02e-05	0.00193	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85598939	chr15:85191438~85213905:+
THCA	cis	rs7196129	0.932	rs11574938	ENSG00000183604.13	SMG1P5	4.31	2.02e-05	0.00193	0.2	0.19	Monocyte count;	chr16:30474072	chr16:30267553~30335374:-
THCA	cis	rs12681288	0.792	rs4735972	ENSG00000260721.1	AF067845.1	4.31	2.02e-05	0.00193	0.22	0.19	Schizophrenia;	chr8:1048618	chr8:1368642~1369833:-
THCA	cis	rs6479891	0.908	rs7078456	ENSG00000272767.1	JMJD1C-AS1	-4.31	2.02e-05	0.00193	-0.27	-0.19	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63465229~63466563:+
THCA	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-4.31	2.02e-05	0.00193	-0.2	-0.19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
THCA	cis	rs56114371	0.53	rs9357045	ENSG00000226314.6	ZNF192P1	-4.31	2.02e-05	0.00193	-0.26	-0.19	Breast cancer;	chr6:27721148	chr6:28161781~28169594:+
THCA	cis	rs919433	0.647	rs1979239	ENSG00000231621.1	AC013264.2	-4.31	2.02e-05	0.00193	-0.21	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197633592	chr2:197197991~197199273:+
THCA	cis	rs9959145	1	rs9959145	ENSG00000267199.1	RP11-861E21.2	4.31	2.02e-05	0.00193	0.25	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12606464	chr18:12438890~12448205:+
THCA	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	4.31	2.02e-05	0.00193	0.23	0.19	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
THCA	cis	rs6728642	1	rs80303184	ENSG00000230606.9	AC159540.1	4.31	2.02e-05	0.00193	0.31	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97349066	chr2:97416165~97433527:-
THCA	cis	rs453301	0.686	rs17702602	ENSG00000233609.3	RP11-62H7.2	-4.31	2.03e-05	0.00193	-0.19	-0.19	Joint mobility (Beighton score);	chr8:9051086	chr8:8961200~8979025:+
THCA	cis	rs1923243	0.561	rs61765597	ENSG00000223479.3	RP4-788P17.1	4.31	2.03e-05	0.00193	0.22	0.19	Migraine;	chr1:73178186	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.561	rs61765598	ENSG00000223479.3	RP4-788P17.1	4.31	2.03e-05	0.00193	0.22	0.19	Migraine;	chr1:73178188	chr1:73635216~73715214:+
THCA	cis	rs4906332	1	rs2065015	ENSG00000269910.1	RP11-73M18.10	-4.31	2.03e-05	0.00193	-0.17	-0.19	Coronary artery disease;	chr14:103437724	chr14:103694516~103695050:-
THCA	cis	rs875971	0.638	rs10249404	ENSG00000272831.1	RP11-792A8.4	-4.31	2.03e-05	0.00193	-0.12	-0.19	Aortic root size;	chr7:66581737	chr7:66739829~66740385:-
THCA	cis	rs1923243	0.778	rs11210144	ENSG00000223479.3	RP4-788P17.1	-4.31	2.03e-05	0.00193	-0.21	-0.19	Migraine;	chr1:73152493	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.778	rs10399932	ENSG00000223479.3	RP4-788P17.1	-4.31	2.03e-05	0.00193	-0.21	-0.19	Migraine;	chr1:73153546	chr1:73635216~73715214:+
THCA	cis	rs2243480	0.522	rs73150635	ENSG00000228409.4	CCT6P1	4.31	2.03e-05	0.00193	0.29	0.19	Diabetic kidney disease;	chr7:66507503	chr7:65751142~65763354:+
THCA	cis	rs2287641	0.826	rs57220223	ENSG00000272156.1	RP11-477N3.1	4.31	2.03e-05	0.00193	0.36	0.19	Cannabis dependence symptom count;	chr2:54050046	chr2:54082554~54085066:+
THCA	cis	rs4763879	0.634	rs7974396	ENSG00000256673.1	RP11-599J14.2	4.31	2.03e-05	0.00193	0.24	0.19	Type 1 diabetes;	chr12:9708101	chr12:9398355~9414851:-
THCA	cis	rs12142240	0.731	rs6658556	ENSG00000232022.5	FAAHP1	-4.31	2.03e-05	0.00193	-0.22	-0.19	Menopause (age at onset);	chr1:46378508	chr1:46432129~46445521:+
THCA	cis	rs10911902	0.643	rs3820181	ENSG00000229739.2	RP11-295K2.3	-4.31	2.03e-05	0.00193	-0.29	-0.19	Schizophrenia;	chr1:186347067	chr1:186435161~186470291:+
THCA	cis	rs9863	1	rs9863	ENSG00000269997.1	RP11-214K3.21	-4.31	2.03e-05	0.00193	-0.25	-0.19	White blood cell count;	chr12:123936906	chr12:123966077~123966629:-
THCA	cis	rs890448	0.828	rs7659504	ENSG00000254531.1	FLJ20021	-4.31	2.03e-05	0.00193	-0.17	-0.19	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101462304	chr4:101347780~101348883:+
THCA	cis	rs12681963	0.61	rs2174133	ENSG00000248159.1	HSPA8P11	-4.31	2.03e-05	0.00193	-0.35	-0.19	Migraine;	chr8:30148247	chr8:30237382~30240997:+
THCA	cis	rs8062405	0.698	rs7188071	ENSG00000261766.1	RP11-22P6.2	4.31	2.03e-05	0.00193	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28862166~28863340:-
THCA	cis	rs7726839	0.54	rs3762951	ENSG00000225138.6	CTD-2228K2.7	4.31	2.03e-05	0.00193	0.23	0.19	Obesity-related traits;	chr5:662498	chr5:473236~480884:+
THCA	cis	rs7726839	0.54	rs7434	ENSG00000225138.6	CTD-2228K2.7	-4.31	2.03e-05	0.00193	-0.23	-0.19	Obesity-related traits;	chr5:660689	chr5:473236~480884:+
THCA	cis	rs1040393	0.767	rs7539995	ENSG00000225171.2	DUTP6	4.31	2.03e-05	0.00193	0.28	0.19	Schizophrenia;	chr1:166967887	chr1:166868748~166869209:+
THCA	cis	rs1040393	0.767	rs10737531	ENSG00000225171.2	DUTP6	4.31	2.03e-05	0.00193	0.28	0.19	Schizophrenia;	chr1:166971662	chr1:166868748~166869209:+
THCA	cis	rs2692947	0.537	rs12471472	ENSG00000235959.1	AC009237.17	-4.31	2.03e-05	0.00193	-0.22	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95539707	chr2:95640181~95640604:-
THCA	cis	rs6121246	0.609	rs6060955	ENSG00000230613.1	HM13-AS1	4.31	2.03e-05	0.00193	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31797268	chr20:31567707~31573263:-
THCA	cis	rs1232027	0.656	rs1650665	ENSG00000249655.1	CTC-325J23.2	4.31	2.03e-05	0.00193	0.22	0.19	Huntington's disease progression;	chr5:80666759	chr5:80630313~80631590:-
THCA	cis	rs6870983	0.895	rs33703	ENSG00000247828.6	TMEM161B-AS1	-4.31	2.03e-05	0.00193	-0.18	-0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88270914	chr5:88268895~88436685:+
THCA	cis	rs6012564	1	rs2426109	ENSG00000230758.1	SNAP23P	-4.31	2.03e-05	0.00193	-0.24	-0.19	Anger;	chr20:49046090	chr20:49038357~49038602:-
THCA	cis	rs12428035	1	rs75192006	ENSG00000247400.3	DNAJC3-AS1	-4.31	2.03e-05	0.00193	-0.19	-0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95651370	chr13:95648733~95676925:-
THCA	cis	rs28829049	0.597	rs2313509	ENSG00000270728.1	RP4-657E11.10	-4.31	2.03e-05	0.00193	-0.14	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19111366	chr1:19297080~19297903:+
THCA	cis	rs763121	0.853	rs2072795	ENSG00000235209.1	CTA-150C2.13	-4.31	2.03e-05	0.00193	-0.26	-0.19	Menopause (age at onset);	chr22:38668204	chr22:38921227~38924708:+
THCA	cis	rs227275	0.525	rs3974604	ENSG00000248971.2	KRT8P46	-4.31	2.03e-05	0.00193	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102728746~102730171:-
THCA	cis	rs8105895	0.935	rs62110993	ENSG00000269345.1	VN1R85P	4.31	2.03e-05	0.00193	0.27	0.19	Body mass index (change over time);	chr19:22085458	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62111027	ENSG00000269345.1	VN1R85P	4.31	2.03e-05	0.00193	0.27	0.19	Body mass index (change over time);	chr19:22086217	chr19:22174766~22175191:-
THCA	cis	rs4805272	0.962	rs2870545	ENSG00000267799.1	MAN1A2P1	4.31	2.03e-05	0.00193	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833854	chr19:28790812~28792871:-
THCA	cis	rs4950322	0.58	rs7515160	ENSG00000180867.10	PDIA3P1	4.31	2.03e-05	0.00193	0.19	0.19	Protein quantitative trait loci;	chr1:147120714	chr1:147178113~147179622:+
THCA	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-4.31	2.03e-05	0.00193	-0.12	-0.19	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
THCA	cis	rs11673344	0.642	rs12462487	ENSG00000268499.1	CTB-102L5.8	-4.31	2.03e-05	0.00193	-0.2	-0.19	Obesity-related traits;	chr19:37311211	chr19:38199836~38200934:+
THCA	cis	rs6600671	1	rs4844380	ENSG00000275585.1	CH17-118O6.3	-4.31	2.03e-05	0.00193	-0.23	-0.19	Hip geometry;	chr1:121451764	chr1:120985692~121052167:-
THCA	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-4.31	2.03e-05	0.00193	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-4.31	2.03e-05	0.00193	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
THCA	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-4.31	2.03e-05	0.00193	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
THCA	cis	rs9437689	0.624	rs2391388	ENSG00000235501.4	RP4-639F20.1	-4.31	2.03e-05	0.00193	-0.22	-0.19	Phospholipid levels (plasma);	chr1:95020269	chr1:94927566~94963270:+
THCA	cis	rs9902453	0.612	rs2617868	ENSG00000263370.1	RP11-68I3.5	-4.31	2.03e-05	0.00193	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29746229	chr17:29639627~29640825:+
THCA	cis	rs7267979	1	rs1888997	ENSG00000274973.1	RP13-401N8.7	4.31	2.03e-05	0.00193	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs3002698	ENSG00000274973.1	RP13-401N8.7	4.31	2.03e-05	0.00193	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2424710	ENSG00000274973.1	RP13-401N8.7	-4.31	2.03e-05	0.00193	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6115140	ENSG00000274973.1	RP13-401N8.7	-4.31	2.03e-05	0.00193	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25845497~25845862:+
THCA	cis	rs4820294	1	rs4820294	ENSG00000233360.4	Z83844.1	4.31	2.03e-05	0.00193	0.23	0.19	Fat distribution (HIV);	chr22:37675036	chr22:37641832~37658377:-
THCA	cis	rs10484434	0.792	rs66505449	ENSG00000272462.2	U91328.19	4.31	2.03e-05	0.00193	0.21	0.19	HIV-1 viral setpoint;	chr6:26031257	chr6:25992662~26001775:+
THCA	cis	rs4308124	0.708	rs28871990	ENSG00000230499.1	AC108463.1	-4.31	2.03e-05	0.00193	-0.29	-0.19	Vitiligo;	chr2:111204864	chr2:111195963~111206494:+
THCA	cis	rs791590	0.54	rs11596136	ENSG00000229664.1	RP11-536K7.5	-4.31	2.03e-05	0.00193	-0.23	-0.19	Soluble interleukin-2 receptor subunit alpha;	chr10:5999910	chr10:6025978~6036427:+
THCA	cis	rs9595908	0.655	rs56080053	ENSG00000212293.1	SNORA16	4.31	2.03e-05	0.00193	0.23	0.19	Body mass index;	chr13:32720045	chr13:32420390~32420516:-
THCA	cis	rs919433	0.519	rs700658	ENSG00000231621.1	AC013264.2	-4.31	2.03e-05	0.00194	-0.21	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197790283	chr2:197197991~197199273:+
THCA	cis	rs4713118	0.505	rs276371	ENSG00000273712.1	RP5-874C20.7	4.31	2.03e-05	0.00194	0.21	0.19	Parkinson's disease;	chr6:27942930	chr6:28315613~28315883:-
THCA	cis	rs2886497	0.57	rs7095622	ENSG00000224215.1	RP11-371A19.2	-4.31	2.03e-05	0.00194	-0.22	-0.19	Major depression and alcohol dependence;	chr10:23393899	chr10:23343957~23345181:+
THCA	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-4.3	2.03e-05	0.00194	-0.22	-0.19	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-4.3	2.03e-05	0.00194	-0.22	-0.19	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-4.3	2.03e-05	0.00194	-0.22	-0.19	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-4.3	2.03e-05	0.00194	-0.22	-0.19	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-4.3	2.03e-05	0.00194	-0.22	-0.19	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-4.3	2.03e-05	0.00194	-0.22	-0.19	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-4.3	2.03e-05	0.00194	-0.22	-0.19	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-4.3	2.03e-05	0.00194	-0.22	-0.19	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
THCA	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	4.3	2.03e-05	0.00194	0.22	0.19	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	4.3	2.03e-05	0.00194	0.22	0.19	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	4.3	2.03e-05	0.00194	0.22	0.19	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
THCA	cis	rs2446066	0.872	rs11614010	ENSG00000257379.1	RP11-793H13.8	4.3	2.03e-05	0.00194	0.3	0.19	Red blood cell count;	chr12:53426253	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.872	rs10876453	ENSG00000257379.1	RP11-793H13.8	4.3	2.03e-05	0.00194	0.3	0.19	Red blood cell count;	chr12:53426404	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.872	rs12811015	ENSG00000257379.1	RP11-793H13.8	4.3	2.03e-05	0.00194	0.3	0.19	Red blood cell count;	chr12:53426941	chr12:53441741~53467528:+
THCA	cis	rs9818758	0.607	rs56004653	ENSG00000270441.1	RP11-694I15.7	4.3	2.03e-05	0.00194	0.31	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49034795	chr3:49140086~49160851:-
THCA	cis	rs7587476	0.906	rs17487792	ENSG00000229267.2	AC072062.1	4.3	2.03e-05	0.00194	0.25	0.19	Neuroblastoma;	chr2:214778776	chr2:214810229~214963274:+
THCA	cis	rs17292804	0.506	rs71417868	ENSG00000244691.1	RPL10AP1	-4.3	2.03e-05	0.00194	-0.27	-0.19	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103412119~103412761:-
THCA	cis	rs12478296	1	rs57603292	ENSG00000261186.2	RP11-341N2.1	-4.3	2.04e-05	0.00194	-0.32	-0.19	Obesity-related traits;	chr2:242086386	chr2:242087351~242088457:-
THCA	cis	rs875971	0.545	rs67775320	ENSG00000273142.1	RP11-458F8.4	4.3	2.04e-05	0.00194	0.18	0.19	Aortic root size;	chr7:66193792	chr7:66902857~66906297:+
THCA	cis	rs763121	0.853	rs3761454	ENSG00000273076.1	RP3-508I15.22	4.3	2.04e-05	0.00194	0.2	0.19	Menopause (age at onset);	chr22:38670815	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs3747170	ENSG00000273076.1	RP3-508I15.22	4.3	2.04e-05	0.00194	0.2	0.19	Menopause (age at onset);	chr22:38671326	chr22:38743495~38743910:+
THCA	cis	rs860295	0.812	rs3820594	ENSG00000236675.1	MTX1P1	-4.3	2.04e-05	0.00194	-0.2	-0.19	Body mass index;	chr1:155859720	chr1:155230975~155234325:+
THCA	cis	rs61270009	0.818	rs4916718	ENSG00000247828.6	TMEM161B-AS1	4.3	2.04e-05	0.00194	0.17	0.19	Depressive symptoms;	chr5:88316825	chr5:88268895~88436685:+
THCA	cis	rs7647973	0.516	rs4955418	ENSG00000229759.1	MRPS18AP1	4.3	2.04e-05	0.00194	0.25	0.19	Menarche (age at onset);	chr3:49163194	chr3:48256350~48256938:-
THCA	cis	rs7572644	0.699	rs10177845	ENSG00000223522.1	AC093690.1	4.3	2.04e-05	0.00194	0.23	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27901304	chr2:28307691~28310459:-
THCA	cis	rs62244186	1	rs62244186	ENSG00000214820.3	MPRIPP1	4.3	2.04e-05	0.00194	0.2	0.19	Depressive symptoms;	chr3:44698291	chr3:44579938~44581026:-
THCA	cis	rs10911902	0.643	rs75856021	ENSG00000229739.2	RP11-295K2.3	-4.3	2.04e-05	0.00194	-0.3	-0.19	Schizophrenia;	chr1:186405853	chr1:186435161~186470291:+
THCA	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-4.3	2.04e-05	0.00194	-0.18	-0.19	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
THCA	cis	rs738144	0.687	rs6001225	ENSG00000235209.1	CTA-150C2.13	-4.3	2.04e-05	0.00194	-0.29	-0.19	IgG glycosylation;	chr22:38788634	chr22:38921227~38924708:+
THCA	cis	rs4713118	0.696	rs2394002	ENSG00000220721.1	OR1F12	4.3	2.04e-05	0.00194	0.26	0.19	Parkinson's disease;	chr6:27780236	chr6:28073316~28074233:+
THCA	cis	rs2708377	0.858	rs68045377	ENSG00000247157.5	LINC01252	4.3	2.04e-05	0.00194	0.35	0.19	Bitter taste perception;	chr12:11141853	chr12:11548030~11590369:+
THCA	cis	rs6088813	1	rs224329	ENSG00000279253.1	RP4-614O4.13	-4.3	2.04e-05	0.00194	-0.19	-0.19	Height;	chr20:35431781	chr20:35262727~35264187:-
THCA	cis	rs5758511	0.773	rs62241023	ENSG00000227370.1	RP4-669P10.19	4.3	2.04e-05	0.00194	0.23	0.19	Birth weight;	chr22:41989425	chr22:42132543~42132998:+
THCA	cis	rs13126694	0.71	rs4574459	ENSG00000248429.4	RP11-597D13.9	4.3	2.04e-05	0.00194	0.21	0.19	Blood osmolality (transformed sodium);	chr4:157991482	chr4:158170752~158202877:+
THCA	cis	rs7647973	0.516	rs4955419	ENSG00000229759.1	MRPS18AP1	4.3	2.04e-05	0.00194	0.25	0.19	Menarche (age at onset);	chr3:49163259	chr3:48256350~48256938:-
THCA	cis	rs13325613	0.915	rs7624155	ENSG00000223552.1	RP11-24F11.2	-4.3	2.04e-05	0.00194	-0.29	-0.19	Monocyte count;	chr3:46227645	chr3:46364955~46407059:-
THCA	cis	rs752590	0.806	rs4849174	ENSG00000227359.1	AC017074.2	4.3	2.04e-05	0.00194	0.23	0.19	Mucinous ovarian carcinoma;	chr2:113215890	chr2:113677702~113704078:-
THCA	cis	rs2944755	0.845	rs2977459	ENSG00000279766.1	RP11-642A1.2	4.3	2.04e-05	0.00194	0.26	0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140565770	chr8:140572142~140572812:-
THCA	cis	rs7131987	0.65	rs3782509	ENSG00000273680.1	RP11-996F15.6	4.3	2.04e-05	0.00194	0.28	0.19	QT interval;	chr12:29300845	chr12:29332733~29333383:-
THCA	cis	rs9921338	0.668	rs55870745	ENSG00000262636.1	CTD-3088G3.4	-4.3	2.04e-05	0.00194	-0.29	-0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261245	chr16:11380859~11381118:-
THCA	cis	rs9921338	0.636	rs56350515	ENSG00000262636.1	CTD-3088G3.4	-4.3	2.04e-05	0.00194	-0.29	-0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261247	chr16:11380859~11381118:-
THCA	cis	rs6088813	1	rs6060402	ENSG00000279253.1	RP4-614O4.13	4.3	2.04e-05	0.00194	0.19	0.19	Height;	chr20:35417437	chr20:35262727~35264187:-
THCA	cis	rs79040073	0.532	rs73398284	ENSG00000259531.2	RP11-295H24.3	4.3	2.04e-05	0.00194	0.26	0.19	Lung cancer in ever smokers;	chr15:49422203	chr15:49365124~49366685:-
THCA	cis	rs62292953	0.591	rs74735511	ENSG00000248724.5	NPHP3-AS1	-4.3	2.04e-05	0.00194	-0.43	-0.19	Red cell distribution width;	chr3:132550160	chr3:132721750~132874223:+
THCA	cis	rs4845570	0.764	rs12141652	ENSG00000203288.3	RP11-98D18.9	-4.3	2.04e-05	0.00194	-0.24	-0.19	Coronary artery disease;	chr1:151744235	chr1:151790804~151794402:+
THCA	cis	rs4845570	0.764	rs12122917	ENSG00000203288.3	RP11-98D18.9	-4.3	2.04e-05	0.00194	-0.24	-0.19	Coronary artery disease;	chr1:151744236	chr1:151790804~151794402:+
THCA	cis	rs10946940	0.965	rs62401383	ENSG00000216915.2	RP1-97D16.1	4.3	2.04e-05	0.00194	0.26	0.19	Systemic lupus erythematosus;	chr6:27596768	chr6:27737000~27738494:-
THCA	cis	rs4805272	1	rs9304626	ENSG00000267799.1	MAN1A2P1	4.3	2.04e-05	0.00194	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829347	chr19:28790812~28792871:-
THCA	cis	rs8056446	0.509	rs9922536	ENSG00000276007.1	RP11-358L22.3	-4.3	2.04e-05	0.00194	-0.15	-0.19	Pulmonary function (smoking interaction);	chr16:78137169	chr16:78123243~78124332:+
THCA	cis	rs8056446	0.552	rs9933156	ENSG00000276007.1	RP11-358L22.3	-4.3	2.04e-05	0.00194	-0.15	-0.19	Pulmonary function (smoking interaction);	chr16:78137411	chr16:78123243~78124332:+
THCA	cis	rs8056446	0.51	rs9937449	ENSG00000276007.1	RP11-358L22.3	-4.3	2.04e-05	0.00194	-0.15	-0.19	Pulmonary function (smoking interaction);	chr16:78137479	chr16:78123243~78124332:+
THCA	cis	rs227275	0.556	rs9999303	ENSG00000248971.2	KRT8P46	-4.3	2.04e-05	0.00194	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102728746~102730171:-
THCA	cis	rs73242632	1	rs17828496	ENSG00000269949.1	RP11-738E22.3	4.3	2.04e-05	0.00194	0.52	0.19	Congenital heart disease (maternal effect);	chr4:56988847	chr4:56960927~56961373:-
THCA	cis	rs10266483	0.654	rs6962076	ENSG00000228653.2	HNRNPCP7	4.3	2.04e-05	0.00194	0.19	0.19	Response to statin therapy;	chr7:64559214	chr7:64500825~64501729:+
THCA	cis	rs17270561	0.636	rs9379782	ENSG00000272462.2	U91328.19	-4.3	2.04e-05	0.00194	-0.17	-0.19	Iron status biomarkers;	chr6:25714795	chr6:25992662~26001775:+
THCA	cis	rs10484434	0.901	rs59281021	ENSG00000272462.2	U91328.19	4.3	2.04e-05	0.00195	0.21	0.19	HIV-1 viral setpoint;	chr6:25978803	chr6:25992662~26001775:+
THCA	cis	rs733592	0.931	rs765260	ENSG00000269514.1	RP11-370I10.12	4.3	2.04e-05	0.00195	0.16	0.19	Plateletcrit;	chr12:48038153	chr12:48198387~48202031:+
THCA	cis	rs7833787	0.526	rs11781831	ENSG00000278886.1	RP11-108A14.1	-4.3	2.04e-05	0.00195	-0.27	-0.19	Obesity-related traits;	chr8:18835809	chr8:18864681~18865247:-
THCA	cis	rs5758511	0.634	rs1001587	ENSG00000237037.8	NDUFA6-AS1	-4.3	2.04e-05	0.00195	-0.18	-0.19	Birth weight;	chr22:42274105	chr22:42090931~42137742:+
THCA	cis	rs2836950	0.545	rs8132143	ENSG00000238141.2	BRWD1-AS1	-4.3	2.04e-05	0.00195	-0.22	-0.19	Menarche (age at onset);	chr21:39212332	chr21:39315707~39323218:+
THCA	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	4.3	2.04e-05	0.00195	0.24	0.19	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
THCA	cis	rs442309	0.687	rs10995282	ENSG00000238280.1	RP11-436D10.3	-4.3	2.05e-05	0.00195	-0.24	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62711531	chr10:62793562~62805887:-
THCA	cis	rs8177876	0.749	rs2549891	ENSG00000261838.4	RP11-303E16.6	-4.3	2.05e-05	0.00195	-0.33	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81069854~81076598:+
THCA	cis	rs2281636	0.723	rs2150916	ENSG00000260475.1	RP11-85A1.3	4.3	2.05e-05	0.00195	0.19	0.19	Obesity-related traits;	chr10:99692737	chr10:99621055~99621918:+
THCA	cis	rs9926296	0.632	rs7206546	ENSG00000274627.1	RP11-104N10.2	4.3	2.05e-05	0.00195	0.2	0.19	Vitiligo;	chr16:89732671	chr16:89516797~89522217:+
THCA	cis	rs6121246	0.559	rs1062794	ENSG00000230613.1	HM13-AS1	4.3	2.05e-05	0.00195	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31793955	chr20:31567707~31573263:-
THCA	cis	rs713477	0.505	rs10131672	ENSG00000258413.1	RP11-665C16.6	4.3	2.05e-05	0.00195	0.28	0.19	Pediatric bone mineral content (femoral neck);	chr14:55438373	chr14:55262767~55272075:-
THCA	cis	rs1336149	1	rs1572407	ENSG00000211581.1	MIR765	-4.3	2.05e-05	0.00195	-0.25	-0.19	Chin dimples;	chr1:156976307	chr1:156936131~156936244:-
THCA	cis	rs12549025	0.891	rs2137301	ENSG00000253390.1	CTC-756D1.2	-4.3	2.05e-05	0.00195	-0.35	-0.19	Reticulocyte fraction of red cells;	chr8:23536524	chr8:23458601~23484971:+
THCA	cis	rs1336149	0.967	rs822577	ENSG00000211581.1	MIR765	-4.3	2.05e-05	0.00195	-0.25	-0.19	Chin dimples;	chr1:157002675	chr1:156936131~156936244:-
THCA	cis	rs2717559	0.568	rs35093407	ENSG00000253741.1	CTD-2292P10.4	4.3	2.05e-05	0.00195	0.25	0.19	Urinary tract infection frequency;	chr8:142804085	chr8:142702252~142726973:-
THCA	cis	rs3020736	0.5	rs6002604	ENSG00000237037.8	NDUFA6-AS1	4.3	2.05e-05	0.00195	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs5996109	ENSG00000237037.8	NDUFA6-AS1	4.3	2.05e-05	0.00195	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs5996110	ENSG00000237037.8	NDUFA6-AS1	4.3	2.05e-05	0.00195	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs9620026	ENSG00000237037.8	NDUFA6-AS1	4.3	2.05e-05	0.00195	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs28791586	ENSG00000237037.8	NDUFA6-AS1	4.3	2.05e-05	0.00195	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs2839708	ENSG00000237037.8	NDUFA6-AS1	4.3	2.05e-05	0.00195	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs6519306	ENSG00000237037.8	NDUFA6-AS1	4.3	2.05e-05	0.00195	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42090931~42137742:+
THCA	cis	rs11671653	1	rs59214302	ENSG00000267100.1	ILF3-AS1	4.3	2.05e-05	0.00195	0.21	0.19	LDL cholesterol;	chr19:10725386	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs11669253	ENSG00000267100.1	ILF3-AS1	4.3	2.05e-05	0.00195	0.21	0.19	LDL cholesterol;	chr19:10725653	chr19:10651862~10653844:-
THCA	cis	rs75504410	0.579	rs170908	ENSG00000231160.8	KLF3-AS1	-4.3	2.05e-05	0.00195	-0.14	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38618114	chr4:38612701~38664883:-
THCA	cis	rs9902453	0.808	rs8069669	ENSG00000263370.1	RP11-68I3.5	4.3	2.05e-05	0.00195	0.25	0.19	Coffee consumption (cups per day);	chr17:29912484	chr17:29639627~29640825:+
THCA	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	4.3	2.05e-05	0.00195	0.28	0.19	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
THCA	cis	rs944289	0.932	rs1169151	ENSG00000258844.1	RP11-259K15.2	-4.3	2.05e-05	0.00195	-0.18	-0.19	Thyroid cancer;	chr14:36171395	chr14:36214607~36235608:+
THCA	cis	rs2120243	0.538	rs4680360	ENSG00000241770.1	RP11-555M1.3	4.3	2.05e-05	0.00195	0.26	0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157376690	chr3:157163452~157169133:+
THCA	cis	rs2898290	0.622	rs1382567	ENSG00000251402.3	FAM90A25P	-4.3	2.05e-05	0.00195	-0.25	-0.19	Systolic blood pressure;	chr8:11493390	chr8:12415080~12418090:-
THCA	cis	rs6088813	0.883	rs2425055	ENSG00000279253.1	RP4-614O4.13	-4.3	2.05e-05	0.00195	-0.19	-0.19	Height;	chr20:35315833	chr20:35262727~35264187:-
THCA	cis	rs5758659	0.652	rs133335	ENSG00000273366.1	CTA-989H11.1	4.3	2.05e-05	0.00195	0.23	0.19	Cognitive function;	chr22:42020052	chr22:42278188~42278846:+
THCA	cis	rs1150668	0.796	rs2247002	ENSG00000176933.5	TOB2P1	-4.3	2.05e-05	0.00195	-0.21	-0.19	Pubertal anthropometrics;	chr6:28430174	chr6:28217643~28218634:-
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000176933.5	TOB2P1	-4.3	2.05e-05	0.00195	-0.22	-0.19	Pubertal anthropometrics;	chr6:28197520	chr6:28217643~28218634:-
THCA	cis	rs1346	0.552	rs4326800	ENSG00000245532.5	NEAT1	4.3	2.05e-05	0.00195	0.15	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65599782	chr11:65422774~65445540:+
THCA	cis	rs941408	0.515	rs2110118	ENSG00000261342.1	AC006538.1	4.3	2.05e-05	0.00195	0.21	0.19	Total cholesterol levels;	chr19:2775146	chr19:2727743~2729327:-
THCA	cis	rs10208649	0.611	rs12620667	ENSG00000233266.1	HMGB1P31	4.3	2.05e-05	0.00195	0.36	0.19	Body mass index;	chr2:54063860	chr2:54051334~54051760:+
THCA	cis	rs8067545	0.75	rs4925077	ENSG00000270091.1	RP11-78O7.2	-4.3	2.05e-05	0.00195	-0.14	-0.19	Schizophrenia;	chr17:20078963	chr17:19896590~19897287:-
THCA	cis	rs875971	1	rs1565531	ENSG00000229886.1	RP5-1132H15.3	-4.3	2.05e-05	0.00195	-0.2	-0.19	Aortic root size;	chr7:66198126	chr7:66025126~66031544:-
THCA	cis	rs1842579	0.596	rs12727784	ENSG00000272691.1	RP11-290M5.4	4.3	2.05e-05	0.00195	0.19	0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85802349	chr1:85578500~85578742:-
THCA	cis	rs12534093	0.921	rs11762335	ENSG00000234286.1	AC006026.13	-4.3	2.05e-05	0.00195	-0.31	-0.19	Infant length;Height;	chr7:23455577	chr7:23680195~23680786:-
THCA	cis	rs12534093	0.921	rs12700441	ENSG00000234286.1	AC006026.13	-4.3	2.05e-05	0.00195	-0.31	-0.19	Infant length;Height;	chr7:23456292	chr7:23680195~23680786:-
THCA	cis	rs3770081	1	rs76297018	ENSG00000272564.1	RP11-548P2.2	-4.3	2.05e-05	0.00195	-0.37	-0.19	Facial emotion recognition (sad faces);	chr2:85999884	chr2:85904279~85904727:+
THCA	cis	rs7312933	0.533	rs3747557	ENSG00000257225.1	RP11-328C8.4	4.3	2.05e-05	0.00195	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42324159	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.558	rs11181422	ENSG00000257225.1	RP11-328C8.4	4.3	2.05e-05	0.00195	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42324750	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.531	rs2406674	ENSG00000257225.1	RP11-328C8.4	4.3	2.05e-05	0.00195	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42326348	chr12:42459366~42466128:+
THCA	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	4.3	2.05e-05	0.00195	0.21	0.19	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
THCA	cis	rs796395	0.967	rs550238	ENSG00000232480.1	TGFB2-AS1	-4.3	2.05e-05	0.00195	-0.22	-0.19	Post bronchodilator FEV1/FVC ratio;	chr1:218517606	chr1:218344196~218345678:-
THCA	cis	rs15676	0.947	rs1572912	ENSG00000234771.3	SLC25A25-AS1	-4.3	2.05e-05	0.00195	-0.16	-0.19	Blood metabolite levels;	chr9:128803275	chr9:128108581~128118693:-
THCA	cis	rs10256972	0.552	rs2949195	ENSG00000225146.1	AC073957.15	4.3	2.06e-05	0.00195	0.21	0.19	Endometriosis;Longevity;	chr7:1163069	chr7:1029025~1043891:+
THCA	cis	rs123509	0.731	rs73087348	ENSG00000173811.9	CCDC13-AS1	-4.3	2.06e-05	0.00195	-0.23	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42770079	chr3:42732575~42746768:+
THCA	cis	rs8062405	0.656	rs7189927	ENSG00000261766.1	RP11-22P6.2	4.3	2.06e-05	0.00195	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28862166~28863340:-
THCA	cis	rs4824093	0.61	rs73443923	ENSG00000278869.1	CITF22-49E9.3	4.3	2.06e-05	0.00195	0.41	0.19	Amyotrophic lateral sclerosis (sporadic);	chr22:49891700	chr22:49933198~49934074:-
THCA	cis	rs9813712	0.953	rs7619208	ENSG00000253540.4	FAM86HP	-4.3	2.06e-05	0.00196	-0.24	-0.19	Response to amphetamines;	chr3:130258163	chr3:130099092~130111472:-
THCA	cis	rs2439831	0.681	rs540388	ENSG00000166763.7	STRCP1	4.3	2.06e-05	0.00196	0.26	0.19	Lung cancer in ever smokers;	chr15:43314296	chr15:43699488~43718184:-
THCA	cis	rs10875746	0.903	rs17122666	ENSG00000258273.1	RP11-370I10.4	4.3	2.06e-05	0.00196	0.28	0.19	Longevity (90 years and older);	chr12:48108791	chr12:48333755~48333901:-
THCA	cis	rs875971	0.895	rs12531677	ENSG00000229886.1	RP5-1132H15.3	-4.3	2.06e-05	0.00196	-0.2	-0.19	Aortic root size;	chr7:66304099	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs7798630	ENSG00000229886.1	RP5-1132H15.3	-4.3	2.06e-05	0.00196	-0.2	-0.19	Aortic root size;	chr7:66306492	chr7:66025126~66031544:-
THCA	cis	rs1003247	0.614	rs35760358	ENSG00000271122.1	RP11-379H18.1	4.3	2.06e-05	0.00196	0.13	0.19	Cognitive function;	chr7:35570973	chr7:35695214~35699413:+
THCA	cis	rs1003247	0.637	rs34382573	ENSG00000271122.1	RP11-379H18.1	4.3	2.06e-05	0.00196	0.13	0.19	Cognitive function;	chr7:35571003	chr7:35695214~35699413:+
THCA	cis	rs12410462	0.591	rs2814060	ENSG00000227711.2	RP11-275O4.5	-4.3	2.06e-05	0.00196	-0.24	-0.19	Major depressive disorder;	chr1:227534527	chr1:227509028~227520477:-
THCA	cis	rs12612619	0.732	rs11679681	ENSG00000272148.1	RP11-195B17.1	4.3	2.06e-05	0.00196	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27075611	chr2:27062428~27062907:-
THCA	cis	rs6715284	1	rs6715380	ENSG00000238829.1	RNU7-45P	-4.3	2.06e-05	0.00196	-0.47	-0.19	Rheumatoid arthritis;	chr2:201349782	chr2:201141904~201141966:+
THCA	cis	rs4965006	0.915	rs7969545	ENSG00000255992.1	RP11-417L19.4	-4.3	2.06e-05	0.00196	-0.31	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934612	chr12:131924736~131929351:-
THCA	cis	rs7829975	0.871	rs7829826	ENSG00000253981.4	ALG1L13P	-4.3	2.06e-05	0.00196	-0.18	-0.19	Mood instability;	chr8:8720610	chr8:8236003~8244667:-
THCA	cis	rs494453	0.883	rs474722	ENSG00000227811.2	FAM212B-AS1	-4.3	2.06e-05	0.00196	-0.23	-0.19	Osteoporosis-related phenotypes;	chr1:111674356	chr1:111739841~111747798:+
THCA	cis	rs10911902	0.643	rs3766703	ENSG00000229739.2	RP11-295K2.3	-4.3	2.06e-05	0.00196	-0.3	-0.19	Schizophrenia;	chr1:186346575	chr1:186435161~186470291:+
THCA	cis	rs2836950	0.501	rs11088470	ENSG00000238141.2	BRWD1-AS1	-4.3	2.06e-05	0.00196	-0.22	-0.19	Menarche (age at onset);	chr21:39317236	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.501	rs2836983	ENSG00000238141.2	BRWD1-AS1	-4.3	2.06e-05	0.00196	-0.22	-0.19	Menarche (age at onset);	chr21:39317410	chr21:39315707~39323218:+
THCA	cis	rs17818399	0.926	rs13033177	ENSG00000279254.1	RP11-536C12.1	-4.3	2.06e-05	0.00196	-0.21	-0.19	Height;	chr2:46603923	chr2:46668870~46670778:+
THCA	cis	rs10043228	0.702	rs77320865	ENSG00000250015.1	CTC-339F2.2	4.3	2.06e-05	0.00196	0.24	0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116329449	chr5:116302354~116304134:-
THCA	cis	rs10043228	0.51	rs62384495	ENSG00000250015.1	CTC-339F2.2	4.3	2.06e-05	0.00196	0.24	0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116338573	chr5:116302354~116304134:-
THCA	cis	rs11722779	0.935	rs6533046	ENSG00000248971.2	KRT8P46	-4.3	2.06e-05	0.00196	-0.24	-0.19	Schizophrenia;	chr4:102965917	chr4:102728746~102730171:-
THCA	cis	rs1923243	0.647	rs4650197	ENSG00000223479.3	RP4-788P17.1	-4.3	2.06e-05	0.00196	-0.21	-0.19	Migraine;	chr1:73177309	chr1:73635216~73715214:+
THCA	cis	rs8113308	0.752	rs11879758	ENSG00000275055.1	CTC-471J1.11	-4.3	2.06e-05	0.00196	-0.21	-0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51986911	chr19:52049007~52049754:+
THCA	cis	rs9733	0.744	rs12126004	ENSG00000231073.1	RP11-316M1.3	-4.3	2.06e-05	0.00196	-0.23	-0.19	Tonsillectomy;	chr1:150917401	chr1:150973123~150975534:+
THCA	cis	rs7746199	0.668	rs34864796	ENSG00000220721.1	OR1F12	4.3	2.06e-05	0.00196	0.38	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28073316~28074233:+
THCA	cis	rs763121	0.925	rs9611008	ENSG00000228274.3	RP3-508I15.9	-4.3	2.06e-05	0.00196	-0.2	-0.19	Menopause (age at onset);	chr22:38702782	chr22:38667585~38681820:-
THCA	cis	rs12073837	0.5	rs11118610	ENSG00000238078.1	LINC01352	-4.3	2.06e-05	0.00196	-0.23	-0.19	F-cell distribution;	chr1:220816744	chr1:220829255~220832429:+
THCA	cis	rs4767841	0.805	rs10849696	ENSG00000252886.1	RN7SKP197	-4.3	2.06e-05	0.00196	-0.19	-0.19	Urgency urinary incontinence;	chr12:119771207	chr12:119631090~119631386:-
THCA	cis	rs875971	1	rs709597	ENSG00000229886.1	RP5-1132H15.3	-4.3	2.06e-05	0.00196	-0.2	-0.19	Aortic root size;	chr7:66360996	chr7:66025126~66031544:-
THCA	cis	rs2361718	0.501	rs11869566	ENSG00000275479.1	RP11-334C17.6	4.3	2.06e-05	0.00196	0.18	0.19	Yeast infection;	chr17:80169449	chr17:80149627~80149798:+
THCA	cis	rs9311474	0.629	rs13081028	ENSG00000243224.1	RP5-1157M23.2	-4.3	2.06e-05	0.00196	-0.21	-0.19	Electroencephalogram traits;	chr3:52521300	chr3:52239258~52241097:+
THCA	cis	rs6828666	1	rs6828666	ENSG00000271817.2	U3	-4.3	2.06e-05	0.00196	-0.23	-0.19	Depression;	chr4:158858089	chr4:158700691~158700909:+
THCA	cis	rs875971	0.545	rs2420612	ENSG00000273142.1	RP11-458F8.4	4.3	2.06e-05	0.00196	0.18	0.19	Aortic root size;	chr7:66536825	chr7:66902857~66906297:+
THCA	cis	rs889122	0.765	rs62105756	ENSG00000267289.1	CTD-2623N2.11	4.3	2.07e-05	0.00196	0.25	0.19	Menarche (age at onset);	chr19:9863257	chr19:9834079~9835013:-
THCA	cis	rs113835537	0.877	rs77239910	ENSG00000255517.5	CTD-3074O7.5	-4.3	2.07e-05	0.00196	-0.21	-0.19	Airway imaging phenotypes;	chr11:66562168	chr11:66473490~66480233:-
THCA	cis	rs6728642	0.561	rs62152901	ENSG00000230606.9	AC159540.1	4.3	2.07e-05	0.00196	0.25	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96899161	chr2:97416165~97433527:-
THCA	cis	rs7537765	0.947	rs3753584	ENSG00000242349.4	NPPA-AS1	-4.3	2.07e-05	0.00196	-0.27	-0.19	QRS complex (12-leadsum);	chr1:11804529	chr1:11841017~11848079:+
THCA	cis	rs800160	0.777	rs2173888	ENSG00000199550.1	Y_RNA	4.3	2.07e-05	0.00196	0.3	0.19	Bacteremia;	chr11:2335878	chr11:2372638~2372750:+
THCA	cis	rs6657613	0.628	rs761423	ENSG00000186715.9	MST1L	4.3	2.07e-05	0.00196	0.16	0.19	Hip circumference adjusted for BMI;	chr1:16975177	chr1:16754910~16770237:-
THCA	cis	rs16975963	0.843	rs73041004	ENSG00000226686.6	LINC01535	-4.3	2.07e-05	0.00196	-0.26	-0.19	Longevity;	chr19:37772790	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.843	rs112628349	ENSG00000226686.6	LINC01535	-4.3	2.07e-05	0.00196	-0.26	-0.19	Longevity;	chr19:37777598	chr19:37251912~37265535:+
THCA	cis	rs10483853	0.806	rs8007472	ENSG00000258695.2	RP3-414A15.2	-4.3	2.07e-05	0.00196	-0.27	-0.19	Coronary artery calcification;	chr14:73330041	chr14:73522878~73530610:+
THCA	cis	rs10043228	0.702	rs10054989	ENSG00000250015.1	CTC-339F2.2	4.3	2.07e-05	0.00197	0.24	0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116327428	chr5:116302354~116304134:-
THCA	cis	rs7529073	0.74	rs340883	ENSG00000274895.1	RP11-478J18.2	-4.3	2.07e-05	0.00197	-0.16	-0.19	Schizophrenia;	chr1:213972363	chr1:213983793~213986419:-
THCA	cis	rs2051211	1	rs17037804	ENSG00000229589.1	ACVR2B-AS1	-4.3	2.07e-05	0.00197	-0.2	-0.19	QRS duration;	chr3:38517724	chr3:38451027~38454820:-
THCA	cis	rs9595908	0.693	rs4942911	ENSG00000212293.1	SNORA16	4.3	2.07e-05	0.00197	0.24	0.19	Body mass index;	chr13:32793038	chr13:32420390~32420516:-
THCA	cis	rs8023401	0.507	rs7184016	ENSG00000259705.1	RP11-227D13.1	4.3	2.07e-05	0.00197	0.23	0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48518302	chr15:48645951~48652016:+
THCA	cis	rs656319	0.625	rs4526366	ENSG00000248538.5	RP11-10A14.5	4.3	2.07e-05	0.00197	0.26	0.19	Myopia (pathological);	chr8:10032669	chr8:9189011~9202854:+
THCA	cis	rs9902453	0.765	rs1531553	ENSG00000263370.1	RP11-68I3.5	-4.3	2.07e-05	0.00197	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29739734	chr17:29639627~29640825:+
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000265443.1	CTD-2349P21.6	4.3	2.07e-05	0.00197	0.33	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30726305~30727564:-
THCA	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-4.3	2.07e-05	0.00197	-0.2	-0.19	Height;	chr5:37046524	chr5:36666214~36725195:-
THCA	cis	rs138857	0.515	rs9616373	ENSG00000260613.1	RP3-522J7.6	-4.3	2.07e-05	0.00197	-0.32	-0.19	Mean platelet volume;	chr22:49914949	chr22:49832616~49837786:-
THCA	cis	rs4578769	0.959	rs11082169	ENSG00000265939.1	UBE2CP2	4.3	2.07e-05	0.00197	0.24	0.19	Eosinophil percentage of white cells;	chr18:22850034	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.959	rs2100191	ENSG00000265939.1	UBE2CP2	4.3	2.07e-05	0.00197	0.24	0.19	Eosinophil percentage of white cells;	chr18:22851428	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.959	rs2100190	ENSG00000265939.1	UBE2CP2	4.3	2.07e-05	0.00197	0.24	0.19	Eosinophil percentage of white cells;	chr18:22851857	chr18:22900486~22900995:-
THCA	cis	rs11992162	0.551	rs59191504	ENSG00000254948.1	OR7E158P	4.3	2.07e-05	0.00197	0.24	0.19	Monocyte count;	chr8:11927572	chr8:11919900~11920809:-
THCA	cis	rs847577	0.54	rs3847055	ENSG00000272950.1	RP11-307C18.1	-4.3	2.07e-05	0.00197	-0.27	-0.19	Breast cancer;	chr7:98051333	chr7:98322853~98323430:+
THCA	cis	rs9878978	0.964	rs62233799	ENSG00000237990.3	CNTN4-AS1	4.3	2.07e-05	0.00197	0.22	0.19	Blood pressure (smoking interaction);	chr3:2424077	chr3:3039033~3069242:-
THCA	cis	rs890448	0.93	rs2433296	ENSG00000254531.1	FLJ20021	-4.3	2.07e-05	0.00197	-0.17	-0.19	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101459960	chr4:101347780~101348883:+
THCA	cis	rs591584	0.583	rs57607909	ENSG00000255893.1	RP11-685N10.1	-4.3	2.07e-05	0.00197	-0.24	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94593599	chr11:94472908~94473570:-
THCA	cis	rs5742933	1	rs3791767	ENSG00000253559.1	OSGEPL1-AS1	4.3	2.07e-05	0.00197	0.24	0.19	Ferritin levels;	chr2:189775189	chr2:189762704~189765556:+
THCA	cis	rs6012564	0.929	rs2426114	ENSG00000230758.1	SNAP23P	-4.3	2.07e-05	0.00197	-0.23	-0.19	Anger;	chr20:49075855	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs2426116	ENSG00000230758.1	SNAP23P	-4.3	2.07e-05	0.00197	-0.23	-0.19	Anger;	chr20:49076510	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs2024959	ENSG00000230758.1	SNAP23P	4.3	2.07e-05	0.00197	0.23	0.19	Anger;	chr20:49078854	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs17632	ENSG00000230758.1	SNAP23P	4.3	2.07e-05	0.00197	0.23	0.19	Anger;	chr20:49096526	chr20:49038357~49038602:-
THCA	cis	rs172166	0.56	rs203878	ENSG00000280107.1	AL022393.9	-4.3	2.07e-05	0.00197	-0.19	-0.19	Cardiac Troponin-T levels;	chr6:28081218	chr6:28170845~28172521:+
THCA	cis	rs867371	0.929	rs1045508	ENSG00000278603.1	RP13-608F4.5	-4.3	2.07e-05	0.00197	-0.25	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472203~82472426:+
THCA	cis	rs7474896	0.832	rs2738190	ENSG00000263064.2	RP11-291L22.7	-4.3	2.07e-05	0.00197	-0.33	-0.19	Obesity (extreme);	chr10:37975875	chr10:38448689~38448949:+
THCA	cis	rs4144027	0.935	rs881056	ENSG00000269940.1	RP11-73M18.7	-4.3	2.07e-05	0.00197	-0.2	-0.19	Blood metabolite levels;	chr14:103887888	chr14:103694560~103695170:+
THCA	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	4.3	2.07e-05	0.00197	0.25	0.19	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
THCA	cis	rs3813567	0.759	rs12595350	ENSG00000261143.1	ADAMTS7P3	-4.3	2.07e-05	0.00197	-0.3	-0.19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78661122	chr15:77976042~77993057:+
THCA	cis	rs12935418	0.733	rs35115578	ENSG00000261061.1	RP11-303E16.2	-4.3	2.07e-05	0.00197	-0.25	-0.19	Mean corpuscular volume;	chr16:80946392	chr16:81030770~81031485:+
THCA	cis	rs8058578	0.943	rs35629860	ENSG00000279196.1	RP11-1072A3.3	4.3	2.07e-05	0.00197	0.2	0.19	Multiple myeloma;	chr16:30660211	chr16:30984630~30988270:-
THCA	cis	rs9879311	0.966	rs28113	ENSG00000240288.6	GHRLOS	4.3	2.07e-05	0.00197	0.18	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358959	chr3:10285754~10293449:+
THCA	cis	rs7089973	0.61	rs968848	ENSG00000236799.1	RP11-383C6.2	-4.3	2.07e-05	0.00197	-0.24	-0.19	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114998097	chr10:114994657~114996593:+
THCA	cis	rs4794202	0.629	rs59111282	ENSG00000264920.1	RP11-6N17.4	-4.3	2.07e-05	0.00197	-0.26	-0.19	Alzheimer's disease (cognitive decline);	chr17:47825048	chr17:47891255~47895812:-
THCA	cis	rs7200786	0.654	rs12447132	ENSG00000274038.1	RP11-66H6.4	4.3	2.07e-05	0.00197	0.24	0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10992559	chr16:11056556~11057034:+
THCA	cis	rs17092148	0.887	rs6059919	ENSG00000276073.1	RP5-1125A11.7	-4.3	2.07e-05	0.00197	-0.24	-0.19	Neuroticism;	chr20:34563741	chr20:33985617~33988989:-
THCA	cis	rs881375	0.702	rs3761847	ENSG00000270917.1	RP11-27I1.6	-4.3	2.08e-05	0.00197	-0.26	-0.19	Rheumatoid arthritis;	chr9:120927961	chr9:120812475~120812845:-
THCA	cis	rs1124769	0.5	rs79722088	ENSG00000259378.1	DCAF13P3	-4.3	2.08e-05	0.00197	-0.27	-0.19	Cognitive performance;	chr15:50853702	chr15:50944663~50945996:+
THCA	cis	rs2836974	0.584	rs7276774	ENSG00000255568.3	BRWD1-AS2	-4.3	2.08e-05	0.00197	-0.16	-0.19	Cognitive function;	chr21:39256799	chr21:39313935~39314962:+
THCA	cis	rs1200821	0.535	rs1208784	ENSG00000263064.2	RP11-291L22.7	4.3	2.08e-05	0.00197	0.22	0.19	Hemostatic factors and hematological phenotypes;	chr10:37479505	chr10:38448689~38448949:+
THCA	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-4.3	2.08e-05	0.00197	-0.25	-0.19	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
THCA	cis	rs1728785	1	rs1728784	ENSG00000274698.1	RP11-71L14.4	4.3	2.08e-05	0.00197	0.28	0.19	Ulcerative colitis;	chr16:68557253	chr16:68450283~68452318:+
THCA	cis	rs3002131	0.604	rs2936037	ENSG00000272750.1	RP11-378J18.8	4.3	2.08e-05	0.00197	0.28	0.19	Interleukin-10 levels;	chr1:222575223	chr1:222658867~222661512:-
THCA	cis	rs3002131	0.604	rs2936035	ENSG00000272750.1	RP11-378J18.8	4.3	2.08e-05	0.00197	0.28	0.19	Interleukin-10 levels;	chr1:222575582	chr1:222658867~222661512:-
THCA	cis	rs3002131	0.525	rs2936034	ENSG00000272750.1	RP11-378J18.8	4.3	2.08e-05	0.00197	0.28	0.19	Interleukin-10 levels;	chr1:222575661	chr1:222658867~222661512:-
THCA	cis	rs4713118	0.824	rs9468225	ENSG00000226314.6	ZNF192P1	-4.3	2.08e-05	0.00197	-0.25	-0.19	Parkinson's disease;	chr6:27777940	chr6:28161781~28169594:+
THCA	cis	rs8020441	1	rs72681672	ENSG00000269906.1	RP11-248J18.2	4.3	2.08e-05	0.00197	0.27	0.19	Cognitive performance;	chr14:50702882	chr14:50662511~50663178:-
THCA	cis	rs2904524	0.737	rs74756624	ENSG00000257815.4	RP11-611E13.2	-4.3	2.08e-05	0.00197	-0.28	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70164160	chr12:69904033~70243360:-
THCA	cis	rs2299587	0.5	rs7815785	ENSG00000253671.1	RP11-806O11.1	-4.3	2.08e-05	0.00197	-0.23	-0.19	Economic and political preferences;	chr8:17872829	chr8:17808941~17820868:+
THCA	cis	rs858239	0.899	rs2268747	ENSG00000230042.1	AK3P3	-4.3	2.08e-05	0.00197	-0.26	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23129178~23129841:+
THCA	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	-4.3	2.08e-05	0.00197	-0.09	-0.19	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
THCA	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	-4.3	2.08e-05	0.00197	-0.09	-0.19	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
THCA	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	-4.3	2.08e-05	0.00197	-0.09	-0.19	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
THCA	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	-4.3	2.08e-05	0.00197	-0.09	-0.19	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
THCA	cis	rs9813712	0.953	rs1453258	ENSG00000253540.4	FAM86HP	4.3	2.08e-05	0.00197	0.24	0.19	Response to amphetamines;	chr3:130256454	chr3:130099092~130111472:-
THCA	cis	rs4144027	0.935	rs10139856	ENSG00000269958.1	RP11-73M18.8	-4.3	2.08e-05	0.00197	-0.18	-0.19	Blood metabolite levels;	chr14:103888168	chr14:103696353~103697163:+
THCA	cis	rs5752326	0.51	rs5761546	ENSG00000261188.1	CTA-445C9.14	4.3	2.08e-05	0.00197	0.21	0.19	Ischemic stroke;	chr22:26467066	chr22:26512537~26514568:+
THCA	cis	rs6494488	0.5	rs16948172	ENSG00000259635.1	AC100830.3	4.3	2.08e-05	0.00197	0.44	0.19	Coronary artery disease;	chr15:64678599	chr15:64701248~64719602:+
THCA	cis	rs763121	0.853	rs4821808	ENSG00000273076.1	RP3-508I15.22	4.3	2.08e-05	0.00198	0.19	0.19	Menopause (age at onset);	chr22:38669734	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs4821809	ENSG00000273076.1	RP3-508I15.22	4.3	2.08e-05	0.00198	0.19	0.19	Menopause (age at onset);	chr22:38669738	chr22:38743495~38743910:+
THCA	cis	rs7577696	0.962	rs12989936	ENSG00000276334.1	AL133243.1	-4.3	2.08e-05	0.00198	-0.21	-0.19	Inflammatory biomarkers;	chr2:32043517	chr2:32521927~32523547:+
THCA	cis	rs6472827	0.953	rs4449781	ENSG00000253983.2	RP1-16A9.1	-4.3	2.08e-05	0.00198	-0.32	-0.19	Uterine fibroids;	chr8:74209309	chr8:74199396~74208441:+
THCA	cis	rs72627123	1	rs17093474	ENSG00000259065.1	RP5-1021I20.1	-4.3	2.08e-05	0.00198	-0.29	-0.19	Morning vs. evening chronotype;	chr14:73875710	chr14:73787360~73803270:+
THCA	cis	rs5758659	0.652	rs133335	ENSG00000227370.1	RP4-669P10.19	4.3	2.08e-05	0.00198	0.18	0.19	Cognitive function;	chr22:42020052	chr22:42132543~42132998:+
THCA	cis	rs17772222	0.74	rs61975278	ENSG00000222990.1	RNU4-22P	4.3	2.08e-05	0.00198	0.24	0.19	Coronary artery calcification;	chr14:88511223	chr14:88513498~88513663:+
THCA	cis	rs12150660	0.545	rs28625968	ENSG00000233223.2	AC113189.5	-4.3	2.08e-05	0.00198	-0.17	-0.19	Sex hormone-binding globulin levels;Testosterone levels;	chr17:7571221	chr17:7581964~7584072:-
THCA	cis	rs9878978	0.927	rs62245752	ENSG00000237990.3	CNTN4-AS1	4.3	2.08e-05	0.00198	0.22	0.19	Blood pressure (smoking interaction);	chr3:2420801	chr3:3039033~3069242:-
THCA	cis	rs5758659	0.652	rs6519301	ENSG00000205702.9	CYP2D7	4.3	2.08e-05	0.00198	0.15	0.19	Cognitive function;	chr22:41989963	chr22:42140203~42144577:-
THCA	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	4.3	2.08e-05	0.00198	0.23	0.19	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
THCA	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	4.3	2.08e-05	0.00198	0.23	0.19	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
THCA	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	4.3	2.08e-05	0.00198	0.23	0.19	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
THCA	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	4.3	2.08e-05	0.00198	0.23	0.19	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
THCA	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	4.3	2.08e-05	0.00198	0.23	0.19	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
THCA	cis	rs8058578	1	rs3747481	ENSG00000279196.1	RP11-1072A3.3	4.3	2.08e-05	0.00198	0.2	0.19	Multiple myeloma;	chr16:30655046	chr16:30984630~30988270:-
THCA	cis	rs2732480	0.538	rs2732462	ENSG00000273765.1	RP11-370I10.11	4.3	2.08e-05	0.00198	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48360920~48361377:+
THCA	cis	rs416603	0.967	rs11640138	ENSG00000263080.1	RP11-485G7.5	4.3	2.08e-05	0.00198	0.23	0.19	Type 1 diabetes;	chr16:11268872	chr16:11341809~11345211:-
THCA	cis	rs7474896	0.515	rs662928	ENSG00000120555.12	SEPT7P9	-4.3	2.08e-05	0.00198	-0.26	-0.19	Obesity (extreme);	chr10:38027288	chr10:38383069~38402916:-
THCA	cis	rs12682352	0.605	rs60707155	ENSG00000233609.3	RP11-62H7.2	4.3	2.08e-05	0.00198	0.19	0.19	Neuroticism;	chr8:8866905	chr8:8961200~8979025:+
THCA	cis	rs13113518	1	rs4864549	ENSG00000249700.7	SRD5A3-AS1	4.3	2.08e-05	0.00198	0.24	0.19	Height;	chr4:55554380	chr4:55363971~55395847:-
THCA	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-4.3	2.09e-05	0.00198	-0.18	-0.19	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
THCA	cis	rs5758511	0.68	rs5758682	ENSG00000237037.8	NDUFA6-AS1	-4.3	2.09e-05	0.00198	-0.19	-0.19	Birth weight;	chr22:42249196	chr22:42090931~42137742:+
THCA	cis	rs5758511	0.68	rs34107327	ENSG00000237037.8	NDUFA6-AS1	-4.3	2.09e-05	0.00198	-0.19	-0.19	Birth weight;	chr22:42252347	chr22:42090931~42137742:+
THCA	cis	rs5758511	0.68	rs5758684	ENSG00000237037.8	NDUFA6-AS1	-4.3	2.09e-05	0.00198	-0.19	-0.19	Birth weight;	chr22:42253503	chr22:42090931~42137742:+
THCA	cis	rs1032466	0.912	rs61982196	ENSG00000270062.1	RP11-248J18.3	4.3	2.09e-05	0.00198	0.23	0.19	Dupuytren's disease;	chr14:50611520	chr14:50723777~50724272:-
THCA	cis	rs4785204	1	rs12444810	ENSG00000279356.1	RP11-429P3.8	-4.3	2.09e-05	0.00198	-0.37	-0.19	Esophageal cancer (squamous cell);	chr16:50046686	chr16:50072862~50074986:+
THCA	cis	rs13160562	0.623	rs26509	ENSG00000272109.1	CTD-2260A17.3	4.3	2.09e-05	0.00198	0.24	0.19	Alcohol dependence;	chr5:96746976	chr5:96804353~96806105:+
THCA	cis	rs6560517	0.781	rs2501923	ENSG00000234618.1	RPSAP9	4.3	2.09e-05	0.00198	0.2	0.19	Dialysis-related mortality;	chr9:76390474	chr9:76398699~76399586:+
THCA	cis	rs9549367	0.789	rs6577034	ENSG00000269125.1	RP11-98F14.11	-4.3	2.09e-05	0.00198	-0.22	-0.19	Platelet distribution width;	chr13:113225586	chr13:113165002~113165183:-
THCA	cis	rs6570726	0.791	rs11155433	ENSG00000270638.1	RP3-466P17.1	-4.3	2.09e-05	0.00198	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145735570~145737218:+
THCA	cis	rs7216064	0.953	rs11871285	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844693	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs62084213	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845900	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs7224923	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846149	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs62084214	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67847209	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs2046323	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853811	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.773	rs74541577	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67857535	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs2128792	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861061	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs2365764	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861598	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs59950564	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864743	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs34872586	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867350	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.953	rs58141639	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67868786	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs62084246	ENSG00000278740.1	RP11-147L13.14	4.3	2.09e-05	0.00198	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871795	chr17:68188547~68189165:+
THCA	cis	rs4218	0.597	rs62002543	ENSG00000259732.1	RP11-59H7.3	-4.3	2.09e-05	0.00198	-0.28	-0.19	Social communication problems;	chr15:59066646	chr15:59121034~59133250:+
THCA	cis	rs1556032	0.79	rs424539	ENSG00000225472.1	RP11-120J1.1	4.3	2.09e-05	0.00198	0.18	0.19	AIDS;	chr9:14442597	chr9:14317085~14357908:+
THCA	cis	rs728616	0.614	rs10887199	ENSG00000242600.5	MBL1P	4.3	2.09e-05	0.00198	0.21	0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79943078	chr10:79904898~79950336:+
THCA	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	4.3	2.09e-05	0.00198	0.24	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
THCA	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	4.3	2.09e-05	0.00198	0.23	0.19	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
THCA	cis	rs61270009	0.955	rs12654702	ENSG00000247828.6	TMEM161B-AS1	4.3	2.09e-05	0.00198	0.17	0.19	Depressive symptoms;	chr5:88402882	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs2410766	ENSG00000247828.6	TMEM161B-AS1	4.3	2.09e-05	0.00198	0.17	0.19	Depressive symptoms;	chr5:88405666	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs12523282	ENSG00000247828.6	TMEM161B-AS1	4.3	2.09e-05	0.00198	0.17	0.19	Depressive symptoms;	chr5:88407679	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs12651891	ENSG00000247828.6	TMEM161B-AS1	4.3	2.09e-05	0.00198	0.17	0.19	Depressive symptoms;	chr5:88408187	chr5:88268895~88436685:+
THCA	cis	rs11853189	0.938	rs76053575	ENSG00000259562.2	RP11-762H8.2	4.3	2.09e-05	0.00198	0.19	0.19	Red cell distribution width;	chr15:78310679	chr15:78290527~78291221:-
THCA	cis	rs9595908	0.709	rs7319275	ENSG00000212293.1	SNORA16	4.3	2.09e-05	0.00198	0.23	0.19	Body mass index;	chr13:32733280	chr13:32420390~32420516:-
THCA	cis	rs2657294	0.965	rs2395140	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00198	-0.26	-0.19	Pneumonia;	chr10:75139253	chr10:75276376~75276646:-
THCA	cis	rs2657294	0.965	rs2997754	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00198	-0.26	-0.19	Pneumonia;	chr10:75144379	chr10:75276376~75276646:-
THCA	cis	rs2657294	0.965	rs10824285	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00198	-0.26	-0.19	Pneumonia;	chr10:75153271	chr10:75276376~75276646:-
THCA	cis	rs2657294	0.965	rs2047951	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00198	-0.26	-0.19	Pneumonia;	chr10:75161310	chr10:75276376~75276646:-
THCA	cis	rs2657294	0.965	rs2804523	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00198	-0.26	-0.19	Pneumonia;	chr10:75161584	chr10:75276376~75276646:-
THCA	cis	rs2657294	0.965	rs7899946	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00198	-0.26	-0.19	Pneumonia;	chr10:75166013	chr10:75276376~75276646:-
THCA	cis	rs8028182	0.636	rs62027181	ENSG00000260269.4	CTD-2323K18.1	-4.3	2.09e-05	0.00198	-0.29	-0.19	Sudden cardiac arrest;	chr15:75547611	chr15:75527150~75601205:-
THCA	cis	rs6787172	0.811	rs6441204	ENSG00000272087.1	RP11-379F4.7	4.3	2.09e-05	0.00198	0.17	0.19	Subjective well-being;	chr3:158482424	chr3:158693120~158693768:-
THCA	cis	rs1559040	1	rs6721034	ENSG00000272156.1	RP11-477N3.1	-4.3	2.09e-05	0.00198	-0.32	-0.19	Sudden cardiac arrest;	chr2:54120170	chr2:54082554~54085066:+
THCA	cis	rs4763879	0.778	rs9332411	ENSG00000256673.1	RP11-599J14.2	4.3	2.09e-05	0.00198	0.24	0.19	Type 1 diabetes;	chr12:9681749	chr12:9398355~9414851:-
THCA	cis	rs4648045	0.647	rs230528	ENSG00000246560.2	RP11-10L12.4	-4.3	2.09e-05	0.00198	-0.23	-0.19	Lymphocyte percentage of white cells;	chr4:102536428	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.685	rs4785571	ENSG00000261118.1	RP11-104N10.1	4.3	2.09e-05	0.00199	0.17	0.19	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89492017~89504460:-
THCA	cis	rs42648	0.869	rs3810891	ENSG00000225498.1	AC002064.5	4.3	2.09e-05	0.00199	0.2	0.19	Homocysteine levels;	chr7:90279537	chr7:90312496~90322592:+
THCA	cis	rs2640806	0.506	rs2678329	ENSG00000253105.4	KB-1448A5.1	4.3	2.09e-05	0.00199	0.23	0.19	Obesity-related traits;	chr8:96362425	chr8:96371865~96387438:-
THCA	cis	rs10129255	0.957	rs4387509	ENSG00000211972.2	IGHV3-66	4.3	2.09e-05	0.00199	0.12	0.19	Kawasaki disease;	chr14:106704386	chr14:106675017~106675544:-
THCA	cis	rs1707322	1	rs12077974	ENSG00000281133.1	AL355480.3	-4.3	2.09e-05	0.00199	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45580892~45580996:-
THCA	cis	rs7176527	0.796	rs1057946	ENSG00000225151.9	GOLGA2P7	4.3	2.09e-05	0.00199	0.34	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:84199311~84230136:-
THCA	cis	rs1232027	0.7	rs1677688	ENSG00000249655.1	CTC-325J23.2	4.3	2.09e-05	0.00199	0.22	0.19	Huntington's disease progression;	chr5:80642188	chr5:80630313~80631590:-
THCA	cis	rs6806253	0.816	rs2713589	ENSG00000239405.1	TMED10P2	-4.3	2.09e-05	0.00199	-0.3	-0.19	Pit-and-Fissure caries;	chr3:128571365	chr3:128538020~128538631:+
THCA	cis	rs1150668	0.796	rs1124132	ENSG00000176933.5	TOB2P1	-4.3	2.09e-05	0.00199	-0.21	-0.19	Pubertal anthropometrics;	chr6:28412544	chr6:28217643~28218634:-
THCA	cis	rs7746199	0.736	rs13212318	ENSG00000220721.1	OR1F12	4.3	2.09e-05	0.00199	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs13202291	ENSG00000220721.1	OR1F12	4.3	2.09e-05	0.00199	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.736	rs17750424	ENSG00000220721.1	OR1F12	4.3	2.09e-05	0.00199	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28073316~28074233:+
THCA	cis	rs10452033	0.54	rs62252819	ENSG00000242142.1	SERBP1P3	-4.3	2.09e-05	0.00199	-0.27	-0.19	Electrocardiographic traits;	chr3:53406101	chr3:53064283~53065091:-
THCA	cis	rs57221529	0.766	rs28563961	ENSG00000225138.6	CTD-2228K2.7	4.3	2.09e-05	0.00199	0.26	0.19	Lung disease severity in cystic fibrosis;	chr5:554383	chr5:473236~480884:+
THCA	cis	rs2657294	0.965	rs4746264	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00199	-0.25	-0.19	Pneumonia;	chr10:75114194	chr10:75276376~75276646:-
THCA	cis	rs2657294	0.965	rs9299525	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00199	-0.25	-0.19	Pneumonia;	chr10:75118267	chr10:75276376~75276646:-
THCA	cis	rs2657294	0.965	rs10762658	ENSG00000233313.2	HMGA1P5	-4.3	2.09e-05	0.00199	-0.25	-0.19	Pneumonia;	chr10:75119804	chr10:75276376~75276646:-
THCA	cis	rs7176527	0.8	rs56747535	ENSG00000230373.7	GOLGA6L5P	4.3	2.1e-05	0.00199	0.25	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:84507885~84516814:-
THCA	cis	rs7267979	0.816	rs374701	ENSG00000274973.1	RP13-401N8.7	-4.3	2.1e-05	0.00199	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25845497~25845862:+
THCA	cis	rs7403037	0.565	rs35358454	ENSG00000260760.1	PWRN3	4.3	2.1e-05	0.00199	0.26	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24286089	chr15:24441127~24447967:+
THCA	cis	rs12134133	0.962	rs17258843	ENSG00000237074.1	RP11-6J21.2	4.3	2.1e-05	0.00199	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207249067~207309121:+
THCA	cis	rs5758659	0.714	rs5751216	ENSG00000273366.1	CTA-989H11.1	4.3	2.1e-05	0.00199	0.23	0.19	Cognitive function;	chr22:42112933	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.714	rs5758589	ENSG00000273366.1	CTA-989H11.1	4.3	2.1e-05	0.00199	0.23	0.19	Cognitive function;	chr22:42122378	chr22:42278188~42278846:+
THCA	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-4.3	2.1e-05	0.00199	-0.22	-0.19	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
THCA	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	4.3	2.1e-05	0.00199	0.09	0.19	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
THCA	cis	rs12234571	1	rs59056139	ENSG00000214293.7	APTR	4.3	2.1e-05	0.00199	0.25	0.19	Obesity-related traits;	chr7:77819354	chr7:77657660~77696265:-
THCA	cis	rs1124769	0.685	rs2574754	ENSG00000259378.1	DCAF13P3	4.3	2.1e-05	0.00199	0.29	0.19	Cognitive performance;	chr15:50832242	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.672	rs2663530	ENSG00000259378.1	DCAF13P3	4.3	2.1e-05	0.00199	0.29	0.19	Cognitive performance;	chr15:50835453	chr15:50944663~50945996:+
THCA	cis	rs4714902	0.688	rs13210417	ENSG00000231769.2	RP1-8B1.4	-4.3	2.1e-05	0.00199	-0.17	-0.19	Colonoscopy-negative controls vs population controls;	chr6:46106406	chr6:46097093~46129706:-
THCA	cis	rs6860806	0.507	rs2631369	ENSG00000224431.1	AC063976.7	-4.3	2.1e-05	0.00199	-0.17	-0.19	Breast cancer;	chr5:132369574	chr5:132199456~132203487:+
THCA	cis	rs274567	0.501	rs2631368	ENSG00000224431.1	AC063976.7	-4.3	2.1e-05	0.00199	-0.17	-0.19	Blood metabolite levels;	chr5:132369605	chr5:132199456~132203487:+
THCA	cis	rs10911902	0.643	rs16825248	ENSG00000229739.2	RP11-295K2.3	-4.3	2.1e-05	0.00199	-0.31	-0.19	Schizophrenia;	chr1:186358057	chr1:186435161~186470291:+
THCA	cis	rs786425	0.711	rs1060637	ENSG00000270095.1	RP11-214K3.18	-4.3	2.1e-05	0.00199	-0.23	-0.19	Pubertal anthropometrics;	chr12:123625575	chr12:123971457~123971714:-
THCA	cis	rs9880211	0.752	rs9847427	ENSG00000239213.4	NCK1-AS1	4.3	2.1e-05	0.00199	0.22	0.19	Height;Body mass index;	chr3:136632708	chr3:136841726~136862054:-
THCA	cis	rs699371	0.525	rs1156021	ENSG00000259005.1	RP3-449M8.6	4.3	2.1e-05	0.00199	0.18	0.19	Height;	chr14:74432889	chr14:74474007~74474864:-
THCA	cis	rs7615952	0.512	rs2979336	ENSG00000272840.1	RP11-379B18.6	4.3	2.1e-05	0.00199	0.28	0.19	Blood pressure (smoking interaction);	chr3:125638626	chr3:125774714~125797953:+
THCA	cis	rs4805272	1	rs6509067	ENSG00000267799.1	MAN1A2P1	-4.3	2.1e-05	0.00199	-0.21	-0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28835172	chr19:28790812~28792871:-
THCA	cis	rs786425	0.682	rs12829893	ENSG00000270095.1	RP11-214K3.18	4.3	2.1e-05	0.00199	0.23	0.19	Pubertal anthropometrics;	chr12:123682431	chr12:123971457~123971714:-
THCA	cis	rs6787172	0.811	rs6780896	ENSG00000272087.1	RP11-379F4.7	4.3	2.1e-05	0.00199	0.17	0.19	Subjective well-being;	chr3:158477606	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.728	rs6783284	ENSG00000272087.1	RP11-379F4.7	4.3	2.1e-05	0.00199	0.17	0.19	Subjective well-being;	chr3:158477761	chr3:158693120~158693768:-
THCA	cis	rs72928364	1	rs67946790	ENSG00000256628.3	ZBTB11-AS1	4.3	2.1e-05	0.00199	0.34	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100969838	chr3:101676475~101679217:+
THCA	cis	rs897984	0.553	rs2335013	ENSG00000260911.2	RP11-196G11.2	-4.3	2.1e-05	0.00199	-0.18	-0.19	Dementia with Lewy bodies;	chr16:30866025	chr16:31043150~31049868:+
THCA	cis	rs4144027	0.904	rs10438244	ENSG00000269940.1	RP11-73M18.7	-4.3	2.1e-05	0.00199	-0.2	-0.19	Blood metabolite levels;	chr14:103879848	chr14:103694560~103695170:+
THCA	cis	rs875971	0.862	rs11984115	ENSG00000229886.1	RP5-1132H15.3	-4.3	2.1e-05	0.00199	-0.2	-0.19	Aortic root size;	chr7:66308872	chr7:66025126~66031544:-
THCA	cis	rs1476679	1	rs34919929	ENSG00000078319.8	PMS2P1	-4.3	2.1e-05	0.00199	-0.23	-0.19	Alzheimer's disease (late onset);	chr7:100414711	chr7:100320992~100341908:-
THCA	cis	rs12410462	0.551	rs2814084	ENSG00000227711.2	RP11-275O4.5	-4.3	2.1e-05	0.00199	-0.24	-0.19	Major depressive disorder;	chr1:227526595	chr1:227509028~227520477:-
THCA	cis	rs7474896	0.537	rs2472149	ENSG00000263064.2	RP11-291L22.7	-4.3	2.1e-05	0.00199	-0.26	-0.19	Obesity (extreme);	chr10:37973268	chr10:38448689~38448949:+
THCA	cis	rs4356203	0.905	rs11024159	ENSG00000272034.1	SNORD14A	-4.3	2.1e-05	0.00199	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105795	chr11:17074654~17074744:-
THCA	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	4.3	2.1e-05	0.00199	0.23	0.19	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
THCA	cis	rs6715284	0.892	rs72934991	ENSG00000238829.1	RNU7-45P	-4.3	2.1e-05	0.002	-0.47	-0.19	Rheumatoid arthritis;	chr2:201352338	chr2:201141904~201141966:+
THCA	cis	rs4308124	0.708	rs7585313	ENSG00000230499.1	AC108463.1	-4.3	2.1e-05	0.002	-0.28	-0.19	Vitiligo;	chr2:111217626	chr2:111195963~111206494:+
THCA	cis	rs2554380	0.6	rs6602986	ENSG00000176700.18	SCAND2P	-4.3	2.1e-05	0.002	-0.15	-0.19	Height;	chr15:83778347	chr15:84631451~84647478:+
THCA	cis	rs897984	0.762	rs12930545	ENSG00000275263.1	RP11-1072A3.4	4.3	2.1e-05	0.002	0.23	0.19	Dementia with Lewy bodies;	chr16:30927490	chr16:30956872~30957199:-
THCA	cis	rs897984	0.806	rs10782001	ENSG00000275263.1	RP11-1072A3.4	4.3	2.1e-05	0.002	0.23	0.19	Dementia with Lewy bodies;	chr16:30931304	chr16:30956872~30957199:-
THCA	cis	rs897984	0.806	rs12928852	ENSG00000275263.1	RP11-1072A3.4	4.3	2.1e-05	0.002	0.23	0.19	Dementia with Lewy bodies;	chr16:30932667	chr16:30956872~30957199:-
THCA	cis	rs7577696	0.924	rs6748621	ENSG00000276334.1	AL133243.1	-4.3	2.1e-05	0.002	-0.2	-0.19	Inflammatory biomarkers;	chr2:32037132	chr2:32521927~32523547:+
THCA	cis	rs9796	0.621	rs58109657	ENSG00000247556.5	OIP5-AS1	-4.3	2.1e-05	0.002	-0.15	-0.19	Menopause (age at onset);	chr15:41179552	chr15:41283990~41309737:+
THCA	cis	rs1124769	0.719	rs2619692	ENSG00000259378.1	DCAF13P3	-4.3	2.1e-05	0.002	-0.29	-0.19	Cognitive performance;	chr15:50902968	chr15:50944663~50945996:+
THCA	cis	rs357618	0.897	rs165362	ENSG00000260581.1	CTB-113P19.4	4.3	2.1e-05	0.002	0.26	0.19	Basophil percentage of white cells;	chr5:151483526	chr5:151652275~151655449:+
THCA	cis	rs1923243	0.618	rs4297242	ENSG00000223479.3	RP4-788P17.1	4.3	2.1e-05	0.002	0.22	0.19	Migraine;	chr1:73091801	chr1:73635216~73715214:+
THCA	cis	rs9488822	0.596	rs6568921	ENSG00000237021.2	RP3-486I3.7	4.3	2.1e-05	0.002	0.21	0.19	LDL cholesterol;Cholesterol, total;	chr6:116052453	chr6:116254207~116256743:+
THCA	cis	rs1979679	0.766	rs10843197	ENSG00000247934.4	RP11-967K21.1	4.3	2.11e-05	0.002	0.19	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28518308	chr12:28163298~28190738:-
THCA	cis	rs1046896	0.514	rs67735447	ENSG00000263063.1	RP11-388C12.1	-4.3	2.11e-05	0.002	-0.25	-0.19	Glycated hemoglobin levels;	chr17:82865166	chr17:82713908~82716255:-
THCA	cis	rs786425	0.682	rs7136939	ENSG00000270095.1	RP11-214K3.18	-4.3	2.11e-05	0.002	-0.23	-0.19	Pubertal anthropometrics;	chr12:123705110	chr12:123971457~123971714:-
THCA	cis	rs74233809	1	rs76752100	ENSG00000272912.1	RP11-724N1.1	-4.3	2.11e-05	0.002	-0.36	-0.19	Birth weight;	chr10:103034329	chr10:102914585~102915404:+
THCA	cis	rs7688540	0.511	rs77815676	ENSG00000211553.1	AC253576.2	-4.3	2.11e-05	0.002	-0.3	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:136461~136568:+
THCA	cis	rs780094	0.5	rs12478841	ENSG00000234072.1	AC074117.10	4.3	2.11e-05	0.002	0.15	0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27588855	chr2:27356246~27367622:+
THCA	cis	rs780094	0.5	rs6760250	ENSG00000234072.1	AC074117.10	4.3	2.11e-05	0.002	0.15	0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27589385	chr2:27356246~27367622:+
THCA	cis	rs780094	0.5	rs13022873	ENSG00000234072.1	AC074117.10	4.3	2.11e-05	0.002	0.15	0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27592643	chr2:27356246~27367622:+
THCA	cis	rs4666002	0.956	rs2384656	ENSG00000234072.1	AC074117.10	4.3	2.11e-05	0.002	0.15	0.19	Phospholipid levels (plasma);	chr2:27609188	chr2:27356246~27367622:+
THCA	cis	rs4805272	1	rs888827	ENSG00000267799.1	MAN1A2P1	4.3	2.11e-05	0.002	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834449	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.925	rs9304627	ENSG00000267799.1	MAN1A2P1	4.3	2.11e-05	0.002	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834549	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs7254025	ENSG00000267799.1	MAN1A2P1	4.3	2.11e-05	0.002	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28835199	chr19:28790812~28792871:-
THCA	cis	rs4578769	0.959	rs11082184	ENSG00000265939.1	UBE2CP2	4.3	2.11e-05	0.002	0.24	0.19	Eosinophil percentage of white cells;	chr18:22872288	chr18:22900486~22900995:-
THCA	cis	rs755249	1	rs4660293	ENSG00000237624.1	OXCT2P1	-4.3	2.11e-05	0.002	-0.27	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39514956~39516490:+
THCA	cis	rs6570726	0.791	rs6918814	ENSG00000270638.1	RP3-466P17.1	4.3	2.11e-05	0.002	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145735570~145737218:+
THCA	cis	rs4803480	0.935	rs1476769	ENSG00000270164.1	LINC01480	-4.3	2.11e-05	0.002	-0.2	-0.19	Schizophrenia;	chr19:41577925	chr19:41535183~41536904:+
THCA	cis	rs4803480	0.873	rs1476770	ENSG00000270164.1	LINC01480	-4.3	2.11e-05	0.002	-0.2	-0.19	Schizophrenia;	chr19:41578033	chr19:41535183~41536904:+
THCA	cis	rs7551222	0.614	rs7519417	ENSG00000240219.1	RP11-430C7.5	4.3	2.11e-05	0.002	0.19	0.19	Schizophrenia;	chr1:204480824	chr1:204626775~204629712:+
THCA	cis	rs728616	0.51	rs17679603	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.11e-05	0.002	-0.34	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80421678	chr10:79663088~79826594:-
THCA	cis	rs2948294	0.588	rs7011221	ENSG00000233609.3	RP11-62H7.2	4.3	2.11e-05	0.002	0.19	0.19	Red cell distribution width;	chr8:8256724	chr8:8961200~8979025:+
THCA	cis	rs2948294	0.545	rs11776397	ENSG00000233609.3	RP11-62H7.2	4.3	2.11e-05	0.002	0.19	0.19	Red cell distribution width;	chr8:8257639	chr8:8961200~8979025:+
THCA	cis	rs12410462	0.591	rs68186506	ENSG00000227711.2	RP11-275O4.5	-4.3	2.11e-05	0.002	-0.24	-0.19	Major depressive disorder;	chr1:227639087	chr1:227509028~227520477:-
THCA	cis	rs7429990	0.965	rs35012836	ENSG00000228638.1	FCF1P2	-4.3	2.11e-05	0.002	-0.21	-0.19	Educational attainment (years of education);	chr3:47670000	chr3:48290793~48291375:-
THCA	cis	rs7176527	0.848	rs17600128	ENSG00000225151.9	GOLGA2P7	4.3	2.11e-05	0.002	0.37	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:84199311~84230136:-
THCA	cis	rs13256369	0.95	rs13248096	ENSG00000254153.1	CTA-398F10.2	-4.3	2.11e-05	0.002	-0.22	-0.19	Obesity-related traits;	chr8:8719966	chr8:8456909~8461337:-
THCA	cis	rs7818688	0.51	rs12544717	ENSG00000253528.2	RP11-347C18.4	-4.3	2.11e-05	0.002	-0.31	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95076747	chr8:94974573~94974853:-
THCA	cis	rs12755164	0.771	rs11210085	ENSG00000223479.3	RP4-788P17.1	-4.3	2.11e-05	0.002	-0.21	-0.19	Schizophrenia;	chr1:72896783	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.771	rs1464952	ENSG00000223479.3	RP4-788P17.1	-4.3	2.11e-05	0.002	-0.21	-0.19	Schizophrenia;	chr1:72897316	chr1:73635216~73715214:+
THCA	cis	rs790006	0.959	rs790008	ENSG00000243024.5	RPS11P6	4.3	2.11e-05	0.002	0.23	0.19	Response to cytidine analogues (gemcitabine);	chr12:64210920	chr12:64222337~64397065:+
THCA	cis	rs6442522	0.678	rs11128745	ENSG00000249786.6	EAF1-AS1	4.3	2.11e-05	0.002	0.2	0.19	Uric acid levels;	chr3:15456754	chr3:15436171~15455940:-
THCA	cis	rs8177876	0.658	rs12456	ENSG00000261061.1	RP11-303E16.2	-4.3	2.11e-05	0.002	-0.3	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031454	chr16:81030770~81031485:+
THCA	cis	rs12446554	0.509	rs56108048	ENSG00000261195.1	CTD-2380F24.1	-4.3	2.11e-05	0.002	-0.32	-0.19	Obesity;	chr16:19698457	chr16:19761172~19766099:-
THCA	cis	rs2281603	0.57	rs11623457	ENSG00000272909.1	CTD-2555O16.4	-4.3	2.11e-05	0.002	-0.23	-0.19	Lymphocyte counts;	chr14:64491388	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs1980520	ENSG00000272909.1	CTD-2555O16.4	-4.3	2.11e-05	0.002	-0.23	-0.19	Lymphocyte counts;	chr14:64493128	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs1980519	ENSG00000272909.1	CTD-2555O16.4	-4.3	2.11e-05	0.002	-0.23	-0.19	Lymphocyte counts;	chr14:64493137	chr14:64440369~64442238:-
THCA	cis	rs728616	0.614	rs1998374	ENSG00000242600.5	MBL1P	4.3	2.11e-05	0.002	0.21	0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79942966	chr10:79904898~79950336:+
THCA	cis	rs7044106	0.537	rs10739573	ENSG00000270917.1	RP11-27I1.6	-4.3	2.11e-05	0.002	-0.29	-0.19	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120812475~120812845:-
THCA	cis	rs9810089	0.802	rs833861	ENSG00000273455.1	RP11-305O4.3	4.3	2.11e-05	0.002	0.26	0.19	Gestational age at birth (child effect);	chr3:136512225	chr3:136087475~136087913:-
THCA	cis	rs13256369	0.95	rs13270006	ENSG00000254153.1	CTA-398F10.2	-4.3	2.11e-05	0.002	-0.22	-0.19	Obesity-related traits;	chr8:8716687	chr8:8456909~8461337:-
THCA	cis	rs9902453	0.874	rs3936006	ENSG00000263370.1	RP11-68I3.5	4.3	2.11e-05	0.002	0.25	0.19	Coffee consumption (cups per day);	chr17:29930642	chr17:29639627~29640825:+
THCA	cis	rs2688608	0.967	rs72814394	ENSG00000271816.1	BMS1P4	4.3	2.11e-05	0.002	0.19	0.19	Inflammatory bowel disease;	chr10:73896567	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.967	rs2633299	ENSG00000271816.1	BMS1P4	4.3	2.11e-05	0.002	0.19	0.19	Inflammatory bowel disease;	chr10:73896996	chr10:73699151~73730487:-
THCA	cis	rs4759375	1	rs2271976	ENSG00000256092.2	RP13-942N8.1	-4.3	2.11e-05	0.002	-0.21	-0.19	HDL cholesterol;	chr12:123267179	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs61953394	ENSG00000256092.2	RP13-942N8.1	-4.3	2.11e-05	0.002	-0.21	-0.19	HDL cholesterol;	chr12:123268825	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs11057224	ENSG00000256092.2	RP13-942N8.1	-4.3	2.11e-05	0.002	-0.21	-0.19	HDL cholesterol;	chr12:123270632	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs1109560	ENSG00000256092.2	RP13-942N8.1	-4.3	2.11e-05	0.002	-0.21	-0.19	HDL cholesterol;	chr12:123273358	chr12:123363868~123366113:+
THCA	cis	rs2191566	1	rs7256908	ENSG00000266921.1	RP11-15A1.7	-4.3	2.11e-05	0.002	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44024746	chr19:43996896~44002836:-
THCA	cis	rs12234571	1	rs59900083	ENSG00000214293.7	APTR	4.3	2.11e-05	0.002	0.27	0.19	Obesity-related traits;	chr7:77865031	chr7:77657660~77696265:-
THCA	cis	rs1923243	0.71	rs11210141	ENSG00000223479.3	RP4-788P17.1	4.3	2.11e-05	0.002	0.22	0.19	Migraine;	chr1:73140204	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.74	rs12407163	ENSG00000223479.3	RP4-788P17.1	4.3	2.11e-05	0.002	0.22	0.19	Migraine;	chr1:73141288	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12143587	ENSG00000223479.3	RP4-788P17.1	4.3	2.11e-05	0.002	0.22	0.19	Migraine;	chr1:73143850	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs57852356	ENSG00000223479.3	RP4-788P17.1	4.3	2.11e-05	0.002	0.22	0.19	Migraine;	chr1:73146005	chr1:73635216~73715214:+
THCA	cis	rs875971	0.522	rs709604	ENSG00000234585.5	CCT6P3	-4.3	2.11e-05	0.002	-0.17	-0.19	Aortic root size;	chr7:66032447	chr7:65038354~65074713:+
THCA	cis	rs10090774	0.965	rs4961233	ENSG00000279766.1	RP11-642A1.2	4.3	2.11e-05	0.002	0.24	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140798849	chr8:140572142~140572812:-
THCA	cis	rs4819052	0.851	rs3673	ENSG00000273796.1	LL21NC02-21A1.1	-4.3	2.11e-05	0.002	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45403809~45404369:-
THCA	cis	rs72759215	1	rs72759215	ENSG00000215032.2	GNL3LP1	4.3	2.11e-05	0.002	0.23	0.19	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60891935~60893577:-
THCA	cis	rs67478160	0.619	rs12886363	ENSG00000269940.1	RP11-73M18.7	4.3	2.11e-05	0.002	0.19	0.19	Schizophrenia;	chr14:103807449	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs12880821	ENSG00000269940.1	RP11-73M18.7	4.3	2.11e-05	0.002	0.19	0.19	Schizophrenia;	chr14:103809712	chr14:103694560~103695170:+
THCA	cis	rs8062405	0.655	rs7184597	ENSG00000261766.1	RP11-22P6.2	4.3	2.11e-05	0.002	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28862166~28863340:-
THCA	cis	rs61270009	0.955	rs11748798	ENSG00000247828.6	TMEM161B-AS1	4.3	2.11e-05	0.00201	0.17	0.19	Depressive symptoms;	chr5:88354925	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs11740836	ENSG00000247828.6	TMEM161B-AS1	4.3	2.11e-05	0.00201	0.17	0.19	Depressive symptoms;	chr5:88356311	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.913	rs13154590	ENSG00000247828.6	TMEM161B-AS1	4.3	2.11e-05	0.00201	0.17	0.19	Depressive symptoms;	chr5:88357208	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs2115884	ENSG00000247828.6	TMEM161B-AS1	4.3	2.11e-05	0.00201	0.17	0.19	Depressive symptoms;	chr5:88358839	chr5:88268895~88436685:+
THCA	cis	rs4568518	0.53	rs6967917	ENSG00000279048.1	RP11-511H23.2	4.3	2.11e-05	0.00201	0.12	0.19	Measles;	chr7:17944674	chr7:17940503~17942922:+
THCA	cis	rs867186	0.92	rs56289894	ENSG00000126005.14	MMP24-AS1	-4.3	2.11e-05	0.00201	-0.24	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35131597	chr20:35216462~35278131:-
THCA	cis	rs867186	0.925	rs1033797	ENSG00000126005.14	MMP24-AS1	-4.3	2.11e-05	0.00201	-0.24	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35131884	chr20:35216462~35278131:-
THCA	cis	rs17095355	1	rs731793	ENSG00000203876.8	ADD3-AS1	4.3	2.12e-05	0.00201	0.21	0.19	Biliary atresia;	chr10:109956909	chr10:109940104~110008381:-
THCA	cis	rs964611	0.882	rs4775747	ENSG00000259488.2	RP11-154J22.1	-4.3	2.12e-05	0.00201	-0.17	-0.19	Metabolite levels (Pyroglutamine);	chr15:48346146	chr15:48312353~48331856:-
THCA	cis	rs10946940	0.896	rs12208078	ENSG00000216915.2	RP1-97D16.1	4.3	2.12e-05	0.00201	0.26	0.19	Systemic lupus erythematosus;	chr6:27530802	chr6:27737000~27738494:-
THCA	cis	rs10946940	0.965	rs10946935	ENSG00000216915.2	RP1-97D16.1	4.3	2.12e-05	0.00201	0.26	0.19	Systemic lupus erythematosus;	chr6:27533566	chr6:27737000~27738494:-
THCA	cis	rs17095355	1	rs9630102	ENSG00000203876.8	ADD3-AS1	-4.3	2.12e-05	0.00201	-0.21	-0.19	Biliary atresia;	chr10:109978904	chr10:109940104~110008381:-
THCA	cis	rs3198697	0.663	rs12928099	ENSG00000263335.1	AF001548.5	-4.3	2.12e-05	0.00201	-0.24	-0.19	Triglycerides;	chr16:15056648	chr16:15726674~15732993:+
THCA	cis	rs9902453	0.904	rs12951836	ENSG00000263370.1	RP11-68I3.5	-4.3	2.12e-05	0.00201	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30083259	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs12948898	ENSG00000263370.1	RP11-68I3.5	-4.3	2.12e-05	0.00201	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30083306	chr17:29639627~29640825:+
THCA	cis	rs4938330	0.629	rs12269901	ENSG00000254851.1	RP11-109L13.1	4.3	2.12e-05	0.00201	0.27	0.19	Blood protein levels;	chr11:117103213	chr11:117135528~117138582:+
THCA	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-4.3	2.12e-05	0.00201	-0.24	-0.19	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-4.3	2.12e-05	0.00201	-0.24	-0.19	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
THCA	cis	rs4654783	0.521	rs59709264	ENSG00000228397.1	RP1-224A6.3	4.3	2.12e-05	0.00201	0.28	0.19	Endometriosis;	chr1:22122832	chr1:22023994~22024968:-
THCA	cis	rs10833905	1	rs11026893	ENSG00000246225.5	RP11-17A1.3	-4.3	2.12e-05	0.00201	-0.28	-0.19	Sudden cardiac arrest;	chr11:23002690	chr11:22829380~22945393:+
THCA	cis	rs944289	0.515	rs1755768	ENSG00000258844.1	RP11-259K15.2	4.3	2.12e-05	0.00201	0.19	0.19	Thyroid cancer;	chr14:36192691	chr14:36214607~36235608:+
THCA	cis	rs12681288	0.823	rs2600518	ENSG00000260721.1	AF067845.1	4.3	2.12e-05	0.00201	0.23	0.19	Schizophrenia;	chr8:1057214	chr8:1368642~1369833:-
THCA	cis	rs1129187	0.935	rs4987173	ENSG00000272223.1	RP1-20C7.6	4.3	2.12e-05	0.00201	0.15	0.19	Alzheimer's disease in APOE e4+ carriers;	chr6:42963486	chr6:43033897~43034405:-
THCA	cis	rs875971	0.893	rs62465470	ENSG00000229886.1	RP5-1132H15.3	-4.3	2.12e-05	0.00201	-0.2	-0.19	Aortic root size;	chr7:66136231	chr7:66025126~66031544:-
THCA	cis	rs10090774	0.93	rs4246127	ENSG00000279766.1	RP11-642A1.2	4.3	2.12e-05	0.00201	0.24	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830546	chr8:140572142~140572812:-
THCA	cis	rs8023401	0.529	rs4775762	ENSG00000259705.1	RP11-227D13.1	-4.3	2.12e-05	0.00201	-0.25	-0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48451808	chr15:48645951~48652016:+
THCA	cis	rs6787172	0.755	rs6778202	ENSG00000272087.1	RP11-379F4.7	4.3	2.12e-05	0.00201	0.17	0.19	Subjective well-being;	chr3:158482786	chr3:158693120~158693768:-
THCA	cis	rs997295	0.592	rs2899724	ENSG00000270964.1	RP11-502I4.3	-4.3	2.12e-05	0.00201	-0.16	-0.19	Motion sickness;	chr15:67468470	chr15:67541072~67542604:-
THCA	cis	rs12612619	0.704	rs6714547	ENSG00000272148.1	RP11-195B17.1	4.3	2.12e-05	0.00201	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27098338	chr2:27062428~27062907:-
THCA	cis	rs970548	0.954	rs2291428	ENSG00000230869.1	CTGLF10P	4.3	2.12e-05	0.00201	0.25	0.19	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45463408	chr10:45678692~45700532:+
THCA	cis	rs10090774	0.965	rs4543590	ENSG00000279766.1	RP11-642A1.2	-4.3	2.12e-05	0.00201	-0.24	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140715735	chr8:140572142~140572812:-
THCA	cis	rs12893668	0.703	rs4906337	ENSG00000252469.1	RNU7-160P	4.3	2.12e-05	0.00201	0.23	0.19	Reticulocyte count;	chr14:103574077	chr14:103550345~103550406:+
THCA	cis	rs12893668	0.703	rs7140568	ENSG00000252469.1	RNU7-160P	4.3	2.12e-05	0.00201	0.23	0.19	Reticulocyte count;	chr14:103575037	chr14:103550345~103550406:+
THCA	cis	rs12893668	0.703	rs35026580	ENSG00000252469.1	RNU7-160P	4.3	2.12e-05	0.00201	0.23	0.19	Reticulocyte count;	chr14:103576416	chr14:103550345~103550406:+
THCA	cis	rs9467773	0.838	rs3734540	ENSG00000261353.1	CTA-14H9.5	-4.3	2.12e-05	0.00201	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26463093	chr6:26527063~26527404:+
THCA	cis	rs2380220	0.678	rs4308568	ENSG00000261366.1	MANEA-AS1	4.3	2.12e-05	0.00201	0.19	0.19	Behavioural disinhibition (generation interaction);	chr6:95561649	chr6:95575183~95577450:-
THCA	cis	rs7688014	1	rs7688014	ENSG00000248971.2	KRT8P46	-4.3	2.12e-05	0.00201	-0.24	-0.19	Schizophrenia;	chr4:103053903	chr4:102728746~102730171:-
THCA	cis	rs9307551	0.6	rs11098776	ENSG00000250334.4	LINC00989	-4.3	2.12e-05	0.00201	-0.22	-0.19	Refractive error;	chr4:79617600	chr4:79492416~79576460:+
THCA	cis	rs57339844	1	rs57339844	ENSG00000273080.1	RP11-301O19.1	-4.3	2.12e-05	0.00201	-0.22	-0.19	Mean platelet volume;	chr2:85891155	chr2:86195590~86196049:+
THCA	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	4.3	2.12e-05	0.00201	0.21	0.19	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
THCA	cis	rs4144027	0.904	rs10438242	ENSG00000269940.1	RP11-73M18.7	-4.3	2.12e-05	0.00201	-0.19	-0.19	Blood metabolite levels;	chr14:103878738	chr14:103694560~103695170:+
THCA	cis	rs55702914	0.967	rs61328028	ENSG00000231621.1	AC013264.2	-4.3	2.12e-05	0.00201	-0.19	-0.19	Major depression and alcohol dependence;	chr2:197359030	chr2:197197991~197199273:+
THCA	cis	rs4934494	0.573	rs67157720	ENSG00000240996.1	RP11-80H5.7	-4.29	2.12e-05	0.00201	-0.23	-0.19	Red blood cell count;	chr10:89820415	chr10:89694295~89697928:-
THCA	cis	rs2522056	1	rs11242113	ENSG00000237714.1	P4HA2-AS1	-4.29	2.12e-05	0.00201	-0.28	-0.19	Fibrinogen;Lymphocyte counts;	chr5:132441542	chr5:132184876~132192808:+
THCA	cis	rs9368481	0.645	rs10456350	ENSG00000261353.1	CTA-14H9.5	-4.29	2.13e-05	0.00201	-0.21	-0.19	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26527063~26527404:+
THCA	cis	rs1923243	0.71	rs4603080	ENSG00000223479.3	RP4-788P17.1	4.29	2.13e-05	0.00201	0.22	0.19	Migraine;	chr1:73113554	chr1:73635216~73715214:+
THCA	cis	rs8062405	0.792	rs12446550	ENSG00000270424.1	RP11-1348G14.6	4.29	2.13e-05	0.00201	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28749959~28750595:-
THCA	cis	rs31251	1	rs31251	ENSG00000237714.1	P4HA2-AS1	-4.29	2.13e-05	0.00202	-0.24	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr5:131498253	chr5:132184876~132192808:+
THCA	cis	rs9900062	1	rs11871616	ENSG00000270714.1	MINOS1P2	-4.29	2.13e-05	0.00202	-0.28	-0.19	QT interval;	chr17:64741484	chr17:64747264~64747492:-
THCA	cis	rs5758659	0.652	rs133322	ENSG00000273366.1	CTA-989H11.1	-4.29	2.13e-05	0.00202	-0.24	-0.19	Cognitive function;	chr22:42009655	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.623	rs133328	ENSG00000273366.1	CTA-989H11.1	-4.29	2.13e-05	0.00202	-0.24	-0.19	Cognitive function;	chr22:42012075	chr22:42278188~42278846:+
THCA	cis	rs709400	1	rs3783404	ENSG00000258735.1	LINC00637	4.29	2.13e-05	0.00202	0.25	0.19	Body mass index;	chr14:103652161	chr14:103847721~103858049:+
THCA	cis	rs709400	0.832	rs10145755	ENSG00000258735.1	LINC00637	4.29	2.13e-05	0.00202	0.25	0.19	Body mass index;	chr14:103655647	chr14:103847721~103858049:+
THCA	cis	rs709400	1	rs55885592	ENSG00000258735.1	LINC00637	4.29	2.13e-05	0.00202	0.25	0.19	Body mass index;	chr14:103659687	chr14:103847721~103858049:+
THCA	cis	rs709400	1	rs56660916	ENSG00000258735.1	LINC00637	4.29	2.13e-05	0.00202	0.25	0.19	Body mass index;	chr14:103659800	chr14:103847721~103858049:+
THCA	cis	rs6088813	1	rs6142373	ENSG00000279253.1	RP4-614O4.13	4.29	2.13e-05	0.00202	0.19	0.19	Height;	chr20:35395511	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6579234	ENSG00000279253.1	RP4-614O4.13	4.29	2.13e-05	0.00202	0.19	0.19	Height;	chr20:35395682	chr20:35262727~35264187:-
THCA	cis	rs4908768	0.906	rs78110809	ENSG00000232912.4	RP5-1115A15.1	-4.29	2.13e-05	0.00202	-0.24	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8512949	chr1:8424645~8434838:+
THCA	cis	rs10875746	0.951	rs58865997	ENSG00000258273.1	RP11-370I10.4	4.29	2.13e-05	0.00202	0.28	0.19	Longevity (90 years and older);	chr12:48173090	chr12:48333755~48333901:-
THCA	cis	rs897984	0.806	rs11150600	ENSG00000275263.1	RP11-1072A3.4	4.29	2.13e-05	0.00202	0.23	0.19	Dementia with Lewy bodies;	chr16:30929010	chr16:30956872~30957199:-
THCA	cis	rs7176527	0.796	rs1057946	ENSG00000230373.7	GOLGA6L5P	4.29	2.13e-05	0.00202	0.25	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:84507885~84516814:-
THCA	cis	rs17092148	0.887	rs6059916	ENSG00000276073.1	RP5-1125A11.7	-4.29	2.13e-05	0.00202	-0.23	-0.19	Neuroticism;	chr20:34561057	chr20:33985617~33988989:-
THCA	cis	rs656319	0.625	rs34427895	ENSG00000248538.5	RP11-10A14.5	4.29	2.13e-05	0.00202	0.26	0.19	Myopia (pathological);	chr8:10017711	chr8:9189011~9202854:+
THCA	cis	rs804280	0.565	rs1466785	ENSG00000255046.1	RP11-297N6.4	-4.29	2.13e-05	0.00202	-0.2	-0.19	Myopia (pathological);	chr8:11765947	chr8:11797928~11802568:-
THCA	cis	rs4273100	0.541	rs7501702	ENSG00000263934.3	SNORD3A	-4.29	2.13e-05	0.00202	-0.27	-0.19	Schizophrenia;	chr17:19390414	chr17:19188016~19188714:+
THCA	cis	rs10043228	0.702	rs62384478	ENSG00000250015.1	CTC-339F2.2	4.29	2.13e-05	0.00202	0.24	0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116327284	chr5:116302354~116304134:-
THCA	cis	rs9341808	0.69	rs2505932	ENSG00000272129.1	RP11-250B2.6	4.29	2.13e-05	0.00202	0.24	0.19	Sitting height ratio;	chr6:80129535	chr6:80355424~80356859:+
THCA	cis	rs9625935	0.917	rs1071888	ENSG00000279159.1	RP3-394A18.1	4.29	2.13e-05	0.00202	0.16	0.19	Tonsillectomy;	chr22:29841373	chr22:29978950~30028236:-
THCA	cis	rs10761482	1	rs1350631	ENSG00000254271.1	RP11-131N11.4	4.29	2.13e-05	0.00202	0.26	0.19	Schizophrenia;	chr10:60322811	chr10:60734342~60741828:+
THCA	cis	rs8141529	0.646	rs5752799	ENSG00000226471.5	CTA-292E10.6	-4.29	2.13e-05	0.00202	-0.23	-0.19	Lymphocyte counts;	chr22:28792052	chr22:28800683~28848559:+
THCA	cis	rs897984	0.52	rs4889622	ENSG00000260911.2	RP11-196G11.2	-4.29	2.13e-05	0.00202	-0.18	-0.19	Dementia with Lewy bodies;	chr16:30859636	chr16:31043150~31049868:+
THCA	cis	rs860295	0.58	rs66466805	ENSG00000236675.1	MTX1P1	-4.29	2.13e-05	0.00202	-0.2	-0.19	Body mass index;	chr1:155918875	chr1:155230975~155234325:+
THCA	cis	rs7474896	0.537	rs1779068	ENSG00000226578.1	RP11-258F22.1	4.29	2.13e-05	0.00202	0.27	0.19	Obesity (extreme);	chr10:37961857	chr10:37775371~37784131:-
THCA	cis	rs5758511	0.68	rs1107553	ENSG00000230107.1	CTA-126B4.7	-4.29	2.13e-05	0.00202	-0.23	-0.19	Birth weight;	chr22:42271467	chr22:42438023~42446195:+
THCA	cis	rs8062405	0.721	rs151181	ENSG00000261766.1	RP11-22P6.2	-4.29	2.13e-05	0.00202	-0.18	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28862166~28863340:-
THCA	cis	rs75059851	0.756	rs11223646	ENSG00000280237.1	MIR4697HG	4.29	2.13e-05	0.00202	0.22	0.19	Schizophrenia;	chr11:133969665	chr11:133896438~133901601:-
THCA	cis	rs75059851	0.756	rs11223647	ENSG00000280237.1	MIR4697HG	4.29	2.13e-05	0.00202	0.22	0.19	Schizophrenia;	chr11:133969693	chr11:133896438~133901601:-
THCA	cis	rs1048886	0.938	rs16869158	ENSG00000271967.1	RP11-134K13.4	-4.29	2.13e-05	0.00202	-0.2	-0.19	Type 2 diabetes;	chr6:70399462	chr6:70596438~70596980:+
THCA	cis	rs2251381	0.722	rs2776252	ENSG00000176054.6	RPL23P2	4.29	2.13e-05	0.00202	0.17	0.19	Selective IgA deficiency;	chr21:29159384	chr21:28997613~28998033:-
THCA	cis	rs4805272	1	rs4805272	ENSG00000267799.1	MAN1A2P1	4.29	2.13e-05	0.00202	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28828799	chr19:28790812~28792871:-
THCA	cis	rs4819052	0.84	rs914217	ENSG00000182586.6	LINC00334	-4.29	2.13e-05	0.00202	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45234340~45258730:+
THCA	cis	rs1728785	1	rs698712	ENSG00000274698.1	RP11-71L14.4	4.29	2.13e-05	0.00202	0.27	0.19	Ulcerative colitis;	chr16:68527976	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs4783653	ENSG00000274698.1	RP11-71L14.4	4.29	2.13e-05	0.00202	0.27	0.19	Ulcerative colitis;	chr16:68528912	chr16:68450283~68452318:+
THCA	cis	rs1346	0.501	rs10750762	ENSG00000245532.5	NEAT1	4.29	2.13e-05	0.00202	0.15	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65600834	chr11:65422774~65445540:+
THCA	cis	rs7560272	0.538	rs13000788	ENSG00000273245.1	RP11-434P11.2	-4.29	2.13e-05	0.00202	-0.22	-0.19	Schizophrenia;	chr2:73691185	chr2:73750256~73750786:-
THCA	cis	rs34421088	0.506	rs2572428	ENSG00000154316.13	TDH	-4.29	2.13e-05	0.00202	-0.14	-0.19	Neuroticism;	chr8:11289163	chr8:11339637~11368452:+
THCA	cis	rs427943	0.831	rs412646	ENSG00000223768.1	LINC00205	-4.29	2.13e-05	0.00202	-0.18	-0.19	Body mass index;	chr21:45169288	chr21:45293285~45297354:+
THCA	cis	rs988712	0.705	rs879048	ENSG00000245573.6	BDNF-AS	-4.29	2.13e-05	0.00202	-0.18	-0.19	Obesity;	chr11:27617387	chr11:27506838~27698174:+
THCA	cis	rs2980439	0.525	rs2945238	ENSG00000254153.1	CTA-398F10.2	-4.29	2.13e-05	0.00202	-0.21	-0.19	Neuroticism;	chr8:8312614	chr8:8456909~8461337:-
THCA	cis	rs703842	1	rs703842	ENSG00000270039.1	RP11-571M6.17	4.29	2.13e-05	0.00202	0.22	0.19	Multiple sclerosis;	chr12:57768956	chr12:57803838~57804415:+
THCA	cis	rs6442522	0.64	rs3773447	ENSG00000249786.6	EAF1-AS1	4.29	2.14e-05	0.00202	0.2	0.19	Uric acid levels;	chr3:15478512	chr3:15436171~15455940:-
THCA	cis	rs4767841	0.552	rs11064861	ENSG00000252886.1	RN7SKP197	-4.29	2.14e-05	0.00202	-0.19	-0.19	Urgency urinary incontinence;	chr12:119633855	chr12:119631090~119631386:-
THCA	cis	rs7923837	0.723	rs2153827	ENSG00000236493.2	EIF2S2P3	4.29	2.14e-05	0.00202	0.2	0.19	Multiple sclerosis;Body mass index;	chr10:92664316	chr10:92668745~92669743:-
THCA	cis	rs2822388	0.744	rs11701640	ENSG00000215559.7	ANKRD20A11P	-4.29	2.14e-05	0.00202	-0.39	-0.19	Stroke;	chr21:14062617	chr21:13909574~13980437:-
THCA	cis	rs77972916	0.611	rs10495899	ENSG00000234936.1	AC010883.5	4.29	2.14e-05	0.00202	0.22	0.19	Granulocyte percentage of myeloid white cells;	chr2:43375165	chr2:43229573~43233394:+
THCA	cis	rs8105895	0.935	rs62112362	ENSG00000269345.1	VN1R85P	4.29	2.14e-05	0.00202	0.27	0.19	Body mass index (change over time);	chr19:22110311	chr19:22174766~22175191:-
THCA	cis	rs10875746	0.903	rs725454	ENSG00000258273.1	RP11-370I10.4	4.29	2.14e-05	0.00203	0.28	0.19	Longevity (90 years and older);	chr12:48108317	chr12:48333755~48333901:-
THCA	cis	rs1728785	1	rs11648314	ENSG00000274698.1	RP11-71L14.4	4.29	2.14e-05	0.00203	0.28	0.19	Ulcerative colitis;	chr16:68562872	chr16:68450283~68452318:+
THCA	cis	rs8062405	0.754	rs151179	ENSG00000261766.1	RP11-22P6.2	-4.29	2.14e-05	0.00203	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28862166~28863340:-
THCA	cis	rs4805272	1	rs1363323	ENSG00000267799.1	MAN1A2P1	4.29	2.14e-05	0.00203	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28836045	chr19:28790812~28792871:-
THCA	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	4.29	2.14e-05	0.00203	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
THCA	cis	rs860295	0.812	rs2297775	ENSG00000160766.13	GBAP1	4.29	2.14e-05	0.00203	0.23	0.19	Body mass index;	chr1:155765221	chr1:155213821~155227422:-
THCA	cis	rs1923243	0.647	rs12126062	ENSG00000223479.3	RP4-788P17.1	4.29	2.14e-05	0.00203	0.22	0.19	Migraine;	chr1:73160348	chr1:73635216~73715214:+
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000182586.6	LINC00334	-4.29	2.14e-05	0.00203	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000182586.6	LINC00334	-4.29	2.14e-05	0.00203	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000182586.6	LINC00334	-4.29	2.14e-05	0.00203	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000182586.6	LINC00334	-4.29	2.14e-05	0.00203	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000182586.6	LINC00334	-4.29	2.14e-05	0.00203	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45234340~45258730:+
THCA	cis	rs4950322	0.58	rs2083720	ENSG00000180867.10	PDIA3P1	4.29	2.14e-05	0.00203	0.19	0.19	Protein quantitative trait loci;	chr1:147122296	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.58	rs72706441	ENSG00000180867.10	PDIA3P1	4.29	2.14e-05	0.00203	0.19	0.19	Protein quantitative trait loci;	chr1:147122601	chr1:147178113~147179622:+
THCA	cis	rs1923243	0.587	rs4649972	ENSG00000223479.3	RP4-788P17.1	4.29	2.14e-05	0.00203	0.22	0.19	Migraine;	chr1:72979107	chr1:73635216~73715214:+
THCA	cis	rs7824557	0.583	rs2736292	ENSG00000206014.6	OR7E161P	-4.29	2.14e-05	0.00203	-0.22	-0.19	Retinal vascular caliber;	chr8:11376991	chr8:11928597~11929563:-
THCA	cis	rs801193	1	rs2659912	ENSG00000272831.1	RP11-792A8.4	4.29	2.14e-05	0.00203	0.12	0.19	Aortic root size;	chr7:66693012	chr7:66739829~66740385:-
THCA	cis	rs55702914	1	rs55702914	ENSG00000231621.1	AC013264.2	-4.29	2.14e-05	0.00203	-0.18	-0.19	Major depression and alcohol dependence;	chr2:197349672	chr2:197197991~197199273:+
THCA	cis	rs1823874	0.71	rs58572174	ENSG00000182397.13	DNM1P46	-4.29	2.14e-05	0.00203	-0.23	-0.19	IgG glycosylation;	chr15:99822635	chr15:99790156~99806927:-
THCA	cis	rs1823874	0.677	rs1993295	ENSG00000182397.13	DNM1P46	-4.29	2.14e-05	0.00203	-0.23	-0.19	IgG glycosylation;	chr15:99823332	chr15:99790156~99806927:-
THCA	cis	rs1823874	0.71	rs1993297	ENSG00000182397.13	DNM1P46	-4.29	2.14e-05	0.00203	-0.23	-0.19	IgG glycosylation;	chr15:99823423	chr15:99790156~99806927:-
THCA	cis	rs1823874	0.613	rs4608318	ENSG00000182397.13	DNM1P46	-4.29	2.14e-05	0.00203	-0.23	-0.19	IgG glycosylation;	chr15:99823621	chr15:99790156~99806927:-
THCA	cis	rs1823874	0.677	rs2168069	ENSG00000182397.13	DNM1P46	-4.29	2.14e-05	0.00203	-0.23	-0.19	IgG glycosylation;	chr15:99823798	chr15:99790156~99806927:-
THCA	cis	rs1232027	0.7	rs73765838	ENSG00000249655.1	CTC-325J23.2	4.29	2.14e-05	0.00203	0.22	0.19	Huntington's disease progression;	chr5:80652003	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs73765839	ENSG00000249655.1	CTC-325J23.2	4.29	2.14e-05	0.00203	0.22	0.19	Huntington's disease progression;	chr5:80652004	chr5:80630313~80631590:-
THCA	cis	rs8030605	0.704	rs3848113	ENSG00000277245.1	RP11-48G14.3	4.29	2.14e-05	0.00203	0.34	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56435178	chr15:56447120~56447697:+
THCA	cis	rs3733585	0.579	rs4235353	ENSG00000261490.1	RP11-448G15.3	-4.29	2.14e-05	0.00203	-0.13	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:10121310	chr4:10068089~10073019:-
THCA	cis	rs3733585	0.605	rs4235354	ENSG00000261490.1	RP11-448G15.3	-4.29	2.14e-05	0.00203	-0.13	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:10121318	chr4:10068089~10073019:-
THCA	cis	rs4767841	0.565	rs405300	ENSG00000248636.5	RP11-768F21.1	-4.29	2.14e-05	0.00203	-0.2	-0.19	Urgency urinary incontinence;	chr12:119788269	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.565	rs386928	ENSG00000248636.5	RP11-768F21.1	-4.29	2.14e-05	0.00203	-0.2	-0.19	Urgency urinary incontinence;	chr12:119788628	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.565	rs407464	ENSG00000248636.5	RP11-768F21.1	-4.29	2.14e-05	0.00203	-0.2	-0.19	Urgency urinary incontinence;	chr12:119789059	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.539	rs407692	ENSG00000248636.5	RP11-768F21.1	-4.29	2.14e-05	0.00203	-0.2	-0.19	Urgency urinary incontinence;	chr12:119789119	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.565	rs804716	ENSG00000248636.5	RP11-768F21.1	-4.29	2.14e-05	0.00203	-0.2	-0.19	Urgency urinary incontinence;	chr12:119789578	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.568	rs804717	ENSG00000248636.5	RP11-768F21.1	-4.29	2.14e-05	0.00203	-0.2	-0.19	Urgency urinary incontinence;	chr12:119789616	chr12:119387987~119668079:-
THCA	cis	rs6845263	0.546	rs1834626	ENSG00000254531.1	FLJ20021	-4.29	2.14e-05	0.00203	-0.16	-0.19	Superior crus of antihelix expression;	chr4:101532234	chr4:101347780~101348883:+
THCA	cis	rs9876781	1	rs4858793	ENSG00000244380.1	RP11-24C3.2	-4.29	2.14e-05	0.00203	-0.23	-0.19	Longevity;	chr3:48373517	chr3:48440352~48446656:-
THCA	cis	rs4950322	0.518	rs55697094	ENSG00000271721.1	RP11-337C18.9	4.29	2.14e-05	0.00203	0.22	0.19	Protein quantitative trait loci;	chr1:147121205	chr1:147175602~147177740:+
THCA	cis	rs12887734	0.524	rs4900599	ENSG00000269940.1	RP11-73M18.7	4.29	2.14e-05	0.00203	0.2	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103694560~103695170:+
THCA	cis	rs4845570	0.749	rs11576810	ENSG00000203288.3	RP11-98D18.9	-4.29	2.14e-05	0.00203	-0.24	-0.19	Coronary artery disease;	chr1:151739725	chr1:151790804~151794402:+
THCA	cis	rs758324	0.704	rs31480	ENSG00000237714.1	P4HA2-AS1	-4.29	2.14e-05	0.00203	-0.27	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132060639	chr5:132184876~132192808:+
THCA	cis	rs734999	0.545	rs9970196	ENSG00000225931.3	RP3-395M20.7	-4.29	2.14e-05	0.00203	-0.23	-0.19	Ulcerative colitis;	chr1:2642639	chr1:2566410~2569888:+
THCA	cis	rs4660214	0.568	rs6692769	ENSG00000182109.6	RP11-69E11.4	-4.29	2.14e-05	0.00203	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39217503	chr1:39522280~39546187:-
THCA	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-4.29	2.14e-05	0.00203	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
THCA	cis	rs6517329	0.564	rs67013231	ENSG00000236830.5	CBR3-AS1	-4.29	2.14e-05	0.00203	-0.18	-0.19	Schizophrenia;	chr21:36133804	chr21:36131767~36175815:-
THCA	cis	rs2439831	0.867	rs2412778	ENSG00000205771.5	CATSPER2P1	-4.29	2.14e-05	0.00203	-0.26	-0.19	Lung cancer in ever smokers;	chr15:43368784	chr15:43726918~43747094:-
THCA	cis	rs9863	0.931	rs34180676	ENSG00000270061.1	RP11-214K3.19	-4.29	2.14e-05	0.00203	-0.26	-0.19	White blood cell count;	chr12:123946972	chr12:123969990~123970344:-
THCA	cis	rs9863	0.931	rs7955815	ENSG00000270061.1	RP11-214K3.19	-4.29	2.14e-05	0.00203	-0.26	-0.19	White blood cell count;	chr12:123948159	chr12:123969990~123970344:-
THCA	cis	rs7826238	0.509	rs2948288	ENSG00000233609.3	RP11-62H7.2	4.29	2.14e-05	0.00203	0.19	0.19	Systolic blood pressure;	chr8:8257782	chr8:8961200~8979025:+
THCA	cis	rs7200786	0.692	rs9935445	ENSG00000274038.1	RP11-66H6.4	-4.29	2.15e-05	0.00203	-0.24	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10995532	chr16:11056556~11057034:+
THCA	cis	rs180358	0.588	rs1263167	ENSG00000254851.1	RP11-109L13.1	-4.29	2.15e-05	0.00203	-0.33	-0.19	Multiple sclerosis (severity);	chr11:116807007	chr11:117135528~117138582:+
THCA	cis	rs9902453	0.765	rs2259857	ENSG00000263370.1	RP11-68I3.5	-4.29	2.15e-05	0.00203	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29770762	chr17:29639627~29640825:+
THCA	cis	rs2904524	0.737	rs74993257	ENSG00000257815.4	RP11-611E13.2	-4.29	2.15e-05	0.00203	-0.28	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70165425	chr12:69904033~70243360:-
THCA	cis	rs1577917	0.74	rs2758845	ENSG00000220563.1	PKMP3	-4.29	2.15e-05	0.00203	-0.14	-0.19	Response to antipsychotic treatment;	chr6:85625130	chr6:85659892~85660606:-
THCA	cis	rs4908768	0.906	rs114812780	ENSG00000232912.4	RP5-1115A15.1	-4.29	2.15e-05	0.00203	-0.24	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8468794	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.906	rs12409937	ENSG00000232912.4	RP5-1115A15.1	-4.29	2.15e-05	0.00203	-0.24	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8478242	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.906	rs12402539	ENSG00000232912.4	RP5-1115A15.1	-4.29	2.15e-05	0.00203	-0.24	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8478243	chr1:8424645~8434838:+
THCA	cis	rs4434872	1	rs4434872	ENSG00000223599.1	RP11-216N14.7	4.29	2.15e-05	0.00203	0.33	0.19	Conduct disorder (symptom count);	chr1:153801800	chr1:153852106~153853414:-
THCA	cis	rs2115630	0.905	rs1975277	ENSG00000275120.1	RP11-182J1.17	-4.29	2.15e-05	0.00203	-0.2	-0.19	P wave terminal force;	chr15:84786327	chr15:84599434~84606463:-
THCA	cis	rs734999	0.505	rs4073285	ENSG00000225931.3	RP3-395M20.7	4.29	2.15e-05	0.00203	0.23	0.19	Ulcerative colitis;	chr1:2608357	chr1:2566410~2569888:+
THCA	cis	rs6570726	0.791	rs9399558	ENSG00000270638.1	RP3-466P17.1	4.29	2.15e-05	0.00203	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs9376953	ENSG00000270638.1	RP3-466P17.1	4.29	2.15e-05	0.00203	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs13202312	ENSG00000270638.1	RP3-466P17.1	4.29	2.15e-05	0.00203	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs7765675	ENSG00000270638.1	RP3-466P17.1	4.29	2.15e-05	0.00203	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145735570~145737218:+
THCA	cis	rs2694917	0.625	rs799261	ENSG00000257576.1	RP11-153M3.1	4.29	2.15e-05	0.00203	0.32	0.19	Blood metabolite ratios;	chr12:56530605	chr12:56511002~56512703:+
THCA	cis	rs7824557	0.527	rs2572376	ENSG00000154316.13	TDH	4.29	2.15e-05	0.00203	0.14	0.19	Retinal vascular caliber;	chr8:11380247	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.527	rs2736305	ENSG00000154316.13	TDH	4.29	2.15e-05	0.00203	0.14	0.19	Retinal vascular caliber;	chr8:11380264	chr8:11339637~11368452:+
THCA	cis	rs10875746	0.903	rs11168401	ENSG00000258273.1	RP11-370I10.4	4.29	2.15e-05	0.00203	0.28	0.19	Longevity (90 years and older);	chr12:48087736	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs12304476	ENSG00000258273.1	RP11-370I10.4	4.29	2.15e-05	0.00203	0.28	0.19	Longevity (90 years and older);	chr12:48088370	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs3782911	ENSG00000258273.1	RP11-370I10.4	4.29	2.15e-05	0.00203	0.28	0.19	Longevity (90 years and older);	chr12:48089709	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.859	rs3782910	ENSG00000258273.1	RP11-370I10.4	4.29	2.15e-05	0.00203	0.28	0.19	Longevity (90 years and older);	chr12:48089724	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs61918806	ENSG00000258273.1	RP11-370I10.4	4.29	2.15e-05	0.00203	0.28	0.19	Longevity (90 years and older);	chr12:48090650	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs11168403	ENSG00000258273.1	RP11-370I10.4	4.29	2.15e-05	0.00203	0.28	0.19	Longevity (90 years and older);	chr12:48091175	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs10875740	ENSG00000258273.1	RP11-370I10.4	4.29	2.15e-05	0.00203	0.28	0.19	Longevity (90 years and older);	chr12:48095334	chr12:48333755~48333901:-
THCA	cis	rs1046896	0.739	rs28459016	ENSG00000263063.1	RP11-388C12.1	-4.29	2.15e-05	0.00203	-0.25	-0.19	Glycated hemoglobin levels;	chr17:82783318	chr17:82713908~82716255:-
THCA	cis	rs6918586	0.565	rs13196986	ENSG00000272462.2	U91328.19	4.29	2.15e-05	0.00203	0.17	0.19	Schizophrenia;	chr6:26090224	chr6:25992662~26001775:+
THCA	cis	rs72843506	0.586	rs75374787	ENSG00000261033.1	RP11-209D14.2	4.29	2.15e-05	0.00203	0.38	0.19	Schizophrenia;	chr17:19900805	chr17:20008051~20009234:-
THCA	cis	rs72843506	0.586	rs79829757	ENSG00000261033.1	RP11-209D14.2	4.29	2.15e-05	0.00203	0.38	0.19	Schizophrenia;	chr17:19900844	chr17:20008051~20009234:-
THCA	cis	rs11089937	0.926	rs5750601	ENSG00000211638.2	IGLV8-61	-4.29	2.15e-05	0.00203	-0.14	-0.19	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22098700~22099212:+
THCA	cis	rs9847710	1	rs2564956	ENSG00000242142.1	SERBP1P3	4.29	2.15e-05	0.00203	0.22	0.19	Ulcerative colitis;	chr3:53036446	chr3:53064283~53065091:-
THCA	cis	rs4767841	0.805	rs10849696	ENSG00000248636.5	RP11-768F21.1	-4.29	2.15e-05	0.00203	-0.2	-0.19	Urgency urinary incontinence;	chr12:119771207	chr12:119387987~119668079:-
THCA	cis	rs3864277	0.51	rs31478	ENSG00000237714.1	P4HA2-AS1	4.29	2.15e-05	0.00203	0.24	0.19	Itch intensity from mosquito bite adjusted by bite size;	chr5:132087782	chr5:132184876~132192808:+
THCA	cis	rs910873	1	rs910873	ENSG00000276073.1	RP5-1125A11.7	4.29	2.15e-05	0.00203	0.36	0.19	Melanoma;	chr20:34583968	chr20:33985617~33988989:-
THCA	cis	rs12935418	0.504	rs1549288	ENSG00000278985.1	RP11-303E16.9	4.29	2.15e-05	0.00203	0.2	0.19	Mean corpuscular volume;	chr16:81027156	chr16:80982319~80984094:-
THCA	cis	rs9595908	0.645	rs4942924	ENSG00000212293.1	SNORA16	4.29	2.15e-05	0.00203	0.23	0.19	Body mass index;	chr13:32806987	chr13:32420390~32420516:-
THCA	cis	rs7179456	0.544	rs2555357	ENSG00000245975.2	RP11-30K9.6	4.29	2.15e-05	0.00203	0.18	0.19	Asperger disorder;	chr15:58794916	chr15:58768072~58770974:-
THCA	cis	rs7577696	0.695	rs212748	ENSG00000276334.1	AL133243.1	4.29	2.15e-05	0.00203	0.21	0.19	Inflammatory biomarkers;	chr2:32190677	chr2:32521927~32523547:+
THCA	cis	rs17270561	0.636	rs11794	ENSG00000272462.2	U91328.19	-4.29	2.15e-05	0.00203	-0.17	-0.19	Iron status biomarkers;	chr6:25701490	chr6:25992662~26001775:+
THCA	cis	rs9635324	0.516	rs7165012	ENSG00000223313.1	RNU6-516P	-4.29	2.15e-05	0.00204	-0.21	-0.19	Blood metabolite ratios;Blood metabolite levels;	chr15:40361837	chr15:40529570~40529673:+
THCA	cis	rs2657294	0.796	rs1259499	ENSG00000226051.5	ZNF503-AS1	-4.29	2.15e-05	0.00204	-0.27	-0.19	Pneumonia;	chr10:75228308	chr10:75269819~75373500:+
THCA	cis	rs733592	1	rs733592	ENSG00000269514.1	RP11-370I10.12	4.29	2.15e-05	0.00204	0.16	0.19	Plateletcrit;	chr12:48035993	chr12:48198387~48202031:+
THCA	cis	rs7727544	0.545	rs7716474	ENSG00000233006.5	AC034220.3	4.29	2.15e-05	0.00204	0.16	0.19	Blood metabolite levels;	chr5:132048290	chr5:132311285~132369916:-
THCA	cis	rs6088813	0.883	rs1406949	ENSG00000279253.1	RP4-614O4.13	-4.29	2.15e-05	0.00204	-0.19	-0.19	Height;	chr20:35318101	chr20:35262727~35264187:-
THCA	cis	rs453301	0.631	rs13250781	ENSG00000254153.1	CTA-398F10.2	4.29	2.15e-05	0.00204	0.22	0.19	Joint mobility (Beighton score);	chr8:8935833	chr8:8456909~8461337:-
THCA	cis	rs31251	0.967	rs2240525	ENSG00000224431.1	AC063976.7	4.29	2.15e-05	0.00204	0.16	0.19	Itch intensity from mosquito bite adjusted by bite size;	chr5:131980191	chr5:132199456~132203487:+
THCA	cis	rs8077577	0.747	rs2290505	ENSG00000273018.4	CTD-2303H24.2	4.29	2.15e-05	0.00204	0.29	0.19	Obesity-related traits;	chr17:18233827	chr17:18511221~18551705:-
THCA	cis	rs1023500	0.573	rs4822088	ENSG00000237037.8	NDUFA6-AS1	-4.29	2.15e-05	0.00204	-0.16	-0.19	Schizophrenia;	chr22:42074585	chr22:42090931~42137742:+
THCA	cis	rs875971	1	rs937495	ENSG00000230189.5	GS1-124K5.2	-4.29	2.15e-05	0.00204	-0.13	-0.19	Aortic root size;	chr7:66314811	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs2036264	ENSG00000230189.5	GS1-124K5.2	-4.29	2.15e-05	0.00204	-0.13	-0.19	Aortic root size;	chr7:66334917	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs7783613	ENSG00000230189.5	GS1-124K5.2	-4.29	2.15e-05	0.00204	-0.13	-0.19	Aortic root size;	chr7:66340274	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs778735	ENSG00000230189.5	GS1-124K5.2	4.29	2.15e-05	0.00204	0.13	0.19	Aortic root size;	chr7:66349822	chr7:66409143~66490059:-
THCA	cis	rs875971	0.638	rs10249404	ENSG00000223473.2	GS1-124K5.3	-4.29	2.15e-05	0.00204	-0.13	-0.19	Aortic root size;	chr7:66581737	chr7:66491049~66493566:-
THCA	cis	rs1003719	0.715	rs7277820	ENSG00000230366.8	DSCR9	4.29	2.15e-05	0.00204	0.2	0.19	Eye color traits;	chr21:37208008	chr21:37208503~37221736:+
THCA	cis	rs1003719	0.715	rs2835675	ENSG00000230366.8	DSCR9	4.29	2.15e-05	0.00204	0.2	0.19	Eye color traits;	chr21:37210514	chr21:37208503~37221736:+
THCA	cis	rs2692947	0.77	rs58730124	ENSG00000232931.4	LINC00342	4.29	2.15e-05	0.00204	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95747590	chr2:95807118~95816215:-
THCA	cis	rs4460629	0.905	rs4971077	ENSG00000236675.1	MTX1P1	-4.29	2.15e-05	0.00204	-0.18	-0.19	Serum magnesium levels;	chr1:155156241	chr1:155230975~155234325:+
THCA	cis	rs17801127	0.818	rs35185541	ENSG00000231969.1	AC144449.1	4.29	2.15e-05	0.00204	0.34	0.19	Liver enzyme levels (alanine transaminase);	chr2:149682320	chr2:149587196~149848233:+
THCA	cis	rs11758351	0.518	rs78871852	ENSG00000216331.1	HIST1H1PS1	4.29	2.15e-05	0.00204	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26221338	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.517	rs79958315	ENSG00000216331.1	HIST1H1PS1	4.29	2.15e-05	0.00204	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26221598	chr6:26195566~26195771:+
THCA	cis	rs7088591	0.867	rs58180311	ENSG00000276818.1	AC026393.1	4.29	2.15e-05	0.00204	0.4	0.19	Blood pressure;	chr10:58062308	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs58053151	ENSG00000276818.1	AC026393.1	4.29	2.15e-05	0.00204	0.4	0.19	Blood pressure;	chr10:58062435	chr10:57095699~57095781:+
THCA	cis	rs9902453	0.74	rs2628189	ENSG00000263370.1	RP11-68I3.5	-4.29	2.15e-05	0.00204	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29761795	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2729448	ENSG00000263370.1	RP11-68I3.5	-4.29	2.15e-05	0.00204	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29764935	chr17:29639627~29640825:+
THCA	cis	rs7044106	0.537	rs4434680	ENSG00000270917.1	RP11-27I1.6	-4.29	2.15e-05	0.00204	-0.29	-0.19	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120812475~120812845:-
THCA	cis	rs4934494	0.677	rs72818709	ENSG00000240996.1	RP11-80H5.7	-4.29	2.15e-05	0.00204	-0.22	-0.19	Red blood cell count;	chr10:89611689	chr10:89694295~89697928:-
THCA	cis	rs6921919	0.551	rs13201753	ENSG00000273712.1	RP5-874C20.7	4.29	2.15e-05	0.00204	0.22	0.19	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28315613~28315883:-
THCA	cis	rs2303759	0.551	rs7249040	ENSG00000268686.1	AC010524.2	-4.29	2.15e-05	0.00204	-0.3	-0.19	Multiple sclerosis;	chr19:49287345	chr19:49368705~49388081:-
THCA	cis	rs67981189	0.752	rs221902	ENSG00000269927.1	RP6-91H8.3	-4.29	2.15e-05	0.00204	-0.22	-0.19	Schizophrenia;	chr14:71134362	chr14:71141125~71143253:-
THCA	cis	rs4434138	0.594	rs7653028	ENSG00000243224.1	RP5-1157M23.2	-4.29	2.15e-05	0.00204	-0.21	-0.19	Intelligence (multi-trait analysis);	chr3:52728984	chr3:52239258~52241097:+
THCA	cis	rs7618915	0.501	rs11714030	ENSG00000243224.1	RP5-1157M23.2	-4.29	2.15e-05	0.00204	-0.21	-0.19	Bipolar disorder;	chr3:52731866	chr3:52239258~52241097:+
THCA	cis	rs2677744	1	rs1550636	ENSG00000214432.8	AC068831.10	-4.29	2.16e-05	0.00204	-0.21	-0.19	Attention deficit hyperactivity disorder;	chr15:90934231	chr15:91022619~91036611:+
THCA	cis	rs7267979	1	rs2482931	ENSG00000274973.1	RP13-401N8.7	4.29	2.16e-05	0.00204	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25845497~25845862:+
THCA	cis	rs6121246	0.559	rs6087782	ENSG00000230613.1	HM13-AS1	4.29	2.16e-05	0.00204	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31803777	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6058465	ENSG00000230613.1	HM13-AS1	4.29	2.16e-05	0.00204	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31809888	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6060962	ENSG00000230613.1	HM13-AS1	4.29	2.16e-05	0.00204	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31810044	chr20:31567707~31573263:-
THCA	cis	rs12216545	0.765	rs2373816	ENSG00000241134.3	BET1P1	-4.29	2.16e-05	0.00204	-0.23	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150574041	chr7:150749736~150750094:+
THCA	cis	rs875971	0.862	rs35378740	ENSG00000229886.1	RP5-1132H15.3	4.29	2.16e-05	0.00204	0.2	0.19	Aortic root size;	chr7:66522725	chr7:66025126~66031544:-
THCA	cis	rs2554380	0.628	rs890311	ENSG00000176700.18	SCAND2P	-4.29	2.16e-05	0.00204	-0.14	-0.19	Height;	chr15:83772200	chr15:84631451~84647478:+
THCA	cis	rs11247915	0.644	rs11588739	ENSG00000236782.4	RP11-96L14.7	-4.29	2.16e-05	0.00204	-0.23	-0.19	Obesity-related traits;	chr1:26326828	chr1:26169947~26171821:-
THCA	cis	rs875971	0.895	rs7788984	ENSG00000229886.1	RP5-1132H15.3	4.29	2.16e-05	0.00204	0.2	0.19	Aortic root size;	chr7:66450629	chr7:66025126~66031544:-
THCA	cis	rs9863	0.861	rs4930726	ENSG00000270028.1	RP11-380L11.4	4.29	2.16e-05	0.00204	0.2	0.19	White blood cell count;	chr12:123943784	chr12:123925461~123926083:-
THCA	cis	rs738144	0.687	rs738141	ENSG00000235209.1	CTA-150C2.13	-4.29	2.16e-05	0.00204	-0.3	-0.19	IgG glycosylation;	chr22:38797061	chr22:38921227~38924708:+
THCA	cis	rs7119038	0.73	rs10790269	ENSG00000255239.1	AP002954.6	4.29	2.16e-05	0.00204	0.3	0.19	Sjögren's syndrome;	chr11:118858747	chr11:118688039~118690600:-
THCA	cis	rs11722779	0.903	rs6830193	ENSG00000248971.2	KRT8P46	-4.29	2.16e-05	0.00204	-0.24	-0.19	Schizophrenia;	chr4:102955457	chr4:102728746~102730171:-
THCA	cis	rs78487399	0.808	rs113377695	ENSG00000234936.1	AC010883.5	4.29	2.16e-05	0.00204	0.24	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43608220	chr2:43229573~43233394:+
THCA	cis	rs881827	0.714	rs34038027	ENSG00000230982.1	DSTNP1	4.29	2.16e-05	0.00204	0.2	0.19	Lymphocyte counts;	chr21:46627956	chr21:46653558~46654022:-
THCA	cis	rs4971059	0.629	rs4246529	ENSG00000236675.1	MTX1P1	-4.29	2.16e-05	0.00204	-0.18	-0.19	Breast cancer;	chr1:155142784	chr1:155230975~155234325:+
THCA	cis	rs10875746	0.903	rs4760681	ENSG00000258234.1	RP11-370I10.2	4.29	2.16e-05	0.00204	0.23	0.19	Longevity (90 years and older);	chr12:48111447	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs11168418	ENSG00000258234.1	RP11-370I10.2	4.29	2.16e-05	0.00204	0.23	0.19	Longevity (90 years and older);	chr12:48121971	chr12:48231098~48284210:-
THCA	cis	rs7637701	0.517	rs66538320	ENSG00000240875.4	LINC00886	-4.29	2.16e-05	0.00204	-0.15	-0.19	Breast cancer;	chr3:156674346	chr3:156747346~156817062:-
THCA	cis	rs12216545	0.765	rs10235836	ENSG00000241134.3	BET1P1	4.29	2.16e-05	0.00204	0.23	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150534285	chr7:150749736~150750094:+
THCA	cis	rs10875746	0.951	rs4760690	ENSG00000258273.1	RP11-370I10.4	4.29	2.16e-05	0.00204	0.28	0.19	Longevity (90 years and older);	chr12:48169870	chr12:48333755~48333901:-
THCA	cis	rs902774	0.585	rs7399070	ENSG00000278185.1	RP11-153F5.7	4.29	2.16e-05	0.00204	0.32	0.19	Prostate cancer;	chr12:52961894	chr12:52946614~52947125:-
THCA	cis	rs4656958	0.538	rs4656279	ENSG00000233691.2	RP11-312J18.7	4.29	2.16e-05	0.00204	0.22	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160916504	chr1:160935537~160936126:+
THCA	cis	rs8062405	0.789	rs151174	ENSG00000261766.1	RP11-22P6.2	-4.29	2.16e-05	0.00204	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28862166~28863340:-
THCA	cis	rs67981189	0.896	rs221922	ENSG00000269927.1	RP6-91H8.3	-4.29	2.16e-05	0.00204	-0.22	-0.19	Schizophrenia;	chr14:71118396	chr14:71141125~71143253:-
THCA	cis	rs11976180	1	rs2961117	ENSG00000244198.4	RP4-545C24.1	-4.29	2.16e-05	0.00204	-0.19	-0.19	Obesity-related traits;	chr7:144058160	chr7:144194858~144280547:+
THCA	cis	rs713587	0.719	rs4665736	ENSG00000224165.4	DNAJC27-AS1	4.29	2.16e-05	0.00204	0.11	0.19	Body mass index in non-asthmatics;	chr2:24964730	chr2:24971390~25039694:+
THCA	cis	rs11088226	0.681	rs2833912	ENSG00000186842.4	LINC00846	-4.29	2.16e-05	0.00204	-0.28	-0.19	Gastritis;	chr21:32577512	chr21:32572238~32575881:-
THCA	cis	rs2380205	0.516	rs7919913	ENSG00000232807.2	RP11-536K7.3	4.29	2.16e-05	0.00204	0.19	0.19	Breast cancer;	chr10:5884253	chr10:5934270~5945900:-
THCA	cis	rs8028182	0.636	rs28432989	ENSG00000260269.4	CTD-2323K18.1	-4.29	2.16e-05	0.00204	-0.29	-0.19	Sudden cardiac arrest;	chr15:75475956	chr15:75527150~75601205:-
THCA	cis	rs9467773	1	rs9467773	ENSG00000228223.2	HCG11	-4.29	2.16e-05	0.00204	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26498198	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6926629	ENSG00000228223.2	HCG11	-4.29	2.16e-05	0.00204	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26499675	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6903973	ENSG00000228223.2	HCG11	-4.29	2.16e-05	0.00204	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26499714	chr6:26523450~26526579:+
THCA	cis	rs875971	0.862	rs6460307	ENSG00000229886.1	RP5-1132H15.3	4.29	2.16e-05	0.00204	0.2	0.19	Aortic root size;	chr7:66595884	chr7:66025126~66031544:-
THCA	cis	rs7551222	0.716	rs10494852	ENSG00000240219.1	RP11-430C7.5	-4.29	2.16e-05	0.00205	-0.18	-0.19	Schizophrenia;	chr1:204488658	chr1:204626775~204629712:+
THCA	cis	rs5758511	0.573	rs1569451	ENSG00000281538.1	RP4-669P10.20	4.29	2.16e-05	0.00205	0.19	0.19	Birth weight;	chr22:41836287	chr22:42138060~42139726:+
THCA	cis	rs4879656	0.735	rs10733465	ENSG00000225693.1	LAGE3P1	4.29	2.16e-05	0.00205	0.22	0.19	Menopause (age at onset);	chr9:32932196	chr9:33019682~33020165:-
THCA	cis	rs710913	0.717	rs2068473	ENSG00000182109.6	RP11-69E11.4	-4.29	2.16e-05	0.00205	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39522280~39546187:-
THCA	cis	rs11722779	0.935	rs3857200	ENSG00000248971.2	KRT8P46	-4.29	2.16e-05	0.00205	-0.24	-0.19	Schizophrenia;	chr4:103001864	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs11731885	ENSG00000248971.2	KRT8P46	-4.29	2.16e-05	0.00205	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102728746~102730171:-
THCA	cis	rs1923243	0.587	rs61772284	ENSG00000223479.3	RP4-788P17.1	4.29	2.16e-05	0.00205	0.21	0.19	Migraine;	chr1:72960077	chr1:73635216~73715214:+
THCA	cis	rs459571	0.92	rs455073	ENSG00000235106.7	LINC00094	4.29	2.16e-05	0.00205	0.17	0.19	Platelet distribution width;	chr9:134044019	chr9:134025439~134034666:+
THCA	cis	rs2439831	0.681	rs524527	ENSG00000166763.7	STRCP1	-4.29	2.16e-05	0.00205	-0.26	-0.19	Lung cancer in ever smokers;	chr15:43306918	chr15:43699488~43718184:-
THCA	cis	rs874628	0.576	rs72999466	ENSG00000268650.3	AC068499.10	4.29	2.16e-05	0.00205	0.23	0.19	Multiple sclerosis;	chr19:18137689	chr19:18204730~18220480:+
THCA	cis	rs2886497	0.624	rs10828450	ENSG00000224215.1	RP11-371A19.2	-4.29	2.16e-05	0.00205	-0.22	-0.19	Major depression and alcohol dependence;	chr10:23402709	chr10:23343957~23345181:+
THCA	cis	rs12440869	1	rs12708493	ENSG00000270964.1	RP11-502I4.3	4.29	2.17e-05	0.00205	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67293473	chr15:67541072~67542604:-
THCA	cis	rs8031584	0.678	rs798127	ENSG00000259845.1	HERC2P10	-4.29	2.17e-05	0.00205	-0.27	-0.19	Huntington's disease progression;	chr15:30825200	chr15:30815271~30844153:+
THCA	cis	rs875971	0.83	rs4718358	ENSG00000229886.1	RP5-1132H15.3	4.29	2.17e-05	0.00205	0.2	0.19	Aortic root size;	chr7:66508681	chr7:66025126~66031544:-
THCA	cis	rs1414896	0.646	rs11579311	ENSG00000226026.4	RP11-57H12.3	4.29	2.17e-05	0.00205	0.19	0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95167631	chr1:95163219~95233982:-
THCA	cis	rs957448	0.698	rs116348949	ENSG00000253175.1	RP11-267M23.6	4.29	2.17e-05	0.00205	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94565036~94565715:+
THCA	cis	rs4792901	0.802	rs8079750	ENSG00000267151.3	RP11-100E5.2	4.29	2.17e-05	0.00205	0.21	0.19	Dupuytren's disease;	chr17:43501129	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.759	rs12601484	ENSG00000267151.3	RP11-100E5.2	4.29	2.17e-05	0.00205	0.21	0.19	Dupuytren's disease;	chr17:43501506	chr17:43444707~43451200:+
THCA	cis	rs481331	1	rs481331	ENSG00000215146.4	RP11-313J2.1	-4.29	2.17e-05	0.00205	-0.31	-0.19	Systemic juvenile idiopathic arthritis;	chr10:42507600	chr10:42331866~42367974:-
THCA	cis	rs481331	0.867	rs671528	ENSG00000215146.4	RP11-313J2.1	-4.29	2.17e-05	0.00205	-0.31	-0.19	Systemic juvenile idiopathic arthritis;	chr10:42507602	chr10:42331866~42367974:-
THCA	cis	rs481331	0.866	rs210236	ENSG00000215146.4	RP11-313J2.1	-4.29	2.17e-05	0.00205	-0.31	-0.19	Systemic juvenile idiopathic arthritis;	chr10:42517245	chr10:42331866~42367974:-
THCA	cis	rs860295	0.812	rs12024257	ENSG00000160766.13	GBAP1	-4.29	2.17e-05	0.00205	-0.23	-0.19	Body mass index;	chr1:155810745	chr1:155213821~155227422:-
THCA	cis	rs860295	0.812	rs6657670	ENSG00000160766.13	GBAP1	-4.29	2.17e-05	0.00205	-0.23	-0.19	Body mass index;	chr1:155818076	chr1:155213821~155227422:-
THCA	cis	rs62458065	0.513	rs10268803	ENSG00000231952.3	DPY19L1P2	4.29	2.17e-05	0.00205	0.32	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32508223	chr7:32812757~32838570:+
THCA	cis	rs2836974	0.568	rs2142111	ENSG00000255568.3	BRWD1-AS2	4.29	2.17e-05	0.00205	0.16	0.19	Cognitive function;	chr21:39177363	chr21:39313935~39314962:+
THCA	cis	rs2287838	0.74	rs12974239	ENSG00000267289.1	CTD-2623N2.11	-4.29	2.17e-05	0.00205	-0.23	-0.19	Sleep duration;	chr19:9893664	chr19:9834079~9835013:-
THCA	cis	rs13256369	0.853	rs13256216	ENSG00000254153.1	CTA-398F10.2	-4.29	2.17e-05	0.00205	-0.22	-0.19	Obesity-related traits;	chr8:8720373	chr8:8456909~8461337:-
THCA	cis	rs1823874	0.677	rs4381582	ENSG00000182397.13	DNM1P46	-4.29	2.17e-05	0.00205	-0.22	-0.19	IgG glycosylation;	chr15:99820308	chr15:99790156~99806927:-
THCA	cis	rs12908161	0.96	rs11633450	ENSG00000275120.1	RP11-182J1.17	4.29	2.17e-05	0.00205	0.23	0.19	Schizophrenia;	chr15:84764056	chr15:84599434~84606463:-
THCA	cis	rs2179367	0.537	rs12192159	ENSG00000216906.2	RP11-350J20.9	4.29	2.17e-05	0.00205	0.27	0.19	Dupuytren's disease;	chr6:149445969	chr6:149904243~149906418:+
THCA	cis	rs1853665	0.767	rs17676204	ENSG00000231760.4	RP11-350J20.5	4.29	2.17e-05	0.00205	0.29	0.19	Radiation response;	chr6:149962676	chr6:149796151~149826294:-
THCA	cis	rs728616	0.51	rs34782759	ENSG00000278616.1	BEND3P3	4.29	2.17e-05	0.00205	0.2	0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80435463	chr10:79682997~79685436:+
THCA	cis	rs11089937	0.616	rs11705598	ENSG00000211639.2	IGLV4-60	4.29	2.17e-05	0.00205	0.13	0.19	Periodontitis (PAL4Q3);	chr22:22178837	chr22:22162199~22162681:+
THCA	cis	rs9840812	0.691	rs833752	ENSG00000239213.4	NCK1-AS1	4.29	2.17e-05	0.00205	0.18	0.19	Fibrinogen levels;	chr3:136536327	chr3:136841726~136862054:-
THCA	cis	rs9532669	0.853	rs9315795	ENSG00000229473.2	RGS17P1	4.29	2.17e-05	0.00205	0.24	0.19	Cervical cancer;	chr13:40943382	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.963	rs3764056	ENSG00000229473.2	RGS17P1	4.29	2.17e-05	0.00205	0.24	0.19	Cervical cancer;	chr13:40943849	chr13:40992779~40993331:-
THCA	cis	rs9487094	0.689	rs9487066	ENSG00000223537.2	RP5-919F19.5	-4.29	2.17e-05	0.00205	-0.2	-0.19	Height;	chr6:109347707	chr6:109487906~109506800:+
THCA	cis	rs6121246	0.954	rs6121245	ENSG00000224628.2	RP5-854E16.2	-4.29	2.17e-05	0.00205	-0.26	-0.19	Mean corpuscular hemoglobin;	chr20:31844257	chr20:31285317~31286835:-
THCA	cis	rs6967414	1	rs6967414	ENSG00000187953.9	PMS2CL	-4.29	2.17e-05	0.00205	-0.26	-0.19	Hematocrit;Hemoglobin concentration;	chr7:6710127	chr7:6710128~6753862:+
THCA	cis	rs7577696	0.654	rs212703	ENSG00000276334.1	AL133243.1	4.29	2.17e-05	0.00205	0.21	0.19	Inflammatory biomarkers;	chr2:32221544	chr2:32521927~32523547:+
THCA	cis	rs2436845	0.966	rs3018956	ENSG00000253669.3	KB-1732A1.1	-4.29	2.17e-05	0.00205	-0.2	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102835367	chr8:102805517~102809971:+
THCA	cis	rs7267979	0.789	rs6083841	ENSG00000274414.1	RP5-965G21.4	4.29	2.17e-05	0.00205	0.23	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:25239007~25245229:-
THCA	cis	rs5760842	0.933	rs5760837	ENSG00000236641.1	CTA-221G9.7	-4.29	2.17e-05	0.00205	-0.21	-0.19	Recurrent major depressive disorder;	chr22:25085119	chr22:25212742~25213685:+
THCA	cis	rs1150668	0.699	rs13408	ENSG00000220721.1	OR1F12	4.29	2.17e-05	0.00205	0.21	0.19	Pubertal anthropometrics;	chr6:28244970	chr6:28073316~28074233:+
THCA	cis	rs2439831	0.681	rs11858152	ENSG00000166763.7	STRCP1	4.29	2.17e-05	0.00205	0.26	0.19	Lung cancer in ever smokers;	chr15:43341998	chr15:43699488~43718184:-
THCA	cis	rs795484	0.963	rs795483	ENSG00000275409.1	RP11-131L12.4	-4.29	2.17e-05	0.00205	-0.16	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118152774	chr12:118430147~118430699:+
THCA	cis	rs4915077	0.892	rs4914963	ENSG00000230489.1	VAV3-AS1	4.29	2.17e-05	0.00205	0.34	0.19	Hypothyroidism;	chr1:107843073	chr1:107964443~107994607:+
THCA	cis	rs11096990	0.855	rs2711990	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39150116	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2566173	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39151111	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2711988	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39151128	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2043102	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39151292	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2711986	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39152258	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.75	rs2465242	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39153796	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2465243	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39154036	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2566176	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39154373	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2566178	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39155194	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2711933	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39156090	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2566179	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39156413	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2566180	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39157381	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2566181	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39157987	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.819	rs2381225	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39158915	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.819	rs1367297	ENSG00000249685.1	RP11-360F5.3	-4.29	2.17e-05	0.00205	-0.25	-0.19	Cognitive function;	chr4:39159614	chr4:39133913~39135608:+
THCA	cis	rs10792320	0.576	rs17185413	ENSG00000279491.1	RP11-810P12.7	-4.29	2.17e-05	0.00205	-0.24	-0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61963081	chr11:61967794~61969490:+
THCA	cis	rs801193	0.967	rs34356500	ENSG00000229180.5	GS1-124K5.11	4.29	2.17e-05	0.00205	0.13	0.19	Aortic root size;	chr7:66771620	chr7:66526088~66542624:-
THCA	cis	rs1232027	0.656	rs11950480	ENSG00000249655.1	CTC-325J23.2	4.29	2.17e-05	0.00206	0.22	0.19	Huntington's disease progression;	chr5:80661294	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650685	ENSG00000249655.1	CTC-325J23.2	4.29	2.17e-05	0.00206	0.22	0.19	Huntington's disease progression;	chr5:80661298	chr5:80630313~80631590:-
THCA	cis	rs13434995	0.513	rs62303681	ENSG00000249700.7	SRD5A3-AS1	-4.29	2.17e-05	0.00206	-0.28	-0.19	Adiponectin levels;	chr4:55403812	chr4:55363971~55395847:-
THCA	cis	rs12612619	0.704	rs2384572	ENSG00000272148.1	RP11-195B17.1	4.29	2.17e-05	0.00206	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27101883	chr2:27062428~27062907:-
THCA	cis	rs61160187	0.582	rs56025209	ENSG00000215032.2	GNL3LP1	4.29	2.17e-05	0.00206	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs2049579	ENSG00000215032.2	GNL3LP1	4.29	2.17e-05	0.00206	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60891935~60893577:-
THCA	cis	rs2836974	0.555	rs35909862	ENSG00000255568.3	BRWD1-AS2	-4.29	2.17e-05	0.00206	-0.16	-0.19	Cognitive function;	chr21:39249232	chr21:39313935~39314962:+
THCA	cis	rs4356203	0.905	rs9919600	ENSG00000272034.1	SNORD14A	-4.29	2.17e-05	0.00206	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058198	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs7939750	ENSG00000272034.1	SNORD14A	-4.29	2.17e-05	0.00206	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058208	chr11:17074654~17074744:-
THCA	cis	rs6747952	0.899	rs4663856	ENSG00000279484.1	KLHL30-AS1	4.29	2.17e-05	0.00206	0.18	0.19	Mean corpuscular hemoglobin concentration;	chr2:238180983	chr2:238152889~238155994:-
THCA	cis	rs4714902	0.655	rs7754915	ENSG00000231769.2	RP1-8B1.4	-4.29	2.17e-05	0.00206	-0.19	-0.19	Colonoscopy-negative controls vs population controls;	chr6:46129832	chr6:46097093~46129706:-
THCA	cis	rs786425	0.866	rs7139193	ENSG00000270095.1	RP11-214K3.18	-4.29	2.17e-05	0.00206	-0.22	-0.19	Pubertal anthropometrics;	chr12:123686629	chr12:123971457~123971714:-
THCA	cis	rs800160	0.777	rs11600971	ENSG00000199550.1	Y_RNA	4.29	2.18e-05	0.00206	0.29	0.19	Bacteremia;	chr11:2322211	chr11:2372638~2372750:+
THCA	cis	rs801193	1	rs7785213	ENSG00000272831.1	RP11-792A8.4	-4.29	2.18e-05	0.00206	-0.12	-0.19	Aortic root size;	chr7:66673991	chr7:66739829~66740385:-
THCA	cis	rs801193	0.967	rs2707841	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66692033	chr7:66739829~66740385:-
THCA	cis	rs12034383	0.967	rs12028134	ENSG00000274245.1	RP11-357P18.2	-4.29	2.18e-05	0.00206	-0.17	-0.19	Erythrocyte sedimentation rate;	chr1:207627064	chr1:207372559~207373252:+
THCA	cis	rs875971	1	rs7792762	ENSG00000230189.5	GS1-124K5.2	4.29	2.18e-05	0.00206	0.13	0.19	Aortic root size;	chr7:66539151	chr7:66409143~66490059:-
THCA	cis	rs713587	0.776	rs1172294	ENSG00000224165.4	DNAJC27-AS1	-4.29	2.18e-05	0.00206	-0.11	-0.19	Body mass index in non-asthmatics;	chr2:24946331	chr2:24971390~25039694:+
THCA	cis	rs116248771	0.739	rs12633687	ENSG00000271778.1	RP11-379F4.8	4.29	2.18e-05	0.00206	0.25	0.19	diarrhoeal disease at age 2;	chr3:158620379	chr3:158782547~158783124:+
THCA	cis	rs1346	0.552	rs11227235	ENSG00000245532.5	NEAT1	4.29	2.18e-05	0.00206	0.15	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65599024	chr11:65422774~65445540:+
THCA	cis	rs1346	0.552	rs10896022	ENSG00000245532.5	NEAT1	4.29	2.18e-05	0.00206	0.15	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65599139	chr11:65422774~65445540:+
THCA	cis	rs1346	0.552	rs10791820	ENSG00000245532.5	NEAT1	4.29	2.18e-05	0.00206	0.15	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65599376	chr11:65422774~65445540:+
THCA	cis	rs2692947	0.537	rs72821435	ENSG00000235959.1	AC009237.17	-4.29	2.18e-05	0.00206	-0.21	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95522187	chr2:95640181~95640604:-
THCA	cis	rs2692947	0.537	rs12468117	ENSG00000235959.1	AC009237.17	-4.29	2.18e-05	0.00206	-0.21	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95528835	chr2:95640181~95640604:-
THCA	cis	rs786425	0.74	rs7397160	ENSG00000270095.1	RP11-214K3.18	-4.29	2.18e-05	0.00206	-0.23	-0.19	Pubertal anthropometrics;	chr12:123711672	chr12:123971457~123971714:-
THCA	cis	rs786425	0.601	rs67178535	ENSG00000270095.1	RP11-214K3.18	-4.29	2.18e-05	0.00206	-0.23	-0.19	Pubertal anthropometrics;	chr12:123711752	chr12:123971457~123971714:-
THCA	cis	rs8141529	0.748	rs1318026	ENSG00000226471.5	CTA-292E10.6	-4.29	2.18e-05	0.00206	-0.16	-0.19	Lymphocyte counts;	chr22:28887530	chr22:28800683~28848559:+
THCA	cis	rs9925964	0.748	rs11640961	ENSG00000232748.3	RP11-196G11.6	4.29	2.18e-05	0.00206	0.22	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30968497	chr16:31056460~31062803:+
THCA	cis	rs6001482	0.638	rs5757569	ENSG00000272779.1	LL22NC03-80A10.6	-4.29	2.18e-05	0.00206	-0.22	-0.19	Diastolic blood pressure;	chr22:22230282	chr22:22303224~22310401:+
THCA	cis	rs875971	0.505	rs6955582	ENSG00000164669.11	INTS4P1	-4.29	2.18e-05	0.00206	-0.24	-0.19	Aortic root size;	chr7:65966699	chr7:65141225~65234216:+
THCA	cis	rs12887734	0.524	rs12588797	ENSG00000269940.1	RP11-73M18.7	-4.29	2.18e-05	0.00206	-0.2	-0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103694560~103695170:+
THCA	cis	rs801193	1	rs1553610	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66732246	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs2707845	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66733811	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs2707850	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66738883	chr7:66739829~66740385:-
THCA	cis	rs801193	0.967	rs1110414	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66740595	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs7783924	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66744070	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs7789184	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66745208	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs2707854	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66747610	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs3800812	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66758474	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs4279493	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66761633	chr7:66739829~66740385:-
THCA	cis	rs801193	0.761	rs2659888	ENSG00000272831.1	RP11-792A8.4	4.29	2.18e-05	0.00206	0.12	0.19	Aortic root size;	chr7:66765184	chr7:66739829~66740385:-
THCA	cis	rs2688608	0.869	rs2633308	ENSG00000271816.1	BMS1P4	4.29	2.18e-05	0.00206	0.19	0.19	Inflammatory bowel disease;	chr10:73894146	chr10:73699151~73730487:-
THCA	cis	rs78487399	0.908	rs76501189	ENSG00000234936.1	AC010883.5	4.29	2.18e-05	0.00206	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43579214	chr2:43229573~43233394:+
THCA	cis	rs1124769	0.57	rs2414052	ENSG00000259378.1	DCAF13P3	4.29	2.18e-05	0.00206	0.27	0.19	Cognitive performance;	chr15:50848104	chr15:50944663~50945996:+
THCA	cis	rs3824488	0.667	rs112191650	ENSG00000271384.1	RP11-435O5.7	-4.29	2.18e-05	0.00206	-0.35	-0.19	Neuroticism;	chr9:95442321	chr9:95406990~95407662:-
THCA	cis	rs8062405	0.755	rs62034358	ENSG00000270424.1	RP11-1348G14.6	4.29	2.18e-05	0.00206	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.755	rs12445823	ENSG00000270424.1	RP11-1348G14.6	4.29	2.18e-05	0.00206	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28749959~28750595:-
THCA	cis	rs494453	0.922	rs531083	ENSG00000227811.2	FAM212B-AS1	-4.29	2.18e-05	0.00206	-0.24	-0.19	Osteoporosis-related phenotypes;	chr1:111680532	chr1:111739841~111747798:+
THCA	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	4.29	2.18e-05	0.00206	0.25	0.19	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
THCA	cis	rs10875746	0.768	rs12305182	ENSG00000258273.1	RP11-370I10.4	4.29	2.18e-05	0.00206	0.27	0.19	Longevity (90 years and older);	chr12:48027624	chr12:48333755~48333901:-
THCA	cis	rs709400	1	rs8018979	ENSG00000258735.1	LINC00637	4.29	2.18e-05	0.00206	0.25	0.19	Body mass index;	chr14:103642750	chr14:103847721~103858049:+
THCA	cis	rs911119	0.913	rs6036463	ENSG00000270001.1	RP11-218C14.8	4.29	2.18e-05	0.00206	0.29	0.19	Chronic kidney disease;	chr20:23598303	chr20:23631826~23632316:-
THCA	cis	rs11756659	0.505	rs62392761	ENSG00000272462.2	U91328.19	4.29	2.18e-05	0.00206	0.18	0.19	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25920511	chr6:25992662~26001775:+
THCA	cis	rs5770917	1	rs5770924	ENSG00000273272.1	CTA-384D8.34	4.29	2.18e-05	0.00206	0.31	0.19	Narcolepsy;	chr22:50586113	chr22:50542650~50543011:+
THCA	cis	rs9876781	1	rs898225	ENSG00000244380.1	RP11-24C3.2	-4.29	2.18e-05	0.00206	-0.23	-0.19	Longevity;	chr3:48371689	chr3:48440352~48446656:-
THCA	cis	rs875971	0.66	rs10215132	ENSG00000272831.1	RP11-792A8.4	-4.29	2.18e-05	0.00206	-0.12	-0.19	Aortic root size;	chr7:66589419	chr7:66739829~66740385:-
THCA	cis	rs253959	0.629	rs10054121	ENSG00000271918.1	CTD-2287O16.5	4.29	2.18e-05	0.00206	0.13	0.19	Bipolar disorder and schizophrenia;	chr5:116084271	chr5:116083807~116085416:-
THCA	cis	rs9650657	0.515	rs7820860	ENSG00000254948.1	OR7E158P	4.29	2.18e-05	0.00206	0.24	0.19	Neuroticism;	chr8:11092886	chr8:11919900~11920809:-
THCA	cis	rs11673344	0.562	rs256740	ENSG00000268499.1	CTB-102L5.8	4.29	2.19e-05	0.00206	0.21	0.19	Obesity-related traits;	chr19:37365451	chr19:38199836~38200934:+
THCA	cis	rs4788570	0.615	rs7206470	ENSG00000260185.1	RP11-432I5.6	-4.29	2.19e-05	0.00206	-0.36	-0.19	Intelligence (multi-trait analysis);	chr16:71634897	chr16:71655027~71664212:+
THCA	cis	rs4578769	0.959	rs9961893	ENSG00000265939.1	UBE2CP2	4.29	2.19e-05	0.00206	0.24	0.19	Eosinophil percentage of white cells;	chr18:22849805	chr18:22900486~22900995:-
THCA	cis	rs143626010	1	rs143626010	ENSG00000270424.1	RP11-1348G14.6	4.29	2.19e-05	0.00207	0.24	0.19	Mosquito bite size;	chr16:28528081	chr16:28749959~28750595:-
THCA	cis	rs2191566	0.881	rs1996408	ENSG00000266921.1	RP11-15A1.7	-4.29	2.19e-05	0.00207	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44028579	chr19:43996896~44002836:-
THCA	cis	rs10946940	0.965	rs6910838	ENSG00000219392.1	RP1-265C24.5	4.29	2.19e-05	0.00207	0.23	0.19	Systemic lupus erythematosus;	chr6:27547740	chr6:28115628~28116551:+
THCA	cis	rs7267979	0.903	rs6115118	ENSG00000274973.1	RP13-401N8.7	-4.29	2.19e-05	0.00207	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.903	rs1118963	ENSG00000274973.1	RP13-401N8.7	-4.29	2.19e-05	0.00207	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25845497~25845862:+
THCA	cis	rs875971	0.862	rs4368860	ENSG00000229886.1	RP5-1132H15.3	-4.29	2.19e-05	0.00207	-0.2	-0.19	Aortic root size;	chr7:66143495	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs7809814	ENSG00000229886.1	RP5-1132H15.3	-4.29	2.19e-05	0.00207	-0.2	-0.19	Aortic root size;	chr7:66150410	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs875971	ENSG00000229886.1	RP5-1132H15.3	-4.29	2.19e-05	0.00207	-0.2	-0.19	Aortic root size;	chr7:66152608	chr7:66025126~66031544:-
THCA	cis	rs1023500	0.573	rs6002592	ENSG00000237037.8	NDUFA6-AS1	4.29	2.19e-05	0.00207	0.16	0.19	Schizophrenia;	chr22:42080750	chr22:42090931~42137742:+
THCA	cis	rs9880211	0.613	rs28519617	ENSG00000273486.1	RP11-731C17.2	4.29	2.19e-05	0.00207	0.19	0.19	Height;Body mass index;	chr3:136156088	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.613	rs28669017	ENSG00000273486.1	RP11-731C17.2	4.29	2.19e-05	0.00207	0.19	0.19	Height;Body mass index;	chr3:136156090	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.613	rs10222451	ENSG00000273486.1	RP11-731C17.2	4.29	2.19e-05	0.00207	0.19	0.19	Height;Body mass index;	chr3:136158571	chr3:136837338~136839021:-
THCA	cis	rs6921919	0.887	rs7766356	ENSG00000219392.1	RP1-265C24.5	-4.29	2.19e-05	0.00207	-0.28	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28115628~28116551:+
THCA	cis	rs13068223	0.503	rs34277251	ENSG00000240875.4	LINC00886	-4.29	2.19e-05	0.00207	-0.15	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156747346~156817062:-
THCA	cis	rs6696239	0.911	rs10799422	ENSG00000227711.2	RP11-275O4.5	-4.29	2.19e-05	0.00207	-0.27	-0.19	Height;	chr1:227535260	chr1:227509028~227520477:-
THCA	cis	rs10792320	0.647	rs17185574	ENSG00000279491.1	RP11-810P12.7	4.29	2.19e-05	0.00207	0.24	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61978222	chr11:61967794~61969490:+
THCA	cis	rs3740713	1	rs12289603	ENSG00000256464.1	YWHABP2	4.29	2.19e-05	0.00207	0.34	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr11:18490243~18490955:-
THCA	cis	rs4819052	1	rs28628220	ENSG00000273796.1	LL21NC02-21A1.1	-4.29	2.19e-05	0.00207	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45403809~45404369:-
THCA	cis	rs4819052	1	rs2838830	ENSG00000273796.1	LL21NC02-21A1.1	-4.29	2.19e-05	0.00207	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45403809~45404369:-
THCA	cis	rs7015630	0.866	rs12680009	ENSG00000251136.7	RP11-37B2.1	-4.29	2.19e-05	0.00207	-0.17	-0.19	Inflammatory bowel disease;Crohn's disease;	chr8:89855155	chr8:89609409~89757727:-
THCA	cis	rs3018712	0.532	rs28551086	ENSG00000212093.1	AP000807.1	4.29	2.19e-05	0.00207	0.26	0.19	Total body bone mineral density;	chr11:68633271	chr11:68506083~68506166:-
THCA	cis	rs7129556	0.645	rs598071	ENSG00000254459.1	RP11-91P24.7	4.29	2.19e-05	0.00207	0.24	0.19	Weight loss (gastric bypass surgery);	chr11:77849606	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.69	rs12285765	ENSG00000254459.1	RP11-91P24.7	4.29	2.19e-05	0.00207	0.24	0.19	Weight loss (gastric bypass surgery);	chr11:77857989	chr11:77829654~77872262:-
THCA	cis	rs7617480	0.549	rs9879978	ENSG00000229759.1	MRPS18AP1	4.29	2.19e-05	0.00207	0.29	0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48809167	chr3:48256350~48256938:-
THCA	cis	rs9863	0.931	rs6488914	ENSG00000270061.1	RP11-214K3.19	4.29	2.19e-05	0.00207	0.26	0.19	White blood cell count;	chr12:123963294	chr12:123969990~123970344:-
THCA	cis	rs35740288	0.752	rs11635956	ENSG00000259295.5	CSPG4P12	4.29	2.19e-05	0.00207	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85736697	chr15:85191438~85213905:+
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000265443.1	CTD-2349P21.6	-4.29	2.19e-05	0.00207	-0.33	-0.19	Body mass index;	chr17:30730179	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000265443.1	CTD-2349P21.6	-4.29	2.19e-05	0.00207	-0.33	-0.19	Body mass index;	chr17:30730744	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000265443.1	CTD-2349P21.6	-4.29	2.19e-05	0.00207	-0.33	-0.19	Body mass index;	chr17:30731712	chr17:30726305~30727564:-
THCA	cis	rs10090774	0.965	rs4961290	ENSG00000279766.1	RP11-642A1.2	-4.29	2.19e-05	0.00207	-0.24	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140741613	chr8:140572142~140572812:-
THCA	cis	rs3764021	0.868	rs7306304	ENSG00000256594.6	RP11-705C15.2	4.29	2.19e-05	0.00207	0.15	0.19	Type 1 diabetes;	chr12:9724600	chr12:9633419~9658412:+
THCA	cis	rs3764021	0.837	rs7306557	ENSG00000256594.6	RP11-705C15.2	4.29	2.19e-05	0.00207	0.15	0.19	Type 1 diabetes;	chr12:9724760	chr12:9633419~9658412:+
THCA	cis	rs7711186	0.786	rs7723662	ENSG00000252464.1	RN7SKP70	4.29	2.19e-05	0.00207	0.23	0.19	Urate levels in obese individuals;	chr5:178657165	chr5:178619728~178619998:-
THCA	cis	rs1150668	0.699	rs13408	ENSG00000273712.1	RP5-874C20.7	4.29	2.19e-05	0.00207	0.21	0.19	Pubertal anthropometrics;	chr6:28244970	chr6:28315613~28315883:-
THCA	cis	rs2692947	0.655	rs60090597	ENSG00000232931.4	LINC00342	4.29	2.19e-05	0.00207	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95740518	chr2:95807118~95816215:-
THCA	cis	rs910873	1	rs62212343	ENSG00000276073.1	RP5-1125A11.7	4.29	2.19e-05	0.00207	0.37	0.19	Melanoma;	chr20:34609133	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs9974891	ENSG00000273796.1	LL21NC02-21A1.1	-4.29	2.19e-05	0.00207	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45403809~45404369:-
THCA	cis	rs62025270	0.688	rs76902341	ENSG00000259295.5	CSPG4P12	-4.29	2.19e-05	0.00207	-0.33	-0.19	Idiopathic pulmonary fibrosis;	chr15:85737059	chr15:85191438~85213905:+
THCA	cis	rs9902453	0.817	rs17226179	ENSG00000263370.1	RP11-68I3.5	4.29	2.19e-05	0.00207	0.25	0.19	Coffee consumption (cups per day);	chr17:29841555	chr17:29639627~29640825:+
THCA	cis	rs860295	0.627	rs11264410	ENSG00000160766.13	GBAP1	-4.29	2.19e-05	0.00207	-0.23	-0.19	Body mass index;	chr1:155775558	chr1:155213821~155227422:-
THCA	cis	rs9435732	0.778	rs56047197	ENSG00000186301.8	MST1P2	-4.29	2.19e-05	0.00207	-0.17	-0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17011965	chr1:16645622~16650289:+
THCA	cis	rs12142240	0.659	rs72677602	ENSG00000232022.5	FAAHP1	-4.29	2.19e-05	0.00207	-0.22	-0.19	Menopause (age at onset);	chr1:46371815	chr1:46432129~46445521:+
THCA	cis	rs786425	0.682	rs11611354	ENSG00000270095.1	RP11-214K3.18	-4.29	2.19e-05	0.00207	-0.23	-0.19	Pubertal anthropometrics;	chr12:123669092	chr12:123971457~123971714:-
THCA	cis	rs4650994	0.571	rs6700047	ENSG00000273384.1	RP5-1098D14.1	-4.29	2.19e-05	0.00207	-0.25	-0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178539607	chr1:178651706~178652282:+
THCA	cis	rs4650994	0.571	rs6676507	ENSG00000273384.1	RP5-1098D14.1	-4.29	2.19e-05	0.00207	-0.25	-0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178539608	chr1:178651706~178652282:+
THCA	cis	rs11758351	1	rs2143347	ENSG00000216331.1	HIST1H1PS1	4.29	2.19e-05	0.00207	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26198266	chr6:26195566~26195771:+
THCA	cis	rs7746199	0.736	rs13212318	ENSG00000272009.1	RP1-313I6.12	-4.29	2.19e-05	0.00207	-0.37	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs13202291	ENSG00000272009.1	RP1-313I6.12	-4.29	2.19e-05	0.00207	-0.37	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs17750424	ENSG00000272009.1	RP1-313I6.12	-4.29	2.19e-05	0.00207	-0.37	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28078792~28081130:-
THCA	cis	rs4788570	0.615	rs2334880	ENSG00000260593.1	RP11-432I5.2	-4.29	2.19e-05	0.00207	-0.31	-0.19	Intelligence (multi-trait analysis);	chr16:71619734	chr16:71623708~71626816:-
THCA	cis	rs17095355	1	rs12570145	ENSG00000203876.8	ADD3-AS1	-4.29	2.19e-05	0.00207	-0.22	-0.19	Biliary atresia;	chr10:109953155	chr10:109940104~110008381:-
THCA	cis	rs7216064	0.954	rs8079291	ENSG00000278740.1	RP11-147L13.14	4.29	2.19e-05	0.00207	0.22	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891506	chr17:68188547~68189165:+
THCA	cis	rs2732480	0.538	rs1387260	ENSG00000273765.1	RP11-370I10.11	4.29	2.2e-05	0.00207	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48360920~48361377:+
THCA	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	4.29	2.2e-05	0.00207	0.23	0.19	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
THCA	cis	rs5758659	0.652	rs133303	ENSG00000273366.1	CTA-989H11.1	-4.29	2.2e-05	0.00207	-0.24	-0.19	Cognitive function;	chr22:41999238	chr22:42278188~42278846:+
THCA	cis	rs9311474	0.629	rs7636227	ENSG00000243224.1	RP5-1157M23.2	-4.29	2.2e-05	0.00207	-0.21	-0.19	Electroencephalogram traits;	chr3:52532666	chr3:52239258~52241097:+
THCA	cis	rs2153535	0.56	rs1328866	ENSG00000230939.1	RP11-314C16.1	-4.29	2.2e-05	0.00207	-0.2	-0.19	Motion sickness;	chr6:8653283	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs1328865	ENSG00000230939.1	RP11-314C16.1	-4.29	2.2e-05	0.00207	-0.2	-0.19	Motion sickness;	chr6:8653454	chr6:8784178~8785445:+
THCA	cis	rs7267979	1	rs2482940	ENSG00000274973.1	RP13-401N8.7	4.29	2.2e-05	0.00207	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2027003	ENSG00000274973.1	RP13-401N8.7	4.29	2.2e-05	0.00207	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2027004	ENSG00000274973.1	RP13-401N8.7	4.29	2.2e-05	0.00207	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2500404	ENSG00000274973.1	RP13-401N8.7	4.29	2.2e-05	0.00207	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2500405	ENSG00000274973.1	RP13-401N8.7	4.29	2.2e-05	0.00207	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2482941	ENSG00000274973.1	RP13-401N8.7	4.29	2.2e-05	0.00207	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.903	rs2500423	ENSG00000274973.1	RP13-401N8.7	4.29	2.2e-05	0.00207	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25845497~25845862:+
THCA	cis	rs17853159	1	rs3219484	ENSG00000281912.1	LINC01144	-4.29	2.2e-05	0.00207	-0.27	-0.19	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45334484	chr1:45303910~45305619:+
THCA	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-4.29	2.2e-05	0.00208	-0.12	-0.19	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
THCA	cis	rs16915157	0.557	rs78424567	ENSG00000254271.1	RP11-131N11.4	4.29	2.2e-05	0.00208	0.41	0.19	Schizophrenia;	chr10:60578126	chr10:60734342~60741828:+
THCA	cis	rs860295	0.702	rs475550	ENSG00000160766.13	GBAP1	-4.29	2.2e-05	0.00208	-0.23	-0.19	Body mass index;	chr1:155682290	chr1:155213821~155227422:-
THCA	cis	rs2439831	0.681	rs3742971	ENSG00000166763.7	STRCP1	-4.29	2.2e-05	0.00208	-0.26	-0.19	Lung cancer in ever smokers;	chr15:43330718	chr15:43699488~43718184:-
THCA	cis	rs2243480	0.522	rs73150635	ENSG00000232546.1	RP11-458F8.1	-4.29	2.2e-05	0.00208	-0.33	-0.19	Diabetic kidney disease;	chr7:66507503	chr7:66848496~66858136:+
THCA	cis	rs1728785	0.792	rs1111502	ENSG00000274698.1	RP11-71L14.4	4.29	2.2e-05	0.00208	0.27	0.19	Ulcerative colitis;	chr16:68547306	chr16:68450283~68452318:+
THCA	cis	rs7115242	0.858	rs6589592	ENSG00000280143.1	AP000892.6	4.29	2.2e-05	0.00208	0.35	0.19	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117204967~117210292:+
THCA	cis	rs4718428	1	rs12534637	ENSG00000237310.1	GS1-124K5.4	4.29	2.2e-05	0.00208	0.15	0.19	Corneal structure;	chr7:66862667	chr7:66493706~66495474:+
THCA	cis	rs10129255	0.957	rs67625077	ENSG00000211970.3	IGHV4-61	-4.29	2.2e-05	0.00208	-0.12	-0.19	Kawasaki disease;	chr14:106715436	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.869	rs72690553	ENSG00000211970.3	IGHV4-61	-4.29	2.2e-05	0.00208	-0.12	-0.19	Kawasaki disease;	chr14:106715491	chr14:106639119~106639657:-
THCA	cis	rs4948102	0.686	rs11771788	ENSG00000275875.1	RP11-613E4.5	-4.29	2.2e-05	0.00208	-0.23	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56090347	chr7:55741525~55741869:+
THCA	cis	rs728616	0.51	rs17617406	ENSG00000225484.5	NUTM2B-AS1	4.29	2.2e-05	0.00208	0.33	0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80414800	chr10:79663088~79826594:-
THCA	cis	rs7474896	0.559	rs1208645	ENSG00000120555.12	SEPT7P9	-4.29	2.2e-05	0.00208	-0.25	-0.19	Obesity (extreme);	chr10:37843159	chr10:38383069~38402916:-
THCA	cis	rs4227	0.877	rs4968212	ENSG00000233223.2	AC113189.5	4.29	2.2e-05	0.00208	0.17	0.19	IgA nephropathy;	chr17:7564899	chr17:7581964~7584072:-
THCA	cis	rs9911578	0.835	rs58647683	ENSG00000224738.1	AC099850.1	-4.29	2.2e-05	0.00208	-0.23	-0.19	Intelligence (multi-trait analysis);	chr17:58405833	chr17:59106598~59118267:+
THCA	cis	rs4819052	0.851	rs2236443	ENSG00000273796.1	LL21NC02-21A1.1	-4.29	2.2e-05	0.00208	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45403809~45404369:-
THCA	cis	rs10483853	0.806	rs881035	ENSG00000258695.2	RP3-414A15.2	-4.29	2.2e-05	0.00208	-0.27	-0.19	Coronary artery calcification;	chr14:73402685	chr14:73522878~73530610:+
THCA	cis	rs10421328	0.848	rs10415278	ENSG00000271283.1	CTC-412M14.6	4.29	2.2e-05	0.00208	0.31	0.19	Parental longevity (combined parental age at death);	chr19:19658348	chr19:19699203~19699409:-
THCA	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	4.29	2.2e-05	0.00208	0.21	0.19	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
THCA	cis	rs1923243	0.618	rs12142252	ENSG00000223479.3	RP4-788P17.1	4.29	2.2e-05	0.00208	0.21	0.19	Migraine;	chr1:73085707	chr1:73635216~73715214:+
THCA	cis	rs12755164	0.771	rs10889994	ENSG00000223479.3	RP4-788P17.1	-4.29	2.2e-05	0.00208	-0.21	-0.19	Schizophrenia;	chr1:72852882	chr1:73635216~73715214:+
THCA	cis	rs7824557	0.527	rs2572448	ENSG00000206014.6	OR7E161P	4.29	2.2e-05	0.00208	0.22	0.19	Retinal vascular caliber;	chr8:11381843	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.527	rs2572447	ENSG00000206014.6	OR7E161P	4.29	2.2e-05	0.00208	0.22	0.19	Retinal vascular caliber;	chr8:11382001	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.527	rs2572446	ENSG00000206014.6	OR7E161P	4.29	2.2e-05	0.00208	0.22	0.19	Retinal vascular caliber;	chr8:11382056	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.527	rs10109537	ENSG00000206014.6	OR7E161P	4.29	2.2e-05	0.00208	0.22	0.19	Retinal vascular caliber;	chr8:11382131	chr8:11928597~11929563:-
THCA	cis	rs11771526	1	rs6462350	ENSG00000272905.1	RP11-265E18.1	4.29	2.2e-05	0.00208	0.28	0.19	Body mass index;	chr7:32302388	chr7:32845394~32846061:+
THCA	cis	rs6500602	0.893	rs8061742	ENSG00000280063.1	RP11-295D4.3	4.29	2.2e-05	0.00208	0.11	0.19	Schizophrenia;	chr16:4439435	chr16:4346694~4348648:-
THCA	cis	rs786425	0.966	rs7134896	ENSG00000270095.1	RP11-214K3.18	-4.29	2.2e-05	0.00208	-0.22	-0.19	Pubertal anthropometrics;	chr12:123617311	chr12:123971457~123971714:-
THCA	cis	rs1580019	0.713	rs2122632	ENSG00000231952.3	DPY19L1P2	4.29	2.2e-05	0.00208	0.25	0.19	Cognitive ability;	chr7:32485074	chr7:32812757~32838570:+
THCA	cis	rs2839186	0.869	rs17176513	ENSG00000215424.8	MCM3AP-AS1	4.29	2.2e-05	0.00208	0.11	0.19	Testicular germ cell tumor;	chr21:46262514	chr21:46229217~46259390:+
THCA	cis	rs7179456	0.545	rs507801	ENSG00000245975.2	RP11-30K9.6	4.29	2.2e-05	0.00208	0.19	0.19	Asperger disorder;	chr15:58761146	chr15:58768072~58770974:-
THCA	cis	rs6088590	0.523	rs6059913	ENSG00000276073.1	RP5-1125A11.7	-4.29	2.2e-05	0.00208	-0.17	-0.19	Coronary artery disease;	chr20:34555484	chr20:33985617~33988989:-
THCA	cis	rs12612619	0.667	rs1866559	ENSG00000272148.1	RP11-195B17.1	-4.29	2.21e-05	0.00208	-0.19	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27112718	chr2:27062428~27062907:-
THCA	cis	rs7260598	0.581	rs77986252	ENSG00000268442.1	CTD-2027I19.2	4.29	2.21e-05	0.00208	0.29	0.19	Response to taxane treatment (placlitaxel);	chr19:23805508	chr19:24162370~24163425:-
THCA	cis	rs10875746	0.951	rs8804	ENSG00000258234.1	RP11-370I10.2	4.29	2.21e-05	0.00208	0.23	0.19	Longevity (90 years and older);	chr12:48147974	chr12:48231098~48284210:-
THCA	cis	rs4713118	0.869	rs9295743	ENSG00000220721.1	OR1F12	4.29	2.21e-05	0.00208	0.25	0.19	Parkinson's disease;	chr6:27747323	chr6:28073316~28074233:+
THCA	cis	rs1334894	0.901	rs6906096	ENSG00000228559.1	RP3-340B19.3	-4.29	2.21e-05	0.00208	-0.41	-0.19	Coronary artery disease;	chr6:35532877	chr6:35544632~35545669:+
THCA	cis	rs728616	0.614	rs726014	ENSG00000242600.5	MBL1P	4.29	2.21e-05	0.00208	0.21	0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948988	chr10:79904898~79950336:+
THCA	cis	rs4660214	0.666	rs636083	ENSG00000182109.6	RP11-69E11.4	4.29	2.21e-05	0.00208	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39522280~39546187:-
THCA	cis	rs10911902	0.688	rs113019508	ENSG00000229739.2	RP11-295K2.3	-4.29	2.21e-05	0.00208	-0.29	-0.19	Schizophrenia;	chr1:186349685	chr1:186435161~186470291:+
THCA	cis	rs9388451	0.531	rs9401850	ENSG00000226409.1	RP11-735G4.1	-4.29	2.21e-05	0.00208	-0.24	-0.19	Brugada syndrome;	chr6:125829854	chr6:125370211~125374324:-
THCA	cis	rs2836974	0.899	rs35774464	ENSG00000255568.3	BRWD1-AS2	4.29	2.21e-05	0.00208	0.17	0.19	Cognitive function;	chr21:39208243	chr21:39313935~39314962:+
THCA	cis	rs1728785	1	rs821167	ENSG00000274698.1	RP11-71L14.4	4.29	2.21e-05	0.00208	0.28	0.19	Ulcerative colitis;	chr16:68543319	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.892	rs1617749	ENSG00000274698.1	RP11-71L14.4	4.29	2.21e-05	0.00208	0.28	0.19	Ulcerative colitis;	chr16:68546987	chr16:68450283~68452318:+
THCA	cis	rs8062405	0.723	rs4788077	ENSG00000261766.1	RP11-22P6.2	-4.29	2.21e-05	0.00209	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28862166~28863340:-
THCA	cis	rs6456156	0.846	rs204293	ENSG00000235272.1	FAM103A2P	4.29	2.21e-05	0.00209	0.27	0.19	Primary biliary cholangitis;	chr6:167100993	chr6:166586124~166586477:-
THCA	cis	rs5769765	1	rs1033665	ENSG00000260613.1	RP3-522J7.6	-4.29	2.21e-05	0.00209	-0.24	-0.19	Schizophrenia;	chr22:49858479	chr22:49832616~49837786:-
THCA	cis	rs6121246	0.512	rs45443696	ENSG00000230613.1	HM13-AS1	4.29	2.21e-05	0.00209	0.19	0.19	Mean corpuscular hemoglobin;	chr20:31723593	chr20:31567707~31573263:-
THCA	cis	rs11846409	0.86	rs55745256	ENSG00000211974.3	IGHV2-70	-4.29	2.21e-05	0.00209	-0.19	-0.19	Rheumatic heart disease;	chr14:106632365	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs731013	ENSG00000211974.3	IGHV2-70	-4.29	2.21e-05	0.00209	-0.19	-0.19	Rheumatic heart disease;	chr14:106632481	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs731012	ENSG00000211974.3	IGHV2-70	-4.29	2.21e-05	0.00209	-0.19	-0.19	Rheumatic heart disease;	chr14:106632578	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs731011	ENSG00000211974.3	IGHV2-70	-4.29	2.21e-05	0.00209	-0.19	-0.19	Rheumatic heart disease;	chr14:106632619	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs10138537	ENSG00000211974.3	IGHV2-70	-4.29	2.21e-05	0.00209	-0.19	-0.19	Rheumatic heart disease;	chr14:106632778	chr14:106723574~106724093:-
THCA	cis	rs11846409	0.932	rs756588	ENSG00000211974.3	IGHV2-70	4.29	2.21e-05	0.00209	0.19	0.19	Rheumatic heart disease;	chr14:106632316	chr14:106723574~106724093:-
THCA	cis	rs67478160	0.529	rs12880413	ENSG00000269940.1	RP11-73M18.7	4.29	2.21e-05	0.00209	0.18	0.19	Schizophrenia;	chr14:103801070	chr14:103694560~103695170:+
THCA	cis	rs9921338	0.636	rs56069754	ENSG00000262636.1	CTD-3088G3.4	-4.29	2.21e-05	0.00209	-0.29	-0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11268783	chr16:11380859~11381118:-
THCA	cis	rs17767392	0.781	rs8008605	ENSG00000259146.3	RP1-261D10.2	-4.29	2.21e-05	0.00209	-0.25	-0.19	Mitral valve prolapse;	chr14:71578827	chr14:71292729~71321814:-
THCA	cis	rs2562456	0.793	rs279807	ENSG00000268117.1	VN1R84P	4.29	2.21e-05	0.00209	0.31	0.19	Pain;	chr19:21283020	chr19:21719801~21720035:-
THCA	cis	rs10090774	0.71	rs11166992	ENSG00000280303.2	ERICD	-4.29	2.21e-05	0.00209	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140667371	chr8:140636281~140638283:+
THCA	cis	rs708224	0.967	rs1239402	ENSG00000277342.1	RP11-843B15.4	4.29	2.21e-05	0.00209	0.24	0.19	Pancreatic cancer;	chr12:32287233	chr12:32109076~32109602:+
THCA	cis	rs708224	1	rs1271200	ENSG00000277342.1	RP11-843B15.4	4.29	2.21e-05	0.00209	0.24	0.19	Pancreatic cancer;	chr12:32288336	chr12:32109076~32109602:+
THCA	cis	rs6696239	1	rs74140304	ENSG00000227711.2	RP11-275O4.5	-4.29	2.21e-05	0.00209	-0.27	-0.19	Height;	chr1:227542838	chr1:227509028~227520477:-
THCA	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-4.29	2.21e-05	0.00209	-0.22	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
THCA	cis	rs4948102	0.597	rs12669623	ENSG00000275875.1	RP11-613E4.5	-4.29	2.21e-05	0.00209	-0.23	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55741525~55741869:+
THCA	cis	rs7577696	1	rs7577696	ENSG00000276334.1	AL133243.1	-4.29	2.21e-05	0.00209	-0.2	-0.19	Inflammatory biomarkers;	chr2:32053713	chr2:32521927~32523547:+
THCA	cis	rs9388451	0.531	rs9375414	ENSG00000226409.1	RP11-735G4.1	-4.29	2.21e-05	0.00209	-0.24	-0.19	Brugada syndrome;	chr6:125833329	chr6:125370211~125374324:-
THCA	cis	rs9388451	0.536	rs34725880	ENSG00000226409.1	RP11-735G4.1	-4.29	2.21e-05	0.00209	-0.24	-0.19	Brugada syndrome;	chr6:125834091	chr6:125370211~125374324:-
THCA	cis	rs375092	0.689	rs187985	ENSG00000230658.1	KLHL7-AS1	4.29	2.22e-05	0.00209	0.27	0.19	Personality dimensions;	chr7:23386613	chr7:23101228~23105703:-
THCA	cis	rs11175834	0.557	rs4444128	ENSG00000250748.5	RP11-230G5.2	4.29	2.22e-05	0.00209	0.32	0.19	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65571793	chr12:65466820~65642372:-
THCA	cis	rs6430538	0.646	rs6430539	ENSG00000224043.6	CCNT2-AS1	-4.29	2.22e-05	0.00209	-0.2	-0.19	Parkinson's disease;	chr2:134792160	chr2:134735464~134918710:-
THCA	cis	rs7208859	0.614	rs7216394	ENSG00000263603.1	CTD-2349P21.5	4.29	2.22e-05	0.00209	0.32	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30729469~30731202:+
THCA	cis	rs801193	1	rs2707836	ENSG00000272831.1	RP11-792A8.4	4.29	2.22e-05	0.00209	0.12	0.19	Aortic root size;	chr7:66695448	chr7:66739829~66740385:-
THCA	cis	rs801193	0.844	rs7779971	ENSG00000272831.1	RP11-792A8.4	4.29	2.22e-05	0.00209	0.12	0.19	Aortic root size;	chr7:66696803	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs2659906	ENSG00000272831.1	RP11-792A8.4	4.29	2.22e-05	0.00209	0.12	0.19	Aortic root size;	chr7:66700323	chr7:66739829~66740385:-
THCA	cis	rs62025270	0.522	rs338519	ENSG00000259295.5	CSPG4P12	-4.28	2.22e-05	0.00209	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85191438~85213905:+
THCA	cis	rs6479891	1	rs7099425	ENSG00000272767.1	JMJD1C-AS1	-4.28	2.22e-05	0.00209	-0.27	-0.19	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63465229~63466563:+
THCA	cis	rs3845817	1	rs11126042	ENSG00000237979.1	AC007389.1	-4.28	2.22e-05	0.00209	-0.22	-0.19	Bipolar disorder;	chr2:65536511	chr2:65500993~65502138:-
THCA	cis	rs28386778	0.699	rs12451467	ENSG00000240280.5	TCAM1P	4.28	2.22e-05	0.00209	0.27	0.19	Prudent dietary pattern;	chr17:63931525	chr17:63849292~63864379:+
THCA	cis	rs9302635	0.64	rs9933009	ENSG00000260886.1	TAT-AS1	4.28	2.22e-05	0.00209	0.25	0.19	Blood protein levels;	chr16:72156751	chr16:71565789~71578187:+
THCA	cis	rs1023500	0.505	rs134888	ENSG00000182057.4	OGFRP1	4.28	2.22e-05	0.00209	0.22	0.19	Schizophrenia;	chr22:42278275	chr22:42269753~42275196:+
THCA	cis	rs734999	0.566	rs10797435	ENSG00000225931.3	RP3-395M20.7	4.28	2.22e-05	0.00209	0.23	0.19	Ulcerative colitis;	chr1:2603362	chr1:2566410~2569888:+
THCA	cis	rs734999	0.588	rs4648562	ENSG00000225931.3	RP3-395M20.7	4.28	2.22e-05	0.00209	0.23	0.19	Ulcerative colitis;	chr1:2604174	chr1:2566410~2569888:+
THCA	cis	rs734999	0.566	rs4648563	ENSG00000225931.3	RP3-395M20.7	4.28	2.22e-05	0.00209	0.23	0.19	Ulcerative colitis;	chr1:2604563	chr1:2566410~2569888:+
THCA	cis	rs10895987	0.531	rs2282498	ENSG00000255200.1	AP003068.18	4.28	2.22e-05	0.00209	0.26	0.19	Blood protein levels;	chr11:65088514	chr11:65174117~65176470:-
THCA	cis	rs9652601	0.696	rs12917656	ENSG00000274038.1	RP11-66H6.4	-4.28	2.22e-05	0.00209	-0.23	-0.19	Systemic lupus erythematosus;	chr16:11094005	chr16:11056556~11057034:+
THCA	cis	rs755249	1	rs17513135	ENSG00000237624.1	OXCT2P1	4.28	2.22e-05	0.00209	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39514956~39516490:+
THCA	cis	rs28735056	0.967	rs623546	ENSG00000261126.6	RP11-795F19.1	-4.28	2.22e-05	0.00209	-0.16	-0.19	Schizophrenia;	chr18:79835228	chr18:80046900~80095482:+
THCA	cis	rs786425	0.682	rs7307008	ENSG00000270095.1	RP11-214K3.18	4.28	2.22e-05	0.00209	0.23	0.19	Pubertal anthropometrics;	chr12:123675474	chr12:123971457~123971714:-
THCA	cis	rs138249	1	rs138244	ENSG00000273253.2	RP3-402G11.26	-4.28	2.22e-05	0.00209	-0.19	-0.19	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50126938	chr22:50199090~50200837:-
THCA	cis	rs4835473	0.637	rs2323201	ENSG00000251600.4	RP11-673E1.1	4.28	2.22e-05	0.00209	0.24	0.19	Immature fraction of reticulocytes;	chr4:143765629	chr4:143912331~143982454:+
THCA	cis	rs1923243	0.677	rs4130885	ENSG00000223479.3	RP4-788P17.1	4.28	2.22e-05	0.00209	0.22	0.19	Migraine;	chr1:73109392	chr1:73635216~73715214:+
THCA	cis	rs58365266	1	rs58365266	ENSG00000231464.1	AC024937.4	4.28	2.22e-05	0.00209	0.32	0.19	Red cell distribution width;	chr3:196086886	chr3:195996738~195998233:+
THCA	cis	rs763121	0.962	rs6001159	ENSG00000228274.3	RP3-508I15.9	-4.28	2.22e-05	0.0021	-0.2	-0.19	Menopause (age at onset);	chr22:38570482	chr22:38667585~38681820:-
THCA	cis	rs2822388	0.59	rs2822392	ENSG00000228314.1	CYP4F29P	-4.28	2.22e-05	0.0021	-0.38	-0.19	Stroke;	chr21:14040510	chr21:13843133~13848364:-
THCA	cis	rs6012564	0.964	rs2064853	ENSG00000230758.1	SNAP23P	-4.28	2.22e-05	0.0021	-0.23	-0.19	Anger;	chr20:49058639	chr20:49038357~49038602:-
THCA	cis	rs7824557	0.564	rs2572399	ENSG00000206014.6	OR7E161P	4.28	2.22e-05	0.0021	0.22	0.19	Retinal vascular caliber;	chr8:11377011	chr8:11928597~11929563:-
THCA	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	4.28	2.22e-05	0.0021	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.548	rs1983484	ENSG00000215032.2	GNL3LP1	4.28	2.22e-05	0.0021	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60891935~60893577:-
THCA	cis	rs1823874	0.72	rs7162911	ENSG00000254744.3	CTD-3076O17.1	-4.28	2.22e-05	0.0021	-0.2	-0.19	IgG glycosylation;	chr15:99814845	chr15:99970215~99974010:+
THCA	cis	rs1346	0.58	rs7937415	ENSG00000245532.5	NEAT1	4.28	2.22e-05	0.0021	0.15	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65596487	chr11:65422774~65445540:+
THCA	cis	rs860295	0.836	rs6684889	ENSG00000160766.13	GBAP1	4.28	2.22e-05	0.0021	0.22	0.19	Body mass index;	chr1:155457271	chr1:155213821~155227422:-
THCA	cis	rs1923243	0.647	rs34868208	ENSG00000223479.3	RP4-788P17.1	4.28	2.22e-05	0.0021	0.21	0.19	Migraine;	chr1:73175231	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs34956095	ENSG00000223479.3	RP4-788P17.1	4.28	2.22e-05	0.0021	0.21	0.19	Migraine;	chr1:73175257	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs36051652	ENSG00000223479.3	RP4-788P17.1	4.28	2.22e-05	0.0021	0.21	0.19	Migraine;	chr1:73175318	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs36053729	ENSG00000223479.3	RP4-788P17.1	4.28	2.22e-05	0.0021	0.21	0.19	Migraine;	chr1:73175341	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs35286654	ENSG00000223479.3	RP4-788P17.1	4.28	2.22e-05	0.0021	0.21	0.19	Migraine;	chr1:73175376	chr1:73635216~73715214:+
THCA	cis	rs72819454	0.522	rs72817647	ENSG00000280693.1	SH3PXD2A-AS1	-4.28	2.23e-05	0.0021	-0.35	-0.19	Interleukin-9 levels;	chr10:103768946	chr10:103745966~103755423:+
THCA	cis	rs72819454	0.522	rs11191800	ENSG00000280693.1	SH3PXD2A-AS1	-4.28	2.23e-05	0.0021	-0.35	-0.19	Interleukin-9 levels;	chr10:103771521	chr10:103745966~103755423:+
THCA	cis	rs72819454	0.522	rs911544	ENSG00000280693.1	SH3PXD2A-AS1	-4.28	2.23e-05	0.0021	-0.35	-0.19	Interleukin-9 levels;	chr10:103771936	chr10:103745966~103755423:+
THCA	cis	rs4950322	0.58	rs17359629	ENSG00000180867.10	PDIA3P1	4.28	2.23e-05	0.0021	0.19	0.19	Protein quantitative trait loci;	chr1:147121537	chr1:147178113~147179622:+
THCA	cis	rs12022452	1	rs12048678	ENSG00000237899.1	RP4-739H11.3	-4.28	2.23e-05	0.0021	-0.32	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40669089~40687588:-
THCA	cis	rs4805272	1	rs7257343	ENSG00000267799.1	MAN1A2P1	4.28	2.23e-05	0.0021	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832203	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs7257353	ENSG00000267799.1	MAN1A2P1	4.28	2.23e-05	0.0021	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832217	chr19:28790812~28792871:-
THCA	cis	rs10760158	0.832	rs4837820	ENSG00000226752.6	PSMD5-AS1	-4.28	2.23e-05	0.0021	-0.24	-0.19	Pulse pressure;	chr9:121247816	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs4837821	ENSG00000226752.6	PSMD5-AS1	-4.28	2.23e-05	0.0021	-0.24	-0.19	Pulse pressure;	chr9:121248241	chr9:120824828~120854385:+
THCA	cis	rs6570726	0.791	rs448939	ENSG00000270638.1	RP3-466P17.1	4.28	2.23e-05	0.0021	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145735570~145737218:+
THCA	cis	rs17685	0.753	rs12531559	ENSG00000230882.1	AC005077.14	-4.28	2.23e-05	0.0021	-0.19	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76002379	chr7:76071469~76074963:-
THCA	cis	rs12478296	1	rs6743297	ENSG00000220804.7	AC093642.5	4.28	2.23e-05	0.0021	0.21	0.19	Obesity-related traits;	chr2:242071663	chr2:242088633~242160153:+
THCA	cis	rs12478296	0.892	rs11897561	ENSG00000220804.7	AC093642.5	4.28	2.23e-05	0.0021	0.21	0.19	Obesity-related traits;	chr2:242072825	chr2:242088633~242160153:+
THCA	cis	rs73198271	0.531	rs3748142	ENSG00000253893.2	FAM85B	4.28	2.23e-05	0.0021	0.35	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797845	chr8:8167819~8226614:-
THCA	cis	rs1876905	0.68	rs395564	ENSG00000272356.1	RP5-1112D6.8	-4.28	2.23e-05	0.0021	-0.19	-0.19	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111309203~111313517:+
THCA	cis	rs16852403	0.507	rs451341	ENSG00000224687.1	RASAL2-AS1	-4.28	2.23e-05	0.0021	-0.28	-0.19	Childhood ear infection;	chr1:178128380	chr1:178091508~178093984:-
THCA	cis	rs45509595	0.841	rs17751184	ENSG00000272009.1	RP1-313I6.12	-4.28	2.23e-05	0.0021	-0.37	-0.19	Breast cancer;	chr6:27807250	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs67101035	ENSG00000272009.1	RP1-313I6.12	-4.28	2.23e-05	0.0021	-0.37	-0.19	Depression;	chr6:27831109	chr6:28078792~28081130:-
THCA	cis	rs853679	0.556	rs34706883	ENSG00000272009.1	RP1-313I6.12	-4.28	2.23e-05	0.0021	-0.37	-0.19	Depression;	chr6:27837477	chr6:28078792~28081130:-
THCA	cis	rs67340775	0.748	rs13212651	ENSG00000272009.1	RP1-313I6.12	-4.28	2.23e-05	0.0021	-0.37	-0.19	Lung cancer in ever smokers;	chr6:27839207	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs35819751	ENSG00000272009.1	RP1-313I6.12	-4.28	2.23e-05	0.0021	-0.37	-0.19	Depression;	chr6:27842791	chr6:28078792~28081130:-
THCA	cis	rs61270009	0.955	rs780402	ENSG00000247828.6	TMEM161B-AS1	-4.28	2.23e-05	0.0021	-0.17	-0.19	Depressive symptoms;	chr5:88244890	chr5:88268895~88436685:+
THCA	cis	rs2549003	0.966	rs10072571	ENSG00000237714.1	P4HA2-AS1	-4.28	2.23e-05	0.0021	-0.25	-0.19	Asthma (sex interaction);	chr5:132481019	chr5:132184876~132192808:+
THCA	cis	rs2549003	0.966	rs10065633	ENSG00000237714.1	P4HA2-AS1	-4.28	2.23e-05	0.0021	-0.25	-0.19	Asthma (sex interaction);	chr5:132481024	chr5:132184876~132192808:+
THCA	cis	rs3733585	0.579	rs4235356	ENSG00000261490.1	RP11-448G15.3	-4.28	2.23e-05	0.0021	-0.13	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:10121482	chr4:10068089~10073019:-
THCA	cis	rs1923243	0.71	rs3998	ENSG00000223479.3	RP4-788P17.1	4.28	2.23e-05	0.0021	0.22	0.19	Migraine;	chr1:73150784	chr1:73635216~73715214:+
THCA	cis	rs16852403	0.658	rs10157702	ENSG00000224687.1	RASAL2-AS1	4.28	2.23e-05	0.0021	0.32	0.19	Childhood ear infection;	chr1:178139910	chr1:178091508~178093984:-
THCA	cis	rs7474896	0.559	rs2738185	ENSG00000120555.12	SEPT7P9	-4.28	2.23e-05	0.0021	-0.25	-0.19	Obesity (extreme);	chr10:37958808	chr10:38383069~38402916:-
THCA	cis	rs13256369	1	rs13267501	ENSG00000254153.1	CTA-398F10.2	-4.28	2.23e-05	0.0021	-0.22	-0.19	Obesity-related traits;	chr8:8716548	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs7004438	ENSG00000254153.1	CTA-398F10.2	-4.28	2.23e-05	0.0021	-0.22	-0.19	Obesity-related traits;	chr8:8716869	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs13271966	ENSG00000254153.1	CTA-398F10.2	-4.28	2.23e-05	0.0021	-0.22	-0.19	Obesity-related traits;	chr8:8717962	chr8:8456909~8461337:-
THCA	cis	rs7560272	0.512	rs12998980	ENSG00000273245.1	RP11-434P11.2	-4.28	2.23e-05	0.0021	-0.22	-0.19	Schizophrenia;	chr2:73703599	chr2:73750256~73750786:-
THCA	cis	rs875971	0.862	rs6460302	ENSG00000229886.1	RP5-1132H15.3	4.28	2.23e-05	0.0021	0.2	0.19	Aortic root size;	chr7:66495270	chr7:66025126~66031544:-
THCA	cis	rs17221829	0.965	rs4553368	ENSG00000280385.1	AP000648.5	-4.28	2.23e-05	0.0021	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89726574	chr11:90193614~90198120:+
THCA	cis	rs734999	0.545	rs6666788	ENSG00000225931.3	RP3-395M20.7	-4.28	2.23e-05	0.0021	-0.23	-0.19	Ulcerative colitis;	chr1:2636061	chr1:2566410~2569888:+
THCA	cis	rs734999	0.545	rs28690427	ENSG00000225931.3	RP3-395M20.7	-4.28	2.23e-05	0.0021	-0.23	-0.19	Ulcerative colitis;	chr1:2640384	chr1:2566410~2569888:+
THCA	cis	rs6921919	0.583	rs7764722	ENSG00000273712.1	RP5-874C20.7	4.28	2.23e-05	0.0021	0.22	0.19	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28315613~28315883:-
THCA	cis	rs2191566	1	rs10418363	ENSG00000266921.1	RP11-15A1.7	-4.28	2.23e-05	0.0021	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44021311	chr19:43996896~44002836:-
THCA	cis	rs12893668	0.703	rs7148456	ENSG00000252469.1	RNU7-160P	-4.28	2.23e-05	0.0021	-0.23	-0.19	Reticulocyte count;	chr14:103561933	chr14:103550345~103550406:+
THCA	cis	rs875971	1	rs937495	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.23e-05	0.0021	-0.2	-0.19	Aortic root size;	chr7:66314811	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs2036264	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.23e-05	0.0021	-0.2	-0.19	Aortic root size;	chr7:66334917	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs7783613	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.23e-05	0.0021	-0.2	-0.19	Aortic root size;	chr7:66340274	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs778735	ENSG00000229886.1	RP5-1132H15.3	4.28	2.23e-05	0.0021	0.2	0.19	Aortic root size;	chr7:66349822	chr7:66025126~66031544:-
THCA	cis	rs8028182	0.537	rs4371118	ENSG00000260274.1	RP11-817O13.8	4.28	2.23e-05	0.0021	0.14	0.19	Sudden cardiac arrest;	chr15:75606549	chr15:75368155~75369584:+
THCA	cis	rs800160	0.557	rs800144	ENSG00000199550.1	Y_RNA	4.28	2.23e-05	0.00211	0.26	0.19	Bacteremia;	chr11:2346926	chr11:2372638~2372750:+
THCA	cis	rs800160	0.588	rs800147	ENSG00000199550.1	Y_RNA	4.28	2.23e-05	0.00211	0.26	0.19	Bacteremia;	chr11:2347765	chr11:2372638~2372750:+
THCA	cis	rs4656958	0.538	rs2184066	ENSG00000233691.2	RP11-312J18.7	4.28	2.23e-05	0.00211	0.21	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160914106	chr1:160935537~160936126:+
THCA	cis	rs8020441	1	rs72681677	ENSG00000269906.1	RP11-248J18.2	4.28	2.23e-05	0.00211	0.28	0.19	Cognitive performance;	chr14:50706872	chr14:50662511~50663178:-
THCA	cis	rs617791	0.53	rs55947178	ENSG00000255320.1	RP11-755F10.1	4.28	2.24e-05	0.00211	0.26	0.19	Breast cancer;	chr11:65986759	chr11:66244840~66246239:-
THCA	cis	rs6442522	0.678	rs12634346	ENSG00000249786.6	EAF1-AS1	4.28	2.24e-05	0.00211	0.2	0.19	Uric acid levels;	chr3:15458788	chr3:15436171~15455940:-
THCA	cis	rs62246343	0.516	rs2728934	ENSG00000206573.7	THUMPD3-AS1	4.28	2.24e-05	0.00211	0.13	0.19	Fibrinogen levels;	chr3:9421778	chr3:9349689~9398579:-
THCA	cis	rs8014252	1	rs8020009	ENSG00000259158.2	ADAM20P1	-4.28	2.24e-05	0.00211	-0.22	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70441564	chr14:70468881~70483756:-
THCA	cis	rs860295	0.841	rs7556102	ENSG00000160766.13	GBAP1	4.28	2.24e-05	0.00211	0.22	0.19	Body mass index;	chr1:155398412	chr1:155213821~155227422:-
THCA	cis	rs4950322	0.57	rs17160051	ENSG00000271721.1	RP11-337C18.9	4.28	2.24e-05	0.00211	0.22	0.19	Protein quantitative trait loci;	chr1:147255733	chr1:147175602~147177740:+
THCA	cis	rs7824557	0.564	rs34964435	ENSG00000206014.6	OR7E161P	4.28	2.24e-05	0.00211	0.22	0.19	Retinal vascular caliber;	chr8:11372697	chr8:11928597~11929563:-
THCA	cis	rs7617480	0.648	rs7653408	ENSG00000228638.1	FCF1P2	-4.28	2.24e-05	0.00211	-0.24	-0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48934918	chr3:48290793~48291375:-
THCA	cis	rs739496	0.579	rs7294902	ENSG00000226469.1	ADAM1B	4.28	2.24e-05	0.00211	0.23	0.19	Platelet count;	chr12:111916727	chr12:111927018~111929017:+
THCA	cis	rs739496	0.615	rs7312260	ENSG00000226469.1	ADAM1B	4.28	2.24e-05	0.00211	0.23	0.19	Platelet count;	chr12:111920859	chr12:111927018~111929017:+
THCA	cis	rs6870983	0.895	rs193706	ENSG00000247828.6	TMEM161B-AS1	4.28	2.24e-05	0.00211	0.18	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88338472	chr5:88268895~88436685:+
THCA	cis	rs9341808	0.667	rs2490241	ENSG00000272129.1	RP11-250B2.6	4.28	2.24e-05	0.00211	0.24	0.19	Sitting height ratio;	chr6:80136625	chr6:80355424~80356859:+
THCA	cis	rs9876781	1	rs9815103	ENSG00000244380.1	RP11-24C3.2	4.28	2.24e-05	0.00211	0.23	0.19	Longevity;	chr3:48372725	chr3:48440352~48446656:-
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000251402.3	FAM90A25P	4.28	2.24e-05	0.00211	0.24	0.19	Neuroticism;	chr8:11989569	chr8:12415080~12418090:-
THCA	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-4.28	2.24e-05	0.00211	-0.12	-0.19	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
THCA	cis	rs2657294	0.965	rs7079694	ENSG00000233313.2	HMGA1P5	-4.28	2.24e-05	0.00211	-0.25	-0.19	Pneumonia;	chr10:75136804	chr10:75276376~75276646:-
THCA	cis	rs12440869	1	rs4410030	ENSG00000270964.1	RP11-502I4.3	4.28	2.24e-05	0.00211	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67350301	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs12904476	ENSG00000270964.1	RP11-502I4.3	4.28	2.24e-05	0.00211	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67352544	chr15:67541072~67542604:-
THCA	cis	rs875971	1	rs6979382	ENSG00000230189.5	GS1-124K5.2	4.28	2.24e-05	0.00211	0.13	0.19	Aortic root size;	chr7:66421388	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs6961990	ENSG00000230189.5	GS1-124K5.2	4.28	2.24e-05	0.00211	0.13	0.19	Aortic root size;	chr7:66423583	chr7:66409143~66490059:-
THCA	cis	rs4443100	0.916	rs2078726	ENSG00000230701.2	FBXW4P1	4.28	2.24e-05	0.00211	0.23	0.19	Serum parathyroid hormone levels;	chr22:23040303	chr22:23262767~23265005:+
THCA	cis	rs7560272	0.512	rs13015885	ENSG00000273245.1	RP11-434P11.2	-4.28	2.24e-05	0.00211	-0.22	-0.19	Schizophrenia;	chr2:73693355	chr2:73750256~73750786:-
THCA	cis	rs12497850	0.931	rs12493289	ENSG00000228638.1	FCF1P2	-4.28	2.24e-05	0.00211	-0.21	-0.19	Parkinson's disease;	chr3:48867728	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.865	rs7649458	ENSG00000228638.1	FCF1P2	-4.28	2.24e-05	0.00211	-0.21	-0.19	Parkinson's disease;	chr3:48882694	chr3:48290793~48291375:-
THCA	cis	rs10090774	0.813	rs11166996	ENSG00000279766.1	RP11-642A1.2	-4.28	2.24e-05	0.00211	-0.24	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140712561	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13280245	ENSG00000279766.1	RP11-642A1.2	-4.28	2.24e-05	0.00211	-0.24	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140717211	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs13276301	ENSG00000279766.1	RP11-642A1.2	-4.28	2.24e-05	0.00211	-0.24	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140720628	chr8:140572142~140572812:-
THCA	cis	rs72843506	0.722	rs74255387	ENSG00000261033.1	RP11-209D14.2	4.28	2.24e-05	0.00211	0.37	0.19	Schizophrenia;	chr17:20198070	chr17:20008051~20009234:-
THCA	cis	rs7824557	0.564	rs55758514	ENSG00000206014.6	OR7E161P	4.28	2.24e-05	0.00211	0.22	0.19	Retinal vascular caliber;	chr8:11372750	chr8:11928597~11929563:-
THCA	cis	rs12440869	1	rs12438251	ENSG00000270964.1	RP11-502I4.3	4.28	2.24e-05	0.00211	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67264781	chr15:67541072~67542604:-
THCA	cis	rs6430538	0.671	rs11884708	ENSG00000224043.6	CCNT2-AS1	-4.28	2.24e-05	0.00211	-0.21	-0.19	Parkinson's disease;	chr2:134787712	chr2:134735464~134918710:-
THCA	cis	rs6723108	0.534	rs1016120	ENSG00000224043.6	CCNT2-AS1	-4.28	2.24e-05	0.00211	-0.21	-0.19	Type 2 diabetes;	chr2:134789719	chr2:134735464~134918710:-
THCA	cis	rs17095355	1	rs17126902	ENSG00000203876.8	ADD3-AS1	4.28	2.24e-05	0.00211	0.21	0.19	Biliary atresia;	chr10:109950623	chr10:109940104~110008381:-
THCA	cis	rs78487399	0.634	rs77881454	ENSG00000234936.1	AC010883.5	4.28	2.24e-05	0.00211	0.27	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43530154	chr2:43229573~43233394:+
THCA	cis	rs4805272	1	rs60122378	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830646	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs61697193	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830688	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.962	rs4805274	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28831311	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs4805275	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28831357	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs6509059	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28831866	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs7256538	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832281	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs10423704	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832870	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs10427034	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833112	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs10403537	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833220	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs888833	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833575	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs888831	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833681	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.962	rs888830	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833714	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs888829	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833761	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.962	rs2870543	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833783	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.962	rs2870544	ENSG00000267799.1	MAN1A2P1	4.28	2.24e-05	0.00211	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833826	chr19:28790812~28792871:-
THCA	cis	rs10761482	0.813	rs7083624	ENSG00000254271.1	RP11-131N11.4	4.28	2.24e-05	0.00211	0.25	0.19	Schizophrenia;	chr10:60361481	chr10:60734342~60741828:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000272831.1	RP11-792A8.4	4.28	2.24e-05	0.00211	0.12	0.19	Aortic root size;	chr7:66014585	chr7:66739829~66740385:-
THCA	cis	rs17711722	0.727	rs781151	ENSG00000272831.1	RP11-792A8.4	4.28	2.24e-05	0.00211	0.12	0.19	Calcium levels;	chr7:66014891	chr7:66739829~66740385:-
THCA	cis	rs7200786	0.692	rs1700820	ENSG00000274038.1	RP11-66H6.4	4.28	2.24e-05	0.00211	0.24	0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10962761	chr16:11056556~11057034:+
THCA	cis	rs734999	0.545	rs6684865	ENSG00000225931.3	RP3-395M20.7	-4.28	2.24e-05	0.00211	-0.23	-0.19	Ulcerative colitis;	chr1:2614790	chr1:2566410~2569888:+
THCA	cis	rs7200786	0.692	rs7404554	ENSG00000274038.1	RP11-66H6.4	4.28	2.24e-05	0.00211	0.24	0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10959067	chr16:11056556~11057034:+
THCA	cis	rs9818758	0.607	rs73074866	ENSG00000270441.1	RP11-694I15.7	4.28	2.24e-05	0.00211	0.29	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49589233	chr3:49140086~49160851:-
THCA	cis	rs7267979	0.565	rs13040726	ENSG00000274414.1	RP5-965G21.4	4.28	2.24e-05	0.00211	0.24	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:25239007~25245229:-
THCA	cis	rs4906332	0.754	rs34235720	ENSG00000269940.1	RP11-73M18.7	4.28	2.24e-05	0.00211	0.21	0.19	Coronary artery disease;	chr14:103538631	chr14:103694560~103695170:+
THCA	cis	rs7216064	1	rs8079754	ENSG00000278740.1	RP11-147L13.14	4.28	2.24e-05	0.00211	0.22	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891780	chr17:68188547~68189165:+
THCA	cis	rs7819412	0.594	rs7460507	ENSG00000206014.6	OR7E161P	4.28	2.24e-05	0.00212	0.23	0.19	Triglycerides;	chr8:11111565	chr8:11928597~11929563:-
THCA	cis	rs4971059	0.617	rs12025371	ENSG00000236675.1	MTX1P1	-4.28	2.25e-05	0.00212	-0.18	-0.19	Breast cancer;	chr1:155146851	chr1:155230975~155234325:+
THCA	cis	rs27434	0.602	rs2927620	ENSG00000272109.1	CTD-2260A17.3	-4.28	2.25e-05	0.00212	-0.32	-0.19	Ankylosing spondylitis;	chr5:96845594	chr5:96804353~96806105:+
THCA	cis	rs9902453	0.715	rs2628176	ENSG00000263370.1	RP11-68I3.5	-4.28	2.25e-05	0.00212	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29812274	chr17:29639627~29640825:+
THCA	cis	rs2613964	0.504	rs9288972	ENSG00000240057.4	RP11-572M11.4	-4.28	2.25e-05	0.00212	-0.19	-0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131422	chr3:113019532~113183301:+
THCA	cis	rs2613964	0.504	rs9838215	ENSG00000240057.4	RP11-572M11.4	-4.28	2.25e-05	0.00212	-0.19	-0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131616	chr3:113019532~113183301:+
THCA	cis	rs2613964	0.504	rs9838253	ENSG00000240057.4	RP11-572M11.4	-4.28	2.25e-05	0.00212	-0.19	-0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131678	chr3:113019532~113183301:+
THCA	cis	rs2613964	0.504	rs17317945	ENSG00000240057.4	RP11-572M11.4	-4.28	2.25e-05	0.00212	-0.19	-0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131934	chr3:113019532~113183301:+
THCA	cis	rs2613964	0.504	rs12695288	ENSG00000240057.4	RP11-572M11.4	-4.28	2.25e-05	0.00212	-0.19	-0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113132668	chr3:113019532~113183301:+
THCA	cis	rs2153535	0.585	rs1328870	ENSG00000230939.1	RP11-314C16.1	-4.28	2.25e-05	0.00212	-0.2	-0.19	Motion sickness;	chr6:8637803	chr6:8784178~8785445:+
THCA	cis	rs1048886	0.938	rs6455367	ENSG00000271967.1	RP11-134K13.4	-4.28	2.25e-05	0.00212	-0.2	-0.19	Type 2 diabetes;	chr6:70395775	chr6:70596438~70596980:+
THCA	cis	rs4950322	0.547	rs17355509	ENSG00000180867.10	PDIA3P1	4.28	2.25e-05	0.00212	0.19	0.19	Protein quantitative trait loci;	chr1:147123139	chr1:147178113~147179622:+
THCA	cis	rs2858942	0.575	rs2858011	ENSG00000206168.1	Z69890.1	-4.28	2.25e-05	0.00212	-0.22	-0.19	Mean corpuscular hemoglobin;	chr16:197939	chr16:231134~231472:+
THCA	cis	rs7726354	0.793	rs75433101	ENSG00000271828.1	CTD-2310F14.1	4.28	2.25e-05	0.00212	0.5	0.19	Breast cancer (early onset);	chr5:56706243	chr5:56927874~56929573:+
THCA	cis	rs7726354	0.793	rs111944656	ENSG00000271828.1	CTD-2310F14.1	4.28	2.25e-05	0.00212	0.5	0.19	Breast cancer (early onset);	chr5:56712403	chr5:56927874~56929573:+
THCA	cis	rs7726354	0.793	rs112191071	ENSG00000271828.1	CTD-2310F14.1	4.28	2.25e-05	0.00212	0.5	0.19	Breast cancer (early onset);	chr5:56712414	chr5:56927874~56929573:+
THCA	cis	rs7726354	0.793	rs6883200	ENSG00000271828.1	CTD-2310F14.1	4.28	2.25e-05	0.00212	0.5	0.19	Breast cancer (early onset);	chr5:56714198	chr5:56927874~56929573:+
THCA	cis	rs6449502	0.92	rs2909851	ENSG00000251279.1	CTC-436P18.1	4.28	2.25e-05	0.00212	0.31	0.19	Mean platelet volume;	chr5:61037958	chr5:61162070~61232040:+
THCA	cis	rs763121	0.853	rs6519119	ENSG00000273076.1	RP3-508I15.22	4.28	2.25e-05	0.00212	0.2	0.19	Menopause (age at onset);	chr22:38593002	chr22:38743495~38743910:+
THCA	cis	rs5753037	0.702	rs140100	ENSG00000273350.1	RP4-539M6.20	-4.28	2.25e-05	0.00212	-0.22	-0.19	Type 1 diabetes;	chr22:29732251	chr22:30420512~30420912:+
THCA	cis	rs2361710	1	rs2361710	ENSG00000279259.1	RP11-334C17.3	-4.28	2.25e-05	0.00212	-0.17	-0.19	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80138078	chr17:80147250~80148596:+
THCA	cis	rs17092148	0.887	rs6058104	ENSG00000276073.1	RP5-1125A11.7	-4.28	2.25e-05	0.00212	-0.24	-0.19	Neuroticism;	chr20:34683248	chr20:33985617~33988989:-
THCA	cis	rs6940638	0.744	rs858964	ENSG00000219392.1	RP1-265C24.5	4.28	2.25e-05	0.00212	0.23	0.19	Intelligence (multi-trait analysis);	chr6:27174835	chr6:28115628~28116551:+
THCA	cis	rs10454142	0.845	rs56391806	ENSG00000202227.1	RNU6-282P	4.28	2.25e-05	0.00212	0.22	0.19	Sex hormone-binding globulin levels;	chr2:48404838	chr2:48501922~48502024:-
THCA	cis	rs17382723	0.887	rs75895048	ENSG00000229996.1	AC093585.6	4.28	2.25e-05	0.00212	0.26	0.19	Height;	chr2:241079579	chr2:241010045~241010744:-
THCA	cis	rs755249	0.917	rs72663503	ENSG00000237624.1	OXCT2P1	4.28	2.25e-05	0.00212	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39514956~39516490:+
THCA	cis	rs755249	0.917	rs61779331	ENSG00000237624.1	OXCT2P1	4.28	2.25e-05	0.00212	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39514956~39516490:+
THCA	cis	rs2436845	0.627	rs974758	ENSG00000253320.4	KB-1507C5.2	-4.28	2.25e-05	0.00212	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102825263	chr8:102864300~102977876:+
THCA	cis	rs1005277	0.683	rs7923868	ENSG00000276805.1	RP11-291L22.6	4.28	2.25e-05	0.00212	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38451030~38451785:+
THCA	cis	rs11678584	0.562	rs62136348	ENSG00000276517.1	AL133243.2	-4.28	2.25e-05	0.00212	-0.26	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32599444	chr2:32526504~32529507:+
THCA	cis	rs11673344	0.58	rs320881	ENSG00000268499.1	CTB-102L5.8	-4.28	2.25e-05	0.00212	-0.2	-0.19	Obesity-related traits;	chr19:37246948	chr19:38199836~38200934:+
THCA	cis	rs78487399	0.71	rs79625619	ENSG00000234936.1	AC010883.5	4.28	2.25e-05	0.00212	0.28	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43367344	chr2:43229573~43233394:+
THCA	cis	rs62025270	0.632	rs62022942	ENSG00000259295.5	CSPG4P12	-4.28	2.25e-05	0.00212	-0.33	-0.19	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85191438~85213905:+
THCA	cis	rs2688608	0.839	rs2675662	ENSG00000271816.1	BMS1P4	-4.28	2.25e-05	0.00212	-0.2	-0.19	Inflammatory bowel disease;	chr10:73839369	chr10:73699151~73730487:-
THCA	cis	rs7621025	0.599	rs13063987	ENSG00000239213.4	NCK1-AS1	-4.28	2.25e-05	0.00212	-0.2	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136726555	chr3:136841726~136862054:-
THCA	cis	rs2688608	0.839	rs2633310	ENSG00000271816.1	BMS1P4	-4.28	2.25e-05	0.00212	-0.2	-0.19	Inflammatory bowel disease;	chr10:73834292	chr10:73699151~73730487:-
THCA	cis	rs1232027	0.666	rs1643634	ENSG00000249655.1	CTC-325J23.2	4.28	2.25e-05	0.00212	0.22	0.19	Huntington's disease progression;	chr5:80632080	chr5:80630313~80631590:-
THCA	cis	rs950169	0.922	rs4586394	ENSG00000275120.1	RP11-182J1.17	-4.28	2.25e-05	0.00212	-0.23	-0.19	Schizophrenia;	chr15:84153633	chr15:84599434~84606463:-
THCA	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-4.28	2.25e-05	0.00212	-0.12	-0.19	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
THCA	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-4.28	2.25e-05	0.00212	-0.12	-0.19	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
THCA	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-4.28	2.25e-05	0.00212	-0.12	-0.19	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
THCA	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-4.28	2.25e-05	0.00212	-0.12	-0.19	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-4.28	2.25e-05	0.00212	-0.12	-0.19	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-4.28	2.25e-05	0.00212	-0.12	-0.19	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
THCA	cis	rs35740288	0.77	rs11638379	ENSG00000259295.5	CSPG4P12	4.28	2.25e-05	0.00212	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85568059	chr15:85191438~85213905:+
THCA	cis	rs801193	0.66	rs1962050	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.25e-05	0.00212	-0.2	-0.19	Aortic root size;	chr7:66775021	chr7:66025126~66031544:-
THCA	cis	rs755249	1	rs76841360	ENSG00000237624.1	OXCT2P1	4.28	2.25e-05	0.00212	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594353	chr1:39514956~39516490:+
THCA	cis	rs8081395	0.741	rs1292056	ENSG00000267302.4	RP11-178C3.2	4.28	2.25e-05	0.00212	0.23	0.19	White blood cell count;	chr17:59881686	chr17:59964832~59996972:+
THCA	cis	rs812925	0.519	rs2922089	ENSG00000270820.4	RP11-355B11.2	-4.28	2.25e-05	0.00212	-0.16	-0.19	Immature fraction of reticulocytes;	chr2:61397994	chr2:61471188~61484130:+
THCA	cis	rs812925	0.519	rs2694627	ENSG00000270820.4	RP11-355B11.2	-4.28	2.25e-05	0.00212	-0.16	-0.19	Immature fraction of reticulocytes;	chr2:61398371	chr2:61471188~61484130:+
THCA	cis	rs6479874	0.57	rs2816840	ENSG00000223502.1	RP11-96B5.3	-4.28	2.25e-05	0.00212	-0.22	-0.19	Migraine;	chr10:50988601	chr10:51062579~51068553:-
THCA	cis	rs6479874	0.57	rs2245995	ENSG00000223502.1	RP11-96B5.3	-4.28	2.25e-05	0.00212	-0.22	-0.19	Migraine;	chr10:50989403	chr10:51062579~51068553:-
THCA	cis	rs6442522	0.56	rs13092264	ENSG00000249786.6	EAF1-AS1	4.28	2.25e-05	0.00212	0.2	0.19	Uric acid levels;	chr3:15472790	chr3:15436171~15455940:-
THCA	cis	rs6496932	0.635	rs28559998	ENSG00000259630.2	CTD-2262B20.1	-4.28	2.25e-05	0.00212	-0.23	-0.19	Central corneal thickness;Corneal structure;	chr15:85360605	chr15:85415228~85415633:+
THCA	cis	rs6496932	0.635	rs8023859	ENSG00000259630.2	CTD-2262B20.1	-4.28	2.25e-05	0.00212	-0.23	-0.19	Central corneal thickness;Corneal structure;	chr15:85361540	chr15:85415228~85415633:+
THCA	cis	rs875971	0.638	rs6960778	ENSG00000223473.2	GS1-124K5.3	-4.28	2.25e-05	0.00212	-0.13	-0.19	Aortic root size;	chr7:66606610	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs62466793	ENSG00000272831.1	RP11-792A8.4	4.28	2.25e-05	0.00212	0.12	0.19	Aortic root size;	chr7:66726530	chr7:66739829~66740385:-
THCA	cis	rs4934494	0.768	rs3740034	ENSG00000240996.1	RP11-80H5.7	-4.28	2.25e-05	0.00212	-0.22	-0.19	Red blood cell count;	chr10:89634902	chr10:89694295~89697928:-
THCA	cis	rs7560272	0.502	rs4513320	ENSG00000163016.8	ALMS1P	-4.28	2.25e-05	0.00212	-0.24	-0.19	Schizophrenia;	chr2:73693614	chr2:73644919~73685576:+
THCA	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	4.28	2.26e-05	0.00212	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	4.28	2.26e-05	0.00212	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
THCA	cis	rs10875746	0.951	rs4760689	ENSG00000258273.1	RP11-370I10.4	4.28	2.26e-05	0.00212	0.28	0.19	Longevity (90 years and older);	chr12:48169861	chr12:48333755~48333901:-
THCA	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	4.28	2.26e-05	0.00212	0.23	0.19	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
THCA	cis	rs9595908	0.785	rs9596058	ENSG00000212293.1	SNORA16	4.28	2.26e-05	0.00212	0.22	0.19	Body mass index;	chr13:32669938	chr13:32420390~32420516:-
THCA	cis	rs3764021	0.527	rs3764022	ENSG00000214776.8	RP11-726G1.1	4.28	2.26e-05	0.00212	0.25	0.19	Type 1 diabetes;	chr12:9680928	chr12:9467552~9576275:+
THCA	cis	rs7429990	0.896	rs34448818	ENSG00000228638.1	FCF1P2	-4.28	2.26e-05	0.00212	-0.21	-0.19	Educational attainment (years of education);	chr3:47799822	chr3:48290793~48291375:-
THCA	cis	rs7178424	0.742	rs7170293	ENSG00000259251.2	RP11-643M14.1	4.28	2.26e-05	0.00212	0.2	0.19	Height;	chr15:61944174	chr15:62060503~62062434:+
THCA	cis	rs9929218	0.529	rs17715450	ENSG00000260459.2	FTLP14	4.28	2.26e-05	0.00212	0.22	0.19	Colorectal cancer;	chr16:68695882	chr16:68822587~68823070:+
THCA	cis	rs728616	0.681	rs12769764	ENSG00000225484.5	NUTM2B-AS1	-4.28	2.26e-05	0.00213	-0.24	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80157357	chr10:79663088~79826594:-
THCA	cis	rs11992162	0.569	rs11786149	ENSG00000254948.1	OR7E158P	4.28	2.26e-05	0.00213	0.25	0.19	Monocyte count;	chr8:11943309	chr8:11919900~11920809:-
THCA	cis	rs8062405	0.728	rs8056890	ENSG00000261766.1	RP11-22P6.2	-4.28	2.26e-05	0.00213	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28862166~28863340:-
THCA	cis	rs10043228	0.826	rs17139661	ENSG00000248445.4	SEMA6A-AS1	-4.28	2.26e-05	0.00213	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116387430	chr5:116447547~116508276:+
THCA	cis	rs13256369	1	rs10110591	ENSG00000254153.1	CTA-398F10.2	4.28	2.26e-05	0.00213	0.22	0.19	Obesity-related traits;	chr8:8719098	chr8:8456909~8461337:-
THCA	cis	rs9911578	0.805	rs1811202	ENSG00000224738.1	AC099850.1	-4.28	2.26e-05	0.00213	-0.23	-0.19	Intelligence (multi-trait analysis);	chr17:58377074	chr17:59106598~59118267:+
THCA	cis	rs6012564	0.855	rs6095394	ENSG00000230758.1	SNAP23P	-4.28	2.26e-05	0.00213	-0.24	-0.19	Anger;	chr20:49009007	chr20:49038357~49038602:-
THCA	cis	rs4906332	1	rs3783397	ENSG00000269910.1	RP11-73M18.10	4.28	2.26e-05	0.00213	0.16	0.19	Coronary artery disease;	chr14:103480952	chr14:103694516~103695050:-
THCA	cis	rs12478296	1	rs6739247	ENSG00000220804.7	AC093642.5	4.28	2.26e-05	0.00213	0.21	0.19	Obesity-related traits;	chr2:242097038	chr2:242088633~242160153:+
THCA	cis	rs12049671	0.858	rs10830197	ENSG00000227076.1	RP11-4C20.4	4.28	2.26e-05	0.00213	0.23	0.19	Response to amphetamines;	chr10:127927382	chr10:127934698~127936167:+
THCA	cis	rs11640436	0.57	rs9937609	ENSG00000260922.1	RP11-538I12.3	-4.28	2.26e-05	0.00213	-0.23	-0.19	Lobe attachment (rater-scored or self-reported);	chr16:77270007	chr16:77234877~77290934:+
THCA	cis	rs1336149	0.967	rs822578	ENSG00000211581.1	MIR765	-4.28	2.26e-05	0.00213	-0.25	-0.19	Chin dimples;	chr1:157002686	chr1:156936131~156936244:-
THCA	cis	rs9488822	0.596	rs13192549	ENSG00000237021.2	RP3-486I3.7	4.28	2.26e-05	0.00213	0.21	0.19	LDL cholesterol;Cholesterol, total;	chr6:116017189	chr6:116254207~116256743:+
THCA	cis	rs2836950	0.501	rs2836980	ENSG00000238141.2	BRWD1-AS1	-4.28	2.26e-05	0.00213	-0.22	-0.19	Menarche (age at onset);	chr21:39315692	chr21:39315707~39323218:+
THCA	cis	rs875971	0.502	rs6460311	ENSG00000273142.1	RP11-458F8.4	-4.28	2.26e-05	0.00213	-0.18	-0.19	Aortic root size;	chr7:66646886	chr7:66902857~66906297:+
THCA	cis	rs1023500	0.573	rs2269524	ENSG00000237037.8	NDUFA6-AS1	4.28	2.26e-05	0.00213	0.16	0.19	Schizophrenia;	chr22:42079699	chr22:42090931~42137742:+
THCA	cis	rs7973719	0.865	rs1057225	ENSG00000205885.6	C1RL-AS1	4.28	2.26e-05	0.00213	0.14	0.19	IgG glycosylation;	chr12:7210978	chr12:7108052~7122501:+
THCA	cis	rs1023500	0.505	rs134888	ENSG00000233903.2	Z83851.4	4.28	2.26e-05	0.00213	0.24	0.19	Schizophrenia;	chr22:42278275	chr22:42276355~42277052:+
THCA	cis	rs801193	0.935	rs2659899	ENSG00000272831.1	RP11-792A8.4	4.28	2.26e-05	0.00213	0.12	0.19	Aortic root size;	chr7:66721734	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs1553609	ENSG00000272831.1	RP11-792A8.4	4.28	2.26e-05	0.00213	0.12	0.19	Aortic root size;	chr7:66732152	chr7:66739829~66740385:-
THCA	cis	rs801193	0.967	rs2707853	ENSG00000272831.1	RP11-792A8.4	4.28	2.26e-05	0.00213	0.12	0.19	Aortic root size;	chr7:66749023	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs2659889	ENSG00000272831.1	RP11-792A8.4	4.28	2.26e-05	0.00213	0.12	0.19	Aortic root size;	chr7:66752125	chr7:66739829~66740385:-
THCA	cis	rs944289	0.966	rs34992253	ENSG00000258844.1	RP11-259K15.2	4.28	2.26e-05	0.00213	0.18	0.19	Thyroid cancer;	chr14:36177957	chr14:36214607~36235608:+
THCA	cis	rs2235642	0.592	rs743963	ENSG00000260989.1	LA16c-395F10.2	-4.28	2.26e-05	0.00213	-0.21	-0.19	Coronary artery disease;	chr16:1607349	chr16:1580527~1610328:+
THCA	cis	rs7819412	0.806	rs17723229	ENSG00000206014.6	OR7E161P	4.28	2.26e-05	0.00213	0.23	0.19	Triglycerides;	chr8:11072559	chr8:11928597~11929563:-
THCA	cis	rs755249	0.874	rs61779310	ENSG00000237624.1	OXCT2P1	4.28	2.26e-05	0.00213	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39514956~39516490:+
THCA	cis	rs2380205	0.967	rs7894083	ENSG00000232807.2	RP11-536K7.3	4.28	2.26e-05	0.00213	0.18	0.19	Breast cancer;	chr10:5851305	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs7898042	ENSG00000232807.2	RP11-536K7.3	4.28	2.26e-05	0.00213	0.18	0.19	Breast cancer;	chr10:5851439	chr10:5934270~5945900:-
THCA	cis	rs13108904	0.901	rs2293634	ENSG00000254094.1	AC078852.1	-4.28	2.26e-05	0.00213	-0.22	-0.19	Obesity-related traits;	chr4:1297923	chr4:1356581~1358075:+
THCA	cis	rs10911902	0.643	rs76748438	ENSG00000229739.2	RP11-295K2.3	-4.28	2.26e-05	0.00213	-0.3	-0.19	Schizophrenia;	chr1:186367379	chr1:186435161~186470291:+
THCA	cis	rs2657294	0.965	rs4746270	ENSG00000233313.2	HMGA1P5	-4.28	2.26e-05	0.00213	-0.25	-0.19	Pneumonia;	chr10:75185189	chr10:75276376~75276646:-
THCA	cis	rs7615952	0.688	rs4422259	ENSG00000248787.1	RP11-666A20.4	-4.28	2.26e-05	0.00213	-0.31	-0.19	Blood pressure (smoking interaction);	chr3:125826988	chr3:125908005~125910272:-
THCA	cis	rs8077577	0.708	rs2290504	ENSG00000273018.4	CTD-2303H24.2	4.28	2.26e-05	0.00213	0.29	0.19	Obesity-related traits;	chr17:18233674	chr17:18511221~18551705:-
THCA	cis	rs1559040	1	rs7571660	ENSG00000272156.1	RP11-477N3.1	-4.28	2.26e-05	0.00213	-0.32	-0.19	Sudden cardiac arrest;	chr2:54120247	chr2:54082554~54085066:+
THCA	cis	rs1476587	0.92	rs28526598	ENSG00000224046.1	AC005076.5	4.28	2.26e-05	0.00213	0.21	0.19	Brachial circumference;	chr7:87084982	chr7:87151423~87152420:-
THCA	cis	rs9810089	0.9	rs480162	ENSG00000273455.1	RP11-305O4.3	4.28	2.26e-05	0.00213	0.25	0.19	Gestational age at birth (child effect);	chr3:136349853	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.835	rs654237	ENSG00000273455.1	RP11-305O4.3	4.28	2.26e-05	0.00213	0.25	0.19	Gestational age at birth (child effect);	chr3:136349857	chr3:136087475~136087913:-
THCA	cis	rs7577696	0.785	rs660393	ENSG00000276334.1	AL133243.1	-4.28	2.26e-05	0.00213	-0.2	-0.19	Inflammatory biomarkers;	chr2:32056440	chr2:32521927~32523547:+
THCA	cis	rs10489167	1	rs2361652	ENSG00000237899.1	RP4-739H11.3	-4.28	2.26e-05	0.00213	-0.35	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40755624	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs4660453	ENSG00000237899.1	RP4-739H11.3	-4.28	2.26e-05	0.00213	-0.35	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40756227	chr1:40669089~40687588:-
THCA	cis	rs875971	1	rs11974264	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.26e-05	0.00213	-0.2	-0.19	Aortic root size;	chr7:66182595	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs1540651	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.26e-05	0.00213	-0.2	-0.19	Aortic root size;	chr7:66185134	chr7:66025126~66031544:-
THCA	cis	rs5743077	1	rs5743077	ENSG00000253559.1	OSGEPL1-AS1	-4.28	2.26e-05	0.00213	-0.28	-0.19	Iron status biomarkers (ferritin levels);	chr2:189832613	chr2:189762704~189765556:+
THCA	cis	rs3803452	0.737	rs59560108	ENSG00000277245.1	RP11-48G14.3	4.28	2.26e-05	0.00213	0.28	0.19	Ankle injury;	chr15:57305826	chr15:56447120~56447697:+
THCA	cis	rs6496932	0.802	rs4843047	ENSG00000259630.2	CTD-2262B20.1	4.28	2.26e-05	0.00213	0.24	0.19	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85415228~85415633:+
THCA	cis	rs7267979	0.816	rs8115257	ENSG00000274973.1	RP13-401N8.7	-4.28	2.26e-05	0.00213	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25845497~25845862:+
THCA	cis	rs7474896	0.559	rs1024202	ENSG00000263064.2	RP11-291L22.7	-4.28	2.26e-05	0.00213	-0.26	-0.19	Obesity (extreme);	chr10:37990049	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.537	rs1022449	ENSG00000263064.2	RP11-291L22.7	-4.28	2.26e-05	0.00213	-0.26	-0.19	Obesity (extreme);	chr10:37990539	chr10:38448689~38448949:+
THCA	cis	rs9634489	0.709	rs7321045	ENSG00000247400.3	DNAJC3-AS1	-4.28	2.26e-05	0.00213	-0.12	-0.19	Body mass index;	chr13:96382156	chr13:95648733~95676925:-
THCA	cis	rs6600671	1	rs1986111	ENSG00000275585.1	CH17-118O6.3	-4.28	2.26e-05	0.00213	-0.23	-0.19	Hip geometry;	chr1:121462934	chr1:120985692~121052167:-
THCA	cis	rs2036707	1	rs58806855	ENSG00000274718.1	RP11-346C4.3	4.28	2.26e-05	0.00213	0.38	0.19	Obesity-related traits;	chr13:107831721	chr13:107870383~107873372:+
THCA	cis	rs160451	0.782	rs218920	ENSG00000251136.7	RP11-37B2.1	4.28	2.26e-05	0.00213	0.18	0.19	Leprosy;	chr8:89696607	chr8:89609409~89757727:-
THCA	cis	rs10875746	0.903	rs12306451	ENSG00000258273.1	RP11-370I10.4	4.28	2.27e-05	0.00213	0.28	0.19	Longevity (90 years and older);	chr12:48089458	chr12:48333755~48333901:-
THCA	cis	rs17092148	0.887	rs2068474	ENSG00000276073.1	RP5-1125A11.7	-4.28	2.27e-05	0.00213	-0.24	-0.19	Neuroticism;	chr20:34643275	chr20:33985617~33988989:-
THCA	cis	rs4218	0.689	rs12440692	ENSG00000259732.1	RP11-59H7.3	-4.28	2.27e-05	0.00213	-0.27	-0.19	Social communication problems;	chr15:59090671	chr15:59121034~59133250:+
THCA	cis	rs763121	0.719	rs138699	ENSG00000273076.1	RP3-508I15.22	4.28	2.27e-05	0.00213	0.21	0.19	Menopause (age at onset);	chr22:38733703	chr22:38743495~38743910:+
THCA	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-4.28	2.27e-05	0.00213	-0.27	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
THCA	cis	rs4144027	0.818	rs881057	ENSG00000269940.1	RP11-73M18.7	-4.28	2.27e-05	0.00213	-0.2	-0.19	Blood metabolite levels;	chr14:103887921	chr14:103694560~103695170:+
THCA	cis	rs8113308	0.515	rs68124997	ENSG00000269483.1	AC006272.1	4.28	2.27e-05	0.00213	0.38	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949276	chr19:51839924~51843324:-
THCA	cis	rs9326248	0.53	rs7114963	ENSG00000280143.1	AP000892.6	4.28	2.27e-05	0.00213	0.31	0.19	Blood protein levels;	chr11:117005267	chr11:117204967~117210292:+
THCA	cis	rs7115242	0.72	rs10790169	ENSG00000280143.1	AP000892.6	4.28	2.27e-05	0.00213	0.31	0.19	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.53	rs7950364	ENSG00000280143.1	AP000892.6	4.28	2.27e-05	0.00213	0.31	0.19	Blood protein levels;	chr11:117028170	chr11:117204967~117210292:+
THCA	cis	rs6121246	0.738	rs6121242	ENSG00000230613.1	HM13-AS1	4.28	2.27e-05	0.00213	0.21	0.19	Mean corpuscular hemoglobin;	chr20:31823074	chr20:31567707~31573263:-
THCA	cis	rs2115630	1	rs58581703	ENSG00000275120.1	RP11-182J1.17	-4.28	2.27e-05	0.00213	-0.2	-0.19	P wave terminal force;	chr15:84733704	chr15:84599434~84606463:-
THCA	cis	rs2243480	1	rs316315	ENSG00000232559.3	GS1-124K5.12	-4.28	2.27e-05	0.00213	-0.25	-0.19	Diabetic kidney disease;	chr7:66126218	chr7:66554588~66576923:-
THCA	cis	rs652260	0.603	rs553205	ENSG00000269139.2	CTD-3193O13.8	4.28	2.27e-05	0.00214	0.19	0.19	Menarche (age at onset);	chr19:7844369	chr19:7926001~7926810:+
THCA	cis	rs17801127	0.688	rs13000594	ENSG00000231969.1	AC144449.1	4.28	2.27e-05	0.00214	0.39	0.19	Liver enzyme levels (alanine transaminase);	chr2:149810533	chr2:149587196~149848233:+
THCA	cis	rs875971	0.577	rs35072105	ENSG00000223473.2	GS1-124K5.3	-4.28	2.27e-05	0.00214	-0.13	-0.19	Aortic root size;	chr7:66144830	chr7:66491049~66493566:-
THCA	cis	rs7829975	0.514	rs2920983	ENSG00000233609.3	RP11-62H7.2	4.28	2.27e-05	0.00214	0.18	0.19	Mood instability;	chr8:8410553	chr8:8961200~8979025:+
THCA	cis	rs8031584	0.678	rs798125	ENSG00000259845.1	HERC2P10	-4.28	2.27e-05	0.00214	-0.27	-0.19	Huntington's disease progression;	chr15:30824597	chr15:30815271~30844153:+
THCA	cis	rs12935229	0.867	rs12918088	ENSG00000260922.1	RP11-538I12.3	-4.28	2.27e-05	0.00214	-0.31	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77281219	chr16:77234877~77290934:+
THCA	cis	rs9880211	0.583	rs9870122	ENSG00000273486.1	RP11-731C17.2	4.28	2.27e-05	0.00214	0.19	0.19	Height;Body mass index;	chr3:136101423	chr3:136837338~136839021:-
THCA	cis	rs2299587	0.554	rs7815429	ENSG00000253671.1	RP11-806O11.1	-4.28	2.27e-05	0.00214	-0.23	-0.19	Economic and political preferences;	chr8:17879848	chr8:17808941~17820868:+
THCA	cis	rs728616	0.614	rs61859198	ENSG00000225484.5	NUTM2B-AS1	-4.28	2.27e-05	0.00214	-0.35	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80354872	chr10:79663088~79826594:-
THCA	cis	rs9625935	0.879	rs5752986	ENSG00000279159.1	RP3-394A18.1	4.28	2.27e-05	0.00214	0.15	0.19	Tonsillectomy;	chr22:29955582	chr22:29978950~30028236:-
THCA	cis	rs786425	0.576	rs10846541	ENSG00000270095.1	RP11-214K3.18	-4.28	2.27e-05	0.00214	-0.22	-0.19	Pubertal anthropometrics;	chr12:123691739	chr12:123971457~123971714:-
THCA	cis	rs786425	0.866	rs7137946	ENSG00000270095.1	RP11-214K3.18	-4.28	2.27e-05	0.00214	-0.22	-0.19	Pubertal anthropometrics;	chr12:123692742	chr12:123971457~123971714:-
THCA	cis	rs9973361	0.531	rs17209563	ENSG00000232411.1	AC009495.3	4.28	2.27e-05	0.00214	0.24	0.19	Total body bone mineral density;	chr2:165836141	chr2:165833048~165839098:-
THCA	cis	rs8105895	0.935	rs62112921	ENSG00000269345.1	VN1R85P	4.28	2.27e-05	0.00214	0.27	0.19	Body mass index (change over time);	chr19:22044775	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs75025987	ENSG00000269345.1	VN1R85P	4.28	2.27e-05	0.00214	0.27	0.19	Body mass index (change over time);	chr19:22047867	chr19:22174766~22175191:-
THCA	cis	rs4845570	1	rs17568246	ENSG00000203288.3	RP11-98D18.9	-4.28	2.27e-05	0.00214	-0.24	-0.19	Coronary artery disease;	chr1:151763980	chr1:151790804~151794402:+
THCA	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	4.28	2.27e-05	0.00214	0.22	0.19	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
THCA	cis	rs2898290	0.593	rs2199690	ENSG00000251402.3	FAM90A25P	-4.28	2.27e-05	0.00214	-0.25	-0.19	Systolic blood pressure;	chr8:11482107	chr8:12415080~12418090:-
THCA	cis	rs4713118	0.869	rs9366700	ENSG00000220721.1	OR1F12	4.28	2.27e-05	0.00214	0.25	0.19	Parkinson's disease;	chr6:27729172	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs6456802	ENSG00000220721.1	OR1F12	4.28	2.27e-05	0.00214	0.25	0.19	Parkinson's disease;	chr6:27730576	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs9393851	ENSG00000220721.1	OR1F12	4.28	2.27e-05	0.00214	0.25	0.19	Parkinson's disease;	chr6:27731802	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs9461400	ENSG00000220721.1	OR1F12	4.28	2.27e-05	0.00214	0.25	0.19	Parkinson's disease;	chr6:27732780	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs9295742	ENSG00000220721.1	OR1F12	4.28	2.27e-05	0.00214	0.25	0.19	Parkinson's disease;	chr6:27735053	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs9461401	ENSG00000220721.1	OR1F12	4.28	2.27e-05	0.00214	0.25	0.19	Parkinson's disease;	chr6:27735512	chr6:28073316~28074233:+
THCA	cis	rs3096299	0.719	rs2965817	ENSG00000261118.1	RP11-104N10.1	4.28	2.27e-05	0.00214	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89492017~89504460:-
THCA	cis	rs9879311	0.932	rs7427473	ENSG00000240288.6	GHRLOS	4.28	2.27e-05	0.00214	0.17	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10371513	chr3:10285754~10293449:+
THCA	cis	rs786425	0.711	rs1060639	ENSG00000270095.1	RP11-214K3.18	-4.28	2.27e-05	0.00214	-0.23	-0.19	Pubertal anthropometrics;	chr12:123625441	chr12:123971457~123971714:-
THCA	cis	rs13256369	1	rs12547721	ENSG00000254153.1	CTA-398F10.2	-4.28	2.27e-05	0.00214	-0.22	-0.19	Obesity-related traits;	chr8:8713161	chr8:8456909~8461337:-
THCA	cis	rs875971	1	rs6946143	ENSG00000230189.5	GS1-124K5.2	4.28	2.27e-05	0.00214	0.13	0.19	Aortic root size;	chr7:66114735	chr7:66409143~66490059:-
THCA	cis	rs8177876	0.749	rs935942	ENSG00000261061.1	RP11-303E16.2	4.28	2.27e-05	0.00214	0.25	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81030770~81031485:+
THCA	cis	rs9291683	0.669	rs887733	ENSG00000261490.1	RP11-448G15.3	-4.28	2.27e-05	0.00214	-0.12	-0.19	Bone mineral density;	chr4:10181484	chr4:10068089~10073019:-
THCA	cis	rs1210638	0.706	rs2518798	ENSG00000271275.1	AC007326.9	-4.28	2.27e-05	0.00214	-0.21	-0.19	Response to serotonin reuptake inhibitors in major depressive disorder;	chr22:18982890	chr22:18997138~18997595:-
THCA	cis	rs897984	0.806	rs1458202	ENSG00000275263.1	RP11-1072A3.4	-4.28	2.27e-05	0.00214	-0.23	-0.19	Dementia with Lewy bodies;	chr16:30941881	chr16:30956872~30957199:-
THCA	cis	rs9634489	0.502	rs732103	ENSG00000247400.3	DNAJC3-AS1	-4.28	2.27e-05	0.00214	-0.13	-0.19	Body mass index;	chr13:96447360	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.502	rs2011392	ENSG00000247400.3	DNAJC3-AS1	-4.28	2.27e-05	0.00214	-0.13	-0.19	Body mass index;	chr13:96447721	chr13:95648733~95676925:-
THCA	cis	rs795484	0.633	rs904661	ENSG00000275759.1	RP11-131L12.3	-4.28	2.27e-05	0.00214	-0.19	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118144055	chr12:118428281~118428870:+
THCA	cis	rs6479891	1	rs9414800	ENSG00000272767.1	JMJD1C-AS1	4.28	2.27e-05	0.00214	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63465229~63466563:+
THCA	cis	rs962856	0.633	rs6755775	ENSG00000236780.4	AC078941.1	4.28	2.27e-05	0.00214	0.24	0.19	Pancreatic cancer;	chr2:67371451	chr2:67123357~67215319:-
THCA	cis	rs7577696	0.695	rs212755	ENSG00000276334.1	AL133243.1	4.28	2.27e-05	0.00214	0.21	0.19	Inflammatory biomarkers;	chr2:32198950	chr2:32521927~32523547:+
THCA	cis	rs13113518	1	rs4864546	ENSG00000272969.1	RP11-528I4.2	4.28	2.27e-05	0.00214	0.22	0.19	Height;	chr4:55537960	chr4:55547112~55547889:+
THCA	cis	rs1048886	0.882	rs7767149	ENSG00000271967.1	RP11-134K13.4	-4.28	2.28e-05	0.00214	-0.2	-0.19	Type 2 diabetes;	chr6:70401953	chr6:70596438~70596980:+
THCA	cis	rs4722166	0.508	rs2069832	ENSG00000225541.1	AC002480.5	-4.28	2.28e-05	0.00214	-0.25	-0.19	Lung cancer;	chr7:22727814	chr7:22571607~22661792:-
THCA	cis	rs1800795	0.901	rs2069833	ENSG00000225541.1	AC002480.5	-4.28	2.28e-05	0.00214	-0.25	-0.19	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22571607~22661792:-
THCA	cis	rs4794202	0.629	rs16948662	ENSG00000264920.1	RP11-6N17.4	-4.28	2.28e-05	0.00214	-0.26	-0.19	Alzheimer's disease (cognitive decline);	chr17:47836481	chr17:47891255~47895812:-
THCA	cis	rs11671005	0.779	rs55875034	ENSG00000265272.2	RN7SL693P	4.28	2.28e-05	0.00214	0.27	0.19	Mean platelet volume;	chr19:58472191	chr19:58490797~58491075:+
THCA	cis	rs875971	0.798	rs6460304	ENSG00000229886.1	RP5-1132H15.3	4.28	2.28e-05	0.00214	0.2	0.19	Aortic root size;	chr7:66499741	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6945775	ENSG00000229886.1	RP5-1132H15.3	4.28	2.28e-05	0.00214	0.2	0.19	Aortic root size;	chr7:66503987	chr7:66025126~66031544:-
THCA	cis	rs6747952	0.899	rs12731	ENSG00000279484.1	KLHL30-AS1	4.28	2.28e-05	0.00214	0.18	0.19	Mean corpuscular hemoglobin concentration;	chr2:238179271	chr2:238152889~238155994:-
THCA	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	4.28	2.28e-05	0.00214	0.23	0.19	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
THCA	cis	rs2652822	0.584	rs1017546	ENSG00000259459.4	RP11-321G12.1	4.28	2.28e-05	0.00214	0.16	0.19	Metabolic traits;	chr15:63274503	chr15:63390136~63438320:+
THCA	cis	rs800160	0.858	rs800116	ENSG00000199550.1	Y_RNA	4.28	2.28e-05	0.00214	0.3	0.19	Bacteremia;	chr11:2340394	chr11:2372638~2372750:+
THCA	cis	rs1766786	0.925	rs1779435	ENSG00000231365.4	RP11-418J17.1	-4.28	2.28e-05	0.00214	-0.28	-0.19	Chin dimples;	chr1:118922964	chr1:119140396~119275973:+
THCA	cis	rs6929812	0.665	rs10946920	ENSG00000271755.1	RP1-153G14.4	-4.28	2.28e-05	0.00214	-0.22	-0.19	Neuroticism (multi-trait analysis);	chr6:27461212	chr6:27404010~27406964:-
THCA	cis	rs72843506	0.656	rs74333705	ENSG00000261033.1	RP11-209D14.2	4.28	2.28e-05	0.00214	0.36	0.19	Schizophrenia;	chr17:20097448	chr17:20008051~20009234:-
THCA	cis	rs7208859	0.725	rs9897673	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00214	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30738182~30740275:+
THCA	cis	rs3764021	0.87	rs7307111	ENSG00000256594.6	RP11-705C15.2	4.28	2.28e-05	0.00214	0.15	0.19	Type 1 diabetes;	chr12:9725227	chr12:9633419~9658412:+
THCA	cis	rs8031584	0.679	rs34017474	ENSG00000270015.1	RP11-540B6.6	-4.28	2.28e-05	0.00214	-0.14	-0.19	Huntington's disease progression;	chr15:30938408	chr15:30926514~30928407:+
THCA	cis	rs11220082	0.542	rs11220079	ENSG00000254671.2	STT3A-AS1	-4.28	2.28e-05	0.00214	-0.23	-0.19	Schizophrenia;	chr11:125450033	chr11:125570284~125592568:-
THCA	cis	rs5758511	0.573	rs5996074	ENSG00000281538.1	RP4-669P10.20	4.28	2.28e-05	0.00214	0.19	0.19	Birth weight;	chr22:41840333	chr22:42138060~42139726:+
THCA	cis	rs41342147	0.66	rs11690506	ENSG00000223374.1	AC005104.3	4.28	2.28e-05	0.00214	0.17	0.19	Vitiligo;	chr2:241344751	chr2:241351340~241353104:-
THCA	cis	rs41342147	0.66	rs11683764	ENSG00000223374.1	AC005104.3	4.28	2.28e-05	0.00214	0.17	0.19	Vitiligo;	chr2:241346130	chr2:241351340~241353104:-
THCA	cis	rs7772486	0.806	rs2265477	ENSG00000270638.1	RP3-466P17.1	4.28	2.28e-05	0.00214	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145735570~145737218:+
THCA	cis	rs4908769	0.588	rs2784737	ENSG00000232912.4	RP5-1115A15.1	-4.28	2.28e-05	0.00214	-0.21	-0.19	Allergy;	chr1:8403116	chr1:8424645~8434838:+
THCA	cis	rs7216064	1	rs12451707	ENSG00000278740.1	RP11-147L13.14	4.28	2.28e-05	0.00214	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875482	chr17:68188547~68189165:+
THCA	cis	rs12022452	0.908	rs11811487	ENSG00000237899.1	RP4-739H11.3	-4.28	2.28e-05	0.00214	-0.31	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40669089~40687588:-
THCA	cis	rs7819412	0.669	rs6601568	ENSG00000206014.6	OR7E161P	4.28	2.28e-05	0.00215	0.23	0.19	Triglycerides;	chr8:11215893	chr8:11928597~11929563:-
THCA	cis	rs4660214	0.666	rs4660550	ENSG00000228060.1	RP11-69E11.8	4.28	2.28e-05	0.00215	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39565160~39573203:+
THCA	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	-4.28	2.28e-05	0.00215	-0.09	-0.19	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
THCA	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	4.28	2.28e-05	0.00215	0.24	0.19	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
THCA	cis	rs9487094	0.67	rs2277114	ENSG00000223537.2	RP5-919F19.5	-4.28	2.28e-05	0.00215	-0.2	-0.19	Height;	chr6:109506513	chr6:109487906~109506800:+
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000280107.1	AL022393.9	-4.28	2.28e-05	0.00215	-0.19	-0.19	Pubertal anthropometrics;	chr6:28175232	chr6:28170845~28172521:+
THCA	cis	rs800160	0.72	rs11022259	ENSG00000199550.1	Y_RNA	4.28	2.28e-05	0.00215	0.3	0.19	Bacteremia;	chr11:2317026	chr11:2372638~2372750:+
THCA	cis	rs9911578	0.835	rs10853006	ENSG00000224738.1	AC099850.1	-4.28	2.28e-05	0.00215	-0.23	-0.19	Intelligence (multi-trait analysis);	chr17:58411715	chr17:59106598~59118267:+
THCA	cis	rs1232027	0.7	rs836823	ENSG00000249655.1	CTC-325J23.2	4.28	2.28e-05	0.00215	0.22	0.19	Huntington's disease progression;	chr5:80647895	chr5:80630313~80631590:-
THCA	cis	rs10484434	0.818	rs66536062	ENSG00000272462.2	U91328.19	4.28	2.28e-05	0.00215	0.2	0.19	HIV-1 viral setpoint;	chr6:26012479	chr6:25992662~26001775:+
THCA	cis	rs10875746	0.903	rs12313404	ENSG00000258273.1	RP11-370I10.4	4.28	2.28e-05	0.00215	0.28	0.19	Longevity (90 years and older);	chr12:48098265	chr12:48333755~48333901:-
THCA	cis	rs8062405	0.756	rs151182	ENSG00000261766.1	RP11-22P6.2	-4.28	2.28e-05	0.00215	-0.18	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28862166~28863340:-
THCA	cis	rs6921919	0.638	rs1416920	ENSG00000273712.1	RP5-874C20.7	4.28	2.29e-05	0.00215	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.525	rs1361386	ENSG00000273712.1	RP5-874C20.7	4.28	2.29e-05	0.00215	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.638	rs6456815	ENSG00000273712.1	RP5-874C20.7	4.28	2.29e-05	0.00215	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28315613~28315883:-
THCA	cis	rs10090774	0.71	rs11995103	ENSG00000280303.2	ERICD	-4.28	2.29e-05	0.00215	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140683162	chr8:140636281~140638283:+
THCA	cis	rs4819052	1	rs13047688	ENSG00000273796.1	LL21NC02-21A1.1	-4.28	2.29e-05	0.00215	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45403809~45404369:-
THCA	cis	rs17597773	0.638	rs11118609	ENSG00000272823.1	RP11-295M18.6	4.28	2.29e-05	0.00215	0.24	0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815148	chr1:220828676~220829211:-
THCA	cis	rs1559040	1	rs2112125	ENSG00000272156.1	RP11-477N3.1	-4.28	2.29e-05	0.00215	-0.32	-0.19	Sudden cardiac arrest;	chr2:54120893	chr2:54082554~54085066:+
THCA	cis	rs1559040	1	rs11675345	ENSG00000272156.1	RP11-477N3.1	-4.28	2.29e-05	0.00215	-0.32	-0.19	Sudden cardiac arrest;	chr2:54121713	chr2:54082554~54085066:+
THCA	cis	rs1559040	1	rs72800751	ENSG00000272156.1	RP11-477N3.1	-4.28	2.29e-05	0.00215	-0.32	-0.19	Sudden cardiac arrest;	chr2:54121871	chr2:54082554~54085066:+
THCA	cis	rs4805272	1	rs8113770	ENSG00000267799.1	MAN1A2P1	4.28	2.29e-05	0.00215	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28836829	chr19:28790812~28792871:-
THCA	cis	rs1046896	0.594	rs9914570	ENSG00000263063.1	RP11-388C12.1	-4.28	2.29e-05	0.00215	-0.25	-0.19	Glycated hemoglobin levels;	chr17:82825845	chr17:82713908~82716255:-
THCA	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	4.28	2.29e-05	0.00215	0.18	0.19	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
THCA	cis	rs2974760	0.581	rs2541600	ENSG00000268836.1	LA16c-OS12.2	4.28	2.29e-05	0.00215	0.2	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:149541	chr16:185748~186294:-
THCA	cis	rs734999	0.588	rs78506337	ENSG00000225931.3	RP3-395M20.7	4.28	2.29e-05	0.00215	0.23	0.19	Ulcerative colitis;	chr1:2605656	chr1:2566410~2569888:+
THCA	cis	rs1023500	0.505	rs134887	ENSG00000233903.2	Z83851.4	4.28	2.29e-05	0.00215	0.25	0.19	Schizophrenia;	chr22:42278233	chr22:42276355~42277052:+
THCA	cis	rs10932886	1	rs10177014	ENSG00000224819.1	AC093843.1	4.28	2.29e-05	0.00215	0.19	0.19	Brain imaging;	chr2:220861024	chr2:220791078~220797893:+
THCA	cis	rs6570726	0.791	rs6902410	ENSG00000270638.1	RP3-466P17.1	4.28	2.29e-05	0.00215	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145735570~145737218:+
THCA	cis	rs7216064	1	rs4271626	ENSG00000278740.1	RP11-147L13.14	4.28	2.29e-05	0.00215	0.22	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934017	chr17:68188547~68189165:+
THCA	cis	rs2281636	1	rs2231675	ENSG00000233690.1	EBAG9P1	-4.28	2.29e-05	0.00215	-0.18	-0.19	Obesity-related traits;	chr10:99732484	chr10:99697407~99697949:-
THCA	cis	rs2281636	1	rs2281636	ENSG00000233690.1	EBAG9P1	-4.28	2.29e-05	0.00215	-0.18	-0.19	Obesity-related traits;	chr10:99732646	chr10:99697407~99697949:-
THCA	cis	rs2281636	0.965	rs2006077	ENSG00000233690.1	EBAG9P1	-4.28	2.29e-05	0.00215	-0.18	-0.19	Obesity-related traits;	chr10:99733076	chr10:99697407~99697949:-
THCA	cis	rs12612619	0.704	rs6742004	ENSG00000272148.1	RP11-195B17.1	4.28	2.29e-05	0.00215	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086791	chr2:27062428~27062907:-
THCA	cis	rs8062405	0.728	rs9931989	ENSG00000270424.1	RP11-1348G14.6	-4.28	2.29e-05	0.00215	-0.24	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28749959~28750595:-
THCA	cis	rs2252790	0.64	rs1128261	ENSG00000237021.2	RP3-486I3.7	-4.28	2.29e-05	0.00215	-0.21	-0.19	Fast beta electroencephalogram;	chr6:116277690	chr6:116254207~116256743:+
THCA	cis	rs7474896	0.537	rs1779068	ENSG00000263064.2	RP11-291L22.7	-4.28	2.29e-05	0.00215	-0.26	-0.19	Obesity (extreme);	chr10:37961857	chr10:38448689~38448949:+
THCA	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	4.28	2.29e-05	0.00215	0.22	0.19	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
THCA	cis	rs2436845	0.627	rs2679750	ENSG00000253320.4	KB-1507C5.2	-4.28	2.29e-05	0.00215	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848164	chr8:102864300~102977876:+
THCA	cis	rs2028299	1	rs2028299	ENSG00000259677.1	RP11-493E3.1	4.28	2.29e-05	0.00215	0.25	0.19	Type 2 diabetes;	chr15:89831025	chr15:89876540~89877285:+
THCA	cis	rs11976180	1	rs1320893	ENSG00000244198.4	RP4-545C24.1	-4.28	2.29e-05	0.00215	-0.19	-0.19	Obesity-related traits;	chr7:144055019	chr7:144194858~144280547:+
THCA	cis	rs28448403	1	rs28448403	ENSG00000227888.4	FAM66A	-4.28	2.29e-05	0.00215	-0.26	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr8:11448055	chr8:12362019~12388296:+
THCA	cis	rs10946940	0.965	rs9393830	ENSG00000216915.2	RP1-97D16.1	-4.28	2.29e-05	0.00215	-0.26	-0.19	Systemic lupus erythematosus;	chr6:27619248	chr6:27737000~27738494:-
THCA	cis	rs9868809	0.505	rs11719291	ENSG00000270441.1	RP11-694I15.7	4.28	2.29e-05	0.00215	0.25	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698273	chr3:49140086~49160851:-
THCA	cis	rs17818399	0.926	rs35350086	ENSG00000279254.1	RP11-536C12.1	-4.28	2.29e-05	0.00215	-0.2	-0.19	Height;	chr2:46606897	chr2:46668870~46670778:+
THCA	cis	rs1979679	1	rs11049506	ENSG00000278733.1	RP11-425D17.1	-4.28	2.29e-05	0.00215	-0.21	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28289141	chr12:28185625~28186190:-
THCA	cis	rs708547	0.533	rs3806746	ENSG00000269949.1	RP11-738E22.3	-4.28	2.29e-05	0.00215	-0.24	-0.19	Response to bleomycin (chromatid breaks);	chr4:56907164	chr4:56960927~56961373:-
THCA	cis	rs708547	0.581	rs781661	ENSG00000269949.1	RP11-738E22.3	-4.28	2.29e-05	0.00215	-0.24	-0.19	Response to bleomycin (chromatid breaks);	chr4:56914141	chr4:56960927~56961373:-
THCA	cis	rs2380205	0.967	rs10905303	ENSG00000232807.2	RP11-536K7.3	4.28	2.29e-05	0.00215	0.18	0.19	Breast cancer;	chr10:5852217	chr10:5934270~5945900:-
THCA	cis	rs1577917	0.696	rs2842617	ENSG00000220563.1	PKMP3	-4.28	2.29e-05	0.00215	-0.14	-0.19	Response to antipsychotic treatment;	chr6:85599980	chr6:85659892~85660606:-
THCA	cis	rs7560272	0.538	rs4852976	ENSG00000273245.1	RP11-434P11.2	-4.28	2.29e-05	0.00216	-0.22	-0.19	Schizophrenia;	chr2:73709195	chr2:73750256~73750786:-
THCA	cis	rs4908769	0.624	rs301791	ENSG00000232912.4	RP5-1115A15.1	-4.28	2.29e-05	0.00216	-0.21	-0.19	Allergy;	chr1:8408312	chr1:8424645~8434838:+
THCA	cis	rs875971	0.862	rs2024192	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.29e-05	0.00216	-0.2	-0.19	Aortic root size;	chr7:66576460	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6955837	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.29e-05	0.00216	-0.2	-0.19	Aortic root size;	chr7:66578155	chr7:66025126~66031544:-
THCA	cis	rs875971	0.825	rs10281499	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.29e-05	0.00216	-0.2	-0.19	Aortic root size;	chr7:66583979	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs4718377	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.29e-05	0.00216	-0.2	-0.19	Aortic root size;	chr7:66584691	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs10278014	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.29e-05	0.00216	-0.2	-0.19	Aortic root size;	chr7:66586277	chr7:66025126~66031544:-
THCA	cis	rs12234571	1	rs3750127	ENSG00000214293.7	APTR	4.28	2.29e-05	0.00216	0.24	0.19	Obesity-related traits;	chr7:77697431	chr7:77657660~77696265:-
THCA	cis	rs714027	1	rs5997579	ENSG00000279159.1	RP3-394A18.1	-4.28	2.29e-05	0.00216	-0.14	-0.19	Lymphocyte counts;	chr22:30141537	chr22:29978950~30028236:-
THCA	cis	rs10483853	0.806	rs12436089	ENSG00000258695.2	RP3-414A15.2	-4.28	2.29e-05	0.00216	-0.27	-0.19	Coronary artery calcification;	chr14:73427998	chr14:73522878~73530610:+
THCA	cis	rs9543976	0.544	rs73223950	ENSG00000261105.4	LMO7-AS1	-4.28	2.3e-05	0.00216	-0.35	-0.19	Diabetic retinopathy;	chr13:75524901	chr13:75604700~75635994:-
THCA	cis	rs74233809	0.605	rs999867	ENSG00000213277.3	MARCKSL1P1	4.28	2.3e-05	0.00216	0.3	0.19	Birth weight;	chr10:102744807	chr10:103175554~103176094:+
THCA	cis	rs6878727	0.665	rs161010	ENSG00000253807.4	LINC01170	4.28	2.3e-05	0.00216	0.17	0.19	Breast cancer;	chr5:124339924	chr5:124059794~124405079:-
THCA	cis	rs5758659	0.714	rs5758578	ENSG00000273366.1	CTA-989H11.1	4.28	2.3e-05	0.00216	0.23	0.19	Cognitive function;	chr22:42094288	chr22:42278188~42278846:+
THCA	cis	rs12142240	0.698	rs72677596	ENSG00000232022.5	FAAHP1	-4.28	2.3e-05	0.00216	-0.22	-0.19	Menopause (age at onset);	chr1:46368258	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72677600	ENSG00000232022.5	FAAHP1	-4.28	2.3e-05	0.00216	-0.22	-0.19	Menopause (age at onset);	chr1:46368777	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs55670684	ENSG00000232022.5	FAAHP1	-4.28	2.3e-05	0.00216	-0.22	-0.19	Menopause (age at onset);	chr1:46369467	chr1:46432129~46445521:+
THCA	cis	rs10454142	1	rs10454142	ENSG00000202227.1	RNU6-282P	4.28	2.3e-05	0.00216	0.23	0.19	Sex hormone-binding globulin levels;	chr2:48419260	chr2:48501922~48502024:-
THCA	cis	rs10454142	0.961	rs10454143	ENSG00000202227.1	RNU6-282P	4.28	2.3e-05	0.00216	0.23	0.19	Sex hormone-binding globulin levels;	chr2:48419261	chr2:48501922~48502024:-
THCA	cis	rs7572644	0.782	rs1870325	ENSG00000223522.1	AC093690.1	4.28	2.3e-05	0.00216	0.23	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27921200	chr2:28307691~28310459:-
THCA	cis	rs944289	0.502	rs1958612	ENSG00000257826.1	RP11-116N8.4	-4.28	2.3e-05	0.00216	-0.22	-0.19	Thyroid cancer;	chr14:36204669	chr14:36061026~36067190:-
THCA	cis	rs2191566	0.96	rs367209	ENSG00000266921.1	RP11-15A1.7	4.28	2.3e-05	0.00216	0.18	0.19	Acute lymphoblastic leukemia (childhood);	chr19:44002097	chr19:43996896~44002836:-
THCA	cis	rs801193	1	rs4717310	ENSG00000272831.1	RP11-792A8.4	4.28	2.3e-05	0.00216	0.12	0.19	Aortic root size;	chr7:66696020	chr7:66739829~66740385:-
THCA	cis	rs860295	0.702	rs4971095	ENSG00000160766.13	GBAP1	4.28	2.3e-05	0.00216	0.23	0.19	Body mass index;	chr1:155636433	chr1:155213821~155227422:-
THCA	cis	rs7474896	0.537	rs2472149	ENSG00000226578.1	RP11-258F22.1	4.28	2.3e-05	0.00216	0.27	0.19	Obesity (extreme);	chr10:37973268	chr10:37775371~37784131:-
THCA	cis	rs3764021	0.527	rs10844537	ENSG00000214776.8	RP11-726G1.1	4.28	2.3e-05	0.00216	0.25	0.19	Type 1 diabetes;	chr12:9709528	chr12:9467552~9576275:+
THCA	cis	rs2985684	0.802	rs8015368	ENSG00000278009.1	RP11-649E7.8	4.28	2.3e-05	0.00216	0.27	0.19	Carotid intima media thickness;	chr14:49553792	chr14:49601011~49601124:-
THCA	cis	rs8062405	0.755	rs4788076	ENSG00000270424.1	RP11-1348G14.6	4.28	2.3e-05	0.00216	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28749959~28750595:-
THCA	cis	rs8105895	0.935	rs62112918	ENSG00000269345.1	VN1R85P	4.28	2.3e-05	0.00216	0.27	0.19	Body mass index (change over time);	chr19:22044277	chr19:22174766~22175191:-
THCA	cis	rs7267979	1	rs8125868	ENSG00000276952.1	RP5-965G21.6	-4.28	2.3e-05	0.00216	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25284915~25285588:-
THCA	cis	rs12478296	0.792	rs6755390	ENSG00000220804.7	AC093642.5	4.28	2.3e-05	0.00216	0.22	0.19	Obesity-related traits;	chr2:242070847	chr2:242088633~242160153:+
THCA	cis	rs3796352	1	rs1346719	ENSG00000242142.1	SERBP1P3	-4.28	2.3e-05	0.00216	-0.33	-0.19	Immune reponse to smallpox (secreted IL-2);	chr3:53043356	chr3:53064283~53065091:-
THCA	cis	rs12440869	1	rs11071943	ENSG00000270964.1	RP11-502I4.3	4.28	2.3e-05	0.00216	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67243658	chr15:67541072~67542604:-
THCA	cis	rs151234	0.741	rs10521145	ENSG00000259982.1	CDC37P1	4.28	2.3e-05	0.00216	0.37	0.19	Platelet distribution width;	chr16:28585563	chr16:28700294~28701540:-
THCA	cis	rs2191566	0.845	rs7258517	ENSG00000266921.1	RP11-15A1.7	-4.28	2.3e-05	0.00216	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44031846	chr19:43996896~44002836:-
THCA	cis	rs10208649	0.611	rs75340524	ENSG00000233266.1	HMGB1P31	4.28	2.3e-05	0.00216	0.36	0.19	Body mass index;	chr2:54068793	chr2:54051334~54051760:+
THCA	cis	rs12428035	1	rs77930391	ENSG00000247400.3	DNAJC3-AS1	-4.28	2.3e-05	0.00216	-0.19	-0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95645567	chr13:95648733~95676925:-
THCA	cis	rs13401620	0.745	rs6542545	ENSG00000231013.1	AC013275.2	-4.28	2.3e-05	0.00216	-0.22	-0.19	Breast size;	chr2:119712417	chr2:119476448~119487346:+
THCA	cis	rs17301013	0.803	rs2187562	ENSG00000227373.4	RP11-160H22.5	4.28	2.3e-05	0.00217	0.26	0.19	Systemic lupus erythematosus;	chr1:174842513	chr1:174115300~174160004:-
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000265443.1	CTD-2349P21.6	-4.28	2.3e-05	0.00217	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30726305~30727564:-
THCA	cis	rs1979679	1	rs6487672	ENSG00000247934.4	RP11-967K21.1	-4.28	2.3e-05	0.00217	-0.19	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28270413	chr12:28163298~28190738:-
THCA	cis	rs7312933	0.558	rs3747560	ENSG00000257225.1	RP11-328C8.4	4.28	2.31e-05	0.00217	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42326088	chr12:42459366~42466128:+
THCA	cis	rs854765	0.718	rs12943500	ENSG00000281749.1	Y_RNA	-4.28	2.31e-05	0.00217	-0.25	-0.19	Total body bone mineral density;	chr17:17887274	chr17:18001101~18001195:-
THCA	cis	rs753778	0.628	rs1045248	ENSG00000253210.1	RP11-809O17.1	-4.28	2.31e-05	0.00217	-0.23	-0.19	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141194227	chr8:141126044~141129961:-
THCA	cis	rs708224	0.655	rs792864	ENSG00000277342.1	RP11-843B15.4	4.28	2.31e-05	0.00217	0.25	0.19	Pancreatic cancer;	chr12:32278562	chr12:32109076~32109602:+
THCA	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	4.28	2.31e-05	0.00217	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	4.28	2.31e-05	0.00217	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
THCA	cis	rs6951245	0.872	rs75280240	ENSG00000229043.2	AC091729.9	-4.28	2.31e-05	0.00217	-0.33	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018875	chr7:1160374~1165267:+
THCA	cis	rs1055129	0.516	rs7218498	ENSG00000267801.1	RP11-552F3.9	4.28	2.31e-05	0.00217	0.22	0.19	White matter hyperintensity burden;	chr17:75935766	chr17:75876372~75879546:+
THCA	cis	rs440932	0.798	rs330942	ENSG00000248538.5	RP11-10A14.5	-4.28	2.31e-05	0.00217	-0.24	-0.19	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:9189011~9202854:+
THCA	cis	rs7918232	0.882	rs2149413	ENSG00000262412.1	RP11-85G18.6	-4.28	2.31e-05	0.00217	-0.3	-0.19	Breast cancer;	chr10:27141382	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs4749228	ENSG00000262412.1	RP11-85G18.6	-4.28	2.31e-05	0.00217	-0.3	-0.19	Breast cancer;	chr10:27144689	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs1085782	ENSG00000262412.1	RP11-85G18.6	-4.28	2.31e-05	0.00217	-0.3	-0.19	Breast cancer;	chr10:27151588	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs1775350	ENSG00000262412.1	RP11-85G18.6	-4.28	2.31e-05	0.00217	-0.3	-0.19	Breast cancer;	chr10:27153044	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs788220	ENSG00000262412.1	RP11-85G18.6	-4.28	2.31e-05	0.00217	-0.3	-0.19	Breast cancer;	chr10:27158276	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.882	rs788237	ENSG00000262412.1	RP11-85G18.6	-4.28	2.31e-05	0.00217	-0.3	-0.19	Breast cancer;	chr10:27169003	chr10:27243130~27250804:+
THCA	cis	rs9549367	0.756	rs9549702	ENSG00000269125.1	RP11-98F14.11	-4.28	2.31e-05	0.00217	-0.22	-0.19	Platelet distribution width;	chr13:113227630	chr13:113165002~113165183:-
THCA	cis	rs1728785	0.818	rs11648503	ENSG00000274698.1	RP11-71L14.4	4.28	2.31e-05	0.00217	0.28	0.19	Ulcerative colitis;	chr16:68565035	chr16:68450283~68452318:+
THCA	cis	rs8031584	0.651	rs28664821	ENSG00000215302.7	CTD-3092A11.1	4.28	2.31e-05	0.00217	0.23	0.19	Huntington's disease progression;	chr15:30880120	chr15:30470779~30507623:+
THCA	cis	rs6001482	0.647	rs8140302	ENSG00000272779.1	LL22NC03-80A10.6	-4.28	2.31e-05	0.00217	-0.22	-0.19	Diastolic blood pressure;	chr22:22234843	chr22:22303224~22310401:+
THCA	cis	rs2732480	0.5	rs12829841	ENSG00000273765.1	RP11-370I10.11	4.28	2.31e-05	0.00217	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.523	rs34286639	ENSG00000273765.1	RP11-370I10.11	4.28	2.31e-05	0.00217	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48360920~48361377:+
THCA	cis	rs1387259	0.929	rs11168484	ENSG00000273765.1	RP11-370I10.11	4.28	2.31e-05	0.00217	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48360920~48361377:+
THCA	cis	rs795484	0.963	rs1277441	ENSG00000275409.1	RP11-131L12.4	-4.28	2.31e-05	0.00217	-0.16	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118168184	chr12:118430147~118430699:+
THCA	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	4.28	2.31e-05	0.00217	0.22	0.19	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	4.28	2.31e-05	0.00217	0.22	0.19	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	4.28	2.31e-05	0.00217	0.22	0.19	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	4.28	2.31e-05	0.00217	0.22	0.19	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
THCA	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	4.28	2.31e-05	0.00217	0.23	0.19	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	4.28	2.31e-05	0.00217	0.23	0.19	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	4.28	2.31e-05	0.00217	0.23	0.19	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	4.28	2.31e-05	0.00217	0.23	0.19	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	4.28	2.31e-05	0.00217	0.23	0.19	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	4.28	2.31e-05	0.00217	0.23	0.19	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	4.28	2.31e-05	0.00217	0.23	0.19	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
THCA	cis	rs8020441	0.945	rs72681670	ENSG00000269906.1	RP11-248J18.2	4.28	2.31e-05	0.00217	0.28	0.19	Cognitive performance;	chr14:50702554	chr14:50662511~50663178:-
THCA	cis	rs1800795	0.652	rs7802307	ENSG00000225541.1	AC002480.5	-4.28	2.31e-05	0.00217	-0.25	-0.19	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22571607~22661792:-
THCA	cis	rs7474896	0.515	rs675628	ENSG00000120555.12	SEPT7P9	-4.28	2.31e-05	0.00217	-0.26	-0.19	Obesity (extreme);	chr10:38016403	chr10:38383069~38402916:-
THCA	cis	rs6920372	0.748	rs12528392	ENSG00000223537.2	RP5-919F19.5	-4.28	2.31e-05	0.00217	-0.2	-0.19	Height;	chr6:109747411	chr6:109487906~109506800:+
THCA	cis	rs6920372	0.692	rs11153216	ENSG00000223537.2	RP5-919F19.5	-4.28	2.31e-05	0.00217	-0.2	-0.19	Height;	chr6:109748819	chr6:109487906~109506800:+
THCA	cis	rs6920372	0.748	rs2025147	ENSG00000223537.2	RP5-919F19.5	-4.28	2.31e-05	0.00217	-0.2	-0.19	Height;	chr6:109749564	chr6:109487906~109506800:+
THCA	cis	rs2408955	0.522	rs11168408	ENSG00000273765.1	RP11-370I10.11	-4.28	2.31e-05	0.00217	-0.2	-0.19	Glycated hemoglobin levels;	chr12:48104544	chr12:48360920~48361377:+
THCA	cis	rs854765	0.547	rs9913277	ENSG00000281749.1	Y_RNA	4.28	2.31e-05	0.00217	0.25	0.19	Total body bone mineral density;	chr17:18016435	chr17:18001101~18001195:-
THCA	cis	rs11633886	0.51	rs939423	ENSG00000273972.1	CTD-2306A12.1	4.28	2.31e-05	0.00217	0.21	0.19	Diisocyanate-induced asthma;	chr15:45776743	chr15:45702640~45703183:+
THCA	cis	rs35740288	0.731	rs11634651	ENSG00000259295.5	CSPG4P12	4.28	2.31e-05	0.00217	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85550695	chr15:85191438~85213905:+
THCA	cis	rs1198872	0.812	rs1198860	ENSG00000272275.1	RP11-791G15.2	-4.28	2.31e-05	0.00217	-0.23	-0.19	Cardiac Troponin-T levels;	chr2:10759727	chr2:10767875~10770058:-
THCA	cis	rs1858740	0.509	rs196375	ENSG00000229589.1	ACVR2B-AS1	4.28	2.31e-05	0.00217	0.19	0.19	Schizophrenia;	chr3:38381428	chr3:38451027~38454820:-
THCA	cis	rs931608	0.925	rs11085533	ENSG00000269138.1	ZNF209P	-4.28	2.31e-05	0.00217	-0.27	-0.19	Response to statins (LDL cholesterol change);Dental caries;	chr19:22430078	chr19:22463922~22473036:+
THCA	cis	rs7918232	0.941	rs7907988	ENSG00000262412.1	RP11-85G18.6	4.28	2.31e-05	0.00217	0.3	0.19	Breast cancer;	chr10:27155415	chr10:27243130~27250804:+
THCA	cis	rs728616	0.51	rs17617406	ENSG00000242600.5	MBL1P	-4.28	2.31e-05	0.00217	-0.24	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80414800	chr10:79904898~79950336:+
THCA	cis	rs7267979	0.816	rs376742	ENSG00000277938.1	RP5-965G21.3	4.28	2.31e-05	0.00217	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25229150~25231933:+
THCA	cis	rs3128341	1	rs12123328	ENSG00000227207.2	RPL31P12	4.28	2.31e-05	0.00217	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72367518	chr1:72301472~72301829:+
THCA	cis	rs3128341	1	rs12117250	ENSG00000227207.2	RPL31P12	4.28	2.31e-05	0.00217	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72369116	chr1:72301472~72301829:+
THCA	cis	rs2749592	0.611	rs2505199	ENSG00000226578.1	RP11-258F22.1	-4.28	2.31e-05	0.00217	-0.24	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:38103529	chr10:37775371~37784131:-
THCA	cis	rs2749592	0.588	rs2505192	ENSG00000226578.1	RP11-258F22.1	-4.28	2.31e-05	0.00217	-0.24	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:38106095	chr10:37775371~37784131:-
THCA	cis	rs2749592	0.611	rs176888	ENSG00000226578.1	RP11-258F22.1	-4.28	2.31e-05	0.00217	-0.24	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:38117233	chr10:37775371~37784131:-
THCA	cis	rs13178541	0.745	rs7379714	ENSG00000250378.1	RP11-119J18.1	-4.27	2.32e-05	0.00217	-0.23	-0.19	IgG glycosylation;	chr5:135757447	chr5:135812667~135826582:+
THCA	cis	rs59868192	0.925	rs57556178	ENSG00000246740.2	PLA2G4E-AS1	4.27	2.32e-05	0.00218	0.38	0.19	White blood cell count;	chr15:41950690	chr15:41972763~41999094:+
THCA	cis	rs2657294	0.796	rs4746272	ENSG00000233313.2	HMGA1P5	-4.27	2.32e-05	0.00218	-0.26	-0.19	Pneumonia;	chr10:75203869	chr10:75276376~75276646:-
THCA	cis	rs733592	0.504	rs2261608	ENSG00000269514.1	RP11-370I10.12	-4.27	2.32e-05	0.00218	-0.16	-0.19	Plateletcrit;	chr12:48327851	chr12:48198387~48202031:+
THCA	cis	rs800160	0.777	rs2106606	ENSG00000199550.1	Y_RNA	4.27	2.32e-05	0.00218	0.3	0.19	Bacteremia;	chr11:2336333	chr11:2372638~2372750:+
THCA	cis	rs6088590	1	rs6088615	ENSG00000269202.1	RP4-614O4.12	4.27	2.32e-05	0.00218	0.17	0.19	Coronary artery disease;	chr20:34812671	chr20:35201747~35203288:-
THCA	cis	rs2749592	0.505	rs7915670	ENSG00000276805.1	RP11-291L22.6	-4.27	2.32e-05	0.00218	-0.21	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38451030~38451785:+
THCA	cis	rs4646450	0.735	rs6972337	ENSG00000244219.5	GS1-259H13.2	-4.27	2.32e-05	0.00218	-0.25	-0.19	Blood metabolite levels;	chr7:99345684	chr7:99598066~99610813:+
THCA	cis	rs875971	0.545	rs73142245	ENSG00000273142.1	RP11-458F8.4	4.27	2.32e-05	0.00218	0.18	0.19	Aortic root size;	chr7:66226662	chr7:66902857~66906297:+
THCA	cis	rs12679857	0.686	rs1032129	ENSG00000254278.1	RP11-278I4.2	-4.27	2.32e-05	0.00218	-0.23	-0.19	Type 1 diabetes;	chr8:118939661	chr8:119062942~119068782:-
THCA	cis	rs1962772	0.924	rs11785785	ENSG00000279903.1	RP11-349F21.5	-4.27	2.32e-05	0.00218	-0.24	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17512975	chr8:17500012~17500605:+
THCA	cis	rs10043228	1	rs57434520	ENSG00000250015.1	CTC-339F2.2	4.27	2.32e-05	0.00218	0.24	0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116313068	chr5:116302354~116304134:-
THCA	cis	rs17507216	0.628	rs4627310	ENSG00000255769.6	GOLGA2P10	-4.27	2.32e-05	0.00218	-0.29	-0.19	Excessive daytime sleepiness;	chr15:82708330	chr15:82472993~82513950:-
THCA	cis	rs7572733	0.534	rs700662	ENSG00000231621.1	AC013264.2	-4.27	2.32e-05	0.00218	-0.2	-0.19	Dermatomyositis;	chr2:197804027	chr2:197197991~197199273:+
THCA	cis	rs2522056	0.932	rs1012793	ENSG00000237714.1	P4HA2-AS1	-4.27	2.32e-05	0.00218	-0.28	-0.19	Fibrinogen;Lymphocyte counts;	chr5:132445653	chr5:132184876~132192808:+
THCA	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	4.27	2.32e-05	0.00218	0.22	0.19	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
THCA	cis	rs4144027	0.791	rs66473563	ENSG00000269910.1	RP11-73M18.10	4.27	2.32e-05	0.00218	0.17	0.19	Blood metabolite levels;	chr14:103895534	chr14:103694516~103695050:-
THCA	cis	rs9532669	0.926	rs12428966	ENSG00000229473.2	RGS17P1	4.27	2.32e-05	0.00218	0.25	0.19	Cervical cancer;	chr13:40876552	chr13:40992779~40993331:-
THCA	cis	rs13064773	0.546	rs189303	ENSG00000279311.1	RP11-170K4.2	4.27	2.32e-05	0.00218	0.25	0.19	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158886979	chr3:158869898~158871821:+
THCA	cis	rs13064773	0.546	rs340242	ENSG00000279311.1	RP11-170K4.2	4.27	2.32e-05	0.00218	0.25	0.19	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158887260	chr3:158869898~158871821:+
THCA	cis	rs6517329	0.932	rs4817775	ENSG00000236830.5	CBR3-AS1	4.27	2.32e-05	0.00218	0.18	0.19	Schizophrenia;	chr21:36112764	chr21:36131767~36175815:-
THCA	cis	rs13434995	0.589	rs62305201	ENSG00000249700.7	SRD5A3-AS1	-4.27	2.32e-05	0.00218	-0.28	-0.19	Adiponectin levels;	chr4:55386778	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.589	rs62305202	ENSG00000249700.7	SRD5A3-AS1	-4.27	2.32e-05	0.00218	-0.28	-0.19	Adiponectin levels;	chr4:55386861	chr4:55363971~55395847:-
THCA	cis	rs5758659	0.652	rs133300	ENSG00000273366.1	CTA-989H11.1	-4.27	2.32e-05	0.00218	-0.23	-0.19	Cognitive function;	chr22:41993835	chr22:42278188~42278846:+
THCA	cis	rs151234	0.741	rs56236750	ENSG00000259982.1	CDC37P1	-4.27	2.32e-05	0.00218	-0.39	-0.19	Platelet distribution width;	chr16:28583390	chr16:28700294~28701540:-
THCA	cis	rs151234	0.741	rs11644791	ENSG00000259982.1	CDC37P1	-4.27	2.32e-05	0.00218	-0.39	-0.19	Platelet distribution width;	chr16:28589865	chr16:28700294~28701540:-
THCA	cis	rs151234	0.741	rs3194168	ENSG00000259982.1	CDC37P1	-4.27	2.32e-05	0.00218	-0.39	-0.19	Platelet distribution width;	chr16:28591691	chr16:28700294~28701540:-
THCA	cis	rs60180747	0.818	rs2414902	ENSG00000261318.1	RP11-653J6.1	4.27	2.32e-05	0.00218	0.27	0.19	Testicular germ cell tumor;	chr15:66344180	chr15:66278498~66293357:-
THCA	cis	rs5758511	0.689	rs5758691	ENSG00000227370.1	RP4-669P10.19	4.27	2.32e-05	0.00218	0.21	0.19	Birth weight;	chr22:42272498	chr22:42132543~42132998:+
THCA	cis	rs5758511	0.68	rs1001586	ENSG00000227370.1	RP4-669P10.19	4.27	2.32e-05	0.00218	0.21	0.19	Birth weight;	chr22:42274287	chr22:42132543~42132998:+
THCA	cis	rs17092148	0.836	rs6059910	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.32e-05	0.00218	-0.24	-0.19	Neuroticism;	chr20:34554303	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.887	rs6059915	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.32e-05	0.00218	-0.24	-0.19	Neuroticism;	chr20:34559933	chr20:33985617~33988989:-
THCA	cis	rs36093844	0.752	rs56261432	ENSG00000279742.1	RP11-700A24.1	-4.27	2.32e-05	0.00218	-0.29	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837338	chr11:85852557~85854943:-
THCA	cis	rs860295	0.756	rs7546258	ENSG00000160766.13	GBAP1	-4.27	2.32e-05	0.00218	-0.23	-0.19	Body mass index;	chr1:155728854	chr1:155213821~155227422:-
THCA	cis	rs9863	0.931	rs3186071	ENSG00000270061.1	RP11-214K3.19	-4.27	2.32e-05	0.00218	-0.26	-0.19	White blood cell count;	chr12:123944732	chr12:123969990~123970344:-
THCA	cis	rs12428035	0.656	rs7339059	ENSG00000247400.3	DNAJC3-AS1	4.27	2.32e-05	0.00218	0.18	0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95902223	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.656	rs7334320	ENSG00000247400.3	DNAJC3-AS1	4.27	2.32e-05	0.00218	0.18	0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95902673	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.656	rs9525079	ENSG00000247400.3	DNAJC3-AS1	4.27	2.32e-05	0.00218	0.18	0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95906202	chr13:95648733~95676925:-
THCA	cis	rs858239	0.601	rs929507	ENSG00000226816.2	AC005082.12	4.27	2.32e-05	0.00218	0.27	0.19	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23206013~23208045:+
THCA	cis	rs858239	0.601	rs929508	ENSG00000226816.2	AC005082.12	4.27	2.32e-05	0.00218	0.27	0.19	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23206013~23208045:+
THCA	cis	rs9487094	0.689	rs9487064	ENSG00000223537.2	RP5-919F19.5	-4.27	2.32e-05	0.00218	-0.2	-0.19	Height;	chr6:109346560	chr6:109487906~109506800:+
THCA	cis	rs4767841	0.565	rs203332	ENSG00000252886.1	RN7SKP197	4.27	2.32e-05	0.00218	0.19	0.19	Urgency urinary incontinence;	chr12:119772533	chr12:119631090~119631386:-
THCA	cis	rs3020736	0.5	rs6002614	ENSG00000237037.8	NDUFA6-AS1	4.27	2.32e-05	0.00218	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs2413669	ENSG00000237037.8	NDUFA6-AS1	4.27	2.32e-05	0.00218	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs6002618	ENSG00000237037.8	NDUFA6-AS1	4.27	2.32e-05	0.00218	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs2413672	ENSG00000237037.8	NDUFA6-AS1	4.27	2.32e-05	0.00218	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs6002623	ENSG00000237037.8	NDUFA6-AS1	4.27	2.32e-05	0.00218	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs11090076	ENSG00000237037.8	NDUFA6-AS1	4.27	2.32e-05	0.00218	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs764481	ENSG00000237037.8	NDUFA6-AS1	4.27	2.32e-05	0.00218	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42090931~42137742:+
THCA	cis	rs4819052	1	rs2297284	ENSG00000273796.1	LL21NC02-21A1.1	-4.27	2.32e-05	0.00218	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45403809~45404369:-
THCA	cis	rs4578769	0.959	rs3863525	ENSG00000265939.1	UBE2CP2	4.27	2.32e-05	0.00218	0.24	0.19	Eosinophil percentage of white cells;	chr18:22898714	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.959	rs4800137	ENSG00000265939.1	UBE2CP2	4.27	2.32e-05	0.00218	0.24	0.19	Eosinophil percentage of white cells;	chr18:22899721	chr18:22900486~22900995:-
THCA	cis	rs6430538	0.671	rs10928518	ENSG00000224043.6	CCNT2-AS1	-4.27	2.33e-05	0.00218	-0.21	-0.19	Parkinson's disease;	chr2:134809683	chr2:134735464~134918710:-
THCA	cis	rs4356203	0.905	rs6486354	ENSG00000272034.1	SNORD14A	-4.27	2.33e-05	0.00218	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17178561	chr11:17074654~17074744:-
THCA	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	4.27	2.33e-05	0.00218	0.23	0.19	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
THCA	cis	rs34421088	0.506	rs2572426	ENSG00000154316.13	TDH	-4.27	2.33e-05	0.00218	-0.15	-0.19	Neuroticism;	chr8:11289614	chr8:11339637~11368452:+
THCA	cis	rs710913	0.745	rs67563067	ENSG00000182109.6	RP11-69E11.4	-4.27	2.33e-05	0.00218	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39522280~39546187:-
THCA	cis	rs17772222	0.701	rs1627444	ENSG00000222990.1	RNU4-22P	-4.27	2.33e-05	0.00218	-0.23	-0.19	Coronary artery calcification;	chr14:88413784	chr14:88513498~88513663:+
THCA	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-4.27	2.33e-05	0.00218	-0.19	-0.19	Height;	chr5:36999896	chr5:36666214~36725195:-
THCA	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-4.27	2.33e-05	0.00218	-0.19	-0.19	Height;	chr5:37005003	chr5:36666214~36725195:-
THCA	cis	rs950880	0.677	rs56224165	ENSG00000234389.1	AC007278.3	-4.27	2.33e-05	0.00218	-0.23	-0.19	Serum protein levels (sST2);	chr2:102308763	chr2:102438713~102440475:+
THCA	cis	rs17221829	0.965	rs10830366	ENSG00000280385.1	AP000648.5	-4.27	2.33e-05	0.00218	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89726086	chr11:90193614~90198120:+
THCA	cis	rs4434872	0.536	rs12032520	ENSG00000223599.1	RP11-216N14.7	-4.27	2.33e-05	0.00218	-0.37	-0.19	Conduct disorder (symptom count);	chr1:153923477	chr1:153852106~153853414:-
THCA	cis	rs4434872	0.536	rs12044455	ENSG00000223599.1	RP11-216N14.7	-4.27	2.33e-05	0.00218	-0.37	-0.19	Conduct disorder (symptom count);	chr1:153943405	chr1:153852106~153853414:-
THCA	cis	rs4742903	0.904	rs1333941	ENSG00000270332.1	SMC2-AS1	4.27	2.33e-05	0.00219	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104234105	chr9:104080024~104093073:-
THCA	cis	rs997295	0.713	rs9302245	ENSG00000270964.1	RP11-502I4.3	-4.27	2.33e-05	0.00219	-0.16	-0.19	Motion sickness;	chr15:67728799	chr15:67541072~67542604:-
THCA	cis	rs9475752	0.545	rs41267681	ENSG00000231441.1	RP11-472M19.2	4.27	2.33e-05	0.00219	0.28	0.19	Menarche (age at onset);	chr6:57017085	chr6:56844002~56864078:+
THCA	cis	rs4950322	0.57	rs4950400	ENSG00000180867.10	PDIA3P1	-4.27	2.33e-05	0.00219	-0.19	-0.19	Protein quantitative trait loci;	chr1:147319383	chr1:147178113~147179622:+
THCA	cis	rs1334894	0.892	rs12527303	ENSG00000228559.1	RP3-340B19.3	-4.27	2.33e-05	0.00219	-0.41	-0.19	Coronary artery disease;	chr6:35519957	chr6:35544632~35545669:+
THCA	cis	rs4650994	0.593	rs12040058	ENSG00000273384.1	RP5-1098D14.1	-4.27	2.33e-05	0.00219	-0.25	-0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178534422	chr1:178651706~178652282:+
THCA	cis	rs6600671	0.899	rs2319971	ENSG00000275585.1	CH17-118O6.3	-4.27	2.33e-05	0.00219	-0.24	-0.19	Hip geometry;	chr1:121485184	chr1:120985692~121052167:-
THCA	cis	rs454217	0.773	rs518009	ENSG00000277851.1	RP11-756G20.1	4.27	2.33e-05	0.00219	0.19	0.19	Smoking quantity;	chr12:92339730	chr12:92247756~92363832:-
THCA	cis	rs61270009	0.818	rs6452786	ENSG00000247828.6	TMEM161B-AS1	4.27	2.33e-05	0.00219	0.17	0.19	Depressive symptoms;	chr5:88409022	chr5:88268895~88436685:+
THCA	cis	rs1823874	0.71	rs1840298	ENSG00000182397.13	DNM1P46	-4.27	2.33e-05	0.00219	-0.22	-0.19	IgG glycosylation;	chr15:99821889	chr15:99790156~99806927:-
THCA	cis	rs1823874	0.71	rs67068917	ENSG00000182397.13	DNM1P46	-4.27	2.33e-05	0.00219	-0.22	-0.19	IgG glycosylation;	chr15:99822310	chr15:99790156~99806927:-
THCA	cis	rs7192208	1	rs72628223	ENSG00000260922.1	RP11-538I12.3	4.27	2.33e-05	0.00219	0.35	0.19	White matter integrity;	chr16:77293918	chr16:77234877~77290934:+
THCA	cis	rs10908458	0.808	rs11264322	ENSG00000160766.13	GBAP1	-4.27	2.33e-05	0.00219	-0.21	-0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155115457	chr1:155213821~155227422:-
THCA	cis	rs8177876	0.749	rs2970076	ENSG00000261061.1	RP11-303E16.2	-4.27	2.33e-05	0.00219	-0.25	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056211	chr16:81030770~81031485:+
THCA	cis	rs2334880	0.713	rs4788828	ENSG00000260185.1	RP11-432I5.6	-4.27	2.33e-05	0.00219	-0.36	-0.19	Malaria;	chr16:71690187	chr16:71655027~71664212:+
THCA	cis	rs733592	0.723	rs10875766	ENSG00000269514.1	RP11-370I10.12	-4.27	2.33e-05	0.00219	-0.16	-0.19	Plateletcrit;	chr12:48199797	chr12:48198387~48202031:+
THCA	cis	rs875971	0.798	rs57739047	ENSG00000229886.1	RP5-1132H15.3	4.27	2.33e-05	0.00219	0.2	0.19	Aortic root size;	chr7:66507579	chr7:66025126~66031544:-
THCA	cis	rs875971	0.83	rs6950137	ENSG00000229886.1	RP5-1132H15.3	4.27	2.33e-05	0.00219	0.2	0.19	Aortic root size;	chr7:66511623	chr7:66025126~66031544:-
THCA	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	4.27	2.33e-05	0.00219	0.23	0.19	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	4.27	2.33e-05	0.00219	0.23	0.19	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	4.27	2.33e-05	0.00219	0.23	0.19	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	4.27	2.33e-05	0.00219	0.23	0.19	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	4.27	2.33e-05	0.00219	0.23	0.19	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
THCA	cis	rs7824557	0.527	rs2572369	ENSG00000154316.13	TDH	4.27	2.33e-05	0.00219	0.14	0.19	Retinal vascular caliber;	chr8:11381088	chr8:11339637~11368452:+
THCA	cis	rs12134133	1	rs28371583	ENSG00000237074.1	RP11-6J21.2	4.27	2.33e-05	0.00219	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207249067~207309121:+
THCA	cis	rs2241024	0.53	rs11882251	ENSG00000281468.1	CTC-459F4.9	-4.27	2.33e-05	0.00219	-0.23	-0.19	Testicular germ cell tumor;	chr19:27636293	chr19:27802838~27803472:+
THCA	cis	rs10895987	0.531	rs11227118	ENSG00000255200.1	AP003068.18	4.27	2.33e-05	0.00219	0.26	0.19	Blood protein levels;	chr11:65093183	chr11:65174117~65176470:-
THCA	cis	rs6088590	1	rs6058111	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.33e-05	0.00219	-0.18	-0.19	Coronary artery disease;	chr20:34723195	chr20:33985617~33988989:-
THCA	cis	rs11672691	0.519	rs12973063	ENSG00000270164.1	LINC01480	-4.27	2.33e-05	0.00219	-0.18	-0.19	Prostate cancer;	chr19:41503757	chr19:41535183~41536904:+
THCA	cis	rs758324	0.681	rs423957	ENSG00000237714.1	P4HA2-AS1	4.27	2.33e-05	0.00219	0.28	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131998438	chr5:132184876~132192808:+
THCA	cis	rs8081395	0.836	rs2063353	ENSG00000267302.4	RP11-178C3.2	-4.27	2.33e-05	0.00219	-0.23	-0.19	White blood cell count;	chr17:59811831	chr17:59964832~59996972:+
THCA	cis	rs10484434	0.792	rs9689245	ENSG00000272810.1	U91328.22	4.27	2.33e-05	0.00219	0.2	0.19	HIV-1 viral setpoint;	chr6:26050617	chr6:26013241~26013757:+
THCA	cis	rs10043228	1	rs62384678	ENSG00000248445.4	SEMA6A-AS1	-4.27	2.33e-05	0.00219	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116086991	chr5:116447547~116508276:+
THCA	cis	rs9863	0.931	rs4765335	ENSG00000270028.1	RP11-380L11.4	4.27	2.34e-05	0.00219	0.2	0.19	White blood cell count;	chr12:123946265	chr12:123925461~123926083:-
THCA	cis	rs801193	1	rs62466794	ENSG00000272831.1	RP11-792A8.4	4.27	2.34e-05	0.00219	0.12	0.19	Aortic root size;	chr7:66726592	chr7:66739829~66740385:-
THCA	cis	rs16975963	0.843	rs241955	ENSG00000226686.6	LINC01535	-4.27	2.34e-05	0.00219	-0.26	-0.19	Longevity;	chr19:37788037	chr19:37251912~37265535:+
THCA	cis	rs1075265	0.568	rs10865277	ENSG00000272156.1	RP11-477N3.1	4.27	2.34e-05	0.00219	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54082554~54085066:+
THCA	cis	rs3020736	0.5	rs4147641	ENSG00000237037.8	NDUFA6-AS1	4.27	2.34e-05	0.00219	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs4147640	ENSG00000237037.8	NDUFA6-AS1	4.27	2.34e-05	0.00219	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs1801311	ENSG00000237037.8	NDUFA6-AS1	4.27	2.34e-05	0.00219	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42090931~42137742:+
THCA	cis	rs1023500	0.507	rs6002600	ENSG00000237037.8	NDUFA6-AS1	4.27	2.34e-05	0.00219	0.16	0.19	Schizophrenia;	chr22:42092902	chr22:42090931~42137742:+
THCA	cis	rs8020441	1	rs68120925	ENSG00000269906.1	RP11-248J18.2	4.27	2.34e-05	0.00219	0.27	0.19	Cognitive performance;	chr14:50702540	chr14:50662511~50663178:-
THCA	cis	rs4948102	0.667	rs7811270	ENSG00000275875.1	RP11-613E4.5	-4.27	2.34e-05	0.00219	-0.23	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55741525~55741869:+
THCA	cis	rs2348418	0.67	rs899504	ENSG00000247934.4	RP11-967K21.1	-4.27	2.34e-05	0.00219	-0.17	-0.19	Lung function (FEV1);Lung function (FVC);	chr12:28118723	chr12:28163298~28190738:-
THCA	cis	rs2039553	0.546	rs9530957	ENSG00000227354.5	RBM26-AS1	-4.27	2.34e-05	0.00219	-0.18	-0.19	Pancreatic cancer;	chr13:79768909	chr13:79406309~79424328:+
THCA	cis	rs4748857	0.502	rs10828437	ENSG00000224215.1	RP11-371A19.2	-4.27	2.34e-05	0.00219	-0.22	-0.19	Systemic lupus erythematosus;	chr10:23385231	chr10:23343957~23345181:+
THCA	cis	rs7502590	1	rs72854146	ENSG00000263167.1	RP11-149I9.2	-4.27	2.34e-05	0.00219	-0.29	-0.19	Neuroticism;	chr17:81104810	chr17:81135771~81136256:+
THCA	cis	rs739496	0.615	rs847895	ENSG00000226469.1	ADAM1B	4.27	2.34e-05	0.00219	0.24	0.19	Platelet count;	chr12:111680772	chr12:111927018~111929017:+
THCA	cis	rs656319	0.605	rs13252276	ENSG00000248538.5	RP11-10A14.5	4.27	2.34e-05	0.00219	0.26	0.19	Myopia (pathological);	chr8:10047203	chr8:9189011~9202854:+
THCA	cis	rs9380516	0.627	rs6457836	ENSG00000228559.1	RP3-340B19.3	-4.27	2.34e-05	0.00219	-0.28	-0.19	Hepatitis C induced liver fibrosis;	chr6:35612521	chr6:35544632~35545669:+
THCA	cis	rs9810089	0.843	rs518972	ENSG00000273455.1	RP11-305O4.3	4.27	2.34e-05	0.00219	0.26	0.19	Gestational age at birth (child effect);	chr3:136320426	chr3:136087475~136087913:-
THCA	cis	rs2117029	0.5	rs1054442	ENSG00000258017.1	RP11-386G11.10	-4.27	2.34e-05	0.00219	-0.25	-0.19	Intelligence (multi-trait analysis);	chr12:48995537	chr12:49127782~49147869:+
THCA	cis	rs9302635	0.513	rs3902135	ENSG00000260886.1	TAT-AS1	4.27	2.34e-05	0.00219	0.25	0.19	Blood protein levels;	chr16:72141921	chr16:71565789~71578187:+
THCA	cis	rs9302635	0.513	rs35460163	ENSG00000260886.1	TAT-AS1	4.27	2.34e-05	0.00219	0.25	0.19	Blood protein levels;	chr16:72143161	chr16:71565789~71578187:+
THCA	cis	rs7186908	0.761	rs34714490	ENSG00000260886.1	TAT-AS1	4.27	2.34e-05	0.00219	0.25	0.19	Liver enzyme levels (alkaline phosphatase);	chr16:72143200	chr16:71565789~71578187:+
THCA	cis	rs800160	0.702	rs800126	ENSG00000236264.4	RPL26P30	4.27	2.34e-05	0.0022	0.26	0.19	Bacteremia;	chr11:2344351	chr11:2335132~2335776:-
THCA	cis	rs718433	0.584	rs1002180	ENSG00000211778.2	TRAV4	-4.27	2.34e-05	0.0022	-0.15	-0.19	Intraocular pressure;	chr14:21748768	chr14:21736152~21736982:+
THCA	cis	rs6517329	0.624	rs4817774	ENSG00000236830.5	CBR3-AS1	4.27	2.34e-05	0.0022	0.18	0.19	Schizophrenia;	chr21:36112344	chr21:36131767~36175815:-
THCA	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	4.27	2.34e-05	0.0022	0.21	0.19	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
THCA	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	4.27	2.34e-05	0.0022	0.21	0.19	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
THCA	cis	rs128738	0.5	rs60168911	ENSG00000237714.1	P4HA2-AS1	-4.27	2.34e-05	0.0022	-0.29	-0.19	Giant cell arteritis;	chr5:132229767	chr5:132184876~132192808:+
THCA	cis	rs875971	0.545	rs316328	ENSG00000273142.1	RP11-458F8.4	-4.27	2.34e-05	0.0022	-0.17	-0.19	Aortic root size;	chr7:66143851	chr7:66902857~66906297:+
THCA	cis	rs2749592	0.55	rs12255038	ENSG00000276805.1	RP11-291L22.6	-4.27	2.34e-05	0.0022	-0.21	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38451030~38451785:+
THCA	cis	rs2749592	0.55	rs10764135	ENSG00000276805.1	RP11-291L22.6	-4.27	2.34e-05	0.0022	-0.21	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38451030~38451785:+
THCA	cis	rs7911264	0.765	rs2421941	ENSG00000232709.1	MARK2P9	-4.27	2.34e-05	0.0022	-0.24	-0.19	Inflammatory bowel disease;	chr10:92586152	chr10:92418667~92420875:+
THCA	cis	rs786425	0.966	rs6488883	ENSG00000270095.1	RP11-214K3.18	-4.27	2.34e-05	0.0022	-0.22	-0.19	Pubertal anthropometrics;	chr12:123616800	chr12:123971457~123971714:-
THCA	cis	rs9475752	0.723	rs35942895	ENSG00000231441.1	RP11-472M19.2	4.27	2.34e-05	0.0022	0.21	0.19	Menarche (age at onset);	chr6:56904843	chr6:56844002~56864078:+
THCA	cis	rs12440869	1	rs8029582	ENSG00000270964.1	RP11-502I4.3	-4.27	2.34e-05	0.0022	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67283207	chr15:67541072~67542604:-
THCA	cis	rs62490346	0.534	rs60937041	ENSG00000261451.1	RP11-981G7.1	4.27	2.34e-05	0.0022	0.31	0.19	Chickenpox;	chr8:10365542	chr8:10433672~10438312:+
THCA	cis	rs12034383	0.967	rs7519119	ENSG00000274245.1	RP11-357P18.2	-4.27	2.34e-05	0.0022	-0.17	-0.19	Erythrocyte sedimentation rate;	chr1:207612807	chr1:207372559~207373252:+
THCA	cis	rs12034383	0.967	rs7542544	ENSG00000274245.1	RP11-357P18.2	-4.27	2.34e-05	0.0022	-0.17	-0.19	Erythrocyte sedimentation rate;	chr1:207612878	chr1:207372559~207373252:+
THCA	cis	rs758324	0.755	rs555662	ENSG00000237714.1	P4HA2-AS1	4.27	2.34e-05	0.0022	0.29	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132015210	chr5:132184876~132192808:+
THCA	cis	rs2803122	0.902	rs10757048	ENSG00000273226.1	RP11-513M16.8	-4.27	2.34e-05	0.0022	-0.18	-0.19	Pulse pressure;	chr9:19281101	chr9:19375451~19375996:+
THCA	cis	rs7572644	0.679	rs17006365	ENSG00000223522.1	AC093690.1	4.27	2.35e-05	0.0022	0.22	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27900507	chr2:28307691~28310459:-
THCA	cis	rs138249	0.699	rs138221	ENSG00000273253.2	RP3-402G11.26	-4.27	2.35e-05	0.0022	-0.19	-0.19	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50116870	chr22:50199090~50200837:-
THCA	cis	rs790006	1	rs812590	ENSG00000243024.5	RPS11P6	4.27	2.35e-05	0.0022	0.22	0.19	Response to cytidine analogues (gemcitabine);	chr12:64213702	chr12:64222337~64397065:+
THCA	cis	rs41294858	1	rs41294854	ENSG00000232876.1	CTA-212D2.2	-4.27	2.35e-05	0.0022	-0.39	-0.19	Red blood cell count;	chr6:135080233	chr6:135055033~135060550:+
THCA	cis	rs17412738	0.62	rs17185135	ENSG00000248724.5	NPHP3-AS1	-4.27	2.35e-05	0.0022	-0.34	-0.19	Blood protein levels;	chr3:132426272	chr3:132721750~132874223:+
THCA	cis	rs9880211	0.752	rs9838884	ENSG00000239213.4	NCK1-AS1	4.27	2.35e-05	0.0022	0.22	0.19	Height;Body mass index;	chr3:136736862	chr3:136841726~136862054:-
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000265443.1	CTD-2349P21.6	-4.27	2.35e-05	0.0022	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30726305~30727564:-
THCA	cis	rs793571	0.544	rs11638244	ENSG00000245975.2	RP11-30K9.6	4.27	2.35e-05	0.0022	0.18	0.19	Schizophrenia;	chr15:58614952	chr15:58768072~58770974:-
THCA	cis	rs332034	0.546	rs28823269	ENSG00000253893.2	FAM85B	4.27	2.35e-05	0.0022	0.37	0.19	Conduct disorder (maternal expressed emotions interaction);	chr8:8833007	chr8:8167819~8226614:-
THCA	cis	rs4144027	1	rs4144027	ENSG00000269940.1	RP11-73M18.7	4.27	2.35e-05	0.0022	0.2	0.19	Blood metabolite levels;	chr14:103891301	chr14:103694560~103695170:+
THCA	cis	rs7615952	0.673	rs9289270	ENSG00000248787.1	RP11-666A20.4	-4.27	2.35e-05	0.0022	-0.38	-0.19	Blood pressure (smoking interaction);	chr3:125918136	chr3:125908005~125910272:-
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.35e-05	0.0022	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.35e-05	0.0022	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30738182~30740275:+
THCA	cis	rs944289	0.646	rs408283	ENSG00000258844.1	RP11-259K15.2	4.27	2.35e-05	0.0022	0.17	0.19	Thyroid cancer;	chr14:36073503	chr14:36214607~36235608:+
THCA	cis	rs2286503	0.901	rs10950922	ENSG00000226329.2	AC005682.6	4.27	2.35e-05	0.0022	0.24	0.19	Fibrinogen;	chr7:22814387	chr7:22863874~22881350:-
THCA	cis	rs6870983	0.895	rs2728786	ENSG00000247828.6	TMEM161B-AS1	4.27	2.35e-05	0.0022	0.18	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88318202	chr5:88268895~88436685:+
THCA	cis	rs11951515	0.508	rs7706431	ENSG00000248240.1	RP11-159F24.5	-4.27	2.35e-05	0.0022	-0.21	-0.19	Metabolite levels  (X-11787);	chr5:43582321	chr5:43515274~43525310:+
THCA	cis	rs11951515	0.508	rs6898866	ENSG00000248240.1	RP11-159F24.5	-4.27	2.35e-05	0.0022	-0.21	-0.19	Metabolite levels  (X-11787);	chr5:43586273	chr5:43515274~43525310:+
THCA	cis	rs73198271	0.562	rs3827810	ENSG00000253893.2	FAM85B	4.27	2.35e-05	0.0022	0.34	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801530	chr8:8167819~8226614:-
THCA	cis	rs1790761	0.559	rs10896190	ENSG00000184224.3	C11orf72	4.27	2.35e-05	0.0022	0.26	0.19	Mean corpuscular volume;	chr11:67638652	chr11:67602880~67606706:-
THCA	cis	rs57502260	0.679	rs72936524	ENSG00000212093.1	AP000807.1	4.27	2.35e-05	0.0022	0.26	0.19	Total body bone mineral density (age 45-60);	chr11:68508430	chr11:68506083~68506166:-
THCA	cis	rs4144027	0.935	rs881056	ENSG00000269910.1	RP11-73M18.10	-4.27	2.35e-05	0.0022	-0.18	-0.19	Blood metabolite levels;	chr14:103887888	chr14:103694516~103695050:-
THCA	cis	rs860295	0.812	rs11264413	ENSG00000160766.13	GBAP1	-4.27	2.35e-05	0.0022	-0.23	-0.19	Body mass index;	chr1:155818865	chr1:155213821~155227422:-
THCA	cis	rs15676	0.783	rs2417128	ENSG00000234771.3	SLC25A25-AS1	4.27	2.35e-05	0.0022	0.16	0.19	Blood metabolite levels;	chr9:128809477	chr9:128108581~128118693:-
THCA	cis	rs481331	0.866	rs11499095	ENSG00000215146.4	RP11-313J2.1	4.27	2.35e-05	0.0022	0.3	0.19	Systemic juvenile idiopathic arthritis;	chr10:42488077	chr10:42331866~42367974:-
THCA	cis	rs481331	0.866	rs1855450	ENSG00000215146.4	RP11-313J2.1	4.27	2.35e-05	0.0022	0.3	0.19	Systemic juvenile idiopathic arthritis;	chr10:42488259	chr10:42331866~42367974:-
THCA	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-4.27	2.35e-05	0.0022	-0.22	-0.19	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
THCA	cis	rs1876905	0.764	rs9398265	ENSG00000272356.1	RP5-1112D6.8	-4.27	2.35e-05	0.0022	-0.2	-0.19	Mean corpuscular hemoglobin;	chr6:111101399	chr6:111309203~111313517:+
THCA	cis	rs3750965	1	rs12285715	ENSG00000260895.1	RP11-554A11.7	4.27	2.35e-05	0.0022	0.27	0.19	Hair color;	chr11:69054180	chr11:69103493~69109094:+
THCA	cis	rs12410462	0.591	rs72748074	ENSG00000227711.2	RP11-275O4.5	-4.27	2.35e-05	0.0022	-0.24	-0.19	Major depressive disorder;	chr1:227575585	chr1:227509028~227520477:-
THCA	cis	rs786425	0.509	rs56176939	ENSG00000270095.1	RP11-214K3.18	-4.27	2.35e-05	0.0022	-0.22	-0.19	Pubertal anthropometrics;	chr12:123700282	chr12:123971457~123971714:-
THCA	cis	rs7844233	0.579	rs10090008	ENSG00000254023.1	PKMP4	4.27	2.35e-05	0.0022	0.32	0.19	Breast cancer;	chr8:75674631	chr8:75376709~75377014:+
THCA	cis	rs734999	0.566	rs12748729	ENSG00000225931.3	RP3-395M20.7	-4.27	2.35e-05	0.0022	-0.23	-0.19	Ulcerative colitis;	chr1:2627301	chr1:2566410~2569888:+
THCA	cis	rs734999	0.545	rs12730932	ENSG00000225931.3	RP3-395M20.7	-4.27	2.35e-05	0.0022	-0.23	-0.19	Ulcerative colitis;	chr1:2628150	chr1:2566410~2569888:+
THCA	cis	rs4443100	0.67	rs8139280	ENSG00000230701.2	FBXW4P1	4.27	2.35e-05	0.00221	0.24	0.19	Serum parathyroid hormone levels;	chr22:23063779	chr22:23262767~23265005:+
THCA	cis	rs7829975	0.509	rs2945269	ENSG00000253981.4	ALG1L13P	4.27	2.35e-05	0.00221	0.18	0.19	Mood instability;	chr8:8258056	chr8:8236003~8244667:-
THCA	cis	rs2341873	0.519	rs1533297	ENSG00000204588.5	LINC01123	-4.27	2.35e-05	0.00221	-0.23	-0.19	Neutrophil percentage of white cells;	chr2:110859115	chr2:109987063~109996140:+
THCA	cis	rs332034	0.546	rs28886957	ENSG00000253893.2	FAM85B	4.27	2.35e-05	0.00221	0.37	0.19	Conduct disorder (maternal expressed emotions interaction);	chr8:8832983	chr8:8167819~8226614:-
THCA	cis	rs6088813	0.883	rs1406948	ENSG00000279253.1	RP4-614O4.13	-4.27	2.35e-05	0.00221	-0.19	-0.19	Height;	chr20:35317816	chr20:35262727~35264187:-
THCA	cis	rs453301	0.606	rs6601279	ENSG00000233609.3	RP11-62H7.2	-4.27	2.36e-05	0.00221	-0.19	-0.19	Joint mobility (Beighton score);	chr8:9050721	chr8:8961200~8979025:+
THCA	cis	rs453301	0.606	rs6981060	ENSG00000233609.3	RP11-62H7.2	-4.27	2.36e-05	0.00221	-0.19	-0.19	Joint mobility (Beighton score);	chr8:9050725	chr8:8961200~8979025:+
THCA	cis	rs10483853	0.747	rs2333193	ENSG00000258695.2	RP3-414A15.2	-4.27	2.36e-05	0.00221	-0.27	-0.19	Coronary artery calcification;	chr14:73285359	chr14:73522878~73530610:+
THCA	cis	rs8067545	0.75	rs4924805	ENSG00000270091.1	RP11-78O7.2	-4.27	2.36e-05	0.00221	-0.14	-0.19	Schizophrenia;	chr17:20093892	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs7208025	ENSG00000270091.1	RP11-78O7.2	-4.27	2.36e-05	0.00221	-0.14	-0.19	Schizophrenia;	chr17:20094557	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs7208365	ENSG00000270091.1	RP11-78O7.2	-4.27	2.36e-05	0.00221	-0.14	-0.19	Schizophrenia;	chr17:20094704	chr17:19896590~19897287:-
THCA	cis	rs1971762	0.545	rs7485472	ENSG00000270175.1	RP11-793H13.11	-4.27	2.36e-05	0.00221	-0.13	-0.19	Height;	chr12:53650654	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.545	rs9788134	ENSG00000270175.1	RP11-793H13.11	-4.27	2.36e-05	0.00221	-0.13	-0.19	Height;	chr12:53652283	chr12:53500162~53500936:-
THCA	cis	rs791590	0.941	rs11597237	ENSG00000225948.2	RP11-554I8.1	4.27	2.36e-05	0.00221	0.3	0.19	Soluble interleukin-2 receptor subunit alpha;	chr10:6037054	chr10:6618716~6625346:+
THCA	cis	rs6696239	1	rs7418348	ENSG00000227711.2	RP11-275O4.5	4.27	2.36e-05	0.00221	0.26	0.19	Height;	chr1:227533077	chr1:227509028~227520477:-
THCA	cis	rs900400	0.965	rs67261871	ENSG00000244515.1	KRT18P34	-4.27	2.36e-05	0.00221	-0.22	-0.19	circulating leptin levels adjusted for BMI;Birth weight;Menarche (age at onset);Adiponectin levels in pregnancy;circulating leptin levels;	chr3:157080152	chr3:157162663~157163932:-
THCA	cis	rs7267979	0.833	rs4619688	ENSG00000274973.1	RP13-401N8.7	-4.27	2.36e-05	0.00221	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25845497~25845862:+
THCA	cis	rs420259	0.516	rs12162020	ENSG00000260136.4	CTD-2270L9.4	4.27	2.36e-05	0.00221	0.15	0.19	Bipolar disorder;	chr16:23601870	chr16:23452758~23457606:+
THCA	cis	rs8062405	0.698	rs10499	ENSG00000261766.1	RP11-22P6.2	4.27	2.36e-05	0.00221	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28862166~28863340:-
THCA	cis	rs1204798	1	rs926829	ENSG00000237021.2	RP3-486I3.7	-4.27	2.36e-05	0.00221	-0.21	-0.19	Dental caries;	chr6:116234715	chr6:116254207~116256743:+
THCA	cis	rs10875746	0.903	rs11168414	ENSG00000258273.1	RP11-370I10.4	4.27	2.36e-05	0.00221	0.28	0.19	Longevity (90 years and older);	chr12:48118548	chr12:48333755~48333901:-
THCA	cis	rs10484434	0.901	rs56073264	ENSG00000272810.1	U91328.22	4.27	2.36e-05	0.00221	0.2	0.19	HIV-1 viral setpoint;	chr6:26079188	chr6:26013241~26013757:+
THCA	cis	rs4934494	0.727	rs2418929	ENSG00000240996.1	RP11-80H5.7	-4.27	2.36e-05	0.00221	-0.22	-0.19	Red blood cell count;	chr10:89741720	chr10:89694295~89697928:-
THCA	cis	rs860295	0.58	rs2016251	ENSG00000236675.1	MTX1P1	-4.27	2.36e-05	0.00221	-0.19	-0.19	Body mass index;	chr1:155945197	chr1:155230975~155234325:+
THCA	cis	rs701145	0.537	rs1713842	ENSG00000243069.6	ARHGEF26-AS1	-4.27	2.36e-05	0.00221	-0.36	-0.19	Coronary artery disease;	chr3:154068454	chr3:154024401~154121332:-
THCA	cis	rs758324	0.628	rs61527852	ENSG00000237714.1	P4HA2-AS1	-4.27	2.36e-05	0.00221	-0.42	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132132376	chr5:132184876~132192808:+
THCA	cis	rs758324	0.628	rs73257828	ENSG00000237714.1	P4HA2-AS1	-4.27	2.36e-05	0.00221	-0.42	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132136167	chr5:132184876~132192808:+
THCA	cis	rs12612619	0.689	rs11681145	ENSG00000229122.1	AGBL5-IT1	4.27	2.36e-05	0.00221	0.15	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27067657	chr2:27061038~27061815:+
THCA	cis	rs75059851	0.756	rs73036081	ENSG00000280237.1	MIR4697HG	4.27	2.36e-05	0.00221	0.22	0.19	Schizophrenia;	chr11:133970261	chr11:133896438~133901601:-
THCA	cis	rs75059851	0.756	rs11223649	ENSG00000280237.1	MIR4697HG	4.27	2.36e-05	0.00221	0.22	0.19	Schizophrenia;	chr11:133970576	chr11:133896438~133901601:-
THCA	cis	rs75059851	0.756	rs56241440	ENSG00000280237.1	MIR4697HG	4.27	2.36e-05	0.00221	0.22	0.19	Schizophrenia;	chr11:133970935	chr11:133896438~133901601:-
THCA	cis	rs13256369	0.951	rs12679360	ENSG00000254153.1	CTA-398F10.2	4.27	2.36e-05	0.00221	0.22	0.19	Obesity-related traits;	chr8:8708759	chr8:8456909~8461337:-
THCA	cis	rs4685724	0.65	rs1385467	ENSG00000223727.5	AC026188.1	4.27	2.36e-05	0.00221	0.27	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr3:3982184	chr3:3250687~3627296:-
THCA	cis	rs4908768	0.906	rs55858268	ENSG00000232912.4	RP5-1115A15.1	-4.27	2.36e-05	0.00221	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8494636	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.906	rs12568293	ENSG00000232912.4	RP5-1115A15.1	4.27	2.36e-05	0.00221	0.23	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480852	chr1:8424645~8434838:+
THCA	cis	rs1032466	1	rs1032466	ENSG00000270062.1	RP11-248J18.3	4.27	2.36e-05	0.00221	0.23	0.19	Dupuytren's disease;	chr14:50607743	chr14:50723777~50724272:-
THCA	cis	rs2692947	0.537	rs11679899	ENSG00000235959.1	AC009237.17	-4.27	2.36e-05	0.00221	-0.21	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712414	chr2:95640181~95640604:-
THCA	cis	rs6860806	0.507	rs2631372	ENSG00000237714.1	P4HA2-AS1	4.27	2.36e-05	0.00221	0.26	0.19	Breast cancer;	chr5:132367886	chr5:132184876~132192808:+
THCA	cis	rs7267979	0.744	rs6050463	ENSG00000277938.1	RP5-965G21.3	4.27	2.36e-05	0.00221	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25229150~25231933:+
THCA	cis	rs7181230	0.961	rs7183977	ENSG00000275636.1	RP11-521C20.5	-4.27	2.36e-05	0.00221	-0.2	-0.19	Dehydroepiandrosterone sulphate levels;	chr15:40084891	chr15:40078892~40079347:+
THCA	cis	rs4934494	0.689	rs17127596	ENSG00000240996.1	RP11-80H5.7	4.27	2.36e-05	0.00221	0.21	0.19	Red blood cell count;	chr10:89816128	chr10:89694295~89697928:-
THCA	cis	rs35740288	0.731	rs12913556	ENSG00000259295.5	CSPG4P12	4.27	2.36e-05	0.00221	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85558965	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.731	rs35085180	ENSG00000259295.5	CSPG4P12	4.27	2.36e-05	0.00221	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85559381	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.77	rs75039806	ENSG00000259295.5	CSPG4P12	4.27	2.36e-05	0.00221	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561813	chr15:85191438~85213905:+
THCA	cis	rs7474896	0.778	rs11011440	ENSG00000263064.2	RP11-291L22.7	4.27	2.36e-05	0.00221	0.33	0.19	Obesity (extreme);	chr10:38075213	chr10:38448689~38448949:+
THCA	cis	rs9847710	1	rs12488768	ENSG00000242142.1	SERBP1P3	-4.27	2.36e-05	0.00221	-0.22	-0.19	Ulcerative colitis;	chr3:53052218	chr3:53064283~53065091:-
THCA	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	4.27	2.36e-05	0.00221	0.22	0.19	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
THCA	cis	rs7015630	0.866	rs12675822	ENSG00000251136.7	RP11-37B2.1	4.27	2.37e-05	0.00222	0.17	0.19	Inflammatory bowel disease;Crohn's disease;	chr8:89855255	chr8:89609409~89757727:-
THCA	cis	rs11665867	1	rs11672227	ENSG00000279108.1	CTC-490E21.11	-4.27	2.37e-05	0.00222	-0.27	-0.19	Hematocrit;	chr19:40770981	chr19:40840159~40842039:+
THCA	cis	rs57502260	0.704	rs72936570	ENSG00000212093.1	AP000807.1	4.27	2.37e-05	0.00222	0.26	0.19	Total body bone mineral density (age 45-60);	chr11:68539671	chr11:68506083~68506166:-
THCA	cis	rs57502260	0.704	rs72936599	ENSG00000212093.1	AP000807.1	4.27	2.37e-05	0.00222	0.26	0.19	Total body bone mineral density (age 45-60);	chr11:68552937	chr11:68506083~68506166:-
THCA	cis	rs12440869	1	rs12439028	ENSG00000270964.1	RP11-502I4.3	4.27	2.37e-05	0.00222	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67286617	chr15:67541072~67542604:-
THCA	cis	rs1923243	0.71	rs11210143	ENSG00000223479.3	RP4-788P17.1	4.27	2.37e-05	0.00222	0.21	0.19	Migraine;	chr1:73144347	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4391625	ENSG00000223479.3	RP4-788P17.1	4.27	2.37e-05	0.00222	0.21	0.19	Migraine;	chr1:73144531	chr1:73635216~73715214:+
THCA	cis	rs3764021	0.527	rs10844427	ENSG00000214776.8	RP11-726G1.1	4.27	2.37e-05	0.00222	0.25	0.19	Type 1 diabetes;	chr12:9681798	chr12:9467552~9576275:+
THCA	cis	rs6840258	0.64	rs3193672	ENSG00000251411.1	RP11-397E7.4	-4.27	2.37e-05	0.00222	-0.23	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87161955	chr4:86913266~86914817:-
THCA	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	4.27	2.37e-05	0.00222	0.27	0.19	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
THCA	cis	rs875971	0.545	rs73150604	ENSG00000273142.1	RP11-458F8.4	4.27	2.37e-05	0.00222	0.18	0.19	Aortic root size;	chr7:66480545	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000273142.1	RP11-458F8.4	4.27	2.37e-05	0.00222	0.18	0.19	Aortic root size;	chr7:66481592	chr7:66902857~66906297:+
THCA	cis	rs7190458	0.522	rs72787110	ENSG00000261783.1	RP11-252K23.2	4.27	2.37e-05	0.00222	0.46	0.19	Pancreatic cancer;	chr16:75345635	chr16:75379818~75381260:-
THCA	cis	rs160451	0.811	rs218943	ENSG00000251136.7	RP11-37B2.1	-4.27	2.37e-05	0.00222	-0.17	-0.19	Leprosy;	chr8:89701113	chr8:89609409~89757727:-
THCA	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	4.27	2.37e-05	0.00222	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	4.27	2.37e-05	0.00222	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
THCA	cis	rs4664293	0.74	rs12464577	ENSG00000230783.1	AC009961.2	4.27	2.37e-05	0.00222	0.24	0.19	Monocyte percentage of white cells;	chr2:159816321	chr2:159689217~159690291:-
THCA	cis	rs57502260	0.68	rs7104806	ENSG00000212093.1	AP000807.1	4.27	2.37e-05	0.00222	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68454720	chr11:68506083~68506166:-
THCA	cis	rs4682868	0.611	rs734969	ENSG00000273328.4	RP11-141M3.6	-4.27	2.37e-05	0.00222	-0.23	-0.19	Monocyte percentage of white cells;	chr3:42876414	chr3:42809414~42908105:+
THCA	cis	rs2281603	0.57	rs4632045	ENSG00000272909.1	CTD-2555O16.4	-4.27	2.37e-05	0.00222	-0.23	-0.19	Lymphocyte counts;	chr14:64496408	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs12050238	ENSG00000272909.1	CTD-2555O16.4	-4.27	2.37e-05	0.00222	-0.23	-0.19	Lymphocyte counts;	chr14:64498157	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs12050358	ENSG00000272909.1	CTD-2555O16.4	-4.27	2.37e-05	0.00222	-0.23	-0.19	Lymphocyte counts;	chr14:64499986	chr14:64440369~64442238:-
THCA	cis	rs1842579	0.965	rs6677315	ENSG00000272691.1	RP11-290M5.4	-4.27	2.37e-05	0.00222	-0.2	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85805120	chr1:85578500~85578742:-
THCA	cis	rs181553	0.532	rs2044550	ENSG00000266696.1	RP11-30L3.2	-4.27	2.37e-05	0.00222	-0.25	-0.19	Hip circumference adjusted for BMI;	chr18:49055730	chr18:49205912~49208781:+
THCA	cis	rs1790761	0.692	rs611663	ENSG00000255318.1	RP11-655M14.13	4.27	2.37e-05	0.00222	0.21	0.19	Mean corpuscular volume;	chr11:67544750	chr11:67618279~67627304:-
THCA	cis	rs7924176	0.601	rs2131957	ENSG00000213731.2	RAB5CP1	-4.27	2.37e-05	0.00222	-0.23	-0.19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107171	chr10:74423435~74424014:-
THCA	cis	rs2070488	1	rs7373805	ENSG00000229589.1	ACVR2B-AS1	4.27	2.37e-05	0.00222	0.18	0.19	Electrocardiographic conduction measures;	chr3:38413948	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs13074160	ENSG00000229589.1	ACVR2B-AS1	4.27	2.37e-05	0.00222	0.18	0.19	Electrocardiographic conduction measures;	chr3:38414159	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs13074025	ENSG00000229589.1	ACVR2B-AS1	4.27	2.37e-05	0.00222	0.18	0.19	Electrocardiographic conduction measures;	chr3:38414213	chr3:38451027~38454820:-
THCA	cis	rs2070488	1	rs4147025	ENSG00000229589.1	ACVR2B-AS1	4.27	2.37e-05	0.00222	0.18	0.19	Electrocardiographic conduction measures;	chr3:38415040	chr3:38451027~38454820:-
THCA	cis	rs613391	1	rs613391	ENSG00000224549.1	RP11-370B11.3	4.27	2.37e-05	0.00222	0.23	0.19	Quantitative traits;	chr9:22670716	chr9:22767175~22768316:+
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000273712.1	RP5-874C20.7	4.27	2.37e-05	0.00222	0.21	0.19	Pubertal anthropometrics;	chr6:28259100	chr6:28315613~28315883:-
THCA	cis	rs7267979	0.844	rs35735333	ENSG00000277938.1	RP5-965G21.3	-4.27	2.37e-05	0.00222	-0.16	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25229150~25231933:+
THCA	cis	rs10496034	0.541	rs28710338	ENSG00000237887.1	AC092839.1	-4.27	2.37e-05	0.00222	-0.37	-0.19	Refractive astigmatism;	chr2:54655576	chr2:54529343~54529801:+
THCA	cis	rs2434529	1	rs61189725	ENSG00000245275.6	SAP30L-AS1	4.27	2.37e-05	0.00222	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154257588	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs7733778	ENSG00000245275.6	SAP30L-AS1	4.27	2.37e-05	0.00222	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154261518	chr5:154329437~154445850:-
THCA	cis	rs11633886	0.835	rs4774769	ENSG00000259200.1	RP11-718O11.1	-4.27	2.37e-05	0.00222	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45806495	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.835	rs4774770	ENSG00000259200.1	RP11-718O11.1	-4.27	2.37e-05	0.00222	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45806692	chr15:45705078~45931069:+
THCA	cis	rs7260598	0.539	rs11878343	ENSG00000268442.1	CTD-2027I19.2	4.27	2.37e-05	0.00222	0.29	0.19	Response to taxane treatment (placlitaxel);	chr19:23874804	chr19:24162370~24163425:-
THCA	cis	rs6940638	0.688	rs1028308	ENSG00000219392.1	RP1-265C24.5	-4.27	2.37e-05	0.00222	-0.23	-0.19	Intelligence (multi-trait analysis);	chr6:27161978	chr6:28115628~28116551:+
THCA	cis	rs758324	0.648	rs31473	ENSG00000224431.1	AC063976.7	-4.27	2.37e-05	0.00222	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132068753	chr5:132199456~132203487:+
THCA	cis	rs2436845	0.627	rs1062048	ENSG00000253320.4	KB-1507C5.2	-4.27	2.37e-05	0.00222	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102838824	chr8:102864300~102977876:+
THCA	cis	rs12428035	0.764	rs9525077	ENSG00000247400.3	DNAJC3-AS1	4.27	2.37e-05	0.00222	0.18	0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95888539	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs1330556	ENSG00000247400.3	DNAJC3-AS1	4.27	2.37e-05	0.00222	0.18	0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95889589	chr13:95648733~95676925:-
THCA	cis	rs11658311	0.85	rs73295699	ENSG00000232344.2	AC087163.2	4.27	2.37e-05	0.00222	0.28	0.19	Obsessive-compulsive symptoms;	chr17:17776735	chr17:18010643~18011822:+
THCA	cis	rs11658311	0.85	rs8066159	ENSG00000232344.2	AC087163.2	4.27	2.37e-05	0.00222	0.28	0.19	Obsessive-compulsive symptoms;	chr17:17777405	chr17:18010643~18011822:+
THCA	cis	rs11658311	0.85	rs8066177	ENSG00000232344.2	AC087163.2	4.27	2.37e-05	0.00222	0.28	0.19	Obsessive-compulsive symptoms;	chr17:17777431	chr17:18010643~18011822:+
THCA	cis	rs6517329	0.674	rs1543655	ENSG00000230212.5	AP000688.14	-4.27	2.37e-05	0.00222	-0.25	-0.19	Schizophrenia;	chr21:36111076	chr21:36069642~36126640:-
THCA	cis	rs10256972	0.567	rs2949185	ENSG00000225146.1	AC073957.15	4.27	2.37e-05	0.00222	0.21	0.19	Endometriosis;Longevity;	chr7:1169377	chr7:1029025~1043891:+
THCA	cis	rs7216064	1	rs62085992	ENSG00000278740.1	RP11-147L13.14	4.27	2.37e-05	0.00222	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67926967	chr17:68188547~68189165:+
THCA	cis	rs7923609	0.756	rs7080386	ENSG00000232075.1	MRPL35P2	-4.27	2.37e-05	0.00222	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63288546	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.778	rs7075195	ENSG00000232075.1	MRPL35P2	-4.27	2.37e-05	0.00222	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63290899	chr10:63634317~63634827:-
THCA	cis	rs7665090	0.728	rs227275	ENSG00000230069.3	LRRC37A15P	4.27	2.37e-05	0.00222	0.2	0.19	Primary biliary cholangitis;	chr4:102672741	chr4:102727274~102730721:-
THCA	cis	rs2822388	0.744	rs11701640	ENSG00000228314.1	CYP4F29P	-4.27	2.38e-05	0.00222	-0.38	-0.19	Stroke;	chr21:14062617	chr21:13843133~13848364:-
THCA	cis	rs1728785	1	rs12918865	ENSG00000274698.1	RP11-71L14.4	4.27	2.38e-05	0.00222	0.27	0.19	Ulcerative colitis;	chr16:68532643	chr16:68450283~68452318:+
THCA	cis	rs7178424	0.774	rs7172145	ENSG00000259251.2	RP11-643M14.1	4.27	2.38e-05	0.00222	0.2	0.19	Height;	chr15:61947498	chr15:62060503~62062434:+
THCA	cis	rs17685	0.712	rs60721456	ENSG00000230882.1	AC005077.14	4.27	2.38e-05	0.00222	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76114502	chr7:76071469~76074963:-
THCA	cis	rs2933343	0.601	rs1680759	ENSG00000231305.3	RP11-723O4.2	4.27	2.38e-05	0.00222	0.21	0.19	IgG glycosylation;	chr3:128876053	chr3:128861313~128871540:-
THCA	cis	rs35740288	0.77	rs10520592	ENSG00000259295.5	CSPG4P12	4.27	2.38e-05	0.00222	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85570911	chr15:85191438~85213905:+
THCA	cis	rs17507216	0.628	rs28607761	ENSG00000255769.6	GOLGA2P10	-4.27	2.38e-05	0.00222	-0.29	-0.19	Excessive daytime sleepiness;	chr15:82715317	chr15:82472993~82513950:-
THCA	cis	rs7577696	0.785	rs11683110	ENSG00000276334.1	AL133243.1	-4.27	2.38e-05	0.00223	-0.21	-0.19	Inflammatory biomarkers;	chr2:32124744	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.752	rs12614686	ENSG00000276334.1	AL133243.1	-4.27	2.38e-05	0.00223	-0.21	-0.19	Inflammatory biomarkers;	chr2:32138102	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.785	rs11683842	ENSG00000276334.1	AL133243.1	-4.27	2.38e-05	0.00223	-0.21	-0.19	Inflammatory biomarkers;	chr2:32139062	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.785	rs11689817	ENSG00000276334.1	AL133243.1	-4.27	2.38e-05	0.00223	-0.21	-0.19	Inflammatory biomarkers;	chr2:32139172	chr2:32521927~32523547:+
THCA	cis	rs722599	0.715	rs11851433	ENSG00000279594.1	RP11-950C14.10	4.27	2.38e-05	0.00223	0.2	0.19	IgG glycosylation;	chr14:74872747	chr14:75011269~75012851:-
THCA	cis	rs793571	0.502	rs387812	ENSG00000245975.2	RP11-30K9.6	4.27	2.38e-05	0.00223	0.18	0.19	Schizophrenia;	chr15:58782587	chr15:58768072~58770974:-
THCA	cis	rs793571	0.502	rs421829	ENSG00000245975.2	RP11-30K9.6	4.27	2.38e-05	0.00223	0.18	0.19	Schizophrenia;	chr15:58787703	chr15:58768072~58770974:-
THCA	cis	rs10911902	0.602	rs10494583	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186321363	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs28715477	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186326392	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs74537283	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186328038	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs3736597	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186331918	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs16825183	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186336861	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs3766704	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186342710	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.567	rs76557279	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186344161	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs2272412	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186345817	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs6667940	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186350448	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs6664763	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186357043	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs6689129	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186357078	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs16825243	ENSG00000229739.2	RP11-295K2.3	-4.27	2.38e-05	0.00223	-0.29	-0.19	Schizophrenia;	chr1:186357769	chr1:186435161~186470291:+
THCA	cis	rs804280	0.509	rs13268030	ENSG00000206014.6	OR7E161P	-4.27	2.38e-05	0.00223	-0.23	-0.19	Myopia (pathological);	chr8:11925564	chr8:11928597~11929563:-
THCA	cis	rs801193	0.569	rs10950050	ENSG00000229886.1	RP5-1132H15.3	4.27	2.38e-05	0.00223	0.2	0.19	Aortic root size;	chr7:66774601	chr7:66025126~66031544:-
THCA	cis	rs73787773	0.8	rs78788069	ENSG00000246859.2	STARD4-AS1	4.27	2.38e-05	0.00223	0.29	0.19	Itch intensity from mosquito bite adjusted by bite size;	chr5:112120886	chr5:111512226~111739726:+
THCA	cis	rs7267979	0.844	rs6115188	ENSG00000277938.1	RP5-965G21.3	4.27	2.38e-05	0.00223	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25229150~25231933:+
THCA	cis	rs60180747	1	rs35510028	ENSG00000261318.1	RP11-653J6.1	4.27	2.38e-05	0.00223	0.25	0.19	Testicular germ cell tumor;	chr15:66319741	chr15:66278498~66293357:-
THCA	cis	rs786425	0.866	rs7302449	ENSG00000270095.1	RP11-214K3.18	-4.27	2.38e-05	0.00223	-0.22	-0.19	Pubertal anthropometrics;	chr12:123688199	chr12:123971457~123971714:-
THCA	cis	rs1559040	0.932	rs55672362	ENSG00000272156.1	RP11-477N3.1	-4.27	2.38e-05	0.00223	-0.32	-0.19	Sudden cardiac arrest;	chr2:54130615	chr2:54082554~54085066:+
THCA	cis	rs7521681	0.775	rs10494074	ENSG00000230489.1	VAV3-AS1	-4.27	2.38e-05	0.00223	-0.23	-0.19	Asthma and hay fever;	chr1:107787388	chr1:107964443~107994607:+
THCA	cis	rs7746199	0.736	rs34064842	ENSG00000220721.1	OR1F12	4.27	2.38e-05	0.00223	0.43	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28073316~28074233:+
THCA	cis	rs6560517	0.813	rs2251604	ENSG00000234618.1	RPSAP9	4.27	2.38e-05	0.00223	0.2	0.19	Dialysis-related mortality;	chr9:76392895	chr9:76398699~76399586:+
THCA	cis	rs5751901	0.614	rs6519519	ENSG00000215481.7	BCRP3	-4.27	2.38e-05	0.00223	-0.17	-0.19	Protein quantitative trait loci;	chr22:24595896	chr22:24632915~24653356:+
THCA	cis	rs2790457	0.874	rs1265840	ENSG00000254635.4	WAC-AS1	-4.27	2.38e-05	0.00223	-0.19	-0.19	Multiple myeloma;	chr10:28630712	chr10:28522652~28532743:-
THCA	cis	rs9309711	0.544	rs9752130	ENSG00000271868.1	RP11-1293J14.1	-4.27	2.38e-05	0.00223	-0.26	-0.19	Neurofibrillary tangles;	chr2:3484731	chr2:3496956~3497428:+
THCA	cis	rs2522056	1	rs7730247	ENSG00000237714.1	P4HA2-AS1	-4.27	2.38e-05	0.00223	-0.28	-0.19	Fibrinogen;Lymphocyte counts;	chr5:132445596	chr5:132184876~132192808:+
THCA	cis	rs2562456	0.833	rs11880624	ENSG00000268117.1	VN1R84P	4.27	2.38e-05	0.00223	0.3	0.19	Pain;	chr19:21341028	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62107547	ENSG00000268117.1	VN1R84P	4.27	2.38e-05	0.00223	0.3	0.19	Pain;	chr19:21341245	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs56187954	ENSG00000268117.1	VN1R84P	4.27	2.38e-05	0.00223	0.3	0.19	Pain;	chr19:21345258	chr19:21719801~21720035:-
THCA	cis	rs10875746	0.551	rs10875799	ENSG00000226413.2	OR8T1P	4.27	2.38e-05	0.00223	0.28	0.19	Longevity (90 years and older);	chr12:48347096	chr12:48442030~48442947:-
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000275400.1	RP4-756H11.5	-4.27	2.38e-05	0.00223	-0.21	-0.19	Corneal structure;	chr7:66894282	chr7:66553805~66554199:-
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000275400.1	RP4-756H11.5	-4.27	2.38e-05	0.00223	-0.21	-0.19	Corneal structure;	chr7:66896631	chr7:66553805~66554199:-
THCA	cis	rs9959145	1	rs28815517	ENSG00000267108.1	RP11-861E21.1	4.27	2.38e-05	0.00223	0.23	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12558747	chr18:12432897~12437635:+
THCA	cis	rs4713118	0.513	rs149955	ENSG00000261839.1	RP1-265C24.8	4.27	2.38e-05	0.00223	0.2	0.19	Parkinson's disease;	chr6:28068447	chr6:28136849~28139678:+
THCA	cis	rs2239815	0.515	rs5762829	ENSG00000272858.1	CTA-292E10.8	-4.27	2.38e-05	0.00223	-0.23	-0.19	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28832142	chr22:28814914~28815662:+
THCA	cis	rs7267979	0.966	rs6050611	ENSG00000274973.1	RP13-401N8.7	-4.27	2.38e-05	0.00223	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25845497~25845862:+
THCA	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-4.27	2.38e-05	0.00223	-0.21	-0.19	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
THCA	cis	rs4886920	0.862	rs35020526	ENSG00000260776.4	RP11-114H24.2	-4.27	2.38e-05	0.00223	-0.22	-0.19	Neuroticism;	chr15:77845520	chr15:77914217~77926846:-
THCA	cis	rs271738	0.779	rs271763	ENSG00000231768.1	LINC01354	-4.27	2.38e-05	0.00223	-0.22	-0.19	Bipolar disorder;	chr1:234535219	chr1:234527891~234531779:-
THCA	cis	rs9902453	0.933	rs8080343	ENSG00000263370.1	RP11-68I3.5	4.27	2.38e-05	0.00223	0.24	0.19	Coffee consumption (cups per day);	chr17:30129740	chr17:29639627~29640825:+
THCA	cis	rs12134133	0.962	rs7516416	ENSG00000237074.1	RP11-6J21.2	4.27	2.38e-05	0.00223	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.962	rs6673890	ENSG00000237074.1	RP11-6J21.2	4.27	2.38e-05	0.00223	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207249067~207309121:+
THCA	cis	rs9393813	1	rs6913166	ENSG00000204789.4	ZNF204P	-4.27	2.38e-05	0.00223	-0.15	-0.19	Bipolar disorder;	chr6:27387681	chr6:27357825~27360221:-
THCA	cis	rs12612619	0.761	rs34732613	ENSG00000272148.1	RP11-195B17.1	4.27	2.38e-05	0.00223	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27031928	chr2:27062428~27062907:-
THCA	cis	rs7959452	0.64	rs4761154	ENSG00000274979.1	RP11-1143G9.5	4.27	2.38e-05	0.00223	0.21	0.19	Blood protein levels;	chr12:69311582	chr12:69326574~69331882:-
THCA	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	4.27	2.39e-05	0.00223	0.23	0.19	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	4.27	2.39e-05	0.00223	0.23	0.19	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	4.27	2.39e-05	0.00223	0.23	0.19	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	4.27	2.39e-05	0.00223	0.23	0.19	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	4.27	2.39e-05	0.00223	0.23	0.19	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
THCA	cis	rs288326	0.561	rs79074459	ENSG00000272800.1	RP11-438L19.1	4.27	2.39e-05	0.00223	0.35	0.19	Blood protein levels;	chr2:182902370	chr2:183214319~183215400:+
THCA	cis	rs7918232	0.941	rs7096505	ENSG00000262412.1	RP11-85G18.6	4.27	2.39e-05	0.00223	0.29	0.19	Breast cancer;	chr10:27038070	chr10:27243130~27250804:+
THCA	cis	rs758324	0.717	rs3916444	ENSG00000237714.1	P4HA2-AS1	-4.27	2.39e-05	0.00223	-0.29	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132019259	chr5:132184876~132192808:+
THCA	cis	rs4819052	0.851	rs1056100	ENSG00000182586.6	LINC00334	-4.27	2.39e-05	0.00223	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45234340~45258730:+
THCA	cis	rs181553	0.961	rs10853575	ENSG00000266696.1	RP11-30L3.2	-4.27	2.39e-05	0.00223	-0.24	-0.19	Hip circumference adjusted for BMI;	chr18:49033349	chr18:49205912~49208781:+
THCA	cis	rs8064024	0.508	rs2037912	ENSG00000267077.1	RP11-127I20.5	-4.27	2.39e-05	0.00223	-0.22	-0.19	Cancer;	chr16:4883938	chr16:4795265~4796532:-
THCA	cis	rs2153535	0.518	rs9393051	ENSG00000230939.1	RP11-314C16.1	-4.27	2.39e-05	0.00223	-0.21	-0.19	Motion sickness;	chr6:8638726	chr6:8784178~8785445:+
THCA	cis	rs893363	0.539	rs3774614	ENSG00000271916.1	RP11-884K10.6	-4.27	2.39e-05	0.00223	-0.21	-0.19	Axial length;	chr3:53807437	chr3:53797764~53798019:-
THCA	cis	rs142472947	1	rs142472947	ENSG00000232912.4	RP5-1115A15.1	-4.27	2.39e-05	0.00223	-0.24	-0.19	White blood cell count;	chr1:8460430	chr1:8424645~8434838:+
THCA	cis	rs7216064	0.953	rs11868959	ENSG00000278740.1	RP11-147L13.14	4.27	2.39e-05	0.00223	0.23	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844694	chr17:68188547~68189165:+
THCA	cis	rs75059851	0.756	rs11223659	ENSG00000280237.1	MIR4697HG	4.27	2.39e-05	0.00223	0.22	0.19	Schizophrenia;	chr11:133974813	chr11:133896438~133901601:-
THCA	cis	rs2380205	0.935	rs2380200	ENSG00000232807.2	RP11-536K7.3	4.27	2.39e-05	0.00223	0.18	0.19	Breast cancer;	chr10:5852976	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs9732607	ENSG00000232807.2	RP11-536K7.3	4.27	2.39e-05	0.00223	0.18	0.19	Breast cancer;	chr10:5853138	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs11255555	ENSG00000232807.2	RP11-536K7.3	4.27	2.39e-05	0.00223	0.18	0.19	Breast cancer;	chr10:5853398	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.875	rs10795592	ENSG00000232807.2	RP11-536K7.3	4.27	2.39e-05	0.00223	0.18	0.19	Breast cancer;	chr10:5853792	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs11255558	ENSG00000232807.2	RP11-536K7.3	4.27	2.39e-05	0.00223	0.18	0.19	Breast cancer;	chr10:5854429	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.935	rs7901964	ENSG00000232807.2	RP11-536K7.3	4.27	2.39e-05	0.00223	0.18	0.19	Breast cancer;	chr10:5854938	chr10:5934270~5945900:-
THCA	cis	rs7829975	0.742	rs7832968	ENSG00000254340.1	RP11-10A14.3	4.27	2.39e-05	0.00223	0.21	0.19	Mood instability;	chr8:8795379	chr8:9141424~9145435:+
THCA	cis	rs2898290	0.622	rs17799486	ENSG00000251402.3	FAM90A25P	-4.27	2.39e-05	0.00223	-0.25	-0.19	Systolic blood pressure;	chr8:11482985	chr8:12415080~12418090:-
THCA	cis	rs1728785	1	rs1099296	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68554750	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1645927	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68555397	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1728765	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68555530	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs6499181	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68559099	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs1728787	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68559139	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1645938	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68561294	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1364109	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68561602	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1728789	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68561873	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1615609	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68562498	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1728792	ENSG00000274698.1	RP11-71L14.4	4.27	2.39e-05	0.00223	0.27	0.19	Ulcerative colitis;	chr16:68562631	chr16:68450283~68452318:+
THCA	cis	rs5769765	0.671	rs138844	ENSG00000260613.1	RP3-522J7.6	-4.27	2.39e-05	0.00224	-0.24	-0.19	Schizophrenia;	chr22:49790836	chr22:49832616~49837786:-
THCA	cis	rs10946940	0.864	rs13201411	ENSG00000216915.2	RP1-97D16.1	4.27	2.39e-05	0.00224	0.26	0.19	Systemic lupus erythematosus;	chr6:27530438	chr6:27737000~27738494:-
THCA	cis	rs6565653	0.901	rs7216510	ENSG00000262580.4	RP11-334C17.5	4.27	2.39e-05	0.00224	0.17	0.19	Ischemic stroke;	chr17:80226111	chr17:80200673~80205949:-
THCA	cis	rs6565653	0.934	rs7209632	ENSG00000262580.4	RP11-334C17.5	4.27	2.39e-05	0.00224	0.17	0.19	Ischemic stroke;	chr17:80226114	chr17:80200673~80205949:-
THCA	cis	rs734999	0.588	rs6668149	ENSG00000225931.3	RP3-395M20.7	-4.27	2.39e-05	0.00224	-0.23	-0.19	Ulcerative colitis;	chr1:2626869	chr1:2566410~2569888:+
THCA	cis	rs2562152	0.706	rs216596	ENSG00000226942.2	IL9RP3	-4.27	2.39e-05	0.00224	-0.25	-0.19	Glioblastoma;	chr16:55320	chr16:29336~38321:-
THCA	cis	rs3734266	0.702	rs6941453	ENSG00000272288.4	RP11-140K17.3	-4.27	2.39e-05	0.00224	-0.19	-0.19	Systemic lupus erythematosus;	chr6:34756118	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.639	rs7743724	ENSG00000272288.4	RP11-140K17.3	-4.27	2.39e-05	0.00224	-0.19	-0.19	Systemic lupus erythematosus;	chr6:34757701	chr6:34696317~34697470:+
THCA	cis	rs442309	0.901	rs224033	ENSG00000238280.1	RP11-436D10.3	-4.27	2.39e-05	0.00224	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62762354	chr10:62793562~62805887:-
THCA	cis	rs801193	0.967	rs3800823	ENSG00000272831.1	RP11-792A8.4	-4.27	2.39e-05	0.00224	-0.12	-0.19	Aortic root size;	chr7:66682123	chr7:66739829~66740385:-
THCA	cis	rs8006682	0.503	rs8010235	ENSG00000259038.1	CTD-2325P2.4	4.27	2.39e-05	0.00224	0.24	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68618406	chr14:68627166~68628445:-
THCA	cis	rs10090774	0.71	rs13275969	ENSG00000280303.2	ERICD	-4.27	2.39e-05	0.00224	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140663317	chr8:140636281~140638283:+
THCA	cis	rs9876781	1	rs9311423	ENSG00000244380.1	RP11-24C3.2	4.27	2.39e-05	0.00224	0.23	0.19	Longevity;	chr3:48378818	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs7634377	ENSG00000244380.1	RP11-24C3.2	4.27	2.39e-05	0.00224	0.23	0.19	Longevity;	chr3:48379768	chr3:48440352~48446656:-
THCA	cis	rs17095355	0.818	rs11194981	ENSG00000203876.8	ADD3-AS1	-4.27	2.39e-05	0.00224	-0.21	-0.19	Biliary atresia;	chr10:110101296	chr10:109940104~110008381:-
THCA	cis	rs7838490	0.58	rs13274549	ENSG00000253553.4	RP11-586K2.1	4.27	2.39e-05	0.00224	0.2	0.19	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88509279	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs11989139	ENSG00000253553.4	RP11-586K2.1	4.27	2.39e-05	0.00224	0.2	0.19	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88510492	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs35528030	ENSG00000253553.4	RP11-586K2.1	4.27	2.39e-05	0.00224	0.2	0.19	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88510841	chr8:88326836~88737134:+
THCA	cis	rs2281603	0.57	rs11625265	ENSG00000272909.1	CTD-2555O16.4	-4.27	2.39e-05	0.00224	-0.23	-0.19	Lymphocyte counts;	chr14:64510603	chr14:64440369~64442238:-
THCA	cis	rs11722228	1	rs6823877	ENSG00000261490.1	RP11-448G15.3	-4.27	2.39e-05	0.00224	-0.13	-0.19	Urate levels;Serum uric acid levels;Gout;	chr4:9920307	chr4:10068089~10073019:-
THCA	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	4.27	2.39e-05	0.00224	0.23	0.19	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
THCA	cis	rs74233809	1	rs943037	ENSG00000272912.1	RP11-724N1.1	-4.27	2.39e-05	0.00224	-0.36	-0.19	Birth weight;	chr10:103076162	chr10:102914585~102915404:+
THCA	cis	rs9341808	0.539	rs2490253	ENSG00000272129.1	RP11-250B2.6	4.27	2.4e-05	0.00224	0.24	0.19	Sitting height ratio;	chr6:80186153	chr6:80355424~80356859:+
THCA	cis	rs7432375	0.901	rs6802702	ENSG00000273455.1	RP11-305O4.3	-4.27	2.4e-05	0.00224	-0.26	-0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136770721	chr3:136087475~136087913:-
THCA	cis	rs793571	0.784	rs28800895	ENSG00000245975.2	RP11-30K9.6	4.27	2.4e-05	0.00224	0.21	0.19	Schizophrenia;	chr15:58792837	chr15:58768072~58770974:-
THCA	cis	rs6494488	0.5	rs58590788	ENSG00000259635.1	AC100830.3	-4.27	2.4e-05	0.00224	-0.46	-0.19	Coronary artery disease;	chr15:64667418	chr15:64701248~64719602:+
THCA	cis	rs2414856	0.504	rs67465716	ENSG00000259635.1	AC100830.3	-4.27	2.4e-05	0.00224	-0.46	-0.19	Pulse pressure;Systolic blood pressure;	chr15:64668415	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs113248293	ENSG00000259635.1	AC100830.3	-4.27	2.4e-05	0.00224	-0.46	-0.19	Coronary artery disease;	chr15:64668552	chr15:64701248~64719602:+
THCA	cis	rs6472235	0.586	rs34464051	ENSG00000272010.1	CTD-3025N20.3	-4.27	2.4e-05	0.00224	-0.21	-0.19	Plateletcrit;Myopia (pathological);	chr8:65989769	chr8:65591850~65592472:-
THCA	cis	rs2380205	1	rs867052	ENSG00000232807.2	RP11-536K7.3	4.27	2.4e-05	0.00224	0.18	0.19	Breast cancer;	chr10:5845220	chr10:5934270~5945900:-
THCA	cis	rs4792901	0.959	rs12603053	ENSG00000267151.3	RP11-100E5.2	4.27	2.4e-05	0.00224	0.2	0.19	Dupuytren's disease;	chr17:43550924	chr17:43444707~43451200:+
THCA	cis	rs3002142	0.908	rs3008606	ENSG00000272750.1	RP11-378J18.8	-4.27	2.4e-05	0.00224	-0.26	-0.19	LDL peak particle diameter (total fat intake interaction);	chr1:222611351	chr1:222658867~222661512:-
THCA	cis	rs16852403	0.583	rs964993	ENSG00000224687.1	RASAL2-AS1	4.27	2.4e-05	0.00224	0.32	0.19	Childhood ear infection;	chr1:178093224	chr1:178091508~178093984:-
THCA	cis	rs2549003	1	rs3846732	ENSG00000237714.1	P4HA2-AS1	-4.27	2.4e-05	0.00224	-0.24	-0.19	Asthma (sex interaction);	chr5:132480395	chr5:132184876~132192808:+
THCA	cis	rs7746199	0.673	rs72847313	ENSG00000272009.1	RP1-313I6.12	-4.27	2.4e-05	0.00224	-0.37	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.611	rs17750747	ENSG00000272009.1	RP1-313I6.12	-4.27	2.4e-05	0.00224	-0.37	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28078792~28081130:-
THCA	cis	rs944289	0.966	rs1182929	ENSG00000258844.1	RP11-259K15.2	4.27	2.4e-05	0.00224	0.18	0.19	Thyroid cancer;	chr14:36165946	chr14:36214607~36235608:+
THCA	cis	rs9902453	0.933	rs2054846	ENSG00000263370.1	RP11-68I3.5	-4.27	2.4e-05	0.00224	-0.25	-0.19	Coffee consumption (cups per day);	chr17:30180675	chr17:29639627~29640825:+
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000182586.6	LINC00334	-4.27	2.4e-05	0.00224	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45234340~45258730:+
THCA	cis	rs11671005	0.652	rs11670864	ENSG00000269600.1	AC016629.3	-4.27	2.4e-05	0.00224	-0.28	-0.19	Mean platelet volume;	chr19:58519213	chr19:58593896~58599355:-
THCA	cis	rs9926296	0.632	rs9935559	ENSG00000260259.1	RP11-368I7.4	4.27	2.4e-05	0.00224	0.21	0.19	Vitiligo;	chr16:89734121	chr16:89682620~89686569:-
THCA	cis	rs1048886	0.872	rs7741265	ENSG00000271967.1	RP11-134K13.4	-4.27	2.4e-05	0.00224	-0.21	-0.19	Type 2 diabetes;	chr6:70575675	chr6:70596438~70596980:+
THCA	cis	rs10875746	1	rs10875746	ENSG00000258273.1	RP11-370I10.4	4.27	2.4e-05	0.00224	0.26	0.19	Longevity (90 years and older);	chr12:48124481	chr12:48333755~48333901:-
THCA	cis	rs1707322	0.896	rs946528	ENSG00000281133.1	AL355480.3	4.27	2.4e-05	0.00224	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45580892~45580996:-
THCA	cis	rs6088590	1	rs11696546	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.4e-05	0.00225	-0.18	-0.19	Coronary artery disease;	chr20:34865196	chr20:33985617~33988989:-
THCA	cis	rs875971	0.666	rs13242072	ENSG00000272831.1	RP11-792A8.4	-4.27	2.4e-05	0.00225	-0.12	-0.19	Aortic root size;	chr7:66301001	chr7:66739829~66740385:-
THCA	cis	rs2120243	0.539	rs1869859	ENSG00000241770.1	RP11-555M1.3	-4.27	2.4e-05	0.00225	-0.25	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157389973	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.508	rs1965246	ENSG00000241770.1	RP11-555M1.3	-4.27	2.4e-05	0.00225	-0.25	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157393797	chr3:157163452~157169133:+
THCA	cis	rs2657294	0.965	rs2657285	ENSG00000233313.2	HMGA1P5	-4.27	2.4e-05	0.00225	-0.25	-0.19	Pneumonia;	chr10:75164166	chr10:75276376~75276646:-
THCA	cis	rs1908814	0.516	rs4840597	ENSG00000206014.6	OR7E161P	-4.27	2.4e-05	0.00225	-0.23	-0.19	Neuroticism;	chr8:11938559	chr8:11928597~11929563:-
THCA	cis	rs804280	0.509	rs4841639	ENSG00000206014.6	OR7E161P	-4.27	2.4e-05	0.00225	-0.23	-0.19	Myopia (pathological);	chr8:11938584	chr8:11928597~11929563:-
THCA	cis	rs60733400	0.782	rs4648564	ENSG00000225931.3	RP3-395M20.7	-4.27	2.4e-05	0.00225	-0.23	-0.19	Multiple sclerosis;	chr1:2630730	chr1:2566410~2569888:+
THCA	cis	rs8027521	0.666	rs4776197	ENSG00000280362.1	RP11-643A5.3	4.27	2.4e-05	0.00225	0.24	0.19	Circulating chemerin levels;	chr15:53976878	chr15:53910769~53914712:+
THCA	cis	rs2439831	0.681	rs1095386	ENSG00000166763.7	STRCP1	4.27	2.4e-05	0.00225	0.26	0.19	Lung cancer in ever smokers;	chr15:43317311	chr15:43699488~43718184:-
THCA	cis	rs2980439	0.517	rs17594065	ENSG00000233609.3	RP11-62H7.2	-4.27	2.4e-05	0.00225	-0.19	-0.19	Neuroticism;	chr8:8247883	chr8:8961200~8979025:+
THCA	cis	rs28829049	0.597	rs12740975	ENSG00000270728.1	RP4-657E11.10	-4.27	2.4e-05	0.00225	-0.14	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19111429	chr1:19297080~19297903:+
THCA	cis	rs9863	0.861	rs10846579	ENSG00000269997.1	RP11-214K3.21	-4.27	2.41e-05	0.00225	-0.24	-0.19	White blood cell count;	chr12:123922856	chr12:123966077~123966629:-
THCA	cis	rs9863	0.861	rs11057394	ENSG00000269997.1	RP11-214K3.21	-4.27	2.41e-05	0.00225	-0.24	-0.19	White blood cell count;	chr12:123923129	chr12:123966077~123966629:-
THCA	cis	rs9863	0.861	rs12809125	ENSG00000269997.1	RP11-214K3.21	-4.27	2.41e-05	0.00225	-0.24	-0.19	White blood cell count;	chr12:123923444	chr12:123966077~123966629:-
THCA	cis	rs7647973	0.769	rs4974081	ENSG00000229759.1	MRPS18AP1	-4.27	2.41e-05	0.00225	-0.3	-0.19	Menarche (age at onset);	chr3:49033066	chr3:48256350~48256938:-
THCA	cis	rs67478160	0.654	rs1535097	ENSG00000269940.1	RP11-73M18.7	4.27	2.41e-05	0.00225	0.18	0.19	Schizophrenia;	chr14:103750312	chr14:103694560~103695170:+
THCA	cis	rs6442522	0.56	rs924812	ENSG00000249786.6	EAF1-AS1	4.27	2.41e-05	0.00225	0.2	0.19	Uric acid levels;	chr3:15474974	chr3:15436171~15455940:-
THCA	cis	rs6442522	0.56	rs3816526	ENSG00000249786.6	EAF1-AS1	4.27	2.41e-05	0.00225	0.2	0.19	Uric acid levels;	chr3:15475403	chr3:15436171~15455940:-
THCA	cis	rs786425	0.966	rs786444	ENSG00000270095.1	RP11-214K3.18	-4.27	2.41e-05	0.00225	-0.22	-0.19	Pubertal anthropometrics;	chr12:123580869	chr12:123971457~123971714:-
THCA	cis	rs4664304	0.62	rs3951216	ENSG00000226266.5	AC009961.3	-4.27	2.41e-05	0.00225	-0.23	-0.19	Crohn's disease;Inflammatory bowel disease;	chr2:159854534	chr2:159670708~159712435:-
THCA	cis	rs3740713	1	rs73440634	ENSG00000256464.1	YWHABP2	4.27	2.41e-05	0.00225	0.34	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18451999	chr11:18490243~18490955:-
THCA	cis	rs123509	0.913	rs339685	ENSG00000173811.9	CCDC13-AS1	4.27	2.41e-05	0.00225	0.22	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42741460	chr3:42732575~42746768:+
THCA	cis	rs6600671	1	rs4844616	ENSG00000270231.3	NBPF8P	4.27	2.41e-05	0.00225	0.17	0.19	Hip geometry;	chr1:121429348	chr1:120436353~120467739:+
THCA	cis	rs17801127	0.901	rs34550472	ENSG00000231969.1	AC144449.1	4.27	2.41e-05	0.00225	0.4	0.19	Liver enzyme levels (alanine transaminase);	chr2:149685555	chr2:149587196~149848233:+
THCA	cis	rs7772486	0.754	rs697055	ENSG00000270638.1	RP3-466P17.1	4.27	2.41e-05	0.00225	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145735570~145737218:+
THCA	cis	rs17772222	0.675	rs845769	ENSG00000222990.1	RNU4-22P	-4.27	2.41e-05	0.00225	-0.23	-0.19	Coronary artery calcification;	chr14:88461455	chr14:88513498~88513663:+
THCA	cis	rs3824488	0.667	rs112191650	ENSG00000271155.1	RP11-435O5.5	-4.27	2.41e-05	0.00225	-0.37	-0.19	Neuroticism;	chr9:95442321	chr9:95506235~95507636:+
THCA	cis	rs6449502	0.92	rs11951606	ENSG00000251279.1	CTC-436P18.1	4.27	2.41e-05	0.00225	0.32	0.19	Mean platelet volume;	chr5:61076755	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs13357828	ENSG00000251279.1	CTC-436P18.1	4.27	2.41e-05	0.00225	0.32	0.19	Mean platelet volume;	chr5:61080588	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs114260952	ENSG00000251279.1	CTC-436P18.1	4.27	2.41e-05	0.00225	0.32	0.19	Mean platelet volume;	chr5:61093668	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs295567	ENSG00000251279.1	CTC-436P18.1	4.27	2.41e-05	0.00225	0.32	0.19	Mean platelet volume;	chr5:61101819	chr5:61162070~61232040:+
THCA	cis	rs56313388	0.522	rs8063856	ENSG00000246379.5	RP11-461O7.1	-4.27	2.41e-05	0.00225	-0.2	-0.19	Pulse pressure;	chr16:56143768	chr16:56092987~56191094:-
THCA	cis	rs9467773	1	rs2255070	ENSG00000228223.2	HCG11	-4.27	2.41e-05	0.00225	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26501549	chr6:26523450~26526579:+
THCA	cis	rs36093844	0.66	rs12274717	ENSG00000279742.1	RP11-700A24.1	-4.27	2.41e-05	0.00225	-0.28	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866671	chr11:85852557~85854943:-
THCA	cis	rs875971	0.867	rs1002053	ENSG00000229886.1	RP5-1132H15.3	-4.27	2.41e-05	0.00225	-0.2	-0.19	Aortic root size;	chr7:66333558	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs6460292	ENSG00000229886.1	RP5-1132H15.3	-4.27	2.41e-05	0.00225	-0.2	-0.19	Aortic root size;	chr7:66345088	chr7:66025126~66031544:-
THCA	cis	rs4568518	0.501	rs6966247	ENSG00000279048.1	RP11-511H23.2	4.27	2.41e-05	0.00225	0.12	0.19	Measles;	chr7:17949624	chr7:17940503~17942922:+
THCA	cis	rs28829049	0.597	rs34215816	ENSG00000270728.1	RP4-657E11.10	-4.27	2.41e-05	0.00225	-0.14	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19107459	chr1:19297080~19297903:+
THCA	cis	rs4664293	0.541	rs1863218	ENSG00000230783.1	AC009961.2	4.27	2.41e-05	0.00225	0.24	0.19	Monocyte percentage of white cells;	chr2:159512276	chr2:159689217~159690291:-
THCA	cis	rs812925	0.519	rs2463099	ENSG00000270820.4	RP11-355B11.2	-4.27	2.41e-05	0.00225	-0.16	-0.19	Immature fraction of reticulocytes;	chr2:61391176	chr2:61471188~61484130:+
THCA	cis	rs4767841	0.935	rs7131914	ENSG00000252886.1	RN7SKP197	-4.27	2.41e-05	0.00225	-0.19	-0.19	Urgency urinary incontinence;	chr12:119717772	chr12:119631090~119631386:-
THCA	cis	rs7572644	0.699	rs7577342	ENSG00000223522.1	AC093690.1	-4.27	2.41e-05	0.00225	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27982714	chr2:28307691~28310459:-
THCA	cis	rs3809566	0.637	rs8026047	ENSG00000259459.4	RP11-321G12.1	4.27	2.41e-05	0.00225	0.17	0.19	Platelet count;	chr15:63031148	chr15:63390136~63438320:+
THCA	cis	rs1577917	0.545	rs1832070	ENSG00000220563.1	PKMP3	4.27	2.41e-05	0.00225	0.14	0.19	Response to antipsychotic treatment;	chr6:85773454	chr6:85659892~85660606:-
THCA	cis	rs2299587	0.527	rs10112643	ENSG00000253671.1	RP11-806O11.1	-4.27	2.41e-05	0.00225	-0.22	-0.19	Economic and political preferences;	chr8:17868510	chr8:17808941~17820868:+
THCA	cis	rs2380205	0.967	rs4256891	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5846095	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.935	rs3954757	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5846103	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs4287254	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5846178	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs7897260	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5846464	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs7907795	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5846817	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs7903875	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5846822	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs7898059	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5847075	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs10795590	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5847123	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs10905307	ENSG00000232807.2	RP11-536K7.3	4.27	2.41e-05	0.00225	0.18	0.19	Breast cancer;	chr10:5852537	chr10:5934270~5945900:-
THCA	cis	rs7809950	1	rs10273733	ENSG00000238832.1	snoU109	4.27	2.41e-05	0.00225	0.21	0.19	Coronary artery disease;	chr7:107617676	chr7:107603363~107603507:+
THCA	cis	rs4434872	0.536	rs34579266	ENSG00000223599.1	RP11-216N14.7	-4.27	2.41e-05	0.00225	-0.37	-0.19	Conduct disorder (symptom count);	chr1:153900567	chr1:153852106~153853414:-
THCA	cis	rs61270009	0.955	rs6874182	ENSG00000247828.6	TMEM161B-AS1	4.27	2.41e-05	0.00225	0.17	0.19	Depressive symptoms;	chr5:88407268	chr5:88268895~88436685:+
THCA	cis	rs7829975	0.742	rs882462	ENSG00000233609.3	RP11-62H7.2	4.27	2.41e-05	0.00225	0.19	0.19	Mood instability;	chr8:8821020	chr8:8961200~8979025:+
THCA	cis	rs10833905	1	rs11026883	ENSG00000246225.5	RP11-17A1.3	-4.27	2.41e-05	0.00225	-0.28	-0.19	Sudden cardiac arrest;	chr11:22997005	chr11:22829380~22945393:+
THCA	cis	rs910873	0.505	rs6059969	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.41e-05	0.00225	-0.24	-0.19	Melanoma;	chr20:34657480	chr20:33985617~33988989:-
THCA	cis	rs910873	0.505	rs6058099	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.41e-05	0.00225	-0.24	-0.19	Melanoma;	chr20:34661330	chr20:33985617~33988989:-
THCA	cis	rs2154427	1	rs2833963	ENSG00000238197.4	PAXBP1-AS1	4.27	2.41e-05	0.00225	0.19	0.19	Bilirubin levels;	chr21:32803243	chr21:32728115~32743122:+
THCA	cis	rs12022452	1	rs3738471	ENSG00000237899.1	RP4-739H11.3	-4.27	2.41e-05	0.00225	-0.32	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40669089~40687588:-
THCA	cis	rs2298450	0.593	rs2835326	ENSG00000214867.3	SRSF9P1	4.27	2.41e-05	0.00226	0.25	0.19	Schizophrenia;	chr21:36243433	chr21:36295173~36295702:-
THCA	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	4.27	2.41e-05	0.00226	0.22	0.19	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
THCA	cis	rs3177980	0.564	rs10919252	ENSG00000239494.2	RN7SL333P	-4.27	2.41e-05	0.00226	-0.18	-0.19	Amyotrophic lateral sclerosis;	chr1:169833815	chr1:169859756~169860052:+
THCA	cis	rs3027234	0.724	rs11651453	ENSG00000271002.1	RP11-599B13.8	-4.27	2.41e-05	0.00226	-0.3	-0.19	Telomere length;	chr17:8200377	chr17:8199123~8199437:-
THCA	cis	rs6449502	0.92	rs6871236	ENSG00000251279.1	CTC-436P18.1	4.27	2.41e-05	0.00226	0.32	0.19	Mean platelet volume;	chr5:61075348	chr5:61162070~61232040:+
THCA	cis	rs66782572	1	rs66782572	ENSG00000243224.1	RP5-1157M23.2	-4.27	2.42e-05	0.00226	-0.2	-0.19	Hemoglobin concentration;	chr3:52533601	chr3:52239258~52241097:+
THCA	cis	rs11633886	0.835	rs8041150	ENSG00000259200.1	RP11-718O11.1	-4.27	2.42e-05	0.00226	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45803848	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.869	rs8040361	ENSG00000259200.1	RP11-718O11.1	-4.27	2.42e-05	0.00226	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45803893	chr15:45705078~45931069:+
THCA	cis	rs9341808	0.667	rs2505929	ENSG00000272129.1	RP11-250B2.6	4.27	2.42e-05	0.00226	0.25	0.19	Sitting height ratio;	chr6:80124491	chr6:80355424~80356859:+
THCA	cis	rs4693089	0.604	rs12639933	ENSG00000213608.5	SLC25A14P1	4.27	2.42e-05	0.00226	0.22	0.19	Menopause (age at onset);	chr4:83450999	chr4:83477524~83478424:+
THCA	cis	rs2822388	0.744	rs116889051	ENSG00000215559.7	ANKRD20A11P	-4.27	2.42e-05	0.00226	-0.39	-0.19	Stroke;	chr21:14056106	chr21:13909574~13980437:-
THCA	cis	rs2822388	0.59	rs117422362	ENSG00000215559.7	ANKRD20A11P	-4.27	2.42e-05	0.00226	-0.39	-0.19	Stroke;	chr21:14063419	chr21:13909574~13980437:-
THCA	cis	rs7045881	0.8	rs16910873	ENSG00000254396.1	RP11-56F10.3	-4.27	2.42e-05	0.00226	-0.35	-0.19	Schizophrenia;	chr9:26904701	chr9:27102630~27104728:+
THCA	cis	rs2243480	1	rs1404147	ENSG00000232559.3	GS1-124K5.12	4.27	2.42e-05	0.00226	0.27	0.19	Diabetic kidney disease;	chr7:65799537	chr7:66554588~66576923:-
THCA	cis	rs7560272	0.538	rs12233115	ENSG00000163016.8	ALMS1P	-4.27	2.42e-05	0.00226	-0.24	-0.19	Schizophrenia;	chr2:73704764	chr2:73644919~73685576:+
THCA	cis	rs7560272	0.538	rs11126414	ENSG00000163016.8	ALMS1P	-4.27	2.42e-05	0.00226	-0.24	-0.19	Schizophrenia;	chr2:73704917	chr2:73644919~73685576:+
THCA	cis	rs6686643	1	rs959617	ENSG00000236206.1	RP11-306I1.2	4.26	2.42e-05	0.00226	0.26	0.19	Total ventricular volume;	chr1:165647644	chr1:165598463~165623331:+
THCA	cis	rs1124769	0.719	rs1147140	ENSG00000259378.1	DCAF13P3	-4.26	2.42e-05	0.00226	-0.29	-0.19	Cognitive performance;	chr15:50878226	chr15:50944663~50945996:+
THCA	cis	rs6496044	0.568	rs2880764	ENSG00000259630.2	CTD-2262B20.1	-4.26	2.42e-05	0.00226	-0.21	-0.19	Interstitial lung disease;	chr15:85513177	chr15:85415228~85415633:+
THCA	cis	rs62458065	0.513	rs10265319	ENSG00000231952.3	DPY19L1P2	4.26	2.42e-05	0.00226	0.32	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32531952	chr7:32812757~32838570:+
THCA	cis	rs896854	0.608	rs6991067	ENSG00000253528.2	RP11-347C18.4	4.26	2.42e-05	0.00226	0.22	0.19	Type 2 diabetes;	chr8:94863448	chr8:94974573~94974853:-
THCA	cis	rs8067545	0.611	rs9898080	ENSG00000270091.1	RP11-78O7.2	-4.26	2.42e-05	0.00226	-0.15	-0.19	Schizophrenia;	chr17:20131944	chr17:19896590~19897287:-
THCA	cis	rs35740288	0.929	rs11073537	ENSG00000259295.5	CSPG4P12	4.26	2.42e-05	0.00226	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85769450	chr15:85191438~85213905:+
THCA	cis	rs6496044	0.568	rs11632326	ENSG00000259630.2	CTD-2262B20.1	-4.26	2.42e-05	0.00226	-0.21	-0.19	Interstitial lung disease;	chr15:85536603	chr15:85415228~85415633:+
THCA	cis	rs1842579	1	rs6576792	ENSG00000272691.1	RP11-290M5.4	-4.26	2.42e-05	0.00226	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85820755	chr1:85578500~85578742:-
THCA	cis	rs11220082	0.666	rs2241514	ENSG00000254671.2	STT3A-AS1	-4.26	2.42e-05	0.00226	-0.23	-0.19	Schizophrenia;	chr11:125456130	chr11:125570284~125592568:-
THCA	cis	rs2898290	0.622	rs13272061	ENSG00000251402.3	FAM90A25P	-4.26	2.42e-05	0.00226	-0.25	-0.19	Systolic blood pressure;	chr8:11494752	chr8:12415080~12418090:-
THCA	cis	rs12497850	0.931	rs7647813	ENSG00000228638.1	FCF1P2	-4.26	2.42e-05	0.00226	-0.21	-0.19	Parkinson's disease;	chr3:48795915	chr3:48290793~48291375:-
THCA	cis	rs7246657	0.551	rs28462002	ENSG00000226686.6	LINC01535	-4.26	2.42e-05	0.00226	-0.34	-0.19	Coronary artery calcification;	chr19:37143560	chr19:37251912~37265535:+
THCA	cis	rs4434872	0.536	rs12033532	ENSG00000223599.1	RP11-216N14.7	-4.26	2.42e-05	0.00226	-0.36	-0.19	Conduct disorder (symptom count);	chr1:153916344	chr1:153852106~153853414:-
THCA	cis	rs4218	0.569	rs73418864	ENSG00000259732.1	RP11-59H7.3	-4.26	2.42e-05	0.00226	-0.26	-0.19	Social communication problems;	chr15:59098996	chr15:59121034~59133250:+
THCA	cis	rs7572733	0.534	rs700685	ENSG00000231621.1	AC013264.2	-4.26	2.42e-05	0.00227	-0.2	-0.19	Dermatomyositis;	chr2:197851248	chr2:197197991~197199273:+
THCA	cis	rs9902453	0.709	rs6505162	ENSG00000263370.1	RP11-68I3.5	4.26	2.43e-05	0.00227	0.25	0.19	Coffee consumption (cups per day);	chr17:30117165	chr17:29639627~29640825:+
THCA	cis	rs6517329	0.576	rs7283730	ENSG00000230212.5	AP000688.14	-4.26	2.43e-05	0.00227	-0.24	-0.19	Schizophrenia;	chr21:36123076	chr21:36069642~36126640:-
THCA	cis	rs8062405	0.728	rs11642449	ENSG00000261766.1	RP11-22P6.2	-4.26	2.43e-05	0.00227	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28862166~28863340:-
THCA	cis	rs1046896	0.561	rs8076476	ENSG00000263063.1	RP11-388C12.1	-4.26	2.43e-05	0.00227	-0.25	-0.19	Glycated hemoglobin levels;	chr17:82903141	chr17:82713908~82716255:-
THCA	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-4.26	2.43e-05	0.00227	-0.21	-0.19	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
THCA	cis	rs8062405	0.728	rs8056890	ENSG00000270424.1	RP11-1348G14.6	4.26	2.43e-05	0.00227	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28749959~28750595:-
THCA	cis	rs4713118	0.513	rs149972	ENSG00000261839.1	RP1-265C24.8	4.26	2.43e-05	0.00227	0.2	0.19	Parkinson's disease;	chr6:28015449	chr6:28136849~28139678:+
THCA	cis	rs453301	0.653	rs1562211	ENSG00000254340.1	RP11-10A14.3	-4.26	2.43e-05	0.00227	-0.2	-0.19	Joint mobility (Beighton score);	chr8:9044914	chr8:9141424~9145435:+
THCA	cis	rs6121246	0.909	rs6119729	ENSG00000230613.1	HM13-AS1	-4.26	2.43e-05	0.00227	-0.21	-0.19	Mean corpuscular hemoglobin;	chr20:31825360	chr20:31567707~31573263:-
THCA	cis	rs2153535	0.585	rs58117210	ENSG00000230939.1	RP11-314C16.1	-4.26	2.43e-05	0.00227	-0.2	-0.19	Motion sickness;	chr6:8603881	chr6:8784178~8785445:+
THCA	cis	rs5752326	0.51	rs3213583	ENSG00000261188.1	CTA-445C9.14	4.26	2.43e-05	0.00227	0.2	0.19	Ischemic stroke;	chr22:26465579	chr22:26512537~26514568:+
THCA	cis	rs911555	0.723	rs6575986	ENSG00000269958.1	RP11-73M18.8	4.26	2.43e-05	0.00227	0.18	0.19	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103696353~103697163:+
THCA	cis	rs786425	0.655	rs114208992	ENSG00000270095.1	RP11-214K3.18	-4.26	2.43e-05	0.00227	-0.23	-0.19	Pubertal anthropometrics;	chr12:123684695	chr12:123971457~123971714:-
THCA	cis	rs10489167	1	rs12060189	ENSG00000237899.1	RP4-739H11.3	-4.26	2.43e-05	0.00227	-0.35	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40694609	chr1:40669089~40687588:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000275400.1	RP4-756H11.5	-4.26	2.43e-05	0.00227	-0.18	-0.19	Calcium levels;	chr7:65975383	chr7:66553805~66554199:-
THCA	cis	rs2039553	0.603	rs35516506	ENSG00000227354.5	RBM26-AS1	-4.26	2.43e-05	0.00227	-0.18	-0.19	Pancreatic cancer;	chr13:79793597	chr13:79406309~79424328:+
THCA	cis	rs7267979	0.816	rs6115094	ENSG00000277938.1	RP5-965G21.3	4.26	2.43e-05	0.00227	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25229150~25231933:+
THCA	cis	rs758324	0.628	rs2405266	ENSG00000237714.1	P4HA2-AS1	-4.26	2.43e-05	0.00227	-0.42	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132131038	chr5:132184876~132192808:+
THCA	cis	rs758324	0.628	rs13358835	ENSG00000237714.1	P4HA2-AS1	-4.26	2.43e-05	0.00227	-0.42	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132138477	chr5:132184876~132192808:+
THCA	cis	rs7809799	0.571	rs17161687	ENSG00000244219.5	GS1-259H13.2	4.26	2.43e-05	0.00227	0.4	0.19	Ulcerative colitis;	chr7:99344286	chr7:99598066~99610813:+
THCA	cis	rs962856	0.619	rs6731934	ENSG00000236780.4	AC078941.1	4.26	2.43e-05	0.00227	0.26	0.19	Pancreatic cancer;	chr2:67332421	chr2:67123357~67215319:-
THCA	cis	rs36093844	0.706	rs11828105	ENSG00000279742.1	RP11-700A24.1	-4.26	2.43e-05	0.00227	-0.29	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85839341	chr11:85852557~85854943:-
THCA	cis	rs755249	0.958	rs61781370	ENSG00000237624.1	OXCT2P1	4.26	2.43e-05	0.00227	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39514956~39516490:+
THCA	cis	rs12681288	0.862	rs7015529	ENSG00000260721.1	AF067845.1	4.26	2.43e-05	0.00227	0.24	0.19	Schizophrenia;	chr8:1070249	chr8:1368642~1369833:-
THCA	cis	rs123509	0.687	rs17238972	ENSG00000173811.9	CCDC13-AS1	-4.26	2.43e-05	0.00227	-0.22	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42778483	chr3:42732575~42746768:+
THCA	cis	rs718433	0.584	rs10438076	ENSG00000211778.2	TRAV4	-4.26	2.43e-05	0.00227	-0.15	-0.19	Intraocular pressure;	chr14:21741785	chr14:21736152~21736982:+
THCA	cis	rs1055129	0.56	rs9302994	ENSG00000267801.1	RP11-552F3.9	4.26	2.44e-05	0.00227	0.23	0.19	White matter hyperintensity burden;	chr17:75910853	chr17:75876372~75879546:+
THCA	cis	rs4934494	0.513	rs3824603	ENSG00000232936.4	RP11-80H5.2	4.26	2.44e-05	0.00227	0.24	0.19	Red blood cell count;	chr10:89583850	chr10:89645282~89650667:+
THCA	cis	rs7267979	0.844	rs4815413	ENSG00000277938.1	RP5-965G21.3	-4.26	2.44e-05	0.00227	-0.16	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.844	rs6083824	ENSG00000277938.1	RP5-965G21.3	-4.26	2.44e-05	0.00227	-0.16	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.844	rs6076343	ENSG00000277938.1	RP5-965G21.3	-4.26	2.44e-05	0.00227	-0.16	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25229150~25231933:+
THCA	cis	rs4794202	0.836	rs4794204	ENSG00000264920.1	RP11-6N17.4	-4.26	2.44e-05	0.00228	-0.23	-0.19	Alzheimer's disease (cognitive decline);	chr17:47860421	chr17:47891255~47895812:-
THCA	cis	rs4794202	0.836	rs62066132	ENSG00000264920.1	RP11-6N17.4	-4.26	2.44e-05	0.00228	-0.23	-0.19	Alzheimer's disease (cognitive decline);	chr17:47860557	chr17:47891255~47895812:-
THCA	cis	rs7587476	0.689	rs10498025	ENSG00000229267.2	AC072062.1	-4.26	2.44e-05	0.00228	-0.24	-0.19	Neuroblastoma;	chr2:214884532	chr2:214810229~214963274:+
THCA	cis	rs6730558	0.966	rs3856447	ENSG00000236008.1	AC011747.4	4.26	2.44e-05	0.00228	0.22	0.19	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8610136	chr2:8559833~8583792:-
THCA	cis	rs875971	0.862	rs10274883	ENSG00000229886.1	RP5-1132H15.3	-4.26	2.44e-05	0.00228	-0.2	-0.19	Aortic root size;	chr7:66651104	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs881285	ENSG00000229886.1	RP5-1132H15.3	-4.26	2.44e-05	0.00228	-0.2	-0.19	Aortic root size;	chr7:66654433	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs3846973	ENSG00000229886.1	RP5-1132H15.3	-4.26	2.44e-05	0.00228	-0.2	-0.19	Aortic root size;	chr7:66655048	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs2013908	ENSG00000229886.1	RP5-1132H15.3	-4.26	2.44e-05	0.00228	-0.2	-0.19	Aortic root size;	chr7:66656082	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs2707824	ENSG00000229886.1	RP5-1132H15.3	4.26	2.44e-05	0.00228	0.2	0.19	Aortic root size;	chr7:66724256	chr7:66025126~66031544:-
THCA	cis	rs1232027	0.656	rs1677655	ENSG00000249655.1	CTC-325J23.2	4.26	2.44e-05	0.00228	0.22	0.19	Huntington's disease progression;	chr5:80672677	chr5:80630313~80631590:-
THCA	cis	rs12234571	1	rs75330800	ENSG00000214293.7	APTR	4.26	2.44e-05	0.00228	0.27	0.19	Obesity-related traits;	chr7:77831103	chr7:77657660~77696265:-
THCA	cis	rs2434529	1	rs1422785	ENSG00000245275.6	SAP30L-AS1	4.26	2.44e-05	0.00228	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154277673	chr5:154329437~154445850:-
THCA	cis	rs7577696	0.785	rs7592356	ENSG00000276334.1	AL133243.1	-4.26	2.44e-05	0.00228	-0.21	-0.19	Inflammatory biomarkers;	chr2:32145275	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.785	rs11694630	ENSG00000276334.1	AL133243.1	-4.26	2.44e-05	0.00228	-0.21	-0.19	Inflammatory biomarkers;	chr2:32151132	chr2:32521927~32523547:+
THCA	cis	rs4295623	0.556	rs10903343	ENSG00000270154.1	RP11-419I17.1	4.26	2.44e-05	0.00228	0.24	0.19	Morning vs. evening chronotype;	chr8:11838363	chr8:12476462~12477122:+
THCA	cis	rs9307551	0.817	rs7667469	ENSG00000249646.2	OR7E94P	-4.26	2.44e-05	0.00228	-0.24	-0.19	Refractive error;	chr4:79576538	chr4:79587302~79588130:-
THCA	cis	rs4950322	0.515	rs72691016	ENSG00000180867.10	PDIA3P1	4.26	2.44e-05	0.00228	0.19	0.19	Protein quantitative trait loci;	chr1:147245375	chr1:147178113~147179622:+
THCA	cis	rs9543976	0.614	rs4885308	ENSG00000261105.4	LMO7-AS1	-4.26	2.44e-05	0.00228	-0.34	-0.19	Diabetic retinopathy;	chr13:75532357	chr13:75604700~75635994:-
THCA	cis	rs2298450	0.574	rs1023367	ENSG00000214867.3	SRSF9P1	4.26	2.44e-05	0.00228	0.25	0.19	Schizophrenia;	chr21:36247426	chr21:36295173~36295702:-
THCA	cis	rs6430538	0.621	rs2156003	ENSG00000224043.6	CCNT2-AS1	-4.26	2.44e-05	0.00228	-0.21	-0.19	Parkinson's disease;	chr2:134811678	chr2:134735464~134918710:-
THCA	cis	rs5758659	0.714	rs5758574	ENSG00000281538.1	RP4-669P10.20	-4.26	2.44e-05	0.00228	-0.18	-0.19	Cognitive function;	chr22:42085396	chr22:42138060~42139726:+
THCA	cis	rs9283706	0.655	rs10052743	ENSG00000229666.1	MAST4-AS1	-4.26	2.44e-05	0.00228	-0.27	-0.19	Coronary artery disease;	chr5:66997717	chr5:67001383~67003953:-
THCA	cis	rs34421088	0.532	rs2409754	ENSG00000154316.13	TDH	-4.26	2.44e-05	0.00228	-0.15	-0.19	Neuroticism;	chr8:11298104	chr8:11339637~11368452:+
THCA	cis	rs1113500	0.73	rs1343203	ENSG00000230489.1	VAV3-AS1	-4.26	2.44e-05	0.00228	-0.18	-0.19	Growth-regulated protein alpha levels;	chr1:108048560	chr1:107964443~107994607:+
THCA	cis	rs1728785	0.818	rs11075684	ENSG00000274698.1	RP11-71L14.4	4.26	2.44e-05	0.00228	0.27	0.19	Ulcerative colitis;	chr16:68548462	chr16:68450283~68452318:+
THCA	cis	rs6517329	0.564	rs7282393	ENSG00000236830.5	CBR3-AS1	-4.26	2.44e-05	0.00228	-0.18	-0.19	Schizophrenia;	chr21:36157708	chr21:36131767~36175815:-
THCA	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	4.26	2.44e-05	0.00228	0.21	0.19	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
THCA	cis	rs7923609	0.846	rs7073753	ENSG00000232075.1	MRPL35P2	-4.26	2.45e-05	0.00228	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63303060	chr10:63634317~63634827:-
THCA	cis	rs78487399	0.634	rs6751035	ENSG00000234936.1	AC010883.5	4.26	2.45e-05	0.00228	0.27	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43525268	chr2:43229573~43233394:+
THCA	cis	rs6840258	0.64	rs28882732	ENSG00000251411.1	RP11-397E7.4	-4.26	2.45e-05	0.00228	-0.23	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87154824	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.582	rs7437661	ENSG00000251411.1	RP11-397E7.4	-4.26	2.45e-05	0.00228	-0.23	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87156860	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.582	rs1021104	ENSG00000251411.1	RP11-397E7.4	-4.26	2.45e-05	0.00228	-0.23	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87157017	chr4:86913266~86914817:-
THCA	cis	rs11096990	0.821	rs2711991	ENSG00000249685.1	RP11-360F5.3	-4.26	2.45e-05	0.00228	-0.25	-0.19	Cognitive function;	chr4:39149733	chr4:39133913~39135608:+
THCA	cis	rs4664304	0.739	rs66814375	ENSG00000226266.5	AC009961.3	4.26	2.45e-05	0.00228	0.23	0.19	Crohn's disease;Inflammatory bowel disease;	chr2:159859548	chr2:159670708~159712435:-
THCA	cis	rs7577696	0.785	rs12611678	ENSG00000276334.1	AL133243.1	-4.26	2.45e-05	0.00228	-0.21	-0.19	Inflammatory biomarkers;	chr2:32122716	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.785	rs2294179	ENSG00000276334.1	AL133243.1	-4.26	2.45e-05	0.00228	-0.21	-0.19	Inflammatory biomarkers;	chr2:32128936	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.719	rs3752916	ENSG00000276334.1	AL133243.1	-4.26	2.45e-05	0.00228	-0.21	-0.19	Inflammatory biomarkers;	chr2:32129489	chr2:32521927~32523547:+
THCA	cis	rs6121246	0.954	rs6058470	ENSG00000230613.1	HM13-AS1	4.26	2.45e-05	0.00228	0.21	0.19	Mean corpuscular hemoglobin;	chr20:31829024	chr20:31567707~31573263:-
THCA	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-4.26	2.45e-05	0.00228	-0.22	-0.19	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	4.26	2.45e-05	0.00228	0.22	0.19	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
THCA	cis	rs6940638	0.615	rs9393801	ENSG00000216901.1	AL022393.7	4.26	2.45e-05	0.00228	0.24	0.19	Intelligence (multi-trait analysis);	chr6:27274902	chr6:28176188~28176674:+
THCA	cis	rs1993709	0.558	rs2821248	ENSG00000227207.2	RPL31P12	4.26	2.45e-05	0.00228	0.33	0.19	Obesity (early onset extreme);	chr1:72109877	chr1:72301472~72301829:+
THCA	cis	rs8017455	0.523	rs7151543	ENSG00000259167.2	NMNAT1P1	4.26	2.45e-05	0.00228	0.31	0.19	Hair morphology;	chr14:81082422	chr14:81032529~81033404:+
THCA	cis	rs9368481	0.761	rs9348746	ENSG00000261353.1	CTA-14H9.5	4.26	2.45e-05	0.00228	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26527063~26527404:+
THCA	cis	rs9368481	0.761	rs9379952	ENSG00000261353.1	CTA-14H9.5	4.26	2.45e-05	0.00228	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26527063~26527404:+
THCA	cis	rs9283706	0.608	rs12522430	ENSG00000229666.1	MAST4-AS1	-4.26	2.45e-05	0.00228	-0.29	-0.19	Coronary artery disease;	chr5:67043694	chr5:67001383~67003953:-
THCA	cis	rs4218	0.648	rs58087223	ENSG00000259732.1	RP11-59H7.3	-4.26	2.45e-05	0.00228	-0.27	-0.19	Social communication problems;	chr15:59075132	chr15:59121034~59133250:+
THCA	cis	rs10109025	0.67	rs7825690	ENSG00000261451.1	RP11-981G7.1	-4.26	2.45e-05	0.00229	-0.24	-0.19	Joint mobility (Beighton score);	chr8:11000747	chr8:10433672~10438312:+
THCA	cis	rs12134133	1	rs28371614	ENSG00000237074.1	RP11-6J21.2	4.26	2.45e-05	0.00229	0.19	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207249067~207309121:+
THCA	cis	rs478304	0.903	rs495961	ENSG00000255557.1	RP11-770G2.2	-4.26	2.45e-05	0.00229	-0.21	-0.19	Acne (severe);	chr11:65773415	chr11:65745729~65771585:+
THCA	cis	rs11671005	0.695	rs12972898	ENSG00000268912.1	CTD-2619J13.17	-4.26	2.45e-05	0.00229	-0.19	-0.19	Mean platelet volume;	chr19:58445521	chr19:58428632~58431148:-
THCA	cis	rs1923243	0.71	rs6664103	ENSG00000223479.3	RP4-788P17.1	4.26	2.45e-05	0.00229	0.21	0.19	Migraine;	chr1:73132739	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12131201	ENSG00000223479.3	RP4-788P17.1	4.26	2.45e-05	0.00229	0.21	0.19	Migraine;	chr1:73133545	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4428835	ENSG00000223479.3	RP4-788P17.1	4.26	2.45e-05	0.00229	0.21	0.19	Migraine;	chr1:73133797	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs7547148	ENSG00000223479.3	RP4-788P17.1	4.26	2.45e-05	0.00229	0.21	0.19	Migraine;	chr1:73134581	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12137042	ENSG00000223479.3	RP4-788P17.1	4.26	2.45e-05	0.00229	0.21	0.19	Migraine;	chr1:73135306	chr1:73635216~73715214:+
THCA	cis	rs6121246	0.909	rs6060979	ENSG00000224628.2	RP5-854E16.2	-4.26	2.45e-05	0.00229	-0.26	-0.19	Mean corpuscular hemoglobin;	chr20:31829719	chr20:31285317~31286835:-
THCA	cis	rs8077577	0.747	rs7405677	ENSG00000273018.4	CTD-2303H24.2	4.26	2.45e-05	0.00229	0.29	0.19	Obesity-related traits;	chr17:18227922	chr17:18511221~18551705:-
THCA	cis	rs2839627	0.683	rs11555158	ENSG00000225218.1	AP001628.6	4.26	2.45e-05	0.00229	0.33	0.19	Information processing speed;	chr21:42917804	chr21:42831040~42836477:-
THCA	cis	rs7968440	1	rs2700479	ENSG00000272368.2	RP4-605O3.4	4.26	2.45e-05	0.00229	0.12	0.19	Fibrinogen;	chr12:50626688	chr12:50112197~50165618:+
THCA	cis	rs2191566	0.959	rs7256345	ENSG00000266921.1	RP11-15A1.7	-4.26	2.45e-05	0.00229	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44006753	chr19:43996896~44002836:-
THCA	cis	rs2191566	0.959	rs7255623	ENSG00000266921.1	RP11-15A1.7	-4.26	2.45e-05	0.00229	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44006754	chr19:43996896~44002836:-
THCA	cis	rs1048886	0.938	rs6920515	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.2	-0.19	Type 2 diabetes;	chr6:70580681	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs9455168	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.2	-0.19	Type 2 diabetes;	chr6:70582039	chr6:70596438~70596980:+
THCA	cis	rs9510787	0.538	rs9507137	ENSG00000205861.10	C1QTNF9B-AS1	-4.26	2.45e-05	0.00229	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23655398	chr13:23888889~23897263:+
THCA	cis	rs478304	0.817	rs524475	ENSG00000255557.1	RP11-770G2.2	-4.26	2.45e-05	0.00229	-0.21	-0.19	Acne (severe);	chr11:65750594	chr11:65745729~65771585:+
THCA	cis	rs478304	0.934	rs506853	ENSG00000255557.1	RP11-770G2.2	-4.26	2.45e-05	0.00229	-0.21	-0.19	Acne (severe);	chr11:65753776	chr11:65745729~65771585:+
THCA	cis	rs478304	0.903	rs12293022	ENSG00000255557.1	RP11-770G2.2	-4.26	2.45e-05	0.00229	-0.21	-0.19	Acne (severe);	chr11:65764227	chr11:65745729~65771585:+
THCA	cis	rs478304	0.934	rs603645	ENSG00000255557.1	RP11-770G2.2	-4.26	2.45e-05	0.00229	-0.21	-0.19	Acne (severe);	chr11:65765529	chr11:65745729~65771585:+
THCA	cis	rs4767841	0.539	rs203331	ENSG00000252886.1	RN7SKP197	-4.26	2.45e-05	0.00229	-0.18	-0.19	Urgency urinary incontinence;	chr12:119772466	chr12:119631090~119631386:-
THCA	cis	rs1048886	0.808	rs2293297	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70567100	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs12209965	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70568193	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs12203298	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70568533	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs55795712	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70570725	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs7757026	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70570891	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs12197942	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70571649	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs12197963	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70571718	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs73480275	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70572421	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs76911285	ENSG00000271967.1	RP11-134K13.4	-4.26	2.45e-05	0.00229	-0.21	-0.19	Type 2 diabetes;	chr6:70572479	chr6:70596438~70596980:+
THCA	cis	rs10875746	0.859	rs12305647	ENSG00000258234.1	RP11-370I10.2	4.26	2.45e-05	0.00229	0.23	0.19	Longevity (90 years and older);	chr12:48189178	chr12:48231098~48284210:-
THCA	cis	rs11671005	0.736	rs11668201	ENSG00000265272.2	RN7SL693P	4.26	2.45e-05	0.00229	0.26	0.19	Mean platelet volume;	chr19:58492265	chr19:58490797~58491075:+
THCA	cis	rs10090774	0.932	rs11783270	ENSG00000279766.1	RP11-642A1.2	-4.26	2.45e-05	0.00229	-0.24	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140725695	chr8:140572142~140572812:-
THCA	cis	rs11822910	0.737	rs2581924	ENSG00000265566.2	RN7SL605P	4.26	2.45e-05	0.00229	0.3	0.19	Platelet distribution width;	chr11:57440995	chr11:57528085~57528365:-
THCA	cis	rs2380205	0.967	rs12255077	ENSG00000232807.2	RP11-536K7.3	4.26	2.45e-05	0.00229	0.18	0.19	Breast cancer;	chr10:5856023	chr10:5934270~5945900:-
THCA	cis	rs657075	0.595	rs3749753	ENSG00000237714.1	P4HA2-AS1	-4.26	2.45e-05	0.00229	-0.4	-0.19	Rheumatoid arthritis;	chr5:132251438	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.545	rs17674015	ENSG00000233006.5	AC034220.3	4.26	2.45e-05	0.00229	0.16	0.19	Blood metabolite levels;	chr5:132026085	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.545	rs3916443	ENSG00000233006.5	AC034220.3	4.26	2.45e-05	0.00229	0.16	0.19	Blood metabolite levels;	chr5:132033386	chr5:132311285~132369916:-
THCA	cis	rs4664304	0.708	rs7564243	ENSG00000226266.5	AC009961.3	4.26	2.45e-05	0.00229	0.23	0.19	Crohn's disease;Inflammatory bowel disease;	chr2:159870357	chr2:159670708~159712435:-
THCA	cis	rs4805272	0.962	rs2870546	ENSG00000267799.1	MAN1A2P1	4.26	2.45e-05	0.00229	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833908	chr19:28790812~28792871:-
THCA	cis	rs2822388	0.744	rs116889051	ENSG00000228314.1	CYP4F29P	-4.26	2.45e-05	0.00229	-0.38	-0.19	Stroke;	chr21:14056106	chr21:13843133~13848364:-
THCA	cis	rs2822388	0.59	rs117422362	ENSG00000228314.1	CYP4F29P	-4.26	2.45e-05	0.00229	-0.38	-0.19	Stroke;	chr21:14063419	chr21:13843133~13848364:-
THCA	cis	rs4568518	0.53	rs12699921	ENSG00000279048.1	RP11-511H23.2	4.26	2.45e-05	0.00229	0.12	0.19	Measles;	chr7:17954871	chr7:17940503~17942922:+
THCA	cis	rs970548	0.954	rs11239536	ENSG00000230869.1	CTGLF10P	4.26	2.45e-05	0.00229	0.24	0.19	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45483150	chr10:45678692~45700532:+
THCA	cis	rs12188164	0.515	rs11744936	ENSG00000225138.6	CTD-2228K2.7	4.26	2.45e-05	0.00229	0.2	0.19	Cystic fibrosis severity;	chr5:411997	chr5:473236~480884:+
THCA	cis	rs1876905	0.68	rs3749867	ENSG00000272356.1	RP5-1112D6.8	-4.26	2.45e-05	0.00229	-0.19	-0.19	Mean corpuscular hemoglobin;	chr6:111103615	chr6:111309203~111313517:+
THCA	cis	rs7085104	0.572	rs284857	ENSG00000213061.2	PFN1P11	-4.26	2.45e-05	0.00229	-0.23	-0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814306	chr10:102838011~102845473:-
THCA	cis	rs227275	0.525	rs7698608	ENSG00000248971.2	KRT8P46	-4.26	2.45e-05	0.00229	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102728746~102730171:-
THCA	cis	rs654950	0.841	rs2759247	ENSG00000230638.4	RP11-486B10.4	4.26	2.46e-05	0.00229	0.21	0.19	Airway imaging phenotypes;	chr1:41526085	chr1:41542069~41544310:+
THCA	cis	rs654950	0.841	rs2810549	ENSG00000230638.4	RP11-486B10.4	4.26	2.46e-05	0.00229	0.21	0.19	Airway imaging phenotypes;	chr1:41526090	chr1:41542069~41544310:+
THCA	cis	rs12681288	0.782	rs2600497	ENSG00000260721.1	AF067845.1	4.26	2.46e-05	0.00229	0.24	0.19	Schizophrenia;	chr8:1076220	chr8:1368642~1369833:-
THCA	cis	rs5753037	0.653	rs131270	ENSG00000273350.1	RP4-539M6.20	-4.26	2.46e-05	0.00229	-0.22	-0.19	Type 1 diabetes;	chr22:29753907	chr22:30420512~30420912:+
THCA	cis	rs6878727	0.665	rs698185	ENSG00000253807.4	LINC01170	-4.26	2.46e-05	0.00229	-0.17	-0.19	Breast cancer;	chr5:124328872	chr5:124059794~124405079:-
THCA	cis	rs72753537	0.817	rs4743136	ENSG00000214417.4	KRT18P13	-4.26	2.46e-05	0.00229	-0.22	-0.19	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97845777	chr9:97698922~97700734:+
THCA	cis	rs10833905	1	rs11026934	ENSG00000246225.5	RP11-17A1.3	-4.26	2.46e-05	0.00229	-0.27	-0.19	Sudden cardiac arrest;	chr11:23045574	chr11:22829380~22945393:+
THCA	cis	rs2028299	1	rs4932143	ENSG00000259677.1	RP11-493E3.1	4.26	2.46e-05	0.00229	0.25	0.19	Type 2 diabetes;	chr15:89828835	chr15:89876540~89877285:+
THCA	cis	rs2692947	0.537	rs11164050	ENSG00000235584.2	AC008268.1	-4.26	2.46e-05	0.00229	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95686703	chr2:95666084~95668715:+
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000182586.6	LINC00334	-4.26	2.46e-05	0.00229	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45234340~45258730:+
THCA	cis	rs7085104	0.572	rs284856	ENSG00000213061.2	PFN1P11	-4.26	2.46e-05	0.00229	-0.23	-0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102838011~102845473:-
THCA	cis	rs12915845	0.545	rs7402591	ENSG00000271997.1	RP11-97O12.6	-4.26	2.46e-05	0.00229	-0.13	-0.19	Menarche (age at onset);	chr15:88535203	chr15:88501944~88505787:-
THCA	cis	rs858239	0.539	rs2103281	ENSG00000230042.1	AK3P3	-4.26	2.46e-05	0.00229	-0.26	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23129178~23129841:+
THCA	cis	rs12681288	0.823	rs6994989	ENSG00000260721.1	AF067845.1	4.26	2.46e-05	0.00229	0.23	0.19	Schizophrenia;	chr8:1057284	chr8:1368642~1369833:-
THCA	cis	rs442309	0.967	rs224032	ENSG00000238280.1	RP11-436D10.3	-4.26	2.46e-05	0.00229	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62762069	chr10:62793562~62805887:-
THCA	cis	rs12681963	0.688	rs962420	ENSG00000248159.1	HSPA8P11	4.26	2.46e-05	0.00229	0.34	0.19	Migraine;	chr8:30233419	chr8:30237382~30240997:+
THCA	cis	rs6499188	0.51	rs9923262	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.00229	0.29	0.19	Ulcerative colitis;	chr16:68579203	chr16:68450283~68452318:+
THCA	cis	rs4713118	0.869	rs10214440	ENSG00000220721.1	OR1F12	4.26	2.46e-05	0.00229	0.25	0.19	Parkinson's disease;	chr6:27734661	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs6902689	ENSG00000220721.1	OR1F12	4.26	2.46e-05	0.00229	0.25	0.19	Parkinson's disease;	chr6:27741662	chr6:28073316~28074233:+
THCA	cis	rs2163813	1	rs247778	ENSG00000271499.1	CTC-559E9.9	-4.26	2.46e-05	0.00229	-0.24	-0.19	Toenail selenium levels;	chr19:19731244	chr19:19750618~19752544:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000223473.2	GS1-124K5.3	-4.26	2.46e-05	0.0023	-0.13	-0.19	Aortic root size;	chr7:66113790	chr7:66491049~66493566:-
THCA	cis	rs889398	0.771	rs4985448	ENSG00000226232.7	RP11-419C5.2	-4.26	2.46e-05	0.0023	-0.19	-0.19	Body mass index;	chr16:69865492	chr16:69976388~69996188:-
THCA	cis	rs889398	0.771	rs1566454	ENSG00000226232.7	RP11-419C5.2	-4.26	2.46e-05	0.0023	-0.19	-0.19	Body mass index;	chr16:69866180	chr16:69976388~69996188:-
THCA	cis	rs889398	0.651	rs1566455	ENSG00000226232.7	RP11-419C5.2	-4.26	2.46e-05	0.0023	-0.19	-0.19	Body mass index;	chr16:69866261	chr16:69976388~69996188:-
THCA	cis	rs9314614	0.789	rs2977795	ENSG00000245857.2	GS1-24F4.2	4.26	2.46e-05	0.0023	0.25	0.19	White blood cell count (basophil);IgA nephropathy;	chr8:6852283	chr8:6835554~6885276:+
THCA	cis	rs1728785	1	rs1170426	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.0023	0.27	0.19	Ulcerative colitis;	chr16:68569895	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.892	rs1170427	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.0023	0.27	0.19	Ulcerative colitis;	chr16:68569949	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1170429	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.0023	0.27	0.19	Ulcerative colitis;	chr16:68570223	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.818	rs1170430	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.0023	0.27	0.19	Ulcerative colitis;	chr16:68571051	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1170431	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.0023	0.27	0.19	Ulcerative colitis;	chr16:68571736	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.748	rs889560	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.0023	0.27	0.19	Ulcerative colitis;	chr16:68571881	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1170433	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.0023	0.27	0.19	Ulcerative colitis;	chr16:68572178	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs1183956	ENSG00000274698.1	RP11-71L14.4	4.26	2.46e-05	0.0023	0.27	0.19	Ulcerative colitis;	chr16:68572823	chr16:68450283~68452318:+
THCA	cis	rs7474896	0.537	rs2749586	ENSG00000120555.12	SEPT7P9	-4.26	2.46e-05	0.0023	-0.25	-0.19	Obesity (extreme);	chr10:37981286	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.515	rs2749582	ENSG00000120555.12	SEPT7P9	-4.26	2.46e-05	0.0023	-0.25	-0.19	Obesity (extreme);	chr10:37986356	chr10:38383069~38402916:-
THCA	cis	rs7711186	0.786	rs56299555	ENSG00000252464.1	RN7SKP70	4.26	2.46e-05	0.0023	0.23	0.19	Urate levels in obese individuals;	chr5:178659540	chr5:178619728~178619998:-
THCA	cis	rs3734266	0.702	rs35195182	ENSG00000272288.4	RP11-140K17.3	-4.26	2.46e-05	0.0023	-0.19	-0.19	Systemic lupus erythematosus;	chr6:34741909	chr6:34696317~34697470:+
THCA	cis	rs4742903	0.904	rs1507512	ENSG00000270332.1	SMC2-AS1	4.26	2.46e-05	0.0023	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104242667	chr9:104080024~104093073:-
THCA	cis	rs4965006	0.915	rs4965004	ENSG00000255992.1	RP11-417L19.4	4.26	2.46e-05	0.0023	0.32	0.19	Posterior cortical atrophy and Alzheimer's disease;	chr12:131940155	chr12:131924736~131929351:-
THCA	cis	rs853679	0.723	rs1736904	ENSG00000226314.6	ZNF192P1	-4.26	2.46e-05	0.0023	-0.24	-0.19	Depression;	chr6:28251492	chr6:28161781~28169594:+
THCA	cis	rs9283706	0.608	rs10065036	ENSG00000229666.1	MAST4-AS1	-4.26	2.47e-05	0.0023	-0.28	-0.19	Coronary artery disease;	chr5:67042256	chr5:67001383~67003953:-
THCA	cis	rs1371614	0.501	rs4992933	ENSG00000272148.1	RP11-195B17.1	4.26	2.47e-05	0.0023	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956104	chr2:27062428~27062907:-
THCA	cis	rs9634489	0.502	rs995069	ENSG00000247400.3	DNAJC3-AS1	-4.26	2.47e-05	0.0023	-0.13	-0.19	Body mass index;	chr13:96449025	chr13:95648733~95676925:-
THCA	cis	rs3930017	1	rs3930016	ENSG00000205482.8	AC007000.12	-4.26	2.47e-05	0.0023	-0.18	-0.19	Body mass index;	chr7:77091132	chr7:77052785~77059440:-
THCA	cis	rs6001482	0.523	rs5757595	ENSG00000272779.1	LL22NC03-80A10.6	-4.26	2.47e-05	0.0023	-0.21	-0.19	Diastolic blood pressure;	chr22:22235017	chr22:22303224~22310401:+
THCA	cis	rs9911578	0.835	rs9788975	ENSG00000224738.1	AC099850.1	-4.26	2.47e-05	0.0023	-0.22	-0.19	Intelligence (multi-trait analysis);	chr17:58383439	chr17:59106598~59118267:+
THCA	cis	rs2898290	0.622	rs978802	ENSG00000227888.4	FAM66A	-4.26	2.47e-05	0.0023	-0.25	-0.19	Systolic blood pressure;	chr8:11485769	chr8:12362019~12388296:+
THCA	cis	rs17801127	0.892	rs13005911	ENSG00000231969.1	AC144449.1	-4.26	2.47e-05	0.0023	-0.33	-0.19	Liver enzyme levels (alanine transaminase);	chr2:149698695	chr2:149587196~149848233:+
THCA	cis	rs394563	0.591	rs237012	ENSG00000231760.4	RP11-350J20.5	4.26	2.47e-05	0.0023	0.24	0.19	Dupuytren's disease;	chr6:149408062	chr6:149796151~149826294:-
THCA	cis	rs12264252	0.767	rs7902355	ENSG00000226659.1	RP11-137H2.4	4.26	2.47e-05	0.0023	0.29	0.19	Coronary artery disease;	chr10:80489352	chr10:80529597~80535942:-
THCA	cis	rs9863	0.861	rs9971695	ENSG00000269997.1	RP11-214K3.21	-4.26	2.47e-05	0.0023	-0.24	-0.19	White blood cell count;	chr12:123928944	chr12:123966077~123966629:-
THCA	cis	rs9863	0.827	rs4930706	ENSG00000269997.1	RP11-214K3.21	-4.26	2.47e-05	0.0023	-0.24	-0.19	White blood cell count;	chr12:123932791	chr12:123966077~123966629:-
THCA	cis	rs2839627	0.561	rs6586248	ENSG00000225218.1	AP001628.6	4.26	2.47e-05	0.0023	0.28	0.19	Information processing speed;	chr21:42837702	chr21:42831040~42836477:-
THCA	cis	rs10875746	0.855	rs10875728	ENSG00000258273.1	RP11-370I10.4	4.26	2.47e-05	0.0023	0.27	0.19	Longevity (90 years and older);	chr12:48032609	chr12:48333755~48333901:-
THCA	cis	rs7312933	0.558	rs4768411	ENSG00000257225.1	RP11-328C8.4	4.26	2.47e-05	0.0023	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42461588	chr12:42459366~42466128:+
THCA	cis	rs7911264	0.765	rs7092522	ENSG00000232709.1	MARK2P9	-4.26	2.47e-05	0.0023	-0.24	-0.19	Inflammatory bowel disease;	chr10:92583226	chr10:92418667~92420875:+
THCA	cis	rs7267979	0.844	rs6083851	ENSG00000277938.1	RP5-965G21.3	-4.26	2.47e-05	0.0023	-0.16	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.844	rs4423675	ENSG00000277938.1	RP5-965G21.3	-4.26	2.47e-05	0.0023	-0.16	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25229150~25231933:+
THCA	cis	rs875971	0.706	rs1643374	ENSG00000272831.1	RP11-792A8.4	4.26	2.47e-05	0.0023	0.12	0.19	Aortic root size;	chr7:66407695	chr7:66739829~66740385:-
THCA	cis	rs6870983	0.895	rs33704	ENSG00000247828.6	TMEM161B-AS1	-4.26	2.47e-05	0.0023	-0.18	-0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88265948	chr5:88268895~88436685:+
THCA	cis	rs11026091	1	rs10766814	ENSG00000224513.2	AC109309.4	-4.26	2.47e-05	0.0023	-0.24	-0.19	Multiple sclerosis;	chr11:3238992	chr11:3226061~3232838:+
THCA	cis	rs12887734	0.546	rs12885509	ENSG00000269940.1	RP11-73M18.7	4.26	2.47e-05	0.0023	0.2	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103694560~103695170:+
THCA	cis	rs467650	0.747	rs461409	ENSG00000248489.1	CTD-2007H13.3	-4.26	2.47e-05	0.0023	-0.18	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98594262	chr5:98929171~98995013:+
THCA	cis	rs7572733	0.534	rs700681	ENSG00000231621.1	AC013264.2	-4.26	2.47e-05	0.0023	-0.2	-0.19	Dermatomyositis;	chr2:197846778	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700682	ENSG00000231621.1	AC013264.2	-4.26	2.47e-05	0.0023	-0.2	-0.19	Dermatomyositis;	chr2:197847586	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700683	ENSG00000231621.1	AC013264.2	-4.26	2.47e-05	0.0023	-0.2	-0.19	Dermatomyositis;	chr2:197847608	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700684	ENSG00000231621.1	AC013264.2	-4.26	2.47e-05	0.0023	-0.2	-0.19	Dermatomyositis;	chr2:197848375	chr2:197197991~197199273:+
THCA	cis	rs2070488	0.965	rs2126534	ENSG00000229589.1	ACVR2B-AS1	4.26	2.47e-05	0.0023	0.18	0.19	Electrocardiographic conduction measures;	chr3:38403674	chr3:38451027~38454820:-
THCA	cis	rs1560104	0.709	rs8063664	ENSG00000262801.4	U91319.1	4.26	2.47e-05	0.0023	0.22	0.19	Obesity-related traits;	chr16:12603354	chr16:13246316~13562918:+
THCA	cis	rs11026091	1	rs7103969	ENSG00000224513.2	AC109309.4	-4.26	2.47e-05	0.00231	-0.24	-0.19	Multiple sclerosis;	chr11:3238920	chr11:3226061~3232838:+
THCA	cis	rs11026091	1	rs7123908	ENSG00000224513.2	AC109309.4	-4.26	2.47e-05	0.00231	-0.24	-0.19	Multiple sclerosis;	chr11:3238959	chr11:3226061~3232838:+
THCA	cis	rs4857855	0.731	rs9819402	ENSG00000239405.1	TMED10P2	-4.26	2.47e-05	0.00231	-0.27	-0.19	Eosinophil counts;	chr3:128526866	chr3:128538020~128538631:+
THCA	cis	rs2692947	0.537	rs1345917	ENSG00000235584.2	AC008268.1	-4.26	2.47e-05	0.00231	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95534855	chr2:95666084~95668715:+
THCA	cis	rs11992162	0.967	rs10088415	ENSG00000270154.1	RP11-419I17.1	-4.26	2.47e-05	0.00231	-0.24	-0.19	Monocyte count;	chr8:11973316	chr8:12476462~12477122:+
THCA	cis	rs12142240	0.698	rs17357621	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46342025	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs56909107	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46342552	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs41293285	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46342754	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17357628	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46342790	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17357635	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46342996	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs68191463	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46343023	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.628	rs56126529	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46343188	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs7525309	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46343353	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs7548675	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46343649	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs7515284	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46343747	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs41294456	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46344110	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs66516678	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46344440	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs41294458	ENSG00000232022.5	FAAHP1	-4.26	2.47e-05	0.00231	-0.22	-0.19	Menopause (age at onset);	chr1:46344632	chr1:46432129~46445521:+
THCA	cis	rs12681963	0.541	rs7010163	ENSG00000248159.1	HSPA8P11	4.26	2.47e-05	0.00231	0.35	0.19	Migraine;	chr8:30225049	chr8:30237382~30240997:+
THCA	cis	rs282544	0.632	rs2442107	ENSG00000271752.1	RP11-269M20.3	4.26	2.47e-05	0.00231	0.2	0.19	Myopia (pathological);	chr5:50750133	chr5:50662859~50663266:-
THCA	cis	rs4824093	0.61	rs77128035	ENSG00000278869.1	CITF22-49E9.3	4.26	2.47e-05	0.00231	0.36	0.19	Amyotrophic lateral sclerosis (sporadic);	chr22:49847376	chr22:49933198~49934074:-
THCA	cis	rs9326246	0.545	rs562756	ENSG00000254851.1	RP11-109L13.1	4.26	2.48e-05	0.00231	0.44	0.19	Coronary artery disease;	chr11:116651258	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs563917	ENSG00000254851.1	RP11-109L13.1	4.26	2.48e-05	0.00231	0.44	0.19	Coronary artery disease;	chr11:116651439	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs565607	ENSG00000254851.1	RP11-109L13.1	4.26	2.48e-05	0.00231	0.44	0.19	Coronary artery disease;	chr11:116651613	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs567576	ENSG00000254851.1	RP11-109L13.1	4.26	2.48e-05	0.00231	0.44	0.19	Coronary artery disease;	chr11:116651842	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.659	rs567599	ENSG00000254851.1	RP11-109L13.1	4.26	2.48e-05	0.00231	0.44	0.19	Coronary artery disease;	chr11:116651848	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs3017237	ENSG00000254851.1	RP11-109L13.1	4.26	2.48e-05	0.00231	0.44	0.19	Coronary artery disease;	chr11:116651908	chr11:117135528~117138582:+
THCA	cis	rs7088591	0.764	rs56986369	ENSG00000276818.1	AC026393.1	4.26	2.48e-05	0.00231	0.36	0.19	Blood pressure;	chr10:57953509	chr10:57095699~57095781:+
THCA	cis	rs3096299	0.728	rs1011749	ENSG00000261118.1	RP11-104N10.1	4.26	2.48e-05	0.00231	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89492017~89504460:-
THCA	cis	rs897984	0.806	rs4889571	ENSG00000275263.1	RP11-1072A3.4	4.26	2.48e-05	0.00231	0.23	0.19	Dementia with Lewy bodies;	chr16:30937726	chr16:30956872~30957199:-
THCA	cis	rs897984	0.806	rs11640534	ENSG00000275263.1	RP11-1072A3.4	4.26	2.48e-05	0.00231	0.23	0.19	Dementia with Lewy bodies;	chr16:30938194	chr16:30956872~30957199:-
THCA	cis	rs897984	0.762	rs7206511	ENSG00000275263.1	RP11-1072A3.4	4.26	2.48e-05	0.00231	0.23	0.19	Dementia with Lewy bodies;	chr16:30939031	chr16:30956872~30957199:-
THCA	cis	rs74233809	1	rs75970938	ENSG00000272912.1	RP11-724N1.1	-4.26	2.48e-05	0.00231	-0.36	-0.19	Birth weight;	chr10:103033891	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs79668541	ENSG00000272912.1	RP11-724N1.1	-4.26	2.48e-05	0.00231	-0.36	-0.19	Birth weight;	chr10:103034147	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs3781285	ENSG00000272912.1	RP11-724N1.1	-4.26	2.48e-05	0.00231	-0.36	-0.19	Birth weight;	chr10:103065908	chr10:102914585~102915404:+
THCA	cis	rs7178375	1	rs9806159	ENSG00000269930.1	RP11-932O9.9	-4.26	2.48e-05	0.00231	-0.26	-0.19	Hypertriglyceridemia;	chr15:30917451	chr15:30616958~30617749:+
THCA	cis	rs964611	0.882	rs12148465	ENSG00000259488.2	RP11-154J22.1	4.26	2.48e-05	0.00231	0.17	0.19	Metabolite levels (Pyroglutamine);	chr15:48368261	chr15:48312353~48331856:-
THCA	cis	rs2692947	0.77	rs72492163	ENSG00000232931.4	LINC00342	4.26	2.48e-05	0.00231	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95752068	chr2:95807118~95816215:-
THCA	cis	rs17095355	0.818	rs11194951	ENSG00000203876.8	ADD3-AS1	4.26	2.48e-05	0.00231	0.2	0.19	Biliary atresia;	chr10:110016364	chr10:109940104~110008381:-
THCA	cis	rs708224	1	rs708224	ENSG00000277342.1	RP11-843B15.4	4.26	2.48e-05	0.00231	0.24	0.19	Pancreatic cancer;	chr12:32283475	chr12:32109076~32109602:+
THCA	cis	rs35740288	0.753	rs4843095	ENSG00000259295.5	CSPG4P12	4.26	2.48e-05	0.00231	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85731900	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.822	rs11630549	ENSG00000259295.5	CSPG4P12	4.26	2.48e-05	0.00231	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85732565	chr15:85191438~85213905:+
THCA	cis	rs35740288	0.822	rs56322219	ENSG00000259295.5	CSPG4P12	4.26	2.48e-05	0.00231	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85733109	chr15:85191438~85213905:+
THCA	cis	rs42648	0.935	rs42629	ENSG00000225498.1	AC002064.5	4.26	2.48e-05	0.00231	0.2	0.19	Homocysteine levels;	chr7:90334010	chr7:90312496~90322592:+
THCA	cis	rs4356203	0.905	rs7938820	ENSG00000272034.1	SNORD14A	4.26	2.48e-05	0.00231	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17055905	chr11:17074654~17074744:-
THCA	cis	rs6657613	0.649	rs11203285	ENSG00000186301.8	MST1P2	4.26	2.48e-05	0.00231	0.16	0.19	Hip circumference adjusted for BMI;	chr1:17043625	chr1:16645622~16650289:+
THCA	cis	rs412050	0.793	rs17821866	ENSG00000224086.5	LL22NC03-86G7.1	-4.26	2.48e-05	0.00231	-0.34	-0.19	Attention deficit hyperactivity disorder;	chr22:21988067	chr22:21938293~21977632:+
THCA	cis	rs131805	1	rs3091397	ENSG00000273253.2	RP3-402G11.26	-4.26	2.48e-05	0.00231	-0.22	-0.19	Granulocyte percentage of myeloid white cells;	chr22:50519091	chr22:50199090~50200837:-
THCA	cis	rs7833787	0.526	rs6586769	ENSG00000278886.1	RP11-108A14.1	-4.26	2.48e-05	0.00231	-0.27	-0.19	Obesity-related traits;	chr8:18836699	chr8:18864681~18865247:-
THCA	cis	rs2886497	0.947	rs7079237	ENSG00000224215.1	RP11-371A19.2	-4.26	2.48e-05	0.00231	-0.24	-0.19	Major depression and alcohol dependence;	chr10:23370658	chr10:23343957~23345181:+
THCA	cis	rs4714902	0.655	rs9472701	ENSG00000231769.2	RP1-8B1.4	-4.26	2.48e-05	0.00231	-0.17	-0.19	Colonoscopy-negative controls vs population controls;	chr6:46148712	chr6:46097093~46129706:-
THCA	cis	rs5758659	0.504	rs133367	ENSG00000273366.1	CTA-989H11.1	4.26	2.48e-05	0.00231	0.23	0.19	Cognitive function;	chr22:42067362	chr22:42278188~42278846:+
THCA	cis	rs1923243	0.71	rs7526981	ENSG00000223479.3	RP4-788P17.1	4.26	2.48e-05	0.00231	0.21	0.19	Migraine;	chr1:73130936	chr1:73635216~73715214:+
THCA	cis	rs7312933	0.585	rs7969814	ENSG00000257225.1	RP11-328C8.4	-4.26	2.48e-05	0.00231	-0.2	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42275855	chr12:42459366~42466128:+
THCA	cis	rs4218	0.681	rs17302163	ENSG00000277144.1	RP11-59H7.4	-4.26	2.48e-05	0.00231	-0.27	-0.19	Social communication problems;	chr15:59076773	chr15:59115547~59116089:-
THCA	cis	rs758324	0.947	rs56081930	ENSG00000237714.1	P4HA2-AS1	-4.26	2.48e-05	0.00231	-0.27	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131899581	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs58016983	ENSG00000237714.1	P4HA2-AS1	-4.26	2.48e-05	0.00231	-0.27	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131899582	chr5:132184876~132192808:+
THCA	cis	rs17253792	0.822	rs10139905	ENSG00000186615.9	KTN1-AS1	-4.26	2.48e-05	0.00231	-0.31	-0.19	Putamen volume;	chr14:55703313	chr14:55499278~55580110:-
THCA	cis	rs734999	0.545	rs7368072	ENSG00000225931.3	RP3-395M20.7	4.26	2.48e-05	0.00231	0.23	0.19	Ulcerative colitis;	chr1:2624686	chr1:2566410~2569888:+
THCA	cis	rs1923243	0.587	rs4344272	ENSG00000223479.3	RP4-788P17.1	4.26	2.48e-05	0.00231	0.21	0.19	Migraine;	chr1:72980418	chr1:73635216~73715214:+
THCA	cis	rs4356203	0.905	rs6486352	ENSG00000272034.1	SNORD14A	4.26	2.48e-05	0.00231	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17150823	chr11:17074654~17074744:-
THCA	cis	rs7772486	0.79	rs2250387	ENSG00000270638.1	RP3-466P17.1	4.26	2.48e-05	0.00231	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145735570~145737218:+
THCA	cis	rs804280	0.509	rs13268030	ENSG00000254948.1	OR7E158P	-4.26	2.48e-05	0.00231	-0.24	-0.19	Myopia (pathological);	chr8:11925564	chr8:11919900~11920809:-
THCA	cis	rs67981189	0.758	rs221921	ENSG00000269927.1	RP6-91H8.3	-4.26	2.48e-05	0.00231	-0.22	-0.19	Schizophrenia;	chr14:71119411	chr14:71141125~71143253:-
THCA	cis	rs4788570	0.615	rs8053745	ENSG00000260593.1	RP11-432I5.2	-4.26	2.48e-05	0.00231	-0.31	-0.19	Intelligence (multi-trait analysis);	chr16:71655790	chr16:71623708~71626816:-
THCA	cis	rs9876781	1	rs6784322	ENSG00000244380.1	RP11-24C3.2	4.26	2.48e-05	0.00231	0.23	0.19	Longevity;	chr3:48380745	chr3:48440352~48446656:-
THCA	cis	rs2822388	0.59	rs2822392	ENSG00000215559.7	ANKRD20A11P	-4.26	2.49e-05	0.00232	-0.39	-0.19	Stroke;	chr21:14040510	chr21:13909574~13980437:-
THCA	cis	rs8030605	0.778	rs72742631	ENSG00000277245.1	RP11-48G14.3	4.26	2.49e-05	0.00232	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56394101	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.633	rs117893963	ENSG00000277245.1	RP11-48G14.3	4.26	2.49e-05	0.00232	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56397793	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.778	rs11638076	ENSG00000277245.1	RP11-48G14.3	4.26	2.49e-05	0.00232	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56402219	chr15:56447120~56447697:+
THCA	cis	rs4908768	1	rs7523186	ENSG00000232912.4	RP5-1115A15.1	4.26	2.49e-05	0.00232	0.23	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8595436	chr1:8424645~8434838:+
THCA	cis	rs7267979	0.932	rs2260997	ENSG00000274973.1	RP13-401N8.7	4.26	2.49e-05	0.00232	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25845497~25845862:+
THCA	cis	rs13118159	0.55	rs4974617	ENSG00000254094.1	AC078852.1	-4.26	2.49e-05	0.00232	-0.23	-0.19	Longevity;	chr4:1379870	chr4:1356581~1358075:+
THCA	cis	rs6973609	0.597	rs7811189	ENSG00000271122.1	RP11-379H18.1	4.26	2.49e-05	0.00232	0.13	0.19	Obesity-related traits;	chr7:35568882	chr7:35695214~35699413:+
THCA	cis	rs733592	0.56	rs2158515	ENSG00000258273.1	RP11-370I10.4	4.26	2.49e-05	0.00232	0.23	0.19	Plateletcrit;	chr12:48113885	chr12:48333755~48333901:-
THCA	cis	rs758324	0.648	rs152126	ENSG00000237714.1	P4HA2-AS1	-4.26	2.49e-05	0.00232	-0.27	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132047974	chr5:132184876~132192808:+
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000230712.2	AP000354.4	-4.26	2.49e-05	0.00232	-0.26	-0.19	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:24248074~24249466:-
THCA	cis	rs9880211	0.606	rs9852406	ENSG00000273486.1	RP11-731C17.2	4.26	2.49e-05	0.00232	0.2	0.19	Height;Body mass index;	chr3:135906656	chr3:136837338~136839021:-
THCA	cis	rs10875746	0.903	rs989144	ENSG00000258273.1	RP11-370I10.4	4.26	2.49e-05	0.00232	0.28	0.19	Longevity (90 years and older);	chr12:48090190	chr12:48333755~48333901:-
THCA	cis	rs13068223	0.663	rs12107178	ENSG00000240875.4	LINC00886	-4.26	2.49e-05	0.00232	-0.15	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156747346~156817062:-
THCA	cis	rs11671005	0.737	rs11671033	ENSG00000268049.1	CTD-2619J13.9	-4.26	2.49e-05	0.00232	-0.31	-0.19	Mean platelet volume;	chr19:58452302	chr19:58357999~58359603:+
THCA	cis	rs17270561	0.553	rs9379784	ENSG00000272462.2	U91328.19	-4.26	2.49e-05	0.00232	-0.17	-0.19	Iron status biomarkers;	chr6:25725278	chr6:25992662~26001775:+
THCA	cis	rs75059851	0.756	rs2000853	ENSG00000280237.1	MIR4697HG	4.26	2.49e-05	0.00232	0.22	0.19	Schizophrenia;	chr11:133968522	chr11:133896438~133901601:-
THCA	cis	rs1371614	0.632	rs4665363	ENSG00000229122.1	AGBL5-IT1	-4.26	2.49e-05	0.00232	-0.14	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26933548	chr2:27061038~27061815:+
THCA	cis	rs2836950	0.545	rs11700449	ENSG00000238141.2	BRWD1-AS1	-4.26	2.49e-05	0.00232	-0.22	-0.19	Menarche (age at onset);	chr21:39150493	chr21:39315707~39323218:+
THCA	cis	rs7045881	0.8	rs59175724	ENSG00000254396.1	RP11-56F10.3	4.26	2.49e-05	0.00232	0.34	0.19	Schizophrenia;	chr9:26924486	chr9:27102630~27104728:+
THCA	cis	rs1048886	0.938	rs16869267	ENSG00000271967.1	RP11-134K13.4	-4.26	2.49e-05	0.00232	-0.21	-0.19	Type 2 diabetes;	chr6:70483751	chr6:70596438~70596980:+
THCA	cis	rs2281603	0.762	rs61987034	ENSG00000272909.1	CTD-2555O16.4	-4.26	2.49e-05	0.00232	-0.25	-0.19	Lymphocyte counts;	chr14:64567405	chr14:64440369~64442238:-
THCA	cis	rs12893668	0.703	rs2274267	ENSG00000252469.1	RNU7-160P	4.26	2.49e-05	0.00232	0.23	0.19	Reticulocyte count;	chr14:103563112	chr14:103550345~103550406:+
THCA	cis	rs10932886	1	rs8179787	ENSG00000224819.1	AC093843.1	4.26	2.49e-05	0.00232	0.19	0.19	Brain imaging;	chr2:220849338	chr2:220791078~220797893:+
THCA	cis	rs11992162	0.591	rs35657308	ENSG00000254948.1	OR7E158P	4.26	2.49e-05	0.00232	0.24	0.19	Monocyte count;	chr8:11946893	chr8:11919900~11920809:-
THCA	cis	rs786425	0.804	rs10846535	ENSG00000270095.1	RP11-214K3.18	-4.26	2.49e-05	0.00232	-0.22	-0.19	Pubertal anthropometrics;	chr12:123645841	chr12:123971457~123971714:-
THCA	cis	rs2842992	0.83	rs1475123	ENSG00000237927.1	RP3-393E18.2	-4.26	2.49e-05	0.00232	-0.29	-0.19	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159586955~159589169:-
THCA	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	4.26	2.49e-05	0.00232	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	4.26	2.49e-05	0.00232	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	4.26	2.49e-05	0.00232	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	4.26	2.49e-05	0.00232	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	4.26	2.49e-05	0.00232	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	4.26	2.49e-05	0.00232	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	4.26	2.49e-05	0.00232	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
THCA	cis	rs6921919	0.583	rs11755942	ENSG00000273712.1	RP5-874C20.7	4.26	2.49e-05	0.00232	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28315613~28315883:-
THCA	cis	rs1923243	0.71	rs4520373	ENSG00000223479.3	RP4-788P17.1	4.26	2.49e-05	0.00232	0.21	0.19	Migraine;	chr1:73131646	chr1:73635216~73715214:+
THCA	cis	rs7829975	0.711	rs4841051	ENSG00000253981.4	ALG1L13P	-4.26	2.49e-05	0.00232	-0.18	-0.19	Mood instability;	chr8:8828136	chr8:8236003~8244667:-
THCA	cis	rs2806561	0.606	rs10917335	ENSG00000249087.5	ZNF436-AS1	-4.26	2.49e-05	0.00232	-0.13	-0.19	Height;	chr1:22967643	chr1:23368997~23371839:+
THCA	cis	rs9928842	0.882	rs9319481	ENSG00000261783.1	RP11-252K23.2	4.26	2.49e-05	0.00232	0.37	0.19	Alcoholic chronic pancreatitis;	chr16:75225580	chr16:75379818~75381260:-
THCA	cis	rs9928842	0.882	rs1107593	ENSG00000261783.1	RP11-252K23.2	4.26	2.49e-05	0.00232	0.37	0.19	Alcoholic chronic pancreatitis;	chr16:75227431	chr16:75379818~75381260:-
THCA	cis	rs9928842	0.824	rs12924999	ENSG00000261783.1	RP11-252K23.2	4.26	2.49e-05	0.00232	0.37	0.19	Alcoholic chronic pancreatitis;	chr16:75228527	chr16:75379818~75381260:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000275400.1	RP4-756H11.5	4.26	2.49e-05	0.00232	0.18	0.19	Aortic root size;	chr7:66570949	chr7:66553805~66554199:-
THCA	cis	rs9921338	0.636	rs72771866	ENSG00000262636.1	CTD-3088G3.4	-4.26	2.5e-05	0.00232	-0.29	-0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261365	chr16:11380859~11381118:-
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000275400.1	RP4-756H11.5	-4.26	2.5e-05	0.00232	-0.21	-0.19	Corneal structure;	chr7:66913899	chr7:66553805~66554199:-
THCA	cis	rs8141529	0.748	rs7287918	ENSG00000226471.5	CTA-292E10.6	-4.26	2.5e-05	0.00232	-0.16	-0.19	Lymphocyte counts;	chr22:28885722	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.748	rs1318025	ENSG00000226471.5	CTA-292E10.6	-4.26	2.5e-05	0.00232	-0.16	-0.19	Lymphocyte counts;	chr22:28887769	chr22:28800683~28848559:+
THCA	cis	rs7572733	0.576	rs6734781	ENSG00000231621.1	AC013264.2	-4.26	2.5e-05	0.00232	-0.2	-0.19	Dermatomyositis;	chr2:197895249	chr2:197197991~197199273:+
THCA	cis	rs8177876	0.731	rs74878296	ENSG00000261838.4	RP11-303E16.6	4.26	2.5e-05	0.00232	0.43	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81069854~81076598:+
THCA	cis	rs4785204	1	rs60561577	ENSG00000279356.1	RP11-429P3.8	-4.26	2.5e-05	0.00232	-0.37	-0.19	Esophageal cancer (squamous cell);	chr16:50094661	chr16:50072862~50074986:+
THCA	cis	rs6822297	0.905	rs4519791	ENSG00000240005.4	RP11-293A21.1	4.26	2.5e-05	0.00232	0.21	0.19	Obesity-related traits;	chr4:26882142	chr4:26859806~26860599:-
THCA	cis	rs4767841	1	rs4767839	ENSG00000252886.1	RN7SKP197	-4.26	2.5e-05	0.00232	-0.19	-0.19	Urgency urinary incontinence;	chr12:119722317	chr12:119631090~119631386:-
THCA	cis	rs9843304	0.528	rs12488126	ENSG00000243885.1	RP11-278L15.2	-4.26	2.5e-05	0.00232	-0.21	-0.19	Gallstone disease;	chr3:149474889	chr3:149384179~149385800:-
THCA	cis	rs10771431	1	rs11611670	ENSG00000256427.1	RP11-118B22.4	4.26	2.5e-05	0.00232	0.22	0.19	Breast size;	chr12:9232939	chr12:9246497~9257960:+
THCA	cis	rs11673344	0.642	rs55926714	ENSG00000268499.1	CTB-102L5.8	-4.26	2.5e-05	0.00233	-0.2	-0.19	Obesity-related traits;	chr19:37307974	chr19:38199836~38200934:+
THCA	cis	rs35740288	0.752	rs11636138	ENSG00000259295.5	CSPG4P12	4.26	2.5e-05	0.00233	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744316	chr15:85191438~85213905:+
THCA	cis	rs2948294	0.588	rs4840913	ENSG00000233609.3	RP11-62H7.2	4.26	2.5e-05	0.00233	0.19	0.19	Red cell distribution width;	chr8:8259384	chr8:8961200~8979025:+
THCA	cis	rs1150668	0.796	rs1005125	ENSG00000280107.1	AL022393.9	-4.26	2.5e-05	0.00233	-0.19	-0.19	Pubertal anthropometrics;	chr6:28399578	chr6:28170845~28172521:+
THCA	cis	rs4218	0.608	rs34859729	ENSG00000259732.1	RP11-59H7.3	-4.26	2.5e-05	0.00233	-0.27	-0.19	Social communication problems;	chr15:59070117	chr15:59121034~59133250:+
THCA	cis	rs4144027	0.967	rs4900601	ENSG00000269958.1	RP11-73M18.8	4.26	2.5e-05	0.00233	0.18	0.19	Blood metabolite levels;	chr14:103891739	chr14:103696353~103697163:+
THCA	cis	rs1876905	0.597	rs354526	ENSG00000272356.1	RP5-1112D6.8	-4.26	2.5e-05	0.00233	-0.2	-0.19	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111309203~111313517:+
THCA	cis	rs7621331	1	rs13097946	ENSG00000273486.1	RP11-731C17.2	-4.26	2.5e-05	0.00233	-0.19	-0.19	Waist circumference adjusted for body mass index;	chr3:135994780	chr3:136837338~136839021:-
THCA	cis	rs4743820	0.503	rs4437763	ENSG00000235641.4	LINC00484	4.26	2.5e-05	0.00233	0.24	0.19	Ulcerative colitis;Inflammatory bowel disease;	chr9:91151297	chr9:91159573~91165658:+
THCA	cis	rs42648	0.935	rs2188232	ENSG00000225498.1	AC002064.5	4.26	2.5e-05	0.00233	0.2	0.19	Homocysteine levels;	chr7:90329000	chr7:90312496~90322592:+
THCA	cis	rs42648	0.935	rs2188233	ENSG00000225498.1	AC002064.5	4.26	2.5e-05	0.00233	0.2	0.19	Homocysteine levels;	chr7:90329001	chr7:90312496~90322592:+
THCA	cis	rs758324	0.704	rs493829	ENSG00000237714.1	P4HA2-AS1	-4.26	2.5e-05	0.00233	-0.26	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131961350	chr5:132184876~132192808:+
THCA	cis	rs801193	1	rs2707856	ENSG00000272831.1	RP11-792A8.4	4.26	2.5e-05	0.00233	0.12	0.19	Aortic root size;	chr7:66746023	chr7:66739829~66740385:-
THCA	cis	rs17695224	1	rs17695224	ENSG00000275055.1	CTC-471J1.11	-4.26	2.5e-05	0.00233	-0.16	-0.19	HDL cholesterol;HDL cholesterol levels;	chr19:51820963	chr19:52049007~52049754:+
THCA	cis	rs7985	0.901	rs6005133	ENSG00000244625.4	MIATNB	4.26	2.5e-05	0.00233	0.22	0.19	Electroencephalogram traits;	chr22:26681021	chr22:26672767~26780207:+
THCA	cis	rs116095464	0.558	rs12173015	ENSG00000248925.1	CTD-2083E4.6	-4.26	2.5e-05	0.00233	-0.27	-0.19	Breast cancer;	chr5:269852	chr5:269858~271516:-
THCA	cis	rs2839627	0.561	rs8126478	ENSG00000225218.1	AP001628.6	4.26	2.5e-05	0.00233	0.29	0.19	Information processing speed;	chr21:42898558	chr21:42831040~42836477:-
THCA	cis	rs4713118	0.513	rs149975	ENSG00000261839.1	RP1-265C24.8	4.26	2.5e-05	0.00233	0.2	0.19	Parkinson's disease;	chr6:28018562	chr6:28136849~28139678:+
THCA	cis	rs1061377	0.513	rs6840214	ENSG00000249685.1	RP11-360F5.3	-4.26	2.5e-05	0.00233	-0.27	-0.19	Uric acid levels;	chr4:39118999	chr4:39133913~39135608:+
THCA	cis	rs12681963	0.688	rs16876622	ENSG00000272375.1	RP11-51J9.6	4.26	2.5e-05	0.00233	0.3	0.19	Migraine;	chr8:30178120	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs10503864	ENSG00000272375.1	RP11-51J9.6	-4.26	2.5e-05	0.00233	-0.3	-0.19	Migraine;	chr8:30193697	chr8:30197404~30198048:+
THCA	cis	rs7267979	1	rs2258719	ENSG00000276952.1	RP5-965G21.6	4.26	2.5e-05	0.00233	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25284915~25285588:-
THCA	cis	rs8105895	0.935	rs62110989	ENSG00000269345.1	VN1R85P	4.26	2.5e-05	0.00233	0.27	0.19	Body mass index (change over time);	chr19:22077497	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.935	rs62110992	ENSG00000269345.1	VN1R85P	4.26	2.5e-05	0.00233	0.27	0.19	Body mass index (change over time);	chr19:22078714	chr19:22174766~22175191:-
THCA	cis	rs7772486	0.79	rs2814880	ENSG00000270638.1	RP3-466P17.1	4.26	2.5e-05	0.00233	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs4435956	ENSG00000270638.1	RP3-466P17.1	-4.26	2.5e-05	0.00233	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs6926076	ENSG00000270638.1	RP3-466P17.1	-4.26	2.5e-05	0.00233	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145735570~145737218:+
THCA	cis	rs56313388	0.522	rs1362568	ENSG00000246379.5	RP11-461O7.1	-4.26	2.5e-05	0.00233	-0.2	-0.19	Pulse pressure;	chr16:56133998	chr16:56092987~56191094:-
THCA	cis	rs2033711	0.503	rs7254299	ENSG00000268230.4	CTD-2619J13.8	-4.26	2.5e-05	0.00233	-0.19	-0.19	Uric acid clearance;	chr19:58373598	chr19:58346854~58362751:-
THCA	cis	rs875971	0.929	rs34406470	ENSG00000229886.1	RP5-1132H15.3	4.26	2.51e-05	0.00233	0.2	0.19	Aortic root size;	chr7:66464969	chr7:66025126~66031544:-
THCA	cis	rs8081395	0.836	rs1295926	ENSG00000267302.4	RP11-178C3.2	-4.26	2.51e-05	0.00233	-0.23	-0.19	White blood cell count;	chr17:59832012	chr17:59964832~59996972:+
THCA	cis	rs17818399	0.926	rs13032670	ENSG00000279254.1	RP11-536C12.1	-4.26	2.51e-05	0.00233	-0.2	-0.19	Height;	chr2:46603655	chr2:46668870~46670778:+
THCA	cis	rs7819412	0.807	rs10105315	ENSG00000206014.6	OR7E161P	4.26	2.51e-05	0.00233	0.22	0.19	Triglycerides;	chr8:11074693	chr8:11928597~11929563:-
THCA	cis	rs868036	0.681	rs28626095	ENSG00000270964.1	RP11-502I4.3	-4.26	2.51e-05	0.00233	-0.18	-0.19	Restless legs syndrome;	chr15:67774391	chr15:67541072~67542604:-
THCA	cis	rs4879656	0.741	rs10758183	ENSG00000225693.1	LAGE3P1	4.26	2.51e-05	0.00233	0.22	0.19	Menopause (age at onset);	chr9:33055473	chr9:33019682~33020165:-
THCA	cis	rs35176054	0.73	rs35053579	ENSG00000280693.1	SH3PXD2A-AS1	-4.26	2.51e-05	0.00233	-0.37	-0.19	Atrial fibrillation;	chr10:103750997	chr10:103745966~103755423:+
THCA	cis	rs35176054	0.558	rs11592714	ENSG00000280693.1	SH3PXD2A-AS1	-4.26	2.51e-05	0.00233	-0.37	-0.19	Atrial fibrillation;	chr10:103751889	chr10:103745966~103755423:+
THCA	cis	rs35176054	0.73	rs11592832	ENSG00000280693.1	SH3PXD2A-AS1	-4.26	2.51e-05	0.00233	-0.37	-0.19	Atrial fibrillation;	chr10:103752428	chr10:103745966~103755423:+
THCA	cis	rs35176054	0.73	rs7920154	ENSG00000280693.1	SH3PXD2A-AS1	-4.26	2.51e-05	0.00233	-0.37	-0.19	Atrial fibrillation;	chr10:103754715	chr10:103745966~103755423:+
THCA	cis	rs123509	0.913	rs121993	ENSG00000173811.9	CCDC13-AS1	4.26	2.51e-05	0.00233	0.22	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42735109	chr3:42732575~42746768:+
THCA	cis	rs1577330	0.948	rs10967704	ENSG00000254396.1	RP11-56F10.3	4.26	2.51e-05	0.00233	0.23	0.19	IgG glycosylation;	chr9:27088016	chr9:27102630~27104728:+
THCA	cis	rs3002142	1	rs3008607	ENSG00000272750.1	RP11-378J18.8	-4.26	2.51e-05	0.00233	-0.26	-0.19	LDL peak particle diameter (total fat intake interaction);	chr1:222612350	chr1:222658867~222661512:-
THCA	cis	rs3002142	0.908	rs3008608	ENSG00000272750.1	RP11-378J18.8	-4.26	2.51e-05	0.00233	-0.26	-0.19	LDL peak particle diameter (total fat intake interaction);	chr1:222612656	chr1:222658867~222661512:-
THCA	cis	rs9863	0.794	rs7133378	ENSG00000270028.1	RP11-380L11.4	4.26	2.51e-05	0.00233	0.21	0.19	White blood cell count;	chr12:123924955	chr12:123925461~123926083:-
THCA	cis	rs116248771	0.739	rs10276	ENSG00000271778.1	RP11-379F4.8	4.26	2.51e-05	0.00233	0.25	0.19	diarrhoeal disease at age 2;	chr3:158697377	chr3:158782547~158783124:+
THCA	cis	rs944289	0.615	rs1333312	ENSG00000258844.1	RP11-259K15.2	4.26	2.51e-05	0.00233	0.18	0.19	Thyroid cancer;	chr14:36093396	chr14:36214607~36235608:+
THCA	cis	rs172166	0.637	rs1225597	ENSG00000261839.1	RP1-265C24.8	4.26	2.51e-05	0.00233	0.2	0.19	Cardiac Troponin-T levels;	chr6:28194309	chr6:28136849~28139678:+
THCA	cis	rs172166	0.637	rs1071893	ENSG00000261839.1	RP1-265C24.8	4.26	2.51e-05	0.00233	0.2	0.19	Cardiac Troponin-T levels;	chr6:28199857	chr6:28136849~28139678:+
THCA	cis	rs6449502	0.92	rs295557	ENSG00000251279.1	CTC-436P18.1	4.26	2.51e-05	0.00233	0.32	0.19	Mean platelet volume;	chr5:61105779	chr5:61162070~61232040:+
THCA	cis	rs2033711	0.654	rs734380	ENSG00000269054.1	CTD-2619J13.3	-4.26	2.51e-05	0.00233	-0.16	-0.19	Uric acid clearance;	chr19:58387596	chr19:58362585~58366591:+
THCA	cis	rs12936587	0.581	rs7209595	ENSG00000223979.2	SMCR2	4.26	2.51e-05	0.00234	0.2	0.19	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17729605	chr17:17674026~17677688:-
THCA	cis	rs2070488	1	rs4147024	ENSG00000229589.1	ACVR2B-AS1	4.26	2.51e-05	0.00234	0.18	0.19	Electrocardiographic conduction measures;	chr3:38415173	chr3:38451027~38454820:-
THCA	cis	rs10256972	0.552	rs2960837	ENSG00000225146.1	AC073957.15	4.26	2.51e-05	0.00234	0.21	0.19	Endometriosis;Longevity;	chr7:1164321	chr7:1029025~1043891:+
THCA	cis	rs7924176	0.601	rs7099026	ENSG00000213731.2	RAB5CP1	-4.26	2.51e-05	0.00234	-0.23	-0.19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74423435~74424014:-
THCA	cis	rs1555322	0.872	rs2425046	ENSG00000279253.1	RP4-614O4.13	-4.26	2.51e-05	0.00234	-0.29	-0.19	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35262727~35264187:-
THCA	cis	rs752010	0.875	rs11210502	ENSG00000230638.4	RP11-486B10.4	-4.26	2.51e-05	0.00234	-0.21	-0.19	Lupus nephritis in systemic lupus erythematosus;	chr1:41628041	chr1:41542069~41544310:+
THCA	cis	rs7520050	0.807	rs12025621	ENSG00000280836.1	AL355480.1	4.26	2.51e-05	0.00234	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45581219~45581321:-
THCA	cis	rs4682868	0.611	rs7614670	ENSG00000273328.4	RP11-141M3.6	-4.26	2.51e-05	0.00234	-0.23	-0.19	Monocyte percentage of white cells;	chr3:42879906	chr3:42809414~42908105:+
THCA	cis	rs6570726	0.791	rs1509214	ENSG00000270638.1	RP3-466P17.1	-4.26	2.51e-05	0.00234	-0.16	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145735570~145737218:+
THCA	cis	rs8002861	0.664	rs9533686	ENSG00000274001.1	RP11-5G9.5	4.26	2.51e-05	0.00234	0.23	0.19	Leprosy;	chr13:43894358	chr13:43877715~43878163:-
THCA	cis	rs7520050	0.807	rs28647556	ENSG00000280836.1	AL355480.1	-4.26	2.51e-05	0.00234	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.807	rs4274104	ENSG00000280836.1	AL355480.1	-4.26	2.51e-05	0.00234	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45581219~45581321:-
THCA	cis	rs11658311	0.85	rs8079880	ENSG00000232344.2	AC087163.2	4.26	2.51e-05	0.00234	0.28	0.19	Obsessive-compulsive symptoms;	chr17:17726678	chr17:18010643~18011822:+
THCA	cis	rs4415084	0.774	rs4571481	ENSG00000272335.1	RP11-53O19.3	-4.26	2.51e-05	0.00234	-0.16	-0.19	Breast cancer;	chr5:44687331	chr5:44826076~44828592:+
THCA	cis	rs4415084	0.87	rs10447145	ENSG00000272335.1	RP11-53O19.3	-4.26	2.51e-05	0.00234	-0.16	-0.19	Breast cancer;	chr5:44689694	chr5:44826076~44828592:+
THCA	cis	rs62158800	0.638	rs1155112	ENSG00000237880.1	AC096669.2	4.26	2.51e-05	0.00234	0.2	0.19	Facial morphology (factor 22);	chr2:107684908	chr2:107385632~107542649:-
THCA	cis	rs2692947	0.537	rs72821437	ENSG00000235959.1	AC009237.17	-4.26	2.51e-05	0.00234	-0.21	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95535051	chr2:95640181~95640604:-
THCA	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	4.26	2.51e-05	0.00234	0.22	0.19	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
THCA	cis	rs2439831	0.681	rs484846	ENSG00000166763.7	STRCP1	4.26	2.51e-05	0.00234	0.25	0.19	Lung cancer in ever smokers;	chr15:43308605	chr15:43699488~43718184:-
THCA	cis	rs6828577	0.862	rs298998	ENSG00000281731.1	RP11-384K6.8	4.26	2.52e-05	0.00234	0.22	0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118702312	chr4:118664087~118685341:-
THCA	cis	rs75504410	0.579	rs168088	ENSG00000231160.8	KLF3-AS1	-4.26	2.52e-05	0.00234	-0.14	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38611087	chr4:38612701~38664883:-
THCA	cis	rs75504410	0.579	rs337643	ENSG00000231160.8	KLF3-AS1	-4.26	2.52e-05	0.00234	-0.14	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38611522	chr4:38612701~38664883:-
THCA	cis	rs6138458	1	rs7268095	ENSG00000274173.1	RP4-568C11.4	4.26	2.52e-05	0.00234	0.18	0.19	Blood protein levels;	chr20:24991697	chr20:24931840~24932983:+
THCA	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	4.26	2.52e-05	0.00234	0.23	0.19	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	4.26	2.52e-05	0.00234	0.23	0.19	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
THCA	cis	rs11671005	0.779	rs55875034	ENSG00000268049.1	CTD-2619J13.9	-4.26	2.52e-05	0.00234	-0.3	-0.19	Mean platelet volume;	chr19:58472191	chr19:58357999~58359603:+
THCA	cis	rs427943	0.864	rs2838813	ENSG00000223768.1	LINC00205	-4.26	2.52e-05	0.00234	-0.17	-0.19	Body mass index;	chr21:45207772	chr21:45293285~45297354:+
THCA	cis	rs10833905	0.877	rs11026946	ENSG00000246225.5	RP11-17A1.3	-4.26	2.52e-05	0.00234	-0.28	-0.19	Sudden cardiac arrest;	chr11:23053292	chr11:22829380~22945393:+
THCA	cis	rs9925964	0.933	rs2359612	ENSG00000260911.2	RP11-196G11.2	4.26	2.52e-05	0.00234	0.16	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31092475	chr16:31043150~31049868:+
THCA	cis	rs7141336	1	rs7141114	ENSG00000258884.1	CTD-3035D6.2	4.26	2.52e-05	0.00234	0.25	0.19	Anxiety disorder;	chr14:90819690	chr14:90822365~90828128:-
THCA	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	4.26	2.52e-05	0.00234	0.22	0.19	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
THCA	cis	rs34929064	0.881	rs2961313	ENSG00000179428.2	AC073072.5	-4.26	2.52e-05	0.00234	-0.22	-0.19	Major depression and alcohol dependence;	chr7:22695601	chr7:22725395~22727620:-
THCA	cis	rs9326246	0.545	rs549125	ENSG00000254851.1	RP11-109L13.1	4.26	2.52e-05	0.00234	0.44	0.19	Coronary artery disease;	chr11:116650209	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs533668	ENSG00000254851.1	RP11-109L13.1	4.26	2.52e-05	0.00234	0.44	0.19	Coronary artery disease;	chr11:116650418	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs573985	ENSG00000254851.1	RP11-109L13.1	4.26	2.52e-05	0.00234	0.44	0.19	Coronary artery disease;	chr11:116650599	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs575906	ENSG00000254851.1	RP11-109L13.1	4.26	2.52e-05	0.00234	0.44	0.19	Coronary artery disease;	chr11:116650841	chr11:117135528~117138582:+
THCA	cis	rs6496932	0.802	rs10163187	ENSG00000259630.2	CTD-2262B20.1	4.26	2.52e-05	0.00234	0.23	0.19	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85415228~85415633:+
THCA	cis	rs6840360	0.692	rs4479686	ENSG00000251611.1	RP11-610P16.1	-4.26	2.52e-05	0.00234	-0.14	-0.19	Intelligence (multi-trait analysis);	chr4:151478172	chr4:151407551~151408835:-
THCA	cis	rs780094	0.5	rs74175068	ENSG00000234072.1	AC074117.10	4.26	2.52e-05	0.00234	0.15	0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27610635	chr2:27356246~27367622:+
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000265443.1	CTD-2349P21.6	-4.26	2.52e-05	0.00235	-0.34	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000265443.1	CTD-2349P21.6	-4.26	2.52e-05	0.00235	-0.34	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30726305~30727564:-
THCA	cis	rs2153535	0.561	rs9505511	ENSG00000230939.1	RP11-314C16.1	-4.26	2.52e-05	0.00235	-0.2	-0.19	Motion sickness;	chr6:8667322	chr6:8784178~8785445:+
THCA	cis	rs1124769	0.506	rs2614766	ENSG00000259378.1	DCAF13P3	-4.26	2.52e-05	0.00235	-0.27	-0.19	Cognitive performance;	chr15:50852394	chr15:50944663~50945996:+
THCA	cis	rs2380205	0.967	rs713588	ENSG00000232807.2	RP11-536K7.3	4.26	2.52e-05	0.00235	0.18	0.19	Breast cancer;	chr10:5844999	chr10:5934270~5945900:-
THCA	cis	rs5758659	0.714	rs5758578	ENSG00000281538.1	RP4-669P10.20	-4.26	2.52e-05	0.00235	-0.18	-0.19	Cognitive function;	chr22:42094288	chr22:42138060~42139726:+
THCA	cis	rs7267979	0.934	rs2500399	ENSG00000274973.1	RP13-401N8.7	4.26	2.52e-05	0.00235	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25845497~25845862:+
THCA	cis	rs786425	0.932	rs786448	ENSG00000270095.1	RP11-214K3.18	4.26	2.52e-05	0.00235	0.22	0.19	Pubertal anthropometrics;	chr12:123585667	chr12:123971457~123971714:-
THCA	cis	rs786425	0.966	rs786449	ENSG00000270095.1	RP11-214K3.18	4.26	2.52e-05	0.00235	0.22	0.19	Pubertal anthropometrics;	chr12:123587181	chr12:123971457~123971714:-
THCA	cis	rs786425	0.966	rs6551	ENSG00000270095.1	RP11-214K3.18	4.26	2.52e-05	0.00235	0.22	0.19	Pubertal anthropometrics;	chr12:123597693	chr12:123971457~123971714:-
THCA	cis	rs786425	0.838	rs1543075	ENSG00000270095.1	RP11-214K3.18	4.26	2.52e-05	0.00235	0.22	0.19	Pubertal anthropometrics;	chr12:123601901	chr12:123971457~123971714:-
THCA	cis	rs1842579	0.931	rs1010058	ENSG00000272691.1	RP11-290M5.4	-4.26	2.52e-05	0.00235	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85842542	chr1:85578500~85578742:-
THCA	cis	rs17382723	0.887	rs75895048	ENSG00000225521.1	AC005237.4	4.26	2.52e-05	0.00235	0.25	0.19	Height;	chr2:241079579	chr2:241015599~241064116:-
THCA	cis	rs8028182	0.549	rs7402844	ENSG00000260274.1	RP11-817O13.8	-4.25	2.52e-05	0.00235	-0.14	-0.19	Sudden cardiac arrest;	chr15:75345055	chr15:75368155~75369584:+
THCA	cis	rs7260598	0.685	rs78368900	ENSG00000268442.1	CTD-2027I19.2	4.25	2.52e-05	0.00235	0.29	0.19	Response to taxane treatment (placlitaxel);	chr19:23814332	chr19:24162370~24163425:-
THCA	cis	rs4578769	0.959	rs4800430	ENSG00000265939.1	UBE2CP2	4.25	2.52e-05	0.00235	0.23	0.19	Eosinophil percentage of white cells;	chr18:22803299	chr18:22900486~22900995:-
THCA	cis	rs2348418	0.639	rs2881788	ENSG00000247934.4	RP11-967K21.1	-4.25	2.53e-05	0.00235	-0.17	-0.19	Lung function (FEV1);Lung function (FVC);	chr12:28119641	chr12:28163298~28190738:-
THCA	cis	rs7824557	0.65	rs2572406	ENSG00000154316.13	TDH	-4.25	2.53e-05	0.00235	-0.13	-0.19	Retinal vascular caliber;	chr8:11234743	chr8:11339637~11368452:+
THCA	cis	rs734999	0.545	rs7368105	ENSG00000225931.3	RP3-395M20.7	4.25	2.53e-05	0.00235	0.23	0.19	Ulcerative colitis;	chr1:2625109	chr1:2566410~2569888:+
THCA	cis	rs734999	0.545	rs7364820	ENSG00000225931.3	RP3-395M20.7	4.25	2.53e-05	0.00235	0.23	0.19	Ulcerative colitis;	chr1:2625270	chr1:2566410~2569888:+
THCA	cis	rs5758659	0.714	rs5758574	ENSG00000273366.1	CTA-989H11.1	4.25	2.53e-05	0.00235	0.23	0.19	Cognitive function;	chr22:42085396	chr22:42278188~42278846:+
THCA	cis	rs10760158	0.832	rs4837818	ENSG00000226752.6	PSMD5-AS1	-4.25	2.53e-05	0.00235	-0.23	-0.19	Pulse pressure;	chr9:121240041	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs10760160	ENSG00000226752.6	PSMD5-AS1	-4.25	2.53e-05	0.00235	-0.23	-0.19	Pulse pressure;	chr9:121241048	chr9:120824828~120854385:+
THCA	cis	rs12143943	0.866	rs4252745	ENSG00000240219.1	RP11-430C7.5	-4.25	2.53e-05	0.00235	-0.17	-0.19	Cognitive performance;	chr1:204550059	chr1:204626775~204629712:+
THCA	cis	rs7560272	0.538	rs35767294	ENSG00000273245.1	RP11-434P11.2	-4.25	2.53e-05	0.00235	-0.22	-0.19	Schizophrenia;	chr2:73695707	chr2:73750256~73750786:-
THCA	cis	rs1728785	1	rs1170436	ENSG00000274698.1	RP11-71L14.4	4.25	2.53e-05	0.00235	0.27	0.19	Ulcerative colitis;	chr16:68573583	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs1170437	ENSG00000274698.1	RP11-71L14.4	4.25	2.53e-05	0.00235	0.27	0.19	Ulcerative colitis;	chr16:68574040	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs1170438	ENSG00000274698.1	RP11-71L14.4	4.25	2.53e-05	0.00235	0.27	0.19	Ulcerative colitis;	chr16:68574353	chr16:68450283~68452318:+
THCA	cis	rs853679	0.546	rs35017208	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28377505	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs13213152	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28381921	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs36092177	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28390030	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs13213986	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28390232	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs2232429	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28391855	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs2232426	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28392882	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs34546986	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28394532	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs34871267	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28396455	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs2232423	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28398374	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs35883476	ENSG00000272009.1	RP1-313I6.12	-4.25	2.53e-05	0.00235	-0.37	-0.19	Depression;	chr6:28400731	chr6:28078792~28081130:-
THCA	cis	rs17270561	0.609	rs760698	ENSG00000272462.2	U91328.19	-4.25	2.53e-05	0.00235	-0.17	-0.19	Iron status biomarkers;	chr6:25685661	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs9379778	ENSG00000272462.2	U91328.19	-4.25	2.53e-05	0.00235	-0.17	-0.19	Iron status biomarkers;	chr6:25687351	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4711093	ENSG00000272462.2	U91328.19	-4.25	2.53e-05	0.00235	-0.17	-0.19	Iron status biomarkers;	chr6:25687667	chr6:25992662~26001775:+
THCA	cis	rs1823874	0.653	rs12902823	ENSG00000254744.3	CTD-3076O17.1	-4.25	2.53e-05	0.00235	-0.2	-0.19	IgG glycosylation;	chr15:99812013	chr15:99970215~99974010:+
THCA	cis	rs202072	0.818	rs405078	ENSG00000272379.1	RP1-257A7.5	4.25	2.53e-05	0.00235	0.29	0.19	HIV-1 viral setpoint;	chr6:13279635	chr6:13290018~13290490:-
THCA	cis	rs6840258	0.891	rs1842685	ENSG00000251411.1	RP11-397E7.4	-4.25	2.53e-05	0.00235	-0.23	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87139680	chr4:86913266~86914817:-
THCA	cis	rs4434872	0.536	rs2297895	ENSG00000223599.1	RP11-216N14.7	-4.25	2.53e-05	0.00235	-0.37	-0.19	Conduct disorder (symptom count);	chr1:153941208	chr1:153852106~153853414:-
THCA	cis	rs7181230	1	rs9972424	ENSG00000275636.1	RP11-521C20.5	4.25	2.53e-05	0.00235	0.19	0.19	Dehydroepiandrosterone sulphate levels;	chr15:40073650	chr15:40078892~40079347:+
THCA	cis	rs2692947	0.77	rs72823920	ENSG00000232931.4	LINC00342	4.25	2.53e-05	0.00235	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95765128	chr2:95807118~95816215:-
THCA	cis	rs7824557	0.591	rs2572452	ENSG00000154316.13	TDH	4.25	2.53e-05	0.00235	0.14	0.19	Retinal vascular caliber;	chr8:11370745	chr8:11339637~11368452:+
THCA	cis	rs10833905	1	rs12421624	ENSG00000246225.5	RP11-17A1.3	-4.25	2.53e-05	0.00235	-0.28	-0.19	Sudden cardiac arrest;	chr11:22994882	chr11:22829380~22945393:+
THCA	cis	rs2153535	0.585	rs6915130	ENSG00000230939.1	RP11-314C16.1	-4.25	2.53e-05	0.00235	-0.2	-0.19	Motion sickness;	chr6:8661262	chr6:8784178~8785445:+
THCA	cis	rs758324	0.704	rs40401	ENSG00000237714.1	P4HA2-AS1	-4.25	2.53e-05	0.00235	-0.26	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132060785	chr5:132184876~132192808:+
THCA	cis	rs6449502	0.92	rs329618	ENSG00000251279.1	CTC-436P18.1	4.25	2.53e-05	0.00235	0.34	0.19	Mean platelet volume;	chr5:60993696	chr5:61162070~61232040:+
THCA	cis	rs758324	0.617	rs246842	ENSG00000237714.1	P4HA2-AS1	-4.25	2.53e-05	0.00235	-0.29	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132066108	chr5:132184876~132192808:+
THCA	cis	rs3740713	1	rs73440636	ENSG00000256464.1	YWHABP2	4.25	2.53e-05	0.00235	0.34	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr11:18490243~18490955:-
THCA	cis	rs9549367	0.577	rs776904	ENSG00000269125.1	RP11-98F14.11	-4.25	2.53e-05	0.00235	-0.26	-0.19	Platelet distribution width;	chr13:113156228	chr13:113165002~113165183:-
THCA	cis	rs227275	0.556	rs12508069	ENSG00000248971.2	KRT8P46	-4.25	2.53e-05	0.00236	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102728746~102730171:-
THCA	cis	rs7246760	0.867	rs57999229	ENSG00000267106.4	ZNF561-AS1	4.25	2.53e-05	0.00236	0.36	0.19	Pursuit maintenance gain;	chr19:9706681	chr19:9621291~9645896:+
THCA	cis	rs7182948	1	rs12902107	ENSG00000259531.2	RP11-295H24.3	-4.25	2.53e-05	0.00236	-0.23	-0.19	Lung adenocarcinoma;	chr15:49575126	chr15:49365124~49366685:-
THCA	cis	rs7554547	0.765	rs34175640	ENSG00000199347.1	RNU5E-1	4.25	2.53e-05	0.00236	0.26	0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11892155	chr1:11908152~11908271:+
THCA	cis	rs9879311	0.643	rs1473183	ENSG00000240288.6	GHRLOS	4.25	2.54e-05	0.00236	0.19	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10370143	chr3:10285754~10293449:+
THCA	cis	rs12893668	0.644	rs12890820	ENSG00000252469.1	RNU7-160P	4.25	2.54e-05	0.00236	0.23	0.19	Reticulocyte count;	chr14:103568512	chr14:103550345~103550406:+
THCA	cis	rs8113308	0.689	rs8112515	ENSG00000269483.1	AC006272.1	4.25	2.54e-05	0.00236	0.29	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987997	chr19:51839924~51843324:-
THCA	cis	rs12681288	0.823	rs12681230	ENSG00000260721.1	AF067845.1	4.25	2.54e-05	0.00236	0.23	0.19	Schizophrenia;	chr8:1044422	chr8:1368642~1369833:-
THCA	cis	rs7267979	1	rs6050544	ENSG00000276952.1	RP5-965G21.6	-4.25	2.54e-05	0.00236	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25284915~25285588:-
THCA	cis	rs1005277	0.522	rs289643	ENSG00000226578.1	RP11-258F22.1	-4.25	2.54e-05	0.00236	-0.22	-0.19	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:37775371~37784131:-
THCA	cis	rs10090774	0.965	rs170068	ENSG00000279766.1	RP11-642A1.2	4.25	2.54e-05	0.00236	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141003373	chr8:140572142~140572812:-
THCA	cis	rs910873	0.505	rs6059961	ENSG00000276073.1	RP5-1125A11.7	-4.25	2.54e-05	0.00236	-0.24	-0.19	Melanoma;	chr20:34643686	chr20:33985617~33988989:-
THCA	cis	rs7809615	0.748	rs34257469	ENSG00000244219.5	GS1-259H13.2	-4.25	2.54e-05	0.00236	-0.32	-0.19	Blood metabolite ratios;	chr7:99552562	chr7:99598066~99610813:+
THCA	cis	rs9341808	0.935	rs1535825	ENSG00000272129.1	RP11-250B2.6	-4.25	2.54e-05	0.00236	-0.24	-0.19	Sitting height ratio;	chr6:80228869	chr6:80355424~80356859:+
THCA	cis	rs200972	1	rs200972	ENSG00000280107.1	AL022393.9	-4.25	2.54e-05	0.00236	-0.2	-0.19	Urinary tract infection frequency;	chr6:27891059	chr6:28170845~28172521:+
THCA	cis	rs7614311	0.594	rs2280162	ENSG00000271843.1	RP11-245J9.5	-4.25	2.54e-05	0.00236	-0.3	-0.19	Lung function (FVC);Lung function (FEV1);	chr3:64011815	chr3:64008082~64008692:-
THCA	cis	rs875971	1	rs1144895	ENSG00000272831.1	RP11-792A8.4	-4.25	2.54e-05	0.00236	-0.13	-0.19	Aortic root size;	chr7:66076320	chr7:66739829~66740385:-
THCA	cis	rs34102591	0.826	rs12322694	ENSG00000269997.1	RP11-214K3.21	-4.25	2.54e-05	0.00236	-0.29	-0.19	Schizophrenia;	chr12:123922745	chr12:123966077~123966629:-
THCA	cis	rs10911902	0.643	rs3766707	ENSG00000229739.2	RP11-295K2.3	-4.25	2.54e-05	0.00236	-0.29	-0.19	Schizophrenia;	chr1:186335955	chr1:186435161~186470291:+
THCA	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	4.25	2.54e-05	0.00236	0.22	0.19	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	4.25	2.54e-05	0.00236	0.22	0.19	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
THCA	cis	rs12440869	1	rs8029963	ENSG00000270964.1	RP11-502I4.3	-4.25	2.54e-05	0.00236	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67356317	chr15:67541072~67542604:-
THCA	cis	rs10875746	0.624	rs7297298	ENSG00000258273.1	RP11-370I10.4	4.25	2.54e-05	0.00236	0.27	0.19	Longevity (90 years and older);	chr12:48278523	chr12:48333755~48333901:-
THCA	cis	rs9467773	0.62	rs1027203	ENSG00000124549.13	BTN2A3P	4.25	2.54e-05	0.00236	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26421391~26432383:+
THCA	cis	rs4973397	0.765	rs2290130	ENSG00000224376.1	AC017104.6	4.25	2.54e-05	0.00236	0.22	0.19	Anti-saccade response;	chr2:231398416	chr2:231388976~231394991:+
THCA	cis	rs8141529	0.748	rs5762881	ENSG00000226471.5	CTA-292E10.6	-4.25	2.54e-05	0.00236	-0.16	-0.19	Lymphocyte counts;	chr22:28893358	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.748	rs9620841	ENSG00000226471.5	CTA-292E10.6	-4.25	2.54e-05	0.00236	-0.16	-0.19	Lymphocyte counts;	chr22:28894993	chr22:28800683~28848559:+
THCA	cis	rs9926296	0.609	rs4785714	ENSG00000274627.1	RP11-104N10.2	4.25	2.54e-05	0.00236	0.2	0.19	Vitiligo;	chr16:89731996	chr16:89516797~89522217:+
THCA	cis	rs10208649	1	rs10188834	ENSG00000233266.1	HMGB1P31	4.25	2.54e-05	0.00236	0.46	0.19	Body mass index;	chr2:53937236	chr2:54051334~54051760:+
THCA	cis	rs11672691	0.519	rs10407939	ENSG00000270164.1	LINC01480	-4.25	2.54e-05	0.00236	-0.17	-0.19	Prostate cancer;	chr19:41502561	chr19:41535183~41536904:+
THCA	cis	rs9992667	0.704	rs3900761	ENSG00000231160.8	KLF3-AS1	-4.25	2.54e-05	0.00236	-0.16	-0.19	Eosinophil percentage of granulocytes;	chr4:38609961	chr4:38612701~38664883:-
THCA	cis	rs12682352	0.535	rs12677550	ENSG00000248538.5	RP11-10A14.5	4.25	2.54e-05	0.00236	0.24	0.19	Neuroticism;	chr8:8786812	chr8:9189011~9202854:+
THCA	cis	rs758747	0.574	rs12933120	ENSG00000262312.2	LA16c-390H2.4	4.25	2.54e-05	0.00236	0.24	0.19	Body mass index;	chr16:3584745	chr16:3542739~3545785:+
THCA	cis	rs7267979	0.789	rs62213729	ENSG00000274414.1	RP5-965G21.4	4.25	2.54e-05	0.00236	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:25239007~25245229:-
THCA	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	4.25	2.54e-05	0.00236	0.29	0.19	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
THCA	cis	rs516805	0.923	rs538457	ENSG00000279114.1	RP3-425C14.5	-4.25	2.54e-05	0.00236	-0.19	-0.19	Lymphocyte counts;	chr6:122485610	chr6:122471923~122484161:+
THCA	cis	rs516805	0.961	rs9385248	ENSG00000279114.1	RP3-425C14.5	-4.25	2.54e-05	0.00236	-0.19	-0.19	Lymphocyte counts;	chr6:122490982	chr6:122471923~122484161:+
THCA	cis	rs6012564	1	rs6125540	ENSG00000230758.1	SNAP23P	4.25	2.55e-05	0.00236	0.23	0.19	Anger;	chr20:49087502	chr20:49038357~49038602:-
THCA	cis	rs9902453	0.904	rs4598962	ENSG00000263370.1	RP11-68I3.5	4.25	2.55e-05	0.00236	0.25	0.19	Coffee consumption (cups per day);	chr17:29966930	chr17:29639627~29640825:+
THCA	cis	rs4654783	0.505	rs7544210	ENSG00000228397.1	RP1-224A6.3	-4.25	2.55e-05	0.00237	-0.27	-0.19	Endometriosis;	chr1:22128649	chr1:22023994~22024968:-
THCA	cis	rs8062405	0.69	rs62034351	ENSG00000261766.1	RP11-22P6.2	-4.25	2.55e-05	0.00237	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28862166~28863340:-
THCA	cis	rs10771431	1	rs10771431	ENSG00000256427.1	RP11-118B22.4	4.25	2.55e-05	0.00237	0.21	0.19	Breast size;	chr12:9228263	chr12:9246497~9257960:+
THCA	cis	rs4908768	0.906	rs12117910	ENSG00000232912.4	RP5-1115A15.1	-4.25	2.55e-05	0.00237	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496893	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.906	rs12403339	ENSG00000232912.4	RP5-1115A15.1	-4.25	2.55e-05	0.00237	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8498232	chr1:8424645~8434838:+
THCA	cis	rs6088590	0.965	rs6087639	ENSG00000276073.1	RP5-1125A11.7	-4.25	2.55e-05	0.00237	-0.18	-0.19	Coronary artery disease;	chr20:34856063	chr20:33985617~33988989:-
THCA	cis	rs4748857	0.502	rs4019731	ENSG00000224215.1	RP11-371A19.2	-4.25	2.55e-05	0.00237	-0.22	-0.19	Systemic lupus erythematosus;	chr10:23384369	chr10:23343957~23345181:+
THCA	cis	rs12900463	0.813	rs187316	ENSG00000259728.4	LINC00933	4.25	2.55e-05	0.00237	0.26	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862764	chr15:84570649~84580175:+
THCA	cis	rs656319	0.605	rs13252276	ENSG00000261451.1	RP11-981G7.1	-4.25	2.55e-05	0.00237	-0.25	-0.19	Myopia (pathological);	chr8:10047203	chr8:10433672~10438312:+
THCA	cis	rs7115242	0.748	rs1035237	ENSG00000280143.1	AP000892.6	4.25	2.55e-05	0.00237	0.3	0.19	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117204967~117210292:+
THCA	cis	rs1124769	0.672	rs8043017	ENSG00000259378.1	DCAF13P3	4.25	2.55e-05	0.00237	0.29	0.19	Cognitive performance;	chr15:50871799	chr15:50944663~50945996:+
THCA	cis	rs4650994	0.593	rs12074085	ENSG00000273384.1	RP5-1098D14.1	-4.25	2.55e-05	0.00237	-0.25	-0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178535028	chr1:178651706~178652282:+
THCA	cis	rs12908161	1	rs35960805	ENSG00000188388.10	GOLGA6L3	4.25	2.55e-05	0.00237	0.25	0.19	Schizophrenia;	chr15:84800749	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs12912388	ENSG00000188388.10	GOLGA6L3	4.25	2.55e-05	0.00237	0.25	0.19	Schizophrenia;	chr15:84801319	chr15:85240472~85247170:+
THCA	cis	rs9868809	0.656	rs13324119	ENSG00000270441.1	RP11-694I15.7	4.25	2.55e-05	0.00237	0.26	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48673173	chr3:49140086~49160851:-
THCA	cis	rs7772486	0.79	rs2254283	ENSG00000270638.1	RP3-466P17.1	4.25	2.55e-05	0.00237	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145735570~145737218:+
THCA	cis	rs10875746	0.859	rs11168371	ENSG00000258273.1	RP11-370I10.4	4.25	2.55e-05	0.00237	0.28	0.19	Longevity (90 years and older);	chr12:48043903	chr12:48333755~48333901:-
THCA	cis	rs2933343	0.553	rs71331686	ENSG00000261159.1	RP11-723O4.9	4.25	2.55e-05	0.00237	0.2	0.19	IgG glycosylation;	chr3:128992585	chr3:128859716~128860526:-
THCA	cis	rs6921919	0.525	rs16894095	ENSG00000280107.1	AL022393.9	-4.25	2.55e-05	0.00237	-0.19	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28170845~28172521:+
THCA	cis	rs9595908	0.606	rs4942922	ENSG00000212293.1	SNORA16	4.25	2.55e-05	0.00237	0.23	0.19	Body mass index;	chr13:32806832	chr13:32420390~32420516:-
THCA	cis	rs7432375	0.901	rs35874192	ENSG00000273455.1	RP11-305O4.3	-4.25	2.55e-05	0.00237	-0.26	-0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136751162	chr3:136087475~136087913:-
THCA	cis	rs7432375	0.901	rs900818	ENSG00000273455.1	RP11-305O4.3	-4.25	2.55e-05	0.00237	-0.26	-0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136752973	chr3:136087475~136087913:-
THCA	cis	rs910873	1	rs62211619	ENSG00000276073.1	RP5-1125A11.7	4.25	2.55e-05	0.00237	0.37	0.19	Melanoma;	chr20:34823128	chr20:33985617~33988989:-
THCA	cis	rs910873	0.803	rs62211621	ENSG00000276073.1	RP5-1125A11.7	4.25	2.55e-05	0.00237	0.37	0.19	Melanoma;	chr20:34823858	chr20:33985617~33988989:-
THCA	cis	rs790006	0.959	rs11175284	ENSG00000243024.5	RPS11P6	-4.25	2.55e-05	0.00237	-0.24	-0.19	Response to cytidine analogues (gemcitabine);	chr12:64217273	chr12:64222337~64397065:+
THCA	cis	rs1560104	0.576	rs12708761	ENSG00000260601.1	RP11-552C15.1	-4.25	2.55e-05	0.00237	-0.23	-0.19	Obesity-related traits;	chr16:12617077	chr16:12545482~12546684:+
THCA	cis	rs9902453	0.791	rs2729451	ENSG00000263370.1	RP11-68I3.5	-4.25	2.55e-05	0.00237	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29804316	chr17:29639627~29640825:+
THCA	cis	rs1232027	0.666	rs13161245	ENSG00000249655.1	CTC-325J23.2	4.25	2.55e-05	0.00237	0.22	0.19	Huntington's disease progression;	chr5:80648914	chr5:80630313~80631590:-
THCA	cis	rs7554547	0.685	rs12724129	ENSG00000199347.1	RNU5E-1	-4.25	2.55e-05	0.00237	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11897582	chr1:11908152~11908271:+
THCA	cis	rs763121	0.706	rs3827356	ENSG00000273076.1	RP3-508I15.22	-4.25	2.56e-05	0.00237	-0.19	-0.19	Menopause (age at onset);	chr22:38668801	chr22:38743495~38743910:+
THCA	cis	rs10995505	0.589	rs10822140	ENSG00000232075.1	MRPL35P2	-4.25	2.56e-05	0.00237	-0.29	-0.19	Intelligence (multi-trait analysis);	chr10:63123267	chr10:63634317~63634827:-
THCA	cis	rs10995505	0.589	rs2896496	ENSG00000232075.1	MRPL35P2	-4.25	2.56e-05	0.00237	-0.29	-0.19	Intelligence (multi-trait analysis);	chr10:63123622	chr10:63634317~63634827:-
THCA	cis	rs1046491	1	rs1046491	ENSG00000264964.1	RP11-888D10.3	-4.25	2.56e-05	0.00237	-0.32	-0.19	Scarlet fever;	chr18:9282144	chr18:9315194~9334441:-
THCA	cis	rs800160	0.588	rs800146	ENSG00000199550.1	Y_RNA	4.25	2.56e-05	0.00237	0.27	0.19	Bacteremia;	chr11:2347753	chr11:2372638~2372750:+
THCA	cis	rs8062405	0.723	rs4788079	ENSG00000270424.1	RP11-1348G14.6	4.25	2.56e-05	0.00237	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28749959~28750595:-
THCA	cis	rs75059851	0.756	rs11223656	ENSG00000280237.1	MIR4697HG	4.25	2.56e-05	0.00237	0.22	0.19	Schizophrenia;	chr11:133973078	chr11:133896438~133901601:-
THCA	cis	rs75059851	0.756	rs11223658	ENSG00000280237.1	MIR4697HG	4.25	2.56e-05	0.00237	0.22	0.19	Schizophrenia;	chr11:133973321	chr11:133896438~133901601:-
THCA	cis	rs7577696	0.695	rs12997026	ENSG00000276334.1	AL133243.1	-4.25	2.56e-05	0.00238	-0.21	-0.19	Inflammatory biomarkers;	chr2:32169238	chr2:32521927~32523547:+
THCA	cis	rs481331	0.866	rs12259795	ENSG00000215146.4	RP11-313J2.1	4.25	2.56e-05	0.00238	0.3	0.19	Systemic juvenile idiopathic arthritis;	chr10:42488627	chr10:42331866~42367974:-
THCA	cis	rs12143943	0.834	rs34812029	ENSG00000240219.1	RP11-430C7.5	4.25	2.56e-05	0.00238	0.17	0.19	Cognitive performance;	chr1:204577859	chr1:204626775~204629712:+
THCA	cis	rs4788570	0.615	rs4788822	ENSG00000260185.1	RP11-432I5.6	-4.25	2.56e-05	0.00238	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71647612	chr16:71655027~71664212:+
THCA	cis	rs503425	0.688	rs2510902	ENSG00000255239.1	AP002954.6	-4.25	2.56e-05	0.00238	-0.29	-0.19	Systemic lupus erythematosus;	chr11:118829509	chr11:118688039~118690600:-
THCA	cis	rs4788570	0.615	rs11075894	ENSG00000260185.1	RP11-432I5.6	-4.25	2.56e-05	0.00238	-0.36	-0.19	Intelligence (multi-trait analysis);	chr16:71656127	chr16:71655027~71664212:+
THCA	cis	rs28735056	0.967	rs498541	ENSG00000261126.6	RP11-795F19.1	-4.25	2.56e-05	0.00238	-0.16	-0.19	Schizophrenia;	chr18:79829655	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.933	rs499260	ENSG00000261126.6	RP11-795F19.1	-4.25	2.56e-05	0.00238	-0.16	-0.19	Schizophrenia;	chr18:79829689	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.933	rs499472	ENSG00000261126.6	RP11-795F19.1	-4.25	2.56e-05	0.00238	-0.16	-0.19	Schizophrenia;	chr18:79829759	chr18:80046900~80095482:+
THCA	cis	rs13113518	1	rs7691799	ENSG00000272969.1	RP11-528I4.2	4.25	2.56e-05	0.00238	0.22	0.19	Height;	chr4:55545574	chr4:55547112~55547889:+
THCA	cis	rs13256369	1	rs10095733	ENSG00000254153.1	CTA-398F10.2	-4.25	2.56e-05	0.00238	-0.22	-0.19	Obesity-related traits;	chr8:8717136	chr8:8456909~8461337:-
THCA	cis	rs78487399	0.808	rs13396401	ENSG00000234936.1	AC010883.5	4.25	2.56e-05	0.00238	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43474074	chr2:43229573~43233394:+
THCA	cis	rs11671005	0.737	rs11673101	ENSG00000268049.1	CTD-2619J13.9	-4.25	2.56e-05	0.00238	-0.31	-0.19	Mean platelet volume;	chr19:58483686	chr19:58357999~58359603:+
THCA	cis	rs12935418	0.616	rs12444054	ENSG00000278985.1	RP11-303E16.9	4.25	2.56e-05	0.00238	0.24	0.19	Mean corpuscular volume;	chr16:80930320	chr16:80982319~80984094:-
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000254866.2	DEFB109P3	4.25	2.56e-05	0.00238	0.26	0.19	Neuroticism;	chr8:11986249	chr8:12150895~12151134:-
THCA	cis	rs7824557	0.505	rs2572440	ENSG00000206014.6	OR7E161P	-4.25	2.56e-05	0.00238	-0.22	-0.19	Retinal vascular caliber;	chr8:11391501	chr8:11928597~11929563:-
THCA	cis	rs11881751	0.779	rs10411858	ENSG00000267011.4	CTB-50L17.16	4.25	2.56e-05	0.00238	0.28	0.19	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr19:5036744	chr19:4457962~4471493:-
THCA	cis	rs67981189	0.896	rs2010061	ENSG00000269927.1	RP6-91H8.3	-4.25	2.56e-05	0.00238	-0.22	-0.19	Schizophrenia;	chr14:70899479	chr14:71141125~71143253:-
THCA	cis	rs2657294	0.73	rs1259505	ENSG00000233313.2	HMGA1P5	-4.25	2.56e-05	0.00238	-0.26	-0.19	Pneumonia;	chr10:75237183	chr10:75276376~75276646:-
THCA	cis	rs10946940	0.93	rs12215012	ENSG00000219392.1	RP1-265C24.5	4.25	2.56e-05	0.00238	0.22	0.19	Systemic lupus erythematosus;	chr6:27539715	chr6:28115628~28116551:+
THCA	cis	rs17095355	1	rs56273398	ENSG00000203876.8	ADD3-AS1	-4.25	2.56e-05	0.00238	-0.21	-0.19	Biliary atresia;	chr10:109948425	chr10:109940104~110008381:-
THCA	cis	rs6540731	0.905	rs6695681	ENSG00000226251.4	RP11-15I11.3	-4.25	2.56e-05	0.00238	-0.23	-0.19	Intelligence (childhood);	chr1:212215114	chr1:212225278~212238977:-
THCA	cis	rs6540731	0.905	rs7537062	ENSG00000226251.4	RP11-15I11.3	-4.25	2.56e-05	0.00238	-0.23	-0.19	Intelligence (childhood);	chr1:212215270	chr1:212225278~212238977:-
THCA	cis	rs724818	0.661	rs12499586	ENSG00000251609.2	SETP12	-4.25	2.56e-05	0.00238	-0.49	-0.19	Monobrow thickness;	chr4:120770044	chr4:120895494~120897083:-
THCA	cis	rs1842579	1	rs6698633	ENSG00000272691.1	RP11-290M5.4	-4.25	2.56e-05	0.00238	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85819101	chr1:85578500~85578742:-
THCA	cis	rs9959145	1	rs11660232	ENSG00000267199.1	RP11-861E21.2	4.25	2.56e-05	0.00238	0.24	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12585546	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs28527375	ENSG00000267199.1	RP11-861E21.2	4.25	2.56e-05	0.00238	0.24	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12593394	chr18:12438890~12448205:+
THCA	cis	rs9959145	0.925	rs75813125	ENSG00000267199.1	RP11-861E21.2	4.25	2.56e-05	0.00238	0.24	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12612326	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs28565322	ENSG00000267199.1	RP11-861E21.2	4.25	2.56e-05	0.00238	0.24	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12614184	chr18:12438890~12448205:+
THCA	cis	rs4660214	0.666	rs3116398	ENSG00000228060.1	RP11-69E11.8	4.25	2.57e-05	0.00238	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39565160~39573203:+
THCA	cis	rs6088590	1	rs6120748	ENSG00000276073.1	RP5-1125A11.7	-4.25	2.57e-05	0.00238	-0.18	-0.19	Coronary artery disease;	chr20:34870481	chr20:33985617~33988989:-
THCA	cis	rs6517329	0.61	rs11088339	ENSG00000236830.5	CBR3-AS1	4.25	2.57e-05	0.00238	0.19	0.19	Schizophrenia;	chr21:36126696	chr21:36131767~36175815:-
THCA	cis	rs6657613	0.68	rs9435745	ENSG00000186301.8	MST1P2	4.25	2.57e-05	0.00238	0.16	0.19	Hip circumference adjusted for BMI;	chr1:17044999	chr1:16645622~16650289:+
THCA	cis	rs1232027	0.656	rs1650682	ENSG00000249655.1	CTC-325J23.2	4.25	2.57e-05	0.00238	0.21	0.19	Huntington's disease progression;	chr5:80662112	chr5:80630313~80631590:-
THCA	cis	rs1334894	0.901	rs12528458	ENSG00000228559.1	RP3-340B19.3	-4.25	2.57e-05	0.00238	-0.41	-0.19	Coronary artery disease;	chr6:35537534	chr6:35544632~35545669:+
THCA	cis	rs7267979	0.816	rs443009	ENSG00000274973.1	RP13-401N8.7	4.25	2.57e-05	0.00238	0.22	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25845497~25845862:+
THCA	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	4.25	2.57e-05	0.00238	0.27	0.19	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
THCA	cis	rs77637988	0.516	rs55744465	ENSG00000202227.1	RNU6-282P	4.25	2.57e-05	0.00238	0.22	0.19	Joint mobility (Beighton score);	chr2:48405316	chr2:48501922~48502024:-
THCA	cis	rs3820928	0.904	rs10188570	ENSG00000212391.1	SNORA48	-4.25	2.57e-05	0.00238	-0.22	-0.19	Pulmonary function;	chr2:226927824	chr2:226968989~226969122:-
THCA	cis	rs1923243	0.616	rs7524355	ENSG00000223479.3	RP4-788P17.1	4.25	2.57e-05	0.00238	0.21	0.19	Migraine;	chr1:73130682	chr1:73635216~73715214:+
THCA	cis	rs10090774	0.965	rs306954	ENSG00000279766.1	RP11-642A1.2	4.25	2.57e-05	0.00238	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141002860	chr8:140572142~140572812:-
THCA	cis	rs13098911	0.54	rs9845382	ENSG00000226074.4	PRSS44	-4.25	2.57e-05	0.00238	-0.34	-0.19	Celiac disease;	chr3:46070267	chr3:46809359~46812558:-
THCA	cis	rs7551222	0.752	rs4951407	ENSG00000240219.1	RP11-430C7.5	-4.25	2.57e-05	0.00238	-0.18	-0.19	Schizophrenia;	chr1:204588942	chr1:204626775~204629712:+
THCA	cis	rs1005277	0.522	rs289645	ENSG00000226578.1	RP11-258F22.1	-4.25	2.57e-05	0.00239	-0.22	-0.19	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:37775371~37784131:-
THCA	cis	rs2281603	0.57	rs11158542	ENSG00000259116.1	RP11-973N13.4	4.25	2.57e-05	0.00239	0.16	0.19	Lymphocyte counts;	chr14:64462940	chr14:64514154~64540368:-
THCA	cis	rs34467563	0.626	rs2640811	ENSG00000253105.4	KB-1448A5.1	4.25	2.57e-05	0.00239	0.23	0.19	Lobe attachment (rater-scored or self-reported);	chr8:96366228	chr8:96371865~96387438:-
THCA	cis	rs34467563	0.647	rs2640810	ENSG00000253105.4	KB-1448A5.1	4.25	2.57e-05	0.00239	0.23	0.19	Lobe attachment (rater-scored or self-reported);	chr8:96366248	chr8:96371865~96387438:-
THCA	cis	rs34467563	0.626	rs2678335	ENSG00000253105.4	KB-1448A5.1	4.25	2.57e-05	0.00239	0.23	0.19	Lobe attachment (rater-scored or self-reported);	chr8:96366695	chr8:96371865~96387438:-
THCA	cis	rs7674212	0.541	rs2623070	ENSG00000230069.3	LRRC37A15P	4.25	2.57e-05	0.00239	0.19	0.19	Type 2 diabetes;	chr4:103116231	chr4:102727274~102730721:-
THCA	cis	rs4819052	0.851	rs2236445	ENSG00000182586.6	LINC00334	-4.25	2.57e-05	0.00239	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45234340~45258730:+
THCA	cis	rs617791	0.53	rs10791835	ENSG00000255320.1	RP11-755F10.1	4.25	2.57e-05	0.00239	0.25	0.19	Breast cancer;	chr11:65983453	chr11:66244840~66246239:-
THCA	cis	rs617791	0.53	rs7934543	ENSG00000255320.1	RP11-755F10.1	4.25	2.57e-05	0.00239	0.25	0.19	Breast cancer;	chr11:65985037	chr11:66244840~66246239:-
THCA	cis	rs4925386	1	rs6089351	ENSG00000275437.1	RP5-908M14.10	-4.25	2.57e-05	0.00239	-0.18	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62402236~62405935:-
THCA	cis	rs10844682	0.603	rs10844673	ENSG00000214776.8	RP11-726G1.1	4.25	2.57e-05	0.00239	0.26	0.19	Monocyte percentage of white cells;	chr12:9744969	chr12:9467552~9576275:+
THCA	cis	rs7819412	0.582	rs2409685	ENSG00000261451.1	RP11-981G7.1	-4.25	2.57e-05	0.00239	-0.24	-0.19	Triglycerides;	chr8:11051683	chr8:10433672~10438312:+
THCA	cis	rs75059851	0.756	rs73036086	ENSG00000280237.1	MIR4697HG	4.25	2.57e-05	0.00239	0.22	0.19	Schizophrenia;	chr11:133971887	chr11:133896438~133901601:-
THCA	cis	rs75059851	0.756	rs73036087	ENSG00000280237.1	MIR4697HG	4.25	2.57e-05	0.00239	0.22	0.19	Schizophrenia;	chr11:133972466	chr11:133896438~133901601:-
THCA	cis	rs75059851	0.756	rs11223655	ENSG00000280237.1	MIR4697HG	4.25	2.57e-05	0.00239	0.22	0.19	Schizophrenia;	chr11:133972812	chr11:133896438~133901601:-
THCA	cis	rs9595908	0.709	rs9596222	ENSG00000212293.1	SNORA16	4.25	2.57e-05	0.00239	0.22	0.19	Body mass index;	chr13:32767679	chr13:32420390~32420516:-
THCA	cis	rs4915077	0.773	rs61471569	ENSG00000230489.1	VAV3-AS1	4.25	2.57e-05	0.00239	0.31	0.19	Hypothyroidism;	chr1:107716445	chr1:107964443~107994607:+
THCA	cis	rs8067354	0.872	rs1292060	ENSG00000266701.1	AC005702.4	4.25	2.57e-05	0.00239	0.27	0.19	Hemoglobin concentration;	chr17:59836488	chr17:60042546~60042627:-
THCA	cis	rs756699	0.749	rs244680	ENSG00000279469.1	RP11-215P8.2	-4.25	2.57e-05	0.00239	-0.31	-0.19	Multiple sclerosis;	chr5:134092391	chr5:134394360~134395008:-
THCA	cis	rs150992	0.721	rs2937706	ENSG00000246763.5	RGMB-AS1	4.25	2.57e-05	0.00239	0.2	0.19	Body mass index;	chr5:98990434	chr5:98769618~98773469:-
THCA	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-4.25	2.57e-05	0.00239	-0.23	-0.19	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
THCA	cis	rs227275	0.556	rs6842179	ENSG00000248971.2	KRT8P46	-4.25	2.58e-05	0.00239	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102728746~102730171:-
THCA	cis	rs875971	1	rs1981798	ENSG00000229886.1	RP5-1132H15.3	4.25	2.58e-05	0.00239	0.2	0.19	Aortic root size;	chr7:66489916	chr7:66025126~66031544:-
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000176933.5	TOB2P1	-4.25	2.58e-05	0.00239	-0.21	-0.19	Pubertal anthropometrics;	chr6:28128502	chr6:28217643~28218634:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000223473.2	GS1-124K5.3	-4.25	2.58e-05	0.00239	-0.13	-0.19	Aortic root size;	chr7:66642265	chr7:66491049~66493566:-
THCA	cis	rs6087771	0.89	rs6089056	ENSG00000230613.1	HM13-AS1	4.25	2.58e-05	0.00239	0.18	0.19	Putamen volume;Subcortical brain region volumes;	chr20:31737970	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6060919	ENSG00000230613.1	HM13-AS1	4.25	2.58e-05	0.00239	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31744119	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6060922	ENSG00000230613.1	HM13-AS1	4.25	2.58e-05	0.00239	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31746106	chr20:31567707~31573263:-
THCA	cis	rs9863	0.828	rs12303671	ENSG00000270028.1	RP11-380L11.4	4.25	2.58e-05	0.00239	0.2	0.19	White blood cell count;	chr12:124008063	chr12:123925461~123926083:-
THCA	cis	rs2380205	0.967	rs9663697	ENSG00000232807.2	RP11-536K7.3	4.25	2.58e-05	0.00239	0.18	0.19	Breast cancer;	chr10:5855943	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs9663995	ENSG00000232807.2	RP11-536K7.3	4.25	2.58e-05	0.00239	0.18	0.19	Breast cancer;	chr10:5855981	chr10:5934270~5945900:-
THCA	cis	rs2777491	0.522	rs7169278	ENSG00000247556.5	OIP5-AS1	4.25	2.58e-05	0.00239	0.16	0.19	Ulcerative colitis;	chr15:41404734	chr15:41283990~41309737:+
THCA	cis	rs10090774	0.87	rs10109378	ENSG00000280303.2	ERICD	-4.25	2.58e-05	0.00239	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994574	chr8:140636281~140638283:+
THCA	cis	rs1045529	0.524	rs34251783	ENSG00000254153.1	CTA-398F10.2	4.25	2.58e-05	0.00239	0.21	0.19	Myopia (pathological);Myopia;	chr8:9033866	chr8:8456909~8461337:-
THCA	cis	rs35851103	0.507	rs6601649	ENSG00000227888.4	FAM66A	-4.25	2.58e-05	0.00239	-0.25	-0.19	Neuroticism;	chr8:11999808	chr8:12362019~12388296:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000234585.5	CCT6P3	4.25	2.58e-05	0.00239	0.17	0.19	Aortic root size;	chr7:66008093	chr7:65038354~65074713:+
THCA	cis	rs7829975	0.774	rs1039915	ENSG00000254340.1	RP11-10A14.3	4.25	2.58e-05	0.00239	0.21	0.19	Mood instability;	chr8:8822104	chr8:9141424~9145435:+
THCA	cis	rs7819412	0.936	rs7814499	ENSG00000206014.6	OR7E161P	4.25	2.58e-05	0.00239	0.22	0.19	Triglycerides;	chr8:11183138	chr8:11928597~11929563:-
THCA	cis	rs2434529	1	rs73802972	ENSG00000245275.6	SAP30L-AS1	4.25	2.58e-05	0.00239	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154254758	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs6580066	ENSG00000245275.6	SAP30L-AS1	4.25	2.58e-05	0.00239	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154256033	chr5:154329437~154445850:-
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000275400.1	RP4-756H11.5	-4.25	2.58e-05	0.00239	-0.21	-0.19	Corneal structure;	chr7:66902145	chr7:66553805~66554199:-
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000275400.1	RP4-756H11.5	-4.25	2.58e-05	0.00239	-0.21	-0.19	Corneal structure;	chr7:66904222	chr7:66553805~66554199:-
THCA	cis	rs9863	0.828	rs11057412	ENSG00000270028.1	RP11-380L11.4	4.25	2.58e-05	0.00239	0.2	0.19	White blood cell count;	chr12:124004595	chr12:123925461~123926083:-
THCA	cis	rs4713118	0.824	rs742046	ENSG00000220721.1	OR1F12	4.25	2.58e-05	0.00239	0.26	0.19	Parkinson's disease;	chr6:27771475	chr6:28073316~28074233:+
THCA	cis	rs9510787	0.538	rs9507142	ENSG00000205861.10	C1QTNF9B-AS1	-4.25	2.58e-05	0.00239	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23671309	chr13:23888889~23897263:+
THCA	cis	rs9510787	0.538	rs73156795	ENSG00000205861.10	C1QTNF9B-AS1	-4.25	2.58e-05	0.00239	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23671535	chr13:23888889~23897263:+
THCA	cis	rs9863	0.861	rs12317176	ENSG00000269997.1	RP11-214K3.21	-4.25	2.58e-05	0.00239	-0.24	-0.19	White blood cell count;	chr12:123920171	chr12:123966077~123966629:-
THCA	cis	rs2120243	0.539	rs7629293	ENSG00000241770.1	RP11-555M1.3	-4.25	2.58e-05	0.00239	-0.25	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157396673	chr3:157163452~157169133:+
THCA	cis	rs75059851	0.756	rs7122746	ENSG00000280237.1	MIR4697HG	4.25	2.58e-05	0.00239	0.22	0.19	Schizophrenia;	chr11:133968913	chr11:133896438~133901601:-
THCA	cis	rs7586085	0.868	rs2113841	ENSG00000232411.1	AC009495.3	-4.25	2.58e-05	0.00239	-0.21	-0.19	Total body bone mineral density;	chr2:165765599	chr2:165833048~165839098:-
THCA	cis	rs874628	0.754	rs8112975	ENSG00000268650.3	AC068499.10	4.25	2.58e-05	0.00239	0.21	0.19	Multiple sclerosis;	chr19:18230100	chr19:18204730~18220480:+
THCA	cis	rs4788570	0.543	rs4788820	ENSG00000260185.1	RP11-432I5.6	-4.25	2.58e-05	0.00239	-0.36	-0.19	Intelligence (multi-trait analysis);	chr16:71626212	chr16:71655027~71664212:+
THCA	cis	rs8105895	0.799	rs62112922	ENSG00000269345.1	VN1R85P	4.25	2.58e-05	0.0024	0.27	0.19	Body mass index (change over time);	chr19:22045538	chr19:22174766~22175191:-
THCA	cis	rs12313068	0.6	rs7136207	ENSG00000249094.2	RP1-7G5.6	4.25	2.58e-05	0.0024	0.3	0.19	Intelligence (multi-trait analysis);	chr12:110053682	chr12:109880676~109888467:+
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000229180.5	GS1-124K5.11	4.25	2.58e-05	0.0024	0.16	0.19	Corneal structure;	chr7:66950082	chr7:66526088~66542624:-
THCA	cis	rs7989336	0.663	rs2149315	ENSG00000247400.3	DNAJC3-AS1	-4.25	2.58e-05	0.0024	-0.12	-0.19	Obesity;	chr13:96276513	chr13:95648733~95676925:-
THCA	cis	rs6870983	0.802	rs10074877	ENSG00000247828.6	TMEM161B-AS1	4.25	2.58e-05	0.0024	0.17	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88449565	chr5:88268895~88436685:+
THCA	cis	rs786425	0.833	rs2222061	ENSG00000270095.1	RP11-214K3.18	-4.25	2.58e-05	0.0024	-0.22	-0.19	Pubertal anthropometrics;	chr12:123710382	chr12:123971457~123971714:-
THCA	cis	rs9788682	0.747	rs8042494	ENSG00000261143.1	ADAMTS7P3	-4.25	2.58e-05	0.0024	-0.26	-0.19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615668	chr15:77976042~77993057:+
THCA	cis	rs7829975	0.774	rs57312668	ENSG00000254340.1	RP11-10A14.3	4.25	2.58e-05	0.0024	0.21	0.19	Mood instability;	chr8:8822967	chr8:9141424~9145435:+
THCA	cis	rs8028182	0.549	rs10775209	ENSG00000260274.1	RP11-817O13.8	-4.25	2.58e-05	0.0024	-0.14	-0.19	Sudden cardiac arrest;	chr15:75342418	chr15:75368155~75369584:+
THCA	cis	rs2977125	0.737	rs2947388	ENSG00000251468.2	RP11-369K16.1	-4.25	2.58e-05	0.0024	-0.27	-0.19	Schizophrenia;	chr8:12893648	chr8:12958387~12962200:+
THCA	cis	rs1387259	0.931	rs11168474	ENSG00000273765.1	RP11-370I10.11	4.25	2.58e-05	0.0024	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48360920~48361377:+
THCA	cis	rs962856	1	rs1601531	ENSG00000236780.4	AC078941.1	4.25	2.59e-05	0.0024	0.23	0.19	Pancreatic cancer;	chr2:67370972	chr2:67123357~67215319:-
THCA	cis	rs10932886	1	rs10174155	ENSG00000224819.1	AC093843.1	-4.25	2.59e-05	0.0024	-0.18	-0.19	Brain imaging;	chr2:220860526	chr2:220791078~220797893:+
THCA	cis	rs6847067	0.894	rs72664926	ENSG00000180769.7	WDFY3-AS2	4.25	2.59e-05	0.0024	0.14	0.19	Oropharynx cancer;	chr4:84827743	chr4:84965682~85011277:+
THCA	cis	rs11671005	0.695	rs12972898	ENSG00000268049.1	CTD-2619J13.9	-4.25	2.59e-05	0.0024	-0.31	-0.19	Mean platelet volume;	chr19:58445521	chr19:58357999~58359603:+
THCA	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	4.25	2.59e-05	0.0024	0.24	0.19	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
THCA	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	4.25	2.59e-05	0.0024	0.24	0.19	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
THCA	cis	rs1232027	0.622	rs1677653	ENSG00000249655.1	CTC-325J23.2	4.25	2.59e-05	0.0024	0.22	0.19	Huntington's disease progression;	chr5:80672452	chr5:80630313~80631590:-
THCA	cis	rs801193	0.636	rs10233806	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.59e-05	0.0024	-0.2	-0.19	Aortic root size;	chr7:66653261	chr7:66025126~66031544:-
THCA	cis	rs75059851	0.756	rs7127156	ENSG00000280237.1	MIR4697HG	4.25	2.59e-05	0.0024	0.22	0.19	Schizophrenia;	chr11:133969962	chr11:133896438~133901601:-
THCA	cis	rs881375	0.678	rs3761846	ENSG00000270917.1	RP11-27I1.6	-4.25	2.59e-05	0.0024	-0.25	-0.19	Rheumatoid arthritis;	chr9:120927319	chr9:120812475~120812845:-
THCA	cis	rs1124769	0.672	rs12591438	ENSG00000259378.1	DCAF13P3	4.25	2.59e-05	0.0024	0.29	0.19	Cognitive performance;	chr15:50850995	chr15:50944663~50945996:+
THCA	cis	rs9625935	0.957	rs4823063	ENSG00000279159.1	RP3-394A18.1	-4.25	2.59e-05	0.0024	-0.15	-0.19	Tonsillectomy;	chr22:29912791	chr22:29978950~30028236:-
THCA	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-4.25	2.59e-05	0.0024	-0.21	-0.19	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
THCA	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-4.25	2.59e-05	0.0024	-0.21	-0.19	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
THCA	cis	rs12142240	0.667	rs41293287	ENSG00000232022.5	FAAHP1	-4.25	2.59e-05	0.0024	-0.22	-0.19	Menopause (age at onset);	chr1:46343180	chr1:46432129~46445521:+
THCA	cis	rs11634944	1	rs11632945	ENSG00000257151.1	PWAR6	4.25	2.59e-05	0.0024	0.15	0.19	Interleukin-8 levels;	chr15:24958411	chr15:25031873~25036490:+
THCA	cis	rs889122	0.836	rs56053932	ENSG00000267289.1	CTD-2623N2.11	4.25	2.59e-05	0.0024	0.25	0.19	Menarche (age at onset);	chr19:9892335	chr19:9834079~9835013:-
THCA	cis	rs2439831	0.867	rs6493085	ENSG00000205771.5	CATSPER2P1	-4.25	2.59e-05	0.0024	-0.26	-0.19	Lung cancer in ever smokers;	chr15:43361984	chr15:43726918~43747094:-
THCA	cis	rs3764021	0.87	rs11052710	ENSG00000256594.6	RP11-705C15.2	4.25	2.59e-05	0.0024	0.15	0.19	Type 1 diabetes;	chr12:9723754	chr12:9633419~9658412:+
THCA	cis	rs4699052	0.537	rs1580278	ENSG00000230069.3	LRRC37A15P	4.25	2.59e-05	0.0024	0.2	0.19	Testicular germ cell tumor;	chr4:103219691	chr4:102727274~102730721:-
THCA	cis	rs2434529	1	rs73281445	ENSG00000245275.6	SAP30L-AS1	4.25	2.59e-05	0.0024	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154263989	chr5:154329437~154445850:-
THCA	cis	rs7208859	0.614	rs4794874	ENSG00000263603.1	CTD-2349P21.5	4.25	2.59e-05	0.0024	0.32	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30729469~30731202:+
THCA	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	4.25	2.59e-05	0.0024	0.18	0.19	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
THCA	cis	rs1876905	0.68	rs354527	ENSG00000272356.1	RP5-1112D6.8	-4.25	2.59e-05	0.0024	-0.2	-0.19	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111309203~111313517:+
THCA	cis	rs10875746	0.951	rs10875756	ENSG00000258234.1	RP11-370I10.2	4.25	2.59e-05	0.0024	0.23	0.19	Longevity (90 years and older);	chr12:48168521	chr12:48231098~48284210:-
THCA	cis	rs12440869	1	rs2044329	ENSG00000270964.1	RP11-502I4.3	-4.25	2.59e-05	0.0024	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67308616	chr15:67541072~67542604:-
THCA	cis	rs8031584	0.958	rs11637469	ENSG00000270015.1	RP11-540B6.6	-4.25	2.59e-05	0.0024	-0.15	-0.19	Huntington's disease progression;	chr15:30946580	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.958	rs8034856	ENSG00000270015.1	RP11-540B6.6	-4.25	2.59e-05	0.0024	-0.15	-0.19	Huntington's disease progression;	chr15:30948754	chr15:30926514~30928407:+
THCA	cis	rs7849973	0.532	rs10965507	ENSG00000224549.1	RP11-370B11.3	-4.25	2.59e-05	0.0024	-0.22	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22902232	chr9:22767175~22768316:+
THCA	cis	rs8177876	0.658	rs79603321	ENSG00000261061.1	RP11-303E16.2	-4.25	2.59e-05	0.0024	-0.3	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81039139	chr16:81030770~81031485:+
THCA	cis	rs710865	0.541	rs4066014	ENSG00000270728.1	RP4-657E11.10	-4.25	2.59e-05	0.0024	-0.15	-0.19	Brain structure;	chr1:19229289	chr1:19297080~19297903:+
THCA	cis	rs498872	1	rs498872	ENSG00000255239.1	AP002954.6	4.25	2.59e-05	0.0024	0.27	0.19	Glioma;	chr11:118606652	chr11:118688039~118690600:-
THCA	cis	rs6940638	0.956	rs10946899	ENSG00000224843.5	LINC00240	4.25	2.59e-05	0.00241	0.21	0.19	Intelligence (multi-trait analysis);	chr6:27055915	chr6:26956992~27023924:+
THCA	cis	rs8141529	0.509	rs7287124	ENSG00000272858.1	CTA-292E10.8	-4.25	2.59e-05	0.00241	-0.21	-0.19	Lymphocyte counts;	chr22:28843169	chr22:28814914~28815662:+
THCA	cis	rs16975963	0.843	rs241954	ENSG00000226686.6	LINC01535	-4.25	2.59e-05	0.00241	-0.26	-0.19	Longevity;	chr19:37786890	chr19:37251912~37265535:+
THCA	cis	rs9510787	0.538	rs3751361	ENSG00000205861.10	C1QTNF9B-AS1	-4.25	2.6e-05	0.00241	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23669221	chr13:23888889~23897263:+
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000280069.1	CTD-2349P21.3	-4.25	2.6e-05	0.00241	-0.27	-0.19	Body mass index;	chr17:30690132	chr17:30738182~30740275:+
THCA	cis	rs4950322	0.58	rs17355474	ENSG00000271721.1	RP11-337C18.9	4.25	2.6e-05	0.00241	0.21	0.19	Protein quantitative trait loci;	chr1:147120541	chr1:147175602~147177740:+
THCA	cis	rs11026091	0.87	rs10833535	ENSG00000224513.2	AC109309.4	-4.25	2.6e-05	0.00241	-0.24	-0.19	Multiple sclerosis;	chr11:3238248	chr11:3226061~3232838:+
THCA	cis	rs7560272	0.538	rs12619258	ENSG00000273245.1	RP11-434P11.2	-4.25	2.6e-05	0.00241	-0.22	-0.19	Schizophrenia;	chr2:73708788	chr2:73750256~73750786:-
THCA	cis	rs75059851	0.756	rs7106806	ENSG00000280237.1	MIR4697HG	4.25	2.6e-05	0.00241	0.22	0.19	Schizophrenia;	chr11:133968942	chr11:133896438~133901601:-
THCA	cis	rs9326246	0.545	rs492182	ENSG00000254851.1	RP11-109L13.1	4.25	2.6e-05	0.00241	0.44	0.19	Coronary artery disease;	chr11:116651447	chr11:117135528~117138582:+
THCA	cis	rs875971	1	rs778726	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66363744	chr7:66025126~66031544:-
THCA	cis	rs875971	0.767	rs1695815	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66366357	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs778685	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66371189	chr7:66025126~66031544:-
THCA	cis	rs875971	0.929	rs778682	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66372947	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs11765965	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66377234	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs1643388	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66379575	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs778722	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66379841	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs778721	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66380410	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs778706	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66395437	chr7:66025126~66031544:-
THCA	cis	rs875971	0.895	rs778700	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66401463	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs778699	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66403303	chr7:66025126~66031544:-
THCA	cis	rs875971	0.929	rs778692	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66407462	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs4718343	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66409301	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs1968225	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66409786	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs6460295	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66417741	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs6978721	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66418217	chr7:66025126~66031544:-
THCA	cis	rs7312933	0.584	rs7974654	ENSG00000257225.1	RP11-328C8.4	-4.25	2.6e-05	0.00241	-0.2	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42236664	chr12:42459366~42466128:+
THCA	cis	rs7045881	0.8	rs7875314	ENSG00000254396.1	RP11-56F10.3	4.25	2.6e-05	0.00241	0.36	0.19	Schizophrenia;	chr9:26823345	chr9:27102630~27104728:+
THCA	cis	rs801193	0.569	rs2659893	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66735006	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs2659892	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66735318	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs2707847	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66737884	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs11761542	ENSG00000229886.1	RP5-1132H15.3	4.25	2.6e-05	0.00241	0.2	0.19	Aortic root size;	chr7:66753209	chr7:66025126~66031544:-
THCA	cis	rs8031584	0.918	rs34095794	ENSG00000178081.11	ULK4P3	4.25	2.6e-05	0.00241	0.25	0.19	Huntington's disease progression;	chr15:30977488	chr15:30103720~30131757:+
THCA	cis	rs12478296	0.892	rs60042638	ENSG00000220804.7	AC093642.5	4.25	2.6e-05	0.00241	0.21	0.19	Obesity-related traits;	chr2:242096556	chr2:242088633~242160153:+
THCA	cis	rs1167827	1	rs1167827	ENSG00000205583.12	STAG3L1	4.25	2.6e-05	0.00241	0.23	0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75359194~75395383:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000273024.4	INTS4P2	4.25	2.6e-05	0.00241	0.31	0.19	Diabetic kidney disease;	chr7:66631132	chr7:65647864~65715661:+
THCA	cis	rs964611	0.58	rs75570984	ENSG00000259488.2	RP11-154J22.1	4.25	2.6e-05	0.00241	0.17	0.19	Metabolite levels (Pyroglutamine);	chr15:48361246	chr15:48312353~48331856:-
THCA	cis	rs1923243	0.649	rs7523396	ENSG00000223479.3	RP4-788P17.1	-4.25	2.6e-05	0.00241	-0.21	-0.19	Migraine;	chr1:72906019	chr1:73635216~73715214:+
THCA	cis	rs1942	0.837	rs12440045	ENSG00000247556.5	OIP5-AS1	4.25	2.6e-05	0.00241	0.16	0.19	Eosinophil percentage of granulocytes;	chr15:41490486	chr15:41283990~41309737:+
THCA	cis	rs4245128	0.775	rs11214422	ENSG00000227487.3	NCAM1-AS1	4.25	2.6e-05	0.00241	0.2	0.19	Life satisfaction;	chr11:112932175	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.717	rs11214423	ENSG00000227487.3	NCAM1-AS1	4.25	2.6e-05	0.00241	0.2	0.19	Life satisfaction;	chr11:112932333	chr11:113269532~113273901:-
THCA	cis	rs2153535	0.518	rs6925765	ENSG00000230939.1	RP11-314C16.1	-4.25	2.6e-05	0.00241	-0.2	-0.19	Motion sickness;	chr6:8566471	chr6:8784178~8785445:+
THCA	cis	rs8062405	0.965	rs8049439	ENSG00000261766.1	RP11-22P6.2	-4.25	2.6e-05	0.00241	-0.18	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28862166~28863340:-
THCA	cis	rs1414896	0.646	rs11584734	ENSG00000226026.4	RP11-57H12.3	4.25	2.6e-05	0.00241	0.18	0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95201117	chr1:95163219~95233982:-
THCA	cis	rs7523875	0.605	rs11581409	ENSG00000153363.11	LINC00467	-4.25	2.6e-05	0.00241	-0.17	-0.19	Mean corpuscular volume;	chr1:211284794	chr1:211382803~211435333:+
THCA	cis	rs868036	0.681	rs28688285	ENSG00000270964.1	RP11-502I4.3	-4.25	2.6e-05	0.00241	-0.18	-0.19	Restless legs syndrome;	chr15:67817959	chr15:67541072~67542604:-
THCA	cis	rs6500637	0.686	rs8048701	ENSG00000267077.1	RP11-127I20.5	4.25	2.6e-05	0.00241	0.24	0.19	Cancer;	chr16:4863536	chr16:4795265~4796532:-
THCA	cis	rs4776970	0.632	rs3784706	ENSG00000270964.1	RP11-502I4.3	-4.25	2.6e-05	0.00241	-0.16	-0.19	Body mass index;Waist circumference;	chr15:67737411	chr15:67541072~67542604:-
THCA	cis	rs875971	0.545	rs73142265	ENSG00000273142.1	RP11-458F8.4	4.25	2.6e-05	0.00241	0.18	0.19	Aortic root size;	chr7:66234510	chr7:66902857~66906297:+
THCA	cis	rs465969	1	rs34382476	ENSG00000272356.1	RP5-1112D6.8	4.25	2.6e-05	0.00241	0.29	0.19	Psoriasis;	chr6:111423551	chr6:111309203~111313517:+
THCA	cis	rs1555322	0.872	rs6579227	ENSG00000279253.1	RP4-614O4.13	-4.25	2.6e-05	0.00241	-0.29	-0.19	Attention deficit hyperactivity disorder;	chr20:35291403	chr20:35262727~35264187:-
THCA	cis	rs755249	0.501	rs2484749	ENSG00000228060.1	RP11-69E11.8	4.25	2.6e-05	0.00241	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39565160~39573203:+
THCA	cis	rs61270009	0.955	rs4269995	ENSG00000247828.6	TMEM161B-AS1	4.25	2.6e-05	0.00241	0.17	0.19	Depressive symptoms;	chr5:88405406	chr5:88268895~88436685:+
THCA	cis	rs654950	0.84	rs647146	ENSG00000230638.4	RP11-486B10.4	-4.25	2.6e-05	0.00241	-0.21	-0.19	Airway imaging phenotypes;	chr1:41520615	chr1:41542069~41544310:+
THCA	cis	rs2839627	0.561	rs9977774	ENSG00000225218.1	AP001628.6	4.25	2.6e-05	0.00241	0.29	0.19	Information processing speed;	chr21:42922366	chr21:42831040~42836477:-
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000232559.3	GS1-124K5.12	4.25	2.6e-05	0.00241	0.28	0.19	Diabetic kidney disease;	chr7:65999249	chr7:66554588~66576923:-
THCA	cis	rs8062405	0.755	rs56272201	ENSG00000261766.1	RP11-22P6.2	-4.25	2.61e-05	0.00241	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.755	rs62034355	ENSG00000261766.1	RP11-22P6.2	-4.25	2.61e-05	0.00241	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28862166~28863340:-
THCA	cis	rs28735056	0.933	rs56181785	ENSG00000261126.6	RP11-795F19.1	-4.25	2.61e-05	0.00241	-0.16	-0.19	Schizophrenia;	chr18:79873629	chr18:80046900~80095482:+
THCA	cis	rs10911902	0.602	rs6425024	ENSG00000229739.2	RP11-295K2.3	-4.25	2.61e-05	0.00241	-0.3	-0.19	Schizophrenia;	chr1:186305001	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.602	rs2273778	ENSG00000229739.2	RP11-295K2.3	-4.25	2.61e-05	0.00241	-0.3	-0.19	Schizophrenia;	chr1:186305027	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.602	rs2273777	ENSG00000229739.2	RP11-295K2.3	-4.25	2.61e-05	0.00241	-0.3	-0.19	Schizophrenia;	chr1:186305043	chr1:186435161~186470291:+
THCA	cis	rs7560272	0.501	rs13003035	ENSG00000163016.8	ALMS1P	-4.25	2.61e-05	0.00242	-0.24	-0.19	Schizophrenia;	chr2:73730100	chr2:73644919~73685576:+
THCA	cis	rs7560272	0.501	rs12992607	ENSG00000163016.8	ALMS1P	-4.25	2.61e-05	0.00242	-0.24	-0.19	Schizophrenia;	chr2:73732833	chr2:73644919~73685576:+
THCA	cis	rs8046148	0.586	rs1187411	ENSG00000279356.1	RP11-429P3.8	-4.25	2.61e-05	0.00242	-0.23	-0.19	Testicular germ cell tumor;	chr16:50000769	chr16:50072862~50074986:+
THCA	cis	rs447735	0.507	rs11645271	ENSG00000260259.1	RP11-368I7.4	-4.25	2.61e-05	0.00242	-0.21	-0.19	Hemoglobin concentration;	chr16:89662717	chr16:89682620~89686569:-
THCA	cis	rs6973609	0.524	rs7777942	ENSG00000271122.1	RP11-379H18.1	4.25	2.61e-05	0.00242	0.14	0.19	Obesity-related traits;	chr7:35544568	chr7:35695214~35699413:+
THCA	cis	rs875971	0.862	rs6460290	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.61e-05	0.00242	-0.2	-0.19	Aortic root size;	chr7:66344119	chr7:66025126~66031544:-
THCA	cis	rs8030605	0.704	rs795793	ENSG00000277245.1	RP11-48G14.3	-4.25	2.61e-05	0.00242	-0.34	-0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56444010	chr15:56447120~56447697:+
THCA	cis	rs3177980	0.564	rs10919256	ENSG00000239494.2	RN7SL333P	-4.25	2.61e-05	0.00242	-0.18	-0.19	Amyotrophic lateral sclerosis;	chr1:169847163	chr1:169859756~169860052:+
THCA	cis	rs6496932	0.802	rs12441698	ENSG00000259630.2	CTD-2262B20.1	4.25	2.61e-05	0.00242	0.24	0.19	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85415228~85415633:+
THCA	cis	rs3128341	1	rs79547900	ENSG00000227207.2	RPL31P12	4.25	2.61e-05	0.00242	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72375518	chr1:72301472~72301829:+
THCA	cis	rs113835537	0.935	rs117480267	ENSG00000255517.5	CTD-3074O7.5	-4.25	2.61e-05	0.00242	-0.21	-0.19	Airway imaging phenotypes;	chr11:66631125	chr11:66473490~66480233:-
THCA	cis	rs7577696	0.785	rs7572964	ENSG00000276334.1	AL133243.1	-4.25	2.61e-05	0.00242	-0.21	-0.19	Inflammatory biomarkers;	chr2:32147027	chr2:32521927~32523547:+
THCA	cis	rs4664293	0.565	rs10165197	ENSG00000230783.1	AC009961.2	4.25	2.61e-05	0.00242	0.24	0.19	Monocyte percentage of white cells;	chr2:159537137	chr2:159689217~159690291:-
THCA	cis	rs1204798	1	rs1204811	ENSG00000237021.2	RP3-486I3.7	-4.25	2.61e-05	0.00242	-0.21	-0.19	Dental caries;	chr6:116230940	chr6:116254207~116256743:+
THCA	cis	rs9532669	0.926	rs7329302	ENSG00000229473.2	RGS17P1	-4.25	2.61e-05	0.00242	-0.24	-0.19	Cervical cancer;	chr13:40962396	chr13:40992779~40993331:-
THCA	cis	rs12478296	1	rs73007140	ENSG00000261186.2	RP11-341N2.1	-4.25	2.61e-05	0.00242	-0.29	-0.19	Obesity-related traits;	chr2:242068605	chr2:242087351~242088457:-
THCA	cis	rs7560272	0.502	rs13013228	ENSG00000273245.1	RP11-434P11.2	-4.25	2.61e-05	0.00242	-0.22	-0.19	Schizophrenia;	chr2:73698089	chr2:73750256~73750786:-
THCA	cis	rs2281603	0.621	rs61985668	ENSG00000272909.1	CTD-2555O16.4	-4.25	2.61e-05	0.00242	-0.23	-0.19	Lymphocyte counts;	chr14:64489628	chr14:64440369~64442238:-
THCA	cis	rs73108077	0.92	rs73108088	ENSG00000277112.2	RP11-755J8.1	-4.25	2.61e-05	0.00242	-0.38	-0.19	Red blood cell density in sickle cell anemia;	chr20:31424444	chr20:30681825~30723932:-
THCA	cis	rs9863	0.861	rs12298484	ENSG00000269938.1	RP11-214K3.20	-4.25	2.61e-05	0.00242	-0.24	-0.19	White blood cell count;	chr12:123934127	chr12:123968023~123968579:-
THCA	cis	rs2657294	0.761	rs1259498	ENSG00000233313.2	HMGA1P5	-4.25	2.61e-05	0.00242	-0.26	-0.19	Pneumonia;	chr10:75226983	chr10:75276376~75276646:-
THCA	cis	rs12134133	1	rs11580387	ENSG00000237074.1	RP11-6J21.2	4.25	2.61e-05	0.00242	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs7518565	ENSG00000237074.1	RP11-6J21.2	4.25	2.61e-05	0.00242	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs7532664	ENSG00000237074.1	RP11-6J21.2	4.25	2.61e-05	0.00242	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs55638602	ENSG00000237074.1	RP11-6J21.2	4.25	2.61e-05	0.00242	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs4844588	ENSG00000237074.1	RP11-6J21.2	4.25	2.61e-05	0.00242	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.927	rs4844589	ENSG00000237074.1	RP11-6J21.2	4.25	2.61e-05	0.00242	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207249067~207309121:+
THCA	cis	rs9457247	0.508	rs6941355	ENSG00000235272.1	FAM103A2P	4.25	2.61e-05	0.00242	0.26	0.19	Crohn's disease;	chr6:167092750	chr6:166586124~166586477:-
THCA	cis	rs1552244	0.572	rs6442154	ENSG00000180385.7	EMC3-AS1	4.25	2.61e-05	0.00242	0.24	0.19	Alzheimer's disease;	chr3:10127101	chr3:9986893~10006990:+
THCA	cis	rs2836974	0.568	rs2836969	ENSG00000255568.3	BRWD1-AS2	-4.25	2.61e-05	0.00242	-0.16	-0.19	Cognitive function;	chr21:39276339	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.584	rs6517535	ENSG00000255568.3	BRWD1-AS2	-4.25	2.61e-05	0.00242	-0.16	-0.19	Cognitive function;	chr21:39281426	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.627	rs7278985	ENSG00000255568.3	BRWD1-AS2	-4.25	2.61e-05	0.00242	-0.16	-0.19	Cognitive function;	chr21:39281841	chr21:39313935~39314962:+
THCA	cis	rs6696239	0.915	rs10916161	ENSG00000227711.2	RP11-275O4.5	-4.25	2.61e-05	0.00242	-0.26	-0.19	Height;	chr1:227547167	chr1:227509028~227520477:-
THCA	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	4.25	2.61e-05	0.00242	0.16	0.19	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
THCA	cis	rs8062405	0.688	rs3924376	ENSG00000261766.1	RP11-22P6.2	4.25	2.61e-05	0.00242	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28862166~28863340:-
THCA	cis	rs868036	0.718	rs28399056	ENSG00000270964.1	RP11-502I4.3	-4.25	2.61e-05	0.00242	-0.18	-0.19	Restless legs syndrome;	chr15:67823672	chr15:67541072~67542604:-
THCA	cis	rs868036	0.718	rs7170185	ENSG00000270964.1	RP11-502I4.3	-4.25	2.61e-05	0.00242	-0.18	-0.19	Restless legs syndrome;	chr15:67824962	chr15:67541072~67542604:-
THCA	cis	rs812925	0.502	rs2084318	ENSG00000270820.4	RP11-355B11.2	-4.25	2.61e-05	0.00242	-0.16	-0.19	Immature fraction of reticulocytes;	chr2:61425466	chr2:61471188~61484130:+
THCA	cis	rs17095355	1	rs11194940	ENSG00000203876.8	ADD3-AS1	-4.25	2.61e-05	0.00242	-0.2	-0.19	Biliary atresia;	chr10:109982465	chr10:109940104~110008381:-
THCA	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	4.25	2.61e-05	0.00242	0.2	0.19	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
THCA	cis	rs2380205	1	rs7098372	ENSG00000232807.2	RP11-536K7.3	4.25	2.61e-05	0.00242	0.18	0.19	Breast cancer;	chr10:5844186	chr10:5934270~5945900:-
THCA	cis	rs7474896	0.832	rs2799509	ENSG00000263064.2	RP11-291L22.7	-4.25	2.61e-05	0.00242	-0.33	-0.19	Obesity (extreme);	chr10:37945880	chr10:38448689~38448949:+
THCA	cis	rs2836974	0.568	rs8130795	ENSG00000255568.3	BRWD1-AS2	4.25	2.62e-05	0.00242	0.16	0.19	Cognitive function;	chr21:39178057	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs13339986	ENSG00000255568.3	BRWD1-AS2	4.25	2.62e-05	0.00242	0.17	0.19	Cognitive function;	chr21:39234056	chr21:39313935~39314962:+
THCA	cis	rs10911902	0.643	rs3766702	ENSG00000229739.2	RP11-295K2.3	-4.25	2.62e-05	0.00242	-0.31	-0.19	Schizophrenia;	chr1:186346832	chr1:186435161~186470291:+
THCA	cis	rs9634489	0.502	rs384431	ENSG00000247400.3	DNAJC3-AS1	-4.25	2.62e-05	0.00242	-0.13	-0.19	Body mass index;	chr13:96449642	chr13:95648733~95676925:-
THCA	cis	rs10090774	0.735	rs9324530	ENSG00000280303.2	ERICD	-4.25	2.62e-05	0.00242	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140660808	chr8:140636281~140638283:+
THCA	cis	rs9926296	0.593	rs6500456	ENSG00000274627.1	RP11-104N10.2	-4.25	2.62e-05	0.00242	-0.19	-0.19	Vitiligo;	chr16:89821933	chr16:89516797~89522217:+
THCA	cis	rs10435719	0.809	rs77601743	ENSG00000206014.6	OR7E161P	-4.25	2.62e-05	0.00242	-0.23	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933060	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.678	rs74724594	ENSG00000206014.6	OR7E161P	-4.25	2.62e-05	0.00242	-0.23	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933067	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.702	rs77055881	ENSG00000206014.6	OR7E161P	-4.25	2.62e-05	0.00242	-0.23	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933072	chr8:11928597~11929563:-
THCA	cis	rs42648	0.935	rs42627	ENSG00000225498.1	AC002064.5	4.25	2.62e-05	0.00242	0.2	0.19	Homocysteine levels;	chr7:90332562	chr7:90312496~90322592:+
THCA	cis	rs4767841	0.935	rs2285595	ENSG00000252886.1	RN7SKP197	4.25	2.62e-05	0.00242	0.19	0.19	Urgency urinary incontinence;	chr12:119718603	chr12:119631090~119631386:-
THCA	cis	rs36715	0.904	rs36701	ENSG00000245937.6	LINC01184	4.25	2.62e-05	0.00243	0.24	0.19	Breast cancer;	chr5:128216837	chr5:127940426~128083172:-
THCA	cis	rs2333194	0.846	rs7159794	ENSG00000258695.2	RP3-414A15.2	-4.25	2.62e-05	0.00243	-0.23	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73337735	chr14:73522878~73530610:+
THCA	cis	rs1267303	0.798	rs1267302	ENSG00000232022.5	FAAHP1	-4.25	2.62e-05	0.00243	-0.23	-0.19	Monobrow;	chr1:46524873	chr1:46432129~46445521:+
THCA	cis	rs2303759	0.67	rs45549132	ENSG00000268686.1	AC010524.2	-4.25	2.62e-05	0.00243	-0.3	-0.19	Multiple sclerosis;	chr19:49290771	chr19:49368705~49388081:-
THCA	cis	rs9880211	0.706	rs67382287	ENSG00000239213.4	NCK1-AS1	4.25	2.62e-05	0.00243	0.22	0.19	Height;Body mass index;	chr3:136661617	chr3:136841726~136862054:-
THCA	cis	rs6696239	0.915	rs1495848	ENSG00000227711.2	RP11-275O4.5	4.25	2.62e-05	0.00243	0.26	0.19	Height;	chr1:227546624	chr1:227509028~227520477:-
THCA	cis	rs795484	0.78	rs795476	ENSG00000275409.1	RP11-131L12.4	-4.25	2.62e-05	0.00243	-0.17	-0.19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118184920	chr12:118430147~118430699:+
THCA	cis	rs875971	0.862	rs778684	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66371416	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs778680	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66375427	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs11769079	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66377141	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs1695820	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66379576	chr7:66025126~66031544:-
THCA	cis	rs875971	0.83	rs778715	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66384222	chr7:66025126~66031544:-
THCA	cis	rs875971	0.83	rs809025	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66384832	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs778702	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66399848	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs1643375	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66407690	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs6962717	ENSG00000229886.1	RP5-1132H15.3	4.25	2.62e-05	0.00243	0.2	0.19	Aortic root size;	chr7:66418748	chr7:66025126~66031544:-
THCA	cis	rs478304	0.934	rs1193496	ENSG00000255557.1	RP11-770G2.2	4.25	2.62e-05	0.00243	0.21	0.19	Acne (severe);	chr11:65770085	chr11:65745729~65771585:+
THCA	cis	rs9926296	0.572	rs8046872	ENSG00000260259.1	RP11-368I7.4	-4.25	2.62e-05	0.00243	-0.21	-0.19	Vitiligo;	chr16:89775144	chr16:89682620~89686569:-
THCA	cis	rs7202877	0.656	rs37596	ENSG00000261783.1	RP11-252K23.2	4.25	2.62e-05	0.00243	0.31	0.19	Type 1 diabetes;Type 2 diabetes;	chr16:75464422	chr16:75379818~75381260:-
THCA	cis	rs7824557	0.527	rs2572449	ENSG00000206014.6	OR7E161P	-4.25	2.62e-05	0.00243	-0.22	-0.19	Retinal vascular caliber;	chr8:11381628	chr8:11928597~11929563:-
THCA	cis	rs17301013	0.507	rs72713512	ENSG00000227373.4	RP11-160H22.5	4.25	2.62e-05	0.00243	0.27	0.19	Systemic lupus erythematosus;	chr1:174283505	chr1:174115300~174160004:-
THCA	cis	rs9868809	0.881	rs2286652	ENSG00000270441.1	RP11-694I15.7	4.25	2.62e-05	0.00243	0.26	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48651759	chr3:49140086~49160851:-
THCA	cis	rs699371	0.548	rs2058126	ENSG00000259005.1	RP3-449M8.6	4.25	2.62e-05	0.00243	0.17	0.19	Height;	chr14:74432576	chr14:74474007~74474864:-
THCA	cis	rs394563	0.591	rs237016	ENSG00000231760.4	RP11-350J20.5	4.25	2.62e-05	0.00243	0.24	0.19	Dupuytren's disease;	chr6:149423723	chr6:149796151~149826294:-
THCA	cis	rs1124769	0.672	rs2619696	ENSG00000259378.1	DCAF13P3	-4.25	2.63e-05	0.00243	-0.29	-0.19	Cognitive performance;	chr15:50868814	chr15:50944663~50945996:+
THCA	cis	rs7219021	0.739	rs3760451	ENSG00000248278.1	SUMO2P17	-4.25	2.63e-05	0.00243	-0.25	-0.19	Schizophrenia or bipolar disorder;	chr17:48891815	chr17:48874860~48908983:-
THCA	cis	rs12681963	0.688	rs4733400	ENSG00000248159.1	HSPA8P11	-4.25	2.63e-05	0.00243	-0.35	-0.19	Migraine;	chr8:30154998	chr8:30237382~30240997:+
THCA	cis	rs7088591	0.764	rs17707280	ENSG00000276818.1	AC026393.1	-4.25	2.63e-05	0.00243	-0.41	-0.19	Blood pressure;	chr10:58049286	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs117633847	ENSG00000276818.1	AC026393.1	4.25	2.63e-05	0.00243	0.41	0.19	Blood pressure;	chr10:58046841	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs17707161	ENSG00000276818.1	AC026393.1	4.25	2.63e-05	0.00243	0.41	0.19	Blood pressure;	chr10:58047748	chr10:57095699~57095781:+
THCA	cis	rs11098499	0.863	rs9884402	ENSG00000249244.1	RP11-548H18.2	4.25	2.63e-05	0.00243	0.23	0.19	Corneal astigmatism;	chr4:119568827	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.731	rs9995026	ENSG00000249244.1	RP11-548H18.2	4.25	2.63e-05	0.00243	0.23	0.19	Corneal astigmatism;	chr4:119569344	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	4.25	2.63e-05	0.00243	0.23	0.19	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	4.25	2.63e-05	0.00243	0.23	0.19	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	4.25	2.63e-05	0.00243	0.23	0.19	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
THCA	cis	rs944289	0.616	rs395212	ENSG00000258844.1	RP11-259K15.2	4.25	2.63e-05	0.00243	0.18	0.19	Thyroid cancer;	chr14:36065759	chr14:36214607~36235608:+
THCA	cis	rs2439831	1	rs689754	ENSG00000205771.5	CATSPER2P1	-4.25	2.63e-05	0.00243	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43483697	chr15:43726918~43747094:-
THCA	cis	rs4144027	0.818	rs881057	ENSG00000269910.1	RP11-73M18.10	-4.25	2.63e-05	0.00243	-0.18	-0.19	Blood metabolite levels;	chr14:103887921	chr14:103694516~103695050:-
THCA	cis	rs6845263	0.546	rs2866380	ENSG00000254531.1	FLJ20021	-4.25	2.63e-05	0.00243	-0.16	-0.19	Superior crus of antihelix expression;	chr4:101534886	chr4:101347780~101348883:+
THCA	cis	rs11157436	0.846	rs12435431	ENSG00000211812.1	TRAV26-2	-4.25	2.63e-05	0.00243	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22202583~22203368:+
THCA	cis	rs4705952	0.836	rs10040272	ENSG00000233006.5	AC034220.3	4.25	2.63e-05	0.00243	0.17	0.19	C-reactive protein levels;	chr5:132508888	chr5:132311285~132369916:-
THCA	cis	rs763121	0.853	rs5757162	ENSG00000273076.1	RP3-508I15.22	4.25	2.63e-05	0.00243	0.19	0.19	Menopause (age at onset);	chr22:38597365	chr22:38743495~38743910:+
THCA	cis	rs1232027	0.7	rs1382542	ENSG00000249655.1	CTC-325J23.2	4.25	2.63e-05	0.00243	0.22	0.19	Huntington's disease progression;	chr5:80657762	chr5:80630313~80631590:-
THCA	cis	rs16915157	0.557	rs75849617	ENSG00000254271.1	RP11-131N11.4	4.25	2.63e-05	0.00243	0.41	0.19	Schizophrenia;	chr10:60577716	chr10:60734342~60741828:+
THCA	cis	rs9974653	1	rs9974653	ENSG00000255568.3	BRWD1-AS2	4.25	2.63e-05	0.00243	0.17	0.19	Platelet count;	chr21:39369920	chr21:39313935~39314962:+
THCA	cis	rs9863	0.861	rs11057393	ENSG00000269938.1	RP11-214K3.20	-4.25	2.63e-05	0.00244	-0.23	-0.19	White blood cell count;	chr12:123919222	chr12:123968023~123968579:-
THCA	cis	rs8177876	0.584	rs2602404	ENSG00000261061.1	RP11-303E16.2	4.25	2.63e-05	0.00244	0.25	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056042	chr16:81030770~81031485:+
THCA	cis	rs2153535	0.561	rs2181194	ENSG00000230939.1	RP11-314C16.1	-4.25	2.63e-05	0.00244	-0.2	-0.19	Motion sickness;	chr6:8667318	chr6:8784178~8785445:+
THCA	cis	rs6088580	0.634	rs6059866	ENSG00000276073.1	RP5-1125A11.7	-4.25	2.63e-05	0.00244	-0.16	-0.19	Glomerular filtration rate (creatinine);	chr20:34488005	chr20:33985617~33988989:-
THCA	cis	rs2380220	0.935	rs7748857	ENSG00000261366.1	MANEA-AS1	-4.25	2.63e-05	0.00244	-0.21	-0.19	Behavioural disinhibition (generation interaction);	chr6:95554011	chr6:95575183~95577450:-
THCA	cis	rs172166	0.561	rs149976	ENSG00000280107.1	AL022393.9	4.25	2.63e-05	0.00244	0.19	0.19	Cardiac Troponin-T levels;	chr6:28019998	chr6:28170845~28172521:+
THCA	cis	rs1040393	0.953	rs10753745	ENSG00000225171.2	DUTP6	4.25	2.63e-05	0.00244	0.28	0.19	Schizophrenia;	chr1:166888224	chr1:166868748~166869209:+
THCA	cis	rs75504410	0.579	rs337618	ENSG00000231160.8	KLF3-AS1	-4.25	2.63e-05	0.00244	-0.14	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38619623	chr4:38612701~38664883:-
THCA	cis	rs17074492	0.585	rs9574936	ENSG00000214182.5	PTMAP5	4.25	2.63e-05	0.00244	0.24	0.19	Sjögren's syndrome;	chr13:81641005	chr13:81689911~81691072:+
THCA	cis	rs453301	0.719	rs34004903	ENSG00000254153.1	CTA-398F10.2	4.25	2.63e-05	0.00244	0.21	0.19	Joint mobility (Beighton score);	chr8:9035094	chr8:8456909~8461337:-
THCA	cis	rs713587	0.713	rs4665276	ENSG00000224165.4	DNAJC27-AS1	4.25	2.63e-05	0.00244	0.11	0.19	Body mass index in non-asthmatics;	chr2:24990464	chr2:24971390~25039694:+
THCA	cis	rs3845817	0.868	rs702890	ENSG00000237979.1	AC007389.1	-4.25	2.63e-05	0.00244	-0.22	-0.19	Bipolar disorder;	chr2:65530517	chr2:65500993~65502138:-
THCA	cis	rs801193	0.569	rs2659908	ENSG00000229886.1	RP5-1132H15.3	4.25	2.64e-05	0.00244	0.2	0.19	Aortic root size;	chr7:66695835	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs4717315	ENSG00000229886.1	RP5-1132H15.3	4.25	2.64e-05	0.00244	0.2	0.19	Aortic root size;	chr7:66713338	chr7:66025126~66031544:-
THCA	cis	rs801193	0.527	rs2707837	ENSG00000229886.1	RP5-1132H15.3	4.25	2.64e-05	0.00244	0.2	0.19	Aortic root size;	chr7:66716086	chr7:66025126~66031544:-
THCA	cis	rs801193	0.591	rs4506088	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.64e-05	0.00244	-0.2	-0.19	Aortic root size;	chr7:66670470	chr7:66025126~66031544:-
THCA	cis	rs9902453	0.817	rs2729449	ENSG00000263370.1	RP11-68I3.5	-4.24	2.64e-05	0.00244	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29762733	chr17:29639627~29640825:+
THCA	cis	rs4356203	0.875	rs214935	ENSG00000272034.1	SNORD14A	-4.24	2.64e-05	0.00244	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17171575	chr11:17074654~17074744:-
THCA	cis	rs7267979	1	rs6050559	ENSG00000276952.1	RP5-965G21.6	4.24	2.64e-05	0.00244	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25284915~25285588:-
THCA	cis	rs7809950	0.678	rs75617662	ENSG00000272072.1	CTA-363E19.2	4.24	2.64e-05	0.00244	0.21	0.19	Coronary artery disease;	chr7:107389994	chr7:107192559~107193300:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000223473.2	GS1-124K5.3	-4.24	2.64e-05	0.00244	-0.13	-0.19	Aortic root size;	chr7:66570949	chr7:66491049~66493566:-
THCA	cis	rs6747952	0.899	rs1374387	ENSG00000279484.1	KLHL30-AS1	4.24	2.64e-05	0.00244	0.18	0.19	Mean corpuscular hemoglobin concentration;	chr2:238177046	chr2:238152889~238155994:-
THCA	cis	rs875971	1	rs9986696	ENSG00000229886.1	RP5-1132H15.3	-4.24	2.64e-05	0.00244	-0.2	-0.19	Aortic root size;	chr7:66239589	chr7:66025126~66031544:-
THCA	cis	rs800160	0.777	rs11022291	ENSG00000199550.1	Y_RNA	4.24	2.64e-05	0.00244	0.29	0.19	Bacteremia;	chr11:2324391	chr11:2372638~2372750:+
THCA	cis	rs800160	0.777	rs2651781	ENSG00000199550.1	Y_RNA	4.24	2.64e-05	0.00244	0.29	0.19	Bacteremia;	chr11:2324447	chr11:2372638~2372750:+
THCA	cis	rs7772486	0.806	rs4075696	ENSG00000270638.1	RP3-466P17.1	-4.24	2.64e-05	0.00244	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.806	rs4075695	ENSG00000270638.1	RP3-466P17.1	-4.24	2.64e-05	0.00244	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145735570~145737218:+
THCA	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-4.24	2.64e-05	0.00244	-0.11	-0.19	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
THCA	cis	rs6920965	0.602	rs10872302	ENSG00000237742.5	RP11-624M8.1	-4.24	2.64e-05	0.00244	-0.17	-0.19	High light scatter reticulocyte count;	chr6:125859485	chr6:125578558~125749190:-
THCA	cis	rs4906332	1	rs12885234	ENSG00000269910.1	RP11-73M18.10	4.24	2.64e-05	0.00244	0.16	0.19	Coronary artery disease;	chr14:103422844	chr14:103694516~103695050:-
THCA	cis	rs4906332	0.966	rs35799018	ENSG00000269910.1	RP11-73M18.10	4.24	2.64e-05	0.00244	0.16	0.19	Coronary artery disease;	chr14:103427138	chr14:103694516~103695050:-
THCA	cis	rs34975555	0.614	rs375017	ENSG00000253944.1	RP11-156K13.1	-4.24	2.64e-05	0.00244	-0.3	-0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17994940	chr8:17801345~17861069:+
THCA	cis	rs6878727	0.665	rs256615	ENSG00000253807.4	LINC01170	4.24	2.64e-05	0.00244	0.17	0.19	Breast cancer;	chr5:124324178	chr5:124059794~124405079:-
THCA	cis	rs2302464	1	rs28396343	ENSG00000214846.4	RP11-115L11.1	4.24	2.64e-05	0.00244	0.49	0.19	Cerebrospinal fluid biomarker levels;	chr4:15554422	chr4:15730962~15731627:-
THCA	cis	rs4767841	0.565	rs11064911	ENSG00000248636.5	RP11-768F21.1	-4.24	2.64e-05	0.00244	-0.2	-0.19	Urgency urinary incontinence;	chr12:119793275	chr12:119387987~119668079:-
THCA	cis	rs6973609	0.554	rs58998727	ENSG00000271122.1	RP11-379H18.1	4.24	2.64e-05	0.00244	0.13	0.19	Obesity-related traits;	chr7:35556574	chr7:35695214~35699413:+
THCA	cis	rs9928842	0.771	rs2870471	ENSG00000261783.1	RP11-252K23.2	-4.24	2.64e-05	0.00244	-0.34	-0.19	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75379818~75381260:-
THCA	cis	rs4713118	0.513	rs149989	ENSG00000261839.1	RP1-265C24.8	4.24	2.64e-05	0.00244	0.2	0.19	Parkinson's disease;	chr6:28030406	chr6:28136849~28139678:+
THCA	cis	rs7088591	0.764	rs1860886	ENSG00000276818.1	AC026393.1	4.24	2.64e-05	0.00244	0.36	0.19	Blood pressure;	chr10:57954953	chr10:57095699~57095781:+
THCA	cis	rs6546886	0.957	rs4853005	ENSG00000235499.1	AC073046.25	4.24	2.64e-05	0.00244	0.18	0.19	Dialysis-related mortality;	chr2:74030922	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.957	rs11886928	ENSG00000235499.1	AC073046.25	4.24	2.64e-05	0.00244	0.18	0.19	Dialysis-related mortality;	chr2:74031402	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.957	rs4416242	ENSG00000235499.1	AC073046.25	4.24	2.64e-05	0.00244	0.18	0.19	Dialysis-related mortality;	chr2:74032767	chr2:73985132~73986343:+
THCA	cis	rs62158800	0.526	rs62161276	ENSG00000224568.1	AC096669.3	4.24	2.64e-05	0.00244	0.24	0.19	Facial morphology (factor 22);	chr2:107672556	chr2:107529487~107556326:+
THCA	cis	rs2280018	0.963	rs4985147	ENSG00000263335.1	AF001548.5	-4.24	2.64e-05	0.00244	-0.21	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15726674~15732993:+
THCA	cis	rs6413860	1	rs6413860	ENSG00000260855.1	RP11-439E19.10	-4.24	2.64e-05	0.00244	-0.25	-0.19	Gut microbiome composition (summer);	chr1:246689898	chr1:246772301~246775772:+
THCA	cis	rs9510787	0.538	rs1964161	ENSG00000205861.10	C1QTNF9B-AS1	-4.24	2.64e-05	0.00245	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23656494	chr13:23888889~23897263:+
THCA	cis	rs12223324	0.654	rs10794338	ENSG00000279672.1	CMB9-55F22.1	-4.24	2.64e-05	0.00245	-0.27	-0.19	Fuchs's corneal dystrophy;	chr11:746992	chr11:779617~780755:+
THCA	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	4.24	2.64e-05	0.00245	0.21	0.19	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
THCA	cis	rs2898290	0.622	rs1600250	ENSG00000227888.4	FAM66A	-4.24	2.64e-05	0.00245	-0.25	-0.19	Systolic blood pressure;	chr8:11487916	chr8:12362019~12388296:+
THCA	cis	rs2898290	0.593	rs1600252	ENSG00000227888.4	FAM66A	-4.24	2.64e-05	0.00245	-0.25	-0.19	Systolic blood pressure;	chr8:11488135	chr8:12362019~12388296:+
THCA	cis	rs2439831	0.681	rs484029	ENSG00000166763.7	STRCP1	4.24	2.64e-05	0.00245	0.25	0.19	Lung cancer in ever smokers;	chr15:43327362	chr15:43699488~43718184:-
THCA	cis	rs17723470	1	rs17723470	ENSG00000254427.1	RP11-430H10.1	4.24	2.65e-05	0.00245	0.22	0.19	Thyroid hormone levels;	chr11:45206016	chr11:45355371~45366121:+
THCA	cis	rs7772486	0.79	rs2265469	ENSG00000270638.1	RP3-466P17.1	4.24	2.65e-05	0.00245	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs2265918	ENSG00000270638.1	RP3-466P17.1	4.24	2.65e-05	0.00245	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs2265472	ENSG00000270638.1	RP3-466P17.1	4.24	2.65e-05	0.00245	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs2265919	ENSG00000270638.1	RP3-466P17.1	4.24	2.65e-05	0.00245	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs9403755	ENSG00000270638.1	RP3-466P17.1	-4.24	2.65e-05	0.00245	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145735570~145737218:+
THCA	cis	rs7181230	1	rs11638521	ENSG00000275636.1	RP11-521C20.5	-4.24	2.65e-05	0.00245	-0.19	-0.19	Dehydroepiandrosterone sulphate levels;	chr15:40068113	chr15:40078892~40079347:+
THCA	cis	rs12428035	1	rs2274292	ENSG00000247400.3	DNAJC3-AS1	-4.24	2.65e-05	0.00245	-0.19	-0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95643067	chr13:95648733~95676925:-
THCA	cis	rs12428035	1	rs41277668	ENSG00000247400.3	DNAJC3-AS1	-4.24	2.65e-05	0.00245	-0.19	-0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95643570	chr13:95648733~95676925:-
THCA	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	4.24	2.65e-05	0.00245	0.16	0.19	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
THCA	cis	rs6570726	0.846	rs397311	ENSG00000270638.1	RP3-466P17.1	-4.24	2.65e-05	0.00245	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145735570~145737218:+
THCA	cis	rs4908768	0.906	rs12122851	ENSG00000232912.4	RP5-1115A15.1	4.24	2.65e-05	0.00245	0.23	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8574231	chr1:8424645~8434838:+
THCA	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	4.24	2.65e-05	0.00245	0.23	0.19	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
THCA	cis	rs2153535	0.518	rs9379225	ENSG00000230939.1	RP11-314C16.1	-4.24	2.65e-05	0.00245	-0.21	-0.19	Motion sickness;	chr6:8566027	chr6:8784178~8785445:+
THCA	cis	rs1790761	0.692	rs1148883	ENSG00000255318.1	RP11-655M14.13	4.24	2.65e-05	0.00245	0.21	0.19	Mean corpuscular volume;	chr11:67537215	chr11:67618279~67627304:-
THCA	cis	rs67478160	0.643	rs11624184	ENSG00000269940.1	RP11-73M18.7	4.24	2.65e-05	0.00245	0.19	0.19	Schizophrenia;	chr14:103774661	chr14:103694560~103695170:+
THCA	cis	rs4792901	0.722	rs12603085	ENSG00000267151.3	RP11-100E5.2	4.24	2.65e-05	0.00245	0.21	0.19	Dupuytren's disease;	chr17:43468479	chr17:43444707~43451200:+
THCA	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-4.24	2.65e-05	0.00245	-0.29	-0.19	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
THCA	cis	rs6840258	0.64	rs10025704	ENSG00000251411.1	RP11-397E7.4	-4.24	2.65e-05	0.00245	-0.22	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87207192	chr4:86913266~86914817:-
THCA	cis	rs7665090	0.87	rs228613	ENSG00000230069.3	LRRC37A15P	4.24	2.65e-05	0.00245	0.2	0.19	Primary biliary cholangitis;	chr4:102656308	chr4:102727274~102730721:-
THCA	cis	rs10043228	1	rs17138884	ENSG00000248445.4	SEMA6A-AS1	-4.24	2.65e-05	0.00245	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116089931	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs62384693	ENSG00000248445.4	SEMA6A-AS1	-4.24	2.65e-05	0.00245	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116097784	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384697	ENSG00000248445.4	SEMA6A-AS1	-4.24	2.65e-05	0.00245	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116102587	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384700	ENSG00000248445.4	SEMA6A-AS1	-4.24	2.65e-05	0.00245	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116108108	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs13357258	ENSG00000248445.4	SEMA6A-AS1	-4.24	2.65e-05	0.00245	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116108469	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs6880213	ENSG00000248445.4	SEMA6A-AS1	-4.24	2.65e-05	0.00245	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116111717	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12515308	ENSG00000248445.4	SEMA6A-AS1	-4.24	2.65e-05	0.00245	-0.26	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116114744	chr5:116447547~116508276:+
THCA	cis	rs467650	0.714	rs39785	ENSG00000248489.1	CTD-2007H13.3	-4.24	2.65e-05	0.00245	-0.18	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98579523	chr5:98929171~98995013:+
THCA	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	4.24	2.65e-05	0.00245	0.23	0.19	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
THCA	cis	rs711244	0.756	rs2372786	ENSG00000279519.1	RP11-288C18.1	4.24	2.65e-05	0.00245	0.16	0.19	Mean platelet volume;	chr2:36932656	chr2:36839922~36842539:-
THCA	cis	rs9818758	0.607	rs55873331	ENSG00000270441.1	RP11-694I15.7	4.24	2.65e-05	0.00245	0.29	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49559622	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.505	rs11716159	ENSG00000270441.1	RP11-694I15.7	4.24	2.65e-05	0.00245	0.29	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49594152	chr3:49140086~49160851:-
THCA	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	4.24	2.65e-05	0.00245	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
THCA	cis	rs9843304	0.528	rs1317213	ENSG00000243885.1	RP11-278L15.2	-4.24	2.65e-05	0.00245	-0.21	-0.19	Gallstone disease;	chr3:149473363	chr3:149384179~149385800:-
THCA	cis	rs7208859	0.614	rs216477	ENSG00000263603.1	CTD-2349P21.5	4.24	2.65e-05	0.00245	0.32	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30729469~30731202:+
THCA	cis	rs9926296	0.656	rs2376881	ENSG00000260259.1	RP11-368I7.4	-4.24	2.65e-05	0.00245	-0.21	-0.19	Vitiligo;	chr16:89760603	chr16:89682620~89686569:-
THCA	cis	rs9880211	0.613	rs6799056	ENSG00000273486.1	RP11-731C17.2	4.24	2.65e-05	0.00245	0.19	0.19	Height;Body mass index;	chr3:136083508	chr3:136837338~136839021:-
THCA	cis	rs113835537	0.935	rs79106199	ENSG00000255517.5	CTD-3074O7.5	-4.24	2.66e-05	0.00245	-0.21	-0.19	Airway imaging phenotypes;	chr11:66653047	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.935	rs57043177	ENSG00000255517.5	CTD-3074O7.5	-4.24	2.66e-05	0.00245	-0.21	-0.19	Airway imaging phenotypes;	chr11:66655676	chr11:66473490~66480233:-
THCA	cis	rs494526	0.899	rs10886373	ENSG00000229272.1	RP11-498J9.2	-4.24	2.66e-05	0.00246	-0.21	-0.19	Alcoholic chronic pancreatitis;	chr10:119054937	chr10:119003536~119003884:-
THCA	cis	rs6969780	0.841	rs2301720	ENSG00000233429.8	HOTAIRM1	-4.24	2.66e-05	0.00246	-0.25	-0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156450	chr7:27095647~27100265:+
THCA	cis	rs2434529	1	rs6883228	ENSG00000245275.6	SAP30L-AS1	4.24	2.66e-05	0.00246	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154289595	chr5:154329437~154445850:-
THCA	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-4.24	2.66e-05	0.00246	-0.12	-0.19	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
THCA	cis	rs2179367	0.6	rs9498352	ENSG00000216906.2	RP11-350J20.9	4.24	2.66e-05	0.00246	0.27	0.19	Dupuytren's disease;	chr6:149439108	chr6:149904243~149906418:+
THCA	cis	rs1005277	0.505	rs10827836	ENSG00000275858.1	RP11-291L22.8	-4.24	2.66e-05	0.00246	-0.23	-0.19	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38450738~38451069:-
THCA	cis	rs3764021	0.87	rs7976584	ENSG00000214776.8	RP11-726G1.1	4.24	2.66e-05	0.00246	0.23	0.19	Type 1 diabetes;	chr12:9726059	chr12:9467552~9576275:+
THCA	cis	rs934734	0.532	rs2860773	ENSG00000214533.3	KRT18P33	-4.24	2.66e-05	0.00246	-0.23	-0.19	Rheumatoid arthritis;	chr2:65438507	chr2:65666695~65667737:+
THCA	cis	rs2694917	0.669	rs813497	ENSG00000257576.1	RP11-153M3.1	-4.24	2.66e-05	0.00246	-0.31	-0.19	Blood metabolite ratios;	chr12:56530332	chr12:56511002~56512703:+
THCA	cis	rs7746199	0.673	rs72847313	ENSG00000220721.1	OR1F12	4.24	2.66e-05	0.00246	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28073316~28074233:+
THCA	cis	rs7746199	0.611	rs17750747	ENSG00000220721.1	OR1F12	4.24	2.66e-05	0.00246	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28073316~28074233:+
THCA	cis	rs8077577	0.708	rs4925151	ENSG00000273018.4	CTD-2303H24.2	4.24	2.66e-05	0.00246	0.29	0.19	Obesity-related traits;	chr17:18226818	chr17:18511221~18551705:-
THCA	cis	rs2223471	0.875	rs2235497	ENSG00000060303.5	RPS17P5	-4.24	2.66e-05	0.00246	-0.23	-0.19	Subcutaneous adipose tissue;	chr6:50735361	chr6:50857255~50857662:-
THCA	cis	rs1979679	0.573	rs2348417	ENSG00000247934.4	RP11-967K21.1	4.24	2.66e-05	0.00246	0.19	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582663	chr12:28163298~28190738:-
THCA	cis	rs6121246	0.559	rs6060932	ENSG00000230613.1	HM13-AS1	4.24	2.66e-05	0.00246	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31762742	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.583	rs28815498	ENSG00000230613.1	HM13-AS1	4.24	2.66e-05	0.00246	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31763757	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.512	rs6060938	ENSG00000230613.1	HM13-AS1	4.24	2.66e-05	0.00246	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31775842	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.512	rs6060941	ENSG00000230613.1	HM13-AS1	4.24	2.66e-05	0.00246	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31779580	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6087779	ENSG00000230613.1	HM13-AS1	4.24	2.66e-05	0.00246	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31782763	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.559	rs6060944	ENSG00000230613.1	HM13-AS1	4.24	2.66e-05	0.00246	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31784311	chr20:31567707~31573263:-
THCA	cis	rs7826238	0.524	rs2921055	ENSG00000233609.3	RP11-62H7.2	4.24	2.66e-05	0.00246	0.19	0.19	Systolic blood pressure;	chr8:8461832	chr8:8961200~8979025:+
THCA	cis	rs6001482	0.702	rs5757586	ENSG00000272779.1	LL22NC03-80A10.6	-4.24	2.66e-05	0.00246	-0.21	-0.19	Diastolic blood pressure;	chr22:22234458	chr22:22303224~22310401:+
THCA	cis	rs10256972	0.621	rs2280725	ENSG00000199023.2	MIR339	-4.24	2.66e-05	0.00246	-0.2	-0.19	Endometriosis;Longevity;	chr7:1047790	chr7:1022935~1023045:-
THCA	cis	rs1035144	0.546	rs2215981	ENSG00000258915.1	BHLHB9P1	4.24	2.66e-05	0.00246	0.19	0.19	Male sexual orientation;	chr14:80978623	chr14:80981988~80983638:+
THCA	cis	rs7560272	0.538	rs12052539	ENSG00000273245.1	RP11-434P11.2	4.24	2.66e-05	0.00246	0.22	0.19	Schizophrenia;	chr2:73710026	chr2:73750256~73750786:-
THCA	cis	rs2822388	1	rs2822388	ENSG00000228314.1	CYP4F29P	4.24	2.66e-05	0.00246	0.37	0.19	Stroke;	chr21:14035713	chr21:13843133~13848364:-
THCA	cis	rs4788570	0.615	rs1058750	ENSG00000260185.1	RP11-432I5.6	-4.24	2.66e-05	0.00246	-0.36	-0.19	Intelligence (multi-trait analysis);	chr16:71645154	chr16:71655027~71664212:+
THCA	cis	rs3128341	1	rs72945107	ENSG00000227207.2	RPL31P12	4.24	2.66e-05	0.00246	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72372503	chr1:72301472~72301829:+
THCA	cis	rs3128341	0.941	rs4322186	ENSG00000227207.2	RPL31P12	4.24	2.66e-05	0.00246	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72372878	chr1:72301472~72301829:+
THCA	cis	rs3128341	1	rs1903374	ENSG00000227207.2	RPL31P12	4.24	2.66e-05	0.00246	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72374368	chr1:72301472~72301829:+
THCA	cis	rs10129255	0.912	rs730099	ENSG00000211970.3	IGHV4-61	-4.24	2.66e-05	0.00246	-0.12	-0.19	Kawasaki disease;	chr14:106711838	chr14:106639119~106639657:-
THCA	cis	rs2299587	0.698	rs2283113	ENSG00000253671.1	RP11-806O11.1	-4.24	2.66e-05	0.00246	-0.22	-0.19	Economic and political preferences;	chr8:18022734	chr8:17808941~17820868:+
THCA	cis	rs875971	0.545	rs1796219	ENSG00000273142.1	RP11-458F8.4	-4.24	2.66e-05	0.00246	-0.18	-0.19	Aortic root size;	chr7:66645977	chr7:66902857~66906297:+
THCA	cis	rs2692947	0.77	rs2579552	ENSG00000235584.2	AC008268.1	-4.24	2.66e-05	0.00246	-0.2	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96071335	chr2:95666084~95668715:+
THCA	cis	rs7577696	0.626	rs3769603	ENSG00000276334.1	AL133243.1	-4.24	2.66e-05	0.00246	-0.21	-0.19	Inflammatory biomarkers;	chr2:32135818	chr2:32521927~32523547:+
THCA	cis	rs9863	0.828	rs11057408	ENSG00000269997.1	RP11-214K3.21	-4.24	2.66e-05	0.00246	-0.24	-0.19	White blood cell count;	chr12:123980289	chr12:123966077~123966629:-
THCA	cis	rs73198271	0.71	rs11779561	ENSG00000253893.2	FAM85B	4.24	2.66e-05	0.00246	0.26	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:8167819~8226614:-
THCA	cis	rs2836974	0.674	rs1011413	ENSG00000255568.3	BRWD1-AS2	-4.24	2.67e-05	0.00246	-0.16	-0.19	Cognitive function;	chr21:39266315	chr21:39313935~39314962:+
THCA	cis	rs128738	0.5	rs907368	ENSG00000237714.1	P4HA2-AS1	-4.24	2.67e-05	0.00246	-0.29	-0.19	Giant cell arteritis;	chr5:132238288	chr5:132184876~132192808:+
THCA	cis	rs9341808	0.586	rs3805869	ENSG00000260645.1	RP11-250B2.5	4.24	2.67e-05	0.00246	0.16	0.19	Sitting height ratio;	chr6:80336200	chr6:80466958~80469080:+
THCA	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	4.24	2.67e-05	0.00246	0.21	0.19	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
THCA	cis	rs763121	0.853	rs2235230	ENSG00000235209.1	CTA-150C2.13	-4.24	2.67e-05	0.00246	-0.26	-0.19	Menopause (age at onset);	chr22:38728462	chr22:38921227~38924708:+
THCA	cis	rs7474896	0.537	rs1779068	ENSG00000120555.12	SEPT7P9	-4.24	2.67e-05	0.00246	-0.25	-0.19	Obesity (extreme);	chr10:37961857	chr10:38383069~38402916:-
THCA	cis	rs6570726	0.791	rs1509213	ENSG00000270638.1	RP3-466P17.1	-4.24	2.67e-05	0.00246	-0.16	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145735570~145737218:+
THCA	cis	rs2070488	1	rs2268757	ENSG00000229589.1	ACVR2B-AS1	4.24	2.67e-05	0.00246	0.18	0.19	Electrocardiographic conduction measures;	chr3:38464362	chr3:38451027~38454820:-
THCA	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-4.24	2.67e-05	0.00246	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
THCA	cis	rs1005277	0.505	rs13503	ENSG00000275858.1	RP11-291L22.8	-4.24	2.67e-05	0.00246	-0.23	-0.19	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38450738~38451069:-
THCA	cis	rs812925	0.537	rs10196146	ENSG00000270820.4	RP11-355B11.2	-4.24	2.67e-05	0.00246	-0.16	-0.19	Immature fraction of reticulocytes;	chr2:61378244	chr2:61471188~61484130:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000234585.5	CCT6P3	-4.24	2.67e-05	0.00246	-0.17	-0.19	Aortic root size;	chr7:66018255	chr7:65038354~65074713:+
THCA	cis	rs9863	0.828	rs12833624	ENSG00000269997.1	RP11-214K3.21	-4.24	2.67e-05	0.00247	-0.23	-0.19	White blood cell count;	chr12:123992326	chr12:123966077~123966629:-
THCA	cis	rs9863	0.828	rs34114498	ENSG00000269997.1	RP11-214K3.21	-4.24	2.67e-05	0.00247	-0.23	-0.19	White blood cell count;	chr12:123995826	chr12:123966077~123966629:-
THCA	cis	rs4650994	0.623	rs7534394	ENSG00000273384.1	RP5-1098D14.1	-4.24	2.67e-05	0.00247	-0.25	-0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178653625	chr1:178651706~178652282:+
THCA	cis	rs2562456	0.793	rs627522	ENSG00000268658.4	LINC00664	4.24	2.67e-05	0.00247	0.27	0.19	Pain;	chr19:21313002	chr19:21483374~21503238:+
THCA	cis	rs12893668	0.703	rs7148456	ENSG00000244691.1	RPL10AP1	4.24	2.67e-05	0.00247	0.27	0.19	Reticulocyte count;	chr14:103561933	chr14:103412119~103412761:-
THCA	cis	rs10484434	0.818	rs6935470	ENSG00000272462.2	U91328.19	4.24	2.67e-05	0.00247	0.2	0.19	HIV-1 viral setpoint;	chr6:25990590	chr6:25992662~26001775:+
THCA	cis	rs10484434	0.818	rs2051538	ENSG00000272462.2	U91328.19	4.24	2.67e-05	0.00247	0.2	0.19	HIV-1 viral setpoint;	chr6:25991392	chr6:25992662~26001775:+
THCA	cis	rs6012564	1	rs2426112	ENSG00000230758.1	SNAP23P	-4.24	2.67e-05	0.00247	-0.23	-0.19	Anger;	chr20:49073602	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs2426113	ENSG00000230758.1	SNAP23P	-4.24	2.67e-05	0.00247	-0.23	-0.19	Anger;	chr20:49073652	chr20:49038357~49038602:-
THCA	cis	rs6012564	1	rs3092411	ENSG00000230758.1	SNAP23P	-4.24	2.67e-05	0.00247	-0.23	-0.19	Anger;	chr20:49074054	chr20:49038357~49038602:-
THCA	cis	rs8007846	0.685	rs11621121	ENSG00000276116.2	FUT8-AS1	-4.24	2.67e-05	0.00247	-0.2	-0.19	Multiple sclerosis--Brain Glutamate Levels;	chr14:65355775	chr14:65411170~65412690:-
THCA	cis	rs2749592	0.531	rs10764134	ENSG00000276805.1	RP11-291L22.6	-4.24	2.67e-05	0.00247	-0.2	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38451030~38451785:+
THCA	cis	rs7474896	0.526	rs1208633	ENSG00000226578.1	RP11-258F22.1	4.24	2.67e-05	0.00247	0.27	0.19	Obesity (extreme);	chr10:37867945	chr10:37775371~37784131:-
THCA	cis	rs7474896	0.559	rs1779075	ENSG00000226578.1	RP11-258F22.1	4.24	2.67e-05	0.00247	0.27	0.19	Obesity (extreme);	chr10:37878602	chr10:37775371~37784131:-
THCA	cis	rs7474896	0.559	rs2753880	ENSG00000226578.1	RP11-258F22.1	4.24	2.67e-05	0.00247	0.27	0.19	Obesity (extreme);	chr10:37884410	chr10:37775371~37784131:-
THCA	cis	rs2562456	0.833	rs2650776	ENSG00000268117.1	VN1R84P	4.24	2.67e-05	0.00247	0.31	0.19	Pain;	chr19:21430595	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs2562416	ENSG00000268117.1	VN1R84P	4.24	2.67e-05	0.00247	0.31	0.19	Pain;	chr19:21430609	chr19:21719801~21720035:-
THCA	cis	rs4218	0.648	rs12915899	ENSG00000259732.1	RP11-59H7.3	-4.24	2.67e-05	0.00247	-0.27	-0.19	Social communication problems;	chr15:59084332	chr15:59121034~59133250:+
THCA	cis	rs9573567	0.609	rs9565165	ENSG00000261553.4	RP11-29G8.3	-4.24	2.67e-05	0.00247	-0.36	-0.19	Red blood cell count;Mean corpuscular volume;	chr13:75478654	chr13:75549773~75807120:+
THCA	cis	rs7572644	0.699	rs6547814	ENSG00000223522.1	AC093690.1	-4.24	2.67e-05	0.00247	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27880131	chr2:28307691~28310459:-
THCA	cis	rs7849973	0.864	rs4571809	ENSG00000234840.1	LINC01239	-4.24	2.67e-05	0.00247	-0.23	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22819065	chr9:22646200~22824213:+
THCA	cis	rs7959452	0.57	rs10878964	ENSG00000274979.1	RP11-1143G9.5	-4.24	2.67e-05	0.00247	-0.2	-0.19	Blood protein levels;	chr12:69326911	chr12:69326574~69331882:-
THCA	cis	rs11722779	0.935	rs7681629	ENSG00000248971.2	KRT8P46	-4.24	2.67e-05	0.00247	-0.24	-0.19	Schizophrenia;	chr4:102974407	chr4:102728746~102730171:-
THCA	cis	rs11722779	0.844	rs17033381	ENSG00000248971.2	KRT8P46	-4.24	2.67e-05	0.00247	-0.24	-0.19	Schizophrenia;	chr4:102974952	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs4699044	ENSG00000248971.2	KRT8P46	-4.24	2.67e-05	0.00247	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs4699045	ENSG00000248971.2	KRT8P46	-4.24	2.67e-05	0.00247	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs10015289	ENSG00000248971.2	KRT8P46	-4.24	2.67e-05	0.00247	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102728746~102730171:-
THCA	cis	rs227275	0.556	rs6852141	ENSG00000248971.2	KRT8P46	-4.24	2.67e-05	0.00247	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102728746~102730171:-
THCA	cis	rs228614	0.509	rs4455415	ENSG00000248971.2	KRT8P46	-4.24	2.67e-05	0.00247	-0.24	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102728746~102730171:-
THCA	cis	rs8062405	0.625	rs8060365	ENSG00000261766.1	RP11-22P6.2	4.24	2.67e-05	0.00247	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28862166~28863340:-
THCA	cis	rs77637988	0.631	rs7587385	ENSG00000202227.1	RNU6-282P	4.24	2.67e-05	0.00247	0.2	0.19	Joint mobility (Beighton score);	chr2:48373552	chr2:48501922~48502024:-
THCA	cis	rs77637988	0.631	rs7573316	ENSG00000202227.1	RNU6-282P	4.24	2.67e-05	0.00247	0.2	0.19	Joint mobility (Beighton score);	chr2:48373553	chr2:48501922~48502024:-
THCA	cis	rs7074356	0.915	rs17617970	ENSG00000242600.5	MBL1P	-4.24	2.67e-05	0.00247	-0.25	-0.19	Borderline personality disorder;	chr10:80447136	chr10:79904898~79950336:+
THCA	cis	rs1580019	0.883	rs6945294	ENSG00000231952.3	DPY19L1P2	-4.24	2.67e-05	0.00247	-0.25	-0.19	Cognitive ability;	chr7:32432487	chr7:32812757~32838570:+
THCA	cis	rs4664304	0.742	rs67017730	ENSG00000226266.5	AC009961.3	4.24	2.67e-05	0.00247	0.23	0.19	Crohn's disease;Inflammatory bowel disease;	chr2:159876282	chr2:159670708~159712435:-
THCA	cis	rs8031584	0.678	rs35098644	ENSG00000259845.1	HERC2P10	4.24	2.67e-05	0.00247	0.27	0.19	Huntington's disease progression;	chr15:30853237	chr15:30815271~30844153:+
THCA	cis	rs2179367	0.6	rs9498353	ENSG00000216906.2	RP11-350J20.9	4.24	2.67e-05	0.00247	0.27	0.19	Dupuytren's disease;	chr6:149439860	chr6:149904243~149906418:+
THCA	cis	rs1923243	0.647	rs4367754	ENSG00000223479.3	RP4-788P17.1	4.24	2.67e-05	0.00247	0.21	0.19	Migraine;	chr1:73167486	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210165	ENSG00000223479.3	RP4-788P17.1	4.24	2.67e-05	0.00247	0.21	0.19	Migraine;	chr1:73167725	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.678	rs6684331	ENSG00000223479.3	RP4-788P17.1	4.24	2.67e-05	0.00247	0.21	0.19	Migraine;	chr1:73168445	chr1:73635216~73715214:+
THCA	cis	rs9959145	0.925	rs11664431	ENSG00000267199.1	RP11-861E21.2	4.24	2.67e-05	0.00247	0.25	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12635886	chr18:12438890~12448205:+
THCA	cis	rs734999	0.588	rs2843403	ENSG00000225931.3	RP3-395M20.7	-4.24	2.68e-05	0.00247	-0.23	-0.19	Ulcerative colitis;	chr1:2597658	chr1:2566410~2569888:+
THCA	cis	rs734999	0.549	rs2764840	ENSG00000225931.3	RP3-395M20.7	-4.24	2.68e-05	0.00247	-0.23	-0.19	Ulcerative colitis;	chr1:2597998	chr1:2566410~2569888:+
THCA	cis	rs950169	0.887	rs220333	ENSG00000275120.1	RP11-182J1.17	4.24	2.68e-05	0.00247	0.23	0.19	Schizophrenia;	chr15:84547902	chr15:84599434~84606463:-
THCA	cis	rs1005277	0.505	rs7069702	ENSG00000275858.1	RP11-291L22.8	-4.24	2.68e-05	0.00247	-0.23	-0.19	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38450738~38451069:-
THCA	cis	rs11089937	0.963	rs2226943	ENSG00000211638.2	IGLV8-61	-4.24	2.68e-05	0.00247	-0.14	-0.19	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22098700~22099212:+
THCA	cis	rs7267979	0.844	rs6083845	ENSG00000274973.1	RP13-401N8.7	4.24	2.68e-05	0.00247	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25845497~25845862:+
THCA	cis	rs4819052	0.851	rs2838867	ENSG00000184274.3	LINC00315	-4.24	2.68e-05	0.00247	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:45300245~45305257:-
THCA	cis	rs1728785	1	rs1645976	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68529606	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1728773	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68529741	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1645935	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68529888	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.818	rs1728769	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68530283	chr16:68450283~68452318:+
THCA	cis	rs6499188	0.571	rs1645975	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68530545	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs1645934	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68530587	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs1645974	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68530871	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.901	rs11865339	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68531393	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs11647432	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68531523	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs11075680	ENSG00000274698.1	RP11-71L14.4	4.24	2.68e-05	0.00247	0.26	0.19	Ulcerative colitis;	chr16:68531797	chr16:68450283~68452318:+
THCA	cis	rs440932	0.887	rs398801	ENSG00000254340.1	RP11-10A14.3	-4.24	2.68e-05	0.00247	-0.21	-0.19	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:9141424~9145435:+
THCA	cis	rs56313388	0.522	rs8050235	ENSG00000246379.5	RP11-461O7.1	-4.24	2.68e-05	0.00247	-0.2	-0.19	Pulse pressure;	chr16:56144150	chr16:56092987~56191094:-
THCA	cis	rs67478160	0.654	rs11628240	ENSG00000269940.1	RP11-73M18.7	4.24	2.68e-05	0.00247	0.18	0.19	Schizophrenia;	chr14:103751798	chr14:103694560~103695170:+
THCA	cis	rs394563	0.591	rs237029	ENSG00000231760.4	RP11-350J20.5	4.24	2.68e-05	0.00247	0.24	0.19	Dupuytren's disease;	chr6:149396289	chr6:149796151~149826294:-
THCA	cis	rs394563	0.591	rs237028	ENSG00000231760.4	RP11-350J20.5	4.24	2.68e-05	0.00247	0.24	0.19	Dupuytren's disease;	chr6:149397514	chr6:149796151~149826294:-
THCA	cis	rs4713118	0.869	rs7776351	ENSG00000220721.1	OR1F12	-4.24	2.68e-05	0.00247	-0.25	-0.19	Parkinson's disease;	chr6:27758952	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs7773070	ENSG00000220721.1	OR1F12	4.24	2.68e-05	0.00247	0.25	0.19	Parkinson's disease;	chr6:27761048	chr6:28073316~28074233:+
THCA	cis	rs73198271	0.562	rs2048420	ENSG00000253893.2	FAM85B	4.24	2.68e-05	0.00247	0.34	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8810093	chr8:8167819~8226614:-
THCA	cis	rs1923243	0.647	rs34548060	ENSG00000223479.3	RP4-788P17.1	4.24	2.68e-05	0.00247	0.21	0.19	Migraine;	chr1:73179735	chr1:73635216~73715214:+
THCA	cis	rs7219021	0.739	rs1973404	ENSG00000248278.1	SUMO2P17	-4.24	2.68e-05	0.00247	-0.25	-0.19	Schizophrenia or bipolar disorder;	chr17:48890530	chr17:48874860~48908983:-
THCA	cis	rs42648	0.837	rs10262603	ENSG00000225498.1	AC002064.5	4.24	2.68e-05	0.00247	0.2	0.19	Homocysteine levels;	chr7:90280128	chr7:90312496~90322592:+
THCA	cis	rs7141336	1	rs7141336	ENSG00000258884.1	CTD-3035D6.2	-4.24	2.68e-05	0.00247	-0.25	-0.19	Anxiety disorder;	chr14:90819884	chr14:90822365~90828128:-
THCA	cis	rs465969	1	rs463543	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111346349	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs78945802	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111407143	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs17072683	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111410007	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs17090837	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111430650	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs35208445	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111434944	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs35248830	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111435547	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs35151650	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111436524	chr6:111309203~111313517:+
THCA	cis	rs465969	0.744	rs34089926	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111439043	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs4580915	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111439561	chr6:111309203~111313517:+
THCA	cis	rs465969	0.744	rs7758483	ENSG00000272356.1	RP5-1112D6.8	4.24	2.68e-05	0.00247	0.29	0.19	Psoriasis;	chr6:111467945	chr6:111309203~111313517:+
THCA	cis	rs465969	0.744	rs9400477	ENSG00000272356.1	RP5-1112D6.8	-4.24	2.68e-05	0.00247	-0.29	-0.19	Psoriasis;	chr6:111469440	chr6:111309203~111313517:+
THCA	cis	rs4950322	0.512	rs4625342	ENSG00000271721.1	RP11-337C18.9	-4.24	2.68e-05	0.00247	-0.19	-0.19	Protein quantitative trait loci;	chr1:147369887	chr1:147175602~147177740:+
THCA	cis	rs950169	0.922	rs11635505	ENSG00000275120.1	RP11-182J1.17	-4.24	2.68e-05	0.00247	-0.23	-0.19	Schizophrenia;	chr15:84553803	chr15:84599434~84606463:-
THCA	cis	rs7131987	0.526	rs7954375	ENSG00000275476.1	RP11-996F15.4	4.24	2.68e-05	0.00247	0.19	0.19	QT interval;	chr12:29241487	chr12:29277397~29277882:-
THCA	cis	rs1124769	0.672	rs2574756	ENSG00000259378.1	DCAF13P3	4.24	2.68e-05	0.00248	0.29	0.19	Cognitive performance;	chr15:50837300	chr15:50944663~50945996:+
THCA	cis	rs12134133	0.962	rs7526658	ENSG00000237074.1	RP11-6J21.2	4.24	2.68e-05	0.00248	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207249067~207309121:+
THCA	cis	rs12440869	1	rs9920957	ENSG00000270964.1	RP11-502I4.3	4.24	2.68e-05	0.00248	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67297231	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs17230761	ENSG00000270964.1	RP11-502I4.3	4.24	2.68e-05	0.00248	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67312745	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs28429363	ENSG00000270964.1	RP11-502I4.3	4.24	2.68e-05	0.00248	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67313317	chr15:67541072~67542604:-
THCA	cis	rs2015599	0.56	rs11050147	ENSG00000273680.1	RP11-996F15.6	4.24	2.68e-05	0.00248	0.28	0.19	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29332733~29333383:-
THCA	cis	rs3764021	0.87	rs2192437	ENSG00000214776.8	RP11-726G1.1	4.24	2.68e-05	0.00248	0.23	0.19	Type 1 diabetes;	chr12:9726639	chr12:9467552~9576275:+
THCA	cis	rs3764021	0.87	rs10844617	ENSG00000214776.8	RP11-726G1.1	4.24	2.68e-05	0.00248	0.23	0.19	Type 1 diabetes;	chr12:9726772	chr12:9467552~9576275:+
THCA	cis	rs3764021	0.87	rs2401394	ENSG00000214776.8	RP11-726G1.1	4.24	2.68e-05	0.00248	0.23	0.19	Type 1 diabetes;	chr12:9726830	chr12:9467552~9576275:+
THCA	cis	rs4824093	0.61	rs12106611	ENSG00000278869.1	CITF22-49E9.3	4.24	2.68e-05	0.00248	0.36	0.19	Amyotrophic lateral sclerosis (sporadic);	chr22:49849038	chr22:49933198~49934074:-
THCA	cis	rs17092148	0.887	rs6058077	ENSG00000276073.1	RP5-1125A11.7	-4.24	2.68e-05	0.00248	-0.23	-0.19	Neuroticism;	chr20:34553195	chr20:33985617~33988989:-
THCA	cis	rs4788570	0.615	rs7188675	ENSG00000260593.1	RP11-432I5.2	-4.24	2.68e-05	0.00248	-0.3	-0.19	Intelligence (multi-trait analysis);	chr16:71646099	chr16:71623708~71626816:-
THCA	cis	rs2682471	0.589	rs11053781	ENSG00000245648.1	RP11-277P12.20	4.24	2.68e-05	0.00248	0.2	0.19	Macrophage inflammatory protein 1a levels;	chr12:10384670	chr12:10363769~10398506:+
THCA	cis	rs7711186	0.786	rs60755864	ENSG00000252464.1	RN7SKP70	4.24	2.68e-05	0.00248	0.23	0.19	Urate levels in obese individuals;	chr5:178659511	chr5:178619728~178619998:-
THCA	cis	rs2290416	0.892	rs62522165	ENSG00000253931.1	RP11-909N17.2	4.24	2.68e-05	0.00248	0.38	0.19	Attention deficit hyperactivity disorder;	chr8:143593209	chr8:143412749~143417054:+
THCA	cis	rs6012564	0.893	rs6066909	ENSG00000227431.4	CSE1L-AS1	4.24	2.68e-05	0.00248	0.25	0.19	Anger;	chr20:48913376	chr20:49040463~49046044:-
THCA	cis	rs13325613	0.915	rs35431271	ENSG00000223552.1	RP11-24F11.2	-4.24	2.68e-05	0.00248	-0.29	-0.19	Monocyte count;	chr3:46223821	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.831	rs36000011	ENSG00000223552.1	RP11-24F11.2	-4.24	2.68e-05	0.00248	-0.29	-0.19	Monocyte count;	chr3:46224044	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.748	rs6775046	ENSG00000223552.1	RP11-24F11.2	-4.24	2.68e-05	0.00248	-0.29	-0.19	Monocyte count;	chr3:46227281	chr3:46364955~46407059:-
THCA	cis	rs4356203	0.905	rs1989405	ENSG00000272034.1	SNORD14A	4.24	2.69e-05	0.00248	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17163272	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs214939	ENSG00000272034.1	SNORD14A	4.24	2.69e-05	0.00248	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165992	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs214937	ENSG00000272034.1	SNORD14A	4.24	2.69e-05	0.00248	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17168005	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs214936	ENSG00000272034.1	SNORD14A	4.24	2.69e-05	0.00248	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17169472	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.792	rs620241	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17175343	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.875	rs667984	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179219	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.875	rs527810	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179519	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs589319	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17181050	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs621246	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17182218	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs635802	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17183246	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs662711	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17184641	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs536628	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186545	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs598946	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17187540	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs545773	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192089	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.792	rs677540	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192212	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs512852	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193382	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs511119	ENSG00000272034.1	SNORD14A	-4.24	2.69e-05	0.00248	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193570	chr11:17074654~17074744:-
THCA	cis	rs9868809	0.649	rs17256786	ENSG00000270441.1	RP11-694I15.7	4.24	2.69e-05	0.00248	0.33	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48566583	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.764	rs41290686	ENSG00000270441.1	RP11-694I15.7	4.24	2.69e-05	0.00248	0.33	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48566626	chr3:49140086~49160851:-
THCA	cis	rs12612619	0.627	rs13391244	ENSG00000229122.1	AGBL5-IT1	-4.24	2.69e-05	0.00248	-0.15	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27064741	chr2:27061038~27061815:+
THCA	cis	rs4845570	0.834	rs13376155	ENSG00000203288.3	RP11-98D18.9	-4.24	2.69e-05	0.00248	-0.24	-0.19	Coronary artery disease;	chr1:151748794	chr1:151790804~151794402:+
THCA	cis	rs9902453	0.808	rs76515799	ENSG00000263370.1	RP11-68I3.5	4.24	2.69e-05	0.00248	0.25	0.19	Coffee consumption (cups per day);	chr17:29842473	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.808	rs78154346	ENSG00000263370.1	RP11-68I3.5	4.24	2.69e-05	0.00248	0.25	0.19	Coffee consumption (cups per day);	chr17:29842475	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.808	rs56088359	ENSG00000263370.1	RP11-68I3.5	4.24	2.69e-05	0.00248	0.25	0.19	Coffee consumption (cups per day);	chr17:29846641	chr17:29639627~29640825:+
THCA	cis	rs11758351	0.66	rs16891443	ENSG00000216331.1	HIST1H1PS1	4.24	2.69e-05	0.00248	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26221709	chr6:26195566~26195771:+
THCA	cis	rs62184315	0.629	rs5743072	ENSG00000253559.1	OSGEPL1-AS1	-4.24	2.69e-05	0.00248	-0.25	-0.19	Alcohol dependence (age at onset);	chr2:189832198	chr2:189762704~189765556:+
THCA	cis	rs62025270	0.631	rs55968154	ENSG00000259295.5	CSPG4P12	-4.24	2.69e-05	0.00248	-0.33	-0.19	Idiopathic pulmonary fibrosis;	chr15:85725399	chr15:85191438~85213905:+
THCA	cis	rs62025270	0.688	rs55851385	ENSG00000259295.5	CSPG4P12	-4.24	2.69e-05	0.00248	-0.33	-0.19	Idiopathic pulmonary fibrosis;	chr15:85725400	chr15:85191438~85213905:+
THCA	cis	rs708547	0.581	rs10020462	ENSG00000269949.1	RP11-738E22.3	-4.24	2.69e-05	0.00248	-0.23	-0.19	Response to bleomycin (chromatid breaks);	chr4:56959427	chr4:56960927~56961373:-
THCA	cis	rs516805	1	rs516805	ENSG00000279114.1	RP3-425C14.5	-4.24	2.69e-05	0.00248	-0.19	-0.19	Lymphocyte counts;	chr6:122398486	chr6:122471923~122484161:+
THCA	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	4.24	2.69e-05	0.00248	0.21	0.19	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
THCA	cis	rs11643654	0.605	rs4622508	ENSG00000260818.2	UNGP1	-4.24	2.69e-05	0.00248	-0.18	-0.19	Educational attainment (years of education);	chr16:51174981	chr16:51277852~51279112:+
THCA	cis	rs2806561	0.695	rs66592286	ENSG00000249087.5	ZNF436-AS1	-4.24	2.69e-05	0.00248	-0.13	-0.19	Height;	chr1:23007156	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.695	rs67238799	ENSG00000249087.5	ZNF436-AS1	-4.24	2.69e-05	0.00248	-0.13	-0.19	Height;	chr1:23008519	chr1:23368997~23371839:+
THCA	cis	rs6696239	1	rs12092054	ENSG00000227711.2	RP11-275O4.5	-4.24	2.69e-05	0.00248	-0.27	-0.19	Height;	chr1:227556548	chr1:227509028~227520477:-
THCA	cis	rs6696239	1	rs12123996	ENSG00000227711.2	RP11-275O4.5	-4.24	2.69e-05	0.00248	-0.27	-0.19	Height;	chr1:227557389	chr1:227509028~227520477:-
THCA	cis	rs734999	0.588	rs2764841	ENSG00000225931.3	RP3-395M20.7	-4.24	2.69e-05	0.00248	-0.23	-0.19	Ulcerative colitis;	chr1:2597921	chr1:2566410~2569888:+
THCA	cis	rs357618	1	rs441652	ENSG00000260581.1	CTB-113P19.4	4.24	2.69e-05	0.00248	0.25	0.19	Basophil percentage of white cells;	chr5:151467944	chr5:151652275~151655449:+
THCA	cis	rs734999	0.545	rs28568531	ENSG00000225931.3	RP3-395M20.7	4.24	2.69e-05	0.00248	0.23	0.19	Ulcerative colitis;	chr1:2624201	chr1:2566410~2569888:+
THCA	cis	rs1728785	1	rs1170428	ENSG00000274698.1	RP11-71L14.4	4.24	2.69e-05	0.00248	0.28	0.19	Ulcerative colitis;	chr16:68570085	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs889561	ENSG00000274698.1	RP11-71L14.4	4.24	2.69e-05	0.00248	0.28	0.19	Ulcerative colitis;	chr16:68571838	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1170434	ENSG00000274698.1	RP11-71L14.4	4.24	2.69e-05	0.00248	0.28	0.19	Ulcerative colitis;	chr16:68572687	chr16:68450283~68452318:+
THCA	cis	rs12681963	0.688	rs7015750	ENSG00000248159.1	HSPA8P11	4.24	2.69e-05	0.00248	0.35	0.19	Migraine;	chr8:30196499	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs59483213	ENSG00000248159.1	HSPA8P11	4.24	2.69e-05	0.00248	0.35	0.19	Migraine;	chr8:30200085	chr8:30237382~30240997:+
THCA	cis	rs34929064	0.846	rs59084784	ENSG00000179428.2	AC073072.5	-4.24	2.69e-05	0.00248	-0.22	-0.19	Major depression and alcohol dependence;	chr7:22699943	chr7:22725395~22727620:-
THCA	cis	rs2474937	0.673	rs6428742	ENSG00000231365.4	RP11-418J17.1	4.24	2.69e-05	0.00248	0.19	0.19	Congenital heart malformation;	chr1:118347009	chr1:119140396~119275973:+
THCA	cis	rs4748857	0.502	rs7087405	ENSG00000224215.1	RP11-371A19.2	-4.24	2.69e-05	0.00248	-0.22	-0.19	Systemic lupus erythematosus;	chr10:23385761	chr10:23343957~23345181:+
THCA	cis	rs10489167	1	rs3767954	ENSG00000237899.1	RP4-739H11.3	-4.24	2.69e-05	0.00248	-0.35	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40762771	chr1:40669089~40687588:-
THCA	cis	rs10489167	0.92	rs4660454	ENSG00000237899.1	RP4-739H11.3	-4.24	2.69e-05	0.00248	-0.35	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40763226	chr1:40669089~40687588:-
THCA	cis	rs10256972	0.591	rs6950319	ENSG00000225146.1	AC073957.15	4.24	2.69e-05	0.00248	0.21	0.19	Endometriosis;Longevity;	chr7:1121688	chr7:1029025~1043891:+
THCA	cis	rs7560272	0.588	rs4852959	ENSG00000273245.1	RP11-434P11.2	-4.24	2.69e-05	0.00249	-0.23	-0.19	Schizophrenia;	chr2:73653474	chr2:73750256~73750786:-
THCA	cis	rs12612619	0.696	rs11678188	ENSG00000272148.1	RP11-195B17.1	4.24	2.69e-05	0.00249	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27024964	chr2:27062428~27062907:-
THCA	cis	rs35176054	0.73	rs12779135	ENSG00000280693.1	SH3PXD2A-AS1	-4.24	2.69e-05	0.00249	-0.36	-0.19	Atrial fibrillation;	chr10:103759606	chr10:103745966~103755423:+
THCA	cis	rs4295623	0.559	rs2409836	ENSG00000270154.1	RP11-419I17.1	4.24	2.69e-05	0.00249	0.24	0.19	Morning vs. evening chronotype;	chr8:11831719	chr8:12476462~12477122:+
THCA	cis	rs733592	0.507	rs7304428	ENSG00000258273.1	RP11-370I10.4	4.24	2.69e-05	0.00249	0.23	0.19	Plateletcrit;	chr12:48100492	chr12:48333755~48333901:-
THCA	cis	rs72819454	0.579	rs112995165	ENSG00000280693.1	SH3PXD2A-AS1	-4.24	2.69e-05	0.00249	-0.35	-0.19	Interleukin-9 levels;	chr10:103773216	chr10:103745966~103755423:+
THCA	cis	rs1923243	0.617	rs6424507	ENSG00000223479.3	RP4-788P17.1	-4.24	2.69e-05	0.00249	-0.21	-0.19	Migraine;	chr1:72943300	chr1:73635216~73715214:+
THCA	cis	rs11633886	0.835	rs11633914	ENSG00000259200.1	RP11-718O11.1	-4.24	2.69e-05	0.00249	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45803324	chr15:45705078~45931069:+
THCA	cis	rs7403037	0.617	rs61993101	ENSG00000260760.1	PWRN3	4.24	2.7e-05	0.00249	0.27	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24530788	chr15:24441127~24447967:+
THCA	cis	rs901683	0.702	rs113019116	ENSG00000230869.1	CTGLF10P	-4.24	2.7e-05	0.00249	-0.45	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45598491	chr10:45678692~45700532:+
THCA	cis	rs2153535	0.585	rs1814213	ENSG00000230939.1	RP11-314C16.1	-4.24	2.7e-05	0.00249	-0.2	-0.19	Motion sickness;	chr6:8619632	chr6:8784178~8785445:+
THCA	cis	rs2676071	0.858	rs2670947	ENSG00000259721.1	RP11-758N13.1	4.24	2.7e-05	0.00249	0.22	0.19	Periodontitis (Mean PAL);	chr15:33306649	chr15:32717270~32719007:-
THCA	cis	rs800160	0.72	rs2651791	ENSG00000199550.1	Y_RNA	4.24	2.7e-05	0.00249	0.3	0.19	Bacteremia;	chr11:2337324	chr11:2372638~2372750:+
THCA	cis	rs875971	0.545	rs6460281	ENSG00000273142.1	RP11-458F8.4	4.24	2.7e-05	0.00249	0.18	0.19	Aortic root size;	chr7:66216128	chr7:66902857~66906297:+
THCA	cis	rs2134046	0.587	rs11854289	ENSG00000255769.6	GOLGA2P10	4.24	2.7e-05	0.00249	0.22	0.19	Cognitive ability;	chr15:82266461	chr15:82472993~82513950:-
THCA	cis	rs453301	0.686	rs6748	ENSG00000254153.1	CTA-398F10.2	4.24	2.7e-05	0.00249	0.21	0.19	Joint mobility (Beighton score);	chr8:9033292	chr8:8456909~8461337:-
THCA	cis	rs2692947	0.526	rs58719199	ENSG00000232931.4	LINC00342	4.24	2.7e-05	0.00249	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95912499	chr2:95807118~95816215:-
THCA	cis	rs2692947	0.655	rs4605406	ENSG00000232931.4	LINC00342	4.24	2.7e-05	0.00249	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95917987	chr2:95807118~95816215:-
THCA	cis	rs7267979	0.528	rs34485039	ENSG00000274414.1	RP5-965G21.4	4.24	2.7e-05	0.00249	0.24	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:25239007~25245229:-
THCA	cis	rs61160187	0.667	rs7722373	ENSG00000272308.1	RP11-231G3.1	-4.24	2.7e-05	0.00249	-0.18	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60866457~60866935:-
THCA	cis	rs34929064	0.846	rs2905342	ENSG00000179428.2	AC073072.5	4.24	2.7e-05	0.00249	0.22	0.19	Major depression and alcohol dependence;	chr7:22691425	chr7:22725395~22727620:-
THCA	cis	rs867186	0.925	rs6120843	ENSG00000126005.14	MMP24-AS1	-4.24	2.7e-05	0.00249	-0.24	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35131190	chr20:35216462~35278131:-
THCA	cis	rs4950322	0.58	rs7515160	ENSG00000271721.1	RP11-337C18.9	4.24	2.7e-05	0.00249	0.22	0.19	Protein quantitative trait loci;	chr1:147120714	chr1:147175602~147177740:+
THCA	cis	rs9283706	0.764	rs17218390	ENSG00000229666.1	MAST4-AS1	-4.24	2.7e-05	0.00249	-0.26	-0.19	Coronary artery disease;	chr5:66984598	chr5:67001383~67003953:-
THCA	cis	rs9863	0.896	rs76283024	ENSG00000270061.1	RP11-214K3.19	-4.24	2.7e-05	0.00249	-0.25	-0.19	White blood cell count;	chr12:123982232	chr12:123969990~123970344:-
THCA	cis	rs17772222	0.63	rs61977024	ENSG00000258983.2	RP11-507K2.2	4.24	2.7e-05	0.00249	0.24	0.19	Coronary artery calcification;	chr14:88335961	chr14:88499334~88515502:+
THCA	cis	rs2688608	0.967	rs2688609	ENSG00000271816.1	BMS1P4	-4.24	2.7e-05	0.00249	-0.18	-0.19	Inflammatory bowel disease;	chr10:73898423	chr10:73699151~73730487:-
THCA	cis	rs7618915	0.571	rs2251219	ENSG00000243224.1	RP5-1157M23.2	4.24	2.7e-05	0.00249	0.21	0.19	Bipolar disorder;	chr3:52550771	chr3:52239258~52241097:+
THCA	cis	rs860295	0.58	rs867549	ENSG00000236675.1	MTX1P1	-4.24	2.7e-05	0.00249	-0.19	-0.19	Body mass index;	chr1:155910368	chr1:155230975~155234325:+
THCA	cis	rs13178541	0.81	rs4976496	ENSG00000250378.1	RP11-119J18.1	-4.24	2.7e-05	0.00249	-0.24	-0.19	IgG glycosylation;	chr5:135850086	chr5:135812667~135826582:+
THCA	cis	rs1923243	0.617	rs4294371	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73162600	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6664120	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73162873	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6687721	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73162874	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs6666765	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73163039	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210160	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73163361	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210161	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73163430	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210162	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73163658	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210163	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73163824	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs12742692	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73163993	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.617	rs6686255	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73164967	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6671028	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73165018	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6694634	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73165024	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6697098	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73165088	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6674404	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73165949	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs6700625	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73166129	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.617	rs4537504	ENSG00000223479.3	RP4-788P17.1	4.24	2.7e-05	0.00249	0.21	0.19	Migraine;	chr1:73166311	chr1:73635216~73715214:+
THCA	cis	rs6870983	0.793	rs2728784	ENSG00000247828.6	TMEM161B-AS1	4.24	2.7e-05	0.00249	0.18	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88329020	chr5:88268895~88436685:+
THCA	cis	rs7474896	0.537	rs2749588	ENSG00000263064.2	RP11-291L22.7	4.24	2.7e-05	0.00249	0.26	0.19	Obesity (extreme);	chr10:37980529	chr10:38448689~38448949:+
THCA	cis	rs17095355	0.748	rs2076974	ENSG00000203876.8	ADD3-AS1	4.24	2.7e-05	0.00249	0.2	0.19	Biliary atresia;	chr10:110060553	chr10:109940104~110008381:-
THCA	cis	rs4604234	0.522	rs597950	ENSG00000272129.1	RP11-250B2.6	-4.24	2.7e-05	0.00249	-0.43	-0.19	Cancer;	chr6:80491075	chr6:80355424~80356859:+
THCA	cis	rs75059851	0.756	rs11223654	ENSG00000280237.1	MIR4697HG	4.24	2.7e-05	0.00249	0.22	0.19	Schizophrenia;	chr11:133971684	chr11:133896438~133901601:-
THCA	cis	rs3177980	0.539	rs10919259	ENSG00000239494.2	RN7SL333P	-4.24	2.7e-05	0.00249	-0.18	-0.19	Amyotrophic lateral sclerosis;	chr1:169862062	chr1:169859756~169860052:+
THCA	cis	rs755249	0.508	rs6703800	ENSG00000182109.6	RP11-69E11.4	-4.24	2.7e-05	0.00249	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39160970	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.724	rs12117785	ENSG00000182109.6	RP11-69E11.4	-4.24	2.7e-05	0.00249	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39162739	chr1:39522280~39546187:-
THCA	cis	rs7829975	0.539	rs35571782	ENSG00000233609.3	RP11-62H7.2	4.24	2.7e-05	0.00249	0.19	0.19	Mood instability;	chr8:8284301	chr8:8961200~8979025:+
THCA	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	-4.24	2.7e-05	0.00249	-0.09	-0.19	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
THCA	cis	rs7577696	0.785	rs2886393	ENSG00000276334.1	AL133243.1	-4.24	2.7e-05	0.0025	-0.21	-0.19	Inflammatory biomarkers;	chr2:32146493	chr2:32521927~32523547:+
THCA	cis	rs6940638	0.688	rs9393791	ENSG00000219392.1	RP1-265C24.5	-4.24	2.71e-05	0.0025	-0.23	-0.19	Intelligence (multi-trait analysis);	chr6:27164750	chr6:28115628~28116551:+
THCA	cis	rs10510102	0.516	rs11200306	ENSG00000226864.1	ATE1-AS1	4.24	2.71e-05	0.0025	0.32	0.19	Breast cancer;	chr10:121980862	chr10:121928312~121951965:+
THCA	cis	rs4591358	0.765	rs4355137	ENSG00000223466.1	AC064834.2	4.24	2.71e-05	0.0025	0.22	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195486465	chr2:195533035~195538681:+
THCA	cis	rs6929812	0.934	rs7772160	ENSG00000216915.2	RP1-97D16.1	4.24	2.71e-05	0.0025	0.25	0.19	Neuroticism (multi-trait analysis);	chr6:27444607	chr6:27737000~27738494:-
THCA	cis	rs7711186	0.786	rs7706885	ENSG00000252464.1	RN7SKP70	4.24	2.71e-05	0.0025	0.23	0.19	Urate levels in obese individuals;	chr5:178659804	chr5:178619728~178619998:-
THCA	cis	rs7711186	0.786	rs7706906	ENSG00000252464.1	RN7SKP70	4.24	2.71e-05	0.0025	0.23	0.19	Urate levels in obese individuals;	chr5:178659839	chr5:178619728~178619998:-
THCA	cis	rs7711186	1	rs7711186	ENSG00000252464.1	RN7SKP70	4.24	2.71e-05	0.0025	0.23	0.19	Urate levels in obese individuals;	chr5:178659923	chr5:178619728~178619998:-
THCA	cis	rs12451471	0.637	rs12452616	ENSG00000279259.1	RP11-334C17.3	4.24	2.71e-05	0.0025	0.2	0.19	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80116282	chr17:80147250~80148596:+
THCA	cis	rs5760842	0.967	rs5752054	ENSG00000236641.1	CTA-221G9.7	-4.24	2.71e-05	0.0025	-0.21	-0.19	Recurrent major depressive disorder;	chr22:25084905	chr22:25212742~25213685:+
THCA	cis	rs2806561	0.578	rs6702719	ENSG00000249087.5	ZNF436-AS1	-4.24	2.71e-05	0.0025	-0.13	-0.19	Height;	chr1:22976083	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.664	rs4620508	ENSG00000249087.5	ZNF436-AS1	-4.24	2.71e-05	0.0025	-0.13	-0.19	Height;	chr1:22980945	chr1:23368997~23371839:+
THCA	cis	rs9475752	0.744	rs9296855	ENSG00000231441.1	RP11-472M19.2	-4.24	2.71e-05	0.0025	-0.2	-0.19	Menarche (age at onset);	chr6:56905182	chr6:56844002~56864078:+
THCA	cis	rs9283706	0.608	rs10053537	ENSG00000229666.1	MAST4-AS1	-4.24	2.71e-05	0.0025	-0.27	-0.19	Coronary artery disease;	chr5:67036715	chr5:67001383~67003953:-
THCA	cis	rs9652601	0.691	rs12917716	ENSG00000274038.1	RP11-66H6.4	-4.24	2.71e-05	0.0025	-0.23	-0.19	Systemic lupus erythematosus;	chr16:11095291	chr16:11056556~11057034:+
THCA	cis	rs4646450	0.735	rs10953287	ENSG00000244219.5	GS1-259H13.2	-4.24	2.71e-05	0.0025	-0.25	-0.19	Blood metabolite levels;	chr7:99324799	chr7:99598066~99610813:+
THCA	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	4.24	2.71e-05	0.0025	0.21	0.19	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
THCA	cis	rs116248771	0.549	rs9849301	ENSG00000271778.1	RP11-379F4.8	4.24	2.71e-05	0.0025	0.26	0.19	diarrhoeal disease at age 2;	chr3:158727071	chr3:158782547~158783124:+
THCA	cis	rs847577	0.572	rs847573	ENSG00000272950.1	RP11-307C18.1	-4.24	2.71e-05	0.0025	-0.25	-0.19	Breast cancer;	chr7:98052449	chr7:98322853~98323430:+
THCA	cis	rs7844233	0.579	rs10156227	ENSG00000254023.1	PKMP4	4.24	2.71e-05	0.0025	0.32	0.19	Breast cancer;	chr8:75661625	chr8:75376709~75377014:+
THCA	cis	rs6570726	0.846	rs973856	ENSG00000270638.1	RP3-466P17.1	-4.24	2.71e-05	0.0025	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145735570~145737218:+
THCA	cis	rs868036	0.609	rs13329413	ENSG00000270964.1	RP11-502I4.3	-4.24	2.71e-05	0.0025	-0.18	-0.19	Restless legs syndrome;	chr15:67804788	chr15:67541072~67542604:-
THCA	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	4.24	2.71e-05	0.0025	0.16	0.19	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
THCA	cis	rs2028299	1	rs7111	ENSG00000259677.1	RP11-493E3.1	4.24	2.71e-05	0.0025	0.25	0.19	Type 2 diabetes;	chr15:89830641	chr15:89876540~89877285:+
THCA	cis	rs758324	0.704	rs40401	ENSG00000224431.1	AC063976.7	-4.24	2.71e-05	0.0025	-0.17	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132060785	chr5:132199456~132203487:+
THCA	cis	rs12612619	0.704	rs2384571	ENSG00000272148.1	RP11-195B17.1	4.24	2.71e-05	0.0025	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27101856	chr2:27062428~27062907:-
THCA	cis	rs67478160	0.584	rs2295148	ENSG00000258735.1	LINC00637	-4.24	2.71e-05	0.0025	-0.23	-0.19	Schizophrenia;	chr14:103729273	chr14:103847721~103858049:+
THCA	cis	rs7824557	1	rs2736371	ENSG00000154316.13	TDH	4.24	2.71e-05	0.0025	0.14	0.19	Retinal vascular caliber;	chr8:11248020	chr8:11339637~11368452:+
THCA	cis	rs7826238	0.601	rs2976907	ENSG00000254153.1	CTA-398F10.2	-4.24	2.71e-05	0.0025	-0.22	-0.19	Systolic blood pressure;	chr8:8487658	chr8:8456909~8461337:-
THCA	cis	rs10761482	0.813	rs7087726	ENSG00000254271.1	RP11-131N11.4	4.24	2.71e-05	0.0025	0.26	0.19	Schizophrenia;	chr10:60402824	chr10:60734342~60741828:+
THCA	cis	rs10489167	1	rs2744800	ENSG00000237899.1	RP4-739H11.3	4.24	2.71e-05	0.0025	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40690337	chr1:40669089~40687588:-
THCA	cis	rs9902453	0.845	rs12602426	ENSG00000263370.1	RP11-68I3.5	4.24	2.71e-05	0.0025	0.25	0.19	Coffee consumption (cups per day);	chr17:29831797	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs10853135	ENSG00000263370.1	RP11-68I3.5	4.24	2.71e-05	0.0025	0.25	0.19	Coffee consumption (cups per day);	chr17:29861657	chr17:29639627~29640825:+
THCA	cis	rs988712	0.672	rs35038967	ENSG00000245573.6	BDNF-AS	-4.24	2.71e-05	0.0025	-0.19	-0.19	Obesity;	chr11:27681933	chr11:27506838~27698174:+
THCA	cis	rs858239	0.6	rs10256361	ENSG00000226816.2	AC005082.12	4.24	2.71e-05	0.0025	0.27	0.19	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23206013~23208045:+
THCA	cis	rs2886497	0.624	rs4747469	ENSG00000224215.1	RP11-371A19.2	-4.24	2.71e-05	0.0025	-0.21	-0.19	Major depression and alcohol dependence;	chr10:23401772	chr10:23343957~23345181:+
THCA	cis	rs9717605	0.955	rs73046011	ENSG00000226445.1	XXyac-YX65C7_A.2	4.24	2.71e-05	0.0025	0.24	0.19	Left atrial antero-posterior diameter;	chr6:169246455	chr6:169213254~169239565:+
THCA	cis	rs2439831	0.681	rs3742969	ENSG00000166763.7	STRCP1	4.24	2.71e-05	0.0025	0.25	0.19	Lung cancer in ever smokers;	chr15:43329749	chr15:43699488~43718184:-
THCA	cis	rs11644601	1	rs11644601	ENSG00000260872.1	RP11-680G24.5	4.24	2.71e-05	0.0025	0.21	0.19	Metabolite levels (lipid measures);	chr16:15078261	chr16:15018106~15020488:-
THCA	cis	rs27434	0.605	rs152468	ENSG00000272109.1	CTD-2260A17.3	-4.24	2.71e-05	0.0025	-0.31	-0.19	Ankylosing spondylitis;	chr5:96831833	chr5:96804353~96806105:+
THCA	cis	rs4948102	0.642	rs766333	ENSG00000275875.1	RP11-613E4.5	-4.24	2.71e-05	0.0025	-0.23	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55741525~55741869:+
THCA	cis	rs7824557	0.51	rs4841524	ENSG00000154316.13	TDH	4.24	2.71e-05	0.0025	0.14	0.19	Retinal vascular caliber;	chr8:11385617	chr8:11339637~11368452:+
THCA	cis	rs2334880	0.836	rs9939458	ENSG00000260185.1	RP11-432I5.6	-4.24	2.71e-05	0.0025	-0.36	-0.19	Malaria;	chr16:71633228	chr16:71655027~71664212:+
THCA	cis	rs8030605	0.778	rs72742636	ENSG00000277245.1	RP11-48G14.3	4.24	2.71e-05	0.0025	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56410015	chr15:56447120~56447697:+
THCA	cis	rs1124769	0.57	rs2614768	ENSG00000259378.1	DCAF13P3	-4.24	2.71e-05	0.0025	-0.27	-0.19	Cognitive performance;	chr15:50871261	chr15:50944663~50945996:+
THCA	cis	rs801193	0.591	rs721717	ENSG00000229886.1	RP5-1132H15.3	-4.24	2.71e-05	0.0025	-0.2	-0.19	Aortic root size;	chr7:66665305	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs6951302	ENSG00000229886.1	RP5-1132H15.3	-4.24	2.71e-05	0.0025	-0.2	-0.19	Aortic root size;	chr7:66667525	chr7:66025126~66031544:-
THCA	cis	rs4947019	0.609	rs17070590	ENSG00000223537.2	RP5-919F19.5	-4.24	2.71e-05	0.0025	-0.36	-0.19	Hematological parameters;	chr6:109424420	chr6:109487906~109506800:+
THCA	cis	rs1501911	0.527	rs109843	ENSG00000248489.1	CTD-2007H13.3	4.24	2.71e-05	0.0025	0.17	0.19	Lung function (FEV1/FVC);	chr5:98985233	chr5:98929171~98995013:+
THCA	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	4.24	2.72e-05	0.0025	0.17	0.19	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
THCA	cis	rs1728785	0.901	rs1103286	ENSG00000274698.1	RP11-71L14.4	4.24	2.72e-05	0.0025	0.27	0.19	Ulcerative colitis;	chr16:68544722	chr16:68450283~68452318:+
THCA	cis	rs1577917	0.696	rs2842603	ENSG00000220563.1	PKMP3	-4.24	2.72e-05	0.0025	-0.14	-0.19	Response to antipsychotic treatment;	chr6:85626619	chr6:85659892~85660606:-
THCA	cis	rs4722166	0.508	rs1474348	ENSG00000225541.1	AC002480.5	-4.24	2.72e-05	0.0025	-0.24	-0.19	Lung cancer;	chr7:22728289	chr7:22571607~22661792:-
THCA	cis	rs1923243	0.557	rs12120825	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73155726	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs7538421	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73156441	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs7528640	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73156986	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs12406002	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73157748	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210148	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73158144	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs36118829	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73158170	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.589	rs61767506	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73158781	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs4483359	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73159074	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs4308929	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73159231	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210150	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73159682	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210151	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73159766	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210152	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73159785	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs35446706	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73160735	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs35489458	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73160738	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210155	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73161111	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.617	rs11210157	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73161375	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs4579710	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.0025	0.21	0.19	Migraine;	chr1:73162121	chr1:73635216~73715214:+
THCA	cis	rs28510890	0.51	rs3825982	ENSG00000258676.4	RP11-386M24.3	4.24	2.72e-05	0.00251	0.23	0.19	Lung cancer in ever smokers;	chr15:92617015	chr15:92580829~92600545:+
THCA	cis	rs6570726	0.791	rs418701	ENSG00000270638.1	RP3-466P17.1	4.24	2.72e-05	0.00251	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145735570~145737218:+
THCA	cis	rs755249	0.958	rs17264866	ENSG00000237624.1	OXCT2P1	4.24	2.72e-05	0.00251	0.26	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39514956~39516490:+
THCA	cis	rs7809799	0.571	rs740160	ENSG00000244219.5	GS1-259H13.2	-4.24	2.72e-05	0.00251	-0.43	-0.19	Ulcerative colitis;	chr7:99360257	chr7:99598066~99610813:+
THCA	cis	rs72928364	1	rs2713782	ENSG00000256628.3	ZBTB11-AS1	-4.24	2.72e-05	0.00251	-0.31	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100910460	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs2576387	ENSG00000256628.3	ZBTB11-AS1	-4.24	2.72e-05	0.00251	-0.31	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100910582	chr3:101676475~101679217:+
THCA	cis	rs5758659	0.652	rs5751195	ENSG00000273366.1	CTA-989H11.1	-4.24	2.72e-05	0.00251	-0.23	-0.19	Cognitive function;	chr22:41983997	chr22:42278188~42278846:+
THCA	cis	rs7429990	0.965	rs11709289	ENSG00000228638.1	FCF1P2	-4.24	2.72e-05	0.00251	-0.21	-0.19	Educational attainment (years of education);	chr3:47765159	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs5016900	ENSG00000228638.1	FCF1P2	-4.24	2.72e-05	0.00251	-0.21	-0.19	Educational attainment (years of education);	chr3:47781387	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.93	rs13072132	ENSG00000228638.1	FCF1P2	-4.24	2.72e-05	0.00251	-0.21	-0.19	Educational attainment (years of education);	chr3:47824671	chr3:48290793~48291375:-
THCA	cis	rs7429990	0.965	rs34507589	ENSG00000228638.1	FCF1P2	-4.24	2.72e-05	0.00251	-0.21	-0.19	Educational attainment (years of education);	chr3:47832552	chr3:48290793~48291375:-
THCA	cis	rs1923243	0.647	rs11210164	ENSG00000223479.3	RP4-788P17.1	4.24	2.72e-05	0.00251	0.21	0.19	Migraine;	chr1:73164390	chr1:73635216~73715214:+
THCA	cis	rs12908161	1	rs62019469	ENSG00000188388.10	GOLGA6L3	4.24	2.72e-05	0.00251	0.26	0.19	Schizophrenia;	chr15:84777989	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs12908549	ENSG00000188388.10	GOLGA6L3	4.24	2.72e-05	0.00251	0.26	0.19	Schizophrenia;	chr15:84779120	chr15:85240472~85247170:+
THCA	cis	rs7572733	0.534	rs7604700	ENSG00000231621.1	AC013264.2	-4.24	2.72e-05	0.00251	-0.2	-0.19	Dermatomyositis;	chr2:197853906	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.555	rs1435569	ENSG00000231621.1	AC013264.2	-4.24	2.72e-05	0.00251	-0.2	-0.19	Dermatomyositis;	chr2:197853943	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.514	rs700686	ENSG00000231621.1	AC013264.2	-4.24	2.72e-05	0.00251	-0.2	-0.19	Dermatomyositis;	chr2:197856330	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700687	ENSG00000231621.1	AC013264.2	-4.24	2.72e-05	0.00251	-0.2	-0.19	Dermatomyositis;	chr2:197856836	chr2:197197991~197199273:+
THCA	cis	rs7712401	0.692	rs9327273	ENSG00000249996.1	RP11-359P5.1	4.24	2.72e-05	0.00251	0.19	0.19	Mean platelet volume;	chr5:122737855	chr5:123036271~123054667:+
THCA	cis	rs11634944	1	rs12916854	ENSG00000257151.1	PWAR6	4.24	2.72e-05	0.00251	0.15	0.19	Interleukin-8 levels;	chr15:24955755	chr15:25031873~25036490:+
THCA	cis	rs793571	0.784	rs8029301	ENSG00000245975.2	RP11-30K9.6	4.24	2.72e-05	0.00251	0.2	0.19	Schizophrenia;	chr15:58829637	chr15:58768072~58770974:-
THCA	cis	rs7267979	0.668	rs2387977	ENSG00000276952.1	RP5-965G21.6	-4.24	2.72e-05	0.00251	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:25284915~25285588:-
THCA	cis	rs45509595	0.841	rs17751184	ENSG00000220721.1	OR1F12	4.24	2.72e-05	0.00251	0.43	0.19	Breast cancer;	chr6:27807250	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs67101035	ENSG00000220721.1	OR1F12	4.24	2.72e-05	0.00251	0.43	0.19	Depression;	chr6:27831109	chr6:28073316~28074233:+
THCA	cis	rs853679	0.556	rs34706883	ENSG00000220721.1	OR1F12	4.24	2.72e-05	0.00251	0.43	0.19	Depression;	chr6:27837477	chr6:28073316~28074233:+
THCA	cis	rs67340775	0.748	rs13212651	ENSG00000220721.1	OR1F12	4.24	2.72e-05	0.00251	0.43	0.19	Lung cancer in ever smokers;	chr6:27839207	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs35819751	ENSG00000220721.1	OR1F12	4.24	2.72e-05	0.00251	0.43	0.19	Depression;	chr6:27842791	chr6:28073316~28074233:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000234585.5	CCT6P3	4.24	2.72e-05	0.00251	0.18	0.19	Aortic root size;	chr7:65963835	chr7:65038354~65074713:+
THCA	cis	rs7312933	0.584	rs6582391	ENSG00000257225.1	RP11-328C8.4	-4.24	2.72e-05	0.00251	-0.2	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42240884	chr12:42459366~42466128:+
THCA	cis	rs10790268	1	rs10790268	ENSG00000255239.1	AP002954.6	4.24	2.72e-05	0.00251	0.29	0.19	Rheumatoid arthritis;	chr11:118858682	chr11:118688039~118690600:-
THCA	cis	rs6993270	0.512	rs11992314	ENSG00000245330.4	KB-1471A8.1	-4.24	2.72e-05	0.00251	-0.32	-0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119882138	chr8:119867419~119874488:-
THCA	cis	rs4356203	0.905	rs7396382	ENSG00000272034.1	SNORD14A	4.24	2.72e-05	0.00251	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17129925	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs214906	ENSG00000272034.1	SNORD14A	4.24	2.72e-05	0.00251	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17159793	chr11:17074654~17074744:-
THCA	cis	rs6570726	0.935	rs585292	ENSG00000270638.1	RP3-466P17.1	4.24	2.72e-05	0.00251	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.837	rs419991	ENSG00000270638.1	RP3-466P17.1	4.24	2.72e-05	0.00251	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.875	rs12524077	ENSG00000270638.1	RP3-466P17.1	4.24	2.72e-05	0.00251	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145735570~145737218:+
THCA	cis	rs7264396	1	rs7264396	ENSG00000088340.14	FER1L4	-4.24	2.72e-05	0.00251	-0.18	-0.19	Total cholesterol levels;	chr20:35566823	chr20:35558737~35607562:-
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000265443.1	CTD-2349P21.6	-4.24	2.72e-05	0.00251	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30726305~30727564:-
THCA	cis	rs7829975	0.577	rs17684466	ENSG00000254153.1	CTA-398F10.2	4.24	2.72e-05	0.00251	0.22	0.19	Mood instability;	chr8:8687723	chr8:8456909~8461337:-
THCA	cis	rs61270009	0.955	rs10942528	ENSG00000247828.6	TMEM161B-AS1	4.24	2.72e-05	0.00251	0.17	0.19	Depressive symptoms;	chr5:88314098	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.913	rs13190179	ENSG00000247828.6	TMEM161B-AS1	4.24	2.72e-05	0.00251	0.17	0.19	Depressive symptoms;	chr5:88314755	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs11738675	ENSG00000247828.6	TMEM161B-AS1	4.24	2.72e-05	0.00251	0.17	0.19	Depressive symptoms;	chr5:88315360	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs60331678	ENSG00000247828.6	TMEM161B-AS1	4.24	2.72e-05	0.00251	0.17	0.19	Depressive symptoms;	chr5:88315547	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs10462333	ENSG00000247828.6	TMEM161B-AS1	4.24	2.72e-05	0.00251	0.17	0.19	Depressive symptoms;	chr5:88315871	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs6872897	ENSG00000247828.6	TMEM161B-AS1	4.24	2.72e-05	0.00251	0.17	0.19	Depressive symptoms;	chr5:88322248	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.908	rs16903077	ENSG00000247828.6	TMEM161B-AS1	4.24	2.72e-05	0.00251	0.17	0.19	Depressive symptoms;	chr5:88323008	chr5:88268895~88436685:+
THCA	cis	rs4767841	0.565	rs7953072	ENSG00000248636.5	RP11-768F21.1	-4.24	2.72e-05	0.00251	-0.2	-0.19	Urgency urinary incontinence;	chr12:119790899	chr12:119387987~119668079:-
THCA	cis	rs9840812	0.623	rs9854084	ENSG00000239213.4	NCK1-AS1	4.24	2.72e-05	0.00251	0.18	0.19	Fibrinogen levels;	chr3:136475901	chr3:136841726~136862054:-
THCA	cis	rs2039553	0.52	rs2802640	ENSG00000227354.5	RBM26-AS1	4.24	2.73e-05	0.00251	0.18	0.19	Pancreatic cancer;	chr13:79748735	chr13:79406309~79424328:+
THCA	cis	rs9876781	1	rs6442119	ENSG00000244380.1	RP11-24C3.2	4.24	2.73e-05	0.00251	0.22	0.19	Longevity;	chr3:48398713	chr3:48440352~48446656:-
THCA	cis	rs860295	0.557	rs11264371	ENSG00000160766.13	GBAP1	-4.24	2.73e-05	0.00251	-0.23	-0.19	Body mass index;	chr1:155442246	chr1:155213821~155227422:-
THCA	cis	rs10256972	0.621	rs10951594	ENSG00000199023.2	MIR339	-4.24	2.73e-05	0.00251	-0.2	-0.19	Endometriosis;Longevity;	chr7:1048971	chr7:1022935~1023045:-
THCA	cis	rs782212	0.625	rs11209963	ENSG00000227207.2	RPL31P12	-4.24	2.73e-05	0.00251	-0.3	-0.19	Depression;	chr1:72417620	chr1:72301472~72301829:+
THCA	cis	rs782212	0.592	rs2590942	ENSG00000227207.2	RPL31P12	4.24	2.73e-05	0.00251	0.3	0.19	Depression;	chr1:72419598	chr1:72301472~72301829:+
THCA	cis	rs782212	0.559	rs2815766	ENSG00000227207.2	RPL31P12	4.24	2.73e-05	0.00251	0.3	0.19	Depression;	chr1:72424195	chr1:72301472~72301829:+
THCA	cis	rs11758351	0.587	rs10484436	ENSG00000216331.1	HIST1H1PS1	4.24	2.73e-05	0.00251	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26236927	chr6:26195566~26195771:+
THCA	cis	rs4308124	0.708	rs10179596	ENSG00000230499.1	AC108463.1	-4.24	2.73e-05	0.00251	-0.28	-0.19	Vitiligo;	chr2:111212803	chr2:111195963~111206494:+
THCA	cis	rs709400	0.93	rs61996717	ENSG00000258735.1	LINC00637	4.24	2.73e-05	0.00251	0.25	0.19	Body mass index;	chr14:103582234	chr14:103847721~103858049:+
THCA	cis	rs7045881	0.673	rs17694127	ENSG00000254396.1	RP11-56F10.3	4.24	2.73e-05	0.00251	0.34	0.19	Schizophrenia;	chr9:26862379	chr9:27102630~27104728:+
THCA	cis	rs2436845	0.627	rs2513920	ENSG00000253320.4	KB-1507C5.2	-4.24	2.73e-05	0.00251	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102818464	chr8:102864300~102977876:+
THCA	cis	rs4947019	0.609	rs9487109	ENSG00000223537.2	RP5-919F19.5	-4.24	2.73e-05	0.00251	-0.36	-0.19	Hematological parameters;	chr6:109436323	chr6:109487906~109506800:+
THCA	cis	rs728616	0.681	rs12413174	ENSG00000225484.5	NUTM2B-AS1	-4.24	2.73e-05	0.00251	-0.34	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80302648	chr10:79663088~79826594:-
THCA	cis	rs931127	0.747	rs11820062	ENSG00000214659.4	KRT8P26	4.24	2.73e-05	0.00251	0.17	0.19	Systemic lupus erythematosus;	chr11:65662465	chr11:65726939~65728214:+
THCA	cis	rs8141529	0.632	rs5762803	ENSG00000272858.1	CTA-292E10.8	-4.24	2.73e-05	0.00251	-0.21	-0.19	Lymphocyte counts;	chr22:28797650	chr22:28814914~28815662:+
THCA	cis	rs11621975	0.57	rs67941660	ENSG00000259088.1	CTD-2017C7.2	-4.24	2.73e-05	0.00251	-0.41	-0.19	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101815149	chr14:101796555~101810321:-
THCA	cis	rs67478160	0.595	rs2295146	ENSG00000269940.1	RP11-73M18.7	4.24	2.73e-05	0.00251	0.18	0.19	Schizophrenia;	chr14:103733019	chr14:103694560~103695170:+
THCA	cis	rs7178424	0.711	rs7166891	ENSG00000259251.2	RP11-643M14.1	4.24	2.73e-05	0.00251	0.19	0.19	Height;	chr15:61947105	chr15:62060503~62062434:+
THCA	cis	rs3020736	0.5	rs6002605	ENSG00000237037.8	NDUFA6-AS1	4.24	2.73e-05	0.00251	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42090931~42137742:+
THCA	cis	rs1876905	0.68	rs7767302	ENSG00000272356.1	RP5-1112D6.8	4.24	2.73e-05	0.00252	0.2	0.19	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111309203~111313517:+
THCA	cis	rs7658584	0.945	rs6824268	ENSG00000246375.2	RP11-10L7.1	4.24	2.73e-05	0.00252	0.33	0.19	Squamous cell lung carcinoma;	chr4:88171831	chr4:88284942~88331421:+
THCA	cis	rs9487094	0.67	rs1998811	ENSG00000223537.2	RP5-919F19.5	-4.24	2.73e-05	0.00252	-0.19	-0.19	Height;	chr6:109490935	chr6:109487906~109506800:+
THCA	cis	rs911555	0.723	rs56227024	ENSG00000269958.1	RP11-73M18.8	-4.24	2.73e-05	0.00252	-0.18	-0.19	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103696353~103697163:+
THCA	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	4.24	2.73e-05	0.00252	0.23	0.19	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
THCA	cis	rs6088590	0.965	rs6058108	ENSG00000269202.1	RP4-614O4.12	-4.24	2.73e-05	0.00252	-0.17	-0.19	Coronary artery disease;	chr20:34700851	chr20:35201747~35203288:-
THCA	cis	rs1577917	0.74	rs9353327	ENSG00000220563.1	PKMP3	-4.24	2.73e-05	0.00252	-0.14	-0.19	Response to antipsychotic treatment;	chr6:85684348	chr6:85659892~85660606:-
THCA	cis	rs2281603	0.57	rs2198347	ENSG00000272909.1	CTD-2555O16.4	4.24	2.73e-05	0.00252	0.23	0.19	Lymphocyte counts;	chr14:64502624	chr14:64440369~64442238:-
THCA	cis	rs10761482	0.769	rs990685	ENSG00000254271.1	RP11-131N11.4	4.24	2.73e-05	0.00252	0.26	0.19	Schizophrenia;	chr10:60338391	chr10:60734342~60741828:+
THCA	cis	rs10129255	0.917	rs7142373	ENSG00000211970.3	IGHV4-61	-4.24	2.73e-05	0.00252	-0.12	-0.19	Kawasaki disease;	chr14:106708947	chr14:106639119~106639657:-
THCA	cis	rs7216064	0.953	rs2086744	ENSG00000278740.1	RP11-147L13.14	4.24	2.73e-05	0.00252	0.22	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853159	chr17:68188547~68189165:+
THCA	cis	rs10761482	0.861	rs10740027	ENSG00000254271.1	RP11-131N11.4	4.24	2.73e-05	0.00252	0.26	0.19	Schizophrenia;	chr10:60399903	chr10:60734342~60741828:+
THCA	cis	rs1923243	0.647	rs7514409	ENSG00000223479.3	RP4-788P17.1	4.24	2.73e-05	0.00252	0.21	0.19	Migraine;	chr1:73181365	chr1:73635216~73715214:+
THCA	cis	rs1336149	0.967	rs6664744	ENSG00000211581.1	MIR765	-4.24	2.73e-05	0.00252	-0.25	-0.19	Chin dimples;	chr1:157002189	chr1:156936131~156936244:-
THCA	cis	rs9959145	1	rs9967026	ENSG00000267108.1	RP11-861E21.1	4.24	2.73e-05	0.00252	0.24	0.19	Immune response to smallpox vaccine (IL-6);	chr18:12566484	chr18:12432897~12437635:+
THCA	cis	rs9926296	0.569	rs4785708	ENSG00000260259.1	RP11-368I7.4	4.24	2.73e-05	0.00252	0.21	0.19	Vitiligo;	chr16:89730161	chr16:89682620~89686569:-
THCA	cis	rs1580019	0.713	rs2167274	ENSG00000231952.3	DPY19L1P2	-4.24	2.73e-05	0.00252	-0.24	-0.19	Cognitive ability;	chr7:32485232	chr7:32812757~32838570:+
THCA	cis	rs8062405	1	rs80275162	ENSG00000270424.1	RP11-1348G14.6	4.24	2.73e-05	0.00252	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28749959~28750595:-
THCA	cis	rs7772486	0.84	rs2814864	ENSG00000270638.1	RP3-466P17.1	4.24	2.73e-05	0.00252	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146023910	chr6:145735570~145737218:+
THCA	cis	rs801193	0.569	rs13242290	ENSG00000229886.1	RP5-1132H15.3	-4.24	2.73e-05	0.00252	-0.2	-0.19	Aortic root size;	chr7:66656898	chr7:66025126~66031544:-
THCA	cis	rs8105895	0.935	rs8110975	ENSG00000269345.1	VN1R85P	4.24	2.74e-05	0.00252	0.27	0.19	Body mass index (change over time);	chr19:22057431	chr19:22174766~22175191:-
THCA	cis	rs465969	0.744	rs71562296	ENSG00000272356.1	RP5-1112D6.8	4.24	2.74e-05	0.00252	0.27	0.19	Psoriasis;	chr6:111521444	chr6:111309203~111313517:+
THCA	cis	rs465969	0.744	rs6939657	ENSG00000272356.1	RP5-1112D6.8	4.24	2.74e-05	0.00252	0.27	0.19	Psoriasis;	chr6:111521822	chr6:111309203~111313517:+
THCA	cis	rs6442522	1	rs9847430	ENSG00000249786.6	EAF1-AS1	4.24	2.74e-05	0.00252	0.2	0.19	Uric acid levels;	chr3:15408133	chr3:15436171~15455940:-
THCA	cis	rs6442522	1	rs13075694	ENSG00000249786.6	EAF1-AS1	4.24	2.74e-05	0.00252	0.2	0.19	Uric acid levels;	chr3:15408893	chr3:15436171~15455940:-
THCA	cis	rs6442522	1	rs13075773	ENSG00000249786.6	EAF1-AS1	4.24	2.74e-05	0.00252	0.2	0.19	Uric acid levels;	chr3:15409062	chr3:15436171~15455940:-
THCA	cis	rs7844233	0.579	rs7008656	ENSG00000254023.1	PKMP4	4.24	2.74e-05	0.00252	0.32	0.19	Breast cancer;	chr8:75667775	chr8:75376709~75377014:+
THCA	cis	rs7844233	0.579	rs9298260	ENSG00000254023.1	PKMP4	4.24	2.74e-05	0.00252	0.32	0.19	Breast cancer;	chr8:75668260	chr8:75376709~75377014:+
THCA	cis	rs7844233	0.579	rs12334449	ENSG00000254023.1	PKMP4	4.24	2.74e-05	0.00252	0.32	0.19	Breast cancer;	chr8:75668883	chr8:75376709~75377014:+
THCA	cis	rs7844233	0.579	rs10098814	ENSG00000254023.1	PKMP4	4.24	2.74e-05	0.00252	0.32	0.19	Breast cancer;	chr8:75670011	chr8:75376709~75377014:+
THCA	cis	rs7844233	0.579	rs6984997	ENSG00000254023.1	PKMP4	4.24	2.74e-05	0.00252	0.32	0.19	Breast cancer;	chr8:75673692	chr8:75376709~75377014:+
THCA	cis	rs7844233	0.579	rs28360882	ENSG00000254023.1	PKMP4	4.24	2.74e-05	0.00252	0.32	0.19	Breast cancer;	chr8:75675074	chr8:75376709~75377014:+
THCA	cis	rs7844233	0.579	rs28592728	ENSG00000254023.1	PKMP4	4.24	2.74e-05	0.00252	0.32	0.19	Breast cancer;	chr8:75675139	chr8:75376709~75377014:+
THCA	cis	rs7844233	0.579	rs6990197	ENSG00000254023.1	PKMP4	4.24	2.74e-05	0.00252	0.32	0.19	Breast cancer;	chr8:75676316	chr8:75376709~75377014:+
THCA	cis	rs13256369	1	rs1109619	ENSG00000254153.1	CTA-398F10.2	-4.24	2.74e-05	0.00252	-0.22	-0.19	Obesity-related traits;	chr8:8714106	chr8:8456909~8461337:-
THCA	cis	rs7590368	0.779	rs3856465	ENSG00000272275.1	RP11-791G15.2	4.24	2.74e-05	0.00252	0.27	0.19	Educational attainment (years of education);	chr2:10776544	chr2:10767875~10770058:-
THCA	cis	rs9608946	0.957	rs8141318	ENSG00000279699.1	RP1-102K2.9	4.24	2.74e-05	0.00252	0.23	0.19	Red cell distribution width;	chr22:30479530	chr22:30275215~30276951:-
THCA	cis	rs9634489	0.559	rs1925116	ENSG00000247400.3	DNAJC3-AS1	-4.24	2.74e-05	0.00252	-0.12	-0.19	Body mass index;	chr13:96298316	chr13:95648733~95676925:-
THCA	cis	rs6696239	1	rs7538893	ENSG00000227711.2	RP11-275O4.5	-4.24	2.74e-05	0.00252	-0.27	-0.19	Height;	chr1:227541102	chr1:227509028~227520477:-
THCA	cis	rs17508449	0.504	rs3827733	ENSG00000232450.1	RP4-730K3.3	-4.24	2.74e-05	0.00252	-0.28	-0.19	Leprosy;	chr1:113795967	chr1:113698884~113699631:-
THCA	cis	rs7780883	1	rs7780883	ENSG00000273341.1	RP5-899E9.1	-4.24	2.74e-05	0.00252	-0.22	-0.19	Cervical cancer;	chr7:77433395	chr7:77416673~77425443:+
THCA	cis	rs6001482	0.686	rs9623125	ENSG00000272779.1	LL22NC03-80A10.6	-4.24	2.74e-05	0.00252	-0.21	-0.19	Diastolic blood pressure;	chr22:22234600	chr22:22303224~22310401:+
THCA	cis	rs8014252	0.901	rs80045026	ENSG00000259158.2	ADAM20P1	-4.24	2.74e-05	0.00252	-0.22	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70428366	chr14:70468881~70483756:-
THCA	cis	rs8014252	1	rs8014252	ENSG00000259158.2	ADAM20P1	-4.24	2.74e-05	0.00252	-0.22	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70452982	chr14:70468881~70483756:-
THCA	cis	rs7824557	0.603	rs2736278	ENSG00000206014.6	OR7E161P	-4.24	2.74e-05	0.00252	-0.23	-0.19	Retinal vascular caliber;	chr8:11362272	chr8:11928597~11929563:-
THCA	cis	rs12935229	0.741	rs934125	ENSG00000260922.1	RP11-538I12.3	-4.24	2.74e-05	0.00252	-0.32	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77281546	chr16:77234877~77290934:+
THCA	cis	rs9467773	1	rs9357010	ENSG00000228223.2	HCG11	-4.24	2.74e-05	0.00252	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26523450~26526579:+
THCA	cis	rs2898290	0.622	rs1382567	ENSG00000227888.4	FAM66A	-4.24	2.74e-05	0.00252	-0.25	-0.19	Systolic blood pressure;	chr8:11493390	chr8:12362019~12388296:+
THCA	cis	rs875971	0.638	rs6960778	ENSG00000275400.1	RP4-756H11.5	4.24	2.74e-05	0.00253	0.18	0.19	Aortic root size;	chr7:66606610	chr7:66553805~66554199:-
THCA	cis	rs1923243	0.647	rs4592219	ENSG00000223479.3	RP4-788P17.1	-4.24	2.74e-05	0.00253	-0.21	-0.19	Migraine;	chr1:73178987	chr1:73635216~73715214:+
THCA	cis	rs9532669	0.89	rs11619117	ENSG00000229473.2	RGS17P1	4.24	2.74e-05	0.00253	0.24	0.19	Cervical cancer;	chr13:40880020	chr13:40992779~40993331:-
THCA	cis	rs9902453	0.817	rs2617880	ENSG00000263370.1	RP11-68I3.5	-4.24	2.74e-05	0.00253	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29779100	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.808	rs62068617	ENSG00000263370.1	RP11-68I3.5	4.24	2.74e-05	0.00253	0.25	0.19	Coffee consumption (cups per day);	chr17:29817710	chr17:29639627~29640825:+
THCA	cis	rs4650994	0.593	rs6700266	ENSG00000273384.1	RP5-1098D14.1	4.24	2.74e-05	0.00253	0.25	0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178539795	chr1:178651706~178652282:+
THCA	cis	rs2153535	0.585	rs9406185	ENSG00000230939.1	RP11-314C16.1	-4.24	2.74e-05	0.00253	-0.2	-0.19	Motion sickness;	chr6:8644491	chr6:8784178~8785445:+
THCA	cis	rs752010	0.714	rs6600384	ENSG00000230638.4	RP11-486B10.4	4.24	2.74e-05	0.00253	0.21	0.19	Lupus nephritis in systemic lupus erythematosus;	chr1:41619470	chr1:41542069~41544310:+
THCA	cis	rs11800820	0.615	rs7513288	ENSG00000227953.5	LINC01341	-4.24	2.75e-05	0.00253	-0.17	-0.19	Obesity-related traits;	chr1:246498377	chr1:246776013~246792385:+
THCA	cis	rs3768716	0.5	rs777329	ENSG00000229267.2	AC072062.1	4.24	2.75e-05	0.00253	0.24	0.19	Neuroblastoma;	chr2:214877871	chr2:214810229~214963274:+
THCA	cis	rs4805272	1	rs10411061	ENSG00000267799.1	MAN1A2P1	4.24	2.75e-05	0.00253	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829299	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs10419348	ENSG00000267799.1	MAN1A2P1	4.24	2.75e-05	0.00253	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829480	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs11672592	ENSG00000267799.1	MAN1A2P1	4.24	2.75e-05	0.00253	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829891	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs2042193	ENSG00000267799.1	MAN1A2P1	4.24	2.75e-05	0.00253	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830018	chr19:28790812~28792871:-
THCA	cis	rs12462428	0.513	rs3760673	ENSG00000279748.1	CTD-3222D19.9	4.24	2.75e-05	0.00253	0.2	0.19	Educational attainment (years of education);	chr19:16629303	chr19:16586905~16589409:+
THCA	cis	rs11758351	0.66	rs11753131	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26219156	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs11757754	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26219516	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs55848726	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26224206	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.518	rs79922979	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26224747	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs16891446	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26226768	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs2143345	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26228920	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs16891455	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26230257	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs11759904	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26231215	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs77337633	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26233382	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.587	rs16891456	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26233899	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.587	rs2050950	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26234655	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.588	rs2050948	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26234724	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs75156165	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26235471	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.587	rs16891466	ENSG00000216331.1	HIST1H1PS1	4.24	2.75e-05	0.00253	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26235509	chr6:26195566~26195771:+
THCA	cis	rs6921919	0.806	rs213230	ENSG00000219392.1	RP1-265C24.5	-4.24	2.75e-05	0.00253	-0.23	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28115628~28116551:+
THCA	cis	rs591584	0.63	rs72965819	ENSG00000255893.1	RP11-685N10.1	-4.24	2.75e-05	0.00253	-0.23	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94599244	chr11:94472908~94473570:-
THCA	cis	rs713587	0.713	rs11682135	ENSG00000224165.4	DNAJC27-AS1	4.24	2.75e-05	0.00253	0.11	0.19	Body mass index in non-asthmatics;	chr2:24982508	chr2:24971390~25039694:+
THCA	cis	rs713587	0.713	rs1982200	ENSG00000224165.4	DNAJC27-AS1	4.24	2.75e-05	0.00253	0.11	0.19	Body mass index in non-asthmatics;	chr2:24982558	chr2:24971390~25039694:+
THCA	cis	rs713587	0.713	rs12618252	ENSG00000224165.4	DNAJC27-AS1	4.24	2.75e-05	0.00253	0.11	0.19	Body mass index in non-asthmatics;	chr2:24985081	chr2:24971390~25039694:+
THCA	cis	rs2836974	0.932	rs11910151	ENSG00000255568.3	BRWD1-AS2	4.24	2.75e-05	0.00253	0.17	0.19	Cognitive function;	chr21:39188336	chr21:39313935~39314962:+
THCA	cis	rs2153535	0.518	rs9392232	ENSG00000230939.1	RP11-314C16.1	-4.23	2.75e-05	0.00253	-0.21	-0.19	Motion sickness;	chr6:8636211	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.518	rs9505503	ENSG00000230939.1	RP11-314C16.1	-4.23	2.75e-05	0.00253	-0.21	-0.19	Motion sickness;	chr6:8638572	chr6:8784178~8785445:+
THCA	cis	rs16966142	0.681	rs72813466	ENSG00000260259.1	RP11-368I7.4	-4.23	2.75e-05	0.00253	-0.3	-0.19	Caffeine consumption;	chr16:89982826	chr16:89682620~89686569:-
THCA	cis	rs16966142	0.681	rs56244407	ENSG00000260259.1	RP11-368I7.4	-4.23	2.75e-05	0.00253	-0.3	-0.19	Caffeine consumption;	chr16:89983214	chr16:89682620~89686569:-
THCA	cis	rs11671005	0.693	rs11668821	ENSG00000268049.1	CTD-2619J13.9	-4.23	2.75e-05	0.00253	-0.3	-0.19	Mean platelet volume;	chr19:58444446	chr19:58357999~58359603:+
THCA	cis	rs11671005	0.616	rs12980907	ENSG00000268049.1	CTD-2619J13.9	-4.23	2.75e-05	0.00253	-0.3	-0.19	Mean platelet volume;	chr19:58444959	chr19:58357999~58359603:+
THCA	cis	rs804280	0.56	rs10503426	ENSG00000255046.1	RP11-297N6.4	-4.23	2.75e-05	0.00253	-0.2	-0.19	Myopia (pathological);	chr8:11731874	chr8:11797928~11802568:-
THCA	cis	rs988712	0.705	rs4923461	ENSG00000245573.6	BDNF-AS	-4.23	2.75e-05	0.00253	-0.19	-0.19	Obesity;	chr11:27635363	chr11:27506838~27698174:+
THCA	cis	rs16957091	0.528	rs35326878	ENSG00000205771.5	CATSPER2P1	4.23	2.75e-05	0.00253	0.27	0.19	MGMT methylation in smokers;	chr15:42983379	chr15:43726918~43747094:-
THCA	cis	rs123509	0.913	rs339686	ENSG00000173811.9	CCDC13-AS1	4.23	2.75e-05	0.00253	0.22	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42728196	chr3:42732575~42746768:+
THCA	cis	rs3806843	0.518	rs2563310	ENSG00000202515.1	VTRNA1-3	4.23	2.75e-05	0.00253	0.22	0.19	Depressive symptoms (multi-trait analysis);	chr5:140636156	chr5:140726158~140726246:+
THCA	cis	rs6964833	1	rs4717906	ENSG00000184616.8	AC004166.6	4.23	2.75e-05	0.00253	0.29	0.19	Menarche (age at onset);	chr7:74671923	chr7:74906673~74913256:-
THCA	cis	rs1504749	0.569	rs1007256	ENSG00000254142.2	RP11-53M11.3	-4.23	2.75e-05	0.00253	-0.29	-0.19	Intracranial aneurysm;	chr8:54379276	chr8:54554361~54561927:+
THCA	cis	rs7045881	0.733	rs62544411	ENSG00000254396.1	RP11-56F10.3	4.23	2.75e-05	0.00253	0.34	0.19	Schizophrenia;	chr9:26885775	chr9:27102630~27104728:+
THCA	cis	rs9309473	0.519	rs4852950	ENSG00000273245.1	RP11-434P11.2	-4.23	2.75e-05	0.00253	-0.23	-0.19	Metabolite levels;	chr2:73637543	chr2:73750256~73750786:-
THCA	cis	rs7829975	0.658	rs2409096	ENSG00000233609.3	RP11-62H7.2	4.23	2.75e-05	0.00253	0.19	0.19	Mood instability;	chr8:8834967	chr8:8961200~8979025:+
THCA	cis	rs67478160	0.643	rs8005594	ENSG00000269940.1	RP11-73M18.7	4.23	2.75e-05	0.00254	0.18	0.19	Schizophrenia;	chr14:103813552	chr14:103694560~103695170:+
THCA	cis	rs6963495	0.818	rs1721498	ENSG00000272604.1	RP11-251G23.5	-4.23	2.75e-05	0.00254	-0.24	-0.19	Bipolar disorder (body mass index interaction);	chr7:105538372	chr7:105571083~105573660:+
THCA	cis	rs962856	0.964	rs1486135	ENSG00000236780.4	AC078941.1	4.23	2.75e-05	0.00254	0.23	0.19	Pancreatic cancer;	chr2:67369133	chr2:67123357~67215319:-
THCA	cis	rs962856	1	rs6755797	ENSG00000236780.4	AC078941.1	4.23	2.75e-05	0.00254	0.23	0.19	Pancreatic cancer;	chr2:67371501	chr2:67123357~67215319:-
THCA	cis	rs6832951	1	rs6832951	ENSG00000270480.1	RP11-57B24.1	4.23	2.75e-05	0.00254	0.3	0.19	Lymphocyte counts;	chr4:82635553	chr4:82691737~82692468:+
THCA	cis	rs10911902	0.643	rs76057663	ENSG00000229739.2	RP11-295K2.3	-4.23	2.75e-05	0.00254	-0.3	-0.19	Schizophrenia;	chr1:186325889	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs16825224	ENSG00000229739.2	RP11-295K2.3	-4.23	2.75e-05	0.00254	-0.3	-0.19	Schizophrenia;	chr1:186349723	chr1:186435161~186470291:+
THCA	cis	rs4646450	0.685	rs10258757	ENSG00000244219.5	GS1-259H13.2	-4.23	2.75e-05	0.00254	-0.25	-0.19	Blood metabolite levels;	chr7:99373052	chr7:99598066~99610813:+
THCA	cis	rs7614311	0.636	rs73117045	ENSG00000271843.1	RP11-245J9.5	-4.23	2.76e-05	0.00254	-0.38	-0.19	Lung function (FVC);Lung function (FEV1);	chr3:63924937	chr3:64008082~64008692:-
THCA	cis	rs9878978	1	rs9834459	ENSG00000237990.3	CNTN4-AS1	4.23	2.76e-05	0.00254	0.21	0.19	Blood pressure (smoking interaction);	chr3:2443026	chr3:3039033~3069242:-
THCA	cis	rs7474896	0.515	rs2505233	ENSG00000226578.1	RP11-258F22.1	-4.23	2.76e-05	0.00254	-0.27	-0.19	Obesity (extreme);	chr10:38051337	chr10:37775371~37784131:-
THCA	cis	rs17597773	0.754	rs1826647	ENSG00000272823.1	RP11-295M18.6	-4.23	2.76e-05	0.00254	-0.27	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220857612	chr1:220828676~220829211:-
THCA	cis	rs7542375	0.534	rs1587024	ENSG00000272823.1	RP11-295M18.6	-4.23	2.76e-05	0.00254	-0.27	-0.19	Obesity-related traits;	chr1:220857877	chr1:220828676~220829211:-
THCA	cis	rs35176054	0.73	rs11592750	ENSG00000280693.1	SH3PXD2A-AS1	-4.23	2.76e-05	0.00254	-0.37	-0.19	Atrial fibrillation;	chr10:103751843	chr10:103745966~103755423:+
THCA	cis	rs11096990	0.819	rs2435528	ENSG00000249685.1	RP11-360F5.3	-4.23	2.76e-05	0.00254	-0.25	-0.19	Cognitive function;	chr4:39155916	chr4:39133913~39135608:+
THCA	cis	rs2408955	0.522	rs3997	ENSG00000273765.1	RP11-370I10.11	-4.23	2.76e-05	0.00254	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48087804	chr12:48360920~48361377:+
THCA	cis	rs613391	0.603	rs565595	ENSG00000234840.1	LINC01239	-4.23	2.76e-05	0.00254	-0.22	-0.19	Quantitative traits;	chr9:22724189	chr9:22646200~22824213:+
THCA	cis	rs763121	0.706	rs3827356	ENSG00000235209.1	CTA-150C2.13	-4.23	2.76e-05	0.00254	-0.24	-0.19	Menopause (age at onset);	chr22:38668801	chr22:38921227~38924708:+
THCA	cis	rs1842579	0.898	rs10873722	ENSG00000272691.1	RP11-290M5.4	-4.23	2.76e-05	0.00254	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85814649	chr1:85578500~85578742:-
THCA	cis	rs74233809	1	rs12219901	ENSG00000272912.1	RP11-724N1.1	-4.23	2.76e-05	0.00254	-0.35	-0.19	Birth weight;	chr10:103081210	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs10458729	ENSG00000272912.1	RP11-724N1.1	-4.23	2.76e-05	0.00254	-0.35	-0.19	Birth weight;	chr10:103081722	chr10:102914585~102915404:+
THCA	cis	rs1559040	0.86	rs72800759	ENSG00000272156.1	RP11-477N3.1	-4.23	2.76e-05	0.00254	-0.32	-0.19	Sudden cardiac arrest;	chr2:54133134	chr2:54082554~54085066:+
THCA	cis	rs703842	1	rs11172351	ENSG00000270039.1	RP11-571M6.17	-4.23	2.76e-05	0.00254	-0.22	-0.19	Multiple sclerosis;	chr12:57819702	chr12:57803838~57804415:+
THCA	cis	rs128738	0.5	rs10060025	ENSG00000237714.1	P4HA2-AS1	-4.23	2.76e-05	0.00254	-0.29	-0.19	Giant cell arteritis;	chr5:132239055	chr5:132184876~132192808:+
THCA	cis	rs6683071	0.557	rs4240934	ENSG00000225265.1	TAF1A-AS1	-4.23	2.76e-05	0.00254	-0.25	-0.19	Cognitive performance;	chr1:222730956	chr1:222589825~222593032:+
THCA	cis	rs494526	0.899	rs10886374	ENSG00000229272.1	RP11-498J9.2	-4.23	2.76e-05	0.00254	-0.21	-0.19	Alcoholic chronic pancreatitis;	chr10:119055045	chr10:119003536~119003884:-
THCA	cis	rs4767841	0.565	rs11064906	ENSG00000248636.5	RP11-768F21.1	-4.23	2.76e-05	0.00254	-0.2	-0.19	Urgency urinary incontinence;	chr12:119786180	chr12:119387987~119668079:-
THCA	cis	rs6570726	0.935	rs368848	ENSG00000270638.1	RP3-466P17.1	4.23	2.76e-05	0.00254	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs374000	ENSG00000270638.1	RP3-466P17.1	4.23	2.76e-05	0.00254	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145735570~145737218:+
THCA	cis	rs4713118	0.869	rs9283881	ENSG00000220721.1	OR1F12	4.23	2.76e-05	0.00254	0.25	0.19	Parkinson's disease;	chr6:27747476	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs9283882	ENSG00000220721.1	OR1F12	4.23	2.76e-05	0.00254	0.25	0.19	Parkinson's disease;	chr6:27747479	chr6:28073316~28074233:+
THCA	cis	rs7520050	0.778	rs3014218	ENSG00000280836.1	AL355480.1	4.23	2.76e-05	0.00254	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45581219~45581321:-
THCA	cis	rs10256972	0.539	rs2949174	ENSG00000225146.1	AC073957.15	4.23	2.76e-05	0.00254	0.21	0.19	Endometriosis;Longevity;	chr7:1174287	chr7:1029025~1043891:+
THCA	cis	rs3738443	0.594	rs6664697	ENSG00000259865.1	RP11-488L18.10	-4.23	2.76e-05	0.00254	-0.17	-0.19	Alcohol dependence;	chr1:247217308	chr1:247187281~247188526:-
THCA	cis	rs7212590	0.655	rs34687426	ENSG00000267302.4	RP11-178C3.2	4.23	2.76e-05	0.00254	0.35	0.19	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59920496	chr17:59964832~59996972:+
THCA	cis	rs1707322	1	rs785480	ENSG00000281133.1	AL355480.3	-4.23	2.76e-05	0.00254	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45580892~45580996:-
THCA	cis	rs1923243	0.647	rs35578487	ENSG00000223479.3	RP4-788P17.1	4.23	2.76e-05	0.00254	0.21	0.19	Migraine;	chr1:73179467	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs35209284	ENSG00000223479.3	RP4-788P17.1	4.23	2.76e-05	0.00254	0.21	0.19	Migraine;	chr1:73179555	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.589	rs12137298	ENSG00000223479.3	RP4-788P17.1	4.23	2.76e-05	0.00254	0.21	0.19	Migraine;	chr1:73180056	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.617	rs35350320	ENSG00000223479.3	RP4-788P17.1	4.23	2.76e-05	0.00254	0.21	0.19	Migraine;	chr1:73180137	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210172	ENSG00000223479.3	RP4-788P17.1	4.23	2.76e-05	0.00254	0.21	0.19	Migraine;	chr1:73180402	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.678	rs4601539	ENSG00000223479.3	RP4-788P17.1	4.23	2.76e-05	0.00254	0.21	0.19	Migraine;	chr1:73180634	chr1:73635216~73715214:+
THCA	cis	rs4950322	0.58	rs7514970	ENSG00000271721.1	RP11-337C18.9	4.23	2.76e-05	0.00254	0.21	0.19	Protein quantitative trait loci;	chr1:147120516	chr1:147175602~147177740:+
THCA	cis	rs7259376	0.936	rs55983151	ENSG00000269138.1	ZNF209P	4.23	2.76e-05	0.00254	0.19	0.19	Menopause (age at onset);	chr19:22370134	chr19:22463922~22473036:+
THCA	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	4.23	2.76e-05	0.00254	0.23	0.19	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
THCA	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	4.23	2.76e-05	0.00254	0.23	0.19	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
THCA	cis	rs5758511	0.541	rs6002494	ENSG00000281538.1	RP4-669P10.20	4.23	2.76e-05	0.00254	0.19	0.19	Birth weight;	chr22:41803856	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.513	rs7292782	ENSG00000281538.1	RP4-669P10.20	4.23	2.76e-05	0.00254	0.19	0.19	Birth weight;	chr22:41804320	chr22:42138060~42139726:+
THCA	cis	rs1204798	0.541	rs17077603	ENSG00000237021.2	RP3-486I3.7	-4.23	2.76e-05	0.00254	-0.25	-0.19	Dental caries;	chr6:116151746	chr6:116254207~116256743:+
THCA	cis	rs3818717	0.573	rs941446	ENSG00000281749.1	Y_RNA	-4.23	2.76e-05	0.00254	-0.25	-0.19	Lymphocyte counts;	chr17:17776959	chr17:18001101~18001195:-
THCA	cis	rs7481311	0.956	rs6484308	ENSG00000245573.6	BDNF-AS	4.23	2.76e-05	0.00254	0.19	0.19	Weight;Body mass index;	chr11:27500255	chr11:27506838~27698174:+
THCA	cis	rs67981189	0.821	rs34257131	ENSG00000269927.1	RP6-91H8.3	4.23	2.77e-05	0.00254	0.22	0.19	Schizophrenia;	chr14:71053723	chr14:71141125~71143253:-
THCA	cis	rs17801127	0.901	rs6709817	ENSG00000231969.1	AC144449.1	4.23	2.77e-05	0.00254	0.33	0.19	Liver enzyme levels (alanine transaminase);	chr2:149701004	chr2:149587196~149848233:+
THCA	cis	rs4908768	0.906	rs55830087	ENSG00000232912.4	RP5-1115A15.1	-4.23	2.77e-05	0.00254	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8621491	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.906	rs11121207	ENSG00000232912.4	RP5-1115A15.1	-4.23	2.77e-05	0.00254	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8621789	chr1:8424645~8434838:+
THCA	cis	rs67478160	0.506	rs6575998	ENSG00000269940.1	RP11-73M18.7	4.23	2.77e-05	0.00254	0.19	0.19	Schizophrenia;	chr14:103784080	chr14:103694560~103695170:+
THCA	cis	rs3128341	0.877	rs60012417	ENSG00000227207.2	RPL31P12	4.23	2.77e-05	0.00255	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72368340	chr1:72301472~72301829:+
THCA	cis	rs9925964	0.748	rs4889603	ENSG00000232748.3	RP11-196G11.6	-4.23	2.77e-05	0.00255	-0.22	-0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:31056460~31062803:+
THCA	cis	rs1560104	0.709	rs62027318	ENSG00000259876.1	CTD-3037G24.4	4.23	2.77e-05	0.00255	0.22	0.19	Obesity-related traits;	chr16:12610040	chr16:12556353~12557694:-
THCA	cis	rs10908458	0.808	rs10908456	ENSG00000160766.13	GBAP1	4.23	2.77e-05	0.00255	0.21	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155113672	chr1:155213821~155227422:-
THCA	cis	rs6870983	0.843	rs247915	ENSG00000247828.6	TMEM161B-AS1	4.23	2.77e-05	0.00255	0.18	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88264217	chr5:88268895~88436685:+
THCA	cis	rs964611	0.882	rs7170447	ENSG00000259488.2	RP11-154J22.1	4.23	2.77e-05	0.00255	0.17	0.19	Metabolite levels (Pyroglutamine);	chr15:48361245	chr15:48312353~48331856:-
THCA	cis	rs1923243	0.617	rs4456055	ENSG00000223479.3	RP4-788P17.1	-4.23	2.77e-05	0.00255	-0.21	-0.19	Migraine;	chr1:72969488	chr1:73635216~73715214:+
THCA	cis	rs2803122	0.84	rs10757049	ENSG00000273226.1	RP11-513M16.8	-4.23	2.77e-05	0.00255	-0.17	-0.19	Pulse pressure;	chr9:19281503	chr9:19375451~19375996:+
THCA	cis	rs6921919	0.525	rs16894095	ENSG00000273712.1	RP5-874C20.7	4.23	2.77e-05	0.00255	0.22	0.19	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28315613~28315883:-
THCA	cis	rs9650657	0.501	rs3021500	ENSG00000206014.6	OR7E161P	4.23	2.77e-05	0.00255	0.22	0.19	Neuroticism;	chr8:11166488	chr8:11928597~11929563:-
THCA	cis	rs2898681	0.58	rs41279517	ENSG00000248375.1	RP11-177B4.1	-4.23	2.77e-05	0.00255	-0.39	-0.19	Optic nerve measurement (cup area);	chr4:52863604	chr4:52720081~52720831:-
THCA	cis	rs736408	0.527	rs2336147	ENSG00000243224.1	RP5-1157M23.2	-4.23	2.77e-05	0.00255	-0.2	-0.19	Bipolar disorder;	chr3:52592427	chr3:52239258~52241097:+
THCA	cis	rs1003719	0.667	rs6517404	ENSG00000230366.8	DSCR9	-4.23	2.77e-05	0.00255	-0.19	-0.19	Eye color traits;	chr21:37122618	chr21:37208503~37221736:+
THCA	cis	rs1003247	0.614	rs7456674	ENSG00000271122.1	RP11-379H18.1	4.23	2.77e-05	0.00255	0.13	0.19	Cognitive function;	chr7:35571497	chr7:35695214~35699413:+
THCA	cis	rs77686669	1	rs77686669	ENSG00000078319.8	PMS2P1	-4.23	2.77e-05	0.00255	-0.23	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:100320992~100341908:-
THCA	cis	rs526231	0.67	rs421946	ENSG00000175749.11	EIF3KP1	4.23	2.77e-05	0.00255	0.24	0.19	Primary biliary cholangitis;	chr5:103286340	chr5:103032376~103033031:+
THCA	cis	rs9595908	0.694	rs2224883	ENSG00000212293.1	SNORA16	4.23	2.77e-05	0.00255	0.22	0.19	Body mass index;	chr13:32763753	chr13:32420390~32420516:-
THCA	cis	rs9902453	0.967	rs4473252	ENSG00000263370.1	RP11-68I3.5	4.23	2.77e-05	0.00255	0.25	0.19	Coffee consumption (cups per day);	chr17:30127405	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.836	rs62070337	ENSG00000263370.1	RP11-68I3.5	4.23	2.77e-05	0.00255	0.25	0.19	Coffee consumption (cups per day);	chr17:30139239	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.899	rs8067580	ENSG00000263370.1	RP11-68I3.5	4.23	2.77e-05	0.00255	0.25	0.19	Coffee consumption (cups per day);	chr17:30144230	chr17:29639627~29640825:+
THCA	cis	rs13256369	0.789	rs13282500	ENSG00000253893.2	FAM85B	-4.23	2.77e-05	0.00255	-0.25	-0.19	Obesity-related traits;	chr8:8710979	chr8:8167819~8226614:-
THCA	cis	rs10483853	0.806	rs10146612	ENSG00000258695.2	RP3-414A15.2	-4.23	2.77e-05	0.00255	-0.27	-0.19	Coronary artery calcification;	chr14:73291217	chr14:73522878~73530610:+
THCA	cis	rs3128341	1	rs3101338	ENSG00000227207.2	RPL31P12	4.23	2.77e-05	0.00255	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72284670	chr1:72301472~72301829:+
THCA	cis	rs3128341	1	rs9425089	ENSG00000227207.2	RPL31P12	4.23	2.77e-05	0.00255	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72299399	chr1:72301472~72301829:+
THCA	cis	rs3128341	0.938	rs9425090	ENSG00000227207.2	RPL31P12	4.23	2.77e-05	0.00255	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72299617	chr1:72301472~72301829:+
THCA	cis	rs3128341	1	rs9424981	ENSG00000227207.2	RPL31P12	4.23	2.77e-05	0.00255	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72300402	chr1:72301472~72301829:+
THCA	cis	rs17270561	0.609	rs9366627	ENSG00000272462.2	U91328.19	-4.23	2.77e-05	0.00255	-0.16	-0.19	Iron status biomarkers;	chr6:25686177	chr6:25992662~26001775:+
THCA	cis	rs57502260	0.704	rs923346	ENSG00000212093.1	AP000807.1	4.23	2.77e-05	0.00255	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68414907	chr11:68506083~68506166:-
THCA	cis	rs6828577	0.819	rs298975	ENSG00000281731.1	RP11-384K6.8	-4.23	2.77e-05	0.00255	-0.22	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118715240	chr4:118664087~118685341:-
THCA	cis	rs11633886	0.835	rs3848111	ENSG00000259200.1	RP11-718O11.1	-4.23	2.77e-05	0.00255	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45807349	chr15:45705078~45931069:+
THCA	cis	rs7542375	0.534	rs34179415	ENSG00000272823.1	RP11-295M18.6	-4.23	2.77e-05	0.00255	-0.28	-0.19	Obesity-related traits;	chr1:220870862	chr1:220828676~220829211:-
THCA	cis	rs875971	0.54	rs736270	ENSG00000229180.5	GS1-124K5.11	4.23	2.77e-05	0.00255	0.14	0.19	Aortic root size;	chr7:65963835	chr7:66526088~66542624:-
THCA	cis	rs11771526	1	rs11764617	ENSG00000272905.1	RP11-265E18.1	4.23	2.78e-05	0.00255	0.28	0.19	Body mass index;	chr7:32299490	chr7:32845394~32846061:+
THCA	cis	rs7521681	0.713	rs6583049	ENSG00000230489.1	VAV3-AS1	-4.23	2.78e-05	0.00255	-0.23	-0.19	Asthma and hay fever;	chr1:107794279	chr1:107964443~107994607:+
THCA	cis	rs7844233	0.579	rs7833566	ENSG00000254023.1	PKMP4	4.23	2.78e-05	0.00255	0.32	0.19	Breast cancer;	chr8:75666817	chr8:75376709~75377014:+
THCA	cis	rs7502590	0.92	rs56084168	ENSG00000263167.1	RP11-149I9.2	-4.23	2.78e-05	0.00255	-0.29	-0.19	Neuroticism;	chr17:81110774	chr17:81135771~81136256:+
THCA	cis	rs4950322	0.58	rs2014106	ENSG00000271721.1	RP11-337C18.9	4.23	2.78e-05	0.00256	0.21	0.19	Protein quantitative trait loci;	chr1:147118499	chr1:147175602~147177740:+
THCA	cis	rs9326248	0.53	rs2075292	ENSG00000280143.1	AP000892.6	4.23	2.78e-05	0.00256	0.31	0.19	Blood protein levels;	chr11:116861796	chr11:117204967~117210292:+
THCA	cis	rs1766786	1	rs1779433	ENSG00000231365.4	RP11-418J17.1	-4.23	2.78e-05	0.00256	-0.26	-0.19	Chin dimples;	chr1:118920241	chr1:119140396~119275973:+
THCA	cis	rs10875746	0.903	rs725454	ENSG00000258234.1	RP11-370I10.2	4.23	2.78e-05	0.00256	0.23	0.19	Longevity (90 years and older);	chr12:48108317	chr12:48231098~48284210:-
THCA	cis	rs812925	0.519	rs2694638	ENSG00000270820.4	RP11-355B11.2	-4.23	2.78e-05	0.00256	-0.16	-0.19	Immature fraction of reticulocytes;	chr2:61408228	chr2:61471188~61484130:+
THCA	cis	rs1853665	0.58	rs6557200	ENSG00000231760.4	RP11-350J20.5	-4.23	2.78e-05	0.00256	-0.3	-0.19	Radiation response;	chr6:149951396	chr6:149796151~149826294:-
THCA	cis	rs1823913	0.538	rs13432697	ENSG00000227542.1	AC092614.2	4.23	2.78e-05	0.00256	0.22	0.19	Obesity-related traits;	chr2:191345944	chr2:191229165~191246172:-
THCA	cis	rs12681288	0.823	rs2701909	ENSG00000260721.1	AF067845.1	4.23	2.78e-05	0.00256	0.22	0.19	Schizophrenia;	chr8:1053057	chr8:1368642~1369833:-
THCA	cis	rs790006	1	rs790007	ENSG00000243024.5	RPS11P6	4.23	2.78e-05	0.00256	0.22	0.19	Response to cytidine analogues (gemcitabine);	chr12:64211013	chr12:64222337~64397065:+
THCA	cis	rs910873	0.711	rs62212235	ENSG00000276073.1	RP5-1125A11.7	4.23	2.78e-05	0.00256	0.35	0.19	Melanoma;	chr20:34494366	chr20:33985617~33988989:-
THCA	cis	rs4703129	0.527	rs2042965	ENSG00000248489.1	CTD-2007H13.3	4.23	2.78e-05	0.00256	0.18	0.19	Asperger disorder;	chr5:98509243	chr5:98929171~98995013:+
THCA	cis	rs8031584	0.697	rs798080	ENSG00000259845.1	HERC2P10	-4.23	2.78e-05	0.00256	-0.27	-0.19	Huntington's disease progression;	chr15:30829966	chr15:30815271~30844153:+
THCA	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-4.23	2.78e-05	0.00256	-0.22	-0.19	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-4.23	2.78e-05	0.00256	-0.22	-0.19	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-4.23	2.78e-05	0.00256	-0.22	-0.19	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
THCA	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-4.23	2.78e-05	0.00256	-0.22	-0.19	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
THCA	cis	rs12440869	1	rs11636197	ENSG00000270964.1	RP11-502I4.3	-4.23	2.78e-05	0.00256	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67295030	chr15:67541072~67542604:-
THCA	cis	rs6600671	1	rs12047116	ENSG00000275585.1	CH17-118O6.3	-4.23	2.78e-05	0.00256	-0.23	-0.19	Hip geometry;	chr1:121443912	chr1:120985692~121052167:-
THCA	cis	rs6600671	0.967	rs11249347	ENSG00000275585.1	CH17-118O6.3	-4.23	2.78e-05	0.00256	-0.23	-0.19	Hip geometry;	chr1:121446489	chr1:120985692~121052167:-
THCA	cis	rs2735413	0.632	rs111694993	ENSG00000276007.1	RP11-358L22.3	4.23	2.78e-05	0.00256	0.19	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78060414	chr16:78123243~78124332:+
THCA	cis	rs7824557	0.545	rs34482136	ENSG00000206014.6	OR7E161P	4.23	2.78e-05	0.00256	0.23	0.19	Retinal vascular caliber;	chr8:11370376	chr8:11928597~11929563:-
THCA	cis	rs7572733	0.534	rs7557203	ENSG00000231621.1	AC013264.2	-4.23	2.78e-05	0.00256	-0.2	-0.19	Dermatomyositis;	chr2:197930926	chr2:197197991~197199273:+
THCA	cis	rs6951245	0.872	rs57068908	ENSG00000229043.2	AC091729.9	-4.23	2.78e-05	0.00256	-0.32	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020448	chr7:1160374~1165267:+
THCA	cis	rs8067545	0.75	rs35003563	ENSG00000270091.1	RP11-78O7.2	-4.23	2.78e-05	0.00256	-0.14	-0.19	Schizophrenia;	chr17:20085905	chr17:19896590~19897287:-
THCA	cis	rs72928364	1	rs62275825	ENSG00000256628.3	ZBTB11-AS1	4.23	2.78e-05	0.00256	0.33	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101039866	chr3:101676475~101679217:+
THCA	cis	rs128738	0.5	rs12055301	ENSG00000237714.1	P4HA2-AS1	-4.23	2.78e-05	0.00256	-0.29	-0.19	Giant cell arteritis;	chr5:132236526	chr5:132184876~132192808:+
THCA	cis	rs31251	0.836	rs2549012	ENSG00000224431.1	AC063976.7	-4.23	2.78e-05	0.00256	-0.16	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr5:131324065	chr5:132199456~132203487:+
THCA	cis	rs2281636	0.723	rs11190195	ENSG00000260475.1	RP11-85A1.3	-4.23	2.79e-05	0.00256	-0.19	-0.19	Obesity-related traits;	chr10:99626710	chr10:99621055~99621918:+
THCA	cis	rs9283706	0.852	rs73103937	ENSG00000229666.1	MAST4-AS1	-4.23	2.79e-05	0.00256	-0.26	-0.19	Coronary artery disease;	chr5:66984749	chr5:67001383~67003953:-
THCA	cis	rs6570726	0.902	rs373321	ENSG00000270638.1	RP3-466P17.1	4.23	2.79e-05	0.00256	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.967	rs374728	ENSG00000270638.1	RP3-466P17.1	4.23	2.79e-05	0.00256	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs369214	ENSG00000270638.1	RP3-466P17.1	4.23	2.79e-05	0.00256	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs390252	ENSG00000270638.1	RP3-466P17.1	4.23	2.79e-05	0.00256	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.875	rs373313	ENSG00000270638.1	RP3-466P17.1	4.23	2.79e-05	0.00256	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs380433	ENSG00000270638.1	RP3-466P17.1	4.23	2.79e-05	0.00256	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs367643	ENSG00000270638.1	RP3-466P17.1	4.23	2.79e-05	0.00256	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145735570~145737218:+
THCA	cis	rs10090774	0.83	rs62521902	ENSG00000279766.1	RP11-642A1.2	4.23	2.79e-05	0.00256	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140901675	chr8:140572142~140572812:-
THCA	cis	rs7246760	0.867	rs58461110	ENSG00000267106.4	ZNF561-AS1	4.23	2.79e-05	0.00256	0.36	0.19	Pursuit maintenance gain;	chr19:9722714	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs55800282	ENSG00000267106.4	ZNF561-AS1	4.23	2.79e-05	0.00256	0.36	0.19	Pursuit maintenance gain;	chr19:9722854	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs8107594	ENSG00000267106.4	ZNF561-AS1	4.23	2.79e-05	0.00256	0.36	0.19	Pursuit maintenance gain;	chr19:9725281	chr19:9621291~9645896:+
THCA	cis	rs9879311	0.966	rs4684684	ENSG00000240288.6	GHRLOS	4.23	2.79e-05	0.00256	0.17	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369660	chr3:10285754~10293449:+
THCA	cis	rs72843506	0.586	rs74811834	ENSG00000231258.2	ZSWIM5P2	4.23	2.79e-05	0.00256	0.31	0.19	Schizophrenia;	chr17:19982271	chr17:20583758~20591180:-
THCA	cis	rs12546962	0.739	rs1461727	ENSG00000254153.1	CTA-398F10.2	-4.23	2.79e-05	0.00256	-0.22	-0.19	Body mass index;	chr8:9342840	chr8:8456909~8461337:-
THCA	cis	rs8177876	0.822	rs56119129	ENSG00000261838.4	RP11-303E16.6	4.23	2.79e-05	0.00256	0.33	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.731	rs77145371	ENSG00000261838.4	RP11-303E16.6	4.23	2.79e-05	0.00256	0.33	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.908	rs80187824	ENSG00000261838.4	RP11-303E16.6	4.23	2.79e-05	0.00256	0.33	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81069854~81076598:+
THCA	cis	rs13113518	0.934	rs10866425	ENSG00000249700.7	SRD5A3-AS1	4.23	2.79e-05	0.00256	0.24	0.19	Height;	chr4:55582068	chr4:55363971~55395847:-
THCA	cis	rs3808502	0.509	rs2729940	ENSG00000255046.1	RP11-297N6.4	-4.23	2.79e-05	0.00256	-0.2	-0.19	Neuroticism;	chr8:11524858	chr8:11797928~11802568:-
THCA	cis	rs7447927	0.95	rs13153461	ENSG00000200378.1	RNU5B-4P	-4.23	2.79e-05	0.00256	-0.23	-0.19	Esophageal squamous cell carcinoma;	chr5:139472784	chr5:139447907~139448017:+
THCA	cis	rs12681963	0.688	rs7004466	ENSG00000272375.1	RP11-51J9.6	4.23	2.79e-05	0.00256	0.3	0.19	Migraine;	chr8:30196778	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs7004806	ENSG00000272375.1	RP11-51J9.6	4.23	2.79e-05	0.00256	0.3	0.19	Migraine;	chr8:30197002	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs73242331	ENSG00000272375.1	RP11-51J9.6	4.23	2.79e-05	0.00256	0.3	0.19	Migraine;	chr8:30198328	chr8:30197404~30198048:+
THCA	cis	rs5753037	0.702	rs81800	ENSG00000279699.1	RP1-102K2.9	-4.23	2.79e-05	0.00256	-0.18	-0.19	Type 1 diabetes;	chr22:29804373	chr22:30275215~30276951:-
THCA	cis	rs7809799	0.571	rs66478766	ENSG00000244219.5	GS1-259H13.2	-4.23	2.79e-05	0.00256	-0.42	-0.19	Ulcerative colitis;	chr7:99317778	chr7:99598066~99610813:+
THCA	cis	rs2367725	1	rs2367725	ENSG00000228452.1	RP5-994D16.9	4.23	2.79e-05	0.00256	0.21	0.19	Aging (time to event);	chr1:43750157	chr1:42775813~42776790:-
THCA	cis	rs656319	0.585	rs13272731	ENSG00000248538.5	RP11-10A14.5	4.23	2.79e-05	0.00256	0.26	0.19	Myopia (pathological);	chr8:10049424	chr8:9189011~9202854:+
THCA	cis	rs7219021	0.674	rs9904761	ENSG00000248278.1	SUMO2P17	-4.23	2.79e-05	0.00256	-0.25	-0.19	Schizophrenia or bipolar disorder;	chr17:48879468	chr17:48874860~48908983:-
THCA	cis	rs7560272	0.538	rs17350056	ENSG00000273245.1	RP11-434P11.2	-4.23	2.79e-05	0.00256	-0.22	-0.19	Schizophrenia;	chr2:73695750	chr2:73750256~73750786:-
THCA	cis	rs877529	0.967	rs6001455	ENSG00000279833.1	RP4-742C19.13	-4.23	2.79e-05	0.00256	-0.13	-0.19	Multiple myeloma;	chr22:39151957	chr22:39133090~39136760:+
THCA	cis	rs877529	0.967	rs12158877	ENSG00000279833.1	RP4-742C19.13	-4.23	2.79e-05	0.00256	-0.13	-0.19	Multiple myeloma;	chr22:39153421	chr22:39133090~39136760:+
THCA	cis	rs6494488	0.5	rs66500186	ENSG00000259635.1	AC100830.3	-4.23	2.79e-05	0.00256	-0.46	-0.19	Coronary artery disease;	chr15:64710395	chr15:64701248~64719602:+
THCA	cis	rs875971	0.66	rs1860468	ENSG00000229180.5	GS1-124K5.11	-4.23	2.79e-05	0.00256	-0.13	-0.19	Aortic root size;	chr7:66642265	chr7:66526088~66542624:-
THCA	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-4.23	2.79e-05	0.00256	-0.23	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
THCA	cis	rs6121246	0.559	rs6060933	ENSG00000230613.1	HM13-AS1	4.23	2.79e-05	0.00256	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31764100	chr20:31567707~31573263:-
THCA	cis	rs875971	1	rs6961717	ENSG00000229886.1	RP5-1132H15.3	-4.23	2.79e-05	0.00257	-0.2	-0.19	Aortic root size;	chr7:66122550	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs2087647	ENSG00000229886.1	RP5-1132H15.3	-4.23	2.79e-05	0.00257	-0.2	-0.19	Aortic root size;	chr7:66128201	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs6958484	ENSG00000229886.1	RP5-1132H15.3	-4.23	2.79e-05	0.00257	-0.2	-0.19	Aortic root size;	chr7:66134459	chr7:66025126~66031544:-
THCA	cis	rs2436845	0.651	rs2513912	ENSG00000253320.4	KB-1507C5.2	4.23	2.79e-05	0.00257	0.17	0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102809260	chr8:102864300~102977876:+
THCA	cis	rs7551222	0.646	rs10900590	ENSG00000240219.1	RP11-430C7.5	4.23	2.79e-05	0.00257	0.19	0.19	Schizophrenia;	chr1:204481958	chr1:204626775~204629712:+
THCA	cis	rs4805272	1	rs7246224	ENSG00000267799.1	MAN1A2P1	4.23	2.79e-05	0.00257	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832531	chr19:28790812~28792871:-
THCA	cis	rs1908814	0.516	rs60176945	ENSG00000206014.6	OR7E161P	-4.23	2.79e-05	0.00257	-0.23	-0.19	Neuroticism;	chr8:11939165	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.516	rs56102998	ENSG00000206014.6	OR7E161P	-4.23	2.79e-05	0.00257	-0.23	-0.19	Neuroticism;	chr8:11939166	chr8:11928597~11929563:-
THCA	cis	rs1842579	1	rs10873725	ENSG00000272691.1	RP11-290M5.4	-4.23	2.79e-05	0.00257	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85837229	chr1:85578500~85578742:-
THCA	cis	rs62158800	0.598	rs1606984	ENSG00000237880.1	AC096669.2	4.23	2.79e-05	0.00257	0.2	0.19	Facial morphology (factor 22);	chr2:107675531	chr2:107385632~107542649:-
THCA	cis	rs3824488	0.599	rs357523	ENSG00000271384.1	RP11-435O5.7	-4.23	2.79e-05	0.00257	-0.3	-0.19	Neuroticism;	chr9:95427053	chr9:95406990~95407662:-
THCA	cis	rs875971	0.964	rs778723	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66364510	chr7:66025126~66031544:-
THCA	cis	rs875971	0.929	rs778712	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66384991	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs778710	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66389847	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs778708	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66391332	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs778696	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66405826	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs778694	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66406571	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs4718344	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66409394	chr7:66025126~66031544:-
THCA	cis	rs875971	0.737	rs7803424	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66415618	chr7:66025126~66031544:-
THCA	cis	rs875971	0.83	rs7799834	ENSG00000229886.1	RP5-1132H15.3	4.23	2.79e-05	0.00257	0.2	0.19	Aortic root size;	chr7:66415707	chr7:66025126~66031544:-
THCA	cis	rs875971	0.651	rs313829	ENSG00000232546.1	RP11-458F8.1	-4.23	2.79e-05	0.00257	-0.17	-0.19	Aortic root size;	chr7:66087510	chr7:66848496~66858136:+
THCA	cis	rs2692947	0.526	rs4907225	ENSG00000232931.4	LINC00342	4.23	2.79e-05	0.00257	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95910922	chr2:95807118~95816215:-
THCA	cis	rs5758511	0.634	rs1001587	ENSG00000227370.1	RP4-669P10.19	4.23	2.79e-05	0.00257	0.21	0.19	Birth weight;	chr22:42274105	chr22:42132543~42132998:+
THCA	cis	rs9905704	0.624	rs6503891	ENSG00000224738.1	AC099850.1	4.23	2.8e-05	0.00257	0.23	0.19	Testicular germ cell tumor;	chr17:58988563	chr17:59106598~59118267:+
THCA	cis	rs2281603	0.762	rs12588437	ENSG00000272909.1	CTD-2555O16.4	-4.23	2.8e-05	0.00257	-0.25	-0.19	Lymphocyte counts;	chr14:64580366	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.762	rs12588509	ENSG00000272909.1	CTD-2555O16.4	4.23	2.8e-05	0.00257	0.25	0.19	Lymphocyte counts;	chr14:64580554	chr14:64440369~64442238:-
THCA	cis	rs1923539	0.614	rs1923537	ENSG00000225484.5	NUTM2B-AS1	-4.23	2.8e-05	0.00257	-0.21	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935452	chr10:79663088~79826594:-
THCA	cis	rs7904321	1	rs10822121	ENSG00000232075.1	MRPL35P2	4.23	2.8e-05	0.00257	0.25	0.19	Intelligence (multi-trait analysis);	chr10:63069621	chr10:63634317~63634827:-
THCA	cis	rs7819412	0.818	rs11989439	ENSG00000255046.1	RP11-297N6.4	4.23	2.8e-05	0.00257	0.2	0.19	Triglycerides;	chr8:11198088	chr8:11797928~11802568:-
THCA	cis	rs853679	0.527	rs9461443	ENSG00000261839.1	RP1-265C24.8	4.23	2.8e-05	0.00257	0.23	0.19	Depression;	chr6:28226851	chr6:28136849~28139678:+
THCA	cis	rs8067545	0.75	rs11867585	ENSG00000270091.1	RP11-78O7.2	-4.23	2.8e-05	0.00257	-0.14	-0.19	Schizophrenia;	chr17:20089294	chr17:19896590~19897287:-
THCA	cis	rs17095355	1	rs2419313	ENSG00000203876.8	ADD3-AS1	-4.23	2.8e-05	0.00257	-0.21	-0.19	Biliary atresia;	chr10:109991093	chr10:109940104~110008381:-
THCA	cis	rs1055129	0.56	rs56248937	ENSG00000267801.1	RP11-552F3.9	4.23	2.8e-05	0.00257	0.22	0.19	White matter hyperintensity burden;	chr17:75919072	chr17:75876372~75879546:+
THCA	cis	rs12478296	1	rs4973685	ENSG00000261186.2	RP11-341N2.1	-4.23	2.8e-05	0.00257	-0.32	-0.19	Obesity-related traits;	chr2:242076938	chr2:242087351~242088457:-
THCA	cis	rs1048886	0.938	rs59275635	ENSG00000271967.1	RP11-134K13.4	-4.23	2.8e-05	0.00257	-0.21	-0.19	Type 2 diabetes;	chr6:70444020	chr6:70596438~70596980:+
THCA	cis	rs4308124	0.708	rs6727313	ENSG00000230499.1	AC108463.1	-4.23	2.8e-05	0.00257	-0.28	-0.19	Vitiligo;	chr2:111213963	chr2:111195963~111206494:+
THCA	cis	rs4308124	0.708	rs10178095	ENSG00000230499.1	AC108463.1	-4.23	2.8e-05	0.00257	-0.28	-0.19	Vitiligo;	chr2:111214939	chr2:111195963~111206494:+
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000176933.5	TOB2P1	-4.23	2.8e-05	0.00257	-0.2	-0.19	Pubertal anthropometrics;	chr6:28420988	chr6:28217643~28218634:-
THCA	cis	rs79481398	0.616	rs1280367	ENSG00000276772.1	CTD-2515H24.2	-4.23	2.8e-05	0.00257	-0.23	-0.19	Facial morphology (factor 19);	chr15:57492925	chr15:57553955~57555680:+
THCA	cis	rs4646450	0.735	rs6943920	ENSG00000244219.5	GS1-259H13.2	-4.23	2.8e-05	0.00257	-0.24	-0.19	Blood metabolite levels;	chr7:99410792	chr7:99598066~99610813:+
THCA	cis	rs875971	0.522	rs1617484	ENSG00000234585.5	CCT6P3	4.23	2.8e-05	0.00257	0.18	0.19	Aortic root size;	chr7:65998108	chr7:65038354~65074713:+
THCA	cis	rs17507216	0.718	rs72751675	ENSG00000255769.6	GOLGA2P10	-4.23	2.8e-05	0.00257	-0.3	-0.19	Excessive daytime sleepiness;	chr15:82630452	chr15:82472993~82513950:-
THCA	cis	rs9926296	0.632	rs7184315	ENSG00000274627.1	RP11-104N10.2	4.23	2.8e-05	0.00257	0.2	0.19	Vitiligo;	chr16:89732965	chr16:89516797~89522217:+
THCA	cis	rs71520386	0.579	rs4394299	ENSG00000226329.2	AC005682.6	-4.23	2.8e-05	0.00257	-0.25	-0.19	Fibrinogen levels;	chr7:22825763	chr7:22863874~22881350:-
THCA	cis	rs301901	0.581	rs292175	ENSG00000250155.1	CTD-2353F22.1	-4.23	2.8e-05	0.00257	-0.2	-0.19	Height;	chr5:36832512	chr5:36666214~36725195:-
THCA	cis	rs12410462	0.591	rs2644144	ENSG00000227711.2	RP11-275O4.5	-4.23	2.8e-05	0.00257	-0.24	-0.19	Major depressive disorder;	chr1:227544166	chr1:227509028~227520477:-
THCA	cis	rs2562456	0.833	rs7258099	ENSG00000268117.1	VN1R84P	4.23	2.8e-05	0.00258	0.3	0.19	Pain;	chr19:21352941	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62109229	ENSG00000268117.1	VN1R84P	4.23	2.8e-05	0.00258	0.3	0.19	Pain;	chr19:21354380	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs11670815	ENSG00000268117.1	VN1R84P	4.23	2.8e-05	0.00258	0.3	0.19	Pain;	chr19:21356515	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs11666540	ENSG00000268117.1	VN1R84P	4.23	2.8e-05	0.00258	0.3	0.19	Pain;	chr19:21356550	chr19:21719801~21720035:-
THCA	cis	rs1923243	0.647	rs4607818	ENSG00000223479.3	RP4-788P17.1	4.23	2.8e-05	0.00258	0.21	0.19	Migraine;	chr1:73181261	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs4578169	ENSG00000223479.3	RP4-788P17.1	4.23	2.8e-05	0.00258	0.21	0.19	Migraine;	chr1:73181316	chr1:73635216~73715214:+
THCA	cis	rs8062405	0.755	rs7193402	ENSG00000270424.1	RP11-1348G14.6	4.23	2.8e-05	0.00258	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28749959~28750595:-
THCA	cis	rs8067545	1	rs4925066	ENSG00000270091.1	RP11-78O7.2	-4.23	2.8e-05	0.00258	-0.14	-0.19	Schizophrenia;	chr17:20011979	chr17:19896590~19897287:-
THCA	cis	rs8067545	1	rs28807825	ENSG00000270091.1	RP11-78O7.2	-4.23	2.8e-05	0.00258	-0.14	-0.19	Schizophrenia;	chr17:20039537	chr17:19896590~19897287:-
THCA	cis	rs8067545	1	rs3909258	ENSG00000270091.1	RP11-78O7.2	-4.23	2.8e-05	0.00258	-0.14	-0.19	Schizophrenia;	chr17:20042506	chr17:19896590~19897287:-
THCA	cis	rs12410462	0.591	rs66491073	ENSG00000227711.2	RP11-275O4.5	-4.23	2.81e-05	0.00258	-0.24	-0.19	Major depressive disorder;	chr1:227595020	chr1:227509028~227520477:-
THCA	cis	rs1876905	0.539	rs62420362	ENSG00000272356.1	RP5-1112D6.8	-4.23	2.81e-05	0.00258	-0.2	-0.19	Mean corpuscular hemoglobin;	chr6:111224167	chr6:111309203~111313517:+
THCA	cis	rs11673344	0.563	rs256744	ENSG00000268499.1	CTB-102L5.8	4.23	2.81e-05	0.00258	0.2	0.19	Obesity-related traits;	chr19:37364586	chr19:38199836~38200934:+
THCA	cis	rs591584	0.704	rs2186624	ENSG00000255893.1	RP11-685N10.1	-4.23	2.81e-05	0.00258	-0.22	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94578152	chr11:94472908~94473570:-
THCA	cis	rs591584	0.73	rs2212361	ENSG00000255893.1	RP11-685N10.1	-4.23	2.81e-05	0.00258	-0.22	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94579157	chr11:94472908~94473570:-
THCA	cis	rs42648	0.935	rs42621	ENSG00000225498.1	AC002064.5	4.23	2.81e-05	0.00258	0.2	0.19	Homocysteine levels;	chr7:90327170	chr7:90312496~90322592:+
THCA	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	4.23	2.81e-05	0.00258	0.23	0.19	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	4.23	2.81e-05	0.00258	0.23	0.19	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	4.23	2.81e-05	0.00258	0.23	0.19	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
THCA	cis	rs71636778	0.722	rs34502618	ENSG00000260063.1	RP5-968P14.2	-4.23	2.81e-05	0.00258	-0.26	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767665	chr1:26692132~26694131:-
THCA	cis	rs8056446	0.53	rs9929762	ENSG00000276007.1	RP11-358L22.3	-4.23	2.81e-05	0.00258	-0.14	-0.19	Pulmonary function (smoking interaction);	chr16:78135778	chr16:78123243~78124332:+
THCA	cis	rs1124769	0.57	rs2663528	ENSG00000259378.1	DCAF13P3	-4.23	2.81e-05	0.00258	-0.27	-0.19	Cognitive performance;	chr15:50862707	chr15:50944663~50945996:+
THCA	cis	rs7045881	0.8	rs62544399	ENSG00000254396.1	RP11-56F10.3	4.23	2.81e-05	0.00258	0.34	0.19	Schizophrenia;	chr9:26847979	chr9:27102630~27104728:+
THCA	cis	rs7829975	0.593	rs2921077	ENSG00000233609.3	RP11-62H7.2	4.23	2.81e-05	0.00258	0.18	0.19	Mood instability;	chr8:8446992	chr8:8961200~8979025:+
THCA	cis	rs690037	0.551	rs690522	ENSG00000271964.1	RP11-415F23.2	-4.23	2.81e-05	0.00258	-0.18	-0.19	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16335560	chr3:16314439~16314987:+
THCA	cis	rs901683	0.85	rs113722818	ENSG00000230869.1	CTGLF10P	-4.23	2.81e-05	0.00258	-0.44	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45597760	chr10:45678692~45700532:+
THCA	cis	rs901683	0.85	rs112184470	ENSG00000230869.1	CTGLF10P	-4.23	2.81e-05	0.00258	-0.44	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45597854	chr10:45678692~45700532:+
THCA	cis	rs8177876	0.731	rs74882687	ENSG00000261838.4	RP11-303E16.6	4.23	2.81e-05	0.00258	0.33	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.642	rs76909932	ENSG00000261838.4	RP11-303E16.6	4.23	2.81e-05	0.00258	0.33	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs8177939	ENSG00000261838.4	RP11-303E16.6	4.23	2.81e-05	0.00258	0.33	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81069854~81076598:+
THCA	cis	rs4761470	0.577	rs55836966	ENSG00000258172.1	RP11-1105G2.4	-4.23	2.81e-05	0.00258	-0.27	-0.19	Estradiol plasma levels (breast cancer);	chr12:94287384	chr12:94272150~94277195:-
THCA	cis	rs763121	0.853	rs6001188	ENSG00000273076.1	RP3-508I15.22	4.23	2.81e-05	0.00258	0.19	0.19	Menopause (age at onset);	chr22:38666189	chr22:38743495~38743910:+
THCA	cis	rs607541	1	rs688967	ENSG00000259520.4	CTD-2651B20.3	-4.23	2.81e-05	0.00258	-0.27	-0.19	Obesity-related traits;	chr15:45643929	chr15:45251580~45279251:-
THCA	cis	rs16976116	0.53	rs486913	ENSG00000279145.1	RP11-547D13.1	-4.23	2.81e-05	0.00258	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55121100	chr15:55171972~55178175:-
THCA	cis	rs11088226	0.681	rs2833926	ENSG00000186842.4	LINC00846	-4.23	2.81e-05	0.00258	-0.29	-0.19	Gastritis;	chr21:32602969	chr21:32572238~32575881:-
THCA	cis	rs41313321	0.646	rs56151688	ENSG00000272696.1	RP11-339B21.13	4.23	2.81e-05	0.00258	0.15	0.19	Coenzyme Q10 levels;	chr9:128281635	chr9:128316337~128316909:+
THCA	cis	rs11673344	0.642	rs11083420	ENSG00000268499.1	CTB-102L5.8	-4.23	2.81e-05	0.00258	-0.2	-0.19	Obesity-related traits;	chr19:37317901	chr19:38199836~38200934:+
THCA	cis	rs12234571	0.793	rs4729658	ENSG00000214293.7	APTR	4.23	2.81e-05	0.00258	0.25	0.19	Obesity-related traits;	chr7:77728246	chr7:77657660~77696265:-
THCA	cis	rs7520050	0.933	rs6661163	ENSG00000234329.1	RP11-767N6.2	-4.23	2.81e-05	0.00258	-0.17	-0.19	Reticulocyte count;Red blood cell count;	chr1:45789332	chr1:45651039~45651826:-
THCA	cis	rs6001482	0.679	rs8142710	ENSG00000272779.1	LL22NC03-80A10.6	-4.23	2.81e-05	0.00258	-0.21	-0.19	Diastolic blood pressure;	chr22:22233044	chr22:22303224~22310401:+
THCA	cis	rs875971	0.793	rs460678	ENSG00000272831.1	RP11-792A8.4	4.23	2.81e-05	0.00258	0.13	0.19	Aortic root size;	chr7:66062213	chr7:66739829~66740385:-
THCA	cis	rs2153535	0.585	rs9328500	ENSG00000230939.1	RP11-314C16.1	4.23	2.81e-05	0.00258	0.2	0.19	Motion sickness;	chr6:8658838	chr6:8784178~8785445:+
THCA	cis	rs6845263	0.538	rs2717846	ENSG00000254531.1	FLJ20021	4.23	2.81e-05	0.00258	0.16	0.19	Superior crus of antihelix expression;	chr4:101592323	chr4:101347780~101348883:+
THCA	cis	rs6845263	0.512	rs2615972	ENSG00000254531.1	FLJ20021	4.23	2.81e-05	0.00258	0.16	0.19	Superior crus of antihelix expression;	chr4:101592350	chr4:101347780~101348883:+
THCA	cis	rs6845263	0.511	rs62321926	ENSG00000254531.1	FLJ20021	4.23	2.81e-05	0.00258	0.16	0.19	Superior crus of antihelix expression;	chr4:101592388	chr4:101347780~101348883:+
THCA	cis	rs10760158	0.832	rs4837827	ENSG00000226752.6	PSMD5-AS1	-4.23	2.81e-05	0.00258	-0.23	-0.19	Pulse pressure;	chr9:121277593	chr9:120824828~120854385:+
THCA	cis	rs6657613	0.815	rs9435672	ENSG00000186301.8	MST1P2	4.23	2.81e-05	0.00258	0.16	0.19	Hip circumference adjusted for BMI;	chr1:17016164	chr1:16645622~16650289:+
THCA	cis	rs11771526	0.892	rs62457539	ENSG00000272905.1	RP11-265E18.1	4.23	2.81e-05	0.00258	0.27	0.19	Body mass index;	chr7:32324992	chr7:32845394~32846061:+
THCA	cis	rs453301	0.653	rs1045529	ENSG00000233609.3	RP11-62H7.2	-4.23	2.81e-05	0.00258	-0.18	-0.19	Joint mobility (Beighton score);	chr8:9032588	chr8:8961200~8979025:+
THCA	cis	rs72634501	0.716	rs2282231	ENSG00000228060.1	RP11-69E11.8	-4.23	2.81e-05	0.00258	-0.21	-0.19	HDL cholesterol;	chr1:39103899	chr1:39565160~39573203:+
THCA	cis	rs800160	0.588	rs800150	ENSG00000199550.1	Y_RNA	4.23	2.81e-05	0.00258	0.26	0.19	Bacteremia;	chr11:2349989	chr11:2372638~2372750:+
THCA	cis	rs800160	0.623	rs800152	ENSG00000199550.1	Y_RNA	4.23	2.81e-05	0.00258	0.26	0.19	Bacteremia;	chr11:2350160	chr11:2372638~2372750:+
THCA	cis	rs6479891	1	rs868798	ENSG00000272767.1	JMJD1C-AS1	4.23	2.82e-05	0.00258	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63465229~63466563:+
THCA	cis	rs6657613	0.815	rs735258	ENSG00000186301.8	MST1P2	4.23	2.82e-05	0.00259	0.16	0.19	Hip circumference adjusted for BMI;	chr1:17014651	chr1:16645622~16650289:+
THCA	cis	rs7474896	0.515	rs2738208	ENSG00000120555.12	SEPT7P9	-4.23	2.82e-05	0.00259	-0.25	-0.19	Obesity (extreme);	chr10:38017200	chr10:38383069~38402916:-
THCA	cis	rs6430538	0.646	rs11887093	ENSG00000224043.6	CCNT2-AS1	-4.23	2.82e-05	0.00259	-0.2	-0.19	Parkinson's disease;	chr2:134780848	chr2:134735464~134918710:-
THCA	cis	rs7260598	0.539	rs7255815	ENSG00000268442.1	CTD-2027I19.2	4.23	2.82e-05	0.00259	0.29	0.19	Response to taxane treatment (placlitaxel);	chr19:23832768	chr19:24162370~24163425:-
THCA	cis	rs4356203	0.87	rs12286505	ENSG00000272034.1	SNORD14A	4.23	2.82e-05	0.00259	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17142178	chr11:17074654~17074744:-
THCA	cis	rs4742903	0.846	rs4743699	ENSG00000270332.1	SMC2-AS1	4.23	2.82e-05	0.00259	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104239980	chr9:104080024~104093073:-
THCA	cis	rs739496	0.615	rs12427276	ENSG00000226469.1	ADAM1B	4.23	2.82e-05	0.00259	0.24	0.19	Platelet count;	chr12:111675704	chr12:111927018~111929017:+
THCA	cis	rs875971	0.571	rs78668714	ENSG00000273142.1	RP11-458F8.4	4.23	2.82e-05	0.00259	0.18	0.19	Aortic root size;	chr7:66474464	chr7:66902857~66906297:+
THCA	cis	rs9393777	0.92	rs13207689	ENSG00000272009.1	RP1-313I6.12	-4.23	2.82e-05	0.00259	-0.36	-0.19	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28078792~28081130:-
THCA	cis	rs9527	0.662	rs10883783	ENSG00000236937.2	PTGES3P4	4.23	2.82e-05	0.00259	0.27	0.19	Arsenic metabolism;	chr10:102831395	chr10:102845595~102845950:+
THCA	cis	rs964611	1	rs74012002	ENSG00000259488.2	RP11-154J22.1	-4.23	2.82e-05	0.00259	-0.19	-0.19	Metabolite levels (Pyroglutamine);	chr15:48313250	chr15:48312353~48331856:-
THCA	cis	rs1023500	0.596	rs5758562	ENSG00000237037.8	NDUFA6-AS1	-4.23	2.82e-05	0.00259	-0.17	-0.19	Schizophrenia;	chr22:42052234	chr22:42090931~42137742:+
THCA	cis	rs12612619	0.732	rs1078809	ENSG00000272148.1	RP11-195B17.1	4.23	2.82e-05	0.00259	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27066047	chr2:27062428~27062907:-
THCA	cis	rs12612619	0.732	rs10865461	ENSG00000272148.1	RP11-195B17.1	4.23	2.82e-05	0.00259	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27069783	chr2:27062428~27062907:-
THCA	cis	rs12612619	0.732	rs1053609	ENSG00000272148.1	RP11-195B17.1	4.23	2.82e-05	0.00259	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27070282	chr2:27062428~27062907:-
THCA	cis	rs964611	0.882	rs59324936	ENSG00000259488.2	RP11-154J22.1	-4.23	2.82e-05	0.00259	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48354061	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs73406442	ENSG00000259488.2	RP11-154J22.1	-4.23	2.82e-05	0.00259	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48354146	chr15:48312353~48331856:-
THCA	cis	rs4835473	0.6	rs9997101	ENSG00000251600.4	RP11-673E1.1	4.23	2.82e-05	0.00259	0.24	0.19	Immature fraction of reticulocytes;	chr4:143777892	chr4:143912331~143982454:+
THCA	cis	rs8062405	0.698	rs8046545	ENSG00000261766.1	RP11-22P6.2	4.23	2.82e-05	0.00259	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28862166~28863340:-
THCA	cis	rs12478296	1	rs12474070	ENSG00000220804.7	AC093642.5	4.23	2.82e-05	0.00259	0.21	0.19	Obesity-related traits;	chr2:242097587	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs56102931	ENSG00000220804.7	AC093642.5	4.23	2.82e-05	0.00259	0.21	0.19	Obesity-related traits;	chr2:242097785	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs55732177	ENSG00000220804.7	AC093642.5	4.23	2.82e-05	0.00259	0.21	0.19	Obesity-related traits;	chr2:242097855	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs55758933	ENSG00000220804.7	AC093642.5	4.23	2.82e-05	0.00259	0.21	0.19	Obesity-related traits;	chr2:242098138	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs55717005	ENSG00000220804.7	AC093642.5	4.23	2.82e-05	0.00259	0.21	0.19	Obesity-related traits;	chr2:242098920	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs55814222	ENSG00000220804.7	AC093642.5	4.23	2.82e-05	0.00259	0.21	0.19	Obesity-related traits;	chr2:242099015	chr2:242088633~242160153:+
THCA	cis	rs17221829	0.899	rs10830367	ENSG00000280385.1	AP000648.5	-4.23	2.82e-05	0.00259	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89726232	chr11:90193614~90198120:+
THCA	cis	rs6573604	0.681	rs73278053	ENSG00000276116.2	FUT8-AS1	-4.23	2.82e-05	0.00259	-0.28	-0.19	N-glycan levels;	chr14:65321772	chr14:65411170~65412690:-
THCA	cis	rs1923243	0.681	rs61773608	ENSG00000223479.3	RP4-788P17.1	4.23	2.82e-05	0.00259	0.21	0.19	Migraine;	chr1:73078997	chr1:73635216~73715214:+
THCA	cis	rs7131987	0.565	rs10743652	ENSG00000275476.1	RP11-996F15.4	4.23	2.82e-05	0.00259	0.19	0.19	QT interval;	chr12:29255074	chr12:29277397~29277882:-
THCA	cis	rs1040393	0.953	rs989928	ENSG00000225171.2	DUTP6	4.23	2.82e-05	0.00259	0.28	0.19	Schizophrenia;	chr1:166898830	chr1:166868748~166869209:+
THCA	cis	rs131777	0.576	rs131758	ENSG00000273192.1	CITF22-1A6.3	-4.23	2.82e-05	0.00259	-0.18	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50578653	chr22:49902228~49904576:+
THCA	cis	rs7900823	0.601	rs3847386	ENSG00000230500.1	MKX-AS1	4.23	2.82e-05	0.00259	0.27	0.19	Lung cancer;	chr10:28305295	chr10:27744786~27767794:+
THCA	cis	rs1161098	1	rs1161174	ENSG00000256037.1	MRPL40P1	-4.23	2.82e-05	0.00259	-0.29	-0.19	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67465743	chr12:67351436~67352039:+
THCA	cis	rs6500637	0.58	rs5013674	ENSG00000267077.1	RP11-127I20.5	-4.23	2.82e-05	0.00259	-0.22	-0.19	Cancer;	chr16:4882469	chr16:4795265~4796532:-
THCA	cis	rs1075265	0.547	rs6741891	ENSG00000272156.1	RP11-477N3.1	4.23	2.82e-05	0.00259	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54082554~54085066:+
THCA	cis	rs957448	0.554	rs10956919	ENSG00000253175.1	RP11-267M23.6	4.23	2.82e-05	0.00259	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94565036~94565715:+
THCA	cis	rs4415084	0.87	rs66996829	ENSG00000272335.1	RP11-53O19.3	-4.23	2.82e-05	0.00259	-0.16	-0.19	Breast cancer;	chr5:44649295	chr5:44826076~44828592:+
THCA	cis	rs227275	0.525	rs6853193	ENSG00000248971.2	KRT8P46	-4.23	2.82e-05	0.00259	-0.24	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102728746~102730171:-
THCA	cis	rs7709377	0.556	rs10155643	ENSG00000272265.1	CTD-2287O16.4	-4.23	2.82e-05	0.00259	-0.23	-0.19	Metabolite levels  (X-11787);	chr5:116284322	chr5:116078110~116078570:-
THCA	cis	rs10489167	1	rs34837468	ENSG00000237899.1	RP4-739H11.3	4.23	2.82e-05	0.00259	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40675988	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs9439030	ENSG00000237899.1	RP4-739H11.3	4.23	2.82e-05	0.00259	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40680829	chr1:40669089~40687588:-
THCA	cis	rs10489167	0.915	rs2780951	ENSG00000237899.1	RP4-739H11.3	4.23	2.82e-05	0.00259	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40687072	chr1:40669089~40687588:-
THCA	cis	rs10489167	0.588	rs688860	ENSG00000237899.1	RP4-739H11.3	4.23	2.82e-05	0.00259	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40707376	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs11208754	ENSG00000237899.1	RP4-739H11.3	4.23	2.82e-05	0.00259	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40710637	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs637399	ENSG00000237899.1	RP4-739H11.3	4.23	2.82e-05	0.00259	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40714221	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs4363413	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40722675	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs2361645	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40723957	chr1:40669089~40687588:-
THCA	cis	rs10489167	0.736	rs11208782	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40727382	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs4660450	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40740228	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs7527402	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40742756	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs11208803	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40744116	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs2274956	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40747278	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs7535618	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40750036	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs2885328	ENSG00000237899.1	RP4-739H11.3	-4.23	2.82e-05	0.00259	-0.34	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40754724	chr1:40669089~40687588:-
THCA	cis	rs113835537	0.877	rs3867132	ENSG00000255517.5	CTD-3074O7.5	-4.23	2.82e-05	0.00259	-0.21	-0.19	Airway imaging phenotypes;	chr11:66541798	chr11:66473490~66480233:-
THCA	cis	rs1035144	0.679	rs2284722	ENSG00000259167.2	NMNAT1P1	4.23	2.82e-05	0.00259	0.24	0.19	Male sexual orientation;	chr14:80978023	chr14:81032529~81033404:+
THCA	cis	rs5753037	0.809	rs740041	ENSG00000279699.1	RP1-102K2.9	4.23	2.83e-05	0.00259	0.19	0.19	Type 1 diabetes;	chr22:29804110	chr22:30275215~30276951:-
THCA	cis	rs6001482	0.702	rs9623126	ENSG00000272779.1	LL22NC03-80A10.6	-4.23	2.83e-05	0.00259	-0.21	-0.19	Diastolic blood pressure;	chr22:22234624	chr22:22303224~22310401:+
THCA	cis	rs2836950	0.52	rs8133927	ENSG00000238141.2	BRWD1-AS1	-4.23	2.83e-05	0.00259	-0.22	-0.19	Menarche (age at onset);	chr21:39318035	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.52	rs8133928	ENSG00000238141.2	BRWD1-AS1	-4.23	2.83e-05	0.00259	-0.22	-0.19	Menarche (age at onset);	chr21:39318037	chr21:39315707~39323218:+
THCA	cis	rs3764021	0.87	rs2192437	ENSG00000256594.6	RP11-705C15.2	4.23	2.83e-05	0.00259	0.15	0.19	Type 1 diabetes;	chr12:9726639	chr12:9633419~9658412:+
THCA	cis	rs3764021	0.87	rs10844617	ENSG00000256594.6	RP11-705C15.2	4.23	2.83e-05	0.00259	0.15	0.19	Type 1 diabetes;	chr12:9726772	chr12:9633419~9658412:+
THCA	cis	rs3764021	0.87	rs2401394	ENSG00000256594.6	RP11-705C15.2	4.23	2.83e-05	0.00259	0.15	0.19	Type 1 diabetes;	chr12:9726830	chr12:9633419~9658412:+
THCA	cis	rs607541	1	rs4271550	ENSG00000259520.4	CTD-2651B20.3	-4.23	2.83e-05	0.00259	-0.27	-0.19	Obesity-related traits;	chr15:45644068	chr15:45251580~45279251:-
THCA	cis	rs55702914	0.742	rs34555121	ENSG00000231621.1	AC013264.2	-4.23	2.83e-05	0.00259	-0.19	-0.19	Major depression and alcohol dependence;	chr2:197301329	chr2:197197991~197199273:+
THCA	cis	rs7746199	0.736	rs72845070	ENSG00000220721.1	OR1F12	4.23	2.83e-05	0.00259	0.46	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28073316~28074233:+
THCA	cis	rs2028299	0.839	rs2279849	ENSG00000259677.1	RP11-493E3.1	4.23	2.83e-05	0.00259	0.25	0.19	Type 2 diabetes;	chr15:89901407	chr15:89876540~89877285:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000272831.1	RP11-792A8.4	4.23	2.83e-05	0.00259	0.12	0.19	Aortic root size;	chr7:66376994	chr7:66739829~66740385:-
THCA	cis	rs6479891	0.915	rs9415699	ENSG00000272767.1	JMJD1C-AS1	-4.23	2.83e-05	0.00259	-0.27	-0.19	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs9415696	ENSG00000272767.1	JMJD1C-AS1	4.23	2.83e-05	0.00259	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs9415697	ENSG00000272767.1	JMJD1C-AS1	4.23	2.83e-05	0.00259	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs724553	ENSG00000272767.1	JMJD1C-AS1	4.23	2.83e-05	0.00259	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs4745706	ENSG00000272767.1	JMJD1C-AS1	4.23	2.83e-05	0.00259	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12415038	ENSG00000272767.1	JMJD1C-AS1	4.23	2.83e-05	0.00259	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63465229~63466563:+
THCA	cis	rs2613964	0.504	rs7617193	ENSG00000240057.4	RP11-572M11.4	-4.23	2.83e-05	0.00259	-0.19	-0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130004	chr3:113019532~113183301:+
THCA	cis	rs72928364	1	rs2576391	ENSG00000256628.3	ZBTB11-AS1	-4.23	2.83e-05	0.00259	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100958166	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.932	rs2595894	ENSG00000256628.3	ZBTB11-AS1	-4.23	2.83e-05	0.00259	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100959038	chr3:101676475~101679217:+
THCA	cis	rs10186029	0.509	rs7592621	ENSG00000270659.1	RP11-105N14.1	4.23	2.83e-05	0.0026	0.16	0.19	Systemic sclerosis;	chr2:213076453	chr2:213152970~213153659:+
THCA	cis	rs10186029	0.509	rs7566029	ENSG00000270659.1	RP11-105N14.1	4.23	2.83e-05	0.0026	0.16	0.19	Systemic sclerosis;	chr2:213076465	chr2:213152970~213153659:+
THCA	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-4.23	2.83e-05	0.0026	-0.29	-0.19	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
THCA	cis	rs467650	1	rs468238	ENSG00000246763.5	RGMB-AS1	4.23	2.83e-05	0.0026	0.2	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98640401	chr5:98769618~98773469:-
THCA	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-4.23	2.83e-05	0.0026	-0.12	-0.19	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000182586.6	LINC00334	-4.23	2.83e-05	0.0026	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45234340~45258730:+
THCA	cis	rs7572733	0.576	rs1865586	ENSG00000231621.1	AC013264.2	4.23	2.83e-05	0.0026	0.2	0.19	Dermatomyositis;	chr2:197894144	chr2:197197991~197199273:+
THCA	cis	rs9291683	0.935	rs1860911	ENSG00000261490.1	RP11-448G15.3	4.23	2.83e-05	0.0026	0.12	0.19	Bone mineral density;	chr4:10273433	chr4:10068089~10073019:-
THCA	cis	rs9326246	0.598	rs480823	ENSG00000254851.1	RP11-109L13.1	4.23	2.83e-05	0.0026	0.46	0.19	Coronary artery disease;	chr11:116655013	chr11:117135528~117138582:+
THCA	cis	rs9902453	0.845	rs2628165	ENSG00000263370.1	RP11-68I3.5	4.23	2.83e-05	0.0026	0.25	0.19	Coffee consumption (cups per day);	chr17:29794148	chr17:29639627~29640825:+
THCA	cis	rs801193	0.613	rs2659900	ENSG00000229886.1	RP5-1132H15.3	4.23	2.83e-05	0.0026	0.2	0.19	Aortic root size;	chr7:66719456	chr7:66025126~66031544:-
THCA	cis	rs1971762	0.545	rs7297461	ENSG00000270175.1	RP11-793H13.11	-4.23	2.83e-05	0.0026	-0.13	-0.19	Height;	chr12:53653394	chr12:53500162~53500936:-
THCA	cis	rs7577696	0.538	rs2366736	ENSG00000276334.1	AL133243.1	-4.23	2.83e-05	0.0026	-0.21	-0.19	Inflammatory biomarkers;	chr2:32167379	chr2:32521927~32523547:+
THCA	cis	rs3764021	0.84	rs10743823	ENSG00000256594.6	RP11-705C15.2	4.23	2.83e-05	0.0026	0.15	0.19	Type 1 diabetes;	chr12:9728529	chr12:9633419~9658412:+
THCA	cis	rs7045881	0.736	rs62544396	ENSG00000254396.1	RP11-56F10.3	4.23	2.83e-05	0.0026	0.34	0.19	Schizophrenia;	chr9:26833869	chr9:27102630~27104728:+
THCA	cis	rs5758511	0.573	rs139558	ENSG00000281538.1	RP4-669P10.20	4.23	2.83e-05	0.0026	0.19	0.19	Birth weight;	chr22:41793547	chr22:42138060~42139726:+
THCA	cis	rs591584	0.73	rs11020836	ENSG00000255893.1	RP11-685N10.1	-4.23	2.83e-05	0.0026	-0.22	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94575726	chr11:94472908~94473570:-
THCA	cis	rs17507216	0.628	rs4513065	ENSG00000255769.6	GOLGA2P10	-4.23	2.83e-05	0.0026	-0.29	-0.19	Excessive daytime sleepiness;	chr15:82712096	chr15:82472993~82513950:-
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000265443.1	CTD-2349P21.6	-4.23	2.83e-05	0.0026	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30726305~30727564:-
THCA	cis	rs67478160	0.571	rs1155751	ENSG00000269940.1	RP11-73M18.7	4.23	2.83e-05	0.0026	0.18	0.19	Schizophrenia;	chr14:103820210	chr14:103694560~103695170:+
THCA	cis	rs4660214	0.666	rs6600290	ENSG00000182109.6	RP11-69E11.4	-4.23	2.83e-05	0.0026	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157151	chr1:39522280~39546187:-
THCA	cis	rs4820294	1	rs41280035	ENSG00000233360.4	Z83844.1	4.23	2.83e-05	0.0026	0.23	0.19	Fat distribution (HIV);	chr22:37658031	chr22:37641832~37658377:-
THCA	cis	rs1048886	0.938	rs80138927	ENSG00000271967.1	RP11-134K13.4	-4.23	2.83e-05	0.0026	-0.21	-0.19	Type 2 diabetes;	chr6:70487403	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs6933150	ENSG00000271967.1	RP11-134K13.4	-4.23	2.83e-05	0.0026	-0.21	-0.19	Type 2 diabetes;	chr6:70519176	chr6:70596438~70596980:+
THCA	cis	rs11758351	0.66	rs55643278	ENSG00000216331.1	HIST1H1PS1	4.23	2.84e-05	0.0026	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26222660	chr6:26195566~26195771:+
THCA	cis	rs9863	0.931	rs2178663	ENSG00000270061.1	RP11-214K3.19	-4.23	2.84e-05	0.0026	-0.25	-0.19	White blood cell count;	chr12:123949358	chr12:123969990~123970344:-
THCA	cis	rs28829049	0.861	rs67113006	ENSG00000270728.1	RP4-657E11.10	-4.23	2.84e-05	0.0026	-0.14	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19050072	chr1:19297080~19297903:+
THCA	cis	rs4906332	1	rs3783398	ENSG00000269910.1	RP11-73M18.10	-4.23	2.84e-05	0.0026	-0.17	-0.19	Coronary artery disease;	chr14:103483041	chr14:103694516~103695050:-
THCA	cis	rs755249	0.501	rs2484133	ENSG00000228060.1	RP11-69E11.8	-4.23	2.84e-05	0.0026	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39565160~39573203:+
THCA	cis	rs763121	0.853	rs4820345	ENSG00000273076.1	RP3-508I15.22	4.23	2.84e-05	0.0026	0.2	0.19	Menopause (age at onset);	chr22:38695146	chr22:38743495~38743910:+
THCA	cis	rs62458065	0.513	rs7805536	ENSG00000231952.3	DPY19L1P2	4.23	2.84e-05	0.0026	0.32	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32533958	chr7:32812757~32838570:+
THCA	cis	rs62458065	0.513	rs10268149	ENSG00000231952.3	DPY19L1P2	4.23	2.84e-05	0.0026	0.32	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32535887	chr7:32812757~32838570:+
THCA	cis	rs4713118	0.824	rs7759217	ENSG00000226314.6	ZNF192P1	-4.23	2.84e-05	0.0026	-0.25	-0.19	Parkinson's disease;	chr6:27762684	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.784	rs9468219	ENSG00000226314.6	ZNF192P1	-4.23	2.84e-05	0.0026	-0.25	-0.19	Parkinson's disease;	chr6:27763976	chr6:28161781~28169594:+
THCA	cis	rs17382723	1	rs17382723	ENSG00000229996.1	AC093585.6	4.23	2.84e-05	0.0026	0.25	0.19	Height;	chr2:241114131	chr2:241010045~241010744:-
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000234585.5	CCT6P3	4.23	2.84e-05	0.0026	0.17	0.19	Calcium levels;	chr7:65967580	chr7:65038354~65074713:+
THCA	cis	rs748404	0.556	rs10851414	ENSG00000166763.7	STRCP1	-4.23	2.84e-05	0.0026	-0.2	-0.19	Lung cancer;	chr15:43141734	chr15:43699488~43718184:-
THCA	cis	rs10256972	0.567	rs2960835	ENSG00000225146.1	AC073957.15	4.23	2.84e-05	0.0026	0.21	0.19	Endometriosis;Longevity;	chr7:1163327	chr7:1029025~1043891:+
THCA	cis	rs3764021	0.87	rs7976584	ENSG00000256594.6	RP11-705C15.2	4.23	2.84e-05	0.0026	0.15	0.19	Type 1 diabetes;	chr12:9726059	chr12:9633419~9658412:+
THCA	cis	rs1371614	0.632	rs6707735	ENSG00000272148.1	RP11-195B17.1	4.23	2.84e-05	0.0026	0.18	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26943954	chr2:27062428~27062907:-
THCA	cis	rs2221894	1	rs6558084	ENSG00000251191.6	LINC00589	-4.23	2.84e-05	0.00261	-0.23	-0.19	Obesity-related traits;	chr8:28900115	chr8:29673922~29748109:-
THCA	cis	rs6570726	0.764	rs366673	ENSG00000270638.1	RP3-466P17.1	4.23	2.84e-05	0.00261	0.16	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145735570~145737218:+
THCA	cis	rs858239	0.601	rs764534	ENSG00000230042.1	AK3P3	-4.23	2.84e-05	0.00261	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23129178~23129841:+
THCA	cis	rs858239	0.601	rs2068459	ENSG00000230042.1	AK3P3	-4.23	2.84e-05	0.00261	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23129178~23129841:+
THCA	cis	rs2281603	0.762	rs11850291	ENSG00000272909.1	CTD-2555O16.4	-4.23	2.84e-05	0.00261	-0.25	-0.19	Lymphocyte counts;	chr14:64582676	chr14:64440369~64442238:-
THCA	cis	rs131777	0.545	rs140514	ENSG00000272940.1	CTA-384D8.33	4.23	2.84e-05	0.00261	0.27	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50580150	chr22:50597152~50597599:+
THCA	cis	rs791590	0.54	rs10905599	ENSG00000229664.1	RP11-536K7.5	4.23	2.84e-05	0.00261	0.23	0.19	Soluble interleukin-2 receptor subunit alpha;	chr10:5999960	chr10:6025978~6036427:+
THCA	cis	rs7923837	0.865	rs35978445	ENSG00000236493.2	EIF2S2P3	4.23	2.84e-05	0.00261	0.2	0.19	Multiple sclerosis;Body mass index;	chr10:92664665	chr10:92668745~92669743:-
THCA	cis	rs2836950	0.501	rs4818018	ENSG00000238141.2	BRWD1-AS1	-4.23	2.84e-05	0.00261	-0.22	-0.19	Menarche (age at onset);	chr21:39322146	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.501	rs4818019	ENSG00000238141.2	BRWD1-AS1	-4.23	2.84e-05	0.00261	-0.22	-0.19	Menarche (age at onset);	chr21:39322530	chr21:39315707~39323218:+
THCA	cis	rs17756712	0.609	rs4959352	ENSG00000272463.1	RP11-532F6.3	4.23	2.84e-05	0.00261	0.22	0.19	Vertical cup-disc ratio;	chr6:624922	chr6:708592~711405:-
THCA	cis	rs1232027	0.656	rs1650652	ENSG00000249655.1	CTC-325J23.2	4.23	2.84e-05	0.00261	0.21	0.19	Huntington's disease progression;	chr5:80669546	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650651	ENSG00000249655.1	CTC-325J23.2	4.23	2.84e-05	0.00261	0.21	0.19	Huntington's disease progression;	chr5:80669761	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650650	ENSG00000249655.1	CTC-325J23.2	4.23	2.84e-05	0.00261	0.21	0.19	Huntington's disease progression;	chr5:80669956	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.547	rs1677649	ENSG00000249655.1	CTC-325J23.2	4.23	2.84e-05	0.00261	0.21	0.19	Huntington's disease progression;	chr5:80670378	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.616	rs6151632	ENSG00000249655.1	CTC-325J23.2	4.23	2.84e-05	0.00261	0.21	0.19	Huntington's disease progression;	chr5:80670860	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs6151633	ENSG00000249655.1	CTC-325J23.2	4.23	2.84e-05	0.00261	0.21	0.19	Huntington's disease progression;	chr5:80670947	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1382540	ENSG00000249655.1	CTC-325J23.2	-4.23	2.84e-05	0.00261	-0.22	-0.19	Huntington's disease progression;	chr5:80656346	chr5:80630313~80631590:-
THCA	cis	rs7658584	1	rs60816576	ENSG00000246375.2	RP11-10L7.1	4.23	2.84e-05	0.00261	0.33	0.19	Squamous cell lung carcinoma;	chr4:88175935	chr4:88284942~88331421:+
THCA	cis	rs7658584	1	rs57454797	ENSG00000246375.2	RP11-10L7.1	4.23	2.84e-05	0.00261	0.33	0.19	Squamous cell lung carcinoma;	chr4:88175938	chr4:88284942~88331421:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000229886.1	RP5-1132H15.3	4.23	2.84e-05	0.00261	0.2	0.19	Aortic root size;	chr7:66473171	chr7:66025126~66031544:-
THCA	cis	rs1075265	0.547	rs41385746	ENSG00000272156.1	RP11-477N3.1	-4.23	2.84e-05	0.00261	-0.19	-0.19	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54082554~54085066:+
THCA	cis	rs1971762	0.563	rs4759279	ENSG00000270175.1	RP11-793H13.11	-4.23	2.84e-05	0.00261	-0.13	-0.19	Height;	chr12:53671104	chr12:53500162~53500936:-
THCA	cis	rs9435732	0.62	rs12045097	ENSG00000235241.1	RP11-108M9.5	4.23	2.84e-05	0.00261	0.24	0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17019382	chr1:16889095~16889602:+
THCA	cis	rs7572644	0.699	rs10171517	ENSG00000223522.1	AC093690.1	4.23	2.84e-05	0.00261	0.24	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27867192	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.699	rs898034	ENSG00000223522.1	AC093690.1	4.23	2.84e-05	0.00261	0.24	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27867953	chr2:28307691~28310459:-
THCA	cis	rs4713118	0.869	rs9468214	ENSG00000220721.1	OR1F12	4.23	2.84e-05	0.00261	0.25	0.19	Parkinson's disease;	chr6:27745520	chr6:28073316~28074233:+
THCA	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-4.23	2.84e-05	0.00261	-0.22	-0.19	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
THCA	cis	rs7927592	0.956	rs11228269	ENSG00000160172.9	FAM86C2P	4.23	2.84e-05	0.00261	0.19	0.19	Total body bone mineral density;	chr11:68522328	chr11:67791648~67805336:-
THCA	cis	rs11175834	1	rs11175834	ENSG00000256915.1	RP11-221N13.4	4.23	2.84e-05	0.00261	0.34	0.19	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65598856	chr12:65644334~65663299:+
THCA	cis	rs990871	0.53	rs2422136	ENSG00000227207.2	RPL31P12	-4.23	2.84e-05	0.00261	-0.23	-0.19	Subcutaneous adipose tissue;	chr1:72152861	chr1:72301472~72301829:+
THCA	cis	rs6901152	1	rs6901152	ENSG00000217648.1	RP1-95L4.4	-4.23	2.84e-05	0.00261	-0.2	-0.19	Acute lymphoblastic leukemia (childhood);	chr6:143337875	chr6:143342246~143343383:+
THCA	cis	rs875971	1	rs4718307	ENSG00000229886.1	RP5-1132H15.3	-4.23	2.85e-05	0.00261	-0.2	-0.19	Aortic root size;	chr7:66146001	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs7801282	ENSG00000229886.1	RP5-1132H15.3	-4.23	2.85e-05	0.00261	-0.2	-0.19	Aortic root size;	chr7:66148700	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs55962648	ENSG00000229886.1	RP5-1132H15.3	-4.23	2.85e-05	0.00261	-0.2	-0.19	Aortic root size;	chr7:66160764	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs2420168	ENSG00000229886.1	RP5-1132H15.3	-4.23	2.85e-05	0.00261	-0.2	-0.19	Aortic root size;	chr7:66165644	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs11974219	ENSG00000229886.1	RP5-1132H15.3	-4.23	2.85e-05	0.00261	-0.2	-0.19	Aortic root size;	chr7:66182423	chr7:66025126~66031544:-
THCA	cis	rs12893668	0.644	rs12890820	ENSG00000244691.1	RPL10AP1	-4.23	2.85e-05	0.00261	-0.27	-0.19	Reticulocyte count;	chr14:103568512	chr14:103412119~103412761:-
THCA	cis	rs36093844	0.752	rs78589744	ENSG00000279742.1	RP11-700A24.1	-4.23	2.85e-05	0.00261	-0.29	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85844956	chr11:85852557~85854943:-
THCA	cis	rs4906332	1	rs35224956	ENSG00000244691.1	RPL10AP1	-4.23	2.85e-05	0.00261	-0.24	-0.19	Coronary artery disease;	chr14:103434144	chr14:103412119~103412761:-
THCA	cis	rs57502260	0.749	rs67446678	ENSG00000212093.1	AP000807.1	4.23	2.85e-05	0.00261	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68459998	chr11:68506083~68506166:-
THCA	cis	rs74233809	1	rs11191543	ENSG00000272912.1	RP11-724N1.1	-4.23	2.85e-05	0.00261	-0.35	-0.19	Birth weight;	chr10:103064630	chr10:102914585~102915404:+
THCA	cis	rs801193	0.935	rs2659916	ENSG00000272831.1	RP11-792A8.4	4.23	2.85e-05	0.00261	0.12	0.19	Aortic root size;	chr7:66686365	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs6958520	ENSG00000272831.1	RP11-792A8.4	4.23	2.85e-05	0.00261	0.12	0.19	Aortic root size;	chr7:66686466	chr7:66739829~66740385:-
THCA	cis	rs801193	0.967	rs2707849	ENSG00000272831.1	RP11-792A8.4	4.23	2.85e-05	0.00261	0.12	0.19	Aortic root size;	chr7:66687725	chr7:66739829~66740385:-
THCA	cis	rs875971	0.638	rs7793569	ENSG00000272831.1	RP11-792A8.4	-4.23	2.85e-05	0.00261	-0.12	-0.19	Aortic root size;	chr7:66651646	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs6975195	ENSG00000272831.1	RP11-792A8.4	-4.23	2.85e-05	0.00261	-0.12	-0.19	Aortic root size;	chr7:66659787	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs3857688	ENSG00000272831.1	RP11-792A8.4	-4.23	2.85e-05	0.00261	-0.12	-0.19	Aortic root size;	chr7:66662819	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs2286684	ENSG00000272831.1	RP11-792A8.4	-4.23	2.85e-05	0.00261	-0.12	-0.19	Aortic root size;	chr7:66664843	chr7:66739829~66740385:-
THCA	cis	rs801193	0.935	rs2286683	ENSG00000272831.1	RP11-792A8.4	-4.23	2.85e-05	0.00261	-0.12	-0.19	Aortic root size;	chr7:66664856	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs10274773	ENSG00000272831.1	RP11-792A8.4	-4.23	2.85e-05	0.00261	-0.12	-0.19	Aortic root size;	chr7:66668591	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs11773829	ENSG00000272831.1	RP11-792A8.4	-4.23	2.85e-05	0.00261	-0.12	-0.19	Aortic root size;	chr7:66676087	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs7788576	ENSG00000272831.1	RP11-792A8.4	-4.23	2.85e-05	0.00261	-0.12	-0.19	Aortic root size;	chr7:66683315	chr7:66739829~66740385:-
THCA	cis	rs17695224	1	rs28873836	ENSG00000269483.1	AC006272.1	4.23	2.85e-05	0.00261	0.23	0.19	HDL cholesterol;HDL cholesterol levels;	chr19:51811402	chr19:51839924~51843324:-
THCA	cis	rs13113518	0.934	rs11133397	ENSG00000249700.7	SRD5A3-AS1	4.23	2.85e-05	0.00261	0.24	0.19	Height;	chr4:55534166	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.934	rs11133398	ENSG00000249700.7	SRD5A3-AS1	4.23	2.85e-05	0.00261	0.24	0.19	Height;	chr4:55534180	chr4:55363971~55395847:-
THCA	cis	rs6449502	0.92	rs158563	ENSG00000251279.1	CTC-436P18.1	-4.23	2.85e-05	0.00261	-0.32	-0.19	Mean platelet volume;	chr5:60959177	chr5:61162070~61232040:+
THCA	cis	rs3770081	1	rs61477982	ENSG00000272564.1	RP11-548P2.2	-4.23	2.85e-05	0.00261	-0.33	-0.19	Facial emotion recognition (sad faces);	chr2:85933409	chr2:85904279~85904727:+
THCA	cis	rs9487094	0.626	rs12201444	ENSG00000223537.2	RP5-919F19.5	-4.23	2.85e-05	0.00261	-0.19	-0.19	Height;	chr6:109738751	chr6:109487906~109506800:+
THCA	cis	rs2613964	0.504	rs2399465	ENSG00000240057.4	RP11-572M11.4	-4.23	2.85e-05	0.00261	-0.19	-0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129145	chr3:113019532~113183301:+
THCA	cis	rs2613964	0.504	rs2399466	ENSG00000240057.4	RP11-572M11.4	-4.23	2.85e-05	0.00261	-0.19	-0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129190	chr3:113019532~113183301:+
THCA	cis	rs9595908	0.669	rs9285094	ENSG00000212293.1	SNORA16	4.23	2.85e-05	0.00261	0.22	0.19	Body mass index;	chr13:32761453	chr13:32420390~32420516:-
THCA	cis	rs9309473	1	rs7607014	ENSG00000273245.1	RP11-434P11.2	-4.23	2.85e-05	0.00261	-0.26	-0.19	Metabolite levels;	chr2:73503047	chr2:73750256~73750786:-
THCA	cis	rs1371614	0.632	rs920437	ENSG00000229122.1	AGBL5-IT1	-4.23	2.85e-05	0.00261	-0.14	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26934528	chr2:27061038~27061815:+
THCA	cis	rs7182948	0.957	rs28635979	ENSG00000259531.2	RP11-295H24.3	4.23	2.85e-05	0.00261	0.25	0.19	Lung adenocarcinoma;	chr15:49578973	chr15:49365124~49366685:-
THCA	cis	rs2839186	0.814	rs12482209	ENSG00000215424.8	MCM3AP-AS1	-4.23	2.85e-05	0.00261	-0.11	-0.19	Testicular germ cell tumor;	chr21:46244361	chr21:46229217~46259390:+
THCA	cis	rs17331151	0.573	rs11718060	ENSG00000242142.1	SERBP1P3	-4.23	2.85e-05	0.00261	-0.32	-0.19	Immune reponse to smallpox (secreted IL-2);	chr3:52841530	chr3:53064283~53065091:-
THCA	cis	rs12681366	0.564	rs2165405	ENSG00000261437.1	RP11-22C11.2	4.23	2.85e-05	0.00261	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94442079	chr8:94637285~94639467:-
THCA	cis	rs27434	0.605	rs2351012	ENSG00000272109.1	CTD-2260A17.3	-4.23	2.85e-05	0.00261	-0.31	-0.19	Ankylosing spondylitis;	chr5:96856044	chr5:96804353~96806105:+
THCA	cis	rs7829975	0.84	rs572366	ENSG00000254340.1	RP11-10A14.3	4.23	2.85e-05	0.00261	0.21	0.19	Mood instability;	chr8:8721284	chr8:9141424~9145435:+
THCA	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	4.23	2.85e-05	0.00261	0.21	0.19	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
THCA	cis	rs4908768	0.906	rs7539382	ENSG00000232912.4	RP5-1115A15.1	-4.23	2.85e-05	0.00261	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8519242	chr1:8424645~8434838:+
THCA	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-4.23	2.85e-05	0.00261	-0.23	-0.19	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
THCA	cis	rs12497850	0.863	rs4974084	ENSG00000228638.1	FCF1P2	-4.23	2.85e-05	0.00261	-0.21	-0.19	Parkinson's disease;	chr3:48901647	chr3:48290793~48291375:-
THCA	cis	rs58904263	1	rs58904263	ENSG00000230613.1	HM13-AS1	4.23	2.85e-05	0.00262	0.2	0.19	Monocyte count;	chr20:31813603	chr20:31567707~31573263:-
THCA	cis	rs5758511	0.68	rs739147	ENSG00000227370.1	RP4-669P10.19	4.23	2.85e-05	0.00262	0.21	0.19	Birth weight;	chr22:42275060	chr22:42132543~42132998:+
THCA	cis	rs2380205	0.967	rs12784539	ENSG00000232807.2	RP11-536K7.3	4.23	2.85e-05	0.00262	0.18	0.19	Breast cancer;	chr10:5856158	chr10:5934270~5945900:-
THCA	cis	rs57502260	0.573	rs11228295	ENSG00000212093.1	AP000807.1	4.23	2.86e-05	0.00262	0.22	0.19	Total body bone mineral density (age 45-60);	chr11:68621120	chr11:68506083~68506166:-
THCA	cis	rs7312933	0.567	rs11181399	ENSG00000257225.1	RP11-328C8.4	-4.23	2.86e-05	0.00262	-0.2	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42272610	chr12:42459366~42466128:+
THCA	cis	rs3020736	0.5	rs6002601	ENSG00000237037.8	NDUFA6-AS1	4.23	2.86e-05	0.00262	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42090931~42137742:+
THCA	cis	rs9847710	1	rs2581817	ENSG00000242142.1	SERBP1P3	4.23	2.86e-05	0.00262	0.22	0.19	Ulcerative colitis;	chr3:53037781	chr3:53064283~53065091:-
THCA	cis	rs12440869	1	rs12440869	ENSG00000270964.1	RP11-502I4.3	-4.23	2.86e-05	0.00262	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67318613	chr15:67541072~67542604:-
THCA	cis	rs2692947	0.537	rs72821437	ENSG00000235584.2	AC008268.1	-4.23	2.86e-05	0.00262	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95535051	chr2:95666084~95668715:+
THCA	cis	rs7131987	0.621	rs3782506	ENSG00000273680.1	RP11-996F15.6	-4.23	2.86e-05	0.00262	-0.27	-0.19	QT interval;	chr12:29292489	chr12:29332733~29333383:-
THCA	cis	rs2732480	0.5	rs7966829	ENSG00000273765.1	RP11-370I10.11	4.23	2.86e-05	0.00262	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48360920~48361377:+
THCA	cis	rs7940646	0.861	rs4909945	ENSG00000254554.1	RP11-351I24.1	-4.23	2.86e-05	0.00262	-0.23	-0.19	Platelet aggregation;	chr11:10652192	chr11:10302657~10303704:-
THCA	cis	rs9840812	0.728	rs12630999	ENSG00000239213.4	NCK1-AS1	4.23	2.86e-05	0.00262	0.17	0.19	Fibrinogen levels;	chr3:136582085	chr3:136841726~136862054:-
THCA	cis	rs250518	0.735	rs26575	ENSG00000251467.1	CTC-250P20.2	-4.23	2.86e-05	0.00262	-0.26	-0.19	Mean corpuscular hemoglobin concentration;	chr5:72998631	chr5:72996920~72997642:+
THCA	cis	rs786425	0.932	rs786443	ENSG00000270095.1	RP11-214K3.18	4.23	2.86e-05	0.00262	0.22	0.19	Pubertal anthropometrics;	chr12:123579344	chr12:123971457~123971714:-
THCA	cis	rs709400	1	rs58133129	ENSG00000258735.1	LINC00637	4.23	2.86e-05	0.00262	0.25	0.19	Body mass index;	chr14:103638422	chr14:103847721~103858049:+
THCA	cis	rs7359257	0.576	rs56038097	ENSG00000270964.1	RP11-502I4.3	-4.23	2.86e-05	0.00262	-0.17	-0.19	Menarche (age at onset);	chr15:67612231	chr15:67541072~67542604:-
THCA	cis	rs4664304	0.739	rs2162500	ENSG00000226266.5	AC009961.3	-4.23	2.86e-05	0.00262	-0.23	-0.19	Crohn's disease;Inflammatory bowel disease;	chr2:159852134	chr2:159670708~159712435:-
THCA	cis	rs357894	0.519	rs357893	ENSG00000266696.1	RP11-30L3.2	4.23	2.86e-05	0.00262	0.25	0.19	Dental caries;	chr18:49050848	chr18:49205912~49208781:+
THCA	cis	rs16957091	0.528	rs34745458	ENSG00000205771.5	CATSPER2P1	4.23	2.86e-05	0.00262	0.28	0.19	MGMT methylation in smokers;	chr15:42845003	chr15:43726918~43747094:-
THCA	cis	rs2028299	0.959	rs4932144	ENSG00000259677.1	RP11-493E3.1	4.23	2.86e-05	0.00262	0.25	0.19	Type 2 diabetes;	chr15:89828870	chr15:89876540~89877285:+
THCA	cis	rs11884770	0.522	rs7601647	ENSG00000236432.6	AC097662.2	4.23	2.86e-05	0.00262	0.19	0.19	Advanced age-related macular degeneration;	chr2:227221330	chr2:227221052~227325201:-
THCA	cis	rs7772486	0.79	rs2265917	ENSG00000270638.1	RP3-466P17.1	4.23	2.86e-05	0.00262	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145735570~145737218:+
THCA	cis	rs7737355	0.947	rs4706028	ENSG00000237714.1	P4HA2-AS1	4.23	2.86e-05	0.00262	0.28	0.19	Life satisfaction;	chr5:131610534	chr5:132184876~132192808:+
THCA	cis	rs13113518	0.934	rs10866425	ENSG00000272969.1	RP11-528I4.2	4.23	2.87e-05	0.00263	0.22	0.19	Height;	chr4:55582068	chr4:55547112~55547889:+
THCA	cis	rs944289	0.562	rs2780310	ENSG00000258844.1	RP11-259K15.2	-4.23	2.87e-05	0.00263	-0.18	-0.19	Thyroid cancer;	chr14:36050852	chr14:36214607~36235608:+
THCA	cis	rs7617480	0.558	rs12715430	ENSG00000229759.1	MRPS18AP1	4.23	2.87e-05	0.00263	0.29	0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48905422	chr3:48256350~48256938:-
THCA	cis	rs2361701	0.5	rs12601244	ENSG00000279259.1	RP11-334C17.3	4.23	2.87e-05	0.00263	0.28	0.19	IgG glycosylation;	chr17:80095568	chr17:80147250~80148596:+
THCA	cis	rs8177876	0.543	rs2317086	ENSG00000261838.4	RP11-303E16.6	-4.23	2.87e-05	0.00263	-0.35	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104468	chr16:81069854~81076598:+
THCA	cis	rs2153535	0.585	rs7770688	ENSG00000230939.1	RP11-314C16.1	-4.23	2.87e-05	0.00263	-0.2	-0.19	Motion sickness;	chr6:8648663	chr6:8784178~8785445:+
THCA	cis	rs2221894	1	rs13280242	ENSG00000251191.6	LINC00589	-4.23	2.87e-05	0.00263	-0.23	-0.19	Obesity-related traits;	chr8:28899221	chr8:29673922~29748109:-
THCA	cis	rs3198697	0.617	rs11075253	ENSG00000260872.1	RP11-680G24.5	4.23	2.87e-05	0.00263	0.21	0.19	Triglycerides;	chr16:15054789	chr16:15018106~15020488:-
THCA	cis	rs2434529	1	rs73279685	ENSG00000245275.6	SAP30L-AS1	4.23	2.87e-05	0.00263	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154291416	chr5:154329437~154445850:-
THCA	cis	rs2434529	0.91	rs73279687	ENSG00000245275.6	SAP30L-AS1	4.23	2.87e-05	0.00263	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154292263	chr5:154329437~154445850:-
THCA	cis	rs11671005	0.656	rs11672609	ENSG00000269473.1	CTD-2619J13.19	4.23	2.87e-05	0.00263	0.23	0.19	Mean platelet volume;	chr19:58495557	chr19:58440448~58445849:+
THCA	cis	rs12410462	0.591	rs2814059	ENSG00000227711.2	RP11-275O4.5	-4.23	2.87e-05	0.00263	-0.24	-0.19	Major depressive disorder;	chr1:227533532	chr1:227509028~227520477:-
THCA	cis	rs2128382	0.556	rs2306528	ENSG00000253720.1	RP11-473O4.3	-4.23	2.87e-05	0.00263	-0.29	-0.19	Colorectal cancer;	chr8:129855815	chr8:129939856~129949394:+
THCA	cis	rs854765	0.718	rs7224815	ENSG00000281749.1	Y_RNA	4.23	2.87e-05	0.00263	0.25	0.19	Total body bone mineral density;	chr17:17942486	chr17:18001101~18001195:-
THCA	cis	rs2039553	0.548	rs35661635	ENSG00000227354.5	RBM26-AS1	-4.23	2.87e-05	0.00263	-0.18	-0.19	Pancreatic cancer;	chr13:79752710	chr13:79406309~79424328:+
THCA	cis	rs17772222	0.74	rs10150311	ENSG00000222990.1	RNU4-22P	4.23	2.87e-05	0.00263	0.24	0.19	Coronary artery calcification;	chr14:88510128	chr14:88513498~88513663:+
THCA	cis	rs75920871	0.764	rs76136280	ENSG00000254851.1	RP11-109L13.1	-4.23	2.87e-05	0.00263	-0.39	-0.19	Subjective well-being;	chr11:116917775	chr11:117135528~117138582:+
THCA	cis	rs2270204	0.609	rs724530	ENSG00000273186.1	RP11-339B21.10	4.22	2.87e-05	0.00263	0.29	0.19	Body mass index;	chr9:128305144	chr9:128431598~128432006:+
THCA	cis	rs3755605	0.52	rs481781	ENSG00000242578.1	RP11-469J4.3	4.22	2.87e-05	0.00263	0.21	0.19	Testicular germ cell tumor;	chr3:170222257	chr3:170410512~170418615:+
THCA	cis	rs2115630	0.691	rs2292462	ENSG00000259728.4	LINC00933	-4.22	2.87e-05	0.00263	-0.22	-0.19	P wave terminal force;	chr15:84657523	chr15:84570649~84580175:+
THCA	cis	rs12681288	0.823	rs2701906	ENSG00000260721.1	AF067845.1	4.22	2.87e-05	0.00263	0.22	0.19	Schizophrenia;	chr8:1053316	chr8:1368642~1369833:-
THCA	cis	rs79243044	0.695	rs1433567	ENSG00000224295.2	AC087380.14	-4.22	2.87e-05	0.00263	-0.2	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5523282	chr11:5518441~5524955:-
THCA	cis	rs10411161	0.579	rs59305384	ENSG00000275055.1	CTC-471J1.11	-4.22	2.87e-05	0.00263	-0.18	-0.19	Breast cancer;	chr19:51883811	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs10423838	ENSG00000275055.1	CTC-471J1.11	-4.22	2.87e-05	0.00263	-0.18	-0.19	Breast cancer;	chr19:51884030	chr19:52049007~52049754:+
THCA	cis	rs607541	1	rs4270120	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.87e-05	0.00263	-0.27	-0.19	Obesity-related traits;	chr15:45644036	chr15:45251580~45279251:-
THCA	cis	rs12440869	0.959	rs17296465	ENSG00000270964.1	RP11-502I4.3	4.22	2.87e-05	0.00263	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67310278	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs4776920	ENSG00000270964.1	RP11-502I4.3	4.22	2.87e-05	0.00263	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67316778	chr15:67541072~67542604:-
THCA	cis	rs9527	0.615	rs4919685	ENSG00000236937.2	PTGES3P4	4.22	2.87e-05	0.00263	0.27	0.19	Arsenic metabolism;	chr10:102827605	chr10:102845595~102845950:+
THCA	cis	rs62244186	0.659	rs62251383	ENSG00000214820.3	MPRIPP1	4.22	2.87e-05	0.00263	0.2	0.19	Depressive symptoms;	chr3:44510929	chr3:44579938~44581026:-
THCA	cis	rs6012564	0.826	rs6012570	ENSG00000230758.1	SNAP23P	-4.22	2.87e-05	0.00263	-0.24	-0.19	Anger;	chr20:48952121	chr20:49038357~49038602:-
THCA	cis	rs13178541	0.872	rs7447059	ENSG00000250378.1	RP11-119J18.1	-4.22	2.88e-05	0.00263	-0.22	-0.19	IgG glycosylation;	chr5:135790308	chr5:135812667~135826582:+
THCA	cis	rs1334894	1	rs72913405	ENSG00000228559.1	RP3-340B19.3	-4.22	2.88e-05	0.00263	-0.4	-0.19	Coronary artery disease;	chr6:35562285	chr6:35544632~35545669:+
THCA	cis	rs1334894	0.792	rs56318292	ENSG00000228559.1	RP3-340B19.3	-4.22	2.88e-05	0.00263	-0.4	-0.19	Coronary artery disease;	chr6:35563386	chr6:35544632~35545669:+
THCA	cis	rs2777491	0.574	rs2730056	ENSG00000247556.5	OIP5-AS1	4.22	2.88e-05	0.00263	0.18	0.19	Ulcerative colitis;	chr15:41443587	chr15:41283990~41309737:+
THCA	cis	rs9926296	0.632	rs4785716	ENSG00000260259.1	RP11-368I7.4	-4.22	2.88e-05	0.00263	-0.21	-0.19	Vitiligo;	chr16:89734719	chr16:89682620~89686569:-
THCA	cis	rs78487399	0.614	rs77389971	ENSG00000234936.1	AC010883.5	4.22	2.88e-05	0.00263	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43490945	chr2:43229573~43233394:+
THCA	cis	rs6088813	1	rs6142379	ENSG00000279253.1	RP4-614O4.13	4.22	2.88e-05	0.00264	0.19	0.19	Height;	chr20:35411464	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6087704	ENSG00000279253.1	RP4-614O4.13	4.22	2.88e-05	0.00264	0.19	0.19	Height;	chr20:35413255	chr20:35262727~35264187:-
THCA	cis	rs12234571	1	rs73374113	ENSG00000214293.7	APTR	4.22	2.88e-05	0.00264	0.24	0.19	Obesity-related traits;	chr7:77732629	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs12672657	ENSG00000214293.7	APTR	4.22	2.88e-05	0.00264	0.24	0.19	Obesity-related traits;	chr7:77733091	chr7:77657660~77696265:-
THCA	cis	rs2439831	0.681	rs2278859	ENSG00000205771.5	CATSPER2P1	-4.22	2.88e-05	0.00264	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43340762	chr15:43726918~43747094:-
THCA	cis	rs3002131	0.522	rs2936031	ENSG00000272750.1	RP11-378J18.8	4.22	2.88e-05	0.00264	0.3	0.19	Interleukin-10 levels;	chr1:222582910	chr1:222658867~222661512:-
THCA	cis	rs6828577	0.819	rs1064034	ENSG00000281731.1	RP11-384K6.8	-4.22	2.88e-05	0.00264	-0.22	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118710837	chr4:118664087~118685341:-
THCA	cis	rs6828577	0.819	rs366656	ENSG00000281731.1	RP11-384K6.8	-4.22	2.88e-05	0.00264	-0.22	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118713539	chr4:118664087~118685341:-
THCA	cis	rs13178541	0.81	rs9327728	ENSG00000250378.1	RP11-119J18.1	-4.22	2.88e-05	0.00264	-0.23	-0.19	IgG glycosylation;	chr5:135760318	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.745	rs4605777	ENSG00000250378.1	RP11-119J18.1	-4.22	2.88e-05	0.00264	-0.23	-0.19	IgG glycosylation;	chr5:135760855	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs4452549	ENSG00000250378.1	RP11-119J18.1	-4.22	2.88e-05	0.00264	-0.23	-0.19	IgG glycosylation;	chr5:135762020	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.745	rs35767093	ENSG00000250378.1	RP11-119J18.1	-4.22	2.88e-05	0.00264	-0.23	-0.19	IgG glycosylation;	chr5:135765243	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.745	rs7379919	ENSG00000250378.1	RP11-119J18.1	-4.22	2.88e-05	0.00264	-0.23	-0.19	IgG glycosylation;	chr5:135767028	chr5:135812667~135826582:+
THCA	cis	rs3764021	0.87	rs2401395	ENSG00000256594.6	RP11-705C15.2	4.22	2.88e-05	0.00264	0.15	0.19	Type 1 diabetes;	chr12:9726944	chr12:9633419~9658412:+
THCA	cis	rs7772486	0.754	rs4895682	ENSG00000270638.1	RP3-466P17.1	-4.22	2.88e-05	0.00264	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145735570~145737218:+
THCA	cis	rs607541	0.85	rs74009656	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.88e-05	0.00264	-0.27	-0.19	Obesity-related traits;	chr15:45642809	chr15:45251580~45279251:-
THCA	cis	rs607541	0.85	rs74009657	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.88e-05	0.00264	-0.27	-0.19	Obesity-related traits;	chr15:45642823	chr15:45251580~45279251:-
THCA	cis	rs607541	0.85	rs8036651	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.88e-05	0.00264	-0.27	-0.19	Obesity-related traits;	chr15:45642826	chr15:45251580~45279251:-
THCA	cis	rs607541	1	rs2099880	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.88e-05	0.00264	-0.27	-0.19	Obesity-related traits;	chr15:45642876	chr15:45251580~45279251:-
THCA	cis	rs607541	1	rs2083729	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.88e-05	0.00264	-0.27	-0.19	Obesity-related traits;	chr15:45642961	chr15:45251580~45279251:-
THCA	cis	rs607541	0.85	rs642328	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.88e-05	0.00264	-0.27	-0.19	Obesity-related traits;	chr15:45643152	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.545	rs9450325	ENSG00000220563.1	PKMP3	4.22	2.88e-05	0.00264	0.14	0.19	Response to antipsychotic treatment;	chr6:85766096	chr6:85659892~85660606:-
THCA	cis	rs7246657	0.653	rs10401525	ENSG00000276846.1	CTD-3220F14.3	4.22	2.88e-05	0.00264	0.24	0.19	Coronary artery calcification;	chr19:37168077	chr19:37314868~37315620:-
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000184274.3	LINC00315	-4.22	2.88e-05	0.00264	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000184274.3	LINC00315	-4.22	2.88e-05	0.00264	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45300245~45305257:-
THCA	cis	rs8067545	0.75	rs28666381	ENSG00000270091.1	RP11-78O7.2	-4.22	2.88e-05	0.00264	-0.14	-0.19	Schizophrenia;	chr17:20081496	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs28603224	ENSG00000270091.1	RP11-78O7.2	-4.22	2.88e-05	0.00264	-0.14	-0.19	Schizophrenia;	chr17:20081739	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs28637614	ENSG00000270091.1	RP11-78O7.2	-4.22	2.88e-05	0.00264	-0.14	-0.19	Schizophrenia;	chr17:20081795	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs36077949	ENSG00000270091.1	RP11-78O7.2	-4.22	2.88e-05	0.00264	-0.14	-0.19	Schizophrenia;	chr17:20082469	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs9896411	ENSG00000270091.1	RP11-78O7.2	-4.22	2.88e-05	0.00264	-0.14	-0.19	Schizophrenia;	chr17:20084297	chr17:19896590~19897287:-
THCA	cis	rs427943	0.864	rs2838815	ENSG00000223768.1	LINC00205	-4.22	2.88e-05	0.00264	-0.17	-0.19	Body mass index;	chr21:45209675	chr21:45293285~45297354:+
THCA	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	4.22	2.88e-05	0.00264	0.21	0.19	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
THCA	cis	rs889398	1	rs889399	ENSG00000226232.7	RP11-419C5.2	4.22	2.88e-05	0.00264	0.19	0.19	Body mass index;	chr16:69522680	chr16:69976388~69996188:-
THCA	cis	rs763121	0.819	rs5757126	ENSG00000273076.1	RP3-508I15.22	4.22	2.88e-05	0.00264	0.19	0.19	Menopause (age at onset);	chr22:38527670	chr22:38743495~38743910:+
THCA	cis	rs2286503	0.839	rs2270103	ENSG00000226329.2	AC005682.6	4.22	2.88e-05	0.00264	0.24	0.19	Fibrinogen;	chr7:22823103	chr7:22863874~22881350:-
THCA	cis	rs2286503	0.839	rs10276099	ENSG00000226329.2	AC005682.6	4.22	2.88e-05	0.00264	0.24	0.19	Fibrinogen;	chr7:22823331	chr7:22863874~22881350:-
THCA	cis	rs17689437	1	rs55886823	ENSG00000260084.1	RP11-615I2.1	-4.22	2.88e-05	0.00264	-0.3	-0.19	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68565825	chr16:68573782~68589512:-
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000265443.1	CTD-2349P21.6	-4.22	2.88e-05	0.00264	-0.32	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30726305~30727564:-
THCA	cis	rs9813712	0.953	rs9883455	ENSG00000253540.4	FAM86HP	-4.22	2.88e-05	0.00264	-0.23	-0.19	Response to amphetamines;	chr3:130260088	chr3:130099092~130111472:-
THCA	cis	rs710913	0.618	rs2310799	ENSG00000182109.6	RP11-69E11.4	4.22	2.88e-05	0.00264	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39600950	chr1:39522280~39546187:-
THCA	cis	rs7196129	0.966	rs11150589	ENSG00000183604.13	SMG1P5	4.22	2.88e-05	0.00264	0.2	0.19	Monocyte count;	chr16:30471173	chr16:30267553~30335374:-
THCA	cis	rs12716977	1	rs12716977	ENSG00000183604.13	SMG1P5	4.22	2.88e-05	0.00264	0.2	0.19	Lymphocyte percentage of white cells;Lymphocyte counts;	chr16:30471482	chr16:30267553~30335374:-
THCA	cis	rs116248771	0.549	rs9811858	ENSG00000271778.1	RP11-379F4.8	4.22	2.88e-05	0.00264	0.26	0.19	diarrhoeal disease at age 2;	chr3:158725304	chr3:158782547~158783124:+
THCA	cis	rs343092	1	rs2583938	ENSG00000241749.4	RPSAP52	4.22	2.88e-05	0.00264	0.22	0.19	Type 2 diabetes;	chr12:65821434	chr12:65758020~65826997:-
THCA	cis	rs9926296	0.656	rs2376882	ENSG00000274627.1	RP11-104N10.2	-4.22	2.88e-05	0.00264	-0.2	-0.19	Vitiligo;	chr16:89760594	chr16:89516797~89522217:+
THCA	cis	rs9902453	0.933	rs4470197	ENSG00000263370.1	RP11-68I3.5	4.22	2.88e-05	0.00264	0.24	0.19	Coffee consumption (cups per day);	chr17:30137456	chr17:29639627~29640825:+
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000265443.1	CTD-2349P21.6	-4.22	2.88e-05	0.00264	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30726305~30727564:-
THCA	cis	rs3892630	0.588	rs1976501	ENSG00000267567.1	CTD-2538C1.3	4.22	2.89e-05	0.00264	0.28	0.19	Red blood cell traits;	chr19:32717249	chr19:32718298~32719595:-
THCA	cis	rs801193	1	rs2420824	ENSG00000229886.1	RP5-1132H15.3	-4.22	2.89e-05	0.00264	-0.19	-0.19	Aortic root size;	chr7:66666129	chr7:66025126~66031544:-
THCA	cis	rs7474896	0.778	rs11011384	ENSG00000263064.2	RP11-291L22.7	4.22	2.89e-05	0.00264	0.33	0.19	Obesity (extreme);	chr10:37862034	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.832	rs61857002	ENSG00000263064.2	RP11-291L22.7	4.22	2.89e-05	0.00264	0.33	0.19	Obesity (extreme);	chr10:37883307	chr10:38448689~38448949:+
THCA	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
THCA	cis	rs17092148	1	rs6060047	ENSG00000276073.1	RP5-1125A11.7	4.22	2.89e-05	0.00264	0.23	0.19	Neuroticism;	chr20:34779597	chr20:33985617~33988989:-
THCA	cis	rs8105895	0.935	rs62111038	ENSG00000269345.1	VN1R85P	4.22	2.89e-05	0.00264	0.27	0.19	Body mass index (change over time);	chr19:22103812	chr19:22174766~22175191:-
THCA	cis	rs4144027	0.935	rs10139856	ENSG00000269910.1	RP11-73M18.10	-4.22	2.89e-05	0.00264	-0.18	-0.19	Blood metabolite levels;	chr14:103888168	chr14:103694516~103695050:-
THCA	cis	rs7045881	0.696	rs7871097	ENSG00000254396.1	RP11-56F10.3	4.22	2.89e-05	0.00264	0.25	0.19	Schizophrenia;	chr9:26917693	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.696	rs7871286	ENSG00000254396.1	RP11-56F10.3	4.22	2.89e-05	0.00264	0.25	0.19	Schizophrenia;	chr9:26917720	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.696	rs12002259	ENSG00000254396.1	RP11-56F10.3	4.22	2.89e-05	0.00264	0.25	0.19	Schizophrenia;	chr9:26918232	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.696	rs12002260	ENSG00000254396.1	RP11-56F10.3	4.22	2.89e-05	0.00264	0.25	0.19	Schizophrenia;	chr9:26918234	chr9:27102630~27104728:+
THCA	cis	rs2115630	0.875	rs8039472	ENSG00000259295.5	CSPG4P12	-4.22	2.89e-05	0.00264	-0.26	-0.19	P wave terminal force;	chr15:84818413	chr15:85191438~85213905:+
THCA	cis	rs868036	0.645	rs4776972	ENSG00000270964.1	RP11-502I4.3	-4.22	2.89e-05	0.00264	-0.18	-0.19	Restless legs syndrome;	chr15:67791098	chr15:67541072~67542604:-
THCA	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	4.22	2.89e-05	0.00264	0.22	0.19	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
THCA	cis	rs7474896	0.832	rs2799499	ENSG00000263064.2	RP11-291L22.7	-4.22	2.89e-05	0.00264	-0.33	-0.19	Obesity (extreme);	chr10:37957617	chr10:38448689~38448949:+
THCA	cis	rs4660456	0.597	rs7518568	ENSG00000238287.1	RP11-656D10.3	4.22	2.89e-05	0.00264	0.22	0.19	Platelet count;	chr1:40708508	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.596	rs1534956	ENSG00000238287.1	RP11-656D10.3	4.22	2.89e-05	0.00264	0.22	0.19	Platelet count;	chr1:40720771	chr1:40493157~40508661:-
THCA	cis	rs4144027	0.935	rs10139856	ENSG00000269940.1	RP11-73M18.7	-4.22	2.89e-05	0.00264	-0.19	-0.19	Blood metabolite levels;	chr14:103888168	chr14:103694560~103695170:+
THCA	cis	rs10875746	0.903	rs11168414	ENSG00000258234.1	RP11-370I10.2	4.22	2.89e-05	0.00264	0.23	0.19	Longevity (90 years and older);	chr12:48118548	chr12:48231098~48284210:-
THCA	cis	rs9543976	0.614	rs73223948	ENSG00000261105.4	LMO7-AS1	-4.22	2.89e-05	0.00264	-0.34	-0.19	Diabetic retinopathy;	chr13:75523889	chr13:75604700~75635994:-
THCA	cis	rs7674212	0.541	rs2720460	ENSG00000230069.3	LRRC37A15P	4.22	2.89e-05	0.00264	0.2	0.19	Type 2 diabetes;	chr4:103133529	chr4:102727274~102730721:-
THCA	cis	rs801193	0.569	rs13226966	ENSG00000229886.1	RP5-1132H15.3	4.22	2.89e-05	0.00264	0.2	0.19	Aortic root size;	chr7:66768636	chr7:66025126~66031544:-
THCA	cis	rs4906332	0.966	rs2065016	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103413319	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs34479426	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103415486	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs8012127	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103476425	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs78316803	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103476526	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs17617832	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103476803	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs11625172	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103478575	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs17617935	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103486549	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs17680085	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103486817	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs12896919	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103490376	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs35126287	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103493095	chr14:103694516~103695050:-
THCA	cis	rs4906332	1	rs55930273	ENSG00000269910.1	RP11-73M18.10	4.22	2.89e-05	0.00264	0.16	0.19	Coronary artery disease;	chr14:103493961	chr14:103694516~103695050:-
THCA	cis	rs7131987	0.65	rs7301398	ENSG00000273680.1	RP11-996F15.6	4.22	2.89e-05	0.00264	0.27	0.19	QT interval;	chr12:29302457	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.65	rs7301188	ENSG00000273680.1	RP11-996F15.6	4.22	2.89e-05	0.00264	0.27	0.19	QT interval;	chr12:29302458	chr12:29332733~29333383:-
THCA	cis	rs2281603	0.57	rs10133696	ENSG00000272909.1	CTD-2555O16.4	-4.22	2.89e-05	0.00265	-0.23	-0.19	Lymphocyte counts;	chr14:64504441	chr14:64440369~64442238:-
THCA	cis	rs11671005	0.611	rs56026876	ENSG00000265272.2	RN7SL693P	4.22	2.89e-05	0.00265	0.26	0.19	Mean platelet volume;	chr19:58494790	chr19:58490797~58491075:+
THCA	cis	rs4906332	0.811	rs2021965	ENSG00000269910.1	RP11-73M18.10	-4.22	2.89e-05	0.00265	-0.18	-0.19	Coronary artery disease;	chr14:103530911	chr14:103694516~103695050:-
THCA	cis	rs9549367	0.712	rs2316443	ENSG00000269125.1	RP11-98F14.11	-4.22	2.89e-05	0.00265	-0.22	-0.19	Platelet distribution width;	chr13:113210523	chr13:113165002~113165183:-
THCA	cis	rs128738	0.5	rs2077380	ENSG00000237714.1	P4HA2-AS1	4.22	2.89e-05	0.00265	0.29	0.19	Giant cell arteritis;	chr5:132232924	chr5:132184876~132192808:+
THCA	cis	rs4705962	0.878	rs2299004	ENSG00000230612.2	AC004237.1	4.22	2.89e-05	0.00265	0.24	0.19	Atopic dermatitis;	chr5:132722146	chr5:132688681~132723725:+
THCA	cis	rs3767627	0.585	rs6660842	ENSG00000203819.6	HIST2H2BC	4.22	2.89e-05	0.00265	0.24	0.19	Height;	chr1:149946719	chr1:149850193~149850772:-
THCA	cis	rs2280018	0.538	rs7404526	ENSG00000263335.1	AF001548.5	-4.22	2.89e-05	0.00265	-0.22	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15726674~15732993:+
THCA	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	4.22	2.89e-05	0.00265	0.22	0.19	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
THCA	cis	rs6517329	0.564	rs881712	ENSG00000236830.5	CBR3-AS1	-4.22	2.89e-05	0.00265	-0.18	-0.19	Schizophrenia;	chr21:36135471	chr21:36131767~36175815:-
THCA	cis	rs6051080	1	rs6051080	ENSG00000125804.12	FAM182A	4.22	2.89e-05	0.00265	0.23	0.19	Colorectal or endometrial cancer;	chr20:25995038	chr20:26054655~26086917:+
THCA	cis	rs710913	0.614	rs6672296	ENSG00000182109.6	RP11-69E11.4	4.22	2.89e-05	0.00265	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39605116	chr1:39522280~39546187:-
THCA	cis	rs10875746	0.551	rs11168536	ENSG00000226413.2	OR8T1P	4.22	2.89e-05	0.00265	0.28	0.19	Longevity (90 years and older);	chr12:48351268	chr12:48442030~48442947:-
THCA	cis	rs10761482	0.861	rs4948406	ENSG00000254271.1	RP11-131N11.4	4.22	2.89e-05	0.00265	0.26	0.19	Schizophrenia;	chr10:60350388	chr10:60734342~60741828:+
THCA	cis	rs10483853	0.806	rs11159016	ENSG00000258695.2	RP3-414A15.2	-4.22	2.89e-05	0.00265	-0.27	-0.19	Coronary artery calcification;	chr14:73394553	chr14:73522878~73530610:+
THCA	cis	rs6449502	0.92	rs158926	ENSG00000251279.1	CTC-436P18.1	-4.22	2.89e-05	0.00265	-0.32	-0.19	Mean platelet volume;	chr5:60955380	chr5:61162070~61232040:+
THCA	cis	rs9902453	0.765	rs2169810	ENSG00000263370.1	RP11-68I3.5	4.22	2.89e-05	0.00265	0.25	0.19	Coffee consumption (cups per day);	chr17:29840923	chr17:29639627~29640825:+
THCA	cis	rs786425	0.707	rs1969272	ENSG00000270095.1	RP11-214K3.18	-4.22	2.89e-05	0.00265	-0.22	-0.19	Pubertal anthropometrics;	chr12:123685746	chr12:123971457~123971714:-
THCA	cis	rs4356203	0.905	rs651513	ENSG00000272034.1	SNORD14A	-4.22	2.89e-05	0.00265	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17177781	chr11:17074654~17074744:-
THCA	cis	rs453301	0.562	rs1038248	ENSG00000253893.2	FAM85B	4.22	2.9e-05	0.00265	0.25	0.19	Joint mobility (Beighton score);	chr8:9183348	chr8:8167819~8226614:-
THCA	cis	rs9863	0.861	rs12298484	ENSG00000270061.1	RP11-214K3.19	-4.22	2.9e-05	0.00265	-0.27	-0.19	White blood cell count;	chr12:123934127	chr12:123969990~123970344:-
THCA	cis	rs3750965	0.92	rs4930644	ENSG00000260895.1	RP11-554A11.7	4.22	2.9e-05	0.00265	0.27	0.19	Hair color;	chr11:69051629	chr11:69103493~69109094:+
THCA	cis	rs13064773	0.528	rs340249	ENSG00000279311.1	RP11-170K4.2	4.22	2.9e-05	0.00265	0.25	0.19	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158883023	chr3:158869898~158871821:+
THCA	cis	rs2253762	0.645	rs11200366	ENSG00000276742.1	RP11-500G22.4	-4.22	2.9e-05	0.00265	-0.25	-0.19	Breast cancer;	chr10:122044170	chr10:121956782~121957098:+
THCA	cis	rs10489167	1	rs475268	ENSG00000237899.1	RP4-739H11.3	4.22	2.9e-05	0.00265	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40713183	chr1:40669089~40687588:-
THCA	cis	rs72928364	1	rs2595893	ENSG00000256628.3	ZBTB11-AS1	-4.22	2.9e-05	0.00265	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100958998	chr3:101676475~101679217:+
THCA	cis	rs8067545	0.75	rs7223305	ENSG00000270091.1	RP11-78O7.2	-4.22	2.9e-05	0.00265	-0.14	-0.19	Schizophrenia;	chr17:20087673	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs7208635	ENSG00000270091.1	RP11-78O7.2	-4.22	2.9e-05	0.00265	-0.14	-0.19	Schizophrenia;	chr17:20087677	chr17:19896590~19897287:-
THCA	cis	rs786425	0.682	rs12828408	ENSG00000270095.1	RP11-214K3.18	-4.22	2.9e-05	0.00265	-0.23	-0.19	Pubertal anthropometrics;	chr12:123714171	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs3817309	ENSG00000270095.1	RP11-214K3.18	-4.22	2.9e-05	0.00265	-0.23	-0.19	Pubertal anthropometrics;	chr12:123714174	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs66471742	ENSG00000270095.1	RP11-214K3.18	-4.22	2.9e-05	0.00265	-0.23	-0.19	Pubertal anthropometrics;	chr12:123714459	chr12:123971457~123971714:-
THCA	cis	rs786425	0.682	rs7135267	ENSG00000270095.1	RP11-214K3.18	-4.22	2.9e-05	0.00265	-0.23	-0.19	Pubertal anthropometrics;	chr12:123714573	chr12:123971457~123971714:-
THCA	cis	rs4568518	0.53	rs10950690	ENSG00000279048.1	RP11-511H23.2	4.22	2.9e-05	0.00265	0.12	0.19	Measles;	chr7:17941687	chr7:17940503~17942922:+
THCA	cis	rs724818	0.661	rs12513227	ENSG00000251609.2	SETP12	-4.22	2.9e-05	0.00265	-0.48	-0.19	Monobrow thickness;	chr4:120791321	chr4:120895494~120897083:-
THCA	cis	rs7918232	0.941	rs1755399	ENSG00000262412.1	RP11-85G18.6	4.22	2.9e-05	0.00265	0.3	0.19	Breast cancer;	chr10:27106029	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs1753415	ENSG00000262412.1	RP11-85G18.6	4.22	2.9e-05	0.00265	0.3	0.19	Breast cancer;	chr10:27106173	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.941	rs1753413	ENSG00000262412.1	RP11-85G18.6	4.22	2.9e-05	0.00265	0.3	0.19	Breast cancer;	chr10:27108183	chr10:27243130~27250804:+
THCA	cis	rs7918232	0.83	rs9833	ENSG00000262412.1	RP11-85G18.6	4.22	2.9e-05	0.00265	0.3	0.19	Breast cancer;	chr10:27111932	chr10:27243130~27250804:+
THCA	cis	rs35160687	0.509	rs35723061	ENSG00000273080.1	RP11-301O19.1	-4.22	2.9e-05	0.00265	-0.21	-0.19	Night sleep phenotypes;	chr2:86321965	chr2:86195590~86196049:+
THCA	cis	rs7918232	0.941	rs788210	ENSG00000262412.1	RP11-85G18.6	-4.22	2.9e-05	0.00265	-0.3	-0.19	Breast cancer;	chr10:27188019	chr10:27243130~27250804:+
THCA	cis	rs2434529	1	rs6865148	ENSG00000245275.6	SAP30L-AS1	4.22	2.9e-05	0.00265	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154241455	chr5:154329437~154445850:-
THCA	cis	rs7586673	0.725	rs6715870	ENSG00000235724.7	AC009299.2	-4.22	2.9e-05	0.00265	-0.21	-0.19	Intelligence (multi-trait analysis);	chr2:161038275	chr2:161222785~161308303:-
THCA	cis	rs4767841	0.718	rs203329	ENSG00000252886.1	RN7SKP197	-4.22	2.9e-05	0.00265	-0.19	-0.19	Urgency urinary incontinence;	chr12:119771874	chr12:119631090~119631386:-
THCA	cis	rs2692947	0.537	rs12471472	ENSG00000235584.2	AC008268.1	-4.22	2.9e-05	0.00265	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95539707	chr2:95666084~95668715:+
THCA	cis	rs10484434	0.901	rs1800758	ENSG00000272462.2	U91328.19	4.22	2.9e-05	0.00265	0.21	0.19	HIV-1 viral setpoint;	chr6:26093008	chr6:25992662~26001775:+
THCA	cis	rs11158026	0.517	rs55935131	ENSG00000258413.1	RP11-665C16.6	-4.22	2.9e-05	0.00265	-0.31	-0.19	Parkinson's disease;	chr14:54865054	chr14:55262767~55272075:-
THCA	cis	rs2179367	0.6	rs9498355	ENSG00000216906.2	RP11-350J20.9	-4.22	2.9e-05	0.00266	-0.26	-0.19	Dupuytren's disease;	chr6:149442274	chr6:149904243~149906418:+
THCA	cis	rs5751901	0.614	rs2070477	ENSG00000215481.7	BCRP3	-4.22	2.9e-05	0.00266	-0.17	-0.19	Protein quantitative trait loci;	chr22:24594949	chr22:24632915~24653356:+
THCA	cis	rs2822388	0.59	rs2822387	ENSG00000215559.7	ANKRD20A11P	-4.22	2.9e-05	0.00266	-0.38	-0.19	Stroke;	chr21:14034842	chr21:13909574~13980437:-
THCA	cis	rs801193	0.548	rs2109297	ENSG00000229886.1	RP5-1132H15.3	-4.22	2.9e-05	0.00266	-0.2	-0.19	Aortic root size;	chr7:66657397	chr7:66025126~66031544:-
THCA	cis	rs420259	0.516	rs11074562	ENSG00000260136.4	CTD-2270L9.4	-4.22	2.9e-05	0.00266	-0.15	-0.19	Bipolar disorder;	chr16:23488379	chr16:23452758~23457606:+
THCA	cis	rs796395	0.901	rs3009947	ENSG00000228208.5	C1orf143	-4.22	2.91e-05	0.00266	-0.22	-0.19	Post bronchodilator FEV1/FVC ratio;	chr1:218515813	chr1:218510096~218525978:+
THCA	cis	rs4906332	1	rs35366629	ENSG00000244691.1	RPL10AP1	-4.22	2.91e-05	0.00266	-0.24	-0.19	Coronary artery disease;	chr14:103436717	chr14:103412119~103412761:-
THCA	cis	rs2799081	1	rs2799081	ENSG00000280107.1	AL022393.9	-4.22	2.91e-05	0.00266	-0.2	-0.19	Myopia;	chr6:28302807	chr6:28170845~28172521:+
THCA	cis	rs7267979	1	rs6050566	ENSG00000276952.1	RP5-965G21.6	-4.22	2.91e-05	0.00266	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4813563	ENSG00000276952.1	RP5-965G21.6	-4.22	2.91e-05	0.00266	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs6037103	ENSG00000276952.1	RP5-965G21.6	-4.22	2.91e-05	0.00266	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25284915~25285588:-
THCA	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	4.22	2.91e-05	0.00266	0.29	0.19	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
THCA	cis	rs6828577	0.862	rs298974	ENSG00000281731.1	RP11-384K6.8	-4.22	2.91e-05	0.00266	-0.22	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118714879	chr4:118664087~118685341:-
THCA	cis	rs427943	0.831	rs421716	ENSG00000223768.1	LINC00205	-4.22	2.91e-05	0.00266	-0.17	-0.19	Body mass index;	chr21:45170507	chr21:45293285~45297354:+
THCA	cis	rs3177980	0.529	rs659476	ENSG00000239494.2	RN7SL333P	-4.22	2.91e-05	0.00266	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr1:169938352	chr1:169859756~169860052:+
THCA	cis	rs9843304	0.529	rs72996050	ENSG00000240541.2	TM4SF1-AS1	4.22	2.91e-05	0.00266	0.17	0.19	Gallstone disease;	chr3:149484846	chr3:149377778~149386583:+
THCA	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-4.22	2.91e-05	0.00266	-0.26	-0.19	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
THCA	cis	rs12134133	0.962	rs6682586	ENSG00000237074.1	RP11-6J21.2	4.22	2.91e-05	0.00266	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.962	rs6668560	ENSG00000237074.1	RP11-6J21.2	4.22	2.91e-05	0.00266	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207249067~207309121:+
THCA	cis	rs12440869	1	rs4776921	ENSG00000270964.1	RP11-502I4.3	4.22	2.91e-05	0.00266	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67325731	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs2120837	ENSG00000270964.1	RP11-502I4.3	-4.22	2.91e-05	0.00266	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67284457	chr15:67541072~67542604:-
THCA	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	4.22	2.91e-05	0.00266	0.25	0.19	Myopia;	chr6:28302807	chr6:28943877~28944537:+
THCA	cis	rs7115242	0.92	rs6589574	ENSG00000280143.1	AP000892.6	4.22	2.91e-05	0.00266	0.35	0.19	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117204967~117210292:+
THCA	cis	rs11098499	0.863	rs3822190	ENSG00000249244.1	RP11-548H18.2	4.22	2.91e-05	0.00266	0.23	0.19	Corneal astigmatism;	chr4:119506943	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3822191	ENSG00000249244.1	RP11-548H18.2	4.22	2.91e-05	0.00266	0.23	0.19	Corneal astigmatism;	chr4:119506946	chr4:119391831~119395335:-
THCA	cis	rs12893668	0.703	rs34186780	ENSG00000244691.1	RPL10AP1	-4.22	2.91e-05	0.00266	-0.27	-0.19	Reticulocyte count;	chr14:103561258	chr14:103412119~103412761:-
THCA	cis	rs1560104	0.675	rs9937086	ENSG00000262801.4	U91319.1	4.22	2.91e-05	0.00266	0.22	0.19	Obesity-related traits;	chr16:12611090	chr16:13246316~13562918:+
THCA	cis	rs801193	1	rs2659909	ENSG00000229180.5	GS1-124K5.11	4.22	2.91e-05	0.00266	0.13	0.19	Aortic root size;	chr7:66695292	chr7:66526088~66542624:-
THCA	cis	rs74233809	1	rs11191607	ENSG00000272912.1	RP11-724N1.1	-4.22	2.91e-05	0.00266	-0.34	-0.19	Birth weight;	chr10:103199431	chr10:102914585~102915404:+
THCA	cis	rs7737355	0.947	rs32115	ENSG00000237714.1	P4HA2-AS1	4.22	2.91e-05	0.00266	0.27	0.19	Life satisfaction;	chr5:131715635	chr5:132184876~132192808:+
THCA	cis	rs962856	1	rs1032157	ENSG00000236780.4	AC078941.1	4.22	2.91e-05	0.00266	0.23	0.19	Pancreatic cancer;	chr2:67374684	chr2:67123357~67215319:-
THCA	cis	rs10256972	0.616	rs6463001	ENSG00000199023.2	MIR339	-4.22	2.91e-05	0.00266	-0.2	-0.19	Endometriosis;Longevity;	chr7:1068636	chr7:1022935~1023045:-
THCA	cis	rs875971	0.862	rs28470208	ENSG00000229886.1	RP5-1132H15.3	-4.22	2.91e-05	0.00266	-0.2	-0.19	Aortic root size;	chr7:66119713	chr7:66025126~66031544:-
THCA	cis	rs17382723	0.887	rs1062748	ENSG00000229996.1	AC093585.6	4.22	2.91e-05	0.00266	0.25	0.19	Height;	chr2:241089326	chr2:241010045~241010744:-
THCA	cis	rs7267979	0.565	rs4815437	ENSG00000274414.1	RP5-965G21.4	4.22	2.91e-05	0.00266	0.24	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:25239007~25245229:-
THCA	cis	rs12612619	0.732	rs11681562	ENSG00000272148.1	RP11-195B17.1	4.22	2.91e-05	0.00266	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027735	chr2:27062428~27062907:-
THCA	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	4.22	2.91e-05	0.00266	0.16	0.19	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
THCA	cis	rs7176527	0.848	rs72630461	ENSG00000225151.9	GOLGA2P7	4.22	2.91e-05	0.00266	0.37	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84696913	chr15:84199311~84230136:-
THCA	cis	rs790006	0.874	rs35086651	ENSG00000243024.5	RPS11P6	-4.22	2.91e-05	0.00266	-0.25	-0.19	Response to cytidine analogues (gemcitabine);	chr12:64227995	chr12:64222337~64397065:+
THCA	cis	rs17221829	0.733	rs2388105	ENSG00000280385.1	AP000648.5	4.22	2.91e-05	0.00266	0.19	0.19	Anxiety in major depressive disorder;	chr11:89622149	chr11:90193614~90198120:+
THCA	cis	rs4415084	1	rs2218081	ENSG00000272335.1	RP11-53O19.3	-4.22	2.91e-05	0.00266	-0.16	-0.19	Breast cancer;	chr5:44705038	chr5:44826076~44828592:+
THCA	cis	rs5753037	0.702	rs9614055	ENSG00000279699.1	RP1-102K2.9	4.22	2.91e-05	0.00266	0.18	0.19	Type 1 diabetes;	chr22:29791713	chr22:30275215~30276951:-
THCA	cis	rs73108077	0.915	rs17328705	ENSG00000277112.2	RP11-755J8.1	-4.22	2.91e-05	0.00266	-0.38	-0.19	Red blood cell density in sickle cell anemia;	chr20:31438570	chr20:30681825~30723932:-
THCA	cis	rs7119038	0.774	rs73005426	ENSG00000255422.1	AP002954.4	4.22	2.92e-05	0.00267	0.23	0.19	Sjögren's syndrome;	chr11:118810374	chr11:118704607~118750263:+
THCA	cis	rs9595908	0.669	rs17594908	ENSG00000212293.1	SNORA16	4.22	2.92e-05	0.00267	0.23	0.19	Body mass index;	chr13:32789427	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.669	rs2025474	ENSG00000212293.1	SNORA16	4.22	2.92e-05	0.00267	0.23	0.19	Body mass index;	chr13:32792319	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.669	rs4941669	ENSG00000212293.1	SNORA16	4.22	2.92e-05	0.00267	0.23	0.19	Body mass index;	chr13:32793045	chr13:32420390~32420516:-
THCA	cis	rs17382723	0.775	rs2302042	ENSG00000229996.1	AC093585.6	4.22	2.92e-05	0.00267	0.25	0.19	Height;	chr2:241081108	chr2:241010045~241010744:-
THCA	cis	rs7200786	0.669	rs12443971	ENSG00000274038.1	RP11-66H6.4	4.22	2.92e-05	0.00267	0.25	0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10952969	chr16:11056556~11057034:+
THCA	cis	rs10090774	0.965	rs306952	ENSG00000279766.1	RP11-642A1.2	4.22	2.92e-05	0.00267	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141004870	chr8:140572142~140572812:-
THCA	cis	rs35160687	0.545	rs1863050	ENSG00000273080.1	RP11-301O19.1	-4.22	2.92e-05	0.00267	-0.21	-0.19	Night sleep phenotypes;	chr2:86331253	chr2:86195590~86196049:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000272831.1	RP11-792A8.4	-4.22	2.92e-05	0.00267	-0.12	-0.19	Aortic root size;	chr7:66682114	chr7:66739829~66740385:-
THCA	cis	rs7572644	0.699	rs13400398	ENSG00000223522.1	AC093690.1	4.22	2.92e-05	0.00267	0.22	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27939242	chr2:28307691~28310459:-
THCA	cis	rs8031584	0.958	rs1043742	ENSG00000270015.1	RP11-540B6.6	-4.22	2.92e-05	0.00267	-0.14	-0.19	Huntington's disease progression;	chr15:30940378	chr15:30926514~30928407:+
THCA	cis	rs868036	0.681	rs28670272	ENSG00000270964.1	RP11-502I4.3	4.22	2.92e-05	0.00267	0.17	0.19	Restless legs syndrome;	chr15:67817569	chr15:67541072~67542604:-
THCA	cis	rs11089937	0.616	rs5757244	ENSG00000211639.2	IGLV4-60	4.22	2.92e-05	0.00267	0.13	0.19	Periodontitis (PAL4Q3);	chr22:22176637	chr22:22162199~22162681:+
THCA	cis	rs6088813	1	rs6088820	ENSG00000279253.1	RP4-614O4.13	4.22	2.92e-05	0.00267	0.19	0.19	Height;	chr20:35399495	chr20:35262727~35264187:-
THCA	cis	rs7267979	1	rs6037095	ENSG00000276952.1	RP5-965G21.6	-4.22	2.92e-05	0.00267	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050562	ENSG00000276952.1	RP5-965G21.6	-4.22	2.92e-05	0.00267	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4815407	ENSG00000276952.1	RP5-965G21.6	-4.22	2.92e-05	0.00267	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25284915~25285588:-
THCA	cis	rs13178541	0.745	rs3963615	ENSG00000250378.1	RP11-119J18.1	-4.22	2.92e-05	0.00267	-0.23	-0.19	IgG glycosylation;	chr5:135750292	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.745	rs7380109	ENSG00000250378.1	RP11-119J18.1	-4.22	2.92e-05	0.00267	-0.23	-0.19	IgG glycosylation;	chr5:135751385	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs62365677	ENSG00000250378.1	RP11-119J18.1	-4.22	2.92e-05	0.00267	-0.23	-0.19	IgG glycosylation;	chr5:135752861	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs7380576	ENSG00000250378.1	RP11-119J18.1	-4.22	2.92e-05	0.00267	-0.23	-0.19	IgG glycosylation;	chr5:135752903	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs7380618	ENSG00000250378.1	RP11-119J18.1	-4.22	2.92e-05	0.00267	-0.23	-0.19	IgG glycosylation;	chr5:135753120	chr5:135812667~135826582:+
THCA	cis	rs13034020	0.594	rs10496090	ENSG00000271889.1	RP11-493E12.1	-4.22	2.92e-05	0.00267	-0.26	-0.19	Hodgkin's lymphoma;	chr2:61026898	chr2:61151433~61162105:-
THCA	cis	rs875971	0.571	rs160641	ENSG00000273142.1	RP11-458F8.4	-4.22	2.92e-05	0.00267	-0.18	-0.19	Aortic root size;	chr7:66112359	chr7:66902857~66906297:+
THCA	cis	rs2179367	0.553	rs7762222	ENSG00000216906.2	RP11-350J20.9	4.22	2.92e-05	0.00267	0.27	0.19	Dupuytren's disease;	chr6:149444846	chr6:149904243~149906418:+
THCA	cis	rs9863	0.861	rs7973683	ENSG00000269997.1	RP11-214K3.21	-4.22	2.92e-05	0.00267	-0.23	-0.19	White blood cell count;	chr12:123964676	chr12:123966077~123966629:-
THCA	cis	rs2030746	1	rs2030746	ENSG00000237614.1	AC073257.2	4.22	2.92e-05	0.00267	0.23	0.19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120551912	chr2:120542909~120544326:-
THCA	cis	rs8031584	0.958	rs35256769	ENSG00000270015.1	RP11-540B6.6	-4.22	2.92e-05	0.00267	-0.14	-0.19	Huntington's disease progression;	chr15:30945573	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.958	rs11629793	ENSG00000270015.1	RP11-540B6.6	-4.22	2.92e-05	0.00267	-0.14	-0.19	Huntington's disease progression;	chr15:30946220	chr15:30926514~30928407:+
THCA	cis	rs481331	0.866	rs209385	ENSG00000215146.4	RP11-313J2.1	-4.22	2.92e-05	0.00267	-0.35	-0.19	Systemic juvenile idiopathic arthritis;	chr10:42638913	chr10:42331866~42367974:-
THCA	cis	rs919433	0.519	rs700656	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197788943	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.514	rs770659	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197805030	chr2:197197991~197199273:+
THCA	cis	rs700651	0.821	rs700663	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Intracranial aneurysm;	chr2:197805754	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700664	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197806421	chr2:197197991~197199273:+
THCA	cis	rs700651	0.821	rs700666	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Intracranial aneurysm;	chr2:197808820	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs770657	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197809460	chr2:197197991~197199273:+
THCA	cis	rs700651	0.821	rs771005	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Intracranial aneurysm;	chr2:197811224	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700667	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197812784	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700670	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197822560	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.555	rs700671	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197825277	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs771009	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197826358	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700672	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197826731	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700673	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197828205	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700674	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197828979	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.515	rs700675	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197835492	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs2574832	ENSG00000231621.1	AC013264.2	-4.22	2.92e-05	0.00267	-0.2	-0.19	Dermatomyositis;	chr2:197840094	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700680	ENSG00000231621.1	AC013264.2	4.22	2.92e-05	0.00267	0.2	0.19	Dermatomyositis;	chr2:197843226	chr2:197197991~197199273:+
THCA	cis	rs11633886	0.934	rs11630229	ENSG00000273972.1	CTD-2306A12.1	-4.22	2.92e-05	0.00267	-0.21	-0.19	Diisocyanate-induced asthma;	chr15:45795811	chr15:45702640~45703183:+
THCA	cis	rs875971	1	rs1167411	ENSG00000272831.1	RP11-792A8.4	-4.22	2.92e-05	0.00267	-0.13	-0.19	Aortic root size;	chr7:66074277	chr7:66739829~66740385:-
THCA	cis	rs4415084	0.84	rs60707950	ENSG00000272335.1	RP11-53O19.3	-4.22	2.92e-05	0.00267	-0.16	-0.19	Breast cancer;	chr5:44684141	chr5:44826076~44828592:+
THCA	cis	rs4934494	0.689	rs17127588	ENSG00000240996.1	RP11-80H5.7	-4.22	2.92e-05	0.00267	-0.21	-0.19	Red blood cell count;	chr10:89815887	chr10:89694295~89697928:-
THCA	cis	rs8081395	0.801	rs12938273	ENSG00000267302.4	RP11-178C3.2	-4.22	2.92e-05	0.00267	-0.23	-0.19	White blood cell count;	chr17:59824291	chr17:59964832~59996972:+
THCA	cis	rs8081395	0.836	rs1292061	ENSG00000267302.4	RP11-178C3.2	-4.22	2.92e-05	0.00267	-0.23	-0.19	White blood cell count;	chr17:59833869	chr17:59964832~59996972:+
THCA	cis	rs9926296	0.632	rs4785717	ENSG00000260259.1	RP11-368I7.4	-4.22	2.92e-05	0.00267	-0.21	-0.19	Vitiligo;	chr16:89734725	chr16:89682620~89686569:-
THCA	cis	rs8081395	0.899	rs2645477	ENSG00000267302.4	RP11-178C3.2	-4.22	2.92e-05	0.00267	-0.23	-0.19	White blood cell count;	chr17:59768263	chr17:59964832~59996972:+
THCA	cis	rs11158026	0.501	rs72713460	ENSG00000258413.1	RP11-665C16.6	-4.22	2.92e-05	0.00267	-0.32	-0.19	Parkinson's disease;	chr14:54830325	chr14:55262767~55272075:-
THCA	cis	rs2806561	0.664	rs55764475	ENSG00000249087.5	ZNF436-AS1	-4.22	2.92e-05	0.00267	-0.13	-0.19	Height;	chr1:22992490	chr1:23368997~23371839:+
THCA	cis	rs9307551	0.741	rs1561640	ENSG00000250334.4	LINC00989	-4.22	2.92e-05	0.00267	-0.25	-0.19	Refractive error;	chr4:79498874	chr4:79492416~79576460:+
THCA	cis	rs733175	0.951	rs7669090	ENSG00000261490.1	RP11-448G15.3	4.22	2.92e-05	0.00267	0.15	0.19	Psychosis and Alzheimer's disease;	chr4:10026507	chr4:10068089~10073019:-
THCA	cis	rs9878978	1	rs11716221	ENSG00000237990.3	CNTN4-AS1	4.22	2.92e-05	0.00267	0.21	0.19	Blood pressure (smoking interaction);	chr3:2423054	chr3:3039033~3069242:-
THCA	cis	rs3782089	1	rs11602375	ENSG00000214659.4	KRT8P26	-4.22	2.92e-05	0.00267	-0.34	-0.19	Height;	chr11:65529069	chr11:65726939~65728214:+
THCA	cis	rs3782089	1	rs11600543	ENSG00000214659.4	KRT8P26	-4.22	2.92e-05	0.00267	-0.34	-0.19	Height;	chr11:65531468	chr11:65726939~65728214:+
THCA	cis	rs8017455	0.591	rs2284733	ENSG00000259167.2	NMNAT1P1	4.22	2.92e-05	0.00267	0.3	0.19	Hair morphology;	chr14:81085860	chr14:81032529~81033404:+
THCA	cis	rs8024893	1	rs8024893	ENSG00000215302.7	CTD-3092A11.1	4.22	2.92e-05	0.00267	0.29	0.19	Red cell distribution width;	chr15:31248786	chr15:30470779~30507623:+
THCA	cis	rs75059851	0.778	rs73034263	ENSG00000280237.1	MIR4697HG	4.22	2.92e-05	0.00267	0.22	0.19	Schizophrenia;	chr11:133938143	chr11:133896438~133901601:-
THCA	cis	rs8081395	0.801	rs2777895	ENSG00000267302.4	RP11-178C3.2	-4.22	2.93e-05	0.00267	-0.23	-0.19	White blood cell count;	chr17:59802249	chr17:59964832~59996972:+
THCA	cis	rs8081395	0.769	rs12449331	ENSG00000267302.4	RP11-178C3.2	-4.22	2.93e-05	0.00267	-0.23	-0.19	White blood cell count;	chr17:59806285	chr17:59964832~59996972:+
THCA	cis	rs73108077	1	rs58925751	ENSG00000277112.2	RP11-755J8.1	-4.22	2.93e-05	0.00267	-0.37	-0.19	Red blood cell density in sickle cell anemia;	chr20:31459409	chr20:30681825~30723932:-
THCA	cis	rs11846409	0.932	rs756588	ENSG00000274576.2	IGHV2-70	4.22	2.93e-05	0.00267	0.16	0.19	Rheumatic heart disease;	chr14:106632316	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.86	rs55745256	ENSG00000274576.2	IGHV2-70	-4.22	2.93e-05	0.00267	-0.16	-0.19	Rheumatic heart disease;	chr14:106632365	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs731013	ENSG00000274576.2	IGHV2-70	-4.22	2.93e-05	0.00267	-0.16	-0.19	Rheumatic heart disease;	chr14:106632481	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs731012	ENSG00000274576.2	IGHV2-70	-4.22	2.93e-05	0.00267	-0.16	-0.19	Rheumatic heart disease;	chr14:106632578	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs731011	ENSG00000274576.2	IGHV2-70	-4.22	2.93e-05	0.00267	-0.16	-0.19	Rheumatic heart disease;	chr14:106632619	chr14:106770577~106771020:-
THCA	cis	rs11846409	0.932	rs10138537	ENSG00000274576.2	IGHV2-70	-4.22	2.93e-05	0.00267	-0.16	-0.19	Rheumatic heart disease;	chr14:106632778	chr14:106770577~106771020:-
THCA	cis	rs7617480	0.648	rs7653408	ENSG00000229759.1	MRPS18AP1	4.22	2.93e-05	0.00267	0.29	0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48934918	chr3:48256350~48256938:-
THCA	cis	rs17685	0.725	rs6947068	ENSG00000230882.1	AC005077.14	-4.22	2.93e-05	0.00267	-0.19	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76032738	chr7:76071469~76074963:-
THCA	cis	rs4693089	0.604	rs13141136	ENSG00000213608.5	SLC25A14P1	4.22	2.93e-05	0.00267	0.22	0.19	Menopause (age at onset);	chr4:83448938	chr4:83477524~83478424:+
THCA	cis	rs12612619	0.732	rs2289360	ENSG00000272148.1	RP11-195B17.1	4.22	2.93e-05	0.00268	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27079297	chr2:27062428~27062907:-
THCA	cis	rs156299	0.513	rs156296	ENSG00000234286.1	AC006026.13	4.22	2.93e-05	0.00268	0.25	0.19	Vitamin D levels;	chr7:24196474	chr7:23680195~23680786:-
THCA	cis	rs1993293	0.636	rs2168067	ENSG00000254744.3	CTD-3076O17.1	4.22	2.93e-05	0.00268	0.22	0.19	Coronary artery calcification;	chr15:99758972	chr15:99970215~99974010:+
THCA	cis	rs12681963	0.764	rs7824731	ENSG00000248159.1	HSPA8P11	-4.22	2.93e-05	0.00268	-0.36	-0.19	Migraine;	chr8:30139509	chr8:30237382~30240997:+
THCA	cis	rs17685	0.753	rs11972240	ENSG00000230882.1	AC005077.14	4.22	2.93e-05	0.00268	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76064761	chr7:76071469~76074963:-
THCA	cis	rs2522056	1	rs6874639	ENSG00000237714.1	P4HA2-AS1	4.22	2.93e-05	0.00268	0.28	0.19	Fibrinogen;Lymphocyte counts;	chr5:132443024	chr5:132184876~132192808:+
THCA	cis	rs10875746	0.903	rs58952582	ENSG00000258273.1	RP11-370I10.4	4.22	2.93e-05	0.00268	0.28	0.19	Longevity (90 years and older);	chr12:48064665	chr12:48333755~48333901:-
THCA	cis	rs10761482	0.813	rs12776510	ENSG00000254271.1	RP11-131N11.4	4.22	2.93e-05	0.00268	0.26	0.19	Schizophrenia;	chr10:60408170	chr10:60734342~60741828:+
THCA	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-4.22	2.93e-05	0.00268	-0.19	-0.19	Height;	chr5:36968438	chr5:36666214~36725195:-
THCA	cis	rs11771526	0.892	rs1376282	ENSG00000272905.1	RP11-265E18.1	4.22	2.93e-05	0.00268	0.27	0.19	Body mass index;	chr7:32330880	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.892	rs76035550	ENSG00000272905.1	RP11-265E18.1	4.22	2.93e-05	0.00268	0.27	0.19	Body mass index;	chr7:32331747	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.892	rs62457540	ENSG00000272905.1	RP11-265E18.1	4.22	2.93e-05	0.00268	0.27	0.19	Body mass index;	chr7:32332587	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.892	rs62457541	ENSG00000272905.1	RP11-265E18.1	4.22	2.93e-05	0.00268	0.27	0.19	Body mass index;	chr7:32332954	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.892	rs11764802	ENSG00000272905.1	RP11-265E18.1	4.22	2.93e-05	0.00268	0.27	0.19	Body mass index;	chr7:32333366	chr7:32845394~32846061:+
THCA	cis	rs12497850	0.864	rs4279134	ENSG00000228638.1	FCF1P2	-4.22	2.93e-05	0.00268	-0.21	-0.19	Parkinson's disease;	chr3:49119243	chr3:48290793~48291375:-
THCA	cis	rs7267979	1	rs6050631	ENSG00000276952.1	RP5-965G21.6	4.22	2.93e-05	0.00268	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25284915~25285588:-
THCA	cis	rs28735056	0.935	rs72980082	ENSG00000261126.6	RP11-795F19.1	-4.22	2.93e-05	0.00268	-0.16	-0.19	Schizophrenia;	chr18:79870170	chr18:80046900~80095482:+
THCA	cis	rs4792901	0.959	rs12103443	ENSG00000267151.3	RP11-100E5.2	4.22	2.93e-05	0.00268	0.2	0.19	Dupuytren's disease;	chr17:43553890	chr17:43444707~43451200:+
THCA	cis	rs12134133	1	rs11580382	ENSG00000237074.1	RP11-6J21.2	4.22	2.93e-05	0.00268	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207249067~207309121:+
THCA	cis	rs72843506	0.722	rs117096120	ENSG00000261033.1	RP11-209D14.2	4.22	2.93e-05	0.00268	0.36	0.19	Schizophrenia;	chr17:20264380	chr17:20008051~20009234:-
THCA	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	4.22	2.93e-05	0.00268	0.23	0.19	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
THCA	cis	rs62244186	0.627	rs12386385	ENSG00000214820.3	MPRIPP1	4.22	2.93e-05	0.00268	0.21	0.19	Depressive symptoms;	chr3:44416048	chr3:44579938~44581026:-
THCA	cis	rs4660456	0.572	rs1008204	ENSG00000238287.1	RP11-656D10.3	4.22	2.93e-05	0.00268	0.22	0.19	Platelet count;	chr1:40700189	chr1:40493157~40508661:-
THCA	cis	rs4356203	0.905	rs7946010	ENSG00000272034.1	SNORD14A	4.22	2.94e-05	0.00268	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17154510	chr11:17074654~17074744:-
THCA	cis	rs875971	0.965	rs7794930	ENSG00000230189.5	GS1-124K5.2	-4.22	2.94e-05	0.00268	-0.12	-0.19	Aortic root size;	chr7:66313559	chr7:66409143~66490059:-
THCA	cis	rs41313321	0.541	rs1468648	ENSG00000272696.1	RP11-339B21.13	-4.22	2.94e-05	0.00268	-0.14	-0.19	Coenzyme Q10 levels;	chr9:128295706	chr9:128316337~128316909:+
THCA	cis	rs7772486	0.79	rs6917482	ENSG00000270638.1	RP3-466P17.1	-4.22	2.94e-05	0.00268	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs4566902	ENSG00000270638.1	RP3-466P17.1	-4.22	2.94e-05	0.00268	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs11760	ENSG00000270638.1	RP3-466P17.1	4.22	2.94e-05	0.00268	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs1062067	ENSG00000270638.1	RP3-466P17.1	4.22	2.94e-05	0.00268	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs2256998	ENSG00000270638.1	RP3-466P17.1	4.22	2.94e-05	0.00268	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145735570~145737218:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000272831.1	RP11-792A8.4	-4.22	2.94e-05	0.00268	-0.12	-0.19	Cotinine glucuronidation;	chr7:66580525	chr7:66739829~66740385:-
THCA	cis	rs6565180	0.525	rs1132812	ENSG00000273724.1	RP11-347C12.12	4.22	2.94e-05	0.00268	0.21	0.19	Tonsillectomy;	chr16:30186830	chr16:30336400~30343336:+
THCA	cis	rs4664293	0.541	rs1425047	ENSG00000230783.1	AC009961.2	4.22	2.94e-05	0.00268	0.23	0.19	Monocyte percentage of white cells;	chr2:159517946	chr2:159689217~159690291:-
THCA	cis	rs4785204	0.618	rs9939479	ENSG00000279356.1	RP11-429P3.8	-4.22	2.94e-05	0.00268	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50002051	chr16:50072862~50074986:+
THCA	cis	rs3020736	0.5	rs8143153	ENSG00000237037.8	NDUFA6-AS1	4.22	2.94e-05	0.00268	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42090931~42137742:+
THCA	cis	rs4938303	0.633	rs12799441	ENSG00000254851.1	RP11-109L13.1	4.22	2.94e-05	0.00268	0.33	0.19	Triglycerides;	chr11:116687799	chr11:117135528~117138582:+
THCA	cis	rs875971	1	rs3735148	ENSG00000229886.1	RP5-1132H15.3	4.22	2.94e-05	0.00268	0.2	0.19	Aortic root size;	chr7:66506022	chr7:66025126~66031544:-
THCA	cis	rs6494488	0.5	rs72741357	ENSG00000259635.1	AC100830.3	-4.22	2.94e-05	0.00268	-0.49	-0.19	Coronary artery disease;	chr15:64491253	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs116857608	ENSG00000259635.1	AC100830.3	-4.22	2.94e-05	0.00268	-0.49	-0.19	Coronary artery disease;	chr15:64505969	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741373	ENSG00000259635.1	AC100830.3	-4.22	2.94e-05	0.00268	-0.49	-0.19	Coronary artery disease;	chr15:64508662	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741379	ENSG00000259635.1	AC100830.3	-4.22	2.94e-05	0.00268	-0.49	-0.19	Coronary artery disease;	chr15:64512564	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741381	ENSG00000259635.1	AC100830.3	-4.22	2.94e-05	0.00268	-0.49	-0.19	Coronary artery disease;	chr15:64514362	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741385	ENSG00000259635.1	AC100830.3	-4.22	2.94e-05	0.00268	-0.49	-0.19	Coronary artery disease;	chr15:64517112	chr15:64701248~64719602:+
THCA	cis	rs8067545	0.75	rs4267380	ENSG00000270091.1	RP11-78O7.2	-4.22	2.94e-05	0.00269	-0.14	-0.19	Schizophrenia;	chr17:20068251	chr17:19896590~19897287:-
THCA	cis	rs10435719	0.78	rs9692662	ENSG00000254948.1	OR7E158P	-4.22	2.94e-05	0.00269	-0.24	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.899	rs9693925	ENSG00000254948.1	OR7E158P	-4.22	2.94e-05	0.00269	-0.24	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:11919900~11920809:-
THCA	cis	rs1371614	0.588	rs13017554	ENSG00000272148.1	RP11-195B17.1	4.22	2.94e-05	0.00269	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26948114	chr2:27062428~27062907:-
THCA	cis	rs10875746	0.669	rs4760701	ENSG00000226413.2	OR8T1P	4.22	2.94e-05	0.00269	0.27	0.19	Longevity (90 years and older);	chr12:48304735	chr12:48442030~48442947:-
THCA	cis	rs16975963	0.843	rs3848624	ENSG00000226686.6	LINC01535	-4.22	2.94e-05	0.00269	-0.26	-0.19	Longevity;	chr19:37772176	chr19:37251912~37265535:+
THCA	cis	rs7474896	0.559	rs1024202	ENSG00000120555.12	SEPT7P9	-4.22	2.94e-05	0.00269	-0.25	-0.19	Obesity (extreme);	chr10:37990049	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.537	rs1022449	ENSG00000120555.12	SEPT7P9	-4.22	2.94e-05	0.00269	-0.25	-0.19	Obesity (extreme);	chr10:37990539	chr10:38383069~38402916:-
THCA	cis	rs7560272	0.538	rs4241257	ENSG00000163016.8	ALMS1P	-4.22	2.94e-05	0.00269	-0.24	-0.19	Schizophrenia;	chr2:73711480	chr2:73644919~73685576:+
THCA	cis	rs7119038	0.818	rs11217042	ENSG00000255422.1	AP002954.4	4.22	2.94e-05	0.00269	0.23	0.19	Sjögren's syndrome;	chr11:118811819	chr11:118704607~118750263:+
THCA	cis	rs7119038	0.818	rs17122453	ENSG00000255422.1	AP002954.4	4.22	2.94e-05	0.00269	0.23	0.19	Sjögren's syndrome;	chr11:118812855	chr11:118704607~118750263:+
THCA	cis	rs59868192	0.925	rs72726041	ENSG00000246740.2	PLA2G4E-AS1	4.22	2.94e-05	0.00269	0.38	0.19	White blood cell count;	chr15:41974756	chr15:41972763~41999094:+
THCA	cis	rs529866	0.5	rs918739	ENSG00000263080.1	RP11-485G7.5	-4.22	2.94e-05	0.00269	-0.23	-0.19	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11341809~11345211:-
THCA	cis	rs1009077	0.578	rs2389863	ENSG00000245958.5	RP11-33B1.1	-4.22	2.94e-05	0.00269	-0.22	-0.19	Endometriosis;	chr4:119586509	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.531	rs10012485	ENSG00000245958.5	RP11-33B1.1	-4.22	2.94e-05	0.00269	-0.22	-0.19	Endometriosis;	chr4:119587143	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs28412979	ENSG00000245958.5	RP11-33B1.1	-4.22	2.94e-05	0.00269	-0.22	-0.19	Endometriosis;	chr4:119588726	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs13115778	ENSG00000245958.5	RP11-33B1.1	-4.22	2.94e-05	0.00269	-0.22	-0.19	Endometriosis;	chr4:119589380	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs7659250	ENSG00000245958.5	RP11-33B1.1	-4.22	2.94e-05	0.00269	-0.22	-0.19	Endometriosis;	chr4:119590820	chr4:119454791~119552025:+
THCA	cis	rs1971762	0.527	rs6580953	ENSG00000270175.1	RP11-793H13.11	-4.22	2.94e-05	0.00269	-0.13	-0.19	Height;	chr12:53627354	chr12:53500162~53500936:-
THCA	cis	rs7849973	0.625	rs62574663	ENSG00000234840.1	LINC01239	-4.22	2.94e-05	0.00269	-0.24	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22812209	chr9:22646200~22824213:+
THCA	cis	rs7711186	0.786	rs60391242	ENSG00000252464.1	RN7SKP70	4.22	2.94e-05	0.00269	0.23	0.19	Urate levels in obese individuals;	chr5:178659539	chr5:178619728~178619998:-
THCA	cis	rs7208859	0.725	rs9910051	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.94e-05	0.00269	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.725	rs7210904	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.94e-05	0.00269	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.725	rs9915802	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.94e-05	0.00269	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.725	rs7342938	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.94e-05	0.00269	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.725	rs6505215	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.94e-05	0.00269	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30738182~30740275:+
THCA	cis	rs1048886	0.938	rs12526827	ENSG00000271967.1	RP11-134K13.4	-4.22	2.94e-05	0.00269	-0.21	-0.19	Type 2 diabetes;	chr6:70449931	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs6901904	ENSG00000271967.1	RP11-134K13.4	-4.22	2.94e-05	0.00269	-0.21	-0.19	Type 2 diabetes;	chr6:70471972	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs73482557	ENSG00000271967.1	RP11-134K13.4	-4.22	2.94e-05	0.00269	-0.21	-0.19	Type 2 diabetes;	chr6:70473810	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs11965656	ENSG00000271967.1	RP11-134K13.4	-4.22	2.94e-05	0.00269	-0.21	-0.19	Type 2 diabetes;	chr6:70473917	chr6:70596438~70596980:+
THCA	cis	rs4906332	0.966	rs17679729	ENSG00000269910.1	RP11-73M18.10	4.22	2.94e-05	0.00269	0.16	0.19	Coronary artery disease;	chr14:103457975	chr14:103694516~103695050:-
THCA	cis	rs4906332	0.933	rs35999760	ENSG00000269910.1	RP11-73M18.10	4.22	2.94e-05	0.00269	0.16	0.19	Coronary artery disease;	chr14:103458144	chr14:103694516~103695050:-
THCA	cis	rs4906332	0.966	rs12185021	ENSG00000269910.1	RP11-73M18.10	4.22	2.94e-05	0.00269	0.16	0.19	Coronary artery disease;	chr14:103461468	chr14:103694516~103695050:-
THCA	cis	rs9813712	0.78	rs55929137	ENSG00000253540.4	FAM86HP	4.22	2.94e-05	0.00269	0.23	0.19	Response to amphetamines;	chr3:130236002	chr3:130099092~130111472:-
THCA	cis	rs970548	0.954	rs11239528	ENSG00000230869.1	CTGLF10P	4.22	2.95e-05	0.00269	0.24	0.19	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45459588	chr10:45678692~45700532:+
THCA	cis	rs72928364	1	rs17399603	ENSG00000256628.3	ZBTB11-AS1	4.22	2.95e-05	0.00269	0.33	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101017295	chr3:101676475~101679217:+
THCA	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	4.22	2.95e-05	0.00269	0.22	0.19	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	4.22	2.95e-05	0.00269	0.22	0.19	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
THCA	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	4.22	2.95e-05	0.00269	0.22	0.19	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
THCA	cis	rs10875746	0.903	rs11168420	ENSG00000258273.1	RP11-370I10.4	4.22	2.95e-05	0.00269	0.28	0.19	Longevity (90 years and older);	chr12:48122113	chr12:48333755~48333901:-
THCA	cis	rs2836974	0.897	rs3945	ENSG00000255568.3	BRWD1-AS2	4.22	2.95e-05	0.00269	0.17	0.19	Cognitive function;	chr21:39194141	chr21:39313935~39314962:+
THCA	cis	rs478304	0.903	rs546202	ENSG00000255557.1	RP11-770G2.2	4.22	2.95e-05	0.00269	0.21	0.19	Acne (severe);	chr11:65742553	chr11:65745729~65771585:+
THCA	cis	rs8077577	0.708	rs7211573	ENSG00000273018.4	CTD-2303H24.2	4.22	2.95e-05	0.00269	0.29	0.19	Obesity-related traits;	chr17:18228299	chr17:18511221~18551705:-
THCA	cis	rs7474896	0.583	rs10764144	ENSG00000226578.1	RP11-258F22.1	-4.22	2.95e-05	0.00269	-0.26	-0.19	Obesity (extreme);	chr10:37686804	chr10:37775371~37784131:-
THCA	cis	rs786425	0.683	rs11572920	ENSG00000270095.1	RP11-214K3.18	-4.22	2.95e-05	0.00269	-0.23	-0.19	Pubertal anthropometrics;	chr12:123635436	chr12:123971457~123971714:-
THCA	cis	rs548181	0.736	rs556884	ENSG00000254671.2	STT3A-AS1	-4.22	2.95e-05	0.00269	-0.38	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125680154	chr11:125570284~125592568:-
THCA	cis	rs12612619	0.732	rs11677841	ENSG00000272148.1	RP11-195B17.1	4.22	2.95e-05	0.00269	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27017081	chr2:27062428~27062907:-
THCA	cis	rs801193	0.935	rs3800820	ENSG00000272831.1	RP11-792A8.4	-4.22	2.95e-05	0.00269	-0.12	-0.19	Aortic root size;	chr7:66682191	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs2003301	ENSG00000272831.1	RP11-792A8.4	-4.22	2.95e-05	0.00269	-0.12	-0.19	Aortic root size;	chr7:66682669	chr7:66739829~66740385:-
THCA	cis	rs9902453	0.874	rs7213517	ENSG00000263370.1	RP11-68I3.5	-4.22	2.95e-05	0.00269	-0.24	-0.19	Coffee consumption (cups per day);	chr17:30074722	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.904	rs7218379	ENSG00000263370.1	RP11-68I3.5	-4.22	2.95e-05	0.00269	-0.24	-0.19	Coffee consumption (cups per day);	chr17:30075719	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.817	rs7217961	ENSG00000263370.1	RP11-68I3.5	-4.22	2.95e-05	0.00269	-0.24	-0.19	Coffee consumption (cups per day);	chr17:30076094	chr17:29639627~29640825:+
THCA	cis	rs6715284	1	rs72934999	ENSG00000238829.1	RNU7-45P	-4.22	2.95e-05	0.00269	-0.45	-0.19	Rheumatoid arthritis;	chr2:201358801	chr2:201141904~201141966:+
THCA	cis	rs6715284	1	rs72937106	ENSG00000238829.1	RNU7-45P	-4.22	2.95e-05	0.00269	-0.45	-0.19	Rheumatoid arthritis;	chr2:201360797	chr2:201141904~201141966:+
THCA	cis	rs6715284	1	rs72937118	ENSG00000238829.1	RNU7-45P	-4.22	2.95e-05	0.00269	-0.45	-0.19	Rheumatoid arthritis;	chr2:201364804	chr2:201141904~201141966:+
THCA	cis	rs6472827	0.953	rs35446151	ENSG00000253983.2	RP1-16A9.1	-4.22	2.95e-05	0.00269	-0.31	-0.19	Uterine fibroids;	chr8:74209236	chr8:74199396~74208441:+
THCA	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	4.22	2.95e-05	0.00269	0.16	0.19	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
THCA	cis	rs7487075	0.93	rs11183468	ENSG00000272369.1	RP11-446N19.1	4.22	2.95e-05	0.00269	0.15	0.19	Itch intensity from mosquito bite;	chr12:46412478	chr12:46537502~46652550:+
THCA	cis	rs3738443	0.645	rs55768801	ENSG00000259865.1	RP11-488L18.10	4.22	2.95e-05	0.00269	0.17	0.19	Alcohol dependence;	chr1:247199688	chr1:247187281~247188526:-
THCA	cis	rs11098499	0.618	rs35265692	ENSG00000249244.1	RP11-548H18.2	4.22	2.95e-05	0.0027	0.22	0.19	Corneal astigmatism;	chr4:119403980	chr4:119391831~119395335:-
THCA	cis	rs72928364	1	rs2576369	ENSG00000256628.3	ZBTB11-AS1	-4.22	2.95e-05	0.0027	-0.3	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100899311	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.932	rs2245266	ENSG00000256628.3	ZBTB11-AS1	-4.22	2.95e-05	0.0027	-0.3	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100899929	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs2713793	ENSG00000256628.3	ZBTB11-AS1	-4.22	2.95e-05	0.0027	-0.3	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100900330	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.932	rs9832195	ENSG00000256628.3	ZBTB11-AS1	-4.22	2.95e-05	0.0027	-0.3	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100903548	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs2713789	ENSG00000256628.3	ZBTB11-AS1	-4.22	2.95e-05	0.0027	-0.3	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100904560	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.872	rs2713787	ENSG00000256628.3	ZBTB11-AS1	-4.22	2.95e-05	0.0027	-0.3	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100905594	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs4060963	ENSG00000256628.3	ZBTB11-AS1	-4.22	2.95e-05	0.0027	-0.3	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100905717	chr3:101676475~101679217:+
THCA	cis	rs1334894	0.584	rs2067997	ENSG00000228559.1	RP3-340B19.3	4.22	2.95e-05	0.0027	0.3	0.19	Coronary artery disease;	chr6:35503469	chr6:35544632~35545669:+
THCA	cis	rs607541	1	rs593126	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.95e-05	0.0027	-0.27	-0.19	Obesity-related traits;	chr15:45643579	chr15:45251580~45279251:-
THCA	cis	rs607541	1	rs644493	ENSG00000259520.4	CTD-2651B20.3	-4.22	2.95e-05	0.0027	-0.27	-0.19	Obesity-related traits;	chr15:45643618	chr15:45251580~45279251:-
THCA	cis	rs801193	0.569	rs2659907	ENSG00000229886.1	RP5-1132H15.3	4.22	2.95e-05	0.0027	0.2	0.19	Aortic root size;	chr7:66699045	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	4.22	2.95e-05	0.0027	0.22	0.19	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
THCA	cis	rs12234571	1	rs76940820	ENSG00000214293.7	APTR	4.22	2.95e-05	0.0027	0.24	0.19	Obesity-related traits;	chr7:77904997	chr7:77657660~77696265:-
THCA	cis	rs42648	0.935	rs42635	ENSG00000225498.1	AC002064.5	4.22	2.95e-05	0.0027	0.2	0.19	Homocysteine levels;	chr7:90336884	chr7:90312496~90322592:+
THCA	cis	rs2562456	0.876	rs2650844	ENSG00000268521.1	VN1R83P	4.22	2.95e-05	0.0027	0.18	0.19	Pain;	chr19:21419288	chr19:21289554~21289998:-
THCA	cis	rs7474896	0.832	rs11011426	ENSG00000263064.2	RP11-291L22.7	4.22	2.96e-05	0.0027	0.34	0.19	Obesity (extreme);	chr10:38025128	chr10:38448689~38448949:+
THCA	cis	rs2562456	0.755	rs2562421	ENSG00000268658.4	LINC00664	-4.22	2.96e-05	0.0027	-0.28	-0.19	Pain;	chr19:21448502	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.793	rs2562420	ENSG00000268658.4	LINC00664	-4.22	2.96e-05	0.0027	-0.28	-0.19	Pain;	chr19:21448503	chr19:21483374~21503238:+
THCA	cis	rs1842579	0.898	rs6576790	ENSG00000272691.1	RP11-290M5.4	-4.22	2.96e-05	0.0027	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85808906	chr1:85578500~85578742:-
THCA	cis	rs7122539	0.734	rs2513658	ENSG00000275484.1	CTC-1337H24.4	4.22	2.96e-05	0.0027	0.14	0.19	HIV-1 susceptibility;	chr11:66860778	chr11:67374416~67374932:+
THCA	cis	rs6570726	0.764	rs448258	ENSG00000270638.1	RP3-466P17.1	4.22	2.96e-05	0.0027	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145735570~145737218:+
THCA	cis	rs6121246	0.559	rs6058468	ENSG00000230613.1	HM13-AS1	4.22	2.96e-05	0.0027	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31818645	chr20:31567707~31573263:-
THCA	cis	rs4660214	0.666	rs596062	ENSG00000228060.1	RP11-69E11.8	-4.22	2.96e-05	0.0027	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39360333	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs61783383	ENSG00000228060.1	RP11-69E11.8	4.22	2.96e-05	0.0027	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341346	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs6704246	ENSG00000228060.1	RP11-69E11.8	4.22	2.96e-05	0.0027	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39343612	chr1:39565160~39573203:+
THCA	cis	rs481331	0.5	rs210260	ENSG00000215146.4	RP11-313J2.1	-4.22	2.96e-05	0.0027	-0.3	-0.19	Systemic juvenile idiopathic arthritis;	chr10:42542439	chr10:42331866~42367974:-
THCA	cis	rs4713118	0.588	rs200994	ENSG00000261839.1	RP1-265C24.8	-4.22	2.96e-05	0.0027	-0.22	-0.19	Parkinson's disease;	chr6:27846035	chr6:28136849~28139678:+
THCA	cis	rs1560104	0.675	rs8063669	ENSG00000262801.4	U91319.1	4.22	2.96e-05	0.0027	0.22	0.19	Obesity-related traits;	chr16:12603379	chr16:13246316~13562918:+
THCA	cis	rs2278702	0.943	rs78815690	ENSG00000259495.2	RP11-210M15.2	-4.22	2.96e-05	0.0027	-0.28	-0.19	Bipolar disorder;	chr15:80391946	chr15:80344853~80403575:-
THCA	cis	rs2278702	0.943	rs57525871	ENSG00000259495.2	RP11-210M15.2	-4.22	2.96e-05	0.0027	-0.28	-0.19	Bipolar disorder;	chr15:80392605	chr15:80344853~80403575:-
THCA	cis	rs12928939	0.517	rs12934512	ENSG00000260886.1	TAT-AS1	4.22	2.96e-05	0.0027	0.27	0.19	Post bronchodilator FEV1;	chr16:71931327	chr16:71565789~71578187:+
THCA	cis	rs12928939	0.517	rs12445641	ENSG00000260886.1	TAT-AS1	4.22	2.96e-05	0.0027	0.27	0.19	Post bronchodilator FEV1;	chr16:71933880	chr16:71565789~71578187:+
THCA	cis	rs12928939	0.517	rs12149325	ENSG00000260886.1	TAT-AS1	4.22	2.96e-05	0.0027	0.27	0.19	Post bronchodilator FEV1;	chr16:71934244	chr16:71565789~71578187:+
THCA	cis	rs1728785	1	rs7195979	ENSG00000274698.1	RP11-71L14.4	4.22	2.96e-05	0.0027	0.28	0.19	Ulcerative colitis;	chr16:68552898	chr16:68450283~68452318:+
THCA	cis	rs11758351	1	rs75921373	ENSG00000216331.1	HIST1H1PS1	4.22	2.96e-05	0.0027	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26191615	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs41266807	ENSG00000216331.1	HIST1H1PS1	4.22	2.96e-05	0.0027	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26199594	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs16891397	ENSG00000216331.1	HIST1H1PS1	4.22	2.96e-05	0.0027	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26200028	chr6:26195566~26195771:+
THCA	cis	rs12234571	1	rs58575675	ENSG00000214293.7	APTR	4.22	2.96e-05	0.0027	0.24	0.19	Obesity-related traits;	chr7:77809175	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs58695035	ENSG00000214293.7	APTR	4.22	2.96e-05	0.0027	0.24	0.19	Obesity-related traits;	chr7:77809177	chr7:77657660~77696265:-
THCA	cis	rs2251260	1	rs2251244	ENSG00000232774.6	FLJ22447	-4.22	2.96e-05	0.00271	-0.29	-0.19	Yeast infection;	chr14:61556546	chr14:61570540~61658696:+
THCA	cis	rs13256369	1	rs12550762	ENSG00000254153.1	CTA-398F10.2	-4.22	2.97e-05	0.00271	-0.21	-0.19	Obesity-related traits;	chr8:8719025	chr8:8456909~8461337:-
THCA	cis	rs2360027	0.627	rs1213905	ENSG00000231365.4	RP11-418J17.1	4.22	2.97e-05	0.00271	0.17	0.19	Tonsillectomy;	chr1:118562278	chr1:119140396~119275973:+
THCA	cis	rs8027521	0.666	rs11071013	ENSG00000280362.1	RP11-643A5.3	4.22	2.97e-05	0.00271	0.24	0.19	Circulating chemerin levels;	chr15:53973487	chr15:53910769~53914712:+
THCA	cis	rs11822910	0.911	rs11828218	ENSG00000265566.2	RN7SL605P	4.22	2.97e-05	0.00271	0.29	0.19	Platelet distribution width;	chr11:57428750	chr11:57528085~57528365:-
THCA	cis	rs75504410	0.579	rs337621	ENSG00000231160.8	KLF3-AS1	-4.22	2.97e-05	0.00271	-0.14	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38621801	chr4:38612701~38664883:-
THCA	cis	rs2030746	0.836	rs6724056	ENSG00000237614.1	AC073257.2	4.22	2.97e-05	0.00271	0.23	0.19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120549811	chr2:120542909~120544326:-
THCA	cis	rs2153535	0.585	rs11243268	ENSG00000230939.1	RP11-314C16.1	-4.22	2.97e-05	0.00271	-0.2	-0.19	Motion sickness;	chr6:8662375	chr6:8784178~8785445:+
THCA	cis	rs2836950	0.527	rs2836958	ENSG00000238141.2	BRWD1-AS1	-4.22	2.97e-05	0.00271	-0.22	-0.19	Menarche (age at onset);	chr21:39251600	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.565	rs7278297	ENSG00000238141.2	BRWD1-AS1	-4.22	2.97e-05	0.00271	-0.22	-0.19	Menarche (age at onset);	chr21:39253826	chr21:39315707~39323218:+
THCA	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	4.22	2.97e-05	0.00271	0.22	0.19	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	4.22	2.97e-05	0.00271	0.22	0.19	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
THCA	cis	rs481331	0.8	rs9422635	ENSG00000215146.4	RP11-313J2.1	4.22	2.97e-05	0.00271	0.33	0.19	Systemic juvenile idiopathic arthritis;	chr10:42663717	chr10:42331866~42367974:-
THCA	cis	rs1577917	0.545	rs7755958	ENSG00000220563.1	PKMP3	4.22	2.97e-05	0.00271	0.14	0.19	Response to antipsychotic treatment;	chr6:85778793	chr6:85659892~85660606:-
THCA	cis	rs9393777	0.778	rs4452638	ENSG00000220721.1	OR1F12	-4.22	2.97e-05	0.00271	-0.37	-0.19	Intelligence (multi-trait analysis);	chr6:27261486	chr6:28073316~28074233:+
THCA	cis	rs709400	1	rs61995780	ENSG00000258735.1	LINC00637	4.22	2.97e-05	0.00271	0.25	0.19	Body mass index;	chr14:103654275	chr14:103847721~103858049:+
THCA	cis	rs709400	1	rs57218990	ENSG00000258735.1	LINC00637	4.22	2.97e-05	0.00271	0.25	0.19	Body mass index;	chr14:103661670	chr14:103847721~103858049:+
THCA	cis	rs4713118	0.869	rs6922574	ENSG00000220721.1	OR1F12	4.22	2.97e-05	0.00271	0.25	0.19	Parkinson's disease;	chr6:27725224	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.869	rs9348775	ENSG00000220721.1	OR1F12	4.22	2.97e-05	0.00271	0.25	0.19	Parkinson's disease;	chr6:27727550	chr6:28073316~28074233:+
THCA	cis	rs897984	0.806	rs8050588	ENSG00000275263.1	RP11-1072A3.4	-4.22	2.97e-05	0.00271	-0.22	-0.19	Dementia with Lewy bodies;	chr16:30926478	chr16:30956872~30957199:-
THCA	cis	rs1842579	1	rs11161687	ENSG00000272691.1	RP11-290M5.4	-4.22	2.97e-05	0.00271	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85835957	chr1:85578500~85578742:-
THCA	cis	rs2380220	0.541	rs72928283	ENSG00000261366.1	MANEA-AS1	4.22	2.97e-05	0.00271	0.21	0.19	Behavioural disinhibition (generation interaction);	chr6:95634614	chr6:95575183~95577450:-
THCA	cis	rs61270009	0.955	rs390856	ENSG00000247828.6	TMEM161B-AS1	4.22	2.97e-05	0.00271	0.17	0.19	Depressive symptoms;	chr5:88251742	chr5:88268895~88436685:+
THCA	cis	rs8067545	0.611	rs1992561	ENSG00000270091.1	RP11-78O7.2	4.22	2.97e-05	0.00271	0.14	0.19	Schizophrenia;	chr17:20315806	chr17:19896590~19897287:-
THCA	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	4.22	2.97e-05	0.00271	0.23	0.19	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000182586.6	LINC00334	-4.22	2.97e-05	0.00271	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45234340~45258730:+
THCA	cis	rs78487399	0.731	rs72790940	ENSG00000234936.1	AC010883.5	4.22	2.97e-05	0.00271	0.24	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43541406	chr2:43229573~43233394:+
THCA	cis	rs8077577	0.895	rs62073615	ENSG00000273018.4	CTD-2303H24.2	-4.22	2.97e-05	0.00271	-0.32	-0.19	Obesity-related traits;	chr17:18177015	chr17:18511221~18551705:-
THCA	cis	rs5015933	0.767	rs12339434	ENSG00000232630.1	PRPS1P2	-4.22	2.97e-05	0.00271	-0.13	-0.19	Body mass index;	chr9:125376602	chr9:125150653~125151589:+
THCA	cis	rs5015933	0.864	rs10819049	ENSG00000232630.1	PRPS1P2	-4.22	2.97e-05	0.00271	-0.13	-0.19	Body mass index;	chr9:125376805	chr9:125150653~125151589:+
THCA	cis	rs57221529	0.655	rs11948381	ENSG00000225138.6	CTD-2228K2.7	4.22	2.97e-05	0.00271	0.22	0.19	Lung disease severity in cystic fibrosis;	chr5:568298	chr5:473236~480884:+
THCA	cis	rs12681366	0.537	rs2919664	ENSG00000261437.1	RP11-22C11.2	4.22	2.97e-05	0.00271	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94456485	chr8:94637285~94639467:-
THCA	cis	rs1371614	0.566	rs11695406	ENSG00000272148.1	RP11-195B17.1	-4.22	2.97e-05	0.00271	-0.17	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26955261	chr2:27062428~27062907:-
THCA	cis	rs6751744	0.772	rs11901769	ENSG00000226266.5	AC009961.3	-4.22	2.97e-05	0.00271	-0.24	-0.19	Dysphagia;	chr2:159489746	chr2:159670708~159712435:-
THCA	cis	rs4908768	1	rs12122666	ENSG00000232912.4	RP5-1115A15.1	4.22	2.97e-05	0.00271	0.22	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8681379	chr1:8424645~8434838:+
THCA	cis	rs9510787	0.538	rs3794346	ENSG00000205861.10	C1QTNF9B-AS1	-4.22	2.97e-05	0.00271	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23654875	chr13:23888889~23897263:+
THCA	cis	rs797680	0.598	rs3754186	ENSG00000223745.6	RP4-717I23.3	4.22	2.97e-05	0.00271	0.11	0.19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93246225	chr1:93262186~93346025:-
THCA	cis	rs11955398	0.522	rs329624	ENSG00000272308.1	RP11-231G3.1	-4.22	2.97e-05	0.00271	-0.2	-0.19	Intelligence (multi-trait analysis);	chr5:60989310	chr5:60866457~60866935:-
THCA	cis	rs11955398	0.502	rs162251	ENSG00000272308.1	RP11-231G3.1	-4.22	2.97e-05	0.00271	-0.2	-0.19	Intelligence (multi-trait analysis);	chr5:60996457	chr5:60866457~60866935:-
THCA	cis	rs11955398	0.502	rs162249	ENSG00000272308.1	RP11-231G3.1	-4.22	2.97e-05	0.00271	-0.2	-0.19	Intelligence (multi-trait analysis);	chr5:60999753	chr5:60866457~60866935:-
THCA	cis	rs7520050	0.778	rs12404197	ENSG00000280836.1	AL355480.1	4.22	2.97e-05	0.00271	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.801	rs6703960	ENSG00000280836.1	AL355480.1	4.22	2.97e-05	0.00271	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45581219~45581321:-
THCA	cis	rs1346	0.58	rs10750763	ENSG00000245532.5	NEAT1	4.22	2.97e-05	0.00271	0.14	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65600963	chr11:65422774~65445540:+
THCA	cis	rs9549367	0.577	rs3024713	ENSG00000269125.1	RP11-98F14.11	-4.22	2.97e-05	0.00271	-0.26	-0.19	Platelet distribution width;	chr13:113159007	chr13:113165002~113165183:-
THCA	cis	rs9926296	0.607	rs11076629	ENSG00000260259.1	RP11-368I7.4	-4.22	2.97e-05	0.00271	-0.2	-0.19	Vitiligo;	chr16:89808851	chr16:89682620~89686569:-
THCA	cis	rs9393777	0.777	rs56114371	ENSG00000220721.1	OR1F12	4.22	2.97e-05	0.00271	0.43	0.19	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28073316~28074233:+
THCA	cis	rs4845570	1	rs4845570	ENSG00000249602.1	RP11-98D18.3	4.22	2.97e-05	0.00271	0.27	0.19	Coronary artery disease;	chr1:151786628	chr1:151763384~151769501:-
THCA	cis	rs1387259	0.839	rs7487682	ENSG00000273765.1	RP11-370I10.11	-4.22	2.97e-05	0.00271	-0.19	-0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48360920~48361377:+
THCA	cis	rs10761482	0.954	rs10761475	ENSG00000254271.1	RP11-131N11.4	4.22	2.98e-05	0.00271	0.25	0.19	Schizophrenia;	chr10:60301499	chr10:60734342~60741828:+
THCA	cis	rs12893668	0.703	rs4906337	ENSG00000244691.1	RPL10AP1	-4.22	2.98e-05	0.00271	-0.27	-0.19	Reticulocyte count;	chr14:103574077	chr14:103412119~103412761:-
THCA	cis	rs12893668	0.703	rs7140568	ENSG00000244691.1	RPL10AP1	-4.22	2.98e-05	0.00271	-0.27	-0.19	Reticulocyte count;	chr14:103575037	chr14:103412119~103412761:-
THCA	cis	rs12893668	0.703	rs35026580	ENSG00000244691.1	RPL10AP1	-4.22	2.98e-05	0.00271	-0.27	-0.19	Reticulocyte count;	chr14:103576416	chr14:103412119~103412761:-
THCA	cis	rs875971	1	rs10244498	ENSG00000229886.1	RP5-1132H15.3	4.22	2.98e-05	0.00271	0.2	0.19	Aortic root size;	chr7:66651069	chr7:66025126~66031544:-
THCA	cis	rs9905704	0.647	rs3809723	ENSG00000224738.1	AC099850.1	4.22	2.98e-05	0.00271	0.23	0.19	Testicular germ cell tumor;	chr17:58984617	chr17:59106598~59118267:+
THCA	cis	rs801193	1	rs2659909	ENSG00000275400.1	RP4-756H11.5	-4.22	2.98e-05	0.00271	-0.18	-0.19	Aortic root size;	chr7:66695292	chr7:66553805~66554199:-
THCA	cis	rs7493	0.901	rs11764079	ENSG00000233942.1	AC004012.1	-4.22	2.98e-05	0.00271	-0.29	-0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95396917	chr7:95471835~95473998:+
THCA	cis	rs4947019	0.609	rs4946972	ENSG00000223537.2	RP5-919F19.5	-4.22	2.98e-05	0.00271	-0.35	-0.19	Hematological parameters;	chr6:109400025	chr6:109487906~109506800:+
THCA	cis	rs9532669	0.89	rs9532676	ENSG00000229473.2	RGS17P1	4.22	2.98e-05	0.00271	0.24	0.19	Cervical cancer;	chr13:40935626	chr13:40992779~40993331:-
THCA	cis	rs1923243	0.649	rs9970090	ENSG00000223479.3	RP4-788P17.1	-4.22	2.98e-05	0.00271	-0.2	-0.19	Migraine;	chr1:72916673	chr1:73635216~73715214:+
THCA	cis	rs2944755	0.959	rs2977491	ENSG00000279766.1	RP11-642A1.2	-4.22	2.98e-05	0.00272	-0.27	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140564178	chr8:140572142~140572812:-
THCA	cis	rs897984	0.806	rs8052245	ENSG00000275263.1	RP11-1072A3.4	4.22	2.98e-05	0.00272	0.23	0.19	Dementia with Lewy bodies;	chr16:30905109	chr16:30956872~30957199:-
THCA	cis	rs1048886	0.872	rs12216376	ENSG00000271967.1	RP11-134K13.4	4.22	2.98e-05	0.00272	0.2	0.19	Type 2 diabetes;	chr6:70568521	chr6:70596438~70596980:+
THCA	cis	rs875971	1	rs11971949	ENSG00000229886.1	RP5-1132H15.3	-4.22	2.98e-05	0.00272	-0.2	-0.19	Aortic root size;	chr7:66161027	chr7:66025126~66031544:-
THCA	cis	rs9291683	0.632	rs10939669	ENSG00000250413.1	RP11-448G15.1	-4.22	2.98e-05	0.00272	-0.18	-0.19	Bone mineral density;	chr4:10044203	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.632	rs11734375	ENSG00000250413.1	RP11-448G15.1	-4.22	2.98e-05	0.00272	-0.18	-0.19	Bone mineral density;	chr4:10044674	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.595	rs35250962	ENSG00000250413.1	RP11-448G15.1	-4.22	2.98e-05	0.00272	-0.18	-0.19	Bone mineral density;	chr4:10046647	chr4:10006482~10009725:+
THCA	cis	rs654950	0.775	rs28972757	ENSG00000230638.4	RP11-486B10.4	4.22	2.98e-05	0.00272	0.21	0.19	Airway imaging phenotypes;	chr1:41527342	chr1:41542069~41544310:+
THCA	cis	rs7474896	0.537	rs2505255	ENSG00000120555.12	SEPT7P9	4.22	2.98e-05	0.00272	0.25	0.19	Obesity (extreme);	chr10:38070714	chr10:38383069~38402916:-
THCA	cis	rs4973397	0.765	rs10445830	ENSG00000224376.1	AC017104.6	4.22	2.98e-05	0.00272	0.21	0.19	Anti-saccade response;	chr2:231399262	chr2:231388976~231394991:+
THCA	cis	rs1124769	0.748	rs2289304	ENSG00000259378.1	DCAF13P3	4.22	2.98e-05	0.00272	0.29	0.19	Cognitive performance;	chr15:50997198	chr15:50944663~50945996:+
THCA	cis	rs1003719	0.591	rs1053984	ENSG00000230366.8	DSCR9	4.22	2.98e-05	0.00272	0.2	0.19	Eye color traits;	chr21:37201717	chr21:37208503~37221736:+
THCA	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-4.22	2.98e-05	0.00272	-0.18	-0.19	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-4.22	2.98e-05	0.00272	-0.18	-0.19	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-4.22	2.98e-05	0.00272	-0.18	-0.19	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-4.22	2.98e-05	0.00272	-0.18	-0.19	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
THCA	cis	rs867186	1	rs114948279	ENSG00000126005.14	MMP24-AS1	-4.22	2.98e-05	0.00272	-0.3	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35145838	chr20:35216462~35278131:-
THCA	cis	rs9341808	0.667	rs806783	ENSG00000272129.1	RP11-250B2.6	-4.22	2.98e-05	0.00272	-0.25	-0.19	Sitting height ratio;	chr6:80233226	chr6:80355424~80356859:+
THCA	cis	rs6012564	0.58	rs6095352	ENSG00000227431.4	CSE1L-AS1	-4.22	2.98e-05	0.00272	-0.25	-0.19	Anger;	chr20:48895255	chr20:49040463~49046044:-
THCA	cis	rs7618915	0.781	rs12489732	ENSG00000243224.1	RP5-1157M23.2	-4.22	2.98e-05	0.00272	-0.21	-0.19	Bipolar disorder;	chr3:52532804	chr3:52239258~52241097:+
THCA	cis	rs17742757	0.522	rs28377323	ENSG00000254527.1	ENPP7P12	-4.22	2.98e-05	0.00272	-0.24	-0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11473262	chr8:12205759~12206389:-
THCA	cis	rs11220082	0.666	rs12224788	ENSG00000254671.2	STT3A-AS1	-4.22	2.98e-05	0.00272	-0.22	-0.19	Schizophrenia;	chr11:125459165	chr11:125570284~125592568:-
THCA	cis	rs62292953	0.591	rs11915472	ENSG00000248724.5	NPHP3-AS1	-4.22	2.98e-05	0.00272	-0.42	-0.19	Red cell distribution width;	chr3:132532097	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.591	rs11923334	ENSG00000248724.5	NPHP3-AS1	-4.22	2.98e-05	0.00272	-0.42	-0.19	Red cell distribution width;	chr3:132532106	chr3:132721750~132874223:+
THCA	cis	rs2613964	0.504	rs4682466	ENSG00000240057.4	RP11-572M11.4	4.22	2.98e-05	0.00272	0.19	0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130841	chr3:113019532~113183301:+
THCA	cis	rs13178541	0.872	rs4447978	ENSG00000250378.1	RP11-119J18.1	4.22	2.98e-05	0.00272	0.24	0.19	IgG glycosylation;	chr5:135839129	chr5:135812667~135826582:+
THCA	cis	rs454217	0.846	rs413415	ENSG00000277851.1	RP11-756G20.1	4.22	2.98e-05	0.00272	0.19	0.19	Smoking quantity;	chr12:92327115	chr12:92247756~92363832:-
THCA	cis	rs2070488	1	rs17733640	ENSG00000229589.1	ACVR2B-AS1	4.22	2.98e-05	0.00272	0.18	0.19	Electrocardiographic conduction measures;	chr3:38405251	chr3:38451027~38454820:-
THCA	cis	rs1046491	0.614	rs58098476	ENSG00000264964.1	RP11-888D10.3	4.22	2.98e-05	0.00272	0.36	0.19	Scarlet fever;	chr18:9302735	chr18:9315194~9334441:-
THCA	cis	rs7554547	0.765	rs2050270	ENSG00000199347.1	RNU5E-1	-4.22	2.98e-05	0.00272	-0.26	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11886399	chr1:11908152~11908271:+
THCA	cis	rs1232027	0.622	rs2897262	ENSG00000249655.1	CTC-325J23.2	-4.22	2.98e-05	0.00272	-0.21	-0.19	Huntington's disease progression;	chr5:80666857	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650670	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665030	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1382543	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665136	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1824837	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665422	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs6151612	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665469	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs6151613	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665470	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1824838	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665493	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.582	rs6151614	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665516	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.616	rs1824839	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665543	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.582	rs6151618	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665854	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.616	rs6151619	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665856	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.582	rs1677628	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80665962	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.616	rs1677629	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80666022	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677635	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80666349	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650667	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80666407	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650666	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80666620	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677638	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80666726	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677639	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80666729	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677640	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667045	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.588	rs1677641	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667100	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650664	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667204	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650663	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667378	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650662	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667468	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677642	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667499	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650661	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667544	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1650659	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667718	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650658	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80667832	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677643	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80668121	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1677644	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80668157	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.523	rs1650657	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80668430	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677645	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80668600	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1650656	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80668981	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650655	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80668989	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677647	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80668997	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650654	ENSG00000249655.1	CTC-325J23.2	4.22	2.98e-05	0.00272	0.21	0.19	Huntington's disease progression;	chr5:80669201	chr5:80630313~80631590:-
THCA	cis	rs3128341	1	rs6682389	ENSG00000227207.2	RPL31P12	4.22	2.98e-05	0.00272	0.3	0.19	Intelligence (multi-trait analysis);	chr1:72347374	chr1:72301472~72301829:+
THCA	cis	rs875971	0.545	rs2279757	ENSG00000273142.1	RP11-458F8.4	4.22	2.98e-05	0.00272	0.18	0.19	Aortic root size;	chr7:66363676	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000273142.1	RP11-458F8.4	4.22	2.98e-05	0.00272	0.18	0.19	Aortic root size;	chr7:66374173	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000273142.1	RP11-458F8.4	4.22	2.98e-05	0.00272	0.18	0.19	Aortic root size;	chr7:66387213	chr7:66902857~66906297:+
THCA	cis	rs2128382	0.556	rs10956502	ENSG00000253720.1	RP11-473O4.3	-4.22	2.98e-05	0.00272	-0.28	-0.19	Colorectal cancer;	chr8:129867769	chr8:129939856~129949394:+
THCA	cis	rs6806253	0.838	rs13094018	ENSG00000239405.1	TMED10P2	4.22	2.98e-05	0.00272	0.29	0.19	Pit-and-Fissure caries;	chr3:128560414	chr3:128538020~128538631:+
THCA	cis	rs12893668	0.703	rs2274267	ENSG00000244691.1	RPL10AP1	-4.22	2.99e-05	0.00272	-0.27	-0.19	Reticulocyte count;	chr14:103563112	chr14:103412119~103412761:-
THCA	cis	rs74233809	1	rs11191582	ENSG00000272912.1	RP11-724N1.1	-4.22	2.99e-05	0.00272	-0.36	-0.19	Birth weight;	chr10:103153896	chr10:102914585~102915404:+
THCA	cis	rs1414896	0.624	rs4949999	ENSG00000226026.4	RP11-57H12.3	-4.22	2.99e-05	0.00272	-0.18	-0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95186227	chr1:95163219~95233982:-
THCA	cis	rs62158800	0.598	rs12329017	ENSG00000224568.1	AC096669.3	4.22	2.99e-05	0.00272	0.24	0.19	Facial morphology (factor 22);	chr2:107668402	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.526	rs13408969	ENSG00000224568.1	AC096669.3	4.22	2.99e-05	0.00272	0.24	0.19	Facial morphology (factor 22);	chr2:107669138	chr2:107529487~107556326:+
THCA	cis	rs34421088	0.532	rs2736388	ENSG00000154316.13	TDH	-4.22	2.99e-05	0.00272	-0.14	-0.19	Neuroticism;	chr8:11302079	chr8:11339637~11368452:+
THCA	cis	rs1150668	0.796	rs728122	ENSG00000176933.5	TOB2P1	-4.22	2.99e-05	0.00272	-0.2	-0.19	Pubertal anthropometrics;	chr6:28431347	chr6:28217643~28218634:-
THCA	cis	rs1150668	0.799	rs1150705	ENSG00000220721.1	OR1F12	4.22	2.99e-05	0.00272	0.21	0.19	Pubertal anthropometrics;	chr6:28226008	chr6:28073316~28074233:+
THCA	cis	rs972578	0.791	rs2179259	ENSG00000274717.1	RP1-47A17.1	-4.22	2.99e-05	0.00272	-0.2	-0.19	Mean platelet volume;	chr22:43009062	chr22:42791814~42794313:-
THCA	cis	rs3020736	0.5	rs8138678	ENSG00000237037.8	NDUFA6-AS1	4.22	2.99e-05	0.00272	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42090931~42137742:+
THCA	cis	rs6496044	0.507	rs8034676	ENSG00000259276.1	RP11-815J21.3	-4.22	2.99e-05	0.00272	-0.21	-0.19	Interstitial lung disease;	chr15:85616031	chr15:85621264~85627689:-
THCA	cis	rs7424096	0.651	rs58370258	ENSG00000279519.1	RP11-288C18.1	4.22	2.99e-05	0.00272	0.16	0.19	High light scatter reticulocyte percentage of red cells;	chr2:36940048	chr2:36839922~36842539:-
THCA	cis	rs4906332	1	rs28711288	ENSG00000244691.1	RPL10AP1	-4.22	2.99e-05	0.00272	-0.24	-0.19	Coronary artery disease;	chr14:103439789	chr14:103412119~103412761:-
THCA	cis	rs7267979	1	rs6515651	ENSG00000276952.1	RP5-965G21.6	-4.22	2.99e-05	0.00272	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2424716	ENSG00000276952.1	RP5-965G21.6	4.22	2.99e-05	0.00272	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs761025	ENSG00000276952.1	RP5-965G21.6	4.22	2.99e-05	0.00272	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25284915~25285588:-
THCA	cis	rs6479891	1	rs9414799	ENSG00000272767.1	JMJD1C-AS1	4.22	2.99e-05	0.00272	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs4746119	ENSG00000272767.1	JMJD1C-AS1	4.22	2.99e-05	0.00272	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63465229~63466563:+
THCA	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	4.22	2.99e-05	0.00273	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
THCA	cis	rs1150668	0.83	rs2023493	ENSG00000176933.5	TOB2P1	-4.22	2.99e-05	0.00273	-0.21	-0.19	Pubertal anthropometrics;	chr6:28432385	chr6:28217643~28218634:-
THCA	cis	rs10875746	0.903	rs10875738	ENSG00000258273.1	RP11-370I10.4	4.22	2.99e-05	0.00273	0.28	0.19	Longevity (90 years and older);	chr12:48079956	chr12:48333755~48333901:-
THCA	cis	rs13113518	0.934	rs11935823	ENSG00000272969.1	RP11-528I4.2	4.22	2.99e-05	0.00273	0.22	0.19	Height;	chr4:55589624	chr4:55547112~55547889:+
THCA	cis	rs465969	0.744	rs79052344	ENSG00000272356.1	RP5-1112D6.8	4.22	2.99e-05	0.00273	0.28	0.19	Psoriasis;	chr6:111550755	chr6:111309203~111313517:+
THCA	cis	rs9650657	0.585	rs4841401	ENSG00000261451.1	RP11-981G7.1	-4.22	2.99e-05	0.00273	-0.24	-0.19	Neuroticism;	chr8:10632082	chr8:10433672~10438312:+
THCA	cis	rs15676	0.947	rs10988124	ENSG00000234771.3	SLC25A25-AS1	4.22	2.99e-05	0.00273	0.16	0.19	Blood metabolite levels;	chr9:128807066	chr9:128108581~128118693:-
THCA	cis	rs10761482	0.906	rs991405	ENSG00000254271.1	RP11-131N11.4	-4.22	2.99e-05	0.00273	-0.26	-0.19	Schizophrenia;	chr10:60334444	chr10:60734342~60741828:+
THCA	cis	rs4273100	1	rs16960158	ENSG00000263934.3	SNORD3A	4.22	2.99e-05	0.00273	0.29	0.19	Schizophrenia;	chr17:19259739	chr17:19188016~19188714:+
THCA	cis	rs12681366	0.511	rs2919670	ENSG00000261437.1	RP11-22C11.2	4.22	2.99e-05	0.00273	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94444390	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.537	rs2197004	ENSG00000261437.1	RP11-22C11.2	4.22	2.99e-05	0.00273	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94444748	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.537	rs2919667	ENSG00000261437.1	RP11-22C11.2	4.22	2.99e-05	0.00273	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94452974	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.537	rs2919656	ENSG00000261437.1	RP11-22C11.2	4.22	2.99e-05	0.00273	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94460806	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.537	rs3019284	ENSG00000261437.1	RP11-22C11.2	4.22	2.99e-05	0.00273	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94460848	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.537	rs2381886	ENSG00000261437.1	RP11-22C11.2	4.22	2.99e-05	0.00273	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94464825	chr8:94637285~94639467:-
THCA	cis	rs453301	0.606	rs7462373	ENSG00000233609.3	RP11-62H7.2	-4.22	2.99e-05	0.00273	-0.18	-0.19	Joint mobility (Beighton score);	chr8:9041808	chr8:8961200~8979025:+
THCA	cis	rs12234571	1	rs111703270	ENSG00000214293.7	APTR	4.22	2.99e-05	0.00273	0.24	0.19	Obesity-related traits;	chr7:77740119	chr7:77657660~77696265:-
THCA	cis	rs6479891	1	rs7087279	ENSG00000272767.1	JMJD1C-AS1	-4.22	2.99e-05	0.00273	-0.27	-0.19	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63465229~63466563:+
THCA	cis	rs2980439	0.517	rs793753	ENSG00000254153.1	CTA-398F10.2	4.22	2.99e-05	0.00273	0.21	0.19	Neuroticism;	chr8:8247837	chr8:8456909~8461337:-
THCA	cis	rs7847628	0.765	rs10985024	ENSG00000270917.1	RP11-27I1.6	-4.22	2.99e-05	0.00273	-0.29	-0.19	Birth weight;	chr9:120754534	chr9:120812475~120812845:-
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000280107.1	AL022393.9	-4.22	2.99e-05	0.00273	-0.19	-0.19	Pubertal anthropometrics;	chr6:28294921	chr6:28170845~28172521:+
THCA	cis	rs763121	0.853	rs6519120	ENSG00000273076.1	RP3-508I15.22	-4.22	2.99e-05	0.00273	-0.19	-0.19	Menopause (age at onset);	chr22:38595388	chr22:38743495~38743910:+
THCA	cis	rs2439831	0.681	rs7168940	ENSG00000205771.5	CATSPER2P1	-4.22	2.99e-05	0.00273	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43341136	chr15:43726918~43747094:-
THCA	cis	rs6494488	0.5	rs112640485	ENSG00000259635.1	AC100830.3	-4.22	2.99e-05	0.00273	-0.49	-0.19	Coronary artery disease;	chr15:64448611	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741336	ENSG00000259635.1	AC100830.3	-4.22	2.99e-05	0.00273	-0.49	-0.19	Coronary artery disease;	chr15:64465718	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs112190405	ENSG00000259635.1	AC100830.3	-4.22	2.99e-05	0.00273	-0.49	-0.19	Coronary artery disease;	chr15:64473826	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741344	ENSG00000259635.1	AC100830.3	-4.22	2.99e-05	0.00273	-0.49	-0.19	Coronary artery disease;	chr15:64475332	chr15:64701248~64719602:+
THCA	cis	rs4819052	0.851	rs1056099	ENSG00000273796.1	LL21NC02-21A1.1	-4.22	2.99e-05	0.00273	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.851	rs2236446	ENSG00000273796.1	LL21NC02-21A1.1	-4.22	2.99e-05	0.00273	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45403809~45404369:-
THCA	cis	rs9316337	0.933	rs1409071	ENSG00000236953.1	ZDHHC20-IT1	4.22	2.99e-05	0.00273	0.2	0.19	Schizophrenia;	chr13:21388634	chr13:21376977~21377874:-
THCA	cis	rs7968440	1	rs2684900	ENSG00000272368.2	RP4-605O3.4	4.22	3e-05	0.00273	0.12	0.19	Fibrinogen;	chr12:50625773	chr12:50112197~50165618:+
THCA	cis	rs7968440	0.933	rs2700480	ENSG00000272368.2	RP4-605O3.4	4.22	3e-05	0.00273	0.12	0.19	Fibrinogen;	chr12:50628648	chr12:50112197~50165618:+
THCA	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-4.22	3e-05	0.00273	-0.21	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
THCA	cis	rs9625935	0.833	rs5752968	ENSG00000279159.1	RP3-394A18.1	4.22	3e-05	0.00273	0.15	0.19	Tonsillectomy;	chr22:29837457	chr22:29978950~30028236:-
THCA	cis	rs728616	0.681	rs55838345	ENSG00000225484.5	NUTM2B-AS1	-4.21	3e-05	0.00273	-0.34	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80325364	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs61859191	ENSG00000225484.5	NUTM2B-AS1	-4.21	3e-05	0.00273	-0.34	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80331271	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs17678338	ENSG00000225484.5	NUTM2B-AS1	-4.21	3e-05	0.00273	-0.34	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80338390	chr10:79663088~79826594:-
THCA	cis	rs9650657	0.504	rs6986032	ENSG00000255046.1	RP11-297N6.4	4.21	3e-05	0.00273	0.2	0.19	Neuroticism;	chr8:11174731	chr8:11797928~11802568:-
THCA	cis	rs12440869	1	rs4597266	ENSG00000270964.1	RP11-502I4.3	-4.21	3e-05	0.00273	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67287643	chr15:67541072~67542604:-
THCA	cis	rs17594362	0.573	rs12429969	ENSG00000264190.1	MIR5006	4.21	3e-05	0.00273	0.36	0.19	Multiple sclerosis;	chr13:41545706	chr13:41568286~41568395:-
THCA	cis	rs9435732	1	rs2076600	ENSG00000186301.8	MST1P2	-4.21	3e-05	0.00273	-0.17	-0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17010896	chr1:16645622~16650289:+
THCA	cis	rs12440869	1	rs8032438	ENSG00000270964.1	RP11-502I4.3	4.21	3e-05	0.00273	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67323615	chr15:67541072~67542604:-
THCA	cis	rs2617170	0.961	rs1841957	ENSG00000245648.1	RP11-277P12.20	4.21	3e-05	0.00273	0.19	0.19	Behcet's disease;	chr12:10409426	chr12:10363769~10398506:+
THCA	cis	rs343092	0.935	rs2257883	ENSG00000241749.4	RPSAP52	4.21	3e-05	0.00273	0.22	0.19	Type 2 diabetes;	chr12:65822382	chr12:65758020~65826997:-
THCA	cis	rs897876	0.817	rs840795	ENSG00000281920.1	RP11-418H16.1	4.21	3e-05	0.00273	0.24	0.19	Pulse pressure in young-onset hypertension;	chr2:65551256	chr2:65623272~65628424:+
THCA	cis	rs6600671	1	rs4844381	ENSG00000275585.1	CH17-118O6.3	-4.21	3e-05	0.00273	-0.23	-0.19	Hip geometry;	chr1:121443040	chr1:120985692~121052167:-
THCA	cis	rs459482	0.504	rs469073	ENSG00000228318.3	AP001610.5	4.21	3e-05	0.00273	0.24	0.19	IgG glycosylation;	chr21:41444274	chr21:41441056~41445708:-
THCA	cis	rs9900062	0.586	rs6504250	ENSG00000270714.1	MINOS1P2	-4.21	3e-05	0.00273	-0.27	-0.19	QT interval;	chr17:64684435	chr17:64747264~64747492:-
THCA	cis	rs4619206	1	rs4619206	ENSG00000243663.1	RPS4XP14	-4.21	3e-05	0.00274	-0.19	-0.19	Lung cancer in ever smokers;	chr12:893691	chr12:1757231~1758011:-
THCA	cis	rs10895987	0.531	rs11227120	ENSG00000255200.1	AP003068.18	4.21	3e-05	0.00274	0.26	0.19	Blood protein levels;	chr11:65097387	chr11:65174117~65176470:-
THCA	cis	rs2898290	0.622	rs978803	ENSG00000254527.1	ENPP7P12	4.21	3e-05	0.00274	0.24	0.19	Systolic blood pressure;	chr8:11485966	chr8:12205759~12206389:-
THCA	cis	rs890448	0.774	rs6848852	ENSG00000254531.1	FLJ20021	4.21	3e-05	0.00274	0.17	0.19	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101526997	chr4:101347780~101348883:+
THCA	cis	rs4743820	0.503	rs10820834	ENSG00000235641.4	LINC00484	4.21	3e-05	0.00274	0.23	0.19	Ulcerative colitis;Inflammatory bowel disease;	chr9:91155158	chr9:91159573~91165658:+
THCA	cis	rs804280	0.509	rs10109241	ENSG00000206014.6	OR7E161P	-4.21	3e-05	0.00274	-0.23	-0.19	Myopia (pathological);	chr8:11927476	chr8:11928597~11929563:-
THCA	cis	rs9311474	0.629	rs7639267	ENSG00000243224.1	RP5-1157M23.2	-4.21	3e-05	0.00274	-0.2	-0.19	Electroencephalogram traits;	chr3:52534789	chr3:52239258~52241097:+
THCA	cis	rs4971059	0.629	rs11264333	ENSG00000236675.1	MTX1P1	-4.21	3e-05	0.00274	-0.18	-0.19	Breast cancer;	chr1:155135811	chr1:155230975~155234325:+
THCA	cis	rs12143943	0.866	rs4252726	ENSG00000240219.1	RP11-430C7.5	4.21	3.01e-05	0.00274	0.17	0.19	Cognitive performance;	chr1:204544274	chr1:204626775~204629712:+
THCA	cis	rs12143943	0.834	rs10900598	ENSG00000240219.1	RP11-430C7.5	4.21	3.01e-05	0.00274	0.17	0.19	Cognitive performance;	chr1:204556440	chr1:204626775~204629712:+
THCA	cis	rs12143943	0.866	rs12030639	ENSG00000240219.1	RP11-430C7.5	4.21	3.01e-05	0.00274	0.17	0.19	Cognitive performance;	chr1:204561796	chr1:204626775~204629712:+
THCA	cis	rs12143943	0.866	rs12032618	ENSG00000240219.1	RP11-430C7.5	4.21	3.01e-05	0.00274	0.17	0.19	Cognitive performance;	chr1:204563531	chr1:204626775~204629712:+
THCA	cis	rs12549025	0.715	rs10503726	ENSG00000253390.1	CTC-756D1.2	-4.21	3.01e-05	0.00274	-0.29	-0.19	Reticulocyte fraction of red cells;	chr8:23539753	chr8:23458601~23484971:+
THCA	cis	rs67981189	0.821	rs12896370	ENSG00000269927.1	RP6-91H8.3	4.21	3.01e-05	0.00274	0.22	0.19	Schizophrenia;	chr14:71054623	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.821	rs2286310	ENSG00000269927.1	RP6-91H8.3	4.21	3.01e-05	0.00274	0.22	0.19	Schizophrenia;	chr14:71056888	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.821	rs61990419	ENSG00000269927.1	RP6-91H8.3	4.21	3.01e-05	0.00274	0.22	0.19	Schizophrenia;	chr14:71069570	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.784	rs58984901	ENSG00000269927.1	RP6-91H8.3	4.21	3.01e-05	0.00274	0.22	0.19	Schizophrenia;	chr14:71085271	chr14:71141125~71143253:-
THCA	cis	rs1494961	0.523	rs28828184	ENSG00000213608.5	SLC25A14P1	-4.21	3.01e-05	0.00274	-0.23	-0.19	Oral cavity and pharyngeal cancer;	chr4:83521179	chr4:83477524~83478424:+
THCA	cis	rs9905704	0.647	rs12944274	ENSG00000224738.1	AC099850.1	-4.21	3.01e-05	0.00274	-0.23	-0.19	Testicular germ cell tumor;	chr17:58963932	chr17:59106598~59118267:+
THCA	cis	rs7824557	0.591	rs2736283	ENSG00000154316.13	TDH	4.21	3.01e-05	0.00274	0.14	0.19	Retinal vascular caliber;	chr8:11368401	chr8:11339637~11368452:+
THCA	cis	rs10760158	0.832	rs10513365	ENSG00000226752.6	PSMD5-AS1	-4.21	3.01e-05	0.00274	-0.23	-0.19	Pulse pressure;	chr9:121258647	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.768	rs2149805	ENSG00000226752.6	PSMD5-AS1	-4.21	3.01e-05	0.00274	-0.23	-0.19	Pulse pressure;	chr9:121259221	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs4837826	ENSG00000226752.6	PSMD5-AS1	-4.21	3.01e-05	0.00274	-0.23	-0.19	Pulse pressure;	chr9:121261851	chr9:120824828~120854385:+
THCA	cis	rs1728785	1	rs7202306	ENSG00000274698.1	RP11-71L14.4	4.21	3.01e-05	0.00274	0.27	0.19	Ulcerative colitis;	chr16:68553781	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.688	rs7203363	ENSG00000274698.1	RP11-71L14.4	4.21	3.01e-05	0.00274	0.27	0.19	Ulcerative colitis;	chr16:68553789	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.892	rs1103955	ENSG00000274698.1	RP11-71L14.4	4.21	3.01e-05	0.00274	0.27	0.19	Ulcerative colitis;	chr16:68554585	chr16:68450283~68452318:+
THCA	cis	rs4919694	0.536	rs12414777	ENSG00000213061.2	PFN1P11	4.21	3.01e-05	0.00274	0.28	0.19	Arsenic metabolism;	chr10:102938024	chr10:102838011~102845473:-
THCA	cis	rs2223471	0.967	rs3765306	ENSG00000060303.5	RPS17P5	4.21	3.01e-05	0.00274	0.23	0.19	Subcutaneous adipose tissue;	chr6:50745071	chr6:50857255~50857662:-
THCA	cis	rs2732480	0.5	rs7315820	ENSG00000273765.1	RP11-370I10.11	4.21	3.01e-05	0.00274	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48360920~48361377:+
THCA	cis	rs2688482	0.557	rs2550236	ENSG00000207650.1	MIR570	4.21	3.01e-05	0.00274	0.25	0.19	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195699401~195699497:+
THCA	cis	rs1075265	0.568	rs7604357	ENSG00000272156.1	RP11-477N3.1	4.21	3.01e-05	0.00274	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54082554~54085066:+
THCA	cis	rs17270561	0.609	rs4711096	ENSG00000272462.2	U91328.19	-4.21	3.01e-05	0.00274	-0.16	-0.19	Iron status biomarkers;	chr6:25726826	chr6:25992662~26001775:+
THCA	cis	rs875971	0.895	rs7788984	ENSG00000230189.5	GS1-124K5.2	4.21	3.01e-05	0.00274	0.12	0.19	Aortic root size;	chr7:66450629	chr7:66409143~66490059:-
THCA	cis	rs2839186	0.814	rs2839167	ENSG00000215424.8	MCM3AP-AS1	4.21	3.01e-05	0.00274	0.11	0.19	Testicular germ cell tumor;	chr21:46241673	chr21:46229217~46259390:+
THCA	cis	rs2286503	0.839	rs2240728	ENSG00000228649.7	AC005682.5	4.21	3.01e-05	0.00274	0.23	0.19	Fibrinogen;	chr7:22812880	chr7:22854178~22861579:+
THCA	cis	rs10129255	0.556	rs9324093	ENSG00000211970.3	IGHV4-61	-4.21	3.01e-05	0.00274	-0.11	-0.19	Kawasaki disease;	chr14:106683893	chr14:106639119~106639657:-
THCA	cis	rs7772486	0.79	rs6926657	ENSG00000270638.1	RP3-466P17.1	-4.21	3.01e-05	0.00274	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145735570~145737218:+
THCA	cis	rs6442522	0.64	rs2655258	ENSG00000249786.6	EAF1-AS1	4.21	3.01e-05	0.00274	0.2	0.19	Uric acid levels;	chr3:15484387	chr3:15436171~15455940:-
THCA	cis	rs10833905	1	rs112686297	ENSG00000246225.5	RP11-17A1.3	-4.21	3.01e-05	0.00274	-0.27	-0.19	Sudden cardiac arrest;	chr11:23001448	chr11:22829380~22945393:+
THCA	cis	rs919433	0.647	rs13404366	ENSG00000231621.1	AC013264.2	-4.21	3.01e-05	0.00274	-0.21	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197657908	chr2:197197991~197199273:+
THCA	cis	rs7259376	0.84	rs8106611	ENSG00000269138.1	ZNF209P	4.21	3.01e-05	0.00274	0.19	0.19	Menopause (age at onset);	chr19:22386816	chr19:22463922~22473036:+
THCA	cis	rs494526	0.899	rs3740553	ENSG00000229272.1	RP11-498J9.2	-4.21	3.01e-05	0.00274	-0.21	-0.19	Alcoholic chronic pancreatitis;	chr10:119044234	chr10:119003536~119003884:-
THCA	cis	rs6430538	0.671	rs13390951	ENSG00000224043.6	CCNT2-AS1	-4.21	3.01e-05	0.00274	-0.21	-0.19	Parkinson's disease;	chr2:134824558	chr2:134735464~134918710:-
THCA	cis	rs9573567	0.609	rs79938109	ENSG00000261553.4	RP11-29G8.3	-4.21	3.01e-05	0.00274	-0.37	-0.19	Red blood cell count;Mean corpuscular volume;	chr13:75467476	chr13:75549773~75807120:+
THCA	cis	rs6517329	0.61	rs11088339	ENSG00000230212.5	AP000688.14	-4.21	3.01e-05	0.00274	-0.24	-0.19	Schizophrenia;	chr21:36126696	chr21:36069642~36126640:-
THCA	cis	rs786425	0.804	rs11057320	ENSG00000270095.1	RP11-214K3.18	-4.21	3.01e-05	0.00274	-0.22	-0.19	Pubertal anthropometrics;	chr12:123656815	chr12:123971457~123971714:-
THCA	cis	rs1783925	0.529	rs11220072	ENSG00000254671.2	STT3A-AS1	-4.21	3.01e-05	0.00274	-0.23	-0.19	Formal thought disorder in schizophrenia;	chr11:125436560	chr11:125570284~125592568:-
THCA	cis	rs4578769	0.918	rs4800138	ENSG00000265939.1	UBE2CP2	-4.21	3.01e-05	0.00274	-0.23	-0.19	Eosinophil percentage of white cells;	chr18:22934334	chr18:22900486~22900995:-
THCA	cis	rs7829975	0.774	rs1703982	ENSG00000253981.4	ALG1L13P	-4.21	3.01e-05	0.00274	-0.18	-0.19	Mood instability;	chr8:8740878	chr8:8236003~8244667:-
THCA	cis	rs6921919	0.583	rs2071965	ENSG00000273712.1	RP5-874C20.7	4.21	3.02e-05	0.00274	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28315613~28315883:-
THCA	cis	rs459571	0.959	rs392134	ENSG00000235106.7	LINC00094	4.21	3.02e-05	0.00275	0.17	0.19	Platelet distribution width;	chr9:134043886	chr9:134025439~134034666:+
THCA	cis	rs9326246	0.545	rs491022	ENSG00000254851.1	RP11-109L13.1	4.21	3.02e-05	0.00275	0.44	0.19	Coronary artery disease;	chr11:116651271	chr11:117135528~117138582:+
THCA	cis	rs755249	1	rs4660303	ENSG00000237624.1	OXCT2P1	4.21	3.02e-05	0.00275	0.26	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594801	chr1:39514956~39516490:+
THCA	cis	rs962856	1	rs6722203	ENSG00000236780.4	AC078941.1	4.21	3.02e-05	0.00275	0.23	0.19	Pancreatic cancer;	chr2:67342061	chr2:67123357~67215319:-
THCA	cis	rs17685	0.632	rs1859793	ENSG00000230882.1	AC005077.14	4.21	3.02e-05	0.00275	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76191965	chr7:76071469~76074963:-
THCA	cis	rs3764021	0.87	rs2401393	ENSG00000256594.6	RP11-705C15.2	4.21	3.02e-05	0.00275	0.15	0.19	Type 1 diabetes;	chr12:9726488	chr12:9633419~9658412:+
THCA	cis	rs17723470	0.55	rs7128207	ENSG00000254427.1	RP11-430H10.1	-4.21	3.02e-05	0.00275	-0.18	-0.19	Thyroid hormone levels;	chr11:45208510	chr11:45355371~45366121:+
THCA	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-4.21	3.02e-05	0.00275	-0.12	-0.19	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
THCA	cis	rs9393813	0.967	rs1883403	ENSG00000204789.4	ZNF204P	-4.21	3.02e-05	0.00275	-0.15	-0.19	Bipolar disorder;	chr6:27382550	chr6:27357825~27360221:-
THCA	cis	rs6828577	0.779	rs419292	ENSG00000281731.1	RP11-384K6.8	-4.21	3.02e-05	0.00275	-0.22	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118712975	chr4:118664087~118685341:-
THCA	cis	rs6828577	0.819	rs368669	ENSG00000281731.1	RP11-384K6.8	-4.21	3.02e-05	0.00275	-0.22	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118713120	chr4:118664087~118685341:-
THCA	cis	rs16915157	0.557	rs74659950	ENSG00000254271.1	RP11-131N11.4	4.21	3.02e-05	0.00275	0.41	0.19	Schizophrenia;	chr10:60573859	chr10:60734342~60741828:+
THCA	cis	rs4819052	1	rs13052356	ENSG00000273796.1	LL21NC02-21A1.1	-4.21	3.02e-05	0.00275	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45403809~45404369:-
THCA	cis	rs67478160	0.643	rs2024667	ENSG00000269940.1	RP11-73M18.7	4.21	3.02e-05	0.00275	0.18	0.19	Schizophrenia;	chr14:103745192	chr14:103694560~103695170:+
THCA	cis	rs4925386	0.959	rs6121989	ENSG00000275437.1	RP5-908M14.10	-4.21	3.02e-05	0.00275	-0.18	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62402236~62405935:-
THCA	cis	rs77637988	0.604	rs7566239	ENSG00000202227.1	RNU6-282P	4.21	3.02e-05	0.00275	0.2	0.19	Joint mobility (Beighton score);	chr2:48371743	chr2:48501922~48502024:-
THCA	cis	rs786425	0.627	rs7133734	ENSG00000270095.1	RP11-214K3.18	-4.21	3.02e-05	0.00275	-0.23	-0.19	Pubertal anthropometrics;	chr12:123712188	chr12:123971457~123971714:-
THCA	cis	rs9843304	0.528	rs9860963	ENSG00000243885.1	RP11-278L15.2	-4.21	3.02e-05	0.00275	-0.21	-0.19	Gallstone disease;	chr3:149479678	chr3:149384179~149385800:-
THCA	cis	rs3820928	0.647	rs2115597	ENSG00000212391.1	SNORA48	-4.21	3.02e-05	0.00275	-0.21	-0.19	Pulmonary function;	chr2:226926502	chr2:226968989~226969122:-
THCA	cis	rs8067545	0.75	rs9915758	ENSG00000270091.1	RP11-78O7.2	-4.21	3.02e-05	0.00275	-0.14	-0.19	Schizophrenia;	chr17:20061462	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs9897246	ENSG00000270091.1	RP11-78O7.2	-4.21	3.02e-05	0.00275	-0.14	-0.19	Schizophrenia;	chr17:20062389	chr17:19896590~19897287:-
THCA	cis	rs7259376	0.936	rs8110854	ENSG00000269138.1	ZNF209P	4.21	3.02e-05	0.00275	0.19	0.19	Menopause (age at onset);	chr19:22366651	chr19:22463922~22473036:+
THCA	cis	rs481331	0.866	rs1831915	ENSG00000215146.4	RP11-313J2.1	4.21	3.02e-05	0.00275	0.3	0.19	Systemic juvenile idiopathic arthritis;	chr10:42494262	chr10:42331866~42367974:-
THCA	cis	rs4788570	0.615	rs10852503	ENSG00000260185.1	RP11-432I5.6	-4.21	3.02e-05	0.00275	-0.36	-0.19	Intelligence (multi-trait analysis);	chr16:71618324	chr16:71655027~71664212:+
THCA	cis	rs7511006	0.893	rs760743	ENSG00000272836.1	RP3-402G11.27	-4.21	3.02e-05	0.00275	-0.16	-0.19	Obesity-related traits;	chr22:50208946	chr22:50205585~50206062:-
THCA	cis	rs739496	0.615	rs630616	ENSG00000226469.1	ADAM1B	4.21	3.02e-05	0.00275	0.24	0.19	Platelet count;	chr12:111721162	chr12:111927018~111929017:+
THCA	cis	rs3096299	0.632	rs4399533	ENSG00000261118.1	RP11-104N10.1	4.21	3.02e-05	0.00275	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89492017~89504460:-
THCA	cis	rs4950322	1	rs4950322	ENSG00000226015.2	CCT8P1	-4.21	3.02e-05	0.00275	-0.24	-0.19	Protein quantitative trait loci;	chr1:147383114	chr1:147203276~147204932:-
THCA	cis	rs962856	1	rs962856	ENSG00000236780.4	AC078941.1	4.21	3.02e-05	0.00275	0.23	0.19	Pancreatic cancer;	chr2:67366671	chr2:67123357~67215319:-
THCA	cis	rs6570726	0.791	rs10457788	ENSG00000270638.1	RP3-466P17.1	4.21	3.02e-05	0.00275	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145735570~145737218:+
THCA	cis	rs4660214	0.666	rs11205698	ENSG00000182109.6	RP11-69E11.4	-4.21	3.03e-05	0.00275	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39158708	chr1:39522280~39546187:-
THCA	cis	rs6570726	0.764	rs9399553	ENSG00000270638.1	RP3-466P17.1	4.21	3.03e-05	0.00275	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145735570~145737218:+
THCA	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-4.21	3.03e-05	0.00275	-0.22	-0.19	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
THCA	cis	rs7182948	1	rs8040436	ENSG00000259531.2	RP11-295H24.3	-4.21	3.03e-05	0.00275	-0.22	-0.19	Lung adenocarcinoma;	chr15:49522831	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs1605480	ENSG00000259531.2	RP11-295H24.3	-4.21	3.03e-05	0.00275	-0.22	-0.19	Lung adenocarcinoma;	chr15:49526646	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs1546424	ENSG00000259531.2	RP11-295H24.3	-4.21	3.03e-05	0.00275	-0.22	-0.19	Lung adenocarcinoma;	chr15:49531030	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs1546425	ENSG00000259531.2	RP11-295H24.3	-4.21	3.03e-05	0.00275	-0.22	-0.19	Lung adenocarcinoma;	chr15:49531152	chr15:49365124~49366685:-
THCA	cis	rs875971	1	rs9986696	ENSG00000230189.5	GS1-124K5.2	-4.21	3.03e-05	0.00276	-0.12	-0.19	Aortic root size;	chr7:66239589	chr7:66409143~66490059:-
THCA	cis	rs6570726	0.764	rs9403733	ENSG00000270638.1	RP3-466P17.1	4.21	3.03e-05	0.00276	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.738	rs6917199	ENSG00000270638.1	RP3-466P17.1	4.21	3.03e-05	0.00276	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145735570~145737218:+
THCA	cis	rs711244	0.748	rs11124555	ENSG00000279519.1	RP11-288C18.1	4.21	3.03e-05	0.00276	0.16	0.19	Mean platelet volume;	chr2:36949070	chr2:36839922~36842539:-
THCA	cis	rs9532669	1	rs9532669	ENSG00000229473.2	RGS17P1	4.21	3.03e-05	0.00276	0.24	0.19	Cervical cancer;	chr13:40927414	chr13:40992779~40993331:-
THCA	cis	rs10761482	0.861	rs10821728	ENSG00000254271.1	RP11-131N11.4	4.21	3.03e-05	0.00276	0.25	0.19	Schizophrenia;	chr10:60339377	chr10:60734342~60741828:+
THCA	cis	rs9880211	0.752	rs9881831	ENSG00000239213.4	NCK1-AS1	4.21	3.03e-05	0.00276	0.22	0.19	Height;Body mass index;	chr3:136670876	chr3:136841726~136862054:-
THCA	cis	rs8077577	0.943	rs62072467	ENSG00000273018.4	CTD-2303H24.2	-4.21	3.03e-05	0.00276	-0.33	-0.19	Obesity-related traits;	chr17:18213141	chr17:18511221~18551705:-
THCA	cis	rs8105895	0.935	rs62112364	ENSG00000269345.1	VN1R85P	4.21	3.03e-05	0.00276	0.26	0.19	Body mass index (change over time);	chr19:22112101	chr19:22174766~22175191:-
THCA	cis	rs6570726	0.791	rs446362	ENSG00000270638.1	RP3-466P17.1	4.21	3.03e-05	0.00276	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs414600	ENSG00000270638.1	RP3-466P17.1	4.21	3.03e-05	0.00276	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs6915094	ENSG00000270638.1	RP3-466P17.1	4.21	3.03e-05	0.00276	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs365869	ENSG00000270638.1	RP3-466P17.1	4.21	3.03e-05	0.00276	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145735570~145737218:+
THCA	cis	rs7586879	0.593	rs10200566	ENSG00000224165.4	DNAJC27-AS1	4.21	3.03e-05	0.00276	0.11	0.19	Body mass index;	chr2:24907593	chr2:24971390~25039694:+
THCA	cis	rs7914558	0.966	rs11191438	ENSG00000213061.2	PFN1P11	4.21	3.03e-05	0.00276	0.23	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102838011~102845473:-
THCA	cis	rs1075265	0.633	rs4671190	ENSG00000272156.1	RP11-477N3.1	4.21	3.03e-05	0.00276	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54082554~54085066:+
THCA	cis	rs4805272	0.962	rs55811684	ENSG00000267799.1	MAN1A2P1	4.21	3.03e-05	0.00276	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28828842	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs4804854	ENSG00000267799.1	MAN1A2P1	4.21	3.03e-05	0.00276	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829151	chr19:28790812~28792871:-
THCA	cis	rs2286503	0.78	rs929464	ENSG00000226329.2	AC005682.6	4.21	3.03e-05	0.00276	0.24	0.19	Fibrinogen;	chr7:22835151	chr7:22863874~22881350:-
THCA	cis	rs6570726	0.935	rs407721	ENSG00000270638.1	RP3-466P17.1	4.21	3.04e-05	0.00276	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs408768	ENSG00000270638.1	RP3-466P17.1	4.21	3.04e-05	0.00276	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145735570~145737218:+
THCA	cis	rs9467773	0.595	rs2172007	ENSG00000124549.13	BTN2A3P	4.21	3.04e-05	0.00276	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26421391~26432383:+
THCA	cis	rs801193	0.548	rs2659891	ENSG00000229886.1	RP5-1132H15.3	4.21	3.04e-05	0.00276	0.2	0.19	Aortic root size;	chr7:66736127	chr7:66025126~66031544:-
THCA	cis	rs801193	0.548	rs7805152	ENSG00000229886.1	RP5-1132H15.3	4.21	3.04e-05	0.00276	0.2	0.19	Aortic root size;	chr7:66744266	chr7:66025126~66031544:-
THCA	cis	rs454217	0.846	rs2119575	ENSG00000277851.1	RP11-756G20.1	4.21	3.04e-05	0.00276	0.19	0.19	Smoking quantity;	chr12:92309812	chr12:92247756~92363832:-
THCA	cis	rs9880211	0.8	rs9873536	ENSG00000239213.4	NCK1-AS1	4.21	3.04e-05	0.00276	0.22	0.19	Height;Body mass index;	chr3:136755425	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.8	rs9813376	ENSG00000239213.4	NCK1-AS1	4.21	3.04e-05	0.00276	0.22	0.19	Height;Body mass index;	chr3:136756584	chr3:136841726~136862054:-
THCA	cis	rs801193	1	rs4717319	ENSG00000272831.1	RP11-792A8.4	4.21	3.04e-05	0.00276	0.12	0.19	Aortic root size;	chr7:66777606	chr7:66739829~66740385:-
THCA	cis	rs801193	0.904	rs4718403	ENSG00000272831.1	RP11-792A8.4	4.21	3.04e-05	0.00276	0.12	0.19	Aortic root size;	chr7:66777742	chr7:66739829~66740385:-
THCA	cis	rs6433895	0.71	rs11692625	ENSG00000236153.1	AC104076.3	-4.21	3.04e-05	0.00276	-0.24	-0.19	Lymphocyte counts;	chr2:181150757	chr2:180979427~180980090:-
THCA	cis	rs4950322	0.57	rs72691012	ENSG00000271721.1	RP11-337C18.9	4.21	3.04e-05	0.00276	0.21	0.19	Protein quantitative trait loci;	chr1:147239751	chr1:147175602~147177740:+
THCA	cis	rs12908161	1	rs17601029	ENSG00000188388.10	GOLGA6L3	4.21	3.04e-05	0.00276	0.25	0.19	Schizophrenia;	chr15:84804478	chr15:85240472~85247170:+
THCA	cis	rs10090774	0.71	rs11995103	ENSG00000279766.1	RP11-642A1.2	-4.21	3.04e-05	0.00276	-0.24	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140683162	chr8:140572142~140572812:-
THCA	cis	rs607541	1	rs8036075	ENSG00000259520.4	CTD-2651B20.3	-4.21	3.04e-05	0.00276	-0.27	-0.19	Obesity-related traits;	chr15:45642723	chr15:45251580~45279251:-
THCA	cis	rs9902453	0.967	rs11080121	ENSG00000263370.1	RP11-68I3.5	4.21	3.04e-05	0.00276	0.25	0.19	Coffee consumption (cups per day);	chr17:30201824	chr17:29639627~29640825:+
THCA	cis	rs7200786	0.692	rs1700818	ENSG00000274038.1	RP11-66H6.4	-4.21	3.04e-05	0.00276	-0.24	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10963412	chr16:11056556~11057034:+
THCA	cis	rs7520050	0.751	rs2991975	ENSG00000280836.1	AL355480.1	4.21	3.04e-05	0.00276	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45581219~45581321:-
THCA	cis	rs11756659	0.653	rs62394537	ENSG00000272462.2	U91328.19	4.21	3.04e-05	0.00276	0.19	0.19	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25963715	chr6:25992662~26001775:+
THCA	cis	rs12497850	0.931	rs11705888	ENSG00000228638.1	FCF1P2	-4.21	3.04e-05	0.00276	-0.21	-0.19	Parkinson's disease;	chr3:48779856	chr3:48290793~48291375:-
THCA	cis	rs227932	0.571	rs798641	ENSG00000234286.1	AC006026.13	4.21	3.04e-05	0.00276	0.39	0.19	Schizophrenia;	chr7:23581318	chr7:23680195~23680786:-
THCA	cis	rs2030746	0.899	rs11686154	ENSG00000237614.1	AC073257.2	4.21	3.04e-05	0.00276	0.23	0.19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120553361	chr2:120542909~120544326:-
THCA	cis	rs4879656	0.872	rs10813930	ENSG00000225693.1	LAGE3P1	-4.21	3.04e-05	0.00277	-0.2	-0.19	Menopause (age at onset);	chr9:33064338	chr9:33019682~33020165:-
THCA	cis	rs17095355	0.901	rs7069128	ENSG00000203876.8	ADD3-AS1	4.21	3.04e-05	0.00277	0.21	0.19	Biliary atresia;	chr10:110000317	chr10:109940104~110008381:-
THCA	cis	rs7826238	0.601	rs2979206	ENSG00000254153.1	CTA-398F10.2	-4.21	3.04e-05	0.00277	-0.22	-0.19	Systolic blood pressure;	chr8:8488071	chr8:8456909~8461337:-
THCA	cis	rs6416877	0.819	rs6502708	ENSG00000277491.1	RP11-676J12.9	-4.21	3.04e-05	0.00277	-0.23	-0.19	Myeloid white cell count;	chr17:1450472	chr17:795306~795794:+
THCA	cis	rs6570726	0.791	rs6570692	ENSG00000270638.1	RP3-466P17.1	4.21	3.04e-05	0.00277	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145735570~145737218:+
THCA	cis	rs1510552	0.882	rs78766172	ENSG00000270659.1	RP11-105N14.1	4.21	3.04e-05	0.00277	0.18	0.19	Contrast sensitivity;	chr2:214103084	chr2:213152970~213153659:+
THCA	cis	rs733592	1	rs1859440	ENSG00000269514.1	RP11-370I10.12	4.21	3.04e-05	0.00277	0.16	0.19	Plateletcrit;	chr12:48033546	chr12:48198387~48202031:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000275400.1	RP4-756H11.5	-4.21	3.04e-05	0.00277	-0.18	-0.19	Aortic root size;	chr7:65930047	chr7:66553805~66554199:-
THCA	cis	rs9291683	0.655	rs35750364	ENSG00000250413.1	RP11-448G15.1	-4.21	3.04e-05	0.00277	-0.18	-0.19	Bone mineral density;	chr4:10047425	chr4:10006482~10009725:+
THCA	cis	rs160451	0.782	rs1603288	ENSG00000251136.7	RP11-37B2.1	-4.21	3.04e-05	0.00277	-0.18	-0.19	Leprosy;	chr8:89701036	chr8:89609409~89757727:-
THCA	cis	rs17685	0.753	rs1637045	ENSG00000230882.1	AC005077.14	4.21	3.04e-05	0.00277	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76074577	chr7:76071469~76074963:-
THCA	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	4.21	3.04e-05	0.00277	0.27	0.19	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
THCA	cis	rs7772486	0.701	rs2244308	ENSG00000270638.1	RP3-466P17.1	4.21	3.04e-05	0.00277	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145735570~145737218:+
THCA	cis	rs1842579	0.932	rs4912446	ENSG00000272691.1	RP11-290M5.4	-4.21	3.04e-05	0.00277	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85837025	chr1:85578500~85578742:-
THCA	cis	rs10435719	0.647	rs10092605	ENSG00000206014.6	OR7E161P	-4.21	3.04e-05	0.00277	-0.23	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:11928597~11929563:-
THCA	cis	rs442309	1	rs224058	ENSG00000238280.1	RP11-436D10.3	4.21	3.04e-05	0.00277	0.22	0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62739105	chr10:62793562~62805887:-
THCA	cis	rs9840812	0.655	rs4452981	ENSG00000239213.4	NCK1-AS1	4.21	3.04e-05	0.00277	0.17	0.19	Fibrinogen levels;	chr3:136588925	chr3:136841726~136862054:-
THCA	cis	rs1950832	0.566	rs1900599	ENSG00000258636.1	CTD-2298J14.2	-4.21	3.04e-05	0.00277	-0.25	-0.19	Urate levels in obese individuals;	chr14:41671998	chr14:41587861~41604856:-
THCA	cis	rs6840360	0.547	rs9991859	ENSG00000251611.1	RP11-610P16.1	-4.21	3.04e-05	0.00277	-0.14	-0.19	Intelligence (multi-trait analysis);	chr4:151344420	chr4:151407551~151408835:-
THCA	cis	rs591584	0.73	rs10765688	ENSG00000255893.1	RP11-685N10.1	-4.21	3.04e-05	0.00277	-0.22	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94576693	chr11:94472908~94473570:-
THCA	cis	rs591584	0.73	rs72963850	ENSG00000255893.1	RP11-685N10.1	-4.21	3.04e-05	0.00277	-0.22	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94577566	chr11:94472908~94473570:-
THCA	cis	rs8031584	0.918	rs3817498	ENSG00000178081.11	ULK4P3	4.21	3.04e-05	0.00277	0.25	0.19	Huntington's disease progression;	chr15:30976578	chr15:30103720~30131757:+
THCA	cis	rs1728785	1	rs1645979	ENSG00000274698.1	RP11-71L14.4	4.21	3.04e-05	0.00277	0.28	0.19	Ulcerative colitis;	chr16:68569757	chr16:68450283~68452318:+
THCA	cis	rs875971	1	rs10257427	ENSG00000229886.1	RP5-1132H15.3	-4.21	3.05e-05	0.00277	-0.2	-0.19	Aortic root size;	chr7:66278221	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs10215948	ENSG00000229886.1	RP5-1132H15.3	-4.21	3.05e-05	0.00277	-0.2	-0.19	Aortic root size;	chr7:66282799	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs55748098	ENSG00000229886.1	RP5-1132H15.3	-4.21	3.05e-05	0.00277	-0.2	-0.19	Aortic root size;	chr7:66298631	chr7:66025126~66031544:-
THCA	cis	rs9902453	0.765	rs2250320	ENSG00000263370.1	RP11-68I3.5	-4.21	3.05e-05	0.00277	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29801639	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2467334	ENSG00000263370.1	RP11-68I3.5	-4.21	3.05e-05	0.00277	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29808490	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.817	rs2321333	ENSG00000263370.1	RP11-68I3.5	4.21	3.05e-05	0.00277	0.25	0.19	Coffee consumption (cups per day);	chr17:29813839	chr17:29639627~29640825:+
THCA	cis	rs2281603	0.762	rs10130241	ENSG00000272909.1	CTD-2555O16.4	-4.21	3.05e-05	0.00277	-0.25	-0.19	Lymphocyte counts;	chr14:64577402	chr14:64440369~64442238:-
THCA	cis	rs75059851	0.756	rs11223651	ENSG00000280237.1	MIR4697HG	-4.21	3.05e-05	0.00277	-0.22	-0.19	Schizophrenia;	chr11:133971139	chr11:133896438~133901601:-
THCA	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-4.21	3.05e-05	0.00277	-0.12	-0.19	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
THCA	cis	rs62158800	0.638	rs1155112	ENSG00000224568.1	AC096669.3	4.21	3.05e-05	0.00277	0.25	0.19	Facial morphology (factor 22);	chr2:107684908	chr2:107529487~107556326:+
THCA	cis	rs2028299	0.839	rs3844575	ENSG00000259677.1	RP11-493E3.1	4.21	3.05e-05	0.00277	0.25	0.19	Type 2 diabetes;	chr15:89900515	chr15:89876540~89877285:+
THCA	cis	rs1003719	0.667	rs8127148	ENSG00000230366.8	DSCR9	-4.21	3.05e-05	0.00277	-0.19	-0.19	Eye color traits;	chr21:37108992	chr21:37208503~37221736:+
THCA	cis	rs1048886	0.816	rs73489091	ENSG00000271967.1	RP11-134K13.4	-4.21	3.05e-05	0.00277	-0.2	-0.19	Type 2 diabetes;	chr6:70561813	chr6:70596438~70596980:+
THCA	cis	rs1009077	0.61	rs7670921	ENSG00000245958.5	RP11-33B1.1	-4.21	3.05e-05	0.00277	-0.22	-0.19	Endometriosis;	chr4:119597867	chr4:119454791~119552025:+
THCA	cis	rs4646450	0.735	rs2286162	ENSG00000244219.5	GS1-259H13.2	-4.21	3.05e-05	0.00277	-0.26	-0.19	Blood metabolite levels;	chr7:99358181	chr7:99598066~99610813:+
THCA	cis	rs2015599	0.56	rs3948497	ENSG00000273680.1	RP11-996F15.6	4.21	3.05e-05	0.00277	0.28	0.19	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29332733~29333383:-
THCA	cis	rs7246760	0.867	rs68041339	ENSG00000267106.4	ZNF561-AS1	4.21	3.05e-05	0.00277	0.35	0.19	Pursuit maintenance gain;	chr19:9708175	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs56377135	ENSG00000267106.4	ZNF561-AS1	4.21	3.05e-05	0.00277	0.35	0.19	Pursuit maintenance gain;	chr19:9709440	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs55914342	ENSG00000267106.4	ZNF561-AS1	4.21	3.05e-05	0.00277	0.35	0.19	Pursuit maintenance gain;	chr19:9713771	chr19:9621291~9645896:+
THCA	cis	rs7243790	0.774	rs7240534	ENSG00000277324.1	RP11-850A17.1	-4.21	3.05e-05	0.00277	-0.2	-0.19	Diastolic blood pressure;	chr18:54359527	chr18:54268346~54270028:-
THCA	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-4.21	3.05e-05	0.00277	-0.12	-0.19	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-4.21	3.05e-05	0.00277	-0.12	-0.19	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
THCA	cis	rs138024639	1	rs138024639	ENSG00000272009.1	RP1-313I6.12	-4.21	3.05e-05	0.00277	-0.36	-0.19	Breast cancer;	chr6:28468244	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs55690788	ENSG00000272009.1	RP1-313I6.12	-4.21	3.05e-05	0.00277	-0.36	-0.19	Depression;	chr6:28468368	chr6:28078792~28081130:-
THCA	cis	rs9532669	0.963	rs4343141	ENSG00000229473.2	RGS17P1	4.21	3.05e-05	0.00277	0.24	0.19	Cervical cancer;	chr13:40940497	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.963	rs3887418	ENSG00000229473.2	RGS17P1	4.21	3.05e-05	0.00277	0.24	0.19	Cervical cancer;	chr13:40940560	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs1056820	ENSG00000229473.2	RGS17P1	4.21	3.05e-05	0.00277	0.24	0.19	Cervical cancer;	chr13:40941150	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532678	ENSG00000229473.2	RGS17P1	4.21	3.05e-05	0.00277	0.24	0.19	Cervical cancer;	chr13:40941862	chr13:40992779~40993331:-
THCA	cis	rs12234571	1	rs6961117	ENSG00000214293.7	APTR	4.21	3.05e-05	0.00277	0.24	0.19	Obesity-related traits;	chr7:77769464	chr7:77657660~77696265:-
THCA	cis	rs1414896	0.646	rs12132107	ENSG00000226026.4	RP11-57H12.3	-4.21	3.05e-05	0.00277	-0.18	-0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95200088	chr1:95163219~95233982:-
THCA	cis	rs10875746	0.903	rs12301339	ENSG00000258273.1	RP11-370I10.4	4.21	3.05e-05	0.00277	0.28	0.19	Longevity (90 years and older);	chr12:48081450	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs886588	ENSG00000258273.1	RP11-370I10.4	4.21	3.05e-05	0.00277	0.28	0.19	Longevity (90 years and older);	chr12:48083639	chr12:48333755~48333901:-
THCA	cis	rs62158800	0.598	rs1606985	ENSG00000224568.1	AC096669.3	4.21	3.05e-05	0.00277	0.24	0.19	Facial morphology (factor 22);	chr2:107675347	chr2:107529487~107556326:+
THCA	cis	rs9625935	0.871	rs2412960	ENSG00000279159.1	RP3-394A18.1	4.21	3.05e-05	0.00277	0.15	0.19	Tonsillectomy;	chr22:29967459	chr22:29978950~30028236:-
THCA	cis	rs7968440	1	rs2731440	ENSG00000272368.2	RP4-605O3.4	4.21	3.05e-05	0.00277	0.12	0.19	Fibrinogen;	chr12:50663844	chr12:50112197~50165618:+
THCA	cis	rs7968440	1	rs2731439	ENSG00000272368.2	RP4-605O3.4	4.21	3.05e-05	0.00277	0.12	0.19	Fibrinogen;	chr12:50666567	chr12:50112197~50165618:+
THCA	cis	rs7045881	0.8	rs57890470	ENSG00000254396.1	RP11-56F10.3	4.21	3.05e-05	0.00278	0.34	0.19	Schizophrenia;	chr9:26909450	chr9:27102630~27104728:+
THCA	cis	rs9970896	0.85	rs10927063	ENSG00000237845.1	RP5-940F7.2	-4.21	3.05e-05	0.00278	-0.36	-0.19	Monocyte percentage of white cells;	chr1:235935148	chr1:235942553~235943805:-
THCA	cis	rs9970896	0.85	rs10927064	ENSG00000237845.1	RP5-940F7.2	-4.21	3.05e-05	0.00278	-0.36	-0.19	Monocyte percentage of white cells;	chr1:235935296	chr1:235942553~235943805:-
THCA	cis	rs881375	0.678	rs10760128	ENSG00000270917.1	RP11-27I1.6	-4.21	3.05e-05	0.00278	-0.26	-0.19	Rheumatoid arthritis;	chr9:120934047	chr9:120812475~120812845:-
THCA	cis	rs17767294	0.612	rs9461425	ENSG00000261839.1	RP1-265C24.8	4.21	3.05e-05	0.00278	0.3	0.19	Parkinson's disease;	chr6:27951910	chr6:28136849~28139678:+
THCA	cis	rs1979679	0.573	rs7134807	ENSG00000247934.4	RP11-967K21.1	-4.21	3.05e-05	0.00278	-0.19	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28576317	chr12:28163298~28190738:-
THCA	cis	rs786425	0.682	rs1139320	ENSG00000270095.1	RP11-214K3.18	-4.21	3.05e-05	0.00278	-0.23	-0.19	Pubertal anthropometrics;	chr12:123712552	chr12:123971457~123971714:-
THCA	cis	rs9652601	0.649	rs12599402	ENSG00000274038.1	RP11-66H6.4	-4.21	3.05e-05	0.00278	-0.23	-0.19	Systemic lupus erythematosus;	chr16:11096031	chr16:11056556~11057034:+
THCA	cis	rs2303759	0.666	rs66967196	ENSG00000268686.1	AC010524.2	-4.21	3.06e-05	0.00278	-0.29	-0.19	Multiple sclerosis;	chr19:49305637	chr19:49368705~49388081:-
THCA	cis	rs12612619	0.627	rs13391244	ENSG00000272148.1	RP11-195B17.1	-4.21	3.06e-05	0.00278	-0.19	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27064741	chr2:27062428~27062907:-
THCA	cis	rs2414856	0.51	rs73456908	ENSG00000259635.1	AC100830.3	-4.21	3.06e-05	0.00278	-0.45	-0.19	Pulse pressure;Systolic blood pressure;	chr15:64702905	chr15:64701248~64719602:+
THCA	cis	rs2033711	0.87	rs4801583	ENSG00000268049.1	CTD-2619J13.9	-4.21	3.06e-05	0.00278	-0.24	-0.19	Uric acid clearance;	chr19:58407038	chr19:58357999~58359603:+
THCA	cis	rs9283706	0.593	rs10068079	ENSG00000229666.1	MAST4-AS1	-4.21	3.06e-05	0.00278	-0.27	-0.19	Coronary artery disease;	chr5:66997816	chr5:67001383~67003953:-
THCA	cis	rs62184315	0.938	rs17806132	ENSG00000253559.1	OSGEPL1-AS1	4.21	3.06e-05	0.00278	0.27	0.19	Alcohol dependence (age at onset);	chr2:189843561	chr2:189762704~189765556:+
THCA	cis	rs4785204	1	rs7191384	ENSG00000279356.1	RP11-429P3.8	-4.21	3.06e-05	0.00278	-0.36	-0.19	Esophageal cancer (squamous cell);	chr16:50070323	chr16:50072862~50074986:+
THCA	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-4.21	3.06e-05	0.00278	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
THCA	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-4.21	3.06e-05	0.00278	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
THCA	cis	rs988712	0.672	rs16917237	ENSG00000245573.6	BDNF-AS	4.21	3.06e-05	0.00278	0.19	0.19	Obesity;	chr11:27680836	chr11:27506838~27698174:+
THCA	cis	rs6870983	0.895	rs193707	ENSG00000247828.6	TMEM161B-AS1	4.21	3.06e-05	0.00278	0.18	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88236441	chr5:88268895~88436685:+
THCA	cis	rs755249	0.833	rs61779313	ENSG00000237624.1	OXCT2P1	4.21	3.06e-05	0.00278	0.26	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39514956~39516490:+
THCA	cis	rs875971	0.965	rs697968	ENSG00000272831.1	RP11-792A8.4	-4.21	3.06e-05	0.00278	-0.12	-0.19	Aortic root size;	chr7:66070046	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs1183245	ENSG00000272831.1	RP11-792A8.4	-4.21	3.06e-05	0.00278	-0.12	-0.19	Aortic root size;	chr7:66076198	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs1144894	ENSG00000272831.1	RP11-792A8.4	-4.21	3.06e-05	0.00278	-0.12	-0.19	Aortic root size;	chr7:66077907	chr7:66739829~66740385:-
THCA	cis	rs2657294	1	rs2657294	ENSG00000226051.5	ZNF503-AS1	-4.21	3.06e-05	0.00278	-0.26	-0.19	Pneumonia;	chr10:75193267	chr10:75269819~75373500:+
THCA	cis	rs9840812	0.623	rs4678433	ENSG00000239213.4	NCK1-AS1	4.21	3.06e-05	0.00278	0.18	0.19	Fibrinogen levels;	chr3:136546840	chr3:136841726~136862054:-
THCA	cis	rs4591358	0.734	rs1553255	ENSG00000223466.1	AC064834.2	-4.21	3.06e-05	0.00278	-0.22	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195492147	chr2:195533035~195538681:+
THCA	cis	rs2839627	0.638	rs8134227	ENSG00000225218.1	AP001628.6	4.21	3.06e-05	0.00278	0.32	0.19	Information processing speed;	chr21:42837792	chr21:42831040~42836477:-
THCA	cis	rs7551222	0.614	rs4951385	ENSG00000240219.1	RP11-430C7.5	4.21	3.06e-05	0.00278	0.19	0.19	Schizophrenia;	chr1:204485037	chr1:204626775~204629712:+
THCA	cis	rs9625935	0.957	rs36605	ENSG00000279159.1	RP3-394A18.1	-4.21	3.06e-05	0.00278	-0.16	-0.19	Tonsillectomy;	chr22:29944367	chr22:29978950~30028236:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000234585.5	CCT6P3	4.21	3.06e-05	0.00278	0.17	0.19	Aortic root size;	chr7:65966699	chr7:65038354~65074713:+
THCA	cis	rs2434529	1	rs73804388	ENSG00000245275.6	SAP30L-AS1	4.21	3.06e-05	0.00278	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154295084	chr5:154329437~154445850:-
THCA	cis	rs2434529	0.868	rs7730945	ENSG00000245275.6	SAP30L-AS1	4.21	3.06e-05	0.00278	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154300142	chr5:154329437~154445850:-
THCA	cis	rs9902453	0.934	rs11080120	ENSG00000263370.1	RP11-68I3.5	4.21	3.06e-05	0.00278	0.24	0.19	Coffee consumption (cups per day);	chr17:30180003	chr17:29639627~29640825:+
THCA	cis	rs10266483	0.883	rs683689	ENSG00000271550.1	BNIP3P11	4.21	3.06e-05	0.00278	0.24	0.19	Response to statin therapy;	chr7:64282165	chr7:64678954~64687393:-
THCA	cis	rs11088226	0.801	rs2833886	ENSG00000186842.4	LINC00846	-4.21	3.06e-05	0.00278	-0.24	-0.19	Gastritis;	chr21:32551562	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.846	rs13047501	ENSG00000186842.4	LINC00846	-4.21	3.06e-05	0.00278	-0.24	-0.19	Gastritis;	chr21:32552350	chr21:32572238~32575881:-
THCA	cis	rs4805272	0.962	rs4387706	ENSG00000267799.1	MAN1A2P1	4.21	3.06e-05	0.00278	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834652	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.962	rs1363328	ENSG00000267799.1	MAN1A2P1	4.21	3.06e-05	0.00278	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834656	chr19:28790812~28792871:-
THCA	cis	rs1728785	0.901	rs6499186	ENSG00000274698.1	RP11-71L14.4	4.21	3.06e-05	0.00278	0.28	0.19	Ulcerative colitis;	chr16:68626662	chr16:68450283~68452318:+
THCA	cis	rs786425	0.868	rs786447	ENSG00000270095.1	RP11-214K3.18	4.21	3.06e-05	0.00278	0.22	0.19	Pubertal anthropometrics;	chr12:123585120	chr12:123971457~123971714:-
THCA	cis	rs293748	0.66	rs61748200	ENSG00000250155.1	CTD-2353F22.1	-4.21	3.06e-05	0.00278	-0.27	-0.19	Obesity-related traits;	chr5:37036390	chr5:36666214~36725195:-
THCA	cis	rs34929064	0.846	rs2905340	ENSG00000179428.2	AC073072.5	4.21	3.06e-05	0.00278	0.22	0.19	Major depression and alcohol dependence;	chr7:22687579	chr7:22725395~22727620:-
THCA	cis	rs2836974	0.932	rs13048178	ENSG00000255568.3	BRWD1-AS2	4.21	3.06e-05	0.00279	0.17	0.19	Cognitive function;	chr21:39189086	chr21:39313935~39314962:+
THCA	cis	rs6494488	0.5	rs72741328	ENSG00000259635.1	AC100830.3	-4.21	3.07e-05	0.00279	-0.49	-0.19	Coronary artery disease;	chr15:64442140	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741329	ENSG00000259635.1	AC100830.3	-4.21	3.07e-05	0.00279	-0.49	-0.19	Coronary artery disease;	chr15:64443892	chr15:64701248~64719602:+
THCA	cis	rs1836229	1	rs1434273	ENSG00000225706.1	PTPRD-AS1	-4.21	3.07e-05	0.00279	-0.22	-0.19	Restless legs syndrome;	chr9:8817060	chr9:8858130~8862255:+
THCA	cis	rs6600671	0.934	rs12060031	ENSG00000275585.1	CH17-118O6.3	4.21	3.07e-05	0.00279	0.24	0.19	Hip geometry;	chr1:121501652	chr1:120985692~121052167:-
THCA	cis	rs4763879	0.865	rs4763839	ENSG00000256673.1	RP11-599J14.2	4.21	3.07e-05	0.00279	0.24	0.19	Type 1 diabetes;	chr12:9730104	chr12:9398355~9414851:-
THCA	cis	rs4906332	0.754	rs34235720	ENSG00000252469.1	RNU7-160P	4.21	3.07e-05	0.00279	0.23	0.19	Coronary artery disease;	chr14:103538631	chr14:103550345~103550406:+
THCA	cis	rs3740713	1	rs73438631	ENSG00000256464.1	YWHABP2	4.21	3.07e-05	0.00279	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr11:18490243~18490955:-
THCA	cis	rs12440869	1	rs11639194	ENSG00000270964.1	RP11-502I4.3	4.21	3.07e-05	0.00279	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67347900	chr15:67541072~67542604:-
THCA	cis	rs7647973	0.696	rs3087866	ENSG00000228638.1	FCF1P2	-4.21	3.07e-05	0.00279	-0.23	-0.19	Menarche (age at onset);	chr3:49017259	chr3:48290793~48291375:-
THCA	cis	rs6088813	1	rs6087703	ENSG00000279253.1	RP4-614O4.13	4.21	3.07e-05	0.00279	0.19	0.19	Height;	chr20:35408630	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.857	rs6142378	ENSG00000279253.1	RP4-614O4.13	4.21	3.07e-05	0.00279	0.19	0.19	Height;	chr20:35409488	chr20:35262727~35264187:-
THCA	cis	rs73411413	0.661	rs11599981	ENSG00000233930.3	KRTAP5-AS1	-4.21	3.07e-05	0.00279	-0.25	-0.19	Myringotomy;	chr11:1498833	chr11:1571353~1599184:+
THCA	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	4.21	3.07e-05	0.00279	0.22	0.19	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	4.21	3.07e-05	0.00279	0.22	0.19	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	4.21	3.07e-05	0.00279	0.22	0.19	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
THCA	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-4.21	3.07e-05	0.00279	-0.22	-0.19	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
THCA	cis	rs67981189	0.821	rs8007026	ENSG00000269927.1	RP6-91H8.3	4.21	3.07e-05	0.00279	0.22	0.19	Schizophrenia;	chr14:70997667	chr14:71141125~71143253:-
THCA	cis	rs1009077	0.61	rs2389866	ENSG00000245958.5	RP11-33B1.1	-4.21	3.07e-05	0.00279	-0.22	-0.19	Endometriosis;	chr4:119594108	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.579	rs10032993	ENSG00000245958.5	RP11-33B1.1	-4.21	3.07e-05	0.00279	-0.22	-0.19	Endometriosis;	chr4:119595462	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.504	rs9998919	ENSG00000245958.5	RP11-33B1.1	-4.21	3.07e-05	0.00279	-0.22	-0.19	Endometriosis;	chr4:119595538	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.61	rs2389869	ENSG00000245958.5	RP11-33B1.1	-4.21	3.07e-05	0.00279	-0.22	-0.19	Endometriosis;	chr4:119596336	chr4:119454791~119552025:+
THCA	cis	rs6433895	0.667	rs35702511	ENSG00000236153.1	AC104076.3	-4.21	3.07e-05	0.00279	-0.24	-0.19	Lymphocyte counts;	chr2:181153379	chr2:180979427~180980090:-
THCA	cis	rs4660214	0.666	rs10888682	ENSG00000182109.6	RP11-69E11.4	-4.21	3.07e-05	0.00279	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157635	chr1:39522280~39546187:-
THCA	cis	rs2163813	1	rs247776	ENSG00000271499.1	CTC-559E9.9	-4.21	3.07e-05	0.00279	-0.24	-0.19	Toenail selenium levels;	chr19:19731806	chr19:19750618~19752544:+
THCA	cis	rs4713118	0.869	rs4713121	ENSG00000220721.1	OR1F12	4.21	3.07e-05	0.00279	0.26	0.19	Parkinson's disease;	chr6:27754285	chr6:28073316~28074233:+
THCA	cis	rs9926296	0.656	rs2376884	ENSG00000274627.1	RP11-104N10.2	-4.21	3.07e-05	0.00279	-0.2	-0.19	Vitiligo;	chr16:89760514	chr16:89516797~89522217:+
THCA	cis	rs9926296	0.656	rs2376883	ENSG00000274627.1	RP11-104N10.2	-4.21	3.07e-05	0.00279	-0.2	-0.19	Vitiligo;	chr16:89760518	chr16:89516797~89522217:+
THCA	cis	rs7294478	0.839	rs6487849	ENSG00000256967.1	RP11-273B20.1	4.21	3.07e-05	0.00279	0.15	0.19	Neuritic plaque;	chr12:7111103	chr12:7129079~7131198:-
THCA	cis	rs5758659	0.714	rs2413668	ENSG00000281538.1	RP4-669P10.20	-4.21	3.07e-05	0.00279	-0.17	-0.19	Cognitive function;	chr22:42109837	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.657	rs5758587	ENSG00000281538.1	RP4-669P10.20	-4.21	3.07e-05	0.00279	-0.17	-0.19	Cognitive function;	chr22:42121632	chr22:42138060~42139726:+
THCA	cis	rs1396485	0.607	rs7721593	ENSG00000248445.4	SEMA6A-AS1	-4.21	3.08e-05	0.00279	-0.18	-0.19	Inflammatory biomarkers;	chr5:116328360	chr5:116447547~116508276:+
THCA	cis	rs7267979	0.528	rs6076366	ENSG00000274414.1	RP5-965G21.4	4.21	3.08e-05	0.00279	0.23	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:25239007~25245229:-
THCA	cis	rs4767841	0.935	rs7299963	ENSG00000252886.1	RN7SKP197	-4.21	3.08e-05	0.00279	-0.19	-0.19	Urgency urinary incontinence;	chr12:119720398	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.935	rs3213625	ENSG00000252886.1	RN7SKP197	-4.21	3.08e-05	0.00279	-0.19	-0.19	Urgency urinary incontinence;	chr12:119720724	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.935	rs3213626	ENSG00000252886.1	RN7SKP197	-4.21	3.08e-05	0.00279	-0.19	-0.19	Urgency urinary incontinence;	chr12:119720736	chr12:119631090~119631386:-
THCA	cis	rs875971	0.522	rs4718286	ENSG00000275400.1	RP4-756H11.5	-4.21	3.08e-05	0.00279	-0.18	-0.19	Aortic root size;	chr7:65827777	chr7:66553805~66554199:-
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000275400.1	RP4-756H11.5	-4.21	3.08e-05	0.00279	-0.18	-0.19	Calcium levels;	chr7:65837419	chr7:66553805~66554199:-
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000275400.1	RP4-756H11.5	-4.21	3.08e-05	0.00279	-0.18	-0.19	Calcium levels;	chr7:65872915	chr7:66553805~66554199:-
THCA	cis	rs758324	0.687	rs473753	ENSG00000224431.1	AC063976.7	-4.21	3.08e-05	0.00279	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132165441	chr5:132199456~132203487:+
THCA	cis	rs8031584	0.918	rs61997138	ENSG00000270015.1	RP11-540B6.6	-4.21	3.08e-05	0.00279	-0.14	-0.19	Huntington's disease progression;	chr15:30978573	chr15:30926514~30928407:+
THCA	cis	rs10844706	0.73	rs12317499	ENSG00000214776.8	RP11-726G1.1	4.21	3.08e-05	0.00279	0.25	0.19	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9732764	chr12:9467552~9576275:+
THCA	cis	rs1035144	0.654	rs4903956	ENSG00000259167.2	NMNAT1P1	4.21	3.08e-05	0.0028	0.24	0.19	Male sexual orientation;	chr14:80978136	chr14:81032529~81033404:+
THCA	cis	rs11758351	1	rs80259160	ENSG00000216331.1	HIST1H1PS1	4.21	3.08e-05	0.0028	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26189971	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.929	rs75475698	ENSG00000216331.1	HIST1H1PS1	4.21	3.08e-05	0.0028	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26190381	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs78012445	ENSG00000216331.1	HIST1H1PS1	4.21	3.08e-05	0.0028	0.31	0.19	Renal underexcretion gout;Gout;	chr6:26194852	chr6:26195566~26195771:+
THCA	cis	rs17801127	0.818	rs17496121	ENSG00000231969.1	AC144449.1	4.21	3.08e-05	0.0028	0.33	0.19	Liver enzyme levels (alanine transaminase);	chr2:149654906	chr2:149587196~149848233:+
THCA	cis	rs4718428	0.924	rs6971897	ENSG00000229886.1	RP5-1132H15.3	4.21	3.08e-05	0.0028	0.2	0.19	Corneal structure;	chr7:66947787	chr7:66025126~66031544:-
THCA	cis	rs5758659	0.714	rs133373	ENSG00000273366.1	CTA-989H11.1	-4.21	3.08e-05	0.0028	-0.22	-0.19	Cognitive function;	chr22:42069784	chr22:42278188~42278846:+
THCA	cis	rs62158800	0.598	rs10175087	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107671547	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs6746783	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107672162	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs6747019	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107672377	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs1606987	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107673961	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs10177715	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107675826	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs6542728	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107676853	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs6542729	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107676878	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs1400118	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107677403	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs1568055	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107678382	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.638	rs1157314	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107679182	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs1543138	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107679537	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs1516204	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107680431	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs4676149	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107682249	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs10171365	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107683345	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.714	rs1533430	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107684470	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.673	rs1533429	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107684561	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.638	rs1155113	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107684805	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.638	rs1155111	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107685150	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.638	rs1155110	ENSG00000224568.1	AC096669.3	4.21	3.08e-05	0.0028	0.24	0.19	Facial morphology (factor 22);	chr2:107685214	chr2:107529487~107556326:+
THCA	cis	rs2033711	0.837	rs3764535	ENSG00000232098.3	CTD-2619J13.14	4.21	3.08e-05	0.0028	0.17	0.19	Uric acid clearance;	chr19:58417685	chr19:58404238~58408484:-
THCA	cis	rs4718428	1	rs1830070	ENSG00000237310.1	GS1-124K5.4	4.21	3.08e-05	0.0028	0.14	0.19	Corneal structure;	chr7:66884684	chr7:66493706~66495474:+
THCA	cis	rs6012564	0.893	rs4810896	ENSG00000227431.4	CSE1L-AS1	-4.21	3.08e-05	0.0028	-0.24	-0.19	Anger;	chr20:48918761	chr20:49040463~49046044:-
THCA	cis	rs3096299	0.685	rs4238830	ENSG00000261118.1	RP11-104N10.1	4.21	3.08e-05	0.0028	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89492017~89504460:-
THCA	cis	rs9573567	0.609	rs75945965	ENSG00000261553.4	RP11-29G8.3	-4.21	3.08e-05	0.0028	-0.36	-0.19	Red blood cell count;Mean corpuscular volume;	chr13:75474998	chr13:75549773~75807120:+
THCA	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	4.21	3.08e-05	0.0028	0.29	0.19	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
THCA	cis	rs9921338	0.54	rs2868409	ENSG00000263080.1	RP11-485G7.5	4.21	3.08e-05	0.0028	0.22	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11323512	chr16:11341809~11345211:-
THCA	cis	rs3020736	0.5	rs6002616	ENSG00000237037.8	NDUFA6-AS1	4.21	3.08e-05	0.0028	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42090931~42137742:+
THCA	cis	rs3020736	0.5	rs7364293	ENSG00000237037.8	NDUFA6-AS1	4.21	3.08e-05	0.0028	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42090931~42137742:+
THCA	cis	rs6570726	0.791	rs436498	ENSG00000270638.1	RP3-466P17.1	4.21	3.08e-05	0.0028	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145735570~145737218:+
THCA	cis	rs964611	0.938	rs12592157	ENSG00000259488.2	RP11-154J22.1	-4.21	3.08e-05	0.0028	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48331327	chr15:48312353~48331856:-
THCA	cis	rs11098499	0.863	rs9997631	ENSG00000249244.1	RP11-548H18.2	4.21	3.08e-05	0.0028	0.22	0.19	Corneal astigmatism;	chr4:119548840	chr4:119391831~119395335:-
THCA	cis	rs941408	0.515	rs1005556	ENSG00000261342.1	AC006538.1	4.21	3.08e-05	0.0028	0.21	0.19	Total cholesterol levels;	chr19:2778545	chr19:2727743~2729327:-
THCA	cis	rs17801127	0.901	rs13026469	ENSG00000231969.1	AC144449.1	4.21	3.08e-05	0.0028	0.32	0.19	Liver enzyme levels (alanine transaminase);	chr2:149698874	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.901	rs13011748	ENSG00000231969.1	AC144449.1	4.21	3.08e-05	0.0028	0.32	0.19	Liver enzyme levels (alanine transaminase);	chr2:149699081	chr2:149587196~149848233:+
THCA	cis	rs875971	0.502	rs11769702	ENSG00000273142.1	RP11-458F8.4	4.21	3.08e-05	0.0028	0.18	0.19	Aortic root size;	chr7:66255529	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs6970498	ENSG00000273142.1	RP11-458F8.4	4.21	3.08e-05	0.0028	0.18	0.19	Aortic root size;	chr7:66275908	chr7:66902857~66906297:+
THCA	cis	rs881375	0.678	rs10739581	ENSG00000270917.1	RP11-27I1.6	-4.21	3.08e-05	0.0028	-0.25	-0.19	Rheumatoid arthritis;	chr9:120934593	chr9:120812475~120812845:-
THCA	cis	rs250585	0.79	rs181835	ENSG00000260136.4	CTD-2270L9.4	4.21	3.08e-05	0.0028	0.15	0.19	Egg allergy;	chr16:23385792	chr16:23452758~23457606:+
THCA	cis	rs2120243	0.501	rs1456107	ENSG00000241770.1	RP11-555M1.3	-4.21	3.09e-05	0.0028	-0.25	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157401731	chr3:157163452~157169133:+
THCA	cis	rs17689437	0.958	rs17622185	ENSG00000275383.1	RP11-615I2.6	4.21	3.09e-05	0.0028	0.3	0.19	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68574186	chr16:68591382~68594424:+
THCA	cis	rs6573604	0.681	rs10147958	ENSG00000276116.2	FUT8-AS1	-4.21	3.09e-05	0.0028	-0.29	-0.19	N-glycan levels;	chr14:65312115	chr14:65411170~65412690:-
THCA	cis	rs77972916	0.536	rs7562101	ENSG00000234936.1	AC010883.5	4.21	3.09e-05	0.0028	0.21	0.19	Granulocyte percentage of myeloid white cells;	chr2:43365617	chr2:43229573~43233394:+
THCA	cis	rs6822297	0.905	rs7672936	ENSG00000240005.4	RP11-293A21.1	-4.21	3.09e-05	0.0028	-0.21	-0.19	Obesity-related traits;	chr4:26882786	chr4:26859806~26860599:-
THCA	cis	rs591584	0.73	rs72963846	ENSG00000255893.1	RP11-685N10.1	-4.21	3.09e-05	0.0028	-0.22	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94574596	chr11:94472908~94473570:-
THCA	cis	rs893363	0.559	rs893365	ENSG00000271916.1	RP11-884K10.6	-4.21	3.09e-05	0.0028	-0.21	-0.19	Axial length;	chr3:53807119	chr3:53797764~53798019:-
THCA	cis	rs2549003	0.933	rs3846731	ENSG00000237714.1	P4HA2-AS1	-4.21	3.09e-05	0.0028	-0.24	-0.19	Asthma (sex interaction);	chr5:132478572	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs7734334	ENSG00000237714.1	P4HA2-AS1	-4.21	3.09e-05	0.0028	-0.24	-0.19	Asthma (sex interaction);	chr5:132479312	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs7735073	ENSG00000237714.1	P4HA2-AS1	-4.21	3.09e-05	0.0028	-0.24	-0.19	Asthma (sex interaction);	chr5:132479665	chr5:132184876~132192808:+
THCA	cis	rs2980439	0.517	rs17594065	ENSG00000254153.1	CTA-398F10.2	4.21	3.09e-05	0.0028	0.21	0.19	Neuroticism;	chr8:8247883	chr8:8456909~8461337:-
THCA	cis	rs1124769	0.719	rs2614774	ENSG00000259378.1	DCAF13P3	-4.21	3.09e-05	0.0028	-0.29	-0.19	Cognitive performance;	chr15:50877678	chr15:50944663~50945996:+
THCA	cis	rs1728785	0.818	rs1645984	ENSG00000274698.1	RP11-71L14.4	4.21	3.09e-05	0.0028	0.27	0.19	Ulcerative colitis;	chr16:68594947	chr16:68450283~68452318:+
THCA	cis	rs13108904	0.935	rs2199956	ENSG00000254094.1	AC078852.1	-4.21	3.09e-05	0.0028	-0.21	-0.19	Obesity-related traits;	chr4:1255131	chr4:1356581~1358075:+
THCA	cis	rs3764021	0.527	rs11052426	ENSG00000214776.8	RP11-726G1.1	4.21	3.09e-05	0.0028	0.25	0.19	Type 1 diabetes;	chr12:9688330	chr12:9467552~9576275:+
THCA	cis	rs3764021	0.527	rs17806710	ENSG00000214776.8	RP11-726G1.1	4.21	3.09e-05	0.0028	0.25	0.19	Type 1 diabetes;	chr12:9688368	chr12:9467552~9576275:+
THCA	cis	rs7772486	0.79	rs9376971	ENSG00000270638.1	RP3-466P17.1	-4.21	3.09e-05	0.0028	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs4314514	ENSG00000270638.1	RP3-466P17.1	-4.21	3.09e-05	0.0028	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.72	rs9403757	ENSG00000270638.1	RP3-466P17.1	-4.21	3.09e-05	0.0028	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145735570~145737218:+
THCA	cis	rs250518	0.926	rs1912005	ENSG00000272081.1	CTD-2376I4.2	-4.21	3.09e-05	0.00281	-0.24	-0.19	Mean corpuscular hemoglobin concentration;	chr5:72772227	chr5:72955206~72955699:-
THCA	cis	rs5752326	0.51	rs3747134	ENSG00000261188.1	CTA-445C9.14	-4.21	3.09e-05	0.00281	-0.18	-0.19	Ischemic stroke;	chr22:26482015	chr22:26512537~26514568:+
THCA	cis	rs9467773	0.844	rs2393669	ENSG00000228223.2	HCG11	-4.21	3.09e-05	0.00281	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26503645	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9461259	ENSG00000228223.2	HCG11	-4.21	3.09e-05	0.00281	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26504607	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9467774	ENSG00000228223.2	HCG11	-4.21	3.09e-05	0.00281	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26504808	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs3736781	ENSG00000228223.2	HCG11	-4.21	3.09e-05	0.00281	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26505134	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs3736782	ENSG00000228223.2	HCG11	-4.21	3.09e-05	0.00281	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26505175	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs2208331	ENSG00000228223.2	HCG11	-4.21	3.09e-05	0.00281	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26507091	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9393728	ENSG00000228223.2	HCG11	-4.21	3.09e-05	0.00281	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26509102	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs1056667	ENSG00000228223.2	HCG11	-4.21	3.09e-05	0.00281	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26510336	chr6:26523450~26526579:+
THCA	cis	rs10875746	0.855	rs11168369	ENSG00000258273.1	RP11-370I10.4	4.21	3.09e-05	0.00281	0.28	0.19	Longevity (90 years and older);	chr12:48037385	chr12:48333755~48333901:-
THCA	cis	rs481331	0.799	rs210241	ENSG00000215146.4	RP11-313J2.1	-4.21	3.09e-05	0.00281	-0.3	-0.19	Systemic juvenile idiopathic arthritis;	chr10:42525810	chr10:42331866~42367974:-
THCA	cis	rs13401620	0.674	rs11680502	ENSG00000231013.1	AC013275.2	-4.21	3.09e-05	0.00281	-0.22	-0.19	Breast size;	chr2:119717110	chr2:119476448~119487346:+
THCA	cis	rs11096990	0.855	rs2711989	ENSG00000249685.1	RP11-360F5.3	-4.21	3.09e-05	0.00281	-0.25	-0.19	Cognitive function;	chr4:39150416	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.855	rs2566169	ENSG00000249685.1	RP11-360F5.3	-4.21	3.09e-05	0.00281	-0.25	-0.19	Cognitive function;	chr4:39150420	chr4:39133913~39135608:+
THCA	cis	rs9847710	0.791	rs6808387	ENSG00000242142.1	SERBP1P3	-4.21	3.09e-05	0.00281	-0.22	-0.19	Ulcerative colitis;	chr3:53045716	chr3:53064283~53065091:-
THCA	cis	rs4906332	1	rs3783400	ENSG00000269910.1	RP11-73M18.10	4.21	3.09e-05	0.00281	0.16	0.19	Coronary artery disease;	chr14:103500708	chr14:103694516~103695050:-
THCA	cis	rs8113308	1	rs6509600	ENSG00000269483.1	AC006272.1	4.21	3.09e-05	0.00281	0.28	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939336	chr19:51839924~51843324:-
THCA	cis	rs2692947	0.77	rs12471925	ENSG00000232931.4	LINC00342	4.21	3.09e-05	0.00281	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95889774	chr2:95807118~95816215:-
THCA	cis	rs12234571	1	rs77445032	ENSG00000214293.7	APTR	4.21	3.09e-05	0.00281	0.24	0.19	Obesity-related traits;	chr7:77758177	chr7:77657660~77696265:-
THCA	cis	rs1048886	0.938	rs59698166	ENSG00000271967.1	RP11-134K13.4	-4.21	3.09e-05	0.00281	-0.21	-0.19	Type 2 diabetes;	chr6:70442273	chr6:70596438~70596980:+
THCA	cis	rs4908769	0.66	rs159961	ENSG00000232912.4	RP5-1115A15.1	4.21	3.09e-05	0.00281	0.21	0.19	Allergy;	chr1:8424168	chr1:8424645~8434838:+
THCA	cis	rs4908769	0.66	rs301797	ENSG00000232912.4	RP5-1115A15.1	4.21	3.09e-05	0.00281	0.21	0.19	Allergy;	chr1:8427263	chr1:8424645~8434838:+
THCA	cis	rs7176527	0.848	rs3748374	ENSG00000230373.7	GOLGA6L5P	4.21	3.09e-05	0.00281	0.25	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:84507885~84516814:-
THCA	cis	rs10761482	0.861	rs10761488	ENSG00000254271.1	RP11-131N11.4	4.21	3.1e-05	0.00281	0.26	0.19	Schizophrenia;	chr10:60346234	chr10:60734342~60741828:+
THCA	cis	rs3892630	0.588	rs7260037	ENSG00000267567.1	CTD-2538C1.3	4.21	3.1e-05	0.00281	0.28	0.19	Red blood cell traits;	chr19:32751795	chr19:32718298~32719595:-
THCA	cis	rs3892630	0.588	rs7245709	ENSG00000267567.1	CTD-2538C1.3	4.21	3.1e-05	0.00281	0.28	0.19	Red blood cell traits;	chr19:32751849	chr19:32718298~32719595:-
THCA	cis	rs656319	0.513	rs17746245	ENSG00000261451.1	RP11-981G7.1	4.21	3.1e-05	0.00281	0.24	0.19	Myopia (pathological);	chr8:10124176	chr8:10433672~10438312:+
THCA	cis	rs6687821	0.515	rs496675	ENSG00000261737.1	RP4-612B15.3	-4.21	3.1e-05	0.00281	-0.29	-0.19	Yeast infection;	chr1:86858756	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs552483	ENSG00000261737.1	RP4-612B15.3	-4.21	3.1e-05	0.00281	-0.29	-0.19	Yeast infection;	chr1:86860335	chr1:86703502~86704462:-
THCA	cis	rs875971	0.558	rs4433015	ENSG00000223473.2	GS1-124K5.3	-4.21	3.1e-05	0.00281	-0.13	-0.19	Aortic root size;	chr7:66174736	chr7:66491049~66493566:-
THCA	cis	rs72928364	0.929	rs13059867	ENSG00000256628.3	ZBTB11-AS1	4.21	3.1e-05	0.00281	0.34	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101046704	chr3:101676475~101679217:+
THCA	cis	rs41313321	0.688	rs73672490	ENSG00000272696.1	RP11-339B21.13	4.21	3.1e-05	0.00281	0.15	0.19	Coenzyme Q10 levels;	chr9:128293454	chr9:128316337~128316909:+
THCA	cis	rs41313321	0.736	rs7028431	ENSG00000272696.1	RP11-339B21.13	4.21	3.1e-05	0.00281	0.15	0.19	Coenzyme Q10 levels;	chr9:128293987	chr9:128316337~128316909:+
THCA	cis	rs72928364	1	rs2576365	ENSG00000256628.3	ZBTB11-AS1	-4.21	3.1e-05	0.00281	-0.31	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100902582	chr3:101676475~101679217:+
THCA	cis	rs4646450	0.636	rs6953476	ENSG00000244219.5	GS1-259H13.2	-4.21	3.1e-05	0.00281	-0.25	-0.19	Blood metabolite levels;	chr7:99323977	chr7:99598066~99610813:+
THCA	cis	rs1979679	0.659	rs11049461	ENSG00000247934.4	RP11-967K21.1	-4.21	3.1e-05	0.00281	-0.21	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207688	chr12:28163298~28190738:-
THCA	cis	rs6500602	0.893	rs4786490	ENSG00000280063.1	RP11-295D4.3	-4.21	3.1e-05	0.00281	-0.1	-0.19	Schizophrenia;	chr16:4441189	chr16:4346694~4348648:-
THCA	cis	rs72949976	0.864	rs13389834	ENSG00000270659.1	RP11-105N14.1	4.21	3.1e-05	0.00281	0.15	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213160388	chr2:213152970~213153659:+
THCA	cis	rs62458065	0.513	rs9655340	ENSG00000231952.3	DPY19L1P2	-4.21	3.1e-05	0.00281	-0.31	-0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32496308	chr7:32812757~32838570:+
THCA	cis	rs4512344	0.514	rs13255193	ENSG00000227888.4	FAM66A	-4.21	3.1e-05	0.00281	-0.24	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11451683	chr8:12362019~12388296:+
THCA	cis	rs4538475	0.556	rs4613561	ENSG00000214846.4	RP11-115L11.1	4.21	3.1e-05	0.00281	0.26	0.19	Parkinson's disease;	chr4:15736267	chr4:15730962~15731627:-
THCA	cis	rs34929064	0.881	rs2961311	ENSG00000179428.2	AC073072.5	4.21	3.1e-05	0.00281	0.22	0.19	Major depression and alcohol dependence;	chr7:22687919	chr7:22725395~22727620:-
THCA	cis	rs494526	0.899	rs10787899	ENSG00000229272.1	RP11-498J9.2	-4.21	3.1e-05	0.00281	-0.21	-0.19	Alcoholic chronic pancreatitis;	chr10:119039143	chr10:119003536~119003884:-
THCA	cis	rs4706831	0.663	rs1984242	ENSG00000260645.1	RP11-250B2.5	4.21	3.1e-05	0.00281	0.16	0.19	Joint mobility (Beighton score);	chr6:80341528	chr6:80466958~80469080:+
THCA	cis	rs957448	0.554	rs12540967	ENSG00000253175.1	RP11-267M23.6	4.21	3.1e-05	0.00281	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94565036~94565715:+
THCA	cis	rs957448	0.554	rs4735297	ENSG00000253175.1	RP11-267M23.6	4.21	3.1e-05	0.00281	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94565036~94565715:+
THCA	cis	rs957448	0.554	rs72674877	ENSG00000253175.1	RP11-267M23.6	4.21	3.1e-05	0.00281	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94565036~94565715:+
THCA	cis	rs9900062	0.546	rs2676294	ENSG00000270714.1	MINOS1P2	4.21	3.1e-05	0.00281	0.26	0.19	QT interval;	chr17:64714646	chr17:64747264~64747492:-
THCA	cis	rs7621025	0.675	rs34602896	ENSG00000239213.4	NCK1-AS1	-4.21	3.1e-05	0.00281	-0.19	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136627543	chr3:136841726~136862054:-
THCA	cis	rs755249	0.959	rs72663520	ENSG00000237624.1	OXCT2P1	4.21	3.1e-05	0.00281	0.26	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39514956~39516490:+
THCA	cis	rs6964833	0.935	rs34630792	ENSG00000184616.8	AC004166.6	4.21	3.1e-05	0.00281	0.3	0.19	Menarche (age at onset);	chr7:74646869	chr7:74906673~74913256:-
THCA	cis	rs12915845	0.584	rs17196732	ENSG00000271997.1	RP11-97O12.6	4.21	3.1e-05	0.00281	0.13	0.19	Menarche (age at onset);	chr15:88526068	chr15:88501944~88505787:-
THCA	cis	rs1023500	0.505	rs134891	ENSG00000273366.1	CTA-989H11.1	-4.21	3.1e-05	0.00282	-0.23	-0.19	Schizophrenia;	chr22:42279876	chr22:42278188~42278846:+
THCA	cis	rs7824557	0.564	rs2736288	ENSG00000206014.6	OR7E161P	4.21	3.1e-05	0.00282	0.22	0.19	Retinal vascular caliber;	chr8:11370591	chr8:11928597~11929563:-
THCA	cis	rs7267979	0.903	rs6132819	ENSG00000274973.1	RP13-401N8.7	-4.21	3.1e-05	0.00282	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25845497~25845862:+
THCA	cis	rs959260	1	rs4789180	ENSG00000263843.1	RP11-649A18.12	4.21	3.1e-05	0.00282	0.2	0.19	Systemic lupus erythematosus;	chr17:75378315	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs4789181	ENSG00000263843.1	RP11-649A18.12	4.21	3.1e-05	0.00282	0.2	0.19	Systemic lupus erythematosus;	chr17:75378559	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs2053157	ENSG00000263843.1	RP11-649A18.12	4.21	3.1e-05	0.00282	0.2	0.19	Systemic lupus erythematosus;	chr17:75382514	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs8081927	ENSG00000263843.1	RP11-649A18.12	4.21	3.1e-05	0.00282	0.2	0.19	Systemic lupus erythematosus;	chr17:75383004	chr17:75271369~75273895:+
THCA	cis	rs959260	0.925	rs1108355	ENSG00000263843.1	RP11-649A18.12	4.21	3.1e-05	0.00282	0.2	0.19	Systemic lupus erythematosus;	chr17:75387832	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs9892325	ENSG00000263843.1	RP11-649A18.12	4.21	3.1e-05	0.00282	0.2	0.19	Systemic lupus erythematosus;	chr17:75398368	chr17:75271369~75273895:+
THCA	cis	rs1923243	0.814	rs6696689	ENSG00000223479.3	RP4-788P17.1	-4.21	3.1e-05	0.00282	-0.21	-0.19	Migraine;	chr1:73110457	chr1:73635216~73715214:+
THCA	cis	rs4218	0.648	rs10851642	ENSG00000259732.1	RP11-59H7.3	-4.21	3.1e-05	0.00282	-0.27	-0.19	Social communication problems;	chr15:59077909	chr15:59121034~59133250:+
THCA	cis	rs4218	0.648	rs60285686	ENSG00000259732.1	RP11-59H7.3	-4.21	3.1e-05	0.00282	-0.27	-0.19	Social communication problems;	chr15:59079829	chr15:59121034~59133250:+
THCA	cis	rs4218	0.648	rs60741546	ENSG00000259732.1	RP11-59H7.3	-4.21	3.1e-05	0.00282	-0.27	-0.19	Social communication problems;	chr15:59079831	chr15:59121034~59133250:+
THCA	cis	rs35740288	0.77	rs11633893	ENSG00000259295.5	CSPG4P12	-4.21	3.1e-05	0.00282	-0.29	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605207	chr15:85191438~85213905:+
THCA	cis	rs9880211	0.571	rs34428695	ENSG00000239213.4	NCK1-AS1	4.21	3.1e-05	0.00282	0.27	0.19	Height;Body mass index;	chr3:136315899	chr3:136841726~136862054:-
THCA	cis	rs9880211	0.571	rs35522825	ENSG00000239213.4	NCK1-AS1	4.21	3.1e-05	0.00282	0.27	0.19	Height;Body mass index;	chr3:136319356	chr3:136841726~136862054:-
THCA	cis	rs6920372	0.708	rs13198852	ENSG00000223537.2	RP5-919F19.5	-4.21	3.1e-05	0.00282	-0.19	-0.19	Height;	chr6:109747119	chr6:109487906~109506800:+
THCA	cis	rs7829975	0.84	rs572366	ENSG00000233609.3	RP11-62H7.2	4.21	3.1e-05	0.00282	0.19	0.19	Mood instability;	chr8:8721284	chr8:8961200~8979025:+
THCA	cis	rs8081395	0.805	rs1295927	ENSG00000267302.4	RP11-178C3.2	4.21	3.1e-05	0.00282	0.23	0.19	White blood cell count;	chr17:59852174	chr17:59964832~59996972:+
THCA	cis	rs914615	0.508	rs4390169	ENSG00000236675.1	MTX1P1	4.21	3.1e-05	0.00282	0.18	0.19	Urinary albumin-to-creatinine ratio;	chr1:155133578	chr1:155230975~155234325:+
THCA	cis	rs7555523	0.887	rs4657477	ENSG00000224358.1	RP11-466F5.8	-4.21	3.1e-05	0.00282	-0.29	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165766938	chr1:165768929~165775176:+
THCA	cis	rs2281636	0.723	rs1128642	ENSG00000260475.1	RP11-85A1.3	4.21	3.1e-05	0.00282	0.19	0.19	Obesity-related traits;	chr10:99711938	chr10:99621055~99621918:+
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000220721.1	OR1F12	4.21	3.1e-05	0.00282	0.21	0.19	Pubertal anthropometrics;	chr6:28197520	chr6:28073316~28074233:+
THCA	cis	rs812925	0.519	rs10199672	ENSG00000270820.4	RP11-355B11.2	-4.21	3.1e-05	0.00282	-0.16	-0.19	Immature fraction of reticulocytes;	chr2:61400499	chr2:61471188~61484130:+
THCA	cis	rs7267979	0.816	rs390123	ENSG00000277938.1	RP5-965G21.3	4.21	3.1e-05	0.00282	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.816	rs404775	ENSG00000277938.1	RP5-965G21.3	4.21	3.1e-05	0.00282	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25229150~25231933:+
THCA	cis	rs17772222	0.511	rs12880017	ENSG00000258983.2	RP11-507K2.2	4.21	3.1e-05	0.00282	0.22	0.19	Coronary artery calcification;	chr14:88840228	chr14:88499334~88515502:+
THCA	cis	rs12681963	0.688	rs7004466	ENSG00000248159.1	HSPA8P11	4.21	3.1e-05	0.00282	0.36	0.19	Migraine;	chr8:30196778	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs7004806	ENSG00000248159.1	HSPA8P11	4.21	3.1e-05	0.00282	0.36	0.19	Migraine;	chr8:30197002	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs73242331	ENSG00000248159.1	HSPA8P11	4.21	3.1e-05	0.00282	0.36	0.19	Migraine;	chr8:30198328	chr8:30237382~30240997:+
THCA	cis	rs2836974	0.526	rs418359	ENSG00000255568.3	BRWD1-AS2	-4.21	3.11e-05	0.00282	-0.15	-0.19	Cognitive function;	chr21:39164808	chr21:39313935~39314962:+
THCA	cis	rs12893668	0.673	rs2296482	ENSG00000252469.1	RNU7-160P	4.21	3.11e-05	0.00282	0.23	0.19	Reticulocyte count;	chr14:103563482	chr14:103550345~103550406:+
THCA	cis	rs7202877	0.539	rs17764278	ENSG00000261783.1	RP11-252K23.2	-4.21	3.11e-05	0.00282	-0.46	-0.19	Type 1 diabetes;Type 2 diabetes;	chr16:75340131	chr16:75379818~75381260:-
THCA	cis	rs2055729	0.591	rs17150950	ENSG00000248538.5	RP11-10A14.5	-4.21	3.11e-05	0.00282	-0.24	-0.19	Multiple myeloma (hyperdiploidy);	chr8:10023499	chr8:9189011~9202854:+
THCA	cis	rs7760535	0.711	rs240959	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.11e-05	0.00282	-0.17	-0.19	Metabolic traits;	chr6:111298810	chr6:111277932~111278742:+
THCA	cis	rs2839627	0.638	rs28567463	ENSG00000225218.1	AP001628.6	4.21	3.11e-05	0.00282	0.32	0.19	Information processing speed;	chr21:42855347	chr21:42831040~42836477:-
THCA	cis	rs9326246	0.545	rs480028	ENSG00000254851.1	RP11-109L13.1	4.21	3.11e-05	0.00282	0.43	0.19	Coronary artery disease;	chr11:116652053	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs499563	ENSG00000254851.1	RP11-109L13.1	4.21	3.11e-05	0.00282	0.43	0.19	Coronary artery disease;	chr11:116652244	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs483747	ENSG00000254851.1	RP11-109L13.1	4.21	3.11e-05	0.00282	0.43	0.19	Coronary artery disease;	chr11:116652450	chr11:117135528~117138582:+
THCA	cis	rs1923243	0.649	rs7525762	ENSG00000223479.3	RP4-788P17.1	-4.21	3.11e-05	0.00282	-0.21	-0.19	Migraine;	chr1:72906133	chr1:73635216~73715214:+
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000275400.1	RP4-756H11.5	-4.21	3.11e-05	0.00282	-0.21	-0.19	Corneal structure;	chr7:66938233	chr7:66553805~66554199:-
THCA	cis	rs7136259	0.562	rs4842667	ENSG00000258302.2	RP11-981P6.1	4.21	3.11e-05	0.00282	0.16	0.19	Coronary heart disease;	chr12:89572877	chr12:89561129~89594878:+
THCA	cis	rs801193	0.636	rs2659895	ENSG00000229886.1	RP5-1132H15.3	4.21	3.11e-05	0.00282	0.2	0.19	Aortic root size;	chr7:66731484	chr7:66025126~66031544:-
THCA	cis	rs9876781	1	rs1459242	ENSG00000244380.1	RP11-24C3.2	-4.21	3.11e-05	0.00282	-0.22	-0.19	Longevity;	chr3:48372047	chr3:48440352~48446656:-
THCA	cis	rs875971	1	rs7781698	ENSG00000229886.1	RP5-1132H15.3	4.21	3.11e-05	0.00282	0.2	0.19	Aortic root size;	chr7:66431325	chr7:66025126~66031544:-
THCA	cis	rs1075265	0.568	rs959286	ENSG00000272156.1	RP11-477N3.1	4.21	3.11e-05	0.00282	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54082554~54085066:+
THCA	cis	rs1075265	0.527	rs959285	ENSG00000272156.1	RP11-477N3.1	4.21	3.11e-05	0.00282	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54082554~54085066:+
THCA	cis	rs7737355	0.628	rs75544080	ENSG00000224431.1	AC063976.7	-4.21	3.11e-05	0.00282	-0.27	-0.19	Life satisfaction;	chr5:131549822	chr5:132199456~132203487:+
THCA	cis	rs1396485	0.544	rs56306460	ENSG00000248445.4	SEMA6A-AS1	-4.21	3.11e-05	0.00282	-0.19	-0.19	Inflammatory biomarkers;	chr5:116102667	chr5:116447547~116508276:+
THCA	cis	rs7402982	0.934	rs8028620	ENSG00000278022.1	RP11-35O15.2	-4.21	3.11e-05	0.00282	-0.19	-0.19	Birth weight;	chr15:98659646	chr15:98660210~98660668:+
THCA	cis	rs6570726	0.905	rs430248	ENSG00000270638.1	RP3-466P17.1	4.21	3.11e-05	0.00282	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs406343	ENSG00000270638.1	RP3-466P17.1	4.21	3.11e-05	0.00282	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145735570~145737218:+
THCA	cis	rs62158800	0.598	rs10865014	ENSG00000224568.1	AC096669.3	4.21	3.11e-05	0.00282	0.23	0.19	Facial morphology (factor 22);	chr2:107674316	chr2:107529487~107556326:+
THCA	cis	rs12887734	0.546	rs4906376	ENSG00000269910.1	RP11-73M18.10	4.21	3.11e-05	0.00282	0.18	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805828	chr14:103694516~103695050:-
THCA	cis	rs1232027	0.656	rs1650671	ENSG00000249655.1	CTC-325J23.2	4.21	3.11e-05	0.00282	0.21	0.19	Huntington's disease progression;	chr5:80664449	chr5:80630313~80631590:-
THCA	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	4.21	3.11e-05	0.00282	0.18	0.19	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
THCA	cis	rs889398	0.967	rs62052816	ENSG00000226232.7	RP11-419C5.2	4.21	3.11e-05	0.00282	0.19	0.19	Body mass index;	chr16:69529503	chr16:69976388~69996188:-
THCA	cis	rs6121246	0.908	rs6089094	ENSG00000224628.2	RP5-854E16.2	-4.21	3.11e-05	0.00282	-0.26	-0.19	Mean corpuscular hemoglobin;	chr20:31843968	chr20:31285317~31286835:-
THCA	cis	rs7746199	0.673	rs35501037	ENSG00000220721.1	OR1F12	4.21	3.11e-05	0.00282	0.43	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28073316~28074233:+
THCA	cis	rs9467773	0.596	rs3001369	ENSG00000228223.2	HCG11	-4.21	3.11e-05	0.00282	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26523450~26526579:+
THCA	cis	rs9341808	0.53	rs3805877	ENSG00000260645.1	RP11-250B2.5	4.21	3.11e-05	0.00282	0.16	0.19	Sitting height ratio;	chr6:80321812	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.53	rs3805876	ENSG00000260645.1	RP11-250B2.5	4.21	3.11e-05	0.00282	0.16	0.19	Sitting height ratio;	chr6:80321822	chr6:80466958~80469080:+
THCA	cis	rs75504410	0.649	rs337640	ENSG00000231160.8	KLF3-AS1	-4.21	3.11e-05	0.00282	-0.14	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38606468	chr4:38612701~38664883:-
THCA	cis	rs7923609	0.846	rs7090111	ENSG00000232075.1	MRPL35P2	-4.21	3.11e-05	0.00282	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63318234	chr10:63634317~63634827:-
THCA	cis	rs6088590	0.735	rs6060001	ENSG00000269202.1	RP4-614O4.12	4.21	3.11e-05	0.00282	0.16	0.19	Coronary artery disease;	chr20:34706549	chr20:35201747~35203288:-
THCA	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-4.21	3.11e-05	0.00282	-0.19	-0.19	Height;	chr5:37072722	chr5:36666214~36725195:-
THCA	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	4.21	3.11e-05	0.00282	0.23	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
THCA	cis	rs8113308	1	rs8104737	ENSG00000269483.1	AC006272.1	4.21	3.11e-05	0.00283	0.29	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938444	chr19:51839924~51843324:-
THCA	cis	rs853679	0.769	rs7752448	ENSG00000280107.1	AL022393.9	-4.21	3.11e-05	0.00283	-0.31	-0.19	Depression;	chr6:28333322	chr6:28170845~28172521:+
THCA	cis	rs910873	0.901	rs2424995	ENSG00000276073.1	RP5-1125A11.7	4.21	3.12e-05	0.00283	0.37	0.19	Melanoma;	chr20:34576711	chr20:33985617~33988989:-
THCA	cis	rs12428035	0.536	rs72636562	ENSG00000247400.3	DNAJC3-AS1	-4.21	3.12e-05	0.00283	-0.18	-0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95910513	chr13:95648733~95676925:-
THCA	cis	rs12234571	0.744	rs17157284	ENSG00000214293.7	APTR	4.21	3.12e-05	0.00283	0.24	0.19	Obesity-related traits;	chr7:77750413	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs4729710	ENSG00000214293.7	APTR	4.21	3.12e-05	0.00283	0.24	0.19	Obesity-related traits;	chr7:77764422	chr7:77657660~77696265:-
THCA	cis	rs2692947	0.832	rs2438978	ENSG00000232931.4	LINC00342	4.21	3.12e-05	0.00283	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96013992	chr2:95807118~95816215:-
THCA	cis	rs10266483	0.921	rs651934	ENSG00000271550.1	BNIP3P11	4.21	3.12e-05	0.00283	0.24	0.19	Response to statin therapy;	chr7:64283972	chr7:64678954~64687393:-
THCA	cis	rs12129938	0.911	rs12140862	ENSG00000231940.1	RPS7P3	4.21	3.12e-05	0.00283	0.26	0.19	Thyroid cancer;	chr1:233276739	chr1:233288868~233289447:-
THCA	cis	rs586716	0.548	rs505447	ENSG00000224549.1	RP11-370B11.3	4.21	3.12e-05	0.00283	0.21	0.19	Tuberculosis;	chr9:22455893	chr9:22767175~22768316:+
THCA	cis	rs875971	0.964	rs6978429	ENSG00000229886.1	RP5-1132H15.3	4.21	3.12e-05	0.00283	0.2	0.19	Aortic root size;	chr7:66494889	chr7:66025126~66031544:-
THCA	cis	rs875971	0.929	rs12535036	ENSG00000229886.1	RP5-1132H15.3	4.21	3.12e-05	0.00283	0.2	0.19	Aortic root size;	chr7:66499076	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs12698523	ENSG00000229886.1	RP5-1132H15.3	4.21	3.12e-05	0.00283	0.2	0.19	Aortic root size;	chr7:66503126	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs6970030	ENSG00000229886.1	RP5-1132H15.3	4.21	3.12e-05	0.00283	0.2	0.19	Aortic root size;	chr7:66503692	chr7:66025126~66031544:-
THCA	cis	rs875971	0.928	rs6970357	ENSG00000229886.1	RP5-1132H15.3	4.21	3.12e-05	0.00283	0.2	0.19	Aortic root size;	chr7:66503891	chr7:66025126~66031544:-
THCA	cis	rs6756513	0.5	rs1013083	ENSG00000231024.1	AC092431.3	-4.21	3.12e-05	0.00283	-0.28	-0.19	Breast cancer;Platelet count;	chr2:69872292	chr2:69700192~69713847:-
THCA	cis	rs123509	0.913	rs123506	ENSG00000173811.9	CCDC13-AS1	4.21	3.12e-05	0.00283	0.21	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42734484	chr3:42732575~42746768:+
THCA	cis	rs12030196	1	rs751187	ENSG00000230812.4	LINC01358	4.21	3.12e-05	0.00283	0.24	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59011719	chr1:59020387~59044614:+
THCA	cis	rs10043228	0.702	rs12521345	ENSG00000250015.1	CTC-339F2.2	4.21	3.12e-05	0.00283	0.23	0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116317162	chr5:116302354~116304134:-
THCA	cis	rs13098911	0.54	rs9824651	ENSG00000226074.4	PRSS44	-4.21	3.12e-05	0.00283	-0.34	-0.19	Celiac disease;	chr3:46066793	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs9825081	ENSG00000226074.4	PRSS44	-4.21	3.12e-05	0.00283	-0.34	-0.19	Celiac disease;	chr3:46066908	chr3:46809359~46812558:-
THCA	cis	rs2836974	1	rs28360661	ENSG00000255568.3	BRWD1-AS2	4.21	3.12e-05	0.00283	0.17	0.19	Cognitive function;	chr21:39310046	chr21:39313935~39314962:+
THCA	cis	rs7176527	0.706	rs35641144	ENSG00000225151.9	GOLGA2P7	4.21	3.12e-05	0.00283	0.36	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84723543	chr15:84199311~84230136:-
THCA	cis	rs6479891	1	rs9414780	ENSG00000272767.1	JMJD1C-AS1	4.21	3.12e-05	0.00283	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63465229~63466563:+
THCA	cis	rs17801127	0.748	rs74989730	ENSG00000231969.1	AC144449.1	4.21	3.12e-05	0.00283	0.45	0.19	Liver enzyme levels (alanine transaminase);	chr2:149857790	chr2:149587196~149848233:+
THCA	cis	rs7088591	0.867	rs115213581	ENSG00000276818.1	AC026393.1	4.21	3.12e-05	0.00283	0.4	0.19	Blood pressure;	chr10:57972309	chr10:57095699~57095781:+
THCA	cis	rs2028299	0.879	rs3803534	ENSG00000259677.1	RP11-493E3.1	4.21	3.12e-05	0.00283	0.25	0.19	Type 2 diabetes;	chr15:89898638	chr15:89876540~89877285:+
THCA	cis	rs12478296	1	rs59036157	ENSG00000261186.2	RP11-341N2.1	-4.21	3.12e-05	0.00283	-0.31	-0.19	Obesity-related traits;	chr2:242098077	chr2:242087351~242088457:-
THCA	cis	rs12478296	1	rs56323081	ENSG00000261186.2	RP11-341N2.1	-4.21	3.12e-05	0.00283	-0.31	-0.19	Obesity-related traits;	chr2:242098656	chr2:242087351~242088457:-
THCA	cis	rs9527	0.545	rs35756290	ENSG00000236937.2	PTGES3P4	4.21	3.12e-05	0.00283	0.27	0.19	Arsenic metabolism;	chr10:102825815	chr10:102845595~102845950:+
THCA	cis	rs9475752	0.711	rs9296856	ENSG00000231441.1	RP11-472M19.2	4.21	3.12e-05	0.00283	0.2	0.19	Menarche (age at onset);	chr6:56905327	chr6:56844002~56864078:+
THCA	cis	rs394563	0.591	rs805026	ENSG00000231760.4	RP11-350J20.5	4.21	3.12e-05	0.00283	0.24	0.19	Dupuytren's disease;	chr6:149407118	chr6:149796151~149826294:-
THCA	cis	rs9326248	0.53	rs2000615	ENSG00000280143.1	AP000892.6	4.21	3.12e-05	0.00283	0.3	0.19	Blood protein levels;	chr11:117045103	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.53	rs10790172	ENSG00000280143.1	AP000892.6	4.21	3.12e-05	0.00283	0.3	0.19	Blood protein levels;	chr11:117057024	chr11:117204967~117210292:+
THCA	cis	rs7181230	1	rs28587891	ENSG00000275636.1	RP11-521C20.5	4.21	3.12e-05	0.00283	0.18	0.19	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:40078892~40079347:+
THCA	cis	rs72949976	0.864	rs10176806	ENSG00000270659.1	RP11-105N14.1	4.21	3.12e-05	0.00283	0.15	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213157872	chr2:213152970~213153659:+
THCA	cis	rs3796352	0.568	rs11713376	ENSG00000242142.1	SERBP1P3	-4.21	3.12e-05	0.00283	-0.34	-0.19	Immune reponse to smallpox (secreted IL-2);	chr3:52924911	chr3:53064283~53065091:-
THCA	cis	rs7658584	1	rs13135956	ENSG00000246375.2	RP11-10L7.1	4.21	3.13e-05	0.00283	0.34	0.19	Squamous cell lung carcinoma;	chr4:88176741	chr4:88284942~88331421:+
THCA	cis	rs8031584	0.652	rs2691683	ENSG00000178081.11	ULK4P3	-4.21	3.13e-05	0.00283	-0.25	-0.19	Huntington's disease progression;	chr15:30842857	chr15:30103720~30131757:+
THCA	cis	rs12887734	0.524	rs4906363	ENSG00000269940.1	RP11-73M18.7	4.21	3.13e-05	0.00283	0.2	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103694560~103695170:+
THCA	cis	rs10129255	0.912	rs61996059	ENSG00000211970.3	IGHV4-61	-4.21	3.13e-05	0.00283	-0.12	-0.19	Kawasaki disease;	chr14:106716897	chr14:106639119~106639657:-
THCA	cis	rs911119	0.657	rs2145231	ENSG00000270001.1	RP11-218C14.8	4.21	3.13e-05	0.00283	0.3	0.19	Chronic kidney disease;	chr20:23644910	chr20:23631826~23632316:-
THCA	cis	rs3764021	1	rs3764021	ENSG00000214776.8	RP11-726G1.1	4.21	3.13e-05	0.00283	0.23	0.19	Type 1 diabetes;	chr12:9681032	chr12:9467552~9576275:+
THCA	cis	rs6449502	0.92	rs6449509	ENSG00000251279.1	CTC-436P18.1	-4.21	3.13e-05	0.00284	-0.33	-0.19	Mean platelet volume;	chr5:60883474	chr5:61162070~61232040:+
THCA	cis	rs12497850	0.931	rs4974082	ENSG00000228638.1	FCF1P2	-4.21	3.13e-05	0.00284	-0.2	-0.19	Parkinson's disease;	chr3:48961890	chr3:48290793~48291375:-
THCA	cis	rs6921919	0.697	rs12180820	ENSG00000219392.1	RP1-265C24.5	4.2	3.13e-05	0.00284	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28115628~28116551:+
THCA	cis	rs2836974	0.568	rs377098	ENSG00000255568.3	BRWD1-AS2	-4.2	3.13e-05	0.00284	-0.15	-0.19	Cognitive function;	chr21:39163290	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.568	rs371625	ENSG00000255568.3	BRWD1-AS2	-4.2	3.13e-05	0.00284	-0.15	-0.19	Cognitive function;	chr21:39163345	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.568	rs452377	ENSG00000255568.3	BRWD1-AS2	4.2	3.13e-05	0.00284	0.15	0.19	Cognitive function;	chr21:39165257	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.568	rs419469	ENSG00000255568.3	BRWD1-AS2	4.2	3.13e-05	0.00284	0.15	0.19	Cognitive function;	chr21:39165308	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.568	rs429955	ENSG00000255568.3	BRWD1-AS2	4.2	3.13e-05	0.00284	0.15	0.19	Cognitive function;	chr21:39167834	chr21:39313935~39314962:+
THCA	cis	rs59868192	0.85	rs72726043	ENSG00000246740.2	PLA2G4E-AS1	4.2	3.13e-05	0.00284	0.38	0.19	White blood cell count;	chr15:41975154	chr15:41972763~41999094:+
THCA	cis	rs2777491	0.574	rs72739644	ENSG00000247556.5	OIP5-AS1	4.2	3.13e-05	0.00284	0.18	0.19	Ulcerative colitis;	chr15:41427508	chr15:41283990~41309737:+
THCA	cis	rs4218	0.597	rs12442301	ENSG00000259732.1	RP11-59H7.3	-4.2	3.13e-05	0.00284	-0.27	-0.19	Social communication problems;	chr15:59065968	chr15:59121034~59133250:+
THCA	cis	rs2676071	0.858	rs2670945	ENSG00000259721.1	RP11-758N13.1	-4.2	3.13e-05	0.00284	-0.22	-0.19	Periodontitis (Mean PAL);	chr15:33307207	chr15:32717270~32719007:-
THCA	cis	rs2904524	1	rs74716820	ENSG00000257815.4	RP11-611E13.2	-4.2	3.13e-05	0.00284	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70246074	chr12:69904033~70243360:-
THCA	cis	rs2033711	0.84	rs3764533	ENSG00000232098.3	CTD-2619J13.14	4.2	3.13e-05	0.00284	0.17	0.19	Uric acid clearance;	chr19:58417827	chr19:58404238~58408484:-
THCA	cis	rs7829975	0.511	rs2955578	ENSG00000233609.3	RP11-62H7.2	4.2	3.13e-05	0.00284	0.18	0.19	Mood instability;	chr8:8279561	chr8:8961200~8979025:+
THCA	cis	rs4578769	0.918	rs3851821	ENSG00000265939.1	UBE2CP2	4.2	3.13e-05	0.00284	0.23	0.19	Eosinophil percentage of white cells;	chr18:22882492	chr18:22900486~22900995:-
THCA	cis	rs2777491	1	rs66538814	ENSG00000247556.5	OIP5-AS1	4.2	3.13e-05	0.00284	0.16	0.19	Ulcerative colitis;	chr15:41393719	chr15:41283990~41309737:+
THCA	cis	rs7200786	0.715	rs8050144	ENSG00000274038.1	RP11-66H6.4	-4.2	3.13e-05	0.00284	-0.24	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10996230	chr16:11056556~11057034:+
THCA	cis	rs2688482	0.512	rs3103954	ENSG00000207650.1	MIR570	4.2	3.13e-05	0.00284	0.25	0.19	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195699401~195699497:+
THCA	cis	rs7647973	0.807	rs4955416	ENSG00000228638.1	FCF1P2	-4.2	3.13e-05	0.00284	-0.23	-0.19	Menarche (age at onset);	chr3:49070995	chr3:48290793~48291375:-
THCA	cis	rs1414896	0.692	rs4146666	ENSG00000226026.4	RP11-57H12.3	4.2	3.13e-05	0.00284	0.18	0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95238173	chr1:95163219~95233982:-
THCA	cis	rs17685	0.712	rs28506984	ENSG00000230882.1	AC005077.14	4.2	3.13e-05	0.00284	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76134166	chr7:76071469~76074963:-
THCA	cis	rs2858942	0.602	rs1211375	ENSG00000206168.1	Z69890.1	4.2	3.13e-05	0.00284	0.21	0.19	Mean corpuscular hemoglobin;	chr16:190281	chr16:231134~231472:+
THCA	cis	rs6921919	0.583	rs7740351	ENSG00000273712.1	RP5-874C20.7	4.2	3.13e-05	0.00284	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs16894108	ENSG00000273712.1	RP5-874C20.7	4.2	3.13e-05	0.00284	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28315613~28315883:-
THCA	cis	rs1389724	0.632	rs11102160	ENSG00000259834.1	RP11-284N8.3	4.2	3.13e-05	0.00284	0.17	0.19	Schizophrenia;	chr1:110788802	chr1:110653560~110657040:-
THCA	cis	rs2898290	0.5	rs11998678	ENSG00000254948.1	OR7E158P	4.2	3.13e-05	0.00284	0.23	0.19	Systolic blood pressure;	chr8:11972641	chr8:11919900~11920809:-
THCA	cis	rs2904524	0.867	rs17107870	ENSG00000257815.4	RP11-611E13.2	-4.2	3.14e-05	0.00284	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70251669	chr12:69904033~70243360:-
THCA	cis	rs12478296	1	rs7603984	ENSG00000261186.2	RP11-341N2.1	-4.2	3.14e-05	0.00284	-0.31	-0.19	Obesity-related traits;	chr2:242105143	chr2:242087351~242088457:-
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000280107.1	AL022393.9	-4.2	3.14e-05	0.00284	-0.18	-0.19	Pubertal anthropometrics;	chr6:28230503	chr6:28170845~28172521:+
THCA	cis	rs7772486	0.754	rs702318	ENSG00000270638.1	RP3-466P17.1	-4.2	3.14e-05	0.00284	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145735570~145737218:+
THCA	cis	rs10761482	0.861	rs7096426	ENSG00000254271.1	RP11-131N11.4	-4.2	3.14e-05	0.00284	-0.25	-0.19	Schizophrenia;	chr10:60346787	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs7097138	ENSG00000254271.1	RP11-131N11.4	4.2	3.14e-05	0.00284	0.25	0.19	Schizophrenia;	chr10:60346997	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs7084803	ENSG00000254271.1	RP11-131N11.4	4.2	3.14e-05	0.00284	0.25	0.19	Schizophrenia;	chr10:60347343	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs7100985	ENSG00000254271.1	RP11-131N11.4	4.2	3.14e-05	0.00284	0.25	0.19	Schizophrenia;	chr10:60347408	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.769	rs4948403	ENSG00000254271.1	RP11-131N11.4	4.2	3.14e-05	0.00284	0.25	0.19	Schizophrenia;	chr10:60347904	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs1380458	ENSG00000254271.1	RP11-131N11.4	4.2	3.14e-05	0.00284	0.25	0.19	Schizophrenia;	chr10:60347932	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10821737	ENSG00000254271.1	RP11-131N11.4	4.2	3.14e-05	0.00284	0.25	0.19	Schizophrenia;	chr10:60348044	chr10:60734342~60741828:+
THCA	cis	rs8062405	0.728	rs11642449	ENSG00000270424.1	RP11-1348G14.6	4.2	3.14e-05	0.00284	0.23	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28749959~28750595:-
THCA	cis	rs758324	0.68	rs156043	ENSG00000224431.1	AC063976.7	-4.2	3.14e-05	0.00284	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132156157	chr5:132199456~132203487:+
THCA	cis	rs4948102	0.642	rs6593297	ENSG00000275875.1	RP11-613E4.5	4.2	3.14e-05	0.00284	0.23	0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55741525~55741869:+
THCA	cis	rs4948102	0.599	rs2230197	ENSG00000275875.1	RP11-613E4.5	-4.2	3.14e-05	0.00284	-0.23	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55741525~55741869:+
THCA	cis	rs62158800	0.598	rs13416107	ENSG00000224568.1	AC096669.3	4.2	3.14e-05	0.00284	0.24	0.19	Facial morphology (factor 22);	chr2:107670987	chr2:107529487~107556326:+
THCA	cis	rs4218	0.681	rs1074701	ENSG00000259732.1	RP11-59H7.3	-4.2	3.14e-05	0.00284	-0.26	-0.19	Social communication problems;	chr15:59073862	chr15:59121034~59133250:+
THCA	cis	rs3799379	0.53	rs10456045	ENSG00000124549.13	BTN2A3P	4.2	3.14e-05	0.00284	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26404730	chr6:26421391~26432383:+
THCA	cis	rs1728785	0.901	rs698715	ENSG00000274698.1	RP11-71L14.4	4.2	3.14e-05	0.00284	0.27	0.19	Ulcerative colitis;	chr16:68526993	chr16:68450283~68452318:+
THCA	cis	rs1728785	0.786	rs1728770	ENSG00000274698.1	RP11-71L14.4	4.2	3.14e-05	0.00284	0.27	0.19	Ulcerative colitis;	chr16:68530221	chr16:68450283~68452318:+
THCA	cis	rs11638352	0.661	rs2555376	ENSG00000166763.7	STRCP1	4.2	3.14e-05	0.00284	0.36	0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44158793	chr15:43699488~43718184:-
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000220721.1	OR1F12	4.2	3.14e-05	0.00284	0.21	0.19	Pubertal anthropometrics;	chr6:28128502	chr6:28073316~28074233:+
THCA	cis	rs17507216	0.718	rs7165690	ENSG00000255769.6	GOLGA2P10	-4.2	3.14e-05	0.00284	-0.3	-0.19	Excessive daytime sleepiness;	chr15:82654804	chr15:82472993~82513950:-
THCA	cis	rs35176054	0.73	rs7906955	ENSG00000280693.1	SH3PXD2A-AS1	-4.2	3.14e-05	0.00285	-0.36	-0.19	Atrial fibrillation;	chr10:103758786	chr10:103745966~103755423:+
THCA	cis	rs7968440	0.808	rs67218241	ENSG00000272368.2	RP4-605O3.4	4.2	3.14e-05	0.00285	0.12	0.19	Fibrinogen;	chr12:50761639	chr12:50112197~50165618:+
THCA	cis	rs10208649	0.831	rs10209918	ENSG00000233266.1	HMGB1P31	4.2	3.14e-05	0.00285	0.46	0.19	Body mass index;	chr2:53688174	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.731	rs78472090	ENSG00000233266.1	HMGB1P31	4.2	3.14e-05	0.00285	0.46	0.19	Body mass index;	chr2:53688318	chr2:54051334~54051760:+
THCA	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	4.2	3.14e-05	0.00285	0.22	0.19	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	4.2	3.14e-05	0.00285	0.22	0.19	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	4.2	3.14e-05	0.00285	0.22	0.19	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
THCA	cis	rs2732480	0.538	rs2468943	ENSG00000257735.1	RP11-370I10.6	-4.2	3.14e-05	0.00285	-0.21	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48350945~48442411:+
THCA	cis	rs9880211	0.613	rs6767060	ENSG00000273486.1	RP11-731C17.2	4.2	3.14e-05	0.00285	0.19	0.19	Height;Body mass index;	chr3:136148248	chr3:136837338~136839021:-
THCA	cis	rs8113308	0.752	rs113374423	ENSG00000275055.1	CTC-471J1.11	-4.2	3.14e-05	0.00285	-0.2	-0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987699	chr19:52049007~52049754:+
THCA	cis	rs8113308	0.752	rs73068868	ENSG00000275055.1	CTC-471J1.11	-4.2	3.14e-05	0.00285	-0.2	-0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987748	chr19:52049007~52049754:+
THCA	cis	rs7577696	0.785	rs7592239	ENSG00000276334.1	AL133243.1	-4.2	3.14e-05	0.00285	-0.2	-0.19	Inflammatory biomarkers;	chr2:32145189	chr2:32521927~32523547:+
THCA	cis	rs6921919	0.673	rs13201681	ENSG00000272009.1	RP1-313I6.12	-4.2	3.14e-05	0.00285	-0.36	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28078792~28081130:-
THCA	cis	rs6921919	0.778	rs67381177	ENSG00000272009.1	RP1-313I6.12	-4.2	3.14e-05	0.00285	-0.36	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28078792~28081130:-
THCA	cis	rs113835537	0.935	rs117131621	ENSG00000255517.5	CTD-3074O7.5	-4.2	3.14e-05	0.00285	-0.21	-0.19	Airway imaging phenotypes;	chr11:66654863	chr11:66473490~66480233:-
THCA	cis	rs394563	0.591	rs237035	ENSG00000231760.4	RP11-350J20.5	4.2	3.14e-05	0.00285	0.24	0.19	Dupuytren's disease;	chr6:149389712	chr6:149796151~149826294:-
THCA	cis	rs950169	0.922	rs11635505	ENSG00000188388.10	GOLGA6L3	-4.2	3.14e-05	0.00285	-0.25	-0.19	Schizophrenia;	chr15:84553803	chr15:85240472~85247170:+
THCA	cis	rs7809950	0.678	rs7790080	ENSG00000272072.1	CTA-363E19.2	4.2	3.14e-05	0.00285	0.2	0.19	Coronary artery disease;	chr7:107390877	chr7:107192559~107193300:-
THCA	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-4.2	3.14e-05	0.00285	-0.25	-0.19	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
THCA	cis	rs4714902	0.688	rs4496799	ENSG00000231769.2	RP1-8B1.4	-4.2	3.15e-05	0.00285	-0.17	-0.19	Colonoscopy-negative controls vs population controls;	chr6:46102670	chr6:46097093~46129706:-
THCA	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-4.2	3.15e-05	0.00285	-0.22	-0.19	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
THCA	cis	rs11678584	0.506	rs35286811	ENSG00000276517.1	AL133243.2	-4.2	3.15e-05	0.00285	-0.28	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32575355	chr2:32526504~32529507:+
THCA	cis	rs11633886	0.967	rs11629760	ENSG00000259200.1	RP11-718O11.1	-4.2	3.15e-05	0.00285	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45800549	chr15:45705078~45931069:+
THCA	cis	rs6573604	0.681	rs10144503	ENSG00000276116.2	FUT8-AS1	-4.2	3.15e-05	0.00285	-0.29	-0.19	N-glycan levels;	chr14:65317391	chr14:65411170~65412690:-
THCA	cis	rs17685	0.753	rs7788763	ENSG00000227038.2	AC005077.12	-4.2	3.15e-05	0.00285	-0.19	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76022347	chr7:76090431~76108779:-
THCA	cis	rs2153535	0.585	rs9393056	ENSG00000230939.1	RP11-314C16.1	-4.2	3.15e-05	0.00285	-0.2	-0.19	Motion sickness;	chr6:8667641	chr6:8784178~8785445:+
THCA	cis	rs893363	0.522	rs2241808	ENSG00000271916.1	RP11-884K10.6	-4.2	3.15e-05	0.00285	-0.2	-0.19	Axial length;	chr3:53822626	chr3:53797764~53798019:-
THCA	cis	rs7923609	0.812	rs10822155	ENSG00000232075.1	MRPL35P2	-4.2	3.15e-05	0.00285	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63311455	chr10:63634317~63634827:-
THCA	cis	rs12440869	1	rs17295739	ENSG00000270964.1	RP11-502I4.3	4.2	3.15e-05	0.00285	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67243093	chr15:67541072~67542604:-
THCA	cis	rs62158800	0.683	rs67372209	ENSG00000224568.1	AC096669.3	4.2	3.15e-05	0.00285	0.24	0.19	Facial morphology (factor 22);	chr2:107682933	chr2:107529487~107556326:+
THCA	cis	rs7560272	0.538	rs11126415	ENSG00000163016.8	ALMS1P	-4.2	3.15e-05	0.00285	-0.23	-0.19	Schizophrenia;	chr2:73709373	chr2:73644919~73685576:+
THCA	cis	rs7560272	0.538	rs12053242	ENSG00000163016.8	ALMS1P	-4.2	3.15e-05	0.00285	-0.23	-0.19	Schizophrenia;	chr2:73710041	chr2:73644919~73685576:+
THCA	cis	rs7577696	0.924	rs7586448	ENSG00000276334.1	AL133243.1	-4.2	3.15e-05	0.00285	-0.2	-0.19	Inflammatory biomarkers;	chr2:32043571	chr2:32521927~32523547:+
THCA	cis	rs7772486	0.754	rs4896838	ENSG00000270638.1	RP3-466P17.1	-4.2	3.15e-05	0.00285	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145735570~145737218:+
THCA	cis	rs607541	0.764	rs629880	ENSG00000259520.4	CTD-2651B20.3	-4.2	3.15e-05	0.00285	-0.27	-0.19	Obesity-related traits;	chr15:45642612	chr15:45251580~45279251:-
THCA	cis	rs7809950	0.798	rs2701687	ENSG00000238832.1	snoU109	4.2	3.15e-05	0.00285	0.21	0.19	Coronary artery disease;	chr7:107664183	chr7:107603363~107603507:+
THCA	cis	rs889122	0.765	rs10425422	ENSG00000267289.1	CTD-2623N2.11	4.2	3.15e-05	0.00285	0.24	0.19	Menarche (age at onset);	chr19:9872345	chr19:9834079~9835013:-
THCA	cis	rs889122	0.684	rs1978453	ENSG00000267289.1	CTD-2623N2.11	4.2	3.15e-05	0.00285	0.24	0.19	Menarche (age at onset);	chr19:9872769	chr19:9834079~9835013:-
THCA	cis	rs889122	0.729	rs10413248	ENSG00000267289.1	CTD-2623N2.11	4.2	3.15e-05	0.00285	0.24	0.19	Menarche (age at onset);	chr19:9873420	chr19:9834079~9835013:-
THCA	cis	rs1861628	0.512	rs1548943	ENSG00000237930.1	AC007563.4	-4.2	3.15e-05	0.00285	-0.3	-0.19	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216754174	chr2:216785774~216786144:-
THCA	cis	rs17666538	0.585	rs4333567	ENSG00000254207.1	RP11-43A14.1	4.2	3.15e-05	0.00285	0.43	0.19	IgG glycosylation;	chr8:686611	chr8:725188~725877:-
THCA	cis	rs6560517	0.957	rs11144864	ENSG00000234618.1	RPSAP9	4.2	3.15e-05	0.00286	0.2	0.19	Dialysis-related mortality;	chr9:76381854	chr9:76398699~76399586:+
THCA	cis	rs2281636	0.6	rs56901709	ENSG00000260475.1	RP11-85A1.3	4.2	3.15e-05	0.00286	0.19	0.19	Obesity-related traits;	chr10:99639205	chr10:99621055~99621918:+
THCA	cis	rs9510787	0.538	rs9510804	ENSG00000205861.10	C1QTNF9B-AS1	-4.2	3.15e-05	0.00286	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23673665	chr13:23888889~23897263:+
THCA	cis	rs9510787	0.538	rs73156800	ENSG00000205861.10	C1QTNF9B-AS1	-4.2	3.15e-05	0.00286	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23676355	chr13:23888889~23897263:+
THCA	cis	rs6442522	0.568	rs3773461	ENSG00000249786.6	EAF1-AS1	4.2	3.15e-05	0.00286	0.2	0.19	Uric acid levels;	chr3:15453151	chr3:15436171~15455940:-
THCA	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-4.2	3.15e-05	0.00286	-0.18	-0.19	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
THCA	cis	rs227275	0.556	rs724447	ENSG00000248971.2	KRT8P46	4.2	3.15e-05	0.00286	0.23	0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102728746~102730171:-
THCA	cis	rs11641365	0.517	rs73262667	ENSG00000278341.1	RP5-1142A6.10	-4.2	3.15e-05	0.00286	-0.32	-0.19	Autism spectrum disorder-related traits;	chr16:88713345	chr16:88708956~88710437:-
THCA	cis	rs7551222	0.614	rs4951386	ENSG00000240219.1	RP11-430C7.5	4.2	3.15e-05	0.00286	0.18	0.19	Schizophrenia;	chr1:204485419	chr1:204626775~204629712:+
THCA	cis	rs7045881	0.735	rs7019692	ENSG00000254396.1	RP11-56F10.3	4.2	3.15e-05	0.00286	0.24	0.19	Schizophrenia;	chr9:26927855	chr9:27102630~27104728:+
THCA	cis	rs4237845	0.537	rs7969844	ENSG00000270039.1	RP11-571M6.17	-4.2	3.15e-05	0.00286	-0.21	-0.19	Intelligence (multi-trait analysis);	chr12:57884488	chr12:57803838~57804415:+
THCA	cis	rs2439831	0.867	rs7170489	ENSG00000205771.5	CATSPER2P1	-4.2	3.15e-05	0.00286	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43344453	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs16957630	ENSG00000205771.5	CATSPER2P1	-4.2	3.15e-05	0.00286	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43350582	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs16957632	ENSG00000205771.5	CATSPER2P1	-4.2	3.15e-05	0.00286	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43350699	chr15:43726918~43747094:-
THCA	cis	rs128738	0.505	rs13190293	ENSG00000237714.1	P4HA2-AS1	-4.2	3.15e-05	0.00286	-0.29	-0.19	Giant cell arteritis;	chr5:132231233	chr5:132184876~132192808:+
THCA	cis	rs7085104	0.514	rs284855	ENSG00000213061.2	PFN1P11	-4.2	3.15e-05	0.00286	-0.23	-0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102838011~102845473:-
THCA	cis	rs11671653	1	rs76291634	ENSG00000267100.1	ILF3-AS1	4.2	3.16e-05	0.00286	0.21	0.19	LDL cholesterol;	chr19:10725869	chr19:10651862~10653844:-
THCA	cis	rs453301	0.506	rs686189	ENSG00000254153.1	CTA-398F10.2	4.2	3.16e-05	0.00286	0.2	0.19	Joint mobility (Beighton score);	chr8:8766127	chr8:8456909~8461337:-
THCA	cis	rs330071	0.557	rs405001	ENSG00000254153.1	CTA-398F10.2	4.2	3.16e-05	0.00286	0.2	0.19	Acne (severe);	chr8:9307870	chr8:8456909~8461337:-
THCA	cis	rs1414896	0.646	rs965314	ENSG00000226026.4	RP11-57H12.3	-4.2	3.16e-05	0.00286	-0.18	-0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95168166	chr1:95163219~95233982:-
THCA	cis	rs1414896	0.646	rs17409555	ENSG00000226026.4	RP11-57H12.3	-4.2	3.16e-05	0.00286	-0.18	-0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95209154	chr1:95163219~95233982:-
THCA	cis	rs2839186	0.5	rs13052701	ENSG00000239415.1	AP001469.9	4.2	3.16e-05	0.00286	0.22	0.19	Testicular germ cell tumor;	chr21:46240131	chr21:46251549~46254133:-
THCA	cis	rs11583043	0.957	rs6667932	ENSG00000233184.5	RP11-421L21.3	4.2	3.16e-05	0.00286	0.2	0.19	Inflammatory bowel disease;Ulcerative colitis;	chr1:101038199	chr1:101025878~101087268:+
THCA	cis	rs9309473	0.519	rs2421574	ENSG00000163016.8	ALMS1P	-4.2	3.16e-05	0.00286	-0.23	-0.19	Metabolite levels;	chr2:73681640	chr2:73644919~73685576:+
THCA	cis	rs10875746	0.951	rs2228500	ENSG00000258234.1	RP11-370I10.2	-4.2	3.16e-05	0.00286	-0.22	-0.19	Longevity (90 years and older);	chr12:48132929	chr12:48231098~48284210:-
THCA	cis	rs763121	0.853	rs5750626	ENSG00000273076.1	RP3-508I15.22	4.2	3.16e-05	0.00286	0.19	0.19	Menopause (age at onset);	chr22:38581885	chr22:38743495~38743910:+
THCA	cis	rs4950322	0.518	rs56151278	ENSG00000226015.2	CCT8P1	4.2	3.16e-05	0.00286	0.22	0.19	Protein quantitative trait loci;	chr1:147117421	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.518	rs4950306	ENSG00000226015.2	CCT8P1	4.2	3.16e-05	0.00286	0.22	0.19	Protein quantitative trait loci;	chr1:147117838	chr1:147203276~147204932:-
THCA	cis	rs6472827	0.953	rs6472828	ENSG00000253983.2	RP1-16A9.1	-4.2	3.16e-05	0.00286	-0.31	-0.19	Uterine fibroids;	chr8:74210961	chr8:74199396~74208441:+
THCA	cis	rs2676071	0.767	rs907953	ENSG00000259721.1	RP11-758N13.1	-4.2	3.16e-05	0.00286	-0.24	-0.19	Periodontitis (Mean PAL);	chr15:33318904	chr15:32717270~32719007:-
THCA	cis	rs10875746	0.551	rs3751273	ENSG00000226413.2	OR8T1P	4.2	3.16e-05	0.00286	0.27	0.19	Longevity (90 years and older);	chr12:48345655	chr12:48442030~48442947:-
THCA	cis	rs7181230	1	rs28620926	ENSG00000275636.1	RP11-521C20.5	4.2	3.16e-05	0.00286	0.19	0.19	Dehydroepiandrosterone sulphate levels;	chr15:40064970	chr15:40078892~40079347:+
THCA	cis	rs79481398	0.584	rs11856034	ENSG00000276772.1	CTD-2515H24.2	4.2	3.16e-05	0.00286	0.23	0.19	Facial morphology (factor 19);	chr15:57486126	chr15:57553955~57555680:+
THCA	cis	rs1842579	0.658	rs11161676	ENSG00000272691.1	RP11-290M5.4	-4.2	3.16e-05	0.00286	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85803578	chr1:85578500~85578742:-
THCA	cis	rs7772486	0.79	rs2243665	ENSG00000270638.1	RP3-466P17.1	4.2	3.16e-05	0.00286	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145735570~145737218:+
THCA	cis	rs447735	0.587	rs11640702	ENSG00000260259.1	RP11-368I7.4	-4.2	3.16e-05	0.00286	-0.21	-0.19	Hemoglobin concentration;	chr16:89662761	chr16:89682620~89686569:-
THCA	cis	rs11658311	1	rs11656769	ENSG00000232344.2	AC087163.2	4.2	3.16e-05	0.00286	0.28	0.19	Obsessive-compulsive symptoms;	chr17:17696536	chr17:18010643~18011822:+
THCA	cis	rs7824557	0.527	rs2572376	ENSG00000206014.6	OR7E161P	4.2	3.16e-05	0.00286	0.22	0.19	Retinal vascular caliber;	chr8:11380247	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.527	rs2736305	ENSG00000206014.6	OR7E161P	4.2	3.16e-05	0.00286	0.22	0.19	Retinal vascular caliber;	chr8:11380264	chr8:11928597~11929563:-
THCA	cis	rs1560104	0.675	rs9927247	ENSG00000259876.1	CTD-3037G24.4	4.2	3.16e-05	0.00286	0.22	0.19	Obesity-related traits;	chr16:12611124	chr16:12556353~12557694:-
THCA	cis	rs8141529	0.748	rs2064261	ENSG00000226471.5	CTA-292E10.6	-4.2	3.16e-05	0.00286	-0.16	-0.19	Lymphocyte counts;	chr22:28891742	chr22:28800683~28848559:+
THCA	cis	rs7726839	0.526	rs11960158	ENSG00000225138.6	CTD-2228K2.7	4.2	3.16e-05	0.00286	0.22	0.19	Obesity-related traits;	chr5:568550	chr5:473236~480884:+
THCA	cis	rs13256369	0.762	rs13278972	ENSG00000248538.5	RP11-10A14.5	-4.2	3.16e-05	0.00286	-0.25	-0.19	Obesity-related traits;	chr8:8739670	chr8:9189011~9202854:+
THCA	cis	rs2434529	1	rs73802964	ENSG00000245275.6	SAP30L-AS1	4.2	3.16e-05	0.00286	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154243261	chr5:154329437~154445850:-
THCA	cis	rs4718428	1	rs1830070	ENSG00000229886.1	RP5-1132H15.3	4.2	3.16e-05	0.00286	0.2	0.19	Corneal structure;	chr7:66884684	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs35149210	ENSG00000229886.1	RP5-1132H15.3	4.2	3.16e-05	0.00286	0.2	0.19	Aortic root size;	chr7:66464938	chr7:66025126~66031544:-
THCA	cis	rs9510787	0.537	rs3794344	ENSG00000205861.10	C1QTNF9B-AS1	-4.2	3.16e-05	0.00286	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23658569	chr13:23888889~23897263:+
THCA	cis	rs9902453	0.765	rs6505143	ENSG00000263370.1	RP11-68I3.5	4.2	3.16e-05	0.00287	0.25	0.19	Coffee consumption (cups per day);	chr17:29823567	chr17:29639627~29640825:+
THCA	cis	rs9625935	0.879	rs36591	ENSG00000279159.1	RP3-394A18.1	4.2	3.16e-05	0.00287	0.15	0.19	Tonsillectomy;	chr22:29932774	chr22:29978950~30028236:-
THCA	cis	rs4144027	0.904	rs10438244	ENSG00000269958.1	RP11-73M18.8	-4.2	3.17e-05	0.00287	-0.18	-0.19	Blood metabolite levels;	chr14:103879848	chr14:103696353~103697163:+
THCA	cis	rs7216064	0.953	rs12601759	ENSG00000265055.1	AC145343.2	4.2	3.17e-05	0.00287	0.27	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67959168	chr17:68096046~68101474:-
THCA	cis	rs2070488	1	rs13089394	ENSG00000229589.1	ACVR2B-AS1	4.2	3.17e-05	0.00287	0.18	0.19	Electrocardiographic conduction measures;	chr3:38404818	chr3:38451027~38454820:-
THCA	cis	rs9316337	0.864	rs4769163	ENSG00000236953.1	ZDHHC20-IT1	-4.2	3.17e-05	0.00287	-0.2	-0.19	Schizophrenia;	chr13:21371729	chr13:21376977~21377874:-
THCA	cis	rs6840258	0.64	rs66527077	ENSG00000251411.1	RP11-397E7.4	-4.2	3.17e-05	0.00287	-0.22	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87188846	chr4:86913266~86914817:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000272831.1	RP11-792A8.4	-4.2	3.17e-05	0.00287	-0.12	-0.19	Aortic root size;	chr7:66570949	chr7:66739829~66740385:-
THCA	cis	rs4788570	0.615	rs10852503	ENSG00000260593.1	RP11-432I5.2	-4.2	3.17e-05	0.00287	-0.3	-0.19	Intelligence (multi-trait analysis);	chr16:71618324	chr16:71623708~71626816:-
THCA	cis	rs7182948	1	rs1605483	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49533639	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs8034473	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49537443	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs967892	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49540056	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs967893	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49540071	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.958	rs1848286	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49545346	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs11070705	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49551454	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs2413963	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49555934	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs1395900	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49557400	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs11070707	ENSG00000259531.2	RP11-295H24.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Lung adenocarcinoma;	chr15:49567438	chr15:49365124~49366685:-
THCA	cis	rs12034383	0.902	rs2274566	ENSG00000274245.1	RP11-357P18.2	4.2	3.17e-05	0.00287	0.17	0.19	Erythrocyte sedimentation rate;	chr1:207580000	chr1:207372559~207373252:+
THCA	cis	rs12935229	0.623	rs9939072	ENSG00000260922.1	RP11-538I12.3	-4.2	3.17e-05	0.00287	-0.28	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77267417	chr16:77234877~77290934:+
THCA	cis	rs4906332	0.966	rs12894275	ENSG00000269910.1	RP11-73M18.10	-4.2	3.17e-05	0.00287	-0.16	-0.19	Coronary artery disease;	chr14:103435087	chr14:103694516~103695050:-
THCA	cis	rs6591182	0.504	rs7116712	ENSG00000245532.5	NEAT1	-4.2	3.17e-05	0.00287	-0.13	-0.19	Non-alcoholic fatty liver disease histology (lobular);	chr11:65605047	chr11:65422774~65445540:+
THCA	cis	rs4660456	0.572	rs7519348	ENSG00000238287.1	RP11-656D10.3	-4.2	3.17e-05	0.00287	-0.22	-0.19	Platelet count;	chr1:40694532	chr1:40493157~40508661:-
THCA	cis	rs896854	0.608	rs7004862	ENSG00000253528.2	RP11-347C18.4	4.2	3.17e-05	0.00287	0.21	0.19	Type 2 diabetes;	chr8:94864735	chr8:94974573~94974853:-
THCA	cis	rs786425	0.711	rs36018806	ENSG00000270095.1	RP11-214K3.18	-4.2	3.17e-05	0.00287	-0.23	-0.19	Pubertal anthropometrics;	chr12:123630005	chr12:123971457~123971714:-
THCA	cis	rs13118159	0.509	rs7681872	ENSG00000254094.1	AC078852.1	-4.2	3.17e-05	0.00287	-0.22	-0.19	Longevity;	chr4:1382947	chr4:1356581~1358075:+
THCA	cis	rs889398	0.771	rs1566453	ENSG00000226232.7	RP11-419C5.2	-4.2	3.17e-05	0.00287	-0.19	-0.19	Body mass index;	chr16:69865884	chr16:69976388~69996188:-
THCA	cis	rs10875746	0.81	rs10875732	ENSG00000258273.1	RP11-370I10.4	4.2	3.17e-05	0.00287	0.28	0.19	Longevity (90 years and older);	chr12:48048322	chr12:48333755~48333901:-
THCA	cis	rs9341808	0.652	rs2505940	ENSG00000272129.1	RP11-250B2.6	4.2	3.17e-05	0.00287	0.24	0.19	Sitting height ratio;	chr6:80141474	chr6:80355424~80356859:+
THCA	cis	rs11673344	0.526	rs8101610	ENSG00000267422.1	CTD-2554C21.1	-4.2	3.17e-05	0.00287	-0.19	-0.19	Obesity-related traits;	chr19:37566604	chr19:37779686~37792865:+
THCA	cis	rs4805272	1	rs888832	ENSG00000267799.1	MAN1A2P1	4.2	3.17e-05	0.00287	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833656	chr19:28790812~28792871:-
THCA	cis	rs9527	0.637	rs11191424	ENSG00000272912.1	RP11-724N1.1	-4.2	3.17e-05	0.00287	-0.23	-0.19	Arsenic metabolism;	chr10:102866129	chr10:102914585~102915404:+
THCA	cis	rs12142240	0.66	rs72885163	ENSG00000232022.5	FAAHP1	-4.2	3.17e-05	0.00287	-0.21	-0.19	Menopause (age at onset);	chr1:46341445	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs68083747	ENSG00000232022.5	FAAHP1	-4.2	3.17e-05	0.00287	-0.21	-0.19	Menopause (age at onset);	chr1:46341744	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs66972124	ENSG00000232022.5	FAAHP1	-4.2	3.17e-05	0.00287	-0.21	-0.19	Menopause (age at onset);	chr1:46341773	chr1:46432129~46445521:+
THCA	cis	rs875971	0.929	rs6970860	ENSG00000229886.1	RP5-1132H15.3	4.2	3.17e-05	0.00287	0.2	0.19	Aortic root size;	chr7:66511647	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs6957199	ENSG00000229886.1	RP5-1132H15.3	4.2	3.17e-05	0.00287	0.2	0.19	Aortic root size;	chr7:66513532	chr7:66025126~66031544:-
THCA	cis	rs2777491	0.54	rs7164684	ENSG00000247556.5	OIP5-AS1	4.2	3.18e-05	0.00287	0.18	0.19	Ulcerative colitis;	chr15:41412810	chr15:41283990~41309737:+
THCA	cis	rs9813712	0.909	rs1453257	ENSG00000253540.4	FAM86HP	-4.2	3.18e-05	0.00287	-0.23	-0.19	Response to amphetamines;	chr3:130258730	chr3:130099092~130111472:-
THCA	cis	rs9813712	0.953	rs1453256	ENSG00000253540.4	FAM86HP	-4.2	3.18e-05	0.00287	-0.23	-0.19	Response to amphetamines;	chr3:130258787	chr3:130099092~130111472:-
THCA	cis	rs9813712	0.953	rs935916	ENSG00000253540.4	FAM86HP	-4.2	3.18e-05	0.00287	-0.23	-0.19	Response to amphetamines;	chr3:130258931	chr3:130099092~130111472:-
THCA	cis	rs4792901	0.918	rs12103666	ENSG00000267151.3	RP11-100E5.2	4.2	3.18e-05	0.00287	0.2	0.19	Dupuytren's disease;	chr17:43558942	chr17:43444707~43451200:+
THCA	cis	rs7968440	0.933	rs2684889	ENSG00000272368.2	RP4-605O3.4	4.2	3.18e-05	0.00287	0.12	0.19	Fibrinogen;	chr12:50686091	chr12:50112197~50165618:+
THCA	cis	rs7968440	1	rs2700482	ENSG00000272368.2	RP4-605O3.4	4.2	3.18e-05	0.00287	0.12	0.19	Fibrinogen;	chr12:50689482	chr12:50112197~50165618:+
THCA	cis	rs10760158	0.832	rs12238702	ENSG00000226752.6	PSMD5-AS1	-4.2	3.18e-05	0.00287	-0.23	-0.19	Pulse pressure;	chr9:121237547	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs10985188	ENSG00000226752.6	PSMD5-AS1	-4.2	3.18e-05	0.00287	-0.23	-0.19	Pulse pressure;	chr9:121237747	chr9:120824828~120854385:+
THCA	cis	rs6001482	0.679	rs5750786	ENSG00000272779.1	LL22NC03-80A10.6	-4.2	3.18e-05	0.00288	-0.21	-0.19	Diastolic blood pressure;	chr22:22235358	chr22:22303224~22310401:+
THCA	cis	rs3764021	0.527	rs10844456	ENSG00000214776.8	RP11-726G1.1	4.2	3.18e-05	0.00288	0.25	0.19	Type 1 diabetes;	chr12:9689319	chr12:9467552~9576275:+
THCA	cis	rs4742903	0.904	rs7048676	ENSG00000270332.1	SMC2-AS1	4.2	3.18e-05	0.00288	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104236068	chr9:104080024~104093073:-
THCA	cis	rs7402982	0.625	rs4966009	ENSG00000259424.1	RP11-35O15.1	4.2	3.18e-05	0.00288	0.2	0.19	Birth weight;	chr15:98660267	chr15:98646951~98647371:-
THCA	cis	rs478304	0.593	rs75162774	ENSG00000255557.1	RP11-770G2.2	4.2	3.18e-05	0.00288	0.23	0.19	Acne (severe);	chr11:65725012	chr11:65745729~65771585:+
THCA	cis	rs2070488	0.965	rs6599206	ENSG00000229589.1	ACVR2B-AS1	-4.2	3.18e-05	0.00288	-0.18	-0.19	Electrocardiographic conduction measures;	chr3:38503858	chr3:38451027~38454820:-
THCA	cis	rs875971	0.545	rs6979636	ENSG00000273142.1	RP11-458F8.4	4.2	3.18e-05	0.00288	0.18	0.19	Aortic root size;	chr7:66276638	chr7:66902857~66906297:+
THCA	cis	rs8031584	0.918	rs34331396	ENSG00000270015.1	RP11-540B6.6	-4.2	3.18e-05	0.00288	-0.14	-0.19	Huntington's disease progression;	chr15:30956533	chr15:30926514~30928407:+
THCA	cis	rs801193	1	rs2707856	ENSG00000223473.2	GS1-124K5.3	4.2	3.18e-05	0.00288	0.12	0.19	Aortic root size;	chr7:66746023	chr7:66491049~66493566:-
THCA	cis	rs6494488	0.5	rs72741386	ENSG00000259635.1	AC100830.3	-4.2	3.18e-05	0.00288	-0.49	-0.19	Coronary artery disease;	chr15:64519884	chr15:64701248~64719602:+
THCA	cis	rs8003054	0.589	rs999692	ENSG00000258515.1	RP11-203M5.7	-4.2	3.18e-05	0.00288	-0.13	-0.19	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20449506	chr14:20451305~20451918:+
THCA	cis	rs3796352	0.667	rs9968117	ENSG00000242142.1	SERBP1P3	-4.2	3.18e-05	0.00288	-0.33	-0.19	Immune reponse to smallpox (secreted IL-2);	chr3:52804638	chr3:53064283~53065091:-
THCA	cis	rs12428035	0.764	rs72636556	ENSG00000247400.3	DNAJC3-AS1	-4.2	3.18e-05	0.00288	-0.18	-0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95898481	chr13:95648733~95676925:-
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000273796.1	LL21NC02-21A1.1	-4.2	3.18e-05	0.00288	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45403809~45404369:-
THCA	cis	rs11971779	0.711	rs6961204	ENSG00000252332.1	RNU6-911P	-4.2	3.18e-05	0.00288	-0.24	-0.19	Diisocyanate-induced asthma;	chr7:139362653	chr7:139448740~139448843:+
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000234585.5	CCT6P3	4.2	3.18e-05	0.00288	0.17	0.19	Calcium levels;	chr7:65941231	chr7:65038354~65074713:+
THCA	cis	rs6442522	0.526	rs909354	ENSG00000249786.6	EAF1-AS1	4.2	3.18e-05	0.00288	0.2	0.19	Uric acid levels;	chr3:15478737	chr3:15436171~15455940:-
THCA	cis	rs6878727	0.813	rs2194106	ENSG00000253807.4	LINC01170	-4.2	3.18e-05	0.00288	-0.19	-0.19	Breast cancer;	chr5:124368581	chr5:124059794~124405079:-
THCA	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	4.2	3.18e-05	0.00288	0.29	0.19	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
THCA	cis	rs2115630	0.967	rs7171167	ENSG00000275120.1	RP11-182J1.17	-4.2	3.18e-05	0.00288	-0.2	-0.19	P wave terminal force;	chr15:84695892	chr15:84599434~84606463:-
THCA	cis	rs7246657	0.507	rs8107654	ENSG00000276846.1	CTD-3220F14.3	4.2	3.18e-05	0.00288	0.23	0.19	Coronary artery calcification;	chr19:36962632	chr19:37314868~37315620:-
THCA	cis	rs801193	0.66	rs10950049	ENSG00000229886.1	RP5-1132H15.3	4.2	3.18e-05	0.00288	0.2	0.19	Aortic root size;	chr7:66765873	chr7:66025126~66031544:-
THCA	cis	rs962856	1	rs6739392	ENSG00000236780.4	AC078941.1	4.2	3.18e-05	0.00288	0.23	0.19	Pancreatic cancer;	chr2:67374839	chr2:67123357~67215319:-
THCA	cis	rs7829975	0.902	rs485107	ENSG00000253981.4	ALG1L13P	-4.2	3.18e-05	0.00288	-0.18	-0.19	Mood instability;	chr8:8723898	chr8:8236003~8244667:-
THCA	cis	rs12612619	0.677	rs2053386	ENSG00000272148.1	RP11-195B17.1	4.2	3.18e-05	0.00288	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27021844	chr2:27062428~27062907:-
THCA	cis	rs801193	1	rs2420824	ENSG00000229180.5	GS1-124K5.11	-4.2	3.18e-05	0.00288	-0.13	-0.19	Aortic root size;	chr7:66666129	chr7:66526088~66542624:-
THCA	cis	rs2617170	0.732	rs2734423	ENSG00000245648.1	RP11-277P12.20	4.2	3.18e-05	0.00288	0.2	0.19	Behcet's disease;	chr12:10429008	chr12:10363769~10398506:+
THCA	cis	rs4938303	0.633	rs35963862	ENSG00000254851.1	RP11-109L13.1	4.2	3.19e-05	0.00288	0.32	0.19	Triglycerides;	chr11:116679180	chr11:117135528~117138582:+
THCA	cis	rs889398	0.56	rs4985445	ENSG00000226232.7	RP11-419C5.2	-4.2	3.19e-05	0.00288	-0.18	-0.19	Body mass index;	chr16:69833932	chr16:69976388~69996188:-
THCA	cis	rs5758659	0.652	rs6519301	ENSG00000281538.1	RP4-669P10.20	4.2	3.19e-05	0.00288	0.18	0.19	Cognitive function;	chr22:41989963	chr22:42138060~42139726:+
THCA	cis	rs656319	0.565	rs73189192	ENSG00000248538.5	RP11-10A14.5	4.2	3.19e-05	0.00288	0.26	0.19	Myopia (pathological);	chr8:10053129	chr8:9189011~9202854:+
THCA	cis	rs2562784	0.638	rs2585056	ENSG00000225151.9	GOLGA2P7	-4.2	3.19e-05	0.00288	-0.35	-0.19	Height;	chr15:83613463	chr15:84199311~84230136:-
THCA	cis	rs9543976	0.614	rs73223955	ENSG00000261105.4	LMO7-AS1	-4.2	3.19e-05	0.00288	-0.33	-0.19	Diabetic retinopathy;	chr13:75529075	chr13:75604700~75635994:-
THCA	cis	rs71520386	0.561	rs10274260	ENSG00000226329.2	AC005682.6	-4.2	3.19e-05	0.00288	-0.24	-0.19	Fibrinogen levels;	chr7:22805227	chr7:22863874~22881350:-
THCA	cis	rs11846409	1	rs11846409	ENSG00000274576.2	IGHV2-70	-4.2	3.19e-05	0.00288	-0.16	-0.19	Rheumatic heart disease;	chr14:106645692	chr14:106770577~106771020:-
THCA	cis	rs2303759	0.709	rs3760667	ENSG00000268686.1	AC010524.2	-4.2	3.19e-05	0.00288	-0.29	-0.19	Multiple sclerosis;	chr19:49311575	chr19:49368705~49388081:-
THCA	cis	rs2303759	0.709	rs10414921	ENSG00000268686.1	AC010524.2	-4.2	3.19e-05	0.00288	-0.29	-0.19	Multiple sclerosis;	chr19:49319790	chr19:49368705~49388081:-
THCA	cis	rs2303759	0.709	rs10411679	ENSG00000268686.1	AC010524.2	-4.2	3.19e-05	0.00288	-0.29	-0.19	Multiple sclerosis;	chr19:49323223	chr19:49368705~49388081:-
THCA	cis	rs2303759	0.709	rs8102658	ENSG00000268686.1	AC010524.2	-4.2	3.19e-05	0.00288	-0.29	-0.19	Multiple sclerosis;	chr19:49325598	chr19:49368705~49388081:-
THCA	cis	rs4788570	0.615	rs7193549	ENSG00000260593.1	RP11-432I5.2	-4.2	3.19e-05	0.00288	-0.31	-0.19	Intelligence (multi-trait analysis);	chr16:71615513	chr16:71623708~71626816:-
THCA	cis	rs9876781	0.56	rs4558783	ENSG00000244380.1	RP11-24C3.2	-4.2	3.19e-05	0.00289	-0.23	-0.19	Longevity;	chr3:48365972	chr3:48440352~48446656:-
THCA	cis	rs4713118	0.662	rs149969	ENSG00000219891.2	ZSCAN12P1	4.2	3.19e-05	0.00289	0.25	0.19	Parkinson's disease;	chr6:28009959	chr6:28091154~28093664:+
THCA	cis	rs10411161	0.702	rs79180893	ENSG00000275055.1	CTC-471J1.11	-4.2	3.19e-05	0.00289	-0.19	-0.19	Breast cancer;	chr19:51892362	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs11879436	ENSG00000275055.1	CTC-471J1.11	-4.2	3.19e-05	0.00289	-0.19	-0.19	Breast cancer;	chr19:51894562	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs10420224	ENSG00000275055.1	CTC-471J1.11	-4.2	3.19e-05	0.00289	-0.19	-0.19	Breast cancer;	chr19:51895702	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs75647161	ENSG00000275055.1	CTC-471J1.11	-4.2	3.19e-05	0.00289	-0.19	-0.19	Breast cancer;	chr19:51895731	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs17778790	ENSG00000275055.1	CTC-471J1.11	-4.2	3.19e-05	0.00289	-0.19	-0.19	Breast cancer;	chr19:51896306	chr19:52049007~52049754:+
THCA	cis	rs2708377	0.789	rs3911150	ENSG00000247157.5	LINC01252	-4.2	3.19e-05	0.00289	-0.33	-0.19	Bitter taste perception;	chr12:11049649	chr12:11548030~11590369:+
THCA	cis	rs12073837	0.5	rs2807845	ENSG00000238078.1	LINC01352	-4.2	3.19e-05	0.00289	-0.23	-0.19	F-cell distribution;	chr1:220822945	chr1:220829255~220832429:+
THCA	cis	rs8062405	0.824	rs4788084	ENSG00000270424.1	RP11-1348G14.6	4.2	3.19e-05	0.00289	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28749959~28750595:-
THCA	cis	rs7209700	0.547	rs61131650	ENSG00000228782.6	CTD-2026D20.3	-4.2	3.19e-05	0.00289	-0.21	-0.19	IgG glycosylation;	chr17:47266961	chr17:47450568~47492492:-
THCA	cis	rs12451471	0.637	rs7567	ENSG00000279259.1	RP11-334C17.3	-4.2	3.19e-05	0.00289	-0.2	-0.19	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80119750	chr17:80147250~80148596:+
THCA	cis	rs7819412	1	rs7819412	ENSG00000206014.6	OR7E161P	-4.2	3.19e-05	0.00289	-0.22	-0.19	Triglycerides;	chr8:11187652	chr8:11928597~11929563:-
THCA	cis	rs801193	0.904	rs4718405	ENSG00000230295.1	RP11-458F8.2	-4.2	3.19e-05	0.00289	-0.15	-0.19	Aortic root size;	chr7:66789659	chr7:66880708~66882981:+
THCA	cis	rs13434995	0.513	rs60097207	ENSG00000249700.7	SRD5A3-AS1	-4.2	3.19e-05	0.00289	-0.27	-0.19	Adiponectin levels;	chr4:55406696	chr4:55363971~55395847:-
THCA	cis	rs786425	0.677	rs11834141	ENSG00000270095.1	RP11-214K3.18	-4.2	3.19e-05	0.00289	-0.23	-0.19	Pubertal anthropometrics;	chr12:123666149	chr12:123971457~123971714:-
THCA	cis	rs786425	0.59	rs7296804	ENSG00000270095.1	RP11-214K3.18	-4.2	3.19e-05	0.00289	-0.23	-0.19	Pubertal anthropometrics;	chr12:123669316	chr12:123971457~123971714:-
THCA	cis	rs5753037	0.653	rs140121	ENSG00000273350.1	RP4-539M6.20	-4.2	3.19e-05	0.00289	-0.21	-0.19	Type 1 diabetes;	chr22:29742700	chr22:30420512~30420912:+
THCA	cis	rs4664293	0.737	rs1549579	ENSG00000230783.1	AC009961.2	-4.2	3.19e-05	0.00289	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159812150	chr2:159689217~159690291:-
THCA	cis	rs4713118	0.523	rs2179096	ENSG00000280107.1	AL022393.9	-4.2	3.19e-05	0.00289	-0.19	-0.19	Parkinson's disease;	chr6:27698141	chr6:28170845~28172521:+
THCA	cis	rs9393813	0.529	rs4711155	ENSG00000204789.4	ZNF204P	-4.2	3.19e-05	0.00289	-0.15	-0.19	Bipolar disorder;	chr6:27478667	chr6:27357825~27360221:-
THCA	cis	rs7572733	0.534	rs696817	ENSG00000231621.1	AC013264.2	-4.2	3.2e-05	0.00289	-0.2	-0.19	Dermatomyositis;	chr2:197857501	chr2:197197991~197199273:+
THCA	cis	rs6570726	0.791	rs408443	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs436156	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145735570~145737218:+
THCA	cis	rs7577696	0.671	rs72863940	ENSG00000276334.1	AL133243.1	-4.2	3.2e-05	0.00289	-0.2	-0.19	Inflammatory biomarkers;	chr2:32169605	chr2:32521927~32523547:+
THCA	cis	rs6570726	0.791	rs447992	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs425999	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs387376	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.764	rs1912023	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs9376945	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.755	rs451699	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs401561	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs405206	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs374478	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145735570~145737218:+
THCA	cis	rs8031584	0.918	rs11639169	ENSG00000270015.1	RP11-540B6.6	-4.2	3.2e-05	0.00289	-0.15	-0.19	Huntington's disease progression;	chr15:30963235	chr15:30926514~30928407:+
THCA	cis	rs4144027	0.869	rs55924227	ENSG00000269910.1	RP11-73M18.10	4.2	3.2e-05	0.00289	0.17	0.19	Blood metabolite levels;	chr14:103895013	chr14:103694516~103695050:-
THCA	cis	rs738722	0.808	rs5752775	ENSG00000272858.1	CTA-292E10.8	-4.2	3.2e-05	0.00289	-0.19	-0.19	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28711207	chr22:28814914~28815662:+
THCA	cis	rs2754412	1	rs2754412	ENSG00000120555.12	SEPT7P9	4.2	3.2e-05	0.00289	0.21	0.19	Breast cancer;	chr10:38338906	chr10:38383069~38402916:-
THCA	cis	rs6496932	0.802	rs6497006	ENSG00000259630.2	CTD-2262B20.1	4.2	3.2e-05	0.00289	0.23	0.19	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85415228~85415633:+
THCA	cis	rs6756513	0.5	rs17037193	ENSG00000231024.1	AC092431.3	-4.2	3.2e-05	0.00289	-0.28	-0.19	Breast cancer;Platelet count;	chr2:69876372	chr2:69700192~69713847:-
THCA	cis	rs867186	1	rs11907010	ENSG00000126005.14	MMP24-AS1	-4.2	3.2e-05	0.00289	-0.3	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35149858	chr20:35216462~35278131:-
THCA	cis	rs6977955	1	rs67250450	ENSG00000234336.5	JAZF1-AS1	-4.2	3.2e-05	0.00289	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr7:28135367	chr7:28180322~28243917:+
THCA	cis	rs7615952	0.512	rs2979351	ENSG00000272840.1	RP11-379B18.6	4.2	3.2e-05	0.00289	0.27	0.19	Blood pressure (smoking interaction);	chr3:125644755	chr3:125774714~125797953:+
THCA	cis	rs10435719	0.867	rs62493601	ENSG00000254948.1	OR7E158P	-4.2	3.2e-05	0.00289	-0.24	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:11919900~11920809:-
THCA	cis	rs17772222	0.565	rs845759	ENSG00000222990.1	RNU4-22P	-4.2	3.2e-05	0.00289	-0.23	-0.19	Coronary artery calcification;	chr14:88415538	chr14:88513498~88513663:+
THCA	cis	rs8177876	0.822	rs4889231	ENSG00000261838.4	RP11-303E16.6	-4.2	3.2e-05	0.00289	-0.32	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81069854~81076598:+
THCA	cis	rs7520050	0.966	rs6429582	ENSG00000234329.1	RP11-767N6.2	4.2	3.2e-05	0.00289	0.17	0.19	Reticulocyte count;Red blood cell count;	chr1:45856171	chr1:45651039~45651826:-
THCA	cis	rs4308124	0.708	rs6749633	ENSG00000230499.1	AC108463.1	4.2	3.2e-05	0.00289	0.28	0.19	Vitiligo;	chr2:111230439	chr2:111195963~111206494:+
THCA	cis	rs6570726	0.818	rs437147	ENSG00000270638.1	RP3-466P17.1	4.2	3.2e-05	0.00289	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145735570~145737218:+
THCA	cis	rs6657613	0.815	rs9435741	ENSG00000186301.8	MST1P2	4.2	3.2e-05	0.0029	0.16	0.19	Hip circumference adjusted for BMI;	chr1:17017409	chr1:16645622~16650289:+
THCA	cis	rs4906332	1	rs35366629	ENSG00000269910.1	RP11-73M18.10	4.2	3.2e-05	0.0029	0.16	0.19	Coronary artery disease;	chr14:103436717	chr14:103694516~103695050:-
THCA	cis	rs853679	0.527	rs1997660	ENSG00000176933.5	TOB2P1	-4.2	3.2e-05	0.0029	-0.21	-0.19	Depression;	chr6:28301886	chr6:28217643~28218634:-
THCA	cis	rs2028299	0.839	rs2279848	ENSG00000259677.1	RP11-493E3.1	4.2	3.2e-05	0.0029	0.25	0.19	Type 2 diabetes;	chr15:89901449	chr15:89876540~89877285:+
THCA	cis	rs4081724	0.565	rs73024238	ENSG00000267296.2	CEBPA-AS1	4.2	3.2e-05	0.0029	0.29	0.19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33310182	chr19:33302857~33305054:+
THCA	cis	rs4081724	0.565	rs7251505	ENSG00000267296.2	CEBPA-AS1	4.2	3.2e-05	0.0029	0.29	0.19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33311636	chr19:33302857~33305054:+
THCA	cis	rs17270561	0.609	rs1408271	ENSG00000272462.2	U91328.19	-4.2	3.2e-05	0.0029	-0.16	-0.19	Iron status biomarkers;	chr6:25859393	chr6:25992662~26001775:+
THCA	cis	rs7179456	0.515	rs602602	ENSG00000245975.2	RP11-30K9.6	4.2	3.2e-05	0.0029	0.18	0.19	Asperger disorder;	chr15:58764824	chr15:58768072~58770974:-
THCA	cis	rs11168351	0.75	rs11168366	ENSG00000273765.1	RP11-370I10.11	-4.2	3.2e-05	0.0029	-0.2	-0.19	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48360920~48361377:+
THCA	cis	rs2039553	0.548	rs11619959	ENSG00000227354.5	RBM26-AS1	-4.2	3.2e-05	0.0029	-0.18	-0.19	Pancreatic cancer;	chr13:79762510	chr13:79406309~79424328:+
THCA	cis	rs801193	1	rs2659915	ENSG00000272831.1	RP11-792A8.4	4.2	3.2e-05	0.0029	0.12	0.19	Aortic root size;	chr7:66688114	chr7:66739829~66740385:-
THCA	cis	rs12497850	0.931	rs7616815	ENSG00000228638.1	FCF1P2	-4.2	3.2e-05	0.0029	-0.2	-0.19	Parkinson's disease;	chr3:48742282	chr3:48290793~48291375:-
THCA	cis	rs10090774	0.71	rs10104479	ENSG00000280303.2	ERICD	-4.2	3.21e-05	0.0029	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140683972	chr8:140636281~140638283:+
THCA	cis	rs1836229	0.869	rs7864663	ENSG00000225706.1	PTPRD-AS1	-4.2	3.21e-05	0.0029	-0.22	-0.19	Restless legs syndrome;	chr9:8824417	chr9:8858130~8862255:+
THCA	cis	rs2115630	0.967	rs7171167	ENSG00000259295.5	CSPG4P12	-4.2	3.21e-05	0.0029	-0.26	-0.19	P wave terminal force;	chr15:84695892	chr15:85191438~85213905:+
THCA	cis	rs7968440	1	rs7305655	ENSG00000272368.2	RP4-605O3.4	-4.2	3.21e-05	0.0029	-0.12	-0.19	Fibrinogen;	chr12:50611506	chr12:50112197~50165618:+
THCA	cis	rs7737355	0.773	rs3756291	ENSG00000237714.1	P4HA2-AS1	4.2	3.21e-05	0.0029	0.26	0.19	Life satisfaction;	chr5:131591129	chr5:132184876~132192808:+
THCA	cis	rs27434	0.615	rs61112531	ENSG00000272109.1	CTD-2260A17.3	4.2	3.21e-05	0.0029	0.31	0.19	Ankylosing spondylitis;	chr5:96856117	chr5:96804353~96806105:+
THCA	cis	rs72819454	0.522	rs4917399	ENSG00000280693.1	SH3PXD2A-AS1	-4.2	3.21e-05	0.0029	-0.35	-0.19	Interleukin-9 levels;	chr10:103769861	chr10:103745966~103755423:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000272831.1	RP11-792A8.4	-4.2	3.21e-05	0.0029	-0.12	-0.19	Aortic root size;	chr7:66113790	chr7:66739829~66740385:-
THCA	cis	rs7403037	0.583	rs4778296	ENSG00000260760.1	PWRN3	4.2	3.21e-05	0.0029	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24373429	chr15:24441127~24447967:+
THCA	cis	rs7731390	0.717	rs113742046	ENSG00000233006.5	AC034220.3	4.2	3.21e-05	0.0029	0.27	0.19	IgG glycosylation;	chr5:132275302	chr5:132311285~132369916:-
THCA	cis	rs10484434	0.901	rs59281021	ENSG00000272810.1	U91328.22	4.2	3.21e-05	0.0029	0.19	0.19	HIV-1 viral setpoint;	chr6:25978803	chr6:26013241~26013757:+
THCA	cis	rs758324	0.606	rs804437	ENSG00000224431.1	AC063976.7	-4.2	3.21e-05	0.0029	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132165007	chr5:132199456~132203487:+
THCA	cis	rs55702914	0.712	rs10931778	ENSG00000231621.1	AC013264.2	4.2	3.21e-05	0.0029	0.18	0.19	Major depression and alcohol dependence;	chr2:197284198	chr2:197197991~197199273:+
THCA	cis	rs2777491	0.522	rs7173571	ENSG00000247556.5	OIP5-AS1	4.2	3.21e-05	0.0029	0.16	0.19	Ulcerative colitis;	chr15:41420609	chr15:41283990~41309737:+
THCA	cis	rs13182402	1	rs13177576	ENSG00000230929.5	RP11-395C3.1	-4.2	3.21e-05	0.0029	-0.38	-0.19	Osteoporosis;	chr5:126581557	chr5:126628019~126628319:-
THCA	cis	rs10761482	0.861	rs7084499	ENSG00000254271.1	RP11-131N11.4	4.2	3.21e-05	0.0029	0.25	0.19	Schizophrenia;	chr10:60347124	chr10:60734342~60741828:+
THCA	cis	rs9834970	0.588	rs28522146	ENSG00000281100.1	RP11-640L9.2	-4.2	3.21e-05	0.0029	-0.2	-0.19	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36865331	chr3:36823151~36825158:-
THCA	cis	rs56046484	0.871	rs7177110	ENSG00000259630.2	CTD-2262B20.1	-4.2	3.21e-05	0.0029	-0.26	-0.19	Testicular germ cell tumor;	chr15:85128524	chr15:85415228~85415633:+
THCA	cis	rs17122278	1	rs11552421	ENSG00000243431.1	RPL5P30	4.2	3.21e-05	0.0029	0.19	0.19	Total cholesterol levels;	chr11:118559804	chr11:118560690~118561580:+
THCA	cis	rs7259376	0.905	rs7258446	ENSG00000269138.1	ZNF209P	4.2	3.21e-05	0.0029	0.19	0.19	Menopause (age at onset);	chr19:22367539	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs17391718	ENSG00000269138.1	ZNF209P	4.2	3.21e-05	0.0029	0.19	0.19	Menopause (age at onset);	chr19:22371352	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.905	rs56027264	ENSG00000269138.1	ZNF209P	4.2	3.21e-05	0.0029	0.19	0.19	Menopause (age at onset);	chr19:22371552	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs1865075	ENSG00000269138.1	ZNF209P	4.2	3.21e-05	0.0029	0.19	0.19	Menopause (age at onset);	chr19:22372052	chr19:22463922~22473036:+
THCA	cis	rs875971	0.862	rs1612452	ENSG00000229886.1	RP5-1132H15.3	-4.2	3.21e-05	0.0029	-0.2	-0.19	Aortic root size;	chr7:66108909	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs1167390	ENSG00000229886.1	RP5-1132H15.3	-4.2	3.21e-05	0.0029	-0.2	-0.19	Aortic root size;	chr7:66110906	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs35034167	ENSG00000229886.1	RP5-1132H15.3	-4.2	3.21e-05	0.0029	-0.2	-0.19	Aortic root size;	chr7:66115179	chr7:66025126~66031544:-
THCA	cis	rs4699052	0.963	rs11733615	ENSG00000246560.2	RP11-10L12.4	4.2	3.21e-05	0.0029	0.23	0.19	Testicular germ cell tumor;	chr4:103236007	chr4:102828055~102844075:+
THCA	cis	rs2919009	0.509	rs17100858	ENSG00000271670.1	RP11-95I16.4	4.2	3.21e-05	0.0029	0.21	0.19	Obesity-related traits;	chr10:120783858	chr10:120879256~120880667:-
THCA	cis	rs67478160	0.619	rs12878682	ENSG00000269940.1	RP11-73M18.7	4.2	3.21e-05	0.0029	0.18	0.19	Schizophrenia;	chr14:103767290	chr14:103694560~103695170:+
THCA	cis	rs988712	0.705	rs4074134	ENSG00000245573.6	BDNF-AS	-4.2	3.21e-05	0.00291	-0.19	-0.19	Obesity;	chr11:27625738	chr11:27506838~27698174:+
THCA	cis	rs60180747	0.909	rs56913458	ENSG00000261318.1	RP11-653J6.1	4.2	3.21e-05	0.00291	0.26	0.19	Testicular germ cell tumor;	chr15:66410007	chr15:66278498~66293357:-
THCA	cis	rs3755605	0.728	rs57184265	ENSG00000242578.1	RP11-469J4.3	4.2	3.21e-05	0.00291	0.21	0.19	Testicular germ cell tumor;	chr3:170189965	chr3:170410512~170418615:+
THCA	cis	rs2251381	0.565	rs2832279	ENSG00000176054.6	RPL23P2	4.2	3.21e-05	0.00291	0.16	0.19	Selective IgA deficiency;	chr21:29241145	chr21:28997613~28998033:-
THCA	cis	rs710913	0.717	rs2243761	ENSG00000182109.6	RP11-69E11.4	-4.2	3.22e-05	0.00291	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39522280~39546187:-
THCA	cis	rs253959	0.739	rs168826	ENSG00000250015.1	CTC-339F2.2	-4.2	3.22e-05	0.00291	-0.17	-0.19	Bipolar disorder and schizophrenia;	chr5:116299083	chr5:116302354~116304134:-
THCA	cis	rs875971	0.83	rs6976714	ENSG00000229886.1	RP5-1132H15.3	4.2	3.22e-05	0.00291	0.2	0.19	Aortic root size;	chr7:66426474	chr7:66025126~66031544:-
THCA	cis	rs875971	0.651	rs2420596	ENSG00000229886.1	RP5-1132H15.3	4.2	3.22e-05	0.00291	0.2	0.19	Aortic root size;	chr7:66450996	chr7:66025126~66031544:-
THCA	cis	rs875971	0.52	rs2420597	ENSG00000229886.1	RP5-1132H15.3	4.2	3.22e-05	0.00291	0.2	0.19	Aortic root size;	chr7:66450999	chr7:66025126~66031544:-
THCA	cis	rs7824557	0.564	rs11782430	ENSG00000206014.6	OR7E161P	4.2	3.22e-05	0.00291	0.22	0.19	Retinal vascular caliber;	chr8:11368562	chr8:11928597~11929563:-
THCA	cis	rs7968440	1	rs2700485	ENSG00000272368.2	RP4-605O3.4	4.2	3.22e-05	0.00291	0.12	0.19	Fibrinogen;	chr12:50710209	chr12:50112197~50165618:+
THCA	cis	rs7968440	1	rs2250752	ENSG00000272368.2	RP4-605O3.4	4.2	3.22e-05	0.00291	0.12	0.19	Fibrinogen;	chr12:50712308	chr12:50112197~50165618:+
THCA	cis	rs2286503	0.839	rs2240726	ENSG00000228649.7	AC005682.5	4.2	3.22e-05	0.00291	0.23	0.19	Fibrinogen;	chr7:22813516	chr7:22854178~22861579:+
THCA	cis	rs7045881	0.8	rs62544402	ENSG00000254396.1	RP11-56F10.3	4.2	3.22e-05	0.00291	0.33	0.19	Schizophrenia;	chr9:26856754	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.8	rs62544403	ENSG00000254396.1	RP11-56F10.3	4.2	3.22e-05	0.00291	0.33	0.19	Schizophrenia;	chr9:26857316	chr9:27102630~27104728:+
THCA	cis	rs3733585	0.605	rs56178126	ENSG00000261490.1	RP11-448G15.3	-4.2	3.22e-05	0.00291	-0.13	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:10121957	chr4:10068089~10073019:-
THCA	cis	rs1075265	0.584	rs11896781	ENSG00000272156.1	RP11-477N3.1	4.2	3.22e-05	0.00291	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54082554~54085066:+
THCA	cis	rs4434872	0.525	rs11264824	ENSG00000223599.1	RP11-216N14.7	-4.2	3.22e-05	0.00291	-0.36	-0.19	Conduct disorder (symptom count);	chr1:154000695	chr1:153852106~153853414:-
THCA	cis	rs1075265	0.584	rs34769118	ENSG00000272156.1	RP11-477N3.1	4.2	3.22e-05	0.00291	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54082554~54085066:+
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000275400.1	RP4-756H11.5	-4.2	3.22e-05	0.00291	-0.18	-0.19	Calcium levels;	chr7:65892789	chr7:66553805~66554199:-
THCA	cis	rs17685	0.753	rs2302435	ENSG00000230882.1	AC005077.14	-4.2	3.22e-05	0.00291	-0.19	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76047669	chr7:76071469~76074963:-
THCA	cis	rs17685	0.725	rs2302436	ENSG00000230882.1	AC005077.14	-4.2	3.22e-05	0.00291	-0.19	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76047670	chr7:76071469~76074963:-
THCA	cis	rs6570726	0.791	rs11155426	ENSG00000270638.1	RP3-466P17.1	4.2	3.22e-05	0.00291	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145735570~145737218:+
THCA	cis	rs6921919	0.945	rs61289879	ENSG00000280107.1	AL022393.9	-4.2	3.22e-05	0.00291	-0.23	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28170845~28172521:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000182586.6	LINC00334	-4.2	3.22e-05	0.00291	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45234340~45258730:+
THCA	cis	rs4144027	0.967	rs56126771	ENSG00000269940.1	RP11-73M18.7	4.2	3.22e-05	0.00291	0.19	0.19	Blood metabolite levels;	chr14:103894806	chr14:103694560~103695170:+
THCA	cis	rs9926296	0.643	rs12596429	ENSG00000260259.1	RP11-368I7.4	-4.2	3.22e-05	0.00291	-0.21	-0.19	Vitiligo;	chr16:89774966	chr16:89682620~89686569:-
THCA	cis	rs160451	0.774	rs218896	ENSG00000251136.7	RP11-37B2.1	-4.2	3.22e-05	0.00291	-0.17	-0.19	Leprosy;	chr8:89714370	chr8:89609409~89757727:-
THCA	cis	rs11673344	0.542	rs1667380	ENSG00000267260.1	CTD-2162K18.4	-4.2	3.22e-05	0.00291	-0.23	-0.19	Obesity-related traits;	chr19:37001848	chr19:36773153~36777078:+
THCA	cis	rs1572312	0.551	rs4915723	ENSG00000237928.4	NFIA-AS2	4.2	3.22e-05	0.00291	0.25	0.19	Maximal oxygen uptake response;	chr1:60967464	chr1:60940239~60970776:-
THCA	cis	rs12134133	1	rs7522618	ENSG00000237074.1	RP11-6J21.2	4.2	3.22e-05	0.00291	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207249067~207309121:+
THCA	cis	rs71520386	0.632	rs10224419	ENSG00000226329.2	AC005682.6	4.2	3.22e-05	0.00291	0.25	0.19	Fibrinogen levels;	chr7:22830397	chr7:22863874~22881350:-
THCA	cis	rs7267979	1	rs2482911	ENSG00000276952.1	RP5-965G21.6	-4.2	3.22e-05	0.00291	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25284915~25285588:-
THCA	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	4.2	3.22e-05	0.00291	0.22	0.19	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
THCA	cis	rs10761482	0.954	rs10821714	ENSG00000254271.1	RP11-131N11.4	4.2	3.22e-05	0.00291	0.25	0.19	Schizophrenia;	chr10:60305373	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.954	rs12261675	ENSG00000254271.1	RP11-131N11.4	4.2	3.22e-05	0.00291	0.25	0.19	Schizophrenia;	chr10:60305499	chr10:60734342~60741828:+
THCA	cis	rs7824557	0.564	rs2572400	ENSG00000206014.6	OR7E161P	4.2	3.22e-05	0.00291	0.22	0.19	Retinal vascular caliber;	chr8:11376858	chr8:11928597~11929563:-
THCA	cis	rs10760158	0.832	rs10985192	ENSG00000226752.6	PSMD5-AS1	-4.2	3.22e-05	0.00291	-0.23	-0.19	Pulse pressure;	chr9:121254162	chr9:120824828~120854385:+
THCA	cis	rs7824557	0.51	rs1435274	ENSG00000206014.6	OR7E161P	4.2	3.22e-05	0.00291	0.22	0.19	Retinal vascular caliber;	chr8:11378401	chr8:11928597~11929563:-
THCA	cis	rs172166	0.516	rs1225715	ENSG00000176933.5	TOB2P1	4.2	3.22e-05	0.00291	0.21	0.19	Cardiac Troponin-T levels;	chr6:28145595	chr6:28217643~28218634:-
THCA	cis	rs12681366	0.537	rs2919659	ENSG00000261437.1	RP11-22C11.2	4.2	3.22e-05	0.00291	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94459544	chr8:94637285~94639467:-
THCA	cis	rs6940638	0.688	rs9295730	ENSG00000219392.1	RP1-265C24.5	-4.2	3.22e-05	0.00291	-0.22	-0.19	Intelligence (multi-trait analysis);	chr6:27161027	chr6:28115628~28116551:+
THCA	cis	rs2039553	0.517	rs4885658	ENSG00000227354.5	RBM26-AS1	-4.2	3.23e-05	0.00291	-0.18	-0.19	Pancreatic cancer;	chr13:79756983	chr13:79406309~79424328:+
THCA	cis	rs12478296	0.892	rs11893879	ENSG00000261186.2	RP11-341N2.1	-4.2	3.23e-05	0.00291	-0.29	-0.19	Obesity-related traits;	chr2:242068260	chr2:242087351~242088457:-
THCA	cis	rs1560104	0.709	rs62027316	ENSG00000262801.4	U91319.1	4.2	3.23e-05	0.00292	0.22	0.19	Obesity-related traits;	chr16:12609991	chr16:13246316~13562918:+
THCA	cis	rs6845263	0.546	rs9917976	ENSG00000254531.1	FLJ20021	-4.2	3.23e-05	0.00292	-0.16	-0.19	Superior crus of antihelix expression;	chr4:101534624	chr4:101347780~101348883:+
THCA	cis	rs7020830	0.516	rs36047049	ENSG00000281649.1	EBLN3	-4.2	3.23e-05	0.00292	-0.19	-0.19	Schizophrenia;	chr9:37375475	chr9:37079857~37090507:+
THCA	cis	rs860295	0.812	rs12081192	ENSG00000236675.1	MTX1P1	-4.2	3.23e-05	0.00292	-0.2	-0.19	Body mass index;	chr1:155768253	chr1:155230975~155234325:+
THCA	cis	rs8028182	0.636	rs7163907	ENSG00000260269.4	CTD-2323K18.1	-4.2	3.23e-05	0.00292	-0.29	-0.19	Sudden cardiac arrest;	chr15:75552756	chr15:75527150~75601205:-
THCA	cis	rs2221894	0.96	rs7837112	ENSG00000251191.6	LINC00589	-4.2	3.23e-05	0.00292	-0.23	-0.19	Obesity-related traits;	chr8:28907976	chr8:29673922~29748109:-
THCA	cis	rs7045881	0.8	rs7871722	ENSG00000254396.1	RP11-56F10.3	4.2	3.23e-05	0.00292	0.35	0.19	Schizophrenia;	chr9:26822997	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.8	rs7874676	ENSG00000254396.1	RP11-56F10.3	4.2	3.23e-05	0.00292	0.35	0.19	Schizophrenia;	chr9:26823003	chr9:27102630~27104728:+
THCA	cis	rs1075265	0.528	rs2018747	ENSG00000272156.1	RP11-477N3.1	4.2	3.23e-05	0.00292	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54082554~54085066:+
THCA	cis	rs17604090	1	rs67970052	ENSG00000227855.3	DPY19L2P3	4.2	3.23e-05	0.00292	0.25	0.19	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29615422	chr7:29650227~29742594:+
THCA	cis	rs4853525	0.561	rs13414648	ENSG00000235852.1	AC005540.3	4.2	3.23e-05	0.00292	0.21	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929310	chr2:190880797~190882059:-
THCA	cis	rs2333194	0.707	rs10134224	ENSG00000258695.2	RP3-414A15.2	-4.2	3.23e-05	0.00292	-0.23	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73315235	chr14:73522878~73530610:+
THCA	cis	rs2333194	0.875	rs7140876	ENSG00000258695.2	RP3-414A15.2	-4.2	3.23e-05	0.00292	-0.23	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73326230	chr14:73522878~73530610:+
THCA	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	-4.2	3.23e-05	0.00292	-0.09	-0.19	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
THCA	cis	rs1113500	0.805	rs11185244	ENSG00000230489.1	VAV3-AS1	-4.2	3.23e-05	0.00292	-0.17	-0.19	Growth-regulated protein alpha levels;	chr1:108058525	chr1:107964443~107994607:+
THCA	cis	rs1113500	0.814	rs1592282	ENSG00000230489.1	VAV3-AS1	-4.2	3.23e-05	0.00292	-0.17	-0.19	Growth-regulated protein alpha levels;	chr1:108058743	chr1:107964443~107994607:+
THCA	cis	rs1923243	0.814	rs12033354	ENSG00000223479.3	RP4-788P17.1	4.2	3.23e-05	0.00292	0.21	0.19	Migraine;	chr1:73108258	chr1:73635216~73715214:+
THCA	cis	rs10833905	0.878	rs10833933	ENSG00000246225.5	RP11-17A1.3	-4.2	3.23e-05	0.00292	-0.28	-0.19	Sudden cardiac arrest;	chr11:23081076	chr11:22829380~22945393:+
THCA	cis	rs8081395	0.801	rs2665404	ENSG00000267302.4	RP11-178C3.2	4.2	3.23e-05	0.00292	0.22	0.19	White blood cell count;	chr17:59798035	chr17:59964832~59996972:+
THCA	cis	rs9326248	0.569	rs4938315	ENSG00000280143.1	AP000892.6	4.2	3.23e-05	0.00292	0.29	0.19	Blood protein levels;	chr11:116860489	chr11:117204967~117210292:+
THCA	cis	rs10875746	0.855	rs10875729	ENSG00000258273.1	RP11-370I10.4	4.2	3.23e-05	0.00292	0.28	0.19	Longevity (90 years and older);	chr12:48032943	chr12:48333755~48333901:-
THCA	cis	rs11096990	0.819	rs2711992	ENSG00000249685.1	RP11-360F5.3	-4.2	3.23e-05	0.00292	-0.24	-0.19	Cognitive function;	chr4:39148651	chr4:39133913~39135608:+
THCA	cis	rs12541437	1	rs12541437	ENSG00000253327.2	RAD21-AS1	-4.2	3.23e-05	0.00292	-0.21	-0.19	Gut microbiome composition (winter);	chr8:116906658	chr8:116874424~116876868:+
THCA	cis	rs7085104	0.572	rs284860	ENSG00000213061.2	PFN1P11	-4.2	3.23e-05	0.00292	-0.23	-0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102813206	chr10:102838011~102845473:-
THCA	cis	rs3892630	0.588	rs2287881	ENSG00000267475.1	CTD-2538C1.2	4.2	3.23e-05	0.00292	0.25	0.19	Red blood cell traits;	chr19:32842249	chr19:32687089~32691750:-
THCA	cis	rs12440869	1	rs6494639	ENSG00000270964.1	RP11-502I4.3	-4.2	3.23e-05	0.00292	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67238061	chr15:67541072~67542604:-
THCA	cis	rs875971	1	rs2077593	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66427543	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs4717292	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66430611	chr7:66025126~66031544:-
THCA	cis	rs875971	0.895	rs10755833	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66448930	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs12668936	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66449417	chr7:66025126~66031544:-
THCA	cis	rs875971	0.895	rs1833495	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66456608	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs6945032	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66457499	chr7:66025126~66031544:-
THCA	cis	rs875971	0.929	rs12673810	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66458866	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs6961155	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66468308	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs7789768	ENSG00000229886.1	RP5-1132H15.3	4.2	3.23e-05	0.00292	0.2	0.19	Aortic root size;	chr7:66473993	chr7:66025126~66031544:-
THCA	cis	rs2434529	0.84	rs10477095	ENSG00000245275.6	SAP30L-AS1	4.2	3.23e-05	0.00292	0.2	0.19	Autism spectrum disorder or schizophrenia;	chr5:154242534	chr5:154329437~154445850:-
THCA	cis	rs2115630	0.691	rs8040066	ENSG00000176700.18	SCAND2P	-4.2	3.23e-05	0.00292	-0.12	-0.19	P wave terminal force;	chr15:84633234	chr15:84631451~84647478:+
THCA	cis	rs9717605	1	rs73046018	ENSG00000226445.1	XXyac-YX65C7_A.2	4.2	3.23e-05	0.00292	0.23	0.19	Left atrial antero-posterior diameter;	chr6:169247495	chr6:169213254~169239565:+
THCA	cis	rs9717605	1	rs73046021	ENSG00000226445.1	XXyac-YX65C7_A.2	4.2	3.23e-05	0.00292	0.23	0.19	Left atrial antero-posterior diameter;	chr6:169247514	chr6:169213254~169239565:+
THCA	cis	rs9717605	1	rs12181068	ENSG00000226445.1	XXyac-YX65C7_A.2	4.2	3.23e-05	0.00292	0.23	0.19	Left atrial antero-posterior diameter;	chr6:169248281	chr6:169213254~169239565:+
THCA	cis	rs734999	0.572	rs3748816	ENSG00000225931.3	RP3-395M20.7	4.2	3.23e-05	0.00292	0.23	0.19	Ulcerative colitis;	chr1:2595307	chr1:2566410~2569888:+
THCA	cis	rs5758511	0.68	rs5758692	ENSG00000230107.1	CTA-126B4.7	-4.2	3.23e-05	0.00292	-0.23	-0.19	Birth weight;	chr22:42273023	chr22:42438023~42446195:+
THCA	cis	rs2408955	0.521	rs11168437	ENSG00000273765.1	RP11-370I10.11	4.2	3.23e-05	0.00292	0.19	0.19	Glycated hemoglobin levels;	chr12:48172373	chr12:48360920~48361377:+
THCA	cis	rs711244	0.682	rs7605601	ENSG00000279519.1	RP11-288C18.1	4.2	3.23e-05	0.00292	0.16	0.19	Mean platelet volume;	chr2:36920832	chr2:36839922~36842539:-
THCA	cis	rs7818688	0.653	rs11783522	ENSG00000253528.2	RP11-347C18.4	-4.2	3.23e-05	0.00292	-0.28	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94874396	chr8:94974573~94974853:-
THCA	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-4.2	3.23e-05	0.00292	-0.19	-0.19	Height;	chr5:37045739	chr5:36666214~36725195:-
THCA	cis	rs8067545	0.75	rs4925079	ENSG00000270091.1	RP11-78O7.2	-4.2	3.23e-05	0.00292	-0.14	-0.19	Schizophrenia;	chr17:20083548	chr17:19896590~19897287:-
THCA	cis	rs7267979	1	rs4815408	ENSG00000276952.1	RP5-965G21.6	-4.2	3.23e-05	0.00292	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25284915~25285588:-
THCA	cis	rs853679	0.567	rs13209596	ENSG00000273712.1	RP5-874C20.7	4.2	3.23e-05	0.00292	0.23	0.19	Depression;	chr6:28428413	chr6:28315613~28315883:-
THCA	cis	rs853679	0.567	rs9969098	ENSG00000273712.1	RP5-874C20.7	4.2	3.23e-05	0.00292	0.23	0.19	Depression;	chr6:28430971	chr6:28315613~28315883:-
THCA	cis	rs853679	0.567	rs7740429	ENSG00000273712.1	RP5-874C20.7	4.2	3.23e-05	0.00292	0.23	0.19	Depression;	chr6:28431469	chr6:28315613~28315883:-
THCA	cis	rs853679	0.567	rs16894106	ENSG00000273712.1	RP5-874C20.7	4.2	3.23e-05	0.00292	0.23	0.19	Depression;	chr6:28432562	chr6:28315613~28315883:-
THCA	cis	rs74233809	1	rs12219027	ENSG00000272912.1	RP11-724N1.1	-4.2	3.24e-05	0.00292	-0.35	-0.19	Birth weight;	chr10:103051446	chr10:102914585~102915404:+
THCA	cis	rs9438901	0.614	rs2375278	ENSG00000224183.1	SDHDP6	4.2	3.24e-05	0.00292	0.31	0.19	Red cell distribution width;	chr1:25202547	chr1:25294164~25294643:-
THCA	cis	rs2286503	0.839	rs1054471	ENSG00000228649.7	AC005682.5	4.2	3.24e-05	0.00292	0.23	0.19	Fibrinogen;	chr7:22813024	chr7:22854178~22861579:+
THCA	cis	rs8081395	0.741	rs180520	ENSG00000267302.4	RP11-178C3.2	4.2	3.24e-05	0.00292	0.22	0.19	White blood cell count;	chr17:59937788	chr17:59964832~59996972:+
THCA	cis	rs34421088	0.576	rs2736369	ENSG00000255046.1	RP11-297N6.4	4.2	3.24e-05	0.00292	0.22	0.19	Neuroticism;	chr8:11243889	chr8:11797928~11802568:-
THCA	cis	rs896854	0.715	rs12548874	ENSG00000253528.2	RP11-347C18.4	-4.2	3.24e-05	0.00292	-0.22	-0.19	Type 2 diabetes;	chr8:94922936	chr8:94974573~94974853:-
THCA	cis	rs9902453	0.765	rs2127001	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29771201	chr17:29639627~29640825:+
THCA	cis	rs2333194	0.875	rs28716532	ENSG00000258695.2	RP3-414A15.2	-4.2	3.24e-05	0.00293	-0.23	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73302547	chr14:73522878~73530610:+
THCA	cis	rs710913	0.557	rs1180320	ENSG00000182109.6	RP11-69E11.4	4.2	3.24e-05	0.00293	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39616330	chr1:39522280~39546187:-
THCA	cis	rs9532669	0.926	rs9532671	ENSG00000229473.2	RGS17P1	4.2	3.24e-05	0.00293	0.24	0.19	Cervical cancer;	chr13:40927761	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.833	rs9532672	ENSG00000229473.2	RGS17P1	4.2	3.24e-05	0.00293	0.24	0.19	Cervical cancer;	chr13:40928285	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.963	rs7324625	ENSG00000229473.2	RGS17P1	4.2	3.24e-05	0.00293	0.24	0.19	Cervical cancer;	chr13:40928606	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4454835	ENSG00000229473.2	RGS17P1	4.2	3.24e-05	0.00293	0.24	0.19	Cervical cancer;	chr13:40928978	chr13:40992779~40993331:-
THCA	cis	rs7773456	0.533	rs9350190	ENSG00000227116.1	RP3-471C18.1	4.2	3.24e-05	0.00293	0.22	0.19	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19730427~19734567:-
THCA	cis	rs7651778	0.588	rs7638936	ENSG00000243926.1	TIPARP-AS1	-4.2	3.24e-05	0.00293	-0.19	-0.19	Corneal astigmatism;	chr3:156621843	chr3:156671862~156674378:-
THCA	cis	rs2278702	0.943	rs78285258	ENSG00000259495.2	RP11-210M15.2	-4.2	3.24e-05	0.00293	-0.28	-0.19	Bipolar disorder;	chr15:80392771	chr15:80344853~80403575:-
THCA	cis	rs10090774	0.965	rs7010459	ENSG00000279766.1	RP11-642A1.2	4.2	3.24e-05	0.00293	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140821142	chr8:140572142~140572812:-
THCA	cis	rs1559040	1	rs35641543	ENSG00000272156.1	RP11-477N3.1	-4.2	3.24e-05	0.00293	-0.32	-0.19	Sudden cardiac arrest;	chr2:54120176	chr2:54082554~54085066:+
THCA	cis	rs6490294	0.571	rs11066119	ENSG00000226469.1	ADAM1B	4.2	3.24e-05	0.00293	0.26	0.19	Mean platelet volume;	chr12:111996700	chr12:111927018~111929017:+
THCA	cis	rs9902453	0.765	rs2729447	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29771984	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2628180	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29774705	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.74	rs2729446	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29775481	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2729440	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29779856	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.74	rs2244247	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29783156	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.74	rs2617884	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29793412	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2617883	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29793470	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs2729436	ENSG00000263370.1	RP11-68I3.5	-4.2	3.24e-05	0.00293	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29793652	chr17:29639627~29640825:+
THCA	cis	rs6921919	0.832	rs17312661	ENSG00000219392.1	RP1-265C24.5	-4.2	3.24e-05	0.00293	-0.27	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28115628~28116551:+
THCA	cis	rs79243044	0.93	rs1498480	ENSG00000224295.2	AC087380.14	-4.2	3.24e-05	0.00293	-0.19	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5528024	chr11:5518441~5524955:-
THCA	cis	rs9341808	0.6	rs668329	ENSG00000272129.1	RP11-250B2.6	-4.2	3.24e-05	0.00293	-0.24	-0.19	Sitting height ratio;	chr6:80258861	chr6:80355424~80356859:+
THCA	cis	rs881375	0.715	rs11794516	ENSG00000270917.1	RP11-27I1.6	-4.2	3.25e-05	0.00293	-0.26	-0.19	Rheumatoid arthritis;	chr9:120877952	chr9:120812475~120812845:-
THCA	cis	rs7178909	0.835	rs2174292	ENSG00000259677.1	RP11-493E3.1	4.2	3.25e-05	0.00293	0.23	0.19	Common traits (Other);	chr15:89872349	chr15:89876540~89877285:+
THCA	cis	rs6430585	0.941	rs12469551	ENSG00000231890.6	DARS-AS1	4.2	3.25e-05	0.00293	0.22	0.19	Corneal structure;	chr2:135752442	chr2:135985176~136022593:+
THCA	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	4.2	3.25e-05	0.00293	0.22	0.19	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
THCA	cis	rs1908814	0.51	rs57655799	ENSG00000254948.1	OR7E158P	-4.2	3.25e-05	0.00293	-0.23	-0.19	Neuroticism;	chr8:11924908	chr8:11919900~11920809:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000234585.5	CCT6P3	4.2	3.25e-05	0.00293	0.17	0.19	Aortic root size;	chr7:65964026	chr7:65038354~65074713:+
THCA	cis	rs3790606	1	rs3790606	ENSG00000273483.1	RP4-671G15.2	-4.2	3.25e-05	0.00293	-0.2	-0.19	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr1:112509564	chr1:112517799~112518441:-
THCA	cis	rs6496044	0.507	rs8034676	ENSG00000259295.5	CSPG4P12	4.2	3.25e-05	0.00293	0.25	0.19	Interstitial lung disease;	chr15:85616031	chr15:85191438~85213905:+
THCA	cis	rs10844706	0.699	rs1008610	ENSG00000214776.8	RP11-726G1.1	4.2	3.25e-05	0.00293	0.24	0.19	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9731264	chr12:9467552~9576275:+
THCA	cis	rs9926296	0.618	rs8058179	ENSG00000274627.1	RP11-104N10.2	4.2	3.25e-05	0.00293	0.19	0.19	Vitiligo;	chr16:89780579	chr16:89516797~89522217:+
THCA	cis	rs586688	0.543	rs1267115	ENSG00000224536.1	RP11-134G8.7	-4.2	3.25e-05	0.00293	-0.28	-0.19	Obesity-related traits;	chr1:201707184	chr1:201507241~201533608:+
THCA	cis	rs758324	0.732	rs152198	ENSG00000224431.1	AC063976.7	-4.2	3.25e-05	0.00293	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132103117	chr5:132199456~132203487:+
THCA	cis	rs10844706	0.676	rs10844657	ENSG00000214776.8	RP11-726G1.1	4.2	3.25e-05	0.00293	0.25	0.19	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9740617	chr12:9467552~9576275:+
THCA	cis	rs950169	0.686	rs12906474	ENSG00000188388.10	GOLGA6L3	4.2	3.25e-05	0.00293	0.25	0.19	Schizophrenia;	chr15:84566006	chr15:85240472~85247170:+
THCA	cis	rs950169	0.81	rs2879976	ENSG00000188388.10	GOLGA6L3	4.2	3.25e-05	0.00293	0.25	0.19	Schizophrenia;	chr15:84566347	chr15:85240472~85247170:+
THCA	cis	rs786425	0.682	rs7399224	ENSG00000270095.1	RP11-214K3.18	-4.2	3.25e-05	0.00293	-0.23	-0.19	Pubertal anthropometrics;	chr12:123711309	chr12:123971457~123971714:-
THCA	cis	rs2625529	0.938	rs2723343	ENSG00000260037.4	CTD-2524L6.3	-4.2	3.25e-05	0.00294	-0.27	-0.19	Red blood cell count;	chr15:71815928	chr15:71818396~71823384:+
THCA	cis	rs2839627	0.564	rs2839595	ENSG00000225218.1	AP001628.6	4.2	3.25e-05	0.00294	0.32	0.19	Information processing speed;	chr21:42878856	chr21:42831040~42836477:-
THCA	cis	rs2839627	0.513	rs67571721	ENSG00000225218.1	AP001628.6	4.2	3.25e-05	0.00294	0.32	0.19	Information processing speed;	chr21:42886336	chr21:42831040~42836477:-
THCA	cis	rs2839627	0.638	rs60342559	ENSG00000225218.1	AP001628.6	4.2	3.25e-05	0.00294	0.32	0.19	Information processing speed;	chr21:42889941	chr21:42831040~42836477:-
THCA	cis	rs2839627	0.683	rs6586259	ENSG00000225218.1	AP001628.6	4.2	3.25e-05	0.00294	0.32	0.19	Information processing speed;	chr21:42895156	chr21:42831040~42836477:-
THCA	cis	rs2839627	0.638	rs9974287	ENSG00000225218.1	AP001628.6	4.2	3.25e-05	0.00294	0.32	0.19	Information processing speed;	chr21:42896893	chr21:42831040~42836477:-
THCA	cis	rs67478160	0.643	rs2887282	ENSG00000269940.1	RP11-73M18.7	4.2	3.25e-05	0.00294	0.18	0.19	Schizophrenia;	chr14:103814397	chr14:103694560~103695170:+
THCA	cis	rs1055129	0.56	rs9891076	ENSG00000267801.1	RP11-552F3.9	4.2	3.25e-05	0.00294	0.22	0.19	White matter hyperintensity burden;	chr17:75915634	chr17:75876372~75879546:+
THCA	cis	rs7838490	0.58	rs7813334	ENSG00000253553.4	RP11-586K2.1	4.2	3.25e-05	0.00294	0.2	0.19	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88516834	chr8:88326836~88737134:+
THCA	cis	rs10761482	0.861	rs10761484	ENSG00000254271.1	RP11-131N11.4	4.2	3.25e-05	0.00294	0.25	0.19	Schizophrenia;	chr10:60338700	chr10:60734342~60741828:+
THCA	cis	rs944289	0.74	rs885535	ENSG00000258844.1	RP11-259K15.2	4.2	3.25e-05	0.00294	0.17	0.19	Thyroid cancer;	chr14:36082574	chr14:36214607~36235608:+
THCA	cis	rs2039553	0.591	rs7984156	ENSG00000227354.5	RBM26-AS1	-4.2	3.25e-05	0.00294	-0.18	-0.19	Pancreatic cancer;	chr13:79800402	chr13:79406309~79424328:+
THCA	cis	rs11672691	0.519	rs7249258	ENSG00000270164.1	LINC01480	4.2	3.25e-05	0.00294	0.17	0.19	Prostate cancer;	chr19:41501959	chr19:41535183~41536904:+
THCA	cis	rs12893668	0.703	rs34896432	ENSG00000244691.1	RPL10AP1	-4.2	3.25e-05	0.00294	-0.27	-0.19	Reticulocyte count;	chr14:103561658	chr14:103412119~103412761:-
THCA	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	-4.2	3.25e-05	0.00294	-0.09	-0.19	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
THCA	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	-4.2	3.25e-05	0.00294	-0.09	-0.19	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
THCA	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	-4.2	3.25e-05	0.00294	-0.09	-0.19	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
THCA	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-4.2	3.26e-05	0.00294	-0.29	-0.19	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
THCA	cis	rs2554380	0.628	rs11853983	ENSG00000176700.18	SCAND2P	4.2	3.26e-05	0.00294	0.14	0.19	Height;	chr15:83794058	chr15:84631451~84647478:+
THCA	cis	rs17507216	0.588	rs28864981	ENSG00000255769.6	GOLGA2P10	-4.2	3.26e-05	0.00294	-0.29	-0.19	Excessive daytime sleepiness;	chr15:82695420	chr15:82472993~82513950:-
THCA	cis	rs17507216	0.628	rs8032321	ENSG00000255769.6	GOLGA2P10	-4.2	3.26e-05	0.00294	-0.29	-0.19	Excessive daytime sleepiness;	chr15:82698956	chr15:82472993~82513950:-
THCA	cis	rs17507216	0.628	rs8040488	ENSG00000255769.6	GOLGA2P10	-4.2	3.26e-05	0.00294	-0.29	-0.19	Excessive daytime sleepiness;	chr15:82699081	chr15:82472993~82513950:-
THCA	cis	rs763121	0.853	rs3788544	ENSG00000273076.1	RP3-508I15.22	4.2	3.26e-05	0.00294	0.19	0.19	Menopause (age at onset);	chr22:38668961	chr22:38743495~38743910:+
THCA	cis	rs12928939	0.518	rs12445564	ENSG00000260886.1	TAT-AS1	4.2	3.26e-05	0.00294	0.26	0.19	Post bronchodilator FEV1;	chr16:71909406	chr16:71565789~71578187:+
THCA	cis	rs5769765	0.862	rs138870	ENSG00000260613.1	RP3-522J7.6	-4.2	3.26e-05	0.00294	-0.23	-0.19	Schizophrenia;	chr22:49816089	chr22:49832616~49837786:-
THCA	cis	rs9818758	0.545	rs55921200	ENSG00000270441.1	RP11-694I15.7	4.2	3.26e-05	0.00294	0.3	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49151883	chr3:49140086~49160851:-
THCA	cis	rs12928939	0.517	rs8050058	ENSG00000260886.1	TAT-AS1	4.2	3.26e-05	0.00294	0.26	0.19	Post bronchodilator FEV1;	chr16:71947471	chr16:71565789~71578187:+
THCA	cis	rs67478160	0.654	rs4906365	ENSG00000269910.1	RP11-73M18.10	4.2	3.26e-05	0.00294	0.17	0.19	Schizophrenia;	chr14:103762893	chr14:103694516~103695050:-
THCA	cis	rs7923609	0.846	rs10761739	ENSG00000232075.1	MRPL35P2	4.2	3.26e-05	0.00294	0.25	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63302248	chr10:63634317~63634827:-
THCA	cis	rs6828577	0.862	rs298994	ENSG00000281731.1	RP11-384K6.8	-4.2	3.26e-05	0.00294	-0.22	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118706098	chr4:118664087~118685341:-
THCA	cis	rs7572733	0.534	rs4550664	ENSG00000231621.1	AC013264.2	-4.2	3.26e-05	0.00294	-0.2	-0.19	Dermatomyositis;	chr2:197826681	chr2:197197991~197199273:+
THCA	cis	rs10760158	0.832	rs10760164	ENSG00000226752.6	PSMD5-AS1	-4.2	3.26e-05	0.00294	-0.23	-0.19	Pulse pressure;	chr9:121248884	chr9:120824828~120854385:+
THCA	cis	rs2732480	0.5	rs1387257	ENSG00000273765.1	RP11-370I10.11	4.2	3.26e-05	0.00294	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48360920~48361377:+
THCA	cis	rs2836974	0.899	rs34176878	ENSG00000255568.3	BRWD1-AS2	4.2	3.26e-05	0.00294	0.17	0.19	Cognitive function;	chr21:39176929	chr21:39313935~39314962:+
THCA	cis	rs2286503	1	rs2286499	ENSG00000226329.2	AC005682.6	4.2	3.26e-05	0.00294	0.23	0.19	Fibrinogen;	chr7:22817858	chr7:22863874~22881350:-
THCA	cis	rs7045881	0.66	rs16910888	ENSG00000254396.1	RP11-56F10.3	4.2	3.26e-05	0.00294	0.25	0.19	Schizophrenia;	chr9:26919668	chr9:27102630~27104728:+
THCA	cis	rs801193	0.569	rs11772819	ENSG00000229886.1	RP5-1132H15.3	4.2	3.26e-05	0.00294	0.2	0.19	Aortic root size;	chr7:66752983	chr7:66025126~66031544:-
THCA	cis	rs801193	0.569	rs7800620	ENSG00000229886.1	RP5-1132H15.3	4.2	3.26e-05	0.00294	0.2	0.19	Aortic root size;	chr7:66758701	chr7:66025126~66031544:-
THCA	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-4.19	3.26e-05	0.00295	-0.12	-0.19	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
THCA	cis	rs4237845	0.537	rs9645819	ENSG00000270039.1	RP11-571M6.17	-4.19	3.26e-05	0.00295	-0.21	-0.19	Intelligence (multi-trait analysis);	chr12:57876280	chr12:57803838~57804415:+
THCA	cis	rs7520050	0.751	rs2230657	ENSG00000281133.1	AL355480.3	4.19	3.26e-05	0.00295	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45580892~45580996:-
THCA	cis	rs10256972	0.514	rs2140578	ENSG00000225146.1	AC073957.15	4.19	3.26e-05	0.00295	0.21	0.19	Endometriosis;Longevity;	chr7:1174367	chr7:1029025~1043891:+
THCA	cis	rs11633886	0.934	rs11631912	ENSG00000259200.1	RP11-718O11.1	-4.19	3.26e-05	0.00295	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45797218	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.934	rs12901750	ENSG00000259200.1	RP11-718O11.1	-4.19	3.26e-05	0.00295	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45797432	chr15:45705078~45931069:+
THCA	cis	rs10129255	0.784	rs7147210	ENSG00000211972.2	IGHV3-66	4.19	3.26e-05	0.00295	0.12	0.19	Kawasaki disease;	chr14:106705271	chr14:106675017~106675544:-
THCA	cis	rs7824557	0.564	rs2043508	ENSG00000206014.6	OR7E161P	4.19	3.26e-05	0.00295	0.22	0.19	Retinal vascular caliber;	chr8:11369897	chr8:11928597~11929563:-
THCA	cis	rs1113500	0.805	rs11185248	ENSG00000230489.1	VAV3-AS1	4.19	3.27e-05	0.00295	0.17	0.19	Growth-regulated protein alpha levels;	chr1:108068379	chr1:107964443~107994607:+
THCA	cis	rs17507216	0.718	rs7161977	ENSG00000255769.6	GOLGA2P10	-4.19	3.27e-05	0.00295	-0.3	-0.19	Excessive daytime sleepiness;	chr15:82646782	chr15:82472993~82513950:-
THCA	cis	rs67478160	0.643	rs11847468	ENSG00000269940.1	RP11-73M18.7	4.19	3.27e-05	0.00295	0.18	0.19	Schizophrenia;	chr14:103753958	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.595	rs67768834	ENSG00000269940.1	RP11-73M18.7	4.19	3.27e-05	0.00295	0.18	0.19	Schizophrenia;	chr14:103754748	chr14:103694560~103695170:+
THCA	cis	rs11634944	1	rs4906939	ENSG00000257151.1	PWAR6	4.19	3.27e-05	0.00295	0.14	0.19	Interleukin-8 levels;	chr15:24956432	chr15:25031873~25036490:+
THCA	cis	rs7894407	0.594	rs1163238	ENSG00000272912.1	RP11-724N1.1	4.19	3.27e-05	0.00295	0.23	0.19	White matter hyperintensity burden;	chr10:103184236	chr10:102914585~102915404:+
THCA	cis	rs4805272	1	rs2870547	ENSG00000267799.1	MAN1A2P1	4.19	3.27e-05	0.00295	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833959	chr19:28790812~28792871:-
THCA	cis	rs1048886	0.935	rs3193656	ENSG00000271967.1	RP11-134K13.4	-4.19	3.27e-05	0.00295	-0.21	-0.19	Type 2 diabetes;	chr6:70560840	chr6:70596438~70596980:+
THCA	cis	rs13118159	0.55	rs28733902	ENSG00000254094.1	AC078852.1	-4.19	3.27e-05	0.00295	-0.23	-0.19	Longevity;	chr4:1381001	chr4:1356581~1358075:+
THCA	cis	rs1124609	1	rs1365506	ENSG00000244879.4	GABPB1-AS1	4.19	3.27e-05	0.00295	0.24	0.19	Subjective well-being;	chr15:50184942	chr15:50354959~50372202:+
THCA	cis	rs9925964	0.748	rs11640961	ENSG00000279196.1	RP11-1072A3.3	-4.19	3.27e-05	0.00295	-0.18	-0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30968497	chr16:30984630~30988270:-
THCA	cis	rs8067545	1	rs34291370	ENSG00000270091.1	RP11-78O7.2	-4.19	3.27e-05	0.00295	-0.14	-0.19	Schizophrenia;	chr17:20039022	chr17:19896590~19897287:-
THCA	cis	rs3177980	0.958	rs10489179	ENSG00000239494.2	RN7SL333P	-4.19	3.27e-05	0.00295	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr1:169750696	chr1:169859756~169860052:+
THCA	cis	rs2839627	0.513	rs7282879	ENSG00000225218.1	AP001628.6	4.19	3.27e-05	0.00295	0.28	0.19	Information processing speed;	chr21:42866415	chr21:42831040~42836477:-
THCA	cis	rs2692947	0.794	rs2692893	ENSG00000235584.2	AC008268.1	-4.19	3.27e-05	0.00295	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96090799	chr2:95666084~95668715:+
THCA	cis	rs3796352	0.667	rs9831977	ENSG00000242142.1	SERBP1P3	-4.19	3.27e-05	0.00295	-0.35	-0.19	Immune reponse to smallpox (secreted IL-2);	chr3:52820124	chr3:53064283~53065091:-
THCA	cis	rs2692947	0.631	rs2312954	ENSG00000235584.2	AC008268.1	4.19	3.27e-05	0.00295	0.19	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96106699	chr2:95666084~95668715:+
THCA	cis	rs17270561	0.779	rs1165200	ENSG00000272462.2	U91328.19	4.19	3.27e-05	0.00295	0.17	0.19	Iron status biomarkers;	chr6:25874984	chr6:25992662~26001775:+
THCA	cis	rs858239	0.537	rs10279691	ENSG00000230042.1	AK3P3	-4.19	3.27e-05	0.00295	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23129178~23129841:+
THCA	cis	rs2281636	1	rs2804418	ENSG00000233690.1	EBAG9P1	-4.19	3.27e-05	0.00295	-0.18	-0.19	Obesity-related traits;	chr10:99752337	chr10:99697407~99697949:-
THCA	cis	rs1371614	0.632	rs6759548	ENSG00000229122.1	AGBL5-IT1	4.19	3.27e-05	0.00295	0.14	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26938192	chr2:27061038~27061815:+
THCA	cis	rs2836974	0.568	rs414850	ENSG00000255568.3	BRWD1-AS2	4.19	3.27e-05	0.00295	0.15	0.19	Cognitive function;	chr21:39171411	chr21:39313935~39314962:+
THCA	cis	rs11634944	1	rs11634690	ENSG00000257151.1	PWAR6	4.19	3.27e-05	0.00295	0.14	0.19	Interleukin-8 levels;	chr15:24952988	chr15:25031873~25036490:+
THCA	cis	rs71520386	0.583	rs28799344	ENSG00000226329.2	AC005682.6	-4.19	3.27e-05	0.00295	-0.24	-0.19	Fibrinogen levels;	chr7:22805647	chr7:22863874~22881350:-
THCA	cis	rs71520386	0.583	rs35322907	ENSG00000226329.2	AC005682.6	-4.19	3.27e-05	0.00295	-0.24	-0.19	Fibrinogen levels;	chr7:22806592	chr7:22863874~22881350:-
THCA	cis	rs8141529	0.871	rs5762877	ENSG00000272858.1	CTA-292E10.8	-4.19	3.27e-05	0.00295	-0.2	-0.19	Lymphocyte counts;	chr22:28881567	chr22:28814914~28815662:+
THCA	cis	rs10483853	0.806	rs7140324	ENSG00000258695.2	RP3-414A15.2	-4.19	3.27e-05	0.00295	-0.27	-0.19	Coronary artery calcification;	chr14:73420982	chr14:73522878~73530610:+
THCA	cis	rs4767841	0.594	rs390366	ENSG00000248636.5	RP11-768F21.1	-4.19	3.27e-05	0.00295	-0.19	-0.19	Urgency urinary incontinence;	chr12:119785518	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.537	rs385844	ENSG00000248636.5	RP11-768F21.1	-4.19	3.27e-05	0.00295	-0.19	-0.19	Urgency urinary incontinence;	chr12:119785964	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.565	rs369180	ENSG00000248636.5	RP11-768F21.1	-4.19	3.27e-05	0.00295	-0.19	-0.19	Urgency urinary incontinence;	chr12:119786421	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.565	rs400551	ENSG00000248636.5	RP11-768F21.1	-4.19	3.27e-05	0.00295	-0.19	-0.19	Urgency urinary incontinence;	chr12:119786547	chr12:119387987~119668079:-
THCA	cis	rs1577330	0.796	rs10812525	ENSG00000254396.1	RP11-56F10.3	4.19	3.27e-05	0.00295	0.23	0.19	IgG glycosylation;	chr9:27084464	chr9:27102630~27104728:+
THCA	cis	rs2836974	0.568	rs442972	ENSG00000255568.3	BRWD1-AS2	-4.19	3.27e-05	0.00295	-0.15	-0.19	Cognitive function;	chr21:39162831	chr21:39313935~39314962:+
THCA	cis	rs1971762	0.545	rs876252	ENSG00000270175.1	RP11-793H13.11	-4.19	3.27e-05	0.00295	-0.13	-0.19	Height;	chr12:53677638	chr12:53500162~53500936:-
THCA	cis	rs7267979	0.78	rs2500413	ENSG00000125804.12	FAM182A	-4.19	3.27e-05	0.00295	-0.24	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.714	rs2474763	ENSG00000125804.12	FAM182A	-4.19	3.27e-05	0.00295	-0.24	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:26054655~26086917:+
THCA	cis	rs4218	0.689	rs12907187	ENSG00000259732.1	RP11-59H7.3	-4.19	3.27e-05	0.00295	-0.26	-0.19	Social communication problems;	chr15:59100607	chr15:59121034~59133250:+
THCA	cis	rs13113518	1	rs11133388	ENSG00000272969.1	RP11-528I4.2	-4.19	3.27e-05	0.00295	-0.22	-0.19	Height;	chr4:55477866	chr4:55547112~55547889:+
THCA	cis	rs1267303	0.675	rs1267313	ENSG00000232022.5	FAAHP1	-4.19	3.27e-05	0.00295	-0.22	-0.19	Monobrow;	chr1:46520650	chr1:46432129~46445521:+
THCA	cis	rs1267303	0.675	rs7519040	ENSG00000232022.5	FAAHP1	4.19	3.27e-05	0.00295	0.22	0.19	Monobrow;	chr1:46520969	chr1:46432129~46445521:+
THCA	cis	rs4845570	1	rs11586946	ENSG00000249602.1	RP11-98D18.3	-4.19	3.27e-05	0.00295	-0.29	-0.19	Coronary artery disease;	chr1:151797330	chr1:151763384~151769501:-
THCA	cis	rs2836950	0.545	rs2836922	ENSG00000238141.2	BRWD1-AS1	-4.19	3.27e-05	0.00295	-0.21	-0.19	Menarche (age at onset);	chr21:39144382	chr21:39315707~39323218:+
THCA	cis	rs2281603	0.517	rs10134770	ENSG00000259116.1	RP11-973N13.4	-4.19	3.27e-05	0.00295	-0.18	-0.19	Lymphocyte counts;	chr14:64596597	chr14:64514154~64540368:-
THCA	cis	rs2153535	0.561	rs9405407	ENSG00000230939.1	RP11-314C16.1	-4.19	3.27e-05	0.00295	-0.2	-0.19	Motion sickness;	chr6:8665199	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs9378566	ENSG00000230939.1	RP11-314C16.1	-4.19	3.27e-05	0.00295	-0.2	-0.19	Motion sickness;	chr6:8665203	chr6:8784178~8785445:+
THCA	cis	rs3824488	0.705	rs16909967	ENSG00000271155.1	RP11-435O5.5	-4.19	3.27e-05	0.00295	-0.29	-0.19	Neuroticism;	chr9:95534644	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.681	rs111336625	ENSG00000271155.1	RP11-435O5.5	-4.19	3.27e-05	0.00295	-0.29	-0.19	Neuroticism;	chr9:95534905	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.705	rs113851275	ENSG00000271155.1	RP11-435O5.5	-4.19	3.27e-05	0.00295	-0.29	-0.19	Neuroticism;	chr9:95534938	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.705	rs78007483	ENSG00000271155.1	RP11-435O5.5	-4.19	3.27e-05	0.00295	-0.29	-0.19	Neuroticism;	chr9:95535240	chr9:95506235~95507636:+
THCA	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	4.19	3.27e-05	0.00295	0.22	0.19	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
THCA	cis	rs9634489	0.502	rs9513143	ENSG00000247400.3	DNAJC3-AS1	-4.19	3.28e-05	0.00295	-0.12	-0.19	Body mass index;	chr13:96433316	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.502	rs7320228	ENSG00000247400.3	DNAJC3-AS1	-4.19	3.28e-05	0.00295	-0.12	-0.19	Body mass index;	chr13:96433694	chr13:95648733~95676925:-
THCA	cis	rs6517329	0.526	rs2835291	ENSG00000236830.5	CBR3-AS1	4.19	3.28e-05	0.00295	0.18	0.19	Schizophrenia;	chr21:36166622	chr21:36131767~36175815:-
THCA	cis	rs589448	0.902	rs315113	ENSG00000274979.1	RP11-1143G9.5	4.19	3.28e-05	0.00296	0.2	0.19	Cerebrospinal fluid biomarker levels;	chr12:69392763	chr12:69326574~69331882:-
THCA	cis	rs7560272	0.538	rs13000788	ENSG00000163016.8	ALMS1P	-4.19	3.28e-05	0.00296	-0.23	-0.19	Schizophrenia;	chr2:73691185	chr2:73644919~73685576:+
THCA	cis	rs868036	0.718	rs4776982	ENSG00000270964.1	RP11-502I4.3	4.19	3.28e-05	0.00296	0.17	0.19	Restless legs syndrome;	chr15:67822636	chr15:67541072~67542604:-
THCA	cis	rs4568518	0.53	rs10226084	ENSG00000279048.1	RP11-511H23.2	4.19	3.28e-05	0.00296	0.12	0.19	Measles;	chr7:17957989	chr7:17940503~17942922:+
THCA	cis	rs427691	0.625	rs845740	ENSG00000271849.1	CTC-332L22.1	-4.19	3.28e-05	0.00296	-0.27	-0.19	Autism spectrum disorder or schizophrenia;	chr5:109683201	chr5:109687802~109688329:-
THCA	cis	rs17507216	0.958	rs28648832	ENSG00000255769.6	GOLGA2P10	-4.19	3.28e-05	0.00296	-0.27	-0.19	Excessive daytime sleepiness;	chr15:82567642	chr15:82472993~82513950:-
THCA	cis	rs67839313	1	rs67839313	ENSG00000273855.1	RP11-133K1.12	4.19	3.28e-05	0.00296	0.29	0.19	Type 2 diabetes;	chr15:40327523	chr15:40285468~40285909:-
THCA	cis	rs8030605	0.704	rs11638060	ENSG00000277245.1	RP11-48G14.3	-4.19	3.28e-05	0.00296	-0.32	-0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56450702	chr15:56447120~56447697:+
THCA	cis	rs953301	0.793	rs74125022	ENSG00000229808.1	RP11-456P18.2	-4.19	3.28e-05	0.00296	-0.52	-0.19	Left atrial antero-posterior diameter;	chr1:161842858	chr1:161890833~161892196:+
THCA	cis	rs62158800	0.789	rs62158805	ENSG00000224568.1	AC096669.3	4.19	3.28e-05	0.00296	0.38	0.19	Facial morphology (factor 22);	chr2:107598151	chr2:107529487~107556326:+
THCA	cis	rs113817606	1	rs113817606	ENSG00000273549.1	Metazoa_SRP	4.19	3.28e-05	0.00296	0.39	0.19	Daytime sleep phenotypes;	chr5:179629159	chr5:179629151~179629410:+
THCA	cis	rs9341808	0.622	rs682482	ENSG00000272129.1	RP11-250B2.6	-4.19	3.28e-05	0.00296	-0.24	-0.19	Sitting height ratio;	chr6:80251422	chr6:80355424~80356859:+
THCA	cis	rs6517329	0.649	rs11088338	ENSG00000230212.5	AP000688.14	-4.19	3.28e-05	0.00296	-0.24	-0.19	Schizophrenia;	chr21:36122719	chr21:36069642~36126640:-
THCA	cis	rs7119038	0.818	rs4938572	ENSG00000255239.1	AP002954.6	4.19	3.28e-05	0.00296	0.29	0.19	Sjögren's syndrome;	chr11:118870222	chr11:118688039~118690600:-
THCA	cis	rs227584	0.663	rs3180912	ENSG00000267080.4	ASB16-AS1	-4.19	3.28e-05	0.00296	-0.16	-0.19	Bone mineral density;Bone mineral density (hip);	chr17:44182095	chr17:44175973~44186717:-
THCA	cis	rs17095355	1	rs17126931	ENSG00000203876.8	ADD3-AS1	-4.19	3.28e-05	0.00296	-0.23	-0.19	Biliary atresia;	chr10:109994875	chr10:109940104~110008381:-
THCA	cis	rs9393813	0.516	rs4713099	ENSG00000204789.4	ZNF204P	-4.19	3.28e-05	0.00296	-0.15	-0.19	Bipolar disorder;	chr6:27437423	chr6:27357825~27360221:-
THCA	cis	rs7737355	0.891	rs78235696	ENSG00000224431.1	AC063976.7	-4.19	3.28e-05	0.00296	-0.27	-0.19	Life satisfaction;	chr5:131476356	chr5:132199456~132203487:+
THCA	cis	rs8030605	0.85	rs72736484	ENSG00000277245.1	RP11-48G14.3	4.19	3.28e-05	0.00296	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56115970	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.925	rs116140504	ENSG00000277245.1	RP11-48G14.3	4.19	3.28e-05	0.00296	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56118720	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.85	rs72736501	ENSG00000277245.1	RP11-48G14.3	4.19	3.28e-05	0.00296	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56130863	chr15:56447120~56447697:+
THCA	cis	rs7045881	0.8	rs7036871	ENSG00000254396.1	RP11-56F10.3	4.19	3.28e-05	0.00296	0.34	0.19	Schizophrenia;	chr9:26866644	chr9:27102630~27104728:+
THCA	cis	rs12935229	0.756	rs13335140	ENSG00000260922.1	RP11-538I12.3	4.19	3.28e-05	0.00296	0.29	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77260352	chr16:77234877~77290934:+
THCA	cis	rs8062405	0.756	rs151301	ENSG00000261766.1	RP11-22P6.2	-4.19	3.28e-05	0.00296	-0.18	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28862166~28863340:-
THCA	cis	rs11175834	0.655	rs11175839	ENSG00000277945.1	RP11-677M24.1	4.19	3.28e-05	0.00296	0.27	0.19	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65613113	chr12:65830750~65831050:+
THCA	cis	rs4713118	0.955	rs9468206	ENSG00000261839.1	RP1-265C24.8	4.19	3.28e-05	0.00296	0.21	0.19	Parkinson's disease;	chr6:27722674	chr6:28136849~28139678:+
THCA	cis	rs10946940	0.965	rs6910838	ENSG00000216915.2	RP1-97D16.1	4.19	3.28e-05	0.00296	0.26	0.19	Systemic lupus erythematosus;	chr6:27547740	chr6:27737000~27738494:-
THCA	cis	rs4906332	1	rs11541718	ENSG00000269910.1	RP11-73M18.10	4.19	3.28e-05	0.00296	0.17	0.19	Coronary artery disease;	chr14:103385827	chr14:103694516~103695050:-
THCA	cis	rs7119038	0.865	rs4936443	ENSG00000255239.1	AP002954.6	4.19	3.28e-05	0.00296	0.29	0.19	Sjögren's syndrome;	chr11:118870155	chr11:118688039~118690600:-
THCA	cis	rs10043228	0.702	rs1582430	ENSG00000250015.1	CTC-339F2.2	4.19	3.28e-05	0.00296	0.23	0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116325734	chr5:116302354~116304134:-
THCA	cis	rs6696239	1	rs12093031	ENSG00000227711.2	RP11-275O4.5	4.19	3.28e-05	0.00296	0.26	0.19	Height;	chr1:227556174	chr1:227509028~227520477:-
THCA	cis	rs7560272	0.538	rs17434655	ENSG00000273245.1	RP11-434P11.2	4.19	3.29e-05	0.00296	0.21	0.19	Schizophrenia;	chr2:73695962	chr2:73750256~73750786:-
THCA	cis	rs1728785	1	rs4783657	ENSG00000274698.1	RP11-71L14.4	4.19	3.29e-05	0.00296	0.27	0.19	Ulcerative colitis;	chr16:68552419	chr16:68450283~68452318:+
THCA	cis	rs709400	0.93	rs10149249	ENSG00000258735.1	LINC00637	4.19	3.29e-05	0.00297	0.25	0.19	Body mass index;	chr14:103581420	chr14:103847721~103858049:+
THCA	cis	rs2692947	0.537	rs1364394	ENSG00000235959.1	AC009237.17	4.19	3.29e-05	0.00297	0.21	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95529982	chr2:95640181~95640604:-
THCA	cis	rs13118159	0.55	rs10016557	ENSG00000254094.1	AC078852.1	4.19	3.29e-05	0.00297	0.23	0.19	Longevity;	chr4:1369840	chr4:1356581~1358075:+
THCA	cis	rs9902453	0.817	rs9909128	ENSG00000263370.1	RP11-68I3.5	4.19	3.29e-05	0.00297	0.24	0.19	Coffee consumption (cups per day);	chr17:29834464	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.765	rs12601647	ENSG00000263370.1	RP11-68I3.5	4.19	3.29e-05	0.00297	0.24	0.19	Coffee consumption (cups per day);	chr17:29837935	chr17:29639627~29640825:+
THCA	cis	rs7267979	1	rs11087520	ENSG00000276952.1	RP5-965G21.6	4.19	3.29e-05	0.00297	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs398036	ENSG00000276952.1	RP5-965G21.6	4.19	3.29e-05	0.00297	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs397119	ENSG00000276952.1	RP5-965G21.6	4.19	3.29e-05	0.00297	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25284915~25285588:-
THCA	cis	rs9840812	0.639	rs610860	ENSG00000239213.4	NCK1-AS1	4.19	3.29e-05	0.00297	0.21	0.19	Fibrinogen levels;	chr3:136333974	chr3:136841726~136862054:-
THCA	cis	rs9902453	0.935	rs4310926	ENSG00000263370.1	RP11-68I3.5	4.19	3.29e-05	0.00297	0.24	0.19	Coffee consumption (cups per day);	chr17:30106257	chr17:29639627~29640825:+
THCA	cis	rs12554020	0.504	rs115096608	ENSG00000227603.1	RP11-165J3.6	4.19	3.29e-05	0.00297	0.31	0.19	Schizophrenia;	chr9:93662119	chr9:93435332~93437121:-
THCA	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	4.19	3.29e-05	0.00297	0.26	0.19	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
THCA	cis	rs7577696	0.627	rs10208246	ENSG00000276334.1	AL133243.1	4.19	3.29e-05	0.00297	0.21	0.19	Inflammatory biomarkers;	chr2:32161590	chr2:32521927~32523547:+
THCA	cis	rs7560272	0.538	rs12233115	ENSG00000273245.1	RP11-434P11.2	-4.19	3.29e-05	0.00297	-0.22	-0.19	Schizophrenia;	chr2:73704764	chr2:73750256~73750786:-
THCA	cis	rs7560272	0.538	rs11126414	ENSG00000273245.1	RP11-434P11.2	-4.19	3.29e-05	0.00297	-0.22	-0.19	Schizophrenia;	chr2:73704917	chr2:73750256~73750786:-
THCA	cis	rs6964833	1	rs6964833	ENSG00000184616.8	AC004166.6	4.19	3.29e-05	0.00297	0.29	0.19	Menarche (age at onset);	chr7:74687575	chr7:74906673~74913256:-
THCA	cis	rs7572733	0.534	rs11899188	ENSG00000231621.1	AC013264.2	-4.19	3.29e-05	0.00297	-0.2	-0.19	Dermatomyositis;	chr2:197875397	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs734037	ENSG00000231621.1	AC013264.2	-4.19	3.29e-05	0.00297	-0.2	-0.19	Dermatomyositis;	chr2:197884545	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.555	rs13395030	ENSG00000231621.1	AC013264.2	-4.19	3.29e-05	0.00297	-0.2	-0.19	Dermatomyositis;	chr2:197886082	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs2060488	ENSG00000231621.1	AC013264.2	-4.19	3.29e-05	0.00297	-0.2	-0.19	Dermatomyositis;	chr2:197886913	chr2:197197991~197199273:+
THCA	cis	rs6878727	0.552	rs168891	ENSG00000253807.4	LINC01170	4.19	3.29e-05	0.00297	0.19	0.19	Breast cancer;	chr5:124346229	chr5:124059794~124405079:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000229180.5	GS1-124K5.11	4.19	3.29e-05	0.00297	0.13	0.19	Aortic root size;	chr7:65975357	chr7:66526088~66542624:-
THCA	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-4.19	3.29e-05	0.00297	-0.22	-0.19	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
THCA	cis	rs11668609	0.515	rs11668661	ENSG00000268442.1	CTD-2027I19.2	4.19	3.29e-05	0.00297	0.29	0.19	Response to taxane treatment (docetaxel);	chr19:23825708	chr19:24162370~24163425:-
THCA	cis	rs427691	0.625	rs845739	ENSG00000271849.1	CTC-332L22.1	-4.19	3.3e-05	0.00297	-0.27	-0.19	Autism spectrum disorder or schizophrenia;	chr5:109682839	chr5:109687802~109688329:-
THCA	cis	rs780094	0.5	rs1919127	ENSG00000234072.1	AC074117.10	4.19	3.3e-05	0.00297	0.15	0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27578626	chr2:27356246~27367622:+
THCA	cis	rs763121	0.962	rs2071887	ENSG00000235209.1	CTA-150C2.13	4.19	3.3e-05	0.00297	0.23	0.19	Menopause (age at onset);	chr22:38483005	chr22:38921227~38924708:+
THCA	cis	rs7824557	0.527	rs2572369	ENSG00000206014.6	OR7E161P	4.19	3.3e-05	0.00297	0.22	0.19	Retinal vascular caliber;	chr8:11381088	chr8:11928597~11929563:-
THCA	cis	rs3096299	0.719	rs12934708	ENSG00000261118.1	RP11-104N10.1	4.19	3.3e-05	0.00297	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89492017~89504460:-
THCA	cis	rs6570726	0.791	rs401331	ENSG00000270638.1	RP3-466P17.1	4.19	3.3e-05	0.00297	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145735570~145737218:+
THCA	cis	rs3770081	1	rs17026729	ENSG00000272564.1	RP11-548P2.2	-4.19	3.3e-05	0.00297	-0.34	-0.19	Facial emotion recognition (sad faces);	chr2:85875055	chr2:85904279~85904727:+
THCA	cis	rs875971	0.862	rs6971059	ENSG00000229886.1	RP5-1132H15.3	-4.19	3.3e-05	0.00297	-0.2	-0.19	Aortic root size;	chr7:66602045	chr7:66025126~66031544:-
THCA	cis	rs875971	0.825	rs7384021	ENSG00000229886.1	RP5-1132H15.3	-4.19	3.3e-05	0.00297	-0.2	-0.19	Aortic root size;	chr7:66612917	chr7:66025126~66031544:-
THCA	cis	rs875971	0.825	rs66981195	ENSG00000229886.1	RP5-1132H15.3	-4.19	3.3e-05	0.00297	-0.2	-0.19	Aortic root size;	chr7:66614048	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs3926380	ENSG00000229886.1	RP5-1132H15.3	-4.19	3.3e-05	0.00297	-0.2	-0.19	Aortic root size;	chr7:66615658	chr7:66025126~66031544:-
THCA	cis	rs875971	0.825	rs1860472	ENSG00000229886.1	RP5-1132H15.3	-4.19	3.3e-05	0.00297	-0.2	-0.19	Aortic root size;	chr7:66617736	chr7:66025126~66031544:-
THCA	cis	rs35740288	0.731	rs11638407	ENSG00000259295.5	CSPG4P12	4.19	3.3e-05	0.00297	0.29	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85551424	chr15:85191438~85213905:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000273142.1	RP11-458F8.4	4.19	3.3e-05	0.00298	0.18	0.19	Aortic root size;	chr7:66376216	chr7:66902857~66906297:+
THCA	cis	rs9467773	0.534	rs34453863	ENSG00000261353.1	CTA-14H9.5	-4.19	3.3e-05	0.00298	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26527063~26527404:+
THCA	cis	rs2280018	0.526	rs2966129	ENSG00000255277.3	ABCC6P2	-4.19	3.3e-05	0.00298	-0.22	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:14820792~14824702:-
THCA	cis	rs10875746	0.855	rs12296244	ENSG00000258273.1	RP11-370I10.4	4.19	3.3e-05	0.00298	0.27	0.19	Longevity (90 years and older);	chr12:48047696	chr12:48333755~48333901:-
THCA	cis	rs4971059	0.654	rs4276913	ENSG00000236675.1	MTX1P1	-4.19	3.3e-05	0.00298	-0.18	-0.19	Breast cancer;	chr1:155159197	chr1:155230975~155234325:+
THCA	cis	rs2439831	0.681	rs484029	ENSG00000205771.5	CATSPER2P1	-4.19	3.3e-05	0.00298	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43327362	chr15:43726918~43747094:-
THCA	cis	rs12410462	0.591	rs2819498	ENSG00000227711.2	RP11-275O4.5	-4.19	3.3e-05	0.00298	-0.23	-0.19	Major depressive disorder;	chr1:227536700	chr1:227509028~227520477:-
THCA	cis	rs17772222	0.701	rs845757	ENSG00000222990.1	RNU4-22P	-4.19	3.3e-05	0.00298	-0.23	-0.19	Coronary artery calcification;	chr14:88455372	chr14:88513498~88513663:+
THCA	cis	rs11673344	0.598	rs826326	ENSG00000267260.1	CTD-2162K18.4	-4.19	3.3e-05	0.00298	-0.22	-0.19	Obesity-related traits;	chr19:37003863	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.542	rs826328	ENSG00000267260.1	CTD-2162K18.4	-4.19	3.3e-05	0.00298	-0.22	-0.19	Obesity-related traits;	chr19:37004479	chr19:36773153~36777078:+
THCA	cis	rs2645424	0.686	rs2294140	ENSG00000255046.1	RP11-297N6.4	-4.19	3.3e-05	0.00298	-0.2	-0.19	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr8:11797928~11802568:-
THCA	cis	rs17801127	0.748	rs71413657	ENSG00000231969.1	AC144449.1	4.19	3.3e-05	0.00298	0.33	0.19	Liver enzyme levels (alanine transaminase);	chr2:149656807	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.748	rs2192896	ENSG00000231969.1	AC144449.1	4.19	3.3e-05	0.00298	0.33	0.19	Liver enzyme levels (alanine transaminase);	chr2:149659554	chr2:149587196~149848233:+
THCA	cis	rs786425	0.618	rs12817576	ENSG00000270095.1	RP11-214K3.18	-4.19	3.3e-05	0.00298	-0.23	-0.19	Pubertal anthropometrics;	chr12:123641792	chr12:123971457~123971714:-
THCA	cis	rs786425	0.618	rs11572952	ENSG00000270095.1	RP11-214K3.18	-4.19	3.3e-05	0.00298	-0.23	-0.19	Pubertal anthropometrics;	chr12:123645262	chr12:123971457~123971714:-
THCA	cis	rs1023500	0.573	rs133370	ENSG00000237037.8	NDUFA6-AS1	-4.19	3.31e-05	0.00298	-0.15	-0.19	Schizophrenia;	chr22:42069256	chr22:42090931~42137742:+
THCA	cis	rs1023500	0.551	rs133371	ENSG00000237037.8	NDUFA6-AS1	-4.19	3.31e-05	0.00298	-0.15	-0.19	Schizophrenia;	chr22:42069570	chr22:42090931~42137742:+
THCA	cis	rs1023500	0.573	rs133374	ENSG00000237037.8	NDUFA6-AS1	-4.19	3.31e-05	0.00298	-0.15	-0.19	Schizophrenia;	chr22:42069937	chr22:42090931~42137742:+
THCA	cis	rs3764021	0.527	rs10844503	ENSG00000214776.8	RP11-726G1.1	4.19	3.31e-05	0.00298	0.25	0.19	Type 1 diabetes;	chr12:9701660	chr12:9467552~9576275:+
THCA	cis	rs1728785	1	rs7205960	ENSG00000274698.1	RP11-71L14.4	4.19	3.31e-05	0.00298	0.26	0.19	Ulcerative colitis;	chr16:68531701	chr16:68450283~68452318:+
THCA	cis	rs9300255	0.602	rs2510885	ENSG00000235423.7	RP11-282O18.3	4.19	3.31e-05	0.00298	0.19	0.19	Neutrophil percentage of white cells;	chr12:123130266	chr12:123252030~123261483:-
THCA	cis	rs62244186	0.627	rs3935212	ENSG00000214820.3	MPRIPP1	4.19	3.31e-05	0.00298	0.21	0.19	Depressive symptoms;	chr3:44419462	chr3:44579938~44581026:-
THCA	cis	rs78487399	0.908	rs79563258	ENSG00000234936.1	AC010883.5	4.19	3.31e-05	0.00298	0.24	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43621276	chr2:43229573~43233394:+
THCA	cis	rs1876905	0.597	rs1150076	ENSG00000272356.1	RP5-1112D6.8	-4.19	3.31e-05	0.00298	-0.2	-0.19	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111309203~111313517:+
THCA	cis	rs9467773	0.525	rs1535274	ENSG00000228223.2	HCG11	-4.19	3.31e-05	0.00298	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.565	rs6925047	ENSG00000228223.2	HCG11	-4.19	3.31e-05	0.00298	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.565	rs4343916	ENSG00000228223.2	HCG11	-4.19	3.31e-05	0.00298	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26523450~26526579:+
THCA	cis	rs763121	0.853	rs138705	ENSG00000228274.3	RP3-508I15.9	-4.19	3.31e-05	0.00298	-0.22	-0.19	Menopause (age at onset);	chr22:38737798	chr22:38667585~38681820:-
THCA	cis	rs1124769	0.672	rs12050528	ENSG00000259378.1	DCAF13P3	4.19	3.31e-05	0.00298	0.29	0.19	Cognitive performance;	chr15:50810917	chr15:50944663~50945996:+
THCA	cis	rs6921919	0.583	rs3734563	ENSG00000273712.1	RP5-874C20.7	4.19	3.31e-05	0.00298	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs1591913	ENSG00000273712.1	RP5-874C20.7	4.19	3.31e-05	0.00298	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28315613~28315883:-
THCA	cis	rs10435719	0.899	rs11250177	ENSG00000206014.6	OR7E161P	-4.19	3.31e-05	0.00298	-0.23	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:11928597~11929563:-
THCA	cis	rs7131987	0.65	rs7957339	ENSG00000273680.1	RP11-996F15.6	4.19	3.31e-05	0.00298	0.26	0.19	QT interval;	chr12:29303562	chr12:29332733~29333383:-
THCA	cis	rs2033711	0.87	rs6510152	ENSG00000269054.1	CTD-2619J13.3	-4.19	3.31e-05	0.00298	-0.15	-0.19	Uric acid clearance;	chr19:58441952	chr19:58362585~58366591:+
THCA	cis	rs7824557	0.564	rs2572395	ENSG00000206014.6	OR7E161P	4.19	3.31e-05	0.00298	0.22	0.19	Retinal vascular caliber;	chr8:11377851	chr8:11928597~11929563:-
THCA	cis	rs12451471	0.667	rs12942002	ENSG00000279259.1	RP11-334C17.3	-4.19	3.31e-05	0.00298	-0.2	-0.19	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80127830	chr17:80147250~80148596:+
THCA	cis	rs8031584	0.679	rs34017474	ENSG00000178081.11	ULK4P3	4.19	3.31e-05	0.00298	0.23	0.19	Huntington's disease progression;	chr15:30938408	chr15:30103720~30131757:+
THCA	cis	rs7572644	0.679	rs9679543	ENSG00000223522.1	AC093690.1	-4.19	3.31e-05	0.00298	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27828084	chr2:28307691~28310459:-
THCA	cis	rs10761482	0.861	rs4520549	ENSG00000254271.1	RP11-131N11.4	4.19	3.31e-05	0.00298	0.25	0.19	Schizophrenia;	chr10:60344758	chr10:60734342~60741828:+
THCA	cis	rs2836974	0.932	rs2234543	ENSG00000255568.3	BRWD1-AS2	4.19	3.31e-05	0.00298	0.17	0.19	Cognitive function;	chr21:39200146	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.899	rs2836938	ENSG00000255568.3	BRWD1-AS2	4.19	3.31e-05	0.00298	0.17	0.19	Cognitive function;	chr21:39202265	chr21:39313935~39314962:+
THCA	cis	rs8067545	0.586	rs2703770	ENSG00000270091.1	RP11-78O7.2	4.19	3.31e-05	0.00298	0.15	0.19	Schizophrenia;	chr17:20220615	chr17:19896590~19897287:-
THCA	cis	rs3738443	1	rs80080331	ENSG00000259865.1	RP11-488L18.10	4.19	3.31e-05	0.00299	0.22	0.19	Alcohol dependence;	chr1:247182910	chr1:247187281~247188526:-
THCA	cis	rs250585	0.85	rs250588	ENSG00000260136.4	CTD-2270L9.4	4.19	3.31e-05	0.00299	0.15	0.19	Egg allergy;	chr16:23388733	chr16:23452758~23457606:+
THCA	cis	rs2153535	0.585	rs7739573	ENSG00000230939.1	RP11-314C16.1	4.19	3.31e-05	0.00299	0.2	0.19	Motion sickness;	chr6:8659671	chr6:8784178~8785445:+
THCA	cis	rs9959145	1	rs1592641	ENSG00000267199.1	RP11-861E21.2	-4.19	3.31e-05	0.00299	-0.24	-0.19	Immune response to smallpox vaccine (IL-6);	chr18:12647241	chr18:12438890~12448205:+
THCA	cis	rs9926296	0.609	rs4785710	ENSG00000274627.1	RP11-104N10.2	4.19	3.31e-05	0.00299	0.2	0.19	Vitiligo;	chr16:89730348	chr16:89516797~89522217:+
THCA	cis	rs4660214	0.666	rs598415	ENSG00000182109.6	RP11-69E11.4	4.19	3.31e-05	0.00299	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39522280~39546187:-
THCA	cis	rs240993	0.812	rs9398272	ENSG00000271789.1	RP5-1112D6.7	4.19	3.31e-05	0.00299	0.23	0.19	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:111297126~111298510:+
THCA	cis	rs4972806	0.814	rs966801	ENSG00000226363.3	HAGLROS	-4.19	3.31e-05	0.00299	-0.22	-0.19	IgG glycosylation;	chr2:176173099	chr2:176177717~176179008:+
THCA	cis	rs786425	0.899	rs1515814	ENSG00000270095.1	RP11-214K3.18	-4.19	3.32e-05	0.00299	-0.22	-0.19	Pubertal anthropometrics;	chr12:123624152	chr12:123971457~123971714:-
THCA	cis	rs79243044	0.931	rs10769042	ENSG00000224295.2	AC087380.14	-4.19	3.32e-05	0.00299	-0.19	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5533624	chr11:5518441~5524955:-
THCA	cis	rs4713118	0.513	rs202908	ENSG00000261839.1	RP1-265C24.8	4.19	3.32e-05	0.00299	0.2	0.19	Parkinson's disease;	chr6:28043773	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.513	rs156739	ENSG00000261839.1	RP1-265C24.8	4.19	3.32e-05	0.00299	0.2	0.19	Parkinson's disease;	chr6:28045632	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.513	rs149958	ENSG00000261839.1	RP1-265C24.8	4.19	3.32e-05	0.00299	0.2	0.19	Parkinson's disease;	chr6:28045839	chr6:28136849~28139678:+
THCA	cis	rs6921919	0.697	rs12180820	ENSG00000273712.1	RP5-874C20.7	-4.19	3.32e-05	0.00299	-0.23	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28315613~28315883:-
THCA	cis	rs10760158	0.8	rs10818520	ENSG00000226752.6	PSMD5-AS1	-4.19	3.32e-05	0.00299	-0.23	-0.19	Pulse pressure;	chr9:121256395	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs10818522	ENSG00000226752.6	PSMD5-AS1	-4.19	3.32e-05	0.00299	-0.23	-0.19	Pulse pressure;	chr9:121256732	chr9:120824828~120854385:+
THCA	cis	rs17801127	0.688	rs34250677	ENSG00000231969.1	AC144449.1	4.19	3.32e-05	0.00299	0.39	0.19	Liver enzyme levels (alanine transaminase);	chr2:149790443	chr2:149587196~149848233:+
THCA	cis	rs734999	0.505	rs4445406	ENSG00000225931.3	RP3-395M20.7	4.19	3.32e-05	0.00299	0.23	0.19	Ulcerative colitis;	chr1:2607961	chr1:2566410~2569888:+
THCA	cis	rs8067545	0.514	rs12449662	ENSG00000261033.1	RP11-209D14.2	-4.19	3.32e-05	0.00299	-0.27	-0.19	Schizophrenia;	chr17:19994532	chr17:20008051~20009234:-
THCA	cis	rs853679	0.824	rs34712084	ENSG00000273712.1	RP5-874C20.7	4.19	3.32e-05	0.00299	0.33	0.19	Depression;	chr6:28076050	chr6:28315613~28315883:-
THCA	cis	rs853679	0.824	rs1321505	ENSG00000273712.1	RP5-874C20.7	4.19	3.32e-05	0.00299	0.33	0.19	Depression;	chr6:28085045	chr6:28315613~28315883:-
THCA	cis	rs853679	0.882	rs9468287	ENSG00000273712.1	RP5-874C20.7	4.19	3.32e-05	0.00299	0.33	0.19	Depression;	chr6:28111963	chr6:28315613~28315883:-
THCA	cis	rs12612619	0.732	rs7560595	ENSG00000272148.1	RP11-195B17.1	4.19	3.32e-05	0.00299	0.17	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006504	chr2:27062428~27062907:-
THCA	cis	rs7520050	0.807	rs4660312	ENSG00000280836.1	AL355480.1	-4.19	3.32e-05	0.00299	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.807	rs4468203	ENSG00000280836.1	AL355480.1	-4.19	3.32e-05	0.00299	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45581219~45581321:-
THCA	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-4.19	3.32e-05	0.00299	-0.22	-0.19	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
THCA	cis	rs786425	0.707	rs1051793	ENSG00000278112.1	RP11-972P1.11	4.19	3.32e-05	0.00299	0.19	0.19	Pubertal anthropometrics;	chr12:123659848	chr12:123519390~123519856:-
THCA	cis	rs786425	0.676	rs4930708	ENSG00000278112.1	RP11-972P1.11	4.19	3.32e-05	0.00299	0.19	0.19	Pubertal anthropometrics;	chr12:123661150	chr12:123519390~123519856:-
THCA	cis	rs875971	1	rs709595	ENSG00000229886.1	RP5-1132H15.3	4.19	3.32e-05	0.00299	0.2	0.19	Aortic root size;	chr7:66352346	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs811880	ENSG00000229886.1	RP5-1132H15.3	4.19	3.32e-05	0.00299	0.2	0.19	Aortic root size;	chr7:66353659	chr7:66025126~66031544:-
THCA	cis	rs875971	0.965	rs9969301	ENSG00000229886.1	RP5-1132H15.3	-4.19	3.32e-05	0.00299	-0.2	-0.19	Aortic root size;	chr7:66316668	chr7:66025126~66031544:-
THCA	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	4.19	3.32e-05	0.00299	0.22	0.19	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
THCA	cis	rs711244	0.756	rs2717493	ENSG00000279519.1	RP11-288C18.1	-4.19	3.32e-05	0.00299	-0.16	-0.19	Mean platelet volume;	chr2:36895409	chr2:36839922~36842539:-
THCA	cis	rs1560104	0.709	rs35456341	ENSG00000262801.4	U91319.1	4.19	3.33e-05	0.00299	0.22	0.19	Obesity-related traits;	chr16:12610010	chr16:13246316~13562918:+
THCA	cis	rs1232027	0.622	rs1677708	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80662220	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650681	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80662439	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs56357417	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80662517	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650680	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80662547	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1650678	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80662892	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650677	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80663434	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1650676	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80663579	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650675	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80663705	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650674	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.00299	0.21	0.19	Huntington's disease progression;	chr5:80663864	chr5:80630313~80631590:-
THCA	cis	rs2898290	0.622	rs4840567	ENSG00000254527.1	ENPP7P12	-4.19	3.33e-05	0.00299	-0.24	-0.19	Systolic blood pressure;	chr8:11490116	chr8:12205759~12206389:-
THCA	cis	rs1232027	0.656	rs1650668	ENSG00000249655.1	CTC-325J23.2	4.19	3.33e-05	0.003	0.21	0.19	Huntington's disease progression;	chr5:80666136	chr5:80630313~80631590:-
THCA	cis	rs8009147	1	rs8009147	ENSG00000269940.1	RP11-73M18.7	4.19	3.33e-05	0.003	0.18	0.19	Autism spectrum disorder or schizophrenia;	chr14:103798325	chr14:103694560~103695170:+
THCA	cis	rs2446066	0.872	rs2071558	ENSG00000257379.1	RP11-793H13.8	4.19	3.33e-05	0.003	0.29	0.19	Red blood cell count;	chr12:53425683	chr12:53441741~53467528:+
THCA	cis	rs9876781	0.624	rs12491849	ENSG00000244380.1	RP11-24C3.2	4.19	3.33e-05	0.003	0.23	0.19	Longevity;	chr3:48489975	chr3:48440352~48446656:-
THCA	cis	rs7824557	0.591	rs2043510	ENSG00000154316.13	TDH	4.19	3.33e-05	0.003	0.14	0.19	Retinal vascular caliber;	chr8:11367659	chr8:11339637~11368452:+
THCA	cis	rs11779988	0.545	rs208749	ENSG00000253671.1	RP11-806O11.1	-4.19	3.33e-05	0.003	-0.25	-0.19	Breast cancer;	chr8:17919695	chr8:17808941~17820868:+
THCA	cis	rs9840812	0.592	rs35418151	ENSG00000239213.4	NCK1-AS1	4.19	3.33e-05	0.003	0.17	0.19	Fibrinogen levels;	chr3:136443779	chr3:136841726~136862054:-
THCA	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	4.19	3.33e-05	0.003	0.22	0.19	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
THCA	cis	rs1923243	0.71	rs4452995	ENSG00000223479.3	RP4-788P17.1	4.19	3.33e-05	0.003	0.21	0.19	Migraine;	chr1:73147877	chr1:73635216~73715214:+
THCA	cis	rs5758659	0.622	rs6519298	ENSG00000270083.1	RP1-257I20.14	4.19	3.33e-05	0.003	0.21	0.19	Cognitive function;	chr22:41968993	chr22:42089630~42090028:-
THCA	cis	rs11146838	1	rs11146838	ENSG00000272983.1	RP11-508N22.12	4.19	3.33e-05	0.003	0.16	0.19	Breast cancer;	chr10:38856846	chr10:38137337~38144399:+
THCA	cis	rs2836974	0.897	rs13049280	ENSG00000255568.3	BRWD1-AS2	4.19	3.33e-05	0.003	0.17	0.19	Cognitive function;	chr21:39222730	chr21:39313935~39314962:+
THCA	cis	rs8031584	0.918	rs34693097	ENSG00000270015.1	RP11-540B6.6	-4.19	3.33e-05	0.003	-0.14	-0.19	Huntington's disease progression;	chr15:30961781	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.918	rs35784593	ENSG00000270015.1	RP11-540B6.6	-4.19	3.33e-05	0.003	-0.14	-0.19	Huntington's disease progression;	chr15:30962385	chr15:30926514~30928407:+
THCA	cis	rs4767841	1	rs2996029	ENSG00000252886.1	RN7SKP197	-4.19	3.33e-05	0.003	-0.19	-0.19	Urgency urinary incontinence;	chr12:119727377	chr12:119631090~119631386:-
THCA	cis	rs1046491	0.901	rs11081463	ENSG00000264964.1	RP11-888D10.3	4.19	3.33e-05	0.003	0.32	0.19	Scarlet fever;	chr18:9152877	chr18:9315194~9334441:-
THCA	cis	rs6546886	0.957	rs6546887	ENSG00000235499.1	AC073046.25	4.19	3.33e-05	0.003	0.18	0.19	Dialysis-related mortality;	chr2:74023654	chr2:73985132~73986343:+
THCA	cis	rs3892630	0.818	rs80137870	ENSG00000267475.1	CTD-2538C1.2	-4.19	3.33e-05	0.003	-0.27	-0.19	Red blood cell traits;	chr19:32691844	chr19:32687089~32691750:-
THCA	cis	rs7923837	1	rs1112718	ENSG00000236493.2	EIF2S2P3	4.19	3.33e-05	0.003	0.19	0.19	Multiple sclerosis;Body mass index;	chr10:92719350	chr10:92668745~92669743:-
THCA	cis	rs6963495	0.818	rs6957192	ENSG00000272604.1	RP11-251G23.5	-4.19	3.33e-05	0.003	-0.25	-0.19	Bipolar disorder (body mass index interaction);	chr7:105509808	chr7:105571083~105573660:+
THCA	cis	rs2380220	0.72	rs9398251	ENSG00000261366.1	MANEA-AS1	-4.19	3.33e-05	0.003	-0.19	-0.19	Behavioural disinhibition (generation interaction);	chr6:95536833	chr6:95575183~95577450:-
THCA	cis	rs17685	0.712	rs7785025	ENSG00000227038.2	AC005077.12	-4.19	3.33e-05	0.003	-0.19	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:75998783	chr7:76090431~76108779:-
THCA	cis	rs1577917	0.682	rs1173417	ENSG00000220563.1	PKMP3	4.19	3.33e-05	0.003	0.14	0.19	Response to antipsychotic treatment;	chr6:85694223	chr6:85659892~85660606:-
THCA	cis	rs6921919	0.525	rs11760133	ENSG00000273712.1	RP5-874C20.7	4.19	3.33e-05	0.003	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28315613~28315883:-
THCA	cis	rs2153535	0.585	rs9378565	ENSG00000230939.1	RP11-314C16.1	-4.19	3.33e-05	0.003	-0.2	-0.19	Motion sickness;	chr6:8664580	chr6:8784178~8785445:+
THCA	cis	rs4742903	0.904	rs2417487	ENSG00000270332.1	SMC2-AS1	4.19	3.33e-05	0.003	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104125300	chr9:104080024~104093073:-
THCA	cis	rs6878727	0.665	rs256852	ENSG00000253807.4	LINC01170	4.19	3.33e-05	0.003	0.17	0.19	Breast cancer;	chr5:124326978	chr5:124059794~124405079:-
THCA	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	4.19	3.33e-05	0.003	0.14	0.19	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
THCA	cis	rs7045881	0.8	rs7018962	ENSG00000254396.1	RP11-56F10.3	4.19	3.33e-05	0.003	0.34	0.19	Schizophrenia;	chr9:26899692	chr9:27102630~27104728:+
THCA	cis	rs17331151	0.573	rs13080929	ENSG00000242142.1	SERBP1P3	-4.19	3.33e-05	0.003	-0.32	-0.19	Immune reponse to smallpox (secreted IL-2);	chr3:52851096	chr3:53064283~53065091:-
THCA	cis	rs11069062	0.866	rs10774986	ENSG00000270482.1	RP11-131L12.2	4.19	3.33e-05	0.003	0.15	0.19	Obesity-related traits;	chr12:118715870	chr12:118375350~118376275:-
THCA	cis	rs2839186	0.967	rs9637172	ENSG00000215424.8	MCM3AP-AS1	4.19	3.33e-05	0.003	0.11	0.19	Testicular germ cell tumor;	chr21:46265873	chr21:46229217~46259390:+
THCA	cis	rs2839186	1	rs2839186	ENSG00000215424.8	MCM3AP-AS1	4.19	3.33e-05	0.003	0.11	0.19	Testicular germ cell tumor;	chr21:46270154	chr21:46229217~46259390:+
THCA	cis	rs868036	0.681	rs1026737	ENSG00000270964.1	RP11-502I4.3	-4.19	3.34e-05	0.003	-0.17	-0.19	Restless legs syndrome;	chr15:67814734	chr15:67541072~67542604:-
THCA	cis	rs791590	0.54	rs10905604	ENSG00000229664.1	RP11-536K7.5	-4.19	3.34e-05	0.003	-0.23	-0.19	Soluble interleukin-2 receptor subunit alpha;	chr10:6003415	chr10:6025978~6036427:+
THCA	cis	rs753778	0.667	rs10092439	ENSG00000253210.1	RP11-809O17.1	-4.19	3.34e-05	0.003	-0.23	-0.19	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141200782	chr8:141126044~141129961:-
THCA	cis	rs12915845	0.545	rs1583794	ENSG00000271997.1	RP11-97O12.6	-4.19	3.34e-05	0.003	-0.13	-0.19	Menarche (age at onset);	chr15:88533413	chr15:88501944~88505787:-
THCA	cis	rs7824557	0.564	rs12550129	ENSG00000206014.6	OR7E161P	4.19	3.34e-05	0.003	0.22	0.19	Retinal vascular caliber;	chr8:11376408	chr8:11928597~11929563:-
THCA	cis	rs2337406	0.538	rs2015470	ENSG00000274576.2	IGHV2-70	-4.19	3.34e-05	0.003	-0.15	-0.19	Alzheimer's disease (late onset);	chr14:106631885	chr14:106770577~106771020:-
THCA	cis	rs11096990	0.855	rs2566168	ENSG00000249685.1	RP11-360F5.3	-4.19	3.34e-05	0.003	-0.24	-0.19	Cognitive function;	chr4:39150053	chr4:39133913~39135608:+
THCA	cis	rs10405744	0.546	rs113134267	ENSG00000267419.1	CTC-559E9.6	-4.19	3.34e-05	0.003	-0.35	-0.19	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);	chr19:19821226	chr19:19776602~19834927:+
THCA	cis	rs4218	0.597	rs10431762	ENSG00000259732.1	RP11-59H7.3	-4.19	3.34e-05	0.003	-0.27	-0.19	Social communication problems;	chr15:59066330	chr15:59121034~59133250:+
THCA	cis	rs599083	0.53	rs576118	ENSG00000212093.1	AP000807.1	-4.19	3.34e-05	0.003	-0.21	-0.19	Bone mineral density (spine);	chr11:68410240	chr11:68506083~68506166:-
THCA	cis	rs4718428	1	rs4718428	ENSG00000229180.5	GS1-124K5.11	4.19	3.34e-05	0.003	0.13	0.19	Corneal structure;	chr7:66956459	chr7:66526088~66542624:-
THCA	cis	rs4578769	0.959	rs3851819	ENSG00000265939.1	UBE2CP2	4.19	3.34e-05	0.003	0.23	0.19	Eosinophil percentage of white cells;	chr18:22881321	chr18:22900486~22900995:-
THCA	cis	rs7474896	0.537	rs2749588	ENSG00000120555.12	SEPT7P9	4.19	3.34e-05	0.003	0.25	0.19	Obesity (extreme);	chr10:37980529	chr10:38383069~38402916:-
THCA	cis	rs2980439	0.557	rs2921056	ENSG00000233609.3	RP11-62H7.2	4.19	3.34e-05	0.003	0.18	0.19	Neuroticism;	chr8:8461672	chr8:8961200~8979025:+
THCA	cis	rs4776970	0.632	rs55993790	ENSG00000270964.1	RP11-502I4.3	-4.19	3.34e-05	0.00301	-0.16	-0.19	Body mass index;Waist circumference;	chr15:67734184	chr15:67541072~67542604:-
THCA	cis	rs11846409	0.932	rs73378155	ENSG00000274576.2	IGHV2-70	-4.19	3.34e-05	0.00301	-0.15	-0.19	Rheumatic heart disease;	chr14:106637840	chr14:106770577~106771020:-
THCA	cis	rs1065656	0.553	rs344357	ENSG00000261123.1	RP11-304L19.3	-4.19	3.34e-05	0.00301	-0.24	-0.19	Insulin-like growth factors;	chr16:1786254	chr16:2094830~2097026:-
THCA	cis	rs8031584	0.958	rs3512	ENSG00000270015.1	RP11-540B6.6	-4.19	3.34e-05	0.00301	-0.14	-0.19	Huntington's disease progression;	chr15:30942802	chr15:30926514~30928407:+
THCA	cis	rs2904967	0.537	rs7116674	ENSG00000254614.2	AP003068.23	4.19	3.34e-05	0.00301	0.4	0.19	Mean corpuscular volume;	chr11:65195487	chr11:65177606~65181834:-
THCA	cis	rs11633886	0.934	rs8031071	ENSG00000273972.1	CTD-2306A12.1	-4.19	3.34e-05	0.00301	-0.2	-0.19	Diisocyanate-induced asthma;	chr15:45789955	chr15:45702640~45703183:+
THCA	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	4.19	3.34e-05	0.00301	0.22	0.19	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	4.19	3.34e-05	0.00301	0.22	0.19	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
THCA	cis	rs2980439	0.557	rs2976876	ENSG00000233609.3	RP11-62H7.2	4.19	3.34e-05	0.00301	0.18	0.19	Neuroticism;	chr8:8461340	chr8:8961200~8979025:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000229886.1	RP5-1132H15.3	4.19	3.34e-05	0.00301	0.2	0.19	Aortic root size;	chr7:66749580	chr7:66025126~66031544:-
THCA	cis	rs801193	0.66	rs4610622	ENSG00000229886.1	RP5-1132H15.3	4.19	3.34e-05	0.00301	0.2	0.19	Aortic root size;	chr7:66759510	chr7:66025126~66031544:-
THCA	cis	rs656319	0.605	rs17747335	ENSG00000261451.1	RP11-981G7.1	-4.19	3.34e-05	0.00301	-0.24	-0.19	Myopia (pathological);	chr8:10145676	chr8:10433672~10438312:+
THCA	cis	rs7267979	0.903	rs6107015	ENSG00000274973.1	RP13-401N8.7	-4.19	3.34e-05	0.00301	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25845497~25845862:+
THCA	cis	rs9625935	0.957	rs36604	ENSG00000279159.1	RP3-394A18.1	4.19	3.34e-05	0.00301	0.15	0.19	Tonsillectomy;	chr22:29944149	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs36606	ENSG00000279159.1	RP3-394A18.1	4.19	3.34e-05	0.00301	0.15	0.19	Tonsillectomy;	chr22:29944421	chr22:29978950~30028236:-
THCA	cis	rs4950322	0.57	rs4593887	ENSG00000271721.1	RP11-337C18.9	4.19	3.34e-05	0.00301	0.21	0.19	Protein quantitative trait loci;	chr1:147234246	chr1:147175602~147177740:+
THCA	cis	rs2380205	1	rs12253826	ENSG00000232807.2	RP11-536K7.3	4.19	3.34e-05	0.00301	0.18	0.19	Breast cancer;	chr10:5844418	chr10:5934270~5945900:-
THCA	cis	rs1560104	0.709	rs2903042	ENSG00000262801.4	U91319.1	4.19	3.34e-05	0.00301	0.22	0.19	Obesity-related traits;	chr16:12604249	chr16:13246316~13562918:+
THCA	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	4.19	3.34e-05	0.00301	0.22	0.19	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	4.19	3.34e-05	0.00301	0.22	0.19	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
THCA	cis	rs6693017	1	rs7530493	ENSG00000272823.1	RP11-295M18.6	-4.19	3.34e-05	0.00301	-0.28	-0.19	Monocyte early outgrowth colony forming units;	chr1:220816358	chr1:220828676~220829211:-
THCA	cis	rs12935418	0.583	rs7186230	ENSG00000278985.1	RP11-303E16.9	4.19	3.34e-05	0.00301	0.24	0.19	Mean corpuscular volume;	chr16:80930723	chr16:80982319~80984094:-
THCA	cis	rs7246760	0.867	rs61011126	ENSG00000267106.4	ZNF561-AS1	4.19	3.34e-05	0.00301	0.35	0.19	Pursuit maintenance gain;	chr19:9703745	chr19:9621291~9645896:+
THCA	cis	rs17092148	0.887	rs4911430	ENSG00000276073.1	RP5-1125A11.7	-4.19	3.34e-05	0.00301	-0.23	-0.19	Neuroticism;	chr20:34557600	chr20:33985617~33988989:-
THCA	cis	rs875971	0.522	rs4502988	ENSG00000234585.5	CCT6P3	4.19	3.35e-05	0.00301	0.17	0.19	Aortic root size;	chr7:65832759	chr7:65038354~65074713:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000234585.5	CCT6P3	4.19	3.35e-05	0.00301	0.17	0.19	Aortic root size;	chr7:65951183	chr7:65038354~65074713:+
THCA	cis	rs708547	0.581	rs13121027	ENSG00000269949.1	RP11-738E22.3	-4.19	3.35e-05	0.00301	-0.23	-0.19	Response to bleomycin (chromatid breaks);	chr4:56947203	chr4:56960927~56961373:-
THCA	cis	rs7045881	0.673	rs55805136	ENSG00000254396.1	RP11-56F10.3	4.19	3.35e-05	0.00301	0.33	0.19	Schizophrenia;	chr9:26869203	chr9:27102630~27104728:+
THCA	cis	rs8062405	0.755	rs55792032	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00301	0.23	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28749959~28750595:-
THCA	cis	rs2590942	0.783	rs61765650	ENSG00000227207.2	RPL31P12	4.19	3.35e-05	0.00301	0.32	0.19	Childhood body mass index;	chr1:72287429	chr1:72301472~72301829:+
THCA	cis	rs10861661	0.963	rs7977765	ENSG00000260329.1	RP11-412D9.4	-4.19	3.35e-05	0.00301	-0.2	-0.19	Triglyceride levels;	chr12:106811612	chr12:106954029~106955497:-
THCA	cis	rs13064773	0.502	rs340250	ENSG00000279311.1	RP11-170K4.2	4.19	3.35e-05	0.00301	0.25	0.19	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158882862	chr3:158869898~158871821:+
THCA	cis	rs13064773	0.546	rs340246	ENSG00000279311.1	RP11-170K4.2	4.19	3.35e-05	0.00301	0.25	0.19	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158884079	chr3:158869898~158871821:+
THCA	cis	rs9393777	0.778	rs13212921	ENSG00000280107.1	AL022393.9	-4.19	3.35e-05	0.00301	-0.32	-0.19	Intelligence (multi-trait analysis);	chr6:27237643	chr6:28170845~28172521:+
THCA	cis	rs1129187	0.967	rs6941212	ENSG00000272223.1	RP1-20C7.6	4.19	3.35e-05	0.00301	0.14	0.19	Alzheimer's disease in APOE e4+ carriers;	chr6:42948182	chr6:43033897~43034405:-
THCA	cis	rs8062405	0.721	rs151303	ENSG00000261766.1	RP11-22P6.2	-4.19	3.35e-05	0.00301	-0.18	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28862166~28863340:-
THCA	cis	rs4081724	0.565	rs73024301	ENSG00000267296.2	CEBPA-AS1	4.19	3.35e-05	0.00301	0.31	0.19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33312285	chr19:33302857~33305054:+
THCA	cis	rs2361718	0.501	rs8065486	ENSG00000275479.1	RP11-334C17.6	-4.19	3.35e-05	0.00301	-0.17	-0.19	Yeast infection;	chr17:80164397	chr17:80149627~80149798:+
THCA	cis	rs875971	1	rs12533997	ENSG00000229886.1	RP5-1132H15.3	4.19	3.35e-05	0.00301	0.2	0.19	Aortic root size;	chr7:66500390	chr7:66025126~66031544:-
THCA	cis	rs758324	0.68	rs154732	ENSG00000224431.1	AC063976.7	-4.19	3.35e-05	0.00301	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132136181	chr5:132199456~132203487:+
THCA	cis	rs10946940	0.93	rs12215012	ENSG00000216915.2	RP1-97D16.1	4.19	3.35e-05	0.00301	0.26	0.19	Systemic lupus erythematosus;	chr6:27539715	chr6:27737000~27738494:-
THCA	cis	rs7474896	0.583	rs7071147	ENSG00000120555.12	SEPT7P9	4.19	3.35e-05	0.00302	0.25	0.19	Obesity (extreme);	chr10:37714448	chr10:38383069~38402916:-
THCA	cis	rs8062405	1	rs3088215	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs28403629	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs61737565	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs4788099	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs9972693	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.964	rs9972768	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.965	rs62037363	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs7205323	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs4788101	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62037364	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62037365	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.929	rs11150609	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.737	rs11861132	ENSG00000270424.1	RP11-1348G14.6	4.19	3.35e-05	0.00302	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28749959~28750595:-
THCA	cis	rs7914558	0.646	rs10883795	ENSG00000213277.3	MARCKSL1P1	4.19	3.35e-05	0.00302	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894820	chr10:103175554~103176094:+
THCA	cis	rs7914558	0.646	rs10883796	ENSG00000213277.3	MARCKSL1P1	4.19	3.35e-05	0.00302	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895558	chr10:103175554~103176094:+
THCA	cis	rs7914558	0.646	rs4363528	ENSG00000213277.3	MARCKSL1P1	4.19	3.35e-05	0.00302	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895758	chr10:103175554~103176094:+
THCA	cis	rs6715284	1	rs6711127	ENSG00000238829.1	RNU7-45P	-4.19	3.35e-05	0.00302	-0.46	-0.19	Rheumatoid arthritis;	chr2:201348792	chr2:201141904~201141966:+
THCA	cis	rs6715284	1	rs72934973	ENSG00000238829.1	RNU7-45P	-4.19	3.35e-05	0.00302	-0.46	-0.19	Rheumatoid arthritis;	chr2:201349211	chr2:201141904~201141966:+
THCA	cis	rs6442522	0.678	rs924813	ENSG00000249786.6	EAF1-AS1	4.19	3.35e-05	0.00302	0.2	0.19	Uric acid levels;	chr3:15471292	chr3:15436171~15455940:-
THCA	cis	rs875971	0.522	rs6960048	ENSG00000275400.1	RP4-756H11.5	-4.19	3.35e-05	0.00302	-0.18	-0.19	Aortic root size;	chr7:65943052	chr7:66553805~66554199:-
THCA	cis	rs17666538	0.585	rs1669733	ENSG00000254207.1	RP11-43A14.1	-4.19	3.35e-05	0.00302	-0.38	-0.19	IgG glycosylation;	chr8:656696	chr8:725188~725877:-
THCA	cis	rs1979679	0.581	rs1405812	ENSG00000278733.1	RP11-425D17.1	-4.19	3.35e-05	0.00302	-0.22	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28476043	chr12:28185625~28186190:-
THCA	cis	rs791590	0.762	rs17147986	ENSG00000229664.1	RP11-536K7.5	-4.19	3.35e-05	0.00302	-0.31	-0.19	Soluble interleukin-2 receptor subunit alpha;	chr10:5996515	chr10:6025978~6036427:+
THCA	cis	rs934734	0.511	rs62141115	ENSG00000214533.3	KRT18P33	-4.19	3.35e-05	0.00302	-0.23	-0.19	Rheumatoid arthritis;	chr2:65445058	chr2:65666695~65667737:+
THCA	cis	rs728616	0.51	rs34782759	ENSG00000242600.5	MBL1P	4.19	3.35e-05	0.00302	0.24	0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80435463	chr10:79904898~79950336:+
THCA	cis	rs4700393	0.517	rs12523070	ENSG00000272308.1	RP11-231G3.1	4.19	3.36e-05	0.00302	0.23	0.19	Intelligence (multi-trait analysis);	chr5:60795496	chr5:60866457~60866935:-
THCA	cis	rs867371	0.929	rs7173852	ENSG00000278603.1	RP13-608F4.5	4.19	3.36e-05	0.00302	0.24	0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472203~82472426:+
THCA	cis	rs4245128	0.717	rs2361225	ENSG00000227487.3	NCAM1-AS1	4.19	3.36e-05	0.00302	0.2	0.19	Life satisfaction;	chr11:112943884	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.775	rs2361226	ENSG00000227487.3	NCAM1-AS1	4.19	3.36e-05	0.00302	0.2	0.19	Life satisfaction;	chr11:112943885	chr11:113269532~113273901:-
THCA	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	4.19	3.36e-05	0.00302	0.22	0.19	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
THCA	cis	rs791590	0.941	rs12722553	ENSG00000225948.2	RP11-554I8.1	-4.19	3.36e-05	0.00302	-0.29	-0.19	Soluble interleukin-2 receptor subunit alpha;	chr10:6029321	chr10:6618716~6625346:+
THCA	cis	rs7824557	0.614	rs10503421	ENSG00000154316.13	TDH	-4.19	3.36e-05	0.00302	-0.15	-0.19	Retinal vascular caliber;	chr8:11363804	chr8:11339637~11368452:+
THCA	cis	rs6517329	0.674	rs1543655	ENSG00000236830.5	CBR3-AS1	4.19	3.36e-05	0.00302	0.18	0.19	Schizophrenia;	chr21:36111076	chr21:36131767~36175815:-
THCA	cis	rs733592	0.524	rs10875726	ENSG00000258273.1	RP11-370I10.4	4.19	3.36e-05	0.00302	0.23	0.19	Plateletcrit;	chr12:48032209	chr12:48333755~48333901:-
THCA	cis	rs733592	0.524	rs10875727	ENSG00000258273.1	RP11-370I10.4	4.19	3.36e-05	0.00302	0.23	0.19	Plateletcrit;	chr12:48032360	chr12:48333755~48333901:-
THCA	cis	rs17292804	0.527	rs12887734	ENSG00000252469.1	RNU7-160P	4.19	3.36e-05	0.00302	0.22	0.19	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103550345~103550406:+
THCA	cis	rs858239	0.601	rs12539331	ENSG00000230042.1	AK3P3	-4.19	3.36e-05	0.00302	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23129178~23129841:+
THCA	cis	rs7577696	0.711	rs385076	ENSG00000276334.1	AL133243.1	4.19	3.36e-05	0.00302	0.21	0.19	Inflammatory biomarkers;	chr2:32264782	chr2:32521927~32523547:+
THCA	cis	rs4218	0.689	rs35066133	ENSG00000259732.1	RP11-59H7.3	-4.19	3.36e-05	0.00302	-0.26	-0.19	Social communication problems;	chr15:59081917	chr15:59121034~59133250:+
THCA	cis	rs748404	0.601	rs530118	ENSG00000249839.1	AC011330.5	4.19	3.36e-05	0.00302	0.22	0.19	Lung cancer;	chr15:43186313	chr15:43663654~43684339:-
THCA	cis	rs1267303	0.642	rs61783087	ENSG00000232022.5	FAAHP1	4.19	3.36e-05	0.00302	0.23	0.19	Monobrow;	chr1:46534283	chr1:46432129~46445521:+
THCA	cis	rs1267303	0.642	rs3737740	ENSG00000232022.5	FAAHP1	4.19	3.36e-05	0.00302	0.23	0.19	Monobrow;	chr1:46534924	chr1:46432129~46445521:+
THCA	cis	rs7968440	0.966	rs1521516	ENSG00000272368.2	RP4-605O3.4	4.19	3.36e-05	0.00302	0.12	0.19	Fibrinogen;	chr12:50661925	chr12:50112197~50165618:+
THCA	cis	rs55692468	0.606	rs1878632	ENSG00000213197.3	AC012066.1	-4.19	3.36e-05	0.00302	-0.25	-0.19	Intraocular pressure;	chr2:152466644	chr2:152389937~152390630:+
THCA	cis	rs2055729	0.591	rs6987670	ENSG00000248538.5	RP11-10A14.5	-4.19	3.36e-05	0.00302	-0.24	-0.19	Multiple myeloma (hyperdiploidy);	chr8:10025667	chr8:9189011~9202854:+
THCA	cis	rs11105298	0.891	rs11105318	ENSG00000266347.2	AC068641.1	4.19	3.36e-05	0.00302	0.25	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89592833~89592927:+
THCA	cis	rs11098499	0.863	rs10018280	ENSG00000249244.1	RP11-548H18.2	4.19	3.36e-05	0.00302	0.22	0.19	Corneal astigmatism;	chr4:119556984	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs6534141	ENSG00000249244.1	RP11-548H18.2	4.19	3.36e-05	0.00302	0.22	0.19	Corneal astigmatism;	chr4:119564068	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs2127823	ENSG00000249244.1	RP11-548H18.2	4.19	3.36e-05	0.00302	0.22	0.19	Corneal astigmatism;	chr4:119564515	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs3775858	ENSG00000249244.1	RP11-548H18.2	4.19	3.36e-05	0.00302	0.22	0.19	Corneal astigmatism;	chr4:119564873	chr4:119391831~119395335:-
THCA	cis	rs67478160	0.583	rs12879612	ENSG00000269940.1	RP11-73M18.7	4.19	3.36e-05	0.00302	0.18	0.19	Schizophrenia;	chr14:103767281	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs4900594	ENSG00000269940.1	RP11-73M18.7	4.19	3.36e-05	0.00302	0.18	0.19	Schizophrenia;	chr14:103784669	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs3742369	ENSG00000269940.1	RP11-73M18.7	4.19	3.36e-05	0.00302	0.18	0.19	Schizophrenia;	chr14:103784939	chr14:103694560~103695170:+
THCA	cis	rs13108904	0.557	rs1680033	ENSG00000254094.1	AC078852.1	4.19	3.36e-05	0.00302	0.23	0.19	Obesity-related traits;	chr4:1249616	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.557	rs1680030	ENSG00000254094.1	AC078852.1	4.19	3.36e-05	0.00302	0.23	0.19	Obesity-related traits;	chr4:1251712	chr4:1356581~1358075:+
THCA	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	4.19	3.36e-05	0.00302	0.22	0.19	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
THCA	cis	rs3824488	0.6	rs16909865	ENSG00000271384.1	RP11-435O5.7	4.19	3.36e-05	0.00302	0.34	0.19	Neuroticism;	chr9:95445020	chr9:95406990~95407662:-
THCA	cis	rs6088813	0.857	rs1886692	ENSG00000279253.1	RP4-614O4.13	4.19	3.36e-05	0.00302	0.19	0.19	Height;	chr20:35398746	chr20:35262727~35264187:-
THCA	cis	rs654950	0.934	rs665223	ENSG00000230638.4	RP11-486B10.4	4.19	3.36e-05	0.00302	0.23	0.19	Airway imaging phenotypes;	chr1:41534983	chr1:41542069~41544310:+
THCA	cis	rs9733	0.715	rs12402006	ENSG00000231073.1	RP11-316M1.3	-4.19	3.36e-05	0.00302	-0.23	-0.19	Tonsillectomy;	chr1:150897353	chr1:150973123~150975534:+
THCA	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-4.19	3.36e-05	0.00302	-0.19	-0.19	Height;	chr5:37061159	chr5:36666214~36725195:-
THCA	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-4.19	3.36e-05	0.00302	-0.19	-0.19	Height;	chr5:37068442	chr5:36666214~36725195:-
THCA	cis	rs10761482	0.861	rs7089563	ENSG00000254271.1	RP11-131N11.4	4.19	3.36e-05	0.00302	0.26	0.19	Schizophrenia;	chr10:60350140	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs7073512	ENSG00000254271.1	RP11-131N11.4	4.19	3.36e-05	0.00302	0.26	0.19	Schizophrenia;	chr10:60350168	chr10:60734342~60741828:+
THCA	cis	rs4144027	0.935	rs8008020	ENSG00000269910.1	RP11-73M18.10	-4.19	3.36e-05	0.00302	-0.17	-0.19	Blood metabolite levels;	chr14:103889546	chr14:103694516~103695050:-
THCA	cis	rs860295	0.58	rs867548	ENSG00000236675.1	MTX1P1	-4.19	3.36e-05	0.00302	-0.19	-0.19	Body mass index;	chr1:155910217	chr1:155230975~155234325:+
THCA	cis	rs860295	0.58	rs867550	ENSG00000236675.1	MTX1P1	-4.19	3.36e-05	0.00302	-0.19	-0.19	Body mass index;	chr1:155910600	chr1:155230975~155234325:+
THCA	cis	rs4245128	0.775	rs10789927	ENSG00000227487.3	NCAM1-AS1	4.19	3.36e-05	0.00302	0.2	0.19	Life satisfaction;	chr11:112938929	chr11:113269532~113273901:-
THCA	cis	rs10833905	0.818	rs10833930	ENSG00000246225.5	RP11-17A1.3	-4.19	3.36e-05	0.00302	-0.28	-0.19	Sudden cardiac arrest;	chr11:23075624	chr11:22829380~22945393:+
THCA	cis	rs9840812	0.725	rs696517	ENSG00000239213.4	NCK1-AS1	4.19	3.36e-05	0.00303	0.2	0.19	Fibrinogen levels;	chr3:136348813	chr3:136841726~136862054:-
THCA	cis	rs12134133	1	rs2802235	ENSG00000237074.1	RP11-6J21.2	4.19	3.36e-05	0.00303	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs2490261	ENSG00000237074.1	RP11-6J21.2	4.19	3.36e-05	0.00303	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207249067~207309121:+
THCA	cis	rs7773456	0.533	rs9368127	ENSG00000227116.1	RP3-471C18.1	4.19	3.36e-05	0.00303	0.22	0.19	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19730427~19734567:-
THCA	cis	rs8077577	0.708	rs3829590	ENSG00000273018.4	CTD-2303H24.2	4.19	3.36e-05	0.00303	0.29	0.19	Obesity-related traits;	chr17:18230951	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.708	rs3829589	ENSG00000273018.4	CTD-2303H24.2	4.19	3.36e-05	0.00303	0.29	0.19	Obesity-related traits;	chr17:18230952	chr17:18511221~18551705:-
THCA	cis	rs2303759	0.709	rs2278405	ENSG00000268686.1	AC010524.2	4.19	3.36e-05	0.00303	0.29	0.19	Multiple sclerosis;	chr19:49309146	chr19:49368705~49388081:-
THCA	cis	rs2303759	0.709	rs10422677	ENSG00000268686.1	AC010524.2	-4.19	3.36e-05	0.00303	-0.29	-0.19	Multiple sclerosis;	chr19:49321033	chr19:49368705~49388081:-
THCA	cis	rs2303759	0.709	rs7256363	ENSG00000268686.1	AC010524.2	-4.19	3.36e-05	0.00303	-0.29	-0.19	Multiple sclerosis;	chr19:49324547	chr19:49368705~49388081:-
THCA	cis	rs2303759	0.709	rs8102574	ENSG00000268686.1	AC010524.2	-4.19	3.36e-05	0.00303	-0.29	-0.19	Multiple sclerosis;	chr19:49325640	chr19:49368705~49388081:-
THCA	cis	rs10484434	0.748	rs62396165	ENSG00000272810.1	U91328.22	4.19	3.36e-05	0.00303	0.2	0.19	HIV-1 viral setpoint;	chr6:26090153	chr6:26013241~26013757:+
THCA	cis	rs4788570	0.543	rs4788820	ENSG00000260593.1	RP11-432I5.2	-4.19	3.37e-05	0.00303	-0.3	-0.19	Intelligence (multi-trait analysis);	chr16:71626212	chr16:71623708~71626816:-
THCA	cis	rs7131987	0.676	rs10843407	ENSG00000275476.1	RP11-996F15.4	4.19	3.37e-05	0.00303	0.19	0.19	QT interval;	chr12:29397311	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.675	rs2194515	ENSG00000275476.1	RP11-996F15.4	4.19	3.37e-05	0.00303	0.19	0.19	QT interval;	chr12:29397450	chr12:29277397~29277882:-
THCA	cis	rs6088590	0.648	rs6059991	ENSG00000276073.1	RP5-1125A11.7	-4.19	3.37e-05	0.00303	-0.17	-0.19	Coronary artery disease;	chr20:34693032	chr20:33985617~33988989:-
THCA	cis	rs700651	0.789	rs6434949	ENSG00000231621.1	AC013264.2	-4.19	3.37e-05	0.00303	-0.2	-0.19	Intracranial aneurysm;	chr2:197990786	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.515	rs6724526	ENSG00000231621.1	AC013264.2	-4.19	3.37e-05	0.00303	-0.2	-0.19	Dermatomyositis;	chr2:197993677	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.515	rs893808	ENSG00000231621.1	AC013264.2	-4.19	3.37e-05	0.00303	-0.2	-0.19	Dermatomyositis;	chr2:197996113	chr2:197197991~197199273:+
THCA	cis	rs1204798	1	rs1204801	ENSG00000237021.2	RP3-486I3.7	-4.19	3.37e-05	0.00303	-0.2	-0.19	Dental caries;	chr6:116224545	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1209223	ENSG00000237021.2	RP3-486I3.7	-4.19	3.37e-05	0.00303	-0.2	-0.19	Dental caries;	chr6:116226426	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1204807	ENSG00000237021.2	RP3-486I3.7	-4.19	3.37e-05	0.00303	-0.2	-0.19	Dental caries;	chr6:116228118	chr6:116254207~116256743:+
THCA	cis	rs12755164	0.714	rs12129942	ENSG00000223479.3	RP4-788P17.1	4.19	3.37e-05	0.00303	0.2	0.19	Schizophrenia;	chr1:72843399	chr1:73635216~73715214:+
THCA	cis	rs6088813	0.925	rs4353719	ENSG00000279253.1	RP4-614O4.13	4.19	3.37e-05	0.00303	0.19	0.19	Height;	chr20:35389546	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.89	rs6088817	ENSG00000279253.1	RP4-614O4.13	4.19	3.37e-05	0.00303	0.19	0.19	Height;	chr20:35397173	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6142374	ENSG00000279253.1	RP4-614O4.13	4.19	3.37e-05	0.00303	0.19	0.19	Height;	chr20:35397765	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6088821	ENSG00000279253.1	RP4-614O4.13	4.19	3.37e-05	0.00303	0.19	0.19	Height;	chr20:35399773	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6088823	ENSG00000279253.1	RP4-614O4.13	4.19	3.37e-05	0.00303	0.19	0.19	Height;	chr20:35406462	chr20:35262727~35264187:-
THCA	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	4.19	3.37e-05	0.00303	0.16	0.19	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
THCA	cis	rs4646450	0.735	rs10255399	ENSG00000244219.5	GS1-259H13.2	-4.19	3.37e-05	0.00303	-0.25	-0.19	Blood metabolite levels;	chr7:99372501	chr7:99598066~99610813:+
THCA	cis	rs4646450	0.735	rs10270917	ENSG00000244219.5	GS1-259H13.2	-4.19	3.37e-05	0.00303	-0.25	-0.19	Blood metabolite levels;	chr7:99372591	chr7:99598066~99610813:+
THCA	cis	rs7220401	0.515	rs8080772	ENSG00000264290.1	RP11-68I3.4	-4.19	3.37e-05	0.00303	-0.16	-0.19	Coronary artery disease;	chr17:30086111	chr17:29569580~29570519:+
THCA	cis	rs3020736	0.5	rs4147638	ENSG00000237037.8	NDUFA6-AS1	4.19	3.37e-05	0.00303	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42090931~42137742:+
THCA	cis	rs11158026	0.501	rs67620272	ENSG00000258413.1	RP11-665C16.6	-4.19	3.37e-05	0.00303	-0.31	-0.19	Parkinson's disease;	chr14:54884861	chr14:55262767~55272075:-
THCA	cis	rs9595908	0.645	rs56399737	ENSG00000212293.1	SNORA16	4.19	3.37e-05	0.00303	0.22	0.19	Body mass index;	chr13:32807583	chr13:32420390~32420516:-
THCA	cis	rs6494488	0.5	rs72741320	ENSG00000259635.1	AC100830.3	-4.19	3.37e-05	0.00303	-0.49	-0.19	Coronary artery disease;	chr15:64429546	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs78659827	ENSG00000259635.1	AC100830.3	-4.19	3.37e-05	0.00303	-0.49	-0.19	Coronary artery disease;	chr15:64429728	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741325	ENSG00000259635.1	AC100830.3	-4.19	3.37e-05	0.00303	-0.49	-0.19	Coronary artery disease;	chr15:64438185	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741327	ENSG00000259635.1	AC100830.3	-4.19	3.37e-05	0.00303	-0.49	-0.19	Coronary artery disease;	chr15:64438623	chr15:64701248~64719602:+
THCA	cis	rs801193	1	rs10234018	ENSG00000229886.1	RP5-1132H15.3	-4.19	3.37e-05	0.00303	-0.19	-0.19	Aortic root size;	chr7:66681297	chr7:66025126~66031544:-
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000182586.6	LINC00334	-4.19	3.37e-05	0.00303	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45234340~45258730:+
THCA	cis	rs1842579	1	rs12091583	ENSG00000272691.1	RP11-290M5.4	-4.19	3.37e-05	0.00303	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85819425	chr1:85578500~85578742:-
THCA	cis	rs7208859	0.673	rs999796	ENSG00000280069.1	CTD-2349P21.3	-4.19	3.37e-05	0.00303	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30738182~30740275:+
THCA	cis	rs5758659	0.652	rs133322	ENSG00000205702.9	CYP2D7	4.19	3.37e-05	0.00303	0.14	0.19	Cognitive function;	chr22:42009655	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.623	rs133328	ENSG00000205702.9	CYP2D7	4.19	3.37e-05	0.00303	0.14	0.19	Cognitive function;	chr22:42012075	chr22:42140203~42144577:-
THCA	cis	rs6443245	0.591	rs2648574	ENSG00000227110.5	LMCD1-AS1	-4.19	3.37e-05	0.00303	-0.23	-0.19	Daytime sleep phenotypes;	chr3:9593350	chr3:7952805~8611924:-
THCA	cis	rs1577330	0.898	rs4394491	ENSG00000254396.1	RP11-56F10.3	4.19	3.37e-05	0.00303	0.23	0.19	IgG glycosylation;	chr9:27092256	chr9:27102630~27104728:+
THCA	cis	rs1577330	0.948	rs7859996	ENSG00000254396.1	RP11-56F10.3	4.19	3.37e-05	0.00303	0.23	0.19	IgG glycosylation;	chr9:27075398	chr9:27102630~27104728:+
THCA	cis	rs9902453	0.967	rs12449783	ENSG00000263370.1	RP11-68I3.5	4.19	3.37e-05	0.00303	0.25	0.19	Coffee consumption (cups per day);	chr17:30200635	chr17:29639627~29640825:+
THCA	cis	rs7968440	1	rs2252589	ENSG00000272368.2	RP4-605O3.4	4.19	3.37e-05	0.00303	0.12	0.19	Fibrinogen;	chr12:50648174	chr12:50112197~50165618:+
THCA	cis	rs4957048	0.577	rs56294732	ENSG00000225138.6	CTD-2228K2.7	4.19	3.37e-05	0.00303	0.22	0.19	Ulcerative colitis;	chr5:568029	chr5:473236~480884:+
THCA	cis	rs2836974	0.932	rs8128734	ENSG00000255568.3	BRWD1-AS2	4.19	3.37e-05	0.00303	0.17	0.19	Cognitive function;	chr21:39197585	chr21:39313935~39314962:+
THCA	cis	rs7141336	0.965	rs8017072	ENSG00000258884.1	CTD-3035D6.2	-4.19	3.37e-05	0.00303	-0.26	-0.19	Anxiety disorder;	chr14:90814615	chr14:90822365~90828128:-
THCA	cis	rs13113518	0.902	rs12642716	ENSG00000272969.1	RP11-528I4.2	4.19	3.37e-05	0.00303	0.22	0.19	Height;	chr4:55479996	chr4:55547112~55547889:+
THCA	cis	rs4218	0.681	rs12913177	ENSG00000277144.1	RP11-59H7.4	4.19	3.37e-05	0.00303	0.26	0.19	Social communication problems;	chr15:59066273	chr15:59115547~59116089:-
THCA	cis	rs35771425	0.619	rs7538812	ENSG00000153363.11	LINC00467	-4.19	3.37e-05	0.00303	-0.15	-0.19	Educational attainment (years of education);	chr1:211268844	chr1:211382803~211435333:+
THCA	cis	rs4218	0.648	rs1074702	ENSG00000259732.1	RP11-59H7.3	-4.19	3.37e-05	0.00303	-0.27	-0.19	Social communication problems;	chr15:59073900	chr15:59121034~59133250:+
THCA	cis	rs4788570	0.615	rs7193549	ENSG00000260185.1	RP11-432I5.6	-4.19	3.37e-05	0.00303	-0.36	-0.19	Intelligence (multi-trait analysis);	chr16:71615513	chr16:71655027~71664212:+
THCA	cis	rs4713118	0.869	rs6901520	ENSG00000220721.1	OR1F12	4.19	3.37e-05	0.00303	0.25	0.19	Parkinson's disease;	chr6:27746796	chr6:28073316~28074233:+
THCA	cis	rs17689437	1	rs7196911	ENSG00000260084.1	RP11-615I2.1	-4.19	3.37e-05	0.00303	-0.3	-0.19	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68553340	chr16:68573782~68589512:-
THCA	cis	rs17689437	1	rs11859322	ENSG00000260084.1	RP11-615I2.1	-4.19	3.37e-05	0.00303	-0.3	-0.19	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68557483	chr16:68573782~68589512:-
THCA	cis	rs17689437	1	rs11859375	ENSG00000260084.1	RP11-615I2.1	-4.19	3.37e-05	0.00303	-0.3	-0.19	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68560943	chr16:68573782~68589512:-
THCA	cis	rs4886920	0.802	rs7164558	ENSG00000260776.4	RP11-114H24.2	-4.19	3.37e-05	0.00303	-0.22	-0.19	Neuroticism;	chr15:77854040	chr15:77914217~77926846:-
THCA	cis	rs472402	0.56	rs2303705	ENSG00000250056.4	LINC01018	-4.19	3.38e-05	0.00303	-0.22	-0.19	Response to amphetamines;	chr5:6621904	chr5:6582136~6588499:+
THCA	cis	rs959260	1	rs9902966	ENSG00000263843.1	RP11-649A18.12	4.19	3.38e-05	0.00303	0.2	0.19	Systemic lupus erythematosus;	chr17:75366066	chr17:75271369~75273895:+
THCA	cis	rs17680741	0.697	rs35414786	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.38e-05	0.00303	-0.28	-0.19	Coronary artery disease;	chr10:80478647	chr10:79663088~79826594:-
THCA	cis	rs4568518	0.557	rs13224298	ENSG00000279048.1	RP11-511H23.2	4.19	3.38e-05	0.00304	0.12	0.19	Measles;	chr7:17962503	chr7:17940503~17942922:+
THCA	cis	rs1371614	0.523	rs7585127	ENSG00000272148.1	RP11-195B17.1	4.19	3.38e-05	0.00304	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956503	chr2:27062428~27062907:-
THCA	cis	rs8062405	0.755	rs4788073	ENSG00000270424.1	RP11-1348G14.6	4.19	3.38e-05	0.00304	0.23	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28749959~28750595:-
THCA	cis	rs5769765	0.778	rs4574208	ENSG00000260613.1	RP3-522J7.6	4.19	3.38e-05	0.00304	0.24	0.19	Schizophrenia;	chr22:49863090	chr22:49832616~49837786:-
THCA	cis	rs564343	0.563	rs570760	ENSG00000255320.1	RP11-755F10.1	-4.19	3.38e-05	0.00304	-0.23	-0.19	Obesity (early onset extreme);	chr11:66066160	chr11:66244840~66246239:-
THCA	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-4.19	3.38e-05	0.00304	-0.22	-0.19	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
THCA	cis	rs7085104	0.572	rs284858	ENSG00000213061.2	PFN1P11	-4.19	3.38e-05	0.00304	-0.22	-0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102838011~102845473:-
THCA	cis	rs875971	0.895	rs12698520	ENSG00000229886.1	RP5-1132H15.3	4.19	3.38e-05	0.00304	0.2	0.19	Aortic root size;	chr7:66453720	chr7:66025126~66031544:-
THCA	cis	rs7131987	0.565	rs7968883	ENSG00000275476.1	RP11-996F15.4	4.19	3.38e-05	0.00304	0.19	0.19	QT interval;	chr12:29241258	chr12:29277397~29277882:-
THCA	cis	rs4356203	0.905	rs550667	ENSG00000272034.1	SNORD14A	-4.19	3.38e-05	0.00304	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197428	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs656623	ENSG00000272034.1	SNORD14A	-4.19	3.38e-05	0.00304	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197632	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs594034	ENSG00000272034.1	SNORD14A	-4.19	3.38e-05	0.00304	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17200833	chr11:17074654~17074744:-
THCA	cis	rs5758511	0.596	rs55644935	ENSG00000227370.1	RP4-669P10.19	4.19	3.38e-05	0.00304	0.21	0.19	Birth weight;	chr22:42270063	chr22:42132543~42132998:+
THCA	cis	rs17292804	0.506	rs71417868	ENSG00000252469.1	RNU7-160P	4.19	3.38e-05	0.00304	0.22	0.19	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103550345~103550406:+
THCA	cis	rs7617480	0.648	rs6766238	ENSG00000229759.1	MRPS18AP1	4.19	3.38e-05	0.00304	0.29	0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48764496	chr3:48256350~48256938:-
THCA	cis	rs2549003	1	rs2070722	ENSG00000237714.1	P4HA2-AS1	-4.19	3.38e-05	0.00304	-0.24	-0.19	Asthma (sex interaction);	chr5:132488794	chr5:132184876~132192808:+
THCA	cis	rs2434529	1	rs76969299	ENSG00000245275.6	SAP30L-AS1	4.19	3.38e-05	0.00304	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154252778	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs73802970	ENSG00000245275.6	SAP30L-AS1	4.19	3.38e-05	0.00304	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154253839	chr5:154329437~154445850:-
THCA	cis	rs453301	0.686	rs7814328	ENSG00000254153.1	CTA-398F10.2	4.19	3.38e-05	0.00304	0.21	0.19	Joint mobility (Beighton score);	chr8:9018719	chr8:8456909~8461337:-
THCA	cis	rs7824557	0.564	rs13274106	ENSG00000206014.6	OR7E161P	4.19	3.38e-05	0.00304	0.22	0.19	Retinal vascular caliber;	chr8:11376449	chr8:11928597~11929563:-
THCA	cis	rs1560104	0.597	rs13338716	ENSG00000260601.1	RP11-552C15.1	-4.19	3.38e-05	0.00304	-0.23	-0.19	Obesity-related traits;	chr16:12617477	chr16:12545482~12546684:+
THCA	cis	rs8040855	0.644	rs4635318	ENSG00000259630.2	CTD-2262B20.1	4.19	3.38e-05	0.00304	0.22	0.19	Bulimia nervosa;	chr15:85183506	chr15:85415228~85415633:+
THCA	cis	rs11089937	0.585	rs6001229	ENSG00000211639.2	IGLV4-60	-4.19	3.39e-05	0.00304	-0.15	-0.19	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22162199~22162681:+
THCA	cis	rs1923243	0.659	rs10749815	ENSG00000223479.3	RP4-788P17.1	-4.19	3.39e-05	0.00304	-0.21	-0.19	Migraine;	chr1:73174446	chr1:73635216~73715214:+
THCA	cis	rs9902453	0.904	rs9900974	ENSG00000263370.1	RP11-68I3.5	-4.19	3.39e-05	0.00304	-0.24	-0.19	Coffee consumption (cups per day);	chr17:30037438	chr17:29639627~29640825:+
THCA	cis	rs13217239	0.646	rs9393789	ENSG00000124549.13	BTN2A3P	-4.19	3.39e-05	0.00304	-0.18	-0.19	Schizophrenia;	chr6:27099249	chr6:26421391~26432383:+
THCA	cis	rs60733400	0.817	rs4648657	ENSG00000225931.3	RP3-395M20.7	-4.19	3.39e-05	0.00304	-0.22	-0.19	Multiple sclerosis;	chr1:2629296	chr1:2566410~2569888:+
THCA	cis	rs4785204	0.867	rs4785377	ENSG00000279356.1	RP11-429P3.8	-4.19	3.39e-05	0.00304	-0.36	-0.19	Esophageal cancer (squamous cell);	chr16:50047464	chr16:50072862~50074986:+
THCA	cis	rs12931792	0.782	rs12927190	ENSG00000273724.1	RP11-347C12.12	4.19	3.39e-05	0.00304	0.21	0.19	Tonsillectomy;	chr16:30158072	chr16:30336400~30343336:+
THCA	cis	rs6479891	0.915	rs10740110	ENSG00000272767.1	JMJD1C-AS1	-4.19	3.39e-05	0.00304	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63465229~63466563:+
THCA	cis	rs7824557	0.564	rs2572394	ENSG00000206014.6	OR7E161P	4.19	3.39e-05	0.00304	0.22	0.19	Retinal vascular caliber;	chr8:11377884	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs2437152	ENSG00000206014.6	OR7E161P	4.19	3.39e-05	0.00304	0.22	0.19	Retinal vascular caliber;	chr8:11377988	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs2736300	ENSG00000206014.6	OR7E161P	4.19	3.39e-05	0.00304	0.22	0.19	Retinal vascular caliber;	chr8:11378070	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs2572392	ENSG00000206014.6	OR7E161P	4.19	3.39e-05	0.00304	0.22	0.19	Retinal vascular caliber;	chr8:11378096	chr8:11928597~11929563:-
THCA	cis	rs6546886	0.912	rs6745236	ENSG00000235499.1	AC073046.25	4.19	3.39e-05	0.00304	0.18	0.19	Dialysis-related mortality;	chr2:74056601	chr2:73985132~73986343:+
THCA	cis	rs3096299	0.719	rs2965945	ENSG00000261118.1	RP11-104N10.1	4.19	3.39e-05	0.00304	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89492017~89504460:-
THCA	cis	rs6878727	0.516	rs43174	ENSG00000253807.4	LINC01170	4.19	3.39e-05	0.00305	0.19	0.19	Breast cancer;	chr5:124322247	chr5:124059794~124405079:-
THCA	cis	rs6715284	1	rs2272390	ENSG00000238829.1	RNU7-45P	-4.19	3.39e-05	0.00305	-0.46	-0.19	Rheumatoid arthritis;	chr2:201330588	chr2:201141904~201141966:+
THCA	cis	rs6921919	0.583	rs1054372	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs9468354	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs7773051	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs12697938	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs13437294	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.609	rs9468357	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs34513104	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs9461456	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.525	rs9468360	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs16894021	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs11751693	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs7749736	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.525	rs9468361	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs7775132	ENSG00000273712.1	RP5-874C20.7	4.19	3.39e-05	0.00305	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28315613~28315883:-
THCA	cis	rs9634489	0.709	rs9556582	ENSG00000247400.3	DNAJC3-AS1	-4.19	3.39e-05	0.00305	-0.12	-0.19	Body mass index;	chr13:96388277	chr13:95648733~95676925:-
THCA	cis	rs800132	0.618	rs2234308	ENSG00000236264.4	RPL26P30	-4.19	3.39e-05	0.00305	-0.35	-0.19	Breast cancer;	chr11:2316463	chr11:2335132~2335776:-
THCA	cis	rs1560104	0.536	rs12708760	ENSG00000260601.1	RP11-552C15.1	-4.19	3.39e-05	0.00305	-0.23	-0.19	Obesity-related traits;	chr16:12617071	chr16:12545482~12546684:+
THCA	cis	rs1560104	0.597	rs13334919	ENSG00000260601.1	RP11-552C15.1	-4.19	3.39e-05	0.00305	-0.23	-0.19	Obesity-related traits;	chr16:12617300	chr16:12545482~12546684:+
THCA	cis	rs7520050	0.807	rs6656279	ENSG00000280836.1	AL355480.1	-4.19	3.39e-05	0.00305	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.807	rs6671802	ENSG00000280836.1	AL355480.1	-4.19	3.39e-05	0.00305	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45581219~45581321:-
THCA	cis	rs1009077	0.61	rs2389864	ENSG00000245958.5	RP11-33B1.1	-4.19	3.39e-05	0.00305	-0.22	-0.19	Endometriosis;	chr4:119589595	chr4:119454791~119552025:+
THCA	cis	rs7111546	0.945	rs7127004	ENSG00000246225.5	RP11-17A1.3	4.19	3.39e-05	0.00305	0.33	0.19	Dialysis-related mortality;	chr11:22814967	chr11:22829380~22945393:+
THCA	cis	rs2179367	0.6	rs1001305	ENSG00000216906.2	RP11-350J20.9	4.19	3.39e-05	0.00305	0.26	0.19	Dupuytren's disease;	chr6:149436808	chr6:149904243~149906418:+
THCA	cis	rs12681366	0.537	rs9297939	ENSG00000261437.1	RP11-22C11.2	4.19	3.39e-05	0.00305	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94467961	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.564	rs10808669	ENSG00000261437.1	RP11-22C11.2	4.19	3.39e-05	0.00305	0.18	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94468833	chr8:94637285~94639467:-
THCA	cis	rs7520050	0.807	rs5021934	ENSG00000280836.1	AL355480.1	4.19	3.39e-05	0.00305	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45581219~45581321:-
THCA	cis	rs79481398	0.553	rs76977681	ENSG00000276772.1	CTD-2515H24.2	-4.19	3.39e-05	0.00305	-0.22	-0.19	Facial morphology (factor 19);	chr15:57481723	chr15:57553955~57555680:+
THCA	cis	rs17597773	1	rs17597773	ENSG00000238078.1	LINC01352	-4.19	3.4e-05	0.00305	-0.27	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220881419	chr1:220829255~220832429:+
THCA	cis	rs1150668	0.835	rs203869	ENSG00000280107.1	AL022393.9	-4.19	3.4e-05	0.00305	-0.18	-0.19	Pubertal anthropometrics;	chr6:28073041	chr6:28170845~28172521:+
THCA	cis	rs9534288	0.956	rs962694	ENSG00000235903.6	CPB2-AS1	4.19	3.4e-05	0.00305	0.27	0.19	Blood protein levels;	chr13:46044891	chr13:46052806~46113332:+
THCA	cis	rs4785204	0.618	rs8046829	ENSG00000279356.1	RP11-429P3.8	-4.19	3.4e-05	0.00305	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:49999967	chr16:50072862~50074986:+
THCA	cis	rs7537765	1	rs6669371	ENSG00000242349.4	NPPA-AS1	-4.19	3.4e-05	0.00305	-0.26	-0.19	QRS complex (12-leadsum);	chr1:11822085	chr1:11841017~11848079:+
THCA	cis	rs4824093	0.61	rs7410534	ENSG00000278869.1	CITF22-49E9.3	4.19	3.4e-05	0.00305	0.39	0.19	Amyotrophic lateral sclerosis (sporadic);	chr22:49896277	chr22:49933198~49934074:-
THCA	cis	rs4906332	1	rs55731474	ENSG00000252469.1	RNU7-160P	4.19	3.4e-05	0.00305	0.2	0.19	Coronary artery disease;	chr14:103412144	chr14:103550345~103550406:+
THCA	cis	rs317865	1	rs317864	ENSG00000263327.5	TAPT1-AS1	-4.19	3.4e-05	0.00305	-0.29	-0.19	Kidney disease (early stage) in type 1 diabetes;	chr4:16156198	chr4:16226685~16320140:+
THCA	cis	rs875971	0.545	rs73146609	ENSG00000273142.1	RP11-458F8.4	4.19	3.4e-05	0.00305	0.18	0.19	Aortic root size;	chr7:66302477	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000273142.1	RP11-458F8.4	4.19	3.4e-05	0.00305	0.18	0.19	Aortic root size;	chr7:66305392	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000273142.1	RP11-458F8.4	4.19	3.4e-05	0.00305	0.18	0.19	Aortic root size;	chr7:66318029	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000273142.1	RP11-458F8.4	4.19	3.4e-05	0.00305	0.18	0.19	Aortic root size;	chr7:66325577	chr7:66902857~66906297:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000273142.1	RP11-458F8.4	4.19	3.4e-05	0.00305	0.18	0.19	Aortic root size;	chr7:66339619	chr7:66902857~66906297:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000234585.5	CCT6P3	-4.19	3.4e-05	0.00305	-0.17	-0.19	Aortic root size;	chr7:65950660	chr7:65038354~65074713:+
THCA	cis	rs1414896	0.572	rs10782999	ENSG00000226026.4	RP11-57H12.3	-4.19	3.4e-05	0.00305	-0.18	-0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95169046	chr1:95163219~95233982:-
THCA	cis	rs4934494	0.813	rs34928397	ENSG00000240996.1	RP11-80H5.7	-4.19	3.4e-05	0.00305	-0.22	-0.19	Red blood cell count;	chr10:89766842	chr10:89694295~89697928:-
THCA	cis	rs34792	0.528	rs153803	ENSG00000207425.1	Y_RNA	4.19	3.4e-05	0.00305	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15458303	chr16:14915457~14915556:-
THCA	cis	rs7927592	0.956	rs12365160	ENSG00000160172.9	FAM86C2P	4.19	3.4e-05	0.00305	0.19	0.19	Total body bone mineral density;	chr11:68482951	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.956	rs11228256	ENSG00000160172.9	FAM86C2P	4.19	3.4e-05	0.00305	0.19	0.19	Total body bone mineral density;	chr11:68483992	chr11:67791648~67805336:-
THCA	cis	rs3892630	0.619	rs61062732	ENSG00000267475.1	CTD-2538C1.2	-4.19	3.4e-05	0.00305	-0.26	-0.19	Red blood cell traits;	chr19:32813811	chr19:32687089~32691750:-
THCA	cis	rs8067354	0.872	rs7224006	ENSG00000266701.1	AC005702.4	-4.19	3.4e-05	0.00305	-0.26	-0.19	Hemoglobin concentration;	chr17:59818977	chr17:60042546~60042627:-
THCA	cis	rs8067354	0.872	rs1295925	ENSG00000266701.1	AC005702.4	-4.19	3.4e-05	0.00305	-0.26	-0.19	Hemoglobin concentration;	chr17:59832902	chr17:60042546~60042627:-
THCA	cis	rs71636778	1	rs71636778	ENSG00000260063.1	RP5-968P14.2	-4.19	3.4e-05	0.00305	-0.26	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26778121	chr1:26692132~26694131:-
THCA	cis	rs4785204	0.717	rs11863493	ENSG00000279356.1	RP11-429P3.8	-4.19	3.4e-05	0.00305	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50012053	chr16:50072862~50074986:+
THCA	cis	rs8031584	0.918	rs1425292	ENSG00000270015.1	RP11-540B6.6	-4.19	3.4e-05	0.00305	-0.15	-0.19	Huntington's disease progression;	chr15:30993219	chr15:30926514~30928407:+
THCA	cis	rs8113308	0.752	rs11882377	ENSG00000275055.1	CTC-471J1.11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:52000877	chr19:52049007~52049754:+
THCA	cis	rs875971	0.838	rs2173570	ENSG00000229886.1	RP5-1132H15.3	-4.19	3.4e-05	0.00305	-0.2	-0.19	Aortic root size;	chr7:66297976	chr7:66025126~66031544:-
THCA	cis	rs9467773	1	rs9393731	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs11756120	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9393732	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.967	rs9358954	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs28558133	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs10946834	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs10946835	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9467778	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs2393670	ENSG00000228223.2	HCG11	-4.19	3.4e-05	0.00305	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26523450~26526579:+
THCA	cis	rs12440869	1	rs7177772	ENSG00000270964.1	RP11-502I4.3	-4.19	3.4e-05	0.00305	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67321156	chr15:67541072~67542604:-
THCA	cis	rs1150668	0.796	rs2531825	ENSG00000280107.1	AL022393.9	-4.19	3.4e-05	0.00305	-0.18	-0.19	Pubertal anthropometrics;	chr6:28381487	chr6:28170845~28172521:+
THCA	cis	rs4805272	0.962	rs7255736	ENSG00000267799.1	MAN1A2P1	4.19	3.4e-05	0.00306	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830512	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.925	rs7260432	ENSG00000267799.1	MAN1A2P1	4.19	3.4e-05	0.00306	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830570	chr19:28790812~28792871:-
THCA	cis	rs4356203	0.905	rs10832743	ENSG00000272034.1	SNORD14A	-4.19	3.4e-05	0.00306	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17194933	chr11:17074654~17074744:-
THCA	cis	rs2153535	0.585	rs1041279	ENSG00000230939.1	RP11-314C16.1	-4.19	3.4e-05	0.00306	-0.2	-0.19	Motion sickness;	chr6:8650293	chr6:8784178~8785445:+
THCA	cis	rs2154427	1	rs2833962	ENSG00000238197.4	PAXBP1-AS1	4.19	3.4e-05	0.00306	0.19	0.19	Bilirubin levels;	chr21:32801979	chr21:32728115~32743122:+
THCA	cis	rs13178541	0.745	rs9986164	ENSG00000250378.1	RP11-119J18.1	-4.18	3.4e-05	0.00306	-0.24	-0.19	IgG glycosylation;	chr5:135827074	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs9986268	ENSG00000250378.1	RP11-119J18.1	-4.18	3.4e-05	0.00306	-0.24	-0.19	IgG glycosylation;	chr5:135827124	chr5:135812667~135826582:+
THCA	cis	rs9388451	0.505	rs6920965	ENSG00000226409.1	RP11-735G4.1	-4.18	3.41e-05	0.00306	-0.23	-0.19	Brugada syndrome;	chr6:125857965	chr6:125370211~125374324:-
THCA	cis	rs2070488	0.965	rs9877282	ENSG00000229589.1	ACVR2B-AS1	-4.18	3.41e-05	0.00306	-0.18	-0.19	Electrocardiographic conduction measures;	chr3:38499961	chr3:38451027~38454820:-
THCA	cis	rs73108077	1	rs73110016	ENSG00000277112.2	RP11-755J8.1	-4.18	3.41e-05	0.00306	-0.38	-0.19	Red blood cell density in sickle cell anemia;	chr20:31432402	chr20:30681825~30723932:-
THCA	cis	rs9316337	0.933	rs3759472	ENSG00000236953.1	ZDHHC20-IT1	-4.18	3.41e-05	0.00306	-0.2	-0.19	Schizophrenia;	chr13:21374849	chr13:21376977~21377874:-
THCA	cis	rs12142240	0.698	rs17361763	ENSG00000232022.5	FAAHP1	-4.18	3.41e-05	0.00306	-0.21	-0.19	Menopause (age at onset);	chr1:46344998	chr1:46432129~46445521:+
THCA	cis	rs6479891	1	rs4746974	ENSG00000272767.1	JMJD1C-AS1	4.18	3.41e-05	0.00306	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63465229~63466563:+
THCA	cis	rs17221829	0.528	rs2860553	ENSG00000280385.1	AP000648.5	-4.18	3.41e-05	0.00306	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89622128	chr11:90193614~90198120:+
THCA	cis	rs2904524	0.609	rs2099373	ENSG00000257815.4	RP11-611E13.2	-4.18	3.41e-05	0.00306	-0.28	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70380680	chr12:69904033~70243360:-
THCA	cis	rs3758911	0.964	rs10789608	ENSG00000255353.1	RP11-382M14.1	-4.18	3.41e-05	0.00306	-0.24	-0.19	Coronary artery disease;	chr11:107314132	chr11:107176286~107177530:+
THCA	cis	rs7560272	0.538	rs7599453	ENSG00000163016.8	ALMS1P	-4.18	3.41e-05	0.00306	-0.23	-0.19	Schizophrenia;	chr2:73710774	chr2:73644919~73685576:+
THCA	cis	rs156299	0.513	rs156292	ENSG00000234286.1	AC006026.13	4.18	3.41e-05	0.00306	0.25	0.19	Vitamin D levels;	chr7:24197413	chr7:23680195~23680786:-
THCA	cis	rs6573604	0.681	rs10132229	ENSG00000276116.2	FUT8-AS1	-4.18	3.41e-05	0.00306	-0.3	-0.19	N-glycan levels;	chr14:65310842	chr14:65411170~65412690:-
THCA	cis	rs72928364	1	rs13079002	ENSG00000256628.3	ZBTB11-AS1	4.18	3.41e-05	0.00306	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100911297	chr3:101676475~101679217:+
THCA	cis	rs875971	0.964	rs60193905	ENSG00000229886.1	RP5-1132H15.3	4.18	3.41e-05	0.00306	0.2	0.19	Aortic root size;	chr7:66506273	chr7:66025126~66031544:-
THCA	cis	rs875971	0.929	rs10950041	ENSG00000229886.1	RP5-1132H15.3	4.18	3.41e-05	0.00306	0.2	0.19	Aortic root size;	chr7:66508888	chr7:66025126~66031544:-
THCA	cis	rs7552393	0.932	rs10159391	ENSG00000233008.4	RP11-475O6.1	-4.18	3.41e-05	0.00306	-0.2	-0.19	Select biomarker traits;	chr1:83792498	chr1:83575776~83861023:-
THCA	cis	rs10805346	0.558	rs12506562	ENSG00000261490.1	RP11-448G15.3	4.18	3.41e-05	0.00306	0.12	0.19	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10105330	chr4:10068089~10073019:-
THCA	cis	rs7432375	0.901	rs1729951	ENSG00000273455.1	RP11-305O4.3	-4.18	3.41e-05	0.00306	-0.25	-0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136781891	chr3:136087475~136087913:-
THCA	cis	rs2944755	1	rs2944755	ENSG00000279766.1	RP11-642A1.2	4.18	3.41e-05	0.00306	0.27	0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140564095	chr8:140572142~140572812:-
THCA	cis	rs2708377	0.656	rs116607079	ENSG00000247157.5	LINC01252	4.18	3.41e-05	0.00306	0.34	0.19	Bitter taste perception;	chr12:11109445	chr12:11548030~11590369:+
THCA	cis	rs2708377	0.929	rs73066828	ENSG00000247157.5	LINC01252	4.18	3.41e-05	0.00306	0.34	0.19	Bitter taste perception;	chr12:11118055	chr12:11548030~11590369:+
THCA	cis	rs2708377	0.656	rs73066852	ENSG00000247157.5	LINC01252	4.18	3.41e-05	0.00306	0.34	0.19	Bitter taste perception;	chr12:11123942	chr12:11548030~11590369:+
THCA	cis	rs2708377	0.858	rs117212341	ENSG00000247157.5	LINC01252	4.18	3.41e-05	0.00306	0.34	0.19	Bitter taste perception;	chr12:11129957	chr12:11548030~11590369:+
THCA	cis	rs2708377	0.858	rs115781584	ENSG00000247157.5	LINC01252	4.18	3.41e-05	0.00306	0.34	0.19	Bitter taste perception;	chr12:11151961	chr12:11548030~11590369:+
THCA	cis	rs74233809	1	rs34747231	ENSG00000272912.1	RP11-724N1.1	-4.18	3.41e-05	0.00306	-0.35	-0.19	Birth weight;	chr10:103182487	chr10:102914585~102915404:+
THCA	cis	rs941408	0.515	rs1640262	ENSG00000261342.1	AC006538.1	-4.18	3.41e-05	0.00306	-0.21	-0.19	Total cholesterol levels;	chr19:2779136	chr19:2727743~2729327:-
THCA	cis	rs9921338	0.668	rs193778	ENSG00000262636.1	CTD-3088G3.4	-4.18	3.41e-05	0.00306	-0.28	-0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11257354	chr16:11380859~11381118:-
THCA	cis	rs786425	0.646	rs11612927	ENSG00000270095.1	RP11-214K3.18	-4.18	3.42e-05	0.00307	-0.23	-0.19	Pubertal anthropometrics;	chr12:123647180	chr12:123971457~123971714:-
THCA	cis	rs12681963	0.688	rs7817838	ENSG00000272375.1	RP11-51J9.6	4.18	3.42e-05	0.00307	0.29	0.19	Migraine;	chr8:30205298	chr8:30197404~30198048:+
THCA	cis	rs12493885	0.769	rs11718319	ENSG00000243069.6	ARHGEF26-AS1	-4.18	3.42e-05	0.00307	-0.36	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059155	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.697	rs11710478	ENSG00000243069.6	ARHGEF26-AS1	-4.18	3.42e-05	0.00307	-0.36	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059248	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.769	rs11710560	ENSG00000243069.6	ARHGEF26-AS1	-4.18	3.42e-05	0.00307	-0.36	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059487	chr3:154024401~154121332:-
THCA	cis	rs1728785	0.901	rs3087783	ENSG00000274698.1	RP11-71L14.4	4.18	3.42e-05	0.00307	0.28	0.19	Ulcerative colitis;	chr16:68565765	chr16:68450283~68452318:+
THCA	cis	rs733592	0.894	rs886589	ENSG00000269514.1	RP11-370I10.12	4.18	3.42e-05	0.00307	0.16	0.19	Plateletcrit;	chr12:48083414	chr12:48198387~48202031:+
THCA	cis	rs6472235	0.564	rs35753080	ENSG00000272010.1	CTD-3025N20.3	-4.18	3.42e-05	0.00307	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:66000762	chr8:65591850~65592472:-
THCA	cis	rs6472235	0.586	rs7814933	ENSG00000272010.1	CTD-3025N20.3	-4.18	3.42e-05	0.00307	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:66000992	chr8:65591850~65592472:-
THCA	cis	rs7178572	0.625	rs12905285	ENSG00000259362.2	RP11-307C19.1	-4.18	3.42e-05	0.00307	-0.23	-0.19	Type 2 diabetes;	chr15:77553470	chr15:77525540~77534110:+
THCA	cis	rs34421088	0.532	rs2736385	ENSG00000154316.13	TDH	-4.18	3.42e-05	0.00307	-0.14	-0.19	Neuroticism;	chr8:11291104	chr8:11339637~11368452:+
THCA	cis	rs79390277	0.579	rs8044066	ENSG00000260459.2	FTLP14	-4.18	3.42e-05	0.00307	-0.35	-0.19	Primary sclerosing cholangitis;	chr16:69079466	chr16:68822587~68823070:+
THCA	cis	rs7614311	0.906	rs832198	ENSG00000271843.1	RP11-245J9.5	-4.18	3.42e-05	0.00307	-0.28	-0.19	Lung function (FVC);Lung function (FEV1);	chr3:63884676	chr3:64008082~64008692:-
THCA	cis	rs7359257	0.576	rs9652480	ENSG00000270964.1	RP11-502I4.3	-4.18	3.42e-05	0.00307	-0.17	-0.19	Menarche (age at onset);	chr15:67554979	chr15:67541072~67542604:-
THCA	cis	rs34792	0.812	rs153789	ENSG00000207425.1	Y_RNA	4.18	3.42e-05	0.00307	0.21	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15500720	chr16:14915457~14915556:-
THCA	cis	rs868036	0.681	rs4776976	ENSG00000270964.1	RP11-502I4.3	-4.18	3.42e-05	0.00307	-0.17	-0.19	Restless legs syndrome;	chr15:67810953	chr15:67541072~67542604:-
THCA	cis	rs465969	0.744	rs574056	ENSG00000272356.1	RP5-1112D6.8	4.18	3.42e-05	0.00307	0.31	0.19	Psoriasis;	chr6:111305787	chr6:111309203~111313517:+
THCA	cis	rs11633886	0.528	rs2247958	ENSG00000273972.1	CTD-2306A12.1	4.18	3.42e-05	0.00307	0.21	0.19	Diisocyanate-induced asthma;	chr15:45807336	chr15:45702640~45703183:+
THCA	cis	rs2688608	0.905	rs2633300	ENSG00000271816.1	BMS1P4	4.18	3.42e-05	0.00307	0.18	0.19	Inflammatory bowel disease;	chr10:73896889	chr10:73699151~73730487:-
THCA	cis	rs9393777	0.92	rs66462181	ENSG00000220721.1	OR1F12	4.18	3.42e-05	0.00307	0.44	0.19	Intelligence (multi-trait analysis);	chr6:27123882	chr6:28073316~28074233:+
THCA	cis	rs758324	0.645	rs154734	ENSG00000224431.1	AC063976.7	-4.18	3.42e-05	0.00307	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132136860	chr5:132199456~132203487:+
THCA	cis	rs28735056	0.967	rs11662248	ENSG00000261126.6	RP11-795F19.1	-4.18	3.42e-05	0.00307	-0.16	-0.19	Schizophrenia;	chr18:79859009	chr18:80046900~80095482:+
THCA	cis	rs7336933	1	rs7336933	ENSG00000278338.3	VWA8-AS1	-4.18	3.42e-05	0.00307	-0.3	-0.19	Calcium levels;	chr13:41984940	chr13:41955808~41981565:+
THCA	cis	rs7968440	0.778	rs111941917	ENSG00000272368.2	RP4-605O3.4	4.18	3.42e-05	0.00307	0.12	0.19	Fibrinogen;	chr12:50764479	chr12:50112197~50165618:+
THCA	cis	rs868036	0.609	rs2278076	ENSG00000270964.1	RP11-502I4.3	-4.18	3.42e-05	0.00307	-0.18	-0.19	Restless legs syndrome;	chr15:67807262	chr15:67541072~67542604:-
THCA	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	4.18	3.42e-05	0.00307	0.22	0.19	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
THCA	cis	rs12143943	0.866	rs35666383	ENSG00000240219.1	RP11-430C7.5	4.18	3.42e-05	0.00307	0.17	0.19	Cognitive performance;	chr1:204523656	chr1:204626775~204629712:+
THCA	cis	rs7178375	1	rs7178533	ENSG00000269930.1	RP11-932O9.9	-4.18	3.42e-05	0.00307	-0.26	-0.19	Hypertriglyceridemia;	chr15:30923773	chr15:30616958~30617749:+
THCA	cis	rs79243044	0.862	rs10160557	ENSG00000224295.2	AC087380.14	-4.18	3.42e-05	0.00307	-0.2	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5525492	chr11:5518441~5524955:-
THCA	cis	rs6433895	0.677	rs6716261	ENSG00000236153.1	AC104076.3	-4.18	3.42e-05	0.00307	-0.23	-0.19	Lymphocyte counts;	chr2:181166505	chr2:180979427~180980090:-
THCA	cis	rs7572644	0.662	rs6706209	ENSG00000223522.1	AC093690.1	4.18	3.42e-05	0.00307	0.22	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27879071	chr2:28307691~28310459:-
THCA	cis	rs7690978	1	rs7690978	ENSG00000260265.1	RP11-44F21.5	4.18	3.42e-05	0.00307	0.25	0.19	Interferon gamma-induced protein 10 levels;	chr4:75066634	chr4:75081702~75084717:-
THCA	cis	rs6500637	0.591	rs2075466	ENSG00000267077.1	RP11-127I20.5	4.18	3.42e-05	0.00307	0.23	0.19	Cancer;	chr16:4822969	chr16:4795265~4796532:-
THCA	cis	rs2253762	0.609	rs10887057	ENSG00000276742.1	RP11-500G22.4	4.18	3.43e-05	0.00307	0.25	0.19	Breast cancer;	chr10:122043799	chr10:121956782~121957098:+
THCA	cis	rs62158211	0.826	rs62158168	ENSG00000240356.5	RP11-395L14.11	-4.18	3.43e-05	0.00307	-0.25	-0.19	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113320804	chr2:113610502~113627090:-
THCA	cis	rs763121	0.719	rs9610995	ENSG00000273076.1	RP3-508I15.22	4.18	3.43e-05	0.00307	0.19	0.19	Menopause (age at onset);	chr22:38661758	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs8142098	ENSG00000273076.1	RP3-508I15.22	4.18	3.43e-05	0.00307	0.19	0.19	Menopause (age at onset);	chr22:38662752	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2413544	ENSG00000273076.1	RP3-508I15.22	4.18	3.43e-05	0.00307	0.19	0.19	Menopause (age at onset);	chr22:38663399	chr22:38743495~38743910:+
THCA	cis	rs763121	0.752	rs5757222	ENSG00000273076.1	RP3-508I15.22	4.18	3.43e-05	0.00307	0.19	0.19	Menopause (age at onset);	chr22:38664468	chr22:38743495~38743910:+
THCA	cis	rs763121	0.819	rs5750658	ENSG00000273076.1	RP3-508I15.22	4.18	3.43e-05	0.00307	0.19	0.19	Menopause (age at onset);	chr22:38664912	chr22:38743495~38743910:+
THCA	cis	rs763121	0.819	rs8137829	ENSG00000273076.1	RP3-508I15.22	4.18	3.43e-05	0.00307	0.19	0.19	Menopause (age at onset);	chr22:38665025	chr22:38743495~38743910:+
THCA	cis	rs3892630	0.588	rs12610342	ENSG00000267567.1	CTD-2538C1.3	4.18	3.43e-05	0.00307	0.27	0.19	Red blood cell traits;	chr19:32759784	chr19:32718298~32719595:-
THCA	cis	rs6019512	0.625	rs6066908	ENSG00000227431.4	CSE1L-AS1	-4.18	3.43e-05	0.00308	-0.22	-0.19	Intelligence (multi-trait analysis);	chr20:48912414	chr20:49040463~49046044:-
THCA	cis	rs6019512	0.625	rs4810893	ENSG00000227431.4	CSE1L-AS1	-4.18	3.43e-05	0.00308	-0.22	-0.19	Intelligence (multi-trait analysis);	chr20:48912974	chr20:49040463~49046044:-
THCA	cis	rs7914558	0.646	rs7100709	ENSG00000213277.3	MARCKSL1P1	4.18	3.43e-05	0.00308	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102889972	chr10:103175554~103176094:+
THCA	cis	rs4713118	0.539	rs200988	ENSG00000220721.1	OR1F12	4.18	3.43e-05	0.00308	0.23	0.19	Parkinson's disease;	chr6:27851575	chr6:28073316~28074233:+
THCA	cis	rs200986	1	rs200986	ENSG00000220721.1	OR1F12	4.18	3.43e-05	0.00308	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28073316~28074233:+
THCA	cis	rs13217239	0.646	rs6456767	ENSG00000124549.13	BTN2A3P	-4.18	3.43e-05	0.00308	-0.18	-0.19	Schizophrenia;	chr6:27102764	chr6:26421391~26432383:+
THCA	cis	rs718433	0.614	rs8017132	ENSG00000211778.2	TRAV4	-4.18	3.43e-05	0.00308	-0.15	-0.19	Intraocular pressure;	chr14:21741081	chr14:21736152~21736982:+
THCA	cis	rs6442522	0.56	rs924811	ENSG00000249786.6	EAF1-AS1	4.18	3.43e-05	0.00308	0.2	0.19	Uric acid levels;	chr3:15475313	chr3:15436171~15455940:-
THCA	cis	rs9467773	0.967	rs9295694	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.967	rs9467775	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9393729	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.967	rs6456732	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs4713006	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.967	rs6924865	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6925703	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6910899	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.967	rs9461267	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.967	rs1056347	ENSG00000228223.2	HCG11	-4.18	3.43e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9295695	ENSG00000228223.2	HCG11	4.18	3.43e-05	0.00308	0.2	0.19	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26523450~26526579:+
THCA	cis	rs13217239	0.572	rs9379958	ENSG00000124549.13	BTN2A3P	-4.18	3.43e-05	0.00308	-0.18	-0.19	Schizophrenia;	chr6:27098384	chr6:26421391~26432383:+
THCA	cis	rs4788570	0.615	rs2052584	ENSG00000260593.1	RP11-432I5.2	4.18	3.43e-05	0.00308	0.3	0.19	Intelligence (multi-trait analysis);	chr16:71655074	chr16:71623708~71626816:-
THCA	cis	rs7688540	0.771	rs7669892	ENSG00000251689.1	RP11-478C6.5	4.18	3.43e-05	0.00308	0.33	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:315464	chr4:269866~270175:-
THCA	cis	rs7924176	0.601	rs3180427	ENSG00000213731.2	RAB5CP1	-4.18	3.43e-05	0.00308	-0.23	-0.19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74121589	chr10:74423435~74424014:-
THCA	cis	rs150992	0.547	rs325217	ENSG00000246763.5	RGMB-AS1	4.18	3.43e-05	0.00308	0.2	0.19	Body mass index;	chr5:98844109	chr5:98769618~98773469:-
THCA	cis	rs7968440	1	rs7968440	ENSG00000272368.2	RP4-605O3.4	4.18	3.43e-05	0.00308	0.12	0.19	Fibrinogen;	chr12:50740958	chr12:50112197~50165618:+
THCA	cis	rs12612619	0.732	rs6547401	ENSG00000272148.1	RP11-195B17.1	4.18	3.43e-05	0.00308	0.17	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27061977	chr2:27062428~27062907:-
THCA	cis	rs9393813	0.868	rs4711154	ENSG00000204789.4	ZNF204P	-4.18	3.43e-05	0.00308	-0.15	-0.19	Bipolar disorder;	chr6:27478580	chr6:27357825~27360221:-
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000184274.3	LINC00315	-4.18	3.43e-05	0.00308	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45300245~45305257:-
THCA	cis	rs1075265	0.547	rs10865279	ENSG00000272156.1	RP11-477N3.1	4.18	3.43e-05	0.00308	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54082554~54085066:+
THCA	cis	rs42648	0.935	rs42644	ENSG00000225498.1	AC002064.5	4.18	3.43e-05	0.00308	0.2	0.19	Homocysteine levels;	chr7:90345550	chr7:90312496~90322592:+
THCA	cis	rs7674212	0.507	rs6843738	ENSG00000248971.2	KRT8P46	-4.18	3.43e-05	0.00308	-0.24	-0.19	Type 2 diabetes;	chr4:103014844	chr4:102728746~102730171:-
THCA	cis	rs4835473	0.637	rs1825040	ENSG00000251600.4	RP11-673E1.1	-4.18	3.43e-05	0.00308	-0.23	-0.19	Immature fraction of reticulocytes;	chr4:143794417	chr4:143912331~143982454:+
THCA	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	4.18	3.43e-05	0.00308	0.22	0.19	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
THCA	cis	rs61270009	0.955	rs4916905	ENSG00000247828.6	TMEM161B-AS1	4.18	3.43e-05	0.00308	0.16	0.19	Depressive symptoms;	chr5:88362244	chr5:88268895~88436685:+
THCA	cis	rs8113308	0.752	rs113374423	ENSG00000269483.1	AC006272.1	4.18	3.44e-05	0.00308	0.29	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987699	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.752	rs73068868	ENSG00000269483.1	AC006272.1	4.18	3.44e-05	0.00308	0.29	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987748	chr19:51839924~51843324:-
THCA	cis	rs8177876	0.822	rs7206814	ENSG00000261061.1	RP11-303E16.2	4.18	3.44e-05	0.00308	0.25	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81030770~81031485:+
THCA	cis	rs7560272	0.538	rs3980695	ENSG00000163016.8	ALMS1P	-4.18	3.44e-05	0.00308	-0.23	-0.19	Schizophrenia;	chr2:73712425	chr2:73644919~73685576:+
THCA	cis	rs67478160	0.679	rs8011109	ENSG00000269940.1	RP11-73M18.7	4.18	3.44e-05	0.00308	0.18	0.19	Schizophrenia;	chr14:103813637	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.655	rs4900598	ENSG00000269940.1	RP11-73M18.7	4.18	3.44e-05	0.00308	0.18	0.19	Schizophrenia;	chr14:103815204	chr14:103694560~103695170:+
THCA	cis	rs2836326	0.954	rs2836315	ENSG00000231123.1	SPATA20P1	4.18	3.44e-05	0.00308	0.27	0.19	Metabolite levels (HVA);	chr21:38343205	chr21:38238227~38238664:-
THCA	cis	rs9467773	1	rs1321480	ENSG00000228223.2	HCG11	-4.18	3.44e-05	0.00308	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26523450~26526579:+
THCA	cis	rs9393813	0.529	rs2064093	ENSG00000204789.4	ZNF204P	4.18	3.44e-05	0.00308	0.15	0.19	Bipolar disorder;	chr6:27474468	chr6:27357825~27360221:-
THCA	cis	rs12478296	1	rs60533128	ENSG00000261186.2	RP11-341N2.1	-4.18	3.44e-05	0.00308	-0.32	-0.19	Obesity-related traits;	chr2:242085937	chr2:242087351~242088457:-
THCA	cis	rs9527	0.641	rs4919684	ENSG00000236937.2	PTGES3P4	4.18	3.44e-05	0.00308	0.27	0.19	Arsenic metabolism;	chr10:102827267	chr10:102845595~102845950:+
THCA	cis	rs4915077	0.649	rs4073682	ENSG00000226822.1	RP11-356N1.2	4.18	3.44e-05	0.00308	0.37	0.19	Hypothyroidism;	chr1:107830216	chr1:108071482~108074519:+
THCA	cis	rs7647973	0.566	rs57630346	ENSG00000229759.1	MRPS18AP1	4.18	3.44e-05	0.00308	0.29	0.19	Menarche (age at onset);	chr3:49048782	chr3:48256350~48256938:-
THCA	cis	rs11634944	0.901	rs2732025	ENSG00000257151.1	PWAR6	-4.18	3.44e-05	0.00308	-0.15	-0.19	Interleukin-8 levels;	chr15:24966663	chr15:25031873~25036490:+
THCA	cis	rs651907	0.737	rs9844218	ENSG00000244119.1	PDCL3P4	-4.18	3.44e-05	0.00308	-0.17	-0.19	Colorectal cancer;	chr3:101866139	chr3:101712472~101713191:+
THCA	cis	rs6088590	0.648	rs6058105	ENSG00000276073.1	RP5-1125A11.7	-4.18	3.44e-05	0.00308	-0.16	-0.19	Coronary artery disease;	chr20:34683915	chr20:33985617~33988989:-
THCA	cis	rs875971	1	rs697970	ENSG00000230189.5	GS1-124K5.2	-4.18	3.44e-05	0.00308	-0.13	-0.19	Aortic root size;	chr7:66095065	chr7:66409143~66490059:-
THCA	cis	rs2692947	0.832	rs2438978	ENSG00000235584.2	AC008268.1	-4.18	3.44e-05	0.00308	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96013992	chr2:95666084~95668715:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000229180.5	GS1-124K5.11	-4.18	3.44e-05	0.00308	-0.13	-0.19	Aortic root size;	chr7:66682114	chr7:66526088~66542624:-
THCA	cis	rs901683	0.85	rs78990676	ENSG00000230869.1	CTGLF10P	-4.18	3.44e-05	0.00309	-0.45	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45606277	chr10:45678692~45700532:+
THCA	cis	rs901683	0.85	rs112114291	ENSG00000230869.1	CTGLF10P	-4.18	3.44e-05	0.00309	-0.45	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45606562	chr10:45678692~45700532:+
THCA	cis	rs7511006	0.859	rs7292228	ENSG00000272836.1	RP3-402G11.27	-4.18	3.44e-05	0.00309	-0.16	-0.19	Obesity-related traits;	chr22:50211131	chr22:50205585~50206062:-
THCA	cis	rs9510787	0.538	rs17079176	ENSG00000205861.10	C1QTNF9B-AS1	-4.18	3.44e-05	0.00309	-0.24	-0.19	Nasopharyngeal carcinoma;	chr13:23678846	chr13:23888889~23897263:+
THCA	cis	rs1387259	0.839	rs7487682	ENSG00000257735.1	RP11-370I10.6	-4.18	3.44e-05	0.00309	-0.21	-0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48350945~48442411:+
THCA	cis	rs7267979	1	rs2258719	ENSG00000274973.1	RP13-401N8.7	-4.18	3.44e-05	0.00309	-0.22	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25845497~25845862:+
THCA	cis	rs7088591	0.867	rs80061506	ENSG00000276818.1	AC026393.1	4.18	3.44e-05	0.00309	0.35	0.19	Blood pressure;	chr10:57948515	chr10:57095699~57095781:+
THCA	cis	rs2898290	0.622	rs7829381	ENSG00000254527.1	ENPP7P12	-4.18	3.44e-05	0.00309	-0.24	-0.19	Systolic blood pressure;	chr8:11487064	chr8:12205759~12206389:-
THCA	cis	rs2898290	0.622	rs11250140	ENSG00000254527.1	ENPP7P12	-4.18	3.44e-05	0.00309	-0.24	-0.19	Systolic blood pressure;	chr8:11489083	chr8:12205759~12206389:-
THCA	cis	rs17074492	0.671	rs56215060	ENSG00000214182.5	PTMAP5	4.18	3.44e-05	0.00309	0.24	0.19	Sjögren's syndrome;	chr13:81618594	chr13:81689911~81691072:+
THCA	cis	rs7520050	0.966	rs11589562	ENSG00000234329.1	RP11-767N6.2	4.18	3.44e-05	0.00309	0.17	0.19	Reticulocyte count;Red blood cell count;	chr1:46001049	chr1:45651039~45651826:-
THCA	cis	rs7712401	0.692	rs6881135	ENSG00000249996.1	RP11-359P5.1	-4.18	3.44e-05	0.00309	-0.18	-0.19	Mean platelet volume;	chr5:122744676	chr5:123036271~123054667:+
THCA	cis	rs13083990	0.919	rs10934578	ENSG00000272758.4	RP11-299J3.8	-4.18	3.45e-05	0.00309	-0.18	-0.19	Cardiac Troponin-T levels;	chr3:122258435	chr3:122416207~122443180:+
THCA	cis	rs875971	0.83	rs12673450	ENSG00000223473.2	GS1-124K5.3	4.18	3.45e-05	0.00309	0.13	0.19	Aortic root size;	chr7:66544233	chr7:66491049~66493566:-
THCA	cis	rs2436845	1	rs2513935	ENSG00000253669.3	KB-1732A1.1	-4.18	3.45e-05	0.00309	-0.19	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102832620	chr8:102805517~102809971:+
THCA	cis	rs15676	0.947	rs6478854	ENSG00000234771.3	SLC25A25-AS1	-4.18	3.45e-05	0.00309	-0.15	-0.19	Blood metabolite levels;	chr9:128826609	chr9:128108581~128118693:-
THCA	cis	rs7260598	0.539	rs76001745	ENSG00000268442.1	CTD-2027I19.2	4.18	3.45e-05	0.00309	0.29	0.19	Response to taxane treatment (placlitaxel);	chr19:23815590	chr19:24162370~24163425:-
THCA	cis	rs7260598	0.539	rs80157088	ENSG00000268442.1	CTD-2027I19.2	4.18	3.45e-05	0.00309	0.29	0.19	Response to taxane treatment (placlitaxel);	chr19:23816494	chr19:24162370~24163425:-
THCA	cis	rs11668609	0.63	rs61557819	ENSG00000268442.1	CTD-2027I19.2	4.18	3.45e-05	0.00309	0.29	0.19	Response to taxane treatment (docetaxel);	chr19:23816543	chr19:24162370~24163425:-
THCA	cis	rs17604090	0.715	rs73088359	ENSG00000223813.2	AC007255.8	4.18	3.45e-05	0.00309	0.17	0.19	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29608062	chr7:29514225~29563670:-
THCA	cis	rs4794202	0.523	rs11871969	ENSG00000264920.1	RP11-6N17.4	-4.18	3.45e-05	0.00309	-0.23	-0.19	Alzheimer's disease (cognitive decline);	chr17:47915256	chr17:47891255~47895812:-
THCA	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	4.18	3.45e-05	0.00309	0.17	0.19	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
THCA	cis	rs9923856	1	rs9923856	ENSG00000263033.2	RP11-396B14.2	-4.18	3.45e-05	0.00309	-0.16	-0.19	Atopic dermatitis;Adult asthma;	chr16:11116558	chr16:11196177~11224969:+
THCA	cis	rs6001482	0.702	rs7286018	ENSG00000272779.1	LL22NC03-80A10.6	-4.18	3.45e-05	0.00309	-0.21	-0.19	Diastolic blood pressure;	chr22:22236464	chr22:22303224~22310401:+
THCA	cis	rs7833787	0.501	rs13256850	ENSG00000278886.1	RP11-108A14.1	-4.18	3.45e-05	0.00309	-0.26	-0.19	Obesity-related traits;	chr8:18832527	chr8:18864681~18865247:-
THCA	cis	rs9341808	0.667	rs583426	ENSG00000272129.1	RP11-250B2.6	-4.18	3.45e-05	0.00309	-0.24	-0.19	Sitting height ratio;	chr6:80236970	chr6:80355424~80356859:+
THCA	cis	rs701145	0.585	rs62276841	ENSG00000243069.6	ARHGEF26-AS1	-4.18	3.45e-05	0.00309	-0.36	-0.19	Coronary artery disease;	chr3:154065856	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713846	ENSG00000243069.6	ARHGEF26-AS1	4.18	3.45e-05	0.00309	0.36	0.19	Coronary artery disease;	chr3:154069843	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727919	ENSG00000243069.6	ARHGEF26-AS1	4.18	3.45e-05	0.00309	0.36	0.19	Coronary artery disease;	chr3:154070968	chr3:154024401~154121332:-
THCA	cis	rs701145	0.537	rs1713847	ENSG00000243069.6	ARHGEF26-AS1	4.18	3.45e-05	0.00309	0.36	0.19	Coronary artery disease;	chr3:154073318	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.872	rs9840371	ENSG00000243069.6	ARHGEF26-AS1	4.18	3.45e-05	0.00309	0.36	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154079040	chr3:154024401~154121332:-
THCA	cis	rs3743266	0.593	rs4775276	ENSG00000240163.1	RP11-745A24.1	4.18	3.45e-05	0.00309	0.22	0.19	Menarche (age at onset);	chr15:60513986	chr15:60390371~60390682:+
THCA	cis	rs7614311	1	rs2087704	ENSG00000271843.1	RP11-245J9.5	4.18	3.45e-05	0.0031	0.27	0.19	Lung function (FVC);Lung function (FEV1);	chr3:63834817	chr3:64008082~64008692:-
THCA	cis	rs613391	0.561	rs1020466	ENSG00000234840.1	LINC01239	-4.18	3.45e-05	0.0031	-0.22	-0.19	Quantitative traits;	chr9:22720922	chr9:22646200~22824213:+
THCA	cis	rs7216064	1	rs11870068	ENSG00000265055.1	AC145343.2	4.18	3.45e-05	0.0031	0.27	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67948399	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs7223813	ENSG00000265055.1	AC145343.2	4.18	3.45e-05	0.0031	0.27	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67949724	chr17:68096046~68101474:-
THCA	cis	rs7216064	0.954	rs4790973	ENSG00000265055.1	AC145343.2	4.18	3.45e-05	0.0031	0.27	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67955017	chr17:68096046~68101474:-
THCA	cis	rs13182402	1	rs17154676	ENSG00000230929.5	RP11-395C3.1	-4.18	3.45e-05	0.0031	-0.38	-0.19	Osteoporosis;	chr5:126576428	chr5:126628019~126628319:-
THCA	cis	rs57221529	0.766	rs4527146	ENSG00000225138.6	CTD-2228K2.7	4.18	3.45e-05	0.0031	0.24	0.19	Lung disease severity in cystic fibrosis;	chr5:555121	chr5:473236~480884:+
THCA	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-4.18	3.45e-05	0.0031	-0.2	-0.19	Asthma;	chr2:102438096	chr2:102438713~102440475:+
THCA	cis	rs8113308	1	rs8105440	ENSG00000269483.1	AC006272.1	4.18	3.45e-05	0.0031	0.28	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948647	chr19:51839924~51843324:-
THCA	cis	rs7927592	0.913	rs12294029	ENSG00000160172.9	FAM86C2P	4.18	3.45e-05	0.0031	0.18	0.19	Total body bone mineral density;	chr11:68489591	chr11:67791648~67805336:-
THCA	cis	rs875971	0.619	rs2302918	ENSG00000223473.2	GS1-124K5.3	4.18	3.46e-05	0.0031	0.12	0.19	Aortic root size;	chr7:66535945	chr7:66491049~66493566:-
THCA	cis	rs8105895	0.935	rs7252547	ENSG00000269345.1	VN1R85P	4.18	3.46e-05	0.0031	0.26	0.19	Body mass index (change over time);	chr19:22122679	chr19:22174766~22175191:-
THCA	cis	rs3748656	0.945	rs2273368	ENSG00000273483.1	RP4-671G15.2	4.18	3.46e-05	0.0031	0.21	0.19	Hip circumference adjusted for BMI;	chr1:112521149	chr1:112517799~112518441:-
THCA	cis	rs1023500	0.551	rs2859438	ENSG00000237037.8	NDUFA6-AS1	-4.18	3.46e-05	0.0031	-0.16	-0.19	Schizophrenia;	chr22:42070976	chr22:42090931~42137742:+
THCA	cis	rs9902453	0.874	rs4474741	ENSG00000263370.1	RP11-68I3.5	-4.18	3.46e-05	0.0031	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29821099	chr17:29639627~29640825:+
THCA	cis	rs67478160	0.619	rs12885018	ENSG00000269940.1	RP11-73M18.7	4.18	3.46e-05	0.0031	0.18	0.19	Schizophrenia;	chr14:103807475	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs12891175	ENSG00000269940.1	RP11-73M18.7	4.18	3.46e-05	0.0031	0.18	0.19	Schizophrenia;	chr14:103807829	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.595	rs12889993	ENSG00000269940.1	RP11-73M18.7	4.18	3.46e-05	0.0031	0.18	0.19	Schizophrenia;	chr14:103807957	chr14:103694560~103695170:+
THCA	cis	rs8014252	1	rs2332382	ENSG00000259158.2	ADAM20P1	4.18	3.46e-05	0.0031	0.22	0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70437428	chr14:70468881~70483756:-
THCA	cis	rs9911578	0.835	rs1476596	ENSG00000224738.1	AC099850.1	4.18	3.46e-05	0.0031	0.22	0.19	Intelligence (multi-trait analysis);	chr17:58407997	chr17:59106598~59118267:+
THCA	cis	rs1232027	0.616	rs6151620	ENSG00000249655.1	CTC-325J23.2	4.18	3.46e-05	0.0031	0.21	0.19	Huntington's disease progression;	chr5:80665923	chr5:80630313~80631590:-
THCA	cis	rs801193	1	rs62466794	ENSG00000223473.2	GS1-124K5.3	4.18	3.46e-05	0.0031	0.12	0.19	Aortic root size;	chr7:66726592	chr7:66491049~66493566:-
THCA	cis	rs3758911	0.964	rs10749896	ENSG00000255353.1	RP11-382M14.1	-4.18	3.46e-05	0.0031	-0.24	-0.19	Coronary artery disease;	chr11:107314102	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.964	rs10789607	ENSG00000255353.1	RP11-382M14.1	-4.18	3.46e-05	0.0031	-0.24	-0.19	Coronary artery disease;	chr11:107314128	chr11:107176286~107177530:+
THCA	cis	rs11758351	1	rs80313145	ENSG00000216331.1	HIST1H1PS1	4.18	3.46e-05	0.0031	0.32	0.19	Renal underexcretion gout;Gout;	chr6:26194737	chr6:26195566~26195771:+
THCA	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	4.18	3.46e-05	0.0031	0.31	0.19	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
THCA	cis	rs8031584	0.958	rs7168641	ENSG00000270015.1	RP11-540B6.6	-4.18	3.46e-05	0.0031	-0.14	-0.19	Huntington's disease progression;	chr15:30943249	chr15:30926514~30928407:+
THCA	cis	rs1853665	0.58	rs4242283	ENSG00000231760.4	RP11-350J20.5	-4.18	3.46e-05	0.0031	-0.3	-0.19	Radiation response;	chr6:149952270	chr6:149796151~149826294:-
THCA	cis	rs11633886	0.585	rs2244179	ENSG00000273972.1	CTD-2306A12.1	4.18	3.46e-05	0.0031	0.21	0.19	Diisocyanate-induced asthma;	chr15:45797924	chr15:45702640~45703183:+
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000182586.6	LINC00334	-4.18	3.46e-05	0.0031	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45234340~45258730:+
THCA	cis	rs27434	0.605	rs1230366	ENSG00000272109.1	CTD-2260A17.3	-4.18	3.46e-05	0.0031	-0.31	-0.19	Ankylosing spondylitis;	chr5:96859577	chr5:96804353~96806105:+
THCA	cis	rs1560104	0.709	rs62027316	ENSG00000259876.1	CTD-3037G24.4	4.18	3.46e-05	0.0031	0.22	0.19	Obesity-related traits;	chr16:12609991	chr16:12556353~12557694:-
THCA	cis	rs4788570	0.615	rs4788550	ENSG00000260185.1	RP11-432I5.6	-4.18	3.46e-05	0.0031	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71686620	chr16:71655027~71664212:+
THCA	cis	rs3783637	0.5	rs72715546	ENSG00000258413.1	RP11-665C16.6	-4.18	3.46e-05	0.0031	-0.37	-0.19	Rheumatoid arthritis;Obesity-related traits;	chr14:54918780	chr14:55262767~55272075:-
THCA	cis	rs7658584	1	rs35228269	ENSG00000246375.2	RP11-10L7.1	4.18	3.46e-05	0.0031	0.33	0.19	Squamous cell lung carcinoma;	chr4:88172838	chr4:88284942~88331421:+
THCA	cis	rs10129255	0.789	rs61997796	ENSG00000280411.1	IGHV1-69-2	-4.18	3.46e-05	0.0031	-0.12	-0.19	Kawasaki disease;	chr14:106813798	chr14:106762092~106762588:-
THCA	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-4.18	3.46e-05	0.0031	-0.18	-0.19	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
THCA	cis	rs4742903	0.967	rs10125661	ENSG00000270332.1	SMC2-AS1	4.18	3.46e-05	0.0031	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104106162	chr9:104080024~104093073:-
THCA	cis	rs151234	0.741	rs151227	ENSG00000259982.1	CDC37P1	-4.18	3.46e-05	0.0031	-0.36	-0.19	Platelet distribution width;	chr16:28538187	chr16:28700294~28701540:-
THCA	cis	rs62244186	0.659	rs9311358	ENSG00000214820.3	MPRIPP1	4.18	3.46e-05	0.0031	0.2	0.19	Depressive symptoms;	chr3:44497256	chr3:44579938~44581026:-
THCA	cis	rs2281603	0.57	rs9323451	ENSG00000272909.1	CTD-2555O16.4	-4.18	3.46e-05	0.0031	-0.23	-0.19	Lymphocyte counts;	chr14:64505031	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.52	rs9323452	ENSG00000272909.1	CTD-2555O16.4	-4.18	3.46e-05	0.0031	-0.23	-0.19	Lymphocyte counts;	chr14:64505426	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs28469649	ENSG00000272909.1	CTD-2555O16.4	-4.18	3.46e-05	0.0031	-0.23	-0.19	Lymphocyte counts;	chr14:64505531	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.57	rs1453007	ENSG00000272909.1	CTD-2555O16.4	-4.18	3.46e-05	0.0031	-0.23	-0.19	Lymphocyte counts;	chr14:64507485	chr14:64440369~64442238:-
THCA	cis	rs7182948	0.793	rs17400916	ENSG00000259531.2	RP11-295H24.3	4.18	3.46e-05	0.0031	0.25	0.19	Lung adenocarcinoma;	chr15:49457107	chr15:49365124~49366685:-
THCA	cis	rs4906332	0.966	rs12894275	ENSG00000244691.1	RPL10AP1	4.18	3.47e-05	0.0031	0.24	0.19	Coronary artery disease;	chr14:103435087	chr14:103412119~103412761:-
THCA	cis	rs3733585	0.683	rs3796839	ENSG00000250413.1	RP11-448G15.1	-4.18	3.47e-05	0.0031	-0.18	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:10008293	chr4:10006482~10009725:+
THCA	cis	rs6715284	0.892	rs56828879	ENSG00000238829.1	RNU7-45P	-4.18	3.47e-05	0.00311	-0.46	-0.19	Rheumatoid arthritis;	chr2:201376600	chr2:201141904~201141966:+
THCA	cis	rs4908768	0.817	rs11587482	ENSG00000232912.4	RP5-1115A15.1	-4.18	3.47e-05	0.00311	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8683136	chr1:8424645~8434838:+
THCA	cis	rs1713985	0.508	rs1277283	ENSG00000269949.1	RP11-738E22.3	-4.18	3.47e-05	0.00311	-0.39	-0.19	Age-related macular degeneration;	chr4:56989475	chr4:56960927~56961373:-
THCA	cis	rs591584	0.73	rs11020840	ENSG00000255893.1	RP11-685N10.1	-4.18	3.47e-05	0.00311	-0.22	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94580348	chr11:94472908~94473570:-
THCA	cis	rs10484434	0.818	rs62394542	ENSG00000272810.1	U91328.22	4.18	3.47e-05	0.00311	0.19	0.19	HIV-1 viral setpoint;	chr6:25991007	chr6:26013241~26013757:+
THCA	cis	rs4947019	0.534	rs75527655	ENSG00000223537.2	RP5-919F19.5	-4.18	3.47e-05	0.00311	-0.35	-0.19	Hematological parameters;	chr6:109392693	chr6:109487906~109506800:+
THCA	cis	rs11992186	0.57	rs17628941	ENSG00000254153.1	CTA-398F10.2	4.18	3.47e-05	0.00311	0.22	0.19	Neuroticism;	chr8:8730024	chr8:8456909~8461337:-
THCA	cis	rs1336149	0.967	rs863717	ENSG00000211581.1	MIR765	4.18	3.47e-05	0.00311	0.24	0.19	Chin dimples;	chr1:157006601	chr1:156936131~156936244:-
THCA	cis	rs7924176	0.601	rs4638254	ENSG00000213731.2	RAB5CP1	-4.18	3.47e-05	0.00311	-0.23	-0.19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74423435~74424014:-
THCA	cis	rs6001482	0.573	rs4990163	ENSG00000272779.1	LL22NC03-80A10.6	-4.18	3.47e-05	0.00311	-0.21	-0.19	Diastolic blood pressure;	chr22:22233778	chr22:22303224~22310401:+
THCA	cis	rs9527	0.662	rs4919686	ENSG00000236937.2	PTGES3P4	4.18	3.47e-05	0.00311	0.27	0.19	Arsenic metabolism;	chr10:102832492	chr10:102845595~102845950:+
THCA	cis	rs13178541	0.745	rs10900833	ENSG00000250378.1	RP11-119J18.1	-4.18	3.47e-05	0.00311	-0.23	-0.19	IgG glycosylation;	chr5:135765741	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.81	rs10900834	ENSG00000250378.1	RP11-119J18.1	-4.18	3.47e-05	0.00311	-0.23	-0.19	IgG glycosylation;	chr5:135765792	chr5:135812667~135826582:+
THCA	cis	rs9902453	0.753	rs7226121	ENSG00000263370.1	RP11-68I3.5	4.18	3.47e-05	0.00311	0.25	0.19	Coffee consumption (cups per day);	chr17:29881107	chr17:29639627~29640825:+
THCA	cis	rs9834970	0.566	rs4327336	ENSG00000281100.1	RP11-640L9.2	-4.18	3.47e-05	0.00311	-0.21	-0.19	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36854779	chr3:36823151~36825158:-
THCA	cis	rs10256972	0.577	rs2949179	ENSG00000225146.1	AC073957.15	4.18	3.47e-05	0.00311	0.21	0.19	Endometriosis;Longevity;	chr7:1170249	chr7:1029025~1043891:+
THCA	cis	rs10256972	0.504	rs2949178	ENSG00000225146.1	AC073957.15	4.18	3.47e-05	0.00311	0.21	0.19	Endometriosis;Longevity;	chr7:1170289	chr7:1029025~1043891:+
THCA	cis	rs2948294	0.566	rs13274039	ENSG00000253981.4	ALG1L13P	4.18	3.47e-05	0.00311	0.18	0.19	Red cell distribution width;	chr8:8254137	chr8:8236003~8244667:-
THCA	cis	rs1560104	0.709	rs62027318	ENSG00000262801.4	U91319.1	4.18	3.47e-05	0.00311	0.22	0.19	Obesity-related traits;	chr16:12610040	chr16:13246316~13562918:+
THCA	cis	rs1048886	0.872	rs12529984	ENSG00000271967.1	RP11-134K13.4	-4.18	3.47e-05	0.00311	-0.22	-0.19	Type 2 diabetes;	chr6:70394764	chr6:70596438~70596980:+
THCA	cis	rs950169	0.65	rs12902052	ENSG00000188388.10	GOLGA6L3	4.18	3.47e-05	0.00311	0.26	0.19	Schizophrenia;	chr15:84582607	chr15:85240472~85247170:+
THCA	cis	rs453301	0.653	rs11784393	ENSG00000254340.1	RP11-10A14.3	4.18	3.47e-05	0.00311	0.2	0.19	Joint mobility (Beighton score);	chr8:9045624	chr8:9141424~9145435:+
THCA	cis	rs2070488	1	rs7433707	ENSG00000229589.1	ACVR2B-AS1	4.18	3.47e-05	0.00311	0.18	0.19	Electrocardiographic conduction measures;	chr3:38401689	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.932	rs4678604	ENSG00000229589.1	ACVR2B-AS1	4.18	3.47e-05	0.00311	0.18	0.19	Electrocardiographic conduction measures;	chr3:38402782	chr3:38451027~38454820:-
THCA	cis	rs6840360	0.573	rs7692939	ENSG00000251611.1	RP11-610P16.1	-4.18	3.47e-05	0.00311	-0.13	-0.19	Intelligence (multi-trait analysis);	chr4:151337303	chr4:151407551~151408835:-
THCA	cis	rs7403037	0.55	rs61995439	ENSG00000260760.1	PWRN3	4.18	3.47e-05	0.00311	0.27	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24479769	chr15:24441127~24447967:+
THCA	cis	rs2777491	0.957	rs16971798	ENSG00000247556.5	OIP5-AS1	-4.18	3.48e-05	0.00311	-0.16	-0.19	Ulcerative colitis;	chr15:41364946	chr15:41283990~41309737:+
THCA	cis	rs2018683	0.707	rs1021689	ENSG00000272568.4	CTB-113D17.1	4.18	3.48e-05	0.00311	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934606	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.707	rs1021690	ENSG00000272568.4	CTB-113D17.1	4.18	3.48e-05	0.00311	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934871	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.707	rs1021691	ENSG00000272568.4	CTB-113D17.1	4.18	3.48e-05	0.00311	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934879	chr7:28979967~29013367:+
THCA	cis	rs6570726	0.791	rs9403729	ENSG00000270638.1	RP3-466P17.1	4.18	3.48e-05	0.00311	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145735570~145737218:+
THCA	cis	rs4218	0.597	rs62002544	ENSG00000259732.1	RP11-59H7.3	-4.18	3.48e-05	0.00311	-0.27	-0.19	Social communication problems;	chr15:59066663	chr15:59121034~59133250:+
THCA	cis	rs4908768	0.906	rs56163601	ENSG00000232912.4	RP5-1115A15.1	-4.18	3.48e-05	0.00311	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8691838	chr1:8424645~8434838:+
THCA	cis	rs875971	0.8	rs427557	ENSG00000272831.1	RP11-792A8.4	4.18	3.48e-05	0.00311	0.12	0.19	Aortic root size;	chr7:66054263	chr7:66739829~66740385:-
THCA	cis	rs2455799	0.613	rs7617039	ENSG00000270409.1	RP11-44D5.1	4.18	3.48e-05	0.00311	0.2	0.19	Mean platelet volume;	chr3:15759233	chr3:15732252~15733470:+
THCA	cis	rs875971	1	rs6460296	ENSG00000229886.1	RP5-1132H15.3	4.18	3.48e-05	0.00311	0.2	0.19	Aortic root size;	chr7:66430152	chr7:66025126~66031544:-
THCA	cis	rs875971	0.895	rs4718349	ENSG00000229886.1	RP5-1132H15.3	4.18	3.48e-05	0.00311	0.2	0.19	Aortic root size;	chr7:66444024	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs2042133	ENSG00000229886.1	RP5-1132H15.3	4.18	3.48e-05	0.00311	0.2	0.19	Aortic root size;	chr7:66466935	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs2161065	ENSG00000229886.1	RP5-1132H15.3	4.18	3.48e-05	0.00311	0.2	0.19	Aortic root size;	chr7:66467918	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs12698521	ENSG00000229886.1	RP5-1132H15.3	4.18	3.48e-05	0.00311	0.2	0.19	Aortic root size;	chr7:66474502	chr7:66025126~66031544:-
THCA	cis	rs12410462	0.551	rs67511833	ENSG00000227711.2	RP11-275O4.5	-4.18	3.48e-05	0.00311	-0.23	-0.19	Major depressive disorder;	chr1:227650813	chr1:227509028~227520477:-
THCA	cis	rs448720	0.595	rs11856862	ENSG00000260657.2	RP11-315D16.4	4.18	3.48e-05	0.00311	0.26	0.19	Cognitive performance;	chr15:67898923	chr15:68267792~68277994:-
THCA	cis	rs448720	0.595	rs8032153	ENSG00000260657.2	RP11-315D16.4	4.18	3.48e-05	0.00311	0.26	0.19	Cognitive performance;	chr15:67902697	chr15:68267792~68277994:-
THCA	cis	rs55702914	0.809	rs2914982	ENSG00000231621.1	AC013264.2	4.18	3.48e-05	0.00311	0.18	0.19	Major depression and alcohol dependence;	chr2:197338069	chr2:197197991~197199273:+
THCA	cis	rs786425	0.77	rs71458814	ENSG00000270095.1	RP11-214K3.18	-4.18	3.48e-05	0.00311	-0.23	-0.19	Pubertal anthropometrics;	chr12:123712344	chr12:123971457~123971714:-
THCA	cis	rs9543976	0.614	rs55983304	ENSG00000261105.4	LMO7-AS1	-4.18	3.48e-05	0.00311	-0.34	-0.19	Diabetic retinopathy;	chr13:75511037	chr13:75604700~75635994:-
THCA	cis	rs7267979	0.565	rs6107059	ENSG00000274414.1	RP5-965G21.4	4.18	3.48e-05	0.00311	0.24	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:25239007~25245229:-
THCA	cis	rs6545883	0.783	rs7355640	ENSG00000271889.1	RP11-493E12.1	4.18	3.48e-05	0.00311	0.18	0.19	Tuberculosis;	chr2:61618350	chr2:61151433~61162105:-
THCA	cis	rs11638352	1	rs11638352	ENSG00000166763.7	STRCP1	-4.18	3.48e-05	0.00312	-0.42	-0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44000939	chr15:43699488~43718184:-
THCA	cis	rs2733201	1	rs12913809	ENSG00000166763.7	STRCP1	-4.18	3.48e-05	0.00312	-0.42	-0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44001013	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs4924731	ENSG00000166763.7	STRCP1	-4.18	3.48e-05	0.00312	-0.42	-0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44004526	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs6493093	ENSG00000166763.7	STRCP1	-4.18	3.48e-05	0.00312	-0.42	-0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44013297	chr15:43699488~43718184:-
THCA	cis	rs7772486	0.79	rs9497425	ENSG00000270638.1	RP3-466P17.1	-4.18	3.48e-05	0.00312	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs9497427	ENSG00000270638.1	RP3-466P17.1	-4.18	3.48e-05	0.00312	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145735570~145737218:+
THCA	cis	rs7617480	0.648	rs6801211	ENSG00000228638.1	FCF1P2	-4.18	3.48e-05	0.00312	-0.23	-0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48736987	chr3:48290793~48291375:-
THCA	cis	rs7560272	0.538	rs11126415	ENSG00000273245.1	RP11-434P11.2	-4.18	3.48e-05	0.00312	-0.22	-0.19	Schizophrenia;	chr2:73709373	chr2:73750256~73750786:-
THCA	cis	rs7560272	0.538	rs12053242	ENSG00000273245.1	RP11-434P11.2	-4.18	3.48e-05	0.00312	-0.22	-0.19	Schizophrenia;	chr2:73710041	chr2:73750256~73750786:-
THCA	cis	rs875971	1	rs4718357	ENSG00000229886.1	RP5-1132H15.3	4.18	3.48e-05	0.00312	0.2	0.19	Aortic root size;	chr7:66495891	chr7:66025126~66031544:-
THCA	cis	rs4771450	0.925	rs7333033	ENSG00000276957.1	RP11-29B2.6	4.18	3.48e-05	0.00312	0.15	0.19	Uric acid levels;	chr13:103325912	chr13:102593338~102593873:-
THCA	cis	rs2836974	0.932	rs6517523	ENSG00000255568.3	BRWD1-AS2	4.18	3.48e-05	0.00312	0.17	0.19	Cognitive function;	chr21:39185406	chr21:39313935~39314962:+
THCA	cis	rs801193	1	rs3778909	ENSG00000272831.1	RP11-792A8.4	4.18	3.48e-05	0.00312	0.12	0.19	Aortic root size;	chr7:66790659	chr7:66739829~66740385:-
THCA	cis	rs7267979	0.816	rs374701	ENSG00000277938.1	RP5-965G21.3	4.18	3.48e-05	0.00312	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25229150~25231933:+
THCA	cis	rs9393813	0.516	rs4711152	ENSG00000204789.4	ZNF204P	4.18	3.48e-05	0.00312	0.15	0.19	Bipolar disorder;	chr6:27412423	chr6:27357825~27360221:-
THCA	cis	rs9467773	0.967	rs1535276	ENSG00000228223.2	HCG11	-4.18	3.48e-05	0.00312	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26520713	chr6:26523450~26526579:+
THCA	cis	rs56313388	0.522	rs995948	ENSG00000246379.5	RP11-461O7.1	-4.18	3.48e-05	0.00312	-0.2	-0.19	Pulse pressure;	chr16:56132675	chr16:56092987~56191094:-
THCA	cis	rs7572733	0.515	rs6726506	ENSG00000231621.1	AC013264.2	-4.18	3.49e-05	0.00312	-0.2	-0.19	Dermatomyositis;	chr2:197981762	chr2:197197991~197199273:+
THCA	cis	rs2286503	0.78	rs2286506	ENSG00000226329.2	AC005682.6	4.18	3.49e-05	0.00312	0.24	0.19	Fibrinogen;	chr7:22815196	chr7:22863874~22881350:-
THCA	cis	rs2286503	0.752	rs2286504	ENSG00000226329.2	AC005682.6	4.18	3.49e-05	0.00312	0.24	0.19	Fibrinogen;	chr7:22815228	chr7:22863874~22881350:-
THCA	cis	rs4950322	0.58	rs972368	ENSG00000180867.10	PDIA3P1	4.18	3.49e-05	0.00312	0.19	0.19	Protein quantitative trait loci;	chr1:147111142	chr1:147178113~147179622:+
THCA	cis	rs67478160	0.643	rs34813623	ENSG00000269940.1	RP11-73M18.7	4.18	3.49e-05	0.00312	0.18	0.19	Schizophrenia;	chr14:103796957	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.608	rs34066659	ENSG00000269940.1	RP11-73M18.7	4.18	3.49e-05	0.00312	0.18	0.19	Schizophrenia;	chr14:103797090	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs7147171	ENSG00000269940.1	RP11-73M18.7	4.18	3.49e-05	0.00312	0.18	0.19	Schizophrenia;	chr14:103798520	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.619	rs11623546	ENSG00000269940.1	RP11-73M18.7	4.18	3.49e-05	0.00312	0.18	0.19	Schizophrenia;	chr14:103802761	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.619	rs55824307	ENSG00000269940.1	RP11-73M18.7	4.18	3.49e-05	0.00312	0.18	0.19	Schizophrenia;	chr14:103804870	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.595	rs12879501	ENSG00000269940.1	RP11-73M18.7	4.18	3.49e-05	0.00312	0.18	0.19	Schizophrenia;	chr14:103806297	chr14:103694560~103695170:+
THCA	cis	rs7243790	0.807	rs13380938	ENSG00000277324.1	RP11-850A17.1	-4.18	3.49e-05	0.00312	-0.19	-0.19	Diastolic blood pressure;	chr18:54369177	chr18:54268346~54270028:-
THCA	cis	rs7712401	0.658	rs4836203	ENSG00000249996.1	RP11-359P5.1	4.18	3.49e-05	0.00312	0.18	0.19	Mean platelet volume;	chr5:122741382	chr5:123036271~123054667:+
THCA	cis	rs9549367	0.577	rs3024718	ENSG00000269125.1	RP11-98F14.11	4.18	3.49e-05	0.00312	0.25	0.19	Platelet distribution width;	chr13:113159539	chr13:113165002~113165183:-
THCA	cis	rs7914558	0.902	rs3736922	ENSG00000236937.2	PTGES3P4	-4.18	3.49e-05	0.00312	-0.24	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102845595~102845950:+
THCA	cis	rs12134133	0.888	rs11580394	ENSG00000237074.1	RP11-6J21.2	4.18	3.49e-05	0.00312	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207249067~207309121:+
THCA	cis	rs8030605	0.704	rs72742667	ENSG00000277245.1	RP11-48G14.3	4.18	3.49e-05	0.00312	0.32	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56448627	chr15:56447120~56447697:+
THCA	cis	rs750460	0.816	rs4886778	ENSG00000261801.4	LOXL1-AS1	4.18	3.49e-05	0.00312	0.2	0.19	Height;	chr15:73933047	chr15:73908071~73928248:-
THCA	cis	rs750460	0.844	rs8027022	ENSG00000261801.4	LOXL1-AS1	4.18	3.49e-05	0.00312	0.2	0.19	Height;	chr15:73933797	chr15:73908071~73928248:-
THCA	cis	rs750460	0.844	rs2028386	ENSG00000261801.4	LOXL1-AS1	4.18	3.49e-05	0.00312	0.2	0.19	Height;	chr15:73934367	chr15:73908071~73928248:-
THCA	cis	rs750460	0.816	rs4337252	ENSG00000261801.4	LOXL1-AS1	4.18	3.49e-05	0.00312	0.2	0.19	Height;	chr15:73934424	chr15:73908071~73928248:-
THCA	cis	rs1560104	0.709	rs2217272	ENSG00000259876.1	CTD-3037G24.4	4.18	3.49e-05	0.00312	0.22	0.19	Obesity-related traits;	chr16:12610654	chr16:12556353~12557694:-
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000182586.6	LINC00334	-4.18	3.49e-05	0.00313	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45234340~45258730:+
THCA	cis	rs1023500	0.596	rs5751209	ENSG00000237037.8	NDUFA6-AS1	-4.18	3.49e-05	0.00313	-0.16	-0.19	Schizophrenia;	chr22:42055599	chr22:42090931~42137742:+
THCA	cis	rs10844706	0.699	rs11052752	ENSG00000214776.8	RP11-726G1.1	4.18	3.49e-05	0.00313	0.24	0.19	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735222	chr12:9467552~9576275:+
THCA	cis	rs6940638	0.688	rs9461335	ENSG00000219392.1	RP1-265C24.5	-4.18	3.49e-05	0.00313	-0.22	-0.19	Intelligence (multi-trait analysis);	chr6:27170750	chr6:28115628~28116551:+
THCA	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	4.18	3.49e-05	0.00313	0.22	0.19	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
THCA	cis	rs4915077	1	rs59093593	ENSG00000226822.1	RP11-356N1.2	4.18	3.49e-05	0.00313	0.37	0.19	Hypothyroidism;	chr1:107806835	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs17020085	ENSG00000226822.1	RP11-356N1.2	4.18	3.49e-05	0.00313	0.37	0.19	Hypothyroidism;	chr1:107809007	chr1:108071482~108074519:+
THCA	cis	rs340849	0.868	rs340851	ENSG00000274895.1	RP11-478J18.2	4.18	3.49e-05	0.00313	0.16	0.19	Alzheimer's disease;	chr1:213939379	chr1:213983793~213986419:-
THCA	cis	rs3892630	0.588	rs28787932	ENSG00000267475.1	CTD-2538C1.2	-4.18	3.49e-05	0.00313	-0.26	-0.19	Red blood cell traits;	chr19:32735323	chr19:32687089~32691750:-
THCA	cis	rs2919009	0.509	rs12255639	ENSG00000271670.1	RP11-95I16.4	4.18	3.49e-05	0.00313	0.21	0.19	Obesity-related traits;	chr10:120784075	chr10:120879256~120880667:-
THCA	cis	rs448720	1	rs379281	ENSG00000260657.2	RP11-315D16.4	-4.18	3.5e-05	0.00313	-0.24	-0.19	Cognitive performance;	chr15:67918362	chr15:68267792~68277994:-
THCA	cis	rs7577696	0.785	rs6723154	ENSG00000276334.1	AL133243.1	-4.18	3.5e-05	0.00313	-0.2	-0.19	Inflammatory biomarkers;	chr2:32140092	chr2:32521927~32523547:+
THCA	cis	rs6840360	0.573	rs4696080	ENSG00000251611.1	RP11-610P16.1	-4.18	3.5e-05	0.00313	-0.14	-0.19	Intelligence (multi-trait analysis);	chr4:151355313	chr4:151407551~151408835:-
THCA	cis	rs17801127	0.818	rs16827349	ENSG00000231969.1	AC144449.1	4.18	3.5e-05	0.00313	0.32	0.19	Liver enzyme levels (alanine transaminase);	chr2:149695891	chr2:149587196~149848233:+
THCA	cis	rs9863	0.828	rs11057408	ENSG00000270061.1	RP11-214K3.19	-4.18	3.5e-05	0.00313	-0.25	-0.19	White blood cell count;	chr12:123980289	chr12:123969990~123970344:-
THCA	cis	rs11971779	0.68	rs73154134	ENSG00000252332.1	RNU6-911P	-4.18	3.5e-05	0.00313	-0.23	-0.19	Diisocyanate-induced asthma;	chr7:139355205	chr7:139448740~139448843:+
THCA	cis	rs922182	0.547	rs6494458	ENSG00000275785.1	RP11-111E14.2	-4.18	3.5e-05	0.00313	-0.21	-0.19	Blood protein levels;	chr15:63978896	chr15:63890030~63890317:+
THCA	cis	rs4950322	0.515	rs11239954	ENSG00000180867.10	PDIA3P1	4.18	3.5e-05	0.00313	0.18	0.19	Protein quantitative trait loci;	chr1:147246045	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.515	rs76327075	ENSG00000180867.10	PDIA3P1	4.18	3.5e-05	0.00313	0.18	0.19	Protein quantitative trait loci;	chr1:147246319	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.515	rs11239958	ENSG00000180867.10	PDIA3P1	4.18	3.5e-05	0.00313	0.18	0.19	Protein quantitative trait loci;	chr1:147247454	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.515	rs12060046	ENSG00000180867.10	PDIA3P1	4.18	3.5e-05	0.00313	0.18	0.19	Protein quantitative trait loci;	chr1:147249278	chr1:147178113~147179622:+
THCA	cis	rs11158026	0.526	rs3783639	ENSG00000258413.1	RP11-665C16.6	-4.18	3.5e-05	0.00313	-0.31	-0.19	Parkinson's disease;	chr14:54881948	chr14:55262767~55272075:-
THCA	cis	rs2018683	0.707	rs4722877	ENSG00000272568.4	CTB-113D17.1	4.18	3.5e-05	0.00313	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933289	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.707	rs4722878	ENSG00000272568.4	CTB-113D17.1	4.18	3.5e-05	0.00313	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933414	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.677	rs2057956	ENSG00000272568.4	CTB-113D17.1	4.18	3.5e-05	0.00313	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933843	chr7:28979967~29013367:+
THCA	cis	rs9902453	0.791	rs7219163	ENSG00000263370.1	RP11-68I3.5	4.18	3.5e-05	0.00313	0.25	0.19	Coffee consumption (cups per day);	chr17:29883685	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs7221516	ENSG00000263370.1	RP11-68I3.5	4.18	3.5e-05	0.00313	0.25	0.19	Coffee consumption (cups per day);	chr17:29905488	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.791	rs9904051	ENSG00000263370.1	RP11-68I3.5	4.18	3.5e-05	0.00313	0.25	0.19	Coffee consumption (cups per day);	chr17:29917104	chr17:29639627~29640825:+
THCA	cis	rs2749592	0.531	rs994804	ENSG00000226578.1	RP11-258F22.1	4.18	3.5e-05	0.00313	0.22	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:37775371~37784131:-
THCA	cis	rs7849270	0.879	rs6478866	ENSG00000204055.4	RP11-247A12.2	-4.18	3.5e-05	0.00313	-0.23	-0.19	Blood metabolite ratios;	chr9:129133585	chr9:129176771~129210548:+
THCA	cis	rs1204798	0.541	rs11789	ENSG00000237021.2	RP3-486I3.7	-4.18	3.5e-05	0.00313	-0.23	-0.19	Dental caries;	chr6:116250954	chr6:116254207~116256743:+
THCA	cis	rs728616	0.614	rs61859196	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.5e-05	0.00313	-0.34	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80349292	chr10:79663088~79826594:-
THCA	cis	rs17685	0.784	rs1637043	ENSG00000230882.1	AC005077.14	4.18	3.5e-05	0.00313	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76069781	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs1639617	ENSG00000230882.1	AC005077.14	4.18	3.5e-05	0.00313	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76072410	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs11982200	ENSG00000230882.1	AC005077.14	4.18	3.5e-05	0.00313	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76085565	chr7:76071469~76074963:-
THCA	cis	rs17685	0.587	rs1623759	ENSG00000230882.1	AC005077.14	4.18	3.5e-05	0.00313	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76095361	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs1637049	ENSG00000230882.1	AC005077.14	4.18	3.5e-05	0.00313	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76100657	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs1637051	ENSG00000230882.1	AC005077.14	4.18	3.5e-05	0.00313	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76101341	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs4573217	ENSG00000230882.1	AC005077.14	4.18	3.5e-05	0.00313	0.19	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76104628	chr7:76071469~76074963:-
THCA	cis	rs113835537	0.866	rs59320108	ENSG00000255517.5	CTD-3074O7.5	-4.18	3.5e-05	0.00313	-0.21	-0.19	Airway imaging phenotypes;	chr11:66598525	chr11:66473490~66480233:-
THCA	cis	rs2797160	0.515	rs4897149	ENSG00000237742.5	RP11-624M8.1	4.18	3.5e-05	0.00313	0.17	0.19	Endometrial cancer;	chr6:125658872	chr6:125578558~125749190:-
THCA	cis	rs1232027	0.656	rs1677623	ENSG00000249655.1	CTC-325J23.2	4.18	3.5e-05	0.00313	0.21	0.19	Huntington's disease progression;	chr5:80663284	chr5:80630313~80631590:-
THCA	cis	rs17801127	0.748	rs67065535	ENSG00000231969.1	AC144449.1	4.18	3.5e-05	0.00313	0.38	0.19	Liver enzyme levels (alanine transaminase);	chr2:149819760	chr2:149587196~149848233:+
THCA	cis	rs7267979	0.816	rs6037158	ENSG00000274973.1	RP13-401N8.7	-4.18	3.5e-05	0.00313	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25845497~25845862:+
THCA	cis	rs9902453	0.845	rs2617875	ENSG00000263370.1	RP11-68I3.5	4.18	3.5e-05	0.00313	0.25	0.19	Coffee consumption (cups per day);	chr17:29763006	chr17:29639627~29640825:+
THCA	cis	rs6430538	0.582	rs1942053	ENSG00000224043.6	CCNT2-AS1	-4.18	3.5e-05	0.00313	-0.21	-0.19	Parkinson's disease;	chr2:134821635	chr2:134735464~134918710:-
THCA	cis	rs6430538	0.597	rs1942054	ENSG00000224043.6	CCNT2-AS1	-4.18	3.5e-05	0.00313	-0.21	-0.19	Parkinson's disease;	chr2:134821643	chr2:134735464~134918710:-
THCA	cis	rs150992	0.609	rs366000	ENSG00000246763.5	RGMB-AS1	-4.18	3.5e-05	0.00313	-0.2	-0.19	Body mass index;	chr5:98991705	chr5:98769618~98773469:-
THCA	cis	rs10871290	0.65	rs28484753	ENSG00000207525.1	Y_RNA	-4.18	3.5e-05	0.00313	-0.23	-0.19	Breast cancer;	chr16:74455497	chr16:74463888~74463988:-
THCA	cis	rs11633886	0.528	rs2460632	ENSG00000273972.1	CTD-2306A12.1	4.18	3.5e-05	0.00314	0.21	0.19	Diisocyanate-induced asthma;	chr15:45803763	chr15:45702640~45703183:+
THCA	cis	rs11089937	0.616	rs4991801	ENSG00000211639.2	IGLV4-60	4.18	3.51e-05	0.00314	0.13	0.19	Periodontitis (PAL4Q3);	chr22:22178958	chr22:22162199~22162681:+
THCA	cis	rs12478296	0.792	rs57482298	ENSG00000261186.2	RP11-341N2.1	-4.18	3.51e-05	0.00314	-0.31	-0.19	Obesity-related traits;	chr2:242068997	chr2:242087351~242088457:-
THCA	cis	rs2018683	0.707	rs2391718	ENSG00000272568.4	CTB-113D17.1	4.18	3.51e-05	0.00314	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935371	chr7:28979967~29013367:+
THCA	cis	rs10911902	0.643	rs75856021	ENSG00000233196.2	GS1-304P7.1	-4.18	3.51e-05	0.00314	-0.3	-0.19	Schizophrenia;	chr1:186405853	chr1:186580515~186581191:-
THCA	cis	rs854765	0.547	rs4365348	ENSG00000281749.1	Y_RNA	4.18	3.51e-05	0.00314	0.24	0.19	Total body bone mineral density;	chr17:18009234	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs7223696	ENSG00000281749.1	Y_RNA	4.18	3.51e-05	0.00314	0.24	0.19	Total body bone mineral density;	chr17:18012477	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs8069811	ENSG00000281749.1	Y_RNA	4.18	3.51e-05	0.00314	0.24	0.19	Total body bone mineral density;	chr17:18018966	chr17:18001101~18001195:-
THCA	cis	rs7647973	0.577	rs6446247	ENSG00000229759.1	MRPS18AP1	4.18	3.51e-05	0.00314	0.28	0.19	Menarche (age at onset);	chr3:49064568	chr3:48256350~48256938:-
THCA	cis	rs801193	0.935	rs2659899	ENSG00000223473.2	GS1-124K5.3	4.18	3.51e-05	0.00314	0.12	0.19	Aortic root size;	chr7:66721734	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs1553609	ENSG00000223473.2	GS1-124K5.3	4.18	3.51e-05	0.00314	0.12	0.19	Aortic root size;	chr7:66732152	chr7:66491049~66493566:-
THCA	cis	rs801193	0.967	rs2707853	ENSG00000223473.2	GS1-124K5.3	4.18	3.51e-05	0.00314	0.12	0.19	Aortic root size;	chr7:66749023	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs2659889	ENSG00000223473.2	GS1-124K5.3	4.18	3.51e-05	0.00314	0.12	0.19	Aortic root size;	chr7:66752125	chr7:66491049~66493566:-
THCA	cis	rs12134133	0.962	rs11120512	ENSG00000237074.1	RP11-6J21.2	-4.18	3.51e-05	0.00314	-0.2	-0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207249067~207309121:+
THCA	cis	rs7772486	0.79	rs2254288	ENSG00000270638.1	RP3-466P17.1	4.18	3.51e-05	0.00314	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145735570~145737218:+
THCA	cis	rs11671653	1	rs111957218	ENSG00000267100.1	ILF3-AS1	4.18	3.51e-05	0.00314	0.2	0.19	LDL cholesterol;	chr19:10728413	chr19:10651862~10653844:-
THCA	cis	rs7829975	0.688	rs7817376	ENSG00000233609.3	RP11-62H7.2	-4.18	3.51e-05	0.00314	-0.19	-0.19	Mood instability;	chr8:8523020	chr8:8961200~8979025:+
THCA	cis	rs4803480	0.872	rs2058149	ENSG00000270164.1	LINC01480	-4.18	3.51e-05	0.00314	-0.2	-0.19	Schizophrenia;	chr19:41580312	chr19:41535183~41536904:+
THCA	cis	rs9863	0.931	rs4575361	ENSG00000270061.1	RP11-214K3.19	-4.18	3.51e-05	0.00314	-0.26	-0.19	White blood cell count;	chr12:123925982	chr12:123969990~123970344:-
THCA	cis	rs8141529	0.509	rs5762853	ENSG00000272858.1	CTA-292E10.8	-4.18	3.51e-05	0.00314	-0.2	-0.19	Lymphocyte counts;	chr22:28849243	chr22:28814914~28815662:+
THCA	cis	rs6981523	0.517	rs13251510	ENSG00000206014.6	OR7E161P	4.18	3.51e-05	0.00314	0.22	0.19	Neuroticism;	chr8:11059464	chr8:11928597~11929563:-
THCA	cis	rs11185790	0.784	rs7916227	ENSG00000232936.4	RP11-80H5.2	4.18	3.51e-05	0.00314	0.23	0.19	Metabolic traits;	chr10:89571241	chr10:89645282~89650667:+
THCA	cis	rs1950832	0.627	rs118064958	ENSG00000258636.1	CTD-2298J14.2	-4.18	3.51e-05	0.00314	-0.25	-0.19	Urate levels in obese individuals;	chr14:41659634	chr14:41587861~41604856:-
THCA	cis	rs9863	0.861	rs77020228	ENSG00000269938.1	RP11-214K3.20	-4.18	3.51e-05	0.00314	-0.23	-0.19	White blood cell count;	chr12:123933925	chr12:123968023~123968579:-
THCA	cis	rs1669338	0.588	rs6788122	ENSG00000271870.1	RP11-97C16.1	4.18	3.51e-05	0.00314	0.17	0.19	White matter integrity;	chr3:3130213	chr3:3152942~3153435:+
THCA	cis	rs10043228	0.826	rs2136208	ENSG00000248445.4	SEMA6A-AS1	-4.18	3.51e-05	0.00314	-0.25	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116159222	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs10056936	ENSG00000248445.4	SEMA6A-AS1	-4.18	3.51e-05	0.00314	-0.25	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116160945	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs76796947	ENSG00000248445.4	SEMA6A-AS1	-4.18	3.51e-05	0.00314	-0.25	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116165343	chr5:116447547~116508276:+
THCA	cis	rs6929812	0.934	rs2064221	ENSG00000216915.2	RP1-97D16.1	4.18	3.51e-05	0.00314	0.25	0.19	Neuroticism (multi-trait analysis);	chr6:27420669	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.967	rs34185469	ENSG00000216915.2	RP1-97D16.1	4.18	3.51e-05	0.00314	0.25	0.19	Neuroticism (multi-trait analysis);	chr6:27424156	chr6:27737000~27738494:-
THCA	cis	rs1232027	0.622	rs857016	ENSG00000249655.1	CTC-325J23.2	4.18	3.51e-05	0.00314	0.22	0.19	Huntington's disease progression;	chr5:80680162	chr5:80630313~80631590:-
THCA	cis	rs2692947	0.537	rs72821435	ENSG00000235584.2	AC008268.1	-4.18	3.51e-05	0.00314	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95522187	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.537	rs12468117	ENSG00000235584.2	AC008268.1	-4.18	3.51e-05	0.00314	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95528835	chr2:95666084~95668715:+
THCA	cis	rs875971	1	rs12532998	ENSG00000229886.1	RP5-1132H15.3	4.18	3.51e-05	0.00314	0.2	0.19	Aortic root size;	chr7:66502472	chr7:66025126~66031544:-
THCA	cis	rs4218	0.681	rs17302163	ENSG00000259732.1	RP11-59H7.3	-4.18	3.51e-05	0.00314	-0.26	-0.19	Social communication problems;	chr15:59076773	chr15:59121034~59133250:+
THCA	cis	rs427943	0.864	rs2838806	ENSG00000223768.1	LINC00205	-4.18	3.51e-05	0.00314	-0.17	-0.19	Body mass index;	chr21:45198686	chr21:45293285~45297354:+
THCA	cis	rs8115854	0.961	rs11906083	ENSG00000269846.1	RP4-621N11.2	4.18	3.51e-05	0.00314	0.25	0.19	Hippocampal atrophy;	chr20:37121592	chr20:37095785~37097178:+
THCA	cis	rs3764021	0.527	rs11052604	ENSG00000214776.8	RP11-726G1.1	4.18	3.51e-05	0.00314	0.25	0.19	Type 1 diabetes;	chr12:9709952	chr12:9467552~9576275:+
THCA	cis	rs61270009	0.955	rs4916907	ENSG00000247828.6	TMEM161B-AS1	4.18	3.52e-05	0.00314	0.16	0.19	Depressive symptoms;	chr5:88364163	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs12657776	ENSG00000247828.6	TMEM161B-AS1	4.18	3.52e-05	0.00314	0.16	0.19	Depressive symptoms;	chr5:88365776	chr5:88268895~88436685:+
THCA	cis	rs10129255	0.872	rs1858683	ENSG00000211972.2	IGHV3-66	4.18	3.52e-05	0.00314	0.11	0.19	Kawasaki disease;	chr14:106670217	chr14:106675017~106675544:-
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000275400.1	RP4-756H11.5	-4.18	3.52e-05	0.00314	-0.18	-0.19	Calcium levels;	chr7:65996954	chr7:66553805~66554199:-
THCA	cis	rs4788570	0.615	rs11075894	ENSG00000260593.1	RP11-432I5.2	-4.18	3.52e-05	0.00314	-0.3	-0.19	Intelligence (multi-trait analysis);	chr16:71656127	chr16:71623708~71626816:-
THCA	cis	rs6012953	0.791	rs2143511	ENSG00000231715.1	COX6CP2	4.18	3.52e-05	0.00314	0.2	0.19	Vitiligo;	chr20:50528132	chr20:50479767~50479991:+
THCA	cis	rs2948294	0.524	rs13270062	ENSG00000254340.1	RP11-10A14.3	4.18	3.52e-05	0.00314	0.21	0.19	Red cell distribution width;	chr8:8255128	chr8:9141424~9145435:+
THCA	cis	rs8067354	0.872	rs2645488	ENSG00000266701.1	AC005702.4	4.18	3.52e-05	0.00314	0.26	0.19	Hemoglobin concentration;	chr17:59812044	chr17:60042546~60042627:-
THCA	cis	rs17074492	0.585	rs17074565	ENSG00000214182.5	PTMAP5	4.18	3.52e-05	0.00314	0.23	0.19	Sjögren's syndrome;	chr13:81668577	chr13:81689911~81691072:+
THCA	cis	rs10744391	0.62	rs11059972	ENSG00000274695.1	RP11-21K12.3	4.18	3.52e-05	0.00315	0.23	0.19	Renal sinus fat;	chr12:128850145	chr12:128826836~128827579:+
THCA	cis	rs7577696	0.708	rs610758	ENSG00000276334.1	AL133243.1	4.18	3.52e-05	0.00315	0.2	0.19	Inflammatory biomarkers;	chr2:31608492	chr2:32521927~32523547:+
THCA	cis	rs4273100	1	rs868698	ENSG00000263934.3	SNORD3A	4.18	3.52e-05	0.00315	0.29	0.19	Schizophrenia;	chr17:19281898	chr17:19188016~19188714:+
THCA	cis	rs194045	0.511	rs1611991	ENSG00000103472.8	RRN3P2	-4.18	3.52e-05	0.00315	-0.23	-0.19	Yu-Zhi constitution type in type 2 diabetes;	chr16:29140272	chr16:29074976~29116718:+
THCA	cis	rs4713118	0.513	rs149897	ENSG00000261839.1	RP1-265C24.8	4.18	3.52e-05	0.00315	0.2	0.19	Parkinson's disease;	chr6:28038872	chr6:28136849~28139678:+
THCA	cis	rs2562456	0.833	rs11666828	ENSG00000268117.1	VN1R84P	4.18	3.52e-05	0.00315	0.31	0.19	Pain;	chr19:21342218	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs11671609	ENSG00000268117.1	VN1R84P	4.18	3.52e-05	0.00315	0.31	0.19	Pain;	chr19:21342769	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs62109212	ENSG00000268117.1	VN1R84P	4.18	3.52e-05	0.00315	0.31	0.19	Pain;	chr19:21343716	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs57250002	ENSG00000268117.1	VN1R84P	4.18	3.52e-05	0.00315	0.31	0.19	Pain;	chr19:21344048	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62109218	ENSG00000268117.1	VN1R84P	4.18	3.52e-05	0.00315	0.31	0.19	Pain;	chr19:21346059	chr19:21719801~21720035:-
THCA	cis	rs56313388	0.505	rs1478465	ENSG00000246379.5	RP11-461O7.1	-4.18	3.52e-05	0.00315	-0.2	-0.19	Pulse pressure;	chr16:56260215	chr16:56092987~56191094:-
THCA	cis	rs7824557	0.564	rs13268126	ENSG00000154316.13	TDH	4.18	3.52e-05	0.00315	0.14	0.19	Retinal vascular caliber;	chr8:11373065	chr8:11339637~11368452:+
THCA	cis	rs62244186	0.659	rs9835270	ENSG00000214820.3	MPRIPP1	4.18	3.52e-05	0.00315	0.2	0.19	Depressive symptoms;	chr3:44512230	chr3:44579938~44581026:-
THCA	cis	rs12440869	1	rs2289788	ENSG00000270964.1	RP11-502I4.3	4.18	3.52e-05	0.00315	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67240036	chr15:67541072~67542604:-
THCA	cis	rs9341808	0.667	rs6938280	ENSG00000272129.1	RP11-250B2.6	4.18	3.52e-05	0.00315	0.24	0.19	Sitting height ratio;	chr6:80188065	chr6:80355424~80356859:+
THCA	cis	rs6878727	0.665	rs256853	ENSG00000253807.4	LINC01170	4.18	3.52e-05	0.00315	0.17	0.19	Breast cancer;	chr5:124326902	chr5:124059794~124405079:-
THCA	cis	rs17092148	0.79	rs6058079	ENSG00000276073.1	RP5-1125A11.7	-4.18	3.52e-05	0.00315	-0.23	-0.19	Neuroticism;	chr20:34555069	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.887	rs2144956	ENSG00000276073.1	RP5-1125A11.7	-4.18	3.52e-05	0.00315	-0.23	-0.19	Neuroticism;	chr20:34558064	chr20:33985617~33988989:-
THCA	cis	rs4767841	0.594	rs3847957	ENSG00000248636.5	RP11-768F21.1	-4.18	3.52e-05	0.00315	-0.2	-0.19	Urgency urinary incontinence;	chr12:119797066	chr12:119387987~119668079:-
THCA	cis	rs12753569	0.837	rs1251490	ENSG00000272855.1	RP5-1102E8.3	4.18	3.52e-05	0.00315	0.24	0.19	Personality dimensions;	chr1:76053008	chr1:76636877~76637339:+
THCA	cis	rs2153535	0.585	rs1983603	ENSG00000230939.1	RP11-314C16.1	-4.18	3.52e-05	0.00315	-0.2	-0.19	Motion sickness;	chr6:8580747	chr6:8784178~8785445:+
THCA	cis	rs8062405	0.72	rs9926245	ENSG00000261766.1	RP11-22P6.2	-4.18	3.52e-05	0.00315	-0.18	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28862166~28863340:-
THCA	cis	rs2886497	0.947	rs4641365	ENSG00000224215.1	RP11-371A19.2	-4.18	3.52e-05	0.00315	-0.24	-0.19	Major depression and alcohol dependence;	chr10:23377333	chr10:23343957~23345181:+
THCA	cis	rs10043228	0.826	rs12520838	ENSG00000248445.4	SEMA6A-AS1	-4.18	3.52e-05	0.00315	-0.25	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116161170	chr5:116447547~116508276:+
THCA	cis	rs6449502	0.541	rs13163684	ENSG00000251279.1	CTC-436P18.1	4.18	3.52e-05	0.00315	0.36	0.19	Mean platelet volume;	chr5:61148444	chr5:61162070~61232040:+
THCA	cis	rs17270561	0.636	rs7453371	ENSG00000272462.2	U91328.19	-4.18	3.52e-05	0.00315	-0.16	-0.19	Iron status biomarkers;	chr6:25719028	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs7450798	ENSG00000272462.2	U91328.19	-4.18	3.52e-05	0.00315	-0.16	-0.19	Iron status biomarkers;	chr6:25719052	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs4712957	ENSG00000272462.2	U91328.19	-4.18	3.52e-05	0.00315	-0.16	-0.19	Iron status biomarkers;	chr6:25719586	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.666	rs17320090	ENSG00000272462.2	U91328.19	-4.18	3.52e-05	0.00315	-0.16	-0.19	Iron status biomarkers;	chr6:25719987	chr6:25992662~26001775:+
THCA	cis	rs30380	0.573	rs469783	ENSG00000272109.1	CTD-2260A17.3	-4.18	3.52e-05	0.00315	-0.23	-0.19	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96804353~96806105:+
THCA	cis	rs17685	0.753	rs13240967	ENSG00000230882.1	AC005077.14	-4.18	3.52e-05	0.00315	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76028879	chr7:76071469~76074963:-
THCA	cis	rs67478160	0.643	rs8003653	ENSG00000269940.1	RP11-73M18.7	4.18	3.52e-05	0.00315	0.18	0.19	Schizophrenia;	chr14:103832499	chr14:103694560~103695170:+
THCA	cis	rs12612619	0.704	rs7602823	ENSG00000272148.1	RP11-195B17.1	-4.18	3.53e-05	0.00315	-0.18	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086538	chr2:27062428~27062907:-
THCA	cis	rs4934494	0.677	rs11185800	ENSG00000240996.1	RP11-80H5.7	-4.18	3.53e-05	0.00315	-0.22	-0.19	Red blood cell count;	chr10:89618323	chr10:89694295~89697928:-
THCA	cis	rs62344088	1	rs56315075	ENSG00000277812.1	AC021087.1	4.18	3.53e-05	0.00315	0.48	0.19	Asthma (childhood onset);	chr5:103789	chr5:262769~262881:+
THCA	cis	rs6671200	0.831	rs34100681	ENSG00000235501.4	RP4-639F20.1	-4.18	3.53e-05	0.00315	-0.39	-0.19	Stearic acid (18:0) levels;	chr1:95137500	chr1:94927566~94963270:+
THCA	cis	rs11773103	1	rs17161329	ENSG00000224046.1	AC005076.5	4.18	3.53e-05	0.00315	0.27	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87140790	chr7:87151423~87152420:-
THCA	cis	rs1204798	0.541	rs11153598	ENSG00000237021.2	RP3-486I3.7	-4.18	3.53e-05	0.00315	-0.25	-0.19	Dental caries;	chr6:116165629	chr6:116254207~116256743:+
THCA	cis	rs2692947	0.77	rs11689832	ENSG00000232931.4	LINC00342	4.18	3.53e-05	0.00315	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95889103	chr2:95807118~95816215:-
THCA	cis	rs758324	0.732	rs154724	ENSG00000224431.1	AC063976.7	-4.18	3.53e-05	0.00315	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132109967	chr5:132199456~132203487:+
THCA	cis	rs1414896	0.692	rs4949948	ENSG00000226026.4	RP11-57H12.3	4.18	3.53e-05	0.00315	0.18	0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95263504	chr1:95163219~95233982:-
THCA	cis	rs10129255	0.509	rs756583	ENSG00000211970.3	IGHV4-61	-4.18	3.53e-05	0.00315	-0.11	-0.19	Kawasaki disease;	chr14:106680002	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.536	rs3944157	ENSG00000211970.3	IGHV4-61	-4.18	3.53e-05	0.00315	-0.11	-0.19	Kawasaki disease;	chr14:106682286	chr14:106639119~106639657:-
THCA	cis	rs763121	0.889	rs1043402	ENSG00000235209.1	CTA-150C2.13	4.18	3.53e-05	0.00315	0.25	0.19	Menopause (age at onset);	chr22:38483683	chr22:38921227~38924708:+
THCA	cis	rs2617170	1	rs2617170	ENSG00000245648.1	RP11-277P12.20	-4.18	3.53e-05	0.00315	-0.19	-0.19	Behcet's disease;	chr12:10408358	chr12:10363769~10398506:+
THCA	cis	rs9341808	0.935	rs9343974	ENSG00000272129.1	RP11-250B2.6	4.18	3.53e-05	0.00316	0.24	0.19	Sitting height ratio;	chr6:80214928	chr6:80355424~80356859:+
THCA	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	4.18	3.53e-05	0.00316	0.22	0.19	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
THCA	cis	rs7829975	0.539	rs940031	ENSG00000254153.1	CTA-398F10.2	4.18	3.53e-05	0.00316	0.22	0.19	Mood instability;	chr8:8689338	chr8:8456909~8461337:-
THCA	cis	rs4722585	0.533	rs12334205	ENSG00000273237.1	CTB-119C2.1	-4.18	3.53e-05	0.00316	-0.18	-0.19	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26162870	chr7:26173533~26174945:-
THCA	cis	rs9863	0.828	rs1187415	ENSG00000269997.1	RP11-214K3.21	4.18	3.53e-05	0.00316	0.22	0.19	White blood cell count;	chr12:124006982	chr12:123966077~123966629:-
THCA	cis	rs2512987	0.723	rs2508304	ENSG00000254731.1	CTD-2005H7.1	-4.18	3.53e-05	0.00316	-0.23	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86704143	chr11:86703099~86714092:+
THCA	cis	rs10435719	0.867	rs62493601	ENSG00000206014.6	OR7E161P	-4.18	3.53e-05	0.00316	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:11928597~11929563:-
THCA	cis	rs11098499	0.82	rs11737395	ENSG00000249244.1	RP11-548H18.2	4.18	3.53e-05	0.00316	0.22	0.19	Corneal astigmatism;	chr4:119599549	chr4:119391831~119395335:-
THCA	cis	rs10129255	0.917	rs7142373	ENSG00000211972.2	IGHV3-66	4.18	3.53e-05	0.00316	0.12	0.19	Kawasaki disease;	chr14:106708947	chr14:106675017~106675544:-
THCA	cis	rs2018683	0.707	rs2057957	ENSG00000272568.4	CTB-113D17.1	-4.18	3.53e-05	0.00316	-0.18	-0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935009	chr7:28979967~29013367:+
THCA	cis	rs7511006	1	rs5771109	ENSG00000272836.1	RP3-402G11.27	-4.18	3.53e-05	0.00316	-0.16	-0.19	Obesity-related traits;	chr22:50240142	chr22:50205585~50206062:-
THCA	cis	rs494453	0.922	rs552802	ENSG00000227811.2	FAM212B-AS1	-4.18	3.53e-05	0.00316	-0.24	-0.19	Osteoporosis-related phenotypes;	chr1:111715923	chr1:111739841~111747798:+
THCA	cis	rs11176749	1	rs12231533	ENSG00000203585.3	RP11-542B15.1	4.18	3.53e-05	0.00316	0.22	0.19	Expressive vocabulary in infants;	chr12:67455502	chr12:67519829~67567126:+
THCA	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-4.18	3.54e-05	0.00316	-0.18	-0.19	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-4.18	3.54e-05	0.00316	-0.18	-0.19	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
THCA	cis	rs801193	1	rs2659909	ENSG00000229886.1	RP5-1132H15.3	4.18	3.54e-05	0.00316	0.19	0.19	Aortic root size;	chr7:66695292	chr7:66025126~66031544:-
THCA	cis	rs160451	0.782	rs2132348	ENSG00000251136.7	RP11-37B2.1	4.18	3.54e-05	0.00316	0.18	0.19	Leprosy;	chr8:89694545	chr8:89609409~89757727:-
THCA	cis	rs6088813	0.922	rs4911493	ENSG00000279253.1	RP4-614O4.13	4.18	3.54e-05	0.00316	0.19	0.19	Height;	chr20:35372996	chr20:35262727~35264187:-
THCA	cis	rs4321325	0.668	rs56346774	ENSG00000236682.1	AC068282.3	-4.18	3.54e-05	0.00316	-0.41	-0.19	Protein C levels;	chr2:127174975	chr2:127389130~127400580:+
THCA	cis	rs6121246	0.609	rs6088997	ENSG00000230613.1	HM13-AS1	-4.18	3.54e-05	0.00316	-0.18	-0.19	Mean corpuscular hemoglobin;	chr20:31702021	chr20:31567707~31573263:-
THCA	cis	rs1862618	0.853	rs6450409	ENSG00000234553.1	AC022431.3	-4.18	3.54e-05	0.00316	-0.22	-0.19	Initial pursuit acceleration;	chr5:56805572	chr5:56536583~56537826:-
THCA	cis	rs7336933	0.866	rs970983	ENSG00000278338.3	VWA8-AS1	4.18	3.54e-05	0.00316	0.31	0.19	Calcium levels;	chr13:41879824	chr13:41955808~41981565:+
THCA	cis	rs4713118	0.513	rs149941	ENSG00000261839.1	RP1-265C24.8	4.18	3.54e-05	0.00316	0.2	0.19	Parkinson's disease;	chr6:28033255	chr6:28136849~28139678:+
THCA	cis	rs2153535	0.585	rs9502734	ENSG00000230939.1	RP11-314C16.1	-4.18	3.54e-05	0.00316	-0.2	-0.19	Motion sickness;	chr6:8631618	chr6:8784178~8785445:+
THCA	cis	rs75059851	0.756	rs7106715	ENSG00000280237.1	MIR4697HG	-4.18	3.54e-05	0.00316	-0.21	-0.19	Schizophrenia;	chr11:133969010	chr11:133896438~133901601:-
THCA	cis	rs911555	0.755	rs11627446	ENSG00000269910.1	RP11-73M18.10	4.18	3.54e-05	0.00316	0.17	0.19	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103694516~103695050:-
THCA	cis	rs1552244	0.572	rs3894322	ENSG00000180385.7	EMC3-AS1	4.18	3.54e-05	0.00316	0.24	0.19	Alzheimer's disease;	chr3:10127281	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs3894323	ENSG00000180385.7	EMC3-AS1	4.18	3.54e-05	0.00316	0.24	0.19	Alzheimer's disease;	chr3:10127283	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs67439440	ENSG00000180385.7	EMC3-AS1	4.18	3.54e-05	0.00316	0.24	0.19	Alzheimer's disease;	chr3:10127819	chr3:9986893~10006990:+
THCA	cis	rs7296418	0.961	rs4148862	ENSG00000256092.2	RP13-942N8.1	4.18	3.54e-05	0.00316	0.14	0.19	Platelet count;	chr12:123084072	chr12:123363868~123366113:+
THCA	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-4.18	3.54e-05	0.00316	-0.24	-0.19	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
THCA	cis	rs13113518	0.934	rs11133397	ENSG00000272969.1	RP11-528I4.2	4.18	3.54e-05	0.00316	0.22	0.19	Height;	chr4:55534166	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.934	rs11133398	ENSG00000272969.1	RP11-528I4.2	4.18	3.54e-05	0.00316	0.22	0.19	Height;	chr4:55534180	chr4:55547112~55547889:+
THCA	cis	rs3892630	0.588	rs12610342	ENSG00000267475.1	CTD-2538C1.2	-4.18	3.54e-05	0.00316	-0.26	-0.19	Red blood cell traits;	chr19:32759784	chr19:32687089~32691750:-
THCA	cis	rs57221529	0.563	rs4957057	ENSG00000225138.6	CTD-2228K2.7	4.18	3.54e-05	0.00316	0.22	0.19	Lung disease severity in cystic fibrosis;	chr5:569115	chr5:473236~480884:+
THCA	cis	rs6600671	1	rs1856572	ENSG00000270231.3	NBPF8P	4.18	3.54e-05	0.00316	0.17	0.19	Hip geometry;	chr1:121427719	chr1:120436353~120467739:+
THCA	cis	rs12915845	0.529	rs7175106	ENSG00000271997.1	RP11-97O12.6	-4.18	3.54e-05	0.00317	-0.13	-0.19	Menarche (age at onset);	chr15:88545493	chr15:88501944~88505787:-
THCA	cis	rs733175	0.904	rs3775944	ENSG00000261490.1	RP11-448G15.3	4.18	3.54e-05	0.00317	0.15	0.19	Psychosis and Alzheimer's disease;	chr4:10018350	chr4:10068089~10073019:-
THCA	cis	rs4742903	1	rs10820603	ENSG00000270332.1	SMC2-AS1	4.18	3.54e-05	0.00317	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104115658	chr9:104080024~104093073:-
THCA	cis	rs7578199	0.576	rs740313	ENSG00000223374.1	AC005104.3	-4.18	3.54e-05	0.00317	-0.13	-0.19	Chronic lymphocytic leukemia;	chr2:241479393	chr2:241351340~241353104:-
THCA	cis	rs964611	0.938	rs12592155	ENSG00000259488.2	RP11-154J22.1	-4.18	3.54e-05	0.00317	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48331303	chr15:48312353~48331856:-
THCA	cis	rs962856	0.619	rs4671795	ENSG00000236780.4	AC078941.1	4.18	3.54e-05	0.00317	0.26	0.19	Pancreatic cancer;	chr2:67339936	chr2:67123357~67215319:-
THCA	cis	rs7219021	0.674	rs11656939	ENSG00000248278.1	SUMO2P17	-4.18	3.55e-05	0.00317	-0.25	-0.19	Schizophrenia or bipolar disorder;	chr17:48887044	chr17:48874860~48908983:-
THCA	cis	rs4144027	1	rs4144027	ENSG00000269910.1	RP11-73M18.10	4.18	3.55e-05	0.00317	0.17	0.19	Blood metabolite levels;	chr14:103891301	chr14:103694516~103695050:-
THCA	cis	rs79243044	0.695	rs317778	ENSG00000224295.2	AC087380.14	4.18	3.55e-05	0.00317	0.19	0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5518855	chr11:5518441~5524955:-
THCA	cis	rs11671653	1	rs7256743	ENSG00000267100.1	ILF3-AS1	4.18	3.55e-05	0.00317	0.22	0.19	LDL cholesterol;	chr19:10722455	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs7257661	ENSG00000267100.1	ILF3-AS1	4.18	3.55e-05	0.00317	0.22	0.19	LDL cholesterol;	chr19:10722456	chr19:10651862~10653844:-
THCA	cis	rs343092	1	rs2583939	ENSG00000241749.4	RPSAP52	4.18	3.55e-05	0.00317	0.22	0.19	Type 2 diabetes;	chr12:65819741	chr12:65758020~65826997:-
THCA	cis	rs2334880	0.713	rs4788828	ENSG00000260593.1	RP11-432I5.2	-4.18	3.55e-05	0.00317	-0.3	-0.19	Malaria;	chr16:71690187	chr16:71623708~71626816:-
THCA	cis	rs481331	0.866	rs6593349	ENSG00000215146.4	RP11-313J2.1	4.18	3.55e-05	0.00317	0.3	0.19	Systemic juvenile idiopathic arthritis;	chr10:42489844	chr10:42331866~42367974:-
THCA	cis	rs8141529	0.509	rs7287124	ENSG00000226471.5	CTA-292E10.6	-4.18	3.55e-05	0.00317	-0.16	-0.19	Lymphocyte counts;	chr22:28843169	chr22:28800683~28848559:+
THCA	cis	rs6657613	0.621	rs11578903	ENSG00000186301.8	MST1P2	4.18	3.55e-05	0.00317	0.16	0.19	Hip circumference adjusted for BMI;	chr1:17051461	chr1:16645622~16650289:+
THCA	cis	rs340849	0.967	rs340868	ENSG00000274895.1	RP11-478J18.2	4.18	3.55e-05	0.00317	0.16	0.19	Alzheimer's disease;	chr1:213955877	chr1:213983793~213986419:-
THCA	cis	rs2904524	0.541	rs1603221	ENSG00000257815.4	RP11-611E13.2	-4.18	3.55e-05	0.00317	-0.15	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70379617	chr12:69904033~70243360:-
THCA	cis	rs1555322	0.872	rs2425048	ENSG00000279253.1	RP4-614O4.13	-4.18	3.55e-05	0.00317	-0.29	-0.19	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35262727~35264187:-
THCA	cis	rs1559040	0.932	rs72800772	ENSG00000272156.1	RP11-477N3.1	-4.18	3.55e-05	0.00317	-0.31	-0.19	Sudden cardiac arrest;	chr2:54145466	chr2:54082554~54085066:+
THCA	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	4.18	3.55e-05	0.00317	0.24	0.19	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
THCA	cis	rs4660214	0.666	rs2256614	ENSG00000228060.1	RP11-69E11.8	-4.18	3.55e-05	0.00317	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39359046	chr1:39565160~39573203:+
THCA	cis	rs728616	0.51	rs12768957	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.55e-05	0.00317	-0.32	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80427537	chr10:79663088~79826594:-
THCA	cis	rs10760158	0.832	rs10818519	ENSG00000226752.6	PSMD5-AS1	-4.17	3.55e-05	0.00317	-0.23	-0.19	Pulse pressure;	chr9:121250657	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs4837825	ENSG00000226752.6	PSMD5-AS1	-4.17	3.55e-05	0.00317	-0.23	-0.19	Pulse pressure;	chr9:121253136	chr9:120824828~120854385:+
THCA	cis	rs11758351	1	rs16891401	ENSG00000216331.1	HIST1H1PS1	4.17	3.55e-05	0.00317	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26202109	chr6:26195566~26195771:+
THCA	cis	rs6756513	0.506	rs7575111	ENSG00000231024.1	AC092431.3	-4.17	3.55e-05	0.00317	-0.32	-0.19	Breast cancer;Platelet count;	chr2:69844397	chr2:69700192~69713847:-
THCA	cis	rs7674212	0.556	rs34475639	ENSG00000248971.2	KRT8P46	-4.17	3.55e-05	0.00317	-0.24	-0.19	Type 2 diabetes;	chr4:103033694	chr4:102728746~102730171:-
THCA	cis	rs1232027	0.656	rs1677690	ENSG00000249655.1	CTC-325J23.2	4.17	3.55e-05	0.00317	0.21	0.19	Huntington's disease progression;	chr5:80661280	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1650683	ENSG00000249655.1	CTC-325J23.2	4.17	3.55e-05	0.00317	0.21	0.19	Huntington's disease progression;	chr5:80661328	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677698	ENSG00000249655.1	CTC-325J23.2	4.17	3.55e-05	0.00317	0.21	0.19	Huntington's disease progression;	chr5:80661664	chr5:80630313~80631590:-
THCA	cis	rs758324	0.687	rs159905	ENSG00000224431.1	AC063976.7	-4.17	3.55e-05	0.00317	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132166810	chr5:132199456~132203487:+
THCA	cis	rs72928364	0.929	rs62275826	ENSG00000256628.3	ZBTB11-AS1	4.17	3.55e-05	0.00318	0.34	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101043800	chr3:101676475~101679217:+
THCA	cis	rs4780355	0.619	rs918737	ENSG00000263080.1	RP11-485G7.5	-4.17	3.55e-05	0.00318	-0.23	-0.19	Crohn's disease and psoriasis;	chr16:11345782	chr16:11341809~11345211:-
THCA	cis	rs9311474	0.597	rs13303	ENSG00000243224.1	RP5-1157M23.2	-4.17	3.55e-05	0.00318	-0.2	-0.19	Electroencephalogram traits;	chr3:52523992	chr3:52239258~52241097:+
THCA	cis	rs1048886	0.872	rs12529284	ENSG00000271967.1	RP11-134K13.4	-4.17	3.55e-05	0.00318	-0.21	-0.19	Type 2 diabetes;	chr6:70553813	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs16869371	ENSG00000271967.1	RP11-134K13.4	-4.17	3.55e-05	0.00318	-0.21	-0.19	Type 2 diabetes;	chr6:70559756	chr6:70596438~70596980:+
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000182586.6	LINC00334	-4.17	3.56e-05	0.00318	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000182586.6	LINC00334	-4.17	3.56e-05	0.00318	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000182586.6	LINC00334	-4.17	3.56e-05	0.00318	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000182586.6	LINC00334	-4.17	3.56e-05	0.00318	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45234340~45258730:+
THCA	cis	rs10186029	0.509	rs10194726	ENSG00000270659.1	RP11-105N14.1	4.17	3.56e-05	0.00318	0.16	0.19	Systemic sclerosis;	chr2:213072152	chr2:213152970~213153659:+
THCA	cis	rs7829975	0.806	rs2428	ENSG00000233609.3	RP11-62H7.2	4.17	3.56e-05	0.00318	0.18	0.19	Mood instability;	chr8:8783635	chr8:8961200~8979025:+
THCA	cis	rs17767294	0.612	rs9461424	ENSG00000261839.1	RP1-265C24.8	4.17	3.56e-05	0.00318	0.3	0.19	Parkinson's disease;	chr6:27951623	chr6:28136849~28139678:+
THCA	cis	rs8067545	0.559	rs3874846	ENSG00000270091.1	RP11-78O7.2	-4.17	3.56e-05	0.00318	-0.14	-0.19	Schizophrenia;	chr17:20394232	chr17:19896590~19897287:-
THCA	cis	rs7824557	0.564	rs13260727	ENSG00000206014.6	OR7E161P	-4.17	3.56e-05	0.00318	-0.22	-0.19	Retinal vascular caliber;	chr8:11375351	chr8:11928597~11929563:-
THCA	cis	rs5769765	0.542	rs5769751	ENSG00000260613.1	RP3-522J7.6	4.17	3.56e-05	0.00318	0.36	0.19	Schizophrenia;	chr22:49849085	chr22:49832616~49837786:-
THCA	cis	rs11098499	0.863	rs3822192	ENSG00000249244.1	RP11-548H18.2	4.17	3.56e-05	0.00318	0.22	0.19	Corneal astigmatism;	chr4:119524565	chr4:119391831~119395335:-
THCA	cis	rs793571	0.544	rs12912699	ENSG00000245975.2	RP11-30K9.6	4.17	3.56e-05	0.00318	0.18	0.19	Schizophrenia;	chr15:58624822	chr15:58768072~58770974:-
THCA	cis	rs700651	0.856	rs9288280	ENSG00000231621.1	AC013264.2	-4.17	3.56e-05	0.00318	-0.2	-0.19	Intracranial aneurysm;	chr2:197879600	chr2:197197991~197199273:+
THCA	cis	rs7267979	0.816	rs390123	ENSG00000274973.1	RP13-401N8.7	-4.17	3.56e-05	0.00318	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.816	rs404775	ENSG00000274973.1	RP13-401N8.7	-4.17	3.56e-05	0.00318	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25845497~25845862:+
THCA	cis	rs9926296	0.632	rs7184315	ENSG00000260259.1	RP11-368I7.4	4.17	3.56e-05	0.00318	0.21	0.19	Vitiligo;	chr16:89732965	chr16:89682620~89686569:-
THCA	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	4.17	3.56e-05	0.00318	0.22	0.19	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
THCA	cis	rs10833905	0.941	rs11026897	ENSG00000246225.5	RP11-17A1.3	-4.17	3.56e-05	0.00318	-0.27	-0.19	Sudden cardiac arrest;	chr11:23005501	chr11:22829380~22945393:+
THCA	cis	rs2380220	0.938	rs6923253	ENSG00000261366.1	MANEA-AS1	-4.17	3.56e-05	0.00318	-0.21	-0.19	Behavioural disinhibition (generation interaction);	chr6:95522265	chr6:95575183~95577450:-
THCA	cis	rs12681288	0.823	rs2701907	ENSG00000260721.1	AF067845.1	4.17	3.56e-05	0.00318	0.22	0.19	Schizophrenia;	chr8:1053292	chr8:1368642~1369833:-
THCA	cis	rs75920871	0.764	rs4938326	ENSG00000254851.1	RP11-109L13.1	-4.17	3.56e-05	0.00318	-0.39	-0.19	Subjective well-being;	chr11:117034748	chr11:117135528~117138582:+
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000182586.6	LINC00334	-4.17	3.56e-05	0.00318	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45234340~45258730:+
THCA	cis	rs7833787	0.718	rs2632853	ENSG00000278886.1	RP11-108A14.1	4.17	3.56e-05	0.00318	0.24	0.19	Obesity-related traits;	chr8:18821794	chr8:18864681~18865247:-
THCA	cis	rs6570726	0.791	rs6913727	ENSG00000270638.1	RP3-466P17.1	4.17	3.56e-05	0.00318	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145735570~145737218:+
THCA	cis	rs2135507	0.802	rs2135505	ENSG00000270480.1	RP11-57B24.1	4.17	3.56e-05	0.00318	0.26	0.19	Juvenile osteochondritis dissecans;	chr4:82664849	chr4:82691737~82692468:+
THCA	cis	rs7537765	0.947	rs17367504	ENSG00000242349.4	NPPA-AS1	-4.17	3.56e-05	0.00318	-0.26	-0.19	QRS complex (12-leadsum);	chr1:11802721	chr1:11841017~11848079:+
THCA	cis	rs868036	0.645	rs4492996	ENSG00000270964.1	RP11-502I4.3	-4.17	3.57e-05	0.00318	-0.17	-0.19	Restless legs syndrome;	chr15:67820902	chr15:67541072~67542604:-
THCA	cis	rs6546886	0.711	rs6712566	ENSG00000257800.1	FNBP1P1	-4.17	3.57e-05	0.00318	-0.2	-0.19	Dialysis-related mortality;	chr2:74018194	chr2:74120680~74123218:+
THCA	cis	rs9847710	1	rs13088455	ENSG00000242142.1	SERBP1P3	-4.17	3.57e-05	0.00318	-0.22	-0.19	Ulcerative colitis;	chr3:53053466	chr3:53064283~53065091:-
THCA	cis	rs2692947	0.537	rs11677429	ENSG00000235584.2	AC008268.1	-4.17	3.57e-05	0.00318	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95527313	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.508	rs2216793	ENSG00000235584.2	AC008268.1	-4.17	3.57e-05	0.00318	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95530574	chr2:95666084~95668715:+
THCA	cis	rs7824557	0.527	rs2572449	ENSG00000154316.13	TDH	-4.17	3.57e-05	0.00318	-0.14	-0.19	Retinal vascular caliber;	chr8:11381628	chr8:11339637~11368452:+
THCA	cis	rs7402982	0.625	rs4966008	ENSG00000278022.1	RP11-35O15.2	4.17	3.57e-05	0.00318	0.2	0.19	Birth weight;	chr15:98660216	chr15:98660210~98660668:+
THCA	cis	rs7809950	0.678	rs7788330	ENSG00000272072.1	CTA-363E19.2	4.17	3.57e-05	0.00319	0.21	0.19	Coronary artery disease;	chr7:107345203	chr7:107192559~107193300:-
THCA	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	4.17	3.57e-05	0.00319	0.2	0.19	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
THCA	cis	rs2676071	0.858	rs2670946	ENSG00000259721.1	RP11-758N13.1	-4.17	3.57e-05	0.00319	-0.22	-0.19	Periodontitis (Mean PAL);	chr15:33306691	chr15:32717270~32719007:-
THCA	cis	rs7829975	0.714	rs60315134	ENSG00000253981.4	ALG1L13P	4.17	3.57e-05	0.00319	0.18	0.19	Mood instability;	chr8:8813089	chr8:8236003~8244667:-
THCA	cis	rs4824093	0.61	rs73441745	ENSG00000278869.1	CITF22-49E9.3	4.17	3.57e-05	0.00319	0.36	0.19	Amyotrophic lateral sclerosis (sporadic);	chr22:49843958	chr22:49933198~49934074:-
THCA	cis	rs1336149	0.967	rs822579	ENSG00000211581.1	MIR765	4.17	3.57e-05	0.00319	0.24	0.19	Chin dimples;	chr1:157005230	chr1:156936131~156936244:-
THCA	cis	rs877529	0.627	rs139426	ENSG00000279833.1	RP4-742C19.13	-4.17	3.57e-05	0.00319	-0.13	-0.19	Multiple myeloma;	chr22:39164661	chr22:39133090~39136760:+
THCA	cis	rs773506	0.692	rs10991835	ENSG00000235641.4	LINC00484	4.17	3.57e-05	0.00319	0.24	0.19	Type 2 diabetes nephropathy;	chr9:91233309	chr9:91159573~91165658:+
THCA	cis	rs2120243	0.539	rs12486427	ENSG00000241770.1	RP11-555M1.3	-4.17	3.57e-05	0.00319	-0.25	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157395487	chr3:157163452~157169133:+
THCA	cis	rs7267979	0.903	rs6115101	ENSG00000274973.1	RP13-401N8.7	-4.17	3.57e-05	0.00319	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.868	rs6107019	ENSG00000274973.1	RP13-401N8.7	-4.17	3.57e-05	0.00319	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25845497~25845862:+
THCA	cis	rs7520050	0.807	rs72688483	ENSG00000280836.1	AL355480.1	-4.17	3.57e-05	0.00319	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45581219~45581321:-
THCA	cis	rs9876781	0.559	rs7610524	ENSG00000244380.1	RP11-24C3.2	4.17	3.57e-05	0.00319	0.23	0.19	Longevity;	chr3:48353882	chr3:48440352~48446656:-
THCA	cis	rs7551222	0.613	rs10900592	ENSG00000240219.1	RP11-430C7.5	4.17	3.57e-05	0.00319	0.19	0.19	Schizophrenia;	chr1:204491553	chr1:204626775~204629712:+
THCA	cis	rs2235642	1	rs2076438	ENSG00000260989.1	LA16c-395F10.2	-4.17	3.57e-05	0.00319	-0.19	-0.19	Coronary artery disease;	chr16:1534617	chr16:1580527~1610328:+
THCA	cis	rs6479891	0.818	rs9415700	ENSG00000272767.1	JMJD1C-AS1	4.17	3.57e-05	0.00319	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs9415701	ENSG00000272767.1	JMJD1C-AS1	4.17	3.57e-05	0.00319	0.27	0.19	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63465229~63466563:+
THCA	cis	rs12142240	0.698	rs17361805	ENSG00000232022.5	FAAHP1	-4.17	3.57e-05	0.00319	-0.21	-0.19	Menopause (age at onset);	chr1:46348295	chr1:46432129~46445521:+
THCA	cis	rs6005807	0.764	rs9620764	ENSG00000226471.5	CTA-292E10.6	-4.17	3.57e-05	0.00319	-0.25	-0.19	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28045483	chr22:28800683~28848559:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000232559.3	GS1-124K5.12	4.17	3.57e-05	0.00319	0.2	0.19	Aortic root size;	chr7:66622723	chr7:66554588~66576923:-
THCA	cis	rs7200543	1	rs16966947	ENSG00000188599.16	NPIPP1	-4.17	3.57e-05	0.00319	-0.15	-0.19	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:15104312~15123498:-
THCA	cis	rs13118159	0.509	rs9683830	ENSG00000254094.1	AC078852.1	-4.17	3.57e-05	0.00319	-0.23	-0.19	Longevity;	chr4:1384085	chr4:1356581~1358075:+
THCA	cis	rs2251188	0.544	rs2464873	ENSG00000187953.9	PMS2CL	-4.17	3.58e-05	0.00319	-0.2	-0.19	Sum basophil neutrophil counts;Neutrophil count;	chr7:6648120	chr7:6710128~6753862:+
THCA	cis	rs801193	0.591	rs2707839	ENSG00000229886.1	RP5-1132H15.3	4.17	3.58e-05	0.00319	0.2	0.19	Aortic root size;	chr7:66728097	chr7:66025126~66031544:-
THCA	cis	rs6088590	1	rs6088615	ENSG00000276073.1	RP5-1125A11.7	4.17	3.58e-05	0.00319	0.17	0.19	Coronary artery disease;	chr20:34812671	chr20:33985617~33988989:-
THCA	cis	rs7968440	0.801	rs7960015	ENSG00000272368.2	RP4-605O3.4	4.17	3.58e-05	0.00319	0.12	0.19	Fibrinogen;	chr12:50751411	chr12:50112197~50165618:+
THCA	cis	rs853679	1	rs6905391	ENSG00000273712.1	RP5-874C20.7	4.17	3.58e-05	0.00319	0.29	0.19	Depression;	chr6:28294909	chr6:28315613~28315883:-
THCA	cis	rs3764021	0.743	rs7973535	ENSG00000256594.6	RP11-705C15.2	4.17	3.58e-05	0.00319	0.15	0.19	Type 1 diabetes;	chr12:9727801	chr12:9633419~9658412:+
THCA	cis	rs3764021	0.87	rs7973638	ENSG00000256594.6	RP11-705C15.2	4.17	3.58e-05	0.00319	0.15	0.19	Type 1 diabetes;	chr12:9727845	chr12:9633419~9658412:+
THCA	cis	rs6442522	0.733	rs4143273	ENSG00000249786.6	EAF1-AS1	-4.17	3.58e-05	0.00319	-0.2	-0.19	Uric acid levels;	chr3:15460301	chr3:15436171~15455940:-
THCA	cis	rs2836974	0.836	rs8129355	ENSG00000255568.3	BRWD1-AS2	4.17	3.58e-05	0.0032	0.17	0.19	Cognitive function;	chr21:39207943	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.899	rs34978594	ENSG00000255568.3	BRWD1-AS2	4.17	3.58e-05	0.0032	0.17	0.19	Cognitive function;	chr21:39208077	chr21:39313935~39314962:+
THCA	cis	rs944289	0.616	rs408783	ENSG00000258844.1	RP11-259K15.2	-4.17	3.58e-05	0.0032	-0.17	-0.19	Thyroid cancer;	chr14:36065667	chr14:36214607~36235608:+
THCA	cis	rs2898290	0.622	rs17799486	ENSG00000227888.4	FAM66A	-4.17	3.58e-05	0.0032	-0.24	-0.19	Systolic blood pressure;	chr8:11482985	chr8:12362019~12388296:+
THCA	cis	rs733175	0.857	rs7666545	ENSG00000261490.1	RP11-448G15.3	4.17	3.58e-05	0.0032	0.15	0.19	Psychosis and Alzheimer's disease;	chr4:10010748	chr4:10068089~10073019:-
THCA	cis	rs7829975	0.577	rs79495969	ENSG00000254153.1	CTA-398F10.2	4.17	3.58e-05	0.0032	0.22	0.19	Mood instability;	chr8:8687740	chr8:8456909~8461337:-
THCA	cis	rs9393777	0.778	rs13219354	ENSG00000280107.1	AL022393.9	-4.17	3.58e-05	0.0032	-0.32	-0.19	Intelligence (multi-trait analysis);	chr6:27217885	chr6:28170845~28172521:+
THCA	cis	rs9393777	0.778	rs67457459	ENSG00000280107.1	AL022393.9	-4.17	3.58e-05	0.0032	-0.32	-0.19	Intelligence (multi-trait analysis);	chr6:27230564	chr6:28170845~28172521:+
THCA	cis	rs1836229	0.839	rs10758996	ENSG00000225706.1	PTPRD-AS1	-4.17	3.58e-05	0.0032	-0.23	-0.19	Restless legs syndrome;	chr9:8827077	chr9:8858130~8862255:+
THCA	cis	rs4934494	0.539	rs11185777	ENSG00000232936.4	RP11-80H5.2	4.17	3.59e-05	0.0032	0.23	0.19	Red blood cell count;	chr10:89594453	chr10:89645282~89650667:+
THCA	cis	rs2434529	0.955	rs73279671	ENSG00000245275.6	SAP30L-AS1	4.17	3.59e-05	0.0032	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154277178	chr5:154329437~154445850:-
THCA	cis	rs7246657	0.551	rs11084873	ENSG00000226686.6	LINC01535	-4.17	3.59e-05	0.0032	-0.32	-0.19	Coronary artery calcification;	chr19:37093008	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.551	rs12978093	ENSG00000226686.6	LINC01535	-4.17	3.59e-05	0.0032	-0.32	-0.19	Coronary artery calcification;	chr19:37093514	chr19:37251912~37265535:+
THCA	cis	rs9911578	0.835	rs9904993	ENSG00000224738.1	AC099850.1	-4.17	3.59e-05	0.0032	-0.22	-0.19	Intelligence (multi-trait analysis);	chr17:58391208	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.867	rs4793941	ENSG00000224738.1	AC099850.1	-4.17	3.59e-05	0.0032	-0.22	-0.19	Intelligence (multi-trait analysis);	chr17:58395005	chr17:59106598~59118267:+
THCA	cis	rs6012564	0.929	rs4810898	ENSG00000230758.1	SNAP23P	-4.17	3.59e-05	0.0032	-0.23	-0.19	Anger;	chr20:48937855	chr20:49038357~49038602:-
THCA	cis	rs9902453	0.765	rs8079209	ENSG00000263370.1	RP11-68I3.5	4.17	3.59e-05	0.0032	0.25	0.19	Coffee consumption (cups per day);	chr17:29859755	chr17:29639627~29640825:+
THCA	cis	rs2439831	0.867	rs6493082	ENSG00000205771.5	CATSPER2P1	-4.17	3.59e-05	0.0032	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43342610	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs8041132	ENSG00000205771.5	CATSPER2P1	-4.17	3.59e-05	0.0032	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43342938	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs16957627	ENSG00000205771.5	CATSPER2P1	-4.17	3.59e-05	0.0032	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43350459	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.717	rs7165471	ENSG00000205771.5	CATSPER2P1	-4.17	3.59e-05	0.0032	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43352590	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.867	rs4075674	ENSG00000205771.5	CATSPER2P1	-4.17	3.59e-05	0.0032	-0.25	-0.19	Lung cancer in ever smokers;	chr15:43358032	chr15:43726918~43747094:-
THCA	cis	rs875971	0.66	rs801193	ENSG00000272831.1	RP11-792A8.4	-4.17	3.59e-05	0.0032	-0.12	-0.19	Aortic root size;	chr7:66565625	chr7:66739829~66740385:-
THCA	cis	rs17685	0.697	rs28689051	ENSG00000230882.1	AC005077.14	4.17	3.59e-05	0.0032	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76134306	chr7:76071469~76074963:-
THCA	cis	rs62158800	0.638	rs1155112	ENSG00000225588.2	AC096669.1	4.17	3.59e-05	0.0032	0.2	0.19	Facial morphology (factor 22);	chr2:107684908	chr2:107362282~107407329:+
THCA	cis	rs17801127	0.818	rs35993252	ENSG00000231969.1	AC144449.1	4.17	3.59e-05	0.0032	0.42	0.19	Liver enzyme levels (alanine transaminase);	chr2:149763303	chr2:149587196~149848233:+
THCA	cis	rs711244	0.756	rs2003585	ENSG00000279519.1	RP11-288C18.1	-4.17	3.59e-05	0.0032	-0.16	-0.19	Mean platelet volume;	chr2:36896240	chr2:36839922~36842539:-
THCA	cis	rs17270561	0.636	rs9393656	ENSG00000272462.2	U91328.19	-4.17	3.59e-05	0.0032	-0.16	-0.19	Iron status biomarkers;	chr6:25721831	chr6:25992662~26001775:+
THCA	cis	rs875971	1	rs6945843	ENSG00000229886.1	RP5-1132H15.3	-4.17	3.59e-05	0.0032	-0.2	-0.19	Aortic root size;	chr7:66269796	chr7:66025126~66031544:-
THCA	cis	rs2039553	0.671	rs2329122	ENSG00000227354.5	RBM26-AS1	4.17	3.59e-05	0.0032	0.18	0.19	Pancreatic cancer;	chr13:79733043	chr13:79406309~79424328:+
THCA	cis	rs13256369	1	rs873063	ENSG00000254153.1	CTA-398F10.2	-4.17	3.59e-05	0.0032	-0.21	-0.19	Obesity-related traits;	chr8:8714937	chr8:8456909~8461337:-
THCA	cis	rs7819412	0.744	rs4841503	ENSG00000206014.6	OR7E161P	4.17	3.59e-05	0.0032	0.22	0.19	Triglycerides;	chr8:11166817	chr8:11928597~11929563:-
THCA	cis	rs1232027	0.622	rs1346463	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80671833	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1677652	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80672135	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677654	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80672511	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs836810	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80676393	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs836809	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80676941	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs836808	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80678751	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs836806	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80679164	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs861372	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80680503	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs844368	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80680563	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs836804	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80680627	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs2618369	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80682639	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677709	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80684910	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650749	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80685725	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1650747	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80685774	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs1620258	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80686189	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs1677630	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80687289	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs836802	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80687981	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.622	rs836800	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80689510	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs836799	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80689949	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs836798	ENSG00000249655.1	CTC-325J23.2	4.17	3.59e-05	0.0032	0.22	0.19	Huntington's disease progression;	chr5:80690088	chr5:80630313~80631590:-
THCA	cis	rs9926296	0.533	rs9938865	ENSG00000274627.1	RP11-104N10.2	-4.17	3.59e-05	0.0032	-0.19	-0.19	Vitiligo;	chr16:89801389	chr16:89516797~89522217:+
THCA	cis	rs4906332	1	rs17617307	ENSG00000244691.1	RPL10AP1	-4.17	3.59e-05	0.00321	-0.24	-0.19	Coronary artery disease;	chr14:103438628	chr14:103412119~103412761:-
THCA	cis	rs4742903	1	rs7854630	ENSG00000270332.1	SMC2-AS1	-4.17	3.59e-05	0.00321	-0.18	-0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104112996	chr9:104080024~104093073:-
THCA	cis	rs8030605	0.704	rs116636952	ENSG00000277245.1	RP11-48G14.3	4.17	3.59e-05	0.00321	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56310866	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.704	rs72740560	ENSG00000277245.1	RP11-48G14.3	4.17	3.59e-05	0.00321	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56321705	chr15:56447120~56447697:+
THCA	cis	rs4950322	0.748	rs56392137	ENSG00000180867.10	PDIA3P1	4.17	3.59e-05	0.00321	0.19	0.19	Protein quantitative trait loci;	chr1:147352450	chr1:147178113~147179622:+
THCA	cis	rs34421088	0.56	rs2248325	ENSG00000255046.1	RP11-297N6.4	4.17	3.59e-05	0.00321	0.2	0.19	Neuroticism;	chr8:11539365	chr8:11797928~11802568:-
THCA	cis	rs34421088	0.56	rs2248316	ENSG00000255046.1	RP11-297N6.4	4.17	3.59e-05	0.00321	0.2	0.19	Neuroticism;	chr8:11539564	chr8:11797928~11802568:-
THCA	cis	rs34421088	0.56	rs2248315	ENSG00000255046.1	RP11-297N6.4	4.17	3.59e-05	0.00321	0.2	0.19	Neuroticism;	chr8:11539577	chr8:11797928~11802568:-
THCA	cis	rs7267979	0.844	rs869358	ENSG00000274973.1	RP13-401N8.7	4.17	3.59e-05	0.00321	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25845497~25845862:+
THCA	cis	rs10484434	0.901	rs2230654	ENSG00000272810.1	U91328.22	-4.17	3.59e-05	0.00321	-0.18	-0.19	HIV-1 viral setpoint;	chr6:26033413	chr6:26013241~26013757:+
THCA	cis	rs10484434	0.818	rs11759668	ENSG00000272810.1	U91328.22	4.17	3.59e-05	0.00321	0.18	0.19	HIV-1 viral setpoint;	chr6:26014261	chr6:26013241~26013757:+
THCA	cis	rs2286503	0.809	rs4719716	ENSG00000226329.2	AC005682.6	4.17	3.59e-05	0.00321	0.23	0.19	Fibrinogen;	chr7:22821750	chr7:22863874~22881350:-
THCA	cis	rs2286503	0.78	rs981792	ENSG00000226329.2	AC005682.6	4.17	3.59e-05	0.00321	0.23	0.19	Fibrinogen;	chr7:22822020	chr7:22863874~22881350:-
THCA	cis	rs2286503	0.839	rs2270108	ENSG00000226329.2	AC005682.6	4.17	3.59e-05	0.00321	0.23	0.19	Fibrinogen;	chr7:22822512	chr7:22863874~22881350:-
THCA	cis	rs2286503	0.839	rs2270107	ENSG00000226329.2	AC005682.6	4.17	3.59e-05	0.00321	0.23	0.19	Fibrinogen;	chr7:22822564	chr7:22863874~22881350:-
THCA	cis	rs2286503	0.839	rs2270105	ENSG00000226329.2	AC005682.6	4.17	3.59e-05	0.00321	0.23	0.19	Fibrinogen;	chr7:22822848	chr7:22863874~22881350:-
THCA	cis	rs934734	0.532	rs6546151	ENSG00000214533.3	KRT18P33	-4.17	3.59e-05	0.00321	-0.23	-0.19	Rheumatoid arthritis;	chr2:65449449	chr2:65666695~65667737:+
THCA	cis	rs420259	0.516	rs432477	ENSG00000260136.4	CTD-2270L9.4	4.17	3.59e-05	0.00321	0.15	0.19	Bipolar disorder;	chr16:23589252	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs460477	ENSG00000260136.4	CTD-2270L9.4	4.17	3.59e-05	0.00321	0.15	0.19	Bipolar disorder;	chr16:23589916	chr16:23452758~23457606:+
THCA	cis	rs4908760	0.613	rs12028160	ENSG00000232912.4	RP5-1115A15.1	-4.17	3.6e-05	0.00321	-0.18	-0.19	Vitiligo;	chr1:8752155	chr1:8424645~8434838:+
THCA	cis	rs6477918	0.598	rs9650733	ENSG00000230185.4	C9orf147	4.17	3.6e-05	0.00321	0.2	0.19	Obstetric antiphospholipid syndrome;	chr9:112439722	chr9:112433816~112487204:-
THCA	cis	rs9595908	0.709	rs9591311	ENSG00000212293.1	SNORA16	4.17	3.6e-05	0.00321	0.22	0.19	Body mass index;	chr13:32757339	chr13:32420390~32420516:-
THCA	cis	rs7267979	0.844	rs4815413	ENSG00000274973.1	RP13-401N8.7	4.17	3.6e-05	0.00321	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.844	rs6083824	ENSG00000274973.1	RP13-401N8.7	4.17	3.6e-05	0.00321	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.844	rs6076343	ENSG00000274973.1	RP13-401N8.7	4.17	3.6e-05	0.00321	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25845497~25845862:+
THCA	cis	rs5758659	0.652	rs133340	ENSG00000273366.1	CTA-989H11.1	4.17	3.6e-05	0.00321	0.23	0.19	Cognitive function;	chr22:42021683	chr22:42278188~42278846:+
THCA	cis	rs2408955	0.501	rs8716	ENSG00000273765.1	RP11-370I10.11	4.17	3.6e-05	0.00321	0.19	0.19	Glycated hemoglobin levels;	chr12:48145699	chr12:48360920~48361377:+
THCA	cis	rs7088591	0.867	rs16911397	ENSG00000276818.1	AC026393.1	4.17	3.6e-05	0.00321	0.4	0.19	Blood pressure;	chr10:57967870	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs58666115	ENSG00000276818.1	AC026393.1	4.17	3.6e-05	0.00321	0.4	0.19	Blood pressure;	chr10:57976045	chr10:57095699~57095781:+
THCA	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	4.17	3.6e-05	0.00321	0.16	0.19	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
THCA	cis	rs73193808	0.639	rs9976274	ENSG00000176054.6	RPL23P2	4.17	3.6e-05	0.00321	0.17	0.19	Coronary artery disease;	chr21:29181615	chr21:28997613~28998033:-
THCA	cis	rs453301	0.682	rs2929451	ENSG00000248538.5	RP11-10A14.5	-4.17	3.6e-05	0.00321	-0.23	-0.19	Joint mobility (Beighton score);	chr8:9227785	chr8:9189011~9202854:+
THCA	cis	rs8067545	1	rs1860302	ENSG00000270091.1	RP11-78O7.2	-4.17	3.6e-05	0.00321	-0.14	-0.19	Schizophrenia;	chr17:20011086	chr17:19896590~19897287:-
THCA	cis	rs8067545	1	rs7211535	ENSG00000270091.1	RP11-78O7.2	-4.17	3.6e-05	0.00321	-0.14	-0.19	Schizophrenia;	chr17:20019051	chr17:19896590~19897287:-
THCA	cis	rs8067545	1	rs2108979	ENSG00000270091.1	RP11-78O7.2	-4.17	3.6e-05	0.00321	-0.14	-0.19	Schizophrenia;	chr17:20025253	chr17:19896590~19897287:-
THCA	cis	rs67478160	0.644	rs7159810	ENSG00000269940.1	RP11-73M18.7	4.17	3.6e-05	0.00321	0.18	0.19	Schizophrenia;	chr14:103827780	chr14:103694560~103695170:+
THCA	cis	rs6696239	0.824	rs7551788	ENSG00000227711.2	RP11-275O4.5	-4.17	3.6e-05	0.00321	-0.26	-0.19	Height;	chr1:227545400	chr1:227509028~227520477:-
THCA	cis	rs4950322	1	rs1806618	ENSG00000226015.2	CCT8P1	4.17	3.6e-05	0.00321	0.23	0.19	Protein quantitative trait loci;	chr1:147377075	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.895	rs17356735	ENSG00000226015.2	CCT8P1	4.17	3.6e-05	0.00321	0.23	0.19	Protein quantitative trait loci;	chr1:147378328	chr1:147203276~147204932:-
THCA	cis	rs1048886	0.938	rs55968813	ENSG00000271967.1	RP11-134K13.4	-4.17	3.6e-05	0.00321	-0.2	-0.19	Type 2 diabetes;	chr6:70514521	chr6:70596438~70596980:+
THCA	cis	rs6754311	0.517	rs1469995	ENSG00000231890.6	DARS-AS1	-4.17	3.6e-05	0.00321	-0.22	-0.19	Mosquito bite size;	chr2:135784989	chr2:135985176~136022593:+
THCA	cis	rs801193	1	rs4717310	ENSG00000223473.2	GS1-124K5.3	4.17	3.6e-05	0.00321	0.12	0.19	Aortic root size;	chr7:66696020	chr7:66491049~66493566:-
THCA	cis	rs733592	0.524	rs10875741	ENSG00000258273.1	RP11-370I10.4	4.17	3.6e-05	0.00321	0.23	0.19	Plateletcrit;	chr12:48099139	chr12:48333755~48333901:-
THCA	cis	rs733592	0.524	rs10875744	ENSG00000258273.1	RP11-370I10.4	-4.17	3.6e-05	0.00321	-0.23	-0.19	Plateletcrit;	chr12:48104657	chr12:48333755~48333901:-
THCA	cis	rs10761482	0.861	rs719095	ENSG00000254271.1	RP11-131N11.4	4.17	3.6e-05	0.00321	0.25	0.19	Schizophrenia;	chr10:60351191	chr10:60734342~60741828:+
THCA	cis	rs61784830	0.71	rs61783251	ENSG00000280836.1	AL355480.1	-4.17	3.6e-05	0.00321	-0.37	-0.19	Iron status biomarkers (total iron binding capacity);	chr1:45902415	chr1:45581219~45581321:-
THCA	cis	rs9309473	0.519	rs1083922	ENSG00000273245.1	RP11-434P11.2	-4.17	3.6e-05	0.00321	-0.23	-0.19	Metabolite levels;	chr2:73476876	chr2:73750256~73750786:-
THCA	cis	rs4218	0.648	rs17236453	ENSG00000259732.1	RP11-59H7.3	-4.17	3.6e-05	0.00321	-0.27	-0.19	Social communication problems;	chr15:59092156	chr15:59121034~59133250:+
THCA	cis	rs7959452	0.535	rs4761228	ENSG00000274979.1	RP11-1143G9.5	-4.17	3.6e-05	0.00321	-0.2	-0.19	Blood protein levels;	chr12:69288547	chr12:69326574~69331882:-
THCA	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	4.17	3.6e-05	0.00321	0.22	0.19	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	4.17	3.6e-05	0.00321	0.22	0.19	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
THCA	cis	rs10875746	0.951	rs4760689	ENSG00000258234.1	RP11-370I10.2	4.17	3.6e-05	0.00321	0.23	0.19	Longevity (90 years and older);	chr12:48169861	chr12:48231098~48284210:-
THCA	cis	rs964611	0.745	rs74011991	ENSG00000259488.2	RP11-154J22.1	-4.17	3.6e-05	0.00321	-0.21	-0.19	Metabolite levels (Pyroglutamine);	chr15:48256154	chr15:48312353~48331856:-
THCA	cis	rs7829975	0.711	rs1039916	ENSG00000253981.4	ALG1L13P	4.17	3.6e-05	0.00321	0.18	0.19	Mood instability;	chr8:8828344	chr8:8236003~8244667:-
THCA	cis	rs972578	1	rs738379	ENSG00000230319.1	AL022476.2	-4.17	3.6e-05	0.00321	-0.2	-0.19	Mean platelet volume;	chr22:43004758	chr22:43038585~43052366:+
THCA	cis	rs9549367	0.711	rs9994	ENSG00000269125.1	RP11-98F14.11	-4.17	3.6e-05	0.00321	-0.22	-0.19	Platelet distribution width;	chr13:113229987	chr13:113165002~113165183:-
THCA	cis	rs13063635	0.79	rs9845542	ENSG00000226074.4	PRSS44	-4.17	3.6e-05	0.00321	-0.32	-0.19	Eosinophil percentage of granulocytes;	chr3:46070377	chr3:46809359~46812558:-
THCA	cis	rs7176527	0.519	rs12148368	ENSG00000225151.9	GOLGA2P7	4.17	3.6e-05	0.00321	0.27	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84199311~84230136:-
THCA	cis	rs758324	0.732	rs156044	ENSG00000224431.1	AC063976.7	-4.17	3.6e-05	0.00321	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132156834	chr5:132199456~132203487:+
THCA	cis	rs758324	0.732	rs156045	ENSG00000224431.1	AC063976.7	-4.17	3.6e-05	0.00321	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132156923	chr5:132199456~132203487:+
THCA	cis	rs758324	0.732	rs156046	ENSG00000224431.1	AC063976.7	-4.17	3.6e-05	0.00321	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132157030	chr5:132199456~132203487:+
THCA	cis	rs2822388	1	rs2822388	ENSG00000215559.7	ANKRD20A11P	4.17	3.6e-05	0.00321	0.38	0.19	Stroke;	chr21:14035713	chr21:13909574~13980437:-
THCA	cis	rs11723261	0.564	rs60994255	ENSG00000211553.1	AC253576.2	-4.17	3.6e-05	0.00321	-0.28	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:136461~136568:+
THCA	cis	rs2898290	0.617	rs13273172	ENSG00000206014.6	OR7E161P	4.17	3.6e-05	0.00322	0.22	0.19	Systolic blood pressure;	chr8:11603602	chr8:11928597~11929563:-
THCA	cis	rs748404	0.556	rs7166467	ENSG00000166763.7	STRCP1	-4.17	3.61e-05	0.00322	-0.2	-0.19	Lung cancer;	chr15:43148324	chr15:43699488~43718184:-
THCA	cis	rs1232027	0.622	rs1346464	ENSG00000249655.1	CTC-325J23.2	4.17	3.61e-05	0.00322	0.22	0.19	Huntington's disease progression;	chr5:80671799	chr5:80630313~80631590:-
THCA	cis	rs10760158	0.8	rs4837823	ENSG00000226752.6	PSMD5-AS1	-4.17	3.61e-05	0.00322	-0.23	-0.19	Pulse pressure;	chr9:121249733	chr9:120824828~120854385:+
THCA	cis	rs9863	0.536	rs4765568	ENSG00000269997.1	RP11-214K3.21	4.17	3.61e-05	0.00322	0.26	0.19	White blood cell count;	chr12:123994614	chr12:123966077~123966629:-
THCA	cis	rs2286503	0.78	rs12113458	ENSG00000226329.2	AC005682.6	4.17	3.61e-05	0.00322	0.24	0.19	Fibrinogen;	chr7:22816009	chr7:22863874~22881350:-
THCA	cis	rs853679	0.723	rs1736904	ENSG00000273712.1	RP5-874C20.7	4.17	3.61e-05	0.00322	0.24	0.19	Depression;	chr6:28251492	chr6:28315613~28315883:-
THCA	cis	rs8077577	0.708	rs7498	ENSG00000273018.4	CTD-2303H24.2	-4.17	3.61e-05	0.00322	-0.27	-0.19	Obesity-related traits;	chr17:18245171	chr17:18511221~18551705:-
THCA	cis	rs6517329	0.649	rs11088338	ENSG00000236830.5	CBR3-AS1	4.17	3.61e-05	0.00322	0.18	0.19	Schizophrenia;	chr21:36122719	chr21:36131767~36175815:-
THCA	cis	rs7267979	0.816	rs405822	ENSG00000277938.1	RP5-965G21.3	4.17	3.61e-05	0.00322	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.816	rs6138593	ENSG00000277938.1	RP5-965G21.3	4.17	3.61e-05	0.00322	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.816	rs409853	ENSG00000277938.1	RP5-965G21.3	4.17	3.61e-05	0.00322	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25229150~25231933:+
THCA	cis	rs67478160	0.619	rs11160759	ENSG00000269940.1	RP11-73M18.7	4.17	3.61e-05	0.00322	0.18	0.19	Schizophrenia;	chr14:103765205	chr14:103694560~103695170:+
THCA	cis	rs763121	0.853	rs7289577	ENSG00000273076.1	RP3-508I15.22	4.17	3.61e-05	0.00322	0.19	0.19	Menopause (age at onset);	chr22:38646209	chr22:38743495~38743910:+
THCA	cis	rs950169	0.922	rs12915832	ENSG00000188388.10	GOLGA6L3	4.17	3.61e-05	0.00322	0.25	0.19	Schizophrenia;	chr15:84568226	chr15:85240472~85247170:+
THCA	cis	rs11098499	0.863	rs10004484	ENSG00000249244.1	RP11-548H18.2	4.17	3.61e-05	0.00322	0.22	0.19	Corneal astigmatism;	chr4:119521273	chr4:119391831~119395335:-
THCA	cis	rs1923243	0.587	rs35531383	ENSG00000223479.3	RP4-788P17.1	4.17	3.61e-05	0.00322	0.21	0.19	Migraine;	chr1:72979484	chr1:73635216~73715214:+
THCA	cis	rs123509	0.913	rs339682	ENSG00000173811.9	CCDC13-AS1	4.17	3.61e-05	0.00322	0.21	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42749631	chr3:42732575~42746768:+
THCA	cis	rs17074492	0.671	rs17074541	ENSG00000214182.5	PTMAP5	4.17	3.61e-05	0.00322	0.24	0.19	Sjögren's syndrome;	chr13:81626987	chr13:81689911~81691072:+
THCA	cis	rs4356203	0.846	rs1685932	ENSG00000272034.1	SNORD14A	-4.17	3.61e-05	0.00322	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17202356	chr11:17074654~17074744:-
THCA	cis	rs1371614	0.502	rs4572551	ENSG00000272148.1	RP11-195B17.1	4.17	3.61e-05	0.00322	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26971145	chr2:27062428~27062907:-
THCA	cis	rs758324	0.755	rs25886	ENSG00000224431.1	AC063976.7	-4.17	3.61e-05	0.00322	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132079373	chr5:132199456~132203487:+
THCA	cis	rs7665090	0.87	rs227361	ENSG00000230069.3	LRRC37A15P	-4.17	3.61e-05	0.00322	-0.19	-0.19	Primary biliary cholangitis;	chr4:102665820	chr4:102727274~102730721:-
THCA	cis	rs4950322	0.515	rs17160050	ENSG00000271721.1	RP11-337C18.9	4.17	3.61e-05	0.00322	0.21	0.19	Protein quantitative trait loci;	chr1:147255558	chr1:147175602~147177740:+
THCA	cis	rs8062405	0.573	rs7140	ENSG00000261766.1	RP11-22P6.2	4.17	3.61e-05	0.00322	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28862166~28863340:-
THCA	cis	rs9813712	0.904	rs6439223	ENSG00000253540.4	FAM86HP	4.17	3.61e-05	0.00322	0.23	0.19	Response to amphetamines;	chr3:130256697	chr3:130099092~130111472:-
THCA	cis	rs12410462	0.591	rs59149651	ENSG00000227711.2	RP11-275O4.5	-4.17	3.61e-05	0.00322	-0.23	-0.19	Major depressive disorder;	chr1:227689550	chr1:227509028~227520477:-
THCA	cis	rs2281636	0.894	rs1541598	ENSG00000233690.1	EBAG9P1	-4.17	3.61e-05	0.00322	-0.18	-0.19	Obesity-related traits;	chr10:99630733	chr10:99697407~99697949:-
THCA	cis	rs7968440	1	rs2684898	ENSG00000272368.2	RP4-605O3.4	4.17	3.61e-05	0.00322	0.12	0.19	Fibrinogen;	chr12:50653042	chr12:50112197~50165618:+
THCA	cis	rs6570726	0.791	rs1280275	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs6900040	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs6923074	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.755	rs2092296	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.755	rs2092297	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.755	rs2103633	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs9373463	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.764	rs9322028	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs12205752	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs9390336	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.738	rs6925594	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs11155432	ENSG00000270638.1	RP3-466P17.1	4.17	3.61e-05	0.00322	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145735570~145737218:+
THCA	cis	rs73198271	0.71	rs11779565	ENSG00000253893.2	FAM85B	4.17	3.61e-05	0.00322	0.26	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822510	chr8:8167819~8226614:-
THCA	cis	rs1334894	0.892	rs72911394	ENSG00000228559.1	RP3-340B19.3	-4.17	3.61e-05	0.00322	-0.39	-0.19	Coronary artery disease;	chr6:35557387	chr6:35544632~35545669:+
THCA	cis	rs1334894	1	rs72911397	ENSG00000228559.1	RP3-340B19.3	-4.17	3.61e-05	0.00322	-0.39	-0.19	Coronary artery disease;	chr6:35558044	chr6:35544632~35545669:+
THCA	cis	rs56313388	0.505	rs11076145	ENSG00000246379.5	RP11-461O7.1	-4.17	3.61e-05	0.00322	-0.2	-0.19	Pulse pressure;	chr16:56215975	chr16:56092987~56191094:-
THCA	cis	rs55702914	0.742	rs6744206	ENSG00000231621.1	AC013264.2	4.17	3.61e-05	0.00322	0.18	0.19	Major depression and alcohol dependence;	chr2:197283798	chr2:197197991~197199273:+
THCA	cis	rs3198697	0.663	rs12928099	ENSG00000260872.1	RP11-680G24.5	4.17	3.62e-05	0.00322	0.2	0.19	Triglycerides;	chr16:15056648	chr16:15018106~15020488:-
THCA	cis	rs11671653	1	rs11671653	ENSG00000267100.1	ILF3-AS1	-4.17	3.62e-05	0.00322	-0.2	-0.19	LDL cholesterol;	chr19:10727810	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs78162577	ENSG00000267100.1	ILF3-AS1	4.17	3.62e-05	0.00322	0.2	0.19	LDL cholesterol;	chr19:10728519	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs59715646	ENSG00000267100.1	ILF3-AS1	4.17	3.62e-05	0.00322	0.2	0.19	LDL cholesterol;	chr19:10728771	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs60755785	ENSG00000267100.1	ILF3-AS1	4.17	3.62e-05	0.00322	0.2	0.19	LDL cholesterol;	chr19:10728818	chr19:10651862~10653844:-
THCA	cis	rs11992162	0.967	rs4841661	ENSG00000270154.1	RP11-419I17.1	4.17	3.62e-05	0.00322	0.23	0.19	Monocyte count;	chr8:11975260	chr8:12476462~12477122:+
THCA	cis	rs11992162	1	rs11994417	ENSG00000270154.1	RP11-419I17.1	4.17	3.62e-05	0.00322	0.23	0.19	Monocyte count;	chr8:11975753	chr8:12476462~12477122:+
THCA	cis	rs8031584	0.678	rs3122	ENSG00000270015.1	RP11-540B6.6	4.17	3.62e-05	0.00322	0.15	0.19	Huntington's disease progression;	chr15:30878087	chr15:30926514~30928407:+
THCA	cis	rs1971762	0.545	rs10783585	ENSG00000270175.1	RP11-793H13.11	-4.17	3.62e-05	0.00322	-0.12	-0.19	Height;	chr12:53583533	chr12:53500162~53500936:-
THCA	cis	rs12142240	0.698	rs56358525	ENSG00000232022.5	FAAHP1	-4.17	3.62e-05	0.00323	-0.21	-0.19	Menopause (age at onset);	chr1:46383848	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.667	rs45524035	ENSG00000232022.5	FAAHP1	-4.17	3.62e-05	0.00323	-0.21	-0.19	Menopause (age at onset);	chr1:46397108	chr1:46432129~46445521:+
THCA	cis	rs868036	0.681	rs13329582	ENSG00000270964.1	RP11-502I4.3	-4.17	3.62e-05	0.00323	-0.17	-0.19	Restless legs syndrome;	chr15:67812270	chr15:67541072~67542604:-
THCA	cis	rs868036	0.681	rs4776978	ENSG00000270964.1	RP11-502I4.3	-4.17	3.62e-05	0.00323	-0.17	-0.19	Restless legs syndrome;	chr15:67815967	chr15:67541072~67542604:-
THCA	cis	rs6671200	0.831	rs9659908	ENSG00000235501.4	RP4-639F20.1	-4.17	3.62e-05	0.00323	-0.37	-0.19	Stearic acid (18:0) levels;	chr1:95190571	chr1:94927566~94963270:+
THCA	cis	rs6671200	1	rs12749053	ENSG00000235501.4	RP4-639F20.1	-4.17	3.62e-05	0.00323	-0.37	-0.19	Stearic acid (18:0) levels;	chr1:95195000	chr1:94927566~94963270:+
THCA	cis	rs6671200	1	rs34037437	ENSG00000235501.4	RP4-639F20.1	-4.17	3.62e-05	0.00323	-0.37	-0.19	Stearic acid (18:0) levels;	chr1:95195365	chr1:94927566~94963270:+
THCA	cis	rs17092148	0.79	rs6087602	ENSG00000276073.1	RP5-1125A11.7	-4.17	3.62e-05	0.00323	-0.23	-0.19	Neuroticism;	chr20:34582885	chr20:33985617~33988989:-
THCA	cis	rs453301	0.624	rs2979256	ENSG00000233609.3	RP11-62H7.2	4.17	3.62e-05	0.00323	0.18	0.19	Joint mobility (Beighton score);	chr8:9014200	chr8:8961200~8979025:+
THCA	cis	rs4713118	0.513	rs156734	ENSG00000261839.1	RP1-265C24.8	4.17	3.62e-05	0.00323	0.2	0.19	Parkinson's disease;	chr6:28039579	chr6:28136849~28139678:+
THCA	cis	rs4792901	0.722	rs12601849	ENSG00000267151.3	RP11-100E5.2	4.17	3.62e-05	0.00323	0.2	0.19	Dupuytren's disease;	chr17:43468920	chr17:43444707~43451200:+
THCA	cis	rs7182948	1	rs12901416	ENSG00000259531.2	RP11-295H24.3	-4.17	3.62e-05	0.00323	-0.22	-0.19	Lung adenocarcinoma;	chr15:49574925	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs12902794	ENSG00000259531.2	RP11-295H24.3	-4.17	3.62e-05	0.00323	-0.22	-0.19	Lung adenocarcinoma;	chr15:49574951	chr15:49365124~49366685:-
THCA	cis	rs3020736	0.5	rs6002603	ENSG00000237037.8	NDUFA6-AS1	4.17	3.62e-05	0.00323	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42090931~42137742:+
THCA	cis	rs10875746	0.951	rs58865997	ENSG00000258234.1	RP11-370I10.2	4.17	3.62e-05	0.00323	0.23	0.19	Longevity (90 years and older);	chr12:48173090	chr12:48231098~48284210:-
THCA	cis	rs881375	0.678	rs10760130	ENSG00000270917.1	RP11-27I1.6	-4.17	3.62e-05	0.00323	-0.26	-0.19	Rheumatoid arthritis;	chr9:120939712	chr9:120812475~120812845:-
THCA	cis	rs453301	0.624	rs2288673	ENSG00000233609.3	RP11-62H7.2	4.17	3.62e-05	0.00323	0.18	0.19	Joint mobility (Beighton score);	chr8:9002766	chr8:8961200~8979025:+
THCA	cis	rs7746199	0.736	rs35848276	ENSG00000272009.1	RP1-313I6.12	-4.17	3.62e-05	0.00323	-0.37	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28078792~28081130:-
THCA	cis	rs10484434	0.818	rs11756400	ENSG00000272810.1	U91328.22	4.17	3.62e-05	0.00323	0.18	0.19	HIV-1 viral setpoint;	chr6:26040625	chr6:26013241~26013757:+
THCA	cis	rs10484434	1	rs11751732	ENSG00000272810.1	U91328.22	4.17	3.62e-05	0.00323	0.18	0.19	HIV-1 viral setpoint;	chr6:26043836	chr6:26013241~26013757:+
THCA	cis	rs10484434	0.818	rs61289224	ENSG00000272810.1	U91328.22	4.17	3.62e-05	0.00323	0.18	0.19	HIV-1 viral setpoint;	chr6:26049068	chr6:26013241~26013757:+
THCA	cis	rs7737355	0.773	rs3756290	ENSG00000237714.1	P4HA2-AS1	4.17	3.62e-05	0.00323	0.26	0.19	Life satisfaction;	chr5:131616057	chr5:132184876~132192808:+
THCA	cis	rs11763147	1	rs11763147	ENSG00000234585.5	CCT6P3	-4.17	3.62e-05	0.00323	-0.17	-0.19	Corneal structure;	chr7:65861834	chr7:65038354~65074713:+
THCA	cis	rs2732480	0.5	rs11168464	ENSG00000273765.1	RP11-370I10.11	4.17	3.62e-05	0.00323	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48360920~48361377:+
THCA	cis	rs7819412	0.811	rs2409691	ENSG00000254948.1	OR7E158P	4.17	3.62e-05	0.00323	0.22	0.19	Triglycerides;	chr8:11085766	chr8:11919900~11920809:-
THCA	cis	rs9341808	0.935	rs942381	ENSG00000272129.1	RP11-250B2.6	4.17	3.62e-05	0.00323	0.24	0.19	Sitting height ratio;	chr6:80170433	chr6:80355424~80356859:+
THCA	cis	rs62158800	0.638	rs1400116	ENSG00000224568.1	AC096669.3	4.17	3.62e-05	0.00323	0.23	0.19	Facial morphology (factor 22);	chr2:107677765	chr2:107529487~107556326:+
THCA	cis	rs1267303	0.675	rs1267312	ENSG00000232022.5	FAAHP1	-4.17	3.62e-05	0.00323	-0.22	-0.19	Monobrow;	chr1:46521076	chr1:46432129~46445521:+
THCA	cis	rs17767294	0.612	rs12332927	ENSG00000226314.6	ZNF192P1	-4.17	3.62e-05	0.00323	-0.32	-0.19	Parkinson's disease;	chr6:27987337	chr6:28161781~28169594:+
THCA	cis	rs9890032	0.542	rs62070645	ENSG00000263531.1	RP13-753N3.1	-4.17	3.62e-05	0.00323	-0.27	-0.19	Hip circumference adjusted for BMI;	chr17:30853978	chr17:30863921~30864940:-
THCA	cis	rs800160	0.702	rs800126	ENSG00000199550.1	Y_RNA	4.17	3.63e-05	0.00323	0.25	0.19	Bacteremia;	chr11:2344351	chr11:2372638~2372750:+
THCA	cis	rs4788570	0.584	rs6499528	ENSG00000260185.1	RP11-432I5.6	-4.17	3.63e-05	0.00323	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71638859	chr16:71655027~71664212:+
THCA	cis	rs9595908	0.709	rs916289	ENSG00000212293.1	SNORA16	4.17	3.63e-05	0.00323	0.22	0.19	Body mass index;	chr13:32792110	chr13:32420390~32420516:-
THCA	cis	rs12906542	0.516	rs10444863	ENSG00000259792.1	RP11-114H24.6	-4.17	3.63e-05	0.00323	-0.3	-0.19	Breast cancer;	chr15:78066495	chr15:77993405~77995289:+
THCA	cis	rs9527	0.637	rs7085104	ENSG00000272912.1	RP11-724N1.1	-4.17	3.63e-05	0.00323	-0.23	-0.19	Arsenic metabolism;	chr10:102869116	chr10:102914585~102915404:+
THCA	cis	rs1267303	0.636	rs1267310	ENSG00000232022.5	FAAHP1	-4.17	3.63e-05	0.00323	-0.22	-0.19	Monobrow;	chr1:46521635	chr1:46432129~46445521:+
THCA	cis	rs1267303	0.675	rs1267309	ENSG00000232022.5	FAAHP1	-4.17	3.63e-05	0.00323	-0.22	-0.19	Monobrow;	chr1:46521670	chr1:46432129~46445521:+
THCA	cis	rs6878727	0.665	rs319628	ENSG00000253807.4	LINC01170	4.17	3.63e-05	0.00323	0.17	0.19	Breast cancer;	chr5:124338442	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.638	rs170345	ENSG00000253807.4	LINC01170	4.17	3.63e-05	0.00323	0.17	0.19	Breast cancer;	chr5:124338824	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.613	rs319627	ENSG00000253807.4	LINC01170	4.17	3.63e-05	0.00323	0.17	0.19	Breast cancer;	chr5:124339100	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.665	rs161012	ENSG00000253807.4	LINC01170	4.17	3.63e-05	0.00323	0.17	0.19	Breast cancer;	chr5:124339297	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.665	rs173958	ENSG00000253807.4	LINC01170	4.17	3.63e-05	0.00323	0.17	0.19	Breast cancer;	chr5:124339549	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.665	rs149628	ENSG00000253807.4	LINC01170	4.17	3.63e-05	0.00323	0.17	0.19	Breast cancer;	chr5:124340520	chr5:124059794~124405079:-
THCA	cis	rs7824557	0.872	rs2572417	ENSG00000255310.2	AF131215.2	-4.17	3.63e-05	0.00323	-0.16	-0.19	Retinal vascular caliber;	chr8:11253953	chr8:11107788~11109726:-
THCA	cis	rs9923856	0.532	rs3743976	ENSG00000263033.2	RP11-396B14.2	-4.17	3.63e-05	0.00323	-0.19	-0.19	Atopic dermatitis;Adult asthma;	chr16:10944967	chr16:11196177~11224969:+
THCA	cis	rs7178424	0.806	rs4775453	ENSG00000259251.2	RP11-643M14.1	4.17	3.63e-05	0.00323	0.19	0.19	Height;	chr15:61925192	chr15:62060503~62062434:+
THCA	cis	rs7711186	0.786	rs11960120	ENSG00000252464.1	RN7SKP70	4.17	3.63e-05	0.00323	0.23	0.19	Urate levels in obese individuals;	chr5:178660630	chr5:178619728~178619998:-
THCA	cis	rs7711186	0.786	rs11960121	ENSG00000252464.1	RN7SKP70	4.17	3.63e-05	0.00323	0.23	0.19	Urate levels in obese individuals;	chr5:178660633	chr5:178619728~178619998:-
THCA	cis	rs7267979	1	rs2424710	ENSG00000276952.1	RP5-965G21.6	4.17	3.63e-05	0.00324	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6115140	ENSG00000276952.1	RP5-965G21.6	4.17	3.63e-05	0.00324	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs1888997	ENSG00000276952.1	RP5-965G21.6	-4.17	3.63e-05	0.00324	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs3002698	ENSG00000276952.1	RP5-965G21.6	-4.17	3.63e-05	0.00324	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25284915~25285588:-
THCA	cis	rs9527	0.83	rs3740392	ENSG00000236937.2	PTGES3P4	4.17	3.63e-05	0.00324	0.28	0.19	Arsenic metabolism;	chr10:102877098	chr10:102845595~102845950:+
THCA	cis	rs7267979	0.844	rs35735333	ENSG00000274973.1	RP13-401N8.7	4.17	3.63e-05	0.00324	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25845497~25845862:+
THCA	cis	rs4819052	1	rs9306123	ENSG00000182586.6	LINC00334	-4.17	3.63e-05	0.00324	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45234340~45258730:+
THCA	cis	rs9307551	0.741	rs1822106	ENSG00000250334.4	LINC00989	-4.17	3.64e-05	0.00324	-0.25	-0.19	Refractive error;	chr4:79487310	chr4:79492416~79576460:+
THCA	cis	rs4788570	0.615	rs1423983	ENSG00000260185.1	RP11-432I5.6	-4.17	3.64e-05	0.00324	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71667345	chr16:71655027~71664212:+
THCA	cis	rs4788570	0.584	rs11862723	ENSG00000260185.1	RP11-432I5.6	-4.17	3.64e-05	0.00324	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71670319	chr16:71655027~71664212:+
THCA	cis	rs78487399	0.808	rs114563746	ENSG00000234936.1	AC010883.5	4.17	3.64e-05	0.00324	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43533741	chr2:43229573~43233394:+
THCA	cis	rs919433	0.647	rs2045242	ENSG00000231621.1	AC013264.2	-4.17	3.64e-05	0.00324	-0.2	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197642925	chr2:197197991~197199273:+
THCA	cis	rs2153535	0.585	rs7763881	ENSG00000230939.1	RP11-314C16.1	4.17	3.64e-05	0.00324	0.2	0.19	Motion sickness;	chr6:8653014	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs1328867	ENSG00000230939.1	RP11-314C16.1	-4.17	3.64e-05	0.00324	-0.2	-0.19	Motion sickness;	chr6:8652454	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.56	rs9405406	ENSG00000230939.1	RP11-314C16.1	-4.17	3.64e-05	0.00324	-0.2	-0.19	Motion sickness;	chr6:8654625	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs1998364	ENSG00000230939.1	RP11-314C16.1	-4.17	3.64e-05	0.00324	-0.2	-0.19	Motion sickness;	chr6:8657091	chr6:8784178~8785445:+
THCA	cis	rs2408955	0.568	rs12099462	ENSG00000273765.1	RP11-370I10.11	-4.17	3.64e-05	0.00324	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48109321	chr12:48360920~48361377:+
THCA	cis	rs7772486	0.79	rs2247206	ENSG00000270638.1	RP3-466P17.1	4.17	3.64e-05	0.00324	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.764	rs2247211	ENSG00000270638.1	RP3-466P17.1	4.17	3.64e-05	0.00324	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145735570~145737218:+
THCA	cis	rs4713118	1	rs13215072	ENSG00000226314.6	ZNF192P1	-4.17	3.64e-05	0.00324	-0.23	-0.19	Parkinson's disease;	chr6:27709949	chr6:28161781~28169594:+
THCA	cis	rs6546886	0.912	rs7606491	ENSG00000235499.1	AC073046.25	4.17	3.64e-05	0.00324	0.17	0.19	Dialysis-related mortality;	chr2:74071831	chr2:73985132~73986343:+
THCA	cis	rs9677476	0.517	rs2368563	ENSG00000224376.1	AC017104.6	4.17	3.64e-05	0.00324	0.19	0.19	Food antigen IgG levels;	chr2:231193779	chr2:231388976~231394991:+
THCA	cis	rs113835537	0.935	rs11550057	ENSG00000255517.5	CTD-3074O7.5	-4.17	3.64e-05	0.00324	-0.21	-0.19	Airway imaging phenotypes;	chr11:66625409	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.935	rs15969	ENSG00000255517.5	CTD-3074O7.5	-4.17	3.64e-05	0.00324	-0.21	-0.19	Airway imaging phenotypes;	chr11:66626916	chr11:66473490~66480233:-
THCA	cis	rs2898290	0.622	rs1478890	ENSG00000251402.3	FAM90A25P	-4.17	3.64e-05	0.00324	-0.24	-0.19	Systolic blood pressure;	chr8:11498093	chr8:12415080~12418090:-
THCA	cis	rs61270009	0.955	rs34241164	ENSG00000247828.6	TMEM161B-AS1	4.17	3.64e-05	0.00324	0.17	0.19	Depressive symptoms;	chr5:88293189	chr5:88268895~88436685:+
THCA	cis	rs13177755	1	rs13177755	ENSG00000247828.6	TMEM161B-AS1	4.17	3.64e-05	0.00324	0.17	0.19	Depressive symptoms (multi-trait analysis);	chr5:88296420	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.955	rs13159835	ENSG00000247828.6	TMEM161B-AS1	4.17	3.64e-05	0.00324	0.17	0.19	Depressive symptoms;	chr5:88305576	chr5:88268895~88436685:+
THCA	cis	rs2944755	0.919	rs2944754	ENSG00000279766.1	RP11-642A1.2	4.17	3.64e-05	0.00324	0.27	0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140564251	chr8:140572142~140572812:-
THCA	cis	rs12478296	1	rs67535150	ENSG00000220804.7	AC093642.5	4.17	3.64e-05	0.00324	0.21	0.19	Obesity-related traits;	chr2:242103948	chr2:242088633~242160153:+
THCA	cis	rs7819412	0.669	rs2409743	ENSG00000206014.6	OR7E161P	4.17	3.64e-05	0.00325	0.22	0.19	Triglycerides;	chr8:11212851	chr8:11928597~11929563:-
THCA	cis	rs172166	0.561	rs149971	ENSG00000280107.1	AL022393.9	-4.17	3.64e-05	0.00325	-0.18	-0.19	Cardiac Troponin-T levels;	chr6:28014374	chr6:28170845~28172521:+
THCA	cis	rs1387259	0.929	rs11168460	ENSG00000273765.1	RP11-370I10.11	4.17	3.64e-05	0.00325	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.5	rs7297824	ENSG00000273765.1	RP11-370I10.11	4.17	3.64e-05	0.00325	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48360920~48361377:+
THCA	cis	rs6687821	0.515	rs496588	ENSG00000261737.1	RP4-612B15.3	-4.17	3.64e-05	0.00325	-0.28	-0.19	Yeast infection;	chr1:86858728	chr1:86703502~86704462:-
THCA	cis	rs5758659	0.633	rs762995	ENSG00000227370.1	RP4-669P10.19	-4.17	3.64e-05	0.00325	-0.17	-0.19	Cognitive function;	chr22:42276118	chr22:42132543~42132998:+
THCA	cis	rs875971	0.522	rs709604	ENSG00000275400.1	RP4-756H11.5	4.17	3.64e-05	0.00325	0.18	0.19	Aortic root size;	chr7:66032447	chr7:66553805~66554199:-
THCA	cis	rs1039766	0.925	rs268850	ENSG00000204929.10	AC074391.1	4.17	3.64e-05	0.00325	0.3	0.19	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr2:65436711~66084639:+
THCA	cis	rs11758351	1	rs76722536	ENSG00000216331.1	HIST1H1PS1	4.17	3.65e-05	0.00325	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26192718	chr6:26195566~26195771:+
THCA	cis	rs7968440	1	rs7977690	ENSG00000272368.2	RP4-605O3.4	4.17	3.65e-05	0.00325	0.12	0.19	Fibrinogen;	chr12:50736631	chr12:50112197~50165618:+
THCA	cis	rs6416877	0.885	rs9747682	ENSG00000277491.1	RP11-676J12.9	-4.17	3.65e-05	0.00325	-0.23	-0.19	Myeloid white cell count;	chr17:1443113	chr17:795306~795794:+
THCA	cis	rs9532669	0.963	rs1571116	ENSG00000229473.2	RGS17P1	4.17	3.65e-05	0.00325	0.24	0.19	Cervical cancer;	chr13:40929765	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.963	rs9532673	ENSG00000229473.2	RGS17P1	4.17	3.65e-05	0.00325	0.24	0.19	Cervical cancer;	chr13:40930412	chr13:40992779~40993331:-
THCA	cis	rs4237845	0.537	rs1599931	ENSG00000270039.1	RP11-571M6.17	-4.17	3.65e-05	0.00325	-0.22	-0.19	Intelligence (multi-trait analysis);	chr12:57865067	chr12:57803838~57804415:+
THCA	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	4.17	3.65e-05	0.00325	0.22	0.19	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
THCA	cis	rs12234571	1	rs73372301	ENSG00000214293.7	APTR	4.17	3.65e-05	0.00325	0.23	0.19	Obesity-related traits;	chr7:77723502	chr7:77657660~77696265:-
THCA	cis	rs7208859	0.623	rs8082537	ENSG00000280069.1	CTD-2349P21.3	-4.17	3.65e-05	0.00325	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30738182~30740275:+
THCA	cis	rs9300255	0.602	rs1727294	ENSG00000235423.7	RP11-282O18.3	4.17	3.65e-05	0.00325	0.19	0.19	Neutrophil percentage of white cells;	chr12:123131967	chr12:123252030~123261483:-
THCA	cis	rs4713118	0.539	rs200967	ENSG00000261839.1	RP1-265C24.8	4.17	3.65e-05	0.00325	0.2	0.19	Parkinson's disease;	chr6:27894349	chr6:28136849~28139678:+
THCA	cis	rs2281636	0.931	rs2804419	ENSG00000233690.1	EBAG9P1	-4.17	3.65e-05	0.00325	-0.18	-0.19	Obesity-related traits;	chr10:99749356	chr10:99697407~99697949:-
THCA	cis	rs7914558	0.646	rs7909286	ENSG00000213277.3	MARCKSL1P1	4.17	3.65e-05	0.00325	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899235	chr10:103175554~103176094:+
THCA	cis	rs7914558	0.646	rs7909591	ENSG00000213277.3	MARCKSL1P1	4.17	3.65e-05	0.00325	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899261	chr10:103175554~103176094:+
THCA	cis	rs7914558	0.621	rs10786722	ENSG00000213277.3	MARCKSL1P1	4.17	3.65e-05	0.00325	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900311	chr10:103175554~103176094:+
THCA	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	4.17	3.65e-05	0.00325	0.28	0.19	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
THCA	cis	rs74233809	1	rs77420391	ENSG00000272912.1	RP11-724N1.1	-4.17	3.65e-05	0.00325	-0.35	-0.19	Birth weight;	chr10:103186066	chr10:102914585~102915404:+
THCA	cis	rs8030605	0.778	rs795785	ENSG00000277245.1	RP11-48G14.3	-4.17	3.65e-05	0.00325	-0.33	-0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56427599	chr15:56447120~56447697:+
THCA	cis	rs2505675	0.665	rs234932	ENSG00000272465.1	RP1-136B1.1	-4.17	3.65e-05	0.00325	-0.26	-0.19	Tuberculosis;	chr6:2220286	chr6:2437549~2438249:+
THCA	cis	rs34787248	1	rs34787248	ENSG00000273712.1	RP5-874C20.7	4.17	3.65e-05	0.00325	0.27	0.19	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28315613~28315883:-
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000182586.6	LINC00334	-4.17	3.65e-05	0.00325	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000182586.6	LINC00334	-4.17	3.65e-05	0.00325	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000182586.6	LINC00334	-4.17	3.65e-05	0.00325	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000182586.6	LINC00334	-4.17	3.65e-05	0.00325	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000182586.6	LINC00334	-4.17	3.65e-05	0.00325	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000182586.6	LINC00334	-4.17	3.65e-05	0.00325	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000182586.6	LINC00334	4.17	3.65e-05	0.00325	0.2	0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45234340~45258730:+
THCA	cis	rs1501911	0.509	rs34487	ENSG00000248489.1	CTD-2007H13.3	4.17	3.65e-05	0.00325	0.17	0.19	Lung function (FEV1/FVC);	chr5:98872725	chr5:98929171~98995013:+
THCA	cis	rs9393813	0.529	rs7761966	ENSG00000204789.4	ZNF204P	-4.17	3.65e-05	0.00325	-0.15	-0.19	Bipolar disorder;	chr6:27477924	chr6:27357825~27360221:-
THCA	cis	rs2380205	0.875	rs10795593	ENSG00000232807.2	RP11-536K7.3	4.17	3.65e-05	0.00325	0.18	0.19	Breast cancer;	chr10:5853793	chr10:5934270~5945900:-
THCA	cis	rs11723261	0.664	rs4627799	ENSG00000250892.1	RP11-1365D11.1	4.17	3.66e-05	0.00325	0.26	0.19	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:201409~205009:-
THCA	cis	rs4591358	0.705	rs6741348	ENSG00000223466.1	AC064834.2	-4.17	3.66e-05	0.00326	-0.22	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195466190	chr2:195533035~195538681:+
THCA	cis	rs2836974	0.568	rs428602	ENSG00000255568.3	BRWD1-AS2	4.17	3.66e-05	0.00326	0.15	0.19	Cognitive function;	chr21:39175078	chr21:39313935~39314962:+
THCA	cis	rs4742903	0.967	rs4743690	ENSG00000270332.1	SMC2-AS1	4.17	3.66e-05	0.00326	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104147296	chr9:104080024~104093073:-
THCA	cis	rs763121	0.853	rs5757196	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38643850	chr22:38743495~38743910:+
THCA	cis	rs763121	0.785	rs5757199	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38644612	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs9610993	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38646813	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757200	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38647486	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757203	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38648147	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2205802	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38650322	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757204	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38650695	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs8138996	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38651430	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs6001182	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38651438	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757208	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38653225	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757211	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38655700	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs6001184	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38656111	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs6001185	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38656150	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2294296	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38657044	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs2064088	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38657377	chr22:38743495~38743910:+
THCA	cis	rs763121	0.853	rs5757213	ENSG00000273076.1	RP3-508I15.22	4.17	3.66e-05	0.00326	0.19	0.19	Menopause (age at onset);	chr22:38657883	chr22:38743495~38743910:+
THCA	cis	rs875971	0.965	rs10267430	ENSG00000229886.1	RP5-1132H15.3	-4.17	3.66e-05	0.00326	-0.2	-0.19	Aortic root size;	chr7:66278036	chr7:66025126~66031544:-
THCA	cis	rs9549367	0.577	rs3024711	ENSG00000269125.1	RP11-98F14.11	-4.17	3.66e-05	0.00326	-0.26	-0.19	Platelet distribution width;	chr13:113158954	chr13:113165002~113165183:-
THCA	cis	rs7176527	0.796	rs72630464	ENSG00000225151.9	GOLGA2P7	4.17	3.66e-05	0.00326	0.36	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84754895	chr15:84199311~84230136:-
THCA	cis	rs10175706	1	rs12474171	ENSG00000256637.5	RP11-76I14.1	-4.17	3.66e-05	0.00326	-0.17	-0.19	Chin dimples;	chr2:104018392	chr2:103874310~104077778:+
THCA	cis	rs2380205	0.967	rs907688	ENSG00000232807.2	RP11-536K7.3	-4.17	3.66e-05	0.00326	-0.17	-0.19	Breast cancer;	chr10:5858859	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.935	rs907686	ENSG00000232807.2	RP11-536K7.3	4.17	3.66e-05	0.00326	0.17	0.19	Breast cancer;	chr10:5858730	chr10:5934270~5945900:-
THCA	cis	rs6657613	0.815	rs2871775	ENSG00000186301.8	MST1P2	4.17	3.66e-05	0.00326	0.15	0.19	Hip circumference adjusted for BMI;	chr1:17019410	chr1:16645622~16650289:+
THCA	cis	rs7838490	0.504	rs7013582	ENSG00000253553.4	RP11-586K2.1	-4.17	3.66e-05	0.00326	-0.19	-0.19	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88505693	chr8:88326836~88737134:+
THCA	cis	rs7577696	0.85	rs11124274	ENSG00000276334.1	AL133243.1	-4.17	3.66e-05	0.00326	-0.2	-0.19	Inflammatory biomarkers;	chr2:32040848	chr2:32521927~32523547:+
THCA	cis	rs889122	1	rs889122	ENSG00000267289.1	CTD-2623N2.11	4.17	3.66e-05	0.00326	0.24	0.19	Menarche (age at onset);	chr19:9885191	chr19:9834079~9835013:-
THCA	cis	rs10186029	0.509	rs13425936	ENSG00000270659.1	RP11-105N14.1	4.17	3.66e-05	0.00326	0.16	0.19	Systemic sclerosis;	chr2:213075622	chr2:213152970~213153659:+
THCA	cis	rs10186029	0.509	rs13426230	ENSG00000270659.1	RP11-105N14.1	4.17	3.66e-05	0.00326	0.16	0.19	Systemic sclerosis;	chr2:213075723	chr2:213152970~213153659:+
THCA	cis	rs6570726	0.791	rs4335004	ENSG00000270638.1	RP3-466P17.1	4.17	3.66e-05	0.00326	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145735570~145737218:+
THCA	cis	rs8033133	0.957	rs7162559	ENSG00000251896.1	SNORD116-27	4.17	3.66e-05	0.00326	0.2	0.19	Blood osmolality (transformed sodium);	chr15:25107194	chr15:25101575~25101666:+
THCA	cis	rs6504249	0.893	rs2521827	ENSG00000270714.1	MINOS1P2	-4.17	3.66e-05	0.00326	-0.26	-0.19	Joint mobility (Beighton score);	chr17:64696610	chr17:64747264~64747492:-
THCA	cis	rs56313388	0.522	rs9939525	ENSG00000246379.5	RP11-461O7.1	-4.17	3.66e-05	0.00326	-0.2	-0.19	Pulse pressure;	chr16:56125218	chr16:56092987~56191094:-
THCA	cis	rs7520050	0.807	rs3013595	ENSG00000280836.1	AL355480.1	-4.17	3.66e-05	0.00326	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45581219~45581321:-
THCA	cis	rs800160	0.557	rs800144	ENSG00000236264.4	RPL26P30	4.17	3.66e-05	0.00326	0.26	0.19	Bacteremia;	chr11:2346926	chr11:2335132~2335776:-
THCA	cis	rs800160	0.588	rs800147	ENSG00000236264.4	RPL26P30	4.17	3.66e-05	0.00326	0.26	0.19	Bacteremia;	chr11:2347765	chr11:2335132~2335776:-
THCA	cis	rs11671005	0.656	rs11671092	ENSG00000269600.1	AC016629.3	-4.17	3.66e-05	0.00326	-0.29	-0.19	Mean platelet volume;	chr19:58497742	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.656	rs55928441	ENSG00000269600.1	AC016629.3	-4.17	3.66e-05	0.00326	-0.29	-0.19	Mean platelet volume;	chr19:58498307	chr19:58593896~58599355:-
THCA	cis	rs2380220	1	rs9400318	ENSG00000261366.1	MANEA-AS1	-4.17	3.66e-05	0.00326	-0.21	-0.19	Behavioural disinhibition (generation interaction);	chr6:95524505	chr6:95575183~95577450:-
THCA	cis	rs142958719	1	rs142958719	ENSG00000237714.1	P4HA2-AS1	-4.17	3.66e-05	0.00326	-0.27	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131897266	chr5:132184876~132192808:+
THCA	cis	rs317865	1	rs317865	ENSG00000263327.5	TAPT1-AS1	-4.17	3.66e-05	0.00326	-0.3	-0.19	Kidney disease (early stage) in type 1 diabetes;	chr4:16155043	chr4:16226685~16320140:+
THCA	cis	rs957448	0.561	rs12679785	ENSG00000253175.1	RP11-267M23.6	4.17	3.66e-05	0.00326	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94565036~94565715:+
THCA	cis	rs957448	0.561	rs13258635	ENSG00000253175.1	RP11-267M23.6	4.17	3.66e-05	0.00326	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94565036~94565715:+
THCA	cis	rs12680842	0.842	rs34691145	ENSG00000253175.1	RP11-267M23.6	4.17	3.66e-05	0.00326	0.23	0.19	Body mass index;	chr8:94597715	chr8:94565036~94565715:+
THCA	cis	rs1371614	0.635	rs9309559	ENSG00000272148.1	RP11-195B17.1	4.17	3.66e-05	0.00326	0.18	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918647	chr2:27062428~27062907:-
THCA	cis	rs78487399	0.808	rs13409687	ENSG00000234936.1	AC010883.5	4.17	3.66e-05	0.00326	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43474012	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs7561114	ENSG00000234936.1	AC010883.5	4.17	3.66e-05	0.00326	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43474812	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs7590220	ENSG00000234936.1	AC010883.5	4.17	3.66e-05	0.00326	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43475012	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6731980	ENSG00000234936.1	AC010883.5	4.17	3.66e-05	0.00326	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43476044	chr2:43229573~43233394:+
THCA	cis	rs6688613	0.685	rs10918600	ENSG00000225171.2	DUTP6	4.17	3.66e-05	0.00326	0.27	0.19	Refractive astigmatism;	chr1:166950105	chr1:166868748~166869209:+
THCA	cis	rs78487399	0.614	rs13422551	ENSG00000234936.1	AC010883.5	4.17	3.66e-05	0.00326	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43497543	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs72865267	ENSG00000234936.1	AC010883.5	4.17	3.66e-05	0.00326	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43499189	chr2:43229573~43233394:+
THCA	cis	rs4853525	0.59	rs13414554	ENSG00000235852.1	AC005540.3	4.17	3.67e-05	0.00326	0.21	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929215	chr2:190880797~190882059:-
THCA	cis	rs10090774	0.544	rs10097013	ENSG00000279766.1	RP11-642A1.2	-4.17	3.67e-05	0.00326	-0.23	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140682362	chr8:140572142~140572812:-
THCA	cis	rs4938303	0.633	rs1960036	ENSG00000254851.1	RP11-109L13.1	4.17	3.67e-05	0.00326	0.32	0.19	Triglycerides;	chr11:116676692	chr11:117135528~117138582:+
THCA	cis	rs4938303	0.633	rs61906104	ENSG00000254851.1	RP11-109L13.1	4.17	3.67e-05	0.00326	0.32	0.19	Triglycerides;	chr11:116679398	chr11:117135528~117138582:+
THCA	cis	rs4938303	0.671	rs35352977	ENSG00000254851.1	RP11-109L13.1	4.17	3.67e-05	0.00326	0.32	0.19	Triglycerides;	chr11:116681756	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.526	rs57654288	ENSG00000267422.1	CTD-2554C21.1	4.17	3.67e-05	0.00326	0.18	0.19	Obesity-related traits;	chr19:37587870	chr19:37779686~37792865:+
THCA	cis	rs12118280	0.56	rs2336024	ENSG00000280186.1	RP11-483I13.6	4.17	3.67e-05	0.00326	0.16	0.19	Myeloid white cell count;	chr1:108214825	chr1:108200413~108202743:+
THCA	cis	rs7829975	0.572	rs28730413	ENSG00000254340.1	RP11-10A14.3	-4.17	3.67e-05	0.00326	-0.21	-0.19	Mood instability;	chr8:8937937	chr8:9141424~9145435:+
THCA	cis	rs67981189	0.896	rs2526882	ENSG00000269927.1	RP6-91H8.3	-4.17	3.67e-05	0.00326	-0.22	-0.19	Schizophrenia;	chr14:70907985	chr14:71141125~71143253:-
THCA	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-4.17	3.67e-05	0.00326	-0.18	-0.19	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-4.17	3.67e-05	0.00326	-0.18	-0.19	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-4.17	3.67e-05	0.00326	-0.18	-0.19	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-4.17	3.67e-05	0.00326	-0.18	-0.19	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
THCA	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-4.17	3.67e-05	0.00326	-0.18	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-4.17	3.67e-05	0.00326	-0.18	-0.19	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
THCA	cis	rs11220082	0.644	rs12577961	ENSG00000254671.2	STT3A-AS1	-4.17	3.67e-05	0.00326	-0.22	-0.19	Schizophrenia;	chr11:125438943	chr11:125570284~125592568:-
THCA	cis	rs4908768	0.906	rs12405049	ENSG00000232912.4	RP5-1115A15.1	-4.17	3.67e-05	0.00326	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8566058	chr1:8424645~8434838:+
THCA	cis	rs897984	0.806	rs10782002	ENSG00000275263.1	RP11-1072A3.4	4.17	3.67e-05	0.00326	0.22	0.19	Dementia with Lewy bodies;	chr16:30935185	chr16:30956872~30957199:-
THCA	cis	rs4803480	0.573	rs2302188	ENSG00000267107.5	PCAT19	-4.17	3.67e-05	0.00326	-0.19	-0.19	Schizophrenia;	chr19:41579520	chr19:41454169~41500649:-
THCA	cis	rs3177980	0.523	rs10919258	ENSG00000239494.2	RN7SL333P	-4.17	3.67e-05	0.00327	-0.17	-0.19	Amyotrophic lateral sclerosis;	chr1:169859930	chr1:169859756~169860052:+
THCA	cis	rs9467773	1	rs9467791	ENSG00000228223.2	HCG11	4.17	3.67e-05	0.00327	0.2	0.19	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26523450~26526579:+
THCA	cis	rs62344088	1	rs10065373	ENSG00000277812.1	AC021087.1	4.17	3.67e-05	0.00327	0.48	0.19	Asthma (childhood onset);	chr5:106704	chr5:262769~262881:+
THCA	cis	rs17301013	0.861	rs10218528	ENSG00000227373.4	RP11-160H22.5	4.17	3.67e-05	0.00327	0.27	0.19	Systemic lupus erythematosus;	chr1:174478450	chr1:174115300~174160004:-
THCA	cis	rs11633886	0.934	rs3858882	ENSG00000273972.1	CTD-2306A12.1	-4.17	3.67e-05	0.00327	-0.2	-0.19	Diisocyanate-induced asthma;	chr15:45788766	chr15:45702640~45703183:+
THCA	cis	rs9625935	0.751	rs62226440	ENSG00000279159.1	RP3-394A18.1	-4.17	3.67e-05	0.00327	-0.14	-0.19	Tonsillectomy;	chr22:30194233	chr22:29978950~30028236:-
THCA	cis	rs4660214	0.724	rs7554301	ENSG00000182109.6	RP11-69E11.4	-4.17	3.67e-05	0.00327	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177792	chr1:39522280~39546187:-
THCA	cis	rs9868809	0.505	rs28567949	ENSG00000270441.1	RP11-694I15.7	4.17	3.67e-05	0.00327	0.25	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707127	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs13316551	ENSG00000270441.1	RP11-694I15.7	4.17	3.67e-05	0.00327	0.25	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707734	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs11706203	ENSG00000270441.1	RP11-694I15.7	4.17	3.67e-05	0.00327	0.25	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48708806	chr3:49140086~49160851:-
THCA	cis	rs17270561	0.609	rs4132072	ENSG00000272462.2	U91328.19	-4.17	3.67e-05	0.00327	-0.16	-0.19	Iron status biomarkers;	chr6:25717615	chr6:25992662~26001775:+
THCA	cis	rs1520333	0.507	rs13279664	ENSG00000254352.1	RP11-578O24.2	-4.17	3.67e-05	0.00327	-0.21	-0.19	Multiple sclerosis;	chr8:78457644	chr8:78723796~78724136:-
THCA	cis	rs7129556	0.69	rs648601	ENSG00000254459.1	RP11-91P24.7	4.17	3.67e-05	0.00327	0.24	0.19	Weight loss (gastric bypass surgery);	chr11:77875864	chr11:77829654~77872262:-
THCA	cis	rs4780401	0.933	rs11075010	ENSG00000274038.1	RP11-66H6.4	-4.17	3.67e-05	0.00327	-0.22	-0.19	Rheumatoid arthritis;	chr16:11732157	chr16:11056556~11057034:+
THCA	cis	rs700651	0.821	rs4850812	ENSG00000231621.1	AC013264.2	4.17	3.67e-05	0.00327	0.2	0.19	Intracranial aneurysm;	chr2:197878931	chr2:197197991~197199273:+
THCA	cis	rs1065852	0.526	rs739296	ENSG00000281538.1	RP4-669P10.20	4.17	3.67e-05	0.00327	0.19	0.19	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993944	chr22:42138060~42139726:+
THCA	cis	rs7829975	0.564	rs2976855	ENSG00000233609.3	RP11-62H7.2	4.17	3.67e-05	0.00327	0.18	0.19	Mood instability;	chr8:8444284	chr8:8961200~8979025:+
THCA	cis	rs150992	0.609	rs1093794	ENSG00000246763.5	RGMB-AS1	-4.17	3.67e-05	0.00327	-0.19	-0.19	Body mass index;	chr5:98993334	chr5:98769618~98773469:-
THCA	cis	rs875971	0.862	rs11763189	ENSG00000229886.1	RP5-1132H15.3	4.17	3.67e-05	0.00327	0.2	0.19	Aortic root size;	chr7:66518542	chr7:66025126~66031544:-
THCA	cis	rs11098499	0.82	rs6829903	ENSG00000249244.1	RP11-548H18.2	4.17	3.67e-05	0.00327	0.22	0.19	Corneal astigmatism;	chr4:119585729	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs7669520	ENSG00000249244.1	RP11-548H18.2	4.17	3.67e-05	0.00327	0.22	0.19	Corneal astigmatism;	chr4:119594123	chr4:119391831~119395335:-
THCA	cis	rs478304	0.934	rs610037	ENSG00000255557.1	RP11-770G2.2	-4.17	3.67e-05	0.00327	-0.2	-0.19	Acne (severe);	chr11:65779386	chr11:65745729~65771585:+
THCA	cis	rs12928939	0.517	rs8049508	ENSG00000260886.1	TAT-AS1	4.17	3.67e-05	0.00327	0.26	0.19	Post bronchodilator FEV1;	chr16:71944410	chr16:71565789~71578187:+
THCA	cis	rs67478160	0.595	rs1475007	ENSG00000269940.1	RP11-73M18.7	4.17	3.67e-05	0.00327	0.18	0.19	Schizophrenia;	chr14:103830810	chr14:103694560~103695170:+
THCA	cis	rs959260	1	rs930298	ENSG00000263843.1	RP11-649A18.12	4.17	3.67e-05	0.00327	0.2	0.19	Systemic lupus erythematosus;	chr17:75408585	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs930299	ENSG00000263843.1	RP11-649A18.12	4.17	3.67e-05	0.00327	0.2	0.19	Systemic lupus erythematosus;	chr17:75408587	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs4789193	ENSG00000263843.1	RP11-649A18.12	-4.17	3.67e-05	0.00327	-0.2	-0.19	Systemic lupus erythematosus;	chr17:75408715	chr17:75271369~75273895:+
THCA	cis	rs1552244	0.608	rs2075310	ENSG00000180385.7	EMC3-AS1	4.17	3.67e-05	0.00327	0.19	0.19	Alzheimer's disease;	chr3:10025967	chr3:9986893~10006990:+
THCA	cis	rs4788570	0.51	rs9931074	ENSG00000260185.1	RP11-432I5.6	-4.17	3.68e-05	0.00327	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71633777	chr16:71655027~71664212:+
THCA	cis	rs7267979	0.816	rs8115257	ENSG00000277938.1	RP5-965G21.3	4.17	3.68e-05	0.00327	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25229150~25231933:+
THCA	cis	rs28476539	0.531	rs13114939	ENSG00000270480.1	RP11-57B24.1	4.17	3.68e-05	0.00327	0.28	0.19	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82619543	chr4:82691737~82692468:+
THCA	cis	rs4906332	0.754	rs34235720	ENSG00000244691.1	RPL10AP1	-4.17	3.68e-05	0.00327	-0.27	-0.19	Coronary artery disease;	chr14:103538631	chr14:103412119~103412761:-
THCA	cis	rs4713118	0.824	rs7759217	ENSG00000220721.1	OR1F12	4.17	3.68e-05	0.00327	0.25	0.19	Parkinson's disease;	chr6:27762684	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.784	rs9468219	ENSG00000220721.1	OR1F12	4.17	3.68e-05	0.00327	0.25	0.19	Parkinson's disease;	chr6:27763976	chr6:28073316~28074233:+
THCA	cis	rs5762752	0.539	rs1807477	ENSG00000272858.1	CTA-292E10.8	-4.17	3.68e-05	0.00327	-0.18	-0.19	Optic disc area;	chr22:28693107	chr22:28814914~28815662:+
THCA	cis	rs10911902	0.643	rs111828305	ENSG00000229739.2	RP11-295K2.3	-4.17	3.68e-05	0.00327	-0.3	-0.19	Schizophrenia;	chr1:186393069	chr1:186435161~186470291:+
THCA	cis	rs10043228	1	rs17138917	ENSG00000248445.4	SEMA6A-AS1	-4.17	3.68e-05	0.00327	-0.25	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116133619	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs9326989	ENSG00000248445.4	SEMA6A-AS1	-4.17	3.68e-05	0.00327	-0.25	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116137594	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs9326990	ENSG00000248445.4	SEMA6A-AS1	-4.17	3.68e-05	0.00327	-0.25	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116138797	chr5:116447547~116508276:+
THCA	cis	rs2274136	1	rs9350052	ENSG00000272269.1	RP11-500C11.3	4.17	3.68e-05	0.00327	0.22	0.19	Obesity-related traits;	chr6:17663941	chr6:17706257~17707344:+
THCA	cis	rs9926296	0.568	rs7203907	ENSG00000274627.1	RP11-104N10.2	-4.17	3.68e-05	0.00327	-0.19	-0.19	Vitiligo;	chr16:89767366	chr16:89516797~89522217:+
THCA	cis	rs4763879	0.739	rs7310460	ENSG00000256673.1	RP11-599J14.2	4.17	3.68e-05	0.00327	0.23	0.19	Type 1 diabetes;	chr12:9688177	chr12:9398355~9414851:-
THCA	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	4.17	3.68e-05	0.00327	0.21	0.19	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
THCA	cis	rs7824557	0.545	rs2572380	ENSG00000206014.6	OR7E161P	4.17	3.68e-05	0.00327	0.22	0.19	Retinal vascular caliber;	chr8:11379968	chr8:11928597~11929563:-
THCA	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	4.17	3.68e-05	0.00327	0.21	0.19	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
THCA	cis	rs5758659	0.679	rs134870	ENSG00000227370.1	RP4-669P10.19	-4.17	3.68e-05	0.00327	-0.17	-0.19	Cognitive function;	chr22:42256311	chr22:42132543~42132998:+
THCA	cis	rs786425	0.683	rs12830927	ENSG00000270095.1	RP11-214K3.18	-4.17	3.68e-05	0.00327	-0.23	-0.19	Pubertal anthropometrics;	chr12:123636444	chr12:123971457~123971714:-
THCA	cis	rs7520050	0.778	rs2991985	ENSG00000280836.1	AL355480.1	4.17	3.68e-05	0.00327	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45581219~45581321:-
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000182586.6	LINC00334	-4.17	3.68e-05	0.00327	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45234340~45258730:+
THCA	cis	rs10875746	0.855	rs10875731	ENSG00000258273.1	RP11-370I10.4	4.17	3.68e-05	0.00327	0.28	0.19	Longevity (90 years and older);	chr12:48038960	chr12:48333755~48333901:-
THCA	cis	rs7726354	0.793	rs73756780	ENSG00000271828.1	CTD-2310F14.1	4.17	3.68e-05	0.00328	0.46	0.19	Breast cancer (early onset);	chr5:56717971	chr5:56927874~56929573:+
THCA	cis	rs970548	0.643	rs12765320	ENSG00000230869.1	CTGLF10P	4.17	3.68e-05	0.00328	0.26	0.19	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435357	chr10:45678692~45700532:+
THCA	cis	rs7572733	0.534	rs1436131	ENSG00000231621.1	AC013264.2	-4.17	3.68e-05	0.00328	-0.2	-0.19	Dermatomyositis;	chr2:197866506	chr2:197197991~197199273:+
THCA	cis	rs2434529	1	rs73293374	ENSG00000245275.6	SAP30L-AS1	4.17	3.68e-05	0.00328	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154244486	chr5:154329437~154445850:-
THCA	cis	rs1129187	0.967	rs9462857	ENSG00000272223.1	RP1-20C7.6	4.17	3.68e-05	0.00328	0.14	0.19	Alzheimer's disease in APOE e4+ carriers;	chr6:42975360	chr6:43033897~43034405:-
THCA	cis	rs858239	0.601	rs10239760	ENSG00000230042.1	AK3P3	-4.17	3.68e-05	0.00328	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23129178~23129841:+
THCA	cis	rs4561483	0.583	rs17236573	ENSG00000263307.1	RP11-166B2.8	-4.17	3.68e-05	0.00328	-0.2	-0.19	Testicular germ cell tumor;	chr16:11900798	chr16:11851649~11895611:+
THCA	cis	rs10875746	0.855	rs12310999	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48053875	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs61918774	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48054351	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.807	rs12297004	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48060037	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs10875735	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48070023	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.855	rs17122620	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48070692	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.859	rs4760680	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48072914	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs11168386	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48074194	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.807	rs12313300	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48076934	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.903	rs12315625	ENSG00000258273.1	RP11-370I10.4	4.17	3.69e-05	0.00328	0.27	0.19	Longevity (90 years and older);	chr12:48078670	chr12:48333755~48333901:-
THCA	cis	rs7267979	0.718	rs2983489	ENSG00000277938.1	RP5-965G21.3	4.17	3.69e-05	0.00328	0.16	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25229150~25231933:+
THCA	cis	rs1387259	0.57	rs12368659	ENSG00000273765.1	RP11-370I10.11	4.17	3.69e-05	0.00328	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48360920~48361377:+
THCA	cis	rs61270009	0.955	rs16903057	ENSG00000247828.6	TMEM161B-AS1	4.17	3.69e-05	0.00328	0.17	0.19	Depressive symptoms;	chr5:88292603	chr5:88268895~88436685:+
THCA	cis	rs6570726	0.791	rs407887	ENSG00000270638.1	RP3-466P17.1	4.17	3.69e-05	0.00328	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.764	rs451108	ENSG00000270638.1	RP3-466P17.1	4.17	3.69e-05	0.00328	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145735570~145737218:+
THCA	cis	rs6500602	0.527	rs13338333	ENSG00000280063.1	RP11-295D4.3	4.17	3.69e-05	0.00328	0.12	0.19	Schizophrenia;	chr16:4393249	chr16:4346694~4348648:-
THCA	cis	rs950169	0.922	rs11631096	ENSG00000188388.10	GOLGA6L3	4.17	3.69e-05	0.00328	0.25	0.19	Schizophrenia;	chr15:84557698	chr15:85240472~85247170:+
THCA	cis	rs600231	0.708	rs682845	ENSG00000254614.2	AP003068.23	4.17	3.69e-05	0.00328	0.24	0.19	Bone mineral density;	chr11:65486730	chr11:65177606~65181834:-
THCA	cis	rs854765	0.693	rs11657074	ENSG00000281749.1	Y_RNA	-4.17	3.69e-05	0.00328	-0.24	-0.19	Total body bone mineral density;	chr17:17867041	chr17:18001101~18001195:-
THCA	cis	rs854765	0.693	rs9907246	ENSG00000281749.1	Y_RNA	-4.17	3.69e-05	0.00328	-0.24	-0.19	Total body bone mineral density;	chr17:17867651	chr17:18001101~18001195:-
THCA	cis	rs6012564	0.893	rs6019516	ENSG00000227431.4	CSE1L-AS1	-4.17	3.69e-05	0.00328	-0.24	-0.19	Anger;	chr20:48913613	chr20:49040463~49046044:-
THCA	cis	rs7045881	0.8	rs62544435	ENSG00000254396.1	RP11-56F10.3	4.17	3.69e-05	0.00328	0.34	0.19	Schizophrenia;	chr9:26900096	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.8	rs10511792	ENSG00000254396.1	RP11-56F10.3	4.17	3.69e-05	0.00328	0.34	0.19	Schizophrenia;	chr9:26901070	chr9:27102630~27104728:+
THCA	cis	rs11673344	0.542	rs826331	ENSG00000267260.1	CTD-2162K18.4	-4.17	3.69e-05	0.00328	-0.22	-0.19	Obesity-related traits;	chr19:37007360	chr19:36773153~36777078:+
THCA	cis	rs1923243	0.589	rs11210159	ENSG00000223479.3	RP4-788P17.1	4.17	3.69e-05	0.00328	0.21	0.19	Migraine;	chr1:73161542	chr1:73635216~73715214:+
THCA	cis	rs16975963	0.843	rs60731897	ENSG00000226686.6	LINC01535	-4.17	3.69e-05	0.00328	-0.26	-0.19	Longevity;	chr19:37778619	chr19:37251912~37265535:+
THCA	cis	rs7819412	0.745	rs4841498	ENSG00000261451.1	RP11-981G7.1	-4.17	3.69e-05	0.00328	-0.24	-0.19	Triglycerides;	chr8:11127922	chr8:10433672~10438312:+
THCA	cis	rs2657294	0.796	rs1259499	ENSG00000233313.2	HMGA1P5	-4.17	3.69e-05	0.00328	-0.25	-0.19	Pneumonia;	chr10:75228308	chr10:75276376~75276646:-
THCA	cis	rs7959452	0.64	rs11177599	ENSG00000274979.1	RP11-1143G9.5	-4.17	3.69e-05	0.00328	-0.2	-0.19	Blood protein levels;	chr12:69328190	chr12:69326574~69331882:-
THCA	cis	rs10851478	0.54	rs16962440	ENSG00000276593.1	RP11-295H24.5	-4.17	3.69e-05	0.00328	-0.21	-0.19	Oral cavity cancer;	chr15:49424648	chr15:49353485~49354034:+
THCA	cis	rs12893668	0.616	rs58033365	ENSG00000252469.1	RNU7-160P	4.17	3.69e-05	0.00328	0.23	0.19	Reticulocyte count;	chr14:103564564	chr14:103550345~103550406:+
THCA	cis	rs12893668	0.645	rs12889403	ENSG00000252469.1	RNU7-160P	4.17	3.69e-05	0.00328	0.23	0.19	Reticulocyte count;	chr14:103568409	chr14:103550345~103550406:+
THCA	cis	rs12893668	0.703	rs12894729	ENSG00000252469.1	RNU7-160P	4.17	3.69e-05	0.00328	0.23	0.19	Reticulocyte count;	chr14:103568955	chr14:103550345~103550406:+
THCA	cis	rs6701713	1	rs6701713	ENSG00000274245.1	RP11-357P18.2	-4.17	3.69e-05	0.00328	-0.21	-0.19	Alzheimer's disease (late onset);	chr1:207612944	chr1:207372559~207373252:+
THCA	cis	rs6701713	0.96	rs2093760	ENSG00000274245.1	RP11-357P18.2	-4.17	3.69e-05	0.00328	-0.21	-0.19	Alzheimer's disease (late onset);	chr1:207613483	chr1:207372559~207373252:+
THCA	cis	rs8031584	0.918	rs35396566	ENSG00000178081.11	ULK4P3	4.17	3.69e-05	0.00328	0.26	0.19	Huntington's disease progression;	chr15:30970854	chr15:30103720~30131757:+
THCA	cis	rs8031584	1	rs35607976	ENSG00000178081.11	ULK4P3	4.17	3.69e-05	0.00328	0.26	0.19	Huntington's disease progression;	chr15:30985585	chr15:30103720~30131757:+
THCA	cis	rs75828804	0.826	rs277506	ENSG00000260922.1	RP11-538I12.3	-4.17	3.69e-05	0.00328	-0.39	-0.19	Intraocular pressure;	chr16:77510543	chr16:77234877~77290934:+
THCA	cis	rs459571	0.959	rs2073818	ENSG00000235106.7	LINC00094	4.17	3.69e-05	0.00329	0.17	0.19	Platelet distribution width;	chr9:134053540	chr9:134025439~134034666:+
THCA	cis	rs2286503	0.839	rs4722189	ENSG00000226329.2	AC005682.6	4.17	3.69e-05	0.00329	0.23	0.19	Fibrinogen;	chr7:22820855	chr7:22863874~22881350:-
THCA	cis	rs758324	0.648	rs152126	ENSG00000224431.1	AC063976.7	-4.17	3.7e-05	0.00329	-0.17	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132047974	chr5:132199456~132203487:+
THCA	cis	rs34421088	0.506	rs2117616	ENSG00000154316.13	TDH	4.17	3.7e-05	0.00329	0.15	0.19	Neuroticism;	chr8:11288402	chr8:11339637~11368452:+
THCA	cis	rs3892630	0.588	rs7260037	ENSG00000267475.1	CTD-2538C1.2	-4.17	3.7e-05	0.00329	-0.26	-0.19	Red blood cell traits;	chr19:32751795	chr19:32687089~32691750:-
THCA	cis	rs3892630	0.588	rs7245709	ENSG00000267475.1	CTD-2538C1.2	-4.17	3.7e-05	0.00329	-0.26	-0.19	Red blood cell traits;	chr19:32751849	chr19:32687089~32691750:-
THCA	cis	rs7829975	0.501	rs2980769	ENSG00000233609.3	RP11-62H7.2	4.17	3.7e-05	0.00329	0.18	0.19	Mood instability;	chr8:8462781	chr8:8961200~8979025:+
THCA	cis	rs6840360	0.608	rs2724556	ENSG00000270265.1	RP11-731D1.4	-4.17	3.7e-05	0.00329	-0.18	-0.19	Intelligence (multi-trait analysis);	chr4:151420565	chr4:151333775~151353224:-
THCA	cis	rs12143943	0.866	rs3789051	ENSG00000240219.1	RP11-430C7.5	4.17	3.7e-05	0.00329	0.16	0.19	Cognitive performance;	chr1:204525308	chr1:204626775~204629712:+
THCA	cis	rs12143943	0.866	rs4252713	ENSG00000240219.1	RP11-430C7.5	4.17	3.7e-05	0.00329	0.16	0.19	Cognitive performance;	chr1:204541400	chr1:204626775~204629712:+
THCA	cis	rs7899106	1	rs76636418	ENSG00000270002.1	RP11-93H12.4	4.17	3.7e-05	0.00329	0.33	0.19	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85599678	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs75071083	ENSG00000270002.1	RP11-93H12.4	4.17	3.7e-05	0.00329	0.33	0.19	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85601298	chr10:85644073~85648066:+
THCA	cis	rs10483853	0.806	rs28653374	ENSG00000258695.2	RP3-414A15.2	-4.17	3.7e-05	0.00329	-0.26	-0.19	Coronary artery calcification;	chr14:73362103	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.806	rs11159014	ENSG00000258695.2	RP3-414A15.2	-4.17	3.7e-05	0.00329	-0.26	-0.19	Coronary artery calcification;	chr14:73363814	chr14:73522878~73530610:+
THCA	cis	rs2777491	0.957	rs6493002	ENSG00000247556.5	OIP5-AS1	4.17	3.7e-05	0.00329	0.16	0.19	Ulcerative colitis;	chr15:41416997	chr15:41283990~41309737:+
THCA	cis	rs17074492	0.585	rs9574938	ENSG00000214182.5	PTMAP5	4.17	3.7e-05	0.00329	0.24	0.19	Sjögren's syndrome;	chr13:81649447	chr13:81689911~81691072:+
THCA	cis	rs10946940	0.965	rs4713112	ENSG00000216915.2	RP1-97D16.1	4.17	3.7e-05	0.00329	0.25	0.19	Systemic lupus erythematosus;	chr6:27549054	chr6:27737000~27738494:-
THCA	cis	rs253959	0.523	rs785367	ENSG00000250015.1	CTC-339F2.2	-4.17	3.7e-05	0.00329	-0.16	-0.19	Bipolar disorder and schizophrenia;	chr5:116308359	chr5:116302354~116304134:-
THCA	cis	rs6840360	0.573	rs6810430	ENSG00000251611.1	RP11-610P16.1	-4.17	3.7e-05	0.00329	-0.13	-0.19	Intelligence (multi-trait analysis);	chr4:151338607	chr4:151407551~151408835:-
THCA	cis	rs2018683	0.707	rs4719961	ENSG00000272568.4	CTB-113D17.1	4.17	3.7e-05	0.00329	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929896	chr7:28979967~29013367:+
THCA	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	4.17	3.7e-05	0.00329	0.22	0.19	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
THCA	cis	rs4700393	0.517	rs13158594	ENSG00000272308.1	RP11-231G3.1	4.17	3.7e-05	0.00329	0.22	0.19	Intelligence (multi-trait analysis);	chr5:60794183	chr5:60866457~60866935:-
THCA	cis	rs6494488	0.5	rs72741332	ENSG00000259635.1	AC100830.3	-4.17	3.7e-05	0.00329	-0.49	-0.19	Coronary artery disease;	chr15:64452591	chr15:64701248~64719602:+
THCA	cis	rs143663961	1	rs143663961	ENSG00000263531.1	RP13-753N3.1	-4.17	3.7e-05	0.00329	-0.27	-0.19	Invasive epithelial ovarian cancer;	chr17:30854207	chr17:30863921~30864940:-
THCA	cis	rs972578	1	rs4822241	ENSG00000230319.1	AL022476.2	4.17	3.7e-05	0.00329	0.2	0.19	Mean platelet volume;	chr22:42973343	chr22:43038585~43052366:+
THCA	cis	rs8014252	1	rs114864695	ENSG00000259158.2	ADAM20P1	-4.17	3.7e-05	0.00329	-0.22	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70458238	chr14:70468881~70483756:-
THCA	cis	rs10792320	0.619	rs17633020	ENSG00000279491.1	RP11-810P12.7	-4.17	3.7e-05	0.00329	-0.23	-0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61977409	chr11:61967794~61969490:+
THCA	cis	rs67340775	0.541	rs200965	ENSG00000220721.1	OR1F12	4.17	3.7e-05	0.00329	0.29	0.19	Lung cancer in ever smokers;	chr6:27898606	chr6:28073316~28074233:+
THCA	cis	rs2018683	0.677	rs12540529	ENSG00000272568.4	CTB-113D17.1	4.17	3.7e-05	0.00329	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929767	chr7:28979967~29013367:+
THCA	cis	rs1023500	0.505	rs134891	ENSG00000233903.2	Z83851.4	4.17	3.7e-05	0.00329	0.23	0.19	Schizophrenia;	chr22:42279876	chr22:42276355~42277052:+
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000182586.6	LINC00334	-4.17	3.7e-05	0.00329	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45234340~45258730:+
THCA	cis	rs1371614	0.531	rs77562583	ENSG00000272148.1	RP11-195B17.1	4.17	3.7e-05	0.00329	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928775	chr2:27062428~27062907:-
THCA	cis	rs7131987	0.527	rs7308534	ENSG00000275476.1	RP11-996F15.4	4.17	3.71e-05	0.00329	0.19	0.19	QT interval;	chr12:29300269	chr12:29277397~29277882:-
THCA	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	4.16	3.71e-05	0.00329	0.22	0.19	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
THCA	cis	rs4787951	0.754	rs2072130	ENSG00000259940.2	CTD-3203P2.1	-4.16	3.71e-05	0.00329	-0.21	-0.19	Eosinophil percentage of white cells;	chr16:27345077	chr16:27213308~27214993:-
THCA	cis	rs564343	0.563	rs574335	ENSG00000255320.1	RP11-755F10.1	4.16	3.71e-05	0.00329	0.23	0.19	Obesity (early onset extreme);	chr11:66065795	chr11:66244840~66246239:-
THCA	cis	rs853679	0.882	rs4713139	ENSG00000273712.1	RP5-874C20.7	4.16	3.71e-05	0.00329	0.32	0.19	Depression;	chr6:28124907	chr6:28315613~28315883:-
THCA	cis	rs17801127	0.818	rs13023298	ENSG00000231969.1	AC144449.1	4.16	3.71e-05	0.0033	0.32	0.19	Liver enzyme levels (alanine transaminase);	chr2:149680521	chr2:149587196~149848233:+
THCA	cis	rs17801127	1	rs13014503	ENSG00000231969.1	AC144449.1	4.16	3.71e-05	0.0033	0.32	0.19	Liver enzyme levels (alanine transaminase);	chr2:149684562	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.901	rs71413658	ENSG00000231969.1	AC144449.1	4.16	3.71e-05	0.0033	0.32	0.19	Liver enzyme levels (alanine transaminase);	chr2:149685661	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.901	rs12233106	ENSG00000231969.1	AC144449.1	4.16	3.71e-05	0.0033	0.32	0.19	Liver enzyme levels (alanine transaminase);	chr2:149687521	chr2:149587196~149848233:+
THCA	cis	rs7674212	0.531	rs6816370	ENSG00000248971.2	KRT8P46	-4.16	3.71e-05	0.0033	-0.23	-0.19	Type 2 diabetes;	chr4:103018276	chr4:102728746~102730171:-
THCA	cis	rs5758511	0.508	rs28715885	ENSG00000237037.8	NDUFA6-AS1	-4.16	3.71e-05	0.0033	-0.2	-0.19	Birth weight;	chr22:42045087	chr22:42090931~42137742:+
THCA	cis	rs5758511	0.508	rs58099562	ENSG00000237037.8	NDUFA6-AS1	-4.16	3.71e-05	0.0033	-0.2	-0.19	Birth weight;	chr22:42057768	chr22:42090931~42137742:+
THCA	cis	rs6472235	0.564	rs62506650	ENSG00000272010.1	CTD-3025N20.3	-4.16	3.71e-05	0.0033	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:66004267	chr8:65591850~65592472:-
THCA	cis	rs6472235	0.586	rs11984602	ENSG00000272010.1	CTD-3025N20.3	-4.16	3.71e-05	0.0033	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:66004338	chr8:65591850~65592472:-
THCA	cis	rs6472235	0.586	rs7812439	ENSG00000272010.1	CTD-3025N20.3	-4.16	3.71e-05	0.0033	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:66005465	chr8:65591850~65592472:-
THCA	cis	rs6472235	0.586	rs950729	ENSG00000272010.1	CTD-3025N20.3	-4.16	3.71e-05	0.0033	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:66005518	chr8:65591850~65592472:-
THCA	cis	rs6472235	0.586	rs2357570	ENSG00000272010.1	CTD-3025N20.3	-4.16	3.71e-05	0.0033	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:66005760	chr8:65591850~65592472:-
THCA	cis	rs6472235	0.586	rs4565445	ENSG00000272010.1	CTD-3025N20.3	4.16	3.71e-05	0.0033	0.2	0.19	Plateletcrit;Myopia (pathological);	chr8:66005841	chr8:65591850~65592472:-
THCA	cis	rs860295	0.557	rs10796944	ENSG00000236675.1	MTX1P1	-4.16	3.71e-05	0.0033	-0.21	-0.19	Body mass index;	chr1:155446537	chr1:155230975~155234325:+
THCA	cis	rs1728785	0.901	rs1170444	ENSG00000274698.1	RP11-71L14.4	4.16	3.71e-05	0.0033	0.26	0.19	Ulcerative colitis;	chr16:68539384	chr16:68450283~68452318:+
THCA	cis	rs1728785	1	rs1170443	ENSG00000274698.1	RP11-71L14.4	4.16	3.71e-05	0.0033	0.26	0.19	Ulcerative colitis;	chr16:68539392	chr16:68450283~68452318:+
THCA	cis	rs758324	0.645	rs247317	ENSG00000224431.1	AC063976.7	-4.16	3.71e-05	0.0033	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132106612	chr5:132199456~132203487:+
THCA	cis	rs656319	0.513	rs6985941	ENSG00000261451.1	RP11-981G7.1	-4.16	3.71e-05	0.0033	-0.24	-0.19	Myopia (pathological);	chr8:10125669	chr8:10433672~10438312:+
THCA	cis	rs13434995	0.635	rs1818461	ENSG00000249700.7	SRD5A3-AS1	-4.16	3.71e-05	0.0033	-0.28	-0.19	Adiponectin levels;	chr4:55379156	chr4:55363971~55395847:-
THCA	cis	rs9928842	0.882	rs9927264	ENSG00000261783.1	RP11-252K23.2	4.16	3.71e-05	0.0033	0.36	0.19	Alcoholic chronic pancreatitis;	chr16:75226343	chr16:75379818~75381260:-
THCA	cis	rs1383484	0.798	rs7179241	ENSG00000225151.9	GOLGA2P7	4.16	3.71e-05	0.0033	0.26	0.19	Height;	chr15:83882959	chr15:84199311~84230136:-
THCA	cis	rs9341808	0.935	rs2298307	ENSG00000272129.1	RP11-250B2.6	4.16	3.71e-05	0.0033	0.23	0.19	Sitting height ratio;	chr6:80106579	chr6:80355424~80356859:+
THCA	cis	rs4950322	0.518	rs61838951	ENSG00000226015.2	CCT8P1	4.16	3.71e-05	0.0033	0.22	0.19	Protein quantitative trait loci;	chr1:147116081	chr1:147203276~147204932:-
THCA	cis	rs6427356	1	rs1176555	ENSG00000237189.1	RP11-85G21.2	-4.16	3.71e-05	0.0033	-0.2	-0.19	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157166750	chr1:157287703~157288053:-
THCA	cis	rs9393777	0.777	rs35984974	ENSG00000272009.1	RP1-313I6.12	-4.16	3.71e-05	0.0033	-0.3	-0.19	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28078792~28081130:-
THCA	cis	rs7551222	0.752	rs2290854	ENSG00000240219.1	RP11-430C7.5	4.16	3.71e-05	0.0033	0.18	0.19	Schizophrenia;	chr1:204546897	chr1:204626775~204629712:+
THCA	cis	rs1200821	0.559	rs9418267	ENSG00000263064.2	RP11-291L22.7	-4.16	3.71e-05	0.0033	-0.21	-0.19	Hemostatic factors and hematological phenotypes;	chr10:37531023	chr10:38448689~38448949:+
THCA	cis	rs365302	0.868	rs381639	ENSG00000235086.1	FNDC1-IT1	-4.16	3.71e-05	0.0033	-0.26	-0.19	Coronary heart disease;	chr6:159232603	chr6:159240786~159243329:+
THCA	cis	rs755249	0.727	rs16826349	ENSG00000237624.1	OXCT2P1	4.16	3.71e-05	0.0033	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39514956~39516490:+
THCA	cis	rs13064773	0.51	rs340280	ENSG00000279311.1	RP11-170K4.2	4.16	3.71e-05	0.0033	0.26	0.19	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158867742	chr3:158869898~158871821:+
THCA	cis	rs10435719	0.753	rs9694940	ENSG00000206014.6	OR7E161P	-4.16	3.71e-05	0.0033	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:11928597~11929563:-
THCA	cis	rs853679	0.527	rs853690	ENSG00000176933.5	TOB2P1	-4.16	3.72e-05	0.0033	-0.21	-0.19	Depression;	chr6:28317705	chr6:28217643~28218634:-
THCA	cis	rs4805272	0.962	rs2042192	ENSG00000267799.1	MAN1A2P1	4.16	3.72e-05	0.0033	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830169	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.962	rs2042191	ENSG00000267799.1	MAN1A2P1	4.16	3.72e-05	0.0033	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830173	chr19:28790812~28792871:-
THCA	cis	rs6138458	0.961	rs11700073	ENSG00000274173.1	RP4-568C11.4	4.16	3.72e-05	0.0033	0.18	0.19	Blood protein levels;	chr20:24994579	chr20:24931840~24932983:+
THCA	cis	rs853679	0.607	rs13194781	ENSG00000220721.1	OR1F12	4.16	3.72e-05	0.0033	0.42	0.19	Depression;	chr6:27847861	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs36116761	ENSG00000220721.1	OR1F12	4.16	3.72e-05	0.0033	0.42	0.19	Depression;	chr6:27850704	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs34194357	ENSG00000220721.1	OR1F12	4.16	3.72e-05	0.0033	0.42	0.19	Depression;	chr6:27850757	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13199772	ENSG00000220721.1	OR1F12	4.16	3.72e-05	0.0033	0.42	0.19	Depression;	chr6:27866307	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13199906	ENSG00000220721.1	OR1F12	4.16	3.72e-05	0.0033	0.42	0.19	Depression;	chr6:27866361	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs17763089	ENSG00000220721.1	OR1F12	4.16	3.72e-05	0.0033	0.42	0.19	Depression;	chr6:27867440	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs17695758	ENSG00000220721.1	OR1F12	4.16	3.72e-05	0.0033	0.42	0.19	Depression;	chr6:27869405	chr6:28073316~28074233:+
THCA	cis	rs57502260	0.704	rs2306862	ENSG00000212093.1	AP000807.1	4.16	3.72e-05	0.0033	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68410042	chr11:68506083~68506166:-
THCA	cis	rs6433895	0.677	rs111242075	ENSG00000236153.1	AC104076.3	-4.16	3.72e-05	0.0033	-0.23	-0.19	Lymphocyte counts;	chr2:181162212	chr2:180979427~180980090:-
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000265443.1	CTD-2349P21.6	-4.16	3.72e-05	0.0033	-0.32	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30726305~30727564:-
THCA	cis	rs12534093	1	rs12534093	ENSG00000234286.1	AC006026.13	-4.16	3.72e-05	0.0033	-0.29	-0.19	Infant length;Height;	chr7:23463355	chr7:23680195~23680786:-
THCA	cis	rs1577917	0.682	rs1173419	ENSG00000220563.1	PKMP3	-4.16	3.72e-05	0.0033	-0.13	-0.19	Response to antipsychotic treatment;	chr6:85692445	chr6:85659892~85660606:-
THCA	cis	rs1150668	1	rs1150668	ENSG00000220721.1	OR1F12	4.16	3.72e-05	0.0033	0.21	0.19	Pubertal anthropometrics;	chr6:28162011	chr6:28073316~28074233:+
THCA	cis	rs6921919	0.697	rs6942030	ENSG00000273712.1	RP5-874C20.7	4.16	3.72e-05	0.0033	0.22	0.19	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28315613~28315883:-
THCA	cis	rs8002861	0.747	rs12866387	ENSG00000274001.1	RP11-5G9.5	4.16	3.72e-05	0.0033	0.22	0.19	Leprosy;	chr13:43817800	chr13:43877715~43878163:-
THCA	cis	rs7824557	0.569	rs2409718	ENSG00000254866.2	DEFB109P3	4.16	3.72e-05	0.0033	0.26	0.19	Retinal vascular caliber;	chr8:11155467	chr8:12150895~12151134:-
THCA	cis	rs2251188	0.609	rs2249765	ENSG00000187953.9	PMS2CL	-4.16	3.72e-05	0.0033	-0.2	-0.19	Sum basophil neutrophil counts;Neutrophil count;	chr7:6654628	chr7:6710128~6753862:+
THCA	cis	rs7208859	0.623	rs122898	ENSG00000265443.1	CTD-2349P21.6	4.16	3.72e-05	0.0033	0.33	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30726305~30727564:-
THCA	cis	rs9534288	0.912	rs3736944	ENSG00000235903.6	CPB2-AS1	4.16	3.72e-05	0.00331	0.27	0.19	Blood protein levels;	chr13:46045181	chr13:46052806~46113332:+
THCA	cis	rs4591358	0.705	rs7585547	ENSG00000223466.1	AC064834.2	4.16	3.72e-05	0.00331	0.22	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195424335	chr2:195533035~195538681:+
THCA	cis	rs8031584	0.958	rs11293	ENSG00000270015.1	RP11-540B6.6	-4.16	3.72e-05	0.00331	-0.14	-0.19	Huntington's disease progression;	chr15:30942778	chr15:30926514~30928407:+
THCA	cis	rs2688608	0.967	rs1815076	ENSG00000271816.1	BMS1P4	4.16	3.72e-05	0.00331	0.18	0.19	Inflammatory bowel disease;	chr10:73900128	chr10:73699151~73730487:-
THCA	cis	rs17221829	0.733	rs11018688	ENSG00000280385.1	AP000648.5	-4.16	3.72e-05	0.00331	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89633656	chr11:90193614~90198120:+
THCA	cis	rs9868809	0.772	rs28452701	ENSG00000270441.1	RP11-694I15.7	4.16	3.72e-05	0.00331	0.25	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48671142	chr3:49140086~49160851:-
THCA	cis	rs7826238	0.539	rs2945891	ENSG00000248538.5	RP11-10A14.5	-4.16	3.72e-05	0.00331	-0.23	-0.19	Systolic blood pressure;	chr8:8297953	chr8:9189011~9202854:+
THCA	cis	rs12142240	0.638	rs6662982	ENSG00000232022.5	FAAHP1	-4.16	3.72e-05	0.00331	-0.22	-0.19	Menopause (age at onset);	chr1:46411508	chr1:46432129~46445521:+
THCA	cis	rs2075824	1	rs694509	ENSG00000267079.1	RP11-820I16.1	4.16	3.72e-05	0.00331	0.24	0.19	Obsessive-compulsive disorder or autism spectrum disorder;	chr18:11975254	chr18:11910634~11914344:-
THCA	cis	rs4356203	0.87	rs214901	ENSG00000272034.1	SNORD14A	4.16	3.72e-05	0.00331	0.19	0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206181	chr11:17074654~17074744:-
THCA	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	4.16	3.72e-05	0.00331	0.2	0.19	Asthma;	chr2:102446466	chr2:102438713~102440475:+
THCA	cis	rs8067545	0.75	rs11869616	ENSG00000270091.1	RP11-78O7.2	-4.16	3.72e-05	0.00331	-0.14	-0.19	Schizophrenia;	chr17:20089400	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs11868084	ENSG00000270091.1	RP11-78O7.2	-4.16	3.72e-05	0.00331	-0.14	-0.19	Schizophrenia;	chr17:20089404	chr17:19896590~19897287:-
THCA	cis	rs8067545	0.75	rs11870111	ENSG00000270091.1	RP11-78O7.2	-4.16	3.72e-05	0.00331	-0.14	-0.19	Schizophrenia;	chr17:20089425	chr17:19896590~19897287:-
THCA	cis	rs910873	1	rs62211619	ENSG00000269202.1	RP4-614O4.12	-4.16	3.73e-05	0.00331	-0.35	-0.19	Melanoma;	chr20:34823128	chr20:35201747~35203288:-
THCA	cis	rs910873	0.803	rs62211621	ENSG00000269202.1	RP4-614O4.12	-4.16	3.73e-05	0.00331	-0.35	-0.19	Melanoma;	chr20:34823858	chr20:35201747~35203288:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000231226.1	TRIM31-AS1	-4.16	3.73e-05	0.00331	-0.29	-0.19	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30105240~30114724:+
THCA	cis	rs7824557	0.564	rs2572389	ENSG00000206014.6	OR7E161P	4.16	3.73e-05	0.00331	0.22	0.19	Retinal vascular caliber;	chr8:11378883	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs2736301	ENSG00000206014.6	OR7E161P	4.16	3.73e-05	0.00331	0.22	0.19	Retinal vascular caliber;	chr8:11378904	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs2736302	ENSG00000206014.6	OR7E161P	4.16	3.73e-05	0.00331	0.22	0.19	Retinal vascular caliber;	chr8:11378910	chr8:11928597~11929563:-
THCA	cis	rs3808502	0.647	rs7821302	ENSG00000206014.6	OR7E161P	4.16	3.73e-05	0.00331	0.22	0.19	Neuroticism;	chr8:11379063	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs7821459	ENSG00000206014.6	OR7E161P	4.16	3.73e-05	0.00331	0.22	0.19	Retinal vascular caliber;	chr8:11379172	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs7834572	ENSG00000206014.6	OR7E161P	4.16	3.73e-05	0.00331	0.22	0.19	Retinal vascular caliber;	chr8:11379176	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs4631424	ENSG00000206014.6	OR7E161P	4.16	3.73e-05	0.00331	0.22	0.19	Retinal vascular caliber;	chr8:11379300	chr8:11928597~11929563:-
THCA	cis	rs2134046	0.555	rs11854483	ENSG00000255769.6	GOLGA2P10	-4.16	3.73e-05	0.00331	-0.22	-0.19	Cognitive ability;	chr15:82267217	chr15:82472993~82513950:-
THCA	cis	rs801193	1	rs2055682	ENSG00000272831.1	RP11-792A8.4	4.16	3.73e-05	0.00331	0.12	0.19	Aortic root size;	chr7:66795302	chr7:66739829~66740385:-
THCA	cis	rs7647973	0.696	rs7100	ENSG00000228638.1	FCF1P2	-4.16	3.73e-05	0.00331	-0.23	-0.19	Menarche (age at onset);	chr3:49015786	chr3:48290793~48291375:-
THCA	cis	rs1728785	1	rs3203684	ENSG00000274698.1	RP11-71L14.4	-4.16	3.73e-05	0.00331	-0.26	-0.19	Ulcerative colitis;	chr16:68566537	chr16:68450283~68452318:+
THCA	cis	rs7267979	0.527	rs6083891	ENSG00000274414.1	RP5-965G21.4	4.16	3.73e-05	0.00331	0.23	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:25239007~25245229:-
THCA	cis	rs786425	0.711	rs1515815	ENSG00000270095.1	RP11-214K3.18	-4.16	3.73e-05	0.00331	-0.23	-0.19	Pubertal anthropometrics;	chr12:123627452	chr12:123971457~123971714:-
THCA	cis	rs6832769	0.922	rs501679	ENSG00000272969.1	RP11-528I4.2	4.16	3.73e-05	0.00331	0.22	0.19	Personality dimensions;	chr4:55371160	chr4:55547112~55547889:+
THCA	cis	rs2153535	0.585	rs9405400	ENSG00000230939.1	RP11-314C16.1	-4.16	3.73e-05	0.00331	-0.2	-0.19	Motion sickness;	chr6:8606895	chr6:8784178~8785445:+
THCA	cis	rs1023500	0.573	rs2413666	ENSG00000273366.1	CTA-989H11.1	-4.16	3.73e-05	0.00331	-0.24	-0.19	Schizophrenia;	chr22:42063618	chr22:42278188~42278846:+
THCA	cis	rs7045881	0.8	rs17694087	ENSG00000254396.1	RP11-56F10.3	4.16	3.73e-05	0.00331	0.34	0.19	Schizophrenia;	chr9:26839503	chr9:27102630~27104728:+
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000182586.6	LINC00334	-4.16	3.73e-05	0.00331	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45234340~45258730:+
THCA	cis	rs9902453	0.765	rs62068653	ENSG00000263370.1	RP11-68I3.5	4.16	3.73e-05	0.00331	0.24	0.19	Coffee consumption (cups per day);	chr17:29885645	chr17:29639627~29640825:+
THCA	cis	rs710913	0.717	rs11206377	ENSG00000182109.6	RP11-69E11.4	4.16	3.73e-05	0.00331	0.17	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39522280~39546187:-
THCA	cis	rs1043595	1	rs1043595	ENSG00000271553.1	RP11-274B21.10	4.16	3.73e-05	0.00331	0.19	0.19	Intelligence (multi-trait analysis);	chr7:128769958	chr7:128667043~128668156:+
THCA	cis	rs7074356	0.915	rs17680103	ENSG00000242600.5	MBL1P	4.16	3.73e-05	0.00331	0.24	0.19	Borderline personality disorder;	chr10:80447862	chr10:79904898~79950336:+
THCA	cis	rs7260598	0.539	rs77931611	ENSG00000268442.1	CTD-2027I19.2	4.16	3.73e-05	0.00331	0.28	0.19	Response to taxane treatment (placlitaxel);	chr19:23834800	chr19:24162370~24163425:-
THCA	cis	rs8067545	0.75	rs4924803	ENSG00000270091.1	RP11-78O7.2	-4.16	3.73e-05	0.00331	-0.14	-0.19	Schizophrenia;	chr17:20088493	chr17:19896590~19897287:-
THCA	cis	rs17270561	0.609	rs9467572	ENSG00000272462.2	U91328.19	4.16	3.73e-05	0.00331	0.16	0.19	Iron status biomarkers;	chr6:25703898	chr6:25992662~26001775:+
THCA	cis	rs7131987	0.683	rs7954278	ENSG00000273680.1	RP11-996F15.6	4.16	3.73e-05	0.00331	0.26	0.19	QT interval;	chr12:29306357	chr12:29332733~29333383:-
THCA	cis	rs1232027	0.7	rs1650696	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80655461	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1650695	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80655563	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643641	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80655672	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1382539	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80656335	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1643639	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80656571	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1650694	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80656607	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677667	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80656722	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.666	rs1650693	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80657008	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1382541	ENSG00000249655.1	CTC-325J23.2	4.16	3.73e-05	0.00331	0.21	0.19	Huntington's disease progression;	chr5:80657665	chr5:80630313~80631590:-
THCA	cis	rs9532669	0.926	rs11147831	ENSG00000229473.2	RGS17P1	4.16	3.73e-05	0.00331	0.23	0.19	Cervical cancer;	chr13:40978593	chr13:40992779~40993331:-
THCA	cis	rs7824557	0.564	rs2572386	ENSG00000206014.6	OR7E161P	4.16	3.73e-05	0.00331	0.22	0.19	Retinal vascular caliber;	chr8:11379466	chr8:11928597~11929563:-
THCA	cis	rs875971	1	rs2420591	ENSG00000229886.1	RP5-1132H15.3	4.16	3.73e-05	0.00331	0.19	0.19	Aortic root size;	chr7:66447394	chr7:66025126~66031544:-
THCA	cis	rs1009077	0.61	rs6842674	ENSG00000245958.5	RP11-33B1.1	-4.16	3.73e-05	0.00331	-0.21	-0.19	Endometriosis;	chr4:119591353	chr4:119454791~119552025:+
THCA	cis	rs66823261	0.778	rs2906332	ENSG00000273402.1	RP5-855D21.2	4.16	3.73e-05	0.00332	0.2	0.19	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:237045~237669:+
THCA	cis	rs6138458	1	rs6138458	ENSG00000274173.1	RP4-568C11.4	4.16	3.73e-05	0.00332	0.18	0.19	Blood protein levels;	chr20:24993133	chr20:24931840~24932983:+
THCA	cis	rs786425	0.538	rs786452	ENSG00000278112.1	RP11-972P1.11	-4.16	3.73e-05	0.00332	-0.17	-0.19	Pubertal anthropometrics;	chr12:123572622	chr12:123519390~123519856:-
THCA	cis	rs970548	0.954	rs10900221	ENSG00000230869.1	CTGLF10P	4.16	3.73e-05	0.00332	0.23	0.19	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45493149	chr10:45678692~45700532:+
THCA	cis	rs2281636	0.823	rs4917877	ENSG00000233690.1	EBAG9P1	4.16	3.73e-05	0.00332	0.18	0.19	Obesity-related traits;	chr10:99670281	chr10:99697407~99697949:-
THCA	cis	rs4218	0.689	rs28391430	ENSG00000259732.1	RP11-59H7.3	-4.16	3.73e-05	0.00332	-0.26	-0.19	Social communication problems;	chr15:59100318	chr15:59121034~59133250:+
THCA	cis	rs1555322	0.818	rs2425021	ENSG00000126005.14	MMP24-AS1	-4.16	3.73e-05	0.00332	-0.25	-0.19	Attention deficit hyperactivity disorder;	chr20:35241975	chr20:35216462~35278131:-
THCA	cis	rs17270561	0.609	rs4711094	ENSG00000272462.2	U91328.19	-4.16	3.74e-05	0.00332	-0.16	-0.19	Iron status biomarkers;	chr6:25705946	chr6:25992662~26001775:+
THCA	cis	rs1552244	0.608	rs2075310	ENSG00000232901.1	CYCSP10	4.16	3.74e-05	0.00332	0.23	0.19	Alzheimer's disease;	chr3:10025967	chr3:10000647~10000940:-
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000176700.18	SCAND2P	-4.16	3.74e-05	0.00332	-0.12	-0.19	P wave terminal force;	chr15:84635039	chr15:84631451~84647478:+
THCA	cis	rs763121	0.853	rs138706	ENSG00000228274.3	RP3-508I15.9	-4.16	3.74e-05	0.00332	-0.21	-0.19	Menopause (age at onset);	chr22:38741829	chr22:38667585~38681820:-
THCA	cis	rs6671200	0.831	rs71654413	ENSG00000235501.4	RP4-639F20.1	-4.16	3.74e-05	0.00332	-0.39	-0.19	Stearic acid (18:0) levels;	chr1:95141532	chr1:94927566~94963270:+
THCA	cis	rs6540731	0.905	rs12028026	ENSG00000226251.4	RP11-15I11.3	-4.16	3.74e-05	0.00332	-0.23	-0.19	Intelligence (childhood);	chr1:212216793	chr1:212225278~212238977:-
THCA	cis	rs12493885	0.818	rs10935971	ENSG00000243069.6	ARHGEF26-AS1	-4.16	3.74e-05	0.00332	-0.36	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154056156	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.818	rs10935972	ENSG00000243069.6	ARHGEF26-AS1	-4.16	3.74e-05	0.00332	-0.36	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154056240	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.818	rs62276828	ENSG00000243069.6	ARHGEF26-AS1	-4.16	3.74e-05	0.00332	-0.36	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154058152	chr3:154024401~154121332:-
THCA	cis	rs17221829	0.626	rs10830340	ENSG00000280385.1	AP000648.5	-4.16	3.74e-05	0.00332	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89680682	chr11:90193614~90198120:+
THCA	cis	rs7824557	0.527	rs4634600	ENSG00000154316.13	TDH	4.16	3.74e-05	0.00332	0.14	0.19	Retinal vascular caliber;	chr8:11381508	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.527	rs4631425	ENSG00000154316.13	TDH	4.16	3.74e-05	0.00332	0.14	0.19	Retinal vascular caliber;	chr8:11381545	chr8:11339637~11368452:+
THCA	cis	rs3808502	0.585	rs4549730	ENSG00000154316.13	TDH	4.16	3.74e-05	0.00332	0.14	0.19	Neuroticism;	chr8:11381569	chr8:11339637~11368452:+
THCA	cis	rs2613964	0.504	rs3995917	ENSG00000240057.4	RP11-572M11.4	4.16	3.74e-05	0.00332	0.19	0.19	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133767	chr3:113019532~113183301:+
THCA	cis	rs4218	0.608	rs59282449	ENSG00000259732.1	RP11-59H7.3	-4.16	3.74e-05	0.00332	-0.26	-0.19	Social communication problems;	chr15:59078881	chr15:59121034~59133250:+
THCA	cis	rs10129255	0.957	rs1056705	ENSG00000211972.2	IGHV3-66	4.16	3.74e-05	0.00332	0.11	0.19	Kawasaki disease;	chr14:106714323	chr14:106675017~106675544:-
THCA	cis	rs8141529	0.509	rs12628211	ENSG00000272858.1	CTA-292E10.8	-4.16	3.74e-05	0.00332	-0.2	-0.19	Lymphocyte counts;	chr22:28843262	chr22:28814914~28815662:+
THCA	cis	rs11779988	0.516	rs426498	ENSG00000253671.1	RP11-806O11.1	-4.16	3.74e-05	0.00332	-0.24	-0.19	Breast cancer;	chr8:18039649	chr8:17808941~17820868:+
THCA	cis	rs1124769	0.57	rs1290084	ENSG00000273674.3	CTD-2378E12.1	-4.16	3.74e-05	0.00332	-0.25	-0.19	Cognitive performance;	chr15:50861748	chr15:50839875~50908599:-
THCA	cis	rs12534093	0.921	rs11763760	ENSG00000234286.1	AC006026.13	-4.16	3.74e-05	0.00332	-0.3	-0.19	Infant length;Height;	chr7:23440848	chr7:23680195~23680786:-
THCA	cis	rs6442522	0.966	rs6792128	ENSG00000249786.6	EAF1-AS1	4.16	3.74e-05	0.00332	0.2	0.19	Uric acid levels;	chr3:15417350	chr3:15436171~15455940:-
THCA	cis	rs7737355	1	rs27873	ENSG00000237714.1	P4HA2-AS1	-4.16	3.74e-05	0.00332	-0.27	-0.19	Life satisfaction;	chr5:131395458	chr5:132184876~132192808:+
THCA	cis	rs75920871	0.688	rs76972960	ENSG00000254851.1	RP11-109L13.1	-4.16	3.74e-05	0.00332	-0.41	-0.19	Subjective well-being;	chr11:117045962	chr11:117135528~117138582:+
THCA	cis	rs8002861	0.664	rs895266	ENSG00000274001.1	RP11-5G9.5	4.16	3.74e-05	0.00332	0.22	0.19	Leprosy;	chr13:43887043	chr13:43877715~43878163:-
THCA	cis	rs13256369	1	rs873064	ENSG00000254153.1	CTA-398F10.2	-4.16	3.74e-05	0.00332	-0.21	-0.19	Obesity-related traits;	chr8:8714870	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs4841016	ENSG00000254153.1	CTA-398F10.2	-4.16	3.74e-05	0.00332	-0.21	-0.19	Obesity-related traits;	chr8:8715051	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs10103769	ENSG00000254153.1	CTA-398F10.2	-4.16	3.74e-05	0.00332	-0.21	-0.19	Obesity-related traits;	chr8:8715526	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs4840352	ENSG00000254153.1	CTA-398F10.2	-4.16	3.74e-05	0.00332	-0.21	-0.19	Obesity-related traits;	chr8:8715998	chr8:8456909~8461337:-
THCA	cis	rs4718428	1	rs4718421	ENSG00000229180.5	GS1-124K5.11	4.16	3.74e-05	0.00332	0.13	0.19	Corneal structure;	chr7:66885313	chr7:66526088~66542624:-
THCA	cis	rs2342371	0.545	rs7646273	ENSG00000273013.1	CTD-2002J20.1	4.16	3.75e-05	0.00333	0.17	0.19	Fat distribution (HIV);	chr3:196484023	chr3:196474801~196475394:+
THCA	cis	rs801193	0.967	rs34356500	ENSG00000223473.2	GS1-124K5.3	4.16	3.75e-05	0.00333	0.12	0.19	Aortic root size;	chr7:66771620	chr7:66491049~66493566:-
THCA	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	4.16	3.75e-05	0.00333	0.17	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
THCA	cis	rs3924048	0.559	rs4075303	ENSG00000276830.1	MIR6730	-4.16	3.75e-05	0.00333	-0.18	-0.19	Optic cup area;	chr1:12566564	chr1:12578957~12579023:-
THCA	cis	rs3002142	0.818	rs3008604	ENSG00000272750.1	RP11-378J18.8	-4.16	3.75e-05	0.00333	-0.26	-0.19	LDL peak particle diameter (total fat intake interaction);	chr1:222609854	chr1:222658867~222661512:-
THCA	cis	rs9693857	0.52	rs7821875	ENSG00000248538.5	RP11-10A14.5	-4.16	3.75e-05	0.00333	-0.25	-0.19	Systolic blood pressure;	chr8:9501802	chr8:9189011~9202854:+
THCA	cis	rs7617480	0.648	rs6796790	ENSG00000228638.1	FCF1P2	-4.16	3.75e-05	0.00333	-0.23	-0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48742884	chr3:48290793~48291375:-
THCA	cis	rs4792901	0.959	rs72833148	ENSG00000267151.3	RP11-100E5.2	4.16	3.75e-05	0.00333	0.2	0.19	Dupuytren's disease;	chr17:43551795	chr17:43444707~43451200:+
THCA	cis	rs12439619	0.508	rs8042665	ENSG00000259429.4	UBE2Q2P2	-4.16	3.75e-05	0.00333	-0.15	-0.19	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82355142~82420075:+
THCA	cis	rs73193808	0.666	rs7276548	ENSG00000176054.6	RPL23P2	4.16	3.75e-05	0.00333	0.17	0.19	Coronary artery disease;	chr21:29180518	chr21:28997613~28998033:-
THCA	cis	rs11671005	0.779	rs11670125	ENSG00000268049.1	CTD-2619J13.9	-4.16	3.75e-05	0.00333	-0.3	-0.19	Mean platelet volume;	chr19:58476023	chr19:58357999~58359603:+
THCA	cis	rs4218	0.569	rs73418864	ENSG00000277144.1	RP11-59H7.4	-4.16	3.75e-05	0.00333	-0.26	-0.19	Social communication problems;	chr15:59098996	chr15:59115547~59116089:-
THCA	cis	rs2018683	0.677	rs55718000	ENSG00000272568.4	CTB-113D17.1	4.16	3.75e-05	0.00333	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936008	chr7:28979967~29013367:+
THCA	cis	rs9902453	0.904	rs12103671	ENSG00000263370.1	RP11-68I3.5	-4.16	3.75e-05	0.00333	-0.24	-0.19	Coffee consumption (cups per day);	chr17:30081199	chr17:29639627~29640825:+
THCA	cis	rs2436845	0.627	rs2570941	ENSG00000253320.4	KB-1507C5.2	-4.16	3.75e-05	0.00333	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102845253	chr8:102864300~102977876:+
THCA	cis	rs2436845	0.627	rs2679747	ENSG00000253320.4	KB-1507C5.2	-4.16	3.75e-05	0.00333	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102845886	chr8:102864300~102977876:+
THCA	cis	rs2380205	0.967	rs7072174	ENSG00000232807.2	RP11-536K7.3	4.16	3.75e-05	0.00333	0.17	0.19	Breast cancer;	chr10:5856839	chr10:5934270~5945900:-
THCA	cis	rs2281603	0.674	rs74883409	ENSG00000272909.1	CTD-2555O16.4	-4.16	3.75e-05	0.00333	-0.25	-0.19	Lymphocyte counts;	chr14:64594361	chr14:64440369~64442238:-
THCA	cis	rs8046148	0.694	rs12923219	ENSG00000279356.1	RP11-429P3.8	4.16	3.75e-05	0.00333	0.23	0.19	Testicular germ cell tumor;	chr16:50018305	chr16:50072862~50074986:+
THCA	cis	rs13325613	0.834	rs13062450	ENSG00000223552.1	RP11-24F11.2	-4.16	3.75e-05	0.00333	-0.29	-0.19	Monocyte count;	chr3:46185679	chr3:46364955~46407059:-
THCA	cis	rs9902453	0.904	rs10853136	ENSG00000263370.1	RP11-68I3.5	-4.16	3.75e-05	0.00333	-0.24	-0.19	Coffee consumption (cups per day);	chr17:30079000	chr17:29639627~29640825:+
THCA	cis	rs12143943	0.835	rs12730457	ENSG00000240219.1	RP11-430C7.5	4.16	3.75e-05	0.00333	0.16	0.19	Cognitive performance;	chr1:204579004	chr1:204626775~204629712:+
THCA	cis	rs10043228	0.826	rs17138907	ENSG00000248445.4	SEMA6A-AS1	-4.16	3.75e-05	0.00333	-0.24	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116131577	chr5:116447547~116508276:+
THCA	cis	rs2692947	0.537	rs4907274	ENSG00000235959.1	AC009237.17	-4.16	3.75e-05	0.00333	-0.21	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95697934	chr2:95640181~95640604:-
THCA	cis	rs700651	0.821	rs770661	ENSG00000231621.1	AC013264.2	-4.16	3.75e-05	0.00333	-0.2	-0.19	Intracranial aneurysm;	chr2:197860720	chr2:197197991~197199273:+
THCA	cis	rs700651	0.821	rs700690	ENSG00000231621.1	AC013264.2	-4.16	3.75e-05	0.00333	-0.2	-0.19	Intracranial aneurysm;	chr2:197862902	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs700692	ENSG00000231621.1	AC013264.2	-4.16	3.75e-05	0.00333	-0.2	-0.19	Dermatomyositis;	chr2:197863776	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs770662	ENSG00000231621.1	AC013264.2	-4.16	3.75e-05	0.00333	-0.2	-0.19	Dermatomyositis;	chr2:197864559	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs1435570	ENSG00000231621.1	AC013264.2	-4.16	3.75e-05	0.00333	-0.2	-0.19	Dermatomyositis;	chr2:197866647	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs6434943	ENSG00000231621.1	AC013264.2	-4.16	3.75e-05	0.00333	-0.2	-0.19	Dermatomyositis;	chr2:197897468	chr2:197197991~197199273:+
THCA	cis	rs7646881	0.544	rs1038885	ENSG00000240207.5	RP11-379F4.4	-4.16	3.75e-05	0.00333	-0.29	-0.19	Tetralogy of Fallot;	chr3:158629222	chr3:158732263~158784070:+
THCA	cis	rs75059851	0.756	rs11223652	ENSG00000280237.1	MIR4697HG	4.16	3.75e-05	0.00333	0.21	0.19	Schizophrenia;	chr11:133971312	chr11:133896438~133901601:-
THCA	cis	rs3198697	0.617	rs11075253	ENSG00000263335.1	AF001548.5	-4.16	3.76e-05	0.00333	-0.24	-0.19	Triglycerides;	chr16:15054789	chr16:15726674~15732993:+
THCA	cis	rs8020441	0.786	rs59498790	ENSG00000269906.1	RP11-248J18.2	4.16	3.76e-05	0.00333	0.27	0.19	Cognitive performance;	chr14:50701211	chr14:50662511~50663178:-
THCA	cis	rs8062405	0.754	rs62034323	ENSG00000270424.1	RP11-1348G14.6	4.16	3.76e-05	0.00333	0.21	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.824	rs62034324	ENSG00000270424.1	RP11-1348G14.6	4.16	3.76e-05	0.00333	0.21	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.824	rs62034326	ENSG00000270424.1	RP11-1348G14.6	4.16	3.76e-05	0.00333	0.21	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28749959~28750595:-
THCA	cis	rs7824557	0.564	rs34964435	ENSG00000154316.13	TDH	4.16	3.76e-05	0.00333	0.14	0.19	Retinal vascular caliber;	chr8:11372697	chr8:11339637~11368452:+
THCA	cis	rs2836974	0.932	rs6517526	ENSG00000255568.3	BRWD1-AS2	4.16	3.76e-05	0.00333	0.17	0.19	Cognitive function;	chr21:39209604	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.932	rs6517527	ENSG00000255568.3	BRWD1-AS2	4.16	3.76e-05	0.00333	0.17	0.19	Cognitive function;	chr21:39209825	chr21:39313935~39314962:+
THCA	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	4.16	3.76e-05	0.00333	0.2	0.19	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
THCA	cis	rs3096299	0.719	rs2353581	ENSG00000261118.1	RP11-104N10.1	4.16	3.76e-05	0.00333	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89492017~89504460:-
THCA	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	4.16	3.76e-05	0.00334	0.22	0.19	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
THCA	cis	rs67478160	0.643	rs12878868	ENSG00000269940.1	RP11-73M18.7	4.16	3.76e-05	0.00334	0.18	0.19	Schizophrenia;	chr14:103767388	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs11626377	ENSG00000269940.1	RP11-73M18.7	4.16	3.76e-05	0.00334	0.18	0.19	Schizophrenia;	chr14:103768020	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs876002	ENSG00000269940.1	RP11-73M18.7	4.16	3.76e-05	0.00334	0.18	0.19	Schizophrenia;	chr14:103773360	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.619	rs11628481	ENSG00000269940.1	RP11-73M18.7	4.16	3.76e-05	0.00334	0.18	0.19	Schizophrenia;	chr14:103775162	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.595	rs8022783	ENSG00000269940.1	RP11-73M18.7	4.16	3.76e-05	0.00334	0.18	0.19	Schizophrenia;	chr14:103779236	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.608	rs11160760	ENSG00000269940.1	RP11-73M18.7	4.16	3.76e-05	0.00334	0.18	0.19	Schizophrenia;	chr14:103782601	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.619	rs11160761	ENSG00000269940.1	RP11-73M18.7	4.16	3.76e-05	0.00334	0.18	0.19	Schizophrenia;	chr14:103788519	chr14:103694560~103695170:+
THCA	cis	rs8067354	0.831	rs2333617	ENSG00000266701.1	AC005702.4	-4.16	3.76e-05	0.00334	-0.26	-0.19	Hemoglobin concentration;	chr17:59818859	chr17:60042546~60042627:-
THCA	cis	rs11658311	0.85	rs8081961	ENSG00000226478.3	UPF3AP1	-4.16	3.76e-05	0.00334	-0.45	-0.19	Obsessive-compulsive symptoms;	chr17:17541052	chr17:16745636~16746761:-
THCA	cis	rs467650	0.927	rs154207	ENSG00000246763.5	RGMB-AS1	4.16	3.76e-05	0.00334	0.19	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98627686	chr5:98769618~98773469:-
THCA	cis	rs8031584	1	rs12906054	ENSG00000178081.11	ULK4P3	4.16	3.76e-05	0.00334	0.26	0.19	Huntington's disease progression;	chr15:30999820	chr15:30103720~30131757:+
THCA	cis	rs4356203	0.905	rs7123301	ENSG00000272034.1	SNORD14A	-4.16	3.76e-05	0.00334	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17141880	chr11:17074654~17074744:-
THCA	cis	rs4713118	0.568	rs9468213	ENSG00000261839.1	RP1-265C24.8	4.16	3.76e-05	0.00334	0.19	0.19	Parkinson's disease;	chr6:27738401	chr6:28136849~28139678:+
THCA	cis	rs853679	0.76	rs9393909	ENSG00000226314.6	ZNF192P1	4.16	3.76e-05	0.00334	0.3	0.19	Depression;	chr6:28239422	chr6:28161781~28169594:+
THCA	cis	rs2235642	0.533	rs2667679	ENSG00000260989.1	LA16c-395F10.2	-4.16	3.76e-05	0.00334	-0.2	-0.19	Coronary artery disease;	chr16:1604945	chr16:1580527~1610328:+
THCA	cis	rs8064024	0.513	rs1049208	ENSG00000267077.1	RP11-127I20.5	-4.16	3.76e-05	0.00334	-0.22	-0.19	Cancer;	chr16:4884548	chr16:4795265~4796532:-
THCA	cis	rs17685	0.736	rs4732594	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76123955	chr7:76071469~76074963:-
THCA	cis	rs17685	0.671	rs60303271	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76130690	chr7:76071469~76074963:-
THCA	cis	rs17685	0.735	rs11763339	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76132223	chr7:76071469~76074963:-
THCA	cis	rs17685	0.775	rs11761172	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76132229	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs11764129	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76132572	chr7:76071469~76074963:-
THCA	cis	rs17685	0.816	rs11763076	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76136645	chr7:76071469~76074963:-
THCA	cis	rs17685	0.623	rs7782808	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76139327	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs6953665	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76139731	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs7778735	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76140919	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs10275521	ENSG00000230882.1	AC005077.14	4.16	3.76e-05	0.00334	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76141654	chr7:76071469~76074963:-
THCA	cis	rs5769765	0.818	rs138850	ENSG00000260613.1	RP3-522J7.6	4.16	3.76e-05	0.00334	0.22	0.19	Schizophrenia;	chr22:49799689	chr22:49832616~49837786:-
THCA	cis	rs1488902	0.796	rs12786451	ENSG00000280367.1	RP11-121L10.2	-4.16	3.76e-05	0.00334	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr11:89541860	chr11:90223153~90226538:+
THCA	cis	rs2898290	0.593	rs2199690	ENSG00000227888.4	FAM66A	-4.16	3.76e-05	0.00334	-0.24	-0.19	Systolic blood pressure;	chr8:11482107	chr8:12362019~12388296:+
THCA	cis	rs11955398	0.502	rs169700	ENSG00000272308.1	RP11-231G3.1	-4.16	3.76e-05	0.00334	-0.19	-0.19	Intelligence (multi-trait analysis);	chr5:60969281	chr5:60866457~60866935:-
THCA	cis	rs4218	0.551	rs12906212	ENSG00000259732.1	RP11-59H7.3	-4.16	3.76e-05	0.00334	-0.26	-0.19	Social communication problems;	chr15:59070556	chr15:59121034~59133250:+
THCA	cis	rs3096299	0.685	rs4785675	ENSG00000261118.1	RP11-104N10.1	4.16	3.76e-05	0.00334	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89492017~89504460:-
THCA	cis	rs4144027	0.967	rs56126771	ENSG00000269910.1	RP11-73M18.10	4.16	3.76e-05	0.00334	0.17	0.19	Blood metabolite levels;	chr14:103894806	chr14:103694516~103695050:-
THCA	cis	rs9393777	0.92	rs13196692	ENSG00000220721.1	OR1F12	4.16	3.77e-05	0.00334	0.42	0.19	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28073316~28074233:+
THCA	cis	rs9393777	0.92	rs34150729	ENSG00000220721.1	OR1F12	4.16	3.77e-05	0.00334	0.42	0.19	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28073316~28074233:+
THCA	cis	rs9393777	0.92	rs13191227	ENSG00000220721.1	OR1F12	4.16	3.77e-05	0.00334	0.42	0.19	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28073316~28074233:+
THCA	cis	rs6938	0.534	rs1133322	ENSG00000260269.4	CTD-2323K18.1	-4.16	3.77e-05	0.00334	-0.27	-0.19	Breast cancer;	chr15:74920016	chr15:75527150~75601205:-
THCA	cis	rs860295	0.58	rs2282301	ENSG00000236675.1	MTX1P1	4.16	3.77e-05	0.00334	0.19	0.19	Body mass index;	chr1:155898834	chr1:155230975~155234325:+
THCA	cis	rs758324	0.732	rs193685	ENSG00000224431.1	AC063976.7	-4.16	3.77e-05	0.00334	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132176584	chr5:132199456~132203487:+
THCA	cis	rs6500550	0.598	rs9989424	ENSG00000276754.1	RP11-461A8.5	-4.16	3.77e-05	0.00334	-0.17	-0.19	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3622586	chr16:3686998~3687380:+
THCA	cis	rs9634489	0.502	rs1164596	ENSG00000247400.3	DNAJC3-AS1	-4.16	3.77e-05	0.00334	-0.12	-0.19	Body mass index;	chr13:96448427	chr13:95648733~95676925:-
THCA	cis	rs9840812	0.637	rs698270	ENSG00000239213.4	NCK1-AS1	4.16	3.77e-05	0.00334	0.18	0.19	Fibrinogen levels;	chr3:136390670	chr3:136841726~136862054:-
THCA	cis	rs6942407	0.696	rs4400318	ENSG00000224046.1	AC005076.5	-4.16	3.77e-05	0.00334	-0.18	-0.19	Food allergy;	chr7:87231208	chr7:87151423~87152420:-
THCA	cis	rs73108077	1	rs73108061	ENSG00000277112.2	RP11-755J8.1	-4.16	3.77e-05	0.00334	-0.38	-0.19	Red blood cell density in sickle cell anemia;	chr20:31413650	chr20:30681825~30723932:-
THCA	cis	rs758324	0.717	rs246999	ENSG00000237714.1	P4HA2-AS1	4.16	3.77e-05	0.00334	0.28	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132012478	chr5:132184876~132192808:+
THCA	cis	rs453301	0.506	rs476845	ENSG00000254153.1	CTA-398F10.2	4.16	3.77e-05	0.00335	0.2	0.19	Joint mobility (Beighton score);	chr8:8765367	chr8:8456909~8461337:-
THCA	cis	rs8113308	0.752	rs11879758	ENSG00000269483.1	AC006272.1	4.16	3.77e-05	0.00335	0.29	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51986911	chr19:51839924~51843324:-
THCA	cis	rs4743820	0.503	rs10991791	ENSG00000235641.4	LINC00484	4.16	3.77e-05	0.00335	0.23	0.19	Ulcerative colitis;Inflammatory bowel disease;	chr9:91159223	chr9:91159573~91165658:+
THCA	cis	rs613391	0.522	rs593909	ENSG00000234840.1	LINC01239	-4.16	3.77e-05	0.00335	-0.22	-0.19	Quantitative traits;	chr9:22730878	chr9:22646200~22824213:+
THCA	cis	rs853679	0.527	rs9468333	ENSG00000176933.5	TOB2P1	-4.16	3.77e-05	0.00335	-0.21	-0.19	Depression;	chr6:28303421	chr6:28217643~28218634:-
THCA	cis	rs7746199	0.736	rs13202295	ENSG00000220721.1	OR1F12	4.16	3.77e-05	0.00335	0.43	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28073316~28074233:+
THCA	cis	rs465969	1	rs35856111	ENSG00000272356.1	RP5-1112D6.8	4.16	3.77e-05	0.00335	0.29	0.19	Psoriasis;	chr6:111452265	chr6:111309203~111313517:+
THCA	cis	rs465969	0.744	rs13220692	ENSG00000272356.1	RP5-1112D6.8	4.16	3.77e-05	0.00335	0.29	0.19	Psoriasis;	chr6:111455836	chr6:111309203~111313517:+
THCA	cis	rs465969	0.793	rs7752225	ENSG00000272356.1	RP5-1112D6.8	-4.16	3.77e-05	0.00335	-0.29	-0.19	Psoriasis;	chr6:111459412	chr6:111309203~111313517:+
THCA	cis	rs6715284	0.892	rs72937112	ENSG00000238829.1	RNU7-45P	-4.16	3.77e-05	0.00335	-0.45	-0.19	Rheumatoid arthritis;	chr2:201363385	chr2:201141904~201141966:+
THCA	cis	rs4656958	0.538	rs7526396	ENSG00000233691.2	RP11-312J18.7	4.16	3.77e-05	0.00335	0.21	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160930954	chr1:160935537~160936126:+
THCA	cis	rs7178375	0.843	rs3794596	ENSG00000269930.1	RP11-932O9.9	-4.16	3.77e-05	0.00335	-0.25	-0.19	Hypertriglyceridemia;	chr15:30930823	chr15:30616958~30617749:+
THCA	cis	rs7246657	0.598	rs28660259	ENSG00000276846.1	CTD-3220F14.3	4.16	3.77e-05	0.00335	0.24	0.19	Coronary artery calcification;	chr19:37167779	chr19:37314868~37315620:-
THCA	cis	rs7520050	0.807	rs28844317	ENSG00000280836.1	AL355480.1	-4.16	3.77e-05	0.00335	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.807	rs6429576	ENSG00000280836.1	AL355480.1	-4.16	3.77e-05	0.00335	-0.23	-0.19	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45581219~45581321:-
THCA	cis	rs6439699	0.941	rs7648568	ENSG00000273486.1	RP11-731C17.2	4.16	3.78e-05	0.00335	0.2	0.19	Intelligence (multi-trait analysis);	chr3:137341847	chr3:136837338~136839021:-
THCA	cis	rs17597773	0.674	rs903319	ENSG00000238078.1	LINC01352	-4.16	3.78e-05	0.00335	-0.27	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812469	chr1:220829255~220832429:+
THCA	cis	rs11976180	0.569	rs12703565	ENSG00000204959.4	ARHGEF34P	4.16	3.78e-05	0.00335	0.27	0.19	Obesity-related traits;	chr7:144057308	chr7:144272445~144286966:-
THCA	cis	rs9733	0.715	rs7534124	ENSG00000231073.1	RP11-316M1.3	-4.16	3.78e-05	0.00335	-0.22	-0.19	Tonsillectomy;	chr1:150766597	chr1:150973123~150975534:+
THCA	cis	rs801193	1	rs62466793	ENSG00000223473.2	GS1-124K5.3	4.16	3.78e-05	0.00335	0.12	0.19	Aortic root size;	chr7:66726530	chr7:66491049~66493566:-
THCA	cis	rs4767841	0.565	rs2240309	ENSG00000248636.5	RP11-768F21.1	4.16	3.78e-05	0.00335	0.19	0.19	Urgency urinary incontinence;	chr12:119783648	chr12:119387987~119668079:-
THCA	cis	rs2579519	0.556	rs4907302	ENSG00000235959.1	AC009237.17	-4.16	3.78e-05	0.00335	-0.21	-0.19	Diastolic blood pressure;	chr2:95551449	chr2:95640181~95640604:-
THCA	cis	rs2692947	0.509	rs79546441	ENSG00000235959.1	AC009237.17	-4.16	3.78e-05	0.00335	-0.21	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95553124	chr2:95640181~95640604:-
THCA	cis	rs1125355	1	rs114087196	ENSG00000243792.1	OR7E89P	-4.16	3.78e-05	0.00335	-0.29	-0.19	Alzheimer's disease in APOE e4+ carriers;	chr2:158849636	chr2:158853755~158854576:+
THCA	cis	rs4660214	0.666	rs11205696	ENSG00000182109.6	RP11-69E11.4	-4.16	3.78e-05	0.00335	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155880	chr1:39522280~39546187:-
THCA	cis	rs4561483	0.549	rs154149	ENSG00000263307.1	RP11-166B2.8	4.16	3.78e-05	0.00335	0.19	0.19	Testicular germ cell tumor;	chr16:11862261	chr16:11851649~11895611:+
THCA	cis	rs2562456	0.833	rs62110367	ENSG00000268117.1	VN1R84P	4.16	3.78e-05	0.00335	0.31	0.19	Pain;	chr19:21365829	chr19:21719801~21720035:-
THCA	cis	rs9475752	0.744	rs11963350	ENSG00000231441.1	RP11-472M19.2	4.16	3.78e-05	0.00335	0.2	0.19	Menarche (age at onset);	chr6:56905958	chr6:56844002~56864078:+
THCA	cis	rs1015362	0.581	rs4911373	ENSG00000275784.1	RP5-1125A11.6	-4.16	3.78e-05	0.00335	-0.22	-0.19	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33989480~33991818:-
THCA	cis	rs12143943	0.866	rs3789052	ENSG00000240219.1	RP11-430C7.5	-4.16	3.78e-05	0.00335	-0.16	-0.19	Cognitive performance;	chr1:204525155	chr1:204626775~204629712:+
THCA	cis	rs11633886	0.934	rs8031071	ENSG00000259200.1	RP11-718O11.1	-4.16	3.78e-05	0.00335	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45789955	chr15:45705078~45931069:+
THCA	cis	rs1923243	0.71	rs7545548	ENSG00000223479.3	RP4-788P17.1	4.16	3.78e-05	0.00335	0.21	0.19	Migraine;	chr1:73181434	chr1:73635216~73715214:+
THCA	cis	rs2120243	0.539	rs35218020	ENSG00000241770.1	RP11-555M1.3	-4.16	3.78e-05	0.00335	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157397627	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs1840673	ENSG00000241770.1	RP11-555M1.3	-4.16	3.78e-05	0.00335	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157400188	chr3:157163452~157169133:+
THCA	cis	rs2303282	0.664	rs67179399	ENSG00000274031.1	RP11-413H22.3	-4.16	3.78e-05	0.00335	-0.22	-0.19	Breast cancer;	chr16:56406289	chr16:56465642~56466162:-
THCA	cis	rs4886920	0.862	rs4886531	ENSG00000260776.4	RP11-114H24.2	-4.16	3.78e-05	0.00335	-0.22	-0.19	Neuroticism;	chr15:77852400	chr15:77914217~77926846:-
THCA	cis	rs9902453	0.838	rs9646436	ENSG00000263370.1	RP11-68I3.5	4.16	3.78e-05	0.00335	0.25	0.19	Coffee consumption (cups per day);	chr17:29882041	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.838	rs9646437	ENSG00000263370.1	RP11-68I3.5	4.16	3.78e-05	0.00335	0.25	0.19	Coffee consumption (cups per day);	chr17:29882047	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.838	rs9646438	ENSG00000263370.1	RP11-68I3.5	4.16	3.78e-05	0.00335	0.25	0.19	Coffee consumption (cups per day);	chr17:29882073	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.808	rs56216220	ENSG00000263370.1	RP11-68I3.5	4.16	3.78e-05	0.00335	0.25	0.19	Coffee consumption (cups per day);	chr17:29882164	chr17:29639627~29640825:+
THCA	cis	rs12234571	1	rs73372287	ENSG00000214293.7	APTR	4.16	3.78e-05	0.00336	0.23	0.19	Obesity-related traits;	chr7:77713268	chr7:77657660~77696265:-
THCA	cis	rs11633886	1	rs11633886	ENSG00000259200.1	RP11-718O11.1	-4.16	3.79e-05	0.00336	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45786109	chr15:45705078~45931069:+
THCA	cis	rs12755164	0.771	rs11210082	ENSG00000223479.3	RP4-788P17.1	-4.16	3.79e-05	0.00336	-0.2	-0.19	Schizophrenia;	chr1:72878283	chr1:73635216~73715214:+
THCA	cis	rs8031584	0.706	rs798084	ENSG00000259845.1	HERC2P10	4.16	3.79e-05	0.00336	0.26	0.19	Huntington's disease progression;	chr15:30834732	chr15:30815271~30844153:+
THCA	cis	rs7312933	0.558	rs4768402	ENSG00000257225.1	RP11-328C8.4	4.16	3.79e-05	0.00336	0.19	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42361774	chr12:42459366~42466128:+
THCA	cis	rs962856	0.575	rs18122	ENSG00000236780.4	AC078941.1	4.16	3.79e-05	0.00336	0.25	0.19	Pancreatic cancer;	chr2:67427302	chr2:67123357~67215319:-
THCA	cis	rs4144027	0.904	rs10438243	ENSG00000269940.1	RP11-73M18.7	-4.16	3.79e-05	0.00336	-0.19	-0.19	Blood metabolite levels;	chr14:103879485	chr14:103694560~103695170:+
THCA	cis	rs1560104	0.597	rs7187433	ENSG00000260601.1	RP11-552C15.1	-4.16	3.79e-05	0.00336	-0.22	-0.19	Obesity-related traits;	chr16:12615251	chr16:12545482~12546684:+
THCA	cis	rs1023500	0.551	rs61665536	ENSG00000237037.8	NDUFA6-AS1	4.16	3.79e-05	0.00336	0.15	0.19	Schizophrenia;	chr22:42116609	chr22:42090931~42137742:+
THCA	cis	rs6500602	0.563	rs917304	ENSG00000280063.1	RP11-295D4.3	4.16	3.79e-05	0.00336	0.11	0.19	Schizophrenia;	chr16:4390425	chr16:4346694~4348648:-
THCA	cis	rs6500602	0.563	rs917305	ENSG00000280063.1	RP11-295D4.3	4.16	3.79e-05	0.00336	0.11	0.19	Schizophrenia;	chr16:4390592	chr16:4346694~4348648:-
THCA	cis	rs8077577	0.895	rs11658477	ENSG00000273018.4	CTD-2303H24.2	-4.16	3.79e-05	0.00336	-0.32	-0.19	Obesity-related traits;	chr17:18141579	chr17:18511221~18551705:-
THCA	cis	rs9863	0.896	rs7307053	ENSG00000270061.1	RP11-214K3.19	4.16	3.79e-05	0.00336	0.25	0.19	White blood cell count;	chr12:124009993	chr12:123969990~123970344:-
THCA	cis	rs804280	0.509	rs12719915	ENSG00000206014.6	OR7E161P	4.16	3.79e-05	0.00336	0.23	0.19	Myopia (pathological);	chr8:11928746	chr8:11928597~11929563:-
THCA	cis	rs8115854	0.961	rs56249676	ENSG00000269846.1	RP4-621N11.2	-4.16	3.79e-05	0.00336	-0.24	-0.19	Hippocampal atrophy;	chr20:37128527	chr20:37095785~37097178:+
THCA	cis	rs8115854	1	rs8115854	ENSG00000269846.1	RP4-621N11.2	-4.16	3.79e-05	0.00336	-0.24	-0.19	Hippocampal atrophy;	chr20:37137934	chr20:37095785~37097178:+
THCA	cis	rs9880211	0.898	rs9866840	ENSG00000239213.4	NCK1-AS1	4.16	3.79e-05	0.00336	0.21	0.19	Height;Body mass index;	chr3:136310416	chr3:136841726~136862054:-
THCA	cis	rs2777491	0.574	rs1757468	ENSG00000247556.5	OIP5-AS1	4.16	3.79e-05	0.00336	0.18	0.19	Ulcerative colitis;	chr15:41451376	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.532	rs316604	ENSG00000247556.5	OIP5-AS1	4.16	3.79e-05	0.00336	0.18	0.19	Ulcerative colitis;	chr15:41483023	chr15:41283990~41309737:+
THCA	cis	rs9970896	1	rs4660130	ENSG00000237845.1	RP5-940F7.2	-4.16	3.79e-05	0.00336	-0.36	-0.19	Monocyte percentage of white cells;	chr1:235936512	chr1:235942553~235943805:-
THCA	cis	rs7208859	0.623	rs609063	ENSG00000265443.1	CTD-2349P21.6	-4.16	3.79e-05	0.00336	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs383436	ENSG00000265443.1	CTD-2349P21.6	-4.16	3.79e-05	0.00336	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000265443.1	CTD-2349P21.6	-4.16	3.79e-05	0.00336	-0.33	-0.19	Body mass index;	chr17:30641132	chr17:30726305~30727564:-
THCA	cis	rs853679	0.769	rs17720293	ENSG00000220721.1	OR1F12	4.16	3.79e-05	0.00336	0.38	0.19	Depression;	chr6:28246920	chr6:28073316~28074233:+
THCA	cis	rs4604234	0.522	rs73479980	ENSG00000272129.1	RP11-250B2.6	-4.16	3.79e-05	0.00336	-0.41	-0.19	Cancer;	chr6:80200255	chr6:80355424~80356859:+
THCA	cis	rs150992	0.609	rs539024	ENSG00000246763.5	RGMB-AS1	4.16	3.79e-05	0.00336	0.19	0.19	Body mass index;	chr5:98997103	chr5:98769618~98773469:-
THCA	cis	rs150992	0.532	rs416750	ENSG00000246763.5	RGMB-AS1	4.16	3.79e-05	0.00336	0.19	0.19	Body mass index;	chr5:98999046	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs819232	ENSG00000246763.5	RGMB-AS1	4.16	3.79e-05	0.00336	0.19	0.19	Body mass index;	chr5:98999416	chr5:98769618~98773469:-
THCA	cis	rs2836974	0.932	rs73221193	ENSG00000255568.3	BRWD1-AS2	4.16	3.79e-05	0.00336	0.17	0.19	Cognitive function;	chr21:39182767	chr21:39313935~39314962:+
THCA	cis	rs2839186	0.508	rs6518278	ENSG00000215424.8	MCM3AP-AS1	-4.16	3.79e-05	0.00336	-0.12	-0.19	Testicular germ cell tumor;	chr21:46220657	chr21:46229217~46259390:+
THCA	cis	rs17095355	1	rs734163	ENSG00000203876.8	ADD3-AS1	-4.16	3.79e-05	0.00336	-0.2	-0.19	Biliary atresia;	chr10:109938434	chr10:109940104~110008381:-
THCA	cis	rs4906332	1	rs28711288	ENSG00000252469.1	RNU7-160P	4.16	3.8e-05	0.00336	0.2	0.19	Coronary artery disease;	chr14:103439789	chr14:103550345~103550406:+
THCA	cis	rs128738	0.5	rs2405271	ENSG00000237714.1	P4HA2-AS1	4.16	3.8e-05	0.00336	0.28	0.19	Giant cell arteritis;	chr5:132237700	chr5:132184876~132192808:+
THCA	cis	rs9902453	0.904	rs11080115	ENSG00000263370.1	RP11-68I3.5	-4.16	3.8e-05	0.00336	-0.24	-0.19	Coffee consumption (cups per day);	chr17:30081052	chr17:29639627~29640825:+
THCA	cis	rs6878727	0.614	rs256614	ENSG00000253807.4	LINC01170	4.16	3.8e-05	0.00336	0.17	0.19	Breast cancer;	chr5:124325091	chr5:124059794~124405079:-
THCA	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	4.16	3.8e-05	0.00337	0.22	0.19	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
THCA	cis	rs1923243	0.71	rs4593761	ENSG00000223479.3	RP4-788P17.1	-4.16	3.8e-05	0.00337	-0.21	-0.19	Migraine;	chr1:73147639	chr1:73635216~73715214:+
THCA	cis	rs1842579	1	rs12088004	ENSG00000272691.1	RP11-290M5.4	-4.16	3.8e-05	0.00337	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85834937	chr1:85578500~85578742:-
THCA	cis	rs1842579	1	rs11161686	ENSG00000272691.1	RP11-290M5.4	-4.16	3.8e-05	0.00337	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85835497	chr1:85578500~85578742:-
THCA	cis	rs172166	0.585	rs149963	ENSG00000220721.1	OR1F12	4.16	3.8e-05	0.00337	0.2	0.19	Cardiac Troponin-T levels;	chr6:28049354	chr6:28073316~28074233:+
THCA	cis	rs9876781	1	rs13069724	ENSG00000244380.1	RP11-24C3.2	4.16	3.8e-05	0.00337	0.22	0.19	Longevity;	chr3:48436629	chr3:48440352~48446656:-
THCA	cis	rs67478160	0.643	rs4906369	ENSG00000269940.1	RP11-73M18.7	4.16	3.8e-05	0.00337	0.18	0.19	Schizophrenia;	chr14:103776121	chr14:103694560~103695170:+
THCA	cis	rs2708377	0.79	rs73051387	ENSG00000247157.5	LINC01252	4.16	3.8e-05	0.00337	0.34	0.19	Bitter taste perception;	chr12:11161864	chr12:11548030~11590369:+
THCA	cis	rs8113308	0.81	rs8105110	ENSG00000269483.1	AC006272.1	4.16	3.8e-05	0.00337	0.31	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948863	chr19:51839924~51843324:-
THCA	cis	rs13256369	1	rs7820159	ENSG00000254153.1	CTA-398F10.2	-4.16	3.8e-05	0.00337	-0.21	-0.19	Obesity-related traits;	chr8:8718705	chr8:8456909~8461337:-
THCA	cis	rs8081395	0.834	rs11650106	ENSG00000267302.4	RP11-178C3.2	-4.16	3.8e-05	0.00337	-0.23	-0.19	White blood cell count;	chr17:59772890	chr17:59964832~59996972:+
THCA	cis	rs28735056	1	rs56197868	ENSG00000261126.6	RP11-795F19.1	-4.16	3.8e-05	0.00337	-0.16	-0.19	Schizophrenia;	chr18:79876077	chr18:80046900~80095482:+
THCA	cis	rs1871744	0.51	rs59409230	ENSG00000246375.2	RP11-10L7.1	4.16	3.8e-05	0.00337	0.28	0.19	Renal underexcretion gout;	chr4:88167177	chr4:88284942~88331421:+
THCA	cis	rs4713118	0.513	rs9368547	ENSG00000261839.1	RP1-265C24.8	4.16	3.8e-05	0.00337	0.2	0.19	Parkinson's disease;	chr6:28060289	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.513	rs183244	ENSG00000261839.1	RP1-265C24.8	4.16	3.8e-05	0.00337	0.2	0.19	Parkinson's disease;	chr6:28064060	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.513	rs149950	ENSG00000261839.1	RP1-265C24.8	4.16	3.8e-05	0.00337	0.2	0.19	Parkinson's disease;	chr6:28065261	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.513	rs149951	ENSG00000261839.1	RP1-265C24.8	4.16	3.8e-05	0.00337	0.2	0.19	Parkinson's disease;	chr6:28065309	chr6:28136849~28139678:+
THCA	cis	rs5758659	0.652	rs129857	ENSG00000205702.9	CYP2D7	-4.16	3.8e-05	0.00337	-0.14	-0.19	Cognitive function;	chr22:42003682	chr22:42140203~42144577:-
THCA	cis	rs6479901	0.548	rs10995441	ENSG00000232075.1	MRPL35P2	-4.16	3.81e-05	0.00337	-0.27	-0.19	Intelligence (multi-trait analysis);	chr10:63109479	chr10:63634317~63634827:-
THCA	cis	rs330048	0.51	rs11784654	ENSG00000253893.2	FAM85B	4.16	3.81e-05	0.00337	0.24	0.19	Systemic lupus erythematosus;	chr8:9112101	chr8:8167819~8226614:-
THCA	cis	rs2439831	0.681	rs498837	ENSG00000166763.7	STRCP1	4.16	3.81e-05	0.00337	0.25	0.19	Lung cancer in ever smokers;	chr15:43315826	chr15:43699488~43718184:-
THCA	cis	rs758324	0.732	rs45511	ENSG00000224431.1	AC063976.7	-4.16	3.81e-05	0.00337	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132103468	chr5:132199456~132203487:+
THCA	cis	rs7176527	0.579	rs366717	ENSG00000229212.6	RP11-561C5.4	4.16	3.81e-05	0.00337	0.29	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85205440~85234795:-
THCA	cis	rs2686555	0.754	rs2461507	ENSG00000277423.1	RP11-173P15.9	-4.16	3.81e-05	0.00337	-0.2	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr12:120646466	chr12:120703867~120704282:+
THCA	cis	rs11633886	0.585	rs2460630	ENSG00000273972.1	CTD-2306A12.1	4.16	3.81e-05	0.00337	0.21	0.19	Diisocyanate-induced asthma;	chr15:45799596	chr15:45702640~45703183:+
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000182586.6	LINC00334	-4.16	3.81e-05	0.00338	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45234340~45258730:+
THCA	cis	rs7617480	0.648	rs9859473	ENSG00000229759.1	MRPS18AP1	4.16	3.81e-05	0.00338	0.28	0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48799749	chr3:48256350~48256938:-
THCA	cis	rs12157904	1	rs12158264	ENSG00000279010.1	RP5-1039K5.19	-4.16	3.81e-05	0.00338	-0.31	-0.19	Response to anti-depressant treatment in major depressive disorder;	chr22:37605497	chr22:37948352~38002889:+
THCA	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-4.16	3.81e-05	0.00338	-0.24	-0.19	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
THCA	cis	rs11673344	0.636	rs7255595	ENSG00000267260.1	CTD-2162K18.4	-4.16	3.81e-05	0.00338	-0.25	-0.19	Obesity-related traits;	chr19:36896260	chr19:36773153~36777078:+
THCA	cis	rs59868192	0.85	rs16972308	ENSG00000246740.2	PLA2G4E-AS1	4.16	3.81e-05	0.00338	0.38	0.19	White blood cell count;	chr15:41945793	chr15:41972763~41999094:+
THCA	cis	rs301901	0.581	rs292174	ENSG00000250155.1	CTD-2353F22.1	-4.16	3.81e-05	0.00338	-0.2	-0.19	Height;	chr5:36832039	chr5:36666214~36725195:-
THCA	cis	rs4938303	0.633	rs567209	ENSG00000254851.1	RP11-109L13.1	4.16	3.81e-05	0.00338	0.32	0.19	Triglycerides;	chr11:116664111	chr11:117135528~117138582:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000223473.2	GS1-124K5.3	-4.16	3.81e-05	0.00338	-0.12	-0.19	Aortic root size;	chr7:66589419	chr7:66491049~66493566:-
THCA	cis	rs6494488	0.5	rs72742988	ENSG00000259635.1	AC100830.3	-4.16	3.81e-05	0.00338	-0.44	-0.19	Coronary artery disease;	chr15:64701891	chr15:64701248~64719602:+
THCA	cis	rs867186	1	rs7269138	ENSG00000126005.14	MMP24-AS1	-4.16	3.81e-05	0.00338	-0.29	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34982204	chr20:35216462~35278131:-
THCA	cis	rs7914558	0.621	rs7896290	ENSG00000213277.3	MARCKSL1P1	4.16	3.81e-05	0.00338	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102896258	chr10:103175554~103176094:+
THCA	cis	rs7914558	0.621	rs12219346	ENSG00000213277.3	MARCKSL1P1	4.16	3.81e-05	0.00338	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102897543	chr10:103175554~103176094:+
THCA	cis	rs2904524	1	rs58612372	ENSG00000257815.4	RP11-611E13.2	-4.16	3.81e-05	0.00338	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70276566	chr12:69904033~70243360:-
THCA	cis	rs1560104	0.675	rs9936549	ENSG00000259876.1	CTD-3037G24.4	4.16	3.81e-05	0.00338	0.22	0.19	Obesity-related traits;	chr16:12611147	chr16:12556353~12557694:-
THCA	cis	rs4906332	1	rs1951389	ENSG00000244691.1	RPL10AP1	-4.16	3.81e-05	0.00338	-0.24	-0.19	Coronary artery disease;	chr14:103432188	chr14:103412119~103412761:-
THCA	cis	rs4906332	0.901	rs4900575	ENSG00000244691.1	RPL10AP1	-4.16	3.81e-05	0.00338	-0.24	-0.19	Coronary artery disease;	chr14:103432832	chr14:103412119~103412761:-
THCA	cis	rs8062405	0.823	rs7202948	ENSG00000270424.1	RP11-1348G14.6	4.16	3.81e-05	0.00338	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28749959~28750595:-
THCA	cis	rs1387259	0.899	rs7307566	ENSG00000273765.1	RP11-370I10.11	4.16	3.81e-05	0.00338	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48360920~48361377:+
THCA	cis	rs12410462	0.551	rs68046179	ENSG00000227711.2	RP11-275O4.5	-4.16	3.81e-05	0.00338	-0.23	-0.19	Major depressive disorder;	chr1:227709934	chr1:227509028~227520477:-
THCA	cis	rs4742903	0.904	rs10991167	ENSG00000270332.1	SMC2-AS1	-4.16	3.81e-05	0.00338	-0.18	-0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104212101	chr9:104080024~104093073:-
THCA	cis	rs7615952	0.546	rs2979333	ENSG00000241278.1	ENPP7P4	4.16	3.81e-05	0.00338	0.26	0.19	Blood pressure (smoking interaction);	chr3:125641499	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.546	rs111812401	ENSG00000241278.1	ENPP7P4	4.16	3.81e-05	0.00338	0.26	0.19	Blood pressure (smoking interaction);	chr3:125642651	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.546	rs2979350	ENSG00000241278.1	ENPP7P4	4.16	3.81e-05	0.00338	0.26	0.19	Blood pressure (smoking interaction);	chr3:125643371	chr3:125848223~125909372:+
THCA	cis	rs12143943	0.866	rs10458588	ENSG00000240219.1	RP11-430C7.5	4.16	3.82e-05	0.00338	0.16	0.19	Cognitive performance;	chr1:204536359	chr1:204626775~204629712:+
THCA	cis	rs7855088	0.789	rs7035650	ENSG00000236130.1	PTCSC2	-4.16	3.82e-05	0.00338	-0.15	-0.19	Serum thyroid-stimulating hormone levels;	chr9:98004560	chr9:97805935~97810008:-
THCA	cis	rs7855088	0.789	rs1010777	ENSG00000236130.1	PTCSC2	-4.16	3.82e-05	0.00338	-0.15	-0.19	Serum thyroid-stimulating hormone levels;	chr9:98005578	chr9:97805935~97810008:-
THCA	cis	rs1908814	0.516	rs58869268	ENSG00000254948.1	OR7E158P	-4.16	3.82e-05	0.00338	-0.24	-0.19	Neuroticism;	chr8:11939586	chr8:11919900~11920809:-
THCA	cis	rs6580649	0.941	rs4760618	ENSG00000273765.1	RP11-370I10.11	-4.16	3.82e-05	0.00338	-0.21	-0.19	Lung cancer;	chr12:48040984	chr12:48360920~48361377:+
THCA	cis	rs875971	0.862	rs11773628	ENSG00000229886.1	RP5-1132H15.3	-4.16	3.82e-05	0.00338	-0.2	-0.19	Aortic root size;	chr7:66517644	chr7:66025126~66031544:-
THCA	cis	rs793571	0.614	rs347117	ENSG00000245975.2	RP11-30K9.6	4.16	3.82e-05	0.00338	0.17	0.19	Schizophrenia;	chr15:58708758	chr15:58768072~58770974:-
THCA	cis	rs6449502	0.541	rs13185516	ENSG00000251279.1	CTC-436P18.1	4.16	3.82e-05	0.00338	0.36	0.19	Mean platelet volume;	chr5:61184745	chr5:61162070~61232040:+
THCA	cis	rs889398	0.9	rs62052815	ENSG00000226232.7	RP11-419C5.2	4.16	3.82e-05	0.00338	0.19	0.19	Body mass index;	chr16:69527923	chr16:69976388~69996188:-
THCA	cis	rs2692947	0.8	rs2692936	ENSG00000235584.2	AC008268.1	-4.16	3.82e-05	0.00338	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96079981	chr2:95666084~95668715:+
THCA	cis	rs6088813	0.883	rs2425055	ENSG00000126005.14	MMP24-AS1	-4.16	3.82e-05	0.00338	-0.19	-0.19	Height;	chr20:35315833	chr20:35216462~35278131:-
THCA	cis	rs9843304	0.528	rs11919764	ENSG00000243885.1	RP11-278L15.2	4.16	3.82e-05	0.00338	0.21	0.19	Gallstone disease;	chr3:149469448	chr3:149384179~149385800:-
THCA	cis	rs7528684	0.546	rs10908583	ENSG00000236731.1	RP4-801G22.2	4.16	3.82e-05	0.00338	0.19	0.19	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157671893	chr1:157629939~157630728:-
THCA	cis	rs9840812	0.623	rs6794351	ENSG00000239213.4	NCK1-AS1	4.16	3.82e-05	0.00338	0.17	0.19	Fibrinogen levels;	chr3:136573437	chr3:136841726~136862054:-
THCA	cis	rs9316337	0.872	rs9580094	ENSG00000236953.1	ZDHHC20-IT1	-4.16	3.82e-05	0.00338	-0.2	-0.19	Schizophrenia;	chr13:21377023	chr13:21376977~21377874:-
THCA	cis	rs7824557	0.564	rs55758514	ENSG00000154316.13	TDH	4.16	3.82e-05	0.00338	0.14	0.19	Retinal vascular caliber;	chr8:11372750	chr8:11339637~11368452:+
THCA	cis	rs5758659	0.569	rs133294	ENSG00000273366.1	CTA-989H11.1	-4.16	3.82e-05	0.00338	-0.23	-0.19	Cognitive function;	chr22:41986801	chr22:42278188~42278846:+
THCA	cis	rs2015599	0.623	rs10843385	ENSG00000273680.1	RP11-996F15.6	4.16	3.82e-05	0.00338	0.27	0.19	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29332733~29333383:-
THCA	cis	rs9902453	0.791	rs28492945	ENSG00000263370.1	RP11-68I3.5	4.16	3.82e-05	0.00338	0.24	0.19	Coffee consumption (cups per day);	chr17:29896964	chr17:29639627~29640825:+
THCA	cis	rs11971779	0.838	rs4728468	ENSG00000252332.1	RNU6-911P	-4.16	3.82e-05	0.00339	-0.23	-0.19	Diisocyanate-induced asthma;	chr7:139438232	chr7:139448740~139448843:+
THCA	cis	rs12440869	1	rs7183186	ENSG00000270964.1	RP11-502I4.3	4.16	3.82e-05	0.00339	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67321754	chr15:67541072~67542604:-
THCA	cis	rs6866614	0.627	rs27437	ENSG00000263597.1	MIR3936	4.16	3.82e-05	0.00339	0.17	0.19	Perceived unattractiveness to mosquitoes;	chr5:132101268	chr5:132365490~132365599:-
THCA	cis	rs548181	0.536	rs503287	ENSG00000254671.2	STT3A-AS1	-4.16	3.82e-05	0.00339	-0.35	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125591893	chr11:125570284~125592568:-
THCA	cis	rs4950322	0.57	rs72691004	ENSG00000271721.1	RP11-337C18.9	4.16	3.82e-05	0.00339	0.21	0.19	Protein quantitative trait loci;	chr1:147234309	chr1:147175602~147177740:+
THCA	cis	rs875971	0.964	rs6978429	ENSG00000230189.5	GS1-124K5.2	4.16	3.82e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66494889	chr7:66409143~66490059:-
THCA	cis	rs875971	0.929	rs12535036	ENSG00000230189.5	GS1-124K5.2	4.16	3.82e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66499076	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs12698523	ENSG00000230189.5	GS1-124K5.2	4.16	3.82e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66503126	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs6970030	ENSG00000230189.5	GS1-124K5.2	4.16	3.82e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66503692	chr7:66409143~66490059:-
THCA	cis	rs875971	0.928	rs6970357	ENSG00000230189.5	GS1-124K5.2	4.16	3.82e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66503891	chr7:66409143~66490059:-
THCA	cis	rs6430585	1	rs6430585	ENSG00000231890.6	DARS-AS1	4.16	3.82e-05	0.00339	0.22	0.19	Corneal structure;	chr2:135749357	chr2:135985176~136022593:+
THCA	cis	rs494526	0.868	rs10787903	ENSG00000229272.1	RP11-498J9.2	-4.16	3.82e-05	0.00339	-0.21	-0.19	Alcoholic chronic pancreatitis;	chr10:119064457	chr10:119003536~119003884:-
THCA	cis	rs5758659	0.652	rs129857	ENSG00000281538.1	RP4-669P10.20	-4.16	3.82e-05	0.00339	-0.17	-0.19	Cognitive function;	chr22:42003682	chr22:42138060~42139726:+
THCA	cis	rs7665090	0.87	rs228623	ENSG00000248971.2	KRT8P46	4.16	3.83e-05	0.00339	0.23	0.19	Primary biliary cholangitis;	chr4:102651163	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.837	rs228624	ENSG00000248971.2	KRT8P46	4.16	3.83e-05	0.00339	0.23	0.19	Primary biliary cholangitis;	chr4:102651283	chr4:102728746~102730171:-
THCA	cis	rs11069062	0.866	rs1829565	ENSG00000270482.1	RP11-131L12.2	4.16	3.83e-05	0.00339	0.15	0.19	Obesity-related traits;	chr12:118723753	chr12:118375350~118376275:-
THCA	cis	rs6540731	0.875	rs10863953	ENSG00000226251.4	RP11-15I11.3	-4.16	3.83e-05	0.00339	-0.23	-0.19	Intelligence (childhood);	chr1:212192458	chr1:212225278~212238977:-
THCA	cis	rs1055129	0.56	rs2666003	ENSG00000267801.1	RP11-552F3.9	4.16	3.83e-05	0.00339	0.21	0.19	White matter hyperintensity burden;	chr17:75946895	chr17:75876372~75879546:+
THCA	cis	rs11633886	0.934	rs2413791	ENSG00000259200.1	RP11-718O11.1	-4.16	3.83e-05	0.00339	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45801195	chr15:45705078~45931069:+
THCA	cis	rs9902453	0.967	rs4429345	ENSG00000263370.1	RP11-68I3.5	-4.16	3.83e-05	0.00339	-0.24	-0.19	Coffee consumption (cups per day);	chr17:30131087	chr17:29639627~29640825:+
THCA	cis	rs950776	0.506	rs12915366	ENSG00000261762.1	RP11-650L12.2	4.16	3.83e-05	0.00339	0.24	0.19	Sudden cardiac arrest;	chr15:78539411	chr15:78589123~78591276:-
THCA	cis	rs950776	0.531	rs12915652	ENSG00000261762.1	RP11-650L12.2	4.16	3.83e-05	0.00339	0.24	0.19	Sudden cardiac arrest;	chr15:78539586	chr15:78589123~78591276:-
THCA	cis	rs1908814	0.516	rs35391955	ENSG00000206014.6	OR7E161P	-4.16	3.83e-05	0.00339	-0.23	-0.19	Neuroticism;	chr8:11939219	chr8:11928597~11929563:-
THCA	cis	rs12497850	0.931	rs7628719	ENSG00000228638.1	FCF1P2	-4.16	3.83e-05	0.00339	-0.2	-0.19	Parkinson's disease;	chr3:48958054	chr3:48290793~48291375:-
THCA	cis	rs4938303	0.633	rs12801136	ENSG00000254851.1	RP11-109L13.1	4.16	3.83e-05	0.00339	0.32	0.19	Triglycerides;	chr11:116677632	chr11:117135528~117138582:+
THCA	cis	rs11668609	0.515	rs74443274	ENSG00000268442.1	CTD-2027I19.2	4.16	3.83e-05	0.00339	0.28	0.19	Response to taxane treatment (docetaxel);	chr19:23838810	chr19:24162370~24163425:-
THCA	cis	rs11089937	0.554	rs5995628	ENSG00000211639.2	IGLV4-60	4.16	3.83e-05	0.00339	0.15	0.19	Periodontitis (PAL4Q3);	chr22:22194768	chr22:22162199~22162681:+
THCA	cis	rs4295623	0.585	rs34421088	ENSG00000255046.1	RP11-297N6.4	4.16	3.83e-05	0.00339	0.2	0.19	Morning vs. evening chronotype;	chr8:11731533	chr8:11797928~11802568:-
THCA	cis	rs77637988	0.604	rs6722246	ENSG00000202227.1	RNU6-282P	4.16	3.83e-05	0.00339	0.2	0.19	Joint mobility (Beighton score);	chr2:48369906	chr2:48501922~48502024:-
THCA	cis	rs12546962	0.705	rs17149279	ENSG00000254153.1	CTA-398F10.2	-4.16	3.83e-05	0.00339	-0.23	-0.19	Body mass index;	chr8:9338128	chr8:8456909~8461337:-
THCA	cis	rs3893377	0.848	rs10023845	ENSG00000214846.4	RP11-115L11.1	-4.16	3.83e-05	0.00339	-0.25	-0.19	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15739628	chr4:15730962~15731627:-
THCA	cis	rs801193	1	rs1553610	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66732246	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs2707845	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66733811	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs2707850	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66738883	chr7:66491049~66493566:-
THCA	cis	rs801193	0.967	rs1110414	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66740595	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs7783924	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66744070	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs7789184	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66745208	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs2707854	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66747610	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs3800812	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66758474	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs4279493	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66761633	chr7:66491049~66493566:-
THCA	cis	rs801193	0.761	rs2659888	ENSG00000223473.2	GS1-124K5.3	4.16	3.83e-05	0.00339	0.12	0.19	Aortic root size;	chr7:66765184	chr7:66491049~66493566:-
THCA	cis	rs17801127	1	rs74750915	ENSG00000231969.1	AC144449.1	4.16	3.83e-05	0.00339	0.42	0.19	Liver enzyme levels (alanine transaminase);	chr2:149717131	chr2:149587196~149848233:+
THCA	cis	rs6878727	0.638	rs42267	ENSG00000253807.4	LINC01170	4.16	3.83e-05	0.00339	0.17	0.19	Breast cancer;	chr5:124320605	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.665	rs1363306	ENSG00000253807.4	LINC01170	4.16	3.83e-05	0.00339	0.17	0.19	Breast cancer;	chr5:124322206	chr5:124059794~124405079:-
THCA	cis	rs6496044	0.507	rs62022863	ENSG00000259276.1	RP11-815J21.3	4.16	3.83e-05	0.00339	0.22	0.19	Interstitial lung disease;	chr15:85618822	chr15:85621264~85627689:-
THCA	cis	rs12428035	0.764	rs9516621	ENSG00000247400.3	DNAJC3-AS1	4.16	3.83e-05	0.00339	0.17	0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95894123	chr13:95648733~95676925:-
THCA	cis	rs6430585	0.591	rs12477421	ENSG00000231890.6	DARS-AS1	-4.16	3.83e-05	0.00339	-0.22	-0.19	Corneal structure;	chr2:135676170	chr2:135985176~136022593:+
THCA	cis	rs875971	0.502	rs2465121	ENSG00000273142.1	RP11-458F8.4	-4.16	3.83e-05	0.00339	-0.18	-0.19	Aortic root size;	chr7:66156017	chr7:66902857~66906297:+
THCA	cis	rs5753037	0.653	rs105311	ENSG00000273350.1	RP4-539M6.20	-4.16	3.83e-05	0.00339	-0.21	-0.19	Type 1 diabetes;	chr22:29741273	chr22:30420512~30420912:+
THCA	cis	rs2904524	1	rs75401536	ENSG00000257815.4	RP11-611E13.2	-4.16	3.83e-05	0.00339	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70264369	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs1524245	ENSG00000257815.4	RP11-611E13.2	-4.16	3.83e-05	0.00339	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70265048	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs4761191	ENSG00000257815.4	RP11-611E13.2	-4.16	3.83e-05	0.00339	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70268594	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs56970859	ENSG00000257815.4	RP11-611E13.2	-4.16	3.83e-05	0.00339	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70270576	chr12:69904033~70243360:-
THCA	cis	rs10435719	0.78	rs9692662	ENSG00000206014.6	OR7E161P	-4.16	3.83e-05	0.00339	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.899	rs9693925	ENSG00000206014.6	OR7E161P	-4.16	3.83e-05	0.00339	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:11928597~11929563:-
THCA	cis	rs9316337	0.933	rs9509670	ENSG00000236953.1	ZDHHC20-IT1	-4.16	3.84e-05	0.0034	-0.2	-0.19	Schizophrenia;	chr13:21379746	chr13:21376977~21377874:-
THCA	cis	rs6600671	0.764	rs6600673	ENSG00000275585.1	CH17-118O6.3	-4.16	3.84e-05	0.0034	-0.23	-0.19	Hip geometry;	chr1:121426988	chr1:120985692~121052167:-
THCA	cis	rs6442522	0.64	rs6762964	ENSG00000249786.6	EAF1-AS1	4.16	3.84e-05	0.0034	0.19	0.19	Uric acid levels;	chr3:15485938	chr3:15436171~15455940:-
THCA	cis	rs801193	0.66	rs2659914	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66691927	chr7:66025126~66031544:-
THCA	cis	rs4908768	0.906	rs11584261	ENSG00000232912.4	RP5-1115A15.1	-4.16	3.84e-05	0.0034	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8500306	chr1:8424645~8434838:+
THCA	cis	rs1055129	0.56	rs2608880	ENSG00000267801.1	RP11-552F3.9	4.16	3.84e-05	0.0034	0.21	0.19	White matter hyperintensity burden;	chr17:75942876	chr17:75876372~75879546:+
THCA	cis	rs8030379	0.967	rs8036748	ENSG00000176700.18	SCAND2P	-4.16	3.84e-05	0.0034	-0.12	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903084	chr15:84631451~84647478:+
THCA	cis	rs7015630	0.827	rs13277948	ENSG00000251136.7	RP11-37B2.1	-4.16	3.84e-05	0.0034	-0.17	-0.19	Inflammatory bowel disease;Crohn's disease;	chr8:89851500	chr8:89609409~89757727:-
THCA	cis	rs10908458	0.743	rs7367207	ENSG00000160766.13	GBAP1	-4.16	3.84e-05	0.0034	-0.2	-0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155107001	chr1:155213821~155227422:-
THCA	cis	rs34929064	0.536	rs2961279	ENSG00000232949.1	AC002480.4	-4.16	3.84e-05	0.0034	-0.24	-0.19	Major depression and alcohol dependence;	chr7:22598535	chr7:22589705~22591622:+
THCA	cis	rs6452790	0.671	rs992623	ENSG00000247828.6	TMEM161B-AS1	-4.16	3.84e-05	0.0034	-0.18	-0.19	Cognitive function;	chr5:88544870	chr5:88268895~88436685:+
THCA	cis	rs7829975	0.6	rs1719381	ENSG00000253981.4	ALG1L13P	-4.16	3.84e-05	0.0034	-0.18	-0.19	Mood instability;	chr8:8744834	chr8:8236003~8244667:-
THCA	cis	rs11633886	0.806	rs11632150	ENSG00000259200.1	RP11-718O11.1	4.16	3.84e-05	0.0034	0.23	0.19	Diisocyanate-induced asthma;	chr15:45760192	chr15:45705078~45931069:+
THCA	cis	rs7809950	0.678	rs7788271	ENSG00000272072.1	CTA-363E19.2	4.16	3.84e-05	0.0034	0.2	0.19	Coronary artery disease;	chr7:107345428	chr7:107192559~107193300:-
THCA	cis	rs1005277	0.579	rs1740735	ENSG00000120555.12	SEPT7P9	4.16	3.84e-05	0.0034	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38383069~38402916:-
THCA	cis	rs7968440	0.931	rs2251024	ENSG00000272368.2	RP4-605O3.4	4.16	3.84e-05	0.0034	0.12	0.19	Fibrinogen;	chr12:50709850	chr12:50112197~50165618:+
THCA	cis	rs875971	1	rs1363055	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66478288	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs9691480	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66479319	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs7789554	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66481051	chr7:66025126~66031544:-
THCA	cis	rs875971	0.895	rs1974769	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66485627	chr7:66025126~66031544:-
THCA	cis	rs875971	0.895	rs6460300	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66487937	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs7803416	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66489212	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs1981799	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66490572	chr7:66025126~66031544:-
THCA	cis	rs875971	0.964	rs2277911	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.0034	0.19	0.19	Aortic root size;	chr7:66493638	chr7:66025126~66031544:-
THCA	cis	rs1842579	1	rs11161678	ENSG00000272691.1	RP11-290M5.4	-4.16	3.84e-05	0.0034	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85815030	chr1:85578500~85578742:-
THCA	cis	rs4906332	0.966	rs35443927	ENSG00000252469.1	RNU7-160P	4.16	3.84e-05	0.0034	0.21	0.19	Coronary artery disease;	chr14:103383378	chr14:103550345~103550406:+
THCA	cis	rs12478296	0.786	rs55876934	ENSG00000220804.7	AC093642.5	4.16	3.84e-05	0.0034	0.21	0.19	Obesity-related traits;	chr2:242091665	chr2:242088633~242160153:+
THCA	cis	rs793571	0.59	rs618684	ENSG00000245975.2	RP11-30K9.6	4.16	3.84e-05	0.0034	0.17	0.19	Schizophrenia;	chr15:58823723	chr15:58768072~58770974:-
THCA	cis	rs4886920	0.775	rs7169661	ENSG00000260776.4	RP11-114H24.2	4.16	3.84e-05	0.0034	0.22	0.19	Neuroticism;	chr15:77854317	chr15:77914217~77926846:-
THCA	cis	rs7219021	0.705	rs67174000	ENSG00000248278.1	SUMO2P17	-4.16	3.84e-05	0.0034	-0.25	-0.19	Schizophrenia or bipolar disorder;	chr17:48905018	chr17:48874860~48908983:-
THCA	cis	rs7219021	0.705	rs28635466	ENSG00000248278.1	SUMO2P17	-4.16	3.84e-05	0.0034	-0.25	-0.19	Schizophrenia or bipolar disorder;	chr17:48906458	chr17:48874860~48908983:-
THCA	cis	rs4947019	0.534	rs9487087	ENSG00000223537.2	RP5-919F19.5	-4.16	3.84e-05	0.0034	-0.35	-0.19	Hematological parameters;	chr6:109401184	chr6:109487906~109506800:+
THCA	cis	rs7824557	0.592	rs920044	ENSG00000154316.13	TDH	-4.16	3.84e-05	0.0034	-0.14	-0.19	Retinal vascular caliber;	chr8:11366804	chr8:11339637~11368452:+
THCA	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	4.16	3.84e-05	0.0034	0.15	0.19	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
THCA	cis	rs9902453	0.933	rs7224199	ENSG00000263370.1	RP11-68I3.5	4.16	3.84e-05	0.0034	0.24	0.19	Coffee consumption (cups per day);	chr17:30196708	chr17:29639627~29640825:+
THCA	cis	rs6496932	0.755	rs56909106	ENSG00000259630.2	CTD-2262B20.1	4.16	3.84e-05	0.0034	0.23	0.19	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85415228~85415633:+
THCA	cis	rs9283706	0.95	rs10053810	ENSG00000229666.1	MAST4-AS1	4.16	3.84e-05	0.0034	0.26	0.19	Coronary artery disease;	chr5:66986070	chr5:67001383~67003953:-
THCA	cis	rs1799922	0.965	rs339050	ENSG00000271553.1	RP11-274B21.10	-4.16	3.84e-05	0.0034	-0.15	-0.19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128746151	chr7:128667043~128668156:+
THCA	cis	rs12935229	0.756	rs67533522	ENSG00000260922.1	RP11-538I12.3	-4.16	3.84e-05	0.0034	-0.3	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77263522	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.542	rs58027728	ENSG00000260922.1	RP11-538I12.3	-4.16	3.84e-05	0.0034	-0.3	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77263908	chr16:77234877~77290934:+
THCA	cis	rs656319	0.513	rs17746227	ENSG00000261451.1	RP11-981G7.1	-4.16	3.85e-05	0.0034	-0.24	-0.19	Myopia (pathological);	chr8:10124144	chr8:10433672~10438312:+
THCA	cis	rs9876781	1	rs13314659	ENSG00000244380.1	RP11-24C3.2	-4.16	3.85e-05	0.0034	-0.22	-0.19	Longevity;	chr3:48407742	chr3:48440352~48446656:-
THCA	cis	rs12681287	0.888	rs13042	ENSG00000254231.1	CTD-2284J15.1	4.16	3.85e-05	0.0034	0.2	0.19	Caudate activity during reward;	chr8:86472684	chr8:86333274~86343314:-
THCA	cis	rs4460629	0.521	rs7367897	ENSG00000160766.13	GBAP1	-4.16	3.85e-05	0.0034	-0.2	-0.19	Serum magnesium levels;	chr1:155110813	chr1:155213821~155227422:-
THCA	cis	rs3750965	0.881	rs61057353	ENSG00000260895.1	RP11-554A11.7	4.16	3.85e-05	0.0034	0.27	0.19	Hair color;	chr11:69049582	chr11:69103493~69109094:+
THCA	cis	rs889398	0.802	rs8050414	ENSG00000226232.7	RP11-419C5.2	-4.16	3.85e-05	0.0034	-0.19	-0.19	Body mass index;	chr16:69852910	chr16:69976388~69996188:-
THCA	cis	rs889398	0.802	rs8051168	ENSG00000226232.7	RP11-419C5.2	-4.16	3.85e-05	0.0034	-0.19	-0.19	Body mass index;	chr16:69853371	chr16:69976388~69996188:-
THCA	cis	rs2836950	0.545	rs2836956	ENSG00000238141.2	BRWD1-AS1	4.16	3.85e-05	0.0034	0.22	0.19	Menarche (age at onset);	chr21:39251092	chr21:39315707~39323218:+
THCA	cis	rs854765	0.718	rs6502629	ENSG00000281749.1	Y_RNA	4.16	3.85e-05	0.0034	0.25	0.19	Total body bone mineral density;	chr17:17966328	chr17:18001101~18001195:-
THCA	cis	rs8062405	0.824	rs28698667	ENSG00000270424.1	RP11-1348G14.6	4.16	3.85e-05	0.00341	0.21	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28749959~28750595:-
THCA	cis	rs10090774	0.965	rs12548549	ENSG00000279766.1	RP11-642A1.2	4.16	3.85e-05	0.00341	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140957173	chr8:140572142~140572812:-
THCA	cis	rs875971	1	rs4717300	ENSG00000229886.1	RP5-1132H15.3	4.16	3.85e-05	0.00341	0.19	0.19	Aortic root size;	chr7:66482393	chr7:66025126~66031544:-
THCA	cis	rs160451	0.745	rs218898	ENSG00000251136.7	RP11-37B2.1	-4.16	3.85e-05	0.00341	-0.18	-0.19	Leprosy;	chr8:89717140	chr8:89609409~89757727:-
THCA	cis	rs875971	1	rs4718357	ENSG00000230189.5	GS1-124K5.2	4.16	3.85e-05	0.00341	0.12	0.19	Aortic root size;	chr7:66495891	chr7:66409143~66490059:-
THCA	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	4.16	3.85e-05	0.00341	0.17	0.19	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
THCA	cis	rs2243480	0.522	rs73150635	ENSG00000232559.3	GS1-124K5.12	4.16	3.85e-05	0.00341	0.36	0.19	Diabetic kidney disease;	chr7:66507503	chr7:66554588~66576923:-
THCA	cis	rs6580649	0.941	rs7957764	ENSG00000273765.1	RP11-370I10.11	-4.16	3.85e-05	0.00341	-0.21	-0.19	Lung cancer;	chr12:48035918	chr12:48360920~48361377:+
THCA	cis	rs9595908	0.709	rs3213532	ENSG00000212293.1	SNORA16	4.16	3.85e-05	0.00341	0.22	0.19	Body mass index;	chr13:32773550	chr13:32420390~32420516:-
THCA	cis	rs4144027	0.869	rs55924227	ENSG00000269940.1	RP11-73M18.7	4.16	3.85e-05	0.00341	0.19	0.19	Blood metabolite levels;	chr14:103895013	chr14:103694560~103695170:+
THCA	cis	rs111669836	1	rs111669836	ENSG00000245532.5	NEAT1	4.16	3.85e-05	0.00341	0.14	0.19	Type 2 diabetes;	chr11:65596914	chr11:65422774~65445540:+
THCA	cis	rs1876905	0.597	rs191631	ENSG00000272356.1	RP5-1112D6.8	-4.16	3.86e-05	0.00341	-0.2	-0.19	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111309203~111313517:+
THCA	cis	rs67340775	0.541	rs200964	ENSG00000220721.1	OR1F12	4.16	3.86e-05	0.00341	0.29	0.19	Lung cancer in ever smokers;	chr6:27899165	chr6:28073316~28074233:+
THCA	cis	rs7577696	0.752	rs12618002	ENSG00000276334.1	AL133243.1	-4.16	3.86e-05	0.00341	-0.2	-0.19	Inflammatory biomarkers;	chr2:32122646	chr2:32521927~32523547:+
THCA	cis	rs7577696	0.785	rs11683760	ENSG00000276334.1	AL133243.1	-4.16	3.86e-05	0.00341	-0.2	-0.19	Inflammatory biomarkers;	chr2:32139024	chr2:32521927~32523547:+
THCA	cis	rs427943	0.798	rs11088983	ENSG00000223768.1	LINC00205	-4.16	3.86e-05	0.00341	-0.17	-0.19	Body mass index;	chr21:45188555	chr21:45293285~45297354:+
THCA	cis	rs427943	0.83	rs11700834	ENSG00000223768.1	LINC00205	-4.16	3.86e-05	0.00341	-0.17	-0.19	Body mass index;	chr21:45188694	chr21:45293285~45297354:+
THCA	cis	rs801193	1	rs2659912	ENSG00000229180.5	GS1-124K5.11	4.16	3.86e-05	0.00341	0.13	0.19	Aortic root size;	chr7:66693012	chr7:66526088~66542624:-
THCA	cis	rs7131987	0.65	rs7954871	ENSG00000273680.1	RP11-996F15.6	4.16	3.86e-05	0.00341	0.26	0.19	QT interval;	chr12:29306799	chr12:29332733~29333383:-
THCA	cis	rs2070488	0.931	rs7630012	ENSG00000229589.1	ACVR2B-AS1	-4.16	3.86e-05	0.00341	-0.17	-0.19	Electrocardiographic conduction measures;	chr3:38510759	chr3:38451027~38454820:-
THCA	cis	rs6696239	1	rs6692376	ENSG00000227711.2	RP11-275O4.5	-4.16	3.86e-05	0.00341	-0.27	-0.19	Height;	chr1:227528368	chr1:227509028~227520477:-
THCA	cis	rs150992	0.609	rs78254063	ENSG00000246763.5	RGMB-AS1	4.16	3.86e-05	0.00341	0.19	0.19	Body mass index;	chr5:98990803	chr5:98769618~98773469:-
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000275400.1	RP4-756H11.5	-4.16	3.86e-05	0.00341	-0.21	-0.19	Corneal structure;	chr7:66950082	chr7:66553805~66554199:-
THCA	cis	rs4780355	0.843	rs243325	ENSG00000263080.1	RP11-485G7.5	4.16	3.86e-05	0.00341	0.23	0.19	Crohn's disease and psoriasis;	chr16:11260640	chr16:11341809~11345211:-
THCA	cis	rs9473147	1	rs9473147	ENSG00000270761.1	RP11-385F7.1	-4.16	3.86e-05	0.00341	-0.15	-0.19	Platelet distribution width;Mean platelet volume;	chr6:47641856	chr6:47477243~47477572:-
THCA	cis	rs763121	0.819	rs5757126	ENSG00000228274.3	RP3-508I15.9	-4.16	3.86e-05	0.00341	-0.21	-0.19	Menopause (age at onset);	chr22:38527670	chr22:38667585~38681820:-
THCA	cis	rs7264396	1	rs224430	ENSG00000088340.14	FER1L4	4.16	3.86e-05	0.00341	0.18	0.19	Total cholesterol levels;	chr20:35565425	chr20:35558737~35607562:-
THCA	cis	rs7264396	1	rs224437	ENSG00000088340.14	FER1L4	4.16	3.86e-05	0.00341	0.18	0.19	Total cholesterol levels;	chr20:35566454	chr20:35558737~35607562:-
THCA	cis	rs1267303	0.716	rs942255	ENSG00000232022.5	FAAHP1	4.16	3.86e-05	0.00341	0.22	0.19	Monobrow;	chr1:46524120	chr1:46432129~46445521:+
THCA	cis	rs6517329	0.564	rs879892	ENSG00000236830.5	CBR3-AS1	-4.16	3.86e-05	0.00341	-0.18	-0.19	Schizophrenia;	chr21:36136580	chr21:36131767~36175815:-
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000220721.1	OR1F12	-4.16	3.86e-05	0.00341	-0.21	-0.19	Pubertal anthropometrics;	chr6:28255953	chr6:28073316~28074233:+
THCA	cis	rs6479891	1	rs9415692	ENSG00000272767.1	JMJD1C-AS1	4.16	3.86e-05	0.00342	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs7081275	ENSG00000272767.1	JMJD1C-AS1	-4.16	3.86e-05	0.00342	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs7895348	ENSG00000272767.1	JMJD1C-AS1	-4.16	3.86e-05	0.00342	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63465229~63466563:+
THCA	cis	rs10760158	0.769	rs10818517	ENSG00000226752.6	PSMD5-AS1	-4.16	3.86e-05	0.00342	-0.23	-0.19	Pulse pressure;	chr9:121242321	chr9:120824828~120854385:+
THCA	cis	rs34421088	0.506	rs4841519	ENSG00000154316.13	TDH	-4.16	3.86e-05	0.00342	-0.14	-0.19	Neuroticism;	chr8:11288719	chr8:11339637~11368452:+
THCA	cis	rs6600671	0.902	rs2222371	ENSG00000275585.1	CH17-118O6.3	4.16	3.86e-05	0.00342	0.24	0.19	Hip geometry;	chr1:121547320	chr1:120985692~121052167:-
THCA	cis	rs911555	0.723	rs4906320	ENSG00000269958.1	RP11-73M18.8	-4.16	3.86e-05	0.00342	-0.18	-0.19	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103696353~103697163:+
THCA	cis	rs6479891	0.915	rs4281380	ENSG00000272767.1	JMJD1C-AS1	-4.16	3.86e-05	0.00342	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63465229~63466563:+
THCA	cis	rs853679	0.76	rs2299029	ENSG00000273712.1	RP5-874C20.7	4.16	3.86e-05	0.00342	0.26	0.19	Depression;	chr6:28231053	chr6:28315613~28315883:-
THCA	cis	rs1950832	0.689	rs712406	ENSG00000258636.1	CTD-2298J14.2	4.16	3.86e-05	0.00342	0.24	0.19	Urate levels in obese individuals;	chr14:41645115	chr14:41587861~41604856:-
THCA	cis	rs4660214	0.59	rs11205885	ENSG00000228060.1	RP11-69E11.8	4.16	3.86e-05	0.00342	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39306633	chr1:39565160~39573203:+
THCA	cis	rs12755164	0.714	rs11210077	ENSG00000223479.3	RP4-788P17.1	-4.16	3.86e-05	0.00342	-0.2	-0.19	Schizophrenia;	chr1:72867480	chr1:73635216~73715214:+
THCA	cis	rs138249	0.934	rs138228	ENSG00000273253.2	RP3-402G11.26	4.15	3.87e-05	0.00342	0.18	0.19	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50118691	chr22:50199090~50200837:-
THCA	cis	rs6001482	0.778	rs1012819	ENSG00000272779.1	LL22NC03-80A10.6	-4.15	3.87e-05	0.00342	-0.21	-0.19	Diastolic blood pressure;	chr22:22238997	chr22:22303224~22310401:+
THCA	cis	rs17597773	0.638	rs17650107	ENSG00000238078.1	LINC01352	-4.15	3.87e-05	0.00342	-0.26	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220813204	chr1:220829255~220832429:+
THCA	cis	rs4948275	0.624	rs2606119	ENSG00000237233.2	TMEM26-AS1	-4.15	3.87e-05	0.00342	-0.25	-0.19	Night sleep phenotypes;	chr10:61597149	chr10:61452639~61481956:+
THCA	cis	rs7188445	0.556	rs7194711	ENSG00000277954.1	RP11-679B19.1	-4.15	3.87e-05	0.00342	-0.21	-0.19	Urate levels;	chr16:79715134	chr16:79202624~79206739:-
THCA	cis	rs11955398	0.522	rs12522154	ENSG00000272308.1	RP11-231G3.1	4.15	3.87e-05	0.00342	0.2	0.19	Intelligence (multi-trait analysis);	chr5:60885673	chr5:60866457~60866935:-
THCA	cis	rs7829975	0.714	rs12544992	ENSG00000253981.4	ALG1L13P	4.15	3.87e-05	0.00342	0.18	0.19	Mood instability;	chr8:8804171	chr8:8236003~8244667:-
THCA	cis	rs55966801	0.68	rs72882960	ENSG00000277290.1	RP11-326C3.16	-4.15	3.87e-05	0.00342	-0.25	-0.19	Plateletcrit;	chr11:268927	chr11:243099~243483:-
THCA	cis	rs17685	0.796	rs3757594	ENSG00000230882.1	AC005077.14	-4.15	3.87e-05	0.00342	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76049326	chr7:76071469~76074963:-
THCA	cis	rs10208649	0.831	rs75123794	ENSG00000233266.1	HMGB1P31	4.15	3.87e-05	0.00342	0.47	0.19	Body mass index;	chr2:53684845	chr2:54051334~54051760:+
THCA	cis	rs28829049	0.597	rs12745238	ENSG00000270728.1	RP4-657E11.10	-4.15	3.87e-05	0.00342	-0.14	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19067216	chr1:19297080~19297903:+
THCA	cis	rs12928939	0.517	rs17358402	ENSG00000260886.1	TAT-AS1	4.15	3.87e-05	0.00342	0.26	0.19	Post bronchodilator FEV1;	chr16:71934024	chr16:71565789~71578187:+
THCA	cis	rs9595908	0.746	rs2301391	ENSG00000212293.1	SNORA16	4.15	3.87e-05	0.00342	0.23	0.19	Body mass index;	chr13:32668398	chr13:32420390~32420516:-
THCA	cis	rs950169	0.881	rs34117475	ENSG00000188388.10	GOLGA6L3	4.15	3.87e-05	0.00342	0.25	0.19	Schizophrenia;	chr15:84565212	chr15:85240472~85247170:+
THCA	cis	rs1019173	0.966	rs10232678	ENSG00000261455.1	LINC01003	-4.15	3.87e-05	0.00342	-0.18	-0.19	Kidney function decline traits;	chr7:152015986	chr7:152463786~152465549:+
THCA	cis	rs901683	0.85	rs60791882	ENSG00000230869.1	CTGLF10P	-4.15	3.87e-05	0.00342	-0.43	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45604590	chr10:45678692~45700532:+
THCA	cis	rs901683	0.85	rs73291195	ENSG00000230869.1	CTGLF10P	-4.15	3.87e-05	0.00342	-0.43	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45605573	chr10:45678692~45700532:+
THCA	cis	rs901683	0.85	rs73291198	ENSG00000230869.1	CTGLF10P	-4.15	3.87e-05	0.00342	-0.43	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45605638	chr10:45678692~45700532:+
THCA	cis	rs9329221	0.621	rs12156350	ENSG00000261451.1	RP11-981G7.1	-4.15	3.87e-05	0.00342	-0.23	-0.19	Neuroticism;	chr8:10411006	chr8:10433672~10438312:+
THCA	cis	rs7259376	1	rs1975174	ENSG00000269345.1	VN1R85P	4.15	3.87e-05	0.00342	0.2	0.19	Menopause (age at onset);	chr19:22332449	chr19:22174766~22175191:-
THCA	cis	rs11694172	0.955	rs62194149	ENSG00000273456.1	RP11-686O6.2	4.15	3.87e-05	0.00343	0.17	0.19	Cholesterol, total;	chr2:202721036	chr2:202374932~202375604:-
THCA	cis	rs2120243	0.539	rs2085315	ENSG00000241770.1	RP11-555M1.3	-4.15	3.87e-05	0.00343	-0.25	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157394833	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.508	rs12492874	ENSG00000241770.1	RP11-555M1.3	-4.15	3.87e-05	0.00343	-0.25	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157395438	chr3:157163452~157169133:+
THCA	cis	rs860295	0.557	rs10796944	ENSG00000160766.13	GBAP1	-4.15	3.88e-05	0.00343	-0.25	-0.19	Body mass index;	chr1:155446537	chr1:155213821~155227422:-
THCA	cis	rs9905704	0.647	rs6503892	ENSG00000224738.1	AC099850.1	4.15	3.88e-05	0.00343	0.23	0.19	Testicular germ cell tumor;	chr17:58989725	chr17:59106598~59118267:+
THCA	cis	rs7829975	0.774	rs57312668	ENSG00000233609.3	RP11-62H7.2	4.15	3.88e-05	0.00343	0.18	0.19	Mood instability;	chr8:8822967	chr8:8961200~8979025:+
THCA	cis	rs7824557	0.527	rs2572448	ENSG00000154316.13	TDH	4.15	3.88e-05	0.00343	0.14	0.19	Retinal vascular caliber;	chr8:11381843	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.527	rs2572447	ENSG00000154316.13	TDH	4.15	3.88e-05	0.00343	0.14	0.19	Retinal vascular caliber;	chr8:11382001	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.527	rs2572446	ENSG00000154316.13	TDH	4.15	3.88e-05	0.00343	0.14	0.19	Retinal vascular caliber;	chr8:11382056	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.527	rs10109537	ENSG00000154316.13	TDH	4.15	3.88e-05	0.00343	0.14	0.19	Retinal vascular caliber;	chr8:11382131	chr8:11339637~11368452:+
THCA	cis	rs6671200	0.831	rs34537407	ENSG00000235501.4	RP4-639F20.1	-4.15	3.88e-05	0.00343	-0.39	-0.19	Stearic acid (18:0) levels;	chr1:95144697	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs34203531	ENSG00000235501.4	RP4-639F20.1	-4.15	3.88e-05	0.00343	-0.39	-0.19	Stearic acid (18:0) levels;	chr1:95146466	chr1:94927566~94963270:+
THCA	cis	rs748404	0.556	rs574856	ENSG00000166763.7	STRCP1	-4.15	3.88e-05	0.00343	-0.2	-0.19	Lung cancer;	chr15:43168636	chr15:43699488~43718184:-
THCA	cis	rs656319	0.559	rs60384372	ENSG00000261451.1	RP11-981G7.1	-4.15	3.88e-05	0.00343	-0.23	-0.19	Myopia (pathological);	chr8:10117074	chr8:10433672~10438312:+
THCA	cis	rs3820928	0.934	rs4675117	ENSG00000212391.1	SNORA48	4.15	3.88e-05	0.00343	0.22	0.19	Pulmonary function;	chr2:226905078	chr2:226968989~226969122:-
THCA	cis	rs6845263	0.512	rs2723047	ENSG00000254531.1	FLJ20021	4.15	3.88e-05	0.00343	0.16	0.19	Superior crus of antihelix expression;	chr4:101592863	chr4:101347780~101348883:+
THCA	cis	rs6845263	0.512	rs2717847	ENSG00000254531.1	FLJ20021	4.15	3.88e-05	0.00343	0.16	0.19	Superior crus of antihelix expression;	chr4:101592886	chr4:101347780~101348883:+
THCA	cis	rs7267979	0.844	rs6115188	ENSG00000274973.1	RP13-401N8.7	-4.15	3.88e-05	0.00343	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25845497~25845862:+
THCA	cis	rs9911578	0.835	rs1990008	ENSG00000224738.1	AC099850.1	-4.15	3.88e-05	0.00343	-0.22	-0.19	Intelligence (multi-trait analysis);	chr17:58382047	chr17:59106598~59118267:+
THCA	cis	rs763121	0.853	rs9622833	ENSG00000273076.1	RP3-508I15.22	4.15	3.88e-05	0.00343	0.19	0.19	Menopause (age at onset);	chr22:38604392	chr22:38743495~38743910:+
THCA	cis	rs7824557	0.569	rs10106207	ENSG00000254866.2	DEFB109P3	4.15	3.88e-05	0.00343	0.26	0.19	Retinal vascular caliber;	chr8:11157828	chr8:12150895~12151134:-
THCA	cis	rs78487399	0.808	rs6732766	ENSG00000234936.1	AC010883.5	4.15	3.88e-05	0.00343	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43485646	chr2:43229573~43233394:+
THCA	cis	rs35740288	0.752	rs11636138	ENSG00000259407.1	RP11-158M2.3	-4.15	3.88e-05	0.00343	-0.23	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744316	chr15:85744109~85750281:-
THCA	cis	rs7818688	0.578	rs11776489	ENSG00000253528.2	RP11-347C18.4	-4.15	3.88e-05	0.00343	-0.28	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94816230	chr8:94974573~94974853:-
THCA	cis	rs6878727	0.626	rs183164	ENSG00000253807.4	LINC01170	4.15	3.88e-05	0.00343	0.17	0.19	Breast cancer;	chr5:124334755	chr5:124059794~124405079:-
THCA	cis	rs8033133	0.581	rs8042796	ENSG00000251896.1	SNORD116-27	-4.15	3.88e-05	0.00343	-0.21	-0.19	Blood osmolality (transformed sodium);	chr15:25082249	chr15:25101575~25101666:+
THCA	cis	rs4713118	0.513	rs149944	ENSG00000261839.1	RP1-265C24.8	4.15	3.88e-05	0.00343	0.2	0.19	Parkinson's disease;	chr6:28035040	chr6:28136849~28139678:+
THCA	cis	rs1559040	0.86	rs78447233	ENSG00000272156.1	RP11-477N3.1	-4.15	3.88e-05	0.00343	-0.31	-0.19	Sudden cardiac arrest;	chr2:54134457	chr2:54082554~54085066:+
THCA	cis	rs734999	0.588	rs745367	ENSG00000225931.3	RP3-395M20.7	4.15	3.88e-05	0.00343	0.23	0.19	Ulcerative colitis;	chr1:2593018	chr1:2566410~2569888:+
THCA	cis	rs734999	0.549	rs3828154	ENSG00000225931.3	RP3-395M20.7	4.15	3.88e-05	0.00343	0.23	0.19	Ulcerative colitis;	chr1:2593504	chr1:2566410~2569888:+
THCA	cis	rs8177876	0.915	rs6420419	ENSG00000261061.1	RP11-303E16.2	4.15	3.88e-05	0.00343	0.25	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094418	chr16:81030770~81031485:+
THCA	cis	rs7829975	0.774	rs1039915	ENSG00000233609.3	RP11-62H7.2	4.15	3.88e-05	0.00343	0.18	0.19	Mood instability;	chr8:8822104	chr8:8961200~8979025:+
THCA	cis	rs11158026	0.526	rs11626210	ENSG00000258413.1	RP11-665C16.6	-4.15	3.88e-05	0.00343	-0.3	-0.19	Parkinson's disease;	chr14:54882831	chr14:55262767~55272075:-
THCA	cis	rs12755164	0.771	rs1525996	ENSG00000223479.3	RP4-788P17.1	-4.15	3.88e-05	0.00343	-0.2	-0.19	Schizophrenia;	chr1:72869052	chr1:73635216~73715214:+
THCA	cis	rs7045881	0.8	rs17694003	ENSG00000254396.1	RP11-56F10.3	4.15	3.88e-05	0.00343	0.35	0.19	Schizophrenia;	chr9:26801743	chr9:27102630~27104728:+
THCA	cis	rs10090774	0.71	rs4413752	ENSG00000280303.2	ERICD	-4.15	3.88e-05	0.00343	-0.17	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140678873	chr8:140636281~140638283:+
THCA	cis	rs3177980	0.539	rs12410352	ENSG00000239494.2	RN7SL333P	-4.15	3.88e-05	0.00343	-0.17	-0.19	Amyotrophic lateral sclerosis;	chr1:169825547	chr1:169859756~169860052:+
THCA	cis	rs7267979	1	rs7020	ENSG00000276952.1	RP5-965G21.6	4.15	3.88e-05	0.00343	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25284915~25285588:-
THCA	cis	rs860295	0.557	rs12091730	ENSG00000160766.13	GBAP1	-4.15	3.89e-05	0.00343	-0.24	-0.19	Body mass index;	chr1:155587180	chr1:155213821~155227422:-
THCA	cis	rs1414896	0.692	rs11165355	ENSG00000226026.4	RP11-57H12.3	4.15	3.89e-05	0.00344	0.18	0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95261104	chr1:95163219~95233982:-
THCA	cis	rs459482	0.504	rs469390	ENSG00000228318.3	AP001610.5	-4.15	3.89e-05	0.00344	-0.23	-0.19	IgG glycosylation;	chr21:41446003	chr21:41441056~41445708:-
THCA	cis	rs10761482	0.861	rs2061490	ENSG00000254271.1	RP11-131N11.4	4.15	3.89e-05	0.00344	0.25	0.19	Schizophrenia;	chr10:60343904	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs2061491	ENSG00000254271.1	RP11-131N11.4	4.15	3.89e-05	0.00344	0.25	0.19	Schizophrenia;	chr10:60343917	chr10:60734342~60741828:+
THCA	cis	rs2251260	1	rs2250772	ENSG00000232774.6	FLJ22447	-4.15	3.89e-05	0.00344	-0.28	-0.19	Yeast infection;	chr14:61552342	chr14:61570540~61658696:+
THCA	cis	rs62025270	0.547	rs338536	ENSG00000259295.5	CSPG4P12	-4.15	3.89e-05	0.00344	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85191438~85213905:+
THCA	cis	rs708224	0.874	rs796955	ENSG00000277342.1	RP11-843B15.4	4.15	3.89e-05	0.00344	0.24	0.19	Pancreatic cancer;	chr12:32278579	chr12:32109076~32109602:+
THCA	cis	rs72928364	1	rs67991823	ENSG00000256628.3	ZBTB11-AS1	4.15	3.89e-05	0.00344	0.33	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100912833	chr3:101676475~101679217:+
THCA	cis	rs7430456	0.901	rs9824206	ENSG00000231574.4	RP11-91K9.1	-4.15	3.89e-05	0.00344	-0.24	-0.19	Breast cancer;	chr3:177742093	chr3:177816865~177899224:+
THCA	cis	rs2058059	0.636	rs3015897	ENSG00000205578.5	POM121B	-4.15	3.89e-05	0.00344	-0.29	-0.19	Subcutaneous adipose tissue;	chr7:72658854	chr7:73293497~73301161:+
THCA	cis	rs17331151	0.512	rs9637477	ENSG00000242142.1	SERBP1P3	4.15	3.89e-05	0.00344	0.28	0.19	Immune reponse to smallpox (secreted IL-2);	chr3:52857410	chr3:53064283~53065091:-
THCA	cis	rs10155981	1	rs10155981	ENSG00000179428.2	AC073072.5	-4.15	3.89e-05	0.00344	-0.3	-0.19	Bilirubin levels;	chr7:22716844	chr7:22725395~22727620:-
THCA	cis	rs12935418	0.616	rs7184568	ENSG00000278985.1	RP11-303E16.9	4.15	3.89e-05	0.00344	0.24	0.19	Mean corpuscular volume;	chr16:80930951	chr16:80982319~80984094:-
THCA	cis	rs919433	0.617	rs13018267	ENSG00000231621.1	AC013264.2	4.15	3.89e-05	0.00344	0.2	0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197680868	chr2:197197991~197199273:+
THCA	cis	rs7824557	0.564	rs12547100	ENSG00000261451.1	RP11-981G7.1	-4.15	3.89e-05	0.00344	-0.24	-0.19	Retinal vascular caliber;	chr8:11385123	chr8:10433672~10438312:+
THCA	cis	rs10761482	0.861	rs4948405	ENSG00000254271.1	RP11-131N11.4	4.15	3.89e-05	0.00344	0.25	0.19	Schizophrenia;	chr10:60348661	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10761489	ENSG00000254271.1	RP11-131N11.4	4.15	3.89e-05	0.00344	0.25	0.19	Schizophrenia;	chr10:60348846	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10761490	ENSG00000254271.1	RP11-131N11.4	4.15	3.89e-05	0.00344	0.25	0.19	Schizophrenia;	chr10:60348908	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10761491	ENSG00000254271.1	RP11-131N11.4	4.15	3.89e-05	0.00344	0.25	0.19	Schizophrenia;	chr10:60348960	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10761492	ENSG00000254271.1	RP11-131N11.4	4.15	3.89e-05	0.00344	0.25	0.19	Schizophrenia;	chr10:60349143	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10733763	ENSG00000254271.1	RP11-131N11.4	4.15	3.89e-05	0.00344	0.25	0.19	Schizophrenia;	chr10:60349522	chr10:60734342~60741828:+
THCA	cis	rs1232027	0.656	rs844369	ENSG00000249655.1	CTC-325J23.2	4.15	3.89e-05	0.00344	0.22	0.19	Huntington's disease progression;	chr5:80697683	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.588	rs836816	ENSG00000249655.1	CTC-325J23.2	4.15	3.89e-05	0.00344	0.22	0.19	Huntington's disease progression;	chr5:80698803	chr5:80630313~80631590:-
THCA	cis	rs7914558	0.646	rs12768205	ENSG00000213277.3	MARCKSL1P1	4.15	3.89e-05	0.00344	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102888092	chr10:103175554~103176094:+
THCA	cis	rs875971	0.545	rs6969224	ENSG00000273142.1	RP11-458F8.4	4.15	3.89e-05	0.00344	0.18	0.19	Aortic root size;	chr7:66370011	chr7:66902857~66906297:+
THCA	cis	rs4788570	0.615	rs4788550	ENSG00000260593.1	RP11-432I5.2	-4.15	3.9e-05	0.00344	-0.3	-0.19	Intelligence (multi-trait analysis);	chr16:71686620	chr16:71623708~71626816:-
THCA	cis	rs13063635	0.79	rs35951367	ENSG00000226074.4	PRSS44	-4.15	3.9e-05	0.00344	-0.33	-0.19	Eosinophil percentage of granulocytes;	chr3:46076947	chr3:46809359~46812558:-
THCA	cis	rs13434995	0.562	rs10529258	ENSG00000249700.7	SRD5A3-AS1	-4.15	3.9e-05	0.00344	-0.27	-0.19	Adiponectin levels;	chr4:55546702	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.512	rs115635692	ENSG00000249700.7	SRD5A3-AS1	-4.15	3.9e-05	0.00344	-0.27	-0.19	Adiponectin levels;	chr4:55546706	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.626	rs116135676	ENSG00000249700.7	SRD5A3-AS1	-4.15	3.9e-05	0.00344	-0.27	-0.19	Adiponectin levels;	chr4:55546707	chr4:55363971~55395847:-
THCA	cis	rs12478296	0.892	rs11893879	ENSG00000220804.7	AC093642.5	4.15	3.9e-05	0.00344	0.2	0.19	Obesity-related traits;	chr2:242068260	chr2:242088633~242160153:+
THCA	cis	rs12451471	0.637	rs12950757	ENSG00000279259.1	RP11-334C17.3	-4.15	3.9e-05	0.00344	-0.19	-0.19	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80123001	chr17:80147250~80148596:+
THCA	cis	rs4648045	0.501	rs4648052	ENSG00000246560.2	RP11-10L12.4	4.15	3.9e-05	0.00344	0.23	0.19	Lymphocyte percentage of white cells;	chr4:102593898	chr4:102828055~102844075:+
THCA	cis	rs4648045	0.501	rs3774964	ENSG00000246560.2	RP11-10L12.4	4.15	3.9e-05	0.00344	0.23	0.19	Lymphocyte percentage of white cells;	chr4:102598330	chr4:102828055~102844075:+
THCA	cis	rs28374715	0.532	rs7164211	ENSG00000247556.5	OIP5-AS1	4.15	3.9e-05	0.00344	0.18	0.19	Ulcerative colitis;	chr15:41412843	chr15:41283990~41309737:+
THCA	cis	rs1501911	0.509	rs327786	ENSG00000248489.1	CTD-2007H13.3	4.15	3.9e-05	0.00345	0.17	0.19	Lung function (FEV1/FVC);	chr5:98878301	chr5:98929171~98995013:+
THCA	cis	rs35176054	0.73	rs34943195	ENSG00000280693.1	SH3PXD2A-AS1	-4.15	3.9e-05	0.00345	-0.36	-0.19	Atrial fibrillation;	chr10:103757733	chr10:103745966~103755423:+
THCA	cis	rs1348850	0.54	rs6737342	ENSG00000280374.1	RP11-337N6.3	-4.15	3.9e-05	0.00345	-0.33	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177554389	chr2:177317715~177318471:-
THCA	cis	rs6756513	0.5	rs56222989	ENSG00000231024.1	AC092431.3	-4.15	3.9e-05	0.00345	-0.28	-0.19	Breast cancer;Platelet count;	chr2:69861998	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs60248458	ENSG00000231024.1	AC092431.3	-4.15	3.9e-05	0.00345	-0.28	-0.19	Breast cancer;Platelet count;	chr2:69866766	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs2124007	ENSG00000231024.1	AC092431.3	-4.15	3.9e-05	0.00345	-0.28	-0.19	Breast cancer;Platelet count;	chr2:69880277	chr2:69700192~69713847:-
THCA	cis	rs9926296	0.618	rs8058179	ENSG00000260259.1	RP11-368I7.4	4.15	3.9e-05	0.00345	0.2	0.19	Vitiligo;	chr16:89780579	chr16:89682620~89686569:-
THCA	cis	rs2298450	0.717	rs8126481	ENSG00000214867.3	SRSF9P1	4.15	3.9e-05	0.00345	0.29	0.19	Schizophrenia;	chr21:36242483	chr21:36295173~36295702:-
THCA	cis	rs9467773	0.595	rs13207371	ENSG00000261353.1	CTA-14H9.5	-4.15	3.9e-05	0.00345	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26527063~26527404:+
THCA	cis	rs7646881	0.544	rs2291594	ENSG00000240207.5	RP11-379F4.4	-4.15	3.9e-05	0.00345	-0.29	-0.19	Tetralogy of Fallot;	chr3:158661047	chr3:158732263~158784070:+
THCA	cis	rs7968440	1	rs2731443	ENSG00000272368.2	RP4-605O3.4	4.15	3.9e-05	0.00345	0.12	0.19	Fibrinogen;	chr12:50700355	chr12:50112197~50165618:+
THCA	cis	rs11758351	1	rs16891378	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26188636	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs74363821	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26189296	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs111596617	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26191450	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs112751982	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26191730	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.925	rs10452600	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26192274	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs79264785	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26193893	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.925	rs78932312	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26194641	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs3734530	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26195180	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs1341759	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26195274	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs76329209	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26196202	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs2143346	ENSG00000216331.1	HIST1H1PS1	-4.15	3.9e-05	0.00345	-0.3	-0.19	Renal underexcretion gout;Gout;	chr6:26198221	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs3757135	ENSG00000216331.1	HIST1H1PS1	4.15	3.9e-05	0.00345	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26200479	chr6:26195566~26195771:+
THCA	cis	rs12893668	0.703	rs4906336	ENSG00000252469.1	RNU7-160P	4.15	3.9e-05	0.00345	0.23	0.19	Reticulocyte count;	chr14:103566928	chr14:103550345~103550406:+
THCA	cis	rs2115630	0.846	rs8024538	ENSG00000259295.5	CSPG4P12	-4.15	3.9e-05	0.00345	-0.26	-0.19	P wave terminal force;	chr15:84825188	chr15:85191438~85213905:+
THCA	cis	rs11247915	0.583	rs66569416	ENSG00000236782.4	RP11-96L14.7	-4.15	3.9e-05	0.00345	-0.22	-0.19	Obesity-related traits;	chr1:26333246	chr1:26169947~26171821:-
THCA	cis	rs7824557	0.527	rs2736296	ENSG00000206014.6	OR7E161P	4.15	3.9e-05	0.00345	0.22	0.19	Retinal vascular caliber;	chr8:11377335	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.51	rs2736297	ENSG00000206014.6	OR7E161P	4.15	3.9e-05	0.00345	0.22	0.19	Retinal vascular caliber;	chr8:11377376	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.527	rs2736298	ENSG00000206014.6	OR7E161P	4.15	3.9e-05	0.00345	0.22	0.19	Retinal vascular caliber;	chr8:11377627	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.527	rs57629785	ENSG00000206014.6	OR7E161P	4.15	3.9e-05	0.00345	0.22	0.19	Retinal vascular caliber;	chr8:11377641	chr8:11928597~11929563:-
THCA	cis	rs7829975	0.511	rs1543238	ENSG00000233609.3	RP11-62H7.2	4.15	3.91e-05	0.00345	0.18	0.19	Mood instability;	chr8:8277287	chr8:8961200~8979025:+
THCA	cis	rs6496044	0.568	rs6496049	ENSG00000259630.2	CTD-2262B20.1	-4.15	3.91e-05	0.00345	-0.2	-0.19	Interstitial lung disease;	chr15:85525974	chr15:85415228~85415633:+
THCA	cis	rs17685	0.672	rs1639623	ENSG00000230882.1	AC005077.14	4.15	3.91e-05	0.00345	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76078633	chr7:76071469~76074963:-
THCA	cis	rs9868809	0.649	rs17256786	ENSG00000229759.1	MRPS18AP1	-4.15	3.91e-05	0.00345	-0.47	-0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48566583	chr3:48256350~48256938:-
THCA	cis	rs9868809	0.764	rs41290686	ENSG00000229759.1	MRPS18AP1	-4.15	3.91e-05	0.00345	-0.47	-0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48566626	chr3:48256350~48256938:-
THCA	cis	rs4908768	0.817	rs11577530	ENSG00000232912.4	RP5-1115A15.1	-4.15	3.91e-05	0.00345	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8683385	chr1:8424645~8434838:+
THCA	cis	rs801193	1	rs3778909	ENSG00000230295.1	RP11-458F8.2	-4.15	3.91e-05	0.00345	-0.14	-0.19	Aortic root size;	chr7:66790659	chr7:66880708~66882981:+
THCA	cis	rs6517329	0.526	rs35433179	ENSG00000236830.5	CBR3-AS1	-4.15	3.91e-05	0.00345	-0.18	-0.19	Schizophrenia;	chr21:36167162	chr21:36131767~36175815:-
THCA	cis	rs4908768	0.906	rs6656249	ENSG00000232912.4	RP5-1115A15.1	-4.15	3.91e-05	0.00345	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8520956	chr1:8424645~8434838:+
THCA	cis	rs12368653	0.525	rs1564374	ENSG00000270039.1	RP11-571M6.17	4.15	3.91e-05	0.00345	0.2	0.19	Multiple sclerosis;	chr12:57616380	chr12:57803838~57804415:+
THCA	cis	rs875971	0.52	rs160645	ENSG00000273142.1	RP11-458F8.4	-4.15	3.91e-05	0.00345	-0.18	-0.19	Aortic root size;	chr7:66091320	chr7:66902857~66906297:+
THCA	cis	rs901683	0.85	rs73291121	ENSG00000230869.1	CTGLF10P	-4.15	3.91e-05	0.00345	-0.43	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45601956	chr10:45678692~45700532:+
THCA	cis	rs8081395	0.741	rs180519	ENSG00000267302.4	RP11-178C3.2	4.15	3.91e-05	0.00345	0.22	0.19	White blood cell count;	chr17:59938910	chr17:59964832~59996972:+
THCA	cis	rs12612619	0.732	rs10432697	ENSG00000272148.1	RP11-195B17.1	4.15	3.91e-05	0.00346	0.17	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27049184	chr2:27062428~27062907:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000275400.1	RP4-756H11.5	-4.15	3.91e-05	0.00346	-0.18	-0.19	Calcium levels;	chr7:65974892	chr7:66553805~66554199:-
THCA	cis	rs6828577	0.862	rs298992	ENSG00000281731.1	RP11-384K6.8	4.15	3.91e-05	0.00346	0.21	0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118720786	chr4:118664087~118685341:-
THCA	cis	rs354225	0.539	rs6708082	ENSG00000162997.14	PRORSD1P	4.15	3.91e-05	0.00346	0.22	0.19	Schizophrenia;	chr2:54731693	chr2:55282319~55284522:+
THCA	cis	rs10484434	0.748	rs62396165	ENSG00000272462.2	U91328.19	4.15	3.91e-05	0.00346	0.2	0.19	HIV-1 viral setpoint;	chr6:26090153	chr6:25992662~26001775:+
THCA	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	4.15	3.92e-05	0.00346	0.21	0.19	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
THCA	cis	rs4845570	0.834	rs7007	ENSG00000203288.3	RP11-98D18.9	-4.15	3.92e-05	0.00346	-0.23	-0.19	Coronary artery disease;	chr1:151763100	chr1:151790804~151794402:+
THCA	cis	rs9532669	0.963	rs4941391	ENSG00000229473.2	RGS17P1	4.15	3.92e-05	0.00346	0.24	0.19	Cervical cancer;	chr13:40939787	chr13:40992779~40993331:-
THCA	cis	rs11633886	0.565	rs17554726	ENSG00000273972.1	CTD-2306A12.1	4.15	3.92e-05	0.00346	0.21	0.19	Diisocyanate-induced asthma;	chr15:45759272	chr15:45702640~45703183:+
THCA	cis	rs1923243	0.677	rs12142471	ENSG00000223479.3	RP4-788P17.1	4.15	3.92e-05	0.00346	0.21	0.19	Migraine;	chr1:73140623	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12121084	ENSG00000223479.3	RP4-788P17.1	4.15	3.92e-05	0.00346	0.21	0.19	Migraine;	chr1:73143321	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs11590930	ENSG00000223479.3	RP4-788P17.1	4.15	3.92e-05	0.00346	0.21	0.19	Migraine;	chr1:73145367	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs60273785	ENSG00000223479.3	RP4-788P17.1	4.15	3.92e-05	0.00346	0.21	0.19	Migraine;	chr1:73145992	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs11576269	ENSG00000223479.3	RP4-788P17.1	4.15	3.92e-05	0.00346	0.21	0.19	Migraine;	chr1:73146277	chr1:73635216~73715214:+
THCA	cis	rs2251260	0.735	rs1068190	ENSG00000232774.6	FLJ22447	-4.15	3.92e-05	0.00346	-0.31	-0.19	Yeast infection;	chr14:61552855	chr14:61570540~61658696:+
THCA	cis	rs889398	0.935	rs12933292	ENSG00000226232.7	RP11-419C5.2	4.15	3.92e-05	0.00346	0.19	0.19	Body mass index;	chr16:69532406	chr16:69976388~69996188:-
THCA	cis	rs896854	0.573	rs13271375	ENSG00000253528.2	RP11-347C18.4	4.15	3.92e-05	0.00346	0.21	0.19	Type 2 diabetes;	chr8:94841679	chr8:94974573~94974853:-
THCA	cis	rs7267979	0.844	rs6083851	ENSG00000274973.1	RP13-401N8.7	4.15	3.92e-05	0.00346	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.844	rs4423675	ENSG00000274973.1	RP13-401N8.7	4.15	3.92e-05	0.00346	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25845497~25845862:+
THCA	cis	rs12893668	0.616	rs58033365	ENSG00000244691.1	RPL10AP1	-4.15	3.92e-05	0.00346	-0.27	-0.19	Reticulocyte count;	chr14:103564564	chr14:103412119~103412761:-
THCA	cis	rs12893668	0.645	rs12889403	ENSG00000244691.1	RPL10AP1	-4.15	3.92e-05	0.00346	-0.27	-0.19	Reticulocyte count;	chr14:103568409	chr14:103412119~103412761:-
THCA	cis	rs12893668	0.703	rs12894729	ENSG00000244691.1	RPL10AP1	-4.15	3.92e-05	0.00346	-0.27	-0.19	Reticulocyte count;	chr14:103568955	chr14:103412119~103412761:-
THCA	cis	rs11671005	0.656	rs11671092	ENSG00000269473.1	CTD-2619J13.19	4.15	3.92e-05	0.00346	0.23	0.19	Mean platelet volume;	chr19:58497742	chr19:58440448~58445849:+
THCA	cis	rs11671005	0.656	rs55928441	ENSG00000269473.1	CTD-2619J13.19	4.15	3.92e-05	0.00346	0.23	0.19	Mean platelet volume;	chr19:58498307	chr19:58440448~58445849:+
THCA	cis	rs12893668	0.608	rs12889721	ENSG00000252469.1	RNU7-160P	4.15	3.92e-05	0.00346	0.23	0.19	Reticulocyte count;	chr14:103568526	chr14:103550345~103550406:+
THCA	cis	rs4713118	0.615	rs9295747	ENSG00000261839.1	RP1-265C24.8	-4.15	3.92e-05	0.00346	-0.2	-0.19	Parkinson's disease;	chr6:27769214	chr6:28136849~28139678:+
THCA	cis	rs6001482	0.679	rs1894238	ENSG00000272779.1	LL22NC03-80A10.6	-4.15	3.92e-05	0.00346	-0.21	-0.19	Diastolic blood pressure;	chr22:22235704	chr22:22303224~22310401:+
THCA	cis	rs17711722	0.701	rs781145	ENSG00000229180.5	GS1-124K5.11	4.15	3.92e-05	0.00346	0.13	0.19	Calcium levels;	chr7:65975383	chr7:66526088~66542624:-
THCA	cis	rs1267303	0.675	rs2476164	ENSG00000232022.5	FAAHP1	-4.15	3.92e-05	0.00346	-0.21	-0.19	Monobrow;	chr1:46519602	chr1:46432129~46445521:+
THCA	cis	rs13256369	0.951	rs13270852	ENSG00000254153.1	CTA-398F10.2	-4.15	3.92e-05	0.00346	-0.21	-0.19	Obesity-related traits;	chr8:8709343	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs13271698	ENSG00000254153.1	CTA-398F10.2	-4.15	3.92e-05	0.00346	-0.21	-0.19	Obesity-related traits;	chr8:8710029	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs12550458	ENSG00000254153.1	CTA-398F10.2	-4.15	3.92e-05	0.00346	-0.21	-0.19	Obesity-related traits;	chr8:8710322	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs12545771	ENSG00000254153.1	CTA-398F10.2	-4.15	3.92e-05	0.00346	-0.21	-0.19	Obesity-related traits;	chr8:8710467	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.95	rs12548792	ENSG00000254153.1	CTA-398F10.2	-4.15	3.92e-05	0.00346	-0.21	-0.19	Obesity-related traits;	chr8:8710521	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.901	rs13251887	ENSG00000254153.1	CTA-398F10.2	-4.15	3.92e-05	0.00346	-0.21	-0.19	Obesity-related traits;	chr8:8711168	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs883648	ENSG00000254153.1	CTA-398F10.2	-4.15	3.92e-05	0.00346	-0.21	-0.19	Obesity-related traits;	chr8:8712011	chr8:8456909~8461337:-
THCA	cis	rs7824557	0.564	rs6601584	ENSG00000227888.4	FAM66A	-4.15	3.92e-05	0.00346	-0.24	-0.19	Retinal vascular caliber;	chr8:11374834	chr8:12362019~12388296:+
THCA	cis	rs3892630	0.588	rs28787932	ENSG00000267567.1	CTD-2538C1.3	4.15	3.92e-05	0.00346	0.27	0.19	Red blood cell traits;	chr19:32735323	chr19:32718298~32719595:-
THCA	cis	rs55692468	0.52	rs62180799	ENSG00000213197.3	AC012066.1	4.15	3.92e-05	0.00346	0.25	0.19	Intraocular pressure;	chr2:152445594	chr2:152389937~152390630:+
THCA	cis	rs7818688	0.614	rs60171840	ENSG00000253528.2	RP11-347C18.4	-4.15	3.92e-05	0.00346	-0.28	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94820292	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.614	rs59265059	ENSG00000253528.2	RP11-347C18.4	-4.15	3.92e-05	0.00346	-0.28	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94820588	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.653	rs4075834	ENSG00000253528.2	RP11-347C18.4	-4.15	3.92e-05	0.00346	-0.28	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94821519	chr8:94974573~94974853:-
THCA	cis	rs4700393	0.52	rs286158	ENSG00000251279.1	CTC-436P18.1	-4.15	3.92e-05	0.00346	-0.26	-0.19	Intelligence (multi-trait analysis);	chr5:60638426	chr5:61162070~61232040:+
THCA	cis	rs2380220	1	rs2380222	ENSG00000261366.1	MANEA-AS1	-4.15	3.92e-05	0.00346	-0.21	-0.19	Behavioural disinhibition (generation interaction);	chr6:95527519	chr6:95575183~95577450:-
THCA	cis	rs2562784	0.587	rs2562763	ENSG00000225151.9	GOLGA2P7	-4.15	3.92e-05	0.00346	-0.34	-0.19	Height;	chr15:83596468	chr15:84199311~84230136:-
THCA	cis	rs7824557	0.564	rs2572379	ENSG00000206014.6	OR7E161P	4.15	3.92e-05	0.00346	0.22	0.19	Retinal vascular caliber;	chr8:11379971	chr8:11928597~11929563:-
THCA	cis	rs3892630	0.588	rs7248798	ENSG00000267567.1	CTD-2538C1.3	4.15	3.92e-05	0.00346	0.27	0.19	Red blood cell traits;	chr19:32812778	chr19:32718298~32719595:-
THCA	cis	rs7136259	0.844	rs1401982	ENSG00000258302.2	RP11-981P6.1	-4.15	3.92e-05	0.00346	-0.16	-0.19	Coronary heart disease;	chr12:89595822	chr12:89561129~89594878:+
THCA	cis	rs8031584	0.918	rs61997140	ENSG00000270015.1	RP11-540B6.6	-4.15	3.93e-05	0.00346	-0.14	-0.19	Huntington's disease progression;	chr15:30985109	chr15:30926514~30928407:+
THCA	cis	rs724818	0.661	rs72678319	ENSG00000251609.2	SETP12	-4.15	3.93e-05	0.00347	-0.52	-0.19	Monobrow thickness;	chr4:120776167	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs1511302	ENSG00000251609.2	SETP12	4.15	3.93e-05	0.00347	0.52	0.19	Monobrow thickness;	chr4:120777467	chr4:120895494~120897083:-
THCA	cis	rs875971	0.522	rs4718286	ENSG00000229180.5	GS1-124K5.11	4.15	3.93e-05	0.00347	0.13	0.19	Aortic root size;	chr7:65827777	chr7:66526088~66542624:-
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000229180.5	GS1-124K5.11	4.15	3.93e-05	0.00347	0.13	0.19	Calcium levels;	chr7:65837419	chr7:66526088~66542624:-
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000229180.5	GS1-124K5.11	4.15	3.93e-05	0.00347	0.13	0.19	Calcium levels;	chr7:65872915	chr7:66526088~66542624:-
THCA	cis	rs13108904	0.557	rs1250086	ENSG00000254094.1	AC078852.1	4.15	3.93e-05	0.00347	0.22	0.19	Obesity-related traits;	chr4:1254263	chr4:1356581~1358075:+
THCA	cis	rs7045881	0.512	rs4621911	ENSG00000254396.1	RP11-56F10.3	4.15	3.93e-05	0.00347	0.23	0.19	Schizophrenia;	chr9:27055285	chr9:27102630~27104728:+
THCA	cis	rs7267979	0.528	rs2387976	ENSG00000274414.1	RP5-965G21.4	4.15	3.93e-05	0.00347	0.23	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:25239007~25245229:-
THCA	cis	rs6545883	0.783	rs6545888	ENSG00000271889.1	RP11-493E12.1	4.15	3.93e-05	0.00347	0.18	0.19	Tuberculosis;	chr2:61618080	chr2:61151433~61162105:-
THCA	cis	rs12440869	1	rs15974	ENSG00000270964.1	RP11-502I4.3	4.15	3.93e-05	0.00347	0.17	0.19	Peak velocity of the mitral A-wave;	chr15:67201248	chr15:67541072~67542604:-
THCA	cis	rs7819412	0.744	rs4841503	ENSG00000254866.2	DEFB109P3	4.15	3.93e-05	0.00347	0.26	0.19	Triglycerides;	chr8:11166817	chr8:12150895~12151134:-
THCA	cis	rs724818	0.661	rs4833182	ENSG00000251609.2	SETP12	-4.15	3.93e-05	0.00347	-0.47	-0.19	Monobrow thickness;	chr4:120801413	chr4:120895494~120897083:-
THCA	cis	rs6747952	0.899	rs6710785	ENSG00000279484.1	KLHL30-AS1	4.15	3.93e-05	0.00347	0.18	0.19	Mean corpuscular hemoglobin concentration;	chr2:238166000	chr2:238152889~238155994:-
THCA	cis	rs11122895	0.509	rs3860380	ENSG00000236307.2	EEF1E1P1	-4.15	3.93e-05	0.00347	-0.23	-0.19	Allergic sensitization;	chr2:111693810	chr2:111887914~111888741:+
THCA	cis	rs7131987	0.565	rs7137141	ENSG00000275476.1	RP11-996F15.4	4.15	3.93e-05	0.00347	0.19	0.19	QT interval;	chr12:29272168	chr12:29277397~29277882:-
THCA	cis	rs6690583	0.623	rs893618	ENSG00000226970.2	RP11-82H13.2	4.15	3.93e-05	0.00347	0.32	0.19	Serum sulfate level;	chr1:85048087	chr1:84244334~84244577:+
THCA	cis	rs853679	0.567	rs13196606	ENSG00000273712.1	RP5-874C20.7	4.15	3.93e-05	0.00347	0.22	0.19	Depression;	chr6:28402301	chr6:28315613~28315883:-
THCA	cis	rs9393813	0.516	rs4713098	ENSG00000204789.4	ZNF204P	-4.15	3.93e-05	0.00347	-0.15	-0.19	Bipolar disorder;	chr6:27435826	chr6:27357825~27360221:-
THCA	cis	rs801193	1	rs2707836	ENSG00000223473.2	GS1-124K5.3	4.15	3.93e-05	0.00347	0.12	0.19	Aortic root size;	chr7:66695448	chr7:66491049~66493566:-
THCA	cis	rs801193	0.844	rs7779971	ENSG00000223473.2	GS1-124K5.3	4.15	3.93e-05	0.00347	0.12	0.19	Aortic root size;	chr7:66696803	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs2659906	ENSG00000223473.2	GS1-124K5.3	4.15	3.93e-05	0.00347	0.12	0.19	Aortic root size;	chr7:66700323	chr7:66491049~66493566:-
THCA	cis	rs804280	0.542	rs36100659	ENSG00000206014.6	OR7E161P	-4.15	3.93e-05	0.00347	-0.23	-0.19	Myopia (pathological);	chr8:11934144	chr8:11928597~11929563:-
THCA	cis	rs7688540	0.8	rs61792060	ENSG00000275426.1	CH17-262A2.1	4.15	3.93e-05	0.00347	0.23	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:149738~150317:+
THCA	cis	rs41342147	0.591	rs3771547	ENSG00000223374.1	AC005104.3	4.15	3.93e-05	0.00347	0.16	0.19	Vitiligo;	chr2:241356858	chr2:241351340~241353104:-
THCA	cis	rs113835537	0.866	rs59566349	ENSG00000255517.5	CTD-3074O7.5	-4.15	3.93e-05	0.00347	-0.21	-0.19	Airway imaging phenotypes;	chr11:66598523	chr11:66473490~66480233:-
THCA	cis	rs113835537	0.935	rs1127145	ENSG00000255517.5	CTD-3074O7.5	-4.15	3.93e-05	0.00347	-0.21	-0.19	Airway imaging phenotypes;	chr11:66605834	chr11:66473490~66480233:-
THCA	cis	rs4713118	0.869	rs6914924	ENSG00000220721.1	OR1F12	4.15	3.93e-05	0.00347	0.24	0.19	Parkinson's disease;	chr6:27743751	chr6:28073316~28074233:+
THCA	cis	rs7577696	0.752	rs12995952	ENSG00000276334.1	AL133243.1	-4.15	3.93e-05	0.00347	-0.2	-0.19	Inflammatory biomarkers;	chr2:32148229	chr2:32521927~32523547:+
THCA	cis	rs7044106	0.655	rs1359329	ENSG00000238181.2	AHCYP2	-4.15	3.93e-05	0.00347	-0.3	-0.19	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120720673~120721972:+
THCA	cis	rs7572733	0.555	rs7561950	ENSG00000231621.1	AC013264.2	-4.15	3.94e-05	0.00347	-0.2	-0.19	Dermatomyositis;	chr2:197889520	chr2:197197991~197199273:+
THCA	cis	rs12935229	0.689	rs17701840	ENSG00000260922.1	RP11-538I12.3	-4.15	3.94e-05	0.00347	-0.3	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77275665	chr16:77234877~77290934:+
THCA	cis	rs4819052	1	rs2297286	ENSG00000182586.6	LINC00334	-4.15	3.94e-05	0.00347	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45234340~45258730:+
THCA	cis	rs6479891	0.908	rs11819167	ENSG00000272767.1	JMJD1C-AS1	4.15	3.94e-05	0.00347	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs1904295	ENSG00000272767.1	JMJD1C-AS1	-4.15	3.94e-05	0.00347	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63465229~63466563:+
THCA	cis	rs6479901	0.512	rs6415875	ENSG00000272767.1	JMJD1C-AS1	-4.15	3.94e-05	0.00347	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63465229~63466563:+
THCA	cis	rs6479901	0.512	rs4439410	ENSG00000272767.1	JMJD1C-AS1	-4.15	3.94e-05	0.00347	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63465229~63466563:+
THCA	cis	rs72827839	0.802	rs4794321	ENSG00000266601.1	RP11-6N17.3	-4.15	3.94e-05	0.00347	-0.22	-0.19	Ease of getting up in the morning;	chr17:47951478	chr17:47929682~47933106:-
THCA	cis	rs6878727	0.626	rs696477	ENSG00000253807.4	LINC01170	4.15	3.94e-05	0.00347	0.17	0.19	Breast cancer;	chr5:124336885	chr5:124059794~124405079:-
THCA	cis	rs758324	0.717	rs7720910	ENSG00000237714.1	P4HA2-AS1	4.15	3.94e-05	0.00347	0.29	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132024654	chr5:132184876~132192808:+
THCA	cis	rs1124769	0.57	rs1276856	ENSG00000259378.1	DCAF13P3	-4.15	3.94e-05	0.00347	-0.26	-0.19	Cognitive performance;	chr15:50863689	chr15:50944663~50945996:+
THCA	cis	rs67478160	0.584	rs12433009	ENSG00000258735.1	LINC00637	-4.15	3.94e-05	0.00348	-0.23	-0.19	Schizophrenia;	chr14:103730068	chr14:103847721~103858049:+
THCA	cis	rs6723108	0.608	rs606076	ENSG00000224043.6	CCNT2-AS1	-4.15	3.94e-05	0.00348	-0.2	-0.19	Type 2 diabetes;	chr2:134536511	chr2:134735464~134918710:-
THCA	cis	rs5758659	0.904	rs134877	ENSG00000273366.1	CTA-989H11.1	-4.15	3.94e-05	0.00348	-0.22	-0.19	Cognitive function;	chr22:42266365	chr22:42278188~42278846:+
THCA	cis	rs454217	0.818	rs381750	ENSG00000277851.1	RP11-756G20.1	4.15	3.94e-05	0.00348	0.19	0.19	Smoking quantity;	chr12:92323106	chr12:92247756~92363832:-
THCA	cis	rs2948294	0.588	rs12544596	ENSG00000233609.3	RP11-62H7.2	4.15	3.94e-05	0.00348	0.19	0.19	Red cell distribution width;	chr8:8258824	chr8:8961200~8979025:+
THCA	cis	rs8033133	0.836	rs11634716	ENSG00000251896.1	SNORD116-27	4.15	3.94e-05	0.00348	0.22	0.19	Blood osmolality (transformed sodium);	chr15:25061499	chr15:25101575~25101666:+
THCA	cis	rs11634944	1	rs28805921	ENSG00000257151.1	PWAR6	4.15	3.94e-05	0.00348	0.14	0.19	Interleukin-8 levels;	chr15:24951290	chr15:25031873~25036490:+
THCA	cis	rs858239	0.6	rs10266123	ENSG00000230042.1	AK3P3	-4.15	3.94e-05	0.00348	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23129178~23129841:+
THCA	cis	rs8062405	0.691	rs11646653	ENSG00000261766.1	RP11-22P6.2	4.15	3.94e-05	0.00348	0.18	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28862166~28863340:-
THCA	cis	rs4819052	1	rs9984901	ENSG00000273796.1	LL21NC02-21A1.1	-4.15	3.94e-05	0.00348	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45403809~45404369:-
THCA	cis	rs17685	0.753	rs6976532	ENSG00000230882.1	AC005077.14	4.15	3.94e-05	0.00348	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76051776	chr7:76071469~76074963:-
THCA	cis	rs12478296	0.892	rs60545379	ENSG00000220804.7	AC093642.5	4.15	3.94e-05	0.00348	0.21	0.19	Obesity-related traits;	chr2:242092239	chr2:242088633~242160153:+
THCA	cis	rs36093844	0.752	rs34106192	ENSG00000279742.1	RP11-700A24.1	-4.15	3.95e-05	0.00348	-0.27	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85845056	chr11:85852557~85854943:-
THCA	cis	rs8062405	0.965	rs56040780	ENSG00000270424.1	RP11-1348G14.6	4.15	3.95e-05	0.00348	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28749959~28750595:-
THCA	cis	rs7267979	1	rs7019	ENSG00000276952.1	RP5-965G21.6	4.15	3.95e-05	0.00348	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25284915~25285588:-
THCA	cis	rs2749592	0.55	rs7917262	ENSG00000226578.1	RP11-258F22.1	4.15	3.95e-05	0.00348	0.22	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:37775371~37784131:-
THCA	cis	rs2749592	0.55	rs9733309	ENSG00000226578.1	RP11-258F22.1	4.15	3.95e-05	0.00348	0.22	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:37775371~37784131:-
THCA	cis	rs11893307	0.851	rs62182472	ENSG00000235852.1	AC005540.3	4.15	3.95e-05	0.00348	0.22	0.19	Mean platelet volume;	chr2:190868102	chr2:190880797~190882059:-
THCA	cis	rs8031584	0.678	rs4779496	ENSG00000178081.11	ULK4P3	4.15	3.95e-05	0.00348	0.25	0.19	Huntington's disease progression;	chr15:30858851	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.678	rs4779497	ENSG00000178081.11	ULK4P3	4.15	3.95e-05	0.00348	0.25	0.19	Huntington's disease progression;	chr15:30859162	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.678	rs8028173	ENSG00000178081.11	ULK4P3	4.15	3.95e-05	0.00348	0.25	0.19	Huntington's disease progression;	chr15:30863546	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.706	rs2177670	ENSG00000178081.11	ULK4P3	4.15	3.95e-05	0.00348	0.25	0.19	Huntington's disease progression;	chr15:30865548	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.678	rs36047941	ENSG00000178081.11	ULK4P3	4.15	3.95e-05	0.00348	0.25	0.19	Huntington's disease progression;	chr15:30867032	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.678	rs4779790	ENSG00000178081.11	ULK4P3	4.15	3.95e-05	0.00348	0.25	0.19	Huntington's disease progression;	chr15:30872392	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.678	rs8035703	ENSG00000178081.11	ULK4P3	4.15	3.95e-05	0.00348	0.25	0.19	Huntington's disease progression;	chr15:30876269	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.578	rs1088473	ENSG00000178081.11	ULK4P3	-4.15	3.95e-05	0.00348	-0.25	-0.19	Huntington's disease progression;	chr15:30847095	chr15:30103720~30131757:+
THCA	cis	rs11219769	0.729	rs55799041	ENSG00000255045.1	RP11-677M14.2	4.15	3.95e-05	0.00348	0.2	0.19	Blood protein levels;	chr11:124733796	chr11:124744634~124746337:-
THCA	cis	rs10761482	0.817	rs4948404	ENSG00000254271.1	RP11-131N11.4	4.15	3.95e-05	0.00348	0.25	0.19	Schizophrenia;	chr10:60348444	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.768	rs3919830	ENSG00000254271.1	RP11-131N11.4	4.15	3.95e-05	0.00348	0.25	0.19	Schizophrenia;	chr10:60348447	chr10:60734342~60741828:+
THCA	cis	rs10911902	0.643	rs74842753	ENSG00000233196.2	GS1-304P7.1	-4.15	3.95e-05	0.00348	-0.31	-0.19	Schizophrenia;	chr1:186390059	chr1:186580515~186581191:-
THCA	cis	rs2243480	0.522	rs431168	ENSG00000230295.1	RP11-458F8.2	-4.15	3.95e-05	0.00348	-0.27	-0.19	Diabetic kidney disease;	chr7:66046617	chr7:66880708~66882981:+
THCA	cis	rs7500321	1	rs7500321	ENSG00000261766.1	RP11-22P6.2	4.15	3.95e-05	0.00348	0.19	0.19	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28862166~28863340:-
THCA	cis	rs758324	0.947	rs2896961	ENSG00000237714.1	P4HA2-AS1	4.15	3.95e-05	0.00348	0.26	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131829313	chr5:132184876~132192808:+
THCA	cis	rs3764021	0.87	rs10466829	ENSG00000256594.6	RP11-705C15.2	4.15	3.95e-05	0.00348	0.15	0.19	Type 1 diabetes;	chr12:9723495	chr12:9633419~9658412:+
THCA	cis	rs17221829	0.733	rs1873083	ENSG00000280385.1	AP000648.5	-4.15	3.95e-05	0.00349	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89663642	chr11:90193614~90198120:+
THCA	cis	rs3845817	1	rs3911863	ENSG00000237979.1	AC007389.1	-4.15	3.95e-05	0.00349	-0.21	-0.19	Bipolar disorder;	chr2:65532630	chr2:65500993~65502138:-
THCA	cis	rs3845817	0.966	rs3845818	ENSG00000237979.1	AC007389.1	-4.15	3.95e-05	0.00349	-0.21	-0.19	Bipolar disorder;	chr2:65533349	chr2:65500993~65502138:-
THCA	cis	rs889398	0.774	rs6499263	ENSG00000226232.7	RP11-419C5.2	-4.15	3.95e-05	0.00349	-0.19	-0.19	Body mass index;	chr16:69856246	chr16:69976388~69996188:-
THCA	cis	rs889398	0.771	rs8048550	ENSG00000226232.7	RP11-419C5.2	-4.15	3.95e-05	0.00349	-0.19	-0.19	Body mass index;	chr16:69857856	chr16:69976388~69996188:-
THCA	cis	rs11220082	0.644	rs36143594	ENSG00000254671.2	STT3A-AS1	-4.15	3.95e-05	0.00349	-0.22	-0.19	Schizophrenia;	chr11:125457076	chr11:125570284~125592568:-
THCA	cis	rs12544026	0.581	rs478917	ENSG00000253669.3	KB-1732A1.1	4.15	3.95e-05	0.00349	0.21	0.19	Major depression and alcohol dependence;	chr8:101876899	chr8:102805517~102809971:+
THCA	cis	rs13325613	0.915	rs2373156	ENSG00000223552.1	RP11-24F11.2	4.15	3.95e-05	0.00349	0.28	0.19	Monocyte count;	chr3:46224888	chr3:46364955~46407059:-
THCA	cis	rs10186029	0.676	rs10804213	ENSG00000270659.1	RP11-105N14.1	-4.15	3.96e-05	0.00349	-0.15	-0.19	Systemic sclerosis;	chr2:213099675	chr2:213152970~213153659:+
THCA	cis	rs2380205	0.689	rs867053	ENSG00000232807.2	RP11-536K7.3	4.15	3.96e-05	0.00349	0.18	0.19	Breast cancer;	chr10:5845207	chr10:5934270~5945900:-
THCA	cis	rs599083	0.569	rs685095	ENSG00000212093.1	AP000807.1	-4.15	3.96e-05	0.00349	-0.21	-0.19	Bone mineral density (spine);	chr11:68402908	chr11:68506083~68506166:-
THCA	cis	rs12234571	1	rs60293809	ENSG00000214293.7	APTR	4.15	3.96e-05	0.00349	0.23	0.19	Obesity-related traits;	chr7:77700879	chr7:77657660~77696265:-
THCA	cis	rs875971	0.83	rs427973	ENSG00000272831.1	RP11-792A8.4	4.15	3.96e-05	0.00349	0.12	0.19	Aortic root size;	chr7:66061661	chr7:66739829~66740385:-
THCA	cis	rs11951515	0.508	rs10059993	ENSG00000248240.1	RP11-159F24.5	-4.15	3.96e-05	0.00349	-0.2	-0.19	Metabolite levels  (X-11787);	chr5:43598250	chr5:43515274~43525310:+
THCA	cis	rs4443100	0.77	rs2330334	ENSG00000230701.2	FBXW4P1	4.15	3.96e-05	0.00349	0.22	0.19	Serum parathyroid hormone levels;	chr22:23021714	chr22:23262767~23265005:+
THCA	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	4.15	3.96e-05	0.00349	0.17	0.19	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	4.15	3.96e-05	0.00349	0.17	0.19	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
THCA	cis	rs2033711	0.503	rs7254299	ENSG00000269473.1	CTD-2619J13.19	4.15	3.96e-05	0.00349	0.17	0.19	Uric acid clearance;	chr19:58373598	chr19:58440448~58445849:+
THCA	cis	rs2505675	0.665	rs234932	ENSG00000250903.7	GMDS-AS1	-4.15	3.96e-05	0.00349	-0.17	-0.19	Tuberculosis;	chr6:2220286	chr6:2245748~2482022:+
THCA	cis	rs7828089	0.875	rs6998575	ENSG00000248738.5	RP11-87E22.2	-4.15	3.96e-05	0.00349	-0.19	-0.19	Verbal declarative memory;	chr8:22396986	chr8:22877972~22888022:+
THCA	cis	rs71636778	0.722	rs12729652	ENSG00000260063.1	RP5-968P14.2	-4.15	3.96e-05	0.00349	-0.26	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26720491	chr1:26692132~26694131:-
THCA	cis	rs9902453	0.866	rs4795529	ENSG00000263370.1	RP11-68I3.5	4.15	3.96e-05	0.00349	0.24	0.19	Coffee consumption (cups per day);	chr17:30116531	chr17:29639627~29640825:+
THCA	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	4.15	3.96e-05	0.00349	0.17	0.19	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	4.15	3.96e-05	0.00349	0.17	0.19	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	4.15	3.96e-05	0.00349	0.17	0.19	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	4.15	3.96e-05	0.00349	0.17	0.19	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
THCA	cis	rs6163	0.588	rs12763284	ENSG00000236937.2	PTGES3P4	-4.15	3.96e-05	0.00349	-0.23	-0.19	Waist circumference;Hip circumference;	chr10:102748445	chr10:102845595~102845950:+
THCA	cis	rs10761482	0.861	rs1814117	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60340139	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs2893830	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60340187	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs1903204	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60340473	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.769	rs10740024	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60341082	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs1473404	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60342558	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10761485	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60342902	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs2061487	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60343084	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs2061488	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60343408	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs2061489	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60343438	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs4456215	ENSG00000254271.1	RP11-131N11.4	4.15	3.96e-05	0.00349	0.25	0.19	Schizophrenia;	chr10:60343491	chr10:60734342~60741828:+
THCA	cis	rs17095355	0.892	rs1571617	ENSG00000203876.8	ADD3-AS1	-4.15	3.96e-05	0.00349	-0.2	-0.19	Biliary atresia;	chr10:109972267	chr10:109940104~110008381:-
THCA	cis	rs9902453	0.817	rs62068625	ENSG00000263370.1	RP11-68I3.5	4.15	3.96e-05	0.00349	0.25	0.19	Coffee consumption (cups per day);	chr17:29849563	chr17:29639627~29640825:+
THCA	cis	rs4947019	0.609	rs79097132	ENSG00000223537.2	RP5-919F19.5	-4.15	3.96e-05	0.00349	-0.35	-0.19	Hematological parameters;	chr6:109404619	chr6:109487906~109506800:+
THCA	cis	rs12893668	0.703	rs4906336	ENSG00000244691.1	RPL10AP1	-4.15	3.96e-05	0.0035	-0.27	-0.19	Reticulocyte count;	chr14:103566928	chr14:103412119~103412761:-
THCA	cis	rs4666002	0.917	rs2068834	ENSG00000234072.1	AC074117.10	4.15	3.96e-05	0.0035	0.15	0.19	Phospholipid levels (plasma);	chr2:27616672	chr2:27356246~27367622:+
THCA	cis	rs12612619	0.732	rs1866654	ENSG00000272148.1	RP11-195B17.1	4.15	3.97e-05	0.0035	0.18	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27040254	chr2:27062428~27062907:-
THCA	cis	rs12073837	0.5	rs11118610	ENSG00000272823.1	RP11-295M18.6	-4.15	3.97e-05	0.0035	-0.21	-0.19	F-cell distribution;	chr1:220816744	chr1:220828676~220829211:-
THCA	cis	rs6840360	0.904	rs73862064	ENSG00000270265.1	RP11-731D1.4	-4.15	3.97e-05	0.0035	-0.18	-0.19	Intelligence (multi-trait analysis);	chr4:151581948	chr4:151333775~151353224:-
THCA	cis	rs4713118	0.513	rs149959	ENSG00000261839.1	RP1-265C24.8	4.15	3.97e-05	0.0035	0.2	0.19	Parkinson's disease;	chr6:28046076	chr6:28136849~28139678:+
THCA	cis	rs72928364	1	rs36165056	ENSG00000256628.3	ZBTB11-AS1	4.15	3.97e-05	0.0035	0.33	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100896971	chr3:101676475~101679217:+
THCA	cis	rs11671653	1	rs11672504	ENSG00000267100.1	ILF3-AS1	4.15	3.97e-05	0.0035	0.21	0.19	LDL cholesterol;	chr19:10720684	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs4334414	ENSG00000267100.1	ILF3-AS1	4.15	3.97e-05	0.0035	0.21	0.19	LDL cholesterol;	chr19:10720997	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs8105939	ENSG00000267100.1	ILF3-AS1	4.15	3.97e-05	0.0035	0.21	0.19	LDL cholesterol;	chr19:10721125	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs8113457	ENSG00000267100.1	ILF3-AS1	4.15	3.97e-05	0.0035	0.21	0.19	LDL cholesterol;	chr19:10721549	chr19:10651862~10653844:-
THCA	cis	rs11671653	1	rs58380026	ENSG00000267100.1	ILF3-AS1	4.15	3.97e-05	0.0035	0.21	0.19	LDL cholesterol;	chr19:10721830	chr19:10651862~10653844:-
THCA	cis	rs10875746	0.768	rs10875724	ENSG00000258273.1	RP11-370I10.4	4.15	3.97e-05	0.0035	0.26	0.19	Longevity (90 years and older);	chr12:48026470	chr12:48333755~48333901:-
THCA	cis	rs897984	0.762	rs7204459	ENSG00000275263.1	RP11-1072A3.4	4.15	3.97e-05	0.0035	0.22	0.19	Dementia with Lewy bodies;	chr16:30972891	chr16:30956872~30957199:-
THCA	cis	rs897984	0.762	rs4889604	ENSG00000275263.1	RP11-1072A3.4	4.15	3.97e-05	0.0035	0.22	0.19	Dementia with Lewy bodies;	chr16:30974673	chr16:30956872~30957199:-
THCA	cis	rs7772486	0.806	rs4243478	ENSG00000270638.1	RP3-466P17.1	-4.15	3.97e-05	0.0035	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145735570~145737218:+
THCA	cis	rs1023500	0.573	rs133377	ENSG00000237037.8	NDUFA6-AS1	-4.15	3.97e-05	0.0035	-0.15	-0.19	Schizophrenia;	chr22:42070946	chr22:42090931~42137742:+
THCA	cis	rs72928364	0.929	rs35999953	ENSG00000256628.3	ZBTB11-AS1	4.15	3.97e-05	0.0035	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100901336	chr3:101676475~101679217:+
THCA	cis	rs4788570	0.578	rs7204992	ENSG00000260185.1	RP11-432I5.6	-4.15	3.97e-05	0.0035	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71624541	chr16:71655027~71664212:+
THCA	cis	rs4650994	0.525	rs11806608	ENSG00000213057.5	C1orf220	-4.15	3.97e-05	0.0035	-0.14	-0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178542240	chr1:178542752~178548889:+
THCA	cis	rs758324	0.898	rs11958749	ENSG00000237714.1	P4HA2-AS1	4.15	3.97e-05	0.0035	0.27	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131830321	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs2404778	ENSG00000237714.1	P4HA2-AS1	4.15	3.97e-05	0.0035	0.27	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131837193	chr5:132184876~132192808:+
THCA	cis	rs9309473	0.66	rs56131703	ENSG00000273245.1	RP11-434P11.2	4.15	3.97e-05	0.0035	0.31	0.19	Metabolite levels;	chr2:73620133	chr2:73750256~73750786:-
THCA	cis	rs8031584	1	rs1474380	ENSG00000270015.1	RP11-540B6.6	-4.15	3.97e-05	0.0035	-0.14	-0.19	Huntington's disease progression;	chr15:30977032	chr15:30926514~30928407:+
THCA	cis	rs854765	0.547	rs7212167	ENSG00000281749.1	Y_RNA	4.15	3.97e-05	0.0035	0.24	0.19	Total body bone mineral density;	chr17:18010190	chr17:18001101~18001195:-
THCA	cis	rs5753037	0.586	rs140120	ENSG00000273350.1	RP4-539M6.20	-4.15	3.97e-05	0.0035	-0.21	-0.19	Type 1 diabetes;	chr22:29742559	chr22:30420512~30420912:+
THCA	cis	rs2380205	0.967	rs12774966	ENSG00000232807.2	RP11-536K7.3	4.15	3.97e-05	0.0035	0.18	0.19	Breast cancer;	chr10:5856135	chr10:5934270~5945900:-
THCA	cis	rs2692947	0.673	rs4907279	ENSG00000235584.2	AC008268.1	-4.15	3.98e-05	0.0035	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95734220	chr2:95666084~95668715:+
THCA	cis	rs12440869	1	rs1992217	ENSG00000270964.1	RP11-502I4.3	-4.15	3.98e-05	0.0035	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67224815	chr15:67541072~67542604:-
THCA	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	4.15	3.98e-05	0.0035	0.21	0.19	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
THCA	cis	rs7586879	0.521	rs1865689	ENSG00000224165.4	DNAJC27-AS1	4.15	3.98e-05	0.0035	0.1	0.19	Body mass index;	chr2:24885328	chr2:24971390~25039694:+
THCA	cis	rs6600671	1	rs1591882	ENSG00000275585.1	CH17-118O6.3	-4.15	3.98e-05	0.0035	-0.22	-0.19	Hip geometry;	chr1:121441455	chr1:120985692~121052167:-
THCA	cis	rs4713118	0.869	rs9283880	ENSG00000220721.1	OR1F12	4.15	3.98e-05	0.0035	0.25	0.19	Parkinson's disease;	chr6:27747464	chr6:28073316~28074233:+
THCA	cis	rs17331151	0.573	rs4687556	ENSG00000242142.1	SERBP1P3	4.15	3.98e-05	0.0035	0.28	0.19	Immune reponse to smallpox (secreted IL-2);	chr3:52856459	chr3:53064283~53065091:-
THCA	cis	rs12900463	0.813	rs306198	ENSG00000275120.1	RP11-182J1.17	-4.15	3.98e-05	0.0035	-0.22	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862138	chr15:84599434~84606463:-
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000182586.6	LINC00334	-4.15	3.98e-05	0.0035	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000182586.6	LINC00334	4.15	3.98e-05	0.0035	0.2	0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45234340~45258730:+
THCA	cis	rs4713118	0.588	rs200994	ENSG00000220721.1	OR1F12	-4.15	3.98e-05	0.00351	-0.25	-0.19	Parkinson's disease;	chr6:27846035	chr6:28073316~28074233:+
THCA	cis	rs2820315	0.867	rs2820317	ENSG00000223774.4	RP11-307B6.3	4.15	3.98e-05	0.00351	0.2	0.19	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201909409	chr1:201893842~201899978:+
THCA	cis	rs9650657	0.529	rs10108618	ENSG00000206014.6	OR7E161P	4.15	3.98e-05	0.00351	0.22	0.19	Neuroticism;	chr8:11095582	chr8:11928597~11929563:-
THCA	cis	rs8067545	1	rs56142708	ENSG00000270091.1	RP11-78O7.2	-4.15	3.98e-05	0.00351	-0.14	-0.19	Schizophrenia;	chr17:20031650	chr17:19896590~19897287:-
THCA	cis	rs1572312	0.551	rs12038942	ENSG00000237928.4	NFIA-AS2	4.15	3.98e-05	0.00351	0.24	0.19	Maximal oxygen uptake response;	chr1:60969403	chr1:60940239~60970776:-
THCA	cis	rs72819454	0.522	rs9665618	ENSG00000280693.1	SH3PXD2A-AS1	-4.15	3.98e-05	0.00351	-0.38	-0.19	Interleukin-9 levels;	chr10:103764550	chr10:103745966~103755423:+
THCA	cis	rs7520050	0.751	rs592214	ENSG00000280836.1	AL355480.1	4.15	3.98e-05	0.00351	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:45558833	chr1:45581219~45581321:-
THCA	cis	rs11931598	0.514	rs10937779	ENSG00000245468.3	RP11-367J11.3	4.15	3.98e-05	0.00351	0.13	0.19	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7037599	chr4:7094571~7103385:-
THCA	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	4.15	3.98e-05	0.00351	0.25	0.19	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
THCA	cis	rs6570726	0.689	rs411785	ENSG00000270638.1	RP3-466P17.1	4.15	3.98e-05	0.00351	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145735570~145737218:+
THCA	cis	rs4415084	0.87	rs920328	ENSG00000272335.1	RP11-53O19.3	-4.15	3.98e-05	0.00351	-0.16	-0.19	Breast cancer;	chr5:44698949	chr5:44826076~44828592:+
THCA	cis	rs8027521	0.666	rs4776196	ENSG00000280362.1	RP11-643A5.3	4.15	3.98e-05	0.00351	0.24	0.19	Circulating chemerin levels;	chr15:53972694	chr15:53910769~53914712:+
THCA	cis	rs4947019	0.609	rs116647873	ENSG00000223537.2	RP5-919F19.5	-4.15	3.98e-05	0.00351	-0.35	-0.19	Hematological parameters;	chr6:109398216	chr6:109487906~109506800:+
THCA	cis	rs2179367	0.881	rs2744432	ENSG00000223701.3	RAET1E-AS1	-4.15	3.98e-05	0.00351	-0.25	-0.19	Dupuytren's disease;	chr6:149422735	chr6:149884431~149919508:+
THCA	cis	rs4561483	0.583	rs9925010	ENSG00000263307.1	RP11-166B2.8	-4.15	3.98e-05	0.00351	-0.2	-0.19	Testicular germ cell tumor;	chr16:11862811	chr16:11851649~11895611:+
THCA	cis	rs4561483	0.545	rs9927446	ENSG00000263307.1	RP11-166B2.8	-4.15	3.98e-05	0.00351	-0.2	-0.19	Testicular germ cell tumor;	chr16:11863307	chr16:11851649~11895611:+
THCA	cis	rs4561483	0.583	rs11647580	ENSG00000263307.1	RP11-166B2.8	-4.15	3.98e-05	0.00351	-0.2	-0.19	Testicular germ cell tumor;	chr16:11863752	chr16:11851649~11895611:+
THCA	cis	rs2070488	0.861	rs2067082	ENSG00000229589.1	ACVR2B-AS1	4.15	3.98e-05	0.00351	0.17	0.19	Electrocardiographic conduction measures;	chr3:38396691	chr3:38451027~38454820:-
THCA	cis	rs10090774	0.965	rs55967138	ENSG00000279766.1	RP11-642A1.2	4.15	3.98e-05	0.00351	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140944327	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs34496768	ENSG00000279766.1	RP11-642A1.2	4.15	3.98e-05	0.00351	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140948091	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs11167012	ENSG00000279766.1	RP11-642A1.2	4.15	3.98e-05	0.00351	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140958309	chr8:140572142~140572812:-
THCA	cis	rs2836974	0.932	rs35571600	ENSG00000255568.3	BRWD1-AS2	4.15	3.98e-05	0.00351	0.16	0.19	Cognitive function;	chr21:39218698	chr21:39313935~39314962:+
THCA	cis	rs2436845	1	rs2513922	ENSG00000253669.3	KB-1732A1.1	-4.15	3.98e-05	0.00351	-0.19	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102817960	chr8:102805517~102809971:+
THCA	cis	rs5758511	0.68	rs56111723	ENSG00000237037.8	NDUFA6-AS1	-4.15	3.99e-05	0.00351	-0.17	-0.19	Birth weight;	chr22:42268877	chr22:42090931~42137742:+
THCA	cis	rs950169	0.922	rs6603022	ENSG00000275120.1	RP11-182J1.17	-4.15	3.99e-05	0.00351	-0.22	-0.19	Schizophrenia;	chr15:84161418	chr15:84599434~84606463:-
THCA	cis	rs1560104	0.709	rs35456341	ENSG00000259876.1	CTD-3037G24.4	4.15	3.99e-05	0.00351	0.22	0.19	Obesity-related traits;	chr16:12610010	chr16:12556353~12557694:-
THCA	cis	rs911555	0.755	rs11620897	ENSG00000269910.1	RP11-73M18.10	4.15	3.99e-05	0.00351	0.17	0.19	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103694516~103695050:-
THCA	cis	rs10266483	0.739	rs12538943	ENSG00000234338.1	RP11-797H7.1	-4.15	3.99e-05	0.00351	-0.15	-0.19	Response to statin therapy;	chr7:64395990	chr7:64835280~64836882:-
THCA	cis	rs4906332	1	rs10459573	ENSG00000244691.1	RPL10AP1	-4.15	3.99e-05	0.00351	-0.24	-0.19	Coronary artery disease;	chr14:103459120	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs4906327	ENSG00000244691.1	RPL10AP1	-4.15	3.99e-05	0.00351	-0.24	-0.19	Coronary artery disease;	chr14:103462702	chr14:103412119~103412761:-
THCA	cis	rs6870983	0.895	rs247916	ENSG00000247828.6	TMEM161B-AS1	4.15	3.99e-05	0.00351	0.18	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88234436	chr5:88268895~88436685:+
THCA	cis	rs6921919	0.609	rs1005127	ENSG00000273712.1	RP5-874C20.7	4.15	3.99e-05	0.00351	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28315613~28315883:-
THCA	cis	rs853679	0.515	rs4580862	ENSG00000273712.1	RP5-874C20.7	4.15	3.99e-05	0.00351	0.21	0.19	Depression;	chr6:28399886	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs4357130	ENSG00000273712.1	RP5-874C20.7	4.15	3.99e-05	0.00351	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28315613~28315883:-
THCA	cis	rs6137726	0.508	rs4815131	ENSG00000237396.1	LINC01384	4.15	3.99e-05	0.00351	0.17	0.19	Amyotrophic lateral sclerosis (sporadic);	chr20:22658994	chr20:22587522~22607517:-
THCA	cis	rs4713118	0.513	rs149945	ENSG00000261839.1	RP1-265C24.8	4.15	3.99e-05	0.00351	0.2	0.19	Parkinson's disease;	chr6:28035075	chr6:28136849~28139678:+
THCA	cis	rs10875746	0.729	rs11168357	ENSG00000258273.1	RP11-370I10.4	4.15	3.99e-05	0.00351	0.27	0.19	Longevity (90 years and older);	chr12:48018355	chr12:48333755~48333901:-
THCA	cis	rs17801127	0.901	rs35635376	ENSG00000231969.1	AC144449.1	4.15	3.99e-05	0.00352	0.34	0.19	Liver enzyme levels (alanine transaminase);	chr2:149707555	chr2:149587196~149848233:+
THCA	cis	rs8081395	0.801	rs2665405	ENSG00000267302.4	RP11-178C3.2	-4.15	3.99e-05	0.00352	-0.22	-0.19	White blood cell count;	chr17:59797931	chr17:59964832~59996972:+
THCA	cis	rs1501911	0.527	rs161934	ENSG00000248489.1	CTD-2007H13.3	-4.15	3.99e-05	0.00352	-0.17	-0.19	Lung function (FEV1/FVC);	chr5:98981283	chr5:98929171~98995013:+
THCA	cis	rs2749592	0.505	rs7915670	ENSG00000226578.1	RP11-258F22.1	4.15	3.99e-05	0.00352	0.22	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:37775371~37784131:-
THCA	cis	rs2777491	1	rs2730057	ENSG00000247556.5	OIP5-AS1	4.15	3.99e-05	0.00352	0.16	0.19	Ulcerative colitis;	chr15:41444077	chr15:41283990~41309737:+
THCA	cis	rs7614311	0.636	rs6802053	ENSG00000271843.1	RP11-245J9.5	-4.15	3.99e-05	0.00352	-0.31	-0.19	Lung function (FVC);Lung function (FEV1);	chr3:64014147	chr3:64008082~64008692:-
THCA	cis	rs1476587	0.92	rs2106953	ENSG00000224046.1	AC005076.5	4.15	3.99e-05	0.00352	0.17	0.19	Brachial circumference;	chr7:87110776	chr7:87151423~87152420:-
THCA	cis	rs1476587	0.92	rs10480551	ENSG00000224046.1	AC005076.5	4.15	3.99e-05	0.00352	0.17	0.19	Brachial circumference;	chr7:87111521	chr7:87151423~87152420:-
THCA	cis	rs1476587	0.92	rs10480553	ENSG00000224046.1	AC005076.5	4.15	3.99e-05	0.00352	0.17	0.19	Brachial circumference;	chr7:87111616	chr7:87151423~87152420:-
THCA	cis	rs1476587	0.92	rs2214351	ENSG00000224046.1	AC005076.5	4.15	3.99e-05	0.00352	0.17	0.19	Brachial circumference;	chr7:87111723	chr7:87151423~87152420:-
THCA	cis	rs7572733	0.534	rs1435568	ENSG00000231621.1	AC013264.2	-4.15	3.99e-05	0.00352	-0.2	-0.19	Dermatomyositis;	chr2:197898155	chr2:197197991~197199273:+
THCA	cis	rs4947019	0.686	rs3757229	ENSG00000223537.2	RP5-919F19.5	-4.15	3.99e-05	0.00352	-0.35	-0.19	Hematological parameters;	chr6:109382935	chr6:109487906~109506800:+
THCA	cis	rs4947019	0.686	rs17070554	ENSG00000223537.2	RP5-919F19.5	-4.15	3.99e-05	0.00352	-0.35	-0.19	Hematological parameters;	chr6:109383183	chr6:109487906~109506800:+
THCA	cis	rs713587	0.967	rs10182181	ENSG00000224165.4	DNAJC27-AS1	4.15	4e-05	0.00352	0.11	0.19	Body mass index in non-asthmatics;	chr2:24927427	chr2:24971390~25039694:+
THCA	cis	rs3177980	0.523	rs12405525	ENSG00000239494.2	RN7SL333P	-4.15	4e-05	0.00352	-0.17	-0.19	Amyotrophic lateral sclerosis;	chr1:169836225	chr1:169859756~169860052:+
THCA	cis	rs919433	0.68	rs8539	ENSG00000231621.1	AC013264.2	-4.15	4e-05	0.00352	-0.2	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197497294	chr2:197197991~197199273:+
THCA	cis	rs427943	0.831	rs399185	ENSG00000223768.1	LINC00205	-4.15	4e-05	0.00352	-0.17	-0.19	Body mass index;	chr21:45170586	chr21:45293285~45297354:+
THCA	cis	rs427943	0.864	rs422870	ENSG00000223768.1	LINC00205	-4.15	4e-05	0.00352	-0.17	-0.19	Body mass index;	chr21:45170965	chr21:45293285~45297354:+
THCA	cis	rs12410462	0.502	rs78101727	ENSG00000227711.2	RP11-275O4.5	-4.15	4e-05	0.00352	-0.36	-0.19	Major depressive disorder;	chr1:227544368	chr1:227509028~227520477:-
THCA	cis	rs7176527	0.747	rs28363946	ENSG00000225151.9	GOLGA2P7	4.15	4e-05	0.00352	0.37	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:84199311~84230136:-
THCA	cis	rs7586085	0.868	rs4667835	ENSG00000232411.1	AC009495.3	4.15	4e-05	0.00352	0.2	0.19	Total body bone mineral density;	chr2:165759045	chr2:165833048~165839098:-
THCA	cis	rs7726839	0.561	rs11955068	ENSG00000225138.6	CTD-2228K2.7	4.15	4e-05	0.00352	0.22	0.19	Obesity-related traits;	chr5:582209	chr5:473236~480884:+
THCA	cis	rs6921919	0.515	rs1558205	ENSG00000280107.1	AL022393.9	4.15	4e-05	0.00352	0.18	0.19	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28170845~28172521:+
THCA	cis	rs7968440	1	rs2731442	ENSG00000272368.2	RP4-605O3.4	4.15	4e-05	0.00352	0.12	0.19	Fibrinogen;	chr12:50660872	chr12:50112197~50165618:+
THCA	cis	rs755249	0.501	rs1889830	ENSG00000182109.6	RP11-69E11.4	-4.15	4e-05	0.00352	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39522280~39546187:-
THCA	cis	rs4906332	1	rs8004780	ENSG00000269910.1	RP11-73M18.10	4.15	4e-05	0.00352	0.16	0.19	Coronary artery disease;	chr14:103387023	chr14:103694516~103695050:-
THCA	cis	rs13178541	0.553	rs4976374	ENSG00000250378.1	RP11-119J18.1	-4.15	4e-05	0.00352	-0.24	-0.19	IgG glycosylation;	chr5:135853131	chr5:135812667~135826582:+
THCA	cis	rs2836950	0.545	rs2836959	ENSG00000238141.2	BRWD1-AS1	-4.15	4e-05	0.00353	-0.21	-0.19	Menarche (age at onset);	chr21:39251742	chr21:39315707~39323218:+
THCA	cis	rs875971	1	rs11974264	ENSG00000230189.5	GS1-124K5.2	-4.15	4e-05	0.00353	-0.12	-0.19	Aortic root size;	chr7:66182595	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs1540651	ENSG00000230189.5	GS1-124K5.2	-4.15	4e-05	0.00353	-0.12	-0.19	Aortic root size;	chr7:66185134	chr7:66409143~66490059:-
THCA	cis	rs1552244	0.572	rs73117481	ENSG00000180385.7	EMC3-AS1	4.15	4.01e-05	0.00353	0.24	0.19	Alzheimer's disease;	chr3:10118448	chr3:9986893~10006990:+
THCA	cis	rs4934494	0.677	rs719909	ENSG00000240996.1	RP11-80H5.7	-4.15	4.01e-05	0.00353	-0.21	-0.19	Red blood cell count;	chr10:89585939	chr10:89694295~89697928:-
THCA	cis	rs9863	0.827	rs12823740	ENSG00000269997.1	RP11-214K3.21	-4.15	4.01e-05	0.00353	-0.22	-0.19	White blood cell count;	chr12:123973455	chr12:123966077~123966629:-
THCA	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-4.15	4.01e-05	0.00353	-0.2	-0.19	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
THCA	cis	rs2290416	0.892	rs59742520	ENSG00000253931.1	RP11-909N17.2	4.15	4.01e-05	0.00353	0.37	0.19	Attention deficit hyperactivity disorder;	chr8:143594064	chr8:143412749~143417054:+
THCA	cis	rs7711186	0.786	rs7719075	ENSG00000252464.1	RN7SKP70	4.15	4.01e-05	0.00353	0.23	0.19	Urate levels in obese individuals;	chr5:178656818	chr5:178619728~178619998:-
THCA	cis	rs6715284	1	rs72937120	ENSG00000238829.1	RNU7-45P	-4.15	4.01e-05	0.00353	-0.45	-0.19	Rheumatoid arthritis;	chr2:201367888	chr2:201141904~201141966:+
THCA	cis	rs2333194	0.869	rs177368	ENSG00000258695.2	RP3-414A15.2	-4.15	4.01e-05	0.00353	-0.23	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73294539	chr14:73522878~73530610:+
THCA	cis	rs5753037	0.64	rs131260	ENSG00000273350.1	RP4-539M6.20	-4.15	4.01e-05	0.00353	-0.21	-0.19	Type 1 diabetes;	chr22:29736975	chr22:30420512~30420912:+
THCA	cis	rs4879656	0.564	rs1537253	ENSG00000225693.1	LAGE3P1	4.15	4.01e-05	0.00353	0.2	0.19	Menopause (age at onset);	chr9:32983373	chr9:33019682~33020165:-
THCA	cis	rs9595908	0.709	rs55797910	ENSG00000212293.1	SNORA16	4.15	4.01e-05	0.00353	0.22	0.19	Body mass index;	chr13:32787154	chr13:32420390~32420516:-
THCA	cis	rs10875746	0.729	rs11168355	ENSG00000258273.1	RP11-370I10.4	-4.15	4.01e-05	0.00353	-0.26	-0.19	Longevity (90 years and older);	chr12:48017195	chr12:48333755~48333901:-
THCA	cis	rs853679	1	rs1936365	ENSG00000273712.1	RP5-874C20.7	-4.15	4.01e-05	0.00353	-0.29	-0.19	Depression;	chr6:28300675	chr6:28315613~28315883:-
THCA	cis	rs10760158	0.769	rs10760161	ENSG00000226752.6	PSMD5-AS1	-4.15	4.01e-05	0.00353	-0.23	-0.19	Pulse pressure;	chr9:121241790	chr9:120824828~120854385:+
THCA	cis	rs7829975	0.626	rs907183	ENSG00000254340.1	RP11-10A14.3	-4.15	4.01e-05	0.00353	-0.21	-0.19	Mood instability;	chr8:8872251	chr8:9141424~9145435:+
THCA	cis	rs7216064	0.911	rs12449442	ENSG00000265055.1	AC145343.2	4.15	4.01e-05	0.00353	0.27	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67951524	chr17:68096046~68101474:-
THCA	cis	rs7166081	1	rs35688953	ENSG00000270964.1	RP11-502I4.3	-4.15	4.01e-05	0.00353	-0.17	-0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67347791	chr15:67541072~67542604:-
THCA	cis	rs791590	1	rs2246031	ENSG00000229664.1	RP11-536K7.5	4.15	4.01e-05	0.00353	0.3	0.19	Soluble interleukin-2 receptor subunit alpha;	chr10:6050247	chr10:6025978~6036427:+
THCA	cis	rs2120243	0.539	rs1545596	ENSG00000241770.1	RP11-555M1.3	-4.15	4.01e-05	0.00353	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157400737	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs1456108	ENSG00000241770.1	RP11-555M1.3	-4.15	4.01e-05	0.00353	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157401265	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs1563420	ENSG00000241770.1	RP11-555M1.3	-4.15	4.01e-05	0.00353	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157401537	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.51	rs7623173	ENSG00000241770.1	RP11-555M1.3	-4.15	4.01e-05	0.00353	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402160	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs2168431	ENSG00000241770.1	RP11-555M1.3	-4.15	4.01e-05	0.00353	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402240	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs2124497	ENSG00000241770.1	RP11-555M1.3	-4.15	4.01e-05	0.00353	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402470	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs2168430	ENSG00000241770.1	RP11-555M1.3	-4.15	4.01e-05	0.00353	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402619	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs2305622	ENSG00000241770.1	RP11-555M1.3	-4.15	4.01e-05	0.00353	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157404715	chr3:157163452~157169133:+
THCA	cis	rs17597773	0.674	rs12117818	ENSG00000238078.1	LINC01352	-4.15	4.01e-05	0.00353	-0.27	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828141	chr1:220829255~220832429:+
THCA	cis	rs10875746	0.951	rs2269935	ENSG00000258273.1	RP11-370I10.4	4.15	4.01e-05	0.00353	0.27	0.19	Longevity (90 years and older);	chr12:48122681	chr12:48333755~48333901:-
THCA	cis	rs1923243	0.589	rs11210158	ENSG00000223479.3	RP4-788P17.1	4.15	4.01e-05	0.00353	0.21	0.19	Migraine;	chr1:73161541	chr1:73635216~73715214:+
THCA	cis	rs2153535	0.56	rs7750064	ENSG00000230939.1	RP11-314C16.1	-4.15	4.01e-05	0.00353	-0.2	-0.19	Motion sickness;	chr6:8632012	chr6:8784178~8785445:+
THCA	cis	rs4886920	0.894	rs12910504	ENSG00000260776.4	RP11-114H24.2	-4.15	4.02e-05	0.00353	-0.22	-0.19	Neuroticism;	chr15:77840005	chr15:77914217~77926846:-
THCA	cis	rs7818688	0.578	rs35518242	ENSG00000253528.2	RP11-347C18.4	-4.15	4.02e-05	0.00353	-0.28	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95066867	chr8:94974573~94974853:-
THCA	cis	rs5758659	0.652	rs5758537	ENSG00000273366.1	CTA-989H11.1	-4.15	4.02e-05	0.00353	-0.23	-0.19	Cognitive function;	chr22:42001038	chr22:42278188~42278846:+
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Body mass index;	chr17:30739311	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Body mass index;	chr17:30745415	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Body mass index;	chr17:30745654	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30726305~30727564:-
THCA	cis	rs1923243	0.71	rs4570373	ENSG00000223479.3	RP4-788P17.1	4.15	4.02e-05	0.00354	0.21	0.19	Migraine;	chr1:73147302	chr1:73635216~73715214:+
THCA	cis	rs116139393	0.517	rs17789570	ENSG00000187953.9	PMS2CL	-4.15	4.02e-05	0.00354	-0.32	-0.19	Alzheimer's disease (APOE e4 interaction);	chr7:6684713	chr7:6710128~6753862:+
THCA	cis	rs116139393	0.517	rs77141752	ENSG00000187953.9	PMS2CL	-4.15	4.02e-05	0.00354	-0.32	-0.19	Alzheimer's disease (APOE e4 interaction);	chr7:6685844	chr7:6710128~6753862:+
THCA	cis	rs116139393	0.517	rs13230987	ENSG00000187953.9	PMS2CL	-4.15	4.02e-05	0.00354	-0.32	-0.19	Alzheimer's disease (APOE e4 interaction);	chr7:6686689	chr7:6710128~6753862:+
THCA	cis	rs6696239	1	rs61835260	ENSG00000227711.2	RP11-275O4.5	-4.15	4.02e-05	0.00354	-0.26	-0.19	Height;	chr1:227515635	chr1:227509028~227520477:-
THCA	cis	rs62244186	0.748	rs13319803	ENSG00000214820.3	MPRIPP1	4.15	4.02e-05	0.00354	0.2	0.19	Depressive symptoms;	chr3:44593969	chr3:44579938~44581026:-
THCA	cis	rs2638953	0.927	rs11049630	ENSG00000247934.4	RP11-967K21.1	-4.15	4.02e-05	0.00354	-0.19	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460240	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.719	rs11049489	ENSG00000247934.4	RP11-967K21.1	-4.15	4.02e-05	0.00354	-0.19	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28259482	chr12:28163298~28190738:-
THCA	cis	rs1023500	0.505	rs134885	ENSG00000233903.2	Z83851.4	4.15	4.02e-05	0.00354	0.23	0.19	Schizophrenia;	chr22:42277805	chr22:42276355~42277052:+
THCA	cis	rs7829975	0.774	rs11775523	ENSG00000253981.4	ALG1L13P	4.15	4.02e-05	0.00354	0.18	0.19	Mood instability;	chr8:8821666	chr8:8236003~8244667:-
THCA	cis	rs2749592	0.55	rs12255038	ENSG00000226578.1	RP11-258F22.1	4.15	4.02e-05	0.00354	0.22	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:37775371~37784131:-
THCA	cis	rs12410462	0.551	rs12085546	ENSG00000227711.2	RP11-275O4.5	-4.15	4.02e-05	0.00354	-0.23	-0.19	Major depressive disorder;	chr1:227698762	chr1:227509028~227520477:-
THCA	cis	rs9987353	0.84	rs329994	ENSG00000254153.1	CTA-398F10.2	4.15	4.02e-05	0.00354	0.2	0.19	Recombination measurement;	chr8:9265723	chr8:8456909~8461337:-
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000265443.1	CTD-2349P21.6	-4.15	4.02e-05	0.00354	-0.32	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30726305~30727564:-
THCA	cis	rs1371614	0.632	rs6738528	ENSG00000272148.1	RP11-195B17.1	-4.15	4.02e-05	0.00354	-0.17	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26926390	chr2:27062428~27062907:-
THCA	cis	rs858239	0.537	rs2286272	ENSG00000230042.1	AK3P3	-4.15	4.02e-05	0.00354	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23129178~23129841:+
THCA	cis	rs858239	0.537	rs6955115	ENSG00000230042.1	AK3P3	-4.15	4.02e-05	0.00354	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23129178~23129841:+
THCA	cis	rs8062405	0.789	rs240704	ENSG00000270424.1	RP11-1348G14.6	4.15	4.02e-05	0.00354	0.21	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28749959~28750595:-
THCA	cis	rs3748682	0.731	rs3891572	ENSG00000252448.1	SNORA63	-4.15	4.02e-05	0.00354	-0.24	-0.19	Hypothyroidism;	chr1:37833204	chr1:37884237~37884317:+
THCA	cis	rs73411413	0.608	rs7126170	ENSG00000233930.3	KRTAP5-AS1	-4.15	4.02e-05	0.00354	-0.26	-0.19	Myringotomy;	chr11:1518157	chr11:1571353~1599184:+
THCA	cis	rs4957048	0.891	rs11960196	ENSG00000225138.6	CTD-2228K2.7	4.15	4.03e-05	0.00354	0.22	0.19	Ulcerative colitis;	chr5:568742	chr5:473236~480884:+
THCA	cis	rs1124769	0.719	rs7170302	ENSG00000259378.1	DCAF13P3	-4.15	4.03e-05	0.00354	-0.29	-0.19	Cognitive performance;	chr15:50918913	chr15:50944663~50945996:+
THCA	cis	rs6479891	0.915	rs10761744	ENSG00000272767.1	JMJD1C-AS1	-4.15	4.03e-05	0.00354	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63465229~63466563:+
THCA	cis	rs6600671	0.934	rs67718113	ENSG00000275585.1	CH17-118O6.3	4.15	4.03e-05	0.00354	0.24	0.19	Hip geometry;	chr1:121497112	chr1:120985692~121052167:-
THCA	cis	rs5758659	0.622	rs129856	ENSG00000273366.1	CTA-989H11.1	-4.15	4.03e-05	0.00354	-0.23	-0.19	Cognitive function;	chr22:42003392	chr22:42278188~42278846:+
THCA	cis	rs2688608	0.967	rs2675663	ENSG00000271816.1	BMS1P4	4.15	4.03e-05	0.00354	0.18	0.19	Inflammatory bowel disease;	chr10:73900512	chr10:73699151~73730487:-
THCA	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	4.15	4.03e-05	0.00354	0.21	0.19	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
THCA	cis	rs12681963	0.688	rs4262289	ENSG00000248159.1	HSPA8P11	4.15	4.03e-05	0.00354	0.37	0.19	Migraine;	chr8:30191588	chr8:30237382~30240997:+
THCA	cis	rs3764021	0.87	rs10844597	ENSG00000214776.8	RP11-726G1.1	4.15	4.03e-05	0.00354	0.23	0.19	Type 1 diabetes;	chr12:9722303	chr12:9467552~9576275:+
THCA	cis	rs5758659	0.652	rs133305	ENSG00000273366.1	CTA-989H11.1	-4.15	4.03e-05	0.00354	-0.23	-0.19	Cognitive function;	chr22:41999956	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.682	rs133306	ENSG00000273366.1	CTA-989H11.1	-4.15	4.03e-05	0.00354	-0.23	-0.19	Cognitive function;	chr22:42000146	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.519	rs133307	ENSG00000273366.1	CTA-989H11.1	-4.15	4.03e-05	0.00354	-0.23	-0.19	Cognitive function;	chr22:42000564	chr22:42278188~42278846:+
THCA	cis	rs11168351	0.864	rs12228750	ENSG00000273765.1	RP11-370I10.11	-4.15	4.03e-05	0.00355	-0.19	-0.19	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48360920~48361377:+
THCA	cis	rs11168351	0.864	rs10875743	ENSG00000273765.1	RP11-370I10.11	-4.15	4.03e-05	0.00355	-0.19	-0.19	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48360920~48361377:+
THCA	cis	rs2337406	0.538	rs10141701	ENSG00000274576.2	IGHV2-70	-4.15	4.03e-05	0.00355	-0.15	-0.19	Alzheimer's disease (late onset);	chr14:106633467	chr14:106770577~106771020:-
THCA	cis	rs34102591	0.577	rs3762102	ENSG00000269997.1	RP11-214K3.21	-4.15	4.03e-05	0.00355	-0.3	-0.19	Schizophrenia;	chr12:123962861	chr12:123966077~123966629:-
THCA	cis	rs365302	1	rs2782552	ENSG00000235086.1	FNDC1-IT1	4.15	4.03e-05	0.00355	0.26	0.19	Coronary heart disease;	chr6:159222664	chr6:159240786~159243329:+
THCA	cis	rs72843506	0.586	rs76886618	ENSG00000231258.2	ZSWIM5P2	4.14	4.03e-05	0.00355	0.31	0.19	Schizophrenia;	chr17:19975483	chr17:20583758~20591180:-
THCA	cis	rs73108077	0.92	rs73248560	ENSG00000277112.2	RP11-755J8.1	-4.14	4.03e-05	0.00355	-0.36	-0.19	Red blood cell density in sickle cell anemia;	chr20:31436938	chr20:30681825~30723932:-
THCA	cis	rs12935229	0.756	rs12931837	ENSG00000260922.1	RP11-538I12.3	-4.14	4.03e-05	0.00355	-0.3	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77280356	chr16:77234877~77290934:+
THCA	cis	rs875971	0.862	rs709596	ENSG00000229886.1	RP5-1132H15.3	4.14	4.03e-05	0.00355	0.19	0.19	Aortic root size;	chr7:66360926	chr7:66025126~66031544:-
THCA	cis	rs2749592	0.55	rs10764135	ENSG00000226578.1	RP11-258F22.1	4.14	4.03e-05	0.00355	0.22	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:37775371~37784131:-
THCA	cis	rs10090774	0.71	rs10104479	ENSG00000279766.1	RP11-642A1.2	-4.14	4.03e-05	0.00355	-0.23	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140683972	chr8:140572142~140572812:-
THCA	cis	rs860295	0.557	rs915181	ENSG00000236675.1	MTX1P1	-4.14	4.03e-05	0.00355	-0.19	-0.19	Body mass index;	chr1:155944981	chr1:155230975~155234325:+
THCA	cis	rs878939	0.625	rs2193352	ENSG00000233690.1	EBAG9P1	4.14	4.04e-05	0.00355	0.24	0.19	Warfarin maintenance dose;	chr10:99586852	chr10:99697407~99697949:-
THCA	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-4.14	4.04e-05	0.00355	-0.18	-0.19	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-4.14	4.04e-05	0.00355	-0.18	-0.19	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
THCA	cis	rs11030122	0.959	rs1869085	ENSG00000230593.3	AC090804.1	4.14	4.04e-05	0.00355	0.24	0.19	Mean platelet volume;Platelet distribution width;	chr11:3883134	chr11:3892398~3892887:-
THCA	cis	rs4835473	0.637	rs1020497	ENSG00000251600.4	RP11-673E1.1	4.14	4.04e-05	0.00355	0.23	0.19	Immature fraction of reticulocytes;	chr4:143741029	chr4:143912331~143982454:+
THCA	cis	rs17074492	0.585	rs73242156	ENSG00000214182.5	PTMAP5	4.14	4.04e-05	0.00355	0.23	0.19	Sjögren's syndrome;	chr13:81663230	chr13:81689911~81691072:+
THCA	cis	rs12534093	0.921	rs12700440	ENSG00000234286.1	AC006026.13	-4.14	4.04e-05	0.00355	-0.3	-0.19	Infant length;Height;	chr7:23453562	chr7:23680195~23680786:-
THCA	cis	rs910873	0.803	rs56238684	ENSG00000276073.1	RP5-1125A11.7	4.14	4.04e-05	0.00355	0.36	0.19	Melanoma;	chr20:34648892	chr20:33985617~33988989:-
THCA	cis	rs3758911	1	rs10890705	ENSG00000255353.1	RP11-382M14.1	-4.14	4.04e-05	0.00355	-0.23	-0.19	Coronary artery disease;	chr11:107315308	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs4387327	ENSG00000255353.1	RP11-382M14.1	-4.14	4.04e-05	0.00355	-0.23	-0.19	Coronary artery disease;	chr11:107315334	chr11:107176286~107177530:+
THCA	cis	rs4713118	0.614	rs9380007	ENSG00000261839.1	RP1-265C24.8	4.14	4.04e-05	0.00355	0.18	0.19	Parkinson's disease;	chr6:27692729	chr6:28136849~28139678:+
THCA	cis	rs35176054	0.818	rs11596328	ENSG00000280693.1	SH3PXD2A-AS1	-4.14	4.04e-05	0.00355	-0.36	-0.19	Atrial fibrillation;	chr10:103733419	chr10:103745966~103755423:+
THCA	cis	rs9311474	0.597	rs6778735	ENSG00000243224.1	RP5-1157M23.2	-4.14	4.04e-05	0.00355	-0.2	-0.19	Electroencephalogram traits;	chr3:52531084	chr3:52239258~52241097:+
THCA	cis	rs2692947	0.77	rs62153678	ENSG00000232931.4	LINC00342	4.14	4.04e-05	0.00355	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892598	chr2:95807118~95816215:-
THCA	cis	rs10483853	0.525	rs2302041	ENSG00000258443.1	RP3-414A15.11	-4.14	4.04e-05	0.00355	-0.28	-0.19	Coronary artery calcification;	chr14:73494166	chr14:73517233~73520648:-
THCA	cis	rs2839186	0.619	rs55689527	ENSG00000239415.1	AP001469.9	4.14	4.04e-05	0.00355	0.2	0.19	Testicular germ cell tumor;	chr21:46202813	chr21:46251549~46254133:-
THCA	cis	rs2281636	0.894	rs10883396	ENSG00000233690.1	EBAG9P1	4.14	4.04e-05	0.00355	0.18	0.19	Obesity-related traits;	chr10:99647135	chr10:99697407~99697949:-
THCA	cis	rs2281636	0.894	rs12771048	ENSG00000233690.1	EBAG9P1	4.14	4.04e-05	0.00355	0.18	0.19	Obesity-related traits;	chr10:99649691	chr10:99697407~99697949:-
THCA	cis	rs972578	0.868	rs1076118	ENSG00000230319.1	AL022476.2	-4.14	4.04e-05	0.00356	-0.2	-0.19	Mean platelet volume;	chr22:42903704	chr22:43038585~43052366:+
THCA	cis	rs7914558	0.646	rs1046778	ENSG00000213277.3	MARCKSL1P1	4.14	4.04e-05	0.00356	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102901727	chr10:103175554~103176094:+
THCA	cis	rs7914558	0.646	rs11191459	ENSG00000213277.3	MARCKSL1P1	4.14	4.04e-05	0.00356	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902361	chr10:103175554~103176094:+
THCA	cis	rs7590368	0.774	rs3932106	ENSG00000272275.1	RP11-791G15.2	4.14	4.05e-05	0.00356	0.27	0.19	Educational attainment (years of education);	chr2:10776282	chr2:10767875~10770058:-
THCA	cis	rs753778	0.628	rs11579	ENSG00000253210.1	RP11-809O17.1	-4.14	4.05e-05	0.00356	-0.22	-0.19	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141195033	chr8:141126044~141129961:-
THCA	cis	rs7772486	0.79	rs9403756	ENSG00000270638.1	RP3-466P17.1	-4.14	4.05e-05	0.00356	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145735570~145737218:+
THCA	cis	rs271738	0.71	rs823485	ENSG00000231768.1	LINC01354	4.14	4.05e-05	0.00356	0.21	0.19	Bipolar disorder;	chr1:234535521	chr1:234527891~234531779:-
THCA	cis	rs4713118	0.869	rs6930992	ENSG00000220721.1	OR1F12	4.14	4.05e-05	0.00356	0.24	0.19	Parkinson's disease;	chr6:27744341	chr6:28073316~28074233:+
THCA	cis	rs9467773	0.595	rs13207371	ENSG00000124549.13	BTN2A3P	4.14	4.05e-05	0.00356	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26421391~26432383:+
THCA	cis	rs2191566	0.664	rs7251083	ENSG00000266921.1	RP11-15A1.7	-4.14	4.05e-05	0.00356	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44047713	chr19:43996896~44002836:-
THCA	cis	rs2191566	0.664	rs7250774	ENSG00000266921.1	RP11-15A1.7	-4.14	4.05e-05	0.00356	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44047714	chr19:43996896~44002836:-
THCA	cis	rs10760158	0.832	rs878691	ENSG00000226752.6	PSMD5-AS1	-4.14	4.05e-05	0.00356	-0.23	-0.19	Pulse pressure;	chr9:121275329	chr9:120824828~120854385:+
THCA	cis	rs189798	0.807	rs9949	ENSG00000253893.2	FAM85B	-4.14	4.05e-05	0.00356	-0.25	-0.19	Myopia (pathological);	chr8:9137002	chr8:8167819~8226614:-
THCA	cis	rs7178424	0.811	rs12910541	ENSG00000259251.2	RP11-643M14.1	4.14	4.05e-05	0.00356	0.19	0.19	Height;	chr15:61956712	chr15:62060503~62062434:+
THCA	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	4.14	4.05e-05	0.00356	0.17	0.19	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
THCA	cis	rs6929812	0.665	rs10946919	ENSG00000271755.1	RP1-153G14.4	4.14	4.05e-05	0.00356	0.21	0.19	Neuroticism (multi-trait analysis);	chr6:27445188	chr6:27404010~27406964:-
THCA	cis	rs62292953	0.591	rs55916362	ENSG00000248724.5	NPHP3-AS1	-4.14	4.05e-05	0.00356	-0.41	-0.19	Red cell distribution width;	chr3:132540744	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.591	rs55726578	ENSG00000248724.5	NPHP3-AS1	-4.14	4.05e-05	0.00356	-0.41	-0.19	Red cell distribution width;	chr3:132540748	chr3:132721750~132874223:+
THCA	cis	rs3740713	1	rs73436638	ENSG00000256464.1	YWHABP2	4.14	4.05e-05	0.00356	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73436642	ENSG00000256464.1	YWHABP2	4.14	4.05e-05	0.00356	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73436666	ENSG00000256464.1	YWHABP2	4.14	4.05e-05	0.00356	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438611	ENSG00000256464.1	YWHABP2	4.14	4.05e-05	0.00356	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs2643872	ENSG00000256464.1	YWHABP2	4.14	4.05e-05	0.00356	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs75381502	ENSG00000256464.1	YWHABP2	4.14	4.05e-05	0.00356	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr11:18490243~18490955:-
THCA	cis	rs8023401	0.507	rs140605	ENSG00000259705.1	RP11-227D13.1	4.14	4.05e-05	0.00356	0.23	0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48497437	chr15:48645951~48652016:+
THCA	cis	rs7903847	0.62	rs10882903	ENSG00000225850.3	RP11-452K12.4	4.14	4.05e-05	0.00356	0.19	0.19	Granulocyte percentage of myeloid white cells;	chr10:97355827	chr10:97334564~97343203:+
THCA	cis	rs2015599	0.623	rs12581107	ENSG00000273680.1	RP11-996F15.6	4.14	4.05e-05	0.00356	0.27	0.19	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29332733~29333383:-
THCA	cis	rs1800682	0.528	rs11202918	ENSG00000261438.1	RP11-399O19.9	-4.14	4.05e-05	0.00356	-0.16	-0.19	Chronic lymphocytic leukemia;	chr10:88982251	chr10:89015836~89017059:+
THCA	cis	rs34421088	0.586	rs2272594	ENSG00000154316.13	TDH	-4.14	4.05e-05	0.00356	-0.14	-0.19	Neuroticism;	chr8:11285116	chr8:11339637~11368452:+
THCA	cis	rs5769765	0.908	rs138891	ENSG00000260613.1	RP3-522J7.6	-4.14	4.05e-05	0.00356	-0.22	-0.19	Schizophrenia;	chr22:49834093	chr22:49832616~49837786:-
THCA	cis	rs5758659	0.652	rs133336	ENSG00000273366.1	CTA-989H11.1	-4.14	4.05e-05	0.00356	-0.23	-0.19	Cognitive function;	chr22:42020299	chr22:42278188~42278846:+
THCA	cis	rs7829975	0.84	rs555617	ENSG00000254340.1	RP11-10A14.3	-4.14	4.05e-05	0.00356	-0.2	-0.19	Mood instability;	chr8:8735335	chr8:9141424~9145435:+
THCA	cis	rs12410462	0.636	rs7413796	ENSG00000227711.2	RP11-275O4.5	-4.14	4.05e-05	0.00356	-0.23	-0.19	Major depressive disorder;	chr1:227553722	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.551	rs74997063	ENSG00000227711.2	RP11-275O4.5	-4.14	4.05e-05	0.00356	-0.23	-0.19	Major depressive disorder;	chr1:227556836	chr1:227509028~227520477:-
THCA	cis	rs944289	0.589	rs847516	ENSG00000258844.1	RP11-259K15.2	-4.14	4.05e-05	0.00356	-0.17	-0.19	Thyroid cancer;	chr14:36060593	chr14:36214607~36235608:+
THCA	cis	rs4950322	0.634	rs4950415	ENSG00000271721.1	RP11-337C18.9	4.14	4.05e-05	0.00356	0.21	0.19	Protein quantitative trait loci;	chr1:147350951	chr1:147175602~147177740:+
THCA	cis	rs4591358	0.765	rs979821	ENSG00000223466.1	AC064834.2	4.14	4.05e-05	0.00356	0.22	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195456015	chr2:195533035~195538681:+
THCA	cis	rs4824093	0.61	rs58888255	ENSG00000278869.1	CITF22-49E9.3	4.14	4.05e-05	0.00356	0.4	0.19	Amyotrophic lateral sclerosis (sporadic);	chr22:49921979	chr22:49933198~49934074:-
THCA	cis	rs4916588	0.697	rs6796963	ENSG00000270170.1	NCBP2-AS2	4.14	4.05e-05	0.00356	0.15	0.19	Night sleep phenotypes;	chr3:196935404	chr3:196942623~196943540:+
THCA	cis	rs6870983	0.857	rs6452788	ENSG00000247828.6	TMEM161B-AS1	4.14	4.06e-05	0.00356	0.16	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88417096	chr5:88268895~88436685:+
THCA	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	4.14	4.06e-05	0.00356	0.2	0.19	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
THCA	cis	rs9980	0.803	rs17299478	ENSG00000226232.7	RP11-419C5.2	-4.14	4.06e-05	0.00357	-0.29	-0.19	Blood osmolality (transformed sodium);	chr16:69741597	chr16:69976388~69996188:-
THCA	cis	rs2281636	0.755	rs2111324	ENSG00000233690.1	EBAG9P1	4.14	4.06e-05	0.00357	0.18	0.19	Obesity-related traits;	chr10:99636807	chr10:99697407~99697949:-
THCA	cis	rs7674212	0.531	rs4699048	ENSG00000248971.2	KRT8P46	-4.14	4.06e-05	0.00357	-0.23	-0.19	Type 2 diabetes;	chr4:103005570	chr4:102728746~102730171:-
THCA	cis	rs6477918	0.598	rs58653211	ENSG00000230185.4	C9orf147	-4.14	4.06e-05	0.00357	-0.2	-0.19	Obstetric antiphospholipid syndrome;	chr9:112406179	chr9:112433816~112487204:-
THCA	cis	rs950169	0.887	rs220333	ENSG00000188388.10	GOLGA6L3	4.14	4.06e-05	0.00357	0.25	0.19	Schizophrenia;	chr15:84547902	chr15:85240472~85247170:+
THCA	cis	rs1371614	0.545	rs3769138	ENSG00000272148.1	RP11-195B17.1	4.14	4.06e-05	0.00357	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946672	chr2:27062428~27062907:-
THCA	cis	rs7968440	1	rs2731434	ENSG00000272368.2	RP4-605O3.4	4.14	4.06e-05	0.00357	0.12	0.19	Fibrinogen;	chr12:50716092	chr12:50112197~50165618:+
THCA	cis	rs17689437	1	rs11864995	ENSG00000260084.1	RP11-615I2.1	-4.14	4.06e-05	0.00357	-0.33	-0.19	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68571320	chr16:68573782~68589512:-
THCA	cis	rs2070488	0.965	rs7640050	ENSG00000229589.1	ACVR2B-AS1	4.14	4.06e-05	0.00357	0.17	0.19	Electrocardiographic conduction measures;	chr3:38484373	chr3:38451027~38454820:-
THCA	cis	rs55966801	0.68	rs17655730	ENSG00000277290.1	RP11-326C3.16	-4.14	4.06e-05	0.00357	-0.23	-0.19	Plateletcrit;	chr11:270715	chr11:243099~243483:-
THCA	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	4.14	4.06e-05	0.00357	0.21	0.19	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
THCA	cis	rs17221829	0.733	rs10501708	ENSG00000280385.1	AP000648.5	-4.14	4.06e-05	0.00357	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89661267	chr11:90193614~90198120:+
THCA	cis	rs5751901	0.688	rs2017869	ENSG00000225098.1	BCRP1	4.14	4.06e-05	0.00357	0.23	0.19	Protein quantitative trait loci;	chr22:24601342	chr22:24259929~24263764:-
THCA	cis	rs9595908	0.709	rs4942897	ENSG00000212293.1	SNORA16	4.14	4.06e-05	0.00357	0.22	0.19	Body mass index;	chr13:32757615	chr13:32420390~32420516:-
THCA	cis	rs6496044	0.568	rs1982742	ENSG00000259630.2	CTD-2262B20.1	-4.14	4.06e-05	0.00357	-0.2	-0.19	Interstitial lung disease;	chr15:85525519	chr15:85415228~85415633:+
THCA	cis	rs6496044	0.568	rs1982743	ENSG00000259630.2	CTD-2262B20.1	-4.14	4.06e-05	0.00357	-0.2	-0.19	Interstitial lung disease;	chr15:85525528	chr15:85415228~85415633:+
THCA	cis	rs10129255	0.879	rs7160512	ENSG00000211972.2	IGHV3-66	4.14	4.07e-05	0.00357	0.11	0.19	Kawasaki disease;	chr14:106694574	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.879	rs7159157	ENSG00000211972.2	IGHV3-66	4.14	4.07e-05	0.00357	0.11	0.19	Kawasaki disease;	chr14:106694578	chr14:106675017~106675544:-
THCA	cis	rs8040855	0.621	rs6496796	ENSG00000259630.2	CTD-2262B20.1	4.14	4.07e-05	0.00357	0.21	0.19	Bulimia nervosa;	chr15:85183617	chr15:85415228~85415633:+
THCA	cis	rs10266483	0.705	rs599522	ENSG00000271550.1	BNIP3P11	4.14	4.07e-05	0.00357	0.24	0.19	Response to statin therapy;	chr7:64298104	chr7:64678954~64687393:-
THCA	cis	rs2191566	0.576	rs436790	ENSG00000277806.1	RP11-15A1.8	-4.14	4.07e-05	0.00357	-0.19	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:43987775	chr19:43976815~43977448:+
THCA	cis	rs4713118	0.513	rs156738	ENSG00000261839.1	RP1-265C24.8	4.14	4.07e-05	0.00357	0.2	0.19	Parkinson's disease;	chr6:28046247	chr6:28136849~28139678:+
THCA	cis	rs67478160	0.619	rs1040813	ENSG00000269940.1	RP11-73M18.7	4.14	4.07e-05	0.00357	0.18	0.19	Schizophrenia;	chr14:103840359	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.619	rs1187416	ENSG00000269940.1	RP11-73M18.7	4.14	4.07e-05	0.00357	0.18	0.19	Schizophrenia;	chr14:103845128	chr14:103694560~103695170:+
THCA	cis	rs6491750	0.557	rs7983728	ENSG00000276957.1	RP11-29B2.6	4.14	4.07e-05	0.00357	0.31	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103499494	chr13:102593338~102593873:-
THCA	cis	rs9902453	0.838	rs8064689	ENSG00000263370.1	RP11-68I3.5	4.14	4.07e-05	0.00357	0.25	0.19	Coffee consumption (cups per day);	chr17:29890035	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.769	rs7210288	ENSG00000263370.1	RP11-68I3.5	4.14	4.07e-05	0.00357	0.25	0.19	Coffee consumption (cups per day);	chr17:29916455	chr17:29639627~29640825:+
THCA	cis	rs4460629	0.521	rs12039316	ENSG00000160766.13	GBAP1	-4.14	4.07e-05	0.00358	-0.2	-0.19	Serum magnesium levels;	chr1:155100745	chr1:155213821~155227422:-
THCA	cis	rs1232027	0.7	rs1643655	ENSG00000249655.1	CTC-325J23.2	4.14	4.07e-05	0.00358	0.21	0.19	Huntington's disease progression;	chr5:80657957	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs2405880	ENSG00000249655.1	CTC-325J23.2	4.14	4.07e-05	0.00358	0.21	0.19	Huntington's disease progression;	chr5:80657974	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677680	ENSG00000249655.1	CTC-325J23.2	4.14	4.07e-05	0.00358	0.21	0.19	Huntington's disease progression;	chr5:80659216	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1643652	ENSG00000249655.1	CTC-325J23.2	4.14	4.07e-05	0.00358	0.21	0.19	Huntington's disease progression;	chr5:80659260	chr5:80630313~80631590:-
THCA	cis	rs2006933	1	rs9914405	ENSG00000267644.1	CTD-2008P7.10	4.14	4.07e-05	0.00358	0.23	0.19	Amyotrophic lateral sclerosis;	chr17:28261333	chr17:28219285~28220005:+
THCA	cis	rs9902453	0.74	rs1382391	ENSG00000263370.1	RP11-68I3.5	-4.14	4.07e-05	0.00358	-0.24	-0.19	Coffee consumption (cups per day);	chr17:29784968	chr17:29639627~29640825:+
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000182586.6	LINC00334	-4.14	4.07e-05	0.00358	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45234340~45258730:+
THCA	cis	rs6701713	1	rs2093761	ENSG00000274245.1	RP11-357P18.2	-4.14	4.07e-05	0.00358	-0.21	-0.19	Alzheimer's disease (late onset);	chr1:207613197	chr1:207372559~207373252:+
THCA	cis	rs4218	0.648	rs12910987	ENSG00000259732.1	RP11-59H7.3	-4.14	4.07e-05	0.00358	-0.26	-0.19	Social communication problems;	chr15:59092782	chr15:59121034~59133250:+
THCA	cis	rs2070488	0.965	rs4679053	ENSG00000229589.1	ACVR2B-AS1	4.14	4.07e-05	0.00358	0.17	0.19	Electrocardiographic conduction measures;	chr3:38482004	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.965	rs1046048	ENSG00000229589.1	ACVR2B-AS1	4.14	4.07e-05	0.00358	0.17	0.19	Electrocardiographic conduction measures;	chr3:38483251	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.965	rs7642472	ENSG00000229589.1	ACVR2B-AS1	4.14	4.07e-05	0.00358	0.17	0.19	Electrocardiographic conduction measures;	chr3:38484076	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.93	rs928813	ENSG00000229589.1	ACVR2B-AS1	4.14	4.07e-05	0.00358	0.17	0.19	Electrocardiographic conduction measures;	chr3:38487046	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.965	rs7433277	ENSG00000229589.1	ACVR2B-AS1	4.14	4.07e-05	0.00358	0.17	0.19	Electrocardiographic conduction measures;	chr3:38488327	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.965	rs1058945	ENSG00000229589.1	ACVR2B-AS1	-4.14	4.07e-05	0.00358	-0.17	-0.19	Electrocardiographic conduction measures;	chr3:38491020	chr3:38451027~38454820:-
THCA	cis	rs2549003	1	rs2070731	ENSG00000237714.1	P4HA2-AS1	-4.14	4.07e-05	0.00358	-0.24	-0.19	Asthma (sex interaction);	chr5:132484106	chr5:132184876~132192808:+
THCA	cis	rs4906332	0.966	rs17679729	ENSG00000244691.1	RPL10AP1	-4.14	4.07e-05	0.00358	-0.24	-0.19	Coronary artery disease;	chr14:103457975	chr14:103412119~103412761:-
THCA	cis	rs4906332	0.933	rs35999760	ENSG00000244691.1	RPL10AP1	-4.14	4.07e-05	0.00358	-0.24	-0.19	Coronary artery disease;	chr14:103458144	chr14:103412119~103412761:-
THCA	cis	rs4906332	0.966	rs12185021	ENSG00000244691.1	RPL10AP1	-4.14	4.07e-05	0.00358	-0.24	-0.19	Coronary artery disease;	chr14:103461468	chr14:103412119~103412761:-
THCA	cis	rs9435732	0.725	rs10437047	ENSG00000235241.1	RP11-108M9.5	4.14	4.07e-05	0.00358	0.24	0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16994933	chr1:16889095~16889602:+
THCA	cis	rs875971	1	rs2420820	ENSG00000229886.1	RP5-1132H15.3	-4.14	4.07e-05	0.00358	-0.2	-0.19	Aortic root size;	chr7:66626920	chr7:66025126~66031544:-
THCA	cis	rs897984	0.762	rs12931046	ENSG00000275263.1	RP11-1072A3.4	4.14	4.07e-05	0.00358	0.22	0.19	Dementia with Lewy bodies;	chr16:30975823	chr16:30956872~30957199:-
THCA	cis	rs172166	0.561	rs149971	ENSG00000220721.1	OR1F12	4.14	4.07e-05	0.00358	0.21	0.19	Cardiac Troponin-T levels;	chr6:28014374	chr6:28073316~28074233:+
THCA	cis	rs10760158	0.832	rs880823	ENSG00000226752.6	PSMD5-AS1	-4.14	4.07e-05	0.00358	-0.23	-0.19	Pulse pressure;	chr9:121276189	chr9:120824828~120854385:+
THCA	cis	rs2380205	0.967	rs11255577	ENSG00000232807.2	RP11-536K7.3	4.14	4.07e-05	0.00358	0.17	0.19	Breast cancer;	chr10:5856207	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs4330991	ENSG00000232807.2	RP11-536K7.3	4.14	4.07e-05	0.00358	0.17	0.19	Breast cancer;	chr10:5856217	chr10:5934270~5945900:-
THCA	cis	rs2153535	0.585	rs9379234	ENSG00000230939.1	RP11-314C16.1	-4.14	4.07e-05	0.00358	-0.2	-0.19	Motion sickness;	chr6:8643520	chr6:8784178~8785445:+
THCA	cis	rs1560104	0.597	rs13338316	ENSG00000260601.1	RP11-552C15.1	-4.14	4.07e-05	0.00358	-0.22	-0.19	Obesity-related traits;	chr16:12617168	chr16:12545482~12546684:+
THCA	cis	rs1560104	0.597	rs13333850	ENSG00000260601.1	RP11-552C15.1	-4.14	4.07e-05	0.00358	-0.22	-0.19	Obesity-related traits;	chr16:12617231	chr16:12545482~12546684:+
THCA	cis	rs357618	1	rs357618	ENSG00000260581.1	CTB-113P19.4	4.14	4.07e-05	0.00358	0.24	0.19	Basophil percentage of white cells;	chr5:151467051	chr5:151652275~151655449:+
THCA	cis	rs2380205	0.967	rs4497300	ENSG00000232807.2	RP11-536K7.3	4.14	4.08e-05	0.00358	0.17	0.19	Breast cancer;	chr10:5856278	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs4294487	ENSG00000232807.2	RP11-536K7.3	4.14	4.08e-05	0.00358	0.17	0.19	Breast cancer;	chr10:5856442	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs4421659	ENSG00000232807.2	RP11-536K7.3	4.14	4.08e-05	0.00358	0.17	0.19	Breast cancer;	chr10:5856443	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.935	rs4468244	ENSG00000232807.2	RP11-536K7.3	4.14	4.08e-05	0.00358	0.17	0.19	Breast cancer;	chr10:5856580	chr10:5934270~5945900:-
THCA	cis	rs1908814	0.516	rs4841641	ENSG00000254948.1	OR7E158P	-4.14	4.08e-05	0.00358	-0.24	-0.19	Neuroticism;	chr8:11940718	chr8:11919900~11920809:-
THCA	cis	rs3742597	0.84	rs10138052	ENSG00000276116.2	FUT8-AS1	-4.14	4.08e-05	0.00358	-0.22	-0.19	N-glycan levels;	chr14:65366722	chr14:65411170~65412690:-
THCA	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-4.14	4.08e-05	0.00358	-0.23	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
THCA	cis	rs8062405	0.723	rs35175818	ENSG00000270424.1	RP11-1348G14.6	4.14	4.08e-05	0.00358	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28749959~28750595:-
THCA	cis	rs13113518	1	rs4865004	ENSG00000272969.1	RP11-528I4.2	4.14	4.08e-05	0.00358	0.22	0.19	Height;	chr4:55515118	chr4:55547112~55547889:+
THCA	cis	rs453301	0.506	rs686189	ENSG00000233609.3	RP11-62H7.2	-4.14	4.08e-05	0.00358	-0.18	-0.19	Joint mobility (Beighton score);	chr8:8766127	chr8:8961200~8979025:+
THCA	cis	rs6723108	0.515	rs1942049	ENSG00000224043.6	CCNT2-AS1	-4.14	4.08e-05	0.00358	-0.2	-0.19	Type 2 diabetes;	chr2:134816798	chr2:134735464~134918710:-
THCA	cis	rs13034020	0.594	rs62150966	ENSG00000271889.1	RP11-493E12.1	-4.14	4.08e-05	0.00358	-0.27	-0.19	Hodgkin's lymphoma;	chr2:60971921	chr2:61151433~61162105:-
THCA	cis	rs11633886	0.835	rs7178907	ENSG00000259200.1	RP11-718O11.1	-4.14	4.08e-05	0.00359	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45809159	chr15:45705078~45931069:+
THCA	cis	rs4950322	0.518	rs61838936	ENSG00000226015.2	CCT8P1	4.14	4.08e-05	0.00359	0.22	0.19	Protein quantitative trait loci;	chr1:147098422	chr1:147203276~147204932:-
THCA	cis	rs6560517	0.874	rs11144871	ENSG00000234618.1	RPSAP9	-4.14	4.08e-05	0.00359	-0.2	-0.19	Dialysis-related mortality;	chr9:76392802	chr9:76398699~76399586:+
THCA	cis	rs57502260	1	rs56312530	ENSG00000212093.1	AP000807.1	4.14	4.08e-05	0.00359	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68451947	chr11:68506083~68506166:-
THCA	cis	rs7246657	0.508	rs10419845	ENSG00000276846.1	CTD-3220F14.3	4.14	4.08e-05	0.00359	0.23	0.19	Coronary artery calcification;	chr19:37000290	chr19:37314868~37315620:-
THCA	cis	rs9510787	0.649	rs9507129	ENSG00000205861.10	C1QTNF9B-AS1	-4.14	4.08e-05	0.00359	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23645284	chr13:23888889~23897263:+
THCA	cis	rs2299587	0.554	rs3913558	ENSG00000253671.1	RP11-806O11.1	-4.14	4.09e-05	0.00359	-0.22	-0.19	Economic and political preferences;	chr8:17890400	chr8:17808941~17820868:+
THCA	cis	rs911555	0.755	rs4143998	ENSG00000269910.1	RP11-73M18.10	4.14	4.09e-05	0.00359	0.17	0.19	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs1138400	ENSG00000269910.1	RP11-73M18.10	4.14	4.09e-05	0.00359	0.17	0.19	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs7147664	ENSG00000269910.1	RP11-73M18.10	4.14	4.09e-05	0.00359	0.17	0.19	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103694516~103695050:-
THCA	cis	rs7615952	0.932	rs6438948	ENSG00000272840.1	RP11-379B18.6	-4.14	4.09e-05	0.00359	-0.31	-0.19	Blood pressure (smoking interaction);	chr3:125931202	chr3:125774714~125797953:+
THCA	cis	rs6479874	0.831	rs2245543	ENSG00000223502.1	RP11-96B5.3	-4.14	4.09e-05	0.00359	-0.23	-0.19	Migraine;	chr10:50985388	chr10:51062579~51068553:-
THCA	cis	rs12681366	0.801	rs6981551	ENSG00000261437.1	RP11-22C11.2	4.14	4.09e-05	0.00359	0.19	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:94637285~94639467:-
THCA	cis	rs7615952	0.546	rs11718647	ENSG00000241278.1	ENPP7P4	4.14	4.09e-05	0.00359	0.26	0.19	Blood pressure (smoking interaction);	chr3:125633178	chr3:125848223~125909372:+
THCA	cis	rs6570726	0.902	rs396681	ENSG00000270638.1	RP3-466P17.1	4.14	4.09e-05	0.00359	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145735570~145737218:+
THCA	cis	rs481331	0.866	rs34920187	ENSG00000215146.4	RP11-313J2.1	4.14	4.09e-05	0.00359	0.29	0.19	Systemic juvenile idiopathic arthritis;	chr10:42497070	chr10:42331866~42367974:-
THCA	cis	rs2408955	0.5	rs12816820	ENSG00000273765.1	RP11-370I10.11	4.14	4.09e-05	0.00359	0.19	0.19	Glycated hemoglobin levels;	chr12:48164542	chr12:48360920~48361377:+
THCA	cis	rs8031584	1	rs890159	ENSG00000178081.11	ULK4P3	4.14	4.09e-05	0.00359	0.26	0.19	Huntington's disease progression;	chr15:30999431	chr15:30103720~30131757:+
THCA	cis	rs8062405	1	rs4788102	ENSG00000270424.1	RP11-1348G14.6	4.14	4.09e-05	0.00359	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28749959~28750595:-
THCA	cis	rs4767841	0.718	rs203329	ENSG00000248636.5	RP11-768F21.1	-4.14	4.09e-05	0.00359	-0.19	-0.19	Urgency urinary incontinence;	chr12:119771874	chr12:119387987~119668079:-
THCA	cis	rs150992	0.587	rs10076291	ENSG00000246763.5	RGMB-AS1	-4.14	4.09e-05	0.00359	-0.19	-0.19	Body mass index;	chr5:99012954	chr5:98769618~98773469:-
THCA	cis	rs7608910	1	rs7608697	ENSG00000271889.1	RP11-493E12.1	4.14	4.09e-05	0.00359	0.19	0.19	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977506	chr2:61151433~61162105:-
THCA	cis	rs7647973	0.769	rs7434187	ENSG00000229759.1	MRPS18AP1	4.14	4.09e-05	0.00359	0.29	0.19	Menarche (age at onset);	chr3:48995534	chr3:48256350~48256938:-
THCA	cis	rs12410462	0.551	rs2012432	ENSG00000227711.2	RP11-275O4.5	-4.14	4.09e-05	0.00359	-0.23	-0.19	Major depressive disorder;	chr1:227678456	chr1:227509028~227520477:-
THCA	cis	rs9650657	0.501	rs3021500	ENSG00000254866.2	DEFB109P3	4.14	4.09e-05	0.00359	0.26	0.19	Neuroticism;	chr8:11166488	chr8:12150895~12151134:-
THCA	cis	rs6845263	0.511	rs13122215	ENSG00000254531.1	FLJ20021	-4.14	4.09e-05	0.00359	-0.16	-0.19	Superior crus of antihelix expression;	chr4:101549281	chr4:101347780~101348883:+
THCA	cis	rs1959947	0.526	rs11622884	ENSG00000251363.2	RP11-129M6.1	4.14	4.09e-05	0.00359	0.25	0.19	Hemostatic factors and hematological phenotypes;	chr14:41101690	chr14:40954898~40975877:+
THCA	cis	rs934734	0.532	rs6752053	ENSG00000214533.3	KRT18P33	-4.14	4.09e-05	0.00359	-0.23	-0.19	Rheumatoid arthritis;	chr2:65439540	chr2:65666695~65667737:+
THCA	cis	rs1204798	0.588	rs1204830	ENSG00000237021.2	RP3-486I3.7	-4.14	4.09e-05	0.00359	-0.22	-0.19	Dental caries;	chr6:116249325	chr6:116254207~116256743:+
THCA	cis	rs72843506	0.586	rs75721433	ENSG00000231258.2	ZSWIM5P2	4.14	4.09e-05	0.00359	0.31	0.19	Schizophrenia;	chr17:19978747	chr17:20583758~20591180:-
THCA	cis	rs2239815	0.515	rs5762849	ENSG00000272858.1	CTA-292E10.8	-4.14	4.09e-05	0.00359	-0.24	-0.19	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28842098	chr22:28814914~28815662:+
THCA	cis	rs2070488	0.965	rs13097628	ENSG00000229589.1	ACVR2B-AS1	4.14	4.09e-05	0.00359	0.17	0.19	Electrocardiographic conduction measures;	chr3:38479665	chr3:38451027~38454820:-
THCA	cis	rs9788682	0.747	rs11637630	ENSG00000261143.1	ADAMTS7P3	4.14	4.09e-05	0.00359	0.25	0.19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78607377	chr15:77976042~77993057:+
THCA	cis	rs2153535	0.518	rs6912560	ENSG00000230939.1	RP11-314C16.1	-4.14	4.09e-05	0.00359	-0.2	-0.19	Motion sickness;	chr6:8563878	chr6:8784178~8785445:+
THCA	cis	rs7560272	0.513	rs7558546	ENSG00000273245.1	RP11-434P11.2	-4.14	4.09e-05	0.00359	-0.21	-0.19	Schizophrenia;	chr2:73710605	chr2:73750256~73750786:-
THCA	cis	rs6687821	0.773	rs12097495	ENSG00000261737.1	RP4-612B15.3	-4.14	4.09e-05	0.0036	-0.32	-0.19	Yeast infection;	chr1:86749925	chr1:86703502~86704462:-
THCA	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-4.14	4.09e-05	0.0036	-0.18	-0.19	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
THCA	cis	rs11239930	0.517	rs556976	ENSG00000278811.3	LINC00624	4.14	4.09e-05	0.0036	0.23	0.19	AIDS progression;	chr1:147073643	chr1:147258885~147517875:-
THCA	cis	rs55726902	0.553	rs2525053	ENSG00000276691.1	RP5-1057I20.5	4.14	4.1e-05	0.0036	0.2	0.19	Allergic disease (asthma, hay fever or eczema);	chr12:47801565	chr12:47788426~47788971:+
THCA	cis	rs55726902	0.553	rs2525052	ENSG00000276691.1	RP5-1057I20.5	4.14	4.1e-05	0.0036	0.2	0.19	Allergic disease (asthma, hay fever or eczema);	chr12:47801641	chr12:47788426~47788971:+
THCA	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-4.14	4.1e-05	0.0036	-0.18	-0.19	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
THCA	cis	rs950169	0.922	rs17531523	ENSG00000275120.1	RP11-182J1.17	4.14	4.1e-05	0.0036	0.23	0.19	Schizophrenia;	chr15:84589218	chr15:84599434~84606463:-
THCA	cis	rs875971	0.597	rs11763224	ENSG00000273142.1	RP11-458F8.4	4.14	4.1e-05	0.0036	0.18	0.19	Aortic root size;	chr7:66518628	chr7:66902857~66906297:+
THCA	cis	rs4908768	0.906	rs12410336	ENSG00000232912.4	RP5-1115A15.1	-4.14	4.1e-05	0.0036	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8563605	chr1:8424645~8434838:+
THCA	cis	rs10256972	0.568	rs1133043	ENSG00000225146.1	AC073957.15	4.14	4.1e-05	0.0036	0.2	0.19	Endometriosis;Longevity;	chr7:1093669	chr7:1029025~1043891:+
THCA	cis	rs6570726	0.791	rs10872577	ENSG00000270638.1	RP3-466P17.1	4.14	4.1e-05	0.0036	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145735570~145737218:+
THCA	cis	rs7267979	0.527	rs6076369	ENSG00000274414.1	RP5-965G21.4	4.14	4.1e-05	0.0036	0.23	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:25239007~25245229:-
THCA	cis	rs2688608	0.901	rs2675671	ENSG00000271816.1	BMS1P4	4.14	4.1e-05	0.0036	0.19	0.19	Inflammatory bowel disease;	chr10:73873002	chr10:73699151~73730487:-
THCA	cis	rs7267979	0.789	rs1983974	ENSG00000274973.1	RP13-401N8.7	4.14	4.1e-05	0.0036	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25845497~25845862:+
THCA	cis	rs736408	0.509	rs1108842	ENSG00000243224.1	RP5-1157M23.2	-4.14	4.1e-05	0.0036	-0.2	-0.19	Bipolar disorder;	chr3:52686064	chr3:52239258~52241097:+
THCA	cis	rs9818758	0.556	rs73077200	ENSG00000270441.1	RP11-694I15.7	4.14	4.1e-05	0.0036	0.3	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49789554	chr3:49140086~49160851:-
THCA	cis	rs4713118	0.523	rs2179096	ENSG00000220721.1	OR1F12	4.14	4.1e-05	0.0036	0.22	0.19	Parkinson's disease;	chr6:27698141	chr6:28073316~28074233:+
THCA	cis	rs4947019	0.686	rs9487083	ENSG00000223537.2	RP5-919F19.5	-4.14	4.1e-05	0.0036	-0.35	-0.19	Hematological parameters;	chr6:109394399	chr6:109487906~109506800:+
THCA	cis	rs9625935	0.957	rs5763689	ENSG00000279159.1	RP3-394A18.1	4.14	4.1e-05	0.0036	0.15	0.19	Tonsillectomy;	chr22:29998634	chr22:29978950~30028236:-
THCA	cis	rs8062405	0.965	rs8049439	ENSG00000270424.1	RP11-1348G14.6	4.14	4.1e-05	0.0036	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28749959~28750595:-
THCA	cis	rs756699	0.749	rs244676	ENSG00000279469.1	RP11-215P8.2	4.14	4.1e-05	0.0036	0.29	0.19	Multiple sclerosis;	chr5:134095924	chr5:134394360~134395008:-
THCA	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	4.14	4.1e-05	0.0036	0.22	0.19	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
THCA	cis	rs1048886	0.938	rs58085250	ENSG00000271967.1	RP11-134K13.4	-4.14	4.1e-05	0.0036	-0.2	-0.19	Type 2 diabetes;	chr6:70508878	chr6:70596438~70596980:+
THCA	cis	rs13323323	1	rs13323323	ENSG00000214820.3	MPRIPP1	4.14	4.1e-05	0.0036	0.22	0.19	IgG glycosylation;	chr3:44291832	chr3:44579938~44581026:-
THCA	cis	rs6701713	1	rs3818361	ENSG00000274245.1	RP11-357P18.2	-4.14	4.1e-05	0.0036	-0.21	-0.19	Alzheimer's disease (late onset);	chr1:207611623	chr1:207372559~207373252:+
THCA	cis	rs12681288	0.523	rs112307130	ENSG00000260721.1	AF067845.1	4.14	4.1e-05	0.0036	0.23	0.19	Schizophrenia;	chr8:1012483	chr8:1368642~1369833:-
THCA	cis	rs7829975	0.744	rs2409092	ENSG00000254340.1	RP11-10A14.3	4.14	4.1e-05	0.0036	0.21	0.19	Mood instability;	chr8:8824682	chr8:9141424~9145435:+
THCA	cis	rs957448	0.554	rs12541408	ENSG00000253175.1	RP11-267M23.6	4.14	4.1e-05	0.0036	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94565036~94565715:+
THCA	cis	rs7772486	0.764	rs9399569	ENSG00000270638.1	RP3-466P17.1	-4.14	4.1e-05	0.0036	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs4360151	ENSG00000270638.1	RP3-466P17.1	-4.14	4.1e-05	0.0036	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145735570~145737218:+
THCA	cis	rs10090774	0.834	rs11997161	ENSG00000280303.2	ERICD	-4.14	4.1e-05	0.0036	-0.17	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140728488	chr8:140636281~140638283:+
THCA	cis	rs1414896	0.646	rs12728422	ENSG00000226026.4	RP11-57H12.3	4.14	4.1e-05	0.0036	0.18	0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95200431	chr1:95163219~95233982:-
THCA	cis	rs9595908	0.709	rs7322505	ENSG00000212293.1	SNORA16	4.14	4.11e-05	0.0036	0.22	0.19	Body mass index;	chr13:32756282	chr13:32420390~32420516:-
THCA	cis	rs10435719	0.809	rs77601743	ENSG00000254948.1	OR7E158P	-4.14	4.11e-05	0.0036	-0.24	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933060	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.678	rs74724594	ENSG00000254948.1	OR7E158P	-4.14	4.11e-05	0.0036	-0.24	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933067	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.702	rs77055881	ENSG00000254948.1	OR7E158P	-4.14	4.11e-05	0.0036	-0.24	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933072	chr8:11919900~11920809:-
THCA	cis	rs10090774	0.87	rs6994744	ENSG00000280303.2	ERICD	4.14	4.11e-05	0.0036	0.17	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140730769	chr8:140636281~140638283:+
THCA	cis	rs453301	0.592	rs4841084	ENSG00000253981.4	ALG1L13P	4.14	4.11e-05	0.0036	0.17	0.19	Joint mobility (Beighton score);	chr8:9026395	chr8:8236003~8244667:-
THCA	cis	rs453301	0.653	rs2956244	ENSG00000253981.4	ALG1L13P	4.14	4.11e-05	0.0036	0.17	0.19	Joint mobility (Beighton score);	chr8:9027656	chr8:8236003~8244667:-
THCA	cis	rs2836974	0.897	rs1571709	ENSG00000255568.3	BRWD1-AS2	4.14	4.11e-05	0.0036	0.16	0.19	Cognitive function;	chr21:39182054	chr21:39313935~39314962:+
THCA	cis	rs412658	0.523	rs440597	ENSG00000269845.1	RP11-420K14.6	-4.14	4.11e-05	0.0036	-0.21	-0.19	Telomere length;	chr19:21913717	chr19:21750747~21753438:+
THCA	cis	rs397969	0.57	rs2108981	ENSG00000261033.1	RP11-209D14.2	-4.14	4.11e-05	0.00361	-0.27	-0.19	Platelet count;	chr17:19975353	chr17:20008051~20009234:-
THCA	cis	rs780094	0.5	rs12473139	ENSG00000234072.1	AC074117.10	4.14	4.11e-05	0.00361	0.15	0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27542720	chr2:27356246~27367622:+
THCA	cis	rs4666002	0.956	rs10169065	ENSG00000234072.1	AC074117.10	4.14	4.11e-05	0.00361	0.15	0.19	Phospholipid levels (plasma);	chr2:27555693	chr2:27356246~27367622:+
THCA	cis	rs4666002	0.956	rs10179872	ENSG00000234072.1	AC074117.10	4.14	4.11e-05	0.00361	0.15	0.19	Phospholipid levels (plasma);	chr2:27555705	chr2:27356246~27367622:+
THCA	cis	rs780094	0.5	rs7570476	ENSG00000234072.1	AC074117.10	4.14	4.11e-05	0.00361	0.15	0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27561791	chr2:27356246~27367622:+
THCA	cis	rs6806253	0.774	rs35778631	ENSG00000239405.1	TMED10P2	4.14	4.11e-05	0.00361	0.29	0.19	Pit-and-Fissure caries;	chr3:128562269	chr3:128538020~128538631:+
THCA	cis	rs4934494	0.634	rs11185791	ENSG00000240996.1	RP11-80H5.7	-4.14	4.11e-05	0.00361	-0.21	-0.19	Red blood cell count;	chr10:89615198	chr10:89694295~89697928:-
THCA	cis	rs7572644	0.64	rs4666022	ENSG00000223522.1	AC093690.1	-4.14	4.11e-05	0.00361	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27834956	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.621	rs4462754	ENSG00000223522.1	AC093690.1	-4.14	4.11e-05	0.00361	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27841127	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.64	rs4564736	ENSG00000223522.1	AC093690.1	-4.14	4.11e-05	0.00361	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27846676	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.64	rs11901133	ENSG00000223522.1	AC093690.1	-4.14	4.11e-05	0.00361	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27846846	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.64	rs4583413	ENSG00000223522.1	AC093690.1	-4.14	4.11e-05	0.00361	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27851957	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.679	rs4447576	ENSG00000223522.1	AC093690.1	-4.14	4.11e-05	0.00361	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27853381	chr2:28307691~28310459:-
THCA	cis	rs10833905	1	rs12420168	ENSG00000246225.5	RP11-17A1.3	-4.14	4.11e-05	0.00361	-0.27	-0.19	Sudden cardiac arrest;	chr11:23002244	chr11:22829380~22945393:+
THCA	cis	rs801193	0.967	rs3800823	ENSG00000229180.5	GS1-124K5.11	-4.14	4.11e-05	0.00361	-0.13	-0.19	Aortic root size;	chr7:66682123	chr7:66526088~66542624:-
THCA	cis	rs1048886	0.872	rs12526164	ENSG00000271967.1	RP11-134K13.4	-4.14	4.11e-05	0.00361	-0.2	-0.19	Type 2 diabetes;	chr6:70527431	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs75782125	ENSG00000271967.1	RP11-134K13.4	-4.14	4.11e-05	0.00361	-0.2	-0.19	Type 2 diabetes;	chr6:70550554	chr6:70596438~70596980:+
THCA	cis	rs4794202	0.534	rs10428	ENSG00000264920.1	RP11-6N17.4	-4.14	4.11e-05	0.00361	-0.22	-0.19	Alzheimer's disease (cognitive decline);	chr17:47837720	chr17:47891255~47895812:-
THCA	cis	rs2562456	0.833	rs62109223	ENSG00000268117.1	VN1R84P	4.14	4.11e-05	0.00361	0.3	0.19	Pain;	chr19:21349591	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62109225	ENSG00000268117.1	VN1R84P	4.14	4.11e-05	0.00361	0.3	0.19	Pain;	chr19:21353861	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.754	rs62109226	ENSG00000268117.1	VN1R84P	4.14	4.11e-05	0.00361	0.3	0.19	Pain;	chr19:21354111	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.754	rs62109227	ENSG00000268117.1	VN1R84P	4.14	4.11e-05	0.00361	0.3	0.19	Pain;	chr19:21354128	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.754	rs62109228	ENSG00000268117.1	VN1R84P	4.14	4.11e-05	0.00361	0.3	0.19	Pain;	chr19:21354129	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs8102783	ENSG00000268117.1	VN1R84P	4.14	4.11e-05	0.00361	0.3	0.19	Pain;	chr19:21355751	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs2061916	ENSG00000268117.1	VN1R84P	4.14	4.11e-05	0.00361	0.3	0.19	Pain;	chr19:21358906	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs4359573	ENSG00000268117.1	VN1R84P	4.14	4.11e-05	0.00361	0.3	0.19	Pain;	chr19:21359494	chr19:21719801~21720035:-
THCA	cis	rs479105	0.605	rs3825342	ENSG00000278356.1	RP11-372B4.3	4.14	4.11e-05	0.00361	0.18	0.19	Gut microbiota (bacterial taxa);	chr12:3261645	chr12:2885819~2886329:+
THCA	cis	rs17772222	0.74	rs11847417	ENSG00000222990.1	RNU4-22P	-4.14	4.11e-05	0.00361	-0.23	-0.19	Coronary artery calcification;	chr14:88510606	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs10138309	ENSG00000222990.1	RNU4-22P	4.14	4.11e-05	0.00361	0.23	0.19	Coronary artery calcification;	chr14:88510352	chr14:88513498~88513663:+
THCA	cis	rs9926296	0.568	rs1230	ENSG00000274627.1	RP11-104N10.2	4.14	4.11e-05	0.00361	0.19	0.19	Vitiligo;	chr16:89738447	chr16:89516797~89522217:+
THCA	cis	rs7474896	0.537	rs2749589	ENSG00000263064.2	RP11-291L22.7	-4.14	4.11e-05	0.00361	-0.25	-0.19	Obesity (extreme);	chr10:37977942	chr10:38448689~38448949:+
THCA	cis	rs1923243	0.649	rs7536364	ENSG00000223479.3	RP4-788P17.1	-4.14	4.11e-05	0.00361	-0.2	-0.19	Migraine;	chr1:72942754	chr1:73635216~73715214:+
THCA	cis	rs7312933	0.531	rs2708059	ENSG00000257225.1	RP11-328C8.4	4.14	4.11e-05	0.00361	0.19	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42457206	chr12:42459366~42466128:+
THCA	cis	rs758324	0.947	rs4705903	ENSG00000237714.1	P4HA2-AS1	4.14	4.11e-05	0.00361	0.27	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131870901	chr5:132184876~132192808:+
THCA	cis	rs2408955	0.541	rs11168428	ENSG00000273765.1	RP11-370I10.11	-4.14	4.11e-05	0.00361	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48153345	chr12:48360920~48361377:+
THCA	cis	rs73193808	0.639	rs2832241	ENSG00000176054.6	RPL23P2	4.14	4.12e-05	0.00361	0.17	0.19	Coronary artery disease;	chr21:29179715	chr21:28997613~28998033:-
THCA	cis	rs72928364	0.929	rs62275197	ENSG00000256628.3	ZBTB11-AS1	4.14	4.12e-05	0.00361	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100964303	chr3:101676475~101679217:+
THCA	cis	rs782212	0.592	rs782240	ENSG00000227207.2	RPL31P12	-4.14	4.12e-05	0.00361	-0.29	-0.19	Depression;	chr1:72440702	chr1:72301472~72301829:+
THCA	cis	rs7216064	1	rs62084238	ENSG00000278740.1	RP11-147L13.14	4.14	4.12e-05	0.00361	0.22	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67860457	chr17:68188547~68189165:+
THCA	cis	rs4718428	1	rs4718421	ENSG00000229886.1	RP5-1132H15.3	4.14	4.12e-05	0.00361	0.2	0.19	Corneal structure;	chr7:66885313	chr7:66025126~66031544:-
THCA	cis	rs2886497	1	rs12355434	ENSG00000224215.1	RP11-371A19.2	-4.14	4.12e-05	0.00361	-0.24	-0.19	Major depression and alcohol dependence;	chr10:23381546	chr10:23343957~23345181:+
THCA	cis	rs11710088	0.626	rs6803863	ENSG00000244503.1	RP11-278L15.6	-4.14	4.12e-05	0.00361	-0.25	-0.19	QRS duration;	chr3:149507931	chr3:149494660~149495995:+
THCA	cis	rs763121	0.853	rs3788545	ENSG00000273076.1	RP3-508I15.22	4.14	4.12e-05	0.00361	0.19	0.19	Menopause (age at onset);	chr22:38669167	chr22:38743495~38743910:+
THCA	cis	rs72928364	0.929	rs13074729	ENSG00000256628.3	ZBTB11-AS1	4.14	4.12e-05	0.00361	0.31	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101046740	chr3:101676475~101679217:+
THCA	cis	rs7552393	0.965	rs1546921	ENSG00000233008.4	RP11-475O6.1	-4.14	4.12e-05	0.00361	-0.2	-0.19	Select biomarker traits;	chr1:83774677	chr1:83575776~83861023:-
THCA	cis	rs7658584	1	rs7682521	ENSG00000246375.2	RP11-10L7.1	4.14	4.12e-05	0.00361	0.32	0.19	Squamous cell lung carcinoma;	chr4:88175275	chr4:88284942~88331421:+
THCA	cis	rs4819052	1	rs2297285	ENSG00000182586.6	LINC00334	4.14	4.12e-05	0.00362	0.23	0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45234340~45258730:+
THCA	cis	rs950169	0.922	rs11630760	ENSG00000188388.10	GOLGA6L3	4.14	4.12e-05	0.00362	0.25	0.19	Schizophrenia;	chr15:84570106	chr15:85240472~85247170:+
THCA	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-4.14	4.12e-05	0.00362	-0.18	-0.19	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-4.14	4.12e-05	0.00362	-0.18	-0.19	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
THCA	cis	rs847577	0.508	rs12538837	ENSG00000272950.1	RP11-307C18.1	4.14	4.12e-05	0.00362	0.25	0.19	Breast cancer;	chr7:98055156	chr7:98322853~98323430:+
THCA	cis	rs853679	0.657	rs1778483	ENSG00000176933.5	TOB2P1	-4.14	4.12e-05	0.00362	-0.22	-0.19	Depression;	chr6:28273214	chr6:28217643~28218634:-
THCA	cis	rs853679	0.657	rs1778482	ENSG00000176933.5	TOB2P1	-4.14	4.12e-05	0.00362	-0.22	-0.19	Depression;	chr6:28273215	chr6:28217643~28218634:-
THCA	cis	rs2070488	0.931	rs6599212	ENSG00000229589.1	ACVR2B-AS1	-4.14	4.12e-05	0.00362	-0.17	-0.19	Electrocardiographic conduction measures;	chr3:38517415	chr3:38451027~38454820:-
THCA	cis	rs250518	1	rs250518	ENSG00000272081.1	CTD-2376I4.2	-4.14	4.12e-05	0.00362	-0.24	-0.19	Mean corpuscular hemoglobin concentration;	chr5:72905231	chr5:72955206~72955699:-
THCA	cis	rs7404843	0.789	rs222907	ENSG00000188599.16	NPIPP1	4.14	4.12e-05	0.00362	0.2	0.19	Testicular germ cell tumor;	chr16:15404950	chr16:15104312~15123498:-
THCA	cis	rs34421088	0.506	rs7813424	ENSG00000154316.13	TDH	-4.14	4.12e-05	0.00362	-0.14	-0.19	Neuroticism;	chr8:11287008	chr8:11339637~11368452:+
THCA	cis	rs6517329	0.649	rs7282480	ENSG00000230212.5	AP000688.14	-4.14	4.12e-05	0.00362	-0.24	-0.19	Schizophrenia;	chr21:36119262	chr21:36069642~36126640:-
THCA	cis	rs10833905	0.818	rs11026965	ENSG00000246225.5	RP11-17A1.3	-4.14	4.12e-05	0.00362	-0.28	-0.19	Sudden cardiac arrest;	chr11:23077734	chr11:22829380~22945393:+
THCA	cis	rs4443100	0.77	rs882513	ENSG00000230701.2	FBXW4P1	4.14	4.13e-05	0.00362	0.22	0.19	Serum parathyroid hormone levels;	chr22:23021552	chr22:23262767~23265005:+
THCA	cis	rs957448	0.607	rs12680842	ENSG00000253175.1	RP11-267M23.6	4.14	4.13e-05	0.00362	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94565036~94565715:+
THCA	cis	rs957448	0.554	rs12680855	ENSG00000253175.1	RP11-267M23.6	4.14	4.13e-05	0.00362	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94565036~94565715:+
THCA	cis	rs7259376	0.936	rs10454118	ENSG00000269138.1	ZNF209P	-4.14	4.13e-05	0.00362	-0.19	-0.19	Menopause (age at onset);	chr19:22376803	chr19:22463922~22473036:+
THCA	cis	rs2333194	0.772	rs8016034	ENSG00000258695.2	RP3-414A15.2	-4.14	4.13e-05	0.00362	-0.23	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73345480	chr14:73522878~73530610:+
THCA	cis	rs5758511	0.633	rs5751258	ENSG00000227370.1	RP4-669P10.19	4.14	4.13e-05	0.00362	0.21	0.19	Birth weight;	chr22:42267865	chr22:42132543~42132998:+
THCA	cis	rs8014252	1	rs1953798	ENSG00000259158.2	ADAM20P1	4.14	4.13e-05	0.00362	0.22	0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70487432	chr14:70468881~70483756:-
THCA	cis	rs7824557	0.591	rs2736282	ENSG00000154316.13	TDH	-4.14	4.13e-05	0.00362	-0.14	-0.19	Retinal vascular caliber;	chr8:11367971	chr8:11339637~11368452:+
THCA	cis	rs656319	0.559	rs17689007	ENSG00000261451.1	RP11-981G7.1	-4.14	4.13e-05	0.00362	-0.23	-0.19	Myopia (pathological);	chr8:10117314	chr8:10433672~10438312:+
THCA	cis	rs763121	0.524	rs760645	ENSG00000225450.1	RP3-508I15.14	-4.14	4.13e-05	0.00362	-0.15	-0.19	Menopause (age at onset);	chr22:38636265	chr22:38739003~38749041:+
THCA	cis	rs2286503	0.839	rs2240728	ENSG00000226329.2	AC005682.6	4.14	4.13e-05	0.00362	0.23	0.19	Fibrinogen;	chr7:22812880	chr7:22863874~22881350:-
THCA	cis	rs3770081	0.536	rs7562837	ENSG00000273080.1	RP11-301O19.1	-4.14	4.13e-05	0.00362	-0.31	-0.19	Facial emotion recognition (sad faces);	chr2:86079128	chr2:86195590~86196049:+
THCA	cis	rs2278702	0.943	rs77597614	ENSG00000259495.2	RP11-210M15.2	-4.14	4.13e-05	0.00362	-0.27	-0.19	Bipolar disorder;	chr15:80394618	chr15:80344853~80403575:-
THCA	cis	rs656319	0.586	rs35013996	ENSG00000248538.5	RP11-10A14.5	4.14	4.13e-05	0.00362	0.25	0.19	Myopia (pathological);	chr8:10089635	chr8:9189011~9202854:+
THCA	cis	rs2408955	0.522	rs973398	ENSG00000273765.1	RP11-370I10.11	-4.14	4.13e-05	0.00362	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48097265	chr12:48360920~48361377:+
THCA	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-4.14	4.13e-05	0.00362	-0.21	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
THCA	cis	rs6921919	0.515	rs1339898	ENSG00000280107.1	AL022393.9	-4.14	4.13e-05	0.00362	-0.18	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28170845~28172521:+
THCA	cis	rs62292953	0.591	rs73860747	ENSG00000248724.5	NPHP3-AS1	-4.14	4.13e-05	0.00362	-0.41	-0.19	Red cell distribution width;	chr3:132539797	chr3:132721750~132874223:+
THCA	cis	rs1003719	0.715	rs762139	ENSG00000230366.8	DSCR9	-4.14	4.13e-05	0.00362	-0.19	-0.19	Eye color traits;	chr21:37196174	chr21:37208503~37221736:+
THCA	cis	rs10911902	0.643	rs79080293	ENSG00000233196.2	GS1-304P7.1	-4.14	4.13e-05	0.00363	-0.3	-0.19	Schizophrenia;	chr1:186379546	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs3766699	ENSG00000233196.2	GS1-304P7.1	-4.14	4.13e-05	0.00363	-0.3	-0.19	Schizophrenia;	chr1:186381179	chr1:186580515~186581191:-
THCA	cis	rs881375	0.678	rs10760129	ENSG00000270917.1	RP11-27I1.6	-4.14	4.13e-05	0.00363	-0.25	-0.19	Rheumatoid arthritis;	chr9:120937905	chr9:120812475~120812845:-
THCA	cis	rs7267979	0.844	rs869358	ENSG00000277938.1	RP5-965G21.3	-4.14	4.13e-05	0.00363	-0.15	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25229150~25231933:+
THCA	cis	rs9902453	0.78	rs62068621	ENSG00000263370.1	RP11-68I3.5	4.14	4.13e-05	0.00363	0.25	0.19	Coffee consumption (cups per day);	chr17:29843364	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.78	rs57037139	ENSG00000263370.1	RP11-68I3.5	4.14	4.13e-05	0.00363	0.25	0.19	Coffee consumption (cups per day);	chr17:29846265	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.817	rs55758314	ENSG00000263370.1	RP11-68I3.5	4.14	4.13e-05	0.00363	0.25	0.19	Coffee consumption (cups per day);	chr17:29846960	chr17:29639627~29640825:+
THCA	cis	rs2018683	0.707	rs10279610	ENSG00000272568.4	CTB-113D17.1	-4.14	4.13e-05	0.00363	-0.18	-0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936079	chr7:28979967~29013367:+
THCA	cis	rs4742903	0.967	rs4743689	ENSG00000270332.1	SMC2-AS1	4.14	4.14e-05	0.00363	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104147019	chr9:104080024~104093073:-
THCA	cis	rs4908768	0.906	rs6678982	ENSG00000232912.4	RP5-1115A15.1	-4.14	4.14e-05	0.00363	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8517126	chr1:8424645~8434838:+
THCA	cis	rs9435732	0.832	rs2076602	ENSG00000235241.1	RP11-108M9.5	4.14	4.14e-05	0.00363	0.24	0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16996703	chr1:16889095~16889602:+
THCA	cis	rs17221829	0.673	rs4491227	ENSG00000280385.1	AP000648.5	-4.14	4.14e-05	0.00363	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89670591	chr11:90193614~90198120:+
THCA	cis	rs7208859	0.614	rs216412	ENSG00000280069.1	CTD-2349P21.3	4.14	4.14e-05	0.00363	0.26	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30738182~30740275:+
THCA	cis	rs3758911	1	rs2046903	ENSG00000255353.1	RP11-382M14.1	-4.14	4.14e-05	0.00363	-0.23	-0.19	Coronary artery disease;	chr11:107315208	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs12286342	ENSG00000255353.1	RP11-382M14.1	-4.14	4.14e-05	0.00363	-0.23	-0.19	Coronary artery disease;	chr11:107315568	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs12273125	ENSG00000255353.1	RP11-382M14.1	-4.14	4.14e-05	0.00363	-0.23	-0.19	Coronary artery disease;	chr11:107315602	chr11:107176286~107177530:+
THCA	cis	rs5753037	0.702	rs5752961	ENSG00000279699.1	RP1-102K2.9	4.14	4.14e-05	0.00363	0.18	0.19	Type 1 diabetes;	chr22:29792095	chr22:30275215~30276951:-
THCA	cis	rs6138458	1	rs6114980	ENSG00000274173.1	RP4-568C11.4	4.14	4.14e-05	0.00363	0.18	0.19	Blood protein levels;	chr20:24993652	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs7269416	ENSG00000274173.1	RP4-568C11.4	4.14	4.14e-05	0.00363	0.18	0.19	Blood protein levels;	chr20:24995560	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs6114984	ENSG00000274173.1	RP4-568C11.4	4.14	4.14e-05	0.00363	0.18	0.19	Blood protein levels;	chr20:24995974	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs6106984	ENSG00000274173.1	RP4-568C11.4	4.14	4.14e-05	0.00363	0.18	0.19	Blood protein levels;	chr20:24996370	chr20:24931840~24932983:+
THCA	cis	rs6138458	1	rs11905625	ENSG00000274173.1	RP4-568C11.4	4.14	4.14e-05	0.00363	0.18	0.19	Blood protein levels;	chr20:24996429	chr20:24931840~24932983:+
THCA	cis	rs2777491	1	rs7167729	ENSG00000247556.5	OIP5-AS1	4.14	4.14e-05	0.00363	0.15	0.19	Ulcerative colitis;	chr15:41428844	chr15:41283990~41309737:+
THCA	cis	rs2777491	1	rs2730055	ENSG00000247556.5	OIP5-AS1	4.14	4.14e-05	0.00363	0.15	0.19	Ulcerative colitis;	chr15:41443510	chr15:41283990~41309737:+
THCA	cis	rs2777491	1	rs2777491	ENSG00000247556.5	OIP5-AS1	4.14	4.14e-05	0.00363	0.15	0.19	Ulcerative colitis;	chr15:41443512	chr15:41283990~41309737:+
THCA	cis	rs12681288	0.862	rs2600493	ENSG00000260721.1	AF067845.1	4.14	4.14e-05	0.00363	0.22	0.19	Schizophrenia;	chr8:1074970	chr8:1368642~1369833:-
THCA	cis	rs4906332	1	rs3783397	ENSG00000244691.1	RPL10AP1	-4.14	4.14e-05	0.00363	-0.24	-0.19	Coronary artery disease;	chr14:103480952	chr14:103412119~103412761:-
THCA	cis	rs6479891	1	rs10733790	ENSG00000272767.1	JMJD1C-AS1	-4.14	4.14e-05	0.00363	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs10761745	ENSG00000272767.1	JMJD1C-AS1	-4.14	4.14e-05	0.00363	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.915	rs7091664	ENSG00000272767.1	JMJD1C-AS1	-4.14	4.14e-05	0.00363	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63465229~63466563:+
THCA	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-4.14	4.14e-05	0.00363	-0.21	-0.19	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
THCA	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-4.14	4.14e-05	0.00363	-0.21	-0.19	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
THCA	cis	rs4648045	0.647	rs1585213	ENSG00000246560.2	RP11-10L12.4	4.14	4.14e-05	0.00363	0.23	0.19	Lymphocyte percentage of white cells;	chr4:102523541	chr4:102828055~102844075:+
THCA	cis	rs4908760	0.539	rs10864367	ENSG00000232912.4	RP5-1115A15.1	4.14	4.14e-05	0.00363	0.18	0.19	Vitiligo;	chr1:8787321	chr1:8424645~8434838:+
THCA	cis	rs9902453	0.791	rs62068629	ENSG00000263370.1	RP11-68I3.5	4.14	4.14e-05	0.00363	0.25	0.19	Coffee consumption (cups per day);	chr17:29860578	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.817	rs1842026	ENSG00000263370.1	RP11-68I3.5	4.14	4.14e-05	0.00363	0.25	0.19	Coffee consumption (cups per day);	chr17:29861093	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.78	rs7210991	ENSG00000263370.1	RP11-68I3.5	4.14	4.14e-05	0.00363	0.25	0.19	Coffee consumption (cups per day);	chr17:29863943	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.817	rs12051834	ENSG00000263370.1	RP11-68I3.5	4.14	4.14e-05	0.00363	0.25	0.19	Coffee consumption (cups per day);	chr17:29865767	chr17:29639627~29640825:+
THCA	cis	rs4443100	0.916	rs6003484	ENSG00000230701.2	FBXW4P1	4.14	4.14e-05	0.00363	0.21	0.19	Serum parathyroid hormone levels;	chr22:23037808	chr22:23262767~23265005:+
THCA	cis	rs111756027	0.679	rs72800078	ENSG00000260922.1	RP11-538I12.3	4.14	4.14e-05	0.00363	0.31	0.19	Bone mineral density (Ward's triangle area);	chr16:77274703	chr16:77234877~77290934:+
THCA	cis	rs6442522	0.56	rs2305614	ENSG00000249786.6	EAF1-AS1	4.14	4.14e-05	0.00363	0.19	0.19	Uric acid levels;	chr3:15475811	chr3:15436171~15455940:-
THCA	cis	rs11710088	0.707	rs35551531	ENSG00000240541.2	TM4SF1-AS1	4.14	4.14e-05	0.00363	0.17	0.19	QRS duration;	chr3:149489199	chr3:149377778~149386583:+
THCA	cis	rs2839627	0.598	rs2246573	ENSG00000225218.1	AP001628.6	-4.14	4.14e-05	0.00363	-0.27	-0.19	Information processing speed;	chr21:42832906	chr21:42831040~42836477:-
THCA	cis	rs853679	0.76	rs9468317	ENSG00000273712.1	RP5-874C20.7	4.14	4.14e-05	0.00363	0.26	0.19	Depression;	chr6:28230678	chr6:28315613~28315883:-
THCA	cis	rs7481311	0.508	rs17309930	ENSG00000245573.6	BDNF-AS	-4.14	4.14e-05	0.00363	-0.22	-0.19	Weight;Body mass index;	chr11:27726946	chr11:27506838~27698174:+
THCA	cis	rs41313321	0.646	rs2416980	ENSG00000272696.1	RP11-339B21.13	4.14	4.14e-05	0.00363	0.15	0.19	Coenzyme Q10 levels;	chr9:128279655	chr9:128316337~128316909:+
THCA	cis	rs58950470	0.521	rs7950197	ENSG00000214659.4	KRT8P26	4.14	4.14e-05	0.00363	0.17	0.19	Schizophrenia;	chr11:65678655	chr11:65726939~65728214:+
THCA	cis	rs472402	0.58	rs6884552	ENSG00000250056.4	LINC01018	-4.14	4.14e-05	0.00363	-0.23	-0.19	Response to amphetamines;	chr5:6661853	chr5:6582136~6588499:+
THCA	cis	rs858239	0.539	rs10254544	ENSG00000230042.1	AK3P3	-4.14	4.14e-05	0.00363	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23129178~23129841:+
THCA	cis	rs2688482	0.557	rs3103952	ENSG00000185485.13	SDHAP1	4.14	4.14e-05	0.00363	0.2	0.19	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195959748~195990318:-
THCA	cis	rs1962772	0.532	rs1858714	ENSG00000279903.1	RP11-349F21.5	-4.14	4.14e-05	0.00363	-0.25	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17521389	chr8:17500012~17500605:+
THCA	cis	rs2836974	0.863	rs1065242	ENSG00000255568.3	BRWD1-AS2	4.14	4.14e-05	0.00363	0.16	0.19	Cognitive function;	chr21:39195790	chr21:39313935~39314962:+
THCA	cis	rs10875746	0.951	rs4760690	ENSG00000258234.1	RP11-370I10.2	4.14	4.14e-05	0.00363	0.22	0.19	Longevity (90 years and older);	chr12:48169870	chr12:48231098~48284210:-
THCA	cis	rs860295	0.812	rs3820594	ENSG00000160766.13	GBAP1	-4.14	4.14e-05	0.00363	-0.22	-0.19	Body mass index;	chr1:155859720	chr1:155213821~155227422:-
THCA	cis	rs2839186	0.588	rs2839140	ENSG00000215424.8	MCM3AP-AS1	-4.14	4.14e-05	0.00363	-0.11	-0.19	Testicular germ cell tumor;	chr21:46196166	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.647	rs9976233	ENSG00000215424.8	MCM3AP-AS1	-4.14	4.14e-05	0.00363	-0.11	-0.19	Testicular germ cell tumor;	chr21:46196999	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.588	rs7280110	ENSG00000215424.8	MCM3AP-AS1	-4.14	4.14e-05	0.00363	-0.11	-0.19	Testicular germ cell tumor;	chr21:46199125	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.616	rs4819213	ENSG00000215424.8	MCM3AP-AS1	-4.14	4.14e-05	0.00363	-0.11	-0.19	Testicular germ cell tumor;	chr21:46199386	chr21:46229217~46259390:+
THCA	cis	rs2342371	0.565	rs7612450	ENSG00000273013.1	CTD-2002J20.1	-4.14	4.14e-05	0.00363	-0.17	-0.19	Fat distribution (HIV);	chr3:196482659	chr3:196474801~196475394:+
THCA	cis	rs1800682	0.528	rs3758485	ENSG00000261438.1	RP11-399O19.9	-4.14	4.15e-05	0.00363	-0.16	-0.19	Chronic lymphocytic leukemia;	chr10:88988090	chr10:89015836~89017059:+
THCA	cis	rs1800682	0.528	rs978522	ENSG00000261438.1	RP11-399O19.9	-4.14	4.15e-05	0.00363	-0.16	-0.19	Chronic lymphocytic leukemia;	chr10:88988581	chr10:89015836~89017059:+
THCA	cis	rs7809615	0.581	rs10277447	ENSG00000244219.5	GS1-259H13.2	-4.14	4.15e-05	0.00363	-0.33	-0.19	Blood metabolite ratios;	chr7:99409140	chr7:99598066~99610813:+
THCA	cis	rs4218	0.681	rs35204615	ENSG00000259732.1	RP11-59H7.3	-4.14	4.15e-05	0.00364	-0.26	-0.19	Social communication problems;	chr15:59099637	chr15:59121034~59133250:+
THCA	cis	rs9902453	0.791	rs2628166	ENSG00000263370.1	RP11-68I3.5	-4.14	4.15e-05	0.00364	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29786105	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.817	rs2729435	ENSG00000263370.1	RP11-68I3.5	-4.14	4.15e-05	0.00364	-0.25	-0.19	Coffee consumption (cups per day);	chr17:29794514	chr17:29639627~29640825:+
THCA	cis	rs6730558	0.899	rs34011894	ENSG00000236008.1	AC011747.4	4.14	4.15e-05	0.00364	0.22	0.19	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8602281	chr2:8559833~8583792:-
THCA	cis	rs72928364	1	rs13092605	ENSG00000256628.3	ZBTB11-AS1	4.14	4.15e-05	0.00364	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100901559	chr3:101676475~101679217:+
THCA	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	4.14	4.15e-05	0.00364	0.16	0.19	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
THCA	cis	rs11176749	0.543	rs1344259	ENSG00000256172.1	RP11-473M14.3	4.14	4.15e-05	0.00364	0.28	0.19	Expressive vocabulary in infants;	chr12:67450006	chr12:67440998~67442559:-
THCA	cis	rs6001482	0.679	rs5995706	ENSG00000272779.1	LL22NC03-80A10.6	-4.14	4.15e-05	0.00364	-0.21	-0.19	Diastolic blood pressure;	chr22:22236371	chr22:22303224~22310401:+
THCA	cis	rs453301	0.686	rs6601280	ENSG00000233609.3	RP11-62H7.2	4.14	4.15e-05	0.00364	0.18	0.19	Joint mobility (Beighton score);	chr8:9051726	chr8:8961200~8979025:+
THCA	cis	rs9326246	0.545	rs528647	ENSG00000254851.1	RP11-109L13.1	4.14	4.15e-05	0.00364	0.43	0.19	Coronary artery disease;	chr11:116653104	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs528732	ENSG00000254851.1	RP11-109L13.1	4.14	4.15e-05	0.00364	0.43	0.19	Coronary artery disease;	chr11:116653127	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs3017778	ENSG00000254851.1	RP11-109L13.1	4.14	4.15e-05	0.00364	0.43	0.19	Coronary artery disease;	chr11:116653214	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs3017779	ENSG00000254851.1	RP11-109L13.1	4.14	4.15e-05	0.00364	0.43	0.19	Coronary artery disease;	chr11:116653271	chr11:117135528~117138582:+
THCA	cis	rs250585	0.736	rs465193	ENSG00000260136.4	CTD-2270L9.4	4.14	4.15e-05	0.00364	0.14	0.19	Egg allergy;	chr16:23585662	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs801754	ENSG00000260136.4	CTD-2270L9.4	4.14	4.15e-05	0.00364	0.14	0.19	Bipolar disorder;	chr16:23586557	chr16:23452758~23457606:+
THCA	cis	rs875971	0.545	rs313828	ENSG00000273142.1	RP11-458F8.4	-4.14	4.15e-05	0.00364	-0.18	-0.19	Aortic root size;	chr7:66087627	chr7:66902857~66906297:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000273142.1	RP11-458F8.4	-4.14	4.15e-05	0.00364	-0.18	-0.19	Aortic root size;	chr7:66089365	chr7:66902857~66906297:+
THCA	cis	rs9863	0.828	rs11057412	ENSG00000269997.1	RP11-214K3.21	-4.14	4.15e-05	0.00364	-0.22	-0.19	White blood cell count;	chr12:124004595	chr12:123966077~123966629:-
THCA	cis	rs1836229	0.874	rs7864437	ENSG00000225706.1	PTPRD-AS1	-4.14	4.15e-05	0.00364	-0.22	-0.19	Restless legs syndrome;	chr9:8824219	chr9:8858130~8862255:+
THCA	cis	rs12022452	0.544	rs11208423	ENSG00000237899.1	RP4-739H11.3	-4.14	4.15e-05	0.00364	-0.28	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40669089~40687588:-
THCA	cis	rs2070488	0.965	rs35553573	ENSG00000229589.1	ACVR2B-AS1	4.14	4.15e-05	0.00364	0.18	0.19	Electrocardiographic conduction measures;	chr3:38399948	chr3:38451027~38454820:-
THCA	cis	rs1414896	0.646	rs10158681	ENSG00000226026.4	RP11-57H12.3	4.14	4.15e-05	0.00364	0.18	0.19	Non-alcoholic fatty liver disease histology (AST);	chr1:95201223	chr1:95163219~95233982:-
THCA	cis	rs786425	0.682	rs11612479	ENSG00000270095.1	RP11-214K3.18	-4.14	4.15e-05	0.00364	-0.22	-0.19	Pubertal anthropometrics;	chr12:123670979	chr12:123971457~123971714:-
THCA	cis	rs4805272	1	rs56131999	ENSG00000267799.1	MAN1A2P1	4.14	4.15e-05	0.00364	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28828690	chr19:28790812~28792871:-
THCA	cis	rs7829975	0.517	rs12542733	ENSG00000253981.4	ALG1L13P	-4.14	4.15e-05	0.00364	-0.17	-0.19	Mood instability;	chr8:8967348	chr8:8236003~8244667:-
THCA	cis	rs801193	1	rs3778909	ENSG00000223473.2	GS1-124K5.3	4.14	4.15e-05	0.00364	0.12	0.19	Aortic root size;	chr7:66790659	chr7:66491049~66493566:-
THCA	cis	rs1923243	0.749	rs6680104	ENSG00000223479.3	RP4-788P17.1	-4.14	4.15e-05	0.00364	-0.21	-0.19	Migraine;	chr1:73074947	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.786	rs12046843	ENSG00000223479.3	RP4-788P17.1	-4.14	4.15e-05	0.00364	-0.21	-0.19	Migraine;	chr1:73086424	chr1:73635216~73715214:+
THCA	cis	rs9876781	0.563	rs4858821	ENSG00000229759.1	MRPS18AP1	-4.14	4.15e-05	0.00364	-0.24	-0.19	Longevity;	chr3:48512515	chr3:48256350~48256938:-
THCA	cis	rs875971	0.619	rs12533585	ENSG00000275400.1	RP4-756H11.5	-4.14	4.16e-05	0.00364	-0.17	-0.19	Aortic root size;	chr7:66519618	chr7:66553805~66554199:-
THCA	cis	rs8050907	0.744	rs9938647	ENSG00000278434.1	RP11-709D24.8	-4.14	4.16e-05	0.00364	-0.42	-0.19	Obesity-related traits;	chr16:4522150	chr16:4532216~4533670:-
THCA	cis	rs8050907	0.744	rs9922933	ENSG00000278434.1	RP11-709D24.8	-4.14	4.16e-05	0.00364	-0.42	-0.19	Obesity-related traits;	chr16:4522601	chr16:4532216~4533670:-
THCA	cis	rs7737355	0.773	rs4705895	ENSG00000237714.1	P4HA2-AS1	4.14	4.16e-05	0.00365	0.26	0.19	Life satisfaction;	chr5:131766501	chr5:132184876~132192808:+
THCA	cis	rs736408	0.608	rs35004449	ENSG00000243224.1	RP5-1157M23.2	-4.14	4.16e-05	0.00365	-0.22	-0.19	Bipolar disorder;	chr3:52818881	chr3:52239258~52241097:+
THCA	cis	rs10129255	0.536	rs10139058	ENSG00000211970.3	IGHV4-61	-4.14	4.16e-05	0.00365	-0.11	-0.19	Kawasaki disease;	chr14:106685899	chr14:106639119~106639657:-
THCA	cis	rs6686643	1	rs957644	ENSG00000236206.1	RP11-306I1.2	4.14	4.16e-05	0.00365	0.25	0.19	Total ventricular volume;	chr1:165646920	chr1:165598463~165623331:+
THCA	cis	rs3845817	1	rs3845817	ENSG00000237979.1	AC007389.1	-4.14	4.16e-05	0.00365	-0.21	-0.19	Bipolar disorder;	chr2:65531391	chr2:65500993~65502138:-
THCA	cis	rs5758511	0.573	rs738248	ENSG00000281538.1	RP4-669P10.20	4.14	4.16e-05	0.00365	0.18	0.19	Birth weight;	chr22:41800463	chr22:42138060~42139726:+
THCA	cis	rs5758511	0.573	rs5996069	ENSG00000281538.1	RP4-669P10.20	4.14	4.16e-05	0.00365	0.18	0.19	Birth weight;	chr22:41805181	chr22:42138060~42139726:+
THCA	cis	rs858239	0.6	rs4628176	ENSG00000230042.1	AK3P3	-4.14	4.16e-05	0.00365	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23129178~23129841:+
THCA	cis	rs858239	0.6	rs10488077	ENSG00000230042.1	AK3P3	-4.14	4.16e-05	0.00365	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23129178~23129841:+
THCA	cis	rs7267979	0.933	rs2424708	ENSG00000274973.1	RP13-401N8.7	-4.14	4.16e-05	0.00365	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs884613	ENSG00000274973.1	RP13-401N8.7	4.14	4.16e-05	0.00365	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs1888998	ENSG00000274973.1	RP13-401N8.7	4.14	4.16e-05	0.00365	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2500433	ENSG00000274973.1	RP13-401N8.7	4.14	4.16e-05	0.00365	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2482948	ENSG00000274973.1	RP13-401N8.7	4.14	4.16e-05	0.00365	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs2482919	ENSG00000274973.1	RP13-401N8.7	4.14	4.16e-05	0.00365	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25845497~25845862:+
THCA	cis	rs7267979	1	rs6037086	ENSG00000274973.1	RP13-401N8.7	4.14	4.16e-05	0.00365	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.966	rs2482923	ENSG00000274973.1	RP13-401N8.7	4.14	4.16e-05	0.00365	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25845497~25845862:+
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000184274.3	LINC00315	-4.14	4.16e-05	0.00365	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45300245~45305257:-
THCA	cis	rs4767841	0.565	rs386259	ENSG00000248636.5	RP11-768F21.1	-4.14	4.16e-05	0.00365	-0.19	-0.19	Urgency urinary incontinence;	chr12:119787908	chr12:119387987~119668079:-
THCA	cis	rs4950322	0.58	rs7515160	ENSG00000226015.2	CCT8P1	4.14	4.16e-05	0.00365	0.22	0.19	Protein quantitative trait loci;	chr1:147120714	chr1:147203276~147204932:-
THCA	cis	rs6546886	0.625	rs76483403	ENSG00000217702.2	RP11-287D1.4	-4.14	4.17e-05	0.00365	-0.32	-0.19	Dialysis-related mortality;	chr2:74026281	chr2:74130583~74135395:+
THCA	cis	rs2836974	0.965	rs34578707	ENSG00000255568.3	BRWD1-AS2	4.14	4.17e-05	0.00365	0.17	0.19	Cognitive function;	chr21:39303241	chr21:39313935~39314962:+
THCA	cis	rs4908768	0.906	rs11121213	ENSG00000232912.4	RP5-1115A15.1	-4.14	4.17e-05	0.00365	-0.22	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8668128	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.725	rs11121214	ENSG00000232912.4	RP5-1115A15.1	-4.14	4.17e-05	0.00365	-0.22	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8668606	chr1:8424645~8434838:+
THCA	cis	rs9880211	0.58	rs56308637	ENSG00000273486.1	RP11-731C17.2	4.14	4.17e-05	0.00365	0.2	0.19	Height;Body mass index;	chr3:135920806	chr3:136837338~136839021:-
THCA	cis	rs875971	0.965	rs7794930	ENSG00000229886.1	RP5-1132H15.3	-4.14	4.17e-05	0.00365	-0.19	-0.19	Aortic root size;	chr7:66313559	chr7:66025126~66031544:-
THCA	cis	rs4713118	0.55	rs9368527	ENSG00000216915.2	RP1-97D16.1	-4.14	4.17e-05	0.00365	-0.25	-0.19	Parkinson's disease;	chr6:27711666	chr6:27737000~27738494:-
THCA	cis	rs4759375	1	rs4759377	ENSG00000256092.2	RP13-942N8.1	-4.14	4.17e-05	0.00365	-0.2	-0.19	HDL cholesterol;	chr12:123312302	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs10082867	ENSG00000256092.2	RP13-942N8.1	-4.14	4.17e-05	0.00365	-0.2	-0.19	HDL cholesterol;	chr12:123312450	chr12:123363868~123366113:+
THCA	cis	rs6442522	0.61	rs6808644	ENSG00000249786.6	EAF1-AS1	4.14	4.17e-05	0.00365	0.19	0.19	Uric acid levels;	chr3:15485540	chr3:15436171~15455940:-
THCA	cis	rs9863	0.828	rs4765541	ENSG00000269997.1	RP11-214K3.21	-4.14	4.17e-05	0.00365	-0.22	-0.19	White blood cell count;	chr12:123981448	chr12:123966077~123966629:-
THCA	cis	rs1842579	1	rs4912437	ENSG00000272691.1	RP11-290M5.4	-4.14	4.17e-05	0.00365	-0.19	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85840198	chr1:85578500~85578742:-
THCA	cis	rs2303759	0.626	rs12982246	ENSG00000268686.1	AC010524.2	-4.14	4.17e-05	0.00365	-0.29	-0.19	Multiple sclerosis;	chr19:49297912	chr19:49368705~49388081:-
THCA	cis	rs7142002	0.649	rs2150539	ENSG00000271780.1	RP11-1017G21.5	-4.14	4.17e-05	0.00365	-0.29	-0.19	Autism;	chr14:102205004	chr14:101948347~101949425:+
THCA	cis	rs10129255	0.536	rs8004835	ENSG00000211970.3	IGHV4-61	-4.14	4.17e-05	0.00365	-0.1	-0.19	Kawasaki disease;	chr14:106686361	chr14:106639119~106639657:-
THCA	cis	rs8040855	0.542	rs2342122	ENSG00000259630.2	CTD-2262B20.1	4.14	4.17e-05	0.00366	0.21	0.19	Bulimia nervosa;	chr15:85185304	chr15:85415228~85415633:+
THCA	cis	rs8040855	0.644	rs2342120	ENSG00000259630.2	CTD-2262B20.1	4.14	4.17e-05	0.00366	0.21	0.19	Bulimia nervosa;	chr15:85185589	chr15:85415228~85415633:+
THCA	cis	rs748404	1	rs17779494	ENSG00000166763.7	STRCP1	-4.14	4.17e-05	0.00366	-0.22	-0.19	Lung cancer;	chr15:43287025	chr15:43699488~43718184:-
THCA	cis	rs12200782	0.649	rs7757048	ENSG00000124549.13	BTN2A3P	-4.14	4.17e-05	0.00366	-0.22	-0.19	Small cell lung carcinoma;	chr6:26389811	chr6:26421391~26432383:+
THCA	cis	rs914615	0.508	rs4971079	ENSG00000236675.1	MTX1P1	-4.14	4.17e-05	0.00366	-0.17	-0.19	Urinary albumin-to-creatinine ratio;	chr1:155157915	chr1:155230975~155234325:+
THCA	cis	rs7772486	0.79	rs1133832	ENSG00000270638.1	RP3-466P17.1	-4.14	4.17e-05	0.00366	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145735570~145737218:+
THCA	cis	rs607541	0.764	rs629466	ENSG00000259520.4	CTD-2651B20.3	-4.14	4.18e-05	0.00366	-0.27	-0.19	Obesity-related traits;	chr15:45642547	chr15:45251580~45279251:-
THCA	cis	rs1836229	0.874	rs1434254	ENSG00000225706.1	PTPRD-AS1	4.14	4.18e-05	0.00366	0.21	0.19	Restless legs syndrome;	chr9:8826278	chr9:8858130~8862255:+
THCA	cis	rs564343	0.583	rs571374	ENSG00000255320.1	RP11-755F10.1	-4.14	4.18e-05	0.00366	-0.23	-0.19	Obesity (early onset extreme);	chr11:66050121	chr11:66244840~66246239:-
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00366	0.2	0.19	Corneal structure;	chr7:66925268	chr7:66025126~66031544:-
THCA	cis	rs7131987	0.565	rs10743652	ENSG00000257176.2	RP11-996F15.2	4.14	4.18e-05	0.00366	0.19	0.19	QT interval;	chr12:29255074	chr12:29280418~29317848:-
THCA	cis	rs875971	1	rs6946143	ENSG00000229886.1	RP5-1132H15.3	4.14	4.18e-05	0.00366	0.2	0.19	Aortic root size;	chr7:66114735	chr7:66025126~66031544:-
THCA	cis	rs12893668	0.703	rs8017993	ENSG00000252469.1	RNU7-160P	4.14	4.18e-05	0.00366	0.22	0.19	Reticulocyte count;	chr14:103581397	chr14:103550345~103550406:+
THCA	cis	rs12264252	0.767	rs35998463	ENSG00000226659.1	RP11-137H2.4	4.14	4.18e-05	0.00366	0.27	0.19	Coronary artery disease;	chr10:80485754	chr10:80529597~80535942:-
THCA	cis	rs7481311	0.508	rs12273363	ENSG00000245573.6	BDNF-AS	-4.14	4.18e-05	0.00366	-0.22	-0.19	Weight;Body mass index;	chr11:27723312	chr11:27506838~27698174:+
THCA	cis	rs1580019	0.922	rs1376289	ENSG00000231952.3	DPY19L1P2	4.14	4.18e-05	0.00366	0.25	0.19	Cognitive ability;	chr7:32447368	chr7:32812757~32838570:+
THCA	cis	rs11673344	0.764	rs569371	ENSG00000267260.1	CTD-2162K18.4	-4.14	4.18e-05	0.00366	-0.23	-0.19	Obesity-related traits;	chr19:36963095	chr19:36773153~36777078:+
THCA	cis	rs6012564	0.963	rs6125551	ENSG00000227431.4	CSE1L-AS1	-4.14	4.18e-05	0.00366	-0.23	-0.19	Anger;	chr20:49103849	chr20:49040463~49046044:-
THCA	cis	rs2070488	0.965	rs2051215	ENSG00000229589.1	ACVR2B-AS1	-4.14	4.18e-05	0.00366	-0.17	-0.19	Electrocardiographic conduction measures;	chr3:38518854	chr3:38451027~38454820:-
THCA	cis	rs959260	0.765	rs12945469	ENSG00000263843.1	RP11-649A18.12	4.14	4.18e-05	0.00366	0.2	0.19	Systemic lupus erythematosus;	chr17:75376162	chr17:75271369~75273895:+
THCA	cis	rs28475163	0.958	rs7395116	ENSG00000255328.1	RP11-326C3.12	-4.14	4.18e-05	0.00366	-0.25	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:324880	chr11:327171~330122:+
THCA	cis	rs7829975	0.742	rs1533059	ENSG00000253981.4	ALG1L13P	-4.14	4.18e-05	0.00366	-0.18	-0.19	Mood instability;	chr8:8827443	chr8:8236003~8244667:-
THCA	cis	rs11971779	0.666	rs6467847	ENSG00000252332.1	RNU6-911P	-4.14	4.18e-05	0.00366	-0.22	-0.19	Diisocyanate-induced asthma;	chr7:139394690	chr7:139448740~139448843:+
THCA	cis	rs10129255	0.957	rs67625077	ENSG00000211972.2	IGHV3-66	4.14	4.18e-05	0.00366	0.11	0.19	Kawasaki disease;	chr14:106715436	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.869	rs72690553	ENSG00000211972.2	IGHV3-66	4.14	4.18e-05	0.00366	0.11	0.19	Kawasaki disease;	chr14:106715491	chr14:106675017~106675544:-
THCA	cis	rs17221829	0.673	rs10830335	ENSG00000280385.1	AP000648.5	-4.14	4.18e-05	0.00366	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89670766	chr11:90193614~90198120:+
THCA	cis	rs7131987	0.903	rs918873	ENSG00000257599.1	OVCH1-AS1	-4.14	4.18e-05	0.00366	-0.23	-0.19	QT interval;	chr12:29237568	chr12:29389294~29487488:+
THCA	cis	rs8062405	0.755	rs2077031	ENSG00000270424.1	RP11-1348G14.6	4.14	4.18e-05	0.00366	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28749959~28750595:-
THCA	cis	rs13256369	0.95	rs1522839	ENSG00000254153.1	CTA-398F10.2	-4.14	4.18e-05	0.00366	-0.21	-0.19	Obesity-related traits;	chr8:8722943	chr8:8456909~8461337:-
THCA	cis	rs7914558	0.902	rs7092200	ENSG00000236937.2	PTGES3P4	4.14	4.18e-05	0.00366	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103085115	chr10:102845595~102845950:+
THCA	cis	rs7824557	0.564	rs2736290	ENSG00000206014.6	OR7E161P	4.14	4.18e-05	0.00366	0.22	0.19	Retinal vascular caliber;	chr8:11376789	chr8:11928597~11929563:-
THCA	cis	rs2239815	0.545	rs5762855	ENSG00000272858.1	CTA-292E10.8	-4.14	4.18e-05	0.00367	-0.24	-0.19	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28850617	chr22:28814914~28815662:+
THCA	cis	rs427943	0.864	rs2246081	ENSG00000223768.1	LINC00205	-4.14	4.18e-05	0.00367	-0.17	-0.19	Body mass index;	chr21:45204434	chr21:45293285~45297354:+
THCA	cis	rs10954779	0.764	rs16877794	ENSG00000127589.4	TUBBP1	-4.14	4.18e-05	0.00367	-0.22	-0.19	Intelligence (multi-trait analysis);	chr8:31158766	chr8:30351873~30353518:+
THCA	cis	rs2806561	0.734	rs1952527	ENSG00000249087.5	ZNF436-AS1	-4.14	4.19e-05	0.00367	-0.12	-0.19	Height;	chr1:23074476	chr1:23368997~23371839:+
THCA	cis	rs4409675	0.956	rs4072743	ENSG00000227050.1	RP11-460I13.2	4.14	4.19e-05	0.00367	0.25	0.19	Corneal astigmatism;	chr1:27944423	chr1:27938875~27960193:-
THCA	cis	rs7131987	0.565	rs10843365	ENSG00000275476.1	RP11-996F15.4	4.14	4.19e-05	0.00367	0.18	0.19	QT interval;	chr12:29252691	chr12:29277397~29277882:-
THCA	cis	rs17221829	0.733	rs72952851	ENSG00000280385.1	AP000648.5	-4.14	4.19e-05	0.00367	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89660327	chr11:90193614~90198120:+
THCA	cis	rs7855088	0.789	rs56145417	ENSG00000236130.1	PTCSC2	-4.14	4.19e-05	0.00367	-0.15	-0.19	Serum thyroid-stimulating hormone levels;	chr9:97980623	chr9:97805935~97810008:-
THCA	cis	rs4356203	0.875	rs680205	ENSG00000272034.1	SNORD14A	-4.14	4.19e-05	0.00367	-0.19	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186210	chr11:17074654~17074744:-
THCA	cis	rs10090774	0.965	rs4327896	ENSG00000279766.1	RP11-642A1.2	4.14	4.19e-05	0.00367	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140847223	chr8:140572142~140572812:-
THCA	cis	rs2018683	0.7	rs13227954	ENSG00000272568.4	CTB-113D17.1	-4.14	4.19e-05	0.00367	-0.19	-0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28977572	chr7:28979967~29013367:+
THCA	cis	rs6942407	0.546	rs2373387	ENSG00000224046.1	AC005076.5	-4.14	4.19e-05	0.00367	-0.18	-0.19	Food allergy;	chr7:87116632	chr7:87151423~87152420:-
THCA	cis	rs763121	0.853	rs5757181	ENSG00000273076.1	RP3-508I15.22	4.14	4.19e-05	0.00367	0.19	0.19	Menopause (age at onset);	chr22:38617517	chr22:38743495~38743910:+
THCA	cis	rs4805272	1	rs10412433	ENSG00000267799.1	MAN1A2P1	4.14	4.19e-05	0.00367	0.21	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829256	chr19:28790812~28792871:-
THCA	cis	rs7520050	0.778	rs3014216	ENSG00000234329.1	RP11-767N6.2	4.14	4.19e-05	0.00367	0.17	0.19	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45651039~45651826:-
THCA	cis	rs7074356	0.915	rs1870146	ENSG00000242600.5	MBL1P	-4.14	4.19e-05	0.00367	-0.24	-0.19	Borderline personality disorder;	chr10:80450623	chr10:79904898~79950336:+
THCA	cis	rs7200786	0.692	rs8055544	ENSG00000274038.1	RP11-66H6.4	4.14	4.19e-05	0.00367	0.23	0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10997704	chr16:11056556~11057034:+
THCA	cis	rs6878727	0.588	rs698178	ENSG00000253807.4	LINC01170	4.14	4.19e-05	0.00367	0.18	0.19	Breast cancer;	chr5:124332455	chr5:124059794~124405079:-
THCA	cis	rs6121246	0.909	rs6119729	ENSG00000224628.2	RP5-854E16.2	4.14	4.19e-05	0.00367	0.26	0.19	Mean corpuscular hemoglobin;	chr20:31825360	chr20:31285317~31286835:-
THCA	cis	rs34792	0.889	rs2445475	ENSG00000207425.1	Y_RNA	4.14	4.19e-05	0.00367	0.21	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508247	chr16:14915457~14915556:-
THCA	cis	rs804280	0.662	rs11250164	ENSG00000254948.1	OR7E158P	4.14	4.19e-05	0.00367	0.25	0.19	Myopia (pathological);	chr8:11753177	chr8:11919900~11920809:-
THCA	cis	rs11992162	0.967	rs10112888	ENSG00000270154.1	RP11-419I17.1	4.14	4.19e-05	0.00367	0.23	0.19	Monocyte count;	chr8:11972699	chr8:12476462~12477122:+
THCA	cis	rs34467563	0.626	rs2640817	ENSG00000253105.4	KB-1448A5.1	4.14	4.19e-05	0.00367	0.23	0.19	Lobe attachment (rater-scored or self-reported);	chr8:96364090	chr8:96371865~96387438:-
THCA	cis	rs6019512	0.525	rs6125554	ENSG00000227431.4	CSE1L-AS1	4.14	4.2e-05	0.00367	0.22	0.19	Intelligence (multi-trait analysis);	chr20:49111570	chr20:49040463~49046044:-
THCA	cis	rs78487399	0.808	rs7556744	ENSG00000234936.1	AC010883.5	-4.14	4.2e-05	0.00367	-0.25	-0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43445656	chr2:43229573~43233394:+
THCA	cis	rs6687821	0.515	rs523679	ENSG00000261737.1	RP4-612B15.3	-4.14	4.2e-05	0.00367	-0.28	-0.19	Yeast infection;	chr1:86902412	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs525519	ENSG00000261737.1	RP4-612B15.3	-4.14	4.2e-05	0.00367	-0.28	-0.19	Yeast infection;	chr1:86902611	chr1:86703502~86704462:-
THCA	cis	rs9810089	0.934	rs66691851	ENSG00000273455.1	RP11-305O4.3	4.14	4.2e-05	0.00367	0.25	0.19	Gestational age at birth (child effect);	chr3:136435986	chr3:136087475~136087913:-
THCA	cis	rs4947019	0.609	rs9487082	ENSG00000223537.2	RP5-919F19.5	-4.14	4.2e-05	0.00367	-0.35	-0.19	Hematological parameters;	chr6:109388333	chr6:109487906~109506800:+
THCA	cis	rs875971	0.825	rs28480509	ENSG00000229886.1	RP5-1132H15.3	-4.14	4.2e-05	0.00367	-0.2	-0.19	Aortic root size;	chr7:66634237	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs9791712	ENSG00000229886.1	RP5-1132H15.3	-4.14	4.2e-05	0.00367	-0.2	-0.19	Aortic root size;	chr7:66640176	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs9791713	ENSG00000229886.1	RP5-1132H15.3	-4.14	4.2e-05	0.00367	-0.2	-0.19	Aortic root size;	chr7:66640211	chr7:66025126~66031544:-
THCA	cis	rs28829049	0.76	rs12563795	ENSG00000270728.1	RP4-657E11.10	-4.14	4.2e-05	0.00367	-0.14	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19020784	chr1:19297080~19297903:+
THCA	cis	rs11992162	0.56	rs13256329	ENSG00000254948.1	OR7E158P	4.14	4.2e-05	0.00367	0.23	0.19	Monocyte count;	chr8:11924705	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.638	rs67146188	ENSG00000254948.1	OR7E158P	4.14	4.2e-05	0.00367	0.23	0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:11919900~11920809:-
THCA	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-4.14	4.2e-05	0.00367	-0.18	-0.19	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
THCA	cis	rs854765	0.693	rs12941039	ENSG00000281749.1	Y_RNA	-4.14	4.2e-05	0.00367	-0.24	-0.19	Total body bone mineral density;	chr17:17862341	chr17:18001101~18001195:-
THCA	cis	rs7833787	0.526	rs748208	ENSG00000278886.1	RP11-108A14.1	4.14	4.2e-05	0.00367	0.27	0.19	Obesity-related traits;	chr8:18855003	chr8:18864681~18865247:-
THCA	cis	rs1232027	0.656	rs1650653	ENSG00000249655.1	CTC-325J23.2	-4.14	4.2e-05	0.00367	-0.21	-0.19	Huntington's disease progression;	chr5:80669438	chr5:80630313~80631590:-
THCA	cis	rs875971	0.545	rs1638735	ENSG00000273024.4	INTS4P2	-4.14	4.2e-05	0.00367	-0.23	-0.19	Aortic root size;	chr7:66630751	chr7:65647864~65715661:+
THCA	cis	rs3764021	0.509	rs10844569	ENSG00000214776.8	RP11-726G1.1	4.14	4.2e-05	0.00368	0.25	0.19	Type 1 diabetes;	chr12:9717756	chr12:9467552~9576275:+
THCA	cis	rs9717605	1	rs9505896	ENSG00000226445.1	XXyac-YX65C7_A.2	4.14	4.2e-05	0.00368	0.23	0.19	Left atrial antero-posterior diameter;	chr6:169246825	chr6:169213254~169239565:+
THCA	cis	rs259991	1	rs259991	ENSG00000235590.6	GNAS-AS1	-4.14	4.2e-05	0.00368	-0.4	-0.19	Attention function in attention deficit hyperactive disorder;	chr20:59153293	chr20:58818919~58850903:-
THCA	cis	rs800160	0.777	rs11529118	ENSG00000199550.1	Y_RNA	-4.14	4.2e-05	0.00368	-0.28	-0.19	Bacteremia;	chr11:2322636	chr11:2372638~2372750:+
THCA	cis	rs6443245	0.591	rs2648575	ENSG00000227110.5	LMCD1-AS1	-4.14	4.2e-05	0.00368	-0.22	-0.19	Daytime sleep phenotypes;	chr3:9593344	chr3:7952805~8611924:-
THCA	cis	rs957448	0.561	rs4734282	ENSG00000253175.1	RP11-267M23.6	4.14	4.2e-05	0.00368	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94565036~94565715:+
THCA	cis	rs138249	0.902	rs138240	ENSG00000273253.2	RP3-402G11.26	4.14	4.2e-05	0.00368	0.18	0.19	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50125752	chr22:50199090~50200837:-
THCA	cis	rs1971762	0.527	rs1683151	ENSG00000270175.1	RP11-793H13.11	4.14	4.2e-05	0.00368	0.13	0.19	Height;	chr12:53552435	chr12:53500162~53500936:-
THCA	cis	rs911555	0.673	rs7144271	ENSG00000269958.1	RP11-73M18.8	4.14	4.2e-05	0.00368	0.18	0.19	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs10148970	ENSG00000269958.1	RP11-73M18.8	4.14	4.2e-05	0.00368	0.18	0.19	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103696353~103697163:+
THCA	cis	rs2692947	0.644	rs772175	ENSG00000235584.2	AC008268.1	-4.14	4.2e-05	0.00368	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96278815	chr2:95666084~95668715:+
THCA	cis	rs59918340	0.548	rs10102728	ENSG00000253307.1	RP11-10J21.4	4.14	4.2e-05	0.00368	0.25	0.19	Immature fraction of reticulocytes;	chr8:141195865	chr8:141252286~141253292:-
THCA	cis	rs10833905	0.816	rs10767006	ENSG00000246225.5	RP11-17A1.3	-4.14	4.2e-05	0.00368	-0.27	-0.19	Sudden cardiac arrest;	chr11:23089086	chr11:22829380~22945393:+
THCA	cis	rs17193922	0.876	rs17194040	ENSG00000279344.1	RP11-44F14.7	4.14	4.2e-05	0.00368	0.21	0.19	Hip circumference adjusted for BMI;	chr16:53516986	chr16:53478957~53481550:-
THCA	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-4.14	4.2e-05	0.00368	-0.18	-0.19	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
THCA	cis	rs10435719	0.899	rs7815595	ENSG00000206014.6	OR7E161P	-4.14	4.2e-05	0.00368	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.834	rs11250176	ENSG00000206014.6	OR7E161P	-4.14	4.2e-05	0.00368	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.516	rs4367597	ENSG00000206014.6	OR7E161P	-4.14	4.2e-05	0.00368	-0.22	-0.19	Neuroticism;	chr8:11936020	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.899	rs9329251	ENSG00000206014.6	OR7E161P	-4.14	4.2e-05	0.00368	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:11928597~11929563:-
THCA	cis	rs17685	0.753	rs1104878	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76056275	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs869805	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76059278	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs869806	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76059305	chr7:76071469~76074963:-
THCA	cis	rs17685	0.672	rs1639618	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76072669	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs1637044	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76074426	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs1639620	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76074772	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs4552844	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76088777	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs4732578	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76092214	chr7:76071469~76074963:-
THCA	cis	rs17685	0.625	rs1639630	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76101181	chr7:76071469~76074963:-
THCA	cis	rs17685	0.784	rs1613890	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76105719	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs10245584	ENSG00000230882.1	AC005077.14	4.14	4.2e-05	0.00368	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76116548	chr7:76071469~76074963:-
THCA	cis	rs4656958	0.557	rs949691	ENSG00000233691.2	RP11-312J18.7	4.14	4.2e-05	0.00368	0.21	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160923993	chr1:160935537~160936126:+
THCA	cis	rs7959452	0.64	rs4761233	ENSG00000274979.1	RP11-1143G9.5	-4.14	4.2e-05	0.00368	-0.2	-0.19	Blood protein levels;	chr12:69329100	chr12:69326574~69331882:-
THCA	cis	rs1876905	0.597	rs354546	ENSG00000272356.1	RP5-1112D6.8	-4.13	4.2e-05	0.00368	-0.2	-0.19	Mean corpuscular hemoglobin;	chr6:111211927	chr6:111309203~111313517:+
THCA	cis	rs1908814	0.516	rs13275143	ENSG00000254948.1	OR7E158P	-4.13	4.21e-05	0.00368	-0.24	-0.19	Neuroticism;	chr8:11939481	chr8:11919900~11920809:-
THCA	cis	rs17270561	0.583	rs6908713	ENSG00000272462.2	U91328.19	4.13	4.21e-05	0.00368	0.16	0.19	Iron status biomarkers;	chr6:25703383	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.583	rs6908407	ENSG00000272462.2	U91328.19	4.13	4.21e-05	0.00368	0.16	0.19	Iron status biomarkers;	chr6:25703428	chr6:25992662~26001775:+
THCA	cis	rs17301013	0.729	rs12094143	ENSG00000227373.4	RP11-160H22.5	4.13	4.21e-05	0.00368	0.26	0.19	Systemic lupus erythematosus;	chr1:174511986	chr1:174115300~174160004:-
THCA	cis	rs10833905	1	rs11026880	ENSG00000246225.5	RP11-17A1.3	-4.13	4.21e-05	0.00368	-0.27	-0.19	Sudden cardiac arrest;	chr11:22994273	chr11:22829380~22945393:+
THCA	cis	rs4906332	1	rs12147655	ENSG00000252469.1	RNU7-160P	4.13	4.21e-05	0.00368	0.21	0.19	Coronary artery disease;	chr14:103384569	chr14:103550345~103550406:+
THCA	cis	rs6754311	0.517	rs1469996	ENSG00000231890.6	DARS-AS1	-4.13	4.21e-05	0.00368	-0.22	-0.19	Mosquito bite size;	chr2:135784990	chr2:135985176~136022593:+
THCA	cis	rs10946940	0.632	rs9366698	ENSG00000216901.1	AL022393.7	4.13	4.21e-05	0.00368	0.24	0.19	Systemic lupus erythematosus;	chr6:27704256	chr6:28176188~28176674:+
THCA	cis	rs3750082	1	rs3750082	ENSG00000231952.3	DPY19L1P2	4.13	4.21e-05	0.00368	0.24	0.19	Glomerular filtration rate (creatinine);	chr7:32880315	chr7:32812757~32838570:+
THCA	cis	rs3750082	0.926	rs11762628	ENSG00000231952.3	DPY19L1P2	4.13	4.21e-05	0.00368	0.24	0.19	Glomerular filtration rate (creatinine);	chr7:32886959	chr7:32812757~32838570:+
THCA	cis	rs2286503	0.839	rs1054471	ENSG00000226329.2	AC005682.6	4.13	4.21e-05	0.00368	0.23	0.19	Fibrinogen;	chr7:22813024	chr7:22863874~22881350:-
THCA	cis	rs78153629	0.92	rs7164321	ENSG00000259330.1	INAFM2	-4.13	4.21e-05	0.00368	-0.23	-0.19	Heschl's gyrus morphology;	chr15:40383128	chr15:40325216~40326715:+
THCA	cis	rs28530618	0.564	rs4911248	ENSG00000175730.8	BAK1P1	-4.13	4.21e-05	0.00368	-0.21	-0.19	Birth weight;	chr20:32626432	chr20:32690180~32690815:-
THCA	cis	rs925946	0.64	rs56133711	ENSG00000245573.6	BDNF-AS	-4.13	4.21e-05	0.00369	-0.2	-0.19	Weight;Body mass index;	chr11:27701787	chr11:27506838~27698174:+
THCA	cis	rs875971	0.66	rs28698552	ENSG00000275400.1	RP4-756H11.5	-4.13	4.21e-05	0.00369	-0.17	-0.19	Aortic root size;	chr7:66540031	chr7:66553805~66554199:-
THCA	cis	rs3177980	0.539	rs67274208	ENSG00000239494.2	RN7SL333P	-4.13	4.21e-05	0.00369	-0.17	-0.19	Amyotrophic lateral sclerosis;	chr1:169821020	chr1:169859756~169860052:+
THCA	cis	rs9309473	0.606	rs77962988	ENSG00000273245.1	RP11-434P11.2	4.13	4.21e-05	0.00369	0.32	0.19	Metabolite levels;	chr2:73658963	chr2:73750256~73750786:-
THCA	cis	rs17095355	1	rs12571872	ENSG00000203876.8	ADD3-AS1	-4.13	4.21e-05	0.00369	-0.22	-0.19	Biliary atresia;	chr10:109916356	chr10:109940104~110008381:-
THCA	cis	rs962856	0.575	rs644032	ENSG00000236780.4	AC078941.1	4.13	4.21e-05	0.00369	0.25	0.19	Pancreatic cancer;	chr2:67432524	chr2:67123357~67215319:-
THCA	cis	rs13256369	0.901	rs12679831	ENSG00000254153.1	CTA-398F10.2	-4.13	4.21e-05	0.00369	-0.21	-0.19	Obesity-related traits;	chr8:8708901	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.901	rs12681327	ENSG00000254153.1	CTA-398F10.2	-4.13	4.21e-05	0.00369	-0.21	-0.19	Obesity-related traits;	chr8:8708904	chr8:8456909~8461337:-
THCA	cis	rs6921919	0.583	rs3800328	ENSG00000273712.1	RP5-874C20.7	4.13	4.22e-05	0.00369	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs740621	ENSG00000273712.1	RP5-874C20.7	4.13	4.22e-05	0.00369	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs740622	ENSG00000273712.1	RP5-874C20.7	4.13	4.22e-05	0.00369	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28315613~28315883:-
THCA	cis	rs4785204	1	rs4785379	ENSG00000279356.1	RP11-429P3.8	-4.13	4.22e-05	0.00369	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50055462	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs55647424	ENSG00000279356.1	RP11-429P3.8	-4.13	4.22e-05	0.00369	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50058584	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs56337141	ENSG00000279356.1	RP11-429P3.8	-4.13	4.22e-05	0.00369	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50058779	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs12448508	ENSG00000279356.1	RP11-429P3.8	-4.13	4.22e-05	0.00369	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50059627	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs12446947	ENSG00000279356.1	RP11-429P3.8	-4.13	4.22e-05	0.00369	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50061474	chr16:50072862~50074986:+
THCA	cis	rs6061231	0.505	rs13037253	ENSG00000275437.1	RP5-908M14.10	4.13	4.22e-05	0.00369	0.19	0.19	Colorectal cancer;	chr20:62353668	chr20:62402236~62405935:-
THCA	cis	rs2638953	0.853	rs10506038	ENSG00000247934.4	RP11-967K21.1	4.13	4.22e-05	0.00369	0.19	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506239	chr12:28163298~28190738:-
THCA	cis	rs6560517	0.874	rs3739729	ENSG00000234618.1	RPSAP9	-4.13	4.22e-05	0.00369	-0.2	-0.19	Dialysis-related mortality;	chr9:76394223	chr9:76398699~76399586:+
THCA	cis	rs6560517	0.957	rs4372070	ENSG00000234618.1	RPSAP9	-4.13	4.22e-05	0.00369	-0.2	-0.19	Dialysis-related mortality;	chr9:76397742	chr9:76398699~76399586:+
THCA	cis	rs2281603	0.762	rs61987035	ENSG00000272909.1	CTD-2555O16.4	-4.13	4.22e-05	0.00369	-0.25	-0.19	Lymphocyte counts;	chr14:64571149	chr14:64440369~64442238:-
THCA	cis	rs2281603	0.762	rs10150987	ENSG00000272909.1	CTD-2555O16.4	-4.13	4.22e-05	0.00369	-0.25	-0.19	Lymphocyte counts;	chr14:64571472	chr14:64440369~64442238:-
THCA	cis	rs57502260	0.573	rs12291008	ENSG00000212093.1	AP000807.1	4.13	4.22e-05	0.00369	0.21	0.19	Total body bone mineral density (age 45-60);	chr11:68621604	chr11:68506083~68506166:-
THCA	cis	rs9291683	0.609	rs12507050	ENSG00000250413.1	RP11-448G15.1	-4.13	4.22e-05	0.00369	-0.18	-0.19	Bone mineral density;	chr4:10005681	chr4:10006482~10009725:+
THCA	cis	rs7829975	0.742	rs882462	ENSG00000254340.1	RP11-10A14.3	4.13	4.22e-05	0.00369	0.21	0.19	Mood instability;	chr8:8821020	chr8:9141424~9145435:+
THCA	cis	rs11633886	0.934	rs3858882	ENSG00000259200.1	RP11-718O11.1	-4.13	4.22e-05	0.00369	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45788766	chr15:45705078~45931069:+
THCA	cis	rs748404	0.601	rs489964	ENSG00000249839.1	AC011330.5	4.13	4.22e-05	0.00369	0.22	0.19	Lung cancer;	chr15:43225356	chr15:43663654~43684339:-
THCA	cis	rs6496044	0.963	rs7165300	ENSG00000259295.5	CSPG4P12	4.13	4.22e-05	0.00369	0.24	0.19	Interstitial lung disease;	chr15:85526838	chr15:85191438~85213905:+
THCA	cis	rs1979679	0.918	rs10771427	ENSG00000247934.4	RP11-967K21.1	-4.13	4.22e-05	0.00369	-0.19	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28452493	chr12:28163298~28190738:-
THCA	cis	rs4767841	0.806	rs1122119	ENSG00000252886.1	RN7SKP197	-4.13	4.22e-05	0.00369	-0.19	-0.19	Urgency urinary incontinence;	chr12:119748903	chr12:119631090~119631386:-
THCA	cis	rs10484434	0.818	rs6906460	ENSG00000272462.2	U91328.19	4.13	4.22e-05	0.00369	0.19	0.19	HIV-1 viral setpoint;	chr6:25977133	chr6:25992662~26001775:+
THCA	cis	rs6496932	0.802	rs2063442	ENSG00000259630.2	CTD-2262B20.1	4.13	4.22e-05	0.00369	0.23	0.19	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85415228~85415633:+
THCA	cis	rs13113518	0.934	rs11935823	ENSG00000249700.7	SRD5A3-AS1	4.13	4.22e-05	0.00369	0.23	0.19	Height;	chr4:55589624	chr4:55363971~55395847:-
THCA	cis	rs13325613	0.834	rs35587265	ENSG00000223552.1	RP11-24F11.2	-4.13	4.22e-05	0.00369	-0.33	-0.19	Monocyte count;	chr3:46217805	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35335084	ENSG00000223552.1	RP11-24F11.2	-4.13	4.22e-05	0.00369	-0.33	-0.19	Monocyte count;	chr3:46218467	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34625088	ENSG00000223552.1	RP11-24F11.2	-4.13	4.22e-05	0.00369	-0.33	-0.19	Monocyte count;	chr3:46218548	chr3:46364955~46407059:-
THCA	cis	rs875971	1	rs3735148	ENSG00000230189.5	GS1-124K5.2	4.13	4.22e-05	0.00369	0.12	0.19	Aortic root size;	chr7:66506022	chr7:66409143~66490059:-
THCA	cis	rs7923609	0.518	rs10995418	ENSG00000232075.1	MRPL35P2	-4.13	4.22e-05	0.00369	-0.25	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63070830	chr10:63634317~63634827:-
THCA	cis	rs7178375	1	rs7178375	ENSG00000269930.1	RP11-932O9.9	-4.13	4.22e-05	0.00369	-0.26	-0.19	Hypertriglyceridemia;	chr15:30923732	chr15:30616958~30617749:+
THCA	cis	rs7711186	0.786	rs1531539	ENSG00000252464.1	RN7SKP70	4.13	4.22e-05	0.0037	0.22	0.19	Urate levels in obese individuals;	chr5:178657842	chr5:178619728~178619998:-
THCA	cis	rs6088590	1	rs12626122	ENSG00000269202.1	RP4-614O4.12	-4.13	4.22e-05	0.0037	-0.17	-0.19	Coronary artery disease;	chr20:34837997	chr20:35201747~35203288:-
THCA	cis	rs7336933	0.932	rs4942082	ENSG00000278338.3	VWA8-AS1	-4.13	4.22e-05	0.0037	-0.31	-0.19	Calcium levels;	chr13:41954835	chr13:41955808~41981565:+
THCA	cis	rs7336933	0.932	rs7320843	ENSG00000278338.3	VWA8-AS1	-4.13	4.22e-05	0.0037	-0.31	-0.19	Calcium levels;	chr13:41955622	chr13:41955808~41981565:+
THCA	cis	rs5758511	0.633	rs5758689	ENSG00000230107.1	CTA-126B4.7	-4.13	4.23e-05	0.0037	-0.23	-0.19	Birth weight;	chr22:42268966	chr22:42438023~42446195:+
THCA	cis	rs9634489	0.56	rs601674	ENSG00000247400.3	DNAJC3-AS1	-4.13	4.23e-05	0.0037	-0.12	-0.19	Body mass index;	chr13:96429206	chr13:95648733~95676925:-
THCA	cis	rs2289125	0.762	rs10830278	ENSG00000280367.1	RP11-121L10.2	-4.13	4.23e-05	0.0037	-0.21	-0.19	Pulse pressure;	chr11:89483257	chr11:90223153~90226538:+
THCA	cis	rs7824557	0.564	rs6601584	ENSG00000206014.6	OR7E161P	4.13	4.23e-05	0.0037	0.22	0.19	Retinal vascular caliber;	chr8:11374834	chr8:11928597~11929563:-
THCA	cis	rs9329221	0.619	rs591346	ENSG00000248538.5	RP11-10A14.5	4.13	4.23e-05	0.0037	0.25	0.19	Neuroticism;	chr8:9960555	chr8:9189011~9202854:+
THCA	cis	rs1923243	0.647	rs11210156	ENSG00000223479.3	RP4-788P17.1	4.13	4.23e-05	0.0037	0.21	0.19	Migraine;	chr1:73161319	chr1:73635216~73715214:+
THCA	cis	rs1129187	0.967	rs3805952	ENSG00000272223.1	RP1-20C7.6	4.13	4.23e-05	0.0037	0.14	0.19	Alzheimer's disease in APOE e4+ carriers;	chr6:42969388	chr6:43033897~43034405:-
THCA	cis	rs1129187	0.967	rs3805951	ENSG00000272223.1	RP1-20C7.6	4.13	4.23e-05	0.0037	0.14	0.19	Alzheimer's disease in APOE e4+ carriers;	chr6:42969438	chr6:43033897~43034405:-
THCA	cis	rs12234571	1	rs112986492	ENSG00000214293.7	APTR	4.13	4.23e-05	0.0037	0.27	0.19	Obesity-related traits;	chr7:77756154	chr7:77657660~77696265:-
THCA	cis	rs12142240	0.738	rs67545510	ENSG00000232022.5	FAAHP1	-4.13	4.23e-05	0.0037	-0.21	-0.19	Menopause (age at onset);	chr1:46340570	chr1:46432129~46445521:+
THCA	cis	rs950169	0.922	rs11631096	ENSG00000275120.1	RP11-182J1.17	4.13	4.23e-05	0.0037	0.22	0.19	Schizophrenia;	chr15:84557698	chr15:84599434~84606463:-
THCA	cis	rs7259376	0.936	rs1975173	ENSG00000269345.1	VN1R85P	4.13	4.23e-05	0.0037	0.2	0.19	Menopause (age at onset);	chr19:22351736	chr19:22174766~22175191:-
THCA	cis	rs2380205	0.967	rs2203197	ENSG00000232807.2	RP11-536K7.3	-4.13	4.23e-05	0.0037	-0.17	-0.19	Breast cancer;	chr10:5862955	chr10:5934270~5945900:-
THCA	cis	rs11658311	0.85	rs60889477	ENSG00000232344.2	AC087163.2	4.13	4.23e-05	0.0037	0.25	0.19	Obsessive-compulsive symptoms;	chr17:17772231	chr17:18010643~18011822:+
THCA	cis	rs4906332	0.966	rs7401563	ENSG00000244691.1	RPL10AP1	-4.13	4.23e-05	0.0037	-0.24	-0.19	Coronary artery disease;	chr14:103498088	chr14:103412119~103412761:-
THCA	cis	rs3734266	0.702	rs4646933	ENSG00000272288.4	RP11-140K17.3	-4.13	4.24e-05	0.00371	-0.19	-0.19	Systemic lupus erythematosus;	chr6:34882883	chr6:34696317~34697470:+
THCA	cis	rs5751614	0.577	rs11090227	ENSG00000240160.3	RN7SL263P	4.13	4.24e-05	0.00371	0.22	0.19	Height;	chr22:23285436	chr22:23261782~23262071:-
THCA	cis	rs9788682	0.747	rs938682	ENSG00000261143.1	ADAMTS7P3	-4.13	4.24e-05	0.00371	-0.26	-0.19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78604205	chr15:77976042~77993057:+
THCA	cis	rs7614311	0.636	rs73117047	ENSG00000271843.1	RP11-245J9.5	-4.13	4.24e-05	0.00371	-0.37	-0.19	Lung function (FVC);Lung function (FEV1);	chr3:63925103	chr3:64008082~64008692:-
THCA	cis	rs7614311	0.636	rs73117057	ENSG00000271843.1	RP11-245J9.5	-4.13	4.24e-05	0.00371	-0.37	-0.19	Lung function (FVC);Lung function (FEV1);	chr3:63930013	chr3:64008082~64008692:-
THCA	cis	rs12935418	0.616	rs56299740	ENSG00000278985.1	RP11-303E16.9	4.13	4.24e-05	0.00371	0.24	0.19	Mean corpuscular volume;	chr16:80930272	chr16:80982319~80984094:-
THCA	cis	rs35146811	0.586	rs12666107	ENSG00000078319.8	PMS2P1	4.13	4.24e-05	0.00371	0.24	0.19	Coronary artery disease;	chr7:100180396	chr7:100320992~100341908:-
THCA	cis	rs7260598	0.502	rs59816383	ENSG00000268442.1	CTD-2027I19.2	4.13	4.24e-05	0.00371	0.28	0.19	Response to taxane treatment (placlitaxel);	chr19:23836786	chr19:24162370~24163425:-
THCA	cis	rs4714902	0.688	rs9369597	ENSG00000231769.2	RP1-8B1.4	-4.13	4.24e-05	0.00371	-0.18	-0.19	Colonoscopy-negative controls vs population controls;	chr6:46082861	chr6:46097093~46129706:-
THCA	cis	rs4713118	1	rs1139226	ENSG00000226314.6	ZNF192P1	-4.13	4.24e-05	0.00371	-0.23	-0.19	Parkinson's disease;	chr6:27707511	chr6:28161781~28169594:+
THCA	cis	rs4713118	1	rs9468195	ENSG00000226314.6	ZNF192P1	-4.13	4.24e-05	0.00371	-0.23	-0.19	Parkinson's disease;	chr6:27708530	chr6:28161781~28169594:+
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000265443.1	CTD-2349P21.6	-4.13	4.24e-05	0.00371	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30726305~30727564:-
THCA	cis	rs1577917	0.74	rs12212560	ENSG00000220563.1	PKMP3	-4.13	4.24e-05	0.00371	-0.14	-0.19	Response to antipsychotic treatment;	chr6:85632961	chr6:85659892~85660606:-
THCA	cis	rs6570726	0.738	rs7746330	ENSG00000270638.1	RP3-466P17.1	4.13	4.24e-05	0.00371	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145735570~145737218:+
THCA	cis	rs12935229	0.756	rs67261439	ENSG00000260922.1	RP11-538I12.3	-4.13	4.24e-05	0.00371	-0.3	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77273560	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.756	rs60755592	ENSG00000260922.1	RP11-538I12.3	-4.13	4.24e-05	0.00371	-0.3	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77273725	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.756	rs36045444	ENSG00000260922.1	RP11-538I12.3	-4.13	4.24e-05	0.00371	-0.3	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77275305	chr16:77234877~77290934:+
THCA	cis	rs4460629	0.901	rs4745	ENSG00000236675.1	MTX1P1	4.13	4.24e-05	0.00371	0.18	0.19	Serum magnesium levels;	chr1:155133751	chr1:155230975~155234325:+
THCA	cis	rs9393777	0.92	rs13196692	ENSG00000272009.1	RP1-313I6.12	-4.13	4.24e-05	0.00371	-0.35	-0.19	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28078792~28081130:-
THCA	cis	rs9393777	0.92	rs34150729	ENSG00000272009.1	RP1-313I6.12	-4.13	4.24e-05	0.00371	-0.35	-0.19	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28078792~28081130:-
THCA	cis	rs9393777	0.92	rs13191227	ENSG00000272009.1	RP1-313I6.12	-4.13	4.24e-05	0.00371	-0.35	-0.19	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28078792~28081130:-
THCA	cis	rs9314614	1	rs2978894	ENSG00000245857.2	GS1-24F4.2	4.13	4.25e-05	0.00371	0.24	0.19	White blood cell count (basophil);IgA nephropathy;	chr8:6836107	chr8:6835554~6885276:+
THCA	cis	rs7833787	0.501	rs13272436	ENSG00000278886.1	RP11-108A14.1	-4.13	4.25e-05	0.00371	-0.26	-0.19	Obesity-related traits;	chr8:18830619	chr8:18864681~18865247:-
THCA	cis	rs4660214	0.666	rs2275187	ENSG00000228060.1	RP11-69E11.8	4.13	4.25e-05	0.00371	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297570	chr1:39565160~39573203:+
THCA	cis	rs6540731	0.905	rs6540729	ENSG00000226251.4	RP11-15I11.3	-4.13	4.25e-05	0.00371	-0.23	-0.19	Intelligence (childhood);	chr1:212214566	chr1:212225278~212238977:-
THCA	cis	rs7572733	0.534	rs1401092	ENSG00000231621.1	AC013264.2	4.13	4.25e-05	0.00371	0.2	0.19	Dermatomyositis;	chr2:197927596	chr2:197197991~197199273:+
THCA	cis	rs10833905	1	rs11026884	ENSG00000246225.5	RP11-17A1.3	-4.13	4.25e-05	0.00371	-0.27	-0.19	Sudden cardiac arrest;	chr11:22997830	chr11:22829380~22945393:+
THCA	cis	rs357618	1	rs357620	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151467560	chr5:151652275~151655449:+
THCA	cis	rs357618	0.931	rs394736	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151467948	chr5:151652275~151655449:+
THCA	cis	rs357618	0.965	rs357621	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151467993	chr5:151652275~151655449:+
THCA	cis	rs357618	1	rs193299	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151468094	chr5:151652275~151655449:+
THCA	cis	rs357618	0.965	rs187180	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151468434	chr5:151652275~151655449:+
THCA	cis	rs357618	1	rs357622	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151468844	chr5:151652275~151655449:+
THCA	cis	rs357618	1	rs357623	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151468939	chr5:151652275~151655449:+
THCA	cis	rs357618	1	rs357624	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151469140	chr5:151652275~151655449:+
THCA	cis	rs357618	1	rs357625	ENSG00000260581.1	CTB-113P19.4	4.13	4.25e-05	0.00371	0.24	0.19	Basophil percentage of white cells;	chr5:151469313	chr5:151652275~151655449:+
THCA	cis	rs2692947	0.55	rs4613327	ENSG00000235584.2	AC008268.1	-4.13	4.25e-05	0.00371	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95918075	chr2:95666084~95668715:+
THCA	cis	rs858239	0.6	rs6461691	ENSG00000230042.1	AK3P3	-4.13	4.25e-05	0.00371	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23129178~23129841:+
THCA	cis	rs138341189	1	rs138341189	ENSG00000212093.1	AP000807.1	4.13	4.25e-05	0.00371	0.24	0.19	Monobrow;	chr11:68456954	chr11:68506083~68506166:-
THCA	cis	rs10761482	0.861	rs2061492	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60344258	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10761486	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60344545	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10761487	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60344551	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.728	rs4290174	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60344825	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs4291629	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60345000	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.683	rs4488150	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60345160	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs10821735	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60345222	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs10994309	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60345439	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.817	rs2061484	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60345740	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs2061486	ENSG00000254271.1	RP11-131N11.4	4.13	4.25e-05	0.00371	0.25	0.19	Schizophrenia;	chr10:60346158	chr10:60734342~60741828:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000229180.5	GS1-124K5.11	-4.13	4.25e-05	0.00371	-0.13	-0.19	Aortic root size;	chr7:66113790	chr7:66526088~66542624:-
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000237310.1	GS1-124K5.4	4.13	4.25e-05	0.00371	0.14	0.19	Corneal structure;	chr7:66925268	chr7:66493706~66495474:+
THCA	cis	rs2836974	0.565	rs34304022	ENSG00000255568.3	BRWD1-AS2	4.13	4.25e-05	0.00371	0.21	0.19	Cognitive function;	chr21:39207693	chr21:39313935~39314962:+
THCA	cis	rs5742933	0.696	rs6748102	ENSG00000253559.1	OSGEPL1-AS1	-4.13	4.25e-05	0.00372	-0.28	-0.19	Ferritin levels;	chr2:189760786	chr2:189762704~189765556:+
THCA	cis	rs6479891	1	rs7070052	ENSG00000272767.1	JMJD1C-AS1	-4.13	4.25e-05	0.00372	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63465229~63466563:+
THCA	cis	rs7010876	0.657	rs4463475	ENSG00000253553.4	RP11-586K2.1	-4.13	4.25e-05	0.00372	-0.2	-0.19	Schizophrenia;	chr8:88312619	chr8:88326836~88737134:+
THCA	cis	rs56313388	0.522	rs9936154	ENSG00000246379.5	RP11-461O7.1	-4.13	4.25e-05	0.00372	-0.2	-0.19	Pulse pressure;	chr16:56181429	chr16:56092987~56191094:-
THCA	cis	rs2692947	0.537	rs11164050	ENSG00000235959.1	AC009237.17	-4.13	4.25e-05	0.00372	-0.2	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95686703	chr2:95640181~95640604:-
THCA	cis	rs1572312	0.748	rs12038941	ENSG00000237928.4	NFIA-AS2	4.13	4.25e-05	0.00372	0.24	0.19	Maximal oxygen uptake response;	chr1:60969397	chr1:60940239~60970776:-
THCA	cis	rs12546962	0.626	rs17149807	ENSG00000254153.1	CTA-398F10.2	-4.13	4.25e-05	0.00372	-0.23	-0.19	Body mass index;	chr8:9335417	chr8:8456909~8461337:-
THCA	cis	rs9341808	0.754	rs6918172	ENSG00000260645.1	RP11-250B2.5	4.13	4.25e-05	0.00372	0.16	0.19	Sitting height ratio;	chr6:80309525	chr6:80466958~80469080:+
THCA	cis	rs11673344	0.526	rs55754546	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37552860	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.526	rs17244713	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37559938	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.526	rs17244769	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37562031	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.526	rs8111790	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37565861	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.526	rs55909413	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37578663	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.526	rs55865869	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37578683	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.502	rs17304703	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37582646	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.526	rs73033122	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37586006	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.526	rs2306201	ENSG00000267422.1	CTD-2554C21.1	4.13	4.25e-05	0.00372	0.19	0.19	Obesity-related traits;	chr19:37586573	chr19:37779686~37792865:+
THCA	cis	rs734999	0.588	rs3748817	ENSG00000225931.3	RP3-395M20.7	4.13	4.25e-05	0.00372	0.23	0.19	Ulcerative colitis;	chr1:2594226	chr1:2566410~2569888:+
THCA	cis	rs734999	0.549	rs2764845	ENSG00000225931.3	RP3-395M20.7	-4.13	4.25e-05	0.00372	-0.23	-0.19	Ulcerative colitis;	chr1:2597560	chr1:2566410~2569888:+
THCA	cis	rs4879656	0.564	rs4879657	ENSG00000225693.1	LAGE3P1	-4.13	4.25e-05	0.00372	-0.2	-0.19	Menopause (age at onset);	chr9:33012467	chr9:33019682~33020165:-
THCA	cis	rs4879656	0.525	rs7852206	ENSG00000225693.1	LAGE3P1	-4.13	4.25e-05	0.00372	-0.2	-0.19	Menopause (age at onset);	chr9:33017383	chr9:33019682~33020165:-
THCA	cis	rs1048886	0.872	rs56074506	ENSG00000271967.1	RP11-134K13.4	-4.13	4.25e-05	0.00372	-0.2	-0.19	Type 2 diabetes;	chr6:70558066	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.808	rs6941595	ENSG00000271967.1	RP11-134K13.4	-4.13	4.25e-05	0.00372	-0.2	-0.19	Type 2 diabetes;	chr6:70558710	chr6:70596438~70596980:+
THCA	cis	rs1971762	0.527	rs4019971	ENSG00000270175.1	RP11-793H13.11	-4.13	4.25e-05	0.00372	-0.12	-0.19	Height;	chr12:53584931	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.545	rs10876466	ENSG00000270175.1	RP11-793H13.11	-4.13	4.25e-05	0.00372	-0.12	-0.19	Height;	chr12:53587642	chr12:53500162~53500936:-
THCA	cis	rs1577917	0.74	rs2758843	ENSG00000220563.1	PKMP3	-4.13	4.25e-05	0.00372	-0.14	-0.19	Response to antipsychotic treatment;	chr6:85618713	chr6:85659892~85660606:-
THCA	cis	rs12935418	0.616	rs77336552	ENSG00000278985.1	RP11-303E16.9	4.13	4.25e-05	0.00372	0.28	0.19	Mean corpuscular volume;	chr16:80942989	chr16:80982319~80984094:-
THCA	cis	rs4973397	0.765	rs13030174	ENSG00000224376.1	AC017104.6	4.13	4.25e-05	0.00372	0.21	0.19	Anti-saccade response;	chr2:231406573	chr2:231388976~231394991:+
THCA	cis	rs867186	0.541	rs117391907	ENSG00000126005.14	MMP24-AS1	-4.13	4.25e-05	0.00372	-0.38	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34751008	chr20:35216462~35278131:-
THCA	cis	rs67478160	0.643	rs11160762	ENSG00000269940.1	RP11-73M18.7	-4.13	4.26e-05	0.00372	-0.18	-0.19	Schizophrenia;	chr14:103788746	chr14:103694560~103695170:+
THCA	cis	rs4237845	0.537	rs7312623	ENSG00000270039.1	RP11-571M6.17	-4.13	4.26e-05	0.00372	-0.21	-0.19	Intelligence (multi-trait analysis);	chr12:57868740	chr12:57803838~57804415:+
THCA	cis	rs758324	0.732	rs154730	ENSG00000224431.1	AC063976.7	-4.13	4.26e-05	0.00372	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132132814	chr5:132199456~132203487:+
THCA	cis	rs758324	0.732	rs154733	ENSG00000224431.1	AC063976.7	-4.13	4.26e-05	0.00372	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132136673	chr5:132199456~132203487:+
THCA	cis	rs3820928	0.692	rs2396434	ENSG00000212391.1	SNORA48	-4.13	4.26e-05	0.00372	-0.21	-0.19	Pulmonary function;	chr2:226910507	chr2:226968989~226969122:-
THCA	cis	rs62244186	0.606	rs6798590	ENSG00000214820.3	MPRIPP1	4.13	4.26e-05	0.00372	0.2	0.19	Depressive symptoms;	chr3:44515369	chr3:44579938~44581026:-
THCA	cis	rs1232027	0.656	rs1650737	ENSG00000249655.1	CTC-325J23.2	4.13	4.26e-05	0.00372	0.21	0.19	Huntington's disease progression;	chr5:80705966	chr5:80630313~80631590:-
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000265443.1	CTD-2349P21.6	-4.13	4.26e-05	0.00372	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30726305~30727564:-
THCA	cis	rs2380205	0.689	rs12779398	ENSG00000232807.2	RP11-536K7.3	4.13	4.26e-05	0.00372	0.18	0.19	Breast cancer;	chr10:5854662	chr10:5934270~5945900:-
THCA	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-4.13	4.26e-05	0.00372	-0.18	-0.19	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-4.13	4.26e-05	0.00372	-0.18	-0.19	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
THCA	cis	rs61160187	0.582	rs4700407	ENSG00000215032.2	GNL3LP1	-4.13	4.26e-05	0.00372	-0.22	-0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60891935~60893577:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000229886.1	RP5-1132H15.3	-4.13	4.26e-05	0.00372	-0.19	-0.19	Aortic root size;	chr7:66570949	chr7:66025126~66031544:-
THCA	cis	rs72827839	0.802	rs12951323	ENSG00000266601.1	RP11-6N17.3	-4.13	4.26e-05	0.00372	-0.21	-0.19	Ease of getting up in the morning;	chr17:47950199	chr17:47929682~47933106:-
THCA	cis	rs11758351	0.778	rs41266801	ENSG00000216331.1	HIST1H1PS1	4.13	4.26e-05	0.00372	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26197265	chr6:26195566~26195771:+
THCA	cis	rs36093844	0.66	rs1445500	ENSG00000279742.1	RP11-700A24.1	-4.13	4.26e-05	0.00372	-0.29	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85831439	chr11:85852557~85854943:-
THCA	cis	rs2434529	1	rs17627296	ENSG00000245275.6	SAP30L-AS1	4.13	4.26e-05	0.00372	0.24	0.19	Autism spectrum disorder or schizophrenia;	chr5:154248785	chr5:154329437~154445850:-
THCA	cis	rs4915077	0.892	rs17020064	ENSG00000226822.1	RP11-356N1.2	4.13	4.26e-05	0.00372	0.37	0.19	Hypothyroidism;	chr1:107795178	chr1:108071482~108074519:+
THCA	cis	rs6439699	0.941	rs16844702	ENSG00000273486.1	RP11-731C17.2	4.13	4.26e-05	0.00372	0.2	0.19	Intelligence (multi-trait analysis);	chr3:137326858	chr3:136837338~136839021:-
THCA	cis	rs2286503	0.839	rs2240726	ENSG00000226329.2	AC005682.6	4.13	4.26e-05	0.00372	0.23	0.19	Fibrinogen;	chr7:22813516	chr7:22863874~22881350:-
THCA	cis	rs72928364	0.932	rs2576372	ENSG00000256628.3	ZBTB11-AS1	-4.13	4.26e-05	0.00373	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100920792	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs2576377	ENSG00000256628.3	ZBTB11-AS1	-4.13	4.26e-05	0.00373	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100928905	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.769	rs2713748	ENSG00000256628.3	ZBTB11-AS1	-4.13	4.26e-05	0.00373	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100936735	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs2713764	ENSG00000256628.3	ZBTB11-AS1	-4.13	4.26e-05	0.00373	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100944723	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.872	rs2576382	ENSG00000256628.3	ZBTB11-AS1	-4.13	4.26e-05	0.00373	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100948985	chr3:101676475~101679217:+
THCA	cis	rs2448490	0.642	rs507859	ENSG00000255557.1	RP11-770G2.2	-4.13	4.26e-05	0.00373	-0.21	-0.19	Platelet count;	chr11:65704511	chr11:65745729~65771585:+
THCA	cis	rs889122	0.765	rs16996255	ENSG00000267289.1	CTD-2623N2.11	4.13	4.26e-05	0.00373	0.24	0.19	Menarche (age at onset);	chr19:9872134	chr19:9834079~9835013:-
THCA	cis	rs41294858	1	rs75375208	ENSG00000232876.1	CTA-212D2.2	-4.13	4.26e-05	0.00373	-0.38	-0.19	Red blood cell count;	chr6:135081951	chr6:135055033~135060550:+
THCA	cis	rs41294858	1	rs113033196	ENSG00000232876.1	CTA-212D2.2	-4.13	4.26e-05	0.00373	-0.38	-0.19	Red blood cell count;	chr6:135082789	chr6:135055033~135060550:+
THCA	cis	rs10090774	0.965	rs12550497	ENSG00000279766.1	RP11-642A1.2	4.13	4.26e-05	0.00373	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140935418	chr8:140572142~140572812:-
THCA	cis	rs9863	0.861	rs4765528	ENSG00000269997.1	RP11-214K3.21	4.13	4.26e-05	0.00373	0.24	0.19	White blood cell count;	chr12:123977707	chr12:123966077~123966629:-
THCA	cis	rs7772486	0.79	rs9386141	ENSG00000270638.1	RP3-466P17.1	-4.13	4.26e-05	0.00373	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145735570~145737218:+
THCA	cis	rs6968802	1	rs6968802	ENSG00000233264.2	AC006042.8	4.13	4.26e-05	0.00373	0.25	0.19	Granulocyte percentage of myeloid white cells;	chr7:8016446	chr7:7980312~7982228:+
THCA	cis	rs3924048	0.559	rs6541037	ENSG00000276830.1	MIR6730	-4.13	4.26e-05	0.00373	-0.18	-0.19	Optic cup area;	chr1:12566126	chr1:12578957~12579023:-
THCA	cis	rs1346	0.552	rs7946115	ENSG00000245532.5	NEAT1	4.13	4.27e-05	0.00373	0.14	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65598721	chr11:65422774~65445540:+
THCA	cis	rs1346	0.58	rs7932616	ENSG00000245532.5	NEAT1	4.13	4.27e-05	0.00373	0.14	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65598769	chr11:65422774~65445540:+
THCA	cis	rs6494488	0.5	rs28398966	ENSG00000259635.1	AC100830.3	-4.13	4.27e-05	0.00373	-0.44	-0.19	Coronary artery disease;	chr15:64731927	chr15:64701248~64719602:+
THCA	cis	rs941408	0.515	rs1736188	ENSG00000261342.1	AC006538.1	4.13	4.27e-05	0.00373	0.21	0.19	Total cholesterol levels;	chr19:2782370	chr19:2727743~2729327:-
THCA	cis	rs970548	0.954	rs72796498	ENSG00000230869.1	CTGLF10P	4.13	4.27e-05	0.00373	0.23	0.19	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45486771	chr10:45678692~45700532:+
THCA	cis	rs6903823	0.527	rs4713158	ENSG00000176933.5	TOB2P1	-4.13	4.27e-05	0.00373	-0.21	-0.19	Pulmonary function;	chr6:28309994	chr6:28217643~28218634:-
THCA	cis	rs755249	1	rs2293476	ENSG00000237624.1	OXCT2P1	-4.13	4.27e-05	0.00373	-0.26	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39514956~39516490:+
THCA	cis	rs12134133	0.752	rs4844579	ENSG00000237074.1	RP11-6J21.2	4.13	4.27e-05	0.00373	0.2	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207249067~207309121:+
THCA	cis	rs4950322	0.58	rs17359629	ENSG00000271721.1	RP11-337C18.9	4.13	4.27e-05	0.00373	0.21	0.19	Protein quantitative trait loci;	chr1:147121537	chr1:147175602~147177740:+
THCA	cis	rs11668609	0.872	rs8102565	ENSG00000268442.1	CTD-2027I19.2	-4.13	4.27e-05	0.00373	-0.25	-0.19	Response to taxane treatment (docetaxel);	chr19:23884546	chr19:24162370~24163425:-
THCA	cis	rs957448	0.561	rs58663902	ENSG00000253175.1	RP11-267M23.6	4.13	4.27e-05	0.00373	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94565036~94565715:+
THCA	cis	rs10833905	0.877	rs11026951	ENSG00000246225.5	RP11-17A1.3	-4.13	4.27e-05	0.00373	-0.27	-0.19	Sudden cardiac arrest;	chr11:23054964	chr11:22829380~22945393:+
THCA	cis	rs4792901	0.722	rs35714338	ENSG00000267151.3	RP11-100E5.2	4.13	4.27e-05	0.00373	0.2	0.19	Dupuytren's disease;	chr17:43536845	chr17:43444707~43451200:+
THCA	cis	rs1908814	0.516	rs13281315	ENSG00000206014.6	OR7E161P	-4.13	4.27e-05	0.00373	-0.22	-0.19	Neuroticism;	chr8:11937346	chr8:11928597~11929563:-
THCA	cis	rs10191559	0.638	rs4666988	ENSG00000236153.1	AC104076.3	-4.13	4.27e-05	0.00373	-0.2	-0.19	Red blood cell count;	chr2:180968140	chr2:180979427~180980090:-
THCA	cis	rs6479891	1	rs9415705	ENSG00000272767.1	JMJD1C-AS1	4.13	4.27e-05	0.00373	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63465229~63466563:+
THCA	cis	rs2436845	1	rs892484	ENSG00000253669.3	KB-1732A1.1	4.13	4.27e-05	0.00373	0.19	0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102862333	chr8:102805517~102809971:+
THCA	cis	rs9926296	0.581	rs6500457	ENSG00000274627.1	RP11-104N10.2	4.13	4.27e-05	0.00373	0.18	0.19	Vitiligo;	chr16:89832356	chr16:89516797~89522217:+
THCA	cis	rs10411161	0.702	rs7247017	ENSG00000275055.1	CTC-471J1.11	-4.13	4.27e-05	0.00373	-0.18	-0.19	Breast cancer;	chr19:51888516	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs7256926	ENSG00000275055.1	CTC-471J1.11	-4.13	4.27e-05	0.00373	-0.18	-0.19	Breast cancer;	chr19:51888735	chr19:52049007~52049754:+
THCA	cis	rs7772486	0.79	rs9497435	ENSG00000270638.1	RP3-466P17.1	-4.13	4.27e-05	0.00373	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs9791313	ENSG00000270638.1	RP3-466P17.1	-4.13	4.27e-05	0.00373	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145735570~145737218:+
THCA	cis	rs735539	0.555	rs8001310	ENSG00000278291.1	RP11-172H24.4	4.13	4.27e-05	0.00373	0.25	0.19	Dental caries;	chr13:20765561	chr13:20699307~20703718:-
THCA	cis	rs2904524	0.588	rs60881781	ENSG00000257815.4	RP11-611E13.2	-4.13	4.27e-05	0.00373	-0.15	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70373544	chr12:69904033~70243360:-
THCA	cis	rs6560517	1	rs10869767	ENSG00000234618.1	RPSAP9	-4.13	4.27e-05	0.00373	-0.2	-0.19	Dialysis-related mortality;	chr9:76404895	chr9:76398699~76399586:+
THCA	cis	rs1232027	0.656	rs836801	ENSG00000249655.1	CTC-325J23.2	4.13	4.27e-05	0.00373	0.22	0.19	Huntington's disease progression;	chr5:80689137	chr5:80630313~80631590:-
THCA	cis	rs10489167	1	rs589609	ENSG00000237899.1	RP4-739H11.3	4.13	4.27e-05	0.00373	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40671449	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs572777	ENSG00000237899.1	RP4-739H11.3	4.13	4.27e-05	0.00373	0.34	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40674629	chr1:40669089~40687588:-
THCA	cis	rs2380220	0.72	rs9374178	ENSG00000261366.1	MANEA-AS1	-4.13	4.28e-05	0.00373	-0.19	-0.19	Behavioural disinhibition (generation interaction);	chr6:95532098	chr6:95575183~95577450:-
THCA	cis	rs2380220	0.72	rs9400397	ENSG00000261366.1	MANEA-AS1	-4.13	4.28e-05	0.00373	-0.19	-0.19	Behavioural disinhibition (generation interaction);	chr6:95532747	chr6:95575183~95577450:-
THCA	cis	rs8030605	0.633	rs72740541	ENSG00000277245.1	RP11-48G14.3	4.13	4.28e-05	0.00373	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56300222	chr15:56447120~56447697:+
THCA	cis	rs4654783	0.627	rs1046310	ENSG00000228397.1	RP1-224A6.3	4.13	4.28e-05	0.00373	0.27	0.19	Endometriosis;	chr1:22117394	chr1:22023994~22024968:-
THCA	cis	rs62458065	0.64	rs10241303	ENSG00000231952.3	DPY19L1P2	4.13	4.28e-05	0.00374	0.32	0.19	Metabolite levels (HVA/MHPG ratio);	chr7:32494591	chr7:32812757~32838570:+
THCA	cis	rs2790457	0.76	rs1265834	ENSG00000254635.4	WAC-AS1	4.13	4.28e-05	0.00374	0.19	0.19	Multiple myeloma;	chr10:28652932	chr10:28522652~28532743:-
THCA	cis	rs7267979	0.868	rs6138553	ENSG00000274973.1	RP13-401N8.7	-4.13	4.28e-05	0.00374	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.903	rs6115109	ENSG00000274973.1	RP13-401N8.7	-4.13	4.28e-05	0.00374	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25845497~25845862:+
THCA	cis	rs1800682	0.528	rs4934434	ENSG00000261438.1	RP11-399O19.9	-4.13	4.28e-05	0.00374	-0.16	-0.19	Chronic lymphocytic leukemia;	chr10:88987412	chr10:89015836~89017059:+
THCA	cis	rs123509	0.913	rs339661	ENSG00000173811.9	CCDC13-AS1	4.13	4.28e-05	0.00374	0.21	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42712412	chr3:42732575~42746768:+
THCA	cis	rs2033711	0.87	rs7259841	ENSG00000269054.1	CTD-2619J13.3	-4.13	4.28e-05	0.00374	-0.15	-0.19	Uric acid clearance;	chr19:58439756	chr19:58362585~58366591:+
THCA	cis	rs1577917	0.74	rs7752502	ENSG00000220563.1	PKMP3	4.13	4.28e-05	0.00374	0.13	0.19	Response to antipsychotic treatment;	chr6:85700933	chr6:85659892~85660606:-
THCA	cis	rs10256972	0.552	rs6978842	ENSG00000225146.1	AC073957.15	4.13	4.28e-05	0.00374	0.2	0.19	Endometriosis;Longevity;	chr7:1164963	chr7:1029025~1043891:+
THCA	cis	rs651907	0.817	rs617688	ENSG00000256628.3	ZBTB11-AS1	4.13	4.28e-05	0.00374	0.2	0.19	Colorectal cancer;	chr3:101873442	chr3:101676475~101679217:+
THCA	cis	rs6921919	0.638	rs9468344	ENSG00000219392.1	RP1-265C24.5	-4.13	4.28e-05	0.00374	-0.22	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28115628~28116551:+
THCA	cis	rs2075824	1	rs585283	ENSG00000267079.1	RP11-820I16.1	4.13	4.28e-05	0.00374	0.24	0.19	Obsessive-compulsive disorder or autism spectrum disorder;	chr18:11974762	chr18:11910634~11914344:-
THCA	cis	rs897984	0.881	rs12920259	ENSG00000260911.2	RP11-196G11.2	-4.13	4.28e-05	0.00374	-0.16	-0.19	Dementia with Lewy bodies;	chr16:30869978	chr16:31043150~31049868:+
THCA	cis	rs2028299	0.92	rs4932265	ENSG00000259677.1	RP11-493E3.1	4.13	4.28e-05	0.00374	0.25	0.19	Type 2 diabetes;	chr15:89880061	chr15:89876540~89877285:+
THCA	cis	rs2342371	0.848	rs7433483	ENSG00000273013.1	CTD-2002J20.1	4.13	4.29e-05	0.00374	0.18	0.19	Fat distribution (HIV);	chr3:196490167	chr3:196474801~196475394:+
THCA	cis	rs78487399	0.665	rs17031016	ENSG00000234936.1	AC010883.5	4.13	4.29e-05	0.00374	0.24	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43537303	chr2:43229573~43233394:+
THCA	cis	rs12680842	0.883	rs13265241	ENSG00000253175.1	RP11-267M23.6	4.13	4.29e-05	0.00374	0.23	0.19	Body mass index;	chr8:94575129	chr8:94565036~94565715:+
THCA	cis	rs3020736	0.5	rs6002597	ENSG00000237037.8	NDUFA6-AS1	4.13	4.29e-05	0.00374	0.16	0.19	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42090931~42137742:+
THCA	cis	rs2298450	0.563	rs55801841	ENSG00000214867.3	SRSF9P1	4.13	4.29e-05	0.00374	0.3	0.19	Schizophrenia;	chr21:36258447	chr21:36295173~36295702:-
THCA	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	4.13	4.29e-05	0.00375	0.17	0.19	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	4.13	4.29e-05	0.00375	0.17	0.19	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	4.13	4.29e-05	0.00375	0.22	0.19	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
THCA	cis	rs1387259	0.79	rs2732445	ENSG00000273765.1	RP11-370I10.11	4.13	4.29e-05	0.00375	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48360920~48361377:+
THCA	cis	rs4218	0.681	rs10518996	ENSG00000259732.1	RP11-59H7.3	-4.13	4.29e-05	0.00375	-0.26	-0.19	Social communication problems;	chr15:59085247	chr15:59121034~59133250:+
THCA	cis	rs2562152	0.744	rs1045001	ENSG00000226942.2	IL9RP3	4.13	4.29e-05	0.00375	0.24	0.19	Glioblastoma;	chr16:57275	chr16:29336~38321:-
THCA	cis	rs801193	1	rs4717319	ENSG00000223473.2	GS1-124K5.3	4.13	4.29e-05	0.00375	0.12	0.19	Aortic root size;	chr7:66777606	chr7:66491049~66493566:-
THCA	cis	rs801193	0.904	rs4718403	ENSG00000223473.2	GS1-124K5.3	4.13	4.29e-05	0.00375	0.12	0.19	Aortic root size;	chr7:66777742	chr7:66491049~66493566:-
THCA	cis	rs7772697	0.632	rs10457842	ENSG00000223701.3	RAET1E-AS1	-4.13	4.29e-05	0.00375	-0.26	-0.19	Diabetic retinopathy;	chr6:149094468	chr6:149884431~149919508:+
THCA	cis	rs34929064	0.536	rs2905307	ENSG00000232949.1	AC002480.4	4.13	4.29e-05	0.00375	0.24	0.19	Major depression and alcohol dependence;	chr7:22599344	chr7:22589705~22591622:+
THCA	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	4.13	4.29e-05	0.00375	0.15	0.19	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
THCA	cis	rs8177876	0.822	rs7185637	ENSG00000261061.1	RP11-303E16.2	4.13	4.29e-05	0.00375	0.25	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81089551	chr16:81030770~81031485:+
THCA	cis	rs10266483	0.639	rs6952592	ENSG00000271550.1	BNIP3P11	4.13	4.29e-05	0.00375	0.24	0.19	Response to statin therapy;	chr7:64293667	chr7:64678954~64687393:-
THCA	cis	rs10266483	0.705	rs660228	ENSG00000271550.1	BNIP3P11	4.13	4.29e-05	0.00375	0.24	0.19	Response to statin therapy;	chr7:64295867	chr7:64678954~64687393:-
THCA	cis	rs10875746	0.855	rs2269936	ENSG00000258273.1	RP11-370I10.4	4.13	4.29e-05	0.00375	0.27	0.19	Longevity (90 years and older);	chr12:48031452	chr12:48333755~48333901:-
THCA	cis	rs77972916	0.536	rs59362315	ENSG00000234936.1	AC010883.5	4.13	4.3e-05	0.00375	0.2	0.19	Granulocyte percentage of myeloid white cells;	chr2:43367792	chr2:43229573~43233394:+
THCA	cis	rs2505675	0.563	rs163074	ENSG00000250903.7	GMDS-AS1	-4.13	4.3e-05	0.00375	-0.18	-0.19	Tuberculosis;	chr6:2215388	chr6:2245748~2482022:+
THCA	cis	rs2797160	0.651	rs6569436	ENSG00000226409.1	RP11-735G4.1	4.13	4.3e-05	0.00375	0.23	0.19	Endometrial cancer;	chr6:125710958	chr6:125370211~125374324:-
THCA	cis	rs12755164	0.771	rs1525979	ENSG00000223479.3	RP4-788P17.1	-4.13	4.3e-05	0.00375	-0.2	-0.19	Schizophrenia;	chr1:72848864	chr1:73635216~73715214:+
THCA	cis	rs62025270	0.547	rs338520	ENSG00000259295.5	CSPG4P12	4.13	4.3e-05	0.00375	0.27	0.19	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85191438~85213905:+
THCA	cis	rs11634944	0.63	rs705	ENSG00000251896.1	SNORD116-27	-4.13	4.3e-05	0.00375	-0.21	-0.19	Interleukin-8 levels;	chr15:24974365	chr15:25101575~25101666:+
THCA	cis	rs17604090	0.938	rs850027	ENSG00000227855.3	DPY19L2P3	4.13	4.3e-05	0.00375	0.22	0.19	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29636176	chr7:29650227~29742594:+
THCA	cis	rs7487075	0.93	rs4076484	ENSG00000272369.1	RP11-446N19.1	4.13	4.3e-05	0.00375	0.14	0.19	Itch intensity from mosquito bite;	chr12:46440129	chr12:46537502~46652550:+
THCA	cis	rs7487075	0.823	rs34472481	ENSG00000272369.1	RP11-446N19.1	4.13	4.3e-05	0.00375	0.14	0.19	Itch intensity from mosquito bite;	chr12:46442565	chr12:46537502~46652550:+
THCA	cis	rs7572644	0.64	rs4666024	ENSG00000223522.1	AC093690.1	4.13	4.3e-05	0.00375	0.22	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27850112	chr2:28307691~28310459:-
THCA	cis	rs10200159	1	rs10204169	ENSG00000272606.1	RP11-554J4.1	4.13	4.3e-05	0.00375	0.36	0.19	Vitiligo;	chr2:55663468	chr2:55617909~55618373:+
THCA	cis	rs7621331	1	rs9843725	ENSG00000273486.1	RP11-731C17.2	4.13	4.3e-05	0.00375	0.18	0.19	Waist circumference adjusted for body mass index;	chr3:135984023	chr3:136837338~136839021:-
THCA	cis	rs4950322	0.58	rs17355474	ENSG00000226015.2	CCT8P1	4.13	4.3e-05	0.00375	0.22	0.19	Protein quantitative trait loci;	chr1:147120541	chr1:147203276~147204932:-
THCA	cis	rs875971	1	rs1544549	ENSG00000229886.1	RP5-1132H15.3	-4.13	4.3e-05	0.00375	-0.19	-0.19	Aortic root size;	chr7:66625676	chr7:66025126~66031544:-
THCA	cis	rs4705962	0.837	rs1468215	ENSG00000230612.2	AC004237.1	4.13	4.3e-05	0.00375	0.23	0.19	Atopic dermatitis;	chr5:132700797	chr5:132688681~132723725:+
THCA	cis	rs4705962	0.701	rs3213639	ENSG00000230612.2	AC004237.1	4.13	4.3e-05	0.00375	0.23	0.19	Atopic dermatitis;	chr5:132702507	chr5:132688681~132723725:+
THCA	cis	rs4767841	0.537	rs413236	ENSG00000248636.5	RP11-768F21.1	-4.13	4.3e-05	0.00375	-0.19	-0.19	Urgency urinary incontinence;	chr12:119790268	chr12:119387987~119668079:-
THCA	cis	rs875971	0.929	rs6970860	ENSG00000230189.5	GS1-124K5.2	4.13	4.3e-05	0.00375	0.12	0.19	Aortic root size;	chr7:66511647	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs6957199	ENSG00000230189.5	GS1-124K5.2	4.13	4.3e-05	0.00375	0.12	0.19	Aortic root size;	chr7:66513532	chr7:66409143~66490059:-
THCA	cis	rs4742903	1	rs7350148	ENSG00000270332.1	SMC2-AS1	4.13	4.3e-05	0.00375	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104120804	chr9:104080024~104093073:-
THCA	cis	rs868036	0.718	rs28587941	ENSG00000270964.1	RP11-502I4.3	-4.13	4.3e-05	0.00375	-0.17	-0.19	Restless legs syndrome;	chr15:67830171	chr15:67541072~67542604:-
THCA	cis	rs868036	0.718	rs4776985	ENSG00000270964.1	RP11-502I4.3	-4.13	4.3e-05	0.00375	-0.17	-0.19	Restless legs syndrome;	chr15:67830683	chr15:67541072~67542604:-
THCA	cis	rs12142240	0.698	rs41293273	ENSG00000232022.5	FAAHP1	-4.13	4.3e-05	0.00375	-0.21	-0.19	Menopause (age at onset);	chr1:46340721	chr1:46432129~46445521:+
THCA	cis	rs950169	0.922	rs11633075	ENSG00000188388.10	GOLGA6L3	4.13	4.3e-05	0.00375	0.25	0.19	Schizophrenia;	chr15:84570741	chr15:85240472~85247170:+
THCA	cis	rs964611	0.882	rs4630496	ENSG00000259488.2	RP11-154J22.1	-4.13	4.3e-05	0.00376	-0.18	-0.19	Metabolite levels (Pyroglutamine);	chr15:48366466	chr15:48312353~48331856:-
THCA	cis	rs758324	0.687	rs246351	ENSG00000224431.1	AC063976.7	-4.13	4.3e-05	0.00376	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132173578	chr5:132199456~132203487:+
THCA	cis	rs6012564	0.788	rs6095404	ENSG00000227431.4	CSE1L-AS1	4.13	4.3e-05	0.00376	0.22	0.19	Anger;	chr20:49040144	chr20:49040463~49046044:-
THCA	cis	rs9534288	0.833	rs56813530	ENSG00000235903.6	CPB2-AS1	4.13	4.3e-05	0.00376	0.27	0.19	Blood protein levels;	chr13:46047904	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.912	rs9534297	ENSG00000235903.6	CPB2-AS1	4.13	4.3e-05	0.00376	0.27	0.19	Blood protein levels;	chr13:46050495	chr13:46052806~46113332:+
THCA	cis	rs548181	0.736	rs543389	ENSG00000254671.2	STT3A-AS1	-4.13	4.31e-05	0.00376	-0.36	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125594946	chr11:125570284~125592568:-
THCA	cis	rs7968440	0.902	rs2684901	ENSG00000272368.2	RP4-605O3.4	4.13	4.31e-05	0.00376	0.12	0.19	Fibrinogen;	chr12:50657985	chr12:50112197~50165618:+
THCA	cis	rs9341808	0.935	rs9448894	ENSG00000272129.1	RP11-250B2.6	4.13	4.31e-05	0.00376	0.23	0.19	Sitting height ratio;	chr6:80127536	chr6:80355424~80356859:+
THCA	cis	rs4646450	0.735	rs10272998	ENSG00000244219.5	GS1-259H13.2	-4.13	4.31e-05	0.00376	-0.25	-0.19	Blood metabolite levels;	chr7:99336295	chr7:99598066~99610813:+
THCA	cis	rs10129255	1	rs8010605	ENSG00000211972.2	IGHV3-66	4.13	4.31e-05	0.00376	0.11	0.19	Kawasaki disease;	chr14:106678742	chr14:106675017~106675544:-
THCA	cis	rs10256972	0.516	rs12702081	ENSG00000225146.1	AC073957.15	4.13	4.31e-05	0.00376	0.2	0.19	Endometriosis;Longevity;	chr7:1101892	chr7:1029025~1043891:+
THCA	cis	rs3096299	0.685	rs3803682	ENSG00000261118.1	RP11-104N10.1	4.13	4.31e-05	0.00376	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89492017~89504460:-
THCA	cis	rs1334894	0.892	rs11545925	ENSG00000228559.1	RP3-340B19.3	-4.13	4.31e-05	0.00376	-0.4	-0.19	Coronary artery disease;	chr6:35574749	chr6:35544632~35545669:+
THCA	cis	rs4218	0.648	rs57361749	ENSG00000259732.1	RP11-59H7.3	-4.13	4.31e-05	0.00376	-0.26	-0.19	Social communication problems;	chr15:59091352	chr15:59121034~59133250:+
THCA	cis	rs4218	0.608	rs16941014	ENSG00000259732.1	RP11-59H7.3	-4.13	4.31e-05	0.00376	-0.26	-0.19	Social communication problems;	chr15:59091503	chr15:59121034~59133250:+
THCA	cis	rs7871764	0.881	rs35017035	ENSG00000260947.1	RP11-384P7.7	4.13	4.31e-05	0.00376	0.31	0.19	Height;	chr9:34072896	chr9:33697459~33700986:+
THCA	cis	rs35740288	0.77	rs1382538	ENSG00000259295.5	CSPG4P12	4.13	4.31e-05	0.00376	0.3	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85622665	chr15:85191438~85213905:+
THCA	cis	rs4908760	0.965	rs7542312	ENSG00000270282.1	RP5-1115A15.2	4.13	4.31e-05	0.00376	0.22	0.19	Vitiligo;	chr1:8513412	chr1:8512653~8513021:+
THCA	cis	rs2221894	1	rs6558085	ENSG00000251191.6	LINC00589	-4.13	4.31e-05	0.00376	-0.23	-0.19	Obesity-related traits;	chr8:28945415	chr8:29673922~29748109:-
THCA	cis	rs2380205	0.967	rs4009521	ENSG00000232807.2	RP11-536K7.3	4.13	4.31e-05	0.00376	0.18	0.19	Breast cancer;	chr10:5846127	chr10:5934270~5945900:-
THCA	cis	rs7621025	0.63	rs1681818	ENSG00000239213.4	NCK1-AS1	-4.13	4.31e-05	0.00376	-0.19	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136754831	chr3:136841726~136862054:-
THCA	cis	rs1346	0.58	rs948577	ENSG00000245532.5	NEAT1	4.13	4.31e-05	0.00376	0.14	0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65597847	chr11:65422774~65445540:+
THCA	cis	rs35160687	0.509	rs13024436	ENSG00000273080.1	RP11-301O19.1	-4.13	4.31e-05	0.00376	-0.21	-0.19	Night sleep phenotypes;	chr2:86307398	chr2:86195590~86196049:+
THCA	cis	rs1577330	0.8	rs7030567	ENSG00000254396.1	RP11-56F10.3	4.13	4.31e-05	0.00376	0.23	0.19	IgG glycosylation;	chr9:27078059	chr9:27102630~27104728:+
THCA	cis	rs9611565	0.512	rs9607841	ENSG00000237037.8	NDUFA6-AS1	4.13	4.31e-05	0.00376	0.18	0.19	Vitiligo;	chr22:41790834	chr22:42090931~42137742:+
THCA	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	4.13	4.31e-05	0.00376	0.22	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	4.13	4.31e-05	0.00376	0.22	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	4.13	4.31e-05	0.00376	0.22	0.19	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
THCA	cis	rs5758659	0.652	rs133322	ENSG00000270083.1	RP1-257I20.14	4.13	4.31e-05	0.00376	0.2	0.19	Cognitive function;	chr22:42009655	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.623	rs133328	ENSG00000270083.1	RP1-257I20.14	4.13	4.31e-05	0.00376	0.2	0.19	Cognitive function;	chr22:42012075	chr22:42089630~42090028:-
THCA	cis	rs1371614	0.655	rs4665927	ENSG00000272148.1	RP11-195B17.1	-4.13	4.31e-05	0.00376	-0.17	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26926498	chr2:27062428~27062907:-
THCA	cis	rs5758659	0.652	rs133300	ENSG00000270083.1	RP1-257I20.14	4.13	4.31e-05	0.00376	0.2	0.19	Cognitive function;	chr22:41993835	chr22:42089630~42090028:-
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000176700.18	SCAND2P	-4.13	4.31e-05	0.00376	-0.12	-0.19	P wave terminal force;	chr15:84654022	chr15:84631451~84647478:+
THCA	cis	rs875971	0.965	rs10267430	ENSG00000230189.5	GS1-124K5.2	-4.13	4.32e-05	0.00377	-0.12	-0.19	Aortic root size;	chr7:66278036	chr7:66409143~66490059:-
THCA	cis	rs3177980	0.529	rs516793	ENSG00000239494.2	RN7SL333P	-4.13	4.32e-05	0.00377	-0.18	-0.19	Amyotrophic lateral sclerosis;	chr1:169938074	chr1:169859756~169860052:+
THCA	cis	rs9902453	0.834	rs9901694	ENSG00000263370.1	RP11-68I3.5	4.13	4.32e-05	0.00377	0.24	0.19	Coffee consumption (cups per day);	chr17:29944627	chr17:29639627~29640825:+
THCA	cis	rs36093844	0.706	rs1445501	ENSG00000279742.1	RP11-700A24.1	-4.13	4.32e-05	0.00377	-0.29	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85831833	chr11:85852557~85854943:-
THCA	cis	rs2625529	0.818	rs16956241	ENSG00000260037.4	CTD-2524L6.3	-4.13	4.32e-05	0.00377	-0.26	-0.19	Red blood cell count;	chr15:71819347	chr15:71818396~71823384:+
THCA	cis	rs6787172	0.811	rs939117	ENSG00000272087.1	RP11-379F4.7	-4.13	4.32e-05	0.00377	-0.17	-0.19	Subjective well-being;	chr3:158483080	chr3:158693120~158693768:-
THCA	cis	rs11220082	0.698	rs35285862	ENSG00000254671.2	STT3A-AS1	-4.13	4.32e-05	0.00377	-0.22	-0.19	Schizophrenia;	chr11:125435199	chr11:125570284~125592568:-
THCA	cis	rs9481169	0.557	rs34896684	ENSG00000272356.1	RP5-1112D6.8	4.13	4.32e-05	0.00377	0.3	0.19	Inflammatory skin disease;	chr6:111572034	chr6:111309203~111313517:+
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000182586.6	LINC00334	-4.13	4.32e-05	0.00377	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45234340~45258730:+
THCA	cis	rs6498068	0.633	rs1504884	ENSG00000260468.1	LINC01290	-4.13	4.32e-05	0.00377	-0.25	-0.19	Metabolite levels (MHPG);	chr16:10538128	chr16:10514842~10528202:-
THCA	cis	rs2191566	0.664	rs62115482	ENSG00000266921.1	RP11-15A1.7	-4.13	4.32e-05	0.00377	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44049930	chr19:43996896~44002836:-
THCA	cis	rs17270561	0.609	rs9356984	ENSG00000272462.2	U91328.19	4.13	4.32e-05	0.00377	0.16	0.19	Iron status biomarkers;	chr6:25725253	chr6:25992662~26001775:+
THCA	cis	rs2070488	0.965	rs4679060	ENSG00000229589.1	ACVR2B-AS1	-4.13	4.32e-05	0.00377	-0.17	-0.19	Electrocardiographic conduction measures;	chr3:38494770	chr3:38451027~38454820:-
THCA	cis	rs4906332	1	rs2065015	ENSG00000244691.1	RPL10AP1	4.13	4.32e-05	0.00377	0.24	0.19	Coronary artery disease;	chr14:103437724	chr14:103412119~103412761:-
THCA	cis	rs253959	0.672	rs1133186	ENSG00000271918.1	CTD-2287O16.5	4.13	4.32e-05	0.00377	0.12	0.19	Bipolar disorder and schizophrenia;	chr5:116084718	chr5:116083807~116085416:-
THCA	cis	rs113520408	1	rs113520408	ENSG00000271553.1	RP11-274B21.10	-4.13	4.32e-05	0.00377	-0.19	-0.19	Educational attainment (years of education);	chr7:128762728	chr7:128667043~128668156:+
THCA	cis	rs2933343	0.553	rs789212	ENSG00000261159.1	RP11-723O4.9	4.13	4.33e-05	0.00377	0.19	0.19	IgG glycosylation;	chr3:128968069	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.553	rs35979399	ENSG00000261159.1	RP11-723O4.9	4.13	4.33e-05	0.00377	0.19	0.19	IgG glycosylation;	chr3:128978470	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.533	rs11915889	ENSG00000261159.1	RP11-723O4.9	4.13	4.33e-05	0.00377	0.19	0.19	IgG glycosylation;	chr3:128982023	chr3:128859716~128860526:-
THCA	cis	rs6517329	0.6	rs6517330	ENSG00000230212.5	AP000688.14	-4.13	4.33e-05	0.00377	-0.24	-0.19	Schizophrenia;	chr21:36117163	chr21:36069642~36126640:-
THCA	cis	rs2745572	0.688	rs2317961	ENSG00000272279.1	RP11-157J24.2	4.13	4.33e-05	0.00377	0.25	0.19	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1532881	chr6:1528364~1528911:-
THCA	cis	rs9987353	0.544	rs2929469	ENSG00000248538.5	RP11-10A14.5	-4.13	4.33e-05	0.00377	-0.24	-0.19	Recombination measurement;	chr8:9205146	chr8:9189011~9202854:+
THCA	cis	rs10129255	0.957	rs10132367	ENSG00000211972.2	IGHV3-66	4.13	4.33e-05	0.00377	0.11	0.19	Kawasaki disease;	chr14:106690981	chr14:106675017~106675544:-
THCA	cis	rs6088813	0.883	rs1406948	ENSG00000126005.14	MMP24-AS1	-4.13	4.33e-05	0.00377	-0.19	-0.19	Height;	chr20:35317816	chr20:35216462~35278131:-
THCA	cis	rs4237845	0.537	rs12312955	ENSG00000270039.1	RP11-571M6.17	-4.13	4.33e-05	0.00377	-0.21	-0.19	Intelligence (multi-trait analysis);	chr12:57871440	chr12:57803838~57804415:+
THCA	cis	rs4906332	1	rs2065017	ENSG00000244691.1	RPL10AP1	-4.13	4.33e-05	0.00377	-0.24	-0.19	Coronary artery disease;	chr14:103413242	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs12885762	ENSG00000244691.1	RPL10AP1	-4.13	4.33e-05	0.00377	-0.24	-0.19	Coronary artery disease;	chr14:103415863	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs12892062	ENSG00000244691.1	RPL10AP1	-4.13	4.33e-05	0.00377	-0.24	-0.19	Coronary artery disease;	chr14:103417175	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs7155980	ENSG00000244691.1	RPL10AP1	-4.13	4.33e-05	0.00377	-0.24	-0.19	Coronary artery disease;	chr14:103456082	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs8012623	ENSG00000244691.1	RPL10AP1	-4.13	4.33e-05	0.00377	-0.24	-0.19	Coronary artery disease;	chr14:103470749	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs34347076	ENSG00000244691.1	RPL10AP1	-4.13	4.33e-05	0.00377	-0.24	-0.19	Coronary artery disease;	chr14:103488732	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs35344594	ENSG00000244691.1	RPL10AP1	-4.13	4.33e-05	0.00377	-0.24	-0.19	Coronary artery disease;	chr14:103489455	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs2065018	ENSG00000244691.1	RPL10AP1	4.13	4.33e-05	0.00377	0.24	0.19	Coronary artery disease;	chr14:103412850	chr14:103412119~103412761:-
THCA	cis	rs7824557	0.564	rs12547100	ENSG00000227888.4	FAM66A	-4.13	4.33e-05	0.00377	-0.24	-0.19	Retinal vascular caliber;	chr8:11385123	chr8:12362019~12388296:+
THCA	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	4.13	4.33e-05	0.00378	0.2	0.19	Asthma;	chr2:102446780	chr2:102438713~102440475:+
THCA	cis	rs427943	0.8	rs8134836	ENSG00000223768.1	LINC00205	-4.13	4.33e-05	0.00378	-0.17	-0.19	Body mass index;	chr21:45206864	chr21:45293285~45297354:+
THCA	cis	rs9595908	0.709	rs3492	ENSG00000212293.1	SNORA16	4.13	4.33e-05	0.00378	0.22	0.19	Body mass index;	chr13:32775203	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.709	rs7326102	ENSG00000212293.1	SNORA16	4.13	4.33e-05	0.00378	0.22	0.19	Body mass index;	chr13:32777857	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.669	rs17516561	ENSG00000212293.1	SNORA16	4.13	4.33e-05	0.00378	0.22	0.19	Body mass index;	chr13:32782063	chr13:32420390~32420516:-
THCA	cis	rs172166	0.585	rs149963	ENSG00000280107.1	AL022393.9	-4.13	4.33e-05	0.00378	-0.18	-0.19	Cardiac Troponin-T levels;	chr6:28049354	chr6:28170845~28172521:+
THCA	cis	rs5753618	1	rs5753618	ENSG00000235573.2	RP3-412A9.12	-4.13	4.33e-05	0.00378	-0.22	-0.19	Colorectal cancer;	chr22:31442532	chr22:31113017~31113396:+
THCA	cis	rs801193	0.904	rs4718405	ENSG00000229886.1	RP5-1132H15.3	4.13	4.33e-05	0.00378	0.19	0.19	Aortic root size;	chr7:66789659	chr7:66025126~66031544:-
THCA	cis	rs4906332	1	rs1951389	ENSG00000252469.1	RNU7-160P	4.13	4.33e-05	0.00378	0.2	0.19	Coronary artery disease;	chr14:103432188	chr14:103550345~103550406:+
THCA	cis	rs4906332	0.901	rs4900575	ENSG00000252469.1	RNU7-160P	4.13	4.33e-05	0.00378	0.2	0.19	Coronary artery disease;	chr14:103432832	chr14:103550345~103550406:+
THCA	cis	rs268134	0.553	rs35493937	ENSG00000204929.10	AC074391.1	-4.13	4.33e-05	0.00378	-0.27	-0.19	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65344005	chr2:65436711~66084639:+
THCA	cis	rs7904321	1	rs10822120	ENSG00000232075.1	MRPL35P2	4.13	4.33e-05	0.00378	0.25	0.19	Intelligence (multi-trait analysis);	chr10:63069554	chr10:63634317~63634827:-
THCA	cis	rs643955	0.609	rs13259465	ENSG00000261451.1	RP11-981G7.1	-4.13	4.33e-05	0.00378	-0.24	-0.19	Systemic lupus erythematosus;	chr8:10125443	chr8:10433672~10438312:+
THCA	cis	rs7403037	0.583	rs61993093	ENSG00000260760.1	PWRN3	4.13	4.33e-05	0.00378	0.27	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24516210	chr15:24441127~24447967:+
THCA	cis	rs7554547	0.905	rs4993564	ENSG00000199347.1	RNU5E-1	-4.13	4.33e-05	0.00378	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr1:11908152~11908271:+
THCA	cis	rs1039766	0.866	rs2160263	ENSG00000204929.10	AC074391.1	4.13	4.33e-05	0.00378	0.3	0.19	Lung adenocarcinoma;Lung cancer;	chr2:65282104	chr2:65436711~66084639:+
THCA	cis	rs10510102	0.507	rs12244092	ENSG00000226864.1	ATE1-AS1	4.13	4.33e-05	0.00378	0.3	0.19	Breast cancer;	chr10:122005769	chr10:121928312~121951965:+
THCA	cis	rs61270009	0.687	rs10942530	ENSG00000247828.6	TMEM161B-AS1	4.13	4.33e-05	0.00378	0.17	0.19	Depressive symptoms;	chr5:88414221	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs10942531	ENSG00000247828.6	TMEM161B-AS1	4.13	4.33e-05	0.00378	0.17	0.19	Macular telangiectasia type 2;	chr5:88414280	chr5:88268895~88436685:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000229180.5	GS1-124K5.11	4.13	4.33e-05	0.00378	0.13	0.19	Aortic root size;	chr7:65930047	chr7:66526088~66542624:-
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000265443.1	CTD-2349P21.6	-4.13	4.33e-05	0.00378	-0.32	-0.19	Body mass index;	chr17:30737900	chr17:30726305~30727564:-
THCA	cis	rs758324	0.732	rs247293	ENSG00000224431.1	AC063976.7	-4.13	4.33e-05	0.00378	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132121469	chr5:132199456~132203487:+
THCA	cis	rs2562456	0.754	rs11666213	ENSG00000268117.1	VN1R84P	4.13	4.33e-05	0.00378	0.3	0.19	Pain;	chr19:21422843	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62110429	ENSG00000268117.1	VN1R84P	4.13	4.33e-05	0.00378	0.3	0.19	Pain;	chr19:21430984	chr19:21719801~21720035:-
THCA	cis	rs7903847	0.62	rs7923385	ENSG00000225850.3	RP11-452K12.4	4.13	4.33e-05	0.00378	0.19	0.19	Granulocyte percentage of myeloid white cells;	chr10:97357340	chr10:97334564~97343203:+
THCA	cis	rs5758659	0.594	rs739292	ENSG00000270083.1	RP1-257I20.14	4.13	4.34e-05	0.00378	0.2	0.19	Cognitive function;	chr22:41972853	chr22:42089630~42090028:-
THCA	cis	rs13102973	0.6	rs13122485	ENSG00000250144.1	RP11-553P9.1	-4.13	4.34e-05	0.00378	-0.13	-0.19	Subjective well-being;	chr4:134913282	chr4:135045464~135046850:+
THCA	cis	rs7045881	0.696	rs10812492	ENSG00000254396.1	RP11-56F10.3	4.13	4.34e-05	0.00378	0.25	0.19	Schizophrenia;	chr9:26909067	chr9:27102630~27104728:+
THCA	cis	rs2657294	0.965	rs7088974	ENSG00000233313.2	HMGA1P5	-4.13	4.34e-05	0.00378	-0.25	-0.19	Pneumonia;	chr10:75131338	chr10:75276376~75276646:-
THCA	cis	rs202072	1	rs202070	ENSG00000272379.1	RP1-257A7.5	4.13	4.34e-05	0.00378	0.28	0.19	HIV-1 viral setpoint;	chr6:13267706	chr6:13290018~13290490:-
THCA	cis	rs7809799	0.571	rs11978345	ENSG00000244219.5	GS1-259H13.2	-4.13	4.34e-05	0.00378	-0.41	-0.19	Ulcerative colitis;	chr7:99332413	chr7:99598066~99610813:+
THCA	cis	rs3758911	0.828	rs10789605	ENSG00000255353.1	RP11-382M14.1	-4.13	4.34e-05	0.00378	-0.24	-0.19	Coronary artery disease;	chr11:107313859	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.828	rs10789606	ENSG00000255353.1	RP11-382M14.1	-4.13	4.34e-05	0.00378	-0.24	-0.19	Coronary artery disease;	chr11:107313862	chr11:107176286~107177530:+
THCA	cis	rs9925964	0.748	rs4889603	ENSG00000279196.1	RP11-1072A3.3	4.13	4.34e-05	0.00378	0.18	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:30984630~30988270:-
THCA	cis	rs8081395	0.737	rs4968401	ENSG00000267302.4	RP11-178C3.2	-4.13	4.34e-05	0.00378	-0.22	-0.19	White blood cell count;	chr17:59963369	chr17:59964832~59996972:+
THCA	cis	rs4869313	0.668	rs1056893	ENSG00000247121.5	CTD-2260A17.2	4.13	4.34e-05	0.00378	0.14	0.19	Pediatric autoimmune diseases;	chr5:96909735	chr5:96814028~96935809:-
THCA	cis	rs11176749	1	rs11176749	ENSG00000256172.1	RP11-473M14.3	4.13	4.34e-05	0.00378	0.27	0.19	Expressive vocabulary in infants;	chr12:67459004	chr12:67440998~67442559:-
THCA	cis	rs7432375	0.901	rs7616204	ENSG00000273455.1	RP11-305O4.3	-4.13	4.34e-05	0.00378	-0.25	-0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136725747	chr3:136087475~136087913:-
THCA	cis	rs17853159	0.558	rs111309476	ENSG00000281912.1	LINC01144	-4.13	4.34e-05	0.00378	-0.2	-0.19	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45290897	chr1:45303910~45305619:+
THCA	cis	rs17853159	0.558	rs11211091	ENSG00000281912.1	LINC01144	-4.13	4.34e-05	0.00378	-0.2	-0.19	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45291452	chr1:45303910~45305619:+
THCA	cis	rs17853159	0.51	rs28704653	ENSG00000281912.1	LINC01144	-4.13	4.34e-05	0.00378	-0.2	-0.19	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45294019	chr1:45303910~45305619:+
THCA	cis	rs17853159	0.614	rs6688723	ENSG00000281912.1	LINC01144	-4.13	4.34e-05	0.00378	-0.2	-0.19	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45297870	chr1:45303910~45305619:+
THCA	cis	rs79243044	0.71	rs10160673	ENSG00000224295.2	AC087380.14	4.13	4.34e-05	0.00379	0.19	0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5525360	chr11:5518441~5524955:-
THCA	cis	rs875971	0.545	rs73136346	ENSG00000273142.1	RP11-458F8.4	-4.13	4.34e-05	0.00379	-0.18	-0.19	Aortic root size;	chr7:66101095	chr7:66902857~66906297:+
THCA	cis	rs854765	0.583	rs6502627	ENSG00000281749.1	Y_RNA	4.13	4.34e-05	0.00379	0.24	0.19	Total body bone mineral density;	chr17:17946357	chr17:18001101~18001195:-
THCA	cis	rs9650657	0.571	rs11783247	ENSG00000269899.1	RP11-589N15.2	4.13	4.34e-05	0.00379	0.21	0.19	Neuroticism;	chr8:10931365	chr8:11846154~11846391:-
THCA	cis	rs301901	1	rs210540	ENSG00000250155.1	CTD-2353F22.1	-4.13	4.34e-05	0.00379	-0.19	-0.19	Height;	chr5:36804263	chr5:36666214~36725195:-
THCA	cis	rs2692947	0.8	rs2692948	ENSG00000235584.2	AC008268.1	-4.13	4.34e-05	0.00379	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007817	chr2:95666084~95668715:+
THCA	cis	rs7182948	0.957	rs17483139	ENSG00000259531.2	RP11-295H24.3	4.13	4.34e-05	0.00379	0.24	0.19	Lung adenocarcinoma;	chr15:49712315	chr15:49365124~49366685:-
THCA	cis	rs41342147	0.66	rs12468518	ENSG00000223374.1	AC005104.3	4.13	4.34e-05	0.00379	0.17	0.19	Vitiligo;	chr2:241325211	chr2:241351340~241353104:-
THCA	cis	rs889398	0.835	rs62050037	ENSG00000226232.7	RP11-419C5.2	4.13	4.34e-05	0.00379	0.18	0.19	Body mass index;	chr16:69750767	chr16:69976388~69996188:-
THCA	cis	rs4805272	1	rs7254988	ENSG00000267799.1	MAN1A2P1	4.13	4.35e-05	0.00379	0.2	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28835250	chr19:28790812~28792871:-
THCA	cis	rs1065656	0.5	rs2575352	ENSG00000261123.1	RP11-304L19.3	4.13	4.35e-05	0.00379	0.26	0.19	Insulin-like growth factors;	chr16:1785392	chr16:2094830~2097026:-
THCA	cis	rs10208649	0.522	rs13395449	ENSG00000233266.1	HMGB1P31	4.13	4.35e-05	0.00379	0.53	0.19	Body mass index;	chr2:54178063	chr2:54051334~54051760:+
THCA	cis	rs42648	0.869	rs3810890	ENSG00000225498.1	AC002064.5	4.13	4.35e-05	0.00379	0.19	0.19	Homocysteine levels;	chr7:90279519	chr7:90312496~90322592:+
THCA	cis	rs3740713	1	rs73436645	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr11:18490243~18490955:-
THCA	cis	rs3740713	0.925	rs73436650	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73436655	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr11:18490243~18490955:-
THCA	cis	rs3740713	0.92	rs80254575	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73436662	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs113725670	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73436682	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73436685	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs2056781	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73436701	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438607	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs75010364	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438627	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438634	ENSG00000256464.1	YWHABP2	4.13	4.35e-05	0.00379	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr11:18490243~18490955:-
THCA	cis	rs57502260	0.915	rs75202638	ENSG00000212093.1	AP000807.1	4.13	4.35e-05	0.00379	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68442953	chr11:68506083~68506166:-
THCA	cis	rs62025270	0.547	rs386346	ENSG00000259295.5	CSPG4P12	-4.13	4.35e-05	0.00379	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85191438~85213905:+
THCA	cis	rs8058578	0.945	rs34480360	ENSG00000279196.1	RP11-1072A3.3	4.13	4.35e-05	0.00379	0.19	0.19	Multiple myeloma;	chr16:30787368	chr16:30984630~30988270:-
THCA	cis	rs9878978	0.893	rs13091098	ENSG00000237990.3	CNTN4-AS1	4.13	4.35e-05	0.00379	0.2	0.19	Blood pressure (smoking interaction);	chr3:2422166	chr3:3039033~3069242:-
THCA	cis	rs858239	0.539	rs10270695	ENSG00000226816.2	AC005082.12	-4.13	4.35e-05	0.00379	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23206013~23208045:+
THCA	cis	rs1577917	0.74	rs2842614	ENSG00000220563.1	PKMP3	-4.13	4.35e-05	0.00379	-0.14	-0.19	Response to antipsychotic treatment;	chr6:85596351	chr6:85659892~85660606:-
THCA	cis	rs17689437	0.958	rs11075683	ENSG00000260084.1	RP11-615I2.1	-4.13	4.35e-05	0.00379	-0.3	-0.19	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68547574	chr16:68573782~68589512:-
THCA	cis	rs2836974	0.533	rs418298	ENSG00000255568.3	BRWD1-AS2	4.13	4.35e-05	0.00379	0.15	0.19	Cognitive function;	chr21:39164728	chr21:39313935~39314962:+
THCA	cis	rs599083	0.53	rs640569	ENSG00000212093.1	AP000807.1	-4.13	4.35e-05	0.00379	-0.2	-0.19	Bone mineral density (spine);	chr11:68417352	chr11:68506083~68506166:-
THCA	cis	rs599083	0.53	rs2472415	ENSG00000212093.1	AP000807.1	-4.13	4.35e-05	0.00379	-0.2	-0.19	Bone mineral density (spine);	chr11:68418148	chr11:68506083~68506166:-
THCA	cis	rs801193	1	rs7782320	ENSG00000230295.1	RP11-458F8.2	-4.13	4.35e-05	0.00379	-0.14	-0.19	Aortic root size;	chr7:66712111	chr7:66880708~66882981:+
THCA	cis	rs3750965	0.92	rs896978	ENSG00000260895.1	RP11-554A11.7	4.13	4.35e-05	0.00379	0.26	0.19	Hair color;	chr11:69061461	chr11:69103493~69109094:+
THCA	cis	rs10129255	0.83	rs61997609	ENSG00000211972.2	IGHV3-66	4.13	4.35e-05	0.00379	0.11	0.19	Kawasaki disease;	chr14:106692376	chr14:106675017~106675544:-
THCA	cis	rs13108904	0.557	rs1250095	ENSG00000254094.1	AC078852.1	4.13	4.35e-05	0.00379	0.23	0.19	Obesity-related traits;	chr4:1245524	chr4:1356581~1358075:+
THCA	cis	rs9311474	0.629	rs4282054	ENSG00000243224.1	RP5-1157M23.2	-4.13	4.35e-05	0.00379	-0.2	-0.19	Electroencephalogram traits;	chr3:52532049	chr3:52239258~52241097:+
THCA	cis	rs3770081	1	rs2303340	ENSG00000273080.1	RP11-301O19.1	-4.13	4.35e-05	0.00379	-0.41	-0.19	Facial emotion recognition (sad faces);	chr2:86106070	chr2:86195590~86196049:+
THCA	cis	rs9595908	0.709	rs9315179	ENSG00000212293.1	SNORA16	4.13	4.35e-05	0.00379	0.22	0.19	Body mass index;	chr13:32773889	chr13:32420390~32420516:-
THCA	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	4.13	4.35e-05	0.00379	0.26	0.19	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
THCA	cis	rs73193808	0.639	rs2832248	ENSG00000176054.6	RPL23P2	4.13	4.35e-05	0.00379	0.17	0.19	Coronary artery disease;	chr21:29184660	chr21:28997613~28998033:-
THCA	cis	rs8027521	0.738	rs4145152	ENSG00000280362.1	RP11-643A5.3	4.13	4.35e-05	0.00379	0.23	0.19	Circulating chemerin levels;	chr15:53963308	chr15:53910769~53914712:+
THCA	cis	rs2434529	1	rs60552828	ENSG00000245275.6	SAP30L-AS1	4.13	4.35e-05	0.00379	0.22	0.19	Autism spectrum disorder or schizophrenia;	chr5:154276024	chr5:154329437~154445850:-
THCA	cis	rs12439619	0.53	rs7162177	ENSG00000259429.4	UBE2Q2P2	-4.13	4.35e-05	0.00379	-0.15	-0.19	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82355142~82420075:+
THCA	cis	rs4908768	0.906	rs56305243	ENSG00000232912.4	RP5-1115A15.1	-4.13	4.35e-05	0.00379	-0.22	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665361	chr1:8424645~8434838:+
THCA	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-4.13	4.35e-05	0.00379	-0.24	-0.19	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
THCA	cis	rs758324	0.773	rs608834	ENSG00000237714.1	P4HA2-AS1	-4.13	4.36e-05	0.00379	-0.26	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131935835	chr5:132184876~132192808:+
THCA	cis	rs12546962	0.705	rs12677965	ENSG00000254153.1	CTA-398F10.2	-4.13	4.36e-05	0.0038	-0.23	-0.19	Body mass index;	chr8:9336186	chr8:8456909~8461337:-
THCA	cis	rs9532669	0.963	rs9315794	ENSG00000229473.2	RGS17P1	4.13	4.36e-05	0.0038	0.23	0.19	Cervical cancer;	chr13:40939489	chr13:40992779~40993331:-
THCA	cis	rs934734	0.532	rs13383320	ENSG00000214533.3	KRT18P33	-4.13	4.36e-05	0.0038	-0.23	-0.19	Rheumatoid arthritis;	chr2:65418003	chr2:65666695~65667737:+
THCA	cis	rs8177876	0.642	rs56032321	ENSG00000261838.4	RP11-303E16.6	4.13	4.36e-05	0.0038	0.32	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81069854~81076598:+
THCA	cis	rs10483853	0.806	rs10132830	ENSG00000258695.2	RP3-414A15.2	-4.13	4.36e-05	0.0038	-0.26	-0.19	Coronary artery calcification;	chr14:73422139	chr14:73522878~73530610:+
THCA	cis	rs10483853	0.806	rs10135560	ENSG00000258695.2	RP3-414A15.2	-4.13	4.36e-05	0.0038	-0.26	-0.19	Coronary artery calcification;	chr14:73422717	chr14:73522878~73530610:+
THCA	cis	rs60180747	0.909	rs11629783	ENSG00000261318.1	RP11-653J6.1	-4.13	4.36e-05	0.0038	-0.26	-0.19	Testicular germ cell tumor;	chr15:66449049	chr15:66278498~66293357:-
THCA	cis	rs2018683	0.707	rs917216	ENSG00000272568.4	CTB-113D17.1	4.13	4.36e-05	0.0038	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931855	chr7:28979967~29013367:+
THCA	cis	rs478304	0.593	rs2236682	ENSG00000255557.1	RP11-770G2.2	4.13	4.36e-05	0.0038	0.22	0.19	Acne (severe);	chr11:65712619	chr11:65745729~65771585:+
THCA	cis	rs478304	0.593	rs7120713	ENSG00000255557.1	RP11-770G2.2	4.13	4.36e-05	0.0038	0.22	0.19	Acne (severe);	chr11:65715903	chr11:65745729~65771585:+
THCA	cis	rs7192208	0.748	rs72628224	ENSG00000260922.1	RP11-538I12.3	4.13	4.36e-05	0.0038	0.34	0.19	White matter integrity;	chr16:77295373	chr16:77234877~77290934:+
THCA	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-4.13	4.36e-05	0.0038	-0.2	-0.19	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
THCA	cis	rs13178541	0.638	rs11242276	ENSG00000250378.1	RP11-119J18.1	-4.13	4.36e-05	0.0038	-0.22	-0.19	IgG glycosylation;	chr5:135777323	chr5:135812667~135826582:+
THCA	cis	rs6688613	0.685	rs6427047	ENSG00000225171.2	DUTP6	-4.13	4.36e-05	0.0038	-0.26	-0.19	Refractive astigmatism;	chr1:166945021	chr1:166868748~166869209:+
THCA	cis	rs11992162	0.967	rs7836456	ENSG00000255046.1	RP11-297N6.4	-4.13	4.36e-05	0.0038	-0.2	-0.19	Monocyte count;	chr8:11971666	chr8:11797928~11802568:-
THCA	cis	rs2153535	0.526	rs9505487	ENSG00000230939.1	RP11-314C16.1	-4.13	4.36e-05	0.0038	-0.2	-0.19	Motion sickness;	chr6:8593521	chr6:8784178~8785445:+
THCA	cis	rs6921919	0.583	rs4254981	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.525	rs6929825	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs35599905	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs1124131	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs6899389	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs6922374	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs6899603	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs6922429	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs6922169	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.559	rs13210866	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.609	rs36018474	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs13201726	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs2027361	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs4642462	ENSG00000273712.1	RP5-874C20.7	4.13	4.36e-05	0.0038	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28315613~28315883:-
THCA	cis	rs7833787	0.501	rs1492286	ENSG00000278886.1	RP11-108A14.1	-4.13	4.36e-05	0.0038	-0.27	-0.19	Obesity-related traits;	chr8:18827038	chr8:18864681~18865247:-
THCA	cis	rs9810089	0.814	rs834305	ENSG00000273455.1	RP11-305O4.3	4.13	4.36e-05	0.0038	0.25	0.19	Gestational age at birth (child effect);	chr3:136400512	chr3:136087475~136087913:-
THCA	cis	rs11220082	0.666	rs12789687	ENSG00000254671.2	STT3A-AS1	-4.13	4.36e-05	0.0038	-0.22	-0.19	Schizophrenia;	chr11:125461254	chr11:125570284~125592568:-
THCA	cis	rs11220082	0.666	rs12223186	ENSG00000254671.2	STT3A-AS1	-4.13	4.36e-05	0.0038	-0.22	-0.19	Schizophrenia;	chr11:125461743	chr11:125570284~125592568:-
THCA	cis	rs7474896	0.832	rs2076809	ENSG00000263064.2	RP11-291L22.7	4.13	4.37e-05	0.0038	0.32	0.19	Obesity (extreme);	chr10:37704039	chr10:38448689~38448949:+
THCA	cis	rs35851103	0.506	rs4841659	ENSG00000206014.6	OR7E161P	-4.13	4.37e-05	0.0038	-0.22	-0.19	Neuroticism;	chr8:11970691	chr8:11928597~11929563:-
THCA	cis	rs875971	0.66	rs801192	ENSG00000275400.1	RP4-756H11.5	4.13	4.37e-05	0.0038	0.17	0.19	Aortic root size;	chr7:66566965	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs801190	ENSG00000275400.1	RP4-756H11.5	4.13	4.37e-05	0.0038	0.17	0.19	Aortic root size;	chr7:66568046	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs3857686	ENSG00000275400.1	RP4-756H11.5	4.13	4.37e-05	0.0038	0.17	0.19	Aortic root size;	chr7:66571204	chr7:66553805~66554199:-
THCA	cis	rs875971	0.638	rs6460305	ENSG00000275400.1	RP4-756H11.5	4.13	4.37e-05	0.0038	0.17	0.19	Aortic root size;	chr7:66595421	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs10272357	ENSG00000275400.1	RP4-756H11.5	4.13	4.37e-05	0.0038	0.17	0.19	Aortic root size;	chr7:66598087	chr7:66553805~66554199:-
THCA	cis	rs9863	0.931	rs4930721	ENSG00000269938.1	RP11-214K3.20	-4.13	4.37e-05	0.0038	-0.23	-0.19	White blood cell count;	chr12:123933342	chr12:123968023~123968579:-
THCA	cis	rs3755605	0.695	rs6444900	ENSG00000242578.1	RP11-469J4.3	4.13	4.37e-05	0.00381	0.21	0.19	Testicular germ cell tumor;	chr3:170119731	chr3:170410512~170418615:+
THCA	cis	rs970548	0.954	rs61854096	ENSG00000230869.1	CTGLF10P	4.13	4.37e-05	0.00381	0.23	0.19	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45485736	chr10:45678692~45700532:+
THCA	cis	rs10129255	0.957	rs2013423	ENSG00000211972.2	IGHV3-66	4.13	4.37e-05	0.00381	0.11	0.19	Kawasaki disease;	chr14:106690675	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs56134540	ENSG00000211972.2	IGHV3-66	4.13	4.37e-05	0.00381	0.11	0.19	Kawasaki disease;	chr14:106691290	chr14:106675017~106675544:-
THCA	cis	rs7511006	1	rs7511006	ENSG00000272836.1	RP3-402G11.27	-4.13	4.37e-05	0.00381	-0.15	-0.19	Obesity-related traits;	chr22:50237830	chr22:50205585~50206062:-
THCA	cis	rs7511006	1	rs7290710	ENSG00000272836.1	RP3-402G11.27	-4.13	4.37e-05	0.00381	-0.15	-0.19	Obesity-related traits;	chr22:50239025	chr22:50205585~50206062:-
THCA	cis	rs6517329	0.649	rs2409758	ENSG00000230212.5	AP000688.14	-4.13	4.37e-05	0.00381	-0.23	-0.19	Schizophrenia;	chr21:36118357	chr21:36069642~36126640:-
THCA	cis	rs13118159	0.899	rs3796613	ENSG00000254094.1	AC078852.1	-4.13	4.37e-05	0.00381	-0.21	-0.19	Longevity;	chr4:1359533	chr4:1356581~1358075:+
THCA	cis	rs919433	0.679	rs13000656	ENSG00000231621.1	AC013264.2	4.13	4.37e-05	0.00381	0.21	0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197657402	chr2:197197991~197199273:+
THCA	cis	rs7809950	0.678	rs7777950	ENSG00000272072.1	CTA-363E19.2	4.13	4.37e-05	0.00381	0.2	0.19	Coronary artery disease;	chr7:107364227	chr7:107192559~107193300:-
THCA	cis	rs6715284	0.579	rs6716325	ENSG00000238829.1	RNU7-45P	-4.13	4.37e-05	0.00381	-0.45	-0.19	Rheumatoid arthritis;	chr2:201335540	chr2:201141904~201141966:+
THCA	cis	rs6570726	0.875	rs416243	ENSG00000270638.1	RP3-466P17.1	4.13	4.37e-05	0.00381	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145735570~145737218:+
THCA	cis	rs804280	0.662	rs11784693	ENSG00000254948.1	OR7E158P	4.13	4.37e-05	0.00381	0.25	0.19	Myopia (pathological);	chr8:11753165	chr8:11919900~11920809:-
THCA	cis	rs6479891	0.722	rs4746951	ENSG00000272767.1	JMJD1C-AS1	4.13	4.37e-05	0.00381	0.24	0.19	Arthritis (juvenile idiopathic);	chr10:63123839	chr10:63465229~63466563:+
THCA	cis	rs7824557	0.505	rs2736313	ENSG00000206014.6	OR7E161P	-4.13	4.37e-05	0.00381	-0.22	-0.19	Retinal vascular caliber;	chr8:11229433	chr8:11928597~11929563:-
THCA	cis	rs12612619	0.732	rs7560144	ENSG00000272148.1	RP11-195B17.1	4.13	4.38e-05	0.00381	0.17	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057592	chr2:27062428~27062907:-
THCA	cis	rs3198697	1	rs3198697	ENSG00000260872.1	RP11-680G24.5	4.13	4.38e-05	0.00381	0.19	0.19	Triglycerides;	chr16:15036083	chr16:15018106~15020488:-
THCA	cis	rs4434872	0.536	rs1127092	ENSG00000223599.1	RP11-216N14.7	-4.13	4.38e-05	0.00381	-0.36	-0.19	Conduct disorder (symptom count);	chr1:153806760	chr1:153852106~153853414:-
THCA	cis	rs763121	0.925	rs17032	ENSG00000228274.3	RP3-508I15.9	-4.13	4.38e-05	0.00381	-0.2	-0.19	Menopause (age at onset);	chr22:38734838	chr22:38667585~38681820:-
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000265443.1	CTD-2349P21.6	-4.13	4.38e-05	0.00381	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30726305~30727564:-
THCA	cis	rs4742903	0.904	rs10123189	ENSG00000270332.1	SMC2-AS1	4.13	4.38e-05	0.00381	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104238359	chr9:104080024~104093073:-
THCA	cis	rs7402982	0.647	rs34038360	ENSG00000259424.1	RP11-35O15.1	4.13	4.38e-05	0.00381	0.19	0.19	Birth weight;	chr15:98658344	chr15:98646951~98647371:-
THCA	cis	rs494526	0.967	rs1500986	ENSG00000229272.1	RP11-498J9.2	-4.13	4.38e-05	0.00381	-0.21	-0.19	Alcoholic chronic pancreatitis;	chr10:119029035	chr10:119003536~119003884:-
THCA	cis	rs9326246	0.545	rs516043	ENSG00000254851.1	RP11-109L13.1	4.13	4.38e-05	0.00381	0.42	0.19	Coronary artery disease;	chr11:116648867	chr11:117135528~117138582:+
THCA	cis	rs2191566	0.664	rs3810406	ENSG00000266921.1	RP11-15A1.7	-4.13	4.38e-05	0.00381	-0.17	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44052228	chr19:43996896~44002836:-
THCA	cis	rs4767841	0.565	rs7133437	ENSG00000252886.1	RN7SKP197	-4.13	4.38e-05	0.00381	-0.18	-0.19	Urgency urinary incontinence;	chr12:119778806	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.625	rs7969405	ENSG00000252886.1	RN7SKP197	-4.13	4.38e-05	0.00381	-0.18	-0.19	Urgency urinary incontinence;	chr12:119780035	chr12:119631090~119631386:-
THCA	cis	rs600231	0.708	rs602838	ENSG00000254614.2	AP003068.23	4.13	4.38e-05	0.00381	0.24	0.19	Bone mineral density;	chr11:65485776	chr11:65177606~65181834:-
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000265443.1	CTD-2349P21.6	-4.13	4.38e-05	0.00382	-0.31	-0.19	Body mass index;	chr17:30752751	chr17:30726305~30727564:-
THCA	cis	rs11671005	0.737	rs11673101	ENSG00000265272.2	RN7SL693P	4.13	4.38e-05	0.00382	0.27	0.19	Mean platelet volume;	chr19:58483686	chr19:58490797~58491075:+
THCA	cis	rs2018683	0.707	rs10279870	ENSG00000272568.4	CTB-113D17.1	4.13	4.38e-05	0.00382	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929318	chr7:28979967~29013367:+
THCA	cis	rs3755605	0.76	rs10936612	ENSG00000242578.1	RP11-469J4.3	4.13	4.38e-05	0.00382	0.21	0.19	Testicular germ cell tumor;	chr3:170127086	chr3:170410512~170418615:+
THCA	cis	rs9650657	0.504	rs6601565	ENSG00000255046.1	RP11-297N6.4	4.13	4.38e-05	0.00382	0.2	0.19	Neuroticism;	chr8:11174719	chr8:11797928~11802568:-
THCA	cis	rs9611565	0.592	rs12484467	ENSG00000237037.8	NDUFA6-AS1	4.13	4.38e-05	0.00382	0.18	0.19	Vitiligo;	chr22:41561606	chr22:42090931~42137742:+
THCA	cis	rs656319	0.559	rs17689037	ENSG00000261451.1	RP11-981G7.1	-4.13	4.38e-05	0.00382	-0.23	-0.19	Myopia (pathological);	chr8:10117348	chr8:10433672~10438312:+
THCA	cis	rs1476587	0.92	rs10487071	ENSG00000224046.1	AC005076.5	4.13	4.38e-05	0.00382	0.17	0.19	Brachial circumference;	chr7:87108266	chr7:87151423~87152420:-
THCA	cis	rs9402682	0.558	rs6929404	ENSG00000232876.1	CTA-212D2.2	-4.13	4.38e-05	0.00382	-0.26	-0.19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135132889	chr6:135055033~135060550:+
THCA	cis	rs11633886	0.934	rs11630229	ENSG00000259200.1	RP11-718O11.1	-4.13	4.38e-05	0.00382	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45795811	chr15:45705078~45931069:+
THCA	cis	rs6479891	0.915	rs2616628	ENSG00000272767.1	JMJD1C-AS1	4.13	4.38e-05	0.00382	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs2393980	ENSG00000272767.1	JMJD1C-AS1	4.13	4.38e-05	0.00382	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12414159	ENSG00000272767.1	JMJD1C-AS1	4.13	4.38e-05	0.00382	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs10995543	ENSG00000272767.1	JMJD1C-AS1	4.13	4.38e-05	0.00382	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.818	rs2393976	ENSG00000272767.1	JMJD1C-AS1	4.13	4.38e-05	0.00382	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs72837056	ENSG00000272767.1	JMJD1C-AS1	4.13	4.38e-05	0.00382	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.818	rs11815969	ENSG00000272767.1	JMJD1C-AS1	4.13	4.38e-05	0.00382	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63465229~63466563:+
THCA	cis	rs7818688	0.578	rs13279040	ENSG00000253528.2	RP11-347C18.4	-4.13	4.38e-05	0.00382	-0.28	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95068161	chr8:94974573~94974853:-
THCA	cis	rs7927592	0.956	rs7106259	ENSG00000160172.9	FAM86C2P	4.12	4.38e-05	0.00382	0.18	0.19	Total body bone mineral density;	chr11:68531044	chr11:67791648~67805336:-
THCA	cis	rs2590942	0.506	rs12742474	ENSG00000227207.2	RPL31P12	4.12	4.38e-05	0.00382	0.33	0.19	Childhood body mass index;	chr1:72091465	chr1:72301472~72301829:+
THCA	cis	rs72928364	1	rs35974360	ENSG00000256628.3	ZBTB11-AS1	4.12	4.39e-05	0.00382	0.33	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101038441	chr3:101676475~101679217:+
THCA	cis	rs4767841	0.537	rs7299548	ENSG00000252886.1	RN7SKP197	-4.12	4.39e-05	0.00382	-0.18	-0.19	Urgency urinary incontinence;	chr12:119778650	chr12:119631090~119631386:-
THCA	cis	rs875971	0.789	rs7808013	ENSG00000229886.1	RP5-1132H15.3	-4.12	4.39e-05	0.00382	-0.2	-0.19	Aortic root size;	chr7:66606209	chr7:66025126~66031544:-
THCA	cis	rs2164068	0.57	rs700677	ENSG00000231621.1	AC013264.2	4.12	4.39e-05	0.00382	0.19	0.19	Allergy;	chr2:197837700	chr2:197197991~197199273:+
THCA	cis	rs889398	0.967	rs2032912	ENSG00000226232.7	RP11-419C5.2	4.12	4.39e-05	0.00382	0.18	0.19	Body mass index;	chr16:69534400	chr16:69976388~69996188:-
THCA	cis	rs4906332	1	rs4900574	ENSG00000252469.1	RNU7-160P	-4.12	4.39e-05	0.00382	-0.2	-0.19	Coronary artery disease;	chr14:103412687	chr14:103550345~103550406:+
THCA	cis	rs860295	0.557	rs11264371	ENSG00000236675.1	MTX1P1	-4.12	4.39e-05	0.00382	-0.2	-0.19	Body mass index;	chr1:155442246	chr1:155230975~155234325:+
THCA	cis	rs7131987	0.565	rs10843365	ENSG00000257176.2	RP11-996F15.2	4.12	4.39e-05	0.00382	0.19	0.19	QT interval;	chr12:29252691	chr12:29280418~29317848:-
THCA	cis	rs853679	0.882	rs9461432	ENSG00000273712.1	RP5-874C20.7	4.12	4.39e-05	0.00382	0.32	0.19	Depression;	chr6:28119105	chr6:28315613~28315883:-
THCA	cis	rs72615157	0.606	rs941288	ENSG00000242294.5	STAG3L5P	4.12	4.39e-05	0.00382	0.11	0.19	Lung function (FEV1/FVC);	chr7:100179185	chr7:100336079~100351900:+
THCA	cis	rs733175	0.951	rs6846692	ENSG00000261490.1	RP11-448G15.3	4.12	4.39e-05	0.00382	0.15	0.19	Psychosis and Alzheimer's disease;	chr4:10029509	chr4:10068089~10073019:-
THCA	cis	rs7824557	0.564	rs11782430	ENSG00000154316.13	TDH	4.12	4.39e-05	0.00382	0.14	0.19	Retinal vascular caliber;	chr8:11368562	chr8:11339637~11368452:+
THCA	cis	rs1836229	0.805	rs10815964	ENSG00000225706.1	PTPRD-AS1	-4.12	4.39e-05	0.00382	-0.22	-0.19	Restless legs syndrome;	chr9:8826108	chr9:8858130~8862255:+
THCA	cis	rs7520050	0.778	rs3014216	ENSG00000281133.1	AL355480.3	-4.12	4.39e-05	0.00382	-0.22	-0.19	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45580892~45580996:-
THCA	cis	rs7824557	0.564	rs13260727	ENSG00000154316.13	TDH	-4.12	4.39e-05	0.00382	-0.14	-0.19	Retinal vascular caliber;	chr8:11375351	chr8:11339637~11368452:+
THCA	cis	rs3002142	0.908	rs3002143	ENSG00000272750.1	RP11-378J18.8	-4.12	4.39e-05	0.00382	-0.25	-0.19	LDL peak particle diameter (total fat intake interaction);	chr1:222615512	chr1:222658867~222661512:-
THCA	cis	rs17095355	0.792	rs61881587	ENSG00000203876.8	ADD3-AS1	-4.12	4.39e-05	0.00382	-0.21	-0.19	Biliary atresia;	chr10:109999952	chr10:109940104~110008381:-
THCA	cis	rs2286503	0.78	rs2240727	ENSG00000228649.7	AC005682.5	4.12	4.39e-05	0.00382	0.23	0.19	Fibrinogen;	chr7:22812893	chr7:22854178~22861579:+
THCA	cis	rs17685	0.712	rs60232511	ENSG00000230882.1	AC005077.14	4.12	4.39e-05	0.00382	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76170764	chr7:76071469~76074963:-
THCA	cis	rs7572733	0.534	rs1401091	ENSG00000231621.1	AC013264.2	4.12	4.39e-05	0.00382	0.2	0.19	Dermatomyositis;	chr2:197925699	chr2:197197991~197199273:+
THCA	cis	rs4713118	0.869	rs9283883	ENSG00000220721.1	OR1F12	4.12	4.39e-05	0.00383	0.25	0.19	Parkinson's disease;	chr6:27747691	chr6:28073316~28074233:+
THCA	cis	rs11247915	0.622	rs36024412	ENSG00000236782.4	RP11-96L14.7	-4.12	4.39e-05	0.00383	-0.23	-0.19	Obesity-related traits;	chr1:26343953	chr1:26169947~26171821:-
THCA	cis	rs600231	0.554	rs1346	ENSG00000245532.5	NEAT1	4.12	4.4e-05	0.00383	0.16	0.19	Bone mineral density;	chr11:65569780	chr11:65422774~65445540:+
THCA	cis	rs1552244	0.572	rs7645759	ENSG00000180385.7	EMC3-AS1	4.12	4.4e-05	0.00383	0.24	0.19	Alzheimer's disease;	chr3:10115684	chr3:9986893~10006990:+
THCA	cis	rs13178541	0.81	rs7705245	ENSG00000250378.1	RP11-119J18.1	-4.12	4.4e-05	0.00383	-0.24	-0.19	IgG glycosylation;	chr5:135849056	chr5:135812667~135826582:+
THCA	cis	rs181553	0.664	rs1965843	ENSG00000266696.1	RP11-30L3.2	4.12	4.4e-05	0.00383	0.23	0.19	Hip circumference adjusted for BMI;	chr18:49155947	chr18:49205912~49208781:+
THCA	cis	rs74233809	1	rs11191587	ENSG00000272912.1	RP11-724N1.1	-4.12	4.4e-05	0.00383	-0.34	-0.19	Birth weight;	chr10:103169959	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs11191593	ENSG00000272912.1	RP11-724N1.1	-4.12	4.4e-05	0.00383	-0.34	-0.19	Birth weight;	chr10:103179458	chr10:102914585~102915404:+
THCA	cis	rs6696239	0.956	rs12138229	ENSG00000227711.2	RP11-275O4.5	-4.12	4.4e-05	0.00383	-0.25	-0.19	Height;	chr1:227712437	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.956	rs11576992	ENSG00000227711.2	RP11-275O4.5	-4.12	4.4e-05	0.00383	-0.25	-0.19	Height;	chr1:227714105	chr1:227509028~227520477:-
THCA	cis	rs6878727	0.665	rs698184	ENSG00000253807.4	LINC01170	-4.12	4.4e-05	0.00383	-0.17	-0.19	Breast cancer;	chr5:124328916	chr5:124059794~124405079:-
THCA	cis	rs3740713	1	rs75740864	ENSG00000256464.1	YWHABP2	4.12	4.4e-05	0.00383	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr11:18490243~18490955:-
THCA	cis	rs11146838	1	rs11146838	ENSG00000099251.13	HSD17B7P2	4.12	4.4e-05	0.00383	0.16	0.19	Breast cancer;	chr10:38856846	chr10:38356380~38378505:+
THCA	cis	rs7267979	1	rs2482927	ENSG00000276952.1	RP5-965G21.6	-4.12	4.4e-05	0.00383	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25284915~25285588:-
THCA	cis	rs7617480	0.648	rs9864243	ENSG00000229759.1	MRPS18AP1	4.12	4.4e-05	0.00383	0.28	0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48945299	chr3:48256350~48256938:-
THCA	cis	rs1267303	0.675	rs1745370	ENSG00000232022.5	FAAHP1	-4.12	4.4e-05	0.00383	-0.22	-0.19	Monobrow;	chr1:46517191	chr1:46432129~46445521:+
THCA	cis	rs16852403	0.505	rs316270	ENSG00000224687.1	RASAL2-AS1	-4.12	4.4e-05	0.00383	-0.27	-0.19	Childhood ear infection;	chr1:178195622	chr1:178091508~178093984:-
THCA	cis	rs4819052	0.679	rs28623526	ENSG00000273796.1	LL21NC02-21A1.1	-4.12	4.4e-05	0.00383	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45403809~45404369:-
THCA	cis	rs13325613	0.834	rs3136672	ENSG00000223552.1	RP11-24F11.2	-4.12	4.4e-05	0.00383	-0.27	-0.19	Monocyte count;	chr3:46201294	chr3:46364955~46407059:-
THCA	cis	rs17095355	0.748	rs2060675	ENSG00000203876.8	ADD3-AS1	4.12	4.4e-05	0.00383	0.2	0.19	Biliary atresia;	chr10:110013665	chr10:109940104~110008381:-
THCA	cis	rs796395	0.576	rs903349	ENSG00000232480.1	TGFB2-AS1	-4.12	4.4e-05	0.00383	-0.21	-0.19	Post bronchodilator FEV1/FVC ratio;	chr1:218467954	chr1:218344196~218345678:-
THCA	cis	rs11673344	0.526	rs35153242	ENSG00000267422.1	CTD-2554C21.1	-4.12	4.4e-05	0.00383	-0.19	-0.19	Obesity-related traits;	chr19:37660841	chr19:37779686~37792865:+
THCA	cis	rs1560104	0.709	rs9806831	ENSG00000259876.1	CTD-3037G24.4	4.12	4.4e-05	0.00383	0.22	0.19	Obesity-related traits;	chr16:12610538	chr16:12556353~12557694:-
THCA	cis	rs7824557	0.583	rs2736306	ENSG00000206014.6	OR7E161P	-4.12	4.4e-05	0.00383	-0.22	-0.19	Retinal vascular caliber;	chr8:11382253	chr8:11928597~11929563:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000229180.5	GS1-124K5.11	-4.12	4.4e-05	0.00383	-0.13	-0.19	Aortic root size;	chr7:66570949	chr7:66526088~66542624:-
THCA	cis	rs8062405	0.824	rs62034319	ENSG00000270424.1	RP11-1348G14.6	4.12	4.4e-05	0.00383	0.21	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28749959~28750595:-
THCA	cis	rs4650994	0.571	rs11588907	ENSG00000273384.1	RP5-1098D14.1	-4.12	4.41e-05	0.00383	-0.24	-0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178540327	chr1:178651706~178652282:+
THCA	cis	rs1334894	0.892	rs9689799	ENSG00000228559.1	RP3-340B19.3	-4.12	4.41e-05	0.00383	-0.41	-0.19	Coronary artery disease;	chr6:35505280	chr6:35544632~35545669:+
THCA	cis	rs736408	0.562	rs13071584	ENSG00000243224.1	RP5-1157M23.2	-4.12	4.41e-05	0.00383	-0.2	-0.19	Bipolar disorder;	chr3:52770471	chr3:52239258~52241097:+
THCA	cis	rs736408	0.522	rs998909	ENSG00000243224.1	RP5-1157M23.2	-4.12	4.41e-05	0.00383	-0.2	-0.19	Bipolar disorder;	chr3:52771077	chr3:52239258~52241097:+
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000229180.5	GS1-124K5.11	-4.12	4.41e-05	0.00384	-0.15	-0.19	Corneal structure;	chr7:66872661	chr7:66526088~66542624:-
THCA	cis	rs116139393	0.571	rs3801035	ENSG00000187953.9	PMS2CL	-4.12	4.41e-05	0.00384	-0.32	-0.19	Alzheimer's disease (APOE e4 interaction);	chr7:6695903	chr7:6710128~6753862:+
THCA	cis	rs116139393	0.634	rs17789828	ENSG00000187953.9	PMS2CL	-4.12	4.41e-05	0.00384	-0.32	-0.19	Alzheimer's disease (APOE e4 interaction);	chr7:6699006	chr7:6710128~6753862:+
THCA	cis	rs7119	0.637	rs12913005	ENSG00000259362.2	RP11-307C19.1	-4.12	4.41e-05	0.00384	-0.27	-0.19	Type 2 diabetes;	chr15:77564229	chr15:77525540~77534110:+
THCA	cis	rs3892630	0.588	rs2112917	ENSG00000267475.1	CTD-2538C1.2	-4.12	4.41e-05	0.00384	-0.25	-0.19	Red blood cell traits;	chr19:32826637	chr19:32687089~32691750:-
THCA	cis	rs420259	0.516	rs11642434	ENSG00000260136.4	CTD-2270L9.4	4.12	4.41e-05	0.00384	0.15	0.19	Bipolar disorder;	chr16:23528916	chr16:23452758~23457606:+
THCA	cis	rs10802047	0.609	rs10923658	ENSG00000231365.4	RP11-418J17.1	-4.12	4.41e-05	0.00384	-0.19	-0.19	Relative hand skill in reading disability;	chr1:118730156	chr1:119140396~119275973:+
THCA	cis	rs12935229	0.756	rs12149530	ENSG00000260922.1	RP11-538I12.3	-4.12	4.41e-05	0.00384	-0.3	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77272806	chr16:77234877~77290934:+
THCA	cis	rs651907	0.64	rs771574	ENSG00000256628.3	ZBTB11-AS1	4.12	4.41e-05	0.00384	0.21	0.19	Colorectal cancer;	chr3:101901838	chr3:101676475~101679217:+
THCA	cis	rs9402682	0.629	rs2223385	ENSG00000232876.1	CTA-212D2.2	-4.12	4.41e-05	0.00384	-0.25	-0.19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135114033	chr6:135055033~135060550:+
THCA	cis	rs7178375	0.941	rs35497908	ENSG00000269930.1	RP11-932O9.9	-4.12	4.41e-05	0.00384	-0.25	-0.19	Hypertriglyceridemia;	chr15:30931868	chr15:30616958~30617749:+
THCA	cis	rs17801127	0.818	rs34131478	ENSG00000231969.1	AC144449.1	4.12	4.41e-05	0.00384	0.38	0.19	Liver enzyme levels (alanine transaminase);	chr2:149802126	chr2:149587196~149848233:+
THCA	cis	rs9532669	0.926	rs9532654	ENSG00000229473.2	RGS17P1	4.12	4.41e-05	0.00384	0.24	0.19	Cervical cancer;	chr13:40909812	chr13:40992779~40993331:-
THCA	cis	rs950169	0.922	rs11630507	ENSG00000275120.1	RP11-182J1.17	4.12	4.41e-05	0.00384	0.22	0.19	Schizophrenia;	chr15:84552494	chr15:84599434~84606463:-
THCA	cis	rs4906332	0.966	rs2065016	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103413319	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs34479426	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103415486	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs8012127	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103476425	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs78316803	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103476526	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs17617832	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103476803	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs11625172	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103478575	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs17617935	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103486549	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs17680085	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103486817	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs12896919	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103490376	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs35126287	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103493095	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs55930273	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103493961	chr14:103412119~103412761:-
THCA	cis	rs875971	0.66	rs10263935	ENSG00000223473.2	GS1-124K5.3	4.12	4.41e-05	0.00384	0.12	0.19	Aortic root size;	chr7:66631041	chr7:66491049~66493566:-
THCA	cis	rs55702914	0.904	rs73050839	ENSG00000231621.1	AC013264.2	-4.12	4.41e-05	0.00384	-0.18	-0.19	Major depression and alcohol dependence;	chr2:197366494	chr2:197197991~197199273:+
THCA	cis	rs12440869	0.96	rs8034421	ENSG00000270964.1	RP11-502I4.3	4.12	4.41e-05	0.00384	0.16	0.19	Peak velocity of the mitral A-wave;	chr15:67210234	chr15:67541072~67542604:-
THCA	cis	rs58365266	1	rs58365266	ENSG00000207650.1	MIR570	4.12	4.41e-05	0.00384	0.27	0.19	Red cell distribution width;	chr3:196086886	chr3:195699401~195699497:+
THCA	cis	rs72627509	0.638	rs12648928	ENSG00000269949.1	RP11-738E22.3	4.12	4.41e-05	0.00384	0.31	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57036340	chr4:56960927~56961373:-
THCA	cis	rs4906332	0.868	rs4900578	ENSG00000244691.1	RPL10AP1	-4.12	4.41e-05	0.00384	-0.24	-0.19	Coronary artery disease;	chr14:103459673	chr14:103412119~103412761:-
THCA	cis	rs72928364	1	rs41386544	ENSG00000256628.3	ZBTB11-AS1	-4.12	4.42e-05	0.00384	-0.32	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101040223	chr3:101676475~101679217:+
THCA	cis	rs2692947	0.832	rs2579550	ENSG00000235584.2	AC008268.1	-4.12	4.42e-05	0.00384	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96076196	chr2:95666084~95668715:+
THCA	cis	rs2380205	0.967	rs907685	ENSG00000232807.2	RP11-536K7.3	4.12	4.42e-05	0.00384	0.17	0.19	Breast cancer;	chr10:5858369	chr10:5934270~5945900:-
THCA	cis	rs2436845	0.627	rs34352733	ENSG00000253320.4	KB-1507C5.2	-4.12	4.42e-05	0.00384	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102819280	chr8:102864300~102977876:+
THCA	cis	rs875971	0.545	rs313830	ENSG00000273024.4	INTS4P2	4.12	4.42e-05	0.00384	0.24	0.19	Aortic root size;	chr7:66086944	chr7:65647864~65715661:+
THCA	cis	rs3893377	0.848	rs10222984	ENSG00000214846.4	RP11-115L11.1	4.12	4.42e-05	0.00384	0.25	0.19	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15740080	chr4:15730962~15731627:-
THCA	cis	rs10435719	0.867	rs6999030	ENSG00000254948.1	OR7E158P	-4.12	4.42e-05	0.00384	-0.23	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.834	rs6985792	ENSG00000254948.1	OR7E158P	-4.12	4.42e-05	0.00384	-0.23	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:11919900~11920809:-
THCA	cis	rs5758659	1	rs5758677	ENSG00000273366.1	CTA-989H11.1	-4.12	4.42e-05	0.00384	-0.23	-0.19	Cognitive function;	chr22:42247033	chr22:42278188~42278846:+
THCA	cis	rs699371	0.503	rs12894033	ENSG00000270000.1	RP3-449M8.9	4.12	4.42e-05	0.00384	0.18	0.19	Height;	chr14:74428651	chr14:74471930~74472360:-
THCA	cis	rs10050311	0.698	rs78818211	ENSG00000251411.1	RP11-397E7.4	-4.12	4.42e-05	0.00384	-0.22	-0.19	Insulin-related traits;	chr4:86715235	chr4:86913266~86914817:-
THCA	cis	rs4688759	0.609	rs113176147	ENSG00000270441.1	RP11-694I15.7	4.12	4.42e-05	0.00384	0.3	0.19	Blood protein levels;	chr3:49497006	chr3:49140086~49160851:-
THCA	cis	rs786425	0.677	rs10846537	ENSG00000278112.1	RP11-972P1.11	4.12	4.42e-05	0.00384	0.18	0.19	Pubertal anthropometrics;	chr12:123653799	chr12:123519390~123519856:-
THCA	cis	rs801193	1	rs17566701	ENSG00000230295.1	RP11-458F8.2	-4.12	4.42e-05	0.00384	-0.15	-0.19	Aortic root size;	chr7:66728196	chr7:66880708~66882981:+
THCA	cis	rs4578769	0.959	rs3911557	ENSG00000265939.1	UBE2CP2	-4.12	4.42e-05	0.00384	-0.23	-0.19	Eosinophil percentage of white cells;	chr18:22892600	chr18:22900486~22900995:-
THCA	cis	rs1198872	0.892	rs1198866	ENSG00000272275.1	RP11-791G15.2	-4.12	4.42e-05	0.00384	-0.22	-0.19	Cardiac Troponin-T levels;	chr2:10761664	chr2:10767875~10770058:-
THCA	cis	rs3733585	0.605	rs4697708	ENSG00000261490.1	RP11-448G15.3	-4.12	4.42e-05	0.00384	-0.12	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:10119565	chr4:10068089~10073019:-
THCA	cis	rs4803480	0.543	rs7257282	ENSG00000267107.5	PCAT19	4.12	4.42e-05	0.00385	0.22	0.19	Schizophrenia;	chr19:41536585	chr19:41454169~41500649:-
THCA	cis	rs332034	0.591	rs7017739	ENSG00000253893.2	FAM85B	4.12	4.42e-05	0.00385	0.33	0.19	Conduct disorder (maternal expressed emotions interaction);	chr8:8850129	chr8:8167819~8226614:-
THCA	cis	rs1861628	0.512	rs6435953	ENSG00000237930.1	AC007563.4	4.12	4.42e-05	0.00385	0.27	0.19	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216763364	chr2:216785774~216786144:-
THCA	cis	rs893363	0.583	rs4687586	ENSG00000271916.1	RP11-884K10.6	-4.12	4.42e-05	0.00385	-0.23	-0.19	Axial length;	chr3:53803944	chr3:53797764~53798019:-
THCA	cis	rs8062405	0.754	rs149299	ENSG00000261766.1	RP11-22P6.2	-4.12	4.42e-05	0.00385	-0.18	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28862166~28863340:-
THCA	cis	rs7577696	0.695	rs6716179	ENSG00000276334.1	AL133243.1	-4.12	4.42e-05	0.00385	-0.2	-0.19	Inflammatory biomarkers;	chr2:32168007	chr2:32521927~32523547:+
THCA	cis	rs6696239	1	rs951084	ENSG00000227711.2	RP11-275O4.5	-4.12	4.42e-05	0.00385	-0.27	-0.19	Height;	chr1:227512551	chr1:227509028~227520477:-
THCA	cis	rs56379725	1	rs56379725	ENSG00000214783.8	POLR2J4	4.12	4.42e-05	0.00385	0.24	0.19	Peak insulin response;	chr7:43819816	chr7:43940895~44019175:-
THCA	cis	rs72949976	1	rs72949976	ENSG00000270659.1	RP11-105N14.1	4.12	4.42e-05	0.00385	0.15	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213169380	chr2:213152970~213153659:+
THCA	cis	rs9595908	0.686	rs9591314	ENSG00000212293.1	SNORA16	4.12	4.43e-05	0.00385	0.22	0.19	Body mass index;	chr13:32760248	chr13:32420390~32420516:-
THCA	cis	rs1908814	0.516	rs13281077	ENSG00000206014.6	OR7E161P	-4.12	4.43e-05	0.00385	-0.22	-0.19	Neuroticism;	chr8:11937305	chr8:11928597~11929563:-
THCA	cis	rs7560272	0.564	rs4852939	ENSG00000273245.1	RP11-434P11.2	4.12	4.43e-05	0.00385	0.22	0.19	Schizophrenia;	chr2:73629642	chr2:73750256~73750786:-
THCA	cis	rs3128341	1	rs78095791	ENSG00000227207.2	RPL31P12	4.12	4.43e-05	0.00385	0.29	0.19	Intelligence (multi-trait analysis);	chr1:72346274	chr1:72301472~72301829:+
THCA	cis	rs17604090	0.887	rs7795109	ENSG00000227855.3	DPY19L2P3	4.12	4.43e-05	0.00385	0.22	0.19	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29626628	chr7:29650227~29742594:+
THCA	cis	rs2839186	0.9	rs2839196	ENSG00000215424.8	MCM3AP-AS1	4.12	4.43e-05	0.00385	0.11	0.19	Testicular germ cell tumor;	chr21:46288123	chr21:46229217~46259390:+
THCA	cis	rs13034020	0.79	rs13026050	ENSG00000271889.1	RP11-493E12.1	-4.12	4.43e-05	0.00385	-0.27	-0.19	Hodgkin's lymphoma;	chr2:60908878	chr2:61151433~61162105:-
THCA	cis	rs4908768	0.501	rs1463051	ENSG00000270282.1	RP5-1115A15.2	-4.12	4.43e-05	0.00385	-0.22	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8512653~8513021:+
THCA	cis	rs7818688	0.578	rs71532343	ENSG00000253528.2	RP11-347C18.4	-4.12	4.43e-05	0.00385	-0.28	-0.19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95064585	chr8:94974573~94974853:-
THCA	cis	rs10875746	0.903	rs17122666	ENSG00000258234.1	RP11-370I10.2	4.12	4.43e-05	0.00385	0.22	0.19	Longevity (90 years and older);	chr12:48108791	chr12:48231098~48284210:-
THCA	cis	rs10181042	0.565	rs3108630	ENSG00000270820.4	RP11-355B11.2	-4.12	4.43e-05	0.00385	-0.15	-0.19	Crohn's disease;	chr2:61041025	chr2:61471188~61484130:+
THCA	cis	rs7136259	0.844	rs2681485	ENSG00000258302.2	RP11-981P6.1	-4.12	4.43e-05	0.00385	-0.16	-0.19	Coronary heart disease;	chr12:89631845	chr12:89561129~89594878:+
THCA	cis	rs9595908	0.568	rs4942923	ENSG00000212293.1	SNORA16	4.12	4.43e-05	0.00385	0.22	0.19	Body mass index;	chr13:32806887	chr13:32420390~32420516:-
THCA	cis	rs3767627	1	rs10494260	ENSG00000203819.6	HIST2H2BC	4.12	4.43e-05	0.00385	0.26	0.19	Height;	chr1:149971856	chr1:149850193~149850772:-
THCA	cis	rs17092148	0.887	rs2295443	ENSG00000276073.1	RP5-1125A11.7	-4.12	4.43e-05	0.00385	-0.23	-0.19	Neuroticism;	chr20:34586023	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.836	rs4564863	ENSG00000276073.1	RP5-1125A11.7	-4.12	4.43e-05	0.00385	-0.23	-0.19	Neuroticism;	chr20:34591563	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.887	rs6059936	ENSG00000276073.1	RP5-1125A11.7	-4.12	4.43e-05	0.00385	-0.23	-0.19	Neuroticism;	chr20:34596445	chr20:33985617~33988989:-
THCA	cis	rs740160	0.51	rs733991	ENSG00000244219.5	GS1-259H13.2	-4.12	4.43e-05	0.00385	-0.28	-0.19	Dehydroepiandrosterone sulphate levels;	chr7:99297627	chr7:99598066~99610813:+
THCA	cis	rs875971	0.545	rs73376394	ENSG00000273142.1	RP11-458F8.4	4.12	4.43e-05	0.00385	0.17	0.19	Aortic root size;	chr7:66172694	chr7:66902857~66906297:+
THCA	cis	rs9309473	0.95	rs6745480	ENSG00000273245.1	RP11-434P11.2	4.12	4.43e-05	0.00385	0.25	0.19	Metabolite levels;	chr2:73612928	chr2:73750256~73750786:-
THCA	cis	rs6696239	1	rs10916157	ENSG00000227711.2	RP11-275O4.5	-4.12	4.43e-05	0.00385	-0.26	-0.19	Height;	chr1:227526776	chr1:227509028~227520477:-
THCA	cis	rs9595908	0.686	rs8001047	ENSG00000212293.1	SNORA16	-4.12	4.43e-05	0.00385	-0.21	-0.19	Body mass index;	chr13:32802746	chr13:32420390~32420516:-
THCA	cis	rs6088813	1	rs2248393	ENSG00000279253.1	RP4-614O4.13	-4.12	4.43e-05	0.00386	-0.18	-0.19	Height;	chr20:35338300	chr20:35262727~35264187:-
THCA	cis	rs4803480	0.786	rs4803479	ENSG00000270164.1	LINC01480	-4.12	4.43e-05	0.00386	-0.16	-0.19	Schizophrenia;	chr19:41551234	chr19:41535183~41536904:+
THCA	cis	rs6496932	0.802	rs56306166	ENSG00000259630.2	CTD-2262B20.1	4.12	4.44e-05	0.00386	0.23	0.19	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85415228~85415633:+
THCA	cis	rs12410462	0.551	rs12059899	ENSG00000227711.2	RP11-275O4.5	-4.12	4.44e-05	0.00386	-0.22	-0.19	Major depressive disorder;	chr1:227675708	chr1:227509028~227520477:-
THCA	cis	rs3808502	0.534	rs1529858	ENSG00000154316.13	TDH	-4.12	4.44e-05	0.00386	-0.14	-0.19	Neuroticism;	chr8:11288153	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.619	rs7012218	ENSG00000154316.13	TDH	-4.12	4.44e-05	0.00386	-0.14	-0.19	Retinal vascular caliber;	chr8:11288167	chr8:11339637~11368452:+
THCA	cis	rs3808502	0.501	rs7012219	ENSG00000154316.13	TDH	-4.12	4.44e-05	0.00386	-0.14	-0.19	Neuroticism;	chr8:11288170	chr8:11339637~11368452:+
THCA	cis	rs2562456	0.754	rs112195516	ENSG00000268117.1	VN1R84P	4.12	4.44e-05	0.00386	0.3	0.19	Pain;	chr19:21410849	chr19:21719801~21720035:-
THCA	cis	rs57502260	0.764	rs7105218	ENSG00000212093.1	AP000807.1	4.12	4.44e-05	0.00386	0.24	0.19	Total body bone mineral density (age 45-60);	chr11:68454993	chr11:68506083~68506166:-
THCA	cis	rs988712	0.705	rs10767654	ENSG00000245573.6	BDNF-AS	4.12	4.44e-05	0.00386	0.18	0.19	Obesity;	chr11:27618676	chr11:27506838~27698174:+
THCA	cis	rs55661361	0.708	rs12278912	ENSG00000245498.5	RP11-677M14.7	4.12	4.44e-05	0.00386	0.14	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742263	chr11:124800450~124834487:+
THCA	cis	rs801193	0.935	rs11772264	ENSG00000230295.1	RP11-458F8.2	-4.12	4.44e-05	0.00386	-0.14	-0.19	Aortic root size;	chr7:66711400	chr7:66880708~66882981:+
THCA	cis	rs4906332	0.966	rs12588705	ENSG00000244691.1	RPL10AP1	-4.12	4.44e-05	0.00386	-0.24	-0.19	Coronary artery disease;	chr14:103399140	chr14:103412119~103412761:-
THCA	cis	rs4906332	0.966	rs59858038	ENSG00000244691.1	RPL10AP1	-4.12	4.44e-05	0.00386	-0.24	-0.19	Coronary artery disease;	chr14:103400765	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs12889703	ENSG00000244691.1	RPL10AP1	-4.12	4.44e-05	0.00386	-0.24	-0.19	Coronary artery disease;	chr14:103406614	chr14:103412119~103412761:-
THCA	cis	rs1665050	0.598	rs8041221	ENSG00000277144.1	RP11-59H7.4	-4.12	4.44e-05	0.00386	-0.25	-0.19	Atopic dermatitis;	chr15:59042609	chr15:59115547~59116089:-
THCA	cis	rs6921919	0.583	rs6928771	ENSG00000273712.1	RP5-874C20.7	4.12	4.44e-05	0.00386	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28315613~28315883:-
THCA	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	4.12	4.44e-05	0.00386	0.17	0.19	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	4.12	4.44e-05	0.00386	0.17	0.19	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	4.12	4.44e-05	0.00386	0.17	0.19	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
THCA	cis	rs4767841	0.565	rs440299	ENSG00000248636.5	RP11-768F21.1	-4.12	4.44e-05	0.00386	-0.19	-0.19	Urgency urinary incontinence;	chr12:119782478	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.565	rs385959	ENSG00000248636.5	RP11-768F21.1	-4.12	4.44e-05	0.00386	-0.19	-0.19	Urgency urinary incontinence;	chr12:119782785	chr12:119387987~119668079:-
THCA	cis	rs7208859	0.573	rs216442	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.44e-05	0.00386	-0.32	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs216445	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.44e-05	0.00386	-0.32	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs216446	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.44e-05	0.00386	-0.32	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30726305~30727564:-
THCA	cis	rs6433895	0.677	rs11693055	ENSG00000236153.1	AC104076.3	-4.12	4.44e-05	0.00386	-0.23	-0.19	Lymphocyte counts;	chr2:181168567	chr2:180979427~180980090:-
THCA	cis	rs911555	0.755	rs7148567	ENSG00000269958.1	RP11-73M18.8	4.12	4.44e-05	0.00386	0.18	0.19	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs10144051	ENSG00000269958.1	RP11-73M18.8	4.12	4.44e-05	0.00386	0.18	0.19	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103696353~103697163:+
THCA	cis	rs1232027	0.656	rs28027	ENSG00000249655.1	CTC-325J23.2	-4.12	4.44e-05	0.00386	-0.21	-0.19	Huntington's disease progression;	chr5:80756984	chr5:80630313~80631590:-
THCA	cis	rs3824488	0.765	rs74607569	ENSG00000271155.1	RP11-435O5.5	-4.12	4.45e-05	0.00386	-0.28	-0.19	Neuroticism;	chr9:95534841	chr9:95506235~95507636:+
THCA	cis	rs9796	0.621	rs691702	ENSG00000247556.5	OIP5-AS1	4.12	4.45e-05	0.00386	0.15	0.19	Menopause (age at onset);	chr15:41182201	chr15:41283990~41309737:+
THCA	cis	rs9796	0.621	rs690733	ENSG00000247556.5	OIP5-AS1	4.12	4.45e-05	0.00386	0.15	0.19	Menopause (age at onset);	chr15:41184267	chr15:41283990~41309737:+
THCA	cis	rs607541	0.85	rs673208	ENSG00000259520.4	CTD-2651B20.3	-4.12	4.45e-05	0.00386	-0.27	-0.19	Obesity-related traits;	chr15:45644094	chr15:45251580~45279251:-
THCA	cis	rs6479891	1	rs11814792	ENSG00000272767.1	JMJD1C-AS1	4.12	4.45e-05	0.00386	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12413415	ENSG00000272767.1	JMJD1C-AS1	4.12	4.45e-05	0.00386	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63465229~63466563:+
THCA	cis	rs34792	0.528	rs153804	ENSG00000207425.1	Y_RNA	4.12	4.45e-05	0.00387	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15459197	chr16:14915457~14915556:-
THCA	cis	rs12410462	0.551	rs16848029	ENSG00000227711.2	RP11-275O4.5	-4.12	4.45e-05	0.00387	-0.23	-0.19	Major depressive disorder;	chr1:227657582	chr1:227509028~227520477:-
THCA	cis	rs2617170	0.961	rs2617171	ENSG00000245648.1	RP11-277P12.20	4.12	4.45e-05	0.00387	0.19	0.19	Behcet's disease;	chr12:10408680	chr12:10363769~10398506:+
THCA	cis	rs1862618	0.853	rs1833896	ENSG00000234553.1	AC022431.3	-4.12	4.45e-05	0.00387	-0.21	-0.19	Initial pursuit acceleration;	chr5:56801842	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs1862619	ENSG00000234553.1	AC022431.3	-4.12	4.45e-05	0.00387	-0.21	-0.19	Initial pursuit acceleration;	chr5:56802429	chr5:56536583~56537826:-
THCA	cis	rs7737355	0.738	rs13174592	ENSG00000237714.1	P4HA2-AS1	4.12	4.45e-05	0.00387	0.26	0.19	Life satisfaction;	chr5:131628007	chr5:132184876~132192808:+
THCA	cis	rs962856	0.964	rs2171175	ENSG00000236780.4	AC078941.1	4.12	4.45e-05	0.00387	0.22	0.19	Pancreatic cancer;	chr2:67413595	chr2:67123357~67215319:-
THCA	cis	rs17496827	0.753	rs4673024	ENSG00000261428.2	RP11-16P6.1	4.12	4.45e-05	0.00387	0.19	0.19	Anorexia nervosa;	chr2:222496434	chr2:222566899~222569719:-
THCA	cis	rs11951515	0.508	rs7705166	ENSG00000248240.1	RP11-159F24.5	-4.12	4.45e-05	0.00387	-0.2	-0.19	Metabolite levels  (X-11787);	chr5:43587346	chr5:43515274~43525310:+
THCA	cis	rs9863	0.827	rs4930724	ENSG00000269997.1	RP11-214K3.21	-4.12	4.45e-05	0.00387	-0.23	-0.19	White blood cell count;	chr12:123939270	chr12:123966077~123966629:-
THCA	cis	rs7216064	1	rs12451721	ENSG00000278740.1	RP11-147L13.14	4.12	4.45e-05	0.00387	0.22	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942959	chr17:68188547~68189165:+
THCA	cis	rs2590942	0.606	rs2815748	ENSG00000227207.2	RPL31P12	-4.12	4.45e-05	0.00387	-0.3	-0.19	Childhood body mass index;	chr1:72350464	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.786	rs2815747	ENSG00000227207.2	RPL31P12	-4.12	4.45e-05	0.00387	-0.3	-0.19	Childhood body mass index;	chr1:72355443	chr1:72301472~72301829:+
THCA	cis	rs3767627	0.505	rs3738320	ENSG00000203819.6	HIST2H2BC	4.12	4.45e-05	0.00387	0.23	0.19	Height;	chr1:150010677	chr1:149850193~149850772:-
THCA	cis	rs2289700	1	rs8034542	ENSG00000252061.1	RNU6-415P	-4.12	4.45e-05	0.00387	-0.36	-0.19	Bipolar disorder;	chr15:78936029	chr15:78898840~78898936:-
THCA	cis	rs9810089	0.868	rs4630889	ENSG00000273455.1	RP11-305O4.3	4.12	4.45e-05	0.00387	0.24	0.19	Gestational age at birth (child effect);	chr3:136559409	chr3:136087475~136087913:-
THCA	cis	rs734999	0.588	rs4648653	ENSG00000225931.3	RP3-395M20.7	4.12	4.45e-05	0.00387	0.22	0.19	Ulcerative colitis;	chr1:2604456	chr1:2566410~2569888:+
THCA	cis	rs5753037	0.838	rs140145	ENSG00000279699.1	RP1-102K2.9	4.12	4.45e-05	0.00387	0.19	0.19	Type 1 diabetes;	chr22:29782316	chr22:30275215~30276951:-
THCA	cis	rs2380205	0.967	rs10905316	ENSG00000232807.2	RP11-536K7.3	4.12	4.45e-05	0.00387	0.18	0.19	Breast cancer;	chr10:5856777	chr10:5934270~5945900:-
THCA	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	4.12	4.45e-05	0.00387	0.17	0.19	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
THCA	cis	rs7615952	0.8	rs13086460	ENSG00000272840.1	RP11-379B18.6	4.12	4.45e-05	0.00387	0.31	0.19	Blood pressure (smoking interaction);	chr3:125927574	chr3:125774714~125797953:+
THCA	cis	rs5769765	0.908	rs138889	ENSG00000260613.1	RP3-522J7.6	-4.12	4.45e-05	0.00387	-0.22	-0.19	Schizophrenia;	chr22:49833025	chr22:49832616~49837786:-
THCA	cis	rs2251188	0.632	rs2464877	ENSG00000187953.9	PMS2CL	-4.12	4.46e-05	0.00387	-0.2	-0.19	Sum basophil neutrophil counts;Neutrophil count;	chr7:6655087	chr7:6710128~6753862:+
THCA	cis	rs9902453	0.967	rs1906450	ENSG00000263370.1	RP11-68I3.5	4.12	4.46e-05	0.00387	0.25	0.19	Coffee consumption (cups per day);	chr17:30188726	chr17:29639627~29640825:+
THCA	cis	rs7520050	0.807	rs3013594	ENSG00000280836.1	AL355480.1	-4.12	4.46e-05	0.00387	-0.22	-0.19	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45581219~45581321:-
THCA	cis	rs2039553	0.574	rs2248413	ENSG00000227354.5	RBM26-AS1	4.12	4.46e-05	0.00387	0.17	0.19	Pancreatic cancer;	chr13:79746028	chr13:79406309~79424328:+
THCA	cis	rs6981523	0.517	rs13251510	ENSG00000261451.1	RP11-981G7.1	-4.12	4.46e-05	0.00387	-0.23	-0.19	Neuroticism;	chr8:11059464	chr8:10433672~10438312:+
THCA	cis	rs8023401	0.507	rs755251	ENSG00000259705.1	RP11-227D13.1	4.12	4.46e-05	0.00387	0.22	0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48519823	chr15:48645951~48652016:+
THCA	cis	rs4660214	0.724	rs10888683	ENSG00000228060.1	RP11-69E11.8	-4.12	4.46e-05	0.00387	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157997	chr1:39565160~39573203:+
THCA	cis	rs7829975	0.582	rs11783950	ENSG00000254340.1	RP11-10A14.3	-4.12	4.46e-05	0.00387	-0.22	-0.19	Mood instability;	chr8:8740321	chr8:9141424~9145435:+
THCA	cis	rs151234	0.741	rs11074908	ENSG00000259982.1	CDC37P1	-4.12	4.46e-05	0.00387	-0.39	-0.19	Platelet distribution width;	chr16:28597035	chr16:28700294~28701540:-
THCA	cis	rs6964833	1	rs34324835	ENSG00000184616.8	AC004166.6	4.12	4.46e-05	0.00388	0.29	0.19	Menarche (age at onset);	chr7:74717986	chr7:74906673~74913256:-
THCA	cis	rs12410462	0.591	rs2644146	ENSG00000227711.2	RP11-275O4.5	-4.12	4.46e-05	0.00388	-0.23	-0.19	Major depressive disorder;	chr1:227546216	chr1:227509028~227520477:-
THCA	cis	rs9902453	0.817	rs62068620	ENSG00000263370.1	RP11-68I3.5	4.12	4.46e-05	0.00388	0.25	0.19	Coffee consumption (cups per day);	chr17:29840656	chr17:29639627~29640825:+
THCA	cis	rs6696239	1	rs6702653	ENSG00000227711.2	RP11-275O4.5	-4.12	4.46e-05	0.00388	-0.26	-0.19	Height;	chr1:227516218	chr1:227509028~227520477:-
THCA	cis	rs75828804	0.826	rs7186764	ENSG00000260922.1	RP11-538I12.3	-4.12	4.47e-05	0.00388	-0.39	-0.19	Intraocular pressure;	chr16:77523935	chr16:77234877~77290934:+
THCA	cis	rs9291683	0.552	rs17187075	ENSG00000250413.1	RP11-448G15.1	-4.12	4.47e-05	0.00388	-0.18	-0.19	Bone mineral density;	chr4:9988704	chr4:10006482~10009725:+
THCA	cis	rs11247915	0.622	rs4072445	ENSG00000236782.4	RP11-96L14.7	-4.12	4.47e-05	0.00388	-0.23	-0.19	Obesity-related traits;	chr1:26337728	chr1:26169947~26171821:-
THCA	cis	rs397969	0.596	rs12450857	ENSG00000261033.1	RP11-209D14.2	-4.12	4.47e-05	0.00388	-0.26	-0.19	Platelet count;	chr17:19991935	chr17:20008051~20009234:-
THCA	cis	rs2179367	0.613	rs12207261	ENSG00000216906.2	RP11-350J20.9	4.12	4.47e-05	0.00388	0.23	0.19	Dupuytren's disease;	chr6:149423722	chr6:149904243~149906418:+
THCA	cis	rs2153535	0.518	rs1328859	ENSG00000230939.1	RP11-314C16.1	-4.12	4.47e-05	0.00388	-0.2	-0.19	Motion sickness;	chr6:8562582	chr6:8784178~8785445:+
THCA	cis	rs453301	0.624	rs6987558	ENSG00000233609.3	RP11-62H7.2	4.12	4.47e-05	0.00388	0.18	0.19	Joint mobility (Beighton score);	chr8:9005011	chr8:8961200~8979025:+
THCA	cis	rs875971	1	rs6958271	ENSG00000229886.1	RP5-1132H15.3	4.12	4.47e-05	0.00388	0.19	0.19	Aortic root size;	chr7:66514344	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs6958277	ENSG00000229886.1	RP5-1132H15.3	4.12	4.47e-05	0.00388	0.19	0.19	Aortic root size;	chr7:66514362	chr7:66025126~66031544:-
THCA	cis	rs4713118	0.539	rs200951	ENSG00000220721.1	OR1F12	4.12	4.47e-05	0.00388	0.23	0.19	Parkinson's disease;	chr6:27868152	chr6:28073316~28074233:+
THCA	cis	rs13325613	0.666	rs13082995	ENSG00000223552.1	RP11-24F11.2	-4.12	4.47e-05	0.00388	-0.29	-0.19	Monocyte count;	chr3:46200985	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs3136673	ENSG00000223552.1	RP11-24F11.2	-4.12	4.47e-05	0.00388	-0.29	-0.19	Monocyte count;	chr3:46201124	chr3:46364955~46407059:-
THCA	cis	rs7474896	0.537	rs1208587	ENSG00000226578.1	RP11-258F22.1	4.12	4.47e-05	0.00388	0.26	0.19	Obesity (extreme);	chr10:37918831	chr10:37775371~37784131:-
THCA	cis	rs1580019	0.922	rs59938271	ENSG00000231952.3	DPY19L1P2	-4.12	4.47e-05	0.00388	-0.25	-0.19	Cognitive ability;	chr7:32445232	chr7:32812757~32838570:+
THCA	cis	rs1371614	0.61	rs3820822	ENSG00000229122.1	AGBL5-IT1	-4.12	4.47e-05	0.00388	-0.14	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26932994	chr2:27061038~27061815:+
THCA	cis	rs793571	0.784	rs12915713	ENSG00000245975.2	RP11-30K9.6	4.12	4.47e-05	0.00388	0.2	0.19	Schizophrenia;	chr15:58815663	chr15:58768072~58770974:-
THCA	cis	rs10090774	0.71	rs13264524	ENSG00000279766.1	RP11-642A1.2	-4.12	4.47e-05	0.00388	-0.23	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140644559	chr8:140572142~140572812:-
THCA	cis	rs934734	0.532	rs12185610	ENSG00000214533.3	KRT18P33	-4.12	4.47e-05	0.00388	-0.23	-0.19	Rheumatoid arthritis;	chr2:65434334	chr2:65666695~65667737:+
THCA	cis	rs5758659	0.967	rs5751250	ENSG00000273366.1	CTA-989H11.1	-4.12	4.47e-05	0.00388	-0.23	-0.19	Cognitive function;	chr22:42243639	chr22:42278188~42278846:+
THCA	cis	rs4705962	0.765	rs10036532	ENSG00000230612.2	AC004237.1	4.12	4.47e-05	0.00388	0.23	0.19	Atopic dermatitis;	chr5:132710123	chr5:132688681~132723725:+
THCA	cis	rs4705962	0.796	rs11740584	ENSG00000230612.2	AC004237.1	4.12	4.47e-05	0.00388	0.23	0.19	Atopic dermatitis;	chr5:132711097	chr5:132688681~132723725:+
THCA	cis	rs4705962	0.837	rs6864565	ENSG00000230612.2	AC004237.1	4.12	4.47e-05	0.00388	0.23	0.19	Atopic dermatitis;	chr5:132712279	chr5:132688681~132723725:+
THCA	cis	rs4578769	0.959	rs3851820	ENSG00000265939.1	UBE2CP2	4.12	4.47e-05	0.00388	0.23	0.19	Eosinophil percentage of white cells;	chr18:22881359	chr18:22900486~22900995:-
THCA	cis	rs657075	0.595	rs4877	ENSG00000237714.1	P4HA2-AS1	-4.12	4.47e-05	0.00388	-0.42	-0.19	Rheumatoid arthritis;	chr5:132271895	chr5:132184876~132192808:+
THCA	cis	rs4915077	1	rs79271996	ENSG00000226822.1	RP11-356N1.2	4.12	4.47e-05	0.00388	0.32	0.19	Hypothyroidism;	chr1:107808148	chr1:108071482~108074519:+
THCA	cis	rs67478160	0.704	rs12894254	ENSG00000269940.1	RP11-73M18.7	4.12	4.47e-05	0.00389	0.18	0.19	Schizophrenia;	chr14:103824612	chr14:103694560~103695170:+
THCA	cis	rs8030605	0.704	rs1593456	ENSG00000277245.1	RP11-48G14.3	4.12	4.47e-05	0.00389	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56301510	chr15:56447120~56447697:+
THCA	cis	rs7824557	0.547	rs4512344	ENSG00000255495.1	AC145124.2	-4.12	4.48e-05	0.00389	-0.22	-0.19	Retinal vascular caliber;	chr8:11221272	chr8:12194467~12196280:+
THCA	cis	rs5015933	0.801	rs4240490	ENSG00000232630.1	PRPS1P2	-4.12	4.48e-05	0.00389	-0.12	-0.19	Body mass index;	chr9:125377728	chr9:125150653~125151589:+
THCA	cis	rs3096299	0.658	rs12443705	ENSG00000261118.1	RP11-104N10.1	4.12	4.48e-05	0.00389	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89492017~89504460:-
THCA	cis	rs442309	1	rs224148	ENSG00000238280.1	RP11-436D10.3	-4.12	4.48e-05	0.00389	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62726879	chr10:62793562~62805887:-
THCA	cis	rs442309	1	rs224149	ENSG00000238280.1	RP11-436D10.3	-4.12	4.48e-05	0.00389	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62727313	chr10:62793562~62805887:-
THCA	cis	rs442309	1	rs224150	ENSG00000238280.1	RP11-436D10.3	-4.12	4.48e-05	0.00389	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62728327	chr10:62793562~62805887:-
THCA	cis	rs442309	1	rs190113	ENSG00000238280.1	RP11-436D10.3	-4.12	4.48e-05	0.00389	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62728463	chr10:62793562~62805887:-
THCA	cis	rs442309	1	rs442309	ENSG00000238280.1	RP11-436D10.3	-4.12	4.48e-05	0.00389	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62730735	chr10:62793562~62805887:-
THCA	cis	rs442309	1	rs224048	ENSG00000238280.1	RP11-436D10.3	-4.12	4.48e-05	0.00389	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62731789	chr10:62793562~62805887:-
THCA	cis	rs442309	1	rs224052	ENSG00000238280.1	RP11-436D10.3	-4.12	4.48e-05	0.00389	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62734414	chr10:62793562~62805887:-
THCA	cis	rs442309	1	rs224057	ENSG00000238280.1	RP11-436D10.3	-4.12	4.48e-05	0.00389	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62738008	chr10:62793562~62805887:-
THCA	cis	rs62158800	0.852	rs7422236	ENSG00000237880.1	AC096669.2	4.12	4.48e-05	0.00389	0.27	0.19	Facial morphology (factor 22);	chr2:107687092	chr2:107385632~107542649:-
THCA	cis	rs758324	0.617	rs12719447	ENSG00000237714.1	P4HA2-AS1	4.12	4.48e-05	0.00389	0.27	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131782407	chr5:132184876~132192808:+
THCA	cis	rs150992	0.711	rs1069182	ENSG00000241597.2	CTD-2007H13.1	4.12	4.48e-05	0.00389	0.24	0.19	Body mass index;	chr5:98806512	chr5:98954394~98954972:+
THCA	cis	rs150992	0.673	rs992773	ENSG00000241597.2	CTD-2007H13.1	4.12	4.48e-05	0.00389	0.24	0.19	Body mass index;	chr5:98808169	chr5:98954394~98954972:+
THCA	cis	rs4759375	0.748	rs73230017	ENSG00000256092.2	RP13-942N8.1	-4.12	4.48e-05	0.00389	-0.25	-0.19	HDL cholesterol;	chr12:122933684	chr12:123363868~123366113:+
THCA	cis	rs61142792	1	rs73336014	ENSG00000272459.1	RP11-1277A3.3	4.12	4.48e-05	0.00389	0.42	0.19	Alzheimer disease and age of onset;	chr5:177539622	chr5:177554824~177555364:+
THCA	cis	rs7432375	0.901	rs1681817	ENSG00000273455.1	RP11-305O4.3	-4.12	4.48e-05	0.00389	-0.25	-0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136754886	chr3:136087475~136087913:-
THCA	cis	rs758324	0.773	rs4705901	ENSG00000237714.1	P4HA2-AS1	4.12	4.48e-05	0.00389	0.26	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131811300	chr5:132184876~132192808:+
THCA	cis	rs758324	0.773	rs2404776	ENSG00000237714.1	P4HA2-AS1	4.12	4.48e-05	0.00389	0.26	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131833244	chr5:132184876~132192808:+
THCA	cis	rs758324	0.853	rs1604082	ENSG00000237714.1	P4HA2-AS1	4.12	4.48e-05	0.00389	0.26	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131841224	chr5:132184876~132192808:+
THCA	cis	rs2732480	0.5	rs12828309	ENSG00000273765.1	RP11-370I10.11	4.12	4.48e-05	0.00389	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48360920~48361377:+
THCA	cis	rs12234571	0.744	rs2301938	ENSG00000214293.7	APTR	4.12	4.48e-05	0.00389	0.24	0.19	Obesity-related traits;	chr7:77696032	chr7:77657660~77696265:-
THCA	cis	rs476633	0.708	rs8030657	ENSG00000247556.5	OIP5-AS1	4.12	4.48e-05	0.00389	0.16	0.19	Glomerular filtration rate (creatinine);	chr15:41152781	chr15:41283990~41309737:+
THCA	cis	rs476633	0.708	rs8031159	ENSG00000247556.5	OIP5-AS1	4.12	4.48e-05	0.00389	0.16	0.19	Glomerular filtration rate (creatinine);	chr15:41153001	chr15:41283990~41309737:+
THCA	cis	rs476633	0.708	rs9888708	ENSG00000247556.5	OIP5-AS1	4.12	4.48e-05	0.00389	0.16	0.19	Glomerular filtration rate (creatinine);	chr15:41153832	chr15:41283990~41309737:+
THCA	cis	rs476633	0.708	rs28629856	ENSG00000247556.5	OIP5-AS1	4.12	4.48e-05	0.00389	0.16	0.19	Glomerular filtration rate (creatinine);	chr15:41154752	chr15:41283990~41309737:+
THCA	cis	rs476633	0.708	rs28547298	ENSG00000247556.5	OIP5-AS1	4.12	4.48e-05	0.00389	0.16	0.19	Glomerular filtration rate (creatinine);	chr15:41154753	chr15:41283990~41309737:+
THCA	cis	rs476633	0.708	rs28656781	ENSG00000247556.5	OIP5-AS1	4.12	4.48e-05	0.00389	0.16	0.19	Glomerular filtration rate (creatinine);	chr15:41155242	chr15:41283990~41309737:+
THCA	cis	rs11158026	0.576	rs56013432	ENSG00000258413.1	RP11-665C16.6	-4.12	4.48e-05	0.00389	-0.3	-0.19	Parkinson's disease;	chr14:54884461	chr14:55262767~55272075:-
THCA	cis	rs17801127	0.748	rs34247742	ENSG00000231969.1	AC144449.1	4.12	4.48e-05	0.00389	0.39	0.19	Liver enzyme levels (alanine transaminase);	chr2:149771152	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.748	rs72992402	ENSG00000231969.1	AC144449.1	4.12	4.48e-05	0.00389	0.39	0.19	Liver enzyme levels (alanine transaminase);	chr2:149771773	chr2:149587196~149848233:+
THCA	cis	rs5753037	0.653	rs131265	ENSG00000273350.1	RP4-539M6.20	-4.12	4.49e-05	0.00389	-0.21	-0.19	Type 1 diabetes;	chr22:29749602	chr22:30420512~30420912:+
THCA	cis	rs10175706	1	rs2376068	ENSG00000256637.5	RP11-76I14.1	-4.12	4.49e-05	0.00389	-0.17	-0.19	Chin dimples;	chr2:104028646	chr2:103874310~104077778:+
THCA	cis	rs4700393	0.517	rs13183561	ENSG00000272308.1	RP11-231G3.1	4.12	4.49e-05	0.0039	0.22	0.19	Intelligence (multi-trait analysis);	chr5:60803976	chr5:60866457~60866935:-
THCA	cis	rs3015497	0.789	rs10133849	ENSG00000270062.1	RP11-248J18.3	4.12	4.49e-05	0.0039	0.21	0.19	Mean platelet volume;	chr14:50654982	chr14:50723777~50724272:-
THCA	cis	rs10875746	0.669	rs10431526	ENSG00000226413.2	OR8T1P	4.12	4.49e-05	0.0039	0.26	0.19	Longevity (90 years and older);	chr12:48296360	chr12:48442030~48442947:-
THCA	cis	rs10050311	0.698	rs67867077	ENSG00000251411.1	RP11-397E7.4	-4.12	4.49e-05	0.0039	-0.22	-0.19	Insulin-related traits;	chr4:86722593	chr4:86913266~86914817:-
THCA	cis	rs6942407	0.649	rs6975202	ENSG00000224046.1	AC005076.5	-4.12	4.49e-05	0.0039	-0.18	-0.19	Food allergy;	chr7:87231066	chr7:87151423~87152420:-
THCA	cis	rs4785204	1	rs72796115	ENSG00000279356.1	RP11-429P3.8	-4.12	4.49e-05	0.0039	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50043811	chr16:50072862~50074986:+
THCA	cis	rs11671005	0.779	rs3794970	ENSG00000268049.1	CTD-2619J13.9	4.12	4.49e-05	0.0039	0.29	0.19	Mean platelet volume;	chr19:58474893	chr19:58357999~58359603:+
THCA	cis	rs4713118	0.591	rs2056924	ENSG00000261839.1	RP1-265C24.8	4.12	4.49e-05	0.0039	0.19	0.19	Parkinson's disease;	chr6:27722395	chr6:28136849~28139678:+
THCA	cis	rs4906332	1	rs12896612	ENSG00000244691.1	RPL10AP1	-4.12	4.49e-05	0.0039	-0.24	-0.19	Coronary artery disease;	chr14:103411531	chr14:103412119~103412761:-
THCA	cis	rs801193	1	rs2659909	ENSG00000223473.2	GS1-124K5.3	4.12	4.49e-05	0.0039	0.12	0.19	Aortic root size;	chr7:66695292	chr7:66491049~66493566:-
THCA	cis	rs7166081	1	rs8038652	ENSG00000270964.1	RP11-502I4.3	-4.12	4.49e-05	0.0039	-0.17	-0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67259726	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs12443472	ENSG00000270964.1	RP11-502I4.3	-4.12	4.49e-05	0.0039	-0.17	-0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67263620	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs8042237	ENSG00000270964.1	RP11-502I4.3	-4.12	4.49e-05	0.0039	-0.17	-0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67264287	chr15:67541072~67542604:-
THCA	cis	rs7474896	0.537	rs2749589	ENSG00000120555.12	SEPT7P9	-4.12	4.49e-05	0.0039	-0.25	-0.19	Obesity (extreme);	chr10:37977942	chr10:38383069~38402916:-
THCA	cis	rs12612619	0.591	rs12714092	ENSG00000272148.1	RP11-195B17.1	-4.12	4.49e-05	0.0039	-0.18	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092014	chr2:27062428~27062907:-
THCA	cis	rs2733201	1	rs8036541	ENSG00000166763.7	STRCP1	-4.12	4.49e-05	0.0039	-0.42	-0.19	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44027179	chr15:43699488~43718184:-
THCA	cis	rs73191547	0.59	rs10110380	ENSG00000261451.1	RP11-981G7.1	4.12	4.49e-05	0.0039	0.23	0.19	Schizophrenia;	chr8:10220296	chr8:10433672~10438312:+
THCA	cis	rs4950322	0.58	rs17359629	ENSG00000226015.2	CCT8P1	4.12	4.49e-05	0.0039	0.22	0.19	Protein quantitative trait loci;	chr1:147121537	chr1:147203276~147204932:-
THCA	cis	rs10761482	0.769	rs4442496	ENSG00000254271.1	RP11-131N11.4	4.12	4.49e-05	0.0039	0.25	0.19	Schizophrenia;	chr10:60341613	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs4336985	ENSG00000254271.1	RP11-131N11.4	4.12	4.49e-05	0.0039	0.25	0.19	Schizophrenia;	chr10:60341616	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs4600155	ENSG00000254271.1	RP11-131N11.4	4.12	4.49e-05	0.0039	0.25	0.19	Schizophrenia;	chr10:60341623	chr10:60734342~60741828:+
THCA	cis	rs9863	0.828	rs1187415	ENSG00000270028.1	RP11-380L11.4	-4.12	4.49e-05	0.0039	-0.19	-0.19	White blood cell count;	chr12:124006982	chr12:123925461~123926083:-
THCA	cis	rs2060793	0.506	rs10741658	ENSG00000251991.1	RNU7-49P	4.12	4.49e-05	0.0039	0.21	0.19	Vitamin D levels;	chr11:14903190	chr11:14478892~14478953:+
THCA	cis	rs394563	0.601	rs432582	ENSG00000268592.3	RAET1E-AS1	4.12	4.49e-05	0.0039	0.26	0.19	Dupuytren's disease;	chr6:149473007	chr6:149863494~149919507:+
THCA	cis	rs11671005	0.735	rs12977592	ENSG00000268049.1	CTD-2619J13.9	-4.12	4.5e-05	0.0039	-0.27	-0.19	Mean platelet volume;	chr19:58449689	chr19:58357999~58359603:+
THCA	cis	rs9902453	0.808	rs4595850	ENSG00000263370.1	RP11-68I3.5	4.12	4.5e-05	0.0039	0.25	0.19	Coffee consumption (cups per day);	chr17:29879308	chr17:29639627~29640825:+
THCA	cis	rs13113518	1	rs4864549	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55554380	chr4:55547112~55547889:+
THCA	cis	rs878939	0.625	rs7476059	ENSG00000233690.1	EBAG9P1	4.12	4.5e-05	0.0039	0.24	0.19	Warfarin maintenance dose;	chr10:99587281	chr10:99697407~99697949:-
THCA	cis	rs710913	0.646	rs2695325	ENSG00000182109.6	RP11-69E11.4	4.12	4.5e-05	0.0039	0.17	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39607957	chr1:39522280~39546187:-
THCA	cis	rs7904321	1	rs7914355	ENSG00000232075.1	MRPL35P2	4.12	4.5e-05	0.0039	0.25	0.19	Intelligence (multi-trait analysis);	chr10:63077818	chr10:63634317~63634827:-
THCA	cis	rs2904524	1	rs2870881	ENSG00000257815.4	RP11-611E13.2	-4.12	4.5e-05	0.0039	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70257881	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs76608560	ENSG00000257815.4	RP11-611E13.2	-4.12	4.5e-05	0.0039	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70259132	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs74993103	ENSG00000257815.4	RP11-611E13.2	-4.12	4.5e-05	0.0039	-0.18	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70259786	chr12:69904033~70243360:-
THCA	cis	rs13113518	0.966	rs11133387	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55475130	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs4864999	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55476736	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs12506788	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55477426	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs10517344	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55477545	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs10462032	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55479069	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs12501636	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55482317	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs6858803	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55484534	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13114841	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55485974	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs939823	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55487368	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs6838882	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55489310	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13146987	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55491628	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs7677085	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55495801	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs12510681	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55496737	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs12500162	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55496933	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.934	rs3805155	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55497842	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs7686261	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55500224	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11729220	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55501629	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11133390	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55501726	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11133391	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55501788	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs13133484	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55504176	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.934	rs13127906	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55504201	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs6849433	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55506498	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs12501327	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55507248	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11133392	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55507729	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs6838305	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55508587	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.902	rs12503578	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55509367	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs3828480	ENSG00000272969.1	RP11-528I4.2	4.12	4.5e-05	0.0039	0.21	0.19	Height;	chr4:55510352	chr4:55547112~55547889:+
THCA	cis	rs6477918	0.598	rs4978489	ENSG00000230185.4	C9orf147	-4.12	4.5e-05	0.0039	-0.2	-0.19	Obstetric antiphospholipid syndrome;	chr9:112404866	chr9:112433816~112487204:-
THCA	cis	rs6477918	0.598	rs1571638	ENSG00000230185.4	C9orf147	-4.12	4.5e-05	0.0039	-0.2	-0.19	Obstetric antiphospholipid syndrome;	chr9:112407124	chr9:112433816~112487204:-
THCA	cis	rs2579519	0.547	rs11683523	ENSG00000232931.4	LINC00342	4.12	4.5e-05	0.0039	0.15	0.19	Diastolic blood pressure;	chr2:95879107	chr2:95807118~95816215:-
THCA	cis	rs7809950	0.593	rs62482503	ENSG00000272072.1	CTA-363E19.2	4.12	4.5e-05	0.0039	0.2	0.19	Coronary artery disease;	chr7:107347543	chr7:107192559~107193300:-
THCA	cis	rs11758351	1	rs11754744	ENSG00000216331.1	HIST1H1PS1	4.12	4.5e-05	0.0039	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26202377	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs11755210	ENSG00000216331.1	HIST1H1PS1	4.12	4.5e-05	0.0039	0.3	0.19	Renal underexcretion gout;Gout;	chr6:26202540	chr6:26195566~26195771:+
THCA	cis	rs1200821	0.529	rs4934856	ENSG00000263064.2	RP11-291L22.7	-4.12	4.5e-05	0.0039	-0.21	-0.19	Hemostatic factors and hematological phenotypes;	chr10:37518919	chr10:38448689~38448949:+
THCA	cis	rs11250098	0.547	rs2409764	ENSG00000255046.1	RP11-297N6.4	-4.12	4.5e-05	0.0039	-0.19	-0.19	Morning vs. evening chronotype;	chr8:11423764	chr8:11797928~11802568:-
THCA	cis	rs12440869	1	rs8035235	ENSG00000270964.1	RP11-502I4.3	-4.12	4.5e-05	0.0039	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67262699	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs8038044	ENSG00000270964.1	RP11-502I4.3	-4.12	4.5e-05	0.0039	-0.17	-0.19	Peak velocity of the mitral A-wave;	chr15:67272058	chr15:67541072~67542604:-
THCA	cis	rs11633886	0.902	rs7167219	ENSG00000259200.1	RP11-718O11.1	-4.12	4.5e-05	0.0039	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45793086	chr15:45705078~45931069:+
THCA	cis	rs804280	0.509	rs10109241	ENSG00000254948.1	OR7E158P	-4.12	4.5e-05	0.0039	-0.23	-0.19	Myopia (pathological);	chr8:11927476	chr8:11919900~11920809:-
THCA	cis	rs3935996	0.965	rs9633424	ENSG00000233147.1	RP11-90C4.1	-4.12	4.5e-05	0.00391	-0.16	-0.19	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55860855	chr1:55823807~55868248:+
THCA	cis	rs6828577	0.862	rs299005	ENSG00000281731.1	RP11-384K6.8	-4.12	4.5e-05	0.00391	-0.21	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118674209	chr4:118664087~118685341:-
THCA	cis	rs1015362	0.54	rs2378026	ENSG00000275784.1	RP5-1125A11.6	-4.12	4.5e-05	0.00391	-0.22	-0.19	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33989480~33991818:-
THCA	cis	rs72949976	1	rs62186569	ENSG00000270659.1	RP11-105N14.1	4.12	4.5e-05	0.00391	0.15	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213169427	chr2:213152970~213153659:+
THCA	cis	rs394563	0.517	rs385303	ENSG00000268592.3	RAET1E-AS1	4.12	4.5e-05	0.00391	0.26	0.19	Dupuytren's disease;	chr6:149457928	chr6:149863494~149919507:+
THCA	cis	rs2439831	1	rs471229	ENSG00000205771.5	CATSPER2P1	-4.12	4.5e-05	0.00391	-0.24	-0.19	Lung cancer in ever smokers;	chr15:43441796	chr15:43726918~43747094:-
THCA	cis	rs1923243	0.587	rs4409593	ENSG00000223479.3	RP4-788P17.1	4.12	4.5e-05	0.00391	0.2	0.19	Migraine;	chr1:72971892	chr1:73635216~73715214:+
THCA	cis	rs150992	0.609	rs447044	ENSG00000246763.5	RGMB-AS1	4.12	4.5e-05	0.00391	0.19	0.19	Body mass index;	chr5:98995572	chr5:98769618~98773469:-
THCA	cis	rs2692947	0.599	rs7561198	ENSG00000235584.2	AC008268.1	4.12	4.5e-05	0.00391	0.19	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96109233	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.702	rs2312955	ENSG00000235584.2	AC008268.1	4.12	4.5e-05	0.00391	0.19	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96111420	chr2:95666084~95668715:+
THCA	cis	rs6940638	0.688	rs9461335	ENSG00000220721.1	OR1F12	4.12	4.5e-05	0.00391	0.22	0.19	Intelligence (multi-trait analysis);	chr6:27170750	chr6:28073316~28074233:+
THCA	cis	rs9816784	0.901	rs12490036	ENSG00000185485.13	SDHAP1	-4.12	4.5e-05	0.00391	-0.15	-0.19	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195959748~195990318:-
THCA	cis	rs11603020	0.95	rs28362950	ENSG00000254602.1	AP000662.4	-4.12	4.5e-05	0.00391	-0.22	-0.19	Blood protein levels;	chr11:57604445	chr11:57638024~57652790:+
THCA	cis	rs11088226	0.681	rs4547609	ENSG00000186842.4	LINC00846	-4.12	4.5e-05	0.00391	-0.27	-0.19	Gastritis;	chr21:32581232	chr21:32572238~32575881:-
THCA	cis	rs10090774	0.965	rs1031262	ENSG00000280303.2	ERICD	-4.12	4.51e-05	0.00391	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140975806	chr8:140636281~140638283:+
THCA	cis	rs12893668	0.703	rs55751606	ENSG00000252469.1	RNU7-160P	4.12	4.51e-05	0.00391	0.23	0.19	Reticulocyte count;	chr14:103562469	chr14:103550345~103550406:+
THCA	cis	rs875971	0.862	rs778720	ENSG00000229886.1	RP5-1132H15.3	-4.12	4.51e-05	0.00391	-0.19	-0.19	Aortic root size;	chr7:66381288	chr7:66025126~66031544:-
THCA	cis	rs10761482	0.861	rs10821733	ENSG00000254271.1	RP11-131N11.4	4.12	4.51e-05	0.00391	0.25	0.19	Schizophrenia;	chr10:60343647	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs10821734	ENSG00000254271.1	RP11-131N11.4	4.12	4.51e-05	0.00391	0.25	0.19	Schizophrenia;	chr10:60343654	chr10:60734342~60741828:+
THCA	cis	rs12234571	1	rs114716826	ENSG00000214293.7	APTR	4.12	4.51e-05	0.00391	0.26	0.19	Obesity-related traits;	chr7:77796028	chr7:77657660~77696265:-
THCA	cis	rs7809950	0.678	rs982447	ENSG00000272072.1	CTA-363E19.2	4.12	4.51e-05	0.00391	0.2	0.19	Coronary artery disease;	chr7:107333089	chr7:107192559~107193300:-
THCA	cis	rs5758659	0.652	rs129857	ENSG00000270083.1	RP1-257I20.14	-4.12	4.51e-05	0.00391	-0.2	-0.19	Cognitive function;	chr22:42003682	chr22:42089630~42090028:-
THCA	cis	rs357618	0.581	rs165366	ENSG00000260581.1	CTB-113P19.4	4.12	4.51e-05	0.00391	0.29	0.19	Basophil percentage of white cells;	chr5:151487347	chr5:151652275~151655449:+
THCA	cis	rs801193	0.548	rs6975044	ENSG00000229886.1	RP5-1132H15.3	4.12	4.51e-05	0.00391	0.2	0.19	Aortic root size;	chr7:66762495	chr7:66025126~66031544:-
THCA	cis	rs1023500	0.505	rs134889	ENSG00000233903.2	Z83851.4	4.12	4.51e-05	0.00391	0.23	0.19	Schizophrenia;	chr22:42278344	chr22:42276355~42277052:+
THCA	cis	rs6715284	1	rs72934960	ENSG00000238829.1	RNU7-45P	-4.12	4.51e-05	0.00391	-0.45	-0.19	Rheumatoid arthritis;	chr2:201340026	chr2:201141904~201141966:+
THCA	cis	rs4763879	0.502	rs11052552	ENSG00000214776.8	RP11-726G1.1	4.12	4.51e-05	0.00391	0.22	0.19	Type 1 diabetes;	chr12:9703362	chr12:9467552~9576275:+
THCA	cis	rs881375	0.692	rs2072438	ENSG00000270917.1	RP11-27I1.6	-4.12	4.51e-05	0.00391	-0.25	-0.19	Rheumatoid arthritis;	chr9:120889023	chr9:120812475~120812845:-
THCA	cis	rs1862618	0.853	rs1559282	ENSG00000234553.1	AC022431.3	-4.12	4.51e-05	0.00391	-0.21	-0.19	Initial pursuit acceleration;	chr5:56803548	chr5:56536583~56537826:-
THCA	cis	rs1129187	0.934	rs9471974	ENSG00000272223.1	RP1-20C7.6	4.12	4.51e-05	0.00391	0.14	0.19	Alzheimer's disease in APOE e4+ carriers;	chr6:42951246	chr6:43033897~43034405:-
THCA	cis	rs6942407	0.592	rs1024457	ENSG00000224046.1	AC005076.5	-4.12	4.51e-05	0.00391	-0.18	-0.19	Food allergy;	chr7:87134826	chr7:87151423~87152420:-
THCA	cis	rs1267303	0.798	rs1267304	ENSG00000232022.5	FAAHP1	-4.12	4.51e-05	0.00391	-0.22	-0.19	Monobrow;	chr1:46524754	chr1:46432129~46445521:+
THCA	cis	rs2302464	1	rs6811179	ENSG00000214846.4	RP11-115L11.1	4.12	4.51e-05	0.00391	0.41	0.19	Cerebrospinal fluid biomarker levels;	chr4:15683728	chr4:15730962~15731627:-
THCA	cis	rs1204798	0.588	rs1204831	ENSG00000237021.2	RP3-486I3.7	-4.12	4.51e-05	0.00391	-0.22	-0.19	Dental caries;	chr6:116249661	chr6:116254207~116256743:+
THCA	cis	rs10090774	0.71	rs11166990	ENSG00000280303.2	ERICD	4.12	4.51e-05	0.00391	0.17	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140653873	chr8:140636281~140638283:+
THCA	cis	rs6088813	1	rs1406947	ENSG00000279253.1	RP4-614O4.13	4.12	4.51e-05	0.00391	0.18	0.19	Height;	chr20:35381727	chr20:35262727~35264187:-
THCA	cis	rs150992	0.714	rs76798907	ENSG00000246763.5	RGMB-AS1	4.12	4.51e-05	0.00391	0.19	0.19	Body mass index;	chr5:98990780	chr5:98769618~98773469:-
THCA	cis	rs2281636	0.894	rs11190196	ENSG00000233690.1	EBAG9P1	4.12	4.51e-05	0.00391	0.18	0.19	Obesity-related traits;	chr10:99626757	chr10:99697407~99697949:-
THCA	cis	rs3015497	0.789	rs1389652	ENSG00000270062.1	RP11-248J18.3	4.12	4.51e-05	0.00392	0.21	0.19	Mean platelet volume;	chr14:50658522	chr14:50723777~50724272:-
THCA	cis	rs73198271	0.562	rs35432123	ENSG00000253893.2	FAM85B	4.12	4.51e-05	0.00392	0.33	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8813508	chr8:8167819~8226614:-
THCA	cis	rs4819052	0.851	rs8126930	ENSG00000182586.6	LINC00334	-4.12	4.51e-05	0.00392	-0.19	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45234340~45258730:+
THCA	cis	rs1800682	0.528	rs3903454	ENSG00000261438.1	RP11-399O19.9	-4.12	4.51e-05	0.00392	-0.16	-0.19	Chronic lymphocytic leukemia;	chr10:88983677	chr10:89015836~89017059:+
THCA	cis	rs9368481	0.761	rs9357030	ENSG00000261353.1	CTA-14H9.5	4.12	4.51e-05	0.00392	0.2	0.19	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26527063~26527404:+
THCA	cis	rs860295	0.557	rs6696019	ENSG00000236675.1	MTX1P1	-4.12	4.51e-05	0.00392	-0.19	-0.19	Body mass index;	chr1:155895186	chr1:155230975~155234325:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000229180.5	GS1-124K5.11	4.12	4.52e-05	0.00392	0.13	0.19	Aortic root size;	chr7:66014585	chr7:66526088~66542624:-
THCA	cis	rs17711722	0.727	rs781151	ENSG00000229180.5	GS1-124K5.11	4.12	4.52e-05	0.00392	0.13	0.19	Calcium levels;	chr7:66014891	chr7:66526088~66542624:-
THCA	cis	rs755249	0.567	rs67408364	ENSG00000182109.6	RP11-69E11.4	4.12	4.52e-05	0.00392	0.2	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39522280~39546187:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000229180.5	GS1-124K5.11	4.12	4.52e-05	0.00392	0.13	0.19	Aortic root size;	chr7:65966699	chr7:66526088~66542624:-
THCA	cis	rs1971762	0.545	rs11170632	ENSG00000270175.1	RP11-793H13.11	4.12	4.52e-05	0.00392	0.12	0.19	Height;	chr12:53654151	chr12:53500162~53500936:-
THCA	cis	rs3734266	0.702	rs16895659	ENSG00000272288.4	RP11-140K17.3	-4.12	4.52e-05	0.00392	-0.18	-0.19	Systemic lupus erythematosus;	chr6:34923091	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs28360525	ENSG00000272288.4	RP11-140K17.3	-4.12	4.52e-05	0.00392	-0.18	-0.19	Systemic lupus erythematosus;	chr6:34923261	chr6:34696317~34697470:+
THCA	cis	rs3734266	0.702	rs6457797	ENSG00000272288.4	RP11-140K17.3	-4.12	4.52e-05	0.00392	-0.18	-0.19	Systemic lupus erythematosus;	chr6:34929397	chr6:34696317~34697470:+
THCA	cis	rs36093844	0.706	rs78680968	ENSG00000279742.1	RP11-700A24.1	-4.12	4.52e-05	0.00392	-0.29	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85832437	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs76852274	ENSG00000279742.1	RP11-700A24.1	-4.12	4.52e-05	0.00392	-0.29	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85832717	chr11:85852557~85854943:-
THCA	cis	rs1971762	0.545	rs3864905	ENSG00000270175.1	RP11-793H13.11	-4.12	4.52e-05	0.00392	-0.12	-0.19	Height;	chr12:53664540	chr12:53500162~53500936:-
THCA	cis	rs4591358	0.765	rs1392658	ENSG00000223466.1	AC064834.2	4.12	4.52e-05	0.00392	0.22	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195463666	chr2:195533035~195538681:+
THCA	cis	rs6479891	1	rs72837070	ENSG00000272767.1	JMJD1C-AS1	4.12	4.52e-05	0.00392	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs61853635	ENSG00000272767.1	JMJD1C-AS1	4.12	4.52e-05	0.00392	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63465229~63466563:+
THCA	cis	rs7554547	0.765	rs4845886	ENSG00000199347.1	RNU5E-1	-4.12	4.52e-05	0.00392	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11888603	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs4846069	ENSG00000199347.1	RNU5E-1	-4.12	4.52e-05	0.00392	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11888974	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs11121837	ENSG00000199347.1	RNU5E-1	-4.12	4.52e-05	0.00392	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11889414	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.765	rs4846070	ENSG00000199347.1	RNU5E-1	-4.12	4.52e-05	0.00392	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11889464	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.739	rs61527718	ENSG00000199347.1	RNU5E-1	-4.12	4.52e-05	0.00392	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11889583	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.714	rs4846071	ENSG00000199347.1	RNU5E-1	-4.12	4.52e-05	0.00392	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11889612	chr1:11908152~11908271:+
THCA	cis	rs1023500	0.573	rs133380	ENSG00000270083.1	RP1-257I20.14	4.12	4.52e-05	0.00392	0.2	0.19	Schizophrenia;	chr22:42072906	chr22:42089630~42090028:-
THCA	cis	rs801193	0.66	rs2659914	ENSG00000230189.5	GS1-124K5.2	4.12	4.52e-05	0.00392	0.12	0.19	Aortic root size;	chr7:66691927	chr7:66409143~66490059:-
THCA	cis	rs1009077	0.61	rs6822275	ENSG00000245958.5	RP11-33B1.1	-4.12	4.52e-05	0.00392	-0.21	-0.19	Endometriosis;	chr4:119588472	chr4:119454791~119552025:+
THCA	cis	rs10090774	0.965	rs1397381	ENSG00000280303.2	ERICD	-4.12	4.52e-05	0.00392	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992798	chr8:140636281~140638283:+
THCA	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	4.12	4.52e-05	0.00392	0.22	0.19	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
THCA	cis	rs2120243	0.534	rs35004310	ENSG00000241770.1	RP11-555M1.3	-4.12	4.52e-05	0.00392	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157396011	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs12638732	ENSG00000241770.1	RP11-555M1.3	-4.12	4.52e-05	0.00392	-0.24	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157396082	chr3:157163452~157169133:+
THCA	cis	rs150992	0.609	rs78721487	ENSG00000246763.5	RGMB-AS1	4.12	4.52e-05	0.00392	0.19	0.19	Body mass index;	chr5:98992926	chr5:98769618~98773469:-
THCA	cis	rs2797160	0.651	rs1268092	ENSG00000226409.1	RP11-735G4.1	-4.12	4.52e-05	0.00392	-0.23	-0.19	Endometrial cancer;	chr6:125707897	chr6:125370211~125374324:-
THCA	cis	rs9925964	0.935	rs4527034	ENSG00000260911.2	RP11-196G11.2	4.12	4.52e-05	0.00392	0.15	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31120293	chr16:31043150~31049868:+
THCA	cis	rs651907	0.64	rs771573	ENSG00000256628.3	ZBTB11-AS1	4.12	4.53e-05	0.00392	0.21	0.19	Colorectal cancer;	chr3:101902052	chr3:101676475~101679217:+
THCA	cis	rs911555	0.713	rs10162425	ENSG00000269958.1	RP11-73M18.8	4.12	4.53e-05	0.00392	0.18	0.19	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103696353~103697163:+
THCA	cis	rs10911902	0.643	rs76991105	ENSG00000229739.2	RP11-295K2.3	-4.12	4.53e-05	0.00393	-0.3	-0.19	Schizophrenia;	chr1:186376920	chr1:186435161~186470291:+
THCA	cis	rs7560272	0.513	rs7558546	ENSG00000163016.8	ALMS1P	-4.12	4.53e-05	0.00393	-0.23	-0.19	Schizophrenia;	chr2:73710605	chr2:73644919~73685576:+
THCA	cis	rs1371614	0.523	rs11904656	ENSG00000272148.1	RP11-195B17.1	4.12	4.53e-05	0.00393	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950381	chr2:27062428~27062907:-
THCA	cis	rs7914558	1	rs11191542	ENSG00000272912.1	RP11-724N1.1	-4.12	4.53e-05	0.00393	-0.22	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064567	chr10:102914585~102915404:+
THCA	cis	rs1232027	0.7	rs1643635	ENSG00000249655.1	CTC-325J23.2	4.12	4.53e-05	0.00393	0.22	0.19	Huntington's disease progression;	chr5:80632397	chr5:80630313~80631590:-
THCA	cis	rs4218	0.531	rs10431791	ENSG00000277144.1	RP11-59H7.4	-4.12	4.53e-05	0.00393	-0.25	-0.19	Social communication problems;	chr15:59055159	chr15:59115547~59116089:-
THCA	cis	rs1124769	0.57	rs1903589	ENSG00000273674.3	CTD-2378E12.1	-4.12	4.53e-05	0.00393	-0.25	-0.19	Cognitive performance;	chr15:50852087	chr15:50839875~50908599:-
THCA	cis	rs2408955	0.522	rs4760679	ENSG00000273765.1	RP11-370I10.11	-4.12	4.53e-05	0.00393	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48067852	chr12:48360920~48361377:+
THCA	cis	rs2281636	0.894	rs7077070	ENSG00000233690.1	EBAG9P1	4.12	4.53e-05	0.00393	0.18	0.19	Obesity-related traits;	chr10:99692220	chr10:99697407~99697949:-
THCA	cis	rs12142240	0.698	rs6696777	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46345298	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6659228	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46345355	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6697123	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46345638	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs67487250	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46345661	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs112089006	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46346688	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72677585	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46346702	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17357676	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46346772	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17361791	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46346847	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72885198	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46347216	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.66	rs72886903	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46348188	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs68112720	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46348216	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72677587	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46348310	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17361812	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46348336	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs66575205	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46348420	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72886907	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46348593	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72886911	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46348680	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs56344958	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46348846	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.583	rs5013330	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46349482	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17357683	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46349706	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6667861	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350077	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1057533	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350164	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1057534	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350208	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1057535	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350226	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1135459	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350258	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1135460	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350298	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1475390	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350668	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1475389	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350757	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1475388	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350793	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs57267378	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350972	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs58162700	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46350987	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs966907	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46351453	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.621	rs66828173	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352494	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.659	rs72677591	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352547	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs41294476	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352702	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17413694	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352744	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs77185326	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352745	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs41294478	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352770	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17413701	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352780	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs7515598	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352807	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.692	rs7529674	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46352836	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs12385697	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46353226	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs12385695	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46353349	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.66	rs6679080	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46354107	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6690075	ENSG00000232022.5	FAAHP1	-4.12	4.53e-05	0.00393	-0.21	-0.19	Menopause (age at onset);	chr1:46354176	chr1:46432129~46445521:+
THCA	cis	rs13256369	0.951	rs13260947	ENSG00000254153.1	CTA-398F10.2	-4.12	4.53e-05	0.00393	-0.21	-0.19	Obesity-related traits;	chr8:8708373	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.951	rs13259955	ENSG00000254153.1	CTA-398F10.2	-4.12	4.53e-05	0.00393	-0.21	-0.19	Obesity-related traits;	chr8:8708375	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs885000	ENSG00000254153.1	CTA-398F10.2	-4.12	4.53e-05	0.00393	-0.21	-0.19	Obesity-related traits;	chr8:8711365	chr8:8456909~8461337:-
THCA	cis	rs13256369	1	rs13266699	ENSG00000254153.1	CTA-398F10.2	4.12	4.53e-05	0.00393	0.21	0.19	Obesity-related traits;	chr8:8712803	chr8:8456909~8461337:-
THCA	cis	rs6828577	0.862	rs298983	ENSG00000281731.1	RP11-384K6.8	-4.12	4.53e-05	0.00393	-0.21	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118683647	chr4:118664087~118685341:-
THCA	cis	rs34779708	0.733	rs61449529	ENSG00000233200.1	RP11-324I22.2	4.12	4.53e-05	0.00393	0.23	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs59287215	ENSG00000233200.1	RP11-324I22.2	4.12	4.53e-05	0.00393	0.23	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.702	rs35969476	ENSG00000233200.1	RP11-324I22.2	4.12	4.53e-05	0.00393	0.23	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35219894~35230598:-
THCA	cis	rs9816784	0.901	rs56253832	ENSG00000207650.1	MIR570	4.12	4.53e-05	0.00393	0.19	0.19	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195699401~195699497:+
THCA	cis	rs2434529	1	rs58599922	ENSG00000245275.6	SAP30L-AS1	4.12	4.53e-05	0.00393	0.23	0.19	Autism spectrum disorder or schizophrenia;	chr5:154236789	chr5:154329437~154445850:-
THCA	cis	rs2657294	0.965	rs2657286	ENSG00000233313.2	HMGA1P5	4.12	4.53e-05	0.00393	0.25	0.19	Pneumonia;	chr10:75145940	chr10:75276376~75276646:-
THCA	cis	rs42648	0.902	rs17874789	ENSG00000225498.1	AC002064.5	-4.12	4.53e-05	0.00393	-0.19	-0.19	Homocysteine levels;	chr7:90371846	chr7:90312496~90322592:+
THCA	cis	rs748404	1	rs748404	ENSG00000166763.7	STRCP1	4.12	4.53e-05	0.00393	0.22	0.19	Lung cancer;	chr15:43267033	chr15:43699488~43718184:-
THCA	cis	rs875971	1	rs697970	ENSG00000272831.1	RP11-792A8.4	-4.12	4.53e-05	0.00393	-0.12	-0.19	Aortic root size;	chr7:66095065	chr7:66739829~66740385:-
THCA	cis	rs10540	0.915	rs12419209	ENSG00000279672.1	CMB9-55F22.1	4.12	4.53e-05	0.00393	0.37	0.19	Body mass index;	chr11:494510	chr11:779617~780755:+
THCA	cis	rs516805	0.886	rs557528	ENSG00000279114.1	RP3-425C14.5	-4.12	4.53e-05	0.00393	-0.19	-0.19	Lymphocyte counts;	chr6:122482793	chr6:122471923~122484161:+
THCA	cis	rs516805	0.961	rs559721	ENSG00000279114.1	RP3-425C14.5	-4.12	4.53e-05	0.00393	-0.19	-0.19	Lymphocyte counts;	chr6:122482796	chr6:122471923~122484161:+
THCA	cis	rs853679	0.567	rs16894091	ENSG00000273712.1	RP5-874C20.7	-4.12	4.53e-05	0.00393	-0.23	-0.19	Depression;	chr6:28422360	chr6:28315613~28315883:-
THCA	cis	rs6747952	0.866	rs11689193	ENSG00000279484.1	KLHL30-AS1	4.12	4.54e-05	0.00393	0.18	0.19	Mean corpuscular hemoglobin concentration;	chr2:238166024	chr2:238152889~238155994:-
THCA	cis	rs711244	0.811	rs45504994	ENSG00000279519.1	RP11-288C18.1	4.12	4.54e-05	0.00393	0.15	0.19	Mean platelet volume;	chr2:36911322	chr2:36839922~36842539:-
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Body mass index;	chr17:30751280	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000265443.1	CTD-2349P21.6	-4.12	4.54e-05	0.00393	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30726305~30727564:-
THCA	cis	rs12612619	0.732	rs11680096	ENSG00000272148.1	RP11-195B17.1	4.12	4.54e-05	0.00393	0.17	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27050703	chr2:27062428~27062907:-
THCA	cis	rs988712	0.705	rs35051342	ENSG00000245573.6	BDNF-AS	-4.12	4.54e-05	0.00393	-0.19	-0.19	Obesity;	chr11:27612826	chr11:27506838~27698174:+
THCA	cis	rs2018683	0.707	rs7799357	ENSG00000272568.4	CTB-113D17.1	4.12	4.54e-05	0.00393	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930501	chr7:28979967~29013367:+
THCA	cis	rs7264396	0.887	rs4911503	ENSG00000088340.14	FER1L4	4.12	4.54e-05	0.00393	0.17	0.19	Total cholesterol levels;	chr20:35475270	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs750487	ENSG00000088340.14	FER1L4	4.12	4.54e-05	0.00393	0.17	0.19	Total cholesterol levels;	chr20:35478820	chr20:35558737~35607562:-
THCA	cis	rs13325613	0.834	rs35775079	ENSG00000223552.1	RP11-24F11.2	-4.12	4.54e-05	0.00394	-0.33	-0.19	Monocyte count;	chr3:46220620	chr3:46364955~46407059:-
THCA	cis	rs478304	0.593	rs6591188	ENSG00000255557.1	RP11-770G2.2	4.12	4.54e-05	0.00394	0.22	0.19	Acne (severe);	chr11:65700482	chr11:65745729~65771585:+
THCA	cis	rs10435719	0.58	rs13260712	ENSG00000254948.1	OR7E158P	4.12	4.54e-05	0.00394	0.23	0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:11919900~11920809:-
THCA	cis	rs11992162	0.551	rs13268217	ENSG00000254948.1	OR7E158P	4.12	4.54e-05	0.00394	0.23	0.19	Monocyte count;	chr8:11925100	chr8:11919900~11920809:-
THCA	cis	rs11992162	0.573	rs13264994	ENSG00000254948.1	OR7E158P	4.12	4.54e-05	0.00394	0.23	0.19	Monocyte count;	chr8:11925250	chr8:11919900~11920809:-
THCA	cis	rs11992162	0.573	rs13275808	ENSG00000254948.1	OR7E158P	4.12	4.54e-05	0.00394	0.23	0.19	Monocyte count;	chr8:11925306	chr8:11919900~11920809:-
THCA	cis	rs4713118	0.615	rs57252182	ENSG00000280107.1	AL022393.9	-4.12	4.54e-05	0.00394	-0.2	-0.19	Parkinson's disease;	chr6:27752470	chr6:28170845~28172521:+
THCA	cis	rs34034915	1	rs34034915	ENSG00000280107.1	AL022393.9	-4.12	4.54e-05	0.00394	-0.2	-0.19	Hepatitis A;	chr6:27752924	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.527	rs36042294	ENSG00000280107.1	AL022393.9	-4.12	4.54e-05	0.00394	-0.2	-0.19	Parkinson's disease;	chr6:27752933	chr6:28170845~28172521:+
THCA	cis	rs765787	0.53	rs2554454	ENSG00000259932.1	CTD-2651B20.7	4.12	4.55e-05	0.00394	0.23	0.19	Uric acid levels;	chr15:45229338	chr15:45198517~45199139:-
THCA	cis	rs1232027	0.7	rs1650692	ENSG00000249655.1	CTC-325J23.2	4.12	4.55e-05	0.00394	0.21	0.19	Huntington's disease progression;	chr5:80657574	chr5:80630313~80631590:-
THCA	cis	rs6120849	0.754	rs3818253	ENSG00000269202.1	RP4-614O4.12	-4.12	4.55e-05	0.00394	-0.2	-0.19	Protein C levels;	chr20:35009073	chr20:35201747~35203288:-
THCA	cis	rs962856	0.575	rs612624	ENSG00000236780.4	AC078941.1	4.12	4.55e-05	0.00394	0.25	0.19	Pancreatic cancer;	chr2:67430179	chr2:67123357~67215319:-
THCA	cis	rs8031584	0.958	rs7176569	ENSG00000270015.1	RP11-540B6.6	4.12	4.55e-05	0.00394	0.14	0.19	Huntington's disease progression;	chr15:30952292	chr15:30926514~30928407:+
THCA	cis	rs6690583	0.623	rs12041012	ENSG00000226970.2	RP11-82H13.2	4.12	4.55e-05	0.00394	0.33	0.19	Serum sulfate level;	chr1:85049961	chr1:84244334~84244577:+
THCA	cis	rs2033711	0.87	rs7409473	ENSG00000269054.1	CTD-2619J13.3	-4.12	4.55e-05	0.00394	-0.15	-0.19	Uric acid clearance;	chr19:58427798	chr19:58362585~58366591:+
THCA	cis	rs2033711	0.87	rs7408188	ENSG00000269054.1	CTD-2619J13.3	-4.12	4.55e-05	0.00394	-0.15	-0.19	Uric acid clearance;	chr19:58428022	chr19:58362585~58366591:+
THCA	cis	rs2033711	0.87	rs1051500	ENSG00000269054.1	CTD-2619J13.3	-4.12	4.55e-05	0.00394	-0.15	-0.19	Uric acid clearance;	chr19:58433035	chr19:58362585~58366591:+
THCA	cis	rs5758511	0.68	rs5758667	ENSG00000237037.8	NDUFA6-AS1	-4.12	4.55e-05	0.00394	-0.18	-0.19	Birth weight;	chr22:42237198	chr22:42090931~42137742:+
THCA	cis	rs3763267	0.522	rs58955525	ENSG00000226445.1	XXyac-YX65C7_A.2	4.12	4.55e-05	0.00394	0.36	0.19	Blood protein levels;	chr6:169193706	chr6:169213254~169239565:+
THCA	cis	rs1908814	0.516	rs58869268	ENSG00000206014.6	OR7E161P	-4.12	4.55e-05	0.00394	-0.22	-0.19	Neuroticism;	chr8:11939586	chr8:11928597~11929563:-
THCA	cis	rs7537605	0.538	rs4915074	ENSG00000230489.1	VAV3-AS1	-4.12	4.55e-05	0.00394	-0.21	-0.19	Hashimoto thyroiditis versus Graves' disease;	chr1:107791812	chr1:107964443~107994607:+
THCA	cis	rs7176527	1	rs3762168	ENSG00000230373.7	GOLGA6L5P	4.12	4.55e-05	0.00394	0.23	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:84507885~84516814:-
THCA	cis	rs74233809	1	rs11191531	ENSG00000272912.1	RP11-724N1.1	-4.12	4.55e-05	0.00394	-0.35	-0.19	Birth weight;	chr10:103047141	chr10:102914585~102915404:+
THCA	cis	rs901683	0.85	rs73291122	ENSG00000230869.1	CTGLF10P	-4.12	4.55e-05	0.00394	-0.43	-0.19	Mean corpuscular volume;Red blood cell traits;	chr10:45603955	chr10:45678692~45700532:+
THCA	cis	rs150992	0.711	rs331918	ENSG00000246763.5	RGMB-AS1	4.12	4.55e-05	0.00394	0.2	0.19	Body mass index;	chr5:98823040	chr5:98769618~98773469:-
THCA	cis	rs150992	0.673	rs331929	ENSG00000246763.5	RGMB-AS1	4.12	4.55e-05	0.00394	0.2	0.19	Body mass index;	chr5:98830528	chr5:98769618~98773469:-
THCA	cis	rs9650657	0.504	rs7813802	ENSG00000206014.6	OR7E161P	-4.12	4.55e-05	0.00394	-0.22	-0.19	Neuroticism;	chr8:11176467	chr8:11928597~11929563:-
THCA	cis	rs911555	0.723	rs56227024	ENSG00000269910.1	RP11-73M18.10	-4.12	4.55e-05	0.00394	-0.17	-0.19	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103694516~103695050:-
THCA	cis	rs758324	0.687	rs156056	ENSG00000224431.1	AC063976.7	-4.12	4.55e-05	0.00394	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132137957	chr5:132199456~132203487:+
THCA	cis	rs4660456	0.913	rs2361651	ENSG00000272145.1	NFYC-AS1	-4.12	4.55e-05	0.00394	-0.14	-0.19	Platelet count;	chr1:40764542	chr1:40690380~40692066:-
THCA	cis	rs4824093	0.61	rs13340054	ENSG00000278869.1	CITF22-49E9.3	4.12	4.55e-05	0.00394	0.37	0.19	Amyotrophic lateral sclerosis (sporadic);	chr22:49918078	chr22:49933198~49934074:-
THCA	cis	rs7162943	1	rs7162943	ENSG00000260123.1	RP11-326A19.4	4.12	4.55e-05	0.00394	0.24	0.19	Mean platelet volume;	chr15:89072044	chr15:89041223~89082819:+
THCA	cis	rs1125355	0.964	rs72939969	ENSG00000243792.1	OR7E89P	-4.12	4.55e-05	0.00394	-0.28	-0.19	Alzheimer's disease in APOE e4+ carriers;	chr2:158845256	chr2:158853755~158854576:+
THCA	cis	rs6504108	0.874	rs4794447	ENSG00000264920.1	RP11-6N17.4	-4.12	4.55e-05	0.00394	-0.17	-0.19	Body mass index;	chr17:48103362	chr17:47891255~47895812:-
THCA	cis	rs6479891	1	rs4133250	ENSG00000272767.1	JMJD1C-AS1	-4.12	4.55e-05	0.00394	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs10995506	ENSG00000272767.1	JMJD1C-AS1	-4.12	4.55e-05	0.00394	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs10740117	ENSG00000272767.1	JMJD1C-AS1	-4.12	4.55e-05	0.00394	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs6479894	ENSG00000272767.1	JMJD1C-AS1	-4.12	4.55e-05	0.00394	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63465229~63466563:+
THCA	cis	rs7166081	1	rs10152913	ENSG00000270964.1	RP11-502I4.3	-4.12	4.55e-05	0.00395	-0.17	-0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67354990	chr15:67541072~67542604:-
THCA	cis	rs7200543	1	rs7200543	ENSG00000188599.16	NPIPP1	4.12	4.55e-05	0.00395	0.14	0.19	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:15104312~15123498:-
THCA	cis	rs1476587	1	rs2106951	ENSG00000224046.1	AC005076.5	-4.12	4.56e-05	0.00395	-0.19	-0.19	Brachial circumference;	chr7:87105694	chr7:87151423~87152420:-
THCA	cis	rs3755605	0.728	rs56403328	ENSG00000242578.1	RP11-469J4.3	4.12	4.56e-05	0.00395	0.21	0.19	Testicular germ cell tumor;	chr3:170116132	chr3:170410512~170418615:+
THCA	cis	rs16986825	0.664	rs5997409	ENSG00000272858.1	CTA-292E10.8	-4.12	4.56e-05	0.00395	-0.23	-0.19	Pancreatic cancer;	chr22:28826108	chr22:28814914~28815662:+
THCA	cis	rs950169	0.922	rs11638445	ENSG00000188388.10	GOLGA6L3	4.12	4.56e-05	0.00395	0.25	0.19	Schizophrenia;	chr15:84594463	chr15:85240472~85247170:+
THCA	cis	rs11089937	0.929	rs5757155	ENSG00000263366.2	LL22NC03-33B6.4	-4.12	4.56e-05	0.00395	-0.22	-0.19	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22114844~22118005:-
THCA	cis	rs801193	1	rs7785213	ENSG00000223473.2	GS1-124K5.3	-4.12	4.56e-05	0.00395	-0.12	-0.19	Aortic root size;	chr7:66673991	chr7:66491049~66493566:-
THCA	cis	rs801193	0.967	rs2707841	ENSG00000223473.2	GS1-124K5.3	4.12	4.56e-05	0.00395	0.12	0.19	Aortic root size;	chr7:66692033	chr7:66491049~66493566:-
THCA	cis	rs13108904	0.557	rs1250098	ENSG00000254094.1	AC078852.1	4.12	4.56e-05	0.00395	0.22	0.19	Obesity-related traits;	chr4:1244468	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.557	rs1250097	ENSG00000254094.1	AC078852.1	4.12	4.56e-05	0.00395	0.22	0.19	Obesity-related traits;	chr4:1244550	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.557	rs1680041	ENSG00000254094.1	AC078852.1	4.12	4.56e-05	0.00395	0.22	0.19	Obesity-related traits;	chr4:1244733	chr4:1356581~1358075:+
THCA	cis	rs301901	0.965	rs2886201	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.56e-05	0.00395	-0.19	-0.19	Height;	chr5:36796728	chr5:36666214~36725195:-
THCA	cis	rs7178909	0.835	rs12437459	ENSG00000259677.1	RP11-493E3.1	4.12	4.56e-05	0.00395	0.22	0.19	Common traits (Other);	chr15:89877541	chr15:89876540~89877285:+
THCA	cis	rs1348850	0.645	rs10181259	ENSG00000280374.1	RP11-337N6.3	-4.12	4.56e-05	0.00395	-0.29	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177563528	chr2:177317715~177318471:-
THCA	cis	rs12935418	0.672	rs9925780	ENSG00000278985.1	RP11-303E16.9	4.12	4.56e-05	0.00395	0.21	0.19	Mean corpuscular volume;	chr16:81011571	chr16:80982319~80984094:-
THCA	cis	rs156299	0.513	rs156283	ENSG00000234286.1	AC006026.13	4.12	4.56e-05	0.00395	0.24	0.19	Vitamin D levels;	chr7:24199565	chr7:23680195~23680786:-
THCA	cis	rs7688540	0.8	rs10003142	ENSG00000275426.1	CH17-262A2.1	4.12	4.56e-05	0.00395	0.23	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs11723803	ENSG00000275426.1	CH17-262A2.1	4.12	4.56e-05	0.00395	0.23	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:149738~150317:+
THCA	cis	rs7403037	0.761	rs61995448	ENSG00000260760.1	PWRN3	4.12	4.56e-05	0.00395	0.26	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24504876	chr15:24441127~24447967:+
THCA	cis	rs1908814	0.503	rs34657250	ENSG00000206014.6	OR7E161P	4.12	4.56e-05	0.00395	0.23	0.19	Neuroticism;	chr8:11937864	chr8:11928597~11929563:-
THCA	cis	rs7577696	0.785	rs3851310	ENSG00000276334.1	AL133243.1	-4.12	4.56e-05	0.00395	-0.2	-0.19	Inflammatory biomarkers;	chr2:32142917	chr2:32521927~32523547:+
THCA	cis	rs875971	1	rs11971949	ENSG00000230189.5	GS1-124K5.2	-4.12	4.56e-05	0.00395	-0.12	-0.19	Aortic root size;	chr7:66161027	chr7:66409143~66490059:-
THCA	cis	rs1371614	0.545	rs12105356	ENSG00000272148.1	RP11-195B17.1	4.12	4.56e-05	0.00395	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26952702	chr2:27062428~27062907:-
THCA	cis	rs78487399	0.908	rs80144434	ENSG00000234936.1	AC010883.5	4.12	4.56e-05	0.00395	0.24	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617501	chr2:43229573~43233394:+
THCA	cis	rs78487399	1	rs79611878	ENSG00000234936.1	AC010883.5	4.12	4.56e-05	0.00395	0.24	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617664	chr2:43229573~43233394:+
THCA	cis	rs4246307	0.668	rs4467054	ENSG00000189419.6	SPATA41	4.12	4.56e-05	0.00395	0.22	0.19	Hip circumference adjusted for BMI;	chr15:100255167	chr15:100344457~100349655:-
THCA	cis	rs1908814	0.541	rs7824267	ENSG00000206014.6	OR7E161P	-4.12	4.56e-05	0.00395	-0.22	-0.19	Neuroticism;	chr8:11936770	chr8:11928597~11929563:-
THCA	cis	rs2749592	0.531	rs10764134	ENSG00000226578.1	RP11-258F22.1	4.12	4.56e-05	0.00395	0.22	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:37775371~37784131:-
THCA	cis	rs950169	0.881	rs150965	ENSG00000275120.1	RP11-182J1.17	4.12	4.56e-05	0.00395	0.22	0.19	Schizophrenia;	chr15:84537296	chr15:84599434~84606463:-
THCA	cis	rs4950322	1	rs4448568	ENSG00000226015.2	CCT8P1	4.12	4.56e-05	0.00395	0.23	0.19	Protein quantitative trait loci;	chr1:147377296	chr1:147203276~147204932:-
THCA	cis	rs893363	0.522	rs2241807	ENSG00000271916.1	RP11-884K10.6	-4.12	4.57e-05	0.00395	-0.2	-0.19	Axial length;	chr3:53823131	chr3:53797764~53798019:-
THCA	cis	rs67839313	1	rs11856877	ENSG00000273855.1	RP11-133K1.12	4.12	4.57e-05	0.00395	0.28	0.19	Type 2 diabetes;	chr15:40328359	chr15:40285468~40285909:-
THCA	cis	rs9393777	0.92	rs13195040	ENSG00000226314.6	ZNF192P1	4.12	4.57e-05	0.00395	0.36	0.19	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28161781~28169594:+
THCA	cis	rs3824488	0.705	rs28520360	ENSG00000271155.1	RP11-435O5.5	-4.12	4.57e-05	0.00395	-0.28	-0.19	Neuroticism;	chr9:95521298	chr9:95506235~95507636:+
THCA	cis	rs16852403	0.619	rs6685876	ENSG00000224687.1	RASAL2-AS1	4.12	4.57e-05	0.00395	0.31	0.19	Childhood ear infection;	chr1:178165984	chr1:178091508~178093984:-
THCA	cis	rs4726279	1	rs4726279	ENSG00000020219.9	CCT8L1P	4.12	4.57e-05	0.00395	0.25	0.19	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr7:153359535	chr7:152445477~152447150:+
THCA	cis	rs2549003	1	rs2549003	ENSG00000237714.1	P4HA2-AS1	-4.12	4.57e-05	0.00396	-0.23	-0.19	Asthma (sex interaction);	chr5:132493605	chr5:132184876~132192808:+
THCA	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	4.12	4.57e-05	0.00396	0.15	0.19	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
THCA	cis	rs9834970	0.588	rs4642070	ENSG00000281100.1	RP11-640L9.2	-4.12	4.57e-05	0.00396	-0.2	-0.19	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36859453	chr3:36823151~36825158:-
THCA	cis	rs7618915	1	rs3852064	ENSG00000243224.1	RP5-1157M23.2	-4.12	4.57e-05	0.00396	-0.2	-0.19	Bipolar disorder;	chr3:52315396	chr3:52239258~52241097:+
THCA	cis	rs7246967	0.611	rs56944174	ENSG00000198153.8	ZNF849P	-4.12	4.57e-05	0.00396	-0.34	-0.19	Bronchopulmonary dysplasia;	chr19:22738872	chr19:22685167~22686732:+
THCA	cis	rs950169	0.84	rs62019457	ENSG00000275120.1	RP11-182J1.17	4.12	4.57e-05	0.00396	0.22	0.19	Schizophrenia;	chr15:84558911	chr15:84599434~84606463:-
THCA	cis	rs950169	0.922	rs67804993	ENSG00000275120.1	RP11-182J1.17	4.12	4.57e-05	0.00396	0.22	0.19	Schizophrenia;	chr15:84560799	chr15:84599434~84606463:-
THCA	cis	rs6560517	1	rs6560517	ENSG00000234618.1	RPSAP9	4.12	4.57e-05	0.00396	0.2	0.19	Dialysis-related mortality;	chr9:76423254	chr9:76398699~76399586:+
THCA	cis	rs758324	0.773	rs804058	ENSG00000237714.1	P4HA2-AS1	-4.12	4.57e-05	0.00396	-0.26	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131930669	chr5:132184876~132192808:+
THCA	cis	rs722599	0.683	rs17102847	ENSG00000279594.1	RP11-950C14.10	-4.12	4.57e-05	0.00396	-0.19	-0.19	IgG glycosylation;	chr14:74858077	chr14:75011269~75012851:-
THCA	cis	rs7264396	0.573	rs58355182	ENSG00000088340.14	FER1L4	4.12	4.57e-05	0.00396	0.17	0.19	Total cholesterol levels;	chr20:35487861	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.778	rs6120959	ENSG00000088340.14	FER1L4	4.12	4.57e-05	0.00396	0.17	0.19	Total cholesterol levels;	chr20:35490022	chr20:35558737~35607562:-
THCA	cis	rs4908768	0.906	rs74324642	ENSG00000232912.4	RP5-1115A15.1	-4.12	4.57e-05	0.00396	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8560113	chr1:8424645~8434838:+
THCA	cis	rs357618	1	rs357627	ENSG00000260581.1	CTB-113P19.4	4.11	4.57e-05	0.00396	0.24	0.19	Basophil percentage of white cells;	chr5:151470699	chr5:151652275~151655449:+
THCA	cis	rs357618	1	rs357628	ENSG00000260581.1	CTB-113P19.4	4.11	4.57e-05	0.00396	0.24	0.19	Basophil percentage of white cells;	chr5:151470791	chr5:151652275~151655449:+
THCA	cis	rs357618	1	rs165352	ENSG00000260581.1	CTB-113P19.4	4.11	4.57e-05	0.00396	0.24	0.19	Basophil percentage of white cells;	chr5:151476546	chr5:151652275~151655449:+
THCA	cis	rs357618	1	rs165353	ENSG00000260581.1	CTB-113P19.4	4.11	4.57e-05	0.00396	0.24	0.19	Basophil percentage of white cells;	chr5:151477196	chr5:151652275~151655449:+
THCA	cis	rs2221894	0.96	rs1487970	ENSG00000251191.6	LINC00589	4.11	4.57e-05	0.00396	0.23	0.19	Obesity-related traits;	chr8:29031649	chr8:29673922~29748109:-
THCA	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	4.11	4.57e-05	0.00396	0.17	0.19	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
THCA	cis	rs9650657	0.504	rs2409724	ENSG00000206014.6	OR7E161P	4.11	4.57e-05	0.00396	0.22	0.19	Neuroticism;	chr8:11184133	chr8:11928597~11929563:-
THCA	cis	rs16944613	0.541	rs7183319	ENSG00000259212.1	CTD-3065B20.2	4.11	4.57e-05	0.00396	0.29	0.19	Colorectal cancer;	chr15:90551800	chr15:90595840~90596447:-
THCA	cis	rs16944613	0.541	rs4566137	ENSG00000259212.1	CTD-3065B20.2	4.11	4.57e-05	0.00396	0.29	0.19	Colorectal cancer;	chr15:90554732	chr15:90595840~90596447:-
THCA	cis	rs10435719	0.773	rs7842810	ENSG00000206014.6	OR7E161P	-4.11	4.57e-05	0.00396	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:11928597~11929563:-
THCA	cis	rs62229266	0.626	rs7280896	ENSG00000230212.5	AP000688.14	-4.11	4.57e-05	0.00396	-0.23	-0.19	Mitral valve prolapse;	chr21:36088608	chr21:36069642~36126640:-
THCA	cis	rs7737355	0.853	rs31586	ENSG00000237714.1	P4HA2-AS1	4.11	4.57e-05	0.00396	0.26	0.19	Life satisfaction;	chr5:131665003	chr5:132184876~132192808:+
THCA	cis	rs10107145	0.509	rs73209954	ENSG00000280294.1	RP11-177H2.1	4.11	4.58e-05	0.00396	0.16	0.19	Systolic blood pressure;	chr8:10903157	chr8:10856085~10859436:-
THCA	cis	rs11026091	1	rs7104488	ENSG00000224513.2	AC109309.4	-4.11	4.58e-05	0.00396	-0.23	-0.19	Multiple sclerosis;	chr11:3238600	chr11:3226061~3232838:+
THCA	cis	rs6479891	1	rs72829170	ENSG00000272767.1	JMJD1C-AS1	4.11	4.58e-05	0.00396	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs61855465	ENSG00000272767.1	JMJD1C-AS1	4.11	4.58e-05	0.00396	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12413730	ENSG00000272767.1	JMJD1C-AS1	4.11	4.58e-05	0.00396	0.26	0.19	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63465229~63466563:+
THCA	cis	rs2191566	0.747	rs4803667	ENSG00000266921.1	RP11-15A1.7	-4.11	4.58e-05	0.00396	-0.18	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44029451	chr19:43996896~44002836:-
THCA	cis	rs7914558	0.966	rs1591915	ENSG00000213061.2	PFN1P11	4.11	4.58e-05	0.00396	0.23	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102838011~102845473:-
THCA	cis	rs9902453	0.967	rs4493117	ENSG00000263370.1	RP11-68I3.5	4.11	4.58e-05	0.00397	0.24	0.19	Coffee consumption (cups per day);	chr17:30162752	chr17:29639627~29640825:+
THCA	cis	rs801193	0.967	rs3800823	ENSG00000230295.1	RP11-458F8.2	4.11	4.58e-05	0.00397	0.14	0.19	Aortic root size;	chr7:66682123	chr7:66880708~66882981:+
THCA	cis	rs8030605	0.704	rs72742652	ENSG00000277245.1	RP11-48G14.3	4.11	4.58e-05	0.00397	0.33	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56430236	chr15:56447120~56447697:+
THCA	cis	rs4906332	0.933	rs34606394	ENSG00000244691.1	RPL10AP1	-4.11	4.58e-05	0.00397	-0.24	-0.19	Coronary artery disease;	chr14:103449299	chr14:103412119~103412761:-
THCA	cis	rs13178541	0.81	rs9327731	ENSG00000250378.1	RP11-119J18.1	-4.11	4.58e-05	0.00397	-0.24	-0.19	IgG glycosylation;	chr5:135861438	chr5:135812667~135826582:+
THCA	cis	rs9733	0.744	rs3754211	ENSG00000231073.1	RP11-316M1.3	4.11	4.58e-05	0.00397	0.22	0.19	Tonsillectomy;	chr1:150979381	chr1:150973123~150975534:+
THCA	cis	rs950169	0.8	rs34302901	ENSG00000275120.1	RP11-182J1.17	4.11	4.58e-05	0.00397	0.22	0.19	Schizophrenia;	chr15:84567712	chr15:84599434~84606463:-
THCA	cis	rs2836974	0.897	rs2836933	ENSG00000255568.3	BRWD1-AS2	4.11	4.58e-05	0.00397	0.16	0.19	Cognitive function;	chr21:39192276	chr21:39313935~39314962:+
THCA	cis	rs875971	0.522	rs781144	ENSG00000234585.5	CCT6P3	4.11	4.58e-05	0.00397	0.17	0.19	Aortic root size;	chr7:65975357	chr7:65038354~65074713:+
THCA	cis	rs7216064	0.953	rs62086043	ENSG00000265055.1	AC145343.2	4.11	4.58e-05	0.00397	0.26	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971887	chr17:68096046~68101474:-
THCA	cis	rs953301	0.546	rs10494361	ENSG00000229808.1	RP11-456P18.2	4.11	4.58e-05	0.00397	0.51	0.19	Left atrial antero-posterior diameter;	chr1:161961083	chr1:161890833~161892196:+
THCA	cis	rs12234571	1	rs9640669	ENSG00000214293.7	APTR	4.11	4.59e-05	0.00397	0.23	0.19	Obesity-related traits;	chr7:77825743	chr7:77657660~77696265:-
THCA	cis	rs6580649	0.941	rs4760615	ENSG00000273765.1	RP11-370I10.11	4.11	4.59e-05	0.00397	0.21	0.19	Lung cancer;	chr12:48034367	chr12:48360920~48361377:+
THCA	cis	rs800160	0.777	rs10765944	ENSG00000199550.1	Y_RNA	4.11	4.59e-05	0.00397	0.29	0.19	Bacteremia;	chr11:2326964	chr11:2372638~2372750:+
THCA	cis	rs889398	0.741	rs11075744	ENSG00000226232.7	RP11-419C5.2	-4.11	4.59e-05	0.00397	-0.18	-0.19	Body mass index;	chr16:69875212	chr16:69976388~69996188:-
THCA	cis	rs4879656	0.564	rs20583	ENSG00000225693.1	LAGE3P1	-4.11	4.59e-05	0.00397	-0.2	-0.19	Menopause (age at onset);	chr9:33026574	chr9:33019682~33020165:-
THCA	cis	rs6570726	0.935	rs432086	ENSG00000270638.1	RP3-466P17.1	-4.11	4.59e-05	0.00397	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs397418	ENSG00000270638.1	RP3-466P17.1	4.11	4.59e-05	0.00397	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs419854	ENSG00000270638.1	RP3-466P17.1	4.11	4.59e-05	0.00397	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs365658	ENSG00000270638.1	RP3-466P17.1	4.11	4.59e-05	0.00397	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145735570~145737218:+
THCA	cis	rs35740288	0.822	rs2241268	ENSG00000259295.5	CSPG4P12	4.11	4.59e-05	0.00397	0.29	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85735078	chr15:85191438~85213905:+
THCA	cis	rs858239	0.602	rs6953996	ENSG00000230042.1	AK3P3	-4.11	4.59e-05	0.00397	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23129178~23129841:+
THCA	cis	rs6921919	0.583	rs6907950	ENSG00000273712.1	RP5-874C20.7	4.11	4.59e-05	0.00397	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28315613~28315883:-
THCA	cis	rs1048886	1	rs1048886	ENSG00000271967.1	RP11-134K13.4	-4.11	4.59e-05	0.00397	-0.19	-0.19	Type 2 diabetes;	chr6:70579486	chr6:70596438~70596980:+
THCA	cis	rs10090774	1	rs6578139	ENSG00000279766.1	RP11-642A1.2	-4.11	4.59e-05	0.00397	-0.23	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140823431	chr8:140572142~140572812:-
THCA	cis	rs11030122	1	rs11030122	ENSG00000230593.3	AC090804.1	4.11	4.59e-05	0.00397	0.24	0.19	Mean platelet volume;Platelet distribution width;	chr11:3865946	chr11:3892398~3892887:-
THCA	cis	rs12121840	0.607	rs285435	ENSG00000237463.4	RP11-280O1.2	4.11	4.59e-05	0.00397	0.17	0.19	Interleukin-1-receptor antagonist levels;	chr1:165549243	chr1:165476841~165582155:-
THCA	cis	rs6938	0.596	rs11630918	ENSG00000260269.4	CTD-2323K18.1	-4.11	4.59e-05	0.00398	-0.27	-0.19	Breast cancer;	chr15:74863555	chr15:75527150~75601205:-
THCA	cis	rs7131987	0.903	rs67150462	ENSG00000257599.1	OVCH1-AS1	-4.11	4.59e-05	0.00398	-0.23	-0.19	QT interval;	chr12:29240392	chr12:29389294~29487488:+
THCA	cis	rs2617170	0.961	rs11053802	ENSG00000245648.1	RP11-277P12.20	4.11	4.59e-05	0.00398	0.19	0.19	Behcet's disease;	chr12:10444608	chr12:10363769~10398506:+
THCA	cis	rs7552393	0.965	rs6576947	ENSG00000233008.4	RP11-475O6.1	-4.11	4.59e-05	0.00398	-0.2	-0.19	Select biomarker traits;	chr1:83798419	chr1:83575776~83861023:-
THCA	cis	rs9788682	0.747	rs7183604	ENSG00000261143.1	ADAMTS7P3	4.11	4.6e-05	0.00398	0.25	0.19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78606871	chr15:77976042~77993057:+
THCA	cis	rs9291683	0.588	rs17247314	ENSG00000250413.1	RP11-448G15.1	-4.11	4.6e-05	0.00398	-0.18	-0.19	Bone mineral density;	chr4:10003119	chr4:10006482~10009725:+
THCA	cis	rs755249	0.727	rs2242500	ENSG00000237624.1	OXCT2P1	4.11	4.6e-05	0.00398	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39514956~39516490:+
THCA	cis	rs7829975	0.774	rs35431455	ENSG00000233609.3	RP11-62H7.2	4.11	4.6e-05	0.00398	0.18	0.19	Mood instability;	chr8:8816226	chr8:8961200~8979025:+
THCA	cis	rs6442522	0.526	rs3773448	ENSG00000249786.6	EAF1-AS1	4.11	4.6e-05	0.00398	0.19	0.19	Uric acid levels;	chr3:15477755	chr3:15436171~15455940:-
THCA	cis	rs8081395	0.707	rs1024637	ENSG00000267302.4	RP11-178C3.2	-4.11	4.6e-05	0.00398	-0.22	-0.19	White blood cell count;	chr17:59961532	chr17:59964832~59996972:+
THCA	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-4.11	4.6e-05	0.00398	-0.2	-0.19	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
THCA	cis	rs4906332	0.899	rs12888042	ENSG00000244691.1	RPL10AP1	-4.11	4.6e-05	0.00398	-0.24	-0.19	Coronary artery disease;	chr14:103425372	chr14:103412119~103412761:-
THCA	cis	rs4906332	1	rs17617094	ENSG00000244691.1	RPL10AP1	-4.11	4.6e-05	0.00398	-0.24	-0.19	Coronary artery disease;	chr14:103427091	chr14:103412119~103412761:-
THCA	cis	rs1204798	0.636	rs4946141	ENSG00000237021.2	RP3-486I3.7	-4.11	4.6e-05	0.00398	-0.23	-0.19	Dental caries;	chr6:116157788	chr6:116254207~116256743:+
THCA	cis	rs2280018	0.526	rs2966128	ENSG00000255277.3	ABCC6P2	4.11	4.6e-05	0.00398	0.21	0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:14820792~14824702:-
THCA	cis	rs7487637	0.529	rs11168244	ENSG00000257488.4	RP5-1057I20.2	4.11	4.6e-05	0.00398	0.31	0.19	Mononucleosis;	chr12:47809158	chr12:47826854~47837898:+
THCA	cis	rs427943	0.83	rs984791	ENSG00000223768.1	LINC00205	-4.11	4.6e-05	0.00398	-0.17	-0.19	Body mass index;	chr21:45178205	chr21:45293285~45297354:+
THCA	cis	rs4794202	0.534	rs8078688	ENSG00000264920.1	RP11-6N17.4	-4.11	4.6e-05	0.00398	-0.22	-0.19	Alzheimer's disease (cognitive decline);	chr17:47842503	chr17:47891255~47895812:-
THCA	cis	rs2227564	0.794	rs2688607	ENSG00000271816.1	BMS1P4	-4.11	4.6e-05	0.00398	-0.2	-0.19	Crohn's disease;Inflammatory bowel disease;	chr10:73903978	chr10:73699151~73730487:-
THCA	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-4.11	4.6e-05	0.00398	-0.18	-0.19	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
THCA	cis	rs758324	0.947	rs72793241	ENSG00000237714.1	P4HA2-AS1	-4.11	4.6e-05	0.00398	-0.26	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131905192	chr5:132184876~132192808:+
THCA	cis	rs5006884	0.585	rs12804113	ENSG00000167355.6	AC104389.28	-4.11	4.6e-05	0.00398	-0.32	-0.19	Fetal hemoglobin levels;	chr11:5408663	chr11:5304976~5505652:-
THCA	cis	rs7927592	0.956	rs7126340	ENSG00000160172.9	FAM86C2P	4.11	4.6e-05	0.00398	0.18	0.19	Total body bone mineral density;	chr11:68489825	chr11:67791648~67805336:-
THCA	cis	rs3755605	0.697	rs6766729	ENSG00000242578.1	RP11-469J4.3	4.11	4.6e-05	0.00398	0.21	0.19	Testicular germ cell tumor;	chr3:170188156	chr3:170410512~170418615:+
THCA	cis	rs9534288	0.913	rs9534298	ENSG00000235903.6	CPB2-AS1	4.11	4.6e-05	0.00398	0.27	0.19	Blood protein levels;	chr13:46051431	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.913	rs9534299	ENSG00000235903.6	CPB2-AS1	4.11	4.6e-05	0.00398	0.27	0.19	Blood protein levels;	chr13:46051451	chr13:46052806~46113332:+
THCA	cis	rs1267303	0.637	rs1745371	ENSG00000232022.5	FAAHP1	4.11	4.6e-05	0.00398	0.21	0.19	Monobrow;	chr1:46519520	chr1:46432129~46445521:+
THCA	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	4.11	4.6e-05	0.00398	0.17	0.19	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
THCA	cis	rs11633886	0.934	rs11631912	ENSG00000273972.1	CTD-2306A12.1	-4.11	4.6e-05	0.00398	-0.2	-0.19	Diisocyanate-induced asthma;	chr15:45797218	chr15:45702640~45703183:+
THCA	cis	rs11633886	0.934	rs12901750	ENSG00000273972.1	CTD-2306A12.1	-4.11	4.6e-05	0.00398	-0.2	-0.19	Diisocyanate-induced asthma;	chr15:45797432	chr15:45702640~45703183:+
THCA	cis	rs7551222	0.646	rs6594015	ENSG00000240219.1	RP11-430C7.5	4.11	4.6e-05	0.00398	0.18	0.19	Schizophrenia;	chr1:204492494	chr1:204626775~204629712:+
THCA	cis	rs4561483	0.549	rs33657	ENSG00000263307.1	RP11-166B2.8	4.11	4.6e-05	0.00398	0.19	0.19	Testicular germ cell tumor;	chr16:11875867	chr16:11851649~11895611:+
THCA	cis	rs10050311	0.698	rs10516778	ENSG00000251411.1	RP11-397E7.4	-4.11	4.6e-05	0.00398	-0.22	-0.19	Insulin-related traits;	chr4:86714898	chr4:86913266~86914817:-
THCA	cis	rs10050311	0.698	rs17454154	ENSG00000251411.1	RP11-397E7.4	-4.11	4.6e-05	0.00398	-0.22	-0.19	Insulin-related traits;	chr4:86715007	chr4:86913266~86914817:-
THCA	cis	rs9926296	0.605	rs886952	ENSG00000274627.1	RP11-104N10.2	-4.11	4.6e-05	0.00398	-0.19	-0.19	Vitiligo;	chr16:89770373	chr16:89516797~89522217:+
THCA	cis	rs34421088	0.56	rs11780851	ENSG00000255046.1	RP11-297N6.4	4.11	4.6e-05	0.00398	0.2	0.19	Neuroticism;	chr8:11543607	chr8:11797928~11802568:-
THCA	cis	rs9650657	0.504	rs10093053	ENSG00000206014.6	OR7E161P	4.11	4.61e-05	0.00398	0.22	0.19	Neuroticism;	chr8:11179678	chr8:11928597~11929563:-
THCA	cis	rs7829975	0.744	rs2409092	ENSG00000253981.4	ALG1L13P	4.11	4.61e-05	0.00398	0.18	0.19	Mood instability;	chr8:8824682	chr8:8236003~8244667:-
THCA	cis	rs5769765	1	rs5769760	ENSG00000260613.1	RP3-522J7.6	4.11	4.61e-05	0.00398	0.24	0.19	Schizophrenia;	chr22:49866048	chr22:49832616~49837786:-
THCA	cis	rs2380205	0.689	rs12769593	ENSG00000232807.2	RP11-536K7.3	4.11	4.61e-05	0.00399	0.18	0.19	Breast cancer;	chr10:5856030	chr10:5934270~5945900:-
THCA	cis	rs9291683	0.588	rs17247314	ENSG00000261490.1	RP11-448G15.3	4.11	4.61e-05	0.00399	0.11	0.19	Bone mineral density;	chr4:10003119	chr4:10068089~10073019:-
THCA	cis	rs9326248	0.53	rs2155583	ENSG00000280143.1	AP000892.6	4.11	4.61e-05	0.00399	0.29	0.19	Blood protein levels;	chr11:117044501	chr11:117204967~117210292:+
THCA	cis	rs13102973	0.64	rs6829739	ENSG00000250144.1	RP11-553P9.1	-4.11	4.61e-05	0.00399	-0.13	-0.19	Subjective well-being;	chr4:134914634	chr4:135045464~135046850:+
THCA	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-4.11	4.61e-05	0.00399	-0.17	-0.19	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-4.11	4.61e-05	0.00399	-0.17	-0.19	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	4.11	4.61e-05	0.00399	0.17	0.19	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
THCA	cis	rs7927592	0.956	rs10896334	ENSG00000160172.9	FAM86C2P	4.11	4.61e-05	0.00399	0.18	0.19	Total body bone mineral density;	chr11:68514026	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.956	rs10896337	ENSG00000160172.9	FAM86C2P	4.11	4.61e-05	0.00399	0.18	0.19	Total body bone mineral density;	chr11:68516768	chr11:67791648~67805336:-
THCA	cis	rs1048886	0.872	rs77054685	ENSG00000271967.1	RP11-134K13.4	-4.11	4.61e-05	0.00399	-0.19	-0.19	Type 2 diabetes;	chr6:70572469	chr6:70596438~70596980:+
THCA	cis	rs2120243	0.539	rs6441126	ENSG00000241770.1	RP11-555M1.3	-4.11	4.61e-05	0.00399	-0.25	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157377227	chr3:157163452~157169133:+
THCA	cis	rs12681963	0.688	rs7010839	ENSG00000248159.1	HSPA8P11	-4.11	4.61e-05	0.00399	-0.34	-0.19	Migraine;	chr8:30223451	chr8:30237382~30240997:+
THCA	cis	rs409045	0.525	rs452688	ENSG00000271874.1	CTD-2024P10.2	-4.11	4.61e-05	0.00399	-0.23	-0.19	Left ventricular mass;	chr5:34628325	chr5:34651457~34651888:-
THCA	cis	rs7572644	0.766	rs10180107	ENSG00000223522.1	AC093690.1	-4.11	4.61e-05	0.00399	-0.24	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28017658	chr2:28307691~28310459:-
THCA	cis	rs758324	0.627	rs269900	ENSG00000224431.1	AC063976.7	-4.11	4.61e-05	0.00399	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132146551	chr5:132199456~132203487:+
THCA	cis	rs2299587	0.554	rs11778309	ENSG00000253671.1	RP11-806O11.1	-4.11	4.61e-05	0.00399	-0.22	-0.19	Economic and political preferences;	chr8:17889924	chr8:17808941~17820868:+
THCA	cis	rs4767841	0.565	rs7133437	ENSG00000248636.5	RP11-768F21.1	-4.11	4.61e-05	0.00399	-0.19	-0.19	Urgency urinary incontinence;	chr12:119778806	chr12:119387987~119668079:-
THCA	cis	rs4767841	0.625	rs7969405	ENSG00000248636.5	RP11-768F21.1	-4.11	4.61e-05	0.00399	-0.19	-0.19	Urgency urinary incontinence;	chr12:119780035	chr12:119387987~119668079:-
THCA	cis	rs8062405	0.656	rs7189927	ENSG00000270424.1	RP11-1348G14.6	-4.11	4.61e-05	0.00399	-0.23	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28749959~28750595:-
THCA	cis	rs113835537	0.877	rs57127845	ENSG00000255517.5	CTD-3074O7.5	-4.11	4.61e-05	0.00399	-0.2	-0.19	Airway imaging phenotypes;	chr11:66550854	chr11:66473490~66480233:-
THCA	cis	rs9911578	0.835	rs3744093	ENSG00000224738.1	AC099850.1	-4.11	4.61e-05	0.00399	-0.22	-0.19	Intelligence (multi-trait analysis);	chr17:58415439	chr17:59106598~59118267:+
THCA	cis	rs4950322	0.58	rs4950308	ENSG00000271721.1	RP11-337C18.9	4.11	4.61e-05	0.00399	0.21	0.19	Protein quantitative trait loci;	chr1:147120092	chr1:147175602~147177740:+
THCA	cis	rs6142618	0.583	rs2235904	ENSG00000224452.1	RSL24D1P6	4.11	4.61e-05	0.00399	0.22	0.19	Inflammatory bowel disease;	chr20:32133909	chr20:32170390~32170790:-
THCA	cis	rs7520050	0.553	rs2993263	ENSG00000234329.1	RP11-767N6.2	4.11	4.61e-05	0.00399	0.17	0.19	Reticulocyte count;Red blood cell count;	chr1:45555958	chr1:45651039~45651826:-
THCA	cis	rs3734266	0.702	rs6457798	ENSG00000272288.4	RP11-140K17.3	-4.11	4.62e-05	0.00399	-0.18	-0.19	Systemic lupus erythematosus;	chr6:34929422	chr6:34696317~34697470:+
THCA	cis	rs12755164	0.771	rs12066492	ENSG00000223479.3	RP4-788P17.1	-4.11	4.62e-05	0.00399	-0.2	-0.19	Schizophrenia;	chr1:72852984	chr1:73635216~73715214:+
THCA	cis	rs2342371	0.701	rs4916498	ENSG00000273013.1	CTD-2002J20.1	4.11	4.62e-05	0.00399	0.18	0.19	Fat distribution (HIV);	chr3:196476090	chr3:196474801~196475394:+
THCA	cis	rs804280	0.543	rs13261205	ENSG00000206014.6	OR7E161P	-4.11	4.62e-05	0.00399	-0.22	-0.19	Myopia (pathological);	chr8:11933707	chr8:11928597~11929563:-
THCA	cis	rs804280	0.518	rs34266352	ENSG00000206014.6	OR7E161P	-4.11	4.62e-05	0.00399	-0.22	-0.19	Myopia (pathological);	chr8:11933953	chr8:11928597~11929563:-
THCA	cis	rs804280	0.542	rs34117651	ENSG00000206014.6	OR7E161P	-4.11	4.62e-05	0.00399	-0.22	-0.19	Myopia (pathological);	chr8:11934108	chr8:11928597~11929563:-
THCA	cis	rs7551222	0.789	rs2290855	ENSG00000240219.1	RP11-430C7.5	4.11	4.62e-05	0.00399	0.17	0.19	Schizophrenia;	chr1:204546735	chr1:204626775~204629712:+
THCA	cis	rs919433	0.679	rs7600862	ENSG00000231621.1	AC013264.2	-4.11	4.62e-05	0.00399	-0.2	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197669790	chr2:197197991~197199273:+
THCA	cis	rs4282054	0.631	rs13081155	ENSG00000243224.1	RP5-1157M23.2	-4.11	4.62e-05	0.00399	-0.19	-0.19	Cognitive function;	chr3:52698413	chr3:52239258~52241097:+
THCA	cis	rs4908760	0.539	rs6698830	ENSG00000232912.4	RP5-1115A15.1	4.11	4.62e-05	0.00399	0.17	0.19	Vitiligo;	chr1:8794486	chr1:8424645~8434838:+
THCA	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-4.11	4.62e-05	0.00399	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
THCA	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	4.11	4.62e-05	0.004	0.22	0.19	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
THCA	cis	rs7824557	0.564	rs1435275	ENSG00000206014.6	OR7E161P	4.11	4.62e-05	0.004	0.22	0.19	Retinal vascular caliber;	chr8:11378226	chr8:11928597~11929563:-
THCA	cis	rs944289	0.617	rs1537428	ENSG00000258844.1	RP11-259K15.2	-4.11	4.62e-05	0.004	-0.17	-0.19	Thyroid cancer;	chr14:36117579	chr14:36214607~36235608:+
THCA	cis	rs13113518	0.966	rs4864544	ENSG00000272969.1	RP11-528I4.2	4.11	4.62e-05	0.004	0.21	0.19	Height;	chr4:55515292	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs6847529	ENSG00000272969.1	RP11-528I4.2	4.11	4.62e-05	0.004	0.21	0.19	Height;	chr4:55518776	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs6822740	ENSG00000272969.1	RP11-528I4.2	4.11	4.62e-05	0.004	0.21	0.19	Height;	chr4:55518922	chr4:55547112~55547889:+
THCA	cis	rs8020441	1	rs72681673	ENSG00000269906.1	RP11-248J18.2	4.11	4.62e-05	0.004	0.27	0.19	Cognitive performance;	chr14:50705204	chr14:50662511~50663178:-
THCA	cis	rs6921919	0.583	rs6908137	ENSG00000273712.1	RP5-874C20.7	4.11	4.62e-05	0.004	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28315613~28315883:-
THCA	cis	rs4947019	0.614	rs117663805	ENSG00000223537.2	RP5-919F19.5	-4.11	4.62e-05	0.004	-0.41	-0.19	Hematological parameters;	chr6:109455712	chr6:109487906~109506800:+
THCA	cis	rs7474896	0.515	rs2738203	ENSG00000226578.1	RP11-258F22.1	4.11	4.62e-05	0.004	0.27	0.19	Obesity (extreme);	chr10:37988668	chr10:37775371~37784131:-
THCA	cis	rs1842579	1	rs12727916	ENSG00000272691.1	RP11-290M5.4	-4.11	4.62e-05	0.004	-0.18	-0.19	Coronary artery aneurysm in Kawasaki disease;	chr1:85834128	chr1:85578500~85578742:-
THCA	cis	rs651907	0.763	rs647556	ENSG00000256628.3	ZBTB11-AS1	4.11	4.62e-05	0.004	0.2	0.19	Colorectal cancer;	chr3:101871351	chr3:101676475~101679217:+
THCA	cis	rs62158800	0.789	rs62158808	ENSG00000224568.1	AC096669.3	4.11	4.62e-05	0.004	0.36	0.19	Facial morphology (factor 22);	chr2:107607292	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.925	rs62158810	ENSG00000224568.1	AC096669.3	4.11	4.62e-05	0.004	0.36	0.19	Facial morphology (factor 22);	chr2:107612391	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.789	rs56158390	ENSG00000224568.1	AC096669.3	4.11	4.62e-05	0.004	0.36	0.19	Facial morphology (factor 22);	chr2:107618616	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.925	rs62158827	ENSG00000224568.1	AC096669.3	4.11	4.62e-05	0.004	0.36	0.19	Facial morphology (factor 22);	chr2:107624823	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.925	rs72823069	ENSG00000224568.1	AC096669.3	4.11	4.62e-05	0.004	0.36	0.19	Facial morphology (factor 22);	chr2:107627392	chr2:107529487~107556326:+
THCA	cis	rs12439619	0.739	rs4778988	ENSG00000276710.3	CSPG4P8	-4.11	4.62e-05	0.004	-0.2	-0.19	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82459472~82477258:+
THCA	cis	rs7924176	0.521	rs11001022	ENSG00000232342.6	RP11-46O21.2	4.11	4.63e-05	0.004	0.24	0.19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:74506081~74530553:-
THCA	cis	rs10175706	0.965	rs6543239	ENSG00000256637.5	RP11-76I14.1	-4.11	4.63e-05	0.004	-0.17	-0.19	Chin dimples;	chr2:104073356	chr2:103874310~104077778:+
THCA	cis	rs7927592	0.913	rs10896330	ENSG00000160172.9	FAM86C2P	4.11	4.63e-05	0.004	0.18	0.19	Total body bone mineral density;	chr11:68487530	chr11:67791648~67805336:-
THCA	cis	rs7824557	0.603	rs2246606	ENSG00000154316.13	TDH	-4.11	4.63e-05	0.004	-0.14	-0.19	Retinal vascular caliber;	chr8:11361825	chr8:11339637~11368452:+
THCA	cis	rs13182402	1	rs17154671	ENSG00000230929.5	RP11-395C3.1	-4.11	4.63e-05	0.004	-0.35	-0.19	Osteoporosis;	chr5:126572511	chr5:126628019~126628319:-
THCA	cis	rs4767841	0.537	rs7299548	ENSG00000248636.5	RP11-768F21.1	-4.11	4.63e-05	0.004	-0.19	-0.19	Urgency urinary incontinence;	chr12:119778650	chr12:119387987~119668079:-
THCA	cis	rs10802047	0.587	rs4658992	ENSG00000231365.4	RP11-418J17.1	-4.11	4.63e-05	0.004	-0.19	-0.19	Relative hand skill in reading disability;	chr1:118725682	chr1:119140396~119275973:+
THCA	cis	rs13068223	0.617	rs13061457	ENSG00000240875.4	LINC00886	-4.11	4.63e-05	0.004	-0.15	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156747346~156817062:-
THCA	cis	rs7819412	0.654	rs4840550	ENSG00000206014.6	OR7E161P	4.11	4.63e-05	0.004	0.22	0.19	Triglycerides;	chr8:11171520	chr8:11928597~11929563:-
THCA	cis	rs9595908	0.694	rs3752474	ENSG00000212293.1	SNORA16	4.11	4.63e-05	0.004	0.22	0.19	Body mass index;	chr13:32758510	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.709	rs7988089	ENSG00000212293.1	SNORA16	4.11	4.63e-05	0.004	0.22	0.19	Body mass index;	chr13:32759738	chr13:32420390~32420516:-
THCA	cis	rs2898290	0.592	rs2736342	ENSG00000227888.4	FAM66A	-4.11	4.63e-05	0.004	-0.24	-0.19	Systolic blood pressure;	chr8:11489780	chr8:12362019~12388296:+
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000182586.6	LINC00334	-4.11	4.63e-05	0.004	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45234340~45258730:+
THCA	cis	rs7824557	0.51	rs1435274	ENSG00000154316.13	TDH	4.11	4.63e-05	0.004	0.14	0.19	Retinal vascular caliber;	chr8:11378401	chr8:11339637~11368452:+
THCA	cis	rs8067545	0.75	rs34290687	ENSG00000270091.1	RP11-78O7.2	-4.11	4.63e-05	0.00401	-0.14	-0.19	Schizophrenia;	chr17:20087898	chr17:19896590~19897287:-
THCA	cis	rs7923609	0.875	rs10761741	ENSG00000232075.1	MRPL35P2	-4.11	4.63e-05	0.00401	-0.24	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63306426	chr10:63634317~63634827:-
THCA	cis	rs4237845	0.537	rs10747787	ENSG00000270039.1	RP11-571M6.17	-4.11	4.63e-05	0.00401	-0.2	-0.19	Intelligence (multi-trait analysis);	chr12:57866874	chr12:57803838~57804415:+
THCA	cis	rs9880211	0.613	rs67109185	ENSG00000273486.1	RP11-731C17.2	4.11	4.63e-05	0.00401	0.18	0.19	Height;Body mass index;	chr3:136108550	chr3:136837338~136839021:-
THCA	cis	rs9880211	0.613	rs12695644	ENSG00000273486.1	RP11-731C17.2	4.11	4.63e-05	0.00401	0.18	0.19	Height;Body mass index;	chr3:136126096	chr3:136837338~136839021:-
THCA	cis	rs13113518	0.738	rs6849883	ENSG00000223305.1	RN7SKP30	4.11	4.63e-05	0.00401	0.24	0.19	Height;	chr4:55387515	chr4:55540502~55540835:-
THCA	cis	rs7267979	1	rs6083828	ENSG00000276952.1	RP5-965G21.6	-4.11	4.63e-05	0.00401	-0.19	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25284915~25285588:-
THCA	cis	rs9863	0.828	rs4765562	ENSG00000269997.1	RP11-214K3.21	-4.11	4.63e-05	0.00401	-0.22	-0.19	White blood cell count;	chr12:123988024	chr12:123966077~123966629:-
THCA	cis	rs7267979	0.866	rs2424698	ENSG00000274973.1	RP13-401N8.7	-4.11	4.64e-05	0.00401	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25845497~25845862:+
THCA	cis	rs2015599	0.601	rs17715086	ENSG00000273680.1	RP11-996F15.6	4.11	4.64e-05	0.00401	0.27	0.19	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29332733~29333383:-
THCA	cis	rs28476539	0.501	rs28512217	ENSG00000270480.1	RP11-57B24.1	4.11	4.64e-05	0.00401	0.28	0.19	Sum neutrophil eosinophil counts;Granulocyte count;	chr4:82618943	chr4:82691737~82692468:+
THCA	cis	rs7552393	1	rs6576943	ENSG00000233008.4	RP11-475O6.1	-4.11	4.64e-05	0.00401	-0.2	-0.19	Select biomarker traits;	chr1:83781747	chr1:83575776~83861023:-
THCA	cis	rs13113518	1	rs13122619	ENSG00000272969.1	RP11-528I4.2	4.11	4.64e-05	0.00401	0.21	0.19	Height;	chr4:55479339	chr4:55547112~55547889:+
THCA	cis	rs11671005	0.696	rs73066211	ENSG00000252334.1	RNU6-1337P	4.11	4.64e-05	0.00401	0.29	0.19	Mean platelet volume;	chr19:58485712	chr19:58483749~58483843:-
THCA	cis	rs4792901	0.765	rs28874115	ENSG00000267151.3	RP11-100E5.2	4.11	4.64e-05	0.00401	0.21	0.19	Dupuytren's disease;	chr17:43460886	chr17:43444707~43451200:+
THCA	cis	rs78487399	0.808	rs6737882	ENSG00000234936.1	AC010883.5	4.11	4.64e-05	0.00401	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43504769	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6757251	ENSG00000234936.1	AC010883.5	4.11	4.64e-05	0.00401	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43507708	chr2:43229573~43233394:+
THCA	cis	rs9834970	0.588	rs9985296	ENSG00000281100.1	RP11-640L9.2	4.11	4.64e-05	0.00401	0.2	0.19	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36848130	chr3:36823151~36825158:-
THCA	cis	rs875971	0.66	rs7807930	ENSG00000275400.1	RP4-756H11.5	4.11	4.64e-05	0.00401	0.17	0.19	Aortic root size;	chr7:66622178	chr7:66553805~66554199:-
THCA	cis	rs2777491	0.574	rs316616	ENSG00000247556.5	OIP5-AS1	4.11	4.64e-05	0.00401	0.18	0.19	Ulcerative colitis;	chr15:41454078	chr15:41283990~41309737:+
THCA	cis	rs6929812	0.967	rs6926142	ENSG00000216915.2	RP1-97D16.1	4.11	4.64e-05	0.00401	0.24	0.19	Neuroticism (multi-trait analysis);	chr6:27427985	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.967	rs2893916	ENSG00000216915.2	RP1-97D16.1	4.11	4.64e-05	0.00401	0.24	0.19	Neuroticism (multi-trait analysis);	chr6:27428879	chr6:27737000~27738494:-
THCA	cis	rs7131987	0.621	rs11050181	ENSG00000273680.1	RP11-996F15.6	4.11	4.64e-05	0.00401	0.26	0.19	QT interval;	chr12:29314736	chr12:29332733~29333383:-
THCA	cis	rs295490	0.831	rs3772871	ENSG00000272656.1	RP11-219D15.3	-4.11	4.64e-05	0.00401	-0.34	-0.19	PR interval in Tripanosoma cruzi seropositivity;	chr3:139522774	chr3:139349024~139349371:-
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000230295.1	RP11-458F8.2	-4.11	4.64e-05	0.00401	-0.26	-0.19	Diabetic kidney disease;	chr7:66009932	chr7:66880708~66882981:+
THCA	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-4.11	4.65e-05	0.00401	-0.19	-0.19	Height;	chr5:36941456	chr5:36666214~36725195:-
THCA	cis	rs156299	0.513	rs156290	ENSG00000234286.1	AC006026.13	4.11	4.65e-05	0.00401	0.24	0.19	Vitamin D levels;	chr7:24197611	chr7:23680195~23680786:-
THCA	cis	rs11030122	0.959	rs10160415	ENSG00000230593.3	AC090804.1	4.11	4.65e-05	0.00401	0.25	0.19	Mean platelet volume;Platelet distribution width;	chr11:3888536	chr11:3892398~3892887:-
THCA	cis	rs9818758	0.607	rs12185979	ENSG00000270441.1	RP11-694I15.7	4.11	4.65e-05	0.00402	0.3	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49614537	chr3:49140086~49160851:-
THCA	cis	rs10489167	1	rs823682	ENSG00000237899.1	RP4-739H11.3	-4.11	4.65e-05	0.00402	-0.33	-0.19	Depressive and manic episodes in bipolar disorder;	chr1:40765385	chr1:40669089~40687588:-
THCA	cis	rs6957923	0.5	rs67397633	ENSG00000234286.1	AC006026.13	-4.11	4.65e-05	0.00402	-0.29	-0.19	Height;	chr7:23451571	chr7:23680195~23680786:-
THCA	cis	rs728616	0.558	rs7097080	ENSG00000225484.5	NUTM2B-AS1	-4.11	4.65e-05	0.00402	-0.3	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406944	chr10:79663088~79826594:-
THCA	cis	rs758324	0.617	rs9717078	ENSG00000237714.1	P4HA2-AS1	4.11	4.65e-05	0.00402	0.26	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131835198	chr5:132184876~132192808:+
THCA	cis	rs59868192	0.925	rs58818261	ENSG00000246740.2	PLA2G4E-AS1	4.11	4.65e-05	0.00402	0.37	0.19	White blood cell count;	chr15:41950900	chr15:41972763~41999094:+
THCA	cis	rs6570726	0.791	rs1280276	ENSG00000270638.1	RP3-466P17.1	4.11	4.65e-05	0.00402	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145735570~145737218:+
THCA	cis	rs6822297	1	rs6822297	ENSG00000240005.4	RP11-293A21.1	-4.11	4.65e-05	0.00402	-0.2	-0.19	Obesity-related traits;	chr4:26999373	chr4:26859806~26860599:-
THCA	cis	rs6570726	0.791	rs6912079	ENSG00000270638.1	RP3-466P17.1	4.11	4.65e-05	0.00402	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145735570~145737218:+
THCA	cis	rs8141529	0.509	rs6005927	ENSG00000272858.1	CTA-292E10.8	-4.11	4.65e-05	0.00402	-0.2	-0.19	Lymphocyte counts;	chr22:28859896	chr22:28814914~28815662:+
THCA	cis	rs3764400	0.506	rs56103412	ENSG00000278765.1	RP5-890E16.5	4.11	4.65e-05	0.00402	0.36	0.19	Body mass index;	chr17:48464940	chr17:48066704~48067293:-
THCA	cis	rs758324	0.732	rs247285	ENSG00000224431.1	AC063976.7	-4.11	4.65e-05	0.00402	-0.19	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132129995	chr5:132199456~132203487:+
THCA	cis	rs7267979	0.933	rs1130694	ENSG00000276952.1	RP5-965G21.6	4.11	4.65e-05	0.00402	0.2	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25284915~25285588:-
THCA	cis	rs4767841	0.539	rs203331	ENSG00000248636.5	RP11-768F21.1	-4.11	4.65e-05	0.00402	-0.19	-0.19	Urgency urinary incontinence;	chr12:119772466	chr12:119387987~119668079:-
THCA	cis	rs6964833	1	rs17515241	ENSG00000184616.8	AC004166.6	-4.11	4.65e-05	0.00402	-0.29	-0.19	Menarche (age at onset);	chr7:74717695	chr7:74906673~74913256:-
THCA	cis	rs1150668	0.699	rs1736895	ENSG00000220721.1	OR1F12	4.11	4.65e-05	0.00402	0.21	0.19	Pubertal anthropometrics;	chr6:28252048	chr6:28073316~28074233:+
THCA	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	4.11	4.65e-05	0.00402	0.22	0.19	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
THCA	cis	rs728616	0.614	rs17678737	ENSG00000225484.5	NUTM2B-AS1	-4.11	4.65e-05	0.00402	-0.33	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80374229	chr10:79663088~79826594:-
THCA	cis	rs728616	0.558	rs17616958	ENSG00000225484.5	NUTM2B-AS1	-4.11	4.65e-05	0.00402	-0.33	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377705	chr10:79663088~79826594:-
THCA	cis	rs728616	0.558	rs17616964	ENSG00000225484.5	NUTM2B-AS1	-4.11	4.65e-05	0.00402	-0.33	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377785	chr10:79663088~79826594:-
THCA	cis	rs2692947	0.537	rs1364394	ENSG00000235584.2	AC008268.1	4.11	4.65e-05	0.00402	0.18	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95529982	chr2:95666084~95668715:+
THCA	cis	rs11955398	0.62	rs6449512	ENSG00000272308.1	RP11-231G3.1	-4.11	4.65e-05	0.00402	-0.18	-0.19	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60866457~60866935:-
THCA	cis	rs5758511	0.573	rs738248	ENSG00000230107.1	CTA-126B4.7	4.11	4.65e-05	0.00402	0.2	0.19	Birth weight;	chr22:41800463	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.573	rs5996069	ENSG00000230107.1	CTA-126B4.7	4.11	4.65e-05	0.00402	0.2	0.19	Birth weight;	chr22:41805181	chr22:42438023~42446195:+
THCA	cis	rs7968440	0.736	rs7978559	ENSG00000272368.2	RP4-605O3.4	4.11	4.65e-05	0.00402	0.12	0.19	Fibrinogen;	chr12:50794855	chr12:50112197~50165618:+
THCA	cis	rs7968440	0.808	rs7958114	ENSG00000272368.2	RP4-605O3.4	4.11	4.65e-05	0.00402	0.12	0.19	Fibrinogen;	chr12:50796909	chr12:50112197~50165618:+
THCA	cis	rs5751614	0.537	rs7288846	ENSG00000240160.3	RN7SL263P	-4.11	4.66e-05	0.00402	-0.23	-0.19	Height;	chr22:23281097	chr22:23261782~23262071:-
THCA	cis	rs4950322	0.512	rs2353974	ENSG00000180867.10	PDIA3P1	-4.11	4.66e-05	0.00402	-0.16	-0.19	Protein quantitative trait loci;	chr1:147384534	chr1:147178113~147179622:+
THCA	cis	rs2018683	0.677	rs12531456	ENSG00000272568.4	CTB-113D17.1	4.11	4.66e-05	0.00402	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930994	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.707	rs2391717	ENSG00000272568.4	CTB-113D17.1	4.11	4.66e-05	0.00402	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931545	chr7:28979967~29013367:+
THCA	cis	rs2018683	0.707	rs917215	ENSG00000272568.4	CTB-113D17.1	4.11	4.66e-05	0.00402	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931750	chr7:28979967~29013367:+
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000265443.1	CTD-2349P21.6	-4.11	4.66e-05	0.00402	-0.31	-0.19	Body mass index;	chr17:30741407	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000265443.1	CTD-2349P21.6	-4.11	4.66e-05	0.00402	-0.31	-0.19	Body mass index;	chr17:30745674	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000265443.1	CTD-2349P21.6	-4.11	4.66e-05	0.00402	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30726305~30727564:-
THCA	cis	rs6696239	1	rs6689375	ENSG00000227711.2	RP11-275O4.5	-4.11	4.66e-05	0.00402	-0.26	-0.19	Height;	chr1:227533926	chr1:227509028~227520477:-
THCA	cis	rs4792901	0.959	rs28659819	ENSG00000267151.3	RP11-100E5.2	4.11	4.66e-05	0.00402	0.19	0.19	Dupuytren's disease;	chr17:43550162	chr17:43444707~43451200:+
THCA	cis	rs3770081	1	rs78468492	ENSG00000272564.1	RP11-548P2.2	-4.11	4.66e-05	0.00402	-0.33	-0.19	Facial emotion recognition (sad faces);	chr2:85855906	chr2:85904279~85904727:+
THCA	cis	rs7474896	0.515	rs2738208	ENSG00000263064.2	RP11-291L22.7	-4.11	4.66e-05	0.00403	-0.25	-0.19	Obesity (extreme);	chr10:38017200	chr10:38448689~38448949:+
THCA	cis	rs657075	0.595	rs6864922	ENSG00000237714.1	P4HA2-AS1	-4.11	4.66e-05	0.00403	-0.41	-0.19	Rheumatoid arthritis;	chr5:132280597	chr5:132184876~132192808:+
THCA	cis	rs17685	0.753	rs1637037	ENSG00000230882.1	AC005077.14	4.11	4.66e-05	0.00403	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76063609	chr7:76071469~76074963:-
THCA	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	4.11	4.66e-05	0.00403	0.17	0.19	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
THCA	cis	rs6600671	1	rs10794671	ENSG00000270231.3	NBPF8P	4.11	4.66e-05	0.00403	0.17	0.19	Hip geometry;	chr1:121426382	chr1:120436353~120467739:+
THCA	cis	rs591584	0.666	rs1939139	ENSG00000255893.1	RP11-685N10.1	-4.11	4.66e-05	0.00403	-0.21	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94573836	chr11:94472908~94473570:-
THCA	cis	rs459482	0.504	rs469483	ENSG00000228318.3	AP001610.5	4.11	4.66e-05	0.00403	0.23	0.19	IgG glycosylation;	chr21:41446588	chr21:41441056~41445708:-
THCA	cis	rs16957091	0.528	rs12914380	ENSG00000205771.5	CATSPER2P1	4.11	4.66e-05	0.00403	0.27	0.19	MGMT methylation in smokers;	chr15:42950070	chr15:43726918~43747094:-
THCA	cis	rs8177876	0.841	rs8177851	ENSG00000261061.1	RP11-303E16.2	-4.11	4.67e-05	0.00403	-0.33	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81092747	chr16:81030770~81031485:+
THCA	cis	rs2298450	0.563	rs4817787	ENSG00000214867.3	SRSF9P1	-4.11	4.67e-05	0.00403	-0.3	-0.19	Schizophrenia;	chr21:36236727	chr21:36295173~36295702:-
THCA	cis	rs6456156	0.967	rs150108	ENSG00000235272.1	FAM103A2P	4.11	4.67e-05	0.00403	0.26	0.19	Primary biliary cholangitis;	chr6:167099665	chr6:166586124~166586477:-
THCA	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	4.11	4.67e-05	0.00403	0.22	0.19	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
THCA	cis	rs7267979	0.816	rs405822	ENSG00000274973.1	RP13-401N8.7	-4.11	4.67e-05	0.00403	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.816	rs6138593	ENSG00000274973.1	RP13-401N8.7	-4.11	4.67e-05	0.00403	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.816	rs409853	ENSG00000274973.1	RP13-401N8.7	-4.11	4.67e-05	0.00403	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25845497~25845862:+
THCA	cis	rs467650	0.714	rs171529	ENSG00000248489.1	CTD-2007H13.3	4.11	4.67e-05	0.00403	0.17	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98593098	chr5:98929171~98995013:+
THCA	cis	rs656319	0.585	rs13272731	ENSG00000261451.1	RP11-981G7.1	-4.11	4.67e-05	0.00403	-0.25	-0.19	Myopia (pathological);	chr8:10049424	chr8:10433672~10438312:+
THCA	cis	rs7246967	0.551	rs62121805	ENSG00000198153.8	ZNF849P	-4.11	4.67e-05	0.00403	-0.34	-0.19	Bronchopulmonary dysplasia;	chr19:22726178	chr19:22685167~22686732:+
THCA	cis	rs867186	0.614	rs74358111	ENSG00000126005.14	MMP24-AS1	-4.11	4.67e-05	0.00403	-0.38	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34811274	chr20:35216462~35278131:-
THCA	cis	rs8062405	0.723	rs762633	ENSG00000270424.1	RP11-1348G14.6	4.11	4.67e-05	0.00403	0.24	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28749959~28750595:-
THCA	cis	rs7208859	0.673	rs423151	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.67e-05	0.00403	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30738182~30740275:+
THCA	cis	rs13113518	1	rs9312661	ENSG00000272969.1	RP11-528I4.2	4.11	4.67e-05	0.00403	0.21	0.19	Height;	chr4:55476159	chr4:55547112~55547889:+
THCA	cis	rs7560272	0.501	rs2421675	ENSG00000273245.1	RP11-434P11.2	-4.11	4.67e-05	0.00403	-0.21	-0.19	Schizophrenia;	chr2:73728174	chr2:73750256~73750786:-
THCA	cis	rs713587	0.646	rs2384061	ENSG00000224165.4	DNAJC27-AS1	-4.11	4.67e-05	0.00403	-0.11	-0.19	Body mass index in non-asthmatics;	chr2:24912751	chr2:24971390~25039694:+
THCA	cis	rs11673344	0.526	rs2291001	ENSG00000267422.1	CTD-2554C21.1	4.11	4.67e-05	0.00404	0.19	0.19	Obesity-related traits;	chr19:37594431	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.518	rs73033134	ENSG00000267422.1	CTD-2554C21.1	4.11	4.67e-05	0.00404	0.19	0.19	Obesity-related traits;	chr19:37596046	chr19:37779686~37792865:+
THCA	cis	rs950776	0.518	rs952216	ENSG00000261762.1	RP11-650L12.2	4.11	4.67e-05	0.00404	0.24	0.19	Sudden cardiac arrest;	chr15:78526860	chr15:78589123~78591276:-
THCA	cis	rs12893668	0.703	rs34026011	ENSG00000252469.1	RNU7-160P	4.11	4.67e-05	0.00404	0.22	0.19	Reticulocyte count;	chr14:103584546	chr14:103550345~103550406:+
THCA	cis	rs10043228	1	rs62384468	ENSG00000248445.4	SEMA6A-AS1	-4.11	4.67e-05	0.00404	-0.25	-0.19	Asthma or chronic obstructive pulmonary disease;	chr5:116288153	chr5:116447547~116508276:+
THCA	cis	rs27419	0.617	rs1544770	ENSG00000272123.1	CTD-2366F13.2	4.11	4.67e-05	0.00404	0.21	0.19	Schizophrenia;	chr5:53124722	chr5:53089016~53089468:-
THCA	cis	rs9309473	0.606	rs6759452	ENSG00000273245.1	RP11-434P11.2	4.11	4.68e-05	0.00404	0.32	0.19	Metabolite levels;	chr2:73651225	chr2:73750256~73750786:-
THCA	cis	rs7267979	0.844	rs6107027	ENSG00000274973.1	RP13-401N8.7	-4.11	4.68e-05	0.00404	-0.21	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25845497~25845862:+
THCA	cis	rs12134133	1	rs1782468	ENSG00000237074.1	RP11-6J21.2	4.11	4.68e-05	0.00404	0.19	0.19	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207249067~207309121:+
THCA	cis	rs651907	0.817	rs650567	ENSG00000256628.3	ZBTB11-AS1	4.11	4.68e-05	0.00404	0.2	0.19	Colorectal cancer;	chr3:101875558	chr3:101676475~101679217:+
THCA	cis	rs11176749	1	rs17782266	ENSG00000203585.3	RP11-542B15.1	4.11	4.68e-05	0.00404	0.22	0.19	Expressive vocabulary in infants;	chr12:67457508	chr12:67519829~67567126:+
THCA	cis	rs113835537	0.877	rs2229455	ENSG00000255517.5	CTD-3074O7.5	-4.11	4.68e-05	0.00404	-0.19	-0.19	Airway imaging phenotypes;	chr11:66560584	chr11:66473490~66480233:-
THCA	cis	rs7267979	0.903	rs2500400	ENSG00000276952.1	RP5-965G21.6	-4.11	4.68e-05	0.00404	-0.19	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25284915~25285588:-
THCA	cis	rs9467773	0.595	rs12525810	ENSG00000261353.1	CTA-14H9.5	-4.11	4.68e-05	0.00404	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26527063~26527404:+
THCA	cis	rs9283706	0.608	rs71626484	ENSG00000229666.1	MAST4-AS1	-4.11	4.68e-05	0.00404	-0.27	-0.19	Coronary artery disease;	chr5:67038674	chr5:67001383~67003953:-
THCA	cis	rs9283706	0.608	rs13171572	ENSG00000229666.1	MAST4-AS1	-4.11	4.68e-05	0.00404	-0.27	-0.19	Coronary artery disease;	chr5:67038724	chr5:67001383~67003953:-
THCA	cis	rs9283706	0.608	rs12523505	ENSG00000229666.1	MAST4-AS1	-4.11	4.68e-05	0.00404	-0.27	-0.19	Coronary artery disease;	chr5:67038803	chr5:67001383~67003953:-
THCA	cis	rs875971	1	rs4717300	ENSG00000230189.5	GS1-124K5.2	4.11	4.68e-05	0.00404	0.12	0.19	Aortic root size;	chr7:66482393	chr7:66409143~66490059:-
THCA	cis	rs9307551	0.817	rs11098762	ENSG00000249646.2	OR7E94P	-4.11	4.68e-05	0.00404	-0.23	-0.19	Refractive error;	chr4:79575097	chr4:79587302~79588130:-
THCA	cis	rs4906332	1	rs12885234	ENSG00000244691.1	RPL10AP1	-4.11	4.68e-05	0.00404	-0.24	-0.19	Coronary artery disease;	chr14:103422844	chr14:103412119~103412761:-
THCA	cis	rs4906332	0.966	rs35799018	ENSG00000244691.1	RPL10AP1	-4.11	4.68e-05	0.00404	-0.24	-0.19	Coronary artery disease;	chr14:103427138	chr14:103412119~103412761:-
THCA	cis	rs12410462	0.515	rs10916192	ENSG00000227711.2	RP11-275O4.5	-4.11	4.68e-05	0.00404	-0.23	-0.19	Major depressive disorder;	chr1:227664883	chr1:227509028~227520477:-
THCA	cis	rs9341808	0.727	rs9361599	ENSG00000260645.1	RP11-250B2.5	4.11	4.68e-05	0.00404	0.16	0.19	Sitting height ratio;	chr6:80315525	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.754	rs9352817	ENSG00000260645.1	RP11-250B2.5	4.11	4.68e-05	0.00404	0.16	0.19	Sitting height ratio;	chr6:80316162	chr6:80466958~80469080:+
THCA	cis	rs9948	0.5	rs62152903	ENSG00000230606.9	AC159540.1	4.11	4.68e-05	0.00404	0.25	0.19	Erectile dysfunction and prostate cancer treatment;	chr2:96904640	chr2:97416165~97433527:-
THCA	cis	rs6728642	0.561	rs58984980	ENSG00000230606.9	AC159540.1	4.11	4.68e-05	0.00404	0.25	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96905022	chr2:97416165~97433527:-
THCA	cis	rs970548	0.954	rs12249012	ENSG00000230869.1	CTGLF10P	4.11	4.68e-05	0.00404	0.23	0.19	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45497022	chr10:45678692~45700532:+
THCA	cis	rs13113518	0.967	rs4340844	ENSG00000272969.1	RP11-528I4.2	4.11	4.68e-05	0.00404	0.21	0.19	Height;	chr4:55462689	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs1522112	ENSG00000272969.1	RP11-528I4.2	4.11	4.68e-05	0.00404	0.21	0.19	Height;	chr4:55463606	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs4864997	ENSG00000272969.1	RP11-528I4.2	4.11	4.68e-05	0.00404	0.21	0.19	Height;	chr4:55466010	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs960152	ENSG00000272969.1	RP11-528I4.2	4.11	4.68e-05	0.00404	0.21	0.19	Height;	chr4:55467308	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.967	rs12644948	ENSG00000272969.1	RP11-528I4.2	4.11	4.68e-05	0.00404	0.21	0.19	Height;	chr4:55470266	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs3805151	ENSG00000272969.1	RP11-528I4.2	4.11	4.68e-05	0.00404	0.21	0.19	Height;	chr4:55470874	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13118237	ENSG00000272969.1	RP11-528I4.2	4.11	4.68e-05	0.00404	0.21	0.19	Height;	chr4:55474259	chr4:55547112~55547889:+
THCA	cis	rs1499614	0.522	rs13247442	ENSG00000228409.4	CCT6P1	4.11	4.68e-05	0.00404	0.28	0.19	Gout;	chr7:66723871	chr7:65751142~65763354:+
THCA	cis	rs801193	1	rs4717319	ENSG00000230295.1	RP11-458F8.2	-4.11	4.69e-05	0.00404	-0.14	-0.19	Aortic root size;	chr7:66777606	chr7:66880708~66882981:+
THCA	cis	rs801193	0.904	rs4718403	ENSG00000230295.1	RP11-458F8.2	-4.11	4.69e-05	0.00404	-0.14	-0.19	Aortic root size;	chr7:66777742	chr7:66880708~66882981:+
THCA	cis	rs8031584	0.678	rs3122	ENSG00000259845.1	HERC2P10	-4.11	4.69e-05	0.00404	-0.26	-0.19	Huntington's disease progression;	chr15:30878087	chr15:30815271~30844153:+
THCA	cis	rs7914558	0.966	rs10748839	ENSG00000213061.2	PFN1P11	4.11	4.69e-05	0.00405	0.23	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:102838011~102845473:-
THCA	cis	rs12612619	0.659	rs12997235	ENSG00000272148.1	RP11-195B17.1	-4.11	4.69e-05	0.00405	-0.17	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006211	chr2:27062428~27062907:-
THCA	cis	rs2806561	0.734	rs2235548	ENSG00000249087.5	ZNF436-AS1	-4.11	4.69e-05	0.00405	-0.13	-0.19	Height;	chr1:23067569	chr1:23368997~23371839:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000182586.6	LINC00334	-4.11	4.69e-05	0.00405	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45234340~45258730:+
THCA	cis	rs3169166	0.546	rs2280366	ENSG00000259562.2	RP11-762H8.2	-4.11	4.69e-05	0.00405	-0.11	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78293556	chr15:78290527~78291221:-
THCA	cis	rs734999	0.566	rs4648658	ENSG00000225931.3	RP3-395M20.7	-4.11	4.69e-05	0.00405	-0.22	-0.19	Ulcerative colitis;	chr1:2629443	chr1:2566410~2569888:+
THCA	cis	rs5758659	0.652	rs6519301	ENSG00000270083.1	RP1-257I20.14	4.11	4.69e-05	0.00405	0.2	0.19	Cognitive function;	chr22:41989963	chr22:42089630~42090028:-
THCA	cis	rs2474937	0.561	rs6659955	ENSG00000231365.4	RP11-418J17.1	4.11	4.69e-05	0.00405	0.19	0.19	Congenital heart malformation;	chr1:118381414	chr1:119140396~119275973:+
THCA	cis	rs12681963	0.614	rs12677295	ENSG00000248159.1	HSPA8P11	4.11	4.69e-05	0.00405	0.35	0.19	Migraine;	chr8:30242306	chr8:30237382~30240997:+
THCA	cis	rs8062405	0.755	rs62031607	ENSG00000261766.1	RP11-22P6.2	-4.11	4.69e-05	0.00405	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28862166~28863340:-
THCA	cis	rs10760158	0.832	rs10760166	ENSG00000226752.6	PSMD5-AS1	-4.11	4.69e-05	0.00405	-0.23	-0.19	Pulse pressure;	chr9:121264336	chr9:120824828~120854385:+
THCA	cis	rs7193541	0.965	rs4402594	ENSG00000262904.1	TMPOP2	-4.11	4.69e-05	0.00405	-0.22	-0.19	Multiple myeloma;	chr16:74667462	chr16:74667506~74668706:+
THCA	cis	rs11773103	1	rs73204819	ENSG00000224046.1	AC005076.5	4.11	4.69e-05	0.00405	0.28	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87141009	chr7:87151423~87152420:-
THCA	cis	rs2286503	0.78	rs2240727	ENSG00000226329.2	AC005682.6	4.11	4.69e-05	0.00405	0.23	0.19	Fibrinogen;	chr7:22812893	chr7:22863874~22881350:-
THCA	cis	rs684603	1	rs684603	ENSG00000254459.1	RP11-91P24.7	4.11	4.69e-05	0.00405	0.27	0.19	Number of common colds;	chr11:78102803	chr11:77829654~77872262:-
THCA	cis	rs9890032	0.542	rs35840638	ENSG00000263531.1	RP13-753N3.1	-4.11	4.69e-05	0.00405	-0.26	-0.19	Hip circumference adjusted for BMI;	chr17:30924623	chr17:30863921~30864940:-
THCA	cis	rs5770917	1	rs5770917	ENSG00000273272.1	CTA-384D8.34	4.11	4.69e-05	0.00405	0.28	0.19	Narcolepsy;	chr22:50578924	chr22:50542650~50543011:+
THCA	cis	rs7647973	0.925	rs6769821	ENSG00000228638.1	FCF1P2	-4.11	4.69e-05	0.00405	-0.22	-0.19	Menarche (age at onset);	chr3:49207224	chr3:48290793~48291375:-
THCA	cis	rs4218	0.689	rs12900369	ENSG00000259732.1	RP11-59H7.3	-4.11	4.69e-05	0.00405	-0.26	-0.19	Social communication problems;	chr15:59099254	chr15:59121034~59133250:+
THCA	cis	rs4218	0.689	rs28514475	ENSG00000259732.1	RP11-59H7.3	-4.11	4.69e-05	0.00405	-0.26	-0.19	Social communication problems;	chr15:59099896	chr15:59121034~59133250:+
THCA	cis	rs4218	0.689	rs28610479	ENSG00000259732.1	RP11-59H7.3	-4.11	4.69e-05	0.00405	-0.26	-0.19	Social communication problems;	chr15:59099906	chr15:59121034~59133250:+
THCA	cis	rs11633886	0.677	rs11633202	ENSG00000259200.1	RP11-718O11.1	-4.11	4.69e-05	0.00405	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45760722	chr15:45705078~45931069:+
THCA	cis	rs2274136	1	rs7740055	ENSG00000272269.1	RP11-500C11.3	4.11	4.69e-05	0.00405	0.22	0.19	Obesity-related traits;	chr6:17664179	chr6:17706257~17707344:+
THCA	cis	rs2274136	0.948	rs6935037	ENSG00000272269.1	RP11-500C11.3	4.11	4.69e-05	0.00405	0.22	0.19	Obesity-related traits;	chr6:17665771	chr6:17706257~17707344:+
THCA	cis	rs13113518	0.966	rs13108409	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55520278	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11726198	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55523835	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs11133396	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55524246	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs7675109	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55525589	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs4865005	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55525781	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13108499	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55526514	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13116194	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55531150	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13117836	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55531218	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs7668429	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55531811	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13113518	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55533481	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13152173	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55534788	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13141049	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55535489	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.967	rs12507722	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55536421	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.967	rs7696832	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55537080	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs34648901	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55541259	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.902	rs12505266	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55546002	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs56154935	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55546378	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs7662966	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55548261	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13115828	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55551447	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs13136282	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55551845	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11934897	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55553396	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.934	rs11932293	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55554025	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs4865011	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55554456	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs4865013	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55559957	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs13144598	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55570311	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs11942472	ENSG00000272969.1	RP11-528I4.2	4.11	4.69e-05	0.00405	0.21	0.19	Height;	chr4:55574959	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs4865007	ENSG00000272969.1	RP11-528I4.2	-4.11	4.69e-05	0.00405	-0.21	-0.19	Height;	chr4:55537550	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs4864548	ENSG00000272969.1	RP11-528I4.2	-4.11	4.69e-05	0.00405	-0.21	-0.19	Height;	chr4:55547636	chr4:55547112~55547889:+
THCA	cis	rs801193	0.904	rs4718405	ENSG00000223473.2	GS1-124K5.3	4.11	4.7e-05	0.00405	0.12	0.19	Aortic root size;	chr7:66789659	chr7:66491049~66493566:-
THCA	cis	rs8031584	0.678	rs798125	ENSG00000178081.11	ULK4P3	-4.11	4.7e-05	0.00405	-0.25	-0.19	Huntington's disease progression;	chr15:30824597	chr15:30103720~30131757:+
THCA	cis	rs1908814	0.51	rs57655799	ENSG00000206014.6	OR7E161P	-4.11	4.7e-05	0.00405	-0.22	-0.19	Neuroticism;	chr8:11924908	chr8:11928597~11929563:-
THCA	cis	rs801193	1	rs2659909	ENSG00000272831.1	RP11-792A8.4	4.11	4.7e-05	0.00405	0.12	0.19	Aortic root size;	chr7:66695292	chr7:66739829~66740385:-
THCA	cis	rs4906332	1	rs12879663	ENSG00000244691.1	RPL10AP1	-4.11	4.7e-05	0.00405	-0.24	-0.19	Coronary artery disease;	chr14:103407878	chr14:103412119~103412761:-
THCA	cis	rs7111546	0.565	rs79085089	ENSG00000246225.5	RP11-17A1.3	4.11	4.7e-05	0.00405	0.33	0.19	Dialysis-related mortality;	chr11:22940163	chr11:22829380~22945393:+
THCA	cis	rs3808502	0.527	rs4410870	ENSG00000154316.13	TDH	4.11	4.7e-05	0.00405	0.15	0.19	Neuroticism;	chr8:11298611	chr8:11339637~11368452:+
THCA	cis	rs7819412	0.775	rs4840551	ENSG00000255046.1	RP11-297N6.4	4.11	4.7e-05	0.00405	0.2	0.19	Triglycerides;	chr8:11171530	chr8:11797928~11802568:-
THCA	cis	rs10266483	0.661	rs608769	ENSG00000271550.1	BNIP3P11	4.11	4.7e-05	0.00406	0.24	0.19	Response to statin therapy;	chr7:64292783	chr7:64678954~64687393:-
THCA	cis	rs785830	0.523	rs2484966	ENSG00000231808.2	LINC01388	-4.11	4.7e-05	0.00406	-0.22	-0.19	Platelet distribution width;	chr9:216493	chr9:112713~113754:-
THCA	cis	rs13102973	0.64	rs6833827	ENSG00000250144.1	RP11-553P9.1	-4.11	4.7e-05	0.00406	-0.13	-0.19	Subjective well-being;	chr4:134918576	chr4:135045464~135046850:+
THCA	cis	rs6756513	0.5	rs17037194	ENSG00000231024.1	AC092431.3	4.11	4.7e-05	0.00406	0.27	0.19	Breast cancer;Platelet count;	chr2:69876670	chr2:69700192~69713847:-
THCA	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-4.11	4.7e-05	0.00406	-0.11	-0.19	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
THCA	cis	rs6845263	0.536	rs9991697	ENSG00000254531.1	FLJ20021	-4.11	4.7e-05	0.00406	-0.16	-0.19	Superior crus of antihelix expression;	chr4:101555781	chr4:101347780~101348883:+
THCA	cis	rs6845263	0.511	rs10024842	ENSG00000254531.1	FLJ20021	-4.11	4.7e-05	0.00406	-0.16	-0.19	Superior crus of antihelix expression;	chr4:101555787	chr4:101347780~101348883:+
THCA	cis	rs8113308	0.752	rs8113758	ENSG00000269483.1	AC006272.1	4.11	4.7e-05	0.00406	0.27	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51990054	chr19:51839924~51843324:-
THCA	cis	rs758324	0.773	rs13183449	ENSG00000237714.1	P4HA2-AS1	4.11	4.71e-05	0.00406	0.26	0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131780389	chr5:132184876~132192808:+
THCA	cis	rs1560104	0.675	rs9927247	ENSG00000262801.4	U91319.1	4.11	4.71e-05	0.00406	0.22	0.19	Obesity-related traits;	chr16:12611124	chr16:13246316~13562918:+
THCA	cis	rs7111546	0.565	rs77132694	ENSG00000246225.5	RP11-17A1.3	4.11	4.71e-05	0.00406	0.33	0.19	Dialysis-related mortality;	chr11:22929757	chr11:22829380~22945393:+
THCA	cis	rs4218	0.681	rs58335303	ENSG00000259732.1	RP11-59H7.3	-4.11	4.71e-05	0.00406	-0.26	-0.19	Social communication problems;	chr15:59073206	chr15:59121034~59133250:+
THCA	cis	rs12755164	0.771	rs7546928	ENSG00000223479.3	RP4-788P17.1	4.11	4.71e-05	0.00406	0.2	0.19	Schizophrenia;	chr1:72845859	chr1:73635216~73715214:+
THCA	cis	rs2436845	0.783	rs1062315	ENSG00000253320.4	KB-1507C5.2	-4.11	4.71e-05	0.00406	-0.16	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102826936	chr8:102864300~102977876:+
THCA	cis	rs4705962	0.837	rs2285700	ENSG00000230612.2	AC004237.1	4.11	4.71e-05	0.00406	0.23	0.19	Atopic dermatitis;	chr5:132703440	chr5:132688681~132723725:+
THCA	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	4.11	4.71e-05	0.00406	0.17	0.19	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	4.11	4.71e-05	0.00406	0.17	0.19	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	4.11	4.71e-05	0.00406	0.17	0.19	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	4.11	4.71e-05	0.00406	0.17	0.19	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	4.11	4.71e-05	0.00406	0.17	0.19	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
THCA	cis	rs7819412	0.654	rs6987059	ENSG00000206014.6	OR7E161P	4.11	4.71e-05	0.00406	0.22	0.19	Triglycerides;	chr8:11213548	chr8:11928597~11929563:-
THCA	cis	rs867186	1	rs80277764	ENSG00000126005.14	MMP24-AS1	-4.11	4.71e-05	0.00406	-0.3	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35151653	chr20:35216462~35278131:-
THCA	cis	rs4972806	0.775	rs2857534	ENSG00000226363.3	HAGLROS	-4.11	4.71e-05	0.00406	-0.21	-0.19	IgG glycosylation;	chr2:176170948	chr2:176177717~176179008:+
THCA	cis	rs786425	0.966	rs7302183	ENSG00000270095.1	RP11-214K3.18	-4.11	4.71e-05	0.00406	-0.21	-0.19	Pubertal anthropometrics;	chr12:123619913	chr12:123971457~123971714:-
THCA	cis	rs11694172	0.955	rs62194152	ENSG00000273456.1	RP11-686O6.2	4.11	4.71e-05	0.00406	0.17	0.19	Cholesterol, total;	chr2:202730647	chr2:202374932~202375604:-
THCA	cis	rs7178909	0.872	rs17241560	ENSG00000259677.1	RP11-493E3.1	4.11	4.71e-05	0.00406	0.22	0.19	Common traits (Other);	chr15:89885970	chr15:89876540~89877285:+
THCA	cis	rs7178375	1	rs1474382	ENSG00000269930.1	RP11-932O9.9	-4.11	4.71e-05	0.00407	-0.25	-0.19	Hypertriglyceridemia;	chr15:30922446	chr15:30616958~30617749:+
THCA	cis	rs1560104	0.709	rs9806831	ENSG00000262801.4	U91319.1	4.11	4.71e-05	0.00407	0.22	0.19	Obesity-related traits;	chr16:12610538	chr16:13246316~13562918:+
THCA	cis	rs13256369	0.901	rs12681298	ENSG00000254153.1	CTA-398F10.2	4.11	4.71e-05	0.00407	0.21	0.19	Obesity-related traits;	chr8:8708725	chr8:8456909~8461337:-
THCA	cis	rs2408955	0.521	rs10875749	ENSG00000273765.1	RP11-370I10.11	-4.11	4.71e-05	0.00407	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48138134	chr12:48360920~48361377:+
THCA	cis	rs2408955	0.521	rs7301003	ENSG00000273765.1	RP11-370I10.11	4.11	4.71e-05	0.00407	0.19	0.19	Glycated hemoglobin levels;	chr12:48156444	chr12:48360920~48361377:+
THCA	cis	rs4705962	0.796	rs6864396	ENSG00000230612.2	AC004237.1	4.11	4.71e-05	0.00407	0.23	0.19	Atopic dermatitis;	chr5:132712183	chr5:132688681~132723725:+
THCA	cis	rs2853333	0.622	rs2519962	ENSG00000269553.1	U62631.5	-4.11	4.72e-05	0.00407	-0.21	-0.19	Red blood cell count;	chr19:35261788	chr19:35330843~35331920:+
THCA	cis	rs28735056	0.904	rs62103183	ENSG00000261126.6	RP11-795F19.1	4.11	4.72e-05	0.00407	0.15	0.19	Schizophrenia;	chr18:79866564	chr18:80046900~80095482:+
THCA	cis	rs3755605	0.728	rs10936614	ENSG00000242578.1	RP11-469J4.3	-4.11	4.72e-05	0.00407	-0.21	-0.19	Testicular germ cell tumor;	chr3:170162296	chr3:170410512~170418615:+
THCA	cis	rs75504410	0.737	rs3796535	ENSG00000231160.8	KLF3-AS1	-4.11	4.72e-05	0.00407	-0.2	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38691304	chr4:38612701~38664883:-
THCA	cis	rs75504410	0.737	rs3796536	ENSG00000231160.8	KLF3-AS1	-4.11	4.72e-05	0.00407	-0.2	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38691319	chr4:38612701~38664883:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000229180.5	GS1-124K5.11	-4.11	4.72e-05	0.00407	-0.13	-0.19	Aortic root size;	chr7:66144830	chr7:66526088~66542624:-
THCA	cis	rs73173548	0.528	rs34857793	ENSG00000247828.6	TMEM161B-AS1	4.11	4.72e-05	0.00407	0.17	0.19	Macular telangiectasia type 2;	chr5:88467749	chr5:88268895~88436685:+
THCA	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	4.11	4.72e-05	0.00407	0.22	0.19	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	4.11	4.72e-05	0.00407	0.22	0.19	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.863	rs6833334	ENSG00000249244.1	RP11-548H18.2	4.11	4.72e-05	0.00407	0.22	0.19	Corneal astigmatism;	chr4:119583072	chr4:119391831~119395335:-
THCA	cis	rs78487399	0.808	rs13417883	ENSG00000234936.1	AC010883.5	4.11	4.72e-05	0.00407	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43473015	chr2:43229573~43233394:+
THCA	cis	rs7773456	0.576	rs4140624	ENSG00000227116.1	RP3-471C18.1	4.11	4.72e-05	0.00407	0.22	0.19	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19730427~19734567:-
THCA	cis	rs1035144	0.583	rs35472552	ENSG00000259167.2	NMNAT1P1	4.11	4.72e-05	0.00407	0.24	0.19	Male sexual orientation;	chr14:81001906	chr14:81032529~81033404:+
THCA	cis	rs7924176	0.502	rs12784355	ENSG00000232342.6	RP11-46O21.2	4.11	4.72e-05	0.00407	0.23	0.19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74506081~74530553:-
THCA	cis	rs11931598	0.511	rs35772786	ENSG00000245468.3	RP11-367J11.3	4.11	4.72e-05	0.00407	0.13	0.19	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7019484	chr4:7094571~7103385:-
THCA	cis	rs72949976	0.934	rs10197392	ENSG00000270659.1	RP11-105N14.1	4.11	4.72e-05	0.00407	0.15	0.19	Squamous cell lung carcinoma;Lung cancer;	chr2:213173454	chr2:213152970~213153659:+
THCA	cis	rs2933343	0.7	rs1683787	ENSG00000231305.3	RP11-723O4.2	-4.11	4.72e-05	0.00407	-0.2	-0.19	IgG glycosylation;	chr3:128908178	chr3:128861313~128871540:-
THCA	cis	rs738722	0.836	rs5752774	ENSG00000272858.1	CTA-292E10.8	-4.11	4.72e-05	0.00407	-0.19	-0.19	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28709622	chr22:28814914~28815662:+
THCA	cis	rs1979679	0.686	rs4348940	ENSG00000278733.1	RP11-425D17.1	-4.11	4.72e-05	0.00407	-0.2	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28437804	chr12:28185625~28186190:-
THCA	cis	rs11039571	0.588	rs61917001	ENSG00000200090.1	Y_RNA	4.11	4.72e-05	0.00407	0.16	0.19	D-dimer levels;	chr11:48212115	chr11:47726894~47726992:-
THCA	cis	rs9902453	0.808	rs10445400	ENSG00000263370.1	RP11-68I3.5	4.11	4.72e-05	0.00407	0.24	0.19	Coffee consumption (cups per day);	chr17:29856041	chr17:29639627~29640825:+
THCA	cis	rs12478296	1	rs4973685	ENSG00000220804.7	AC093642.5	4.11	4.72e-05	0.00407	0.22	0.19	Obesity-related traits;	chr2:242076938	chr2:242088633~242160153:+
THCA	cis	rs354225	0.512	rs17046257	ENSG00000162997.14	PRORSD1P	-4.11	4.72e-05	0.00407	-0.24	-0.19	Schizophrenia;	chr2:54722648	chr2:55282319~55284522:+
THCA	cis	rs7088591	0.867	rs61298392	ENSG00000276818.1	AC026393.1	4.11	4.73e-05	0.00407	0.4	0.19	Blood pressure;	chr10:58004956	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs61579731	ENSG00000276818.1	AC026393.1	4.11	4.73e-05	0.00407	0.4	0.19	Blood pressure;	chr10:58005169	chr10:57095699~57095781:+
THCA	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-4.11	4.73e-05	0.00407	-0.18	-0.19	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
THCA	cis	rs7560272	0.501	rs12624267	ENSG00000273245.1	RP11-434P11.2	-4.11	4.73e-05	0.00407	-0.21	-0.19	Schizophrenia;	chr2:73759804	chr2:73750256~73750786:-
THCA	cis	rs9543976	0.623	rs9544004	ENSG00000261105.4	LMO7-AS1	4.11	4.73e-05	0.00407	0.26	0.19	Diabetic retinopathy;	chr13:75617748	chr13:75604700~75635994:-
THCA	cis	rs9543976	0.588	rs7324195	ENSG00000261105.4	LMO7-AS1	4.11	4.73e-05	0.00407	0.26	0.19	Diabetic retinopathy;	chr13:75618386	chr13:75604700~75635994:-
THCA	cis	rs881375	0.678	rs10985102	ENSG00000270917.1	RP11-27I1.6	-4.11	4.73e-05	0.00408	-0.25	-0.19	Rheumatoid arthritis;	chr9:120945219	chr9:120812475~120812845:-
THCA	cis	rs786425	0.966	rs4456350	ENSG00000270095.1	RP11-214K3.18	-4.11	4.73e-05	0.00408	-0.21	-0.19	Pubertal anthropometrics;	chr12:123573942	chr12:123971457~123971714:-
THCA	cis	rs9898058	0.545	rs75764946	ENSG00000279036.1	RP11-81K2.2	-4.11	4.73e-05	0.00408	-0.3	-0.19	Milk allergy;	chr17:49705503	chr17:49494223~49497800:-
THCA	cis	rs2320614	0.679	rs10857352	ENSG00000250027.1	RP11-563E2.2	-4.11	4.73e-05	0.00408	-0.17	-0.19	Lung adenocarcinoma;	chr4:163180330	chr4:163108785~163119965:+
THCA	cis	rs2320614	0.679	rs10001148	ENSG00000250027.1	RP11-563E2.2	-4.11	4.73e-05	0.00408	-0.17	-0.19	Lung adenocarcinoma;	chr4:163180462	chr4:163108785~163119965:+
THCA	cis	rs34421088	0.56	rs2467520	ENSG00000255046.1	RP11-297N6.4	4.11	4.73e-05	0.00408	0.2	0.19	Neuroticism;	chr8:11541444	chr8:11797928~11802568:-
THCA	cis	rs2115536	0.935	rs11854390	ENSG00000278600.1	RP11-81A1.6	-4.11	4.73e-05	0.00408	-0.12	-0.19	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79932475	chr15:79920195~79922455:-
THCA	cis	rs6828577	0.819	rs298984	ENSG00000281731.1	RP11-384K6.8	-4.11	4.73e-05	0.00408	-0.21	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118682650	chr4:118664087~118685341:-
THCA	cis	rs6828577	0.862	rs167246	ENSG00000281731.1	RP11-384K6.8	-4.11	4.73e-05	0.00408	-0.21	-0.19	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118684965	chr4:118664087~118685341:-
THCA	cis	rs7182948	0.914	rs28766285	ENSG00000259531.2	RP11-295H24.3	4.11	4.73e-05	0.00408	0.24	0.19	Lung adenocarcinoma;	chr15:49699898	chr15:49365124~49366685:-
THCA	cis	rs78487399	0.808	rs6746632	ENSG00000234936.1	AC010883.5	4.11	4.73e-05	0.00408	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43485024	chr2:43229573~43233394:+
THCA	cis	rs2153535	0.585	rs6900539	ENSG00000230939.1	RP11-314C16.1	-4.11	4.73e-05	0.00408	-0.2	-0.19	Motion sickness;	chr6:8592054	chr6:8784178~8785445:+
THCA	cis	rs2562456	0.755	rs11670868	ENSG00000268117.1	VN1R84P	4.11	4.73e-05	0.00408	0.3	0.19	Pain;	chr19:21373613	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs55961038	ENSG00000268117.1	VN1R84P	4.11	4.73e-05	0.00408	0.3	0.19	Pain;	chr19:21375205	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs2358993	ENSG00000268117.1	VN1R84P	4.11	4.73e-05	0.00408	0.3	0.19	Pain;	chr19:21375367	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs11672583	ENSG00000268117.1	VN1R84P	4.11	4.73e-05	0.00408	0.3	0.19	Pain;	chr19:21379363	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs17680605	ENSG00000268117.1	VN1R84P	4.11	4.73e-05	0.00408	0.3	0.19	Pain;	chr19:21379646	chr19:21719801~21720035:-
THCA	cis	rs652260	0.646	rs693941	ENSG00000269139.2	CTD-3193O13.8	4.11	4.73e-05	0.00408	0.18	0.19	Menarche (age at onset);	chr19:7838965	chr19:7926001~7926810:+
THCA	cis	rs875971	0.619	rs2302918	ENSG00000272831.1	RP11-792A8.4	4.11	4.73e-05	0.00408	0.11	0.19	Aortic root size;	chr7:66535945	chr7:66739829~66740385:-
THCA	cis	rs7402982	0.625	rs7179841	ENSG00000259424.1	RP11-35O15.1	4.11	4.73e-05	0.00408	0.2	0.19	Birth weight;	chr15:98661423	chr15:98646951~98647371:-
THCA	cis	rs972578	0.765	rs7511534	ENSG00000274717.1	RP1-47A17.1	4.11	4.73e-05	0.00408	0.19	0.19	Mean platelet volume;	chr22:42976366	chr22:42791814~42794313:-
THCA	cis	rs9467773	0.595	rs12525810	ENSG00000124549.13	BTN2A3P	4.11	4.73e-05	0.00408	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26421391~26432383:+
THCA	cis	rs962856	0.964	rs1486133	ENSG00000236780.4	AC078941.1	-4.11	4.73e-05	0.00408	-0.22	-0.19	Pancreatic cancer;	chr2:67414889	chr2:67123357~67215319:-
THCA	cis	rs858239	0.899	rs2268745	ENSG00000230042.1	AK3P3	-4.11	4.73e-05	0.00408	-0.26	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23129178~23129841:+
THCA	cis	rs7837860	0.504	rs4147332	ENSG00000253553.4	RP11-586K2.1	-4.11	4.74e-05	0.00408	-0.19	-0.19	Autism spectrum disorder or schizophrenia;	chr8:88268634	chr8:88326836~88737134:+
THCA	cis	rs7010876	0.657	rs1401864	ENSG00000253553.4	RP11-586K2.1	-4.11	4.74e-05	0.00408	-0.19	-0.19	Schizophrenia;	chr8:88273178	chr8:88326836~88737134:+
THCA	cis	rs758324	0.648	rs31474	ENSG00000224431.1	AC063976.7	-4.11	4.74e-05	0.00408	-0.17	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132069334	chr5:132199456~132203487:+
THCA	cis	rs17685	0.753	rs4728550	ENSG00000230882.1	AC005077.14	-4.11	4.74e-05	0.00408	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76041670	chr7:76071469~76074963:-
THCA	cis	rs4792901	0.765	rs12600416	ENSG00000267151.3	RP11-100E5.2	4.11	4.74e-05	0.00408	0.2	0.19	Dupuytren's disease;	chr17:43469190	chr17:43444707~43451200:+
THCA	cis	rs3755605	0.728	rs11921468	ENSG00000242578.1	RP11-469J4.3	4.11	4.74e-05	0.00408	0.21	0.19	Testicular germ cell tumor;	chr3:170161570	chr3:170410512~170418615:+
THCA	cis	rs15676	1	rs10988125	ENSG00000234771.3	SLC25A25-AS1	4.11	4.74e-05	0.00408	0.15	0.19	Blood metabolite levels;	chr9:128810624	chr9:128108581~128118693:-
THCA	cis	rs2562456	0.833	rs62110428	ENSG00000268117.1	VN1R84P	4.11	4.74e-05	0.00408	0.3	0.19	Pain;	chr19:21430854	chr19:21719801~21720035:-
THCA	cis	rs10090774	0.965	rs62521937	ENSG00000279766.1	RP11-642A1.2	4.11	4.74e-05	0.00408	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140963425	chr8:140572142~140572812:-
THCA	cis	rs1124769	0.778	rs12902649	ENSG00000259378.1	DCAF13P3	4.11	4.74e-05	0.00408	0.29	0.19	Cognitive performance;	chr15:51039413	chr15:50944663~50945996:+
THCA	cis	rs72928364	1	rs13099053	ENSG00000256628.3	ZBTB11-AS1	4.11	4.74e-05	0.00409	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100902060	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs41273557	ENSG00000256628.3	ZBTB11-AS1	4.11	4.74e-05	0.00409	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100902839	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs79265689	ENSG00000256628.3	ZBTB11-AS1	4.11	4.74e-05	0.00409	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100902840	chr3:101676475~101679217:+
THCA	cis	rs709400	1	rs7150141	ENSG00000258735.1	LINC00637	4.11	4.74e-05	0.00409	0.24	0.19	Body mass index;	chr14:103663015	chr14:103847721~103858049:+
THCA	cis	rs2886497	1	rs11013429	ENSG00000224215.1	RP11-371A19.2	-4.11	4.74e-05	0.00409	-0.24	-0.19	Major depression and alcohol dependence;	chr10:23382361	chr10:23343957~23345181:+
THCA	cis	rs4718428	1	rs1830070	ENSG00000229180.5	GS1-124K5.11	4.11	4.74e-05	0.00409	0.13	0.19	Corneal structure;	chr7:66884684	chr7:66526088~66542624:-
THCA	cis	rs271738	0.743	rs271764	ENSG00000231768.1	LINC01354	-4.11	4.74e-05	0.00409	-0.21	-0.19	Bipolar disorder;	chr1:234537527	chr1:234527891~234531779:-
THCA	cis	rs4713118	0.615	rs57252182	ENSG00000220721.1	OR1F12	4.11	4.74e-05	0.00409	0.22	0.19	Parkinson's disease;	chr6:27752470	chr6:28073316~28074233:+
THCA	cis	rs34034915	1	rs34034915	ENSG00000220721.1	OR1F12	4.11	4.74e-05	0.00409	0.22	0.19	Hepatitis A;	chr6:27752924	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.527	rs36042294	ENSG00000220721.1	OR1F12	4.11	4.74e-05	0.00409	0.22	0.19	Parkinson's disease;	chr6:27752933	chr6:28073316~28074233:+
THCA	cis	rs7711186	0.786	rs12654187	ENSG00000252464.1	RN7SKP70	4.11	4.74e-05	0.00409	0.2	0.19	Urate levels in obese individuals;	chr5:178650474	chr5:178619728~178619998:-
THCA	cis	rs8062405	0.721	rs151181	ENSG00000270424.1	RP11-1348G14.6	4.11	4.75e-05	0.00409	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28749959~28750595:-
THCA	cis	rs9810089	0.934	rs684195	ENSG00000273455.1	RP11-305O4.3	4.11	4.75e-05	0.00409	0.24	0.19	Gestational age at birth (child effect);	chr3:136274757	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.934	rs1279949	ENSG00000273455.1	RP11-305O4.3	4.11	4.75e-05	0.00409	0.24	0.19	Gestational age at birth (child effect);	chr3:136278028	chr3:136087475~136087913:-
THCA	cis	rs17221829	0.699	rs78403327	ENSG00000280385.1	AP000648.5	-4.11	4.75e-05	0.00409	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89651057	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.673	rs10765226	ENSG00000280385.1	AP000648.5	-4.11	4.75e-05	0.00409	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89651845	chr11:90193614~90198120:+
THCA	cis	rs7521681	0.838	rs7523266	ENSG00000230489.1	VAV3-AS1	4.11	4.75e-05	0.00409	0.21	0.19	Asthma and hay fever;	chr1:107767602	chr1:107964443~107994607:+
THCA	cis	rs1560104	0.556	rs7188416	ENSG00000260601.1	RP11-552C15.1	-4.11	4.75e-05	0.00409	-0.22	-0.19	Obesity-related traits;	chr16:12615754	chr16:12545482~12546684:+
THCA	cis	rs6929812	0.934	rs6908553	ENSG00000216915.2	RP1-97D16.1	4.11	4.75e-05	0.00409	0.24	0.19	Neuroticism (multi-trait analysis);	chr6:27411593	chr6:27737000~27738494:-
THCA	cis	rs12129938	0.868	rs12133184	ENSG00000231940.1	RPS7P3	4.11	4.75e-05	0.00409	0.25	0.19	Thyroid cancer;	chr1:233276649	chr1:233288868~233289447:-
THCA	cis	rs8105895	1	rs17450788	ENSG00000269345.1	VN1R85P	4.11	4.75e-05	0.00409	0.26	0.19	Body mass index (change over time);	chr19:22041953	chr19:22174766~22175191:-
THCA	cis	rs156299	0.513	rs198296	ENSG00000234286.1	AC006026.13	4.11	4.75e-05	0.00409	0.24	0.19	Vitamin D levels;	chr7:24198562	chr7:23680195~23680786:-
THCA	cis	rs6517329	0.649	rs4817776	ENSG00000230212.5	AP000688.14	-4.11	4.75e-05	0.00409	-0.23	-0.19	Schizophrenia;	chr21:36121124	chr21:36069642~36126640:-
THCA	cis	rs2333194	0.772	rs8009466	ENSG00000258695.2	RP3-414A15.2	-4.11	4.75e-05	0.0041	-0.23	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73365605	chr14:73522878~73530610:+
THCA	cis	rs9810089	0.814	rs866758	ENSG00000273455.1	RP11-305O4.3	4.11	4.75e-05	0.0041	0.25	0.19	Gestational age at birth (child effect);	chr3:136399028	chr3:136087475~136087913:-
THCA	cis	rs11658311	0.85	rs60549849	ENSG00000232344.2	AC087163.2	4.11	4.75e-05	0.0041	0.26	0.19	Obsessive-compulsive symptoms;	chr17:17768773	chr17:18010643~18011822:+
THCA	cis	rs11658311	0.85	rs56022233	ENSG00000232344.2	AC087163.2	4.11	4.75e-05	0.0041	0.26	0.19	Obsessive-compulsive symptoms;	chr17:17768801	chr17:18010643~18011822:+
THCA	cis	rs11658311	0.85	rs73295691	ENSG00000232344.2	AC087163.2	4.11	4.75e-05	0.0041	0.26	0.19	Obsessive-compulsive symptoms;	chr17:17771394	chr17:18010643~18011822:+
THCA	cis	rs4705962	0.743	rs6896296	ENSG00000230612.2	AC004237.1	4.11	4.75e-05	0.0041	0.23	0.19	Atopic dermatitis;	chr5:132723006	chr5:132688681~132723725:+
THCA	cis	rs1267303	0.71	rs1535739	ENSG00000232022.5	FAAHP1	-4.11	4.75e-05	0.0041	-0.2	-0.19	Monobrow;	chr1:46492047	chr1:46432129~46445521:+
THCA	cis	rs3824488	0.705	rs60529258	ENSG00000271155.1	RP11-435O5.5	-4.11	4.75e-05	0.0041	-0.29	-0.19	Neuroticism;	chr9:95543226	chr9:95506235~95507636:+
THCA	cis	rs13083990	0.92	rs13061521	ENSG00000272758.4	RP11-299J3.8	4.11	4.75e-05	0.0041	0.18	0.19	Cardiac Troponin-T levels;	chr3:122295835	chr3:122416207~122443180:+
THCA	cis	rs2524005	1	rs2524005	ENSG00000224312.1	MCCD1P2	4.11	4.75e-05	0.0041	0.31	0.19	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29994437~29995314:-
THCA	cis	rs340849	0.703	rs12130674	ENSG00000274895.1	RP11-478J18.2	-4.11	4.75e-05	0.0041	-0.16	-0.19	Alzheimer's disease;	chr1:213948652	chr1:213983793~213986419:-
THCA	cis	rs1560104	0.536	rs9933641	ENSG00000260601.1	RP11-552C15.1	-4.11	4.76e-05	0.0041	-0.22	-0.19	Obesity-related traits;	chr16:12615413	chr16:12545482~12546684:+
THCA	cis	rs7552393	0.932	rs6576946	ENSG00000233008.4	RP11-475O6.1	-4.11	4.76e-05	0.0041	-0.2	-0.19	Select biomarker traits;	chr1:83797950	chr1:83575776~83861023:-
THCA	cis	rs16944613	0.541	rs7494949	ENSG00000259212.1	CTD-3065B20.2	4.11	4.76e-05	0.0041	0.29	0.19	Colorectal cancer;	chr15:90547162	chr15:90595840~90596447:-
THCA	cis	rs7131987	0.527	rs7308534	ENSG00000257176.2	RP11-996F15.2	4.11	4.76e-05	0.0041	0.19	0.19	QT interval;	chr12:29300269	chr12:29280418~29317848:-
THCA	cis	rs67478160	0.643	rs6575999	ENSG00000269940.1	RP11-73M18.7	4.11	4.76e-05	0.0041	0.18	0.19	Schizophrenia;	chr14:103784272	chr14:103694560~103695170:+
THCA	cis	rs4722166	0.598	rs4722179	ENSG00000225541.1	AC002480.5	-4.11	4.76e-05	0.0041	-0.21	-0.19	Lung cancer;	chr7:22764242	chr7:22571607~22661792:-
THCA	cis	rs12612619	0.695	rs10207670	ENSG00000229122.1	AGBL5-IT1	-4.11	4.76e-05	0.0041	-0.15	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020133	chr2:27061038~27061815:+
THCA	cis	rs459571	0.959	rs461462	ENSG00000235106.7	LINC00094	4.11	4.76e-05	0.0041	0.16	0.19	Platelet distribution width;	chr9:134046150	chr9:134025439~134034666:+
THCA	cis	rs911555	0.723	rs7144010	ENSG00000269958.1	RP11-73M18.8	-4.11	4.76e-05	0.0041	-0.17	-0.19	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103696353~103697163:+
THCA	cis	rs10186029	0.509	rs13387516	ENSG00000270659.1	RP11-105N14.1	4.11	4.76e-05	0.0041	0.16	0.19	Systemic sclerosis;	chr2:213080617	chr2:213152970~213153659:+
THCA	cis	rs2692947	0.683	rs1813381	ENSG00000232931.4	LINC00342	-4.11	4.76e-05	0.0041	-0.16	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95757191	chr2:95807118~95816215:-
THCA	cis	rs786425	0.55	rs7957429	ENSG00000270095.1	RP11-214K3.18	-4.11	4.76e-05	0.0041	-0.23	-0.19	Pubertal anthropometrics;	chr12:123697596	chr12:123971457~123971714:-
THCA	cis	rs75504410	0.737	rs76640612	ENSG00000231160.8	KLF3-AS1	-4.11	4.76e-05	0.0041	-0.2	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38695579	chr4:38612701~38664883:-
THCA	cis	rs12478296	0.681	rs55802421	ENSG00000220804.7	AC093642.5	4.11	4.76e-05	0.0041	0.21	0.19	Obesity-related traits;	chr2:242091811	chr2:242088633~242160153:+
THCA	cis	rs12478296	0.681	rs56357900	ENSG00000220804.7	AC093642.5	4.11	4.76e-05	0.0041	0.21	0.19	Obesity-related traits;	chr2:242091815	chr2:242088633~242160153:+
THCA	cis	rs4237845	0.537	rs12426201	ENSG00000270039.1	RP11-571M6.17	-4.11	4.76e-05	0.0041	-0.21	-0.19	Intelligence (multi-trait analysis);	chr12:57865969	chr12:57803838~57804415:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000214533.3	KRT18P33	-4.11	4.76e-05	0.0041	-0.23	-0.19	Rheumatoid arthritis;	chr2:65427878	chr2:65666695~65667737:+
THCA	cis	rs934734	0.532	rs2028151	ENSG00000214533.3	KRT18P33	-4.11	4.76e-05	0.0041	-0.23	-0.19	Rheumatoid arthritis;	chr2:65428479	chr2:65666695~65667737:+
THCA	cis	rs6940638	0.688	rs7744759	ENSG00000219392.1	RP1-265C24.5	-4.11	4.76e-05	0.0041	-0.22	-0.19	Intelligence (multi-trait analysis);	chr6:27152047	chr6:28115628~28116551:+
THCA	cis	rs7968440	0.838	rs7979165	ENSG00000272368.2	RP4-605O3.4	4.11	4.77e-05	0.0041	0.12	0.19	Fibrinogen;	chr12:50754774	chr12:50112197~50165618:+
THCA	cis	rs78487399	0.71	rs7572923	ENSG00000234936.1	AC010883.5	4.11	4.77e-05	0.0041	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43457970	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7599799	ENSG00000234936.1	AC010883.5	4.11	4.77e-05	0.0041	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43458354	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7573500	ENSG00000234936.1	AC010883.5	4.11	4.77e-05	0.0041	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43458486	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs17030835	ENSG00000234936.1	AC010883.5	4.11	4.77e-05	0.0041	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43459106	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs79955955	ENSG00000234936.1	AC010883.5	4.11	4.77e-05	0.0041	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43459846	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs17030845	ENSG00000234936.1	AC010883.5	4.11	4.77e-05	0.0041	0.25	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43460740	chr2:43229573~43233394:+
THCA	cis	rs911555	0.662	rs4906322	ENSG00000269910.1	RP11-73M18.10	-4.11	4.77e-05	0.0041	-0.17	-0.19	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103694516~103695050:-
THCA	cis	rs4713118	0.513	rs149962	ENSG00000261839.1	RP1-265C24.8	4.11	4.77e-05	0.00411	0.19	0.19	Parkinson's disease;	chr6:28048140	chr6:28136849~28139678:+
THCA	cis	rs8141529	0.748	rs132533	ENSG00000226471.5	CTA-292E10.6	4.11	4.77e-05	0.00411	0.15	0.19	Lymphocyte counts;	chr22:28903583	chr22:28800683~28848559:+
THCA	cis	rs13102973	0.64	rs13113331	ENSG00000250144.1	RP11-553P9.1	-4.11	4.77e-05	0.00411	-0.13	-0.19	Subjective well-being;	chr4:134917574	chr4:135045464~135046850:+
THCA	cis	rs13102973	0.64	rs13140829	ENSG00000250144.1	RP11-553P9.1	-4.11	4.77e-05	0.00411	-0.13	-0.19	Subjective well-being;	chr4:134917663	chr4:135045464~135046850:+
THCA	cis	rs13102973	0.64	rs10434069	ENSG00000250144.1	RP11-553P9.1	-4.11	4.77e-05	0.00411	-0.13	-0.19	Subjective well-being;	chr4:134919623	chr4:135045464~135046850:+
THCA	cis	rs13102973	0.64	rs10434071	ENSG00000250144.1	RP11-553P9.1	-4.11	4.77e-05	0.00411	-0.13	-0.19	Subjective well-being;	chr4:134920925	chr4:135045464~135046850:+
THCA	cis	rs3755605	0.727	rs6799087	ENSG00000242578.1	RP11-469J4.3	4.1	4.77e-05	0.00411	0.21	0.19	Testicular germ cell tumor;	chr3:170155618	chr3:170410512~170418615:+
THCA	cis	rs875971	0.83	rs587360	ENSG00000272831.1	RP11-792A8.4	4.1	4.77e-05	0.00411	0.12	0.19	Aortic root size;	chr7:66057711	chr7:66739829~66740385:-
THCA	cis	rs7259376	0.936	rs6511344	ENSG00000269345.1	VN1R85P	4.1	4.77e-05	0.00411	0.2	0.19	Menopause (age at onset);	chr19:22352871	chr19:22174766~22175191:-
THCA	cis	rs934734	0.532	rs10184881	ENSG00000214533.3	KRT18P33	-4.1	4.77e-05	0.00411	-0.23	-0.19	Rheumatoid arthritis;	chr2:65457018	chr2:65666695~65667737:+
THCA	cis	rs11971779	0.793	rs9632774	ENSG00000252332.1	RNU6-911P	-4.1	4.77e-05	0.00411	-0.22	-0.19	Diisocyanate-induced asthma;	chr7:139452816	chr7:139448740~139448843:+
THCA	cis	rs7264396	0.677	rs6060553	ENSG00000088340.14	FER1L4	4.1	4.77e-05	0.00411	0.19	0.19	Total cholesterol levels;	chr20:35679464	chr20:35558737~35607562:-
THCA	cis	rs9467773	0.933	rs2024970	ENSG00000261353.1	CTA-14H9.5	-4.1	4.77e-05	0.00411	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26497292	chr6:26527063~26527404:+
THCA	cis	rs7818382	0.967	rs7812465	ENSG00000253528.2	RP11-347C18.4	-4.1	4.77e-05	0.00411	-0.21	-0.19	Alzheimer's disease (late onset);	chr8:95038329	chr8:94974573~94974853:-
THCA	cis	rs7474896	0.775	rs12357391	ENSG00000263064.2	RP11-291L22.7	4.1	4.77e-05	0.00411	0.32	0.19	Obesity (extreme);	chr10:37689546	chr10:38448689~38448949:+
THCA	cis	rs12493885	0.818	rs61791545	ENSG00000243069.6	ARHGEF26-AS1	-4.1	4.77e-05	0.00411	-0.35	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154051099	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.818	rs73160504	ENSG00000243069.6	ARHGEF26-AS1	-4.1	4.77e-05	0.00411	-0.35	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154055595	chr3:154024401~154121332:-
THCA	cis	rs9481169	0.85	rs13210247	ENSG00000272356.1	RP5-1112D6.8	4.1	4.77e-05	0.00411	0.26	0.19	Inflammatory skin disease;	chr6:111601517	chr6:111309203~111313517:+
THCA	cis	rs4915077	0.773	rs17019768	ENSG00000230489.1	VAV3-AS1	4.1	4.77e-05	0.00411	0.3	0.19	Hypothyroidism;	chr1:107720934	chr1:107964443~107994607:+
THCA	cis	rs4295623	0.553	rs11250163	ENSG00000255046.1	RP11-297N6.4	-4.1	4.77e-05	0.00411	-0.2	-0.19	Morning vs. evening chronotype;	chr8:11738928	chr8:11797928~11802568:-
THCA	cis	rs340849	0.74	rs6540809	ENSG00000274895.1	RP11-478J18.2	-4.1	4.77e-05	0.00411	-0.16	-0.19	Alzheimer's disease;	chr1:213945000	chr1:213983793~213986419:-
THCA	cis	rs9863	0.828	rs12833624	ENSG00000270061.1	RP11-214K3.19	-4.1	4.77e-05	0.00411	-0.24	-0.19	White blood cell count;	chr12:123992326	chr12:123969990~123970344:-
THCA	cis	rs9863	0.828	rs34114498	ENSG00000270061.1	RP11-214K3.19	-4.1	4.77e-05	0.00411	-0.24	-0.19	White blood cell count;	chr12:123995826	chr12:123969990~123970344:-
THCA	cis	rs8070290	1	rs8070290	ENSG00000277491.1	RP11-676J12.9	-4.1	4.77e-05	0.00411	-0.22	-0.19	Lymphocyte percentage of white cells;	chr17:1428243	chr17:795306~795794:+
THCA	cis	rs12440869	1	rs7166809	ENSG00000270964.1	RP11-502I4.3	-4.1	4.78e-05	0.00411	-0.16	-0.19	Peak velocity of the mitral A-wave;	chr15:67282366	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs10851773	ENSG00000270964.1	RP11-502I4.3	-4.1	4.78e-05	0.00411	-0.16	-0.19	Peak velocity of the mitral A-wave;	chr15:67298007	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs4776918	ENSG00000270964.1	RP11-502I4.3	-4.1	4.78e-05	0.00411	-0.16	-0.19	Peak velocity of the mitral A-wave;	chr15:67312152	chr15:67541072~67542604:-
THCA	cis	rs1923243	0.681	rs11210146	ENSG00000223479.3	RP4-788P17.1	-4.1	4.78e-05	0.00411	-0.2	-0.19	Migraine;	chr1:73156324	chr1:73635216~73715214:+
THCA	cis	rs11633886	0.806	rs2037051	ENSG00000259200.1	RP11-718O11.1	4.1	4.78e-05	0.00411	0.23	0.19	Diisocyanate-induced asthma;	chr15:45763660	chr15:45705078~45931069:+
THCA	cis	rs881375	0.631	rs2416808	ENSG00000270917.1	RP11-27I1.6	-4.1	4.78e-05	0.00411	-0.25	-0.19	Rheumatoid arthritis;	chr9:120944005	chr9:120812475~120812845:-
THCA	cis	rs642858	0.83	rs9376507	ENSG00000234147.1	RP3-460G2.2	-4.1	4.78e-05	0.00411	-0.23	-0.19	Type 2 diabetes;	chr6:140256961	chr6:140845958~140852924:-
THCA	cis	rs8067545	0.611	rs2042046	ENSG00000270091.1	RP11-78O7.2	-4.1	4.78e-05	0.00411	-0.14	-0.19	Schizophrenia;	chr17:20115528	chr17:19896590~19897287:-
THCA	cis	rs6121246	0.559	rs6060915	ENSG00000230613.1	HM13-AS1	4.1	4.78e-05	0.00411	0.18	0.19	Mean corpuscular hemoglobin;	chr20:31742503	chr20:31567707~31573263:-
THCA	cis	rs7914558	0.932	rs4307650	ENSG00000213061.2	PFN1P11	4.1	4.78e-05	0.00411	0.23	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:102838011~102845473:-
THCA	cis	rs16957091	0.528	rs8037613	ENSG00000205771.5	CATSPER2P1	4.1	4.78e-05	0.00411	0.26	0.19	MGMT methylation in smokers;	chr15:42861247	chr15:43726918~43747094:-
THCA	cis	rs3169166	0.527	rs1996625	ENSG00000259562.2	RP11-762H8.2	-4.1	4.78e-05	0.00411	-0.12	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78308752	chr15:78290527~78291221:-
THCA	cis	rs149026780	1	rs149026780	ENSG00000230606.9	AC159540.1	4.1	4.78e-05	0.00411	0.3	0.19	Monocyte chemoattractant protein-3 levels;	chr2:97215875	chr2:97416165~97433527:-
THCA	cis	rs6500602	0.893	rs4786489	ENSG00000280063.1	RP11-295D4.3	4.1	4.78e-05	0.00411	0.11	0.19	Schizophrenia;	chr16:4435526	chr16:4346694~4348648:-
THCA	cis	rs1019173	0.816	rs7808913	ENSG00000261455.1	LINC01003	4.1	4.78e-05	0.00411	0.17	0.19	Kidney function decline traits;	chr7:152019364	chr7:152463786~152465549:+
THCA	cis	rs1023500	0.505	rs134885	ENSG00000273366.1	CTA-989H11.1	-4.1	4.78e-05	0.00411	-0.22	-0.19	Schizophrenia;	chr22:42277805	chr22:42278188~42278846:+
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.78e-05	0.00411	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30726305~30727564:-
THCA	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	4.1	4.78e-05	0.00412	0.26	0.19	Depression;	chr6:28251492	chr6:28176188~28176674:+
THCA	cis	rs8067545	0.75	rs4925081	ENSG00000270091.1	RP11-78O7.2	4.1	4.78e-05	0.00412	0.14	0.19	Schizophrenia;	chr17:20088680	chr17:19896590~19897287:-
THCA	cis	rs4761702	0.516	rs7398486	ENSG00000257322.4	RP11-511B23.2	4.1	4.78e-05	0.00412	0.23	0.19	Immature fraction of reticulocytes;	chr12:93301372	chr12:93003415~93215679:-
THCA	cis	rs62244186	0.711	rs6778410	ENSG00000214820.3	MPRIPP1	4.1	4.78e-05	0.00412	0.19	0.19	Depressive symptoms;	chr3:44702501	chr3:44579938~44581026:-
THCA	cis	rs467650	0.683	rs251534	ENSG00000248489.1	CTD-2007H13.3	4.1	4.78e-05	0.00412	0.17	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98598221	chr5:98929171~98995013:+
THCA	cis	rs17685	0.753	rs2868203	ENSG00000230882.1	AC005077.14	-4.1	4.78e-05	0.00412	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76050708	chr7:76071469~76074963:-
THCA	cis	rs8077577	0.671	rs6502641	ENSG00000273018.4	CTD-2303H24.2	4.1	4.78e-05	0.00412	0.27	0.19	Obesity-related traits;	chr17:18229665	chr17:18511221~18551705:-
THCA	cis	rs9368481	0.594	rs2636425	ENSG00000261353.1	CTA-14H9.5	-4.1	4.78e-05	0.00412	-0.2	-0.19	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26527063~26527404:+
THCA	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	4.1	4.78e-05	0.00412	0.17	0.19	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
THCA	cis	rs42648	0.935	rs7793743	ENSG00000225498.1	AC002064.5	-4.1	4.78e-05	0.00412	-0.19	-0.19	Homocysteine levels;	chr7:90402305	chr7:90312496~90322592:+
THCA	cis	rs2692947	0.509	rs4907303	ENSG00000235959.1	AC009237.17	-4.1	4.79e-05	0.00412	-0.2	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95551486	chr2:95640181~95640604:-
THCA	cis	rs7923609	0.875	rs10740118	ENSG00000232075.1	MRPL35P2	4.1	4.79e-05	0.00412	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63341447	chr10:63634317~63634827:-
THCA	cis	rs801193	1	rs2055682	ENSG00000229180.5	GS1-124K5.11	4.1	4.79e-05	0.00412	0.13	0.19	Aortic root size;	chr7:66795302	chr7:66526088~66542624:-
THCA	cis	rs9309473	0.5	rs12472502	ENSG00000273245.1	RP11-434P11.2	-4.1	4.79e-05	0.00412	-0.22	-0.19	Metabolite levels;	chr2:73632057	chr2:73750256~73750786:-
THCA	cis	rs748404	0.601	rs502157	ENSG00000205771.5	CATSPER2P1	4.1	4.79e-05	0.00412	0.19	0.19	Lung cancer;	chr15:43236375	chr15:43726918~43747094:-
THCA	cis	rs7923609	0.818	rs10822159	ENSG00000232075.1	MRPL35P2	-4.1	4.79e-05	0.00412	-0.24	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63336490	chr10:63634317~63634827:-
THCA	cis	rs9634489	0.59	rs9556537	ENSG00000247400.3	DNAJC3-AS1	-4.1	4.79e-05	0.00412	-0.12	-0.19	Body mass index;	chr13:96267808	chr13:95648733~95676925:-
THCA	cis	rs3892630	0.62	rs10413279	ENSG00000267567.1	CTD-2538C1.3	4.1	4.79e-05	0.00412	0.26	0.19	Red blood cell traits;	chr19:32691840	chr19:32718298~32719595:-
THCA	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	4.1	4.79e-05	0.00412	0.17	0.19	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
THCA	cis	rs13434995	0.513	rs2171617	ENSG00000249700.7	SRD5A3-AS1	4.1	4.79e-05	0.00412	0.28	0.19	Adiponectin levels;	chr4:55591023	chr4:55363971~55395847:-
THCA	cis	rs7474896	0.778	rs12571785	ENSG00000263064.2	RP11-291L22.7	4.1	4.79e-05	0.00412	0.32	0.19	Obesity (extreme);	chr10:37922471	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.725	rs11011405	ENSG00000263064.2	RP11-291L22.7	4.1	4.79e-05	0.00412	0.32	0.19	Obesity (extreme);	chr10:37926673	chr10:38448689~38448949:+
THCA	cis	rs3002131	0.736	rs2936027	ENSG00000272750.1	RP11-378J18.8	4.1	4.79e-05	0.00412	0.29	0.19	Interleukin-10 levels;	chr1:222588974	chr1:222658867~222661512:-
THCA	cis	rs11673344	0.642	rs12462708	ENSG00000268499.1	CTB-102L5.8	4.1	4.79e-05	0.00412	0.2	0.19	Obesity-related traits;	chr19:37306676	chr19:38199836~38200934:+
THCA	cis	rs3764021	0.87	rs2401393	ENSG00000214776.8	RP11-726G1.1	4.1	4.79e-05	0.00412	0.23	0.19	Type 1 diabetes;	chr12:9726488	chr12:9467552~9576275:+
THCA	cis	rs10904908	0.795	rs359283	ENSG00000229124.5	VIM-AS1	4.1	4.79e-05	0.00412	0.18	0.19	Cholesterol, total;Total cholesterol levels;	chr10:17284255	chr10:17214239~17229985:-
THCA	cis	rs8020441	0.838	rs4901051	ENSG00000269906.1	RP11-248J18.2	4.1	4.79e-05	0.00412	0.27	0.19	Cognitive performance;	chr14:50698050	chr14:50662511~50663178:-
THCA	cis	rs7200786	0.593	rs1700819	ENSG00000274038.1	RP11-66H6.4	-4.1	4.79e-05	0.00413	-0.23	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10963066	chr16:11056556~11057034:+
THCA	cis	rs6570726	0.791	rs370654	ENSG00000270638.1	RP3-466P17.1	4.1	4.79e-05	0.00413	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145735570~145737218:+
THCA	cis	rs12887734	0.524	rs722637	ENSG00000258735.1	LINC00637	4.1	4.79e-05	0.00413	0.24	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103847721~103858049:+
THCA	cis	rs8007846	0.685	rs1954052	ENSG00000276116.2	FUT8-AS1	-4.1	4.79e-05	0.00413	-0.19	-0.19	Multiple sclerosis--Brain Glutamate Levels;	chr14:65338991	chr14:65411170~65412690:-
THCA	cis	rs6479891	1	rs9414793	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.79e-05	0.00413	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63465229~63466563:+
THCA	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	4.1	4.79e-05	0.00413	0.21	0.19	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
THCA	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	4.1	4.79e-05	0.00413	0.17	0.19	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	4.1	4.79e-05	0.00413	0.17	0.19	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	4.1	4.79e-05	0.00413	0.17	0.19	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	4.1	4.79e-05	0.00413	0.17	0.19	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
THCA	cis	rs11220082	0.787	rs34632138	ENSG00000254671.2	STT3A-AS1	-4.1	4.79e-05	0.00413	-0.23	-0.19	Schizophrenia;	chr11:125428402	chr11:125570284~125592568:-
THCA	cis	rs9902453	0.904	rs9897794	ENSG00000263370.1	RP11-68I3.5	4.1	4.8e-05	0.00413	0.24	0.19	Coffee consumption (cups per day);	chr17:29969309	chr17:29639627~29640825:+
THCA	cis	rs875971	0.638	rs10249404	ENSG00000230295.1	RP11-458F8.2	4.1	4.8e-05	0.00413	0.14	0.19	Aortic root size;	chr7:66581737	chr7:66880708~66882981:+
THCA	cis	rs860295	0.812	rs10908481	ENSG00000160766.13	GBAP1	-4.1	4.8e-05	0.00413	-0.22	-0.19	Body mass index;	chr1:155743859	chr1:155213821~155227422:-
THCA	cis	rs3792900	0.509	rs2194138	ENSG00000271824.1	AC009014.3	4.1	4.8e-05	0.00413	0.19	0.19	Blood protein levels;Insomnia;	chr5:136235330	chr5:136191468~136193134:-
THCA	cis	rs227275	0.525	rs7660298	ENSG00000248971.2	KRT8P46	-4.1	4.8e-05	0.00413	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.87	rs228616	ENSG00000230069.3	LRRC37A15P	4.1	4.8e-05	0.00413	0.19	0.19	Primary biliary cholangitis;	chr4:102658534	chr4:102727274~102730721:-
THCA	cis	rs7844233	0.579	rs10096438	ENSG00000254023.1	PKMP4	4.1	4.8e-05	0.00413	0.31	0.19	Breast cancer;	chr8:75678146	chr8:75376709~75377014:+
THCA	cis	rs7267979	1	rs12428	ENSG00000274973.1	RP13-401N8.7	4.1	4.8e-05	0.00413	0.21	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25845497~25845862:+
THCA	cis	rs156299	0.513	rs156284	ENSG00000234286.1	AC006026.13	4.1	4.8e-05	0.00413	0.24	0.19	Vitamin D levels;	chr7:24199494	chr7:23680195~23680786:-
THCA	cis	rs2221894	0.922	rs2323134	ENSG00000251191.6	LINC00589	-4.1	4.8e-05	0.00413	-0.22	-0.19	Obesity-related traits;	chr8:28982405	chr8:29673922~29748109:-
THCA	cis	rs801193	0.967	rs34356500	ENSG00000275400.1	RP4-756H11.5	-4.1	4.8e-05	0.00413	-0.17	-0.19	Aortic root size;	chr7:66771620	chr7:66553805~66554199:-
THCA	cis	rs7481311	0.508	rs12288512	ENSG00000245573.6	BDNF-AS	4.1	4.8e-05	0.00413	0.21	0.19	Weight;Body mass index;	chr11:27726124	chr11:27506838~27698174:+
THCA	cis	rs28829049	0.683	rs1077976	ENSG00000270728.1	RP4-657E11.10	-4.1	4.8e-05	0.00413	-0.13	-0.19	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19034272	chr1:19297080~19297903:+
THCA	cis	rs4841097	0.806	rs6992247	ENSG00000233609.3	RP11-62H7.2	4.1	4.8e-05	0.00413	0.19	0.19	Platelet distribution width;	chr8:9090959	chr8:8961200~8979025:+
THCA	cis	rs12428035	0.505	rs4409947	ENSG00000247400.3	DNAJC3-AS1	4.1	4.8e-05	0.00413	0.16	0.19	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95830495	chr13:95648733~95676925:-
THCA	cis	rs72928364	1	rs7431835	ENSG00000256628.3	ZBTB11-AS1	4.1	4.8e-05	0.00413	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100923879	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs13077353	ENSG00000256628.3	ZBTB11-AS1	4.1	4.8e-05	0.00413	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100931463	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs17398421	ENSG00000256628.3	ZBTB11-AS1	4.1	4.8e-05	0.00413	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100954063	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs34719725	ENSG00000256628.3	ZBTB11-AS1	4.1	4.8e-05	0.00413	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100958648	chr3:101676475~101679217:+
THCA	cis	rs2692947	0.55	rs4613327	ENSG00000232931.4	LINC00342	4.1	4.8e-05	0.00413	0.16	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95918075	chr2:95807118~95816215:-
THCA	cis	rs57221529	0.766	rs12519469	ENSG00000225138.6	CTD-2228K2.7	4.1	4.8e-05	0.00413	0.23	0.19	Lung disease severity in cystic fibrosis;	chr5:581657	chr5:473236~480884:+
THCA	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	4.1	4.8e-05	0.00413	0.24	0.19	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
THCA	cis	rs9863	0.861	rs9971695	ENSG00000270061.1	RP11-214K3.19	-4.1	4.8e-05	0.00413	-0.25	-0.19	White blood cell count;	chr12:123928944	chr12:123969990~123970344:-
THCA	cis	rs9863	0.827	rs4930706	ENSG00000270061.1	RP11-214K3.19	-4.1	4.8e-05	0.00413	-0.25	-0.19	White blood cell count;	chr12:123932791	chr12:123969990~123970344:-
THCA	cis	rs7554547	0.69	rs7516708	ENSG00000199347.1	RNU5E-1	-4.1	4.8e-05	0.00413	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11890148	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.739	rs4846073	ENSG00000199347.1	RNU5E-1	-4.1	4.8e-05	0.00413	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11890521	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs57678332	ENSG00000199347.1	RNU5E-1	-4.1	4.8e-05	0.00413	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11890834	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.765	rs57176983	ENSG00000199347.1	RNU5E-1	-4.1	4.8e-05	0.00413	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11891041	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs1321072	ENSG00000199347.1	RNU5E-1	-4.1	4.8e-05	0.00413	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11891261	chr1:11908152~11908271:+
THCA	cis	rs1334894	0.892	rs72913412	ENSG00000228559.1	RP3-340B19.3	-4.1	4.8e-05	0.00413	-0.39	-0.19	Coronary artery disease;	chr6:35568877	chr6:35544632~35545669:+
THCA	cis	rs13113518	1	rs3762837	ENSG00000272969.1	RP11-528I4.2	4.1	4.8e-05	0.00413	0.21	0.19	Height;	chr4:55511198	chr4:55547112~55547889:+
THCA	cis	rs2898290	0.622	rs978803	ENSG00000227888.4	FAM66A	4.1	4.8e-05	0.00413	0.24	0.19	Systolic blood pressure;	chr8:11485966	chr8:12362019~12388296:+
THCA	cis	rs758324	0.645	rs754127	ENSG00000224431.1	AC063976.7	-4.1	4.8e-05	0.00413	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132180037	chr5:132199456~132203487:+
THCA	cis	rs55966801	0.624	rs741736	ENSG00000277290.1	RP11-326C3.16	-4.1	4.8e-05	0.00413	-0.24	-0.19	Plateletcrit;	chr11:256978	chr11:243099~243483:-
THCA	cis	rs9902453	0.726	rs4795523	ENSG00000263370.1	RP11-68I3.5	4.1	4.8e-05	0.00413	0.24	0.19	Coffee consumption (cups per day);	chr17:29849296	chr17:29639627~29640825:+
THCA	cis	rs6449502	0.841	rs34598	ENSG00000251279.1	CTC-436P18.1	4.1	4.8e-05	0.00413	0.33	0.19	Mean platelet volume;	chr5:61060656	chr5:61162070~61232040:+
THCA	cis	rs4886920	0.748	rs8036045	ENSG00000260776.4	RP11-114H24.2	-4.1	4.81e-05	0.00414	-0.22	-0.19	Neuroticism;	chr15:77855299	chr15:77914217~77926846:-
THCA	cis	rs867186	0.698	rs17406518	ENSG00000279253.1	RP4-614O4.13	-4.1	4.81e-05	0.00414	-0.29	-0.19	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35211373	chr20:35262727~35264187:-
THCA	cis	rs448720	1	rs35768117	ENSG00000260657.2	RP11-315D16.4	-4.1	4.81e-05	0.00414	-0.23	-0.19	Cognitive performance;	chr15:67911903	chr15:68267792~68277994:-
THCA	cis	rs836788	0.608	rs26779	ENSG00000251221.1	LINC01337	-4.1	4.81e-05	0.00414	-0.19	-0.19	Glomerular filtration rate (creatinine);	chr5:80763384	chr5:80608623~80622524:-
THCA	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	4.1	4.81e-05	0.00414	0.22	0.19	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
THCA	cis	rs7335046	0.536	rs7992229	ENSG00000234005.3	GAPDHP22	-4.1	4.81e-05	0.00414	-0.23	-0.19	Basal cell carcinoma;	chr13:99388725	chr13:99190579~99190991:-
THCA	cis	rs950776	0.518	rs12900783	ENSG00000261762.1	RP11-650L12.2	4.1	4.81e-05	0.00414	0.24	0.19	Sudden cardiac arrest;	chr15:78523181	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12594391	ENSG00000261762.1	RP11-650L12.2	4.1	4.81e-05	0.00414	0.24	0.19	Sudden cardiac arrest;	chr15:78523898	chr15:78589123~78591276:-
THCA	cis	rs3177980	0.71	rs4140655	ENSG00000239494.2	RN7SL333P	-4.1	4.81e-05	0.00414	-0.18	-0.19	Amyotrophic lateral sclerosis;	chr1:169697456	chr1:169859756~169860052:+
THCA	cis	rs7182948	0.918	rs2413947	ENSG00000259531.2	RP11-295H24.3	-4.1	4.81e-05	0.00414	-0.22	-0.19	Lung adenocarcinoma;	chr15:49465188	chr15:49365124~49366685:-
THCA	cis	rs412658	0.504	rs385774	ENSG00000269845.1	RP11-420K14.6	-4.1	4.81e-05	0.00414	-0.22	-0.19	Telomere length;	chr19:21913273	chr19:21750747~21753438:+
THCA	cis	rs1232027	0.7	rs1222809	ENSG00000249655.1	CTC-325J23.2	4.1	4.81e-05	0.00414	0.22	0.19	Huntington's disease progression;	chr5:80621698	chr5:80630313~80631590:-
THCA	cis	rs11168351	0.833	rs6580652	ENSG00000273765.1	RP11-370I10.11	-4.1	4.81e-05	0.00414	-0.19	-0.19	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48360920~48361377:+
THCA	cis	rs2039553	0.574	rs2802641	ENSG00000227354.5	RBM26-AS1	4.1	4.81e-05	0.00414	0.18	0.19	Pancreatic cancer;	chr13:79749820	chr13:79406309~79424328:+
THCA	cis	rs7927592	0.956	rs12274114	ENSG00000160172.9	FAM86C2P	4.1	4.81e-05	0.00414	0.18	0.19	Total body bone mineral density;	chr11:68488109	chr11:67791648~67805336:-
THCA	cis	rs8141529	0.515	rs13056243	ENSG00000272858.1	CTA-292E10.8	4.1	4.81e-05	0.00414	0.23	0.19	Lymphocyte counts;	chr22:28953318	chr22:28814914~28815662:+
THCA	cis	rs8192917	0.511	rs35328996	ENSG00000258744.1	RP11-80A15.1	-4.1	4.81e-05	0.00414	-0.32	-0.19	Vitiligo;	chr14:24598038	chr14:24501594~24508688:+
THCA	cis	rs4321325	0.733	rs79995601	ENSG00000236682.1	AC068282.3	-4.1	4.81e-05	0.00414	-0.38	-0.19	Protein C levels;	chr2:127189876	chr2:127389130~127400580:+
THCA	cis	rs4934494	0.677	rs12774378	ENSG00000240996.1	RP11-80H5.7	-4.1	4.81e-05	0.00414	-0.22	-0.19	Red blood cell count;	chr10:89571864	chr10:89694295~89697928:-
THCA	cis	rs34421088	0.532	rs1545073	ENSG00000154316.13	TDH	-4.1	4.82e-05	0.00414	-0.14	-0.19	Neuroticism;	chr8:11310191	chr8:11339637~11368452:+
THCA	cis	rs62158800	0.598	rs57147583	ENSG00000237880.1	AC096669.2	4.1	4.82e-05	0.00414	0.19	0.19	Facial morphology (factor 22);	chr2:107668603	chr2:107385632~107542649:-
THCA	cis	rs7824557	0.51	rs4841524	ENSG00000227888.4	FAM66A	-4.1	4.82e-05	0.00414	-0.24	-0.19	Retinal vascular caliber;	chr8:11385617	chr8:12362019~12388296:+
THCA	cis	rs2574985	0.548	rs2339506	ENSG00000279863.1	RP11-521C22.2	4.1	4.82e-05	0.00414	0.21	0.19	Subjective well-being;	chr10:50498938	chr10:50334538~50336123:+
THCA	cis	rs7560272	0.512	rs13026192	ENSG00000163016.8	ALMS1P	-4.1	4.82e-05	0.00414	-0.23	-0.19	Schizophrenia;	chr2:73699945	chr2:73644919~73685576:+
THCA	cis	rs9863	0.794	rs7133378	ENSG00000269938.1	RP11-214K3.20	-4.1	4.82e-05	0.00414	-0.22	-0.19	White blood cell count;	chr12:123924955	chr12:123968023~123968579:-
THCA	cis	rs3755605	0.52	rs1082976	ENSG00000242578.1	RP11-469J4.3	-4.1	4.82e-05	0.00414	-0.21	-0.19	Testicular germ cell tumor;	chr3:170221102	chr3:170410512~170418615:+
THCA	cis	rs77637988	0.578	rs4953572	ENSG00000202227.1	RNU6-282P	-4.1	4.82e-05	0.00414	-0.19	-0.19	Joint mobility (Beighton score);	chr2:48396868	chr2:48501922~48502024:-
THCA	cis	rs7520050	0.778	rs2088102	ENSG00000280836.1	AL355480.1	4.1	4.82e-05	0.00414	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45581219~45581321:-
THCA	cis	rs357618	1	rs357629	ENSG00000260581.1	CTB-113P19.4	-4.1	4.82e-05	0.00414	-0.24	-0.19	Basophil percentage of white cells;	chr5:151471385	chr5:151652275~151655449:+
THCA	cis	rs4666002	0.871	rs10208529	ENSG00000234072.1	AC074117.10	4.1	4.82e-05	0.00415	0.15	0.19	Phospholipid levels (plasma);	chr2:27563321	chr2:27356246~27367622:+
THCA	cis	rs7209700	0.547	rs11657517	ENSG00000228782.6	CTD-2026D20.3	-4.1	4.82e-05	0.00415	-0.21	-0.19	IgG glycosylation;	chr17:47266347	chr17:47450568~47492492:-
THCA	cis	rs733175	0.951	rs6826764	ENSG00000261490.1	RP11-448G15.3	-4.1	4.82e-05	0.00415	-0.15	-0.19	Psychosis and Alzheimer's disease;	chr4:10029170	chr4:10068089~10073019:-
THCA	cis	rs17666538	0.535	rs168062	ENSG00000254207.1	RP11-43A14.1	4.1	4.82e-05	0.00415	0.36	0.19	IgG glycosylation;	chr8:682444	chr8:725188~725877:-
THCA	cis	rs7918232	0.882	rs6415983	ENSG00000262412.1	RP11-85G18.6	4.1	4.82e-05	0.00415	0.28	0.19	Breast cancer;	chr10:27068282	chr10:27243130~27250804:+
THCA	cis	rs78487399	0.71	rs6743071	ENSG00000234936.1	AC010883.5	4.1	4.82e-05	0.00415	0.27	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43359148	chr2:43229573~43233394:+
THCA	cis	rs4533267	0.843	rs11247173	ENSG00000189419.6	SPATA41	4.1	4.82e-05	0.00415	0.24	0.19	Height;	chr15:100255008	chr15:100344457~100349655:-
THCA	cis	rs7616559	1	rs7616559	ENSG00000244515.1	KRT18P34	4.1	4.82e-05	0.00415	0.25	0.19	Carotid artery intima media thickness (sex interaction);	chr3:157010821	chr3:157162663~157163932:-
THCA	cis	rs10090774	1	rs12542138	ENSG00000279766.1	RP11-642A1.2	4.1	4.82e-05	0.00415	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140823839	chr8:140572142~140572812:-
THCA	cis	rs7824557	0.614	rs2736286	ENSG00000154316.13	TDH	4.1	4.82e-05	0.00415	0.14	0.19	Retinal vascular caliber;	chr8:11369595	chr8:11339637~11368452:+
THCA	cis	rs11771526	0.901	rs62457502	ENSG00000272905.1	RP11-265E18.1	4.1	4.82e-05	0.00415	0.25	0.19	Body mass index;	chr7:32291185	chr7:32845394~32846061:+
THCA	cis	rs1714507	0.533	rs1714516	ENSG00000272247.1	RP11-379F4.9	-4.1	4.82e-05	0.00415	-0.18	-0.19	Subjective well-being;	chr3:158575835	chr3:158801257~158801935:-
THCA	cis	rs6496044	0.568	rs2344436	ENSG00000259630.2	CTD-2262B20.1	-4.1	4.82e-05	0.00415	-0.2	-0.19	Interstitial lung disease;	chr15:85531675	chr15:85415228~85415633:+
THCA	cis	rs6496044	0.568	rs6496065	ENSG00000259630.2	CTD-2262B20.1	-4.1	4.82e-05	0.00415	-0.2	-0.19	Interstitial lung disease;	chr15:85532141	chr15:85415228~85415633:+
THCA	cis	rs6496044	0.568	rs6496066	ENSG00000259630.2	CTD-2262B20.1	-4.1	4.82e-05	0.00415	-0.2	-0.19	Interstitial lung disease;	chr15:85532231	chr15:85415228~85415633:+
THCA	cis	rs11971779	0.774	rs7785906	ENSG00000252332.1	RNU6-911P	-4.1	4.83e-05	0.00415	-0.22	-0.19	Diisocyanate-induced asthma;	chr7:139437906	chr7:139448740~139448843:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Body mass index;	chr17:30756962	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Body mass index;	chr17:30758695	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Body mass index;	chr17:30772984	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Body mass index;	chr17:30779631	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000265443.1	CTD-2349P21.6	-4.1	4.83e-05	0.00415	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000265443.1	CTD-2349P21.6	4.1	4.83e-05	0.00415	0.31	0.19	Body mass index;	chr17:30767864	chr17:30726305~30727564:-
THCA	cis	rs1816213	1	rs16859180	ENSG00000273466.1	RP11-548H3.1	4.1	4.83e-05	0.00415	0.29	0.19	Diastolic blood pressure;	chr2:218688745	chr2:218633256~218634014:-
THCA	cis	rs897984	0.568	rs11862962	ENSG00000279196.1	RP11-1072A3.3	4.1	4.83e-05	0.00415	0.21	0.19	Dementia with Lewy bodies;	chr16:30898385	chr16:30984630~30988270:-
THCA	cis	rs4908768	0.906	rs10492965	ENSG00000232912.4	RP5-1115A15.1	-4.1	4.83e-05	0.00415	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8538068	chr1:8424645~8434838:+
THCA	cis	rs2836974	0.932	rs56306759	ENSG00000255568.3	BRWD1-AS2	4.1	4.83e-05	0.00415	0.16	0.19	Cognitive function;	chr21:39236180	chr21:39313935~39314962:+
THCA	cis	rs5758511	0.596	rs55644935	ENSG00000237037.8	NDUFA6-AS1	-4.1	4.83e-05	0.00415	-0.17	-0.19	Birth weight;	chr22:42270063	chr22:42090931~42137742:+
THCA	cis	rs10875746	0.855	rs10875730	ENSG00000258273.1	RP11-370I10.4	4.1	4.83e-05	0.00415	0.27	0.19	Longevity (90 years and older);	chr12:48034092	chr12:48333755~48333901:-
THCA	cis	rs9634489	0.59	rs1927793	ENSG00000247400.3	DNAJC3-AS1	-4.1	4.83e-05	0.00415	-0.12	-0.19	Body mass index;	chr13:96269033	chr13:95648733~95676925:-
THCA	cis	rs4700393	0.52	rs206789	ENSG00000251279.1	CTC-436P18.1	-4.1	4.83e-05	0.00415	-0.26	-0.19	Intelligence (multi-trait analysis);	chr5:60608144	chr5:61162070~61232040:+
THCA	cis	rs7403037	0.583	rs35844465	ENSG00000260760.1	PWRN3	4.1	4.83e-05	0.00415	0.27	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24423096	chr15:24441127~24447967:+
THCA	cis	rs12681366	0.801	rs2011246	ENSG00000261437.1	RP11-22C11.2	4.1	4.83e-05	0.00415	0.19	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.801	rs2043988	ENSG00000261437.1	RP11-22C11.2	4.1	4.83e-05	0.00415	0.19	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.801	rs2930956	ENSG00000261437.1	RP11-22C11.2	4.1	4.83e-05	0.00415	0.19	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.801	rs55963151	ENSG00000261437.1	RP11-22C11.2	4.1	4.83e-05	0.00415	0.19	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:94637285~94639467:-
THCA	cis	rs6416877	0.921	rs8082128	ENSG00000277491.1	RP11-676J12.9	-4.1	4.83e-05	0.00415	-0.23	-0.19	Myeloid white cell count;	chr17:1440890	chr17:795306~795794:+
THCA	cis	rs4908768	0.906	rs28422051	ENSG00000232912.4	RP5-1115A15.1	-4.1	4.83e-05	0.00415	-0.23	-0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8558278	chr1:8424645~8434838:+
THCA	cis	rs941408	0.515	rs1640265	ENSG00000261342.1	AC006538.1	4.1	4.83e-05	0.00415	0.21	0.19	Total cholesterol levels;	chr19:2784407	chr19:2727743~2729327:-
THCA	cis	rs724818	0.661	rs10006287	ENSG00000251609.2	SETP12	-4.1	4.83e-05	0.00415	-0.5	-0.19	Monobrow thickness;	chr4:120789649	chr4:120895494~120897083:-
THCA	cis	rs9879311	0.966	rs4684685	ENSG00000240288.6	GHRLOS	4.1	4.83e-05	0.00415	0.17	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369869	chr3:10285754~10293449:+
THCA	cis	rs1971762	0.712	rs7302232	ENSG00000270175.1	RP11-793H13.11	-4.1	4.83e-05	0.00415	-0.12	-0.19	Height;	chr12:53571639	chr12:53500162~53500936:-
THCA	cis	rs6600671	0.967	rs4844613	ENSG00000275585.1	CH17-118O6.3	-4.1	4.83e-05	0.00415	-0.23	-0.19	Hip geometry;	chr1:121431913	chr1:120985692~121052167:-
THCA	cis	rs919433	0.679	rs9967823	ENSG00000231621.1	AC013264.2	-4.1	4.83e-05	0.00415	-0.2	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197666805	chr2:197197991~197199273:+
THCA	cis	rs71520386	0.53	rs10256628	ENSG00000226329.2	AC005682.6	-4.1	4.83e-05	0.00415	-0.24	-0.19	Fibrinogen levels;	chr7:22843640	chr7:22863874~22881350:-
THCA	cis	rs4788570	0.615	rs2032918	ENSG00000260185.1	RP11-432I5.6	-4.1	4.83e-05	0.00415	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71669533	chr16:71655027~71664212:+
THCA	cis	rs4788570	0.584	rs11075898	ENSG00000260185.1	RP11-432I5.6	-4.1	4.83e-05	0.00415	-0.35	-0.19	Intelligence (multi-trait analysis);	chr16:71671312	chr16:71655027~71664212:+
THCA	cis	rs7809615	0.579	rs11980999	ENSG00000244219.5	GS1-259H13.2	-4.1	4.83e-05	0.00415	-0.39	-0.19	Blood metabolite ratios;	chr7:99375675	chr7:99598066~99610813:+
THCA	cis	rs73173548	0.528	rs12189274	ENSG00000247828.6	TMEM161B-AS1	-4.1	4.83e-05	0.00415	-0.17	-0.19	Macular telangiectasia type 2;	chr5:88468669	chr5:88268895~88436685:+
THCA	cis	rs7560272	0.501	rs12713789	ENSG00000273245.1	RP11-434P11.2	-4.1	4.83e-05	0.00415	-0.21	-0.19	Schizophrenia;	chr2:73718473	chr2:73750256~73750786:-
THCA	cis	rs7560272	0.501	rs12713790	ENSG00000273245.1	RP11-434P11.2	-4.1	4.83e-05	0.00415	-0.21	-0.19	Schizophrenia;	chr2:73718484	chr2:73750256~73750786:-
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000265443.1	CTD-2349P21.6	4.1	4.83e-05	0.00415	0.32	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30726305~30727564:-
THCA	cis	rs8062405	0.679	rs72793818	ENSG00000270424.1	RP11-1348G14.6	4.1	4.83e-05	0.00415	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28749959~28750595:-
THCA	cis	rs7131987	0.65	rs4331146	ENSG00000273680.1	RP11-996F15.6	4.1	4.83e-05	0.00416	0.26	0.19	QT interval;	chr12:29287150	chr12:29332733~29333383:-
THCA	cis	rs8024893	0.764	rs7182721	ENSG00000215302.7	CTD-3092A11.1	4.1	4.83e-05	0.00416	0.29	0.19	Red cell distribution width;	chr15:31239730	chr15:30470779~30507623:+
THCA	cis	rs17772222	0.701	rs376698	ENSG00000222990.1	RNU4-22P	-4.1	4.84e-05	0.00416	-0.23	-0.19	Coronary artery calcification;	chr14:88391886	chr14:88513498~88513663:+
THCA	cis	rs11951515	0.508	rs67261887	ENSG00000248240.1	RP11-159F24.5	-4.1	4.84e-05	0.00416	-0.2	-0.19	Metabolite levels  (X-11787);	chr5:43612339	chr5:43515274~43525310:+
THCA	cis	rs17221829	0.703	rs10047486	ENSG00000280385.1	AP000648.5	-4.1	4.84e-05	0.00416	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89672022	chr11:90193614~90198120:+
THCA	cis	rs78487399	0.808	rs10200815	ENSG00000234936.1	AC010883.5	4.1	4.84e-05	0.00416	0.24	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446134	chr2:43229573~43233394:+
THCA	cis	rs11089937	0.963	rs5757078	ENSG00000211638.2	IGLV8-61	-4.1	4.84e-05	0.00416	-0.14	-0.19	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22098700~22099212:+
THCA	cis	rs11719291	0.915	rs11557629	ENSG00000270441.1	RP11-694I15.7	4.1	4.84e-05	0.00416	0.24	0.19	Cognitive function;	chr3:48694790	chr3:49140086~49160851:-
THCA	cis	rs7824557	0.564	rs13260727	ENSG00000227888.4	FAM66A	4.1	4.84e-05	0.00416	0.23	0.19	Retinal vascular caliber;	chr8:11375351	chr8:12362019~12388296:+
THCA	cis	rs9341808	0.556	rs1474791	ENSG00000260645.1	RP11-250B2.5	4.1	4.84e-05	0.00416	0.16	0.19	Sitting height ratio;	chr6:80323380	chr6:80466958~80469080:+
THCA	cis	rs4819052	1	rs2297286	ENSG00000273796.1	LL21NC02-21A1.1	-4.1	4.84e-05	0.00416	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45403809~45404369:-
THCA	cis	rs2439831	0.681	rs526450	ENSG00000166763.7	STRCP1	4.1	4.84e-05	0.00416	0.25	0.19	Lung cancer in ever smokers;	chr15:43307127	chr15:43699488~43718184:-
THCA	cis	rs12906542	0.516	rs12593545	ENSG00000259792.1	RP11-114H24.6	-4.1	4.84e-05	0.00416	-0.29	-0.19	Breast cancer;	chr15:78045597	chr15:77993405~77995289:+
THCA	cis	rs1346	0.58	rs11227234	ENSG00000245532.5	NEAT1	-4.1	4.84e-05	0.00416	-0.14	-0.19	Vertical cup-disc ratio;Optic cup area;	chr11:65597700	chr11:65422774~65445540:+
THCA	cis	rs6600671	0.934	rs11249431	ENSG00000275585.1	CH17-118O6.3	4.1	4.84e-05	0.00416	0.23	0.19	Hip geometry;	chr1:121544405	chr1:120985692~121052167:-
THCA	cis	rs11176749	1	rs78418655	ENSG00000203585.3	RP11-542B15.1	4.1	4.84e-05	0.00416	0.22	0.19	Expressive vocabulary in infants;	chr12:67457434	chr12:67519829~67567126:+
THCA	cis	rs10435719	0.509	rs13248956	ENSG00000206014.6	OR7E161P	-4.1	4.84e-05	0.00416	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932259	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.528	rs13250020	ENSG00000206014.6	OR7E161P	-4.1	4.84e-05	0.00416	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932260	chr8:11928597~11929563:-
THCA	cis	rs6496044	0.548	rs7163032	ENSG00000259630.2	CTD-2262B20.1	-4.1	4.84e-05	0.00416	-0.2	-0.19	Interstitial lung disease;	chr15:85529188	chr15:85415228~85415633:+
THCA	cis	rs2191566	0.664	rs4803669	ENSG00000266921.1	RP11-15A1.7	-4.1	4.84e-05	0.00416	-0.17	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44035809	chr19:43996896~44002836:-
THCA	cis	rs643955	0.583	rs13250399	ENSG00000248538.5	RP11-10A14.5	4.1	4.84e-05	0.00416	0.25	0.19	Systemic lupus erythematosus;	chr8:10015300	chr8:9189011~9202854:+
THCA	cis	rs734999	0.545	rs4474198	ENSG00000225931.3	RP3-395M20.7	4.1	4.85e-05	0.00416	0.22	0.19	Ulcerative colitis;	chr1:2622319	chr1:2566410~2569888:+
THCA	cis	rs2281636	0.754	rs7087826	ENSG00000233690.1	EBAG9P1	4.1	4.85e-05	0.00416	0.18	0.19	Obesity-related traits;	chr10:99604588	chr10:99697407~99697949:-
THCA	cis	rs7171869	1	rs7171869	ENSG00000261143.1	ADAMTS7P3	4.1	4.85e-05	0.00416	0.25	0.19	Post bronchodilator FEV1;	chr15:78608567	chr15:77976042~77993057:+
THCA	cis	rs13113518	1	rs2279458	ENSG00000272969.1	RP11-528I4.2	4.1	4.85e-05	0.00416	0.21	0.19	Height;	chr4:55562653	chr4:55547112~55547889:+
THCA	cis	rs72627509	0.638	rs12642622	ENSG00000269949.1	RP11-738E22.3	4.1	4.85e-05	0.00416	0.31	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57036110	chr4:56960927~56961373:-
THCA	cis	rs1030877	1	rs1030877	ENSG00000235319.1	AC012360.4	-4.1	4.85e-05	0.00417	-0.21	-0.19	Obesity-related traits;	chr2:105294056	chr2:105324210~105330529:+
THCA	cis	rs1009077	0.518	rs28382361	ENSG00000260091.1	RP11-33B1.4	-4.1	4.85e-05	0.00417	-0.18	-0.19	Endometriosis;	chr4:119601926	chr4:119409333~119410233:+
THCA	cis	rs5758511	0.633	rs5758689	ENSG00000227370.1	RP4-669P10.19	4.1	4.85e-05	0.00417	0.21	0.19	Birth weight;	chr22:42268966	chr22:42132543~42132998:+
THCA	cis	rs953301	0.546	rs41271953	ENSG00000229808.1	RP11-456P18.2	-4.1	4.85e-05	0.00417	-0.51	-0.19	Left atrial antero-posterior diameter;	chr1:161961259	chr1:161890833~161892196:+
THCA	cis	rs4664293	0.769	rs10171236	ENSG00000230783.1	AC009961.2	-4.1	4.85e-05	0.00417	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159729752	chr2:159689217~159690291:-
THCA	cis	rs4792901	0.918	rs2343133	ENSG00000267151.3	RP11-100E5.2	4.1	4.85e-05	0.00417	0.19	0.19	Dupuytren's disease;	chr17:43562189	chr17:43444707~43451200:+
THCA	cis	rs3755605	0.728	rs11915943	ENSG00000242578.1	RP11-469J4.3	4.1	4.85e-05	0.00417	0.21	0.19	Testicular germ cell tumor;	chr3:170163562	chr3:170410512~170418615:+
THCA	cis	rs17826219	0.561	rs562840	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.85e-05	0.00417	-0.26	-0.19	Body mass index;	chr17:30622372	chr17:30738182~30740275:+
THCA	cis	rs6580649	0.883	rs7967762	ENSG00000273765.1	RP11-370I10.11	-4.1	4.85e-05	0.00417	-0.21	-0.19	Lung cancer;	chr12:48026431	chr12:48360920~48361377:+
THCA	cis	rs8031584	0.918	rs3817498	ENSG00000270015.1	RP11-540B6.6	-4.1	4.85e-05	0.00417	-0.14	-0.19	Huntington's disease progression;	chr15:30976578	chr15:30926514~30928407:+
THCA	cis	rs6671200	0.831	rs35917978	ENSG00000235501.4	RP4-639F20.1	-4.1	4.85e-05	0.00417	-0.38	-0.19	Stearic acid (18:0) levels;	chr1:95138432	chr1:94927566~94963270:+
THCA	cis	rs2153535	0.518	rs6926976	ENSG00000230939.1	RP11-314C16.1	4.1	4.85e-05	0.00417	0.2	0.19	Motion sickness;	chr6:8622045	chr6:8784178~8785445:+
THCA	cis	rs5752326	0.867	rs713900	ENSG00000261188.1	CTA-445C9.14	4.1	4.85e-05	0.00417	0.25	0.19	Ischemic stroke;	chr22:26502276	chr22:26512537~26514568:+
THCA	cis	rs6921919	0.583	rs6928773	ENSG00000273712.1	RP5-874C20.7	4.1	4.85e-05	0.00417	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28315613~28315883:-
THCA	cis	rs250518	0.708	rs258893	ENSG00000251467.1	CTC-250P20.2	4.1	4.85e-05	0.00417	0.25	0.19	Mean corpuscular hemoglobin concentration;	chr5:73009376	chr5:72996920~72997642:+
THCA	cis	rs9595908	0.746	rs2031355	ENSG00000212293.1	SNORA16	4.1	4.85e-05	0.00417	0.22	0.19	Body mass index;	chr13:32641495	chr13:32420390~32420516:-
THCA	cis	rs1923243	0.558	rs4328030	ENSG00000223479.3	RP4-788P17.1	4.1	4.85e-05	0.00417	0.2	0.19	Migraine;	chr1:72973245	chr1:73635216~73715214:+
THCA	cis	rs12497850	0.931	rs1134591	ENSG00000228638.1	FCF1P2	-4.1	4.85e-05	0.00417	-0.2	-0.19	Parkinson's disease;	chr3:48935459	chr3:48290793~48291375:-
THCA	cis	rs10489167	1	rs489213	ENSG00000237899.1	RP4-739H11.3	4.1	4.85e-05	0.00417	0.33	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40700811	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs2744796	ENSG00000237899.1	RP4-739H11.3	4.1	4.85e-05	0.00417	0.33	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40704684	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs823681	ENSG00000237899.1	RP4-739H11.3	4.1	4.85e-05	0.00417	0.33	0.19	Depressive and manic episodes in bipolar disorder;	chr1:40765752	chr1:40669089~40687588:-
THCA	cis	rs12755164	0.702	rs940918	ENSG00000223479.3	RP4-788P17.1	-4.1	4.85e-05	0.00417	-0.2	-0.19	Schizophrenia;	chr1:72872731	chr1:73635216~73715214:+
THCA	cis	rs6472235	0.586	rs7818219	ENSG00000272010.1	CTD-3025N20.3	-4.1	4.86e-05	0.00417	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:66006888	chr8:65591850~65592472:-
THCA	cis	rs10129255	0.912	rs8009135	ENSG00000211972.2	IGHV3-66	4.1	4.86e-05	0.00417	0.11	0.19	Kawasaki disease;	chr14:106777528	chr14:106675017~106675544:-
THCA	cis	rs2154427	0.872	rs76549663	ENSG00000238197.4	PAXBP1-AS1	4.1	4.86e-05	0.00417	0.19	0.19	Bilirubin levels;	chr21:32727457	chr21:32728115~32743122:+
THCA	cis	rs2154427	0.872	rs78882615	ENSG00000238197.4	PAXBP1-AS1	4.1	4.86e-05	0.00417	0.19	0.19	Bilirubin levels;	chr21:32728337	chr21:32728115~32743122:+
THCA	cis	rs7403037	0.833	rs4778463	ENSG00000260760.1	PWRN3	4.1	4.86e-05	0.00417	0.2	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24373557	chr15:24441127~24447967:+
THCA	cis	rs816535	1	rs816535	ENSG00000274973.1	RP13-401N8.7	-4.1	4.86e-05	0.00417	-0.24	-0.19	Parkinson disease and lewy body pathology;	chr20:26275360	chr20:25845497~25845862:+
THCA	cis	rs1125355	0.964	rs72939960	ENSG00000243792.1	OR7E89P	-4.1	4.86e-05	0.00417	-0.28	-0.19	Alzheimer's disease in APOE e4+ carriers;	chr2:158844648	chr2:158853755~158854576:+
THCA	cis	rs755249	0.501	rs2484749	ENSG00000182109.6	RP11-69E11.4	-4.1	4.86e-05	0.00417	-0.19	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39522280~39546187:-
THCA	cis	rs7809615	0.748	rs66509940	ENSG00000244219.5	GS1-259H13.2	-4.1	4.86e-05	0.00417	-0.31	-0.19	Blood metabolite ratios;	chr7:99503880	chr7:99598066~99610813:+
THCA	cis	rs28735056	0.592	rs2277725	ENSG00000261126.6	RP11-795F19.1	-4.1	4.86e-05	0.00417	-0.15	-0.19	Schizophrenia;	chr18:79934168	chr18:80046900~80095482:+
THCA	cis	rs67981189	0.896	rs7146591	ENSG00000269927.1	RP6-91H8.3	-4.1	4.86e-05	0.00418	-0.21	-0.19	Schizophrenia;	chr14:70971511	chr14:71141125~71143253:-
THCA	cis	rs2286503	0.78	rs1304431	ENSG00000226329.2	AC005682.6	4.1	4.86e-05	0.00418	0.23	0.19	Fibrinogen;	chr7:22825793	chr7:22863874~22881350:-
THCA	cis	rs2590942	0.838	rs34361149	ENSG00000227207.2	RPL31P12	4.1	4.86e-05	0.00418	0.31	0.19	Childhood body mass index;	chr1:72284787	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.838	rs61765651	ENSG00000227207.2	RPL31P12	4.1	4.86e-05	0.00418	0.31	0.19	Childhood body mass index;	chr1:72288631	chr1:72301472~72301829:+
THCA	cis	rs9796	0.621	rs28737302	ENSG00000247556.5	OIP5-AS1	4.1	4.86e-05	0.00418	0.15	0.19	Menopause (age at onset);	chr15:41177745	chr15:41283990~41309737:+
THCA	cis	rs9796	0.621	rs1659228	ENSG00000247556.5	OIP5-AS1	4.1	4.86e-05	0.00418	0.15	0.19	Menopause (age at onset);	chr15:41179780	chr15:41283990~41309737:+
THCA	cis	rs2153535	0.585	rs9406188	ENSG00000230939.1	RP11-314C16.1	-4.1	4.86e-05	0.00418	-0.19	-0.19	Motion sickness;	chr6:8667604	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.585	rs9328501	ENSG00000230939.1	RP11-314C16.1	-4.1	4.86e-05	0.00418	-0.19	-0.19	Motion sickness;	chr6:8669287	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.56	rs9379239	ENSG00000230939.1	RP11-314C16.1	-4.1	4.86e-05	0.00418	-0.19	-0.19	Motion sickness;	chr6:8670263	chr6:8784178~8785445:+
THCA	cis	rs9818758	0.607	rs56004653	ENSG00000229759.1	MRPS18AP1	-4.1	4.86e-05	0.00418	-0.43	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49034795	chr3:48256350~48256938:-
THCA	cis	rs7188445	0.556	rs7203910	ENSG00000277954.1	RP11-679B19.1	-4.1	4.86e-05	0.00418	-0.21	-0.19	Urate levels;	chr16:79711722	chr16:79202624~79206739:-
THCA	cis	rs459571	0.876	rs2520095	ENSG00000235106.7	LINC00094	4.1	4.86e-05	0.00418	0.16	0.19	Platelet distribution width;	chr9:134054446	chr9:134025439~134034666:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000275400.1	RP4-756H11.5	-4.1	4.86e-05	0.00418	-0.18	-0.19	Aortic root size;	chr7:65931217	chr7:66553805~66554199:-
THCA	cis	rs7246657	0.598	rs10417545	ENSG00000276846.1	CTD-3220F14.3	4.1	4.86e-05	0.00418	0.24	0.19	Coronary artery calcification;	chr19:37163361	chr19:37314868~37315620:-
THCA	cis	rs3892630	0.878	rs6510277	ENSG00000267475.1	CTD-2538C1.2	-4.1	4.86e-05	0.00418	-0.27	-0.19	Red blood cell traits;	chr19:32692763	chr19:32687089~32691750:-
THCA	cis	rs3892630	0.817	rs12609866	ENSG00000267475.1	CTD-2538C1.2	-4.1	4.86e-05	0.00418	-0.27	-0.19	Red blood cell traits;	chr19:32693506	chr19:32687089~32691750:-
THCA	cis	rs1371614	0.655	rs7579579	ENSG00000272148.1	RP11-195B17.1	-4.1	4.86e-05	0.00418	-0.17	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928974	chr2:27062428~27062907:-
THCA	cis	rs9341808	0.667	rs3805919	ENSG00000272129.1	RP11-250B2.6	4.1	4.86e-05	0.00418	0.23	0.19	Sitting height ratio;	chr6:80197092	chr6:80355424~80356859:+
THCA	cis	rs748404	0.915	rs35535692	ENSG00000249839.1	AC011330.5	-4.1	4.86e-05	0.00418	-0.28	-0.19	Lung cancer;	chr15:43252037	chr15:43663654~43684339:-
THCA	cis	rs875971	0.54	rs4717275	ENSG00000275400.1	RP4-756H11.5	4.1	4.87e-05	0.00418	0.18	0.19	Aortic root size;	chr7:65800193	chr7:66553805~66554199:-
THCA	cis	rs2732480	0.5	rs2932093	ENSG00000273765.1	RP11-370I10.11	4.1	4.87e-05	0.00418	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48360920~48361377:+
THCA	cis	rs2018683	0.649	rs12536605	ENSG00000272568.4	CTB-113D17.1	4.1	4.87e-05	0.00418	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930883	chr7:28979967~29013367:+
THCA	cis	rs1204798	1	rs1204800	ENSG00000237021.2	RP3-486I3.7	4.1	4.87e-05	0.00418	0.2	0.19	Dental caries;	chr6:116222931	chr6:116254207~116256743:+
THCA	cis	rs4713118	1	rs4713118	ENSG00000226314.6	ZNF192P1	-4.1	4.87e-05	0.00418	-0.23	-0.19	Parkinson's disease;	chr6:27709015	chr6:28161781~28169594:+
THCA	cis	rs1048886	0.872	rs2207423	ENSG00000271967.1	RP11-134K13.4	-4.1	4.87e-05	0.00418	-0.2	-0.19	Type 2 diabetes;	chr6:70537682	chr6:70596438~70596980:+
THCA	cis	rs3824488	0.705	rs16909923	ENSG00000271155.1	RP11-435O5.5	-4.1	4.87e-05	0.00418	-0.28	-0.19	Neuroticism;	chr9:95521708	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.705	rs16909930	ENSG00000271155.1	RP11-435O5.5	-4.1	4.87e-05	0.00418	-0.28	-0.19	Neuroticism;	chr9:95522076	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.705	rs28682502	ENSG00000271155.1	RP11-435O5.5	-4.1	4.87e-05	0.00418	-0.28	-0.19	Neuroticism;	chr9:95522717	chr9:95506235~95507636:+
THCA	cis	rs12612619	0.724	rs7355650	ENSG00000272148.1	RP11-195B17.1	-4.1	4.87e-05	0.00418	-0.18	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27022607	chr2:27062428~27062907:-
THCA	cis	rs13178541	0.872	rs10900836	ENSG00000250378.1	RP11-119J18.1	-4.1	4.87e-05	0.00418	-0.22	-0.19	IgG glycosylation;	chr5:135788139	chr5:135812667~135826582:+
THCA	cis	rs9595908	0.709	rs7322668	ENSG00000212293.1	SNORA16	4.1	4.87e-05	0.00418	0.21	0.19	Body mass index;	chr13:32780298	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.709	rs7318610	ENSG00000212293.1	SNORA16	4.1	4.87e-05	0.00418	0.21	0.19	Body mass index;	chr13:32781912	chr13:32420390~32420516:-
THCA	cis	rs854765	0.547	rs4643387	ENSG00000281749.1	Y_RNA	4.1	4.87e-05	0.00419	0.24	0.19	Total body bone mineral density;	chr17:18069659	chr17:18001101~18001195:-
THCA	cis	rs7914558	0.646	rs10883799	ENSG00000213277.3	MARCKSL1P1	4.1	4.87e-05	0.00419	0.2	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102903553	chr10:103175554~103176094:+
THCA	cis	rs2408955	0.561	rs9971924	ENSG00000273765.1	RP11-370I10.11	-4.1	4.87e-05	0.00419	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48086049	chr12:48360920~48361377:+
THCA	cis	rs2408955	0.522	rs7139330	ENSG00000273765.1	RP11-370I10.11	-4.1	4.87e-05	0.00419	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48089701	chr12:48360920~48361377:+
THCA	cis	rs2408955	0.522	rs2051851	ENSG00000273765.1	RP11-370I10.11	-4.1	4.87e-05	0.00419	-0.19	-0.19	Glycated hemoglobin levels;	chr12:48092157	chr12:48360920~48361377:+
THCA	cis	rs2692947	0.832	rs2692954	ENSG00000235584.2	AC008268.1	-4.1	4.87e-05	0.00419	-0.19	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96017630	chr2:95666084~95668715:+
THCA	cis	rs10911902	0.643	rs10494584	ENSG00000229739.2	RP11-295K2.3	-4.1	4.87e-05	0.00419	-0.29	-0.19	Schizophrenia;	chr1:186321389	chr1:186435161~186470291:+
THCA	cis	rs17756712	0.537	rs4960127	ENSG00000272463.1	RP11-532F6.3	4.1	4.87e-05	0.00419	0.22	0.19	Vertical cup-disc ratio;	chr6:624892	chr6:708592~711405:-
THCA	cis	rs8020441	1	rs8020441	ENSG00000269906.1	RP11-248J18.2	4.1	4.88e-05	0.00419	0.26	0.19	Cognitive performance;	chr14:50704161	chr14:50662511~50663178:-
THCA	cis	rs4853525	0.59	rs13399044	ENSG00000235852.1	AC005540.3	4.1	4.88e-05	0.00419	0.21	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190944844	chr2:190880797~190882059:-
THCA	cis	rs1009077	0.627	rs28625289	ENSG00000260091.1	RP11-33B1.4	-4.1	4.88e-05	0.00419	-0.18	-0.19	Endometriosis;	chr4:119601850	chr4:119409333~119410233:+
THCA	cis	rs3892630	0.588	rs8106748	ENSG00000267475.1	CTD-2538C1.2	-4.1	4.88e-05	0.00419	-0.25	-0.19	Red blood cell traits;	chr19:32791891	chr19:32687089~32691750:-
THCA	cis	rs72827839	1	rs79799256	ENSG00000228782.6	CTD-2026D20.3	4.1	4.88e-05	0.00419	0.24	0.19	Ease of getting up in the morning;	chr17:48476979	chr17:47450568~47492492:-
THCA	cis	rs72827839	1	rs72827901	ENSG00000228782.6	CTD-2026D20.3	4.1	4.88e-05	0.00419	0.24	0.19	Ease of getting up in the morning;	chr17:48477094	chr17:47450568~47492492:-
THCA	cis	rs11633886	0.677	rs17630344	ENSG00000259200.1	RP11-718O11.1	-4.1	4.88e-05	0.00419	-0.23	-0.19	Diisocyanate-induced asthma;	chr15:45759724	chr15:45705078~45931069:+
THCA	cis	rs2275906	0.748	rs11969868	ENSG00000272462.2	U91328.19	4.1	4.88e-05	0.00419	0.19	0.19	Urate levels in lean individuals;	chr6:25878278	chr6:25992662~26001775:+
THCA	cis	rs7707921	0.881	rs111907176	ENSG00000251374.1	RPS23P5	4.1	4.88e-05	0.00419	0.27	0.19	Breast cancer;	chr5:82016580	chr5:82265157~82265259:-
THCA	cis	rs858239	0.511	rs10256996	ENSG00000226816.2	AC005082.12	-4.1	4.88e-05	0.00419	-0.26	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23206013~23208045:+
THCA	cis	rs6479901	0.512	rs7100372	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.88e-05	0.00419	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.778	rs7896676	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.88e-05	0.00419	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.915	rs7896677	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.88e-05	0.00419	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.841	rs7085869	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.88e-05	0.00419	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.818	rs9299455	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.88e-05	0.00419	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs7899715	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.88e-05	0.00419	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs4525102	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.88e-05	0.00419	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.841	rs7092504	ENSG00000272767.1	JMJD1C-AS1	-4.1	4.88e-05	0.00419	-0.26	-0.19	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63465229~63466563:+
THCA	cis	rs1075265	0.568	rs10865278	ENSG00000272156.1	RP11-477N3.1	4.1	4.88e-05	0.00419	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54082554~54085066:+
THCA	cis	rs8030605	0.85	rs1553738	ENSG00000277245.1	RP11-48G14.3	4.1	4.88e-05	0.00419	0.32	0.19	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56078753	chr15:56447120~56447697:+
THCA	cis	rs67478160	0.643	rs7156697	ENSG00000269940.1	RP11-73M18.7	4.1	4.88e-05	0.00419	0.18	0.19	Schizophrenia;	chr14:103744799	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.679	rs7156834	ENSG00000269940.1	RP11-73M18.7	4.1	4.88e-05	0.00419	0.18	0.19	Schizophrenia;	chr14:103744843	chr14:103694560~103695170:+
THCA	cis	rs9843304	0.624	rs13061914	ENSG00000240541.2	TM4SF1-AS1	4.1	4.88e-05	0.00419	0.16	0.19	Gallstone disease;	chr3:149484345	chr3:149377778~149386583:+
THCA	cis	rs9843304	0.529	rs61382471	ENSG00000240541.2	TM4SF1-AS1	4.1	4.88e-05	0.00419	0.16	0.19	Gallstone disease;	chr3:149484373	chr3:149377778~149386583:+
THCA	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	4.1	4.88e-05	0.00419	0.22	0.19	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
THCA	cis	rs1046896	0.731	rs8067667	ENSG00000263063.1	RP11-388C12.1	-4.1	4.88e-05	0.00419	-0.24	-0.19	Glycated hemoglobin levels;	chr17:82827999	chr17:82713908~82716255:-
THCA	cis	rs2777491	1	rs316605	ENSG00000247556.5	OIP5-AS1	4.1	4.88e-05	0.00419	0.15	0.19	Ulcerative colitis;	chr15:41479393	chr15:41283990~41309737:+
THCA	cis	rs9467773	0.869	rs9295689	ENSG00000261353.1	CTA-14H9.5	-4.1	4.88e-05	0.00419	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26455583	chr6:26527063~26527404:+
THCA	cis	rs9341808	0.739	rs4706831	ENSG00000260645.1	RP11-250B2.5	4.1	4.88e-05	0.00419	0.16	0.19	Sitting height ratio;	chr6:80297982	chr6:80466958~80469080:+
THCA	cis	rs3755605	0.728	rs7638591	ENSG00000242578.1	RP11-469J4.3	4.1	4.88e-05	0.00419	0.21	0.19	Testicular germ cell tumor;	chr3:170120212	chr3:170410512~170418615:+
THCA	cis	rs59918340	0.616	rs3739222	ENSG00000253307.1	RP11-10J21.4	4.1	4.88e-05	0.00419	0.25	0.19	Immature fraction of reticulocytes;	chr8:141195805	chr8:141252286~141253292:-
THCA	cis	rs2474937	0.561	rs2359839	ENSG00000231365.4	RP11-418J17.1	4.1	4.88e-05	0.00419	0.18	0.19	Congenital heart malformation;	chr1:118383244	chr1:119140396~119275973:+
THCA	cis	rs738722	0.836	rs1547014	ENSG00000272858.1	CTA-292E10.8	-4.1	4.88e-05	0.00419	-0.19	-0.19	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28704723	chr22:28814914~28815662:+
THCA	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	4.1	4.88e-05	0.00419	0.2	0.19	Asthma;	chr2:102437614	chr2:102438713~102440475:+
THCA	cis	rs9543976	0.614	rs60497706	ENSG00000261105.4	LMO7-AS1	-4.1	4.88e-05	0.00419	-0.33	-0.19	Diabetic retinopathy;	chr13:75509549	chr13:75604700~75635994:-
THCA	cis	rs78487399	0.71	rs76857293	ENSG00000234936.1	AC010883.5	4.1	4.88e-05	0.0042	0.27	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43364537	chr2:43229573~43233394:+
THCA	cis	rs7824557	0.507	rs7010590	ENSG00000206014.6	OR7E161P	-4.1	4.89e-05	0.0042	-0.22	-0.19	Retinal vascular caliber;	chr8:11205373	chr8:11928597~11929563:-
THCA	cis	rs4925386	0.819	rs2890083	ENSG00000275437.1	RP5-908M14.10	-4.1	4.89e-05	0.0042	-0.17	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62336902	chr20:62402236~62405935:-
THCA	cis	rs7614311	0.552	rs73117078	ENSG00000271843.1	RP11-245J9.5	-4.1	4.89e-05	0.0042	-0.37	-0.19	Lung function (FVC);Lung function (FEV1);	chr3:63956408	chr3:64008082~64008692:-
THCA	cis	rs11175194	0.655	rs11175195	ENSG00000255642.1	PABPC1P4	-4.1	4.89e-05	0.0042	-0.36	-0.19	Epithelial ovarian cancer;	chr12:63871944	chr12:63822021~63823895:+
THCA	cis	rs1075265	0.584	rs7558126	ENSG00000272156.1	RP11-477N3.1	4.1	4.89e-05	0.0042	0.19	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54082554~54085066:+
THCA	cis	rs6088813	1	rs6060401	ENSG00000279253.1	RP4-614O4.13	4.1	4.89e-05	0.0042	0.18	0.19	Height;	chr20:35417411	chr20:35262727~35264187:-
THCA	cis	rs6479891	0.63	rs10995447	ENSG00000272767.1	JMJD1C-AS1	4.1	4.89e-05	0.0042	0.24	0.19	Arthritis (juvenile idiopathic);	chr10:63119761	chr10:63465229~63466563:+
THCA	cis	rs7088591	0.558	rs57392412	ENSG00000276818.1	AC026393.1	4.1	4.89e-05	0.0042	0.35	0.19	Blood pressure;	chr10:58058901	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.558	rs57910753	ENSG00000276818.1	AC026393.1	4.1	4.89e-05	0.0042	0.35	0.19	Blood pressure;	chr10:58059771	chr10:57095699~57095781:+
THCA	cis	rs5753037	0.63	rs140111	ENSG00000273350.1	RP4-539M6.20	-4.1	4.89e-05	0.0042	-0.21	-0.19	Type 1 diabetes;	chr22:29735581	chr22:30420512~30420912:+
THCA	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	4.1	4.89e-05	0.0042	0.14	0.19	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
THCA	cis	rs735539	0.555	rs4608189	ENSG00000278291.1	RP11-172H24.4	4.1	4.89e-05	0.0042	0.25	0.19	Dental caries;	chr13:20769070	chr13:20699307~20703718:-
THCA	cis	rs2836974	0.739	rs12482181	ENSG00000255568.3	BRWD1-AS2	4.1	4.89e-05	0.0042	0.16	0.19	Cognitive function;	chr21:39176926	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs14194	ENSG00000255568.3	BRWD1-AS2	4.1	4.89e-05	0.0042	0.16	0.19	Cognitive function;	chr21:39177540	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.831	rs6517521	ENSG00000255568.3	BRWD1-AS2	4.1	4.89e-05	0.0042	0.16	0.19	Cognitive function;	chr21:39179662	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.829	rs34227163	ENSG00000255568.3	BRWD1-AS2	4.1	4.89e-05	0.0042	0.16	0.19	Cognitive function;	chr21:39180017	chr21:39313935~39314962:+
THCA	cis	rs7904321	1	rs1010890	ENSG00000232075.1	MRPL35P2	-4.1	4.89e-05	0.0042	-0.25	-0.19	Intelligence (multi-trait analysis);	chr10:63079305	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs1010889	ENSG00000232075.1	MRPL35P2	-4.1	4.89e-05	0.0042	-0.25	-0.19	Intelligence (multi-trait analysis);	chr10:63079682	chr10:63634317~63634827:-
THCA	cis	rs1560104	0.709	rs2217272	ENSG00000262801.4	U91319.1	4.1	4.89e-05	0.0042	0.22	0.19	Obesity-related traits;	chr16:12610654	chr16:13246316~13562918:+
THCA	cis	rs1124769	0.654	rs12914185	ENSG00000259378.1	DCAF13P3	4.1	4.89e-05	0.0042	0.29	0.19	Cognitive performance;	chr15:51071687	chr15:50944663~50945996:+
THCA	cis	rs36093844	0.706	rs79907592	ENSG00000279742.1	RP11-700A24.1	-4.1	4.89e-05	0.0042	-0.28	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85847024	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.752	rs78820266	ENSG00000279742.1	RP11-700A24.1	-4.1	4.89e-05	0.0042	-0.28	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85847214	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs7102361	ENSG00000279742.1	RP11-700A24.1	-4.1	4.89e-05	0.0042	-0.28	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85849096	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs75217143	ENSG00000279742.1	RP11-700A24.1	-4.1	4.89e-05	0.0042	-0.28	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85851227	chr11:85852557~85854943:-
THCA	cis	rs6019512	0.625	rs6012556	ENSG00000227431.4	CSE1L-AS1	-4.1	4.89e-05	0.0042	-0.22	-0.19	Intelligence (multi-trait analysis);	chr20:48911906	chr20:49040463~49046044:-
THCA	cis	rs2191566	0.664	rs4482396	ENSG00000266921.1	RP11-15A1.7	-4.1	4.89e-05	0.0042	-0.17	-0.19	Acute lymphoblastic leukemia (childhood);	chr19:44057847	chr19:43996896~44002836:-
THCA	cis	rs10435719	0.744	rs11250175	ENSG00000206014.6	OR7E161P	-4.1	4.89e-05	0.0042	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.516	rs13252853	ENSG00000206014.6	OR7E161P	-4.1	4.89e-05	0.0042	-0.22	-0.19	Neuroticism;	chr8:11935465	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.516	rs13252854	ENSG00000206014.6	OR7E161P	-4.1	4.89e-05	0.0042	-0.22	-0.19	Neuroticism;	chr8:11935469	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.516	rs13279577	ENSG00000206014.6	OR7E161P	-4.1	4.89e-05	0.0042	-0.22	-0.19	Neuroticism;	chr8:11935587	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.516	rs10112958	ENSG00000206014.6	OR7E161P	-4.1	4.89e-05	0.0042	-0.22	-0.19	Neuroticism;	chr8:11935631	chr8:11928597~11929563:-
THCA	cis	rs3096299	0.754	rs2965816	ENSG00000261118.1	RP11-104N10.1	-4.1	4.89e-05	0.0042	-0.16	-0.19	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89492017~89504460:-
THCA	cis	rs11088226	0.846	rs2154500	ENSG00000186842.4	LINC00846	-4.1	4.89e-05	0.0042	-0.24	-0.19	Gastritis;	chr21:32554081	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.846	rs2154501	ENSG00000186842.4	LINC00846	-4.1	4.89e-05	0.0042	-0.24	-0.19	Gastritis;	chr21:32554141	chr21:32572238~32575881:-
THCA	cis	rs2832191	0.647	rs11170	ENSG00000176054.6	RPL23P2	4.1	4.9e-05	0.0042	0.17	0.19	Dental caries;	chr21:29005769	chr21:28997613~28998033:-
THCA	cis	rs9543976	0.623	rs7986566	ENSG00000261105.4	LMO7-AS1	4.1	4.9e-05	0.0042	0.26	0.19	Diabetic retinopathy;	chr13:75623795	chr13:75604700~75635994:-
THCA	cis	rs17366136	1	rs17366136	ENSG00000232949.1	AC002480.4	-4.1	4.9e-05	0.0042	-0.23	-0.19	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr7:22561508	chr7:22589705~22591622:+
THCA	cis	rs4561483	0.549	rs6498251	ENSG00000263307.1	RP11-166B2.8	-4.1	4.9e-05	0.0042	-0.19	-0.19	Testicular germ cell tumor;	chr16:11858433	chr16:11851649~11895611:+
THCA	cis	rs801193	1	rs1553610	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66732246	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs2707845	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66733811	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs2707850	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66738883	chr7:66526088~66542624:-
THCA	cis	rs801193	0.967	rs1110414	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66740595	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs7783924	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66744070	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs7789184	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66745208	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs2707854	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66747610	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs3800812	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66758474	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs4279493	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66761633	chr7:66526088~66542624:-
THCA	cis	rs801193	0.761	rs2659888	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.0042	0.13	0.19	Aortic root size;	chr7:66765184	chr7:66526088~66542624:-
THCA	cis	rs10129255	0.957	rs1024349	ENSG00000211972.2	IGHV3-66	4.1	4.9e-05	0.0042	0.11	0.19	Kawasaki disease;	chr14:106689997	chr14:106675017~106675544:-
THCA	cis	rs2290416	0.892	rs34178175	ENSG00000253931.1	RP11-909N17.2	4.1	4.9e-05	0.0042	0.36	0.19	Attention deficit hyperactivity disorder;	chr8:143582517	chr8:143412749~143417054:+
THCA	cis	rs9341808	0.935	rs4706113	ENSG00000272129.1	RP11-250B2.6	4.1	4.9e-05	0.0042	0.23	0.19	Sitting height ratio;	chr6:80129598	chr6:80355424~80356859:+
THCA	cis	rs12410462	0.551	rs67216605	ENSG00000227711.2	RP11-275O4.5	-4.1	4.9e-05	0.0042	-0.23	-0.19	Major depressive disorder;	chr1:227713936	chr1:227509028~227520477:-
THCA	cis	rs9467773	0.523	rs2498399	ENSG00000124549.13	BTN2A3P	4.1	4.9e-05	0.00421	0.18	0.19	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26421391~26432383:+
THCA	cis	rs12493885	0.818	rs1521324	ENSG00000243069.6	ARHGEF26-AS1	-4.1	4.9e-05	0.00421	-0.35	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154041074	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.818	rs55681005	ENSG00000243069.6	ARHGEF26-AS1	-4.1	4.9e-05	0.00421	-0.35	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154041468	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.818	rs73158491	ENSG00000243069.6	ARHGEF26-AS1	-4.1	4.9e-05	0.00421	-0.35	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154046323	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.818	rs61791543	ENSG00000243069.6	ARHGEF26-AS1	-4.1	4.9e-05	0.00421	-0.35	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154049008	chr3:154024401~154121332:-
THCA	cis	rs10129255	1	rs10137758	ENSG00000211970.3	IGHV4-61	-4.1	4.9e-05	0.00421	-0.11	-0.19	Kawasaki disease;	chr14:106697673	chr14:106639119~106639657:-
THCA	cis	rs4561483	0.583	rs1029285	ENSG00000263307.1	RP11-166B2.8	-4.1	4.9e-05	0.00421	-0.19	-0.19	Testicular germ cell tumor;	chr16:11893261	chr16:11851649~11895611:+
THCA	cis	rs10860794	0.593	rs9787990	ENSG00000274560.1	RP11-285E23.2	-4.1	4.9e-05	0.00421	-0.13	-0.19	Blood protein levels;	chr12:101861178	chr12:101696002~101696450:-
THCA	cis	rs752590	0.566	rs6542126	ENSG00000227359.1	AC017074.2	-4.1	4.9e-05	0.00421	-0.28	-0.19	Mucinous ovarian carcinoma;	chr2:113264992	chr2:113677702~113704078:-
THCA	cis	rs7829975	0.711	rs4481596	ENSG00000254340.1	RP11-10A14.3	4.1	4.9e-05	0.00421	0.21	0.19	Mood instability;	chr8:8846820	chr8:9141424~9145435:+
THCA	cis	rs911555	0.603	rs11626562	ENSG00000269940.1	RP11-73M18.7	4.1	4.9e-05	0.00421	0.19	0.19	Intelligence (multi-trait analysis);	chr14:103379025	chr14:103694560~103695170:+
THCA	cis	rs494003	1	rs72922733	ENSG00000214659.4	KRT8P26	4.1	4.9e-05	0.00421	0.22	0.19	Systemic lupus erythematosus;	chr11:65753275	chr11:65726939~65728214:+
THCA	cis	rs7777677	0.925	rs6969951	ENSG00000211750.2	TRBV24-1	4.1	4.9e-05	0.00421	0.19	0.19	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142656701~142657213:+
THCA	cis	rs801193	1	rs2707836	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.00421	0.13	0.19	Aortic root size;	chr7:66695448	chr7:66526088~66542624:-
THCA	cis	rs801193	0.844	rs7779971	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.00421	0.13	0.19	Aortic root size;	chr7:66696803	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs2659906	ENSG00000229180.5	GS1-124K5.11	4.1	4.9e-05	0.00421	0.13	0.19	Aortic root size;	chr7:66700323	chr7:66526088~66542624:-
THCA	cis	rs4742903	1	rs1026181	ENSG00000270332.1	SMC2-AS1	4.1	4.9e-05	0.00421	0.17	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104131053	chr9:104080024~104093073:-
THCA	cis	rs7904321	0.966	rs10822128	ENSG00000232075.1	MRPL35P2	-4.1	4.9e-05	0.00421	-0.25	-0.19	Intelligence (multi-trait analysis);	chr10:63083347	chr10:63634317~63634827:-
THCA	cis	rs4950322	0.512	rs2883318	ENSG00000226015.2	CCT8P1	4.1	4.91e-05	0.00421	0.19	0.19	Protein quantitative trait loci;	chr1:147377422	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.512	rs12409455	ENSG00000226015.2	CCT8P1	4.1	4.91e-05	0.00421	0.19	0.19	Protein quantitative trait loci;	chr1:147378563	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.6	rs11240014	ENSG00000226015.2	CCT8P1	4.1	4.91e-05	0.00421	0.19	0.19	Protein quantitative trait loci;	chr1:147380674	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.576	rs11240015	ENSG00000226015.2	CCT8P1	4.1	4.91e-05	0.00421	0.19	0.19	Protein quantitative trait loci;	chr1:147380813	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.553	rs12093870	ENSG00000226015.2	CCT8P1	4.1	4.91e-05	0.00421	0.19	0.19	Protein quantitative trait loci;	chr1:147380815	chr1:147203276~147204932:-
THCA	cis	rs11157436	0.918	rs1983519	ENSG00000211812.1	TRAV26-2	-4.1	4.91e-05	0.00421	-0.17	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22202583~22203368:+
THCA	cis	rs7528684	0.546	rs10908584	ENSG00000236731.1	RP4-801G22.2	4.1	4.91e-05	0.00421	0.19	0.19	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157671968	chr1:157629939~157630728:-
THCA	cis	rs9341808	0.667	rs12209624	ENSG00000272129.1	RP11-250B2.6	4.1	4.91e-05	0.00421	0.23	0.19	Sitting height ratio;	chr6:80209416	chr6:80355424~80356859:+
THCA	cis	rs2836974	0.897	rs2836944	ENSG00000255568.3	BRWD1-AS2	4.1	4.91e-05	0.00421	0.16	0.19	Cognitive function;	chr21:39221613	chr21:39313935~39314962:+
THCA	cis	rs9928842	0.882	rs3169330	ENSG00000261783.1	RP11-252K23.2	4.1	4.91e-05	0.00421	0.37	0.19	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs1983372	ENSG00000229886.1	RP5-1132H15.3	-4.1	4.91e-05	0.00421	-0.19	-0.19	Aortic root size;	chr7:66146364	chr7:66025126~66031544:-
THCA	cis	rs6687821	0.515	rs5859	ENSG00000261737.1	RP4-612B15.3	-4.1	4.91e-05	0.00421	-0.28	-0.19	Yeast infection;	chr1:86862842	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs554213	ENSG00000261737.1	RP4-612B15.3	-4.1	4.91e-05	0.00421	-0.28	-0.19	Yeast infection;	chr1:86876474	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs576955	ENSG00000261737.1	RP4-612B15.3	-4.1	4.91e-05	0.00421	-0.28	-0.19	Yeast infection;	chr1:86876627	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs502404	ENSG00000261737.1	RP4-612B15.3	-4.1	4.91e-05	0.00421	-0.28	-0.19	Yeast infection;	chr1:86878204	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs507966	ENSG00000261737.1	RP4-612B15.3	-4.1	4.91e-05	0.00421	-0.28	-0.19	Yeast infection;	chr1:86904391	chr1:86703502~86704462:-
THCA	cis	rs7111546	0.565	rs7107247	ENSG00000246225.5	RP11-17A1.3	4.1	4.91e-05	0.00421	0.33	0.19	Dialysis-related mortality;	chr11:22926453	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.565	rs74493240	ENSG00000246225.5	RP11-17A1.3	4.1	4.91e-05	0.00421	0.33	0.19	Dialysis-related mortality;	chr11:22929576	chr11:22829380~22945393:+
THCA	cis	rs9878978	1	rs9878978	ENSG00000237990.3	CNTN4-AS1	4.1	4.91e-05	0.00421	0.19	0.19	Blood pressure (smoking interaction);	chr3:2444285	chr3:3039033~3069242:-
THCA	cis	rs7616559	0.749	rs6765256	ENSG00000244515.1	KRT18P34	-4.1	4.91e-05	0.00421	-0.24	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:157035949	chr3:157162663~157163932:-
THCA	cis	rs6730558	0.899	rs4669301	ENSG00000236008.1	AC011747.4	4.1	4.91e-05	0.00421	0.22	0.19	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8602631	chr2:8559833~8583792:-
THCA	cis	rs7899106	1	rs58702504	ENSG00000270002.1	RP11-93H12.4	4.1	4.91e-05	0.00422	0.31	0.19	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85589591	chr10:85644073~85648066:+
THCA	cis	rs758324	0.732	rs149432	ENSG00000224431.1	AC063976.7	-4.1	4.91e-05	0.00422	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132105807	chr5:132199456~132203487:+
THCA	cis	rs11185790	0.784	rs11185819	ENSG00000232936.4	RP11-80H5.2	-4.1	4.91e-05	0.00422	-0.23	-0.19	Metabolic traits;	chr10:89626739	chr10:89645282~89650667:+
THCA	cis	rs2015599	0.549	rs7311081	ENSG00000257176.2	RP11-996F15.2	4.1	4.91e-05	0.00422	0.18	0.19	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.517	rs7295212	ENSG00000257176.2	RP11-996F15.2	4.1	4.91e-05	0.00422	0.18	0.19	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29280418~29317848:-
THCA	cis	rs2797160	0.547	rs1418645	ENSG00000226409.1	RP11-735G4.1	-4.1	4.91e-05	0.00422	-0.23	-0.19	Endometrial cancer;	chr6:125625330	chr6:125370211~125374324:-
THCA	cis	rs1371614	0.679	rs4441421	ENSG00000272148.1	RP11-195B17.1	4.1	4.92e-05	0.00422	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26919223	chr2:27062428~27062907:-
THCA	cis	rs881375	0.715	rs10985073	ENSG00000270917.1	RP11-27I1.6	-4.1	4.92e-05	0.00422	-0.25	-0.19	Rheumatoid arthritis;	chr9:120881577	chr9:120812475~120812845:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000275400.1	RP4-756H11.5	-4.1	4.92e-05	0.00422	-0.18	-0.19	Calcium levels;	chr7:65853042	chr7:66553805~66554199:-
THCA	cis	rs875971	0.516	rs6945322	ENSG00000275400.1	RP4-756H11.5	-4.1	4.92e-05	0.00422	-0.18	-0.19	Aortic root size;	chr7:65871069	chr7:66553805~66554199:-
THCA	cis	rs1923243	0.647	rs11210153	ENSG00000223479.3	RP4-788P17.1	4.1	4.92e-05	0.00422	0.21	0.19	Migraine;	chr1:73160079	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.647	rs11210154	ENSG00000223479.3	RP4-788P17.1	4.1	4.92e-05	0.00422	0.21	0.19	Migraine;	chr1:73160110	chr1:73635216~73715214:+
THCA	cis	rs7829975	0.744	rs2409092	ENSG00000233609.3	RP11-62H7.2	4.1	4.92e-05	0.00422	0.18	0.19	Mood instability;	chr8:8824682	chr8:8961200~8979025:+
THCA	cis	rs13113518	1	rs11724094	ENSG00000272969.1	RP11-528I4.2	4.1	4.92e-05	0.00422	0.21	0.19	Height;	chr4:55501479	chr4:55547112~55547889:+
THCA	cis	rs10090774	0.93	rs2369410	ENSG00000279766.1	RP11-642A1.2	4.1	4.92e-05	0.00422	0.22	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140900541	chr8:140572142~140572812:-
THCA	cis	rs6479891	0.908	rs16918603	ENSG00000272767.1	JMJD1C-AS1	4.1	4.92e-05	0.00422	0.28	0.19	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.908	rs4746201	ENSG00000272767.1	JMJD1C-AS1	4.1	4.92e-05	0.00422	0.28	0.19	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63465229~63466563:+
THCA	cis	rs10833905	1	rs3909703	ENSG00000246225.5	RP11-17A1.3	-4.1	4.92e-05	0.00422	-0.27	-0.19	Sudden cardiac arrest;	chr11:22999094	chr11:22829380~22945393:+
THCA	cis	rs6570726	0.791	rs12208812	ENSG00000270638.1	RP3-466P17.1	4.1	4.92e-05	0.00422	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145735570~145737218:+
THCA	cis	rs34421088	0.532	rs2736390	ENSG00000154316.13	TDH	-4.1	4.92e-05	0.00422	-0.14	-0.19	Neuroticism;	chr8:11304287	chr8:11339637~11368452:+
THCA	cis	rs7089973	0.61	rs968849	ENSG00000236799.1	RP11-383C6.2	-4.1	4.92e-05	0.00422	-0.23	-0.19	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114997972	chr10:114994657~114996593:+
THCA	cis	rs55966801	0.786	rs72865316	ENSG00000277290.1	RP11-326C3.16	-4.1	4.92e-05	0.00422	-0.25	-0.19	Plateletcrit;	chr11:247028	chr11:243099~243483:-
THCA	cis	rs4245128	0.775	rs2218618	ENSG00000227487.3	NCAM1-AS1	4.1	4.92e-05	0.00422	0.19	0.19	Life satisfaction;	chr11:112949746	chr11:113269532~113273901:-
THCA	cis	rs6088590	0.965	rs6119534	ENSG00000276073.1	RP5-1125A11.7	-4.1	4.93e-05	0.00422	-0.17	-0.19	Coronary artery disease;	chr20:34853454	chr20:33985617~33988989:-
THCA	cis	rs2704588	0.505	rs28718401	ENSG00000270720.1	RP11-84C13.2	-4.1	4.93e-05	0.00422	-0.35	-0.19	Longevity;	chr4:89051438	chr4:89119284~89119871:+
THCA	cis	rs12935418	0.583	rs7206625	ENSG00000278985.1	RP11-303E16.9	4.1	4.93e-05	0.00422	0.23	0.19	Mean corpuscular volume;	chr16:80930536	chr16:80982319~80984094:-
THCA	cis	rs1876905	0.597	rs1215964	ENSG00000272356.1	RP5-1112D6.8	-4.1	4.93e-05	0.00423	-0.19	-0.19	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111309203~111313517:+
THCA	cis	rs7665090	0.87	rs228613	ENSG00000248971.2	KRT8P46	4.1	4.93e-05	0.00423	0.22	0.19	Primary biliary cholangitis;	chr4:102656308	chr4:102728746~102730171:-
THCA	cis	rs7824557	0.527	rs2409756	ENSG00000154316.13	TDH	4.1	4.93e-05	0.00423	0.14	0.19	Retinal vascular caliber;	chr8:11384516	chr8:11339637~11368452:+
THCA	cis	rs10833905	0.938	rs11026935	ENSG00000246225.5	RP11-17A1.3	-4.1	4.93e-05	0.00423	-0.27	-0.19	Sudden cardiac arrest;	chr11:23046740	chr11:22829380~22945393:+
THCA	cis	rs2239815	0.515	rs9625595	ENSG00000272858.1	CTA-292E10.8	-4.1	4.93e-05	0.00423	-0.24	-0.19	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28842925	chr22:28814914~28815662:+
THCA	cis	rs16986825	0.607	rs5762852	ENSG00000272858.1	CTA-292E10.8	-4.1	4.93e-05	0.00423	-0.24	-0.19	Pancreatic cancer;	chr22:28846485	chr22:28814914~28815662:+
THCA	cis	rs2239815	0.515	rs9625600	ENSG00000272858.1	CTA-292E10.8	-4.1	4.93e-05	0.00423	-0.24	-0.19	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28848407	chr22:28814914~28815662:+
THCA	cis	rs1048886	0.872	rs10945230	ENSG00000271967.1	RP11-134K13.4	-4.1	4.93e-05	0.00423	-0.2	-0.19	Type 2 diabetes;	chr6:70572031	chr6:70596438~70596980:+
THCA	cis	rs7615952	0.512	rs4234285	ENSG00000272840.1	RP11-379B18.6	4.1	4.93e-05	0.00423	0.26	0.19	Blood pressure (smoking interaction);	chr3:125685633	chr3:125774714~125797953:+
THCA	cis	rs1124769	0.57	rs4142324	ENSG00000259378.1	DCAF13P3	4.1	4.93e-05	0.00423	0.26	0.19	Cognitive performance;	chr15:50871860	chr15:50944663~50945996:+
THCA	cis	rs11634944	0.676	rs220027	ENSG00000251896.1	SNORD116-27	-4.1	4.93e-05	0.00423	-0.21	-0.19	Interleukin-8 levels;	chr15:24951813	chr15:25101575~25101666:+
THCA	cis	rs890448	0.896	rs9884436	ENSG00000254531.1	FLJ20021	-4.1	4.93e-05	0.00423	-0.16	-0.19	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101492114	chr4:101347780~101348883:+
THCA	cis	rs7737355	0.947	rs3776005	ENSG00000237714.1	P4HA2-AS1	4.1	4.93e-05	0.00423	0.26	0.19	Life satisfaction;	chr5:131543310	chr5:132184876~132192808:+
THCA	cis	rs9868809	0.649	rs3733086	ENSG00000270441.1	RP11-694I15.7	4.1	4.93e-05	0.00423	0.26	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48662086	chr3:49140086~49160851:-
THCA	cis	rs4714902	0.723	rs7772635	ENSG00000231769.2	RP1-8B1.4	-4.1	4.93e-05	0.00423	-0.18	-0.19	Colonoscopy-negative controls vs population controls;	chr6:46090624	chr6:46097093~46129706:-
THCA	cis	rs1124769	0.57	rs17702978	ENSG00000259378.1	DCAF13P3	4.1	4.93e-05	0.00423	0.26	0.19	Cognitive performance;	chr15:50868358	chr15:50944663~50945996:+
THCA	cis	rs17685	0.753	rs1639609	ENSG00000230882.1	AC005077.14	4.1	4.93e-05	0.00423	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76054263	chr7:76071469~76074963:-
THCA	cis	rs4664304	0.62	rs10168271	ENSG00000226266.5	AC009961.3	-4.1	4.93e-05	0.00423	-0.22	-0.19	Crohn's disease;Inflammatory bowel disease;	chr2:159872675	chr2:159670708~159712435:-
THCA	cis	rs11694172	0.955	rs12476638	ENSG00000273456.1	RP11-686O6.2	4.1	4.94e-05	0.00423	0.17	0.19	Cholesterol, total;	chr2:202708665	chr2:202374932~202375604:-
THCA	cis	rs12488721	1	rs12488721	ENSG00000273455.1	RP11-305O4.3	4.1	4.94e-05	0.00423	0.24	0.19	Neuroticism;	chr3:136273803	chr3:136087475~136087913:-
THCA	cis	rs9341808	0.714	rs4256394	ENSG00000272129.1	RP11-250B2.6	4.1	4.94e-05	0.00423	0.23	0.19	Sitting height ratio;	chr6:80172425	chr6:80355424~80356859:+
THCA	cis	rs7968440	1	rs2251603	ENSG00000272368.2	RP4-605O3.4	-4.1	4.94e-05	0.00423	-0.12	-0.19	Fibrinogen;	chr12:50655870	chr12:50112197~50165618:+
THCA	cis	rs1039766	0.925	rs268863	ENSG00000204929.10	AC074391.1	4.1	4.94e-05	0.00423	0.3	0.19	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr2:65436711~66084639:+
THCA	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-4.1	4.94e-05	0.00423	-0.11	-0.19	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
THCA	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-4.1	4.94e-05	0.00423	-0.11	-0.19	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
THCA	cis	rs6963495	0.818	rs1721500	ENSG00000272604.1	RP11-251G23.5	4.1	4.94e-05	0.00423	0.24	0.19	Bipolar disorder (body mass index interaction);	chr7:105578786	chr7:105571083~105573660:+
THCA	cis	rs17221829	0.549	rs7114659	ENSG00000280385.1	AP000648.5	-4.1	4.94e-05	0.00424	-0.19	-0.19	Anxiety in major depressive disorder;	chr11:89650256	chr11:90193614~90198120:+
THCA	cis	rs453301	0.686	rs11787026	ENSG00000233609.3	RP11-62H7.2	4.1	4.94e-05	0.00424	0.18	0.19	Joint mobility (Beighton score);	chr8:9044861	chr8:8961200~8979025:+
THCA	cis	rs7849973	0.57	rs2086011	ENSG00000224549.1	RP11-370B11.3	-4.1	4.94e-05	0.00424	-0.21	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22890636	chr9:22767175~22768316:+
THCA	cis	rs1023500	0.505	rs134889	ENSG00000182057.4	OGFRP1	4.1	4.94e-05	0.00424	0.21	0.19	Schizophrenia;	chr22:42278344	chr22:42269753~42275196:+
THCA	cis	rs875971	1	rs1363055	ENSG00000230189.5	GS1-124K5.2	4.1	4.94e-05	0.00424	0.12	0.19	Aortic root size;	chr7:66478288	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs9691480	ENSG00000230189.5	GS1-124K5.2	4.1	4.94e-05	0.00424	0.12	0.19	Aortic root size;	chr7:66479319	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs7789554	ENSG00000230189.5	GS1-124K5.2	4.1	4.94e-05	0.00424	0.12	0.19	Aortic root size;	chr7:66481051	chr7:66409143~66490059:-
THCA	cis	rs875971	0.895	rs1974769	ENSG00000230189.5	GS1-124K5.2	4.1	4.94e-05	0.00424	0.12	0.19	Aortic root size;	chr7:66485627	chr7:66409143~66490059:-
THCA	cis	rs875971	0.895	rs6460300	ENSG00000230189.5	GS1-124K5.2	4.1	4.94e-05	0.00424	0.12	0.19	Aortic root size;	chr7:66487937	chr7:66409143~66490059:-
THCA	cis	rs875971	0.862	rs7803416	ENSG00000230189.5	GS1-124K5.2	4.1	4.94e-05	0.00424	0.12	0.19	Aortic root size;	chr7:66489212	chr7:66409143~66490059:-
THCA	cis	rs875971	0.862	rs1981799	ENSG00000230189.5	GS1-124K5.2	4.1	4.94e-05	0.00424	0.12	0.19	Aortic root size;	chr7:66490572	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs2277911	ENSG00000230189.5	GS1-124K5.2	4.1	4.94e-05	0.00424	0.12	0.19	Aortic root size;	chr7:66493638	chr7:66409143~66490059:-
THCA	cis	rs10411161	0.752	rs10404812	ENSG00000275055.1	CTC-471J1.11	-4.1	4.94e-05	0.00424	-0.18	-0.19	Breast cancer;	chr19:51897438	chr19:52049007~52049754:+
THCA	cis	rs2777491	0.957	rs7163788	ENSG00000247556.5	OIP5-AS1	4.1	4.94e-05	0.00424	0.15	0.19	Ulcerative colitis;	chr15:41412591	chr15:41283990~41309737:+
THCA	cis	rs4081724	0.572	rs12151047	ENSG00000267296.2	CEBPA-AS1	4.1	4.94e-05	0.00424	0.31	0.19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33319372	chr19:33302857~33305054:+
THCA	cis	rs740160	0.681	rs6960810	ENSG00000244219.5	GS1-259H13.2	-4.1	4.94e-05	0.00424	-0.33	-0.19	Dehydroepiandrosterone sulphate levels;	chr7:99408072	chr7:99598066~99610813:+
THCA	cis	rs75920871	0.764	rs4938338	ENSG00000254851.1	RP11-109L13.1	-4.1	4.94e-05	0.00424	-0.41	-0.19	Subjective well-being;	chr11:117102178	chr11:117135528~117138582:+
THCA	cis	rs13178541	0.81	rs4466158	ENSG00000250378.1	RP11-119J18.1	-4.1	4.94e-05	0.00424	-0.23	-0.19	IgG glycosylation;	chr5:135829468	chr5:135812667~135826582:+
THCA	cis	rs7583236	0.929	rs2901932	ENSG00000179818.12	PCBP1-AS1	-4.1	4.94e-05	0.00424	-0.18	-0.19	Obesity-related traits;	chr2:69957863	chr2:69962263~70103220:-
THCA	cis	rs9847710	1	rs9847710	ENSG00000242142.1	SERBP1P3	4.1	4.94e-05	0.00424	0.21	0.19	Ulcerative colitis;	chr3:53028645	chr3:53064283~53065091:-
THCA	cis	rs7554547	0.739	rs2050269	ENSG00000199347.1	RNU5E-1	-4.1	4.94e-05	0.00424	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11886432	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.765	rs2050268	ENSG00000199347.1	RNU5E-1	-4.1	4.94e-05	0.00424	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11886487	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.765	rs2050267	ENSG00000199347.1	RNU5E-1	-4.1	4.94e-05	0.00424	-0.25	-0.19	Nonsyndromic cleft lip with cleft palate;	chr1:11886516	chr1:11908152~11908271:+
THCA	cis	rs1371614	0.632	rs6708148	ENSG00000229122.1	AGBL5-IT1	4.1	4.94e-05	0.00424	0.13	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944452	chr2:27061038~27061815:+
THCA	cis	rs1476587	0.92	rs10480552	ENSG00000224046.1	AC005076.5	4.1	4.94e-05	0.00424	0.17	0.19	Brachial circumference;	chr7:87111546	chr7:87151423~87152420:-
THCA	cis	rs2153535	0.609	rs2146159	ENSG00000230939.1	RP11-314C16.1	-4.1	4.95e-05	0.00424	-0.2	-0.19	Motion sickness;	chr6:8667222	chr6:8784178~8785445:+
THCA	cis	rs9902453	0.765	rs8071576	ENSG00000263370.1	RP11-68I3.5	4.1	4.95e-05	0.00424	0.24	0.19	Coffee consumption (cups per day);	chr17:29861536	chr17:29639627~29640825:+
THCA	cis	rs854765	0.616	rs8070624	ENSG00000281749.1	Y_RNA	4.1	4.95e-05	0.00424	0.24	0.19	Total body bone mineral density;	chr17:17940082	chr17:18001101~18001195:-
THCA	cis	rs1046491	1	rs1034486	ENSG00000264964.1	RP11-888D10.3	-4.1	4.95e-05	0.00424	-0.31	-0.19	Scarlet fever;	chr18:9251238	chr18:9315194~9334441:-
THCA	cis	rs9309473	0.898	rs6546851	ENSG00000273245.1	RP11-434P11.2	4.1	4.95e-05	0.00424	0.25	0.19	Metabolite levels;	chr2:73606156	chr2:73750256~73750786:-
THCA	cis	rs7772486	0.79	rs9497424	ENSG00000270638.1	RP3-466P17.1	-4.1	4.95e-05	0.00424	-0.14	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145735570~145737218:+
THCA	cis	rs7824557	0.603	rs2246606	ENSG00000206014.6	OR7E161P	-4.1	4.95e-05	0.00424	-0.22	-0.19	Retinal vascular caliber;	chr8:11361825	chr8:11928597~11929563:-
THCA	cis	rs6988985	0.589	rs6471580	ENSG00000253741.1	CTD-2292P10.4	-4.1	4.95e-05	0.00424	-0.23	-0.19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905285	chr8:142702252~142726973:-
THCA	cis	rs17711722	1	rs17711722	ENSG00000275400.1	RP4-756H11.5	4.1	4.95e-05	0.00424	0.18	0.19	Calcium levels;	chr7:65806210	chr7:66553805~66554199:-
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000275400.1	RP4-756H11.5	4.1	4.95e-05	0.00424	0.18	0.19	Calcium levels;	chr7:65808508	chr7:66553805~66554199:-
THCA	cis	rs62158800	0.852	rs1516200	ENSG00000224568.1	AC096669.3	4.1	4.95e-05	0.00424	0.33	0.19	Facial morphology (factor 22);	chr2:107686924	chr2:107529487~107556326:+
THCA	cis	rs3824488	0.92	rs113154802	ENSG00000271155.1	RP11-435O5.5	-4.1	4.95e-05	0.00424	-0.33	-0.19	Neuroticism;	chr9:95516131	chr9:95506235~95507636:+
THCA	cis	rs7182948	1	rs79916480	ENSG00000259531.2	RP11-295H24.3	4.1	4.95e-05	0.00424	0.24	0.19	Lung adenocarcinoma;	chr15:49529766	chr15:49365124~49366685:-
THCA	cis	rs875971	0.522	rs9530	ENSG00000229180.5	GS1-124K5.11	4.1	4.95e-05	0.00424	0.13	0.19	Aortic root size;	chr7:65960907	chr7:66526088~66542624:-
THCA	cis	rs2562456	0.833	rs11667361	ENSG00000268117.1	VN1R84P	4.1	4.95e-05	0.00424	0.29	0.19	Pain;	chr19:21356580	chr19:21719801~21720035:-
THCA	cis	rs801193	0.935	rs3800820	ENSG00000230295.1	RP11-458F8.2	4.1	4.95e-05	0.00424	0.14	0.19	Aortic root size;	chr7:66682191	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs2003301	ENSG00000230295.1	RP11-458F8.2	4.1	4.95e-05	0.00424	0.14	0.19	Aortic root size;	chr7:66682669	chr7:66880708~66882981:+
THCA	cis	rs10875746	0.551	rs2054903	ENSG00000226413.2	OR8T1P	4.1	4.95e-05	0.00424	0.27	0.19	Longevity (90 years and older);	chr12:48330710	chr12:48442030~48442947:-
THCA	cis	rs9302635	0.513	rs12444701	ENSG00000260886.1	TAT-AS1	4.1	4.95e-05	0.00424	0.24	0.19	Blood protein levels;	chr16:72121341	chr16:71565789~71578187:+
THCA	cis	rs9302635	0.513	rs8061282	ENSG00000260886.1	TAT-AS1	4.1	4.95e-05	0.00424	0.24	0.19	Blood protein levels;	chr16:72122039	chr16:71565789~71578187:+
THCA	cis	rs9302635	0.513	rs8061459	ENSG00000260886.1	TAT-AS1	4.1	4.95e-05	0.00424	0.24	0.19	Blood protein levels;	chr16:72122164	chr16:71565789~71578187:+
THCA	cis	rs12497850	0.931	rs9311434	ENSG00000228638.1	FCF1P2	-4.1	4.95e-05	0.00424	-0.2	-0.19	Parkinson's disease;	chr3:48846714	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.931	rs7623023	ENSG00000228638.1	FCF1P2	-4.1	4.95e-05	0.00424	-0.2	-0.19	Parkinson's disease;	chr3:48876805	chr3:48290793~48291375:-
THCA	cis	rs2154427	0.655	rs844996	ENSG00000238197.4	PAXBP1-AS1	-4.1	4.95e-05	0.00425	-0.19	-0.19	Bilirubin levels;	chr21:32669216	chr21:32728115~32743122:+
THCA	cis	rs854765	0.547	rs8075189	ENSG00000281749.1	Y_RNA	4.1	4.95e-05	0.00425	0.24	0.19	Total body bone mineral density;	chr17:17998632	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs7209003	ENSG00000281749.1	Y_RNA	4.1	4.95e-05	0.00425	0.24	0.19	Total body bone mineral density;	chr17:18004079	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs12150369	ENSG00000281749.1	Y_RNA	4.1	4.95e-05	0.00425	0.24	0.19	Total body bone mineral density;	chr17:18007700	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs9897761	ENSG00000281749.1	Y_RNA	4.1	4.95e-05	0.00425	0.24	0.19	Total body bone mineral density;	chr17:18008697	chr17:18001101~18001195:-
THCA	cis	rs15676	0.947	rs2997913	ENSG00000234771.3	SLC25A25-AS1	4.1	4.95e-05	0.00425	0.15	0.19	Blood metabolite levels;	chr9:128826754	chr9:128108581~128118693:-
THCA	cis	rs9818758	0.556	rs11716614	ENSG00000229759.1	MRPS18AP1	-4.1	4.95e-05	0.00425	-0.42	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48979775	chr3:48256350~48256938:-
THCA	cis	rs2153535	0.585	rs9379226	ENSG00000230939.1	RP11-314C16.1	-4.1	4.96e-05	0.00425	-0.19	-0.19	Motion sickness;	chr6:8584232	chr6:8784178~8785445:+
THCA	cis	rs6005807	0.688	rs5997389	ENSG00000272858.1	CTA-292E10.8	-4.1	4.96e-05	0.00425	-0.36	-0.19	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28738731	chr22:28814914~28815662:+
THCA	cis	rs9810089	0.934	rs570621	ENSG00000273455.1	RP11-305O4.3	4.1	4.96e-05	0.00425	0.24	0.19	Gestational age at birth (child effect);	chr3:136281901	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.814	rs1279424	ENSG00000273455.1	RP11-305O4.3	4.1	4.96e-05	0.00425	0.24	0.19	Gestational age at birth (child effect);	chr3:136288491	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.843	rs556788	ENSG00000273455.1	RP11-305O4.3	4.1	4.96e-05	0.00425	0.24	0.19	Gestational age at birth (child effect);	chr3:136308707	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.872	rs527888	ENSG00000273455.1	RP11-305O4.3	4.1	4.96e-05	0.00425	0.24	0.19	Gestational age at birth (child effect);	chr3:136312516	chr3:136087475~136087913:-
THCA	cis	rs4268898	0.735	rs12469585	ENSG00000242628.4	AC009228.1	-4.1	4.96e-05	0.00425	-0.22	-0.19	Asthma;	chr2:24266185	chr2:24214381~24221516:+
THCA	cis	rs6496044	0.568	rs10468112	ENSG00000259630.2	CTD-2262B20.1	-4.1	4.96e-05	0.00425	-0.2	-0.19	Interstitial lung disease;	chr15:85530193	chr15:85415228~85415633:+
THCA	cis	rs17095355	0.901	rs11194947	ENSG00000203876.8	ADD3-AS1	-4.1	4.96e-05	0.00425	-0.21	-0.19	Biliary atresia;	chr10:110003973	chr10:109940104~110008381:-
THCA	cis	rs2299587	0.554	rs17634704	ENSG00000253671.1	RP11-806O11.1	-4.1	4.96e-05	0.00425	-0.22	-0.19	Economic and political preferences;	chr8:17895797	chr8:17808941~17820868:+
THCA	cis	rs9818758	0.607	rs4855860	ENSG00000270441.1	RP11-694I15.7	-4.1	4.96e-05	0.00425	-0.28	-0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49488611	chr3:49140086~49160851:-
THCA	cis	rs4803480	0.554	rs12462194	ENSG00000270164.1	LINC01480	-4.1	4.96e-05	0.00425	-0.16	-0.19	Schizophrenia;	chr19:41565931	chr19:41535183~41536904:+
THCA	cis	rs36093844	0.626	rs72959177	ENSG00000279742.1	RP11-700A24.1	-4.1	4.96e-05	0.00425	-0.25	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85988019	chr11:85852557~85854943:-
THCA	cis	rs763512	0.532	rs3110626	ENSG00000276054.1	RP11-378E13.3	-4.1	4.96e-05	0.00425	-0.3	-0.19	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37536300	chr17:37386886~37387926:+
THCA	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	4.1	4.96e-05	0.00425	0.27	0.19	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
THCA	cis	rs67478160	0.619	rs12886363	ENSG00000258534.1	CTD-2134A5.4	-4.1	4.96e-05	0.00425	-0.19	-0.19	Schizophrenia;	chr14:103807449	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs12880821	ENSG00000258534.1	CTD-2134A5.4	-4.1	4.96e-05	0.00425	-0.19	-0.19	Schizophrenia;	chr14:103809712	chr14:103854366~103880111:-
THCA	cis	rs6496044	0.527	rs7163068	ENSG00000259630.2	CTD-2262B20.1	-4.1	4.96e-05	0.00425	-0.2	-0.19	Interstitial lung disease;	chr15:85529235	chr15:85415228~85415633:+
THCA	cis	rs2436845	0.627	rs3018954	ENSG00000253320.4	KB-1507C5.2	-4.1	4.96e-05	0.00425	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102821343	chr8:102864300~102977876:+
THCA	cis	rs2436845	0.627	rs2513915	ENSG00000253320.4	KB-1507C5.2	-4.1	4.96e-05	0.00425	-0.17	-0.19	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102822312	chr8:102864300~102977876:+
THCA	cis	rs453301	0.631	rs7843369	ENSG00000233609.3	RP11-62H7.2	-4.1	4.96e-05	0.00425	-0.19	-0.19	Joint mobility (Beighton score);	chr8:8940276	chr8:8961200~8979025:+
THCA	cis	rs41342147	0.66	rs78522331	ENSG00000223374.1	AC005104.3	4.1	4.96e-05	0.00425	0.17	0.19	Vitiligo;	chr2:241311475	chr2:241351340~241353104:-
THCA	cis	rs2474937	0.561	rs6428746	ENSG00000231365.4	RP11-418J17.1	4.1	4.97e-05	0.00425	0.19	0.19	Congenital heart malformation;	chr1:118384347	chr1:119140396~119275973:+
THCA	cis	rs2474937	0.561	rs10802025	ENSG00000231365.4	RP11-418J17.1	4.1	4.97e-05	0.00425	0.19	0.19	Congenital heart malformation;	chr1:118385050	chr1:119140396~119275973:+
THCA	cis	rs10090774	0.93	rs11774305	ENSG00000280303.2	ERICD	-4.1	4.97e-05	0.00425	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140971098	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13253978	ENSG00000280303.2	ERICD	-4.1	4.97e-05	0.00425	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140971655	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.93	rs8180948	ENSG00000280303.2	ERICD	-4.1	4.97e-05	0.00425	-0.18	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140972554	chr8:140636281~140638283:+
THCA	cis	rs5751614	0.537	rs9624074	ENSG00000240160.3	RN7SL263P	4.1	4.97e-05	0.00426	0.23	0.19	Height;	chr22:23283143	chr22:23261782~23262071:-
THCA	cis	rs9863	0.896	rs4930722	ENSG00000270061.1	RP11-214K3.19	-4.1	4.97e-05	0.00426	-0.26	-0.19	White blood cell count;	chr12:123938728	chr12:123969990~123970344:-
THCA	cis	rs453301	0.686	rs2409120	ENSG00000254340.1	RP11-10A14.3	-4.1	4.97e-05	0.00426	-0.21	-0.19	Joint mobility (Beighton score);	chr8:9025061	chr8:9141424~9145435:+
THCA	cis	rs472402	0.58	rs8192186	ENSG00000250056.4	LINC01018	-4.1	4.97e-05	0.00426	-0.22	-0.19	Response to amphetamines;	chr5:6651896	chr5:6582136~6588499:+
THCA	cis	rs75920871	0.541	rs76690043	ENSG00000254851.1	RP11-109L13.1	-4.1	4.97e-05	0.00426	-0.38	-0.19	Subjective well-being;	chr11:116930813	chr11:117135528~117138582:+
THCA	cis	rs2839186	0.786	rs7409792	ENSG00000215424.8	MCM3AP-AS1	4.1	4.97e-05	0.00426	0.11	0.19	Testicular germ cell tumor;	chr21:46271815	chr21:46229217~46259390:+
THCA	cis	rs7824557	0.843	rs2736375	ENSG00000255495.1	AC145124.2	-4.1	4.97e-05	0.00426	-0.2	-0.19	Retinal vascular caliber;	chr8:11258240	chr8:12194467~12196280:+
THCA	cis	rs957448	0.561	rs34471170	ENSG00000253175.1	RP11-267M23.6	4.1	4.97e-05	0.00426	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94565036~94565715:+
THCA	cis	rs957448	0.561	rs9642927	ENSG00000253175.1	RP11-267M23.6	4.1	4.97e-05	0.00426	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94565036~94565715:+
THCA	cis	rs957448	0.529	rs9642928	ENSG00000253175.1	RP11-267M23.6	4.1	4.97e-05	0.00426	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94565036~94565715:+
THCA	cis	rs957448	0.561	rs1808488	ENSG00000253175.1	RP11-267M23.6	4.1	4.97e-05	0.00426	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94565036~94565715:+
THCA	cis	rs957448	0.583	rs754275	ENSG00000253175.1	RP11-267M23.6	4.1	4.97e-05	0.00426	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94565036~94565715:+
THCA	cis	rs957448	0.561	rs1426172	ENSG00000253175.1	RP11-267M23.6	4.1	4.97e-05	0.00426	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94565036~94565715:+
THCA	cis	rs10895275	0.561	rs11602707	ENSG00000277459.1	RP11-732A21.3	4.09	4.97e-05	0.00426	0.17	0.19	Migraine;	chr11:102174912	chr11:102109827~102110457:-
THCA	cis	rs736408	0.583	rs2710323	ENSG00000243224.1	RP5-1157M23.2	-4.09	4.97e-05	0.00426	-0.2	-0.19	Bipolar disorder;	chr3:52781889	chr3:52239258~52241097:+
THCA	cis	rs9341808	0.714	rs9448911	ENSG00000272129.1	RP11-250B2.6	4.09	4.97e-05	0.00426	0.23	0.19	Sitting height ratio;	chr6:80204142	chr6:80355424~80356859:+
THCA	cis	rs1823874	0.581	rs11855419	ENSG00000254744.3	CTD-3076O17.1	4.09	4.97e-05	0.00426	0.22	0.19	IgG glycosylation;	chr15:99787275	chr15:99970215~99974010:+
THCA	cis	rs7583236	1	rs7577762	ENSG00000179818.12	PCBP1-AS1	-4.09	4.97e-05	0.00426	-0.19	-0.19	Obesity-related traits;	chr2:69957458	chr2:69962263~70103220:-
THCA	cis	rs7487075	0.93	rs4076248	ENSG00000272369.1	RP11-446N19.1	4.09	4.97e-05	0.00426	0.14	0.19	Itch intensity from mosquito bite;	chr12:46439822	chr12:46537502~46652550:+
THCA	cis	rs758324	0.732	rs2550973	ENSG00000224431.1	AC063976.7	-4.09	4.97e-05	0.00426	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132175448	chr5:132199456~132203487:+
THCA	cis	rs7904321	1	rs7904321	ENSG00000232075.1	MRPL35P2	-4.09	4.97e-05	0.00426	-0.25	-0.19	Intelligence (multi-trait analysis);	chr10:63080905	chr10:63634317~63634827:-
THCA	cis	rs9326246	0.598	rs481843	ENSG00000254851.1	RP11-109L13.1	4.09	4.98e-05	0.00426	0.42	0.19	Coronary artery disease;	chr11:116655150	chr11:117135528~117138582:+
THCA	cis	rs8141529	0.719	rs5762880	ENSG00000226471.5	CTA-292E10.6	-4.09	4.98e-05	0.00426	-0.15	-0.19	Lymphocyte counts;	chr22:28891828	chr22:28800683~28848559:+
THCA	cis	rs8141529	0.702	rs8137262	ENSG00000226471.5	CTA-292E10.6	-4.09	4.98e-05	0.00426	-0.15	-0.19	Lymphocyte counts;	chr22:28896147	chr22:28800683~28848559:+
THCA	cis	rs9796	0.621	rs2918462	ENSG00000247556.5	OIP5-AS1	-4.09	4.98e-05	0.00426	-0.15	-0.19	Menopause (age at onset);	chr15:41189056	chr15:41283990~41309737:+
THCA	cis	rs860295	0.812	rs11264413	ENSG00000236675.1	MTX1P1	-4.09	4.98e-05	0.00426	-0.19	-0.19	Body mass index;	chr1:155818865	chr1:155230975~155234325:+
THCA	cis	rs150992	0.587	rs11960896	ENSG00000246763.5	RGMB-AS1	-4.09	4.98e-05	0.00426	-0.19	-0.19	Body mass index;	chr5:99014294	chr5:98769618~98773469:-
THCA	cis	rs12546962	0.593	rs61198364	ENSG00000254153.1	CTA-398F10.2	-4.09	4.98e-05	0.00426	-0.23	-0.19	Body mass index;	chr8:9334787	chr8:8456909~8461337:-
THCA	cis	rs681524	1	rs681524	ENSG00000254851.1	RP11-109L13.1	-4.09	4.98e-05	0.00426	-0.49	-0.19	Hearing function;	chr11:116877598	chr11:117135528~117138582:+
THCA	cis	rs9863	0.896	rs7311233	ENSG00000270061.1	RP11-214K3.19	4.09	4.98e-05	0.00426	0.25	0.19	White blood cell count;	chr12:123991393	chr12:123969990~123970344:-
THCA	cis	rs5997397	0.967	rs5752791	ENSG00000272858.1	CTA-292E10.8	4.09	4.98e-05	0.00426	0.18	0.19	Red cell distribution width;	chr22:28757559	chr22:28814914~28815662:+
THCA	cis	rs9595908	0.686	rs7988353	ENSG00000212293.1	SNORA16	4.09	4.98e-05	0.00427	0.21	0.19	Body mass index;	chr13:32760250	chr13:32420390~32420516:-
THCA	cis	rs763121	0.819	rs5757133	ENSG00000273076.1	RP3-508I15.22	-4.09	4.98e-05	0.00427	-0.18	-0.19	Menopause (age at onset);	chr22:38551830	chr22:38743495~38743910:+
THCA	cis	rs4934494	0.677	rs10881608	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89614892	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs10881610	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89615076	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185792	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89615210	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185793	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89615467	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185794	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89615662	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185795	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89615672	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185796	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89615725	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs12219790	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89615734	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185797	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89616041	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185798	ENSG00000240996.1	RP11-80H5.7	-4.09	4.98e-05	0.00427	-0.21	-0.19	Red blood cell count;	chr10:89616211	chr10:89694295~89697928:-
THCA	cis	rs9467773	1	rs6922824	ENSG00000228223.2	HCG11	4.09	4.98e-05	0.00427	0.2	0.19	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26523450~26526579:+
THCA	cis	rs16944613	0.541	rs4288973	ENSG00000259212.1	CTD-3065B20.2	4.09	4.98e-05	0.00427	0.28	0.19	Colorectal cancer;	chr15:90550444	chr15:90595840~90596447:-
THCA	cis	rs11723261	0.582	rs11735742	ENSG00000250892.1	RP11-1365D11.1	-4.09	4.98e-05	0.00427	-0.26	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:201409~205009:-
THCA	cis	rs17270561	0.609	rs9379783	ENSG00000272462.2	U91328.19	-4.09	4.98e-05	0.00427	-0.16	-0.19	Iron status biomarkers;	chr6:25724979	chr6:25992662~26001775:+
THCA	cis	rs2115630	0.936	rs8033459	ENSG00000259295.5	CSPG4P12	-4.09	4.98e-05	0.00427	-0.25	-0.19	P wave terminal force;	chr15:84710027	chr15:85191438~85213905:+
THCA	cis	rs1267303	0.642	rs116078607	ENSG00000232022.5	FAAHP1	4.09	4.98e-05	0.00427	0.23	0.19	Monobrow;	chr1:46533566	chr1:46432129~46445521:+
THCA	cis	rs1267303	0.642	rs114746843	ENSG00000232022.5	FAAHP1	4.09	4.98e-05	0.00427	0.23	0.19	Monobrow;	chr1:46533567	chr1:46432129~46445521:+
THCA	cis	rs9840812	0.623	rs1394092	ENSG00000239213.4	NCK1-AS1	4.09	4.98e-05	0.00427	0.17	0.19	Fibrinogen levels;	chr3:136477229	chr3:136841726~136862054:-
THCA	cis	rs2921073	0.51	rs2976945	ENSG00000233609.3	RP11-62H7.2	4.09	4.98e-05	0.00427	0.17	0.19	Parkinson's disease;	chr8:8413361	chr8:8961200~8979025:+
THCA	cis	rs17221829	0.733	rs10830333	ENSG00000280385.1	AP000648.5	-4.09	4.98e-05	0.00427	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89666056	chr11:90193614~90198120:+
THCA	cis	rs733175	0.855	rs10006397	ENSG00000261490.1	RP11-448G15.3	4.09	4.98e-05	0.00427	0.15	0.19	Psychosis and Alzheimer's disease;	chr4:10034516	chr4:10068089~10073019:-
THCA	cis	rs733175	0.953	rs4485819	ENSG00000261490.1	RP11-448G15.3	4.09	4.98e-05	0.00427	0.15	0.19	Psychosis and Alzheimer's disease;	chr4:10035769	chr4:10068089~10073019:-
THCA	cis	rs3169166	0.546	rs4887027	ENSG00000259562.2	RP11-762H8.2	4.09	4.98e-05	0.00427	0.12	0.19	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78287599	chr15:78290527~78291221:-
THCA	cis	rs950169	0.84	rs72748702	ENSG00000275120.1	RP11-182J1.17	4.09	4.98e-05	0.00427	0.22	0.19	Schizophrenia;	chr15:84246494	chr15:84599434~84606463:-
THCA	cis	rs853679	0.607	rs68188794	ENSG00000272009.1	RP1-313I6.12	-4.09	4.99e-05	0.00427	-0.36	-0.19	Depression;	chr6:28112999	chr6:28078792~28081130:-
THCA	cis	rs7520050	0.771	rs4660882	ENSG00000280836.1	AL355480.1	-4.09	4.99e-05	0.00427	-0.22	-0.19	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45581219~45581321:-
THCA	cis	rs295490	0.748	rs80175427	ENSG00000272656.1	RP11-219D15.3	4.09	4.99e-05	0.00427	0.34	0.19	PR interval in Tripanosoma cruzi seropositivity;	chr3:139498904	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs17494482	ENSG00000272656.1	RP11-219D15.3	4.09	4.99e-05	0.00427	0.34	0.19	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499028	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs2882080	ENSG00000272656.1	RP11-219D15.3	4.09	4.99e-05	0.00427	0.34	0.19	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499109	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs2882081	ENSG00000272656.1	RP11-219D15.3	4.09	4.99e-05	0.00427	0.34	0.19	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499427	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs7428398	ENSG00000272656.1	RP11-219D15.3	4.09	4.99e-05	0.00427	0.34	0.19	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499687	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs77398474	ENSG00000272656.1	RP11-219D15.3	4.09	4.99e-05	0.00427	0.34	0.19	PR interval in Tripanosoma cruzi seropositivity;	chr3:139502307	chr3:139349024~139349371:-
THCA	cis	rs950169	0.922	rs11630507	ENSG00000188388.10	GOLGA6L3	4.09	4.99e-05	0.00427	0.25	0.19	Schizophrenia;	chr15:84552494	chr15:85240472~85247170:+
THCA	cis	rs7474896	0.583	rs10827818	ENSG00000120555.12	SEPT7P9	4.09	4.99e-05	0.00427	0.24	0.19	Obesity (extreme);	chr10:37711928	chr10:38383069~38402916:-
THCA	cis	rs1198872	0.892	rs1198862	ENSG00000272275.1	RP11-791G15.2	-4.09	4.99e-05	0.00427	-0.22	-0.19	Cardiac Troponin-T levels;	chr2:10760201	chr2:10767875~10770058:-
THCA	cis	rs1198872	0.892	rs1198863	ENSG00000272275.1	RP11-791G15.2	-4.09	4.99e-05	0.00427	-0.22	-0.19	Cardiac Troponin-T levels;	chr2:10760349	chr2:10767875~10770058:-
THCA	cis	rs7615952	0.932	rs13086087	ENSG00000272840.1	RP11-379B18.6	4.09	4.99e-05	0.00427	0.31	0.19	Blood pressure (smoking interaction);	chr3:125927438	chr3:125774714~125797953:+
THCA	cis	rs4950322	1	rs72694715	ENSG00000226015.2	CCT8P1	4.09	4.99e-05	0.00427	0.23	0.19	Protein quantitative trait loci;	chr1:147368468	chr1:147203276~147204932:-
THCA	cis	rs17723470	0.607	rs10444286	ENSG00000254427.1	RP11-430H10.1	4.09	4.99e-05	0.00427	0.22	0.19	Thyroid hormone levels;	chr11:45192069	chr11:45355371~45366121:+
THCA	cis	rs16852403	0.531	rs608656	ENSG00000224687.1	RASAL2-AS1	-4.09	4.99e-05	0.00427	-0.26	-0.19	Childhood ear infection;	chr1:178232012	chr1:178091508~178093984:-
THCA	cis	rs5758511	0.633	rs5758690	ENSG00000237037.8	NDUFA6-AS1	-4.09	4.99e-05	0.00427	-0.17	-0.19	Birth weight;	chr22:42272289	chr22:42090931~42137742:+
THCA	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	4.09	4.99e-05	0.00427	0.17	0.19	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
THCA	cis	rs9733	0.744	rs11204725	ENSG00000231073.1	RP11-316M1.3	-4.09	4.99e-05	0.00427	-0.22	-0.19	Tonsillectomy;	chr1:150770224	chr1:150973123~150975534:+
THCA	cis	rs17253792	0.822	rs8013714	ENSG00000186615.9	KTN1-AS1	-4.09	4.99e-05	0.00427	-0.3	-0.19	Putamen volume;	chr14:55705568	chr14:55499278~55580110:-
THCA	cis	rs1923243	0.714	rs4292907	ENSG00000223479.3	RP4-788P17.1	4.09	4.99e-05	0.00428	0.2	0.19	Migraine;	chr1:73093491	chr1:73635216~73715214:+
THCA	cis	rs1908814	0.516	rs13275143	ENSG00000206014.6	OR7E161P	-4.09	4.99e-05	0.00428	-0.22	-0.19	Neuroticism;	chr8:11939481	chr8:11928597~11929563:-
THCA	cis	rs12478296	0.792	rs3924263	ENSG00000220804.7	AC093642.5	4.09	4.99e-05	0.00428	0.2	0.19	Obesity-related traits;	chr2:242063016	chr2:242088633~242160153:+
THCA	cis	rs12478296	1	rs7420157	ENSG00000220804.7	AC093642.5	4.09	4.99e-05	0.00428	0.2	0.19	Obesity-related traits;	chr2:242063053	chr2:242088633~242160153:+
THCA	cis	rs6138458	1	rs6114988	ENSG00000274173.1	RP4-568C11.4	4.09	4.99e-05	0.00428	0.18	0.19	Blood protein levels;	chr20:24996950	chr20:24931840~24932983:+
THCA	cis	rs472402	0.56	rs2288444	ENSG00000250056.4	LINC01018	-4.09	5e-05	0.00428	-0.22	-0.19	Response to amphetamines;	chr5:6619810	chr5:6582136~6588499:+
THCA	cis	rs11633886	0.604	rs11635633	ENSG00000273972.1	CTD-2306A12.1	4.09	5e-05	0.00428	0.2	0.19	Diisocyanate-induced asthma;	chr15:45832827	chr15:45702640~45703183:+
THCA	cis	rs957448	0.561	rs7459558	ENSG00000253175.1	RP11-267M23.6	4.09	5e-05	0.00428	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94565036~94565715:+
THCA	cis	rs6921919	0.583	rs7759191	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs7764737	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs9461458	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.609	rs9468365	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs1361385	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs1416918	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs9468367	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs9461459	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs28360638	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs9468368	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28315613~28315883:-
THCA	cis	rs6921919	0.583	rs2041230	ENSG00000273712.1	RP5-874C20.7	4.09	5e-05	0.00428	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28315613~28315883:-
THCA	cis	rs2948294	0.588	rs4840913	ENSG00000254340.1	RP11-10A14.3	4.09	5e-05	0.00428	0.21	0.19	Red cell distribution width;	chr8:8259384	chr8:9141424~9145435:+
THCA	cis	rs9500256	0.934	rs1343391	ENSG00000239650.4	GUSBP4	4.09	5e-05	0.00428	0.18	0.19	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57919784~57930291:-
THCA	cis	rs9902453	0.689	rs7216948	ENSG00000263370.1	RP11-68I3.5	4.09	5e-05	0.00428	0.24	0.19	Coffee consumption (cups per day);	chr17:29876155	chr17:29639627~29640825:+
THCA	cis	rs11250097	0.528	rs36043848	ENSG00000206014.6	OR7E161P	4.09	5e-05	0.00428	0.22	0.19	Neuroticism;	chr8:11452024	chr8:11928597~11929563:-
THCA	cis	rs4660214	0.724	rs10888683	ENSG00000182109.6	RP11-69E11.4	4.09	5e-05	0.00428	0.18	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157997	chr1:39522280~39546187:-
THCA	cis	rs6696239	0.956	rs6678802	ENSG00000227711.2	RP11-275O4.5	-4.09	5e-05	0.00428	-0.25	-0.19	Height;	chr1:227652030	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.911	rs10799437	ENSG00000227711.2	RP11-275O4.5	-4.09	5e-05	0.00428	-0.25	-0.19	Height;	chr1:227652145	chr1:227509028~227520477:-
THCA	cis	rs7829975	0.681	rs2271342	ENSG00000233609.3	RP11-62H7.2	4.09	5e-05	0.00428	0.18	0.19	Mood instability;	chr8:8786428	chr8:8961200~8979025:+
THCA	cis	rs8040855	0.644	rs7495437	ENSG00000259630.2	CTD-2262B20.1	4.09	5e-05	0.00428	0.21	0.19	Bulimia nervosa;	chr15:85183059	chr15:85415228~85415633:+
THCA	cis	rs786425	0.966	rs3748269	ENSG00000270095.1	RP11-214K3.18	-4.09	5e-05	0.00428	-0.21	-0.19	Pubertal anthropometrics;	chr12:123615378	chr12:123971457~123971714:-
THCA	cis	rs13325613	0.834	rs34611049	ENSG00000223552.1	RP11-24F11.2	-4.09	5e-05	0.00428	-0.27	-0.19	Monocyte count;	chr3:46199334	chr3:46364955~46407059:-
THCA	cis	rs7824557	0.872	rs1347410	ENSG00000255495.1	AC145124.2	-4.09	5e-05	0.00428	-0.2	-0.19	Retinal vascular caliber;	chr8:11253733	chr8:12194467~12196280:+
THCA	cis	rs1923243	0.814	rs11210127	ENSG00000223479.3	RP4-788P17.1	-4.09	5e-05	0.00428	-0.2	-0.19	Migraine;	chr1:73113959	chr1:73635216~73715214:+
THCA	cis	rs4767841	0.935	rs2936831	ENSG00000252886.1	RN7SKP197	-4.09	5e-05	0.00428	-0.19	-0.19	Urgency urinary incontinence;	chr12:119726459	chr12:119631090~119631386:-
THCA	cis	rs5769765	0.955	rs6520066	ENSG00000260613.1	RP3-522J7.6	-4.09	5e-05	0.00428	-0.22	-0.19	Schizophrenia;	chr22:49901340	chr22:49832616~49837786:-
THCA	cis	rs11672691	0.792	rs7248215	ENSG00000270164.1	LINC01480	-4.09	5e-05	0.00428	-0.17	-0.19	Prostate cancer;	chr19:41493212	chr19:41535183~41536904:+
THCA	cis	rs7829975	0.742	rs882462	ENSG00000253981.4	ALG1L13P	4.09	5.01e-05	0.00428	0.18	0.19	Mood instability;	chr8:8821020	chr8:8236003~8244667:-
THCA	cis	rs6878727	0.552	rs4836073	ENSG00000253807.4	LINC01170	-4.09	5.01e-05	0.00428	-0.19	-0.19	Breast cancer;	chr5:124360069	chr5:124059794~124405079:-
THCA	cis	rs7267979	0.727	rs2474765	ENSG00000277938.1	RP5-965G21.3	4.09	5.01e-05	0.00429	0.15	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.764	rs2474767	ENSG00000277938.1	RP5-965G21.3	4.09	5.01e-05	0.00429	0.15	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25229150~25231933:+
THCA	cis	rs10090774	0.965	rs62521905	ENSG00000279766.1	RP11-642A1.2	4.09	5.01e-05	0.00429	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140911652	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs6987946	ENSG00000279766.1	RP11-642A1.2	4.09	5.01e-05	0.00429	0.23	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140917560	chr8:140572142~140572812:-
THCA	cis	rs4218	0.681	rs1867757	ENSG00000277144.1	RP11-59H7.4	-4.09	5.01e-05	0.00429	-0.26	-0.19	Social communication problems;	chr15:59072315	chr15:59115547~59116089:-
THCA	cis	rs35176054	0.73	rs71476605	ENSG00000280693.1	SH3PXD2A-AS1	-4.09	5.01e-05	0.00429	-0.36	-0.19	Atrial fibrillation;	chr10:103748744	chr10:103745966~103755423:+
THCA	cis	rs10911902	0.601	rs16825279	ENSG00000229739.2	RP11-295K2.3	-4.09	5.01e-05	0.00429	-0.29	-0.19	Schizophrenia;	chr1:186385523	chr1:186435161~186470291:+
THCA	cis	rs10435719	0.899	rs11250177	ENSG00000254948.1	OR7E158P	-4.09	5.01e-05	0.00429	-0.23	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:11919900~11920809:-
THCA	cis	rs5758511	0.68	rs739146	ENSG00000227370.1	RP4-669P10.19	4.09	5.01e-05	0.00429	0.21	0.19	Birth weight;	chr22:42264408	chr22:42132543~42132998:+
THCA	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	4.09	5.01e-05	0.00429	0.17	0.19	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
THCA	cis	rs3743266	0.613	rs10851681	ENSG00000240163.1	RP11-745A24.1	4.09	5.01e-05	0.00429	0.21	0.19	Menarche (age at onset);	chr15:60439939	chr15:60390371~60390682:+
THCA	cis	rs8031584	0.723	rs711224	ENSG00000178081.11	ULK4P3	-4.09	5.01e-05	0.00429	-0.24	-0.19	Huntington's disease progression;	chr15:30835718	chr15:30103720~30131757:+
THCA	cis	rs7819412	0.74	rs28633434	ENSG00000255046.1	RP11-297N6.4	4.09	5.01e-05	0.00429	0.2	0.19	Triglycerides;	chr8:11196413	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.564	rs2736304	ENSG00000206014.6	OR7E161P	4.09	5.01e-05	0.00429	0.21	0.19	Retinal vascular caliber;	chr8:11379455	chr8:11928597~11929563:-
THCA	cis	rs116248771	0.739	rs12185969	ENSG00000271778.1	RP11-379F4.8	4.09	5.01e-05	0.00429	0.25	0.19	diarrhoeal disease at age 2;	chr3:158643091	chr3:158782547~158783124:+
THCA	cis	rs1371614	0.632	rs3739088	ENSG00000229122.1	AGBL5-IT1	-4.09	5.01e-05	0.00429	-0.14	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944916	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.632	rs3769135	ENSG00000229122.1	AGBL5-IT1	-4.09	5.01e-05	0.00429	-0.14	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26945543	chr2:27061038~27061815:+
THCA	cis	rs17221829	0.673	rs56004718	ENSG00000280385.1	AP000648.5	-4.09	5.01e-05	0.00429	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89680022	chr11:90193614~90198120:+
THCA	cis	rs1023500	0.573	rs2413666	ENSG00000237037.8	NDUFA6-AS1	-4.09	5.01e-05	0.00429	-0.15	-0.19	Schizophrenia;	chr22:42063618	chr22:42090931~42137742:+
THCA	cis	rs2836974	0.965	rs9941894	ENSG00000255568.3	BRWD1-AS2	4.09	5.01e-05	0.00429	0.17	0.19	Cognitive function;	chr21:39262132	chr21:39313935~39314962:+
THCA	cis	rs8062405	1	rs55991577	ENSG00000270424.1	RP11-1348G14.6	4.09	5.01e-05	0.00429	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs56358680	ENSG00000270424.1	RP11-1348G14.6	4.09	5.01e-05	0.00429	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62036626	ENSG00000270424.1	RP11-1348G14.6	4.09	5.01e-05	0.00429	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62036657	ENSG00000270424.1	RP11-1348G14.6	4.09	5.01e-05	0.00429	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs12444171	ENSG00000270424.1	RP11-1348G14.6	4.09	5.01e-05	0.00429	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs56404918	ENSG00000270424.1	RP11-1348G14.6	4.09	5.01e-05	0.00429	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs55719896	ENSG00000270424.1	RP11-1348G14.6	4.09	5.01e-05	0.00429	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs55830740	ENSG00000270424.1	RP11-1348G14.6	4.09	5.01e-05	0.00429	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28749959~28750595:-
THCA	cis	rs4664293	0.707	rs7563956	ENSG00000230783.1	AC009961.2	4.09	5.01e-05	0.00429	0.23	0.19	Monocyte percentage of white cells;	chr2:159815943	chr2:159689217~159690291:-
THCA	cis	rs36715	1	rs40527	ENSG00000245937.6	LINC01184	4.09	5.01e-05	0.00429	0.21	0.19	Breast cancer;	chr5:128214560	chr5:127940426~128083172:-
THCA	cis	rs1552244	0.554	rs6762397	ENSG00000269982.1	RP11-1020A11.2	4.09	5.01e-05	0.00429	0.13	0.19	Alzheimer's disease;	chr3:9966156	chr3:9958717~9962539:+
THCA	cis	rs7178375	1	rs1474381	ENSG00000269930.1	RP11-932O9.9	-4.09	5.01e-05	0.00429	-0.25	-0.19	Hypertriglyceridemia;	chr15:30922788	chr15:30616958~30617749:+
THCA	cis	rs6545883	0.718	rs6715259	ENSG00000270820.4	RP11-355B11.2	4.09	5.01e-05	0.00429	0.15	0.19	Tuberculosis;	chr2:61624710	chr2:61471188~61484130:+
THCA	cis	rs6856693	0.905	rs2139178	ENSG00000251139.2	RP11-701P16.2	4.09	5.02e-05	0.00429	0.22	0.19	Menopause (age at onset);	chr4:184823875	chr4:184813619~184821300:+
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000275400.1	RP4-756H11.5	-4.09	5.02e-05	0.00429	-0.18	-0.19	Calcium levels;	chr7:65903721	chr7:66553805~66554199:-
THCA	cis	rs1124769	0.619	rs7170036	ENSG00000259378.1	DCAF13P3	4.09	5.02e-05	0.00429	0.26	0.19	Cognitive performance;	chr15:50956106	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.619	rs8182062	ENSG00000259378.1	DCAF13P3	4.09	5.02e-05	0.00429	0.26	0.19	Cognitive performance;	chr15:50962305	chr15:50944663~50945996:+
THCA	cis	rs801193	1	rs62466793	ENSG00000229180.5	GS1-124K5.11	4.09	5.02e-05	0.00429	0.13	0.19	Aortic root size;	chr7:66726530	chr7:66526088~66542624:-
THCA	cis	rs71520386	0.632	rs10253651	ENSG00000226329.2	AC005682.6	-4.09	5.02e-05	0.00429	-0.24	-0.19	Fibrinogen levels;	chr7:22830564	chr7:22863874~22881350:-
THCA	cis	rs786425	0.77	rs7960951	ENSG00000278112.1	RP11-972P1.11	4.09	5.02e-05	0.00429	0.18	0.19	Pubertal anthropometrics;	chr12:123681282	chr12:123519390~123519856:-
THCA	cis	rs453301	0.522	rs1964356	ENSG00000233609.3	RP11-62H7.2	4.09	5.02e-05	0.0043	0.18	0.19	Joint mobility (Beighton score);	chr8:8995760	chr8:8961200~8979025:+
THCA	cis	rs3755605	0.728	rs6804888	ENSG00000242578.1	RP11-469J4.3	4.09	5.02e-05	0.0043	0.21	0.19	Testicular germ cell tumor;	chr3:170090051	chr3:170410512~170418615:+
THCA	cis	rs150992	0.711	rs326489	ENSG00000246763.5	RGMB-AS1	4.09	5.02e-05	0.0043	0.2	0.19	Body mass index;	chr5:98841105	chr5:98769618~98773469:-
THCA	cis	rs10435719	0.718	rs7813935	ENSG00000206014.6	OR7E161P	-4.09	5.02e-05	0.0043	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.504	rs7830734	ENSG00000206014.6	OR7E161P	-4.09	5.02e-05	0.0043	-0.22	-0.19	Neuroticism;	chr8:11938130	chr8:11928597~11929563:-
THCA	cis	rs875971	0.83	rs427575	ENSG00000272831.1	RP11-792A8.4	4.09	5.02e-05	0.0043	0.12	0.19	Aortic root size;	chr7:66054232	chr7:66739829~66740385:-
THCA	cis	rs17597773	0.755	rs10863570	ENSG00000272823.1	RP11-295M18.6	-4.09	5.02e-05	0.0043	-0.26	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220857247	chr1:220828676~220829211:-
THCA	cis	rs7772697	0.635	rs7773409	ENSG00000223701.3	RAET1E-AS1	-4.09	5.02e-05	0.0043	-0.26	-0.19	Diabetic retinopathy;	chr6:149093240	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.635	rs1890612	ENSG00000223701.3	RAET1E-AS1	-4.09	5.02e-05	0.0043	-0.26	-0.19	Diabetic retinopathy;	chr6:149093325	chr6:149884431~149919508:+
THCA	cis	rs4650994	0.525	rs4650991	ENSG00000213057.5	C1orf220	-4.09	5.02e-05	0.0043	-0.14	-0.19	HDL cholesterol;HDL cholesterol levels;	chr1:178542030	chr1:178542752~178548889:+
THCA	cis	rs758324	0.732	rs45512	ENSG00000224431.1	AC063976.7	-4.09	5.02e-05	0.0043	-0.18	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132103643	chr5:132199456~132203487:+
THCA	cis	rs7577696	0.654	rs212757	ENSG00000276334.1	AL133243.1	4.09	5.02e-05	0.0043	0.2	0.19	Inflammatory biomarkers;	chr2:32200009	chr2:32521927~32523547:+
THCA	cis	rs472402	0.58	rs4702373	ENSG00000250056.4	LINC01018	-4.09	5.02e-05	0.0043	-0.23	-0.19	Response to amphetamines;	chr5:6633109	chr5:6582136~6588499:+
THCA	cis	rs17092148	0.887	rs6059937	ENSG00000276073.1	RP5-1125A11.7	-4.09	5.03e-05	0.0043	-0.22	-0.19	Neuroticism;	chr20:34598396	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.887	rs2378199	ENSG00000276073.1	RP5-1125A11.7	-4.09	5.03e-05	0.0043	-0.22	-0.19	Neuroticism;	chr20:34598676	chr20:33985617~33988989:-
THCA	cis	rs10256972	0.504	rs3735687	ENSG00000225146.1	AC073957.15	4.09	5.03e-05	0.0043	0.2	0.19	Endometriosis;Longevity;	chr7:1026661	chr7:1029025~1043891:+
THCA	cis	rs875971	0.545	rs1638735	ENSG00000232546.1	RP11-458F8.1	4.09	5.03e-05	0.0043	0.18	0.19	Aortic root size;	chr7:66630751	chr7:66848496~66858136:+
THCA	cis	rs8105895	0.935	rs1560716	ENSG00000269345.1	VN1R85P	4.09	5.03e-05	0.0043	0.26	0.19	Body mass index (change over time);	chr19:22123099	chr19:22174766~22175191:-
THCA	cis	rs79040073	0.594	rs75929244	ENSG00000259531.2	RP11-295H24.3	4.09	5.03e-05	0.0043	0.25	0.19	Lung cancer in ever smokers;	chr15:49419763	chr15:49365124~49366685:-
THCA	cis	rs758324	0.891	rs652839	ENSG00000237714.1	P4HA2-AS1	-4.09	5.03e-05	0.0043	-0.26	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:131945413	chr5:132184876~132192808:+
THCA	cis	rs8073060	0.586	rs225291	ENSG00000267321.1	RP11-1094M14.11	-4.09	5.03e-05	0.0043	-0.11	-0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35600107	chr17:35568120~35574792:+
THCA	cis	rs34792	0.637	rs2450356	ENSG00000207425.1	Y_RNA	4.09	5.03e-05	0.0043	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:14915457~14915556:-
THCA	cis	rs1167832	0.645	rs1167829	ENSG00000278416.1	PMS2L2	-4.09	5.03e-05	0.0043	-0.29	-0.19	Ankle injury;	chr7:75535697	chr7:75344015~75359550:-
THCA	cis	rs6671200	0.831	rs12742928	ENSG00000235501.4	RP4-639F20.1	-4.09	5.03e-05	0.0043	-0.38	-0.19	Stearic acid (18:0) levels;	chr1:95142839	chr1:94927566~94963270:+
THCA	cis	rs7396835	0.8	rs6589572	ENSG00000280143.1	AP000892.6	4.09	5.03e-05	0.0043	0.29	0.19	Quantitative traits;	chr11:116810847	chr11:117204967~117210292:+
THCA	cis	rs7819412	0.634	rs4841485	ENSG00000261451.1	RP11-981G7.1	4.09	5.03e-05	0.0043	0.23	0.19	Triglycerides;	chr8:11052426	chr8:10433672~10438312:+
THCA	cis	rs2726040	0.902	rs33957528	ENSG00000270424.1	RP11-1348G14.6	-4.09	5.03e-05	0.00431	-0.2	-0.19	Hip circumference;	chr16:28296619	chr16:28749959~28750595:-
THCA	cis	rs10744391	0.62	rs11059973	ENSG00000274695.1	RP11-21K12.3	-4.09	5.03e-05	0.00431	-0.23	-0.19	Renal sinus fat;	chr12:128850269	chr12:128826836~128827579:+
THCA	cis	rs2562456	0.52	rs279793	ENSG00000268117.1	VN1R84P	4.09	5.03e-05	0.00431	0.29	0.19	Pain;	chr19:21272972	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.52	rs660063	ENSG00000268117.1	VN1R84P	-4.09	5.03e-05	0.00431	-0.29	-0.19	Pain;	chr19:21271103	chr19:21719801~21720035:-
THCA	cis	rs7665090	0.87	rs228616	ENSG00000248971.2	KRT8P46	4.09	5.03e-05	0.00431	0.22	0.19	Primary biliary cholangitis;	chr4:102658534	chr4:102728746~102730171:-
THCA	cis	rs9393777	0.92	rs55834529	ENSG00000220721.1	OR1F12	4.09	5.03e-05	0.00431	0.44	0.19	Intelligence (multi-trait analysis);	chr6:27104763	chr6:28073316~28074233:+
THCA	cis	rs12440869	1	rs7163460	ENSG00000270964.1	RP11-502I4.3	4.09	5.03e-05	0.00431	0.16	0.19	Peak velocity of the mitral A-wave;	chr15:67318880	chr15:67541072~67542604:-
THCA	cis	rs7586673	0.725	rs6757645	ENSG00000235724.7	AC009299.2	-4.09	5.03e-05	0.00431	-0.21	-0.19	Intelligence (multi-trait analysis);	chr2:161034871	chr2:161222785~161308303:-
THCA	cis	rs7208859	0.673	rs450585	ENSG00000280069.1	CTD-2349P21.3	-4.09	5.04e-05	0.00431	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30738182~30740275:+
THCA	cis	rs5769765	0.624	rs2285187	ENSG00000260613.1	RP3-522J7.6	-4.09	5.04e-05	0.00431	-0.23	-0.19	Schizophrenia;	chr22:49791784	chr22:49832616~49837786:-
THCA	cis	rs2590942	0.838	rs2613507	ENSG00000227207.2	RPL31P12	-4.09	5.04e-05	0.00431	-0.3	-0.19	Childhood body mass index;	chr1:72368820	chr1:72301472~72301829:+
THCA	cis	rs9625935	0.879	rs5763640	ENSG00000279159.1	RP3-394A18.1	4.09	5.04e-05	0.00431	0.15	0.19	Tonsillectomy;	chr22:29957263	chr22:29978950~30028236:-
THCA	cis	rs9625935	0.957	rs5763644	ENSG00000279159.1	RP3-394A18.1	4.09	5.04e-05	0.00431	0.15	0.19	Tonsillectomy;	chr22:29959687	chr22:29978950~30028236:-
THCA	cis	rs10050311	0.746	rs17420607	ENSG00000251411.1	RP11-397E7.4	-4.09	5.04e-05	0.00431	-0.22	-0.19	Insulin-related traits;	chr4:86749048	chr4:86913266~86914817:-
THCA	cis	rs73173548	0.528	rs13161403	ENSG00000247828.6	TMEM161B-AS1	4.09	5.04e-05	0.00431	0.17	0.19	Macular telangiectasia type 2;	chr5:88471144	chr5:88268895~88436685:+
THCA	cis	rs962856	0.964	rs12473253	ENSG00000236780.4	AC078941.1	4.09	5.04e-05	0.00431	0.22	0.19	Pancreatic cancer;	chr2:67419189	chr2:67123357~67215319:-
THCA	cis	rs4822983	0.516	rs1018512	ENSG00000272858.1	CTA-292E10.8	-4.09	5.04e-05	0.00431	-0.2	-0.19	Esophageal cancer (squamous cell);	chr22:28606095	chr22:28814914~28815662:+
THCA	cis	rs2288884	0.676	rs58197197	ENSG00000269483.1	AC006272.1	4.09	5.04e-05	0.00431	0.27	0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52000405	chr19:51839924~51843324:-
THCA	cis	rs1371614	0.566	rs11902826	ENSG00000229122.1	AGBL5-IT1	-4.09	5.04e-05	0.00431	-0.13	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26954677	chr2:27061038~27061815:+
THCA	cis	rs4950322	0.58	rs972368	ENSG00000226015.2	CCT8P1	4.09	5.04e-05	0.00431	0.21	0.19	Protein quantitative trait loci;	chr1:147111142	chr1:147203276~147204932:-
THCA	cis	rs12472274	0.618	rs12477307	ENSG00000279484.1	KLHL30-AS1	4.09	5.04e-05	0.00431	0.19	0.19	Phospholipid levels (plasma);	chr2:238201873	chr2:238152889~238155994:-
THCA	cis	rs17221829	0.681	rs75322840	ENSG00000280385.1	AP000648.5	-4.09	5.04e-05	0.00431	-0.18	-0.19	Anxiety in major depressive disorder;	chr11:89657226	chr11:90193614~90198120:+
THCA	cis	rs4700393	0.517	rs71592685	ENSG00000272308.1	RP11-231G3.1	4.09	5.04e-05	0.00431	0.22	0.19	Intelligence (multi-trait analysis);	chr5:60825411	chr5:60866457~60866935:-
THCA	cis	rs4934494	0.677	rs943125	ENSG00000240996.1	RP11-80H5.7	-4.09	5.04e-05	0.00431	-0.21	-0.19	Red blood cell count;	chr10:89619789	chr10:89694295~89697928:-
THCA	cis	rs2933343	0.7	rs789233	ENSG00000231305.3	RP11-723O4.2	4.09	5.04e-05	0.00431	0.2	0.19	IgG glycosylation;	chr3:128884307	chr3:128861313~128871540:-
THCA	cis	rs62244186	0.632	rs1402751	ENSG00000214820.3	MPRIPP1	4.09	5.04e-05	0.00431	0.2	0.19	Depressive symptoms;	chr3:44552538	chr3:44579938~44581026:-
THCA	cis	rs3096299	0.685	rs3803681	ENSG00000261118.1	RP11-104N10.1	4.09	5.04e-05	0.00431	0.16	0.19	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89492017~89504460:-
THCA	cis	rs2129782	0.557	rs75414440	ENSG00000253553.4	RP11-586K2.1	4.09	5.04e-05	0.00431	0.34	0.19	Electrodermal activity;	chr8:88591552	chr8:88326836~88737134:+
THCA	cis	rs4950322	0.947	rs72694723	ENSG00000226015.2	CCT8P1	4.09	5.04e-05	0.00431	0.23	0.19	Protein quantitative trait loci;	chr1:147373174	chr1:147203276~147204932:-
THCA	cis	rs875971	0.522	rs4718285	ENSG00000275400.1	RP4-756H11.5	-4.09	5.04e-05	0.00431	-0.18	-0.19	Aortic root size;	chr7:65827018	chr7:66553805~66554199:-
THCA	cis	rs73108077	1	rs73108042	ENSG00000277112.2	RP11-755J8.1	-4.09	5.04e-05	0.00431	-0.39	-0.19	Red blood cell density in sickle cell anemia;	chr20:31403854	chr20:30681825~30723932:-
THCA	cis	rs972578	0.691	rs5758965	ENSG00000274717.1	RP1-47A17.1	-4.09	5.05e-05	0.00431	-0.19	-0.19	Mean platelet volume;	chr22:42830593	chr22:42791814~42794313:-
THCA	cis	rs4934494	0.677	rs730287	ENSG00000240996.1	RP11-80H5.7	-4.09	5.05e-05	0.00432	-0.21	-0.19	Red blood cell count;	chr10:89616589	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs1815338	ENSG00000240996.1	RP11-80H5.7	-4.09	5.05e-05	0.00432	-0.21	-0.19	Red blood cell count;	chr10:89616934	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs1075374	ENSG00000240996.1	RP11-80H5.7	-4.09	5.05e-05	0.00432	-0.21	-0.19	Red blood cell count;	chr10:89617218	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185799	ENSG00000240996.1	RP11-80H5.7	-4.09	5.05e-05	0.00432	-0.21	-0.19	Red blood cell count;	chr10:89617709	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185801	ENSG00000240996.1	RP11-80H5.7	-4.09	5.05e-05	0.00432	-0.21	-0.19	Red blood cell count;	chr10:89618959	chr10:89694295~89697928:-
THCA	cis	rs4934494	0.677	rs11185802	ENSG00000240996.1	RP11-80H5.7	-4.09	5.05e-05	0.00432	-0.21	-0.19	Red blood cell count;	chr10:89618997	chr10:89694295~89697928:-
THCA	cis	rs10435719	0.867	rs35778860	ENSG00000206014.6	OR7E161P	-4.09	5.05e-05	0.00432	-0.22	-0.19	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:11928597~11929563:-
THCA	cis	rs6121246	0.909	rs6058460	ENSG00000224628.2	RP5-854E16.2	-4.09	5.05e-05	0.00432	-0.25	-0.19	Mean corpuscular hemoglobin;	chr20:31775268	chr20:31285317~31286835:-
THCA	cis	rs9926296	0.581	rs1108064	ENSG00000274627.1	RP11-104N10.2	-4.09	5.05e-05	0.00432	-0.19	-0.19	Vitiligo;	chr16:89827742	chr16:89516797~89522217:+
THCA	cis	rs950169	0.526	rs698620	ENSG00000176700.18	SCAND2P	-4.09	5.05e-05	0.00432	-0.12	-0.19	Schizophrenia;	chr15:84633977	chr15:84631451~84647478:+
THCA	cis	rs1124769	0.748	rs17647040	ENSG00000259378.1	DCAF13P3	-4.09	5.05e-05	0.00432	-0.29	-0.19	Cognitive performance;	chr15:51063729	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs10851493	ENSG00000259378.1	DCAF13P3	4.09	5.05e-05	0.00432	0.29	0.19	Cognitive performance;	chr15:51056489	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs17703518	ENSG00000259378.1	DCAF13P3	4.09	5.05e-05	0.00432	0.29	0.19	Cognitive performance;	chr15:51063746	chr15:50944663~50945996:+
THCA	cis	rs11955398	0.502	rs158914	ENSG00000272308.1	RP11-231G3.1	4.09	5.05e-05	0.00432	0.19	0.19	Intelligence (multi-trait analysis);	chr5:60950582	chr5:60866457~60866935:-
THCA	cis	rs875971	0.964	rs6945019	ENSG00000229886.1	RP5-1132H15.3	4.09	5.05e-05	0.00432	0.19	0.19	Aortic root size;	chr7:66457471	chr7:66025126~66031544:-
THCA	cis	rs7616559	0.649	rs1384541	ENSG00000244515.1	KRT18P34	-4.09	5.05e-05	0.00432	-0.22	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:157008077	chr3:157162663~157163932:-
THCA	cis	rs13053817	0.898	rs35847236	ENSG00000279159.1	RP3-394A18.1	4.09	5.05e-05	0.00432	0.2	0.19	Carotid atherosclerosis in HIV infection;	chr22:29470605	chr22:29978950~30028236:-
THCA	cis	rs73193808	0.639	rs9984810	ENSG00000176054.6	RPL23P2	4.09	5.06e-05	0.00432	0.17	0.19	Coronary artery disease;	chr21:29181059	chr21:28997613~28998033:-
THCA	cis	rs73193808	0.614	rs4817274	ENSG00000176054.6	RPL23P2	4.09	5.06e-05	0.00432	0.17	0.19	Coronary artery disease;	chr21:29181296	chr21:28997613~28998033:-
THCA	cis	rs73193808	0.59	rs2832244	ENSG00000176054.6	RPL23P2	4.09	5.06e-05	0.00432	0.17	0.19	Coronary artery disease;	chr21:29181713	chr21:28997613~28998033:-
THCA	cis	rs9534288	0.912	rs2404732	ENSG00000235903.6	CPB2-AS1	4.09	5.06e-05	0.00432	0.27	0.19	Blood protein levels;	chr13:46044476	chr13:46052806~46113332:+
THCA	cis	rs12143943	0.934	rs12027855	ENSG00000240219.1	RP11-430C7.5	4.09	5.06e-05	0.00432	0.16	0.19	Cognitive performance;	chr1:204626416	chr1:204626775~204629712:+
THCA	cis	rs801193	0.935	rs3800820	ENSG00000223473.2	GS1-124K5.3	-4.09	5.06e-05	0.00432	-0.12	-0.19	Aortic root size;	chr7:66682191	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs2003301	ENSG00000223473.2	GS1-124K5.3	-4.09	5.06e-05	0.00432	-0.12	-0.19	Aortic root size;	chr7:66682669	chr7:66491049~66493566:-
THCA	cis	rs4713118	0.523	rs2179096	ENSG00000261839.1	RP1-265C24.8	4.09	5.06e-05	0.00432	0.19	0.19	Parkinson's disease;	chr6:27698141	chr6:28136849~28139678:+
THCA	cis	rs6560517	0.915	rs4745541	ENSG00000234618.1	RPSAP9	-4.09	5.06e-05	0.00432	-0.2	-0.19	Dialysis-related mortality;	chr9:76390347	chr9:76398699~76399586:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-4.09	5.06e-05	0.00432	-0.21	-0.19	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
THCA	cis	rs11771526	0.901	rs11760534	ENSG00000272905.1	RP11-265E18.1	4.09	5.06e-05	0.00433	0.26	0.19	Body mass index;	chr7:32223354	chr7:32845394~32846061:+
THCA	cis	rs10090774	0.735	rs10108814	ENSG00000280303.2	ERICD	-4.09	5.06e-05	0.00433	-0.17	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708215	chr8:140636281~140638283:+
THCA	cis	rs8077577	0.895	rs62073602	ENSG00000273018.4	CTD-2303H24.2	-4.09	5.06e-05	0.00433	-0.3	-0.19	Obesity-related traits;	chr17:18154593	chr17:18511221~18551705:-
THCA	cis	rs875971	0.638	rs7793569	ENSG00000230295.1	RP11-458F8.2	4.09	5.06e-05	0.00433	0.14	0.19	Aortic root size;	chr7:66651646	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs6975195	ENSG00000230295.1	RP11-458F8.2	4.09	5.06e-05	0.00433	0.14	0.19	Aortic root size;	chr7:66659787	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs3857688	ENSG00000230295.1	RP11-458F8.2	4.09	5.06e-05	0.00433	0.14	0.19	Aortic root size;	chr7:66662819	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs2286684	ENSG00000230295.1	RP11-458F8.2	4.09	5.06e-05	0.00433	0.14	0.19	Aortic root size;	chr7:66664843	chr7:66880708~66882981:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000230295.1	RP11-458F8.2	4.09	5.06e-05	0.00433	0.14	0.19	Aortic root size;	chr7:66664856	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs10274773	ENSG00000230295.1	RP11-458F8.2	4.09	5.06e-05	0.00433	0.14	0.19	Aortic root size;	chr7:66668591	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs11773829	ENSG00000230295.1	RP11-458F8.2	4.09	5.06e-05	0.00433	0.14	0.19	Aortic root size;	chr7:66676087	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs7788576	ENSG00000230295.1	RP11-458F8.2	4.09	5.06e-05	0.00433	0.14	0.19	Aortic root size;	chr7:66683315	chr7:66880708~66882981:+
THCA	cis	rs801193	0.935	rs2659916	ENSG00000230295.1	RP11-458F8.2	-4.09	5.06e-05	0.00433	-0.14	-0.19	Aortic root size;	chr7:66686365	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs6958520	ENSG00000230295.1	RP11-458F8.2	-4.09	5.06e-05	0.00433	-0.14	-0.19	Aortic root size;	chr7:66686466	chr7:66880708~66882981:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000230295.1	RP11-458F8.2	-4.09	5.06e-05	0.00433	-0.14	-0.19	Aortic root size;	chr7:66687725	chr7:66880708~66882981:+
THCA	cis	rs6570726	0.791	rs383841	ENSG00000270638.1	RP3-466P17.1	-4.09	5.06e-05	0.00433	-0.15	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145735570~145737218:+
THCA	cis	rs75920871	0.688	rs7109876	ENSG00000254851.1	RP11-109L13.1	-4.09	5.06e-05	0.00433	-0.38	-0.19	Subjective well-being;	chr11:116977932	chr11:117135528~117138582:+
THCA	cis	rs10761482	0.861	rs4245587	ENSG00000254271.1	RP11-131N11.4	4.09	5.06e-05	0.00433	0.25	0.19	Schizophrenia;	chr10:60341831	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs4245588	ENSG00000254271.1	RP11-131N11.4	4.09	5.06e-05	0.00433	0.25	0.19	Schizophrenia;	chr10:60341988	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs2169081	ENSG00000254271.1	RP11-131N11.4	4.09	5.06e-05	0.00433	0.25	0.19	Schizophrenia;	chr10:60342631	chr10:60734342~60741828:+
THCA	cis	rs2676071	0.668	rs2676072	ENSG00000259721.1	RP11-758N13.1	-4.09	5.06e-05	0.00433	-0.22	-0.19	Periodontitis (Mean PAL);	chr15:33306010	chr15:32717270~32719007:-
THCA	cis	rs6840360	0.573	rs2407171	ENSG00000251611.1	RP11-610P16.1	-4.09	5.06e-05	0.00433	-0.13	-0.19	Intelligence (multi-trait analysis);	chr4:151335630	chr4:151407551~151408835:-
THCA	cis	rs7264396	0.887	rs2236164	ENSG00000088340.14	FER1L4	4.09	5.06e-05	0.00433	0.17	0.19	Total cholesterol levels;	chr20:35509524	chr20:35558737~35607562:-
THCA	cis	rs6120849	0.754	rs6120790	ENSG00000269202.1	RP4-614O4.12	-4.09	5.07e-05	0.00433	-0.2	-0.19	Protein C levels;	chr20:35011287	chr20:35201747~35203288:-
THCA	cis	rs2549003	0.934	rs2549006	ENSG00000237714.1	P4HA2-AS1	4.09	5.07e-05	0.00433	0.24	0.19	Asthma (sex interaction);	chr5:132491373	chr5:132184876~132192808:+
THCA	cis	rs613391	0.536	rs682022	ENSG00000234840.1	LINC01239	-4.09	5.07e-05	0.00433	-0.21	-0.19	Quantitative traits;	chr9:22722160	chr9:22646200~22824213:+
THCA	cis	rs3892630	0.588	rs8106748	ENSG00000267567.1	CTD-2538C1.3	4.09	5.07e-05	0.00433	0.27	0.19	Red blood cell traits;	chr19:32791891	chr19:32718298~32719595:-
THCA	cis	rs2688608	0.967	rs9971038	ENSG00000271816.1	BMS1P4	4.09	5.07e-05	0.00433	0.18	0.19	Inflammatory bowel disease;	chr10:73901391	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.967	rs9971040	ENSG00000271816.1	BMS1P4	4.09	5.07e-05	0.00433	0.18	0.19	Inflammatory bowel disease;	chr10:73901404	chr10:73699151~73730487:-
THCA	cis	rs472402	0.623	rs7707877	ENSG00000250056.4	LINC01018	-4.09	5.07e-05	0.00433	-0.22	-0.19	Response to amphetamines;	chr5:6635833	chr5:6582136~6588499:+
THCA	cis	rs7550636	1	rs7550636	ENSG00000276735.1	Metazoa_SRP	-4.09	5.07e-05	0.00433	-0.23	-0.19	Coronary artery calcification;	chr1:192837111	chr1:193236794~193237107:-
THCA	cis	rs7773456	0.576	rs12206194	ENSG00000227116.1	RP3-471C18.1	-4.09	5.07e-05	0.00433	-0.22	-0.19	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19730427~19734567:-
THCA	cis	rs8062405	0.824	rs7191618	ENSG00000261766.1	RP11-22P6.2	-4.09	5.07e-05	0.00433	-0.17	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.754	rs3859172	ENSG00000261766.1	RP11-22P6.2	-4.09	5.07e-05	0.00433	-0.17	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28862166~28863340:-
THCA	cis	rs7918232	0.83	rs7087033	ENSG00000262412.1	RP11-85G18.6	4.09	5.07e-05	0.00433	0.29	0.19	Breast cancer;	chr10:27103593	chr10:27243130~27250804:+
THCA	cis	rs7824557	0.564	rs2572386	ENSG00000154316.13	TDH	4.09	5.07e-05	0.00433	0.14	0.19	Retinal vascular caliber;	chr8:11379466	chr8:11339637~11368452:+
THCA	cis	rs2281636	0.824	rs2160620	ENSG00000233690.1	EBAG9P1	4.09	5.07e-05	0.00433	0.18	0.19	Obesity-related traits;	chr10:99627261	chr10:99697407~99697949:-
THCA	cis	rs3806843	0.569	rs753279	ENSG00000202515.1	VTRNA1-3	4.09	5.07e-05	0.00433	0.21	0.19	Depressive symptoms (multi-trait analysis);	chr5:140644233	chr5:140726158~140726246:+
THCA	cis	rs7616559	0.719	rs9860977	ENSG00000244515.1	KRT18P34	-4.09	5.07e-05	0.00433	-0.23	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:157056048	chr3:157162663~157163932:-
THCA	cis	rs1023500	0.552	rs5758566	ENSG00000237037.8	NDUFA6-AS1	-4.09	5.07e-05	0.00433	-0.15	-0.19	Schizophrenia;	chr22:42058350	chr22:42090931~42137742:+
THCA	cis	rs2933343	0.601	rs1680758	ENSG00000231305.3	RP11-723O4.2	4.09	5.07e-05	0.00434	0.2	0.19	IgG glycosylation;	chr3:128876054	chr3:128861313~128871540:-
THCA	cis	rs7131987	0.565	rs1991113	ENSG00000275476.1	RP11-996F15.4	-4.09	5.07e-05	0.00434	-0.18	-0.19	QT interval;	chr12:29239070	chr12:29277397~29277882:-
THCA	cis	rs734999	0.545	rs12749591	ENSG00000225931.3	RP3-395M20.7	-4.09	5.08e-05	0.00434	-0.22	-0.19	Ulcerative colitis;	chr1:2631811	chr1:2566410~2569888:+
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000182586.6	LINC00334	-4.09	5.08e-05	0.00434	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45234340~45258730:+
THCA	cis	rs858239	0.6	rs10241208	ENSG00000230042.1	AK3P3	-4.09	5.08e-05	0.00434	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23129178~23129841:+
THCA	cis	rs478304	0.593	rs9666878	ENSG00000255557.1	RP11-770G2.2	-4.09	5.08e-05	0.00434	-0.22	-0.19	Acne (severe);	chr11:65708345	chr11:65745729~65771585:+
THCA	cis	rs13178541	0.81	rs6879905	ENSG00000250378.1	RP11-119J18.1	-4.09	5.08e-05	0.00434	-0.24	-0.19	IgG glycosylation;	chr5:135854608	chr5:135812667~135826582:+
THCA	cis	rs1389724	0.648	rs1160412	ENSG00000259834.1	RP11-284N8.3	-4.09	5.08e-05	0.00434	-0.16	-0.19	Schizophrenia;	chr1:110773324	chr1:110653560~110657040:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000229180.5	GS1-124K5.11	4.09	5.08e-05	0.00434	0.13	0.19	Calcium levels;	chr7:65892789	chr7:66526088~66542624:-
THCA	cis	rs7520050	0.778	rs3013597	ENSG00000280836.1	AL355480.1	-4.09	5.08e-05	0.00434	-0.22	-0.19	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45581219~45581321:-
THCA	cis	rs11971779	0.68	rs11765421	ENSG00000252332.1	RNU6-911P	-4.09	5.08e-05	0.00434	-0.21	-0.19	Diisocyanate-induced asthma;	chr7:139340348	chr7:139448740~139448843:+
THCA	cis	rs860295	0.812	rs12024257	ENSG00000236675.1	MTX1P1	-4.09	5.08e-05	0.00434	-0.19	-0.19	Body mass index;	chr1:155810745	chr1:155230975~155234325:+
THCA	cis	rs860295	0.812	rs6657670	ENSG00000236675.1	MTX1P1	-4.09	5.08e-05	0.00434	-0.19	-0.19	Body mass index;	chr1:155818076	chr1:155230975~155234325:+
THCA	cis	rs875971	0.52	rs160645	ENSG00000273024.4	INTS4P2	4.09	5.08e-05	0.00434	0.24	0.19	Aortic root size;	chr7:66091320	chr7:65647864~65715661:+
THCA	cis	rs6921919	0.697	rs758398	ENSG00000273712.1	RP5-874C20.7	4.09	5.08e-05	0.00434	0.22	0.19	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28315613~28315883:-
THCA	cis	rs2933343	0.621	rs789242	ENSG00000231305.3	RP11-723O4.2	4.09	5.09e-05	0.00434	0.2	0.19	IgG glycosylation;	chr3:128866864	chr3:128861313~128871540:-
THCA	cis	rs1476587	0.92	rs2106952	ENSG00000224046.1	AC005076.5	4.09	5.09e-05	0.00435	0.17	0.19	Brachial circumference;	chr7:87110707	chr7:87151423~87152420:-
THCA	cis	rs11951515	0.508	rs10065689	ENSG00000248240.1	RP11-159F24.5	-4.09	5.09e-05	0.00435	-0.2	-0.19	Metabolite levels  (X-11787);	chr5:43604156	chr5:43515274~43525310:+
THCA	cis	rs67478160	0.643	rs12880167	ENSG00000269940.1	RP11-73M18.7	4.09	5.09e-05	0.00435	0.18	0.19	Schizophrenia;	chr14:103834492	chr14:103694560~103695170:+
THCA	cis	rs853679	0.567	rs6905380	ENSG00000273712.1	RP5-874C20.7	4.09	5.09e-05	0.00435	0.22	0.19	Depression;	chr6:28407125	chr6:28315613~28315883:-
THCA	cis	rs13108904	0.901	rs6851528	ENSG00000254094.1	AC078852.1	-4.09	5.09e-05	0.00435	-0.21	-0.19	Obesity-related traits;	chr4:1302221	chr4:1356581~1358075:+
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000272831.1	RP11-792A8.4	4.09	5.09e-05	0.00435	0.12	0.19	Calcium levels;	chr7:65806798	chr7:66739829~66740385:-
THCA	cis	rs875971	0.545	rs313830	ENSG00000273142.1	RP11-458F8.4	-4.09	5.09e-05	0.00435	-0.18	-0.19	Aortic root size;	chr7:66086944	chr7:66902857~66906297:+
THCA	cis	rs72928364	1	rs62273925	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100922951	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs1036467	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100923960	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.929	rs17284842	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100926103	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs36156426	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100927399	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs13060137	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100929083	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs62273927	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100929596	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs34315591	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100930239	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs13100301	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100932878	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs62273928	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100933356	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs34565718	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100934046	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs34275644	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100939221	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs35630894	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100942490	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs35617051	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100943972	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs62273935	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100950732	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs73143088	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100953743	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs13080859	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100959216	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs35530876	ENSG00000256628.3	ZBTB11-AS1	4.09	5.09e-05	0.00435	0.32	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100961648	chr3:101676475~101679217:+
THCA	cis	rs8062405	0.755	rs7186573	ENSG00000270424.1	RP11-1348G14.6	4.09	5.09e-05	0.00435	0.23	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28749959~28750595:-
THCA	cis	rs2836974	0.897	rs2836923	ENSG00000255568.3	BRWD1-AS2	4.09	5.09e-05	0.00435	0.16	0.19	Cognitive function;	chr21:39152310	chr21:39313935~39314962:+
THCA	cis	rs5758659	1	rs5758660	ENSG00000273366.1	CTA-989H11.1	-4.09	5.09e-05	0.00435	-0.22	-0.19	Cognitive function;	chr22:42227712	chr22:42278188~42278846:+
THCA	cis	rs7551222	0.691	rs11240760	ENSG00000240219.1	RP11-430C7.5	4.09	5.09e-05	0.00435	0.17	0.19	Schizophrenia;	chr1:204578140	chr1:204626775~204629712:+
THCA	cis	rs17095355	0.901	rs12572168	ENSG00000203876.8	ADD3-AS1	-4.09	5.09e-05	0.00435	-0.22	-0.19	Biliary atresia;	chr10:110005028	chr10:109940104~110008381:-
THCA	cis	rs1124769	0.748	rs12912106	ENSG00000259378.1	DCAF13P3	4.09	5.09e-05	0.00435	0.29	0.19	Cognitive performance;	chr15:51067255	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs57324163	ENSG00000259378.1	DCAF13P3	4.09	5.09e-05	0.00435	0.29	0.19	Cognitive performance;	chr15:51069551	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs11070832	ENSG00000259378.1	DCAF13P3	4.09	5.09e-05	0.00435	0.29	0.19	Cognitive performance;	chr15:51070642	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.7	rs12900777	ENSG00000259378.1	DCAF13P3	4.09	5.09e-05	0.00435	0.29	0.19	Cognitive performance;	chr15:51072382	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.654	rs12593764	ENSG00000259378.1	DCAF13P3	4.09	5.09e-05	0.00435	0.29	0.19	Cognitive performance;	chr15:51072743	chr15:50944663~50945996:+
THCA	cis	rs964611	0.882	rs11630744	ENSG00000259488.2	RP11-154J22.1	4.09	5.09e-05	0.00435	0.17	0.19	Metabolite levels (Pyroglutamine);	chr15:48355310	chr15:48312353~48331856:-
THCA	cis	rs9309473	0.95	rs11126412	ENSG00000273245.1	RP11-434P11.2	4.09	5.09e-05	0.00435	0.27	0.19	Metabolite levels;	chr2:73660507	chr2:73750256~73750786:-
THCA	cis	rs4742903	0.967	rs6479215	ENSG00000270332.1	SMC2-AS1	-4.09	5.09e-05	0.00435	-0.17	-0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104122962	chr9:104080024~104093073:-
THCA	cis	rs6921919	0.583	rs16894060	ENSG00000273712.1	RP5-874C20.7	4.09	5.09e-05	0.00435	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28315613~28315883:-
THCA	cis	rs4742903	0.765	rs4743700	ENSG00000270332.1	SMC2-AS1	4.09	5.09e-05	0.00435	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104243187	chr9:104080024~104093073:-
THCA	cis	rs9510787	0.538	rs9510800	ENSG00000205861.10	C1QTNF9B-AS1	-4.09	5.09e-05	0.00435	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23666146	chr13:23888889~23897263:+
THCA	cis	rs7707921	0.881	rs17243791	ENSG00000251374.1	RPS23P5	4.09	5.09e-05	0.00435	0.27	0.19	Breast cancer;	chr5:82026728	chr5:82265157~82265259:-
THCA	cis	rs10911902	0.643	rs75158977	ENSG00000229739.2	RP11-295K2.3	-4.09	5.09e-05	0.00435	-0.29	-0.19	Schizophrenia;	chr1:186324597	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.602	rs3736595	ENSG00000229739.2	RP11-295K2.3	-4.09	5.09e-05	0.00435	-0.29	-0.19	Schizophrenia;	chr1:186331745	chr1:186435161~186470291:+
THCA	cis	rs10911902	0.643	rs3753565	ENSG00000229739.2	RP11-295K2.3	4.09	5.09e-05	0.00435	0.29	0.19	Schizophrenia;	chr1:186347356	chr1:186435161~186470291:+
THCA	cis	rs2933343	0.649	rs789219	ENSG00000231305.3	RP11-723O4.2	4.09	5.1e-05	0.00435	0.2	0.19	IgG glycosylation;	chr3:128873677	chr3:128861313~128871540:-
THCA	cis	rs1048886	0.872	rs73480280	ENSG00000271967.1	RP11-134K13.4	-4.09	5.1e-05	0.00435	-0.2	-0.19	Type 2 diabetes;	chr6:70572972	chr6:70596438~70596980:+
THCA	cis	rs1232027	0.656	rs863214	ENSG00000249655.1	CTC-325J23.2	4.09	5.1e-05	0.00435	0.21	0.19	Huntington's disease progression;	chr5:80688895	chr5:80630313~80631590:-
THCA	cis	rs6964833	1	rs36044436	ENSG00000184616.8	AC004166.6	4.09	5.1e-05	0.00435	0.29	0.19	Menarche (age at onset);	chr7:74675495	chr7:74906673~74913256:-
THCA	cis	rs853679	0.505	rs200992	ENSG00000280107.1	AL022393.9	-4.09	5.1e-05	0.00435	-0.29	-0.19	Depression;	chr6:27846899	chr6:28170845~28172521:+
THCA	cis	rs3177980	0.539	rs12742961	ENSG00000239494.2	RN7SL333P	-4.09	5.1e-05	0.00435	-0.17	-0.19	Amyotrophic lateral sclerosis;	chr1:169825721	chr1:169859756~169860052:+
THCA	cis	rs11976180	0.569	rs12703565	ENSG00000244479.5	OR2A1-AS1	4.09	5.1e-05	0.00435	0.26	0.19	Obesity-related traits;	chr7:144057308	chr7:144251264~144356181:-
THCA	cis	rs17095355	0.901	rs12569425	ENSG00000203876.8	ADD3-AS1	-4.09	5.1e-05	0.00435	-0.21	-0.19	Biliary atresia;	chr10:109998419	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.901	rs9783184	ENSG00000203876.8	ADD3-AS1	-4.09	5.1e-05	0.00435	-0.21	-0.19	Biliary atresia;	chr10:110000741	chr10:109940104~110008381:-
THCA	cis	rs17685	0.753	rs4732542	ENSG00000227038.2	AC005077.12	4.09	5.1e-05	0.00435	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76033885	chr7:76090431~76108779:-
THCA	cis	rs8113308	0.752	rs11882377	ENSG00000269483.1	AC006272.1	4.09	5.1e-05	0.00436	0.28	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:52000877	chr19:51839924~51843324:-
THCA	cis	rs4785204	1	rs72796155	ENSG00000279356.1	RP11-429P3.8	-4.09	5.1e-05	0.00436	-0.35	-0.19	Esophageal cancer (squamous cell);	chr16:50087852	chr16:50072862~50074986:+
THCA	cis	rs3002131	0.688	rs2936040	ENSG00000272750.1	RP11-378J18.8	4.09	5.1e-05	0.00436	0.28	0.19	Interleukin-10 levels;	chr1:222590319	chr1:222658867~222661512:-
THCA	cis	rs62292953	0.589	rs74915889	ENSG00000248724.5	NPHP3-AS1	-4.09	5.1e-05	0.00436	-0.34	-0.19	Red cell distribution width;	chr3:132417408	chr3:132721750~132874223:+
THCA	cis	rs2749592	0.55	rs7081464	ENSG00000226578.1	RP11-258F22.1	4.09	5.1e-05	0.00436	0.21	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:37775371~37784131:-
THCA	cis	rs17798991	1	rs17798991	ENSG00000267674.1	RP11-813F20.2	4.09	5.1e-05	0.00436	0.17	0.19	Obesity-related traits;	chr18:49594946	chr18:49739823~49742063:-
THCA	cis	rs34421088	0.532	rs4515509	ENSG00000154316.13	TDH	-4.09	5.1e-05	0.00436	-0.14	-0.19	Neuroticism;	chr8:11314614	chr8:11339637~11368452:+
THCA	cis	rs12142240	0.698	rs6679898	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46354917	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs10158236	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46355224	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.667	rs66990604	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46356401	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs112068407	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46356619	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.66	rs112560929	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46356625	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs10158572	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46356768	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs10158130	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46356928	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.73	rs56030283	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46357421	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs55971480	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46357534	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs66911505	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46357626	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72677593	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46358691	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72677594	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46358699	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.66	rs7520497	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46359247	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.692	rs7532149	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46359260	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs28578741	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46359504	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs56063031	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46359761	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs67276232	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46359812	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.667	rs55887761	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46360915	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs9661240	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46361378	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1053627	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46362056	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1053628	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46362097	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6429599	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46362199	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17361819	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46362437	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs67142569	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46362788	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17361833	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46363028	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17357711	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46363341	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6683192	ENSG00000232022.5	FAAHP1	-4.09	5.1e-05	0.00436	-0.21	-0.19	Menopause (age at onset);	chr1:46364585	chr1:46432129~46445521:+
THCA	cis	rs4218	0.648	rs2289895	ENSG00000259732.1	RP11-59H7.3	-4.09	5.1e-05	0.00436	-0.26	-0.19	Social communication problems;	chr15:59089570	chr15:59121034~59133250:+
THCA	cis	rs4409675	0.913	rs4072744	ENSG00000227050.1	RP11-460I13.2	4.09	5.1e-05	0.00436	0.25	0.19	Corneal astigmatism;	chr1:27944528	chr1:27938875~27960193:-
THCA	cis	rs4072705	0.646	rs4838187	ENSG00000224020.1	MIR181A2HG	-4.09	5.1e-05	0.00436	-0.17	-0.19	Menarche (age at onset);	chr9:124479797	chr9:124658467~124698631:+
THCA	cis	rs2692947	0.537	rs11685849	ENSG00000235584.2	AC008268.1	-4.09	5.1e-05	0.00436	-0.2	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578056	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.537	rs11688045	ENSG00000235584.2	AC008268.1	-4.09	5.1e-05	0.00436	-0.2	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578057	chr2:95666084~95668715:+
THCA	cis	rs10090774	0.71	rs13268718	ENSG00000280303.2	ERICD	-4.09	5.1e-05	0.00436	-0.17	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140677101	chr8:140636281~140638283:+
THCA	cis	rs1015362	0.503	rs4911371	ENSG00000275784.1	RP5-1125A11.6	-4.09	5.1e-05	0.00436	-0.22	-0.19	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33989480~33991818:-
THCA	cis	rs11633886	0.934	rs66526505	ENSG00000259200.1	RP11-718O11.1	-4.09	5.1e-05	0.00436	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45797548	chr15:45705078~45931069:+
THCA	cis	rs7616559	0.789	rs4680336	ENSG00000244515.1	KRT18P34	-4.09	5.11e-05	0.00436	-0.23	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:157052899	chr3:157162663~157163932:-
THCA	cis	rs12681288	0.823	rs2701905	ENSG00000260721.1	AF067845.1	4.09	5.11e-05	0.00436	0.22	0.19	Schizophrenia;	chr8:1053482	chr8:1368642~1369833:-
THCA	cis	rs4908760	0.516	rs11121232	ENSG00000232912.4	RP5-1115A15.1	4.09	5.11e-05	0.00436	0.17	0.19	Vitiligo;	chr1:8790650	chr1:8424645~8434838:+
THCA	cis	rs2333021	1	rs4899453	ENSG00000258376.2	RP4-647C14.2	4.09	5.11e-05	0.00436	0.22	0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73021883	chr14:73242651~73245979:-
THCA	cis	rs7119038	0.818	rs4936444	ENSG00000255239.1	AP002954.6	4.09	5.11e-05	0.00436	0.28	0.19	Sjögren's syndrome;	chr11:118872629	chr11:118688039~118690600:-
THCA	cis	rs2239815	0.515	rs5762848	ENSG00000272858.1	CTA-292E10.8	-4.09	5.11e-05	0.00436	-0.24	-0.19	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28840320	chr22:28814914~28815662:+
THCA	cis	rs2239815	0.515	rs12170231	ENSG00000272858.1	CTA-292E10.8	-4.09	5.11e-05	0.00436	-0.24	-0.19	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28841836	chr22:28814914~28815662:+
THCA	cis	rs9467773	0.933	rs35355150	ENSG00000228223.2	HCG11	-4.09	5.11e-05	0.00436	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26523450~26526579:+
THCA	cis	rs9595908	0.669	rs28637641	ENSG00000212293.1	SNORA16	4.09	5.11e-05	0.00436	0.23	0.19	Body mass index;	chr13:32726997	chr13:32420390~32420516:-
THCA	cis	rs7674212	0.541	rs2720458	ENSG00000230069.3	LRRC37A15P	-4.09	5.11e-05	0.00436	-0.19	-0.19	Type 2 diabetes;	chr4:103131806	chr4:102727274~102730721:-
THCA	cis	rs6772849	0.708	rs12491942	ENSG00000242551.2	POU5F1P6	-4.09	5.11e-05	0.00436	-0.25	-0.19	Monocyte percentage of white cells;Monocyte count;	chr3:128702626	chr3:128674735~128677005:-
THCA	cis	rs494526	0.808	rs4751690	ENSG00000229272.1	RP11-498J9.2	-4.09	5.11e-05	0.00436	-0.21	-0.19	Alcoholic chronic pancreatitis;	chr10:119090425	chr10:119003536~119003884:-
THCA	cis	rs12440869	1	rs975946	ENSG00000270964.1	RP11-502I4.3	-4.09	5.11e-05	0.00436	-0.16	-0.19	Peak velocity of the mitral A-wave;	chr15:67316267	chr15:67541072~67542604:-
THCA	cis	rs9326248	0.53	rs562179	ENSG00000280143.1	AP000892.6	4.09	5.11e-05	0.00436	0.3	0.19	Blood protein levels;	chr11:116934488	chr11:117204967~117210292:+
THCA	cis	rs10844706	0.699	rs10844627	ENSG00000214776.8	RP11-726G1.1	4.09	5.11e-05	0.00436	0.24	0.19	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733781	chr12:9467552~9576275:+
THCA	cis	rs10844706	0.699	rs10844632	ENSG00000214776.8	RP11-726G1.1	4.09	5.11e-05	0.00436	0.24	0.19	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734309	chr12:9467552~9576275:+
THCA	cis	rs786425	0.618	rs7294984	ENSG00000270095.1	RP11-214K3.18	-4.09	5.11e-05	0.00436	-0.22	-0.19	Pubertal anthropometrics;	chr12:123657202	chr12:123971457~123971714:-
THCA	cis	rs786425	0.594	rs6488888	ENSG00000270095.1	RP11-214K3.18	-4.09	5.11e-05	0.00436	-0.22	-0.19	Pubertal anthropometrics;	chr12:123658044	chr12:123971457~123971714:-
THCA	cis	rs7586085	1	rs11677550	ENSG00000232411.1	AC009495.3	-4.09	5.11e-05	0.00436	-0.2	-0.19	Total body bone mineral density;	chr2:165704922	chr2:165833048~165839098:-
THCA	cis	rs1204798	0.588	rs1204816	ENSG00000237021.2	RP3-486I3.7	-4.09	5.11e-05	0.00436	-0.22	-0.19	Dental caries;	chr6:116238862	chr6:116254207~116256743:+
THCA	cis	rs7551222	0.752	rs11240758	ENSG00000240219.1	RP11-430C7.5	4.09	5.11e-05	0.00437	0.17	0.19	Schizophrenia;	chr1:204559523	chr1:204626775~204629712:+
THCA	cis	rs34421088	0.56	rs2245250	ENSG00000255046.1	RP11-297N6.4	4.09	5.11e-05	0.00437	0.2	0.19	Neuroticism;	chr8:11543171	chr8:11797928~11802568:-
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000265443.1	CTD-2349P21.6	-4.09	5.12e-05	0.00437	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30726305~30727564:-
THCA	cis	rs4792901	0.808	rs10853083	ENSG00000267151.3	RP11-100E5.2	4.09	5.12e-05	0.00437	0.19	0.19	Dupuytren's disease;	chr17:43558972	chr17:43444707~43451200:+
THCA	cis	rs72772090	0.614	rs10447215	ENSG00000248734.2	CTD-2260A17.1	-4.09	5.12e-05	0.00437	-0.33	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96720669	chr5:96784777~96785999:+
THCA	cis	rs755249	0.51	rs582883	ENSG00000228060.1	RP11-69E11.8	-4.09	5.12e-05	0.00437	-0.18	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39565160~39573203:+
THCA	cis	rs7212590	0.529	rs60283440	ENSG00000267302.4	RP11-178C3.2	4.09	5.12e-05	0.00437	0.34	0.19	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59916887	chr17:59964832~59996972:+
THCA	cis	rs9326246	0.545	rs499790	ENSG00000254851.1	RP11-109L13.1	4.09	5.12e-05	0.00437	0.42	0.19	Coronary artery disease;	chr11:116649022	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs544479	ENSG00000254851.1	RP11-109L13.1	4.09	5.12e-05	0.00437	0.42	0.19	Coronary artery disease;	chr11:116649681	chr11:117135528~117138582:+
THCA	cis	rs9326246	0.545	rs506222	ENSG00000254851.1	RP11-109L13.1	4.09	5.12e-05	0.00437	0.42	0.19	Coronary artery disease;	chr11:116649717	chr11:117135528~117138582:+
THCA	cis	rs7746199	0.736	rs35037868	ENSG00000220721.1	OR1F12	4.09	5.12e-05	0.00437	0.43	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28073316~28074233:+
THCA	cis	rs10256972	0.869	rs1007766	ENSG00000225146.1	AC073957.15	4.09	5.12e-05	0.00437	0.19	0.19	Endometriosis;Longevity;	chr7:995267	chr7:1029025~1043891:+
THCA	cis	rs7176527	0.848	rs72630462	ENSG00000225151.9	GOLGA2P7	4.09	5.12e-05	0.00437	0.36	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:84199311~84230136:-
THCA	cis	rs2067615	0.521	rs1216002	ENSG00000260329.1	RP11-412D9.4	-4.09	5.12e-05	0.00437	-0.17	-0.19	Heart rate;	chr12:106819823	chr12:106954029~106955497:-
THCA	cis	rs7760535	0.711	rs240965	ENSG00000230177.1	RP5-1112D6.4	-4.09	5.12e-05	0.00437	-0.16	-0.19	Metabolic traits;	chr6:111323321	chr6:111277932~111278742:+
THCA	cis	rs875971	1	rs12532998	ENSG00000230189.5	GS1-124K5.2	4.09	5.12e-05	0.00437	0.12	0.19	Aortic root size;	chr7:66502472	chr7:66409143~66490059:-
THCA	cis	rs6933660	0.646	rs3736176	ENSG00000219395.2	HSPA8P15	-4.09	5.12e-05	0.00437	-0.16	-0.19	Menarche (age at onset);	chr6:151452185	chr6:151411259~151413945:-
THCA	cis	rs6933660	0.646	rs3816778	ENSG00000219395.2	HSPA8P15	-4.09	5.12e-05	0.00437	-0.16	-0.19	Menarche (age at onset);	chr6:151452218	chr6:151411259~151413945:-
THCA	cis	rs8177876	0.822	rs1563077	ENSG00000261838.4	RP11-303E16.6	4.09	5.12e-05	0.00437	0.32	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81069854~81076598:+
THCA	cis	rs62158800	0.925	rs62158830	ENSG00000224568.1	AC096669.3	4.09	5.12e-05	0.00437	0.36	0.19	Facial morphology (factor 22);	chr2:107634350	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.925	rs62158832	ENSG00000224568.1	AC096669.3	4.09	5.12e-05	0.00437	0.36	0.19	Facial morphology (factor 22);	chr2:107635124	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.852	rs62158834	ENSG00000224568.1	AC096669.3	4.09	5.12e-05	0.00437	0.36	0.19	Facial morphology (factor 22);	chr2:107639879	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.703	rs55940013	ENSG00000224568.1	AC096669.3	4.09	5.12e-05	0.00437	0.36	0.19	Facial morphology (factor 22);	chr2:107642672	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.852	rs62158837	ENSG00000224568.1	AC096669.3	4.09	5.12e-05	0.00437	0.36	0.19	Facial morphology (factor 22);	chr2:107643102	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.852	rs62158838	ENSG00000224568.1	AC096669.3	4.09	5.12e-05	0.00437	0.36	0.19	Facial morphology (factor 22);	chr2:107644754	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.852	rs62158839	ENSG00000224568.1	AC096669.3	4.09	5.12e-05	0.00437	0.36	0.19	Facial morphology (factor 22);	chr2:107645837	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.852	rs17021579	ENSG00000224568.1	AC096669.3	4.09	5.12e-05	0.00437	0.36	0.19	Facial morphology (factor 22);	chr2:107650274	chr2:107529487~107556326:+
THCA	cis	rs881827	0.619	rs2070436	ENSG00000230982.1	DSTNP1	4.09	5.12e-05	0.00437	0.21	0.19	Lymphocyte counts;	chr21:46658699	chr21:46653558~46654022:-
THCA	cis	rs2692947	0.673	rs1168965	ENSG00000235584.2	AC008268.1	4.09	5.12e-05	0.00437	0.19	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96122160	chr2:95666084~95668715:+
THCA	cis	rs4705962	0.8	rs6865485	ENSG00000230612.2	AC004237.1	4.09	5.12e-05	0.00437	0.23	0.19	Atopic dermatitis;	chr5:132699880	chr5:132688681~132723725:+
THCA	cis	rs6671200	0.831	rs71654410	ENSG00000235501.4	RP4-639F20.1	-4.09	5.12e-05	0.00437	-0.39	-0.19	Stearic acid (18:0) levels;	chr1:95134408	chr1:94927566~94963270:+
THCA	cis	rs7819412	0.775	rs2001329	ENSG00000206014.6	OR7E161P	4.09	5.13e-05	0.00437	0.21	0.19	Triglycerides;	chr8:11129349	chr8:11928597~11929563:-
THCA	cis	rs3892630	0.612	rs10413282	ENSG00000267567.1	CTD-2538C1.3	4.09	5.13e-05	0.00437	0.26	0.19	Red blood cell traits;	chr19:32691845	chr19:32718298~32719595:-
THCA	cis	rs950169	0.922	rs12912934	ENSG00000188388.10	GOLGA6L3	4.09	5.13e-05	0.00438	0.25	0.19	Schizophrenia;	chr15:84571216	chr15:85240472~85247170:+
THCA	cis	rs950169	0.922	rs62021167	ENSG00000188388.10	GOLGA6L3	4.09	5.13e-05	0.00438	0.25	0.19	Schizophrenia;	chr15:84574820	chr15:85240472~85247170:+
THCA	cis	rs7849973	0.506	rs10511707	ENSG00000224549.1	RP11-370B11.3	-4.09	5.13e-05	0.00438	-0.21	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22912325	chr9:22767175~22768316:+
THCA	cis	rs7746199	0.736	rs13193542	ENSG00000272009.1	RP1-313I6.12	-4.09	5.13e-05	0.00438	-0.36	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28078792~28081130:-
THCA	cis	rs7746199	0.736	rs13193480	ENSG00000272009.1	RP1-313I6.12	-4.09	5.13e-05	0.00438	-0.36	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28078792~28081130:-
THCA	cis	rs1580019	0.922	rs1466147	ENSG00000231952.3	DPY19L1P2	-4.09	5.13e-05	0.00438	-0.24	-0.19	Cognitive ability;	chr7:32446650	chr7:32812757~32838570:+
THCA	cis	rs1124769	0.748	rs35551186	ENSG00000259378.1	DCAF13P3	4.09	5.13e-05	0.00438	0.29	0.19	Cognitive performance;	chr15:51016011	chr15:50944663~50945996:+
THCA	cis	rs800160	0.72	rs2106604	ENSG00000199550.1	Y_RNA	4.09	5.13e-05	0.00438	0.29	0.19	Bacteremia;	chr11:2319927	chr11:2372638~2372750:+
THCA	cis	rs7178375	1	rs28881289	ENSG00000269930.1	RP11-932O9.9	-4.09	5.13e-05	0.00438	-0.25	-0.19	Hypertriglyceridemia;	chr15:30931752	chr15:30616958~30617749:+
THCA	cis	rs7474896	0.778	rs11011431	ENSG00000263064.2	RP11-291L22.7	4.09	5.13e-05	0.00438	0.32	0.19	Obesity (extreme);	chr10:38046335	chr10:38448689~38448949:+
THCA	cis	rs150992	0.609	rs161935	ENSG00000246763.5	RGMB-AS1	4.09	5.13e-05	0.00438	0.19	0.19	Body mass index;	chr5:98982733	chr5:98769618~98773469:-
THCA	cis	rs150992	0.632	rs161936	ENSG00000246763.5	RGMB-AS1	4.09	5.13e-05	0.00438	0.19	0.19	Body mass index;	chr5:98982953	chr5:98769618~98773469:-
THCA	cis	rs7312933	0.592	rs1551210	ENSG00000257225.1	RP11-328C8.4	-4.09	5.13e-05	0.00438	-0.19	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42472072	chr12:42459366~42466128:+
THCA	cis	rs8031584	0.958	rs34294266	ENSG00000270015.1	RP11-540B6.6	-4.09	5.13e-05	0.00438	-0.14	-0.19	Huntington's disease progression;	chr15:30954637	chr15:30926514~30928407:+
THCA	cis	rs5758659	0.692	rs5751251	ENSG00000237037.8	NDUFA6-AS1	4.09	5.13e-05	0.00438	0.14	0.19	Cognitive function;	chr22:42244600	chr22:42090931~42137742:+
THCA	cis	rs7847628	0.765	rs7026635	ENSG00000270917.1	RP11-27I1.6	4.09	5.13e-05	0.00438	0.28	0.19	Birth weight;	chr9:120787749	chr9:120812475~120812845:-
THCA	cis	rs7264396	0.887	rs6120951	ENSG00000088340.14	FER1L4	4.09	5.14e-05	0.00438	0.17	0.19	Total cholesterol levels;	chr20:35457370	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs58458373	ENSG00000088340.14	FER1L4	4.09	5.14e-05	0.00438	0.17	0.19	Total cholesterol levels;	chr20:35457790	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs3818441	ENSG00000088340.14	FER1L4	4.09	5.14e-05	0.00438	0.17	0.19	Total cholesterol levels;	chr20:35458678	chr20:35558737~35607562:-
THCA	cis	rs12410462	0.551	rs1923821	ENSG00000227711.2	RP11-275O4.5	-4.09	5.14e-05	0.00438	-0.22	-0.19	Major depressive disorder;	chr1:227674354	chr1:227509028~227520477:-
THCA	cis	rs3892630	0.878	rs2903759	ENSG00000267475.1	CTD-2538C1.2	-4.09	5.14e-05	0.00438	-0.27	-0.19	Red blood cell traits;	chr19:32705041	chr19:32687089~32691750:-
THCA	cis	rs8115854	0.961	rs1076687	ENSG00000269846.1	RP4-621N11.2	-4.09	5.14e-05	0.00438	-0.24	-0.19	Hippocampal atrophy;	chr20:37182638	chr20:37095785~37097178:+
THCA	cis	rs8115854	0.922	rs16986470	ENSG00000269846.1	RP4-621N11.2	-4.09	5.14e-05	0.00438	-0.24	-0.19	Hippocampal atrophy;	chr20:37184123	chr20:37095785~37097178:+
THCA	cis	rs8141529	0.588	rs10222249	ENSG00000226471.5	CTA-292E10.6	-4.09	5.14e-05	0.00438	-0.16	-0.19	Lymphocyte counts;	chr22:28861159	chr22:28800683~28848559:+
THCA	cis	rs3781264	0.848	rs7099485	ENSG00000273450.1	RP11-76P2.4	4.09	5.14e-05	0.00438	0.23	0.19	Esophageal cancer and gastric cancer;	chr10:94305937	chr10:94314907~94315327:-
THCA	cis	rs9634489	0.59	rs9300341	ENSG00000247400.3	DNAJC3-AS1	-4.09	5.14e-05	0.00438	-0.12	-0.19	Body mass index;	chr13:96274610	chr13:95648733~95676925:-
THCA	cis	rs1023500	0.506	rs6002625	ENSG00000237037.8	NDUFA6-AS1	4.09	5.14e-05	0.00438	0.16	0.19	Schizophrenia;	chr22:42121685	chr22:42090931~42137742:+
THCA	cis	rs11153306	0.552	rs12196381	ENSG00000231889.6	TRAF3IP2-AS1	-4.09	5.14e-05	0.00438	-0.16	-0.19	Tonsillectomy;	chr6:111618197	chr6:111483511~111598302:+
THCA	cis	rs9876781	0.56	rs2362451	ENSG00000244380.1	RP11-24C3.2	-4.09	5.14e-05	0.00438	-0.22	-0.19	Longevity;	chr3:48358338	chr3:48440352~48446656:-
THCA	cis	rs5752326	0.51	rs5752333	ENSG00000261188.1	CTA-445C9.14	4.09	5.14e-05	0.00438	0.18	0.19	Ischemic stroke;	chr22:26483001	chr22:26512537~26514568:+
THCA	cis	rs12935229	0.756	rs34807040	ENSG00000260922.1	RP11-538I12.3	-4.09	5.14e-05	0.00438	-0.29	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77280004	chr16:77234877~77290934:+
THCA	cis	rs181553	0.504	rs60901553	ENSG00000264269.1	RP11-15F12.1	4.09	5.14e-05	0.00438	0.28	0.19	Hip circumference adjusted for BMI;	chr18:49460364	chr18:49023703~49048474:+
THCA	cis	rs2836974	0.897	rs34394827	ENSG00000255568.3	BRWD1-AS2	4.09	5.14e-05	0.00439	0.16	0.19	Cognitive function;	chr21:39156161	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs35386515	ENSG00000255568.3	BRWD1-AS2	4.09	5.14e-05	0.00439	0.16	0.19	Cognitive function;	chr21:39160121	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs2836925	ENSG00000255568.3	BRWD1-AS2	4.09	5.14e-05	0.00439	0.16	0.19	Cognitive function;	chr21:39160427	chr21:39313935~39314962:+
THCA	cis	rs4568518	0.53	rs10269921	ENSG00000279048.1	RP11-511H23.2	4.09	5.14e-05	0.00439	0.12	0.19	Measles;	chr7:17958317	chr7:17940503~17942922:+
THCA	cis	rs5769765	0.908	rs138866	ENSG00000260613.1	RP3-522J7.6	4.09	5.14e-05	0.00439	0.22	0.19	Schizophrenia;	chr22:49812255	chr22:49832616~49837786:-
THCA	cis	rs55966801	0.68	rs17655663	ENSG00000277290.1	RP11-326C3.16	-4.09	5.14e-05	0.00439	-0.24	-0.19	Plateletcrit;	chr11:268940	chr11:243099~243483:-
THCA	cis	rs860295	0.702	rs12025532	ENSG00000236675.1	MTX1P1	-4.09	5.14e-05	0.00439	-0.19	-0.19	Body mass index;	chr1:155399511	chr1:155230975~155234325:+
THCA	cis	rs11030122	0.959	rs7111609	ENSG00000230593.3	AC090804.1	4.09	5.14e-05	0.00439	0.24	0.19	Mean platelet volume;Platelet distribution width;	chr11:3885087	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.959	rs7131437	ENSG00000230593.3	AC090804.1	4.09	5.14e-05	0.00439	0.24	0.19	Mean platelet volume;Platelet distribution width;	chr11:3885161	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.959	rs10835238	ENSG00000230593.3	AC090804.1	4.09	5.14e-05	0.00439	0.24	0.19	Mean platelet volume;Platelet distribution width;	chr11:3886063	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.959	rs10835239	ENSG00000230593.3	AC090804.1	4.09	5.14e-05	0.00439	0.24	0.19	Mean platelet volume;Platelet distribution width;	chr11:3886149	chr11:3892398~3892887:-
THCA	cis	rs11175834	0.655	rs10047609	ENSG00000256915.1	RP11-221N13.4	-4.09	5.14e-05	0.00439	-0.33	-0.19	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65582534	chr12:65644334~65663299:+
THCA	cis	rs34792	0.853	rs153807	ENSG00000207425.1	Y_RNA	4.09	5.14e-05	0.00439	0.2	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15462646	chr16:14915457~14915556:-
THCA	cis	rs10833905	0.938	rs12285669	ENSG00000246225.5	RP11-17A1.3	-4.09	5.15e-05	0.00439	-0.26	-0.19	Sudden cardiac arrest;	chr11:23041871	chr11:22829380~22945393:+
THCA	cis	rs4144027	0.904	rs10438242	ENSG00000269958.1	RP11-73M18.8	-4.09	5.15e-05	0.00439	-0.17	-0.19	Blood metabolite levels;	chr14:103878738	chr14:103696353~103697163:+
THCA	cis	rs7474896	0.832	rs11011401	ENSG00000263064.2	RP11-291L22.7	4.09	5.15e-05	0.00439	0.32	0.19	Obesity (extreme);	chr10:37918490	chr10:38448689~38448949:+
THCA	cis	rs9717605	1	rs12178180	ENSG00000226445.1	XXyac-YX65C7_A.2	4.09	5.15e-05	0.00439	0.23	0.19	Left atrial antero-posterior diameter;	chr6:169248672	chr6:169213254~169239565:+
THCA	cis	rs801193	1	rs2659912	ENSG00000223473.2	GS1-124K5.3	4.09	5.15e-05	0.00439	0.12	0.19	Aortic root size;	chr7:66693012	chr7:66491049~66493566:-
THCA	cis	rs8062405	1	rs11861174	ENSG00000270424.1	RP11-1348G14.6	4.09	5.15e-05	0.00439	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62037367	ENSG00000270424.1	RP11-1348G14.6	4.09	5.15e-05	0.00439	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs7198606	ENSG00000270424.1	RP11-1348G14.6	4.09	5.15e-05	0.00439	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.929	rs11864750	ENSG00000270424.1	RP11-1348G14.6	4.09	5.15e-05	0.00439	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.964	rs7193733	ENSG00000270424.1	RP11-1348G14.6	4.09	5.15e-05	0.00439	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs8055982	ENSG00000270424.1	RP11-1348G14.6	4.09	5.15e-05	0.00439	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs7498665	ENSG00000270424.1	RP11-1348G14.6	4.09	5.15e-05	0.00439	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.964	rs11864107	ENSG00000270424.1	RP11-1348G14.6	4.09	5.15e-05	0.00439	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28749959~28750595:-
THCA	cis	rs4660456	0.504	rs542214	ENSG00000272145.1	NFYC-AS1	-4.09	5.15e-05	0.00439	-0.14	-0.19	Platelet count;	chr1:40632806	chr1:40690380~40692066:-
THCA	cis	rs8070128	0.568	rs3935505	ENSG00000281749.1	Y_RNA	4.09	5.15e-05	0.00439	0.25	0.19	Total body bone mineral density;	chr17:17978706	chr17:18001101~18001195:-
THCA	cis	rs9510787	0.563	rs9510801	ENSG00000205861.10	C1QTNF9B-AS1	-4.09	5.15e-05	0.00439	-0.25	-0.19	Nasopharyngeal carcinoma;	chr13:23666592	chr13:23888889~23897263:+
THCA	cis	rs4713118	0.513	rs149942	ENSG00000261839.1	RP1-265C24.8	4.09	5.15e-05	0.00439	0.19	0.19	Parkinson's disease;	chr6:28033832	chr6:28136849~28139678:+
THCA	cis	rs1371614	0.545	rs3769137	ENSG00000272148.1	RP11-195B17.1	-4.09	5.15e-05	0.00439	-0.17	-0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946622	chr2:27062428~27062907:-
THCA	cis	rs12440869	1	rs7162340	ENSG00000270964.1	RP11-502I4.3	-4.09	5.15e-05	0.00439	-0.16	-0.19	Peak velocity of the mitral A-wave;	chr15:67340091	chr15:67541072~67542604:-
THCA	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	4.09	5.15e-05	0.00439	0.23	0.19	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
THCA	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	4.09	5.15e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
THCA	cis	rs8081395	0.711	rs11368	ENSG00000267302.4	RP11-178C3.2	4.09	5.15e-05	0.0044	0.22	0.19	White blood cell count;	chr17:59954051	chr17:59964832~59996972:+
THCA	cis	rs9326248	0.569	rs11216161	ENSG00000280143.1	AP000892.6	4.09	5.15e-05	0.0044	0.25	0.19	Blood protein levels;	chr11:116850485	chr11:117204967~117210292:+
THCA	cis	rs2154427	1	rs2833954	ENSG00000238197.4	PAXBP1-AS1	4.09	5.16e-05	0.0044	0.18	0.19	Bilirubin levels;	chr21:32790574	chr21:32728115~32743122:+
THCA	cis	rs2154427	1	rs75419790	ENSG00000238197.4	PAXBP1-AS1	4.09	5.16e-05	0.0044	0.18	0.19	Bilirubin levels;	chr21:32794782	chr21:32728115~32743122:+
THCA	cis	rs899997	1	rs11633170	ENSG00000261143.1	ADAMTS7P3	-4.09	5.16e-05	0.0044	-0.26	-0.19	Coronary artery disease or large artery stroke;	chr15:78712300	chr15:77976042~77993057:+
THCA	cis	rs4853525	0.59	rs3771310	ENSG00000235852.1	AC005540.3	4.09	5.16e-05	0.0044	0.2	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190908462	chr2:190880797~190882059:-
THCA	cis	rs4853525	0.59	rs2355570	ENSG00000235852.1	AC005540.3	4.09	5.16e-05	0.0044	0.2	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190916443	chr2:190880797~190882059:-
THCA	cis	rs4853525	0.59	rs3771308	ENSG00000235852.1	AC005540.3	4.09	5.16e-05	0.0044	0.2	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190936179	chr2:190880797~190882059:-
THCA	cis	rs4853525	0.561	rs10931476	ENSG00000235852.1	AC005540.3	4.09	5.16e-05	0.0044	0.2	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190938082	chr2:190880797~190882059:-
THCA	cis	rs4853525	0.504	rs2883582	ENSG00000235852.1	AC005540.3	4.09	5.16e-05	0.0044	0.2	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190939306	chr2:190880797~190882059:-
THCA	cis	rs4853525	0.59	rs2203715	ENSG00000235852.1	AC005540.3	4.09	5.16e-05	0.0044	0.2	0.19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190944157	chr2:190880797~190882059:-
THCA	cis	rs13434995	0.513	rs11240	ENSG00000249700.7	SRD5A3-AS1	-4.09	5.16e-05	0.0044	-0.26	-0.19	Adiponectin levels;	chr4:55453183	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs7676245	ENSG00000249700.7	SRD5A3-AS1	-4.09	5.16e-05	0.0044	-0.26	-0.19	Adiponectin levels;	chr4:55455150	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62303711	ENSG00000249700.7	SRD5A3-AS1	-4.09	5.16e-05	0.0044	-0.26	-0.19	Adiponectin levels;	chr4:55458325	chr4:55363971~55395847:-
THCA	cis	rs10875746	0.669	rs11168516	ENSG00000226413.2	OR8T1P	4.09	5.16e-05	0.0044	0.26	0.19	Longevity (90 years and older);	chr12:48308282	chr12:48442030~48442947:-
THCA	cis	rs2115630	0.967	rs8028490	ENSG00000275120.1	RP11-182J1.17	-4.09	5.16e-05	0.0044	-0.19	-0.19	P wave terminal force;	chr15:84734657	chr15:84599434~84606463:-
THCA	cis	rs7702057	0.53	rs6890263	ENSG00000272265.1	CTD-2287O16.4	4.09	5.16e-05	0.0044	0.33	0.19	Amyotrophic lateral sclerosis;	chr5:116079739	chr5:116078110~116078570:-
THCA	cis	rs7924176	0.521	rs12415957	ENSG00000232342.6	RP11-46O21.2	-4.09	5.16e-05	0.0044	-0.24	-0.19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:74506081~74530553:-
THCA	cis	rs17095355	0.818	rs4275548	ENSG00000203876.8	ADD3-AS1	-4.09	5.16e-05	0.0044	-0.19	-0.19	Biliary atresia;	chr10:110151213	chr10:109940104~110008381:-
THCA	cis	rs2836974	0.897	rs2836928	ENSG00000255568.3	BRWD1-AS2	4.09	5.16e-05	0.0044	0.17	0.19	Cognitive function;	chr21:39171394	chr21:39313935~39314962:+
THCA	cis	rs9291683	0.605	rs73224439	ENSG00000261490.1	RP11-448G15.3	-4.09	5.16e-05	0.0044	-0.12	-0.19	Bone mineral density;	chr4:10330194	chr4:10068089~10073019:-
THCA	cis	rs12440869	1	rs7176337	ENSG00000270964.1	RP11-502I4.3	-4.09	5.16e-05	0.0044	-0.16	-0.19	Peak velocity of the mitral A-wave;	chr15:67257462	chr15:67541072~67542604:-
THCA	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	4.09	5.16e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	4.09	5.16e-05	0.0044	0.17	0.19	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
THCA	cis	rs7829975	0.511	rs1401390	ENSG00000233609.3	RP11-62H7.2	4.09	5.16e-05	0.0044	0.18	0.19	Mood instability;	chr8:8278888	chr8:8961200~8979025:+
THCA	cis	rs8062405	0.72	rs9926245	ENSG00000270424.1	RP11-1348G14.6	4.09	5.16e-05	0.0044	0.21	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28749959~28750595:-
THCA	cis	rs2154427	0.872	rs80141393	ENSG00000238197.4	PAXBP1-AS1	4.09	5.16e-05	0.0044	0.19	0.19	Bilirubin levels;	chr21:32725993	chr21:32728115~32743122:+
THCA	cis	rs4805272	0.962	rs8101324	ENSG00000267799.1	MAN1A2P1	4.09	5.16e-05	0.0044	0.2	0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840622	chr19:28790812~28792871:-
THCA	cis	rs67478160	0.643	rs11628332	ENSG00000269940.1	RP11-73M18.7	4.09	5.16e-05	0.0044	0.17	0.19	Schizophrenia;	chr14:103774804	chr14:103694560~103695170:+
THCA	cis	rs12440869	1	rs8038166	ENSG00000270964.1	RP11-502I4.3	-4.09	5.16e-05	0.0044	-0.16	-0.19	Peak velocity of the mitral A-wave;	chr15:67310676	chr15:67541072~67542604:-
THCA	cis	rs972578	1	rs4822242	ENSG00000230319.1	AL022476.2	4.09	5.16e-05	0.0044	0.2	0.19	Mean platelet volume;	chr22:42979433	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs5759071	ENSG00000230319.1	AL022476.2	4.09	5.16e-05	0.0044	0.2	0.19	Mean platelet volume;	chr22:42979944	chr22:43038585~43052366:+
THCA	cis	rs181553	0.504	rs62102906	ENSG00000266696.1	RP11-30L3.2	-4.09	5.16e-05	0.0044	-0.27	-0.19	Hip circumference adjusted for BMI;	chr18:49461098	chr18:49205912~49208781:+
THCA	cis	rs801193	1	rs2707856	ENSG00000275400.1	RP4-756H11.5	-4.09	5.16e-05	0.0044	-0.17	-0.19	Aortic root size;	chr7:66746023	chr7:66553805~66554199:-
THCA	cis	rs950169	0.84	rs62019457	ENSG00000188388.10	GOLGA6L3	4.09	5.16e-05	0.0044	0.25	0.19	Schizophrenia;	chr15:84558911	chr15:85240472~85247170:+
THCA	cis	rs950169	0.922	rs67804993	ENSG00000188388.10	GOLGA6L3	4.09	5.16e-05	0.0044	0.25	0.19	Schizophrenia;	chr15:84560799	chr15:85240472~85247170:+
THCA	cis	rs6494488	0.5	rs67927052	ENSG00000259635.1	AC100830.3	-4.09	5.16e-05	0.0044	-0.43	-0.19	Coronary artery disease;	chr15:64665124	chr15:64701248~64719602:+
THCA	cis	rs651907	0.64	rs771575	ENSG00000256628.3	ZBTB11-AS1	4.09	5.16e-05	0.0044	0.21	0.19	Colorectal cancer;	chr3:101900515	chr3:101676475~101679217:+
THCA	cis	rs7726839	0.561	rs72703058	ENSG00000225138.6	CTD-2228K2.7	4.09	5.17e-05	0.0044	0.21	0.19	Obesity-related traits;	chr5:584404	chr5:473236~480884:+
THCA	cis	rs34845616	0.813	rs36086419	ENSG00000280237.1	MIR4697HG	4.09	5.17e-05	0.0044	0.19	0.19	Hand grip strength;	chr11:133891820	chr11:133896438~133901601:-
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000182586.6	LINC00334	-4.09	5.17e-05	0.00441	-0.2	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45234340~45258730:+
THCA	cis	rs737008	0.922	rs28567501	ENSG00000263080.1	RP11-485G7.5	-4.09	5.17e-05	0.00441	-0.22	-0.19	Obesity-related traits;	chr16:11285071	chr16:11341809~11345211:-
THCA	cis	rs9634489	0.502	rs417259	ENSG00000247400.3	DNAJC3-AS1	-4.09	5.17e-05	0.00441	-0.12	-0.19	Body mass index;	chr13:96450583	chr13:95648733~95676925:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000226314.6	ZNF192P1	-4.09	5.17e-05	0.00441	-0.2	-0.19	Cardiac Troponin-T levels;	chr6:28200255	chr6:28161781~28169594:+
THCA	cis	rs4908760	0.539	rs6690928	ENSG00000232912.4	RP5-1115A15.1	4.09	5.17e-05	0.00441	0.17	0.19	Vitiligo;	chr1:8799432	chr1:8424645~8434838:+
THCA	cis	rs7956611	0.564	rs4144465	ENSG00000213343.5	RPL21P18	-4.09	5.17e-05	0.00441	-0.21	-0.19	Age of smoking initiation;	chr12:66520412	chr12:66037235~66037714:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000273142.1	RP11-458F8.4	4.09	5.17e-05	0.00441	0.18	0.19	Aortic root size;	chr7:66221293	chr7:66902857~66906297:+
THCA	cis	rs4561483	0.583	rs62038798	ENSG00000263307.1	RP11-166B2.8	-4.09	5.17e-05	0.00441	-0.19	-0.19	Testicular germ cell tumor;	chr16:11907712	chr16:11851649~11895611:+
THCA	cis	rs4561483	0.583	rs12149833	ENSG00000263307.1	RP11-166B2.8	-4.09	5.17e-05	0.00441	-0.19	-0.19	Testicular germ cell tumor;	chr16:11909866	chr16:11851649~11895611:+
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000219891.2	ZSCAN12P1	4.09	5.18e-05	0.00441	0.25	0.19	Parkinson's disease;	chr6:28062721	chr6:28091154~28093664:+
THCA	cis	rs9534288	0.912	rs4941540	ENSG00000235903.6	CPB2-AS1	4.09	5.18e-05	0.00441	0.26	0.19	Blood protein levels;	chr13:46030575	chr13:46052806~46113332:+
THCA	cis	rs9534288	1	rs9534288	ENSG00000235903.6	CPB2-AS1	4.09	5.18e-05	0.00441	0.26	0.19	Blood protein levels;	chr13:46031306	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.956	rs2094244	ENSG00000235903.6	CPB2-AS1	4.09	5.18e-05	0.00441	0.26	0.19	Blood protein levels;	chr13:46031668	chr13:46052806~46113332:+
THCA	cis	rs1124769	0.57	rs1290084	ENSG00000259378.1	DCAF13P3	-4.09	5.18e-05	0.00441	-0.26	-0.19	Cognitive performance;	chr15:50861748	chr15:50944663~50945996:+
THCA	cis	rs1113500	0.575	rs1781070	ENSG00000230489.1	VAV3-AS1	4.09	5.18e-05	0.00441	0.17	0.19	Growth-regulated protein alpha levels;	chr1:108027076	chr1:107964443~107994607:+
THCA	cis	rs800160	0.545	rs2521285	ENSG00000236264.4	RPL26P30	4.09	5.18e-05	0.00441	0.25	0.19	Bacteremia;	chr11:2320606	chr11:2335132~2335776:-
THCA	cis	rs800160	0.623	rs2651844	ENSG00000236264.4	RPL26P30	4.09	5.18e-05	0.00441	0.25	0.19	Bacteremia;	chr11:2320631	chr11:2335132~2335776:-
THCA	cis	rs950169	0.887	rs71395453	ENSG00000188388.10	GOLGA6L3	4.09	5.18e-05	0.00441	0.25	0.19	Schizophrenia;	chr15:84570259	chr15:85240472~85247170:+
THCA	cis	rs7166081	1	rs1444935	ENSG00000270964.1	RP11-502I4.3	-4.09	5.18e-05	0.00441	-0.17	-0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67343082	chr15:67541072~67542604:-
THCA	cis	rs12935418	0.887	rs3743503	ENSG00000261838.4	RP11-303E16.6	4.09	5.18e-05	0.00441	0.3	0.19	Mean corpuscular volume;	chr16:81022836	chr16:81069854~81076598:+
THCA	cis	rs875971	1	rs1167612	ENSG00000230189.5	GS1-124K5.2	-4.09	5.18e-05	0.00441	-0.12	-0.19	Aortic root size;	chr7:66102989	chr7:66409143~66490059:-
THCA	cis	rs465969	0.744	rs13212489	ENSG00000272356.1	RP5-1112D6.8	4.09	5.18e-05	0.00441	0.27	0.19	Psoriasis;	chr6:111536863	chr6:111309203~111313517:+
THCA	cis	rs465969	0.744	rs76257900	ENSG00000272356.1	RP5-1112D6.8	4.09	5.18e-05	0.00441	0.27	0.19	Psoriasis;	chr6:111537286	chr6:111309203~111313517:+
THCA	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	4.09	5.18e-05	0.00441	0.3	0.19	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
THCA	cis	rs9393777	0.92	rs35716472	ENSG00000220721.1	OR1F12	4.09	5.18e-05	0.00441	0.36	0.19	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28073316~28074233:+
THCA	cis	rs4742903	0.904	rs28658011	ENSG00000270332.1	SMC2-AS1	4.09	5.18e-05	0.00441	0.18	0.19	Breast cancer;High-grade serous ovarian cancer;	chr9:104244644	chr9:104080024~104093073:-
THCA	cis	rs7583236	0.85	rs7577869	ENSG00000179818.12	PCBP1-AS1	4.09	5.18e-05	0.00441	0.19	0.19	Obesity-related traits;	chr2:69957557	chr2:69962263~70103220:-
THCA	cis	rs801193	0.967	rs34356500	ENSG00000272831.1	RP11-792A8.4	4.09	5.18e-05	0.00441	0.12	0.19	Aortic root size;	chr7:66771620	chr7:66739829~66740385:-
THCA	cis	rs8017455	0.523	rs7150193	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81096098	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs10146192	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81096237	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs10146203	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81096279	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs10141777	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81098030	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs2300529	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81098161	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs2300530	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81098650	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs2300532	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81098781	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs10136213	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81100018	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs2300533	ENSG00000259167.2	NMNAT1P1	4.09	5.18e-05	0.00441	0.27	0.19	Hair morphology;	chr14:81100131	chr14:81032529~81033404:+
THCA	cis	rs73198271	0.531	rs112930476	ENSG00000253893.2	FAM85B	4.09	5.18e-05	0.00442	0.32	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8814041	chr8:8167819~8226614:-
THCA	cis	rs6847067	0.929	rs72664934	ENSG00000180769.7	WDFY3-AS2	4.08	5.18e-05	0.00442	0.14	0.19	Oropharynx cancer;	chr4:84859500	chr4:84965682~85011277:+
THCA	cis	rs950776	0.79	rs2067808	ENSG00000261762.1	RP11-650L12.2	4.08	5.18e-05	0.00442	0.25	0.19	Sudden cardiac arrest;	chr15:78619438	chr15:78589123~78591276:-
THCA	cis	rs6433895	0.677	rs11692430	ENSG00000236153.1	AC104076.3	-4.08	5.18e-05	0.00442	-0.23	-0.19	Lymphocyte counts;	chr2:181171344	chr2:180979427~180980090:-
THCA	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	4.08	5.19e-05	0.00442	0.22	0.19	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
THCA	cis	rs6472235	0.586	rs17306183	ENSG00000272010.1	CTD-3025N20.3	-4.08	5.19e-05	0.00442	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:65992140	chr8:65591850~65592472:-
THCA	cis	rs6472235	0.524	rs11985050	ENSG00000272010.1	CTD-3025N20.3	-4.08	5.19e-05	0.00442	-0.2	-0.19	Plateletcrit;Myopia (pathological);	chr8:65992811	chr8:65591850~65592472:-
THCA	cis	rs1908814	0.516	rs60176945	ENSG00000254948.1	OR7E158P	-4.08	5.19e-05	0.00442	-0.23	-0.19	Neuroticism;	chr8:11939165	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.516	rs56102998	ENSG00000254948.1	OR7E158P	-4.08	5.19e-05	0.00442	-0.23	-0.19	Neuroticism;	chr8:11939166	chr8:11919900~11920809:-
THCA	cis	rs953301	0.546	rs73021203	ENSG00000229808.1	RP11-456P18.2	-4.08	5.19e-05	0.00442	-0.52	-0.19	Left atrial antero-posterior diameter;	chr1:161961712	chr1:161890833~161892196:+
THCA	cis	rs7131987	0.565	rs7976227	ENSG00000275476.1	RP11-996F15.4	4.08	5.19e-05	0.00442	0.18	0.19	QT interval;	chr12:29264843	chr12:29277397~29277882:-
THCA	cis	rs4886920	0.574	rs12438272	ENSG00000260776.4	RP11-114H24.2	4.08	5.19e-05	0.00442	0.27	0.19	Neuroticism;	chr15:77836977	chr15:77914217~77926846:-
THCA	cis	rs4906332	1	rs8004780	ENSG00000252469.1	RNU7-160P	4.08	5.19e-05	0.00442	0.2	0.19	Coronary artery disease;	chr14:103387023	chr14:103550345~103550406:+
THCA	cis	rs2153535	0.585	rs9505512	ENSG00000230939.1	RP11-314C16.1	-4.08	5.19e-05	0.00442	-0.19	-0.19	Motion sickness;	chr6:8667337	chr6:8784178~8785445:+
THCA	cis	rs10844706	0.699	rs10844620	ENSG00000214776.8	RP11-726G1.1	4.08	5.19e-05	0.00442	0.24	0.19	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9729910	chr12:9467552~9576275:+
THCA	cis	rs1371614	0.632	rs3739085	ENSG00000272148.1	RP11-195B17.1	4.08	5.19e-05	0.00442	0.17	0.19	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26940176	chr2:27062428~27062907:-
THCA	cis	rs9898058	0.769	rs12150425	ENSG00000279036.1	RP11-81K2.2	-4.08	5.19e-05	0.00442	-0.29	-0.19	Milk allergy;	chr17:49836570	chr17:49494223~49497800:-
THCA	cis	rs8062405	0.754	rs151179	ENSG00000270424.1	RP11-1348G14.6	4.08	5.19e-05	0.00442	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28749959~28750595:-
THCA	cis	rs4908760	0.539	rs7513880	ENSG00000232912.4	RP5-1115A15.1	4.08	5.19e-05	0.00442	0.17	0.19	Vitiligo;	chr1:8779241	chr1:8424645~8434838:+
THCA	cis	rs10175706	1	rs7568863	ENSG00000256637.5	RP11-76I14.1	-4.08	5.19e-05	0.00443	-0.16	-0.19	Chin dimples;	chr2:104026208	chr2:103874310~104077778:+
THCA	cis	rs293748	0.882	rs34525350	ENSG00000250155.1	CTD-2353F22.1	-4.08	5.2e-05	0.00443	-0.25	-0.19	Obesity-related traits;	chr5:37089535	chr5:36666214~36725195:-
THCA	cis	rs10186029	0.676	rs10187830	ENSG00000270659.1	RP11-105N14.1	-4.08	5.2e-05	0.00443	-0.15	-0.19	Systemic sclerosis;	chr2:213100072	chr2:213152970~213153659:+
THCA	cis	rs10186029	0.676	rs10932464	ENSG00000270659.1	RP11-105N14.1	-4.08	5.2e-05	0.00443	-0.15	-0.19	Systemic sclerosis;	chr2:213103591	chr2:213152970~213153659:+
THCA	cis	rs10186029	0.676	rs10932465	ENSG00000270659.1	RP11-105N14.1	-4.08	5.2e-05	0.00443	-0.15	-0.19	Systemic sclerosis;	chr2:213103665	chr2:213152970~213153659:+
THCA	cis	rs10186029	0.676	rs10497991	ENSG00000270659.1	RP11-105N14.1	-4.08	5.2e-05	0.00443	-0.15	-0.19	Systemic sclerosis;	chr2:213104051	chr2:213152970~213153659:+
THCA	cis	rs4792901	0.879	rs12600482	ENSG00000267151.3	RP11-100E5.2	4.08	5.2e-05	0.00443	0.19	0.19	Dupuytren's disease;	chr17:43553229	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.959	rs12603797	ENSG00000267151.3	RP11-100E5.2	4.08	5.2e-05	0.00443	0.19	0.19	Dupuytren's disease;	chr17:43553445	chr17:43444707~43451200:+
THCA	cis	rs7572644	0.64	rs13027666	ENSG00000223522.1	AC093690.1	-4.08	5.2e-05	0.00443	-0.22	-0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27835566	chr2:28307691~28310459:-
THCA	cis	rs17382723	0.887	rs61234509	ENSG00000229996.1	AC093585.6	4.08	5.2e-05	0.00443	0.24	0.19	Height;	chr2:241090322	chr2:241010045~241010744:-
THCA	cis	rs7520050	0.751	rs2991975	ENSG00000281133.1	AL355480.3	4.08	5.2e-05	0.00443	0.21	0.19	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45580892~45580996:-
THCA	cis	rs2333194	0.846	rs6574118	ENSG00000258695.2	RP3-414A15.2	-4.08	5.2e-05	0.00443	-0.22	-0.19	Bipolar disorder with mood-incongruent psychosis;	chr14:73345284	chr14:73522878~73530610:+
THCA	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-4.08	5.2e-05	0.00443	-0.24	-0.19	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
THCA	cis	rs7131987	0.565	rs10843372	ENSG00000275476.1	RP11-996F15.4	4.08	5.2e-05	0.00443	0.18	0.19	QT interval;	chr12:29262863	chr12:29277397~29277882:-
THCA	cis	rs7777677	0.925	rs4726542	ENSG00000211750.2	TRBV24-1	-4.08	5.2e-05	0.00443	-0.19	-0.19	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142656701~142657213:+
THCA	cis	rs1396485	0.607	rs57777176	ENSG00000248445.4	SEMA6A-AS1	-4.08	5.2e-05	0.00443	-0.18	-0.19	Inflammatory biomarkers;	chr5:116108224	chr5:116447547~116508276:+
THCA	cis	rs1396485	0.607	rs4921059	ENSG00000248445.4	SEMA6A-AS1	-4.08	5.2e-05	0.00443	-0.18	-0.19	Inflammatory biomarkers;	chr5:116108903	chr5:116447547~116508276:+
THCA	cis	rs6723108	0.678	rs578384	ENSG00000224043.6	CCNT2-AS1	-4.08	5.2e-05	0.00443	-0.22	-0.19	Type 2 diabetes;	chr2:134530343	chr2:134735464~134918710:-
THCA	cis	rs2777491	1	rs7168177	ENSG00000247556.5	OIP5-AS1	4.08	5.2e-05	0.00443	0.15	0.19	Ulcerative colitis;	chr15:41423387	chr15:41283990~41309737:+
THCA	cis	rs7760535	0.93	rs10872069	ENSG00000255389.1	C6orf3	-4.08	5.2e-05	0.00443	-0.18	-0.19	Metabolic traits;	chr6:111540523	chr6:111599875~111602295:+
THCA	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-4.08	5.2e-05	0.00443	-0.21	-0.19	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
THCA	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-4.08	5.2e-05	0.00443	-0.21	-0.19	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
THCA	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-4.08	5.2e-05	0.00443	-0.21	-0.19	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
THCA	cis	rs6671200	0.831	rs71654412	ENSG00000235501.4	RP4-639F20.1	-4.08	5.2e-05	0.00443	-0.39	-0.19	Stearic acid (18:0) levels;	chr1:95136137	chr1:94927566~94963270:+
THCA	cis	rs4578769	0.959	rs1031651	ENSG00000265939.1	UBE2CP2	4.08	5.2e-05	0.00443	0.23	0.19	Eosinophil percentage of white cells;	chr18:22915716	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.959	rs4800439	ENSG00000265939.1	UBE2CP2	4.08	5.2e-05	0.00443	0.23	0.19	Eosinophil percentage of white cells;	chr18:22920492	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.959	rs8096389	ENSG00000265939.1	UBE2CP2	4.08	5.2e-05	0.00443	0.23	0.19	Eosinophil percentage of white cells;	chr18:22921952	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.959	rs9949696	ENSG00000265939.1	UBE2CP2	4.08	5.2e-05	0.00443	0.23	0.19	Eosinophil percentage of white cells;	chr18:22923688	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.959	rs930910	ENSG00000265939.1	UBE2CP2	4.08	5.2e-05	0.00443	0.23	0.19	Eosinophil percentage of white cells;	chr18:22930178	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.76	rs7227956	ENSG00000265939.1	UBE2CP2	4.08	5.2e-05	0.00443	0.23	0.19	Eosinophil percentage of white cells;	chr18:22933855	chr18:22900486~22900995:-
THCA	cis	rs60180747	1	rs59718328	ENSG00000261318.1	RP11-653J6.1	4.08	5.2e-05	0.00443	0.24	0.19	Testicular germ cell tumor;	chr15:66370282	chr15:66278498~66293357:-
THCA	cis	rs60180747	1	rs60180747	ENSG00000261318.1	RP11-653J6.1	4.08	5.2e-05	0.00443	0.24	0.19	Testicular germ cell tumor;	chr15:66370923	chr15:66278498~66293357:-
THCA	cis	rs758324	0.628	rs75624804	ENSG00000237714.1	P4HA2-AS1	-4.08	5.2e-05	0.00443	-0.4	-0.19	Alzheimer's disease in APOE e4- carriers;	chr5:132157682	chr5:132184876~132192808:+
THCA	cis	rs6845263	0.546	rs11936512	ENSG00000254531.1	FLJ20021	4.08	5.2e-05	0.00443	0.16	0.19	Superior crus of antihelix expression;	chr4:101530153	chr4:101347780~101348883:+
THCA	cis	rs4356203	0.905	rs214940	ENSG00000272034.1	SNORD14A	-4.08	5.2e-05	0.00443	-0.18	-0.19	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165308	chr11:17074654~17074744:-
THCA	cis	rs804280	0.509	rs13276433	ENSG00000206014.6	OR7E161P	-4.08	5.21e-05	0.00443	-0.22	-0.19	Myopia (pathological);	chr8:11925527	chr8:11928597~11929563:-
THCA	cis	rs1048886	0.872	rs6916974	ENSG00000271967.1	RP11-134K13.4	-4.08	5.21e-05	0.00443	-0.2	-0.19	Type 2 diabetes;	chr6:70564254	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs56179165	ENSG00000271967.1	RP11-134K13.4	-4.08	5.21e-05	0.00443	-0.2	-0.19	Type 2 diabetes;	chr6:70564767	chr6:70596438~70596980:+
THCA	cis	rs2153535	0.585	rs6934905	ENSG00000230939.1	RP11-314C16.1	-4.08	5.21e-05	0.00443	-0.19	-0.19	Motion sickness;	chr6:8661326	chr6:8784178~8785445:+
THCA	cis	rs11603020	0.95	rs78364821	ENSG00000254602.1	AP000662.4	-4.08	5.21e-05	0.00443	-0.22	-0.19	Blood protein levels;	chr11:57603269	chr11:57638024~57652790:+
THCA	cis	rs12118280	0.531	rs2336019	ENSG00000280186.1	RP11-483I13.6	4.08	5.21e-05	0.00443	0.15	0.19	Myeloid white cell count;	chr1:108215134	chr1:108200413~108202743:+
THCA	cis	rs67981189	0.788	rs34093157	ENSG00000269927.1	RP6-91H8.3	4.08	5.21e-05	0.00443	0.21	0.19	Schizophrenia;	chr14:71101966	chr14:71141125~71143253:-
THCA	cis	rs4272720	0.639	rs12255090	ENSG00000234736.4	FAM170B-AS1	-4.08	5.21e-05	0.00443	-0.2	-0.19	Platelet count;Plateletcrit;	chr10:49069653	chr10:49121839~49151547:+
THCA	cis	rs1035144	0.679	rs72693068	ENSG00000259167.2	NMNAT1P1	4.08	5.21e-05	0.00443	0.23	0.19	Male sexual orientation;	chr14:80979394	chr14:81032529~81033404:+
THCA	cis	rs1035144	0.679	rs72693070	ENSG00000259167.2	NMNAT1P1	4.08	5.21e-05	0.00443	0.23	0.19	Male sexual orientation;	chr14:80979587	chr14:81032529~81033404:+
THCA	cis	rs1035144	0.679	rs72693073	ENSG00000259167.2	NMNAT1P1	4.08	5.21e-05	0.00443	0.23	0.19	Male sexual orientation;	chr14:80980213	chr14:81032529~81033404:+
THCA	cis	rs7824557	0.545	rs2572380	ENSG00000154316.13	TDH	4.08	5.21e-05	0.00444	0.14	0.19	Retinal vascular caliber;	chr8:11379968	chr8:11339637~11368452:+
THCA	cis	rs2271404	0.506	rs12329287	ENSG00000227992.1	AC108463.2	4.08	5.21e-05	0.00444	0.25	0.19	Atopic dermatitis;	chr2:111237710	chr2:111203964~111206215:-
THCA	cis	rs11633886	0.967	rs11629760	ENSG00000273972.1	CTD-2306A12.1	-4.08	5.21e-05	0.00444	-0.2	-0.19	Diisocyanate-induced asthma;	chr15:45800549	chr15:45702640~45703183:+
THCA	cis	rs12612619	0.732	rs11679069	ENSG00000272148.1	RP11-195B17.1	4.08	5.21e-05	0.00444	0.17	0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27047443	chr2:27062428~27062907:-
THCA	cis	rs75828804	1	rs7192903	ENSG00000260922.1	RP11-538I12.3	-4.08	5.21e-05	0.00444	-0.37	-0.19	Intraocular pressure;	chr16:77531005	chr16:77234877~77290934:+
THCA	cis	rs75828804	0.826	rs7193432	ENSG00000260922.1	RP11-538I12.3	-4.08	5.21e-05	0.00444	-0.37	-0.19	Intraocular pressure;	chr16:77531239	chr16:77234877~77290934:+
THCA	cis	rs793571	0.566	rs610877	ENSG00000245975.2	RP11-30K9.6	4.08	5.21e-05	0.00444	0.17	0.19	Schizophrenia;	chr15:58811129	chr15:58768072~58770974:-
THCA	cis	rs2562456	0.833	rs2359145	ENSG00000268117.1	VN1R84P	4.08	5.21e-05	0.00444	0.3	0.19	Pain;	chr19:21409791	chr19:21719801~21720035:-
THCA	cis	rs9309473	0.948	rs2421577	ENSG00000273245.1	RP11-434P11.2	4.08	5.21e-05	0.00444	0.25	0.19	Metabolite levels;	chr2:73613871	chr2:73750256~73750786:-
THCA	cis	rs2154427	0.872	rs10446070	ENSG00000238197.4	PAXBP1-AS1	4.08	5.21e-05	0.00444	0.19	0.19	Bilirubin levels;	chr21:32638314	chr21:32728115~32743122:+
THCA	cis	rs7045881	0.735	rs12342005	ENSG00000254396.1	RP11-56F10.3	4.08	5.21e-05	0.00444	0.24	0.19	Schizophrenia;	chr9:26898073	chr9:27102630~27104728:+
THCA	cis	rs6940638	0.688	rs6921388	ENSG00000220721.1	OR1F12	4.08	5.21e-05	0.00444	0.22	0.19	Intelligence (multi-trait analysis);	chr6:27112426	chr6:28073316~28074233:+
THCA	cis	rs11153306	0.791	rs9387017	ENSG00000231889.6	TRAF3IP2-AS1	4.08	5.21e-05	0.00444	0.16	0.19	Tonsillectomy;	chr6:111622803	chr6:111483511~111598302:+
THCA	cis	rs2898681	0.528	rs73814883	ENSG00000248375.1	RP11-177B4.1	-4.08	5.21e-05	0.00444	-0.38	-0.19	Optic nerve measurement (cup area);	chr4:52861887	chr4:52720081~52720831:-
THCA	cis	rs10932679	0.708	rs741382	ENSG00000229352.1	AC007563.3	4.08	5.21e-05	0.00444	0.29	0.19	Pulse pressure;	chr2:216817524	chr2:216799608~216805335:+
THCA	cis	rs7267979	0.934	rs2500399	ENSG00000276952.1	RP5-965G21.6	-4.08	5.21e-05	0.00444	-0.2	-0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25284915~25285588:-
THCA	cis	rs10761482	0.813	rs4948407	ENSG00000254271.1	RP11-131N11.4	4.08	5.22e-05	0.00444	0.25	0.19	Schizophrenia;	chr10:60350441	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.859	rs4948408	ENSG00000254271.1	RP11-131N11.4	4.08	5.22e-05	0.00444	0.25	0.19	Schizophrenia;	chr10:60350455	chr10:60734342~60741828:+
THCA	cis	rs1005277	0.522	rs289647	ENSG00000276805.1	RP11-291L22.6	4.08	5.22e-05	0.00444	0.19	0.19	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38451030~38451785:+
THCA	cis	rs11634944	0.593	rs12050838	ENSG00000257151.1	PWAR6	4.08	5.22e-05	0.00444	0.14	0.19	Interleukin-8 levels;	chr15:24972464	chr15:25031873~25036490:+
THCA	cis	rs17772222	0.74	rs3783885	ENSG00000222990.1	RNU4-22P	4.08	5.22e-05	0.00444	0.23	0.19	Coronary artery calcification;	chr14:88510714	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs11159857	ENSG00000222990.1	RNU4-22P	4.08	5.22e-05	0.00444	0.23	0.19	Coronary artery calcification;	chr14:88510796	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs4390529	ENSG00000222990.1	RNU4-22P	4.08	5.22e-05	0.00444	0.23	0.19	Coronary artery calcification;	chr14:88510853	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.771	rs4516145	ENSG00000222990.1	RNU4-22P	4.08	5.22e-05	0.00444	0.23	0.19	Coronary artery calcification;	chr14:88510953	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs4594187	ENSG00000222990.1	RNU4-22P	4.08	5.22e-05	0.00444	0.23	0.19	Coronary artery calcification;	chr14:88511071	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs4514599	ENSG00000222990.1	RNU4-22P	4.08	5.22e-05	0.00444	0.23	0.19	Coronary artery calcification;	chr14:88511083	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs73317739	ENSG00000222990.1	RNU4-22P	4.08	5.22e-05	0.00444	0.23	0.19	Coronary artery calcification;	chr14:88511400	chr14:88513498~88513663:+
THCA	cis	rs17685	0.753	rs13240404	ENSG00000230882.1	AC005077.14	-4.08	5.22e-05	0.00444	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76046401	chr7:76071469~76074963:-
THCA	cis	rs17685	0.697	rs2302437	ENSG00000230882.1	AC005077.14	-4.08	5.22e-05	0.00444	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76047698	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs3757593	ENSG00000230882.1	AC005077.14	-4.08	5.22e-05	0.00444	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76049417	chr7:76071469~76074963:-
THCA	cis	rs6494488	0.5	rs112691501	ENSG00000259635.1	AC100830.3	-4.08	5.22e-05	0.00444	-0.48	-0.19	Coronary artery disease;	chr15:64627061	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742972	ENSG00000259635.1	AC100830.3	-4.08	5.22e-05	0.00444	-0.48	-0.19	Coronary artery disease;	chr15:64641918	chr15:64701248~64719602:+
THCA	cis	rs988712	0.705	rs1829469	ENSG00000245573.6	BDNF-AS	-4.08	5.22e-05	0.00444	-0.18	-0.19	Obesity;	chr11:27709009	chr11:27506838~27698174:+
THCA	cis	rs2120243	0.592	rs1456110	ENSG00000241770.1	RP11-555M1.3	-4.08	5.22e-05	0.00444	-0.23	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr3:157388283	chr3:157163452~157169133:+
THCA	cis	rs62244186	0.659	rs12489887	ENSG00000214820.3	MPRIPP1	4.08	5.22e-05	0.00444	0.2	0.19	Depressive symptoms;	chr3:44505632	chr3:44579938~44581026:-
THCA	cis	rs1048886	0.872	rs7756774	ENSG00000271967.1	RP11-134K13.4	-4.08	5.22e-05	0.00444	-0.2	-0.19	Type 2 diabetes;	chr6:70543057	chr6:70596438~70596980:+
THCA	cis	rs897984	0.762	rs2054213	ENSG00000275263.1	RP11-1072A3.4	4.08	5.22e-05	0.00444	0.22	0.19	Dementia with Lewy bodies;	chr16:30960489	chr16:30956872~30957199:-
THCA	cis	rs801193	0.904	rs4718405	ENSG00000232546.1	RP11-458F8.1	-4.08	5.22e-05	0.00444	-0.15	-0.19	Aortic root size;	chr7:66789659	chr7:66848496~66858136:+
THCA	cis	rs1150668	0.83	rs213240	ENSG00000220721.1	OR1F12	4.08	5.22e-05	0.00444	0.21	0.19	Pubertal anthropometrics;	chr6:28348098	chr6:28073316~28074233:+
THCA	cis	rs1993293	0.569	rs62042315	ENSG00000254744.3	CTD-3076O17.1	4.08	5.22e-05	0.00444	0.22	0.19	Coronary artery calcification;	chr15:99751724	chr15:99970215~99974010:+
THCA	cis	rs9393777	0.92	rs34071253	ENSG00000220721.1	OR1F12	4.08	5.22e-05	0.00445	0.36	0.19	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28073316~28074233:+
THCA	cis	rs599083	0.59	rs661988	ENSG00000212093.1	AP000807.1	4.08	5.22e-05	0.00445	0.22	0.19	Bone mineral density (spine);	chr11:68421783	chr11:68506083~68506166:-
THCA	cis	rs7617480	0.616	rs9873227	ENSG00000229759.1	MRPS18AP1	4.08	5.22e-05	0.00445	0.29	0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48735675	chr3:48256350~48256938:-
THCA	cis	rs8062405	0.698	rs10499	ENSG00000278665.1	RP11-666O2.4	-4.08	5.22e-05	0.00445	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28599241~28601881:-
THCA	cis	rs10833905	1	rs7924512	ENSG00000246225.5	RP11-17A1.3	-4.08	5.22e-05	0.00445	-0.26	-0.19	Sudden cardiac arrest;	chr11:23025503	chr11:22829380~22945393:+
THCA	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	4.08	5.22e-05	0.00445	0.24	0.19	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
THCA	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-4.08	5.22e-05	0.00445	-0.2	-0.19	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
THCA	cis	rs2692947	0.74	rs4907280	ENSG00000232931.4	LINC00342	4.08	5.22e-05	0.00445	0.15	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95736378	chr2:95807118~95816215:-
THCA	cis	rs7336933	0.932	rs9532958	ENSG00000278338.3	VWA8-AS1	-4.08	5.23e-05	0.00445	-0.31	-0.19	Calcium levels;	chr13:41961799	chr13:41955808~41981565:+
THCA	cis	rs6570726	0.791	rs443628	ENSG00000270638.1	RP3-466P17.1	4.08	5.23e-05	0.00445	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145735570~145737218:+
THCA	cis	rs79481398	0.616	rs2922225	ENSG00000276772.1	CTD-2515H24.2	4.08	5.23e-05	0.00445	0.22	0.19	Facial morphology (factor 19);	chr15:57492283	chr15:57553955~57555680:+
THCA	cis	rs3770081	1	rs58898686	ENSG00000272564.1	RP11-548P2.2	-4.08	5.23e-05	0.00445	-0.37	-0.19	Facial emotion recognition (sad faces);	chr2:85989786	chr2:85904279~85904727:+
THCA	cis	rs1125355	0.69	rs11691004	ENSG00000243792.1	OR7E89P	4.08	5.23e-05	0.00445	0.27	0.19	Alzheimer's disease in APOE e4+ carriers;	chr2:158787663	chr2:158853755~158854576:+
THCA	cis	rs7833787	0.693	rs2638630	ENSG00000278886.1	RP11-108A14.1	4.08	5.23e-05	0.00445	0.24	0.19	Obesity-related traits;	chr8:18821726	chr8:18864681~18865247:-
THCA	cis	rs957448	0.539	rs9643346	ENSG00000253175.1	RP11-267M23.6	4.08	5.23e-05	0.00445	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94565036~94565715:+
THCA	cis	rs17095355	1	rs55683820	ENSG00000203876.8	ADD3-AS1	-4.08	5.23e-05	0.00445	-0.22	-0.19	Biliary atresia;	chr10:109905618	chr10:109940104~110008381:-
THCA	cis	rs3783637	0.818	rs8010282	ENSG00000258413.1	RP11-665C16.6	-4.08	5.23e-05	0.00445	-0.38	-0.19	Rheumatoid arthritis;Obesity-related traits;	chr14:54863537	chr14:55262767~55272075:-
THCA	cis	rs3783637	0.818	rs8010689	ENSG00000258413.1	RP11-665C16.6	-4.08	5.23e-05	0.00445	-0.38	-0.19	Rheumatoid arthritis;Obesity-related traits;	chr14:54863538	chr14:55262767~55272075:-
THCA	cis	rs7647973	0.696	rs3087866	ENSG00000229759.1	MRPS18AP1	4.08	5.23e-05	0.00445	0.28	0.19	Menarche (age at onset);	chr3:49017259	chr3:48256350~48256938:-
THCA	cis	rs2836974	0.897	rs8133146	ENSG00000255568.3	BRWD1-AS2	4.08	5.23e-05	0.00445	0.16	0.19	Cognitive function;	chr21:39242372	chr21:39313935~39314962:+
THCA	cis	rs2153535	0.618	rs11243267	ENSG00000230939.1	RP11-314C16.1	-4.08	5.23e-05	0.00445	-0.19	-0.19	Motion sickness;	chr6:8662287	chr6:8784178~8785445:+
THCA	cis	rs4808199	0.895	rs8105094	ENSG00000267481.1	CTC-559E9.5	-4.08	5.23e-05	0.00445	-0.2	-0.19	Nonalcoholic fatty liver disease;	chr19:19263252	chr19:19788755~19790531:-
THCA	cis	rs4808199	0.895	rs8105984	ENSG00000267481.1	CTC-559E9.5	-4.08	5.23e-05	0.00445	-0.2	-0.19	Nonalcoholic fatty liver disease;	chr19:19263259	chr19:19788755~19790531:-
THCA	cis	rs860295	0.836	rs35615695	ENSG00000160766.13	GBAP1	4.08	5.23e-05	0.00445	0.21	0.19	Body mass index;	chr1:155531223	chr1:155213821~155227422:-
THCA	cis	rs12478296	0.901	rs67423532	ENSG00000220804.7	AC093642.5	4.08	5.23e-05	0.00446	0.2	0.19	Obesity-related traits;	chr2:242062568	chr2:242088633~242160153:+
THCA	cis	rs12478296	0.901	rs67951957	ENSG00000220804.7	AC093642.5	4.08	5.23e-05	0.00446	0.2	0.19	Obesity-related traits;	chr2:242062750	chr2:242088633~242160153:+
THCA	cis	rs7264396	0.573	rs55969606	ENSG00000088340.14	FER1L4	4.08	5.23e-05	0.00446	0.17	0.19	Total cholesterol levels;	chr20:35487862	chr20:35558737~35607562:-
THCA	cis	rs10175706	0.965	rs2376064	ENSG00000256637.5	RP11-76I14.1	-4.08	5.24e-05	0.00446	-0.16	-0.19	Chin dimples;	chr2:104072986	chr2:103874310~104077778:+
THCA	cis	rs875971	0.867	rs1002053	ENSG00000230189.5	GS1-124K5.2	-4.08	5.24e-05	0.00446	-0.12	-0.19	Aortic root size;	chr7:66333558	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs6460292	ENSG00000230189.5	GS1-124K5.2	-4.08	5.24e-05	0.00446	-0.12	-0.19	Aortic root size;	chr7:66345088	chr7:66409143~66490059:-
THCA	cis	rs8067545	0.512	rs34726000	ENSG00000261033.1	RP11-209D14.2	-4.08	5.24e-05	0.00446	-0.26	-0.19	Schizophrenia;	chr17:19984508	chr17:20008051~20009234:-
THCA	cis	rs340849	0.967	rs11120231	ENSG00000274895.1	RP11-478J18.2	4.08	5.24e-05	0.00446	0.15	0.19	Alzheimer's disease;	chr1:213936809	chr1:213983793~213986419:-
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000280107.1	AL022393.9	-4.08	5.24e-05	0.00446	-0.18	-0.19	Pubertal anthropometrics;	chr6:28298372	chr6:28170845~28172521:+
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.24e-05	0.00446	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30726305~30727564:-
THCA	cis	rs613391	0.561	rs471112	ENSG00000234840.1	LINC01239	-4.08	5.24e-05	0.00446	-0.21	-0.19	Quantitative traits;	chr9:22720808	chr9:22646200~22824213:+
THCA	cis	rs613391	0.561	rs590268	ENSG00000234840.1	LINC01239	-4.08	5.24e-05	0.00446	-0.21	-0.19	Quantitative traits;	chr9:22720861	chr9:22646200~22824213:+
THCA	cis	rs786425	0.933	rs786423	ENSG00000270095.1	RP11-214K3.18	4.08	5.24e-05	0.00446	0.2	0.19	Pubertal anthropometrics;	chr12:123599351	chr12:123971457~123971714:-
THCA	cis	rs6570726	0.967	rs403584	ENSG00000270638.1	RP3-466P17.1	4.08	5.24e-05	0.00446	0.15	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145735570~145737218:+
THCA	cis	rs2562456	0.833	rs8106025	ENSG00000268658.4	LINC00664	-4.08	5.24e-05	0.00446	-0.27	-0.19	Pain;	chr19:21451922	chr19:21483374~21503238:+
THCA	cis	rs854765	0.547	rs6502632	ENSG00000281749.1	Y_RNA	4.08	5.24e-05	0.00446	0.24	0.19	Total body bone mineral density;	chr17:18009743	chr17:18001101~18001195:-
THCA	cis	rs11633886	0.934	rs4774765	ENSG00000259200.1	RP11-718O11.1	-4.08	5.24e-05	0.00446	-0.22	-0.19	Diisocyanate-induced asthma;	chr15:45796659	chr15:45705078~45931069:+
THCA	cis	rs397969	0.596	rs35925051	ENSG00000261033.1	RP11-209D14.2	-4.08	5.24e-05	0.00446	-0.27	-0.19	Platelet count;	chr17:19974056	chr17:20008051~20009234:-
THCA	cis	rs73230612	1	rs9851136	ENSG00000242767.1	ZBTB20-AS4	4.08	5.24e-05	0.00446	0.25	0.19	Type 2 diabetes;	chr3:115092677	chr3:115100423~115103061:+
THCA	cis	rs4767841	0.565	rs203366	ENSG00000248636.5	RP11-768F21.1	-4.08	5.24e-05	0.00446	-0.19	-0.19	Urgency urinary incontinence;	chr12:119778060	chr12:119387987~119668079:-
THCA	cis	rs4792901	0.722	rs8074904	ENSG00000267151.3	RP11-100E5.2	4.08	5.24e-05	0.00446	0.2	0.19	Dupuytren's disease;	chr17:43494209	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.759	rs75491854	ENSG00000267151.3	RP11-100E5.2	4.08	5.24e-05	0.00446	0.2	0.19	Dupuytren's disease;	chr17:43497282	chr17:43444707~43451200:+
THCA	cis	rs7618915	0.851	rs34228726	ENSG00000243224.1	RP5-1157M23.2	-4.08	5.24e-05	0.00446	-0.2	-0.19	Bipolar disorder;	chr3:52288781	chr3:52239258~52241097:+
THCA	cis	rs9341808	0.591	rs6454147	ENSG00000272129.1	RP11-250B2.6	4.08	5.24e-05	0.00446	0.23	0.19	Sitting height ratio;	chr6:80206611	chr6:80355424~80356859:+
THCA	cis	rs4915077	0.773	rs72705627	ENSG00000230489.1	VAV3-AS1	4.08	5.24e-05	0.00446	0.3	0.19	Hypothyroidism;	chr1:107724998	chr1:107964443~107994607:+
THCA	cis	rs4561483	0.583	rs11075030	ENSG00000263307.1	RP11-166B2.8	-4.08	5.24e-05	0.00446	-0.19	-0.19	Testicular germ cell tumor;	chr16:11882557	chr16:11851649~11895611:+
THCA	cis	rs699371	0.533	rs12893163	ENSG00000270000.1	RP3-449M8.9	4.08	5.24e-05	0.00446	0.18	0.19	Height;	chr14:74428292	chr14:74471930~74472360:-
THCA	cis	rs12681366	0.801	rs2919658	ENSG00000261437.1	RP11-22C11.2	4.08	5.24e-05	0.00446	0.19	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:94637285~94639467:-
THCA	cis	rs2933343	0.649	rs789214	ENSG00000231305.3	RP11-723O4.2	4.08	5.24e-05	0.00446	0.2	0.19	IgG glycosylation;	chr3:128876152	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.729	rs789224	ENSG00000231305.3	RP11-723O4.2	4.08	5.24e-05	0.00446	0.2	0.19	IgG glycosylation;	chr3:128879388	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.761	rs789225	ENSG00000231305.3	RP11-723O4.2	4.08	5.24e-05	0.00446	0.2	0.19	IgG glycosylation;	chr3:128881386	chr3:128861313~128871540:-
THCA	cis	rs10792320	0.565	rs79502317	ENSG00000279491.1	RP11-810P12.7	-4.08	5.25e-05	0.00446	-0.23	-0.19	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61968664	chr11:61967794~61969490:+
THCA	cis	rs7779181	0.508	rs12534148	ENSG00000272905.1	RP11-265E18.1	4.08	5.25e-05	0.00446	0.19	0.19	Body mass index;	chr7:32208699	chr7:32845394~32846061:+
THCA	cis	rs2018683	0.707	rs4722875	ENSG00000272568.4	CTB-113D17.1	4.08	5.25e-05	0.00447	0.18	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930015	chr7:28979967~29013367:+
THCA	cis	rs420259	0.516	rs120962	ENSG00000260136.4	CTD-2270L9.4	4.08	5.25e-05	0.00447	0.14	0.19	Bipolar disorder;	chr16:23578665	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs120961	ENSG00000260136.4	CTD-2270L9.4	4.08	5.25e-05	0.00447	0.14	0.19	Bipolar disorder;	chr16:23578981	chr16:23452758~23457606:+
THCA	cis	rs4819052	1	rs3746980	ENSG00000273796.1	LL21NC02-21A1.1	-4.08	5.25e-05	0.00447	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45403809~45404369:-
THCA	cis	rs10760158	0.769	rs10760162	ENSG00000226752.6	PSMD5-AS1	-4.08	5.25e-05	0.00447	-0.22	-0.19	Pulse pressure;	chr9:121242905	chr9:120824828~120854385:+
THCA	cis	rs2281603	0.762	rs10144661	ENSG00000272909.1	CTD-2555O16.4	-4.08	5.25e-05	0.00447	-0.24	-0.19	Lymphocyte counts;	chr14:64569651	chr14:64440369~64442238:-
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Body mass index;	chr17:30750419	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Body mass index;	chr17:30753533	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Body mass index;	chr17:30794616	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Body mass index;	chr17:30815122	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Body mass index;	chr17:30815823	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.25e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30726305~30727564:-
THCA	cis	rs7264396	0.887	rs736031	ENSG00000088340.14	FER1L4	4.08	5.25e-05	0.00447	0.17	0.19	Total cholesterol levels;	chr20:35460805	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs736032	ENSG00000088340.14	FER1L4	4.08	5.25e-05	0.00447	0.17	0.19	Total cholesterol levels;	chr20:35460841	chr20:35558737~35607562:-
THCA	cis	rs9595908	0.622	rs7983267	ENSG00000212293.1	SNORA16	4.08	5.25e-05	0.00447	0.22	0.19	Body mass index;	chr13:32806767	chr13:32420390~32420516:-
THCA	cis	rs4081724	0.565	rs7253994	ENSG00000267296.2	CEBPA-AS1	4.08	5.25e-05	0.00447	0.29	0.19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33314772	chr19:33302857~33305054:+
THCA	cis	rs6416877	0.921	rs6502685	ENSG00000277491.1	RP11-676J12.9	-4.08	5.25e-05	0.00447	-0.23	-0.19	Myeloid white cell count;	chr17:1431686	chr17:795306~795794:+
THCA	cis	rs1009077	0.627	rs10022664	ENSG00000260091.1	RP11-33B1.4	-4.08	5.25e-05	0.00447	-0.17	-0.19	Endometriosis;	chr4:119607886	chr4:119409333~119410233:+
THCA	cis	rs8024893	1	rs6493544	ENSG00000215302.7	CTD-3092A11.1	4.08	5.25e-05	0.00447	0.28	0.19	Red cell distribution width;	chr15:31245356	chr15:30470779~30507623:+
THCA	cis	rs7829975	0.539	rs71537846	ENSG00000254153.1	CTA-398F10.2	4.08	5.25e-05	0.00447	0.21	0.19	Mood instability;	chr8:8684610	chr8:8456909~8461337:-
THCA	cis	rs860295	0.812	rs4278368	ENSG00000160766.13	GBAP1	-4.08	5.25e-05	0.00447	-0.22	-0.19	Body mass index;	chr1:155752766	chr1:155213821~155227422:-
THCA	cis	rs2797160	0.547	rs9388442	ENSG00000226409.1	RP11-735G4.1	-4.08	5.25e-05	0.00447	-0.23	-0.19	Endometrial cancer;	chr6:125651462	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.515	rs9375409	ENSG00000226409.1	RP11-735G4.1	-4.08	5.25e-05	0.00447	-0.23	-0.19	Endometrial cancer;	chr6:125651652	chr6:125370211~125374324:-
THCA	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	4.08	5.25e-05	0.00447	0.15	0.19	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
THCA	cis	rs9467773	0.572	rs13213953	ENSG00000261353.1	CTA-14H9.5	-4.08	5.25e-05	0.00447	-0.19	-0.19	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26527063~26527404:+
THCA	cis	rs10421328	0.797	rs919778	ENSG00000271283.1	CTC-412M14.6	-4.08	5.25e-05	0.00447	-0.27	-0.19	Parental longevity (combined parental age at death);	chr19:19661913	chr19:19699203~19699409:-
THCA	cis	rs9341808	0.628	rs9294172	ENSG00000272129.1	RP11-250B2.6	4.08	5.25e-05	0.00447	0.23	0.19	Sitting height ratio;	chr6:80208844	chr6:80355424~80356859:+
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000265443.1	CTD-2349P21.6	-4.08	5.26e-05	0.00447	-0.31	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30726305~30727564:-
THCA	cis	rs7182948	0.957	rs78231345	ENSG00000259531.2	RP11-295H24.3	4.08	5.26e-05	0.00447	0.24	0.19	Lung adenocarcinoma;	chr15:49558138	chr15:49365124~49366685:-
THCA	cis	rs7182948	0.957	rs75129298	ENSG00000259531.2	RP11-295H24.3	4.08	5.26e-05	0.00447	0.24	0.19	Lung adenocarcinoma;	chr15:49561113	chr15:49365124~49366685:-
THCA	cis	rs9902453	0.817	rs67206808	ENSG00000263370.1	RP11-68I3.5	4.08	5.26e-05	0.00447	0.24	0.19	Coffee consumption (cups per day);	chr17:29863078	chr17:29639627~29640825:+
THCA	cis	rs9291683	0.62	rs717615	ENSG00000261490.1	RP11-448G15.3	4.08	5.26e-05	0.00447	0.12	0.19	Bone mineral density;	chr4:10103046	chr4:10068089~10073019:-
THCA	cis	rs2590942	0.506	rs1905978	ENSG00000227207.2	RPL31P12	4.08	5.26e-05	0.00447	0.31	0.19	Childhood body mass index;	chr1:72100117	chr1:72301472~72301829:+
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000280107.1	AL022393.9	-4.08	5.26e-05	0.00447	-0.18	-0.19	Pubertal anthropometrics;	chr6:28420988	chr6:28170845~28172521:+
THCA	cis	rs875971	0.502	rs2946580	ENSG00000273142.1	RP11-458F8.4	-4.08	5.26e-05	0.00447	-0.18	-0.19	Aortic root size;	chr7:66066855	chr7:66902857~66906297:+
THCA	cis	rs17685	0.743	rs10277259	ENSG00000230882.1	AC005077.14	4.08	5.26e-05	0.00447	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76173356	chr7:76071469~76074963:-
THCA	cis	rs3177980	0.564	rs2205846	ENSG00000239494.2	RN7SL333P	-4.08	5.26e-05	0.00447	-0.17	-0.19	Amyotrophic lateral sclerosis;	chr1:169796758	chr1:169859756~169860052:+
THCA	cis	rs7264396	0.887	rs8116304	ENSG00000088340.14	FER1L4	4.08	5.26e-05	0.00447	0.17	0.19	Total cholesterol levels;	chr20:35466584	chr20:35558737~35607562:-
THCA	cis	rs2299587	0.554	rs3853530	ENSG00000253671.1	RP11-806O11.1	-4.08	5.26e-05	0.00447	-0.22	-0.19	Economic and political preferences;	chr8:17890911	chr8:17808941~17820868:+
THCA	cis	rs13083990	0.919	rs3804590	ENSG00000272758.4	RP11-299J3.8	4.08	5.26e-05	0.00447	0.18	0.19	Cardiac Troponin-T levels;	chr3:122259226	chr3:122416207~122443180:+
THCA	cis	rs4713118	0.505	rs156740	ENSG00000176933.5	TOB2P1	-4.08	5.26e-05	0.00448	-0.2	-0.19	Parkinson's disease;	chr6:27992657	chr6:28217643~28218634:-
THCA	cis	rs7432375	0.933	rs55970317	ENSG00000273455.1	RP11-305O4.3	4.08	5.26e-05	0.00448	0.24	0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136634351	chr3:136087475~136087913:-
THCA	cis	rs9595908	0.709	rs2025473	ENSG00000212293.1	SNORA16	4.08	5.26e-05	0.00448	0.22	0.19	Body mass index;	chr13:32791632	chr13:32420390~32420516:-
THCA	cis	rs2474937	0.561	rs6428744	ENSG00000231365.4	RP11-418J17.1	4.08	5.26e-05	0.00448	0.18	0.19	Congenital heart malformation;	chr1:118382820	chr1:119140396~119275973:+
THCA	cis	rs2474937	0.561	rs4642877	ENSG00000231365.4	RP11-418J17.1	4.08	5.26e-05	0.00448	0.18	0.19	Congenital heart malformation;	chr1:118383032	chr1:119140396~119275973:+
THCA	cis	rs2474937	0.561	rs2359838	ENSG00000231365.4	RP11-418J17.1	4.08	5.26e-05	0.00448	0.18	0.19	Congenital heart malformation;	chr1:118383108	chr1:119140396~119275973:+
THCA	cis	rs5758659	0.652	rs133313	ENSG00000273366.1	CTA-989H11.1	-4.08	5.26e-05	0.00448	-0.22	-0.19	Cognitive function;	chr22:42005745	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.652	rs133314	ENSG00000273366.1	CTA-989H11.1	-4.08	5.26e-05	0.00448	-0.22	-0.19	Cognitive function;	chr22:42005837	chr22:42278188~42278846:+
THCA	cis	rs6845263	0.511	rs1365386	ENSG00000254531.1	FLJ20021	-4.08	5.26e-05	0.00448	-0.16	-0.19	Superior crus of antihelix expression;	chr4:101563119	chr4:101347780~101348883:+
THCA	cis	rs7474896	0.583	rs12776092	ENSG00000120555.12	SEPT7P9	4.08	5.26e-05	0.00448	0.24	0.19	Obesity (extreme);	chr10:37726867	chr10:38383069~38402916:-
THCA	cis	rs7474896	0.583	rs11011347	ENSG00000120555.12	SEPT7P9	4.08	5.26e-05	0.00448	0.24	0.19	Obesity (extreme);	chr10:37730336	chr10:38383069~38402916:-
THCA	cis	rs12591650	1	rs12591650	ENSG00000259591.1	RP11-554D20.1	4.08	5.26e-05	0.00448	0.27	0.19	Subcutaneous adipose tissue;	chr15:60768508	chr15:60763906~60765625:+
THCA	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	4.08	5.27e-05	0.00448	0.17	0.18	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
THCA	cis	rs7119038	0.818	rs6421571	ENSG00000255239.1	AP002954.6	4.08	5.27e-05	0.00448	0.28	0.18	Sjögren's syndrome;	chr11:118873063	chr11:118688039~118690600:-
THCA	cis	rs1371614	0.632	rs4665929	ENSG00000229122.1	AGBL5-IT1	-4.08	5.27e-05	0.00448	-0.14	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26932981	chr2:27061038~27061815:+
THCA	cis	rs12900463	0.813	rs306198	ENSG00000259728.4	LINC00933	-4.08	5.27e-05	0.00448	-0.25	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862138	chr15:84570649~84580175:+
THCA	cis	rs7264396	0.887	rs1570841	ENSG00000088340.14	FER1L4	4.08	5.27e-05	0.00448	0.17	0.18	Total cholesterol levels;	chr20:35460341	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs1886696	ENSG00000088340.14	FER1L4	4.08	5.27e-05	0.00448	0.17	0.18	Total cholesterol levels;	chr20:35467881	chr20:35558737~35607562:-
THCA	cis	rs9902453	0.967	rs4325622	ENSG00000263370.1	RP11-68I3.5	4.08	5.27e-05	0.00448	0.24	0.18	Coffee consumption (cups per day);	chr17:30199457	chr17:29639627~29640825:+
THCA	cis	rs7178375	1	rs11070678	ENSG00000269930.1	RP11-932O9.9	-4.08	5.27e-05	0.00448	-0.25	-0.18	Hypertriglyceridemia;	chr15:30927561	chr15:30616958~30617749:+
THCA	cis	rs17772222	0.582	rs1288122	ENSG00000222990.1	RNU4-22P	-4.08	5.27e-05	0.00448	-0.22	-0.18	Coronary artery calcification;	chr14:88472736	chr14:88513498~88513663:+
THCA	cis	rs5758659	1	rs5758659	ENSG00000273366.1	CTA-989H11.1	-4.08	5.27e-05	0.00448	-0.22	-0.18	Cognitive function;	chr22:42225997	chr22:42278188~42278846:+
THCA	cis	rs4604234	0.708	rs11961412	ENSG00000260645.1	RP11-250B2.5	-4.08	5.27e-05	0.00448	-0.3	-0.18	Cancer;	chr6:80342179	chr6:80466958~80469080:+
THCA	cis	rs11673344	0.633	rs519606	ENSG00000267260.1	CTD-2162K18.4	-4.08	5.27e-05	0.00448	-0.23	-0.18	Obesity-related traits;	chr19:36942327	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.67	rs35011739	ENSG00000267260.1	CTD-2162K18.4	-4.08	5.27e-05	0.00448	-0.23	-0.18	Obesity-related traits;	chr19:36943328	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.704	rs540451	ENSG00000267260.1	CTD-2162K18.4	-4.08	5.27e-05	0.00448	-0.23	-0.18	Obesity-related traits;	chr19:36944619	chr19:36773153~36777078:+
THCA	cis	rs13325613	0.834	rs41432345	ENSG00000223552.1	RP11-24F11.2	-4.08	5.27e-05	0.00448	-0.28	-0.18	Monocyte count;	chr3:46208883	chr3:46364955~46407059:-
THCA	cis	rs12681366	0.537	rs10095298	ENSG00000261437.1	RP11-22C11.2	4.08	5.27e-05	0.00448	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94472353	chr8:94637285~94639467:-
THCA	cis	rs8062405	0.698	rs7188071	ENSG00000270424.1	RP11-1348G14.6	-4.08	5.27e-05	0.00448	-0.23	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28749959~28750595:-
THCA	cis	rs8141529	0.748	rs5762882	ENSG00000226471.5	CTA-292E10.6	-4.08	5.27e-05	0.00449	-0.15	-0.18	Lymphocyte counts;	chr22:28894692	chr22:28800683~28848559:+
THCA	cis	rs8099594	0.565	rs4939849	ENSG00000266696.1	RP11-30L3.2	-4.08	5.27e-05	0.00449	-0.23	-0.18	Height;	chr18:49201252	chr18:49205912~49208781:+
THCA	cis	rs17027258	0.609	rs4851005	ENSG00000234389.1	AC007278.3	-4.08	5.28e-05	0.00449	-0.21	-0.18	White blood cell types;	chr2:102395092	chr2:102438713~102440475:+
THCA	cis	rs896854	0.552	rs2515236	ENSG00000253528.2	RP11-347C18.4	-4.08	5.28e-05	0.00449	-0.23	-0.18	Type 2 diabetes;	chr8:94922679	chr8:94974573~94974853:-
THCA	cis	rs7520050	0.807	rs4353138	ENSG00000280836.1	AL355480.1	4.08	5.28e-05	0.00449	0.23	0.18	Reticulocyte count;Red blood cell count;	chr1:45754131	chr1:45581219~45581321:-
THCA	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	4.08	5.28e-05	0.00449	0.14	0.18	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
THCA	cis	rs495337	0.76	rs6125813	ENSG00000229222.1	KRT18P4	-4.08	5.28e-05	0.00449	-0.23	-0.18	Psoriasis;	chr20:49924646	chr20:49956745~49958032:+
THCA	cis	rs758324	0.531	rs74698078	ENSG00000224431.1	AC063976.7	-4.08	5.28e-05	0.00449	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132078028	chr5:132199456~132203487:+
THCA	cis	rs7773456	0.576	rs6924929	ENSG00000227116.1	RP3-471C18.1	4.08	5.28e-05	0.00449	0.22	0.18	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19730427~19734567:-
THCA	cis	rs2562456	0.833	rs55875743	ENSG00000268117.1	VN1R84P	4.08	5.28e-05	0.00449	0.3	0.18	Pain;	chr19:21383393	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62110416	ENSG00000268117.1	VN1R84P	4.08	5.28e-05	0.00449	0.3	0.18	Pain;	chr19:21401924	chr19:21719801~21720035:-
THCA	cis	rs7923609	0.846	rs7896518	ENSG00000232075.1	MRPL35P2	-4.08	5.28e-05	0.00449	-0.24	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63344740	chr10:63634317~63634827:-
THCA	cis	rs17772222	0.655	rs816072	ENSG00000222990.1	RNU4-22P	-4.08	5.28e-05	0.00449	-0.22	-0.18	Coronary artery calcification;	chr14:88484335	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.655	rs1152376	ENSG00000222990.1	RNU4-22P	-4.08	5.28e-05	0.00449	-0.22	-0.18	Coronary artery calcification;	chr14:88495121	chr14:88513498~88513663:+
THCA	cis	rs1950832	0.689	rs712407	ENSG00000258636.1	CTD-2298J14.2	4.08	5.28e-05	0.00449	0.24	0.18	Urate levels in obese individuals;	chr14:41648171	chr14:41587861~41604856:-
THCA	cis	rs10895987	0.531	rs7943007	ENSG00000255200.1	AP003068.18	-4.08	5.28e-05	0.00449	-0.25	-0.18	Blood protein levels;	chr11:65089626	chr11:65174117~65176470:-
THCA	cis	rs701145	0.585	rs62276842	ENSG00000243069.6	ARHGEF26-AS1	-4.08	5.28e-05	0.00449	-0.32	-0.18	Coronary artery disease;	chr3:154066259	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1612933	ENSG00000243069.6	ARHGEF26-AS1	-4.08	5.28e-05	0.00449	-0.32	-0.18	Coronary artery disease;	chr3:154068330	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713843	ENSG00000243069.6	ARHGEF26-AS1	-4.08	5.28e-05	0.00449	-0.32	-0.18	Coronary artery disease;	chr3:154068605	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1620712	ENSG00000243069.6	ARHGEF26-AS1	4.08	5.28e-05	0.00449	0.32	0.18	Coronary artery disease;	chr3:154072261	chr3:154024401~154121332:-
THCA	cis	rs10155981	0.85	rs7801617	ENSG00000179428.2	AC073072.5	-4.08	5.28e-05	0.00449	-0.28	-0.18	Bilirubin levels;	chr7:22718463	chr7:22725395~22727620:-
THCA	cis	rs4266290	0.542	rs10516292	ENSG00000214846.4	RP11-115L11.1	4.08	5.28e-05	0.00449	0.27	0.18	Parkinson's disease;	chr4:15748080	chr4:15730962~15731627:-
THCA	cis	rs10043228	0.702	rs2068456	ENSG00000250015.1	CTC-339F2.2	4.08	5.28e-05	0.00449	0.23	0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116291873	chr5:116302354~116304134:-
THCA	cis	rs1204798	0.541	rs57296292	ENSG00000237021.2	RP3-486I3.7	-4.08	5.29e-05	0.00449	-0.24	-0.18	Dental caries;	chr6:116140451	chr6:116254207~116256743:+
THCA	cis	rs972578	0.765	rs4820499	ENSG00000274717.1	RP1-47A17.1	-4.08	5.29e-05	0.00449	-0.19	-0.18	Mean platelet volume;	chr22:42979135	chr22:42791814~42794313:-
THCA	cis	rs10761482	0.69	rs4406773	ENSG00000254271.1	RP11-131N11.4	4.08	5.29e-05	0.00449	0.25	0.18	Schizophrenia;	chr10:60344816	chr10:60734342~60741828:+
THCA	cis	rs9435732	0.778	rs3738815	ENSG00000235241.1	RP11-108M9.5	4.08	5.29e-05	0.00449	0.24	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16988207	chr1:16889095~16889602:+
THCA	cis	rs4788570	0.615	rs889568	ENSG00000260593.1	RP11-432I5.2	-4.08	5.29e-05	0.00449	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71738496	chr16:71623708~71626816:-
THCA	cis	rs860295	1	rs822478	ENSG00000236675.1	MTX1P1	4.08	5.29e-05	0.00449	0.18	0.18	Body mass index;	chr1:155824178	chr1:155230975~155234325:+
THCA	cis	rs853679	0.825	rs8180562	ENSG00000273712.1	RP5-874C20.7	4.08	5.29e-05	0.00449	0.32	0.18	Depression;	chr6:28173682	chr6:28315613~28315883:-
THCA	cis	rs853679	0.882	rs9380064	ENSG00000273712.1	RP5-874C20.7	4.08	5.29e-05	0.00449	0.32	0.18	Depression;	chr6:28175340	chr6:28315613~28315883:-
THCA	cis	rs12478296	1	rs113129906	ENSG00000261186.2	RP11-341N2.1	-4.08	5.29e-05	0.00449	-0.32	-0.18	Obesity-related traits;	chr2:242062102	chr2:242087351~242088457:-
THCA	cis	rs6570726	0.791	rs400329	ENSG00000270638.1	RP3-466P17.1	4.08	5.29e-05	0.00449	0.15	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.791	rs435671	ENSG00000270638.1	RP3-466P17.1	4.08	5.29e-05	0.00449	0.15	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.764	rs367065	ENSG00000270638.1	RP3-466P17.1	4.08	5.29e-05	0.00449	0.15	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145735570~145737218:+
THCA	cis	rs9863	0.804	rs80270210	ENSG00000270061.1	RP11-214K3.19	-4.08	5.29e-05	0.00449	-0.25	-0.18	White blood cell count;	chr12:123962850	chr12:123969990~123970344:-
THCA	cis	rs10760158	0.832	rs13292100	ENSG00000226752.6	PSMD5-AS1	-4.08	5.29e-05	0.0045	-0.22	-0.18	Pulse pressure;	chr9:121278719	chr9:120824828~120854385:+
THCA	cis	rs2333194	0.875	rs10220356	ENSG00000258695.2	RP3-414A15.2	4.08	5.29e-05	0.0045	0.22	0.18	Bipolar disorder with mood-incongruent psychosis;	chr14:73342768	chr14:73522878~73530610:+
THCA	cis	rs4218	0.638	rs12437587	ENSG00000259732.1	RP11-59H7.3	-4.08	5.29e-05	0.0045	-0.25	-0.18	Social communication problems;	chr15:59072785	chr15:59121034~59133250:+
THCA	cis	rs11671005	0.656	rs11672609	ENSG00000252334.1	RNU6-1337P	4.08	5.29e-05	0.0045	0.29	0.18	Mean platelet volume;	chr19:58495557	chr19:58483749~58483843:-
THCA	cis	rs9717605	1	rs73046034	ENSG00000226445.1	XXyac-YX65C7_A.2	4.08	5.29e-05	0.0045	0.23	0.18	Left atrial antero-posterior diameter;	chr6:169252164	chr6:169213254~169239565:+
THCA	cis	rs9717605	1	rs9717605	ENSG00000226445.1	XXyac-YX65C7_A.2	4.08	5.29e-05	0.0045	0.23	0.18	Left atrial antero-posterior diameter;	chr6:169252297	chr6:169213254~169239565:+
THCA	cis	rs5758659	0.569	rs133294	ENSG00000205702.9	CYP2D7	4.08	5.29e-05	0.0045	0.14	0.18	Cognitive function;	chr22:41986801	chr22:42140203~42144577:-
THCA	cis	rs453301	0.631	rs11779804	ENSG00000233609.3	RP11-62H7.2	-4.08	5.29e-05	0.0045	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8940442	chr8:8961200~8979025:+
THCA	cis	rs5758511	0.68	rs5758692	ENSG00000227370.1	RP4-669P10.19	4.08	5.29e-05	0.0045	0.2	0.18	Birth weight;	chr22:42273023	chr22:42132543~42132998:+
THCA	cis	rs7951911	1	rs966904	ENSG00000254427.1	RP11-430H10.1	4.08	5.29e-05	0.0045	0.29	0.18	IgG glycosylation;	chr11:45083252	chr11:45355371~45366121:+
THCA	cis	rs2039553	0.583	rs2329137	ENSG00000227354.5	RBM26-AS1	-4.08	5.29e-05	0.0045	-0.17	-0.18	Pancreatic cancer;	chr13:79763536	chr13:79406309~79424328:+
THCA	cis	rs7267979	1	rs2500424	ENSG00000276952.1	RP5-965G21.6	-4.08	5.29e-05	0.0045	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25284915~25285588:-
THCA	cis	rs7737355	0.773	rs31252	ENSG00000237714.1	P4HA2-AS1	4.08	5.29e-05	0.0045	0.25	0.18	Life satisfaction;	chr5:131497740	chr5:132184876~132192808:+
THCA	cis	rs950776	0.518	rs11632604	ENSG00000261762.1	RP11-650L12.2	4.08	5.3e-05	0.0045	0.23	0.18	Sudden cardiac arrest;	chr15:78529572	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12910289	ENSG00000261762.1	RP11-650L12.2	4.08	5.3e-05	0.0045	0.23	0.18	Sudden cardiac arrest;	chr15:78529723	chr15:78589123~78591276:-
THCA	cis	rs8031584	0.918	rs34095794	ENSG00000270015.1	RP11-540B6.6	-4.08	5.3e-05	0.0045	-0.14	-0.18	Huntington's disease progression;	chr15:30977488	chr15:30926514~30928407:+
THCA	cis	rs9810089	0.934	rs1153877	ENSG00000273455.1	RP11-305O4.3	4.08	5.3e-05	0.0045	0.24	0.18	Gestational age at birth (child effect);	chr3:136286083	chr3:136087475~136087913:-
THCA	cis	rs7178424	0.742	rs12911564	ENSG00000259251.2	RP11-643M14.1	4.08	5.3e-05	0.0045	0.18	0.18	Height;	chr15:61919777	chr15:62060503~62062434:+
THCA	cis	rs875971	1	rs875971	ENSG00000230189.5	GS1-124K5.2	-4.08	5.3e-05	0.0045	-0.12	-0.18	Aortic root size;	chr7:66152608	chr7:66409143~66490059:-
THCA	cis	rs10844706	0.699	rs10844633	ENSG00000214776.8	RP11-726G1.1	4.08	5.3e-05	0.0045	0.24	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734790	chr12:9467552~9576275:+
THCA	cis	rs7521902	0.614	rs3820282	ENSG00000228397.1	RP1-224A6.3	-4.08	5.3e-05	0.0045	-0.34	-0.18	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22141722	chr1:22023994~22024968:-
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000182586.6	LINC00334	-4.08	5.3e-05	0.0045	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45234340~45258730:+
THCA	cis	rs5751901	1	rs5751901	ENSG00000225098.1	BCRP1	-4.08	5.3e-05	0.0045	-0.21	-0.18	Protein quantitative trait loci;	chr22:24596299	chr22:24259929~24263764:-
THCA	cis	rs7551222	0.752	rs12138846	ENSG00000240219.1	RP11-430C7.5	4.08	5.3e-05	0.0045	0.17	0.18	Schizophrenia;	chr1:204587350	chr1:204626775~204629712:+
THCA	cis	rs2380205	0.651	rs1512694	ENSG00000232807.2	RP11-536K7.3	4.08	5.3e-05	0.0045	0.17	0.18	Breast cancer;	chr10:5874808	chr10:5934270~5945900:-
THCA	cis	rs6878727	0.552	rs161008	ENSG00000253807.4	LINC01170	4.08	5.3e-05	0.0045	0.18	0.18	Breast cancer;	chr5:124344459	chr5:124059794~124405079:-
THCA	cis	rs720064	0.586	rs891282	ENSG00000264745.1	TTC39C-AS1	4.08	5.3e-05	0.0045	0.2	0.18	Strep throat;	chr18:23959096	chr18:23994213~24015339:-
THCA	cis	rs2164273	0.528	rs3824212	ENSG00000154316.13	TDH	-4.08	5.3e-05	0.00451	-0.14	-0.18	Extraversion;	chr8:11285409	chr8:11339637~11368452:+
THCA	cis	rs12682352	0.579	rs7006589	ENSG00000248538.5	RP11-10A14.5	-4.08	5.3e-05	0.00451	-0.24	-0.18	Neuroticism;	chr8:8810976	chr8:9189011~9202854:+
THCA	cis	rs1003719	0.843	rs1003721	ENSG00000230366.8	DSCR9	-4.08	5.3e-05	0.00451	-0.19	-0.18	Eye color traits;	chr21:37120357	chr21:37208503~37221736:+
THCA	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	4.08	5.3e-05	0.00451	0.22	0.18	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
THCA	cis	rs481331	0.932	rs210228	ENSG00000215146.4	RP11-313J2.1	-4.08	5.3e-05	0.00451	-0.29	-0.18	Systemic juvenile idiopathic arthritis;	chr10:42507610	chr10:42331866~42367974:-
THCA	cis	rs7819412	0.775	rs4841490	ENSG00000261451.1	RP11-981G7.1	-4.08	5.3e-05	0.00451	-0.23	-0.18	Triglycerides;	chr8:11079381	chr8:10433672~10438312:+
THCA	cis	rs911555	0.755	rs8016676	ENSG00000269910.1	RP11-73M18.10	-4.08	5.31e-05	0.00451	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103694516~103695050:-
THCA	cis	rs67981189	0.865	rs2810071	ENSG00000269927.1	RP6-91H8.3	-4.08	5.31e-05	0.00451	-0.21	-0.18	Schizophrenia;	chr14:70920931	chr14:71141125~71143253:-
THCA	cis	rs2692947	0.537	rs12478605	ENSG00000235959.1	AC009237.17	-4.08	5.31e-05	0.00451	-0.2	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95711330	chr2:95640181~95640604:-
THCA	cis	rs12935229	0.756	rs34617072	ENSG00000260922.1	RP11-538I12.3	-4.08	5.31e-05	0.00451	-0.29	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77276048	chr16:77234877~77290934:+
THCA	cis	rs17221829	0.733	rs10765227	ENSG00000280385.1	AP000648.5	-4.08	5.31e-05	0.00451	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89651948	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs10765228	ENSG00000280385.1	AP000648.5	-4.08	5.31e-05	0.00451	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89651964	chr11:90193614~90198120:+
THCA	cis	rs7045881	0.733	rs10511791	ENSG00000254396.1	RP11-56F10.3	-4.08	5.31e-05	0.00451	-0.3	-0.18	Schizophrenia;	chr9:26878376	chr9:27102630~27104728:+
THCA	cis	rs150992	0.587	rs10040066	ENSG00000246763.5	RGMB-AS1	-4.08	5.31e-05	0.00451	-0.19	-0.18	Body mass index;	chr5:99001333	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs4565239	ENSG00000246763.5	RGMB-AS1	-4.08	5.31e-05	0.00451	-0.19	-0.18	Body mass index;	chr5:99002144	chr5:98769618~98773469:-
THCA	cis	rs2933343	0.679	rs789254	ENSG00000231305.3	RP11-723O4.2	4.08	5.31e-05	0.00451	0.2	0.18	IgG glycosylation;	chr3:128855750	chr3:128861313~128871540:-
THCA	cis	rs79478560	0.518	rs75454973	ENSG00000270061.1	RP11-214K3.19	-4.08	5.31e-05	0.00451	-0.24	-0.18	Lymphocyte counts;	chr12:123899017	chr12:123969990~123970344:-
THCA	cis	rs62158800	0.925	rs62158828	ENSG00000224568.1	AC096669.3	4.08	5.31e-05	0.00451	0.36	0.18	Facial morphology (factor 22);	chr2:107628364	chr2:107529487~107556326:+
THCA	cis	rs1560104	0.576	rs7186154	ENSG00000260601.1	RP11-552C15.1	-4.08	5.31e-05	0.00451	-0.22	-0.18	Obesity-related traits;	chr16:12615650	chr16:12545482~12546684:+
THCA	cis	rs11694172	0.955	rs35581848	ENSG00000273456.1	RP11-686O6.2	4.08	5.31e-05	0.00451	0.17	0.18	Cholesterol, total;	chr2:202718673	chr2:202374932~202375604:-
THCA	cis	rs11694172	0.955	rs62194147	ENSG00000273456.1	RP11-686O6.2	4.08	5.31e-05	0.00451	0.17	0.18	Cholesterol, total;	chr2:202720225	chr2:202374932~202375604:-
THCA	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-4.08	5.31e-05	0.00451	-0.15	-0.18	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
THCA	cis	rs7267979	0.509	rs6115218	ENSG00000274414.1	RP5-965G21.4	-4.08	5.32e-05	0.00452	-0.25	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25239007~25245229:-
THCA	cis	rs12478296	1	rs56162244	ENSG00000220804.7	AC093642.5	4.08	5.32e-05	0.00452	0.2	0.18	Obesity-related traits;	chr2:242076539	chr2:242088633~242160153:+
THCA	cis	rs4660214	0.666	rs4660550	ENSG00000182109.6	RP11-69E11.4	-4.08	5.32e-05	0.00452	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39522280~39546187:-
THCA	cis	rs6088813	1	rs6142360	ENSG00000279253.1	RP4-614O4.13	4.08	5.32e-05	0.00452	0.18	0.18	Height;	chr20:35372683	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs725908	ENSG00000279253.1	RP4-614O4.13	4.08	5.32e-05	0.00452	0.18	0.18	Height;	chr20:35380264	chr20:35262727~35264187:-
THCA	cis	rs7927592	0.913	rs7116994	ENSG00000160172.9	FAM86C2P	4.08	5.32e-05	0.00452	0.18	0.18	Total body bone mineral density;	chr11:68487159	chr11:67791648~67805336:-
THCA	cis	rs875971	1	rs2420591	ENSG00000230189.5	GS1-124K5.2	4.08	5.32e-05	0.00452	0.12	0.18	Aortic root size;	chr7:66447394	chr7:66409143~66490059:-
THCA	cis	rs7680126	0.633	rs4697975	ENSG00000261490.1	RP11-448G15.3	-4.08	5.32e-05	0.00452	-0.15	-0.18	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10208342	chr4:10068089~10073019:-
THCA	cis	rs875971	0.638	rs7793569	ENSG00000229180.5	GS1-124K5.11	-4.08	5.32e-05	0.00452	-0.13	-0.18	Aortic root size;	chr7:66651646	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs6975195	ENSG00000229180.5	GS1-124K5.11	-4.08	5.32e-05	0.00452	-0.13	-0.18	Aortic root size;	chr7:66659787	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs3857688	ENSG00000229180.5	GS1-124K5.11	-4.08	5.32e-05	0.00452	-0.13	-0.18	Aortic root size;	chr7:66662819	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs2286684	ENSG00000229180.5	GS1-124K5.11	-4.08	5.32e-05	0.00452	-0.13	-0.18	Aortic root size;	chr7:66664843	chr7:66526088~66542624:-
THCA	cis	rs801193	0.935	rs2286683	ENSG00000229180.5	GS1-124K5.11	-4.08	5.32e-05	0.00452	-0.13	-0.18	Aortic root size;	chr7:66664856	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs10274773	ENSG00000229180.5	GS1-124K5.11	-4.08	5.32e-05	0.00452	-0.13	-0.18	Aortic root size;	chr7:66668591	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs11773829	ENSG00000229180.5	GS1-124K5.11	-4.08	5.32e-05	0.00452	-0.13	-0.18	Aortic root size;	chr7:66676087	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs7788576	ENSG00000229180.5	GS1-124K5.11	-4.08	5.32e-05	0.00452	-0.13	-0.18	Aortic root size;	chr7:66683315	chr7:66526088~66542624:-
THCA	cis	rs801193	0.935	rs2659916	ENSG00000229180.5	GS1-124K5.11	4.08	5.32e-05	0.00452	0.13	0.18	Aortic root size;	chr7:66686365	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs6958520	ENSG00000229180.5	GS1-124K5.11	4.08	5.32e-05	0.00452	0.13	0.18	Aortic root size;	chr7:66686466	chr7:66526088~66542624:-
THCA	cis	rs801193	0.967	rs2707849	ENSG00000229180.5	GS1-124K5.11	4.08	5.32e-05	0.00452	0.13	0.18	Aortic root size;	chr7:66687725	chr7:66526088~66542624:-
THCA	cis	rs8006682	0.536	rs2180611	ENSG00000259038.1	CTD-2325P2.4	4.08	5.32e-05	0.00452	0.2	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68653768	chr14:68627166~68628445:-
THCA	cis	rs7487075	0.78	rs12307969	ENSG00000272369.1	RP11-446N19.1	4.08	5.32e-05	0.00452	0.14	0.18	Itch intensity from mosquito bite;	chr12:46365274	chr12:46537502~46652550:+
THCA	cis	rs7200543	1	rs35574015	ENSG00000188599.16	NPIPP1	-4.08	5.32e-05	0.00452	-0.15	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:15104312~15123498:-
THCA	cis	rs6600671	1	rs2185281	ENSG00000275585.1	CH17-118O6.3	-4.08	5.32e-05	0.00452	-0.22	-0.18	Hip geometry;	chr1:121438132	chr1:120985692~121052167:-
THCA	cis	rs2980439	0.525	rs1850511	ENSG00000233609.3	RP11-62H7.2	4.08	5.32e-05	0.00452	0.18	0.18	Neuroticism;	chr8:8312807	chr8:8961200~8979025:+
THCA	cis	rs7045881	0.735	rs7040516	ENSG00000254396.1	RP11-56F10.3	4.08	5.32e-05	0.00452	0.24	0.18	Schizophrenia;	chr9:26897274	chr9:27102630~27104728:+
THCA	cis	rs1198430	0.568	rs1119439	ENSG00000232482.2	RP4-654C18.1	-4.08	5.33e-05	0.00452	-0.32	-0.18	Total cholesterol levels;	chr1:23502412	chr1:23410832~23412146:+
THCA	cis	rs2434529	1	rs56964148	ENSG00000245275.6	SAP30L-AS1	4.08	5.33e-05	0.00452	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154271792	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs6881721	ENSG00000245275.6	SAP30L-AS1	4.08	5.33e-05	0.00452	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154272007	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs7708102	ENSG00000245275.6	SAP30L-AS1	4.08	5.33e-05	0.00452	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154278309	chr5:154329437~154445850:-
THCA	cis	rs2749592	0.55	rs7917262	ENSG00000276805.1	RP11-291L22.6	-4.08	5.33e-05	0.00452	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38451030~38451785:+
THCA	cis	rs2749592	0.55	rs9733309	ENSG00000276805.1	RP11-291L22.6	-4.08	5.33e-05	0.00452	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38451030~38451785:+
THCA	cis	rs4788570	0.584	rs6499530	ENSG00000260593.1	RP11-432I5.2	-4.08	5.33e-05	0.00452	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71689186	chr16:71623708~71626816:-
THCA	cis	rs2933343	0.679	rs789221	ENSG00000231305.3	RP11-723O4.2	4.08	5.33e-05	0.00452	0.2	0.18	IgG glycosylation;	chr3:128872782	chr3:128861313~128871540:-
THCA	cis	rs4934494	0.677	rs11185804	ENSG00000240996.1	RP11-80H5.7	4.08	5.33e-05	0.00452	0.21	0.18	Red blood cell count;	chr10:89619336	chr10:89694295~89697928:-
THCA	cis	rs9400467	0.6	rs4521634	ENSG00000255389.1	C6orf3	-4.08	5.33e-05	0.00453	-0.2	-0.18	Amino acid levels;Blood metabolite levels;	chr6:111523908	chr6:111599875~111602295:+
THCA	cis	rs4805272	0.626	rs6509072	ENSG00000267799.1	MAN1A2P1	4.08	5.33e-05	0.00453	0.22	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840796	chr19:28790812~28792871:-
THCA	cis	rs7829975	0.711	rs4841051	ENSG00000233609.3	RP11-62H7.2	-4.08	5.33e-05	0.00453	-0.18	-0.18	Mood instability;	chr8:8828136	chr8:8961200~8979025:+
THCA	cis	rs801193	0.591	rs2707839	ENSG00000230189.5	GS1-124K5.2	4.08	5.33e-05	0.00453	0.12	0.18	Aortic root size;	chr7:66728097	chr7:66409143~66490059:-
THCA	cis	rs2717559	0.683	rs2717611	ENSG00000253741.1	CTD-2292P10.4	4.08	5.33e-05	0.00453	0.23	0.18	Urinary tract infection frequency;	chr8:142798511	chr8:142702252~142726973:-
THCA	cis	rs9595908	0.746	rs12427832	ENSG00000212293.1	SNORA16	-4.08	5.33e-05	0.00453	-0.22	-0.18	Body mass index;	chr13:32644896	chr13:32420390~32420516:-
THCA	cis	rs17221829	0.733	rs11018726	ENSG00000280385.1	AP000648.5	-4.08	5.33e-05	0.00453	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89680097	chr11:90193614~90198120:+
THCA	cis	rs9500256	0.903	rs726783	ENSG00000239650.4	GUSBP4	4.08	5.33e-05	0.00453	0.18	0.18	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57919784~57930291:-
THCA	cis	rs4950322	0.58	rs2014106	ENSG00000180867.10	PDIA3P1	4.08	5.33e-05	0.00453	0.18	0.18	Protein quantitative trait loci;	chr1:147118499	chr1:147178113~147179622:+
THCA	cis	rs875971	0.793	rs460678	ENSG00000229886.1	RP5-1132H15.3	4.08	5.33e-05	0.00453	0.2	0.18	Aortic root size;	chr7:66062213	chr7:66025126~66031544:-
THCA	cis	rs1046896	0.594	rs8070403	ENSG00000263063.1	RP11-388C12.1	-4.08	5.33e-05	0.00453	-0.24	-0.18	Glycated hemoglobin levels;	chr17:82907528	chr17:82713908~82716255:-
THCA	cis	rs42648	0.935	rs42664	ENSG00000225498.1	AC002064.5	4.08	5.34e-05	0.00453	0.19	0.18	Homocysteine levels;	chr7:90355095	chr7:90312496~90322592:+
THCA	cis	rs7616559	0.849	rs4680333	ENSG00000244515.1	KRT18P34	-4.08	5.34e-05	0.00453	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157038573	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.849	rs10936057	ENSG00000244515.1	KRT18P34	-4.08	5.34e-05	0.00453	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157040868	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.849	rs9838466	ENSG00000244515.1	KRT18P34	-4.08	5.34e-05	0.00453	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157042387	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.849	rs4680334	ENSG00000244515.1	KRT18P34	-4.08	5.34e-05	0.00453	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157043933	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.849	rs2321459	ENSG00000244515.1	KRT18P34	-4.08	5.34e-05	0.00453	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157045097	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.849	rs1351654	ENSG00000244515.1	KRT18P34	-4.08	5.34e-05	0.00453	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157046862	chr3:157162663~157163932:-
THCA	cis	rs8020441	0.945	rs4259956	ENSG00000269906.1	RP11-248J18.2	4.08	5.34e-05	0.00453	0.26	0.18	Cognitive performance;	chr14:50703459	chr14:50662511~50663178:-
THCA	cis	rs2688482	0.512	rs3103953	ENSG00000207650.1	MIR570	-4.08	5.34e-05	0.00453	-0.25	-0.18	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195699401~195699497:+
THCA	cis	rs7829975	0.688	rs6601703	ENSG00000233609.3	RP11-62H7.2	4.08	5.34e-05	0.00453	0.18	0.18	Mood instability;	chr8:8522714	chr8:8961200~8979025:+
THCA	cis	rs2777491	0.789	rs316617	ENSG00000247556.5	OIP5-AS1	-4.08	5.34e-05	0.00453	-0.15	-0.18	Ulcerative colitis;	chr15:41503702	chr15:41283990~41309737:+
THCA	cis	rs7255066	0.597	rs2301275	ENSG00000279095.1	AC092066.1	4.08	5.34e-05	0.00453	0.23	0.18	Multiple sclerosis;	chr19:44643329	chr19:44664131~44666158:+
THCA	cis	rs7520050	0.778	rs3014238	ENSG00000280836.1	AL355480.1	4.08	5.34e-05	0.00453	0.22	0.18	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45581219~45581321:-
THCA	cis	rs6942407	0.546	rs6465093	ENSG00000224046.1	AC005076.5	-4.08	5.34e-05	0.00453	-0.18	-0.18	Food allergy;	chr7:87135561	chr7:87151423~87152420:-
THCA	cis	rs4761470	0.577	rs7302972	ENSG00000258365.1	RP11-1105G2.3	-4.08	5.34e-05	0.00453	-0.21	-0.18	Estradiol plasma levels (breast cancer);	chr12:94288831	chr12:94277758~94282844:-
THCA	cis	rs4767841	0.598	rs203368	ENSG00000248636.5	RP11-768F21.1	-4.08	5.34e-05	0.00453	-0.19	-0.18	Urgency urinary incontinence;	chr12:119778553	chr12:119387987~119668079:-
THCA	cis	rs9435732	0.54	rs9325647	ENSG00000235241.1	RP11-108M9.5	4.08	5.34e-05	0.00454	0.23	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17039305	chr1:16889095~16889602:+
THCA	cis	rs9435732	0.504	rs9787230	ENSG00000235241.1	RP11-108M9.5	4.08	5.34e-05	0.00454	0.23	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17044475	chr1:16889095~16889602:+
THCA	cis	rs763121	0.813	rs4821807	ENSG00000273076.1	RP3-508I15.22	4.08	5.34e-05	0.00454	0.18	0.18	Menopause (age at onset);	chr22:38669577	chr22:38743495~38743910:+
THCA	cis	rs8177876	0.597	rs2317085	ENSG00000261838.4	RP11-303E16.6	-4.08	5.34e-05	0.00454	-0.34	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104460	chr16:81069854~81076598:+
THCA	cis	rs8062405	0.721	rs151303	ENSG00000270424.1	RP11-1348G14.6	4.08	5.34e-05	0.00454	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28749959~28750595:-
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000182586.6	LINC00334	-4.08	5.34e-05	0.00454	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45234340~45258730:+
THCA	cis	rs7296418	0.961	rs1727307	ENSG00000256092.2	RP13-942N8.1	4.08	5.34e-05	0.00454	0.13	0.18	Platelet count;	chr12:123091195	chr12:123363868~123366113:+
THCA	cis	rs3892630	0.817	rs35408716	ENSG00000267475.1	CTD-2538C1.2	-4.08	5.34e-05	0.00454	-0.27	-0.18	Red blood cell traits;	chr19:32697055	chr19:32687089~32691750:-
THCA	cis	rs3892630	0.878	rs66788054	ENSG00000267475.1	CTD-2538C1.2	-4.08	5.34e-05	0.00454	-0.27	-0.18	Red blood cell traits;	chr19:32699240	chr19:32687089~32691750:-
THCA	cis	rs3892630	0.878	rs8112955	ENSG00000267475.1	CTD-2538C1.2	-4.08	5.34e-05	0.00454	-0.27	-0.18	Red blood cell traits;	chr19:32700286	chr19:32687089~32691750:-
THCA	cis	rs6878727	0.626	rs256857	ENSG00000253807.4	LINC01170	4.08	5.34e-05	0.00454	0.16	0.18	Breast cancer;	chr5:124324131	chr5:124059794~124405079:-
THCA	cis	rs7129556	0.728	rs628668	ENSG00000254459.1	RP11-91P24.7	4.08	5.34e-05	0.00454	0.23	0.18	Weight loss (gastric bypass surgery);	chr11:77866448	chr11:77829654~77872262:-
THCA	cis	rs8141529	0.843	rs1065497	ENSG00000272858.1	CTA-292E10.8	-4.08	5.35e-05	0.00454	-0.2	-0.18	Lymphocyte counts;	chr22:28884003	chr22:28814914~28815662:+
THCA	cis	rs7045881	0.733	rs59100252	ENSG00000254396.1	RP11-56F10.3	4.08	5.35e-05	0.00454	0.31	0.18	Schizophrenia;	chr9:26944083	chr9:27102630~27104728:+
THCA	cis	rs7550636	1	rs7534380	ENSG00000276735.1	Metazoa_SRP	4.08	5.35e-05	0.00454	0.23	0.18	Coronary artery calcification;	chr1:192836860	chr1:193236794~193237107:-
THCA	cis	rs6847067	0.965	rs2046402	ENSG00000180769.7	WDFY3-AS2	4.08	5.35e-05	0.00454	0.13	0.18	Oropharynx cancer;	chr4:84841232	chr4:84965682~85011277:+
THCA	cis	rs6479891	1	rs4747045	ENSG00000272767.1	JMJD1C-AS1	4.08	5.35e-05	0.00454	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs4466712	ENSG00000272767.1	JMJD1C-AS1	4.08	5.35e-05	0.00454	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63465229~63466563:+
THCA	cis	rs9677476	0.517	rs62197322	ENSG00000224376.1	AC017104.6	4.08	5.35e-05	0.00454	0.19	0.18	Food antigen IgG levels;	chr2:231196806	chr2:231388976~231394991:+
THCA	cis	rs9595908	0.709	rs9285092	ENSG00000212293.1	SNORA16	4.08	5.35e-05	0.00454	0.22	0.18	Body mass index;	chr13:32745496	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.709	rs4942867	ENSG00000212293.1	SNORA16	4.08	5.35e-05	0.00454	0.22	0.18	Body mass index;	chr13:32745916	chr13:32420390~32420516:-
THCA	cis	rs2455799	0.573	rs2255248	ENSG00000270409.1	RP11-44D5.1	4.08	5.35e-05	0.00454	0.2	0.18	Mean platelet volume;	chr3:15713342	chr3:15732252~15733470:+
THCA	cis	rs1836229	0.874	rs10739173	ENSG00000225706.1	PTPRD-AS1	-4.08	5.35e-05	0.00454	-0.22	-0.18	Restless legs syndrome;	chr9:8827060	chr9:8858130~8862255:+
THCA	cis	rs919433	0.679	rs6719832	ENSG00000231621.1	AC013264.2	4.08	5.35e-05	0.00454	0.2	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197668645	chr2:197197991~197199273:+
THCA	cis	rs13108904	0.65	rs3796618	ENSG00000254094.1	AC078852.1	-4.08	5.35e-05	0.00454	-0.21	-0.18	Obesity-related traits;	chr4:1355814	chr4:1356581~1358075:+
THCA	cis	rs494526	0.868	rs1397617	ENSG00000229272.1	RP11-498J9.2	-4.08	5.35e-05	0.00454	-0.21	-0.18	Alcoholic chronic pancreatitis;	chr10:119073292	chr10:119003536~119003884:-
THCA	cis	rs150992	0.632	rs1472622	ENSG00000246763.5	RGMB-AS1	-4.08	5.35e-05	0.00454	-0.19	-0.18	Body mass index;	chr5:99000749	chr5:98769618~98773469:-
THCA	cis	rs73230612	1	rs7643617	ENSG00000242767.1	ZBTB20-AS4	4.08	5.35e-05	0.00454	0.25	0.18	Type 2 diabetes;	chr3:115034231	chr3:115100423~115103061:+
THCA	cis	rs804280	0.542	rs35647515	ENSG00000206014.6	OR7E161P	-4.08	5.35e-05	0.00454	-0.22	-0.18	Myopia (pathological);	chr8:11934120	chr8:11928597~11929563:-
THCA	cis	rs2915864	0.718	rs2906072	ENSG00000280047.1	CTC-463A16.1	4.08	5.35e-05	0.00454	0.25	0.18	Facial morphology (factor 20);	chr5:142197921	chr5:142165767~142168387:+
THCA	cis	rs71520386	0.632	rs2286509	ENSG00000226329.2	AC005682.6	-4.08	5.35e-05	0.00454	-0.24	-0.18	Fibrinogen levels;	chr7:22814832	chr7:22863874~22881350:-
THCA	cis	rs9435732	0.778	rs9435665	ENSG00000235241.1	RP11-108M9.5	4.08	5.35e-05	0.00454	0.24	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16998042	chr1:16889095~16889602:+
THCA	cis	rs17382723	0.887	rs78834190	ENSG00000229996.1	AC093585.6	4.08	5.35e-05	0.00454	0.24	0.18	Height;	chr2:241093979	chr2:241010045~241010744:-
THCA	cis	rs1023500	0.505	rs134886	ENSG00000273366.1	CTA-989H11.1	4.08	5.35e-05	0.00454	0.22	0.18	Schizophrenia;	chr22:42277850	chr22:42278188~42278846:+
THCA	cis	rs4237845	0.537	rs59401446	ENSG00000270039.1	RP11-571M6.17	-4.08	5.36e-05	0.00454	-0.2	-0.18	Intelligence (multi-trait analysis);	chr12:57865781	chr12:57803838~57804415:+
THCA	cis	rs7829975	0.593	rs2979241	ENSG00000253981.4	ALG1L13P	4.08	5.36e-05	0.00454	0.17	0.18	Mood instability;	chr8:8445843	chr8:8236003~8244667:-
THCA	cis	rs11671005	0.779	rs3794971	ENSG00000268912.1	CTD-2619J13.17	-4.08	5.36e-05	0.00454	-0.18	-0.18	Mean platelet volume;	chr19:58474499	chr19:58428632~58431148:-
THCA	cis	rs12753569	0.967	rs6696116	ENSG00000272855.1	RP5-1102E8.3	4.08	5.36e-05	0.00455	0.23	0.18	Personality dimensions;	chr1:76018047	chr1:76636877~76637339:+
THCA	cis	rs10911902	0.643	rs75008037	ENSG00000233196.2	GS1-304P7.1	-4.08	5.36e-05	0.00455	-0.3	-0.18	Schizophrenia;	chr1:186371380	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs76554103	ENSG00000233196.2	GS1-304P7.1	-4.08	5.36e-05	0.00455	-0.3	-0.18	Schizophrenia;	chr1:186371402	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs7514615	ENSG00000233196.2	GS1-304P7.1	-4.08	5.36e-05	0.00455	-0.3	-0.18	Schizophrenia;	chr1:186373191	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs6425027	ENSG00000233196.2	GS1-304P7.1	-4.08	5.36e-05	0.00455	-0.3	-0.18	Schizophrenia;	chr1:186376034	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs6425028	ENSG00000233196.2	GS1-304P7.1	-4.08	5.36e-05	0.00455	-0.3	-0.18	Schizophrenia;	chr1:186376149	chr1:186580515~186581191:-
THCA	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	4.08	5.36e-05	0.00455	0.24	0.18	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
THCA	cis	rs8062405	0.69	rs4787458	ENSG00000270424.1	RP11-1348G14.6	4.08	5.36e-05	0.00455	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28749959~28750595:-
THCA	cis	rs1167832	0.645	rs1167828	ENSG00000278416.1	PMS2L2	-4.08	5.36e-05	0.00455	-0.29	-0.18	Ankle injury;	chr7:75534076	chr7:75344015~75359550:-
THCA	cis	rs16852403	0.619	rs10798597	ENSG00000224687.1	RASAL2-AS1	4.08	5.36e-05	0.00455	0.3	0.18	Childhood ear infection;	chr1:178139113	chr1:178091508~178093984:-
THCA	cis	rs4906332	0.899	rs12888042	ENSG00000252469.1	RNU7-160P	4.08	5.36e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103425372	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs17617094	ENSG00000252469.1	RNU7-160P	4.08	5.36e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103427091	chr14:103550345~103550406:+
THCA	cis	rs5758511	0.633	rs5758689	ENSG00000237037.8	NDUFA6-AS1	-4.08	5.36e-05	0.00455	-0.18	-0.18	Birth weight;	chr22:42268966	chr22:42090931~42137742:+
THCA	cis	rs12478296	0.901	rs73007142	ENSG00000261186.2	RP11-341N2.1	-4.08	5.36e-05	0.00455	-0.32	-0.18	Obesity-related traits;	chr2:242068701	chr2:242087351~242088457:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000272831.1	RP11-792A8.4	-4.08	5.36e-05	0.00455	-0.12	-0.18	Aortic root size;	chr7:66144830	chr7:66739829~66740385:-
THCA	cis	rs10090774	0.897	rs306950	ENSG00000279766.1	RP11-642A1.2	4.08	5.36e-05	0.00455	0.23	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141005751	chr8:140572142~140572812:-
THCA	cis	rs8062405	1	rs62037371	ENSG00000270424.1	RP11-1348G14.6	4.08	5.36e-05	0.00455	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28749959~28750595:-
THCA	cis	rs796395	1	rs796395	ENSG00000232480.1	TGFB2-AS1	-4.08	5.36e-05	0.00455	-0.21	-0.18	Post bronchodilator FEV1/FVC ratio;	chr1:218508629	chr1:218344196~218345678:-
THCA	cis	rs2033711	0.87	rs11084545	ENSG00000269054.1	CTD-2619J13.3	-4.08	5.36e-05	0.00455	-0.15	-0.18	Uric acid clearance;	chr19:58440326	chr19:58362585~58366591:+
THCA	cis	rs67478160	0.584	rs2295147	ENSG00000258735.1	LINC00637	4.08	5.36e-05	0.00455	0.23	0.18	Schizophrenia;	chr14:103729327	chr14:103847721~103858049:+
THCA	cis	rs2898290	0.622	rs1600250	ENSG00000254527.1	ENPP7P12	-4.08	5.36e-05	0.00455	-0.24	-0.18	Systolic blood pressure;	chr8:11487916	chr8:12205759~12206389:-
THCA	cis	rs2898290	0.593	rs1600252	ENSG00000254527.1	ENPP7P12	-4.08	5.36e-05	0.00455	-0.24	-0.18	Systolic blood pressure;	chr8:11488135	chr8:12205759~12206389:-
THCA	cis	rs853679	0.556	rs13200214	ENSG00000272009.1	RP1-313I6.12	-4.08	5.36e-05	0.00455	-0.35	-0.18	Depression;	chr6:28049472	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs71559070	ENSG00000272009.1	RP1-313I6.12	-4.08	5.36e-05	0.00455	-0.35	-0.18	Depression;	chr6:28071151	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34166054	ENSG00000272009.1	RP1-313I6.12	-4.08	5.36e-05	0.00455	-0.35	-0.18	Depression;	chr6:28098023	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34662244	ENSG00000272009.1	RP1-313I6.12	-4.08	5.36e-05	0.00455	-0.35	-0.18	Depression;	chr6:28106103	chr6:28078792~28081130:-
THCA	cis	rs35952432	1	rs35952432	ENSG00000272009.1	RP1-313I6.12	-4.08	5.36e-05	0.00455	-0.35	-0.18	Lung cancer;	chr6:28107123	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13203816	ENSG00000272009.1	RP1-313I6.12	-4.08	5.36e-05	0.00455	-0.35	-0.18	Depression;	chr6:28111820	chr6:28078792~28081130:-
THCA	cis	rs853679	0.556	rs34588114	ENSG00000272009.1	RP1-313I6.12	-4.08	5.36e-05	0.00455	-0.35	-0.18	Depression;	chr6:28112850	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs34371502	ENSG00000272009.1	RP1-313I6.12	-4.08	5.36e-05	0.00455	-0.35	-0.18	Depression;	chr6:28113980	chr6:28078792~28081130:-
THCA	cis	rs4906332	1	rs2065017	ENSG00000252469.1	RNU7-160P	4.08	5.37e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103413242	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs12885762	ENSG00000252469.1	RNU7-160P	4.08	5.37e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103415863	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs12892062	ENSG00000252469.1	RNU7-160P	4.08	5.37e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103417175	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs7155980	ENSG00000252469.1	RNU7-160P	4.08	5.37e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103456082	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs8012623	ENSG00000252469.1	RNU7-160P	4.08	5.37e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103470749	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs34347076	ENSG00000252469.1	RNU7-160P	4.08	5.37e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103488732	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs35344594	ENSG00000252469.1	RNU7-160P	4.08	5.37e-05	0.00455	0.2	0.18	Coronary artery disease;	chr14:103489455	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs2065018	ENSG00000252469.1	RNU7-160P	-4.08	5.37e-05	0.00455	-0.2	-0.18	Coronary artery disease;	chr14:103412850	chr14:103550345~103550406:+
THCA	cis	rs8042680	0.503	rs7601	ENSG00000214432.8	AC068831.10	4.08	5.37e-05	0.00455	0.2	0.18	Type 2 diabetes;	chr15:90966362	chr15:91022619~91036611:+
THCA	cis	rs2898290	0.622	rs1382567	ENSG00000254527.1	ENPP7P12	-4.08	5.37e-05	0.00455	-0.23	-0.18	Systolic blood pressure;	chr8:11493390	chr8:12205759~12206389:-
THCA	cis	rs2858942	0.527	rs7198029	ENSG00000206168.1	Z69890.1	-4.08	5.37e-05	0.00455	-0.2	-0.18	Mean corpuscular hemoglobin;	chr16:199465	chr16:231134~231472:+
THCA	cis	rs7551222	0.752	rs11240755	ENSG00000240219.1	RP11-430C7.5	4.08	5.37e-05	0.00455	0.17	0.18	Schizophrenia;	chr1:204509521	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.691	rs4951077	ENSG00000240219.1	RP11-430C7.5	4.08	5.37e-05	0.00455	0.17	0.18	Schizophrenia;	chr1:204513134	chr1:204626775~204629712:+
THCA	cis	rs6439699	0.941	rs66752974	ENSG00000273486.1	RP11-731C17.2	4.08	5.37e-05	0.00456	0.19	0.18	Intelligence (multi-trait analysis);	chr3:137338788	chr3:136837338~136839021:-
THCA	cis	rs17685	0.671	rs10274404	ENSG00000230882.1	AC005077.14	4.08	5.37e-05	0.00456	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76077316	chr7:76071469~76074963:-
THCA	cis	rs2474937	0.617	rs3891360	ENSG00000231365.4	RP11-418J17.1	4.08	5.37e-05	0.00456	0.18	0.18	Congenital heart malformation;	chr1:118349525	chr1:119140396~119275973:+
THCA	cis	rs2474937	0.617	rs9661487	ENSG00000231365.4	RP11-418J17.1	4.08	5.37e-05	0.00456	0.18	0.18	Congenital heart malformation;	chr1:118359721	chr1:119140396~119275973:+
THCA	cis	rs6496932	0.802	rs12439958	ENSG00000259630.2	CTD-2262B20.1	4.08	5.37e-05	0.00456	0.22	0.18	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85415228~85415633:+
THCA	cis	rs4218	0.531	rs12101733	ENSG00000277144.1	RP11-59H7.4	-4.08	5.37e-05	0.00456	-0.25	-0.18	Social communication problems;	chr15:59047566	chr15:59115547~59116089:-
THCA	cis	rs7216064	0.953	rs10445361	ENSG00000278740.1	RP11-147L13.14	-4.08	5.37e-05	0.00456	-0.21	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67966122	chr17:68188547~68189165:+
THCA	cis	rs67478160	0.643	rs2295141	ENSG00000269940.1	RP11-73M18.7	4.08	5.37e-05	0.00456	0.17	0.18	Schizophrenia;	chr14:103746612	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.654	rs1997913	ENSG00000269940.1	RP11-73M18.7	4.08	5.37e-05	0.00456	0.17	0.18	Schizophrenia;	chr14:103747623	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs3818085	ENSG00000269940.1	RP11-73M18.7	4.08	5.37e-05	0.00456	0.17	0.18	Schizophrenia;	chr14:103749648	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.643	rs1535098	ENSG00000269940.1	RP11-73M18.7	4.08	5.37e-05	0.00456	0.17	0.18	Schizophrenia;	chr14:103750176	chr14:103694560~103695170:+
THCA	cis	rs793571	0.822	rs1078001	ENSG00000245975.2	RP11-30K9.6	-4.08	5.37e-05	0.00456	-0.2	-0.18	Schizophrenia;	chr15:58875666	chr15:58768072~58770974:-
THCA	cis	rs755249	0.762	rs1775654	ENSG00000228060.1	RP11-69E11.8	-4.08	5.38e-05	0.00456	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39565160~39573203:+
THCA	cis	rs34929064	0.781	rs2905324	ENSG00000179428.2	AC073072.5	-4.08	5.38e-05	0.00456	-0.21	-0.18	Major depression and alcohol dependence;	chr7:22669384	chr7:22725395~22727620:-
THCA	cis	rs72627509	0.587	rs17087401	ENSG00000269949.1	RP11-738E22.3	4.08	5.38e-05	0.00456	0.3	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57034989	chr4:56960927~56961373:-
THCA	cis	rs12681366	0.563	rs6999103	ENSG00000261437.1	RP11-22C11.2	4.08	5.38e-05	0.00456	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94470309	chr8:94637285~94639467:-
THCA	cis	rs709400	1	rs10135248	ENSG00000258735.1	LINC00637	4.08	5.38e-05	0.00456	0.23	0.18	Body mass index;	chr14:103655973	chr14:103847721~103858049:+
THCA	cis	rs9880211	0.606	rs1403767	ENSG00000273486.1	RP11-731C17.2	4.08	5.38e-05	0.00456	0.19	0.18	Height;Body mass index;	chr3:135949874	chr3:136837338~136839021:-
THCA	cis	rs6494488	0.5	rs72742987	ENSG00000259635.1	AC100830.3	-4.08	5.38e-05	0.00456	-0.47	-0.18	Coronary artery disease;	chr15:64701558	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742989	ENSG00000259635.1	AC100830.3	-4.08	5.38e-05	0.00456	-0.47	-0.18	Coronary artery disease;	chr15:64702265	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs80142506	ENSG00000259635.1	AC100830.3	-4.08	5.38e-05	0.00456	-0.47	-0.18	Coronary artery disease;	chr15:64702948	chr15:64701248~64719602:+
THCA	cis	rs11242704	0.603	rs4431475	ENSG00000272279.1	RP11-157J24.2	-4.08	5.38e-05	0.00456	-0.3	-0.18	Response to hepatitis C treatment;	chr6:1532651	chr6:1528364~1528911:-
THCA	cis	rs875971	1	rs6946143	ENSG00000272831.1	RP11-792A8.4	4.08	5.38e-05	0.00456	0.12	0.18	Aortic root size;	chr7:66114735	chr7:66739829~66740385:-
THCA	cis	rs7074356	0.604	rs9665678	ENSG00000225484.5	NUTM2B-AS1	-4.08	5.38e-05	0.00456	-0.29	-0.18	Borderline personality disorder;	chr10:80473786	chr10:79663088~79826594:-
THCA	cis	rs2058059	0.681	rs2844177	ENSG00000205578.5	POM121B	-4.08	5.38e-05	0.00456	-0.29	-0.18	Subcutaneous adipose tissue;	chr7:72657954	chr7:73293497~73301161:+
THCA	cis	rs4713118	0.824	rs9366702	ENSG00000220721.1	OR1F12	4.08	5.38e-05	0.00457	0.25	0.18	Parkinson's disease;	chr6:27766691	chr6:28073316~28074233:+
THCA	cis	rs6088813	1	rs6088825	ENSG00000279253.1	RP4-614O4.13	4.08	5.38e-05	0.00457	0.18	0.18	Height;	chr20:35408169	chr20:35262727~35264187:-
THCA	cis	rs75422866	0.541	rs61918136	ENSG00000280054.1	RP1-197B17.7	4.08	5.38e-05	0.00457	0.38	0.18	Pneumonia;	chr12:47566798	chr12:47728151~47730598:-
THCA	cis	rs71520386	0.607	rs11767419	ENSG00000226329.2	AC005682.6	-4.08	5.39e-05	0.00457	-0.24	-0.18	Fibrinogen levels;	chr7:22839364	chr7:22863874~22881350:-
THCA	cis	rs3781264	0.816	rs2274223	ENSG00000273450.1	RP11-76P2.4	4.08	5.39e-05	0.00457	0.23	0.18	Esophageal cancer and gastric cancer;	chr10:94306584	chr10:94314907~94315327:-
THCA	cis	rs896854	0.573	rs11996455	ENSG00000253528.2	RP11-347C18.4	4.08	5.39e-05	0.00457	0.21	0.18	Type 2 diabetes;	chr8:94841480	chr8:94974573~94974853:-
THCA	cis	rs832187	0.64	rs56293138	ENSG00000224479.4	AC136289.1	4.08	5.39e-05	0.00457	0.23	0.18	Schizophrenia;	chr3:63903259	chr3:63742293~63827445:-
THCA	cis	rs7528684	0.565	rs10908587	ENSG00000236731.1	RP4-801G22.2	4.08	5.39e-05	0.00457	0.19	0.18	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157673789	chr1:157629939~157630728:-
THCA	cis	rs7772486	0.782	rs7747576	ENSG00000270638.1	RP3-466P17.1	-4.08	5.39e-05	0.00457	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs9399571	ENSG00000270638.1	RP3-466P17.1	-4.08	5.39e-05	0.00457	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145735570~145737218:+
THCA	cis	rs7246657	0.508	rs1628959	ENSG00000276846.1	CTD-3220F14.3	4.08	5.39e-05	0.00457	0.21	0.18	Coronary artery calcification;	chr19:36999474	chr19:37314868~37315620:-
THCA	cis	rs911555	0.723	rs11160751	ENSG00000269958.1	RP11-73M18.8	4.08	5.39e-05	0.00457	0.17	0.18	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103696353~103697163:+
THCA	cis	rs12118280	0.513	rs6694641	ENSG00000280186.1	RP11-483I13.6	4.08	5.39e-05	0.00457	0.15	0.18	Myeloid white cell count;	chr1:108212960	chr1:108200413~108202743:+
THCA	cis	rs459571	0.959	rs2520100	ENSG00000235106.7	LINC00094	4.08	5.39e-05	0.00457	0.16	0.18	Platelet distribution width;	chr9:134053015	chr9:134025439~134034666:+
THCA	cis	rs2191566	0.887	rs55703004	ENSG00000266921.1	RP11-15A1.7	-4.08	5.39e-05	0.00457	-0.17	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44000629	chr19:43996896~44002836:-
THCA	cis	rs4788570	0.584	rs6499529	ENSG00000260185.1	RP11-432I5.6	-4.08	5.39e-05	0.00457	-0.34	-0.18	Intelligence (multi-trait analysis);	chr16:71681475	chr16:71655027~71664212:+
THCA	cis	rs7136259	0.844	rs1689040	ENSG00000258302.2	RP11-981P6.1	4.08	5.39e-05	0.00457	0.16	0.18	Coronary heart disease;	chr12:89584456	chr12:89561129~89594878:+
THCA	cis	rs6921919	0.945	rs16901847	ENSG00000219392.1	RP1-265C24.5	-4.08	5.39e-05	0.00457	-0.25	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28115628~28116551:+
THCA	cis	rs4906332	1	rs12879663	ENSG00000269910.1	RP11-73M18.10	4.08	5.39e-05	0.00457	0.16	0.18	Coronary artery disease;	chr14:103407878	chr14:103694516~103695050:-
THCA	cis	rs9843304	0.685	rs35815132	ENSG00000240541.2	TM4SF1-AS1	-4.08	5.39e-05	0.00457	-0.17	-0.18	Gallstone disease;	chr3:149501673	chr3:149377778~149386583:+
THCA	cis	rs17095355	0.71	rs2150211	ENSG00000203876.8	ADD3-AS1	-4.08	5.4e-05	0.00458	-0.2	-0.18	Biliary atresia;	chr10:110095656	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.818	rs928213	ENSG00000203876.8	ADD3-AS1	-4.08	5.4e-05	0.00458	-0.2	-0.18	Biliary atresia;	chr10:110096466	chr10:109940104~110008381:-
THCA	cis	rs8062405	0.755	rs1074631	ENSG00000261766.1	RP11-22P6.2	4.08	5.4e-05	0.00458	0.19	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28862166~28863340:-
THCA	cis	rs5751614	0.557	rs16802	ENSG00000240160.3	RN7SL263P	-4.08	5.4e-05	0.00458	-0.23	-0.18	Height;	chr22:23290326	chr22:23261782~23262071:-
THCA	cis	rs17095355	1	rs17126877	ENSG00000203876.8	ADD3-AS1	-4.08	5.4e-05	0.00458	-0.21	-0.18	Biliary atresia;	chr10:109913028	chr10:109940104~110008381:-
THCA	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	4.08	5.4e-05	0.00458	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	4.08	5.4e-05	0.00458	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
THCA	cis	rs875971	0.545	rs313828	ENSG00000273024.4	INTS4P2	4.08	5.4e-05	0.00458	0.24	0.18	Aortic root size;	chr7:66087627	chr7:65647864~65715661:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000273024.4	INTS4P2	4.08	5.4e-05	0.00458	0.24	0.18	Aortic root size;	chr7:66089365	chr7:65647864~65715661:+
THCA	cis	rs2039553	0.574	rs2248409	ENSG00000227354.5	RBM26-AS1	4.08	5.4e-05	0.00458	0.18	0.18	Pancreatic cancer;	chr13:79746210	chr13:79406309~79424328:+
THCA	cis	rs2836974	0.549	rs34160989	ENSG00000255568.3	BRWD1-AS2	4.08	5.4e-05	0.00458	0.21	0.18	Cognitive function;	chr21:39182192	chr21:39313935~39314962:+
THCA	cis	rs7824557	0.628	rs7820301	ENSG00000154316.13	TDH	-4.08	5.4e-05	0.00458	-0.14	-0.18	Retinal vascular caliber;	chr8:11371163	chr8:11339637~11368452:+
THCA	cis	rs4883201	1	rs4883201	ENSG00000245105.2	A2M-AS1	-4.08	5.4e-05	0.00458	-0.2	-0.18	Total cholesterol levels;Cholesterol, total;	chr12:8929985	chr12:9065177~9068060:+
THCA	cis	rs72928364	1	rs13072000	ENSG00000256628.3	ZBTB11-AS1	4.08	5.4e-05	0.00458	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100906978	chr3:101676475~101679217:+
THCA	cis	rs9595908	0.686	rs1015364	ENSG00000212293.1	SNORA16	4.07	5.4e-05	0.00458	0.22	0.18	Body mass index;	chr13:32784455	chr13:32420390~32420516:-
THCA	cis	rs1371614	0.545	rs3769136	ENSG00000272148.1	RP11-195B17.1	4.07	5.4e-05	0.00458	0.17	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26945875	chr2:27062428~27062907:-
THCA	cis	rs9902453	1	rs9906340	ENSG00000263370.1	RP11-68I3.5	-4.07	5.4e-05	0.00458	-0.24	-0.18	Coffee consumption (cups per day);	chr17:30071959	chr17:29639627~29640825:+
THCA	cis	rs12681963	0.688	rs2341177	ENSG00000248159.1	HSPA8P11	-4.07	5.41e-05	0.00458	-0.35	-0.18	Migraine;	chr8:30146977	chr8:30237382~30240997:+
THCA	cis	rs9959145	1	rs28821540	ENSG00000267199.1	RP11-861E21.2	4.07	5.41e-05	0.00458	0.24	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12558309	chr18:12438890~12448205:+
THCA	cis	rs7131987	0.868	rs7958210	ENSG00000275476.1	RP11-996F15.4	-4.07	5.41e-05	0.00458	-0.18	-0.18	QT interval;	chr12:29242248	chr12:29277397~29277882:-
THCA	cis	rs711244	0.744	rs62132550	ENSG00000279519.1	RP11-288C18.1	4.07	5.41e-05	0.00458	0.15	0.18	Mean platelet volume;	chr2:36913942	chr2:36839922~36842539:-
THCA	cis	rs12681366	0.801	rs1372048	ENSG00000261437.1	RP11-22C11.2	4.07	5.41e-05	0.00458	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94637285~94639467:-
THCA	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-4.07	5.41e-05	0.00458	-0.37	-0.18	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
THCA	cis	rs6494488	0.5	rs111737146	ENSG00000259635.1	AC100830.3	-4.07	5.41e-05	0.00458	-0.48	-0.18	Coronary artery disease;	chr15:64712641	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742993	ENSG00000259635.1	AC100830.3	-4.07	5.41e-05	0.00458	-0.48	-0.18	Coronary artery disease;	chr15:64713824	chr15:64701248~64719602:+
THCA	cis	rs9326248	0.53	rs588918	ENSG00000280143.1	AP000892.6	4.07	5.41e-05	0.00458	0.29	0.18	Blood protein levels;	chr11:116985926	chr11:117204967~117210292:+
THCA	cis	rs285757	0.532	rs8037891	ENSG00000258741.3	RP11-386M24.4	4.07	5.41e-05	0.00459	0.19	0.18	HIV-1 susceptibility;	chr15:92663546	chr15:92715710~92734195:-
THCA	cis	rs1124769	0.625	rs12591735	ENSG00000259378.1	DCAF13P3	4.07	5.41e-05	0.00459	0.29	0.18	Cognitive performance;	chr15:51100089	chr15:50944663~50945996:+
THCA	cis	rs1971762	0.527	rs2365343	ENSG00000270175.1	RP11-793H13.11	4.07	5.41e-05	0.00459	0.12	0.18	Height;	chr12:53644365	chr12:53500162~53500936:-
THCA	cis	rs4938303	0.633	rs61906081	ENSG00000254851.1	RP11-109L13.1	4.07	5.41e-05	0.00459	0.31	0.18	Triglycerides;	chr11:116666342	chr11:117135528~117138582:+
THCA	cis	rs4908768	0.501	rs2016084	ENSG00000270282.1	RP5-1115A15.2	4.07	5.41e-05	0.00459	0.22	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8512653~8513021:+
THCA	cis	rs7212590	0.655	rs8067568	ENSG00000267302.4	RP11-178C3.2	4.07	5.41e-05	0.00459	0.34	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59921854	chr17:59964832~59996972:+
THCA	cis	rs17345786	0.52	rs13062677	ENSG00000256628.3	ZBTB11-AS1	4.07	5.41e-05	0.00459	0.2	0.18	Colonoscopy-negative controls vs population controls;	chr3:101586234	chr3:101676475~101679217:+
THCA	cis	rs1633360	1	rs1633360	ENSG00000270039.1	RP11-571M6.17	4.07	5.41e-05	0.00459	0.19	0.18	Rheumatoid arthritis;	chr12:57714269	chr12:57803838~57804415:+
THCA	cis	rs3812831	0.695	rs6560935	ENSG00000264539.1	MIR548AR	4.07	5.41e-05	0.00459	0.19	0.18	Schizophrenia;	chr13:114180392	chr13:114244505~114244561:+
THCA	cis	rs516805	0.923	rs491171	ENSG00000279114.1	RP3-425C14.5	-4.07	5.41e-05	0.00459	-0.18	-0.18	Lymphocyte counts;	chr6:122408021	chr6:122471923~122484161:+
THCA	cis	rs516805	0.923	rs556675	ENSG00000279114.1	RP3-425C14.5	-4.07	5.41e-05	0.00459	-0.18	-0.18	Lymphocyte counts;	chr6:122408083	chr6:122471923~122484161:+
THCA	cis	rs516805	0.923	rs487487	ENSG00000279114.1	RP3-425C14.5	-4.07	5.41e-05	0.00459	-0.18	-0.18	Lymphocyte counts;	chr6:122422357	chr6:122471923~122484161:+
THCA	cis	rs516805	0.961	rs556439	ENSG00000279114.1	RP3-425C14.5	-4.07	5.41e-05	0.00459	-0.18	-0.18	Lymphocyte counts;	chr6:122423864	chr6:122471923~122484161:+
THCA	cis	rs516805	0.961	rs572632	ENSG00000279114.1	RP3-425C14.5	-4.07	5.41e-05	0.00459	-0.18	-0.18	Lymphocyte counts;	chr6:122437753	chr6:122471923~122484161:+
THCA	cis	rs801193	0.613	rs2016325	ENSG00000230295.1	RP11-458F8.2	4.07	5.42e-05	0.00459	0.15	0.18	Aortic root size;	chr7:66858513	chr7:66880708~66882981:+
THCA	cis	rs6701713	0.879	rs4562624	ENSG00000274245.1	RP11-357P18.2	-4.07	5.42e-05	0.00459	-0.24	-0.18	Alzheimer's disease (late onset);	chr1:207512620	chr1:207372559~207373252:+
THCA	cis	rs9810089	0.802	rs73222302	ENSG00000273455.1	RP11-305O4.3	4.07	5.42e-05	0.00459	0.24	0.18	Gestational age at birth (child effect);	chr3:136379243	chr3:136087475~136087913:-
THCA	cis	rs2732480	0.5	rs2450989	ENSG00000273765.1	RP11-370I10.11	-4.07	5.42e-05	0.00459	-0.18	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48360920~48361377:+
THCA	cis	rs71386921	1	rs71386921	ENSG00000262412.1	RP11-85G18.6	4.07	5.42e-05	0.00459	0.27	0.18	Breast cancer;	chr10:27189786	chr10:27243130~27250804:+
THCA	cis	rs3740713	1	rs76586692	ENSG00000256464.1	YWHABP2	4.07	5.42e-05	0.00459	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs76062966	ENSG00000256464.1	YWHABP2	4.07	5.42e-05	0.00459	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr11:18490243~18490955:-
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.42e-05	0.00459	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30726305~30727564:-
THCA	cis	rs9634489	0.709	rs912690	ENSG00000247400.3	DNAJC3-AS1	-4.07	5.42e-05	0.00459	-0.12	-0.18	Body mass index;	chr13:96368451	chr13:95648733~95676925:-
THCA	cis	rs656319	0.629	rs11774276	ENSG00000261451.1	RP11-981G7.1	-4.07	5.42e-05	0.00459	-0.26	-0.18	Myopia (pathological);	chr8:10212799	chr8:10433672~10438312:+
THCA	cis	rs7208859	0.573	rs11654035	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.42e-05	0.0046	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30726305~30727564:-
THCA	cis	rs12368653	0.557	rs903067	ENSG00000270039.1	RP11-571M6.17	-4.07	5.42e-05	0.0046	-0.2	-0.18	Multiple sclerosis;	chr12:57618074	chr12:57803838~57804415:+
THCA	cis	rs2836974	0.644	rs7281853	ENSG00000255568.3	BRWD1-AS2	-4.07	5.42e-05	0.0046	-0.15	-0.18	Cognitive function;	chr21:39321564	chr21:39313935~39314962:+
THCA	cis	rs758324	0.947	rs1604080	ENSG00000237714.1	P4HA2-AS1	-4.07	5.43e-05	0.0046	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131840951	chr5:132184876~132192808:+
THCA	cis	rs755249	0.701	rs1180342	ENSG00000237624.1	OXCT2P1	-4.07	5.43e-05	0.0046	-0.21	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39514956~39516490:+
THCA	cis	rs6903823	0.527	rs4713158	ENSG00000220721.1	OR1F12	4.07	5.43e-05	0.0046	0.21	0.18	Pulmonary function;	chr6:28309994	chr6:28073316~28074233:+
THCA	cis	rs4561483	0.514	rs33639	ENSG00000263307.1	RP11-166B2.8	4.07	5.43e-05	0.0046	0.19	0.18	Testicular germ cell tumor;	chr16:11895642	chr16:11851649~11895611:+
THCA	cis	rs2412819	0.571	rs62018900	ENSG00000166763.7	STRCP1	4.07	5.43e-05	0.0046	0.26	0.18	Lung cancer;	chr15:43633252	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.545	rs35333173	ENSG00000166763.7	STRCP1	4.07	5.43e-05	0.0046	0.26	0.18	Lung cancer;	chr15:43640818	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs112667279	ENSG00000166763.7	STRCP1	4.07	5.43e-05	0.0046	0.26	0.18	Lung cancer;	chr15:43649258	chr15:43699488~43718184:-
THCA	cis	rs962856	0.897	rs644055	ENSG00000236780.4	AC078941.1	4.07	5.43e-05	0.0046	0.22	0.18	Pancreatic cancer;	chr2:67432539	chr2:67123357~67215319:-
THCA	cis	rs6968419	0.788	rs72603592	ENSG00000237870.5	AC073130.1	4.07	5.43e-05	0.0046	0.2	0.18	Intraocular pressure;	chr7:116191141	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.788	rs6946058	ENSG00000237870.5	AC073130.1	4.07	5.43e-05	0.0046	0.2	0.18	Intraocular pressure;	chr7:116199199	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.788	rs1317791	ENSG00000237870.5	AC073130.1	4.07	5.43e-05	0.0046	0.2	0.18	Intraocular pressure;	chr7:116199667	chr7:116275606~116286734:-
THCA	cis	rs2243480	0.522	rs778717	ENSG00000232559.3	GS1-124K5.12	4.07	5.43e-05	0.0046	0.35	0.18	Diabetic kidney disease;	chr7:66383164	chr7:66554588~66576923:-
THCA	cis	rs17270561	0.609	rs7772382	ENSG00000272462.2	U91328.19	-4.07	5.43e-05	0.0046	-0.16	-0.18	Iron status biomarkers;	chr6:25707888	chr6:25992662~26001775:+
THCA	cis	rs875971	0.83	rs427973	ENSG00000229886.1	RP5-1132H15.3	4.07	5.43e-05	0.0046	0.2	0.18	Aortic root size;	chr7:66061661	chr7:66025126~66031544:-
THCA	cis	rs56313388	0.505	rs9302680	ENSG00000246379.5	RP11-461O7.1	-4.07	5.43e-05	0.0046	-0.19	-0.18	Pulse pressure;	chr16:56235980	chr16:56092987~56191094:-
THCA	cis	rs4512344	0.514	rs13255193	ENSG00000254527.1	ENPP7P12	-4.07	5.43e-05	0.0046	-0.23	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11451683	chr8:12205759~12206389:-
THCA	cis	rs6416877	0.885	rs12948875	ENSG00000277491.1	RP11-676J12.9	-4.07	5.43e-05	0.0046	-0.22	-0.18	Myeloid white cell count;	chr17:1444355	chr17:795306~795794:+
THCA	cis	rs2933343	0.621	rs728838	ENSG00000231305.3	RP11-723O4.2	4.07	5.43e-05	0.0046	0.2	0.18	IgG glycosylation;	chr3:128870170	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.649	rs728839	ENSG00000231305.3	RP11-723O4.2	4.07	5.43e-05	0.0046	0.2	0.18	IgG glycosylation;	chr3:128870516	chr3:128861313~128871540:-
THCA	cis	rs7136259	0.537	rs10858911	ENSG00000258302.2	RP11-981P6.1	-4.07	5.43e-05	0.0046	-0.16	-0.18	Coronary heart disease;	chr12:89569364	chr12:89561129~89594878:+
THCA	cis	rs301901	0.581	rs158409	ENSG00000250155.1	CTD-2353F22.1	-4.07	5.43e-05	0.0046	-0.19	-0.18	Height;	chr5:36848456	chr5:36666214~36725195:-
THCA	cis	rs1560104	0.709	rs7194367	ENSG00000262801.4	U91319.1	4.07	5.43e-05	0.0046	0.22	0.18	Obesity-related traits;	chr16:12604376	chr16:13246316~13562918:+
THCA	cis	rs4742903	0.904	rs10114234	ENSG00000270332.1	SMC2-AS1	-4.07	5.43e-05	0.0046	-0.18	-0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104241365	chr9:104080024~104093073:-
THCA	cis	rs2980439	0.525	rs1850511	ENSG00000253981.4	ALG1L13P	4.07	5.44e-05	0.0046	0.17	0.18	Neuroticism;	chr8:8312807	chr8:8236003~8244667:-
THCA	cis	rs6494488	0.5	rs72742997	ENSG00000259635.1	AC100830.3	-4.07	5.44e-05	0.0046	-0.48	-0.18	Coronary artery disease;	chr15:64717328	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742999	ENSG00000259635.1	AC100830.3	-4.07	5.44e-05	0.0046	-0.48	-0.18	Coronary artery disease;	chr15:64718311	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72743002	ENSG00000259635.1	AC100830.3	-4.07	5.44e-05	0.0046	-0.48	-0.18	Coronary artery disease;	chr15:64718996	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744704	ENSG00000259635.1	AC100830.3	-4.07	5.44e-05	0.0046	-0.48	-0.18	Coronary artery disease;	chr15:64719308	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744710	ENSG00000259635.1	AC100830.3	-4.07	5.44e-05	0.0046	-0.48	-0.18	Coronary artery disease;	chr15:64721879	chr15:64701248~64719602:+
THCA	cis	rs5758659	0.652	rs133321	ENSG00000273366.1	CTA-989H11.1	-4.07	5.44e-05	0.0046	-0.22	-0.18	Cognitive function;	chr22:42009318	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.652	rs133323	ENSG00000273366.1	CTA-989H11.1	-4.07	5.44e-05	0.0046	-0.22	-0.18	Cognitive function;	chr22:42009918	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.652	rs133327	ENSG00000273366.1	CTA-989H11.1	-4.07	5.44e-05	0.0046	-0.22	-0.18	Cognitive function;	chr22:42011685	chr22:42278188~42278846:+
THCA	cis	rs5758659	0.652	rs133330	ENSG00000273366.1	CTA-989H11.1	-4.07	5.44e-05	0.0046	-0.22	-0.18	Cognitive function;	chr22:42013452	chr22:42278188~42278846:+
THCA	cis	rs9880211	0.644	rs35352346	ENSG00000273486.1	RP11-731C17.2	4.07	5.44e-05	0.00461	0.18	0.18	Height;Body mass index;	chr3:136162646	chr3:136837338~136839021:-
THCA	cis	rs3758911	0.964	rs7358296	ENSG00000255353.1	RP11-382M14.1	-4.07	5.44e-05	0.00461	-0.23	-0.18	Coronary artery disease;	chr11:107403212	chr11:107176286~107177530:+
THCA	cis	rs16957091	0.528	rs35900502	ENSG00000205771.5	CATSPER2P1	4.07	5.44e-05	0.00461	0.26	0.18	MGMT methylation in smokers;	chr15:43081731	chr15:43726918~43747094:-
THCA	cis	rs78487399	0.831	rs17031142	ENSG00000234936.1	AC010883.5	4.07	5.44e-05	0.00461	0.23	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43620507	chr2:43229573~43233394:+
THCA	cis	rs150992	0.79	rs161731	ENSG00000246763.5	RGMB-AS1	4.07	5.44e-05	0.00461	0.19	0.18	Body mass index;	chr5:98984339	chr5:98769618~98773469:-
THCA	cis	rs6121246	0.909	rs6058450	ENSG00000224628.2	RP5-854E16.2	-4.07	5.44e-05	0.00461	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31756108	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6060929	ENSG00000224628.2	RP5-854E16.2	-4.07	5.44e-05	0.00461	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31758111	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6119720	ENSG00000224628.2	RP5-854E16.2	-4.07	5.44e-05	0.00461	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31759765	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6087778	ENSG00000224628.2	RP5-854E16.2	-4.07	5.44e-05	0.00461	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31766339	chr20:31285317~31286835:-
THCA	cis	rs9902453	0.967	rs34323226	ENSG00000263370.1	RP11-68I3.5	4.07	5.44e-05	0.00461	0.24	0.18	Coffee consumption (cups per day);	chr17:30190436	chr17:29639627~29640825:+
THCA	cis	rs4443100	0.958	rs5996459	ENSG00000230701.2	FBXW4P1	4.07	5.44e-05	0.00461	0.22	0.18	Serum parathyroid hormone levels;	chr22:23048953	chr22:23262767~23265005:+
THCA	cis	rs9543976	0.623	rs9318361	ENSG00000261105.4	LMO7-AS1	4.07	5.44e-05	0.00461	0.26	0.18	Diabetic retinopathy;	chr13:75602944	chr13:75604700~75635994:-
THCA	cis	rs970548	1	rs58865519	ENSG00000230869.1	CTGLF10P	4.07	5.44e-05	0.00461	0.23	0.18	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45515443	chr10:45678692~45700532:+
THCA	cis	rs1048886	0.938	rs12528866	ENSG00000271967.1	RP11-134K13.4	-4.07	5.44e-05	0.00461	-0.2	-0.18	Type 2 diabetes;	chr6:70478144	chr6:70596438~70596980:+
THCA	cis	rs3748682	0.861	rs72661832	ENSG00000252448.1	SNORA63	-4.07	5.44e-05	0.00461	-0.24	-0.18	Hypothyroidism;	chr1:37795061	chr1:37884237~37884317:+
THCA	cis	rs12497850	0.931	rs7431710	ENSG00000228638.1	FCF1P2	-4.07	5.44e-05	0.00461	-0.2	-0.18	Parkinson's disease;	chr3:48898150	chr3:48290793~48291375:-
THCA	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	4.07	5.44e-05	0.00461	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
THCA	cis	rs11971779	0.68	rs4398844	ENSG00000252332.1	RNU6-911P	-4.07	5.45e-05	0.00461	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139358393	chr7:139448740~139448843:+
THCA	cis	rs7267979	1	rs4815424	ENSG00000276952.1	RP5-965G21.6	-4.07	5.45e-05	0.00461	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25284915~25285588:-
THCA	cis	rs8062405	0.824	rs7191618	ENSG00000270424.1	RP11-1348G14.6	4.07	5.45e-05	0.00461	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.754	rs3859172	ENSG00000270424.1	RP11-1348G14.6	4.07	5.45e-05	0.00461	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28749959~28750595:-
THCA	cis	rs1023500	0.529	rs133375	ENSG00000237037.8	NDUFA6-AS1	-4.07	5.45e-05	0.00461	-0.15	-0.18	Schizophrenia;	chr22:42070505	chr22:42090931~42137742:+
THCA	cis	rs76382185	0.756	rs34749125	ENSG00000233184.5	RP11-421L21.3	4.07	5.45e-05	0.00461	0.26	0.18	Lymphocyte counts;	chr1:101122823	chr1:101025878~101087268:+
THCA	cis	rs7618915	1	rs3852063	ENSG00000243224.1	RP5-1157M23.2	-4.07	5.45e-05	0.00461	-0.2	-0.18	Bipolar disorder;	chr3:52315188	chr3:52239258~52241097:+
THCA	cis	rs12681963	0.688	rs4262289	ENSG00000272375.1	RP11-51J9.6	4.07	5.45e-05	0.00461	0.3	0.18	Migraine;	chr8:30191588	chr8:30197404~30198048:+
THCA	cis	rs6479901	0.557	rs7920768	ENSG00000272767.1	JMJD1C-AS1	-4.07	5.45e-05	0.00461	-0.26	-0.18	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63465229~63466563:+
THCA	cis	rs7208859	0.623	rs170051	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.45e-05	0.00461	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.51	rs216402	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.45e-05	0.00461	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs216434	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.45e-05	0.00461	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs216436	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.45e-05	0.00461	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.45e-05	0.00461	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs216439	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.45e-05	0.00461	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30726305~30727564:-
THCA	cis	rs34638657	0.536	rs2967327	ENSG00000261235.1	RP11-510J16.5	4.07	5.45e-05	0.00461	0.22	0.18	Lung adenocarcinoma;	chr16:82155052	chr16:82044336~82139631:-
THCA	cis	rs10200159	1	rs13407344	ENSG00000272606.1	RP11-554J4.1	4.07	5.45e-05	0.00462	0.35	0.18	Vitiligo;	chr2:55648233	chr2:55617909~55618373:+
THCA	cis	rs10200159	1	rs13382187	ENSG00000272606.1	RP11-554J4.1	4.07	5.45e-05	0.00462	0.35	0.18	Vitiligo;	chr2:55648611	chr2:55617909~55618373:+
THCA	cis	rs1923243	0.71	rs67437638	ENSG00000223479.3	RP4-788P17.1	4.07	5.45e-05	0.00462	0.21	0.18	Migraine;	chr1:73178327	chr1:73635216~73715214:+
THCA	cis	rs73173548	0.528	rs6872276	ENSG00000247828.6	TMEM161B-AS1	4.07	5.45e-05	0.00462	0.17	0.18	Macular telangiectasia type 2;	chr5:88473903	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.557	rs71580759	ENSG00000247828.6	TMEM161B-AS1	4.07	5.45e-05	0.00462	0.17	0.18	Macular telangiectasia type 2;	chr5:88474306	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs74429030	ENSG00000247828.6	TMEM161B-AS1	4.07	5.45e-05	0.00462	0.17	0.18	Macular telangiectasia type 2;	chr5:88474689	chr5:88268895~88436685:+
THCA	cis	rs5758659	0.652	rs133324	ENSG00000273366.1	CTA-989H11.1	-4.07	5.45e-05	0.00462	-0.22	-0.18	Cognitive function;	chr22:42010367	chr22:42278188~42278846:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000230295.1	RP11-458F8.2	4.07	5.45e-05	0.00462	0.14	0.18	Aortic root size;	chr7:66682114	chr7:66880708~66882981:+
THCA	cis	rs459482	0.504	rs467773	ENSG00000228318.3	AP001610.5	4.07	5.45e-05	0.00462	0.22	0.18	IgG glycosylation;	chr21:41446179	chr21:41441056~41445708:-
THCA	cis	rs459482	0.504	rs363882	ENSG00000228318.3	AP001610.5	4.07	5.45e-05	0.00462	0.22	0.18	IgG glycosylation;	chr21:41446346	chr21:41441056~41445708:-
THCA	cis	rs879500	0.961	rs1604816	ENSG00000227279.1	AC015933.2	4.07	5.45e-05	0.00462	0.21	0.18	Lung function (FVC);	chr18:28526972	chr18:27954519~27963687:+
THCA	cis	rs879500	0.961	rs56173206	ENSG00000227279.1	AC015933.2	4.07	5.45e-05	0.00462	0.21	0.18	Lung function (FVC);	chr18:28528974	chr18:27954519~27963687:+
THCA	cis	rs879500	0.961	rs72892329	ENSG00000227279.1	AC015933.2	4.07	5.45e-05	0.00462	0.21	0.18	Lung function (FVC);	chr18:28529234	chr18:27954519~27963687:+
THCA	cis	rs879500	0.961	rs12455753	ENSG00000227279.1	AC015933.2	4.07	5.45e-05	0.00462	0.21	0.18	Lung function (FVC);	chr18:28530384	chr18:27954519~27963687:+
THCA	cis	rs879500	0.961	rs72892336	ENSG00000227279.1	AC015933.2	4.07	5.45e-05	0.00462	0.21	0.18	Lung function (FVC);	chr18:28532131	chr18:27954519~27963687:+
THCA	cis	rs879500	0.961	rs72892337	ENSG00000227279.1	AC015933.2	4.07	5.45e-05	0.00462	0.21	0.18	Lung function (FVC);	chr18:28532220	chr18:27954519~27963687:+
THCA	cis	rs240993	0.595	rs3777912	ENSG00000271789.1	RP5-1112D6.7	4.07	5.45e-05	0.00462	0.19	0.18	Inflammatory skin disease;Psoriasis;	chr6:111581473	chr6:111297126~111298510:+
THCA	cis	rs7166081	1	rs4352000	ENSG00000270964.1	RP11-502I4.3	-4.07	5.45e-05	0.00462	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67351367	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs34221449	ENSG00000270964.1	RP11-502I4.3	-4.07	5.45e-05	0.00462	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67351925	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs35011221	ENSG00000270964.1	RP11-502I4.3	-4.07	5.45e-05	0.00462	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67352675	chr15:67541072~67542604:-
THCA	cis	rs5753037	0.653	rs131266	ENSG00000273350.1	RP4-539M6.20	-4.07	5.45e-05	0.00462	-0.21	-0.18	Type 1 diabetes;	chr22:29749728	chr22:30420512~30420912:+
THCA	cis	rs4915077	0.892	rs17020181	ENSG00000226822.1	RP11-356N1.2	4.07	5.45e-05	0.00462	0.37	0.18	Hypothyroidism;	chr1:107853340	chr1:108071482~108074519:+
THCA	cis	rs7267979	0.866	rs2424699	ENSG00000274973.1	RP13-401N8.7	-4.07	5.46e-05	0.00462	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25845497~25845862:+
THCA	cis	rs9650657	0.801	rs7018334	ENSG00000255310.2	AF131215.2	-4.07	5.46e-05	0.00462	-0.16	-0.18	Neuroticism;	chr8:10754565	chr8:11107788~11109726:-
THCA	cis	rs4915077	0.892	rs17020181	ENSG00000230489.1	VAV3-AS1	4.07	5.46e-05	0.00462	0.32	0.18	Hypothyroidism;	chr1:107853340	chr1:107964443~107994607:+
THCA	cis	rs17253792	0.822	rs74051609	ENSG00000186615.9	KTN1-AS1	-4.07	5.46e-05	0.00462	-0.3	-0.18	Putamen volume;	chr14:55704414	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs8006705	ENSG00000186615.9	KTN1-AS1	-4.07	5.46e-05	0.00462	-0.3	-0.18	Putamen volume;	chr14:55704565	chr14:55499278~55580110:-
THCA	cis	rs4218	0.689	rs12902628	ENSG00000259732.1	RP11-59H7.3	-4.07	5.46e-05	0.00462	-0.26	-0.18	Social communication problems;	chr15:59100193	chr15:59121034~59133250:+
THCA	cis	rs919433	0.679	rs10931788	ENSG00000231621.1	AC013264.2	-4.07	5.46e-05	0.00462	-0.2	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197666360	chr2:197197991~197199273:+
THCA	cis	rs738722	0.808	rs5752776	ENSG00000272858.1	CTA-292E10.8	-4.07	5.46e-05	0.00462	-0.18	-0.18	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28712241	chr22:28814914~28815662:+
THCA	cis	rs6570726	0.935	rs392014	ENSG00000270638.1	RP3-466P17.1	4.07	5.46e-05	0.00462	0.15	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145735570~145737218:+
THCA	cis	rs6570726	1	rs436066	ENSG00000270638.1	RP3-466P17.1	4.07	5.46e-05	0.00462	0.15	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145735570~145737218:+
THCA	cis	rs6570726	1	rs441477	ENSG00000270638.1	RP3-466P17.1	4.07	5.46e-05	0.00462	0.15	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145735570~145737218:+
THCA	cis	rs7474896	0.537	rs2749586	ENSG00000263064.2	RP11-291L22.7	-4.07	5.46e-05	0.00462	-0.25	-0.18	Obesity (extreme);	chr10:37981286	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.515	rs2749582	ENSG00000263064.2	RP11-291L22.7	-4.07	5.46e-05	0.00462	-0.25	-0.18	Obesity (extreme);	chr10:37986356	chr10:38448689~38448949:+
THCA	cis	rs1790761	0.505	rs6591245	ENSG00000255318.1	RP11-655M14.13	-4.07	5.46e-05	0.00462	-0.2	-0.18	Mean corpuscular volume;	chr11:67543465	chr11:67618279~67627304:-
THCA	cis	rs3755605	0.727	rs10936613	ENSG00000242578.1	RP11-469J4.3	4.07	5.46e-05	0.00462	0.21	0.18	Testicular germ cell tumor;	chr3:170127145	chr3:170410512~170418615:+
THCA	cis	rs7267979	1	rs2482940	ENSG00000276952.1	RP5-965G21.6	-4.07	5.46e-05	0.00462	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2027003	ENSG00000276952.1	RP5-965G21.6	-4.07	5.46e-05	0.00462	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2027004	ENSG00000276952.1	RP5-965G21.6	-4.07	5.46e-05	0.00462	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2500404	ENSG00000276952.1	RP5-965G21.6	-4.07	5.46e-05	0.00462	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2500405	ENSG00000276952.1	RP5-965G21.6	-4.07	5.46e-05	0.00462	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2482941	ENSG00000276952.1	RP5-965G21.6	-4.07	5.46e-05	0.00462	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.903	rs2500423	ENSG00000276952.1	RP5-965G21.6	-4.07	5.46e-05	0.00462	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25284915~25285588:-
THCA	cis	rs911555	0.755	rs2273702	ENSG00000269958.1	RP11-73M18.8	-4.07	5.46e-05	0.00462	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103696353~103697163:+
THCA	cis	rs3755605	0.694	rs34124911	ENSG00000242578.1	RP11-469J4.3	4.07	5.46e-05	0.00462	0.21	0.18	Testicular germ cell tumor;	chr3:170136883	chr3:170410512~170418615:+
THCA	cis	rs6067053	0.558	rs79274472	ENSG00000230758.1	SNAP23P	4.07	5.46e-05	0.00462	0.23	0.18	Intelligence (multi-trait analysis);	chr20:49297643	chr20:49038357~49038602:-
THCA	cis	rs586688	0.582	rs1270536	ENSG00000224536.1	RP11-134G8.7	-4.07	5.46e-05	0.00462	-0.28	-0.18	Obesity-related traits;	chr1:201701748	chr1:201507241~201533608:+
THCA	cis	rs586688	0.582	rs662852	ENSG00000224536.1	RP11-134G8.7	-4.07	5.46e-05	0.00462	-0.28	-0.18	Obesity-related traits;	chr1:201703486	chr1:201507241~201533608:+
THCA	cis	rs9316337	0.843	rs61950006	ENSG00000236953.1	ZDHHC20-IT1	-4.07	5.46e-05	0.00462	-0.19	-0.18	Schizophrenia;	chr13:21379894	chr13:21376977~21377874:-
THCA	cis	rs6840360	0.615	rs4696097	ENSG00000251611.1	RP11-610P16.1	4.07	5.46e-05	0.00463	0.14	0.18	Intelligence (multi-trait analysis);	chr4:151558613	chr4:151407551~151408835:-
THCA	cis	rs78487399	0.808	rs13431070	ENSG00000234936.1	AC010883.5	-4.07	5.46e-05	0.00463	-0.23	-0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43494815	chr2:43229573~43233394:+
THCA	cis	rs10186029	0.68	rs12694293	ENSG00000270659.1	RP11-105N14.1	-4.07	5.46e-05	0.00463	-0.15	-0.18	Systemic sclerosis;	chr2:213072497	chr2:213152970~213153659:+
THCA	cis	rs12440869	1	rs7176940	ENSG00000270964.1	RP11-502I4.3	4.07	5.47e-05	0.00463	0.16	0.18	Peak velocity of the mitral A-wave;	chr15:67257512	chr15:67541072~67542604:-
THCA	cis	rs7809950	0.815	rs62482495	ENSG00000272072.1	CTA-363E19.2	4.07	5.47e-05	0.00463	0.2	0.18	Coronary artery disease;	chr7:107324564	chr7:107192559~107193300:-
THCA	cis	rs1023500	0.505	rs134886	ENSG00000233903.2	Z83851.4	-4.07	5.47e-05	0.00463	-0.23	-0.18	Schizophrenia;	chr22:42277850	chr22:42276355~42277052:+
THCA	cis	rs3738443	0.951	rs55914345	ENSG00000259865.1	RP11-488L18.10	4.07	5.47e-05	0.00463	0.2	0.18	Alcohol dependence;	chr1:247216105	chr1:247187281~247188526:-
THCA	cis	rs9283706	0.608	rs13189948	ENSG00000229666.1	MAST4-AS1	-4.07	5.47e-05	0.00463	-0.27	-0.18	Coronary artery disease;	chr5:67059478	chr5:67001383~67003953:-
THCA	cis	rs5758511	0.541	rs6002494	ENSG00000230107.1	CTA-126B4.7	4.07	5.47e-05	0.00463	0.19	0.18	Birth weight;	chr22:41803856	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.513	rs7292782	ENSG00000230107.1	CTA-126B4.7	4.07	5.47e-05	0.00463	0.19	0.18	Birth weight;	chr22:41804320	chr22:42438023~42446195:+
THCA	cis	rs7520050	0.966	rs10789481	ENSG00000234329.1	RP11-767N6.2	-4.07	5.47e-05	0.00463	-0.16	-0.18	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:45651039~45651826:-
THCA	cis	rs7069191	0.668	rs10994491	ENSG00000254271.1	RP11-131N11.4	4.07	5.47e-05	0.00463	0.28	0.18	Pediatric bone mineral density (spine);	chr10:60744463	chr10:60734342~60741828:+
THCA	cis	rs7403037	0.652	rs12902094	ENSG00000260760.1	PWRN3	4.07	5.47e-05	0.00463	0.26	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24518439	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.617	rs12906381	ENSG00000260760.1	PWRN3	4.07	5.47e-05	0.00463	0.26	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24518445	chr15:24441127~24447967:+
THCA	cis	rs8177876	0.822	rs9923732	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs9933184	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs9926174	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.642	rs8052490	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs8056972	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs74437879	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs76948085	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs80315956	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.642	rs16954572	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs9929586	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs9938965	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs7204040	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.731	rs7188508	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs28672349	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs4306521	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs4324142	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.642	rs4324143	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.818	rs59177227	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs59685942	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs10514515	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs1410	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs1412	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs1414	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs8177950	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.731	rs8177948	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs8177940	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.73	rs76656387	ENSG00000261838.4	RP11-303E16.6	4.07	5.47e-05	0.00463	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81069854~81076598:+
THCA	cis	rs17181170	0.819	rs62257761	ENSG00000239572.1	RP11-451B8.1	-4.07	5.47e-05	0.00463	-0.22	-0.18	Prostate cancer;	chr3:87105777	chr3:87731402~87793629:-
THCA	cis	rs3105593	0.933	rs3131597	ENSG00000242737.1	RP11-562A8.1	4.07	5.47e-05	0.00463	0.23	0.18	QT interval;	chr15:50536798	chr15:50466738~50467096:+
THCA	cis	rs10256972	0.552	rs2960830	ENSG00000225146.1	AC073957.15	4.07	5.47e-05	0.00463	0.2	0.18	Endometriosis;Longevity;	chr7:1161005	chr7:1029025~1043891:+
THCA	cis	rs17685	0.753	rs10233282	ENSG00000230882.1	AC005077.14	4.07	5.47e-05	0.00463	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76160763	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs10251863	ENSG00000230882.1	AC005077.14	4.07	5.47e-05	0.00463	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76160874	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs9691174	ENSG00000230882.1	AC005077.14	4.07	5.47e-05	0.00463	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76161087	chr7:76071469~76074963:-
THCA	cis	rs17685	0.664	rs9801113	ENSG00000230882.1	AC005077.14	4.07	5.47e-05	0.00463	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76162713	chr7:76071469~76074963:-
THCA	cis	rs17685	0.558	rs60787921	ENSG00000230882.1	AC005077.14	4.07	5.47e-05	0.00463	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76163526	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs56965035	ENSG00000230882.1	AC005077.14	4.07	5.47e-05	0.00463	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76166352	chr7:76071469~76074963:-
THCA	cis	rs17685	0.672	rs56343450	ENSG00000230882.1	AC005077.14	4.07	5.47e-05	0.00463	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76166917	chr7:76071469~76074963:-
THCA	cis	rs9307551	0.576	rs13104474	ENSG00000250334.4	LINC00989	-4.07	5.47e-05	0.00463	-0.2	-0.18	Refractive error;	chr4:79618576	chr4:79492416~79576460:+
THCA	cis	rs67478160	0.643	rs2295145	ENSG00000269910.1	RP11-73M18.10	4.07	5.47e-05	0.00463	0.16	0.18	Schizophrenia;	chr14:103735967	chr14:103694516~103695050:-
THCA	cis	rs2797160	0.522	rs6925158	ENSG00000226409.1	RP11-735G4.1	-4.07	5.47e-05	0.00463	-0.23	-0.18	Endometrial cancer;	chr6:125619042	chr6:125370211~125374324:-
THCA	cis	rs5753037	0.702	rs140101	ENSG00000273350.1	RP4-539M6.20	-4.07	5.47e-05	0.00463	-0.21	-0.18	Type 1 diabetes;	chr22:29732391	chr22:30420512~30420912:+
THCA	cis	rs758324	0.732	rs156059	ENSG00000224431.1	AC063976.7	-4.07	5.47e-05	0.00463	-0.19	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132143938	chr5:132199456~132203487:+
THCA	cis	rs875971	0.965	rs28682868	ENSG00000230189.5	GS1-124K5.2	-4.07	5.47e-05	0.00463	-0.12	-0.18	Aortic root size;	chr7:66224822	chr7:66409143~66490059:-
THCA	cis	rs2549003	1	rs2070723	ENSG00000237714.1	P4HA2-AS1	-4.07	5.48e-05	0.00463	-0.23	-0.18	Asthma (sex interaction);	chr5:132487495	chr5:132184876~132192808:+
THCA	cis	rs7829975	0.501	rs74345345	ENSG00000254153.1	CTA-398F10.2	4.07	5.48e-05	0.00463	0.22	0.18	Mood instability;	chr8:8720925	chr8:8456909~8461337:-
THCA	cis	rs795484	0.926	rs353894	ENSG00000275409.1	RP11-131L12.4	-4.07	5.48e-05	0.00463	-0.15	-0.18	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118195702	chr12:118430147~118430699:+
THCA	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	4.07	5.48e-05	0.00463	0.11	0.18	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
THCA	cis	rs5758511	0.68	rs5758688	ENSG00000227370.1	RP4-669P10.19	4.07	5.48e-05	0.00463	0.21	0.18	Birth weight;	chr22:42266495	chr22:42132543~42132998:+
THCA	cis	rs853679	0.527	rs853690	ENSG00000220721.1	OR1F12	4.07	5.48e-05	0.00463	0.21	0.18	Depression;	chr6:28317705	chr6:28073316~28074233:+
THCA	cis	rs7726839	0.561	rs3915384	ENSG00000225138.6	CTD-2228K2.7	4.07	5.48e-05	0.00464	0.21	0.18	Obesity-related traits;	chr5:573280	chr5:473236~480884:+
THCA	cis	rs6496932	0.802	rs12442399	ENSG00000259630.2	CTD-2262B20.1	4.07	5.48e-05	0.00464	0.22	0.18	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85415228~85415633:+
THCA	cis	rs6496932	0.802	rs8038403	ENSG00000259630.2	CTD-2262B20.1	4.07	5.48e-05	0.00464	0.22	0.18	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85415228~85415633:+
THCA	cis	rs7521902	0.66	rs61768001	ENSG00000228397.1	RP1-224A6.3	-4.07	5.48e-05	0.00464	-0.33	-0.18	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22139327	chr1:22023994~22024968:-
THCA	cis	rs17853159	0.558	rs2096437	ENSG00000281912.1	LINC01144	-4.07	5.48e-05	0.00464	-0.2	-0.18	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45282709	chr1:45303910~45305619:+
THCA	cis	rs17853159	0.558	rs2096436	ENSG00000281912.1	LINC01144	-4.07	5.48e-05	0.00464	-0.2	-0.18	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45282897	chr1:45303910~45305619:+
THCA	cis	rs2836974	0.932	rs2836955	ENSG00000255568.3	BRWD1-AS2	4.07	5.48e-05	0.00464	0.16	0.18	Cognitive function;	chr21:39247961	chr21:39313935~39314962:+
THCA	cis	rs4664304	0.789	rs7595388	ENSG00000226266.5	AC009961.3	4.07	5.48e-05	0.00464	0.23	0.18	Crohn's disease;Inflammatory bowel disease;	chr2:159899834	chr2:159670708~159712435:-
THCA	cis	rs7560272	0.538	rs7370393	ENSG00000273245.1	RP11-434P11.2	-4.07	5.48e-05	0.00464	-0.21	-0.18	Schizophrenia;	chr2:73698509	chr2:73750256~73750786:-
THCA	cis	rs6671200	0.831	rs36101683	ENSG00000235501.4	RP4-639F20.1	-4.07	5.48e-05	0.00464	-0.38	-0.18	Stearic acid (18:0) levels;	chr1:95146690	chr1:94927566~94963270:+
THCA	cis	rs13098911	0.54	rs17215981	ENSG00000226074.4	PRSS44	4.07	5.48e-05	0.00464	0.35	0.18	Celiac disease;	chr3:46082926	chr3:46809359~46812558:-
THCA	cis	rs3758911	0.751	rs590699	ENSG00000255353.1	RP11-382M14.1	4.07	5.49e-05	0.00464	0.23	0.18	Coronary artery disease;	chr11:107447553	chr11:107176286~107177530:+
THCA	cis	rs7615952	0.673	rs115942855	ENSG00000248787.1	RP11-666A20.4	-4.07	5.49e-05	0.00464	-0.37	-0.18	Blood pressure (smoking interaction);	chr3:125883117	chr3:125908005~125910272:-
THCA	cis	rs7267979	1	rs2482931	ENSG00000276952.1	RP5-965G21.6	-4.07	5.49e-05	0.00464	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25284915~25285588:-
THCA	cis	rs11992162	0.507	rs60902764	ENSG00000254948.1	OR7E158P	4.07	5.49e-05	0.00464	0.23	0.18	Monocyte count;	chr8:11927482	chr8:11919900~11920809:-
THCA	cis	rs2115630	0.936	rs11073663	ENSG00000259295.5	CSPG4P12	-4.07	5.49e-05	0.00464	-0.25	-0.18	P wave terminal force;	chr15:84717037	chr15:85191438~85213905:+
THCA	cis	rs11633886	0.585	rs11070473	ENSG00000259200.1	RP11-718O11.1	-4.07	5.49e-05	0.00464	-0.23	-0.18	Diisocyanate-induced asthma;	chr15:45789560	chr15:45705078~45931069:+
THCA	cis	rs7176527	0.848	rs1374463	ENSG00000225151.9	GOLGA2P7	4.07	5.49e-05	0.00464	0.36	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:84199311~84230136:-
THCA	cis	rs6939532	0.522	rs9379870	ENSG00000124549.13	BTN2A3P	-4.07	5.49e-05	0.00465	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26374182	chr6:26421391~26432383:+
THCA	cis	rs9611565	0.649	rs139559	ENSG00000237037.8	NDUFA6-AS1	4.07	5.49e-05	0.00465	0.16	0.18	Vitiligo;	chr22:41795632	chr22:42090931~42137742:+
THCA	cis	rs7914558	1	rs10883824	ENSG00000272912.1	RP11-724N1.1	-4.07	5.49e-05	0.00465	-0.22	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103053140	chr10:102914585~102915404:+
THCA	cis	rs2221894	1	rs12674777	ENSG00000251191.6	LINC00589	-4.07	5.49e-05	0.00465	-0.22	-0.18	Obesity-related traits;	chr8:28986204	chr8:29673922~29748109:-
THCA	cis	rs2221894	0.96	rs10093622	ENSG00000251191.6	LINC00589	-4.07	5.49e-05	0.00465	-0.22	-0.18	Obesity-related traits;	chr8:29005420	chr8:29673922~29748109:-
THCA	cis	rs1979679	0.766	rs11049365	ENSG00000247934.4	RP11-967K21.1	-4.07	5.49e-05	0.00465	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28138401	chr12:28163298~28190738:-
THCA	cis	rs6570726	0.935	rs430561	ENSG00000270638.1	RP3-466P17.1	4.07	5.49e-05	0.00465	0.15	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145735570~145737218:+
THCA	cis	rs2303282	0.664	rs4784664	ENSG00000274031.1	RP11-413H22.3	-4.07	5.49e-05	0.00465	-0.22	-0.18	Breast cancer;	chr16:56413374	chr16:56465642~56466162:-
THCA	cis	rs7914558	0.966	rs10786745	ENSG00000213061.2	PFN1P11	4.07	5.49e-05	0.00465	0.23	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:102838011~102845473:-
THCA	cis	rs7246967	0.673	rs62119090	ENSG00000198153.8	ZNF849P	-4.07	5.5e-05	0.00465	-0.34	-0.18	Bronchopulmonary dysplasia;	chr19:22741112	chr19:22685167~22686732:+
THCA	cis	rs150992	0.547	rs325217	ENSG00000241597.2	CTD-2007H13.1	-4.07	5.5e-05	0.00465	-0.24	-0.18	Body mass index;	chr5:98844109	chr5:98954394~98954972:+
THCA	cis	rs2839186	0.814	rs2276257	ENSG00000215424.8	MCM3AP-AS1	4.07	5.5e-05	0.00465	0.11	0.18	Testicular germ cell tumor;	chr21:46291315	chr21:46229217~46259390:+
THCA	cis	rs7267979	0.816	rs376742	ENSG00000274973.1	RP13-401N8.7	-4.07	5.5e-05	0.00465	-0.21	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25845497~25845862:+
THCA	cis	rs7615952	0.866	rs6438949	ENSG00000272840.1	RP11-379B18.6	4.07	5.5e-05	0.00465	0.3	0.18	Blood pressure (smoking interaction);	chr3:125931221	chr3:125774714~125797953:+
THCA	cis	rs728616	0.681	rs55899456	ENSG00000225484.5	NUTM2B-AS1	-4.07	5.5e-05	0.00465	-0.33	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80290890	chr10:79663088~79826594:-
THCA	cis	rs2289681	0.573	rs75810445	ENSG00000280022.1	RP11-707O23.1	4.07	5.5e-05	0.00465	0.39	0.18	Cognitive function;	chr17:44863410	chr17:45592621~45593369:+
THCA	cis	rs2289681	0.573	rs16939653	ENSG00000280022.1	RP11-707O23.1	4.07	5.5e-05	0.00465	0.39	0.18	Cognitive function;	chr17:44873085	chr17:45592621~45593369:+
THCA	cis	rs2289681	0.573	rs114312108	ENSG00000280022.1	RP11-707O23.1	4.07	5.5e-05	0.00465	0.39	0.18	Cognitive function;	chr17:44881007	chr17:45592621~45593369:+
THCA	cis	rs2289681	0.573	rs55782331	ENSG00000280022.1	RP11-707O23.1	4.07	5.5e-05	0.00465	0.39	0.18	Cognitive function;	chr17:44882555	chr17:45592621~45593369:+
THCA	cis	rs713587	1	rs713587	ENSG00000224165.4	DNAJC27-AS1	-4.07	5.5e-05	0.00465	-0.1	-0.18	Body mass index in non-asthmatics;	chr2:24935412	chr2:24971390~25039694:+
THCA	cis	rs2018683	0.683	rs12538606	ENSG00000272568.4	CTB-113D17.1	4.07	5.5e-05	0.00465	0.18	0.18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929791	chr7:28979967~29013367:+
THCA	cis	rs9990333	0.762	rs6810239	ENSG00000207650.1	MIR570	-4.07	5.5e-05	0.00465	-0.19	-0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085292	chr3:195699401~195699497:+
THCA	cis	rs9512730	0.871	rs7992877	ENSG00000234031.1	RPS3AP44	-4.07	5.5e-05	0.00465	-0.2	-0.18	Schizophrenia;	chr13:27492729	chr13:26576886~26577675:+
THCA	cis	rs10911902	0.601	rs16825279	ENSG00000233196.2	GS1-304P7.1	-4.07	5.5e-05	0.00465	-0.3	-0.18	Schizophrenia;	chr1:186385523	chr1:186580515~186581191:-
THCA	cis	rs1501911	0.713	rs10479344	ENSG00000246763.5	RGMB-AS1	-4.07	5.5e-05	0.00465	-0.19	-0.18	Lung function (FEV1/FVC);	chr5:99012676	chr5:98769618~98773469:-
THCA	cis	rs8031584	1	rs35239376	ENSG00000178081.11	ULK4P3	4.07	5.5e-05	0.00465	0.26	0.18	Huntington's disease progression;	chr15:30998335	chr15:30103720~30131757:+
THCA	cis	rs9435732	0.778	rs2076604	ENSG00000235241.1	RP11-108M9.5	4.07	5.5e-05	0.00465	0.24	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16991570	chr1:16889095~16889602:+
THCA	cis	rs11971779	0.68	rs7783619	ENSG00000252332.1	RNU6-911P	-4.07	5.51e-05	0.00466	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139376691	chr7:139448740~139448843:+
THCA	cis	rs17853159	0.558	rs28664913	ENSG00000281912.1	LINC01144	-4.07	5.51e-05	0.00466	-0.2	-0.18	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45295788	chr1:45303910~45305619:+
THCA	cis	rs1005277	0.691	rs2474558	ENSG00000272983.1	RP11-508N22.12	-4.07	5.51e-05	0.00466	-0.16	-0.18	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38137337~38144399:+
THCA	cis	rs11971779	0.838	rs11764161	ENSG00000252332.1	RNU6-911P	-4.07	5.51e-05	0.00466	-0.23	-0.18	Diisocyanate-induced asthma;	chr7:139430452	chr7:139448740~139448843:+
THCA	cis	rs17666538	0.792	rs1669715	ENSG00000254207.1	RP11-43A14.1	4.07	5.51e-05	0.00466	0.37	0.18	IgG glycosylation;	chr8:643641	chr8:725188~725877:-
THCA	cis	rs11069062	0.866	rs12296422	ENSG00000270482.1	RP11-131L12.2	4.07	5.51e-05	0.00466	0.15	0.18	Obesity-related traits;	chr12:118711511	chr12:118375350~118376275:-
THCA	cis	rs1728785	0.901	rs11075687	ENSG00000274698.1	RP11-71L14.4	4.07	5.51e-05	0.00466	0.27	0.18	Ulcerative colitis;	chr16:68621991	chr16:68450283~68452318:+
THCA	cis	rs8014252	1	rs4902817	ENSG00000259158.2	ADAM20P1	-4.07	5.51e-05	0.00466	-0.21	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70421081	chr14:70468881~70483756:-
THCA	cis	rs2839627	0.561	rs4148970	ENSG00000225218.1	AP001628.6	4.07	5.51e-05	0.00466	0.27	0.18	Information processing speed;	chr21:42893183	chr21:42831040~42836477:-
THCA	cis	rs9534288	0.957	rs2404731	ENSG00000235903.6	CPB2-AS1	4.07	5.51e-05	0.00466	0.26	0.18	Blood protein levels;	chr13:46044249	chr13:46052806~46113332:+
THCA	cis	rs7572733	0.515	rs11891555	ENSG00000231621.1	AC013264.2	-4.07	5.51e-05	0.00466	-0.2	-0.18	Dermatomyositis;	chr2:197988816	chr2:197197991~197199273:+
THCA	cis	rs1923243	0.71	rs4650196	ENSG00000223479.3	RP4-788P17.1	4.07	5.51e-05	0.00466	0.21	0.18	Migraine;	chr1:73172117	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12124553	ENSG00000223479.3	RP4-788P17.1	4.07	5.51e-05	0.00466	0.21	0.18	Migraine;	chr1:73174844	chr1:73635216~73715214:+
THCA	cis	rs950776	0.518	rs2869055	ENSG00000261762.1	RP11-650L12.2	-4.07	5.51e-05	0.00466	-0.23	-0.18	Sudden cardiac arrest;	chr15:78530046	chr15:78589123~78591276:-
THCA	cis	rs12142240	0.738	rs10489769	ENSG00000232022.5	FAAHP1	-4.07	5.51e-05	0.00466	-0.21	-0.18	Menopause (age at onset);	chr1:46341031	chr1:46432129~46445521:+
THCA	cis	rs9926296	0.542	rs12599531	ENSG00000274627.1	RP11-104N10.2	4.07	5.51e-05	0.00466	0.19	0.18	Vitiligo;	chr16:89842993	chr16:89516797~89522217:+
THCA	cis	rs10129255	0.957	rs1056705	ENSG00000211970.3	IGHV4-61	-4.07	5.51e-05	0.00466	-0.11	-0.18	Kawasaki disease;	chr14:106714323	chr14:106639119~106639657:-
THCA	cis	rs2408955	0.504	rs11168441	ENSG00000273765.1	RP11-370I10.11	4.07	5.51e-05	0.00466	0.18	0.18	Glycated hemoglobin levels;	chr12:48182271	chr12:48360920~48361377:+
THCA	cis	rs875971	1	rs6963646	ENSG00000230189.5	GS1-124K5.2	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66220780	chr7:66409143~66490059:-
THCA	cis	rs78487399	0.808	rs7587268	ENSG00000234936.1	AC010883.5	4.07	5.51e-05	0.00466	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446753	chr2:43229573~43233394:+
THCA	cis	rs875971	0.638	rs7793569	ENSG00000223473.2	GS1-124K5.3	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66651646	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs6975195	ENSG00000223473.2	GS1-124K5.3	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66659787	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs3857688	ENSG00000223473.2	GS1-124K5.3	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66662819	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs2286684	ENSG00000223473.2	GS1-124K5.3	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66664843	chr7:66491049~66493566:-
THCA	cis	rs801193	0.935	rs2286683	ENSG00000223473.2	GS1-124K5.3	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66664856	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs10274773	ENSG00000223473.2	GS1-124K5.3	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66668591	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs11773829	ENSG00000223473.2	GS1-124K5.3	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66676087	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs7788576	ENSG00000223473.2	GS1-124K5.3	-4.07	5.51e-05	0.00466	-0.12	-0.18	Aortic root size;	chr7:66683315	chr7:66491049~66493566:-
THCA	cis	rs801193	0.935	rs2659916	ENSG00000223473.2	GS1-124K5.3	4.07	5.51e-05	0.00466	0.12	0.18	Aortic root size;	chr7:66686365	chr7:66491049~66493566:-
THCA	cis	rs801193	1	rs6958520	ENSG00000223473.2	GS1-124K5.3	4.07	5.51e-05	0.00466	0.12	0.18	Aortic root size;	chr7:66686466	chr7:66491049~66493566:-
THCA	cis	rs801193	0.967	rs2707849	ENSG00000223473.2	GS1-124K5.3	4.07	5.51e-05	0.00466	0.12	0.18	Aortic root size;	chr7:66687725	chr7:66491049~66493566:-
THCA	cis	rs6012953	0.967	rs4496379	ENSG00000231715.1	COX6CP2	-4.07	5.51e-05	0.00466	-0.19	-0.18	Vitiligo;	chr20:50543407	chr20:50479767~50479991:+
THCA	cis	rs4742903	0.904	rs10991187	ENSG00000270332.1	SMC2-AS1	4.07	5.51e-05	0.00466	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104233990	chr9:104080024~104093073:-
THCA	cis	rs4788570	0.615	rs1058750	ENSG00000260593.1	RP11-432I5.2	-4.07	5.52e-05	0.00466	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71645154	chr16:71623708~71626816:-
THCA	cis	rs3738443	0.951	rs61840056	ENSG00000259865.1	RP11-488L18.10	4.07	5.52e-05	0.00467	0.2	0.18	Alcohol dependence;	chr1:247205930	chr1:247187281~247188526:-
THCA	cis	rs3738443	1	rs61840059	ENSG00000259865.1	RP11-488L18.10	4.07	5.52e-05	0.00467	0.2	0.18	Alcohol dependence;	chr1:247207676	chr1:247187281~247188526:-
THCA	cis	rs5758511	0.68	rs5758688	ENSG00000237037.8	NDUFA6-AS1	-4.07	5.52e-05	0.00467	-0.18	-0.18	Birth weight;	chr22:42266495	chr22:42090931~42137742:+
THCA	cis	rs454217	0.791	rs337650	ENSG00000277851.1	RP11-756G20.1	4.07	5.52e-05	0.00467	0.19	0.18	Smoking quantity;	chr12:92309130	chr12:92247756~92363832:-
THCA	cis	rs9549367	0.569	rs3024719	ENSG00000269125.1	RP11-98F14.11	-4.07	5.52e-05	0.00467	-0.25	-0.18	Platelet distribution width;	chr13:113159911	chr13:113165002~113165183:-
THCA	cis	rs2919009	0.607	rs2919007	ENSG00000271670.1	RP11-95I16.4	4.07	5.52e-05	0.00467	0.21	0.18	Obesity-related traits;	chr10:120842499	chr10:120879256~120880667:-
THCA	cis	rs2919009	0.709	rs55710400	ENSG00000271670.1	RP11-95I16.4	4.07	5.52e-05	0.00467	0.22	0.18	Obesity-related traits;	chr10:120802676	chr10:120879256~120880667:-
THCA	cis	rs13113518	1	rs13133579	ENSG00000272969.1	RP11-528I4.2	4.07	5.52e-05	0.00467	0.21	0.18	Height;	chr4:55459921	chr4:55547112~55547889:+
THCA	cis	rs10090774	0.965	rs6578146	ENSG00000279766.1	RP11-642A1.2	4.07	5.52e-05	0.00467	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955768	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.965	rs6578147	ENSG00000279766.1	RP11-642A1.2	4.07	5.52e-05	0.00467	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955769	chr8:140572142~140572812:-
THCA	cis	rs758324	0.606	rs101194	ENSG00000224431.1	AC063976.7	-4.07	5.52e-05	0.00467	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132179720	chr5:132199456~132203487:+
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.52e-05	0.00467	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.52e-05	0.00467	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30726305~30727564:-
THCA	cis	rs889398	0.904	rs4783721	ENSG00000226232.7	RP11-419C5.2	4.07	5.52e-05	0.00467	0.18	0.18	Body mass index;	chr16:69527253	chr16:69976388~69996188:-
THCA	cis	rs7474896	0.559	rs2738185	ENSG00000263064.2	RP11-291L22.7	-4.07	5.52e-05	0.00467	-0.25	-0.18	Obesity (extreme);	chr10:37958808	chr10:38448689~38448949:+
THCA	cis	rs7711186	0.786	rs11740530	ENSG00000252464.1	RN7SKP70	4.07	5.52e-05	0.00467	0.22	0.18	Urate levels in obese individuals;	chr5:178656316	chr5:178619728~178619998:-
THCA	cis	rs11671653	1	rs74562182	ENSG00000267100.1	ILF3-AS1	4.07	5.52e-05	0.00467	0.21	0.18	LDL cholesterol;	chr19:10724936	chr19:10651862~10653844:-
THCA	cis	rs9925964	0.804	rs9926533	ENSG00000260911.2	RP11-196G11.2	-4.07	5.53e-05	0.00467	-0.15	-0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31002858	chr16:31043150~31049868:+
THCA	cis	rs8022179	0.566	rs959083	ENSG00000244691.1	RPL10AP1	-4.07	5.53e-05	0.00467	-0.26	-0.18	Monocyte count;	chr14:103356350	chr14:103412119~103412761:-
THCA	cis	rs3755605	0.52	rs1082975	ENSG00000242578.1	RP11-469J4.3	4.07	5.53e-05	0.00467	0.21	0.18	Testicular germ cell tumor;	chr3:170221724	chr3:170410512~170418615:+
THCA	cis	rs7267979	0.78	rs2500413	ENSG00000274973.1	RP13-401N8.7	-4.07	5.53e-05	0.00467	-0.21	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.714	rs2474763	ENSG00000274973.1	RP13-401N8.7	-4.07	5.53e-05	0.00467	-0.21	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25845497~25845862:+
THCA	cis	rs17604090	0.526	rs10260080	ENSG00000227855.3	DPY19L2P3	4.07	5.53e-05	0.00467	0.27	0.18	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29718325	chr7:29650227~29742594:+
THCA	cis	rs8064024	0.538	rs11076854	ENSG00000267077.1	RP11-127I20.5	-4.07	5.53e-05	0.00467	-0.21	-0.18	Cancer;	chr16:4879268	chr16:4795265~4796532:-
THCA	cis	rs2439831	0.867	rs933941	ENSG00000205771.5	CATSPER2P1	-4.07	5.53e-05	0.00467	-0.24	-0.18	Lung cancer in ever smokers;	chr15:43340028	chr15:43726918~43747094:-
THCA	cis	rs4906332	1	rs35862113	ENSG00000244691.1	RPL10AP1	-4.07	5.53e-05	0.00467	-0.24	-0.18	Coronary artery disease;	chr14:103390892	chr14:103412119~103412761:-
THCA	cis	rs4906332	0.84	rs34161327	ENSG00000244691.1	RPL10AP1	-4.07	5.53e-05	0.00467	-0.24	-0.18	Coronary artery disease;	chr14:103390988	chr14:103412119~103412761:-
THCA	cis	rs7632954	0.632	rs7633250	ENSG00000227110.5	LMCD1-AS1	4.07	5.53e-05	0.00467	0.23	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8474007	chr3:7952805~8611924:-
THCA	cis	rs4934494	0.677	rs12777243	ENSG00000240996.1	RP11-80H5.7	-4.07	5.53e-05	0.00467	-0.22	-0.18	Red blood cell count;	chr10:89576360	chr10:89694295~89697928:-
THCA	cis	rs591584	0.73	rs2155098	ENSG00000255893.1	RP11-685N10.1	-4.07	5.54e-05	0.00468	-0.22	-0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94588886	chr11:94472908~94473570:-
THCA	cis	rs591584	0.693	rs11020845	ENSG00000255893.1	RP11-685N10.1	-4.07	5.54e-05	0.00468	-0.22	-0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94589186	chr11:94472908~94473570:-
THCA	cis	rs591584	0.693	rs11020846	ENSG00000255893.1	RP11-685N10.1	-4.07	5.54e-05	0.00468	-0.22	-0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94589187	chr11:94472908~94473570:-
THCA	cis	rs7824557	0.527	rs2409756	ENSG00000255495.1	AC145124.2	-4.07	5.54e-05	0.00468	-0.21	-0.18	Retinal vascular caliber;	chr8:11384516	chr8:12194467~12196280:+
THCA	cis	rs1971762	0.527	rs1247957	ENSG00000270175.1	RP11-793H13.11	4.07	5.54e-05	0.00468	0.12	0.18	Height;	chr12:53567709	chr12:53500162~53500936:-
THCA	cis	rs2028299	0.879	rs4932262	ENSG00000259677.1	RP11-493E3.1	4.07	5.54e-05	0.00468	0.25	0.18	Type 2 diabetes;	chr15:89896365	chr15:89876540~89877285:+
THCA	cis	rs2898290	0.622	rs978802	ENSG00000254527.1	ENPP7P12	-4.07	5.54e-05	0.00468	-0.23	-0.18	Systolic blood pressure;	chr8:11485769	chr8:12205759~12206389:-
THCA	cis	rs7656342	0.535	rs13116446	ENSG00000250342.1	SNRPCP16	-4.07	5.54e-05	0.00468	-0.25	-0.18	Gut microbiota (bacterial taxa);	chr4:9858273	chr4:9051842~9052051:-
THCA	cis	rs7819412	0.744	rs4841503	ENSG00000261451.1	RP11-981G7.1	-4.07	5.54e-05	0.00468	-0.23	-0.18	Triglycerides;	chr8:11166817	chr8:10433672~10438312:+
THCA	cis	rs9863	0.861	rs10846579	ENSG00000270061.1	RP11-214K3.19	-4.07	5.54e-05	0.00468	-0.24	-0.18	White blood cell count;	chr12:123922856	chr12:123969990~123970344:-
THCA	cis	rs9863	0.861	rs11057394	ENSG00000270061.1	RP11-214K3.19	-4.07	5.54e-05	0.00468	-0.24	-0.18	White blood cell count;	chr12:123923129	chr12:123969990~123970344:-
THCA	cis	rs9863	0.861	rs12809125	ENSG00000270061.1	RP11-214K3.19	-4.07	5.54e-05	0.00468	-0.24	-0.18	White blood cell count;	chr12:123923444	chr12:123969990~123970344:-
THCA	cis	rs10090774	0.901	rs11781597	ENSG00000280303.2	ERICD	-4.07	5.54e-05	0.00468	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140995643	chr8:140636281~140638283:+
THCA	cis	rs3755605	0.728	rs11718963	ENSG00000242578.1	RP11-469J4.3	4.07	5.54e-05	0.00468	0.21	0.18	Testicular germ cell tumor;	chr3:170184973	chr3:170410512~170418615:+
THCA	cis	rs7829975	0.806	rs2428	ENSG00000253981.4	ALG1L13P	4.07	5.54e-05	0.00468	0.17	0.18	Mood instability;	chr8:8783635	chr8:8236003~8244667:-
THCA	cis	rs7259376	0.777	rs7247735	ENSG00000269138.1	ZNF209P	-4.07	5.54e-05	0.00468	-0.19	-0.18	Menopause (age at onset);	chr19:22392686	chr19:22463922~22473036:+
THCA	cis	rs8062405	0.895	rs56186137	ENSG00000270424.1	RP11-1348G14.6	4.07	5.54e-05	0.00468	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28749959~28750595:-
THCA	cis	rs4819052	0.632	rs4819050	ENSG00000273796.1	LL21NC02-21A1.1	-4.07	5.54e-05	0.00468	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45403809~45404369:-
THCA	cis	rs12612619	0.689	rs1124649	ENSG00000272148.1	RP11-195B17.1	-4.07	5.54e-05	0.00468	-0.19	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27037601	chr2:27062428~27062907:-
THCA	cis	rs7170668	0.965	rs9920389	ENSG00000259134.4	LINC00924	4.07	5.54e-05	0.00468	0.23	0.18	Motion sickness;	chr15:95488331	chr15:95433095~95507847:+
THCA	cis	rs756699	0.749	rs244689	ENSG00000279469.1	RP11-215P8.2	-4.07	5.54e-05	0.00468	-0.28	-0.18	Multiple sclerosis;	chr5:134087125	chr5:134394360~134395008:-
THCA	cis	rs6494488	0.5	rs76625439	ENSG00000259635.1	AC100830.3	-4.07	5.54e-05	0.00468	-0.48	-0.18	Coronary artery disease;	chr15:64726705	chr15:64701248~64719602:+
THCA	cis	rs804280	1	rs804280	ENSG00000254948.1	OR7E158P	-4.07	5.54e-05	0.00468	-0.23	-0.18	Myopia (pathological);	chr8:11755189	chr8:11919900~11920809:-
THCA	cis	rs56046484	0.797	rs907260	ENSG00000259630.2	CTD-2262B20.1	4.07	5.54e-05	0.00468	0.26	0.18	Testicular germ cell tumor;	chr15:85133526	chr15:85415228~85415633:+
THCA	cis	rs1993293	0.636	rs749516	ENSG00000254744.3	CTD-3076O17.1	4.07	5.54e-05	0.00468	0.21	0.18	Coronary artery calcification;	chr15:99754345	chr15:99970215~99974010:+
THCA	cis	rs7045881	0.733	rs62544413	ENSG00000254396.1	RP11-56F10.3	4.07	5.54e-05	0.00468	0.33	0.18	Schizophrenia;	chr9:26889136	chr9:27102630~27104728:+
THCA	cis	rs875971	0.522	rs6960048	ENSG00000229180.5	GS1-124K5.11	4.07	5.54e-05	0.00468	0.13	0.18	Aortic root size;	chr7:65943052	chr7:66526088~66542624:-
THCA	cis	rs7267979	0.753	rs400357	ENSG00000274973.1	RP13-401N8.7	-4.07	5.55e-05	0.00468	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25845497~25845862:+
THCA	cis	rs12893668	0.703	rs4906338	ENSG00000252469.1	RNU7-160P	4.07	5.55e-05	0.00469	0.22	0.18	Reticulocyte count;	chr14:103584020	chr14:103550345~103550406:+
THCA	cis	rs4308124	0.708	rs6716091	ENSG00000230499.1	AC108463.1	-4.07	5.55e-05	0.00469	-0.27	-0.18	Vitiligo;	chr2:111233556	chr2:111195963~111206494:+
THCA	cis	rs2562456	0.833	rs11666447	ENSG00000268117.1	VN1R84P	4.07	5.55e-05	0.00469	0.3	0.18	Pain;	chr19:21416270	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs11666525	ENSG00000268117.1	VN1R84P	4.07	5.55e-05	0.00469	0.3	0.18	Pain;	chr19:21416503	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs62110424	ENSG00000268117.1	VN1R84P	4.07	5.55e-05	0.00469	0.3	0.18	Pain;	chr19:21416835	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs3853837	ENSG00000268117.1	VN1R84P	4.07	5.55e-05	0.00469	0.3	0.18	Pain;	chr19:21419172	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.793	rs3853838	ENSG00000268117.1	VN1R84P	4.07	5.55e-05	0.00469	0.3	0.18	Pain;	chr19:21419192	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs62110426	ENSG00000268117.1	VN1R84P	4.07	5.55e-05	0.00469	0.3	0.18	Pain;	chr19:21420124	chr19:21719801~21720035:-
THCA	cis	rs1908814	0.516	rs13281315	ENSG00000254948.1	OR7E158P	-4.07	5.55e-05	0.00469	-0.23	-0.18	Neuroticism;	chr8:11937346	chr8:11919900~11920809:-
THCA	cis	rs875971	0.54	rs736270	ENSG00000229886.1	RP5-1132H15.3	4.07	5.55e-05	0.00469	0.19	0.18	Aortic root size;	chr7:65963835	chr7:66025126~66031544:-
THCA	cis	rs3740713	1	rs57311859	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr11:18490243~18490955:-
THCA	cis	rs3740713	0.92	rs112973292	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr11:18490243~18490955:-
THCA	cis	rs3740713	0.92	rs73438656	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr11:18490243~18490955:-
THCA	cis	rs3740713	0.92	rs73438659	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438666	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs16935424	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438674	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438690	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438695	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73440606	ENSG00000256464.1	YWHABP2	4.07	5.55e-05	0.00469	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr11:18490243~18490955:-
THCA	cis	rs71520386	0.632	rs1474349	ENSG00000226329.2	AC005682.6	-4.07	5.55e-05	0.00469	-0.24	-0.18	Fibrinogen levels;	chr7:22814146	chr7:22863874~22881350:-
THCA	cis	rs1125355	1	rs1125355	ENSG00000243792.1	OR7E89P	-4.07	5.55e-05	0.00469	-0.28	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158844068	chr2:158853755~158854576:+
THCA	cis	rs10833905	1	rs12279454	ENSG00000246225.5	RP11-17A1.3	-4.07	5.55e-05	0.00469	-0.26	-0.18	Sudden cardiac arrest;	chr11:23020769	chr11:22829380~22945393:+
THCA	cis	rs7583236	0.568	rs10182547	ENSG00000179818.12	PCBP1-AS1	-4.07	5.55e-05	0.00469	-0.19	-0.18	Obesity-related traits;	chr2:69954843	chr2:69962263~70103220:-
THCA	cis	rs7809950	0.559	rs2248465	ENSG00000238832.1	snoU109	4.07	5.55e-05	0.00469	0.21	0.18	Coronary artery disease;	chr7:107663183	chr7:107603363~107603507:+
THCA	cis	rs10771431	0.935	rs1117735	ENSG00000256427.1	RP11-118B22.4	4.07	5.55e-05	0.00469	0.21	0.18	Breast size;	chr12:9220132	chr12:9246497~9257960:+
THCA	cis	rs71520386	0.898	rs12536091	ENSG00000228649.7	AC005682.5	-4.07	5.55e-05	0.00469	-0.28	-0.18	Fibrinogen levels;	chr7:22788581	chr7:22854178~22861579:+
THCA	cis	rs7267979	0.727	rs4815431	ENSG00000274973.1	RP13-401N8.7	4.07	5.55e-05	0.00469	0.21	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25845497~25845862:+
THCA	cis	rs1383484	1	rs28612730	ENSG00000259728.4	LINC00933	-4.07	5.55e-05	0.00469	-0.23	-0.18	Height;	chr15:83842454	chr15:84570649~84580175:+
THCA	cis	rs459571	0.959	rs460888	ENSG00000235106.7	LINC00094	4.07	5.55e-05	0.00469	0.16	0.18	Platelet distribution width;	chr9:134048001	chr9:134025439~134034666:+
THCA	cis	rs8054556	0.708	rs2278557	ENSG00000183604.13	SMG1P5	-4.07	5.55e-05	0.00469	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr16:30082458	chr16:30267553~30335374:-
THCA	cis	rs2235642	0.701	rs2281230	ENSG00000260989.1	LA16c-395F10.2	-4.07	5.55e-05	0.00469	-0.2	-0.18	Coronary artery disease;	chr16:1551766	chr16:1580527~1610328:+
THCA	cis	rs11175194	0.655	rs68047317	ENSG00000255850.1	TMEM5-AS1	4.07	5.55e-05	0.00469	0.36	0.18	Epithelial ovarian cancer;	chr12:63871384	chr12:63808845~63822156:-
THCA	cis	rs11239930	0.56	rs632334	ENSG00000278811.3	LINC00624	4.07	5.56e-05	0.00469	0.22	0.18	AIDS progression;	chr1:147079972	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.538	rs630630	ENSG00000278811.3	LINC00624	4.07	5.56e-05	0.00469	0.22	0.18	AIDS progression;	chr1:147080377	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.538	rs618575	ENSG00000278811.3	LINC00624	4.07	5.56e-05	0.00469	0.22	0.18	AIDS progression;	chr1:147080759	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.517	rs4950354	ENSG00000278811.3	LINC00624	4.07	5.56e-05	0.00469	0.22	0.18	AIDS progression;	chr1:147082674	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.538	rs4950355	ENSG00000278811.3	LINC00624	4.07	5.56e-05	0.00469	0.22	0.18	AIDS progression;	chr1:147082700	chr1:147258885~147517875:-
THCA	cis	rs12893668	0.667	rs8017628	ENSG00000244691.1	RPL10AP1	-4.07	5.56e-05	0.00469	-0.26	-0.18	Reticulocyte count;	chr14:103581091	chr14:103412119~103412761:-
THCA	cis	rs4950322	1	rs72694720	ENSG00000226015.2	CCT8P1	4.07	5.56e-05	0.00469	0.23	0.18	Protein quantitative trait loci;	chr1:147371939	chr1:147203276~147204932:-
THCA	cis	rs6860806	0.631	rs6863548	ENSG00000263597.1	MIR3936	4.07	5.56e-05	0.00469	0.18	0.18	Breast cancer;	chr5:132240227	chr5:132365490~132365599:-
THCA	cis	rs2933343	0.621	rs789249	ENSG00000231305.3	RP11-723O4.2	4.07	5.56e-05	0.00469	0.2	0.18	IgG glycosylation;	chr3:128859610	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.621	rs789241	ENSG00000231305.3	RP11-723O4.2	4.07	5.56e-05	0.00469	0.2	0.18	IgG glycosylation;	chr3:128866909	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.649	rs2638845	ENSG00000231305.3	RP11-723O4.2	4.07	5.56e-05	0.00469	0.2	0.18	IgG glycosylation;	chr3:128868526	chr3:128861313~128871540:-
THCA	cis	rs34034104	1	rs34034104	ENSG00000223313.1	RNU6-516P	4.07	5.56e-05	0.00469	0.24	0.18	Itch intensity from mosquito bite;Itch intensity from mosquito bite adjusted by bite size;	chr15:40432834	chr15:40529570~40529673:+
THCA	cis	rs701145	0.585	rs6789213	ENSG00000243069.6	ARHGEF26-AS1	4.07	5.56e-05	0.00469	0.35	0.18	Coronary artery disease;	chr3:154075006	chr3:154024401~154121332:-
THCA	cis	rs17695224	0.545	rs4802884	ENSG00000275055.1	CTC-471J1.11	-4.07	5.56e-05	0.00469	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51845202	chr19:52049007~52049754:+
THCA	cis	rs72831838	0.537	rs72954658	ENSG00000227359.1	AC017074.2	4.07	5.56e-05	0.00469	0.3	0.18	Mucinous ovarian carcinoma;	chr2:113273023	chr2:113677702~113704078:-
THCA	cis	rs10435719	0.902	rs6601633	ENSG00000206014.6	OR7E161P	4.07	5.56e-05	0.00469	0.22	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11928597~11929563:-
THCA	cis	rs8105895	0.935	rs7260331	ENSG00000269345.1	VN1R85P	4.07	5.56e-05	0.0047	0.25	0.18	Body mass index (change over time);	chr19:22108969	chr19:22174766~22175191:-
THCA	cis	rs9595908	0.645	rs7983065	ENSG00000212293.1	SNORA16	4.07	5.56e-05	0.0047	0.22	0.18	Body mass index;	chr13:32806648	chr13:32420390~32420516:-
THCA	cis	rs7267979	1	rs2387881	ENSG00000276952.1	RP5-965G21.6	-4.07	5.56e-05	0.0047	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25284915~25285588:-
THCA	cis	rs7432375	0.966	rs7618871	ENSG00000273455.1	RP11-305O4.3	-4.07	5.56e-05	0.0047	-0.24	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136681578	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.903	rs10935185	ENSG00000273455.1	RP11-305O4.3	4.07	5.56e-05	0.0047	0.24	0.18	Gestational age at birth (child effect);	chr3:136571687	chr3:136087475~136087913:-
THCA	cis	rs599083	0.53	rs667126	ENSG00000212093.1	AP000807.1	-4.07	5.56e-05	0.0047	-0.2	-0.18	Bone mineral density (spine);	chr11:68410260	chr11:68506083~68506166:-
THCA	cis	rs13434995	0.513	rs17721497	ENSG00000249700.7	SRD5A3-AS1	4.07	5.56e-05	0.0047	0.27	0.18	Adiponectin levels;	chr4:55445081	chr4:55363971~55395847:-
THCA	cis	rs5758659	0.652	rs133326	ENSG00000205702.9	CYP2D7	4.07	5.56e-05	0.0047	0.14	0.18	Cognitive function;	chr22:42010881	chr22:42140203~42144577:-
THCA	cis	rs10186029	0.509	rs2371793	ENSG00000270659.1	RP11-105N14.1	4.07	5.56e-05	0.0047	0.16	0.18	Systemic sclerosis;	chr2:213080358	chr2:213152970~213153659:+
THCA	cis	rs1923243	0.649	rs4526565	ENSG00000223479.3	RP4-788P17.1	-4.07	5.56e-05	0.0047	-0.2	-0.18	Migraine;	chr1:72936319	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.592	rs4271155	ENSG00000223479.3	RP4-788P17.1	-4.07	5.56e-05	0.0047	-0.2	-0.18	Migraine;	chr1:72936327	chr1:73635216~73715214:+
THCA	cis	rs2721195	0.967	rs748193	ENSG00000265393.1	CTD-2517M22.17	-4.07	5.57e-05	0.0047	-0.23	-0.18	Age at first birth;	chr8:144456732	chr8:144512567~144513672:+
THCA	cis	rs2836974	0.897	rs34035316	ENSG00000255568.3	BRWD1-AS2	4.07	5.57e-05	0.0047	0.16	0.18	Cognitive function;	chr21:39222097	chr21:39313935~39314962:+
THCA	cis	rs8105895	0.935	rs988211	ENSG00000269345.1	VN1R85P	4.07	5.57e-05	0.0047	0.26	0.18	Body mass index (change over time);	chr19:22119734	chr19:22174766~22175191:-
THCA	cis	rs4337869	0.502	rs4337870	ENSG00000250492.1	INTS6P1	-4.07	5.57e-05	0.0047	-0.23	-0.18	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr5:38728159	chr5:39718984~39721513:-
THCA	cis	rs34421088	0.56	rs2467520	ENSG00000206014.6	OR7E161P	4.07	5.57e-05	0.0047	0.22	0.18	Neuroticism;	chr8:11541444	chr8:11928597~11929563:-
THCA	cis	rs6496932	0.774	rs12901648	ENSG00000259630.2	CTD-2262B20.1	-4.07	5.57e-05	0.0047	-0.27	-0.18	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:85415228~85415633:+
THCA	cis	rs911555	0.692	rs7140647	ENSG00000269910.1	RP11-73M18.10	-4.07	5.57e-05	0.0047	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103694516~103695050:-
THCA	cis	rs2033711	0.84	rs4801590	ENSG00000269054.1	CTD-2619J13.3	-4.07	5.57e-05	0.0047	-0.15	-0.18	Uric acid clearance;	chr19:58450446	chr19:58362585~58366591:+
THCA	cis	rs11089937	0.555	rs6001226	ENSG00000211639.2	IGLV4-60	4.07	5.57e-05	0.0047	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22162199~22162681:+
THCA	cis	rs3764021	0.87	rs10844622	ENSG00000256594.6	RP11-705C15.2	4.07	5.57e-05	0.0047	0.15	0.18	Type 1 diabetes;	chr12:9732486	chr12:9633419~9658412:+
THCA	cis	rs17772222	0.74	rs61975276	ENSG00000222990.1	RNU4-22P	4.07	5.57e-05	0.0047	0.23	0.18	Coronary artery calcification;	chr14:88511193	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs61975277	ENSG00000222990.1	RNU4-22P	4.07	5.57e-05	0.0047	0.23	0.18	Coronary artery calcification;	chr14:88511202	chr14:88513498~88513663:+
THCA	cis	rs763121	0.889	rs9610971	ENSG00000273076.1	RP3-508I15.22	4.07	5.57e-05	0.0047	0.19	0.18	Menopause (age at onset);	chr22:38514805	chr22:38743495~38743910:+
THCA	cis	rs6921919	0.945	rs16901847	ENSG00000280107.1	AL022393.9	-4.07	5.57e-05	0.0047	-0.22	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28170845~28172521:+
THCA	cis	rs73230612	1	rs9815319	ENSG00000242767.1	ZBTB20-AS4	4.07	5.57e-05	0.0047	0.24	0.18	Type 2 diabetes;	chr3:115073807	chr3:115100423~115103061:+
THCA	cis	rs3755605	0.52	rs1082978	ENSG00000242578.1	RP11-469J4.3	4.07	5.57e-05	0.0047	0.21	0.18	Testicular germ cell tumor;	chr3:170219204	chr3:170410512~170418615:+
THCA	cis	rs2342371	0.565	rs13084212	ENSG00000273013.1	CTD-2002J20.1	4.07	5.57e-05	0.0047	0.17	0.18	Fat distribution (HIV);	chr3:196485340	chr3:196474801~196475394:+
THCA	cis	rs6964833	0.873	rs4717905	ENSG00000184616.8	AC004166.6	4.07	5.57e-05	0.0047	0.28	0.18	Menarche (age at onset);	chr7:74668903	chr7:74906673~74913256:-
THCA	cis	rs34779708	0.733	rs16935945	ENSG00000233200.1	RP11-324I22.2	4.07	5.57e-05	0.0047	0.23	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs12777960	ENSG00000233200.1	RP11-324I22.2	4.07	5.57e-05	0.0047	0.23	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35219894~35230598:-
THCA	cis	rs58521262	0.652	rs4024169	ENSG00000198153.8	ZNF849P	-4.07	5.57e-05	0.00471	-0.23	-0.18	Testicular germ cell tumor;	chr19:22718861	chr19:22685167~22686732:+
THCA	cis	rs1923243	0.649	rs4579707	ENSG00000223479.3	RP4-788P17.1	-4.07	5.57e-05	0.00471	-0.2	-0.18	Migraine;	chr1:72930844	chr1:73635216~73715214:+
THCA	cis	rs7819412	0.593	rs11778398	ENSG00000255310.2	AF131215.2	-4.07	5.58e-05	0.00471	-0.17	-0.18	Triglycerides;	chr8:11116733	chr8:11107788~11109726:-
THCA	cis	rs1389724	0.606	rs11102163	ENSG00000259834.1	RP11-284N8.3	4.07	5.58e-05	0.00471	0.16	0.18	Schizophrenia;	chr1:110792058	chr1:110653560~110657040:-
THCA	cis	rs3740713	1	rs73440615	ENSG00000256464.1	YWHABP2	4.07	5.58e-05	0.00471	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr11:18490243~18490955:-
THCA	cis	rs7809615	0.581	rs57980352	ENSG00000244219.5	GS1-259H13.2	-4.07	5.58e-05	0.00471	-0.39	-0.18	Blood metabolite ratios;	chr7:99387785	chr7:99598066~99610813:+
THCA	cis	rs1232027	0.656	rs836795	ENSG00000249655.1	CTC-325J23.2	4.07	5.58e-05	0.00471	0.21	0.18	Huntington's disease progression;	chr5:80716252	chr5:80630313~80631590:-
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Body mass index;	chr17:30758740	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Body mass index;	chr17:30774046	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs12006	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000265443.1	CTD-2349P21.6	-4.07	5.58e-05	0.00471	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30726305~30727564:-
THCA	cis	rs75504410	0.85	rs77248011	ENSG00000231160.8	KLF3-AS1	-4.07	5.58e-05	0.00471	-0.21	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38606680	chr4:38612701~38664883:-
THCA	cis	rs60180747	1	rs16953563	ENSG00000261318.1	RP11-653J6.1	-4.07	5.58e-05	0.00471	-0.24	-0.18	Testicular germ cell tumor;	chr15:66394432	chr15:66278498~66293357:-
THCA	cis	rs17695224	0.545	rs11666614	ENSG00000275055.1	CTC-471J1.11	-4.07	5.58e-05	0.00471	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51842833	chr19:52049007~52049754:+
THCA	cis	rs11971779	0.816	rs11979272	ENSG00000252332.1	RNU6-911P	-4.07	5.58e-05	0.00471	-0.24	-0.18	Diisocyanate-induced asthma;	chr7:139389323	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.941	rs7800795	ENSG00000252332.1	RNU6-911P	-4.07	5.58e-05	0.00471	-0.24	-0.18	Diisocyanate-induced asthma;	chr7:139395602	chr7:139448740~139448843:+
THCA	cis	rs893363	0.559	rs3774611	ENSG00000271916.1	RP11-884K10.6	-4.07	5.58e-05	0.00471	-0.2	-0.18	Axial length;	chr3:53806638	chr3:53797764~53798019:-
THCA	cis	rs12612619	0.689	rs6711384	ENSG00000272148.1	RP11-195B17.1	4.07	5.58e-05	0.00471	0.18	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057224	chr2:27062428~27062907:-
THCA	cis	rs12612619	0.677	rs3754733	ENSG00000272148.1	RP11-195B17.1	4.07	5.58e-05	0.00471	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27026377	chr2:27062428~27062907:-
THCA	cis	rs67478160	0.619	rs2368560	ENSG00000269940.1	RP11-73M18.7	4.07	5.58e-05	0.00471	0.18	0.18	Schizophrenia;	chr14:103806974	chr14:103694560~103695170:+
THCA	cis	rs10875746	0.855	rs73102065	ENSG00000258234.1	RP11-370I10.2	4.07	5.58e-05	0.00471	0.22	0.18	Longevity (90 years and older);	chr12:48098824	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.855	rs73102067	ENSG00000258234.1	RP11-370I10.2	4.07	5.58e-05	0.00471	0.22	0.18	Longevity (90 years and older);	chr12:48100643	chr12:48231098~48284210:-
THCA	cis	rs7088591	0.867	rs117489669	ENSG00000276818.1	AC026393.1	4.07	5.59e-05	0.00471	0.4	0.18	Blood pressure;	chr10:58018946	chr10:57095699~57095781:+
THCA	cis	rs75504410	0.579	rs337626	ENSG00000231160.8	KLF3-AS1	-4.07	5.59e-05	0.00471	-0.13	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38629856	chr4:38612701~38664883:-
THCA	cis	rs780094	0.5	rs7577311	ENSG00000234072.1	AC074117.10	4.07	5.59e-05	0.00471	0.14	0.18	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27571054	chr2:27356246~27367622:+
THCA	cis	rs338389	0.591	rs8037902	ENSG00000260657.2	RP11-315D16.4	4.07	5.59e-05	0.00471	0.22	0.18	Survival in rectal cancer;	chr15:67988365	chr15:68267792~68277994:-
THCA	cis	rs78487399	0.71	rs17031133	ENSG00000234936.1	AC010883.5	-4.07	5.59e-05	0.00471	-0.23	-0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617694	chr2:43229573~43233394:+
THCA	cis	rs1371614	0.61	rs6547317	ENSG00000272148.1	RP11-195B17.1	4.07	5.59e-05	0.00471	0.17	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929051	chr2:27062428~27062907:-
THCA	cis	rs6142618	0.783	rs6057548	ENSG00000224452.1	RSL24D1P6	-4.07	5.59e-05	0.00471	-0.23	-0.18	Inflammatory bowel disease;	chr20:32266575	chr20:32170390~32170790:-
THCA	cis	rs4763879	0.739	rs7310460	ENSG00000214776.8	RP11-726G1.1	-4.07	5.59e-05	0.00471	-0.22	-0.18	Type 1 diabetes;	chr12:9688177	chr12:9467552~9576275:+
THCA	cis	rs11960179	0.892	rs6877445	ENSG00000250066.1	RP11-141O11.1	-4.07	5.59e-05	0.00472	-0.33	-0.18	Glomerular filtration rate (creatinine);	chr5:68482223	chr5:68963246~68967845:+
THCA	cis	rs6732426	0.66	rs11124931	ENSG00000279873.2	LINC01126	4.07	5.59e-05	0.00472	0.14	0.18	Hair morphology;	chr2:43372113	chr2:43227210~43228855:+
THCA	cis	rs6683071	0.557	rs2378605	ENSG00000225265.1	TAF1A-AS1	4.07	5.59e-05	0.00472	0.24	0.18	Cognitive performance;	chr1:222732211	chr1:222589825~222593032:+
THCA	cis	rs10860794	0.569	rs1073083	ENSG00000274560.1	RP11-285E23.2	-4.07	5.59e-05	0.00472	-0.13	-0.18	Blood protein levels;	chr12:101701162	chr12:101696002~101696450:-
THCA	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	4.07	5.59e-05	0.00472	0.23	0.18	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
THCA	cis	rs3892630	0.757	rs8109823	ENSG00000267475.1	CTD-2538C1.2	-4.07	5.59e-05	0.00472	-0.26	-0.18	Red blood cell traits;	chr19:32692410	chr19:32687089~32691750:-
THCA	cis	rs10435719	0.902	rs4840599	ENSG00000206014.6	OR7E161P	4.07	5.59e-05	0.00472	0.22	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11928597~11929563:-
THCA	cis	rs17286411	0.671	rs4788554	ENSG00000260185.1	RP11-432I5.6	-4.07	5.59e-05	0.00472	-0.26	-0.18	Blood protein levels;	chr16:71751914	chr16:71655027~71664212:+
THCA	cis	rs1923243	0.714	rs6672279	ENSG00000223479.3	RP4-788P17.1	-4.07	5.59e-05	0.00472	-0.2	-0.18	Migraine;	chr1:73160844	chr1:73635216~73715214:+
THCA	cis	rs589448	0.902	rs642786	ENSG00000274979.1	RP11-1143G9.5	-4.07	5.59e-05	0.00472	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69364682	chr12:69326574~69331882:-
THCA	cis	rs589448	0.902	rs315131	ENSG00000274979.1	RP11-1143G9.5	-4.07	5.59e-05	0.00472	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69368059	chr12:69326574~69331882:-
THCA	cis	rs589448	0.902	rs315138	ENSG00000274979.1	RP11-1143G9.5	-4.07	5.59e-05	0.00472	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69371070	chr12:69326574~69331882:-
THCA	cis	rs589448	0.902	rs528974	ENSG00000274979.1	RP11-1143G9.5	-4.07	5.59e-05	0.00472	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69372138	chr12:69326574~69331882:-
THCA	cis	rs800160	0.72	rs2651782	ENSG00000199550.1	Y_RNA	4.07	5.59e-05	0.00472	0.28	0.18	Bacteremia;	chr11:2324612	chr11:2372638~2372750:+
THCA	cis	rs934734	0.532	rs10153675	ENSG00000214533.3	KRT18P33	-4.07	5.59e-05	0.00472	-0.23	-0.18	Rheumatoid arthritis;	chr2:65422446	chr2:65666695~65667737:+
THCA	cis	rs9810089	0.934	rs10935184	ENSG00000273455.1	RP11-305O4.3	4.07	5.59e-05	0.00472	0.24	0.18	Gestational age at birth (child effect);	chr3:136434626	chr3:136087475~136087913:-
THCA	cis	rs6847067	0.965	rs2869216	ENSG00000180769.7	WDFY3-AS2	4.07	5.59e-05	0.00472	0.13	0.18	Oropharynx cancer;	chr4:84844388	chr4:84965682~85011277:+
THCA	cis	rs10484434	1	rs17596719	ENSG00000272462.2	U91328.19	-4.07	5.59e-05	0.00472	-0.21	-0.18	HIV-1 viral setpoint;	chr6:26096966	chr6:25992662~26001775:+
THCA	cis	rs25645	0.792	rs8077456	ENSG00000264968.1	RP11-387H17.4	-4.07	5.6e-05	0.00472	-0.17	-0.18	Myeloid white cell count;	chr17:39972512	chr17:39927742~39939601:+
THCA	cis	rs73193808	0.639	rs7277858	ENSG00000176054.6	RPL23P2	4.07	5.6e-05	0.00472	0.16	0.18	Coronary artery disease;	chr21:29180556	chr21:28997613~28998033:-
THCA	cis	rs9309473	0.606	rs78941213	ENSG00000273245.1	RP11-434P11.2	4.07	5.6e-05	0.00472	0.31	0.18	Metabolite levels;	chr2:73658010	chr2:73750256~73750786:-
THCA	cis	rs123509	0.687	rs73075297	ENSG00000173811.9	CCDC13-AS1	-4.07	5.6e-05	0.00472	-0.21	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42790974	chr3:42732575~42746768:+
THCA	cis	rs123509	0.687	rs73075301	ENSG00000173811.9	CCDC13-AS1	-4.07	5.6e-05	0.00472	-0.21	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42791158	chr3:42732575~42746768:+
THCA	cis	rs123509	0.687	rs73077214	ENSG00000173811.9	CCDC13-AS1	-4.07	5.6e-05	0.00472	-0.21	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42796528	chr3:42732575~42746768:+
THCA	cis	rs2916733	0.548	rs1373306	ENSG00000246089.3	RP11-115C21.2	4.07	5.6e-05	0.00472	0.18	0.18	Epirubicin-induced leukopenia;	chr8:6449801	chr8:6403551~6407142:-
THCA	cis	rs7615952	0.543	rs4645102	ENSG00000272840.1	RP11-379B18.6	4.07	5.6e-05	0.00472	0.26	0.18	Blood pressure (smoking interaction);	chr3:125705597	chr3:125774714~125797953:+
THCA	cis	rs7578199	0.552	rs905661	ENSG00000223374.1	AC005104.3	-4.07	5.6e-05	0.00472	-0.13	-0.18	Chronic lymphocytic leukemia;	chr2:241505625	chr2:241351340~241353104:-
THCA	cis	rs801193	1	rs7785213	ENSG00000229180.5	GS1-124K5.11	-4.07	5.6e-05	0.00472	-0.13	-0.18	Aortic root size;	chr7:66673991	chr7:66526088~66542624:-
THCA	cis	rs801193	0.967	rs2707841	ENSG00000229180.5	GS1-124K5.11	4.07	5.6e-05	0.00472	0.13	0.18	Aortic root size;	chr7:66692033	chr7:66526088~66542624:-
THCA	cis	rs11633886	0.585	rs12915174	ENSG00000259200.1	RP11-718O11.1	4.07	5.6e-05	0.00472	0.23	0.18	Diisocyanate-induced asthma;	chr15:45787505	chr15:45705078~45931069:+
THCA	cis	rs944289	0.868	rs2415316	ENSG00000258844.1	RP11-259K15.2	4.07	5.6e-05	0.00472	0.17	0.18	Thyroid cancer;	chr14:36139806	chr14:36214607~36235608:+
THCA	cis	rs448720	1	rs4777009	ENSG00000260657.2	RP11-315D16.4	-4.07	5.6e-05	0.00472	-0.23	-0.18	Cognitive performance;	chr15:67908169	chr15:68267792~68277994:-
THCA	cis	rs959260	1	rs6501786	ENSG00000263843.1	RP11-649A18.12	-4.07	5.6e-05	0.00472	-0.2	-0.18	Systemic lupus erythematosus;	chr17:75382694	chr17:75271369~75273895:+
THCA	cis	rs13191038	1	rs13191038	ENSG00000272009.1	RP1-313I6.12	-4.07	5.6e-05	0.00472	-0.35	-0.18	Urinary tract infection frequency;	chr6:28515140	chr6:28078792~28081130:-
THCA	cis	rs1124769	0.748	rs17703435	ENSG00000259378.1	DCAF13P3	4.07	5.6e-05	0.00472	0.28	0.18	Cognitive performance;	chr15:51011007	chr15:50944663~50945996:+
THCA	cis	rs12893668	0.667	rs71417869	ENSG00000244691.1	RPL10AP1	-4.07	5.6e-05	0.00472	-0.26	-0.18	Reticulocyte count;	chr14:103611097	chr14:103412119~103412761:-
THCA	cis	rs875971	0.545	rs1638735	ENSG00000273142.1	RP11-458F8.4	4.07	5.6e-05	0.00472	0.17	0.18	Aortic root size;	chr7:66630751	chr7:66902857~66906297:+
THCA	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	4.07	5.6e-05	0.00472	0.22	0.18	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
THCA	cis	rs853679	0.766	rs9368561	ENSG00000273712.1	RP5-874C20.7	4.07	5.6e-05	0.00472	0.32	0.18	Depression;	chr6:28200565	chr6:28315613~28315883:-
THCA	cis	rs7572644	0.64	rs4555299	ENSG00000223522.1	AC093690.1	-4.07	5.6e-05	0.00473	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27848323	chr2:28307691~28310459:-
THCA	cis	rs9902453	0.967	rs17825877	ENSG00000263370.1	RP11-68I3.5	4.07	5.6e-05	0.00473	0.24	0.18	Coffee consumption (cups per day);	chr17:30188170	chr17:29639627~29640825:+
THCA	cis	rs7181230	1	rs7181230	ENSG00000275636.1	RP11-521C20.5	4.07	5.6e-05	0.00473	0.18	0.18	Dehydroepiandrosterone sulphate levels;	chr15:40068540	chr15:40078892~40079347:+
THCA	cis	rs11673344	0.526	rs17303902	ENSG00000267422.1	CTD-2554C21.1	4.07	5.6e-05	0.00473	0.18	0.18	Obesity-related traits;	chr19:37551912	chr19:37779686~37792865:+
THCA	cis	rs10938353	0.68	rs66691259	ENSG00000273369.1	RP11-700J17.1	4.07	5.6e-05	0.00473	0.21	0.18	Body mass index;	chr4:44705036	chr4:44693946~44694386:-
THCA	cis	rs2455799	0.573	rs2455793	ENSG00000270409.1	RP11-44D5.1	-4.07	5.61e-05	0.00473	-0.19	-0.18	Mean platelet volume;	chr3:15702337	chr3:15732252~15733470:+
THCA	cis	rs11758351	0.66	rs11755943	ENSG00000216331.1	HIST1H1PS1	4.07	5.61e-05	0.00473	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26211140	chr6:26195566~26195771:+
THCA	cis	rs7264396	0.836	rs6088880	ENSG00000088340.14	FER1L4	-4.07	5.61e-05	0.00473	-0.18	-0.18	Total cholesterol levels;	chr20:35577660	chr20:35558737~35607562:-
THCA	cis	rs7264396	1	rs6088881	ENSG00000088340.14	FER1L4	-4.07	5.61e-05	0.00473	-0.18	-0.18	Total cholesterol levels;	chr20:35577687	chr20:35558737~35607562:-
THCA	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	4.07	5.61e-05	0.00473	0.17	0.18	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
THCA	cis	rs78153629	1	rs75278386	ENSG00000259330.1	INAFM2	-4.07	5.61e-05	0.00473	-0.22	-0.18	Heschl's gyrus morphology;	chr15:40386111	chr15:40325216~40326715:+
THCA	cis	rs78153629	0.92	rs113189667	ENSG00000259330.1	INAFM2	-4.07	5.61e-05	0.00473	-0.22	-0.18	Heschl's gyrus morphology;	chr15:40388488	chr15:40325216~40326715:+
THCA	cis	rs78153629	1	rs78604110	ENSG00000259330.1	INAFM2	-4.07	5.61e-05	0.00473	-0.22	-0.18	Heschl's gyrus morphology;	chr15:40389653	chr15:40325216~40326715:+
THCA	cis	rs10761482	0.813	rs4948411	ENSG00000254271.1	RP11-131N11.4	4.07	5.61e-05	0.00473	0.25	0.18	Schizophrenia;	chr10:60356317	chr10:60734342~60741828:+
THCA	cis	rs156299	0.513	rs156297	ENSG00000234286.1	AC006026.13	4.07	5.61e-05	0.00473	0.24	0.18	Vitamin D levels;	chr7:24196026	chr7:23680195~23680786:-
THCA	cis	rs9402682	0.628	rs6914717	ENSG00000232876.1	CTA-212D2.2	-4.07	5.61e-05	0.00473	-0.25	-0.18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135135620	chr6:135055033~135060550:+
THCA	cis	rs9510787	0.538	rs9510807	ENSG00000205861.10	C1QTNF9B-AS1	-4.07	5.61e-05	0.00473	-0.24	-0.18	Nasopharyngeal carcinoma;	chr13:23683108	chr13:23888889~23897263:+
THCA	cis	rs6840360	0.692	rs4479686	ENSG00000270265.1	RP11-731D1.4	-4.07	5.61e-05	0.00473	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151478172	chr4:151333775~151353224:-
THCA	cis	rs13064773	0.528	rs340281	ENSG00000279311.1	RP11-170K4.2	4.07	5.61e-05	0.00473	0.24	0.18	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158867414	chr3:158869898~158871821:+
THCA	cis	rs988712	0.705	rs4244531	ENSG00000245573.6	BDNF-AS	-4.07	5.61e-05	0.00473	-0.18	-0.18	Obesity;	chr11:27635703	chr11:27506838~27698174:+
THCA	cis	rs6940729	1	rs6940729	ENSG00000270761.1	RP11-385F7.1	-4.07	5.61e-05	0.00473	-0.14	-0.18	Plasma homocysteine levels;	chr6:47585184	chr6:47477243~47477572:-
THCA	cis	rs911555	0.755	rs34411783	ENSG00000269910.1	RP11-73M18.10	-4.07	5.61e-05	0.00473	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103694516~103695050:-
THCA	cis	rs4853525	0.651	rs62182473	ENSG00000235852.1	AC005540.3	4.07	5.61e-05	0.00473	0.19	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190876270	chr2:190880797~190882059:-
THCA	cis	rs4646450	0.636	rs10279308	ENSG00000244219.5	GS1-259H13.2	-4.07	5.61e-05	0.00473	-0.27	-0.18	Blood metabolite levels;	chr7:99407883	chr7:99598066~99610813:+
THCA	cis	rs1385374	0.698	rs35892635	ENSG00000274695.1	RP11-21K12.3	4.07	5.61e-05	0.00473	0.38	0.18	Systemic lupus erythematosus;	chr12:128841056	chr12:128826836~128827579:+
THCA	cis	rs13113518	0.902	rs11133386	ENSG00000272969.1	RP11-528I4.2	4.07	5.61e-05	0.00473	0.21	0.18	Height;	chr4:55461320	chr4:55547112~55547889:+
THCA	cis	rs962856	0.964	rs601827	ENSG00000236780.4	AC078941.1	4.07	5.61e-05	0.00473	0.22	0.18	Pancreatic cancer;	chr2:67435398	chr2:67123357~67215319:-
THCA	cis	rs4950322	0.57	rs11800580	ENSG00000271721.1	RP11-337C18.9	-4.07	5.61e-05	0.00473	-0.21	-0.18	Protein quantitative trait loci;	chr1:147261053	chr1:147175602~147177740:+
THCA	cis	rs730566	1	rs4858819	ENSG00000229759.1	MRPS18AP1	-4.07	5.62e-05	0.00474	-0.23	-0.18	Prion diseases;	chr3:48436678	chr3:48256350~48256938:-
THCA	cis	rs453301	0.686	rs6987107	ENSG00000233609.3	RP11-62H7.2	-4.07	5.62e-05	0.00474	-0.18	-0.18	Joint mobility (Beighton score);	chr8:9036071	chr8:8961200~8979025:+
THCA	cis	rs1267303	0.642	rs2404611	ENSG00000232022.5	FAAHP1	4.07	5.62e-05	0.00474	0.22	0.18	Monobrow;	chr1:46531455	chr1:46432129~46445521:+
THCA	cis	rs3748682	0.821	rs12751325	ENSG00000252448.1	SNORA63	-4.07	5.62e-05	0.00474	-0.23	-0.18	Hypothyroidism;	chr1:37823711	chr1:37884237~37884317:+
THCA	cis	rs7818688	0.578	rs4355737	ENSG00000253528.2	RP11-347C18.4	-4.07	5.62e-05	0.00474	-0.28	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94814945	chr8:94974573~94974853:-
THCA	cis	rs801193	0.66	rs2659897	ENSG00000230189.5	GS1-124K5.2	-4.07	5.62e-05	0.00474	-0.12	-0.18	Aortic root size;	chr7:66722728	chr7:66409143~66490059:-
THCA	cis	rs589448	0.902	rs315134	ENSG00000274979.1	RP11-1143G9.5	-4.07	5.62e-05	0.00474	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69368933	chr12:69326574~69331882:-
THCA	cis	rs9902453	0.933	rs1128156	ENSG00000263370.1	RP11-68I3.5	4.07	5.62e-05	0.00474	0.24	0.18	Coffee consumption (cups per day);	chr17:30186158	chr17:29639627~29640825:+
THCA	cis	rs2018683	0.707	rs917218	ENSG00000272568.4	CTB-113D17.1	4.07	5.62e-05	0.00474	0.18	0.18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935505	chr7:28979967~29013367:+
THCA	cis	rs4272720	0.639	rs4481947	ENSG00000234736.4	FAM170B-AS1	-4.07	5.62e-05	0.00474	-0.2	-0.18	Platelet count;Plateletcrit;	chr10:49068252	chr10:49121839~49151547:+
THCA	cis	rs7131987	0.65	rs7973786	ENSG00000273680.1	RP11-996F15.6	4.07	5.62e-05	0.00474	0.26	0.18	QT interval;	chr12:29309811	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.718	rs7976961	ENSG00000273680.1	RP11-996F15.6	4.07	5.62e-05	0.00474	0.26	0.18	QT interval;	chr12:29310155	chr12:29332733~29333383:-
THCA	cis	rs4950322	0.58	rs17355474	ENSG00000180867.10	PDIA3P1	4.07	5.63e-05	0.00474	0.18	0.18	Protein quantitative trait loci;	chr1:147120541	chr1:147178113~147179622:+
THCA	cis	rs17689437	0.958	rs55759919	ENSG00000260084.1	RP11-615I2.1	-4.07	5.63e-05	0.00474	-0.32	-0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68532725	chr16:68573782~68589512:-
THCA	cis	rs4788570	0.615	rs7195059	ENSG00000260593.1	RP11-432I5.2	-4.07	5.63e-05	0.00474	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71684463	chr16:71623708~71626816:-
THCA	cis	rs1371614	0.632	rs7599286	ENSG00000272148.1	RP11-195B17.1	4.07	5.63e-05	0.00474	0.17	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929530	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.61	rs2384511	ENSG00000272148.1	RP11-195B17.1	4.07	5.63e-05	0.00474	0.17	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929867	chr2:27062428~27062907:-
THCA	cis	rs7572644	0.64	rs9678430	ENSG00000223522.1	AC093690.1	-4.07	5.63e-05	0.00474	-0.22	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27834262	chr2:28307691~28310459:-
THCA	cis	rs6479891	1	rs4745729	ENSG00000272767.1	JMJD1C-AS1	4.07	5.63e-05	0.00475	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12416349	ENSG00000272767.1	JMJD1C-AS1	4.07	5.63e-05	0.00475	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63465229~63466563:+
THCA	cis	rs7267979	1	rs2424713	ENSG00000276952.1	RP5-965G21.6	4.07	5.63e-05	0.00475	0.2	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2387885	ENSG00000276952.1	RP5-965G21.6	-4.07	5.63e-05	0.00475	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25284915~25285588:-
THCA	cis	rs1577917	0.74	rs2758842	ENSG00000220563.1	PKMP3	-4.07	5.63e-05	0.00475	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85599013	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.572	rs911927	ENSG00000220563.1	PKMP3	-4.07	5.63e-05	0.00475	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85618142	chr6:85659892~85660606:-
THCA	cis	rs7267979	1	rs2500432	ENSG00000276952.1	RP5-965G21.6	4.06	5.63e-05	0.00475	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25284915~25285588:-
THCA	cis	rs7824557	0.564	rs2736293	ENSG00000206014.6	OR7E161P	4.06	5.63e-05	0.00475	0.21	0.18	Retinal vascular caliber;	chr8:11377104	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs2736294	ENSG00000206014.6	OR7E161P	4.06	5.63e-05	0.00475	0.21	0.18	Retinal vascular caliber;	chr8:11377117	chr8:11928597~11929563:-
THCA	cis	rs11971779	0.59	rs6467839	ENSG00000252332.1	RNU6-911P	-4.06	5.63e-05	0.00475	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139378044	chr7:139448740~139448843:+
THCA	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
THCA	cis	rs7674212	0.531	rs2866416	ENSG00000248971.2	KRT8P46	-4.06	5.63e-05	0.00475	-0.23	-0.18	Type 2 diabetes;	chr4:102959554	chr4:102728746~102730171:-
THCA	cis	rs7312933	0.558	rs7305397	ENSG00000257225.1	RP11-328C8.4	-4.06	5.63e-05	0.00475	-0.2	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42456256	chr12:42459366~42466128:+
THCA	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	4.06	5.63e-05	0.00475	0.17	0.18	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
THCA	cis	rs11633886	0.546	rs1033167	ENSG00000273972.1	CTD-2306A12.1	-4.06	5.63e-05	0.00475	-0.21	-0.18	Diisocyanate-induced asthma;	chr15:45747340	chr15:45702640~45703183:+
THCA	cis	rs10792320	1	rs12799017	ENSG00000279491.1	RP11-810P12.7	-4.06	5.63e-05	0.00475	-0.19	-0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61971073	chr11:61967794~61969490:+
THCA	cis	rs7617480	0.648	rs9284885	ENSG00000228638.1	FCF1P2	-4.06	5.64e-05	0.00475	-0.22	-0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48845667	chr3:48290793~48291375:-
THCA	cis	rs1993293	0.636	rs2924778	ENSG00000254744.3	CTD-3076O17.1	4.06	5.64e-05	0.00475	0.21	0.18	Coronary artery calcification;	chr15:99758621	chr15:99970215~99974010:+
THCA	cis	rs1232027	0.656	rs836813	ENSG00000249655.1	CTC-325J23.2	4.06	5.64e-05	0.00475	0.21	0.18	Huntington's disease progression;	chr5:80675694	chr5:80630313~80631590:-
THCA	cis	rs4906332	1	rs10459573	ENSG00000252469.1	RNU7-160P	4.06	5.64e-05	0.00475	0.2	0.18	Coronary artery disease;	chr14:103459120	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs4906327	ENSG00000252469.1	RNU7-160P	4.06	5.64e-05	0.00475	0.2	0.18	Coronary artery disease;	chr14:103462702	chr14:103550345~103550406:+
THCA	cis	rs427691	0.625	rs845735	ENSG00000271849.1	CTC-332L22.1	4.06	5.64e-05	0.00475	0.26	0.18	Autism spectrum disorder or schizophrenia;	chr5:109688170	chr5:109687802~109688329:-
THCA	cis	rs853679	0.545	rs35949109	ENSG00000220721.1	OR1F12	4.06	5.64e-05	0.00475	0.3	0.18	Depression;	chr6:28058148	chr6:28073316~28074233:+
THCA	cis	rs4767841	1	rs4767841	ENSG00000252886.1	RN7SKP197	-4.06	5.64e-05	0.00475	-0.18	-0.18	Urgency urinary incontinence;	chr12:119724394	chr12:119631090~119631386:-
THCA	cis	rs3824488	0.79	rs80317870	ENSG00000271155.1	RP11-435O5.5	-4.06	5.64e-05	0.00475	-0.29	-0.18	Neuroticism;	chr9:95520072	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.79	rs78843682	ENSG00000271155.1	RP11-435O5.5	-4.06	5.64e-05	0.00475	-0.29	-0.18	Neuroticism;	chr9:95520132	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.79	rs76062908	ENSG00000271155.1	RP11-435O5.5	-4.06	5.64e-05	0.00475	-0.29	-0.18	Neuroticism;	chr9:95520246	chr9:95506235~95507636:+
THCA	cis	rs4906332	1	rs3783398	ENSG00000244691.1	RPL10AP1	4.06	5.64e-05	0.00475	0.24	0.18	Coronary artery disease;	chr14:103483041	chr14:103412119~103412761:-
THCA	cis	rs372883	0.648	rs382732	ENSG00000176054.6	RPL23P2	4.06	5.64e-05	0.00475	0.17	0.18	Pancreatic cancer;	chr21:29346689	chr21:28997613~28998033:-
THCA	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	4.06	5.64e-05	0.00475	0.22	0.18	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	4.06	5.64e-05	0.00475	0.22	0.18	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
THCA	cis	rs3020264	0.566	rs2911968	ENSG00000271743.1	CTD-2541M15.3	4.06	5.64e-05	0.00475	0.22	0.18	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6630984	chr8:6615604~6617198:-
THCA	cis	rs1908814	0.516	rs4840597	ENSG00000254948.1	OR7E158P	-4.06	5.64e-05	0.00475	-0.23	-0.18	Neuroticism;	chr8:11938559	chr8:11919900~11920809:-
THCA	cis	rs804280	0.509	rs4841639	ENSG00000254948.1	OR7E158P	-4.06	5.64e-05	0.00475	-0.23	-0.18	Myopia (pathological);	chr8:11938584	chr8:11919900~11920809:-
THCA	cis	rs7267979	1	rs2482943	ENSG00000276952.1	RP5-965G21.6	-4.06	5.64e-05	0.00475	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2500418	ENSG00000276952.1	RP5-965G21.6	-4.06	5.64e-05	0.00475	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25284915~25285588:-
THCA	cis	rs7819412	0.765	rs17783634	ENSG00000255046.1	RP11-297N6.4	4.06	5.64e-05	0.00475	0.2	0.18	Triglycerides;	chr8:11196588	chr8:11797928~11802568:-
THCA	cis	rs13113518	0.966	rs7677952	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55425312	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs1047354	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55429416	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs1056547	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55430596	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs1056545	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55430730	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs5863	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55430740	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs6828570	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55431595	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs3749474	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55434518	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs1474271	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55435912	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11937487	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55436576	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs3805146	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55436985	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11133378	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55439472	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11942279	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55439652	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs3805148	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55440643	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11133380	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55441110	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs12510110	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55441567	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs12510990	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55441907	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs3805149	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55442184	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11945370	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55442875	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.966	rs12647677	ENSG00000272969.1	RP11-528I4.2	4.06	5.64e-05	0.00475	0.21	0.18	Height;	chr4:55444253	chr4:55547112~55547889:+
THCA	cis	rs4718428	0.924	rs6971897	ENSG00000229180.5	GS1-124K5.11	4.06	5.64e-05	0.00475	0.13	0.18	Corneal structure;	chr7:66947787	chr7:66526088~66542624:-
THCA	cis	rs2474937	0.561	rs10923563	ENSG00000231365.4	RP11-418J17.1	4.06	5.64e-05	0.00475	0.19	0.18	Congenital heart malformation;	chr1:118391750	chr1:119140396~119275973:+
THCA	cis	rs6449502	0.702	rs7717909	ENSG00000251279.1	CTC-436P18.1	-4.06	5.64e-05	0.00475	-0.29	-0.18	Mean platelet volume;	chr5:60841443	chr5:61162070~61232040:+
THCA	cis	rs7937	0.87	rs7252227	ENSG00000279108.1	CTC-490E21.11	-4.06	5.64e-05	0.00475	-0.2	-0.18	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40795210	chr19:40840159~40842039:+
THCA	cis	rs12612619	0.732	rs11126836	ENSG00000272148.1	RP11-195B17.1	4.06	5.64e-05	0.00476	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27050260	chr2:27062428~27062907:-
THCA	cis	rs13083990	0.919	rs3792289	ENSG00000272758.4	RP11-299J3.8	4.06	5.65e-05	0.00476	0.18	0.18	Cardiac Troponin-T levels;	chr3:122274753	chr3:122416207~122443180:+
THCA	cis	rs295490	0.831	rs57707457	ENSG00000272656.1	RP11-219D15.3	4.06	5.65e-05	0.00476	0.34	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520256	chr3:139349024~139349371:-
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000182586.6	LINC00334	-4.06	5.65e-05	0.00476	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45234340~45258730:+
THCA	cis	rs6504108	0.624	rs10853098	ENSG00000264920.1	RP11-6N17.4	-4.06	5.65e-05	0.00476	-0.16	-0.18	Body mass index;	chr17:48159219	chr17:47891255~47895812:-
THCA	cis	rs6088813	0.635	rs2145082	ENSG00000126005.14	MMP24-AS1	4.06	5.65e-05	0.00476	0.2	0.18	Height;	chr20:35317523	chr20:35216462~35278131:-
THCA	cis	rs7826238	0.594	rs2948285	ENSG00000233609.3	RP11-62H7.2	4.06	5.65e-05	0.00476	0.18	0.18	Systolic blood pressure;	chr8:8273016	chr8:8961200~8979025:+
THCA	cis	rs9467773	1	rs9467779	ENSG00000228223.2	HCG11	4.06	5.65e-05	0.00476	0.2	0.18	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26523450~26526579:+
THCA	cis	rs2749592	0.531	rs1208559	ENSG00000275858.1	RP11-291L22.8	-4.06	5.65e-05	0.00476	-0.22	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38450738~38451069:-
THCA	cis	rs16852403	0.583	rs10913506	ENSG00000224687.1	RASAL2-AS1	4.06	5.65e-05	0.00476	0.3	0.18	Childhood ear infection;	chr1:178123098	chr1:178091508~178093984:-
THCA	cis	rs2735413	0.75	rs75500355	ENSG00000276007.1	RP11-358L22.3	4.06	5.65e-05	0.00476	0.18	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78041499	chr16:78123243~78124332:+
THCA	cis	rs6728642	0.519	rs4260285	ENSG00000230606.9	AC159540.1	4.06	5.65e-05	0.00476	0.23	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96904344	chr2:97416165~97433527:-
THCA	cis	rs791590	0.941	rs4625363	ENSG00000229664.1	RP11-536K7.5	-4.06	5.65e-05	0.00476	-0.3	-0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:6030541	chr10:6025978~6036427:+
THCA	cis	rs6693017	0.818	rs61830270	ENSG00000238078.1	LINC01352	-4.06	5.65e-05	0.00476	-0.29	-0.18	Monocyte early outgrowth colony forming units;	chr1:220806392	chr1:220829255~220832429:+
THCA	cis	rs7726839	0.561	rs56410216	ENSG00000225138.6	CTD-2228K2.7	4.06	5.65e-05	0.00476	0.21	0.18	Obesity-related traits;	chr5:583101	chr5:473236~480884:+
THCA	cis	rs7726839	0.561	rs4957048	ENSG00000225138.6	CTD-2228K2.7	4.06	5.65e-05	0.00476	0.21	0.18	Obesity-related traits;	chr5:583327	chr5:473236~480884:+
THCA	cis	rs321358	1	rs12419222	ENSG00000271390.1	RP11-89C3.3	4.06	5.66e-05	0.00476	0.31	0.18	Body mass index;	chr11:111128439	chr11:111089870~111090368:-
THCA	cis	rs4713118	0.662	rs149947	ENSG00000219891.2	ZSCAN12P1	4.06	5.66e-05	0.00476	0.25	0.18	Parkinson's disease;	chr6:28004655	chr6:28091154~28093664:+
THCA	cis	rs8067545	1	rs7218708	ENSG00000270091.1	RP11-78O7.2	-4.06	5.66e-05	0.00476	-0.14	-0.18	Schizophrenia;	chr17:20023523	chr17:19896590~19897287:-
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000251402.3	FAM90A25P	-4.06	5.66e-05	0.00476	-0.23	-0.18	Neuroticism;	chr8:11986249	chr8:12415080~12418090:-
THCA	cis	rs7634476	1	rs7634476	ENSG00000273455.1	RP11-305O4.3	-4.06	5.66e-05	0.00476	-0.24	-0.18	Neuroticism;	chr3:136679545	chr3:136087475~136087913:-
THCA	cis	rs8082590	1	rs8082590	ENSG00000281749.1	Y_RNA	-4.06	5.66e-05	0.00477	-0.24	-0.18	Schizophrenia;	chr17:18055088	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs2955356	ENSG00000281749.1	Y_RNA	-4.06	5.66e-05	0.00477	-0.24	-0.18	Total body bone mineral density;	chr17:18061403	chr17:18001101~18001195:-
THCA	cis	rs12612619	0.689	rs11681145	ENSG00000272148.1	RP11-195B17.1	4.06	5.66e-05	0.00477	0.18	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27067657	chr2:27062428~27062907:-
THCA	cis	rs9650657	0.504	rs6601565	ENSG00000261451.1	RP11-981G7.1	-4.06	5.66e-05	0.00477	-0.24	-0.18	Neuroticism;	chr8:11174719	chr8:10433672~10438312:+
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000176700.18	SCAND2P	4.06	5.66e-05	0.00477	0.12	0.18	P wave terminal force;	chr15:84655131	chr15:84631451~84647478:+
THCA	cis	rs616597	0.725	rs2925334	ENSG00000256628.3	ZBTB11-AS1	4.06	5.66e-05	0.00477	0.2	0.18	Ulcerative colitis;	chr3:101853978	chr3:101676475~101679217:+
THCA	cis	rs7615952	0.599	rs2333408	ENSG00000241288.6	RP11-379B18.5	-4.06	5.66e-05	0.00477	-0.2	-0.18	Blood pressure (smoking interaction);	chr3:126013255	chr3:125827238~125916384:-
THCA	cis	rs7904321	1	rs10822127	ENSG00000232075.1	MRPL35P2	-4.06	5.66e-05	0.00477	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63080725	chr10:63634317~63634827:-
THCA	cis	rs875971	0.66	rs3764903	ENSG00000229180.5	GS1-124K5.11	-4.06	5.66e-05	0.00477	-0.13	-0.18	Aortic root size;	chr7:66633495	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs1860470	ENSG00000229180.5	GS1-124K5.11	-4.06	5.66e-05	0.00477	-0.13	-0.18	Aortic root size;	chr7:66638707	chr7:66526088~66542624:-
THCA	cis	rs2019137	0.589	rs7560701	ENSG00000234997.1	AC016745.3	4.06	5.66e-05	0.00477	0.18	0.18	Lymphocyte counts;	chr2:113269305	chr2:113424495~113425324:+
THCA	cis	rs9595908	0.869	rs9595949	ENSG00000212293.1	SNORA16	4.06	5.66e-05	0.00477	0.21	0.18	Body mass index;	chr13:32629939	chr13:32420390~32420516:-
THCA	cis	rs4538475	0.556	rs4403048	ENSG00000214846.4	RP11-115L11.1	4.06	5.66e-05	0.00477	0.25	0.18	Parkinson's disease;	chr4:15735497	chr4:15730962~15731627:-
THCA	cis	rs2235642	0.75	rs2974845	ENSG00000260989.1	LA16c-395F10.2	-4.06	5.67e-05	0.00477	-0.19	-0.18	Coronary artery disease;	chr16:1598161	chr16:1580527~1610328:+
THCA	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-4.06	5.67e-05	0.00477	-0.26	-0.18	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
THCA	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-4.06	5.67e-05	0.00477	-0.22	-0.18	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
THCA	cis	rs3764021	0.933	rs10492165	ENSG00000214776.8	RP11-726G1.1	4.06	5.67e-05	0.00477	0.22	0.18	Type 1 diabetes;	chr12:9733365	chr12:9467552~9576275:+
THCA	cis	rs74233809	0.71	rs4147157	ENSG00000213277.3	MARCKSL1P1	4.06	5.67e-05	0.00477	0.3	0.18	Birth weight;	chr10:102776603	chr10:103175554~103176094:+
THCA	cis	rs3935996	0.965	rs3924189	ENSG00000233147.1	RP11-90C4.1	-4.06	5.67e-05	0.00477	-0.16	-0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55857903	chr1:55823807~55868248:+
THCA	cis	rs6517329	0.649	rs2242798	ENSG00000230212.5	AP000688.14	-4.06	5.67e-05	0.00477	-0.23	-0.18	Schizophrenia;	chr21:36120583	chr21:36069642~36126640:-
THCA	cis	rs1048886	0.938	rs55990553	ENSG00000271967.1	RP11-134K13.4	-4.06	5.67e-05	0.00477	-0.2	-0.18	Type 2 diabetes;	chr6:70436610	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs77691649	ENSG00000271967.1	RP11-134K13.4	-4.06	5.67e-05	0.00477	-0.2	-0.18	Type 2 diabetes;	chr6:70438815	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs9455113	ENSG00000271967.1	RP11-134K13.4	-4.06	5.67e-05	0.00477	-0.2	-0.18	Type 2 diabetes;	chr6:70447967	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs73478819	ENSG00000271967.1	RP11-134K13.4	-4.06	5.67e-05	0.00477	-0.2	-0.18	Type 2 diabetes;	chr6:70473382	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs73482554	ENSG00000271967.1	RP11-134K13.4	-4.06	5.67e-05	0.00477	-0.2	-0.18	Type 2 diabetes;	chr6:70473706	chr6:70596438~70596980:+
THCA	cis	rs7554547	0.791	rs2064614	ENSG00000199347.1	RNU5E-1	-4.06	5.67e-05	0.00477	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11893883	chr1:11908152~11908271:+
THCA	cis	rs6494488	0.5	rs72744714	ENSG00000259635.1	AC100830.3	-4.06	5.67e-05	0.00477	-0.48	-0.18	Coronary artery disease;	chr15:64723851	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744715	ENSG00000259635.1	AC100830.3	-4.06	5.67e-05	0.00477	-0.48	-0.18	Coronary artery disease;	chr15:64723946	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744719	ENSG00000259635.1	AC100830.3	-4.06	5.67e-05	0.00477	-0.48	-0.18	Coronary artery disease;	chr15:64726729	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744722	ENSG00000259635.1	AC100830.3	-4.06	5.67e-05	0.00477	-0.48	-0.18	Coronary artery disease;	chr15:64728254	chr15:64701248~64719602:+
THCA	cis	rs4144027	0.967	rs72712857	ENSG00000269910.1	RP11-73M18.10	4.06	5.67e-05	0.00477	0.16	0.18	Blood metabolite levels;	chr14:103896336	chr14:103694516~103695050:-
THCA	cis	rs9921338	0.781	rs7205925	ENSG00000262703.1	RP11-485G7.6	-4.06	5.67e-05	0.00477	-0.25	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11368621	chr16:11348143~11349321:-
THCA	cis	rs6479891	1	rs9415708	ENSG00000272767.1	JMJD1C-AS1	4.06	5.67e-05	0.00477	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12784772	ENSG00000272767.1	JMJD1C-AS1	4.06	5.67e-05	0.00477	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs77494594	ENSG00000272767.1	JMJD1C-AS1	4.06	5.67e-05	0.00477	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63465229~63466563:+
THCA	cis	rs5758659	0.652	rs133324	ENSG00000205702.9	CYP2D7	4.06	5.67e-05	0.00478	0.14	0.18	Cognitive function;	chr22:42010367	chr22:42140203~42144577:-
THCA	cis	rs599083	0.53	rs583545	ENSG00000212093.1	AP000807.1	-4.06	5.67e-05	0.00478	-0.2	-0.18	Bone mineral density (spine);	chr11:68411167	chr11:68506083~68506166:-
THCA	cis	rs599083	0.53	rs689179	ENSG00000212093.1	AP000807.1	-4.06	5.67e-05	0.00478	-0.2	-0.18	Bone mineral density (spine);	chr11:68411698	chr11:68506083~68506166:-
THCA	cis	rs1790761	0.505	rs34802338	ENSG00000255318.1	RP11-655M14.13	-4.06	5.67e-05	0.00478	-0.2	-0.18	Mean corpuscular volume;	chr11:67544995	chr11:67618279~67627304:-
THCA	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	4.06	5.67e-05	0.00478	0.22	0.18	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
THCA	cis	rs12143943	0.774	rs6594014	ENSG00000240219.1	RP11-430C7.5	4.06	5.67e-05	0.00478	0.16	0.18	Cognitive performance;	chr1:204480306	chr1:204626775~204629712:+
THCA	cis	rs11247915	0.561	rs11583258	ENSG00000236782.4	RP11-96L14.7	-4.06	5.68e-05	0.00478	-0.22	-0.18	Obesity-related traits;	chr1:26297779	chr1:26169947~26171821:-
THCA	cis	rs28735056	1	rs28865701	ENSG00000261126.6	RP11-795F19.1	-4.06	5.68e-05	0.00478	-0.15	-0.18	Schizophrenia;	chr18:79860911	chr18:80046900~80095482:+
THCA	cis	rs2919009	0.545	rs11199680	ENSG00000271670.1	RP11-95I16.4	-4.06	5.68e-05	0.00478	-0.19	-0.18	Obesity-related traits;	chr10:120957788	chr10:120879256~120880667:-
THCA	cis	rs3824488	0.705	rs16909964	ENSG00000271155.1	RP11-435O5.5	-4.06	5.68e-05	0.00478	-0.28	-0.18	Neuroticism;	chr9:95534436	chr9:95506235~95507636:+
THCA	cis	rs7259376	0.936	rs1865074	ENSG00000269138.1	ZNF209P	4.06	5.68e-05	0.00478	0.19	0.18	Menopause (age at onset);	chr19:22372147	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs1865073	ENSG00000269138.1	ZNF209P	4.06	5.68e-05	0.00478	0.19	0.18	Menopause (age at onset);	chr19:22372178	chr19:22463922~22473036:+
THCA	cis	rs10484434	0.901	rs62396167	ENSG00000272810.1	U91328.22	4.06	5.68e-05	0.00478	0.2	0.18	HIV-1 viral setpoint;	chr6:26113314	chr6:26013241~26013757:+
THCA	cis	rs2657294	0.895	rs2395137	ENSG00000233313.2	HMGA1P5	-4.06	5.68e-05	0.00478	-0.25	-0.18	Pneumonia;	chr10:75088235	chr10:75276376~75276646:-
THCA	cis	rs2549003	1	rs2549002	ENSG00000237714.1	P4HA2-AS1	4.06	5.68e-05	0.00478	0.23	0.18	Asthma (sex interaction);	chr5:132493886	chr5:132184876~132192808:+
THCA	cis	rs4785204	0.618	rs12445755	ENSG00000279356.1	RP11-429P3.8	-4.06	5.68e-05	0.00478	-0.33	-0.18	Esophageal cancer (squamous cell);	chr16:50001034	chr16:50072862~50074986:+
THCA	cis	rs67981189	0.896	rs2526878	ENSG00000269927.1	RP6-91H8.3	-4.06	5.68e-05	0.00478	-0.21	-0.18	Schizophrenia;	chr14:70910578	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.865	rs2526876	ENSG00000269927.1	RP6-91H8.3	-4.06	5.68e-05	0.00478	-0.21	-0.18	Schizophrenia;	chr14:70911471	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs2526874	ENSG00000269927.1	RP6-91H8.3	-4.06	5.68e-05	0.00478	-0.21	-0.18	Schizophrenia;	chr14:70914502	chr14:71141125~71143253:-
THCA	cis	rs28735056	0.967	rs56328473	ENSG00000261126.6	RP11-795F19.1	-4.06	5.68e-05	0.00478	-0.15	-0.18	Schizophrenia;	chr18:79876101	chr18:80046900~80095482:+
THCA	cis	rs3790606	0.96	rs11102484	ENSG00000273483.1	RP4-671G15.2	4.06	5.68e-05	0.00478	0.19	0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr1:112509108	chr1:112517799~112518441:-
THCA	cis	rs1555322	0.789	rs10211823	ENSG00000126005.14	MMP24-AS1	-4.06	5.68e-05	0.00478	-0.25	-0.18	Attention deficit hyperactivity disorder;	chr20:35220467	chr20:35216462~35278131:-
THCA	cis	rs10761482	0.861	rs4620673	ENSG00000254271.1	RP11-131N11.4	-4.06	5.68e-05	0.00478	-0.25	-0.18	Schizophrenia;	chr10:60344946	chr10:60734342~60741828:+
THCA	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	4.06	5.68e-05	0.00478	0.21	0.18	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
THCA	cis	rs10938353	0.68	rs6828324	ENSG00000273369.1	RP11-700J17.1	-4.06	5.68e-05	0.00478	-0.22	-0.18	Body mass index;	chr4:44776331	chr4:44693946~44694386:-
THCA	cis	rs763121	0.849	rs12004	ENSG00000235209.1	CTA-150C2.13	4.06	5.68e-05	0.00478	0.24	0.18	Menopause (age at onset);	chr22:38481456	chr22:38921227~38924708:+
THCA	cis	rs2274136	0.948	rs2328136	ENSG00000272269.1	RP11-500C11.3	4.06	5.68e-05	0.00478	0.22	0.18	Obesity-related traits;	chr6:17709320	chr6:17706257~17707344:+
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000182586.6	LINC00334	4.06	5.68e-05	0.00478	0.19	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45234340~45258730:+
THCA	cis	rs73198271	0.562	rs55961293	ENSG00000253893.2	FAM85B	4.06	5.68e-05	0.00478	0.33	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8817968	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.562	rs55657655	ENSG00000253893.2	FAM85B	4.06	5.68e-05	0.00478	0.33	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8817981	chr8:8167819~8226614:-
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000265443.1	CTD-2349P21.6	-4.06	5.68e-05	0.00478	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30726305~30727564:-
THCA	cis	rs34102591	0.784	rs7964945	ENSG00000269997.1	RP11-214K3.21	-4.06	5.68e-05	0.00478	-0.29	-0.18	Schizophrenia;	chr12:123953121	chr12:123966077~123966629:-
THCA	cis	rs17270561	0.609	rs9393655	ENSG00000272462.2	U91328.19	-4.06	5.68e-05	0.00478	-0.16	-0.18	Iron status biomarkers;	chr6:25711110	chr6:25992662~26001775:+
THCA	cis	rs4886920	0.894	rs4886932	ENSG00000260776.4	RP11-114H24.2	-4.06	5.68e-05	0.00478	-0.21	-0.18	Neuroticism;	chr15:77838755	chr15:77914217~77926846:-
THCA	cis	rs801193	0.569	rs35070132	ENSG00000229886.1	RP5-1132H15.3	4.06	5.68e-05	0.00478	0.2	0.18	Aortic root size;	chr7:66773096	chr7:66025126~66031544:-
THCA	cis	rs4272720	0.639	rs12256777	ENSG00000234736.4	FAM170B-AS1	-4.06	5.68e-05	0.00478	-0.2	-0.18	Platelet count;Plateletcrit;	chr10:49073835	chr10:49121839~49151547:+
THCA	cis	rs2898290	0.622	rs978804	ENSG00000254527.1	ENPP7P12	-4.06	5.68e-05	0.00478	-0.23	-0.18	Systolic blood pressure;	chr8:11486164	chr8:12205759~12206389:-
THCA	cis	rs2692947	0.537	rs1834135	ENSG00000235584.2	AC008268.1	-4.06	5.69e-05	0.00479	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578477	chr2:95666084~95668715:+
THCA	cis	rs7111546	0.565	rs7928831	ENSG00000246225.5	RP11-17A1.3	4.06	5.69e-05	0.00479	0.32	0.18	Dialysis-related mortality;	chr11:22922402	chr11:22829380~22945393:+
THCA	cis	rs6479891	1	rs11818194	ENSG00000272767.1	JMJD1C-AS1	4.06	5.69e-05	0.00479	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63465229~63466563:+
THCA	cis	rs9733	0.635	rs486836	ENSG00000231073.1	RP11-316M1.3	-4.06	5.69e-05	0.00479	-0.22	-0.18	Tonsillectomy;	chr1:150903491	chr1:150973123~150975534:+
THCA	cis	rs9810089	0.835	rs655836	ENSG00000273455.1	RP11-305O4.3	4.06	5.69e-05	0.00479	0.24	0.18	Gestational age at birth (child effect);	chr3:136378734	chr3:136087475~136087913:-
THCA	cis	rs17597773	0.638	rs17650107	ENSG00000272823.1	RP11-295M18.6	-4.06	5.69e-05	0.00479	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220813204	chr1:220828676~220829211:-
THCA	cis	rs875971	0.558	rs4433015	ENSG00000229180.5	GS1-124K5.11	-4.06	5.69e-05	0.00479	-0.13	-0.18	Aortic root size;	chr7:66174736	chr7:66526088~66542624:-
THCA	cis	rs7829975	0.582	rs448231	ENSG00000254340.1	RP11-10A14.3	-4.06	5.69e-05	0.00479	-0.21	-0.18	Mood instability;	chr8:8932549	chr8:9141424~9145435:+
THCA	cis	rs17095355	0.901	rs61881586	ENSG00000203876.8	ADD3-AS1	-4.06	5.69e-05	0.00479	-0.21	-0.18	Biliary atresia;	chr10:109998661	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.901	rs6584964	ENSG00000203876.8	ADD3-AS1	-4.06	5.69e-05	0.00479	-0.21	-0.18	Biliary atresia;	chr10:109999402	chr10:109940104~110008381:-
THCA	cis	rs875971	1	rs6958271	ENSG00000230189.5	GS1-124K5.2	4.06	5.69e-05	0.00479	0.12	0.18	Aortic root size;	chr7:66514344	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs6958277	ENSG00000230189.5	GS1-124K5.2	4.06	5.69e-05	0.00479	0.12	0.18	Aortic root size;	chr7:66514362	chr7:66409143~66490059:-
THCA	cis	rs7403037	0.527	rs4778426	ENSG00000260760.1	PWRN3	-4.06	5.69e-05	0.00479	-0.22	-0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24212440	chr15:24441127~24447967:+
THCA	cis	rs150992	0.587	rs12189335	ENSG00000246763.5	RGMB-AS1	-4.06	5.69e-05	0.00479	-0.19	-0.18	Body mass index;	chr5:99009311	chr5:98769618~98773469:-
THCA	cis	rs875971	0.66	rs10215132	ENSG00000275400.1	RP4-756H11.5	4.06	5.69e-05	0.00479	0.17	0.18	Aortic root size;	chr7:66589419	chr7:66553805~66554199:-
THCA	cis	rs7111546	0.565	rs74997654	ENSG00000246225.5	RP11-17A1.3	4.06	5.69e-05	0.00479	0.32	0.18	Dialysis-related mortality;	chr11:22932766	chr11:22829380~22945393:+
THCA	cis	rs9473147	0.843	rs12202615	ENSG00000270761.1	RP11-385F7.1	-4.06	5.69e-05	0.00479	-0.15	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47650435	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.843	rs7772202	ENSG00000270761.1	RP11-385F7.1	-4.06	5.69e-05	0.00479	-0.15	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47653843	chr6:47477243~47477572:-
THCA	cis	rs7924176	0.601	rs10824073	ENSG00000213731.2	RAB5CP1	-4.06	5.69e-05	0.00479	-0.22	-0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74423435~74424014:-
THCA	cis	rs801193	1	rs10234018	ENSG00000275400.1	RP4-756H11.5	4.06	5.69e-05	0.00479	0.17	0.18	Aortic root size;	chr7:66681297	chr7:66553805~66554199:-
THCA	cis	rs1387259	0.839	rs7486941	ENSG00000273765.1	RP11-370I10.11	-4.06	5.7e-05	0.00479	-0.18	-0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48360920~48361377:+
THCA	cis	rs5758659	0.652	rs133321	ENSG00000205702.9	CYP2D7	4.06	5.7e-05	0.00479	0.14	0.18	Cognitive function;	chr22:42009318	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.652	rs133323	ENSG00000205702.9	CYP2D7	4.06	5.7e-05	0.00479	0.14	0.18	Cognitive function;	chr22:42009918	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.652	rs133327	ENSG00000205702.9	CYP2D7	4.06	5.7e-05	0.00479	0.14	0.18	Cognitive function;	chr22:42011685	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.652	rs133330	ENSG00000205702.9	CYP2D7	4.06	5.7e-05	0.00479	0.14	0.18	Cognitive function;	chr22:42013452	chr22:42140203~42144577:-
THCA	cis	rs2179367	0.613	rs12207047	ENSG00000216906.2	RP11-350J20.9	4.06	5.7e-05	0.00479	0.23	0.18	Dupuytren's disease;	chr6:149423496	chr6:149904243~149906418:+
THCA	cis	rs4908760	0.931	rs1463049	ENSG00000270282.1	RP5-1115A15.2	4.06	5.7e-05	0.00479	0.22	0.18	Vitiligo;	chr1:8537049	chr1:8512653~8513021:+
THCA	cis	rs11633886	0.528	rs2899383	ENSG00000259200.1	RP11-718O11.1	4.06	5.7e-05	0.0048	0.22	0.18	Diisocyanate-induced asthma;	chr15:45804853	chr15:45705078~45931069:+
THCA	cis	rs427691	0.625	rs370575	ENSG00000271849.1	CTC-332L22.1	-4.06	5.7e-05	0.0048	-0.25	-0.18	Autism spectrum disorder or schizophrenia;	chr5:109675587	chr5:109687802~109688329:-
THCA	cis	rs800160	0.777	rs2521294	ENSG00000199550.1	Y_RNA	4.06	5.7e-05	0.0048	0.28	0.18	Bacteremia;	chr11:2327548	chr11:2372638~2372750:+
THCA	cis	rs4660214	0.724	rs10788933	ENSG00000182109.6	RP11-69E11.4	-4.06	5.7e-05	0.0048	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39229483	chr1:39522280~39546187:-
THCA	cis	rs853679	1	rs11965538	ENSG00000273712.1	RP5-874C20.7	4.06	5.7e-05	0.0048	0.29	0.18	Depression;	chr6:28272137	chr6:28315613~28315883:-
THCA	cis	rs853679	0.882	rs2743555	ENSG00000273712.1	RP5-874C20.7	4.06	5.7e-05	0.0048	0.29	0.18	Depression;	chr6:28273304	chr6:28315613~28315883:-
THCA	cis	rs853679	1	rs1419183	ENSG00000273712.1	RP5-874C20.7	4.06	5.7e-05	0.0048	0.29	0.18	Depression;	chr6:28275017	chr6:28315613~28315883:-
THCA	cis	rs853679	1	rs6901575	ENSG00000273712.1	RP5-874C20.7	4.06	5.7e-05	0.0048	0.29	0.18	Depression;	chr6:28283207	chr6:28315613~28315883:-
THCA	cis	rs853679	1	rs1679709	ENSG00000273712.1	RP5-874C20.7	-4.06	5.7e-05	0.0048	-0.29	-0.18	Depression;	chr6:28260564	chr6:28315613~28315883:-
THCA	cis	rs853679	1	rs1778511	ENSG00000273712.1	RP5-874C20.7	-4.06	5.7e-05	0.0048	-0.29	-0.18	Depression;	chr6:28261633	chr6:28315613~28315883:-
THCA	cis	rs4321325	0.546	rs11886766	ENSG00000236682.1	AC068282.3	-4.06	5.7e-05	0.0048	-0.38	-0.18	Protein C levels;	chr2:127191045	chr2:127389130~127400580:+
THCA	cis	rs10090774	0.965	rs57416159	ENSG00000279766.1	RP11-642A1.2	4.06	5.7e-05	0.0048	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140736896	chr8:140572142~140572812:-
THCA	cis	rs253959	0.672	rs4921056	ENSG00000271918.1	CTD-2287O16.5	4.06	5.7e-05	0.0048	0.12	0.18	Bipolar disorder and schizophrenia;	chr5:116087237	chr5:116083807~116085416:-
THCA	cis	rs801193	1	rs2055682	ENSG00000230295.1	RP11-458F8.2	-4.06	5.7e-05	0.0048	-0.14	-0.18	Aortic root size;	chr7:66795302	chr7:66880708~66882981:+
THCA	cis	rs3892630	0.529	rs35300319	ENSG00000267567.1	CTD-2538C1.3	4.06	5.7e-05	0.0048	0.27	0.18	Red blood cell traits;	chr19:32919042	chr19:32718298~32719595:-
THCA	cis	rs7560272	0.538	rs1806683	ENSG00000163016.8	ALMS1P	4.06	5.7e-05	0.0048	0.23	0.18	Schizophrenia;	chr2:73712685	chr2:73644919~73685576:+
THCA	cis	rs4434872	0.525	rs12042836	ENSG00000223599.1	RP11-216N14.7	-4.06	5.7e-05	0.0048	-0.36	-0.18	Conduct disorder (symptom count);	chr1:154004680	chr1:153852106~153853414:-
THCA	cis	rs4434872	0.525	rs9700537	ENSG00000223599.1	RP11-216N14.7	-4.06	5.7e-05	0.0048	-0.36	-0.18	Conduct disorder (symptom count);	chr1:154005373	chr1:153852106~153853414:-
THCA	cis	rs28735056	0.904	rs62103174	ENSG00000261126.6	RP11-795F19.1	4.06	5.7e-05	0.0048	0.15	0.18	Schizophrenia;	chr18:79861048	chr18:80046900~80095482:+
THCA	cis	rs9467773	1	rs1321481	ENSG00000228223.2	HCG11	-4.06	5.7e-05	0.0048	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.967	rs6932865	ENSG00000228223.2	HCG11	-4.06	5.7e-05	0.0048	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6933176	ENSG00000228223.2	HCG11	-4.06	5.7e-05	0.0048	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26523450~26526579:+
THCA	cis	rs11673344	0.526	rs17305193	ENSG00000267422.1	CTD-2554C21.1	4.06	5.7e-05	0.0048	0.18	0.18	Obesity-related traits;	chr19:37598764	chr19:37779686~37792865:+
THCA	cis	rs10200159	1	rs12616982	ENSG00000272606.1	RP11-554J4.1	4.06	5.7e-05	0.0048	0.35	0.18	Vitiligo;	chr2:55647676	chr2:55617909~55618373:+
THCA	cis	rs1876905	0.764	rs6934341	ENSG00000272356.1	RP5-1112D6.8	-4.06	5.71e-05	0.0048	-0.19	-0.18	Mean corpuscular hemoglobin;	chr6:111098387	chr6:111309203~111313517:+
THCA	cis	rs911555	0.755	rs975892	ENSG00000269910.1	RP11-73M18.10	4.06	5.71e-05	0.0048	0.17	0.18	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103694516~103695050:-
THCA	cis	rs9868809	0.505	rs28657585	ENSG00000270441.1	RP11-694I15.7	4.06	5.71e-05	0.0048	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698783	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs9882549	ENSG00000270441.1	RP11-694I15.7	4.06	5.71e-05	0.0048	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711925	chr3:49140086~49160851:-
THCA	cis	rs10421328	0.848	rs867616	ENSG00000271283.1	CTC-412M14.6	4.06	5.71e-05	0.0048	0.29	0.18	Parental longevity (combined parental age at death);	chr19:19646873	chr19:19699203~19699409:-
THCA	cis	rs791590	0.941	rs12722559	ENSG00000225948.2	RP11-554I8.1	4.06	5.71e-05	0.0048	0.3	0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:6028310	chr10:6618716~6625346:+
THCA	cis	rs875971	0.545	rs12670811	ENSG00000273142.1	RP11-458F8.4	4.06	5.71e-05	0.0048	0.17	0.18	Aortic root size;	chr7:66358032	chr7:66902857~66906297:+
THCA	cis	rs988712	0.516	rs6484320	ENSG00000245573.6	BDNF-AS	4.06	5.71e-05	0.0048	0.18	0.18	Obesity;	chr11:27681641	chr11:27506838~27698174:+
THCA	cis	rs7824557	0.564	rs2736295	ENSG00000206014.6	OR7E161P	-4.06	5.71e-05	0.0048	-0.22	-0.18	Retinal vascular caliber;	chr8:11377271	chr8:11928597~11929563:-
THCA	cis	rs7264396	0.887	rs2281849	ENSG00000088340.14	FER1L4	4.06	5.71e-05	0.0048	0.17	0.18	Total cholesterol levels;	chr20:35472461	chr20:35558737~35607562:-
THCA	cis	rs9393777	0.844	rs35909544	ENSG00000280107.1	AL022393.9	-4.06	5.71e-05	0.0048	-0.32	-0.18	Intelligence (multi-trait analysis);	chr6:27195677	chr6:28170845~28172521:+
THCA	cis	rs4886920	0.855	rs7183989	ENSG00000260776.4	RP11-114H24.2	-4.06	5.71e-05	0.0048	-0.21	-0.18	Neuroticism;	chr15:77813238	chr15:77914217~77926846:-
THCA	cis	rs12682352	0.602	rs6988939	ENSG00000248538.5	RP11-10A14.5	-4.06	5.71e-05	0.0048	-0.23	-0.18	Neuroticism;	chr8:8809406	chr8:9189011~9202854:+
THCA	cis	rs3755605	0.728	rs16847919	ENSG00000242578.1	RP11-469J4.3	4.06	5.71e-05	0.0048	0.21	0.18	Testicular germ cell tumor;	chr3:170174510	chr3:170410512~170418615:+
THCA	cis	rs3755605	0.694	rs6765667	ENSG00000242578.1	RP11-469J4.3	4.06	5.71e-05	0.0048	0.21	0.18	Testicular germ cell tumor;	chr3:170175610	chr3:170410512~170418615:+
THCA	cis	rs2253762	0.527	rs11200323	ENSG00000226864.1	ATE1-AS1	-4.06	5.71e-05	0.0048	-0.27	-0.18	Breast cancer;	chr10:122008869	chr10:121928312~121951965:+
THCA	cis	rs17685	0.753	rs2108274	ENSG00000230882.1	AC005077.14	4.06	5.71e-05	0.0048	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76152318	chr7:76071469~76074963:-
THCA	cis	rs8028182	0.525	rs9920028	ENSG00000260274.1	RP11-817O13.8	4.06	5.71e-05	0.0048	0.13	0.18	Sudden cardiac arrest;	chr15:75635376	chr15:75368155~75369584:+
THCA	cis	rs12935229	0.756	rs66771322	ENSG00000260922.1	RP11-538I12.3	-4.06	5.71e-05	0.00481	-0.29	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77273522	chr16:77234877~77290934:+
THCA	cis	rs7424096	0.527	rs4670637	ENSG00000279519.1	RP11-288C18.1	4.06	5.71e-05	0.00481	0.15	0.18	High light scatter reticulocyte percentage of red cells;	chr2:36937714	chr2:36839922~36842539:-
THCA	cis	rs11679564	0.714	rs4670638	ENSG00000279519.1	RP11-288C18.1	4.06	5.71e-05	0.00481	0.15	0.18	Immature fraction of reticulocytes;	chr2:36937768	chr2:36839922~36842539:-
THCA	cis	rs2342371	0.527	rs7643192	ENSG00000273013.1	CTD-2002J20.1	4.06	5.71e-05	0.00481	0.17	0.18	Fat distribution (HIV);	chr3:196483719	chr3:196474801~196475394:+
THCA	cis	rs6696239	0.956	rs12133625	ENSG00000227711.2	RP11-275O4.5	-4.06	5.71e-05	0.00481	-0.25	-0.18	Height;	chr1:227656481	chr1:227509028~227520477:-
THCA	cis	rs13325613	0.834	rs13095940	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46205325	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13096307	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46205462	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.749	rs13096371	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46205605	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs34865316	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46205965	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs3176826	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46206093	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs3176825	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46206733	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs3176824	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46206894	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34423195	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46208231	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs3181080	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46208438	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34919616	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46208517	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs3181078	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46209093	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs3181076	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46209242	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.831	rs35354367	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46209308	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34280313	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46211014	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.749	rs13070099	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46211723	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34047458	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46212108	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35429781	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46212116	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35614049	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46213985	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs71327039	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46215805	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34531115	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46216205	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35617677	ENSG00000223552.1	RP11-24F11.2	-4.06	5.72e-05	0.00481	-0.33	-0.18	Monocyte count;	chr3:46217249	chr3:46364955~46407059:-
THCA	cis	rs12497850	0.864	rs6779394	ENSG00000228638.1	FCF1P2	-4.06	5.72e-05	0.00481	-0.2	-0.18	Parkinson's disease;	chr3:49120338	chr3:48290793~48291375:-
THCA	cis	rs9926296	0.656	rs2376881	ENSG00000274627.1	RP11-104N10.2	-4.06	5.72e-05	0.00481	-0.19	-0.18	Vitiligo;	chr16:89760603	chr16:89516797~89522217:+
THCA	cis	rs10875746	0.551	rs3185921	ENSG00000226413.2	OR8T1P	4.06	5.72e-05	0.00481	0.27	0.18	Longevity (90 years and older);	chr12:48340948	chr12:48442030~48442947:-
THCA	cis	rs4578769	0.959	rs7226652	ENSG00000265939.1	UBE2CP2	4.06	5.72e-05	0.00481	0.22	0.18	Eosinophil percentage of white cells;	chr18:22904043	chr18:22900486~22900995:-
THCA	cis	rs7115242	0.844	rs645258	ENSG00000280143.1	AP000892.6	4.06	5.72e-05	0.00481	0.34	0.18	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117204967~117210292:+
THCA	cis	rs2944755	0.919	rs6578115	ENSG00000279766.1	RP11-642A1.2	-4.06	5.72e-05	0.00481	-0.25	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140565760	chr8:140572142~140572812:-
THCA	cis	rs755249	0.508	rs10888688	ENSG00000182109.6	RP11-69E11.4	-4.06	5.72e-05	0.00481	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39171633	chr1:39522280~39546187:-
THCA	cis	rs10457678	0.531	rs11155013	ENSG00000225415.2	RP3-509I19.1	-4.06	5.72e-05	0.00481	-0.25	-0.18	Colorectal or endometrial cancer;	chr6:138830701	chr6:138822747~138823799:+
THCA	cis	rs875971	0.545	rs73136346	ENSG00000273024.4	INTS4P2	4.06	5.72e-05	0.00481	0.24	0.18	Aortic root size;	chr7:66101095	chr7:65647864~65715661:+
THCA	cis	rs1232027	0.656	rs1677682	ENSG00000249655.1	CTC-325J23.2	4.06	5.72e-05	0.00481	0.21	0.18	Huntington's disease progression;	chr5:80660774	chr5:80630313~80631590:-
THCA	cis	rs701145	0.585	rs1727944	ENSG00000243069.6	ARHGEF26-AS1	-4.06	5.72e-05	0.00481	-0.35	-0.18	Coronary artery disease;	chr3:154108814	chr3:154024401~154121332:-
THCA	cis	rs889312	0.961	rs961847	ENSG00000271828.1	CTD-2310F14.1	-4.06	5.72e-05	0.00481	-0.26	-0.18	Breast cancer (early onset);Breast cancer;	chr5:56745237	chr5:56927874~56929573:+
THCA	cis	rs2974760	0.606	rs2858918	ENSG00000268836.1	LA16c-OS12.2	4.06	5.72e-05	0.00481	0.18	0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151184	chr16:185748~186294:-
THCA	cis	rs4785204	1	rs72796169	ENSG00000279356.1	RP11-429P3.8	-4.06	5.72e-05	0.00481	-0.35	-0.18	Esophageal cancer (squamous cell);	chr16:50098156	chr16:50072862~50074986:+
THCA	cis	rs11671005	0.696	rs73066211	ENSG00000268049.1	CTD-2619J13.9	-4.06	5.72e-05	0.00481	-0.29	-0.18	Mean platelet volume;	chr19:58485712	chr19:58357999~58359603:+
THCA	cis	rs853679	0.538	rs13199081	ENSG00000273712.1	RP5-874C20.7	4.06	5.72e-05	0.00481	0.23	0.18	Depression;	chr6:28364057	chr6:28315613~28315883:-
THCA	cis	rs4578769	0.959	rs3898593	ENSG00000265939.1	UBE2CP2	4.06	5.73e-05	0.00481	0.23	0.18	Eosinophil percentage of white cells;	chr18:22909074	chr18:22900486~22900995:-
THCA	cis	rs360071	0.528	rs360093	ENSG00000242861.1	RP11-285F7.2	-4.06	5.73e-05	0.00481	-0.16	-0.18	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);	chr1:225877045	chr1:225840883~225846522:-
THCA	cis	rs919433	0.679	rs1598469	ENSG00000231621.1	AC013264.2	-4.06	5.73e-05	0.00481	-0.2	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197650934	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs10203581	ENSG00000231621.1	AC013264.2	-4.06	5.73e-05	0.00481	-0.2	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197651176	chr2:197197991~197199273:+
THCA	cis	rs28735056	0.935	rs11662267	ENSG00000261126.6	RP11-795F19.1	-4.06	5.73e-05	0.00482	-0.15	-0.18	Schizophrenia;	chr18:79881902	chr18:80046900~80095482:+
THCA	cis	rs11673344	0.704	rs826262	ENSG00000267260.1	CTD-2162K18.4	-4.06	5.73e-05	0.00482	-0.23	-0.18	Obesity-related traits;	chr19:36928540	chr19:36773153~36777078:+
THCA	cis	rs8105895	0.935	rs1560717	ENSG00000269345.1	VN1R85P	4.06	5.73e-05	0.00482	0.26	0.18	Body mass index (change over time);	chr19:22109445	chr19:22174766~22175191:-
THCA	cis	rs7550636	1	rs12404140	ENSG00000276735.1	Metazoa_SRP	4.06	5.73e-05	0.00482	0.23	0.18	Coronary artery calcification;	chr1:192837675	chr1:193236794~193237107:-
THCA	cis	rs3738443	0.594	rs60050650	ENSG00000259865.1	RP11-488L18.10	4.06	5.73e-05	0.00482	0.16	0.18	Alcohol dependence;	chr1:247213474	chr1:247187281~247188526:-
THCA	cis	rs2904524	0.541	rs11178209	ENSG00000257815.4	RP11-611E13.2	-4.06	5.73e-05	0.00482	-0.15	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70378864	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.541	rs11531260	ENSG00000257815.4	RP11-611E13.2	-4.06	5.73e-05	0.00482	-0.15	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70379155	chr12:69904033~70243360:-
THCA	cis	rs9843304	0.585	rs9842139	ENSG00000243885.1	RP11-278L15.2	-4.06	5.73e-05	0.00482	-0.2	-0.18	Gallstone disease;	chr3:149489730	chr3:149384179~149385800:-
THCA	cis	rs4767841	0.565	rs203366	ENSG00000252886.1	RN7SKP197	-4.06	5.73e-05	0.00482	-0.18	-0.18	Urgency urinary incontinence;	chr12:119778060	chr12:119631090~119631386:-
THCA	cis	rs4081724	0.565	rs12150908	ENSG00000267296.2	CEBPA-AS1	4.06	5.73e-05	0.00482	0.3	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33317239	chr19:33302857~33305054:+
THCA	cis	rs10844706	0.699	rs10772087	ENSG00000214776.8	RP11-726G1.1	4.06	5.73e-05	0.00482	0.24	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9730515	chr12:9467552~9576275:+
THCA	cis	rs36093844	0.752	rs56202113	ENSG00000279742.1	RP11-700A24.1	-4.06	5.74e-05	0.00482	-0.28	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85842515	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs17817230	ENSG00000279742.1	RP11-700A24.1	-4.06	5.74e-05	0.00482	-0.28	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85843014	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.706	rs76504433	ENSG00000279742.1	RP11-700A24.1	-4.06	5.74e-05	0.00482	-0.28	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85843217	chr11:85852557~85854943:-
THCA	cis	rs1371614	0.566	rs1440042	ENSG00000272148.1	RP11-195B17.1	4.06	5.74e-05	0.00482	0.17	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26964946	chr2:27062428~27062907:-
THCA	cis	rs9863	0.861	rs11057396	ENSG00000269938.1	RP11-214K3.20	-4.06	5.74e-05	0.00482	-0.22	-0.18	White blood cell count;	chr12:123934515	chr12:123968023~123968579:-
THCA	cis	rs9595908	0.709	rs7983889	ENSG00000212293.1	SNORA16	4.06	5.74e-05	0.00482	0.22	0.18	Body mass index;	chr13:32785441	chr13:32420390~32420516:-
THCA	cis	rs6479891	1	rs72837025	ENSG00000272767.1	JMJD1C-AS1	4.06	5.74e-05	0.00482	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63465229~63466563:+
THCA	cis	rs1560104	0.675	rs9936549	ENSG00000262801.4	U91319.1	4.06	5.74e-05	0.00483	0.22	0.18	Obesity-related traits;	chr16:12611147	chr16:13246316~13562918:+
THCA	cis	rs10027350	0.927	rs1035091	ENSG00000281501.1	SEPSECS-AS1	4.06	5.74e-05	0.00483	0.21	0.18	Childhood ear infection;	chr4:25150252	chr4:25160641~25201440:+
THCA	cis	rs4443100	0.634	rs9612209	ENSG00000230701.2	FBXW4P1	4.06	5.74e-05	0.00483	0.22	0.18	Serum parathyroid hormone levels;	chr22:23017286	chr22:23262767~23265005:+
THCA	cis	rs7914558	1	rs943036	ENSG00000272912.1	RP11-724N1.1	-4.06	5.74e-05	0.00483	-0.21	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103076290	chr10:102914585~102915404:+
THCA	cis	rs1559040	0.86	rs72800775	ENSG00000272156.1	RP11-477N3.1	-4.06	5.74e-05	0.00483	-0.3	-0.18	Sudden cardiac arrest;	chr2:54152457	chr2:54082554~54085066:+
THCA	cis	rs12612619	0.704	rs2119026	ENSG00000272148.1	RP11-195B17.1	-4.06	5.74e-05	0.00483	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27087525	chr2:27062428~27062907:-
THCA	cis	rs7521902	0.66	rs56318008	ENSG00000228397.1	RP1-224A6.3	-4.06	5.74e-05	0.00483	-0.34	-0.18	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22143914	chr1:22023994~22024968:-
THCA	cis	rs7521902	0.66	rs55938609	ENSG00000228397.1	RP1-224A6.3	-4.06	5.74e-05	0.00483	-0.34	-0.18	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22143958	chr1:22023994~22024968:-
THCA	cis	rs67981189	0.858	rs221927	ENSG00000269927.1	RP6-91H8.3	-4.06	5.74e-05	0.00483	-0.21	-0.18	Schizophrenia;	chr14:71112024	chr14:71141125~71143253:-
THCA	cis	rs4820294	1	rs929039	ENSG00000233360.4	Z83844.1	4.06	5.74e-05	0.00483	0.22	0.18	Fat distribution (HIV);	chr22:37675504	chr22:37641832~37658377:-
THCA	cis	rs8017455	0.523	rs10133458	ENSG00000259167.2	NMNAT1P1	4.06	5.74e-05	0.00483	0.27	0.18	Hair morphology;	chr14:81099574	chr14:81032529~81033404:+
THCA	cis	rs962856	1	rs4671794	ENSG00000236780.4	AC078941.1	4.06	5.74e-05	0.00483	0.22	0.18	Pancreatic cancer;	chr2:67339526	chr2:67123357~67215319:-
THCA	cis	rs6671200	0.831	rs35466718	ENSG00000235501.4	RP4-639F20.1	-4.06	5.74e-05	0.00483	-0.38	-0.18	Stearic acid (18:0) levels;	chr1:95131568	chr1:94927566~94963270:+
THCA	cis	rs7737355	0.891	rs78235696	ENSG00000237714.1	P4HA2-AS1	-4.06	5.74e-05	0.00483	-0.39	-0.18	Life satisfaction;	chr5:131476356	chr5:132184876~132192808:+
THCA	cis	rs17270561	0.697	rs9366633	ENSG00000272462.2	U91328.19	-4.06	5.74e-05	0.00483	-0.15	-0.18	Iron status biomarkers;	chr6:25837826	chr6:25992662~26001775:+
THCA	cis	rs950169	0.922	rs11639244	ENSG00000275120.1	RP11-182J1.17	4.06	5.74e-05	0.00483	0.22	0.18	Schizophrenia;	chr15:84163898	chr15:84599434~84606463:-
THCA	cis	rs4713118	0.513	rs200971	ENSG00000261839.1	RP1-265C24.8	4.06	5.75e-05	0.00483	0.2	0.18	Parkinson's disease;	chr6:27891126	chr6:28136849~28139678:+
THCA	cis	rs8020441	0.891	rs112124522	ENSG00000269906.1	RP11-248J18.2	4.06	5.75e-05	0.00483	0.26	0.18	Cognitive performance;	chr14:50700784	chr14:50662511~50663178:-
THCA	cis	rs2590942	0.838	rs2613504	ENSG00000227207.2	RPL31P12	-4.06	5.75e-05	0.00483	-0.29	-0.18	Childhood body mass index;	chr1:72370057	chr1:72301472~72301829:+
THCA	cis	rs950776	0.518	rs12910100	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78530325	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12915428	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78531026	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs11630349	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78532266	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12906284	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78532763	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12906846	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78532953	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12907169	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78533156	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12906951	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78533220	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs56007453	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78533897	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12916999	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78534570	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs3813572	ENSG00000261762.1	RP11-650L12.2	4.06	5.75e-05	0.00483	0.23	0.18	Sudden cardiac arrest;	chr15:78540246	chr15:78589123~78591276:-
THCA	cis	rs2412819	0.571	rs56226333	ENSG00000166763.7	STRCP1	4.06	5.75e-05	0.00483	0.25	0.18	Lung cancer;	chr15:43632410	chr15:43699488~43718184:-
THCA	cis	rs11763147	1	rs11763147	ENSG00000229180.5	GS1-124K5.11	-4.06	5.75e-05	0.00483	-0.13	-0.18	Corneal structure;	chr7:65861834	chr7:66526088~66542624:-
THCA	cis	rs7474896	1	rs10764141	ENSG00000263064.2	RP11-291L22.7	4.06	5.75e-05	0.00483	0.29	0.18	Obesity (extreme);	chr10:37652326	chr10:38448689~38448949:+
THCA	cis	rs7688540	0.771	rs10005733	ENSG00000250892.1	RP11-1365D11.1	4.06	5.75e-05	0.00483	0.26	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:201409~205009:-
THCA	cis	rs718433	0.816	rs11621221	ENSG00000211778.2	TRAV4	-4.06	5.75e-05	0.00483	-0.14	-0.18	Intraocular pressure;	chr14:21754101	chr14:21736152~21736982:+
THCA	cis	rs964611	0.748	rs61248772	ENSG00000259488.2	RP11-154J22.1	-4.06	5.75e-05	0.00483	-0.19	-0.18	Metabolite levels (Pyroglutamine);	chr15:48306529	chr15:48312353~48331856:-
THCA	cis	rs964611	1	rs7168752	ENSG00000259488.2	RP11-154J22.1	-4.06	5.75e-05	0.00483	-0.19	-0.18	Metabolite levels (Pyroglutamine);	chr15:48308583	chr15:48312353~48331856:-
THCA	cis	rs964611	1	rs79040993	ENSG00000259488.2	RP11-154J22.1	-4.06	5.75e-05	0.00483	-0.19	-0.18	Metabolite levels (Pyroglutamine);	chr15:48309949	chr15:48312353~48331856:-
THCA	cis	rs964611	0.935	rs76749119	ENSG00000259488.2	RP11-154J22.1	-4.06	5.75e-05	0.00483	-0.19	-0.18	Metabolite levels (Pyroglutamine);	chr15:48312868	chr15:48312353~48331856:-
THCA	cis	rs964611	1	rs74012001	ENSG00000259488.2	RP11-154J22.1	-4.06	5.75e-05	0.00483	-0.19	-0.18	Metabolite levels (Pyroglutamine);	chr15:48313011	chr15:48312353~48331856:-
THCA	cis	rs7632954	0.567	rs9864415	ENSG00000227110.5	LMCD1-AS1	-4.06	5.75e-05	0.00483	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8470982	chr3:7952805~8611924:-
THCA	cis	rs2028299	0.92	rs8027198	ENSG00000259677.1	RP11-493E3.1	4.06	5.75e-05	0.00483	0.25	0.18	Type 2 diabetes;	chr15:89883457	chr15:89876540~89877285:+
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000265443.1	CTD-2349P21.6	-4.06	5.75e-05	0.00483	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000265443.1	CTD-2349P21.6	-4.06	5.75e-05	0.00483	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30726305~30727564:-
THCA	cis	rs13064773	0.528	rs340269	ENSG00000279311.1	RP11-170K4.2	4.06	5.75e-05	0.00483	0.24	0.18	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158876736	chr3:158869898~158871821:+
THCA	cis	rs9532669	0.963	rs9532662	ENSG00000229473.2	RGS17P1	4.06	5.75e-05	0.00484	0.22	0.18	Cervical cancer;	chr13:40926215	chr13:40992779~40993331:-
THCA	cis	rs337161	0.935	rs11588866	ENSG00000221571.3	RNU6ATAC35P	-4.06	5.75e-05	0.00484	-0.21	-0.18	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220789111	chr1:220825620~220826063:+
THCA	cis	rs10027350	0.964	rs3756208	ENSG00000281501.1	SEPSECS-AS1	4.06	5.76e-05	0.00484	0.21	0.18	Childhood ear infection;	chr4:25132047	chr4:25160641~25201440:+
THCA	cis	rs2115536	0.72	rs12916091	ENSG00000278600.1	RP11-81A1.6	-4.06	5.76e-05	0.00484	-0.12	-0.18	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79930230	chr15:79920195~79922455:-
THCA	cis	rs2115630	0.967	rs8027779	ENSG00000259295.5	CSPG4P12	-4.06	5.76e-05	0.00484	-0.25	-0.18	P wave terminal force;	chr15:84712154	chr15:85191438~85213905:+
THCA	cis	rs71520386	0.632	rs10254365	ENSG00000226329.2	AC005682.6	-4.06	5.76e-05	0.00484	-0.24	-0.18	Fibrinogen levels;	chr7:22825135	chr7:22863874~22881350:-
THCA	cis	rs875971	0.597	rs11771318	ENSG00000236529.1	RP13-254B10.1	-4.06	5.76e-05	0.00484	-0.22	-0.18	Aortic root size;	chr7:66597493	chr7:65840212~65840596:+
THCA	cis	rs2839186	0.903	rs61182475	ENSG00000215424.8	MCM3AP-AS1	4.06	5.76e-05	0.00484	0.11	0.18	Testicular germ cell tumor;	chr21:46287136	chr21:46229217~46259390:+
THCA	cis	rs4237845	0.537	rs10877031	ENSG00000270039.1	RP11-571M6.17	-4.06	5.76e-05	0.00484	-0.21	-0.18	Intelligence (multi-trait analysis);	chr12:57872912	chr12:57803838~57804415:+
THCA	cis	rs4237845	0.514	rs4760339	ENSG00000270039.1	RP11-571M6.17	-4.06	5.76e-05	0.00484	-0.21	-0.18	Intelligence (multi-trait analysis);	chr12:57874366	chr12:57803838~57804415:+
THCA	cis	rs4648045	0.647	rs17032705	ENSG00000246560.2	RP11-10L12.4	4.06	5.76e-05	0.00484	0.23	0.18	Lymphocyte percentage of white cells;	chr4:102511817	chr4:102828055~102844075:+
THCA	cis	rs801193	0.66	rs2659897	ENSG00000229886.1	RP5-1132H15.3	-4.06	5.76e-05	0.00484	-0.19	-0.18	Aortic root size;	chr7:66722728	chr7:66025126~66031544:-
THCA	cis	rs6479901	0.557	rs1009984	ENSG00000272767.1	JMJD1C-AS1	-4.06	5.76e-05	0.00484	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63465229~63466563:+
THCA	cis	rs9693857	0.52	rs11249927	ENSG00000248538.5	RP11-10A14.5	-4.06	5.76e-05	0.00484	-0.24	-0.18	Systolic blood pressure;	chr8:9504096	chr8:9189011~9202854:+
THCA	cis	rs4785204	0.85	rs72796146	ENSG00000279356.1	RP11-429P3.8	-4.06	5.76e-05	0.00484	-0.35	-0.18	Esophageal cancer (squamous cell);	chr16:50077531	chr16:50072862~50074986:+
THCA	cis	rs4646450	0.735	rs3801288	ENSG00000244219.5	GS1-259H13.2	-4.06	5.76e-05	0.00484	-0.24	-0.18	Blood metabolite levels;	chr7:99348285	chr7:99598066~99610813:+
THCA	cis	rs3764021	0.87	rs10844622	ENSG00000214776.8	RP11-726G1.1	4.06	5.76e-05	0.00484	0.22	0.18	Type 1 diabetes;	chr12:9732486	chr12:9467552~9576275:+
THCA	cis	rs6138458	1	rs6114981	ENSG00000274173.1	RP4-568C11.4	-4.06	5.76e-05	0.00484	-0.18	-0.18	Blood protein levels;	chr20:24993765	chr20:24931840~24932983:+
THCA	cis	rs4356203	0.87	rs7925692	ENSG00000272034.1	SNORD14A	4.06	5.76e-05	0.00484	0.18	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17249575	chr11:17074654~17074744:-
THCA	cis	rs9959145	1	rs78874284	ENSG00000267199.1	RP11-861E21.2	4.06	5.76e-05	0.00484	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12630717	chr18:12438890~12448205:+
THCA	cis	rs7621025	0.63	rs1681816	ENSG00000239213.4	NCK1-AS1	-4.06	5.76e-05	0.00484	-0.18	-0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136755920	chr3:136841726~136862054:-
THCA	cis	rs6940638	0.513	rs4424065	ENSG00000124549.13	BTN2A3P	-4.06	5.76e-05	0.00484	-0.17	-0.18	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26421391~26432383:+
THCA	cis	rs9467773	1	rs4713008	ENSG00000228223.2	HCG11	-4.06	5.77e-05	0.00485	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26523450~26526579:+
THCA	cis	rs1728785	0.901	rs11075688	ENSG00000274698.1	RP11-71L14.4	-4.06	5.77e-05	0.00485	-0.26	-0.18	Ulcerative colitis;	chr16:68622021	chr16:68450283~68452318:+
THCA	cis	rs2677744	1	rs1266483	ENSG00000214432.8	AC068831.10	-4.06	5.77e-05	0.00485	-0.19	-0.18	Attention deficit hyperactivity disorder;	chr15:90919176	chr15:91022619~91036611:+
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000273796.1	LL21NC02-21A1.1	-4.06	5.77e-05	0.00485	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45403809~45404369:-
THCA	cis	rs7259376	0.875	rs1091182	ENSG00000269345.1	VN1R85P	-4.06	5.77e-05	0.00485	-0.2	-0.18	Menopause (age at onset);	chr19:22292820	chr19:22174766~22175191:-
THCA	cis	rs7809615	0.748	rs11973173	ENSG00000244219.5	GS1-259H13.2	-4.06	5.77e-05	0.00485	-0.3	-0.18	Blood metabolite ratios;	chr7:99434776	chr7:99598066~99610813:+
THCA	cis	rs2434529	1	rs57192789	ENSG00000245275.6	SAP30L-AS1	4.06	5.77e-05	0.00485	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154268774	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs17552495	ENSG00000245275.6	SAP30L-AS1	4.06	5.77e-05	0.00485	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154269554	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs3959918	ENSG00000245275.6	SAP30L-AS1	4.06	5.77e-05	0.00485	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154271453	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs6882166	ENSG00000245275.6	SAP30L-AS1	-4.06	5.77e-05	0.00485	-0.22	-0.18	Autism spectrum disorder or schizophrenia;	chr5:154272043	chr5:154329437~154445850:-
THCA	cis	rs17597773	0.638	rs6541161	ENSG00000238078.1	LINC01352	-4.06	5.77e-05	0.00485	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220820922	chr1:220829255~220832429:+
THCA	cis	rs1577330	0.851	rs10967706	ENSG00000254396.1	RP11-56F10.3	4.06	5.77e-05	0.00485	0.22	0.18	IgG glycosylation;	chr9:27090332	chr9:27102630~27104728:+
THCA	cis	rs2235642	0.75	rs2755185	ENSG00000260989.1	LA16c-395F10.2	-4.06	5.77e-05	0.00485	-0.19	-0.18	Coronary artery disease;	chr16:1595826	chr16:1580527~1610328:+
THCA	cis	rs763121	0.651	rs738249	ENSG00000273076.1	RP3-508I15.22	4.06	5.77e-05	0.00485	0.19	0.18	Menopause (age at onset);	chr22:38641974	chr22:38743495~38743910:+
THCA	cis	rs75504410	0.579	rs2637712	ENSG00000231160.8	KLF3-AS1	-4.06	5.78e-05	0.00485	-0.13	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38624896	chr4:38612701~38664883:-
THCA	cis	rs6088813	1	rs4911496	ENSG00000279253.1	RP4-614O4.13	-4.06	5.78e-05	0.00485	-0.17	-0.18	Height;	chr20:35384250	chr20:35262727~35264187:-
THCA	cis	rs17666538	0.585	rs4735812	ENSG00000254207.1	RP11-43A14.1	4.06	5.78e-05	0.00485	0.36	0.18	IgG glycosylation;	chr8:657766	chr8:725188~725877:-
THCA	cis	rs17666538	0.539	rs1703925	ENSG00000254207.1	RP11-43A14.1	4.06	5.78e-05	0.00485	0.36	0.18	IgG glycosylation;	chr8:658279	chr8:725188~725877:-
THCA	cis	rs4785204	1	rs1861662	ENSG00000279356.1	RP11-429P3.8	4.06	5.78e-05	0.00485	0.35	0.18	Esophageal cancer (squamous cell);	chr16:50073472	chr16:50072862~50074986:+
THCA	cis	rs8062405	0.824	rs4788085	ENSG00000270424.1	RP11-1348G14.6	4.06	5.78e-05	0.00485	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.824	rs28772958	ENSG00000270424.1	RP11-1348G14.6	4.06	5.78e-05	0.00485	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.789	rs2106480	ENSG00000270424.1	RP11-1348G14.6	4.06	5.78e-05	0.00485	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28749959~28750595:-
THCA	cis	rs2286503	0.752	rs6461669	ENSG00000226329.2	AC005682.6	4.06	5.78e-05	0.00486	0.23	0.18	Fibrinogen;	chr7:22818447	chr7:22863874~22881350:-
THCA	cis	rs2692947	0.759	rs2692937	ENSG00000235584.2	AC008268.1	-4.06	5.78e-05	0.00486	-0.19	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96086123	chr2:95666084~95668715:+
THCA	cis	rs1040393	0.903	rs4656517	ENSG00000225171.2	DUTP6	-4.06	5.78e-05	0.00486	-0.26	-0.18	Schizophrenia;	chr1:166886822	chr1:166868748~166869209:+
THCA	cis	rs854765	0.547	rs9912096	ENSG00000281749.1	Y_RNA	4.06	5.78e-05	0.00486	0.23	0.18	Total body bone mineral density;	chr17:17993359	chr17:18001101~18001195:-
THCA	cis	rs4886920	0.894	rs6495252	ENSG00000260776.4	RP11-114H24.2	4.06	5.78e-05	0.00486	0.21	0.18	Neuroticism;	chr15:77825343	chr15:77914217~77926846:-
THCA	cis	rs7520050	0.667	rs11211176	ENSG00000281133.1	AL355480.3	4.06	5.78e-05	0.00486	0.22	0.18	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45580892~45580996:-
THCA	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	4.06	5.78e-05	0.00486	0.17	0.18	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
THCA	cis	rs13217239	0.646	rs9379956	ENSG00000124549.13	BTN2A3P	-4.06	5.79e-05	0.00486	-0.17	-0.18	Schizophrenia;	chr6:27065956	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs7747454	ENSG00000124549.13	BTN2A3P	-4.06	5.79e-05	0.00486	-0.17	-0.18	Schizophrenia;	chr6:27066474	chr6:26421391~26432383:+
THCA	cis	rs2120243	0.539	rs1456097	ENSG00000241770.1	RP11-555M1.3	-4.06	5.79e-05	0.00486	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157380841	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs1840668	ENSG00000241770.1	RP11-555M1.3	-4.06	5.79e-05	0.00486	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157380932	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.565	rs13087207	ENSG00000241770.1	RP11-555M1.3	-4.06	5.79e-05	0.00486	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157381849	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs10936086	ENSG00000241770.1	RP11-555M1.3	-4.06	5.79e-05	0.00486	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157382070	chr3:157163452~157169133:+
THCA	cis	rs9303029	0.932	rs9905527	ENSG00000265458.1	RP13-20L14.6	4.06	5.79e-05	0.00486	0.22	0.18	Protein quantitative trait loci;	chr17:82482049	chr17:82454273~82458521:-
THCA	cis	rs613391	0.561	rs589423	ENSG00000234840.1	LINC01239	-4.06	5.79e-05	0.00486	-0.21	-0.18	Quantitative traits;	chr9:22721049	chr9:22646200~22824213:+
THCA	cis	rs7572644	0.712	rs1911128	ENSG00000223522.1	AC093690.1	4.06	5.79e-05	0.00486	0.23	0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28056782	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.766	rs1911127	ENSG00000223522.1	AC093690.1	4.06	5.79e-05	0.00486	0.23	0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28056826	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.766	rs6758799	ENSG00000223522.1	AC093690.1	4.06	5.79e-05	0.00486	0.23	0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28061766	chr2:28307691~28310459:-
THCA	cis	rs4660214	0.666	rs1984143	ENSG00000228060.1	RP11-69E11.8	4.06	5.79e-05	0.00486	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs12025847	ENSG00000228060.1	RP11-69E11.8	4.06	5.79e-05	0.00486	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39565160~39573203:+
THCA	cis	rs7968440	0.808	rs67934435	ENSG00000272368.2	RP4-605O3.4	4.06	5.79e-05	0.00486	0.12	0.18	Fibrinogen;	chr12:50823401	chr12:50112197~50165618:+
THCA	cis	rs11603020	0.95	rs11229063	ENSG00000254602.1	AP000662.4	-4.06	5.79e-05	0.00486	-0.22	-0.18	Blood protein levels;	chr11:57602257	chr11:57638024~57652790:+
THCA	cis	rs13098911	0.54	rs36039366	ENSG00000226074.4	PRSS44	-4.06	5.79e-05	0.00486	-0.34	-0.18	Celiac disease;	chr3:45962045	chr3:46809359~46812558:-
THCA	cis	rs10435719	0.647	rs10092605	ENSG00000254948.1	OR7E158P	-4.06	5.79e-05	0.00486	-0.23	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:11919900~11920809:-
THCA	cis	rs10761482	0.861	rs7085259	ENSG00000254271.1	RP11-131N11.4	4.06	5.79e-05	0.00486	0.24	0.18	Schizophrenia;	chr10:60347660	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs4948402	ENSG00000254271.1	RP11-131N11.4	4.06	5.79e-05	0.00486	0.24	0.18	Schizophrenia;	chr10:60347694	chr10:60734342~60741828:+
THCA	cis	rs11603020	1	rs11603020	ENSG00000254602.1	AP000662.4	4.06	5.79e-05	0.00486	0.21	0.18	Blood protein levels;	chr11:57606859	chr11:57638024~57652790:+
THCA	cis	rs801193	1	rs2420824	ENSG00000275400.1	RP4-756H11.5	4.06	5.79e-05	0.00486	0.17	0.18	Aortic root size;	chr7:66666129	chr7:66553805~66554199:-
THCA	cis	rs8141529	0.664	rs5762861	ENSG00000226471.5	CTA-292E10.6	-4.06	5.79e-05	0.00486	-0.16	-0.18	Lymphocyte counts;	chr22:28854517	chr22:28800683~28848559:+
THCA	cis	rs3808502	0.563	rs12541800	ENSG00000206014.6	OR7E161P	-4.06	5.79e-05	0.00487	-0.21	-0.18	Neuroticism;	chr8:11565563	chr8:11928597~11929563:-
THCA	cis	rs2334880	0.61	rs8051767	ENSG00000260185.1	RP11-432I5.6	-4.06	5.79e-05	0.00487	-0.34	-0.18	Malaria;	chr16:71697817	chr16:71655027~71664212:+
THCA	cis	rs73198271	0.562	rs76960788	ENSG00000253893.2	FAM85B	4.06	5.79e-05	0.00487	0.33	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8816539	chr8:8167819~8226614:-
THCA	cis	rs9868809	0.881	rs9878063	ENSG00000270441.1	RP11-694I15.7	4.06	5.8e-05	0.00487	0.22	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48641538	chr3:49140086~49160851:-
THCA	cis	rs17772222	0.74	rs10138002	ENSG00000222990.1	RNU4-22P	-4.06	5.8e-05	0.00487	-0.22	-0.18	Coronary artery calcification;	chr14:88510071	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.653	rs1346996	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88507174	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs7160471	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88507241	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs9323830	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88507260	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs7160647	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88507340	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs7143642	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88507616	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs10143744	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88508073	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs1999177	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88508298	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs1999176	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88508371	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs1864746	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88508455	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs1864747	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88508523	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs7151164	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88509329	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs12433026	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88509495	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs10138139	ENSG00000222990.1	RNU4-22P	4.06	5.8e-05	0.00487	0.22	0.18	Coronary artery calcification;	chr14:88510027	chr14:88513498~88513663:+
THCA	cis	rs867371	0.929	rs1501371	ENSG00000278603.1	RP13-608F4.5	4.06	5.8e-05	0.00487	0.24	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472203~82472426:+
THCA	cis	rs7798970	0.645	rs10229160	ENSG00000225498.1	AC002064.5	-4.06	5.8e-05	0.00487	-0.19	-0.18	Inflammatory skin disease;	chr7:90015111	chr7:90312496~90322592:+
THCA	cis	rs11992162	0.548	rs4841631	ENSG00000254948.1	OR7E158P	4.06	5.8e-05	0.00487	0.23	0.18	Monocyte count;	chr8:11924159	chr8:11919900~11920809:-
THCA	cis	rs5751614	0.557	rs928781	ENSG00000236611.1	AP000343.2	4.06	5.8e-05	0.00487	0.24	0.18	Height;	chr22:23257826	chr22:23326616~23328493:+
THCA	cis	rs9543976	0.623	rs8192764	ENSG00000261105.4	LMO7-AS1	4.06	5.8e-05	0.00487	0.25	0.18	Diabetic retinopathy;	chr13:75605079	chr13:75604700~75635994:-
THCA	cis	rs3781264	0.816	rs7084339	ENSG00000273450.1	RP11-76P2.4	-4.06	5.8e-05	0.00487	-0.22	-0.18	Esophageal cancer and gastric cancer;	chr10:94283975	chr10:94314907~94315327:-
THCA	cis	rs7824557	0.592	rs2572371	ENSG00000154316.13	TDH	-4.06	5.8e-05	0.00487	-0.14	-0.18	Retinal vascular caliber;	chr8:11366284	chr8:11339637~11368452:+
THCA	cis	rs459571	1	rs459571	ENSG00000235106.7	LINC00094	4.06	5.8e-05	0.00487	0.16	0.18	Platelet distribution width;	chr9:134047504	chr9:134025439~134034666:+
THCA	cis	rs7737355	0.947	rs3776007	ENSG00000237714.1	P4HA2-AS1	-4.06	5.8e-05	0.00487	-0.26	-0.18	Life satisfaction;	chr5:131539392	chr5:132184876~132192808:+
THCA	cis	rs7824557	0.564	rs2572379	ENSG00000154316.13	TDH	4.06	5.8e-05	0.00487	0.14	0.18	Retinal vascular caliber;	chr8:11379971	chr8:11339637~11368452:+
THCA	cis	rs6939532	0.517	rs733528	ENSG00000124549.13	BTN2A3P	-4.06	5.8e-05	0.00487	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26374675	chr6:26421391~26432383:+
THCA	cis	rs7179456	0.513	rs593742	ENSG00000245975.2	RP11-30K9.6	4.06	5.8e-05	0.00487	0.18	0.18	Asperger disorder;	chr15:58753575	chr15:58768072~58770974:-
THCA	cis	rs7088591	0.867	rs41497349	ENSG00000276818.1	AC026393.1	4.06	5.8e-05	0.00487	0.38	0.18	Blood pressure;	chr10:58021410	chr10:57095699~57095781:+
THCA	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-4.06	5.8e-05	0.00487	-0.11	-0.18	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
THCA	cis	rs17685	0.725	rs4476928	ENSG00000227038.2	AC005077.12	-4.06	5.81e-05	0.00487	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76012789	chr7:76090431~76108779:-
THCA	cis	rs394563	0.591	rs237019	ENSG00000231760.4	RP11-350J20.5	4.06	5.81e-05	0.00487	0.23	0.18	Dupuytren's disease;	chr6:149405928	chr6:149796151~149826294:-
THCA	cis	rs7246967	0.541	rs16999009	ENSG00000198153.8	ZNF849P	4.06	5.81e-05	0.00488	0.28	0.18	Bronchopulmonary dysplasia;	chr19:22726856	chr19:22685167~22686732:+
THCA	cis	rs1971762	0.545	rs4759280	ENSG00000270175.1	RP11-793H13.11	-4.06	5.81e-05	0.00488	-0.12	-0.18	Height;	chr12:53671174	chr12:53500162~53500936:-
THCA	cis	rs3755605	0.728	rs7638448	ENSG00000242578.1	RP11-469J4.3	4.06	5.81e-05	0.00488	0.21	0.18	Testicular germ cell tumor;	chr3:170083749	chr3:170410512~170418615:+
THCA	cis	rs9970896	0.522	rs10803124	ENSG00000237845.1	RP5-940F7.2	-4.06	5.81e-05	0.00488	-0.33	-0.18	Monocyte percentage of white cells;	chr1:235883078	chr1:235942553~235943805:-
THCA	cis	rs4578769	0.959	rs9955664	ENSG00000265939.1	UBE2CP2	4.06	5.81e-05	0.00488	0.22	0.18	Eosinophil percentage of white cells;	chr18:22901330	chr18:22900486~22900995:-
THCA	cis	rs854765	0.583	rs4534911	ENSG00000281749.1	Y_RNA	4.06	5.81e-05	0.00488	0.24	0.18	Total body bone mineral density;	chr17:17949016	chr17:18001101~18001195:-
THCA	cis	rs703842	0.616	rs10783850	ENSG00000270039.1	RP11-571M6.17	-4.06	5.81e-05	0.00488	-0.22	-0.18	Multiple sclerosis;	chr12:57835594	chr12:57803838~57804415:+
THCA	cis	rs1577917	0.958	rs4707223	ENSG00000220563.1	PKMP3	-4.06	5.81e-05	0.00488	-0.14	-0.18	Response to antipsychotic treatment;	chr6:85800084	chr6:85659892~85660606:-
THCA	cis	rs7829975	0.774	rs35431455	ENSG00000254340.1	RP11-10A14.3	4.06	5.81e-05	0.00488	0.2	0.18	Mood instability;	chr8:8816226	chr8:9141424~9145435:+
THCA	cis	rs4915077	1	rs78288858	ENSG00000226822.1	RP11-356N1.2	4.06	5.82e-05	0.00488	0.36	0.18	Hypothyroidism;	chr1:107819671	chr1:108071482~108074519:+
THCA	cis	rs10833905	0.938	rs10833919	ENSG00000246225.5	RP11-17A1.3	-4.06	5.82e-05	0.00488	-0.26	-0.18	Sudden cardiac arrest;	chr11:23042483	chr11:22829380~22945393:+
THCA	cis	rs1065852	0.526	rs11090066	ENSG00000232710.1	RP4-669P10.16	-4.06	5.82e-05	0.00488	-0.23	-0.18	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002191	chr22:42136433~42139927:-
THCA	cis	rs12935229	0.756	rs36076586	ENSG00000260922.1	RP11-538I12.3	-4.06	5.82e-05	0.00488	-0.29	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77273046	chr16:77234877~77290934:+
THCA	cis	rs11643134	1	rs11643134	ENSG00000259940.2	CTD-3203P2.1	-4.06	5.82e-05	0.00489	-0.2	-0.18	Night sleep phenotypes;	chr16:27231559	chr16:27213308~27214993:-
THCA	cis	rs4906332	0.933	rs34606394	ENSG00000252469.1	RNU7-160P	4.06	5.82e-05	0.00489	0.2	0.18	Coronary artery disease;	chr14:103449299	chr14:103550345~103550406:+
THCA	cis	rs11089937	0.929	rs2236727	ENSG00000263366.2	LL22NC03-33B6.4	-4.06	5.82e-05	0.00489	-0.23	-0.18	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22114844~22118005:-
THCA	cis	rs78487399	0.808	rs77972916	ENSG00000234936.1	AC010883.5	4.06	5.82e-05	0.00489	0.31	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534973	chr2:43229573~43233394:+
THCA	cis	rs6591182	0.504	rs7130955	ENSG00000245532.5	NEAT1	-4.06	5.82e-05	0.00489	-0.12	-0.18	Non-alcoholic fatty liver disease histology (lobular);	chr11:65605109	chr11:65422774~65445540:+
THCA	cis	rs3020264	0.544	rs1834451	ENSG00000271743.1	CTD-2541M15.3	-4.06	5.82e-05	0.00489	-0.22	-0.18	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6633660	chr8:6615604~6617198:-
THCA	cis	rs7487075	0.619	rs4077707	ENSG00000274723.1	RP11-618L22.1	4.06	5.82e-05	0.00489	0.18	0.18	Itch intensity from mosquito bite;	chr12:46464715	chr12:46970504~46972155:+
THCA	cis	rs7809950	0.678	rs4730235	ENSG00000272072.1	CTA-363E19.2	4.06	5.82e-05	0.00489	0.2	0.18	Coronary artery disease;	chr7:107382061	chr7:107192559~107193300:-
THCA	cis	rs12234571	1	rs17159264	ENSG00000214293.7	APTR	4.06	5.82e-05	0.00489	0.23	0.18	Obesity-related traits;	chr7:77895372	chr7:77657660~77696265:-
THCA	cis	rs13126694	0.633	rs4388135	ENSG00000248429.4	RP11-597D13.9	4.06	5.82e-05	0.00489	0.2	0.18	Blood osmolality (transformed sodium);	chr4:158093301	chr4:158170752~158202877:+
THCA	cis	rs42648	0.869	rs2027965	ENSG00000225498.1	AC002064.5	4.06	5.82e-05	0.00489	0.19	0.18	Homocysteine levels;	chr7:90283199	chr7:90312496~90322592:+
THCA	cis	rs4713118	0.662	rs156744	ENSG00000219891.2	ZSCAN12P1	4.06	5.83e-05	0.00489	0.25	0.18	Parkinson's disease;	chr6:27999496	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000219891.2	ZSCAN12P1	-4.06	5.83e-05	0.00489	-0.25	-0.18	Parkinson's disease;	chr6:28002253	chr6:28091154~28093664:+
THCA	cis	rs786425	0.77	rs7958693	ENSG00000278112.1	RP11-972P1.11	4.06	5.83e-05	0.00489	0.18	0.18	Pubertal anthropometrics;	chr12:123678203	chr12:123519390~123519856:-
THCA	cis	rs7614311	0.731	rs6445387	ENSG00000271843.1	RP11-245J9.5	-4.06	5.83e-05	0.00489	-0.31	-0.18	Lung function (FVC);Lung function (FEV1);	chr3:63977002	chr3:64008082~64008692:-
THCA	cis	rs7798970	0.645	rs10244641	ENSG00000225498.1	AC002064.5	-4.06	5.83e-05	0.00489	-0.19	-0.18	Inflammatory skin disease;	chr7:90016612	chr7:90312496~90322592:+
THCA	cis	rs12681963	0.688	rs73236825	ENSG00000248159.1	HSPA8P11	4.06	5.83e-05	0.00489	0.34	0.18	Migraine;	chr8:30229590	chr8:30237382~30240997:+
THCA	cis	rs800160	0.668	rs10734191	ENSG00000199550.1	Y_RNA	4.06	5.83e-05	0.00489	0.28	0.18	Bacteremia;	chr11:2319772	chr11:2372638~2372750:+
THCA	cis	rs2898290	0.593	rs2199690	ENSG00000254527.1	ENPP7P12	-4.06	5.83e-05	0.00489	-0.23	-0.18	Systolic blood pressure;	chr8:11482107	chr8:12205759~12206389:-
THCA	cis	rs71520386	0.632	rs10279864	ENSG00000226329.2	AC005682.6	-4.06	5.83e-05	0.00489	-0.24	-0.18	Fibrinogen levels;	chr7:22824205	chr7:22863874~22881350:-
THCA	cis	rs1198872	0.892	rs10427170	ENSG00000272275.1	RP11-791G15.2	4.06	5.83e-05	0.00489	0.22	0.18	Cardiac Troponin-T levels;	chr2:10762044	chr2:10767875~10770058:-
THCA	cis	rs9902453	0.868	rs9902340	ENSG00000263370.1	RP11-68I3.5	-4.06	5.83e-05	0.00489	-0.23	-0.18	Coffee consumption (cups per day);	chr17:30149440	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.9	rs9910970	ENSG00000263370.1	RP11-68I3.5	4.06	5.83e-05	0.00489	0.23	0.18	Coffee consumption (cups per day);	chr17:30151311	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.934	rs8079028	ENSG00000263370.1	RP11-68I3.5	4.06	5.83e-05	0.00489	0.23	0.18	Coffee consumption (cups per day);	chr17:30157216	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.833	rs7216631	ENSG00000263370.1	RP11-68I3.5	4.06	5.83e-05	0.00489	0.23	0.18	Coffee consumption (cups per day);	chr17:30168094	chr17:29639627~29640825:+
THCA	cis	rs4218	0.681	rs6494069	ENSG00000259732.1	RP11-59H7.3	-4.06	5.83e-05	0.00489	-0.25	-0.18	Social communication problems;	chr15:59094151	chr15:59121034~59133250:+
THCA	cis	rs7616559	0.962	rs1032042	ENSG00000244515.1	KRT18P34	4.06	5.84e-05	0.0049	0.24	0.18	Carotid artery intima media thickness (sex interaction);	chr3:157028910	chr3:157162663~157163932:-
THCA	cis	rs3177980	0.564	rs2272918	ENSG00000239494.2	RN7SL333P	-4.06	5.84e-05	0.0049	-0.17	-0.18	Amyotrophic lateral sclerosis;	chr1:169849739	chr1:169859756~169860052:+
THCA	cis	rs3740713	1	rs113497813	ENSG00000256464.1	YWHABP2	4.06	5.84e-05	0.0049	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438697	ENSG00000256464.1	YWHABP2	4.06	5.84e-05	0.0049	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs114330751	ENSG00000256464.1	YWHABP2	4.06	5.84e-05	0.0049	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr11:18490243~18490955:-
THCA	cis	rs6546886	0.957	rs4364046	ENSG00000235499.1	AC073046.25	-4.06	5.84e-05	0.0049	-0.17	-0.18	Dialysis-related mortality;	chr2:74029178	chr2:73985132~73986343:+
THCA	cis	rs472402	0.54	rs2288445	ENSG00000250056.4	LINC01018	-4.06	5.84e-05	0.0049	-0.22	-0.18	Response to amphetamines;	chr5:6619979	chr5:6582136~6588499:+
THCA	cis	rs34779708	0.766	rs7897088	ENSG00000233200.1	RP11-324I22.2	4.06	5.84e-05	0.0049	0.23	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35219894~35230598:-
THCA	cis	rs7560272	0.723	rs7585119	ENSG00000273245.1	RP11-434P11.2	4.06	5.84e-05	0.0049	0.22	0.18	Schizophrenia;	chr2:73497552	chr2:73750256~73750786:-
THCA	cis	rs12755164	0.771	rs1917881	ENSG00000223479.3	RP4-788P17.1	-4.06	5.84e-05	0.0049	-0.19	-0.18	Schizophrenia;	chr1:72848079	chr1:73635216~73715214:+
THCA	cis	rs2749592	0.513	rs9417249	ENSG00000263064.2	RP11-291L22.7	-4.06	5.84e-05	0.0049	-0.21	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37548227	chr10:38448689~38448949:+
THCA	cis	rs9467773	1	rs9467782	ENSG00000228223.2	HCG11	-4.06	5.84e-05	0.0049	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.935	rs9461270	ENSG00000228223.2	HCG11	-4.06	5.84e-05	0.0049	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26523450~26526579:+
THCA	cis	rs6067053	0.633	rs7266044	ENSG00000230758.1	SNAP23P	-4.06	5.84e-05	0.0049	-0.23	-0.18	Intelligence (multi-trait analysis);	chr20:49274119	chr20:49038357~49038602:-
THCA	cis	rs2665103	0.61	rs56398167	ENSG00000276710.3	CSPG4P8	-4.06	5.84e-05	0.0049	-0.17	-0.18	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82459472~82477258:+
THCA	cis	rs11098499	0.738	rs72918577	ENSG00000249244.1	RP11-548H18.2	4.06	5.84e-05	0.0049	0.22	0.18	Corneal astigmatism;	chr4:119405546	chr4:119391831~119395335:-
THCA	cis	rs4834770	1	rs10034579	ENSG00000260091.1	RP11-33B1.4	-4.06	5.84e-05	0.0049	-0.13	-0.18	Blood protein levels;	chr4:119322874	chr4:119409333~119410233:+
THCA	cis	rs8020441	0.945	rs57182174	ENSG00000269906.1	RP11-248J18.2	4.06	5.84e-05	0.0049	0.26	0.18	Cognitive performance;	chr14:50701220	chr14:50662511~50663178:-
THCA	cis	rs1035144	0.654	rs3783951	ENSG00000259167.2	NMNAT1P1	4.06	5.84e-05	0.0049	0.23	0.18	Male sexual orientation;	chr14:80981752	chr14:81032529~81033404:+
THCA	cis	rs1035144	0.679	rs4903959	ENSG00000259167.2	NMNAT1P1	4.06	5.84e-05	0.0049	0.23	0.18	Male sexual orientation;	chr14:80982276	chr14:81032529~81033404:+
THCA	cis	rs13325613	0.834	rs13095946	ENSG00000223552.1	RP11-24F11.2	-4.06	5.84e-05	0.0049	-0.32	-0.18	Monocyte count;	chr3:46212321	chr3:46364955~46407059:-
THCA	cis	rs34929064	0.918	rs2961300	ENSG00000179428.2	AC073072.5	4.06	5.84e-05	0.0049	0.21	0.18	Major depression and alcohol dependence;	chr7:22669165	chr7:22725395~22727620:-
THCA	cis	rs2562784	0.597	rs2562785	ENSG00000225151.9	GOLGA2P7	-4.06	5.84e-05	0.0049	-0.33	-0.18	Height;	chr15:83617269	chr15:84199311~84230136:-
THCA	cis	rs9926296	0.706	rs2159115	ENSG00000260259.1	RP11-368I7.4	-4.06	5.84e-05	0.0049	-0.21	-0.18	Vitiligo;	chr16:89765411	chr16:89682620~89686569:-
THCA	cis	rs7617480	0.648	rs9284885	ENSG00000229759.1	MRPS18AP1	4.06	5.84e-05	0.0049	0.28	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48845667	chr3:48256350~48256938:-
THCA	cis	rs2434529	0.84	rs6885686	ENSG00000245275.6	SAP30L-AS1	-4.06	5.84e-05	0.0049	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr5:154285309	chr5:154329437~154445850:-
THCA	cis	rs9733	0.688	rs12725667	ENSG00000231073.1	RP11-316M1.3	-4.06	5.85e-05	0.0049	-0.22	-0.18	Tonsillectomy;	chr1:150793594	chr1:150973123~150975534:+
THCA	cis	rs6540731	0.87	rs1967114	ENSG00000226251.4	RP11-15I11.3	4.06	5.85e-05	0.0049	0.22	0.18	Intelligence (childhood);	chr1:212201994	chr1:212225278~212238977:-
THCA	cis	rs804280	0.527	rs2686187	ENSG00000255046.1	RP11-297N6.4	-4.06	5.85e-05	0.0049	-0.17	-0.18	Myopia (pathological);	chr8:11797287	chr8:11797928~11802568:-
THCA	cis	rs7616559	0.812	rs2128536	ENSG00000244515.1	KRT18P34	-4.06	5.85e-05	0.0049	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157049273	chr3:157162663~157163932:-
THCA	cis	rs10844706	0.699	rs11052750	ENSG00000214776.8	RP11-726G1.1	4.06	5.85e-05	0.0049	0.23	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735090	chr12:9467552~9576275:+
THCA	cis	rs10844706	0.699	rs11052751	ENSG00000214776.8	RP11-726G1.1	4.06	5.85e-05	0.0049	0.23	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735136	chr12:9467552~9576275:+
THCA	cis	rs11673344	0.526	rs73035160	ENSG00000267422.1	CTD-2554C21.1	4.06	5.85e-05	0.0049	0.19	0.18	Obesity-related traits;	chr19:37655135	chr19:37779686~37792865:+
THCA	cis	rs11673344	0.526	rs1871196	ENSG00000267422.1	CTD-2554C21.1	4.06	5.85e-05	0.0049	0.19	0.18	Obesity-related traits;	chr19:37656022	chr19:37779686~37792865:+
THCA	cis	rs34421088	0.506	rs10091637	ENSG00000154316.13	TDH	-4.06	5.85e-05	0.0049	-0.14	-0.18	Neuroticism;	chr8:11286805	chr8:11339637~11368452:+
THCA	cis	rs4767841	0.935	rs4766946	ENSG00000252886.1	RN7SKP197	-4.06	5.85e-05	0.00491	-0.19	-0.18	Urgency urinary incontinence;	chr12:119723516	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.935	rs4767840	ENSG00000252886.1	RN7SKP197	-4.06	5.85e-05	0.00491	-0.19	-0.18	Urgency urinary incontinence;	chr12:119724393	chr12:119631090~119631386:-
THCA	cis	rs738722	1	rs738722	ENSG00000272858.1	CTA-292E10.8	4.06	5.85e-05	0.00491	0.19	0.18	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28734024	chr22:28814914~28815662:+
THCA	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	4.06	5.85e-05	0.00491	0.17	0.18	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
THCA	cis	rs3738443	1	rs61840057	ENSG00000259865.1	RP11-488L18.10	4.06	5.85e-05	0.00491	0.2	0.18	Alcohol dependence;	chr1:247206054	chr1:247187281~247188526:-
THCA	cis	rs1009077	0.627	rs12642735	ENSG00000260091.1	RP11-33B1.4	-4.06	5.85e-05	0.00491	-0.17	-0.18	Endometriosis;	chr4:119603465	chr4:119409333~119410233:+
THCA	cis	rs1009077	0.627	rs3733526	ENSG00000260091.1	RP11-33B1.4	-4.06	5.85e-05	0.00491	-0.17	-0.18	Endometriosis;	chr4:119607172	chr4:119409333~119410233:+
THCA	cis	rs13325613	0.749	rs4443214	ENSG00000223552.1	RP11-24F11.2	-4.06	5.85e-05	0.00491	-0.26	-0.18	Monocyte count;	chr3:46136372	chr3:46364955~46407059:-
THCA	cis	rs801193	1	rs2659915	ENSG00000223473.2	GS1-124K5.3	4.06	5.85e-05	0.00491	0.12	0.18	Aortic root size;	chr7:66688114	chr7:66491049~66493566:-
THCA	cis	rs78153629	1	rs7169404	ENSG00000259330.1	INAFM2	-4.06	5.85e-05	0.00491	-0.22	-0.18	Heschl's gyrus morphology;	chr15:40383242	chr15:40325216~40326715:+
THCA	cis	rs78153629	0.841	rs7169262	ENSG00000259330.1	INAFM2	-4.06	5.85e-05	0.00491	-0.22	-0.18	Heschl's gyrus morphology;	chr15:40383292	chr15:40325216~40326715:+
THCA	cis	rs78153629	1	rs79044944	ENSG00000259330.1	INAFM2	-4.06	5.85e-05	0.00491	-0.22	-0.18	Heschl's gyrus morphology;	chr15:40384084	chr15:40325216~40326715:+
THCA	cis	rs62158800	0.852	rs62161279	ENSG00000237880.1	AC096669.2	4.06	5.85e-05	0.00491	0.3	0.18	Facial morphology (factor 22);	chr2:107693623	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.777	rs62161303	ENSG00000237880.1	AC096669.2	4.06	5.85e-05	0.00491	0.3	0.18	Facial morphology (factor 22);	chr2:107699211	chr2:107385632~107542649:-
THCA	cis	rs10050311	0.8	rs2230600	ENSG00000251411.1	RP11-397E7.4	4.06	5.86e-05	0.00491	0.22	0.18	Insulin-related traits;	chr4:86769845	chr4:86913266~86914817:-
THCA	cis	rs156299	0.513	rs156294	ENSG00000234286.1	AC006026.13	4.06	5.86e-05	0.00491	0.24	0.18	Vitamin D levels;	chr7:24197048	chr7:23680195~23680786:-
THCA	cis	rs13113518	1	rs4864990	ENSG00000272969.1	RP11-528I4.2	4.06	5.86e-05	0.00491	0.21	0.18	Height;	chr4:55447523	chr4:55547112~55547889:+
THCA	cis	rs17666538	0.535	rs1669658	ENSG00000254207.1	RP11-43A14.1	4.06	5.86e-05	0.00491	0.36	0.18	IgG glycosylation;	chr8:657380	chr8:725188~725877:-
THCA	cis	rs3764021	0.87	rs2401391	ENSG00000256594.6	RP11-705C15.2	4.06	5.86e-05	0.00491	0.14	0.18	Type 1 diabetes;	chr12:9725987	chr12:9633419~9658412:+
THCA	cis	rs17597773	0.638	rs12129004	ENSG00000272823.1	RP11-295M18.6	-4.06	5.86e-05	0.00491	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812173	chr1:220828676~220829211:-
THCA	cis	rs7396835	0.866	rs7927820	ENSG00000280143.1	AP000892.6	4.06	5.86e-05	0.00491	0.28	0.18	Quantitative traits;	chr11:116811440	chr11:117204967~117210292:+
THCA	cis	rs7824557	0.564	rs13268126	ENSG00000227888.4	FAM66A	-4.06	5.86e-05	0.00491	-0.23	-0.18	Retinal vascular caliber;	chr8:11373065	chr8:12362019~12388296:+
THCA	cis	rs4664293	0.801	rs7589771	ENSG00000230783.1	AC009961.2	-4.06	5.86e-05	0.00491	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159727621	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.801	rs7607143	ENSG00000230783.1	AC009961.2	-4.06	5.86e-05	0.00491	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159728250	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.833	rs10170336	ENSG00000230783.1	AC009961.2	-4.06	5.86e-05	0.00491	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159732832	chr2:159689217~159690291:-
THCA	cis	rs6921919	0.583	rs35560946	ENSG00000273712.1	RP5-874C20.7	4.06	5.86e-05	0.00491	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28315613~28315883:-
THCA	cis	rs10043228	0.826	rs10478276	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.86e-05	0.00492	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116092480	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.793	rs10069656	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.86e-05	0.00492	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116092747	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs1581024	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.86e-05	0.00492	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116099562	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs1876674	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.86e-05	0.00492	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116115272	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs12521815	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.86e-05	0.00492	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116116625	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs10478277	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.86e-05	0.00492	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116116872	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs10478278	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.86e-05	0.00492	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116117061	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs4532392	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.86e-05	0.00492	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116119808	chr5:116447547~116508276:+
THCA	cis	rs9326246	0.545	rs504268	ENSG00000254851.1	RP11-109L13.1	4.06	5.86e-05	0.00492	0.41	0.18	Coronary artery disease;	chr11:116649487	chr11:117135528~117138582:+
THCA	cis	rs7267979	1	rs4815412	ENSG00000276952.1	RP5-965G21.6	4.06	5.87e-05	0.00492	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25284915~25285588:-
THCA	cis	rs35146811	0.735	rs1043915	ENSG00000078319.8	PMS2P1	4.06	5.87e-05	0.00492	0.23	0.18	Coronary artery disease;	chr7:100202222	chr7:100320992~100341908:-
THCA	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	4.06	5.87e-05	0.00492	0.2	0.18	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	4.06	5.87e-05	0.00492	0.2	0.18	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
THCA	cis	rs13434995	0.513	rs550144	ENSG00000249700.7	SRD5A3-AS1	4.06	5.87e-05	0.00492	0.26	0.18	Adiponectin levels;	chr4:55415317	chr4:55363971~55395847:-
THCA	cis	rs9902453	0.817	rs59420007	ENSG00000263370.1	RP11-68I3.5	4.06	5.87e-05	0.00492	0.24	0.18	Coffee consumption (cups per day);	chr17:29869096	chr17:29639627~29640825:+
THCA	cis	rs77972916	0.611	rs11693190	ENSG00000234936.1	AC010883.5	4.06	5.87e-05	0.00492	0.21	0.18	Granulocyte percentage of myeloid white cells;	chr2:43375276	chr2:43229573~43233394:+
THCA	cis	rs4938303	0.718	rs4938300	ENSG00000254851.1	RP11-109L13.1	4.05	5.87e-05	0.00492	0.31	0.18	Triglycerides;	chr11:116696903	chr11:117135528~117138582:+
THCA	cis	rs71520386	0.632	rs12532938	ENSG00000226329.2	AC005682.6	-4.05	5.87e-05	0.00492	-0.24	-0.18	Fibrinogen levels;	chr7:22820876	chr7:22863874~22881350:-
THCA	cis	rs875971	0.862	rs778724	ENSG00000229886.1	RP5-1132H15.3	4.05	5.87e-05	0.00492	0.19	0.18	Aortic root size;	chr7:66364304	chr7:66025126~66031544:-
THCA	cis	rs713587	0.646	rs34697209	ENSG00000224165.4	DNAJC27-AS1	-4.05	5.87e-05	0.00492	-0.1	-0.18	Body mass index in non-asthmatics;	chr2:24904525	chr2:24971390~25039694:+
THCA	cis	rs13113518	0.902	rs3805150	ENSG00000272969.1	RP11-528I4.2	4.05	5.87e-05	0.00492	0.21	0.18	Height;	chr4:55446869	chr4:55547112~55547889:+
THCA	cis	rs962856	0.575	rs1486134	ENSG00000236780.4	AC078941.1	4.05	5.87e-05	0.00492	0.25	0.18	Pancreatic cancer;	chr2:67412637	chr2:67123357~67215319:-
THCA	cis	rs7615952	0.599	rs6438955	ENSG00000241288.6	RP11-379B18.5	-4.05	5.87e-05	0.00492	-0.2	-0.18	Blood pressure (smoking interaction);	chr3:126011490	chr3:125827238~125916384:-
THCA	cis	rs10129255	0.826	rs7150693	ENSG00000211972.2	IGHV3-66	4.05	5.87e-05	0.00492	0.11	0.18	Kawasaki disease;	chr14:106705382	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.869	rs7150549	ENSG00000211972.2	IGHV3-66	4.05	5.87e-05	0.00492	0.11	0.18	Kawasaki disease;	chr14:106705441	chr14:106675017~106675544:-
THCA	cis	rs71520386	0.632	rs10269414	ENSG00000226329.2	AC005682.6	-4.05	5.87e-05	0.00492	-0.24	-0.18	Fibrinogen levels;	chr7:22816674	chr7:22863874~22881350:-
THCA	cis	rs71520386	0.632	rs2286500	ENSG00000226329.2	AC005682.6	-4.05	5.87e-05	0.00492	-0.24	-0.18	Fibrinogen levels;	chr7:22817185	chr7:22863874~22881350:-
THCA	cis	rs2342371	0.848	rs13092653	ENSG00000273013.1	CTD-2002J20.1	4.05	5.87e-05	0.00492	0.18	0.18	Fat distribution (HIV);	chr3:196473317	chr3:196474801~196475394:+
THCA	cis	rs7572644	0.64	rs12464988	ENSG00000223522.1	AC093690.1	-4.05	5.87e-05	0.00493	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27835359	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.656	rs34096628	ENSG00000223522.1	AC093690.1	-4.05	5.87e-05	0.00493	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27838123	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.64	rs9678336	ENSG00000223522.1	AC093690.1	-4.05	5.87e-05	0.00493	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27842537	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.679	rs4419196	ENSG00000223522.1	AC093690.1	-4.05	5.87e-05	0.00493	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27852431	chr2:28307691~28310459:-
THCA	cis	rs17597773	0.755	rs10863570	ENSG00000238078.1	LINC01352	-4.05	5.88e-05	0.00493	-0.27	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220857247	chr1:220829255~220832429:+
THCA	cis	rs11089937	0.651	rs928894	ENSG00000211639.2	IGLV4-60	4.05	5.88e-05	0.00493	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22185882	chr22:22162199~22162681:+
THCA	cis	rs6840360	0.692	rs1838043	ENSG00000270265.1	RP11-731D1.4	-4.05	5.88e-05	0.00493	-0.17	-0.18	Intelligence (multi-trait analysis);	chr4:151490310	chr4:151333775~151353224:-
THCA	cis	rs6494488	0.5	rs72742957	ENSG00000259635.1	AC100830.3	-4.05	5.88e-05	0.00493	-0.47	-0.18	Coronary artery disease;	chr15:64613028	chr15:64701248~64719602:+
THCA	cis	rs2414856	0.51	rs112523289	ENSG00000259635.1	AC100830.3	-4.05	5.88e-05	0.00493	-0.47	-0.18	Pulse pressure;Systolic blood pressure;	chr15:64613636	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs112698132	ENSG00000259635.1	AC100830.3	-4.05	5.88e-05	0.00493	-0.47	-0.18	Coronary artery disease;	chr15:64614214	chr15:64701248~64719602:+
THCA	cis	rs7707921	0.881	rs2629744	ENSG00000251374.1	RPS23P5	4.05	5.88e-05	0.00493	0.26	0.18	Breast cancer;	chr5:82086178	chr5:82265157~82265259:-
THCA	cis	rs7528684	0.546	rs11264794	ENSG00000236731.1	RP4-801G22.2	-4.05	5.88e-05	0.00493	-0.19	-0.18	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157677999	chr1:157629939~157630728:-
THCA	cis	rs55702914	0.839	rs2059922	ENSG00000231621.1	AC013264.2	4.05	5.88e-05	0.00493	0.18	0.18	Major depression and alcohol dependence;	chr2:197324179	chr2:197197991~197199273:+
THCA	cis	rs55702914	0.809	rs3097385	ENSG00000231621.1	AC013264.2	4.05	5.88e-05	0.00493	0.18	0.18	Major depression and alcohol dependence;	chr2:197334573	chr2:197197991~197199273:+
THCA	cis	rs115575488	0.61	rs12741635	ENSG00000231365.4	RP11-418J17.1	4.05	5.88e-05	0.00493	0.23	0.18	Lobe attachment (rater-scored or self-reported);	chr1:119051198	chr1:119140396~119275973:+
THCA	cis	rs17507216	0.681	rs28877110	ENSG00000255769.6	GOLGA2P10	-4.05	5.88e-05	0.00493	-0.29	-0.18	Excessive daytime sleepiness;	chr15:82672111	chr15:82472993~82513950:-
THCA	cis	rs17507216	0.609	rs1431716	ENSG00000255769.6	GOLGA2P10	-4.05	5.88e-05	0.00493	-0.29	-0.18	Excessive daytime sleepiness;	chr15:82676180	chr15:82472993~82513950:-
THCA	cis	rs1040	0.727	rs7382431	ENSG00000261039.2	RP11-417E7.2	-4.05	5.88e-05	0.00493	-0.2	-0.18	Joint mobility (Beighton score);	chr6:169221734	chr6:169175304~169182740:-
THCA	cis	rs4321325	0.733	rs4510165	ENSG00000236682.1	AC068282.3	-4.05	5.88e-05	0.00493	-0.38	-0.18	Protein C levels;	chr2:127178708	chr2:127389130~127400580:+
THCA	cis	rs75504410	0.85	rs4833076	ENSG00000231160.8	KLF3-AS1	4.05	5.88e-05	0.00493	0.21	0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38620745	chr4:38612701~38664883:-
THCA	cis	rs4742903	0.904	rs10121829	ENSG00000270332.1	SMC2-AS1	4.05	5.88e-05	0.00493	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104231715	chr9:104080024~104093073:-
THCA	cis	rs9307551	0.817	rs11098764	ENSG00000249646.2	OR7E94P	-4.05	5.88e-05	0.00493	-0.23	-0.18	Refractive error;	chr4:79578860	chr4:79587302~79588130:-
THCA	cis	rs61142792	1	rs335472	ENSG00000272459.1	RP11-1277A3.3	-4.05	5.88e-05	0.00493	-0.4	-0.18	Alzheimer disease and age of onset;	chr5:177557162	chr5:177554824~177555364:+
THCA	cis	rs7432375	1	rs6439649	ENSG00000273455.1	RP11-305O4.3	-4.05	5.88e-05	0.00493	-0.24	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136652849	chr3:136087475~136087913:-
THCA	cis	rs6019512	0.625	rs1997852	ENSG00000227431.4	CSE1L-AS1	4.05	5.88e-05	0.00493	0.22	0.18	Intelligence (multi-trait analysis);	chr20:48910022	chr20:49040463~49046044:-
THCA	cis	rs17801127	0.818	rs12233215	ENSG00000231969.1	AC144449.1	4.05	5.88e-05	0.00493	0.31	0.18	Liver enzyme levels (alanine transaminase);	chr2:149690793	chr2:149587196~149848233:+
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000265443.1	CTD-2349P21.6	-4.05	5.88e-05	0.00493	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30726305~30727564:-
THCA	cis	rs6019512	0.647	rs4810888	ENSG00000227431.4	CSE1L-AS1	-4.05	5.88e-05	0.00493	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48906783	chr20:49040463~49046044:-
THCA	cis	rs6019512	0.625	rs4810890	ENSG00000227431.4	CSE1L-AS1	-4.05	5.88e-05	0.00493	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48908920	chr20:49040463~49046044:-
THCA	cis	rs6019512	0.625	rs4810891	ENSG00000227431.4	CSE1L-AS1	-4.05	5.88e-05	0.00493	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48908981	chr20:49040463~49046044:-
THCA	cis	rs6019512	0.604	rs1997850	ENSG00000227431.4	CSE1L-AS1	-4.05	5.88e-05	0.00493	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48909823	chr20:49040463~49046044:-
THCA	cis	rs6019512	0.625	rs1997853	ENSG00000227431.4	CSE1L-AS1	-4.05	5.88e-05	0.00493	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48910083	chr20:49040463~49046044:-
THCA	cis	rs7572733	0.555	rs6729473	ENSG00000231621.1	AC013264.2	-4.05	5.89e-05	0.00493	-0.19	-0.18	Dermatomyositis;	chr2:197899204	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs6760891	ENSG00000231621.1	AC013264.2	-4.05	5.89e-05	0.00493	-0.19	-0.18	Dermatomyositis;	chr2:197903442	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs7572123	ENSG00000231621.1	AC013264.2	-4.05	5.89e-05	0.00493	-0.19	-0.18	Dermatomyositis;	chr2:197904913	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs4850813	ENSG00000231621.1	AC013264.2	4.05	5.89e-05	0.00493	0.19	0.18	Dermatomyositis;	chr2:197911258	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs10931794	ENSG00000231621.1	AC013264.2	4.05	5.89e-05	0.00493	0.19	0.18	Dermatomyositis;	chr2:197911416	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.555	rs2341778	ENSG00000231621.1	AC013264.2	4.05	5.89e-05	0.00493	0.19	0.18	Dermatomyositis;	chr2:197911822	chr2:197197991~197199273:+
THCA	cis	rs116175783	1	rs4309587	ENSG00000227403.1	AC009299.3	4.05	5.89e-05	0.00493	0.44	0.18	Intelligence (multi-trait analysis);	chr2:161700077	chr2:161244739~161249050:+
THCA	cis	rs7572733	0.534	rs1401095	ENSG00000231621.1	AC013264.2	4.05	5.89e-05	0.00493	0.19	0.18	Dermatomyositis;	chr2:197915143	chr2:197197991~197199273:+
THCA	cis	rs7568498	1	rs10164593	ENSG00000235724.7	AC009299.2	4.05	5.89e-05	0.00493	0.26	0.18	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161125461	chr2:161222785~161308303:-
THCA	cis	rs11247915	0.622	rs34370465	ENSG00000236782.4	RP11-96L14.7	-4.05	5.89e-05	0.00493	-0.23	-0.18	Obesity-related traits;	chr1:26344118	chr1:26169947~26171821:-
THCA	cis	rs972578	1	rs4820500	ENSG00000230319.1	AL022476.2	4.05	5.89e-05	0.00494	0.19	0.18	Mean platelet volume;	chr22:42983367	chr22:43038585~43052366:+
THCA	cis	rs78487399	0.908	rs74869386	ENSG00000234936.1	AC010883.5	4.05	5.89e-05	0.00494	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43622591	chr2:43229573~43233394:+
THCA	cis	rs7560272	0.501	rs11891140	ENSG00000273245.1	RP11-434P11.2	-4.05	5.89e-05	0.00494	-0.21	-0.18	Schizophrenia;	chr2:73716957	chr2:73750256~73750786:-
THCA	cis	rs4906332	0.966	rs7401563	ENSG00000252469.1	RNU7-160P	4.05	5.89e-05	0.00494	0.2	0.18	Coronary artery disease;	chr14:103498088	chr14:103550345~103550406:+
THCA	cis	rs9467773	1	rs1884946	ENSG00000228223.2	HCG11	-4.05	5.89e-05	0.00494	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26523450~26526579:+
THCA	cis	rs5758659	0.652	rs133301	ENSG00000273366.1	CTA-989H11.1	-4.05	5.89e-05	0.00494	-0.22	-0.18	Cognitive function;	chr22:41994089	chr22:42278188~42278846:+
THCA	cis	rs804280	0.509	rs9886639	ENSG00000206014.6	OR7E161P	-4.05	5.89e-05	0.00494	-0.22	-0.18	Myopia (pathological);	chr8:11927020	chr8:11928597~11929563:-
THCA	cis	rs6019512	0.647	rs6066906	ENSG00000227431.4	CSE1L-AS1	-4.05	5.89e-05	0.00494	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48911114	chr20:49040463~49046044:-
THCA	cis	rs6019512	0.625	rs6019514	ENSG00000227431.4	CSE1L-AS1	-4.05	5.89e-05	0.00494	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48911502	chr20:49040463~49046044:-
THCA	cis	rs6019512	0.549	rs6019515	ENSG00000227431.4	CSE1L-AS1	-4.05	5.89e-05	0.00494	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48911800	chr20:49040463~49046044:-
THCA	cis	rs1040	0.69	rs9393165	ENSG00000261039.2	RP11-417E7.2	-4.05	5.89e-05	0.00494	-0.2	-0.18	Joint mobility (Beighton score);	chr6:169220152	chr6:169175304~169182740:-
THCA	cis	rs6088813	1	rs6088816	ENSG00000279253.1	RP4-614O4.13	4.05	5.89e-05	0.00494	0.18	0.18	Height;	chr20:35394632	chr20:35262727~35264187:-
THCA	cis	rs6088813	0.961	rs1886691	ENSG00000279253.1	RP4-614O4.13	4.05	5.89e-05	0.00494	0.18	0.18	Height;	chr20:35398468	chr20:35262727~35264187:-
THCA	cis	rs6088813	1	rs6142376	ENSG00000279253.1	RP4-614O4.13	4.05	5.89e-05	0.00494	0.18	0.18	Height;	chr20:35404958	chr20:35262727~35264187:-
THCA	cis	rs7131987	0.644	rs1436323	ENSG00000257176.2	RP11-996F15.2	4.05	5.89e-05	0.00494	0.18	0.18	QT interval;	chr12:29401808	chr12:29280418~29317848:-
THCA	cis	rs6449502	0.536	rs28409386	ENSG00000251279.1	CTC-436P18.1	4.05	5.89e-05	0.00494	0.33	0.18	Mean platelet volume;	chr5:61190761	chr5:61162070~61232040:+
THCA	cis	rs3734729	1	rs9384299	ENSG00000218358.2	RAET1K	4.05	5.9e-05	0.00494	0.53	0.18	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150256931	chr6:149998019~150005157:-
THCA	cis	rs12134133	1	rs2782842	ENSG00000237074.1	RP11-6J21.2	4.05	5.9e-05	0.00494	0.2	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207249067~207309121:+
THCA	cis	rs4915077	0.892	rs4914963	ENSG00000226822.1	RP11-356N1.2	4.05	5.9e-05	0.00494	0.37	0.18	Hypothyroidism;	chr1:107843073	chr1:108071482~108074519:+
THCA	cis	rs17597773	0.638	rs881995	ENSG00000272823.1	RP11-295M18.6	-4.05	5.9e-05	0.00494	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220811152	chr1:220828676~220829211:-
THCA	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	4.05	5.9e-05	0.00494	0.17	0.18	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
THCA	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	4.05	5.9e-05	0.00494	0.15	0.18	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
THCA	cis	rs2299587	0.554	rs2073565	ENSG00000253671.1	RP11-806O11.1	-4.05	5.9e-05	0.00494	-0.22	-0.18	Economic and political preferences;	chr8:17886140	chr8:17808941~17820868:+
THCA	cis	rs2299587	0.554	rs2073566	ENSG00000253671.1	RP11-806O11.1	-4.05	5.9e-05	0.00494	-0.22	-0.18	Economic and political preferences;	chr8:17886146	chr8:17808941~17820868:+
THCA	cis	rs7824557	0.564	rs2736304	ENSG00000154316.13	TDH	4.05	5.9e-05	0.00494	0.14	0.18	Retinal vascular caliber;	chr8:11379455	chr8:11339637~11368452:+
THCA	cis	rs6963495	0.818	rs73192145	ENSG00000272604.1	RP11-251G23.5	4.05	5.9e-05	0.00494	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105563181	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73192149	ENSG00000272604.1	RP11-251G23.5	4.05	5.9e-05	0.00494	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105570463	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.745	rs73192152	ENSG00000272604.1	RP11-251G23.5	4.05	5.9e-05	0.00494	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105571811	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.745	rs73192153	ENSG00000272604.1	RP11-251G23.5	4.05	5.9e-05	0.00494	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105571971	chr7:105571083~105573660:+
THCA	cis	rs10833905	1	rs28591594	ENSG00000246225.5	RP11-17A1.3	-4.05	5.9e-05	0.00494	-0.26	-0.18	Sudden cardiac arrest;	chr11:23022338	chr11:22829380~22945393:+
THCA	cis	rs10833905	1	rs3909702	ENSG00000246225.5	RP11-17A1.3	-4.05	5.9e-05	0.00494	-0.26	-0.18	Sudden cardiac arrest;	chr11:23022607	chr11:22829380~22945393:+
THCA	cis	rs10833905	1	rs5005787	ENSG00000246225.5	RP11-17A1.3	-4.05	5.9e-05	0.00494	-0.26	-0.18	Sudden cardiac arrest;	chr11:23022940	chr11:22829380~22945393:+
THCA	cis	rs854765	0.552	rs6502624	ENSG00000281749.1	Y_RNA	4.05	5.9e-05	0.00494	0.23	0.18	Total body bone mineral density;	chr17:17944622	chr17:18001101~18001195:-
THCA	cis	rs9393813	0.868	rs2393963	ENSG00000204789.4	ZNF204P	-4.05	5.9e-05	0.00495	-0.15	-0.18	Bipolar disorder;	chr6:27507321	chr6:27357825~27360221:-
THCA	cis	rs6019512	0.625	rs6019513	ENSG00000227431.4	CSE1L-AS1	-4.05	5.9e-05	0.00495	-0.22	-0.18	Intelligence (multi-trait analysis);	chr20:48910269	chr20:49040463~49046044:-
THCA	cis	rs2342371	0.565	rs11185543	ENSG00000273013.1	CTD-2002J20.1	4.05	5.9e-05	0.00495	0.17	0.18	Fat distribution (HIV);	chr3:196488789	chr3:196474801~196475394:+
THCA	cis	rs599083	0.53	rs546803	ENSG00000212093.1	AP000807.1	-4.05	5.9e-05	0.00495	-0.2	-0.18	Bone mineral density (spine);	chr11:68418924	chr11:68506083~68506166:-
THCA	cis	rs7616559	0.849	rs1384542	ENSG00000244515.1	KRT18P34	4.05	5.9e-05	0.00495	0.24	0.18	Carotid artery intima media thickness (sex interaction);	chr3:157038871	chr3:157162663~157163932:-
THCA	cis	rs12755164	0.771	rs2841192	ENSG00000223479.3	RP4-788P17.1	-4.05	5.91e-05	0.00495	-0.2	-0.18	Schizophrenia;	chr1:72841944	chr1:73635216~73715214:+
THCA	cis	rs9595908	0.709	rs4942880	ENSG00000212293.1	SNORA16	4.05	5.91e-05	0.00495	0.21	0.18	Body mass index;	chr13:32751641	chr13:32420390~32420516:-
THCA	cis	rs7312933	0.645	rs11181404	ENSG00000257225.1	RP11-328C8.4	-4.05	5.91e-05	0.00495	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42290038	chr12:42459366~42466128:+
THCA	cis	rs11671653	1	rs8112837	ENSG00000267100.1	ILF3-AS1	4.05	5.91e-05	0.00495	0.2	0.18	LDL cholesterol;	chr19:10726354	chr19:10651862~10653844:-
THCA	cis	rs1124769	0.57	rs2614765	ENSG00000273674.3	CTD-2378E12.1	-4.05	5.91e-05	0.00495	-0.24	-0.18	Cognitive performance;	chr15:50851805	chr15:50839875~50908599:-
THCA	cis	rs9843304	0.501	rs34540967	ENSG00000240541.2	TM4SF1-AS1	4.05	5.91e-05	0.00495	0.16	0.18	Gallstone disease;	chr3:149486594	chr3:149377778~149386583:+
THCA	cis	rs7166081	1	rs12911370	ENSG00000270964.1	RP11-502I4.3	-4.05	5.91e-05	0.00495	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67253983	chr15:67541072~67542604:-
THCA	cis	rs1267303	0.675	rs1267308	ENSG00000232022.5	FAAHP1	-4.05	5.91e-05	0.00495	-0.22	-0.18	Monobrow;	chr1:46522046	chr1:46432129~46445521:+
THCA	cis	rs7829975	0.653	rs13259070	ENSG00000233609.3	RP11-62H7.2	4.05	5.91e-05	0.00495	0.18	0.18	Mood instability;	chr8:8833277	chr8:8961200~8979025:+
THCA	cis	rs8059260	0.541	rs16958028	ENSG00000274038.1	RP11-66H6.4	-4.05	5.91e-05	0.00495	-0.4	-0.18	Alcohol consumption over the past year;	chr16:11082811	chr16:11056556~11057034:+
THCA	cis	rs7111546	0.565	rs77267842	ENSG00000246225.5	RP11-17A1.3	4.05	5.91e-05	0.00495	0.33	0.18	Dialysis-related mortality;	chr11:22939122	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.565	rs7118222	ENSG00000246225.5	RP11-17A1.3	4.05	5.91e-05	0.00495	0.33	0.18	Dialysis-related mortality;	chr11:22939720	chr11:22829380~22945393:+
THCA	cis	rs2275906	0.748	rs11964886	ENSG00000272462.2	U91328.19	4.05	5.91e-05	0.00495	0.19	0.18	Urate levels in lean individuals;	chr6:25878151	chr6:25992662~26001775:+
THCA	cis	rs4950322	0.512	rs2353974	ENSG00000226015.2	CCT8P1	-4.05	5.91e-05	0.00495	-0.19	-0.18	Protein quantitative trait loci;	chr1:147384534	chr1:147203276~147204932:-
THCA	cis	rs1048886	0.872	rs6911983	ENSG00000271967.1	RP11-134K13.4	-4.05	5.91e-05	0.00495	-0.2	-0.18	Type 2 diabetes;	chr6:70563858	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9455161	ENSG00000271967.1	RP11-134K13.4	-4.05	5.91e-05	0.00495	-0.2	-0.18	Type 2 diabetes;	chr6:70565476	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9455163	ENSG00000271967.1	RP11-134K13.4	-4.05	5.91e-05	0.00495	-0.2	-0.18	Type 2 diabetes;	chr6:70570054	chr6:70596438~70596980:+
THCA	cis	rs11239930	0.538	rs3011810	ENSG00000278811.3	LINC00624	4.05	5.91e-05	0.00495	0.22	0.18	AIDS progression;	chr1:147082079	chr1:147258885~147517875:-
THCA	cis	rs357618	0.581	rs165328	ENSG00000260581.1	CTB-113P19.4	4.05	5.91e-05	0.00495	0.28	0.18	Basophil percentage of white cells;	chr5:151494210	chr5:151652275~151655449:+
THCA	cis	rs755249	1	rs12037222	ENSG00000237624.1	OXCT2P1	4.05	5.91e-05	0.00495	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39599289	chr1:39514956~39516490:+
THCA	cis	rs2153535	0.518	rs9392227	ENSG00000230939.1	RP11-314C16.1	-4.05	5.91e-05	0.00495	-0.2	-0.18	Motion sickness;	chr6:8581553	chr6:8784178~8785445:+
THCA	cis	rs1971762	0.527	rs7311902	ENSG00000270175.1	RP11-793H13.11	-4.05	5.91e-05	0.00495	-0.12	-0.18	Height;	chr12:53621452	chr12:53500162~53500936:-
THCA	cis	rs7219021	0.674	rs4793990	ENSG00000248278.1	SUMO2P17	4.05	5.91e-05	0.00495	0.24	0.18	Schizophrenia or bipolar disorder;	chr17:48883398	chr17:48874860~48908983:-
THCA	cis	rs7904321	0.597	rs10995426	ENSG00000232075.1	MRPL35P2	-4.05	5.91e-05	0.00495	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63080258	chr10:63634317~63634827:-
THCA	cis	rs11971779	0.938	rs11981688	ENSG00000252332.1	RNU6-911P	-4.05	5.91e-05	0.00495	-0.23	-0.18	Diisocyanate-induced asthma;	chr7:139404149	chr7:139448740~139448843:+
THCA	cis	rs9733	0.744	rs4970976	ENSG00000231073.1	RP11-316M1.3	-4.05	5.91e-05	0.00495	-0.22	-0.18	Tonsillectomy;	chr1:150807048	chr1:150973123~150975534:+
THCA	cis	rs7246967	0.673	rs34126042	ENSG00000198153.8	ZNF849P	-4.05	5.91e-05	0.00495	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22726416	chr19:22685167~22686732:+
THCA	cis	rs755249	0.508	rs586057	ENSG00000228060.1	RP11-69E11.8	-4.05	5.91e-05	0.00495	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39565160~39573203:+
THCA	cis	rs7829975	0.774	rs1039915	ENSG00000253981.4	ALG1L13P	4.05	5.91e-05	0.00495	0.18	0.18	Mood instability;	chr8:8822104	chr8:8236003~8244667:-
THCA	cis	rs2380220	1	rs2380220	ENSG00000261366.1	MANEA-AS1	-4.05	5.92e-05	0.00495	-0.21	-0.18	Behavioural disinhibition (generation interaction);	chr6:95519536	chr6:95575183~95577450:-
THCA	cis	rs10908458	0.584	rs10908454	ENSG00000160766.13	GBAP1	-4.05	5.92e-05	0.00496	-0.2	-0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155093940	chr1:155213821~155227422:-
THCA	cis	rs4714902	0.655	rs1048077	ENSG00000231769.2	RP1-8B1.4	4.05	5.92e-05	0.00496	0.18	0.18	Colonoscopy-negative controls vs population controls;	chr6:46144652	chr6:46097093~46129706:-
THCA	cis	rs7829975	0.559	rs4841025	ENSG00000253981.4	ALG1L13P	-4.05	5.92e-05	0.00496	-0.17	-0.18	Mood instability;	chr8:8745650	chr8:8236003~8244667:-
THCA	cis	rs9311474	0.629	rs11709284	ENSG00000243224.1	RP5-1157M23.2	-4.05	5.92e-05	0.00496	-0.19	-0.18	Electroencephalogram traits;	chr3:52525689	chr3:52239258~52241097:+
THCA	cis	rs1048886	0.938	rs7759464	ENSG00000271967.1	RP11-134K13.4	-4.05	5.92e-05	0.00496	-0.19	-0.18	Type 2 diabetes;	chr6:70422469	chr6:70596438~70596980:+
THCA	cis	rs4788570	0.615	rs8053745	ENSG00000260185.1	RP11-432I5.6	-4.05	5.92e-05	0.00496	-0.34	-0.18	Intelligence (multi-trait analysis);	chr16:71655790	chr16:71655027~71664212:+
THCA	cis	rs8062405	0.755	rs1074631	ENSG00000270424.1	RP11-1348G14.6	-4.05	5.92e-05	0.00496	-0.23	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28749959~28750595:-
THCA	cis	rs3743266	0.634	rs7165874	ENSG00000240163.1	RP11-745A24.1	4.05	5.92e-05	0.00496	0.21	0.18	Menarche (age at onset);	chr15:60492410	chr15:60390371~60390682:+
THCA	cis	rs7088591	0.867	rs78874564	ENSG00000276818.1	AC026393.1	4.05	5.92e-05	0.00496	0.39	0.18	Blood pressure;	chr10:57990887	chr10:57095699~57095781:+
THCA	cis	rs7312933	0.558	rs1796384	ENSG00000257225.1	RP11-328C8.4	4.05	5.92e-05	0.00496	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42386766	chr12:42459366~42466128:+
THCA	cis	rs4767841	0.537	rs385930	ENSG00000252886.1	RN7SKP197	-4.05	5.92e-05	0.00496	-0.18	-0.18	Urgency urinary incontinence;	chr12:119781260	chr12:119631090~119631386:-
THCA	cis	rs651907	0.817	rs654102	ENSG00000256628.3	ZBTB11-AS1	4.05	5.92e-05	0.00496	0.2	0.18	Colorectal cancer;	chr3:101889311	chr3:101676475~101679217:+
THCA	cis	rs4295623	0.585	rs13259242	ENSG00000255046.1	RP11-297N6.4	4.05	5.92e-05	0.00496	0.19	0.18	Morning vs. evening chronotype;	chr8:11735524	chr8:11797928~11802568:-
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000254948.1	OR7E158P	4.05	5.92e-05	0.00496	0.22	0.18	Neuroticism;	chr8:11986249	chr8:11919900~11920809:-
THCA	cis	rs495337	0.735	rs636987	ENSG00000229222.1	KRT18P4	-4.05	5.92e-05	0.00496	-0.23	-0.18	Psoriasis;	chr20:49907751	chr20:49956745~49958032:+
THCA	cis	rs73222236	0.75	rs7648591	ENSG00000273486.1	RP11-731C17.2	4.05	5.92e-05	0.00496	0.16	0.18	Coronary artery disease;	chr3:136507541	chr3:136837338~136839021:-
THCA	cis	rs832187	0.593	rs3774713	ENSG00000224479.4	AC136289.1	4.05	5.92e-05	0.00496	0.23	0.18	Schizophrenia;	chr3:63932016	chr3:63742293~63827445:-
THCA	cis	rs9309473	0.95	rs13431529	ENSG00000273245.1	RP11-434P11.2	4.05	5.92e-05	0.00496	0.26	0.18	Metabolite levels;	chr2:73648914	chr2:73750256~73750786:-
THCA	cis	rs9863	0.828	rs11057412	ENSG00000270061.1	RP11-214K3.19	-4.05	5.92e-05	0.00496	-0.24	-0.18	White blood cell count;	chr12:124004595	chr12:123969990~123970344:-
THCA	cis	rs61270009	0.955	rs13172095	ENSG00000247828.6	TMEM161B-AS1	-4.05	5.92e-05	0.00496	-0.16	-0.18	Depressive symptoms;	chr5:88295130	chr5:88268895~88436685:+
THCA	cis	rs11176749	1	rs11176749	ENSG00000203585.3	RP11-542B15.1	4.05	5.92e-05	0.00496	0.21	0.18	Expressive vocabulary in infants;	chr12:67459004	chr12:67519829~67567126:+
THCA	cis	rs7616559	0.627	rs1482855	ENSG00000244515.1	KRT18P34	4.05	5.92e-05	0.00496	0.21	0.18	Carotid artery intima media thickness (sex interaction);	chr3:157029556	chr3:157162663~157163932:-
THCA	cis	rs13434995	0.513	rs13134079	ENSG00000249700.7	SRD5A3-AS1	4.05	5.93e-05	0.00496	0.26	0.18	Adiponectin levels;	chr4:55542021	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs1021307	ENSG00000249700.7	SRD5A3-AS1	4.05	5.93e-05	0.00496	0.26	0.18	Adiponectin levels;	chr4:55529547	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs1021306	ENSG00000249700.7	SRD5A3-AS1	4.05	5.93e-05	0.00496	0.26	0.18	Adiponectin levels;	chr4:55529777	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs6554285	ENSG00000249700.7	SRD5A3-AS1	4.05	5.93e-05	0.00496	0.26	0.18	Adiponectin levels;	chr4:55533953	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs7660668	ENSG00000249700.7	SRD5A3-AS1	4.05	5.93e-05	0.00496	0.26	0.18	Adiponectin levels;	chr4:55535530	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs7698022	ENSG00000249700.7	SRD5A3-AS1	4.05	5.93e-05	0.00496	0.26	0.18	Adiponectin levels;	chr4:55541180	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs1048004	ENSG00000249700.7	SRD5A3-AS1	-4.05	5.93e-05	0.00496	-0.26	-0.18	Adiponectin levels;	chr4:55434042	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs1801260	ENSG00000249700.7	SRD5A3-AS1	-4.05	5.93e-05	0.00496	-0.26	-0.18	Adiponectin levels;	chr4:55435202	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs17721215	ENSG00000249700.7	SRD5A3-AS1	-4.05	5.93e-05	0.00496	-0.26	-0.18	Adiponectin levels;	chr4:55437620	chr4:55363971~55395847:-
THCA	cis	rs7259376	0.871	rs2360622	ENSG00000269138.1	ZNF209P	4.05	5.93e-05	0.00496	0.18	0.18	Menopause (age at onset);	chr19:22387820	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.837	rs16999542	ENSG00000269138.1	ZNF209P	4.05	5.93e-05	0.00496	0.18	0.18	Menopause (age at onset);	chr19:22390290	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.902	rs10408428	ENSG00000269138.1	ZNF209P	-4.05	5.93e-05	0.00496	-0.18	-0.18	Menopause (age at onset);	chr19:22395221	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.694	rs75653200	ENSG00000269138.1	ZNF209P	-4.05	5.93e-05	0.00496	-0.18	-0.18	Menopause (age at onset);	chr19:22396701	chr19:22463922~22473036:+
THCA	cis	rs17801127	0.901	rs7608496	ENSG00000231969.1	AC144449.1	4.05	5.93e-05	0.00496	0.36	0.18	Liver enzyme levels (alanine transaminase);	chr2:149784299	chr2:149587196~149848233:+
THCA	cis	rs7829975	0.774	rs57312668	ENSG00000253981.4	ALG1L13P	4.05	5.93e-05	0.00496	0.18	0.18	Mood instability;	chr8:8822967	chr8:8236003~8244667:-
THCA	cis	rs17382723	0.887	rs60134249	ENSG00000229996.1	AC093585.6	4.05	5.93e-05	0.00496	0.24	0.18	Height;	chr2:241103233	chr2:241010045~241010744:-
THCA	cis	rs17382723	0.887	rs58343802	ENSG00000229996.1	AC093585.6	4.05	5.93e-05	0.00496	0.24	0.18	Height;	chr2:241103398	chr2:241010045~241010744:-
THCA	cis	rs2380205	0.666	rs11819695	ENSG00000232807.2	RP11-536K7.3	4.05	5.93e-05	0.00496	0.18	0.18	Breast cancer;	chr10:5845316	chr10:5934270~5945900:-
THCA	cis	rs11633886	0.785	rs11637965	ENSG00000259200.1	RP11-718O11.1	-4.05	5.93e-05	0.00497	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45772645	chr15:45705078~45931069:+
THCA	cis	rs12234571	1	rs78163487	ENSG00000214293.7	APTR	4.05	5.93e-05	0.00497	0.23	0.18	Obesity-related traits;	chr7:77901796	chr7:77657660~77696265:-
THCA	cis	rs17772222	0.74	rs61984675	ENSG00000222990.1	RNU4-22P	4.05	5.93e-05	0.00497	0.23	0.18	Coronary artery calcification;	chr14:88511236	chr14:88513498~88513663:+
THCA	cis	rs394563	0.559	rs13219868	ENSG00000231760.4	RP11-350J20.5	-4.05	5.93e-05	0.00497	-0.23	-0.18	Dupuytren's disease;	chr6:149365382	chr6:149796151~149826294:-
THCA	cis	rs4767841	0.868	rs1318272	ENSG00000252886.1	RN7SKP197	-4.05	5.93e-05	0.00497	-0.18	-0.18	Urgency urinary incontinence;	chr12:119751883	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.901	rs904654	ENSG00000252886.1	RN7SKP197	-4.05	5.93e-05	0.00497	-0.18	-0.18	Urgency urinary incontinence;	chr12:119752083	chr12:119631090~119631386:-
THCA	cis	rs2853333	0.622	rs2853332	ENSG00000269553.1	U62631.5	-4.05	5.93e-05	0.00497	-0.21	-0.18	Red blood cell count;	chr19:35255803	chr19:35330843~35331920:+
THCA	cis	rs17666538	0.585	rs6559063	ENSG00000254207.1	RP11-43A14.1	4.05	5.93e-05	0.00497	0.36	0.18	IgG glycosylation;	chr8:673051	chr8:725188~725877:-
THCA	cis	rs2434529	0.911	rs73281513	ENSG00000245275.6	SAP30L-AS1	4.05	5.93e-05	0.00497	0.23	0.18	Autism spectrum disorder or schizophrenia;	chr5:154307884	chr5:154329437~154445850:-
THCA	cis	rs12134133	1	rs2802237	ENSG00000237074.1	RP11-6J21.2	4.05	5.93e-05	0.00497	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207249067~207309121:+
THCA	cis	rs4950322	0.634	rs4950415	ENSG00000180867.10	PDIA3P1	4.05	5.93e-05	0.00497	0.18	0.18	Protein quantitative trait loci;	chr1:147350951	chr1:147178113~147179622:+
THCA	cis	rs7737355	0.947	rs6884741	ENSG00000237714.1	P4HA2-AS1	4.05	5.93e-05	0.00497	0.26	0.18	Life satisfaction;	chr5:131558920	chr5:132184876~132192808:+
THCA	cis	rs950776	0.518	rs11636131	ENSG00000261762.1	RP11-650L12.2	4.05	5.94e-05	0.00497	0.23	0.18	Sudden cardiac arrest;	chr15:78529264	chr15:78589123~78591276:-
THCA	cis	rs6556937	0.736	rs1421911	ENSG00000272109.1	CTD-2260A17.3	4.05	5.94e-05	0.00497	0.31	0.18	Blood protein levels;	chr5:96665243	chr5:96804353~96806105:+
THCA	cis	rs4713118	0.866	rs9468217	ENSG00000261839.1	RP1-265C24.8	4.05	5.94e-05	0.00497	0.22	0.18	Parkinson's disease;	chr6:27758688	chr6:28136849~28139678:+
THCA	cis	rs1842579	1	rs6576791	ENSG00000272691.1	RP11-290M5.4	-4.05	5.94e-05	0.00497	-0.18	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85820457	chr1:85578500~85578742:-
THCA	cis	rs755249	0.51	rs613511	ENSG00000228060.1	RP11-69E11.8	-4.05	5.94e-05	0.00497	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs629093	ENSG00000228060.1	RP11-69E11.8	-4.05	5.94e-05	0.00497	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs1180383	ENSG00000228060.1	RP11-69E11.8	-4.05	5.94e-05	0.00497	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380595	chr1:39565160~39573203:+
THCA	cis	rs599083	0.53	rs686921	ENSG00000212093.1	AP000807.1	-4.05	5.94e-05	0.00497	-0.2	-0.18	Bone mineral density (spine);	chr11:68403365	chr11:68506083~68506166:-
THCA	cis	rs11694172	0.826	rs56712316	ENSG00000273456.1	RP11-686O6.2	4.05	5.94e-05	0.00497	0.17	0.18	Cholesterol, total;	chr2:202766724	chr2:202374932~202375604:-
THCA	cis	rs11694172	0.826	rs16839311	ENSG00000273456.1	RP11-686O6.2	4.05	5.94e-05	0.00497	0.17	0.18	Cholesterol, total;	chr2:202766833	chr2:202374932~202375604:-
THCA	cis	rs5753037	0.653	rs140123	ENSG00000273350.1	RP4-539M6.20	4.05	5.94e-05	0.00497	0.21	0.18	Type 1 diabetes;	chr22:29747217	chr22:30420512~30420912:+
THCA	cis	rs7554547	0.791	rs6665662	ENSG00000199347.1	RNU5E-1	-4.05	5.94e-05	0.00497	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11891804	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs34117126	ENSG00000199347.1	RNU5E-1	-4.05	5.94e-05	0.00497	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11892138	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs17037520	ENSG00000199347.1	RNU5E-1	-4.05	5.94e-05	0.00497	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11892349	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs12749498	ENSG00000199347.1	RNU5E-1	-4.05	5.94e-05	0.00497	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11892570	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs12036266	ENSG00000199347.1	RNU5E-1	-4.05	5.94e-05	0.00497	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11893257	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs2065611	ENSG00000199347.1	RNU5E-1	-4.05	5.94e-05	0.00497	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11893469	chr1:11908152~11908271:+
THCA	cis	rs7554547	0.791	rs4492637	ENSG00000199347.1	RNU5E-1	-4.05	5.94e-05	0.00497	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11895787	chr1:11908152~11908271:+
THCA	cis	rs10489167	1	rs823680	ENSG00000237899.1	RP4-739H11.3	4.05	5.94e-05	0.00497	0.33	0.18	Depressive and manic episodes in bipolar disorder;	chr1:40767212	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs823679	ENSG00000237899.1	RP4-739H11.3	4.05	5.94e-05	0.00497	0.33	0.18	Depressive and manic episodes in bipolar disorder;	chr1:40767542	chr1:40669089~40687588:-
THCA	cis	rs758324	0.732	rs154729	ENSG00000224431.1	AC063976.7	-4.05	5.94e-05	0.00497	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132113356	chr5:132199456~132203487:+
THCA	cis	rs2562784	0.638	rs2585054	ENSG00000225151.9	GOLGA2P7	4.05	5.94e-05	0.00497	0.33	0.18	Height;	chr15:83604576	chr15:84199311~84230136:-
THCA	cis	rs944289	0.646	rs429041	ENSG00000258844.1	RP11-259K15.2	-4.05	5.94e-05	0.00497	-0.16	-0.18	Thyroid cancer;	chr14:36071930	chr14:36214607~36235608:+
THCA	cis	rs944289	0.646	rs368772	ENSG00000258844.1	RP11-259K15.2	-4.05	5.94e-05	0.00497	-0.16	-0.18	Thyroid cancer;	chr14:36071955	chr14:36214607~36235608:+
THCA	cis	rs944289	0.646	rs4981320	ENSG00000258844.1	RP11-259K15.2	-4.05	5.94e-05	0.00497	-0.16	-0.18	Thyroid cancer;	chr14:36072456	chr14:36214607~36235608:+
THCA	cis	rs8007846	0.65	rs4899174	ENSG00000276116.2	FUT8-AS1	4.05	5.94e-05	0.00498	0.19	0.18	Multiple sclerosis--Brain Glutamate Levels;	chr14:65344682	chr14:65411170~65412690:-
THCA	cis	rs2298450	0.717	rs62232370	ENSG00000214867.3	SRSF9P1	4.05	5.95e-05	0.00498	0.27	0.18	Schizophrenia;	chr21:36257927	chr21:36295173~36295702:-
THCA	cis	rs13113518	1	rs4864542	ENSG00000272969.1	RP11-528I4.2	-4.05	5.95e-05	0.00498	-0.21	-0.18	Height;	chr4:55487920	chr4:55547112~55547889:+
THCA	cis	rs950169	0.922	rs4842940	ENSG00000275120.1	RP11-182J1.17	-4.05	5.95e-05	0.00498	-0.22	-0.18	Schizophrenia;	chr15:84162473	chr15:84599434~84606463:-
THCA	cis	rs950169	0.922	rs4842941	ENSG00000275120.1	RP11-182J1.17	-4.05	5.95e-05	0.00498	-0.22	-0.18	Schizophrenia;	chr15:84162560	chr15:84599434~84606463:-
THCA	cis	rs950169	0.922	rs12911223	ENSG00000275120.1	RP11-182J1.17	-4.05	5.95e-05	0.00498	-0.22	-0.18	Schizophrenia;	chr15:84162919	chr15:84599434~84606463:-
THCA	cis	rs801193	1	rs2420824	ENSG00000272831.1	RP11-792A8.4	-4.05	5.95e-05	0.00498	-0.11	-0.18	Aortic root size;	chr7:66666129	chr7:66739829~66740385:-
THCA	cis	rs7267979	0.816	rs6037158	ENSG00000277938.1	RP5-965G21.3	4.05	5.95e-05	0.00498	0.15	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25229150~25231933:+
THCA	cis	rs2562456	0.793	rs2650819	ENSG00000268658.4	LINC00664	-4.05	5.95e-05	0.00498	-0.27	-0.18	Pain;	chr19:21456071	chr19:21483374~21503238:+
THCA	cis	rs11168351	0.927	rs7971880	ENSG00000273765.1	RP11-370I10.11	4.05	5.95e-05	0.00498	0.19	0.18	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48360920~48361377:+
THCA	cis	rs970548	0.865	rs12246131	ENSG00000230869.1	CTGLF10P	4.05	5.95e-05	0.00498	0.23	0.18	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45498334	chr10:45678692~45700532:+
THCA	cis	rs970548	0.908	rs11239538	ENSG00000230869.1	CTGLF10P	4.05	5.95e-05	0.00498	0.23	0.18	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45499148	chr10:45678692~45700532:+
THCA	cis	rs970548	0.954	rs7076198	ENSG00000230869.1	CTGLF10P	4.05	5.95e-05	0.00498	0.23	0.18	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45500861	chr10:45678692~45700532:+
THCA	cis	rs1908814	0.516	rs10113062	ENSG00000206014.6	OR7E161P	-4.05	5.95e-05	0.00498	-0.22	-0.18	Neuroticism;	chr8:11935740	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.516	rs10113145	ENSG00000206014.6	OR7E161P	-4.05	5.95e-05	0.00498	-0.22	-0.18	Neuroticism;	chr8:11935786	chr8:11928597~11929563:-
THCA	cis	rs7617480	0.756	rs990211	ENSG00000229759.1	MRPS18AP1	4.05	5.95e-05	0.00498	0.29	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48683607	chr3:48256350~48256938:-
THCA	cis	rs793571	0.544	rs1427282	ENSG00000245975.2	RP11-30K9.6	4.05	5.95e-05	0.00498	0.17	0.18	Schizophrenia;	chr15:58622127	chr15:58768072~58770974:-
THCA	cis	rs8062405	0.823	rs7202948	ENSG00000261766.1	RP11-22P6.2	-4.05	5.95e-05	0.00498	-0.17	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28862166~28863340:-
THCA	cis	rs3755605	0.52	rs1705579	ENSG00000242578.1	RP11-469J4.3	4.05	5.95e-05	0.00498	0.21	0.18	Testicular germ cell tumor;	chr3:170218756	chr3:170410512~170418615:+
THCA	cis	rs3755605	0.52	rs1082977	ENSG00000242578.1	RP11-469J4.3	4.05	5.95e-05	0.00498	0.21	0.18	Testicular germ cell tumor;	chr3:170220597	chr3:170410512~170418615:+
THCA	cis	rs6964833	1	rs35203738	ENSG00000184616.8	AC004166.6	4.05	5.96e-05	0.00498	0.28	0.18	Menarche (age at onset);	chr7:74690864	chr7:74906673~74913256:-
THCA	cis	rs9923856	0.614	rs2241099	ENSG00000263033.2	RP11-396B14.2	-4.05	5.96e-05	0.00498	-0.17	-0.18	Atopic dermatitis;Adult asthma;	chr16:11131207	chr16:11196177~11224969:+
THCA	cis	rs12682352	0.602	rs1473029	ENSG00000248538.5	RP11-10A14.5	-4.05	5.96e-05	0.00498	-0.23	-0.18	Neuroticism;	chr8:8811407	chr8:9189011~9202854:+
THCA	cis	rs7267979	1	rs2500448	ENSG00000276952.1	RP5-965G21.6	-4.05	5.96e-05	0.00498	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.873	rs6083853	ENSG00000276952.1	RP5-965G21.6	-4.05	5.96e-05	0.00498	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.934	rs2482913	ENSG00000276952.1	RP5-965G21.6	-4.05	5.96e-05	0.00498	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25284915~25285588:-
THCA	cis	rs758324	0.947	rs924434	ENSG00000237714.1	P4HA2-AS1	4.05	5.96e-05	0.00499	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131807676	chr5:132184876~132192808:+
THCA	cis	rs6715284	0.786	rs56360544	ENSG00000183308.6	AC005037.3	4.05	5.96e-05	0.00499	0.45	0.18	Rheumatoid arthritis;	chr2:201415911	chr2:200963263~201009102:+
THCA	cis	rs6715284	0.786	rs78374785	ENSG00000183308.6	AC005037.3	4.05	5.96e-05	0.00499	0.45	0.18	Rheumatoid arthritis;	chr2:201418196	chr2:200963263~201009102:+
THCA	cis	rs17092148	0.887	rs4302281	ENSG00000276073.1	RP5-1125A11.7	4.05	5.96e-05	0.00499	0.22	0.18	Neuroticism;	chr20:34583841	chr20:33985617~33988989:-
THCA	cis	rs6496044	0.963	rs11853972	ENSG00000259295.5	CSPG4P12	4.05	5.96e-05	0.00499	0.23	0.18	Interstitial lung disease;	chr15:85519209	chr15:85191438~85213905:+
THCA	cis	rs6496044	1	rs6496044	ENSG00000259295.5	CSPG4P12	4.05	5.96e-05	0.00499	0.23	0.18	Interstitial lung disease;	chr15:85524075	chr15:85191438~85213905:+
THCA	cis	rs6840258	0.64	rs28505236	ENSG00000251411.1	RP11-397E7.4	-4.05	5.96e-05	0.00499	-0.21	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87172309	chr4:86913266~86914817:-
THCA	cis	rs1669338	0.507	rs4685606	ENSG00000271870.1	RP11-97C16.1	4.05	5.96e-05	0.00499	0.17	0.18	White matter integrity;	chr3:3136289	chr3:3152942~3153435:+
THCA	cis	rs8062405	0.754	rs149299	ENSG00000270424.1	RP11-1348G14.6	4.05	5.96e-05	0.00499	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28749959~28750595:-
THCA	cis	rs447735	0.565	rs10852626	ENSG00000274627.1	RP11-104N10.2	-4.05	5.96e-05	0.00499	-0.19	-0.18	Hemoglobin concentration;	chr16:89848225	chr16:89516797~89522217:+
THCA	cis	rs172166	0.769	rs149965	ENSG00000261839.1	RP1-265C24.8	4.05	5.96e-05	0.00499	0.19	0.18	Cardiac Troponin-T levels;	chr6:28050911	chr6:28136849~28139678:+
THCA	cis	rs9926296	0.548	rs6500439	ENSG00000274627.1	RP11-104N10.2	-4.05	5.96e-05	0.00499	-0.19	-0.18	Vitiligo;	chr16:89741867	chr16:89516797~89522217:+
THCA	cis	rs2732480	0.5	rs1552550	ENSG00000273765.1	RP11-370I10.11	4.05	5.96e-05	0.00499	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.5	rs2450991	ENSG00000273765.1	RP11-370I10.11	4.05	5.96e-05	0.00499	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48360920~48361377:+
THCA	cis	rs10984970	1	rs10984970	ENSG00000238181.2	AHCYP2	4.05	5.97e-05	0.00499	0.48	0.18	Lung cancer;	chr9:120638143	chr9:120720673~120721972:+
THCA	cis	rs8062405	0.755	rs56209193	ENSG00000270424.1	RP11-1348G14.6	4.05	5.97e-05	0.00499	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28749959~28750595:-
THCA	cis	rs1009077	0.61	rs1987179	ENSG00000245958.5	RP11-33B1.1	4.05	5.97e-05	0.00499	0.21	0.18	Endometriosis;	chr4:119598779	chr4:119454791~119552025:+
THCA	cis	rs2153535	0.585	rs9393057	ENSG00000230939.1	RP11-314C16.1	4.05	5.97e-05	0.00499	0.19	0.18	Motion sickness;	chr6:8668067	chr6:8784178~8785445:+
THCA	cis	rs9926296	0.572	rs2079671	ENSG00000260259.1	RP11-368I7.4	-4.05	5.97e-05	0.00499	-0.19	-0.18	Vitiligo;	chr16:89818573	chr16:89682620~89686569:-
THCA	cis	rs8007846	0.685	rs12886005	ENSG00000276116.2	FUT8-AS1	4.05	5.97e-05	0.00499	0.19	0.18	Multiple sclerosis--Brain Glutamate Levels;	chr14:65342529	chr14:65411170~65412690:-
THCA	cis	rs12887734	0.546	rs4906376	ENSG00000258534.1	CTD-2134A5.4	-4.05	5.97e-05	0.00499	-0.2	-0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805828	chr14:103854366~103880111:-
THCA	cis	rs72928364	0.86	rs13081830	ENSG00000256628.3	ZBTB11-AS1	4.05	5.97e-05	0.00499	0.33	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101072418	chr3:101676475~101679217:+
THCA	cis	rs2836950	0.501	rs11702505	ENSG00000238141.2	BRWD1-AS1	-4.05	5.97e-05	0.00499	-0.21	-0.18	Menarche (age at onset);	chr21:39328688	chr21:39315707~39323218:+
THCA	cis	rs2836950	0.501	rs2836985	ENSG00000238141.2	BRWD1-AS1	-4.05	5.97e-05	0.00499	-0.21	-0.18	Menarche (age at onset);	chr21:39329243	chr21:39315707~39323218:+
THCA	cis	rs6472827	0.953	rs4604419	ENSG00000253983.2	RP1-16A9.1	4.05	5.97e-05	0.00499	0.3	0.18	Uterine fibroids;	chr8:74209330	chr8:74199396~74208441:+
THCA	cis	rs8067545	0.64	rs17759083	ENSG00000261033.1	RP11-209D14.2	-4.05	5.97e-05	0.00499	-0.24	-0.18	Schizophrenia;	chr17:20060292	chr17:20008051~20009234:-
THCA	cis	rs35176054	0.643	rs112169230	ENSG00000280693.1	SH3PXD2A-AS1	-4.05	5.97e-05	0.00499	-0.35	-0.18	Atrial fibrillation;	chr10:103742021	chr10:103745966~103755423:+
THCA	cis	rs9902453	0.817	rs1038089	ENSG00000263370.1	RP11-68I3.5	4.05	5.97e-05	0.00499	0.24	0.18	Coffee consumption (cups per day);	chr17:29851706	chr17:29639627~29640825:+
THCA	cis	rs2836974	0.831	rs2836921	ENSG00000255568.3	BRWD1-AS2	4.05	5.97e-05	0.005	0.16	0.18	Cognitive function;	chr21:39144144	chr21:39313935~39314962:+
THCA	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-4.05	5.97e-05	0.005	-0.19	-0.18	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
THCA	cis	rs3740713	1	rs61081934	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr11:18490243~18490955:-
THCA	cis	rs3740713	0.92	rs112818034	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs76708296	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438668	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs75647856	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438687	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs74663287	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73438699	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73440604	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs73440610	ENSG00000256464.1	YWHABP2	4.05	5.97e-05	0.005	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr11:18490243~18490955:-
THCA	cis	rs7960884	0.655	rs11609215	ENSG00000177359.16	RP11-551L14.1	4.05	5.97e-05	0.005	0.21	0.18	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31234164	chr12:31111652~31206154:-
THCA	cis	rs9920506	0.518	rs11072774	ENSG00000261143.1	ADAMTS7P3	-4.05	5.97e-05	0.005	-0.28	-0.18	Post bronchodilator FEV1;	chr15:78660355	chr15:77976042~77993057:+
THCA	cis	rs758324	0.732	rs45236	ENSG00000224431.1	AC063976.7	-4.05	5.97e-05	0.005	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132104927	chr5:132199456~132203487:+
THCA	cis	rs321358	0.943	rs17537987	ENSG00000271390.1	RP11-89C3.3	4.05	5.97e-05	0.005	0.31	0.18	Body mass index;	chr11:111134144	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs73019218	ENSG00000271390.1	RP11-89C3.3	4.05	5.97e-05	0.005	0.31	0.18	Body mass index;	chr11:111134521	chr11:111089870~111090368:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000230795.2	HLA-K	-4.05	5.98e-05	0.005	-0.29	-0.18	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29926459~29929232:+
THCA	cis	rs7616559	0.962	rs6769719	ENSG00000244515.1	KRT18P34	4.05	5.98e-05	0.005	0.25	0.18	Carotid artery intima media thickness (sex interaction);	chr3:157001905	chr3:157162663~157163932:-
THCA	cis	rs8113308	1	rs6509600	ENSG00000275055.1	CTC-471J1.11	-4.05	5.98e-05	0.005	-0.19	-0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939336	chr19:52049007~52049754:+
THCA	cis	rs586688	0.625	rs602668	ENSG00000224536.1	RP11-134G8.7	4.05	5.98e-05	0.005	0.27	0.18	Obesity-related traits;	chr1:201688581	chr1:201507241~201533608:+
THCA	cis	rs4081724	0.565	rs73026209	ENSG00000267296.2	CEBPA-AS1	4.05	5.98e-05	0.005	0.29	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33315704	chr19:33302857~33305054:+
THCA	cis	rs4081724	0.565	rs118046236	ENSG00000267296.2	CEBPA-AS1	4.05	5.98e-05	0.005	0.29	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33316199	chr19:33302857~33305054:+
THCA	cis	rs17331151	0.573	rs2240916	ENSG00000242142.1	SERBP1P3	-4.05	5.98e-05	0.005	-0.29	-0.18	Immune reponse to smallpox (secreted IL-2);	chr3:52825196	chr3:53064283~53065091:-
THCA	cis	rs17331151	0.541	rs11709430	ENSG00000242142.1	SERBP1P3	-4.05	5.98e-05	0.005	-0.29	-0.18	Immune reponse to smallpox (secreted IL-2);	chr3:52828039	chr3:53064283~53065091:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000272831.1	RP11-792A8.4	4.05	5.98e-05	0.005	0.12	0.18	Calcium levels;	chr7:65751755	chr7:66739829~66740385:-
THCA	cis	rs340849	0.501	rs7550337	ENSG00000274895.1	RP11-478J18.2	-4.05	5.98e-05	0.005	-0.15	-0.18	Alzheimer's disease;	chr1:213926373	chr1:213983793~213986419:-
THCA	cis	rs10932679	0.654	rs35169442	ENSG00000229352.1	AC007563.3	4.05	5.98e-05	0.005	0.29	0.18	Pulse pressure;	chr2:216814704	chr2:216799608~216805335:+
THCA	cis	rs17092148	1	rs6060017	ENSG00000276073.1	RP5-1125A11.7	-4.05	5.98e-05	0.005	-0.21	-0.18	Neuroticism;	chr20:34725238	chr20:33985617~33988989:-
THCA	cis	rs13098911	0.54	rs9838450	ENSG00000226074.4	PRSS44	-4.05	5.98e-05	0.005	-0.3	-0.18	Celiac disease;	chr3:46081841	chr3:46809359~46812558:-
THCA	cis	rs2732480	0.5	rs2450986	ENSG00000273765.1	RP11-370I10.11	4.05	5.98e-05	0.005	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48360920~48361377:+
THCA	cis	rs2274136	1	rs2274136	ENSG00000272269.1	RP11-500C11.3	4.05	5.98e-05	0.005	0.21	0.18	Obesity-related traits;	chr6:17632830	chr6:17706257~17707344:+
THCA	cis	rs7131987	0.585	rs2059362	ENSG00000257176.2	RP11-996F15.2	4.05	5.98e-05	0.005	0.19	0.18	QT interval;	chr12:29243072	chr12:29280418~29317848:-
THCA	cis	rs34792	0.528	rs153800	ENSG00000207425.1	Y_RNA	4.05	5.98e-05	0.005	0.2	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15455900	chr16:14915457~14915556:-
THCA	cis	rs10844706	0.699	rs10844635	ENSG00000214776.8	RP11-726G1.1	4.05	5.99e-05	0.00501	0.23	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735313	chr12:9467552~9576275:+
THCA	cis	rs10844706	0.699	rs10844637	ENSG00000214776.8	RP11-726G1.1	4.05	5.99e-05	0.00501	0.23	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735495	chr12:9467552~9576275:+
THCA	cis	rs10844706	0.699	rs10844638	ENSG00000214776.8	RP11-726G1.1	4.05	5.99e-05	0.00501	0.23	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735800	chr12:9467552~9576275:+
THCA	cis	rs4713118	0.738	rs200465	ENSG00000220721.1	OR1F12	4.05	5.99e-05	0.00501	0.24	0.18	Parkinson's disease;	chr6:27789875	chr6:28073316~28074233:+
THCA	cis	rs7010876	0.545	rs1519930	ENSG00000253553.4	RP11-586K2.1	-4.05	5.99e-05	0.00501	-0.2	-0.18	Schizophrenia;	chr8:88283723	chr8:88326836~88737134:+
THCA	cis	rs12612619	0.667	rs7605526	ENSG00000272148.1	RP11-195B17.1	4.05	5.99e-05	0.00501	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27122616	chr2:27062428~27062907:-
THCA	cis	rs9393777	0.778	rs66841633	ENSG00000226314.6	ZNF192P1	-4.05	5.99e-05	0.00501	-0.37	-0.18	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28161781~28169594:+
THCA	cis	rs9868809	0.505	rs56735597	ENSG00000270441.1	RP11-694I15.7	4.05	5.99e-05	0.00501	0.26	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48727735	chr3:49140086~49160851:-
THCA	cis	rs11673344	0.504	rs2595555	ENSG00000267260.1	CTD-2162K18.4	-4.05	5.99e-05	0.00501	-0.22	-0.18	Obesity-related traits;	chr19:37000219	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.504	rs1667377	ENSG00000267260.1	CTD-2162K18.4	-4.05	5.99e-05	0.00501	-0.22	-0.18	Obesity-related traits;	chr19:37000966	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs1667379	ENSG00000267260.1	CTD-2162K18.4	-4.05	5.99e-05	0.00501	-0.22	-0.18	Obesity-related traits;	chr19:37001192	chr19:36773153~36777078:+
THCA	cis	rs7674212	0.541	rs2720448	ENSG00000230069.3	LRRC37A15P	-4.05	5.99e-05	0.00501	-0.18	-0.18	Type 2 diabetes;	chr4:103109432	chr4:102727274~102730721:-
THCA	cis	rs7674212	0.541	rs2623064	ENSG00000230069.3	LRRC37A15P	-4.05	5.99e-05	0.00501	-0.18	-0.18	Type 2 diabetes;	chr4:103109635	chr4:102727274~102730721:-
THCA	cis	rs7818688	0.653	rs16893774	ENSG00000253528.2	RP11-347C18.4	4.05	5.99e-05	0.00501	0.27	0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94883748	chr8:94974573~94974853:-
THCA	cis	rs4568518	0.53	rs6970593	ENSG00000279048.1	RP11-511H23.2	-4.05	5.99e-05	0.00501	-0.12	-0.18	Measles;	chr7:17949736	chr7:17940503~17942922:+
THCA	cis	rs911555	0.755	rs12436729	ENSG00000269958.1	RP11-73M18.8	-4.05	5.99e-05	0.00501	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103696353~103697163:+
THCA	cis	rs6940638	0.715	rs9348751	ENSG00000220721.1	OR1F12	4.05	5.99e-05	0.00501	0.22	0.18	Intelligence (multi-trait analysis);	chr6:27099411	chr6:28073316~28074233:+
THCA	cis	rs6449502	0.92	rs2950232	ENSG00000251279.1	CTC-436P18.1	4.05	5.99e-05	0.00501	0.29	0.18	Mean platelet volume;	chr5:61027292	chr5:61162070~61232040:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000234585.5	CCT6P3	4.05	5.99e-05	0.00501	0.17	0.18	Aortic root size;	chr7:66008701	chr7:65038354~65074713:+
THCA	cis	rs3128341	1	rs6697541	ENSG00000227207.2	RPL31P12	4.05	5.99e-05	0.00501	0.29	0.18	Intelligence (multi-trait analysis);	chr1:72353677	chr1:72301472~72301829:+
THCA	cis	rs3764021	0.84	rs12304510	ENSG00000214776.8	RP11-726G1.1	4.05	5.99e-05	0.00501	0.22	0.18	Type 1 diabetes;	chr12:9732930	chr12:9467552~9576275:+
THCA	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	4.05	5.99e-05	0.00501	0.15	0.18	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
THCA	cis	rs3935996	0.965	rs11206670	ENSG00000233147.1	RP11-90C4.1	-4.05	5.99e-05	0.00501	-0.16	-0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55856641	chr1:55823807~55868248:+
THCA	cis	rs9543976	0.623	rs6562915	ENSG00000261105.4	LMO7-AS1	4.05	6e-05	0.00501	0.25	0.18	Diabetic retinopathy;	chr13:75596750	chr13:75604700~75635994:-
THCA	cis	rs2274136	0.817	rs4716168	ENSG00000272269.1	RP11-500C11.3	4.05	6e-05	0.00501	0.22	0.18	Obesity-related traits;	chr6:17643229	chr6:17706257~17707344:+
THCA	cis	rs2274136	0.948	rs3777713	ENSG00000272269.1	RP11-500C11.3	4.05	6e-05	0.00501	0.22	0.18	Obesity-related traits;	chr6:17650089	chr6:17706257~17707344:+
THCA	cis	rs5758659	0.594	rs739292	ENSG00000281538.1	RP4-669P10.20	4.05	6e-05	0.00501	0.17	0.18	Cognitive function;	chr22:41972853	chr22:42138060~42139726:+
THCA	cis	rs12544026	0.581	rs472638	ENSG00000253669.3	KB-1732A1.1	-4.05	6e-05	0.00501	-0.21	-0.18	Major depression and alcohol dependence;	chr8:101866801	chr8:102805517~102809971:+
THCA	cis	rs9634489	0.512	rs7337860	ENSG00000247400.3	DNAJC3-AS1	-4.05	6e-05	0.00501	-0.12	-0.18	Body mass index;	chr13:96284887	chr13:95648733~95676925:-
THCA	cis	rs801193	0.569	rs6978178	ENSG00000229886.1	RP5-1132H15.3	-4.05	6e-05	0.00501	-0.19	-0.18	Aortic root size;	chr7:66658097	chr7:66025126~66031544:-
THCA	cis	rs7968440	1	rs10747586	ENSG00000272368.2	RP4-605O3.4	-4.05	6e-05	0.00501	-0.12	-0.18	Fibrinogen;	chr12:50589782	chr12:50112197~50165618:+
THCA	cis	rs7259376	0.525	rs1704016	ENSG00000269138.1	ZNF209P	4.05	6e-05	0.00501	0.17	0.18	Menopause (age at onset);	chr19:22452581	chr19:22463922~22473036:+
THCA	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-4.05	6e-05	0.00502	-0.21	-0.18	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
THCA	cis	rs17123764	0.71	rs74089182	ENSG00000257464.1	RP11-161H23.8	-4.05	6e-05	0.00502	-0.32	-0.18	Intelligence (multi-trait analysis);	chr12:49669985	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.71	rs57191490	ENSG00000257464.1	RP11-161H23.8	-4.05	6e-05	0.00502	-0.32	-0.18	Intelligence (multi-trait analysis);	chr12:49671106	chr12:49442424~49442652:-
THCA	cis	rs700651	0.789	rs62277902	ENSG00000231621.1	AC013264.2	4.05	6e-05	0.00502	0.2	0.18	Intracranial aneurysm;	chr2:198014719	chr2:197197991~197199273:+
THCA	cis	rs11175834	0.655	rs11175829	ENSG00000256915.1	RP11-221N13.4	4.05	6e-05	0.00502	0.32	0.18	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65587275	chr12:65644334~65663299:+
THCA	cis	rs9788682	0.747	rs4887069	ENSG00000261143.1	ADAMTS7P3	-4.05	6e-05	0.00502	-0.26	-0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78616728	chr15:77976042~77993057:+
THCA	cis	rs271738	0.779	rs2487589	ENSG00000231768.1	LINC01354	-4.05	6e-05	0.00502	-0.21	-0.18	Bipolar disorder;	chr1:234532457	chr1:234527891~234531779:-
THCA	cis	rs2657294	0.796	rs7082123	ENSG00000233313.2	HMGA1P5	-4.05	6e-05	0.00502	-0.25	-0.18	Pneumonia;	chr10:75091101	chr10:75276376~75276646:-
THCA	cis	rs7267979	0.565	rs958075	ENSG00000274414.1	RP5-965G21.4	4.05	6e-05	0.00502	0.23	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:25239007~25245229:-
THCA	cis	rs7707921	0.881	rs324914	ENSG00000251374.1	RPS23P5	-4.05	6e-05	0.00502	-0.27	-0.18	Breast cancer;	chr5:82094131	chr5:82265157~82265259:-
THCA	cis	rs12142240	0.698	rs17361950	ENSG00000232022.5	FAAHP1	-4.05	6e-05	0.00502	-0.21	-0.18	Menopause (age at onset);	chr1:46398478	chr1:46432129~46445521:+
THCA	cis	rs61270009	0.955	rs450202	ENSG00000247828.6	TMEM161B-AS1	-4.05	6e-05	0.00502	-0.17	-0.18	Depressive symptoms;	chr5:88222635	chr5:88268895~88436685:+
THCA	cis	rs7989336	0.501	rs7985691	ENSG00000247400.3	DNAJC3-AS1	-4.05	6e-05	0.00502	-0.12	-0.18	Obesity;	chr13:96354909	chr13:95648733~95676925:-
THCA	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-4.05	6e-05	0.00502	-0.21	-0.18	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
THCA	cis	rs7259376	0.902	rs12610462	ENSG00000269138.1	ZNF209P	4.05	6.01e-05	0.00502	0.19	0.18	Menopause (age at onset);	chr19:22368660	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs16999064	ENSG00000269138.1	ZNF209P	4.05	6.01e-05	0.00502	0.19	0.18	Menopause (age at onset);	chr19:22369800	chr19:22463922~22473036:+
THCA	cis	rs9810089	0.814	rs696518	ENSG00000273455.1	RP11-305O4.3	4.05	6.01e-05	0.00502	0.24	0.18	Gestational age at birth (child effect);	chr3:136401458	chr3:136087475~136087913:-
THCA	cis	rs11089937	0.963	rs5757098	ENSG00000211638.2	IGLV8-61	4.05	6.01e-05	0.00502	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22098700~22099212:+
THCA	cis	rs7819412	1	rs2409722	ENSG00000206014.6	OR7E161P	4.05	6.01e-05	0.00502	0.21	0.18	Triglycerides;	chr8:11182307	chr8:11928597~11929563:-
THCA	cis	rs11176749	1	rs11176747	ENSG00000203585.3	RP11-542B15.1	4.05	6.01e-05	0.00502	0.21	0.18	Expressive vocabulary in infants;	chr12:67454664	chr12:67519829~67567126:+
THCA	cis	rs9595908	0.709	rs9285093	ENSG00000212293.1	SNORA16	4.05	6.01e-05	0.00502	0.21	0.18	Body mass index;	chr13:32745500	chr13:32420390~32420516:-
THCA	cis	rs8024893	0.764	rs7178760	ENSG00000270055.1	CTD-3092A11.2	4.05	6.01e-05	0.00502	0.24	0.18	Red cell distribution width;	chr15:31239170	chr15:30487963~30490313:+
THCA	cis	rs801193	0.66	rs974239	ENSG00000229886.1	RP5-1132H15.3	4.05	6.01e-05	0.00502	0.19	0.18	Aortic root size;	chr7:66748504	chr7:66025126~66031544:-
THCA	cis	rs2839186	0.558	rs2968	ENSG00000215424.8	MCM3AP-AS1	-4.05	6.01e-05	0.00502	-0.11	-0.18	Testicular germ cell tumor;	chr21:46188666	chr21:46229217~46259390:+
THCA	cis	rs11633886	0.806	rs7163618	ENSG00000259200.1	RP11-718O11.1	-4.05	6.01e-05	0.00502	-0.23	-0.18	Diisocyanate-induced asthma;	chr15:45758649	chr15:45705078~45931069:+
THCA	cis	rs56318008	0.773	rs17837951	ENSG00000228397.1	RP1-224A6.3	-4.05	6.01e-05	0.00502	-0.33	-0.18	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22062379	chr1:22023994~22024968:-
THCA	cis	rs4803480	0.935	rs758349	ENSG00000270164.1	LINC01480	-4.05	6.01e-05	0.00502	-0.19	-0.18	Schizophrenia;	chr19:41578753	chr19:41535183~41536904:+
THCA	cis	rs4788570	0.615	rs7190487	ENSG00000260185.1	RP11-432I5.6	-4.05	6.01e-05	0.00502	-0.35	-0.18	Intelligence (multi-trait analysis);	chr16:71614714	chr16:71655027~71664212:+
THCA	cis	rs9970896	0.579	rs7534625	ENSG00000237845.1	RP5-940F7.2	-4.05	6.01e-05	0.00502	-0.33	-0.18	Monocyte percentage of white cells;	chr1:235883940	chr1:235942553~235943805:-
THCA	cis	rs79481398	0.616	rs11857296	ENSG00000276772.1	CTD-2515H24.2	-4.05	6.01e-05	0.00502	-0.24	-0.18	Facial morphology (factor 19);	chr15:57497699	chr15:57553955~57555680:+
THCA	cis	rs2839186	1	rs2839181	ENSG00000215424.8	MCM3AP-AS1	4.05	6.01e-05	0.00503	0.11	0.18	Testicular germ cell tumor;	chr21:46266025	chr21:46229217~46259390:+
THCA	cis	rs7578199	0.538	rs11683555	ENSG00000223374.1	AC005104.3	-4.05	6.01e-05	0.00503	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241470666	chr2:241351340~241353104:-
THCA	cis	rs3755605	0.52	rs28857583	ENSG00000242578.1	RP11-469J4.3	4.05	6.01e-05	0.00503	0.21	0.18	Testicular germ cell tumor;	chr3:170217576	chr3:170410512~170418615:+
THCA	cis	rs7246967	0.673	rs62122382	ENSG00000198153.8	ZNF849P	-4.05	6.01e-05	0.00503	-0.34	-0.18	Bronchopulmonary dysplasia;	chr19:22798046	chr19:22685167~22686732:+
THCA	cis	rs4908768	0.815	rs11589090	ENSG00000232912.4	RP5-1115A15.1	-4.05	6.02e-05	0.00503	-0.23	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8465555	chr1:8424645~8434838:+
THCA	cis	rs1560104	0.584	rs12921820	ENSG00000262801.4	U91319.1	4.05	6.02e-05	0.00503	0.21	0.18	Obesity-related traits;	chr16:12606775	chr16:13246316~13562918:+
THCA	cis	rs2153535	0.585	rs1033803	ENSG00000230939.1	RP11-314C16.1	-4.05	6.02e-05	0.00503	-0.19	-0.18	Motion sickness;	chr6:8674779	chr6:8784178~8785445:+
THCA	cis	rs2729354	0.768	rs2581922	ENSG00000254602.1	AP000662.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Blood protein levels;	chr11:57497927	chr11:57638024~57652790:+
THCA	cis	rs11673344	0.704	rs1644711	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36926420	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.704	rs1726719	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36927130	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.704	rs485034	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36931455	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.704	rs517110	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36931492	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.734	rs2551047	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36935174	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.704	rs551717	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36936977	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.704	rs826290	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36937543	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.67	rs505717	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36939414	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.704	rs544543	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36939921	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.67	rs568654	ENSG00000267260.1	CTD-2162K18.4	-4.05	6.02e-05	0.00503	-0.23	-0.18	Obesity-related traits;	chr19:36940285	chr19:36773153~36777078:+
THCA	cis	rs12682352	0.602	rs28399241	ENSG00000248538.5	RP11-10A14.5	-4.05	6.02e-05	0.00503	-0.23	-0.18	Neuroticism;	chr8:8805705	chr8:9189011~9202854:+
THCA	cis	rs447735	0.587	rs7188458	ENSG00000260259.1	RP11-368I7.4	4.05	6.02e-05	0.00503	0.2	0.18	Hemoglobin concentration;	chr16:89660076	chr16:89682620~89686569:-
THCA	cis	rs4759375	1	rs10773006	ENSG00000256092.2	RP13-942N8.1	-4.05	6.02e-05	0.00503	-0.2	-0.18	HDL cholesterol;	chr12:123305504	chr12:123363868~123366113:+
THCA	cis	rs6479891	1	rs4746149	ENSG00000272767.1	JMJD1C-AS1	-4.05	6.02e-05	0.00503	-0.25	-0.18	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63465229~63466563:+
THCA	cis	rs6546550	0.901	rs10205487	ENSG00000179818.12	PCBP1-AS1	4.05	6.02e-05	0.00503	0.15	0.18	Prevalent atrial fibrillation;	chr2:69924339	chr2:69962263~70103220:-
THCA	cis	rs791590	0.941	rs12722559	ENSG00000229664.1	RP11-536K7.5	-4.05	6.02e-05	0.00503	-0.32	-0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:6028310	chr10:6025978~6036427:+
THCA	cis	rs4906332	0.868	rs4900578	ENSG00000252469.1	RNU7-160P	4.05	6.02e-05	0.00503	0.2	0.18	Coronary artery disease;	chr14:103459673	chr14:103550345~103550406:+
THCA	cis	rs7208859	0.673	rs216440	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.02e-05	0.00503	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30738182~30740275:+
THCA	cis	rs9595908	0.746	rs9591222	ENSG00000212293.1	SNORA16	4.05	6.02e-05	0.00503	0.22	0.18	Body mass index;	chr13:32653261	chr13:32420390~32420516:-
THCA	cis	rs4538475	0.556	rs4266290	ENSG00000214846.4	RP11-115L11.1	4.05	6.02e-05	0.00503	0.25	0.18	Parkinson's disease;	chr4:15735495	chr4:15730962~15731627:-
THCA	cis	rs2836974	0.897	rs35064900	ENSG00000255568.3	BRWD1-AS2	4.05	6.02e-05	0.00503	0.16	0.18	Cognitive function;	chr21:39183566	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs36113648	ENSG00000255568.3	BRWD1-AS2	4.05	6.02e-05	0.00503	0.16	0.18	Cognitive function;	chr21:39183571	chr21:39313935~39314962:+
THCA	cis	rs2051773	0.567	rs7130826	ENSG00000184669.7	OR7E14P	-4.05	6.02e-05	0.00503	-0.25	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17016246	chr11:17013998~17053024:+
THCA	cis	rs16957091	0.528	rs4924699	ENSG00000205771.5	CATSPER2P1	4.05	6.03e-05	0.00503	0.26	0.18	MGMT methylation in smokers;	chr15:42908911	chr15:43726918~43747094:-
THCA	cis	rs11658311	0.85	rs11652525	ENSG00000232344.2	AC087163.2	4.05	6.03e-05	0.00503	0.28	0.18	Obsessive-compulsive symptoms;	chr17:17758241	chr17:18010643~18011822:+
THCA	cis	rs889512	0.731	rs3743614	ENSG00000261783.1	RP11-252K23.2	4.05	6.03e-05	0.00504	0.36	0.18	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75247060	chr16:75379818~75381260:-
THCA	cis	rs7829975	0.871	rs572307	ENSG00000233609.3	RP11-62H7.2	-4.05	6.03e-05	0.00504	-0.18	-0.18	Mood instability;	chr8:8721301	chr8:8961200~8979025:+
THCA	cis	rs4650994	0.55	rs11581618	ENSG00000273384.1	RP5-1098D14.1	-4.05	6.03e-05	0.00504	-0.25	-0.18	HDL cholesterol;HDL cholesterol levels;	chr1:178603585	chr1:178651706~178652282:+
THCA	cis	rs11157436	1	rs72638482	ENSG00000211812.1	TRAV26-2	-4.05	6.03e-05	0.00504	-0.17	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22202583~22203368:+
THCA	cis	rs9314614	0.934	rs2980955	ENSG00000245857.2	GS1-24F4.2	4.05	6.04e-05	0.00504	0.23	0.18	White blood cell count (basophil);IgA nephropathy;	chr8:6836912	chr8:6835554~6885276:+
THCA	cis	rs72928364	0.86	rs13085636	ENSG00000256628.3	ZBTB11-AS1	4.05	6.04e-05	0.00504	0.33	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101078260	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.86	rs62274066	ENSG00000256628.3	ZBTB11-AS1	4.05	6.04e-05	0.00504	0.33	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101082335	chr3:101676475~101679217:+
THCA	cis	rs4713118	0.911	rs9295746	ENSG00000261839.1	RP1-265C24.8	4.05	6.04e-05	0.00504	0.22	0.18	Parkinson's disease;	chr6:27762285	chr6:28136849~28139678:+
THCA	cis	rs6940638	0.688	rs9379960	ENSG00000220721.1	OR1F12	4.05	6.04e-05	0.00504	0.22	0.18	Intelligence (multi-trait analysis);	chr6:27153546	chr6:28073316~28074233:+
THCA	cis	rs7131987	0.65	rs10843384	ENSG00000273680.1	RP11-996F15.6	4.05	6.04e-05	0.00504	0.26	0.18	QT interval;	chr12:29319476	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.65	rs11050188	ENSG00000273680.1	RP11-996F15.6	4.05	6.04e-05	0.00504	0.26	0.18	QT interval;	chr12:29320175	chr12:29332733~29333383:-
THCA	cis	rs2191566	0.664	rs62115477	ENSG00000266921.1	RP11-15A1.7	-4.05	6.04e-05	0.00505	-0.17	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44038874	chr19:43996896~44002836:-
THCA	cis	rs10875746	0.768	rs4760609	ENSG00000258273.1	RP11-370I10.4	-4.05	6.04e-05	0.00505	-0.25	-0.18	Longevity (90 years and older);	chr12:48021974	chr12:48333755~48333901:-
THCA	cis	rs5751614	1	rs1004040	ENSG00000240160.3	RN7SL263P	4.05	6.04e-05	0.00505	0.2	0.18	Height;	chr22:23242945	chr22:23261782~23262071:-
THCA	cis	rs9316337	0.52	rs8001135	ENSG00000236953.1	ZDHHC20-IT1	-4.05	6.04e-05	0.00505	-0.21	-0.18	Schizophrenia;	chr13:21441112	chr13:21376977~21377874:-
THCA	cis	rs758324	0.687	rs152047	ENSG00000224431.1	AC063976.7	-4.05	6.04e-05	0.00505	-0.19	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132213245	chr5:132199456~132203487:+
THCA	cis	rs2898681	0.618	rs116241740	ENSG00000248375.1	RP11-177B4.1	-4.05	6.04e-05	0.00505	-0.38	-0.18	Optic nerve measurement (cup area);	chr4:52867356	chr4:52720081~52720831:-
THCA	cis	rs11971779	0.616	rs6467836	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139338771	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6467837	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139338829	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6963867	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139375218	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.618	rs10085814	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139379343	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.715	rs10085527	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139379614	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.65	rs10085842	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139379836	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.648	rs28754644	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139380311	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.715	rs6954219	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139380364	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6467840	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139380655	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.564	rs6467841	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139381346	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs7792752	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139381450	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs6974907	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139383983	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.584	rs10236055	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139385245	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.584	rs6942519	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139385344	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6467843	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139385777	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs2355785	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139386237	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.588	rs6972408	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139386728	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.625	rs2355784	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139387747	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs2883772	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139388010	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs28579232	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139388370	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs2355783	ENSG00000252332.1	RNU6-911P	-4.05	6.04e-05	0.00505	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139391133	chr7:139448740~139448843:+
THCA	cis	rs11671005	0.779	rs3794970	ENSG00000268912.1	CTD-2619J13.17	4.05	6.04e-05	0.00505	0.17	0.18	Mean platelet volume;	chr19:58474893	chr19:58428632~58431148:-
THCA	cis	rs763121	0.853	rs2235230	ENSG00000273076.1	RP3-508I15.22	-4.05	6.04e-05	0.00505	-0.19	-0.18	Menopause (age at onset);	chr22:38728462	chr22:38743495~38743910:+
THCA	cis	rs931608	1	rs10408585	ENSG00000269138.1	ZNF209P	-4.05	6.05e-05	0.00505	-0.27	-0.18	Response to statins (LDL cholesterol change);Dental caries;	chr19:22430445	chr19:22463922~22473036:+
THCA	cis	rs931608	1	rs931608	ENSG00000269138.1	ZNF209P	-4.05	6.05e-05	0.00505	-0.27	-0.18	Response to statins (LDL cholesterol change);Dental caries;	chr19:22431320	chr19:22463922~22473036:+
THCA	cis	rs6933660	0.683	rs6916340	ENSG00000219395.2	HSPA8P15	-4.05	6.05e-05	0.00505	-0.16	-0.18	Menarche (age at onset);	chr6:151457929	chr6:151411259~151413945:-
THCA	cis	rs11153306	0.765	rs7740180	ENSG00000231889.6	TRAF3IP2-AS1	4.05	6.05e-05	0.00505	0.16	0.18	Tonsillectomy;	chr6:111623335	chr6:111483511~111598302:+
THCA	cis	rs11153306	0.818	rs1476043	ENSG00000231889.6	TRAF3IP2-AS1	4.05	6.05e-05	0.00505	0.16	0.18	Tonsillectomy;	chr6:111623776	chr6:111483511~111598302:+
THCA	cis	rs10484434	0.901	rs62394550	ENSG00000272810.1	U91328.22	4.05	6.05e-05	0.00505	0.18	0.18	HIV-1 viral setpoint;	chr6:26034024	chr6:26013241~26013757:+
THCA	cis	rs8031584	0.678	rs798127	ENSG00000178081.11	ULK4P3	-4.05	6.05e-05	0.00505	-0.24	-0.18	Huntington's disease progression;	chr15:30825200	chr15:30103720~30131757:+
THCA	cis	rs854765	0.624	rs11657423	ENSG00000281749.1	Y_RNA	-4.05	6.05e-05	0.00505	-0.24	-0.18	Total body bone mineral density;	chr17:17825260	chr17:18001101~18001195:-
THCA	cis	rs3177980	0.794	rs4987354	ENSG00000239494.2	RN7SL333P	-4.05	6.05e-05	0.00505	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:169697730	chr1:169859756~169860052:+
THCA	cis	rs13434995	0.513	rs73236142	ENSG00000249700.7	SRD5A3-AS1	-4.05	6.05e-05	0.00505	-0.26	-0.18	Adiponectin levels;	chr4:55446143	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs67963898	ENSG00000249700.7	SRD5A3-AS1	-4.05	6.05e-05	0.00505	-0.26	-0.18	Adiponectin levels;	chr4:55475520	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62303718	ENSG00000249700.7	SRD5A3-AS1	-4.05	6.05e-05	0.00505	-0.26	-0.18	Adiponectin levels;	chr4:55476770	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs17722870	ENSG00000249700.7	SRD5A3-AS1	-4.05	6.05e-05	0.00505	-0.26	-0.18	Adiponectin levels;	chr4:55478519	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs55885973	ENSG00000249700.7	SRD5A3-AS1	-4.05	6.05e-05	0.00505	-0.26	-0.18	Adiponectin levels;	chr4:55480054	chr4:55363971~55395847:-
THCA	cis	rs728616	0.614	rs61859196	ENSG00000278616.1	BEND3P3	4.05	6.05e-05	0.00505	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80349292	chr10:79682997~79685436:+
THCA	cis	rs35791980	0.527	rs78893933	ENSG00000273341.1	RP5-899E9.1	-4.05	6.05e-05	0.00505	-0.19	-0.18	Pursuit maintenance gain;	chr7:77302928	chr7:77416673~77425443:+
THCA	cis	rs2281636	0.823	rs11190225	ENSG00000233690.1	EBAG9P1	4.05	6.05e-05	0.00505	0.18	0.18	Obesity-related traits;	chr10:99657156	chr10:99697407~99697949:-
THCA	cis	rs2072883	0.646	rs4822254	ENSG00000230319.1	AL022476.2	4.05	6.05e-05	0.00505	0.2	0.18	Schizophrenia;	chr22:43040588	chr22:43038585~43052366:+
THCA	cis	rs9467773	1	rs4871	ENSG00000228223.2	HCG11	-4.05	6.05e-05	0.00505	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26523450~26526579:+
THCA	cis	rs6828577	0.606	rs441216	ENSG00000281731.1	RP11-384K6.8	-4.05	6.05e-05	0.00505	-0.23	-0.18	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118709247	chr4:118664087~118685341:-
THCA	cis	rs10844706	0.699	rs10844636	ENSG00000214776.8	RP11-726G1.1	-4.05	6.05e-05	0.00505	-0.23	-0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735420	chr12:9467552~9576275:+
THCA	cis	rs6479891	1	rs61853336	ENSG00000272767.1	JMJD1C-AS1	4.05	6.05e-05	0.00505	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63465229~63466563:+
THCA	cis	rs4886920	0.855	rs4886526	ENSG00000260776.4	RP11-114H24.2	-4.05	6.05e-05	0.00505	-0.21	-0.18	Neuroticism;	chr15:77821079	chr15:77914217~77926846:-
THCA	cis	rs7474896	0.559	rs1208560	ENSG00000263064.2	RP11-291L22.7	-4.05	6.05e-05	0.00505	-0.24	-0.18	Obesity (extreme);	chr10:37932690	chr10:38448689~38448949:+
THCA	cis	rs7045881	0.667	rs6475948	ENSG00000254396.1	RP11-56F10.3	4.05	6.05e-05	0.00506	0.24	0.18	Schizophrenia;	chr9:26899458	chr9:27102630~27104728:+
THCA	cis	rs1124769	0.748	rs12595551	ENSG00000259378.1	DCAF13P3	4.05	6.06e-05	0.00506	0.28	0.18	Cognitive performance;	chr15:51080985	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.778	rs12595600	ENSG00000259378.1	DCAF13P3	4.05	6.06e-05	0.00506	0.28	0.18	Cognitive performance;	chr15:51081106	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs12591434	ENSG00000259378.1	DCAF13P3	4.05	6.06e-05	0.00506	0.28	0.18	Cognitive performance;	chr15:51081782	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs72727114	ENSG00000259378.1	DCAF13P3	4.05	6.06e-05	0.00506	0.28	0.18	Cognitive performance;	chr15:51082720	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs72727115	ENSG00000259378.1	DCAF13P3	4.05	6.06e-05	0.00506	0.28	0.18	Cognitive performance;	chr15:51082852	chr15:50944663~50945996:+
THCA	cis	rs7614311	0.596	rs2888013	ENSG00000271843.1	RP11-245J9.5	-4.05	6.06e-05	0.00506	-0.28	-0.18	Lung function (FVC);Lung function (FEV1);	chr3:64019550	chr3:64008082~64008692:-
THCA	cis	rs12681288	0.823	rs2701908	ENSG00000260721.1	AF067845.1	4.05	6.06e-05	0.00506	0.21	0.18	Schizophrenia;	chr8:1053250	chr8:1368642~1369833:-
THCA	cis	rs2980439	0.525	rs1850511	ENSG00000254153.1	CTA-398F10.2	-4.05	6.06e-05	0.00506	-0.2	-0.18	Neuroticism;	chr8:8312807	chr8:8456909~8461337:-
THCA	cis	rs9467773	0.572	rs62394558	ENSG00000261353.1	CTA-14H9.5	-4.05	6.06e-05	0.00506	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26527063~26527404:+
THCA	cis	rs911555	0.723	rs4906324	ENSG00000269910.1	RP11-73M18.10	-4.05	6.06e-05	0.00506	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103694516~103695050:-
THCA	cis	rs911555	0.723	rs2273701	ENSG00000269910.1	RP11-73M18.10	-4.05	6.06e-05	0.00506	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103694516~103695050:-
THCA	cis	rs1204798	0.636	rs59276499	ENSG00000237021.2	RP3-486I3.7	-4.05	6.06e-05	0.00506	-0.23	-0.18	Dental caries;	chr6:116138195	chr6:116254207~116256743:+
THCA	cis	rs2732480	0.577	rs1489109	ENSG00000257735.1	RP11-370I10.6	4.05	6.06e-05	0.00506	0.22	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.577	rs1489108	ENSG00000257735.1	RP11-370I10.6	4.05	6.06e-05	0.00506	0.22	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48350945~48442411:+
THCA	cis	rs11247915	0.6	rs3795686	ENSG00000236782.4	RP11-96L14.7	-4.05	6.06e-05	0.00506	-0.22	-0.18	Obesity-related traits;	chr1:26255600	chr1:26169947~26171821:-
THCA	cis	rs875971	0.789	rs28815324	ENSG00000273142.1	RP11-458F8.4	-4.05	6.06e-05	0.00506	-0.17	-0.18	Aortic root size;	chr7:66100789	chr7:66902857~66906297:+
THCA	cis	rs2521295	1	rs2521295	ENSG00000199550.1	Y_RNA	4.05	6.06e-05	0.00506	0.28	0.18	Monocyte count;	chr11:2327630	chr11:2372638~2372750:+
THCA	cis	rs6696239	0.911	rs12138198	ENSG00000227711.2	RP11-275O4.5	-4.05	6.06e-05	0.00506	-0.25	-0.18	Height;	chr1:227712349	chr1:227509028~227520477:-
THCA	cis	rs75059851	1	rs73036065	ENSG00000280237.1	MIR4697HG	4.05	6.06e-05	0.00506	0.21	0.18	Schizophrenia;	chr11:133960172	chr11:133896438~133901601:-
THCA	cis	rs6453278	0.52	rs13182877	ENSG00000250802.5	ZBED3-AS1	-4.05	6.06e-05	0.00506	-0.18	-0.18	Autism;	chr5:77098755	chr5:77086740~77166909:+
THCA	cis	rs6453278	0.559	rs13168613	ENSG00000250802.5	ZBED3-AS1	-4.05	6.06e-05	0.00506	-0.18	-0.18	Autism;	chr5:77098757	chr5:77086740~77166909:+
THCA	cis	rs9341808	0.935	rs2322633	ENSG00000272129.1	RP11-250B2.6	-4.05	6.06e-05	0.00506	-0.23	-0.18	Sitting height ratio;	chr6:80136272	chr6:80355424~80356859:+
THCA	cis	rs9813712	0.953	rs896822	ENSG00000253540.4	FAM86HP	-4.05	6.06e-05	0.00506	-0.22	-0.18	Response to amphetamines;	chr3:130259987	chr3:130099092~130111472:-
THCA	cis	rs13083990	0.959	rs1472621	ENSG00000272758.4	RP11-299J3.8	4.05	6.06e-05	0.00506	0.18	0.18	Cardiac Troponin-T levels;	chr3:122293879	chr3:122416207~122443180:+
THCA	cis	rs13083990	0.959	rs10934582	ENSG00000272758.4	RP11-299J3.8	4.05	6.06e-05	0.00506	0.18	0.18	Cardiac Troponin-T levels;	chr3:122294507	chr3:122416207~122443180:+
THCA	cis	rs16975963	0.644	rs78644049	ENSG00000276846.1	CTD-3220F14.3	-4.05	6.06e-05	0.00506	-0.17	-0.18	Longevity;	chr19:37622141	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.644	rs75499934	ENSG00000276846.1	CTD-3220F14.3	-4.05	6.06e-05	0.00506	-0.17	-0.18	Longevity;	chr19:37622142	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.604	rs17305326	ENSG00000276846.1	CTD-3220F14.3	-4.05	6.06e-05	0.00506	-0.17	-0.18	Longevity;	chr19:37628646	chr19:37314868~37315620:-
THCA	cis	rs6600671	1	rs10794671	ENSG00000275585.1	CH17-118O6.3	-4.05	6.06e-05	0.00506	-0.22	-0.18	Hip geometry;	chr1:121426382	chr1:120985692~121052167:-
THCA	cis	rs1075265	0.584	rs1833497	ENSG00000272156.1	RP11-477N3.1	4.05	6.06e-05	0.00506	0.19	0.18	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54082554~54085066:+
THCA	cis	rs6822297	0.838	rs10470822	ENSG00000240005.4	RP11-293A21.1	4.05	6.06e-05	0.00506	0.2	0.18	Obesity-related traits;	chr4:26937030	chr4:26859806~26860599:-
THCA	cis	rs12681366	0.801	rs72674819	ENSG00000261437.1	RP11-22C11.2	4.05	6.07e-05	0.00506	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94468072	chr8:94637285~94639467:-
THCA	cis	rs9595908	0.785	rs2301390	ENSG00000212293.1	SNORA16	4.05	6.07e-05	0.00506	0.21	0.18	Body mass index;	chr13:32649307	chr13:32420390~32420516:-
THCA	cis	rs459571	0.959	rs465535	ENSG00000235106.7	LINC00094	4.05	6.07e-05	0.00507	0.16	0.18	Platelet distribution width;	chr9:134045783	chr9:134025439~134034666:+
THCA	cis	rs459571	1	rs456207	ENSG00000235106.7	LINC00094	4.05	6.07e-05	0.00507	0.16	0.18	Platelet distribution width;	chr9:134046018	chr9:134025439~134034666:+
THCA	cis	rs61160187	0.605	rs10068474	ENSG00000251279.1	CTC-436P18.1	4.05	6.07e-05	0.00507	0.23	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782085	chr5:61162070~61232040:+
THCA	cis	rs854765	0.547	rs4459604	ENSG00000281749.1	Y_RNA	4.05	6.07e-05	0.00507	0.23	0.18	Total body bone mineral density;	chr17:17985235	chr17:18001101~18001195:-
THCA	cis	rs9868809	0.772	rs2286651	ENSG00000270441.1	RP11-694I15.7	4.05	6.07e-05	0.00507	0.25	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48656714	chr3:49140086~49160851:-
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000182586.6	LINC00334	-4.05	6.07e-05	0.00507	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000182586.6	LINC00334	-4.05	6.07e-05	0.00507	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45234340~45258730:+
THCA	cis	rs9595908	0.785	rs9596032	ENSG00000212293.1	SNORA16	4.05	6.07e-05	0.00507	0.21	0.18	Body mass index;	chr13:32654708	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.746	rs2301393	ENSG00000212293.1	SNORA16	4.05	6.07e-05	0.00507	0.21	0.18	Body mass index;	chr13:32658298	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs7985656	ENSG00000212293.1	SNORA16	4.05	6.07e-05	0.00507	0.21	0.18	Body mass index;	chr13:32664414	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9596056	ENSG00000212293.1	SNORA16	4.05	6.07e-05	0.00507	0.21	0.18	Body mass index;	chr13:32669402	chr13:32420390~32420516:-
THCA	cis	rs911555	0.723	rs4906324	ENSG00000269958.1	RP11-73M18.8	-4.05	6.07e-05	0.00507	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103696353~103697163:+
THCA	cis	rs911555	0.723	rs2273701	ENSG00000269958.1	RP11-73M18.8	-4.05	6.07e-05	0.00507	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103696353~103697163:+
THCA	cis	rs6570726	0.902	rs973855	ENSG00000270638.1	RP3-466P17.1	-4.05	6.07e-05	0.00507	-0.15	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145735570~145737218:+
THCA	cis	rs13113518	1	rs56362210	ENSG00000272969.1	RP11-528I4.2	4.05	6.07e-05	0.00507	0.21	0.18	Height;	chr4:55540972	chr4:55547112~55547889:+
THCA	cis	rs35146811	0.735	rs2528900	ENSG00000078319.8	PMS2P1	-4.05	6.07e-05	0.00507	-0.23	-0.18	Coronary artery disease;	chr7:100207696	chr7:100320992~100341908:-
THCA	cis	rs78487399	0.808	rs6726917	ENSG00000234936.1	AC010883.5	4.05	6.08e-05	0.00507	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43526774	chr2:43229573~43233394:+
THCA	cis	rs4561483	0.603	rs11075033	ENSG00000263307.1	RP11-166B2.8	-4.05	6.08e-05	0.00507	-0.19	-0.18	Testicular germ cell tumor;	chr16:11912481	chr16:11851649~11895611:+
THCA	cis	rs12478296	0.901	rs58906257	ENSG00000220804.7	AC093642.5	4.05	6.08e-05	0.00507	0.2	0.18	Obesity-related traits;	chr2:242086097	chr2:242088633~242160153:+
THCA	cis	rs911555	0.723	rs4906320	ENSG00000269910.1	RP11-73M18.10	-4.05	6.08e-05	0.00507	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103694516~103695050:-
THCA	cis	rs10484434	0.901	rs56073264	ENSG00000272462.2	U91328.19	4.05	6.08e-05	0.00507	0.2	0.18	HIV-1 viral setpoint;	chr6:26079188	chr6:25992662~26001775:+
THCA	cis	rs9307551	0.817	rs4975057	ENSG00000249646.2	OR7E94P	-4.05	6.08e-05	0.00507	-0.23	-0.18	Refractive error;	chr4:79567191	chr4:79587302~79588130:-
THCA	cis	rs6570726	0.791	rs392612	ENSG00000270638.1	RP3-466P17.1	-4.05	6.08e-05	0.00507	-0.15	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145735570~145737218:+
THCA	cis	rs72949976	0.934	rs13406406	ENSG00000270659.1	RP11-105N14.1	4.05	6.08e-05	0.00507	0.14	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213170102	chr2:213152970~213153659:+
THCA	cis	rs111756027	0.54	rs17701858	ENSG00000260922.1	RP11-538I12.3	4.05	6.08e-05	0.00507	0.26	0.18	Bone mineral density (Ward's triangle area);	chr16:77276582	chr16:77234877~77290934:+
THCA	cis	rs10090774	0.965	rs7813058	ENSG00000280303.2	ERICD	-4.05	6.08e-05	0.00507	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994094	chr8:140636281~140638283:+
THCA	cis	rs10266483	0.705	rs1111649	ENSG00000271550.1	BNIP3P11	4.05	6.08e-05	0.00507	0.23	0.18	Response to statin therapy;	chr7:64296435	chr7:64678954~64687393:-
THCA	cis	rs10760158	0.832	rs10985194	ENSG00000226752.6	PSMD5-AS1	-4.05	6.08e-05	0.00507	-0.22	-0.18	Pulse pressure;	chr9:121265434	chr9:120824828~120854385:+
THCA	cis	rs739496	0.615	rs617044	ENSG00000226469.1	ADAM1B	4.05	6.08e-05	0.00507	0.23	0.18	Platelet count;	chr12:111695071	chr12:111927018~111929017:+
THCA	cis	rs739496	0.615	rs602276	ENSG00000226469.1	ADAM1B	4.05	6.08e-05	0.00507	0.23	0.18	Platelet count;	chr12:111696120	chr12:111927018~111929017:+
THCA	cis	rs5758659	0.714	rs133373	ENSG00000205702.9	CYP2D7	4.05	6.08e-05	0.00507	0.14	0.18	Cognitive function;	chr22:42069784	chr22:42140203~42144577:-
THCA	cis	rs5751901	0.614	rs6519520	ENSG00000128262.7	POM121L9P	-4.05	6.08e-05	0.00507	-0.19	-0.18	Protein quantitative trait loci;	chr22:24595928	chr22:24251828~24265525:+
THCA	cis	rs150992	0.585	rs331931	ENSG00000246763.5	RGMB-AS1	4.05	6.08e-05	0.00507	0.19	0.18	Body mass index;	chr5:98834012	chr5:98769618~98773469:-
THCA	cis	rs7267979	0.844	rs2257649	ENSG00000274973.1	RP13-401N8.7	-4.05	6.08e-05	0.00508	-0.21	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25845497~25845862:+
THCA	cis	rs35176054	0.73	rs34936990	ENSG00000280693.1	SH3PXD2A-AS1	-4.05	6.08e-05	0.00508	-0.35	-0.18	Atrial fibrillation;	chr10:103763658	chr10:103745966~103755423:+
THCA	cis	rs734999	0.545	rs4074789	ENSG00000225931.3	RP3-395M20.7	4.05	6.08e-05	0.00508	0.22	0.18	Ulcerative colitis;	chr1:2606025	chr1:2566410~2569888:+
THCA	cis	rs3198697	1	rs3198697	ENSG00000263335.1	AF001548.5	-4.05	6.08e-05	0.00508	-0.22	-0.18	Triglycerides;	chr16:15036083	chr16:15726674~15732993:+
THCA	cis	rs3740713	1	rs113036885	ENSG00000256464.1	YWHABP2	4.05	6.08e-05	0.00508	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs112410494	ENSG00000256464.1	YWHABP2	4.05	6.08e-05	0.00508	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr11:18490243~18490955:-
THCA	cis	rs3740713	1	rs74741949	ENSG00000256464.1	YWHABP2	4.05	6.08e-05	0.00508	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr11:18490243~18490955:-
THCA	cis	rs2820315	0.505	rs10800792	ENSG00000223774.4	RP11-307B6.3	-4.05	6.08e-05	0.00508	-0.18	-0.18	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201842016	chr1:201893842~201899978:+
THCA	cis	rs35146811	0.625	rs2906645	ENSG00000078319.8	PMS2P1	-4.05	6.08e-05	0.00508	-0.23	-0.18	Coronary artery disease;	chr7:100220236	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs858506	ENSG00000078319.8	PMS2P1	-4.05	6.08e-05	0.00508	-0.23	-0.18	Coronary artery disease;	chr7:100222427	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.695	rs858508	ENSG00000078319.8	PMS2P1	-4.05	6.08e-05	0.00508	-0.23	-0.18	Coronary artery disease;	chr7:100223758	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.659	rs863450	ENSG00000078319.8	PMS2P1	-4.05	6.08e-05	0.00508	-0.23	-0.18	Coronary artery disease;	chr7:100224062	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs858512	ENSG00000078319.8	PMS2P1	-4.05	6.08e-05	0.00508	-0.23	-0.18	Coronary artery disease;	chr7:100226830	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.7	rs858513	ENSG00000078319.8	PMS2P1	-4.05	6.08e-05	0.00508	-0.23	-0.18	Coronary artery disease;	chr7:100227935	chr7:100320992~100341908:-
THCA	cis	rs308403	0.509	rs13122636	ENSG00000224786.1	CETN4P	4.05	6.08e-05	0.00508	0.19	0.18	Blood protein levels;	chr4:122749890	chr4:122730548~122732193:-
THCA	cis	rs17221829	0.733	rs10830329	ENSG00000280385.1	AP000648.5	-4.05	6.08e-05	0.00508	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89657444	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.703	rs12418019	ENSG00000280385.1	AP000648.5	-4.05	6.08e-05	0.00508	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89658589	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.71	rs12421890	ENSG00000280385.1	AP000648.5	-4.05	6.08e-05	0.00508	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89658631	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.703	rs10765229	ENSG00000280385.1	AP000648.5	-4.05	6.08e-05	0.00508	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89659407	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs11018715	ENSG00000280385.1	AP000648.5	-4.05	6.08e-05	0.00508	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89661294	chr11:90193614~90198120:+
THCA	cis	rs13256369	0.901	rs4841015	ENSG00000254153.1	CTA-398F10.2	-4.05	6.09e-05	0.00508	-0.21	-0.18	Obesity-related traits;	chr8:8709630	chr8:8456909~8461337:-
THCA	cis	rs7267979	1	rs7018	ENSG00000276952.1	RP5-965G21.6	4.05	6.09e-05	0.00508	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4815404	ENSG00000276952.1	RP5-965G21.6	-4.05	6.09e-05	0.00508	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6083805	ENSG00000276952.1	RP5-965G21.6	-4.05	6.09e-05	0.00508	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25284915~25285588:-
THCA	cis	rs1150668	0.799	rs9301	ENSG00000280107.1	AL022393.9	-4.05	6.09e-05	0.00508	-0.18	-0.18	Pubertal anthropometrics;	chr6:28324929	chr6:28170845~28172521:+
THCA	cis	rs13434995	0.513	rs12509047	ENSG00000249700.7	SRD5A3-AS1	4.05	6.09e-05	0.00508	0.26	0.18	Adiponectin levels;	chr4:55545245	chr4:55363971~55395847:-
THCA	cis	rs3812831	0.635	rs6560937	ENSG00000264539.1	MIR548AR	4.05	6.09e-05	0.00508	0.19	0.18	Schizophrenia;	chr13:114180516	chr13:114244505~114244561:+
THCA	cis	rs3824488	0.652	rs57793730	ENSG00000271155.1	RP11-435O5.5	-4.05	6.09e-05	0.00508	-0.28	-0.18	Neuroticism;	chr9:95523754	chr9:95506235~95507636:+
THCA	cis	rs804280	0.542	rs35647515	ENSG00000254948.1	OR7E158P	-4.05	6.09e-05	0.00508	-0.23	-0.18	Myopia (pathological);	chr8:11934120	chr8:11919900~11920809:-
THCA	cis	rs17772222	0.63	rs61977024	ENSG00000258789.1	RP11-507K2.3	-4.05	6.09e-05	0.00508	-0.19	-0.18	Coronary artery calcification;	chr14:88335961	chr14:88551597~88552493:+
THCA	cis	rs7432375	0.804	rs6764567	ENSG00000273455.1	RP11-305O4.3	-4.05	6.09e-05	0.00508	-0.24	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136706672	chr3:136087475~136087913:-
THCA	cis	rs17689437	0.914	rs55652840	ENSG00000260084.1	RP11-615I2.1	-4.05	6.09e-05	0.00508	-0.3	-0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68528195	chr16:68573782~68589512:-
THCA	cis	rs944289	0.646	rs8008989	ENSG00000258844.1	RP11-259K15.2	4.05	6.09e-05	0.00508	0.17	0.18	Thyroid cancer;	chr14:36088871	chr14:36214607~36235608:+
THCA	cis	rs17095355	0.688	rs1349348	ENSG00000203876.8	ADD3-AS1	4.05	6.09e-05	0.00508	0.2	0.18	Biliary atresia;	chr10:110034796	chr10:109940104~110008381:-
THCA	cis	rs9302635	0.513	rs3812987	ENSG00000260886.1	TAT-AS1	4.05	6.09e-05	0.00508	0.23	0.18	Blood protein levels;	chr16:72125021	chr16:71565789~71578187:+
THCA	cis	rs758324	0.773	rs630044	ENSG00000237714.1	P4HA2-AS1	4.05	6.09e-05	0.00508	0.25	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131922685	chr5:132184876~132192808:+
THCA	cis	rs7772486	0.742	rs4896851	ENSG00000270638.1	RP3-466P17.1	-4.05	6.09e-05	0.00508	-0.15	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145957823	chr6:145735570~145737218:+
THCA	cis	rs7617480	0.648	rs14018	ENSG00000229759.1	MRPS18AP1	4.05	6.09e-05	0.00508	0.29	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48746837	chr3:48256350~48256938:-
THCA	cis	rs72928364	1	rs35509049	ENSG00000256628.3	ZBTB11-AS1	4.05	6.09e-05	0.00508	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100941920	chr3:101676475~101679217:+
THCA	cis	rs6696239	0.956	rs6426471	ENSG00000227711.2	RP11-275O4.5	-4.05	6.09e-05	0.00508	-0.25	-0.18	Height;	chr1:227666115	chr1:227509028~227520477:-
THCA	cis	rs2980439	0.525	rs2945238	ENSG00000233609.3	RP11-62H7.2	4.05	6.09e-05	0.00508	0.18	0.18	Neuroticism;	chr8:8312614	chr8:8961200~8979025:+
THCA	cis	rs7572733	0.534	rs10211202	ENSG00000231621.1	AC013264.2	-4.05	6.09e-05	0.00508	-0.19	-0.18	Dermatomyositis;	chr2:197907217	chr2:197197991~197199273:+
THCA	cis	rs867371	0.502	rs8025964	ENSG00000276710.3	CSPG4P8	-4.05	6.09e-05	0.00508	-0.18	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82459472~82477258:+
THCA	cis	rs2474937	0.535	rs4141768	ENSG00000231365.4	RP11-418J17.1	4.05	6.09e-05	0.00508	0.18	0.18	Congenital heart malformation;	chr1:118382222	chr1:119140396~119275973:+
THCA	cis	rs972578	0.967	rs2038059	ENSG00000274717.1	RP1-47A17.1	-4.05	6.09e-05	0.00508	-0.19	-0.18	Mean platelet volume;	chr22:42938392	chr22:42791814~42794313:-
THCA	cis	rs4656958	0.557	rs11265526	ENSG00000233691.2	RP11-312J18.7	4.05	6.09e-05	0.00508	0.21	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160926080	chr1:160935537~160936126:+
THCA	cis	rs701145	0.585	rs896013	ENSG00000243069.6	ARHGEF26-AS1	4.05	6.09e-05	0.00508	0.34	0.18	Coronary artery disease;	chr3:154146084	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1542254	ENSG00000243069.6	ARHGEF26-AS1	4.05	6.09e-05	0.00508	0.34	0.18	Coronary artery disease;	chr3:154146507	chr3:154024401~154121332:-
THCA	cis	rs853679	0.76	rs11967137	ENSG00000273712.1	RP5-874C20.7	4.05	6.09e-05	0.00508	0.25	0.18	Depression;	chr6:28231986	chr6:28315613~28315883:-
THCA	cis	rs7951911	0.915	rs56113106	ENSG00000254427.1	RP11-430H10.1	4.05	6.1e-05	0.00509	0.34	0.18	IgG glycosylation;	chr11:45065600	chr11:45355371~45366121:+
THCA	cis	rs2589113	0.609	rs2576697	ENSG00000162997.14	PRORSD1P	4.05	6.1e-05	0.00509	0.32	0.18	Height;	chr2:55298000	chr2:55282319~55284522:+
THCA	cis	rs2589113	0.702	rs2576698	ENSG00000162997.14	PRORSD1P	4.05	6.1e-05	0.00509	0.32	0.18	Height;	chr2:55298010	chr2:55282319~55284522:+
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000265443.1	CTD-2349P21.6	-4.05	6.1e-05	0.00509	-0.31	-0.18	Body mass index;	chr17:30776148	chr17:30726305~30727564:-
THCA	cis	rs17723470	0.579	rs11038341	ENSG00000254427.1	RP11-430H10.1	4.05	6.1e-05	0.00509	0.21	0.18	Thyroid hormone levels;	chr11:45181661	chr11:45355371~45366121:+
THCA	cis	rs2948294	0.566	rs13261997	ENSG00000253981.4	ALG1L13P	4.05	6.1e-05	0.00509	0.18	0.18	Red cell distribution width;	chr8:8254773	chr8:8236003~8244667:-
THCA	cis	rs1971762	0.527	rs7976398	ENSG00000270175.1	RP11-793H13.11	-4.05	6.1e-05	0.00509	-0.12	-0.18	Height;	chr12:53635078	chr12:53500162~53500936:-
THCA	cis	rs2820315	0.867	rs2820318	ENSG00000223774.4	RP11-307B6.3	4.05	6.1e-05	0.00509	0.2	0.18	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201909492	chr1:201893842~201899978:+
THCA	cis	rs6442522	0.611	rs1983085	ENSG00000249786.6	EAF1-AS1	-4.05	6.1e-05	0.00509	-0.19	-0.18	Uric acid levels;	chr3:15488036	chr3:15436171~15455940:-
THCA	cis	rs6724465	0.636	rs6436119	ENSG00000272644.1	RP11-33O4.1	4.05	6.1e-05	0.00509	0.24	0.18	Height;	chr2:219154306	chr2:219069354~219069809:-
THCA	cis	rs7826238	0.539	rs2945891	ENSG00000233609.3	RP11-62H7.2	4.05	6.1e-05	0.00509	0.18	0.18	Systolic blood pressure;	chr8:8297953	chr8:8961200~8979025:+
THCA	cis	rs360071	0.528	rs360094	ENSG00000242861.1	RP11-285F7.2	4.05	6.1e-05	0.00509	0.16	0.18	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);	chr1:225877146	chr1:225840883~225846522:-
THCA	cis	rs5758511	0.68	rs739146	ENSG00000270083.1	RP1-257I20.14	-4.05	6.1e-05	0.00509	-0.24	-0.18	Birth weight;	chr22:42264408	chr22:42089630~42090028:-
THCA	cis	rs7192208	1	rs16945470	ENSG00000260922.1	RP11-538I12.3	4.05	6.1e-05	0.00509	0.32	0.18	White matter integrity;	chr16:77295511	chr16:77234877~77290934:+
THCA	cis	rs7192208	1	rs7192208	ENSG00000260922.1	RP11-538I12.3	4.05	6.1e-05	0.00509	0.32	0.18	White matter integrity;	chr16:77295744	chr16:77234877~77290934:+
THCA	cis	rs847845	0.535	rs72892238	ENSG00000272288.4	RP11-140K17.3	-4.05	6.1e-05	0.00509	-0.23	-0.18	Non-small cell lung cancer;	chr6:34755359	chr6:34696317~34697470:+
THCA	cis	rs2120243	0.51	rs10936087	ENSG00000241770.1	RP11-555M1.3	-4.05	6.1e-05	0.00509	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157388839	chr3:157163452~157169133:+
THCA	cis	rs4767841	0.537	rs385930	ENSG00000248636.5	RP11-768F21.1	-4.05	6.1e-05	0.00509	-0.19	-0.18	Urgency urinary incontinence;	chr12:119781260	chr12:119387987~119668079:-
THCA	cis	rs10256972	0.521	rs871019	ENSG00000225146.1	AC073957.15	4.05	6.1e-05	0.00509	0.19	0.18	Endometriosis;Longevity;	chr7:1065594	chr7:1029025~1043891:+
THCA	cis	rs2524005	1	rs2524005	ENSG00000238024.1	DDX39BP2	4.05	6.1e-05	0.00509	0.28	0.18	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29993209~29993605:+
THCA	cis	rs8177876	0.822	rs9925940	ENSG00000261838.4	RP11-303E16.6	4.05	6.1e-05	0.00509	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.822	rs9925943	ENSG00000261838.4	RP11-303E16.6	4.05	6.1e-05	0.00509	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81069854~81076598:+
THCA	cis	rs17221829	0.673	rs10830334	ENSG00000280385.1	AP000648.5	-4.05	6.1e-05	0.00509	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89670753	chr11:90193614~90198120:+
THCA	cis	rs1541160	1	rs1541160	ENSG00000239494.2	RN7SL333P	4.05	6.1e-05	0.00509	0.18	0.18	Amyotrophic lateral sclerosis;	chr1:170026661	chr1:169859756~169860052:+
THCA	cis	rs12681366	0.801	rs2919657	ENSG00000261437.1	RP11-22C11.2	4.05	6.1e-05	0.00509	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94460724	chr8:94637285~94639467:-
THCA	cis	rs4713118	0.615	rs57252182	ENSG00000216901.1	AL022393.7	4.05	6.1e-05	0.00509	0.24	0.18	Parkinson's disease;	chr6:27752470	chr6:28176188~28176674:+
THCA	cis	rs34034915	1	rs34034915	ENSG00000216901.1	AL022393.7	4.05	6.1e-05	0.00509	0.24	0.18	Hepatitis A;	chr6:27752924	chr6:28176188~28176674:+
THCA	cis	rs4713118	0.527	rs36042294	ENSG00000216901.1	AL022393.7	4.05	6.1e-05	0.00509	0.24	0.18	Parkinson's disease;	chr6:27752933	chr6:28176188~28176674:+
THCA	cis	rs7267979	0.808	rs84816	ENSG00000276952.1	RP5-965G21.6	4.05	6.1e-05	0.00509	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25284915~25285588:-
THCA	cis	rs6088590	0.71	rs6059992	ENSG00000269202.1	RP4-614O4.12	-4.05	6.1e-05	0.00509	-0.16	-0.18	Coronary artery disease;	chr20:34694471	chr20:35201747~35203288:-
THCA	cis	rs10090774	0.965	rs12677559	ENSG00000279766.1	RP11-642A1.2	4.05	6.1e-05	0.00509	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140946805	chr8:140572142~140572812:-
THCA	cis	rs427943	0.864	rs373037	ENSG00000223768.1	LINC00205	-4.05	6.11e-05	0.00509	-0.17	-0.18	Body mass index;	chr21:45172001	chr21:45293285~45297354:+
THCA	cis	rs4788570	0.584	rs6499530	ENSG00000260185.1	RP11-432I5.6	-4.05	6.11e-05	0.00509	-0.34	-0.18	Intelligence (multi-trait analysis);	chr16:71689186	chr16:71655027~71664212:+
THCA	cis	rs1385374	0.698	rs12822119	ENSG00000274695.1	RP11-21K12.3	4.05	6.11e-05	0.00509	0.39	0.18	Systemic lupus erythematosus;	chr12:128848131	chr12:128826836~128827579:+
THCA	cis	rs4561483	0.583	rs11075032	ENSG00000263307.1	RP11-166B2.8	-4.05	6.11e-05	0.00509	-0.19	-0.18	Testicular germ cell tumor;	chr16:11910593	chr16:11851649~11895611:+
THCA	cis	rs7974517	1	rs7974517	ENSG00000272368.2	RP4-605O3.4	-4.05	6.11e-05	0.00509	-0.11	-0.18	Male-pattern baldness;	chr12:50751299	chr12:50112197~50165618:+
THCA	cis	rs3128341	1	rs12137749	ENSG00000227207.2	RPL31P12	4.05	6.11e-05	0.00509	0.29	0.18	Intelligence (multi-trait analysis);	chr1:72355026	chr1:72301472~72301829:+
THCA	cis	rs3734266	0.702	rs1051115	ENSG00000272288.4	RP11-140K17.3	-4.05	6.11e-05	0.00509	-0.18	-0.18	Systemic lupus erythematosus;	chr6:34887971	chr6:34696317~34697470:+
THCA	cis	rs4295623	0.816	rs35558975	ENSG00000270154.1	RP11-419I17.1	-4.05	6.11e-05	0.00509	-0.23	-0.18	Morning vs. evening chronotype;	chr8:11726967	chr8:12476462~12477122:+
THCA	cis	rs7246657	0.508	rs1644702	ENSG00000276846.1	CTD-3220F14.3	4.05	6.11e-05	0.00509	0.21	0.18	Coronary artery calcification;	chr19:37001005	chr19:37314868~37315620:-
THCA	cis	rs6494488	0.5	rs72741368	ENSG00000259635.1	AC100830.3	-4.05	6.11e-05	0.00509	-0.46	-0.18	Coronary artery disease;	chr15:64502573	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741369	ENSG00000259635.1	AC100830.3	-4.05	6.11e-05	0.00509	-0.46	-0.18	Coronary artery disease;	chr15:64504849	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs79652764	ENSG00000259635.1	AC100830.3	-4.05	6.11e-05	0.00509	-0.46	-0.18	Coronary artery disease;	chr15:64508333	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs56076814	ENSG00000259635.1	AC100830.3	-4.05	6.11e-05	0.00509	-0.46	-0.18	Coronary artery disease;	chr15:64515585	chr15:64701248~64719602:+
THCA	cis	rs6517329	0.7	rs11911678	ENSG00000236830.5	CBR3-AS1	4.05	6.11e-05	0.00509	0.18	0.18	Schizophrenia;	chr21:36110704	chr21:36131767~36175815:-
THCA	cis	rs34792	0.688	rs170168	ENSG00000207425.1	Y_RNA	-4.05	6.11e-05	0.00509	-0.2	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507138	chr16:14915457~14915556:-
THCA	cis	rs9309473	0.95	rs1052162	ENSG00000273245.1	RP11-434P11.2	-4.05	6.11e-05	0.0051	-0.24	-0.18	Metabolite levels;	chr2:73602245	chr2:73750256~73750786:-
THCA	cis	rs4144027	0.869	rs55924227	ENSG00000269958.1	RP11-73M18.8	4.05	6.11e-05	0.0051	0.17	0.18	Blood metabolite levels;	chr14:103895013	chr14:103696353~103697163:+
THCA	cis	rs447735	0.566	rs258337	ENSG00000274627.1	RP11-104N10.2	4.05	6.11e-05	0.0051	0.18	0.18	Hemoglobin concentration;	chr16:89654302	chr16:89516797~89522217:+
THCA	cis	rs7119038	0.818	rs76704408	ENSG00000255422.1	AP002954.4	4.05	6.11e-05	0.0051	0.22	0.18	Sjögren's syndrome;	chr11:118812618	chr11:118704607~118750263:+
THCA	cis	rs13113518	1	rs13132420	ENSG00000272969.1	RP11-528I4.2	-4.05	6.11e-05	0.0051	-0.21	-0.18	Height;	chr4:55526646	chr4:55547112~55547889:+
THCA	cis	rs12200782	0.649	rs7756881	ENSG00000124549.13	BTN2A3P	-4.05	6.11e-05	0.0051	-0.22	-0.18	Small cell lung carcinoma;	chr6:26389698	chr6:26421391~26432383:+
THCA	cis	rs7617480	0.648	rs6801211	ENSG00000229759.1	MRPS18AP1	4.05	6.11e-05	0.0051	0.28	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48736987	chr3:48256350~48256938:-
THCA	cis	rs10760158	0.832	rs10818523	ENSG00000226752.6	PSMD5-AS1	-4.05	6.11e-05	0.0051	-0.22	-0.18	Pulse pressure;	chr9:121265809	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs963003	ENSG00000226752.6	PSMD5-AS1	-4.05	6.11e-05	0.0051	-0.22	-0.18	Pulse pressure;	chr9:121272531	chr9:120824828~120854385:+
THCA	cis	rs6938	0.662	rs12487	ENSG00000260269.4	CTD-2323K18.1	-4.04	6.12e-05	0.0051	-0.26	-0.18	Breast cancer;	chr15:74844353	chr15:75527150~75601205:-
THCA	cis	rs4792901	0.918	rs79158595	ENSG00000267151.3	RP11-100E5.2	4.04	6.12e-05	0.0051	0.19	0.18	Dupuytren's disease;	chr17:43545844	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.959	rs3765174	ENSG00000267151.3	RP11-100E5.2	4.04	6.12e-05	0.0051	0.19	0.18	Dupuytren's disease;	chr17:43546302	chr17:43444707~43451200:+
THCA	cis	rs2115630	0.641	rs11073613	ENSG00000259295.5	CSPG4P12	-4.04	6.12e-05	0.0051	-0.25	-0.18	P wave terminal force;	chr15:84642662	chr15:85191438~85213905:+
THCA	cis	rs12612619	0.732	rs3806520	ENSG00000272148.1	RP11-195B17.1	4.04	6.12e-05	0.0051	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27053334	chr2:27062428~27062907:-
THCA	cis	rs7829975	0.777	rs486781	ENSG00000254340.1	RP11-10A14.3	-4.04	6.12e-05	0.0051	-0.2	-0.18	Mood instability;	chr8:8782230	chr8:9141424~9145435:+
THCA	cis	rs964611	0.935	rs7495591	ENSG00000259488.2	RP11-154J22.1	-4.04	6.12e-05	0.0051	-0.2	-0.18	Metabolite levels (Pyroglutamine);	chr15:48278571	chr15:48312353~48331856:-
THCA	cis	rs964611	0.935	rs74011994	ENSG00000259488.2	RP11-154J22.1	-4.04	6.12e-05	0.0051	-0.2	-0.18	Metabolite levels (Pyroglutamine);	chr15:48283226	chr15:48312353~48331856:-
THCA	cis	rs758324	0.732	rs152051	ENSG00000224431.1	AC063976.7	-4.04	6.12e-05	0.0051	-0.19	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132203332	chr5:132199456~132203487:+
THCA	cis	rs9926296	0.529	rs7195906	ENSG00000274627.1	RP11-104N10.2	-4.04	6.12e-05	0.0051	-0.19	-0.18	Vitiligo;	chr16:89739939	chr16:89516797~89522217:+
THCA	cis	rs3764021	0.87	rs10492166	ENSG00000256594.6	RP11-705C15.2	4.04	6.12e-05	0.0051	0.14	0.18	Type 1 diabetes;	chr12:9733403	chr12:9633419~9658412:+
THCA	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-4.04	6.12e-05	0.0051	-0.33	-0.18	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
THCA	cis	rs123509	0.687	rs73077220	ENSG00000173811.9	CCDC13-AS1	-4.04	6.12e-05	0.0051	-0.21	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42800848	chr3:42732575~42746768:+
THCA	cis	rs12476592	0.602	rs10176522	ENSG00000242412.1	DBIL5P2	4.04	6.12e-05	0.0051	0.24	0.18	Childhood ear infection;	chr2:63495299	chr2:63117851~63119542:-
THCA	cis	rs7572733	0.534	rs700688	ENSG00000231621.1	AC013264.2	4.04	6.12e-05	0.0051	0.19	0.18	Dermatomyositis;	chr2:197859109	chr2:197197991~197199273:+
THCA	cis	rs7737355	0.898	rs13164236	ENSG00000237714.1	P4HA2-AS1	4.04	6.12e-05	0.0051	0.26	0.18	Life satisfaction;	chr5:131744115	chr5:132184876~132192808:+
THCA	cis	rs4767841	0.967	rs12296121	ENSG00000252886.1	RN7SKP197	-4.04	6.12e-05	0.0051	-0.18	-0.18	Urgency urinary incontinence;	chr12:119722116	chr12:119631090~119631386:-
THCA	cis	rs15676	0.812	rs10819447	ENSG00000234771.3	SLC25A25-AS1	4.04	6.12e-05	0.00511	0.15	0.18	Blood metabolite levels;	chr9:128814137	chr9:128108581~128118693:-
THCA	cis	rs57502260	0.651	rs3781586	ENSG00000212093.1	AP000807.1	4.04	6.12e-05	0.00511	0.24	0.18	Total body bone mineral density (age 45-60);	chr11:68431925	chr11:68506083~68506166:-
THCA	cis	rs724818	0.661	rs10026533	ENSG00000251609.2	SETP12	-4.04	6.12e-05	0.00511	-0.48	-0.18	Monobrow thickness;	chr4:120772904	chr4:120895494~120897083:-
THCA	cis	rs4934494	0.677	rs11185773	ENSG00000240996.1	RP11-80H5.7	-4.04	6.12e-05	0.00511	-0.21	-0.18	Red blood cell count;	chr10:89589574	chr10:89694295~89697928:-
THCA	cis	rs2235642	0.551	rs1966171	ENSG00000280231.1	LA16c-380F5.3	-4.04	6.12e-05	0.00511	-0.22	-0.18	Coronary artery disease;	chr16:1512803	chr16:1553655~1554130:-
THCA	cis	rs3096299	0.719	rs2911265	ENSG00000261118.1	RP11-104N10.1	4.04	6.12e-05	0.00511	0.15	0.18	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89492017~89504460:-
THCA	cis	rs9843304	0.529	rs34895718	ENSG00000240541.2	TM4SF1-AS1	4.04	6.12e-05	0.00511	0.16	0.18	Gallstone disease;	chr3:149487430	chr3:149377778~149386583:+
THCA	cis	rs2080501	0.628	rs28971165	ENSG00000275155.1	CTD-2595P9.4	-4.04	6.13e-05	0.00511	-0.17	-0.18	IgG glycosylation;	chr16:49627792	chr16:49847018~49847632:-
THCA	cis	rs7824557	0.507	rs7010590	ENSG00000255495.1	AC145124.2	4.04	6.13e-05	0.00511	0.21	0.18	Retinal vascular caliber;	chr8:11205373	chr8:12194467~12196280:+
THCA	cis	rs613391	0.561	rs10811762	ENSG00000234840.1	LINC01239	-4.04	6.13e-05	0.00511	-0.21	-0.18	Quantitative traits;	chr9:22716471	chr9:22646200~22824213:+
THCA	cis	rs2749592	0.55	rs4934881	ENSG00000276805.1	RP11-291L22.6	-4.04	6.13e-05	0.00511	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:38451030~38451785:+
THCA	cis	rs150992	0.631	rs112047336	ENSG00000246763.5	RGMB-AS1	4.04	6.13e-05	0.00511	0.19	0.18	Body mass index;	chr5:98990041	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs112042355	ENSG00000246763.5	RGMB-AS1	4.04	6.13e-05	0.00511	0.19	0.18	Body mass index;	chr5:98990046	chr5:98769618~98773469:-
THCA	cis	rs10875746	0.903	rs12313404	ENSG00000258234.1	RP11-370I10.2	4.04	6.13e-05	0.00511	0.22	0.18	Longevity (90 years and older);	chr12:48098265	chr12:48231098~48284210:-
THCA	cis	rs10411262	0.868	rs7250264	ENSG00000245598.5	DACT3-AS1	-4.04	6.13e-05	0.00511	-0.21	-0.18	Tonsillectomy;	chr19:46684181	chr19:46660364~46677447:+
THCA	cis	rs10435719	0.764	rs10103485	ENSG00000206014.6	OR7E161P	-4.04	6.13e-05	0.00511	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:11928597~11929563:-
THCA	cis	rs9595908	0.84	rs2301388	ENSG00000212293.1	SNORA16	4.04	6.13e-05	0.00511	0.21	0.18	Body mass index;	chr13:32648478	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.758	rs2301389	ENSG00000212293.1	SNORA16	4.04	6.13e-05	0.00511	0.21	0.18	Body mass index;	chr13:32648694	chr13:32420390~32420516:-
THCA	cis	rs11239930	0.538	rs4950359	ENSG00000278811.3	LINC00624	4.04	6.13e-05	0.00511	0.22	0.18	AIDS progression;	chr1:147087196	chr1:147258885~147517875:-
THCA	cis	rs1923243	0.71	rs4650194	ENSG00000223479.3	RP4-788P17.1	4.04	6.14e-05	0.00511	0.2	0.18	Migraine;	chr1:73170923	chr1:73635216~73715214:+
THCA	cis	rs791590	0.941	rs4625363	ENSG00000225948.2	RP11-554I8.1	4.04	6.14e-05	0.00512	0.29	0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:6030541	chr10:6618716~6625346:+
THCA	cis	rs240993	0.595	rs4947127	ENSG00000271789.1	RP5-1112D6.7	4.04	6.14e-05	0.00512	0.19	0.18	Inflammatory skin disease;Psoriasis;	chr6:111581595	chr6:111297126~111298510:+
THCA	cis	rs1908814	0.516	rs7825529	ENSG00000206014.6	OR7E161P	-4.04	6.14e-05	0.00512	-0.22	-0.18	Neuroticism;	chr8:11936935	chr8:11928597~11929563:-
THCA	cis	rs2880765	0.546	rs8042776	ENSG00000259630.2	CTD-2262B20.1	-4.04	6.14e-05	0.00512	-0.2	-0.18	Coronary artery disease;	chr15:85512398	chr15:85415228~85415633:+
THCA	cis	rs7617480	0.587	rs9311431	ENSG00000229759.1	MRPS18AP1	4.04	6.14e-05	0.00512	0.29	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48811354	chr3:48256350~48256938:-
THCA	cis	rs7617480	0.648	rs4974088	ENSG00000229759.1	MRPS18AP1	4.04	6.14e-05	0.00512	0.29	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48861316	chr3:48256350~48256938:-
THCA	cis	rs4886920	1	rs4886920	ENSG00000260776.4	RP11-114H24.2	-4.04	6.14e-05	0.00512	-0.23	-0.18	Neuroticism;	chr15:77821710	chr15:77914217~77926846:-
THCA	cis	rs2298450	0.717	rs2835324	ENSG00000214867.3	SRSF9P1	-4.04	6.14e-05	0.00512	-0.27	-0.18	Schizophrenia;	chr21:36238253	chr21:36295173~36295702:-
THCA	cis	rs1150668	0.799	rs853684	ENSG00000280107.1	AL022393.9	-4.04	6.14e-05	0.00512	-0.18	-0.18	Pubertal anthropometrics;	chr6:28326773	chr6:28170845~28172521:+
THCA	cis	rs9902453	0.845	rs12452201	ENSG00000263370.1	RP11-68I3.5	4.04	6.14e-05	0.00512	0.24	0.18	Coffee consumption (cups per day);	chr17:29887155	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.817	rs55974138	ENSG00000263370.1	RP11-68I3.5	4.04	6.14e-05	0.00512	0.24	0.18	Coffee consumption (cups per day);	chr17:29888528	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs58575982	ENSG00000263370.1	RP11-68I3.5	4.04	6.14e-05	0.00512	0.24	0.18	Coffee consumption (cups per day);	chr17:29894758	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs2321493	ENSG00000263370.1	RP11-68I3.5	4.04	6.14e-05	0.00512	0.24	0.18	Coffee consumption (cups per day);	chr17:29903341	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.808	rs12452288	ENSG00000263370.1	RP11-68I3.5	4.04	6.14e-05	0.00512	0.24	0.18	Coffee consumption (cups per day);	chr17:29908202	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.791	rs55655651	ENSG00000263370.1	RP11-68I3.5	4.04	6.14e-05	0.00512	0.24	0.18	Coffee consumption (cups per day);	chr17:29917268	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.845	rs12601963	ENSG00000263370.1	RP11-68I3.5	4.04	6.14e-05	0.00512	0.24	0.18	Coffee consumption (cups per day);	chr17:29919340	chr17:29639627~29640825:+
THCA	cis	rs1371614	0.632	rs7599286	ENSG00000229122.1	AGBL5-IT1	4.04	6.15e-05	0.00512	0.13	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929530	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.61	rs2384511	ENSG00000229122.1	AGBL5-IT1	4.04	6.15e-05	0.00512	0.13	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929867	chr2:27061038~27061815:+
THCA	cis	rs2070074	0.591	rs12001648	ENSG00000230074.1	RP11-195F19.9	-4.04	6.15e-05	0.00512	-0.37	-0.18	CTACK levels;	chr9:34585387	chr9:34665665~34681298:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000164669.11	INTS4P1	-4.04	6.15e-05	0.00512	-0.23	-0.18	Aortic root size;	chr7:65963835	chr7:65141225~65234216:+
THCA	cis	rs701145	0.585	rs4680125	ENSG00000243069.6	ARHGEF26-AS1	-4.04	6.15e-05	0.00513	-0.35	-0.18	Coronary artery disease;	chr3:154066909	chr3:154024401~154121332:-
THCA	cis	rs5771242	0.518	rs7290465	ENSG00000273137.1	RP3-402G11.28	4.04	6.15e-05	0.00513	0.14	0.18	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50241329	chr22:50208461~50209542:-
THCA	cis	rs1124769	0.748	rs35372376	ENSG00000259378.1	DCAF13P3	4.04	6.15e-05	0.00513	0.28	0.18	Cognitive performance;	chr15:51016774	chr15:50944663~50945996:+
THCA	cis	rs2281636	0.792	rs10883385	ENSG00000233690.1	EBAG9P1	4.04	6.15e-05	0.00513	0.17	0.18	Obesity-related traits;	chr10:99621956	chr10:99697407~99697949:-
THCA	cis	rs7838490	0.504	rs7834603	ENSG00000253553.4	RP11-586K2.1	4.04	6.15e-05	0.00513	0.19	0.18	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88521862	chr8:88326836~88737134:+
THCA	cis	rs1124769	0.523	rs1276855	ENSG00000273674.3	CTD-2378E12.1	-4.04	6.15e-05	0.00513	-0.25	-0.18	Cognitive performance;	chr15:50862083	chr15:50839875~50908599:-
THCA	cis	rs9467773	1	rs9467783	ENSG00000228223.2	HCG11	-4.04	6.15e-05	0.00513	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26523450~26526579:+
THCA	cis	rs6730558	0.899	rs13034698	ENSG00000236008.1	AC011747.4	4.04	6.15e-05	0.00513	0.21	0.18	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8602387	chr2:8559833~8583792:-
THCA	cis	rs61160187	0.788	rs12519587	ENSG00000272308.1	RP11-231G3.1	-4.04	6.15e-05	0.00513	-0.18	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60791073	chr5:60866457~60866935:-
THCA	cis	rs2239547	0.618	rs1573815	ENSG00000243224.1	RP5-1157M23.2	4.04	6.15e-05	0.00513	0.22	0.18	Schizophrenia;	chr3:52836116	chr3:52239258~52241097:+
THCA	cis	rs6500637	0.58	rs2660243	ENSG00000267077.1	RP11-127I20.5	-4.04	6.15e-05	0.00513	-0.22	-0.18	Cancer;	chr16:4891396	chr16:4795265~4796532:-
THCA	cis	rs4722166	0.532	rs1880242	ENSG00000225541.1	AC002480.5	4.04	6.16e-05	0.00513	0.2	0.18	Lung cancer;	chr7:22719988	chr7:22571607~22661792:-
THCA	cis	rs1577330	0.752	rs6475955	ENSG00000254396.1	RP11-56F10.3	4.04	6.16e-05	0.00513	0.22	0.18	IgG glycosylation;	chr9:27073847	chr9:27102630~27104728:+
THCA	cis	rs7923609	0.846	rs9787438	ENSG00000232075.1	MRPL35P2	-4.04	6.16e-05	0.00513	-0.24	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63278270	chr10:63634317~63634827:-
THCA	cis	rs2853333	0.6	rs916147	ENSG00000269553.1	U62631.5	-4.04	6.16e-05	0.00513	-0.2	-0.18	Red blood cell count;	chr19:35266347	chr19:35330843~35331920:+
THCA	cis	rs11168936	0.637	rs10875942	ENSG00000258017.1	RP11-386G11.10	4.04	6.16e-05	0.00513	0.25	0.18	Cancer (pleiotropy);	chr12:49277071	chr12:49127782~49147869:+
THCA	cis	rs465969	1	rs459048	ENSG00000272356.1	RP5-1112D6.8	4.04	6.16e-05	0.00513	0.28	0.18	Psoriasis;	chr6:111368429	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs479343	ENSG00000272356.1	RP5-1112D6.8	4.04	6.16e-05	0.00513	0.28	0.18	Psoriasis;	chr6:111369701	chr6:111309203~111313517:+
THCA	cis	rs465969	0.744	rs458017	ENSG00000272356.1	RP5-1112D6.8	4.04	6.16e-05	0.00513	0.28	0.18	Psoriasis;	chr6:111374888	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs13213522	ENSG00000272356.1	RP5-1112D6.8	4.04	6.16e-05	0.00513	0.28	0.18	Psoriasis;	chr6:111384138	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs17510761	ENSG00000272356.1	RP5-1112D6.8	4.04	6.16e-05	0.00513	0.28	0.18	Psoriasis;	chr6:111387380	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs17510733	ENSG00000272356.1	RP5-1112D6.8	4.04	6.16e-05	0.00513	0.28	0.18	Psoriasis;	chr6:111389715	chr6:111309203~111313517:+
THCA	cis	rs6479891	1	rs4746994	ENSG00000272767.1	JMJD1C-AS1	4.04	6.16e-05	0.00513	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12415984	ENSG00000272767.1	JMJD1C-AS1	4.04	6.16e-05	0.00513	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63465229~63466563:+
THCA	cis	rs35600665	0.527	rs35791112	ENSG00000260760.1	PWRN3	4.04	6.16e-05	0.00513	0.26	0.18	Obesity-related traits;	chr15:24500145	chr15:24441127~24447967:+
THCA	cis	rs1580019	0.844	rs1376290	ENSG00000231952.3	DPY19L1P2	-4.04	6.16e-05	0.00513	-0.24	-0.18	Cognitive ability;	chr7:32447310	chr7:32812757~32838570:+
THCA	cis	rs17221829	0.626	rs2931188	ENSG00000280385.1	AP000648.5	-4.04	6.16e-05	0.00513	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89622260	chr11:90193614~90198120:+
THCA	cis	rs4824093	0.61	rs28473584	ENSG00000278869.1	CITF22-49E9.3	4.04	6.16e-05	0.00513	0.39	0.18	Amyotrophic lateral sclerosis (sporadic);	chr22:49921765	chr22:49933198~49934074:-
THCA	cis	rs35146811	0.538	rs3823642	ENSG00000078319.8	PMS2P1	4.04	6.16e-05	0.00513	0.23	0.18	Coronary artery disease;	chr7:100198449	chr7:100320992~100341908:-
THCA	cis	rs10090774	0.67	rs13273943	ENSG00000280303.2	ERICD	-4.04	6.16e-05	0.00513	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140724786	chr8:140636281~140638283:+
THCA	cis	rs78487399	0.808	rs17031001	ENSG00000234936.1	AC010883.5	4.04	6.16e-05	0.00514	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534079	chr2:43229573~43233394:+
THCA	cis	rs6479891	1	rs12416113	ENSG00000272767.1	JMJD1C-AS1	4.04	6.16e-05	0.00514	0.25	0.18	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63465229~63466563:+
THCA	cis	rs7913069	1	rs7913069	ENSG00000260461.1	RP11-541N10.3	4.04	6.17e-05	0.00514	0.46	0.18	Uterine fibroids;	chr10:103954641	chr10:103877374~103879761:-
THCA	cis	rs3820928	0.709	rs10178202	ENSG00000212391.1	SNORA48	-4.04	6.17e-05	0.00514	-0.2	-0.18	Pulmonary function;	chr2:227049845	chr2:226968989~226969122:-
THCA	cis	rs7131987	0.903	rs7970390	ENSG00000275476.1	RP11-996F15.4	-4.04	6.17e-05	0.00514	-0.18	-0.18	QT interval;	chr12:29245722	chr12:29277397~29277882:-
THCA	cis	rs340849	1	rs340849	ENSG00000274895.1	RP11-478J18.2	4.04	6.17e-05	0.00514	0.15	0.18	Alzheimer's disease;	chr1:213944747	chr1:213983793~213986419:-
THCA	cis	rs340849	0.935	rs340847	ENSG00000274895.1	RP11-478J18.2	4.04	6.17e-05	0.00514	0.15	0.18	Alzheimer's disease;	chr1:213947603	chr1:213983793~213986419:-
THCA	cis	rs72928364	1	rs2713786	ENSG00000256628.3	ZBTB11-AS1	4.04	6.17e-05	0.00514	0.3	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100959676	chr3:101676475~101679217:+
THCA	cis	rs11089937	0.616	rs5995616	ENSG00000211639.2	IGLV4-60	-4.04	6.17e-05	0.00514	-0.13	-0.18	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22162199~22162681:+
THCA	cis	rs4705952	0.832	rs4546372	ENSG00000233006.5	AC034220.3	4.04	6.17e-05	0.00514	0.17	0.18	C-reactive protein levels;	chr5:132505617	chr5:132311285~132369916:-
THCA	cis	rs758324	0.687	rs154484	ENSG00000224431.1	AC063976.7	-4.04	6.17e-05	0.00514	-0.19	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132214749	chr5:132199456~132203487:+
THCA	cis	rs7829975	0.774	rs11775523	ENSG00000254340.1	RP11-10A14.3	4.04	6.17e-05	0.00514	0.2	0.18	Mood instability;	chr8:8821666	chr8:9141424~9145435:+
THCA	cis	rs929354	0.566	rs6979947	ENSG00000224629.1	RP5-1142J19.2	4.04	6.17e-05	0.00514	0.19	0.18	Body mass index;	chr7:157213169	chr7:157263022~157263229:-
THCA	cis	rs7142002	0.568	rs3783370	ENSG00000272444.1	RP11-1017G21.6	-4.04	6.17e-05	0.00514	-0.22	-0.18	Autism;	chr14:101919120	chr14:101952416~101953063:+
THCA	cis	rs9450351	0.744	rs7738777	ENSG00000203875.9	SNHG5	-4.04	6.17e-05	0.00514	-0.36	-0.18	Interferon gamma-induced protein 10 levels;	chr6:85923468	chr6:85660950~85678736:-
THCA	cis	rs9902453	0.817	rs4794861	ENSG00000263370.1	RP11-68I3.5	4.04	6.17e-05	0.00514	0.24	0.18	Coffee consumption (cups per day);	chr17:29856156	chr17:29639627~29640825:+
THCA	cis	rs2836974	0.897	rs34599551	ENSG00000255568.3	BRWD1-AS2	4.04	6.17e-05	0.00514	0.16	0.18	Cognitive function;	chr21:39222972	chr21:39313935~39314962:+
THCA	cis	rs13434995	0.513	rs1979604	ENSG00000249700.7	SRD5A3-AS1	4.04	6.17e-05	0.00514	0.26	0.18	Adiponectin levels;	chr4:55552588	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.537	rs4865012	ENSG00000249700.7	SRD5A3-AS1	4.04	6.17e-05	0.00514	0.26	0.18	Adiponectin levels;	chr4:55554619	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs6846764	ENSG00000249700.7	SRD5A3-AS1	4.04	6.17e-05	0.00514	0.26	0.18	Adiponectin levels;	chr4:55557322	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs6853506	ENSG00000249700.7	SRD5A3-AS1	4.04	6.17e-05	0.00514	0.26	0.18	Adiponectin levels;	chr4:55558207	chr4:55363971~55395847:-
THCA	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	4.04	6.17e-05	0.00514	0.22	0.18	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
THCA	cis	rs36093844	0.626	rs72959197	ENSG00000279742.1	RP11-700A24.1	-4.04	6.17e-05	0.00514	-0.25	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85999953	chr11:85852557~85854943:-
THCA	cis	rs3892630	0.878	rs8108621	ENSG00000267475.1	CTD-2538C1.2	-4.04	6.17e-05	0.00514	-0.26	-0.18	Red blood cell traits;	chr19:32692385	chr19:32687089~32691750:-
THCA	cis	rs7264396	0.943	rs1810741	ENSG00000088340.14	FER1L4	4.04	6.17e-05	0.00514	0.17	0.18	Total cholesterol levels;	chr20:35521887	chr20:35558737~35607562:-
THCA	cis	rs3748682	0.861	rs2291297	ENSG00000252448.1	SNORA63	-4.04	6.17e-05	0.00514	-0.23	-0.18	Hypothyroidism;	chr1:37806988	chr1:37884237~37884317:+
THCA	cis	rs74233809	0.901	rs12416331	ENSG00000272912.1	RP11-724N1.1	-4.04	6.17e-05	0.00514	-0.34	-0.18	Birth weight;	chr10:103169157	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs79237883	ENSG00000272912.1	RP11-724N1.1	-4.04	6.17e-05	0.00514	-0.34	-0.18	Birth weight;	chr10:103181189	chr10:102914585~102915404:+
THCA	cis	rs9341808	0.667	rs10943698	ENSG00000272129.1	RP11-250B2.6	4.04	6.18e-05	0.00514	0.23	0.18	Sitting height ratio;	chr6:80224584	chr6:80355424~80356859:+
THCA	cis	rs28735056	0.904	rs11665111	ENSG00000261126.6	RP11-795F19.1	4.04	6.18e-05	0.00514	0.15	0.18	Schizophrenia;	chr18:79862996	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.875	rs62103176	ENSG00000261126.6	RP11-795F19.1	4.04	6.18e-05	0.00514	0.15	0.18	Schizophrenia;	chr18:79863611	chr18:80046900~80095482:+
THCA	cis	rs7508	0.511	rs208026	ENSG00000253671.1	RP11-806O11.1	-4.04	6.18e-05	0.00514	-0.24	-0.18	Atrial fibrillation;	chr8:18020646	chr8:17808941~17820868:+
THCA	cis	rs17689437	1	rs56207945	ENSG00000260084.1	RP11-615I2.1	-4.04	6.18e-05	0.00514	-0.32	-0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68555509	chr16:68573782~68589512:-
THCA	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	4.04	6.18e-05	0.00514	0.22	0.18	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	4.04	6.18e-05	0.00514	0.22	0.18	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
THCA	cis	rs858239	0.699	rs858260	ENSG00000230042.1	AK3P3	-4.04	6.18e-05	0.00514	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23129178~23129841:+
THCA	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-4.04	6.18e-05	0.00514	-0.21	-0.18	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
THCA	cis	rs71520386	0.632	rs12532922	ENSG00000226329.2	AC005682.6	-4.04	6.18e-05	0.00515	-0.24	-0.18	Fibrinogen levels;	chr7:22820796	chr7:22863874~22881350:-
THCA	cis	rs71520386	0.632	rs10224533	ENSG00000226329.2	AC005682.6	-4.04	6.18e-05	0.00515	-0.24	-0.18	Fibrinogen levels;	chr7:22821522	chr7:22863874~22881350:-
THCA	cis	rs71520386	0.632	rs35353454	ENSG00000226329.2	AC005682.6	-4.04	6.18e-05	0.00515	-0.24	-0.18	Fibrinogen levels;	chr7:22822120	chr7:22863874~22881350:-
THCA	cis	rs357618	0.897	rs357630	ENSG00000260581.1	CTB-113P19.4	4.04	6.18e-05	0.00515	0.24	0.18	Basophil percentage of white cells;	chr5:151471697	chr5:151652275~151655449:+
THCA	cis	rs11633886	0.806	rs2037050	ENSG00000259200.1	RP11-718O11.1	-4.04	6.18e-05	0.00515	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45763839	chr15:45705078~45931069:+
THCA	cis	rs4834770	1	rs878374	ENSG00000260091.1	RP11-33B1.4	-4.04	6.18e-05	0.00515	-0.13	-0.18	Blood protein levels;	chr4:119316409	chr4:119409333~119410233:+
THCA	cis	rs7294478	0.648	rs2290237	ENSG00000256967.1	RP11-273B20.1	4.04	6.18e-05	0.00515	0.14	0.18	Neuritic plaque;	chr12:7124640	chr12:7129079~7131198:-
THCA	cis	rs12497850	0.931	rs11920534	ENSG00000228638.1	FCF1P2	-4.04	6.18e-05	0.00515	-0.2	-0.18	Parkinson's disease;	chr3:48900328	chr3:48290793~48291375:-
THCA	cis	rs1048886	0.938	rs2273210	ENSG00000271967.1	RP11-134K13.4	-4.04	6.18e-05	0.00515	-0.19	-0.18	Type 2 diabetes;	chr6:70480874	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs6913548	ENSG00000271967.1	RP11-134K13.4	-4.04	6.18e-05	0.00515	-0.19	-0.18	Type 2 diabetes;	chr6:70519167	chr6:70596438~70596980:+
THCA	cis	rs607541	0.85	rs12594997	ENSG00000259520.4	CTD-2651B20.3	-4.04	6.18e-05	0.00515	-0.36	-0.18	Obesity-related traits;	chr15:45637226	chr15:45251580~45279251:-
THCA	cis	rs10266483	0.739	rs2692099	ENSG00000234338.1	RP11-797H7.1	4.04	6.18e-05	0.00515	0.13	0.18	Response to statin therapy;	chr7:64307384	chr7:64835280~64836882:-
THCA	cis	rs1964356	0.967	rs17701675	ENSG00000233609.3	RP11-62H7.2	-4.04	6.18e-05	0.00515	-0.17	-0.18	Mean corpuscular volume;	chr8:8993123	chr8:8961200~8979025:+
THCA	cis	rs2334880	0.587	rs8058188	ENSG00000260886.1	TAT-AS1	4.04	6.18e-05	0.00515	0.25	0.18	Malaria;	chr16:71641233	chr16:71565789~71578187:+
THCA	cis	rs4742903	0.935	rs9942894	ENSG00000270332.1	SMC2-AS1	4.04	6.18e-05	0.00515	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104152624	chr9:104080024~104093073:-
THCA	cis	rs1560104	0.709	rs3919630	ENSG00000262801.4	U91319.1	4.04	6.18e-05	0.00515	0.21	0.18	Obesity-related traits;	chr16:12607086	chr16:13246316~13562918:+
THCA	cis	rs7045881	0.877	rs17840677	ENSG00000254396.1	RP11-56F10.3	4.04	6.18e-05	0.00515	0.28	0.18	Schizophrenia;	chr9:26777706	chr9:27102630~27104728:+
THCA	cis	rs1048886	0.938	rs2295200	ENSG00000271967.1	RP11-134K13.4	-4.04	6.19e-05	0.00515	-0.2	-0.18	Type 2 diabetes;	chr6:70523848	chr6:70596438~70596980:+
THCA	cis	rs7737355	0.947	rs10073137	ENSG00000237714.1	P4HA2-AS1	4.04	6.19e-05	0.00515	0.26	0.18	Life satisfaction;	chr5:131755396	chr5:132184876~132192808:+
THCA	cis	rs9595908	0.746	rs17516171	ENSG00000212293.1	SNORA16	4.04	6.19e-05	0.00515	0.22	0.18	Body mass index;	chr13:32694914	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.746	rs3848087	ENSG00000212293.1	SNORA16	4.04	6.19e-05	0.00515	0.22	0.18	Body mass index;	chr13:32697637	chr13:32420390~32420516:-
THCA	cis	rs7737355	0.898	rs32109	ENSG00000237714.1	P4HA2-AS1	4.04	6.19e-05	0.00515	0.26	0.18	Life satisfaction;	chr5:131705897	chr5:132184876~132192808:+
THCA	cis	rs8030379	0.519	rs11259926	ENSG00000259728.4	LINC00933	4.04	6.19e-05	0.00515	0.24	0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897496	chr15:84570649~84580175:+
THCA	cis	rs654950	0.875	rs2759248	ENSG00000230638.4	RP11-486B10.4	4.04	6.19e-05	0.00515	0.2	0.18	Airway imaging phenotypes;	chr1:41525124	chr1:41542069~41544310:+
THCA	cis	rs9863	0.896	rs34854841	ENSG00000270061.1	RP11-214K3.19	-4.04	6.19e-05	0.00515	-0.25	-0.18	White blood cell count;	chr12:123966957	chr12:123969990~123970344:-
THCA	cis	rs2836974	0.863	rs8128026	ENSG00000255568.3	BRWD1-AS2	4.04	6.19e-05	0.00515	0.16	0.18	Cognitive function;	chr21:39161776	chr21:39313935~39314962:+
THCA	cis	rs12887734	0.524	rs4906364	ENSG00000269940.1	RP11-73M18.7	4.04	6.19e-05	0.00516	0.19	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103694560~103695170:+
THCA	cis	rs1371614	0.632	rs6547318	ENSG00000229122.1	AGBL5-IT1	4.04	6.19e-05	0.00516	0.13	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26930613	chr2:27061038~27061815:+
THCA	cis	rs10090774	0.965	rs7005909	ENSG00000279766.1	RP11-642A1.2	4.04	6.19e-05	0.00516	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140973600	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.83	rs2369409	ENSG00000279766.1	RP11-642A1.2	4.04	6.19e-05	0.00516	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140979771	chr8:140572142~140572812:-
THCA	cis	rs4834770	1	rs4336213	ENSG00000249244.1	RP11-548H18.2	4.04	6.19e-05	0.00516	0.2	0.18	Blood protein levels;	chr4:119315314	chr4:119391831~119395335:-
THCA	cis	rs6067053	0.533	rs6067019	ENSG00000230758.1	SNAP23P	4.04	6.19e-05	0.00516	0.23	0.18	Intelligence (multi-trait analysis);	chr20:49211989	chr20:49038357~49038602:-
THCA	cis	rs8062405	0.964	rs78613234	ENSG00000270424.1	RP11-1348G14.6	4.04	6.19e-05	0.00516	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62036624	ENSG00000270424.1	RP11-1348G14.6	4.04	6.19e-05	0.00516	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28749959~28750595:-
THCA	cis	rs459571	0.959	rs465724	ENSG00000235106.7	LINC00094	4.04	6.2e-05	0.00516	0.16	0.18	Platelet distribution width;	chr9:134044975	chr9:134025439~134034666:+
THCA	cis	rs890448	0.802	rs6847576	ENSG00000254531.1	FLJ20021	-4.04	6.2e-05	0.00516	-0.17	-0.18	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101512473	chr4:101347780~101348883:+
THCA	cis	rs890448	0.802	rs6847253	ENSG00000254531.1	FLJ20021	-4.04	6.2e-05	0.00516	-0.17	-0.18	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101512517	chr4:101347780~101348883:+
THCA	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	4.04	6.2e-05	0.00516	0.24	0.18	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
THCA	cis	rs9300255	0.51	rs1790086	ENSG00000235423.7	RP11-282O18.3	4.04	6.2e-05	0.00516	0.2	0.18	Neutrophil percentage of white cells;	chr12:123187971	chr12:123252030~123261483:-
THCA	cis	rs9341808	0.667	rs7746917	ENSG00000272129.1	RP11-250B2.6	4.04	6.2e-05	0.00516	0.23	0.18	Sitting height ratio;	chr6:80221786	chr6:80355424~80356859:+
THCA	cis	rs6500637	0.57	rs1049205	ENSG00000267077.1	RP11-127I20.5	-4.04	6.2e-05	0.00516	-0.21	-0.18	Cancer;	chr16:4892098	chr16:4795265~4796532:-
THCA	cis	rs9435732	0.832	rs7531163	ENSG00000186301.8	MST1P2	-4.04	6.2e-05	0.00516	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16986959	chr1:16645622~16650289:+
THCA	cis	rs9435732	0.524	rs9435660	ENSG00000186301.8	MST1P2	-4.04	6.2e-05	0.00516	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16987578	chr1:16645622~16650289:+
THCA	cis	rs4908768	0.906	rs2144463	ENSG00000232912.4	RP5-1115A15.1	-4.04	6.2e-05	0.00516	-0.22	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8523234	chr1:8424645~8434838:+
THCA	cis	rs4908768	0.906	rs12145445	ENSG00000232912.4	RP5-1115A15.1	-4.04	6.2e-05	0.00516	-0.22	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8544311	chr1:8424645~8434838:+
THCA	cis	rs4908760	0.899	rs61783642	ENSG00000270282.1	RP5-1115A15.2	4.04	6.2e-05	0.00516	0.21	0.18	Vitiligo;	chr1:8531338	chr1:8512653~8513021:+
THCA	cis	rs4272720	0.666	rs35341824	ENSG00000234736.4	FAM170B-AS1	-4.04	6.2e-05	0.00516	-0.2	-0.18	Platelet count;Plateletcrit;	chr10:49075199	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.639	rs4400713	ENSG00000234736.4	FAM170B-AS1	-4.04	6.2e-05	0.00516	-0.2	-0.18	Platelet count;Plateletcrit;	chr10:49075862	chr10:49121839~49151547:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000229886.1	RP5-1132H15.3	-4.04	6.2e-05	0.00516	-0.2	-0.18	Aortic root size;	chr7:66597493	chr7:66025126~66031544:-
THCA	cis	rs4950322	0.58	rs2014106	ENSG00000226015.2	CCT8P1	4.04	6.2e-05	0.00516	0.21	0.18	Protein quantitative trait loci;	chr1:147118499	chr1:147203276~147204932:-
THCA	cis	rs757110	0.803	rs7928810	ENSG00000260196.1	RP1-239B22.5	4.04	6.2e-05	0.00516	0.2	0.18	Type 2 diabetes;	chr11:17350896	chr11:17380649~17383531:+
THCA	cis	rs3105593	0.933	rs7175532	ENSG00000242737.1	RP11-562A8.1	4.04	6.2e-05	0.00516	0.23	0.18	QT interval;	chr15:50537846	chr15:50466738~50467096:+
THCA	cis	rs12134133	1	rs2782846	ENSG00000237074.1	RP11-6J21.2	4.04	6.2e-05	0.00516	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207249067~207309121:+
THCA	cis	rs7267979	1	rs6138572	ENSG00000276952.1	RP5-965G21.6	4.04	6.2e-05	0.00516	0.2	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6138575	ENSG00000276952.1	RP5-965G21.6	4.04	6.2e-05	0.00516	0.2	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs11087521	ENSG00000276952.1	RP5-965G21.6	4.04	6.2e-05	0.00516	0.2	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25284915~25285588:-
THCA	cis	rs10540	1	rs61876339	ENSG00000279672.1	CMB9-55F22.1	4.04	6.2e-05	0.00516	0.36	0.18	Body mass index;	chr11:495283	chr11:779617~780755:+
THCA	cis	rs854765	0.618	rs9908017	ENSG00000281749.1	Y_RNA	-4.04	6.2e-05	0.00516	-0.23	-0.18	Total body bone mineral density;	chr17:17871108	chr17:18001101~18001195:-
THCA	cis	rs9450351	0.744	rs9450317	ENSG00000203875.9	SNHG5	-4.04	6.2e-05	0.00516	-0.36	-0.18	Interferon gamma-induced protein 10 levels;	chr6:85715052	chr6:85660950~85678736:-
THCA	cis	rs6942407	0.546	rs10952896	ENSG00000224046.1	AC005076.5	-4.04	6.2e-05	0.00516	-0.18	-0.18	Food allergy;	chr7:87136447	chr7:87151423~87152420:-
THCA	cis	rs2281603	0.521	rs10142879	ENSG00000272909.1	CTD-2555O16.4	-4.04	6.2e-05	0.00516	-0.22	-0.18	Lymphocyte counts;	chr14:64499124	chr14:64440369~64442238:-
THCA	cis	rs7432375	1	rs10935186	ENSG00000273455.1	RP11-305O4.3	4.04	6.2e-05	0.00516	0.24	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136627364	chr3:136087475~136087913:-
THCA	cis	rs11971779	0.68	rs2355786	ENSG00000252332.1	RNU6-911P	4.04	6.2e-05	0.00516	0.21	0.18	Diisocyanate-induced asthma;	chr7:139380876	chr7:139448740~139448843:+
THCA	cis	rs9863	0.861	rs11057397	ENSG00000269938.1	RP11-214K3.20	-4.04	6.2e-05	0.00517	-0.22	-0.18	White blood cell count;	chr12:123935181	chr12:123968023~123968579:-
THCA	cis	rs868036	0.645	rs28539889	ENSG00000270964.1	RP11-502I4.3	-4.04	6.21e-05	0.00517	-0.17	-0.18	Restless legs syndrome;	chr15:67829090	chr15:67541072~67542604:-
THCA	cis	rs4713118	0.581	rs200504	ENSG00000226314.6	ZNF192P1	-4.04	6.21e-05	0.00517	-0.25	-0.18	Parkinson's disease;	chr6:27818042	chr6:28161781~28169594:+
THCA	cis	rs5753037	0.838	rs5752975	ENSG00000279699.1	RP1-102K2.9	4.04	6.21e-05	0.00517	0.18	0.18	Type 1 diabetes;	chr22:29878346	chr22:30275215~30276951:-
THCA	cis	rs701145	0.585	rs1727958	ENSG00000243069.6	ARHGEF26-AS1	4.04	6.21e-05	0.00517	0.35	0.18	Coronary artery disease;	chr3:154107011	chr3:154024401~154121332:-
THCA	cis	rs7826238	0.566	rs2945886	ENSG00000233609.3	RP11-62H7.2	4.04	6.21e-05	0.00517	0.18	0.18	Systolic blood pressure;	chr8:8290748	chr8:8961200~8979025:+
THCA	cis	rs7554547	0.622	rs28455075	ENSG00000199347.1	RNU5E-1	-4.04	6.21e-05	0.00517	-0.27	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11879663	chr1:11908152~11908271:+
THCA	cis	rs2562456	0.755	rs11670868	ENSG00000268278.1	RP11-420K14.1	4.04	6.21e-05	0.00517	0.26	0.18	Pain;	chr19:21373613	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs55961038	ENSG00000268278.1	RP11-420K14.1	4.04	6.21e-05	0.00517	0.26	0.18	Pain;	chr19:21375205	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs2358993	ENSG00000268278.1	RP11-420K14.1	4.04	6.21e-05	0.00517	0.26	0.18	Pain;	chr19:21375367	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs11672583	ENSG00000268278.1	RP11-420K14.1	4.04	6.21e-05	0.00517	0.26	0.18	Pain;	chr19:21379363	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs17680605	ENSG00000268278.1	RP11-420K14.1	4.04	6.21e-05	0.00517	0.26	0.18	Pain;	chr19:21379646	chr19:21637974~21656300:+
THCA	cis	rs8062405	0.755	rs12447461	ENSG00000270424.1	RP11-1348G14.6	4.04	6.21e-05	0.00517	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28749959~28750595:-
THCA	cis	rs9532669	0.963	rs9532681	ENSG00000229473.2	RGS17P1	4.04	6.21e-05	0.00517	0.23	0.18	Cervical cancer;	chr13:40951633	chr13:40992779~40993331:-
THCA	cis	rs9928842	1	rs7202566	ENSG00000261783.1	RP11-252K23.2	4.04	6.21e-05	0.00517	0.34	0.18	Alcoholic chronic pancreatitis;	chr16:75213746	chr16:75379818~75381260:-
THCA	cis	rs7621025	0.554	rs1471740	ENSG00000239213.4	NCK1-AS1	4.04	6.21e-05	0.00517	0.17	0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136609428	chr3:136841726~136862054:-
THCA	cis	rs4742903	0.967	rs10820599	ENSG00000270332.1	SMC2-AS1	4.04	6.21e-05	0.00517	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104094410	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.967	rs10820600	ENSG00000270332.1	SMC2-AS1	4.04	6.21e-05	0.00517	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104094411	chr9:104080024~104093073:-
THCA	cis	rs41342147	0.591	rs11554054	ENSG00000223374.1	AC005104.3	4.04	6.21e-05	0.00517	0.16	0.18	Vitiligo;	chr2:241315452	chr2:241351340~241353104:-
THCA	cis	rs11971779	0.941	rs1127424	ENSG00000252332.1	RNU6-911P	-4.04	6.21e-05	0.00517	-0.23	-0.18	Diisocyanate-induced asthma;	chr7:139422914	chr7:139448740~139448843:+
THCA	cis	rs7259376	0.936	rs12151261	ENSG00000269138.1	ZNF209P	-4.04	6.21e-05	0.00517	-0.18	-0.18	Menopause (age at onset);	chr19:22405127	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs8111665	ENSG00000269138.1	ZNF209P	-4.04	6.21e-05	0.00517	-0.18	-0.18	Menopause (age at onset);	chr19:22405757	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs7247220	ENSG00000269138.1	ZNF209P	-4.04	6.21e-05	0.00517	-0.18	-0.18	Menopause (age at onset);	chr19:22406687	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs12983542	ENSG00000269138.1	ZNF209P	-4.04	6.21e-05	0.00517	-0.18	-0.18	Menopause (age at onset);	chr19:22407783	chr19:22463922~22473036:+
THCA	cis	rs3177980	0.918	rs10800473	ENSG00000239494.2	RN7SL333P	-4.04	6.21e-05	0.00517	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:169756891	chr1:169859756~169860052:+
THCA	cis	rs28829049	0.861	rs28631243	ENSG00000270728.1	RP4-657E11.10	-4.04	6.21e-05	0.00517	-0.13	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19023589	chr1:19297080~19297903:+
THCA	cis	rs1124769	0.57	rs1276856	ENSG00000273674.3	CTD-2378E12.1	-4.04	6.21e-05	0.00517	-0.24	-0.18	Cognitive performance;	chr15:50863689	chr15:50839875~50908599:-
THCA	cis	rs4908768	0.501	rs6577494	ENSG00000270282.1	RP5-1115A15.2	4.04	6.21e-05	0.00517	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8512653~8513021:+
THCA	cis	rs3824488	0.705	rs16909975	ENSG00000271155.1	RP11-435O5.5	-4.04	6.21e-05	0.00517	-0.3	-0.18	Neuroticism;	chr9:95544847	chr9:95506235~95507636:+
THCA	cis	rs8177876	0.822	rs7203546	ENSG00000261061.1	RP11-303E16.2	4.04	6.21e-05	0.00517	0.24	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81030770~81031485:+
THCA	cis	rs12612619	0.732	rs6716275	ENSG00000272148.1	RP11-195B17.1	-4.04	6.21e-05	0.00517	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004839	chr2:27062428~27062907:-
THCA	cis	rs1129187	0.935	rs9986447	ENSG00000272223.1	RP1-20C7.6	-4.04	6.21e-05	0.00517	-0.14	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr6:42975041	chr6:43033897~43034405:-
THCA	cis	rs2777491	1	rs11631770	ENSG00000247556.5	OIP5-AS1	4.04	6.22e-05	0.00517	0.15	0.18	Ulcerative colitis;	chr15:41444861	chr15:41283990~41309737:+
THCA	cis	rs7711186	0.656	rs73804422	ENSG00000252464.1	RN7SKP70	4.04	6.22e-05	0.00517	0.22	0.18	Urate levels in obese individuals;	chr5:178657323	chr5:178619728~178619998:-
THCA	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	4.04	6.22e-05	0.00517	0.17	0.18	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
THCA	cis	rs35740288	1	rs11637212	ENSG00000259295.5	CSPG4P12	-4.04	6.22e-05	0.00517	-0.28	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85749866	chr15:85191438~85213905:+
THCA	cis	rs11694172	0.908	rs12464670	ENSG00000273456.1	RP11-686O6.2	4.04	6.22e-05	0.00517	0.17	0.18	Cholesterol, total;	chr2:202708432	chr2:202374932~202375604:-
THCA	cis	rs950169	0.922	rs17531523	ENSG00000188388.10	GOLGA6L3	4.04	6.22e-05	0.00517	0.25	0.18	Schizophrenia;	chr15:84589218	chr15:85240472~85247170:+
THCA	cis	rs1232027	0.656	rs1650672	ENSG00000249655.1	CTC-325J23.2	4.04	6.22e-05	0.00518	0.21	0.18	Huntington's disease progression;	chr5:80663915	chr5:80630313~80631590:-
THCA	cis	rs10861661	0.963	rs11113118	ENSG00000260329.1	RP11-412D9.4	-4.04	6.22e-05	0.00518	-0.19	-0.18	Triglyceride levels;	chr12:106805364	chr12:106954029~106955497:-
THCA	cis	rs1560104	0.675	rs9937086	ENSG00000259876.1	CTD-3037G24.4	4.04	6.22e-05	0.00518	0.21	0.18	Obesity-related traits;	chr16:12611090	chr16:12556353~12557694:-
THCA	cis	rs10875746	0.669	rs9634261	ENSG00000226413.2	OR8T1P	4.04	6.22e-05	0.00518	0.25	0.18	Longevity (90 years and older);	chr12:48293088	chr12:48442030~48442947:-
THCA	cis	rs17666538	0.585	rs336437	ENSG00000254207.1	RP11-43A14.1	4.04	6.22e-05	0.00518	0.36	0.18	IgG glycosylation;	chr8:686251	chr8:725188~725877:-
THCA	cis	rs13434995	0.562	rs73236140	ENSG00000249700.7	SRD5A3-AS1	-4.04	6.22e-05	0.00518	-0.26	-0.18	Adiponectin levels;	chr4:55440049	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62303691	ENSG00000249700.7	SRD5A3-AS1	-4.04	6.22e-05	0.00518	-0.26	-0.18	Adiponectin levels;	chr4:55442085	chr4:55363971~55395847:-
THCA	cis	rs795484	0.926	rs353888	ENSG00000275409.1	RP11-131L12.4	-4.04	6.22e-05	0.00518	-0.15	-0.18	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118212556	chr12:118430147~118430699:+
THCA	cis	rs2364403	1	rs12091273	ENSG00000236675.1	MTX1P1	-4.04	6.22e-05	0.00518	-0.2	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:155959771	chr1:155230975~155234325:+
THCA	cis	rs1538970	0.924	rs12046816	ENSG00000234329.1	RP11-767N6.2	4.04	6.22e-05	0.00518	0.18	0.18	Platelet count;	chr1:45425871	chr1:45651039~45651826:-
THCA	cis	rs9863	0.861	rs11835839	ENSG00000270061.1	RP11-214K3.19	-4.04	6.22e-05	0.00518	-0.24	-0.18	White blood cell count;	chr12:123946502	chr12:123969990~123970344:-
THCA	cis	rs7824557	0.603	rs2736278	ENSG00000154316.13	TDH	-4.04	6.22e-05	0.00518	-0.14	-0.18	Retinal vascular caliber;	chr8:11362272	chr8:11339637~11368452:+
THCA	cis	rs11673344	0.542	rs826325	ENSG00000267260.1	CTD-2162K18.4	-4.04	6.22e-05	0.00518	-0.22	-0.18	Obesity-related traits;	chr19:37003580	chr19:36773153~36777078:+
THCA	cis	rs1577330	0.898	rs640282	ENSG00000254396.1	RP11-56F10.3	4.04	6.23e-05	0.00518	0.22	0.18	IgG glycosylation;	chr9:27097032	chr9:27102630~27104728:+
THCA	cis	rs8062405	1	rs62036617	ENSG00000270424.1	RP11-1348G14.6	4.04	6.23e-05	0.00518	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs4788095	ENSG00000270424.1	RP11-1348G14.6	4.04	6.23e-05	0.00518	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.964	rs72793809	ENSG00000270424.1	RP11-1348G14.6	4.04	6.23e-05	0.00518	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62036620	ENSG00000270424.1	RP11-1348G14.6	4.04	6.23e-05	0.00518	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62036621	ENSG00000270424.1	RP11-1348G14.6	4.04	6.23e-05	0.00518	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28749959~28750595:-
THCA	cis	rs9309473	0.519	rs2421586	ENSG00000273245.1	RP11-434P11.2	-4.04	6.23e-05	0.00518	-0.22	-0.18	Metabolite levels;	chr2:73672592	chr2:73750256~73750786:-
THCA	cis	rs16975963	0.79	rs11083434	ENSG00000226686.6	LINC01535	-4.04	6.23e-05	0.00518	-0.25	-0.18	Longevity;	chr19:37793313	chr19:37251912~37265535:+
THCA	cis	rs12544026	0.644	rs2155938	ENSG00000253669.3	KB-1732A1.1	-4.04	6.23e-05	0.00518	-0.21	-0.18	Major depression and alcohol dependence;	chr8:101835034	chr8:102805517~102809971:+
THCA	cis	rs5753037	0.702	rs131301	ENSG00000279699.1	RP1-102K2.9	4.04	6.23e-05	0.00518	0.17	0.18	Type 1 diabetes;	chr22:29789900	chr22:30275215~30276951:-
THCA	cis	rs6453278	0.559	rs13183218	ENSG00000250802.5	ZBED3-AS1	-4.04	6.23e-05	0.00518	-0.18	-0.18	Autism;	chr5:77098982	chr5:77086740~77166909:+
THCA	cis	rs13083990	0.959	rs10934583	ENSG00000272758.4	RP11-299J3.8	4.04	6.23e-05	0.00518	0.18	0.18	Cardiac Troponin-T levels;	chr3:122294557	chr3:122416207~122443180:+
THCA	cis	rs1538970	0.924	rs1826691	ENSG00000234329.1	RP11-767N6.2	-4.04	6.23e-05	0.00518	-0.18	-0.18	Platelet count;	chr1:45415590	chr1:45651039~45651826:-
THCA	cis	rs16975963	0.644	rs59426132	ENSG00000276846.1	CTD-3220F14.3	-4.04	6.23e-05	0.00518	-0.17	-0.18	Longevity;	chr19:37601869	chr19:37314868~37315620:-
THCA	cis	rs4767841	0.565	rs4462403	ENSG00000252886.1	RN7SKP197	-4.04	6.23e-05	0.00519	-0.18	-0.18	Urgency urinary incontinence;	chr12:119773788	chr12:119631090~119631386:-
THCA	cis	rs6449502	0.92	rs295565	ENSG00000251279.1	CTC-436P18.1	4.04	6.23e-05	0.00519	0.32	0.18	Mean platelet volume;	chr5:61102330	chr5:61162070~61232040:+
THCA	cis	rs9510787	0.543	rs3794348	ENSG00000205861.10	C1QTNF9B-AS1	-4.04	6.23e-05	0.00519	-0.24	-0.18	Nasopharyngeal carcinoma;	chr13:23638815	chr13:23888889~23897263:+
THCA	cis	rs2408955	0.521	rs10875753	ENSG00000273765.1	RP11-370I10.11	4.04	6.23e-05	0.00519	0.18	0.18	Glycated hemoglobin levels;	chr12:48163358	chr12:48360920~48361377:+
THCA	cis	rs801193	1	rs3778909	ENSG00000229180.5	GS1-124K5.11	4.04	6.24e-05	0.00519	0.13	0.18	Aortic root size;	chr7:66790659	chr7:66526088~66542624:-
THCA	cis	rs10484434	0.792	rs11961143	ENSG00000272810.1	U91328.22	4.04	6.24e-05	0.00519	0.18	0.18	HIV-1 viral setpoint;	chr6:26032645	chr6:26013241~26013757:+
THCA	cis	rs9863	0.931	rs11057407	ENSG00000270061.1	RP11-214K3.19	-4.04	6.24e-05	0.00519	-0.25	-0.18	White blood cell count;	chr12:123965282	chr12:123969990~123970344:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000265443.1	CTD-2349P21.6	-4.04	6.24e-05	0.00519	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000265443.1	CTD-2349P21.6	-4.04	6.24e-05	0.00519	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30726305~30727564:-
THCA	cis	rs867186	1	rs58088385	ENSG00000126005.14	MMP24-AS1	-4.04	6.24e-05	0.00519	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35160426	chr20:35216462~35278131:-
THCA	cis	rs4718428	1	rs4718421	ENSG00000237310.1	GS1-124K5.4	4.04	6.24e-05	0.00519	0.14	0.18	Corneal structure;	chr7:66885313	chr7:66493706~66495474:+
THCA	cis	rs4664293	0.801	rs7590595	ENSG00000230783.1	AC009961.2	-4.04	6.24e-05	0.00519	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159715198	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.801	rs6432552	ENSG00000230783.1	AC009961.2	-4.04	6.24e-05	0.00519	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159717613	chr2:159689217~159690291:-
THCA	cis	rs9810089	0.814	rs864437	ENSG00000273455.1	RP11-305O4.3	4.04	6.24e-05	0.00519	0.24	0.18	Gestational age at birth (child effect);	chr3:136401067	chr3:136087475~136087913:-
THCA	cis	rs7178375	1	rs4779797	ENSG00000269930.1	RP11-932O9.9	4.04	6.24e-05	0.00519	0.24	0.18	Hypertriglyceridemia;	chr15:30916222	chr15:30616958~30617749:+
THCA	cis	rs7560272	0.538	rs4852977	ENSG00000163016.8	ALMS1P	-4.04	6.24e-05	0.00519	-0.23	-0.18	Schizophrenia;	chr2:73711168	chr2:73644919~73685576:+
THCA	cis	rs5758659	0.652	rs5751195	ENSG00000281538.1	RP4-669P10.20	4.04	6.24e-05	0.00519	0.17	0.18	Cognitive function;	chr22:41983997	chr22:42138060~42139726:+
THCA	cis	rs9595908	0.606	rs4942925	ENSG00000212293.1	SNORA16	4.04	6.24e-05	0.00519	0.22	0.18	Body mass index;	chr13:32807106	chr13:32420390~32420516:-
THCA	cis	rs11971779	0.646	rs58682779	ENSG00000252332.1	RNU6-911P	-4.04	6.24e-05	0.00519	-0.23	-0.18	Diisocyanate-induced asthma;	chr7:139399966	chr7:139448740~139448843:+
THCA	cis	rs901683	1	rs9422657	ENSG00000230869.1	CTGLF10P	-4.04	6.24e-05	0.00519	-0.44	-0.18	Mean corpuscular volume;Red blood cell traits;	chr10:45557613	chr10:45678692~45700532:+
THCA	cis	rs4879656	0.8	rs10971379	ENSG00000225693.1	LAGE3P1	-4.04	6.24e-05	0.00519	-0.19	-0.18	Menopause (age at onset);	chr9:33064932	chr9:33019682~33020165:-
THCA	cis	rs35146811	0.731	rs2257213	ENSG00000078319.8	PMS2P1	-4.04	6.24e-05	0.00519	-0.23	-0.18	Coronary artery disease;	chr7:100212490	chr7:100320992~100341908:-
THCA	cis	rs11976180	1	rs2961134	ENSG00000244198.4	RP4-545C24.1	-4.04	6.24e-05	0.00519	-0.18	-0.18	Obesity-related traits;	chr7:144073969	chr7:144194858~144280547:+
THCA	cis	rs301901	0.897	rs12657771	ENSG00000250155.1	CTD-2353F22.1	-4.04	6.24e-05	0.00519	-0.19	-0.18	Height;	chr5:36787860	chr5:36666214~36725195:-
THCA	cis	rs7200543	0.666	rs34955778	ENSG00000188599.16	NPIPP1	-4.04	6.24e-05	0.00519	-0.13	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15045737	chr16:15104312~15123498:-
THCA	cis	rs72928364	0.932	rs2245473	ENSG00000256628.3	ZBTB11-AS1	-4.04	6.25e-05	0.00519	-0.3	-0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100897292	chr3:101676475~101679217:+
THCA	cis	rs793571	0.65	rs12899638	ENSG00000245975.2	RP11-30K9.6	4.04	6.25e-05	0.00519	0.17	0.18	Schizophrenia;	chr15:58628076	chr15:58768072~58770974:-
THCA	cis	rs589448	0.902	rs315124	ENSG00000274979.1	RP11-1143G9.5	-4.04	6.25e-05	0.00519	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69377947	chr12:69326574~69331882:-
THCA	cis	rs9650657	0.53	rs6982381	ENSG00000254948.1	OR7E158P	4.04	6.25e-05	0.00519	0.23	0.18	Neuroticism;	chr8:11094990	chr8:11919900~11920809:-
THCA	cis	rs11694172	0.955	rs56074256	ENSG00000273456.1	RP11-686O6.2	4.04	6.25e-05	0.0052	0.17	0.18	Cholesterol, total;	chr2:202710383	chr2:202374932~202375604:-
THCA	cis	rs6012564	0.928	rs6095396	ENSG00000230758.1	SNAP23P	-4.04	6.25e-05	0.0052	-0.22	-0.18	Anger;	chr20:49010633	chr20:49038357~49038602:-
THCA	cis	rs786425	0.77	rs7134074	ENSG00000278112.1	RP11-972P1.11	4.04	6.25e-05	0.0052	0.18	0.18	Pubertal anthropometrics;	chr12:123675338	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs35158437	ENSG00000278112.1	RP11-972P1.11	4.04	6.25e-05	0.0052	0.18	0.18	Pubertal anthropometrics;	chr12:123676217	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs7313261	ENSG00000278112.1	RP11-972P1.11	4.04	6.25e-05	0.0052	0.18	0.18	Pubertal anthropometrics;	chr12:123682390	chr12:123519390~123519856:-
THCA	cis	rs589448	0.872	rs315111	ENSG00000274979.1	RP11-1143G9.5	-4.04	6.25e-05	0.0052	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69390915	chr12:69326574~69331882:-
THCA	cis	rs801193	1	rs2420824	ENSG00000223473.2	GS1-124K5.3	-4.04	6.25e-05	0.0052	-0.12	-0.18	Aortic root size;	chr7:66666129	chr7:66491049~66493566:-
THCA	cis	rs481331	0.866	rs209391	ENSG00000215146.4	RP11-313J2.1	-4.04	6.25e-05	0.0052	-0.34	-0.18	Systemic juvenile idiopathic arthritis;	chr10:42632947	chr10:42331866~42367974:-
THCA	cis	rs16852403	0.583	rs10494510	ENSG00000224687.1	RASAL2-AS1	4.04	6.25e-05	0.0052	0.3	0.18	Childhood ear infection;	chr1:178105446	chr1:178091508~178093984:-
THCA	cis	rs5758659	0.622	rs6519298	ENSG00000205702.9	CYP2D7	4.04	6.25e-05	0.0052	0.14	0.18	Cognitive function;	chr22:41968993	chr22:42140203~42144577:-
THCA	cis	rs2281636	0.754	rs4919364	ENSG00000233690.1	EBAG9P1	4.04	6.25e-05	0.0052	0.18	0.18	Obesity-related traits;	chr10:99604947	chr10:99697407~99697949:-
THCA	cis	rs6939532	0.522	rs6933583	ENSG00000124549.13	BTN2A3P	-4.04	6.25e-05	0.0052	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26355055	chr6:26421391~26432383:+
THCA	cis	rs6860806	0.507	rs2631372	ENSG00000224431.1	AC063976.7	4.04	6.25e-05	0.0052	0.16	0.18	Breast cancer;	chr5:132367886	chr5:132199456~132203487:+
THCA	cis	rs7616559	0.849	rs6441108	ENSG00000244515.1	KRT18P34	-4.04	6.25e-05	0.0052	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157054154	chr3:157162663~157163932:-
THCA	cis	rs589448	0.902	rs2603090	ENSG00000274979.1	RP11-1143G9.5	-4.04	6.25e-05	0.0052	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69383408	chr12:69326574~69331882:-
THCA	cis	rs10178409	1	rs10178409	ENSG00000273245.1	RP11-434P11.2	4.04	6.25e-05	0.0052	0.27	0.18	Urinary metabolites;	chr2:73628380	chr2:73750256~73750786:-
THCA	cis	rs2835349	0.522	rs2845762	ENSG00000230479.1	AP000695.6	4.04	6.26e-05	0.0052	0.22	0.18	Red blood cell count;	chr21:36445608	chr21:36430360~36481070:+
THCA	cis	rs10484434	0.792	rs66505449	ENSG00000272810.1	U91328.22	4.04	6.26e-05	0.0052	0.19	0.18	HIV-1 viral setpoint;	chr6:26031257	chr6:26013241~26013757:+
THCA	cis	rs1836229	0.874	rs7048621	ENSG00000225706.1	PTPRD-AS1	-4.04	6.26e-05	0.0052	-0.22	-0.18	Restless legs syndrome;	chr9:8832038	chr9:8858130~8862255:+
THCA	cis	rs1836229	0.874	rs7048788	ENSG00000225706.1	PTPRD-AS1	-4.04	6.26e-05	0.0052	-0.22	-0.18	Restless legs syndrome;	chr9:8832169	chr9:8858130~8862255:+
THCA	cis	rs1836229	0.874	rs10121203	ENSG00000225706.1	PTPRD-AS1	-4.04	6.26e-05	0.0052	-0.22	-0.18	Restless legs syndrome;	chr9:8833227	chr9:8858130~8862255:+
THCA	cis	rs12755164	0.771	rs6657272	ENSG00000223479.3	RP4-788P17.1	-4.04	6.26e-05	0.0052	-0.19	-0.18	Schizophrenia;	chr1:72866528	chr1:73635216~73715214:+
THCA	cis	rs763121	0.849	rs12004	ENSG00000273076.1	RP3-508I15.22	4.04	6.26e-05	0.0052	0.18	0.18	Menopause (age at onset);	chr22:38481456	chr22:38743495~38743910:+
THCA	cis	rs17597773	0.638	rs10495152	ENSG00000238078.1	LINC01352	-4.04	6.26e-05	0.0052	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220817013	chr1:220829255~220832429:+
THCA	cis	rs12073837	0.784	rs6673877	ENSG00000238078.1	LINC01352	-4.04	6.26e-05	0.0052	-0.24	-0.18	F-cell distribution;	chr1:220817642	chr1:220829255~220832429:+
THCA	cis	rs4578769	0.918	rs8085287	ENSG00000265939.1	UBE2CP2	4.04	6.26e-05	0.0052	0.22	0.18	Eosinophil percentage of white cells;	chr18:22884208	chr18:22900486~22900995:-
THCA	cis	rs875971	0.545	rs221986	ENSG00000273142.1	RP11-458F8.4	-4.04	6.26e-05	0.00521	-0.17	-0.18	Aortic root size;	chr7:66105323	chr7:66902857~66906297:+
THCA	cis	rs959260	1	rs2033608	ENSG00000263843.1	RP11-649A18.12	4.04	6.26e-05	0.00521	0.2	0.18	Systemic lupus erythematosus;	chr17:75371127	chr17:75271369~75273895:+
THCA	cis	rs4713118	0.662	rs149900	ENSG00000219891.2	ZSCAN12P1	4.04	6.26e-05	0.00521	0.25	0.18	Parkinson's disease;	chr6:28046819	chr6:28091154~28093664:+
THCA	cis	rs57561814	1	rs6949149	ENSG00000179428.2	AC073072.5	-4.04	6.26e-05	0.00521	-0.32	-0.18	Tonsillectomy;	chr7:22709538	chr7:22725395~22727620:-
THCA	cis	rs57561814	0.655	rs8180726	ENSG00000179428.2	AC073072.5	-4.04	6.26e-05	0.00521	-0.32	-0.18	Tonsillectomy;	chr7:22709687	chr7:22725395~22727620:-
THCA	cis	rs911555	0.692	rs7146215	ENSG00000269910.1	RP11-73M18.10	-4.04	6.26e-05	0.00521	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103694516~103695050:-
THCA	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-4.04	6.26e-05	0.00521	-0.22	-0.18	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
THCA	cis	rs453301	0.631	rs4840376	ENSG00000233609.3	RP11-62H7.2	-4.04	6.26e-05	0.00521	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8944591	chr8:8961200~8979025:+
THCA	cis	rs1876206	0.554	rs2448485	ENSG00000259705.1	RP11-227D13.1	4.04	6.26e-05	0.00521	0.22	0.18	Breast cancer;	chr15:48567536	chr15:48645951~48652016:+
THCA	cis	rs61677309	0.809	rs3782042	ENSG00000278376.1	RP11-158I9.8	-4.04	6.26e-05	0.00521	-0.14	-0.18	Lung cancer in ever smokers;	chr11:118315204	chr11:118791254~118793137:+
THCA	cis	rs7403037	1	rs35324226	ENSG00000260760.1	PWRN3	4.04	6.26e-05	0.00521	0.2	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24364852	chr15:24441127~24447967:+
THCA	cis	rs459571	0.959	rs456205	ENSG00000235106.7	LINC00094	4.04	6.26e-05	0.00521	0.16	0.18	Platelet distribution width;	chr9:134046024	chr9:134025439~134034666:+
THCA	cis	rs6570726	0.935	rs385134	ENSG00000270638.1	RP3-466P17.1	4.04	6.26e-05	0.00521	0.15	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145735570~145737218:+
THCA	cis	rs4819052	1	rs733738	ENSG00000273796.1	LL21NC02-21A1.1	4.04	6.26e-05	0.00521	0.21	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45403809~45404369:-
THCA	cis	rs733175	0.855	rs10016075	ENSG00000261490.1	RP11-448G15.3	4.04	6.27e-05	0.00521	0.14	0.18	Psychosis and Alzheimer's disease;	chr4:10005039	chr4:10068089~10073019:-
THCA	cis	rs607541	1	rs675876	ENSG00000259520.4	CTD-2651B20.3	-4.04	6.27e-05	0.00521	-0.26	-0.18	Obesity-related traits;	chr15:45644658	chr15:45251580~45279251:-
THCA	cis	rs607541	0.85	rs675890	ENSG00000259520.4	CTD-2651B20.3	-4.04	6.27e-05	0.00521	-0.26	-0.18	Obesity-related traits;	chr15:45644666	chr15:45251580~45279251:-
THCA	cis	rs2299587	0.554	rs2073567	ENSG00000253671.1	RP11-806O11.1	-4.04	6.27e-05	0.00521	-0.21	-0.18	Economic and political preferences;	chr8:17896525	chr8:17808941~17820868:+
THCA	cis	rs2299587	0.554	rs2283106	ENSG00000253671.1	RP11-806O11.1	-4.04	6.27e-05	0.00521	-0.21	-0.18	Economic and political preferences;	chr8:17896821	chr8:17808941~17820868:+
THCA	cis	rs3781264	0.848	rs6583934	ENSG00000273450.1	RP11-76P2.4	4.04	6.27e-05	0.00521	0.22	0.18	Esophageal cancer and gastric cancer;	chr10:94309648	chr10:94314907~94315327:-
THCA	cis	rs7554547	0.791	rs4846076	ENSG00000199347.1	RNU5E-1	-4.04	6.27e-05	0.00521	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11896708	chr1:11908152~11908271:+
THCA	cis	rs950776	0.518	rs12916483	ENSG00000261762.1	RP11-650L12.2	4.04	6.27e-05	0.00521	0.23	0.18	Sudden cardiac arrest;	chr15:78540055	chr15:78589123~78591276:-
THCA	cis	rs12134133	1	rs10494890	ENSG00000237074.1	RP11-6J21.2	-4.04	6.27e-05	0.00521	-0.19	-0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207249067~207309121:+
THCA	cis	rs12887734	0.524	rs17791722	ENSG00000258534.1	CTD-2134A5.4	-4.04	6.27e-05	0.00521	-0.2	-0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103819873	chr14:103854366~103880111:-
THCA	cis	rs7824557	0.547	rs2409749	ENSG00000255495.1	AC145124.2	-4.04	6.27e-05	0.00521	-0.21	-0.18	Retinal vascular caliber;	chr8:11221440	chr8:12194467~12196280:+
THCA	cis	rs4218	0.681	rs34977427	ENSG00000259732.1	RP11-59H7.3	-4.04	6.27e-05	0.00521	-0.25	-0.18	Social communication problems;	chr15:59098172	chr15:59121034~59133250:+
THCA	cis	rs4913250	1	rs4913250	ENSG00000203585.3	RP11-542B15.1	4.04	6.27e-05	0.00522	0.15	0.18	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr12:67534444	chr12:67519829~67567126:+
THCA	cis	rs6121246	0.697	rs6060912	ENSG00000224628.2	RP5-854E16.2	-4.04	6.28e-05	0.00522	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31737952	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6089058	ENSG00000224628.2	RP5-854E16.2	-4.04	6.28e-05	0.00522	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31738535	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.821	rs6119718	ENSG00000224628.2	RP5-854E16.2	-4.04	6.28e-05	0.00522	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31743271	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.821	rs6058448	ENSG00000224628.2	RP5-854E16.2	-4.04	6.28e-05	0.00522	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31744593	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs8126355	ENSG00000224628.2	RP5-854E16.2	-4.04	6.28e-05	0.00522	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31744857	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6060923	ENSG00000224628.2	RP5-854E16.2	-4.04	6.28e-05	0.00522	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31748852	chr20:31285317~31286835:-
THCA	cis	rs56313388	0.541	rs4471678	ENSG00000246379.5	RP11-461O7.1	-4.04	6.28e-05	0.00522	-0.19	-0.18	Pulse pressure;	chr16:56139341	chr16:56092987~56191094:-
THCA	cis	rs7074356	0.915	rs17618275	ENSG00000242600.5	MBL1P	4.04	6.28e-05	0.00522	0.24	0.18	Borderline personality disorder;	chr10:80458629	chr10:79904898~79950336:+
THCA	cis	rs4845570	1	rs6659705	ENSG00000249602.1	RP11-98D18.3	-4.04	6.28e-05	0.00522	-0.27	-0.18	Coronary artery disease;	chr1:151797274	chr1:151763384~151769501:-
THCA	cis	rs73193808	0.614	rs9976839	ENSG00000176054.6	RPL23P2	4.04	6.28e-05	0.00522	0.16	0.18	Coronary artery disease;	chr21:29190389	chr21:28997613~28998033:-
THCA	cis	rs11658309	1	rs11658309	ENSG00000281749.1	Y_RNA	-4.04	6.28e-05	0.00522	-0.23	-0.18	Strep throat;	chr17:17858933	chr17:18001101~18001195:-
THCA	cis	rs854765	0.693	rs35451946	ENSG00000281749.1	Y_RNA	-4.04	6.28e-05	0.00522	-0.23	-0.18	Total body bone mineral density;	chr17:17860747	chr17:18001101~18001195:-
THCA	cis	rs875971	0.522	rs1617484	ENSG00000164669.11	INTS4P1	-4.04	6.28e-05	0.00522	-0.23	-0.18	Aortic root size;	chr7:65998108	chr7:65141225~65234216:+
THCA	cis	rs5760842	0.967	rs5760830	ENSG00000236641.1	CTA-221G9.7	-4.04	6.28e-05	0.00522	-0.2	-0.18	Recurrent major depressive disorder;	chr22:25081637	chr22:25212742~25213685:+
THCA	cis	rs3808502	0.563	rs12549144	ENSG00000206014.6	OR7E161P	-4.04	6.28e-05	0.00522	-0.21	-0.18	Neuroticism;	chr8:11565352	chr8:11928597~11929563:-
THCA	cis	rs16948098	1	rs16948098	ENSG00000166763.7	STRCP1	4.04	6.28e-05	0.00522	0.37	0.18	Serum albumin level;	chr15:43927409	chr15:43699488~43718184:-
THCA	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	4.04	6.28e-05	0.00522	0.17	0.18	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
THCA	cis	rs728616	0.681	rs17677908	ENSG00000225484.5	NUTM2B-AS1	-4.04	6.28e-05	0.00522	-0.32	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80289847	chr10:79663088~79826594:-
THCA	cis	rs6940638	0.637	rs13217239	ENSG00000219392.1	RP1-265C24.5	-4.04	6.28e-05	0.00522	-0.21	-0.18	Intelligence (multi-trait analysis);	chr6:27287188	chr6:28115628~28116551:+
THCA	cis	rs365302	1	rs365302	ENSG00000235086.1	FNDC1-IT1	-4.04	6.28e-05	0.00522	-0.26	-0.18	Coronary heart disease;	chr6:159225301	chr6:159240786~159243329:+
THCA	cis	rs9810089	0.934	rs696520	ENSG00000273455.1	RP11-305O4.3	4.04	6.28e-05	0.00522	0.24	0.18	Gestational age at birth (child effect);	chr3:136338019	chr3:136087475~136087913:-
THCA	cis	rs4792901	0.543	rs9894814	ENSG00000279602.1	CTD-3014M21.1	-4.04	6.28e-05	0.00522	-0.23	-0.18	Dupuytren's disease;	chr17:43453618	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.507	rs9910371	ENSG00000279602.1	CTD-3014M21.1	-4.04	6.28e-05	0.00522	-0.23	-0.18	Dupuytren's disease;	chr17:43453619	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.543	rs56124217	ENSG00000279602.1	CTD-3014M21.1	-4.04	6.28e-05	0.00522	-0.23	-0.18	Dupuytren's disease;	chr17:43453630	chr17:43360041~43361361:-
THCA	cis	rs9527	0.637	rs12219247	ENSG00000272912.1	RP11-724N1.1	-4.04	6.28e-05	0.00522	-0.22	-0.18	Arsenic metabolism;	chr10:102853604	chr10:102914585~102915404:+
THCA	cis	rs17074492	0.671	rs9565685	ENSG00000214182.5	PTMAP5	4.04	6.28e-05	0.00522	0.23	0.18	Sjögren's syndrome;	chr13:81639256	chr13:81689911~81691072:+
THCA	cis	rs17074492	0.585	rs9565686	ENSG00000214182.5	PTMAP5	4.04	6.28e-05	0.00522	0.23	0.18	Sjögren's syndrome;	chr13:81639332	chr13:81689911~81691072:+
THCA	cis	rs4915077	0.892	rs17020184	ENSG00000230489.1	VAV3-AS1	4.04	6.28e-05	0.00522	0.32	0.18	Hypothyroidism;	chr1:107854484	chr1:107964443~107994607:+
THCA	cis	rs4650994	0.593	rs6676155	ENSG00000273384.1	RP5-1098D14.1	-4.04	6.28e-05	0.00522	-0.24	-0.18	HDL cholesterol;HDL cholesterol levels;	chr1:178539225	chr1:178651706~178652282:+
THCA	cis	rs6494488	0.5	rs56105035	ENSG00000259635.1	AC100830.3	-4.04	6.29e-05	0.00522	-0.46	-0.18	Coronary artery disease;	chr15:64459932	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs55644048	ENSG00000259635.1	AC100830.3	-4.04	6.29e-05	0.00522	-0.46	-0.18	Coronary artery disease;	chr15:64459968	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741334	ENSG00000259635.1	AC100830.3	-4.04	6.29e-05	0.00522	-0.46	-0.18	Coronary artery disease;	chr15:64462791	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741337	ENSG00000259635.1	AC100830.3	-4.04	6.29e-05	0.00522	-0.46	-0.18	Coronary artery disease;	chr15:64468765	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741340	ENSG00000259635.1	AC100830.3	-4.04	6.29e-05	0.00522	-0.46	-0.18	Coronary artery disease;	chr15:64470936	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741343	ENSG00000259635.1	AC100830.3	-4.04	6.29e-05	0.00522	-0.46	-0.18	Coronary artery disease;	chr15:64474799	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741345	ENSG00000259635.1	AC100830.3	-4.04	6.29e-05	0.00522	-0.46	-0.18	Coronary artery disease;	chr15:64475780	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741348	ENSG00000259635.1	AC100830.3	-4.04	6.29e-05	0.00522	-0.46	-0.18	Coronary artery disease;	chr15:64478845	chr15:64701248~64719602:+
THCA	cis	rs2704588	0.542	rs11734924	ENSG00000270720.1	RP11-84C13.2	4.04	6.29e-05	0.00522	0.35	0.18	Longevity;	chr4:89107365	chr4:89119284~89119871:+
THCA	cis	rs7565158	0.507	rs7570749	ENSG00000234308.2	AC093381.2	-4.04	6.29e-05	0.00522	-0.16	-0.18	Body mass index (change over time);	chr2:212743077	chr2:212795331~212819264:+
THCA	cis	rs853679	0.527	rs9468333	ENSG00000220721.1	OR1F12	4.04	6.29e-05	0.00522	0.21	0.18	Depression;	chr6:28303421	chr6:28073316~28074233:+
THCA	cis	rs4808199	0.901	rs12973258	ENSG00000267481.1	CTC-559E9.5	-4.04	6.29e-05	0.00522	-0.18	-0.18	Nonalcoholic fatty liver disease;	chr19:19377909	chr19:19788755~19790531:-
THCA	cis	rs2030746	0.899	rs940688	ENSG00000237614.1	AC073257.2	4.04	6.29e-05	0.00522	0.22	0.18	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120553424	chr2:120542909~120544326:-
THCA	cis	rs13108904	0.901	rs7695691	ENSG00000254094.1	AC078852.1	-4.04	6.29e-05	0.00523	-0.21	-0.18	Obesity-related traits;	chr4:1310844	chr4:1356581~1358075:+
THCA	cis	rs911555	0.755	rs1116095	ENSG00000269910.1	RP11-73M18.10	-4.04	6.29e-05	0.00523	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs8010247	ENSG00000269910.1	RP11-73M18.10	-4.04	6.29e-05	0.00523	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs55742283	ENSG00000269910.1	RP11-73M18.10	-4.04	6.29e-05	0.00523	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs8014800	ENSG00000269910.1	RP11-73M18.10	-4.04	6.29e-05	0.00523	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs12435516	ENSG00000269910.1	RP11-73M18.10	-4.04	6.29e-05	0.00523	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs2756135	ENSG00000269910.1	RP11-73M18.10	-4.04	6.29e-05	0.00523	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103694516~103695050:-
THCA	cis	rs3806843	0.576	rs265316	ENSG00000202515.1	VTRNA1-3	-4.04	6.29e-05	0.00523	-0.22	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140911258	chr5:140726158~140726246:+
THCA	cis	rs11247915	0.6	rs72649360	ENSG00000236782.4	RP11-96L14.7	-4.04	6.29e-05	0.00523	-0.22	-0.18	Obesity-related traits;	chr1:26336413	chr1:26169947~26171821:-
THCA	cis	rs6430585	0.591	rs724326	ENSG00000231890.6	DARS-AS1	-4.04	6.29e-05	0.00523	-0.2	-0.18	Corneal structure;	chr2:135728401	chr2:135985176~136022593:+
THCA	cis	rs4666002	0.956	rs4665383	ENSG00000234072.1	AC074117.10	4.04	6.29e-05	0.00523	0.15	0.18	Phospholipid levels (plasma);	chr2:27568688	chr2:27356246~27367622:+
THCA	cis	rs7818688	0.745	rs73271178	ENSG00000253528.2	RP11-347C18.4	-4.04	6.29e-05	0.00523	-0.28	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94895002	chr8:94974573~94974853:-
THCA	cis	rs12681288	0.55	rs72507624	ENSG00000260721.1	AF067845.1	4.04	6.29e-05	0.00523	0.23	0.18	Schizophrenia;	chr8:1011324	chr8:1368642~1369833:-
THCA	cis	rs2055729	0.557	rs7000542	ENSG00000261451.1	RP11-981G7.1	4.04	6.29e-05	0.00523	0.23	0.18	Multiple myeloma (hyperdiploidy);	chr8:10023625	chr8:10433672~10438312:+
THCA	cis	rs6973609	0.927	rs10238969	ENSG00000271122.1	RP11-379H18.1	4.04	6.29e-05	0.00523	0.12	0.18	Obesity-related traits;	chr7:35569730	chr7:35695214~35699413:+
THCA	cis	rs67340775	0.541	rs200968	ENSG00000220721.1	OR1F12	4.04	6.3e-05	0.00523	0.28	0.18	Lung cancer in ever smokers;	chr6:27891790	chr6:28073316~28074233:+
THCA	cis	rs9393777	0.777	rs35984974	ENSG00000220721.1	OR1F12	4.04	6.3e-05	0.00523	0.35	0.18	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28073316~28074233:+
THCA	cis	rs2014572	0.51	rs8111661	ENSG00000268379.1	CTC-360J11.4	-4.04	6.3e-05	0.00523	-0.21	-0.18	Hyperactive-impulsive symptoms;	chr19:57240958	chr19:57175233~57177921:+
THCA	cis	rs2562456	0.833	rs516519	ENSG00000268278.1	RP11-420K14.1	-4.04	6.3e-05	0.00523	-0.22	-0.18	Pain;	chr19:21298730	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs552800	ENSG00000268278.1	RP11-420K14.1	-4.04	6.3e-05	0.00523	-0.22	-0.18	Pain;	chr19:21301840	chr19:21637974~21656300:+
THCA	cis	rs10200159	1	rs7594497	ENSG00000272606.1	RP11-554J4.1	4.04	6.3e-05	0.00523	0.35	0.18	Vitiligo;	chr2:55645403	chr2:55617909~55618373:+
THCA	cis	rs1850744	0.702	rs10939428	ENSG00000163612.10	FAM86KP	-4.04	6.3e-05	0.00523	-0.4	-0.18	Economic and political preferences;	chr4:9628417	chr4:9153296~9165451:+
THCA	cis	rs7819412	0.745	rs6601569	ENSG00000254839.1	AF131215.6	4.04	6.3e-05	0.00523	0.19	0.18	Triglycerides;	chr8:11216069	chr8:11062647~11067089:-
THCA	cis	rs12440869	1	rs971868	ENSG00000270964.1	RP11-502I4.3	4.04	6.3e-05	0.00523	0.16	0.18	Peak velocity of the mitral A-wave;	chr15:67283158	chr15:67541072~67542604:-
THCA	cis	rs853679	0.666	rs200956	ENSG00000220721.1	OR1F12	4.04	6.3e-05	0.00523	0.26	0.18	Depression;	chr6:27871968	chr6:28073316~28074233:+
THCA	cis	rs17382723	0.887	rs2302047	ENSG00000229996.1	AC093585.6	4.04	6.3e-05	0.00524	0.24	0.18	Height;	chr2:241094355	chr2:241010045~241010744:-
THCA	cis	rs472402	0.56	rs6874005	ENSG00000250056.4	LINC01018	-4.04	6.3e-05	0.00524	-0.22	-0.18	Response to amphetamines;	chr5:6624258	chr5:6582136~6588499:+
THCA	cis	rs800160	0.582	rs2521286	ENSG00000199550.1	Y_RNA	4.04	6.3e-05	0.00524	0.28	0.18	Bacteremia;	chr11:2320741	chr11:2372638~2372750:+
THCA	cis	rs3748656	1	rs2306940	ENSG00000273483.1	RP4-671G15.2	4.04	6.3e-05	0.00524	0.2	0.18	Hip circumference adjusted for BMI;	chr1:112698430	chr1:112517799~112518441:-
THCA	cis	rs6088590	1	rs910870	ENSG00000269202.1	RP4-614O4.12	-4.04	6.3e-05	0.00524	-0.16	-0.18	Coronary artery disease;	chr20:34705089	chr20:35201747~35203288:-
THCA	cis	rs7583236	1	rs11126254	ENSG00000179818.12	PCBP1-AS1	-4.04	6.3e-05	0.00524	-0.18	-0.18	Obesity-related traits;	chr2:69955359	chr2:69962263~70103220:-
THCA	cis	rs17597773	0.674	rs10863568	ENSG00000272823.1	RP11-295M18.6	-4.04	6.3e-05	0.00524	-0.25	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220844737	chr1:220828676~220829211:-
THCA	cis	rs1371614	0.655	rs509047	ENSG00000272148.1	RP11-195B17.1	-4.04	6.3e-05	0.00524	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26905661	chr2:27062428~27062907:-
THCA	cis	rs9534288	0.912	rs9526135	ENSG00000235903.6	CPB2-AS1	4.04	6.3e-05	0.00524	0.27	0.18	Blood protein levels;	chr13:46050857	chr13:46052806~46113332:+
THCA	cis	rs6939532	0.522	rs2073528	ENSG00000124549.13	BTN2A3P	-4.04	6.31e-05	0.00524	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26374915	chr6:26421391~26432383:+
THCA	cis	rs853679	0.76	rs11962305	ENSG00000273712.1	RP5-874C20.7	4.04	6.31e-05	0.00524	0.26	0.18	Depression;	chr6:28232159	chr6:28315613~28315883:-
THCA	cis	rs8023401	0.507	rs589668	ENSG00000259705.1	RP11-227D13.1	4.04	6.31e-05	0.00524	0.22	0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48543738	chr15:48645951~48652016:+
THCA	cis	rs4908768	0.501	rs11121194	ENSG00000270282.1	RP5-1115A15.2	4.04	6.31e-05	0.00524	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8512653~8513021:+
THCA	cis	rs6046396	1	rs6046404	ENSG00000233895.1	RP1-122P22.2	-4.04	6.31e-05	0.00524	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr20:19882918	chr20:19757708~19809675:+
THCA	cis	rs34792	0.637	rs1684547	ENSG00000207425.1	Y_RNA	-4.04	6.31e-05	0.00524	-0.2	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15480604	chr16:14915457~14915556:-
THCA	cis	rs6413860	1	rs6688485	ENSG00000260855.1	RP11-439E19.10	4.04	6.31e-05	0.00524	0.24	0.18	Gut microbiome composition (summer);	chr1:246688754	chr1:246772301~246775772:+
THCA	cis	rs123509	0.687	rs73077208	ENSG00000173811.9	CCDC13-AS1	-4.04	6.31e-05	0.00524	-0.21	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42793713	chr3:42732575~42746768:+
THCA	cis	rs6977955	1	rs2893312	ENSG00000234336.5	JAZF1-AS1	4.04	6.31e-05	0.00524	0.22	0.18	Allergic disease (asthma, hay fever or eczema);	chr7:28130784	chr7:28180322~28243917:+
THCA	cis	rs9660180	0.967	rs12040325	ENSG00000215914.4	MMP23A	-4.04	6.31e-05	0.00524	-0.24	-0.18	Body mass index;	chr1:1770997	chr1:1699942~1701782:+
THCA	cis	rs2434529	1	rs61197056	ENSG00000245275.6	SAP30L-AS1	4.04	6.31e-05	0.00524	0.23	0.18	Autism spectrum disorder or schizophrenia;	chr5:154301648	chr5:154329437~154445850:-
THCA	cis	rs7402982	0.934	rs8027457	ENSG00000278022.1	RP11-35O15.2	-4.04	6.31e-05	0.00524	-0.19	-0.18	Birth weight;	chr15:98660872	chr15:98660210~98660668:+
THCA	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	4.04	6.31e-05	0.00524	0.17	0.18	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
THCA	cis	rs17221829	0.733	rs10830337	ENSG00000280385.1	AP000648.5	-4.04	6.31e-05	0.00524	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89673881	chr11:90193614~90198120:+
THCA	cis	rs1232027	0.7	rs1677694	ENSG00000249655.1	CTC-325J23.2	4.04	6.31e-05	0.00524	0.21	0.18	Huntington's disease progression;	chr5:80640478	chr5:80630313~80631590:-
THCA	cis	rs7586085	1	rs6710518	ENSG00000232411.1	AC009495.3	-4.04	6.31e-05	0.00524	-0.2	-0.18	Total body bone mineral density;	chr2:165726734	chr2:165833048~165839098:-
THCA	cis	rs4356203	0.87	rs7936310	ENSG00000272034.1	SNORD14A	4.04	6.31e-05	0.00524	0.18	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17248741	chr11:17074654~17074744:-
THCA	cis	rs2980439	0.807	rs2980438	ENSG00000233609.3	RP11-62H7.2	4.04	6.32e-05	0.00525	0.18	0.18	Neuroticism;	chr8:8237303	chr8:8961200~8979025:+
THCA	cis	rs1577917	0.74	rs7771612	ENSG00000220563.1	PKMP3	4.04	6.32e-05	0.00525	0.13	0.18	Response to antipsychotic treatment;	chr6:85554656	chr6:85659892~85660606:-
THCA	cis	rs2412819	0.571	rs12900924	ENSG00000166763.7	STRCP1	4.04	6.32e-05	0.00525	0.25	0.18	Lung cancer;	chr15:43737329	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs7174260	ENSG00000166763.7	STRCP1	4.04	6.32e-05	0.00525	0.25	0.18	Lung cancer;	chr15:43751988	chr15:43699488~43718184:-
THCA	cis	rs9733	0.596	rs7412396	ENSG00000231073.1	RP11-316M1.3	4.04	6.32e-05	0.00525	0.23	0.18	Tonsillectomy;	chr1:150694321	chr1:150973123~150975534:+
THCA	cis	rs17767294	0.612	rs9461425	ENSG00000220721.1	OR1F12	4.04	6.32e-05	0.00525	0.34	0.18	Parkinson's disease;	chr6:27951910	chr6:28073316~28074233:+
THCA	cis	rs3812831	0.695	rs10467349	ENSG00000264539.1	MIR548AR	4.04	6.32e-05	0.00525	0.19	0.18	Schizophrenia;	chr13:114173966	chr13:114244505~114244561:+
THCA	cis	rs9467773	1	rs10214634	ENSG00000228223.2	HCG11	-4.04	6.32e-05	0.00525	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26523450~26526579:+
THCA	cis	rs7615952	0.546	rs2976733	ENSG00000272840.1	RP11-379B18.6	4.04	6.32e-05	0.00525	0.26	0.18	Blood pressure (smoking interaction);	chr3:125695294	chr3:125774714~125797953:+
THCA	cis	rs67981189	0.896	rs8003227	ENSG00000269927.1	RP6-91H8.3	4.04	6.32e-05	0.00525	0.21	0.18	Schizophrenia;	chr14:71093635	chr14:71141125~71143253:-
THCA	cis	rs7833787	0.645	rs2638629	ENSG00000278886.1	RP11-108A14.1	4.04	6.32e-05	0.00525	0.23	0.18	Obesity-related traits;	chr8:18821839	chr8:18864681~18865247:-
THCA	cis	rs4561483	0.583	rs11075027	ENSG00000263307.1	RP11-166B2.8	-4.04	6.32e-05	0.00525	-0.19	-0.18	Testicular germ cell tumor;	chr16:11855038	chr16:11851649~11895611:+
THCA	cis	rs150992	0.711	rs326489	ENSG00000241597.2	CTD-2007H13.1	-4.04	6.32e-05	0.00525	-0.24	-0.18	Body mass index;	chr5:98841105	chr5:98954394~98954972:+
THCA	cis	rs7267979	0.932	rs6037125	ENSG00000276952.1	RP5-965G21.6	4.04	6.32e-05	0.00525	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25284915~25285588:-
THCA	cis	rs2015599	0.645	rs12578931	ENSG00000273680.1	RP11-996F15.6	4.04	6.32e-05	0.00525	0.26	0.18	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29332733~29333383:-
THCA	cis	rs2015599	0.623	rs4931174	ENSG00000273680.1	RP11-996F15.6	4.04	6.32e-05	0.00525	0.26	0.18	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29332733~29333383:-
THCA	cis	rs1499614	0.522	rs13247442	ENSG00000230295.1	RP11-458F8.2	-4.04	6.32e-05	0.00525	-0.29	-0.18	Gout;	chr7:66723871	chr7:66880708~66882981:+
THCA	cis	rs2821260	0.668	rs2630390	ENSG00000227207.2	RPL31P12	4.04	6.32e-05	0.00525	0.21	0.18	Intelligence (multi-trait analysis);	chr1:72137717	chr1:72301472~72301829:+
THCA	cis	rs4845570	1	rs7416415	ENSG00000249602.1	RP11-98D18.3	4.04	6.33e-05	0.00525	0.27	0.18	Coronary artery disease;	chr1:151785322	chr1:151763384~151769501:-
THCA	cis	rs6546886	0.912	rs9309478	ENSG00000235499.1	AC073046.25	4.04	6.33e-05	0.00525	0.17	0.18	Dialysis-related mortality;	chr2:74078076	chr2:73985132~73986343:+
THCA	cis	rs17597773	0.674	rs1494371	ENSG00000238078.1	LINC01352	-4.04	6.33e-05	0.00525	-0.26	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841256	chr1:220829255~220832429:+
THCA	cis	rs2039553	0.607	rs10507900	ENSG00000227354.5	RBM26-AS1	-4.04	6.33e-05	0.00525	-0.17	-0.18	Pancreatic cancer;	chr13:79769398	chr13:79406309~79424328:+
THCA	cis	rs11064837	0.504	rs7311445	ENSG00000248636.5	RP11-768F21.1	4.04	6.33e-05	0.00525	0.21	0.18	Schizophrenia;	chr12:119616292	chr12:119387987~119668079:-
THCA	cis	rs9843304	0.529	rs4681510	ENSG00000240541.2	TM4SF1-AS1	4.04	6.33e-05	0.00526	0.16	0.18	Gallstone disease;	chr3:149483786	chr3:149377778~149386583:+
THCA	cis	rs9843304	0.529	rs4681511	ENSG00000240541.2	TM4SF1-AS1	4.04	6.33e-05	0.00526	0.16	0.18	Gallstone disease;	chr3:149483792	chr3:149377778~149386583:+
THCA	cis	rs4906332	1	rs11541718	ENSG00000252469.1	RNU7-160P	4.04	6.33e-05	0.00526	0.2	0.18	Coronary artery disease;	chr14:103385827	chr14:103550345~103550406:+
THCA	cis	rs6762	0.748	rs5030780	ENSG00000255142.1	AP006621.6	4.04	6.33e-05	0.00526	0.13	0.18	Mean platelet volume;	chr11:838110	chr11:781645~782105:+
THCA	cis	rs2839627	0.561	rs7281655	ENSG00000225218.1	AP001628.6	4.04	6.33e-05	0.00526	0.26	0.18	Information processing speed;	chr21:42849633	chr21:42831040~42836477:-
THCA	cis	rs2839627	0.561	rs6586250	ENSG00000225218.1	AP001628.6	4.04	6.33e-05	0.00526	0.26	0.18	Information processing speed;	chr21:42850119	chr21:42831040~42836477:-
THCA	cis	rs2839627	0.598	rs56098337	ENSG00000225218.1	AP001628.6	4.04	6.33e-05	0.00526	0.26	0.18	Information processing speed;	chr21:42851255	chr21:42831040~42836477:-
THCA	cis	rs548181	0.611	rs1293672	ENSG00000254671.2	STT3A-AS1	-4.04	6.33e-05	0.00526	-0.36	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125591139	chr11:125570284~125592568:-
THCA	cis	rs1836229	0.874	rs2053125	ENSG00000225706.1	PTPRD-AS1	-4.04	6.33e-05	0.00526	-0.22	-0.18	Restless legs syndrome;	chr9:8831162	chr9:8858130~8862255:+
THCA	cis	rs62289301	0.531	rs67391897	ENSG00000273133.1	RP11-799M12.2	4.04	6.33e-05	0.00526	0.22	0.18	Joint mobility (Beighton score);	chr4:15456629	chr4:15563698~15564253:-
THCA	cis	rs9467773	0.873	rs9295698	ENSG00000228223.2	HCG11	-4.04	6.33e-05	0.00526	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26523450~26526579:+
THCA	cis	rs752590	0.614	rs7585510	ENSG00000227359.1	AC017074.2	4.04	6.33e-05	0.00526	0.28	0.18	Mucinous ovarian carcinoma;	chr2:113263334	chr2:113677702~113704078:-
THCA	cis	rs752590	0.614	rs7558326	ENSG00000227359.1	AC017074.2	4.04	6.33e-05	0.00526	0.28	0.18	Mucinous ovarian carcinoma;	chr2:113263541	chr2:113677702~113704078:-
THCA	cis	rs2562456	0.833	rs2968076	ENSG00000268658.4	LINC00664	-4.04	6.33e-05	0.00526	-0.27	-0.18	Pain;	chr19:21454299	chr19:21483374~21503238:+
THCA	cis	rs786425	0.77	rs7313140	ENSG00000278112.1	RP11-972P1.11	4.04	6.33e-05	0.00526	0.18	0.18	Pubertal anthropometrics;	chr12:123672641	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs7133199	ENSG00000278112.1	RP11-972P1.11	4.04	6.33e-05	0.00526	0.18	0.18	Pubertal anthropometrics;	chr12:123674638	chr12:123519390~123519856:-
THCA	cis	rs3796352	1	rs3806692	ENSG00000242142.1	SERBP1P3	-4.04	6.33e-05	0.00526	-0.32	-0.18	Immune reponse to smallpox (secreted IL-2);	chr3:53046971	chr3:53064283~53065091:-
THCA	cis	rs7914558	0.966	rs943035	ENSG00000272912.1	RP11-724N1.1	-4.04	6.33e-05	0.00526	-0.21	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103079395	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs7921574	ENSG00000272912.1	RP11-724N1.1	-4.04	6.33e-05	0.00526	-0.21	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103081213	chr10:102914585~102915404:+
THCA	cis	rs55692468	0.606	rs6759772	ENSG00000213197.3	AC012066.1	-4.04	6.33e-05	0.00526	-0.24	-0.18	Intraocular pressure;	chr2:152466210	chr2:152389937~152390630:+
THCA	cis	rs950169	0.881	rs72750843	ENSG00000188388.10	GOLGA6L3	4.04	6.33e-05	0.00526	0.25	0.18	Schizophrenia;	chr15:84592552	chr15:85240472~85247170:+
THCA	cis	rs61160187	0.582	rs4700407	ENSG00000272308.1	RP11-231G3.1	4.04	6.33e-05	0.00526	0.17	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60866457~60866935:-
THCA	cis	rs67981189	0.896	rs58133478	ENSG00000269927.1	RP6-91H8.3	4.04	6.33e-05	0.00526	0.21	0.18	Schizophrenia;	chr14:71058370	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs34763296	ENSG00000269927.1	RP6-91H8.3	4.04	6.33e-05	0.00526	0.21	0.18	Schizophrenia;	chr14:71083458	chr14:71141125~71143253:-
THCA	cis	rs2342371	0.545	rs4393941	ENSG00000273013.1	CTD-2002J20.1	4.04	6.33e-05	0.00526	0.17	0.18	Fat distribution (HIV);	chr3:196479872	chr3:196474801~196475394:+
THCA	cis	rs5758659	0.652	rs133313	ENSG00000205702.9	CYP2D7	4.04	6.33e-05	0.00526	0.14	0.18	Cognitive function;	chr22:42005745	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.652	rs133314	ENSG00000205702.9	CYP2D7	4.04	6.33e-05	0.00526	0.14	0.18	Cognitive function;	chr22:42005837	chr22:42140203~42144577:-
THCA	cis	rs3758911	0.964	rs10789614	ENSG00000255353.1	RP11-382M14.1	-4.04	6.34e-05	0.00526	-0.23	-0.18	Coronary artery disease;	chr11:107318047	chr11:107176286~107177530:+
THCA	cis	rs7824557	0.564	rs2736295	ENSG00000154316.13	TDH	-4.04	6.34e-05	0.00526	-0.14	-0.18	Retinal vascular caliber;	chr8:11377271	chr8:11339637~11368452:+
THCA	cis	rs853679	1	rs853694	ENSG00000273712.1	RP5-874C20.7	4.04	6.34e-05	0.00526	0.28	0.18	Depression;	chr6:28311323	chr6:28315613~28315883:-
THCA	cis	rs1971762	0.527	rs7300936	ENSG00000270175.1	RP11-793H13.11	-4.04	6.34e-05	0.00526	-0.12	-0.18	Height;	chr12:53636802	chr12:53500162~53500936:-
THCA	cis	rs6964833	1	rs13227433	ENSG00000184616.8	AC004166.6	4.04	6.34e-05	0.00526	0.28	0.18	Menarche (age at onset);	chr7:74680386	chr7:74906673~74913256:-
THCA	cis	rs3764021	0.933	rs10492165	ENSG00000256594.6	RP11-705C15.2	4.04	6.34e-05	0.00526	0.14	0.18	Type 1 diabetes;	chr12:9733365	chr12:9633419~9658412:+
THCA	cis	rs67981189	0.778	rs989501	ENSG00000269927.1	RP6-91H8.3	-4.04	6.34e-05	0.00526	-0.2	-0.18	Schizophrenia;	chr14:70894697	chr14:71141125~71143253:-
THCA	cis	rs9902453	0.899	rs1979572	ENSG00000263370.1	RP11-68I3.5	4.04	6.34e-05	0.00526	0.23	0.18	Coffee consumption (cups per day);	chr17:30184960	chr17:29639627~29640825:+
THCA	cis	rs10833905	1	rs61889452	ENSG00000246225.5	RP11-17A1.3	-4.04	6.34e-05	0.00526	-0.26	-0.18	Sudden cardiac arrest;	chr11:23037966	chr11:22829380~22945393:+
THCA	cis	rs10833905	0.938	rs10833918	ENSG00000246225.5	RP11-17A1.3	-4.04	6.34e-05	0.00526	-0.26	-0.18	Sudden cardiac arrest;	chr11:23040402	chr11:22829380~22945393:+
THCA	cis	rs12681366	0.537	rs10956913	ENSG00000261437.1	RP11-22C11.2	4.04	6.34e-05	0.00526	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94471459	chr8:94637285~94639467:-
THCA	cis	rs758324	0.797	rs422130	ENSG00000237714.1	P4HA2-AS1	4.04	6.34e-05	0.00526	0.27	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131990195	chr5:132184876~132192808:+
THCA	cis	rs13434995	0.536	rs62303712	ENSG00000249700.7	SRD5A3-AS1	-4.04	6.34e-05	0.00526	-0.26	-0.18	Adiponectin levels;	chr4:55460484	chr4:55363971~55395847:-
THCA	cis	rs2836950	0.501	rs2836984	ENSG00000238141.2	BRWD1-AS1	-4.04	6.34e-05	0.00527	-0.21	-0.18	Menarche (age at onset);	chr21:39329023	chr21:39315707~39323218:+
THCA	cis	rs758324	0.687	rs185616	ENSG00000224431.1	AC063976.7	-4.04	6.34e-05	0.00527	-0.19	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132208073	chr5:132199456~132203487:+
THCA	cis	rs56318008	0.773	rs2268177	ENSG00000228397.1	RP1-224A6.3	4.04	6.34e-05	0.00527	0.33	0.18	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22088917	chr1:22023994~22024968:-
THCA	cis	rs2274136	0.948	rs6459562	ENSG00000272269.1	RP11-500C11.3	4.04	6.34e-05	0.00527	0.21	0.18	Obesity-related traits;	chr6:17710444	chr6:17706257~17707344:+
THCA	cis	rs2135507	0.817	rs34750303	ENSG00000270480.1	RP11-57B24.1	4.04	6.34e-05	0.00527	0.25	0.18	Juvenile osteochondritis dissecans;	chr4:82664219	chr4:82691737~82692468:+
THCA	cis	rs9840812	0.637	rs667920	ENSG00000239213.4	NCK1-AS1	4.04	6.35e-05	0.00527	0.17	0.18	Fibrinogen levels;	chr3:136350630	chr3:136841726~136862054:-
THCA	cis	rs1371614	0.632	rs6707735	ENSG00000229122.1	AGBL5-IT1	4.04	6.35e-05	0.00527	0.13	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26943954	chr2:27061038~27061815:+
THCA	cis	rs7616559	0.849	rs9852415	ENSG00000244515.1	KRT18P34	-4.04	6.35e-05	0.00527	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157036402	chr3:157162663~157163932:-
THCA	cis	rs727563	0.648	rs6002406	ENSG00000237037.8	NDUFA6-AS1	4.04	6.35e-05	0.00527	0.18	0.18	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr22:42090931~42137742:+
THCA	cis	rs4792901	0.765	rs2127224	ENSG00000267151.3	RP11-100E5.2	4.04	6.35e-05	0.00527	0.2	0.18	Dupuytren's disease;	chr17:43491657	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs28636996	ENSG00000267151.3	RP11-100E5.2	4.04	6.35e-05	0.00527	0.2	0.18	Dupuytren's disease;	chr17:43495418	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs9894910	ENSG00000267151.3	RP11-100E5.2	4.04	6.35e-05	0.00527	0.2	0.18	Dupuytren's disease;	chr17:43496938	chr17:43444707~43451200:+
THCA	cis	rs875971	1	rs709595	ENSG00000230189.5	GS1-124K5.2	4.04	6.35e-05	0.00527	0.12	0.18	Aortic root size;	chr7:66352346	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs811880	ENSG00000230189.5	GS1-124K5.2	4.04	6.35e-05	0.00527	0.12	0.18	Aortic root size;	chr7:66353659	chr7:66409143~66490059:-
THCA	cis	rs875971	0.965	rs9969301	ENSG00000230189.5	GS1-124K5.2	-4.04	6.35e-05	0.00527	-0.12	-0.18	Aortic root size;	chr7:66316668	chr7:66409143~66490059:-
THCA	cis	rs17092148	0.887	rs6120684	ENSG00000276073.1	RP5-1125A11.7	-4.04	6.35e-05	0.00527	-0.22	-0.18	Neuroticism;	chr20:34591984	chr20:33985617~33988989:-
THCA	cis	rs7829975	0.777	rs6989926	ENSG00000254153.1	CTA-398F10.2	4.04	6.35e-05	0.00527	0.2	0.18	Mood instability;	chr8:8689803	chr8:8456909~8461337:-
THCA	cis	rs472402	0.623	rs7727273	ENSG00000250056.4	LINC01018	-4.04	6.35e-05	0.00527	-0.22	-0.18	Response to amphetamines;	chr5:6635820	chr5:6582136~6588499:+
THCA	cis	rs12612619	0.732	rs11687536	ENSG00000272148.1	RP11-195B17.1	-4.04	6.35e-05	0.00527	-0.16	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976886	chr2:27062428~27062907:-
THCA	cis	rs1396485	0.607	rs7721593	ENSG00000250015.1	CTC-339F2.2	4.04	6.35e-05	0.00527	0.2	0.18	Inflammatory biomarkers;	chr5:116328360	chr5:116302354~116304134:-
THCA	cis	rs10276381	0.685	rs56398224	ENSG00000234336.5	JAZF1-AS1	-4.04	6.35e-05	0.00527	-0.34	-0.18	Crohn's disease;	chr7:28166129	chr7:28180322~28243917:+
THCA	cis	rs10761482	0.813	rs10821727	ENSG00000254271.1	RP11-131N11.4	4.04	6.35e-05	0.00527	0.24	0.18	Schizophrenia;	chr10:60339355	chr10:60734342~60741828:+
THCA	cis	rs7131987	0.565	rs7137141	ENSG00000257176.2	RP11-996F15.2	4.04	6.35e-05	0.00527	0.18	0.18	QT interval;	chr12:29272168	chr12:29280418~29317848:-
THCA	cis	rs962856	1	rs11888062	ENSG00000236780.4	AC078941.1	4.04	6.35e-05	0.00527	0.22	0.18	Pancreatic cancer;	chr2:67378226	chr2:67123357~67215319:-
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000251402.3	FAM90A25P	4.04	6.35e-05	0.00527	0.23	0.18	Neuroticism;	chr8:11991324	chr8:12415080~12418090:-
THCA	cis	rs74233809	1	rs12412038	ENSG00000272912.1	RP11-724N1.1	-4.04	6.35e-05	0.00527	-0.34	-0.18	Birth weight;	chr10:103096405	chr10:102914585~102915404:+
THCA	cis	rs9810089	0.903	rs7432375	ENSG00000273455.1	RP11-305O4.3	4.04	6.35e-05	0.00527	0.24	0.18	Gestational age at birth (child effect);	chr3:136569563	chr3:136087475~136087913:-
THCA	cis	rs733592	0.507	rs56129148	ENSG00000258273.1	RP11-370I10.4	4.04	6.35e-05	0.00527	0.22	0.18	Plateletcrit;	chr12:48091747	chr12:48333755~48333901:-
THCA	cis	rs1962772	0.886	rs11203868	ENSG00000279903.1	RP11-349F21.5	-4.04	6.35e-05	0.00527	-0.23	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17511867	chr8:17500012~17500605:+
THCA	cis	rs10760158	0.832	rs10818524	ENSG00000226752.6	PSMD5-AS1	-4.04	6.35e-05	0.00527	-0.22	-0.18	Pulse pressure;	chr9:121267901	chr9:120824828~120854385:+
THCA	cis	rs2562456	0.833	rs2359145	ENSG00000268278.1	RP11-420K14.1	4.04	6.36e-05	0.00527	0.26	0.18	Pain;	chr19:21409791	chr19:21637974~21656300:+
THCA	cis	rs13325613	0.834	rs34059564	ENSG00000223552.1	RP11-24F11.2	-4.04	6.36e-05	0.00528	-0.28	-0.18	Monocyte count;	chr3:46184673	chr3:46364955~46407059:-
THCA	cis	rs962856	0.575	rs632700	ENSG00000236780.4	AC078941.1	4.04	6.36e-05	0.00528	0.25	0.18	Pancreatic cancer;	chr2:67437742	chr2:67123357~67215319:-
THCA	cis	rs7520050	0.966	rs1707321	ENSG00000281133.1	AL355480.3	4.04	6.36e-05	0.00528	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45580892~45580996:-
THCA	cis	rs1124769	0.748	rs3825798	ENSG00000259378.1	DCAF13P3	4.04	6.36e-05	0.00528	0.28	0.18	Cognitive performance;	chr15:51002635	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs12593778	ENSG00000259378.1	DCAF13P3	4.04	6.36e-05	0.00528	0.28	0.18	Cognitive performance;	chr15:51005929	chr15:50944663~50945996:+
THCA	cis	rs6792584	0.72	rs7429940	ENSG00000241316.5	SUCLG2-AS1	-4.04	6.36e-05	0.00528	-0.16	-0.18	Corneal astigmatism;	chr3:67503499	chr3:67654697~67947713:+
THCA	cis	rs867371	0.892	rs4344697	ENSG00000278603.1	RP13-608F4.5	4.04	6.36e-05	0.00528	0.23	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472203~82472426:+
THCA	cis	rs12534093	0.921	rs12533936	ENSG00000234286.1	AC006026.13	-4.04	6.36e-05	0.00528	-0.29	-0.18	Infant length;Height;	chr7:23447633	chr7:23680195~23680786:-
THCA	cis	rs453301	0.509	rs7000323	ENSG00000254153.1	CTA-398F10.2	4.04	6.36e-05	0.00528	0.22	0.18	Joint mobility (Beighton score);	chr8:8934763	chr8:8456909~8461337:-
THCA	cis	rs7923609	0.846	rs7098181	ENSG00000232075.1	MRPL35P2	-4.04	6.36e-05	0.00528	-0.24	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267383	chr10:63634317~63634827:-
THCA	cis	rs7923609	0.846	rs10761731	ENSG00000232075.1	MRPL35P2	-4.04	6.36e-05	0.00528	-0.24	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267850	chr10:63634317~63634827:-
THCA	cis	rs72949976	0.934	rs1441172	ENSG00000270659.1	RP11-105N14.1	4.04	6.36e-05	0.00528	0.14	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213172979	chr2:213152970~213153659:+
THCA	cis	rs6496044	0.611	rs6496055	ENSG00000259630.2	CTD-2262B20.1	-4.04	6.36e-05	0.00528	-0.2	-0.18	Interstitial lung disease;	chr15:85527457	chr15:85415228~85415633:+
THCA	cis	rs10200159	0.744	rs6725101	ENSG00000272606.1	RP11-554J4.1	4.04	6.36e-05	0.00528	0.35	0.18	Vitiligo;	chr2:55659736	chr2:55617909~55618373:+
THCA	cis	rs9863	0.861	rs12317176	ENSG00000270061.1	RP11-214K3.19	-4.04	6.36e-05	0.00528	-0.24	-0.18	White blood cell count;	chr12:123920171	chr12:123969990~123970344:-
THCA	cis	rs7259376	0.902	rs12978477	ENSG00000269345.1	VN1R85P	-4.04	6.36e-05	0.00528	-0.2	-0.18	Menopause (age at onset);	chr19:22394907	chr19:22174766~22175191:-
THCA	cis	rs6600671	1	rs10903159	ENSG00000275585.1	CH17-118O6.3	-4.04	6.36e-05	0.00528	-0.22	-0.18	Hip geometry;	chr1:121440138	chr1:120985692~121052167:-
THCA	cis	rs5006884	0.627	rs7929412	ENSG00000167355.6	AC104389.28	-4.04	6.36e-05	0.00528	-0.31	-0.18	Fetal hemoglobin levels;	chr11:5403200	chr11:5304976~5505652:-
THCA	cis	rs4915077	0.892	rs17020184	ENSG00000226822.1	RP11-356N1.2	4.04	6.36e-05	0.00528	0.36	0.18	Hypothyroidism;	chr1:107854484	chr1:108071482~108074519:+
THCA	cis	rs2836974	0.831	rs34592564	ENSG00000255568.3	BRWD1-AS2	4.04	6.36e-05	0.00528	0.16	0.18	Cognitive function;	chr21:39144362	chr21:39313935~39314962:+
THCA	cis	rs2153535	0.518	rs9328493	ENSG00000230939.1	RP11-314C16.1	-4.04	6.37e-05	0.00528	-0.19	-0.18	Motion sickness;	chr6:8569066	chr6:8784178~8785445:+
THCA	cis	rs16915157	0.512	rs79479106	ENSG00000254271.1	RP11-131N11.4	4.04	6.37e-05	0.00528	0.39	0.18	Schizophrenia;	chr10:60553591	chr10:60734342~60741828:+
THCA	cis	rs10875943	0.751	rs11168962	ENSG00000257464.1	RP11-161H23.8	-4.04	6.37e-05	0.00528	-0.22	-0.18	Prostate cancer;	chr12:49278956	chr12:49442424~49442652:-
THCA	cis	rs440932	1	rs440932	ENSG00000248538.5	RP11-10A14.5	-4.04	6.37e-05	0.00528	-0.22	-0.18	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9189011~9202854:+
THCA	cis	rs7903847	0.667	rs3818787	ENSG00000225850.3	RP11-452K12.4	4.04	6.37e-05	0.00528	0.18	0.18	Granulocyte percentage of myeloid white cells;	chr10:97385422	chr10:97334564~97343203:+
THCA	cis	rs7088591	0.867	rs74882423	ENSG00000276818.1	AC026393.1	4.04	6.37e-05	0.00528	0.39	0.18	Blood pressure;	chr10:57992856	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs77086118	ENSG00000276818.1	AC026393.1	4.04	6.37e-05	0.00528	0.39	0.18	Blood pressure;	chr10:57993151	chr10:57095699~57095781:+
THCA	cis	rs11971779	0.68	rs4732369	ENSG00000252332.1	RNU6-911P	-4.04	6.37e-05	0.00528	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139384427	chr7:139448740~139448843:+
THCA	cis	rs860295	0.557	rs12091730	ENSG00000236675.1	MTX1P1	-4.04	6.37e-05	0.00528	-0.21	-0.18	Body mass index;	chr1:155587180	chr1:155230975~155234325:+
THCA	cis	rs950169	0.84	rs12905223	ENSG00000188388.10	GOLGA6L3	4.04	6.37e-05	0.00528	0.25	0.18	Schizophrenia;	chr15:84571037	chr15:85240472~85247170:+
THCA	cis	rs10802047	0.54	rs6428785	ENSG00000231365.4	RP11-418J17.1	4.04	6.37e-05	0.00528	0.19	0.18	Relative hand skill in reading disability;	chr1:118819896	chr1:119140396~119275973:+
THCA	cis	rs7924176	0.54	rs61866073	ENSG00000232342.6	RP11-46O21.2	4.04	6.37e-05	0.00528	0.23	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.521	rs7098200	ENSG00000232342.6	RP11-46O21.2	-4.04	6.37e-05	0.00528	-0.23	-0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:74506081~74530553:-
THCA	cis	rs2898681	0.567	rs77657787	ENSG00000248375.1	RP11-177B4.1	-4.04	6.37e-05	0.00528	-0.38	-0.18	Optic nerve measurement (cup area);	chr4:52863814	chr4:52720081~52720831:-
THCA	cis	rs988712	0.705	rs1488830	ENSG00000245573.6	BDNF-AS	-4.04	6.37e-05	0.00528	-0.17	-0.18	Obesity;	chr11:27615338	chr11:27506838~27698174:+
THCA	cis	rs875971	0.929	rs34406470	ENSG00000230189.5	GS1-124K5.2	4.04	6.37e-05	0.00528	0.12	0.18	Aortic root size;	chr7:66464969	chr7:66409143~66490059:-
THCA	cis	rs804280	0.517	rs7815179	ENSG00000206014.6	OR7E161P	-4.04	6.37e-05	0.00528	-0.22	-0.18	Myopia (pathological);	chr8:11934539	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.871	rs7815186	ENSG00000206014.6	OR7E161P	-4.04	6.37e-05	0.00528	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:11928597~11929563:-
THCA	cis	rs1908814	0.516	rs7833079	ENSG00000206014.6	OR7E161P	-4.04	6.37e-05	0.00528	-0.22	-0.18	Neuroticism;	chr8:11934620	chr8:11928597~11929563:-
THCA	cis	rs889398	0.616	rs35808754	ENSG00000226232.7	RP11-419C5.2	4.04	6.37e-05	0.00528	0.18	0.18	Body mass index;	chr16:69737807	chr16:69976388~69996188:-
THCA	cis	rs301799	0.505	rs1467013	ENSG00000232912.4	RP5-1115A15.1	4.04	6.37e-05	0.00528	0.18	0.18	Thyroid peroxidase antibody positivity;	chr1:8317768	chr1:8424645~8434838:+
THCA	cis	rs13064773	0.528	rs340278	ENSG00000279311.1	RP11-170K4.2	4.04	6.37e-05	0.00528	0.24	0.18	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158869568	chr3:158869898~158871821:+
THCA	cis	rs9341808	0.622	rs684283	ENSG00000272129.1	RP11-250B2.6	-4.04	6.37e-05	0.00528	-0.23	-0.18	Sitting height ratio;	chr6:80257600	chr6:80355424~80356859:+
THCA	cis	rs13217239	0.646	rs7451149	ENSG00000124549.13	BTN2A3P	-4.04	6.37e-05	0.00529	-0.17	-0.18	Schizophrenia;	chr6:27089739	chr6:26421391~26432383:+
THCA	cis	rs6479891	0.908	rs12412946	ENSG00000272767.1	JMJD1C-AS1	4.03	6.37e-05	0.00529	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs59035163	ENSG00000272767.1	JMJD1C-AS1	4.03	6.37e-05	0.00529	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63465229~63466563:+
THCA	cis	rs1971762	0.527	rs784568	ENSG00000270175.1	RP11-793H13.11	4.03	6.37e-05	0.00529	0.12	0.18	Height;	chr12:53533770	chr12:53500162~53500936:-
THCA	cis	rs875971	1	rs1167612	ENSG00000229886.1	RP5-1132H15.3	-4.03	6.37e-05	0.00529	-0.19	-0.18	Aortic root size;	chr7:66102989	chr7:66025126~66031544:-
THCA	cis	rs67478160	0.643	rs6575997	ENSG00000269910.1	RP11-73M18.10	-4.03	6.37e-05	0.00529	-0.15	-0.18	Schizophrenia;	chr14:103762209	chr14:103694516~103695050:-
THCA	cis	rs9309473	0.898	rs7580750	ENSG00000273245.1	RP11-434P11.2	4.03	6.37e-05	0.00529	0.24	0.18	Metabolite levels;	chr2:73560999	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.898	rs11126403	ENSG00000273245.1	RP11-434P11.2	4.03	6.37e-05	0.00529	0.24	0.18	Metabolite levels;	chr2:73569796	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.898	rs11126404	ENSG00000273245.1	RP11-434P11.2	4.03	6.37e-05	0.00529	0.24	0.18	Metabolite levels;	chr2:73569797	chr2:73750256~73750786:-
THCA	cis	rs3015497	0.763	rs2934689	ENSG00000270062.1	RP11-248J18.3	4.03	6.37e-05	0.00529	0.2	0.18	Mean platelet volume;	chr14:50651609	chr14:50723777~50724272:-
THCA	cis	rs13182402	0.803	rs56227108	ENSG00000230929.5	RP11-395C3.1	-4.03	6.38e-05	0.00529	-0.37	-0.18	Osteoporosis;	chr5:126579682	chr5:126628019~126628319:-
THCA	cis	rs13182402	1	rs34275373	ENSG00000230929.5	RP11-395C3.1	-4.03	6.38e-05	0.00529	-0.37	-0.18	Osteoporosis;	chr5:126580052	chr5:126628019~126628319:-
THCA	cis	rs7176527	0.784	rs62021162	ENSG00000259683.1	RP11-182J1.14	4.03	6.38e-05	0.00529	0.25	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84389729~84395903:+
THCA	cis	rs12681366	0.734	rs6991077	ENSG00000261437.1	RP11-22C11.2	4.03	6.38e-05	0.00529	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94375577	chr8:94637285~94639467:-
THCA	cis	rs74233809	1	rs11191515	ENSG00000272912.1	RP11-724N1.1	-4.03	6.38e-05	0.00529	-0.34	-0.18	Birth weight;	chr10:103016770	chr10:102914585~102915404:+
THCA	cis	rs3128341	1	rs12143898	ENSG00000227207.2	RPL31P12	4.03	6.38e-05	0.00529	0.29	0.18	Intelligence (multi-trait analysis);	chr1:72360489	chr1:72301472~72301829:+
THCA	cis	rs8062405	0.824	rs240702	ENSG00000270424.1	RP11-1348G14.6	4.03	6.38e-05	0.00529	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28749959~28750595:-
THCA	cis	rs10833905	0.938	rs11026939	ENSG00000246225.5	RP11-17A1.3	-4.03	6.38e-05	0.00529	-0.26	-0.18	Sudden cardiac arrest;	chr11:23051420	chr11:22829380~22945393:+
THCA	cis	rs1476587	1	rs13245768	ENSG00000224046.1	AC005076.5	4.03	6.38e-05	0.00529	0.18	0.18	Brachial circumference;	chr7:87104919	chr7:87151423~87152420:-
THCA	cis	rs1850744	0.51	rs1464259	ENSG00000250942.1	ENPP7P11	4.03	6.38e-05	0.00529	0.28	0.18	Economic and political preferences;	chr4:9832838	chr4:9677308~9677934:+
THCA	cis	rs10833905	1	rs11026933	ENSG00000246225.5	RP11-17A1.3	-4.03	6.38e-05	0.00529	-0.26	-0.18	Sudden cardiac arrest;	chr11:23045112	chr11:22829380~22945393:+
THCA	cis	rs11168351	0.889	rs12817104	ENSG00000273765.1	RP11-370I10.11	4.03	6.38e-05	0.00529	0.18	0.18	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48360920~48361377:+
THCA	cis	rs5758659	0.569	rs133293	ENSG00000205702.9	CYP2D7	4.03	6.38e-05	0.00529	0.14	0.18	Cognitive function;	chr22:41986793	chr22:42140203~42144577:-
THCA	cis	rs853679	0.527	rs707907	ENSG00000176933.5	TOB2P1	-4.03	6.38e-05	0.00529	-0.2	-0.18	Depression;	chr6:28323463	chr6:28217643~28218634:-
THCA	cis	rs55966801	0.68	rs56093448	ENSG00000277290.1	RP11-326C3.16	-4.03	6.39e-05	0.0053	-0.23	-0.18	Plateletcrit;	chr11:261209	chr11:243099~243483:-
THCA	cis	rs1023500	0.505	rs134889	ENSG00000273366.1	CTA-989H11.1	-4.03	6.39e-05	0.0053	-0.22	-0.18	Schizophrenia;	chr22:42278344	chr22:42278188~42278846:+
THCA	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	4.03	6.39e-05	0.0053	0.21	0.18	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
THCA	cis	rs6580649	0.941	rs72644847	ENSG00000273765.1	RP11-370I10.11	-4.03	6.39e-05	0.0053	-0.21	-0.18	Lung cancer;	chr12:48122310	chr12:48360920~48361377:+
THCA	cis	rs911555	0.692	rs60235428	ENSG00000269910.1	RP11-73M18.10	-4.03	6.39e-05	0.0053	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103694516~103695050:-
THCA	cis	rs7777677	0.925	rs73543808	ENSG00000211750.2	TRBV24-1	-4.03	6.39e-05	0.0053	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142656701~142657213:+
THCA	cis	rs2836950	0.52	rs59916147	ENSG00000238141.2	BRWD1-AS1	-4.03	6.39e-05	0.0053	-0.21	-0.18	Menarche (age at onset);	chr21:39262776	chr21:39315707~39323218:+
THCA	cis	rs78487399	0.831	rs10495903	ENSG00000234936.1	AC010883.5	4.03	6.39e-05	0.0053	0.23	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43579779	chr2:43229573~43233394:+
THCA	cis	rs7267979	0.565	rs6107060	ENSG00000274414.1	RP5-965G21.4	-4.03	6.39e-05	0.0053	-0.23	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:25239007~25245229:-
THCA	cis	rs9543976	0.614	rs9573577	ENSG00000261105.4	LMO7-AS1	-4.03	6.39e-05	0.0053	-0.32	-0.18	Diabetic retinopathy;	chr13:75529653	chr13:75604700~75635994:-
THCA	cis	rs9926296	0.565	rs8055825	ENSG00000274627.1	RP11-104N10.2	-4.03	6.39e-05	0.0053	-0.19	-0.18	Vitiligo;	chr16:89766440	chr16:89516797~89522217:+
THCA	cis	rs4767841	0.935	rs2936830	ENSG00000252886.1	RN7SKP197	-4.03	6.39e-05	0.0053	-0.18	-0.18	Urgency urinary incontinence;	chr12:119729350	chr12:119631090~119631386:-
THCA	cis	rs2153535	0.518	rs9406181	ENSG00000230939.1	RP11-314C16.1	-4.03	6.39e-05	0.0053	-0.19	-0.18	Motion sickness;	chr6:8569069	chr6:8784178~8785445:+
THCA	cis	rs2303282	0.664	rs2440468	ENSG00000274031.1	RP11-413H22.3	-4.03	6.4e-05	0.0053	-0.22	-0.18	Breast cancer;	chr16:56386682	chr16:56465642~56466162:-
THCA	cis	rs78487399	0.71	rs7567685	ENSG00000234936.1	AC010883.5	4.03	6.4e-05	0.0053	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43441030	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7581586	ENSG00000234936.1	AC010883.5	4.03	6.4e-05	0.0053	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43441037	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs17030800	ENSG00000234936.1	AC010883.5	4.03	6.4e-05	0.0053	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43443864	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.52	rs7609256	ENSG00000234936.1	AC010883.5	4.03	6.4e-05	0.0053	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43445360	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7559842	ENSG00000234936.1	AC010883.5	4.03	6.4e-05	0.0053	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446303	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs78191305	ENSG00000234936.1	AC010883.5	4.03	6.4e-05	0.0053	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446839	chr2:43229573~43233394:+
THCA	cis	rs858239	1	rs199351	ENSG00000230042.1	AK3P3	-4.03	6.4e-05	0.0053	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23129178~23129841:+
THCA	cis	rs6690583	0.623	rs6700723	ENSG00000226970.2	RP11-82H13.2	4.03	6.4e-05	0.0053	0.32	0.18	Serum sulfate level;	chr1:85048551	chr1:84244334~84244577:+
THCA	cis	rs7447927	0.95	rs13181561	ENSG00000200378.1	RNU5B-4P	4.03	6.4e-05	0.0053	0.21	0.18	Esophageal squamous cell carcinoma;	chr5:139471320	chr5:139447907~139448017:+
THCA	cis	rs1048886	0.872	rs9455092	ENSG00000271967.1	RP11-134K13.4	-4.03	6.4e-05	0.00531	-0.19	-0.18	Type 2 diabetes;	chr6:70414826	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9455093	ENSG00000271967.1	RP11-134K13.4	-4.03	6.4e-05	0.00531	-0.19	-0.18	Type 2 diabetes;	chr6:70414827	chr6:70596438~70596980:+
THCA	cis	rs2163813	1	rs17699333	ENSG00000271499.1	CTC-559E9.9	-4.03	6.4e-05	0.00531	-0.22	-0.18	Toenail selenium levels;	chr19:19720735	chr19:19750618~19752544:+
THCA	cis	rs7772697	0.635	rs2185250	ENSG00000223701.3	RAET1E-AS1	4.03	6.4e-05	0.00531	0.25	0.18	Diabetic retinopathy;	chr6:149091092	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.635	rs1890610	ENSG00000223701.3	RAET1E-AS1	-4.03	6.4e-05	0.00531	-0.25	-0.18	Diabetic retinopathy;	chr6:149092843	chr6:149884431~149919508:+
THCA	cis	rs7819412	0.634	rs6987767	ENSG00000261451.1	RP11-981G7.1	4.03	6.4e-05	0.00531	0.23	0.18	Triglycerides;	chr8:11052556	chr8:10433672~10438312:+
THCA	cis	rs8062405	0.723	rs62031562	ENSG00000270424.1	RP11-1348G14.6	4.03	6.4e-05	0.00531	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28749959~28750595:-
THCA	cis	rs4934494	0.677	rs11185790	ENSG00000240996.1	RP11-80H5.7	4.03	6.4e-05	0.00531	0.21	0.18	Red blood cell count;	chr10:89612776	chr10:89694295~89697928:-
THCA	cis	rs12807809	0.588	rs61910607	ENSG00000245498.5	RP11-677M14.7	4.03	6.41e-05	0.00531	0.25	0.18	Schizophrenia;	chr11:124739473	chr11:124800450~124834487:+
THCA	cis	rs6903823	0.508	rs1150721	ENSG00000176933.5	TOB2P1	-4.03	6.41e-05	0.00531	-0.2	-0.18	Pulmonary function;	chr6:28287263	chr6:28217643~28218634:-
THCA	cis	rs6903823	0.508	rs1233660	ENSG00000176933.5	TOB2P1	-4.03	6.41e-05	0.00531	-0.2	-0.18	Pulmonary function;	chr6:28292472	chr6:28217643~28218634:-
THCA	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	4.03	6.41e-05	0.00531	0.22	0.18	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
THCA	cis	rs2303282	0.664	rs4783938	ENSG00000274031.1	RP11-413H22.3	-4.03	6.41e-05	0.00531	-0.22	-0.18	Breast cancer;	chr16:56373111	chr16:56465642~56466162:-
THCA	cis	rs853679	0.585	rs201004	ENSG00000226314.6	ZNF192P1	-4.03	6.41e-05	0.00531	-0.25	-0.18	Depression;	chr6:27837156	chr6:28161781~28169594:+
THCA	cis	rs7432375	0.966	rs6808312	ENSG00000273455.1	RP11-305O4.3	-4.03	6.41e-05	0.00531	-0.24	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136652662	chr3:136087475~136087913:-
THCA	cis	rs9302635	0.678	rs8054585	ENSG00000260886.1	TAT-AS1	4.03	6.41e-05	0.00531	0.23	0.18	Blood protein levels;	chr16:72191415	chr16:71565789~71578187:+
THCA	cis	rs9929218	0.529	rs11640736	ENSG00000260459.2	FTLP14	4.03	6.41e-05	0.00531	0.21	0.18	Colorectal cancer;	chr16:68704421	chr16:68822587~68823070:+
THCA	cis	rs3218092	0.81	rs3218114	ENSG00000213435.3	ATP6V0CP3	4.03	6.41e-05	0.00531	0.3	0.18	Red cell distribution width;	chr6:41934614	chr6:42727234~42727700:+
THCA	cis	rs7560272	0.538	rs4852977	ENSG00000273245.1	RP11-434P11.2	-4.03	6.41e-05	0.00531	-0.21	-0.18	Schizophrenia;	chr2:73711168	chr2:73750256~73750786:-
THCA	cis	rs2039553	0.614	rs4885660	ENSG00000227354.5	RBM26-AS1	-4.03	6.41e-05	0.00531	-0.17	-0.18	Pancreatic cancer;	chr13:79792538	chr13:79406309~79424328:+
THCA	cis	rs9467773	1	rs6940053	ENSG00000228223.2	HCG11	-4.03	6.41e-05	0.00531	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26523450~26526579:+
THCA	cis	rs35146811	0.735	rs6465766	ENSG00000078319.8	PMS2P1	4.03	6.41e-05	0.00532	0.23	0.18	Coronary artery disease;	chr7:100188048	chr7:100320992~100341908:-
THCA	cis	rs7824557	0.564	rs13268126	ENSG00000255495.1	AC145124.2	-4.03	6.41e-05	0.00532	-0.21	-0.18	Retinal vascular caliber;	chr8:11373065	chr8:12194467~12196280:+
THCA	cis	rs495337	0.76	rs2769977	ENSG00000229222.1	KRT18P4	-4.03	6.41e-05	0.00532	-0.23	-0.18	Psoriasis;	chr20:49910927	chr20:49956745~49958032:+
THCA	cis	rs495337	0.646	rs6067267	ENSG00000229222.1	KRT18P4	-4.03	6.41e-05	0.00532	-0.23	-0.18	Psoriasis;	chr20:49911700	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs13040201	ENSG00000229222.1	KRT18P4	-4.03	6.41e-05	0.00532	-0.23	-0.18	Psoriasis;	chr20:49919812	chr20:49956745~49958032:+
THCA	cis	rs495337	0.72	rs2869937	ENSG00000229222.1	KRT18P4	-4.03	6.41e-05	0.00532	-0.23	-0.18	Psoriasis;	chr20:49920081	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs6067270	ENSG00000229222.1	KRT18P4	-4.03	6.41e-05	0.00532	-0.23	-0.18	Psoriasis;	chr20:49920717	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs6122844	ENSG00000229222.1	KRT18P4	-4.03	6.41e-05	0.00532	-0.23	-0.18	Psoriasis;	chr20:49925008	chr20:49956745~49958032:+
THCA	cis	rs495337	0.72	rs6067271	ENSG00000229222.1	KRT18P4	-4.03	6.41e-05	0.00532	-0.23	-0.18	Psoriasis;	chr20:49925126	chr20:49956745~49958032:+
THCA	cis	rs4785204	1	rs72796149	ENSG00000279356.1	RP11-429P3.8	-4.03	6.41e-05	0.00532	-0.34	-0.18	Esophageal cancer (squamous cell);	chr16:50080974	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs72796151	ENSG00000279356.1	RP11-429P3.8	-4.03	6.41e-05	0.00532	-0.34	-0.18	Esophageal cancer (squamous cell);	chr16:50083166	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs72796159	ENSG00000279356.1	RP11-429P3.8	-4.03	6.41e-05	0.00532	-0.34	-0.18	Esophageal cancer (squamous cell);	chr16:50092409	chr16:50072862~50074986:+
THCA	cis	rs4785204	0.867	rs8062668	ENSG00000279356.1	RP11-429P3.8	4.03	6.41e-05	0.00532	0.34	0.18	Esophageal cancer (squamous cell);	chr16:50090838	chr16:50072862~50074986:+
THCA	cis	rs4906332	0.966	rs12588705	ENSG00000252469.1	RNU7-160P	4.03	6.41e-05	0.00532	0.2	0.18	Coronary artery disease;	chr14:103399140	chr14:103550345~103550406:+
THCA	cis	rs4906332	0.966	rs59858038	ENSG00000252469.1	RNU7-160P	4.03	6.41e-05	0.00532	0.2	0.18	Coronary artery disease;	chr14:103400765	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs12889703	ENSG00000252469.1	RNU7-160P	4.03	6.41e-05	0.00532	0.2	0.18	Coronary artery disease;	chr14:103406614	chr14:103550345~103550406:+
THCA	cis	rs804280	0.543	rs13261205	ENSG00000254948.1	OR7E158P	-4.03	6.42e-05	0.00532	-0.23	-0.18	Myopia (pathological);	chr8:11933707	chr8:11919900~11920809:-
THCA	cis	rs804280	0.518	rs34266352	ENSG00000254948.1	OR7E158P	-4.03	6.42e-05	0.00532	-0.23	-0.18	Myopia (pathological);	chr8:11933953	chr8:11919900~11920809:-
THCA	cis	rs804280	0.542	rs34117651	ENSG00000254948.1	OR7E158P	-4.03	6.42e-05	0.00532	-0.23	-0.18	Myopia (pathological);	chr8:11934108	chr8:11919900~11920809:-
THCA	cis	rs8067354	0.789	rs4622571	ENSG00000266701.1	AC005702.4	4.03	6.42e-05	0.00532	0.25	0.18	Hemoglobin concentration;	chr17:59807036	chr17:60042546~60042627:-
THCA	cis	rs9970896	0.579	rs7532893	ENSG00000237845.1	RP5-940F7.2	-4.03	6.42e-05	0.00532	-0.33	-0.18	Monocyte percentage of white cells;	chr1:235884485	chr1:235942553~235943805:-
THCA	cis	rs919433	0.679	rs10931787	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197655891	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs1902249	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197656632	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs67492914	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197658678	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs6737060	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197660161	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs6708239	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197660360	chr2:197197991~197199273:+
THCA	cis	rs919433	0.647	rs6741205	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197661273	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs6741314	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197661364	chr2:197197991~197199273:+
THCA	cis	rs919433	0.588	rs11690163	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197662783	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs61155920	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197664157	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs6757632	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197665542	chr2:197197991~197199273:+
THCA	cis	rs919433	0.679	rs6757669	ENSG00000231621.1	AC013264.2	-4.03	6.42e-05	0.00532	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197665631	chr2:197197991~197199273:+
THCA	cis	rs7560272	0.501	rs4852978	ENSG00000273245.1	RP11-434P11.2	-4.03	6.42e-05	0.00532	-0.21	-0.18	Schizophrenia;	chr2:73715983	chr2:73750256~73750786:-
THCA	cis	rs34421088	0.56	rs2245357	ENSG00000206014.6	OR7E161P	4.03	6.42e-05	0.00532	0.21	0.18	Neuroticism;	chr8:11541975	chr8:11928597~11929563:-
THCA	cis	rs10833905	1	rs61889442	ENSG00000246225.5	RP11-17A1.3	-4.03	6.42e-05	0.00532	-0.26	-0.18	Sudden cardiac arrest;	chr11:23034201	chr11:22829380~22945393:+
THCA	cis	rs529866	0.555	rs367569	ENSG00000263080.1	RP11-485G7.5	4.03	6.42e-05	0.00532	0.23	0.18	Inflammatory bowel disease;Crohn's disease;	chr16:11271643	chr16:11341809~11345211:-
THCA	cis	rs11971779	0.616	rs6967932	ENSG00000252332.1	RNU6-911P	-4.03	6.42e-05	0.00532	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139337635	chr7:139448740~139448843:+
THCA	cis	rs1552244	0.554	rs2272122	ENSG00000269982.1	RP11-1020A11.2	4.03	6.42e-05	0.00532	0.13	0.18	Alzheimer's disease;	chr3:10006291	chr3:9958717~9962539:+
THCA	cis	rs12681366	0.734	rs10102233	ENSG00000261437.1	RP11-22C11.2	4.03	6.42e-05	0.00532	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94389429	chr8:94637285~94639467:-
THCA	cis	rs7264396	0.887	rs6060431	ENSG00000088340.14	FER1L4	4.03	6.42e-05	0.00532	0.17	0.18	Total cholesterol levels;	chr20:35471512	chr20:35558737~35607562:-
THCA	cis	rs495337	0.76	rs2745078	ENSG00000229222.1	KRT18P4	-4.03	6.42e-05	0.00532	-0.23	-0.18	Psoriasis;	chr20:49908923	chr20:49956745~49958032:+
THCA	cis	rs1842579	1	rs11161677	ENSG00000272691.1	RP11-290M5.4	-4.03	6.43e-05	0.00532	-0.18	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85811592	chr1:85578500~85578742:-
THCA	cis	rs9393813	0.901	rs12529756	ENSG00000204789.4	ZNF204P	-4.03	6.43e-05	0.00533	-0.15	-0.18	Bipolar disorder;	chr6:27503669	chr6:27357825~27360221:-
THCA	cis	rs6472827	0.904	rs11996617	ENSG00000253983.2	RP1-16A9.1	-4.03	6.43e-05	0.00533	-0.3	-0.18	Uterine fibroids;	chr8:74208452	chr8:74199396~74208441:+
THCA	cis	rs7560272	0.538	rs1806683	ENSG00000273245.1	RP11-434P11.2	4.03	6.43e-05	0.00533	0.21	0.18	Schizophrenia;	chr2:73712685	chr2:73750256~73750786:-
THCA	cis	rs7267979	0.565	rs3752273	ENSG00000274414.1	RP5-965G21.4	4.03	6.43e-05	0.00533	0.22	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:25239007~25245229:-
THCA	cis	rs1348850	0.801	rs11890163	ENSG00000280374.1	RP11-337N6.3	-4.03	6.43e-05	0.00533	-0.33	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177462406	chr2:177317715~177318471:-
THCA	cis	rs10043228	0.826	rs12153778	ENSG00000248445.4	SEMA6A-AS1	-4.03	6.43e-05	0.00533	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116342931	chr5:116447547~116508276:+
THCA	cis	rs7819412	0.668	rs920047	ENSG00000261451.1	RP11-981G7.1	-4.03	6.43e-05	0.00533	-0.23	-0.18	Triglycerides;	chr8:11229966	chr8:10433672~10438312:+
THCA	cis	rs495337	0.76	rs2254930	ENSG00000229222.1	KRT18P4	-4.03	6.43e-05	0.00533	-0.23	-0.18	Psoriasis;	chr20:49910570	chr20:49956745~49958032:+
THCA	cis	rs12681366	0.592	rs4735291	ENSG00000261437.1	RP11-22C11.2	4.03	6.43e-05	0.00533	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94394914	chr8:94637285~94639467:-
THCA	cis	rs2239815	0.515	rs9625591	ENSG00000272858.1	CTA-292E10.8	-4.03	6.44e-05	0.00533	-0.23	-0.18	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28836576	chr22:28814914~28815662:+
THCA	cis	rs2239815	0.515	rs6005917	ENSG00000272858.1	CTA-292E10.8	-4.03	6.44e-05	0.00533	-0.23	-0.18	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28837498	chr22:28814914~28815662:+
THCA	cis	rs13325613	0.704	rs34920132	ENSG00000223552.1	RP11-24F11.2	-4.03	6.44e-05	0.00533	-0.27	-0.18	Monocyte count;	chr3:46185277	chr3:46364955~46407059:-
THCA	cis	rs427691	0.625	rs845739	ENSG00000249476.1	CTD-2587M2.1	4.03	6.44e-05	0.00533	0.21	0.18	Autism spectrum disorder or schizophrenia;	chr5:109682839	chr5:109237120~109326369:-
THCA	cis	rs860295	0.58	rs10908483	ENSG00000236675.1	MTX1P1	-4.03	6.44e-05	0.00533	-0.19	-0.18	Body mass index;	chr1:155897043	chr1:155230975~155234325:+
THCA	cis	rs1387259	0.859	rs2054905	ENSG00000273765.1	RP11-370I10.11	4.03	6.44e-05	0.00533	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48360920~48361377:+
THCA	cis	rs2732480	0.5	rs2732461	ENSG00000273765.1	RP11-370I10.11	4.03	6.44e-05	0.00533	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48360920~48361377:+
THCA	cis	rs11089937	0.616	rs7291684	ENSG00000211639.2	IGLV4-60	4.03	6.44e-05	0.00533	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs6001219	ENSG00000211639.2	IGLV4-60	4.03	6.44e-05	0.00533	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs5995615	ENSG00000211639.2	IGLV4-60	4.03	6.44e-05	0.00533	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs6001223	ENSG00000211639.2	IGLV4-60	4.03	6.44e-05	0.00533	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs928895	ENSG00000211639.2	IGLV4-60	4.03	6.44e-05	0.00533	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs928896	ENSG00000211639.2	IGLV4-60	4.03	6.44e-05	0.00533	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.616	rs6001224	ENSG00000211639.2	IGLV4-60	4.03	6.44e-05	0.00533	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22162199~22162681:+
THCA	cis	rs12440869	1	rs8991	ENSG00000270964.1	RP11-502I4.3	4.03	6.44e-05	0.00533	0.16	0.18	Peak velocity of the mitral A-wave;	chr15:67201966	chr15:67541072~67542604:-
THCA	cis	rs4908760	0.965	rs10864356	ENSG00000270282.1	RP5-1115A15.2	4.03	6.44e-05	0.00534	0.21	0.18	Vitiligo;	chr1:8509812	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs6668508	ENSG00000270282.1	RP5-1115A15.2	4.03	6.44e-05	0.00534	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8512653~8513021:+
THCA	cis	rs911555	0.617	rs7156036	ENSG00000269958.1	RP11-73M18.8	-4.03	6.44e-05	0.00534	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103696353~103697163:+
THCA	cis	rs911555	0.723	rs6575991	ENSG00000269958.1	RP11-73M18.8	-4.03	6.44e-05	0.00534	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103696353~103697163:+
THCA	cis	rs12546962	0.508	rs62493794	ENSG00000254153.1	CTA-398F10.2	-4.03	6.44e-05	0.00534	-0.23	-0.18	Body mass index;	chr8:9325538	chr8:8456909~8461337:-
THCA	cis	rs11064837	0.504	rs7310148	ENSG00000248636.5	RP11-768F21.1	4.03	6.44e-05	0.00534	0.21	0.18	Schizophrenia;	chr12:119615925	chr12:119387987~119668079:-
THCA	cis	rs494526	0.874	rs11198760	ENSG00000229272.1	RP11-498J9.2	-4.03	6.44e-05	0.00534	-0.2	-0.18	Alcoholic chronic pancreatitis;	chr10:119081666	chr10:119003536~119003884:-
THCA	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-4.03	6.44e-05	0.00534	-0.11	-0.18	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
THCA	cis	rs4906332	1	rs12885234	ENSG00000252469.1	RNU7-160P	4.03	6.44e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103422844	chr14:103550345~103550406:+
THCA	cis	rs4906332	0.966	rs35799018	ENSG00000252469.1	RNU7-160P	4.03	6.44e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103427138	chr14:103550345~103550406:+
THCA	cis	rs10090774	0.965	rs72685787	ENSG00000279766.1	RP11-642A1.2	4.03	6.44e-05	0.00534	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140950016	chr8:140572142~140572812:-
THCA	cis	rs4950322	0.512	rs2353981	ENSG00000226015.2	CCT8P1	-4.03	6.44e-05	0.00534	-0.19	-0.18	Protein quantitative trait loci;	chr1:147368365	chr1:147203276~147204932:-
THCA	cis	rs854765	0.583	rs8075965	ENSG00000281749.1	Y_RNA	4.03	6.45e-05	0.00534	0.23	0.18	Total body bone mineral density;	chr17:17949866	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs4413022	ENSG00000281749.1	Y_RNA	4.03	6.45e-05	0.00534	0.23	0.18	Total body bone mineral density;	chr17:17954966	chr17:18001101~18001195:-
THCA	cis	rs6496044	0.568	rs3743321	ENSG00000259630.2	CTD-2262B20.1	-4.03	6.45e-05	0.00534	-0.2	-0.18	Interstitial lung disease;	chr15:85521737	chr15:85415228~85415633:+
THCA	cis	rs867371	0.896	rs8033831	ENSG00000278603.1	RP13-608F4.5	4.03	6.45e-05	0.00534	0.23	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472203~82472426:+
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000182586.6	LINC00334	-4.03	6.45e-05	0.00534	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45234340~45258730:+
THCA	cis	rs7674212	0.531	rs4698875	ENSG00000248971.2	KRT8P46	-4.03	6.45e-05	0.00534	-0.23	-0.18	Type 2 diabetes;	chr4:103012211	chr4:102728746~102730171:-
THCA	cis	rs11633886	0.835	rs2413793	ENSG00000259200.1	RP11-718O11.1	-4.03	6.45e-05	0.00534	-0.21	-0.18	Diisocyanate-induced asthma;	chr15:45810619	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.835	rs2413794	ENSG00000259200.1	RP11-718O11.1	-4.03	6.45e-05	0.00534	-0.21	-0.18	Diisocyanate-induced asthma;	chr15:45810812	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.835	rs11637752	ENSG00000259200.1	RP11-718O11.1	-4.03	6.45e-05	0.00534	-0.21	-0.18	Diisocyanate-induced asthma;	chr15:45811375	chr15:45705078~45931069:+
THCA	cis	rs12682352	0.652	rs1567398	ENSG00000233609.3	RP11-62H7.2	-4.03	6.45e-05	0.00534	-0.19	-0.18	Neuroticism;	chr8:8869294	chr8:8961200~8979025:+
THCA	cis	rs4906332	0.966	rs2065016	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103413319	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs34479426	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103415486	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs8012127	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103476425	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs78316803	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103476526	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs17617832	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103476803	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs11625172	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103478575	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs17617935	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103486549	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs17680085	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103486817	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs12896919	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103490376	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs35126287	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103493095	chr14:103550345~103550406:+
THCA	cis	rs4906332	1	rs55930273	ENSG00000252469.1	RNU7-160P	4.03	6.45e-05	0.00534	0.2	0.18	Coronary artery disease;	chr14:103493961	chr14:103550345~103550406:+
THCA	cis	rs7615952	0.515	rs7637246	ENSG00000250012.1	RP11-124N2.1	-4.03	6.45e-05	0.00534	-0.18	-0.18	Blood pressure (smoking interaction);	chr3:125959863	chr3:126084220~126095349:+
THCA	cis	rs2120243	0.539	rs722484	ENSG00000241770.1	RP11-555M1.3	-4.03	6.45e-05	0.00534	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157382838	chr3:157163452~157169133:+
THCA	cis	rs962856	0.619	rs6721534	ENSG00000236780.4	AC078941.1	4.03	6.45e-05	0.00534	0.25	0.18	Pancreatic cancer;	chr2:67347530	chr2:67123357~67215319:-
THCA	cis	rs1124769	0.748	rs35111245	ENSG00000259378.1	DCAF13P3	4.03	6.45e-05	0.00534	0.29	0.18	Cognitive performance;	chr15:51069234	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.748	rs12591500	ENSG00000259378.1	DCAF13P3	4.03	6.45e-05	0.00534	0.29	0.18	Cognitive performance;	chr15:51072895	chr15:50944663~50945996:+
THCA	cis	rs72819454	0.579	rs2013456	ENSG00000280693.1	SH3PXD2A-AS1	-4.03	6.45e-05	0.00534	-0.34	-0.18	Interleukin-9 levels;	chr10:103771634	chr10:103745966~103755423:+
THCA	cis	rs16826658	0.931	rs12093861	ENSG00000218510.5	LINC00339	4.03	6.45e-05	0.00534	0.2	0.18	Endometriosis;	chr1:22159184	chr1:22025188~22031223:+
THCA	cis	rs4857855	0.678	rs9819395	ENSG00000239405.1	TMED10P2	4.03	6.46e-05	0.00535	0.27	0.18	Eosinophil counts;	chr3:128526853	chr3:128538020~128538631:+
THCA	cis	rs1908814	0.516	rs7812563	ENSG00000206014.6	OR7E161P	-4.03	6.46e-05	0.00535	-0.22	-0.18	Neuroticism;	chr8:11936979	chr8:11928597~11929563:-
THCA	cis	rs8062405	0.755	rs17707300	ENSG00000270424.1	RP11-1348G14.6	4.03	6.46e-05	0.00535	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28749959~28750595:-
THCA	cis	rs12681366	0.801	rs2919668	ENSG00000261437.1	RP11-22C11.2	4.03	6.46e-05	0.00535	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94449193	chr8:94637285~94639467:-
THCA	cis	rs6088813	0.883	rs1406949	ENSG00000126005.14	MMP24-AS1	-4.03	6.46e-05	0.00535	-0.19	-0.18	Height;	chr20:35318101	chr20:35216462~35278131:-
THCA	cis	rs2364403	0.715	rs12081057	ENSG00000225855.5	RUSC1-AS1	4.03	6.46e-05	0.00535	0.18	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:155952404	chr1:155316863~155324176:-
THCA	cis	rs7572644	0.64	rs12617113	ENSG00000223522.1	AC093690.1	-4.03	6.46e-05	0.00535	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27837070	chr2:28307691~28310459:-
THCA	cis	rs7903847	0.62	rs61863813	ENSG00000225850.3	RP11-452K12.4	4.03	6.46e-05	0.00535	0.19	0.18	Granulocyte percentage of myeloid white cells;	chr10:97353029	chr10:97334564~97343203:+
THCA	cis	rs12935229	1	rs16945428	ENSG00000260922.1	RP11-538I12.3	-4.03	6.46e-05	0.00535	-0.29	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77282363	chr16:77234877~77290934:+
THCA	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	4.03	6.46e-05	0.00535	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
THCA	cis	rs365302	0.951	rs413102	ENSG00000235086.1	FNDC1-IT1	4.03	6.46e-05	0.00535	0.26	0.18	Coronary heart disease;	chr6:159223855	chr6:159240786~159243329:+
THCA	cis	rs1065656	0.571	rs2745170	ENSG00000261123.1	RP11-304L19.3	4.03	6.47e-05	0.00536	0.21	0.18	Insulin-like growth factors;	chr16:1785230	chr16:2094830~2097026:-
THCA	cis	rs7647973	0.696	rs7100	ENSG00000229759.1	MRPS18AP1	4.03	6.47e-05	0.00536	0.28	0.18	Menarche (age at onset);	chr3:49015786	chr3:48256350~48256938:-
THCA	cis	rs853679	1	rs1679732	ENSG00000273712.1	RP5-874C20.7	-4.03	6.47e-05	0.00536	-0.29	-0.18	Depression;	chr6:28253486	chr6:28315613~28315883:-
THCA	cis	rs17221829	0.764	rs7930024	ENSG00000280385.1	AP000648.5	-4.03	6.47e-05	0.00536	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89652870	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.692	rs55823055	ENSG00000280385.1	AP000648.5	-4.03	6.47e-05	0.00536	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89655576	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.645	rs12288897	ENSG00000280385.1	AP000648.5	-4.03	6.47e-05	0.00536	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89655648	chr11:90193614~90198120:+
THCA	cis	rs8062405	0.69	rs62034351	ENSG00000270424.1	RP11-1348G14.6	4.03	6.47e-05	0.00536	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28749959~28750595:-
THCA	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	4.03	6.47e-05	0.00536	0.16	0.18	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	4.03	6.47e-05	0.00536	0.16	0.18	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	4.03	6.47e-05	0.00536	0.16	0.18	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	4.03	6.47e-05	0.00536	0.16	0.18	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
THCA	cis	rs6496044	0.568	rs2880765	ENSG00000259630.2	CTD-2262B20.1	4.03	6.47e-05	0.00536	0.2	0.18	Interstitial lung disease;	chr15:85513231	chr15:85415228~85415633:+
THCA	cis	rs8062405	0.698	rs8046545	ENSG00000278665.1	RP11-666O2.4	-4.03	6.47e-05	0.00536	-0.21	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28599241~28601881:-
THCA	cis	rs295490	0.748	rs10513063	ENSG00000272656.1	RP11-219D15.3	4.03	6.47e-05	0.00536	0.34	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341586	chr3:139349024~139349371:-
THCA	cis	rs4262150	0.803	rs72799144	ENSG00000253921.1	CTB-113P19.3	4.03	6.47e-05	0.00536	0.24	0.18	Bipolar disorder and schizophrenia;	chr5:152723102	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.803	rs72799145	ENSG00000253921.1	CTB-113P19.3	4.03	6.47e-05	0.00536	0.24	0.18	Bipolar disorder and schizophrenia;	chr5:152723103	chr5:151753992~151767247:+
THCA	cis	rs34421088	0.56	rs2248325	ENSG00000206014.6	OR7E161P	4.03	6.47e-05	0.00536	0.21	0.18	Neuroticism;	chr8:11539365	chr8:11928597~11929563:-
THCA	cis	rs34421088	0.56	rs2248316	ENSG00000206014.6	OR7E161P	4.03	6.47e-05	0.00536	0.21	0.18	Neuroticism;	chr8:11539564	chr8:11928597~11929563:-
THCA	cis	rs34421088	0.56	rs2248315	ENSG00000206014.6	OR7E161P	4.03	6.47e-05	0.00536	0.21	0.18	Neuroticism;	chr8:11539577	chr8:11928597~11929563:-
THCA	cis	rs6580649	0.574	rs7964359	ENSG00000273765.1	RP11-370I10.11	4.03	6.47e-05	0.00536	0.17	0.18	Lung cancer;	chr12:48016783	chr12:48360920~48361377:+
THCA	cis	rs9926296	0.605	rs886951	ENSG00000274627.1	RP11-104N10.2	-4.03	6.47e-05	0.00536	-0.19	-0.18	Vitiligo;	chr16:89770457	chr16:89516797~89522217:+
THCA	cis	rs722599	0.715	rs61978928	ENSG00000279594.1	RP11-950C14.10	-4.03	6.48e-05	0.00536	-0.19	-0.18	IgG glycosylation;	chr14:74855011	chr14:75011269~75012851:-
THCA	cis	rs6828577	0.862	rs298995	ENSG00000281731.1	RP11-384K6.8	-4.03	6.48e-05	0.00536	-0.21	-0.18	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118704118	chr4:118664087~118685341:-
THCA	cis	rs16852403	0.619	rs2862317	ENSG00000224687.1	RASAL2-AS1	4.03	6.48e-05	0.00536	0.3	0.18	Childhood ear infection;	chr1:178177143	chr1:178091508~178093984:-
THCA	cis	rs4792901	0.759	rs60442473	ENSG00000267151.3	RP11-100E5.2	4.03	6.48e-05	0.00536	0.2	0.18	Dupuytren's disease;	chr17:43501919	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs76971300	ENSG00000267151.3	RP11-100E5.2	4.03	6.48e-05	0.00536	0.2	0.18	Dupuytren's disease;	chr17:43503220	chr17:43444707~43451200:+
THCA	cis	rs7200543	1	rs3803575	ENSG00000188599.16	NPIPP1	-4.03	6.48e-05	0.00536	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:15104312~15123498:-
THCA	cis	rs758324	0.891	rs4425498	ENSG00000237714.1	P4HA2-AS1	4.03	6.48e-05	0.00536	0.33	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131884317	chr5:132184876~132192808:+
THCA	cis	rs1124769	0.748	rs34013374	ENSG00000259378.1	DCAF13P3	4.03	6.48e-05	0.00536	0.28	0.18	Cognitive performance;	chr15:51076889	chr15:50944663~50945996:+
THCA	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	4.03	6.48e-05	0.00536	0.21	0.18	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	4.03	6.48e-05	0.00536	0.21	0.18	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
THCA	cis	rs10875746	0.903	rs11168370	ENSG00000258273.1	RP11-370I10.4	4.03	6.48e-05	0.00536	0.23	0.18	Longevity (90 years and older);	chr12:48041497	chr12:48333755~48333901:-
THCA	cis	rs12546962	0.51	rs7836983	ENSG00000254153.1	CTA-398F10.2	-4.03	6.48e-05	0.00536	-0.24	-0.18	Body mass index;	chr8:9327420	chr8:8456909~8461337:-
THCA	cis	rs613391	0.522	rs525532	ENSG00000234840.1	LINC01239	-4.03	6.48e-05	0.00536	-0.21	-0.18	Quantitative traits;	chr9:22732228	chr9:22646200~22824213:+
THCA	cis	rs42648	0.905	rs42641	ENSG00000225498.1	AC002064.5	4.03	6.48e-05	0.00536	0.19	0.18	Homocysteine levels;	chr7:90343450	chr7:90312496~90322592:+
THCA	cis	rs758324	0.687	rs156023	ENSG00000224431.1	AC063976.7	-4.03	6.48e-05	0.00537	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132209475	chr5:132199456~132203487:+
THCA	cis	rs7772486	0.79	rs3924498	ENSG00000270638.1	RP3-466P17.1	-4.03	6.48e-05	0.00537	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs9390365	ENSG00000270638.1	RP3-466P17.1	-4.03	6.48e-05	0.00537	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145735570~145737218:+
THCA	cis	rs4218	0.681	rs7178935	ENSG00000259732.1	RP11-59H7.3	-4.03	6.48e-05	0.00537	-0.25	-0.18	Social communication problems;	chr15:59075968	chr15:59121034~59133250:+
THCA	cis	rs7927592	0.956	rs12277225	ENSG00000160172.9	FAM86C2P	4.03	6.49e-05	0.00537	0.18	0.18	Total body bone mineral density;	chr11:68573499	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.871	rs871212	ENSG00000160172.9	FAM86C2P	4.03	6.49e-05	0.00537	0.18	0.18	Total body bone mineral density;	chr11:68581227	chr11:67791648~67805336:-
THCA	cis	rs4886920	0.894	rs4886527	ENSG00000260776.4	RP11-114H24.2	-4.03	6.49e-05	0.00537	-0.21	-0.18	Neuroticism;	chr15:77821215	chr15:77914217~77926846:-
THCA	cis	rs12313068	0.709	rs11829777	ENSG00000249094.2	RP1-7G5.6	4.03	6.49e-05	0.00537	0.29	0.18	Intelligence (multi-trait analysis);	chr12:110065965	chr12:109880676~109888467:+
THCA	cis	rs7521902	0.508	rs12038474	ENSG00000228397.1	RP1-224A6.3	-4.03	6.49e-05	0.00537	-0.32	-0.18	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22076864	chr1:22023994~22024968:-
THCA	cis	rs12440869	0.959	rs7178975	ENSG00000270964.1	RP11-502I4.3	4.03	6.49e-05	0.00537	0.16	0.18	Peak velocity of the mitral A-wave;	chr15:67325063	chr15:67541072~67542604:-
THCA	cis	rs17685	0.753	rs8200	ENSG00000230882.1	AC005077.14	-4.03	6.49e-05	0.00537	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76067288	chr7:76071469~76074963:-
THCA	cis	rs950169	0.922	rs8037078	ENSG00000275120.1	RP11-182J1.17	-4.03	6.49e-05	0.00537	-0.22	-0.18	Schizophrenia;	chr15:84150119	chr15:84599434~84606463:-
THCA	cis	rs9788682	0.747	rs12910984	ENSG00000261143.1	ADAMTS7P3	4.03	6.49e-05	0.00537	0.25	0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78599285	chr15:77976042~77993057:+
THCA	cis	rs9595908	0.869	rs55880225	ENSG00000212293.1	SNORA16	4.03	6.49e-05	0.00537	0.21	0.18	Body mass index;	chr13:32616733	chr13:32420390~32420516:-
THCA	cis	rs763121	0.889	rs2267390	ENSG00000273076.1	RP3-508I15.22	4.03	6.49e-05	0.00537	0.18	0.18	Menopause (age at onset);	chr22:38493652	chr22:38743495~38743910:+
THCA	cis	rs7264396	0.887	rs2236160	ENSG00000088340.14	FER1L4	4.03	6.49e-05	0.00537	0.17	0.18	Total cholesterol levels;	chr20:35513992	chr20:35558737~35607562:-
THCA	cis	rs453301	0.605	rs7843024	ENSG00000233609.3	RP11-62H7.2	-4.03	6.49e-05	0.00537	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8942466	chr8:8961200~8979025:+
THCA	cis	rs453301	0.631	rs7843789	ENSG00000233609.3	RP11-62H7.2	-4.03	6.49e-05	0.00537	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8943051	chr8:8961200~8979025:+
THCA	cis	rs4434872	0.536	rs6427298	ENSG00000223599.1	RP11-216N14.7	4.03	6.49e-05	0.00537	0.34	0.18	Conduct disorder (symptom count);	chr1:153822520	chr1:153852106~153853414:-
THCA	cis	rs72928364	0.929	rs13060849	ENSG00000256628.3	ZBTB11-AS1	4.03	6.49e-05	0.00537	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101054639	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.929	rs13065684	ENSG00000256628.3	ZBTB11-AS1	4.03	6.49e-05	0.00537	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101054894	chr3:101676475~101679217:+
THCA	cis	rs4722166	0.541	rs1800795	ENSG00000225541.1	AC002480.5	-4.03	6.49e-05	0.00537	-0.23	-0.18	Lung cancer;	chr7:22727026	chr7:22571607~22661792:-
THCA	cis	rs911555	0.603	rs11621300	ENSG00000269940.1	RP11-73M18.7	4.03	6.49e-05	0.00537	0.18	0.18	Intelligence (multi-trait analysis);	chr14:103378561	chr14:103694560~103695170:+
THCA	cis	rs4718428	1	rs12534637	ENSG00000229180.5	GS1-124K5.11	4.03	6.49e-05	0.00537	0.13	0.18	Corneal structure;	chr7:66862667	chr7:66526088~66542624:-
THCA	cis	rs5752773	0.513	rs134489	ENSG00000272858.1	CTA-292E10.8	4.03	6.49e-05	0.00537	0.2	0.18	Vertical cup-disc ratio;	chr22:28333779	chr22:28814914~28815662:+
THCA	cis	rs12935229	1	rs1025317	ENSG00000260922.1	RP11-538I12.3	-4.03	6.49e-05	0.00537	-0.3	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77301316	chr16:77234877~77290934:+
THCA	cis	rs1971762	0.527	rs1247956	ENSG00000270175.1	RP11-793H13.11	4.03	6.5e-05	0.00538	0.12	0.18	Height;	chr12:53570030	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.509	rs1247955	ENSG00000270175.1	RP11-793H13.11	4.03	6.5e-05	0.00538	0.12	0.18	Height;	chr12:53570349	chr12:53500162~53500936:-
THCA	cis	rs1635	0.826	rs7750106	ENSG00000216901.1	AL022393.7	4.03	6.5e-05	0.00538	0.38	0.18	Schizophrenia;	chr6:28255902	chr6:28176188~28176674:+
THCA	cis	rs1635	1	rs1635	ENSG00000216901.1	AL022393.7	4.03	6.5e-05	0.00538	0.38	0.18	Schizophrenia;	chr6:28259826	chr6:28176188~28176674:+
THCA	cis	rs9595908	0.785	rs3783267	ENSG00000212293.1	SNORA16	4.03	6.5e-05	0.00538	0.21	0.18	Body mass index;	chr13:32670719	chr13:32420390~32420516:-
THCA	cis	rs2911280	0.764	rs17777603	ENSG00000278985.1	RP11-303E16.9	-4.03	6.5e-05	0.00538	-0.32	-0.18	Dehydroepiandrosterone sulphate levels;	chr16:81530261	chr16:80982319~80984094:-
THCA	cis	rs875971	1	rs10244498	ENSG00000230189.5	GS1-124K5.2	4.03	6.5e-05	0.00538	0.12	0.18	Aortic root size;	chr7:66651069	chr7:66409143~66490059:-
THCA	cis	rs3764021	0.527	rs10844380	ENSG00000214776.8	RP11-726G1.1	4.03	6.5e-05	0.00538	0.24	0.18	Type 1 diabetes;	chr12:9670678	chr12:9467552~9576275:+
THCA	cis	rs791590	0.941	rs12722561	ENSG00000229664.1	RP11-536K7.5	-4.03	6.5e-05	0.00538	-0.31	-0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:6027930	chr10:6025978~6036427:+
THCA	cis	rs7264396	0.887	rs4911502	ENSG00000088340.14	FER1L4	4.03	6.5e-05	0.00538	0.17	0.18	Total cholesterol levels;	chr20:35475209	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs6060434	ENSG00000088340.14	FER1L4	4.03	6.5e-05	0.00538	0.17	0.18	Total cholesterol levels;	chr20:35480557	chr20:35558737~35607562:-
THCA	cis	rs4682868	0.611	rs2888271	ENSG00000273328.4	RP11-141M3.6	-4.03	6.5e-05	0.00538	-0.22	-0.18	Monocyte percentage of white cells;	chr3:42873384	chr3:42809414~42908105:+
THCA	cis	rs7927592	0.956	rs60212556	ENSG00000160172.9	FAM86C2P	4.03	6.5e-05	0.00538	0.18	0.18	Total body bone mineral density;	chr11:68538026	chr11:67791648~67805336:-
THCA	cis	rs2120243	0.591	rs9871290	ENSG00000241770.1	RP11-555M1.3	-4.03	6.5e-05	0.00538	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157381802	chr3:157163452~157169133:+
THCA	cis	rs1559040	0.858	rs72800715	ENSG00000272156.1	RP11-477N3.1	-4.03	6.51e-05	0.00538	-0.31	-0.18	Sudden cardiac arrest;	chr2:54037660	chr2:54082554~54085066:+
THCA	cis	rs5751901	0.614	rs6519519	ENSG00000128262.7	POM121L9P	-4.03	6.51e-05	0.00538	-0.18	-0.18	Protein quantitative trait loci;	chr22:24595896	chr22:24251828~24265525:+
THCA	cis	rs9532669	0.963	rs1056824	ENSG00000229473.2	RGS17P1	4.03	6.51e-05	0.00538	0.22	0.18	Cervical cancer;	chr13:40932748	chr13:40992779~40993331:-
THCA	cis	rs722599	0.748	rs55707505	ENSG00000279594.1	RP11-950C14.10	-4.03	6.51e-05	0.00538	-0.18	-0.18	IgG glycosylation;	chr14:74895849	chr14:75011269~75012851:-
THCA	cis	rs889398	0.967	rs12929503	ENSG00000226232.7	RP11-419C5.2	4.03	6.51e-05	0.00538	0.18	0.18	Body mass index;	chr16:69531558	chr16:69976388~69996188:-
THCA	cis	rs10129255	0.957	rs10140904	ENSG00000211972.2	IGHV3-66	4.03	6.51e-05	0.00538	0.11	0.18	Kawasaki disease;	chr14:106776558	chr14:106675017~106675544:-
THCA	cis	rs10491083	0.661	rs2072150	ENSG00000261996.1	CTC-281F24.1	4.03	6.51e-05	0.00538	0.35	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6661308	chr17:6653464~6655009:-
THCA	cis	rs1113500	0.547	rs12076264	ENSG00000230489.1	VAV3-AS1	4.03	6.51e-05	0.00538	0.17	0.18	Growth-regulated protein alpha levels;	chr1:108014486	chr1:107964443~107994607:+
THCA	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-4.03	6.51e-05	0.00538	-0.18	-0.18	Height;	chr5:36925633	chr5:36666214~36725195:-
THCA	cis	rs4218	0.681	rs2121236	ENSG00000259732.1	RP11-59H7.3	-4.03	6.51e-05	0.00539	-0.25	-0.18	Social communication problems;	chr15:59091923	chr15:59121034~59133250:+
THCA	cis	rs11971779	0.818	rs12056045	ENSG00000252332.1	RNU6-911P	-4.03	6.51e-05	0.00539	-0.23	-0.18	Diisocyanate-induced asthma;	chr7:139340684	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.941	rs74299967	ENSG00000252332.1	RNU6-911P	-4.03	6.51e-05	0.00539	-0.23	-0.18	Diisocyanate-induced asthma;	chr7:139359023	chr7:139448740~139448843:+
THCA	cis	rs17507216	0.671	rs28582623	ENSG00000255769.6	GOLGA2P10	-4.03	6.51e-05	0.00539	-0.27	-0.18	Excessive daytime sleepiness;	chr15:82577381	chr15:82472993~82513950:-
THCA	cis	rs10411262	0.935	rs2312289	ENSG00000245598.5	DACT3-AS1	-4.03	6.51e-05	0.00539	-0.21	-0.18	Tonsillectomy;	chr19:46672358	chr19:46660364~46677447:+
THCA	cis	rs7923609	0.518	rs10761688	ENSG00000232075.1	MRPL35P2	-4.03	6.51e-05	0.00539	-0.24	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63068220	chr10:63634317~63634827:-
THCA	cis	rs7551222	0.721	rs1460036	ENSG00000240219.1	RP11-430C7.5	4.03	6.51e-05	0.00539	0.17	0.18	Schizophrenia;	chr1:204558251	chr1:204626775~204629712:+
THCA	cis	rs9843304	0.585	rs9847009	ENSG00000243885.1	RP11-278L15.2	-4.03	6.51e-05	0.00539	-0.2	-0.18	Gallstone disease;	chr3:149490380	chr3:149384179~149385800:-
THCA	cis	rs78487399	0.808	rs6544664	ENSG00000234936.1	AC010883.5	4.03	6.51e-05	0.00539	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43501969	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs6544665	ENSG00000234936.1	AC010883.5	4.03	6.51e-05	0.00539	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43502073	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6708735	ENSG00000234936.1	AC010883.5	4.03	6.51e-05	0.00539	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43504215	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6544666	ENSG00000234936.1	AC010883.5	4.03	6.51e-05	0.00539	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43505095	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6544668	ENSG00000234936.1	AC010883.5	4.03	6.51e-05	0.00539	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43505349	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7578597	ENSG00000234936.1	AC010883.5	4.03	6.51e-05	0.00539	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43505684	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7564886	ENSG00000234936.1	AC010883.5	4.03	6.51e-05	0.00539	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43505889	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6544669	ENSG00000234936.1	AC010883.5	4.03	6.51e-05	0.00539	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43509032	chr2:43229573~43233394:+
THCA	cis	rs11658311	0.85	rs11653424	ENSG00000232344.2	AC087163.2	-4.03	6.51e-05	0.00539	-0.26	-0.18	Obsessive-compulsive symptoms;	chr17:17743462	chr17:18010643~18011822:+
THCA	cis	rs2380205	0.967	rs4293038	ENSG00000232807.2	RP11-536K7.3	4.03	6.51e-05	0.00539	0.17	0.18	Breast cancer;	chr10:5856196	chr10:5934270~5945900:-
THCA	cis	rs73173548	0.528	rs80083342	ENSG00000247828.6	TMEM161B-AS1	4.03	6.52e-05	0.00539	0.17	0.18	Macular telangiectasia type 2;	chr5:88476921	chr5:88268895~88436685:+
THCA	cis	rs3781264	0.848	rs10882422	ENSG00000273450.1	RP11-76P2.4	-4.03	6.52e-05	0.00539	-0.22	-0.18	Esophageal cancer and gastric cancer;	chr10:94313806	chr10:94314907~94315327:-
THCA	cis	rs2412819	0.571	rs8030536	ENSG00000166763.7	STRCP1	4.03	6.52e-05	0.00539	0.26	0.18	Lung cancer;	chr15:43627365	chr15:43699488~43718184:-
THCA	cis	rs7520050	0.778	rs2991985	ENSG00000281133.1	AL355480.3	4.03	6.52e-05	0.00539	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45580892~45580996:-
THCA	cis	rs11822910	0.911	rs61886978	ENSG00000265566.2	RN7SL605P	4.03	6.52e-05	0.00539	0.28	0.18	Platelet distribution width;	chr11:57427375	chr11:57528085~57528365:-
THCA	cis	rs875971	1	rs12533997	ENSG00000230189.5	GS1-124K5.2	4.03	6.52e-05	0.00539	0.12	0.18	Aortic root size;	chr7:66500390	chr7:66409143~66490059:-
THCA	cis	rs801193	0.636	rs2659895	ENSG00000230189.5	GS1-124K5.2	4.03	6.52e-05	0.00539	0.12	0.18	Aortic root size;	chr7:66731484	chr7:66409143~66490059:-
THCA	cis	rs4742903	0.875	rs7041529	ENSG00000270332.1	SMC2-AS1	4.03	6.52e-05	0.00539	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104229258	chr9:104080024~104093073:-
THCA	cis	rs481331	0.689	rs10508868	ENSG00000215146.4	RP11-313J2.1	4.03	6.52e-05	0.00539	0.31	0.18	Systemic juvenile idiopathic arthritis;	chr10:42729253	chr10:42331866~42367974:-
THCA	cis	rs2235642	0.75	rs1894649	ENSG00000260989.1	LA16c-395F10.2	-4.03	6.52e-05	0.00539	-0.19	-0.18	Coronary artery disease;	chr16:1607283	chr16:1580527~1610328:+
THCA	cis	rs3809566	1	rs10851721	ENSG00000259459.4	RP11-321G12.1	-4.03	6.52e-05	0.00539	-0.16	-0.18	Platelet count;	chr15:63040184	chr15:63390136~63438320:+
THCA	cis	rs7267979	0.816	rs6076358	ENSG00000277938.1	RP5-965G21.3	-4.03	6.52e-05	0.00539	-0.15	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25229150~25231933:+
THCA	cis	rs7707921	0.881	rs74906189	ENSG00000251374.1	RPS23P5	4.03	6.52e-05	0.0054	0.28	0.18	Breast cancer;	chr5:81966104	chr5:82265157~82265259:-
THCA	cis	rs4792901	0.959	rs3826413	ENSG00000267151.3	RP11-100E5.2	-4.03	6.52e-05	0.0054	-0.19	-0.18	Dupuytren's disease;	chr17:43556277	chr17:43444707~43451200:+
THCA	cis	rs6828666	0.774	rs35189787	ENSG00000271817.2	U3	4.03	6.52e-05	0.0054	0.25	0.18	Depression;	chr4:158881115	chr4:158700691~158700909:+
THCA	cis	rs11220082	0.787	rs11220064	ENSG00000254671.2	STT3A-AS1	-4.03	6.52e-05	0.0054	-0.22	-0.18	Schizophrenia;	chr11:125424186	chr11:125570284~125592568:-
THCA	cis	rs6724465	0.673	rs2293081	ENSG00000272644.1	RP11-33O4.1	4.03	6.53e-05	0.0054	0.24	0.18	Height;	chr2:219146370	chr2:219069354~219069809:-
THCA	cis	rs7772486	0.79	rs2254257	ENSG00000270638.1	RP3-466P17.1	4.03	6.53e-05	0.0054	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145735570~145737218:+
THCA	cis	rs472402	0.58	rs11134173	ENSG00000250056.4	LINC01018	-4.03	6.53e-05	0.0054	-0.22	-0.18	Response to amphetamines;	chr5:6659583	chr5:6582136~6588499:+
THCA	cis	rs881375	0.678	rs10818488	ENSG00000270917.1	RP11-27I1.6	-4.03	6.53e-05	0.0054	-0.24	-0.18	Rheumatoid arthritis;	chr9:120942809	chr9:120812475~120812845:-
THCA	cis	rs758324	0.797	rs417585	ENSG00000237714.1	P4HA2-AS1	-4.03	6.53e-05	0.0054	-0.27	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131992205	chr5:132184876~132192808:+
THCA	cis	rs1124769	0.57	rs2414052	ENSG00000273674.3	CTD-2378E12.1	4.03	6.53e-05	0.0054	0.24	0.18	Cognitive performance;	chr15:50848104	chr15:50839875~50908599:-
THCA	cis	rs7623687	0.579	rs73082331	ENSG00000229759.1	MRPS18AP1	4.03	6.53e-05	0.0054	0.35	0.18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr3:48957510	chr3:48256350~48256938:-
THCA	cis	rs11633886	0.842	rs11638816	ENSG00000259200.1	RP11-718O11.1	-4.03	6.53e-05	0.0054	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45778257	chr15:45705078~45931069:+
THCA	cis	rs62244186	0.715	rs10212378	ENSG00000214820.3	MPRIPP1	4.03	6.53e-05	0.0054	0.19	0.18	Depressive symptoms;	chr3:44625794	chr3:44579938~44581026:-
THCA	cis	rs3096299	0.685	rs12446145	ENSG00000261118.1	RP11-104N10.1	4.03	6.53e-05	0.0054	0.15	0.18	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89492017~89504460:-
THCA	cis	rs9543976	0.623	rs8192756	ENSG00000261105.4	LMO7-AS1	4.03	6.53e-05	0.0054	0.25	0.18	Diabetic retinopathy;	chr13:75590802	chr13:75604700~75635994:-
THCA	cis	rs9543976	0.623	rs3783028	ENSG00000261105.4	LMO7-AS1	4.03	6.53e-05	0.0054	0.25	0.18	Diabetic retinopathy;	chr13:75591146	chr13:75604700~75635994:-
THCA	cis	rs9543976	0.623	rs7139740	ENSG00000261105.4	LMO7-AS1	4.03	6.53e-05	0.0054	0.25	0.18	Diabetic retinopathy;	chr13:75592806	chr13:75604700~75635994:-
THCA	cis	rs1204798	0.636	rs11968086	ENSG00000237021.2	RP3-486I3.7	-4.03	6.53e-05	0.0054	-0.23	-0.18	Dental caries;	chr6:116134385	chr6:116254207~116256743:+
THCA	cis	rs801193	1	rs4717310	ENSG00000230295.1	RP11-458F8.2	-4.03	6.53e-05	0.0054	-0.14	-0.18	Aortic root size;	chr7:66696020	chr7:66880708~66882981:+
THCA	cis	rs2659678	0.538	rs17127839	ENSG00000279858.1	RP11-618M23.5	-4.03	6.54e-05	0.0054	-0.19	-0.18	Bone ultrasound measurement (velocity of sound);	chr8:19116298	chr8:19375128~19375622:-
THCA	cis	rs7927592	0.956	rs12271290	ENSG00000160172.9	FAM86C2P	-4.03	6.54e-05	0.00541	-0.18	-0.18	Total body bone mineral density;	chr11:68558768	chr11:67791648~67805336:-
THCA	cis	rs3820928	0.692	rs17416354	ENSG00000212391.1	SNORA48	-4.03	6.54e-05	0.00541	-0.2	-0.18	Pulmonary function;	chr2:226906128	chr2:226968989~226969122:-
THCA	cis	rs7824557	0.737	rs10481445	ENSG00000261451.1	RP11-981G7.1	-4.03	6.54e-05	0.00541	-0.23	-0.18	Retinal vascular caliber;	chr8:11251760	chr8:10433672~10438312:+
THCA	cis	rs7264396	0.887	rs6060438	ENSG00000088340.14	FER1L4	4.03	6.54e-05	0.00541	0.17	0.18	Total cholesterol levels;	chr20:35489577	chr20:35558737~35607562:-
THCA	cis	rs8062405	0.723	rs113208333	ENSG00000270424.1	RP11-1348G14.6	4.03	6.54e-05	0.00541	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28749959~28750595:-
THCA	cis	rs3733585	0.682	rs13124563	ENSG00000250413.1	RP11-448G15.1	-4.03	6.54e-05	0.00541	-0.18	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9925929	chr4:10006482~10009725:+
THCA	cis	rs4434872	0.536	rs7527406	ENSG00000223599.1	RP11-216N14.7	4.03	6.54e-05	0.00541	0.33	0.18	Conduct disorder (symptom count);	chr1:153890880	chr1:153852106~153853414:-
THCA	cis	rs17689437	1	rs7196911	ENSG00000275383.1	RP11-615I2.6	4.03	6.54e-05	0.00541	0.29	0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68553340	chr16:68591382~68594424:+
THCA	cis	rs17689437	1	rs11859322	ENSG00000275383.1	RP11-615I2.6	4.03	6.54e-05	0.00541	0.29	0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68557483	chr16:68591382~68594424:+
THCA	cis	rs17689437	1	rs11859375	ENSG00000275383.1	RP11-615I2.6	4.03	6.54e-05	0.00541	0.29	0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68560943	chr16:68591382~68594424:+
THCA	cis	rs12681963	0.614	rs4409367	ENSG00000272375.1	RP11-51J9.6	4.03	6.54e-05	0.00541	0.29	0.18	Migraine;	chr8:30243112	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs4626556	ENSG00000272375.1	RP11-51J9.6	4.03	6.54e-05	0.00541	0.29	0.18	Migraine;	chr8:30243325	chr8:30197404~30198048:+
THCA	cis	rs8062405	0.625	rs8060365	ENSG00000278665.1	RP11-666O2.4	-4.03	6.54e-05	0.00541	-0.21	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28599241~28601881:-
THCA	cis	rs758324	0.947	rs6861732	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131820769	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs1846650	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131823074	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs13154286	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131824496	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs7734536	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131826431	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs1948704	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131835960	chr5:132184876~132192808:+
THCA	cis	rs758324	0.853	rs6882899	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131836774	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs10052255	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131837413	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs6596039	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131862959	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs6596040	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131863084	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs1500115	ENSG00000237714.1	P4HA2-AS1	4.03	6.54e-05	0.00541	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131880734	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs28537859	ENSG00000237714.1	P4HA2-AS1	-4.03	6.54e-05	0.00541	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131901584	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs72793242	ENSG00000237714.1	P4HA2-AS1	-4.03	6.54e-05	0.00541	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131906813	chr5:132184876~132192808:+
THCA	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-4.03	6.54e-05	0.00541	-0.21	-0.18	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
THCA	cis	rs7551222	0.646	rs7556371	ENSG00000240219.1	RP11-430C7.5	-4.03	6.54e-05	0.00541	-0.18	-0.18	Schizophrenia;	chr1:204488208	chr1:204626775~204629712:+
THCA	cis	rs3824488	0.765	rs28372466	ENSG00000271155.1	RP11-435O5.5	-4.03	6.54e-05	0.00541	-0.27	-0.18	Neuroticism;	chr9:95521419	chr9:95506235~95507636:+
THCA	cis	rs10256972	0.577	rs6962809	ENSG00000225146.1	AC073957.15	4.03	6.54e-05	0.00541	0.2	0.18	Endometriosis;Longevity;	chr7:1169253	chr7:1029025~1043891:+
THCA	cis	rs7216064	0.861	rs12449312	ENSG00000278740.1	RP11-147L13.14	4.03	6.55e-05	0.00541	0.21	0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67833242	chr17:68188547~68189165:+
THCA	cis	rs2980439	0.517	rs712253	ENSG00000233609.3	RP11-62H7.2	-4.03	6.55e-05	0.00541	-0.18	-0.18	Neuroticism;	chr8:8246260	chr8:8961200~8979025:+
THCA	cis	rs8064024	0.604	rs1049212	ENSG00000267077.1	RP11-127I20.5	-4.03	6.55e-05	0.00541	-0.21	-0.18	Cancer;	chr16:4882928	chr16:4795265~4796532:-
THCA	cis	rs4886920	0.894	rs4587942	ENSG00000260776.4	RP11-114H24.2	-4.03	6.55e-05	0.00541	-0.21	-0.18	Neuroticism;	chr15:77827003	chr15:77914217~77926846:-
THCA	cis	rs11123170	0.543	rs2863242	ENSG00000274877.1	RP11-65I12.1	4.03	6.55e-05	0.00541	0.11	0.18	Renal function-related traits (BUN);	chr2:113231659	chr2:113237595~113240825:+
THCA	cis	rs11089937	0.963	rs5757098	ENSG00000263366.2	LL22NC03-33B6.4	4.03	6.55e-05	0.00541	0.22	0.18	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22114844~22118005:-
THCA	cis	rs12142240	0.845	rs4313342	ENSG00000232022.5	FAAHP1	-4.03	6.55e-05	0.00541	-0.21	-0.18	Menopause (age at onset);	chr1:46336232	chr1:46432129~46445521:+
THCA	cis	rs1009077	0.625	rs3756157	ENSG00000260091.1	RP11-33B1.4	-4.03	6.55e-05	0.00541	-0.17	-0.18	Endometriosis;	chr4:119604255	chr4:119409333~119410233:+
THCA	cis	rs1009077	0.627	rs28650385	ENSG00000260091.1	RP11-33B1.4	-4.03	6.55e-05	0.00541	-0.17	-0.18	Endometriosis;	chr4:119605320	chr4:119409333~119410233:+
THCA	cis	rs6671200	1	rs35179427	ENSG00000235501.4	RP4-639F20.1	-4.03	6.55e-05	0.00542	-0.38	-0.18	Stearic acid (18:0) levels;	chr1:95205332	chr1:94927566~94963270:+
THCA	cis	rs4785204	1	rs58069930	ENSG00000279356.1	RP11-429P3.8	-4.03	6.55e-05	0.00542	-0.35	-0.18	Esophageal cancer (squamous cell);	chr16:50033120	chr16:50072862~50074986:+
THCA	cis	rs4660214	0.614	rs6688708	ENSG00000228060.1	RP11-69E11.8	4.03	6.55e-05	0.00542	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39565160~39573203:+
THCA	cis	rs56104184	0.83	rs28556985	ENSG00000243829.1	CTB-33G10.1	-4.03	6.55e-05	0.00542	-0.24	-0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48847892	chr19:49719498~49720081:-
THCA	cis	rs7914558	0.966	rs56946876	ENSG00000213061.2	PFN1P11	4.03	6.55e-05	0.00542	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.933	rs12763665	ENSG00000213061.2	PFN1P11	4.03	6.55e-05	0.00542	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs10786721	ENSG00000213061.2	PFN1P11	4.03	6.55e-05	0.00542	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102838011~102845473:-
THCA	cis	rs6479874	0.51	rs2248908	ENSG00000223502.1	RP11-96B5.3	-4.03	6.55e-05	0.00542	-0.22	-0.18	Migraine;	chr10:50990905	chr10:51062579~51068553:-
THCA	cis	rs9532669	0.926	rs4516083	ENSG00000229473.2	RGS17P1	4.03	6.55e-05	0.00542	0.23	0.18	Cervical cancer;	chr13:40951783	chr13:40992779~40993331:-
THCA	cis	rs9402682	0.663	rs1411919	ENSG00000232876.1	CTA-212D2.2	-4.03	6.55e-05	0.00542	-0.25	-0.18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135110923	chr6:135055033~135060550:+
THCA	cis	rs7474896	0.515	rs662928	ENSG00000263064.2	RP11-291L22.7	-4.03	6.55e-05	0.00542	-0.24	-0.18	Obesity (extreme);	chr10:38027288	chr10:38448689~38448949:+
THCA	cis	rs75059851	1	rs73036064	ENSG00000280237.1	MIR4697HG	4.03	6.55e-05	0.00542	0.21	0.18	Schizophrenia;	chr11:133959547	chr11:133896438~133901601:-
THCA	cis	rs11634944	0.714	rs2554430	ENSG00000251896.1	SNORD116-27	4.03	6.56e-05	0.00542	0.2	0.18	Interleukin-8 levels;	chr15:24949335	chr15:25101575~25101666:+
THCA	cis	rs10090774	0.804	rs4355822	ENSG00000280303.2	ERICD	4.03	6.56e-05	0.00542	0.17	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140736225	chr8:140636281~140638283:+
THCA	cis	rs78487399	0.808	rs17030889	ENSG00000234936.1	AC010883.5	4.03	6.56e-05	0.00542	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43475690	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs6717636	ENSG00000234936.1	AC010883.5	4.03	6.56e-05	0.00542	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43476545	chr2:43229573~43233394:+
THCA	cis	rs17092148	1	rs6088594	ENSG00000276073.1	RP5-1125A11.7	4.03	6.56e-05	0.00542	0.21	0.18	Neuroticism;	chr20:34755354	chr20:33985617~33988989:-
THCA	cis	rs79478560	0.518	rs74815407	ENSG00000270061.1	RP11-214K3.19	-4.03	6.56e-05	0.00542	-0.24	-0.18	Lymphocyte counts;	chr12:123898954	chr12:123969990~123970344:-
THCA	cis	rs12928939	0.517	rs11865456	ENSG00000260886.1	TAT-AS1	4.03	6.56e-05	0.00542	0.25	0.18	Post bronchodilator FEV1;	chr16:71935594	chr16:71565789~71578187:+
THCA	cis	rs17685	0.753	rs2286830	ENSG00000230882.1	AC005077.14	-4.03	6.56e-05	0.00542	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76064645	chr7:76071469~76074963:-
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000265443.1	CTD-2349P21.6	-4.03	6.56e-05	0.00542	-0.29	-0.18	Body mass index;	chr17:30690132	chr17:30726305~30727564:-
THCA	cis	rs9611565	0.592	rs4822044	ENSG00000237037.8	NDUFA6-AS1	4.03	6.56e-05	0.00542	0.18	0.18	Vitiligo;	chr22:41583664	chr22:42090931~42137742:+
THCA	cis	rs4272720	0.639	rs2246673	ENSG00000234736.4	FAM170B-AS1	4.03	6.56e-05	0.00542	0.2	0.18	Platelet count;Plateletcrit;	chr10:49048870	chr10:49121839~49151547:+
THCA	cis	rs7554547	0.791	rs4846074	ENSG00000199347.1	RNU5E-1	-4.03	6.56e-05	0.00543	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11896172	chr1:11908152~11908271:+
THCA	cis	rs17680741	0.955	rs55943223	ENSG00000226659.1	RP11-137H2.4	4.03	6.57e-05	0.00543	0.27	0.18	Coronary artery disease;	chr10:80490816	chr10:80529597~80535942:-
THCA	cis	rs17680741	1	rs7093808	ENSG00000226659.1	RP11-137H2.4	4.03	6.57e-05	0.00543	0.27	0.18	Coronary artery disease;	chr10:80491293	chr10:80529597~80535942:-
THCA	cis	rs1124769	0.748	rs1318765	ENSG00000259378.1	DCAF13P3	4.03	6.57e-05	0.00543	0.28	0.18	Cognitive performance;	chr15:51029750	chr15:50944663~50945996:+
THCA	cis	rs2898290	0.617	rs13278965	ENSG00000206014.6	OR7E161P	-4.03	6.57e-05	0.00543	-0.21	-0.18	Systolic blood pressure;	chr8:11609236	chr8:11928597~11929563:-
THCA	cis	rs7772486	0.79	rs3924499	ENSG00000270638.1	RP3-466P17.1	-4.03	6.57e-05	0.00543	-0.15	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145735570~145737218:+
THCA	cis	rs7829975	0.714	rs11784052	ENSG00000233609.3	RP11-62H7.2	4.03	6.57e-05	0.00543	0.18	0.18	Mood instability;	chr8:8814452	chr8:8961200~8979025:+
THCA	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	4.03	6.57e-05	0.00543	0.21	0.18	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
THCA	cis	rs10875746	0.859	rs11558768	ENSG00000258273.1	RP11-370I10.4	4.03	6.57e-05	0.00543	0.26	0.18	Longevity (90 years and older);	chr12:48184006	chr12:48333755~48333901:-
THCA	cis	rs7474896	0.583	rs10740950	ENSG00000120555.12	SEPT7P9	4.03	6.57e-05	0.00543	0.24	0.18	Obesity (extreme);	chr10:37714568	chr10:38383069~38402916:-
THCA	cis	rs138880	0.542	rs9616393	ENSG00000260613.1	RP3-522J7.6	4.03	6.57e-05	0.00543	0.29	0.18	Schizophrenia;	chr22:49921161	chr22:49832616~49837786:-
THCA	cis	rs67981189	0.896	rs4391999	ENSG00000269927.1	RP6-91H8.3	4.03	6.57e-05	0.00543	0.21	0.18	Schizophrenia;	chr14:70978696	chr14:71141125~71143253:-
THCA	cis	rs765787	0.53	rs2554453	ENSG00000259932.1	CTD-2651B20.7	4.03	6.57e-05	0.00543	0.22	0.18	Uric acid levels;	chr15:45229909	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11858988	ENSG00000259932.1	CTD-2651B20.7	4.03	6.57e-05	0.00543	0.22	0.18	Uric acid levels;	chr15:45229916	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11855435	ENSG00000259932.1	CTD-2651B20.7	4.03	6.57e-05	0.00543	0.22	0.18	Uric acid levels;	chr15:45229919	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2458224	ENSG00000259932.1	CTD-2651B20.7	4.03	6.57e-05	0.00543	0.22	0.18	Uric acid levels;	chr15:45229932	chr15:45198517~45199139:-
THCA	cis	rs12908161	1	rs3803405	ENSG00000188388.10	GOLGA6L3	4.03	6.57e-05	0.00543	0.25	0.18	Schizophrenia;	chr15:84840409	chr15:85240472~85247170:+
THCA	cis	rs9527	0.518	rs11191530	ENSG00000236937.2	PTGES3P4	-4.03	6.58e-05	0.00543	-0.33	-0.18	Arsenic metabolism;	chr10:103040287	chr10:102845595~102845950:+
THCA	cis	rs7404843	0.789	rs222909	ENSG00000188599.16	NPIPP1	4.03	6.58e-05	0.00543	0.19	0.18	Testicular germ cell tumor;	chr16:15405432	chr16:15104312~15123498:-
THCA	cis	rs911555	0.692	rs7146215	ENSG00000269958.1	RP11-73M18.8	-4.03	6.58e-05	0.00543	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103696353~103697163:+
THCA	cis	rs72928364	1	rs34272575	ENSG00000256628.3	ZBTB11-AS1	4.03	6.58e-05	0.00543	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100896563	chr3:101676475~101679217:+
THCA	cis	rs72928364	1	rs41273553	ENSG00000256628.3	ZBTB11-AS1	4.03	6.58e-05	0.00543	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100898688	chr3:101676475~101679217:+
THCA	cis	rs6933660	0.646	rs9397410	ENSG00000219395.2	HSPA8P15	-4.03	6.58e-05	0.00543	-0.16	-0.18	Menarche (age at onset);	chr6:151449368	chr6:151411259~151413945:-
THCA	cis	rs2120243	0.539	rs7617727	ENSG00000241770.1	RP11-555M1.3	4.03	6.58e-05	0.00543	0.24	0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157387769	chr3:157163452~157169133:+
THCA	cis	rs2692947	0.832	rs2692954	ENSG00000232931.4	LINC00342	4.03	6.58e-05	0.00544	0.15	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96017630	chr2:95807118~95816215:-
THCA	cis	rs875971	1	rs778726	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66363744	chr7:66409143~66490059:-
THCA	cis	rs875971	0.767	rs1695815	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66366357	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs778685	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66371189	chr7:66409143~66490059:-
THCA	cis	rs875971	0.929	rs778682	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66372947	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs11765965	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66377234	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs1643388	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66379575	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs778722	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66379841	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs778721	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66380410	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs778706	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66395437	chr7:66409143~66490059:-
THCA	cis	rs875971	0.895	rs778700	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66401463	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs778699	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66403303	chr7:66409143~66490059:-
THCA	cis	rs875971	0.929	rs778692	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66407462	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs4718343	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66409301	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs1968225	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66409786	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs6460295	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66417741	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs6978721	ENSG00000230189.5	GS1-124K5.2	4.03	6.58e-05	0.00544	0.12	0.18	Aortic root size;	chr7:66418217	chr7:66409143~66490059:-
THCA	cis	rs868036	0.645	rs4776987	ENSG00000270964.1	RP11-502I4.3	4.03	6.58e-05	0.00544	0.17	0.18	Restless legs syndrome;	chr15:67831577	chr15:67541072~67542604:-
THCA	cis	rs4660214	0.666	rs11205839	ENSG00000228060.1	RP11-69E11.8	4.03	6.58e-05	0.00544	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39565160~39573203:+
THCA	cis	rs6988985	0.53	rs3819497	ENSG00000247317.3	RP11-273G15.2	-4.03	6.58e-05	0.00544	-0.2	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142842636	chr8:142981738~143018437:-
THCA	cis	rs701145	0.585	rs1727920	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154070799	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1609205	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154076134	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713852	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154077698	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713853	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154077806	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs9839821	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154078534	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1629659	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154080942	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713804	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154081333	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713798	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154089618	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1358405	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154093203	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1527799	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154093437	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs6440935	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154099187	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1534386	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154101246	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs7612886	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154103387	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727946	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154108681	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1624917	ENSG00000243069.6	ARHGEF26-AS1	4.03	6.58e-05	0.00544	0.35	0.18	Coronary artery disease;	chr3:154109511	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs62276840	ENSG00000243069.6	ARHGEF26-AS1	-4.03	6.58e-05	0.00544	-0.35	-0.18	Coronary artery disease;	chr3:154065833	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727923	ENSG00000243069.6	ARHGEF26-AS1	-4.03	6.58e-05	0.00544	-0.35	-0.18	Coronary artery disease;	chr3:154068514	chr3:154024401~154121332:-
THCA	cis	rs724818	0.661	rs17051252	ENSG00000251609.2	SETP12	-4.03	6.58e-05	0.00544	-0.51	-0.18	Monobrow thickness;	chr4:120779564	chr4:120895494~120897083:-
THCA	cis	rs7985	0.901	rs5761679	ENSG00000244625.4	MIATNB	4.03	6.58e-05	0.00544	0.21	0.18	Electroencephalogram traits;	chr22:26681268	chr22:26672767~26780207:+
THCA	cis	rs7246657	0.722	rs958305	ENSG00000226686.6	LINC01535	4.03	6.58e-05	0.00544	0.25	0.18	Coronary artery calcification;	chr19:37698539	chr19:37251912~37265535:+
THCA	cis	rs5006884	0.627	rs12277631	ENSG00000167355.6	AC104389.28	-4.03	6.59e-05	0.00544	-0.31	-0.18	Fetal hemoglobin levels;	chr11:5426105	chr11:5304976~5505652:-
THCA	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-4.03	6.59e-05	0.00544	-0.21	-0.18	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
THCA	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-4.03	6.59e-05	0.00544	-0.22	-0.18	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
THCA	cis	rs2562456	0.833	rs55875743	ENSG00000268278.1	RP11-420K14.1	4.03	6.59e-05	0.00544	0.26	0.18	Pain;	chr19:21383393	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62110416	ENSG00000268278.1	RP11-420K14.1	4.03	6.59e-05	0.00544	0.26	0.18	Pain;	chr19:21401924	chr19:21637974~21656300:+
THCA	cis	rs854765	0.655	rs4470201	ENSG00000281749.1	Y_RNA	4.03	6.59e-05	0.00544	0.23	0.18	Total body bone mineral density;	chr17:17941556	chr17:18001101~18001195:-
THCA	cis	rs736408	0.608	rs4687657	ENSG00000243224.1	RP5-1157M23.2	-4.03	6.59e-05	0.00544	-0.22	-0.18	Bipolar disorder;	chr3:52818522	chr3:52239258~52241097:+
THCA	cis	rs2732480	0.577	rs2732481	ENSG00000257735.1	RP11-370I10.6	4.03	6.59e-05	0.00544	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.557	rs2732484	ENSG00000257735.1	RP11-370I10.6	4.03	6.59e-05	0.00544	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.577	rs2732486	ENSG00000257735.1	RP11-370I10.6	4.03	6.59e-05	0.00544	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.517	rs2634676	ENSG00000257735.1	RP11-370I10.6	4.03	6.59e-05	0.00544	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48350945~48442411:+
THCA	cis	rs4906332	1	rs8004780	ENSG00000244691.1	RPL10AP1	-4.03	6.59e-05	0.00544	-0.23	-0.18	Coronary artery disease;	chr14:103387023	chr14:103412119~103412761:-
THCA	cis	rs343092	1	rs343087	ENSG00000241749.4	RPSAP52	-4.03	6.59e-05	0.00544	-0.21	-0.18	Type 2 diabetes;	chr12:65867144	chr12:65758020~65826997:-
THCA	cis	rs17221829	0.764	rs12146462	ENSG00000280385.1	AP000648.5	-4.03	6.59e-05	0.00544	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89652206	chr11:90193614~90198120:+
THCA	cis	rs11971779	0.616	rs1862878	ENSG00000252332.1	RNU6-911P	-4.03	6.59e-05	0.00544	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139335168	chr7:139448740~139448843:+
THCA	cis	rs4718428	1	rs12534637	ENSG00000229886.1	RP5-1132H15.3	4.03	6.59e-05	0.00544	0.19	0.18	Corneal structure;	chr7:66862667	chr7:66025126~66031544:-
THCA	cis	rs7819412	0.806	rs10113808	ENSG00000261451.1	RP11-981G7.1	-4.03	6.59e-05	0.00545	-0.23	-0.18	Triglycerides;	chr8:11069382	chr8:10433672~10438312:+
THCA	cis	rs9307551	0.741	rs7691868	ENSG00000250334.4	LINC00989	-4.03	6.59e-05	0.00545	-0.24	-0.18	Refractive error;	chr4:79495250	chr4:79492416~79576460:+
THCA	cis	rs4144027	0.967	rs56126771	ENSG00000269958.1	RP11-73M18.8	4.03	6.59e-05	0.00545	0.17	0.18	Blood metabolite levels;	chr14:103894806	chr14:103696353~103697163:+
THCA	cis	rs9608946	1	rs17670707	ENSG00000279699.1	RP1-102K2.9	4.03	6.6e-05	0.00545	0.22	0.18	Red cell distribution width;	chr22:30481949	chr22:30275215~30276951:-
THCA	cis	rs9608946	1	rs2189835	ENSG00000279699.1	RP1-102K2.9	4.03	6.6e-05	0.00545	0.22	0.18	Red cell distribution width;	chr22:30482230	chr22:30275215~30276951:-
THCA	cis	rs9608946	0.956	rs7289820	ENSG00000279699.1	RP1-102K2.9	4.03	6.6e-05	0.00545	0.22	0.18	Red cell distribution width;	chr22:30482677	chr22:30275215~30276951:-
THCA	cis	rs1055129	0.56	rs2305913	ENSG00000267801.1	RP11-552F3.9	4.03	6.6e-05	0.00545	0.21	0.18	White matter hyperintensity burden;	chr17:75926860	chr17:75876372~75879546:+
THCA	cis	rs7737355	0.812	rs40991	ENSG00000237714.1	P4HA2-AS1	4.03	6.6e-05	0.00545	0.26	0.18	Life satisfaction;	chr5:131664961	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs31587	ENSG00000237714.1	P4HA2-AS1	4.03	6.6e-05	0.00545	0.26	0.18	Life satisfaction;	chr5:131665018	chr5:132184876~132192808:+
THCA	cis	rs4767841	0.598	rs203368	ENSG00000252886.1	RN7SKP197	-4.03	6.6e-05	0.00545	-0.18	-0.18	Urgency urinary incontinence;	chr12:119778553	chr12:119631090~119631386:-
THCA	cis	rs6600671	1	rs4844616	ENSG00000275585.1	CH17-118O6.3	-4.03	6.6e-05	0.00545	-0.22	-0.18	Hip geometry;	chr1:121429348	chr1:120985692~121052167:-
THCA	cis	rs10491083	1	rs10491083	ENSG00000261996.1	CTC-281F24.1	4.03	6.6e-05	0.00545	0.35	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6655238	chr17:6653464~6655009:-
THCA	cis	rs9341808	0.754	rs6916405	ENSG00000260645.1	RP11-250B2.5	4.03	6.6e-05	0.00545	0.16	0.18	Sitting height ratio;	chr6:80314471	chr6:80466958~80469080:+
THCA	cis	rs786425	0.77	rs7974279	ENSG00000278112.1	RP11-972P1.11	4.03	6.6e-05	0.00545	0.18	0.18	Pubertal anthropometrics;	chr12:123681864	chr12:123519390~123519856:-
THCA	cis	rs3096299	0.632	rs8051537	ENSG00000261118.1	RP11-104N10.1	4.03	6.6e-05	0.00545	0.15	0.18	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89492017~89504460:-
THCA	cis	rs2839186	0.588	rs2839140	ENSG00000228137.1	AP001469.7	-4.03	6.6e-05	0.00545	-0.18	-0.18	Testicular germ cell tumor;	chr21:46196166	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.647	rs9976233	ENSG00000228137.1	AP001469.7	-4.03	6.6e-05	0.00545	-0.18	-0.18	Testicular germ cell tumor;	chr21:46196999	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.588	rs7280110	ENSG00000228137.1	AP001469.7	-4.03	6.6e-05	0.00545	-0.18	-0.18	Testicular germ cell tumor;	chr21:46199125	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.616	rs4819213	ENSG00000228137.1	AP001469.7	-4.03	6.6e-05	0.00545	-0.18	-0.18	Testicular germ cell tumor;	chr21:46199386	chr21:46246890~46247682:+
THCA	cis	rs8017455	0.523	rs60447919	ENSG00000259167.2	NMNAT1P1	4.03	6.6e-05	0.00545	0.27	0.18	Hair morphology;	chr14:81093256	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs7158747	ENSG00000259167.2	NMNAT1P1	4.03	6.6e-05	0.00545	0.27	0.18	Hair morphology;	chr14:81093663	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs7159477	ENSG00000259167.2	NMNAT1P1	4.03	6.6e-05	0.00545	0.27	0.18	Hair morphology;	chr14:81093948	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs7160204	ENSG00000259167.2	NMNAT1P1	4.03	6.6e-05	0.00545	0.27	0.18	Hair morphology;	chr14:81094160	chr14:81032529~81033404:+
THCA	cis	rs9309473	0.847	rs4547554	ENSG00000273245.1	RP11-434P11.2	4.03	6.6e-05	0.00545	0.26	0.18	Metabolite levels;	chr2:73640735	chr2:73750256~73750786:-
THCA	cis	rs911555	0.617	rs7156036	ENSG00000269910.1	RP11-73M18.10	-4.03	6.6e-05	0.00545	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103694516~103695050:-
THCA	cis	rs911555	0.723	rs6575991	ENSG00000269910.1	RP11-73M18.10	-4.03	6.6e-05	0.00545	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103694516~103695050:-
THCA	cis	rs2120243	0.539	rs6441127	ENSG00000241770.1	RP11-555M1.3	-4.03	6.6e-05	0.00545	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157377718	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs7618737	ENSG00000241770.1	RP11-555M1.3	-4.03	6.6e-05	0.00545	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157377832	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.508	rs4435581	ENSG00000241770.1	RP11-555M1.3	-4.03	6.6e-05	0.00545	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157378428	chr3:157163452~157169133:+
THCA	cis	rs7824557	0.525	rs12682349	ENSG00000261451.1	RP11-981G7.1	4.03	6.6e-05	0.00545	0.23	0.18	Retinal vascular caliber;	chr8:11387794	chr8:10433672~10438312:+
THCA	cis	rs6671200	1	rs933107	ENSG00000235501.4	RP4-639F20.1	4.03	6.6e-05	0.00545	0.35	0.18	Stearic acid (18:0) levels;	chr1:95206673	chr1:94927566~94963270:+
THCA	cis	rs2281636	0.798	rs3184991	ENSG00000260475.1	RP11-85A1.3	-4.03	6.6e-05	0.00545	-0.18	-0.18	Obesity-related traits;	chr10:99755559	chr10:99621055~99621918:+
THCA	cis	rs1075265	0.584	rs1559037	ENSG00000272156.1	RP11-477N3.1	4.03	6.6e-05	0.00545	0.18	0.18	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54082554~54085066:+
THCA	cis	rs9902453	0.967	rs12150261	ENSG00000263370.1	RP11-68I3.5	-4.03	6.6e-05	0.00545	-0.24	-0.18	Coffee consumption (cups per day);	chr17:29993455	chr17:29639627~29640825:+
THCA	cis	rs1125355	0.964	rs11694423	ENSG00000243792.1	OR7E89P	-4.03	6.6e-05	0.00545	-0.27	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158820019	chr2:158853755~158854576:+
THCA	cis	rs13256369	1	rs7843488	ENSG00000254153.1	CTA-398F10.2	-4.03	6.6e-05	0.00545	-0.21	-0.18	Obesity-related traits;	chr8:8718707	chr8:8456909~8461337:-
THCA	cis	rs12887734	0.546	rs12886637	ENSG00000258534.1	CTD-2134A5.4	4.03	6.6e-05	0.00545	0.2	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103854366~103880111:-
THCA	cis	rs4356203	0.87	rs7935219	ENSG00000272034.1	SNORD14A	4.03	6.6e-05	0.00545	0.18	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17146640	chr11:17074654~17074744:-
THCA	cis	rs9467773	1	rs6940188	ENSG00000228223.2	HCG11	-4.03	6.6e-05	0.00545	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26523450~26526579:+
THCA	cis	rs17095355	0.818	rs12261598	ENSG00000203876.8	ADD3-AS1	-4.03	6.61e-05	0.00545	-0.19	-0.18	Biliary atresia;	chr10:110112417	chr10:109940104~110008381:-
THCA	cis	rs427943	0.83	rs983157	ENSG00000223768.1	LINC00205	-4.03	6.61e-05	0.00546	-0.16	-0.18	Body mass index;	chr21:45194313	chr21:45293285~45297354:+
THCA	cis	rs11671653	1	rs1560706	ENSG00000267100.1	ILF3-AS1	4.03	6.61e-05	0.00546	0.2	0.18	LDL cholesterol;	chr19:10727328	chr19:10651862~10653844:-
THCA	cis	rs858239	0.738	rs7807879	ENSG00000230042.1	AK3P3	-4.03	6.61e-05	0.00546	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23129178~23129841:+
THCA	cis	rs9902453	0.967	rs3813034	ENSG00000263370.1	RP11-68I3.5	4.03	6.61e-05	0.00546	0.24	0.18	Coffee consumption (cups per day);	chr17:30197786	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.967	rs1042173	ENSG00000263370.1	RP11-68I3.5	4.03	6.61e-05	0.00546	0.24	0.18	Coffee consumption (cups per day);	chr17:30197993	chr17:29639627~29640825:+
THCA	cis	rs2361701	0.5	rs12602593	ENSG00000279259.1	RP11-334C17.3	4.03	6.61e-05	0.00546	0.27	0.18	IgG glycosylation;	chr17:80103080	chr17:80147250~80148596:+
THCA	cis	rs4713118	0.869	rs4713121	ENSG00000272009.1	RP1-313I6.12	-4.03	6.61e-05	0.00546	-0.21	-0.18	Parkinson's disease;	chr6:27754285	chr6:28078792~28081130:-
THCA	cis	rs28829049	0.895	rs12747682	ENSG00000270728.1	RP4-657E11.10	-4.03	6.61e-05	0.00546	-0.13	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19028011	chr1:19297080~19297903:+
THCA	cis	rs4906332	1	rs13987	ENSG00000252469.1	RNU7-160P	4.03	6.61e-05	0.00546	0.2	0.18	Coronary artery disease;	chr14:103503572	chr14:103550345~103550406:+
THCA	cis	rs28829049	1	rs28829049	ENSG00000270728.1	RP4-657E11.10	-4.03	6.61e-05	0.00546	-0.13	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19022787	chr1:19297080~19297903:+
THCA	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	4.03	6.61e-05	0.00546	0.17	0.18	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
THCA	cis	rs2836950	0.501	rs62223052	ENSG00000238141.2	BRWD1-AS1	-4.03	6.61e-05	0.00546	-0.21	-0.18	Menarche (age at onset);	chr21:39336776	chr21:39315707~39323218:+
THCA	cis	rs35176054	0.73	rs12772158	ENSG00000280693.1	SH3PXD2A-AS1	-4.03	6.61e-05	0.00546	-0.35	-0.18	Atrial fibrillation;	chr10:103742652	chr10:103745966~103755423:+
THCA	cis	rs35176054	0.73	rs12779039	ENSG00000280693.1	SH3PXD2A-AS1	-4.03	6.61e-05	0.00546	-0.35	-0.18	Atrial fibrillation;	chr10:103743078	chr10:103745966~103755423:+
THCA	cis	rs9527	0.637	rs7096169	ENSG00000272912.1	RP11-724N1.1	-4.03	6.62e-05	0.00546	-0.22	-0.18	Arsenic metabolism;	chr10:102858938	chr10:102914585~102915404:+
THCA	cis	rs11673344	0.642	rs55755939	ENSG00000268499.1	CTB-102L5.8	-4.03	6.62e-05	0.00546	-0.19	-0.18	Obesity-related traits;	chr19:37353723	chr19:38199836~38200934:+
THCA	cis	rs1153858	1	rs12593370	ENSG00000275672.1	GATM-AS1	-4.03	6.62e-05	0.00546	-0.19	-0.18	Homoarginine levels;	chr15:45325219	chr15:45378700~45380123:+
THCA	cis	rs4742903	1	rs10761010	ENSG00000270332.1	SMC2-AS1	4.03	6.62e-05	0.00546	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104096507	chr9:104080024~104093073:-
THCA	cis	rs1210638	0.756	rs2518800	ENSG00000271275.1	AC007326.9	4.03	6.62e-05	0.00546	0.19	0.18	Response to serotonin reuptake inhibitors in major depressive disorder;	chr22:18985958	chr22:18997138~18997595:-
THCA	cis	rs656319	0.565	rs73189192	ENSG00000261451.1	RP11-981G7.1	-4.03	6.62e-05	0.00546	-0.24	-0.18	Myopia (pathological);	chr8:10053129	chr8:10433672~10438312:+
THCA	cis	rs600231	0.708	rs1784100	ENSG00000254614.2	AP003068.23	4.03	6.62e-05	0.00546	0.24	0.18	Bone mineral density;	chr11:65481756	chr11:65177606~65181834:-
THCA	cis	rs293748	0.771	rs292196	ENSG00000250155.1	CTD-2353F22.1	4.03	6.62e-05	0.00546	0.24	0.18	Obesity-related traits;	chr5:36914077	chr5:36666214~36725195:-
THCA	cis	rs11633886	0.707	rs11070471	ENSG00000273972.1	CTD-2306A12.1	4.03	6.62e-05	0.00546	0.2	0.18	Diisocyanate-induced asthma;	chr15:45743923	chr15:45702640~45703183:+
THCA	cis	rs7819412	0.806	rs2409689	ENSG00000261451.1	RP11-981G7.1	-4.03	6.62e-05	0.00546	-0.23	-0.18	Triglycerides;	chr8:11075358	chr8:10433672~10438312:+
THCA	cis	rs3738443	1	rs75028588	ENSG00000259865.1	RP11-488L18.10	4.03	6.62e-05	0.00546	0.2	0.18	Alcohol dependence;	chr1:247208350	chr1:247187281~247188526:-
THCA	cis	rs3738443	1	rs56340510	ENSG00000259865.1	RP11-488L18.10	4.03	6.62e-05	0.00546	0.2	0.18	Alcohol dependence;	chr1:247208707	chr1:247187281~247188526:-
THCA	cis	rs17221829	0.635	rs3018758	ENSG00000280385.1	AP000648.5	4.03	6.62e-05	0.00547	0.18	0.18	Anxiety in major depressive disorder;	chr11:89677295	chr11:90193614~90198120:+
THCA	cis	rs78487399	0.808	rs17039133	ENSG00000234936.1	AC010883.5	4.03	6.62e-05	0.00547	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43467431	chr2:43229573~43233394:+
THCA	cis	rs793571	0.59	rs4775094	ENSG00000245975.2	RP11-30K9.6	4.03	6.62e-05	0.00547	0.17	0.18	Schizophrenia;	chr15:58823796	chr15:58768072~58770974:-
THCA	cis	rs4915077	0.773	rs17019810	ENSG00000230489.1	VAV3-AS1	4.03	6.62e-05	0.00547	0.29	0.18	Hypothyroidism;	chr1:107726179	chr1:107964443~107994607:+
THCA	cis	rs7267979	0.789	rs4815400	ENSG00000274973.1	RP13-401N8.7	4.03	6.62e-05	0.00547	0.2	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.844	rs2424703	ENSG00000274973.1	RP13-401N8.7	-4.03	6.62e-05	0.00547	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.74	rs2259961	ENSG00000274973.1	RP13-401N8.7	-4.03	6.62e-05	0.00547	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.844	rs2474780	ENSG00000274973.1	RP13-401N8.7	-4.03	6.62e-05	0.00547	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25845497~25845862:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000275400.1	RP4-756H11.5	-4.03	6.62e-05	0.00547	-0.17	-0.18	Aortic root size;	chr7:66014585	chr7:66553805~66554199:-
THCA	cis	rs17711722	0.727	rs781151	ENSG00000275400.1	RP4-756H11.5	-4.03	6.62e-05	0.00547	-0.17	-0.18	Calcium levels;	chr7:66014891	chr7:66553805~66554199:-
THCA	cis	rs1124769	0.57	rs2663528	ENSG00000273674.3	CTD-2378E12.1	-4.03	6.62e-05	0.00547	-0.24	-0.18	Cognitive performance;	chr15:50862707	chr15:50839875~50908599:-
THCA	cis	rs17092148	0.887	rs6142199	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.62e-05	0.00547	-0.22	-0.18	Neuroticism;	chr20:34574494	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.887	rs6059928	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.62e-05	0.00547	-0.22	-0.18	Neuroticism;	chr20:34579545	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.836	rs4322911	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.62e-05	0.00547	-0.22	-0.18	Neuroticism;	chr20:34594773	chr20:33985617~33988989:-
THCA	cis	rs4218	0.689	rs73418863	ENSG00000259732.1	RP11-59H7.3	-4.03	6.62e-05	0.00547	-0.25	-0.18	Social communication problems;	chr15:59098923	chr15:59121034~59133250:+
THCA	cis	rs2439831	0.681	rs956391	ENSG00000166763.7	STRCP1	-4.03	6.62e-05	0.00547	-0.25	-0.18	Lung cancer in ever smokers;	chr15:43325295	chr15:43699488~43718184:-
THCA	cis	rs3770081	1	rs12612513	ENSG00000273080.1	RP11-301O19.1	-4.03	6.62e-05	0.00547	-0.44	-0.18	Facial emotion recognition (sad faces);	chr2:86074102	chr2:86195590~86196049:+
THCA	cis	rs2342371	0.509	rs9683218	ENSG00000273013.1	CTD-2002J20.1	4.03	6.63e-05	0.00547	0.17	0.18	Fat distribution (HIV);	chr3:196484162	chr3:196474801~196475394:+
THCA	cis	rs181553	0.504	rs66622242	ENSG00000266696.1	RP11-30L3.2	-4.03	6.63e-05	0.00547	-0.26	-0.18	Hip circumference adjusted for BMI;	chr18:49457225	chr18:49205912~49208781:+
THCA	cis	rs1436955	0.754	rs8030016	ENSG00000259251.2	RP11-643M14.1	-4.03	6.63e-05	0.00547	-0.23	-0.18	Type 2 diabetes;	chr15:62107195	chr15:62060503~62062434:+
THCA	cis	rs1436955	0.754	rs16944723	ENSG00000259251.2	RP11-643M14.1	-4.03	6.63e-05	0.00547	-0.23	-0.18	Type 2 diabetes;	chr15:62108848	chr15:62060503~62062434:+
THCA	cis	rs7179456	0.61	rs650366	ENSG00000245975.2	RP11-30K9.6	4.03	6.63e-05	0.00547	0.17	0.18	Asperger disorder;	chr15:58768943	chr15:58768072~58770974:-
THCA	cis	rs9309473	0.95	rs7566364	ENSG00000273245.1	RP11-434P11.2	4.03	6.63e-05	0.00547	0.24	0.18	Metabolite levels;	chr2:73615762	chr2:73750256~73750786:-
THCA	cis	rs2448490	0.642	rs535111	ENSG00000255557.1	RP11-770G2.2	-4.03	6.63e-05	0.00547	-0.21	-0.18	Platelet count;	chr11:65717866	chr11:65745729~65771585:+
THCA	cis	rs1204798	1	rs1204798	ENSG00000237021.2	RP3-486I3.7	-4.03	6.63e-05	0.00547	-0.2	-0.18	Dental caries;	chr6:116222684	chr6:116254207~116256743:+
THCA	cis	rs2721195	0.967	rs748195	ENSG00000265393.1	CTD-2517M22.17	-4.03	6.63e-05	0.00547	-0.22	-0.18	Age at first birth;	chr8:144457131	chr8:144512567~144513672:+
THCA	cis	rs10090774	0.965	rs7824374	ENSG00000279766.1	RP11-642A1.2	4.03	6.63e-05	0.00547	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141006810	chr8:140572142~140572812:-
THCA	cis	rs6870983	0.895	rs2115885	ENSG00000247828.6	TMEM161B-AS1	4.03	6.63e-05	0.00547	0.17	0.18	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88303001	chr5:88268895~88436685:+
THCA	cis	rs2447820	1	rs2447820	ENSG00000249996.1	RP11-359P5.1	4.03	6.63e-05	0.00547	0.22	0.18	Migraine;	chr5:122929041	chr5:123036271~123054667:+
THCA	cis	rs11633886	0.647	rs1520512	ENSG00000259200.1	RP11-718O11.1	-4.03	6.63e-05	0.00547	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45764847	chr15:45705078~45931069:+
THCA	cis	rs7707921	0.602	rs10514231	ENSG00000251374.1	RPS23P5	-4.03	6.63e-05	0.00548	-0.22	-0.18	Breast cancer;	chr5:82011593	chr5:82265157~82265259:-
THCA	cis	rs330048	0.525	rs10112237	ENSG00000253893.2	FAM85B	4.03	6.64e-05	0.00548	0.23	0.18	Systemic lupus erythematosus;	chr8:9215219	chr8:8167819~8226614:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000280128.1	XXbac-BPG283O16.9	4.03	6.64e-05	0.00548	0.21	0.18	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30282349~30286054:-
THCA	cis	rs9595908	0.785	rs17515873	ENSG00000212293.1	SNORA16	4.03	6.64e-05	0.00548	0.21	0.18	Body mass index;	chr13:32647711	chr13:32420390~32420516:-
THCA	cis	rs591584	0.73	rs7342170	ENSG00000255893.1	RP11-685N10.1	-4.03	6.64e-05	0.00548	-0.21	-0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94581311	chr11:94472908~94473570:-
THCA	cis	rs12234571	1	rs73372288	ENSG00000214293.7	APTR	4.03	6.64e-05	0.00548	0.22	0.18	Obesity-related traits;	chr7:77714581	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs73372292	ENSG00000214293.7	APTR	4.03	6.64e-05	0.00548	0.22	0.18	Obesity-related traits;	chr7:77716610	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs12673402	ENSG00000214293.7	APTR	4.03	6.64e-05	0.00548	0.22	0.18	Obesity-related traits;	chr7:77729666	chr7:77657660~77696265:-
THCA	cis	rs10200159	0.744	rs10496044	ENSG00000272606.1	RP11-554J4.1	4.03	6.64e-05	0.00548	0.35	0.18	Vitiligo;	chr2:55660614	chr2:55617909~55618373:+
THCA	cis	rs7838490	0.504	rs11989655	ENSG00000253553.4	RP11-586K2.1	-4.02	6.64e-05	0.00548	-0.19	-0.18	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88517849	chr8:88326836~88737134:+
THCA	cis	rs6570726	0.902	rs406979	ENSG00000270638.1	RP3-466P17.1	4.02	6.64e-05	0.00548	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145735570~145737218:+
THCA	cis	rs910873	0.505	rs7261964	ENSG00000276073.1	RP5-1125A11.7	-4.02	6.64e-05	0.00548	-0.23	-0.18	Melanoma;	chr20:34617207	chr20:33985617~33988989:-
THCA	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	4.02	6.64e-05	0.00548	0.19	0.18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
THCA	cis	rs9818758	0.607	rs11716445	ENSG00000270441.1	RP11-694I15.7	4.02	6.64e-05	0.00548	0.29	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49368662	chr3:49140086~49160851:-
THCA	cis	rs4927850	0.501	rs9881504	ENSG00000226155.1	AC124944.3	-4.02	6.64e-05	0.00548	-0.22	-0.18	Pancreatic cancer;	chr3:195929743	chr3:195912049~195913986:+
THCA	cis	rs9595908	0.785	rs7326314	ENSG00000212293.1	SNORA16	4.02	6.64e-05	0.00548	0.21	0.18	Body mass index;	chr13:32706422	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs2183873	ENSG00000212293.1	SNORA16	4.02	6.64e-05	0.00548	0.21	0.18	Body mass index;	chr13:32710508	chr13:32420390~32420516:-
THCA	cis	rs7182948	1	rs17480434	ENSG00000259531.2	RP11-295H24.3	4.02	6.64e-05	0.00548	0.23	0.18	Lung adenocarcinoma;	chr15:49521146	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs28492008	ENSG00000259531.2	RP11-295H24.3	4.02	6.64e-05	0.00548	0.23	0.18	Lung adenocarcinoma;	chr15:49530588	chr15:49365124~49366685:-
THCA	cis	rs6121246	0.954	rs6058470	ENSG00000224628.2	RP5-854E16.2	-4.02	6.64e-05	0.00548	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31829024	chr20:31285317~31286835:-
THCA	cis	rs9393777	0.841	rs67092078	ENSG00000220721.1	OR1F12	4.02	6.65e-05	0.00548	0.42	0.18	Intelligence (multi-trait analysis);	chr6:27086993	chr6:28073316~28074233:+
THCA	cis	rs875971	0.66	rs7807930	ENSG00000229180.5	GS1-124K5.11	-4.02	6.65e-05	0.00548	-0.13	-0.18	Aortic root size;	chr7:66622178	chr7:66526088~66542624:-
THCA	cis	rs860295	0.812	rs7556519	ENSG00000236675.1	MTX1P1	-4.02	6.65e-05	0.00549	-0.19	-0.18	Body mass index;	chr1:155857755	chr1:155230975~155234325:+
THCA	cis	rs448720	1	rs11853797	ENSG00000260657.2	RP11-315D16.4	4.02	6.65e-05	0.00549	0.23	0.18	Cognitive performance;	chr15:67908240	chr15:68267792~68277994:-
THCA	cis	rs7904321	0.966	rs10761692	ENSG00000232075.1	MRPL35P2	-4.02	6.65e-05	0.00549	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63075288	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs10761693	ENSG00000232075.1	MRPL35P2	-4.02	6.65e-05	0.00549	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63075290	chr10:63634317~63634827:-
THCA	cis	rs5758511	0.68	rs5758698	ENSG00000270083.1	RP1-257I20.14	-4.02	6.65e-05	0.00549	-0.23	-0.18	Birth weight;	chr22:42288812	chr22:42089630~42090028:-
THCA	cis	rs10411161	0.702	rs10403189	ENSG00000275055.1	CTC-471J1.11	4.02	6.65e-05	0.00549	0.18	0.18	Breast cancer;	chr19:51897420	chr19:52049007~52049754:+
THCA	cis	rs17685	0.633	rs3801471	ENSG00000230882.1	AC005077.14	4.02	6.65e-05	0.00549	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76066870	chr7:76071469~76074963:-
THCA	cis	rs6494488	0.5	rs72741387	ENSG00000259635.1	AC100830.3	-4.02	6.65e-05	0.00549	-0.46	-0.18	Coronary artery disease;	chr15:64524135	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs55978417	ENSG00000259635.1	AC100830.3	-4.02	6.65e-05	0.00549	-0.46	-0.18	Coronary artery disease;	chr15:64525170	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741393	ENSG00000259635.1	AC100830.3	-4.02	6.65e-05	0.00549	-0.46	-0.18	Coronary artery disease;	chr15:64527957	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741399	ENSG00000259635.1	AC100830.3	-4.02	6.65e-05	0.00549	-0.46	-0.18	Coronary artery disease;	chr15:64532837	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs113494617	ENSG00000259635.1	AC100830.3	-4.02	6.65e-05	0.00549	-0.46	-0.18	Coronary artery disease;	chr15:64544306	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742907	ENSG00000259635.1	AC100830.3	-4.02	6.65e-05	0.00549	-0.46	-0.18	Coronary artery disease;	chr15:64545736	chr15:64701248~64719602:+
THCA	cis	rs8062405	0.755	rs17640009	ENSG00000270424.1	RP11-1348G14.6	4.02	6.65e-05	0.00549	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28749959~28750595:-
THCA	cis	rs12118280	0.513	rs4915106	ENSG00000280186.1	RP11-483I13.6	4.02	6.65e-05	0.00549	0.15	0.18	Myeloid white cell count;	chr1:108210765	chr1:108200413~108202743:+
THCA	cis	rs7312933	0.703	rs11181380	ENSG00000257225.1	RP11-328C8.4	-4.02	6.65e-05	0.00549	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42222238	chr12:42459366~42466128:+
THCA	cis	rs2380205	0.651	rs7072283	ENSG00000232807.2	RP11-536K7.3	4.02	6.65e-05	0.00549	0.17	0.18	Breast cancer;	chr10:5876684	chr10:5934270~5945900:-
THCA	cis	rs2590942	0.838	rs1993709	ENSG00000227207.2	RPL31P12	-4.02	6.65e-05	0.00549	-0.29	-0.18	Childhood body mass index;	chr1:72372846	chr1:72301472~72301829:+
THCA	cis	rs6101567	0.517	rs725259	ENSG00000224635.1	RP4-564F22.5	-4.02	6.65e-05	0.00549	-0.23	-0.18	Nose size;	chr20:39302575	chr20:38406011~38416797:-
THCA	cis	rs7267979	1	rs4815417	ENSG00000276952.1	RP5-965G21.6	-4.02	6.65e-05	0.00549	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25284915~25285588:-
THCA	cis	rs701145	0.762	rs896014	ENSG00000243069.6	ARHGEF26-AS1	4.02	6.65e-05	0.00549	0.35	0.18	Coronary artery disease;	chr3:154124902	chr3:154024401~154121332:-
THCA	cis	rs919433	0.679	rs7564924	ENSG00000231621.1	AC013264.2	-4.02	6.66e-05	0.00549	-0.19	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197649153	chr2:197197991~197199273:+
THCA	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-4.02	6.66e-05	0.00549	-0.22	-0.18	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
THCA	cis	rs13325613	0.834	rs13061548	ENSG00000223552.1	RP11-24F11.2	-4.02	6.66e-05	0.00549	-0.27	-0.18	Monocyte count;	chr3:46185154	chr3:46364955~46407059:-
THCA	cis	rs6840258	0.891	rs10032710	ENSG00000251411.1	RP11-397E7.4	-4.02	6.66e-05	0.00549	-0.22	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87145107	chr4:86913266~86914817:-
THCA	cis	rs3812831	0.599	rs428636	ENSG00000264539.1	MIR548AR	4.02	6.66e-05	0.00549	0.19	0.18	Schizophrenia;	chr13:114161658	chr13:114244505~114244561:+
THCA	cis	rs1125355	1	rs72943174	ENSG00000243792.1	OR7E89P	-4.02	6.66e-05	0.00549	-0.27	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158843688	chr2:158853755~158854576:+
THCA	cis	rs1125355	1	rs72943176	ENSG00000243792.1	OR7E89P	-4.02	6.66e-05	0.00549	-0.27	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158843689	chr2:158853755~158854576:+
THCA	cis	rs1125355	0.964	rs72943178	ENSG00000243792.1	OR7E89P	-4.02	6.66e-05	0.00549	-0.27	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158843707	chr2:158853755~158854576:+
THCA	cis	rs1125355	1	rs1125354	ENSG00000243792.1	OR7E89P	-4.02	6.66e-05	0.00549	-0.27	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158844053	chr2:158853755~158854576:+
THCA	cis	rs494526	0.736	rs2152240	ENSG00000229272.1	RP11-498J9.2	4.02	6.66e-05	0.00549	0.21	0.18	Alcoholic chronic pancreatitis;	chr10:119062521	chr10:119003536~119003884:-
THCA	cis	rs4792901	0.685	rs9898065	ENSG00000267151.3	RP11-100E5.2	4.02	6.66e-05	0.00549	0.2	0.18	Dupuytren's disease;	chr17:43485105	chr17:43444707~43451200:+
THCA	cis	rs62158211	0.908	rs62158169	ENSG00000240356.5	RP11-395L14.11	-4.02	6.66e-05	0.00549	-0.25	-0.18	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113324250	chr2:113610502~113627090:-
THCA	cis	rs2572431	0.543	rs2256016	ENSG00000154316.13	TDH	-4.02	6.66e-05	0.00549	-0.14	-0.18	Neuroticism;	chr8:11305093	chr8:11339637~11368452:+
THCA	cis	rs875971	0.619	rs10278371	ENSG00000275400.1	RP4-756H11.5	4.02	6.66e-05	0.0055	0.17	0.18	Aortic root size;	chr7:66586553	chr7:66553805~66554199:-
THCA	cis	rs7674212	0.541	rs2720464	ENSG00000230069.3	LRRC37A15P	-4.02	6.66e-05	0.0055	-0.18	-0.18	Type 2 diabetes;	chr4:103152044	chr4:102727274~102730721:-
THCA	cis	rs548181	0.611	rs562599	ENSG00000254671.2	STT3A-AS1	-4.02	6.66e-05	0.0055	-0.36	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125590056	chr11:125570284~125592568:-
THCA	cis	rs3820928	0.709	rs2894627	ENSG00000212391.1	SNORA48	-4.02	6.67e-05	0.0055	-0.2	-0.18	Pulmonary function;	chr2:227045455	chr2:226968989~226969122:-
THCA	cis	rs3015497	0.753	rs4643225	ENSG00000270062.1	RP11-248J18.3	4.02	6.67e-05	0.0055	0.2	0.18	Mean platelet volume;	chr14:50655487	chr14:50723777~50724272:-
THCA	cis	rs4934494	0.677	rs56160723	ENSG00000240996.1	RP11-80H5.7	-4.02	6.67e-05	0.0055	-0.21	-0.18	Red blood cell count;	chr10:89613874	chr10:89694295~89697928:-
THCA	cis	rs34421088	0.56	rs2618434	ENSG00000255046.1	RP11-297N6.4	4.02	6.67e-05	0.0055	0.19	0.18	Neuroticism;	chr8:11541356	chr8:11797928~11802568:-
THCA	cis	rs10256972	0.684	rs4724039	ENSG00000199023.2	MIR339	-4.02	6.67e-05	0.0055	-0.19	-0.18	Endometriosis;Longevity;	chr7:1071997	chr7:1022935~1023045:-
THCA	cis	rs1232027	0.7	rs1677695	ENSG00000249655.1	CTC-325J23.2	4.02	6.67e-05	0.0055	0.21	0.18	Huntington's disease progression;	chr5:80640457	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.7	rs1677693	ENSG00000249655.1	CTC-325J23.2	4.02	6.67e-05	0.0055	0.21	0.18	Huntington's disease progression;	chr5:80640499	chr5:80630313~80631590:-
THCA	cis	rs9307551	0.744	rs2165388	ENSG00000249646.2	OR7E94P	-4.02	6.67e-05	0.0055	-0.24	-0.18	Refractive error;	chr4:79552322	chr4:79587302~79588130:-
THCA	cis	rs17286411	0.67	rs62053108	ENSG00000260185.1	RP11-432I5.6	-4.02	6.67e-05	0.0055	-0.26	-0.18	Blood protein levels;	chr16:71662117	chr16:71655027~71664212:+
THCA	cis	rs4908760	0.613	rs2401189	ENSG00000232912.4	RP5-1115A15.1	4.02	6.67e-05	0.0055	0.17	0.18	Vitiligo;	chr1:8758541	chr1:8424645~8434838:+
THCA	cis	rs72827839	0.802	rs1986693	ENSG00000266601.1	RP11-6N17.3	-4.02	6.67e-05	0.0055	-0.21	-0.18	Ease of getting up in the morning;	chr17:47948790	chr17:47929682~47933106:-
THCA	cis	rs3790606	1	rs3790605	ENSG00000273483.1	RP4-671G15.2	4.02	6.67e-05	0.0055	0.19	0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr1:112509533	chr1:112517799~112518441:-
THCA	cis	rs4805272	0.962	rs7257609	ENSG00000267799.1	MAN1A2P1	4.02	6.67e-05	0.0055	0.2	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832445	chr19:28790812~28792871:-
THCA	cis	rs4805272	1	rs7256685	ENSG00000267799.1	MAN1A2P1	4.02	6.67e-05	0.0055	0.2	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28832450	chr19:28790812~28792871:-
THCA	cis	rs13256369	0.95	rs13255655	ENSG00000254153.1	CTA-398F10.2	-4.02	6.67e-05	0.0055	-0.21	-0.18	Obesity-related traits;	chr8:8720226	chr8:8456909~8461337:-
THCA	cis	rs17801127	0.901	rs16827309	ENSG00000231969.1	AC144449.1	4.02	6.67e-05	0.0055	0.32	0.18	Liver enzyme levels (alanine transaminase);	chr2:149666098	chr2:149587196~149848233:+
THCA	cis	rs4713118	0.619	rs200486	ENSG00000226314.6	ZNF192P1	-4.02	6.67e-05	0.0055	-0.25	-0.18	Parkinson's disease;	chr6:27811728	chr6:28161781~28169594:+
THCA	cis	rs8059260	0.877	rs6498146	ENSG00000274038.1	RP11-66H6.4	4.02	6.67e-05	0.0055	0.25	0.18	Alcohol consumption over the past year;	chr16:11012850	chr16:11056556~11057034:+
THCA	cis	rs7829975	0.66	rs10093926	ENSG00000233609.3	RP11-62H7.2	-4.02	6.67e-05	0.0055	-0.18	-0.18	Mood instability;	chr8:8691510	chr8:8961200~8979025:+
THCA	cis	rs8062405	0.755	rs4149398	ENSG00000270424.1	RP11-1348G14.6	4.02	6.67e-05	0.0055	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28749959~28750595:-
THCA	cis	rs2694917	0.669	rs2657896	ENSG00000257576.1	RP11-153M3.1	4.02	6.67e-05	0.0055	0.31	0.18	Blood metabolite ratios;	chr12:56535910	chr12:56511002~56512703:+
THCA	cis	rs12908161	0.96	rs11633450	ENSG00000188388.10	GOLGA6L3	4.02	6.67e-05	0.0055	0.24	0.18	Schizophrenia;	chr15:84764056	chr15:85240472~85247170:+
THCA	cis	rs9863	0.828	rs12303671	ENSG00000269997.1	RP11-214K3.21	-4.02	6.67e-05	0.0055	-0.22	-0.18	White blood cell count;	chr12:124008063	chr12:123966077~123966629:-
THCA	cis	rs6500596	0.57	rs8055628	ENSG00000280063.1	RP11-295D4.3	4.02	6.68e-05	0.00551	0.11	0.18	Schizophrenia;	chr16:4397476	chr16:4346694~4348648:-
THCA	cis	rs9595908	0.568	rs4942926	ENSG00000212293.1	SNORA16	4.02	6.68e-05	0.00551	0.22	0.18	Body mass index;	chr13:32807204	chr13:32420390~32420516:-
THCA	cis	rs1048886	0.872	rs9455181	ENSG00000271967.1	RP11-134K13.4	-4.02	6.68e-05	0.00551	-0.2	-0.18	Type 2 diabetes;	chr6:70593014	chr6:70596438~70596980:+
THCA	cis	rs17092148	0.887	rs4911431	ENSG00000276073.1	RP5-1125A11.7	-4.02	6.68e-05	0.00551	-0.22	-0.18	Neuroticism;	chr20:34570514	chr20:33985617~33988989:-
THCA	cis	rs2898290	0.694	rs2248909	ENSG00000255046.1	RP11-297N6.4	4.02	6.68e-05	0.00551	0.19	0.18	Systolic blood pressure;	chr8:11534584	chr8:11797928~11802568:-
THCA	cis	rs7763441	0.506	rs9405168	ENSG00000250903.7	GMDS-AS1	4.02	6.68e-05	0.00551	0.16	0.18	Monobrow;	chr6:2453561	chr6:2245748~2482022:+
THCA	cis	rs67478160	0.619	rs2368560	ENSG00000258534.1	CTD-2134A5.4	-4.02	6.68e-05	0.00551	-0.18	-0.18	Schizophrenia;	chr14:103806974	chr14:103854366~103880111:-
THCA	cis	rs2904524	0.541	rs10879134	ENSG00000257815.4	RP11-611E13.2	4.02	6.68e-05	0.00551	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70386879	chr12:69904033~70243360:-
THCA	cis	rs6570726	0.967	rs439017	ENSG00000270638.1	RP3-466P17.1	4.02	6.68e-05	0.00551	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145735570~145737218:+
THCA	cis	rs867186	1	rs6579208	ENSG00000126005.14	MMP24-AS1	-4.02	6.68e-05	0.00551	-0.29	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35010809	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs7273734	ENSG00000126005.14	MMP24-AS1	-4.02	6.68e-05	0.00551	-0.29	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35011600	chr20:35216462~35278131:-
THCA	cis	rs6939532	0.522	rs9358933	ENSG00000124549.13	BTN2A3P	-4.02	6.68e-05	0.00551	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26363460	chr6:26421391~26432383:+
THCA	cis	rs801193	1	rs2707836	ENSG00000230295.1	RP11-458F8.2	-4.02	6.68e-05	0.00551	-0.14	-0.18	Aortic root size;	chr7:66695448	chr7:66880708~66882981:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000230295.1	RP11-458F8.2	-4.02	6.68e-05	0.00551	-0.14	-0.18	Aortic root size;	chr7:66696803	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs2659906	ENSG00000230295.1	RP11-458F8.2	-4.02	6.68e-05	0.00551	-0.14	-0.18	Aortic root size;	chr7:66700323	chr7:66880708~66882981:+
THCA	cis	rs4244255	1	rs12570933	ENSG00000260461.1	RP11-541N10.3	-4.02	6.68e-05	0.00551	-0.46	-0.18	Differentiated thyroid cancer;	chr10:103946033	chr10:103877374~103879761:-
THCA	cis	rs2191566	0.96	rs2270196	ENSG00000266921.1	RP11-15A1.7	4.02	6.68e-05	0.00551	0.17	0.18	Acute lymphoblastic leukemia (childhood);	chr19:44002471	chr19:43996896~44002836:-
THCA	cis	rs1836229	0.874	rs10119815	ENSG00000225706.1	PTPRD-AS1	-4.02	6.68e-05	0.00551	-0.22	-0.18	Restless legs syndrome;	chr9:8826783	chr9:8858130~8862255:+
THCA	cis	rs1836229	0.839	rs10116689	ENSG00000225706.1	PTPRD-AS1	-4.02	6.68e-05	0.00551	-0.22	-0.18	Restless legs syndrome;	chr9:8826788	chr9:8858130~8862255:+
THCA	cis	rs9543976	0.688	rs56084319	ENSG00000261105.4	LMO7-AS1	-4.02	6.68e-05	0.00551	-0.32	-0.18	Diabetic retinopathy;	chr13:75536543	chr13:75604700~75635994:-
THCA	cis	rs12928939	0.517	rs12149307	ENSG00000260886.1	TAT-AS1	4.02	6.68e-05	0.00551	0.26	0.18	Post bronchodilator FEV1;	chr16:71934188	chr16:71565789~71578187:+
THCA	cis	rs12928939	0.517	rs10852507	ENSG00000260886.1	TAT-AS1	4.02	6.68e-05	0.00551	0.26	0.18	Post bronchodilator FEV1;	chr16:71937997	chr16:71565789~71578187:+
THCA	cis	rs11157436	0.918	rs7159024	ENSG00000211812.1	TRAV26-2	-4.02	6.68e-05	0.00551	-0.17	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22202583~22203368:+
THCA	cis	rs1204798	1	rs1204789	ENSG00000237021.2	RP3-486I3.7	-4.02	6.68e-05	0.00551	-0.2	-0.18	Dental caries;	chr6:116215449	chr6:116254207~116256743:+
THCA	cis	rs72819454	0.522	rs11191803	ENSG00000280693.1	SH3PXD2A-AS1	-4.02	6.68e-05	0.00551	-0.34	-0.18	Interleukin-9 levels;	chr10:103775289	chr10:103745966~103755423:+
THCA	cis	rs2455799	0.613	rs6789076	ENSG00000270409.1	RP11-44D5.1	4.02	6.68e-05	0.00551	0.2	0.18	Mean platelet volume;	chr3:15766218	chr3:15732252~15733470:+
THCA	cis	rs6600671	1	rs1856572	ENSG00000275585.1	CH17-118O6.3	-4.02	6.68e-05	0.00551	-0.22	-0.18	Hip geometry;	chr1:121427719	chr1:120985692~121052167:-
THCA	cis	rs9341808	0.667	rs1575541	ENSG00000272129.1	RP11-250B2.6	4.02	6.68e-05	0.00551	0.23	0.18	Sitting height ratio;	chr6:80207768	chr6:80355424~80356859:+
THCA	cis	rs4742903	0.904	rs10124553	ENSG00000270332.1	SMC2-AS1	4.02	6.68e-05	0.00551	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104231617	chr9:104080024~104093073:-
THCA	cis	rs11191419	1	rs11191419	ENSG00000272912.1	RP11-724N1.1	-4.02	6.68e-05	0.00551	-0.22	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102914585~102915404:+
THCA	cis	rs2039553	0.603	rs7327527	ENSG00000227354.5	RBM26-AS1	-4.02	6.69e-05	0.00551	-0.17	-0.18	Pancreatic cancer;	chr13:79786265	chr13:79406309~79424328:+
THCA	cis	rs7819412	0.775	rs4841489	ENSG00000261451.1	RP11-981G7.1	-4.02	6.69e-05	0.00551	-0.22	-0.18	Triglycerides;	chr8:11079301	chr8:10433672~10438312:+
THCA	cis	rs13064773	0.546	rs340254	ENSG00000279311.1	RP11-170K4.2	4.02	6.69e-05	0.00551	0.24	0.18	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158879470	chr3:158869898~158871821:+
THCA	cis	rs11239930	0.517	rs942689	ENSG00000278811.3	LINC00624	4.02	6.69e-05	0.00551	0.22	0.18	AIDS progression;	chr1:147079231	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.517	rs632861	ENSG00000278811.3	LINC00624	4.02	6.69e-05	0.00551	0.22	0.18	AIDS progression;	chr1:147079826	chr1:147258885~147517875:-
THCA	cis	rs8062405	1	rs8062405	ENSG00000270424.1	RP11-1348G14.6	-4.02	6.69e-05	0.00551	-0.21	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28749959~28750595:-
THCA	cis	rs1047014	0.778	rs6922714	ENSG00000226786.2	RP1-167F1.2	-4.02	6.69e-05	0.00551	-0.17	-0.18	Height;	chr6:19831329	chr6:19534944~19839080:-
THCA	cis	rs62158800	0.598	rs1606986	ENSG00000224568.1	AC096669.3	4.02	6.69e-05	0.00551	0.23	0.18	Facial morphology (factor 22);	chr2:107673996	chr2:107529487~107556326:+
THCA	cis	rs2235642	0.75	rs763152	ENSG00000260989.1	LA16c-395F10.2	-4.02	6.69e-05	0.00551	-0.19	-0.18	Coronary artery disease;	chr16:1608055	chr16:1580527~1610328:+
THCA	cis	rs2235642	0.717	rs9937922	ENSG00000260989.1	LA16c-395F10.2	-4.02	6.69e-05	0.00551	-0.19	-0.18	Coronary artery disease;	chr16:1608153	chr16:1580527~1610328:+
THCA	cis	rs17221829	0.703	rs12365715	ENSG00000280385.1	AP000648.5	-4.02	6.69e-05	0.00551	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89640907	chr11:90193614~90198120:+
THCA	cis	rs934734	0.532	rs7569257	ENSG00000214533.3	KRT18P33	-4.02	6.69e-05	0.00551	-0.23	-0.18	Rheumatoid arthritis;	chr2:65429842	chr2:65666695~65667737:+
THCA	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	4.02	6.69e-05	0.00552	0.21	0.18	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
THCA	cis	rs709400	1	rs6593	ENSG00000258735.1	LINC00637	4.02	6.69e-05	0.00552	0.24	0.18	Body mass index;	chr14:103696945	chr14:103847721~103858049:+
THCA	cis	rs911555	0.723	rs7149767	ENSG00000269958.1	RP11-73M18.8	-4.02	6.69e-05	0.00552	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103696353~103697163:+
THCA	cis	rs911555	0.692	rs7145753	ENSG00000269958.1	RP11-73M18.8	-4.02	6.69e-05	0.00552	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103696353~103697163:+
THCA	cis	rs752010	0.714	rs10890144	ENSG00000230638.4	RP11-486B10.4	-4.02	6.69e-05	0.00552	-0.2	-0.18	Lupus nephritis in systemic lupus erythematosus;	chr1:41619726	chr1:41542069~41544310:+
THCA	cis	rs10186029	0.509	rs62187851	ENSG00000270659.1	RP11-105N14.1	4.02	6.7e-05	0.00552	0.16	0.18	Systemic sclerosis;	chr2:213075650	chr2:213152970~213153659:+
THCA	cis	rs4538475	0.556	rs4263397	ENSG00000214846.4	RP11-115L11.1	-4.02	6.7e-05	0.00552	-0.24	-0.18	Parkinson's disease;	chr4:15737767	chr4:15730962~15731627:-
THCA	cis	rs4950322	0.748	rs17360812	ENSG00000271721.1	RP11-337C18.9	-4.02	6.7e-05	0.00552	-0.21	-0.18	Protein quantitative trait loci;	chr1:147355010	chr1:147175602~147177740:+
THCA	cis	rs8062405	0.573	rs11645306	ENSG00000261766.1	RP11-22P6.2	4.02	6.7e-05	0.00552	0.19	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28862166~28863340:-
THCA	cis	rs17020136	0.506	rs6708973	ENSG00000225402.1	AC010878.3	4.02	6.7e-05	0.00552	0.21	0.18	QRS duration;	chr2:37181631	chr2:37816915~37817961:+
THCA	cis	rs860295	0.871	rs34632540	ENSG00000160766.13	GBAP1	4.02	6.7e-05	0.00552	0.21	0.18	Body mass index;	chr1:155642406	chr1:155213821~155227422:-
THCA	cis	rs4788570	0.584	rs6499534	ENSG00000260593.1	RP11-432I5.2	-4.02	6.7e-05	0.00552	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71721375	chr16:71623708~71626816:-
THCA	cis	rs8062405	1	rs8055138	ENSG00000270424.1	RP11-1348G14.6	4.02	6.7e-05	0.00552	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28749959~28750595:-
THCA	cis	rs2281603	0.598	rs10151656	ENSG00000259116.1	RP11-973N13.4	-4.02	6.7e-05	0.00552	-0.17	-0.18	Lymphocyte counts;	chr14:64594970	chr14:64514154~64540368:-
THCA	cis	rs4144027	0.904	rs10438243	ENSG00000269910.1	RP11-73M18.10	-4.02	6.7e-05	0.00552	-0.16	-0.18	Blood metabolite levels;	chr14:103879485	chr14:103694516~103695050:-
THCA	cis	rs4767841	0.625	rs7967982	ENSG00000248636.5	RP11-768F21.1	-4.02	6.7e-05	0.00552	-0.18	-0.18	Urgency urinary incontinence;	chr12:119776032	chr12:119387987~119668079:-
THCA	cis	rs1204798	1	rs1204788	ENSG00000237021.2	RP3-486I3.7	-4.02	6.7e-05	0.00553	-0.2	-0.18	Dental caries;	chr6:116215088	chr6:116254207~116256743:+
THCA	cis	rs36093844	0.626	rs11234502	ENSG00000279742.1	RP11-700A24.1	-4.02	6.7e-05	0.00553	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85985767	chr11:85852557~85854943:-
THCA	cis	rs4908768	0.501	rs7520617	ENSG00000270282.1	RP5-1115A15.2	4.02	6.7e-05	0.00553	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8512653~8513021:+
THCA	cis	rs964611	0.748	rs55831142	ENSG00000259488.2	RP11-154J22.1	-4.02	6.71e-05	0.00553	-0.2	-0.18	Metabolite levels (Pyroglutamine);	chr15:48277319	chr15:48312353~48331856:-
THCA	cis	rs7131987	0.903	rs918873	ENSG00000275476.1	RP11-996F15.4	-4.02	6.71e-05	0.00553	-0.18	-0.18	QT interval;	chr12:29237568	chr12:29277397~29277882:-
THCA	cis	rs1161098	1	rs1161173	ENSG00000256037.1	MRPL40P1	-4.02	6.71e-05	0.00553	-0.27	-0.18	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67467305	chr12:67351436~67352039:+
THCA	cis	rs5751614	0.537	rs5996508	ENSG00000240160.3	RN7SL263P	4.02	6.71e-05	0.00553	0.24	0.18	Height;	chr22:23270441	chr22:23261782~23262071:-
THCA	cis	rs11672691	0.829	rs8112363	ENSG00000270164.1	LINC01480	-4.02	6.71e-05	0.00553	-0.16	-0.18	Prostate cancer;	chr19:41483803	chr19:41535183~41536904:+
THCA	cis	rs12142240	0.698	rs41534051	ENSG00000232022.5	FAAHP1	-4.02	6.71e-05	0.00553	-0.21	-0.18	Menopause (age at onset);	chr1:46363062	chr1:46432129~46445521:+
THCA	cis	rs9926296	0.656	rs2376882	ENSG00000260259.1	RP11-368I7.4	-4.02	6.71e-05	0.00553	-0.2	-0.18	Vitiligo;	chr16:89760594	chr16:89682620~89686569:-
THCA	cis	rs7914558	1	rs7920251	ENSG00000213061.2	PFN1P11	4.02	6.71e-05	0.00553	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:102838011~102845473:-
THCA	cis	rs17092148	1	rs62211617	ENSG00000276073.1	RP5-1125A11.7	4.02	6.71e-05	0.00553	0.22	0.18	Neuroticism;	chr20:34812552	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs11699062	ENSG00000276073.1	RP5-1125A11.7	4.02	6.71e-05	0.00553	0.22	0.18	Neuroticism;	chr20:34812576	chr20:33985617~33988989:-
THCA	cis	rs1520333	0.54	rs10957891	ENSG00000254352.1	RP11-578O24.2	-4.02	6.71e-05	0.00553	-0.21	-0.18	Multiple sclerosis;	chr8:78456278	chr8:78723796~78724136:-
THCA	cis	rs2120243	0.539	rs9878474	ENSG00000241770.1	RP11-555M1.3	4.02	6.71e-05	0.00553	0.24	0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157405358	chr3:157163452~157169133:+
THCA	cis	rs738722	0.808	rs4822983	ENSG00000272858.1	CTA-292E10.8	4.02	6.71e-05	0.00553	0.19	0.18	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28719078	chr22:28814914~28815662:+
THCA	cis	rs7044106	0.578	rs4837788	ENSG00000238181.2	AHCYP2	-4.02	6.71e-05	0.00553	-0.29	-0.18	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120720673~120721972:+
THCA	cis	rs11651753	0.935	rs2525109	ENSG00000264920.1	RP11-6N17.4	4.02	6.71e-05	0.00553	0.15	0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964961	chr17:47891255~47895812:-
THCA	cis	rs11651753	0.935	rs2525110	ENSG00000264920.1	RP11-6N17.4	4.02	6.71e-05	0.00553	0.15	0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964999	chr17:47891255~47895812:-
THCA	cis	rs3764021	0.87	rs10772085	ENSG00000214776.8	RP11-726G1.1	4.02	6.71e-05	0.00553	0.22	0.18	Type 1 diabetes;	chr12:9724281	chr12:9467552~9576275:+
THCA	cis	rs7572644	0.68	rs12465012	ENSG00000223522.1	AC093690.1	-4.02	6.71e-05	0.00553	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27805324	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.64	rs4665392	ENSG00000223522.1	AC093690.1	-4.02	6.71e-05	0.00553	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27806782	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.679	rs12986980	ENSG00000223522.1	AC093690.1	-4.02	6.71e-05	0.00553	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27807570	chr2:28307691~28310459:-
THCA	cis	rs8062405	0.755	rs56272201	ENSG00000270424.1	RP11-1348G14.6	4.02	6.71e-05	0.00553	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.755	rs62034355	ENSG00000270424.1	RP11-1348G14.6	4.02	6.71e-05	0.00553	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28749959~28750595:-
THCA	cis	rs36093844	0.626	rs12270433	ENSG00000279742.1	RP11-700A24.1	-4.02	6.71e-05	0.00553	-0.25	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86052277	chr11:85852557~85854943:-
THCA	cis	rs9595908	0.544	rs7328213	ENSG00000212293.1	SNORA16	4.02	6.71e-05	0.00553	0.21	0.18	Body mass index;	chr13:32803692	chr13:32420390~32420516:-
THCA	cis	rs7809950	0.678	rs77395658	ENSG00000272072.1	CTA-363E19.2	4.02	6.71e-05	0.00553	0.19	0.18	Coronary artery disease;	chr7:107360206	chr7:107192559~107193300:-
THCA	cis	rs365302	1	rs684052	ENSG00000235086.1	FNDC1-IT1	4.02	6.72e-05	0.00553	0.26	0.18	Coronary heart disease;	chr6:159230215	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs485626	ENSG00000235086.1	FNDC1-IT1	4.02	6.72e-05	0.00553	0.26	0.18	Coronary heart disease;	chr6:159230247	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs485557	ENSG00000235086.1	FNDC1-IT1	4.02	6.72e-05	0.00553	0.26	0.18	Coronary heart disease;	chr6:159230271	chr6:159240786~159243329:+
THCA	cis	rs7487075	0.78	rs10785624	ENSG00000272369.1	RP11-446N19.1	4.02	6.72e-05	0.00553	0.14	0.18	Itch intensity from mosquito bite;	chr12:46373004	chr12:46537502~46652550:+
THCA	cis	rs7487075	0.78	rs2279559	ENSG00000272369.1	RP11-446N19.1	4.02	6.72e-05	0.00553	0.14	0.18	Itch intensity from mosquito bite;	chr12:46373392	chr12:46537502~46652550:+
THCA	cis	rs9959145	1	rs76195993	ENSG00000267199.1	RP11-861E21.2	4.02	6.72e-05	0.00554	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12651888	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs74732619	ENSG00000267199.1	RP11-861E21.2	4.02	6.72e-05	0.00554	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12652017	chr18:12438890~12448205:+
THCA	cis	rs853679	0.567	rs7774981	ENSG00000273712.1	RP5-874C20.7	4.02	6.72e-05	0.00554	0.22	0.18	Depression;	chr6:28379133	chr6:28315613~28315883:-
THCA	cis	rs853679	0.567	rs7754960	ENSG00000273712.1	RP5-874C20.7	4.02	6.72e-05	0.00554	0.22	0.18	Depression;	chr6:28379168	chr6:28315613~28315883:-
THCA	cis	rs4938303	0.633	rs528806	ENSG00000254851.1	RP11-109L13.1	4.02	6.72e-05	0.00554	0.32	0.18	Triglycerides;	chr11:116659197	chr11:117135528~117138582:+
THCA	cis	rs3764021	0.509	rs10772070	ENSG00000214776.8	RP11-726G1.1	4.02	6.72e-05	0.00554	0.24	0.18	Type 1 diabetes;	chr12:9717320	chr12:9467552~9576275:+
THCA	cis	rs1836229	0.874	rs10120450	ENSG00000225706.1	PTPRD-AS1	-4.02	6.72e-05	0.00554	-0.22	-0.18	Restless legs syndrome;	chr9:8826588	chr9:8858130~8862255:+
THCA	cis	rs2836974	0.831	rs34294410	ENSG00000255568.3	BRWD1-AS2	4.02	6.72e-05	0.00554	0.16	0.18	Cognitive function;	chr21:39183234	chr21:39313935~39314962:+
THCA	cis	rs6701713	0.959	rs10863420	ENSG00000274245.1	RP11-357P18.2	-4.02	6.72e-05	0.00554	-0.21	-0.18	Alzheimer's disease (late onset);	chr1:207626529	chr1:207372559~207373252:+
THCA	cis	rs591584	0.73	rs112062277	ENSG00000255893.1	RP11-685N10.1	-4.02	6.72e-05	0.00554	-0.21	-0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94581107	chr11:94472908~94473570:-
THCA	cis	rs9990333	0.762	rs6810239	ENSG00000226155.1	AC124944.3	4.02	6.72e-05	0.00554	0.21	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085292	chr3:195912049~195913986:+
THCA	cis	rs7520050	0.966	rs6429582	ENSG00000280836.1	AL355480.1	-4.02	6.72e-05	0.00554	-0.22	-0.18	Reticulocyte count;Red blood cell count;	chr1:45856171	chr1:45581219~45581321:-
THCA	cis	rs8030605	0.633	rs72740533	ENSG00000277245.1	RP11-48G14.3	4.02	6.72e-05	0.00554	0.32	0.18	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56296080	chr15:56447120~56447697:+
THCA	cis	rs8030605	0.633	rs72740534	ENSG00000277245.1	RP11-48G14.3	4.02	6.72e-05	0.00554	0.32	0.18	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56296206	chr15:56447120~56447697:+
THCA	cis	rs853679	0.723	rs1736904	ENSG00000220721.1	OR1F12	4.02	6.73e-05	0.00554	0.24	0.18	Depression;	chr6:28251492	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.662	rs149961	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28047791	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28056708	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28056792	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28057501	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28057708	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28058299	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28058358	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28059910	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28060612	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28060704	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000219891.2	ZSCAN12P1	4.02	6.73e-05	0.00554	0.24	0.18	Parkinson's disease;	chr6:28062059	chr6:28091154~28093664:+
THCA	cis	rs4295623	0.585	rs13259242	ENSG00000270154.1	RP11-419I17.1	-4.02	6.73e-05	0.00554	-0.22	-0.18	Morning vs. evening chronotype;	chr8:11735524	chr8:12476462~12477122:+
THCA	cis	rs9341808	0.667	rs3828753	ENSG00000272129.1	RP11-250B2.6	4.02	6.73e-05	0.00554	0.23	0.18	Sitting height ratio;	chr6:80203029	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.591	rs7741013	ENSG00000272129.1	RP11-250B2.6	4.02	6.73e-05	0.00554	0.23	0.18	Sitting height ratio;	chr6:80206613	chr6:80355424~80356859:+
THCA	cis	rs7031325	0.819	rs10758801	ENSG00000229611.1	RP11-390F4.10	4.02	6.73e-05	0.00554	0.2	0.18	Systemic lupus erythematosus;	chr9:6657192	chr9:6704471~6707780:+
THCA	cis	rs36093844	0.664	rs111395809	ENSG00000279742.1	RP11-700A24.1	-4.02	6.73e-05	0.00554	-0.25	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86055093	chr11:85852557~85854943:-
THCA	cis	rs7617480	0.585	rs7373072	ENSG00000229759.1	MRPS18AP1	4.02	6.73e-05	0.00554	0.27	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48922584	chr3:48256350~48256938:-
THCA	cis	rs800160	0.777	rs2521283	ENSG00000199550.1	Y_RNA	4.02	6.73e-05	0.00555	0.28	0.18	Bacteremia;	chr11:2320342	chr11:2372638~2372750:+
THCA	cis	rs453301	0.686	rs11785634	ENSG00000254340.1	RP11-10A14.3	-4.02	6.73e-05	0.00555	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9035087	chr8:9141424~9145435:+
THCA	cis	rs11030122	0.877	rs10835226	ENSG00000230593.3	AC090804.1	4.02	6.74e-05	0.00555	0.25	0.18	Mean platelet volume;Platelet distribution width;	chr11:3873037	chr11:3892398~3892887:-
THCA	cis	rs35146811	0.735	rs1138417	ENSG00000078319.8	PMS2P1	-4.02	6.74e-05	0.00555	-0.22	-0.18	Coronary artery disease;	chr7:100209523	chr7:100320992~100341908:-
THCA	cis	rs801193	0.935	rs2659899	ENSG00000230295.1	RP11-458F8.2	-4.02	6.74e-05	0.00555	-0.14	-0.18	Aortic root size;	chr7:66721734	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs1553609	ENSG00000230295.1	RP11-458F8.2	-4.02	6.74e-05	0.00555	-0.14	-0.18	Aortic root size;	chr7:66732152	chr7:66880708~66882981:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000230295.1	RP11-458F8.2	-4.02	6.74e-05	0.00555	-0.14	-0.18	Aortic root size;	chr7:66749023	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs2659889	ENSG00000230295.1	RP11-458F8.2	-4.02	6.74e-05	0.00555	-0.14	-0.18	Aortic root size;	chr7:66752125	chr7:66880708~66882981:+
THCA	cis	rs12612619	0.732	rs2053385	ENSG00000272148.1	RP11-195B17.1	4.02	6.74e-05	0.00555	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27008277	chr2:27062428~27062907:-
THCA	cis	rs12612619	0.732	rs1465881	ENSG00000272148.1	RP11-195B17.1	4.02	6.74e-05	0.00555	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27014746	chr2:27062428~27062907:-
THCA	cis	rs2299587	0.554	rs13253029	ENSG00000253671.1	RP11-806O11.1	-4.02	6.74e-05	0.00555	-0.21	-0.18	Economic and political preferences;	chr8:17892113	chr8:17808941~17820868:+
THCA	cis	rs67478160	0.643	rs8004408	ENSG00000269940.1	RP11-73M18.7	4.02	6.74e-05	0.00555	0.17	0.18	Schizophrenia;	chr14:103737601	chr14:103694560~103695170:+
THCA	cis	rs4792901	0.765	rs12601607	ENSG00000267151.3	RP11-100E5.2	4.02	6.74e-05	0.00555	0.2	0.18	Dupuytren's disease;	chr17:43461415	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.729	rs12603131	ENSG00000267151.3	RP11-100E5.2	4.02	6.74e-05	0.00555	0.2	0.18	Dupuytren's disease;	chr17:43461471	chr17:43444707~43451200:+
THCA	cis	rs867186	1	rs74626382	ENSG00000126005.14	MMP24-AS1	-4.02	6.74e-05	0.00555	-0.29	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35158865	chr20:35216462~35278131:-
THCA	cis	rs7259376	0.875	rs6511345	ENSG00000269138.1	ZNF209P	4.02	6.74e-05	0.00555	0.18	0.18	Menopause (age at onset);	chr19:22354634	chr19:22463922~22473036:+
THCA	cis	rs10043228	0.702	rs7711510	ENSG00000250015.1	CTC-339F2.2	4.02	6.75e-05	0.00556	0.23	0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116296556	chr5:116302354~116304134:-
THCA	cis	rs12893668	0.645	rs35229468	ENSG00000252469.1	RNU7-160P	4.02	6.75e-05	0.00556	0.22	0.18	Reticulocyte count;	chr14:103585720	chr14:103550345~103550406:+
THCA	cis	rs9309473	0.898	rs10201159	ENSG00000273245.1	RP11-434P11.2	4.02	6.75e-05	0.00556	0.26	0.18	Metabolite levels;	chr2:73631838	chr2:73750256~73750786:-
THCA	cis	rs3015497	0.594	rs35637875	ENSG00000270062.1	RP11-248J18.3	4.02	6.75e-05	0.00556	0.21	0.18	Mean platelet volume;	chr14:50665815	chr14:50723777~50724272:-
THCA	cis	rs7617480	0.648	rs6796790	ENSG00000229759.1	MRPS18AP1	4.02	6.75e-05	0.00556	0.28	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48742884	chr3:48256350~48256938:-
THCA	cis	rs8062405	0.756	rs151301	ENSG00000270424.1	RP11-1348G14.6	4.02	6.75e-05	0.00556	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28749959~28750595:-
THCA	cis	rs7089973	0.551	rs7087420	ENSG00000236799.1	RP11-383C6.2	-4.02	6.75e-05	0.00556	-0.21	-0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:115010242	chr10:114994657~114996593:+
THCA	cis	rs9905704	0.647	rs12940492	ENSG00000224738.1	AC099850.1	4.02	6.75e-05	0.00556	0.22	0.18	Testicular germ cell tumor;	chr17:58877294	chr17:59106598~59118267:+
THCA	cis	rs12887734	0.524	rs4900599	ENSG00000258534.1	CTD-2134A5.4	-4.02	6.75e-05	0.00556	-0.2	-0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103854366~103880111:-
THCA	cis	rs8113308	0.81	rs8104626	ENSG00000269483.1	AC006272.1	4.02	6.76e-05	0.00556	0.31	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51977364	chr19:51839924~51843324:-
THCA	cis	rs11758351	0.66	rs113205297	ENSG00000216331.1	HIST1H1PS1	4.02	6.76e-05	0.00556	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26210580	chr6:26195566~26195771:+
THCA	cis	rs9926296	0.656	rs2376884	ENSG00000260259.1	RP11-368I7.4	-4.02	6.76e-05	0.00556	-0.2	-0.18	Vitiligo;	chr16:89760514	chr16:89682620~89686569:-
THCA	cis	rs9926296	0.656	rs2376883	ENSG00000260259.1	RP11-368I7.4	-4.02	6.76e-05	0.00556	-0.2	-0.18	Vitiligo;	chr16:89760518	chr16:89682620~89686569:-
THCA	cis	rs7267979	0.873	rs6115093	ENSG00000274973.1	RP13-401N8.7	-4.02	6.76e-05	0.00557	-0.21	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25845497~25845862:+
THCA	cis	rs701145	0.585	rs959376	ENSG00000243069.6	ARHGEF26-AS1	4.02	6.76e-05	0.00557	0.34	0.18	Coronary artery disease;	chr3:154148918	chr3:154024401~154121332:-
THCA	cis	rs6442522	0.644	rs6442528	ENSG00000249786.6	EAF1-AS1	4.02	6.76e-05	0.00557	0.19	0.18	Uric acid levels;	chr3:15463717	chr3:15436171~15455940:-
THCA	cis	rs893363	0.636	rs4687587	ENSG00000271916.1	RP11-884K10.6	4.02	6.76e-05	0.00557	0.21	0.18	Axial length;	chr3:53815483	chr3:53797764~53798019:-
THCA	cis	rs2692947	0.644	rs772178	ENSG00000235584.2	AC008268.1	4.02	6.76e-05	0.00557	0.18	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96297946	chr2:95666084~95668715:+
THCA	cis	rs1005277	0.505	rs200939	ENSG00000275858.1	RP11-291L22.8	4.02	6.76e-05	0.00557	0.22	0.18	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38450738~38451069:-
THCA	cis	rs7577696	0.695	rs212749	ENSG00000276334.1	AL133243.1	4.02	6.76e-05	0.00557	0.2	0.18	Inflammatory biomarkers;	chr2:32190908	chr2:32521927~32523547:+
THCA	cis	rs11603020	0.95	rs28362949	ENSG00000254602.1	AP000662.4	-4.02	6.76e-05	0.00557	-0.21	-0.18	Blood protein levels;	chr11:57604438	chr11:57638024~57652790:+
THCA	cis	rs7267979	0.816	rs422148	ENSG00000277938.1	RP5-965G21.3	4.02	6.76e-05	0.00557	0.15	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25229150~25231933:+
THCA	cis	rs67981189	0.789	rs12101246	ENSG00000269927.1	RP6-91H8.3	4.02	6.77e-05	0.00557	0.21	0.18	Schizophrenia;	chr14:71084618	chr14:71141125~71143253:-
THCA	cis	rs9796	0.621	rs1659227	ENSG00000247556.5	OIP5-AS1	-4.02	6.77e-05	0.00557	-0.14	-0.18	Menopause (age at onset);	chr15:41180200	chr15:41283990~41309737:+
THCA	cis	rs4906332	0.966	rs17679729	ENSG00000252469.1	RNU7-160P	4.02	6.77e-05	0.00557	0.2	0.18	Coronary artery disease;	chr14:103457975	chr14:103550345~103550406:+
THCA	cis	rs4906332	0.933	rs35999760	ENSG00000252469.1	RNU7-160P	4.02	6.77e-05	0.00557	0.2	0.18	Coronary artery disease;	chr14:103458144	chr14:103550345~103550406:+
THCA	cis	rs4906332	0.966	rs12185021	ENSG00000252469.1	RNU7-160P	4.02	6.77e-05	0.00557	0.2	0.18	Coronary artery disease;	chr14:103461468	chr14:103550345~103550406:+
THCA	cis	rs12478296	0.792	rs6738361	ENSG00000261186.2	RP11-341N2.1	-4.02	6.77e-05	0.00557	-0.3	-0.18	Obesity-related traits;	chr2:242072106	chr2:242087351~242088457:-
THCA	cis	rs1979679	0.959	rs75757272	ENSG00000247934.4	RP11-967K21.1	-4.02	6.77e-05	0.00557	-0.19	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28251809	chr12:28163298~28190738:-
THCA	cis	rs7671266	0.532	rs7349721	ENSG00000261490.1	RP11-448G15.3	4.02	6.77e-05	0.00557	0.14	0.18	Cardiovascular disease risk factors;	chr4:10040938	chr4:10068089~10073019:-
THCA	cis	rs7259376	0.837	rs10420149	ENSG00000269138.1	ZNF209P	-4.02	6.77e-05	0.00557	-0.18	-0.18	Menopause (age at onset);	chr19:22400123	chr19:22463922~22473036:+
THCA	cis	rs9650657	0.535	rs7011756	ENSG00000254866.2	DEFB109P3	4.02	6.77e-05	0.00558	0.25	0.18	Neuroticism;	chr8:11162068	chr8:12150895~12151134:-
THCA	cis	rs7737355	0.947	rs3776030	ENSG00000237714.1	P4HA2-AS1	-4.02	6.77e-05	0.00558	-0.26	-0.18	Life satisfaction;	chr5:131441045	chr5:132184876~132192808:+
THCA	cis	rs754466	0.606	rs12356375	ENSG00000213514.2	RP11-428P16.2	4.02	6.77e-05	0.00558	0.2	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77834756	chr10:77730766~77734769:+
THCA	cis	rs801193	1	rs62466794	ENSG00000230295.1	RP11-458F8.2	-4.02	6.77e-05	0.00558	-0.14	-0.18	Aortic root size;	chr7:66726592	chr7:66880708~66882981:+
THCA	cis	rs42648	0.87	rs7783199	ENSG00000225498.1	AC002064.5	-4.02	6.77e-05	0.00558	-0.19	-0.18	Homocysteine levels;	chr7:90369991	chr7:90312496~90322592:+
THCA	cis	rs911555	0.723	rs6575982	ENSG00000269958.1	RP11-73M18.8	-4.02	6.77e-05	0.00558	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103696353~103697163:+
THCA	cis	rs7838490	0.527	rs6990293	ENSG00000253553.4	RP11-586K2.1	4.02	6.77e-05	0.00558	0.19	0.18	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88527298	chr8:88326836~88737134:+
THCA	cis	rs7838490	0.504	rs67422774	ENSG00000253553.4	RP11-586K2.1	4.02	6.77e-05	0.00558	0.19	0.18	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88539660	chr8:88326836~88737134:+
THCA	cis	rs61160187	0.582	rs7713481	ENSG00000272308.1	RP11-231G3.1	-4.02	6.77e-05	0.00558	-0.18	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60866457~60866935:-
THCA	cis	rs6456156	0.774	rs1012657	ENSG00000235272.1	FAM103A2P	-4.02	6.77e-05	0.00558	-0.25	-0.18	Primary biliary cholangitis;	chr6:167111654	chr6:166586124~166586477:-
THCA	cis	rs7119	0.604	rs939488	ENSG00000259362.2	RP11-307C19.1	4.02	6.78e-05	0.00558	0.26	0.18	Type 2 diabetes;	chr15:77575438	chr15:77525540~77534110:+
THCA	cis	rs59972978	0.562	rs6099653	ENSG00000124097.7	HMGB1P1	4.02	6.78e-05	0.00558	0.24	0.18	Alcohol consumption;	chr20:57487747	chr20:57488392~57489027:-
THCA	cis	rs2439831	0.681	rs2278858	ENSG00000166763.7	STRCP1	4.02	6.78e-05	0.00558	0.28	0.18	Lung cancer in ever smokers;	chr15:43340557	chr15:43699488~43718184:-
THCA	cis	rs1371614	0.611	rs3845685	ENSG00000272148.1	RP11-195B17.1	-4.02	6.78e-05	0.00558	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26907464	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.611	rs7557229	ENSG00000272148.1	RP11-195B17.1	-4.02	6.78e-05	0.00558	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908023	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.611	rs3910615	ENSG00000272148.1	RP11-195B17.1	-4.02	6.78e-05	0.00558	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908154	chr2:27062428~27062907:-
THCA	cis	rs11098499	0.955	rs13129661	ENSG00000249244.1	RP11-548H18.2	4.02	6.78e-05	0.00558	0.21	0.18	Corneal astigmatism;	chr4:119231754	chr4:119391831~119395335:-
THCA	cis	rs2239815	0.515	rs5752810	ENSG00000272858.1	CTA-292E10.8	-4.02	6.78e-05	0.00558	-0.23	-0.18	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28829535	chr22:28814914~28815662:+
THCA	cis	rs6942407	0.649	rs4727146	ENSG00000224046.1	AC005076.5	-4.02	6.78e-05	0.00558	-0.18	-0.18	Food allergy;	chr7:87227239	chr7:87151423~87152420:-
THCA	cis	rs12900463	0.752	rs12904777	ENSG00000275120.1	RP11-182J1.17	4.02	6.78e-05	0.00558	0.2	0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:84599434~84606463:-
THCA	cis	rs7267979	0.844	rs8184820	ENSG00000274973.1	RP13-401N8.7	4.02	6.78e-05	0.00558	0.21	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25845497~25845862:+
THCA	cis	rs7264396	0.887	rs11698935	ENSG00000088340.14	FER1L4	4.02	6.78e-05	0.00558	0.17	0.18	Total cholesterol levels;	chr20:35487189	chr20:35558737~35607562:-
THCA	cis	rs1048886	0.938	rs9455094	ENSG00000271967.1	RP11-134K13.4	-4.02	6.78e-05	0.00558	-0.19	-0.18	Type 2 diabetes;	chr6:70417201	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs7766075	ENSG00000271967.1	RP11-134K13.4	-4.02	6.78e-05	0.00558	-0.19	-0.18	Type 2 diabetes;	chr6:70418235	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs3889007	ENSG00000271967.1	RP11-134K13.4	-4.02	6.78e-05	0.00558	-0.19	-0.18	Type 2 diabetes;	chr6:70419086	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs3846750	ENSG00000271967.1	RP11-134K13.4	-4.02	6.78e-05	0.00558	-0.19	-0.18	Type 2 diabetes;	chr6:70419576	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs9446245	ENSG00000271967.1	RP11-134K13.4	-4.02	6.78e-05	0.00558	-0.19	-0.18	Type 2 diabetes;	chr6:70424555	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9455097	ENSG00000271967.1	RP11-134K13.4	-4.02	6.78e-05	0.00558	-0.19	-0.18	Type 2 diabetes;	chr6:70425153	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9455101	ENSG00000271967.1	RP11-134K13.4	-4.02	6.78e-05	0.00558	-0.19	-0.18	Type 2 diabetes;	chr6:70431863	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs9446248	ENSG00000271967.1	RP11-134K13.4	-4.02	6.78e-05	0.00558	-0.19	-0.18	Type 2 diabetes;	chr6:70434702	chr6:70596438~70596980:+
THCA	cis	rs4356203	0.87	rs214925	ENSG00000272034.1	SNORD14A	-4.02	6.78e-05	0.00558	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17213037	chr11:17074654~17074744:-
THCA	cis	rs944289	0.616	rs1742867	ENSG00000258844.1	RP11-259K15.2	-4.02	6.78e-05	0.00558	-0.17	-0.18	Thyroid cancer;	chr14:36067937	chr14:36214607~36235608:+
THCA	cis	rs2380205	0.967	rs2380208	ENSG00000232807.2	RP11-536K7.3	-4.02	6.78e-05	0.00558	-0.17	-0.18	Breast cancer;	chr10:5858069	chr10:5934270~5945900:-
THCA	cis	rs7804306	0.522	rs34261596	ENSG00000233264.2	AC006042.8	4.02	6.78e-05	0.00558	0.25	0.18	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036054	chr7:7980312~7982228:+
THCA	cis	rs964611	0.882	rs7162774	ENSG00000259488.2	RP11-154J22.1	4.02	6.78e-05	0.00558	0.18	0.18	Metabolite levels (Pyroglutamine);	chr15:48367336	chr15:48312353~48331856:-
THCA	cis	rs9991779	0.563	rs6844246	ENSG00000237125.7	HAND2-AS1	4.02	6.78e-05	0.00558	0.28	0.18	Pediatric bone mineral content (hip);	chr4:173982198	chr4:173527270~173591324:+
THCA	cis	rs853679	0.585	rs201001	ENSG00000226314.6	ZNF192P1	-4.02	6.79e-05	0.00558	-0.25	-0.18	Depression;	chr6:27841121	chr6:28161781~28169594:+
THCA	cis	rs853679	0.585	rs201000	ENSG00000226314.6	ZNF192P1	-4.02	6.79e-05	0.00558	-0.25	-0.18	Depression;	chr6:27841381	chr6:28161781~28169594:+
THCA	cis	rs6963495	0.818	rs6961233	ENSG00000272604.1	RP11-251G23.5	4.02	6.79e-05	0.00558	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105510022	chr7:105571083~105573660:+
THCA	cis	rs9926296	0.572	rs8046872	ENSG00000274627.1	RP11-104N10.2	-4.02	6.79e-05	0.00559	-0.19	-0.18	Vitiligo;	chr16:89775144	chr16:89516797~89522217:+
THCA	cis	rs6701713	0.919	rs2296160	ENSG00000274245.1	RP11-357P18.2	-4.02	6.79e-05	0.00559	-0.21	-0.18	Alzheimer's disease (late onset);	chr1:207621975	chr1:207372559~207373252:+
THCA	cis	rs7208859	0.673	rs216420	ENSG00000280069.1	CTD-2349P21.3	-4.02	6.79e-05	0.00559	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30738182~30740275:+
THCA	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	4.02	6.79e-05	0.00559	0.21	0.18	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
THCA	cis	rs343092	0.938	rs343093	ENSG00000241749.4	RPSAP52	-4.02	6.79e-05	0.00559	-0.2	-0.18	Type 2 diabetes;	chr12:65861225	chr12:65758020~65826997:-
THCA	cis	rs1204798	0.945	rs1204786	ENSG00000237021.2	RP3-486I3.7	-4.02	6.79e-05	0.00559	-0.2	-0.18	Dental caries;	chr6:116213083	chr6:116254207~116256743:+
THCA	cis	rs3096299	0.658	rs34590044	ENSG00000261118.1	RP11-104N10.1	4.02	6.79e-05	0.00559	0.15	0.18	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89492017~89504460:-
THCA	cis	rs2898290	0.622	rs7822109	ENSG00000254527.1	ENPP7P12	-4.02	6.79e-05	0.00559	-0.23	-0.18	Systolic blood pressure;	chr8:11491638	chr8:12205759~12206389:-
THCA	cis	rs4660214	0.756	rs11205823	ENSG00000182109.6	RP11-69E11.4	-4.02	6.79e-05	0.00559	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39522280~39546187:-
THCA	cis	rs9595908	0.758	rs9591219	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32653020	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.758	rs9591220	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32653059	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs12428283	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32653775	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9596035	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32654803	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9591226	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32655322	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs7335546	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32658197	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9591228	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32658632	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9591230	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32663944	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs2874282	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32665876	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9596051	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32666528	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9596057	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32669831	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9596059	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32670145	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9596060	ENSG00000212293.1	SNORA16	4.02	6.8e-05	0.00559	0.21	0.18	Body mass index;	chr13:32670467	chr13:32420390~32420516:-
THCA	cis	rs7737355	0.947	rs4705894	ENSG00000237714.1	P4HA2-AS1	4.02	6.8e-05	0.00559	0.26	0.18	Life satisfaction;	chr5:131743595	chr5:132184876~132192808:+
THCA	cis	rs758324	0.853	rs4705902	ENSG00000237714.1	P4HA2-AS1	4.02	6.8e-05	0.00559	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131814574	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs4705838	ENSG00000237714.1	P4HA2-AS1	4.02	6.8e-05	0.00559	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131814900	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs6861174	ENSG00000237714.1	P4HA2-AS1	4.02	6.8e-05	0.00559	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131820436	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs1875177	ENSG00000237714.1	P4HA2-AS1	4.02	6.8e-05	0.00559	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131866932	chr5:132184876~132192808:+
THCA	cis	rs758324	0.853	rs6865911	ENSG00000237714.1	P4HA2-AS1	4.02	6.8e-05	0.00559	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131868966	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs4493667	ENSG00000237714.1	P4HA2-AS1	-4.02	6.8e-05	0.00559	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131911525	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs60847707	ENSG00000237714.1	P4HA2-AS1	-4.02	6.8e-05	0.00559	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131916861	chr5:132184876~132192808:+
THCA	cis	rs1019173	1	rs9655613	ENSG00000261455.1	LINC01003	4.02	6.8e-05	0.00559	0.17	0.18	Kidney function decline traits;	chr7:152016433	chr7:152463786~152465549:+
THCA	cis	rs453301	0.686	rs4840389	ENSG00000254340.1	RP11-10A14.3	-4.02	6.8e-05	0.00559	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9026993	chr8:9141424~9145435:+
THCA	cis	rs453301	0.658	rs13271797	ENSG00000254340.1	RP11-10A14.3	-4.02	6.8e-05	0.00559	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9028444	chr8:9141424~9145435:+
THCA	cis	rs9307551	0.779	rs13124357	ENSG00000249646.2	OR7E94P	-4.02	6.8e-05	0.00559	-0.23	-0.18	Refractive error;	chr4:79591148	chr4:79587302~79588130:-
THCA	cis	rs6479891	1	rs10761730	ENSG00000272767.1	JMJD1C-AS1	-4.02	6.8e-05	0.00559	-0.25	-0.18	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs7916282	ENSG00000272767.1	JMJD1C-AS1	-4.02	6.8e-05	0.00559	-0.25	-0.18	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.915	rs9415682	ENSG00000272767.1	JMJD1C-AS1	-4.02	6.8e-05	0.00559	-0.25	-0.18	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.778	rs10761735	ENSG00000272767.1	JMJD1C-AS1	-4.02	6.8e-05	0.00559	-0.25	-0.18	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs9414786	ENSG00000272767.1	JMJD1C-AS1	-4.02	6.8e-05	0.00559	-0.25	-0.18	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.822	rs6479892	ENSG00000272767.1	JMJD1C-AS1	-4.02	6.8e-05	0.00559	-0.25	-0.18	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63465229~63466563:+
THCA	cis	rs6940638	0.688	rs1028308	ENSG00000220721.1	OR1F12	4.02	6.8e-05	0.00559	0.22	0.18	Intelligence (multi-trait analysis);	chr6:27161978	chr6:28073316~28074233:+
THCA	cis	rs6939532	0.522	rs4712981	ENSG00000124549.13	BTN2A3P	-4.02	6.8e-05	0.00559	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26361202	chr6:26421391~26432383:+
THCA	cis	rs6939532	0.544	rs10946816	ENSG00000124549.13	BTN2A3P	-4.02	6.8e-05	0.00559	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26361718	chr6:26421391~26432383:+
THCA	cis	rs944289	0.616	rs6571735	ENSG00000258844.1	RP11-259K15.2	4.02	6.8e-05	0.00559	0.16	0.18	Thyroid cancer;	chr14:36089428	chr14:36214607~36235608:+
THCA	cis	rs9634489	0.59	rs1927794	ENSG00000247400.3	DNAJC3-AS1	-4.02	6.8e-05	0.00559	-0.12	-0.18	Body mass index;	chr13:96268795	chr13:95648733~95676925:-
THCA	cis	rs11758351	0.866	rs2022448	ENSG00000216331.1	HIST1H1PS1	4.02	6.8e-05	0.00559	0.28	0.18	Renal underexcretion gout;Gout;	chr6:26207700	chr6:26195566~26195771:+
THCA	cis	rs4660214	0.694	rs16866216	ENSG00000182109.6	RP11-69E11.4	-4.02	6.8e-05	0.0056	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39208916	chr1:39522280~39546187:-
THCA	cis	rs875971	1	rs2220626	ENSG00000272831.1	RP11-792A8.4	-4.02	6.8e-05	0.0056	-0.12	-0.18	Aortic root size;	chr7:66081075	chr7:66739829~66740385:-
THCA	cis	rs6847067	0.965	rs17009249	ENSG00000180769.7	WDFY3-AS2	-4.02	6.8e-05	0.0056	-0.13	-0.18	Oropharynx cancer;	chr4:84746674	chr4:84965682~85011277:+
THCA	cis	rs4664304	0.62	rs55664214	ENSG00000226266.5	AC009961.3	4.02	6.8e-05	0.0056	0.22	0.18	Crohn's disease;Inflammatory bowel disease;	chr2:159851548	chr2:159670708~159712435:-
THCA	cis	rs10043228	0.826	rs12514785	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116139040	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs77148055	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116174223	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384213	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116191098	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs35696109	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116192059	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384215	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116192501	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384235	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116198537	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384236	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116198940	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384238	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116206834	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs77849630	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116221203	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs75080838	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116221770	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384253	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116227718	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs17139224	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116232496	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs1422500	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116233615	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs1592917	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116233717	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12153717	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116236217	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.59	rs10519448	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116238364	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12521612	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116246908	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs79889615	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116255595	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12520632	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116256069	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62385980	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116257211	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62385993	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116266557	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs17139314	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116271430	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12515251	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116291269	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384476	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116313812	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12521440	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116334667	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.793	rs62384491	ENSG00000248445.4	SEMA6A-AS1	-4.02	6.8e-05	0.0056	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116337061	chr5:116447547~116508276:+
THCA	cis	rs5997397	0.967	rs5762777	ENSG00000272858.1	CTA-292E10.8	-4.02	6.8e-05	0.0056	-0.18	-0.18	Red cell distribution width;	chr22:28754056	chr22:28814914~28815662:+
THCA	cis	rs2549003	0.966	rs2706386	ENSG00000237714.1	P4HA2-AS1	4.02	6.8e-05	0.0056	0.23	0.18	Asthma (sex interaction);	chr5:132496995	chr5:132184876~132192808:+
THCA	cis	rs17685	0.753	rs6951808	ENSG00000230882.1	AC005077.14	4.02	6.8e-05	0.0056	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76143095	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs10952840	ENSG00000230882.1	AC005077.14	4.02	6.8e-05	0.0056	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76143560	chr7:76071469~76074963:-
THCA	cis	rs17685	0.672	rs10952841	ENSG00000230882.1	AC005077.14	4.02	6.8e-05	0.0056	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76149308	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs1806885	ENSG00000230882.1	AC005077.14	4.02	6.8e-05	0.0056	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76156294	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs1859791	ENSG00000230882.1	AC005077.14	4.02	6.8e-05	0.0056	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76156725	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs6464999	ENSG00000230882.1	AC005077.14	4.02	6.8e-05	0.0056	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76157997	chr7:76071469~76074963:-
THCA	cis	rs17685	0.753	rs6465000	ENSG00000230882.1	AC005077.14	4.02	6.8e-05	0.0056	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76158099	chr7:76071469~76074963:-
THCA	cis	rs11758351	0.66	rs56398712	ENSG00000216331.1	HIST1H1PS1	4.02	6.81e-05	0.0056	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26213640	chr6:26195566~26195771:+
THCA	cis	rs34421088	0.532	rs1369368	ENSG00000154316.13	TDH	-4.02	6.81e-05	0.0056	-0.14	-0.18	Neuroticism;	chr8:11292704	chr8:11339637~11368452:+
THCA	cis	rs7726839	0.561	rs72703050	ENSG00000225138.6	CTD-2228K2.7	4.02	6.81e-05	0.0056	0.21	0.18	Obesity-related traits;	chr5:582802	chr5:473236~480884:+
THCA	cis	rs13098911	0.54	rs13098366	ENSG00000226074.4	PRSS44	-4.02	6.81e-05	0.0056	-0.32	-0.18	Celiac disease;	chr3:46075295	chr3:46809359~46812558:-
THCA	cis	rs66823261	0.741	rs7841786	ENSG00000273402.1	RP5-855D21.2	4.02	6.81e-05	0.0056	0.19	0.18	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:237045~237669:+
THCA	cis	rs4218	0.681	rs7178935	ENSG00000277144.1	RP11-59H7.4	-4.02	6.81e-05	0.0056	-0.25	-0.18	Social communication problems;	chr15:59075968	chr15:59115547~59116089:-
THCA	cis	rs6715284	0.786	rs55724588	ENSG00000183308.6	AC005037.3	4.02	6.81e-05	0.0056	0.45	0.18	Rheumatoid arthritis;	chr2:201442897	chr2:200963263~201009102:+
THCA	cis	rs934734	0.532	rs7569113	ENSG00000214533.3	KRT18P33	4.02	6.81e-05	0.0056	0.22	0.18	Rheumatoid arthritis;	chr2:65429907	chr2:65666695~65667737:+
THCA	cis	rs8073060	0.586	rs225292	ENSG00000267321.1	RP11-1094M14.11	-4.02	6.81e-05	0.0056	-0.11	-0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35599364	chr17:35568120~35574792:+
THCA	cis	rs453301	0.631	rs11780774	ENSG00000233609.3	RP11-62H7.2	-4.02	6.81e-05	0.0056	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8941601	chr8:8961200~8979025:+
THCA	cis	rs295490	0.748	rs41356949	ENSG00000272656.1	RP11-219D15.3	4.02	6.81e-05	0.0056	0.34	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469580	chr3:139349024~139349371:-
THCA	cis	rs4767841	1	rs7961569	ENSG00000252886.1	RN7SKP197	4.02	6.81e-05	0.0056	0.18	0.18	Urgency urinary incontinence;	chr12:119719540	chr12:119631090~119631386:-
THCA	cis	rs11633886	0.806	rs62006211	ENSG00000259200.1	RP11-718O11.1	-4.02	6.81e-05	0.00561	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45767378	chr15:45705078~45931069:+
THCA	cis	rs13108904	0.967	rs62293658	ENSG00000254094.1	AC078852.1	4.02	6.81e-05	0.00561	0.21	0.18	Obesity-related traits;	chr4:1282628	chr4:1356581~1358075:+
THCA	cis	rs11638352	1	rs2412848	ENSG00000166763.7	STRCP1	4.02	6.81e-05	0.00561	0.41	0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43977409	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs2930528	ENSG00000166763.7	STRCP1	4.02	6.81e-05	0.00561	0.41	0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43978333	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs11632901	ENSG00000166763.7	STRCP1	-4.02	6.81e-05	0.00561	-0.41	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43988055	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs6493092	ENSG00000166763.7	STRCP1	-4.02	6.81e-05	0.00561	-0.41	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43997220	chr15:43699488~43718184:-
THCA	cis	rs709400	1	rs3915733	ENSG00000258735.1	LINC00637	4.02	6.81e-05	0.00561	0.24	0.18	Body mass index;	chr14:103681016	chr14:103847721~103858049:+
THCA	cis	rs12440869	1	rs28571147	ENSG00000270964.1	RP11-502I4.3	4.02	6.81e-05	0.00561	0.16	0.18	Peak velocity of the mitral A-wave;	chr15:67336311	chr15:67541072~67542604:-
THCA	cis	rs10875746	0.669	rs10431526	ENSG00000258273.1	RP11-370I10.4	4.02	6.81e-05	0.00561	0.26	0.18	Longevity (90 years and older);	chr12:48296360	chr12:48333755~48333901:-
THCA	cis	rs8062405	0.573	rs7187575	ENSG00000261766.1	RP11-22P6.2	4.02	6.82e-05	0.00561	0.18	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28862166~28863340:-
THCA	cis	rs7131987	0.526	rs7954375	ENSG00000257176.2	RP11-996F15.2	4.02	6.82e-05	0.00561	0.18	0.18	QT interval;	chr12:29241487	chr12:29280418~29317848:-
THCA	cis	rs911555	0.755	rs17841064	ENSG00000269910.1	RP11-73M18.10	4.02	6.82e-05	0.00561	0.16	0.18	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103694516~103695050:-
THCA	cis	rs801193	1	rs2707856	ENSG00000230295.1	RP11-458F8.2	-4.02	6.82e-05	0.00561	-0.14	-0.18	Aortic root size;	chr7:66746023	chr7:66880708~66882981:+
THCA	cis	rs5769765	1	rs761879	ENSG00000260613.1	RP3-522J7.6	4.02	6.82e-05	0.00561	0.22	0.18	Schizophrenia;	chr22:49847562	chr22:49832616~49837786:-
THCA	cis	rs12755164	0.771	rs11210080	ENSG00000223479.3	RP4-788P17.1	-4.02	6.82e-05	0.00561	-0.2	-0.18	Schizophrenia;	chr1:72870580	chr1:73635216~73715214:+
THCA	cis	rs6061231	0.561	rs67072353	ENSG00000275437.1	RP5-908M14.10	4.02	6.82e-05	0.00561	0.2	0.18	Colorectal cancer;	chr20:62365646	chr20:62402236~62405935:-
THCA	cis	rs7618915	0.798	rs353547	ENSG00000243224.1	RP5-1157M23.2	4.02	6.82e-05	0.00561	0.18	0.18	Bipolar disorder;	chr3:52234850	chr3:52239258~52241097:+
THCA	cis	rs4908760	0.613	rs12403640	ENSG00000232912.4	RP5-1115A15.1	4.02	6.82e-05	0.00561	0.17	0.18	Vitiligo;	chr1:8757804	chr1:8424645~8434838:+
THCA	cis	rs12234571	0.744	rs17159512	ENSG00000214293.7	APTR	4.02	6.82e-05	0.00561	0.22	0.18	Obesity-related traits;	chr7:77927697	chr7:77657660~77696265:-
THCA	cis	rs3924048	0.559	rs6541038	ENSG00000276830.1	MIR6730	-4.02	6.82e-05	0.00561	-0.18	-0.18	Optic cup area;	chr1:12566181	chr1:12578957~12579023:-
THCA	cis	rs3812831	0.669	rs382913	ENSG00000264539.1	MIR548AR	4.02	6.82e-05	0.00561	0.19	0.18	Schizophrenia;	chr13:114162780	chr13:114244505~114244561:+
THCA	cis	rs3812831	0.695	rs3118895	ENSG00000264539.1	MIR548AR	4.02	6.82e-05	0.00561	0.19	0.18	Schizophrenia;	chr13:114166267	chr13:114244505~114244561:+
THCA	cis	rs4767841	0.625	rs7967982	ENSG00000252886.1	RN7SKP197	-4.02	6.83e-05	0.00561	-0.18	-0.18	Urgency urinary incontinence;	chr12:119776032	chr12:119631090~119631386:-
THCA	cis	rs307896	0.909	rs884171	ENSG00000211513.4	MIR320E	-4.02	6.83e-05	0.00561	-0.23	-0.18	Multiple sclerosis;	chr19:47213090	chr19:46709271~46709382:-
THCA	cis	rs4950322	0.512	rs10736839	ENSG00000226015.2	CCT8P1	-4.02	6.83e-05	0.00561	-0.19	-0.18	Protein quantitative trait loci;	chr1:147370431	chr1:147203276~147204932:-
THCA	cis	rs4803480	0.542	rs7255742	ENSG00000267107.5	PCAT19	4.02	6.83e-05	0.00561	0.2	0.18	Schizophrenia;	chr19:41543459	chr19:41454169~41500649:-
THCA	cis	rs2721195	0.967	rs1480000	ENSG00000265393.1	CTD-2517M22.17	4.02	6.83e-05	0.00562	0.22	0.18	Age at first birth;	chr8:144476624	chr8:144512567~144513672:+
THCA	cis	rs7707921	0.881	rs73134709	ENSG00000251374.1	RPS23P5	4.02	6.83e-05	0.00562	0.26	0.18	Breast cancer;	chr5:81972680	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.752	rs34981833	ENSG00000251374.1	RPS23P5	4.02	6.83e-05	0.00562	0.26	0.18	Breast cancer;	chr5:81976913	chr5:82265157~82265259:-
THCA	cis	rs8003054	0.616	rs17277375	ENSG00000258515.1	RP11-203M5.7	4.02	6.83e-05	0.00562	0.12	0.18	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20441313	chr14:20451305~20451918:+
THCA	cis	rs111756027	0.51	rs11862602	ENSG00000260922.1	RP11-538I12.3	4.02	6.83e-05	0.00562	0.27	0.18	Bone mineral density (Ward's triangle area);	chr16:77233519	chr16:77234877~77290934:+
THCA	cis	rs962856	1	rs979043	ENSG00000236780.4	AC078941.1	4.02	6.84e-05	0.00562	0.22	0.18	Pancreatic cancer;	chr2:67339149	chr2:67123357~67215319:-
THCA	cis	rs6570726	0.905	rs421032	ENSG00000270638.1	RP3-466P17.1	4.02	6.84e-05	0.00562	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs9390329	ENSG00000270638.1	RP3-466P17.1	4.02	6.84e-05	0.00562	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs371744	ENSG00000270638.1	RP3-466P17.1	4.02	6.84e-05	0.00562	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145735570~145737218:+
THCA	cis	rs4272720	0.639	rs59553572	ENSG00000234736.4	FAM170B-AS1	-4.02	6.84e-05	0.00562	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49072882	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.639	rs59869834	ENSG00000234736.4	FAM170B-AS1	-4.02	6.84e-05	0.00562	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49072883	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.639	rs17011746	ENSG00000234736.4	FAM170B-AS1	-4.02	6.84e-05	0.00562	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49073044	chr10:49121839~49151547:+
THCA	cis	rs10411262	0.935	rs314666	ENSG00000245598.5	DACT3-AS1	-4.02	6.84e-05	0.00562	-0.21	-0.18	Tonsillectomy;	chr19:46673568	chr19:46660364~46677447:+
THCA	cis	rs11176749	0.543	rs10878618	ENSG00000256172.1	RP11-473M14.3	4.02	6.84e-05	0.00563	0.27	0.18	Expressive vocabulary in infants;	chr12:67446727	chr12:67440998~67442559:-
THCA	cis	rs11176749	0.543	rs10878620	ENSG00000256172.1	RP11-473M14.3	4.02	6.84e-05	0.00563	0.27	0.18	Expressive vocabulary in infants;	chr12:67446838	chr12:67440998~67442559:-
THCA	cis	rs12681366	0.762	rs7831073	ENSG00000261437.1	RP11-22C11.2	4.02	6.84e-05	0.00563	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94342138	chr8:94637285~94639467:-
THCA	cis	rs867186	1	rs79048371	ENSG00000126005.14	MMP24-AS1	-4.02	6.84e-05	0.00563	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35143681	chr20:35216462~35278131:-
THCA	cis	rs3128341	1	rs6660464	ENSG00000227207.2	RPL31P12	4.02	6.84e-05	0.00563	0.29	0.18	Intelligence (multi-trait analysis);	chr1:72361266	chr1:72301472~72301829:+
THCA	cis	rs9595908	0.785	rs7326809	ENSG00000212293.1	SNORA16	4.02	6.84e-05	0.00563	0.21	0.18	Body mass index;	chr13:32662135	chr13:32420390~32420516:-
THCA	cis	rs10256972	0.685	rs10263665	ENSG00000225146.1	AC073957.15	4.02	6.84e-05	0.00563	0.19	0.18	Endometriosis;Longevity;	chr7:1070992	chr7:1029025~1043891:+
THCA	cis	rs741677	0.963	rs8064649	ENSG00000231784.7	DBIL5P	4.02	6.84e-05	0.00563	0.2	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:569370	chr17:752660~755336:+
THCA	cis	rs741677	0.963	rs441821	ENSG00000231784.7	DBIL5P	4.02	6.84e-05	0.00563	0.2	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:571154	chr17:752660~755336:+
THCA	cis	rs5760842	0.967	rs5760844	ENSG00000236641.1	CTA-221G9.7	-4.02	6.85e-05	0.00563	-0.2	-0.18	Recurrent major depressive disorder;	chr22:25087218	chr22:25212742~25213685:+
THCA	cis	rs11658311	0.85	rs8064558	ENSG00000226478.3	UPF3AP1	-4.02	6.85e-05	0.00563	-0.44	-0.18	Obsessive-compulsive symptoms;	chr17:17540963	chr17:16745636~16746761:-
THCA	cis	rs11658311	0.85	rs73978969	ENSG00000226478.3	UPF3AP1	-4.02	6.85e-05	0.00563	-0.44	-0.18	Obsessive-compulsive symptoms;	chr17:17541476	chr17:16745636~16746761:-
THCA	cis	rs4845570	0.85	rs4618976	ENSG00000249602.1	RP11-98D18.3	4.02	6.85e-05	0.00563	0.27	0.18	Coronary artery disease;	chr1:151794112	chr1:151763384~151769501:-
THCA	cis	rs3812831	0.695	rs423237	ENSG00000264539.1	MIR548AR	4.02	6.85e-05	0.00563	0.19	0.18	Schizophrenia;	chr13:114165480	chr13:114244505~114244561:+
THCA	cis	rs1371614	0.632	rs6708148	ENSG00000272148.1	RP11-195B17.1	4.02	6.85e-05	0.00563	0.17	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944452	chr2:27062428~27062907:-
THCA	cis	rs1552244	0.688	rs9875667	ENSG00000232901.1	CYCSP10	4.02	6.85e-05	0.00563	0.23	0.18	Alzheimer's disease;	chr3:10138357	chr3:10000647~10000940:-
THCA	cis	rs2904524	1	rs17108018	ENSG00000257815.4	RP11-611E13.2	-4.02	6.85e-05	0.00563	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70343166	chr12:69904033~70243360:-
THCA	cis	rs4819052	1	rs13047688	ENSG00000182586.6	LINC00334	-4.02	6.85e-05	0.00563	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45234340~45258730:+
THCA	cis	rs12935229	0.756	rs17712844	ENSG00000260922.1	RP11-538I12.3	-4.02	6.85e-05	0.00563	-0.29	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77280087	chr16:77234877~77290934:+
THCA	cis	rs5751168	0.834	rs398182	ENSG00000240160.3	RN7SL263P	4.02	6.85e-05	0.00563	0.25	0.18	Prostate cancer (SNP x SNP interaction);	chr22:22485078	chr22:23261782~23262071:-
THCA	cis	rs7432375	0.566	rs835636	ENSG00000273486.1	RP11-731C17.2	4.02	6.85e-05	0.00563	0.15	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136955658	chr3:136837338~136839021:-
THCA	cis	rs1232027	0.656	rs836794	ENSG00000249655.1	CTC-325J23.2	4.02	6.85e-05	0.00563	0.22	0.18	Huntington's disease progression;	chr5:80716432	chr5:80630313~80631590:-
THCA	cis	rs2033711	0.503	rs6510141	ENSG00000268895.4	A1BG-AS1	4.02	6.85e-05	0.00563	0.22	0.18	Uric acid clearance;	chr19:58374419	chr19:58347751~58355183:+
THCA	cis	rs6933660	0.8	rs6931104	ENSG00000219395.2	HSPA8P15	-4.02	6.85e-05	0.00563	-0.16	-0.18	Menarche (age at onset);	chr6:151465042	chr6:151411259~151413945:-
THCA	cis	rs2115630	0.691	rs2292462	ENSG00000259295.5	CSPG4P12	-4.02	6.85e-05	0.00563	-0.24	-0.18	P wave terminal force;	chr15:84657523	chr15:85191438~85213905:+
THCA	cis	rs12908161	1	rs35630683	ENSG00000188388.10	GOLGA6L3	4.02	6.85e-05	0.00563	0.24	0.18	Schizophrenia;	chr15:84806000	chr15:85240472~85247170:+
THCA	cis	rs35828350	1	rs35828350	ENSG00000188388.10	GOLGA6L3	4.02	6.85e-05	0.00563	0.24	0.18	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:85240472~85247170:+
THCA	cis	rs12908161	1	rs56864281	ENSG00000188388.10	GOLGA6L3	4.02	6.85e-05	0.00563	0.24	0.18	Schizophrenia;	chr15:84814418	chr15:85240472~85247170:+
THCA	cis	rs1930961	1	rs6004673	ENSG00000272942.1	CTA-246H3.12	-4.02	6.86e-05	0.00564	-0.29	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25434324~25435070:-
THCA	cis	rs8062405	1	rs8061590	ENSG00000270424.1	RP11-1348G14.6	4.02	6.86e-05	0.00564	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28749959~28750595:-
THCA	cis	rs4578769	0.879	rs7243408	ENSG00000265939.1	UBE2CP2	4.02	6.86e-05	0.00564	0.22	0.18	Eosinophil percentage of white cells;	chr18:22861647	chr18:22900486~22900995:-
THCA	cis	rs8024893	0.764	rs8035110	ENSG00000215302.7	CTD-3092A11.1	4.02	6.86e-05	0.00564	0.29	0.18	Red cell distribution width;	chr15:31241884	chr15:30470779~30507623:+
THCA	cis	rs8024893	0.764	rs8036245	ENSG00000215302.7	CTD-3092A11.1	4.02	6.86e-05	0.00564	0.29	0.18	Red cell distribution width;	chr15:31242211	chr15:30470779~30507623:+
THCA	cis	rs10875746	0.669	rs2279464	ENSG00000226413.2	OR8T1P	4.02	6.86e-05	0.00564	0.26	0.18	Longevity (90 years and older);	chr12:48296626	chr12:48442030~48442947:-
THCA	cis	rs17685	0.753	rs4728586	ENSG00000230882.1	AC005077.14	4.02	6.86e-05	0.00564	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76173551	chr7:76071469~76074963:-
THCA	cis	rs151234	0.741	rs11647881	ENSG00000259982.1	CDC37P1	-4.02	6.86e-05	0.00564	-0.38	-0.18	Platelet distribution width;	chr16:28594852	chr16:28700294~28701540:-
THCA	cis	rs5997397	0.933	rs5762783	ENSG00000272858.1	CTA-292E10.8	-4.02	6.86e-05	0.00564	-0.19	-0.18	Red cell distribution width;	chr22:28769537	chr22:28814914~28815662:+
THCA	cis	rs7551222	0.752	rs16853865	ENSG00000240219.1	RP11-430C7.5	4.02	6.86e-05	0.00564	0.17	0.18	Schizophrenia;	chr1:204496531	chr1:204626775~204629712:+
THCA	cis	rs7829975	0.846	rs11779061	ENSG00000233609.3	RP11-62H7.2	-4.02	6.86e-05	0.00564	-0.18	-0.18	Mood instability;	chr8:8691922	chr8:8961200~8979025:+
THCA	cis	rs7088591	0.867	rs76157364	ENSG00000276818.1	AC026393.1	4.02	6.86e-05	0.00564	0.38	0.18	Blood pressure;	chr10:57986395	chr10:57095699~57095781:+
THCA	cis	rs4759375	1	rs10846506	ENSG00000256092.2	RP13-942N8.1	-4.02	6.86e-05	0.00564	-0.2	-0.18	HDL cholesterol;	chr12:123293268	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs73231952	ENSG00000256092.2	RP13-942N8.1	-4.02	6.86e-05	0.00564	-0.2	-0.18	HDL cholesterol;	chr12:123300991	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs10773004	ENSG00000256092.2	RP13-942N8.1	-4.02	6.86e-05	0.00564	-0.2	-0.18	HDL cholesterol;	chr12:123304211	chr12:123363868~123366113:+
THCA	cis	rs9595908	0.869	rs7983457	ENSG00000212293.1	SNORA16	-4.02	6.86e-05	0.00564	-0.21	-0.18	Body mass index;	chr13:32631797	chr13:32420390~32420516:-
THCA	cis	rs2298450	0.717	rs2835328	ENSG00000214867.3	SRSF9P1	4.02	6.86e-05	0.00564	0.27	0.18	Schizophrenia;	chr21:36250617	chr21:36295173~36295702:-
THCA	cis	rs17286411	0.639	rs34734042	ENSG00000260185.1	RP11-432I5.6	-4.02	6.86e-05	0.00564	-0.26	-0.18	Blood protein levels;	chr16:71721769	chr16:71655027~71664212:+
THCA	cis	rs9307551	0.817	rs11098766	ENSG00000249646.2	OR7E94P	-4.02	6.86e-05	0.00564	-0.23	-0.18	Refractive error;	chr4:79579266	chr4:79587302~79588130:-
THCA	cis	rs5758659	0.714	rs7245	ENSG00000273366.1	CTA-989H11.1	4.02	6.86e-05	0.00564	0.22	0.18	Cognitive function;	chr22:42085845	chr22:42278188~42278846:+
THCA	cis	rs12544026	0.55	rs479041	ENSG00000253669.3	KB-1732A1.1	-4.02	6.86e-05	0.00564	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101860937	chr8:102805517~102809971:+
THCA	cis	rs3755605	0.728	rs6444903	ENSG00000242578.1	RP11-469J4.3	4.02	6.86e-05	0.00564	0.2	0.18	Testicular germ cell tumor;	chr3:170177236	chr3:170410512~170418615:+
THCA	cis	rs7178424	0.774	rs13379947	ENSG00000259251.2	RP11-643M14.1	4.02	6.86e-05	0.00564	0.19	0.18	Height;	chr15:61892602	chr15:62060503~62062434:+
THCA	cis	rs4742903	0.967	rs7023085	ENSG00000270332.1	SMC2-AS1	4.02	6.86e-05	0.00564	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104141984	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.967	rs10991120	ENSG00000270332.1	SMC2-AS1	4.02	6.86e-05	0.00564	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104146770	chr9:104080024~104093073:-
THCA	cis	rs4713118	0.911	rs9461406	ENSG00000261839.1	RP1-265C24.8	-4.02	6.86e-05	0.00564	-0.21	-0.18	Parkinson's disease;	chr6:27751985	chr6:28136849~28139678:+
THCA	cis	rs7772486	0.79	rs2247429	ENSG00000270638.1	RP3-466P17.1	4.02	6.87e-05	0.00564	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs2247666	ENSG00000270638.1	RP3-466P17.1	4.02	6.87e-05	0.00564	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs3923579	ENSG00000270638.1	RP3-466P17.1	-4.02	6.87e-05	0.00564	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145735570~145737218:+
THCA	cis	rs4434872	0.536	rs1541	ENSG00000223599.1	RP11-216N14.7	4.02	6.87e-05	0.00564	0.33	0.18	Conduct disorder (symptom count);	chr1:153873058	chr1:153852106~153853414:-
THCA	cis	rs11089937	0.616	rs6001227	ENSG00000211639.2	IGLV4-60	4.02	6.87e-05	0.00564	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22162199~22162681:+
THCA	cis	rs2018683	0.739	rs10233884	ENSG00000272568.4	CTB-113D17.1	4.02	6.87e-05	0.00564	0.18	0.18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932690	chr7:28979967~29013367:+
THCA	cis	rs11239930	0.538	rs9663073	ENSG00000278811.3	LINC00624	4.02	6.87e-05	0.00565	0.21	0.18	AIDS progression;	chr1:147083022	chr1:147258885~147517875:-
THCA	cis	rs7551222	0.752	rs4252687	ENSG00000240219.1	RP11-430C7.5	4.02	6.87e-05	0.00565	0.17	0.18	Schizophrenia;	chr1:204528207	chr1:204626775~204629712:+
THCA	cis	rs3770081	1	rs78032828	ENSG00000273080.1	RP11-301O19.1	-4.02	6.87e-05	0.00565	-0.4	-0.18	Facial emotion recognition (sad faces);	chr2:86081909	chr2:86195590~86196049:+
THCA	cis	rs4218	0.689	rs60262196	ENSG00000259732.1	RP11-59H7.3	-4.02	6.87e-05	0.00565	-0.26	-0.18	Social communication problems;	chr15:59088853	chr15:59121034~59133250:+
THCA	cis	rs9693857	0.518	rs35589912	ENSG00000254153.1	CTA-398F10.2	4.02	6.87e-05	0.00565	0.22	0.18	Systolic blood pressure;	chr8:9420478	chr8:8456909~8461337:-
THCA	cis	rs10911902	0.561	rs78701198	ENSG00000233196.2	GS1-304P7.1	-4.02	6.87e-05	0.00565	-0.28	-0.18	Schizophrenia;	chr1:186380240	chr1:186580515~186581191:-
THCA	cis	rs9921338	0.509	rs7199847	ENSG00000262636.1	CTD-3088G3.4	4.02	6.87e-05	0.00565	0.24	0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353415	chr16:11380859~11381118:-
THCA	cis	rs7259376	0.905	rs8112246	ENSG00000269138.1	ZNF209P	4.02	6.87e-05	0.00565	0.18	0.18	Menopause (age at onset);	chr19:22384645	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.846	rs4024624	ENSG00000269138.1	ZNF209P	4.02	6.87e-05	0.00565	0.18	0.18	Menopause (age at onset);	chr19:22385462	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.846	rs5014503	ENSG00000269138.1	ZNF209P	4.02	6.87e-05	0.00565	0.18	0.18	Menopause (age at onset);	chr19:22385538	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.818	rs8101997	ENSG00000269138.1	ZNF209P	4.02	6.87e-05	0.00565	0.18	0.18	Menopause (age at onset);	chr19:22385630	chr19:22463922~22473036:+
THCA	cis	rs964611	1	rs74011998	ENSG00000259488.2	RP11-154J22.1	-4.02	6.88e-05	0.00565	-0.19	-0.18	Metabolite levels (Pyroglutamine);	chr15:48304516	chr15:48312353~48331856:-
THCA	cis	rs4742903	0.875	rs10820609	ENSG00000270332.1	SMC2-AS1	4.02	6.88e-05	0.00565	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104145051	chr9:104080024~104093073:-
THCA	cis	rs2120243	0.539	rs1585080	ENSG00000241770.1	RP11-555M1.3	-4.02	6.88e-05	0.00565	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157389193	chr3:157163452~157169133:+
THCA	cis	rs9393813	1	rs9393813	ENSG00000204789.4	ZNF204P	4.02	6.88e-05	0.00565	0.15	0.18	Bipolar disorder;	chr6:27363817	chr6:27357825~27360221:-
THCA	cis	rs9595908	0.758	rs2031354	ENSG00000212293.1	SNORA16	4.02	6.88e-05	0.00565	0.21	0.18	Body mass index;	chr13:32641454	chr13:32420390~32420516:-
THCA	cis	rs1048886	0.872	rs73474966	ENSG00000271967.1	RP11-134K13.4	-4.02	6.88e-05	0.00565	-0.19	-0.18	Type 2 diabetes;	chr6:70427988	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs9455104	ENSG00000271967.1	RP11-134K13.4	-4.02	6.88e-05	0.00565	-0.19	-0.18	Type 2 diabetes;	chr6:70433762	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9455105	ENSG00000271967.1	RP11-134K13.4	-4.02	6.88e-05	0.00565	-0.19	-0.18	Type 2 diabetes;	chr6:70433778	chr6:70596438~70596980:+
THCA	cis	rs62246343	0.564	rs17050383	ENSG00000254485.4	RP11-380O24.1	4.02	6.88e-05	0.00565	0.23	0.18	Fibrinogen levels;	chr3:9472896	chr3:9292588~9363303:-
THCA	cis	rs944289	0.617	rs1952708	ENSG00000258844.1	RP11-259K15.2	4.02	6.88e-05	0.00565	0.17	0.18	Thyroid cancer;	chr14:36113126	chr14:36214607~36235608:+
THCA	cis	rs944289	0.617	rs12432682	ENSG00000258844.1	RP11-259K15.2	4.02	6.88e-05	0.00565	0.17	0.18	Thyroid cancer;	chr14:36114058	chr14:36214607~36235608:+
THCA	cis	rs944289	0.617	rs7156229	ENSG00000258844.1	RP11-259K15.2	4.02	6.88e-05	0.00565	0.17	0.18	Thyroid cancer;	chr14:36114780	chr14:36214607~36235608:+
THCA	cis	rs944289	0.617	rs7156269	ENSG00000258844.1	RP11-259K15.2	4.02	6.88e-05	0.00565	0.17	0.18	Thyroid cancer;	chr14:36114849	chr14:36214607~36235608:+
THCA	cis	rs944289	0.617	rs2415314	ENSG00000258844.1	RP11-259K15.2	4.02	6.88e-05	0.00565	0.17	0.18	Thyroid cancer;	chr14:36115335	chr14:36214607~36235608:+
THCA	cis	rs944289	0.617	rs1159048	ENSG00000258844.1	RP11-259K15.2	4.02	6.88e-05	0.00565	0.17	0.18	Thyroid cancer;	chr14:36115428	chr14:36214607~36235608:+
THCA	cis	rs944289	0.617	rs1475715	ENSG00000258844.1	RP11-259K15.2	4.02	6.88e-05	0.00565	0.17	0.18	Thyroid cancer;	chr14:36116017	chr14:36214607~36235608:+
THCA	cis	rs5758511	0.68	rs5758688	ENSG00000230107.1	CTA-126B4.7	-4.02	6.88e-05	0.00565	-0.22	-0.18	Birth weight;	chr22:42266495	chr22:42438023~42446195:+
THCA	cis	rs1799922	1	rs11653	ENSG00000271553.1	RP11-274B21.10	-4.02	6.88e-05	0.00565	-0.16	-0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128769526	chr7:128667043~128668156:+
THCA	cis	rs1510272	0.81	rs907059	ENSG00000243926.1	TIPARP-AS1	-4.02	6.88e-05	0.00565	-0.19	-0.18	Testicular germ cell tumor;	chr3:156574572	chr3:156671862~156674378:-
THCA	cis	rs6586163	1	rs7097572	ENSG00000261438.1	RP11-399O19.9	4.02	6.88e-05	0.00565	0.15	0.18	Chronic lymphocytic leukemia;	chr10:88993503	chr10:89015836~89017059:+
THCA	cis	rs73191547	0.501	rs6986885	ENSG00000261451.1	RP11-981G7.1	4.02	6.88e-05	0.00565	0.22	0.18	Schizophrenia;	chr8:10120961	chr8:10433672~10438312:+
THCA	cis	rs28735056	1	rs3826576	ENSG00000261126.6	RP11-795F19.1	-4.02	6.88e-05	0.00565	-0.15	-0.18	Schizophrenia;	chr18:79873976	chr18:80046900~80095482:+
THCA	cis	rs2380205	0.967	rs7099029	ENSG00000232807.2	RP11-536K7.3	4.02	6.88e-05	0.00566	0.17	0.18	Breast cancer;	chr10:5857225	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.967	rs4567357	ENSG00000232807.2	RP11-536K7.3	4.02	6.88e-05	0.00566	0.17	0.18	Breast cancer;	chr10:5857320	chr10:5934270~5945900:-
THCA	cis	rs4934494	0.677	rs11185780	ENSG00000240996.1	RP11-80H5.7	4.02	6.88e-05	0.00566	0.21	0.18	Red blood cell count;	chr10:89603867	chr10:89694295~89697928:-
THCA	cis	rs7665090	0.87	rs228615	ENSG00000248971.2	KRT8P46	4.02	6.88e-05	0.00566	0.22	0.18	Primary biliary cholangitis;	chr4:102658303	chr4:102728746~102730171:-
THCA	cis	rs3824488	0.705	rs61660304	ENSG00000271155.1	RP11-435O5.5	-4.02	6.88e-05	0.00566	-0.28	-0.18	Neuroticism;	chr9:95542358	chr9:95506235~95507636:+
THCA	cis	rs7577696	0.695	rs7581432	ENSG00000276334.1	AL133243.1	-4.02	6.89e-05	0.00566	-0.2	-0.18	Inflammatory biomarkers;	chr2:32170246	chr2:32521927~32523547:+
THCA	cis	rs8177876	0.822	rs4324141	ENSG00000261838.4	RP11-303E16.6	-4.02	6.89e-05	0.00566	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81069854~81076598:+
THCA	cis	rs12935418	0.83	rs12448368	ENSG00000261838.4	RP11-303E16.6	-4.02	6.89e-05	0.00566	-0.28	-0.18	Mean corpuscular volume;	chr16:81011342	chr16:81069854~81076598:+
THCA	cis	rs17853159	0.51	rs11586623	ENSG00000281912.1	LINC01144	-4.02	6.89e-05	0.00566	-0.23	-0.18	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45292839	chr1:45303910~45305619:+
THCA	cis	rs9843304	0.529	rs4681512	ENSG00000240541.2	TM4SF1-AS1	4.02	6.89e-05	0.00566	0.16	0.18	Gallstone disease;	chr3:149485654	chr3:149377778~149386583:+
THCA	cis	rs853679	1	rs853679	ENSG00000273712.1	RP5-874C20.7	4.02	6.89e-05	0.00566	0.28	0.18	Depression;	chr6:28329086	chr6:28315613~28315883:-
THCA	cis	rs853679	1	rs853678	ENSG00000273712.1	RP5-874C20.7	4.02	6.89e-05	0.00566	0.28	0.18	Depression;	chr6:28329536	chr6:28315613~28315883:-
THCA	cis	rs6667605	0.527	rs6673993	ENSG00000225931.3	RP3-395M20.7	4.02	6.89e-05	0.00566	0.22	0.18	Ulcerative colitis;Inflammatory bowel disease;	chr1:2620632	chr1:2566410~2569888:+
THCA	cis	rs763121	0.853	rs138712	ENSG00000228274.3	RP3-508I15.9	-4.02	6.89e-05	0.00566	-0.21	-0.18	Menopause (age at onset);	chr22:38745595	chr22:38667585~38681820:-
THCA	cis	rs4763879	0.634	rs7974396	ENSG00000214776.8	RP11-726G1.1	-4.02	6.89e-05	0.00566	-0.22	-0.18	Type 1 diabetes;	chr12:9708101	chr12:9467552~9576275:+
THCA	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-4.02	6.89e-05	0.00566	-0.24	-0.18	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
THCA	cis	rs9527	0.662	rs743575	ENSG00000236937.2	PTGES3P4	4.02	6.89e-05	0.00566	0.26	0.18	Arsenic metabolism;	chr10:102835149	chr10:102845595~102845950:+
THCA	cis	rs1908814	0.516	rs10113042	ENSG00000206014.6	OR7E161P	-4.02	6.89e-05	0.00566	-0.21	-0.18	Neuroticism;	chr8:11935669	chr8:11928597~11929563:-
THCA	cis	rs9595908	0.832	rs9315172	ENSG00000212293.1	SNORA16	4.02	6.89e-05	0.00566	0.22	0.18	Body mass index;	chr13:32634035	chr13:32420390~32420516:-
THCA	cis	rs12234571	1	rs17158641	ENSG00000214293.7	APTR	4.02	6.89e-05	0.00566	0.23	0.18	Obesity-related traits;	chr7:77839120	chr7:77657660~77696265:-
THCA	cis	rs13118159	0.836	rs2276903	ENSG00000254094.1	AC078852.1	-4.02	6.89e-05	0.00566	-0.21	-0.18	Longevity;	chr4:1349617	chr4:1356581~1358075:+
THCA	cis	rs1048886	0.872	rs10945235	ENSG00000271967.1	RP11-134K13.4	-4.02	6.89e-05	0.00566	-0.2	-0.18	Type 2 diabetes;	chr6:70595342	chr6:70596438~70596980:+
THCA	cis	rs10186029	0.509	rs6435756	ENSG00000270659.1	RP11-105N14.1	4.02	6.89e-05	0.00566	0.15	0.18	Systemic sclerosis;	chr2:213076555	chr2:213152970~213153659:+
THCA	cis	rs801193	1	rs1553610	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66732246	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs2707845	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66733811	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs2707850	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66738883	chr7:66880708~66882981:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66740595	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs7783924	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66744070	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs7789184	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66745208	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs2707854	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66747610	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs3800812	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66758474	chr7:66880708~66882981:+
THCA	cis	rs801193	1	rs4279493	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66761633	chr7:66880708~66882981:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000230295.1	RP11-458F8.2	-4.02	6.89e-05	0.00566	-0.14	-0.18	Aortic root size;	chr7:66765184	chr7:66880708~66882981:+
THCA	cis	rs1913185	0.787	rs59850864	ENSG00000240032.1	RP11-274H2.3	-4.02	6.89e-05	0.00566	-0.27	-0.18	Obesity-related traits;	chr3:146111375	chr3:146066344~146069185:-
THCA	cis	rs17685	0.753	rs10476	ENSG00000230882.1	AC005077.14	-4.02	6.89e-05	0.00566	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76067102	chr7:76071469~76074963:-
THCA	cis	rs897984	0.762	rs4889599	ENSG00000275263.1	RP11-1072A3.4	4.02	6.9e-05	0.00566	0.21	0.18	Dementia with Lewy bodies;	chr16:30957268	chr16:30956872~30957199:-
THCA	cis	rs897984	0.721	rs2305884	ENSG00000275263.1	RP11-1072A3.4	4.02	6.9e-05	0.00566	0.21	0.18	Dementia with Lewy bodies;	chr16:30959420	chr16:30956872~30957199:-
THCA	cis	rs7951911	0.915	rs12285394	ENSG00000254427.1	RP11-430H10.1	-4.02	6.9e-05	0.00566	-0.33	-0.18	IgG glycosylation;	chr11:45071817	chr11:45355371~45366121:+
THCA	cis	rs7131987	0.565	rs7976227	ENSG00000257176.2	RP11-996F15.2	4.02	6.9e-05	0.00566	0.18	0.18	QT interval;	chr12:29264843	chr12:29280418~29317848:-
THCA	cis	rs6540731	0.905	rs12073206	ENSG00000226251.4	RP11-15I11.3	-4.02	6.9e-05	0.00566	-0.22	-0.18	Intelligence (childhood);	chr1:212214294	chr1:212225278~212238977:-
THCA	cis	rs1371614	0.523	rs893789	ENSG00000272148.1	RP11-195B17.1	4.02	6.9e-05	0.00566	0.17	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26961102	chr2:27062428~27062907:-
THCA	cis	rs13108904	0.935	rs1732100	ENSG00000254094.1	AC078852.1	4.02	6.9e-05	0.00566	0.21	0.18	Obesity-related traits;	chr4:1287973	chr4:1356581~1358075:+
THCA	cis	rs1612141	1	rs1778378	ENSG00000251363.2	RP11-129M6.1	-4.02	6.9e-05	0.00566	-0.27	-0.18	QT interval (drug interaction);	chr14:41227598	chr14:40954898~40975877:+
THCA	cis	rs2562784	0.587	rs2732161	ENSG00000225151.9	GOLGA2P7	-4.02	6.9e-05	0.00567	-0.32	-0.18	Height;	chr15:83602031	chr15:84199311~84230136:-
THCA	cis	rs7542375	0.534	rs56369151	ENSG00000272823.1	RP11-295M18.6	-4.02	6.9e-05	0.00567	-0.26	-0.18	Obesity-related traits;	chr1:220865711	chr1:220828676~220829211:-
THCA	cis	rs6487679	0.526	rs34362	ENSG00000256069.6	A2MP1	-4.02	6.9e-05	0.00567	-0.21	-0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9232829	chr12:9228533~9275817:-
THCA	cis	rs17685	0.753	rs13240967	ENSG00000227038.2	AC005077.12	-4.02	6.9e-05	0.00567	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76028879	chr7:76090431~76108779:-
THCA	cis	rs6977955	1	rs4722760	ENSG00000234336.5	JAZF1-AS1	4.02	6.9e-05	0.00567	0.22	0.18	Allergic disease (asthma, hay fever or eczema);	chr7:28132564	chr7:28180322~28243917:+
THCA	cis	rs758324	0.947	rs13170693	ENSG00000237714.1	P4HA2-AS1	4.02	6.9e-05	0.00567	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131852133	chr5:132184876~132192808:+
THCA	cis	rs60180747	1	rs112981358	ENSG00000261318.1	RP11-653J6.1	4.02	6.9e-05	0.00567	0.24	0.18	Testicular germ cell tumor;	chr15:66361108	chr15:66278498~66293357:-
THCA	cis	rs2898290	0.622	rs17799486	ENSG00000254527.1	ENPP7P12	-4.02	6.9e-05	0.00567	-0.23	-0.18	Systolic blood pressure;	chr8:11482985	chr8:12205759~12206389:-
THCA	cis	rs2562456	0.833	rs2928211	ENSG00000268278.1	RP11-420K14.1	-4.02	6.9e-05	0.00567	-0.22	-0.18	Pain;	chr19:21358495	chr19:21637974~21656300:+
THCA	cis	rs7010876	0.632	rs10100297	ENSG00000253553.4	RP11-586K2.1	-4.02	6.9e-05	0.00567	-0.19	-0.18	Schizophrenia;	chr8:88298339	chr8:88326836~88737134:+
THCA	cis	rs2749592	0.55	rs7081464	ENSG00000276805.1	RP11-291L22.6	-4.02	6.9e-05	0.00567	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38451030~38451785:+
THCA	cis	rs7914558	0.933	rs10786729	ENSG00000213061.2	PFN1P11	4.02	6.9e-05	0.00567	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102959621	chr10:102838011~102845473:-
THCA	cis	rs6878727	0.626	rs161007	ENSG00000253807.4	LINC01170	4.02	6.9e-05	0.00567	0.16	0.18	Breast cancer;	chr5:124344690	chr5:124059794~124405079:-
THCA	cis	rs911555	0.723	rs7144010	ENSG00000269910.1	RP11-73M18.10	-4.02	6.9e-05	0.00567	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103694516~103695050:-
THCA	cis	rs295490	0.748	rs1602626	ENSG00000272656.1	RP11-219D15.3	-4.02	6.9e-05	0.00567	-0.35	-0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139364928	chr3:139349024~139349371:-
THCA	cis	rs9326246	0.545	rs480878	ENSG00000254851.1	RP11-109L13.1	4.02	6.91e-05	0.00567	0.41	0.18	Coronary artery disease;	chr11:116652137	chr11:117135528~117138582:+
THCA	cis	rs860295	0.702	rs34124416	ENSG00000236675.1	MTX1P1	-4.02	6.91e-05	0.00567	-0.19	-0.18	Body mass index;	chr1:155608258	chr1:155230975~155234325:+
THCA	cis	rs10175706	1	rs12477850	ENSG00000256637.5	RP11-76I14.1	-4.02	6.91e-05	0.00567	-0.16	-0.18	Chin dimples;	chr2:104018467	chr2:103874310~104077778:+
THCA	cis	rs7259376	0.905	rs12608842	ENSG00000269138.1	ZNF209P	-4.02	6.91e-05	0.00567	-0.18	-0.18	Menopause (age at onset);	chr19:22365211	chr19:22463922~22473036:+
THCA	cis	rs62158800	0.598	rs1606984	ENSG00000225588.2	AC096669.1	4.02	6.91e-05	0.00567	0.18	0.18	Facial morphology (factor 22);	chr2:107675531	chr2:107362282~107407329:+
THCA	cis	rs6433895	0.736	rs11893772	ENSG00000236153.1	AC104076.3	-4.02	6.91e-05	0.00567	-0.22	-0.18	Lymphocyte counts;	chr2:181124584	chr2:180979427~180980090:-
THCA	cis	rs7824557	0.547	rs2409745	ENSG00000254866.2	DEFB109P3	-4.02	6.91e-05	0.00567	-0.25	-0.18	Retinal vascular caliber;	chr8:11219126	chr8:12150895~12151134:-
THCA	cis	rs34779708	0.733	rs7070778	ENSG00000233200.1	RP11-324I22.2	4.02	6.91e-05	0.00567	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35219894~35230598:-
THCA	cis	rs6747488	0.529	rs665237	ENSG00000276517.1	AL133243.2	4.02	6.91e-05	0.00567	0.16	0.18	Interleukin-18 levels;	chr2:31644874	chr2:32526504~32529507:+
THCA	cis	rs6806253	0.73	rs75077124	ENSG00000239405.1	TMED10P2	4.02	6.91e-05	0.00567	0.29	0.18	Pit-and-Fissure caries;	chr3:128538363	chr3:128538020~128538631:+
THCA	cis	rs733592	0.507	rs10875739	ENSG00000258273.1	RP11-370I10.4	-4.02	6.91e-05	0.00567	-0.22	-0.18	Plateletcrit;	chr12:48087136	chr12:48333755~48333901:-
THCA	cis	rs72928364	0.929	rs35850913	ENSG00000256628.3	ZBTB11-AS1	4.02	6.91e-05	0.00567	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101056236	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.858	rs66598219	ENSG00000256628.3	ZBTB11-AS1	4.02	6.91e-05	0.00567	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101060591	chr3:101676475~101679217:+
THCA	cis	rs709400	0.93	rs28513222	ENSG00000258735.1	LINC00637	4.02	6.91e-05	0.00567	0.24	0.18	Body mass index;	chr14:103561732	chr14:103847721~103858049:+
THCA	cis	rs875971	1	rs10257427	ENSG00000230189.5	GS1-124K5.2	-4.02	6.91e-05	0.00567	-0.12	-0.18	Aortic root size;	chr7:66278221	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs10215948	ENSG00000230189.5	GS1-124K5.2	-4.02	6.91e-05	0.00567	-0.12	-0.18	Aortic root size;	chr7:66282799	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs55748098	ENSG00000230189.5	GS1-124K5.2	-4.02	6.91e-05	0.00567	-0.12	-0.18	Aortic root size;	chr7:66298631	chr7:66409143~66490059:-
THCA	cis	rs7402982	0.625	rs4966011	ENSG00000259424.1	RP11-35O15.1	4.02	6.91e-05	0.00568	0.18	0.18	Birth weight;	chr15:98660777	chr15:98646951~98647371:-
THCA	cis	rs9990333	0.6	rs6793116	ENSG00000226155.1	AC124944.3	4.02	6.91e-05	0.00568	0.21	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085217	chr3:195912049~195913986:+
THCA	cis	rs3824488	0.6	rs16909865	ENSG00000271155.1	RP11-435O5.5	4.02	6.91e-05	0.00568	0.35	0.18	Neuroticism;	chr9:95445020	chr9:95506235~95507636:+
THCA	cis	rs950169	0.922	rs11633534	ENSG00000188388.10	GOLGA6L3	4.02	6.91e-05	0.00568	0.25	0.18	Schizophrenia;	chr15:84581411	chr15:85240472~85247170:+
THCA	cis	rs4845570	0.92	rs6694952	ENSG00000249602.1	RP11-98D18.3	4.02	6.91e-05	0.00568	0.27	0.18	Coronary artery disease;	chr1:151787655	chr1:151763384~151769501:-
THCA	cis	rs9595908	0.785	rs9315177	ENSG00000212293.1	SNORA16	4.02	6.91e-05	0.00568	0.21	0.18	Body mass index;	chr13:32696214	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9596081	ENSG00000212293.1	SNORA16	4.02	6.91e-05	0.00568	0.21	0.18	Body mass index;	chr13:32698405	chr13:32420390~32420516:-
THCA	cis	rs1023500	0.551	rs133379	ENSG00000237037.8	NDUFA6-AS1	-4.02	6.92e-05	0.00568	-0.15	-0.18	Schizophrenia;	chr22:42072531	chr22:42090931~42137742:+
THCA	cis	rs1055129	0.537	rs1135640	ENSG00000267801.1	RP11-552F3.9	-4.02	6.92e-05	0.00568	-0.21	-0.18	White matter hyperintensity burden;	chr17:75953459	chr17:75876372~75879546:+
THCA	cis	rs4713118	0.539	rs200951	ENSG00000226314.6	ZNF192P1	-4.01	6.92e-05	0.00568	-0.22	-0.18	Parkinson's disease;	chr6:27868152	chr6:28161781~28169594:+
THCA	cis	rs62244186	0.715	rs13321717	ENSG00000214820.3	MPRIPP1	4.01	6.92e-05	0.00568	0.19	0.18	Depressive symptoms;	chr3:44625963	chr3:44579938~44581026:-
THCA	cis	rs11583043	0.575	rs658861	ENSG00000233184.5	RP11-421L21.3	-4.01	6.92e-05	0.00568	-0.19	-0.18	Inflammatory bowel disease;Ulcerative colitis;	chr1:101118685	chr1:101025878~101087268:+
THCA	cis	rs8031584	0.697	rs798080	ENSG00000178081.11	ULK4P3	-4.01	6.92e-05	0.00568	-0.24	-0.18	Huntington's disease progression;	chr15:30829966	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.723	rs11632229	ENSG00000259845.1	HERC2P10	-4.01	6.92e-05	0.00568	-0.25	-0.18	Huntington's disease progression;	chr15:30887331	chr15:30815271~30844153:+
THCA	cis	rs3809566	0.526	rs35829897	ENSG00000259459.4	RP11-321G12.1	4.01	6.92e-05	0.00568	0.19	0.18	Platelet count;	chr15:63042489	chr15:63390136~63438320:+
THCA	cis	rs17221829	0.733	rs11018725	ENSG00000280385.1	AP000648.5	-4.01	6.92e-05	0.00568	-0.17	-0.18	Anxiety in major depressive disorder;	chr11:89680083	chr11:90193614~90198120:+
THCA	cis	rs250585	0.736	rs250583	ENSG00000260136.4	CTD-2270L9.4	-4.01	6.92e-05	0.00568	-0.14	-0.18	Egg allergy;	chr16:23392189	chr16:23452758~23457606:+
THCA	cis	rs858239	0.699	rs955187	ENSG00000230042.1	AK3P3	4.01	6.92e-05	0.00568	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23129178~23129841:+
THCA	cis	rs9733	0.744	rs12125650	ENSG00000231073.1	RP11-316M1.3	-4.01	6.92e-05	0.00568	-0.22	-0.18	Tonsillectomy;	chr1:150787698	chr1:150973123~150975534:+
THCA	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	4.01	6.92e-05	0.00568	0.2	0.18	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	4.01	6.92e-05	0.00568	0.2	0.18	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	4.01	6.92e-05	0.00568	0.2	0.18	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	4.01	6.92e-05	0.00568	0.2	0.18	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	4.01	6.92e-05	0.00568	0.2	0.18	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
THCA	cis	rs4906332	1	rs13987	ENSG00000244691.1	RPL10AP1	-4.01	6.92e-05	0.00568	-0.23	-0.18	Coronary artery disease;	chr14:103503572	chr14:103412119~103412761:-
THCA	cis	rs7267979	1	rs13038834	ENSG00000276952.1	RP5-965G21.6	4.01	6.92e-05	0.00568	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25284915~25285588:-
THCA	cis	rs854765	0.583	rs4925123	ENSG00000281749.1	Y_RNA	-4.01	6.92e-05	0.00568	-0.23	-0.18	Total body bone mineral density;	chr17:17881060	chr17:18001101~18001195:-
THCA	cis	rs2692947	0.77	rs62153678	ENSG00000235584.2	AC008268.1	-4.01	6.93e-05	0.00568	-0.19	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892598	chr2:95666084~95668715:+
THCA	cis	rs4886920	0.666	rs11629621	ENSG00000260776.4	RP11-114H24.2	4.01	6.93e-05	0.00568	0.21	0.18	Neuroticism;	chr15:77788395	chr15:77914217~77926846:-
THCA	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-4.01	6.93e-05	0.00569	-0.2	-0.18	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
THCA	cis	rs1520333	0.54	rs61334537	ENSG00000254352.1	RP11-578O24.2	-4.01	6.93e-05	0.00569	-0.21	-0.18	Multiple sclerosis;	chr8:78451390	chr8:78723796~78724136:-
THCA	cis	rs1520333	0.54	rs59995609	ENSG00000254352.1	RP11-578O24.2	-4.01	6.93e-05	0.00569	-0.21	-0.18	Multiple sclerosis;	chr8:78451391	chr8:78723796~78724136:-
THCA	cis	rs36093844	0.699	rs4015260	ENSG00000279742.1	RP11-700A24.1	-4.01	6.93e-05	0.00569	-0.28	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85847844	chr11:85852557~85854943:-
THCA	cis	rs12681366	0.762	rs7824722	ENSG00000261437.1	RP11-22C11.2	4.01	6.93e-05	0.00569	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94338623	chr8:94637285~94639467:-
THCA	cis	rs858239	0.614	rs2014816	ENSG00000230042.1	AK3P3	-4.01	6.93e-05	0.00569	-0.23	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23129178~23129841:+
THCA	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	4.01	6.93e-05	0.00569	0.21	0.18	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	4.01	6.93e-05	0.00569	0.21	0.18	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	4.01	6.93e-05	0.00569	0.21	0.18	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	4.01	6.93e-05	0.00569	0.21	0.18	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	4.01	6.93e-05	0.00569	0.21	0.18	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	4.01	6.93e-05	0.00569	0.21	0.18	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	4.01	6.93e-05	0.00569	0.21	0.18	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
THCA	cis	rs9467773	1	rs767471	ENSG00000228223.2	HCG11	-4.01	6.93e-05	0.00569	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26523450~26526579:+
THCA	cis	rs801193	1	rs62466793	ENSG00000230295.1	RP11-458F8.2	-4.01	6.93e-05	0.00569	-0.14	-0.18	Aortic root size;	chr7:66726530	chr7:66880708~66882981:+
THCA	cis	rs4950322	0.518	rs61838936	ENSG00000271721.1	RP11-337C18.9	4.01	6.93e-05	0.00569	0.21	0.18	Protein quantitative trait loci;	chr1:147098422	chr1:147175602~147177740:+
THCA	cis	rs73191547	0.615	rs10089666	ENSG00000261451.1	RP11-981G7.1	4.01	6.93e-05	0.00569	0.23	0.18	Schizophrenia;	chr8:10225530	chr8:10433672~10438312:+
THCA	cis	rs3755605	0.728	rs6808369	ENSG00000242578.1	RP11-469J4.3	4.01	6.93e-05	0.00569	0.2	0.18	Testicular germ cell tumor;	chr3:170089028	chr3:170410512~170418615:+
THCA	cis	rs2434529	1	rs1422790	ENSG00000245275.6	SAP30L-AS1	4.01	6.94e-05	0.00569	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154237418	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs6893675	ENSG00000245275.6	SAP30L-AS1	4.01	6.94e-05	0.00569	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154239316	chr5:154329437~154445850:-
THCA	cis	rs1125355	1	rs116204562	ENSG00000243792.1	OR7E89P	-4.01	6.94e-05	0.00569	-0.28	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158849713	chr2:158853755~158854576:+
THCA	cis	rs13113518	1	rs1554483	ENSG00000272969.1	RP11-528I4.2	4.01	6.94e-05	0.00569	0.21	0.18	Height;	chr4:55455650	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs1464490	ENSG00000272969.1	RP11-528I4.2	4.01	6.94e-05	0.00569	0.21	0.18	Height;	chr4:55456620	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs10517346	ENSG00000272969.1	RP11-528I4.2	4.01	6.94e-05	0.00569	0.21	0.18	Height;	chr4:55457027	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs11133384	ENSG00000272969.1	RP11-528I4.2	4.01	6.94e-05	0.00569	0.21	0.18	Height;	chr4:55457086	chr4:55547112~55547889:+
THCA	cis	rs3812831	0.695	rs7998546	ENSG00000264539.1	MIR548AR	4.01	6.94e-05	0.00569	0.19	0.18	Schizophrenia;	chr13:114174439	chr13:114244505~114244561:+
THCA	cis	rs8070624	0.543	rs11870660	ENSG00000281749.1	Y_RNA	4.01	6.94e-05	0.00569	0.23	0.18	Total body bone mineral density;	chr17:17973782	chr17:18001101~18001195:-
THCA	cis	rs6840360	0.573	rs4696249	ENSG00000251611.1	RP11-610P16.1	-4.01	6.94e-05	0.00569	-0.13	-0.18	Intelligence (multi-trait analysis);	chr4:151343495	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.573	rs10024721	ENSG00000251611.1	RP11-610P16.1	-4.01	6.94e-05	0.00569	-0.13	-0.18	Intelligence (multi-trait analysis);	chr4:151344179	chr4:151407551~151408835:-
THCA	cis	rs2434529	0.911	rs73805839	ENSG00000245275.6	SAP30L-AS1	4.01	6.94e-05	0.00569	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154273167	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs73281459	ENSG00000245275.6	SAP30L-AS1	4.01	6.94e-05	0.00569	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154273370	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs73281462	ENSG00000245275.6	SAP30L-AS1	4.01	6.94e-05	0.00569	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154274876	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs73281463	ENSG00000245275.6	SAP30L-AS1	4.01	6.94e-05	0.00569	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154275315	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs73281464	ENSG00000245275.6	SAP30L-AS1	4.01	6.94e-05	0.00569	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr5:154275577	chr5:154329437~154445850:-
THCA	cis	rs801193	1	rs17566701	ENSG00000229180.5	GS1-124K5.11	4.01	6.94e-05	0.00569	0.13	0.18	Aortic root size;	chr7:66728196	chr7:66526088~66542624:-
THCA	cis	rs858239	0.669	rs1990365	ENSG00000226816.2	AC005082.12	4.01	6.94e-05	0.00569	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23206013~23208045:+
THCA	cis	rs11758351	0.734	rs56220351	ENSG00000216331.1	HIST1H1PS1	4.01	6.94e-05	0.00569	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26206656	chr6:26195566~26195771:+
THCA	cis	rs12234571	1	rs7799614	ENSG00000214293.7	APTR	4.01	6.94e-05	0.00569	0.22	0.18	Obesity-related traits;	chr7:77740666	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs6980016	ENSG00000214293.7	APTR	4.01	6.94e-05	0.00569	0.22	0.18	Obesity-related traits;	chr7:77751448	chr7:77657660~77696265:-
THCA	cis	rs2692947	0.77	rs72492163	ENSG00000235584.2	AC008268.1	-4.01	6.94e-05	0.00569	-0.19	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95752068	chr2:95666084~95668715:+
THCA	cis	rs881375	0.715	rs7858209	ENSG00000270917.1	RP11-27I1.6	-4.01	6.94e-05	0.00569	-0.24	-0.18	Rheumatoid arthritis;	chr9:120883482	chr9:120812475~120812845:-
THCA	cis	rs881375	0.715	rs10760119	ENSG00000270917.1	RP11-27I1.6	-4.01	6.94e-05	0.00569	-0.24	-0.18	Rheumatoid arthritis;	chr9:120883782	chr9:120812475~120812845:-
THCA	cis	rs4950322	0.58	rs4950371	ENSG00000226015.2	CCT8P1	4.01	6.94e-05	0.0057	0.21	0.18	Protein quantitative trait loci;	chr1:147114243	chr1:147203276~147204932:-
THCA	cis	rs7135809	0.57	rs11060239	ENSG00000279500.1	RP11-21K12.2	4.01	6.94e-05	0.0057	0.12	0.18	Interleukin-8 levels;	chr12:129294628	chr12:128813186~128814750:-
THCA	cis	rs922182	0.547	rs12594348	ENSG00000275785.1	RP11-111E14.2	-4.01	6.94e-05	0.0057	-0.21	-0.18	Blood protein levels;	chr15:63976928	chr15:63890030~63890317:+
THCA	cis	rs728616	0.614	rs17678737	ENSG00000278616.1	BEND3P3	4.01	6.94e-05	0.0057	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80374229	chr10:79682997~79685436:+
THCA	cis	rs728616	0.558	rs17616958	ENSG00000278616.1	BEND3P3	4.01	6.94e-05	0.0057	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377705	chr10:79682997~79685436:+
THCA	cis	rs728616	0.558	rs17616964	ENSG00000278616.1	BEND3P3	4.01	6.94e-05	0.0057	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377785	chr10:79682997~79685436:+
THCA	cis	rs782212	0.592	rs61771778	ENSG00000227207.2	RPL31P12	4.01	6.94e-05	0.0057	0.3	0.18	Depression;	chr1:72461172	chr1:72301472~72301829:+
THCA	cis	rs7819412	0.668	rs920047	ENSG00000206014.6	OR7E161P	4.01	6.94e-05	0.0057	0.21	0.18	Triglycerides;	chr8:11229966	chr8:11928597~11929563:-
THCA	cis	rs7216064	0.734	rs11653507	ENSG00000265055.1	AC145343.2	4.01	6.94e-05	0.0057	0.25	0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67895948	chr17:68096046~68101474:-
THCA	cis	rs10256972	0.552	rs2960831	ENSG00000225146.1	AC073957.15	4.01	6.94e-05	0.0057	0.2	0.18	Endometriosis;Longevity;	chr7:1161556	chr7:1029025~1043891:+
THCA	cis	rs877529	0.967	rs139400	ENSG00000279833.1	RP4-742C19.13	-4.01	6.94e-05	0.0057	-0.12	-0.18	Multiple myeloma;	chr22:39149391	chr22:39133090~39136760:+
THCA	cis	rs8031584	0.918	rs61997139	ENSG00000178081.11	ULK4P3	4.01	6.94e-05	0.0057	0.23	0.18	Huntington's disease progression;	chr15:30981399	chr15:30103720~30131757:+
THCA	cis	rs12681366	0.734	rs16916788	ENSG00000261437.1	RP11-22C11.2	4.01	6.94e-05	0.0057	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94387390	chr8:94637285~94639467:-
THCA	cis	rs7737355	0.947	rs6864173	ENSG00000237714.1	P4HA2-AS1	4.01	6.95e-05	0.0057	0.26	0.18	Life satisfaction;	chr5:131536129	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs6875058	ENSG00000237714.1	P4HA2-AS1	4.01	6.95e-05	0.0057	0.26	0.18	Life satisfaction;	chr5:131547009	chr5:132184876~132192808:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000232546.1	RP11-458F8.1	4.01	6.95e-05	0.0057	0.15	0.18	Aortic root size;	chr7:66836124	chr7:66848496~66858136:+
THCA	cis	rs17597773	0.674	rs10863569	ENSG00000272823.1	RP11-295M18.6	-4.01	6.95e-05	0.0057	-0.25	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220845598	chr1:220828676~220829211:-
THCA	cis	rs6496932	0.563	rs2344083	ENSG00000218052.5	ADAMTS7P4	-4.01	6.95e-05	0.0057	-0.21	-0.18	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85255369~85330334:-
THCA	cis	rs38055	0.668	rs62357407	ENSG00000247796.2	CTD-2366F13.1	4.01	6.95e-05	0.0057	0.18	0.18	Acne (severe);	chr5:53200622	chr5:53109842~53115126:+
THCA	cis	rs4822983	0.516	rs1303845	ENSG00000272858.1	CTA-292E10.8	4.01	6.95e-05	0.0057	0.21	0.18	Esophageal cancer (squamous cell);	chr22:28326547	chr22:28814914~28815662:+
THCA	cis	rs7403037	1	rs1498568	ENSG00000260760.1	PWRN3	4.01	6.95e-05	0.0057	0.2	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24349740	chr15:24441127~24447967:+
THCA	cis	rs7560272	0.538	rs12052539	ENSG00000163016.8	ALMS1P	4.01	6.95e-05	0.0057	0.22	0.18	Schizophrenia;	chr2:73710026	chr2:73644919~73685576:+
THCA	cis	rs9923856	0.695	rs13337334	ENSG00000263033.2	RP11-396B14.2	-4.01	6.95e-05	0.0057	-0.16	-0.18	Atopic dermatitis;Adult asthma;	chr16:11000561	chr16:11196177~11224969:+
THCA	cis	rs12612619	0.667	rs11126871	ENSG00000272148.1	RP11-195B17.1	-4.01	6.95e-05	0.0057	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27121589	chr2:27062428~27062907:-
THCA	cis	rs6728642	0.519	rs62152905	ENSG00000230606.9	AC159540.1	4.01	6.95e-05	0.0057	0.25	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96906485	chr2:97416165~97433527:-
THCA	cis	rs6728642	0.519	rs72811651	ENSG00000230606.9	AC159540.1	4.01	6.95e-05	0.0057	0.25	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96906492	chr2:97416165~97433527:-
THCA	cis	rs7665090	0.806	rs413967	ENSG00000248971.2	KRT8P46	4.01	6.95e-05	0.0057	0.22	0.18	Primary biliary cholangitis;	chr4:102662039	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.806	rs404574	ENSG00000248971.2	KRT8P46	4.01	6.95e-05	0.0057	0.22	0.18	Primary biliary cholangitis;	chr4:102662051	chr4:102728746~102730171:-
THCA	cis	rs6517329	0.576	rs7283730	ENSG00000236830.5	CBR3-AS1	4.01	6.95e-05	0.0057	0.17	0.18	Schizophrenia;	chr21:36123076	chr21:36131767~36175815:-
THCA	cis	rs893818	0.851	rs59755145	ENSG00000261801.4	LOXL1-AS1	4.01	6.95e-05	0.0057	0.22	0.18	Exfoliation glaucoma or exfoliation syndrome;	chr15:73938319	chr15:73908071~73928248:-
THCA	cis	rs4742903	0.875	rs1857980	ENSG00000270332.1	SMC2-AS1	4.01	6.96e-05	0.00571	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104229984	chr9:104080024~104093073:-
THCA	cis	rs11633886	0.934	rs1554420	ENSG00000259200.1	RP11-718O11.1	-4.01	6.96e-05	0.00571	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45784990	chr15:45705078~45931069:+
THCA	cis	rs7264396	0.887	rs4911510	ENSG00000088340.14	FER1L4	4.01	6.96e-05	0.00571	0.17	0.18	Total cholesterol levels;	chr20:35505325	chr20:35558737~35607562:-
THCA	cis	rs8046148	0.586	rs11076510	ENSG00000279356.1	RP11-429P3.8	4.01	6.96e-05	0.00571	0.22	0.18	Testicular germ cell tumor;	chr16:50013385	chr16:50072862~50074986:+
THCA	cis	rs35146811	0.66	rs3779046	ENSG00000078319.8	PMS2P1	4.01	6.96e-05	0.00571	0.22	0.18	Coronary artery disease;	chr7:100181620	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.66	rs3779045	ENSG00000078319.8	PMS2P1	4.01	6.96e-05	0.00571	0.22	0.18	Coronary artery disease;	chr7:100181636	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.7	rs4729579	ENSG00000078319.8	PMS2P1	4.01	6.96e-05	0.00571	0.22	0.18	Coronary artery disease;	chr7:100182659	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.7	rs7788301	ENSG00000078319.8	PMS2P1	4.01	6.96e-05	0.00571	0.22	0.18	Coronary artery disease;	chr7:100185130	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs2272344	ENSG00000078319.8	PMS2P1	4.01	6.96e-05	0.00571	0.22	0.18	Coronary artery disease;	chr7:100189196	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs11764176	ENSG00000078319.8	PMS2P1	4.01	6.96e-05	0.00571	0.22	0.18	Coronary artery disease;	chr7:100189341	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs6948729	ENSG00000078319.8	PMS2P1	4.01	6.96e-05	0.00571	0.22	0.18	Coronary artery disease;	chr7:100189749	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs11767968	ENSG00000078319.8	PMS2P1	4.01	6.96e-05	0.00571	0.22	0.18	Coronary artery disease;	chr7:100193348	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs1061230	ENSG00000078319.8	PMS2P1	-4.01	6.96e-05	0.00571	-0.22	-0.18	Coronary artery disease;	chr7:100209642	chr7:100320992~100341908:-
THCA	cis	rs9595908	0.785	rs7332884	ENSG00000212293.1	SNORA16	4.01	6.96e-05	0.00571	0.21	0.18	Body mass index;	chr13:32642412	chr13:32420390~32420516:-
THCA	cis	rs7824557	0.843	rs2572418	ENSG00000255310.2	AF131215.2	-4.01	6.96e-05	0.00571	-0.15	-0.18	Retinal vascular caliber;	chr8:11255580	chr8:11107788~11109726:-
THCA	cis	rs7296418	0.961	rs11608811	ENSG00000256092.2	RP13-942N8.1	4.01	6.96e-05	0.00571	0.13	0.18	Platelet count;	chr12:123044509	chr12:123363868~123366113:+
THCA	cis	rs17095355	1	rs752584	ENSG00000203876.8	ADD3-AS1	-4.01	6.96e-05	0.00571	-0.21	-0.18	Biliary atresia;	chr10:109923176	chr10:109940104~110008381:-
THCA	cis	rs10050311	0.746	rs969734	ENSG00000251411.1	RP11-397E7.4	-4.01	6.96e-05	0.00571	-0.21	-0.18	Insulin-related traits;	chr4:86744231	chr4:86913266~86914817:-
THCA	cis	rs7312933	0.703	rs10880264	ENSG00000257225.1	RP11-328C8.4	-4.01	6.96e-05	0.00571	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42192733	chr12:42459366~42466128:+
THCA	cis	rs72928364	1	rs34999788	ENSG00000256628.3	ZBTB11-AS1	4.01	6.96e-05	0.00571	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100898824	chr3:101676475~101679217:+
THCA	cis	rs911555	0.723	rs12436956	ENSG00000269958.1	RP11-73M18.8	-4.01	6.96e-05	0.00571	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103696353~103697163:+
THCA	cis	rs874628	0.686	rs56252442	ENSG00000268650.3	AC068499.10	4.01	6.96e-05	0.00571	0.22	0.18	Multiple sclerosis;	chr19:18118398	chr19:18204730~18220480:+
THCA	cis	rs2524276	1	rs2524276	ENSG00000231402.1	WASF5P	-4.01	6.96e-05	0.00571	-0.4	-0.18	Capecitabine sensitivity;	chr6:31440488	chr6:31287510~31288964:-
THCA	cis	rs858239	0.669	rs10950940	ENSG00000230042.1	AK3P3	4.01	6.96e-05	0.00571	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23129178~23129841:+
THCA	cis	rs6479891	1	rs9415680	ENSG00000272767.1	JMJD1C-AS1	-4.01	6.96e-05	0.00571	-0.25	-0.18	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63465229~63466563:+
THCA	cis	rs2735413	0.67	rs11861339	ENSG00000276007.1	RP11-358L22.3	4.01	6.97e-05	0.00571	0.18	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78060493	chr16:78123243~78124332:+
THCA	cis	rs1048886	0.872	rs9455162	ENSG00000271967.1	RP11-134K13.4	-4.01	6.97e-05	0.00571	-0.19	-0.18	Type 2 diabetes;	chr6:70568398	chr6:70596438~70596980:+
THCA	cis	rs4906332	1	rs7155822	ENSG00000252469.1	RNU7-160P	4.01	6.97e-05	0.00571	0.2	0.18	Coronary artery disease;	chr14:103456053	chr14:103550345~103550406:+
THCA	cis	rs2839186	0.749	rs62226488	ENSG00000215424.8	MCM3AP-AS1	4.01	6.97e-05	0.00571	0.1	0.18	Testicular germ cell tumor;	chr21:46290603	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.749	rs62226489	ENSG00000215424.8	MCM3AP-AS1	4.01	6.97e-05	0.00571	0.1	0.18	Testicular germ cell tumor;	chr21:46290605	chr21:46229217~46259390:+
THCA	cis	rs1075265	0.584	rs7590846	ENSG00000272156.1	RP11-477N3.1	4.01	6.97e-05	0.00572	0.18	0.18	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54082554~54085066:+
THCA	cis	rs9595908	0.785	rs7981925	ENSG00000212293.1	SNORA16	4.01	6.97e-05	0.00572	0.21	0.18	Body mass index;	chr13:32693706	chr13:32420390~32420516:-
THCA	cis	rs11673344	0.526	rs17305823	ENSG00000267422.1	CTD-2554C21.1	-4.01	6.97e-05	0.00572	-0.18	-0.18	Obesity-related traits;	chr19:37644145	chr19:37779686~37792865:+
THCA	cis	rs7178424	0.875	rs12912208	ENSG00000259251.2	RP11-643M14.1	4.01	6.97e-05	0.00572	0.18	0.18	Height;	chr15:62062371	chr15:62060503~62062434:+
THCA	cis	rs853679	0.607	rs34243448	ENSG00000220721.1	OR1F12	4.01	6.97e-05	0.00572	0.41	0.18	Depression;	chr6:28225324	chr6:28073316~28074233:+
THCA	cis	rs7200543	1	rs1135999	ENSG00000188599.16	NPIPP1	-4.01	6.97e-05	0.00572	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:15104312~15123498:-
THCA	cis	rs7200543	1	rs1136001	ENSG00000188599.16	NPIPP1	-4.01	6.97e-05	0.00572	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:15104312~15123498:-
THCA	cis	rs7200543	1	rs2740	ENSG00000188599.16	NPIPP1	-4.01	6.97e-05	0.00572	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:15104312~15123498:-
THCA	cis	rs2562456	0.876	rs11085468	ENSG00000268278.1	RP11-420K14.1	4.01	6.97e-05	0.00572	0.22	0.18	Pain;	chr19:21569087	chr19:21637974~21656300:+
THCA	cis	rs2777491	0.957	rs8026197	ENSG00000247556.5	OIP5-AS1	4.01	6.97e-05	0.00572	0.15	0.18	Ulcerative colitis;	chr15:41419249	chr15:41283990~41309737:+
THCA	cis	rs2777491	0.957	rs8027626	ENSG00000247556.5	OIP5-AS1	4.01	6.97e-05	0.00572	0.15	0.18	Ulcerative colitis;	chr15:41419316	chr15:41283990~41309737:+
THCA	cis	rs28643277	0.641	rs4750658	ENSG00000237470.3	DCLRE1CP1	4.01	6.97e-05	0.00572	0.24	0.18	Periodontitis (CDC/AAP);	chr10:15496219	chr10:15015370~15021863:-
THCA	cis	rs6688613	0.759	rs61815132	ENSG00000225171.2	DUTP6	-4.01	6.98e-05	0.00572	-0.27	-0.18	Refractive astigmatism;	chr1:166951674	chr1:166868748~166869209:+
THCA	cis	rs2274136	1	rs1886328	ENSG00000272269.1	RP11-500C11.3	4.01	6.98e-05	0.00572	0.21	0.18	Obesity-related traits;	chr6:17634792	chr6:17706257~17707344:+
THCA	cis	rs17095355	0.901	rs10399964	ENSG00000203876.8	ADD3-AS1	-4.01	6.98e-05	0.00572	-0.21	-0.18	Biliary atresia;	chr10:109894351	chr10:109940104~110008381:-
THCA	cis	rs13118159	0.573	rs4974618	ENSG00000254094.1	AC078852.1	-4.01	6.98e-05	0.00572	-0.22	-0.18	Longevity;	chr4:1379875	chr4:1356581~1358075:+
THCA	cis	rs950169	0.845	rs4106951	ENSG00000275120.1	RP11-182J1.17	4.01	6.98e-05	0.00572	0.22	0.18	Schizophrenia;	chr15:84164642	chr15:84599434~84606463:-
THCA	cis	rs7688540	0.771	rs11737268	ENSG00000250892.1	RP11-1365D11.1	4.01	6.98e-05	0.00572	0.27	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:201409~205009:-
THCA	cis	rs7688540	0.771	rs11726829	ENSG00000250892.1	RP11-1365D11.1	4.01	6.98e-05	0.00572	0.27	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:201409~205009:-
THCA	cis	rs801193	1	rs2659912	ENSG00000230295.1	RP11-458F8.2	-4.01	6.98e-05	0.00572	-0.14	-0.18	Aortic root size;	chr7:66693012	chr7:66880708~66882981:+
THCA	cis	rs8062405	0.723	rs4788077	ENSG00000270424.1	RP11-1348G14.6	4.01	6.98e-05	0.00572	0.23	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28749959~28750595:-
THCA	cis	rs2839186	0.564	rs4819215	ENSG00000228137.1	AP001469.7	4.01	6.98e-05	0.00572	0.18	0.18	Testicular germ cell tumor;	chr21:46203659	chr21:46246890~46247682:+
THCA	cis	rs7312933	0.703	rs12371615	ENSG00000257225.1	RP11-328C8.4	-4.01	6.98e-05	0.00572	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42170187	chr12:42459366~42466128:+
THCA	cis	rs4660214	0.724	rs11205695	ENSG00000182109.6	RP11-69E11.4	-4.01	6.98e-05	0.00573	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155285	chr1:39522280~39546187:-
THCA	cis	rs613391	0.561	rs682908	ENSG00000234840.1	LINC01239	-4.01	6.98e-05	0.00573	-0.21	-0.18	Quantitative traits;	chr9:22721975	chr9:22646200~22824213:+
THCA	cis	rs34421088	0.56	rs2618434	ENSG00000206014.6	OR7E161P	4.01	6.98e-05	0.00573	0.21	0.18	Neuroticism;	chr8:11541356	chr8:11928597~11929563:-
THCA	cis	rs11771526	0.792	rs17161104	ENSG00000272905.1	RP11-265E18.1	4.01	6.99e-05	0.00573	0.23	0.18	Body mass index;	chr7:32258970	chr7:32845394~32846061:+
THCA	cis	rs9595908	0.792	rs61947055	ENSG00000212293.1	SNORA16	4.01	6.99e-05	0.00573	0.21	0.18	Body mass index;	chr13:32614414	chr13:32420390~32420516:-
THCA	cis	rs6828577	0.862	rs298991	ENSG00000281731.1	RP11-384K6.8	-4.01	6.99e-05	0.00573	-0.21	-0.18	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118724845	chr4:118664087~118685341:-
THCA	cis	rs42648	0.905	rs42622	ENSG00000225498.1	AC002064.5	4.01	6.99e-05	0.00573	0.19	0.18	Homocysteine levels;	chr7:90327510	chr7:90312496~90322592:+
THCA	cis	rs42648	0.935	rs42624	ENSG00000225498.1	AC002064.5	4.01	6.99e-05	0.00573	0.19	0.18	Homocysteine levels;	chr7:90328227	chr7:90312496~90322592:+
THCA	cis	rs2836974	0.897	rs2836927	ENSG00000255568.3	BRWD1-AS2	4.01	6.99e-05	0.00573	0.16	0.18	Cognitive function;	chr21:39171290	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs2836929	ENSG00000255568.3	BRWD1-AS2	4.01	6.99e-05	0.00573	0.16	0.18	Cognitive function;	chr21:39171885	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.899	rs8127087	ENSG00000255568.3	BRWD1-AS2	4.01	6.99e-05	0.00573	0.16	0.18	Cognitive function;	chr21:39172576	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs2836932	ENSG00000255568.3	BRWD1-AS2	4.01	6.99e-05	0.00573	0.16	0.18	Cognitive function;	chr21:39174791	chr21:39313935~39314962:+
THCA	cis	rs9868809	0.772	rs13070798	ENSG00000270441.1	RP11-694I15.7	-4.01	6.99e-05	0.00573	-0.22	-0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48668501	chr3:49140086~49160851:-
THCA	cis	rs4660214	0.666	rs663449	ENSG00000228060.1	RP11-69E11.8	-4.01	6.99e-05	0.00573	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39565160~39573203:+
THCA	cis	rs11992162	0.508	rs7003792	ENSG00000254948.1	OR7E158P	4.01	6.99e-05	0.00573	0.22	0.18	Monocyte count;	chr8:11923955	chr8:11919900~11920809:-
THCA	cis	rs4950322	0.518	rs56151278	ENSG00000271721.1	RP11-337C18.9	4.01	6.99e-05	0.00573	0.21	0.18	Protein quantitative trait loci;	chr1:147117421	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.518	rs4950306	ENSG00000271721.1	RP11-337C18.9	4.01	6.99e-05	0.00573	0.21	0.18	Protein quantitative trait loci;	chr1:147117838	chr1:147175602~147177740:+
THCA	cis	rs911555	0.755	rs8018400	ENSG00000269910.1	RP11-73M18.10	-4.01	6.99e-05	0.00573	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103694516~103695050:-
THCA	cis	rs2777491	1	rs1757455	ENSG00000247556.5	OIP5-AS1	4.01	6.99e-05	0.00573	0.15	0.18	Ulcerative colitis;	chr15:41469134	chr15:41283990~41309737:+
THCA	cis	rs6545883	0.63	rs12998475	ENSG00000270820.4	RP11-355B11.2	-4.01	6.99e-05	0.00573	-0.15	-0.18	Tuberculosis;	chr2:61210352	chr2:61471188~61484130:+
THCA	cis	rs7554547	0.716	rs34954501	ENSG00000201801.1	RNU5E-4P	4.01	6.99e-05	0.00573	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11878146	chr1:11909808~11909927:-
THCA	cis	rs7615952	0.932	rs3811679	ENSG00000272840.1	RP11-379B18.6	4.01	6.99e-05	0.00573	0.3	0.18	Blood pressure (smoking interaction);	chr3:125929440	chr3:125774714~125797953:+
THCA	cis	rs302972	0.826	rs303005	ENSG00000168405.13	CMAHP	4.01	6.99e-05	0.00573	0.39	0.18	Creatinine levels in ischemic stroke;	chr6:25086416	chr6:25081068~25166555:-
THCA	cis	rs613391	0.603	rs628225	ENSG00000234840.1	LINC01239	-4.01	6.99e-05	0.00573	-0.21	-0.18	Quantitative traits;	chr9:22741676	chr9:22646200~22824213:+
THCA	cis	rs6453278	0.66	rs13178961	ENSG00000250802.5	ZBED3-AS1	-4.01	6.99e-05	0.00573	-0.18	-0.18	Autism;	chr5:77100623	chr5:77086740~77166909:+
THCA	cis	rs13113518	1	rs4864994	ENSG00000272969.1	RP11-528I4.2	4.01	7e-05	0.00573	0.21	0.18	Height;	chr4:55451955	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs4864995	ENSG00000272969.1	RP11-528I4.2	4.01	7e-05	0.00573	0.21	0.18	Height;	chr4:55452853	chr4:55547112~55547889:+
THCA	cis	rs13113518	1	rs12651640	ENSG00000272969.1	RP11-528I4.2	4.01	7e-05	0.00573	0.21	0.18	Height;	chr4:55454154	chr4:55547112~55547889:+
THCA	cis	rs3015497	0.789	rs923908	ENSG00000270062.1	RP11-248J18.3	4.01	7e-05	0.00573	0.2	0.18	Mean platelet volume;	chr14:50656877	chr14:50723777~50724272:-
THCA	cis	rs858239	0.738	rs13225593	ENSG00000226816.2	AC005082.12	4.01	7e-05	0.00573	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23206013~23208045:+
THCA	cis	rs28374715	0.532	rs316606	ENSG00000247556.5	OIP5-AS1	4.01	7e-05	0.00573	0.17	0.18	Ulcerative colitis;	chr15:41480004	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.532	rs316607	ENSG00000247556.5	OIP5-AS1	4.01	7e-05	0.00573	0.17	0.18	Ulcerative colitis;	chr15:41480495	chr15:41283990~41309737:+
THCA	cis	rs61160187	0.582	rs1471488	ENSG00000272308.1	RP11-231G3.1	-4.01	7e-05	0.00573	-0.17	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60866457~60866935:-
THCA	cis	rs523522	0.602	rs7132474	ENSG00000278344.1	RP11-18C24.8	4.01	7e-05	0.00573	0.24	0.18	High light scatter reticulocyte count;	chr12:120429193	chr12:120500735~120501090:-
THCA	cis	rs853679	0.546	rs34676049	ENSG00000272009.1	RP1-313I6.12	-4.01	7e-05	0.00574	-0.37	-0.18	Depression;	chr6:28485841	chr6:28078792~28081130:-
THCA	cis	rs7904321	1	rs12780096	ENSG00000232075.1	MRPL35P2	-4.01	7e-05	0.00574	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63081597	chr10:63634317~63634827:-
THCA	cis	rs9863	0.861	rs3802999	ENSG00000269938.1	RP11-214K3.20	-4.01	7e-05	0.00574	-0.22	-0.18	White blood cell count;	chr12:123929551	chr12:123968023~123968579:-
THCA	cis	rs548181	0.621	rs2912098	ENSG00000254671.2	STT3A-AS1	-4.01	7e-05	0.00574	-0.34	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125658674	chr11:125570284~125592568:-
THCA	cis	rs2434529	0.784	rs74746650	ENSG00000245275.6	SAP30L-AS1	4.01	7e-05	0.00574	0.25	0.18	Autism spectrum disorder or schizophrenia;	chr5:154265036	chr5:154329437~154445850:-
THCA	cis	rs7829975	0.511	rs2948286	ENSG00000233609.3	RP11-62H7.2	4.01	7e-05	0.00574	0.18	0.18	Mood instability;	chr8:8272638	chr8:8961200~8979025:+
THCA	cis	rs2290416	0.892	rs61652493	ENSG00000253931.1	RP11-909N17.2	4.01	7e-05	0.00574	0.37	0.18	Attention deficit hyperactivity disorder;	chr8:143586994	chr8:143412749~143417054:+
THCA	cis	rs911555	0.723	rs7149767	ENSG00000269910.1	RP11-73M18.10	-4.01	7e-05	0.00574	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103694516~103695050:-
THCA	cis	rs911555	0.692	rs7145753	ENSG00000269910.1	RP11-73M18.10	-4.01	7e-05	0.00574	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103694516~103695050:-
THCA	cis	rs900400	0.897	rs10049088	ENSG00000244515.1	KRT18P34	-4.01	7e-05	0.00574	-0.21	-0.18	circulating leptin levels adjusted for BMI;Birth weight;Menarche (age at onset);Adiponectin levels in pregnancy;circulating leptin levels;	chr3:157079859	chr3:157162663~157163932:-
THCA	cis	rs10043228	1	rs62384471	ENSG00000248445.4	SEMA6A-AS1	-4.01	7e-05	0.00574	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116295576	chr5:116447547~116508276:+
THCA	cis	rs9650657	0.775	rs10100265	ENSG00000255310.2	AF131215.2	-4.01	7.01e-05	0.00574	-0.15	-0.18	Neuroticism;	chr8:10775649	chr8:11107788~11109726:-
THCA	cis	rs944289	0.646	rs8007617	ENSG00000258844.1	RP11-259K15.2	4.01	7.01e-05	0.00574	0.16	0.18	Thyroid cancer;	chr14:36088883	chr14:36214607~36235608:+
THCA	cis	rs4906332	0.966	rs35443927	ENSG00000244691.1	RPL10AP1	-4.01	7.01e-05	0.00574	-0.24	-0.18	Coronary artery disease;	chr14:103383378	chr14:103412119~103412761:-
THCA	cis	rs6988985	0.589	rs13252628	ENSG00000253741.1	CTD-2292P10.4	4.01	7.01e-05	0.00574	0.23	0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142913528	chr8:142702252~142726973:-
THCA	cis	rs7131987	0.565	rs10843372	ENSG00000257176.2	RP11-996F15.2	4.01	7.01e-05	0.00574	0.18	0.18	QT interval;	chr12:29262863	chr12:29280418~29317848:-
THCA	cis	rs453301	0.686	rs2409120	ENSG00000233609.3	RP11-62H7.2	-4.01	7.01e-05	0.00574	-0.18	-0.18	Joint mobility (Beighton score);	chr8:9025061	chr8:8961200~8979025:+
THCA	cis	rs17221829	0.599	rs7112871	ENSG00000280385.1	AP000648.5	-4.01	7.01e-05	0.00575	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89671661	chr11:90193614~90198120:+
THCA	cis	rs4906332	0.754	rs34235720	ENSG00000269958.1	RP11-73M18.8	4.01	7.01e-05	0.00575	0.18	0.18	Coronary artery disease;	chr14:103538631	chr14:103696353~103697163:+
THCA	cis	rs11089937	0.523	rs4821832	ENSG00000211639.2	IGLV4-60	4.01	7.01e-05	0.00575	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22188499	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.523	rs4820352	ENSG00000211639.2	IGLV4-60	4.01	7.01e-05	0.00575	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22189203	chr22:22162199~22162681:+
THCA	cis	rs10833905	0.938	rs11026931	ENSG00000246225.5	RP11-17A1.3	-4.01	7.02e-05	0.00575	-0.26	-0.18	Sudden cardiac arrest;	chr11:23043651	chr11:22829380~22945393:+
THCA	cis	rs6121246	0.738	rs2376996	ENSG00000224628.2	RP5-854E16.2	-4.01	7.02e-05	0.00575	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31728864	chr20:31285317~31286835:-
THCA	cis	rs9326246	0.545	rs513533	ENSG00000254851.1	RP11-109L13.1	4.01	7.02e-05	0.00575	0.41	0.18	Coronary artery disease;	chr11:116648641	chr11:117135528~117138582:+
THCA	cis	rs7264396	0.887	rs2236165	ENSG00000088340.14	FER1L4	4.01	7.02e-05	0.00575	0.17	0.18	Total cholesterol levels;	chr20:35508896	chr20:35558737~35607562:-
THCA	cis	rs465969	0.546	rs77990243	ENSG00000272356.1	RP5-1112D6.8	4.01	7.02e-05	0.00575	0.26	0.18	Psoriasis;	chr6:111513183	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs4509157	ENSG00000272356.1	RP5-1112D6.8	4.01	7.02e-05	0.00575	0.26	0.18	Psoriasis;	chr6:111513875	chr6:111309203~111313517:+
THCA	cis	rs7474896	0.583	rs34185758	ENSG00000226578.1	RP11-258F22.1	-4.01	7.02e-05	0.00575	-0.26	-0.18	Obesity (extreme);	chr10:37701926	chr10:37775371~37784131:-
THCA	cis	rs9863	0.896	rs12824567	ENSG00000270061.1	RP11-214K3.19	-4.01	7.02e-05	0.00575	-0.24	-0.18	White blood cell count;	chr12:124010656	chr12:123969990~123970344:-
THCA	cis	rs9595908	0.785	rs9596109	ENSG00000212293.1	SNORA16	4.01	7.02e-05	0.00575	0.21	0.18	Body mass index;	chr13:32712611	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.536	rs73452706	ENSG00000212293.1	SNORA16	4.01	7.02e-05	0.00575	0.21	0.18	Body mass index;	chr13:32718155	chr13:32420390~32420516:-
THCA	cis	rs801193	1	rs7785213	ENSG00000230295.1	RP11-458F8.2	4.01	7.02e-05	0.00575	0.14	0.18	Aortic root size;	chr7:66673991	chr7:66880708~66882981:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000230295.1	RP11-458F8.2	-4.01	7.02e-05	0.00575	-0.14	-0.18	Aortic root size;	chr7:66692033	chr7:66880708~66882981:+
THCA	cis	rs4308124	0.708	rs6747657	ENSG00000230499.1	AC108463.1	-4.01	7.02e-05	0.00575	-0.27	-0.18	Vitiligo;	chr2:111245586	chr2:111195963~111206494:+
THCA	cis	rs12722605	0.54	rs36059985	ENSG00000229664.1	RP11-536K7.5	4.01	7.02e-05	0.00575	0.24	0.18	Inflammatory biomarkers;	chr10:5996788	chr10:6025978~6036427:+
THCA	cis	rs4792901	0.918	rs76798487	ENSG00000267151.3	RP11-100E5.2	4.01	7.02e-05	0.00575	0.19	0.18	Dupuytren's disease;	chr17:43556023	chr17:43444707~43451200:+
THCA	cis	rs34792	0.821	rs2450357	ENSG00000207425.1	Y_RNA	4.01	7.02e-05	0.00575	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15474475	chr16:14915457~14915556:-
THCA	cis	rs4713118	0.505	rs276371	ENSG00000220721.1	OR1F12	4.01	7.02e-05	0.00575	0.2	0.18	Parkinson's disease;	chr6:27942930	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.955	rs9468200	ENSG00000261839.1	RP1-265C24.8	4.01	7.02e-05	0.00575	0.21	0.18	Parkinson's disease;	chr6:27715284	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.955	rs34752872	ENSG00000261839.1	RP1-265C24.8	4.01	7.02e-05	0.00575	0.21	0.18	Parkinson's disease;	chr6:27715465	chr6:28136849~28139678:+
THCA	cis	rs35176054	0.73	rs12776858	ENSG00000280693.1	SH3PXD2A-AS1	-4.01	7.02e-05	0.00575	-0.35	-0.18	Atrial fibrillation;	chr10:103764406	chr10:103745966~103755423:+
THCA	cis	rs10266483	0.739	rs12665990	ENSG00000234338.1	RP11-797H7.1	-4.01	7.02e-05	0.00575	-0.15	-0.18	Response to statin therapy;	chr7:64404622	chr7:64835280~64836882:-
THCA	cis	rs7688540	0.61	rs6830496	ENSG00000211553.1	AC253576.2	-4.01	7.02e-05	0.00576	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:136461~136568:+
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000184274.3	LINC00315	-4.01	7.02e-05	0.00576	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45300245~45305257:-
THCA	cis	rs427943	0.83	rs2838800	ENSG00000223768.1	LINC00205	-4.01	7.03e-05	0.00576	-0.16	-0.18	Body mass index;	chr21:45177922	chr21:45293285~45297354:+
THCA	cis	rs7829975	0.774	rs13259216	ENSG00000254340.1	RP11-10A14.3	4.01	7.03e-05	0.00576	0.2	0.18	Mood instability;	chr8:8816091	chr8:9141424~9145435:+
THCA	cis	rs5758511	0.633	rs5751258	ENSG00000237037.8	NDUFA6-AS1	-4.01	7.03e-05	0.00576	-0.17	-0.18	Birth weight;	chr22:42267865	chr22:42090931~42137742:+
THCA	cis	rs10802047	0.54	rs1578003	ENSG00000231365.4	RP11-418J17.1	4.01	7.03e-05	0.00576	0.18	0.18	Relative hand skill in reading disability;	chr1:118840463	chr1:119140396~119275973:+
THCA	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	4.01	7.03e-05	0.00576	0.19	0.18	Asthma;	chr2:102431747	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	4.01	7.03e-05	0.00576	0.19	0.18	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	4.01	7.03e-05	0.00576	0.19	0.18	Asthma;	chr2:102432120	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	4.01	7.03e-05	0.00576	0.19	0.18	Asthma;	chr2:102432614	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	4.01	7.03e-05	0.00576	0.19	0.18	Asthma;	chr2:102433405	chr2:102438713~102440475:+
THCA	cis	rs9543976	0.623	rs6562913	ENSG00000261105.4	LMO7-AS1	4.01	7.03e-05	0.00576	0.25	0.18	Diabetic retinopathy;	chr13:75593297	chr13:75604700~75635994:-
THCA	cis	rs1383484	0.761	rs11259923	ENSG00000225151.9	GOLGA2P7	4.01	7.03e-05	0.00576	0.25	0.18	Height;	chr15:83866952	chr15:84199311~84230136:-
THCA	cis	rs854765	0.547	rs2955383	ENSG00000281749.1	Y_RNA	4.01	7.03e-05	0.00576	0.23	0.18	Total body bone mineral density;	chr17:18038050	chr17:18001101~18001195:-
THCA	cis	rs11992162	0.591	rs4240678	ENSG00000254948.1	OR7E158P	4.01	7.03e-05	0.00576	0.22	0.18	Monocyte count;	chr8:11944917	chr8:11919900~11920809:-
THCA	cis	rs11771526	0.892	rs62457504	ENSG00000272905.1	RP11-265E18.1	4.01	7.03e-05	0.00576	0.26	0.18	Body mass index;	chr7:32296485	chr7:32845394~32846061:+
THCA	cis	rs6903823	0.508	rs1150718	ENSG00000176933.5	TOB2P1	-4.01	7.03e-05	0.00576	-0.2	-0.18	Pulmonary function;	chr6:28289170	chr6:28217643~28218634:-
THCA	cis	rs7707921	0.881	rs324910	ENSG00000251374.1	RPS23P5	4.01	7.03e-05	0.00576	0.26	0.18	Breast cancer;	chr5:82104445	chr5:82265157~82265259:-
THCA	cis	rs6121246	0.56	rs6088854	ENSG00000230613.1	HM13-AS1	4.01	7.03e-05	0.00576	0.23	0.18	Mean corpuscular hemoglobin;	chr20:31637554	chr20:31567707~31573263:-
THCA	cis	rs6540731	0.805	rs7530375	ENSG00000226251.4	RP11-15I11.3	-4.01	7.03e-05	0.00576	-0.22	-0.18	Intelligence (childhood);	chr1:212197963	chr1:212225278~212238977:-
THCA	cis	rs6540731	0.595	rs61828662	ENSG00000226251.4	RP11-15I11.3	-4.01	7.03e-05	0.00576	-0.22	-0.18	Intelligence (childhood);	chr1:212198822	chr1:212225278~212238977:-
THCA	cis	rs6540731	0.536	rs61828663	ENSG00000226251.4	RP11-15I11.3	-4.01	7.03e-05	0.00576	-0.22	-0.18	Intelligence (childhood);	chr1:212198823	chr1:212225278~212238977:-
THCA	cis	rs6540731	0.84	rs11119879	ENSG00000226251.4	RP11-15I11.3	-4.01	7.03e-05	0.00576	-0.22	-0.18	Intelligence (childhood);	chr1:212199006	chr1:212225278~212238977:-
THCA	cis	rs6540731	0.84	rs10863954	ENSG00000226251.4	RP11-15I11.3	-4.01	7.03e-05	0.00576	-0.22	-0.18	Intelligence (childhood);	chr1:212199944	chr1:212225278~212238977:-
THCA	cis	rs427691	0.625	rs845740	ENSG00000249476.1	CTD-2587M2.1	4.01	7.03e-05	0.00576	0.21	0.18	Autism spectrum disorder or schizophrenia;	chr5:109683201	chr5:109237120~109326369:-
THCA	cis	rs3935996	0.965	rs4926698	ENSG00000233147.1	RP11-90C4.1	4.01	7.04e-05	0.00576	0.16	0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55862923	chr1:55823807~55868248:+
THCA	cis	rs17270561	0.636	rs1575535	ENSG00000272462.2	U91328.19	-4.01	7.04e-05	0.00576	-0.15	-0.18	Iron status biomarkers;	chr6:25809681	chr6:25992662~26001775:+
THCA	cis	rs5769765	0.908	rs138864	ENSG00000260613.1	RP3-522J7.6	-4.01	7.04e-05	0.00576	-0.22	-0.18	Schizophrenia;	chr22:49811064	chr22:49832616~49837786:-
THCA	cis	rs12887734	0.546	rs12885509	ENSG00000258534.1	CTD-2134A5.4	-4.01	7.04e-05	0.00576	-0.19	-0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103854366~103880111:-
THCA	cis	rs7829975	0.871	rs777709	ENSG00000253981.4	ALG1L13P	-4.01	7.04e-05	0.00576	-0.17	-0.18	Mood instability;	chr8:8726362	chr8:8236003~8244667:-
THCA	cis	rs6963495	0.818	rs116845562	ENSG00000272604.1	RP11-251G23.5	4.01	7.04e-05	0.00576	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105576591	chr7:105571083~105573660:+
THCA	cis	rs9595908	0.785	rs4942791	ENSG00000212293.1	SNORA16	4.01	7.04e-05	0.00577	0.21	0.18	Body mass index;	chr13:32663085	chr13:32420390~32420516:-
THCA	cis	rs17221829	0.673	rs10741307	ENSG00000280385.1	AP000648.5	-4.01	7.04e-05	0.00577	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89634103	chr11:90193614~90198120:+
THCA	cis	rs36093844	0.626	rs41381550	ENSG00000279742.1	RP11-700A24.1	4.01	7.04e-05	0.00577	0.24	0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85956045	chr11:85852557~85854943:-
THCA	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	4.01	7.04e-05	0.00577	0.19	0.18	Asthma;	chr2:102426252	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	4.01	7.04e-05	0.00577	0.19	0.18	Asthma;	chr2:102427407	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	4.01	7.04e-05	0.00577	0.19	0.18	Asthma;	chr2:102427715	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	4.01	7.04e-05	0.00577	0.19	0.18	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	4.01	7.04e-05	0.00577	0.19	0.18	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
THCA	cis	rs7182948	0.957	rs1588127	ENSG00000259531.2	RP11-295H24.3	4.01	7.04e-05	0.00577	0.23	0.18	Lung adenocarcinoma;	chr15:49555814	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs28465200	ENSG00000259531.2	RP11-295H24.3	4.01	7.04e-05	0.00577	0.23	0.18	Lung adenocarcinoma;	chr15:49564594	chr15:49365124~49366685:-
THCA	cis	rs9400467	1	rs9400467	ENSG00000271789.1	RP5-1112D6.7	4.01	7.04e-05	0.00577	0.18	0.18	Amino acid levels;Blood metabolite levels;	chr6:111102812	chr6:111297126~111298510:+
THCA	cis	rs4272720	0.51	rs17011757	ENSG00000234736.4	FAM170B-AS1	-4.01	7.04e-05	0.00577	-0.2	-0.18	Platelet count;Plateletcrit;	chr10:49079753	chr10:49121839~49151547:+
THCA	cis	rs1371614	0.655	rs7579579	ENSG00000229122.1	AGBL5-IT1	-4.01	7.04e-05	0.00577	-0.13	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928974	chr2:27061038~27061815:+
THCA	cis	rs1383484	0.798	rs1871731	ENSG00000225151.9	GOLGA2P7	4.01	7.04e-05	0.00577	0.25	0.18	Height;	chr15:83869280	chr15:84199311~84230136:-
THCA	cis	rs2380205	0.538	rs1976655	ENSG00000232807.2	RP11-536K7.3	4.01	7.04e-05	0.00577	0.18	0.18	Breast cancer;	chr10:5880766	chr10:5934270~5945900:-
THCA	cis	rs4718428	1	rs12534637	ENSG00000275400.1	RP4-756H11.5	-4.01	7.04e-05	0.00577	-0.18	-0.18	Corneal structure;	chr7:66862667	chr7:66553805~66554199:-
THCA	cis	rs7615952	1	rs9289275	ENSG00000272840.1	RP11-379B18.6	4.01	7.04e-05	0.00577	0.3	0.18	Blood pressure (smoking interaction);	chr3:125929816	chr3:125774714~125797953:+
THCA	cis	rs4834770	1	rs6823963	ENSG00000260091.1	RP11-33B1.4	-4.01	7.04e-05	0.00577	-0.13	-0.18	Blood protein levels;	chr4:119321009	chr4:119409333~119410233:+
THCA	cis	rs4834770	1	rs4834771	ENSG00000260091.1	RP11-33B1.4	-4.01	7.04e-05	0.00577	-0.13	-0.18	Blood protein levels;	chr4:119321617	chr4:119409333~119410233:+
THCA	cis	rs4834770	1	rs1397613	ENSG00000260091.1	RP11-33B1.4	-4.01	7.04e-05	0.00577	-0.13	-0.18	Blood protein levels;	chr4:119321774	chr4:119409333~119410233:+
THCA	cis	rs4834770	1	rs2282688	ENSG00000260091.1	RP11-33B1.4	-4.01	7.04e-05	0.00577	-0.13	-0.18	Blood protein levels;	chr4:119322567	chr4:119409333~119410233:+
THCA	cis	rs35176054	0.73	rs34880818	ENSG00000280693.1	SH3PXD2A-AS1	-4.01	7.04e-05	0.00577	-0.35	-0.18	Atrial fibrillation;	chr10:103762002	chr10:103745966~103755423:+
THCA	cis	rs11158026	0.526	rs8020798	ENSG00000258413.1	RP11-665C16.6	-4.01	7.04e-05	0.00577	-0.3	-0.18	Parkinson's disease;	chr14:54886650	chr14:55262767~55272075:-
THCA	cis	rs181553	0.961	rs1288812	ENSG00000266696.1	RP11-30L3.2	4.01	7.05e-05	0.00577	0.22	0.18	Hip circumference adjusted for BMI;	chr18:49041111	chr18:49205912~49208781:+
THCA	cis	rs7119038	0.615	rs10892274	ENSG00000255422.1	AP002954.4	4.01	7.05e-05	0.00577	0.21	0.18	Sjögren's syndrome;	chr11:118734754	chr11:118704607~118750263:+
THCA	cis	rs1124769	0.57	rs2614768	ENSG00000273674.3	CTD-2378E12.1	-4.01	7.05e-05	0.00577	-0.24	-0.18	Cognitive performance;	chr15:50871261	chr15:50839875~50908599:-
THCA	cis	rs1930961	0.558	rs5996951	ENSG00000272977.1	CTA-390C10.10	-4.01	7.05e-05	0.00577	-0.29	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25476218~25479971:+
THCA	cis	rs11971779	0.715	rs10265	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139341406	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs6965143	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139341862	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs11771715	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139342750	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.648	rs4732367	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139343356	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs7808740	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139344209	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.715	rs6943973	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139345147	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs4077889	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139349168	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs11980313	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139349897	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.584	rs6962029	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139349973	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6962186	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139350060	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.523	rs10234578	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139353242	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs7784192	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139354903	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs7801613	ENSG00000252332.1	RNU6-911P	4.01	7.05e-05	0.00577	0.21	0.18	Diisocyanate-induced asthma;	chr7:139355181	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs3924296	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139357181	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.527	rs4379397	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139358639	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.774	rs6467838	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139358755	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6961812	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139359062	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6962366	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139359121	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs3924445	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139359426	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.585	rs3922848	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139361464	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.59	rs6944104	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139366374	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs6944244	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139366440	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6962637	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139366604	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs7799598	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139367087	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.553	rs7799742	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139367132	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs10229249	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139367764	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs11772026	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139367843	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs1133067	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139368323	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs1133068	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139368397	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.648	rs9656512	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139369300	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6949599	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139369442	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs6949963	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139369579	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.555	rs6950143	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139369672	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6954531	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139369960	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6954547	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139369988	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs7788777	ENSG00000252332.1	RNU6-911P	-4.01	7.05e-05	0.00577	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139370447	chr7:139448740~139448843:+
THCA	cis	rs9905704	0.846	rs302851	ENSG00000224738.1	AC099850.1	4.01	7.05e-05	0.00577	0.23	0.18	Testicular germ cell tumor;	chr17:58608063	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.846	rs302877	ENSG00000224738.1	AC099850.1	4.01	7.05e-05	0.00577	0.23	0.18	Testicular germ cell tumor;	chr17:58686657	chr17:59106598~59118267:+
THCA	cis	rs6442522	0.643	rs7620149	ENSG00000249786.6	EAF1-AS1	-4.01	7.05e-05	0.00577	-0.19	-0.18	Uric acid levels;	chr3:15459389	chr3:15436171~15455940:-
THCA	cis	rs801193	1	rs2707856	ENSG00000229180.5	GS1-124K5.11	4.01	7.05e-05	0.00577	0.12	0.18	Aortic root size;	chr7:66746023	chr7:66526088~66542624:-
THCA	cis	rs41298830	1	rs2238776	ENSG00000236670.1	KRT18P5	4.01	7.05e-05	0.00577	0.27	0.18	Tonsillectomy;	chr22:19770369	chr22:20482815~20484105:-
THCA	cis	rs910316	1	rs10136948	ENSG00000259138.1	RP11-950C14.7	4.01	7.05e-05	0.00577	0.16	0.18	Height;	chr14:75044372	chr14:75127153~75136930:+
THCA	cis	rs11758351	0.715	rs75390741	ENSG00000216331.1	HIST1H1PS1	4.01	7.05e-05	0.00577	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26209556	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs113208674	ENSG00000216331.1	HIST1H1PS1	4.01	7.05e-05	0.00577	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26210237	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.66	rs77130538	ENSG00000216331.1	HIST1H1PS1	4.01	7.05e-05	0.00577	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26210495	chr6:26195566~26195771:+
THCA	cis	rs7845219	0.539	rs10441538	ENSG00000253528.2	RP11-347C18.4	4.01	7.05e-05	0.00577	0.21	0.18	Type 2 diabetes;	chr8:94856380	chr8:94974573~94974853:-
THCA	cis	rs11148252	0.774	rs9536066	ENSG00000273784.3	RP11-78J21.7	-4.01	7.05e-05	0.00577	-0.19	-0.18	Lewy body disease;	chr13:52409846	chr13:52600042~52642542:+
THCA	cis	rs10175706	1	rs6543238	ENSG00000256637.5	RP11-76I14.1	-4.01	7.06e-05	0.00578	-0.16	-0.18	Chin dimples;	chr2:104043360	chr2:103874310~104077778:+
THCA	cis	rs41342147	0.66	rs10933553	ENSG00000223374.1	AC005104.3	4.01	7.06e-05	0.00578	0.16	0.18	Vitiligo;	chr2:241347332	chr2:241351340~241353104:-
THCA	cis	rs3740713	1	rs73438604	ENSG00000256464.1	YWHABP2	4.01	7.06e-05	0.00578	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr11:18490243~18490955:-
THCA	cis	rs17666538	0.792	rs1979174	ENSG00000254207.1	RP11-43A14.1	4.01	7.06e-05	0.00578	0.36	0.18	IgG glycosylation;	chr8:642274	chr8:725188~725877:-
THCA	cis	rs11239930	0.538	rs17160592	ENSG00000278811.3	LINC00624	4.01	7.06e-05	0.00578	0.21	0.18	AIDS progression;	chr1:147083644	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.538	rs56060937	ENSG00000278811.3	LINC00624	4.01	7.06e-05	0.00578	0.21	0.18	AIDS progression;	chr1:147083854	chr1:147258885~147517875:-
THCA	cis	rs6500602	0.964	rs13335685	ENSG00000280063.1	RP11-295D4.3	4.01	7.06e-05	0.00578	0.1	0.18	Schizophrenia;	chr16:4419283	chr16:4346694~4348648:-
THCA	cis	rs4705962	0.878	rs7717027	ENSG00000230612.2	AC004237.1	4.01	7.06e-05	0.00578	0.23	0.18	Atopic dermatitis;	chr5:132722787	chr5:132688681~132723725:+
THCA	cis	rs9876781	0.507	rs1824362	ENSG00000244380.1	RP11-24C3.2	-4.01	7.06e-05	0.00578	-0.22	-0.18	Longevity;	chr3:48360459	chr3:48440352~48446656:-
THCA	cis	rs4780401	0.901	rs34774904	ENSG00000274038.1	RP11-66H6.4	-4.01	7.06e-05	0.00578	-0.22	-0.18	Rheumatoid arthritis;	chr16:11723251	chr16:11056556~11057034:+
THCA	cis	rs67478160	0.571	rs1155751	ENSG00000258534.1	CTD-2134A5.4	-4.01	7.06e-05	0.00578	-0.18	-0.18	Schizophrenia;	chr14:103820210	chr14:103854366~103880111:-
THCA	cis	rs5758659	0.652	rs133340	ENSG00000281538.1	RP4-669P10.20	-4.01	7.06e-05	0.00578	-0.17	-0.18	Cognitive function;	chr22:42021683	chr22:42138060~42139726:+
THCA	cis	rs62158800	0.598	rs13416107	ENSG00000237880.1	AC096669.2	4.01	7.06e-05	0.00578	0.19	0.18	Facial morphology (factor 22);	chr2:107670987	chr2:107385632~107542649:-
THCA	cis	rs7246967	0.673	rs9676498	ENSG00000198153.8	ZNF849P	-4.01	7.06e-05	0.00578	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22727708	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs16998998	ENSG00000198153.8	ZNF849P	-4.01	7.06e-05	0.00578	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22728314	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs9677019	ENSG00000198153.8	ZNF849P	-4.01	7.06e-05	0.00578	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22729857	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs2361260	ENSG00000198153.8	ZNF849P	4.01	7.06e-05	0.00578	0.28	0.18	Bronchopulmonary dysplasia;	chr19:22731342	chr19:22685167~22686732:+
THCA	cis	rs17221829	0.673	rs10765225	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89651820	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.764	rs7945447	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89652902	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.764	rs7931085	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89653029	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.764	rs6483020	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89653216	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.627	rs7130892	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89653438	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.673	rs10830324	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89655677	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.645	rs10830325	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89655900	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs10830326	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89655942	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs10830327	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89655954	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.549	rs1844196	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89656088	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.61	rs1844195	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89656164	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.617	rs1844194	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89656199	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs12277139	ENSG00000280385.1	AP000648.5	-4.01	7.06e-05	0.00578	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89656438	chr11:90193614~90198120:+
THCA	cis	rs1923243	0.617	rs4341323	ENSG00000223479.3	RP4-788P17.1	4.01	7.06e-05	0.00578	0.2	0.18	Migraine;	chr1:73150928	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs61767607	ENSG00000223479.3	RP4-788P17.1	4.01	7.06e-05	0.00578	0.2	0.18	Migraine;	chr1:73151740	chr1:73635216~73715214:+
THCA	cis	rs9291683	0.609	rs3796836	ENSG00000250413.1	RP11-448G15.1	-4.01	7.06e-05	0.00578	-0.17	-0.18	Bone mineral density;	chr4:10009721	chr4:10006482~10009725:+
THCA	cis	rs5758659	0.652	rs133326	ENSG00000273366.1	CTA-989H11.1	-4.01	7.06e-05	0.00578	-0.22	-0.18	Cognitive function;	chr22:42010881	chr22:42278188~42278846:+
THCA	cis	rs701145	0.585	rs1470664	ENSG00000243069.6	ARHGEF26-AS1	4.01	7.06e-05	0.00578	0.33	0.18	Coronary artery disease;	chr3:154147404	chr3:154024401~154121332:-
THCA	cis	rs7819412	0.505	rs67849263	ENSG00000261451.1	RP11-981G7.1	-4.01	7.07e-05	0.00578	-0.24	-0.18	Triglycerides;	chr8:11150034	chr8:10433672~10438312:+
THCA	cis	rs738322	0.577	rs4820320	ENSG00000277385.1	Metazoa_SRP	-4.01	7.07e-05	0.00578	-0.21	-0.18	Cutaneous nevi;	chr22:38176970	chr22:38281028~38281289:-
THCA	cis	rs7267979	0.739	rs6138555	ENSG00000274973.1	RP13-401N8.7	-4.01	7.07e-05	0.00578	-0.21	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25845497~25845862:+
THCA	cis	rs4409675	0.641	rs4908379	ENSG00000227050.1	RP11-460I13.2	4.01	7.07e-05	0.00578	0.25	0.18	Corneal astigmatism;	chr1:27946505	chr1:27938875~27960193:-
THCA	cis	rs4834770	1	rs6857641	ENSG00000260091.1	RP11-33B1.4	-4.01	7.07e-05	0.00579	-0.13	-0.18	Blood protein levels;	chr4:119322356	chr4:119409333~119410233:+
THCA	cis	rs4409675	0.868	rs28904872	ENSG00000227050.1	RP11-460I13.2	-4.01	7.07e-05	0.00579	-0.26	-0.18	Corneal astigmatism;	chr1:27903300	chr1:27938875~27960193:-
THCA	cis	rs6878727	0.665	rs698182	ENSG00000253807.4	LINC01170	4.01	7.07e-05	0.00579	0.16	0.18	Breast cancer;	chr5:124331449	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.665	rs698181	ENSG00000253807.4	LINC01170	4.01	7.07e-05	0.00579	0.16	0.18	Breast cancer;	chr5:124331576	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.638	rs698180	ENSG00000253807.4	LINC01170	4.01	7.07e-05	0.00579	0.16	0.18	Breast cancer;	chr5:124332284	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.665	rs698179	ENSG00000253807.4	LINC01170	4.01	7.07e-05	0.00579	0.16	0.18	Breast cancer;	chr5:124332379	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.589	rs190464	ENSG00000253807.4	LINC01170	4.01	7.07e-05	0.00579	0.16	0.18	Breast cancer;	chr5:124333037	chr5:124059794~124405079:-
THCA	cis	rs7927592	0.912	rs55767696	ENSG00000160172.9	FAM86C2P	4.01	7.07e-05	0.00579	0.18	0.18	Total body bone mineral density;	chr11:68607652	chr11:67791648~67805336:-
THCA	cis	rs4908768	0.906	rs12401496	ENSG00000232912.4	RP5-1115A15.1	-4.01	7.07e-05	0.00579	-0.22	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540342	chr1:8424645~8434838:+
THCA	cis	rs875971	0.505	rs6955582	ENSG00000275400.1	RP4-756H11.5	-4.01	7.07e-05	0.00579	-0.17	-0.18	Aortic root size;	chr7:65966699	chr7:66553805~66554199:-
THCA	cis	rs4906332	1	rs3783400	ENSG00000244691.1	RPL10AP1	-4.01	7.07e-05	0.00579	-0.23	-0.18	Coronary artery disease;	chr14:103500708	chr14:103412119~103412761:-
THCA	cis	rs11971779	0.527	rs1076349	ENSG00000252332.1	RNU6-911P	-4.01	7.07e-05	0.00579	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139441748	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.65	rs4732380	ENSG00000252332.1	RNU6-911P	-4.01	7.07e-05	0.00579	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139442113	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.715	rs6467853	ENSG00000252332.1	RNU6-911P	-4.01	7.07e-05	0.00579	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139442281	chr7:139448740~139448843:+
THCA	cis	rs6487679	0.543	rs4883222	ENSG00000111788.10	RP11-22B23.1	4.01	7.08e-05	0.00579	0.3	0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9223819	chr12:9277235~9313241:+
THCA	cis	rs1208285	0.964	rs9389106	ENSG00000232310.5	RP11-557H15.4	4.01	7.08e-05	0.00579	0.23	0.18	Infantile hypertrophic pyloric stenosis;	chr6:133829318	chr6:134525314~134659836:-
THCA	cis	rs11176749	1	rs12231533	ENSG00000256172.1	RP11-473M14.3	4.01	7.08e-05	0.00579	0.26	0.18	Expressive vocabulary in infants;	chr12:67455502	chr12:67440998~67442559:-
THCA	cis	rs1124769	0.506	rs2614766	ENSG00000273674.3	CTD-2378E12.1	-4.01	7.08e-05	0.00579	-0.24	-0.18	Cognitive performance;	chr15:50852394	chr15:50839875~50908599:-
THCA	cis	rs6560517	1	rs11144880	ENSG00000234618.1	RPSAP9	-4.01	7.08e-05	0.00579	-0.2	-0.18	Dialysis-related mortality;	chr9:76410759	chr9:76398699~76399586:+
THCA	cis	rs9283706	0.513	rs7707409	ENSG00000229666.1	MAST4-AS1	-4.01	7.08e-05	0.00579	-0.27	-0.18	Coronary artery disease;	chr5:67056061	chr5:67001383~67003953:-
THCA	cis	rs4578769	0.55	rs9953702	ENSG00000273232.1	RP11-370A5.2	4.01	7.08e-05	0.00579	0.25	0.18	Eosinophil percentage of white cells;	chr18:22971001	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs9951157	ENSG00000273232.1	RP11-370A5.2	4.01	7.08e-05	0.00579	0.25	0.18	Eosinophil percentage of white cells;	chr18:22974173	chr18:22882825~22883357:-
THCA	cis	rs2153535	0.585	rs1328858	ENSG00000230939.1	RP11-314C16.1	4.01	7.08e-05	0.00579	0.19	0.18	Motion sickness;	chr6:8563218	chr6:8784178~8785445:+
THCA	cis	rs911555	0.755	rs35233301	ENSG00000269910.1	RP11-73M18.10	-4.01	7.08e-05	0.00579	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103694516~103695050:-
THCA	cis	rs1876206	0.529	rs1807301	ENSG00000259705.1	RP11-227D13.1	4.01	7.08e-05	0.0058	0.21	0.18	Breast cancer;	chr15:48618043	chr15:48645951~48652016:+
THCA	cis	rs6728642	0.519	rs62152906	ENSG00000230606.9	AC159540.1	4.01	7.08e-05	0.0058	0.25	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96906533	chr2:97416165~97433527:-
THCA	cis	rs6787172	1	rs6787172	ENSG00000272087.1	RP11-379F4.7	4.01	7.08e-05	0.0058	0.16	0.18	Subjective well-being;	chr3:158470022	chr3:158693120~158693768:-
THCA	cis	rs17221829	0.733	rs1962259	ENSG00000280385.1	AP000648.5	-4.01	7.08e-05	0.0058	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89647469	chr11:90193614~90198120:+
THCA	cis	rs9300255	0.544	rs10772995	ENSG00000235423.7	RP11-282O18.3	4.01	7.08e-05	0.0058	0.2	0.18	Neutrophil percentage of white cells;	chr12:123187214	chr12:123252030~123261483:-
THCA	cis	rs7312933	0.703	rs10492388	ENSG00000257225.1	RP11-328C8.4	-4.01	7.08e-05	0.0058	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42214199	chr12:42459366~42466128:+
THCA	cis	rs34975555	0.892	rs7843729	ENSG00000253671.1	RP11-806O11.1	4.01	7.09e-05	0.0058	0.28	0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17941006	chr8:17808941~17820868:+
THCA	cis	rs9843304	0.585	rs9837351	ENSG00000243885.1	RP11-278L15.2	-4.01	7.09e-05	0.0058	-0.2	-0.18	Gallstone disease;	chr3:149492312	chr3:149384179~149385800:-
THCA	cis	rs9450351	0.744	rs9444371	ENSG00000203875.9	SNHG5	-4.01	7.09e-05	0.0058	-0.35	-0.18	Interferon gamma-induced protein 10 levels;	chr6:85950676	chr6:85660950~85678736:-
THCA	cis	rs755249	0.508	rs12023553	ENSG00000182109.6	RP11-69E11.4	-4.01	7.09e-05	0.0058	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39205820	chr1:39522280~39546187:-
THCA	cis	rs2153535	0.585	rs9379238	ENSG00000230939.1	RP11-314C16.1	-4.01	7.09e-05	0.0058	-0.19	-0.18	Motion sickness;	chr6:8667806	chr6:8784178~8785445:+
THCA	cis	rs7824557	0.527	rs4634600	ENSG00000261451.1	RP11-981G7.1	-4.01	7.09e-05	0.0058	-0.22	-0.18	Retinal vascular caliber;	chr8:11381508	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.527	rs4631425	ENSG00000261451.1	RP11-981G7.1	-4.01	7.09e-05	0.0058	-0.22	-0.18	Retinal vascular caliber;	chr8:11381545	chr8:10433672~10438312:+
THCA	cis	rs3808502	0.585	rs4549730	ENSG00000261451.1	RP11-981G7.1	-4.01	7.09e-05	0.0058	-0.22	-0.18	Neuroticism;	chr8:11381569	chr8:10433672~10438312:+
THCA	cis	rs35146811	0.735	rs1727139	ENSG00000078319.8	PMS2P1	-4.01	7.09e-05	0.0058	-0.22	-0.18	Coronary artery disease;	chr7:100217744	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs1727140	ENSG00000078319.8	PMS2P1	-4.01	7.09e-05	0.0058	-0.22	-0.18	Coronary artery disease;	chr7:100217776	chr7:100320992~100341908:-
THCA	cis	rs9733	0.744	rs2089081	ENSG00000231073.1	RP11-316M1.3	-4.01	7.09e-05	0.0058	-0.22	-0.18	Tonsillectomy;	chr1:150827641	chr1:150973123~150975534:+
THCA	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	4.01	7.09e-05	0.0058	0.17	0.18	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
THCA	cis	rs9393777	0.92	rs67859638	ENSG00000272009.1	RP1-313I6.12	-4.01	7.09e-05	0.0058	-0.36	-0.18	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28078792~28081130:-
THCA	cis	rs4578769	0.842	rs7243256	ENSG00000265939.1	UBE2CP2	4.01	7.09e-05	0.0058	0.22	0.18	Eosinophil percentage of white cells;	chr18:22936411	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.842	rs9966323	ENSG00000265939.1	UBE2CP2	4.01	7.09e-05	0.0058	0.22	0.18	Eosinophil percentage of white cells;	chr18:22936418	chr18:22900486~22900995:-
THCA	cis	rs1023500	0.551	rs2854837	ENSG00000237037.8	NDUFA6-AS1	-4.01	7.09e-05	0.0058	-0.15	-0.18	Schizophrenia;	chr22:42062477	chr22:42090931~42137742:+
THCA	cis	rs4845570	1	rs11585294	ENSG00000249602.1	RP11-98D18.3	-4.01	7.09e-05	0.0058	-0.28	-0.18	Coronary artery disease;	chr1:151797411	chr1:151763384~151769501:-
THCA	cis	rs67981189	0.896	rs3814869	ENSG00000269927.1	RP6-91H8.3	4.01	7.09e-05	0.0058	0.2	0.18	Schizophrenia;	chr14:71028982	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs17108925	ENSG00000269927.1	RP6-91H8.3	4.01	7.09e-05	0.0058	0.2	0.18	Schizophrenia;	chr14:71033010	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs28374308	ENSG00000269927.1	RP6-91H8.3	4.01	7.09e-05	0.0058	0.2	0.18	Schizophrenia;	chr14:71035040	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs8016506	ENSG00000269927.1	RP6-91H8.3	4.01	7.09e-05	0.0058	0.2	0.18	Schizophrenia;	chr14:71039600	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.858	rs35631530	ENSG00000269927.1	RP6-91H8.3	4.01	7.09e-05	0.0058	0.2	0.18	Schizophrenia;	chr14:71041312	chr14:71141125~71143253:-
THCA	cis	rs6822297	0.905	rs4692137	ENSG00000240005.4	RP11-293A21.1	-4.01	7.09e-05	0.0058	-0.2	-0.18	Obesity-related traits;	chr4:27003613	chr4:26859806~26860599:-
THCA	cis	rs7707921	0.881	rs6875409	ENSG00000251374.1	RPS23P5	4.01	7.09e-05	0.0058	0.26	0.18	Breast cancer;	chr5:82001258	chr5:82265157~82265259:-
THCA	cis	rs6878727	0.85	rs6881377	ENSG00000253807.4	LINC01170	-4.01	7.1e-05	0.0058	-0.17	-0.18	Breast cancer;	chr5:124396066	chr5:124059794~124405079:-
THCA	cis	rs987724	0.964	rs1995425	ENSG00000240875.4	LINC00886	-4.01	7.1e-05	0.0058	-0.15	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156944020	chr3:156747346~156817062:-
THCA	cis	rs17092148	1	rs3787223	ENSG00000276073.1	RP5-1125A11.7	4.01	7.1e-05	0.0058	0.21	0.18	Neuroticism;	chr20:34743581	chr20:33985617~33988989:-
THCA	cis	rs4604234	0.522	rs3805914	ENSG00000272129.1	RP11-250B2.6	4.01	7.1e-05	0.0058	0.41	0.18	Cancer;	chr6:80206269	chr6:80355424~80356859:+
THCA	cis	rs10875746	0.768	rs4760676	ENSG00000258273.1	RP11-370I10.4	4.01	7.1e-05	0.0058	0.25	0.18	Longevity (90 years and older);	chr12:48027880	chr12:48333755~48333901:-
THCA	cis	rs5751614	1	rs2283805	ENSG00000240160.3	RN7SL263P	4.01	7.1e-05	0.00581	0.2	0.18	Height;	chr22:23247755	chr22:23261782~23262071:-
THCA	cis	rs3812831	0.662	rs407531	ENSG00000264539.1	MIR548AR	4.01	7.1e-05	0.00581	0.19	0.18	Schizophrenia;	chr13:114163743	chr13:114244505~114244561:+
THCA	cis	rs3812831	0.695	rs422149	ENSG00000264539.1	MIR548AR	4.01	7.1e-05	0.00581	0.19	0.18	Schizophrenia;	chr13:114165611	chr13:114244505~114244561:+
THCA	cis	rs6921919	0.945	rs7765989	ENSG00000219392.1	RP1-265C24.5	-4.01	7.1e-05	0.00581	-0.24	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28115628~28116551:+
THCA	cis	rs3818717	0.539	rs12950737	ENSG00000281749.1	Y_RNA	-4.01	7.1e-05	0.00581	-0.23	-0.18	Lymphocyte counts;	chr17:17775259	chr17:18001101~18001195:-
THCA	cis	rs7192208	0.85	rs16945464	ENSG00000260922.1	RP11-538I12.3	4.01	7.1e-05	0.00581	0.27	0.18	White matter integrity;	chr16:77292827	chr16:77234877~77290934:+
THCA	cis	rs7819412	0.765	rs7000132	ENSG00000206014.6	OR7E161P	4.01	7.1e-05	0.00581	0.22	0.18	Triglycerides;	chr8:11173426	chr8:11928597~11929563:-
THCA	cis	rs2836950	0.545	rs11700813	ENSG00000238141.2	BRWD1-AS1	-4.01	7.1e-05	0.00581	-0.21	-0.18	Menarche (age at onset);	chr21:39145543	chr21:39315707~39323218:+
THCA	cis	rs4308124	0.708	rs2137168	ENSG00000230499.1	AC108463.1	-4.01	7.1e-05	0.00581	-0.27	-0.18	Vitiligo;	chr2:111228932	chr2:111195963~111206494:+
THCA	cis	rs559928	0.548	rs11231713	ENSG00000236935.1	AP003774.1	4.01	7.1e-05	0.00581	0.27	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164377	chr11:64325050~64329504:-
THCA	cis	rs559928	0.593	rs112275221	ENSG00000236935.1	AP003774.1	4.01	7.1e-05	0.00581	0.27	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64169522	chr11:64325050~64329504:-
THCA	cis	rs10200159	1	rs10172181	ENSG00000272606.1	RP11-554J4.1	4.01	7.1e-05	0.00581	0.35	0.18	Vitiligo;	chr2:55664005	chr2:55617909~55618373:+
THCA	cis	rs6878727	0.665	rs2633536	ENSG00000253807.4	LINC01170	4.01	7.1e-05	0.00581	0.16	0.18	Breast cancer;	chr5:124331729	chr5:124059794~124405079:-
THCA	cis	rs7711186	0.786	rs6880343	ENSG00000252464.1	RN7SKP70	-4.01	7.1e-05	0.00581	-0.22	-0.18	Urate levels in obese individuals;	chr5:178657486	chr5:178619728~178619998:-
THCA	cis	rs11123170	0.543	rs4849180	ENSG00000274877.1	RP11-65I12.1	4.01	7.11e-05	0.00581	0.11	0.18	Renal function-related traits (BUN);	chr2:113227609	chr2:113237595~113240825:+
THCA	cis	rs11123170	0.543	rs35222158	ENSG00000274877.1	RP11-65I12.1	4.01	7.11e-05	0.00581	0.11	0.18	Renal function-related traits (BUN);	chr2:113229052	chr2:113237595~113240825:+
THCA	cis	rs10911902	0.643	rs75906210	ENSG00000233196.2	GS1-304P7.1	-4.01	7.11e-05	0.00581	-0.29	-0.18	Schizophrenia;	chr1:186365092	chr1:186580515~186581191:-
THCA	cis	rs804280	0.662	rs11784764	ENSG00000270154.1	RP11-419I17.1	-4.01	7.11e-05	0.00581	-0.25	-0.18	Myopia (pathological);	chr8:11753365	chr8:12476462~12477122:+
THCA	cis	rs7178909	0.902	rs3853640	ENSG00000259677.1	RP11-493E3.1	4.01	7.11e-05	0.00581	0.22	0.18	Common traits (Other);	chr15:89900488	chr15:89876540~89877285:+
THCA	cis	rs6687821	0.506	rs559491	ENSG00000261737.1	RP4-612B15.3	-4.01	7.11e-05	0.00581	-0.29	-0.18	Yeast infection;	chr1:86853136	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.548	rs492624	ENSG00000261737.1	RP4-612B15.3	-4.01	7.11e-05	0.00581	-0.29	-0.18	Yeast infection;	chr1:86854981	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.548	rs539915	ENSG00000261737.1	RP4-612B15.3	-4.01	7.11e-05	0.00581	-0.29	-0.18	Yeast infection;	chr1:86856101	chr1:86703502~86704462:-
THCA	cis	rs7927592	0.956	rs7116899	ENSG00000160172.9	FAM86C2P	4.01	7.11e-05	0.00581	0.18	0.18	Total body bone mineral density;	chr11:68618067	chr11:67791648~67805336:-
THCA	cis	rs150992	0.673	rs331934	ENSG00000241597.2	CTD-2007H13.1	4.01	7.11e-05	0.00581	0.24	0.18	Body mass index;	chr5:98804016	chr5:98954394~98954972:+
THCA	cis	rs150992	0.673	rs331545	ENSG00000241597.2	CTD-2007H13.1	4.01	7.11e-05	0.00581	0.24	0.18	Body mass index;	chr5:98810402	chr5:98954394~98954972:+
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000280069.1	CTD-2349P21.3	-4.01	7.11e-05	0.00581	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs216433	ENSG00000280069.1	CTD-2349P21.3	-4.01	7.11e-05	0.00581	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30738182~30740275:+
THCA	cis	rs12142240	0.698	rs17361887	ENSG00000232022.5	FAAHP1	-4.01	7.11e-05	0.00582	-0.21	-0.18	Menopause (age at onset);	chr1:46369103	chr1:46432129~46445521:+
THCA	cis	rs6940638	0.688	rs7744759	ENSG00000220721.1	OR1F12	4.01	7.11e-05	0.00582	0.22	0.18	Intelligence (multi-trait analysis);	chr6:27152047	chr6:28073316~28074233:+
THCA	cis	rs9650657	0.504	rs6986032	ENSG00000261451.1	RP11-981G7.1	-4.01	7.11e-05	0.00582	-0.23	-0.18	Neuroticism;	chr8:11174731	chr8:10433672~10438312:+
THCA	cis	rs34421088	0.532	rs11782742	ENSG00000154316.13	TDH	-4.01	7.11e-05	0.00582	-0.13	-0.18	Neuroticism;	chr8:11307500	chr8:11339637~11368452:+
THCA	cis	rs11673344	0.502	rs62108306	ENSG00000267640.4	CTD-2554C21.2	4.01	7.11e-05	0.00582	0.14	0.18	Obesity-related traits;	chr19:37691789	chr19:37817359~37826638:+
THCA	cis	rs11673344	0.536	rs7259272	ENSG00000267640.4	CTD-2554C21.2	4.01	7.11e-05	0.00582	0.14	0.18	Obesity-related traits;	chr19:37692214	chr19:37817359~37826638:+
THCA	cis	rs301901	1	rs13176880	ENSG00000250155.1	CTD-2353F22.1	-4.01	7.11e-05	0.00582	-0.19	-0.18	Height;	chr5:37081780	chr5:36666214~36725195:-
THCA	cis	rs17095355	0.892	rs7085888	ENSG00000203876.8	ADD3-AS1	4.01	7.11e-05	0.00582	0.19	0.18	Biliary atresia;	chr10:109954172	chr10:109940104~110008381:-
THCA	cis	rs6723226	0.739	rs2069213	ENSG00000276517.1	AL133243.2	-4.01	7.12e-05	0.00582	-0.18	-0.18	Intelligence (multi-trait analysis);	chr2:32518017	chr2:32526504~32529507:+
THCA	cis	rs4879656	0.966	rs10813912	ENSG00000225693.1	LAGE3P1	-4.01	7.12e-05	0.00582	-0.2	-0.18	Menopause (age at onset);	chr9:32975212	chr9:33019682~33020165:-
THCA	cis	rs2562456	0.793	rs627522	ENSG00000268278.1	RP11-420K14.1	4.01	7.12e-05	0.00582	0.22	0.18	Pain;	chr19:21313002	chr19:21637974~21656300:+
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000182586.6	LINC00334	-4.01	7.12e-05	0.00582	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45234340~45258730:+
THCA	cis	rs17221829	0.733	rs11018686	ENSG00000280385.1	AP000648.5	-4.01	7.12e-05	0.00582	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89632073	chr11:90193614~90198120:+
THCA	cis	rs11073619	0.572	rs35984335	ENSG00000259728.4	LINC00933	-4.01	7.12e-05	0.00582	-0.34	-0.18	Positive affect;	chr15:84393638	chr15:84570649~84580175:+
THCA	cis	rs9890032	0.52	rs2321926	ENSG00000276250.1	CTD-2349P21.12	-4.01	7.12e-05	0.00582	-0.15	-0.18	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30803654~30804077:+
THCA	cis	rs1009077	0.582	rs4626181	ENSG00000260091.1	RP11-33B1.4	-4.01	7.12e-05	0.00582	-0.17	-0.18	Endometriosis;	chr4:119609956	chr4:119409333~119410233:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000275400.1	RP4-756H11.5	4.01	7.12e-05	0.00582	0.17	0.18	Cotinine glucuronidation;	chr7:66580525	chr7:66553805~66554199:-
THCA	cis	rs6479891	1	rs61853589	ENSG00000272767.1	JMJD1C-AS1	4.01	7.12e-05	0.00582	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs9414803	ENSG00000272767.1	JMJD1C-AS1	4.01	7.12e-05	0.00582	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs9415707	ENSG00000272767.1	JMJD1C-AS1	4.01	7.12e-05	0.00582	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12413029	ENSG00000272767.1	JMJD1C-AS1	4.01	7.12e-05	0.00582	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63465229~63466563:+
THCA	cis	rs11030122	0.959	rs10835231	ENSG00000230593.3	AC090804.1	4.01	7.12e-05	0.00582	0.24	0.18	Mean platelet volume;Platelet distribution width;	chr11:3878863	chr11:3892398~3892887:-
THCA	cis	rs6997458	0.874	rs13252971	ENSG00000253549.4	RP11-317J10.2	4.01	7.12e-05	0.00582	0.18	0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85357055	chr8:85441851~85464915:-
THCA	cis	rs10090774	0.76	rs13276886	ENSG00000280303.2	ERICD	-4.01	7.12e-05	0.00582	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140720791	chr8:140636281~140638283:+
THCA	cis	rs7688540	0.771	rs7669892	ENSG00000275426.1	CH17-262A2.1	-4.01	7.12e-05	0.00582	-0.21	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:315464	chr4:149738~150317:+
THCA	cis	rs7713065	0.959	rs2548992	ENSG00000237714.1	P4HA2-AS1	4.01	7.12e-05	0.00582	0.27	0.18	Lung function (FEV1/FVC);	chr5:132472976	chr5:132184876~132192808:+
THCA	cis	rs1714507	0.533	rs1435642	ENSG00000272247.1	RP11-379F4.9	4.01	7.12e-05	0.00582	0.18	0.18	Subjective well-being;	chr3:158582432	chr3:158801257~158801935:-
THCA	cis	rs12142240	0.698	rs12385696	ENSG00000232022.5	FAAHP1	-4.01	7.12e-05	0.00582	-0.21	-0.18	Menopause (age at onset);	chr1:46353164	chr1:46432129~46445521:+
THCA	cis	rs150992	0.587	rs75001231	ENSG00000246763.5	RGMB-AS1	4.01	7.12e-05	0.00582	0.19	0.18	Body mass index;	chr5:98990085	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs2927647	ENSG00000246763.5	RGMB-AS1	4.01	7.12e-05	0.00582	0.19	0.18	Body mass index;	chr5:98990161	chr5:98769618~98773469:-
THCA	cis	rs804280	0.517	rs7815179	ENSG00000254948.1	OR7E158P	-4.01	7.12e-05	0.00582	-0.23	-0.18	Myopia (pathological);	chr8:11934539	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.871	rs7815186	ENSG00000254948.1	OR7E158P	-4.01	7.12e-05	0.00582	-0.23	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.516	rs7833079	ENSG00000254948.1	OR7E158P	-4.01	7.12e-05	0.00582	-0.23	-0.18	Neuroticism;	chr8:11934620	chr8:11919900~11920809:-
THCA	cis	rs11088226	0.598	rs79634586	ENSG00000186842.4	LINC00846	-4.01	7.12e-05	0.00582	-0.28	-0.18	Gastritis;	chr21:32587053	chr21:32572238~32575881:-
THCA	cis	rs72799341	0.706	rs889555	ENSG00000279196.1	RP11-1072A3.3	4.01	7.12e-05	0.00582	0.19	0.18	Diastolic blood pressure;	chr16:31111250	chr16:30984630~30988270:-
THCA	cis	rs11658311	0.85	rs11651383	ENSG00000232344.2	AC087163.2	4.01	7.12e-05	0.00582	0.26	0.18	Obsessive-compulsive symptoms;	chr17:17754164	chr17:18010643~18011822:+
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000265443.1	CTD-2349P21.6	-4.01	7.13e-05	0.00583	-0.29	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000265443.1	CTD-2349P21.6	-4.01	7.13e-05	0.00583	-0.29	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30726305~30727564:-
THCA	cis	rs12612619	0.695	rs4665935	ENSG00000272148.1	RP11-195B17.1	-4.01	7.13e-05	0.00583	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27007024	chr2:27062428~27062907:-
THCA	cis	rs10484434	0.901	rs36125084	ENSG00000272810.1	U91328.22	4.01	7.13e-05	0.00583	0.18	0.18	HIV-1 viral setpoint;	chr6:25969884	chr6:26013241~26013757:+
THCA	cis	rs2455799	0.613	rs12491914	ENSG00000270409.1	RP11-44D5.1	-4.01	7.13e-05	0.00583	-0.19	-0.18	Mean platelet volume;	chr3:15767165	chr3:15732252~15733470:+
THCA	cis	rs7665090	1	rs2125211	ENSG00000251288.2	RP11-10L12.2	4.01	7.13e-05	0.00583	0.23	0.18	Primary biliary cholangitis;	chr4:102638719	chr4:102751401~102752641:+
THCA	cis	rs728616	0.614	rs61859199	ENSG00000278616.1	BEND3P3	4.01	7.13e-05	0.00583	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr10:79682997~79685436:+
THCA	cis	rs728616	0.614	rs1538818	ENSG00000278616.1	BEND3P3	4.01	7.13e-05	0.00583	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80363037	chr10:79682997~79685436:+
THCA	cis	rs728616	0.614	rs61859209	ENSG00000278616.1	BEND3P3	4.01	7.13e-05	0.00583	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr10:79682997~79685436:+
THCA	cis	rs728616	0.614	rs61859210	ENSG00000278616.1	BEND3P3	4.01	7.13e-05	0.00583	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80371712	chr10:79682997~79685436:+
THCA	cis	rs10043228	0.702	rs10519455	ENSG00000250015.1	CTC-339F2.2	4.01	7.13e-05	0.00583	0.23	0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116304281	chr5:116302354~116304134:-
THCA	cis	rs1055129	0.56	rs3682	ENSG00000267801.1	RP11-552F3.9	4.01	7.13e-05	0.00583	0.21	0.18	White matter hyperintensity burden;	chr17:75946069	chr17:75876372~75879546:+
THCA	cis	rs11822910	0.871	rs2581928	ENSG00000265566.2	RN7SL605P	-4.01	7.13e-05	0.00583	-0.29	-0.18	Platelet distribution width;	chr11:57435317	chr11:57528085~57528365:-
THCA	cis	rs7312933	0.558	rs1796382	ENSG00000257225.1	RP11-328C8.4	4.01	7.13e-05	0.00583	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42447153	chr12:42459366~42466128:+
THCA	cis	rs8017455	0.523	rs10142959	ENSG00000259167.2	NMNAT1P1	4.01	7.14e-05	0.00583	0.26	0.18	Hair morphology;	chr14:81095299	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs7144998	ENSG00000259167.2	NMNAT1P1	4.01	7.14e-05	0.00583	0.26	0.18	Hair morphology;	chr14:81095567	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs2075178	ENSG00000259167.2	NMNAT1P1	4.01	7.14e-05	0.00583	0.26	0.18	Hair morphology;	chr14:81096464	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs2075179	ENSG00000259167.2	NMNAT1P1	4.01	7.14e-05	0.00583	0.26	0.18	Hair morphology;	chr14:81096654	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs17111471	ENSG00000259167.2	NMNAT1P1	4.01	7.14e-05	0.00583	0.26	0.18	Hair morphology;	chr14:81099418	chr14:81032529~81033404:+
THCA	cis	rs7772486	0.719	rs4391282	ENSG00000270638.1	RP3-466P17.1	-4.01	7.14e-05	0.00583	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145735570~145737218:+
THCA	cis	rs357618	0.531	rs152389	ENSG00000260581.1	CTB-113P19.4	4.01	7.14e-05	0.00583	0.28	0.18	Basophil percentage of white cells;	chr5:151482619	chr5:151652275~151655449:+
THCA	cis	rs7246967	0.551	rs7249473	ENSG00000198153.8	ZNF849P	-4.01	7.14e-05	0.00583	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22723892	chr19:22685167~22686732:+
THCA	cis	rs13217239	0.646	rs7768407	ENSG00000124549.13	BTN2A3P	4.01	7.14e-05	0.00583	0.17	0.18	Schizophrenia;	chr6:27049016	chr6:26421391~26432383:+
THCA	cis	rs2115630	1	rs7183401	ENSG00000275120.1	RP11-182J1.17	-4.01	7.14e-05	0.00583	-0.18	-0.18	P wave terminal force;	chr15:84828713	chr15:84599434~84606463:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000272831.1	RP11-792A8.4	-4.01	7.14e-05	0.00583	-0.12	-0.18	Aortic root size;	chr7:66093491	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs1182882	ENSG00000272831.1	RP11-792A8.4	-4.01	7.14e-05	0.00583	-0.12	-0.18	Aortic root size;	chr7:66097076	chr7:66739829~66740385:-
THCA	cis	rs7818688	0.614	rs16917093	ENSG00000253528.2	RP11-347C18.4	-4.01	7.14e-05	0.00584	-0.27	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94857892	chr8:94974573~94974853:-
THCA	cis	rs10129255	0.957	rs8014696	ENSG00000211972.2	IGHV3-66	-4.01	7.14e-05	0.00584	-0.11	-0.18	Kawasaki disease;	chr14:106769752	chr14:106675017~106675544:-
THCA	cis	rs9813712	0.953	rs6782280	ENSG00000253540.4	FAM86HP	4.01	7.14e-05	0.00584	0.22	0.18	Response to amphetamines;	chr3:130245370	chr3:130099092~130111472:-
THCA	cis	rs4533267	0.843	rs4074096	ENSG00000189419.6	SPATA41	4.01	7.14e-05	0.00584	0.24	0.18	Height;	chr15:100255443	chr15:100344457~100349655:-
THCA	cis	rs2070488	0.861	rs1858740	ENSG00000229589.1	ACVR2B-AS1	4.01	7.15e-05	0.00584	0.17	0.18	Electrocardiographic conduction measures;	chr3:38396881	chr3:38451027~38454820:-
THCA	cis	rs7259376	0.936	rs2195965	ENSG00000269138.1	ZNF209P	4.01	7.15e-05	0.00584	0.18	0.18	Menopause (age at onset);	chr19:22355309	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs2195964	ENSG00000269138.1	ZNF209P	4.01	7.15e-05	0.00584	0.18	0.18	Menopause (age at onset);	chr19:22355536	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.905	rs2082480	ENSG00000269138.1	ZNF209P	4.01	7.15e-05	0.00584	0.18	0.18	Menopause (age at onset);	chr19:22355848	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs58170323	ENSG00000269138.1	ZNF209P	4.01	7.15e-05	0.00584	0.18	0.18	Menopause (age at onset);	chr19:22356313	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs2099354	ENSG00000269138.1	ZNF209P	4.01	7.15e-05	0.00584	0.18	0.18	Menopause (age at onset);	chr19:22356730	chr19:22463922~22473036:+
THCA	cis	rs1032466	1	rs61982174	ENSG00000270062.1	RP11-248J18.3	4.01	7.15e-05	0.00584	0.21	0.18	Dupuytren's disease;	chr14:50584114	chr14:50723777~50724272:-
THCA	cis	rs1032466	1	rs3759589	ENSG00000270062.1	RP11-248J18.3	4.01	7.15e-05	0.00584	0.21	0.18	Dupuytren's disease;	chr14:50586250	chr14:50723777~50724272:-
THCA	cis	rs962856	0.575	rs588779	ENSG00000236780.4	AC078941.1	4.01	7.15e-05	0.00584	0.24	0.18	Pancreatic cancer;	chr2:67438819	chr2:67123357~67215319:-
THCA	cis	rs10200159	1	rs10172506	ENSG00000272606.1	RP11-554J4.1	4.01	7.15e-05	0.00584	0.35	0.18	Vitiligo;	chr2:55638334	chr2:55617909~55618373:+
THCA	cis	rs10200159	1	rs7558127	ENSG00000272606.1	RP11-554J4.1	4.01	7.15e-05	0.00584	0.35	0.18	Vitiligo;	chr2:55639470	chr2:55617909~55618373:+
THCA	cis	rs9468186	1	rs9468186	ENSG00000220721.1	OR1F12	4.01	7.15e-05	0.00584	0.22	0.18	Neuroticism;	chr6:27658852	chr6:28073316~28074233:+
THCA	cis	rs4906332	1	rs3783400	ENSG00000259775.1	RP11-45P15.4	-4.01	7.15e-05	0.00584	-0.16	-0.18	Coronary artery disease;	chr14:103500708	chr14:103331674~103332367:-
THCA	cis	rs28510890	0.508	rs6496962	ENSG00000258647.4	LINC00930	4.01	7.15e-05	0.00584	0.2	0.18	Lung cancer in ever smokers;	chr15:92614992	chr15:92567818~92572042:-
THCA	cis	rs11089937	0.651	rs2330015	ENSG00000211639.2	IGLV4-60	-4.01	7.15e-05	0.00584	-0.13	-0.18	Periodontitis (PAL4Q3);	chr22:22182566	chr22:22162199~22162681:+
THCA	cis	rs453301	0.686	rs4840389	ENSG00000233609.3	RP11-62H7.2	-4.01	7.15e-05	0.00584	-0.18	-0.18	Joint mobility (Beighton score);	chr8:9026993	chr8:8961200~8979025:+
THCA	cis	rs453301	0.658	rs13271797	ENSG00000233609.3	RP11-62H7.2	-4.01	7.15e-05	0.00584	-0.18	-0.18	Joint mobility (Beighton score);	chr8:9028444	chr8:8961200~8979025:+
THCA	cis	rs10411161	0.702	rs892039	ENSG00000275055.1	CTC-471J1.11	-4.01	7.15e-05	0.00584	-0.18	-0.18	Breast cancer;	chr19:51893288	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs2867319	ENSG00000275055.1	CTC-471J1.11	-4.01	7.15e-05	0.00584	-0.18	-0.18	Breast cancer;	chr19:51893907	chr19:52049007~52049754:+
THCA	cis	rs9388451	0.505	rs9372828	ENSG00000226409.1	RP11-735G4.1	-4.01	7.15e-05	0.00585	-0.22	-0.18	Brugada syndrome;	chr6:125854039	chr6:125370211~125374324:-
THCA	cis	rs13096357	0.52	rs17080319	ENSG00000270441.1	RP11-694I15.7	4.01	7.15e-05	0.00585	0.24	0.18	Cognitive ability (multi-trait analysis);	chr3:48695047	chr3:49140086~49160851:-
THCA	cis	rs11719291	0.667	rs9877542	ENSG00000270441.1	RP11-694I15.7	4.01	7.15e-05	0.00585	0.24	0.18	Cognitive function;	chr3:48711112	chr3:49140086~49160851:-
THCA	cis	rs1913185	0.787	rs1449442	ENSG00000261051.1	RP11-274H2.5	-4.01	7.15e-05	0.00585	-0.25	-0.18	Obesity-related traits;	chr3:146082133	chr3:146059585~146061679:-
THCA	cis	rs9611565	0.592	rs4822038	ENSG00000237037.8	NDUFA6-AS1	4.01	7.16e-05	0.00585	0.18	0.18	Vitiligo;	chr22:41562491	chr22:42090931~42137742:+
THCA	cis	rs11148252	0.774	rs7993748	ENSG00000273784.3	RP11-78J21.7	-4.01	7.16e-05	0.00585	-0.19	-0.18	Lewy body disease;	chr13:52367496	chr13:52600042~52642542:+
THCA	cis	rs6430585	0.941	rs6708957	ENSG00000231890.6	DARS-AS1	-4.01	7.16e-05	0.00585	-0.21	-0.18	Corneal structure;	chr2:135762473	chr2:135985176~136022593:+
THCA	cis	rs4789693	1	rs4789693	ENSG00000260011.2	RP13-20L14.1	-4.01	7.16e-05	0.00585	-0.18	-0.18	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82381110~82382690:-
THCA	cis	rs7615952	0.611	rs7632305	ENSG00000248787.1	RP11-666A20.4	-4.01	7.16e-05	0.00585	-0.35	-0.18	Blood pressure (smoking interaction);	chr3:125915924	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.673	rs9841194	ENSG00000248787.1	RP11-666A20.4	-4.01	7.16e-05	0.00585	-0.35	-0.18	Blood pressure (smoking interaction);	chr3:125916896	chr3:125908005~125910272:-
THCA	cis	rs12681366	0.708	rs12680213	ENSG00000261437.1	RP11-22C11.2	4.01	7.16e-05	0.00585	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94387588	chr8:94637285~94639467:-
THCA	cis	rs17270561	0.666	rs12209856	ENSG00000272462.2	U91328.19	-4.01	7.16e-05	0.00585	-0.15	-0.18	Iron status biomarkers;	chr6:25793445	chr6:25992662~26001775:+
THCA	cis	rs6988985	0.589	rs6987382	ENSG00000253741.1	CTD-2292P10.4	-4.01	7.16e-05	0.00585	-0.22	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905775	chr8:142702252~142726973:-
THCA	cis	rs3015497	0.789	rs11621971	ENSG00000270062.1	RP11-248J18.3	-4.01	7.16e-05	0.00585	-0.21	-0.18	Mean platelet volume;	chr14:50657809	chr14:50723777~50724272:-
THCA	cis	rs11751172	0.651	rs12201995	ENSG00000271857.1	RP1-244F24.1	4.01	7.16e-05	0.00585	0.12	0.18	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45571327	chr6:45421079~45422005:-
THCA	cis	rs801193	1	rs4717319	ENSG00000229180.5	GS1-124K5.11	4.01	7.16e-05	0.00585	0.12	0.18	Aortic root size;	chr7:66777606	chr7:66526088~66542624:-
THCA	cis	rs801193	0.904	rs4718403	ENSG00000229180.5	GS1-124K5.11	4.01	7.16e-05	0.00585	0.12	0.18	Aortic root size;	chr7:66777742	chr7:66526088~66542624:-
THCA	cis	rs6500602	0.592	rs28789232	ENSG00000280063.1	RP11-295D4.3	4.01	7.16e-05	0.00585	0.11	0.18	Schizophrenia;	chr16:4397551	chr16:4346694~4348648:-
THCA	cis	rs4788570	0.584	rs8051968	ENSG00000260593.1	RP11-432I5.2	-4.01	7.16e-05	0.00585	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71728075	chr16:71623708~71626816:-
THCA	cis	rs3748656	0.943	rs2009056	ENSG00000273483.1	RP4-671G15.2	4.01	7.16e-05	0.00585	0.2	0.18	Hip circumference adjusted for BMI;	chr1:112693608	chr1:112517799~112518441:-
THCA	cis	rs17685	0.725	rs7807647	ENSG00000227038.2	AC005077.12	-4.01	7.16e-05	0.00585	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:75999351	chr7:76090431~76108779:-
THCA	cis	rs755249	0.756	rs72637908	ENSG00000182109.6	RP11-69E11.4	4.01	7.16e-05	0.00585	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39522280~39546187:-
THCA	cis	rs1008126	0.918	rs2075040	ENSG00000234715.1	CTB-107G13.1	4.01	7.17e-05	0.00585	0.22	0.18	Metabolite levels (Pyroglutamine);	chr7:103522400	chr7:103445207~103514007:+
THCA	cis	rs4803480	0.872	rs10420470	ENSG00000270164.1	LINC01480	-4.01	7.17e-05	0.00585	-0.19	-0.18	Schizophrenia;	chr19:41567075	chr19:41535183~41536904:+
THCA	cis	rs7264396	0.79	rs6060562	ENSG00000088340.14	FER1L4	4.01	7.17e-05	0.00585	0.18	0.18	Total cholesterol levels;	chr20:35694131	chr20:35558737~35607562:-
THCA	cis	rs593531	0.513	rs7947911	ENSG00000255440.1	RP11-632K5.2	-4.01	7.17e-05	0.00585	-0.22	-0.18	Neuroticism;	chr11:74312706	chr11:74409060~74416379:+
THCA	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-4.01	7.17e-05	0.00586	-0.18	-0.18	Asthma;	chr2:102392894	chr2:102438713~102440475:+
THCA	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-4.01	7.17e-05	0.00586	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
THCA	cis	rs910316	1	rs175512	ENSG00000259138.1	RP11-950C14.7	-4.01	7.17e-05	0.00586	-0.16	-0.18	Height;	chr14:75056679	chr14:75127153~75136930:+
THCA	cis	rs5758659	0.652	rs133335	ENSG00000270083.1	RP1-257I20.14	-4.01	7.17e-05	0.00586	-0.19	-0.18	Cognitive function;	chr22:42020052	chr22:42089630~42090028:-
THCA	cis	rs6674176	0.569	rs11210935	ENSG00000237950.1	RP11-7O11.3	4.01	7.17e-05	0.00586	0.17	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43903772	chr1:43944370~43946551:-
THCA	cis	rs1552244	0.515	rs28853661	ENSG00000180385.7	EMC3-AS1	4.01	7.17e-05	0.00586	0.23	0.18	Alzheimer's disease;	chr3:10135975	chr3:9986893~10006990:+
THCA	cis	rs11665867	1	rs73047068	ENSG00000279108.1	CTC-490E21.11	-4.01	7.17e-05	0.00586	-0.26	-0.18	Hematocrit;	chr19:40791201	chr19:40840159~40842039:+
THCA	cis	rs858239	0.899	rs10085838	ENSG00000230042.1	AK3P3	-4.01	7.17e-05	0.00586	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23129178~23129841:+
THCA	cis	rs8073060	0.518	rs225285	ENSG00000255987.1	TOMM20P2	-4.01	7.17e-05	0.00586	-0.19	-0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35604065	chr17:35514766~35515186:-
THCA	cis	rs11722779	0.844	rs7694724	ENSG00000248971.2	KRT8P46	-4.01	7.17e-05	0.00586	-0.22	-0.18	Schizophrenia;	chr4:103041375	chr4:102728746~102730171:-
THCA	cis	rs9291683	0.575	rs3756223	ENSG00000261490.1	RP11-448G15.3	4.01	7.17e-05	0.00586	0.11	0.18	Bone mineral density;	chr4:10104173	chr4:10068089~10073019:-
THCA	cis	rs3755605	0.728	rs2901549	ENSG00000242578.1	RP11-469J4.3	4.01	7.18e-05	0.00586	0.2	0.18	Testicular germ cell tumor;	chr3:170176555	chr3:170410512~170418615:+
THCA	cis	rs11931598	0.513	rs3857170	ENSG00000245468.3	RP11-367J11.3	4.01	7.18e-05	0.00586	0.13	0.18	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7001639	chr4:7094571~7103385:-
THCA	cis	rs763121	0.853	rs5750672	ENSG00000235209.1	CTA-150C2.13	-4.01	7.18e-05	0.00586	-0.24	-0.18	Menopause (age at onset);	chr22:38708163	chr22:38921227~38924708:+
THCA	cis	rs17695224	0.545	rs8099997	ENSG00000275055.1	CTC-471J1.11	-4.01	7.18e-05	0.00586	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51842216	chr19:52049007~52049754:+
THCA	cis	rs357618	0.581	rs165331	ENSG00000260581.1	CTB-113P19.4	-4.01	7.18e-05	0.00586	-0.28	-0.18	Basophil percentage of white cells;	chr5:151496406	chr5:151652275~151655449:+
THCA	cis	rs253959	0.739	rs1421842	ENSG00000250015.1	CTC-339F2.2	-4.01	7.18e-05	0.00586	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr5:116298593	chr5:116302354~116304134:-
THCA	cis	rs2251260	0.945	rs2247196	ENSG00000232774.6	FLJ22447	-4.01	7.18e-05	0.00586	-0.28	-0.18	Yeast infection;	chr14:61557599	chr14:61570540~61658696:+
THCA	cis	rs763121	0.849	rs12004	ENSG00000228274.3	RP3-508I15.9	-4.01	7.18e-05	0.00586	-0.2	-0.18	Menopause (age at onset);	chr22:38481456	chr22:38667585~38681820:-
THCA	cis	rs6696239	0.956	rs6691443	ENSG00000227711.2	RP11-275O4.5	4.01	7.18e-05	0.00586	0.25	0.18	Height;	chr1:227661012	chr1:227509028~227520477:-
THCA	cis	rs17221829	0.703	rs10830347	ENSG00000280385.1	AP000648.5	-4.01	7.18e-05	0.00586	-0.17	-0.18	Anxiety in major depressive disorder;	chr11:89681997	chr11:90193614~90198120:+
THCA	cis	rs2806561	0.734	rs2143156	ENSG00000249087.5	ZNF436-AS1	-4.01	7.18e-05	0.00586	-0.12	-0.18	Height;	chr1:23048136	chr1:23368997~23371839:+
THCA	cis	rs589448	0.902	rs2603089	ENSG00000274979.1	RP11-1143G9.5	4.01	7.18e-05	0.00587	0.19	0.18	Cerebrospinal fluid biomarker levels;	chr12:69383020	chr12:69326574~69331882:-
THCA	cis	rs875971	0.522	rs1617484	ENSG00000272831.1	RP11-792A8.4	4.01	7.18e-05	0.00587	0.12	0.18	Aortic root size;	chr7:65998108	chr7:66739829~66740385:-
THCA	cis	rs4886920	0.862	rs11631822	ENSG00000260776.4	RP11-114H24.2	-4.01	7.18e-05	0.00587	-0.21	-0.18	Neuroticism;	chr15:77815324	chr15:77914217~77926846:-
THCA	cis	rs7623291	0.504	rs13095759	ENSG00000272699.1	RP11-145M9.5	-4.01	7.19e-05	0.00587	-0.29	-0.18	Left ventricular obstructive tract defect (inherited effect);	chr3:178636147	chr3:179405448~179405944:+
THCA	cis	rs11710088	0.634	rs13095959	ENSG00000240541.2	TM4SF1-AS1	4.01	7.19e-05	0.00587	0.17	0.18	QRS duration;	chr3:149489409	chr3:149377778~149386583:+
THCA	cis	rs754466	0.606	rs56402185	ENSG00000213514.2	RP11-428P16.2	4.01	7.19e-05	0.00587	0.2	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77826090	chr10:77730766~77734769:+
THCA	cis	rs4081724	0.638	rs17601990	ENSG00000267296.2	CEBPA-AS1	4.01	7.19e-05	0.00587	0.23	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33351374	chr19:33302857~33305054:+
THCA	cis	rs9595908	0.746	rs9591229	ENSG00000212293.1	SNORA16	4.01	7.19e-05	0.00587	0.22	0.18	Body mass index;	chr13:32658870	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.746	rs4942792	ENSG00000212293.1	SNORA16	4.01	7.19e-05	0.00587	0.22	0.18	Body mass index;	chr13:32663326	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.746	rs9596048	ENSG00000212293.1	SNORA16	4.01	7.19e-05	0.00587	0.22	0.18	Body mass index;	chr13:32664595	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.746	rs1029306	ENSG00000212293.1	SNORA16	4.01	7.19e-05	0.00587	0.22	0.18	Body mass index;	chr13:32707695	chr13:32420390~32420516:-
THCA	cis	rs2243480	0.706	rs6460257	ENSG00000229180.5	GS1-124K5.11	4.01	7.19e-05	0.00587	0.18	0.18	Diabetic kidney disease;	chr7:65731813	chr7:66526088~66542624:-
THCA	cis	rs4788570	0.545	rs8044144	ENSG00000260593.1	RP11-432I5.2	-4.01	7.19e-05	0.00587	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71749218	chr16:71623708~71626816:-
THCA	cis	rs3824488	0.705	rs16909927	ENSG00000271155.1	RP11-435O5.5	4.01	7.19e-05	0.00587	0.27	0.18	Neuroticism;	chr9:95521893	chr9:95506235~95507636:+
THCA	cis	rs10875746	0.729	rs11168357	ENSG00000269514.1	RP11-370I10.12	4.01	7.19e-05	0.00587	0.18	0.18	Longevity (90 years and older);	chr12:48018355	chr12:48198387~48202031:+
THCA	cis	rs7267979	0.816	rs422148	ENSG00000274973.1	RP13-401N8.7	-4.01	7.19e-05	0.00587	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25845497~25845862:+
THCA	cis	rs6840360	0.573	rs11099807	ENSG00000251611.1	RP11-610P16.1	-4.01	7.19e-05	0.00587	-0.13	-0.18	Intelligence (multi-trait analysis);	chr4:151348076	chr4:151407551~151408835:-
THCA	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	4.01	7.19e-05	0.00587	0.23	0.18	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
THCA	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-4.01	7.19e-05	0.00587	-0.22	-0.18	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
THCA	cis	rs7824557	0.564	rs2572395	ENSG00000154316.13	TDH	4.01	7.19e-05	0.00587	0.14	0.18	Retinal vascular caliber;	chr8:11377851	chr8:11339637~11368452:+
THCA	cis	rs7829975	0.572	rs28446104	ENSG00000254340.1	RP11-10A14.3	-4.01	7.19e-05	0.00587	-0.21	-0.18	Mood instability;	chr8:8938391	chr8:9141424~9145435:+
THCA	cis	rs4713118	0.629	rs149899	ENSG00000219891.2	ZSCAN12P1	4.01	7.19e-05	0.00587	0.24	0.18	Parkinson's disease;	chr6:28052201	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000219891.2	ZSCAN12P1	4.01	7.19e-05	0.00587	0.24	0.18	Parkinson's disease;	chr6:28053036	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000219891.2	ZSCAN12P1	4.01	7.19e-05	0.00587	0.24	0.18	Parkinson's disease;	chr6:28053042	chr6:28091154~28093664:+
THCA	cis	rs2733201	1	rs4923969	ENSG00000166763.7	STRCP1	-4.01	7.2e-05	0.00587	-0.4	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44016338	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs8037441	ENSG00000166763.7	STRCP1	-4.01	7.2e-05	0.00587	-0.4	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44019718	chr15:43699488~43718184:-
THCA	cis	rs875971	0.545	rs12670811	ENSG00000273024.4	INTS4P2	-4.01	7.2e-05	0.00587	-0.23	-0.18	Aortic root size;	chr7:66358032	chr7:65647864~65715661:+
THCA	cis	rs7904321	1	rs7913757	ENSG00000232075.1	MRPL35P2	-4.01	7.2e-05	0.00587	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63077596	chr10:63634317~63634827:-
THCA	cis	rs7246967	0.551	rs8103204	ENSG00000198153.8	ZNF849P	-4.01	7.2e-05	0.00588	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22753715	chr19:22685167~22686732:+
THCA	cis	rs9926296	0.535	rs36022917	ENSG00000274627.1	RP11-104N10.2	-4.01	7.2e-05	0.00588	-0.18	-0.18	Vitiligo;	chr16:89826830	chr16:89516797~89522217:+
THCA	cis	rs9926296	0.562	rs4785725	ENSG00000274627.1	RP11-104N10.2	-4.01	7.2e-05	0.00588	-0.18	-0.18	Vitiligo;	chr16:89826835	chr16:89516797~89522217:+
THCA	cis	rs17092148	1	rs17092148	ENSG00000276073.1	RP5-1125A11.7	-4.01	7.2e-05	0.00588	-0.22	-0.18	Neuroticism;	chr20:34847358	chr20:33985617~33988989:-
THCA	cis	rs2274136	1	rs4367384	ENSG00000272269.1	RP11-500C11.3	4.01	7.2e-05	0.00588	0.21	0.18	Obesity-related traits;	chr6:17667404	chr6:17706257~17707344:+
THCA	cis	rs5758659	0.652	rs133303	ENSG00000234009.1	RPL5P34	-4.01	7.2e-05	0.00588	-0.17	-0.18	Cognitive function;	chr22:41999238	chr22:42776406~42777296:-
THCA	cis	rs7707921	0.846	rs4293895	ENSG00000251374.1	RPS23P5	4.01	7.2e-05	0.00588	0.26	0.18	Breast cancer;	chr5:82129773	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.881	rs1428940	ENSG00000251374.1	RPS23P5	4.01	7.2e-05	0.00588	0.26	0.18	Breast cancer;	chr5:82152176	chr5:82265157~82265259:-
THCA	cis	rs6878727	0.741	rs2161233	ENSG00000253807.4	LINC01170	-4.01	7.2e-05	0.00588	-0.19	-0.18	Breast cancer;	chr5:124385298	chr5:124059794~124405079:-
THCA	cis	rs5769765	0.955	rs1321	ENSG00000260613.1	RP3-522J7.6	-4.01	7.2e-05	0.00588	-0.22	-0.18	Schizophrenia;	chr22:49903787	chr22:49832616~49837786:-
THCA	cis	rs453301	0.657	rs36056437	ENSG00000254153.1	CTA-398F10.2	4.01	7.2e-05	0.00588	0.21	0.18	Joint mobility (Beighton score);	chr8:8935355	chr8:8456909~8461337:-
THCA	cis	rs4947019	0.609	rs749621	ENSG00000223537.2	RP5-919F19.5	-4.01	7.2e-05	0.00588	-0.34	-0.18	Hematological parameters;	chr6:109441397	chr6:109487906~109506800:+
THCA	cis	rs8130944	0.73	rs2250870	ENSG00000225731.1	AP001627.1	4.01	7.2e-05	0.00588	0.22	0.18	Perceived unattractiveness to mosquitoes;	chr21:42737077	chr21:42733594~42741758:-
THCA	cis	rs911555	0.755	rs1116095	ENSG00000269958.1	RP11-73M18.8	-4.01	7.2e-05	0.00588	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs8010247	ENSG00000269958.1	RP11-73M18.8	-4.01	7.2e-05	0.00588	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs55742283	ENSG00000269958.1	RP11-73M18.8	-4.01	7.2e-05	0.00588	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs8014800	ENSG00000269958.1	RP11-73M18.8	-4.01	7.2e-05	0.00588	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs12435516	ENSG00000269958.1	RP11-73M18.8	-4.01	7.2e-05	0.00588	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs2756135	ENSG00000269958.1	RP11-73M18.8	-4.01	7.2e-05	0.00588	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103696353~103697163:+
THCA	cis	rs10492201	0.529	rs4913390	ENSG00000255733.4	IFNG-AS1	-4.01	7.2e-05	0.00588	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993696	chr12:67989445~68234686:+
THCA	cis	rs10492201	0.529	rs11176998	ENSG00000255733.4	IFNG-AS1	-4.01	7.2e-05	0.00588	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993774	chr12:67989445~68234686:+
THCA	cis	rs7521681	0.714	rs6678494	ENSG00000230489.1	VAV3-AS1	-4.01	7.2e-05	0.00588	-0.2	-0.18	Asthma and hay fever;	chr1:107763715	chr1:107964443~107994607:+
THCA	cis	rs35740288	0.77	rs11634177	ENSG00000259295.5	CSPG4P12	-4.01	7.2e-05	0.00588	-0.29	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605159	chr15:85191438~85213905:+
THCA	cis	rs3774959	0.527	rs4648011	ENSG00000246560.2	RP11-10L12.4	-4.01	7.21e-05	0.00588	-0.22	-0.18	Ulcerative colitis;	chr4:102554287	chr4:102828055~102844075:+
THCA	cis	rs10833905	1	rs7107632	ENSG00000246225.5	RP11-17A1.3	-4.01	7.21e-05	0.00588	-0.26	-0.18	Sudden cardiac arrest;	chr11:23044835	chr11:22829380~22945393:+
THCA	cis	rs9863	0.861	rs34878139	ENSG00000270061.1	RP11-214K3.19	-4	7.21e-05	0.00589	-0.23	-0.18	White blood cell count;	chr12:123961706	chr12:123969990~123970344:-
THCA	cis	rs9863	0.861	rs11833002	ENSG00000270061.1	RP11-214K3.19	-4	7.21e-05	0.00589	-0.23	-0.18	White blood cell count;	chr12:123962069	chr12:123969990~123970344:-
THCA	cis	rs4761702	0.614	rs11106976	ENSG00000257322.4	RP11-511B23.2	-4	7.21e-05	0.00589	-0.27	-0.18	Immature fraction of reticulocytes;	chr12:93327763	chr12:93003415~93215679:-
THCA	cis	rs34779708	0.643	rs4275563	ENSG00000233200.1	RP11-324I22.2	4	7.21e-05	0.00589	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35219894~35230598:-
THCA	cis	rs10833905	0.938	rs10833923	ENSG00000246225.5	RP11-17A1.3	-4	7.21e-05	0.00589	-0.26	-0.18	Sudden cardiac arrest;	chr11:23050982	chr11:22829380~22945393:+
THCA	cis	rs11603020	0.95	rs78624400	ENSG00000254602.1	AP000662.4	-4	7.22e-05	0.00589	-0.21	-0.18	Blood protein levels;	chr11:57607990	chr11:57638024~57652790:+
THCA	cis	rs12234571	1	rs73372281	ENSG00000214293.7	APTR	4	7.22e-05	0.00589	0.22	0.18	Obesity-related traits;	chr7:77705076	chr7:77657660~77696265:-
THCA	cis	rs11710088	0.931	rs4320033	ENSG00000244503.1	RP11-278L15.6	4	7.22e-05	0.00589	0.23	0.18	QRS duration;	chr3:149481468	chr3:149494660~149495995:+
THCA	cis	rs7188861	0.603	rs2113260	ENSG00000262703.1	RP11-485G7.6	4	7.22e-05	0.00589	0.21	0.18	HDL cholesterol;	chr16:11362136	chr16:11348143~11349321:-
THCA	cis	rs2191566	0.506	rs396116	ENSG00000277806.1	RP11-15A1.8	4	7.22e-05	0.00589	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43990431	chr19:43976815~43977448:+
THCA	cis	rs17604090	0.938	rs850029	ENSG00000227855.3	DPY19L2P3	4	7.22e-05	0.00589	0.22	0.18	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29638471	chr7:29650227~29742594:+
THCA	cis	rs7819412	0.875	rs11250121	ENSG00000206014.6	OR7E161P	4	7.22e-05	0.00589	0.21	0.18	Triglycerides;	chr8:11202802	chr8:11928597~11929563:-
THCA	cis	rs2033711	0.84	rs10423138	ENSG00000268049.1	CTD-2619J13.9	-4	7.22e-05	0.00589	-0.23	-0.18	Uric acid clearance;	chr19:58416935	chr19:58357999~58359603:+
THCA	cis	rs4266290	0.671	rs884474	ENSG00000214846.4	RP11-115L11.1	4	7.22e-05	0.00589	0.26	0.18	Parkinson's disease;	chr4:15754647	chr4:15730962~15731627:-
THCA	cis	rs12681366	0.761	rs2197003	ENSG00000261437.1	RP11-22C11.2	4	7.22e-05	0.00589	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94444758	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.801	rs2921386	ENSG00000261437.1	RP11-22C11.2	4	7.22e-05	0.00589	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94446672	chr8:94637285~94639467:-
THCA	cis	rs7045881	0.735	rs10967594	ENSG00000254396.1	RP11-56F10.3	4	7.22e-05	0.00589	0.24	0.18	Schizophrenia;	chr9:26910953	chr9:27102630~27104728:+
THCA	cis	rs6963495	0.818	rs17343556	ENSG00000272604.1	RP11-251G23.5	4	7.22e-05	0.00589	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105510825	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190149	ENSG00000272604.1	RP11-251G23.5	4	7.22e-05	0.00589	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105512346	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190151	ENSG00000272604.1	RP11-251G23.5	4	7.22e-05	0.00589	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105512440	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190155	ENSG00000272604.1	RP11-251G23.5	4	7.22e-05	0.00589	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105513088	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190156	ENSG00000272604.1	RP11-251G23.5	4	7.22e-05	0.00589	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105513120	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190158	ENSG00000272604.1	RP11-251G23.5	4	7.22e-05	0.00589	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105513496	chr7:105571083~105573660:+
THCA	cis	rs7617480	0.585	rs7373072	ENSG00000228638.1	FCF1P2	-4	7.22e-05	0.00589	-0.22	-0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48922584	chr3:48290793~48291375:-
THCA	cis	rs1124769	0.57	rs7181593	ENSG00000273674.3	CTD-2378E12.1	-4	7.22e-05	0.00589	-0.24	-0.18	Cognitive performance;	chr15:50853917	chr15:50839875~50908599:-
THCA	cis	rs10129255	0.957	rs8005468	ENSG00000211972.2	IGHV3-66	4	7.22e-05	0.00589	0.11	0.18	Kawasaki disease;	chr14:106686431	chr14:106675017~106675544:-
THCA	cis	rs7129556	0.69	rs24356	ENSG00000254459.1	RP11-91P24.7	4	7.22e-05	0.00589	0.23	0.18	Weight loss (gastric bypass surgery);	chr11:77856482	chr11:77829654~77872262:-
THCA	cis	rs2904524	0.867	rs10879121	ENSG00000257815.4	RP11-611E13.2	-4	7.23e-05	0.0059	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70277447	chr12:69904033~70243360:-
THCA	cis	rs804280	1	rs804281	ENSG00000206014.6	OR7E161P	-4	7.23e-05	0.0059	-0.22	-0.18	Myopia (pathological);	chr8:11754356	chr8:11928597~11929563:-
THCA	cis	rs3767627	0.505	rs58700306	ENSG00000203819.6	HIST2H2BC	4	7.23e-05	0.0059	0.23	0.18	Height;	chr1:150023547	chr1:149850193~149850772:-
THCA	cis	rs4081724	0.565	rs56317325	ENSG00000267296.2	CEBPA-AS1	4	7.23e-05	0.0059	0.29	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33310031	chr19:33302857~33305054:+
THCA	cis	rs271738	0.642	rs271767	ENSG00000231768.1	LINC01354	-4	7.23e-05	0.0059	-0.21	-0.18	Bipolar disorder;	chr1:234539219	chr1:234527891~234531779:-
THCA	cis	rs3770081	1	rs75713195	ENSG00000273080.1	RP11-301O19.1	-4	7.23e-05	0.0059	-0.43	-0.18	Facial emotion recognition (sad faces);	chr2:86063536	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs79152960	ENSG00000273080.1	RP11-301O19.1	-4	7.23e-05	0.0059	-0.43	-0.18	Facial emotion recognition (sad faces);	chr2:86063538	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs57398459	ENSG00000273080.1	RP11-301O19.1	-4	7.23e-05	0.0059	-0.43	-0.18	Facial emotion recognition (sad faces);	chr2:86064203	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs77309268	ENSG00000273080.1	RP11-301O19.1	-4	7.23e-05	0.0059	-0.43	-0.18	Facial emotion recognition (sad faces);	chr2:86066171	chr2:86195590~86196049:+
THCA	cis	rs41294858	0.908	rs79562575	ENSG00000232876.1	CTA-212D2.2	-4	7.23e-05	0.0059	-0.37	-0.18	Red blood cell count;	chr6:135082974	chr6:135055033~135060550:+
THCA	cis	rs2692947	0.727	rs749457	ENSG00000232931.4	LINC00342	4	7.23e-05	0.0059	0.14	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96130205	chr2:95807118~95816215:-
THCA	cis	rs728616	0.558	rs2880599	ENSG00000278616.1	BEND3P3	4	7.23e-05	0.0059	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80404679	chr10:79682997~79685436:+
THCA	cis	rs7737355	0.947	rs40989	ENSG00000237714.1	P4HA2-AS1	4	7.23e-05	0.0059	0.26	0.18	Life satisfaction;	chr5:131656591	chr5:132184876~132192808:+
THCA	cis	rs227275	0.53	rs3960788	ENSG00000251288.2	RP11-10L12.2	-4	7.23e-05	0.0059	-0.24	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102751401~102752641:+
THCA	cis	rs1035144	0.704	rs77647068	ENSG00000259167.2	NMNAT1P1	4	7.23e-05	0.0059	0.23	0.18	Male sexual orientation;	chr14:80979232	chr14:81032529~81033404:+
THCA	cis	rs9990333	0.6	rs6793116	ENSG00000207650.1	MIR570	-4	7.23e-05	0.0059	-0.19	-0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085217	chr3:195699401~195699497:+
THCA	cis	rs2006933	1	rs9900311	ENSG00000267644.1	CTD-2008P7.10	4	7.23e-05	0.0059	0.22	0.18	Amyotrophic lateral sclerosis;	chr17:28268381	chr17:28219285~28220005:+
THCA	cis	rs867186	1	rs78967641	ENSG00000126005.14	MMP24-AS1	-4	7.23e-05	0.0059	-0.29	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35195250	chr20:35216462~35278131:-
THCA	cis	rs12129938	0.866	rs10489808	ENSG00000231940.1	RPS7P3	-4	7.23e-05	0.0059	-0.24	-0.18	Thyroid cancer;	chr1:233261521	chr1:233288868~233289447:-
THCA	cis	rs76878669	0.793	rs10791867	ENSG00000255320.1	RP11-755F10.1	4	7.23e-05	0.0059	0.24	0.18	Educational attainment (years of education);	chr11:66313740	chr11:66244840~66246239:-
THCA	cis	rs11185790	0.784	rs11185763	ENSG00000232936.4	RP11-80H5.2	4	7.24e-05	0.0059	0.23	0.18	Metabolic traits;	chr10:89578068	chr10:89645282~89650667:+
THCA	cis	rs11185790	0.784	rs12773938	ENSG00000232936.4	RP11-80H5.2	4	7.24e-05	0.0059	0.23	0.18	Metabolic traits;	chr10:89578918	chr10:89645282~89650667:+
THCA	cis	rs2033711	0.87	rs3764534	ENSG00000269867.1	CTD-2583A14.8	-4	7.24e-05	0.0059	-0.15	-0.18	Uric acid clearance;	chr19:58417769	chr19:57867038~57868172:-
THCA	cis	rs11758351	0.715	rs76130408	ENSG00000216331.1	HIST1H1PS1	4	7.24e-05	0.0059	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26208734	chr6:26195566~26195771:+
THCA	cis	rs7819412	0.654	rs4840550	ENSG00000280294.1	RP11-177H2.1	4	7.24e-05	0.00591	0.15	0.18	Triglycerides;	chr8:11171520	chr8:10856085~10859436:-
THCA	cis	rs17092148	1	rs62211612	ENSG00000276073.1	RP5-1125A11.7	4	7.24e-05	0.00591	0.21	0.18	Neuroticism;	chr20:34798353	chr20:33985617~33988989:-
THCA	cis	rs12368653	0.591	rs1552842	ENSG00000270039.1	RP11-571M6.17	-4	7.24e-05	0.00591	-0.19	-0.18	Multiple sclerosis;	chr12:57618380	chr12:57803838~57804415:+
THCA	cis	rs5006884	0.627	rs4910780	ENSG00000167355.6	AC104389.28	4	7.24e-05	0.00591	0.3	0.18	Fetal hemoglobin levels;	chr11:5384893	chr11:5304976~5505652:-
THCA	cis	rs343092	0.873	rs2260663	ENSG00000241749.4	RPSAP52	4	7.24e-05	0.00591	0.21	0.18	Type 2 diabetes;	chr12:65780449	chr12:65758020~65826997:-
THCA	cis	rs4727027	0.704	rs13221837	ENSG00000244560.5	RP4-800G7.2	-4	7.24e-05	0.00591	-0.11	-0.18	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149206505	chr7:149285281~149297312:+
THCA	cis	rs12440869	1	rs28693872	ENSG00000270964.1	RP11-502I4.3	4	7.24e-05	0.00591	0.16	0.18	Peak velocity of the mitral A-wave;	chr15:67209444	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs28418884	ENSG00000270964.1	RP11-502I4.3	4	7.24e-05	0.00591	0.16	0.18	Peak velocity of the mitral A-wave;	chr15:67209639	chr15:67541072~67542604:-
THCA	cis	rs2579519	0.556	rs4907302	ENSG00000235584.2	AC008268.1	-4	7.24e-05	0.00591	-0.18	-0.18	Diastolic blood pressure;	chr2:95551449	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.509	rs79546441	ENSG00000235584.2	AC008268.1	-4	7.24e-05	0.00591	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95553124	chr2:95666084~95668715:+
THCA	cis	rs4713118	0.868	rs9468220	ENSG00000272009.1	RP1-313I6.12	4	7.24e-05	0.00591	0.22	0.18	Parkinson's disease;	chr6:27765197	chr6:28078792~28081130:-
THCA	cis	rs10043228	0.826	rs77863323	ENSG00000248445.4	SEMA6A-AS1	-4	7.25e-05	0.00591	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116113415	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs79404901	ENSG00000248445.4	SEMA6A-AS1	-4	7.25e-05	0.00591	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116113635	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs1876673	ENSG00000248445.4	SEMA6A-AS1	-4	7.25e-05	0.00591	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116115076	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12516100	ENSG00000248445.4	SEMA6A-AS1	-4	7.25e-05	0.00591	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116116053	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12520076	ENSG00000248445.4	SEMA6A-AS1	-4	7.25e-05	0.00591	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116123133	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12514600	ENSG00000248445.4	SEMA6A-AS1	-4	7.25e-05	0.00591	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116134958	chr5:116447547~116508276:+
THCA	cis	rs11758351	0.866	rs56186759	ENSG00000216331.1	HIST1H1PS1	4	7.25e-05	0.00591	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26206953	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.866	rs55815656	ENSG00000216331.1	HIST1H1PS1	4	7.25e-05	0.00591	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26207075	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.866	rs77889957	ENSG00000216331.1	HIST1H1PS1	4	7.25e-05	0.00591	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26207207	chr6:26195566~26195771:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000273796.1	LL21NC02-21A1.1	-4	7.25e-05	0.00591	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45403809~45404369:-
THCA	cis	rs4788570	0.615	rs1423983	ENSG00000260593.1	RP11-432I5.2	-4	7.25e-05	0.00591	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71667345	chr16:71623708~71626816:-
THCA	cis	rs4788570	0.584	rs11862723	ENSG00000260593.1	RP11-432I5.2	-4	7.25e-05	0.00591	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71670319	chr16:71623708~71626816:-
THCA	cis	rs957448	0.561	rs4735302	ENSG00000253175.1	RP11-267M23.6	-4	7.25e-05	0.00591	-0.23	-0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94565036~94565715:+
THCA	cis	rs854765	0.505	rs2955358	ENSG00000281749.1	Y_RNA	-4	7.25e-05	0.00592	-0.23	-0.18	Total body bone mineral density;	chr17:18043309	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs2955355	ENSG00000281749.1	Y_RNA	-4	7.25e-05	0.00592	-0.23	-0.18	Total body bone mineral density;	chr17:18045161	chr17:18001101~18001195:-
THCA	cis	rs4713118	0.629	rs203888	ENSG00000219891.2	ZSCAN12P1	4	7.25e-05	0.00592	0.24	0.18	Parkinson's disease;	chr6:28053811	chr6:28091154~28093664:+
THCA	cis	rs13118159	0.556	rs4974615	ENSG00000254094.1	AC078852.1	4	7.25e-05	0.00592	0.22	0.18	Longevity;	chr4:1379763	chr4:1356581~1358075:+
THCA	cis	rs9595908	0.785	rs7317147	ENSG00000212293.1	SNORA16	4	7.26e-05	0.00592	0.21	0.18	Body mass index;	chr13:32670838	chr13:32420390~32420516:-
THCA	cis	rs5751614	1	rs5996505	ENSG00000240160.3	RN7SL263P	4	7.26e-05	0.00592	0.2	0.18	Height;	chr22:23247296	chr22:23261782~23262071:-
THCA	cis	rs9510787	0.649	rs7992255	ENSG00000205861.10	C1QTNF9B-AS1	-4	7.26e-05	0.00592	-0.23	-0.18	Nasopharyngeal carcinoma;	chr13:23640674	chr13:23888889~23897263:+
THCA	cis	rs656319	0.586	rs35013996	ENSG00000261451.1	RP11-981G7.1	-4	7.26e-05	0.00592	-0.24	-0.18	Myopia (pathological);	chr8:10089635	chr8:10433672~10438312:+
THCA	cis	rs13434995	0.513	rs6802	ENSG00000249700.7	SRD5A3-AS1	-4	7.26e-05	0.00592	-0.26	-0.18	Adiponectin levels;	chr4:55425934	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62303722	ENSG00000249700.7	SRD5A3-AS1	-4	7.26e-05	0.00592	-0.26	-0.18	Adiponectin levels;	chr4:55482076	chr4:55363971~55395847:-
THCA	cis	rs1039766	1	rs268870	ENSG00000204929.10	AC074391.1	4	7.26e-05	0.00592	0.29	0.18	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr2:65436711~66084639:+
THCA	cis	rs2342371	0.565	rs9858020	ENSG00000273013.1	CTD-2002J20.1	-4	7.26e-05	0.00592	-0.17	-0.18	Fat distribution (HIV);	chr3:196492923	chr3:196474801~196475394:+
THCA	cis	rs7824557	0.564	rs7828263	ENSG00000255495.1	AC145124.2	-4	7.26e-05	0.00592	-0.21	-0.18	Retinal vascular caliber;	chr8:11374377	chr8:12194467~12196280:+
THCA	cis	rs17507216	0.718	rs28587782	ENSG00000255769.6	GOLGA2P10	-4	7.27e-05	0.00592	-0.27	-0.18	Excessive daytime sleepiness;	chr15:82576881	chr15:82472993~82513950:-
THCA	cis	rs2191566	0.691	rs8104605	ENSG00000266921.1	RP11-15A1.7	4	7.27e-05	0.00593	0.16	0.18	Acute lymphoblastic leukemia (childhood);	chr19:44084863	chr19:43996896~44002836:-
THCA	cis	rs860295	0.812	rs12407800	ENSG00000236675.1	MTX1P1	-4	7.27e-05	0.00593	-0.19	-0.18	Body mass index;	chr1:155790951	chr1:155230975~155234325:+
THCA	cis	rs227275	0.556	rs7676765	ENSG00000248971.2	KRT8P46	4	7.27e-05	0.00593	0.23	0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102728746~102730171:-
THCA	cis	rs3892630	0.588	rs7248798	ENSG00000267475.1	CTD-2538C1.2	-4	7.27e-05	0.00593	-0.25	-0.18	Red blood cell traits;	chr19:32812778	chr19:32687089~32691750:-
THCA	cis	rs9660180	0.967	rs11260623	ENSG00000215914.4	MMP23A	-4	7.27e-05	0.00593	-0.24	-0.18	Body mass index;	chr1:1850017	chr1:1699942~1701782:+
THCA	cis	rs7246760	0.867	rs16981648	ENSG00000267106.4	ZNF561-AS1	4	7.27e-05	0.00593	0.33	0.18	Pursuit maintenance gain;	chr19:9693748	chr19:9621291~9645896:+
THCA	cis	rs67981189	0.896	rs4048474	ENSG00000269927.1	RP6-91H8.3	4	7.27e-05	0.00593	0.21	0.18	Schizophrenia;	chr14:71060982	chr14:71141125~71143253:-
THCA	cis	rs12612619	0.658	rs112794902	ENSG00000272148.1	RP11-195B17.1	4	7.27e-05	0.00593	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26928718	chr2:27062428~27062907:-
THCA	cis	rs12612619	0.658	rs77920959	ENSG00000272148.1	RP11-195B17.1	4	7.27e-05	0.00593	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26928722	chr2:27062428~27062907:-
THCA	cis	rs9543976	0.623	rs7982517	ENSG00000261105.4	LMO7-AS1	4	7.27e-05	0.00593	0.25	0.18	Diabetic retinopathy;	chr13:75587903	chr13:75604700~75635994:-
THCA	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	4	7.27e-05	0.00593	0.16	0.18	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
THCA	cis	rs71520386	0.607	rs28617621	ENSG00000226329.2	AC005682.6	-4	7.27e-05	0.00593	-0.24	-0.18	Fibrinogen levels;	chr7:22818063	chr7:22863874~22881350:-
THCA	cis	rs7550636	0.836	rs4140450	ENSG00000276735.1	Metazoa_SRP	-4	7.27e-05	0.00593	-0.22	-0.18	Coronary artery calcification;	chr1:192876677	chr1:193236794~193237107:-
THCA	cis	rs9283706	0.594	rs7734953	ENSG00000229666.1	MAST4-AS1	-4	7.27e-05	0.00593	-0.27	-0.18	Coronary artery disease;	chr5:67054115	chr5:67001383~67003953:-
THCA	cis	rs2836974	0.897	rs13052882	ENSG00000255568.3	BRWD1-AS2	4	7.27e-05	0.00593	0.16	0.18	Cognitive function;	chr21:39183425	chr21:39313935~39314962:+
THCA	cis	rs453301	0.686	rs11785634	ENSG00000233609.3	RP11-62H7.2	-4	7.27e-05	0.00593	-0.18	-0.18	Joint mobility (Beighton score);	chr8:9035087	chr8:8961200~8979025:+
THCA	cis	rs17767294	0.612	rs9461424	ENSG00000220721.1	OR1F12	4	7.27e-05	0.00593	0.33	0.18	Parkinson's disease;	chr6:27951623	chr6:28073316~28074233:+
THCA	cis	rs12129938	0.91	rs12118544	ENSG00000231940.1	RPS7P3	4	7.27e-05	0.00593	0.24	0.18	Thyroid cancer;	chr1:233260549	chr1:233288868~233289447:-
THCA	cis	rs4792901	0.722	rs34558675	ENSG00000267151.3	RP11-100E5.2	4	7.27e-05	0.00593	0.2	0.18	Dupuytren's disease;	chr17:43473223	chr17:43444707~43451200:+
THCA	cis	rs4908769	0.66	rs13596	ENSG00000232912.4	RP5-1115A15.1	-4	7.28e-05	0.00593	-0.2	-0.18	Allergy;	chr1:8361143	chr1:8424645~8434838:+
THCA	cis	rs2562784	0.638	rs2585045	ENSG00000225151.9	GOLGA2P7	-4	7.28e-05	0.00593	-0.34	-0.18	Height;	chr15:83637562	chr15:84199311~84230136:-
THCA	cis	rs4218	0.531	rs8026611	ENSG00000277144.1	RP11-59H7.4	-4	7.28e-05	0.00593	-0.24	-0.18	Social communication problems;	chr15:59048927	chr15:59115547~59116089:-
THCA	cis	rs9467773	1	rs6456733	ENSG00000228223.2	HCG11	-4	7.28e-05	0.00593	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6456734	ENSG00000228223.2	HCG11	-4	7.28e-05	0.00593	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs1535277	ENSG00000228223.2	HCG11	-4	7.28e-05	0.00593	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs1884948	ENSG00000228223.2	HCG11	-4	7.28e-05	0.00593	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26523450~26526579:+
THCA	cis	rs10875746	0.729	rs11168355	ENSG00000269514.1	RP11-370I10.12	-4	7.28e-05	0.00593	-0.18	-0.18	Longevity (90 years and older);	chr12:48017195	chr12:48198387~48202031:+
THCA	cis	rs10050311	0.586	rs2054592	ENSG00000251411.1	RP11-397E7.4	-4	7.28e-05	0.00593	-0.22	-0.18	Insulin-related traits;	chr4:86752292	chr4:86913266~86914817:-
THCA	cis	rs10050311	0.746	rs17454662	ENSG00000251411.1	RP11-397E7.4	-4	7.28e-05	0.00593	-0.22	-0.18	Insulin-related traits;	chr4:86752611	chr4:86913266~86914817:-
THCA	cis	rs10050311	0.746	rs72665791	ENSG00000251411.1	RP11-397E7.4	-4	7.28e-05	0.00593	-0.22	-0.18	Insulin-related traits;	chr4:86757634	chr4:86913266~86914817:-
THCA	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	4	7.28e-05	0.00593	0.11	0.18	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
THCA	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	4	7.28e-05	0.00593	0.11	0.18	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
THCA	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	4	7.28e-05	0.00593	0.11	0.18	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	4	7.28e-05	0.00593	0.11	0.18	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.912	rs67410411	ENSG00000211972.2	IGHV3-66	4	7.28e-05	0.00593	0.11	0.18	Kawasaki disease;	chr14:106680324	chr14:106675017~106675544:-
THCA	cis	rs2549003	1	rs2548997	ENSG00000237714.1	P4HA2-AS1	4	7.28e-05	0.00593	0.23	0.18	Asthma (sex interaction);	chr5:132499703	chr5:132184876~132192808:+
THCA	cis	rs10435719	0.61	rs76311455	ENSG00000254948.1	OR7E158P	-4	7.28e-05	0.00593	-0.23	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933017	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.61	rs80269926	ENSG00000254948.1	OR7E158P	-4	7.28e-05	0.00593	-0.23	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933018	chr8:11919900~11920809:-
THCA	cis	rs10155981	0.85	rs73274210	ENSG00000179428.2	AC073072.5	-4	7.28e-05	0.00593	-0.29	-0.18	Bilirubin levels;	chr7:22716427	chr7:22725395~22727620:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000229180.5	GS1-124K5.11	4	7.28e-05	0.00593	0.13	0.18	Calcium levels;	chr7:65853042	chr7:66526088~66542624:-
THCA	cis	rs875971	0.516	rs6945322	ENSG00000229180.5	GS1-124K5.11	4	7.28e-05	0.00593	0.13	0.18	Aortic root size;	chr7:65871069	chr7:66526088~66542624:-
THCA	cis	rs7923609	0.518	rs7068145	ENSG00000232075.1	MRPL35P2	-4	7.28e-05	0.00593	-0.24	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63067903	chr10:63634317~63634827:-
THCA	cis	rs4767841	1	rs10849691	ENSG00000252886.1	RN7SKP197	-4	7.28e-05	0.00593	-0.18	-0.18	Urgency urinary incontinence;	chr12:119716449	chr12:119631090~119631386:-
THCA	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	4	7.28e-05	0.00593	0.23	0.18	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
THCA	cis	rs9341808	0.667	rs3805913	ENSG00000272129.1	RP11-250B2.6	4	7.28e-05	0.00593	0.23	0.18	Sitting height ratio;	chr6:80217605	chr6:80355424~80356859:+
THCA	cis	rs9309711	0.736	rs9309717	ENSG00000271868.1	RP11-1293J14.1	4	7.28e-05	0.00593	0.25	0.18	Neurofibrillary tangles;	chr2:3491307	chr2:3496956~3497428:+
THCA	cis	rs10860794	0.627	rs12230626	ENSG00000274560.1	RP11-285E23.2	-4	7.28e-05	0.00593	-0.13	-0.18	Blood protein levels;	chr12:101881699	chr12:101696002~101696450:-
THCA	cis	rs2904524	0.541	rs10879133	ENSG00000257815.4	RP11-611E13.2	-4	7.28e-05	0.00594	-0.14	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70386680	chr12:69904033~70243360:-
THCA	cis	rs12893668	0.703	rs55751606	ENSG00000244691.1	RPL10AP1	-4	7.28e-05	0.00594	-0.26	-0.18	Reticulocyte count;	chr14:103562469	chr14:103412119~103412761:-
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000229180.5	GS1-124K5.11	4	7.28e-05	0.00594	0.13	0.18	Calcium levels;	chr7:65903721	chr7:66526088~66542624:-
THCA	cis	rs7772486	0.754	rs1415746	ENSG00000270638.1	RP3-466P17.1	-4	7.29e-05	0.00594	-0.15	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145735570~145737218:+
THCA	cis	rs12908161	0.853	rs12912342	ENSG00000188388.10	GOLGA6L3	4	7.29e-05	0.00594	0.23	0.18	Schizophrenia;	chr15:84704985	chr15:85240472~85247170:+
THCA	cis	rs17711722	0.701	rs781143	ENSG00000229180.5	GS1-124K5.11	4	7.29e-05	0.00594	0.13	0.18	Calcium levels;	chr7:65974892	chr7:66526088~66542624:-
THCA	cis	rs944289	0.74	rs376927	ENSG00000258844.1	RP11-259K15.2	4	7.29e-05	0.00594	0.16	0.18	Thyroid cancer;	chr14:36078725	chr14:36214607~36235608:+
THCA	cis	rs7267979	0.932	rs6107052	ENSG00000276952.1	RP5-965G21.6	4	7.29e-05	0.00594	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25284915~25285588:-
THCA	cis	rs3935740	1	rs3935740	ENSG00000271983.1	RP11-28H5.2	4	7.29e-05	0.00594	0.23	0.18	Parkinson's disease;	chr15:81334384	chr15:80693216~80693707:-
THCA	cis	rs6921919	0.609	rs67211468	ENSG00000273712.1	RP5-874C20.7	4	7.29e-05	0.00594	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28315613~28315883:-
THCA	cis	rs1923243	0.71	rs34193223	ENSG00000223479.3	RP4-788P17.1	4	7.29e-05	0.00594	0.2	0.18	Migraine;	chr1:73149343	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12724133	ENSG00000223479.3	RP4-788P17.1	4	7.29e-05	0.00594	0.2	0.18	Migraine;	chr1:73149930	chr1:73635216~73715214:+
THCA	cis	rs7336933	0.688	rs9532942	ENSG00000278338.3	VWA8-AS1	-4	7.29e-05	0.00594	-0.3	-0.18	Calcium levels;	chr13:41868941	chr13:41955808~41981565:+
THCA	cis	rs9341808	0.556	rs1535075	ENSG00000260645.1	RP11-250B2.5	4	7.29e-05	0.00594	0.16	0.18	Sitting height ratio;	chr6:80325089	chr6:80466958~80469080:+
THCA	cis	rs6121246	0.821	rs7265413	ENSG00000224628.2	RP5-854E16.2	-4	7.3e-05	0.00595	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31730120	chr20:31285317~31286835:-
THCA	cis	rs10875746	0.669	rs10875767	ENSG00000258273.1	RP11-370I10.4	4	7.3e-05	0.00595	0.25	0.18	Longevity (90 years and older);	chr12:48205474	chr12:48333755~48333901:-
THCA	cis	rs875971	0.964	rs60193905	ENSG00000230189.5	GS1-124K5.2	4	7.3e-05	0.00595	0.12	0.18	Aortic root size;	chr7:66506273	chr7:66409143~66490059:-
THCA	cis	rs875971	0.929	rs10950041	ENSG00000230189.5	GS1-124K5.2	4	7.3e-05	0.00595	0.12	0.18	Aortic root size;	chr7:66508888	chr7:66409143~66490059:-
THCA	cis	rs2948294	0.524	rs13270062	ENSG00000233609.3	RP11-62H7.2	4	7.3e-05	0.00595	0.18	0.18	Red cell distribution width;	chr8:8255128	chr8:8961200~8979025:+
THCA	cis	rs7088591	0.867	rs114408524	ENSG00000276818.1	AC026393.1	4	7.3e-05	0.00595	0.38	0.18	Blood pressure;	chr10:58003293	chr10:57095699~57095781:+
THCA	cis	rs1714507	0.533	rs2731118	ENSG00000272247.1	RP11-379F4.9	4	7.3e-05	0.00595	0.18	0.18	Subjective well-being;	chr3:158589942	chr3:158801257~158801935:-
THCA	cis	rs1714507	0.533	rs2573179	ENSG00000272247.1	RP11-379F4.9	4	7.3e-05	0.00595	0.18	0.18	Subjective well-being;	chr3:158590018	chr3:158801257~158801935:-
THCA	cis	rs12544026	0.581	rs489973	ENSG00000253669.3	KB-1732A1.1	-4	7.3e-05	0.00595	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101864945	chr8:102805517~102809971:+
THCA	cis	rs13434995	0.513	rs62305265	ENSG00000249700.7	SRD5A3-AS1	-4	7.3e-05	0.00595	-0.26	-0.18	Adiponectin levels;	chr4:55503474	chr4:55363971~55395847:-
THCA	cis	rs758324	0.687	rs246353	ENSG00000224431.1	AC063976.7	-4	7.3e-05	0.00595	-0.19	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132171379	chr5:132199456~132203487:+
THCA	cis	rs1009077	0.627	rs4597811	ENSG00000260091.1	RP11-33B1.4	-4	7.3e-05	0.00595	-0.17	-0.18	Endometriosis;	chr4:119610044	chr4:119409333~119410233:+
THCA	cis	rs9902453	0.817	rs4294865	ENSG00000263370.1	RP11-68I3.5	4	7.3e-05	0.00595	0.24	0.18	Coffee consumption (cups per day);	chr17:29878718	chr17:29639627~29640825:+
THCA	cis	rs801193	0.935	rs2659899	ENSG00000229180.5	GS1-124K5.11	4	7.3e-05	0.00595	0.12	0.18	Aortic root size;	chr7:66721734	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs1553609	ENSG00000229180.5	GS1-124K5.11	4	7.3e-05	0.00595	0.12	0.18	Aortic root size;	chr7:66732152	chr7:66526088~66542624:-
THCA	cis	rs801193	0.967	rs2707853	ENSG00000229180.5	GS1-124K5.11	4	7.3e-05	0.00595	0.12	0.18	Aortic root size;	chr7:66749023	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs2659889	ENSG00000229180.5	GS1-124K5.11	4	7.3e-05	0.00595	0.12	0.18	Aortic root size;	chr7:66752125	chr7:66526088~66542624:-
THCA	cis	rs4705962	0.878	rs2051809	ENSG00000230612.2	AC004237.1	4	7.31e-05	0.00595	0.23	0.18	Atopic dermatitis;	chr5:132721182	chr5:132688681~132723725:+
THCA	cis	rs9863	0.898	rs7301953	ENSG00000269938.1	RP11-214K3.20	-4	7.31e-05	0.00595	-0.22	-0.18	White blood cell count;	chr12:123921324	chr12:123968023~123968579:-
THCA	cis	rs1371614	0.632	rs920437	ENSG00000272148.1	RP11-195B17.1	-4	7.31e-05	0.00595	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26934528	chr2:27062428~27062907:-
THCA	cis	rs7560272	0.501	rs11126417	ENSG00000163016.8	ALMS1P	4	7.31e-05	0.00595	0.23	0.18	Schizophrenia;	chr2:73747188	chr2:73644919~73685576:+
THCA	cis	rs4845570	1	rs6681093	ENSG00000203288.3	RP11-98D18.9	-4	7.31e-05	0.00595	-0.21	-0.18	Coronary artery disease;	chr1:151782808	chr1:151790804~151794402:+
THCA	cis	rs8067545	0.64	rs10083840	ENSG00000261033.1	RP11-209D14.2	-4	7.31e-05	0.00595	-0.23	-0.18	Schizophrenia;	chr17:20062659	chr17:20008051~20009234:-
THCA	cis	rs10411161	0.58	rs3848561	ENSG00000275055.1	CTC-471J1.11	-4	7.31e-05	0.00595	-0.15	-0.18	Breast cancer;	chr19:51876370	chr19:52049007~52049754:+
THCA	cis	rs7267979	0.789	rs4815429	ENSG00000274973.1	RP13-401N8.7	4	7.31e-05	0.00596	0.2	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25845497~25845862:+
THCA	cis	rs10489167	1	rs9438945	ENSG00000237899.1	RP4-739H11.3	-4	7.31e-05	0.00596	-0.33	-0.18	Depressive and manic episodes in bipolar disorder;	chr1:40673912	chr1:40669089~40687588:-
THCA	cis	rs7927592	1	rs7927592	ENSG00000160172.9	FAM86C2P	4	7.31e-05	0.00596	0.18	0.18	Total body bone mineral density;	chr11:68602492	chr11:67791648~67805336:-
THCA	cis	rs4759375	1	rs3088303	ENSG00000256092.2	RP13-942N8.1	-4	7.31e-05	0.00596	-0.2	-0.18	HDL cholesterol;	chr12:123294942	chr12:123363868~123366113:+
THCA	cis	rs4759375	0.51	rs12367421	ENSG00000256092.2	RP13-942N8.1	-4	7.31e-05	0.00596	-0.2	-0.18	HDL cholesterol;	chr12:123299144	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs12317452	ENSG00000256092.2	RP13-942N8.1	-4	7.31e-05	0.00596	-0.2	-0.18	HDL cholesterol;	chr12:123303699	chr12:123363868~123366113:+
THCA	cis	rs1035144	0.679	rs4903958	ENSG00000259167.2	NMNAT1P1	-4	7.31e-05	0.00596	-0.23	-0.18	Male sexual orientation;	chr14:80982258	chr14:81032529~81033404:+
THCA	cis	rs6479891	0.908	rs2616631	ENSG00000272767.1	JMJD1C-AS1	4	7.31e-05	0.00596	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs2466128	ENSG00000272767.1	JMJD1C-AS1	4	7.31e-05	0.00596	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs2719815	ENSG00000272767.1	JMJD1C-AS1	4	7.31e-05	0.00596	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs2616630	ENSG00000272767.1	JMJD1C-AS1	4	7.31e-05	0.00596	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs2616629	ENSG00000272767.1	JMJD1C-AS1	4	7.31e-05	0.00596	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63465229~63466563:+
THCA	cis	rs2028299	0.879	rs4932263	ENSG00000259677.1	RP11-493E3.1	4	7.31e-05	0.00596	0.24	0.18	Type 2 diabetes;	chr15:89896395	chr15:89876540~89877285:+
THCA	cis	rs7904321	0.809	rs6479869	ENSG00000232075.1	MRPL35P2	-4	7.31e-05	0.00596	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63076537	chr10:63634317~63634827:-
THCA	cis	rs7904321	0.869	rs6479870	ENSG00000232075.1	MRPL35P2	-4	7.31e-05	0.00596	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63076540	chr10:63634317~63634827:-
THCA	cis	rs11247915	0.583	rs34058882	ENSG00000236782.4	RP11-96L14.7	-4	7.32e-05	0.00596	-0.22	-0.18	Obesity-related traits;	chr1:26333303	chr1:26169947~26171821:-
THCA	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
THCA	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
THCA	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-4	7.32e-05	0.00596	-0.21	-0.18	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
THCA	cis	rs8062405	1	rs3888190	ENSG00000270424.1	RP11-1348G14.6	4	7.32e-05	0.00596	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28749959~28750595:-
THCA	cis	rs17801127	0.901	rs6727151	ENSG00000231969.1	AC144449.1	4	7.32e-05	0.00596	0.31	0.18	Liver enzyme levels (alanine transaminase);	chr2:149697470	chr2:149587196~149848233:+
THCA	cis	rs7474896	0.515	rs2505233	ENSG00000263064.2	RP11-291L22.7	4	7.32e-05	0.00596	0.25	0.18	Obesity (extreme);	chr10:38051337	chr10:38448689~38448949:+
THCA	cis	rs1923243	0.778	rs4366276	ENSG00000223479.3	RP4-788P17.1	-4	7.32e-05	0.00596	-0.2	-0.18	Migraine;	chr1:73141909	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.778	rs4634854	ENSG00000223479.3	RP4-788P17.1	-4	7.32e-05	0.00596	-0.2	-0.18	Migraine;	chr1:73142283	chr1:73635216~73715214:+
THCA	cis	rs453301	0.624	rs2288671	ENSG00000233609.3	RP11-62H7.2	4	7.32e-05	0.00596	0.17	0.18	Joint mobility (Beighton score);	chr8:9003384	chr8:8961200~8979025:+
THCA	cis	rs801193	1	rs4717310	ENSG00000229180.5	GS1-124K5.11	4	7.32e-05	0.00596	0.12	0.18	Aortic root size;	chr7:66696020	chr7:66526088~66542624:-
THCA	cis	rs6671200	0.831	rs12753865	ENSG00000235501.4	RP4-639F20.1	-4	7.32e-05	0.00596	-0.38	-0.18	Stearic acid (18:0) levels;	chr1:95130397	chr1:94927566~94963270:+
THCA	cis	rs11220082	0.602	rs10893383	ENSG00000254671.2	STT3A-AS1	-4	7.32e-05	0.00596	-0.21	-0.18	Schizophrenia;	chr11:125466237	chr11:125570284~125592568:-
THCA	cis	rs6012564	0.614	rs6019508	ENSG00000227431.4	CSE1L-AS1	-4	7.32e-05	0.00596	-0.21	-0.18	Anger;	chr20:48905546	chr20:49040463~49046044:-
THCA	cis	rs7170668	0.597	rs17491052	ENSG00000259134.4	LINC00924	4	7.32e-05	0.00596	0.24	0.18	Motion sickness;	chr15:95456500	chr15:95433095~95507847:+
THCA	cis	rs293748	0.882	rs158794	ENSG00000250155.1	CTD-2353F22.1	-4	7.32e-05	0.00596	-0.25	-0.18	Obesity-related traits;	chr5:36882986	chr5:36666214~36725195:-
THCA	cis	rs1124769	0.57	rs1903588	ENSG00000273674.3	CTD-2378E12.1	-4	7.32e-05	0.00596	-0.24	-0.18	Cognitive performance;	chr15:50851849	chr15:50839875~50908599:-
THCA	cis	rs5760842	1	rs5760842	ENSG00000236641.1	CTA-221G9.7	-4	7.32e-05	0.00596	-0.2	-0.18	Recurrent major depressive disorder;	chr22:25087024	chr22:25212742~25213685:+
THCA	cis	rs5758511	0.633	rs5751258	ENSG00000230107.1	CTA-126B4.7	-4	7.32e-05	0.00597	-0.22	-0.18	Birth weight;	chr22:42267865	chr22:42438023~42446195:+
THCA	cis	rs4443100	0.77	rs876101	ENSG00000230701.2	FBXW4P1	4	7.32e-05	0.00597	0.21	0.18	Serum parathyroid hormone levels;	chr22:23022202	chr22:23262767~23265005:+
THCA	cis	rs7819412	1	rs2409722	ENSG00000255046.1	RP11-297N6.4	4	7.33e-05	0.00597	0.19	0.18	Triglycerides;	chr8:11182307	chr8:11797928~11802568:-
THCA	cis	rs17095355	0.901	rs17126938	ENSG00000203876.8	ADD3-AS1	-4	7.33e-05	0.00597	-0.21	-0.18	Biliary atresia;	chr10:110001593	chr10:109940104~110008381:-
THCA	cis	rs874628	0.686	rs11666906	ENSG00000268650.3	AC068499.10	4	7.33e-05	0.00597	0.21	0.18	Multiple sclerosis;	chr19:18131088	chr19:18204730~18220480:+
THCA	cis	rs9650657	0.504	rs10108347	ENSG00000255046.1	RP11-297N6.4	4	7.33e-05	0.00597	0.19	0.18	Neuroticism;	chr8:11176008	chr8:11797928~11802568:-
THCA	cis	rs987724	0.929	rs2321455	ENSG00000240875.4	LINC00886	-4	7.33e-05	0.00597	-0.15	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156975806	chr3:156747346~156817062:-
THCA	cis	rs7127129	0.777	rs7932334	ENSG00000246889.2	AP000487.5	-4	7.33e-05	0.00597	-0.19	-0.18	Aortic root size;	chr11:70160920	chr11:70372246~70398488:-
THCA	cis	rs5751614	1	rs2267018	ENSG00000240160.3	RN7SL263P	4	7.33e-05	0.00597	0.2	0.18	Height;	chr22:23246006	chr22:23261782~23262071:-
THCA	cis	rs9990333	0.87	rs58758084	ENSG00000207650.1	MIR570	-4	7.34e-05	0.00597	-0.19	-0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196086110	chr3:195699401~195699497:+
THCA	cis	rs2039553	0.716	rs2262460	ENSG00000227354.5	RBM26-AS1	4	7.34e-05	0.00597	0.17	0.18	Pancreatic cancer;	chr13:79736661	chr13:79406309~79424328:+
THCA	cis	rs7737355	0.947	rs28720007	ENSG00000237714.1	P4HA2-AS1	4	7.34e-05	0.00597	0.26	0.18	Life satisfaction;	chr5:131742016	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs2108869	ENSG00000237714.1	P4HA2-AS1	4	7.34e-05	0.00597	0.26	0.18	Life satisfaction;	chr5:131751187	chr5:132184876~132192808:+
THCA	cis	rs10435719	0.867	rs34465618	ENSG00000206014.6	OR7E161P	-4	7.34e-05	0.00597	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.867	rs34583868	ENSG00000206014.6	OR7E161P	-4	7.34e-05	0.00597	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:11928597~11929563:-
THCA	cis	rs801193	0.613	rs2659900	ENSG00000230189.5	GS1-124K5.2	4	7.34e-05	0.00598	0.12	0.18	Aortic root size;	chr7:66719456	chr7:66409143~66490059:-
THCA	cis	rs7088591	0.867	rs58716440	ENSG00000276818.1	AC026393.1	4	7.34e-05	0.00598	0.39	0.18	Blood pressure;	chr10:58005342	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs60284769	ENSG00000276818.1	AC026393.1	4	7.34e-05	0.00598	0.39	0.18	Blood pressure;	chr10:58005811	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs76171723	ENSG00000276818.1	AC026393.1	4	7.34e-05	0.00598	0.39	0.18	Blood pressure;	chr10:58006945	chr10:57095699~57095781:+
THCA	cis	rs6449502	1	rs4700392	ENSG00000251279.1	CTC-436P18.1	-4	7.34e-05	0.00598	-0.29	-0.18	Mean platelet volume;	chr5:60798439	chr5:61162070~61232040:+
THCA	cis	rs13178541	0.641	rs10062107	ENSG00000250378.1	RP11-119J18.1	-4	7.34e-05	0.00598	-0.21	-0.18	IgG glycosylation;	chr5:135804913	chr5:135812667~135826582:+
THCA	cis	rs7737355	0.947	rs6596029	ENSG00000237714.1	P4HA2-AS1	4	7.34e-05	0.00598	0.26	0.18	Life satisfaction;	chr5:131563386	chr5:132184876~132192808:+
THCA	cis	rs7577696	0.695	rs10172468	ENSG00000276334.1	AL133243.1	4	7.34e-05	0.00598	0.2	0.18	Inflammatory biomarkers;	chr2:32207128	chr2:32521927~32523547:+
THCA	cis	rs2721195	0.967	rs10108150	ENSG00000265393.1	CTD-2517M22.17	4	7.34e-05	0.00598	0.23	0.18	Age at first birth;	chr8:144462092	chr8:144512567~144513672:+
THCA	cis	rs1520333	0.54	rs7817497	ENSG00000254352.1	RP11-578O24.2	-4	7.34e-05	0.00598	-0.21	-0.18	Multiple sclerosis;	chr8:78479436	chr8:78723796~78724136:-
THCA	cis	rs4578769	0.531	rs12969559	ENSG00000273232.1	RP11-370A5.2	4	7.34e-05	0.00598	0.25	0.18	Eosinophil percentage of white cells;	chr18:22913702	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs12326874	ENSG00000273232.1	RP11-370A5.2	4	7.34e-05	0.00598	0.25	0.18	Eosinophil percentage of white cells;	chr18:22926670	chr18:22882825~22883357:-
THCA	cis	rs591584	0.73	rs72963868	ENSG00000255893.1	RP11-685N10.1	-4	7.34e-05	0.00598	-0.21	-0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94584543	chr11:94472908~94473570:-
THCA	cis	rs4666002	0.956	rs3749147	ENSG00000234072.1	AC074117.10	4	7.35e-05	0.00598	0.15	0.18	Phospholipid levels (plasma);	chr2:27629051	chr2:27356246~27367622:+
THCA	cis	rs7899106	0.803	rs17399739	ENSG00000270002.1	RP11-93H12.4	4	7.35e-05	0.00598	0.31	0.18	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85731093	chr10:85644073~85648066:+
THCA	cis	rs17286411	0.639	rs12444484	ENSG00000260185.1	RP11-432I5.6	-4	7.35e-05	0.00598	-0.25	-0.18	Blood protein levels;	chr16:71627633	chr16:71655027~71664212:+
THCA	cis	rs7924176	0.521	rs11000986	ENSG00000232342.6	RP11-46O21.2	4	7.35e-05	0.00598	0.23	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.521	rs10824147	ENSG00000232342.6	RP11-46O21.2	4	7.35e-05	0.00598	0.23	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.521	rs12359775	ENSG00000232342.6	RP11-46O21.2	4	7.35e-05	0.00598	0.23	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.521	rs11516630	ENSG00000232342.6	RP11-46O21.2	4	7.35e-05	0.00598	0.23	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:74506081~74530553:-
THCA	cis	rs2340727	0.66	rs6427642	ENSG00000229808.1	RP11-456P18.2	-4	7.35e-05	0.00598	-0.25	-0.18	White blood cell count;Hematology traits;	chr1:161974963	chr1:161890833~161892196:+
THCA	cis	rs202072	1	rs202072	ENSG00000272379.1	RP1-257A7.5	-4	7.35e-05	0.00598	-0.27	-0.18	HIV-1 viral setpoint;	chr6:13267979	chr6:13290018~13290490:-
THCA	cis	rs875971	0.862	rs1860469	ENSG00000229886.1	RP5-1132H15.3	-4	7.35e-05	0.00598	-0.19	-0.18	Aortic root size;	chr7:66641888	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs4718383	ENSG00000229886.1	RP5-1132H15.3	-4	7.35e-05	0.00598	-0.19	-0.18	Aortic root size;	chr7:66643422	chr7:66025126~66031544:-
THCA	cis	rs253959	0.739	rs153613	ENSG00000250015.1	CTC-339F2.2	-4	7.35e-05	0.00598	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr5:116297777	chr5:116302354~116304134:-
THCA	cis	rs8046148	1	rs4785381	ENSG00000279356.1	RP11-429P3.8	4	7.35e-05	0.00599	0.25	0.18	Testicular germ cell tumor;	chr16:50099878	chr16:50072862~50074986:+
THCA	cis	rs10256972	0.616	rs6957733	ENSG00000225146.1	AC073957.15	4	7.35e-05	0.00599	0.19	0.18	Endometriosis;Longevity;	chr7:1066691	chr7:1029025~1043891:+
THCA	cis	rs2904524	1	rs12300190	ENSG00000257815.4	RP11-611E13.2	4	7.35e-05	0.00599	0.17	0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70359240	chr12:69904033~70243360:-
THCA	cis	rs1232027	0.616	rs26267	ENSG00000249655.1	CTC-325J23.2	-4	7.35e-05	0.00599	-0.21	-0.18	Huntington's disease progression;	chr5:80744855	chr5:80630313~80631590:-
THCA	cis	rs1232027	0.656	rs32959	ENSG00000249655.1	CTC-325J23.2	-4	7.35e-05	0.00599	-0.21	-0.18	Huntington's disease progression;	chr5:80746236	chr5:80630313~80631590:-
THCA	cis	rs253959	0.672	rs4920903	ENSG00000271918.1	CTD-2287O16.5	4	7.35e-05	0.00599	0.12	0.18	Bipolar disorder and schizophrenia;	chr5:116085892	chr5:116083807~116085416:-
THCA	cis	rs10860794	0.627	rs11111065	ENSG00000274560.1	RP11-285E23.2	-4	7.35e-05	0.00599	-0.13	-0.18	Blood protein levels;	chr12:101862272	chr12:101696002~101696450:-
THCA	cis	rs11992162	0.967	rs4840601	ENSG00000270154.1	RP11-419I17.1	4	7.35e-05	0.00599	0.23	0.18	Monocyte count;	chr8:11971221	chr8:12476462~12477122:+
THCA	cis	rs9302690	1	rs16957051	ENSG00000205361.7	MT1DP	4	7.36e-05	0.00599	0.33	0.18	Blood protein levels;	chr16:57434496	chr16:56643705~56644786:+
THCA	cis	rs6902257	0.744	rs2496681	ENSG00000272129.1	RP11-250B2.6	-4	7.36e-05	0.00599	-0.45	-0.18	Obesity-related traits;	chr6:80618260	chr6:80355424~80356859:+
THCA	cis	rs1504749	0.569	rs10958404	ENSG00000254142.2	RP11-53M11.3	-4	7.36e-05	0.00599	-0.28	-0.18	Intracranial aneurysm;	chr8:54394213	chr8:54554361~54561927:+
THCA	cis	rs2692947	0.537	rs2320170	ENSG00000235584.2	AC008268.1	4	7.36e-05	0.00599	0.18	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95574025	chr2:95666084~95668715:+
THCA	cis	rs1005277	0.505	rs200935	ENSG00000275858.1	RP11-291L22.8	4	7.36e-05	0.00599	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38450738~38451069:-
THCA	cis	rs736408	0.561	rs2276815	ENSG00000243224.1	RP5-1157M23.2	-4	7.36e-05	0.00599	-0.21	-0.18	Bipolar disorder;	chr3:52819731	chr3:52239258~52241097:+
THCA	cis	rs763121	0.853	rs138709	ENSG00000228274.3	RP3-508I15.9	-4	7.36e-05	0.00599	-0.21	-0.18	Menopause (age at onset);	chr22:38743211	chr22:38667585~38681820:-
THCA	cis	rs5758511	0.68	rs56111723	ENSG00000230107.1	CTA-126B4.7	-4	7.36e-05	0.00599	-0.22	-0.18	Birth weight;	chr22:42268877	chr22:42438023~42446195:+
THCA	cis	rs9291683	0.679	rs2241483	ENSG00000261490.1	RP11-448G15.3	-4	7.36e-05	0.00599	-0.11	-0.18	Bone mineral density;	chr4:10098207	chr4:10068089~10073019:-
THCA	cis	rs7119	0.637	rs2667775	ENSG00000259362.2	RP11-307C19.1	4	7.36e-05	0.00599	0.25	0.18	Type 2 diabetes;	chr15:77572460	chr15:77525540~77534110:+
THCA	cis	rs62158800	0.85	rs56721931	ENSG00000224568.1	AC096669.3	4	7.36e-05	0.00599	0.34	0.18	Facial morphology (factor 22);	chr2:107614359	chr2:107529487~107556326:+
THCA	cis	rs8177876	0.749	rs11865207	ENSG00000261061.1	RP11-303E16.2	-4	7.36e-05	0.00599	-0.23	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr16:81030770~81031485:+
THCA	cis	rs6940638	0.688	rs9393790	ENSG00000219392.1	RP1-265C24.5	4	7.36e-05	0.00599	0.21	0.18	Intelligence (multi-trait analysis);	chr6:27146273	chr6:28115628~28116551:+
THCA	cis	rs10435719	0.744	rs11250175	ENSG00000254948.1	OR7E158P	-4	7.36e-05	0.00599	-0.23	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.516	rs13252853	ENSG00000254948.1	OR7E158P	-4	7.36e-05	0.00599	-0.23	-0.18	Neuroticism;	chr8:11935465	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.516	rs13252854	ENSG00000254948.1	OR7E158P	-4	7.36e-05	0.00599	-0.23	-0.18	Neuroticism;	chr8:11935469	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.516	rs13279577	ENSG00000254948.1	OR7E158P	-4	7.36e-05	0.00599	-0.23	-0.18	Neuroticism;	chr8:11935587	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.516	rs10112958	ENSG00000254948.1	OR7E158P	-4	7.36e-05	0.00599	-0.23	-0.18	Neuroticism;	chr8:11935631	chr8:11919900~11920809:-
THCA	cis	rs4878712	0.715	rs2381718	ENSG00000230188.1	RP11-405L18.4	-4	7.36e-05	0.00599	-0.23	-0.18	HIV-1 susceptibility;	chr9:37648370	chr9:37490421~37490893:-
THCA	cis	rs740160	0.558	rs12538893	ENSG00000244219.5	GS1-259H13.2	-4	7.36e-05	0.00599	-0.28	-0.18	Dehydroepiandrosterone sulphate levels;	chr7:99310874	chr7:99598066~99610813:+
THCA	cis	rs4272720	0.535	rs12261297	ENSG00000234736.4	FAM170B-AS1	-4	7.36e-05	0.00599	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49085213	chr10:49121839~49151547:+
THCA	cis	rs17074492	0.671	rs17074524	ENSG00000214182.5	PTMAP5	4	7.36e-05	0.00599	0.23	0.18	Sjögren's syndrome;	chr13:81612739	chr13:81689911~81691072:+
THCA	cis	rs17074492	0.671	rs2329199	ENSG00000214182.5	PTMAP5	4	7.36e-05	0.00599	0.23	0.18	Sjögren's syndrome;	chr13:81615512	chr13:81689911~81691072:+
THCA	cis	rs741677	1	rs9911960	ENSG00000231784.7	DBIL5P	4	7.36e-05	0.00599	0.2	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:563358	chr17:752660~755336:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000229180.5	GS1-124K5.11	4	7.36e-05	0.00599	0.13	0.18	Aortic root size;	chr7:65827018	chr7:66526088~66542624:-
THCA	cis	rs7940646	0.906	rs4442541	ENSG00000254554.1	RP11-351I24.1	4	7.36e-05	0.00599	0.22	0.18	Platelet aggregation;	chr11:10647625	chr11:10302657~10303704:-
THCA	cis	rs853679	0.546	rs13214023	ENSG00000220721.1	OR1F12	-4	7.36e-05	0.00599	-0.36	-0.18	Depression;	chr6:28364364	chr6:28073316~28074233:+
THCA	cis	rs17092148	1	rs2425003	ENSG00000276073.1	RP5-1125A11.7	4	7.37e-05	0.00599	0.21	0.18	Neuroticism;	chr20:34815781	chr20:33985617~33988989:-
THCA	cis	rs10833905	1	rs10833906	ENSG00000246225.5	RP11-17A1.3	4	7.37e-05	0.006	0.25	0.18	Sudden cardiac arrest;	chr11:23023828	chr11:22829380~22945393:+
THCA	cis	rs459482	0.501	rs148214	ENSG00000228318.3	AP001610.5	4	7.37e-05	0.006	0.22	0.18	IgG glycosylation;	chr21:41442291	chr21:41441056~41445708:-
THCA	cis	rs1501911	0.53	rs162611	ENSG00000241597.2	CTD-2007H13.1	4	7.37e-05	0.006	0.24	0.18	Lung function (FEV1/FVC);	chr5:98809801	chr5:98954394~98954972:+
THCA	cis	rs1383484	0.798	rs28728297	ENSG00000225151.9	GOLGA2P7	4	7.37e-05	0.006	0.25	0.18	Height;	chr15:83877660	chr15:84199311~84230136:-
THCA	cis	rs1383484	0.798	rs28578450	ENSG00000225151.9	GOLGA2P7	4	7.37e-05	0.006	0.25	0.18	Height;	chr15:83877661	chr15:84199311~84230136:-
THCA	cis	rs150992	0.751	rs172874	ENSG00000246763.5	RGMB-AS1	4	7.37e-05	0.006	0.19	0.18	Body mass index;	chr5:98969402	chr5:98769618~98773469:-
THCA	cis	rs7560272	0.501	rs17350188	ENSG00000163016.8	ALMS1P	4	7.37e-05	0.006	0.22	0.18	Schizophrenia;	chr2:73737715	chr2:73644919~73685576:+
THCA	cis	rs6517329	0.513	rs2284622	ENSG00000236830.5	CBR3-AS1	4	7.37e-05	0.006	0.17	0.18	Schizophrenia;	chr21:36172082	chr21:36131767~36175815:-
THCA	cis	rs6517329	0.513	rs9680108	ENSG00000236830.5	CBR3-AS1	4	7.37e-05	0.006	0.17	0.18	Schizophrenia;	chr21:36172604	chr21:36131767~36175815:-
THCA	cis	rs6517329	0.513	rs8131593	ENSG00000236830.5	CBR3-AS1	4	7.37e-05	0.006	0.17	0.18	Schizophrenia;	chr21:36173290	chr21:36131767~36175815:-
THCA	cis	rs7927592	0.956	rs7124078	ENSG00000160172.9	FAM86C2P	4	7.37e-05	0.006	0.18	0.18	Total body bone mineral density;	chr11:68531165	chr11:67791648~67805336:-
THCA	cis	rs9926296	0.568	rs886950	ENSG00000274627.1	RP11-104N10.2	-4	7.37e-05	0.006	-0.18	-0.18	Vitiligo;	chr16:89770464	chr16:89516797~89522217:+
THCA	cis	rs664172	1	rs664172	ENSG00000261143.1	ADAMTS7P3	-4	7.37e-05	0.006	-0.25	-0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78570420	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.748	rs667282	ENSG00000261143.1	ADAMTS7P3	-4	7.37e-05	0.006	-0.25	-0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78571130	chr15:77976042~77993057:+
THCA	cis	rs655720	1	rs655720	ENSG00000239213.4	NCK1-AS1	4	7.37e-05	0.006	0.17	0.18	Coronary artery disease;	chr3:136384425	chr3:136841726~136862054:-
THCA	cis	rs2692947	0.526	rs4907225	ENSG00000235584.2	AC008268.1	-4	7.37e-05	0.006	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95910922	chr2:95666084~95668715:+
THCA	cis	rs1538970	0.924	rs7531253	ENSG00000234329.1	RP11-767N6.2	4	7.37e-05	0.006	0.18	0.18	Platelet count;	chr1:45424511	chr1:45651039~45651826:-
THCA	cis	rs1538970	0.924	rs11211108	ENSG00000234329.1	RP11-767N6.2	4	7.37e-05	0.006	0.18	0.18	Platelet count;	chr1:45425480	chr1:45651039~45651826:-
THCA	cis	rs2290416	0.892	rs76225457	ENSG00000253931.1	RP11-909N17.2	4	7.37e-05	0.006	0.36	0.18	Attention deficit hyperactivity disorder;	chr8:143583882	chr8:143412749~143417054:+
THCA	cis	rs62158800	0.598	rs12329017	ENSG00000237880.1	AC096669.2	4	7.37e-05	0.006	0.19	0.18	Facial morphology (factor 22);	chr2:107668402	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.526	rs13408969	ENSG00000237880.1	AC096669.2	4	7.37e-05	0.006	0.19	0.18	Facial morphology (factor 22);	chr2:107669138	chr2:107385632~107542649:-
THCA	cis	rs6061231	0.761	rs2427312	ENSG00000275437.1	RP5-908M14.10	4	7.37e-05	0.006	0.2	0.18	Colorectal cancer;	chr20:62395535	chr20:62402236~62405935:-
THCA	cis	rs9902453	0.934	rs4427857	ENSG00000263370.1	RP11-68I3.5	4	7.38e-05	0.006	0.23	0.18	Coffee consumption (cups per day);	chr17:30130971	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.868	rs9896012	ENSG00000263370.1	RP11-68I3.5	4	7.38e-05	0.006	0.23	0.18	Coffee consumption (cups per day);	chr17:30143073	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.868	rs9890075	ENSG00000263370.1	RP11-68I3.5	4	7.38e-05	0.006	0.23	0.18	Coffee consumption (cups per day);	chr17:30143446	chr17:29639627~29640825:+
THCA	cis	rs7737355	0.947	rs251014	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Life satisfaction;	chr5:131693770	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.853	rs593767	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Life satisfaction;	chr5:131707967	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs2191001	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Life satisfaction;	chr5:131760984	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.898	rs1016068	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Life satisfaction;	chr5:131764553	chr5:132184876~132192808:+
THCA	cis	rs758324	1	rs758324	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131773852	chr5:132184876~132192808:+
THCA	cis	rs758324	0.898	rs6877358	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131775667	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs10478989	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131780362	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs4705835	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131781206	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs7725924	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131782472	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs9327622	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131789387	chr5:132184876~132192808:+
THCA	cis	rs758324	0.898	rs11956351	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131801531	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs1500114	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131802427	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs4705900	ENSG00000237714.1	P4HA2-AS1	4	7.38e-05	0.006	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131804548	chr5:132184876~132192808:+
THCA	cis	rs9926296	0.533	rs12102290	ENSG00000274627.1	RP11-104N10.2	-4	7.38e-05	0.006	-0.19	-0.18	Vitiligo;	chr16:89746209	chr16:89516797~89522217:+
THCA	cis	rs9926296	0.533	rs12102297	ENSG00000274627.1	RP11-104N10.2	-4	7.38e-05	0.006	-0.19	-0.18	Vitiligo;	chr16:89746354	chr16:89516797~89522217:+
THCA	cis	rs8115854	0.845	rs62206539	ENSG00000269846.1	RP4-621N11.2	-4	7.38e-05	0.006	-0.24	-0.18	Hippocampal atrophy;	chr20:37175379	chr20:37095785~37097178:+
THCA	cis	rs479105	0.603	rs3782780	ENSG00000278356.1	RP11-372B4.3	4	7.38e-05	0.006	0.18	0.18	Gut microbiota (bacterial taxa);	chr12:3257469	chr12:2885819~2886329:+
THCA	cis	rs1908814	0.516	rs4841641	ENSG00000206014.6	OR7E161P	-4	7.38e-05	0.006	-0.22	-0.18	Neuroticism;	chr8:11940718	chr8:11928597~11929563:-
THCA	cis	rs12681366	0.683	rs56285115	ENSG00000261437.1	RP11-22C11.2	4	7.38e-05	0.006	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94389244	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.734	rs16916796	ENSG00000261437.1	RP11-22C11.2	4	7.38e-05	0.006	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94390001	chr8:94637285~94639467:-
THCA	cis	rs7474896	0.832	rs12570108	ENSG00000263064.2	RP11-291L22.7	4	7.38e-05	0.006	0.31	0.18	Obesity (extreme);	chr10:37667075	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.832	rs11011318	ENSG00000263064.2	RP11-291L22.7	4	7.38e-05	0.006	0.31	0.18	Obesity (extreme);	chr10:37667628	chr10:38448689~38448949:+
THCA	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	4	7.38e-05	0.006	0.21	0.18	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
THCA	cis	rs12546962	0.626	rs17149797	ENSG00000254153.1	CTA-398F10.2	4	7.38e-05	0.006	0.22	0.18	Body mass index;	chr8:9332461	chr8:8456909~8461337:-
THCA	cis	rs12900463	0.813	rs186266	ENSG00000259728.4	LINC00933	4	7.38e-05	0.00601	0.24	0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:84570649~84580175:+
THCA	cis	rs722599	0.847	rs2058919	ENSG00000279594.1	RP11-950C14.10	-4	7.38e-05	0.00601	-0.18	-0.18	IgG glycosylation;	chr14:74844109	chr14:75011269~75012851:-
THCA	cis	rs2732480	0.577	rs2732479	ENSG00000257735.1	RP11-370I10.6	4	7.38e-05	0.00601	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.537	rs1061986	ENSG00000257735.1	RP11-370I10.6	4	7.38e-05	0.00601	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48350945~48442411:+
THCA	cis	rs2276314	0.512	rs17562898	ENSG00000278986.1	RP11-723J4.3	4	7.38e-05	0.00601	0.31	0.18	Endometriosis;Drug-induced torsades de pointes;	chr18:35997212	chr18:35972151~35973916:+
THCA	cis	rs7119038	0.865	rs7951740	ENSG00000255239.1	AP002954.6	4	7.38e-05	0.00601	0.28	0.18	Sjögren's syndrome;	chr11:118869709	chr11:118688039~118690600:-
THCA	cis	rs2549003	1	rs2549004	ENSG00000237714.1	P4HA2-AS1	4	7.39e-05	0.00601	0.23	0.18	Asthma (sex interaction);	chr5:132492133	chr5:132184876~132192808:+
THCA	cis	rs150992	0.678	rs327793	ENSG00000241597.2	CTD-2007H13.1	-4	7.39e-05	0.00601	-0.23	-0.18	Body mass index;	chr5:98913717	chr5:98954394~98954972:+
THCA	cis	rs875971	0.658	rs432667	ENSG00000272831.1	RP11-792A8.4	4	7.39e-05	0.00601	0.12	0.18	Aortic root size;	chr7:66049646	chr7:66739829~66740385:-
THCA	cis	rs6772849	0.768	rs4521246	ENSG00000242551.2	POU5F1P6	4	7.39e-05	0.00601	0.25	0.18	Monocyte percentage of white cells;Monocyte count;	chr3:128702323	chr3:128674735~128677005:-
THCA	cis	rs6995541	0.647	rs7000939	ENSG00000248896.2	CTD-2135J3.3	-4	7.39e-05	0.00601	-0.22	-0.18	Triglyceride levels;	chr8:10831364	chr8:10729314~10771392:+
THCA	cis	rs3015497	0.789	rs8003372	ENSG00000270062.1	RP11-248J18.3	4	7.39e-05	0.00601	0.2	0.18	Mean platelet volume;	chr14:50635633	chr14:50723777~50724272:-
THCA	cis	rs7914558	0.966	rs10748836	ENSG00000213061.2	PFN1P11	4	7.39e-05	0.00601	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102934160	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs10786727	ENSG00000213061.2	PFN1P11	4	7.39e-05	0.00601	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102938766	chr10:102838011~102845473:-
THCA	cis	rs10802047	0.596	rs2659211	ENSG00000231365.4	RP11-418J17.1	-4	7.39e-05	0.00602	-0.18	-0.18	Relative hand skill in reading disability;	chr1:118625086	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.632	rs2659212	ENSG00000231365.4	RP11-418J17.1	-4	7.39e-05	0.00602	-0.18	-0.18	Relative hand skill in reading disability;	chr1:118625106	chr1:119140396~119275973:+
THCA	cis	rs6715284	0.786	rs61695176	ENSG00000183308.6	AC005037.3	4	7.39e-05	0.00602	0.45	0.18	Rheumatoid arthritis;	chr2:201468592	chr2:200963263~201009102:+
THCA	cis	rs6715284	0.786	rs73988793	ENSG00000183308.6	AC005037.3	4	7.39e-05	0.00602	0.45	0.18	Rheumatoid arthritis;	chr2:201473570	chr2:200963263~201009102:+
THCA	cis	rs10090774	0.965	rs4961300	ENSG00000279766.1	RP11-642A1.2	4	7.39e-05	0.00602	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140900768	chr8:140572142~140572812:-
THCA	cis	rs12493885	0.654	rs11925207	ENSG00000243069.6	ARHGEF26-AS1	-4	7.39e-05	0.00602	-0.34	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:153982097	chr3:154024401~154121332:-
THCA	cis	rs911555	0.662	rs4906322	ENSG00000269958.1	RP11-73M18.8	-4	7.39e-05	0.00602	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103696353~103697163:+
THCA	cis	rs4915077	0.892	rs41486546	ENSG00000226822.1	RP11-356N1.2	4	7.4e-05	0.00602	0.33	0.18	Hypothyroidism;	chr1:107756357	chr1:108071482~108074519:+
THCA	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	4	7.4e-05	0.00602	0.21	0.18	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
THCA	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	4	7.4e-05	0.00602	0.21	0.18	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	4	7.4e-05	0.00602	0.21	0.18	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	4	7.4e-05	0.00602	0.21	0.18	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	4	7.4e-05	0.00602	0.21	0.18	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	4	7.4e-05	0.00602	0.21	0.18	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
THCA	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	4	7.4e-05	0.00602	0.11	0.18	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
THCA	cis	rs1923243	0.71	rs4571921	ENSG00000223479.3	RP4-788P17.1	-4	7.4e-05	0.00602	-0.2	-0.18	Migraine;	chr1:73147743	chr1:73635216~73715214:+
THCA	cis	rs2072883	0.669	rs5759111	ENSG00000230319.1	AL022476.2	-4	7.4e-05	0.00602	-0.2	-0.18	Schizophrenia;	chr22:43046593	chr22:43038585~43052366:+
THCA	cis	rs4972539	0.547	rs2289396	ENSG00000238133.5	MLK7-AS1	4	7.4e-05	0.00602	0.24	0.18	Parental longevity (mother's age at death);	chr2:173209679	chr2:173166446~173282036:-
THCA	cis	rs67478160	0.619	rs12897150	ENSG00000269940.1	RP11-73M18.7	4	7.4e-05	0.00602	0.17	0.18	Schizophrenia;	chr14:103853193	chr14:103694560~103695170:+
THCA	cis	rs9595908	0.785	rs60088097	ENSG00000212293.1	SNORA16	4	7.4e-05	0.00602	0.21	0.18	Body mass index;	chr13:32678043	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs7328827	ENSG00000212293.1	SNORA16	4	7.4e-05	0.00602	0.21	0.18	Body mass index;	chr13:32686650	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs3858846	ENSG00000212293.1	SNORA16	4	7.4e-05	0.00602	0.21	0.18	Body mass index;	chr13:32687408	chr13:32420390~32420516:-
THCA	cis	rs4792901	0.879	rs939357	ENSG00000267151.3	RP11-100E5.2	4	7.4e-05	0.00602	0.19	0.18	Dupuytren's disease;	chr17:43572644	chr17:43444707~43451200:+
THCA	cis	rs17221829	0.703	rs75183199	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89623819	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.769	rs11018674	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89623945	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs12283497	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89624739	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.644	rs72971008	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89625538	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs72971009	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89625672	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs72971011	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89625690	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs12365125	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89626761	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.703	rs4237550	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89627417	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs4753223	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89627485	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs10830299	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89629502	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs11018681	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89631275	chr11:90193614~90198120:+
THCA	cis	rs4072705	0.605	rs10986358	ENSG00000224020.1	MIR181A2HG	-4	7.4e-05	0.00602	-0.19	-0.18	Menarche (age at onset);	chr9:124531906	chr9:124658467~124698631:+
THCA	cis	rs2904524	0.541	rs10784839	ENSG00000257815.4	RP11-611E13.2	-4	7.4e-05	0.00602	-0.14	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70380985	chr12:69904033~70243360:-
THCA	cis	rs17221829	0.733	rs12281810	ENSG00000280385.1	AP000648.5	-4	7.4e-05	0.00602	-0.17	-0.18	Anxiety in major depressive disorder;	chr11:89676427	chr11:90193614~90198120:+
THCA	cis	rs2980439	0.556	rs2921059	ENSG00000233609.3	RP11-62H7.2	4	7.4e-05	0.00602	0.18	0.18	Neuroticism;	chr8:8460377	chr8:8961200~8979025:+
THCA	cis	rs2071303	0.836	rs198835	ENSG00000272810.1	U91328.22	4	7.4e-05	0.00602	0.2	0.18	Intelligence (multi-trait analysis);	chr6:26113766	chr6:26013241~26013757:+
THCA	cis	rs11638352	1	rs2412853	ENSG00000166763.7	STRCP1	-4	7.41e-05	0.00602	-0.4	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44003059	chr15:43699488~43718184:-
THCA	cis	rs2980439	0.607	rs2980419	ENSG00000253981.4	ALG1L13P	4	7.41e-05	0.00602	0.17	0.18	Neuroticism;	chr8:8256619	chr8:8236003~8244667:-
THCA	cis	rs55692468	0.54	rs4664586	ENSG00000213197.3	AC012066.1	-4	7.41e-05	0.00602	-0.24	-0.18	Intraocular pressure;	chr2:152467557	chr2:152389937~152390630:+
THCA	cis	rs1204798	0.588	rs15679	ENSG00000237021.2	RP3-486I3.7	-4	7.41e-05	0.00603	-0.22	-0.18	Dental caries;	chr6:116244562	chr6:116254207~116256743:+
THCA	cis	rs9291683	0.595	rs35501905	ENSG00000261490.1	RP11-448G15.3	4	7.41e-05	0.00603	0.11	0.18	Bone mineral density;	chr4:10051807	chr4:10068089~10073019:-
THCA	cis	rs11250098	0.547	rs2409764	ENSG00000227888.4	FAM66A	4	7.41e-05	0.00603	0.22	0.18	Morning vs. evening chronotype;	chr8:11423764	chr8:12362019~12388296:+
THCA	cis	rs12478296	1	rs73007129	ENSG00000261186.2	RP11-341N2.1	-4	7.41e-05	0.00603	-0.31	-0.18	Obesity-related traits;	chr2:242058404	chr2:242087351~242088457:-
THCA	cis	rs738722	0.78	rs2078555	ENSG00000272858.1	CTA-292E10.8	4	7.41e-05	0.00603	0.19	0.18	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28714771	chr22:28814914~28815662:+
THCA	cis	rs10090774	0.862	rs62524109	ENSG00000279766.1	RP11-642A1.2	4	7.41e-05	0.00603	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140797368	chr8:140572142~140572812:-
THCA	cis	rs2033711	0.902	rs4801589	ENSG00000232098.3	CTD-2619J13.14	4	7.41e-05	0.00603	0.16	0.18	Uric acid clearance;	chr19:58442031	chr19:58404238~58408484:-
THCA	cis	rs9876781	0.872	rs11797	ENSG00000244380.1	RP11-24C3.2	4	7.41e-05	0.00603	0.22	0.18	Longevity;	chr3:48467186	chr3:48440352~48446656:-
THCA	cis	rs10276381	0.579	rs11520706	ENSG00000234336.5	JAZF1-AS1	4	7.41e-05	0.00603	0.33	0.18	Crohn's disease;	chr7:28163129	chr7:28180322~28243917:+
THCA	cis	rs77972916	0.611	rs6709988	ENSG00000234936.1	AC010883.5	4	7.41e-05	0.00603	0.21	0.18	Granulocyte percentage of myeloid white cells;	chr2:43374178	chr2:43229573~43233394:+
THCA	cis	rs11671005	0.571	rs56243535	ENSG00000265272.2	RN7SL693P	4	7.41e-05	0.00603	0.25	0.18	Mean platelet volume;	chr19:58494783	chr19:58490797~58491075:+
THCA	cis	rs7707921	0.881	rs73136782	ENSG00000251374.1	RPS23P5	4	7.41e-05	0.00603	0.26	0.18	Breast cancer;	chr5:82147701	chr5:82265157~82265259:-
THCA	cis	rs11756659	0.653	rs185635	ENSG00000272462.2	U91328.19	4	7.41e-05	0.00603	0.17	0.18	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25956881	chr6:25992662~26001775:+
THCA	cis	rs9341808	1	rs1359239	ENSG00000272129.1	RP11-250B2.6	4	7.41e-05	0.00603	0.22	0.18	Sitting height ratio;	chr6:80246429	chr6:80355424~80356859:+
THCA	cis	rs240993	0.595	rs3777911	ENSG00000271789.1	RP5-1112D6.7	4	7.42e-05	0.00603	0.19	0.18	Inflammatory skin disease;Psoriasis;	chr6:111581277	chr6:111297126~111298510:+
THCA	cis	rs13113518	1	rs55699500	ENSG00000272969.1	RP11-528I4.2	4	7.42e-05	0.00603	0.21	0.18	Height;	chr4:55540912	chr4:55547112~55547889:+
THCA	cis	rs6442522	0.678	rs3773451	ENSG00000249786.6	EAF1-AS1	4	7.42e-05	0.00603	0.19	0.18	Uric acid levels;	chr3:15468626	chr3:15436171~15455940:-
THCA	cis	rs17122278	1	rs73022058	ENSG00000243431.1	RPL5P30	4	7.42e-05	0.00603	0.19	0.18	Total cholesterol levels;	chr11:118552957	chr11:118560690~118561580:+
THCA	cis	rs4834770	1	rs4834770	ENSG00000260091.1	RP11-33B1.4	-4	7.42e-05	0.00603	-0.13	-0.18	Blood protein levels;	chr4:119320694	chr4:119409333~119410233:+
THCA	cis	rs3758911	1	rs10789611	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107316810	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs10789612	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107316931	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs10890707	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107317153	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs10890708	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107317315	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.964	rs10890709	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107317378	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.964	rs10890711	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107317424	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.964	rs12290112	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107317487	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.964	rs12270655	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107317507	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.964	rs10890712	ENSG00000255353.1	RP11-382M14.1	-4	7.42e-05	0.00603	-0.22	-0.18	Coronary artery disease;	chr11:107317583	chr11:107176286~107177530:+
THCA	cis	rs2549003	0.933	rs7719499	ENSG00000237714.1	P4HA2-AS1	-4	7.42e-05	0.00603	-0.24	-0.18	Asthma (sex interaction);	chr5:132478399	chr5:132184876~132192808:+
THCA	cis	rs4713118	0.824	rs9468223	ENSG00000220721.1	OR1F12	4	7.42e-05	0.00603	0.24	0.18	Parkinson's disease;	chr6:27772887	chr6:28073316~28074233:+
THCA	cis	rs6442522	0.678	rs13059607	ENSG00000249786.6	EAF1-AS1	4	7.42e-05	0.00604	0.19	0.18	Uric acid levels;	chr3:15465901	chr3:15436171~15455940:-
THCA	cis	rs6442522	0.678	rs3732722	ENSG00000249786.6	EAF1-AS1	4	7.42e-05	0.00604	0.19	0.18	Uric acid levels;	chr3:15466254	chr3:15436171~15455940:-
THCA	cis	rs8099594	0.565	rs1943001	ENSG00000266696.1	RP11-30L3.2	4	7.42e-05	0.00604	0.23	0.18	Height;	chr18:49193057	chr18:49205912~49208781:+
THCA	cis	rs763512	0.532	rs3094499	ENSG00000276054.1	RP11-378E13.3	4	7.42e-05	0.00604	0.28	0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37531234	chr17:37386886~37387926:+
THCA	cis	rs9634489	0.59	rs9556538	ENSG00000247400.3	DNAJC3-AS1	-4	7.42e-05	0.00604	-0.12	-0.18	Body mass index;	chr13:96268166	chr13:95648733~95676925:-
THCA	cis	rs11971779	0.553	rs36002669	ENSG00000252332.1	RNU6-911P	-4	7.42e-05	0.00604	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139428415	chr7:139448740~139448843:+
THCA	cis	rs447735	0.587	rs11640702	ENSG00000274627.1	RP11-104N10.2	-4	7.42e-05	0.00604	-0.19	-0.18	Hemoglobin concentration;	chr16:89662761	chr16:89516797~89522217:+
THCA	cis	rs9595908	0.785	rs9315174	ENSG00000212293.1	SNORA16	4	7.43e-05	0.00604	0.21	0.18	Body mass index;	chr13:32645750	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.758	rs7329120	ENSG00000212293.1	SNORA16	4	7.43e-05	0.00604	0.21	0.18	Body mass index;	chr13:32646605	chr13:32420390~32420516:-
THCA	cis	rs10129255	0.957	rs8009638	ENSG00000211972.2	IGHV3-66	4	7.43e-05	0.00604	0.11	0.18	Kawasaki disease;	chr14:106777570	chr14:106675017~106675544:-
THCA	cis	rs16975963	0.843	rs73041022	ENSG00000226686.6	LINC01535	-4	7.43e-05	0.00604	-0.25	-0.18	Longevity;	chr19:37781754	chr19:37251912~37265535:+
THCA	cis	rs6723108	0.694	rs666614	ENSG00000224043.6	CCNT2-AS1	4	7.43e-05	0.00604	0.19	0.18	Type 2 diabetes;	chr2:134532882	chr2:134735464~134918710:-
THCA	cis	rs34421088	0.56	rs1478898	ENSG00000255046.1	RP11-297N6.4	4	7.43e-05	0.00604	0.19	0.18	Neuroticism;	chr8:11537570	chr8:11797928~11802568:-
THCA	cis	rs3764021	0.933	rs2268146	ENSG00000256594.6	RP11-705C15.2	4	7.43e-05	0.00604	0.14	0.18	Type 1 diabetes;	chr12:9716675	chr12:9633419~9658412:+
THCA	cis	rs4713118	0.525	rs9357042	ENSG00000216915.2	RP1-97D16.1	-4	7.43e-05	0.00604	-0.24	-0.18	Parkinson's disease;	chr6:27615016	chr6:27737000~27738494:-
THCA	cis	rs6546537	0.911	rs4852898	ENSG00000231024.1	AC092431.3	4	7.43e-05	0.00604	0.24	0.18	Serum thyroid-stimulating hormone levels;	chr2:69645665	chr2:69700192~69713847:-
THCA	cis	rs9788682	0.748	rs569207	ENSG00000261143.1	ADAMTS7P3	4	7.43e-05	0.00604	0.25	0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78580777	chr15:77976042~77993057:+
THCA	cis	rs494003	1	rs12287832	ENSG00000214659.4	KRT8P26	4	7.43e-05	0.00604	0.22	0.18	Systemic lupus erythematosus;	chr11:65786021	chr11:65726939~65728214:+
THCA	cis	rs16975963	0.644	rs12459013	ENSG00000276846.1	CTD-3220F14.3	-4	7.43e-05	0.00604	-0.17	-0.18	Longevity;	chr19:37638596	chr19:37314868~37315620:-
THCA	cis	rs427394	0.659	rs274674	ENSG00000248677.1	CTD-2044J15.1	4	7.43e-05	0.00604	0.18	0.18	Menopause (age at onset);	chr5:6755347	chr5:6686325~6707711:-
THCA	cis	rs7737355	0.812	rs6596008	ENSG00000224431.1	AC063976.7	-4	7.43e-05	0.00604	-0.17	-0.18	Life satisfaction;	chr5:131267426	chr5:132199456~132203487:+
THCA	cis	rs804280	0.542	rs36100659	ENSG00000254948.1	OR7E158P	-4	7.43e-05	0.00604	-0.23	-0.18	Myopia (pathological);	chr8:11934144	chr8:11919900~11920809:-
THCA	cis	rs4879656	0.872	rs12375624	ENSG00000225693.1	LAGE3P1	-4	7.43e-05	0.00604	-0.19	-0.18	Menopause (age at onset);	chr9:33017140	chr9:33019682~33020165:-
THCA	cis	rs9595908	0.785	rs4942829	ENSG00000212293.1	SNORA16	4	7.44e-05	0.00604	0.21	0.18	Body mass index;	chr13:32708994	chr13:32420390~32420516:-
THCA	cis	rs10875746	0.859	rs12305511	ENSG00000258273.1	RP11-370I10.4	-4	7.44e-05	0.00604	-0.26	-0.18	Longevity (90 years and older);	chr12:48188933	chr12:48333755~48333901:-
THCA	cis	rs12681963	0.614	rs2341178	ENSG00000248159.1	HSPA8P11	4	7.44e-05	0.00604	0.32	0.18	Migraine;	chr8:30240679	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs2341179	ENSG00000248159.1	HSPA8P11	4	7.44e-05	0.00604	0.32	0.18	Migraine;	chr8:30243250	chr8:30237382~30240997:+
THCA	cis	rs4245128	0.775	rs2218617	ENSG00000227487.3	NCAM1-AS1	4	7.44e-05	0.00605	0.18	0.18	Life satisfaction;	chr11:112949270	chr11:113269532~113273901:-
THCA	cis	rs10200159	0.793	rs13383352	ENSG00000272606.1	RP11-554J4.1	4	7.44e-05	0.00605	0.34	0.18	Vitiligo;	chr2:55643692	chr2:55617909~55618373:+
THCA	cis	rs4321325	0.733	rs4284779	ENSG00000236682.1	AC068282.3	-4	7.44e-05	0.00605	-0.38	-0.18	Protein C levels;	chr2:127188924	chr2:127389130~127400580:+
THCA	cis	rs11633886	0.656	rs17556590	ENSG00000273972.1	CTD-2306A12.1	-4	7.44e-05	0.00605	-0.2	-0.18	Diisocyanate-induced asthma;	chr15:45835153	chr15:45702640~45703183:+
THCA	cis	rs2180341	0.711	rs4371861	ENSG00000220522.2	RP1-177A13.1	4	7.44e-05	0.00605	0.21	0.18	Breast cancer;	chr6:127247302	chr6:127416535~127416952:-
THCA	cis	rs67981189	0.865	rs2189806	ENSG00000269927.1	RP6-91H8.3	-4	7.44e-05	0.00605	-0.21	-0.18	Schizophrenia;	chr14:70921681	chr14:71141125~71143253:-
THCA	cis	rs8040855	0.624	rs12903975	ENSG00000225151.9	GOLGA2P7	-4	7.44e-05	0.00605	-0.24	-0.18	Bulimia nervosa;	chr15:85006004	chr15:84199311~84230136:-
THCA	cis	rs782212	0.592	rs1599339	ENSG00000227207.2	RPL31P12	4	7.44e-05	0.00605	0.28	0.18	Depression;	chr1:72380507	chr1:72301472~72301829:+
THCA	cis	rs2033711	0.84	rs10423138	ENSG00000269867.1	CTD-2583A14.8	-4	7.45e-05	0.00605	-0.15	-0.18	Uric acid clearance;	chr19:58416935	chr19:57867038~57868172:-
THCA	cis	rs75059851	1	rs3758927	ENSG00000280237.1	MIR4697HG	-4	7.45e-05	0.00605	-0.21	-0.18	Schizophrenia;	chr11:133959749	chr11:133896438~133901601:-
THCA	cis	rs1371614	0.632	rs3739085	ENSG00000229122.1	AGBL5-IT1	4	7.45e-05	0.00605	0.13	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26940176	chr2:27061038~27061815:+
THCA	cis	rs9478638	0.507	rs2184406	ENSG00000235381.1	RP11-477D19.2	-4	7.45e-05	0.00605	-0.15	-0.18	Electroencephalogram traits;	chr6:155308544	chr6:155253139~155256724:-
THCA	cis	rs6504108	0.581	rs55982346	ENSG00000264920.1	RP11-6N17.4	-4	7.45e-05	0.00605	-0.15	-0.18	Body mass index;	chr17:48198512	chr17:47891255~47895812:-
THCA	cis	rs758324	0.947	rs804059	ENSG00000237714.1	P4HA2-AS1	-4	7.45e-05	0.00605	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131934443	chr5:132184876~132192808:+
THCA	cis	rs758324	0.891	rs491624	ENSG00000237714.1	P4HA2-AS1	-4	7.45e-05	0.00605	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131934529	chr5:132184876~132192808:+
THCA	cis	rs1122401	0.515	rs2548638	ENSG00000280159.1	CTD-2591A1.1	4	7.45e-05	0.00605	0.29	0.18	Smoking initiation;	chr5:54573746	chr5:54643557~54645987:+
THCA	cis	rs9287719	0.837	rs4233883	ENSG00000243819.4	RN7SL832P	4	7.45e-05	0.00605	0.14	0.18	Prostate cancer;	chr2:10615470	chr2:10690344~10692099:+
THCA	cis	rs7615952	0.611	rs9681518	ENSG00000248787.1	RP11-666A20.4	-4	7.45e-05	0.00605	-0.36	-0.18	Blood pressure (smoking interaction);	chr3:125896287	chr3:125908005~125910272:-
THCA	cis	rs4767841	0.904	rs2074052	ENSG00000252886.1	RN7SKP197	-4	7.45e-05	0.00605	-0.18	-0.18	Urgency urinary incontinence;	chr12:119758409	chr12:119631090~119631386:-
THCA	cis	rs11756659	0.653	rs199738	ENSG00000272462.2	U91328.19	4	7.45e-05	0.00606	0.17	0.18	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25963228	chr6:25992662~26001775:+
THCA	cis	rs12478296	1	rs56292923	ENSG00000220804.7	AC093642.5	4	7.45e-05	0.00606	0.2	0.18	Obesity-related traits;	chr2:242097835	chr2:242088633~242160153:+
THCA	cis	rs7264396	0.79	rs6121026	ENSG00000088340.14	FER1L4	4	7.45e-05	0.00606	0.18	0.18	Total cholesterol levels;	chr20:35678961	chr20:35558737~35607562:-
THCA	cis	rs1404100	0.51	rs2341683	ENSG00000240476.1	LINC00973	-4	7.45e-05	0.00606	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99069807	chr3:98981058~98983096:+
THCA	cis	rs721917	0.525	rs1054053	ENSG00000244733.5	RP11-506M13.3	-4	7.45e-05	0.00606	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2758558	ENSG00000244733.5	RP11-506M13.3	-4	7.45e-05	0.00606	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79660891~79677996:+
THCA	cis	rs16944613	0.528	rs6416554	ENSG00000259212.1	CTD-3065B20.2	4	7.45e-05	0.00606	0.28	0.18	Colorectal cancer;	chr15:90595058	chr15:90595840~90596447:-
THCA	cis	rs7312933	0.703	rs10880259	ENSG00000257225.1	RP11-328C8.4	-4	7.45e-05	0.00606	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42164201	chr12:42459366~42466128:+
THCA	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	4	7.45e-05	0.00606	0.19	0.18	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
THCA	cis	rs7312933	0.576	rs11181364	ENSG00000257225.1	RP11-328C8.4	-4	7.46e-05	0.00606	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42173998	chr12:42459366~42466128:+
THCA	cis	rs10875746	0.859	rs12305647	ENSG00000258273.1	RP11-370I10.4	4	7.46e-05	0.00606	0.26	0.18	Longevity (90 years and older);	chr12:48189178	chr12:48333755~48333901:-
THCA	cis	rs4742903	0.967	rs2122577	ENSG00000270332.1	SMC2-AS1	4	7.46e-05	0.00606	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104104422	chr9:104080024~104093073:-
THCA	cis	rs7083	0.84	rs509565	ENSG00000254851.1	RP11-109L13.1	4	7.46e-05	0.00606	0.24	0.18	Blood protein levels;	chr11:117249757	chr11:117135528~117138582:+
THCA	cis	rs10186029	0.676	rs4673721	ENSG00000270659.1	RP11-105N14.1	-4	7.46e-05	0.00606	-0.14	-0.18	Systemic sclerosis;	chr2:213076919	chr2:213152970~213153659:+
THCA	cis	rs1055129	0.537	rs2467100	ENSG00000267801.1	RP11-552F3.9	4	7.46e-05	0.00606	0.21	0.18	White matter hyperintensity burden;	chr17:75952957	chr17:75876372~75879546:+
THCA	cis	rs758324	0.687	rs301834	ENSG00000224431.1	AC063976.7	-4	7.46e-05	0.00606	-0.19	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132166212	chr5:132199456~132203487:+
THCA	cis	rs860295	0.702	rs12239100	ENSG00000236675.1	MTX1P1	-4	7.46e-05	0.00606	-0.19	-0.18	Body mass index;	chr1:155458685	chr1:155230975~155234325:+
THCA	cis	rs12073837	0.5	rs4143772	ENSG00000221571.3	RNU6ATAC35P	-4	7.46e-05	0.00606	-0.16	-0.18	F-cell distribution;	chr1:220815004	chr1:220825620~220826063:+
THCA	cis	rs3764021	0.84	rs12304510	ENSG00000256594.6	RP11-705C15.2	4	7.46e-05	0.00606	0.14	0.18	Type 1 diabetes;	chr12:9732930	chr12:9633419~9658412:+
THCA	cis	rs987724	0.778	rs35874547	ENSG00000240875.4	LINC00886	-4	7.46e-05	0.00606	-0.15	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156972867	chr3:156747346~156817062:-
THCA	cis	rs4950322	0.515	rs72691016	ENSG00000271721.1	RP11-337C18.9	4	7.46e-05	0.00606	0.2	0.18	Protein quantitative trait loci;	chr1:147245375	chr1:147175602~147177740:+
THCA	cis	rs7259376	0.936	rs4932759	ENSG00000269138.1	ZNF209P	4	7.46e-05	0.00606	0.18	0.18	Menopause (age at onset);	chr19:22357303	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs12608491	ENSG00000269138.1	ZNF209P	4	7.46e-05	0.00606	0.18	0.18	Menopause (age at onset);	chr19:22358825	chr19:22463922~22473036:+
THCA	cis	rs12935418	0.733	rs35115578	ENSG00000261838.4	RP11-303E16.6	4	7.46e-05	0.00606	0.29	0.18	Mean corpuscular volume;	chr16:80946392	chr16:81069854~81076598:+
THCA	cis	rs9902453	0.904	rs7212292	ENSG00000263370.1	RP11-68I3.5	-4	7.46e-05	0.00606	-0.23	-0.18	Coffee consumption (cups per day);	chr17:30082246	chr17:29639627~29640825:+
THCA	cis	rs9309473	1	rs58603761	ENSG00000273245.1	RP11-434P11.2	4	7.46e-05	0.00606	0.24	0.18	Metabolite levels;	chr2:73499478	chr2:73750256~73750786:-
THCA	cis	rs10435719	0.764	rs10103485	ENSG00000254948.1	OR7E158P	-4	7.46e-05	0.00606	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:11919900~11920809:-
THCA	cis	rs3740713	0.669	rs34740438	ENSG00000256464.1	YWHABP2	4	7.46e-05	0.00606	0.3	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr11:18490243~18490955:-
THCA	cis	rs12134133	1	rs2564973	ENSG00000237074.1	RP11-6J21.2	4	7.46e-05	0.00606	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207249067~207309121:+
THCA	cis	rs728616	0.558	rs35547640	ENSG00000278616.1	BEND3P3	4	7.46e-05	0.00606	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80379394	chr10:79682997~79685436:+
THCA	cis	rs1371614	0.61	rs6547317	ENSG00000229122.1	AGBL5-IT1	4	7.46e-05	0.00606	0.13	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929051	chr2:27061038~27061815:+
THCA	cis	rs17221829	0.703	rs10830336	ENSG00000280385.1	AP000648.5	-4	7.47e-05	0.00607	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89673293	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs11600011	ENSG00000280385.1	AP000648.5	-4	7.47e-05	0.00607	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89674812	chr11:90193614~90198120:+
THCA	cis	rs728616	0.558	rs2343302	ENSG00000278616.1	BEND3P3	4	7.47e-05	0.00607	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80403430	chr10:79682997~79685436:+
THCA	cis	rs9863	0.861	rs3789967	ENSG00000270061.1	RP11-214K3.19	-4	7.47e-05	0.00607	-0.23	-0.18	White blood cell count;	chr12:123962792	chr12:123969990~123970344:-
THCA	cis	rs28735056	0.62	rs12456484	ENSG00000261126.6	RP11-795F19.1	4	7.47e-05	0.00607	0.15	0.18	Schizophrenia;	chr18:79917315	chr18:80046900~80095482:+
THCA	cis	rs3755605	0.728	rs1386333	ENSG00000242578.1	RP11-469J4.3	4	7.47e-05	0.00607	0.2	0.18	Testicular germ cell tumor;	chr3:170176892	chr3:170410512~170418615:+
THCA	cis	rs17270561	0.636	rs6456694	ENSG00000272462.2	U91328.19	-4	7.47e-05	0.00607	-0.16	-0.18	Iron status biomarkers;	chr6:25712666	chr6:25992662~26001775:+
THCA	cis	rs11633886	0.622	rs60175246	ENSG00000273972.1	CTD-2306A12.1	-4	7.47e-05	0.00607	-0.2	-0.18	Diisocyanate-induced asthma;	chr15:45836933	chr15:45702640~45703183:+
THCA	cis	rs34421088	0.506	rs4841518	ENSG00000154316.13	TDH	-4	7.47e-05	0.00607	-0.13	-0.18	Neuroticism;	chr8:11288454	chr8:11339637~11368452:+
THCA	cis	rs7923609	0.518	rs10822119	ENSG00000232075.1	MRPL35P2	-4	7.47e-05	0.00607	-0.24	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63068814	chr10:63634317~63634827:-
THCA	cis	rs548181	0.736	rs1941558	ENSG00000254671.2	STT3A-AS1	-4	7.47e-05	0.00607	-0.35	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125555710	chr11:125570284~125592568:-
THCA	cis	rs266717	0.816	rs266754	ENSG00000234197.1	ETV5-AS1	-4	7.47e-05	0.00607	-0.14	-0.18	Adiponectin levels;	chr3:186791177	chr3:186079170~186080947:+
THCA	cis	rs1577917	0.958	rs6454487	ENSG00000220563.1	PKMP3	4	7.47e-05	0.00607	0.14	0.18	Response to antipsychotic treatment;	chr6:85737150	chr6:85659892~85660606:-
THCA	cis	rs972578	1	rs5759078	ENSG00000230319.1	AL022476.2	4	7.47e-05	0.00607	0.19	0.18	Mean platelet volume;	chr22:42997036	chr22:43038585~43052366:+
THCA	cis	rs9534288	0.912	rs4942468	ENSG00000235903.6	CPB2-AS1	4	7.47e-05	0.00607	0.26	0.18	Blood protein levels;	chr13:46044155	chr13:46052806~46113332:+
THCA	cis	rs2303282	0.664	rs2432540	ENSG00000274031.1	RP11-413H22.3	4	7.47e-05	0.00607	0.21	0.18	Breast cancer;	chr16:56385716	chr16:56465642~56466162:-
THCA	cis	rs7312933	0.703	rs7957471	ENSG00000257225.1	RP11-328C8.4	-4	7.47e-05	0.00607	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42151789	chr12:42459366~42466128:+
THCA	cis	rs9921338	0.923	rs4563054	ENSG00000262703.1	RP11-485G7.6	4	7.47e-05	0.00607	0.3	0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353689	chr16:11348143~11349321:-
THCA	cis	rs4792901	0.802	rs12602059	ENSG00000267151.3	RP11-100E5.2	4	7.47e-05	0.00607	0.2	0.18	Dupuytren's disease;	chr17:43496362	chr17:43444707~43451200:+
THCA	cis	rs1039766	1	rs268861	ENSG00000204929.10	AC074391.1	4	7.47e-05	0.00607	0.29	0.18	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr2:65436711~66084639:+
THCA	cis	rs1039766	1	rs268862	ENSG00000204929.10	AC074391.1	4	7.47e-05	0.00607	0.29	0.18	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr2:65436711~66084639:+
THCA	cis	rs2806561	0.734	rs7548692	ENSG00000249087.5	ZNF436-AS1	-4	7.47e-05	0.00607	-0.12	-0.18	Height;	chr1:23028384	chr1:23368997~23371839:+
THCA	cis	rs2191566	0.54	rs436739	ENSG00000277806.1	RP11-15A1.8	4	7.47e-05	0.00607	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43991401	chr19:43976815~43977448:+
THCA	cis	rs9717605	0.954	rs73046008	ENSG00000226445.1	XXyac-YX65C7_A.2	4	7.48e-05	0.00607	0.22	0.18	Left atrial antero-posterior diameter;	chr6:169246104	chr6:169213254~169239565:+
THCA	cis	rs9717605	1	rs73046010	ENSG00000226445.1	XXyac-YX65C7_A.2	4	7.48e-05	0.00607	0.22	0.18	Left atrial antero-posterior diameter;	chr6:169246314	chr6:169213254~169239565:+
THCA	cis	rs801193	1	rs62466794	ENSG00000229180.5	GS1-124K5.11	4	7.48e-05	0.00607	0.12	0.18	Aortic root size;	chr7:66726592	chr7:66526088~66542624:-
THCA	cis	rs867371	0.826	rs2047678	ENSG00000255769.6	GOLGA2P10	-4	7.48e-05	0.00607	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472993~82513950:-
THCA	cis	rs3755605	0.728	rs56772533	ENSG00000242578.1	RP11-469J4.3	4	7.48e-05	0.00607	0.21	0.18	Testicular germ cell tumor;	chr3:170183694	chr3:170410512~170418615:+
THCA	cis	rs3755605	0.728	rs17200223	ENSG00000242578.1	RP11-469J4.3	4	7.48e-05	0.00607	0.21	0.18	Testicular germ cell tumor;	chr3:170184291	chr3:170410512~170418615:+
THCA	cis	rs875971	1	rs2220626	ENSG00000230189.5	GS1-124K5.2	-4	7.48e-05	0.00607	-0.12	-0.18	Aortic root size;	chr7:66081075	chr7:66409143~66490059:-
THCA	cis	rs17507216	0.588	rs4778687	ENSG00000255769.6	GOLGA2P10	-4	7.48e-05	0.00607	-0.27	-0.18	Excessive daytime sleepiness;	chr15:82649085	chr15:82472993~82513950:-
THCA	cis	rs7959452	0.535	rs11177577	ENSG00000274979.1	RP11-1143G9.5	-4	7.48e-05	0.00607	-0.19	-0.18	Blood protein levels;	chr12:69278011	chr12:69326574~69331882:-
THCA	cis	rs62158211	0.955	rs7556815	ENSG00000240356.5	RP11-395L14.11	-4	7.48e-05	0.00607	-0.25	-0.18	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr2:113610502~113627090:-
THCA	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	4	7.48e-05	0.00607	0.21	0.18	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
THCA	cis	rs4742903	1	rs2274724	ENSG00000270332.1	SMC2-AS1	4	7.48e-05	0.00607	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104098287	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.967	rs10820601	ENSG00000270332.1	SMC2-AS1	4	7.48e-05	0.00607	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104099000	chr9:104080024~104093073:-
THCA	cis	rs3755605	0.728	rs6444902	ENSG00000242578.1	RP11-469J4.3	4	7.48e-05	0.00607	0.2	0.18	Testicular germ cell tumor;	chr3:170177230	chr3:170410512~170418615:+
THCA	cis	rs3750965	0.734	rs11604251	ENSG00000260895.1	RP11-554A11.7	-4	7.48e-05	0.00608	-0.25	-0.18	Hair color;	chr11:69052961	chr11:69103493~69109094:+
THCA	cis	rs755249	0.727	rs16826349	ENSG00000182109.6	RP11-69E11.4	4	7.48e-05	0.00608	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39522280~39546187:-
THCA	cis	rs17772222	0.701	rs453112	ENSG00000222990.1	RNU4-22P	-4	7.48e-05	0.00608	-0.22	-0.18	Coronary artery calcification;	chr14:88392657	chr14:88513498~88513663:+
THCA	cis	rs394563	0.517	rs377454	ENSG00000231760.4	RP11-350J20.5	4	7.48e-05	0.00608	0.26	0.18	Dupuytren's disease;	chr6:149469957	chr6:149796151~149826294:-
THCA	cis	rs801193	1	rs2659915	ENSG00000229180.5	GS1-124K5.11	4	7.48e-05	0.00608	0.12	0.18	Aortic root size;	chr7:66688114	chr7:66526088~66542624:-
THCA	cis	rs11992162	0.573	rs61468577	ENSG00000254948.1	OR7E158P	4	7.48e-05	0.00608	0.23	0.18	Monocyte count;	chr8:11927416	chr8:11919900~11920809:-
THCA	cis	rs13256369	1	rs13282915	ENSG00000254153.1	CTA-398F10.2	-4	7.48e-05	0.00608	-0.2	-0.18	Obesity-related traits;	chr8:8713381	chr8:8456909~8461337:-
THCA	cis	rs9900062	0.546	rs2676289	ENSG00000270714.1	MINOS1P2	4	7.48e-05	0.00608	0.24	0.18	QT interval;	chr17:64709620	chr17:64747264~64747492:-
THCA	cis	rs7989336	0.612	rs1927790	ENSG00000247400.3	DNAJC3-AS1	-4	7.48e-05	0.00608	-0.11	-0.18	Obesity;	chr13:96269937	chr13:95648733~95676925:-
THCA	cis	rs1876449	0.871	rs2105683	ENSG00000266171.1	RP11-769O8.1	4	7.48e-05	0.00608	0.2	0.18	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr18:1475826	chr18:735746~737459:+
THCA	cis	rs8179	0.761	rs42032	ENSG00000230927.2	TMBIM7P	4	7.49e-05	0.00608	0.26	0.18	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92608112	chr7:92412976~92439562:-
THCA	cis	rs910316	0.875	rs12588099	ENSG00000259138.1	RP11-950C14.7	4	7.49e-05	0.00608	0.16	0.18	Height;	chr14:75127759	chr14:75127153~75136930:+
THCA	cis	rs8031584	1	rs8031584	ENSG00000178081.11	ULK4P3	4	7.49e-05	0.00608	0.25	0.18	Huntington's disease progression;	chr15:30995140	chr15:30103720~30131757:+
THCA	cis	rs1198872	0.892	rs1198865	ENSG00000272275.1	RP11-791G15.2	-4	7.49e-05	0.00608	-0.21	-0.18	Cardiac Troponin-T levels;	chr2:10760936	chr2:10767875~10770058:-
THCA	cis	rs8067354	0.83	rs2453913	ENSG00000266701.1	AC005702.4	4	7.49e-05	0.00608	0.25	0.18	Hemoglobin concentration;	chr17:59782789	chr17:60042546~60042627:-
THCA	cis	rs1577917	0.655	rs7742691	ENSG00000220563.1	PKMP3	4	7.49e-05	0.00608	0.13	0.18	Response to antipsychotic treatment;	chr6:85568973	chr6:85659892~85660606:-
THCA	cis	rs7798970	0.645	rs12536744	ENSG00000225498.1	AC002064.5	-4	7.49e-05	0.00608	-0.19	-0.18	Inflammatory skin disease;	chr7:90015424	chr7:90312496~90322592:+
THCA	cis	rs7798970	0.645	rs4358735	ENSG00000225498.1	AC002064.5	-4	7.49e-05	0.00608	-0.19	-0.18	Inflammatory skin disease;	chr7:90015779	chr7:90312496~90322592:+
THCA	cis	rs7088591	0.867	rs1930469	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58007771	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs79547940	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58008999	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs76201797	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58009440	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs79999754	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58009553	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs76349114	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58010356	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs16911605	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58010879	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs79495287	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58010901	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs75107759	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58011108	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs977764	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58011722	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs59332725	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58012237	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.764	rs61287415	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58012577	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs16911609	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58014224	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs1889067	ENSG00000276818.1	AC026393.1	4	7.49e-05	0.00608	0.38	0.18	Blood pressure;	chr10:58017054	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs977765	ENSG00000276818.1	AC026393.1	-4	7.49e-05	0.00608	-0.38	-0.18	Blood pressure;	chr10:58011708	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs16911625	ENSG00000276818.1	AC026393.1	-4	7.49e-05	0.00608	-0.38	-0.18	Blood pressure;	chr10:58017816	chr10:57095699~57095781:+
THCA	cis	rs6430538	0.671	rs1942050	ENSG00000224043.6	CCNT2-AS1	4	7.49e-05	0.00608	0.2	0.18	Parkinson's disease;	chr2:134817013	chr2:134735464~134918710:-
THCA	cis	rs4908768	0.501	rs1922983	ENSG00000270282.1	RP5-1115A15.2	4	7.49e-05	0.00608	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8512653~8513021:+
THCA	cis	rs5753037	0.653	rs131273	ENSG00000279699.1	RP1-102K2.9	4	7.49e-05	0.00608	0.18	0.18	Type 1 diabetes;	chr22:29757732	chr22:30275215~30276951:-
THCA	cis	rs2735413	0.75	rs76833828	ENSG00000276007.1	RP11-358L22.3	4	7.49e-05	0.00608	0.17	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78037098	chr16:78123243~78124332:+
THCA	cis	rs7572733	0.534	rs1589162	ENSG00000231621.1	AC013264.2	-4	7.49e-05	0.00608	-0.19	-0.18	Dermatomyositis;	chr2:197917968	chr2:197197991~197199273:+
THCA	cis	rs12134133	0.688	rs6540875	ENSG00000237074.1	RP11-6J21.2	4	7.49e-05	0.00608	0.2	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.719	rs6696142	ENSG00000237074.1	RP11-6J21.2	4	7.49e-05	0.00608	0.2	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.752	rs57003024	ENSG00000237074.1	RP11-6J21.2	4	7.49e-05	0.00608	0.2	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207249067~207309121:+
THCA	cis	rs301901	1	rs300049	ENSG00000250155.1	CTD-2353F22.1	-4	7.49e-05	0.00608	-0.19	-0.18	Height;	chr5:37083971	chr5:36666214~36725195:-
THCA	cis	rs988712	0.672	rs36029218	ENSG00000245573.6	BDNF-AS	-4	7.5e-05	0.00609	-0.18	-0.18	Obesity;	chr11:27626824	chr11:27506838~27698174:+
THCA	cis	rs988712	0.705	rs4923457	ENSG00000245573.6	BDNF-AS	-4	7.5e-05	0.00609	-0.18	-0.18	Obesity;	chr11:27627033	chr11:27506838~27698174:+
THCA	cis	rs2364403	1	rs12091361	ENSG00000236675.1	MTX1P1	-4	7.5e-05	0.00609	-0.2	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:155959882	chr1:155230975~155234325:+
THCA	cis	rs4746818	1	rs10998614	ENSG00000229001.1	ACTBP14	-4	7.5e-05	0.00609	-0.29	-0.18	Left atrial antero-posterior diameter;	chr10:69163591	chr10:69022778~69023866:+
THCA	cis	rs4820834	0.542	rs5749077	ENSG00000272689.1	RP4-539M6.21	-4	7.5e-05	0.00609	-0.27	-0.18	Coronary artery calcification;	chr22:30364829	chr22:30421206~30421536:-
THCA	cis	rs4713118	0.955	rs9468204	ENSG00000261839.1	RP1-265C24.8	4	7.5e-05	0.00609	0.2	0.18	Parkinson's disease;	chr6:27721030	chr6:28136849~28139678:+
THCA	cis	rs73173548	0.502	rs71639110	ENSG00000247828.6	TMEM161B-AS1	4	7.5e-05	0.00609	0.16	0.18	Macular telangiectasia type 2;	chr5:88422222	chr5:88268895~88436685:+
THCA	cis	rs2129782	0.558	rs60669462	ENSG00000253553.4	RP11-586K2.1	4	7.5e-05	0.00609	0.26	0.18	Electrodermal activity;	chr8:88462575	chr8:88326836~88737134:+
THCA	cis	rs2129782	0.614	rs61341431	ENSG00000253553.4	RP11-586K2.1	4	7.5e-05	0.00609	0.26	0.18	Electrodermal activity;	chr8:88462890	chr8:88326836~88737134:+
THCA	cis	rs11168351	0.927	rs10875716	ENSG00000273765.1	RP11-370I10.11	4	7.5e-05	0.00609	0.18	0.18	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48360920~48361377:+
THCA	cis	rs10191559	0.59	rs10930953	ENSG00000236153.1	AC104076.3	-4	7.5e-05	0.00609	-0.19	-0.18	Red blood cell count;	chr2:181086700	chr2:180979427~180980090:-
THCA	cis	rs1823874	0.584	rs9806196	ENSG00000254744.3	CTD-3076O17.1	-4	7.5e-05	0.00609	-0.19	-0.18	IgG glycosylation;	chr15:99842201	chr15:99970215~99974010:+
THCA	cis	rs7746199	0.736	rs6904596	ENSG00000220721.1	OR1F12	4	7.5e-05	0.00609	0.35	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28073316~28074233:+
THCA	cis	rs10090774	0.965	rs6992780	ENSG00000279766.1	RP11-642A1.2	4	7.5e-05	0.00609	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140901522	chr8:140572142~140572812:-
THCA	cis	rs5758511	0.68	rs5758698	ENSG00000230107.1	CTA-126B4.7	-4	7.5e-05	0.00609	-0.21	-0.18	Birth weight;	chr22:42288812	chr22:42438023~42446195:+
THCA	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	4	7.5e-05	0.00609	0.15	0.18	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
THCA	cis	rs853679	0.556	rs45509595	ENSG00000220721.1	OR1F12	4	7.5e-05	0.00609	0.41	0.18	Depression;	chr6:27873148	chr6:28073316~28074233:+
THCA	cis	rs5997397	0.72	rs132549	ENSG00000272858.1	CTA-292E10.8	4	7.51e-05	0.00609	0.19	0.18	Red cell distribution width;	chr22:28922736	chr22:28814914~28815662:+
THCA	cis	rs2221894	0.959	rs28679662	ENSG00000251191.6	LINC00589	4	7.51e-05	0.00609	0.22	0.18	Obesity-related traits;	chr8:29033270	chr8:29673922~29748109:-
THCA	cis	rs7312933	0.558	rs1796388	ENSG00000257225.1	RP11-328C8.4	4	7.51e-05	0.00609	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42392185	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.531	rs1796380	ENSG00000257225.1	RP11-328C8.4	4	7.51e-05	0.00609	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42397741	chr12:42459366~42466128:+
THCA	cis	rs8115854	0.961	rs6031886	ENSG00000269846.1	RP4-621N11.2	-3.99	7.51e-05	0.00609	-0.23	-0.18	Hippocampal atrophy;	chr20:37181969	chr20:37095785~37097178:+
THCA	cis	rs7208859	0.673	rs216411	ENSG00000280069.1	CTD-2349P21.3	3.99	7.51e-05	0.0061	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30738182~30740275:+
THCA	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	3.99	7.51e-05	0.0061	0.2	0.18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
THCA	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-3.99	7.51e-05	0.0061	-0.21	-0.18	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
THCA	cis	rs6430585	0.527	rs1446586	ENSG00000231890.6	DARS-AS1	3.99	7.51e-05	0.0061	0.21	0.18	Corneal structure;	chr2:135649875	chr2:135985176~136022593:+
THCA	cis	rs7772486	0.727	rs10223508	ENSG00000270638.1	RP3-466P17.1	-3.99	7.51e-05	0.0061	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145735570~145737218:+
THCA	cis	rs1124769	0.719	rs1009882	ENSG00000259378.1	DCAF13P3	3.99	7.51e-05	0.0061	0.28	0.18	Cognitive performance;	chr15:51099519	chr15:50944663~50945996:+
THCA	cis	rs7968440	1	rs67701624	ENSG00000272368.2	RP4-605O3.4	3.99	7.51e-05	0.0061	0.12	0.18	Fibrinogen;	chr12:50535155	chr12:50112197~50165618:+
THCA	cis	rs7968440	1	rs66644594	ENSG00000272368.2	RP4-605O3.4	3.99	7.51e-05	0.0061	0.12	0.18	Fibrinogen;	chr12:50539200	chr12:50112197~50165618:+
THCA	cis	rs7968440	0.966	rs68171620	ENSG00000272368.2	RP4-605O3.4	3.99	7.51e-05	0.0061	0.12	0.18	Fibrinogen;	chr12:50543755	chr12:50112197~50165618:+
THCA	cis	rs7508	0.509	rs414260	ENSG00000253671.1	RP11-806O11.1	-3.99	7.51e-05	0.0061	-0.23	-0.18	Atrial fibrillation;	chr8:18046813	chr8:17808941~17820868:+
THCA	cis	rs1232027	0.656	rs1650688	ENSG00000249655.1	CTC-325J23.2	3.99	7.51e-05	0.0061	0.21	0.18	Huntington's disease progression;	chr5:80660310	chr5:80630313~80631590:-
THCA	cis	rs6940638	0.615	rs9393801	ENSG00000219392.1	RP1-265C24.5	-3.99	7.51e-05	0.0061	-0.21	-0.18	Intelligence (multi-trait analysis);	chr6:27274902	chr6:28115628~28116551:+
THCA	cis	rs4272720	0.639	rs2137911	ENSG00000234736.4	FAM170B-AS1	3.99	7.51e-05	0.0061	0.19	0.18	Platelet count;Plateletcrit;	chr10:49049685	chr10:49121839~49151547:+
THCA	cis	rs4788570	0.647	rs904764	ENSG00000260593.1	RP11-432I5.2	-3.99	7.51e-05	0.0061	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71738892	chr16:71623708~71626816:-
THCA	cis	rs5758659	0.652	rs133313	ENSG00000270083.1	RP1-257I20.14	3.99	7.51e-05	0.0061	0.19	0.18	Cognitive function;	chr22:42005745	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.652	rs133314	ENSG00000270083.1	RP1-257I20.14	3.99	7.51e-05	0.0061	0.19	0.18	Cognitive function;	chr22:42005837	chr22:42089630~42090028:-
THCA	cis	rs4470077	1	rs7156648	ENSG00000258413.1	RP11-665C16.6	-3.99	7.51e-05	0.0061	-0.31	-0.18	Platelet count;	chr14:55431681	chr14:55262767~55272075:-
THCA	cis	rs4819052	1	rs2297284	ENSG00000182586.6	LINC00334	-3.99	7.51e-05	0.0061	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45234340~45258730:+
THCA	cis	rs5752326	0.51	rs877593	ENSG00000261188.1	CTA-445C9.14	3.99	7.52e-05	0.0061	0.19	0.18	Ischemic stroke;	chr22:26471689	chr22:26512537~26514568:+
THCA	cis	rs642803	1	rs642803	ENSG00000255557.1	RP11-770G2.2	-3.99	7.52e-05	0.0061	-0.19	-0.18	Urate levels;	chr11:65793149	chr11:65745729~65771585:+
THCA	cis	rs472402	0.58	rs3736316	ENSG00000250056.4	LINC01018	-3.99	7.52e-05	0.0061	-0.22	-0.18	Response to amphetamines;	chr5:6656097	chr5:6582136~6588499:+
THCA	cis	rs472402	0.58	rs10060745	ENSG00000250056.4	LINC01018	-3.99	7.52e-05	0.0061	-0.22	-0.18	Response to amphetamines;	chr5:6657890	chr5:6582136~6588499:+
THCA	cis	rs793571	0.521	rs12594872	ENSG00000245975.2	RP11-30K9.6	3.99	7.52e-05	0.0061	0.17	0.18	Schizophrenia;	chr15:58620550	chr15:58768072~58770974:-
THCA	cis	rs6121246	0.909	rs6089070	ENSG00000230613.1	HM13-AS1	-3.99	7.52e-05	0.0061	-0.2	-0.18	Mean corpuscular hemoglobin;	chr20:31789970	chr20:31567707~31573263:-
THCA	cis	rs6504108	0.647	rs3805370	ENSG00000264920.1	RP11-6N17.4	-3.99	7.52e-05	0.0061	-0.15	-0.18	Body mass index;	chr17:48181731	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.647	rs3805371	ENSG00000264920.1	RP11-6N17.4	-3.99	7.52e-05	0.0061	-0.15	-0.18	Body mass index;	chr17:48181739	chr17:47891255~47895812:-
THCA	cis	rs7989336	0.637	rs9554333	ENSG00000247400.3	DNAJC3-AS1	-3.99	7.52e-05	0.0061	-0.11	-0.18	Obesity;	chr13:96270462	chr13:95648733~95676925:-
THCA	cis	rs5758659	0.652	rs133301	ENSG00000270083.1	RP1-257I20.14	3.99	7.52e-05	0.0061	0.19	0.18	Cognitive function;	chr22:41994089	chr22:42089630~42090028:-
THCA	cis	rs7178424	0.729	rs12909947	ENSG00000259251.2	RP11-643M14.1	3.99	7.52e-05	0.0061	0.18	0.18	Height;	chr15:61956353	chr15:62060503~62062434:+
THCA	cis	rs5758659	0.652	rs133324	ENSG00000270083.1	RP1-257I20.14	3.99	7.52e-05	0.0061	0.19	0.18	Cognitive function;	chr22:42010367	chr22:42089630~42090028:-
THCA	cis	rs7818688	0.578	rs11779506	ENSG00000253528.2	RP11-347C18.4	-3.99	7.52e-05	0.0061	-0.27	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95062674	chr8:94974573~94974853:-
THCA	cis	rs12681366	0.734	rs16916802	ENSG00000261437.1	RP11-22C11.2	3.99	7.52e-05	0.0061	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94397280	chr8:94637285~94639467:-
THCA	cis	rs73198271	0.562	rs73519953	ENSG00000253893.2	FAM85B	3.99	7.52e-05	0.00611	0.3	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802768	chr8:8167819~8226614:-
THCA	cis	rs7777677	1	rs7777677	ENSG00000211750.2	TRBV24-1	-3.99	7.52e-05	0.00611	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142656701~142657213:+
THCA	cis	rs271738	0.71	rs6673823	ENSG00000231768.1	LINC01354	-3.99	7.52e-05	0.00611	-0.21	-0.18	Bipolar disorder;	chr1:234532534	chr1:234527891~234531779:-
THCA	cis	rs2236521	0.714	rs6062210	ENSG00000273619.1	RP5-908M14.9	-3.99	7.53e-05	0.00611	-0.13	-0.18	Pelvic organ prolapse;	chr20:62315319	chr20:62386303~62386970:-
THCA	cis	rs2364403	1	rs2364403	ENSG00000236675.1	MTX1P1	-3.99	7.53e-05	0.00611	-0.2	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:155957961	chr1:155230975~155234325:+
THCA	cis	rs2904524	0.737	rs41329849	ENSG00000257815.4	RP11-611E13.2	3.99	7.53e-05	0.00611	0.25	0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70418082	chr12:69904033~70243360:-
THCA	cis	rs1504749	0.569	rs6986393	ENSG00000254142.2	RP11-53M11.3	3.99	7.53e-05	0.00611	0.27	0.18	Intracranial aneurysm;	chr8:54382307	chr8:54554361~54561927:+
THCA	cis	rs16957091	0.528	rs72713784	ENSG00000205771.5	CATSPER2P1	3.99	7.53e-05	0.00611	0.25	0.18	MGMT methylation in smokers;	chr15:42823738	chr15:43726918~43747094:-
THCA	cis	rs950169	0.845	rs4502182	ENSG00000275120.1	RP11-182J1.17	3.99	7.53e-05	0.00611	0.22	0.18	Schizophrenia;	chr15:84254768	chr15:84599434~84606463:-
THCA	cis	rs440932	1	rs378974	ENSG00000248538.5	RP11-10A14.5	-3.99	7.53e-05	0.00611	-0.22	-0.18	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:9189011~9202854:+
THCA	cis	rs4915077	0.892	rs79566197	ENSG00000230489.1	VAV3-AS1	3.99	7.53e-05	0.00611	0.32	0.18	Hypothyroidism;	chr1:107860073	chr1:107964443~107994607:+
THCA	cis	rs2836974	0.897	rs68090597	ENSG00000255568.3	BRWD1-AS2	3.99	7.53e-05	0.00611	0.16	0.18	Cognitive function;	chr21:39163707	chr21:39313935~39314962:+
THCA	cis	rs2221894	1	rs7842492	ENSG00000251191.6	LINC00589	-3.99	7.53e-05	0.00611	-0.22	-0.18	Obesity-related traits;	chr8:29012120	chr8:29673922~29748109:-
THCA	cis	rs964611	0.938	rs7163887	ENSG00000259488.2	RP11-154J22.1	3.99	7.53e-05	0.00611	0.17	0.18	Metabolite levels (Pyroglutamine);	chr15:48367357	chr15:48312353~48331856:-
THCA	cis	rs2342371	0.545	rs7646174	ENSG00000273013.1	CTD-2002J20.1	3.99	7.53e-05	0.00611	0.17	0.18	Fat distribution (HIV);	chr3:196483937	chr3:196474801~196475394:+
THCA	cis	rs853679	0.607	rs34788973	ENSG00000220721.1	OR1F12	3.99	7.53e-05	0.00611	0.4	0.18	Depression;	chr6:27911422	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs61742093	ENSG00000220721.1	OR1F12	3.99	7.53e-05	0.00611	0.4	0.18	Depression;	chr6:27912204	chr6:28073316~28074233:+
THCA	cis	rs7267979	0.714	rs1555329	ENSG00000125804.12	FAM182A	-3.99	7.53e-05	0.00611	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.714	rs3787082	ENSG00000125804.12	FAM182A	-3.99	7.53e-05	0.00611	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:26054655~26086917:+
THCA	cis	rs7267979	0.714	rs6115107	ENSG00000125804.12	FAM182A	-3.99	7.53e-05	0.00611	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:26054655~26086917:+
THCA	cis	rs853679	0.607	rs66886492	ENSG00000272009.1	RP1-313I6.12	-3.99	7.53e-05	0.00611	-0.36	-0.18	Depression;	chr6:28121953	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs35345226	ENSG00000272009.1	RP1-313I6.12	-3.99	7.53e-05	0.00611	-0.36	-0.18	Depression;	chr6:28123802	chr6:28078792~28081130:-
THCA	cis	rs874628	0.686	rs11666281	ENSG00000268650.3	AC068499.10	3.99	7.53e-05	0.00611	0.21	0.18	Multiple sclerosis;	chr19:18123778	chr19:18204730~18220480:+
THCA	cis	rs7193541	0.965	rs7184423	ENSG00000262904.1	TMPOP2	-3.99	7.54e-05	0.00612	-0.22	-0.18	Multiple myeloma;	chr16:74675839	chr16:74667506~74668706:+
THCA	cis	rs9844666	0.512	rs1401545	ENSG00000273486.1	RP11-731C17.2	3.99	7.54e-05	0.00612	0.17	0.18	Height;	chr3:135903639	chr3:136837338~136839021:-
THCA	cis	rs6499188	0.522	rs10153230	ENSG00000274698.1	RP11-71L14.4	3.99	7.54e-05	0.00612	0.25	0.18	Ulcerative colitis;	chr16:68637838	chr16:68450283~68452318:+
THCA	cis	rs7045881	0.576	rs7857669	ENSG00000254396.1	RP11-56F10.3	-3.99	7.54e-05	0.00612	-0.22	-0.18	Schizophrenia;	chr9:27032387	chr9:27102630~27104728:+
THCA	cis	rs8017455	0.523	rs10142999	ENSG00000259167.2	NMNAT1P1	3.99	7.54e-05	0.00612	0.26	0.18	Hair morphology;	chr14:81095081	chr14:81032529~81033404:+
THCA	cis	rs7551222	0.752	rs6681905	ENSG00000240219.1	RP11-430C7.5	3.99	7.54e-05	0.00612	0.17	0.18	Schizophrenia;	chr1:204566661	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.752	rs6594016	ENSG00000240219.1	RP11-430C7.5	3.99	7.54e-05	0.00612	0.17	0.18	Schizophrenia;	chr1:204570334	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.716	rs7541589	ENSG00000240219.1	RP11-430C7.5	3.99	7.54e-05	0.00612	0.17	0.18	Schizophrenia;	chr1:204573393	chr1:204626775~204629712:+
THCA	cis	rs5758511	0.68	rs5758698	ENSG00000227370.1	RP4-669P10.19	3.99	7.54e-05	0.00612	0.2	0.18	Birth weight;	chr22:42288812	chr22:42132543~42132998:+
THCA	cis	rs6546550	0.901	rs3771531	ENSG00000179818.12	PCBP1-AS1	-3.99	7.54e-05	0.00612	-0.14	-0.18	Prevalent atrial fibrillation;	chr2:69936902	chr2:69962263~70103220:-
THCA	cis	rs42648	0.869	rs10251227	ENSG00000225498.1	AC002064.5	3.99	7.54e-05	0.00612	0.19	0.18	Homocysteine levels;	chr7:90262972	chr7:90312496~90322592:+
THCA	cis	rs12544026	0.548	rs487863	ENSG00000253669.3	KB-1732A1.1	-3.99	7.54e-05	0.00612	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101899884	chr8:102805517~102809971:+
THCA	cis	rs6442522	0.673	rs1869855	ENSG00000249786.6	EAF1-AS1	3.99	7.54e-05	0.00612	0.18	0.18	Uric acid levels;	chr3:15459635	chr3:15436171~15455940:-
THCA	cis	rs4886920	0.894	rs1123552	ENSG00000260776.4	RP11-114H24.2	-3.99	7.54e-05	0.00612	-0.21	-0.18	Neuroticism;	chr15:77817077	chr15:77914217~77926846:-
THCA	cis	rs56046484	0.956	rs17540501	ENSG00000259630.2	CTD-2262B20.1	-3.99	7.54e-05	0.00612	-0.27	-0.18	Testicular germ cell tumor;	chr15:85094870	chr15:85415228~85415633:+
THCA	cis	rs7178424	0.875	rs1436966	ENSG00000259251.2	RP11-643M14.1	-3.99	7.54e-05	0.00612	-0.18	-0.18	Height;	chr15:62066483	chr15:62060503~62062434:+
THCA	cis	rs7208859	0.673	rs216435	ENSG00000280069.1	CTD-2349P21.3	-3.99	7.55e-05	0.00612	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30738182~30740275:+
THCA	cis	rs7772486	0.79	rs1062068	ENSG00000270638.1	RP3-466P17.1	3.99	7.55e-05	0.00612	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs6923545	ENSG00000270638.1	RP3-466P17.1	-3.99	7.55e-05	0.00612	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.754	rs6922507	ENSG00000270638.1	RP3-466P17.1	-3.99	7.55e-05	0.00612	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs4075694	ENSG00000270638.1	RP3-466P17.1	-3.99	7.55e-05	0.00612	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145735570~145737218:+
THCA	cis	rs5758659	0.652	rs133321	ENSG00000270083.1	RP1-257I20.14	3.99	7.55e-05	0.00612	0.19	0.18	Cognitive function;	chr22:42009318	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.652	rs133323	ENSG00000270083.1	RP1-257I20.14	3.99	7.55e-05	0.00612	0.19	0.18	Cognitive function;	chr22:42009918	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.652	rs133327	ENSG00000270083.1	RP1-257I20.14	3.99	7.55e-05	0.00612	0.19	0.18	Cognitive function;	chr22:42011685	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.652	rs133330	ENSG00000270083.1	RP1-257I20.14	3.99	7.55e-05	0.00612	0.19	0.18	Cognitive function;	chr22:42013452	chr22:42089630~42090028:-
THCA	cis	rs150992	0.609	rs2927648	ENSG00000246763.5	RGMB-AS1	3.99	7.55e-05	0.00612	0.19	0.18	Body mass index;	chr5:98990273	chr5:98769618~98773469:-
THCA	cis	rs708224	0.702	rs813784	ENSG00000274964.1	RP11-817I4.1	3.99	7.55e-05	0.00612	0.19	0.18	Pancreatic cancer;	chr12:32285823	chr12:32339368~32340724:+
THCA	cis	rs12681963	0.764	rs1877184	ENSG00000248159.1	HSPA8P11	-3.99	7.55e-05	0.00612	-0.33	-0.18	Migraine;	chr8:30142424	chr8:30237382~30240997:+
THCA	cis	rs785830	0.523	rs529045	ENSG00000231808.2	LINC01388	-3.99	7.55e-05	0.00612	-0.21	-0.18	Platelet distribution width;	chr9:217397	chr9:112713~113754:-
THCA	cis	rs9291683	0.62	rs11722946	ENSG00000261490.1	RP11-448G15.3	-3.99	7.55e-05	0.00612	-0.11	-0.18	Bone mineral density;	chr4:10124366	chr4:10068089~10073019:-
THCA	cis	rs10129255	0.957	rs11847726	ENSG00000280411.1	IGHV1-69-2	-3.99	7.55e-05	0.00612	-0.11	-0.18	Kawasaki disease;	chr14:106779116	chr14:106762092~106762588:-
THCA	cis	rs4460629	0.521	rs4361977	ENSG00000160766.13	GBAP1	-3.99	7.55e-05	0.00612	-0.2	-0.18	Serum magnesium levels;	chr1:155103603	chr1:155213821~155227422:-
THCA	cis	rs73108077	1	rs73108095	ENSG00000277112.2	RP11-755J8.1	-3.99	7.55e-05	0.00612	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31428519	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.915	rs73110028	ENSG00000277112.2	RP11-755J8.1	-3.99	7.55e-05	0.00612	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31439633	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.915	rs746053	ENSG00000277112.2	RP11-755J8.1	-3.99	7.55e-05	0.00612	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31440944	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs73116222	ENSG00000277112.2	RP11-755J8.1	-3.99	7.55e-05	0.00612	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31444393	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs73116224	ENSG00000277112.2	RP11-755J8.1	-3.99	7.55e-05	0.00612	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31444913	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs73116226	ENSG00000277112.2	RP11-755J8.1	-3.99	7.55e-05	0.00612	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31445905	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs73116229	ENSG00000277112.2	RP11-755J8.1	-3.99	7.55e-05	0.00612	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31446433	chr20:30681825~30723932:-
THCA	cis	rs712039	0.958	rs1016679	ENSG00000276054.1	RP11-378E13.3	-3.99	7.55e-05	0.00612	-0.26	-0.18	Tuberculosis;	chr17:37514228	chr17:37386886~37387926:+
THCA	cis	rs1871744	0.551	rs35683035	ENSG00000246375.2	RP11-10L7.1	3.99	7.55e-05	0.00612	0.27	0.18	Renal underexcretion gout;	chr4:88165189	chr4:88284942~88331421:+
THCA	cis	rs9595908	0.746	rs9596076	ENSG00000212293.1	SNORA16	3.99	7.55e-05	0.00613	0.22	0.18	Body mass index;	chr13:32693515	chr13:32420390~32420516:-
THCA	cis	rs1964356	0.967	rs2953802	ENSG00000233609.3	RP11-62H7.2	3.99	7.55e-05	0.00613	0.17	0.18	Mean corpuscular volume;	chr8:8994371	chr8:8961200~8979025:+
THCA	cis	rs2839186	0.843	rs17182671	ENSG00000215424.8	MCM3AP-AS1	3.99	7.55e-05	0.00613	0.1	0.18	Testicular germ cell tumor;	chr21:46276324	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.739	rs7282763	ENSG00000215424.8	MCM3AP-AS1	3.99	7.55e-05	0.00613	0.1	0.18	Testicular germ cell tumor;	chr21:46276886	chr21:46229217~46259390:+
THCA	cis	rs11239930	0.538	rs719969	ENSG00000278811.3	LINC00624	3.99	7.55e-05	0.00613	0.21	0.18	AIDS progression;	chr1:147084111	chr1:147258885~147517875:-
THCA	cis	rs1713985	0.508	rs1277282	ENSG00000269949.1	RP11-738E22.3	3.99	7.56e-05	0.00613	0.37	0.18	Age-related macular degeneration;	chr4:56989653	chr4:56960927~56961373:-
THCA	cis	rs1713985	0.508	rs1277286	ENSG00000269949.1	RP11-738E22.3	-3.99	7.56e-05	0.00613	-0.37	-0.18	Age-related macular degeneration;	chr4:56988132	chr4:56960927~56961373:-
THCA	cis	rs7968440	0.808	rs1613835	ENSG00000272368.2	RP4-605O3.4	3.99	7.56e-05	0.00613	0.12	0.18	Fibrinogen;	chr12:50811283	chr12:50112197~50165618:+
THCA	cis	rs7968440	0.808	rs1659387	ENSG00000272368.2	RP4-605O3.4	3.99	7.56e-05	0.00613	0.12	0.18	Fibrinogen;	chr12:50811284	chr12:50112197~50165618:+
THCA	cis	rs2574985	0.586	rs978588	ENSG00000279863.1	RP11-521C22.2	3.99	7.56e-05	0.00613	0.21	0.18	Subjective well-being;	chr10:50475144	chr10:50334538~50336123:+
THCA	cis	rs5006884	0.627	rs71488553	ENSG00000167355.6	AC104389.28	-3.99	7.56e-05	0.00613	-0.31	-0.18	Fetal hemoglobin levels;	chr11:5393066	chr11:5304976~5505652:-
THCA	cis	rs74233809	1	rs9633712	ENSG00000272912.1	RP11-724N1.1	-3.99	7.56e-05	0.00613	-0.33	-0.18	Birth weight;	chr10:103114004	chr10:102914585~102915404:+
THCA	cis	rs74233809	0.786	rs11191564	ENSG00000272912.1	RP11-724N1.1	-3.99	7.56e-05	0.00613	-0.33	-0.18	Birth weight;	chr10:103118786	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs1060240	ENSG00000272912.1	RP11-724N1.1	-3.99	7.56e-05	0.00613	-0.33	-0.18	Birth weight;	chr10:103123580	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs10883835	ENSG00000272912.1	RP11-724N1.1	-3.99	7.56e-05	0.00613	-0.33	-0.18	Birth weight;	chr10:103124451	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs732998	ENSG00000272912.1	RP11-724N1.1	3.99	7.56e-05	0.00613	0.33	0.18	Birth weight;	chr10:103138144	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs11191575	ENSG00000272912.1	RP11-724N1.1	-3.99	7.56e-05	0.00613	-0.33	-0.18	Birth weight;	chr10:103138580	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs79993475	ENSG00000272912.1	RP11-724N1.1	-3.99	7.56e-05	0.00613	-0.33	-0.18	Birth weight;	chr10:103141274	chr10:102914585~102915404:+
THCA	cis	rs1538970	0.884	rs61788261	ENSG00000234329.1	RP11-767N6.2	3.99	7.56e-05	0.00613	0.18	0.18	Platelet count;	chr1:45433442	chr1:45651039~45651826:-
THCA	cis	rs1538970	0.924	rs4660855	ENSG00000234329.1	RP11-767N6.2	3.99	7.56e-05	0.00613	0.18	0.18	Platelet count;	chr1:45434123	chr1:45651039~45651826:-
THCA	cis	rs9309473	0.519	rs2421584	ENSG00000273245.1	RP11-434P11.2	-3.99	7.56e-05	0.00613	-0.22	-0.18	Metabolite levels;	chr2:73671725	chr2:73750256~73750786:-
THCA	cis	rs7824557	0.564	rs2572394	ENSG00000154316.13	TDH	3.99	7.56e-05	0.00613	0.13	0.18	Retinal vascular caliber;	chr8:11377884	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs2437152	ENSG00000154316.13	TDH	3.99	7.56e-05	0.00613	0.13	0.18	Retinal vascular caliber;	chr8:11377988	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs2736300	ENSG00000154316.13	TDH	3.99	7.56e-05	0.00613	0.13	0.18	Retinal vascular caliber;	chr8:11378070	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs2572392	ENSG00000154316.13	TDH	3.99	7.56e-05	0.00613	0.13	0.18	Retinal vascular caliber;	chr8:11378096	chr8:11339637~11368452:+
THCA	cis	rs700651	0.752	rs7592556	ENSG00000231621.1	AC013264.2	-3.99	7.56e-05	0.00613	-0.19	-0.18	Intracranial aneurysm;	chr2:198026297	chr2:197197991~197199273:+
THCA	cis	rs700651	0.753	rs10207232	ENSG00000231621.1	AC013264.2	-3.99	7.56e-05	0.00613	-0.19	-0.18	Intracranial aneurysm;	chr2:198029089	chr2:197197991~197199273:+
THCA	cis	rs875971	0.66	rs10229345	ENSG00000229180.5	GS1-124K5.11	3.99	7.56e-05	0.00613	0.13	0.18	Aortic root size;	chr7:66517181	chr7:66526088~66542624:-
THCA	cis	rs6442522	0.56	rs2255897	ENSG00000249786.6	EAF1-AS1	-3.99	7.56e-05	0.00613	-0.19	-0.18	Uric acid levels;	chr3:15479170	chr3:15436171~15455940:-
THCA	cis	rs6929812	0.702	rs979353	ENSG00000271755.1	RP1-153G14.4	3.99	7.56e-05	0.00613	0.2	0.18	Neuroticism (multi-trait analysis);	chr6:27433159	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.664	rs6914542	ENSG00000271755.1	RP1-153G14.4	3.99	7.56e-05	0.00613	0.2	0.18	Neuroticism (multi-trait analysis);	chr6:27435446	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs57647048	ENSG00000271755.1	RP1-153G14.4	3.99	7.56e-05	0.00613	0.2	0.18	Neuroticism (multi-trait analysis);	chr6:27441385	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs55705181	ENSG00000271755.1	RP1-153G14.4	3.99	7.56e-05	0.00613	0.2	0.18	Neuroticism (multi-trait analysis);	chr6:27441508	chr6:27404010~27406964:-
THCA	cis	rs4925386	0.681	rs2427295	ENSG00000275437.1	RP5-908M14.10	3.99	7.57e-05	0.00613	0.18	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62402236~62405935:-
THCA	cis	rs4925386	0.681	rs2427296	ENSG00000275437.1	RP5-908M14.10	3.99	7.57e-05	0.00613	0.18	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62402236~62405935:-
THCA	cis	rs6732426	0.721	rs35491011	ENSG00000279873.2	LINC01126	3.99	7.57e-05	0.00614	0.14	0.18	Hair morphology;	chr2:43386851	chr2:43227210~43228855:+
THCA	cis	rs8031584	0.918	rs61997139	ENSG00000270015.1	RP11-540B6.6	-3.99	7.57e-05	0.00614	-0.14	-0.18	Huntington's disease progression;	chr15:30981399	chr15:30926514~30928407:+
THCA	cis	rs11633886	0.967	rs884305	ENSG00000259200.1	RP11-718O11.1	-3.99	7.57e-05	0.00614	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45783116	chr15:45705078~45931069:+
THCA	cis	rs741677	0.929	rs741678	ENSG00000231784.7	DBIL5P	3.99	7.57e-05	0.00614	0.2	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:561051	chr17:752660~755336:+
THCA	cis	rs4819052	1	rs2838847	ENSG00000273796.1	LL21NC02-21A1.1	-3.99	7.57e-05	0.00614	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45403809~45404369:-
THCA	cis	rs4845875	0.504	rs11121832	ENSG00000242349.4	NPPA-AS1	3.99	7.57e-05	0.00614	0.2	0.18	Midregional pro atrial natriuretic peptide levels;	chr1:11800063	chr1:11841017~11848079:+
THCA	cis	rs2252521	0.583	rs161050	ENSG00000272568.4	CTB-113D17.1	3.99	7.58e-05	0.00614	0.2	0.18	Cognitive performance;	chr7:29059657	chr7:28979967~29013367:+
THCA	cis	rs17221829	0.673	rs10830330	ENSG00000280385.1	AP000648.5	-3.99	7.58e-05	0.00614	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89659631	chr11:90193614~90198120:+
THCA	cis	rs4742903	1	rs4742905	ENSG00000270332.1	SMC2-AS1	3.99	7.58e-05	0.00614	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104094691	chr9:104080024~104093073:-
THCA	cis	rs4742903	1	rs4742906	ENSG00000270332.1	SMC2-AS1	3.99	7.58e-05	0.00614	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104094797	chr9:104080024~104093073:-
THCA	cis	rs7551222	0.634	rs11801289	ENSG00000240219.1	RP11-430C7.5	3.99	7.58e-05	0.00614	0.17	0.18	Schizophrenia;	chr1:204559841	chr1:204626775~204629712:+
THCA	cis	rs1124769	0.619	rs7170036	ENSG00000273674.3	CTD-2378E12.1	3.99	7.58e-05	0.00614	0.24	0.18	Cognitive performance;	chr15:50956106	chr15:50839875~50908599:-
THCA	cis	rs1124769	0.619	rs8182062	ENSG00000273674.3	CTD-2378E12.1	3.99	7.58e-05	0.00614	0.24	0.18	Cognitive performance;	chr15:50962305	chr15:50839875~50908599:-
THCA	cis	rs62246343	0.516	rs2251166	ENSG00000206573.7	THUMPD3-AS1	3.99	7.58e-05	0.00614	0.13	0.18	Fibrinogen levels;	chr3:9400053	chr3:9349689~9398579:-
THCA	cis	rs7200543	1	rs6498541	ENSG00000188599.16	NPIPP1	-3.99	7.58e-05	0.00614	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:15104312~15123498:-
THCA	cis	rs10492201	0.529	rs740420	ENSG00000255733.4	IFNG-AS1	-3.99	7.58e-05	0.00614	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007862	chr12:67989445~68234686:+
THCA	cis	rs10492201	0.554	rs2870962	ENSG00000255733.4	IFNG-AS1	-3.99	7.58e-05	0.00614	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68008143	chr12:67989445~68234686:+
THCA	cis	rs8130944	1	rs4920141	ENSG00000225731.1	AP001627.1	-3.99	7.58e-05	0.00614	-0.21	-0.18	Perceived unattractiveness to mosquitoes;	chr21:42721519	chr21:42733594~42741758:-
THCA	cis	rs9309473	0.5	rs6546862	ENSG00000273245.1	RP11-434P11.2	-3.99	7.58e-05	0.00614	-0.21	-0.18	Metabolite levels;	chr2:73633221	chr2:73750256~73750786:-
THCA	cis	rs8020441	0.891	rs61362797	ENSG00000269906.1	RP11-248J18.2	3.99	7.58e-05	0.00614	0.26	0.18	Cognitive performance;	chr14:50701034	chr14:50662511~50663178:-
THCA	cis	rs9291683	0.585	rs12648479	ENSG00000261490.1	RP11-448G15.3	-3.99	7.58e-05	0.00614	-0.11	-0.18	Bone mineral density;	chr4:10102947	chr4:10068089~10073019:-
THCA	cis	rs1876206	0.529	rs2437948	ENSG00000259705.1	RP11-227D13.1	3.99	7.58e-05	0.00614	0.22	0.18	Breast cancer;	chr15:48557531	chr15:48645951~48652016:+
THCA	cis	rs67981189	0.865	rs34488204	ENSG00000269927.1	RP6-91H8.3	3.99	7.58e-05	0.00614	0.2	0.18	Schizophrenia;	chr14:71028571	chr14:71141125~71143253:-
THCA	cis	rs150992	0.711	rs331918	ENSG00000241597.2	CTD-2007H13.1	-3.99	7.58e-05	0.00615	-0.23	-0.18	Body mass index;	chr5:98823040	chr5:98954394~98954972:+
THCA	cis	rs150992	0.673	rs331929	ENSG00000241597.2	CTD-2007H13.1	-3.99	7.58e-05	0.00615	-0.23	-0.18	Body mass index;	chr5:98830528	chr5:98954394~98954972:+
THCA	cis	rs4272720	0.666	rs12774293	ENSG00000234736.4	FAM170B-AS1	-3.99	7.58e-05	0.00615	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49059448	chr10:49121839~49151547:+
THCA	cis	rs910873	1	rs56020497	ENSG00000269202.1	RP4-614O4.12	-3.99	7.58e-05	0.00615	-0.33	-0.18	Melanoma;	chr20:34578666	chr20:35201747~35203288:-
THCA	cis	rs910873	1	rs17305573	ENSG00000269202.1	RP4-614O4.12	-3.99	7.58e-05	0.00615	-0.33	-0.18	Melanoma;	chr20:34592348	chr20:35201747~35203288:-
THCA	cis	rs9303542	0.729	rs4793846	ENSG00000278765.1	RP5-890E16.5	-3.99	7.58e-05	0.00615	-0.24	-0.18	Epithelial ovarian cancer;Ovarian cancer;	chr17:48455544	chr17:48066704~48067293:-
THCA	cis	rs962856	0.575	rs1195666	ENSG00000236780.4	AC078941.1	3.99	7.58e-05	0.00615	0.24	0.18	Pancreatic cancer;	chr2:67424598	chr2:67123357~67215319:-
THCA	cis	rs6878727	0.741	rs12656951	ENSG00000253807.4	LINC01170	-3.99	7.59e-05	0.00615	-0.19	-0.18	Breast cancer;	chr5:124390896	chr5:124059794~124405079:-
THCA	cis	rs1552244	0.515	rs111560858	ENSG00000180385.7	EMC3-AS1	3.99	7.59e-05	0.00615	0.23	0.18	Alzheimer's disease;	chr3:10125161	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs17032426	ENSG00000180385.7	EMC3-AS1	3.99	7.59e-05	0.00615	0.23	0.18	Alzheimer's disease;	chr3:10125428	chr3:9986893~10006990:+
THCA	cis	rs878939	0.625	rs17493485	ENSG00000233690.1	EBAG9P1	3.99	7.59e-05	0.00615	0.24	0.18	Warfarin maintenance dose;	chr10:99584123	chr10:99697407~99697949:-
THCA	cis	rs748404	1	rs66651343	ENSG00000166763.7	STRCP1	3.99	7.59e-05	0.00615	0.22	0.18	Lung cancer;	chr15:43265806	chr15:43699488~43718184:-
THCA	cis	rs7924176	0.521	rs10509347	ENSG00000232342.6	RP11-46O21.2	3.99	7.59e-05	0.00615	0.23	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:74506081~74530553:-
THCA	cis	rs6792584	0.743	rs7645087	ENSG00000241316.5	SUCLG2-AS1	3.99	7.59e-05	0.00615	0.18	0.18	Corneal astigmatism;	chr3:67455700	chr3:67654697~67947713:+
THCA	cis	rs4819052	1	rs13052356	ENSG00000182586.6	LINC00334	-3.99	7.59e-05	0.00615	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45234340~45258730:+
THCA	cis	rs2180341	0.781	rs877102	ENSG00000220522.2	RP1-177A13.1	3.99	7.59e-05	0.00615	0.22	0.18	Breast cancer;	chr6:127265941	chr6:127416535~127416952:-
THCA	cis	rs11603020	0.95	rs11229066	ENSG00000254602.1	AP000662.4	-3.99	7.59e-05	0.00615	-0.21	-0.18	Blood protein levels;	chr11:57607398	chr11:57638024~57652790:+
THCA	cis	rs7759001	0.744	rs1014227	ENSG00000271755.1	RP1-153G14.4	3.99	7.59e-05	0.00615	0.21	0.18	Glomerular filtration rate (creatinine);	chr6:27476178	chr6:27404010~27406964:-
THCA	cis	rs4561483	0.583	rs33636	ENSG00000263307.1	RP11-166B2.8	3.99	7.59e-05	0.00615	0.19	0.18	Testicular germ cell tumor;	chr16:11896466	chr16:11851649~11895611:+
THCA	cis	rs10129255	0.957	rs28887506	ENSG00000280411.1	IGHV1-69-2	-3.99	7.59e-05	0.00615	-0.11	-0.18	Kawasaki disease;	chr14:106785589	chr14:106762092~106762588:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000272831.1	RP11-792A8.4	3.99	7.59e-05	0.00615	0.11	0.18	Calcium levels;	chr7:65800652	chr7:66739829~66740385:-
THCA	cis	rs875971	0.789	rs28815324	ENSG00000273024.4	INTS4P2	3.99	7.59e-05	0.00615	0.23	0.18	Aortic root size;	chr7:66100789	chr7:65647864~65715661:+
THCA	cis	rs2006933	1	rs9900311	ENSG00000237575.4	PYY2	3.99	7.59e-05	0.00615	0.22	0.18	Amyotrophic lateral sclerosis;	chr17:28268381	chr17:28226563~28228065:+
THCA	cis	rs17801127	0.818	rs16827347	ENSG00000231969.1	AC144449.1	3.99	7.59e-05	0.00615	0.31	0.18	Liver enzyme levels (alanine transaminase);	chr2:149694371	chr2:149587196~149848233:+
THCA	cis	rs6963495	0.745	rs73192150	ENSG00000272604.1	RP11-251G23.5	3.99	7.6e-05	0.00616	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105571163	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.745	rs73192151	ENSG00000272604.1	RP11-251G23.5	3.99	7.6e-05	0.00616	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105571429	chr7:105571083~105573660:+
THCA	cis	rs3924048	0.559	rs6541039	ENSG00000276830.1	MIR6730	-3.99	7.6e-05	0.00616	-0.18	-0.18	Optic cup area;	chr1:12566232	chr1:12578957~12579023:-
THCA	cis	rs7131987	0.683	rs12366505	ENSG00000273680.1	RP11-996F15.6	3.99	7.6e-05	0.00616	0.25	0.18	QT interval;	chr12:29321177	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.65	rs12366527	ENSG00000273680.1	RP11-996F15.6	3.99	7.6e-05	0.00616	0.25	0.18	QT interval;	chr12:29321323	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.65	rs7311912	ENSG00000273680.1	RP11-996F15.6	3.99	7.6e-05	0.00616	0.25	0.18	QT interval;	chr12:29322770	chr12:29332733~29333383:-
THCA	cis	rs12682352	0.602	rs11783966	ENSG00000248538.5	RP11-10A14.5	3.99	7.6e-05	0.00616	0.23	0.18	Neuroticism;	chr8:8807637	chr8:9189011~9202854:+
THCA	cis	rs2033711	0.728	rs4801586	ENSG00000269867.1	CTD-2583A14.8	-3.99	7.6e-05	0.00616	-0.15	-0.18	Uric acid clearance;	chr19:58423161	chr19:57867038~57868172:-
THCA	cis	rs858239	0.568	rs6970694	ENSG00000230042.1	AK3P3	-3.99	7.6e-05	0.00616	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23129178~23129841:+
THCA	cis	rs860295	0.702	rs11264381	ENSG00000236675.1	MTX1P1	3.99	7.6e-05	0.00616	0.19	0.18	Body mass index;	chr1:155552781	chr1:155230975~155234325:+
THCA	cis	rs2274136	0.947	rs4236172	ENSG00000272269.1	RP11-500C11.3	3.99	7.6e-05	0.00616	0.21	0.18	Obesity-related traits;	chr6:17639232	chr6:17706257~17707344:+
THCA	cis	rs2153535	0.518	rs9393054	ENSG00000230939.1	RP11-314C16.1	-3.99	7.6e-05	0.00616	-0.2	-0.18	Motion sickness;	chr6:8647209	chr6:8784178~8785445:+
THCA	cis	rs9393777	0.92	rs35768595	ENSG00000220721.1	OR1F12	3.99	7.6e-05	0.00616	0.42	0.18	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28073316~28074233:+
THCA	cis	rs2221894	0.853	rs1976610	ENSG00000251191.6	LINC00589	-3.99	7.6e-05	0.00616	-0.22	-0.18	Obesity-related traits;	chr8:28926498	chr8:29673922~29748109:-
THCA	cis	rs853679	0.527	rs1997660	ENSG00000220721.1	OR1F12	3.99	7.6e-05	0.00616	0.2	0.18	Depression;	chr6:28301886	chr6:28073316~28074233:+
THCA	cis	rs10129255	1	rs10129319	ENSG00000211972.2	IGHV3-66	3.99	7.61e-05	0.00616	0.11	0.18	Kawasaki disease;	chr14:106767996	chr14:106675017~106675544:-
THCA	cis	rs6126019	1	rs6126019	ENSG00000231715.1	COX6CP2	3.99	7.61e-05	0.00616	0.2	0.18	Hematocrit;Red blood cell count;	chr20:50485053	chr20:50479767~50479991:+
THCA	cis	rs854765	0.565	rs4072738	ENSG00000281749.1	Y_RNA	3.99	7.61e-05	0.00616	0.23	0.18	Total body bone mineral density;	chr17:17981233	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs4072739	ENSG00000281749.1	Y_RNA	3.99	7.61e-05	0.00616	0.23	0.18	Total body bone mineral density;	chr17:17981346	chr17:18001101~18001195:-
THCA	cis	rs710913	0.618	rs11206437	ENSG00000182109.6	RP11-69E11.4	3.99	7.61e-05	0.00616	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613039	chr1:39522280~39546187:-
THCA	cis	rs2836974	0.897	rs2026265	ENSG00000255568.3	BRWD1-AS2	3.99	7.61e-05	0.00616	0.16	0.18	Cognitive function;	chr21:39223591	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs1984022	ENSG00000255568.3	BRWD1-AS2	3.99	7.61e-05	0.00616	0.16	0.18	Cognitive function;	chr21:39224159	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs8128102	ENSG00000255568.3	BRWD1-AS2	3.99	7.61e-05	0.00616	0.16	0.18	Cognitive function;	chr21:39234488	chr21:39313935~39314962:+
THCA	cis	rs150992	0.609	rs363929	ENSG00000246763.5	RGMB-AS1	3.99	7.61e-05	0.00616	0.19	0.18	Body mass index;	chr5:98985933	chr5:98769618~98773469:-
THCA	cis	rs2120243	0.539	rs4640512	ENSG00000241770.1	RP11-555M1.3	-3.99	7.61e-05	0.00616	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157402277	chr3:157163452~157169133:+
THCA	cis	rs321358	1	rs321368	ENSG00000271390.1	RP11-89C3.3	3.99	7.61e-05	0.00616	0.3	0.18	Body mass index;	chr11:111129033	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321369	ENSG00000271390.1	RP11-89C3.3	3.99	7.61e-05	0.00616	0.3	0.18	Body mass index;	chr11:111129797	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321370	ENSG00000271390.1	RP11-89C3.3	3.99	7.61e-05	0.00616	0.3	0.18	Body mass index;	chr11:111129959	chr11:111089870~111090368:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000230189.5	GS1-124K5.2	-3.99	7.61e-05	0.00616	-0.12	-0.18	Aortic root size;	chr7:66093491	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs1182882	ENSG00000230189.5	GS1-124K5.2	-3.99	7.61e-05	0.00616	-0.12	-0.18	Aortic root size;	chr7:66097076	chr7:66409143~66490059:-
THCA	cis	rs758324	0.717	rs17132324	ENSG00000237714.1	P4HA2-AS1	3.99	7.61e-05	0.00616	0.28	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132028286	chr5:132184876~132192808:+
THCA	cis	rs16975963	0.644	rs7248397	ENSG00000276846.1	CTD-3220F14.3	-3.99	7.61e-05	0.00616	-0.17	-0.18	Longevity;	chr19:37642310	chr19:37314868~37315620:-
THCA	cis	rs13401620	0.745	rs72834886	ENSG00000231013.1	AC013275.2	-3.99	7.61e-05	0.00616	-0.21	-0.18	Breast size;	chr2:119709929	chr2:119476448~119487346:+
THCA	cis	rs1538970	0.924	rs10890327	ENSG00000234329.1	RP11-767N6.2	3.99	7.61e-05	0.00617	0.18	0.18	Platelet count;	chr1:45425786	chr1:45651039~45651826:-
THCA	cis	rs80262450	1	rs80262450	ENSG00000260302.1	RP11-973H7.1	3.99	7.61e-05	0.00617	0.36	0.18	Inflammatory bowel disease;Crohn's disease;	chr18:12818923	chr18:12774651~12775923:-
THCA	cis	rs10200159	1	rs13430684	ENSG00000272606.1	RP11-554J4.1	3.99	7.61e-05	0.00617	0.34	0.18	Vitiligo;	chr2:55642709	chr2:55617909~55618373:+
THCA	cis	rs875971	0.662	rs448725	ENSG00000272831.1	RP11-792A8.4	3.99	7.61e-05	0.00617	0.12	0.18	Aortic root size;	chr7:66049641	chr7:66739829~66740385:-
THCA	cis	rs150992	0.585	rs331931	ENSG00000241597.2	CTD-2007H13.1	-3.99	7.61e-05	0.00617	-0.23	-0.18	Body mass index;	chr5:98834012	chr5:98954394~98954972:+
THCA	cis	rs9302635	0.513	rs8044555	ENSG00000260886.1	TAT-AS1	3.99	7.62e-05	0.00617	0.23	0.18	Blood protein levels;	chr16:72118856	chr16:71565789~71578187:+
THCA	cis	rs5015933	0.801	rs2416961	ENSG00000232630.1	PRPS1P2	-3.99	7.62e-05	0.00617	-0.12	-0.18	Body mass index;	chr9:125378078	chr9:125150653~125151589:+
THCA	cis	rs74233809	0.591	rs284853	ENSG00000213277.3	MARCKSL1P1	-3.99	7.62e-05	0.00617	-0.25	-0.18	Birth weight;	chr10:102814885	chr10:103175554~103176094:+
THCA	cis	rs172166	0.561	rs149976	ENSG00000220721.1	OR1F12	-3.99	7.62e-05	0.00617	-0.2	-0.18	Cardiac Troponin-T levels;	chr6:28019998	chr6:28073316~28074233:+
THCA	cis	rs7178375	1	rs7169064	ENSG00000269930.1	RP11-932O9.9	-3.99	7.62e-05	0.00617	-0.25	-0.18	Hypertriglyceridemia;	chr15:30918659	chr15:30616958~30617749:+
THCA	cis	rs1383484	0.798	rs28645965	ENSG00000225151.9	GOLGA2P7	3.99	7.62e-05	0.00617	0.25	0.18	Height;	chr15:83869893	chr15:84199311~84230136:-
THCA	cis	rs1383484	0.798	rs28545666	ENSG00000225151.9	GOLGA2P7	3.99	7.62e-05	0.00617	0.25	0.18	Height;	chr15:83869959	chr15:84199311~84230136:-
THCA	cis	rs7176527	0.8	rs56747535	ENSG00000229212.6	RP11-561C5.4	3.99	7.62e-05	0.00617	0.32	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85205440~85234795:-
THCA	cis	rs7914558	1	rs10786733	ENSG00000272912.1	RP11-724N1.1	-3.99	7.62e-05	0.00617	-0.21	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103035190	chr10:102914585~102915404:+
THCA	cis	rs2120243	0.592	rs7618502	ENSG00000241770.1	RP11-555M1.3	-3.99	7.62e-05	0.00617	-0.23	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157377755	chr3:157163452~157169133:+
THCA	cis	rs7267979	1	rs7267979	ENSG00000276952.1	RP5-965G21.6	3.99	7.62e-05	0.00617	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25284915~25285588:-
THCA	cis	rs7923609	0.518	rs4261180	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63071689	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs10822123	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63072760	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs10761690	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63073303	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs10822124	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63073970	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs10761694	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63075442	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs1396962	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63075733	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs4746866	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63075964	chr10:63634317~63634827:-
THCA	cis	rs7904321	0.933	rs4746868	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63076104	chr10:63634317~63634827:-
THCA	cis	rs7904321	0.966	rs6479871	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63076685	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs6479872	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63076712	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs1553785	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63076918	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs1553784	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63077119	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs1553783	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63077160	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs10761695	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63077382	chr10:63634317~63634827:-
THCA	cis	rs7904321	1	rs10761696	ENSG00000232075.1	MRPL35P2	-3.99	7.62e-05	0.00617	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63077484	chr10:63634317~63634827:-
THCA	cis	rs9650657	0.538	rs6984496	ENSG00000269899.1	RP11-589N15.2	3.99	7.62e-05	0.00617	0.2	0.18	Neuroticism;	chr8:10938583	chr8:11846154~11846391:-
THCA	cis	rs950169	0.8	rs34302901	ENSG00000188388.10	GOLGA6L3	3.99	7.62e-05	0.00617	0.24	0.18	Schizophrenia;	chr15:84567712	chr15:85240472~85247170:+
THCA	cis	rs2033711	0.783	rs8113810	ENSG00000269867.1	CTD-2583A14.8	-3.99	7.62e-05	0.00617	-0.15	-0.18	Uric acid clearance;	chr19:58420739	chr19:57867038~57868172:-
THCA	cis	rs2033711	0.87	rs4801270	ENSG00000269867.1	CTD-2583A14.8	-3.99	7.62e-05	0.00617	-0.15	-0.18	Uric acid clearance;	chr19:58421395	chr19:57867038~57868172:-
THCA	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	3.99	7.62e-05	0.00617	0.21	0.18	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
THCA	cis	rs657075	0.512	rs68115520	ENSG00000237714.1	P4HA2-AS1	-3.99	7.62e-05	0.00617	-0.37	-0.18	Rheumatoid arthritis;	chr5:132253999	chr5:132184876~132192808:+
THCA	cis	rs7131987	0.903	rs7974221	ENSG00000275476.1	RP11-996F15.4	-3.99	7.62e-05	0.00617	-0.17	-0.18	QT interval;	chr12:29246515	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.868	rs11050151	ENSG00000275476.1	RP11-996F15.4	-3.99	7.62e-05	0.00617	-0.17	-0.18	QT interval;	chr12:29250075	chr12:29277397~29277882:-
THCA	cis	rs2221894	0.959	rs6558089	ENSG00000251191.6	LINC00589	3.99	7.62e-05	0.00618	0.22	0.18	Obesity-related traits;	chr8:29036720	chr8:29673922~29748109:-
THCA	cis	rs2221894	0.959	rs2129784	ENSG00000251191.6	LINC00589	3.99	7.62e-05	0.00618	0.22	0.18	Obesity-related traits;	chr8:29042480	chr8:29673922~29748109:-
THCA	cis	rs709400	1	rs861536	ENSG00000258735.1	LINC00637	3.99	7.63e-05	0.00618	0.24	0.18	Body mass index;	chr14:103701227	chr14:103847721~103858049:+
THCA	cis	rs34975555	0.892	rs6990560	ENSG00000253671.1	RP11-806O11.1	-3.99	7.63e-05	0.00618	-0.28	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17949161	chr8:17808941~17820868:+
THCA	cis	rs6504108	0.624	rs1316657	ENSG00000264920.1	RP11-6N17.4	-3.99	7.63e-05	0.00618	-0.15	-0.18	Body mass index;	chr17:48174029	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs1002330	ENSG00000264920.1	RP11-6N17.4	-3.99	7.63e-05	0.00618	-0.15	-0.18	Body mass index;	chr17:48176153	chr17:47891255~47895812:-
THCA	cis	rs6546886	0.912	rs6745576	ENSG00000235499.1	AC073046.25	-3.99	7.63e-05	0.00618	-0.17	-0.18	Dialysis-related mortality;	chr2:74077251	chr2:73985132~73986343:+
THCA	cis	rs2239547	0.618	rs4687663	ENSG00000243224.1	RP5-1157M23.2	-3.99	7.63e-05	0.00618	-0.21	-0.18	Schizophrenia;	chr3:52836602	chr3:52239258~52241097:+
THCA	cis	rs78487399	0.808	rs10189235	ENSG00000234936.1	AC010883.5	3.99	7.63e-05	0.00618	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43518381	chr2:43229573~43233394:+
THCA	cis	rs7760535	0.656	rs1883136	ENSG00000230177.1	RP5-1112D6.4	-3.99	7.63e-05	0.00618	-0.15	-0.18	Metabolic traits;	chr6:111585820	chr6:111277932~111278742:+
THCA	cis	rs78487399	0.908	rs6749617	ENSG00000234936.1	AC010883.5	-3.99	7.63e-05	0.00618	-0.22	-0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43618190	chr2:43229573~43233394:+
THCA	cis	rs6137726	0.508	rs4815134	ENSG00000237396.1	LINC01384	3.99	7.63e-05	0.00618	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22663923	chr20:22587522~22607517:-
THCA	cis	rs409045	0.686	rs12189242	ENSG00000271874.1	CTD-2024P10.2	-3.99	7.63e-05	0.00618	-0.29	-0.18	Left ventricular mass;	chr5:34627561	chr5:34651457~34651888:-
THCA	cis	rs9558942	0.564	rs943797	ENSG00000277863.1	RP11-282A11.4	-3.99	7.63e-05	0.00618	-0.22	-0.18	Obesity-related traits;	chr13:107063131	chr13:106903150~106904099:-
THCA	cis	rs9558942	0.564	rs1927756	ENSG00000277863.1	RP11-282A11.4	-3.99	7.64e-05	0.00618	-0.22	-0.18	Obesity-related traits;	chr13:107065631	chr13:106903150~106904099:-
THCA	cis	rs73108077	1	rs73116272	ENSG00000277112.2	RP11-755J8.1	-3.99	7.64e-05	0.00618	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31467430	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs117762506	ENSG00000277112.2	RP11-755J8.1	-3.99	7.64e-05	0.00618	-0.35	-0.18	Red blood cell density in sickle cell anemia;	chr20:31467935	chr20:30681825~30723932:-
THCA	cis	rs74233809	1	rs11191519	ENSG00000272912.1	RP11-724N1.1	-3.99	7.64e-05	0.00618	-0.33	-0.18	Birth weight;	chr10:103025161	chr10:102914585~102915404:+
THCA	cis	rs2762353	0.505	rs2096386	ENSG00000272462.2	U91328.19	3.99	7.64e-05	0.00618	0.14	0.18	Blood metabolite levels;	chr6:25787589	chr6:25992662~26001775:+
THCA	cis	rs2412819	0.571	rs17727853	ENSG00000166763.7	STRCP1	3.99	7.64e-05	0.00618	0.25	0.18	Lung cancer;	chr15:43630299	chr15:43699488~43718184:-
THCA	cis	rs586688	0.582	rs550365	ENSG00000224536.1	RP11-134G8.7	-3.99	7.64e-05	0.00618	-0.28	-0.18	Obesity-related traits;	chr1:201696150	chr1:201507241~201533608:+
THCA	cis	rs858239	1	rs156425	ENSG00000230042.1	AK3P3	3.99	7.64e-05	0.00619	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23129178~23129841:+
THCA	cis	rs8058578	0.832	rs7500719	ENSG00000260911.2	RP11-196G11.2	3.99	7.64e-05	0.00619	0.16	0.18	Multiple myeloma;	chr16:30829556	chr16:31043150~31049868:+
THCA	cis	rs4718428	1	rs1830070	ENSG00000275400.1	RP4-756H11.5	-3.99	7.64e-05	0.00619	-0.18	-0.18	Corneal structure;	chr7:66884684	chr7:66553805~66554199:-
THCA	cis	rs11771526	0.901	rs10239582	ENSG00000272905.1	RP11-265E18.1	3.99	7.64e-05	0.00619	0.23	0.18	Body mass index;	chr7:32258504	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.792	rs17161105	ENSG00000272905.1	RP11-265E18.1	3.99	7.64e-05	0.00619	0.23	0.18	Body mass index;	chr7:32259575	chr7:32845394~32846061:+
THCA	cis	rs9844666	0.518	rs13097248	ENSG00000273486.1	RP11-731C17.2	3.99	7.64e-05	0.00619	0.23	0.18	Height;	chr3:136054627	chr3:136837338~136839021:-
THCA	cis	rs7429990	0.864	rs1403579	ENSG00000228638.1	FCF1P2	-3.99	7.64e-05	0.00619	-0.18	-0.18	Educational attainment (years of education);	chr3:47617889	chr3:48290793~48291375:-
THCA	cis	rs11069062	0.954	rs11836583	ENSG00000270482.1	RP11-131L12.2	-3.99	7.64e-05	0.00619	-0.15	-0.18	Obesity-related traits;	chr12:118750141	chr12:118375350~118376275:-
THCA	cis	rs2243480	0.706	rs6460257	ENSG00000273024.4	INTS4P2	3.99	7.64e-05	0.00619	0.28	0.18	Diabetic kidney disease;	chr7:65731813	chr7:65647864~65715661:+
THCA	cis	rs654950	0.934	rs653369	ENSG00000230638.4	RP11-486B10.4	3.99	7.64e-05	0.00619	0.22	0.18	Airway imaging phenotypes;	chr1:41536705	chr1:41542069~41544310:+
THCA	cis	rs9868809	0.505	rs9811027	ENSG00000270441.1	RP11-694I15.7	3.99	7.64e-05	0.00619	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48687581	chr3:49140086~49160851:-
THCA	cis	rs12497850	0.863	rs4858799	ENSG00000270441.1	RP11-694I15.7	3.99	7.64e-05	0.00619	0.24	0.18	Parkinson's disease;	chr3:48690771	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs13434258	ENSG00000270441.1	RP11-694I15.7	3.99	7.64e-05	0.00619	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701058	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs11706983	ENSG00000270441.1	RP11-694I15.7	3.99	7.64e-05	0.00619	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701245	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs35064573	ENSG00000270441.1	RP11-694I15.7	3.99	7.64e-05	0.00619	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48702847	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs9877685	ENSG00000270441.1	RP11-694I15.7	3.99	7.64e-05	0.00619	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711155	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs13063223	ENSG00000270441.1	RP11-694I15.7	3.99	7.64e-05	0.00619	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48712907	chr3:49140086~49160851:-
THCA	cis	rs11719291	0.915	rs9834996	ENSG00000270441.1	RP11-694I15.7	3.99	7.64e-05	0.00619	0.24	0.18	Cognitive function;	chr3:48717444	chr3:49140086~49160851:-
THCA	cis	rs755249	0.509	rs11206378	ENSG00000228060.1	RP11-69E11.8	3.99	7.64e-05	0.00619	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39565160~39573203:+
THCA	cis	rs9341808	0.905	rs3805903	ENSG00000272129.1	RP11-250B2.6	3.99	7.65e-05	0.00619	0.23	0.18	Sitting height ratio;	chr6:80266112	chr6:80355424~80356859:+
THCA	cis	rs17301013	0.729	rs12094143	ENSG00000270084.1	GAS5-AS1	-3.99	7.65e-05	0.00619	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174511986	chr1:173863248~173863941:+
THCA	cis	rs2290416	0.892	rs77370907	ENSG00000253931.1	RP11-909N17.2	3.99	7.65e-05	0.00619	0.36	0.18	Attention deficit hyperactivity disorder;	chr8:143582805	chr8:143412749~143417054:+
THCA	cis	rs7474896	0.515	rs624359	ENSG00000263064.2	RP11-291L22.7	-3.99	7.65e-05	0.00619	-0.24	-0.18	Obesity (extreme);	chr10:38010204	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.537	rs598857	ENSG00000263064.2	RP11-291L22.7	-3.99	7.65e-05	0.00619	-0.24	-0.18	Obesity (extreme);	chr10:38013998	chr10:38448689~38448949:+
THCA	cis	rs4705962	0.878	rs2074529	ENSG00000230612.2	AC004237.1	3.99	7.65e-05	0.00619	0.22	0.18	Atopic dermatitis;	chr5:132720455	chr5:132688681~132723725:+
THCA	cis	rs4788570	0.584	rs8051968	ENSG00000260185.1	RP11-432I5.6	-3.99	7.65e-05	0.00619	-0.33	-0.18	Intelligence (multi-trait analysis);	chr16:71728075	chr16:71655027~71664212:+
THCA	cis	rs11971779	0.715	rs6467854	ENSG00000252332.1	RNU6-911P	-3.99	7.65e-05	0.00619	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139442337	chr7:139448740~139448843:+
THCA	cis	rs12935418	0.672	rs78895138	ENSG00000261061.1	RP11-303E16.2	-3.99	7.65e-05	0.00619	-0.18	-0.18	Mean corpuscular volume;	chr16:81014820	chr16:81030770~81031485:+
THCA	cis	rs6453278	0.732	rs6868455	ENSG00000250802.5	ZBED3-AS1	3.99	7.65e-05	0.00619	0.18	0.18	Autism;	chr5:77102798	chr5:77086740~77166909:+
THCA	cis	rs4950322	1	rs72694715	ENSG00000271721.1	RP11-337C18.9	3.99	7.65e-05	0.00619	0.22	0.18	Protein quantitative trait loci;	chr1:147368468	chr1:147175602~147177740:+
THCA	cis	rs10129255	0.828	rs10140989	ENSG00000211972.2	IGHV3-66	3.99	7.65e-05	0.00619	0.11	0.18	Kawasaki disease;	chr14:106668657	chr14:106675017~106675544:-
THCA	cis	rs3748656	1	rs1110042	ENSG00000273483.1	RP4-671G15.2	3.99	7.65e-05	0.00619	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112693912	chr1:112517799~112518441:-
THCA	cis	rs3748656	1	rs3748656	ENSG00000273483.1	RP4-671G15.2	3.99	7.65e-05	0.00619	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112694059	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.832	rs883593	ENSG00000273483.1	RP4-671G15.2	3.99	7.65e-05	0.00619	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112694549	chr1:112517799~112518441:-
THCA	cis	rs11153306	0.529	rs11153303	ENSG00000231889.6	TRAF3IP2-AS1	3.99	7.65e-05	0.00619	0.16	0.18	Tonsillectomy;	chr6:111616672	chr6:111483511~111598302:+
THCA	cis	rs7259376	0.936	rs7256749	ENSG00000269345.1	VN1R85P	-3.99	7.65e-05	0.0062	-0.2	-0.18	Menopause (age at onset);	chr19:22409487	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.869	rs11673228	ENSG00000269345.1	VN1R85P	-3.99	7.65e-05	0.0062	-0.2	-0.18	Menopause (age at onset);	chr19:22413282	chr19:22174766~22175191:-
THCA	cis	rs4785763	0.57	rs4785759	ENSG00000260259.1	RP11-368I7.4	-3.99	7.65e-05	0.0062	-0.19	-0.18	Melanoma;	chr16:89984472	chr16:89682620~89686569:-
THCA	cis	rs2288884	0.505	rs8110213	ENSG00000260160.1	CTC-471J1.2	-3.99	7.66e-05	0.0062	-0.2	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51958730	chr19:52058490~52063703:-
THCA	cis	rs13113518	1	rs11133381	ENSG00000272969.1	RP11-528I4.2	3.99	7.66e-05	0.0062	0.21	0.18	Height;	chr4:55450812	chr4:55547112~55547889:+
THCA	cis	rs733175	0.857	rs3796838	ENSG00000261490.1	RP11-448G15.3	3.99	7.66e-05	0.0062	0.14	0.18	Psychosis and Alzheimer's disease;	chr4:10009406	chr4:10068089~10073019:-
THCA	cis	rs741677	0.963	rs7214033	ENSG00000231784.7	DBIL5P	3.99	7.66e-05	0.0062	0.2	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:568933	chr17:752660~755336:+
THCA	cis	rs72928364	1	rs4928096	ENSG00000256628.3	ZBTB11-AS1	3.99	7.66e-05	0.0062	0.29	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100900916	chr3:101676475~101679217:+
THCA	cis	rs9309473	1	rs2421555	ENSG00000273245.1	RP11-434P11.2	3.99	7.66e-05	0.0062	0.24	0.18	Metabolite levels;	chr2:73589828	chr2:73750256~73750786:-
THCA	cis	rs427394	0.659	rs274675	ENSG00000248677.1	CTD-2044J15.1	3.99	7.66e-05	0.0062	0.18	0.18	Menopause (age at onset);	chr5:6755206	chr5:6686325~6707711:-
THCA	cis	rs7136702	1	rs7136702	ENSG00000272368.2	RP4-605O3.4	3.99	7.66e-05	0.0062	0.1	0.18	Colorectal cancer (SNP x SNP interaction);	chr12:50486433	chr12:50112197~50165618:+
THCA	cis	rs321358	0.945	rs7112932	ENSG00000271390.1	RP11-89C3.3	3.99	7.66e-05	0.0062	0.31	0.18	Body mass index;	chr11:111101099	chr11:111089870~111090368:-
THCA	cis	rs78487399	0.908	rs55640722	ENSG00000234936.1	AC010883.5	3.99	7.66e-05	0.0062	0.22	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43618901	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs6725688	ENSG00000234936.1	AC010883.5	3.99	7.66e-05	0.0062	0.22	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43619414	chr2:43229573~43233394:+
THCA	cis	rs7702057	0.53	rs56953556	ENSG00000272265.1	CTD-2287O16.4	3.99	7.66e-05	0.0062	0.33	0.18	Amyotrophic lateral sclerosis;	chr5:116076903	chr5:116078110~116078570:-
THCA	cis	rs944289	0.711	rs7148603	ENSG00000258844.1	RP11-259K15.2	3.99	7.66e-05	0.0062	0.18	0.18	Thyroid cancer;	chr14:36214573	chr14:36214607~36235608:+
THCA	cis	rs889398	0.741	rs3790076	ENSG00000226232.7	RP11-419C5.2	3.99	7.66e-05	0.0062	0.18	0.18	Body mass index;	chr16:69873542	chr16:69976388~69996188:-
THCA	cis	rs9392556	0.6	rs611500	ENSG00000272248.1	RP3-406P24.4	3.99	7.66e-05	0.0062	0.23	0.18	Blood metabolite levels;	chr6:4126529	chr6:4018713~4019202:+
THCA	cis	rs9959145	1	rs9989546	ENSG00000267199.1	RP11-861E21.2	3.99	7.66e-05	0.0062	0.24	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12562538	chr18:12438890~12448205:+
THCA	cis	rs972578	0.765	rs713717	ENSG00000274717.1	RP1-47A17.1	-3.99	7.66e-05	0.0062	-0.19	-0.18	Mean platelet volume;	chr22:43000103	chr22:42791814~42794313:-
THCA	cis	rs10457838	0.549	rs2500542	ENSG00000231760.4	RP11-350J20.5	-3.99	7.66e-05	0.0062	-0.24	-0.18	Post-traumatic stress disorder;	chr6:149010068	chr6:149796151~149826294:-
THCA	cis	rs343092	1	rs971779	ENSG00000241749.4	RPSAP52	3.99	7.67e-05	0.0062	0.21	0.18	Type 2 diabetes;	chr12:65788675	chr12:65758020~65826997:-
THCA	cis	rs10200159	0.793	rs6545512	ENSG00000272606.1	RP11-554J4.1	3.99	7.67e-05	0.0062	0.34	0.18	Vitiligo;	chr2:55656896	chr2:55617909~55618373:+
THCA	cis	rs6687821	0.515	rs512912	ENSG00000261737.1	RP4-612B15.3	-3.99	7.67e-05	0.00621	-0.27	-0.18	Yeast infection;	chr1:86898359	chr1:86703502~86704462:-
THCA	cis	rs6101567	0.517	rs6124135	ENSG00000224635.1	RP4-564F22.5	3.99	7.67e-05	0.00621	0.22	0.18	Nose size;	chr20:39299832	chr20:38406011~38416797:-
THCA	cis	rs1923243	0.71	rs12128855	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73168330	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs6699861	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73168938	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12136496	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73169098	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs12122520	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73169494	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4593762	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73170435	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4492565	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73170489	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.743	rs4650193	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73170819	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.648	rs11589897	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73171320	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.649	rs11582461	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73171400	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs11210168	ENSG00000223479.3	RP4-788P17.1	3.99	7.67e-05	0.00621	0.2	0.18	Migraine;	chr1:73171487	chr1:73635216~73715214:+
THCA	cis	rs7945705	0.935	rs2568064	ENSG00000254860.4	TMEM9B-AS1	-3.99	7.67e-05	0.00621	-0.2	-0.18	Hemoglobin concentration;	chr11:8831138	chr11:8964675~8977527:+
THCA	cis	rs7829975	0.688	rs7826654	ENSG00000233609.3	RP11-62H7.2	3.99	7.67e-05	0.00621	0.18	0.18	Mood instability;	chr8:8521596	chr8:8961200~8979025:+
THCA	cis	rs7829975	0.688	rs7826660	ENSG00000233609.3	RP11-62H7.2	3.99	7.67e-05	0.00621	0.18	0.18	Mood instability;	chr8:8521597	chr8:8961200~8979025:+
THCA	cis	rs6430538	0.621	rs6753223	ENSG00000224043.6	CCNT2-AS1	-3.99	7.67e-05	0.00621	-0.2	-0.18	Parkinson's disease;	chr2:134818902	chr2:134735464~134918710:-
THCA	cis	rs62158800	0.526	rs62161276	ENSG00000237880.1	AC096669.2	3.99	7.67e-05	0.00621	0.19	0.18	Facial morphology (factor 22);	chr2:107672556	chr2:107385632~107542649:-
THCA	cis	rs2904524	0.541	rs77082716	ENSG00000257815.4	RP11-611E13.2	-3.99	7.67e-05	0.00621	-0.14	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70385171	chr12:69904033~70243360:-
THCA	cis	rs944289	0.617	rs7151738	ENSG00000258844.1	RP11-259K15.2	3.99	7.67e-05	0.00621	0.17	0.18	Thyroid cancer;	chr14:36114670	chr14:36214607~36235608:+
THCA	cis	rs7819412	0.66	rs7462931	ENSG00000261451.1	RP11-981G7.1	-3.99	7.67e-05	0.00621	-0.23	-0.18	Triglycerides;	chr8:11052833	chr8:10433672~10438312:+
THCA	cis	rs1853665	1	rs6933094	ENSG00000218358.2	RAET1K	-3.99	7.67e-05	0.00621	-0.3	-0.18	Radiation response;	chr6:149976467	chr6:149998019~150005157:-
THCA	cis	rs6696239	0.956	rs6426470	ENSG00000227711.2	RP11-275O4.5	-3.99	7.67e-05	0.00621	-0.25	-0.18	Height;	chr1:227665920	chr1:227509028~227520477:-
THCA	cis	rs2806561	0.734	rs10799788	ENSG00000249087.5	ZNF436-AS1	-3.99	7.67e-05	0.00621	-0.12	-0.18	Height;	chr1:23030371	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.704	rs6680974	ENSG00000249087.5	ZNF436-AS1	-3.99	7.67e-05	0.00621	-0.12	-0.18	Height;	chr1:23049740	chr1:23368997~23371839:+
THCA	cis	rs11971779	0.68	rs111461944	ENSG00000252332.1	RNU6-911P	-3.99	7.67e-05	0.00621	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139393157	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs12154842	ENSG00000252332.1	RNU6-911P	-3.99	7.67e-05	0.00621	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139393738	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6467846	ENSG00000252332.1	RNU6-911P	-3.99	7.67e-05	0.00621	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139394639	chr7:139448740~139448843:+
THCA	cis	rs7737355	0.898	rs2161414	ENSG00000237714.1	P4HA2-AS1	3.99	7.68e-05	0.00621	0.26	0.18	Life satisfaction;	chr5:131727380	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs2108871	ENSG00000237714.1	P4HA2-AS1	3.99	7.68e-05	0.00621	0.26	0.18	Life satisfaction;	chr5:131753351	chr5:132184876~132192808:+
THCA	cis	rs7552393	0.932	rs17129520	ENSG00000233008.4	RP11-475O6.1	3.99	7.68e-05	0.00621	0.2	0.18	Select biomarker traits;	chr1:83794974	chr1:83575776~83861023:-
THCA	cis	rs12893668	0.703	rs2403197	ENSG00000252469.1	RNU7-160P	3.99	7.68e-05	0.00621	0.22	0.18	Reticulocyte count;	chr14:103587427	chr14:103550345~103550406:+
THCA	cis	rs4947019	1	rs12206574	ENSG00000260273.1	RP11-425D10.10	3.99	7.68e-05	0.00621	0.32	0.18	Hematological parameters;	chr6:109746570	chr6:109382795~109383666:+
THCA	cis	rs7829975	0.714	rs59046059	ENSG00000253981.4	ALG1L13P	3.99	7.68e-05	0.00621	0.17	0.18	Mood instability;	chr8:8813226	chr8:8236003~8244667:-
THCA	cis	rs9990333	0.87	rs58758084	ENSG00000226155.1	AC124944.3	3.99	7.68e-05	0.00621	0.21	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196086110	chr3:195912049~195913986:+
THCA	cis	rs150992	0.609	rs77892628	ENSG00000246763.5	RGMB-AS1	3.99	7.68e-05	0.00621	0.19	0.18	Body mass index;	chr5:98990624	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs77231989	ENSG00000246763.5	RGMB-AS1	3.99	7.68e-05	0.00621	0.19	0.18	Body mass index;	chr5:98990650	chr5:98769618~98773469:-
THCA	cis	rs150992	0.631	rs79191251	ENSG00000246763.5	RGMB-AS1	3.99	7.68e-05	0.00621	0.19	0.18	Body mass index;	chr5:98990680	chr5:98769618~98773469:-
THCA	cis	rs10090774	0.87	rs4563941	ENSG00000280303.2	ERICD	-3.99	7.68e-05	0.00621	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140722653	chr8:140636281~140638283:+
THCA	cis	rs4356203	0.87	rs214900	ENSG00000272034.1	SNORD14A	3.99	7.68e-05	0.00621	0.18	0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206215	chr11:17074654~17074744:-
THCA	cis	rs6494488	0.5	rs68142176	ENSG00000259635.1	AC100830.3	-3.99	7.68e-05	0.00622	-0.42	-0.18	Coronary artery disease;	chr15:64663027	chr15:64701248~64719602:+
THCA	cis	rs9867325	0.778	rs9877089	ENSG00000239213.4	NCK1-AS1	3.99	7.68e-05	0.00622	0.21	0.18	Body mass index;	chr3:136937751	chr3:136841726~136862054:-
THCA	cis	rs10954779	0.764	rs6994361	ENSG00000127589.4	TUBBP1	3.99	7.68e-05	0.00622	0.21	0.18	Intelligence (multi-trait analysis);	chr8:31161169	chr8:30351873~30353518:+
THCA	cis	rs9595908	0.669	rs56291634	ENSG00000212293.1	SNORA16	3.99	7.68e-05	0.00622	0.22	0.18	Body mass index;	chr13:32720404	chr13:32420390~32420516:-
THCA	cis	rs75920871	0.688	rs77320801	ENSG00000254851.1	RP11-109L13.1	-3.99	7.69e-05	0.00622	-0.4	-0.18	Subjective well-being;	chr11:116965633	chr11:117135528~117138582:+
THCA	cis	rs1950832	0.689	rs712405	ENSG00000258636.1	CTD-2298J14.2	-3.99	7.69e-05	0.00622	-0.23	-0.18	Urate levels in obese individuals;	chr14:41645024	chr14:41587861~41604856:-
THCA	cis	rs8115854	0.922	rs6031914	ENSG00000269846.1	RP4-621N11.2	-3.99	7.69e-05	0.00622	-0.23	-0.18	Hippocampal atrophy;	chr20:37185599	chr20:37095785~37097178:+
THCA	cis	rs150992	0.587	rs1393210	ENSG00000246763.5	RGMB-AS1	-3.99	7.69e-05	0.00622	-0.19	-0.18	Body mass index;	chr5:99025892	chr5:98769618~98773469:-
THCA	cis	rs150992	0.587	rs11242567	ENSG00000246763.5	RGMB-AS1	-3.99	7.69e-05	0.00622	-0.19	-0.18	Body mass index;	chr5:99028686	chr5:98769618~98773469:-
THCA	cis	rs927821	0.838	rs6584500	ENSG00000203886.4	CYP17A1-AS1	-3.99	7.69e-05	0.00622	-0.23	-0.18	Social autistic-like traits;	chr10:102445747	chr10:102832721~102834516:+
THCA	cis	rs12410462	0.502	rs77615958	ENSG00000227711.2	RP11-275O4.5	-3.99	7.69e-05	0.00622	-0.35	-0.18	Major depressive disorder;	chr1:227618382	chr1:227509028~227520477:-
THCA	cis	rs6921919	0.789	rs13210258	ENSG00000219392.1	RP1-265C24.5	-3.99	7.69e-05	0.00622	-0.22	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28115628~28116551:+
THCA	cis	rs9309473	1	rs11903916	ENSG00000273245.1	RP11-434P11.2	3.99	7.69e-05	0.00622	0.24	0.18	Metabolite levels;	chr2:73588201	chr2:73750256~73750786:-
THCA	cis	rs3748656	1	rs17030651	ENSG00000273483.1	RP4-671G15.2	3.99	7.69e-05	0.00622	0.2	0.18	Hip circumference adjusted for BMI;	chr1:112696760	chr1:112517799~112518441:-
THCA	cis	rs9532669	0.926	rs2183144	ENSG00000229473.2	RGS17P1	-3.99	7.69e-05	0.00622	-0.23	-0.18	Cervical cancer;	chr13:40862129	chr13:40992779~40993331:-
THCA	cis	rs4950322	0.58	rs972368	ENSG00000271721.1	RP11-337C18.9	3.99	7.69e-05	0.00622	0.2	0.18	Protein quantitative trait loci;	chr1:147111142	chr1:147175602~147177740:+
THCA	cis	rs10833905	0.759	rs12224706	ENSG00000246225.5	RP11-17A1.3	-3.99	7.69e-05	0.00622	-0.25	-0.18	Sudden cardiac arrest;	chr11:23035226	chr11:22829380~22945393:+
THCA	cis	rs683257	0.81	rs7770900	ENSG00000234147.1	RP3-460G2.2	-3.99	7.69e-05	0.00622	-0.32	-0.18	Facial emotion recognition (angry faces);	chr6:140896625	chr6:140845958~140852924:-
THCA	cis	rs2191566	0.576	rs448692	ENSG00000277806.1	RP11-15A1.8	-3.99	7.69e-05	0.00622	-0.18	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:43990578	chr19:43976815~43977448:+
THCA	cis	rs7578199	0.576	rs11682299	ENSG00000223374.1	AC005104.3	-3.99	7.69e-05	0.00622	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241470480	chr2:241351340~241353104:-
THCA	cis	rs7578199	0.576	rs11682333	ENSG00000223374.1	AC005104.3	-3.99	7.69e-05	0.00622	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241470518	chr2:241351340~241353104:-
THCA	cis	rs7578199	0.538	rs6707883	ENSG00000223374.1	AC005104.3	-3.99	7.69e-05	0.00622	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241471369	chr2:241351340~241353104:-
THCA	cis	rs7259376	0.902	rs12978477	ENSG00000269138.1	ZNF209P	-3.99	7.69e-05	0.00622	-0.18	-0.18	Menopause (age at onset);	chr19:22394907	chr19:22463922~22473036:+
THCA	cis	rs8113308	0.515	rs73066981	ENSG00000269483.1	AC006272.1	3.99	7.69e-05	0.00622	0.38	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51959146	chr19:51839924~51843324:-
THCA	cis	rs7829975	0.774	rs35039922	ENSG00000233609.3	RP11-62H7.2	3.99	7.69e-05	0.00622	0.18	0.18	Mood instability;	chr8:8817815	chr8:8961200~8979025:+
THCA	cis	rs972578	0.765	rs5759081	ENSG00000274717.1	RP1-47A17.1	-3.99	7.7e-05	0.00623	-0.19	-0.18	Mean platelet volume;	chr22:43000439	chr22:42791814~42794313:-
THCA	cis	rs2692947	0.77	rs58730124	ENSG00000235584.2	AC008268.1	-3.99	7.7e-05	0.00623	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95747590	chr2:95666084~95668715:+
THCA	cis	rs721917	0.576	rs2255326	ENSG00000242600.5	MBL1P	-3.99	7.7e-05	0.00623	-0.17	-0.18	Chronic obstructive pulmonary disease;	chr10:79947418	chr10:79904898~79950336:+
THCA	cis	rs962856	0.575	rs2035565	ENSG00000236780.4	AC078941.1	3.99	7.7e-05	0.00623	0.24	0.18	Pancreatic cancer;	chr2:67392524	chr2:67123357~67215319:-
THCA	cis	rs7647973	0.848	rs4955411	ENSG00000228638.1	FCF1P2	-3.99	7.7e-05	0.00623	-0.22	-0.18	Menarche (age at onset);	chr3:49107871	chr3:48290793~48291375:-
THCA	cis	rs7647973	0.848	rs4292260	ENSG00000228638.1	FCF1P2	-3.99	7.7e-05	0.00623	-0.22	-0.18	Menarche (age at onset);	chr3:49111457	chr3:48290793~48291375:-
THCA	cis	rs7829975	0.627	rs876954	ENSG00000254340.1	RP11-10A14.3	3.99	7.7e-05	0.00623	0.21	0.18	Mood instability;	chr8:8453413	chr8:9141424~9145435:+
THCA	cis	rs8017455	0.523	rs2075175	ENSG00000259167.2	NMNAT1P1	3.99	7.7e-05	0.00623	0.26	0.18	Hair morphology;	chr14:81092296	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs2075176	ENSG00000259167.2	NMNAT1P1	3.99	7.7e-05	0.00623	0.26	0.18	Hair morphology;	chr14:81092462	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.523	rs2241120	ENSG00000259167.2	NMNAT1P1	3.99	7.7e-05	0.00623	0.26	0.18	Hair morphology;	chr14:81093087	chr14:81032529~81033404:+
THCA	cis	rs3764021	0.87	rs2401391	ENSG00000214776.8	RP11-726G1.1	3.99	7.7e-05	0.00623	0.22	0.18	Type 1 diabetes;	chr12:9725987	chr12:9467552~9576275:+
THCA	cis	rs11771526	0.901	rs28709683	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32262377	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs7357136	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32262726	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs7357161	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32262863	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs10244622	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32263348	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs62457469	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32263440	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs62457470	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32263904	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs10264511	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32264558	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs10264625	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32264593	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.792	rs10249413	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32264647	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs10252755	ENSG00000272905.1	RP11-265E18.1	3.99	7.7e-05	0.00623	0.24	0.18	Body mass index;	chr7:32265064	chr7:32845394~32846061:+
THCA	cis	rs10090774	0.71	rs11166986	ENSG00000279766.1	RP11-642A1.2	3.99	7.7e-05	0.00623	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140646056	chr8:140572142~140572812:-
THCA	cis	rs3782123	0.514	rs3782119	ENSG00000277290.1	RP11-326C3.16	-3.99	7.7e-05	0.00623	-0.24	-0.18	Red cell distribution width;Glycated hemoglobin levels;	chr11:206421	chr11:243099~243483:-
THCA	cis	rs4434872	0.536	rs2072704	ENSG00000223599.1	RP11-216N14.7	-3.99	7.7e-05	0.00623	-0.33	-0.18	Conduct disorder (symptom count);	chr1:153963067	chr1:153852106~153853414:-
THCA	cis	rs7474896	1	rs11596783	ENSG00000263064.2	RP11-291L22.7	3.99	7.7e-05	0.00623	0.28	0.18	Obesity (extreme);	chr10:37673963	chr10:38448689~38448949:+
THCA	cis	rs17095355	0.901	rs10884919	ENSG00000203876.8	ADD3-AS1	-3.99	7.71e-05	0.00623	-0.2	-0.18	Biliary atresia;	chr10:109998033	chr10:109940104~110008381:-
THCA	cis	rs9788682	0.748	rs637137	ENSG00000261143.1	ADAMTS7P3	-3.99	7.71e-05	0.00623	-0.25	-0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78581634	chr15:77976042~77993057:+
THCA	cis	rs2562456	0.876	rs62110202	ENSG00000268278.1	RP11-420K14.1	3.99	7.71e-05	0.00623	0.22	0.18	Pain;	chr19:21571799	chr19:21637974~21656300:+
THCA	cis	rs3018712	0.532	rs2510397	ENSG00000212093.1	AP000807.1	-3.99	7.71e-05	0.00623	-0.24	-0.18	Total body bone mineral density;	chr11:68652091	chr11:68506083~68506166:-
THCA	cis	rs453301	0.631	rs28572014	ENSG00000233609.3	RP11-62H7.2	-3.99	7.71e-05	0.00623	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8936097	chr8:8961200~8979025:+
THCA	cis	rs4409675	0.871	rs12040493	ENSG00000227050.1	RP11-460I13.2	-3.99	7.71e-05	0.00623	-0.26	-0.18	Corneal astigmatism;	chr1:27908619	chr1:27938875~27960193:-
THCA	cis	rs9863	0.861	rs4930726	ENSG00000270061.1	RP11-214K3.19	-3.99	7.71e-05	0.00624	-0.23	-0.18	White blood cell count;	chr12:123943784	chr12:123969990~123970344:-
THCA	cis	rs17074492	0.671	rs7329313	ENSG00000214182.5	PTMAP5	3.99	7.71e-05	0.00624	0.23	0.18	Sjögren's syndrome;	chr13:81629167	chr13:81689911~81691072:+
THCA	cis	rs17074492	0.671	rs10507923	ENSG00000214182.5	PTMAP5	3.99	7.71e-05	0.00624	0.23	0.18	Sjögren's syndrome;	chr13:81634126	chr13:81689911~81691072:+
THCA	cis	rs3818717	0.538	rs12945601	ENSG00000281749.1	Y_RNA	3.99	7.71e-05	0.00624	0.23	0.18	Lymphocyte counts;	chr17:17750097	chr17:18001101~18001195:-
THCA	cis	rs10504861	0.559	rs1487960	ENSG00000253553.4	RP11-586K2.1	-3.99	7.71e-05	0.00624	-0.19	-0.18	Migraine without aura;	chr8:88531875	chr8:88326836~88737134:+
THCA	cis	rs9527	0.662	rs4919687	ENSG00000236937.2	PTGES3P4	3.99	7.72e-05	0.00624	0.26	0.18	Arsenic metabolism;	chr10:102835491	chr10:102845595~102845950:+
THCA	cis	rs9435732	0.778	rs9435665	ENSG00000268869.4	ESPNP	3.99	7.72e-05	0.00624	0.22	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16998042	chr1:16687339~16720157:-
THCA	cis	rs1023500	0.505	rs134891	ENSG00000182057.4	OGFRP1	3.99	7.72e-05	0.00624	0.21	0.18	Schizophrenia;	chr22:42279876	chr22:42269753~42275196:+
THCA	cis	rs394563	0.589	rs1900300	ENSG00000231760.4	RP11-350J20.5	-3.99	7.72e-05	0.00624	-0.23	-0.18	Dupuytren's disease;	chr6:149320491	chr6:149796151~149826294:-
THCA	cis	rs6494488	0.5	rs67799896	ENSG00000259635.1	AC100830.3	-3.99	7.72e-05	0.00624	-0.42	-0.18	Coronary artery disease;	chr15:64671577	chr15:64701248~64719602:+
THCA	cis	rs150992	0.587	rs4703340	ENSG00000246763.5	RGMB-AS1	-3.99	7.72e-05	0.00624	-0.18	-0.18	Body mass index;	chr5:99009083	chr5:98769618~98773469:-
THCA	cis	rs910316	0.967	rs10142770	ENSG00000259138.1	RP11-950C14.7	3.99	7.72e-05	0.00624	0.16	0.18	Height;	chr14:75058746	chr14:75127153~75136930:+
THCA	cis	rs9309473	0.847	rs13538	ENSG00000273245.1	RP11-434P11.2	3.99	7.72e-05	0.00624	0.26	0.18	Metabolite levels;	chr2:73641201	chr2:73750256~73750786:-
THCA	cis	rs6762	0.55	rs8672	ENSG00000255142.1	AP006621.6	3.99	7.72e-05	0.00624	0.13	0.18	Mean platelet volume;	chr11:838634	chr11:781645~782105:+
THCA	cis	rs4693089	0.604	rs12645412	ENSG00000213608.5	SLC25A14P1	3.99	7.72e-05	0.00625	0.21	0.18	Menopause (age at onset);	chr4:83431597	chr4:83477524~83478424:+
THCA	cis	rs13113518	0.783	rs11943206	ENSG00000223305.1	RN7SKP30	3.99	7.72e-05	0.00625	0.23	0.18	Height;	chr4:55570843	chr4:55540502~55540835:-
THCA	cis	rs7572733	0.534	rs13026569	ENSG00000231621.1	AC013264.2	3.99	7.72e-05	0.00625	0.19	0.18	Dermatomyositis;	chr2:197918606	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.534	rs4850815	ENSG00000231621.1	AC013264.2	3.99	7.72e-05	0.00625	0.19	0.18	Dermatomyositis;	chr2:197921443	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.515	rs12619300	ENSG00000231621.1	AC013264.2	3.99	7.72e-05	0.00625	0.19	0.18	Dermatomyositis;	chr2:197921766	chr2:197197991~197199273:+
THCA	cis	rs10043228	1	rs62384469	ENSG00000248445.4	SEMA6A-AS1	-3.99	7.73e-05	0.00625	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116289267	chr5:116447547~116508276:+
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000182586.6	LINC00334	-3.99	7.73e-05	0.00625	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45234340~45258730:+
THCA	cis	rs5758659	0.569	rs133294	ENSG00000270083.1	RP1-257I20.14	3.99	7.73e-05	0.00625	0.19	0.18	Cognitive function;	chr22:41986801	chr22:42089630~42090028:-
THCA	cis	rs9595908	0.746	rs7985640	ENSG00000212293.1	SNORA16	3.99	7.73e-05	0.00625	0.21	0.18	Body mass index;	chr13:32698228	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9591252	ENSG00000212293.1	SNORA16	3.99	7.73e-05	0.00625	0.21	0.18	Body mass index;	chr13:32698297	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.785	rs9596083	ENSG00000212293.1	SNORA16	3.99	7.73e-05	0.00625	0.21	0.18	Body mass index;	chr13:32700494	chr13:32420390~32420516:-
THCA	cis	rs293748	0.771	rs35701604	ENSG00000250155.1	CTD-2353F22.1	-3.99	7.73e-05	0.00625	-0.24	-0.18	Obesity-related traits;	chr5:37021831	chr5:36666214~36725195:-
THCA	cis	rs340849	0.703	rs17762150	ENSG00000274895.1	RP11-478J18.2	-3.99	7.73e-05	0.00625	-0.15	-0.18	Alzheimer's disease;	chr1:213951475	chr1:213983793~213986419:-
THCA	cis	rs9291059	0.572	rs9831772	ENSG00000236297.1	RP11-175P19.2	3.99	7.73e-05	0.00625	0.39	0.18	Depressive symptoms (multi-trait analysis);	chr3:193648150	chr3:193578812~193593090:-
THCA	cis	rs13113518	0.812	rs4864996	ENSG00000223305.1	RN7SKP30	3.99	7.73e-05	0.00625	0.23	0.18	Height;	chr4:55452921	chr4:55540502~55540835:-
THCA	cis	rs4792901	0.765	rs9894264	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43500629	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs9908678	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43504177	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs55956367	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43504916	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs9907507	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43509677	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.765	rs9908030	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43510523	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs9915326	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43511234	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs9893137	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43513560	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.729	rs9891052	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43515151	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs9895324	ENSG00000267151.3	RP11-100E5.2	3.99	7.73e-05	0.00625	0.2	0.18	Dupuytren's disease;	chr17:43516800	chr17:43444707~43451200:+
THCA	cis	rs17685	0.523	rs10246583	ENSG00000227038.2	AC005077.12	3.99	7.73e-05	0.00625	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76117349	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs55812043	ENSG00000227038.2	AC005077.12	3.99	7.73e-05	0.00625	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76117923	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs10264760	ENSG00000227038.2	AC005077.12	3.99	7.73e-05	0.00625	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76120376	chr7:76090431~76108779:-
THCA	cis	rs5753037	0.838	rs140147	ENSG00000279699.1	RP1-102K2.9	3.99	7.73e-05	0.00625	0.18	0.18	Type 1 diabetes;	chr22:29788610	chr22:30275215~30276951:-
THCA	cis	rs3770081	0.826	rs17026666	ENSG00000272564.1	RP11-548P2.2	-3.99	7.73e-05	0.00625	-0.29	-0.18	Facial emotion recognition (sad faces);	chr2:85847265	chr2:85904279~85904727:+
THCA	cis	rs5758511	0.689	rs56906457	ENSG00000205702.9	CYP2D7	3.99	7.74e-05	0.00625	0.19	0.18	Birth weight;	chr22:42232329	chr22:42140203~42144577:-
THCA	cis	rs6019512	0.625	rs4810885	ENSG00000227431.4	CSE1L-AS1	-3.99	7.74e-05	0.00625	-0.21	-0.18	Intelligence (multi-trait analysis);	chr20:48906417	chr20:49040463~49046044:-
THCA	cis	rs9595908	0.869	rs7998956	ENSG00000212293.1	SNORA16	3.99	7.74e-05	0.00625	0.21	0.18	Body mass index;	chr13:32622239	chr13:32420390~32420516:-
THCA	cis	rs1048886	0.938	rs73482585	ENSG00000271967.1	RP11-134K13.4	-3.99	7.74e-05	0.00625	-0.19	-0.18	Type 2 diabetes;	chr6:70493160	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs2346890	ENSG00000271967.1	RP11-134K13.4	-3.99	7.74e-05	0.00625	-0.19	-0.18	Type 2 diabetes;	chr6:70508055	chr6:70596438~70596980:+
THCA	cis	rs28512361	0.502	rs134859	ENSG00000280383.1	CTA-941F9.10	-3.99	7.74e-05	0.00626	-0.2	-0.18	Breast cancer;	chr22:45670163	chr22:45657019~45680130:+
THCA	cis	rs2682471	0.585	rs4763533	ENSG00000245648.1	RP11-277P12.20	3.99	7.74e-05	0.00626	0.18	0.18	Macrophage inflammatory protein 1a levels;	chr12:10446828	chr12:10363769~10398506:+
THCA	cis	rs1971762	0.545	rs10783586	ENSG00000270175.1	RP11-793H13.11	-3.99	7.74e-05	0.00626	-0.12	-0.18	Height;	chr12:53587037	chr12:53500162~53500936:-
THCA	cis	rs6479874	0.831	rs2660211	ENSG00000223502.1	RP11-96B5.3	-3.99	7.74e-05	0.00626	-0.22	-0.18	Migraine;	chr10:50988101	chr10:51062579~51068553:-
THCA	cis	rs250585	0.736	rs499812	ENSG00000260136.4	CTD-2270L9.4	3.99	7.74e-05	0.00626	0.14	0.18	Egg allergy;	chr16:23399098	chr16:23452758~23457606:+
THCA	cis	rs4713118	0.955	rs9393848	ENSG00000261839.1	RP1-265C24.8	3.99	7.74e-05	0.00626	0.2	0.18	Parkinson's disease;	chr6:27720590	chr6:28136849~28139678:+
THCA	cis	rs758324	0.947	rs687816	ENSG00000237714.1	P4HA2-AS1	-3.99	7.74e-05	0.00626	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131926384	chr5:132184876~132192808:+
THCA	cis	rs17092148	0.945	rs6060042	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.74e-05	0.00626	-0.21	-0.18	Neuroticism;	chr20:34773918	chr20:33985617~33988989:-
THCA	cis	rs7166081	1	rs16950804	ENSG00000270964.1	RP11-502I4.3	-3.99	7.75e-05	0.00626	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67262141	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs8025621	ENSG00000270964.1	RP11-502I4.3	-3.99	7.75e-05	0.00626	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67264388	chr15:67541072~67542604:-
THCA	cis	rs4950322	0.58	rs7514970	ENSG00000226015.2	CCT8P1	3.99	7.75e-05	0.00626	0.21	0.18	Protein quantitative trait loci;	chr1:147120516	chr1:147203276~147204932:-
THCA	cis	rs2364403	1	rs12080846	ENSG00000236675.1	MTX1P1	-3.99	7.75e-05	0.00626	-0.2	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:155959910	chr1:155230975~155234325:+
THCA	cis	rs950169	0.881	rs34117475	ENSG00000275120.1	RP11-182J1.17	3.99	7.75e-05	0.00626	0.21	0.18	Schizophrenia;	chr15:84565212	chr15:84599434~84606463:-
THCA	cis	rs7690839	0.525	rs1795734	ENSG00000270720.1	RP11-84C13.2	-3.99	7.75e-05	0.00626	-0.22	-0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89012479	chr4:89119284~89119871:+
THCA	cis	rs181553	0.664	rs1893529	ENSG00000266696.1	RP11-30L3.2	-3.99	7.75e-05	0.00626	-0.2	-0.18	Hip circumference adjusted for BMI;	chr18:49169906	chr18:49205912~49208781:+
THCA	cis	rs4742903	0.967	rs3739737	ENSG00000270332.1	SMC2-AS1	3.99	7.75e-05	0.00626	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104095911	chr9:104080024~104093073:-
THCA	cis	rs4792901	0.918	rs79868029	ENSG00000267151.3	RP11-100E5.2	3.99	7.75e-05	0.00626	0.19	0.18	Dupuytren's disease;	chr17:43545139	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.918	rs2271959	ENSG00000267151.3	RP11-100E5.2	3.99	7.75e-05	0.00626	0.19	0.18	Dupuytren's disease;	chr17:43545372	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.797	rs118013810	ENSG00000267151.3	RP11-100E5.2	3.99	7.75e-05	0.00626	0.19	0.18	Dupuytren's disease;	chr17:43548776	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.797	rs117711821	ENSG00000267151.3	RP11-100E5.2	3.99	7.75e-05	0.00626	0.19	0.18	Dupuytren's disease;	chr17:43548777	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.959	rs72833147	ENSG00000267151.3	RP11-100E5.2	3.99	7.75e-05	0.00626	0.19	0.18	Dupuytren's disease;	chr17:43549210	chr17:43444707~43451200:+
THCA	cis	rs724818	0.661	rs111357579	ENSG00000251609.2	SETP12	-3.99	7.75e-05	0.00626	-0.51	-0.18	Monobrow thickness;	chr4:120772524	chr4:120895494~120897083:-
THCA	cis	rs6878727	0.741	rs62371676	ENSG00000253807.4	LINC01170	-3.99	7.75e-05	0.00626	-0.19	-0.18	Breast cancer;	chr5:124386789	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.741	rs34206075	ENSG00000253807.4	LINC01170	-3.99	7.75e-05	0.00626	-0.19	-0.18	Breast cancer;	chr5:124387040	chr5:124059794~124405079:-
THCA	cis	rs2692947	0.732	rs56847058	ENSG00000235584.2	AC008268.1	-3.99	7.75e-05	0.00626	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95741145	chr2:95666084~95668715:+
THCA	cis	rs10090774	0.71	rs13266116	ENSG00000279766.1	RP11-642A1.2	-3.99	7.75e-05	0.00626	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140646656	chr8:140572142~140572812:-
THCA	cis	rs7246967	0.673	rs59621958	ENSG00000198153.8	ZNF849P	-3.99	7.75e-05	0.00626	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22757857	chr19:22685167~22686732:+
THCA	cis	rs7528684	0.546	rs2785666	ENSG00000236731.1	RP4-801G22.2	3.99	7.75e-05	0.00627	0.19	0.18	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157655332	chr1:157629939~157630728:-
THCA	cis	rs7528684	0.546	rs2785658	ENSG00000236731.1	RP4-801G22.2	3.99	7.75e-05	0.00627	0.19	0.18	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157661691	chr1:157629939~157630728:-
THCA	cis	rs7528684	0.584	rs12129106	ENSG00000236731.1	RP4-801G22.2	3.99	7.75e-05	0.00627	0.19	0.18	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157666860	chr1:157629939~157630728:-
THCA	cis	rs7829975	0.688	rs7837587	ENSG00000233609.3	RP11-62H7.2	3.99	7.75e-05	0.00627	0.18	0.18	Mood instability;	chr8:8521482	chr8:8961200~8979025:+
THCA	cis	rs7665090	0.87	rs228614	ENSG00000230069.3	LRRC37A15P	3.99	7.75e-05	0.00627	0.19	0.18	Primary biliary cholangitis;	chr4:102657480	chr4:102727274~102730721:-
THCA	cis	rs11771526	0.901	rs11773754	ENSG00000272905.1	RP11-265E18.1	3.99	7.76e-05	0.00627	0.24	0.18	Body mass index;	chr7:32265189	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.792	rs11770580	ENSG00000272905.1	RP11-265E18.1	3.99	7.76e-05	0.00627	0.24	0.18	Body mass index;	chr7:32265397	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs28631129	ENSG00000272905.1	RP11-265E18.1	3.99	7.76e-05	0.00627	0.24	0.18	Body mass index;	chr7:32265432	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs17161123	ENSG00000272905.1	RP11-265E18.1	3.99	7.76e-05	0.00627	0.24	0.18	Body mass index;	chr7:32265814	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs62457472	ENSG00000272905.1	RP11-265E18.1	3.99	7.76e-05	0.00627	0.24	0.18	Body mass index;	chr7:32267273	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs62457473	ENSG00000272905.1	RP11-265E18.1	3.99	7.76e-05	0.00627	0.24	0.18	Body mass index;	chr7:32267378	chr7:32845394~32846061:+
THCA	cis	rs1387259	0.929	rs2634666	ENSG00000273765.1	RP11-370I10.11	3.99	7.76e-05	0.00627	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48360920~48361377:+
THCA	cis	rs1387259	0.929	rs2956703	ENSG00000273765.1	RP11-370I10.11	3.99	7.76e-05	0.00627	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48360920~48361377:+
THCA	cis	rs1387259	0.931	rs1107654	ENSG00000273765.1	RP11-370I10.11	3.99	7.76e-05	0.00627	0.18	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48360920~48361377:+
THCA	cis	rs10090774	0.87	rs7834669	ENSG00000280303.2	ERICD	-3.99	7.76e-05	0.00627	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140724287	chr8:140636281~140638283:+
THCA	cis	rs13108904	0.846	rs9631804	ENSG00000254094.1	AC078852.1	3.99	7.76e-05	0.00627	0.21	0.18	Obesity-related traits;	chr4:1289244	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.846	rs9631805	ENSG00000254094.1	AC078852.1	3.99	7.76e-05	0.00627	0.21	0.18	Obesity-related traits;	chr4:1289247	chr4:1356581~1358075:+
THCA	cis	rs453301	0.719	rs34004903	ENSG00000233609.3	RP11-62H7.2	-3.99	7.76e-05	0.00627	-0.18	-0.18	Joint mobility (Beighton score);	chr8:9035094	chr8:8961200~8979025:+
THCA	cis	rs858239	0.539	rs6461695	ENSG00000230042.1	AK3P3	-3.99	7.76e-05	0.00627	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23129178~23129841:+
THCA	cis	rs9921338	0.597	rs181582	ENSG00000262636.1	CTD-3088G3.4	-3.99	7.76e-05	0.00627	-0.28	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249690	chr16:11380859~11381118:-
THCA	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-3.99	7.76e-05	0.00627	-0.17	-0.18	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.525	rs12506455	ENSG00000250413.1	RP11-448G15.1	-3.99	7.76e-05	0.00627	-0.17	-0.18	Bone mineral density;	chr4:10029945	chr4:10006482~10009725:+
THCA	cis	rs9828933	0.832	rs3774723	ENSG00000224479.4	AC136289.1	3.99	7.76e-05	0.00627	0.27	0.18	Type 2 diabetes;	chr3:63976663	chr3:63742293~63827445:-
THCA	cis	rs9810089	0.711	rs711972	ENSG00000273455.1	RP11-305O4.3	3.99	7.76e-05	0.00627	0.23	0.18	Gestational age at birth (child effect);	chr3:136391176	chr3:136087475~136087913:-
THCA	cis	rs67478160	0.619	rs10083370	ENSG00000269940.1	RP11-73M18.7	-3.99	7.76e-05	0.00627	-0.17	-0.18	Schizophrenia;	chr14:103847845	chr14:103694560~103695170:+
THCA	cis	rs67478160	0.619	rs10083367	ENSG00000269940.1	RP11-73M18.7	-3.99	7.76e-05	0.00627	-0.17	-0.18	Schizophrenia;	chr14:103847846	chr14:103694560~103695170:+
THCA	cis	rs690037	0.78	rs690437	ENSG00000272529.1	RP11-415F23.4	3.99	7.76e-05	0.00627	0.16	0.18	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16339383	chr3:16345126~16346440:+
THCA	cis	rs12451471	0.62	rs11150846	ENSG00000279259.1	RP11-334C17.3	-3.99	7.76e-05	0.00627	-0.18	-0.18	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80124721	chr17:80147250~80148596:+
THCA	cis	rs9907295	0.688	rs2251660	ENSG00000270871.1	AC015849.19	3.99	7.76e-05	0.00627	0.14	0.18	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35816717~35830293:-
THCA	cis	rs79481398	0.555	rs1292363	ENSG00000276772.1	CTD-2515H24.2	3.99	7.76e-05	0.00627	0.21	0.18	Facial morphology (factor 19);	chr15:57491052	chr15:57553955~57555680:+
THCA	cis	rs9660180	0.967	rs6687065	ENSG00000215914.4	MMP23A	-3.99	7.77e-05	0.00627	-0.24	-0.18	Body mass index;	chr1:1847030	chr1:1699942~1701782:+
THCA	cis	rs11633886	0.585	rs2460629	ENSG00000273972.1	CTD-2306A12.1	3.99	7.77e-05	0.00627	0.2	0.18	Diisocyanate-induced asthma;	chr15:45798785	chr15:45702640~45703183:+
THCA	cis	rs2341873	0.506	rs2128814	ENSG00000204588.5	LINC01123	-3.99	7.77e-05	0.00628	-0.2	-0.18	Neutrophil percentage of white cells;	chr2:110924261	chr2:109987063~109996140:+
THCA	cis	rs17685	0.753	rs4398845	ENSG00000230882.1	AC005077.14	3.99	7.77e-05	0.00628	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76087463	chr7:76071469~76074963:-
THCA	cis	rs9926296	0.546	rs6500442	ENSG00000274627.1	RP11-104N10.2	-3.99	7.77e-05	0.00628	-0.18	-0.18	Vitiligo;	chr16:89762454	chr16:89516797~89522217:+
THCA	cis	rs867186	1	rs11906148	ENSG00000126005.14	MMP24-AS1	-3.99	7.77e-05	0.00628	-0.29	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35196218	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs117802529	ENSG00000126005.14	MMP24-AS1	-3.99	7.77e-05	0.00628	-0.29	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35198874	chr20:35216462~35278131:-
THCA	cis	rs1008126	0.918	rs12536415	ENSG00000234715.1	CTB-107G13.1	3.99	7.77e-05	0.00628	0.22	0.18	Metabolite levels (Pyroglutamine);	chr7:103523105	chr7:103445207~103514007:+
THCA	cis	rs4742903	1	rs3739736	ENSG00000270332.1	SMC2-AS1	3.99	7.77e-05	0.00628	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104095627	chr9:104080024~104093073:-
THCA	cis	rs6600671	1	rs11249350	ENSG00000275585.1	CH17-118O6.3	-3.99	7.77e-05	0.00628	-0.22	-0.18	Hip geometry;	chr1:121436587	chr1:120985692~121052167:-
THCA	cis	rs2135507	0.708	rs35857359	ENSG00000270480.1	RP11-57B24.1	3.99	7.77e-05	0.00628	0.25	0.18	Juvenile osteochondritis dissecans;	chr4:82659670	chr4:82691737~82692468:+
THCA	cis	rs12134133	0.752	rs61821050	ENSG00000237074.1	RP11-6J21.2	3.99	7.77e-05	0.00628	0.2	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.752	rs61821051	ENSG00000237074.1	RP11-6J21.2	3.99	7.77e-05	0.00628	0.2	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207249067~207309121:+
THCA	cis	rs4245128	0.736	rs10891477	ENSG00000227487.3	NCAM1-AS1	3.99	7.77e-05	0.00628	0.18	0.18	Life satisfaction;	chr11:112942584	chr11:113269532~113273901:-
THCA	cis	rs786425	0.899	rs1515814	ENSG00000278112.1	RP11-972P1.11	3.99	7.77e-05	0.00628	0.17	0.18	Pubertal anthropometrics;	chr12:123624152	chr12:123519390~123519856:-
THCA	cis	rs172166	0.561	rs149973	ENSG00000280107.1	AL022393.9	-3.99	7.78e-05	0.00628	-0.17	-0.18	Cardiac Troponin-T levels;	chr6:28015835	chr6:28170845~28172521:+
THCA	cis	rs172166	0.561	rs149974	ENSG00000280107.1	AL022393.9	-3.99	7.78e-05	0.00628	-0.17	-0.18	Cardiac Troponin-T levels;	chr6:28017318	chr6:28170845~28172521:+
THCA	cis	rs12047808	0.544	rs3902993	ENSG00000227141.2	RP11-545A16.3	-3.99	7.78e-05	0.00628	-0.25	-0.18	Multiple sclerosis (age of onset);	chr1:179584291	chr1:179586705~179589175:+
THCA	cis	rs2562456	0.833	rs516519	ENSG00000268658.4	LINC00664	-3.99	7.78e-05	0.00628	-0.27	-0.18	Pain;	chr19:21298730	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.833	rs552800	ENSG00000268658.4	LINC00664	-3.99	7.78e-05	0.00628	-0.27	-0.18	Pain;	chr19:21301840	chr19:21483374~21503238:+
THCA	cis	rs17270561	0.666	rs1937129	ENSG00000272462.2	U91328.19	-3.99	7.78e-05	0.00628	-0.15	-0.18	Iron status biomarkers;	chr6:25788904	chr6:25992662~26001775:+
THCA	cis	rs11672691	0.871	rs2191139	ENSG00000270164.1	LINC01480	-3.99	7.78e-05	0.00628	-0.16	-0.18	Prostate cancer;	chr19:41495302	chr19:41535183~41536904:+
THCA	cis	rs853679	0.567	rs1005126	ENSG00000273712.1	RP5-874C20.7	3.99	7.78e-05	0.00628	0.22	0.18	Depression;	chr6:28399846	chr6:28315613~28315883:-
THCA	cis	rs9291683	0.679	rs3756225	ENSG00000261490.1	RP11-448G15.3	-3.99	7.78e-05	0.00628	-0.11	-0.18	Bone mineral density;	chr4:10092509	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.655	rs3822242	ENSG00000261490.1	RP11-448G15.3	-3.99	7.78e-05	0.00628	-0.11	-0.18	Bone mineral density;	chr4:10093280	chr4:10068089~10073019:-
THCA	cis	rs654950	0.875	rs34227270	ENSG00000230638.4	RP11-486B10.4	-3.99	7.78e-05	0.00628	-0.2	-0.18	Airway imaging phenotypes;	chr1:41533296	chr1:41542069~41544310:+
THCA	cis	rs9309473	0.539	rs7574268	ENSG00000273245.1	RP11-434P11.2	-3.99	7.78e-05	0.00628	-0.22	-0.18	Metabolite levels;	chr2:73677745	chr2:73750256~73750786:-
THCA	cis	rs7246967	0.611	rs16999571	ENSG00000198153.8	ZNF849P	-3.99	7.78e-05	0.00628	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22721962	chr19:22685167~22686732:+
THCA	cis	rs12216545	0.711	rs9632622	ENSG00000241134.3	BET1P1	-3.99	7.78e-05	0.00629	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150536131	chr7:150749736~150750094:+
THCA	cis	rs4460629	0.65	rs11264319	ENSG00000225855.5	RUSC1-AS1	3.99	7.78e-05	0.00629	0.12	0.18	Serum magnesium levels;	chr1:155111466	chr1:155316863~155324176:-
THCA	cis	rs17092148	1	rs1884432	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.78e-05	0.00629	-0.21	-0.18	Neuroticism;	chr20:34754636	chr20:33985617~33988989:-
THCA	cis	rs6012953	1	rs6020559	ENSG00000231715.1	COX6CP2	3.99	7.78e-05	0.00629	0.19	0.18	Vitiligo;	chr20:50502094	chr20:50479767~50479991:+
THCA	cis	rs62292953	0.589	rs79152208	ENSG00000248724.5	NPHP3-AS1	-3.99	7.78e-05	0.00629	-0.32	-0.18	Red cell distribution width;	chr3:132437860	chr3:132721750~132874223:+
THCA	cis	rs7259376	0.782	rs113181884	ENSG00000269138.1	ZNF209P	-3.99	7.79e-05	0.00629	-0.19	-0.18	Menopause (age at onset);	chr19:22403282	chr19:22463922~22473036:+
THCA	cis	rs2135507	0.817	rs28717711	ENSG00000270480.1	RP11-57B24.1	3.99	7.79e-05	0.00629	0.25	0.18	Juvenile osteochondritis dissecans;	chr4:82663974	chr4:82691737~82692468:+
THCA	cis	rs9677476	0.517	rs60664562	ENSG00000224376.1	AC017104.6	3.99	7.79e-05	0.00629	0.18	0.18	Food antigen IgG levels;	chr2:231196129	chr2:231388976~231394991:+
THCA	cis	rs1923243	0.71	rs4353041	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73152397	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4454487	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73152665	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs7417820	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73152773	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4454488	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73152946	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4369180	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73153069	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.71	rs4633241	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73153162	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.677	rs12144988	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73153632	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.648	rs12118804	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73153751	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.678	rs4465150	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73154483	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.678	rs34219974	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73154773	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.648	rs61766375	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73154945	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.678	rs68122083	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73155004	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.677	rs7528238	ENSG00000223479.3	RP4-788P17.1	3.99	7.79e-05	0.00629	0.2	0.18	Migraine;	chr1:73156565	chr1:73635216~73715214:+
THCA	cis	rs7926906	0.84	rs7926034	ENSG00000280367.1	RP11-121L10.2	3.99	7.79e-05	0.00629	0.17	0.18	Intelligence (multi-trait analysis);	chr11:90781628	chr11:90223153~90226538:+
THCA	cis	rs72647484	0.558	rs2807366	ENSG00000228397.1	RP1-224A6.3	-3.99	7.79e-05	0.00629	-0.52	-0.18	Colorectal cancer;	chr1:22157419	chr1:22023994~22024968:-
THCA	cis	rs7560272	0.501	rs2421676	ENSG00000163016.8	ALMS1P	-3.99	7.79e-05	0.00629	-0.23	-0.18	Schizophrenia;	chr2:73738960	chr2:73644919~73685576:+
THCA	cis	rs9923856	0.823	rs3862469	ENSG00000263033.2	RP11-396B14.2	-3.99	7.8e-05	0.00629	-0.15	-0.18	Atopic dermatitis;Adult asthma;	chr16:11100223	chr16:11196177~11224969:+
THCA	cis	rs3812831	0.629	rs7318527	ENSG00000264539.1	MIR548AR	3.99	7.8e-05	0.00629	0.19	0.18	Schizophrenia;	chr13:114181481	chr13:114244505~114244561:+
THCA	cis	rs765787	0.53	rs4514617	ENSG00000259932.1	CTD-2651B20.7	3.99	7.8e-05	0.0063	0.22	0.18	Uric acid levels;	chr15:45243241	chr15:45198517~45199139:-
THCA	cis	rs17723470	1	rs12284404	ENSG00000254427.1	RP11-430H10.1	3.99	7.8e-05	0.0063	0.2	0.18	Thyroid hormone levels;	chr11:45207135	chr11:45355371~45366121:+
THCA	cis	rs16957091	0.528	rs72713795	ENSG00000205771.5	CATSPER2P1	3.99	7.8e-05	0.0063	0.25	0.18	MGMT methylation in smokers;	chr15:42849430	chr15:43726918~43747094:-
THCA	cis	rs7259376	0.837	rs1368476	ENSG00000269138.1	ZNF209P	-3.99	7.8e-05	0.0063	-0.18	-0.18	Menopause (age at onset);	chr19:22403390	chr19:22463922~22473036:+
THCA	cis	rs5769765	0.913	rs8135071	ENSG00000260613.1	RP3-522J7.6	-3.99	7.8e-05	0.0063	-0.22	-0.18	Schizophrenia;	chr22:49905939	chr22:49832616~49837786:-
THCA	cis	rs2033711	0.755	rs4801587	ENSG00000269867.1	CTD-2583A14.8	-3.99	7.8e-05	0.0063	-0.15	-0.18	Uric acid clearance;	chr19:58425312	chr19:57867038~57868172:-
THCA	cis	rs5758659	0.652	rs133326	ENSG00000281538.1	RP4-669P10.20	3.99	7.8e-05	0.0063	0.17	0.18	Cognitive function;	chr22:42010881	chr22:42138060~42139726:+
THCA	cis	rs9516	0.9	rs3867277	ENSG00000254974.1	RP11-702H23.2	-3.99	7.8e-05	0.0063	-0.2	-0.18	Facial morphology (factor 15, philtrum width);	chr11:74452278	chr11:74485580~74486051:-
THCA	cis	rs6756513	0.505	rs2228203	ENSG00000231024.1	AC092431.3	-3.99	7.8e-05	0.0063	-0.27	-0.18	Breast cancer;Platelet count;	chr2:69806452	chr2:69700192~69713847:-
THCA	cis	rs1008126	0.8	rs2299331	ENSG00000234715.1	CTB-107G13.1	-3.99	7.81e-05	0.0063	-0.21	-0.18	Metabolite levels (Pyroglutamine);	chr7:103525375	chr7:103445207~103514007:+
THCA	cis	rs9309473	0.95	rs10189885	ENSG00000273245.1	RP11-434P11.2	3.99	7.81e-05	0.0063	0.26	0.18	Metabolite levels;	chr2:73649928	chr2:73750256~73750786:-
THCA	cis	rs9926296	0.548	rs12447465	ENSG00000274627.1	RP11-104N10.2	-3.99	7.81e-05	0.0063	-0.18	-0.18	Vitiligo;	chr16:89763487	chr16:89516797~89522217:+
THCA	cis	rs472402	0.58	rs3822430	ENSG00000250056.4	LINC01018	-3.99	7.81e-05	0.0063	-0.22	-0.18	Response to amphetamines;	chr5:6651857	chr5:6582136~6588499:+
THCA	cis	rs472402	0.58	rs3733773	ENSG00000250056.4	LINC01018	-3.99	7.81e-05	0.0063	-0.22	-0.18	Response to amphetamines;	chr5:6652139	chr5:6582136~6588499:+
THCA	cis	rs472402	0.56	rs10065299	ENSG00000250056.4	LINC01018	-3.99	7.81e-05	0.0063	-0.22	-0.18	Response to amphetamines;	chr5:6654376	chr5:6582136~6588499:+
THCA	cis	rs7176527	0.848	rs1374463	ENSG00000230373.7	GOLGA6L5P	3.99	7.81e-05	0.0063	0.26	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:84507885~84516814:-
THCA	cis	rs2070488	0.965	rs6805386	ENSG00000229589.1	ACVR2B-AS1	-3.99	7.81e-05	0.0063	-0.17	-0.18	Electrocardiographic conduction measures;	chr3:38516430	chr3:38451027~38454820:-
THCA	cis	rs12935418	0.733	rs12448615	ENSG00000278985.1	RP11-303E16.9	3.99	7.81e-05	0.0063	0.27	0.18	Mean corpuscular volume;	chr16:80947132	chr16:80982319~80984094:-
THCA	cis	rs7216064	0.953	rs62086043	ENSG00000278740.1	RP11-147L13.14	3.99	7.81e-05	0.0063	0.2	0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971887	chr17:68188547~68189165:+
THCA	cis	rs12143943	0.934	rs17335392	ENSG00000240219.1	RP11-430C7.5	3.99	7.81e-05	0.0063	0.16	0.18	Cognitive performance;	chr1:204626771	chr1:204626775~204629712:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000275400.1	RP4-756H11.5	-3.99	7.81e-05	0.0063	-0.17	-0.18	Aortic root size;	chr7:66521858	chr7:66553805~66554199:-
THCA	cis	rs12682352	0.602	rs635594	ENSG00000253981.4	ALG1L13P	-3.99	7.81e-05	0.0063	-0.17	-0.18	Neuroticism;	chr8:8755877	chr8:8236003~8244667:-
THCA	cis	rs2070488	0.965	rs6599209	ENSG00000229589.1	ACVR2B-AS1	-3.99	7.81e-05	0.0063	-0.17	-0.18	Electrocardiographic conduction measures;	chr3:38516706	chr3:38451027~38454820:-
THCA	cis	rs3796352	0.667	rs11712872	ENSG00000242142.1	SERBP1P3	-3.99	7.81e-05	0.00631	-0.35	-0.18	Immune reponse to smallpox (secreted IL-2);	chr3:52801498	chr3:53064283~53065091:-
THCA	cis	rs3781264	0.848	rs6583935	ENSG00000273450.1	RP11-76P2.4	3.99	7.81e-05	0.00631	0.22	0.18	Esophageal cancer and gastric cancer;	chr10:94313568	chr10:94314907~94315327:-
THCA	cis	rs4074961	0.669	rs6687545	ENSG00000233621.1	LINC01137	-3.99	7.81e-05	0.00631	-0.19	-0.18	Axial length;	chr1:37605594	chr1:37454879~37474411:-
THCA	cis	rs755249	0.727	rs2242500	ENSG00000182109.6	RP11-69E11.4	3.99	7.81e-05	0.00631	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39522280~39546187:-
THCA	cis	rs2836974	0.568	rs7282604	ENSG00000255568.3	BRWD1-AS2	-3.99	7.81e-05	0.00631	-0.15	-0.18	Cognitive function;	chr21:39164984	chr21:39313935~39314962:+
THCA	cis	rs2524005	1	rs2524005	ENSG00000231130.1	HLA-T	-3.99	7.82e-05	0.00631	-0.28	-0.18	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29896654~29897786:+
THCA	cis	rs520525	0.927	rs583006	ENSG00000271811.1	RP1-79C4.4	3.99	7.82e-05	0.00631	0.23	0.18	Atrial fibrillation;	chr1:170659247	chr1:170667381~170669425:+
THCA	cis	rs3738443	0.951	rs4269806	ENSG00000259865.1	RP11-488L18.10	3.99	7.82e-05	0.00631	0.19	0.18	Alcohol dependence;	chr1:247211721	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.951	rs4551629	ENSG00000259865.1	RP11-488L18.10	3.99	7.82e-05	0.00631	0.19	0.18	Alcohol dependence;	chr1:247211748	chr1:247187281~247188526:-
THCA	cis	rs9307551	0.817	rs6852514	ENSG00000249646.2	OR7E94P	-3.99	7.82e-05	0.00631	-0.23	-0.18	Refractive error;	chr4:79580759	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.744	rs968176	ENSG00000249646.2	OR7E94P	-3.99	7.82e-05	0.00631	-0.23	-0.18	Refractive error;	chr4:79585080	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.817	rs1440852	ENSG00000249646.2	OR7E94P	-3.99	7.82e-05	0.00631	-0.23	-0.18	Refractive error;	chr4:79585435	chr4:79587302~79588130:-
THCA	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	3.99	7.82e-05	0.00631	0.09	0.18	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
THCA	cis	rs8141529	0.719	rs132561	ENSG00000226471.5	CTA-292E10.6	3.99	7.82e-05	0.00631	0.15	0.18	Lymphocyte counts;	chr22:28955191	chr22:28800683~28848559:+
THCA	cis	rs9314614	0.872	rs2738060	ENSG00000245857.2	GS1-24F4.2	3.98	7.82e-05	0.00631	0.23	0.18	White blood cell count (basophil);IgA nephropathy;	chr8:6852411	chr8:6835554~6885276:+
THCA	cis	rs10802047	0.54	rs1006189	ENSG00000231365.4	RP11-418J17.1	3.98	7.82e-05	0.00631	0.18	0.18	Relative hand skill in reading disability;	chr1:118850917	chr1:119140396~119275973:+
THCA	cis	rs2797160	0.547	rs4144549	ENSG00000226409.1	RP11-735G4.1	3.98	7.82e-05	0.00631	0.23	0.18	Endometrial cancer;	chr6:125624105	chr6:125370211~125374324:-
THCA	cis	rs9595908	0.686	rs9596155	ENSG00000212293.1	SNORA16	3.98	7.82e-05	0.00631	0.21	0.18	Body mass index;	chr13:32724002	chr13:32420390~32420516:-
THCA	cis	rs8177876	0.686	rs2602402	ENSG00000261061.1	RP11-303E16.2	-3.98	7.82e-05	0.00631	-0.23	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81052725	chr16:81030770~81031485:+
THCA	cis	rs1371614	0.523	rs2891534	ENSG00000272148.1	RP11-195B17.1	3.98	7.82e-05	0.00631	0.16	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26961578	chr2:27062428~27062907:-
THCA	cis	rs933688	0.526	rs2973468	ENSG00000260871.1	CTD-2373J6.1	-3.98	7.82e-05	0.00631	-0.33	-0.18	Smoking behavior;	chr5:91245062	chr5:90388468~90389363:-
THCA	cis	rs3733585	0.605	rs7656624	ENSG00000261490.1	RP11-448G15.3	-3.98	7.82e-05	0.00631	-0.12	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10119473	chr4:10068089~10073019:-
THCA	cis	rs1667255	1	rs1080094	ENSG00000266521.1	RP11-650P15.1	3.98	7.82e-05	0.00631	0.23	0.18	Retinol levels;	chr18:31593832	chr18:31496645~31497195:-
THCA	cis	rs8115854	0.922	rs6031893	ENSG00000269846.1	RP4-621N11.2	-3.98	7.82e-05	0.00631	-0.23	-0.18	Hippocampal atrophy;	chr20:37184626	chr20:37095785~37097178:+
THCA	cis	rs11719291	0.915	rs1048940	ENSG00000229759.1	MRPS18AP1	-3.98	7.83e-05	0.00631	-0.41	-0.18	Cognitive function;	chr3:48688274	chr3:48256350~48256938:-
THCA	cis	rs9868809	0.505	rs73080312	ENSG00000229759.1	MRPS18AP1	-3.98	7.83e-05	0.00631	-0.41	-0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48700414	chr3:48256350~48256938:-
THCA	cis	rs4934494	0.525	rs10881611	ENSG00000232936.4	RP11-80H5.2	3.98	7.83e-05	0.00632	0.22	0.18	Red blood cell count;	chr10:89623664	chr10:89645282~89650667:+
THCA	cis	rs11176749	1	rs78418655	ENSG00000256172.1	RP11-473M14.3	3.98	7.83e-05	0.00632	0.26	0.18	Expressive vocabulary in infants;	chr12:67457434	chr12:67440998~67442559:-
THCA	cis	rs1552244	0.554	rs17050704	ENSG00000269982.1	RP11-1020A11.2	3.98	7.83e-05	0.00632	0.13	0.18	Alzheimer's disease;	chr3:10004050	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs34883592	ENSG00000269982.1	RP11-1020A11.2	3.98	7.83e-05	0.00632	0.13	0.18	Alzheimer's disease;	chr3:10004481	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs17050705	ENSG00000269982.1	RP11-1020A11.2	3.98	7.83e-05	0.00632	0.13	0.18	Alzheimer's disease;	chr3:10004714	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs2272120	ENSG00000269982.1	RP11-1020A11.2	3.98	7.83e-05	0.00632	0.13	0.18	Alzheimer's disease;	chr3:10005019	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs13079240	ENSG00000269982.1	RP11-1020A11.2	3.98	7.83e-05	0.00632	0.13	0.18	Alzheimer's disease;	chr3:10005562	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs2272121	ENSG00000269982.1	RP11-1020A11.2	3.98	7.83e-05	0.00632	0.13	0.18	Alzheimer's disease;	chr3:10005996	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs3732965	ENSG00000269982.1	RP11-1020A11.2	3.98	7.83e-05	0.00632	0.13	0.18	Alzheimer's disease;	chr3:10007076	chr3:9958717~9962539:+
THCA	cis	rs10266483	0.515	rs6948710	ENSG00000234338.1	RP11-797H7.1	-3.98	7.83e-05	0.00632	-0.15	-0.18	Response to statin therapy;	chr7:64405625	chr7:64835280~64836882:-
THCA	cis	rs2904297	1	rs2904297	ENSG00000261490.1	RP11-448G15.3	-3.98	7.83e-05	0.00632	-0.12	-0.18	Hashimoto thyroiditis versus Graves' disease;	chr4:11038666	chr4:10068089~10073019:-
THCA	cis	rs4713118	0.505	rs276371	ENSG00000261839.1	RP1-265C24.8	3.98	7.83e-05	0.00632	0.17	0.18	Parkinson's disease;	chr6:27942930	chr6:28136849~28139678:+
THCA	cis	rs253959	0.739	rs712573	ENSG00000250015.1	CTC-339F2.2	-3.98	7.83e-05	0.00632	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr5:116302121	chr5:116302354~116304134:-
THCA	cis	rs911555	0.723	rs12894652	ENSG00000269958.1	RP11-73M18.8	-3.98	7.83e-05	0.00632	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103696353~103697163:+
THCA	cis	rs875971	1	rs709597	ENSG00000230189.5	GS1-124K5.2	-3.98	7.83e-05	0.00632	-0.12	-0.18	Aortic root size;	chr7:66360996	chr7:66409143~66490059:-
THCA	cis	rs9650657	0.504	rs10109167	ENSG00000255046.1	RP11-297N6.4	3.98	7.83e-05	0.00632	0.19	0.18	Neuroticism;	chr8:11176016	chr8:11797928~11802568:-
THCA	cis	rs150992	0.673	rs161747	ENSG00000246763.5	RGMB-AS1	-3.98	7.83e-05	0.00632	-0.19	-0.18	Body mass index;	chr5:98920433	chr5:98769618~98773469:-
THCA	cis	rs2070488	0.965	rs2154778	ENSG00000229589.1	ACVR2B-AS1	-3.98	7.83e-05	0.00632	-0.17	-0.18	Electrocardiographic conduction measures;	chr3:38512148	chr3:38451027~38454820:-
THCA	cis	rs2070488	0.965	rs1065800	ENSG00000229589.1	ACVR2B-AS1	-3.98	7.83e-05	0.00632	-0.17	-0.18	Electrocardiographic conduction measures;	chr3:38524989	chr3:38451027~38454820:-
THCA	cis	rs6806253	0.774	rs34704109	ENSG00000239405.1	TMED10P2	3.98	7.84e-05	0.00632	0.29	0.18	Pit-and-Fissure caries;	chr3:128538563	chr3:128538020~128538631:+
THCA	cis	rs2070488	1	rs1002676	ENSG00000229589.1	ACVR2B-AS1	-3.98	7.84e-05	0.00632	-0.17	-0.18	Electrocardiographic conduction measures;	chr3:38403441	chr3:38451027~38454820:-
THCA	cis	rs2562784	0.638	rs2562762	ENSG00000225151.9	GOLGA2P7	-3.98	7.84e-05	0.00632	-0.33	-0.18	Height;	chr15:83598835	chr15:84199311~84230136:-
THCA	cis	rs7904321	0.966	rs1396965	ENSG00000232075.1	MRPL35P2	-3.98	7.84e-05	0.00632	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63079810	chr10:63634317~63634827:-
THCA	cis	rs564343	0.545	rs576836	ENSG00000255120.4	OVOL1-AS1	3.98	7.84e-05	0.00632	0.23	0.18	Obesity (early onset extreme);	chr11:66056098	chr11:65789051~65790868:-
THCA	cis	rs2115630	1	rs11854291	ENSG00000275120.1	RP11-182J1.17	-3.98	7.84e-05	0.00632	-0.19	-0.18	P wave terminal force;	chr15:84820477	chr15:84599434~84606463:-
THCA	cis	rs6690583	0.524	rs12030837	ENSG00000226970.2	RP11-82H13.2	-3.98	7.84e-05	0.00632	-0.31	-0.18	Serum sulfate level;	chr1:85053700	chr1:84244334~84244577:+
THCA	cis	rs2190422	0.551	rs56345626	ENSG00000234715.1	CTB-107G13.1	-3.98	7.84e-05	0.00633	-0.26	-0.18	Morning vs. evening chronotype;	chr7:103515417	chr7:103445207~103514007:+
THCA	cis	rs13034020	0.641	rs34230978	ENSG00000271889.1	RP11-493E12.1	-3.98	7.84e-05	0.00633	-0.25	-0.18	Hodgkin's lymphoma;	chr2:60994388	chr2:61151433~61162105:-
THCA	cis	rs7259376	0.704	rs1897613	ENSG00000269138.1	ZNF209P	3.98	7.84e-05	0.00633	0.18	0.18	Menopause (age at onset);	chr19:22390773	chr19:22463922~22473036:+
THCA	cis	rs6504108	0.624	rs2021811	ENSG00000264920.1	RP11-6N17.4	-3.98	7.84e-05	0.00633	-0.15	-0.18	Body mass index;	chr17:48160420	chr17:47891255~47895812:-
THCA	cis	rs950169	0.922	rs4842939	ENSG00000275120.1	RP11-182J1.17	-3.98	7.84e-05	0.00633	-0.19	-0.18	Schizophrenia;	chr15:84159214	chr15:84599434~84606463:-
THCA	cis	rs1612141	1	rs1782166	ENSG00000251363.2	RP11-129M6.1	-3.98	7.84e-05	0.00633	-0.27	-0.18	QT interval (drug interaction);	chr14:41201450	chr14:40954898~40975877:+
THCA	cis	rs16975963	0.895	rs8103383	ENSG00000226686.6	LINC01535	-3.98	7.84e-05	0.00633	-0.24	-0.18	Longevity;	chr19:37837061	chr19:37251912~37265535:+
THCA	cis	rs293748	0.882	rs151946	ENSG00000250155.1	CTD-2353F22.1	-3.98	7.85e-05	0.00633	-0.25	-0.18	Obesity-related traits;	chr5:36884064	chr5:36666214~36725195:-
THCA	cis	rs293748	0.882	rs158793	ENSG00000250155.1	CTD-2353F22.1	-3.98	7.85e-05	0.00633	-0.25	-0.18	Obesity-related traits;	chr5:36884988	chr5:36666214~36725195:-
THCA	cis	rs73230612	1	rs6805723	ENSG00000242767.1	ZBTB20-AS4	-3.98	7.85e-05	0.00633	-0.24	-0.18	Type 2 diabetes;	chr3:115069821	chr3:115100423~115103061:+
THCA	cis	rs12612619	0.695	rs10207670	ENSG00000272148.1	RP11-195B17.1	-3.98	7.85e-05	0.00633	-0.19	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020133	chr2:27062428~27062907:-
THCA	cis	rs9905704	0.647	rs7221274	ENSG00000224738.1	AC099850.1	3.98	7.85e-05	0.00633	0.22	0.18	Testicular germ cell tumor;	chr17:58930767	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.671	rs28709536	ENSG00000224738.1	AC099850.1	3.98	7.85e-05	0.00633	0.22	0.18	Testicular germ cell tumor;	chr17:58931551	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.647	rs11079367	ENSG00000224738.1	AC099850.1	3.98	7.85e-05	0.00633	0.22	0.18	Testicular germ cell tumor;	chr17:58931663	chr17:59106598~59118267:+
THCA	cis	rs854765	0.594	rs8066560	ENSG00000281749.1	Y_RNA	-3.98	7.85e-05	0.00633	-0.24	-0.18	Total body bone mineral density;	chr17:17824729	chr17:18001101~18001195:-
THCA	cis	rs250518	0.926	rs34669	ENSG00000272081.1	CTD-2376I4.2	-3.98	7.85e-05	0.00633	-0.23	-0.18	Mean corpuscular hemoglobin concentration;	chr5:72866437	chr5:72955206~72955699:-
THCA	cis	rs3764021	0.933	rs2268146	ENSG00000214776.8	RP11-726G1.1	3.98	7.85e-05	0.00633	0.22	0.18	Type 1 diabetes;	chr12:9716675	chr12:9467552~9576275:+
THCA	cis	rs4742903	1	rs3818625	ENSG00000270332.1	SMC2-AS1	3.98	7.85e-05	0.00633	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104094171	chr9:104080024~104093073:-
THCA	cis	rs2380205	0.538	rs11255698	ENSG00000232807.2	RP11-536K7.3	3.98	7.85e-05	0.00633	0.18	0.18	Breast cancer;	chr10:5878930	chr10:5934270~5945900:-
THCA	cis	rs6012564	0.819	rs6012565	ENSG00000230758.1	SNAP23P	-3.98	7.85e-05	0.00633	-0.23	-0.18	Anger;	chr20:48938999	chr20:49038357~49038602:-
THCA	cis	rs4295623	0.816	rs35558975	ENSG00000255046.1	RP11-297N6.4	3.98	7.85e-05	0.00633	0.19	0.18	Morning vs. evening chronotype;	chr8:11726967	chr8:11797928~11802568:-
THCA	cis	rs2239547	0.618	rs13083728	ENSG00000243224.1	RP5-1157M23.2	-3.98	7.85e-05	0.00633	-0.21	-0.18	Schizophrenia;	chr3:52834429	chr3:52239258~52241097:+
THCA	cis	rs4915077	1	rs76590353	ENSG00000226822.1	RP11-356N1.2	3.98	7.85e-05	0.00633	0.32	0.18	Hypothyroidism;	chr1:107800002	chr1:108071482~108074519:+
THCA	cis	rs964611	1	rs16960758	ENSG00000259488.2	RP11-154J22.1	-3.98	7.85e-05	0.00633	-0.18	-0.18	Metabolite levels (Pyroglutamine);	chr15:48314955	chr15:48312353~48331856:-
THCA	cis	rs911555	0.755	rs12436729	ENSG00000269910.1	RP11-73M18.10	-3.98	7.86e-05	0.00634	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103694516~103695050:-
THCA	cis	rs131777	0.577	rs5770928	ENSG00000205559.3	CHKB-AS1	-3.98	7.86e-05	0.00634	-0.23	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50583026~50583877:+
THCA	cis	rs10435719	0.902	rs6601633	ENSG00000254948.1	OR7E158P	3.98	7.86e-05	0.00634	0.23	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11919900~11920809:-
THCA	cis	rs8031584	0.958	rs34909055	ENSG00000270015.1	RP11-540B6.6	-3.98	7.86e-05	0.00634	-0.13	-0.18	Huntington's disease progression;	chr15:30991967	chr15:30926514~30928407:+
THCA	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	3.98	7.86e-05	0.00634	0.17	0.18	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
THCA	cis	rs17221829	0.733	rs112601489	ENSG00000280385.1	AP000648.5	-3.98	7.86e-05	0.00634	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89632681	chr11:90193614~90198120:+
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000265443.1	CTD-2349P21.6	-3.98	7.86e-05	0.00634	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30726305~30727564:-
THCA	cis	rs3818717	0.541	rs55767800	ENSG00000281749.1	Y_RNA	-3.98	7.86e-05	0.00634	-0.23	-0.18	Lymphocyte counts;	chr17:17771653	chr17:18001101~18001195:-
THCA	cis	rs7176527	0.5	rs895571	ENSG00000225151.9	GOLGA2P7	3.98	7.86e-05	0.00634	0.26	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:84199311~84230136:-
THCA	cis	rs448720	0.684	rs338346	ENSG00000260657.2	RP11-315D16.4	-3.98	7.86e-05	0.00634	-0.22	-0.18	Cognitive performance;	chr15:67932831	chr15:68267792~68277994:-
THCA	cis	rs448720	0.684	rs338347	ENSG00000260657.2	RP11-315D16.4	-3.98	7.86e-05	0.00634	-0.22	-0.18	Cognitive performance;	chr15:67933483	chr15:68267792~68277994:-
THCA	cis	rs1371614	0.635	rs12612520	ENSG00000272148.1	RP11-195B17.1	-3.98	7.86e-05	0.00634	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914439	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.635	rs12612619	ENSG00000272148.1	RP11-195B17.1	-3.98	7.86e-05	0.00634	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914803	chr2:27062428~27062907:-
THCA	cis	rs1876905	1	rs1876905	ENSG00000272356.1	RP5-1112D6.8	-3.98	7.86e-05	0.00634	-0.18	-0.18	Mean corpuscular hemoglobin;	chr6:111096756	chr6:111309203~111313517:+
THCA	cis	rs7985	0.967	rs73163299	ENSG00000244625.4	MIATNB	3.98	7.87e-05	0.00634	0.21	0.18	Electroencephalogram traits;	chr22:26671680	chr22:26672767~26780207:+
THCA	cis	rs10435719	0.867	rs34465618	ENSG00000254948.1	OR7E158P	-3.98	7.87e-05	0.00634	-0.23	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.867	rs34583868	ENSG00000254948.1	OR7E158P	-3.98	7.87e-05	0.00634	-0.23	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:11919900~11920809:-
THCA	cis	rs8130944	0.964	rs12626774	ENSG00000235772.1	AP001625.6	3.98	7.87e-05	0.00635	0.2	0.18	Perceived unattractiveness to mosquitoes;	chr21:42718938	chr21:42560374~42561934:-
THCA	cis	rs9959145	1	rs9946557	ENSG00000267199.1	RP11-861E21.2	3.98	7.87e-05	0.00635	0.24	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12563862	chr18:12438890~12448205:+
THCA	cis	rs2904524	1	rs2904524	ENSG00000257815.4	RP11-611E13.2	-3.98	7.87e-05	0.00635	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70296305	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.867	rs77337632	ENSG00000257815.4	RP11-611E13.2	-3.98	7.87e-05	0.00635	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70297167	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs74809484	ENSG00000257815.4	RP11-611E13.2	-3.98	7.87e-05	0.00635	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70299136	chr12:69904033~70243360:-
THCA	cis	rs7927592	0.956	rs55816191	ENSG00000160172.9	FAM86C2P	3.98	7.87e-05	0.00635	0.17	0.18	Total body bone mineral density;	chr11:68495511	chr11:67791648~67805336:-
THCA	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	3.98	7.88e-05	0.00635	0.21	0.18	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	3.98	7.88e-05	0.00635	0.21	0.18	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	3.98	7.88e-05	0.00635	0.21	0.18	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
THCA	cis	rs3764021	0.87	rs7956831	ENSG00000214776.8	RP11-726G1.1	-3.98	7.88e-05	0.00635	-0.22	-0.18	Type 1 diabetes;	chr12:9736561	chr12:9467552~9576275:+
THCA	cis	rs11105298	0.891	rs10777184	ENSG00000266347.2	AC068641.1	3.98	7.88e-05	0.00635	0.23	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89592833~89592927:+
THCA	cis	rs11634944	0.716	rs1030389	ENSG00000257151.1	PWAR6	-3.98	7.88e-05	0.00635	-0.13	-0.18	Interleukin-8 levels;	chr15:25032641	chr15:25031873~25036490:+
THCA	cis	rs12410462	0.551	rs1923819	ENSG00000227711.2	RP11-275O4.5	3.98	7.88e-05	0.00635	0.22	0.18	Major depressive disorder;	chr1:227686613	chr1:227509028~227520477:-
THCA	cis	rs1125355	1	rs111609722	ENSG00000243792.1	OR7E89P	-3.98	7.88e-05	0.00635	-0.28	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158850333	chr2:158853755~158854576:+
THCA	cis	rs860295	0.702	rs3851912	ENSG00000236675.1	MTX1P1	-3.98	7.88e-05	0.00635	-0.19	-0.18	Body mass index;	chr1:155616653	chr1:155230975~155234325:+
THCA	cis	rs13098911	0.54	rs76597151	ENSG00000226074.4	PRSS44	-3.98	7.88e-05	0.00635	-0.33	-0.18	Celiac disease;	chr3:45959735	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs35827997	ENSG00000226074.4	PRSS44	-3.98	7.88e-05	0.00635	-0.33	-0.18	Celiac disease;	chr3:45960228	chr3:46809359~46812558:-
THCA	cis	rs3808502	0.503	rs2061830	ENSG00000206014.6	OR7E161P	-3.98	7.88e-05	0.00635	-0.21	-0.18	Neuroticism;	chr8:11539948	chr8:11928597~11929563:-
THCA	cis	rs853679	0.607	rs13199649	ENSG00000220721.1	OR1F12	3.98	7.88e-05	0.00636	0.41	0.18	Depression;	chr6:27901014	chr6:28073316~28074233:+
THCA	cis	rs733592	0.507	rs3825403	ENSG00000258273.1	RP11-370I10.4	3.98	7.88e-05	0.00636	0.22	0.18	Plateletcrit;	chr12:48063376	chr12:48333755~48333901:-
THCA	cis	rs11168351	0.591	rs4258439	ENSG00000258273.1	RP11-370I10.4	3.98	7.88e-05	0.00636	0.22	0.18	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48333755~48333901:-
THCA	cis	rs733592	0.507	rs10747529	ENSG00000258273.1	RP11-370I10.4	3.98	7.88e-05	0.00636	0.22	0.18	Plateletcrit;	chr12:48079586	chr12:48333755~48333901:-
THCA	cis	rs472402	0.58	rs10076470	ENSG00000250056.4	LINC01018	-3.98	7.88e-05	0.00636	-0.22	-0.18	Response to amphetamines;	chr5:6632762	chr5:6582136~6588499:+
THCA	cis	rs13434995	0.513	rs6554291	ENSG00000249700.7	SRD5A3-AS1	-3.98	7.88e-05	0.00636	-0.25	-0.18	Adiponectin levels;	chr4:55571204	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs7665846	ENSG00000249700.7	SRD5A3-AS1	3.98	7.88e-05	0.00636	0.25	0.18	Adiponectin levels;	chr4:55573078	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs2412658	ENSG00000249700.7	SRD5A3-AS1	3.98	7.88e-05	0.00636	0.25	0.18	Adiponectin levels;	chr4:55577050	chr4:55363971~55395847:-
THCA	cis	rs7737355	0.947	rs9885286	ENSG00000237714.1	P4HA2-AS1	3.98	7.88e-05	0.00636	0.26	0.18	Life satisfaction;	chr5:131547577	chr5:132184876~132192808:+
THCA	cis	rs7520050	0.966	rs1768816	ENSG00000281133.1	AL355480.3	3.98	7.89e-05	0.00636	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45580892~45580996:-
THCA	cis	rs8179	1	rs8179	ENSG00000230927.2	TMBIM7P	-3.98	7.89e-05	0.00636	-0.28	-0.18	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92606850	chr7:92412976~92439562:-
THCA	cis	rs6442522	0.56	rs2305612	ENSG00000249786.6	EAF1-AS1	3.98	7.89e-05	0.00636	0.19	0.18	Uric acid levels;	chr3:15477224	chr3:15436171~15455940:-
THCA	cis	rs17092148	0.731	rs35507767	ENSG00000276073.1	RP5-1125A11.7	-3.98	7.89e-05	0.00636	-0.21	-0.18	Neuroticism;	chr20:34773561	chr20:33985617~33988989:-
THCA	cis	rs2033711	0.87	rs11669741	ENSG00000269054.1	CTD-2619J13.3	3.98	7.89e-05	0.00636	0.15	0.18	Uric acid clearance;	chr19:58449114	chr19:58362585~58366591:+
THCA	cis	rs12474906	0.519	rs13414801	ENSG00000223522.1	AC093690.1	3.98	7.89e-05	0.00636	0.19	0.18	Schizophrenia;	chr2:28067480	chr2:28307691~28310459:-
THCA	cis	rs28735056	0.875	rs62103181	ENSG00000261126.6	RP11-795F19.1	3.98	7.89e-05	0.00636	0.15	0.18	Schizophrenia;	chr18:79865652	chr18:80046900~80095482:+
THCA	cis	rs5753037	0.653	rs131277	ENSG00000279699.1	RP1-102K2.9	3.98	7.89e-05	0.00636	0.18	0.18	Type 1 diabetes;	chr22:29758112	chr22:30275215~30276951:-
THCA	cis	rs2271404	0.506	rs10197366	ENSG00000227992.1	AC108463.2	3.98	7.89e-05	0.00636	0.24	0.18	Atopic dermatitis;	chr2:111239208	chr2:111203964~111206215:-
THCA	cis	rs3764021	0.87	rs7956831	ENSG00000256594.6	RP11-705C15.2	-3.98	7.9e-05	0.00636	-0.14	-0.18	Type 1 diabetes;	chr12:9736561	chr12:9633419~9658412:+
THCA	cis	rs6046396	1	rs2145552	ENSG00000233895.1	RP1-122P22.2	-3.98	7.9e-05	0.00636	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr20:19881604	chr20:19757708~19809675:+
THCA	cis	rs4682868	0.583	rs10865925	ENSG00000273328.4	RP11-141M3.6	-3.98	7.9e-05	0.00636	-0.22	-0.18	Monocyte percentage of white cells;	chr3:42872118	chr3:42809414~42908105:+
THCA	cis	rs365302	1	rs475074	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159227026	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs474108	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159227122	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs531165	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159227188	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs2245986	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159227629	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs416321	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159227875	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs375423	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159227924	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs422470	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159228628	chr6:159240786~159243329:+
THCA	cis	rs365302	0.904	rs422232	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159228713	chr6:159240786~159243329:+
THCA	cis	rs365302	0.904	rs410879	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159228715	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs375150	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159228993	chr6:159240786~159243329:+
THCA	cis	rs365302	0.904	rs392551	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159229142	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs509648	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159229946	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs486468	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159230173	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs485368	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159230329	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs483575	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159230515	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs481899	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159230639	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs480052	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159230837	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs542031	ENSG00000235086.1	FNDC1-IT1	3.98	7.9e-05	0.00636	0.25	0.18	Coronary heart disease;	chr6:159230935	chr6:159240786~159243329:+
THCA	cis	rs365302	0.909	rs12191109	ENSG00000235086.1	FNDC1-IT1	-3.98	7.9e-05	0.00636	-0.25	-0.18	Coronary heart disease;	chr6:159231071	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs823903	ENSG00000235086.1	FNDC1-IT1	-3.98	7.9e-05	0.00636	-0.25	-0.18	Coronary heart disease;	chr6:159231413	chr6:159240786~159243329:+
THCA	cis	rs9733	0.744	rs11204737	ENSG00000231073.1	RP11-316M1.3	-3.98	7.9e-05	0.00636	-0.22	-0.18	Tonsillectomy;	chr1:150875171	chr1:150973123~150975534:+
THCA	cis	rs739496	0.615	rs7978737	ENSG00000226469.1	ADAM1B	3.98	7.9e-05	0.00637	0.23	0.18	Platelet count;	chr12:111758807	chr12:111927018~111929017:+
THCA	cis	rs17123764	0.71	rs58278271	ENSG00000257464.1	RP11-161H23.8	-3.98	7.9e-05	0.00637	-0.32	-0.18	Intelligence (multi-trait analysis);	chr12:49624192	chr12:49442424~49442652:-
THCA	cis	rs7829975	0.624	rs7823056	ENSG00000233609.3	RP11-62H7.2	3.98	7.9e-05	0.00637	0.18	0.18	Mood instability;	chr8:8525195	chr8:8961200~8979025:+
THCA	cis	rs4713118	0.911	rs9461406	ENSG00000272009.1	RP1-313I6.12	3.98	7.9e-05	0.00637	0.21	0.18	Parkinson's disease;	chr6:27751985	chr6:28078792~28081130:-
THCA	cis	rs11710088	0.895	rs66609533	ENSG00000244503.1	RP11-278L15.6	3.98	7.9e-05	0.00637	0.23	0.18	QRS duration;	chr3:149482345	chr3:149494660~149495995:+
THCA	cis	rs11951515	0.508	rs1366410	ENSG00000248240.1	RP11-159F24.5	-3.98	7.9e-05	0.00637	-0.19	-0.18	Metabolite levels  (X-11787);	chr5:43601508	chr5:43515274~43525310:+
THCA	cis	rs1560104	0.709	rs7200211	ENSG00000262801.4	U91319.1	3.98	7.9e-05	0.00637	0.21	0.18	Obesity-related traits;	chr16:12605083	chr16:13246316~13562918:+
THCA	cis	rs4415084	0.716	rs7703497	ENSG00000272335.1	RP11-53O19.3	-3.98	7.9e-05	0.00637	-0.15	-0.18	Breast cancer;	chr5:44856926	chr5:44826076~44828592:+
THCA	cis	rs11239544	1	rs11239544	ENSG00000230869.1	CTGLF10P	3.98	7.9e-05	0.00637	0.22	0.18	Cholesterol, total;	chr10:45512085	chr10:45678692~45700532:+
THCA	cis	rs6479891	1	rs16918567	ENSG00000272767.1	JMJD1C-AS1	3.98	7.9e-05	0.00637	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs16918573	ENSG00000272767.1	JMJD1C-AS1	3.98	7.9e-05	0.00637	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs12414796	ENSG00000272767.1	JMJD1C-AS1	3.98	7.9e-05	0.00637	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63465229~63466563:+
THCA	cis	rs494526	0.769	rs671736	ENSG00000229272.1	RP11-498J9.2	3.98	7.91e-05	0.00637	0.21	0.18	Alcoholic chronic pancreatitis;	chr10:119051561	chr10:119003536~119003884:-
THCA	cis	rs1499614	1	rs1267818	ENSG00000237310.1	GS1-124K5.4	3.98	7.91e-05	0.00637	0.21	0.18	Gout;	chr7:66642037	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000275400.1	RP4-756H11.5	3.98	7.91e-05	0.00637	0.17	0.18	Aortic root size;	chr7:66545590	chr7:66553805~66554199:-
THCA	cis	rs875971	0.638	rs801216	ENSG00000275400.1	RP4-756H11.5	3.98	7.91e-05	0.00637	0.17	0.18	Aortic root size;	chr7:66546680	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs801211	ENSG00000275400.1	RP4-756H11.5	3.98	7.91e-05	0.00637	0.17	0.18	Aortic root size;	chr7:66550702	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000275400.1	RP4-756H11.5	-3.98	7.91e-05	0.00637	-0.17	-0.18	Aortic root size;	chr7:66540165	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs13224319	ENSG00000275400.1	RP4-756H11.5	-3.98	7.91e-05	0.00637	-0.17	-0.18	Aortic root size;	chr7:66542376	chr7:66553805~66554199:-
THCA	cis	rs5758659	0.652	rs129857	ENSG00000273366.1	CTA-989H11.1	3.98	7.91e-05	0.00637	0.22	0.18	Cognitive function;	chr22:42003682	chr22:42278188~42278846:+
THCA	cis	rs7560272	0.501	rs6750494	ENSG00000273245.1	RP11-434P11.2	-3.98	7.91e-05	0.00637	-0.21	-0.18	Schizophrenia;	chr2:73719369	chr2:73750256~73750786:-
THCA	cis	rs4742903	0.875	rs10991192	ENSG00000270332.1	SMC2-AS1	3.98	7.91e-05	0.00637	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104246215	chr9:104080024~104093073:-
THCA	cis	rs875971	0.505	rs1723275	ENSG00000229180.5	GS1-124K5.11	-3.98	7.91e-05	0.00637	-0.13	-0.18	Aortic root size;	chr7:66039646	chr7:66526088~66542624:-
THCA	cis	rs7572733	0.534	rs58374969	ENSG00000231621.1	AC013264.2	-3.98	7.91e-05	0.00638	-0.19	-0.18	Dermatomyositis;	chr2:197899639	chr2:197197991~197199273:+
THCA	cis	rs801193	0.935	rs3800820	ENSG00000229180.5	GS1-124K5.11	-3.98	7.91e-05	0.00638	-0.12	-0.18	Aortic root size;	chr7:66682191	chr7:66526088~66542624:-
THCA	cis	rs801193	1	rs2003301	ENSG00000229180.5	GS1-124K5.11	-3.98	7.91e-05	0.00638	-0.12	-0.18	Aortic root size;	chr7:66682669	chr7:66526088~66542624:-
THCA	cis	rs4906332	1	rs12896612	ENSG00000252469.1	RNU7-160P	3.98	7.91e-05	0.00638	0.2	0.18	Coronary artery disease;	chr14:103411531	chr14:103550345~103550406:+
THCA	cis	rs9393777	0.668	rs16897515	ENSG00000219392.1	RP1-265C24.5	3.98	7.91e-05	0.00638	0.25	0.18	Intelligence (multi-trait analysis);	chr6:27310241	chr6:28115628~28116551:+
THCA	cis	rs8062405	0.573	rs8045689	ENSG00000261766.1	RP11-22P6.2	3.98	7.91e-05	0.00638	0.18	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28862166~28863340:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000229180.5	GS1-124K5.11	3.98	7.91e-05	0.00638	0.13	0.18	Aortic root size;	chr7:65964026	chr7:66526088~66542624:-
THCA	cis	rs9844666	0.512	rs28570106	ENSG00000273486.1	RP11-731C17.2	3.98	7.92e-05	0.00638	0.17	0.18	Height;	chr3:135944454	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9820189	ENSG00000273486.1	RP11-731C17.2	3.98	7.92e-05	0.00638	0.17	0.18	Height;	chr3:135944943	chr3:136837338~136839021:-
THCA	cis	rs6473252	1	rs6473252	ENSG00000254162.1	RP11-48B3.3	-3.98	7.92e-05	0.00638	-0.16	-0.18	Breast cancer;	chr8:80887958	chr8:80535006~80539135:-
THCA	cis	rs12216545	0.711	rs939957	ENSG00000241134.3	BET1P1	-3.98	7.92e-05	0.00638	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150560517	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs939958	ENSG00000241134.3	BET1P1	-3.98	7.92e-05	0.00638	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150560680	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.64	rs1879867	ENSG00000241134.3	BET1P1	-3.98	7.92e-05	0.00638	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150561018	chr7:150749736~150750094:+
THCA	cis	rs6687821	0.681	rs526985	ENSG00000261737.1	RP4-612B15.3	-3.98	7.92e-05	0.00638	-0.29	-0.18	Yeast infection;	chr1:86850735	chr1:86703502~86704462:-
THCA	cis	rs735539	0.521	rs7984503	ENSG00000278291.1	RP11-172H24.4	3.98	7.92e-05	0.00638	0.24	0.18	Dental caries;	chr13:20874347	chr13:20699307~20703718:-
THCA	cis	rs42648	1	rs42656	ENSG00000225498.1	AC002064.5	3.98	7.92e-05	0.00638	0.19	0.18	Homocysteine levels;	chr7:90352322	chr7:90312496~90322592:+
THCA	cis	rs7968440	1	rs11832315	ENSG00000272368.2	RP4-605O3.4	3.98	7.92e-05	0.00638	0.12	0.18	Fibrinogen;	chr12:50550149	chr12:50112197~50165618:+
THCA	cis	rs7968440	1	rs66597435	ENSG00000272368.2	RP4-605O3.4	3.98	7.92e-05	0.00638	0.12	0.18	Fibrinogen;	chr12:50551486	chr12:50112197~50165618:+
THCA	cis	rs7243790	0.805	rs12604412	ENSG00000277324.1	RP11-850A17.1	-3.98	7.93e-05	0.00638	-0.18	-0.18	Diastolic blood pressure;	chr18:54372922	chr18:54268346~54270028:-
THCA	cis	rs8062405	0.573	rs6565300	ENSG00000261766.1	RP11-22P6.2	-3.98	7.93e-05	0.00638	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28862166~28863340:-
THCA	cis	rs11771526	0.686	rs62457501	ENSG00000272905.1	RP11-265E18.1	3.98	7.93e-05	0.00639	0.25	0.18	Body mass index;	chr7:32290334	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs62457503	ENSG00000272905.1	RP11-265E18.1	3.98	7.93e-05	0.00639	0.25	0.18	Body mass index;	chr7:32291368	chr7:32845394~32846061:+
THCA	cis	rs1039766	1	rs268871	ENSG00000204929.10	AC074391.1	3.98	7.93e-05	0.00639	0.29	0.18	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr2:65436711~66084639:+
THCA	cis	rs4713118	0.662	rs175954	ENSG00000219891.2	ZSCAN12P1	3.98	7.93e-05	0.00639	0.24	0.18	Parkinson's disease;	chr6:28043807	chr6:28091154~28093664:+
THCA	cis	rs651907	0.535	rs13085776	ENSG00000244119.1	PDCL3P4	3.98	7.93e-05	0.00639	0.18	0.18	Colorectal cancer;	chr3:101786663	chr3:101712472~101713191:+
THCA	cis	rs911555	0.755	rs975892	ENSG00000269958.1	RP11-73M18.8	3.98	7.93e-05	0.00639	0.17	0.18	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103696353~103697163:+
THCA	cis	rs78487399	0.808	rs77791126	ENSG00000234936.1	AC010883.5	3.98	7.93e-05	0.00639	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43516911	chr2:43229573~43233394:+
THCA	cis	rs1125355	0.964	rs11673825	ENSG00000243792.1	OR7E89P	-3.98	7.93e-05	0.00639	-0.26	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158816114	chr2:158853755~158854576:+
THCA	cis	rs138249	0.763	rs138254	ENSG00000273253.2	RP3-402G11.26	-3.98	7.93e-05	0.00639	-0.18	-0.18	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50132731	chr22:50199090~50200837:-
THCA	cis	rs12935229	0.756	rs9934178	ENSG00000260922.1	RP11-538I12.3	-3.98	7.93e-05	0.00639	-0.27	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77261211	chr16:77234877~77290934:+
THCA	cis	rs9309473	0.519	rs4852951	ENSG00000273245.1	RP11-434P11.2	-3.98	7.94e-05	0.00639	-0.21	-0.18	Metabolite levels;	chr2:73642669	chr2:73750256~73750786:-
THCA	cis	rs854765	0.693	rs12936037	ENSG00000281749.1	Y_RNA	-3.98	7.94e-05	0.00639	-0.23	-0.18	Total body bone mineral density;	chr17:17873931	chr17:18001101~18001195:-
THCA	cis	rs150992	0.587	rs6885458	ENSG00000246763.5	RGMB-AS1	3.98	7.94e-05	0.00639	0.19	0.18	Body mass index;	chr5:99046048	chr5:98769618~98773469:-
THCA	cis	rs4237845	0.788	rs6581157	ENSG00000270039.1	RP11-571M6.17	-3.98	7.94e-05	0.00639	-0.2	-0.18	Intelligence (multi-trait analysis);	chr12:57895010	chr12:57803838~57804415:+
THCA	cis	rs17221829	0.59	rs10830300	ENSG00000280385.1	AP000648.5	-3.98	7.94e-05	0.00639	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89629898	chr11:90193614~90198120:+
THCA	cis	rs115575488	0.683	rs12727967	ENSG00000231365.4	RP11-418J17.1	3.98	7.94e-05	0.0064	0.22	0.18	Lobe attachment (rater-scored or self-reported);	chr1:119053313	chr1:119140396~119275973:+
THCA	cis	rs60180747	0.909	rs78135660	ENSG00000261318.1	RP11-653J6.1	3.98	7.94e-05	0.0064	0.25	0.18	Testicular germ cell tumor;	chr15:66476691	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.909	rs11638268	ENSG00000261318.1	RP11-653J6.1	3.98	7.94e-05	0.0064	0.25	0.18	Testicular germ cell tumor;	chr15:66477826	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.909	rs41277720	ENSG00000261318.1	RP11-653J6.1	3.98	7.94e-05	0.0064	0.25	0.18	Testicular germ cell tumor;	chr15:66481637	chr15:66278498~66293357:-
THCA	cis	rs55702914	0.746	rs7588530	ENSG00000231621.1	AC013264.2	3.98	7.94e-05	0.0064	0.17	0.18	Major depression and alcohol dependence;	chr2:197281974	chr2:197197991~197199273:+
THCA	cis	rs3748656	1	rs34848593	ENSG00000273483.1	RP4-671G15.2	3.98	7.94e-05	0.0064	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112697484	chr1:112517799~112518441:-
THCA	cis	rs3748656	1	rs12133583	ENSG00000273483.1	RP4-671G15.2	3.98	7.94e-05	0.0064	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112698168	chr1:112517799~112518441:-
THCA	cis	rs8017455	0.523	rs7145351	ENSG00000259167.2	NMNAT1P1	3.98	7.94e-05	0.0064	0.26	0.18	Hair morphology;	chr14:81095045	chr14:81032529~81033404:+
THCA	cis	rs8017455	0.584	rs10143087	ENSG00000259167.2	NMNAT1P1	3.98	7.94e-05	0.0064	0.26	0.18	Hair morphology;	chr14:81095213	chr14:81032529~81033404:+
THCA	cis	rs875971	0.666	rs13242072	ENSG00000223473.2	GS1-124K5.3	-3.98	7.94e-05	0.0064	-0.12	-0.18	Aortic root size;	chr7:66301001	chr7:66491049~66493566:-
THCA	cis	rs6988985	0.678	rs10110732	ENSG00000247317.3	RP11-273G15.2	3.98	7.94e-05	0.0064	0.2	0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142914578	chr8:142981738~143018437:-
THCA	cis	rs4819052	1	rs2838847	ENSG00000182586.6	LINC00334	-3.98	7.94e-05	0.0064	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45234340~45258730:+
THCA	cis	rs7212590	0.655	rs8072050	ENSG00000267302.4	RP11-178C3.2	3.98	7.94e-05	0.0064	0.33	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59933611	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.618	rs7217337	ENSG00000267302.4	RP11-178C3.2	3.98	7.94e-05	0.0064	0.33	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59946056	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.618	rs7219051	ENSG00000267302.4	RP11-178C3.2	3.98	7.94e-05	0.0064	0.33	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59955349	chr17:59964832~59996972:+
THCA	cis	rs7616559	0.627	rs1482854	ENSG00000244515.1	KRT18P34	-3.98	7.95e-05	0.0064	-0.21	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157028871	chr3:157162663~157163932:-
THCA	cis	rs5758511	0.68	rs5758686	ENSG00000237037.8	NDUFA6-AS1	-3.98	7.95e-05	0.0064	-0.17	-0.18	Birth weight;	chr22:42259371	chr22:42090931~42137742:+
THCA	cis	rs3770081	0.826	rs1019591	ENSG00000272564.1	RP11-548P2.2	-3.98	7.95e-05	0.0064	-0.34	-0.18	Facial emotion recognition (sad faces);	chr2:86071476	chr2:85904279~85904727:+
THCA	cis	rs3770081	1	rs6750765	ENSG00000272564.1	RP11-548P2.2	-3.98	7.95e-05	0.0064	-0.34	-0.18	Facial emotion recognition (sad faces);	chr2:86073185	chr2:85904279~85904727:+
THCA	cis	rs11673344	0.704	rs1726724	ENSG00000267260.1	CTD-2162K18.4	-3.98	7.95e-05	0.0064	-0.22	-0.18	Obesity-related traits;	chr19:36925890	chr19:36773153~36777078:+
THCA	cis	rs3770081	1	rs74607112	ENSG00000272564.1	RP11-548P2.2	-3.98	7.95e-05	0.0064	-0.33	-0.18	Facial emotion recognition (sad faces);	chr2:86078411	chr2:85904279~85904727:+
THCA	cis	rs12073837	0.5	rs2807845	ENSG00000272823.1	RP11-295M18.6	-3.98	7.95e-05	0.0064	-0.21	-0.18	F-cell distribution;	chr1:220822945	chr1:220828676~220829211:-
THCA	cis	rs4906332	1	rs3783400	ENSG00000252469.1	RNU7-160P	3.98	7.95e-05	0.0064	0.2	0.18	Coronary artery disease;	chr14:103500708	chr14:103550345~103550406:+
THCA	cis	rs34929064	0.536	rs2905306	ENSG00000232949.1	AC002480.4	3.98	7.95e-05	0.0064	0.23	0.18	Major depression and alcohol dependence;	chr7:22599199	chr7:22589705~22591622:+
THCA	cis	rs9543976	0.623	rs4885323	ENSG00000261105.4	LMO7-AS1	3.98	7.95e-05	0.0064	0.25	0.18	Diabetic retinopathy;	chr13:75598278	chr13:75604700~75635994:-
THCA	cis	rs6723108	0.678	rs512375	ENSG00000224043.6	CCNT2-AS1	-3.98	7.95e-05	0.0064	-0.2	-0.18	Type 2 diabetes;	chr2:134527708	chr2:134735464~134918710:-
THCA	cis	rs2736345	0.502	rs12680762	ENSG00000254527.1	ENPP7P12	-3.98	7.95e-05	0.0064	-0.23	-0.18	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11474517	chr8:12205759~12206389:-
THCA	cis	rs7772486	0.754	rs9497434	ENSG00000270638.1	RP3-466P17.1	-3.98	7.95e-05	0.0064	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs6924159	ENSG00000270638.1	RP3-466P17.1	-3.98	7.95e-05	0.0064	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145735570~145737218:+
THCA	cis	rs1577917	0.874	rs1838954	ENSG00000220563.1	PKMP3	-3.98	7.95e-05	0.0064	-0.14	-0.18	Response to antipsychotic treatment;	chr6:85855760	chr6:85659892~85660606:-
THCA	cis	rs7615952	0.741	rs13314845	ENSG00000272840.1	RP11-379B18.6	3.98	7.95e-05	0.0064	0.3	0.18	Blood pressure (smoking interaction);	chr3:125925939	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.733	rs13314847	ENSG00000272840.1	RP11-379B18.6	3.98	7.95e-05	0.0064	0.3	0.18	Blood pressure (smoking interaction);	chr3:125925945	chr3:125774714~125797953:+
THCA	cis	rs17685	0.753	rs2302438	ENSG00000227038.2	AC005077.12	3.98	7.96e-05	0.0064	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76047747	chr7:76090431~76108779:-
THCA	cis	rs13178541	0.81	rs11748975	ENSG00000250378.1	RP11-119J18.1	-3.98	7.96e-05	0.00641	-0.22	-0.18	IgG glycosylation;	chr5:135768875	chr5:135812667~135826582:+
THCA	cis	rs78487399	0.808	rs74600494	ENSG00000234936.1	AC010883.5	3.98	7.96e-05	0.00641	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43516352	chr2:43229573~43233394:+
THCA	cis	rs240993	0.809	rs11153277	ENSG00000255389.1	C6orf3	3.98	7.96e-05	0.00641	0.18	0.18	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111599875~111602295:+
THCA	cis	rs7578199	0.576	rs757974	ENSG00000223374.1	AC005104.3	-3.98	7.96e-05	0.00641	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241460512	chr2:241351340~241353104:-
THCA	cis	rs2562456	0.837	rs11085462	ENSG00000268278.1	RP11-420K14.1	3.98	7.96e-05	0.00641	0.22	0.18	Pain;	chr19:21567449	chr19:21637974~21656300:+
THCA	cis	rs7824557	0.51	rs4841524	ENSG00000261451.1	RP11-981G7.1	-3.98	7.96e-05	0.00641	-0.23	-0.18	Retinal vascular caliber;	chr8:11385617	chr8:10433672~10438312:+
THCA	cis	rs28735056	0.967	rs56071379	ENSG00000261126.6	RP11-795F19.1	-3.98	7.96e-05	0.00641	-0.15	-0.18	Schizophrenia;	chr18:79887406	chr18:80046900~80095482:+
THCA	cis	rs4788570	0.584	rs6499529	ENSG00000260593.1	RP11-432I5.2	-3.98	7.96e-05	0.00641	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71681475	chr16:71623708~71626816:-
THCA	cis	rs4321325	0.733	rs4284778	ENSG00000236682.1	AC068282.3	-3.98	7.96e-05	0.00641	-0.38	-0.18	Protein C levels;	chr2:127188750	chr2:127389130~127400580:+
THCA	cis	rs7069191	0.73	rs10994493	ENSG00000254271.1	RP11-131N11.4	3.98	7.96e-05	0.00641	0.27	0.18	Pediatric bone mineral density (spine);	chr10:60749542	chr10:60734342~60741828:+
THCA	cis	rs72949976	1	rs62186568	ENSG00000270659.1	RP11-105N14.1	3.98	7.96e-05	0.00641	0.14	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213169231	chr2:213152970~213153659:+
THCA	cis	rs72928364	1	rs2245556	ENSG00000256628.3	ZBTB11-AS1	3.98	7.96e-05	0.00641	0.29	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100896706	chr3:101676475~101679217:+
THCA	cis	rs2836974	0.897	rs11911112	ENSG00000255568.3	BRWD1-AS2	3.98	7.96e-05	0.00641	0.16	0.18	Cognitive function;	chr21:39156420	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.831	rs11911149	ENSG00000255568.3	BRWD1-AS2	3.98	7.96e-05	0.00641	0.16	0.18	Cognitive function;	chr21:39156449	chr21:39313935~39314962:+
THCA	cis	rs150992	0.609	rs113868271	ENSG00000246763.5	RGMB-AS1	3.98	7.97e-05	0.00641	0.19	0.18	Body mass index;	chr5:98992741	chr5:98769618~98773469:-
THCA	cis	rs150992	0.631	rs112393710	ENSG00000246763.5	RGMB-AS1	3.98	7.97e-05	0.00641	0.19	0.18	Body mass index;	chr5:98992761	chr5:98769618~98773469:-
THCA	cis	rs150992	0.631	rs111871078	ENSG00000246763.5	RGMB-AS1	3.98	7.97e-05	0.00641	0.19	0.18	Body mass index;	chr5:98992766	chr5:98769618~98773469:-
THCA	cis	rs57502260	1	rs57502260	ENSG00000212093.1	AP000807.1	3.98	7.97e-05	0.00641	0.23	0.18	Total body bone mineral density (age 45-60);	chr11:68453437	chr11:68506083~68506166:-
THCA	cis	rs9990333	1	rs9990333	ENSG00000273009.1	RP11-352G9.1	3.98	7.97e-05	0.00641	0.2	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195913078~195913683:-
THCA	cis	rs6137726	0.508	rs6036169	ENSG00000237396.1	LINC01384	3.98	7.97e-05	0.00641	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22665239	chr20:22587522~22607517:-
THCA	cis	rs1923243	0.649	rs4272573	ENSG00000223479.3	RP4-788P17.1	-3.98	7.97e-05	0.00642	-0.19	-0.18	Migraine;	chr1:72936738	chr1:73635216~73715214:+
THCA	cis	rs15676	0.947	rs3115874	ENSG00000234771.3	SLC25A25-AS1	3.98	7.97e-05	0.00642	0.15	0.18	Blood metabolite levels;	chr9:128817059	chr9:128108581~128118693:-
THCA	cis	rs6517329	0.538	rs12483755	ENSG00000230212.5	AP000688.14	-3.98	7.97e-05	0.00642	-0.22	-0.18	Schizophrenia;	chr21:36136140	chr21:36069642~36126640:-
THCA	cis	rs6430585	0.646	rs12468768	ENSG00000231890.6	DARS-AS1	-3.98	7.97e-05	0.00642	-0.23	-0.18	Corneal structure;	chr2:135737415	chr2:135985176~136022593:+
THCA	cis	rs2896526	0.736	rs78950598	ENSG00000256464.1	YWHABP2	3.98	7.97e-05	0.00642	0.3	0.18	Amyloid A serum levels;	chr11:18375599	chr11:18490243~18490955:-
THCA	cis	rs6963495	0.592	rs114793754	ENSG00000272604.1	RP11-251G23.5	3.98	7.97e-05	0.00642	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105511715	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.519	rs3892297	ENSG00000272604.1	RP11-251G23.5	3.98	7.97e-05	0.00642	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105511726	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.651	rs3892298	ENSG00000272604.1	RP11-251G23.5	3.98	7.97e-05	0.00642	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105511740	chr7:105571083~105573660:+
THCA	cis	rs17495987	0.871	rs73061231	ENSG00000219545.8	UMAD1	3.98	7.97e-05	0.00642	0.18	0.18	Tonsillectomy;	chr7:7864765	chr7:7640711~8004059:+
THCA	cis	rs72627123	1	rs72627119	ENSG00000259065.1	RP5-1021I20.1	-3.98	7.97e-05	0.00642	-0.28	-0.18	Morning vs. evening chronotype;	chr14:73889571	chr14:73787360~73803270:+
THCA	cis	rs6598541	0.814	rs7174918	ENSG00000278090.1	RP11-6O2.2	-3.98	7.98e-05	0.00642	-0.17	-0.18	Urate levels;	chr15:98708127	chr15:99028538~99031053:+
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000229180.5	GS1-124K5.11	3.98	7.98e-05	0.00642	0.13	0.18	Calcium levels;	chr7:65967580	chr7:66526088~66542624:-
THCA	cis	rs12722605	0.54	rs7898880	ENSG00000229664.1	RP11-536K7.5	3.98	7.98e-05	0.00642	0.24	0.18	Inflammatory biomarkers;	chr10:5995590	chr10:6025978~6036427:+
THCA	cis	rs657075	0.595	rs35724182	ENSG00000237714.1	P4HA2-AS1	-3.98	7.98e-05	0.00642	-0.37	-0.18	Rheumatoid arthritis;	chr5:132244608	chr5:132184876~132192808:+
THCA	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	3.98	7.98e-05	0.00642	0.2	0.18	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
THCA	cis	rs253959	0.739	rs712572	ENSG00000250015.1	CTC-339F2.2	-3.98	7.98e-05	0.00642	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr5:116298430	chr5:116302354~116304134:-
THCA	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	3.98	7.98e-05	0.00642	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
THCA	cis	rs12935418	0.583	rs12446698	ENSG00000278985.1	RP11-303E16.9	3.98	7.98e-05	0.00642	0.23	0.18	Mean corpuscular volume;	chr16:80930524	chr16:80982319~80984094:-
THCA	cis	rs5753037	0.803	rs131262	ENSG00000279699.1	RP1-102K2.9	3.98	7.98e-05	0.00642	0.18	0.18	Type 1 diabetes;	chr22:29737055	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.803	rs131263	ENSG00000279699.1	RP1-102K2.9	3.98	7.98e-05	0.00642	0.18	0.18	Type 1 diabetes;	chr22:29737056	chr22:30275215~30276951:-
THCA	cis	rs10496034	0.541	rs3820856	ENSG00000237887.1	AC092839.1	-3.98	7.98e-05	0.00642	-0.33	-0.18	Refractive astigmatism;	chr2:54670978	chr2:54529343~54529801:+
THCA	cis	rs800160	0.545	rs2651843	ENSG00000236264.4	RPL26P30	3.98	7.98e-05	0.00642	0.24	0.18	Bacteremia;	chr11:2320502	chr11:2335132~2335776:-
THCA	cis	rs4908768	0.501	rs6577491	ENSG00000270282.1	RP5-1115A15.2	3.98	7.98e-05	0.00642	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8512653~8513021:+
THCA	cis	rs9902453	0.78	rs10445384	ENSG00000263370.1	RP11-68I3.5	3.98	7.98e-05	0.00642	0.24	0.18	Coffee consumption (cups per day);	chr17:29855667	chr17:29639627~29640825:+
THCA	cis	rs2562456	0.876	rs11085465	ENSG00000268278.1	RP11-420K14.1	-3.98	7.98e-05	0.00642	-0.21	-0.18	Pain;	chr19:21568988	chr19:21637974~21656300:+
THCA	cis	rs6687821	0.681	rs517395	ENSG00000261737.1	RP4-612B15.3	-3.98	7.98e-05	0.00642	-0.29	-0.18	Yeast infection;	chr1:86854562	chr1:86703502~86704462:-
THCA	cis	rs10043228	1	rs12152964	ENSG00000248445.4	SEMA6A-AS1	-3.98	7.98e-05	0.00642	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116274268	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs12522027	ENSG00000248445.4	SEMA6A-AS1	-3.98	7.98e-05	0.00642	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116280834	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs112428033	ENSG00000248445.4	SEMA6A-AS1	-3.98	7.98e-05	0.00642	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116282563	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs76112204	ENSG00000248445.4	SEMA6A-AS1	-3.98	7.98e-05	0.00642	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116283192	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs12520613	ENSG00000248445.4	SEMA6A-AS1	-3.98	7.98e-05	0.00642	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116286023	chr5:116447547~116508276:+
THCA	cis	rs56313388	0.505	rs4783932	ENSG00000246379.5	RP11-461O7.1	3.98	7.98e-05	0.00642	0.19	0.18	Pulse pressure;	chr16:56240589	chr16:56092987~56191094:-
THCA	cis	rs7520050	0.966	rs1707340	ENSG00000281133.1	AL355480.3	3.98	7.98e-05	0.00642	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45580892~45580996:-
THCA	cis	rs7520050	1	rs785473	ENSG00000281133.1	AL355480.3	3.98	7.98e-05	0.00642	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs785472	ENSG00000281133.1	AL355480.3	3.98	7.98e-05	0.00642	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45580892~45580996:-
THCA	cis	rs4699052	1	rs7694190	ENSG00000246560.2	RP11-10L12.4	3.98	7.98e-05	0.00642	0.22	0.18	Testicular germ cell tumor;	chr4:103246860	chr4:102828055~102844075:+
THCA	cis	rs959260	1	rs7221050	ENSG00000263843.1	RP11-649A18.12	3.98	7.99e-05	0.00643	0.19	0.18	Systemic lupus erythematosus;	chr17:75397868	chr17:75271369~75273895:+
THCA	cis	rs13113518	1	rs4864547	ENSG00000272969.1	RP11-528I4.2	3.98	7.99e-05	0.00643	0.21	0.18	Height;	chr4:55538228	chr4:55547112~55547889:+
THCA	cis	rs6443245	0.611	rs2648578	ENSG00000227110.5	LMCD1-AS1	-3.98	7.99e-05	0.00643	-0.21	-0.18	Daytime sleep phenotypes;	chr3:9591145	chr3:7952805~8611924:-
THCA	cis	rs758324	0.947	rs6596041	ENSG00000237714.1	P4HA2-AS1	3.98	7.99e-05	0.00643	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131863167	chr5:132184876~132192808:+
THCA	cis	rs17286411	0.671	rs8048210	ENSG00000260185.1	RP11-432I5.6	3.98	7.99e-05	0.00643	0.25	0.18	Blood protein levels;	chr16:71683502	chr16:71655027~71664212:+
THCA	cis	rs7617773	0.817	rs9819094	ENSG00000199476.1	Y_RNA	-3.98	7.99e-05	0.00643	-0.23	-0.18	Coronary artery disease;	chr3:48278068	chr3:48288587~48288694:+
THCA	cis	rs8020912	0.504	rs3759577	ENSG00000269958.1	RP11-73M18.8	-3.98	7.99e-05	0.00643	-0.18	-0.18	Granulocyte percentage of myeloid white cells;	chr14:103384626	chr14:103696353~103697163:+
THCA	cis	rs9921338	0.632	rs80945	ENSG00000262636.1	CTD-3088G3.4	-3.98	7.99e-05	0.00643	-0.29	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249263	chr16:11380859~11381118:-
THCA	cis	rs5753037	0.838	rs5763565	ENSG00000279699.1	RP1-102K2.9	3.98	7.99e-05	0.00643	0.18	0.18	Type 1 diabetes;	chr22:29875973	chr22:30275215~30276951:-
THCA	cis	rs9291683	0.509	rs998676	ENSG00000250413.1	RP11-448G15.1	3.98	7.99e-05	0.00643	0.18	0.18	Bone mineral density;	chr4:9946940	chr4:10006482~10009725:+
THCA	cis	rs11971779	0.68	rs2355787	ENSG00000252332.1	RNU6-911P	3.98	7.99e-05	0.00643	0.2	0.18	Diisocyanate-induced asthma;	chr7:139405182	chr7:139448740~139448843:+
THCA	cis	rs4792901	0.759	rs2271957	ENSG00000267151.3	RP11-100E5.2	3.98	7.99e-05	0.00643	0.19	0.18	Dupuytren's disease;	chr17:43521572	chr17:43444707~43451200:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000229180.5	GS1-124K5.11	3.98	7.99e-05	0.00643	0.13	0.18	Aortic root size;	chr7:65931217	chr7:66526088~66542624:-
THCA	cis	rs8077577	0.836	rs11652964	ENSG00000273018.4	CTD-2303H24.2	-3.98	7.99e-05	0.00643	-0.32	-0.18	Obesity-related traits;	chr17:18137090	chr17:18511221~18551705:-
THCA	cis	rs754466	0.58	rs12356063	ENSG00000213514.2	RP11-428P16.2	3.98	7.99e-05	0.00643	0.2	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77798373	chr10:77730766~77734769:+
THCA	cis	rs6693017	0.818	rs61830270	ENSG00000272823.1	RP11-295M18.6	-3.98	7.99e-05	0.00643	-0.27	-0.18	Monocyte early outgrowth colony forming units;	chr1:220806392	chr1:220828676~220829211:-
THCA	cis	rs2839186	0.967	rs2839191	ENSG00000215424.8	MCM3AP-AS1	3.98	7.99e-05	0.00643	0.1	0.18	Testicular germ cell tumor;	chr21:46275481	chr21:46229217~46259390:+
THCA	cis	rs4713118	0.669	rs200997	ENSG00000216915.2	RP1-97D16.1	-3.98	7.99e-05	0.00643	-0.25	-0.18	Parkinson's disease;	chr6:27844037	chr6:27737000~27738494:-
THCA	cis	rs62445005	1	rs62445005	ENSG00000281103.1	TRG-AS1	3.98	8e-05	0.00643	0.15	0.18	Shingles;	chr7:38346957	chr7:38341577~38378804:+
THCA	cis	rs4869313	0.668	rs1216569	ENSG00000247121.5	CTD-2260A17.2	-3.98	8e-05	0.00643	-0.14	-0.18	Pediatric autoimmune diseases;	chr5:96926830	chr5:96814028~96935809:-
THCA	cis	rs7985	1	rs3752603	ENSG00000244625.4	MIATNB	3.98	8e-05	0.00643	0.21	0.18	Electroencephalogram traits;	chr22:26668531	chr22:26672767~26780207:+
THCA	cis	rs7985	1	rs7985	ENSG00000244625.4	MIATNB	3.98	8e-05	0.00643	0.21	0.18	Electroencephalogram traits;	chr22:26670572	chr22:26672767~26780207:+
THCA	cis	rs6847067	0.763	rs7654035	ENSG00000180769.7	WDFY3-AS2	3.98	8e-05	0.00643	0.14	0.18	Oropharynx cancer;	chr4:84956971	chr4:84965682~85011277:+
THCA	cis	rs6847067	0.8	rs7694949	ENSG00000180769.7	WDFY3-AS2	3.98	8e-05	0.00643	0.14	0.18	Oropharynx cancer;	chr4:84959676	chr4:84965682~85011277:+
THCA	cis	rs6847067	0.8	rs7661609	ENSG00000180769.7	WDFY3-AS2	3.98	8e-05	0.00643	0.14	0.18	Oropharynx cancer;	chr4:84961696	chr4:84965682~85011277:+
THCA	cis	rs6847067	0.8	rs4624645	ENSG00000180769.7	WDFY3-AS2	3.98	8e-05	0.00643	0.14	0.18	Oropharynx cancer;	chr4:84963222	chr4:84965682~85011277:+
THCA	cis	rs8003054	0.616	rs12050102	ENSG00000258515.1	RP11-203M5.7	3.98	8e-05	0.00643	0.12	0.18	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20442073	chr14:20451305~20451918:+
THCA	cis	rs7586085	0.874	rs11686403	ENSG00000232411.1	AC009495.3	-3.98	8e-05	0.00644	-0.2	-0.18	Total body bone mineral density;	chr2:165750483	chr2:165833048~165839098:-
THCA	cis	rs7586085	0.874	rs13427924	ENSG00000232411.1	AC009495.3	-3.98	8e-05	0.00644	-0.2	-0.18	Total body bone mineral density;	chr2:165751236	chr2:165833048~165839098:-
THCA	cis	rs9595908	0.869	rs9595962	ENSG00000212293.1	SNORA16	3.98	8e-05	0.00644	0.21	0.18	Body mass index;	chr13:32634429	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.869	rs2320301	ENSG00000212293.1	SNORA16	3.98	8e-05	0.00644	0.21	0.18	Body mass index;	chr13:32635067	chr13:32420390~32420516:-
THCA	cis	rs738722	1	rs1033667	ENSG00000272858.1	CTA-292E10.8	3.98	8e-05	0.00644	0.19	0.18	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28734312	chr22:28814914~28815662:+
THCA	cis	rs1510552	0.816	rs13008598	ENSG00000270659.1	RP11-105N14.1	3.98	8e-05	0.00644	0.17	0.18	Contrast sensitivity;	chr2:214136476	chr2:213152970~213153659:+
THCA	cis	rs1510552	0.766	rs12987971	ENSG00000270659.1	RP11-105N14.1	3.98	8e-05	0.00644	0.17	0.18	Contrast sensitivity;	chr2:214136976	chr2:213152970~213153659:+
THCA	cis	rs11971779	0.941	rs6954453	ENSG00000252332.1	RNU6-911P	-3.98	8e-05	0.00644	-0.23	-0.18	Diisocyanate-induced asthma;	chr7:139347048	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.941	rs4732368	ENSG00000252332.1	RNU6-911P	-3.98	8e-05	0.00644	-0.23	-0.18	Diisocyanate-induced asthma;	chr7:139349461	chr7:139448740~139448843:+
THCA	cis	rs7824557	0.527	rs11785394	ENSG00000255495.1	AC145124.2	-3.98	8e-05	0.00644	-0.21	-0.18	Retinal vascular caliber;	chr8:11380520	chr8:12194467~12196280:+
THCA	cis	rs412000	0.56	rs4793583	ENSG00000224738.1	AC099850.1	-3.98	8e-05	0.00644	-0.21	-0.18	Primary tooth development (time to first tooth eruption);	chr17:58374046	chr17:59106598~59118267:+
THCA	cis	rs9863	0.861	rs4765305	ENSG00000270061.1	RP11-214K3.19	-3.98	8e-05	0.00644	-0.23	-0.18	White blood cell count;	chr12:123946065	chr12:123969990~123970344:-
THCA	cis	rs3755605	0.694	rs12487269	ENSG00000242578.1	RP11-469J4.3	3.98	8e-05	0.00644	0.21	0.18	Testicular germ cell tumor;	chr3:170081757	chr3:170410512~170418615:+
THCA	cis	rs7115242	1	rs7115242	ENSG00000280143.1	AP000892.6	-3.98	8e-05	0.00644	-0.32	-0.18	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117204967~117210292:+
THCA	cis	rs931608	0.585	rs73027904	ENSG00000269138.1	ZNF209P	3.98	8e-05	0.00644	0.27	0.18	Response to statins (LDL cholesterol change);Dental caries;	chr19:22351021	chr19:22463922~22473036:+
THCA	cis	rs733592	0.929	rs4760678	ENSG00000269514.1	RP11-370I10.12	3.98	8.01e-05	0.00644	0.15	0.18	Plateletcrit;	chr12:48067798	chr12:48198387~48202031:+
THCA	cis	rs9402682	0.558	rs1570649	ENSG00000232876.1	CTA-212D2.2	-3.98	8.01e-05	0.00644	-0.25	-0.18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135131078	chr6:135055033~135060550:+
THCA	cis	rs7208859	0.573	rs216443	ENSG00000265443.1	CTD-2349P21.6	-3.98	8.01e-05	0.00644	-0.32	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30726305~30727564:-
THCA	cis	rs9309473	0.95	rs6546847	ENSG00000273245.1	RP11-434P11.2	3.98	8.01e-05	0.00644	0.24	0.18	Metabolite levels;	chr2:73558231	chr2:73750256~73750786:-
THCA	cis	rs7927592	0.956	rs10896343	ENSG00000160172.9	FAM86C2P	3.98	8.01e-05	0.00644	0.18	0.18	Total body bone mineral density;	chr11:68550392	chr11:67791648~67805336:-
THCA	cis	rs9393813	1	rs13220817	ENSG00000204789.4	ZNF204P	-3.98	8.01e-05	0.00644	-0.14	-0.18	Bipolar disorder;	chr6:27388748	chr6:27357825~27360221:-
THCA	cis	rs7829975	0.755	rs3789849	ENSG00000233609.3	RP11-62H7.2	3.98	8.01e-05	0.00644	0.17	0.18	Mood instability;	chr8:8829544	chr8:8961200~8979025:+
THCA	cis	rs790006	0.697	rs790016	ENSG00000243024.5	RPS11P6	3.98	8.01e-05	0.00644	0.2	0.18	Response to cytidine analogues (gemcitabine);	chr12:64218152	chr12:64222337~64397065:+
THCA	cis	rs4767841	0.565	rs386259	ENSG00000252886.1	RN7SKP197	-3.98	8.01e-05	0.00644	-0.18	-0.18	Urgency urinary incontinence;	chr12:119787908	chr12:119631090~119631386:-
THCA	cis	rs800160	0.777	rs2521282	ENSG00000199550.1	Y_RNA	3.98	8.01e-05	0.00645	0.28	0.18	Bacteremia;	chr11:2318507	chr11:2372638~2372750:+
THCA	cis	rs11771526	0.901	rs13438711	ENSG00000272905.1	RP11-265E18.1	3.98	8.01e-05	0.00645	0.24	0.18	Body mass index;	chr7:32257698	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs10223907	ENSG00000272905.1	RP11-265E18.1	3.98	8.01e-05	0.00645	0.24	0.18	Body mass index;	chr7:32258201	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.792	rs28394389	ENSG00000272905.1	RP11-265E18.1	3.98	8.01e-05	0.00645	0.24	0.18	Body mass index;	chr7:32258897	chr7:32845394~32846061:+
THCA	cis	rs11771526	1	rs10231440	ENSG00000272905.1	RP11-265E18.1	3.98	8.01e-05	0.00645	0.24	0.18	Body mass index;	chr7:32259823	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs78065961	ENSG00000272905.1	RP11-265E18.1	3.98	8.01e-05	0.00645	0.24	0.18	Body mass index;	chr7:32261355	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs62457467	ENSG00000272905.1	RP11-265E18.1	3.98	8.01e-05	0.00645	0.24	0.18	Body mass index;	chr7:32261489	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs62457468	ENSG00000272905.1	RP11-265E18.1	3.98	8.01e-05	0.00645	0.24	0.18	Body mass index;	chr7:32261729	chr7:32845394~32846061:+
THCA	cis	rs3738443	0.52	rs1771932	ENSG00000259865.1	RP11-488L18.10	3.98	8.01e-05	0.00645	0.16	0.18	Alcohol dependence;	chr1:247218747	chr1:247187281~247188526:-
THCA	cis	rs786425	0.77	rs7308862	ENSG00000278112.1	RP11-972P1.11	3.98	8.01e-05	0.00645	0.18	0.18	Pubertal anthropometrics;	chr12:123686604	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs7297576	ENSG00000278112.1	RP11-972P1.11	3.98	8.01e-05	0.00645	0.18	0.18	Pubertal anthropometrics;	chr12:123686776	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs11609591	ENSG00000278112.1	RP11-972P1.11	3.98	8.01e-05	0.00645	0.18	0.18	Pubertal anthropometrics;	chr12:123689518	chr12:123519390~123519856:-
THCA	cis	rs2732480	0.5	rs11168468	ENSG00000273765.1	RP11-370I10.11	3.98	8.01e-05	0.00645	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48360920~48361377:+
THCA	cis	rs713587	1	rs2384054	ENSG00000224165.4	DNAJC27-AS1	-3.98	8.01e-05	0.00645	-0.1	-0.18	Body mass index in non-asthmatics;	chr2:24933904	chr2:24971390~25039694:+
THCA	cis	rs17301013	0.932	rs6425282	ENSG00000270084.1	GAS5-AS1	-3.98	8.02e-05	0.00645	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174493387	chr1:173863248~173863941:+
THCA	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	3.98	8.02e-05	0.00645	0.23	0.18	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
THCA	cis	rs4908760	0.613	rs4908511	ENSG00000232912.4	RP5-1115A15.1	-3.98	8.02e-05	0.00645	-0.17	-0.18	Vitiligo;	chr1:8752331	chr1:8424645~8434838:+
THCA	cis	rs7829975	0.714	rs4841040	ENSG00000233609.3	RP11-62H7.2	3.98	8.02e-05	0.00645	0.17	0.18	Mood instability;	chr8:8797017	chr8:8961200~8979025:+
THCA	cis	rs17122278	1	rs3741324	ENSG00000243431.1	RPL5P30	3.98	8.02e-05	0.00645	0.18	0.18	Total cholesterol levels;	chr11:118535120	chr11:118560690~118561580:+
THCA	cis	rs7259376	0.936	rs4932760	ENSG00000269138.1	ZNF209P	3.98	8.02e-05	0.00645	0.18	0.18	Menopause (age at onset);	chr19:22357653	chr19:22463922~22473036:+
THCA	cis	rs786425	0.77	rs7313032	ENSG00000278112.1	RP11-972P1.11	3.98	8.02e-05	0.00645	0.17	0.18	Pubertal anthropometrics;	chr12:123688184	chr12:123519390~123519856:-
THCA	cis	rs2221894	1	rs2137471	ENSG00000251191.6	LINC00589	-3.98	8.02e-05	0.00645	-0.22	-0.18	Obesity-related traits;	chr8:28948132	chr8:29673922~29748109:-
THCA	cis	rs2221894	1	rs2292478	ENSG00000251191.6	LINC00589	-3.98	8.02e-05	0.00645	-0.22	-0.18	Obesity-related traits;	chr8:28949839	chr8:29673922~29748109:-
THCA	cis	rs494526	0.769	rs3824830	ENSG00000229272.1	RP11-498J9.2	-3.98	8.02e-05	0.00645	-0.21	-0.18	Alcoholic chronic pancreatitis;	chr10:119081149	chr10:119003536~119003884:-
THCA	cis	rs2645424	0.762	rs2294139	ENSG00000255046.1	RP11-297N6.4	3.98	8.02e-05	0.00645	0.19	0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847933	chr8:11797928~11802568:-
THCA	cis	rs6696239	0.956	rs6659012	ENSG00000227711.2	RP11-275O4.5	-3.98	8.02e-05	0.00645	-0.24	-0.18	Height;	chr1:227641015	chr1:227509028~227520477:-
THCA	cis	rs962856	0.891	rs638190	ENSG00000236780.4	AC078941.1	3.98	8.02e-05	0.00645	0.22	0.18	Pancreatic cancer;	chr2:67434958	chr2:67123357~67215319:-
THCA	cis	rs365302	0.951	rs439251	ENSG00000235086.1	FNDC1-IT1	3.98	8.03e-05	0.00645	0.25	0.18	Coronary heart disease;	chr6:159223166	chr6:159240786~159243329:+
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000229180.5	GS1-124K5.11	3.98	8.03e-05	0.00645	0.13	0.18	Corneal structure;	chr7:66925268	chr7:66526088~66542624:-
THCA	cis	rs2243480	1	rs1638734	ENSG00000237310.1	GS1-124K5.4	3.98	8.03e-05	0.00645	0.21	0.18	Diabetic kidney disease;	chr7:66632552	chr7:66493706~66495474:+
THCA	cis	rs62158800	0.852	rs1516200	ENSG00000237880.1	AC096669.2	3.98	8.03e-05	0.00645	0.26	0.18	Facial morphology (factor 22);	chr2:107686924	chr2:107385632~107542649:-
THCA	cis	rs10175706	1	rs10175706	ENSG00000256637.5	RP11-76I14.1	-3.98	8.03e-05	0.00646	-0.16	-0.18	Chin dimples;	chr2:104015356	chr2:103874310~104077778:+
THCA	cis	rs10175706	1	rs7581688	ENSG00000256637.5	RP11-76I14.1	-3.98	8.03e-05	0.00646	-0.16	-0.18	Chin dimples;	chr2:104016035	chr2:103874310~104077778:+
THCA	cis	rs10200159	0.744	rs6545513	ENSG00000272606.1	RP11-554J4.1	3.98	8.03e-05	0.00646	0.35	0.18	Vitiligo;	chr2:55657729	chr2:55617909~55618373:+
THCA	cis	rs67981189	0.896	rs1859468	ENSG00000269927.1	RP6-91H8.3	-3.98	8.03e-05	0.00646	-0.21	-0.18	Schizophrenia;	chr14:70935573	chr14:71141125~71143253:-
THCA	cis	rs2281636	0.894	rs12782208	ENSG00000233690.1	EBAG9P1	3.98	8.03e-05	0.00646	0.17	0.18	Obesity-related traits;	chr10:99617219	chr10:99697407~99697949:-
THCA	cis	rs2191566	0.576	rs393536	ENSG00000277806.1	RP11-15A1.8	3.98	8.03e-05	0.00646	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43988866	chr19:43976815~43977448:+
THCA	cis	rs13083990	0.919	rs3749208	ENSG00000272758.4	RP11-299J3.8	3.98	8.04e-05	0.00646	0.18	0.18	Cardiac Troponin-T levels;	chr3:122261437	chr3:122416207~122443180:+
THCA	cis	rs758324	0.661	rs246844	ENSG00000237714.1	P4HA2-AS1	-3.98	8.04e-05	0.00646	-0.28	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132065641	chr5:132184876~132192808:+
THCA	cis	rs8115854	0.961	rs6031882	ENSG00000269846.1	RP4-621N11.2	-3.98	8.04e-05	0.00646	-0.23	-0.18	Hippocampal atrophy;	chr20:37181380	chr20:37095785~37097178:+
THCA	cis	rs1552244	0.572	rs3894321	ENSG00000180385.7	EMC3-AS1	3.98	8.04e-05	0.00646	0.23	0.18	Alzheimer's disease;	chr3:10127208	chr3:9986893~10006990:+
THCA	cis	rs765787	0.53	rs2554453	ENSG00000259539.1	CTD-2651B20.1	3.98	8.04e-05	0.00646	0.22	0.18	Uric acid levels;	chr15:45229909	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11858988	ENSG00000259539.1	CTD-2651B20.1	3.98	8.04e-05	0.00646	0.22	0.18	Uric acid levels;	chr15:45229916	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11855435	ENSG00000259539.1	CTD-2651B20.1	3.98	8.04e-05	0.00646	0.22	0.18	Uric acid levels;	chr15:45229919	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2458224	ENSG00000259539.1	CTD-2651B20.1	3.98	8.04e-05	0.00646	0.22	0.18	Uric acid levels;	chr15:45229932	chr15:45152664~45167526:-
THCA	cis	rs9733	0.687	rs11204735	ENSG00000231073.1	RP11-316M1.3	-3.98	8.04e-05	0.00646	-0.22	-0.18	Tonsillectomy;	chr1:150869191	chr1:150973123~150975534:+
THCA	cis	rs9733	0.744	rs12758227	ENSG00000231073.1	RP11-316M1.3	-3.98	8.04e-05	0.00646	-0.22	-0.18	Tonsillectomy;	chr1:150872107	chr1:150973123~150975534:+
THCA	cis	rs875971	0.505	rs1167386	ENSG00000229180.5	GS1-124K5.11	-3.98	8.04e-05	0.00646	-0.13	-0.18	Aortic root size;	chr7:66048109	chr7:66526088~66542624:-
THCA	cis	rs875971	0.505	rs1167385	ENSG00000229180.5	GS1-124K5.11	-3.98	8.04e-05	0.00646	-0.13	-0.18	Aortic root size;	chr7:66048321	chr7:66526088~66542624:-
THCA	cis	rs7615952	0.515	rs7630575	ENSG00000250012.1	RP11-124N2.1	-3.98	8.04e-05	0.00647	-0.17	-0.18	Blood pressure (smoking interaction);	chr3:125963487	chr3:126084220~126095349:+
THCA	cis	rs2839186	0.934	rs17182538	ENSG00000215424.8	MCM3AP-AS1	3.98	8.04e-05	0.00647	0.1	0.18	Testicular germ cell tumor;	chr21:46285759	chr21:46229217~46259390:+
THCA	cis	rs5758659	0.652	rs4822084	ENSG00000270083.1	RP1-257I20.14	-3.98	8.04e-05	0.00647	-0.2	-0.18	Cognitive function;	chr22:42039864	chr22:42089630~42090028:-
THCA	cis	rs7819412	0.715	rs35223712	ENSG00000254839.1	AF131215.6	3.98	8.04e-05	0.00647	0.19	0.18	Triglycerides;	chr8:11186417	chr8:11062647~11067089:-
THCA	cis	rs7259376	0.905	rs2082479	ENSG00000269138.1	ZNF209P	3.98	8.04e-05	0.00647	0.18	0.18	Menopause (age at onset);	chr19:22357045	chr19:22463922~22473036:+
THCA	cis	rs7829975	0.714	rs6994038	ENSG00000253981.4	ALG1L13P	3.98	8.05e-05	0.00647	0.17	0.18	Mood instability;	chr8:8803028	chr8:8236003~8244667:-
THCA	cis	rs9309473	0.948	rs6719753	ENSG00000273245.1	RP11-434P11.2	3.98	8.05e-05	0.00647	0.24	0.18	Metabolite levels;	chr2:73521927	chr2:73750256~73750786:-
THCA	cis	rs34792	0.528	rs222130	ENSG00000207425.1	Y_RNA	-3.98	8.05e-05	0.00647	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15454453	chr16:14915457~14915556:-
THCA	cis	rs7614311	0.509	rs73119034	ENSG00000271843.1	RP11-245J9.5	-3.98	8.05e-05	0.00647	-0.35	-0.18	Lung function (FVC);Lung function (FEV1);	chr3:64007349	chr3:64008082~64008692:-
THCA	cis	rs875971	1	rs1565531	ENSG00000230189.5	GS1-124K5.2	-3.98	8.05e-05	0.00647	-0.12	-0.18	Aortic root size;	chr7:66198126	chr7:66409143~66490059:-
THCA	cis	rs613391	0.555	rs497100	ENSG00000234840.1	LINC01239	-3.98	8.05e-05	0.00647	-0.21	-0.18	Quantitative traits;	chr9:22747409	chr9:22646200~22824213:+
THCA	cis	rs962856	0.619	rs6739471	ENSG00000236780.4	AC078941.1	3.98	8.05e-05	0.00647	0.24	0.18	Pancreatic cancer;	chr2:67358461	chr2:67123357~67215319:-
THCA	cis	rs962856	0.619	rs11890682	ENSG00000236780.4	AC078941.1	3.98	8.05e-05	0.00647	0.24	0.18	Pancreatic cancer;	chr2:67362453	chr2:67123357~67215319:-
THCA	cis	rs900400	0.895	rs17451107	ENSG00000244515.1	KRT18P34	-3.98	8.05e-05	0.00647	-0.21	-0.18	circulating leptin levels adjusted for BMI;Birth weight;Menarche (age at onset);Adiponectin levels in pregnancy;circulating leptin levels;	chr3:157079820	chr3:157162663~157163932:-
THCA	cis	rs7849973	0.667	rs12346016	ENSG00000234840.1	LINC01239	-3.98	8.05e-05	0.00647	-0.23	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22785142	chr9:22646200~22824213:+
THCA	cis	rs17685	0.753	rs12531559	ENSG00000227038.2	AC005077.12	-3.98	8.05e-05	0.00647	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76002379	chr7:76090431~76108779:-
THCA	cis	rs7267979	1	rs6083862	ENSG00000276952.1	RP5-965G21.6	-3.98	8.05e-05	0.00647	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25284915~25285588:-
THCA	cis	rs6546886	0.912	rs10191539	ENSG00000235499.1	AC073046.25	3.98	8.05e-05	0.00647	0.17	0.18	Dialysis-related mortality;	chr2:74042799	chr2:73985132~73986343:+
THCA	cis	rs7481311	0.912	rs10767645	ENSG00000245573.6	BDNF-AS	3.98	8.05e-05	0.00647	0.17	0.18	Weight;Body mass index;	chr11:27523192	chr11:27506838~27698174:+
THCA	cis	rs721917	0.525	rs2258874	ENSG00000244733.5	RP11-506M13.3	-3.98	8.05e-05	0.00647	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79919400	chr10:79660891~79677996:+
THCA	cis	rs524281	0.692	rs2302884	ENSG00000255120.4	OVOL1-AS1	-3.98	8.05e-05	0.00647	-0.26	-0.18	Electroencephalogram traits;	chr11:66056613	chr11:65789051~65790868:-
THCA	cis	rs524281	0.647	rs2302883	ENSG00000255120.4	OVOL1-AS1	-3.98	8.05e-05	0.00647	-0.26	-0.18	Electroencephalogram traits;	chr11:66057523	chr11:65789051~65790868:-
THCA	cis	rs2562456	0.833	rs2928211	ENSG00000268658.4	LINC00664	-3.98	8.05e-05	0.00647	-0.27	-0.18	Pain;	chr19:21358495	chr19:21483374~21503238:+
THCA	cis	rs7267979	0.966	rs3827014	ENSG00000276952.1	RP5-965G21.6	-3.98	8.05e-05	0.00647	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25284915~25285588:-
THCA	cis	rs17221829	0.645	rs4753227	ENSG00000280385.1	AP000648.5	-3.98	8.05e-05	0.00647	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89635934	chr11:90193614~90198120:+
THCA	cis	rs3808502	0.503	rs2061830	ENSG00000255046.1	RP11-297N6.4	-3.98	8.06e-05	0.00648	-0.19	-0.18	Neuroticism;	chr8:11539948	chr8:11797928~11802568:-
THCA	cis	rs10888838	0.818	rs61776465	ENSG00000198711.5	SSBP3-AS1	3.98	8.06e-05	0.00648	0.24	0.18	Mitochondrial DNA levels;	chr1:54229077	chr1:54236440~54239063:+
THCA	cis	rs2688482	0.557	rs2550236	ENSG00000185485.13	SDHAP1	3.98	8.06e-05	0.00648	0.19	0.18	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195959748~195990318:-
THCA	cis	rs1124769	0.5	rs79722088	ENSG00000273674.3	CTD-2378E12.1	-3.98	8.06e-05	0.00648	-0.24	-0.18	Cognitive performance;	chr15:50853702	chr15:50839875~50908599:-
THCA	cis	rs1714507	0.515	rs2731112	ENSG00000272247.1	RP11-379F4.9	-3.98	8.06e-05	0.00648	-0.17	-0.18	Subjective well-being;	chr3:158572439	chr3:158801257~158801935:-
THCA	cis	rs1714507	0.533	rs2731122	ENSG00000272247.1	RP11-379F4.9	-3.98	8.06e-05	0.00648	-0.17	-0.18	Subjective well-being;	chr3:158577491	chr3:158801257~158801935:-
THCA	cis	rs1714507	0.533	rs2731120	ENSG00000272247.1	RP11-379F4.9	3.98	8.06e-05	0.00648	0.17	0.18	Subjective well-being;	chr3:158579844	chr3:158801257~158801935:-
THCA	cis	rs7267979	0.903	rs2474769	ENSG00000276952.1	RP5-965G21.6	3.98	8.06e-05	0.00648	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25284915~25285588:-
THCA	cis	rs12539814	1	rs10487628	ENSG00000204959.4	ARHGEF34P	3.98	8.06e-05	0.00648	0.25	0.18	Diastolic blood pressure;	chr7:144467232	chr7:144272445~144286966:-
THCA	cis	rs4886920	0.519	rs4496098	ENSG00000260776.4	RP11-114H24.2	3.98	8.06e-05	0.00648	0.28	0.18	Neuroticism;	chr15:77825595	chr15:77914217~77926846:-
THCA	cis	rs2039553	0.614	rs9530959	ENSG00000227354.5	RBM26-AS1	-3.98	8.06e-05	0.00648	-0.17	-0.18	Pancreatic cancer;	chr13:79789499	chr13:79406309~79424328:+
THCA	cis	rs293748	0.771	rs292160	ENSG00000250155.1	CTD-2353F22.1	-3.98	8.06e-05	0.00648	-0.24	-0.18	Obesity-related traits;	chr5:36895971	chr5:36666214~36725195:-
THCA	cis	rs4434872	0.536	rs34665499	ENSG00000223599.1	RP11-216N14.7	-3.98	8.06e-05	0.00648	-0.33	-0.18	Conduct disorder (symptom count);	chr1:153919660	chr1:153852106~153853414:-
THCA	cis	rs5015933	0.801	rs7848571	ENSG00000232630.1	PRPS1P2	-3.98	8.06e-05	0.00648	-0.12	-0.18	Body mass index;	chr9:125378927	chr9:125150653~125151589:+
THCA	cis	rs734999	0.505	rs10910108	ENSG00000225931.3	RP3-395M20.7	3.98	8.06e-05	0.00648	0.22	0.18	Ulcerative colitis;	chr1:2608093	chr1:2566410~2569888:+
THCA	cis	rs734999	0.505	rs4278312	ENSG00000225931.3	RP3-395M20.7	3.98	8.06e-05	0.00648	0.22	0.18	Ulcerative colitis;	chr1:2608116	chr1:2566410~2569888:+
THCA	cis	rs6667605	0.527	rs4422947	ENSG00000225931.3	RP3-395M20.7	3.98	8.06e-05	0.00648	0.22	0.18	Ulcerative colitis;Inflammatory bowel disease;	chr1:2608151	chr1:2566410~2569888:+
THCA	cis	rs34421088	0.702	rs7838131	ENSG00000270154.1	RP11-419I17.1	-3.98	8.07e-05	0.00648	-0.21	-0.18	Neuroticism;	chr8:11738654	chr8:12476462~12477122:+
THCA	cis	rs9510787	0.649	rs3794347	ENSG00000205861.10	C1QTNF9B-AS1	-3.98	8.07e-05	0.00648	-0.24	-0.18	Nasopharyngeal carcinoma;	chr13:23641097	chr13:23888889~23897263:+
THCA	cis	rs2360027	0.558	rs10802045	ENSG00000231365.4	RP11-418J17.1	-3.98	8.07e-05	0.00648	-0.18	-0.18	Tonsillectomy;	chr1:118580201	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.619	rs4329498	ENSG00000231365.4	RP11-418J17.1	-3.98	8.07e-05	0.00648	-0.18	-0.18	Tonsillectomy;	chr1:118590986	chr1:119140396~119275973:+
THCA	cis	rs4713118	0.739	rs2893931	ENSG00000220721.1	OR1F12	3.98	8.07e-05	0.00648	0.24	0.18	Parkinson's disease;	chr6:27780231	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.824	rs2092075	ENSG00000220721.1	OR1F12	3.98	8.07e-05	0.00648	0.24	0.18	Parkinson's disease;	chr6:27781551	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.824	rs13211701	ENSG00000220721.1	OR1F12	3.98	8.07e-05	0.00648	0.24	0.18	Parkinson's disease;	chr6:27782300	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.824	rs9468229	ENSG00000220721.1	OR1F12	3.98	8.07e-05	0.00648	0.24	0.18	Parkinson's disease;	chr6:27782307	chr6:28073316~28074233:+
THCA	cis	rs7560272	0.538	rs17434634	ENSG00000273245.1	RP11-434P11.2	-3.98	8.07e-05	0.00648	-0.21	-0.18	Schizophrenia;	chr2:73695799	chr2:73750256~73750786:-
THCA	cis	rs5758659	0.622	rs5758527	ENSG00000281538.1	RP4-669P10.20	3.98	8.07e-05	0.00649	0.17	0.18	Cognitive function;	chr22:41979757	chr22:42138060~42139726:+
THCA	cis	rs2280018	0.581	rs7404524	ENSG00000263335.1	AF001548.5	-3.98	8.07e-05	0.00649	-0.21	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15726674~15732993:+
THCA	cis	rs9650657	0.812	rs6601522	ENSG00000255310.2	AF131215.2	-3.98	8.07e-05	0.00649	-0.15	-0.18	Neuroticism;	chr8:10771551	chr8:11107788~11109726:-
THCA	cis	rs1923243	0.786	rs7532052	ENSG00000223479.3	RP4-788P17.1	-3.98	8.07e-05	0.00649	-0.2	-0.18	Migraine;	chr1:73094289	chr1:73635216~73715214:+
THCA	cis	rs7829975	0.714	rs7823757	ENSG00000233609.3	RP11-62H7.2	3.98	8.07e-05	0.00649	0.17	0.18	Mood instability;	chr8:8812667	chr8:8961200~8979025:+
THCA	cis	rs4788570	0.584	rs6499528	ENSG00000260593.1	RP11-432I5.2	-3.98	8.07e-05	0.00649	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71638859	chr16:71623708~71626816:-
THCA	cis	rs17286411	0.671	rs8048057	ENSG00000260185.1	RP11-432I5.6	-3.98	8.07e-05	0.00649	-0.25	-0.18	Blood protein levels;	chr16:71683481	chr16:71655027~71664212:+
THCA	cis	rs9900062	0.519	rs2676293	ENSG00000270714.1	MINOS1P2	-3.98	8.07e-05	0.00649	-0.24	-0.18	QT interval;	chr17:64714343	chr17:64747264~64747492:-
THCA	cis	rs10932886	0.76	rs1467060	ENSG00000224819.1	AC093843.1	3.98	8.08e-05	0.00649	0.17	0.18	Brain imaging;	chr2:220844903	chr2:220791078~220797893:+
THCA	cis	rs911555	0.755	rs35233301	ENSG00000269958.1	RP11-73M18.8	-3.98	8.08e-05	0.00649	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103696353~103697163:+
THCA	cis	rs7111546	0.887	rs16910190	ENSG00000246225.5	RP11-17A1.3	3.98	8.08e-05	0.00649	0.32	0.18	Dialysis-related mortality;	chr11:22807060	chr11:22829380~22945393:+
THCA	cis	rs7578199	0.576	rs6752327	ENSG00000223374.1	AC005104.3	-3.98	8.08e-05	0.00649	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241465246	chr2:241351340~241353104:-
THCA	cis	rs7578199	0.576	rs437022	ENSG00000223374.1	AC005104.3	-3.98	8.08e-05	0.00649	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241471992	chr2:241351340~241353104:-
THCA	cis	rs7578199	0.564	rs6712206	ENSG00000223374.1	AC005104.3	-3.98	8.08e-05	0.00649	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241472421	chr2:241351340~241353104:-
THCA	cis	rs7578199	0.576	rs10196248	ENSG00000223374.1	AC005104.3	-3.98	8.08e-05	0.00649	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241474493	chr2:241351340~241353104:-
THCA	cis	rs7578199	0.601	rs10184910	ENSG00000223374.1	AC005104.3	-3.98	8.08e-05	0.00649	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241476202	chr2:241351340~241353104:-
THCA	cis	rs7829975	0.533	rs35900578	ENSG00000253981.4	ALG1L13P	3.98	8.08e-05	0.00649	0.18	0.18	Mood instability;	chr8:8862003	chr8:8236003~8244667:-
THCA	cis	rs4742903	0.846	rs7022158	ENSG00000270332.1	SMC2-AS1	3.98	8.08e-05	0.00649	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104162591	chr9:104080024~104093073:-
THCA	cis	rs7973719	0.509	rs3816424	ENSG00000205885.6	C1RL-AS1	3.98	8.08e-05	0.00649	0.14	0.18	IgG glycosylation;	chr12:7207633	chr12:7108052~7122501:+
THCA	cis	rs427394	0.796	rs274683	ENSG00000248677.1	CTD-2044J15.1	3.98	8.08e-05	0.00649	0.17	0.18	Menopause (age at onset);	chr5:6747837	chr5:6686325~6707711:-
THCA	cis	rs4718428	1	rs4718428	ENSG00000237310.1	GS1-124K5.4	3.98	8.08e-05	0.00649	0.13	0.18	Corneal structure;	chr7:66956459	chr7:66493706~66495474:+
THCA	cis	rs4803480	0.507	rs10420992	ENSG00000270164.1	LINC01480	-3.98	8.08e-05	0.00649	-0.16	-0.18	Schizophrenia;	chr19:41558092	chr19:41535183~41536904:+
THCA	cis	rs13063635	0.764	rs74586549	ENSG00000226074.4	PRSS44	-3.98	8.08e-05	0.00649	-0.32	-0.18	Eosinophil percentage of granulocytes;	chr3:45884551	chr3:46809359~46812558:-
THCA	cis	rs860295	0.535	rs2297649	ENSG00000236675.1	MTX1P1	3.98	8.08e-05	0.00649	0.18	0.18	Body mass index;	chr1:155965453	chr1:155230975~155234325:+
THCA	cis	rs879500	0.961	rs72892326	ENSG00000227279.1	AC015933.2	3.98	8.09e-05	0.0065	0.21	0.18	Lung function (FVC);	chr18:28528194	chr18:27954519~27963687:+
THCA	cis	rs838886	0.912	rs838880	ENSG00000275389.1	RP11-214K3.24	3.98	8.09e-05	0.0065	0.24	0.18	HDL cholesterol;	chr12:124777047	chr12:124085761~124088598:+
THCA	cis	rs13217239	0.608	rs6930508	ENSG00000124549.13	BTN2A3P	-3.98	8.09e-05	0.0065	-0.17	-0.18	Schizophrenia;	chr6:27085363	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs2142685	ENSG00000124549.13	BTN2A3P	-3.98	8.09e-05	0.0065	-0.17	-0.18	Schizophrenia;	chr6:27086718	chr6:26421391~26432383:+
THCA	cis	rs5751614	0.967	rs5759663	ENSG00000240160.3	RN7SL263P	3.98	8.09e-05	0.0065	0.2	0.18	Height;	chr22:23247571	chr22:23261782~23262071:-
THCA	cis	rs494003	1	rs11227284	ENSG00000214659.4	KRT8P26	3.98	8.09e-05	0.0065	0.21	0.18	Systemic lupus erythematosus;	chr11:65735753	chr11:65726939~65728214:+
THCA	cis	rs782212	0.592	rs1599337	ENSG00000227207.2	RPL31P12	3.98	8.09e-05	0.0065	0.28	0.18	Depression;	chr1:72380777	chr1:72301472~72301829:+
THCA	cis	rs67981189	0.896	rs2158997	ENSG00000269927.1	RP6-91H8.3	-3.98	8.09e-05	0.0065	-0.2	-0.18	Schizophrenia;	chr14:71031077	chr14:71141125~71143253:-
THCA	cis	rs962856	0.575	rs673005	ENSG00000236780.4	AC078941.1	3.98	8.09e-05	0.0065	0.24	0.18	Pancreatic cancer;	chr2:67427249	chr2:67123357~67215319:-
THCA	cis	rs962856	0.575	rs598108	ENSG00000236780.4	AC078941.1	3.98	8.09e-05	0.0065	0.24	0.18	Pancreatic cancer;	chr2:67429100	chr2:67123357~67215319:-
THCA	cis	rs12681963	0.764	rs11778927	ENSG00000248159.1	HSPA8P11	-3.98	8.09e-05	0.0065	-0.34	-0.18	Migraine;	chr8:30139055	chr8:30237382~30240997:+
THCA	cis	rs472402	0.54	rs10062086	ENSG00000250056.4	LINC01018	-3.98	8.09e-05	0.0065	-0.22	-0.18	Response to amphetamines;	chr5:6632929	chr5:6582136~6588499:+
THCA	cis	rs9467773	1	rs12526680	ENSG00000228223.2	HCG11	-3.98	8.09e-05	0.0065	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26523450~26526579:+
THCA	cis	rs10875943	0.751	rs56222401	ENSG00000257464.1	RP11-161H23.8	-3.98	8.09e-05	0.0065	-0.22	-0.18	Prostate cancer;	chr12:49278931	chr12:49442424~49442652:-
THCA	cis	rs6498068	0.522	rs10775284	ENSG00000260468.1	LINC01290	-3.98	8.1e-05	0.0065	-0.23	-0.18	Metabolite levels (MHPG);	chr16:10535402	chr16:10514842~10528202:-
THCA	cis	rs1552244	0.572	rs57268864	ENSG00000180385.7	EMC3-AS1	3.98	8.1e-05	0.0065	0.23	0.18	Alzheimer's disease;	chr3:10122549	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs59074548	ENSG00000180385.7	EMC3-AS1	3.98	8.1e-05	0.0065	0.23	0.18	Alzheimer's disease;	chr3:10122663	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs3774208	ENSG00000180385.7	EMC3-AS1	3.98	8.1e-05	0.0065	0.23	0.18	Alzheimer's disease;	chr3:10123038	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs6783705	ENSG00000180385.7	EMC3-AS1	3.98	8.1e-05	0.0065	0.23	0.18	Alzheimer's disease;	chr3:10123099	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs68013239	ENSG00000180385.7	EMC3-AS1	3.98	8.1e-05	0.0065	0.23	0.18	Alzheimer's disease;	chr3:10124027	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs68121641	ENSG00000180385.7	EMC3-AS1	3.98	8.1e-05	0.0065	0.23	0.18	Alzheimer's disease;	chr3:10124161	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.515	rs67342818	ENSG00000180385.7	EMC3-AS1	3.98	8.1e-05	0.0065	0.23	0.18	Alzheimer's disease;	chr3:10124722	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs66514627	ENSG00000180385.7	EMC3-AS1	3.98	8.1e-05	0.0065	0.23	0.18	Alzheimer's disease;	chr3:10124948	chr3:9986893~10006990:+
THCA	cis	rs1124769	0.57	rs2663552	ENSG00000273674.3	CTD-2378E12.1	3.98	8.1e-05	0.0065	0.24	0.18	Cognitive performance;	chr15:50839973	chr15:50839875~50908599:-
THCA	cis	rs2638953	0.815	rs11049677	ENSG00000247934.4	RP11-967K21.1	3.98	8.1e-05	0.00651	0.19	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505106	chr12:28163298~28190738:-
THCA	cis	rs354225	0.512	rs6744586	ENSG00000162997.14	PRORSD1P	-3.98	8.1e-05	0.00651	-0.24	-0.18	Schizophrenia;	chr2:54703330	chr2:55282319~55284522:+
THCA	cis	rs2287838	0.967	rs3786694	ENSG00000267370.1	CTD-2623N2.3	3.98	8.1e-05	0.00651	0.17	0.18	Sleep duration;	chr19:9844665	chr19:9756152~9756863:-
THCA	cis	rs11710088	0.931	rs4630883	ENSG00000244503.1	RP11-278L15.6	-3.98	8.1e-05	0.00651	-0.23	-0.18	QRS duration;	chr3:149481373	chr3:149494660~149495995:+
THCA	cis	rs657075	0.595	rs35719560	ENSG00000237714.1	P4HA2-AS1	-3.98	8.1e-05	0.00651	-0.37	-0.18	Rheumatoid arthritis;	chr5:132248702	chr5:132184876~132192808:+
THCA	cis	rs12755164	0.771	rs1525978	ENSG00000223479.3	RP4-788P17.1	-3.98	8.1e-05	0.00651	-0.19	-0.18	Schizophrenia;	chr1:72849211	chr1:73635216~73715214:+
THCA	cis	rs7088591	0.867	rs78086456	ENSG00000276818.1	AC026393.1	3.98	8.1e-05	0.00651	0.39	0.18	Blood pressure;	chr10:58001984	chr10:57095699~57095781:+
THCA	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-3.98	8.1e-05	0.00651	-0.19	-0.18	Asthma;	chr2:102374909	chr2:102438713~102440475:+
THCA	cis	rs55661361	0.553	rs11219765	ENSG00000254941.1	RP11-677M14.5	-3.98	8.1e-05	0.00651	-0.15	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124732351	chr11:124807822~124808269:-
THCA	cis	rs11185790	0.784	rs10881603	ENSG00000232936.4	RP11-80H5.2	3.98	8.11e-05	0.00651	0.22	0.18	Metabolic traits;	chr10:89573917	chr10:89645282~89650667:+
THCA	cis	rs6479891	0.63	rs4545434	ENSG00000272767.1	JMJD1C-AS1	3.98	8.11e-05	0.00651	0.23	0.18	Arthritis (juvenile idiopathic);	chr10:63115985	chr10:63465229~63466563:+
THCA	cis	rs2179367	0.6	rs9498354	ENSG00000216906.2	RP11-350J20.9	-3.98	8.11e-05	0.00651	-0.25	-0.18	Dupuytren's disease;	chr6:149441715	chr6:149904243~149906418:+
THCA	cis	rs7737355	0.947	rs10463887	ENSG00000237714.1	P4HA2-AS1	-3.98	8.11e-05	0.00651	-0.26	-0.18	Life satisfaction;	chr5:131441161	chr5:132184876~132192808:+
THCA	cis	rs12497850	0.931	rs6791542	ENSG00000228638.1	FCF1P2	-3.98	8.11e-05	0.00651	-0.19	-0.18	Parkinson's disease;	chr3:48749786	chr3:48290793~48291375:-
THCA	cis	rs2320614	1	rs2320614	ENSG00000250027.1	RP11-563E2.2	-3.98	8.11e-05	0.00651	-0.16	-0.18	Lung adenocarcinoma;	chr4:163148970	chr4:163108785~163119965:+
THCA	cis	rs17711722	1	rs17711722	ENSG00000229180.5	GS1-124K5.11	-3.98	8.11e-05	0.00652	-0.13	-0.18	Calcium levels;	chr7:65806210	chr7:66526088~66542624:-
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000229180.5	GS1-124K5.11	-3.98	8.11e-05	0.00652	-0.13	-0.18	Calcium levels;	chr7:65808508	chr7:66526088~66542624:-
THCA	cis	rs987724	0.927	rs6803064	ENSG00000240875.4	LINC00886	-3.98	8.11e-05	0.00652	-0.15	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156960821	chr3:156747346~156817062:-
THCA	cis	rs453301	0.653	rs1562211	ENSG00000253981.4	ALG1L13P	-3.98	8.12e-05	0.00652	-0.16	-0.18	Joint mobility (Beighton score);	chr8:9044914	chr8:8236003~8244667:-
THCA	cis	rs6500602	0.928	rs3747581	ENSG00000280063.1	RP11-295D4.3	3.98	8.12e-05	0.00652	0.1	0.18	Schizophrenia;	chr16:4412618	chr16:4346694~4348648:-
THCA	cis	rs7914558	1	rs10883826	ENSG00000272912.1	RP11-724N1.1	-3.98	8.12e-05	0.00652	-0.21	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:102914585~102915404:+
THCA	cis	rs7259376	0.905	rs12608842	ENSG00000269345.1	VN1R85P	-3.98	8.12e-05	0.00652	-0.19	-0.18	Menopause (age at onset);	chr19:22365211	chr19:22174766~22175191:-
THCA	cis	rs1908814	0.516	rs10113042	ENSG00000254948.1	OR7E158P	-3.98	8.12e-05	0.00652	-0.22	-0.18	Neuroticism;	chr8:11935669	chr8:11919900~11920809:-
THCA	cis	rs453301	0.686	rs1045527	ENSG00000233609.3	RP11-62H7.2	-3.98	8.12e-05	0.00652	-0.17	-0.18	Joint mobility (Beighton score);	chr8:9032531	chr8:8961200~8979025:+
THCA	cis	rs1580019	1	rs1580019	ENSG00000231952.3	DPY19L1P2	3.98	8.12e-05	0.00652	0.23	0.18	Cognitive ability;	chr7:32453557	chr7:32812757~32838570:+
THCA	cis	rs17221829	0.739	rs72971036	ENSG00000280385.1	AP000648.5	-3.98	8.12e-05	0.00652	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89637384	chr11:90193614~90198120:+
THCA	cis	rs2732480	1	rs2732480	ENSG00000273765.1	RP11-370I10.11	-3.98	8.12e-05	0.00652	-0.17	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48360920~48361377:+
THCA	cis	rs10875746	0.669	rs10783244	ENSG00000258273.1	RP11-370I10.4	3.98	8.12e-05	0.00652	0.25	0.18	Longevity (90 years and older);	chr12:48271206	chr12:48333755~48333901:-
THCA	cis	rs752590	0.623	rs72831810	ENSG00000227359.1	AC017074.2	3.98	8.12e-05	0.00652	0.32	0.18	Mucinous ovarian carcinoma;	chr2:113221787	chr2:113677702~113704078:-
THCA	cis	rs709400	1	rs2403205	ENSG00000258735.1	LINC00637	3.98	8.13e-05	0.00652	0.24	0.18	Body mass index;	chr14:103677048	chr14:103847721~103858049:+
THCA	cis	rs9660180	0.78	rs12038111	ENSG00000215914.4	MMP23A	-3.98	8.13e-05	0.00653	-0.24	-0.18	Body mass index;	chr1:1772410	chr1:1699942~1701782:+
THCA	cis	rs9660180	0.836	rs12038134	ENSG00000215914.4	MMP23A	-3.98	8.13e-05	0.00653	-0.24	-0.18	Body mass index;	chr1:1772426	chr1:1699942~1701782:+
THCA	cis	rs9392556	0.6	rs661404	ENSG00000272248.1	RP3-406P24.4	3.98	8.13e-05	0.00653	0.22	0.18	Blood metabolite levels;	chr6:4125863	chr6:4018713~4019202:+
THCA	cis	rs5753037	0.653	rs131282	ENSG00000279699.1	RP1-102K2.9	3.98	8.13e-05	0.00653	0.18	0.18	Type 1 diabetes;	chr22:29760619	chr22:30275215~30276951:-
THCA	cis	rs9595908	0.709	rs56347753	ENSG00000212293.1	SNORA16	3.98	8.13e-05	0.00653	0.21	0.18	Body mass index;	chr13:32721685	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.669	rs9596149	ENSG00000212293.1	SNORA16	3.98	8.13e-05	0.00653	0.21	0.18	Body mass index;	chr13:32722533	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.709	rs4281583	ENSG00000212293.1	SNORA16	3.98	8.13e-05	0.00653	0.21	0.18	Body mass index;	chr13:32722781	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.709	rs7322827	ENSG00000212293.1	SNORA16	3.98	8.13e-05	0.00653	0.21	0.18	Body mass index;	chr13:32724396	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.629	rs9596156	ENSG00000212293.1	SNORA16	3.98	8.13e-05	0.00653	0.21	0.18	Body mass index;	chr13:32724977	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.733	rs9591282	ENSG00000212293.1	SNORA16	3.98	8.13e-05	0.00653	0.21	0.18	Body mass index;	chr13:32725844	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.669	rs7319787	ENSG00000212293.1	SNORA16	3.98	8.13e-05	0.00653	0.21	0.18	Body mass index;	chr13:32728320	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.669	rs7331529	ENSG00000212293.1	SNORA16	3.98	8.13e-05	0.00653	0.21	0.18	Body mass index;	chr13:32728409	chr13:32420390~32420516:-
THCA	cis	rs35998080	1	rs35998080	ENSG00000223479.3	RP4-788P17.1	3.98	8.13e-05	0.00653	0.2	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr1:72812932	chr1:73635216~73715214:+
THCA	cis	rs74233809	1	rs12220743	ENSG00000272912.1	RP11-724N1.1	-3.98	8.13e-05	0.00653	-0.33	-0.18	Birth weight;	chr10:103092155	chr10:102914585~102915404:+
THCA	cis	rs758324	0.687	rs141249	ENSG00000224431.1	AC063976.7	-3.98	8.13e-05	0.00653	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132149813	chr5:132199456~132203487:+
THCA	cis	rs2836974	0.799	rs13047550	ENSG00000255568.3	BRWD1-AS2	3.98	8.13e-05	0.00653	0.16	0.18	Cognitive function;	chr21:39143569	chr21:39313935~39314962:+
THCA	cis	rs7264396	0.775	rs2296402	ENSG00000088340.14	FER1L4	3.98	8.13e-05	0.00653	0.16	0.18	Total cholesterol levels;	chr20:35466904	chr20:35558737~35607562:-
THCA	cis	rs2298450	0.717	rs2835330	ENSG00000214867.3	SRSF9P1	3.98	8.13e-05	0.00653	0.27	0.18	Schizophrenia;	chr21:36258875	chr21:36295173~36295702:-
THCA	cis	rs9393813	0.791	rs35690855	ENSG00000204789.4	ZNF204P	-3.98	8.13e-05	0.00653	-0.14	-0.18	Bipolar disorder;	chr6:27373692	chr6:27357825~27360221:-
THCA	cis	rs150992	0.609	rs116183885	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98990735	chr5:98769618~98773469:-
THCA	cis	rs150992	0.534	rs115121903	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98990736	chr5:98769618~98773469:-
THCA	cis	rs150992	0.592	rs2455423	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98990844	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs559574	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98991122	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs443726	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98991163	chr5:98769618~98773469:-
THCA	cis	rs150992	0.592	rs407562	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98991512	chr5:98769618~98773469:-
THCA	cis	rs150992	0.632	rs395668	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98991611	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs449204	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98991775	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs378089	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98991818	chr5:98769618~98773469:-
THCA	cis	rs150992	0.587	rs422127	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98991984	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs113423144	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98992055	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs380156	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98992386	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs2937709	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98993120	chr5:98769618~98773469:-
THCA	cis	rs150992	0.632	rs1104262	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98993145	chr5:98769618~98773469:-
THCA	cis	rs150992	0.609	rs2927654	ENSG00000246763.5	RGMB-AS1	3.98	8.13e-05	0.00653	0.19	0.18	Body mass index;	chr5:98993195	chr5:98769618~98773469:-
THCA	cis	rs12682352	0.602	rs6993494	ENSG00000248538.5	RP11-10A14.5	-3.98	8.14e-05	0.00653	-0.23	-0.18	Neuroticism;	chr8:8809934	chr8:9189011~9202854:+
THCA	cis	rs586688	0.625	rs606114	ENSG00000224536.1	RP11-134G8.7	3.98	8.14e-05	0.00653	0.27	0.18	Obesity-related traits;	chr1:201694973	chr1:201507241~201533608:+
THCA	cis	rs11884770	0.522	rs4616471	ENSG00000236432.6	AC097662.2	3.98	8.14e-05	0.00654	0.18	0.18	Advanced age-related macular degeneration;	chr2:227219858	chr2:227221052~227325201:-
THCA	cis	rs12410462	1	rs76233861	ENSG00000227711.2	RP11-275O4.5	-3.98	8.14e-05	0.00654	-0.29	-0.18	Major depressive disorder;	chr1:227486208	chr1:227509028~227520477:-
THCA	cis	rs321358	0.945	rs73015196	ENSG00000271390.1	RP11-89C3.3	3.98	8.14e-05	0.00654	0.3	0.18	Body mass index;	chr11:111104608	chr11:111089870~111090368:-
THCA	cis	rs6929812	0.967	rs35394453	ENSG00000216915.2	RP1-97D16.1	3.98	8.14e-05	0.00654	0.24	0.18	Neuroticism (multi-trait analysis);	chr6:27446052	chr6:27737000~27738494:-
THCA	cis	rs853679	0.527	rs707907	ENSG00000220721.1	OR1F12	3.97	8.15e-05	0.00654	0.2	0.18	Depression;	chr6:28323463	chr6:28073316~28074233:+
THCA	cis	rs2839186	0.934	rs17176520	ENSG00000215424.8	MCM3AP-AS1	3.97	8.15e-05	0.00654	0.11	0.18	Testicular germ cell tumor;	chr21:46262167	chr21:46229217~46259390:+
THCA	cis	rs12681366	0.734	rs2046664	ENSG00000261437.1	RP11-22C11.2	3.97	8.15e-05	0.00654	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94375713	chr8:94637285~94639467:-
THCA	cis	rs181553	0.504	rs28889615	ENSG00000266696.1	RP11-30L3.2	-3.97	8.15e-05	0.00654	-0.26	-0.18	Hip circumference adjusted for BMI;	chr18:49449084	chr18:49205912~49208781:+
THCA	cis	rs1876905	0.597	rs354538	ENSG00000271789.1	RP5-1112D6.7	-3.97	8.15e-05	0.00654	-0.22	-0.18	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111297126~111298510:+
THCA	cis	rs1876905	0.68	rs434034	ENSG00000271789.1	RP5-1112D6.7	-3.97	8.15e-05	0.00654	-0.22	-0.18	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111297126~111298510:+
THCA	cis	rs7162943	0.887	rs12438271	ENSG00000260123.1	RP11-326A19.4	-3.97	8.15e-05	0.00654	-0.23	-0.18	Mean platelet volume;	chr15:89069996	chr15:89041223~89082819:+
THCA	cis	rs7824557	0.51	rs4841524	ENSG00000255495.1	AC145124.2	-3.97	8.15e-05	0.00654	-0.21	-0.18	Retinal vascular caliber;	chr8:11385617	chr8:12194467~12196280:+
THCA	cis	rs62158800	0.925	rs62158831	ENSG00000224568.1	AC096669.3	3.97	8.15e-05	0.00654	0.34	0.18	Facial morphology (factor 22);	chr2:107634732	chr2:107529487~107556326:+
THCA	cis	rs9926296	0.643	rs12596429	ENSG00000274627.1	RP11-104N10.2	-3.97	8.15e-05	0.00654	-0.18	-0.18	Vitiligo;	chr16:89774966	chr16:89516797~89522217:+
THCA	cis	rs7546	0.501	rs12102426	ENSG00000267077.1	RP11-127I20.5	3.97	8.15e-05	0.00654	0.2	0.18	Cancer;	chr16:4872449	chr16:4795265~4796532:-
THCA	cis	rs17597773	0.638	rs11118615	ENSG00000238078.1	LINC01352	-3.97	8.15e-05	0.00654	-0.25	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220823271	chr1:220829255~220832429:+
THCA	cis	rs7632954	0.596	rs9837823	ENSG00000227110.5	LMCD1-AS1	3.97	8.15e-05	0.00654	0.22	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8472596	chr3:7952805~8611924:-
THCA	cis	rs709400	1	rs709400	ENSG00000258735.1	LINC00637	3.97	8.15e-05	0.00654	0.24	0.18	Body mass index;	chr14:103683138	chr14:103847721~103858049:+
THCA	cis	rs181553	0.664	rs7242217	ENSG00000266696.1	RP11-30L3.2	3.97	8.15e-05	0.00654	0.22	0.18	Hip circumference adjusted for BMI;	chr18:49222689	chr18:49205912~49208781:+
THCA	cis	rs4879656	0.866	rs10971227	ENSG00000225693.1	LAGE3P1	3.97	8.15e-05	0.00654	0.19	0.18	Menopause (age at onset);	chr9:32934619	chr9:33019682~33020165:-
THCA	cis	rs8033133	0.56	rs11161166	ENSG00000251896.1	SNORD116-27	3.97	8.15e-05	0.00655	0.2	0.18	Blood osmolality (transformed sodium);	chr15:25079530	chr15:25101575~25101666:+
THCA	cis	rs13178541	0.641	rs10077151	ENSG00000250378.1	RP11-119J18.1	-3.97	8.16e-05	0.00655	-0.21	-0.18	IgG glycosylation;	chr5:135805145	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs10077216	ENSG00000250378.1	RP11-119J18.1	-3.97	8.16e-05	0.00655	-0.21	-0.18	IgG glycosylation;	chr5:135805239	chr5:135812667~135826582:+
THCA	cis	rs2281636	1	rs2804417	ENSG00000233690.1	EBAG9P1	-3.97	8.16e-05	0.00655	-0.17	-0.18	Obesity-related traits;	chr10:99756458	chr10:99697407~99697949:-
THCA	cis	rs73230612	1	rs1473580	ENSG00000242767.1	ZBTB20-AS4	-3.97	8.16e-05	0.00655	-0.24	-0.18	Type 2 diabetes;	chr3:115071211	chr3:115100423~115103061:+
THCA	cis	rs1371614	0.545	rs13035643	ENSG00000272148.1	RP11-195B17.1	-3.97	8.16e-05	0.00655	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950473	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.545	rs4665930	ENSG00000272148.1	RP11-195B17.1	-3.97	8.16e-05	0.00655	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950652	chr2:27062428~27062907:-
THCA	cis	rs7829975	0.714	rs11784052	ENSG00000253981.4	ALG1L13P	3.97	8.16e-05	0.00655	0.17	0.18	Mood instability;	chr8:8814452	chr8:8236003~8244667:-
THCA	cis	rs11175194	0.744	rs12230811	ENSG00000255642.1	PABPC1P4	-3.97	8.16e-05	0.00655	-0.5	-0.18	Epithelial ovarian cancer;	chr12:63862606	chr12:63822021~63823895:+
THCA	cis	rs11710088	0.895	rs34897827	ENSG00000244503.1	RP11-278L15.6	3.97	8.16e-05	0.00655	0.23	0.18	QRS duration;	chr3:149480543	chr3:149494660~149495995:+
THCA	cis	rs11710088	0.931	rs6440617	ENSG00000244503.1	RP11-278L15.6	3.97	8.16e-05	0.00655	0.23	0.18	QRS duration;	chr3:149481139	chr3:149494660~149495995:+
THCA	cis	rs7264396	0.887	rs6120954	ENSG00000088340.14	FER1L4	3.97	8.16e-05	0.00655	0.16	0.18	Total cholesterol levels;	chr20:35471711	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs6060442	ENSG00000088340.14	FER1L4	3.97	8.16e-05	0.00655	0.16	0.18	Total cholesterol levels;	chr20:35505928	chr20:35558737~35607562:-
THCA	cis	rs11176749	1	rs11176747	ENSG00000256172.1	RP11-473M14.3	3.97	8.16e-05	0.00655	0.26	0.18	Expressive vocabulary in infants;	chr12:67454664	chr12:67440998~67442559:-
THCA	cis	rs4879656	0.872	rs2274767	ENSG00000225693.1	LAGE3P1	-3.97	8.16e-05	0.00655	-0.19	-0.18	Menopause (age at onset);	chr9:33047400	chr9:33019682~33020165:-
THCA	cis	rs4718428	1	rs4718428	ENSG00000229886.1	RP5-1132H15.3	3.97	8.16e-05	0.00655	0.19	0.18	Corneal structure;	chr7:66956459	chr7:66025126~66031544:-
THCA	cis	rs9291683	0.554	rs7668175	ENSG00000261490.1	RP11-448G15.3	-3.97	8.16e-05	0.00655	-0.11	-0.18	Bone mineral density;	chr4:10124158	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.62	rs7699512	ENSG00000261490.1	RP11-448G15.3	-3.97	8.16e-05	0.00655	-0.11	-0.18	Bone mineral density;	chr4:10124184	chr4:10068089~10073019:-
THCA	cis	rs7824557	0.872	rs1347410	ENSG00000255310.2	AF131215.2	-3.97	8.16e-05	0.00655	-0.15	-0.18	Retinal vascular caliber;	chr8:11253733	chr8:11107788~11109726:-
THCA	cis	rs78487399	0.908	rs74915166	ENSG00000234936.1	AC010883.5	3.97	8.16e-05	0.00655	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43623081	chr2:43229573~43233394:+
THCA	cis	rs7989336	0.562	rs7323705	ENSG00000247400.3	DNAJC3-AS1	-3.97	8.17e-05	0.00655	-0.12	-0.18	Obesity;	chr13:96377538	chr13:95648733~95676925:-
THCA	cis	rs3764021	0.509	rs10772073	ENSG00000214776.8	RP11-726G1.1	3.97	8.17e-05	0.00655	0.23	0.18	Type 1 diabetes;	chr12:9717428	chr12:9467552~9576275:+
THCA	cis	rs62292953	0.589	rs79192642	ENSG00000248724.5	NPHP3-AS1	-3.97	8.17e-05	0.00655	-0.32	-0.18	Red cell distribution width;	chr3:132431647	chr3:132721750~132874223:+
THCA	cis	rs57709857	0.915	rs60527016	ENSG00000272092.1	RP11-350N15.5	-3.97	8.17e-05	0.00655	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr8:38442106	chr8:38382364~38383461:+
THCA	cis	rs123509	0.863	rs339662	ENSG00000173811.9	CCDC13-AS1	3.97	8.17e-05	0.00655	0.21	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42710601	chr3:42732575~42746768:+
THCA	cis	rs5758659	0.652	rs133305	ENSG00000270083.1	RP1-257I20.14	3.97	8.17e-05	0.00655	0.19	0.18	Cognitive function;	chr22:41999956	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.682	rs133306	ENSG00000270083.1	RP1-257I20.14	3.97	8.17e-05	0.00655	0.19	0.18	Cognitive function;	chr22:42000146	chr22:42089630~42090028:-
THCA	cis	rs5758659	0.519	rs133307	ENSG00000270083.1	RP1-257I20.14	3.97	8.17e-05	0.00655	0.19	0.18	Cognitive function;	chr22:42000564	chr22:42089630~42090028:-
THCA	cis	rs308403	0.509	rs7690409	ENSG00000224786.1	CETN4P	3.97	8.17e-05	0.00656	0.19	0.18	Blood protein levels;	chr4:122745602	chr4:122730548~122732193:-
THCA	cis	rs2191566	0.664	rs7255701	ENSG00000266921.1	RP11-15A1.7	-3.97	8.17e-05	0.00656	-0.17	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44086405	chr19:43996896~44002836:-
THCA	cis	rs6456156	0.528	rs6936261	ENSG00000235272.1	FAM103A2P	3.97	8.17e-05	0.00656	0.24	0.18	Primary biliary cholangitis;	chr6:167056188	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs13210649	ENSG00000235272.1	FAM103A2P	3.97	8.17e-05	0.00656	0.24	0.18	Primary biliary cholangitis;	chr6:167059705	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs12213801	ENSG00000235272.1	FAM103A2P	3.97	8.17e-05	0.00656	0.24	0.18	Primary biliary cholangitis;	chr6:167060596	chr6:166586124~166586477:-
THCA	cis	rs2839186	0.867	rs13050387	ENSG00000215424.8	MCM3AP-AS1	3.97	8.17e-05	0.00656	0.1	0.18	Testicular germ cell tumor;	chr21:46281509	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.872	rs13046834	ENSG00000215424.8	MCM3AP-AS1	3.97	8.17e-05	0.00656	0.1	0.18	Testicular germ cell tumor;	chr21:46281571	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.721	rs13051200	ENSG00000215424.8	MCM3AP-AS1	3.97	8.17e-05	0.00656	0.1	0.18	Testicular germ cell tumor;	chr21:46281779	chr21:46229217~46259390:+
THCA	cis	rs4713118	0.614	rs9380007	ENSG00000220721.1	OR1F12	3.97	8.17e-05	0.00656	0.2	0.18	Parkinson's disease;	chr6:27692729	chr6:28073316~28074233:+
THCA	cis	rs5758659	0.622	rs129856	ENSG00000270083.1	RP1-257I20.14	3.97	8.17e-05	0.00656	0.19	0.18	Cognitive function;	chr22:42003392	chr22:42089630~42090028:-
THCA	cis	rs7924176	0.521	rs61863363	ENSG00000232342.6	RP11-46O21.2	3.97	8.17e-05	0.00656	0.23	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:74506081~74530553:-
THCA	cis	rs7267979	0.816	rs6076358	ENSG00000274973.1	RP13-401N8.7	3.97	8.17e-05	0.00656	0.2	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25845497~25845862:+
THCA	cis	rs714027	0.545	rs1807513	ENSG00000279699.1	RP1-102K2.9	3.97	8.17e-05	0.00656	0.18	0.18	Lymphocyte counts;	chr22:29893830	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.869	rs5763581	ENSG00000279699.1	RP1-102K2.9	3.97	8.17e-05	0.00656	0.18	0.18	Type 1 diabetes;	chr22:29894644	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.869	rs2189802	ENSG00000279699.1	RP1-102K2.9	3.97	8.17e-05	0.00656	0.18	0.18	Type 1 diabetes;	chr22:29898184	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.834	rs5763589	ENSG00000279699.1	RP1-102K2.9	3.97	8.17e-05	0.00656	0.18	0.18	Type 1 diabetes;	chr22:29899572	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.869	rs5763591	ENSG00000279699.1	RP1-102K2.9	3.97	8.17e-05	0.00656	0.18	0.18	Type 1 diabetes;	chr22:29902197	chr22:30275215~30276951:-
THCA	cis	rs35123781	0.654	rs356484	ENSG00000253404.1	AC034243.1	-3.97	8.18e-05	0.00656	-0.25	-0.18	Schizophrenia;	chr5:139704853	chr5:138744434~138753309:-
THCA	cis	rs2625529	0.938	rs2742323	ENSG00000260037.4	CTD-2524L6.3	3.97	8.18e-05	0.00656	0.25	0.18	Red blood cell count;	chr15:71824437	chr15:71818396~71823384:+
THCA	cis	rs875971	0.658	rs432667	ENSG00000229886.1	RP5-1132H15.3	3.97	8.18e-05	0.00656	0.19	0.18	Aortic root size;	chr7:66049646	chr7:66025126~66031544:-
THCA	cis	rs6012953	0.669	rs3787348	ENSG00000231715.1	COX6CP2	3.97	8.18e-05	0.00656	0.19	0.18	Vitiligo;	chr20:50580461	chr20:50479767~50479991:+
THCA	cis	rs9316337	0.582	rs2315544	ENSG00000236953.1	ZDHHC20-IT1	-3.97	8.18e-05	0.00656	-0.21	-0.18	Schizophrenia;	chr13:21437081	chr13:21376977~21377874:-
THCA	cis	rs11105298	0.891	rs10858898	ENSG00000266347.2	AC068641.1	3.97	8.18e-05	0.00656	0.23	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89592833~89592927:+
THCA	cis	rs2274136	0.894	rs4716165	ENSG00000272269.1	RP11-500C11.3	-3.97	8.18e-05	0.00656	-0.21	-0.18	Obesity-related traits;	chr6:17618292	chr6:17706257~17707344:+
THCA	cis	rs5758659	0.652	rs5758537	ENSG00000270083.1	RP1-257I20.14	3.97	8.18e-05	0.00656	0.19	0.18	Cognitive function;	chr22:42001038	chr22:42089630~42090028:-
THCA	cis	rs10829156	0.607	rs4293025	ENSG00000240291.1	RP11-499P20.2	-3.97	8.18e-05	0.00656	-0.15	-0.18	Sudden cardiac arrest;	chr10:18693315	chr10:18513115~18545651:-
THCA	cis	rs875971	0.638	rs801205	ENSG00000275400.1	RP4-756H11.5	3.97	8.18e-05	0.00656	0.17	0.18	Aortic root size;	chr7:66557157	chr7:66553805~66554199:-
THCA	cis	rs875971	0.617	rs810400	ENSG00000275400.1	RP4-756H11.5	3.97	8.18e-05	0.00656	0.17	0.18	Aortic root size;	chr7:66557902	chr7:66553805~66554199:-
THCA	cis	rs875971	0.638	rs3898855	ENSG00000275400.1	RP4-756H11.5	3.97	8.18e-05	0.00656	0.17	0.18	Aortic root size;	chr7:66571411	chr7:66553805~66554199:-
THCA	cis	rs875971	0.638	rs10278816	ENSG00000275400.1	RP4-756H11.5	3.97	8.18e-05	0.00656	0.17	0.18	Aortic root size;	chr7:66572000	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs10281080	ENSG00000275400.1	RP4-756H11.5	3.97	8.18e-05	0.00656	0.17	0.18	Aortic root size;	chr7:66577454	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs10950044	ENSG00000275400.1	RP4-756H11.5	3.97	8.18e-05	0.00656	0.17	0.18	Aortic root size;	chr7:66577989	chr7:66553805~66554199:-
THCA	cis	rs875971	0.522	rs1968127	ENSG00000275400.1	RP4-756H11.5	3.97	8.18e-05	0.00656	0.17	0.18	Aortic root size;	chr7:66591816	chr7:66553805~66554199:-
THCA	cis	rs7777677	0.925	rs4726546	ENSG00000211750.2	TRBV24-1	-3.97	8.18e-05	0.00656	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142656701~142657213:+
THCA	cis	rs7777677	0.925	rs6960743	ENSG00000211750.2	TRBV24-1	-3.97	8.18e-05	0.00656	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142656701~142657213:+
THCA	cis	rs7777677	0.925	rs6956756	ENSG00000211750.2	TRBV24-1	-3.97	8.18e-05	0.00656	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142656701~142657213:+
THCA	cis	rs7777677	0.889	rs6975391	ENSG00000211750.2	TRBV24-1	-3.97	8.18e-05	0.00656	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142656701~142657213:+
THCA	cis	rs7777677	0.925	rs9655661	ENSG00000211750.2	TRBV24-1	-3.97	8.18e-05	0.00656	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142656701~142657213:+
THCA	cis	rs7777677	0.888	rs9655574	ENSG00000211750.2	TRBV24-1	-3.97	8.18e-05	0.00656	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142656701~142657213:+
THCA	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-3.97	8.18e-05	0.00657	-0.17	-0.18	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
THCA	cis	rs8113308	0.748	rs7251478	ENSG00000269483.1	AC006272.1	3.97	8.18e-05	0.00657	0.3	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51979258	chr19:51839924~51843324:-
THCA	cis	rs2692947	0.795	rs2252697	ENSG00000232931.4	LINC00342	-3.97	8.18e-05	0.00657	-0.15	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96112442	chr2:95807118~95816215:-
THCA	cis	rs875971	0.522	rs4502988	ENSG00000229180.5	GS1-124K5.11	3.97	8.19e-05	0.00657	0.13	0.18	Aortic root size;	chr7:65832759	chr7:66526088~66542624:-
THCA	cis	rs875971	0.522	rs10807697	ENSG00000229180.5	GS1-124K5.11	3.97	8.19e-05	0.00657	0.13	0.18	Aortic root size;	chr7:65951183	chr7:66526088~66542624:-
THCA	cis	rs13434995	0.513	rs62303726	ENSG00000249700.7	SRD5A3-AS1	-3.97	8.19e-05	0.00657	-0.26	-0.18	Adiponectin levels;	chr4:55490415	chr4:55363971~55395847:-
THCA	cis	rs3748656	0.943	rs11102520	ENSG00000273483.1	RP4-671G15.2	3.97	8.19e-05	0.00657	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112692264	chr1:112517799~112518441:-
THCA	cis	rs61142792	1	rs335454	ENSG00000272459.1	RP11-1277A3.3	-3.97	8.19e-05	0.00657	-0.41	-0.18	Alzheimer disease and age of onset;	chr5:177546150	chr5:177554824~177555364:+
THCA	cis	rs7088591	1	rs74928970	ENSG00000276818.1	AC026393.1	3.97	8.19e-05	0.00657	0.37	0.18	Blood pressure;	chr10:57963806	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs75768495	ENSG00000276818.1	AC026393.1	3.97	8.19e-05	0.00657	0.37	0.18	Blood pressure;	chr10:57964142	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs7088591	ENSG00000276818.1	AC026393.1	3.97	8.19e-05	0.00657	0.37	0.18	Blood pressure;	chr10:57964643	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs7071195	ENSG00000276818.1	AC026393.1	3.97	8.19e-05	0.00657	0.37	0.18	Blood pressure;	chr10:57964703	chr10:57095699~57095781:+
THCA	cis	rs800160	0.777	rs2651783	ENSG00000199550.1	Y_RNA	3.97	8.19e-05	0.00657	0.27	0.18	Bacteremia;	chr11:2324660	chr11:2372638~2372750:+
THCA	cis	rs11673344	0.764	rs565721	ENSG00000267260.1	CTD-2162K18.4	-3.97	8.19e-05	0.00657	-0.22	-0.18	Obesity-related traits;	chr19:36964929	chr19:36773153~36777078:+
THCA	cis	rs6504108	0.624	rs1860863	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48127316	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs1860862	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48127474	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.602	rs3944039	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48127708	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs2041572	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48127911	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs758999	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48128653	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs7225865	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48132602	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs34949267	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48134690	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs12941830	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48141769	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs7220768	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48147467	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs7220922	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48147546	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs7225550	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48147881	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs7223867	ENSG00000264920.1	RP11-6N17.4	-3.97	8.19e-05	0.00657	-0.15	-0.18	Body mass index;	chr17:48152794	chr17:47891255~47895812:-
THCA	cis	rs957448	0.503	rs752460	ENSG00000253175.1	RP11-267M23.6	3.97	8.2e-05	0.00657	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94477994	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.801	rs4735293	ENSG00000253175.1	RP11-267M23.6	3.97	8.2e-05	0.00657	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94478175	chr8:94565036~94565715:+
THCA	cis	rs3806843	0.576	rs155360	ENSG00000202515.1	VTRNA1-3	-3.97	8.2e-05	0.00657	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140929431	chr5:140726158~140726246:+
THCA	cis	rs17221829	0.574	rs7930964	ENSG00000280385.1	AP000648.5	-3.97	8.2e-05	0.00657	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89644145	chr11:90193614~90198120:+
THCA	cis	rs6878727	0.665	rs31335	ENSG00000253807.4	LINC01170	3.97	8.2e-05	0.00657	0.16	0.18	Breast cancer;	chr5:124321548	chr5:124059794~124405079:-
THCA	cis	rs9921338	0.632	rs149310	ENSG00000262636.1	CTD-3088G3.4	3.97	8.2e-05	0.00658	0.28	0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11251842	chr16:11380859~11381118:-
THCA	cis	rs2337406	0.714	rs8022729	ENSG00000211974.3	IGHV2-70	3.97	8.2e-05	0.00658	0.18	0.18	Alzheimer's disease (late onset);	chr14:106816928	chr14:106723574~106724093:-
THCA	cis	rs669446	0.528	rs4660743	ENSG00000237950.1	RP11-7O11.3	3.97	8.2e-05	0.00658	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43729733	chr1:43944370~43946551:-
THCA	cis	rs7166081	1	rs12592400	ENSG00000270964.1	RP11-502I4.3	-3.97	8.2e-05	0.00658	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67265672	chr15:67541072~67542604:-
THCA	cis	rs2439831	0.681	rs28594657	ENSG00000166763.7	STRCP1	3.97	8.2e-05	0.00658	0.28	0.18	Lung cancer in ever smokers;	chr15:43296690	chr15:43699488~43718184:-
THCA	cis	rs875971	1	rs35149210	ENSG00000230189.5	GS1-124K5.2	3.97	8.2e-05	0.00658	0.12	0.18	Aortic root size;	chr7:66464938	chr7:66409143~66490059:-
THCA	cis	rs4660214	0.724	rs2484751	ENSG00000182109.6	RP11-69E11.4	-3.97	8.2e-05	0.00658	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39522280~39546187:-
THCA	cis	rs854765	0.575	rs2955357	ENSG00000281749.1	Y_RNA	-3.97	8.2e-05	0.00658	-0.23	-0.18	Total body bone mineral density;	chr17:18043087	chr17:18001101~18001195:-
THCA	cis	rs4604234	0.522	rs59460144	ENSG00000272129.1	RP11-250B2.6	-3.97	8.2e-05	0.00658	-0.4	-0.18	Cancer;	chr6:80188703	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.522	rs12110563	ENSG00000272129.1	RP11-250B2.6	-3.97	8.2e-05	0.00658	-0.4	-0.18	Cancer;	chr6:80192283	chr6:80355424~80356859:+
THCA	cis	rs758324	0.947	rs683749	ENSG00000237714.1	P4HA2-AS1	-3.97	8.2e-05	0.00658	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131947683	chr5:132184876~132192808:+
THCA	cis	rs357618	0.581	rs14160	ENSG00000260581.1	CTB-113P19.4	3.97	8.21e-05	0.00658	0.28	0.18	Basophil percentage of white cells;	chr5:151491719	chr5:151652275~151655449:+
THCA	cis	rs853679	0.607	rs66868086	ENSG00000220721.1	OR1F12	3.97	8.21e-05	0.00658	0.41	0.18	Depression;	chr6:27898124	chr6:28073316~28074233:+
THCA	cis	rs4718428	0.924	rs6971897	ENSG00000237310.1	GS1-124K5.4	3.97	8.21e-05	0.00658	0.13	0.18	Corneal structure;	chr7:66947787	chr7:66493706~66495474:+
THCA	cis	rs7818688	0.614	rs79477990	ENSG00000253528.2	RP11-347C18.4	-3.97	8.21e-05	0.00658	-0.26	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94859908	chr8:94974573~94974853:-
THCA	cis	rs5769765	0.773	rs7410291	ENSG00000260613.1	RP3-522J7.6	-3.97	8.21e-05	0.00658	-0.22	-0.18	Schizophrenia;	chr22:49906430	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.955	rs9616366	ENSG00000260613.1	RP3-522J7.6	-3.97	8.21e-05	0.00658	-0.22	-0.18	Schizophrenia;	chr22:49907530	chr22:49832616~49837786:-
THCA	cis	rs10270805	1	rs10238442	ENSG00000272537.1	GS1-166A23.1	3.97	8.21e-05	0.00658	0.36	0.18	Response to statin therapy;	chr7:16447344	chr7:16471184~16471373:+
THCA	cis	rs6687821	0.515	rs1199726	ENSG00000261737.1	RP4-612B15.3	-3.97	8.21e-05	0.00658	-0.27	-0.18	Yeast infection;	chr1:86951691	chr1:86703502~86704462:-
THCA	cis	rs16975963	0.644	rs73031321	ENSG00000276846.1	CTD-3220F14.3	-3.97	8.21e-05	0.00659	-0.17	-0.18	Longevity;	chr19:37549956	chr19:37314868~37315620:-
THCA	cis	rs8077577	0.671	rs9909104	ENSG00000273018.4	CTD-2303H24.2	-3.97	8.21e-05	0.00659	-0.25	-0.18	Obesity-related traits;	chr17:18344707	chr17:18511221~18551705:-
THCA	cis	rs763121	0.853	rs5750672	ENSG00000225450.1	RP3-508I15.14	3.97	8.21e-05	0.00659	0.14	0.18	Menopause (age at onset);	chr22:38708163	chr22:38739003~38749041:+
THCA	cis	rs8077577	0.945	rs11655731	ENSG00000273018.4	CTD-2303H24.2	-3.97	8.21e-05	0.00659	-0.3	-0.18	Obesity-related traits;	chr17:18204211	chr17:18511221~18551705:-
THCA	cis	rs2979489	0.773	rs2915617	ENSG00000254152.1	CTD-3107M8.2	3.97	8.21e-05	0.00659	0.24	0.18	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Mean corpuscular hemoglobin;Plateletcrit;Sum neutrophil eosinophil counts;Mean corpuscular volume;	chr8:30414794	chr8:30349866~30350347:-
THCA	cis	rs7615952	0.866	rs1976459	ENSG00000272840.1	RP11-379B18.6	3.97	8.21e-05	0.00659	0.3	0.18	Blood pressure (smoking interaction);	chr3:125928643	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.932	rs1976458	ENSG00000272840.1	RP11-379B18.6	3.97	8.21e-05	0.00659	0.3	0.18	Blood pressure (smoking interaction);	chr3:125928669	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.673	rs3811677	ENSG00000272840.1	RP11-379B18.6	3.97	8.21e-05	0.00659	0.3	0.18	Blood pressure (smoking interaction);	chr3:125929237	chr3:125774714~125797953:+
THCA	cis	rs858239	0.899	rs1881203	ENSG00000230042.1	AK3P3	-3.97	8.22e-05	0.00659	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23129178~23129841:+
THCA	cis	rs11971779	0.68	rs10229358	ENSG00000252332.1	RNU6-911P	3.97	8.22e-05	0.00659	0.2	0.18	Diisocyanate-induced asthma;	chr7:139367799	chr7:139448740~139448843:+
THCA	cis	rs4268898	0.722	rs12185638	ENSG00000242628.4	AC009228.1	-3.97	8.22e-05	0.00659	-0.22	-0.18	Asthma;	chr2:24159160	chr2:24214381~24221516:+
THCA	cis	rs4268898	0.722	rs4665253	ENSG00000242628.4	AC009228.1	-3.97	8.22e-05	0.00659	-0.22	-0.18	Asthma;	chr2:24159676	chr2:24214381~24221516:+
THCA	cis	rs1013209	0.689	rs6993585	ENSG00000253837.1	RP11-177H13.2	-3.97	8.22e-05	0.00659	-0.28	-0.18	Height;	chr8:24242997	chr8:23336171~23366125:+
THCA	cis	rs73198271	0.563	rs3748143	ENSG00000253893.2	FAM85B	-3.97	8.22e-05	0.00659	-0.29	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797727	chr8:8167819~8226614:-
THCA	cis	rs2692947	0.526	rs58719199	ENSG00000235584.2	AC008268.1	-3.97	8.22e-05	0.00659	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95912499	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.655	rs4605406	ENSG00000235584.2	AC008268.1	-3.97	8.22e-05	0.00659	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95917987	chr2:95666084~95668715:+
THCA	cis	rs11723261	0.527	rs11731581	ENSG00000250892.1	RP11-1365D11.1	3.97	8.22e-05	0.00659	0.25	0.18	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:201409~205009:-
THCA	cis	rs9868809	0.881	rs2310996	ENSG00000270441.1	RP11-694I15.7	3.97	8.22e-05	0.00659	0.22	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48634401	chr3:49140086~49160851:-
THCA	cis	rs2933343	0.7	rs1683779	ENSG00000231305.3	RP11-723O4.2	3.97	8.22e-05	0.00659	0.2	0.18	IgG glycosylation;	chr3:128923205	chr3:128861313~128871540:-
THCA	cis	rs2948294	0.588	rs4840913	ENSG00000253981.4	ALG1L13P	3.97	8.22e-05	0.00659	0.17	0.18	Red cell distribution width;	chr8:8259384	chr8:8236003~8244667:-
THCA	cis	rs867371	0.656	rs2665103	ENSG00000259429.4	UBE2Q2P2	3.97	8.23e-05	0.00659	0.14	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82355142~82420075:+
THCA	cis	rs4908768	0.501	rs7518608	ENSG00000270282.1	RP5-1115A15.2	3.97	8.23e-05	0.0066	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8512653~8513021:+
THCA	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-3.97	8.23e-05	0.0066	-0.12	-0.18	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
THCA	cis	rs17680741	1	rs17680741	ENSG00000226659.1	RP11-137H2.4	3.97	8.23e-05	0.0066	0.27	0.18	Coronary artery disease;	chr10:80491758	chr10:80529597~80535942:-
THCA	cis	rs8177876	0.554	rs56286107	ENSG00000261838.4	RP11-303E16.6	3.97	8.23e-05	0.0066	0.4	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084227	chr16:81069854~81076598:+
THCA	cis	rs4819052	0.851	rs11558445	ENSG00000273796.1	LL21NC02-21A1.1	-3.97	8.23e-05	0.0066	-0.18	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45403809~45404369:-
THCA	cis	rs5769765	0.955	rs2295406	ENSG00000260613.1	RP3-522J7.6	3.97	8.23e-05	0.0066	0.23	0.18	Schizophrenia;	chr22:49866521	chr22:49832616~49837786:-
THCA	cis	rs42648	0.935	rs42660	ENSG00000225498.1	AC002064.5	3.97	8.23e-05	0.0066	0.18	0.18	Homocysteine levels;	chr7:90353208	chr7:90312496~90322592:+
THCA	cis	rs13098911	0.598	rs34460587	ENSG00000226074.4	PRSS44	-3.97	8.23e-05	0.0066	-0.34	-0.18	Celiac disease;	chr3:46100972	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34452002	ENSG00000226074.4	PRSS44	-3.97	8.23e-05	0.0066	-0.34	-0.18	Celiac disease;	chr3:46101695	chr3:46809359~46812558:-
THCA	cis	rs12681963	0.688	rs7822756	ENSG00000248159.1	HSPA8P11	-3.97	8.23e-05	0.0066	-0.33	-0.18	Migraine;	chr8:30146743	chr8:30237382~30240997:+
THCA	cis	rs62158800	0.683	rs67372209	ENSG00000237880.1	AC096669.2	3.97	8.23e-05	0.0066	0.18	0.18	Facial morphology (factor 22);	chr2:107682933	chr2:107385632~107542649:-
THCA	cis	rs62458065	0.64	rs28587905	ENSG00000231952.3	DPY19L1P2	3.97	8.23e-05	0.0066	0.31	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32493442	chr7:32812757~32838570:+
THCA	cis	rs10454142	0.664	rs72820499	ENSG00000202227.1	RNU6-282P	3.97	8.23e-05	0.0066	0.2	0.18	Sex hormone-binding globulin levels;	chr2:48435941	chr2:48501922~48502024:-
THCA	cis	rs4916588	0.697	rs2054199	ENSG00000270170.1	NCBP2-AS2	3.97	8.23e-05	0.0066	0.14	0.18	Night sleep phenotypes;	chr3:196927558	chr3:196942623~196943540:+
THCA	cis	rs4788570	0.615	rs7206470	ENSG00000260593.1	RP11-432I5.2	-3.97	8.23e-05	0.0066	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71634897	chr16:71623708~71626816:-
THCA	cis	rs12681366	0.734	rs4735292	ENSG00000261437.1	RP11-22C11.2	3.97	8.23e-05	0.0066	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94396503	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.734	rs3019146	ENSG00000261437.1	RP11-22C11.2	3.97	8.23e-05	0.0066	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94401878	chr8:94637285~94639467:-
THCA	cis	rs9595908	0.708	rs12429740	ENSG00000212293.1	SNORA16	3.97	8.23e-05	0.0066	0.22	0.18	Body mass index;	chr13:32684928	chr13:32420390~32420516:-
THCA	cis	rs11884770	0.522	rs12995954	ENSG00000236432.6	AC097662.2	3.97	8.24e-05	0.0066	0.18	0.18	Advanced age-related macular degeneration;	chr2:227219809	chr2:227221052~227325201:-
THCA	cis	rs9863	0.931	rs35825716	ENSG00000270061.1	RP11-214K3.19	-3.97	8.24e-05	0.0066	-0.24	-0.18	White blood cell count;	chr12:123942977	chr12:123969990~123970344:-
THCA	cis	rs13256369	1	rs4840351	ENSG00000254153.1	CTA-398F10.2	-3.97	8.24e-05	0.0066	-0.2	-0.18	Obesity-related traits;	chr8:8715638	chr8:8456909~8461337:-
THCA	cis	rs293748	0.771	rs293746	ENSG00000250155.1	CTD-2353F22.1	-3.97	8.24e-05	0.00661	-0.24	-0.18	Obesity-related traits;	chr5:36895168	chr5:36666214~36725195:-
THCA	cis	rs6756513	0.5	rs36081078	ENSG00000231024.1	AC092431.3	-3.97	8.24e-05	0.00661	-0.27	-0.18	Breast cancer;Platelet count;	chr2:69859231	chr2:69700192~69713847:-
THCA	cis	rs55966801	0.68	rs72882962	ENSG00000277290.1	RP11-326C3.16	-3.97	8.24e-05	0.00661	-0.24	-0.18	Plateletcrit;	chr11:269129	chr11:243099~243483:-
THCA	cis	rs9810089	0.903	rs711975	ENSG00000273455.1	RP11-305O4.3	3.97	8.24e-05	0.00661	0.24	0.18	Gestational age at birth (child effect);	chr3:136517066	chr3:136087475~136087913:-
THCA	cis	rs13217239	0.646	rs62401067	ENSG00000261353.1	CTA-14H9.5	-3.97	8.24e-05	0.00661	-0.19	-0.18	Schizophrenia;	chr6:27050322	chr6:26527063~26527404:+
THCA	cis	rs9309473	0.95	rs6546858	ENSG00000273245.1	RP11-434P11.2	3.97	8.24e-05	0.00661	0.24	0.18	Metabolite levels;	chr2:73611486	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.95	rs6546859	ENSG00000273245.1	RP11-434P11.2	3.97	8.24e-05	0.00661	0.24	0.18	Metabolite levels;	chr2:73614928	chr2:73750256~73750786:-
THCA	cis	rs41342147	0.66	rs12476462	ENSG00000223374.1	AC005104.3	3.97	8.24e-05	0.00661	0.16	0.18	Vitiligo;	chr2:241321247	chr2:241351340~241353104:-
THCA	cis	rs9595908	0.785	rs6561499	ENSG00000212293.1	SNORA16	3.97	8.25e-05	0.00661	0.21	0.18	Body mass index;	chr13:32681075	chr13:32420390~32420516:-
THCA	cis	rs7264396	0.887	rs224360	ENSG00000088340.14	FER1L4	-3.97	8.25e-05	0.00661	-0.16	-0.18	Total cholesterol levels;	chr20:35471850	chr20:35558737~35607562:-
THCA	cis	rs7772486	0.84	rs854144	ENSG00000270638.1	RP3-466P17.1	-3.97	8.25e-05	0.00661	-0.15	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:146039744	chr6:145735570~145737218:+
THCA	cis	rs836788	0.535	rs6151850	ENSG00000251221.1	LINC01337	3.97	8.25e-05	0.00661	0.19	0.18	Glomerular filtration rate (creatinine);	chr5:80793241	chr5:80608623~80622524:-
THCA	cis	rs61142792	1	rs1001530	ENSG00000272459.1	RP11-1277A3.3	3.97	8.25e-05	0.00661	0.4	0.18	Alzheimer disease and age of onset;	chr5:177558514	chr5:177554824~177555364:+
THCA	cis	rs1389724	0.648	rs1908298	ENSG00000259834.1	RP11-284N8.3	3.97	8.25e-05	0.00661	0.16	0.18	Schizophrenia;	chr1:110773593	chr1:110653560~110657040:-
THCA	cis	rs886427	0.517	rs739716	ENSG00000272079.2	LA16c-380H5.5	3.97	8.25e-05	0.00661	0.22	0.18	Metabolic syndrome;	chr16:2936430	chr16:3006120~3007388:+
THCA	cis	rs7772486	0.754	rs702324	ENSG00000270638.1	RP3-466P17.1	-3.97	8.25e-05	0.00661	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145735570~145737218:+
THCA	cis	rs472402	0.623	rs8192131	ENSG00000250056.4	LINC01018	-3.97	8.25e-05	0.00661	-0.22	-0.18	Response to amphetamines;	chr5:6636352	chr5:6582136~6588499:+
THCA	cis	rs472402	0.623	rs8192133	ENSG00000250056.4	LINC01018	-3.97	8.25e-05	0.00661	-0.22	-0.18	Response to amphetamines;	chr5:6636532	chr5:6582136~6588499:+
THCA	cis	rs472402	0.623	rs8192135	ENSG00000250056.4	LINC01018	-3.97	8.25e-05	0.00661	-0.22	-0.18	Response to amphetamines;	chr5:6636644	chr5:6582136~6588499:+
THCA	cis	rs79243044	0.862	rs1846317	ENSG00000224295.2	AC087380.14	-3.97	8.25e-05	0.00661	-0.18	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5528086	chr11:5518441~5524955:-
THCA	cis	rs911555	0.755	rs12432803	ENSG00000269958.1	RP11-73M18.8	-3.97	8.25e-05	0.00661	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs4906329	ENSG00000269958.1	RP11-73M18.8	-3.97	8.25e-05	0.00661	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103696353~103697163:+
THCA	cis	rs1923243	0.814	rs4433341	ENSG00000223479.3	RP4-788P17.1	-3.97	8.25e-05	0.00661	-0.2	-0.18	Migraine;	chr1:73127075	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.758	rs4306085	ENSG00000223479.3	RP4-788P17.1	-3.97	8.25e-05	0.00661	-0.2	-0.18	Migraine;	chr1:73127630	chr1:73635216~73715214:+
THCA	cis	rs10849689	1	rs10849689	ENSG00000249094.2	RP1-7G5.6	3.97	8.26e-05	0.00662	0.28	0.18	Schizophrenia;	chr12:110055417	chr12:109880676~109888467:+
THCA	cis	rs11671005	0.779	rs11670125	ENSG00000268912.1	CTD-2619J13.17	-3.97	8.26e-05	0.00662	-0.17	-0.18	Mean platelet volume;	chr19:58476023	chr19:58428632~58431148:-
THCA	cis	rs875971	0.522	rs1917563	ENSG00000229180.5	GS1-124K5.11	-3.97	8.26e-05	0.00662	-0.13	-0.18	Aortic root size;	chr7:65950660	chr7:66526088~66542624:-
THCA	cis	rs12887734	0.569	rs66953418	ENSG00000258534.1	CTD-2134A5.4	-3.97	8.26e-05	0.00662	-0.19	-0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103854366~103880111:-
THCA	cis	rs12887734	0.546	rs4900597	ENSG00000258534.1	CTD-2134A5.4	3.97	8.26e-05	0.00662	0.19	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103800327	chr14:103854366~103880111:-
THCA	cis	rs944289	0.706	rs11156904	ENSG00000258844.1	RP11-259K15.2	3.97	8.26e-05	0.00662	0.16	0.18	Thyroid cancer;	chr14:36085688	chr14:36214607~36235608:+
THCA	cis	rs4792901	0.765	rs28874115	ENSG00000279602.1	CTD-3014M21.1	-3.97	8.26e-05	0.00662	-0.24	-0.18	Dupuytren's disease;	chr17:43460886	chr17:43360041~43361361:-
THCA	cis	rs2221894	0.853	rs11781448	ENSG00000251191.6	LINC00589	-3.97	8.26e-05	0.00662	-0.22	-0.18	Obesity-related traits;	chr8:28936410	chr8:29673922~29748109:-
THCA	cis	rs1991651	0.578	rs13259086	ENSG00000261451.1	RP11-981G7.1	3.97	8.26e-05	0.00662	0.22	0.18	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632708	chr8:10433672~10438312:+
THCA	cis	rs4705962	0.878	rs2897442	ENSG00000230612.2	AC004237.1	3.97	8.26e-05	0.00662	0.23	0.18	Atopic dermatitis;	chr5:132713335	chr5:132688681~132723725:+
THCA	cis	rs6545883	0.602	rs11125871	ENSG00000270820.4	RP11-355B11.2	-3.97	8.26e-05	0.00662	-0.15	-0.18	Tuberculosis;	chr2:61242991	chr2:61471188~61484130:+
THCA	cis	rs2839186	0.934	rs2839194	ENSG00000215424.8	MCM3AP-AS1	3.97	8.26e-05	0.00662	0.1	0.18	Testicular germ cell tumor;	chr21:46279523	chr21:46229217~46259390:+
THCA	cis	rs1371614	0.588	rs10181727	ENSG00000272148.1	RP11-195B17.1	-3.97	8.27e-05	0.00662	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26948377	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.545	rs1057115	ENSG00000272148.1	RP11-195B17.1	-3.97	8.27e-05	0.00662	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26949201	chr2:27062428~27062907:-
THCA	cis	rs7819412	0.608	rs17780806	ENSG00000255310.2	AF131215.2	-3.97	8.27e-05	0.00662	-0.16	-0.18	Triglycerides;	chr8:11118119	chr8:11107788~11109726:-
THCA	cis	rs5758659	0.967	rs5758670	ENSG00000273366.1	CTA-989H11.1	-3.97	8.27e-05	0.00663	-0.22	-0.18	Cognitive function;	chr22:42240681	chr22:42278188~42278846:+
THCA	cis	rs7551222	0.752	rs885012	ENSG00000240219.1	RP11-430C7.5	3.97	8.27e-05	0.00663	0.17	0.18	Schizophrenia;	chr1:204574873	chr1:204626775~204629712:+
THCA	cis	rs6453278	0.559	rs3934500	ENSG00000250802.5	ZBED3-AS1	-3.97	8.27e-05	0.00663	-0.17	-0.18	Autism;	chr5:77098071	chr5:77086740~77166909:+
THCA	cis	rs6432852	0.516	rs2304002	ENSG00000235192.1	AC009495.2	3.97	8.27e-05	0.00663	0.22	0.18	Diabetic kidney disease;	chr2:165857585	chr2:165794851~165810010:+
THCA	cis	rs2455799	0.634	rs13085226	ENSG00000270409.1	RP11-44D5.1	-3.97	8.27e-05	0.00663	-0.19	-0.18	Mean platelet volume;	chr3:15882243	chr3:15732252~15733470:+
THCA	cis	rs758324	0.947	rs2133707	ENSG00000237714.1	P4HA2-AS1	3.97	8.27e-05	0.00663	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131845587	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs2088719	ENSG00000237714.1	P4HA2-AS1	3.97	8.27e-05	0.00663	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131848746	chr5:132184876~132192808:+
THCA	cis	rs758324	0.898	rs7725041	ENSG00000237714.1	P4HA2-AS1	3.97	8.27e-05	0.00663	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131852810	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs1566427	ENSG00000237714.1	P4HA2-AS1	3.97	8.27e-05	0.00663	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131855979	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs10054618	ENSG00000237714.1	P4HA2-AS1	3.97	8.27e-05	0.00663	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131859309	chr5:132184876~132192808:+
THCA	cis	rs2657294	1	rs2657294	ENSG00000233313.2	HMGA1P5	-3.97	8.27e-05	0.00663	-0.24	-0.18	Pneumonia;	chr10:75193267	chr10:75276376~75276646:-
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000184274.3	LINC00315	3.97	8.28e-05	0.00663	0.22	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45300245~45305257:-
THCA	cis	rs3177980	0.648	rs73026223	ENSG00000239494.2	RN7SL333P	-3.97	8.28e-05	0.00663	-0.17	-0.18	Amyotrophic lateral sclerosis;	chr1:169883372	chr1:169859756~169860052:+
THCA	cis	rs2625529	0.824	rs2279283	ENSG00000260037.4	CTD-2524L6.3	-3.97	8.28e-05	0.00663	-0.25	-0.18	Red blood cell count;	chr15:71951325	chr15:71818396~71823384:+
THCA	cis	rs10435719	0.899	rs7815595	ENSG00000254948.1	OR7E158P	-3.97	8.28e-05	0.00663	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.834	rs11250176	ENSG00000254948.1	OR7E158P	-3.97	8.28e-05	0.00663	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.516	rs4367597	ENSG00000254948.1	OR7E158P	-3.97	8.28e-05	0.00663	-0.22	-0.18	Neuroticism;	chr8:11936020	chr8:11919900~11920809:-
THCA	cis	rs10435719	0.899	rs9329251	ENSG00000254948.1	OR7E158P	-3.97	8.28e-05	0.00663	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:11919900~11920809:-
THCA	cis	rs476633	0.708	rs13329237	ENSG00000247556.5	OIP5-AS1	3.97	8.28e-05	0.00663	0.15	0.18	Glomerular filtration rate (creatinine);	chr15:41158610	chr15:41283990~41309737:+
THCA	cis	rs3105593	0.933	rs2003359	ENSG00000242737.1	RP11-562A8.1	3.97	8.28e-05	0.00663	0.22	0.18	QT interval;	chr15:50540916	chr15:50466738~50467096:+
THCA	cis	rs12332430	1	rs10476890	ENSG00000247199.3	RP11-373N22.3	-3.97	8.28e-05	0.00663	-0.43	-0.18	Post bronchodilator FEV1/FVC ratio in COPD;	chr5:148168700	chr5:148268307~148383783:-
THCA	cis	rs11992162	0.597	rs6996342	ENSG00000254948.1	OR7E158P	3.97	8.28e-05	0.00663	0.22	0.18	Monocyte count;	chr8:11927032	chr8:11919900~11920809:-
THCA	cis	rs2153535	0.518	rs9502728	ENSG00000230939.1	RP11-314C16.1	-3.97	8.28e-05	0.00663	-0.2	-0.18	Motion sickness;	chr6:8602710	chr6:8784178~8785445:+
THCA	cis	rs17221829	0.627	rs12421880	ENSG00000280385.1	AP000648.5	-3.97	8.28e-05	0.00664	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89658545	chr11:90193614~90198120:+
THCA	cis	rs1204798	0.947	rs1204799	ENSG00000237021.2	RP3-486I3.7	-3.97	8.28e-05	0.00664	-0.19	-0.18	Dental caries;	chr6:116222782	chr6:116254207~116256743:+
THCA	cis	rs71520386	0.632	rs12535331	ENSG00000226329.2	AC005682.6	3.97	8.28e-05	0.00664	0.23	0.18	Fibrinogen levels;	chr7:22838485	chr7:22863874~22881350:-
THCA	cis	rs2191566	0.664	rs62115489	ENSG00000266921.1	RP11-15A1.7	-3.97	8.29e-05	0.00664	-0.17	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44074432	chr19:43996896~44002836:-
THCA	cis	rs2562456	0.833	rs62110367	ENSG00000268278.1	RP11-420K14.1	3.97	8.29e-05	0.00664	0.25	0.18	Pain;	chr19:21365829	chr19:21637974~21656300:+
THCA	cis	rs74233809	1	rs11191551	ENSG00000272912.1	RP11-724N1.1	-3.97	8.29e-05	0.00664	-0.33	-0.18	Birth weight;	chr10:103091078	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs17094683	ENSG00000272912.1	RP11-724N1.1	-3.97	8.29e-05	0.00664	-0.33	-0.18	Birth weight;	chr10:103091544	chr10:102914585~102915404:+
THCA	cis	rs62158800	0.598	rs10865014	ENSG00000237880.1	AC096669.2	3.97	8.29e-05	0.00664	0.18	0.18	Facial morphology (factor 22);	chr2:107674316	chr2:107385632~107542649:-
THCA	cis	rs4713118	0.911	rs2394000	ENSG00000261839.1	RP1-265C24.8	3.97	8.29e-05	0.00664	0.2	0.18	Parkinson's disease;	chr6:27719212	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.955	rs9393847	ENSG00000261839.1	RP1-265C24.8	3.97	8.29e-05	0.00664	0.2	0.18	Parkinson's disease;	chr6:27720194	chr6:28136849~28139678:+
THCA	cis	rs288326	0.561	rs77496277	ENSG00000272800.1	RP11-438L19.1	3.97	8.29e-05	0.00664	0.35	0.18	Blood protein levels;	chr2:182896978	chr2:183214319~183215400:+
THCA	cis	rs11884770	0.522	rs6436664	ENSG00000236432.6	AC097662.2	3.97	8.29e-05	0.00664	0.18	0.18	Advanced age-related macular degeneration;	chr2:227219448	chr2:227221052~227325201:-
THCA	cis	rs7829975	0.871	rs777709	ENSG00000254340.1	RP11-10A14.3	-3.97	8.29e-05	0.00664	-0.2	-0.18	Mood instability;	chr8:8726362	chr8:9141424~9145435:+
THCA	cis	rs1124769	0.719	rs4304967	ENSG00000259378.1	DCAF13P3	3.97	8.29e-05	0.00664	0.28	0.18	Cognitive performance;	chr15:51096981	chr15:50944663~50945996:+
THCA	cis	rs494526	0.769	rs669964	ENSG00000229272.1	RP11-498J9.2	3.97	8.29e-05	0.00664	0.21	0.18	Alcoholic chronic pancreatitis;	chr10:119051111	chr10:119003536~119003884:-
THCA	cis	rs34421088	0.56	rs2248699	ENSG00000255046.1	RP11-297N6.4	3.97	8.3e-05	0.00664	0.19	0.18	Neuroticism;	chr8:11536255	chr8:11797928~11802568:-
THCA	cis	rs9926296	0.557	rs11076618	ENSG00000274627.1	RP11-104N10.2	-3.97	8.3e-05	0.00665	-0.19	-0.18	Vitiligo;	chr16:89741297	chr16:89516797~89522217:+
THCA	cis	rs5758511	0.68	rs5758681	ENSG00000237037.8	NDUFA6-AS1	-3.97	8.3e-05	0.00665	-0.17	-0.18	Birth weight;	chr22:42249085	chr22:42090931~42137742:+
THCA	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	3.97	8.3e-05	0.00665	0.2	0.18	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
THCA	cis	rs7246967	0.673	rs36029703	ENSG00000198153.8	ZNF849P	-3.97	8.3e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22723386	chr19:22685167~22686732:+
THCA	cis	rs57502260	0.834	rs3736228	ENSG00000212093.1	AP000807.1	-3.97	8.3e-05	0.00665	-0.24	-0.18	Total body bone mineral density (age 45-60);	chr11:68433827	chr11:68506083~68506166:-
THCA	cis	rs3781264	0.848	rs7897678	ENSG00000273450.1	RP11-76P2.4	3.97	8.31e-05	0.00665	0.22	0.18	Esophageal cancer and gastric cancer;	chr10:94300853	chr10:94314907~94315327:-
THCA	cis	rs3781264	0.804	rs7914672	ENSG00000273450.1	RP11-76P2.4	3.97	8.31e-05	0.00665	0.22	0.18	Esophageal cancer and gastric cancer;	chr10:94301090	chr10:94314907~94315327:-
THCA	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	3.97	8.31e-05	0.00665	0.21	0.18	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
THCA	cis	rs16852403	0.619	rs6701497	ENSG00000224687.1	RASAL2-AS1	3.97	8.31e-05	0.00665	0.29	0.18	Childhood ear infection;	chr1:178145509	chr1:178091508~178093984:-
THCA	cis	rs7179228	1	rs7179228	ENSG00000260657.2	RP11-315D16.4	-3.97	8.31e-05	0.00665	-0.25	-0.18	Systolic blood pressure;	chr15:68330009	chr15:68267792~68277994:-
THCA	cis	rs7481311	0.956	rs6484311	ENSG00000245573.6	BDNF-AS	3.97	8.31e-05	0.00665	0.17	0.18	Weight;Body mass index;	chr11:27510217	chr11:27506838~27698174:+
THCA	cis	rs7246967	0.604	rs58653025	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22758815	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs16999598	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22760323	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs34726149	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22769309	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12985825	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22770649	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs62120125	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22772297	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs2194113	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22775273	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs62120457	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22775717	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs55744741	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22777171	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs4933036	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22780267	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs35061555	ENSG00000198153.8	ZNF849P	-3.97	8.31e-05	0.00665	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22780964	chr19:22685167~22686732:+
THCA	cis	rs6963495	0.769	rs73192134	ENSG00000272604.1	RP11-251G23.5	3.97	8.31e-05	0.00665	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105548891	chr7:105571083~105573660:+
THCA	cis	rs3864261	0.895	rs266421	ENSG00000249085.1	CTD-2631K10.1	-3.97	8.31e-05	0.00665	-0.27	-0.18	Discordance in emotional problems in monozygotic twins;	chr5:72809814	chr5:72794405~72816565:-
THCA	cis	rs11638352	1	rs2412854	ENSG00000166763.7	STRCP1	-3.97	8.31e-05	0.00665	-0.38	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44002274	chr15:43699488~43718184:-
THCA	cis	rs7560272	0.538	rs12619258	ENSG00000163016.8	ALMS1P	-3.97	8.31e-05	0.00665	-0.22	-0.18	Schizophrenia;	chr2:73708788	chr2:73644919~73685576:+
THCA	cis	rs9457247	0.508	rs9457268	ENSG00000235272.1	FAM103A2P	3.97	8.31e-05	0.00665	0.24	0.18	Crohn's disease;	chr6:167090151	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.508	rs6902119	ENSG00000235272.1	FAM103A2P	3.97	8.31e-05	0.00665	0.24	0.18	Crohn's disease;	chr6:167092303	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.508	rs6918286	ENSG00000235272.1	FAM103A2P	3.97	8.31e-05	0.00665	0.24	0.18	Crohn's disease;	chr6:167092341	chr6:166586124~166586477:-
THCA	cis	rs4713118	0.955	rs9468203	ENSG00000261839.1	RP1-265C24.8	3.97	8.31e-05	0.00666	0.2	0.18	Parkinson's disease;	chr6:27720888	chr6:28136849~28139678:+
THCA	cis	rs9923856	0.695	rs723586	ENSG00000263033.2	RP11-396B14.2	-3.97	8.31e-05	0.00666	-0.15	-0.18	Atopic dermatitis;Adult asthma;	chr16:11004522	chr16:11196177~11224969:+
THCA	cis	rs74233809	1	rs11191555	ENSG00000272912.1	RP11-724N1.1	-3.97	8.31e-05	0.00666	-0.33	-0.18	Birth weight;	chr10:103097766	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs11191557	ENSG00000272912.1	RP11-724N1.1	-3.97	8.31e-05	0.00666	-0.33	-0.18	Birth weight;	chr10:103104857	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs11191558	ENSG00000272912.1	RP11-724N1.1	-3.97	8.31e-05	0.00666	-0.33	-0.18	Birth weight;	chr10:103104921	chr10:102914585~102915404:+
THCA	cis	rs713587	0.967	rs713586	ENSG00000224165.4	DNAJC27-AS1	-3.97	8.31e-05	0.00666	-0.1	-0.18	Body mass index in non-asthmatics;	chr2:24935139	chr2:24971390~25039694:+
THCA	cis	rs7583236	1	rs11126252	ENSG00000179818.12	PCBP1-AS1	-3.97	8.32e-05	0.00666	-0.18	-0.18	Obesity-related traits;	chr2:69954022	chr2:69962263~70103220:-
THCA	cis	rs7583236	1	rs7569331	ENSG00000179818.12	PCBP1-AS1	-3.97	8.32e-05	0.00666	-0.18	-0.18	Obesity-related traits;	chr2:69955644	chr2:69962263~70103220:-
THCA	cis	rs17301013	0.932	rs10912804	ENSG00000270084.1	GAS5-AS1	-3.97	8.32e-05	0.00666	-0.19	-0.18	Systemic lupus erythematosus;	chr1:174527412	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.9	rs12088073	ENSG00000270084.1	GAS5-AS1	-3.97	8.32e-05	0.00666	-0.19	-0.18	Systemic lupus erythematosus;	chr1:174528504	chr1:173863248~173863941:+
THCA	cis	rs7829975	0.711	rs1039916	ENSG00000233609.3	RP11-62H7.2	3.97	8.32e-05	0.00666	0.18	0.18	Mood instability;	chr8:8828344	chr8:8961200~8979025:+
THCA	cis	rs2777491	1	rs316610	ENSG00000247556.5	OIP5-AS1	3.97	8.32e-05	0.00666	0.15	0.18	Ulcerative colitis;	chr15:41460654	chr15:41283990~41309737:+
THCA	cis	rs2448490	0.642	rs573589	ENSG00000255557.1	RP11-770G2.2	-3.97	8.32e-05	0.00666	-0.2	-0.18	Platelet count;	chr11:65716510	chr11:65745729~65771585:+
THCA	cis	rs10419113	0.668	rs3746208	ENSG00000268545.1	VN1R107P	3.97	8.32e-05	0.00666	0.21	0.18	Pediatric bone mineral density (spine);	chr19:57688731	chr19:57459912~57460120:+
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000280107.1	AL022393.9	-3.97	8.32e-05	0.00666	-0.18	-0.18	Pubertal anthropometrics;	chr6:28219323	chr6:28170845~28172521:+
THCA	cis	rs758324	0.661	rs31477	ENSG00000237714.1	P4HA2-AS1	-3.97	8.32e-05	0.00666	-0.26	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132086819	chr5:132184876~132192808:+
THCA	cis	rs7726354	0.793	rs16886164	ENSG00000271828.1	CTD-2310F14.1	3.97	8.32e-05	0.00666	0.43	0.18	Breast cancer (early onset);	chr5:56727080	chr5:56927874~56929573:+
THCA	cis	rs36093844	0.626	rs72951268	ENSG00000279742.1	RP11-700A24.1	-3.97	8.32e-05	0.00666	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85985315	chr11:85852557~85854943:-
THCA	cis	rs321358	1	rs321365	ENSG00000271390.1	RP11-89C3.3	3.97	8.32e-05	0.00666	0.3	0.18	Body mass index;	chr11:111126676	chr11:111089870~111090368:-
THCA	cis	rs4746818	1	rs7476357	ENSG00000229001.1	ACTBP14	-3.97	8.33e-05	0.00666	-0.29	-0.18	Left atrial antero-posterior diameter;	chr10:69175904	chr10:69022778~69023866:+
THCA	cis	rs4746818	1	rs4342912	ENSG00000229001.1	ACTBP14	-3.97	8.33e-05	0.00666	-0.29	-0.18	Left atrial antero-posterior diameter;	chr10:69199526	chr10:69022778~69023866:+
THCA	cis	rs9302635	0.513	rs8050238	ENSG00000260886.1	TAT-AS1	3.97	8.33e-05	0.00666	0.23	0.18	Blood protein levels;	chr16:72120288	chr16:71565789~71578187:+
THCA	cis	rs1035144	0.704	rs72693069	ENSG00000259167.2	NMNAT1P1	3.97	8.33e-05	0.00666	0.23	0.18	Male sexual orientation;	chr14:80979518	chr14:81032529~81033404:+
THCA	cis	rs1923243	0.538	rs4449980	ENSG00000223479.3	RP4-788P17.1	3.97	8.33e-05	0.00667	0.2	0.18	Migraine;	chr1:73151998	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.538	rs4356000	ENSG00000223479.3	RP4-788P17.1	3.97	8.33e-05	0.00667	0.2	0.18	Migraine;	chr1:73151999	chr1:73635216~73715214:+
THCA	cis	rs7520050	0.966	rs785464	ENSG00000281133.1	AL355480.3	3.97	8.33e-05	0.00667	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45580892~45580996:-
THCA	cis	rs10129255	0.956	rs10137268	ENSG00000211972.2	IGHV3-66	3.97	8.33e-05	0.00667	0.11	0.18	Kawasaki disease;	chr14:106697402	chr14:106675017~106675544:-
THCA	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	3.97	8.33e-05	0.00667	0.16	0.18	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
THCA	cis	rs1559040	0.932	rs72800765	ENSG00000272156.1	RP11-477N3.1	-3.97	8.33e-05	0.00667	-0.29	-0.18	Sudden cardiac arrest;	chr2:54135930	chr2:54082554~54085066:+
THCA	cis	rs2179367	1	rs2179367	ENSG00000223701.3	RAET1E-AS1	3.97	8.33e-05	0.00667	0.24	0.18	Dupuytren's disease;	chr6:149441401	chr6:149884431~149919508:+
THCA	cis	rs7616559	0.849	rs7627652	ENSG00000244515.1	KRT18P34	-3.97	8.33e-05	0.00667	-0.23	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157055558	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.849	rs7649798	ENSG00000244515.1	KRT18P34	-3.97	8.33e-05	0.00667	-0.23	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157055578	chr3:157162663~157163932:-
THCA	cis	rs10186029	0.68	rs1530238	ENSG00000270659.1	RP11-105N14.1	-3.97	8.33e-05	0.00667	-0.14	-0.18	Systemic sclerosis;	chr2:213093204	chr2:213152970~213153659:+
THCA	cis	rs2904524	1	rs17107926	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70282250	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs17107935	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70286084	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs79224766	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70292399	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs2091131	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70294834	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs17107947	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70295689	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs75796761	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70298071	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs75846246	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70305146	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs4761195	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70306967	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs79903423	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70308032	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs7487329	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70310025	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs77397439	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70313566	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs58828627	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70317513	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs1404124	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70319519	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs74768022	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70333874	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs17107996	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70334297	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs74823021	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70334627	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.881	rs77987335	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70348180	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs80024915	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70353430	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs12299278	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70355852	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs77307893	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70359397	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs78509050	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70359589	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs75899653	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70359894	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs74436265	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70359954	chr12:69904033~70243360:-
THCA	cis	rs2904524	1	rs17108060	ENSG00000257815.4	RP11-611E13.2	-3.97	8.33e-05	0.00667	-0.17	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70361832	chr12:69904033~70243360:-
THCA	cis	rs11133613	0.546	rs6864340	ENSG00000215246.5	RP11-43F13.3	3.97	8.33e-05	0.00667	0.39	0.18	Red cell distribution width;	chr5:892089	chr5:987180~997308:-
THCA	cis	rs17092148	1	rs6058112	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.33e-05	0.00667	-0.21	-0.18	Neuroticism;	chr20:34734202	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs6060040	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.33e-05	0.00667	-0.21	-0.18	Neuroticism;	chr20:34771251	chr20:33985617~33988989:-
THCA	cis	rs2980439	0.517	rs793753	ENSG00000253981.4	ALG1L13P	-3.97	8.33e-05	0.00667	-0.17	-0.18	Neuroticism;	chr8:8247837	chr8:8236003~8244667:-
THCA	cis	rs16944613	0.541	rs6496688	ENSG00000259212.1	CTD-3065B20.2	3.97	8.33e-05	0.00667	0.28	0.18	Colorectal cancer;	chr15:90547149	chr15:90595840~90596447:-
THCA	cis	rs9341808	0.754	rs10733162	ENSG00000260645.1	RP11-250B2.5	3.97	8.34e-05	0.00667	0.15	0.18	Sitting height ratio;	chr6:80313672	chr6:80466958~80469080:+
THCA	cis	rs875971	0.505	rs2462573	ENSG00000229180.5	GS1-124K5.11	-3.97	8.34e-05	0.00667	-0.12	-0.18	Aortic root size;	chr7:66042405	chr7:66526088~66542624:-
THCA	cis	rs12681366	0.734	rs10102496	ENSG00000261437.1	RP11-22C11.2	3.97	8.34e-05	0.00667	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94385953	chr8:94637285~94639467:-
THCA	cis	rs17801127	1	rs17801127	ENSG00000231969.1	AC144449.1	3.97	8.34e-05	0.00667	0.38	0.18	Liver enzyme levels (alanine transaminase);	chr2:149707970	chr2:149587196~149848233:+
THCA	cis	rs7551222	0.716	rs4951078	ENSG00000240219.1	RP11-430C7.5	3.97	8.34e-05	0.00668	0.17	0.18	Schizophrenia;	chr1:204522674	chr1:204626775~204629712:+
THCA	cis	rs34792	0.688	rs153786	ENSG00000207425.1	Y_RNA	-3.97	8.34e-05	0.00668	-0.2	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499857	chr16:14915457~14915556:-
THCA	cis	rs34792	0.626	rs153788	ENSG00000207425.1	Y_RNA	-3.97	8.34e-05	0.00668	-0.2	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15500346	chr16:14915457~14915556:-
THCA	cis	rs6940638	0.688	rs9348750	ENSG00000220721.1	OR1F12	3.97	8.35e-05	0.00668	0.21	0.18	Intelligence (multi-trait analysis);	chr6:27090166	chr6:28073316~28074233:+
THCA	cis	rs7246967	0.673	rs34676724	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22735671	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs16999580	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22740685	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs55684269	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22741745	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs34003335	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22742800	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12974988	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22743163	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs2194112	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22743387	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs34907478	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22746029	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12985495	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22747576	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs8103430	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22748696	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs34174596	ENSG00000198153.8	ZNF849P	-3.97	8.35e-05	0.00668	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22750717	chr19:22685167~22686732:+
THCA	cis	rs3740713	0.925	rs55727925	ENSG00000256464.1	YWHABP2	3.97	8.35e-05	0.00668	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr11:18490243~18490955:-
THCA	cis	rs3824488	0.705	rs57594805	ENSG00000271155.1	RP11-435O5.5	-3.97	8.35e-05	0.00668	-0.27	-0.18	Neuroticism;	chr9:95523595	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.705	rs57594450	ENSG00000271155.1	RP11-435O5.5	-3.97	8.35e-05	0.00668	-0.27	-0.18	Neuroticism;	chr9:95523638	chr9:95506235~95507636:+
THCA	cis	rs7615952	0.673	rs35955861	ENSG00000272840.1	RP11-379B18.6	3.97	8.35e-05	0.00668	0.34	0.18	Blood pressure (smoking interaction);	chr3:125907358	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.673	rs35001498	ENSG00000272840.1	RP11-379B18.6	3.97	8.35e-05	0.00668	0.34	0.18	Blood pressure (smoking interaction);	chr3:125909801	chr3:125774714~125797953:+
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000182586.6	LINC00334	-3.97	8.35e-05	0.00668	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45234340~45258730:+
THCA	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	3.97	8.35e-05	0.00668	0.17	0.18	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
THCA	cis	rs7826238	0.72	rs12546760	ENSG00000253981.4	ALG1L13P	-3.97	8.35e-05	0.00668	-0.17	-0.18	Systolic blood pressure;	chr8:8517326	chr8:8236003~8244667:-
THCA	cis	rs4713118	0.911	rs9295746	ENSG00000272009.1	RP1-313I6.12	-3.97	8.35e-05	0.00668	-0.21	-0.18	Parkinson's disease;	chr6:27762285	chr6:28078792~28081130:-
THCA	cis	rs1204798	0.636	rs60311843	ENSG00000237021.2	RP3-486I3.7	-3.97	8.35e-05	0.00668	-0.22	-0.18	Dental caries;	chr6:116162847	chr6:116254207~116256743:+
THCA	cis	rs1204798	0.636	rs7744989	ENSG00000237021.2	RP3-486I3.7	-3.97	8.35e-05	0.00668	-0.22	-0.18	Dental caries;	chr6:116165297	chr6:116254207~116256743:+
THCA	cis	rs1204798	0.636	rs7748975	ENSG00000237021.2	RP3-486I3.7	-3.97	8.35e-05	0.00668	-0.22	-0.18	Dental caries;	chr6:116171337	chr6:116254207~116256743:+
THCA	cis	rs752590	0.566	rs7595282	ENSG00000227359.1	AC017074.2	3.97	8.35e-05	0.00668	0.27	0.18	Mucinous ovarian carcinoma;	chr2:113271143	chr2:113677702~113704078:-
THCA	cis	rs7312933	0.526	rs1669892	ENSG00000257225.1	RP11-328C8.4	3.97	8.35e-05	0.00668	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42417503	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.558	rs1669936	ENSG00000257225.1	RP11-328C8.4	3.97	8.35e-05	0.00668	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42419707	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.558	rs55702525	ENSG00000257225.1	RP11-328C8.4	3.97	8.35e-05	0.00668	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42420507	chr12:42459366~42466128:+
THCA	cis	rs12681288	0.578	rs10503154	ENSG00000260721.1	AF067845.1	3.97	8.35e-05	0.00668	0.22	0.18	Schizophrenia;	chr8:1019343	chr8:1368642~1369833:-
THCA	cis	rs7618915	1	rs59565798	ENSG00000239557.1	RP11-168J18.6	3.97	8.35e-05	0.00668	0.23	0.18	Bipolar disorder;	chr3:52273153	chr3:52373652~52374882:+
THCA	cis	rs1876905	0.597	rs354551	ENSG00000271789.1	RP5-1112D6.7	-3.97	8.35e-05	0.00668	-0.22	-0.18	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111297126~111298510:+
THCA	cis	rs28735056	1	rs4798922	ENSG00000261126.6	RP11-795F19.1	-3.97	8.35e-05	0.00668	-0.15	-0.18	Schizophrenia;	chr18:79868953	chr18:80046900~80095482:+
THCA	cis	rs28735056	1	rs4798923	ENSG00000261126.6	RP11-795F19.1	-3.97	8.35e-05	0.00668	-0.15	-0.18	Schizophrenia;	chr18:79869373	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.967	rs61090726	ENSG00000261126.6	RP11-795F19.1	-3.97	8.35e-05	0.00668	-0.15	-0.18	Schizophrenia;	chr18:79871219	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.904	rs72980087	ENSG00000261126.6	RP11-795F19.1	-3.97	8.35e-05	0.00668	-0.15	-0.18	Schizophrenia;	chr18:79872194	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.967	rs8091497	ENSG00000261126.6	RP11-795F19.1	-3.97	8.35e-05	0.00668	-0.15	-0.18	Schizophrenia;	chr18:79872565	chr18:80046900~80095482:+
THCA	cis	rs1411478	1	rs6425658	ENSG00000243155.1	RP11-46A10.5	3.97	8.35e-05	0.00668	0.19	0.18	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180987849	chr1:180944042~180976482:-
THCA	cis	rs7131987	0.621	rs6487805	ENSG00000273680.1	RP11-996F15.6	-3.97	8.35e-05	0.00668	-0.25	-0.18	QT interval;	chr12:29304617	chr12:29332733~29333383:-
THCA	cis	rs6494488	0.5	rs72758953	ENSG00000259635.1	AC100830.3	-3.97	8.36e-05	0.00668	-0.47	-0.18	Coronary artery disease;	chr15:64399953	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741303	ENSG00000259635.1	AC100830.3	-3.97	8.36e-05	0.00668	-0.47	-0.18	Coronary artery disease;	chr15:64400219	chr15:64701248~64719602:+
THCA	cis	rs7833787	0.501	rs6992325	ENSG00000278886.1	RP11-108A14.1	3.97	8.36e-05	0.00668	0.25	0.18	Obesity-related traits;	chr8:18832399	chr8:18864681~18865247:-
THCA	cis	rs365302	0.951	rs1762101	ENSG00000235086.1	FNDC1-IT1	3.97	8.36e-05	0.00668	0.25	0.18	Coronary heart disease;	chr6:159222960	chr6:159240786~159243329:+
THCA	cis	rs6479874	0.831	rs2245627	ENSG00000223502.1	RP11-96B5.3	-3.97	8.36e-05	0.00668	-0.22	-0.18	Migraine;	chr10:50985906	chr10:51062579~51068553:-
THCA	cis	rs1501138	0.606	rs7691349	ENSG00000263327.5	TAPT1-AS1	3.97	8.36e-05	0.00668	0.27	0.18	Systemic juvenile idiopathic arthritis;	chr4:16328066	chr4:16226685~16320140:+
THCA	cis	rs987724	0.964	rs9814813	ENSG00000240875.4	LINC00886	-3.97	8.36e-05	0.00668	-0.15	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156962229	chr3:156747346~156817062:-
THCA	cis	rs7267979	0.934	rs2261115	ENSG00000276952.1	RP5-965G21.6	3.97	8.36e-05	0.00668	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2261747	ENSG00000276952.1	RP5-965G21.6	3.97	8.36e-05	0.00668	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25284915~25285588:-
THCA	cis	rs13102973	0.64	rs11722290	ENSG00000250144.1	RP11-553P9.1	-3.97	8.36e-05	0.00669	-0.13	-0.18	Subjective well-being;	chr4:134911113	chr4:135045464~135046850:+
THCA	cis	rs13102973	0.64	rs34037497	ENSG00000250144.1	RP11-553P9.1	-3.97	8.36e-05	0.00669	-0.13	-0.18	Subjective well-being;	chr4:134912543	chr4:135045464~135046850:+
THCA	cis	rs13102973	0.64	rs6857995	ENSG00000250144.1	RP11-553P9.1	-3.97	8.36e-05	0.00669	-0.13	-0.18	Subjective well-being;	chr4:134913038	chr4:135045464~135046850:+
THCA	cis	rs35851103	0.506	rs4841659	ENSG00000255046.1	RP11-297N6.4	-3.97	8.36e-05	0.00669	-0.19	-0.18	Neuroticism;	chr8:11970691	chr8:11797928~11802568:-
THCA	cis	rs3935996	0.965	rs4309021	ENSG00000233147.1	RP11-90C4.1	-3.97	8.36e-05	0.00669	-0.16	-0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55861940	chr1:55823807~55868248:+
THCA	cis	rs7312933	0.501	rs3810793	ENSG00000257225.1	RP11-328C8.4	-3.97	8.36e-05	0.00669	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42335605	chr12:42459366~42466128:+
THCA	cis	rs2836974	0.897	rs12481860	ENSG00000255568.3	BRWD1-AS2	3.97	8.36e-05	0.00669	0.16	0.18	Cognitive function;	chr21:39165910	chr21:39313935~39314962:+
THCA	cis	rs7474896	0.583	rs12783272	ENSG00000226578.1	RP11-258F22.1	-3.97	8.36e-05	0.00669	-0.26	-0.18	Obesity (extreme);	chr10:37735957	chr10:37775371~37784131:-
THCA	cis	rs9291683	0.53	rs13115193	ENSG00000250413.1	RP11-448G15.1	-3.97	8.36e-05	0.00669	-0.17	-0.18	Bone mineral density;	chr4:9980567	chr4:10006482~10009725:+
THCA	cis	rs2252790	0.548	rs114094955	ENSG00000237021.2	RP3-486I3.7	-3.97	8.36e-05	0.00669	-0.22	-0.18	Fast beta electroencephalogram;	chr6:116200001	chr6:116254207~116256743:+
THCA	cis	rs11971779	0.838	rs58074268	ENSG00000252332.1	RNU6-911P	-3.97	8.36e-05	0.00669	-0.22	-0.18	Diisocyanate-induced asthma;	chr7:139424179	chr7:139448740~139448843:+
THCA	cis	rs189798	0.592	rs10111263	ENSG00000254153.1	CTA-398F10.2	3.97	8.36e-05	0.00669	0.19	0.18	Myopia (pathological);	chr8:9111923	chr8:8456909~8461337:-
THCA	cis	rs763121	0.853	rs5757141	ENSG00000273076.1	RP3-508I15.22	3.97	8.37e-05	0.00669	0.18	0.18	Menopause (age at onset);	chr22:38561478	chr22:38743495~38743910:+
THCA	cis	rs4788570	0.511	rs4788830	ENSG00000260593.1	RP11-432I5.2	-3.97	8.37e-05	0.00669	-0.3	-0.18	Intelligence (multi-trait analysis);	chr16:71698364	chr16:71623708~71626816:-
THCA	cis	rs1232027	0.622	rs245332	ENSG00000249655.1	CTC-325J23.2	3.97	8.37e-05	0.00669	0.21	0.18	Huntington's disease progression;	chr5:80730449	chr5:80630313~80631590:-
THCA	cis	rs1336149	0.527	rs1094562	ENSG00000211581.1	MIR765	3.97	8.37e-05	0.00669	0.24	0.18	Chin dimples;	chr1:157064428	chr1:156936131~156936244:-
THCA	cis	rs6504108	0.624	rs3792694	ENSG00000264920.1	RP11-6N17.4	3.97	8.37e-05	0.00669	0.15	0.18	Body mass index;	chr17:48183080	chr17:47891255~47895812:-
THCA	cis	rs2554380	0.628	rs12914377	ENSG00000176700.18	SCAND2P	-3.97	8.37e-05	0.00669	-0.13	-0.18	Height;	chr15:83791941	chr15:84631451~84647478:+
THCA	cis	rs7430456	0.967	rs6780021	ENSG00000231574.4	RP11-91K9.1	-3.97	8.37e-05	0.00669	-0.23	-0.18	Breast cancer;	chr3:177739677	chr3:177816865~177899224:+
THCA	cis	rs6546886	0.912	rs6741544	ENSG00000235499.1	AC073046.25	3.97	8.37e-05	0.00669	0.17	0.18	Dialysis-related mortality;	chr2:74067094	chr2:73985132~73986343:+
THCA	cis	rs7635879	0.558	rs7620530	ENSG00000230102.6	RP11-407B7.1	3.97	8.37e-05	0.00669	0.15	0.18	Breastfeeding duration;	chr3:194017042	chr3:194005259~194070970:-
THCA	cis	rs36093844	0.626	rs12281958	ENSG00000279742.1	RP11-700A24.1	-3.97	8.37e-05	0.0067	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85998907	chr11:85852557~85854943:-
THCA	cis	rs16975963	0.644	rs73033145	ENSG00000276846.1	CTD-3220F14.3	-3.97	8.37e-05	0.0067	-0.17	-0.18	Longevity;	chr19:37606412	chr19:37314868~37315620:-
THCA	cis	rs6921919	1	rs35875412	ENSG00000219392.1	RP1-265C24.5	-3.97	8.37e-05	0.0067	-0.24	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28115628~28116551:+
THCA	cis	rs13113518	0.702	rs78829811	ENSG00000272969.1	RP11-528I4.2	3.97	8.37e-05	0.0067	0.21	0.18	Height;	chr4:55558258	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.702	rs75801206	ENSG00000272969.1	RP11-528I4.2	3.97	8.37e-05	0.0067	0.21	0.18	Height;	chr4:55558259	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.702	rs34658078	ENSG00000272969.1	RP11-528I4.2	3.97	8.37e-05	0.0067	0.21	0.18	Height;	chr4:55558261	chr4:55547112~55547889:+
THCA	cis	rs4713118	0.615	rs57252182	ENSG00000261839.1	RP1-265C24.8	3.97	8.38e-05	0.0067	0.19	0.18	Parkinson's disease;	chr6:27752470	chr6:28136849~28139678:+
THCA	cis	rs34034915	1	rs34034915	ENSG00000261839.1	RP1-265C24.8	3.97	8.38e-05	0.0067	0.19	0.18	Hepatitis A;	chr6:27752924	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.527	rs36042294	ENSG00000261839.1	RP1-265C24.8	3.97	8.38e-05	0.0067	0.19	0.18	Parkinson's disease;	chr6:27752933	chr6:28136849~28139678:+
THCA	cis	rs7968440	1	rs11609231	ENSG00000272368.2	RP4-605O3.4	3.97	8.38e-05	0.0067	0.12	0.18	Fibrinogen;	chr12:50538647	chr12:50112197~50165618:+
THCA	cis	rs739496	0.615	rs609230	ENSG00000226469.1	ADAM1B	-3.97	8.38e-05	0.0067	-0.22	-0.18	Platelet count;	chr12:111709107	chr12:111927018~111929017:+
THCA	cis	rs11758351	1	rs17598927	ENSG00000216331.1	HIST1H1PS1	-3.97	8.38e-05	0.0067	-0.3	-0.18	Renal underexcretion gout;Gout;	chr6:26184412	chr6:26195566~26195771:+
THCA	cis	rs3820928	0.605	rs10186145	ENSG00000212391.1	SNORA48	-3.97	8.38e-05	0.0067	-0.2	-0.18	Pulmonary function;	chr2:226916434	chr2:226968989~226969122:-
THCA	cis	rs950169	0.922	rs12910334	ENSG00000188388.10	GOLGA6L3	3.97	8.38e-05	0.0067	0.24	0.18	Schizophrenia;	chr15:84403620	chr15:85240472~85247170:+
THCA	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	3.97	8.38e-05	0.0067	0.16	0.18	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
THCA	cis	rs12440869	1	rs4776919	ENSG00000270964.1	RP11-502I4.3	-3.97	8.38e-05	0.0067	-0.16	-0.18	Peak velocity of the mitral A-wave;	chr15:67312728	chr15:67541072~67542604:-
THCA	cis	rs12440869	1	rs11071947	ENSG00000270964.1	RP11-502I4.3	-3.97	8.38e-05	0.0067	-0.16	-0.18	Peak velocity of the mitral A-wave;	chr15:67313329	chr15:67541072~67542604:-
THCA	cis	rs2732480	0.577	rs2634678	ENSG00000257735.1	RP11-370I10.6	3.97	8.38e-05	0.0067	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48350945~48442411:+
THCA	cis	rs523522	0.571	rs11065120	ENSG00000278344.1	RP11-18C24.8	3.97	8.38e-05	0.0067	0.23	0.18	High light scatter reticulocyte count;	chr12:120437653	chr12:120500735~120501090:-
THCA	cis	rs4879656	0.835	rs7036559	ENSG00000225693.1	LAGE3P1	-3.97	8.39e-05	0.00671	-0.19	-0.18	Menopause (age at onset);	chr9:33064929	chr9:33019682~33020165:-
THCA	cis	rs12612619	0.704	rs6746337	ENSG00000272148.1	RP11-195B17.1	-3.97	8.39e-05	0.00671	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27118195	chr2:27062428~27062907:-
THCA	cis	rs62244186	0.659	rs12108134	ENSG00000214820.3	MPRIPP1	-3.97	8.39e-05	0.00671	-0.19	-0.18	Depressive symptoms;	chr3:44501538	chr3:44579938~44581026:-
THCA	cis	rs9467773	0.901	rs1407045	ENSG00000228223.2	HCG11	-3.97	8.39e-05	0.00671	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26475927	chr6:26523450~26526579:+
THCA	cis	rs853679	0.607	rs13199649	ENSG00000272009.1	RP1-313I6.12	-3.97	8.39e-05	0.00671	-0.35	-0.18	Depression;	chr6:27901014	chr6:28078792~28081130:-
THCA	cis	rs656319	0.564	rs11776035	ENSG00000261451.1	RP11-981G7.1	-3.97	8.39e-05	0.00671	-0.25	-0.18	Myopia (pathological);	chr8:10214017	chr8:10433672~10438312:+
THCA	cis	rs9291683	0.595	rs11722930	ENSG00000250413.1	RP11-448G15.1	-3.97	8.39e-05	0.00671	-0.17	-0.18	Bone mineral density;	chr4:10033830	chr4:10006482~10009725:+
THCA	cis	rs6496044	0.568	rs6496039	ENSG00000259630.2	CTD-2262B20.1	-3.97	8.39e-05	0.00671	-0.19	-0.18	Interstitial lung disease;	chr15:85518732	chr15:85415228~85415633:+
THCA	cis	rs9316337	0.902	rs12430301	ENSG00000236953.1	ZDHHC20-IT1	-3.97	8.39e-05	0.00671	-0.19	-0.18	Schizophrenia;	chr13:21396590	chr13:21376977~21377874:-
THCA	cis	rs7819412	0.775	rs11773990	ENSG00000261451.1	RP11-981G7.1	-3.97	8.39e-05	0.00671	-0.22	-0.18	Triglycerides;	chr8:11077572	chr8:10433672~10438312:+
THCA	cis	rs7819412	0.775	rs4545055	ENSG00000261451.1	RP11-981G7.1	-3.97	8.39e-05	0.00671	-0.22	-0.18	Triglycerides;	chr8:11077856	chr8:10433672~10438312:+
THCA	cis	rs7819412	0.775	rs2898257	ENSG00000261451.1	RP11-981G7.1	-3.97	8.39e-05	0.00671	-0.22	-0.18	Triglycerides;	chr8:11077858	chr8:10433672~10438312:+
THCA	cis	rs5769765	0.632	rs13056783	ENSG00000260613.1	RP3-522J7.6	3.97	8.39e-05	0.00671	0.23	0.18	Schizophrenia;	chr22:49865504	chr22:49832616~49837786:-
THCA	cis	rs9902453	0.578	rs8073217	ENSG00000263370.1	RP11-68I3.5	3.97	8.39e-05	0.00671	0.24	0.18	Coffee consumption (cups per day);	chr17:29837245	chr17:29639627~29640825:+
THCA	cis	rs7166081	0.951	rs16950805	ENSG00000270964.1	RP11-502I4.3	-3.97	8.39e-05	0.00671	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67268339	chr15:67541072~67542604:-
THCA	cis	rs2290416	0.892	rs3793369	ENSG00000253931.1	RP11-909N17.2	3.97	8.39e-05	0.00671	0.36	0.18	Attention deficit hyperactivity disorder;	chr8:143582165	chr8:143412749~143417054:+
THCA	cis	rs202072	0.725	rs202071	ENSG00000272379.1	RP1-257A7.5	3.97	8.39e-05	0.00671	0.27	0.18	HIV-1 viral setpoint;	chr6:13267926	chr6:13290018~13290490:-
THCA	cis	rs301901	0.965	rs1466862	ENSG00000250155.1	CTD-2353F22.1	-3.97	8.39e-05	0.00671	-0.18	-0.18	Height;	chr5:36791710	chr5:36666214~36725195:-
THCA	cis	rs301901	0.965	rs13170811	ENSG00000250155.1	CTD-2353F22.1	-3.97	8.39e-05	0.00671	-0.18	-0.18	Height;	chr5:36795628	chr5:36666214~36725195:-
THCA	cis	rs2154427	0.872	rs80098814	ENSG00000238197.4	PAXBP1-AS1	3.97	8.39e-05	0.00671	0.19	0.18	Bilirubin levels;	chr21:32760691	chr21:32728115~32743122:+
THCA	cis	rs9905704	0.671	rs4337355	ENSG00000224738.1	AC099850.1	3.97	8.39e-05	0.00671	0.21	0.18	Testicular germ cell tumor;	chr17:58873559	chr17:59106598~59118267:+
THCA	cis	rs12313068	0.709	rs73404675	ENSG00000249094.2	RP1-7G5.6	3.97	8.4e-05	0.00671	0.28	0.18	Intelligence (multi-trait analysis);	chr12:110066297	chr12:109880676~109888467:+
THCA	cis	rs874628	0.686	rs72999447	ENSG00000268650.3	AC068499.10	3.97	8.4e-05	0.00671	0.22	0.18	Multiple sclerosis;	chr19:18126137	chr19:18204730~18220480:+
THCA	cis	rs62158800	0.852	rs62161279	ENSG00000224568.1	AC096669.3	3.97	8.4e-05	0.00671	0.35	0.18	Facial morphology (factor 22);	chr2:107693623	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.777	rs62161303	ENSG00000224568.1	AC096669.3	3.97	8.4e-05	0.00671	0.35	0.18	Facial morphology (factor 22);	chr2:107699211	chr2:107529487~107556326:+
THCA	cis	rs4693089	0.604	rs2047210	ENSG00000213608.5	SLC25A14P1	3.97	8.4e-05	0.00671	0.21	0.18	Menopause (age at onset);	chr4:83432001	chr4:83477524~83478424:+
THCA	cis	rs12134133	1	rs2782854	ENSG00000237074.1	RP11-6J21.2	3.97	8.4e-05	0.00671	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207249067~207309121:+
THCA	cis	rs9844666	0.512	rs9870581	ENSG00000273486.1	RP11-731C17.2	3.97	8.4e-05	0.00671	0.17	0.18	Height;	chr3:135922012	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9833699	ENSG00000273486.1	RP11-731C17.2	3.97	8.4e-05	0.00671	0.17	0.18	Height;	chr3:135922442	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9834624	ENSG00000273486.1	RP11-731C17.2	3.97	8.4e-05	0.00671	0.17	0.18	Height;	chr3:135922852	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9854494	ENSG00000273486.1	RP11-731C17.2	3.97	8.4e-05	0.00671	0.17	0.18	Height;	chr3:135922980	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9875948	ENSG00000273486.1	RP11-731C17.2	3.97	8.4e-05	0.00671	0.17	0.18	Height;	chr3:135923062	chr3:136837338~136839021:-
THCA	cis	rs1923539	0.713	rs1885553	ENSG00000225484.5	NUTM2B-AS1	3.97	8.4e-05	0.00671	0.22	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951955	chr10:79663088~79826594:-
THCA	cis	rs1923539	0.713	rs2758544	ENSG00000225484.5	NUTM2B-AS1	3.97	8.4e-05	0.00671	0.22	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970366	chr10:79663088~79826594:-
THCA	cis	rs10761482	0.954	rs10994305	ENSG00000254271.1	RP11-131N11.4	3.97	8.4e-05	0.00672	0.24	0.18	Schizophrenia;	chr10:60326241	chr10:60734342~60741828:+
THCA	cis	rs10483853	0.579	rs58546337	ENSG00000258443.1	RP3-414A15.11	-3.97	8.4e-05	0.00672	-0.27	-0.18	Coronary artery calcification;	chr14:73483753	chr14:73517233~73520648:-
THCA	cis	rs8062405	1	rs4451951	ENSG00000270424.1	RP11-1348G14.6	3.97	8.4e-05	0.00672	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28749959~28750595:-
THCA	cis	rs4950322	0.857	rs55790545	ENSG00000180867.10	PDIA3P1	3.97	8.41e-05	0.00672	0.18	0.18	Protein quantitative trait loci;	chr1:147366649	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.857	rs7522219	ENSG00000180867.10	PDIA3P1	3.97	8.41e-05	0.00672	0.18	0.18	Protein quantitative trait loci;	chr1:147366904	chr1:147178113~147179622:+
THCA	cis	rs34779708	0.733	rs7081597	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs4007271	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.702	rs4007272	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs4934740	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.702	rs4244995	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs4244997	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs4298846	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs4391768	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs7914468	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs7914560	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs4444023	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs12243593	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs3936502	ENSG00000233200.1	RP11-324I22.2	3.97	8.41e-05	0.00672	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35219894~35230598:-
THCA	cis	rs17689437	0.958	rs72794393	ENSG00000260084.1	RP11-615I2.1	-3.97	8.41e-05	0.00672	-0.31	-0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68537058	chr16:68573782~68589512:-
THCA	cis	rs12681963	0.614	rs2958740	ENSG00000248159.1	HSPA8P11	-3.97	8.41e-05	0.00672	-0.31	-0.18	Migraine;	chr8:30235218	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.688	rs2938229	ENSG00000248159.1	HSPA8P11	3.97	8.41e-05	0.00672	0.31	0.18	Migraine;	chr8:30237431	chr8:30237382~30240997:+
THCA	cis	rs17221829	0.616	rs75627051	ENSG00000280385.1	AP000648.5	-3.97	8.41e-05	0.00672	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89627735	chr11:90193614~90198120:+
THCA	cis	rs6500602	1	rs7204827	ENSG00000280063.1	RP11-295D4.3	3.97	8.41e-05	0.00672	0.1	0.18	Schizophrenia;	chr16:4417532	chr16:4346694~4348648:-
THCA	cis	rs7432375	0.933	rs6791142	ENSG00000273455.1	RP11-305O4.3	3.97	8.41e-05	0.00672	0.24	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136658535	chr3:136087475~136087913:-
THCA	cis	rs17412738	0.651	rs17184819	ENSG00000248724.5	NPHP3-AS1	-3.97	8.41e-05	0.00672	-0.33	-0.18	Blood protein levels;	chr3:132409481	chr3:132721750~132874223:+
THCA	cis	rs3760982	0.585	rs8109478	ENSG00000268601.1	AC115522.3	-3.97	8.41e-05	0.00672	-0.22	-0.18	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794104	chr19:43794309~43795658:-
THCA	cis	rs3760982	0.585	rs8109812	ENSG00000268601.1	AC115522.3	-3.97	8.41e-05	0.00672	-0.22	-0.18	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794342	chr19:43794309~43795658:-
THCA	cis	rs576982	1	rs576982	ENSG00000261143.1	ADAMTS7P3	-3.97	8.41e-05	0.00672	-0.24	-0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78578461	chr15:77976042~77993057:+
THCA	cis	rs4763879	0.594	rs12427310	ENSG00000214776.8	RP11-726G1.1	-3.97	8.41e-05	0.00672	-0.22	-0.18	Type 1 diabetes;	chr12:9707539	chr12:9467552~9576275:+
THCA	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	3.97	8.41e-05	0.00672	0.2	0.18	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
THCA	cis	rs12612619	0.732	rs13021112	ENSG00000272148.1	RP11-195B17.1	3.97	8.41e-05	0.00672	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27036926	chr2:27062428~27062907:-
THCA	cis	rs4788570	0.578	rs7204992	ENSG00000260593.1	RP11-432I5.2	-3.97	8.42e-05	0.00673	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71624541	chr16:71623708~71626816:-
THCA	cis	rs17193922	0.798	rs7203644	ENSG00000279344.1	RP11-44F14.7	3.97	8.42e-05	0.00673	0.2	0.18	Hip circumference adjusted for BMI;	chr16:53513297	chr16:53478957~53481550:-
THCA	cis	rs10090774	0.965	rs4961236	ENSG00000279766.1	RP11-642A1.2	3.97	8.42e-05	0.00673	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140855796	chr8:140572142~140572812:-
THCA	cis	rs78487399	0.808	rs111812200	ENSG00000234936.1	AC010883.5	3.97	8.42e-05	0.00673	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43447139	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs12105786	ENSG00000234936.1	AC010883.5	3.97	8.42e-05	0.00673	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43449294	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.71	rs6731998	ENSG00000234936.1	AC010883.5	3.97	8.42e-05	0.00673	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43450134	chr2:43229573~43233394:+
THCA	cis	rs3748656	1	rs3795819	ENSG00000273483.1	RP4-671G15.2	-3.97	8.42e-05	0.00673	-0.19	-0.18	Hip circumference adjusted for BMI;	chr1:112691557	chr1:112517799~112518441:-
THCA	cis	rs709400	1	rs861539	ENSG00000258735.1	LINC00637	3.97	8.42e-05	0.00673	0.24	0.18	Body mass index;	chr14:103699416	chr14:103847721~103858049:+
THCA	cis	rs11771526	0.901	rs62457471	ENSG00000272905.1	RP11-265E18.1	3.97	8.42e-05	0.00673	0.24	0.18	Body mass index;	chr7:32267125	chr7:32845394~32846061:+
THCA	cis	rs17597773	0.674	rs1335919	ENSG00000272823.1	RP11-295M18.6	-3.97	8.42e-05	0.00673	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220845043	chr1:220828676~220829211:-
THCA	cis	rs8064029	0.803	rs11861487	ENSG00000267077.1	RP11-127I20.5	-3.97	8.42e-05	0.00673	-0.27	-0.18	Cancer;	chr16:4822759	chr16:4795265~4796532:-
THCA	cis	rs4908768	0.501	rs12046643	ENSG00000270282.1	RP5-1115A15.2	3.97	8.42e-05	0.00673	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8512653~8513021:+
THCA	cis	rs4908760	0.965	rs10864353	ENSG00000270282.1	RP5-1115A15.2	3.97	8.42e-05	0.00673	0.21	0.18	Vitiligo;	chr1:8489656	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs6677736	ENSG00000270282.1	RP5-1115A15.2	3.97	8.42e-05	0.00673	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8512653~8513021:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000219891.2	ZSCAN12P1	3.97	8.42e-05	0.00673	0.26	0.18	Depression;	chr6:28096845	chr6:28091154~28093664:+
THCA	cis	rs7208859	0.673	rs216410	ENSG00000280069.1	CTD-2349P21.3	3.97	8.42e-05	0.00673	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30738182~30740275:+
THCA	cis	rs4819052	0.851	rs2256000	ENSG00000273796.1	LL21NC02-21A1.1	-3.97	8.42e-05	0.00673	-0.18	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45403809~45404369:-
THCA	cis	rs9309473	0.519	rs13027816	ENSG00000273245.1	RP11-434P11.2	-3.97	8.42e-05	0.00673	-0.21	-0.18	Metabolite levels;	chr2:73670564	chr2:73750256~73750786:-
THCA	cis	rs62158800	0.598	rs10175087	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107671547	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs6746783	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107672162	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs6747019	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107672377	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs1606987	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107673961	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs10177715	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107675826	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs6542728	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107676853	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs6542729	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107676878	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs1400118	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107677403	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs1568055	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107678382	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.638	rs1157314	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107679182	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs1543138	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107679537	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs1516204	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107680431	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs4676149	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107682249	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs10171365	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107683345	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.714	rs1533430	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107684470	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.673	rs1533429	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107684561	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.638	rs1155113	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107684805	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.638	rs1155111	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107685150	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.638	rs1155110	ENSG00000237880.1	AC096669.2	3.97	8.43e-05	0.00673	0.18	0.18	Facial morphology (factor 22);	chr2:107685214	chr2:107385632~107542649:-
THCA	cis	rs9925964	0.687	rs12917722	ENSG00000279196.1	RP11-1072A3.3	-3.97	8.43e-05	0.00673	-0.17	-0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30937076	chr16:30984630~30988270:-
THCA	cis	rs7829975	0.628	rs1109618	ENSG00000233609.3	RP11-62H7.2	-3.97	8.43e-05	0.00673	-0.19	-0.18	Mood instability;	chr8:8713854	chr8:8961200~8979025:+
THCA	cis	rs151234	0.741	rs151229	ENSG00000259982.1	CDC37P1	-3.97	8.43e-05	0.00673	-0.37	-0.18	Platelet distribution width;	chr16:28573616	chr16:28700294~28701540:-
THCA	cis	rs13108904	0.901	rs1680073	ENSG00000254094.1	AC078852.1	3.97	8.43e-05	0.00673	0.2	0.18	Obesity-related traits;	chr4:1286549	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.875	rs1732099	ENSG00000254094.1	AC078852.1	3.97	8.43e-05	0.00673	0.2	0.18	Obesity-related traits;	chr4:1288908	chr4:1356581~1358075:+
THCA	cis	rs368187	0.71	rs2780303	ENSG00000258844.1	RP11-259K15.2	-3.97	8.43e-05	0.00673	-0.17	-0.18	Thyroid cancer;	chr14:36045580	chr14:36214607~36235608:+
THCA	cis	rs4879656	0.866	rs10971316	ENSG00000225693.1	LAGE3P1	-3.97	8.43e-05	0.00673	-0.19	-0.18	Menopause (age at onset);	chr9:33013964	chr9:33019682~33020165:-
THCA	cis	rs17689437	1	rs11641652	ENSG00000275383.1	RP11-615I2.6	3.97	8.43e-05	0.00673	0.27	0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68554909	chr16:68591382~68594424:+
THCA	cis	rs17689437	1	rs11860220	ENSG00000275383.1	RP11-615I2.6	3.97	8.43e-05	0.00673	0.27	0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68557812	chr16:68591382~68594424:+
THCA	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	3.97	8.43e-05	0.00673	0.17	0.18	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000229180.5	GS1-124K5.11	3.97	8.43e-05	0.00673	0.13	0.18	Aortic root size;	chr7:65967557	chr7:66526088~66542624:-
THCA	cis	rs962856	0.822	rs6546307	ENSG00000236780.4	AC078941.1	3.97	8.43e-05	0.00673	0.22	0.18	Pancreatic cancer;	chr2:67416921	chr2:67123357~67215319:-
THCA	cis	rs35771425	0.619	rs6689078	ENSG00000153363.11	LINC00467	-3.97	8.43e-05	0.00673	-0.14	-0.18	Educational attainment (years of education);	chr1:211303081	chr1:211382803~211435333:+
THCA	cis	rs2692947	0.568	rs57579941	ENSG00000235959.1	AC009237.17	-3.97	8.43e-05	0.00674	-0.2	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95670505	chr2:95640181~95640604:-
THCA	cis	rs9905704	0.647	rs2286299	ENSG00000224738.1	AC099850.1	3.97	8.43e-05	0.00674	0.22	0.18	Testicular germ cell tumor;	chr17:58966006	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.647	rs10221208	ENSG00000224738.1	AC099850.1	3.97	8.43e-05	0.00674	0.22	0.18	Testicular germ cell tumor;	chr17:58970524	chr17:59106598~59118267:+
THCA	cis	rs7196129	0.966	rs12598978	ENSG00000183604.13	SMG1P5	3.97	8.43e-05	0.00674	0.18	0.18	Monocyte count;	chr16:30471219	chr16:30267553~30335374:-
THCA	cis	rs603446	0.967	rs180365	ENSG00000254851.1	RP11-109L13.1	-3.97	8.43e-05	0.00674	-0.24	-0.18	Triglycerides;	chr11:116725458	chr11:117135528~117138582:+
THCA	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-3.97	8.44e-05	0.00674	-0.2	-0.18	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
THCA	cis	rs9309473	0.5	rs2421668	ENSG00000273245.1	RP11-434P11.2	-3.97	8.44e-05	0.00674	-0.21	-0.18	Metabolite levels;	chr2:73657969	chr2:73750256~73750786:-
THCA	cis	rs3126085	0.935	rs11204967	ENSG00000237975.5	FLG-AS1	3.97	8.44e-05	0.00674	0.27	0.18	Atopic dermatitis;	chr1:152277244	chr1:152168125~152445456:+
THCA	cis	rs427394	0.632	rs2279656	ENSG00000248677.1	CTD-2044J15.1	3.97	8.44e-05	0.00674	0.18	0.18	Menopause (age at onset);	chr5:6737463	chr5:6686325~6707711:-
THCA	cis	rs4908768	0.906	rs10492966	ENSG00000232912.4	RP5-1115A15.1	-3.97	8.44e-05	0.00674	-0.22	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8537946	chr1:8424645~8434838:+
THCA	cis	rs2257011	0.76	rs2585059	ENSG00000230373.7	GOLGA6L5P	-3.97	8.44e-05	0.00674	-0.17	-0.18	Height;	chr15:83616602	chr15:84507885~84516814:-
THCA	cis	rs2235642	0.928	rs56289115	ENSG00000260989.1	LA16c-395F10.2	-3.97	8.44e-05	0.00674	-0.19	-0.18	Coronary artery disease;	chr16:1558933	chr16:1580527~1610328:+
THCA	cis	rs3806843	0.52	rs265312	ENSG00000202515.1	VTRNA1-3	-3.97	8.44e-05	0.00674	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140916687	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs155358	ENSG00000202515.1	VTRNA1-3	-3.97	8.44e-05	0.00674	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140917447	chr5:140726158~140726246:+
THCA	cis	rs10090774	0.863	rs7815191	ENSG00000279766.1	RP11-642A1.2	3.97	8.44e-05	0.00674	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140845557	chr8:140572142~140572812:-
THCA	cis	rs8062405	0.895	rs62036658	ENSG00000270424.1	RP11-1348G14.6	3.97	8.44e-05	0.00674	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28749959~28750595:-
THCA	cis	rs17772222	0.511	rs3850392	ENSG00000258983.2	RP11-507K2.2	3.97	8.44e-05	0.00674	0.2	0.18	Coronary artery calcification;	chr14:88833286	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.511	rs7155535	ENSG00000258983.2	RP11-507K2.2	3.97	8.44e-05	0.00674	0.2	0.18	Coronary artery calcification;	chr14:88844002	chr14:88499334~88515502:+
THCA	cis	rs4925386	0.681	rs2427294	ENSG00000275437.1	RP5-908M14.10	3.97	8.44e-05	0.00674	0.18	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352201	chr20:62402236~62405935:-
THCA	cis	rs6929812	0.676	rs760880	ENSG00000271755.1	RP1-153G14.4	3.97	8.44e-05	0.00674	0.2	0.18	Neuroticism (multi-trait analysis);	chr6:27440402	chr6:27404010~27406964:-
THCA	cis	rs875971	0.545	rs73376401	ENSG00000232559.3	GS1-124K5.12	3.97	8.45e-05	0.00675	0.19	0.18	Aortic root size;	chr7:66174841	chr7:66554588~66576923:-
THCA	cis	rs708224	0.513	rs2632359	ENSG00000277342.1	RP11-843B15.4	3.97	8.45e-05	0.00675	0.24	0.18	Pancreatic cancer;	chr12:32289747	chr12:32109076~32109602:+
THCA	cis	rs62158211	0.691	rs1964463	ENSG00000240356.5	RP11-395L14.11	3.97	8.45e-05	0.00675	0.23	0.18	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113311444	chr2:113610502~113627090:-
THCA	cis	rs7809950	0.678	rs6949634	ENSG00000272072.1	CTA-363E19.2	3.97	8.45e-05	0.00675	0.19	0.18	Coronary artery disease;	chr7:107344239	chr7:107192559~107193300:-
THCA	cis	rs5762813	0.524	rs5752815	ENSG00000272858.1	CTA-292E10.8	-3.97	8.45e-05	0.00675	-0.23	-0.18	Hematocrit;Hemoglobin concentration;	chr22:28834745	chr22:28814914~28815662:+
THCA	cis	rs5762813	0.524	rs5762835	ENSG00000272858.1	CTA-292E10.8	-3.97	8.45e-05	0.00675	-0.23	-0.18	Hematocrit;Hemoglobin concentration;	chr22:28834766	chr22:28814914~28815662:+
THCA	cis	rs854765	0.604	rs12948749	ENSG00000281749.1	Y_RNA	-3.97	8.45e-05	0.00675	-0.24	-0.18	Total body bone mineral density;	chr17:18046488	chr17:18001101~18001195:-
THCA	cis	rs10875746	0.669	rs11168508	ENSG00000226413.2	OR8T1P	3.97	8.45e-05	0.00675	0.25	0.18	Longevity (90 years and older);	chr12:48289728	chr12:48442030~48442947:-
THCA	cis	rs9890032	0.532	rs1808257	ENSG00000276250.1	CTD-2349P21.12	-3.97	8.45e-05	0.00675	-0.15	-0.18	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30803654~30804077:+
THCA	cis	rs2562456	0.833	rs2968078	ENSG00000268658.4	LINC00664	-3.97	8.45e-05	0.00675	-0.27	-0.18	Pain;	chr19:21458942	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.755	rs2650773	ENSG00000268658.4	LINC00664	-3.97	8.45e-05	0.00675	-0.27	-0.18	Pain;	chr19:21461286	chr19:21483374~21503238:+
THCA	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-3.97	8.45e-05	0.00675	-0.21	-0.18	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	3.97	8.45e-05	0.00675	0.21	0.18	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
THCA	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	3.97	8.45e-05	0.00675	0.21	0.18	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	3.97	8.45e-05	0.00675	0.21	0.18	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	3.97	8.45e-05	0.00675	0.21	0.18	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	3.97	8.45e-05	0.00675	0.21	0.18	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
THCA	cis	rs7511006	1	rs17836662	ENSG00000273137.1	RP3-402G11.28	3.97	8.45e-05	0.00675	0.12	0.18	Obesity-related traits;	chr22:50233725	chr22:50208461~50209542:-
THCA	cis	rs9341808	0.667	rs7745301	ENSG00000272129.1	RP11-250B2.6	3.97	8.45e-05	0.00675	0.23	0.18	Sitting height ratio;	chr6:80212844	chr6:80355424~80356859:+
THCA	cis	rs7166081	1	rs7182798	ENSG00000270964.1	RP11-502I4.3	-3.97	8.45e-05	0.00675	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67242874	chr15:67541072~67542604:-
THCA	cis	rs10411262	0.935	rs2871987	ENSG00000245598.5	DACT3-AS1	-3.97	8.45e-05	0.00675	-0.21	-0.18	Tonsillectomy;	chr19:46672271	chr19:46660364~46677447:+
THCA	cis	rs877529	0.932	rs139403	ENSG00000279833.1	RP4-742C19.13	-3.97	8.45e-05	0.00675	-0.12	-0.18	Multiple myeloma;	chr22:39151016	chr22:39133090~39136760:+
THCA	cis	rs4780401	0.933	rs12926451	ENSG00000274038.1	RP11-66H6.4	3.97	8.45e-05	0.00675	0.21	0.18	Rheumatoid arthritis;	chr16:11725713	chr16:11056556~11057034:+
THCA	cis	rs11665867	1	rs73047073	ENSG00000279108.1	CTC-490E21.11	-3.97	8.46e-05	0.00675	-0.26	-0.18	Hematocrit;	chr19:40793161	chr19:40840159~40842039:+
THCA	cis	rs6012953	1	rs6020586	ENSG00000231715.1	COX6CP2	3.97	8.46e-05	0.00675	0.19	0.18	Vitiligo;	chr20:50539126	chr20:50479767~50479991:+
THCA	cis	rs6012953	1	rs6063533	ENSG00000231715.1	COX6CP2	-3.97	8.46e-05	0.00675	-0.19	-0.18	Vitiligo;	chr20:50542862	chr20:50479767~50479991:+
THCA	cis	rs2221894	0.922	rs4732657	ENSG00000251191.6	LINC00589	-3.97	8.46e-05	0.00675	-0.22	-0.18	Obesity-related traits;	chr8:28898471	chr8:29673922~29748109:-
THCA	cis	rs459482	0.504	rs469288	ENSG00000228318.3	AP001610.5	3.97	8.46e-05	0.00676	0.22	0.18	IgG glycosylation;	chr21:41445655	chr21:41441056~41445708:-
THCA	cis	rs2299587	0.527	rs7818801	ENSG00000253671.1	RP11-806O11.1	-3.97	8.46e-05	0.00676	-0.21	-0.18	Economic and political preferences;	chr8:17865358	chr8:17808941~17820868:+
THCA	cis	rs472402	0.58	rs11738248	ENSG00000250056.4	LINC01018	-3.97	8.46e-05	0.00676	-0.22	-0.18	Response to amphetamines;	chr5:6657381	chr5:6582136~6588499:+
THCA	cis	rs8054556	0.74	rs12716974	ENSG00000273724.1	RP11-347C12.12	-3.97	8.46e-05	0.00676	-0.17	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30336400~30343336:+
THCA	cis	rs7586085	0.903	rs13431319	ENSG00000232411.1	AC009495.3	3.97	8.46e-05	0.00676	0.19	0.18	Total body bone mineral density;	chr2:165758067	chr2:165833048~165839098:-
THCA	cis	rs7927592	0.546	rs638076	ENSG00000160172.9	FAM86C2P	3.97	8.46e-05	0.00676	0.17	0.18	Total body bone mineral density;	chr11:68435112	chr11:67791648~67805336:-
THCA	cis	rs4713118	0.629	rs203889	ENSG00000219891.2	ZSCAN12P1	3.97	8.46e-05	0.00676	0.24	0.18	Parkinson's disease;	chr6:28053997	chr6:28091154~28093664:+
THCA	cis	rs654950	0.875	rs586055	ENSG00000230638.4	RP11-486B10.4	-3.97	8.46e-05	0.00676	-0.2	-0.18	Airway imaging phenotypes;	chr1:41533405	chr1:41542069~41544310:+
THCA	cis	rs12612619	0.732	rs13020526	ENSG00000272148.1	RP11-195B17.1	3.97	8.46e-05	0.00676	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26981782	chr2:27062428~27062907:-
THCA	cis	rs75504410	0.579	rs3733315	ENSG00000231160.8	KLF3-AS1	-3.97	8.46e-05	0.00676	-0.13	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38630535	chr4:38612701~38664883:-
THCA	cis	rs75504410	0.579	rs191414	ENSG00000231160.8	KLF3-AS1	-3.97	8.46e-05	0.00676	-0.13	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38631676	chr4:38612701~38664883:-
THCA	cis	rs9595908	0.785	rs9591236	ENSG00000212293.1	SNORA16	3.97	8.46e-05	0.00676	0.21	0.18	Body mass index;	chr13:32671667	chr13:32420390~32420516:-
THCA	cis	rs4767841	0.594	rs203364	ENSG00000248636.5	RP11-768F21.1	-3.97	8.47e-05	0.00676	-0.18	-0.18	Urgency urinary incontinence;	chr12:119777265	chr12:119387987~119668079:-
THCA	cis	rs6997458	0.935	rs7824715	ENSG00000253549.4	RP11-317J10.2	3.97	8.47e-05	0.00676	0.18	0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85366148	chr8:85441851~85464915:-
THCA	cis	rs8081395	0.836	rs2150879	ENSG00000267302.4	RP11-178C3.2	-3.97	8.47e-05	0.00676	-0.21	-0.18	White blood cell count;	chr17:59781849	chr17:59964832~59996972:+
THCA	cis	rs9863	0.931	rs4575361	ENSG00000269938.1	RP11-214K3.20	-3.97	8.47e-05	0.00676	-0.22	-0.18	White blood cell count;	chr12:123925982	chr12:123968023~123968579:-
THCA	cis	rs112158604	1	rs112158604	ENSG00000231073.1	RP11-316M1.3	-3.97	8.47e-05	0.00676	-0.22	-0.18	Lymphocyte counts;	chr1:150724325	chr1:150973123~150975534:+
THCA	cis	rs7973719	0.868	rs2053887	ENSG00000205885.6	C1RL-AS1	3.97	8.47e-05	0.00676	0.13	0.18	IgG glycosylation;	chr12:7193934	chr12:7108052~7122501:+
THCA	cis	rs10186029	0.68	rs13007271	ENSG00000270659.1	RP11-105N14.1	-3.97	8.47e-05	0.00676	-0.14	-0.18	Systemic sclerosis;	chr2:213073043	chr2:213152970~213153659:+
THCA	cis	rs10186029	0.68	rs11689451	ENSG00000270659.1	RP11-105N14.1	-3.97	8.47e-05	0.00676	-0.14	-0.18	Systemic sclerosis;	chr2:213073116	chr2:213152970~213153659:+
THCA	cis	rs9532669	0.926	rs11147823	ENSG00000229473.2	RGS17P1	-3.97	8.47e-05	0.00676	-0.23	-0.18	Cervical cancer;	chr13:40878138	chr13:40992779~40993331:-
THCA	cis	rs16957091	0.528	rs36092914	ENSG00000205771.5	CATSPER2P1	3.97	8.47e-05	0.00676	0.26	0.18	MGMT methylation in smokers;	chr15:42808425	chr15:43726918~43747094:-
THCA	cis	rs7615952	0.515	rs4441610	ENSG00000250012.1	RP11-124N2.1	-3.97	8.47e-05	0.00676	-0.17	-0.18	Blood pressure (smoking interaction);	chr3:125962464	chr3:126084220~126095349:+
THCA	cis	rs911555	0.755	rs8014013	ENSG00000269910.1	RP11-73M18.10	-3.97	8.47e-05	0.00676	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103694516~103695050:-
THCA	cis	rs550448	0.755	rs849315	ENSG00000234336.5	JAZF1-AS1	-3.97	8.47e-05	0.00676	-0.29	-0.18	Type 1 diabetes;	chr7:28199241	chr7:28180322~28243917:+
THCA	cis	rs550448	0.716	rs849316	ENSG00000234336.5	JAZF1-AS1	-3.97	8.47e-05	0.00676	-0.29	-0.18	Type 1 diabetes;	chr7:28203215	chr7:28180322~28243917:+
THCA	cis	rs4785204	0.618	rs61664067	ENSG00000279356.1	RP11-429P3.8	-3.97	8.47e-05	0.00676	-0.33	-0.18	Esophageal cancer (squamous cell);	chr16:50013606	chr16:50072862~50074986:+
THCA	cis	rs4785204	0.618	rs57596938	ENSG00000279356.1	RP11-429P3.8	-3.97	8.47e-05	0.00676	-0.33	-0.18	Esophageal cancer (squamous cell);	chr16:50015639	chr16:50072862~50074986:+
THCA	cis	rs6696239	0.956	rs6672530	ENSG00000227711.2	RP11-275O4.5	-3.97	8.47e-05	0.00676	-0.25	-0.18	Height;	chr1:227583515	chr1:227509028~227520477:-
THCA	cis	rs17092148	0.945	rs6060009	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34716170	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.945	rs6087622	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34722667	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs6060025	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34739072	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs910871	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34745404	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs910872	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34746736	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.945	rs17092080	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34747853	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs3787220	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34749948	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs1884431	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34750782	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.945	rs6142237	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34753190	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.943	rs4911160	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34762137	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.945	rs6060034	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34764061	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.945	rs6058115	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34770594	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs6060043	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34776781	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs6058117	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34779102	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs6088603	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34783142	chr20:33985617~33988989:-
THCA	cis	rs17092148	1	rs2378260	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.47e-05	0.00676	-0.21	-0.18	Neuroticism;	chr20:34787094	chr20:33985617~33988989:-
THCA	cis	rs7824557	0.564	rs35009431	ENSG00000255495.1	AC145124.2	-3.97	8.47e-05	0.00676	-0.21	-0.18	Retinal vascular caliber;	chr8:11375279	chr8:12194467~12196280:+
THCA	cis	rs7819412	0.715	rs35223712	ENSG00000280294.1	RP11-177H2.1	3.97	8.47e-05	0.00676	0.15	0.18	Triglycerides;	chr8:11186417	chr8:10856085~10859436:-
THCA	cis	rs2562456	0.755	rs2562421	ENSG00000268278.1	RP11-420K14.1	-3.97	8.47e-05	0.00677	-0.22	-0.18	Pain;	chr19:21448502	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs2562420	ENSG00000268278.1	RP11-420K14.1	-3.97	8.47e-05	0.00677	-0.22	-0.18	Pain;	chr19:21448503	chr19:21637974~21656300:+
THCA	cis	rs4908768	0.501	rs11121186	ENSG00000270282.1	RP5-1115A15.2	3.97	8.48e-05	0.00677	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8512653~8513021:+
THCA	cis	rs3799379	0.55	rs2072804	ENSG00000124549.13	BTN2A3P	-3.97	8.48e-05	0.00677	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26390962	chr6:26421391~26432383:+
THCA	cis	rs748404	0.511	rs12442190	ENSG00000249839.1	AC011330.5	3.97	8.48e-05	0.00677	0.21	0.18	Lung cancer;	chr15:43153107	chr15:43663654~43684339:-
THCA	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-3.97	8.48e-05	0.00677	-0.24	-0.18	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
THCA	cis	rs11800820	0.521	rs3120698	ENSG00000231612.1	RP11-522M21.3	3.97	8.48e-05	0.00677	0.23	0.18	Obesity-related traits;	chr1:246542154	chr1:245673732~245676478:-
THCA	cis	rs12681366	0.537	rs6999976	ENSG00000253175.1	RP11-267M23.6	3.97	8.48e-05	0.00677	0.21	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94470194	chr8:94565036~94565715:+
THCA	cis	rs4908768	0.501	rs1463050	ENSG00000270282.1	RP5-1115A15.2	3.96	8.48e-05	0.00677	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8512653~8513021:+
THCA	cis	rs2058059	0.511	rs6970153	ENSG00000205578.5	POM121B	-3.96	8.48e-05	0.00677	-0.28	-0.18	Subcutaneous adipose tissue;	chr7:72573610	chr7:73293497~73301161:+
THCA	cis	rs9595908	0.832	rs9595976	ENSG00000212293.1	SNORA16	3.96	8.48e-05	0.00677	0.21	0.18	Body mass index;	chr13:32637910	chr13:32420390~32420516:-
THCA	cis	rs10938353	0.638	rs61549581	ENSG00000273369.1	RP11-700J17.1	3.96	8.49e-05	0.00677	0.21	0.18	Body mass index;	chr4:44692702	chr4:44693946~44694386:-
THCA	cis	rs9549367	0.756	rs3861723	ENSG00000269125.1	RP11-98F14.11	-3.96	8.49e-05	0.00677	-0.21	-0.18	Platelet distribution width;	chr13:113256612	chr13:113165002~113165183:-
THCA	cis	rs7777677	0.963	rs7796324	ENSG00000211750.2	TRBV24-1	-3.96	8.49e-05	0.00677	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142656701~142657213:+
THCA	cis	rs970548	0.954	rs61854123	ENSG00000230869.1	CTGLF10P	3.96	8.49e-05	0.00678	0.22	0.18	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45570003	chr10:45678692~45700532:+
THCA	cis	rs301901	0.965	rs13180309	ENSG00000250155.1	CTD-2353F22.1	-3.96	8.49e-05	0.00678	-0.18	-0.18	Height;	chr5:36789899	chr5:36666214~36725195:-
THCA	cis	rs6121246	0.954	rs6060989	ENSG00000224628.2	RP5-854E16.2	-3.96	8.49e-05	0.00678	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31841960	chr20:31285317~31286835:-
THCA	cis	rs12234571	1	rs12667288	ENSG00000214293.7	APTR	3.96	8.49e-05	0.00678	0.22	0.18	Obesity-related traits;	chr7:77777224	chr7:77657660~77696265:-
THCA	cis	rs9329221	0.509	rs3088186	ENSG00000253641.4	RP11-981G7.2	3.96	8.49e-05	0.00678	0.18	0.18	Neuroticism;	chr8:10368845	chr8:10474565~10481974:+
THCA	cis	rs250585	0.688	rs30017	ENSG00000260136.4	CTD-2270L9.4	3.96	8.49e-05	0.00678	0.14	0.18	Egg allergy;	chr16:23400989	chr16:23452758~23457606:+
THCA	cis	rs1853665	0.721	rs62441761	ENSG00000231760.4	RP11-350J20.5	3.96	8.49e-05	0.00678	0.35	0.18	Radiation response;	chr6:149946929	chr6:149796151~149826294:-
THCA	cis	rs9810089	1	rs1279831	ENSG00000273455.1	RP11-305O4.3	3.96	8.49e-05	0.00678	0.24	0.18	Gestational age at birth (child effect);	chr3:136214422	chr3:136087475~136087913:-
THCA	cis	rs2839627	0.638	rs73233314	ENSG00000225218.1	AP001628.6	3.96	8.49e-05	0.00678	0.31	0.18	Information processing speed;	chr21:42877664	chr21:42831040~42836477:-
THCA	cis	rs2839627	0.564	rs57692532	ENSG00000225218.1	AP001628.6	3.96	8.49e-05	0.00678	0.31	0.18	Information processing speed;	chr21:42885173	chr21:42831040~42836477:-
THCA	cis	rs7772697	0.508	rs2153252	ENSG00000223701.3	RAET1E-AS1	-3.96	8.5e-05	0.00678	-0.26	-0.18	Diabetic retinopathy;	chr6:149044928	chr6:149884431~149919508:+
THCA	cis	rs394563	0.591	rs11964335	ENSG00000231760.4	RP11-350J20.5	-3.96	8.5e-05	0.00678	-0.22	-0.18	Dupuytren's disease;	chr6:149336965	chr6:149796151~149826294:-
THCA	cis	rs6504108	0.624	rs17681336	ENSG00000264920.1	RP11-6N17.4	-3.96	8.5e-05	0.00678	-0.15	-0.18	Body mass index;	chr17:48172430	chr17:47891255~47895812:-
THCA	cis	rs740160	0.51	rs12112936	ENSG00000244219.5	GS1-259H13.2	-3.96	8.5e-05	0.00678	-0.27	-0.18	Dehydroepiandrosterone sulphate levels;	chr7:99301877	chr7:99598066~99610813:+
THCA	cis	rs13434995	0.513	rs880358	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.5e-05	0.00678	-0.25	-0.18	Adiponectin levels;	chr4:55410311	chr4:55363971~55395847:-
THCA	cis	rs4767841	0.868	rs2996028	ENSG00000248636.5	RP11-768F21.1	-3.96	8.5e-05	0.00678	-0.19	-0.18	Urgency urinary incontinence;	chr12:119727350	chr12:119387987~119668079:-
THCA	cis	rs642858	0.91	rs982369	ENSG00000234147.1	RP3-460G2.2	-3.96	8.5e-05	0.00678	-0.21	-0.18	Type 2 diabetes;	chr6:140213537	chr6:140845958~140852924:-
THCA	cis	rs642858	0.91	rs1390498	ENSG00000234147.1	RP3-460G2.2	-3.96	8.5e-05	0.00678	-0.21	-0.18	Type 2 diabetes;	chr6:140223330	chr6:140845958~140852924:-
THCA	cis	rs2832077	0.527	rs2776210	ENSG00000232855.5	AF131217.1	-3.96	8.5e-05	0.00679	-0.2	-0.18	Cognitive test performance;	chr21:28896236	chr21:28439346~28674848:-
THCA	cis	rs875971	0.66	rs6460308	ENSG00000275400.1	RP4-756H11.5	3.96	8.5e-05	0.00679	0.17	0.18	Aortic root size;	chr7:66619753	chr7:66553805~66554199:-
THCA	cis	rs1204798	0.636	rs12526817	ENSG00000237021.2	RP3-486I3.7	-3.96	8.5e-05	0.00679	-0.23	-0.18	Dental caries;	chr6:116188473	chr6:116254207~116256743:+
THCA	cis	rs7119	0.635	rs2682910	ENSG00000259362.2	RP11-307C19.1	3.96	8.5e-05	0.00679	0.24	0.18	Type 2 diabetes;	chr15:77587772	chr15:77525540~77534110:+
THCA	cis	rs62158800	0.598	rs1606985	ENSG00000237880.1	AC096669.2	3.96	8.5e-05	0.00679	0.18	0.18	Facial morphology (factor 22);	chr2:107675347	chr2:107385632~107542649:-
THCA	cis	rs950169	0.96	rs35159785	ENSG00000275120.1	RP11-182J1.17	3.96	8.51e-05	0.00679	0.22	0.18	Schizophrenia;	chr15:84135262	chr15:84599434~84606463:-
THCA	cis	rs6973609	0.524	rs10239070	ENSG00000271122.1	RP11-379H18.1	3.96	8.51e-05	0.00679	0.14	0.18	Obesity-related traits;	chr7:35606934	chr7:35695214~35699413:+
THCA	cis	rs478304	0.654	rs7934036	ENSG00000255557.1	RP11-770G2.2	3.96	8.51e-05	0.00679	0.21	0.18	Acne (severe);	chr11:65683549	chr11:65745729~65771585:+
THCA	cis	rs72928364	0.929	rs35333915	ENSG00000256628.3	ZBTB11-AS1	3.96	8.51e-05	0.00679	0.31	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101068217	chr3:101676475~101679217:+
THCA	cis	rs2348418	0.765	rs10843120	ENSG00000278733.1	RP11-425D17.1	3.96	8.51e-05	0.00679	0.16	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28165881	chr12:28185625~28186190:-
THCA	cis	rs7209700	0.614	rs7225927	ENSG00000228782.6	CTD-2026D20.3	-3.96	8.51e-05	0.00679	-0.17	-0.18	IgG glycosylation;	chr17:47246568	chr17:47450568~47492492:-
THCA	cis	rs10090774	0.932	rs61307926	ENSG00000280303.2	ERICD	-3.96	8.51e-05	0.00679	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140932255	chr8:140636281~140638283:+
THCA	cis	rs9307551	0.817	rs12511646	ENSG00000249646.2	OR7E94P	-3.96	8.51e-05	0.00679	-0.23	-0.18	Refractive error;	chr4:79578700	chr4:79587302~79588130:-
THCA	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-3.96	8.51e-05	0.00679	-0.17	-0.18	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
THCA	cis	rs6138458	0.701	rs6050255	ENSG00000274173.1	RP4-568C11.4	3.96	8.52e-05	0.00679	0.16	0.18	Blood protein levels;	chr20:25026453	chr20:24931840~24932983:+
THCA	cis	rs701145	0.585	rs1727940	ENSG00000243069.6	ARHGEF26-AS1	3.96	8.52e-05	0.00679	0.34	0.18	Coronary artery disease;	chr3:154109468	chr3:154024401~154121332:-
THCA	cis	rs10833905	0.877	rs11026945	ENSG00000246225.5	RP11-17A1.3	-3.96	8.52e-05	0.0068	-0.25	-0.18	Sudden cardiac arrest;	chr11:23053115	chr11:22829380~22945393:+
THCA	cis	rs6671200	0.92	rs11165339	ENSG00000235501.4	RP4-639F20.1	3.96	8.52e-05	0.0068	0.36	0.18	Stearic acid (18:0) levels;	chr1:95208508	chr1:94927566~94963270:+
THCA	cis	rs9467773	1	rs1321479	ENSG00000228223.2	HCG11	3.96	8.52e-05	0.0068	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26523450~26526579:+
THCA	cis	rs7829975	0.714	rs11777085	ENSG00000233609.3	RP11-62H7.2	3.96	8.52e-05	0.0068	0.17	0.18	Mood instability;	chr8:8814919	chr8:8961200~8979025:+
THCA	cis	rs7312933	0.558	rs1051453	ENSG00000257225.1	RP11-328C8.4	-3.96	8.52e-05	0.0068	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42458415	chr12:42459366~42466128:+
THCA	cis	rs12234571	0.793	rs73374181	ENSG00000214293.7	APTR	3.96	8.52e-05	0.0068	0.22	0.18	Obesity-related traits;	chr7:77807187	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs6966446	ENSG00000214293.7	APTR	3.96	8.52e-05	0.0068	0.22	0.18	Obesity-related traits;	chr7:77821041	chr7:77657660~77696265:-
THCA	cis	rs7170668	0.896	rs1895648	ENSG00000259134.4	LINC00924	3.96	8.52e-05	0.0068	0.24	0.18	Motion sickness;	chr15:95476410	chr15:95433095~95507847:+
THCA	cis	rs38055	0.668	rs17241927	ENSG00000247796.2	CTD-2366F13.1	3.96	8.52e-05	0.0068	0.18	0.18	Acne (severe);	chr5:53197103	chr5:53109842~53115126:+
THCA	cis	rs38055	0.629	rs62357405	ENSG00000247796.2	CTD-2366F13.1	3.96	8.52e-05	0.0068	0.18	0.18	Acne (severe);	chr5:53199127	chr5:53109842~53115126:+
THCA	cis	rs6696239	0.869	rs61824940	ENSG00000227711.2	RP11-275O4.5	-3.96	8.52e-05	0.0068	-0.25	-0.18	Height;	chr1:227642791	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.911	rs28446171	ENSG00000227711.2	RP11-275O4.5	-3.96	8.52e-05	0.0068	-0.25	-0.18	Height;	chr1:227643475	chr1:227509028~227520477:-
THCA	cis	rs13108904	0.875	rs10024013	ENSG00000254094.1	AC078852.1	3.96	8.52e-05	0.0068	0.2	0.18	Obesity-related traits;	chr4:1287004	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.935	rs1680072	ENSG00000254094.1	AC078852.1	3.96	8.52e-05	0.0068	0.2	0.18	Obesity-related traits;	chr4:1287907	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.935	rs922698	ENSG00000254094.1	AC078852.1	3.96	8.52e-05	0.0068	0.2	0.18	Obesity-related traits;	chr4:1288934	chr4:1356581~1358075:+
THCA	cis	rs4713118	0.868	rs10484401	ENSG00000261839.1	RP1-265C24.8	-3.96	8.52e-05	0.0068	-0.21	-0.18	Parkinson's disease;	chr6:27778811	chr6:28136849~28139678:+
THCA	cis	rs709400	1	rs861538	ENSG00000258735.1	LINC00637	3.96	8.52e-05	0.0068	0.24	0.18	Body mass index;	chr14:103700396	chr14:103847721~103858049:+
THCA	cis	rs17286411	0.671	rs1058747	ENSG00000260185.1	RP11-432I5.6	-3.96	8.52e-05	0.0068	-0.26	-0.18	Blood protein levels;	chr16:71645301	chr16:71655027~71664212:+
THCA	cis	rs7951911	0.915	rs7943822	ENSG00000254427.1	RP11-430H10.1	3.96	8.52e-05	0.0068	0.33	0.18	IgG glycosylation;	chr11:45066834	chr11:45355371~45366121:+
THCA	cis	rs7951911	0.915	rs34290919	ENSG00000254427.1	RP11-430H10.1	3.96	8.52e-05	0.0068	0.33	0.18	IgG glycosylation;	chr11:45069204	chr11:45355371~45366121:+
THCA	cis	rs2386661	0.591	rs11255051	ENSG00000231483.1	RP11-336A10.5	3.96	8.52e-05	0.0068	0.19	0.18	Breast cancer;	chr10:5611487	chr10:5608475~5610793:-
THCA	cis	rs34119086	1	rs34119086	ENSG00000272009.1	RP1-313I6.12	-3.96	8.53e-05	0.0068	-0.35	-0.18	Breast cancer;	chr6:28594471	chr6:28078792~28081130:-
THCA	cis	rs13118159	0.872	rs1882105	ENSG00000254094.1	AC078852.1	-3.96	8.53e-05	0.0068	-0.21	-0.18	Longevity;	chr4:1352168	chr4:1356581~1358075:+
THCA	cis	rs6449502	0.536	rs10471505	ENSG00000251279.1	CTC-436P18.1	3.96	8.53e-05	0.0068	0.32	0.18	Mean platelet volume;	chr5:61192023	chr5:61162070~61232040:+
THCA	cis	rs113835537	0.877	rs2275998	ENSG00000255517.5	CTD-3074O7.5	-3.96	8.53e-05	0.0068	-0.18	-0.18	Airway imaging phenotypes;	chr11:66559110	chr11:66473490~66480233:-
THCA	cis	rs8017455	0.523	rs10129380	ENSG00000259167.2	NMNAT1P1	3.96	8.53e-05	0.0068	0.26	0.18	Hair morphology;	chr14:81097995	chr14:81032529~81033404:+
THCA	cis	rs1993293	0.636	rs1993294	ENSG00000254744.3	CTD-3076O17.1	-3.96	8.53e-05	0.0068	-0.21	-0.18	Coronary artery calcification;	chr15:99757486	chr15:99970215~99974010:+
THCA	cis	rs4660214	0.666	rs7538300	ENSG00000182109.6	RP11-69E11.4	-3.96	8.53e-05	0.0068	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39187092	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.666	rs11205739	ENSG00000182109.6	RP11-69E11.4	-3.96	8.53e-05	0.0068	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39190729	chr1:39522280~39546187:-
THCA	cis	rs111756027	0.539	rs7204015	ENSG00000260922.1	RP11-538I12.3	3.96	8.53e-05	0.0068	0.26	0.18	Bone mineral density (Ward's triangle area);	chr16:77280297	chr16:77234877~77290934:+
THCA	cis	rs7119	0.604	rs2667781	ENSG00000259362.2	RP11-307C19.1	3.96	8.53e-05	0.0068	0.26	0.18	Type 2 diabetes;	chr15:77566277	chr15:77525540~77534110:+
THCA	cis	rs11658311	0.85	rs7214152	ENSG00000226478.3	UPF3AP1	-3.96	8.53e-05	0.0068	-0.43	-0.18	Obsessive-compulsive symptoms;	chr17:17537509	chr17:16745636~16746761:-
THCA	cis	rs6088590	0.735	rs2273684	ENSG00000276073.1	RP5-1125A11.7	3.96	8.53e-05	0.0068	0.16	0.18	Coronary artery disease;	chr20:34941963	chr20:33985617~33988989:-
THCA	cis	rs12544026	0.581	rs485263	ENSG00000253669.3	KB-1732A1.1	-3.96	8.53e-05	0.00681	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101880467	chr8:102805517~102809971:+
THCA	cis	rs78487399	0.808	rs13405076	ENSG00000234936.1	AC010883.5	3.96	8.53e-05	0.00681	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43508214	chr2:43229573~43233394:+
THCA	cis	rs427943	0.83	rs1537123	ENSG00000223768.1	LINC00205	-3.96	8.53e-05	0.00681	-0.16	-0.18	Body mass index;	chr21:45178992	chr21:45293285~45297354:+
THCA	cis	rs8062405	0.824	rs153106	ENSG00000270424.1	RP11-1348G14.6	3.96	8.53e-05	0.00681	0.2	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28749959~28750595:-
THCA	cis	rs62244186	0.714	rs2293600	ENSG00000214820.3	MPRIPP1	-3.96	8.54e-05	0.00681	-0.19	-0.18	Depressive symptoms;	chr3:44557611	chr3:44579938~44581026:-
THCA	cis	rs13129838	1	rs13129838	ENSG00000249646.2	OR7E94P	-3.96	8.54e-05	0.00681	-0.23	-0.18	Myopia;	chr4:79587634	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.817	rs12643976	ENSG00000249646.2	OR7E94P	-3.96	8.54e-05	0.00681	-0.23	-0.18	Refractive error;	chr4:79589616	chr4:79587302~79588130:-
THCA	cis	rs11633886	0.585	rs2460628	ENSG00000259200.1	RP11-718O11.1	3.96	8.54e-05	0.00681	0.22	0.18	Diisocyanate-induced asthma;	chr15:45795754	chr15:45705078~45931069:+
THCA	cis	rs2180341	0.781	rs7742161	ENSG00000220522.2	RP1-177A13.1	3.96	8.54e-05	0.00681	0.22	0.18	Breast cancer;	chr6:127250531	chr6:127416535~127416952:-
THCA	cis	rs6940638	0.662	rs6915678	ENSG00000216901.1	AL022393.7	3.96	8.54e-05	0.00681	0.23	0.18	Intelligence (multi-trait analysis);	chr6:27268087	chr6:28176188~28176674:+
THCA	cis	rs860295	0.702	rs11264366	ENSG00000236675.1	MTX1P1	-3.96	8.54e-05	0.00681	-0.18	-0.18	Body mass index;	chr1:155365620	chr1:155230975~155234325:+
THCA	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	3.96	8.54e-05	0.00681	0.16	0.18	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	3.96	8.54e-05	0.00681	0.16	0.18	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	3.96	8.54e-05	0.00681	0.16	0.18	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	3.96	8.54e-05	0.00681	0.16	0.18	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	3.96	8.54e-05	0.00681	0.16	0.18	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	3.96	8.54e-05	0.00681	0.16	0.18	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	3.96	8.54e-05	0.00681	0.16	0.18	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
THCA	cis	rs34421088	0.56	rs2245357	ENSG00000255046.1	RP11-297N6.4	3.96	8.54e-05	0.00681	0.19	0.18	Neuroticism;	chr8:11541975	chr8:11797928~11802568:-
THCA	cis	rs9796	0.621	rs537244	ENSG00000247556.5	OIP5-AS1	-3.96	8.54e-05	0.00681	-0.14	-0.18	Menopause (age at onset);	chr15:41177115	chr15:41283990~41309737:+
THCA	cis	rs9796	0.621	rs2928142	ENSG00000247556.5	OIP5-AS1	-3.96	8.54e-05	0.00681	-0.14	-0.18	Menopause (age at onset);	chr15:41178251	chr15:41283990~41309737:+
THCA	cis	rs9796	0.621	rs557864	ENSG00000247556.5	OIP5-AS1	-3.96	8.54e-05	0.00681	-0.14	-0.18	Menopause (age at onset);	chr15:41179160	chr15:41283990~41309737:+
THCA	cis	rs1389724	0.648	rs1389718	ENSG00000259834.1	RP11-284N8.3	3.96	8.54e-05	0.00682	0.15	0.18	Schizophrenia;	chr1:110774215	chr1:110653560~110657040:-
THCA	cis	rs11064837	0.504	rs11064845	ENSG00000248636.5	RP11-768F21.1	-3.96	8.55e-05	0.00682	-0.2	-0.18	Schizophrenia;	chr12:119614124	chr12:119387987~119668079:-
THCA	cis	rs4268898	0.965	rs13033241	ENSG00000242628.4	AC009228.1	-3.96	8.55e-05	0.00682	-0.22	-0.18	Asthma;	chr2:24253249	chr2:24214381~24221516:+
THCA	cis	rs11603020	0.95	rs3824988	ENSG00000254602.1	AP000662.4	3.96	8.55e-05	0.00682	0.21	0.18	Blood protein levels;	chr11:57610495	chr11:57638024~57652790:+
THCA	cis	rs9863	0.861	rs12301673	ENSG00000270028.1	RP11-380L11.4	3.96	8.55e-05	0.00682	0.19	0.18	White blood cell count;	chr12:123971271	chr12:123925461~123926083:-
THCA	cis	rs1387259	0.931	rs11168474	ENSG00000257735.1	RP11-370I10.6	3.96	8.55e-05	0.00682	0.21	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48350945~48442411:+
THCA	cis	rs2039553	0.574	rs2783085	ENSG00000227354.5	RBM26-AS1	3.96	8.55e-05	0.00682	0.17	0.18	Pancreatic cancer;	chr13:79747029	chr13:79406309~79424328:+
THCA	cis	rs150992	0.609	rs709390	ENSG00000246763.5	RGMB-AS1	3.96	8.55e-05	0.00682	0.19	0.18	Body mass index;	chr5:98993771	chr5:98769618~98773469:-
THCA	cis	rs7621331	1	rs17196987	ENSG00000273486.1	RP11-731C17.2	3.96	8.55e-05	0.00682	0.17	0.18	Waist circumference adjusted for body mass index;	chr3:135978531	chr3:136837338~136839021:-
THCA	cis	rs7641070	1	rs7641070	ENSG00000273486.1	RP11-731C17.2	3.96	8.55e-05	0.00682	0.17	0.18	Schizophrenia;	chr3:135979287	chr3:136837338~136839021:-
THCA	cis	rs875971	1	rs6961717	ENSG00000230189.5	GS1-124K5.2	-3.96	8.55e-05	0.00682	-0.12	-0.18	Aortic root size;	chr7:66122550	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs2087647	ENSG00000230189.5	GS1-124K5.2	-3.96	8.55e-05	0.00682	-0.12	-0.18	Aortic root size;	chr7:66128201	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs6958484	ENSG00000230189.5	GS1-124K5.2	-3.96	8.55e-05	0.00682	-0.12	-0.18	Aortic root size;	chr7:66134459	chr7:66409143~66490059:-
THCA	cis	rs7616559	0.924	rs4680328	ENSG00000244515.1	KRT18P34	-3.96	8.55e-05	0.00682	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157006928	chr3:157162663~157163932:-
THCA	cis	rs2562456	0.837	rs62110205	ENSG00000268658.4	LINC00664	3.96	8.55e-05	0.00682	0.26	0.18	Pain;	chr19:21577269	chr19:21483374~21503238:+
THCA	cis	rs4266290	0.671	rs868763	ENSG00000214846.4	RP11-115L11.1	-3.96	8.55e-05	0.00682	-0.25	-0.18	Parkinson's disease;	chr4:15754282	chr4:15730962~15731627:-
THCA	cis	rs76878669	0.754	rs10896113	ENSG00000255320.1	RP11-755F10.1	3.96	8.55e-05	0.00682	0.25	0.18	Educational attainment (years of education);	chr11:66349640	chr11:66244840~66246239:-
THCA	cis	rs17286411	0.639	rs78152844	ENSG00000260185.1	RP11-432I5.6	-3.96	8.56e-05	0.00682	-0.25	-0.18	Blood protein levels;	chr16:71625976	chr16:71655027~71664212:+
THCA	cis	rs72928364	0.86	rs34281790	ENSG00000256628.3	ZBTB11-AS1	3.96	8.56e-05	0.00682	0.33	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101071923	chr3:101676475~101679217:+
THCA	cis	rs3792900	0.509	rs6596299	ENSG00000271824.1	AC009014.3	-3.96	8.56e-05	0.00682	-0.19	-0.18	Blood protein levels;Insomnia;	chr5:136234879	chr5:136191468~136193134:-
THCA	cis	rs10129255	0.957	rs61997760	ENSG00000211972.2	IGHV3-66	3.96	8.56e-05	0.00682	0.11	0.18	Kawasaki disease;	chr14:106716993	chr14:106675017~106675544:-
THCA	cis	rs2271404	0.506	rs4848426	ENSG00000227992.1	AC108463.2	3.96	8.56e-05	0.00682	0.24	0.18	Atopic dermatitis;	chr2:111244553	chr2:111203964~111206215:-
THCA	cis	rs934734	0.532	rs1437466	ENSG00000214533.3	KRT18P33	-3.96	8.56e-05	0.00682	-0.22	-0.18	Rheumatoid arthritis;	chr2:65437216	chr2:65666695~65667737:+
THCA	cis	rs10875746	0.669	rs10783244	ENSG00000226413.2	OR8T1P	3.96	8.56e-05	0.00682	0.25	0.18	Longevity (90 years and older);	chr12:48271206	chr12:48442030~48442947:-
THCA	cis	rs12681366	0.763	rs3019277	ENSG00000261437.1	RP11-22C11.2	3.96	8.56e-05	0.00682	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94428195	chr8:94637285~94639467:-
THCA	cis	rs800160	0.588	rs800150	ENSG00000236264.4	RPL26P30	3.96	8.56e-05	0.00682	0.25	0.18	Bacteremia;	chr11:2349989	chr11:2335132~2335776:-
THCA	cis	rs800160	0.623	rs800152	ENSG00000236264.4	RPL26P30	3.96	8.56e-05	0.00682	0.25	0.18	Bacteremia;	chr11:2350160	chr11:2335132~2335776:-
THCA	cis	rs12544026	0.514	rs578603	ENSG00000253669.3	KB-1732A1.1	3.96	8.56e-05	0.00683	0.2	0.18	Major depression and alcohol dependence;	chr8:101872828	chr8:102805517~102809971:+
THCA	cis	rs7829975	0.807	rs519019	ENSG00000253981.4	ALG1L13P	-3.96	8.56e-05	0.00683	-0.17	-0.18	Mood instability;	chr8:8737594	chr8:8236003~8244667:-
THCA	cis	rs9316337	0.591	rs9509687	ENSG00000236953.1	ZDHHC20-IT1	-3.96	8.56e-05	0.00683	-0.2	-0.18	Schizophrenia;	chr13:21414262	chr13:21376977~21377874:-
THCA	cis	rs2299587	0.545	rs12543739	ENSG00000253671.1	RP11-806O11.1	-3.96	8.56e-05	0.00683	-0.21	-0.18	Economic and political preferences;	chr8:17898720	chr8:17808941~17820868:+
THCA	cis	rs9543976	0.557	rs6562916	ENSG00000261105.4	LMO7-AS1	3.96	8.56e-05	0.00683	0.25	0.18	Diabetic retinopathy;	chr13:75597086	chr13:75604700~75635994:-
THCA	cis	rs9543976	0.623	rs4885322	ENSG00000261105.4	LMO7-AS1	3.96	8.56e-05	0.00683	0.25	0.18	Diabetic retinopathy;	chr13:75597195	chr13:75604700~75635994:-
THCA	cis	rs9543976	0.623	rs7996884	ENSG00000261105.4	LMO7-AS1	3.96	8.56e-05	0.00683	0.25	0.18	Diabetic retinopathy;	chr13:75598608	chr13:75604700~75635994:-
THCA	cis	rs9543976	0.623	rs6562918	ENSG00000261105.4	LMO7-AS1	3.96	8.56e-05	0.00683	0.25	0.18	Diabetic retinopathy;	chr13:75600441	chr13:75604700~75635994:-
THCA	cis	rs9543976	0.545	rs2328963	ENSG00000261105.4	LMO7-AS1	3.96	8.56e-05	0.00683	0.25	0.18	Diabetic retinopathy;	chr13:75601390	chr13:75604700~75635994:-
THCA	cis	rs17286411	0.671	rs1582589	ENSG00000260185.1	RP11-432I5.6	-3.96	8.56e-05	0.00683	-0.25	-0.18	Blood protein levels;	chr16:71652151	chr16:71655027~71664212:+
THCA	cis	rs150992	0.57	rs7710032	ENSG00000246763.5	RGMB-AS1	-3.96	8.56e-05	0.00683	-0.19	-0.18	Body mass index;	chr5:99007501	chr5:98769618~98773469:-
THCA	cis	rs7312933	0.703	rs2406567	ENSG00000257225.1	RP11-328C8.4	-3.96	8.56e-05	0.00683	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42157677	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.701	rs10880260	ENSG00000257225.1	RP11-328C8.4	-3.96	8.56e-05	0.00683	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42167596	chr12:42459366~42466128:+
THCA	cis	rs11971779	0.68	rs1862879	ENSG00000252332.1	RNU6-911P	-3.96	8.56e-05	0.00683	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139335205	chr7:139448740~139448843:+
THCA	cis	rs12234571	1	rs73375808	ENSG00000214293.7	APTR	3.96	8.56e-05	0.00683	0.23	0.18	Obesity-related traits;	chr7:77846935	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs73375809	ENSG00000214293.7	APTR	3.96	8.56e-05	0.00683	0.23	0.18	Obesity-related traits;	chr7:77846991	chr7:77657660~77696265:-
THCA	cis	rs1504749	0.569	rs11989813	ENSG00000254142.2	RP11-53M11.3	-3.96	8.56e-05	0.00683	-0.27	-0.18	Intracranial aneurysm;	chr8:54392172	chr8:54554361~54561927:+
THCA	cis	rs67981189	0.579	rs2240533	ENSG00000269927.1	RP6-91H8.3	3.96	8.56e-05	0.00683	0.21	0.18	Schizophrenia;	chr14:71074309	chr14:71141125~71143253:-
THCA	cis	rs548181	0.577	rs569766	ENSG00000254671.2	STT3A-AS1	-3.96	8.56e-05	0.00683	-0.33	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125662474	chr11:125570284~125592568:-
THCA	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	3.96	8.56e-05	0.00683	0.23	0.18	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
THCA	cis	rs7551222	0.721	rs4252717	ENSG00000240219.1	RP11-430C7.5	3.96	8.56e-05	0.00683	0.17	0.18	Schizophrenia;	chr1:204542972	chr1:204626775~204629712:+
THCA	cis	rs7615952	0.932	rs13314869	ENSG00000272840.1	RP11-379B18.6	3.96	8.57e-05	0.00683	0.3	0.18	Blood pressure (smoking interaction);	chr3:125925826	chr3:125774714~125797953:+
THCA	cis	rs13434995	0.513	rs2130040	ENSG00000249700.7	SRD5A3-AS1	3.96	8.57e-05	0.00683	0.25	0.18	Adiponectin levels;	chr4:55564036	chr4:55363971~55395847:-
THCA	cis	rs4272720	0.639	rs2137912	ENSG00000234736.4	FAM170B-AS1	-3.96	8.57e-05	0.00683	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49049280	chr10:49121839~49151547:+
THCA	cis	rs17122278	1	rs2277291	ENSG00000255239.1	AP002954.6	-3.96	8.57e-05	0.00683	-0.33	-0.18	Total cholesterol levels;	chr11:118565041	chr11:118688039~118690600:-
THCA	cis	rs2732480	0.538	rs1387259	ENSG00000257735.1	RP11-370I10.6	-3.96	8.57e-05	0.00683	-0.21	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48350945~48442411:+
THCA	cis	rs17507216	0.628	rs28737193	ENSG00000255769.6	GOLGA2P10	-3.96	8.57e-05	0.00683	-0.27	-0.18	Excessive daytime sleepiness;	chr15:82701318	chr15:82472993~82513950:-
THCA	cis	rs3812831	0.695	rs6560936	ENSG00000264539.1	MIR548AR	-3.96	8.57e-05	0.00683	-0.19	-0.18	Schizophrenia;	chr13:114180497	chr13:114244505~114244561:+
THCA	cis	rs6878727	0.707	rs2220399	ENSG00000253807.4	LINC01170	-3.96	8.57e-05	0.00684	-0.18	-0.18	Breast cancer;	chr5:124371982	chr5:124059794~124405079:-
THCA	cis	rs2562456	0.917	rs2650825	ENSG00000268278.1	RP11-420K14.1	3.96	8.57e-05	0.00684	0.22	0.18	Pain;	chr19:21516423	chr19:21637974~21656300:+
THCA	cis	rs2505675	0.631	rs234913	ENSG00000250903.7	GMDS-AS1	-3.96	8.58e-05	0.00684	-0.17	-0.18	Tuberculosis;	chr6:2209776	chr6:2245748~2482022:+
THCA	cis	rs3755605	0.728	rs6793019	ENSG00000242578.1	RP11-469J4.3	3.96	8.58e-05	0.00684	0.2	0.18	Testicular germ cell tumor;	chr3:170081702	chr3:170410512~170418615:+
THCA	cis	rs7572733	0.935	rs700679	ENSG00000231621.1	AC013264.2	-3.96	8.58e-05	0.00684	-0.17	-0.18	Dermatomyositis;	chr2:197842192	chr2:197197991~197199273:+
THCA	cis	rs7900823	0.528	rs1870097	ENSG00000230500.1	MKX-AS1	-3.96	8.58e-05	0.00684	-0.24	-0.18	Lung cancer;	chr10:28252543	chr10:27744786~27767794:+
THCA	cis	rs7804306	1	rs35143180	ENSG00000233264.2	AC006042.8	3.96	8.58e-05	0.00684	0.31	0.18	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8017141	chr7:7980312~7982228:+
THCA	cis	rs6963495	0.818	rs73192105	ENSG00000272604.1	RP11-251G23.5	3.96	8.58e-05	0.00684	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105527498	chr7:105571083~105573660:+
THCA	cis	rs4742903	0.935	rs10739885	ENSG00000270332.1	SMC2-AS1	3.96	8.58e-05	0.00684	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104150611	chr9:104080024~104093073:-
THCA	cis	rs9309473	0.519	rs2421574	ENSG00000273245.1	RP11-434P11.2	-3.96	8.58e-05	0.00684	-0.2	-0.18	Metabolite levels;	chr2:73681640	chr2:73750256~73750786:-
THCA	cis	rs7578199	0.576	rs9679726	ENSG00000223374.1	AC005104.3	-3.96	8.58e-05	0.00684	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241503432	chr2:241351340~241353104:-
THCA	cis	rs6442522	0.526	rs2168428	ENSG00000249786.6	EAF1-AS1	3.96	8.58e-05	0.00684	0.18	0.18	Uric acid levels;	chr3:15487797	chr3:15436171~15455940:-
THCA	cis	rs13118159	0.641	rs4974598	ENSG00000254094.1	AC078852.1	-3.96	8.58e-05	0.00684	-0.2	-0.18	Longevity;	chr4:1319432	chr4:1356581~1358075:+
THCA	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	3.96	8.58e-05	0.00684	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
THCA	cis	rs150992	0.638	rs466340	ENSG00000241597.2	CTD-2007H13.1	-3.96	8.58e-05	0.00684	-0.23	-0.18	Body mass index;	chr5:98904318	chr5:98954394~98954972:+
THCA	cis	rs150992	0.673	rs326463	ENSG00000241597.2	CTD-2007H13.1	-3.96	8.58e-05	0.00684	-0.23	-0.18	Body mass index;	chr5:98905785	chr5:98954394~98954972:+
THCA	cis	rs150992	0.673	rs327792	ENSG00000241597.2	CTD-2007H13.1	-3.96	8.58e-05	0.00684	-0.23	-0.18	Body mass index;	chr5:98909802	chr5:98954394~98954972:+
THCA	cis	rs9834970	0.787	rs11129735	ENSG00000281100.1	RP11-640L9.2	-3.96	8.58e-05	0.00684	-0.18	-0.18	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36828739	chr3:36823151~36825158:-
THCA	cis	rs853679	0.607	rs66868086	ENSG00000272009.1	RP1-313I6.12	-3.96	8.58e-05	0.00684	-0.35	-0.18	Depression;	chr6:27898124	chr6:28078792~28081130:-
THCA	cis	rs2505675	0.563	rs163074	ENSG00000272465.1	RP1-136B1.1	-3.96	8.59e-05	0.00684	-0.25	-0.18	Tuberculosis;	chr6:2215388	chr6:2437549~2438249:+
THCA	cis	rs7586085	0.903	rs62174818	ENSG00000232411.1	AC009495.3	-3.96	8.59e-05	0.00684	-0.2	-0.18	Total body bone mineral density;	chr2:165754496	chr2:165833048~165839098:-
THCA	cis	rs7586085	0.837	rs41268661	ENSG00000232411.1	AC009495.3	-3.96	8.59e-05	0.00684	-0.2	-0.18	Total body bone mineral density;	chr2:165754576	chr2:165833048~165839098:-
THCA	cis	rs150992	0.609	rs4703049	ENSG00000246763.5	RGMB-AS1	3.96	8.59e-05	0.00684	0.18	0.18	Body mass index;	chr5:99004679	chr5:98769618~98773469:-
THCA	cis	rs2898290	0.694	rs2248909	ENSG00000206014.6	OR7E161P	3.96	8.59e-05	0.00684	0.21	0.18	Systolic blood pressure;	chr8:11534584	chr8:11928597~11929563:-
THCA	cis	rs11971779	0.588	rs2003531	ENSG00000252332.1	RNU6-911P	-3.96	8.59e-05	0.00685	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139441832	chr7:139448740~139448843:+
THCA	cis	rs13113518	1	rs4864993	ENSG00000272969.1	RP11-528I4.2	3.96	8.59e-05	0.00685	0.21	0.18	Height;	chr4:55450662	chr4:55547112~55547889:+
THCA	cis	rs6494488	0.5	rs16948182	ENSG00000259635.1	AC100830.3	-3.96	8.59e-05	0.00685	-0.43	-0.18	Coronary artery disease;	chr15:64687183	chr15:64701248~64719602:+
THCA	cis	rs1404100	0.51	rs1038272	ENSG00000240476.1	LINC00973	-3.96	8.59e-05	0.00685	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067685	chr3:98981058~98983096:+
THCA	cis	rs253959	0.607	rs254152	ENSG00000250015.1	CTC-339F2.2	3.96	8.59e-05	0.00685	0.16	0.18	Bipolar disorder and schizophrenia;	chr5:116306130	chr5:116302354~116304134:-
THCA	cis	rs343092	1	rs2947794	ENSG00000241749.4	RPSAP52	3.96	8.59e-05	0.00685	0.2	0.18	Type 2 diabetes;	chr12:65812818	chr12:65758020~65826997:-
THCA	cis	rs12497850	0.931	rs3774628	ENSG00000228638.1	FCF1P2	-3.96	8.6e-05	0.00685	-0.19	-0.18	Parkinson's disease;	chr3:48764407	chr3:48290793~48291375:-
THCA	cis	rs10090774	0.67	rs13273943	ENSG00000279766.1	RP11-642A1.2	-3.96	8.6e-05	0.00685	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140724786	chr8:140572142~140572812:-
THCA	cis	rs13217239	0.574	rs9366680	ENSG00000124549.13	BTN2A3P	3.96	8.6e-05	0.00685	0.17	0.18	Schizophrenia;	chr6:27038344	chr6:26421391~26432383:+
THCA	cis	rs9926296	0.585	rs1800337	ENSG00000274627.1	RP11-104N10.2	-3.96	8.6e-05	0.00685	-0.18	-0.18	Vitiligo;	chr16:89778786	chr16:89516797~89522217:+
THCA	cis	rs2290416	0.892	rs3829012	ENSG00000253931.1	RP11-909N17.2	3.96	8.6e-05	0.00685	0.36	0.18	Attention deficit hyperactivity disorder;	chr8:143582486	chr8:143412749~143417054:+
THCA	cis	rs728616	0.614	rs61859198	ENSG00000278616.1	BEND3P3	3.96	8.6e-05	0.00685	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80354872	chr10:79682997~79685436:+
THCA	cis	rs6479891	0.915	rs16918601	ENSG00000272767.1	JMJD1C-AS1	3.96	8.6e-05	0.00685	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63465229~63466563:+
THCA	cis	rs2446066	0.872	rs2002555	ENSG00000257379.1	RP11-793H13.8	3.96	8.6e-05	0.00685	0.27	0.18	Red blood cell count;	chr12:53423453	chr12:53441741~53467528:+
THCA	cis	rs2434529	0.744	rs78919325	ENSG00000245275.6	SAP30L-AS1	3.96	8.6e-05	0.00685	0.24	0.18	Autism spectrum disorder or schizophrenia;	chr5:154275680	chr5:154329437~154445850:-
THCA	cis	rs854765	0.583	rs8065416	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17947848	chr17:18001101~18001195:-
THCA	cis	rs854765	0.618	rs8066982	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17948063	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs7214536	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17949132	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs8078105	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17950468	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs4257260	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17953689	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs8065970	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17955457	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs4414547	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17955738	chr17:18001101~18001195:-
THCA	cis	rs854765	0.551	rs8070748	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17956107	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs10048206	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17963583	chr17:18001101~18001195:-
THCA	cis	rs854765	0.551	rs12600546	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17964300	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs7213225	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17965797	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs9635697	ENSG00000281749.1	Y_RNA	3.96	8.6e-05	0.00685	0.23	0.18	Total body bone mineral density;	chr17:17967080	chr17:18001101~18001195:-
THCA	cis	rs1023500	0.505	rs134878	ENSG00000182057.4	OGFRP1	3.96	8.6e-05	0.00685	0.21	0.18	Schizophrenia;	chr22:42267868	chr22:42269753~42275196:+
THCA	cis	rs7188445	0.592	rs17767281	ENSG00000277954.1	RP11-679B19.1	-3.96	8.6e-05	0.00685	-0.2	-0.18	Urate levels;	chr16:79708544	chr16:79202624~79206739:-
THCA	cis	rs2221894	0.96	rs4732893	ENSG00000251191.6	LINC00589	3.96	8.61e-05	0.00686	0.22	0.18	Obesity-related traits;	chr8:28937161	chr8:29673922~29748109:-
THCA	cis	rs9291683	0.597	rs11722989	ENSG00000261490.1	RP11-448G15.3	-3.96	8.61e-05	0.00686	-0.11	-0.18	Bone mineral density;	chr4:10124515	chr4:10068089~10073019:-
THCA	cis	rs972578	0.501	rs5759126	ENSG00000274717.1	RP1-47A17.1	-3.96	8.61e-05	0.00686	-0.19	-0.18	Mean platelet volume;	chr22:43059659	chr22:42791814~42794313:-
THCA	cis	rs911555	0.723	rs6575982	ENSG00000269910.1	RP11-73M18.10	-3.96	8.61e-05	0.00686	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103694516~103695050:-
THCA	cis	rs6546886	0.625	rs12991192	ENSG00000217702.2	RP11-287D1.4	-3.96	8.61e-05	0.00686	-0.3	-0.18	Dialysis-related mortality;	chr2:74082539	chr2:74130583~74135395:+
THCA	cis	rs7798970	0.645	rs10253053	ENSG00000225498.1	AC002064.5	-3.96	8.61e-05	0.00686	-0.19	-0.18	Inflammatory skin disease;	chr7:90018748	chr7:90312496~90322592:+
THCA	cis	rs13178541	0.81	rs2304078	ENSG00000250378.1	RP11-119J18.1	-3.96	8.61e-05	0.00686	-0.23	-0.18	IgG glycosylation;	chr5:135852525	chr5:135812667~135826582:+
THCA	cis	rs5751614	1	rs2267020	ENSG00000240160.3	RN7SL263P	3.96	8.61e-05	0.00686	0.2	0.18	Height;	chr22:23250255	chr22:23261782~23262071:-
THCA	cis	rs7403037	0.617	rs11634882	ENSG00000260760.1	PWRN3	-3.96	8.61e-05	0.00686	-0.25	-0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24493092	chr15:24441127~24447967:+
THCA	cis	rs741677	0.826	rs12938729	ENSG00000231784.7	DBIL5P	3.96	8.61e-05	0.00686	0.2	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:572540	chr17:752660~755336:+
THCA	cis	rs853679	0.607	rs35902873	ENSG00000272009.1	RP1-313I6.12	-3.96	8.61e-05	0.00686	-0.34	-0.18	Depression;	chr6:28091171	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13197574	ENSG00000272009.1	RP1-313I6.12	-3.96	8.61e-05	0.00686	-0.34	-0.18	Depression;	chr6:28092461	chr6:28078792~28081130:-
THCA	cis	rs1923243	0.749	rs11210103	ENSG00000223479.3	RP4-788P17.1	3.96	8.61e-05	0.00686	0.19	0.18	Migraine;	chr1:72994094	chr1:73635216~73715214:+
THCA	cis	rs5751614	1	rs5751614	ENSG00000240160.3	RN7SL263P	3.96	8.61e-05	0.00686	0.2	0.18	Height;	chr22:23250864	chr22:23261782~23262071:-
THCA	cis	rs6740462	1	rs6740462	ENSG00000204929.10	AC074391.1	-3.96	8.61e-05	0.00686	-0.26	-0.18	Inflammatory bowel disease;Crohn's disease;	chr2:65440138	chr2:65436711~66084639:+
THCA	cis	rs965513	0.627	rs10124220	ENSG00000214417.4	KRT18P13	-3.96	8.61e-05	0.00686	-0.17	-0.18	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97820792	chr9:97698922~97700734:+
THCA	cis	rs6963495	0.818	rs73192144	ENSG00000272604.1	RP11-251G23.5	3.96	8.61e-05	0.00686	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105563088	chr7:105571083~105573660:+
THCA	cis	rs2348418	0.765	rs10843119	ENSG00000278733.1	RP11-425D17.1	3.96	8.62e-05	0.00686	0.16	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28164675	chr12:28185625~28186190:-
THCA	cis	rs858239	0.899	rs10262243	ENSG00000230042.1	AK3P3	-3.96	8.62e-05	0.00686	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23129178~23129841:+
THCA	cis	rs7166081	0.95	rs12915601	ENSG00000270964.1	RP11-502I4.3	-3.96	8.62e-05	0.00687	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67338933	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs4238407	ENSG00000270964.1	RP11-502I4.3	-3.96	8.62e-05	0.00687	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67341446	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs4776922	ENSG00000270964.1	RP11-502I4.3	-3.96	8.62e-05	0.00687	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67342099	chr15:67541072~67542604:-
THCA	cis	rs763121	0.853	rs5750672	ENSG00000273076.1	RP3-508I15.22	-3.96	8.62e-05	0.00687	-0.18	-0.18	Menopause (age at onset);	chr22:38708163	chr22:38743495~38743910:+
THCA	cis	rs7646881	0.544	rs17630223	ENSG00000240207.5	RP11-379F4.4	3.96	8.62e-05	0.00687	0.28	0.18	Tetralogy of Fallot;	chr3:158661383	chr3:158732263~158784070:+
THCA	cis	rs7713065	1	rs3749833	ENSG00000237714.1	P4HA2-AS1	-3.96	8.62e-05	0.00687	-0.27	-0.18	Lung function (FEV1/FVC);	chr5:132463934	chr5:132184876~132192808:+
THCA	cis	rs6496044	0.568	rs2880765	ENSG00000259407.1	RP11-158M2.3	3.96	8.62e-05	0.00687	0.18	0.18	Interstitial lung disease;	chr15:85513231	chr15:85744109~85750281:-
THCA	cis	rs11123406	0.651	rs11123407	ENSG00000227992.1	AC108463.2	-3.96	8.62e-05	0.00687	-0.22	-0.18	Type 2 diabetes;	chr2:111193017	chr2:111203964~111206215:-
THCA	cis	rs756699	0.514	rs244685	ENSG00000279469.1	RP11-215P8.2	3.96	8.62e-05	0.00687	0.26	0.18	Multiple sclerosis;	chr5:134088199	chr5:134394360~134395008:-
THCA	cis	rs7824557	0.534	rs10092549	ENSG00000254527.1	ENPP7P12	-3.96	8.62e-05	0.00687	-0.21	-0.18	Retinal vascular caliber;	chr8:11231570	chr8:12205759~12206389:-
THCA	cis	rs7809950	0.678	rs2237665	ENSG00000272072.1	CTA-363E19.2	3.96	8.63e-05	0.00687	0.19	0.18	Coronary artery disease;	chr7:107266553	chr7:107192559~107193300:-
THCA	cis	rs7819412	0.806	rs6980856	ENSG00000261451.1	RP11-981G7.1	3.96	8.63e-05	0.00687	0.23	0.18	Triglycerides;	chr8:11080750	chr8:10433672~10438312:+
THCA	cis	rs250518	0.926	rs266428	ENSG00000272081.1	CTD-2376I4.2	-3.96	8.63e-05	0.00687	-0.23	-0.18	Mean corpuscular hemoglobin concentration;	chr5:72832940	chr5:72955206~72955699:-
THCA	cis	rs11779988	0.543	rs379066	ENSG00000253671.1	RP11-806O11.1	-3.96	8.63e-05	0.00687	-0.22	-0.18	Breast cancer;	chr8:18024326	chr8:17808941~17820868:+
THCA	cis	rs9733	0.818	rs4970924	ENSG00000231073.1	RP11-316M1.3	-3.96	8.63e-05	0.00687	-0.22	-0.18	Tonsillectomy;	chr1:150660603	chr1:150973123~150975534:+
THCA	cis	rs7713065	0.765	rs11242112	ENSG00000263597.1	MIR3936	-3.96	8.63e-05	0.00687	-0.22	-0.18	Lung function (FEV1/FVC);	chr5:132432196	chr5:132365490~132365599:-
THCA	cis	rs4908760	0.965	rs1884352	ENSG00000270282.1	RP5-1115A15.2	3.96	8.63e-05	0.00688	0.21	0.18	Vitiligo;	chr1:8477229	chr1:8512653~8513021:+
THCA	cis	rs9611565	0.659	rs4822034	ENSG00000237037.8	NDUFA6-AS1	3.96	8.63e-05	0.00688	0.17	0.18	Vitiligo;	chr22:41535006	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.625	rs9611606	ENSG00000237037.8	NDUFA6-AS1	3.96	8.63e-05	0.00688	0.17	0.18	Vitiligo;	chr22:41535070	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.659	rs116959331	ENSG00000237037.8	NDUFA6-AS1	3.96	8.63e-05	0.00688	0.17	0.18	Vitiligo;	chr22:41536770	chr22:42090931~42137742:+
THCA	cis	rs6121246	0.657	rs74392247	ENSG00000230613.1	HM13-AS1	3.96	8.63e-05	0.00688	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31653934	chr20:31567707~31573263:-
THCA	cis	rs9309473	1	rs7598419	ENSG00000273245.1	RP11-434P11.2	3.96	8.63e-05	0.00688	0.25	0.18	Metabolite levels;	chr2:73571096	chr2:73750256~73750786:-
THCA	cis	rs9834970	0.76	rs4072458	ENSG00000281100.1	RP11-640L9.2	-3.96	8.64e-05	0.00688	-0.18	-0.18	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36821189	chr3:36823151~36825158:-
THCA	cis	rs724818	0.661	rs896060	ENSG00000251609.2	SETP12	3.96	8.64e-05	0.00688	0.49	0.18	Monobrow thickness;	chr4:120826435	chr4:120895494~120897083:-
THCA	cis	rs9810089	0.786	rs10935183	ENSG00000273455.1	RP11-305O4.3	3.96	8.64e-05	0.00688	0.24	0.18	Gestational age at birth (child effect);	chr3:136430297	chr3:136087475~136087913:-
THCA	cis	rs9650657	0.501	rs3021500	ENSG00000261451.1	RP11-981G7.1	-3.96	8.64e-05	0.00688	-0.23	-0.18	Neuroticism;	chr8:11166488	chr8:10433672~10438312:+
THCA	cis	rs72996113	0.536	rs11224445	ENSG00000248027.1	CTD-2383M3.1	-3.96	8.64e-05	0.00688	-0.36	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100786623	chr11:100684162~100687955:-
THCA	cis	rs4742903	1	rs4742903	ENSG00000270332.1	SMC2-AS1	3.96	8.64e-05	0.00688	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104094512	chr9:104080024~104093073:-
THCA	cis	rs2179367	0.959	rs652807	ENSG00000223701.3	RAET1E-AS1	-3.96	8.64e-05	0.00688	-0.23	-0.18	Dupuytren's disease;	chr6:149416359	chr6:149884431~149919508:+
THCA	cis	rs6840360	0.541	rs4696251	ENSG00000251611.1	RP11-610P16.1	-3.96	8.64e-05	0.00688	-0.13	-0.18	Intelligence (multi-trait analysis);	chr4:151345174	chr4:151407551~151408835:-
THCA	cis	rs6688613	0.685	rs2235184	ENSG00000225171.2	DUTP6	3.96	8.64e-05	0.00688	0.26	0.18	Refractive astigmatism;	chr1:166901291	chr1:166868748~166869209:+
THCA	cis	rs9611565	0.512	rs9611672	ENSG00000237037.8	NDUFA6-AS1	3.96	8.64e-05	0.00688	0.18	0.18	Vitiligo;	chr22:41813918	chr22:42090931~42137742:+
THCA	cis	rs7246967	0.611	rs62120273	ENSG00000198153.8	ZNF849P	-3.96	8.65e-05	0.00688	-0.33	-0.18	Bronchopulmonary dysplasia;	chr19:22679518	chr19:22685167~22686732:+
THCA	cis	rs10844706	0.699	rs10844626	ENSG00000214776.8	RP11-726G1.1	3.96	8.65e-05	0.00689	0.23	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733757	chr12:9467552~9576275:+
THCA	cis	rs10844706	0.699	rs10844630	ENSG00000214776.8	RP11-726G1.1	3.96	8.65e-05	0.00689	0.23	0.18	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734268	chr12:9467552~9576275:+
THCA	cis	rs427943	0.83	rs2838799	ENSG00000223768.1	LINC00205	-3.96	8.65e-05	0.00689	-0.16	-0.18	Body mass index;	chr21:45177062	chr21:45293285~45297354:+
THCA	cis	rs6012953	0.56	rs4811079	ENSG00000231715.1	COX6CP2	-3.96	8.65e-05	0.00689	-0.19	-0.18	Vitiligo;	chr20:50540515	chr20:50479767~50479991:+
THCA	cis	rs2455799	0.613	rs2166759	ENSG00000270409.1	RP11-44D5.1	3.96	8.65e-05	0.00689	0.19	0.18	Mean platelet volume;	chr3:15814778	chr3:15732252~15733470:+
THCA	cis	rs4908768	0.501	rs6669503	ENSG00000270282.1	RP5-1115A15.2	3.96	8.65e-05	0.00689	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8512653~8513021:+
THCA	cis	rs6517329	0.866	rs34163237	ENSG00000236830.5	CBR3-AS1	3.96	8.65e-05	0.00689	0.17	0.18	Schizophrenia;	chr21:36114244	chr21:36131767~36175815:-
THCA	cis	rs7402982	0.934	rs6598539	ENSG00000278022.1	RP11-35O15.2	-3.96	8.65e-05	0.00689	-0.19	-0.18	Birth weight;	chr15:98661254	chr15:98660210~98660668:+
THCA	cis	rs2128382	0.556	rs16904166	ENSG00000253720.1	RP11-473O4.3	3.96	8.65e-05	0.00689	0.27	0.18	Colorectal cancer;	chr8:129870623	chr8:129939856~129949394:+
THCA	cis	rs875971	1	rs2077593	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66427543	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs4717292	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66430611	chr7:66409143~66490059:-
THCA	cis	rs875971	0.895	rs10755833	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66448930	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs12668936	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66449417	chr7:66409143~66490059:-
THCA	cis	rs875971	0.895	rs1833495	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66456608	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs6945032	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66457499	chr7:66409143~66490059:-
THCA	cis	rs875971	0.929	rs12673810	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66458866	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs6961155	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66468308	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs7789768	ENSG00000230189.5	GS1-124K5.2	3.96	8.65e-05	0.00689	0.12	0.18	Aortic root size;	chr7:66473993	chr7:66409143~66490059:-
THCA	cis	rs7614311	0.636	rs73117059	ENSG00000271843.1	RP11-245J9.5	-3.96	8.65e-05	0.00689	-0.35	-0.18	Lung function (FVC);Lung function (FEV1);	chr3:63930352	chr3:64008082~64008692:-
THCA	cis	rs9309473	0.948	rs10170849	ENSG00000273245.1	RP11-434P11.2	3.96	8.65e-05	0.00689	0.24	0.18	Metabolite levels;	chr2:73520805	chr2:73750256~73750786:-
THCA	cis	rs7212590	0.618	rs59767604	ENSG00000267302.4	RP11-178C3.2	3.96	8.65e-05	0.00689	0.33	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59963978	chr17:59964832~59996972:+
THCA	cis	rs875971	0.564	rs313804	ENSG00000229886.1	RP5-1132H15.3	3.96	8.65e-05	0.00689	0.19	0.18	Aortic root size;	chr7:66049635	chr7:66025126~66031544:-
THCA	cis	rs6121246	0.738	rs6121242	ENSG00000224628.2	RP5-854E16.2	-3.96	8.66e-05	0.00689	-0.24	-0.18	Mean corpuscular hemoglobin;	chr20:31823074	chr20:31285317~31286835:-
THCA	cis	rs73193808	0.614	rs2832255	ENSG00000176054.6	RPL23P2	-3.96	8.66e-05	0.00689	-0.16	-0.18	Coronary artery disease;	chr21:29191846	chr21:28997613~28998033:-
THCA	cis	rs1150668	0.745	rs213238	ENSG00000220721.1	OR1F12	3.96	8.66e-05	0.00689	0.2	0.18	Pubertal anthropometrics;	chr6:28354216	chr6:28073316~28074233:+
THCA	cis	rs1499614	1	rs1267817	ENSG00000237310.1	GS1-124K5.4	3.96	8.66e-05	0.00689	0.21	0.18	Gout;	chr7:66645053	chr7:66493706~66495474:+
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000237310.1	GS1-124K5.4	3.96	8.66e-05	0.00689	0.21	0.18	Gout;	chr7:66654674	chr7:66493706~66495474:+
THCA	cis	rs1389724	0.648	rs11102158	ENSG00000259834.1	RP11-284N8.3	3.96	8.66e-05	0.0069	0.16	0.18	Schizophrenia;	chr1:110776060	chr1:110653560~110657040:-
THCA	cis	rs10043228	1	rs77856716	ENSG00000248445.4	SEMA6A-AS1	-3.96	8.66e-05	0.0069	-0.25	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116229963	chr5:116447547~116508276:+
THCA	cis	rs3128341	1	rs12139531	ENSG00000227207.2	RPL31P12	3.96	8.66e-05	0.0069	0.28	0.18	Intelligence (multi-trait analysis);	chr1:72362093	chr1:72301472~72301829:+
THCA	cis	rs7264396	0.887	rs4281980	ENSG00000088340.14	FER1L4	3.96	8.66e-05	0.0069	0.16	0.18	Total cholesterol levels;	chr20:35508752	chr20:35558737~35607562:-
THCA	cis	rs16975963	0.793	rs73041034	ENSG00000226686.6	LINC01535	-3.96	8.66e-05	0.0069	-0.25	-0.18	Longevity;	chr19:37795632	chr19:37251912~37265535:+
THCA	cis	rs1387259	0.619	rs7134565	ENSG00000240399.1	RP1-228P16.1	-3.96	8.66e-05	0.0069	-0.16	-0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48054813~48055591:-
THCA	cis	rs1387259	0.619	rs2130095	ENSG00000240399.1	RP1-228P16.1	-3.96	8.66e-05	0.0069	-0.16	-0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48054813~48055591:-
THCA	cis	rs6138458	0.701	rs6138474	ENSG00000274173.1	RP4-568C11.4	3.96	8.66e-05	0.0069	0.15	0.18	Blood protein levels;	chr20:25031791	chr20:24931840~24932983:+
THCA	cis	rs7899106	1	rs60077596	ENSG00000270002.1	RP11-93H12.4	3.96	8.66e-05	0.0069	0.31	0.18	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85588487	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs12569677	ENSG00000270002.1	RP11-93H12.4	3.96	8.66e-05	0.0069	0.31	0.18	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85592608	chr10:85644073~85648066:+
THCA	cis	rs7899106	0.881	rs56996983	ENSG00000270002.1	RP11-93H12.4	3.96	8.66e-05	0.0069	0.31	0.18	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85593412	chr10:85644073~85648066:+
THCA	cis	rs7899106	1	rs80185028	ENSG00000270002.1	RP11-93H12.4	3.96	8.66e-05	0.0069	0.31	0.18	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85594953	chr10:85644073~85648066:+
THCA	cis	rs2235642	0.717	rs2236269	ENSG00000260989.1	LA16c-395F10.2	-3.96	8.66e-05	0.0069	-0.18	-0.18	Coronary artery disease;	chr16:1602613	chr16:1580527~1610328:+
THCA	cis	rs7246967	0.544	rs400275	ENSG00000198153.8	ZNF849P	-3.96	8.66e-05	0.0069	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22833054	chr19:22685167~22686732:+
THCA	cis	rs13434995	0.513	rs17779627	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55483775	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs55729020	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55491681	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs3805156	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55497925	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62303731	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55499667	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62303732	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55499868	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs56196624	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55500340	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62305264	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55502968	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62305268	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55506991	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62305270	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55507842	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs7681414	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55508890	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs62305271	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55509715	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs10462033	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55511552	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs1915905	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55512381	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs1522109	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.67e-05	0.0069	-0.26	-0.18	Adiponectin levels;	chr4:55514403	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs6554282	ENSG00000249700.7	SRD5A3-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Adiponectin levels;	chr4:55519812	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs6554283	ENSG00000249700.7	SRD5A3-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Adiponectin levels;	chr4:55521053	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs1546004	ENSG00000249700.7	SRD5A3-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Adiponectin levels;	chr4:55521612	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs4865006	ENSG00000249700.7	SRD5A3-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Adiponectin levels;	chr4:55526112	chr4:55363971~55395847:-
THCA	cis	rs6121246	0.954	rs6089093	ENSG00000230613.1	HM13-AS1	3.96	8.67e-05	0.0069	0.2	0.18	Mean corpuscular hemoglobin;	chr20:31833656	chr20:31567707~31573263:-
THCA	cis	rs9283706	0.901	rs10471695	ENSG00000229666.1	MAST4-AS1	-3.96	8.67e-05	0.0069	-0.25	-0.18	Coronary artery disease;	chr5:66988774	chr5:67001383~67003953:-
THCA	cis	rs7737355	0.947	rs10054733	ENSG00000237714.1	P4HA2-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Life satisfaction;	chr5:131653733	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs31583	ENSG00000237714.1	P4HA2-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Life satisfaction;	chr5:131656739	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs31584	ENSG00000237714.1	P4HA2-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Life satisfaction;	chr5:131657431	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs9327620	ENSG00000237714.1	P4HA2-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Life satisfaction;	chr5:131660758	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.898	rs31590	ENSG00000237714.1	P4HA2-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Life satisfaction;	chr5:131669488	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.898	rs26007	ENSG00000237714.1	P4HA2-AS1	3.96	8.67e-05	0.0069	0.26	0.18	Life satisfaction;	chr5:131670663	chr5:132184876~132192808:+
THCA	cis	rs2235642	0.785	rs1057983	ENSG00000260989.1	LA16c-395F10.2	-3.96	8.67e-05	0.0069	-0.18	-0.18	Coronary artery disease;	chr16:1610273	chr16:1580527~1610328:+
THCA	cis	rs7554547	0.703	rs7543258	ENSG00000199347.1	RNU5E-1	-3.96	8.67e-05	0.0069	-0.24	-0.18	Nonsyndromic cleft lip with cleft palate;	chr1:11901599	chr1:11908152~11908271:+
THCA	cis	rs17301013	0.932	rs6425281	ENSG00000270084.1	GAS5-AS1	-3.96	8.67e-05	0.0069	-0.19	-0.18	Systemic lupus erythematosus;	chr1:174449784	chr1:173863248~173863941:+
THCA	cis	rs1371614	0.632	rs4665363	ENSG00000272148.1	RP11-195B17.1	-3.96	8.67e-05	0.0069	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26933548	chr2:27062428~27062907:-
THCA	cis	rs1385374	0.698	rs35984395	ENSG00000274695.1	RP11-21K12.3	3.96	8.67e-05	0.0069	0.37	0.18	Systemic lupus erythematosus;	chr12:128842839	chr12:128826836~128827579:+
THCA	cis	rs1385374	0.764	rs36068387	ENSG00000274695.1	RP11-21K12.3	3.96	8.67e-05	0.0069	0.37	0.18	Systemic lupus erythematosus;	chr12:128844073	chr12:128826836~128827579:+
THCA	cis	rs11089937	0.929	rs5750624	ENSG00000263366.2	LL22NC03-33B6.4	-3.96	8.67e-05	0.0069	-0.22	-0.18	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22114844~22118005:-
THCA	cis	rs12410462	0.591	rs67676707	ENSG00000227711.2	RP11-275O4.5	-3.96	8.67e-05	0.0069	-0.22	-0.18	Major depressive disorder;	chr1:227579464	chr1:227509028~227520477:-
THCA	cis	rs13098911	0.54	rs13093179	ENSG00000226074.4	PRSS44	-3.96	8.67e-05	0.0069	-0.34	-0.18	Celiac disease;	chr3:46104822	chr3:46809359~46812558:-
THCA	cis	rs3770081	1	rs2118521	ENSG00000272564.1	RP11-548P2.2	-3.96	8.67e-05	0.0069	-0.34	-0.18	Facial emotion recognition (sad faces);	chr2:85977256	chr2:85904279~85904727:+
THCA	cis	rs36093844	0.576	rs17745153	ENSG00000279742.1	RP11-700A24.1	-3.96	8.67e-05	0.0069	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86012484	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.626	rs4944552	ENSG00000279742.1	RP11-700A24.1	-3.96	8.67e-05	0.0069	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86012763	chr11:85852557~85854943:-
THCA	cis	rs343092	0.935	rs2583943	ENSG00000241749.4	RPSAP52	3.96	8.68e-05	0.00691	0.21	0.18	Type 2 diabetes;	chr12:65806970	chr12:65758020~65826997:-
THCA	cis	rs6121246	0.908	rs6089094	ENSG00000230613.1	HM13-AS1	3.96	8.68e-05	0.00691	0.19	0.18	Mean corpuscular hemoglobin;	chr20:31843968	chr20:31567707~31573263:-
THCA	cis	rs9926296	0.607	rs11076629	ENSG00000274627.1	RP11-104N10.2	-3.96	8.68e-05	0.00691	-0.18	-0.18	Vitiligo;	chr16:89808851	chr16:89516797~89522217:+
THCA	cis	rs35740288	0.752	rs11635956	ENSG00000259407.1	RP11-158M2.3	-3.96	8.68e-05	0.00691	-0.22	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85736697	chr15:85744109~85750281:-
THCA	cis	rs34975555	0.616	rs7839778	ENSG00000253671.1	RP11-806O11.1	-3.96	8.68e-05	0.00691	-0.26	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17941483	chr8:17808941~17820868:+
THCA	cis	rs10090774	0.71	rs9324533	ENSG00000279766.1	RP11-642A1.2	-3.96	8.68e-05	0.00691	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140681905	chr8:140572142~140572812:-
THCA	cis	rs4808779	0.847	rs8113367	ENSG00000268650.3	AC068499.10	-3.96	8.68e-05	0.00691	-0.18	-0.18	Granulocyte percentage of myeloid white cells;	chr19:18277440	chr19:18204730~18220480:+
THCA	cis	rs4808779	0.924	rs4531856	ENSG00000268650.3	AC068499.10	-3.96	8.68e-05	0.00691	-0.18	-0.18	Granulocyte percentage of myeloid white cells;	chr19:18277573	chr19:18204730~18220480:+
THCA	cis	rs7166081	1	rs4776913	ENSG00000270964.1	RP11-502I4.3	-3.96	8.68e-05	0.00691	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67288018	chr15:67541072~67542604:-
THCA	cis	rs868036	0.718	rs4776984	ENSG00000270964.1	RP11-502I4.3	-3.96	8.68e-05	0.00691	-0.16	-0.18	Restless legs syndrome;	chr15:67825856	chr15:67541072~67542604:-
THCA	cis	rs10833905	1	rs11026927	ENSG00000246225.5	RP11-17A1.3	-3.96	8.68e-05	0.00691	-0.25	-0.18	Sudden cardiac arrest;	chr11:23035103	chr11:22829380~22945393:+
THCA	cis	rs10833905	1	rs10833916	ENSG00000246225.5	RP11-17A1.3	-3.96	8.68e-05	0.00691	-0.25	-0.18	Sudden cardiac arrest;	chr11:23036779	chr11:22829380~22945393:+
THCA	cis	rs10833905	1	rs7934818	ENSG00000246225.5	RP11-17A1.3	-3.96	8.68e-05	0.00691	-0.25	-0.18	Sudden cardiac arrest;	chr11:23039003	chr11:22829380~22945393:+
THCA	cis	rs7824557	0.527	rs2736296	ENSG00000154316.13	TDH	3.96	8.68e-05	0.00691	0.13	0.18	Retinal vascular caliber;	chr8:11377335	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.51	rs2736297	ENSG00000154316.13	TDH	3.96	8.68e-05	0.00691	0.13	0.18	Retinal vascular caliber;	chr8:11377376	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.527	rs2736298	ENSG00000154316.13	TDH	3.96	8.68e-05	0.00691	0.13	0.18	Retinal vascular caliber;	chr8:11377627	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.527	rs57629785	ENSG00000154316.13	TDH	3.96	8.68e-05	0.00691	0.13	0.18	Retinal vascular caliber;	chr8:11377641	chr8:11339637~11368452:+
THCA	cis	rs4713118	0.824	rs2179095	ENSG00000220721.1	OR1F12	-3.96	8.68e-05	0.00691	-0.24	-0.18	Parkinson's disease;	chr6:27783079	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.866	rs2179094	ENSG00000220721.1	OR1F12	3.96	8.68e-05	0.00691	0.24	0.18	Parkinson's disease;	chr6:27774046	chr6:28073316~28074233:+
THCA	cis	rs4947019	1	rs4947019	ENSG00000260273.1	RP11-425D10.10	3.96	8.68e-05	0.00691	0.32	0.18	Hematological parameters;	chr6:109768846	chr6:109382795~109383666:+
THCA	cis	rs1520333	0.54	rs12679690	ENSG00000254352.1	RP11-578O24.2	-3.96	8.68e-05	0.00691	-0.21	-0.18	Multiple sclerosis;	chr8:78454599	chr8:78723796~78724136:-
THCA	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	3.96	8.69e-05	0.00691	0.21	0.18	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	3.96	8.69e-05	0.00691	0.21	0.18	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
THCA	cis	rs10484434	0.792	rs3819406	ENSG00000272462.2	U91328.19	3.96	8.69e-05	0.00691	0.2	0.18	HIV-1 viral setpoint;	chr6:26136593	chr6:25992662~26001775:+
THCA	cis	rs67478160	0.595	rs12433109	ENSG00000269940.1	RP11-73M18.7	3.96	8.69e-05	0.00691	0.17	0.18	Schizophrenia;	chr14:103730270	chr14:103694560~103695170:+
THCA	cis	rs7727544	0.606	rs2631360	ENSG00000263597.1	MIR3936	3.96	8.69e-05	0.00691	0.17	0.18	Blood metabolite levels;	chr5:132371737	chr5:132365490~132365599:-
THCA	cis	rs72843506	0.586	rs73296067	ENSG00000231258.2	ZSWIM5P2	3.96	8.69e-05	0.00691	0.28	0.18	Schizophrenia;	chr17:19976988	chr17:20583758~20591180:-
THCA	cis	rs6088813	1	rs224333	ENSG00000279253.1	RP4-614O4.13	-3.96	8.69e-05	0.00692	-0.18	-0.18	Height;	chr20:35436182	chr20:35262727~35264187:-
THCA	cis	rs4906332	1	rs11541718	ENSG00000244691.1	RPL10AP1	-3.96	8.69e-05	0.00692	-0.23	-0.18	Coronary artery disease;	chr14:103385827	chr14:103412119~103412761:-
THCA	cis	rs911555	0.755	rs2756132	ENSG00000269958.1	RP11-73M18.8	-3.96	8.69e-05	0.00692	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103696353~103697163:+
THCA	cis	rs79040073	0.765	rs7169304	ENSG00000259531.2	RP11-295H24.3	3.96	8.69e-05	0.00692	0.22	0.18	Lung cancer in ever smokers;	chr15:49186829	chr15:49365124~49366685:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000275400.1	RP4-756H11.5	3.96	8.69e-05	0.00692	0.17	0.18	Aortic root size;	chr7:66603522	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs7807944	ENSG00000275400.1	RP4-756H11.5	3.96	8.69e-05	0.00692	0.17	0.18	Aortic root size;	chr7:66622208	chr7:66553805~66554199:-
THCA	cis	rs875971	0.638	rs35986979	ENSG00000275400.1	RP4-756H11.5	3.96	8.69e-05	0.00692	0.17	0.18	Aortic root size;	chr7:66624003	chr7:66553805~66554199:-
THCA	cis	rs7772697	0.508	rs17669546	ENSG00000223701.3	RAET1E-AS1	-3.96	8.7e-05	0.00692	-0.26	-0.18	Diabetic retinopathy;	chr6:149041066	chr6:149884431~149919508:+
THCA	cis	rs2657294	0.796	rs7082123	ENSG00000226051.5	ZNF503-AS1	-3.96	8.7e-05	0.00692	-0.25	-0.18	Pneumonia;	chr10:75091101	chr10:75269819~75373500:+
THCA	cis	rs80130819	1	rs2087343	ENSG00000226413.2	OR8T1P	3.96	8.7e-05	0.00692	0.36	0.18	Prostate cancer;	chr12:48282000	chr12:48442030~48442947:-
THCA	cis	rs7119	0.604	rs2682921	ENSG00000259362.2	RP11-307C19.1	3.96	8.7e-05	0.00692	0.25	0.18	Type 2 diabetes;	chr15:77573117	chr15:77525540~77534110:+
THCA	cis	rs763121	0.853	rs10135	ENSG00000228274.3	RP3-508I15.9	3.96	8.7e-05	0.00692	0.2	0.18	Menopause (age at onset);	chr22:38686169	chr22:38667585~38681820:-
THCA	cis	rs9925964	0.687	rs12917722	ENSG00000260911.2	RP11-196G11.2	-3.96	8.7e-05	0.00692	-0.14	-0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30937076	chr16:31043150~31049868:+
THCA	cis	rs2692947	0.537	rs1364394	ENSG00000168992.4	OR7E102P	-3.96	8.7e-05	0.00692	-0.22	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95529982	chr2:95546531~95547545:+
THCA	cis	rs4792901	0.719	rs28678593	ENSG00000267151.3	RP11-100E5.2	3.96	8.7e-05	0.00692	0.19	0.18	Dupuytren's disease;	chr17:43568307	chr17:43444707~43451200:+
THCA	cis	rs4845570	1	rs3811415	ENSG00000249602.1	RP11-98D18.3	-3.96	8.7e-05	0.00692	-0.28	-0.18	Coronary artery disease;	chr1:151791291	chr1:151763384~151769501:-
THCA	cis	rs2251188	0.632	rs940874	ENSG00000187953.9	PMS2CL	-3.96	8.7e-05	0.00692	-0.2	-0.18	Sum basophil neutrophil counts;Neutrophil count;	chr7:6656703	chr7:6710128~6753862:+
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000272831.1	RP11-792A8.4	3.96	8.7e-05	0.00692	0.11	0.18	Calcium levels;	chr7:65829754	chr7:66739829~66740385:-
THCA	cis	rs862034	0.509	rs12586772	ENSG00000270000.1	RP3-449M8.9	3.96	8.7e-05	0.00692	0.18	0.18	Height;	chr14:74465938	chr14:74471930~74472360:-
THCA	cis	rs448720	0.967	rs338358	ENSG00000260657.2	RP11-315D16.4	-3.96	8.71e-05	0.00693	-0.22	-0.18	Cognitive performance;	chr15:67902716	chr15:68267792~68277994:-
THCA	cis	rs448720	1	rs338359	ENSG00000260657.2	RP11-315D16.4	-3.96	8.71e-05	0.00693	-0.22	-0.18	Cognitive performance;	chr15:67902731	chr15:68267792~68277994:-
THCA	cis	rs7914558	1	rs7896547	ENSG00000213061.2	PFN1P11	3.96	8.71e-05	0.00693	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.933	rs2066323	ENSG00000213061.2	PFN1P11	3.96	8.71e-05	0.00693	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs7899084	ENSG00000213061.2	PFN1P11	3.96	8.71e-05	0.00693	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:102838011~102845473:-
THCA	cis	rs4081724	0.565	rs56355036	ENSG00000267296.2	CEBPA-AS1	3.96	8.71e-05	0.00693	0.29	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33306352	chr19:33302857~33305054:+
THCA	cis	rs7615952	0.604	rs9837847	ENSG00000272840.1	RP11-379B18.6	3.96	8.71e-05	0.00693	0.34	0.18	Blood pressure (smoking interaction);	chr3:125905076	chr3:125774714~125797953:+
THCA	cis	rs61160187	0.582	rs7723901	ENSG00000272308.1	RP11-231G3.1	-3.96	8.71e-05	0.00693	-0.17	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60866457~60866935:-
THCA	cis	rs801193	0.967	rs3800823	ENSG00000232546.1	RP11-458F8.1	3.96	8.71e-05	0.00693	0.15	0.18	Aortic root size;	chr7:66682123	chr7:66848496~66858136:+
THCA	cis	rs1411478	1	rs3789362	ENSG00000243155.1	RP11-46A10.5	3.96	8.71e-05	0.00693	0.19	0.18	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180982556	chr1:180944042~180976482:-
THCA	cis	rs2721195	1	rs750472	ENSG00000265393.1	CTD-2517M22.17	3.96	8.71e-05	0.00693	0.22	0.18	Age at first birth;	chr8:144476070	chr8:144512567~144513672:+
THCA	cis	rs11992162	0.591	rs35657308	ENSG00000227888.4	FAM66A	-3.96	8.71e-05	0.00693	-0.23	-0.18	Monocyte count;	chr8:11946893	chr8:12362019~12388296:+
THCA	cis	rs9341808	0.905	rs9343977	ENSG00000272129.1	RP11-250B2.6	3.96	8.71e-05	0.00693	0.22	0.18	Sitting height ratio;	chr6:80257284	chr6:80355424~80356859:+
THCA	cis	rs3738443	0.569	rs6704060	ENSG00000259865.1	RP11-488L18.10	3.96	8.71e-05	0.00693	0.16	0.18	Alcohol dependence;	chr1:247218222	chr1:247187281~247188526:-
THCA	cis	rs9650657	0.812	rs10107289	ENSG00000255310.2	AF131215.2	-3.96	8.71e-05	0.00693	-0.15	-0.18	Neuroticism;	chr8:10776738	chr8:11107788~11109726:-
THCA	cis	rs12134133	1	rs1429904	ENSG00000237074.1	RP11-6J21.2	3.96	8.71e-05	0.00693	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.962	rs2564970	ENSG00000237074.1	RP11-6J21.2	3.96	8.71e-05	0.00693	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs2782851	ENSG00000237074.1	RP11-6J21.2	3.96	8.71e-05	0.00693	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs2782850	ENSG00000237074.1	RP11-6J21.2	3.96	8.71e-05	0.00693	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207249067~207309121:+
THCA	cis	rs15676	0.561	rs10739736	ENSG00000234771.3	SLC25A25-AS1	3.96	8.71e-05	0.00693	0.15	0.18	Blood metabolite levels;	chr9:128815702	chr9:128108581~128118693:-
THCA	cis	rs34779708	0.733	rs60616028	ENSG00000233200.1	RP11-324I22.2	3.96	8.71e-05	0.00693	0.23	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35254874	chr10:35219894~35230598:-
THCA	cis	rs7119	0.635	rs2667764	ENSG00000259362.2	RP11-307C19.1	3.96	8.72e-05	0.00693	0.23	0.18	Type 2 diabetes;	chr15:77588897	chr15:77525540~77534110:+
THCA	cis	rs2638953	0.815	rs1534340	ENSG00000247934.4	RP11-967K21.1	-3.96	8.72e-05	0.00693	-0.18	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28515550	chr12:28163298~28190738:-
THCA	cis	rs1383484	1	rs4465575	ENSG00000225151.9	GOLGA2P7	3.96	8.72e-05	0.00693	0.24	0.18	Height;	chr15:83844160	chr15:84199311~84230136:-
THCA	cis	rs4713118	0.868	rs9468220	ENSG00000261839.1	RP1-265C24.8	-3.96	8.72e-05	0.00693	-0.22	-0.18	Parkinson's disease;	chr6:27765197	chr6:28136849~28139678:+
THCA	cis	rs240993	0.595	rs3777910	ENSG00000271789.1	RP5-1112D6.7	3.96	8.72e-05	0.00693	0.19	0.18	Inflammatory skin disease;Psoriasis;	chr6:111581248	chr6:111297126~111298510:+
THCA	cis	rs7430456	0.81	rs6443489	ENSG00000231574.4	RP11-91K9.1	-3.96	8.72e-05	0.00694	-0.24	-0.18	Breast cancer;	chr3:177737489	chr3:177816865~177899224:+
THCA	cis	rs1124769	0.57	rs2574757	ENSG00000273674.3	CTD-2378E12.1	3.96	8.72e-05	0.00694	0.24	0.18	Cognitive performance;	chr15:50846263	chr15:50839875~50908599:-
THCA	cis	rs12544026	0.581	rs485252	ENSG00000253669.3	KB-1732A1.1	-3.96	8.72e-05	0.00694	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101880461	chr8:102805517~102809971:+
THCA	cis	rs7824557	0.564	rs2572389	ENSG00000154316.13	TDH	3.96	8.72e-05	0.00694	0.13	0.18	Retinal vascular caliber;	chr8:11378883	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs2736301	ENSG00000154316.13	TDH	3.96	8.72e-05	0.00694	0.13	0.18	Retinal vascular caliber;	chr8:11378904	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs2736302	ENSG00000154316.13	TDH	3.96	8.72e-05	0.00694	0.13	0.18	Retinal vascular caliber;	chr8:11378910	chr8:11339637~11368452:+
THCA	cis	rs3808502	0.647	rs7821302	ENSG00000154316.13	TDH	3.96	8.72e-05	0.00694	0.13	0.18	Neuroticism;	chr8:11379063	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs7821459	ENSG00000154316.13	TDH	3.96	8.72e-05	0.00694	0.13	0.18	Retinal vascular caliber;	chr8:11379172	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs7834572	ENSG00000154316.13	TDH	3.96	8.72e-05	0.00694	0.13	0.18	Retinal vascular caliber;	chr8:11379176	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs4631424	ENSG00000154316.13	TDH	3.96	8.72e-05	0.00694	0.13	0.18	Retinal vascular caliber;	chr8:11379300	chr8:11339637~11368452:+
THCA	cis	rs2657294	0.895	rs4746262	ENSG00000233313.2	HMGA1P5	-3.96	8.72e-05	0.00694	-0.24	-0.18	Pneumonia;	chr10:75093631	chr10:75276376~75276646:-
THCA	cis	rs17597773	0.638	rs17596850	ENSG00000272823.1	RP11-295M18.6	-3.96	8.72e-05	0.00694	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220819001	chr1:220828676~220829211:-
THCA	cis	rs734999	0.505	rs10797437	ENSG00000225931.3	RP3-395M20.7	3.96	8.72e-05	0.00694	0.21	0.18	Ulcerative colitis;	chr1:2607567	chr1:2566410~2569888:+
THCA	cis	rs734999	0.505	rs10910107	ENSG00000225931.3	RP3-395M20.7	3.96	8.72e-05	0.00694	0.21	0.18	Ulcerative colitis;	chr1:2607742	chr1:2566410~2569888:+
THCA	cis	rs734999	0.505	rs4073286	ENSG00000225931.3	RP3-395M20.7	3.96	8.72e-05	0.00694	0.21	0.18	Ulcerative colitis;	chr1:2608462	chr1:2566410~2569888:+
THCA	cis	rs734999	0.505	rs10797438	ENSG00000225931.3	RP3-395M20.7	3.96	8.72e-05	0.00694	0.21	0.18	Ulcerative colitis;	chr1:2608823	chr1:2566410~2569888:+
THCA	cis	rs6667605	0.527	rs12046118	ENSG00000225931.3	RP3-395M20.7	3.96	8.72e-05	0.00694	0.21	0.18	Ulcerative colitis;Inflammatory bowel disease;	chr1:2608904	chr1:2566410~2569888:+
THCA	cis	rs734999	0.505	rs10797439	ENSG00000225931.3	RP3-395M20.7	3.96	8.72e-05	0.00694	0.21	0.18	Ulcerative colitis;	chr1:2608925	chr1:2566410~2569888:+
THCA	cis	rs6667605	0.506	rs10797440	ENSG00000225931.3	RP3-395M20.7	3.96	8.72e-05	0.00694	0.21	0.18	Ulcerative colitis;Inflammatory bowel disease;	chr1:2609830	chr1:2566410~2569888:+
THCA	cis	rs964611	0.935	rs8029972	ENSG00000259488.2	RP11-154J22.1	-3.96	8.72e-05	0.00694	-0.2	-0.18	Metabolite levels (Pyroglutamine);	chr15:48285970	chr15:48312353~48331856:-
THCA	cis	rs13434995	0.513	rs17776975	ENSG00000249700.7	SRD5A3-AS1	-3.96	8.72e-05	0.00694	-0.25	-0.18	Adiponectin levels;	chr4:55410728	chr4:55363971~55395847:-
THCA	cis	rs6137726	0.508	rs6036168	ENSG00000237396.1	LINC01384	3.96	8.72e-05	0.00694	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22662688	chr20:22587522~22607517:-
THCA	cis	rs2721195	0.719	rs4925812	ENSG00000265393.1	CTD-2517M22.17	-3.96	8.72e-05	0.00694	-0.22	-0.18	Age at first birth;	chr8:144582651	chr8:144512567~144513672:+
THCA	cis	rs6142618	0.562	rs6089193	ENSG00000224452.1	RSL24D1P6	3.96	8.73e-05	0.00694	0.21	0.18	Inflammatory bowel disease;	chr20:32141685	chr20:32170390~32170790:-
THCA	cis	rs17772222	0.682	rs1152377	ENSG00000222990.1	RNU4-22P	-3.96	8.73e-05	0.00694	-0.22	-0.18	Coronary artery calcification;	chr14:88496243	chr14:88513498~88513663:+
THCA	cis	rs2732480	0.577	rs2634680	ENSG00000257735.1	RP11-370I10.6	3.96	8.73e-05	0.00694	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48350945~48442411:+
THCA	cis	rs7267979	0.934	rs4815423	ENSG00000276952.1	RP5-965G21.6	-3.96	8.73e-05	0.00694	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25284915~25285588:-
THCA	cis	rs4792901	0.759	rs1382685	ENSG00000267151.3	RP11-100E5.2	3.96	8.73e-05	0.00694	0.2	0.18	Dupuytren's disease;	chr17:43485783	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.765	rs9894019	ENSG00000267151.3	RP11-100E5.2	3.96	8.73e-05	0.00694	0.2	0.18	Dupuytren's disease;	chr17:43488137	chr17:43444707~43451200:+
THCA	cis	rs4671400	0.571	rs62152270	ENSG00000271889.1	RP11-493E12.1	-3.96	8.73e-05	0.00694	-0.2	-0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267125	chr2:61151433~61162105:-
THCA	cis	rs586688	0.625	rs601757	ENSG00000224536.1	RP11-134G8.7	-3.96	8.73e-05	0.00694	-0.27	-0.18	Obesity-related traits;	chr1:201688380	chr1:201507241~201533608:+
THCA	cis	rs793571	0.568	rs6494029	ENSG00000245975.2	RP11-30K9.6	3.96	8.73e-05	0.00694	0.17	0.18	Schizophrenia;	chr15:58631007	chr15:58768072~58770974:-
THCA	cis	rs34421088	0.56	rs1478898	ENSG00000206014.6	OR7E161P	3.96	8.73e-05	0.00694	0.21	0.18	Neuroticism;	chr8:11537570	chr8:11928597~11929563:-
THCA	cis	rs6929812	1	rs6456785	ENSG00000271755.1	RP1-153G14.4	3.96	8.73e-05	0.00694	0.2	0.18	Neuroticism (multi-trait analysis);	chr6:27422620	chr6:27404010~27406964:-
THCA	cis	rs6963495	0.818	rs117845382	ENSG00000272604.1	RP11-251G23.5	3.96	8.73e-05	0.00694	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105511593	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs116457537	ENSG00000272604.1	RP11-251G23.5	3.96	8.73e-05	0.00694	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105511625	chr7:105571083~105573660:+
THCA	cis	rs2692947	0.509	rs4907303	ENSG00000235584.2	AC008268.1	-3.96	8.73e-05	0.00694	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95551486	chr2:95666084~95668715:+
THCA	cis	rs12544026	0.581	rs1144545	ENSG00000253669.3	KB-1732A1.1	-3.96	8.73e-05	0.00694	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101877873	chr8:102805517~102809971:+
THCA	cis	rs4908768	0.871	rs4908775	ENSG00000232912.4	RP5-1115A15.1	-3.96	8.73e-05	0.00694	-0.21	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8734351	chr1:8424645~8434838:+
THCA	cis	rs2033711	0.87	rs3764534	ENSG00000268049.1	CTD-2619J13.9	-3.96	8.73e-05	0.00694	-0.22	-0.18	Uric acid clearance;	chr19:58417769	chr19:58357999~58359603:+
THCA	cis	rs4908769	0.627	rs2252865	ENSG00000232912.4	RP5-1115A15.1	-3.96	8.73e-05	0.00695	-0.2	-0.18	Allergy;	chr1:8362616	chr1:8424645~8434838:+
THCA	cis	rs9309473	1	rs10187192	ENSG00000273245.1	RP11-434P11.2	3.96	8.73e-05	0.00695	0.25	0.18	Metabolite levels;	chr2:73486373	chr2:73750256~73750786:-
THCA	cis	rs4746818	1	rs7899844	ENSG00000229001.1	ACTBP14	-3.96	8.73e-05	0.00695	-0.29	-0.18	Left atrial antero-posterior diameter;	chr10:69189938	chr10:69022778~69023866:+
THCA	cis	rs4746818	1	rs10823313	ENSG00000229001.1	ACTBP14	-3.96	8.73e-05	0.00695	-0.29	-0.18	Left atrial antero-posterior diameter;	chr10:69192359	chr10:69022778~69023866:+
THCA	cis	rs17723470	0.885	rs7940871	ENSG00000254427.1	RP11-430H10.1	3.96	8.74e-05	0.00695	0.2	0.18	Thyroid hormone levels;	chr11:45206279	chr11:45355371~45366121:+
THCA	cis	rs4948275	0.597	rs2650712	ENSG00000237233.2	TMEM26-AS1	-3.96	8.74e-05	0.00695	-0.23	-0.18	Night sleep phenotypes;	chr10:61605901	chr10:61452639~61481956:+
THCA	cis	rs7615304	0.617	rs2054880	ENSG00000243926.1	TIPARP-AS1	-3.96	8.74e-05	0.00695	-0.18	-0.18	Interleukin-2 levels;	chr3:156782192	chr3:156671862~156674378:-
THCA	cis	rs2736345	0.788	rs9693589	ENSG00000254527.1	ENPP7P12	3.96	8.74e-05	0.00695	0.24	0.18	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491452	chr8:12205759~12206389:-
THCA	cis	rs2736345	0.788	rs13277113	ENSG00000254527.1	ENPP7P12	3.96	8.74e-05	0.00695	0.24	0.18	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491677	chr8:12205759~12206389:-
THCA	cis	rs7578199	0.576	rs3771586	ENSG00000223374.1	AC005104.3	-3.96	8.74e-05	0.00695	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241461587	chr2:241351340~241353104:-
THCA	cis	rs962856	0.575	rs3770657	ENSG00000236780.4	AC078941.1	3.96	8.74e-05	0.00695	0.24	0.18	Pancreatic cancer;	chr2:67403848	chr2:67123357~67215319:-
THCA	cis	rs2806561	0.765	rs1757046	ENSG00000249087.5	ZNF436-AS1	-3.96	8.74e-05	0.00695	-0.12	-0.18	Height;	chr1:23185328	chr1:23368997~23371839:+
THCA	cis	rs4767841	0.565	rs433091	ENSG00000248636.5	RP11-768F21.1	3.96	8.74e-05	0.00695	0.18	0.18	Urgency urinary incontinence;	chr12:119790988	chr12:119387987~119668079:-
THCA	cis	rs10089	1	rs3792866	ENSG00000245937.6	LINC01184	3.96	8.74e-05	0.00695	0.2	0.18	Ileal carcinoids;	chr5:128144208	chr5:127940426~128083172:-
THCA	cis	rs2562456	0.833	rs11666447	ENSG00000268278.1	RP11-420K14.1	3.96	8.74e-05	0.00695	0.25	0.18	Pain;	chr19:21416270	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs11666525	ENSG00000268278.1	RP11-420K14.1	3.96	8.74e-05	0.00695	0.25	0.18	Pain;	chr19:21416503	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs62110424	ENSG00000268278.1	RP11-420K14.1	3.96	8.74e-05	0.00695	0.25	0.18	Pain;	chr19:21416835	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs3853837	ENSG00000268278.1	RP11-420K14.1	3.96	8.74e-05	0.00695	0.25	0.18	Pain;	chr19:21419172	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs3853838	ENSG00000268278.1	RP11-420K14.1	3.96	8.74e-05	0.00695	0.25	0.18	Pain;	chr19:21419192	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62110426	ENSG00000268278.1	RP11-420K14.1	3.96	8.74e-05	0.00695	0.25	0.18	Pain;	chr19:21420124	chr19:21637974~21656300:+
THCA	cis	rs10792320	1	rs3758977	ENSG00000279491.1	RP11-810P12.7	-3.96	8.74e-05	0.00695	-0.19	-0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61969772	chr11:61967794~61969490:+
THCA	cis	rs6430538	0.621	rs4953933	ENSG00000224043.6	CCNT2-AS1	-3.96	8.74e-05	0.00695	-0.19	-0.18	Parkinson's disease;	chr2:134786014	chr2:134735464~134918710:-
THCA	cis	rs801193	1	rs10252765	ENSG00000229886.1	RP5-1132H15.3	3.96	8.75e-05	0.00695	0.19	0.18	Aortic root size;	chr7:66763745	chr7:66025126~66031544:-
THCA	cis	rs4792901	0.759	rs3179927	ENSG00000267151.3	RP11-100E5.2	3.96	8.75e-05	0.00696	0.19	0.18	Dupuytren's disease;	chr17:43524543	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.759	rs9915640	ENSG00000267151.3	RP11-100E5.2	3.96	8.75e-05	0.00696	0.19	0.18	Dupuytren's disease;	chr17:43526514	chr17:43444707~43451200:+
THCA	cis	rs35791980	0.82	rs11764672	ENSG00000237815.1	AC007000.11	3.96	8.75e-05	0.00696	0.19	0.18	Pursuit maintenance gain;	chr7:77319874	chr7:77060345~77060479:-
THCA	cis	rs8062405	0.756	rs151182	ENSG00000270424.1	RP11-1348G14.6	3.96	8.75e-05	0.00696	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28749959~28750595:-
THCA	cis	rs17666538	0.585	rs10090260	ENSG00000254207.1	RP11-43A14.1	3.96	8.75e-05	0.00696	0.34	0.18	IgG glycosylation;	chr8:658034	chr8:725188~725877:-
THCA	cis	rs4713118	0.615	rs9295747	ENSG00000220721.1	OR1F12	-3.96	8.75e-05	0.00696	-0.22	-0.18	Parkinson's disease;	chr6:27769214	chr6:28073316~28074233:+
THCA	cis	rs875971	0.642	rs35526611	ENSG00000275400.1	RP4-756H11.5	3.96	8.75e-05	0.00696	0.17	0.18	Aortic root size;	chr7:66629021	chr7:66553805~66554199:-
THCA	cis	rs6496044	0.568	rs12899946	ENSG00000259630.2	CTD-2262B20.1	-3.96	8.75e-05	0.00696	-0.19	-0.18	Interstitial lung disease;	chr15:85522851	chr15:85415228~85415633:+
THCA	cis	rs6496044	0.568	rs12898783	ENSG00000259630.2	CTD-2262B20.1	-3.96	8.75e-05	0.00696	-0.19	-0.18	Interstitial lung disease;	chr15:85522869	chr15:85415228~85415633:+
THCA	cis	rs7829975	0.536	rs2980439	ENSG00000233609.3	RP11-62H7.2	3.96	8.75e-05	0.00696	0.17	0.18	Mood instability;	chr8:8237348	chr8:8961200~8979025:+
THCA	cis	rs713587	0.607	rs6725517	ENSG00000224165.4	DNAJC27-AS1	-3.96	8.75e-05	0.00696	-0.1	-0.18	Body mass index in non-asthmatics;	chr2:24906604	chr2:24971390~25039694:+
THCA	cis	rs4767841	0.537	rs11064919	ENSG00000248636.5	RP11-768F21.1	-3.96	8.75e-05	0.00696	-0.19	-0.18	Urgency urinary incontinence;	chr12:119819078	chr12:119387987~119668079:-
THCA	cis	rs9733	0.744	rs12568757	ENSG00000231073.1	RP11-316M1.3	-3.96	8.75e-05	0.00696	-0.22	-0.18	Tonsillectomy;	chr1:150757317	chr1:150973123~150975534:+
THCA	cis	rs5758659	0.716	rs2143138	ENSG00000227370.1	RP4-669P10.19	-3.96	8.75e-05	0.00696	-0.16	-0.18	Cognitive function;	chr22:42222334	chr22:42132543~42132998:+
THCA	cis	rs4906332	1	rs13987	ENSG00000259775.1	RP11-45P15.4	-3.96	8.75e-05	0.00696	-0.16	-0.18	Coronary artery disease;	chr14:103503572	chr14:103331674~103332367:-
THCA	cis	rs2191566	0.576	rs381983	ENSG00000277806.1	RP11-15A1.8	-3.96	8.76e-05	0.00696	-0.18	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:43990063	chr19:43976815~43977448:+
THCA	cis	rs7131987	0.65	rs16934135	ENSG00000273680.1	RP11-996F15.6	3.96	8.76e-05	0.00696	0.25	0.18	QT interval;	chr12:29331030	chr12:29332733~29333383:-
THCA	cis	rs7520050	0.807	rs28378621	ENSG00000280836.1	AL355480.1	-3.96	8.76e-05	0.00696	-0.22	-0.18	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45581219~45581321:-
THCA	cis	rs4660456	0.572	rs10789191	ENSG00000238287.1	RP11-656D10.3	3.96	8.76e-05	0.00696	0.21	0.18	Platelet count;	chr1:40690819	chr1:40493157~40508661:-
THCA	cis	rs1040393	1	rs1040393	ENSG00000225171.2	DUTP6	3.96	8.76e-05	0.00696	0.26	0.18	Schizophrenia;	chr1:166892359	chr1:166868748~166869209:+
THCA	cis	rs1040393	0.953	rs6427042	ENSG00000225171.2	DUTP6	3.96	8.76e-05	0.00696	0.26	0.18	Schizophrenia;	chr1:166894319	chr1:166868748~166869209:+
THCA	cis	rs55966801	0.624	rs741735	ENSG00000277290.1	RP11-326C3.16	-3.96	8.76e-05	0.00696	-0.23	-0.18	Plateletcrit;	chr11:256976	chr11:243099~243483:-
THCA	cis	rs6163	0.727	rs284862	ENSG00000236937.2	PTGES3P4	-3.96	8.76e-05	0.00696	-0.23	-0.18	Waist circumference;Hip circumference;	chr10:102812324	chr10:102845595~102845950:+
THCA	cis	rs1476587	0.527	rs1859127	ENSG00000224046.1	AC005076.5	-3.96	8.76e-05	0.00697	-0.16	-0.18	Brachial circumference;	chr7:87122826	chr7:87151423~87152420:-
THCA	cis	rs1075265	0.584	rs4671178	ENSG00000272156.1	RP11-477N3.1	-3.96	8.76e-05	0.00697	-0.18	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54082554~54085066:+
THCA	cis	rs7074356	0.831	rs12764048	ENSG00000278616.1	BEND3P3	3.96	8.76e-05	0.00697	0.19	0.18	Borderline personality disorder;	chr10:80389207	chr10:79682997~79685436:+
THCA	cis	rs728616	0.558	rs61859215	ENSG00000278616.1	BEND3P3	3.96	8.76e-05	0.00697	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391392	chr10:79682997~79685436:+
THCA	cis	rs728616	0.558	rs72817596	ENSG00000278616.1	BEND3P3	3.96	8.76e-05	0.00697	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391838	chr10:79682997~79685436:+
THCA	cis	rs7474896	0.515	rs688608	ENSG00000226578.1	RP11-258F22.1	3.96	8.76e-05	0.00697	0.26	0.18	Obesity (extreme);	chr10:38042696	chr10:37775371~37784131:-
THCA	cis	rs2676071	0.767	rs2676084	ENSG00000259721.1	RP11-758N13.1	-3.96	8.77e-05	0.00697	-0.22	-0.18	Periodontitis (Mean PAL);	chr15:33322414	chr15:32717270~32719007:-
THCA	cis	rs651907	0.512	rs771324	ENSG00000256628.3	ZBTB11-AS1	3.96	8.77e-05	0.00697	0.21	0.18	Colorectal cancer;	chr3:101891521	chr3:101676475~101679217:+
THCA	cis	rs6963495	0.818	rs73192122	ENSG00000272604.1	RP11-251G23.5	3.96	8.77e-05	0.00697	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105531024	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73192124	ENSG00000272604.1	RP11-251G23.5	3.96	8.77e-05	0.00697	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105531081	chr7:105571083~105573660:+
THCA	cis	rs748404	0.533	rs11632120	ENSG00000249839.1	AC011330.5	3.96	8.77e-05	0.00697	0.21	0.18	Lung cancer;	chr15:43123175	chr15:43663654~43684339:-
THCA	cis	rs2164068	0.57	rs34608683	ENSG00000231621.1	AC013264.2	3.96	8.77e-05	0.00697	0.18	0.18	Allergy;	chr2:197870988	chr2:197197991~197199273:+
THCA	cis	rs7577696	0.695	rs212713	ENSG00000276334.1	AL133243.1	3.96	8.77e-05	0.00697	0.2	0.18	Inflammatory biomarkers;	chr2:32232468	chr2:32521927~32523547:+
THCA	cis	rs4947019	1	rs11153170	ENSG00000260273.1	RP11-425D10.10	-3.96	8.77e-05	0.00697	-0.34	-0.18	Hematological parameters;	chr6:109331325	chr6:109382795~109383666:+
THCA	cis	rs1876905	0.68	rs9384787	ENSG00000271789.1	RP5-1112D6.7	3.96	8.77e-05	0.00697	0.22	0.18	Mean corpuscular hemoglobin;	chr6:111113707	chr6:111297126~111298510:+
THCA	cis	rs253959	0.607	rs254150	ENSG00000250015.1	CTC-339F2.2	-3.96	8.77e-05	0.00697	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr5:116308018	chr5:116302354~116304134:-
THCA	cis	rs804280	0.509	rs13276433	ENSG00000254948.1	OR7E158P	-3.96	8.77e-05	0.00697	-0.22	-0.18	Myopia (pathological);	chr8:11925527	chr8:11919900~11920809:-
THCA	cis	rs11758351	0.866	rs77205516	ENSG00000216331.1	HIST1H1PS1	3.96	8.77e-05	0.00697	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26205128	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.866	rs11757394	ENSG00000216331.1	HIST1H1PS1	3.96	8.77e-05	0.00697	0.29	0.18	Renal underexcretion gout;Gout;	chr6:26206466	chr6:26195566~26195771:+
THCA	cis	rs4666002	0.917	rs4666000	ENSG00000234072.1	AC074117.10	3.96	8.77e-05	0.00697	0.14	0.18	Phospholipid levels (plasma);	chr2:27616502	chr2:27356246~27367622:+
THCA	cis	rs2839627	0.638	rs7281701	ENSG00000225218.1	AP001628.6	3.96	8.78e-05	0.00697	0.3	0.18	Information processing speed;	chr21:42857186	chr21:42831040~42836477:-
THCA	cis	rs6546886	0.912	rs4073048	ENSG00000235499.1	AC073046.25	3.96	8.78e-05	0.00697	0.17	0.18	Dialysis-related mortality;	chr2:74075371	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.869	rs3902790	ENSG00000235499.1	AC073046.25	3.96	8.78e-05	0.00697	0.17	0.18	Dialysis-related mortality;	chr2:74076076	chr2:73985132~73986343:+
THCA	cis	rs4792901	0.625	rs112302569	ENSG00000267151.3	RP11-100E5.2	3.96	8.78e-05	0.00698	0.21	0.18	Dupuytren's disease;	chr17:43459623	chr17:43444707~43451200:+
THCA	cis	rs927833	0.502	rs7263348	ENSG00000214535.3	RPS15AP1	-3.96	8.78e-05	0.00698	-0.27	-0.18	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr20:21981201	chr20:21166206~21166596:-
THCA	cis	rs150992	0.609	rs7711061	ENSG00000246763.5	RGMB-AS1	-3.96	8.78e-05	0.00698	-0.18	-0.18	Body mass index;	chr5:99003535	chr5:98769618~98773469:-
THCA	cis	rs13083990	0.881	rs13085498	ENSG00000272758.4	RP11-299J3.8	3.96	8.78e-05	0.00698	0.18	0.18	Cardiac Troponin-T levels;	chr3:122292516	chr3:122416207~122443180:+
THCA	cis	rs853679	0.882	rs9468300	ENSG00000273712.1	RP5-874C20.7	3.96	8.78e-05	0.00698	0.31	0.18	Depression;	chr6:28159062	chr6:28315613~28315883:-
THCA	cis	rs3105593	0.933	rs3101850	ENSG00000242737.1	RP11-562A8.1	3.96	8.78e-05	0.00698	0.22	0.18	QT interval;	chr15:50552117	chr15:50466738~50467096:+
THCA	cis	rs748404	0.736	rs542036	ENSG00000205771.5	CATSPER2P1	3.96	8.78e-05	0.00698	0.2	0.18	Lung cancer;	chr15:43248941	chr15:43726918~43747094:-
THCA	cis	rs6494488	0.5	rs72741315	ENSG00000259635.1	AC100830.3	-3.96	8.78e-05	0.00698	-0.47	-0.18	Coronary artery disease;	chr15:64421326	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs55881719	ENSG00000259635.1	AC100830.3	-3.96	8.78e-05	0.00698	-0.47	-0.18	Coronary artery disease;	chr15:64422704	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72741319	ENSG00000259635.1	AC100830.3	-3.96	8.78e-05	0.00698	-0.47	-0.18	Coronary artery disease;	chr15:64424778	chr15:64701248~64719602:+
THCA	cis	rs728616	0.558	rs12772945	ENSG00000278616.1	BEND3P3	3.96	8.78e-05	0.00698	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80394740	chr10:79682997~79685436:+
THCA	cis	rs728616	0.558	rs12414691	ENSG00000278616.1	BEND3P3	3.96	8.78e-05	0.00698	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80397226	chr10:79682997~79685436:+
THCA	cis	rs728616	0.558	rs12767261	ENSG00000278616.1	BEND3P3	3.96	8.78e-05	0.00698	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80402567	chr10:79682997~79685436:+
THCA	cis	rs1204798	1	rs1204780	ENSG00000237021.2	RP3-486I3.7	-3.96	8.78e-05	0.00698	-0.19	-0.18	Dental caries;	chr6:116207951	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1204781	ENSG00000237021.2	RP3-486I3.7	-3.96	8.78e-05	0.00698	-0.19	-0.18	Dental caries;	chr6:116209038	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1204782	ENSG00000237021.2	RP3-486I3.7	-3.96	8.78e-05	0.00698	-0.19	-0.18	Dental caries;	chr6:116209604	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1204783	ENSG00000237021.2	RP3-486I3.7	-3.96	8.78e-05	0.00698	-0.19	-0.18	Dental caries;	chr6:116209632	chr6:116254207~116256743:+
THCA	cis	rs1204798	0.898	rs1204784	ENSG00000237021.2	RP3-486I3.7	-3.96	8.78e-05	0.00698	-0.19	-0.18	Dental caries;	chr6:116209693	chr6:116254207~116256743:+
THCA	cis	rs10090774	0.71	rs13262271	ENSG00000279766.1	RP11-642A1.2	-3.96	8.78e-05	0.00698	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140677795	chr8:140572142~140572812:-
THCA	cis	rs10833905	0.759	rs28526534	ENSG00000246225.5	RP11-17A1.3	-3.96	8.78e-05	0.00698	-0.25	-0.18	Sudden cardiac arrest;	chr11:23033690	chr11:22829380~22945393:+
THCA	cis	rs10833905	0.938	rs61889441	ENSG00000246225.5	RP11-17A1.3	-3.96	8.78e-05	0.00698	-0.25	-0.18	Sudden cardiac arrest;	chr11:23034168	chr11:22829380~22945393:+
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000189316.3	RP11-797H7.5	-3.96	8.78e-05	0.00698	-0.19	-0.18	Calcium levels;	chr7:65800652	chr7:64888527~64890100:-
THCA	cis	rs6747488	0.515	rs600015	ENSG00000276517.1	AL133243.2	-3.96	8.78e-05	0.00698	-0.17	-0.18	Interleukin-18 levels;	chr2:31595231	chr2:32526504~32529507:+
THCA	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	3.96	8.79e-05	0.00698	0.21	0.18	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
THCA	cis	rs11638352	1	rs12324261	ENSG00000166763.7	STRCP1	-3.96	8.79e-05	0.00698	-0.4	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44026273	chr15:43699488~43718184:-
THCA	cis	rs2733201	1	rs11070419	ENSG00000166763.7	STRCP1	-3.96	8.79e-05	0.00698	-0.4	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44034981	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs4924734	ENSG00000166763.7	STRCP1	-3.96	8.79e-05	0.00698	-0.4	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44035872	chr15:43699488~43718184:-
THCA	cis	rs2733201	1	rs4923972	ENSG00000166763.7	STRCP1	-3.96	8.79e-05	0.00698	-0.4	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44037058	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs2899103	ENSG00000166763.7	STRCP1	-3.96	8.79e-05	0.00698	-0.4	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44048357	chr15:43699488~43718184:-
THCA	cis	rs10492201	0.529	rs12422954	ENSG00000255733.4	IFNG-AS1	3.96	8.79e-05	0.00698	0.16	0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007611	chr12:67989445~68234686:+
THCA	cis	rs9309473	0.95	rs2947860	ENSG00000273245.1	RP11-434P11.2	3.96	8.79e-05	0.00698	0.26	0.18	Metabolite levels;	chr2:73628259	chr2:73750256~73750786:-
THCA	cis	rs2281603	0.521	rs6573559	ENSG00000272909.1	CTD-2555O16.4	-3.96	8.79e-05	0.00698	-0.2	-0.18	Lymphocyte counts;	chr14:64456448	chr14:64440369~64442238:-
THCA	cis	rs4869313	0.668	rs2617434	ENSG00000247121.5	CTD-2260A17.2	-3.96	8.79e-05	0.00698	-0.13	-0.18	Pediatric autoimmune diseases;	chr5:96935934	chr5:96814028~96935809:-
THCA	cis	rs1850744	0.51	rs1401441	ENSG00000250942.1	ENPP7P11	3.96	8.79e-05	0.00698	0.23	0.18	Economic and political preferences;	chr4:9830680	chr4:9677308~9677934:+
THCA	cis	rs9393777	0.92	rs13212562	ENSG00000226314.6	ZNF192P1	-3.96	8.79e-05	0.00698	-0.28	-0.18	Intelligence (multi-trait analysis);	chr6:27332531	chr6:28161781~28169594:+
THCA	cis	rs6847067	0.702	rs13110728	ENSG00000180769.7	WDFY3-AS2	3.96	8.79e-05	0.00698	0.13	0.18	Oropharynx cancer;	chr4:84622305	chr4:84965682~85011277:+
THCA	cis	rs2839186	0.967	rs17176131	ENSG00000215424.8	MCM3AP-AS1	3.96	8.79e-05	0.00698	0.1	0.18	Testicular germ cell tumor;	chr21:46285323	chr21:46229217~46259390:+
THCA	cis	rs4713118	0.824	rs9468225	ENSG00000220721.1	OR1F12	3.96	8.79e-05	0.00699	0.24	0.18	Parkinson's disease;	chr6:27777940	chr6:28073316~28074233:+
THCA	cis	rs6921919	0.789	rs17301128	ENSG00000219392.1	RP1-265C24.5	-3.96	8.79e-05	0.00699	-0.22	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28115628~28116551:+
THCA	cis	rs5758511	0.689	rs5758691	ENSG00000230107.1	CTA-126B4.7	-3.96	8.8e-05	0.00699	-0.21	-0.18	Birth weight;	chr22:42272498	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.68	rs1001586	ENSG00000230107.1	CTA-126B4.7	-3.96	8.8e-05	0.00699	-0.21	-0.18	Birth weight;	chr22:42274287	chr22:42438023~42446195:+
THCA	cis	rs12134133	1	rs2661357	ENSG00000237074.1	RP11-6J21.2	3.96	8.8e-05	0.00699	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs2782840	ENSG00000237074.1	RP11-6J21.2	3.96	8.8e-05	0.00699	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207249067~207309121:+
THCA	cis	rs7829975	0.871	rs777709	ENSG00000233609.3	RP11-62H7.2	-3.96	8.8e-05	0.00699	-0.17	-0.18	Mood instability;	chr8:8726362	chr8:8961200~8979025:+
THCA	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	3.96	8.8e-05	0.00699	0.2	0.18	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
THCA	cis	rs9863	0.828	rs12303671	ENSG00000270061.1	RP11-214K3.19	-3.96	8.8e-05	0.00699	-0.23	-0.18	White blood cell count;	chr12:124008063	chr12:123969990~123970344:-
THCA	cis	rs1048886	0.938	rs7775962	ENSG00000271967.1	RP11-134K13.4	-3.96	8.8e-05	0.00699	-0.19	-0.18	Type 2 diabetes;	chr6:70422119	chr6:70596438~70596980:+
THCA	cis	rs6963495	0.606	rs6969426	ENSG00000272604.1	RP11-251G23.5	3.96	8.8e-05	0.00699	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105506703	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs6944787	ENSG00000272604.1	RP11-251G23.5	3.96	8.8e-05	0.00699	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105506862	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190133	ENSG00000272604.1	RP11-251G23.5	3.96	8.8e-05	0.00699	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105507374	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.932	rs55700120	ENSG00000272604.1	RP11-251G23.5	3.96	8.8e-05	0.00699	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105508013	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs6956234	ENSG00000272604.1	RP11-251G23.5	3.96	8.8e-05	0.00699	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105509260	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs6956249	ENSG00000272604.1	RP11-251G23.5	3.96	8.8e-05	0.00699	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105509296	chr7:105571083~105573660:+
THCA	cis	rs4780401	0.933	rs4780396	ENSG00000274038.1	RP11-66H6.4	-3.96	8.8e-05	0.00699	-0.21	-0.18	Rheumatoid arthritis;	chr16:11722815	chr16:11056556~11057034:+
THCA	cis	rs7809950	0.678	rs17154040	ENSG00000272072.1	CTA-363E19.2	-3.96	8.8e-05	0.00699	-0.19	-0.18	Coronary artery disease;	chr7:107364801	chr7:107192559~107193300:-
THCA	cis	rs7927592	0.913	rs10047412	ENSG00000160172.9	FAM86C2P	3.96	8.8e-05	0.00699	0.18	0.18	Total body bone mineral density;	chr11:68465444	chr11:67791648~67805336:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000229180.5	GS1-124K5.11	3.96	8.8e-05	0.00699	0.13	0.18	Calcium levels;	chr7:65941231	chr7:66526088~66542624:-
THCA	cis	rs7829975	0.714	rs4841040	ENSG00000253981.4	ALG1L13P	3.96	8.8e-05	0.00699	0.17	0.18	Mood instability;	chr8:8797017	chr8:8236003~8244667:-
THCA	cis	rs11931598	1	rs11931598	ENSG00000245468.3	RP11-367J11.3	3.96	8.8e-05	0.00699	0.13	0.18	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7045375	chr4:7094571~7103385:-
THCA	cis	rs61270009	0.913	rs357512	ENSG00000247828.6	TMEM161B-AS1	-3.96	8.8e-05	0.00699	-0.16	-0.18	Depressive symptoms;	chr5:88222061	chr5:88268895~88436685:+
THCA	cis	rs62229266	0.626	rs2835268	ENSG00000230212.5	AP000688.14	-3.96	8.8e-05	0.00699	-0.22	-0.18	Mitral valve prolapse;	chr21:36076838	chr21:36069642~36126640:-
THCA	cis	rs7616559	0.893	rs6802521	ENSG00000244515.1	KRT18P34	-3.96	8.81e-05	0.007	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157001107	chr3:157162663~157163932:-
THCA	cis	rs1048886	0.872	rs12527634	ENSG00000271967.1	RP11-134K13.4	-3.96	8.81e-05	0.007	-0.19	-0.18	Type 2 diabetes;	chr6:70510304	chr6:70596438~70596980:+
THCA	cis	rs5762752	0.555	rs695629	ENSG00000272858.1	CTA-292E10.8	-3.96	8.81e-05	0.007	-0.16	-0.18	Optic disc area;	chr22:28438781	chr22:28814914~28815662:+
THCA	cis	rs735539	0.521	rs2818996	ENSG00000278291.1	RP11-172H24.4	3.96	8.81e-05	0.007	0.24	0.18	Dental caries;	chr13:20854132	chr13:20699307~20703718:-
THCA	cis	rs8062405	0.755	rs111693583	ENSG00000270424.1	RP11-1348G14.6	3.96	8.81e-05	0.007	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28749959~28750595:-
THCA	cis	rs7267979	0.744	rs6050464	ENSG00000274973.1	RP13-401N8.7	-3.96	8.81e-05	0.007	-0.21	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25845497~25845862:+
THCA	cis	rs2274136	1	rs6459561	ENSG00000272269.1	RP11-500C11.3	3.96	8.81e-05	0.007	0.21	0.18	Obesity-related traits;	chr6:17657420	chr6:17706257~17707344:+
THCA	cis	rs740160	0.51	rs6973408	ENSG00000244219.5	GS1-259H13.2	-3.96	8.81e-05	0.007	-0.27	-0.18	Dehydroepiandrosterone sulphate levels;	chr7:99303230	chr7:99598066~99610813:+
THCA	cis	rs6446731	1	rs6446731	ENSG00000261643.1	RP11-529E10.6	-3.96	8.81e-05	0.007	-0.16	-0.18	Mean platelet volume;	chr4:3283024	chr4:3503597~3504457:-
THCA	cis	rs2562456	0.754	rs55771551	ENSG00000268278.1	RP11-420K14.1	3.96	8.81e-05	0.007	0.22	0.18	Pain;	chr19:21563578	chr19:21637974~21656300:+
THCA	cis	rs4470077	1	rs10146736	ENSG00000258413.1	RP11-665C16.6	-3.96	8.82e-05	0.007	-0.31	-0.18	Platelet count;	chr14:55431206	chr14:55262767~55272075:-
THCA	cis	rs4470077	0.941	rs10149166	ENSG00000258413.1	RP11-665C16.6	-3.96	8.82e-05	0.007	-0.31	-0.18	Platelet count;	chr14:55431258	chr14:55262767~55272075:-
THCA	cis	rs875971	0.545	rs1638735	ENSG00000232559.3	GS1-124K5.12	3.96	8.82e-05	0.007	0.19	0.18	Aortic root size;	chr7:66630751	chr7:66554588~66576923:-
THCA	cis	rs17597773	0.638	rs17596850	ENSG00000238078.1	LINC01352	-3.96	8.82e-05	0.007	-0.25	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220819001	chr1:220829255~220832429:+
THCA	cis	rs150992	0.64	rs326485	ENSG00000241597.2	CTD-2007H13.1	-3.96	8.82e-05	0.007	-0.23	-0.18	Body mass index;	chr5:98845717	chr5:98954394~98954972:+
THCA	cis	rs1005277	0.522	rs200943	ENSG00000275858.1	RP11-291L22.8	3.96	8.82e-05	0.00701	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.505	rs719569	ENSG00000275858.1	RP11-291L22.8	-3.96	8.82e-05	0.00701	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.505	rs7099777	ENSG00000275858.1	RP11-291L22.8	-3.96	8.82e-05	0.00701	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38450738~38451069:-
THCA	cis	rs131777	0.545	rs131759	ENSG00000272940.1	CTA-384D8.33	3.96	8.82e-05	0.00701	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50577052	chr22:50597152~50597599:+
THCA	cis	rs754133	0.964	rs894738	ENSG00000257534.1	RP11-834C11.10	3.96	8.82e-05	0.00701	0.22	0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54023741	chr12:54162065~54164452:-
THCA	cis	rs7520050	0.833	rs1085242	ENSG00000281133.1	AL355480.3	3.96	8.82e-05	0.00701	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45580892~45580996:-
THCA	cis	rs793571	0.59	rs17190727	ENSG00000245975.2	RP11-30K9.6	3.96	8.82e-05	0.00701	0.17	0.18	Schizophrenia;	chr15:58781591	chr15:58768072~58770974:-
THCA	cis	rs793571	0.566	rs1648532	ENSG00000245975.2	RP11-30K9.6	3.96	8.82e-05	0.00701	0.17	0.18	Schizophrenia;	chr15:58784579	chr15:58768072~58770974:-
THCA	cis	rs7973719	0.833	rs11044332	ENSG00000205885.6	C1RL-AS1	3.96	8.82e-05	0.00701	0.13	0.18	IgG glycosylation;	chr12:7206172	chr12:7108052~7122501:+
THCA	cis	rs2281636	0.894	rs1332103	ENSG00000233690.1	EBAG9P1	3.96	8.82e-05	0.00701	0.17	0.18	Obesity-related traits;	chr10:99616139	chr10:99697407~99697949:-
THCA	cis	rs6938	0.618	rs12911254	ENSG00000260269.4	CTD-2323K18.1	-3.96	8.83e-05	0.00701	-0.26	-0.18	Breast cancer;	chr15:74873994	chr15:75527150~75601205:-
THCA	cis	rs9959145	1	rs111268621	ENSG00000267199.1	RP11-861E21.2	3.96	8.83e-05	0.00701	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12546290	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs9966118	ENSG00000267199.1	RP11-861E21.2	3.96	8.83e-05	0.00701	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12548859	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs77079191	ENSG00000267199.1	RP11-861E21.2	3.96	8.83e-05	0.00701	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12549379	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs1940973	ENSG00000267199.1	RP11-861E21.2	3.96	8.83e-05	0.00701	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12550748	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs79785672	ENSG00000267199.1	RP11-861E21.2	3.96	8.83e-05	0.00701	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12552110	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs77321492	ENSG00000267199.1	RP11-861E21.2	3.96	8.83e-05	0.00701	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12552124	chr18:12438890~12448205:+
THCA	cis	rs7178424	0.711	rs4283171	ENSG00000259251.2	RP11-643M14.1	-3.96	8.83e-05	0.00701	-0.18	-0.18	Height;	chr15:61880185	chr15:62060503~62062434:+
THCA	cis	rs1204798	0.685	rs1204817	ENSG00000237021.2	RP3-486I3.7	-3.96	8.83e-05	0.00701	-0.2	-0.18	Dental caries;	chr6:116239603	chr6:116254207~116256743:+
THCA	cis	rs1204798	0.685	rs1204818	ENSG00000237021.2	RP3-486I3.7	-3.96	8.83e-05	0.00701	-0.2	-0.18	Dental caries;	chr6:116239708	chr6:116254207~116256743:+
THCA	cis	rs669446	0.533	rs3862228	ENSG00000237950.1	RP11-7O11.3	3.96	8.83e-05	0.00701	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43731274	chr1:43944370~43946551:-
THCA	cis	rs694739	0.857	rs574835	ENSG00000236935.1	AP003774.1	3.96	8.83e-05	0.00701	0.19	0.18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343196	chr11:64325050~64329504:-
THCA	cis	rs728616	0.681	rs17677908	ENSG00000278616.1	BEND3P3	3.96	8.83e-05	0.00701	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80289847	chr10:79682997~79685436:+
THCA	cis	rs301901	0.965	rs13158310	ENSG00000250155.1	CTD-2353F22.1	3.96	8.83e-05	0.00701	0.18	0.18	Height;	chr5:36789552	chr5:36666214~36725195:-
THCA	cis	rs7989336	0.574	rs748457	ENSG00000247400.3	DNAJC3-AS1	-3.96	8.83e-05	0.00701	-0.11	-0.18	Obesity;	chr13:96270195	chr13:95648733~95676925:-
THCA	cis	rs12681366	0.881	rs12676373	ENSG00000261437.1	RP11-22C11.2	3.96	8.83e-05	0.00701	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94349890	chr8:94637285~94639467:-
THCA	cis	rs597539	0.552	rs10792006	ENSG00000250508.1	RP11-757G1.6	3.96	8.83e-05	0.00701	0.2	0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68954837	chr11:68870664~68874542:+
THCA	cis	rs17095355	0.642	rs57822924	ENSG00000203876.8	ADD3-AS1	-3.96	8.83e-05	0.00701	-0.2	-0.18	Biliary atresia;	chr10:109942320	chr10:109940104~110008381:-
THCA	cis	rs910316	1	rs12879542	ENSG00000259138.1	RP11-950C14.7	3.95	8.83e-05	0.00701	0.16	0.18	Height;	chr14:75040822	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs4903275	ENSG00000259138.1	RP11-950C14.7	3.95	8.83e-05	0.00701	0.16	0.18	Height;	chr14:75045806	chr14:75127153~75136930:+
THCA	cis	rs11168351	0.927	rs11168342	ENSG00000273765.1	RP11-370I10.11	3.95	8.83e-05	0.00701	0.18	0.18	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48360920~48361377:+
THCA	cis	rs6963495	0.818	rs73192143	ENSG00000272604.1	RP11-251G23.5	3.95	8.83e-05	0.00701	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105561968	chr7:105571083~105573660:+
THCA	cis	rs2839186	0.967	rs4819222	ENSG00000215424.8	MCM3AP-AS1	3.95	8.83e-05	0.00701	0.1	0.18	Testicular germ cell tumor;	chr21:46287864	chr21:46229217~46259390:+
THCA	cis	rs7914558	0.966	rs10786719	ENSG00000213061.2	PFN1P11	-3.95	8.84e-05	0.00702	-0.22	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878235	chr10:102838011~102845473:-
THCA	cis	rs2749592	0.531	rs994804	ENSG00000276805.1	RP11-291L22.6	-3.95	8.84e-05	0.00702	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38451030~38451785:+
THCA	cis	rs2164068	0.547	rs61435657	ENSG00000231621.1	AC013264.2	-3.95	8.84e-05	0.00702	-0.18	-0.18	Allergy;	chr2:197960782	chr2:197197991~197199273:+
THCA	cis	rs9650657	0.771	rs4840516	ENSG00000269918.1	AF131215.9	3.95	8.84e-05	0.00702	0.18	0.18	Neuroticism;	chr8:10809825	chr8:11104691~11106704:-
THCA	cis	rs3742597	0.84	rs66492349	ENSG00000276116.2	FUT8-AS1	-3.95	8.84e-05	0.00702	-0.21	-0.18	N-glycan levels;	chr14:65372771	chr14:65411170~65412690:-
THCA	cis	rs1538970	0.924	rs3790582	ENSG00000234329.1	RP11-767N6.2	3.95	8.84e-05	0.00702	0.18	0.18	Platelet count;	chr1:45421616	chr1:45651039~45651826:-
THCA	cis	rs62158800	0.852	rs57399677	ENSG00000224568.1	AC096669.3	3.95	8.84e-05	0.00702	0.35	0.18	Facial morphology (factor 22);	chr2:107680504	chr2:107529487~107556326:+
THCA	cis	rs150992	0.632	rs34491	ENSG00000246763.5	RGMB-AS1	3.95	8.84e-05	0.00702	0.18	0.18	Body mass index;	chr5:98974118	chr5:98769618~98773469:-
THCA	cis	rs950169	0.65	rs12902052	ENSG00000275120.1	RP11-182J1.17	3.95	8.84e-05	0.00702	0.22	0.18	Schizophrenia;	chr15:84582607	chr15:84599434~84606463:-
THCA	cis	rs1501911	0.611	rs56180458	ENSG00000246763.5	RGMB-AS1	3.95	8.84e-05	0.00702	0.19	0.18	Lung function (FEV1/FVC);	chr5:99043633	chr5:98769618~98773469:-
THCA	cis	rs7551222	0.752	rs10900596	ENSG00000240219.1	RP11-430C7.5	3.95	8.84e-05	0.00702	0.17	0.18	Schizophrenia;	chr1:204553329	chr1:204626775~204629712:+
THCA	cis	rs330071	0.686	rs4841139	ENSG00000254153.1	CTA-398F10.2	-3.95	8.84e-05	0.00702	-0.19	-0.18	Acne (severe);	chr8:9391700	chr8:8456909~8461337:-
THCA	cis	rs2657294	0.895	rs2395137	ENSG00000226051.5	ZNF503-AS1	-3.95	8.84e-05	0.00702	-0.25	-0.18	Pneumonia;	chr10:75088235	chr10:75269819~75373500:+
THCA	cis	rs4915077	1	rs17014208	ENSG00000226822.1	RP11-356N1.2	3.95	8.84e-05	0.00702	0.36	0.18	Hypothyroidism;	chr1:107795876	chr1:108071482~108074519:+
THCA	cis	rs587080	0.654	rs595366	ENSG00000197847.11	SLC22A20	3.95	8.84e-05	0.00702	0.19	0.18	Plateletcrit;	chr11:65429460	chr11:65213840~65242757:+
THCA	cis	rs10875746	0.859	rs4760695	ENSG00000258273.1	RP11-370I10.4	3.95	8.84e-05	0.00702	0.26	0.18	Longevity (90 years and older);	chr12:48198065	chr12:48333755~48333901:-
THCA	cis	rs6121246	0.908	rs17093657	ENSG00000224628.2	RP5-854E16.2	-3.95	8.84e-05	0.00702	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31841091	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.954	rs6060992	ENSG00000224628.2	RP5-854E16.2	-3.95	8.84e-05	0.00702	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31843452	chr20:31285317~31286835:-
THCA	cis	rs17689437	1	rs17689437	ENSG00000260084.1	RP11-615I2.1	3.95	8.84e-05	0.00702	0.31	0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68566448	chr16:68573782~68589512:-
THCA	cis	rs758324	0.732	rs159903	ENSG00000224431.1	AC063976.7	3.95	8.84e-05	0.00702	0.18	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132204360	chr5:132199456~132203487:+
THCA	cis	rs1975197	0.515	rs2570298	ENSG00000225706.1	PTPRD-AS1	-3.95	8.85e-05	0.00702	-0.23	-0.18	Restless legs syndrome;	chr9:8840103	chr9:8858130~8862255:+
THCA	cis	rs8046148	0.906	rs1008815	ENSG00000279356.1	RP11-429P3.8	3.95	8.85e-05	0.00702	0.25	0.18	Testicular germ cell tumor;	chr16:50068309	chr16:50072862~50074986:+
THCA	cis	rs7176527	0.579	rs366717	ENSG00000259683.1	RP11-182J1.14	3.95	8.85e-05	0.00702	0.23	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84389729~84395903:+
THCA	cis	rs6473252	0.934	rs10957985	ENSG00000254162.1	RP11-48B3.3	-3.95	8.85e-05	0.00702	-0.16	-0.18	Breast cancer;	chr8:80877686	chr8:80535006~80539135:-
THCA	cis	rs7914558	1	rs1926030	ENSG00000213061.2	PFN1P11	3.95	8.85e-05	0.00703	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:102838011~102845473:-
THCA	cis	rs4575098	0.681	rs12727614	ENSG00000227741.1	RP11-536C5.7	3.95	8.85e-05	0.00703	0.2	0.18	Monocyte percentage of white cells;	chr1:161127451	chr1:160202199~160208869:-
THCA	cis	rs7829975	0.688	rs7827182	ENSG00000233609.3	RP11-62H7.2	3.95	8.85e-05	0.00703	0.18	0.18	Mood instability;	chr8:8522961	chr8:8961200~8979025:+
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000254414.1	RP11-182J1.1	-3.95	8.85e-05	0.00703	-0.22	-0.18	P wave terminal force;	chr15:84632519	chr15:84631898~84633987:-
THCA	cis	rs4742903	0.904	rs1507510	ENSG00000270332.1	SMC2-AS1	3.95	8.85e-05	0.00703	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104222872	chr9:104080024~104093073:-
THCA	cis	rs875971	0.66	rs10263935	ENSG00000229180.5	GS1-124K5.11	3.95	8.85e-05	0.00703	0.12	0.18	Aortic root size;	chr7:66631041	chr7:66526088~66542624:-
THCA	cis	rs17286411	0.671	rs4788821	ENSG00000260185.1	RP11-432I5.6	-3.95	8.85e-05	0.00703	-0.25	-0.18	Blood protein levels;	chr16:71626407	chr16:71655027~71664212:+
THCA	cis	rs12612619	0.689	rs1124649	ENSG00000229122.1	AGBL5-IT1	-3.95	8.85e-05	0.00703	-0.14	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27037601	chr2:27061038~27061815:+
THCA	cis	rs5758511	0.68	rs56111723	ENSG00000205702.9	CYP2D7	3.95	8.86e-05	0.00703	0.16	0.18	Birth weight;	chr22:42268877	chr22:42140203~42144577:-
THCA	cis	rs2255336	0.657	rs11053765	ENSG00000245648.1	RP11-277P12.20	3.95	8.86e-05	0.00703	0.26	0.18	Blood protein levels;	chr12:10351365	chr12:10363769~10398506:+
THCA	cis	rs11971779	0.68	rs7805824	ENSG00000252332.1	RNU6-911P	3.95	8.86e-05	0.00703	0.2	0.18	Diisocyanate-induced asthma;	chr7:139426423	chr7:139448740~139448843:+
THCA	cis	rs703842	1	rs10877019	ENSG00000270039.1	RP11-571M6.17	3.95	8.86e-05	0.00703	0.21	0.18	Multiple sclerosis;	chr12:57779146	chr12:57803838~57804415:+
THCA	cis	rs2298450	0.654	rs9984891	ENSG00000214867.3	SRSF9P1	3.95	8.86e-05	0.00703	0.27	0.18	Schizophrenia;	chr21:36254081	chr21:36295173~36295702:-
THCA	cis	rs250585	0.85	rs152460	ENSG00000260136.4	CTD-2270L9.4	3.95	8.86e-05	0.00703	0.14	0.18	Egg allergy;	chr16:23562512	chr16:23452758~23457606:+
THCA	cis	rs886427	0.517	rs12918697	ENSG00000272079.2	LA16c-380H5.5	3.95	8.86e-05	0.00703	0.21	0.18	Metabolic syndrome;	chr16:2952850	chr16:3006120~3007388:+
THCA	cis	rs2153535	0.518	rs913571	ENSG00000230939.1	RP11-314C16.1	-3.95	8.86e-05	0.00703	-0.19	-0.18	Motion sickness;	chr6:8591095	chr6:8784178~8785445:+
THCA	cis	rs8062405	0.558	rs231976	ENSG00000261766.1	RP11-22P6.2	-3.95	8.86e-05	0.00703	-0.16	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28862166~28863340:-
THCA	cis	rs35146811	0.695	rs1618851	ENSG00000078319.8	PMS2P1	-3.95	8.86e-05	0.00703	-0.22	-0.18	Coronary artery disease;	chr7:100213020	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs1727130	ENSG00000078319.8	PMS2P1	-3.95	8.86e-05	0.00703	-0.22	-0.18	Coronary artery disease;	chr7:100213841	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs1636975	ENSG00000078319.8	PMS2P1	-3.95	8.86e-05	0.00703	-0.22	-0.18	Coronary artery disease;	chr7:100214466	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.695	rs1727132	ENSG00000078319.8	PMS2P1	-3.95	8.86e-05	0.00703	-0.22	-0.18	Coronary artery disease;	chr7:100214674	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs1727133	ENSG00000078319.8	PMS2P1	-3.95	8.86e-05	0.00703	-0.22	-0.18	Coronary artery disease;	chr7:100215247	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.657	rs36019559	ENSG00000078319.8	PMS2P1	-3.95	8.86e-05	0.00703	-0.22	-0.18	Coronary artery disease;	chr7:100216963	chr7:100320992~100341908:-
THCA	cis	rs7824557	0.564	rs2736293	ENSG00000154316.13	TDH	3.95	8.86e-05	0.00703	0.13	0.18	Retinal vascular caliber;	chr8:11377104	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.564	rs2736294	ENSG00000154316.13	TDH	3.95	8.86e-05	0.00703	0.13	0.18	Retinal vascular caliber;	chr8:11377117	chr8:11339637~11368452:+
THCA	cis	rs4130590	1	rs4130590	ENSG00000271833.1	RP11-356B19.11	3.95	8.86e-05	0.00703	0.19	0.18	Bipolar disorder;	chr9:127345685	chr9:127366770~127367397:+
THCA	cis	rs962856	1	rs6546294	ENSG00000236780.4	AC078941.1	3.95	8.86e-05	0.00703	0.22	0.18	Pancreatic cancer;	chr2:67335098	chr2:67123357~67215319:-
THCA	cis	rs3105593	0.933	rs3105598	ENSG00000242737.1	RP11-562A8.1	3.95	8.86e-05	0.00703	0.23	0.18	QT interval;	chr15:50533069	chr15:50466738~50467096:+
THCA	cis	rs7166081	1	rs1444936	ENSG00000270964.1	RP11-502I4.3	-3.95	8.86e-05	0.00703	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67343211	chr15:67541072~67542604:-
THCA	cis	rs9863	0.896	rs12311114	ENSG00000270061.1	RP11-214K3.19	3.95	8.86e-05	0.00703	0.24	0.18	White blood cell count;	chr12:123976156	chr12:123969990~123970344:-
THCA	cis	rs8105895	0.866	rs62112908	ENSG00000269345.1	VN1R85P	3.95	8.86e-05	0.00703	0.25	0.18	Body mass index (change over time);	chr19:22031154	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.932	rs60548522	ENSG00000269345.1	VN1R85P	3.95	8.86e-05	0.00703	0.25	0.18	Body mass index (change over time);	chr19:22032072	chr19:22174766~22175191:-
THCA	cis	rs8105895	1	rs8105895	ENSG00000269345.1	VN1R85P	3.95	8.86e-05	0.00703	0.25	0.18	Body mass index (change over time);	chr19:22032655	chr19:22174766~22175191:-
THCA	cis	rs8105895	1	rs11881224	ENSG00000269345.1	VN1R85P	3.95	8.86e-05	0.00703	0.25	0.18	Body mass index (change over time);	chr19:22037538	chr19:22174766~22175191:-
THCA	cis	rs8105895	0.932	rs12150930	ENSG00000269345.1	VN1R85P	3.95	8.86e-05	0.00703	0.25	0.18	Body mass index (change over time);	chr19:22040885	chr19:22174766~22175191:-
THCA	cis	rs12681366	0.734	rs13281619	ENSG00000261437.1	RP11-22C11.2	3.95	8.86e-05	0.00703	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94384658	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.708	rs13280849	ENSG00000261437.1	RP11-22C11.2	3.95	8.86e-05	0.00703	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94384731	chr8:94637285~94639467:-
THCA	cis	rs738722	0.836	rs5752773	ENSG00000272858.1	CTA-292E10.8	-3.95	8.86e-05	0.00703	-0.18	-0.18	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28709427	chr22:28814914~28815662:+
THCA	cis	rs6439699	1	rs7648738	ENSG00000273486.1	RP11-731C17.2	3.95	8.87e-05	0.00704	0.19	0.18	Intelligence (multi-trait analysis);	chr3:137289194	chr3:136837338~136839021:-
THCA	cis	rs7829975	0.582	rs6983150	ENSG00000254340.1	RP11-10A14.3	-3.95	8.87e-05	0.00704	-0.2	-0.18	Mood instability;	chr8:8934916	chr8:9141424~9145435:+
THCA	cis	rs2474937	0.531	rs2884802	ENSG00000231365.4	RP11-418J17.1	3.95	8.87e-05	0.00704	0.18	0.18	Congenital heart malformation;	chr1:118388642	chr1:119140396~119275973:+
THCA	cis	rs8020441	0.945	rs61238948	ENSG00000269906.1	RP11-248J18.2	3.95	8.87e-05	0.00704	0.26	0.18	Cognitive performance;	chr14:50700899	chr14:50662511~50663178:-
THCA	cis	rs2191566	0.887	rs55703004	ENSG00000267114.1	CTB-129P6.11	3.95	8.87e-05	0.00704	0.14	0.18	Acute lymphoblastic leukemia (childhood);	chr19:44000629	chr19:44950044~44954007:-
THCA	cis	rs7726839	0.526	rs55647623	ENSG00000225138.6	CTD-2228K2.7	3.95	8.87e-05	0.00704	0.21	0.18	Obesity-related traits;	chr5:567632	chr5:473236~480884:+
THCA	cis	rs7900823	0.528	rs10826433	ENSG00000230500.1	MKX-AS1	3.95	8.87e-05	0.00704	0.25	0.18	Lung cancer;	chr10:28246650	chr10:27744786~27767794:+
THCA	cis	rs1153858	0.895	rs12593402	ENSG00000275672.1	GATM-AS1	-3.95	8.87e-05	0.00704	-0.19	-0.18	Homoarginine levels;	chr15:45325194	chr15:45378700~45380123:+
THCA	cis	rs6995541	0.518	rs13254592	ENSG00000248896.2	CTD-2135J3.3	-3.95	8.87e-05	0.00704	-0.22	-0.18	Triglyceride levels;	chr8:10849761	chr8:10729314~10771392:+
THCA	cis	rs12893668	0.697	rs67899457	ENSG00000244691.1	RPL10AP1	-3.95	8.88e-05	0.00704	-0.25	-0.18	Reticulocyte count;	chr14:103593729	chr14:103412119~103412761:-
THCA	cis	rs6494488	0.5	rs56266896	ENSG00000259635.1	AC100830.3	-3.95	8.88e-05	0.00704	-0.41	-0.18	Coronary artery disease;	chr15:64653928	chr15:64701248~64719602:+
THCA	cis	rs12134133	1	rs2782848	ENSG00000237074.1	RP11-6J21.2	3.95	8.88e-05	0.00704	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.962	rs2039543	ENSG00000237074.1	RP11-6J21.2	3.95	8.88e-05	0.00704	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs2802232	ENSG00000237074.1	RP11-6J21.2	3.95	8.88e-05	0.00704	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.962	rs2782847	ENSG00000237074.1	RP11-6J21.2	3.95	8.88e-05	0.00704	0.19	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207249067~207309121:+
THCA	cis	rs28829049	0.861	rs10492996	ENSG00000270728.1	RP4-657E11.10	-3.95	8.88e-05	0.00704	-0.13	-0.18	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19039058	chr1:19297080~19297903:+
THCA	cis	rs947583	0.588	rs12211505	ENSG00000272189.1	RP3-325F22.5	3.95	8.88e-05	0.00704	0.18	0.18	Phosphorus levels;	chr6:135753683	chr6:136550661~136552554:+
THCA	cis	rs453301	0.624	rs4841083	ENSG00000233609.3	RP11-62H7.2	3.95	8.88e-05	0.00704	0.17	0.18	Joint mobility (Beighton score);	chr8:9012918	chr8:8961200~8979025:+
THCA	cis	rs875971	0.666	rs13242072	ENSG00000232546.1	RP11-458F8.1	3.95	8.88e-05	0.00704	0.15	0.18	Aortic root size;	chr7:66301001	chr7:66848496~66858136:+
THCA	cis	rs9660180	0.837	rs915292	ENSG00000215914.4	MMP23A	-3.95	8.88e-05	0.00705	-0.24	-0.18	Body mass index;	chr1:1860718	chr1:1699942~1701782:+
THCA	cis	rs801193	1	rs10234018	ENSG00000230295.1	RP11-458F8.2	3.95	8.88e-05	0.00705	0.14	0.18	Aortic root size;	chr7:66681297	chr7:66880708~66882981:+
THCA	cis	rs9911578	0.805	rs12601867	ENSG00000224738.1	AC099850.1	-3.95	8.88e-05	0.00705	-0.21	-0.18	Intelligence (multi-trait analysis);	chr17:58377899	chr17:59106598~59118267:+
THCA	cis	rs7166081	1	rs35008245	ENSG00000270964.1	RP11-502I4.3	-3.95	8.88e-05	0.00705	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67322629	chr15:67541072~67542604:-
THCA	cis	rs6496044	0.568	rs7176291	ENSG00000259630.2	CTD-2262B20.1	-3.95	8.88e-05	0.00705	-0.19	-0.18	Interstitial lung disease;	chr15:85524167	chr15:85415228~85415633:+
THCA	cis	rs28735056	0.904	rs12953738	ENSG00000261126.6	RP11-795F19.1	3.95	8.88e-05	0.00705	0.15	0.18	Schizophrenia;	chr18:79867877	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.904	rs35201860	ENSG00000261126.6	RP11-795F19.1	3.95	8.88e-05	0.00705	0.15	0.18	Schizophrenia;	chr18:79868719	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.904	rs12962619	ENSG00000261126.6	RP11-795F19.1	3.95	8.88e-05	0.00705	0.15	0.18	Schizophrenia;	chr18:79868832	chr18:80046900~80095482:+
THCA	cis	rs28735056	0.846	rs12958903	ENSG00000261126.6	RP11-795F19.1	3.95	8.88e-05	0.00705	0.15	0.18	Schizophrenia;	chr18:79868996	chr18:80046900~80095482:+
THCA	cis	rs151234	0.676	rs554206	ENSG00000259982.1	CDC37P1	-3.95	8.89e-05	0.00705	-0.36	-0.18	Platelet distribution width;	chr16:28565048	chr16:28700294~28701540:-
THCA	cis	rs8130944	0.964	rs12626774	ENSG00000225731.1	AP001627.1	3.95	8.89e-05	0.00705	0.2	0.18	Perceived unattractiveness to mosquitoes;	chr21:42718938	chr21:42733594~42741758:-
THCA	cis	rs2436845	0.81	rs2513910	ENSG00000253669.3	KB-1732A1.1	-3.95	8.89e-05	0.00705	-0.18	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102804878	chr8:102805517~102809971:+
THCA	cis	rs7671266	0.532	rs733175	ENSG00000261490.1	RP11-448G15.3	3.95	8.89e-05	0.00705	0.14	0.18	Cardiovascular disease risk factors;	chr4:10048517	chr4:10068089~10073019:-
THCA	cis	rs17685	0.753	rs6951943	ENSG00000230882.1	AC005077.14	3.95	8.89e-05	0.00705	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76143134	chr7:76071469~76074963:-
THCA	cis	rs7572644	0.679	rs6745545	ENSG00000223522.1	AC093690.1	-3.95	8.89e-05	0.00705	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27798978	chr2:28307691~28310459:-
THCA	cis	rs11971779	0.68	rs10242419	ENSG00000252332.1	RNU6-911P	3.95	8.89e-05	0.00705	0.2	0.18	Diisocyanate-induced asthma;	chr7:139404634	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6467848	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139395459	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.648	rs6467849	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139395766	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs1986447	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139397334	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.59	rs9642120	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139399225	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.618	rs9640925	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139400542	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs7804388	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139401667	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs4732373	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139401789	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.618	rs6943788	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139402951	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.523	rs10279160	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139406015	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.59	rs4732374	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139406707	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.648	rs9642121	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139407875	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.584	rs7786469	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139409875	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.584	rs17613864	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139410841	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.555	rs4728466	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139411619	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs4732376	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139413278	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.648	rs10085708	ENSG00000252332.1	RNU6-911P	-3.95	8.89e-05	0.00705	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139426208	chr7:139448740~139448843:+
THCA	cis	rs10454142	0.807	rs13399936	ENSG00000202227.1	RNU6-282P	3.95	8.89e-05	0.00705	0.21	0.18	Sex hormone-binding globulin levels;	chr2:48426987	chr2:48501922~48502024:-
THCA	cis	rs10484434	1	rs62394540	ENSG00000272810.1	U91328.22	3.95	8.89e-05	0.00705	0.2	0.18	HIV-1 viral setpoint;	chr6:25970946	chr6:26013241~26013757:+
THCA	cis	rs12142240	0.698	rs13374893	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46378128	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.621	rs13374968	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46378236	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72679807	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46380818	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs56284503	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46381455	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17361915	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46381649	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.731	rs6681857	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46384452	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.66	rs72890715	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46386405	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs4372193	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46387561	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.659	rs111723629	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46387689	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs3991877	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46388077	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.659	rs1984491	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46392935	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs45449893	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46393352	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs45517837	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46393553	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs932816	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46394077	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72890727	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46394565	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6703374	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46396660	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6703669	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46396883	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs17361936	ENSG00000232022.5	FAAHP1	-3.95	8.89e-05	0.00705	-0.2	-0.18	Menopause (age at onset);	chr1:46397221	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs6695043	ENSG00000232022.5	FAAHP1	3.95	8.89e-05	0.00705	0.2	0.18	Menopause (age at onset);	chr1:46378858	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs1984490	ENSG00000232022.5	FAAHP1	3.95	8.89e-05	0.00705	0.2	0.18	Menopause (age at onset);	chr1:46393062	chr1:46432129~46445521:+
THCA	cis	rs1371614	0.632	rs6547318	ENSG00000272148.1	RP11-195B17.1	3.95	8.9e-05	0.00706	0.17	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26930613	chr2:27062428~27062907:-
THCA	cis	rs11971779	0.648	rs7799165	ENSG00000252332.1	RNU6-911P	-3.95	8.9e-05	0.00706	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139400211	chr7:139448740~139448843:+
THCA	cis	rs321358	0.945	rs7111445	ENSG00000271390.1	RP11-89C3.3	-3.95	8.9e-05	0.00706	-0.3	-0.18	Body mass index;	chr11:111105787	chr11:111089870~111090368:-
THCA	cis	rs7312933	0.618	rs6582390	ENSG00000257225.1	RP11-328C8.4	-3.95	8.9e-05	0.00706	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42240784	chr12:42459366~42466128:+
THCA	cis	rs1580019	0.844	rs1037322	ENSG00000231952.3	DPY19L1P2	-3.95	8.9e-05	0.00706	-0.23	-0.18	Cognitive ability;	chr7:32462245	chr7:32812757~32838570:+
THCA	cis	rs481331	0.799	rs7076849	ENSG00000215146.4	RP11-313J2.1	-3.95	8.9e-05	0.00706	-0.27	-0.18	Systemic juvenile idiopathic arthritis;	chr10:42480411	chr10:42331866~42367974:-
THCA	cis	rs7914558	0.752	rs7896519	ENSG00000272912.1	RP11-724N1.1	-3.95	8.9e-05	0.00706	-0.22	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102914585~102915404:+
THCA	cis	rs7959452	0.535	rs10878953	ENSG00000274979.1	RP11-1143G9.5	-3.95	8.9e-05	0.00706	-0.19	-0.18	Blood protein levels;	chr12:69280407	chr12:69326574~69331882:-
THCA	cis	rs9558942	0.564	rs2245300	ENSG00000277863.1	RP11-282A11.4	-3.95	8.9e-05	0.00706	-0.22	-0.18	Obesity-related traits;	chr13:107069392	chr13:106903150~106904099:-
THCA	cis	rs1923243	0.617	rs4589057	ENSG00000223479.3	RP4-788P17.1	3.95	8.9e-05	0.00706	0.19	0.18	Migraine;	chr1:72946606	chr1:73635216~73715214:+
THCA	cis	rs17685	0.725	rs6947068	ENSG00000227038.2	AC005077.12	-3.95	8.9e-05	0.00706	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76032738	chr7:76090431~76108779:-
THCA	cis	rs4908760	0.965	rs12080583	ENSG00000270282.1	RP5-1115A15.2	3.95	8.9e-05	0.00706	0.21	0.18	Vitiligo;	chr1:8464817	chr1:8512653~8513021:+
THCA	cis	rs911555	0.755	rs12432803	ENSG00000269910.1	RP11-73M18.10	-3.95	8.9e-05	0.00706	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103694516~103695050:-
THCA	cis	rs911555	0.755	rs4906329	ENSG00000269910.1	RP11-73M18.10	-3.95	8.9e-05	0.00706	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103694516~103695050:-
THCA	cis	rs17767294	0.612	rs9461424	ENSG00000272009.1	RP1-313I6.12	-3.95	8.9e-05	0.00706	-0.28	-0.18	Parkinson's disease;	chr6:27951623	chr6:28078792~28081130:-
THCA	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-3.95	8.9e-05	0.00706	-0.17	-0.18	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-3.95	8.9e-05	0.00706	-0.17	-0.18	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
THCA	cis	rs8044868	0.861	rs7192848	ENSG00000260886.1	TAT-AS1	3.95	8.9e-05	0.00706	0.21	0.18	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72173056	chr16:71565789~71578187:+
THCA	cis	rs4742903	1	rs4743687	ENSG00000270332.1	SMC2-AS1	3.95	8.9e-05	0.00706	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104094629	chr9:104080024~104093073:-
THCA	cis	rs478304	0.651	rs4014195	ENSG00000255320.1	RP11-755F10.1	-3.95	8.9e-05	0.00706	-0.23	-0.18	Acne (severe);	chr11:65739351	chr11:66244840~66246239:-
THCA	cis	rs2898290	0.512	rs899366	ENSG00000206014.6	OR7E161P	-3.95	8.9e-05	0.00706	-0.22	-0.18	Systolic blood pressure;	chr8:11572976	chr8:11928597~11929563:-
THCA	cis	rs2071303	0.836	rs198835	ENSG00000272462.2	U91328.19	3.95	8.9e-05	0.00706	0.2	0.18	Intelligence (multi-trait analysis);	chr6:26113766	chr6:25992662~26001775:+
THCA	cis	rs7819412	0.775	rs34094119	ENSG00000261451.1	RP11-981G7.1	-3.95	8.91e-05	0.00706	-0.22	-0.18	Triglycerides;	chr8:11078388	chr8:10433672~10438312:+
THCA	cis	rs266717	0.816	rs266758	ENSG00000234197.1	ETV5-AS1	-3.95	8.91e-05	0.00706	-0.14	-0.18	Adiponectin levels;	chr3:186790568	chr3:186079170~186080947:+
THCA	cis	rs786425	0.77	rs7964443	ENSG00000278112.1	RP11-972P1.11	3.95	8.91e-05	0.00706	0.17	0.18	Pubertal anthropometrics;	chr12:123681953	chr12:123519390~123519856:-
THCA	cis	rs2120243	0.572	rs6441129	ENSG00000241770.1	RP11-555M1.3	3.95	8.91e-05	0.00706	0.24	0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157408039	chr3:157163452~157169133:+
THCA	cis	rs1023500	0.573	rs13057094	ENSG00000237037.8	NDUFA6-AS1	-3.95	8.91e-05	0.00707	-0.15	-0.18	Schizophrenia;	chr22:42074313	chr22:42090931~42137742:+
THCA	cis	rs758324	0.68	rs392149	ENSG00000224431.1	AC063976.7	-3.95	8.91e-05	0.00707	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132114849	chr5:132199456~132203487:+
THCA	cis	rs714027	0.585	rs5752978	ENSG00000279699.1	RP1-102K2.9	3.95	8.91e-05	0.00707	0.18	0.18	Lymphocyte counts;	chr22:29904597	chr22:30275215~30276951:-
THCA	cis	rs6442522	0.526	rs13074638	ENSG00000249786.6	EAF1-AS1	3.95	8.91e-05	0.00707	0.18	0.18	Uric acid levels;	chr3:15477382	chr3:15436171~15455940:-
THCA	cis	rs17801127	1	rs16827351	ENSG00000231969.1	AC144449.1	3.95	8.91e-05	0.00707	0.3	0.18	Liver enzyme levels (alanine transaminase);	chr2:149698116	chr2:149587196~149848233:+
THCA	cis	rs7829975	0.606	rs11776838	ENSG00000254340.1	RP11-10A14.3	-3.95	8.91e-05	0.00707	-0.2	-0.18	Mood instability;	chr8:8937291	chr8:9141424~9145435:+
THCA	cis	rs7914558	0.966	rs10883805	ENSG00000213061.2	PFN1P11	3.95	8.91e-05	0.00707	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102948494	chr10:102838011~102845473:-
THCA	cis	rs6500550	0.636	rs2158443	ENSG00000276754.1	RP11-461A8.5	-3.95	8.91e-05	0.00707	-0.16	-0.18	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3635781	chr16:3686998~3687380:+
THCA	cis	rs7660883	1	rs4693156	ENSG00000251411.1	RP11-397E7.4	3.95	8.92e-05	0.00707	0.17	0.18	HDL cholesterol levels;	chr4:87086075	chr4:86913266~86914817:-
THCA	cis	rs11673344	0.642	rs73025481	ENSG00000268499.1	CTB-102L5.8	-3.95	8.92e-05	0.00707	-0.19	-0.18	Obesity-related traits;	chr19:37346437	chr19:38199836~38200934:+
THCA	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-3.95	8.92e-05	0.00707	-0.19	-0.18	Asthma;	chr2:102394777	chr2:102438713~102440475:+
THCA	cis	rs2251260	1	rs2251260	ENSG00000232774.6	FLJ22447	3.95	8.92e-05	0.00707	0.27	0.18	Yeast infection;	chr14:61557049	chr14:61570540~61658696:+
THCA	cis	rs7551222	0.752	rs11240754	ENSG00000240219.1	RP11-430C7.5	3.95	8.92e-05	0.00707	0.17	0.18	Schizophrenia;	chr1:204508849	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.752	rs11240756	ENSG00000240219.1	RP11-430C7.5	3.95	8.92e-05	0.00707	0.17	0.18	Schizophrenia;	chr1:204513466	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.752	rs4245736	ENSG00000240219.1	RP11-430C7.5	3.95	8.92e-05	0.00707	0.17	0.18	Schizophrenia;	chr1:204517077	chr1:204626775~204629712:+
THCA	cis	rs4908769	0.66	rs10779702	ENSG00000232912.4	RP5-1115A15.1	-3.95	8.92e-05	0.00707	-0.19	-0.18	Allergy;	chr1:8363450	chr1:8424645~8434838:+
THCA	cis	rs4973397	0.509	rs10191571	ENSG00000181798.2	LINC00471	3.95	8.92e-05	0.00707	0.21	0.18	Anti-saccade response;	chr2:231415264	chr2:231508426~231514339:-
THCA	cis	rs2299587	0.554	rs2073564	ENSG00000253671.1	RP11-806O11.1	-3.95	8.92e-05	0.00707	-0.21	-0.18	Economic and political preferences;	chr8:17885832	chr8:17808941~17820868:+
THCA	cis	rs6121246	0.821	rs6121209	ENSG00000224628.2	RP5-854E16.2	-3.95	8.92e-05	0.00707	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31723455	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs57726761	ENSG00000224628.2	RP5-854E16.2	-3.95	8.92e-05	0.00707	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31726243	chr20:31285317~31286835:-
THCA	cis	rs34779708	0.733	rs7083266	ENSG00000233200.1	RP11-324I22.2	3.95	8.92e-05	0.00707	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35219894~35230598:-
THCA	cis	rs9923856	0.573	rs36094971	ENSG00000263033.2	RP11-396B14.2	-3.95	8.92e-05	0.00707	-0.18	-0.18	Atopic dermatitis;Adult asthma;	chr16:10946540	chr16:11196177~11224969:+
THCA	cis	rs7089973	0.584	rs758585	ENSG00000228169.3	PPIAP19	3.95	8.92e-05	0.00708	0.21	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114822801	chr10:114690143~114690634:-
THCA	cis	rs950169	0.922	rs62028133	ENSG00000275120.1	RP11-182J1.17	3.95	8.92e-05	0.00708	0.21	0.18	Schizophrenia;	chr15:84250623	chr15:84599434~84606463:-
THCA	cis	rs950169	0.723	rs17589320	ENSG00000275120.1	RP11-182J1.17	3.95	8.92e-05	0.00708	0.21	0.18	Schizophrenia;	chr15:84251244	chr15:84599434~84606463:-
THCA	cis	rs253959	0.607	rs712574	ENSG00000250015.1	CTC-339F2.2	-3.95	8.93e-05	0.00708	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr5:116309885	chr5:116302354~116304134:-
THCA	cis	rs253959	0.607	rs785369	ENSG00000250015.1	CTC-339F2.2	-3.95	8.93e-05	0.00708	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr5:116310457	chr5:116302354~116304134:-
THCA	cis	rs253959	0.576	rs785370	ENSG00000250015.1	CTC-339F2.2	-3.95	8.93e-05	0.00708	-0.16	-0.18	Bipolar disorder and schizophrenia;	chr5:116311189	chr5:116302354~116304134:-
THCA	cis	rs13098911	0.54	rs35539222	ENSG00000226074.4	PRSS44	-3.95	8.93e-05	0.00708	-0.35	-0.18	Celiac disease;	chr3:46112780	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs35110864	ENSG00000226074.4	PRSS44	-3.95	8.93e-05	0.00708	-0.35	-0.18	Celiac disease;	chr3:46112965	chr3:46809359~46812558:-
THCA	cis	rs7115242	0.8	rs10736487	ENSG00000280143.1	AP000892.6	3.95	8.93e-05	0.00708	0.28	0.18	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117204967~117210292:+
THCA	cis	rs9341808	1	rs9341808	ENSG00000272129.1	RP11-250B2.6	3.95	8.93e-05	0.00708	0.22	0.18	Sitting height ratio;	chr6:80243540	chr6:80355424~80356859:+
THCA	cis	rs13434995	0.588	rs114571142	ENSG00000249700.7	SRD5A3-AS1	-3.95	8.93e-05	0.00708	-0.25	-0.18	Adiponectin levels;	chr4:55412991	chr4:55363971~55395847:-
THCA	cis	rs6963495	0.818	rs117887993	ENSG00000272604.1	RP11-251G23.5	3.95	8.93e-05	0.00708	0.24	0.18	Bipolar disorder (body mass index interaction);	chr7:105553390	chr7:105571083~105573660:+
THCA	cis	rs2236521	0.659	rs72487383	ENSG00000273619.1	RP5-908M14.9	-3.95	8.93e-05	0.00708	-0.13	-0.18	Pelvic organ prolapse;	chr20:62314257	chr20:62386303~62386970:-
THCA	cis	rs346923	1	rs9312711	ENSG00000226950.5	DANCR	3.95	8.93e-05	0.00708	0.2	0.18	Biochemical measures;	chr4:52535980	chr4:52712404~52720351:+
THCA	cis	rs346923	1	rs10027138	ENSG00000226950.5	DANCR	3.95	8.93e-05	0.00708	0.2	0.18	Biochemical measures;	chr4:52536415	chr4:52712404~52720351:+
THCA	cis	rs7763441	0.545	rs9392392	ENSG00000250903.7	GMDS-AS1	3.95	8.93e-05	0.00708	0.16	0.18	Monobrow;	chr6:2453199	chr6:2245748~2482022:+
THCA	cis	rs10916248	1	rs10916248	ENSG00000232628.4	RP11-365O16.3	3.95	8.93e-05	0.00708	0.24	0.18	QT interval (drug interaction);	chr1:224068646	chr1:224208747~224213279:-
THCA	cis	rs965513	0.627	rs7848973	ENSG00000214417.4	KRT18P13	-3.95	8.94e-05	0.00708	-0.16	-0.18	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97826557	chr9:97698922~97700734:+
THCA	cis	rs6142618	0.935	rs4911198	ENSG00000224452.1	RSL24D1P6	-3.95	8.94e-05	0.00708	-0.22	-0.18	Inflammatory bowel disease;	chr20:32139880	chr20:32170390~32170790:-
THCA	cis	rs2474937	0.561	rs7519577	ENSG00000231365.4	RP11-418J17.1	3.95	8.94e-05	0.00708	0.18	0.18	Congenital heart malformation;	chr1:118387066	chr1:119140396~119275973:+
THCA	cis	rs8115854	0.922	rs1076686	ENSG00000269846.1	RP4-621N11.2	-3.95	8.94e-05	0.00708	-0.24	-0.18	Hippocampal atrophy;	chr20:37182664	chr20:37095785~37097178:+
THCA	cis	rs72949976	0.934	rs1922794	ENSG00000270659.1	RP11-105N14.1	3.95	8.94e-05	0.00708	0.14	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213161457	chr2:213152970~213153659:+
THCA	cis	rs1908814	0.541	rs7824267	ENSG00000254948.1	OR7E158P	-3.95	8.94e-05	0.00709	-0.22	-0.18	Neuroticism;	chr8:11936770	chr8:11919900~11920809:-
THCA	cis	rs642803	1	rs557675	ENSG00000255120.4	OVOL1-AS1	-3.95	8.94e-05	0.00709	-0.22	-0.18	Urate levels;	chr11:65799248	chr11:65789051~65790868:-
THCA	cis	rs4713118	0.955	rs9380010	ENSG00000261839.1	RP1-265C24.8	3.95	8.94e-05	0.00709	0.2	0.18	Parkinson's disease;	chr6:27715793	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.955	rs9368528	ENSG00000261839.1	RP1-265C24.8	3.95	8.94e-05	0.00709	0.2	0.18	Parkinson's disease;	chr6:27716019	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.955	rs9380011	ENSG00000261839.1	RP1-265C24.8	3.95	8.94e-05	0.00709	0.2	0.18	Parkinson's disease;	chr6:27716145	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.955	rs9368529	ENSG00000261839.1	RP1-265C24.8	3.95	8.94e-05	0.00709	0.2	0.18	Parkinson's disease;	chr6:27716852	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.955	rs9380012	ENSG00000261839.1	RP1-265C24.8	3.95	8.94e-05	0.00709	0.2	0.18	Parkinson's disease;	chr6:27716875	chr6:28136849~28139678:+
THCA	cis	rs9607412	0.56	rs5756505	ENSG00000233360.4	Z83844.1	-3.95	8.94e-05	0.00709	-0.19	-0.18	Mean corpuscular volume;	chr22:37071314	chr22:37641832~37658377:-
THCA	cis	rs736408	0.509	rs2590838	ENSG00000243224.1	RP5-1157M23.2	-3.95	8.94e-05	0.00709	-0.19	-0.18	Bipolar disorder;	chr3:52588070	chr3:52239258~52241097:+
THCA	cis	rs7312933	0.558	rs1796394	ENSG00000257225.1	RP11-328C8.4	3.95	8.94e-05	0.00709	0.18	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42432557	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.558	rs1669886	ENSG00000257225.1	RP11-328C8.4	3.95	8.94e-05	0.00709	0.18	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42444438	chr12:42459366~42466128:+
THCA	cis	rs7131987	0.65	rs11050187	ENSG00000273680.1	RP11-996F15.6	3.95	8.94e-05	0.00709	0.25	0.18	QT interval;	chr12:29319943	chr12:29332733~29333383:-
THCA	cis	rs9840812	0.592	rs12489577	ENSG00000239213.4	NCK1-AS1	3.95	8.94e-05	0.00709	0.17	0.18	Fibrinogen levels;	chr3:136494303	chr3:136841726~136862054:-
THCA	cis	rs16957091	0.528	rs34920950	ENSG00000205771.5	CATSPER2P1	3.95	8.94e-05	0.00709	0.25	0.18	MGMT methylation in smokers;	chr15:42817281	chr15:43726918~43747094:-
THCA	cis	rs4819052	1	rs28628220	ENSG00000182586.6	LINC00334	-3.95	8.94e-05	0.00709	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45234340~45258730:+
THCA	cis	rs4819052	1	rs2838830	ENSG00000182586.6	LINC00334	-3.95	8.94e-05	0.00709	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45234340~45258730:+
THCA	cis	rs875971	0.929	rs4122249	ENSG00000229886.1	RP5-1132H15.3	3.95	8.94e-05	0.00709	0.18	0.18	Aortic root size;	chr7:66455949	chr7:66025126~66031544:-
THCA	cis	rs12681366	0.881	rs3019150	ENSG00000261437.1	RP11-22C11.2	3.95	8.94e-05	0.00709	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94420055	chr8:94637285~94639467:-
THCA	cis	rs11771526	0.901	rs17161084	ENSG00000272905.1	RP11-265E18.1	3.95	8.94e-05	0.00709	0.24	0.18	Body mass index;	chr7:32253580	chr7:32845394~32846061:+
THCA	cis	rs758324	0.732	rs128738	ENSG00000224431.1	AC063976.7	-3.95	8.94e-05	0.00709	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132205182	chr5:132199456~132203487:+
THCA	cis	rs654950	0.875	rs689076	ENSG00000230638.4	RP11-486B10.4	-3.95	8.95e-05	0.00709	-0.2	-0.18	Airway imaging phenotypes;	chr1:41533456	chr1:41542069~41544310:+
THCA	cis	rs780094	0.5	rs13002853	ENSG00000234072.1	AC074117.10	3.95	8.95e-05	0.00709	0.15	0.18	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27630378	chr2:27356246~27367622:+
THCA	cis	rs9634489	0.59	rs9556541	ENSG00000247400.3	DNAJC3-AS1	-3.95	8.95e-05	0.00709	-0.11	-0.18	Body mass index;	chr13:96271289	chr13:95648733~95676925:-
THCA	cis	rs4245128	0.93	rs7941901	ENSG00000247416.2	RP11-629G13.1	3.95	8.95e-05	0.00709	0.17	0.18	Life satisfaction;	chr11:112907324	chr11:112959279~112963460:-
THCA	cis	rs301807	0.533	rs1466654	ENSG00000232912.4	RP5-1115A15.1	3.95	8.95e-05	0.00709	0.17	0.18	Vitiligo;Sum eosinophil basophil counts;	chr1:8315853	chr1:8424645~8434838:+
THCA	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	3.95	8.95e-05	0.00709	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
THCA	cis	rs7259376	0.905	rs7258446	ENSG00000270947.1	AC025811.3	3.95	8.95e-05	0.00709	0.19	0.18	Menopause (age at onset);	chr19:22367539	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs17391718	ENSG00000270947.1	AC025811.3	3.95	8.95e-05	0.00709	0.19	0.18	Menopause (age at onset);	chr19:22371352	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.905	rs56027264	ENSG00000270947.1	AC025811.3	3.95	8.95e-05	0.00709	0.19	0.18	Menopause (age at onset);	chr19:22371552	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs1865075	ENSG00000270947.1	AC025811.3	3.95	8.95e-05	0.00709	0.19	0.18	Menopause (age at onset);	chr19:22372052	chr19:22455988~22456459:+
THCA	cis	rs2777491	0.507	rs34040639	ENSG00000247556.5	OIP5-AS1	3.95	8.95e-05	0.00709	0.17	0.18	Ulcerative colitis;	chr15:41468609	chr15:41283990~41309737:+
THCA	cis	rs7824557	0.545	rs2572450	ENSG00000154316.13	TDH	3.95	8.95e-05	0.00709	0.14	0.18	Retinal vascular caliber;	chr8:11372129	chr8:11339637~11368452:+
THCA	cis	rs2455799	0.533	rs924754	ENSG00000270409.1	RP11-44D5.1	-3.95	8.95e-05	0.0071	-0.19	-0.18	Mean platelet volume;	chr3:15714708	chr3:15732252~15733470:+
THCA	cis	rs12440869	1	rs10438290	ENSG00000270964.1	RP11-502I4.3	-3.95	8.95e-05	0.0071	-0.16	-0.18	Peak velocity of the mitral A-wave;	chr15:67304477	chr15:67541072~67542604:-
THCA	cis	rs4268898	0.722	rs2288072	ENSG00000242628.4	AC009228.1	-3.95	8.96e-05	0.0071	-0.22	-0.18	Asthma;	chr2:24167648	chr2:24214381~24221516:+
THCA	cis	rs34792	0.528	rs222132	ENSG00000207425.1	Y_RNA	-3.95	8.96e-05	0.0071	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15451243	chr16:14915457~14915556:-
THCA	cis	rs7267979	0.78	rs6050679	ENSG00000274973.1	RP13-401N8.7	-3.95	8.96e-05	0.0071	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25845497~25845862:+
THCA	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	3.95	8.96e-05	0.0071	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
THCA	cis	rs75920871	0.688	rs1473326	ENSG00000254851.1	RP11-109L13.1	-3.95	8.96e-05	0.0071	-0.39	-0.18	Subjective well-being;	chr11:116952956	chr11:117135528~117138582:+
THCA	cis	rs2434529	0.84	rs153441	ENSG00000245275.6	SAP30L-AS1	3.95	8.96e-05	0.0071	0.19	0.18	Autism spectrum disorder or schizophrenia;	chr5:154274519	chr5:154329437~154445850:-
THCA	cis	rs4908760	0.899	rs6577496	ENSG00000270282.1	RP5-1115A15.2	3.95	8.96e-05	0.0071	0.21	0.18	Vitiligo;	chr1:8521168	chr1:8512653~8513021:+
THCA	cis	rs75828804	1	rs76526832	ENSG00000260922.1	RP11-538I12.3	-3.95	8.96e-05	0.0071	-0.38	-0.18	Intraocular pressure;	chr16:77521443	chr16:77234877~77290934:+
THCA	cis	rs7537765	0.793	rs17037425	ENSG00000242349.4	NPPA-AS1	-3.95	8.96e-05	0.0071	-0.25	-0.18	QRS complex (12-leadsum);	chr1:11810326	chr1:11841017~11848079:+
THCA	cis	rs6496044	0.568	rs7166642	ENSG00000259630.2	CTD-2262B20.1	-3.95	8.96e-05	0.0071	-0.19	-0.18	Interstitial lung disease;	chr15:85518040	chr15:85415228~85415633:+
THCA	cis	rs654950	0.934	rs638859	ENSG00000230638.4	RP11-486B10.4	-3.95	8.96e-05	0.0071	-0.22	-0.18	Airway imaging phenotypes;	chr1:41535773	chr1:41542069~41544310:+
THCA	cis	rs823156	0.736	rs823157	ENSG00000226780.1	RP11-38J22.3	3.95	8.96e-05	0.0071	0.29	0.18	Parkinson's disease;	chr1:205796667	chr1:206117783~206126805:+
THCA	cis	rs4746818	1	rs1506770	ENSG00000229001.1	ACTBP14	-3.95	8.96e-05	0.0071	-0.29	-0.18	Left atrial antero-posterior diameter;	chr10:69204601	chr10:69022778~69023866:+
THCA	cis	rs9283706	0.594	rs7717020	ENSG00000229666.1	MAST4-AS1	-3.95	8.96e-05	0.0071	-0.27	-0.18	Coronary artery disease;	chr5:67057494	chr5:67001383~67003953:-
THCA	cis	rs260461	0.92	rs79259289	ENSG00000268516.2	CTD-3138B18.5	-3.95	8.96e-05	0.0071	-0.25	-0.18	Attention deficit hyperactivity disorder;	chr19:58240891	chr19:58257270~58278808:-
THCA	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	3.95	8.97e-05	0.0071	0.16	0.18	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	3.95	8.97e-05	0.0071	0.16	0.18	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
THCA	cis	rs11971779	0.68	rs7795520	ENSG00000252332.1	RNU6-911P	-3.95	8.97e-05	0.0071	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139394461	chr7:139448740~139448843:+
THCA	cis	rs28735056	0.933	rs72980085	ENSG00000261126.6	RP11-795F19.1	-3.95	8.97e-05	0.00711	-0.15	-0.18	Schizophrenia;	chr18:79871679	chr18:80046900~80095482:+
THCA	cis	rs7264396	0.943	rs11167267	ENSG00000088340.14	FER1L4	3.95	8.97e-05	0.00711	0.16	0.18	Total cholesterol levels;	chr20:35521445	chr20:35558737~35607562:-
THCA	cis	rs7586085	1	rs7586085	ENSG00000232411.1	AC009495.3	-3.95	8.97e-05	0.00711	-0.19	-0.18	Total body bone mineral density;	chr2:165720979	chr2:165833048~165839098:-
THCA	cis	rs4713118	0.513	rs200971	ENSG00000220721.1	OR1F12	3.95	8.97e-05	0.00711	0.22	0.18	Parkinson's disease;	chr6:27891126	chr6:28073316~28074233:+
THCA	cis	rs7989336	0.562	rs7324569	ENSG00000247400.3	DNAJC3-AS1	-3.95	8.97e-05	0.00711	-0.12	-0.18	Obesity;	chr13:96377401	chr13:95648733~95676925:-
THCA	cis	rs214785	1	rs214782	ENSG00000226644.4	RP11-128M1.1	3.95	8.97e-05	0.00711	0.18	0.18	Basal cell carcinoma;	chr20:2301324	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214783	ENSG00000226644.4	RP11-128M1.1	3.95	8.97e-05	0.00711	0.18	0.18	Basal cell carcinoma;	chr20:2301403	chr20:2207217~2213151:+
THCA	cis	rs354225	0.785	rs354222	ENSG00000162997.14	PRORSD1P	-3.95	8.97e-05	0.00711	-0.19	-0.18	Schizophrenia;	chr2:54698043	chr2:55282319~55284522:+
THCA	cis	rs465969	0.744	rs3851228	ENSG00000272356.1	RP5-1112D6.8	-3.95	8.97e-05	0.00711	-0.26	-0.18	Psoriasis;	chr6:111526988	chr6:111309203~111313517:+
THCA	cis	rs7010876	0.657	rs1879202	ENSG00000253553.4	RP11-586K2.1	-3.95	8.98e-05	0.00711	-0.19	-0.18	Schizophrenia;	chr8:88285677	chr8:88326836~88737134:+
THCA	cis	rs7819412	0.505	rs17726209	ENSG00000261451.1	RP11-981G7.1	3.95	8.98e-05	0.00711	0.24	0.18	Triglycerides;	chr8:11164675	chr8:10433672~10438312:+
THCA	cis	rs365302	1	rs449385	ENSG00000235086.1	FNDC1-IT1	3.95	8.98e-05	0.00711	0.25	0.18	Coronary heart disease;	chr6:159223286	chr6:159240786~159243329:+
THCA	cis	rs12410462	0.551	rs10047205	ENSG00000227711.2	RP11-275O4.5	3.95	8.98e-05	0.00711	0.22	0.18	Major depressive disorder;	chr1:227643797	chr1:227509028~227520477:-
THCA	cis	rs7824557	0.564	rs2572399	ENSG00000154316.13	TDH	3.95	8.98e-05	0.00711	0.13	0.18	Retinal vascular caliber;	chr8:11377011	chr8:11339637~11368452:+
THCA	cis	rs10540	1	rs10540	ENSG00000279672.1	CMB9-55F22.1	3.95	8.98e-05	0.00711	0.35	0.18	Body mass index;	chr11:494662	chr11:779617~780755:+
THCA	cis	rs17092148	1	rs2425004	ENSG00000276073.1	RP5-1125A11.7	3.95	8.98e-05	0.00711	0.21	0.18	Neuroticism;	chr20:34818153	chr20:33985617~33988989:-
THCA	cis	rs448720	0.684	rs2448134	ENSG00000260657.2	RP11-315D16.4	-3.95	8.98e-05	0.00712	-0.22	-0.18	Cognitive performance;	chr15:67930702	chr15:68267792~68277994:-
THCA	cis	rs3781264	0.848	rs3781265	ENSG00000273450.1	RP11-76P2.4	3.95	8.98e-05	0.00712	0.22	0.18	Esophageal cancer and gastric cancer;	chr10:94303522	chr10:94314907~94315327:-
THCA	cis	rs1204798	1	rs1204793	ENSG00000237021.2	RP3-486I3.7	-3.95	8.98e-05	0.00712	-0.19	-0.18	Dental caries;	chr6:116219679	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1204795	ENSG00000237021.2	RP3-486I3.7	-3.95	8.98e-05	0.00712	-0.19	-0.18	Dental caries;	chr6:116220213	chr6:116254207~116256743:+
THCA	cis	rs1204798	0.947	rs1204797	ENSG00000237021.2	RP3-486I3.7	-3.95	8.98e-05	0.00712	-0.19	-0.18	Dental caries;	chr6:116220384	chr6:116254207~116256743:+
THCA	cis	rs911555	0.692	rs7140647	ENSG00000269958.1	RP11-73M18.8	-3.95	8.99e-05	0.00712	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103696353~103697163:+
THCA	cis	rs6967414	0.786	rs6463578	ENSG00000187953.9	PMS2CL	-3.95	8.99e-05	0.00712	-0.26	-0.18	Hematocrit;Hemoglobin concentration;	chr7:6713419	chr7:6710128~6753862:+
THCA	cis	rs2243480	1	rs2707844	ENSG00000237310.1	GS1-124K5.4	3.95	8.99e-05	0.00712	0.21	0.18	Diabetic kidney disease;	chr7:66594522	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1796220	ENSG00000237310.1	GS1-124K5.4	3.95	8.99e-05	0.00712	0.21	0.18	Diabetic kidney disease;	chr7:66597113	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs2707831	ENSG00000237310.1	GS1-124K5.4	3.95	8.99e-05	0.00712	0.21	0.18	Diabetic kidney disease;	chr7:66597524	chr7:66493706~66495474:+
THCA	cis	rs7119038	0.865	rs4938573	ENSG00000255239.1	AP002954.6	3.95	8.99e-05	0.00712	0.27	0.18	Sjögren's syndrome;	chr11:118871133	chr11:118688039~118690600:-
THCA	cis	rs2735413	0.75	rs60659587	ENSG00000276007.1	RP11-358L22.3	3.95	8.99e-05	0.00712	0.17	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78037657	chr16:78123243~78124332:+
THCA	cis	rs3812831	0.662	rs418027	ENSG00000264539.1	MIR548AR	3.95	8.99e-05	0.00712	0.19	0.18	Schizophrenia;	chr13:114163869	chr13:114244505~114244561:+
THCA	cis	rs2290416	0.681	rs3793371	ENSG00000253931.1	RP11-909N17.2	3.95	8.99e-05	0.00712	0.36	0.18	Attention deficit hyperactivity disorder;	chr8:143582129	chr8:143412749~143417054:+
THCA	cis	rs12893668	0.697	rs67899457	ENSG00000258735.1	LINC00637	-3.95	8.99e-05	0.00712	-0.23	-0.18	Reticulocyte count;	chr14:103593729	chr14:103847721~103858049:+
THCA	cis	rs11176749	1	rs17782266	ENSG00000256172.1	RP11-473M14.3	3.95	8.99e-05	0.00712	0.26	0.18	Expressive vocabulary in infants;	chr12:67457508	chr12:67440998~67442559:-
THCA	cis	rs6840360	0.573	rs11099806	ENSG00000251611.1	RP11-610P16.1	-3.95	8.99e-05	0.00712	-0.13	-0.18	Intelligence (multi-trait analysis);	chr4:151347964	chr4:151407551~151408835:-
THCA	cis	rs972578	0.936	rs6002991	ENSG00000230319.1	AL022476.2	3.95	9e-05	0.00712	0.19	0.18	Mean platelet volume;	chr22:42974254	chr22:43038585~43052366:+
THCA	cis	rs9863	0.861	rs7958691	ENSG00000270061.1	RP11-214K3.19	-3.95	9e-05	0.00713	-0.23	-0.18	White blood cell count;	chr12:123956196	chr12:123969990~123970344:-
THCA	cis	rs4763879	0.778	rs1056151	ENSG00000214776.8	RP11-726G1.1	-3.95	9e-05	0.00713	-0.22	-0.18	Type 1 diabetes;	chr12:9698427	chr12:9467552~9576275:+
THCA	cis	rs853679	1	rs853685	ENSG00000273712.1	RP5-874C20.7	3.95	9e-05	0.00713	0.28	0.18	Depression;	chr6:28321008	chr6:28315613~28315883:-
THCA	cis	rs12126655	1	rs12126655	ENSG00000230489.1	VAV3-AS1	3.95	9e-05	0.00713	0.18	0.18	Plasma thyroid-stimulating hormone levels;	chr1:107814198	chr1:107964443~107994607:+
THCA	cis	rs875971	1	rs4718307	ENSG00000230189.5	GS1-124K5.2	-3.95	9e-05	0.00713	-0.12	-0.18	Aortic root size;	chr7:66146001	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs7801282	ENSG00000230189.5	GS1-124K5.2	-3.95	9e-05	0.00713	-0.12	-0.18	Aortic root size;	chr7:66148700	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs55962648	ENSG00000230189.5	GS1-124K5.2	-3.95	9e-05	0.00713	-0.12	-0.18	Aortic root size;	chr7:66160764	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs2420168	ENSG00000230189.5	GS1-124K5.2	-3.95	9e-05	0.00713	-0.12	-0.18	Aortic root size;	chr7:66165644	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs11974219	ENSG00000230189.5	GS1-124K5.2	-3.95	9e-05	0.00713	-0.12	-0.18	Aortic root size;	chr7:66182423	chr7:66409143~66490059:-
THCA	cis	rs7188445	0.592	rs4404082	ENSG00000277954.1	RP11-679B19.1	3.95	9e-05	0.00713	0.2	0.18	Urate levels;	chr16:79716615	chr16:79202624~79206739:-
THCA	cis	rs801193	0.636	rs10233806	ENSG00000230189.5	GS1-124K5.2	-3.95	9e-05	0.00713	-0.12	-0.18	Aortic root size;	chr7:66653261	chr7:66409143~66490059:-
THCA	cis	rs62158800	0.598	rs1516215	ENSG00000224568.1	AC096669.3	3.95	9e-05	0.00713	0.22	0.18	Facial morphology (factor 22);	chr2:107676325	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs6542730	ENSG00000224568.1	AC096669.3	3.95	9e-05	0.00713	0.22	0.18	Facial morphology (factor 22);	chr2:107676927	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.598	rs1588950	ENSG00000224568.1	AC096669.3	3.95	9e-05	0.00713	0.22	0.18	Facial morphology (factor 22);	chr2:107681369	chr2:107529487~107556326:+
THCA	cis	rs4908760	0.613	rs12024032	ENSG00000232912.4	RP5-1115A15.1	-3.95	9e-05	0.00713	-0.17	-0.18	Vitiligo;	chr1:8748126	chr1:8424645~8434838:+
THCA	cis	rs4604234	0.522	rs3805918	ENSG00000272129.1	RP11-250B2.6	-3.95	9e-05	0.00713	-0.39	-0.18	Cancer;	chr6:80197405	chr6:80355424~80356859:+
THCA	cis	rs7914558	0.966	rs10748837	ENSG00000213061.2	PFN1P11	3.95	9e-05	0.00713	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:102838011~102845473:-
THCA	cis	rs875971	0.66	rs801193	ENSG00000275400.1	RP4-756H11.5	3.95	9.01e-05	0.00713	0.17	0.18	Aortic root size;	chr7:66565625	chr7:66553805~66554199:-
THCA	cis	rs2235642	0.505	rs56359342	ENSG00000260989.1	LA16c-395F10.2	-3.95	9.01e-05	0.00713	-0.19	-0.18	Coronary artery disease;	chr16:1604947	chr16:1580527~1610328:+
THCA	cis	rs75504410	0.579	rs2087661	ENSG00000231160.8	KLF3-AS1	-3.95	9.01e-05	0.00713	-0.13	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38626309	chr4:38612701~38664883:-
THCA	cis	rs656319	0.58	rs13252589	ENSG00000261451.1	RP11-981G7.1	-3.95	9.01e-05	0.00713	-0.23	-0.18	Myopia (pathological);	chr8:10148016	chr8:10433672~10438312:+
THCA	cis	rs7973719	0.865	rs12830671	ENSG00000205885.6	C1RL-AS1	3.95	9.01e-05	0.00713	0.13	0.18	IgG glycosylation;	chr12:7194682	chr12:7108052~7122501:+
THCA	cis	rs7973719	0.865	rs12820829	ENSG00000205885.6	C1RL-AS1	3.95	9.01e-05	0.00713	0.13	0.18	IgG glycosylation;	chr12:7194938	chr12:7108052~7122501:+
THCA	cis	rs12543725	0.601	rs7018178	ENSG00000253307.1	RP11-10J21.4	-3.95	9.01e-05	0.00713	-0.24	-0.18	Birth weight;	chr8:141229111	chr8:141252286~141253292:-
THCA	cis	rs7660883	0.897	rs3775214	ENSG00000251411.1	RP11-397E7.4	3.95	9.01e-05	0.00713	0.17	0.18	HDL cholesterol levels;	chr4:87102147	chr4:86913266~86914817:-
THCA	cis	rs11673344	0.764	rs826303	ENSG00000267260.1	CTD-2162K18.4	-3.95	9.01e-05	0.00713	-0.22	-0.18	Obesity-related traits;	chr19:36951549	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.764	rs529468	ENSG00000267260.1	CTD-2162K18.4	-3.95	9.01e-05	0.00713	-0.22	-0.18	Obesity-related traits;	chr19:36955298	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.764	rs524802	ENSG00000267260.1	CTD-2162K18.4	-3.95	9.01e-05	0.00713	-0.22	-0.18	Obesity-related traits;	chr19:36956045	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.73	rs826314	ENSG00000267260.1	CTD-2162K18.4	-3.95	9.01e-05	0.00713	-0.22	-0.18	Obesity-related traits;	chr19:36959533	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.764	rs474017	ENSG00000267260.1	CTD-2162K18.4	-3.95	9.01e-05	0.00713	-0.22	-0.18	Obesity-related traits;	chr19:36963217	chr19:36773153~36777078:+
THCA	cis	rs12440869	1	rs8031586	ENSG00000270964.1	RP11-502I4.3	-3.95	9.01e-05	0.00714	-0.16	-0.18	Peak velocity of the mitral A-wave;	chr15:67328315	chr15:67541072~67542604:-
THCA	cis	rs9990333	0.544	rs73208092	ENSG00000207650.1	MIR570	3.95	9.01e-05	0.00714	0.2	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195699401~195699497:+
THCA	cis	rs2298450	0.722	rs62232372	ENSG00000214867.3	SRSF9P1	3.95	9.01e-05	0.00714	0.27	0.18	Schizophrenia;	chr21:36259653	chr21:36295173~36295702:-
THCA	cis	rs4886920	0.894	rs7176895	ENSG00000260776.4	RP11-114H24.2	-3.95	9.01e-05	0.00714	-0.21	-0.18	Neuroticism;	chr15:77825458	chr15:77914217~77926846:-
THCA	cis	rs8028182	0.501	rs7166281	ENSG00000260274.1	RP11-817O13.8	-3.95	9.01e-05	0.00714	-0.13	-0.18	Sudden cardiac arrest;	chr15:75635851	chr15:75368155~75369584:+
THCA	cis	rs16852403	0.583	rs12071903	ENSG00000224687.1	RASAL2-AS1	3.95	9.01e-05	0.00714	0.29	0.18	Childhood ear infection;	chr1:178126669	chr1:178091508~178093984:-
THCA	cis	rs11771526	0.786	rs28670858	ENSG00000272905.1	RP11-265E18.1	3.95	9.02e-05	0.00714	0.24	0.18	Body mass index;	chr7:32253514	chr7:32845394~32846061:+
THCA	cis	rs2933343	0.533	rs13086121	ENSG00000261159.1	RP11-723O4.9	3.95	9.02e-05	0.00714	0.19	0.18	IgG glycosylation;	chr3:128985447	chr3:128859716~128860526:-
THCA	cis	rs1975197	0.515	rs2570293	ENSG00000225706.1	PTPRD-AS1	-3.95	9.02e-05	0.00714	-0.23	-0.18	Restless legs syndrome;	chr9:8838530	chr9:8858130~8862255:+
THCA	cis	rs9543976	0.623	rs9543990	ENSG00000261105.4	LMO7-AS1	3.95	9.02e-05	0.00714	0.25	0.18	Diabetic retinopathy;	chr13:75598298	chr13:75604700~75635994:-
THCA	cis	rs736408	0.509	rs13083798	ENSG00000243224.1	RP5-1157M23.2	-3.95	9.02e-05	0.00714	-0.19	-0.18	Bipolar disorder;	chr3:52615732	chr3:52239258~52241097:+
THCA	cis	rs17221829	0.733	rs7945304	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89639356	chr11:90193614~90198120:+
THCA	cis	rs4268898	0.697	rs10445892	ENSG00000242628.4	AC009228.1	-3.95	9.02e-05	0.00714	-0.22	-0.18	Asthma;	chr2:24184089	chr2:24214381~24221516:+
THCA	cis	rs7074356	0.704	rs1417220	ENSG00000278616.1	BEND3P3	3.95	9.02e-05	0.00714	0.16	0.18	Borderline personality disorder;	chr10:80408398	chr10:79682997~79685436:+
THCA	cis	rs59972978	0.593	rs6099651	ENSG00000124097.7	HMGB1P1	3.95	9.02e-05	0.00714	0.24	0.18	Alcohol consumption;	chr20:57487384	chr20:57488392~57489027:-
THCA	cis	rs59972978	0.593	rs6099652	ENSG00000124097.7	HMGB1P1	3.95	9.02e-05	0.00714	0.24	0.18	Alcohol consumption;	chr20:57487387	chr20:57488392~57489027:-
THCA	cis	rs17156371	0.71	rs10906844	ENSG00000182531.7	OR7E115P	-3.95	9.02e-05	0.00714	-0.31	-0.18	Clozapine-induced agranulocytosis;	chr10:15163772	chr10:15007861~15008884:-
THCA	cis	rs11601239	0.585	rs685374	ENSG00000254750.1	CASP1P2	3.95	9.02e-05	0.00714	0.14	0.18	Refractive error;	chr11:105709386	chr11:105063345~105071541:-
THCA	cis	rs42648	0.935	rs42668	ENSG00000225498.1	AC002064.5	3.95	9.02e-05	0.00714	0.18	0.18	Homocysteine levels;	chr7:90357211	chr7:90312496~90322592:+
THCA	cis	rs17221829	0.733	rs117029483	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89632750	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs10830304	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89633586	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.626	rs10830305	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89633626	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.562	rs10830306	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89633811	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs11018689	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89634623	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.673	rs4753228	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89635989	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs12363392	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89637430	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs10765222	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89638941	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs7942295	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89639173	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.739	rs7945443	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89639454	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.574	rs2773245	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89639458	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.703	rs17818747	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89640522	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.673	rs12364712	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89640679	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.645	rs4002142	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89640845	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.668	rs12364732	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89640886	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.614	rs2388202	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89641063	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.528	rs4561217	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89642097	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.525	rs9804670	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89642633	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.645	rs9804648	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89642672	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs1844199	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89643200	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.537	rs7933470	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89643795	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.589	rs7930747	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89643992	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.703	rs7944552	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89644040	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.536	rs7943784	ENSG00000280385.1	AP000648.5	-3.95	9.02e-05	0.00714	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89644142	chr11:90193614~90198120:+
THCA	cis	rs321358	1	rs73021573	ENSG00000271390.1	RP11-89C3.3	3.95	9.03e-05	0.00714	0.31	0.18	Body mass index;	chr11:111155508	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs73003503	ENSG00000271390.1	RP11-89C3.3	3.95	9.03e-05	0.00714	0.31	0.18	Body mass index;	chr11:111158360	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs73003511	ENSG00000271390.1	RP11-89C3.3	3.95	9.03e-05	0.00714	0.31	0.18	Body mass index;	chr11:111160478	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs73003514	ENSG00000271390.1	RP11-89C3.3	3.95	9.03e-05	0.00714	0.31	0.18	Body mass index;	chr11:111160605	chr11:111089870~111090368:-
THCA	cis	rs11633886	0.565	rs28567025	ENSG00000273972.1	CTD-2306A12.1	3.95	9.03e-05	0.00715	0.2	0.18	Diisocyanate-induced asthma;	chr15:45767239	chr15:45702640~45703183:+
THCA	cis	rs17221829	0.702	rs12360859	ENSG00000280385.1	AP000648.5	-3.95	9.03e-05	0.00715	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89626719	chr11:90193614~90198120:+
THCA	cis	rs6545883	0.655	rs11893880	ENSG00000270820.4	RP11-355B11.2	3.95	9.03e-05	0.00715	0.15	0.18	Tuberculosis;	chr2:61194884	chr2:61471188~61484130:+
THCA	cis	rs2120243	0.508	rs1456106	ENSG00000241770.1	RP11-555M1.3	-3.95	9.03e-05	0.00715	-0.23	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157405667	chr3:157163452~157169133:+
THCA	cis	rs2120243	0.539	rs1456105	ENSG00000241770.1	RP11-555M1.3	-3.95	9.03e-05	0.00715	-0.23	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157405672	chr3:157163452~157169133:+
THCA	cis	rs4906332	1	rs3783397	ENSG00000252469.1	RNU7-160P	3.95	9.03e-05	0.00715	0.19	0.18	Coronary artery disease;	chr14:103480952	chr14:103550345~103550406:+
THCA	cis	rs7554511	0.861	rs11583546	ENSG00000260088.1	RP11-92G12.3	-3.95	9.04e-05	0.00715	-0.28	-0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200933479	chr1:200669507~200694250:+
THCA	cis	rs10256972	0.591	rs11766651	ENSG00000225146.1	AC073957.15	3.95	9.04e-05	0.00715	0.2	0.18	Endometriosis;Longevity;	chr7:1122010	chr7:1029025~1043891:+
THCA	cis	rs3809566	0.963	rs3809565	ENSG00000259459.4	RP11-321G12.1	-3.95	9.04e-05	0.00715	-0.15	-0.18	Platelet count;	chr15:63041420	chr15:63390136~63438320:+
THCA	cis	rs6416877	0.921	rs11655449	ENSG00000277491.1	RP11-676J12.9	-3.95	9.04e-05	0.00716	-0.22	-0.18	Myeloid white cell count;	chr17:1424421	chr17:795306~795794:+
THCA	cis	rs9467773	0.595	rs2172007	ENSG00000261353.1	CTA-14H9.5	-3.95	9.04e-05	0.00716	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26527063~26527404:+
THCA	cis	rs5758659	0.594	rs739292	ENSG00000273366.1	CTA-989H11.1	-3.95	9.04e-05	0.00716	-0.22	-0.18	Cognitive function;	chr22:41972853	chr22:42278188~42278846:+
THCA	cis	rs7166081	0.95	rs72625778	ENSG00000270964.1	RP11-502I4.3	-3.95	9.04e-05	0.00716	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67297765	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs12916403	ENSG00000270964.1	RP11-502I4.3	-3.95	9.04e-05	0.00716	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67299327	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs12594234	ENSG00000270964.1	RP11-502I4.3	-3.95	9.04e-05	0.00716	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67303816	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs34310656	ENSG00000270964.1	RP11-502I4.3	-3.95	9.04e-05	0.00716	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67307637	chr15:67541072~67542604:-
THCA	cis	rs1499614	1	rs1882655	ENSG00000237310.1	GS1-124K5.4	-3.95	9.04e-05	0.00716	-0.21	-0.18	Gout;	chr7:66682070	chr7:66493706~66495474:+
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000237310.1	GS1-124K5.4	-3.95	9.04e-05	0.00716	-0.21	-0.18	Gout;	chr7:66682162	chr7:66493706~66495474:+
THCA	cis	rs1499614	0.901	rs3936	ENSG00000237310.1	GS1-124K5.4	3.95	9.04e-05	0.00716	0.21	0.18	Gout;	chr7:66661502	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs1638731	ENSG00000237310.1	GS1-124K5.4	3.95	9.04e-05	0.00716	0.21	0.18	Gout;	chr7:66679692	chr7:66493706~66495474:+
THCA	cis	rs9291683	0.509	rs6849717	ENSG00000250413.1	RP11-448G15.1	3.95	9.04e-05	0.00716	0.17	0.18	Bone mineral density;	chr4:9957095	chr4:10006482~10009725:+
THCA	cis	rs4664308	0.577	rs62175519	ENSG00000226266.5	AC009961.3	-3.95	9.04e-05	0.00716	-0.29	-0.18	Idiopathic membranous nephropathy;	chr2:160059113	chr2:159670708~159712435:-
THCA	cis	rs71520386	0.632	rs9692432	ENSG00000226329.2	AC005682.6	-3.95	9.04e-05	0.00716	-0.23	-0.18	Fibrinogen levels;	chr7:22829244	chr7:22863874~22881350:-
THCA	cis	rs9733	0.681	rs7412746	ENSG00000231073.1	RP11-316M1.3	-3.95	9.04e-05	0.00716	-0.22	-0.18	Tonsillectomy;	chr1:150887995	chr1:150973123~150975534:+
THCA	cis	rs6715284	0.786	rs1009276	ENSG00000183308.6	AC005037.3	-3.95	9.04e-05	0.00716	-0.44	-0.18	Rheumatoid arthritis;	chr2:201458233	chr2:200963263~201009102:+
THCA	cis	rs10875746	0.903	rs2158516	ENSG00000258234.1	RP11-370I10.2	3.95	9.05e-05	0.00716	0.21	0.18	Longevity (90 years and older);	chr12:48097051	chr12:48231098~48284210:-
THCA	cis	rs17221829	0.627	rs10830315	ENSG00000280385.1	AP000648.5	-3.95	9.05e-05	0.00716	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89642406	chr11:90193614~90198120:+
THCA	cis	rs12681366	0.734	rs2291439	ENSG00000261437.1	RP11-22C11.2	3.95	9.05e-05	0.00716	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94407470	chr8:94637285~94639467:-
THCA	cis	rs9818758	0.545	rs55921200	ENSG00000229759.1	MRPS18AP1	-3.95	9.05e-05	0.00716	-0.41	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49151883	chr3:48256350~48256938:-
THCA	cis	rs1552244	0.515	rs67626468	ENSG00000180385.7	EMC3-AS1	3.95	9.05e-05	0.00716	0.23	0.18	Alzheimer's disease;	chr3:10119834	chr3:9986893~10006990:+
THCA	cis	rs11089937	1	rs11089937	ENSG00000263366.2	LL22NC03-33B6.4	-3.95	9.05e-05	0.00716	-0.23	-0.18	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22114844~22118005:-
THCA	cis	rs8062405	1	rs7187776	ENSG00000261766.1	RP11-22P6.2	-3.95	9.05e-05	0.00716	-0.17	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28862166~28863340:-
THCA	cis	rs7259376	0.905	rs62118584	ENSG00000269138.1	ZNF209P	3.95	9.05e-05	0.00716	0.18	0.18	Menopause (age at onset);	chr19:22358340	chr19:22463922~22473036:+
THCA	cis	rs12444979	0.517	rs75594829	ENSG00000261195.1	CTD-2380F24.1	-3.95	9.05e-05	0.00716	-0.29	-0.18	Body mass index;	chr16:19783001	chr16:19761172~19766099:-
THCA	cis	rs12446554	0.528	rs117650757	ENSG00000261195.1	CTD-2380F24.1	-3.95	9.05e-05	0.00716	-0.29	-0.18	Obesity;	chr16:19783003	chr16:19761172~19766099:-
THCA	cis	rs4722166	0.532	rs6963866	ENSG00000225541.1	AC002480.5	-3.95	9.05e-05	0.00716	-0.2	-0.18	Lung cancer;	chr7:22717722	chr7:22571607~22661792:-
THCA	cis	rs7403037	0.583	rs12904497	ENSG00000260760.1	PWRN3	-3.95	9.05e-05	0.00716	-0.25	-0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24564703	chr15:24441127~24447967:+
THCA	cis	rs733175	0.855	rs10022499	ENSG00000261490.1	RP11-448G15.3	3.95	9.05e-05	0.00716	0.13	0.18	Psychosis and Alzheimer's disease;	chr4:10004913	chr4:10068089~10073019:-
THCA	cis	rs733175	0.855	rs9291640	ENSG00000261490.1	RP11-448G15.3	3.95	9.05e-05	0.00716	0.13	0.18	Psychosis and Alzheimer's disease;	chr4:10005462	chr4:10068089~10073019:-
THCA	cis	rs733175	0.855	rs9291641	ENSG00000261490.1	RP11-448G15.3	3.95	9.05e-05	0.00716	0.13	0.18	Psychosis and Alzheimer's disease;	chr4:10005635	chr4:10068089~10073019:-
THCA	cis	rs3024505	1	rs3024495	ENSG00000234219.1	CDCA4P4	3.95	9.05e-05	0.00716	0.28	0.18	Type 1 diabetes;Systemic lupus erythematosus;Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:206769068	chr1:207762584~207763263:+
THCA	cis	rs11658311	0.85	rs58729290	ENSG00000226478.3	UPF3AP1	-3.95	9.05e-05	0.00716	-0.42	-0.18	Obsessive-compulsive symptoms;	chr17:17543626	chr17:16745636~16746761:-
THCA	cis	rs7616559	0.924	rs9867759	ENSG00000244515.1	KRT18P34	-3.95	9.05e-05	0.00716	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157007419	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.82	rs9829700	ENSG00000244515.1	KRT18P34	-3.95	9.05e-05	0.00716	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157007420	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.962	rs9818427	ENSG00000244515.1	KRT18P34	-3.95	9.05e-05	0.00716	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157009043	chr3:157162663~157163932:-
THCA	cis	rs35740288	0.753	rs4843095	ENSG00000259407.1	RP11-158M2.3	-3.95	9.05e-05	0.00716	-0.22	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85731900	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.822	rs11630549	ENSG00000259407.1	RP11-158M2.3	-3.95	9.05e-05	0.00716	-0.22	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85732565	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.822	rs56322219	ENSG00000259407.1	RP11-158M2.3	-3.95	9.05e-05	0.00716	-0.22	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85733109	chr15:85744109~85750281:-
THCA	cis	rs2836974	0.897	rs35391055	ENSG00000255568.3	BRWD1-AS2	3.95	9.05e-05	0.00716	0.16	0.18	Cognitive function;	chr21:39153590	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs2836924	ENSG00000255568.3	BRWD1-AS2	3.95	9.05e-05	0.00716	0.16	0.18	Cognitive function;	chr21:39153713	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs4817996	ENSG00000255568.3	BRWD1-AS2	3.95	9.05e-05	0.00716	0.16	0.18	Cognitive function;	chr21:39153833	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs6517513	ENSG00000255568.3	BRWD1-AS2	3.95	9.05e-05	0.00716	0.16	0.18	Cognitive function;	chr21:39154952	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.899	rs6517514	ENSG00000255568.3	BRWD1-AS2	3.95	9.05e-05	0.00716	0.16	0.18	Cognitive function;	chr21:39155169	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.829	rs8128191	ENSG00000255568.3	BRWD1-AS2	3.95	9.05e-05	0.00716	0.16	0.18	Cognitive function;	chr21:39155385	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.897	rs8132419	ENSG00000255568.3	BRWD1-AS2	3.95	9.05e-05	0.00716	0.16	0.18	Cognitive function;	chr21:39155901	chr21:39313935~39314962:+
THCA	cis	rs2839186	0.619	rs2187118	ENSG00000215424.8	MCM3AP-AS1	3.95	9.05e-05	0.00716	0.1	0.18	Testicular germ cell tumor;	chr21:46191396	chr21:46229217~46259390:+
THCA	cis	rs1009077	0.627	rs7672961	ENSG00000260091.1	RP11-33B1.4	3.95	9.05e-05	0.00716	0.17	0.18	Endometriosis;	chr4:119623194	chr4:119409333~119410233:+
THCA	cis	rs9457247	0.508	rs2285147	ENSG00000235272.1	FAM103A2P	3.95	9.06e-05	0.00717	0.24	0.18	Crohn's disease;	chr6:167092060	chr6:166586124~166586477:-
THCA	cis	rs3764021	0.87	rs11052710	ENSG00000214776.8	RP11-726G1.1	3.95	9.06e-05	0.00717	0.22	0.18	Type 1 diabetes;	chr12:9723754	chr12:9467552~9576275:+
THCA	cis	rs42648	0.72	rs9655741	ENSG00000225498.1	AC002064.5	3.95	9.06e-05	0.00717	0.19	0.18	Homocysteine levels;	chr7:90304560	chr7:90312496~90322592:+
THCA	cis	rs2221894	1	rs2221894	ENSG00000251191.6	LINC00589	-3.95	9.06e-05	0.00717	-0.22	-0.18	Obesity-related traits;	chr8:28933642	chr8:29673922~29748109:-
THCA	cis	rs1383484	1	rs7176613	ENSG00000259728.4	LINC00933	-3.95	9.06e-05	0.00717	-0.22	-0.18	Height;	chr15:83834450	chr15:84570649~84580175:+
THCA	cis	rs6801044	0.65	rs823519	ENSG00000223711.1	AC091633.3	3.95	9.06e-05	0.00717	0.24	0.18	Creatinine levels in ischemic stroke;	chr3:195544046	chr3:195544048~195550581:+
THCA	cis	rs6546886	0.912	rs7560668	ENSG00000235499.1	AC073046.25	3.95	9.06e-05	0.00717	0.17	0.18	Dialysis-related mortality;	chr2:74073590	chr2:73985132~73986343:+
THCA	cis	rs7178424	0.811	rs12593844	ENSG00000259251.2	RP11-643M14.1	3.95	9.06e-05	0.00717	0.18	0.18	Height;	chr15:61954868	chr15:62060503~62062434:+
THCA	cis	rs7772486	0.764	rs2265468	ENSG00000270638.1	RP3-466P17.1	3.95	9.06e-05	0.00717	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145735570~145737218:+
THCA	cis	rs1836229	1	rs1434253	ENSG00000225706.1	PTPRD-AS1	-3.95	9.07e-05	0.00717	-0.21	-0.18	Restless legs syndrome;	chr9:8822069	chr9:8858130~8862255:+
THCA	cis	rs62045844	0.536	rs9940965	ENSG00000261546.1	CTD-2555A7.3	3.95	9.07e-05	0.00717	0.31	0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:89114256	chr16:89113175~89115279:-
THCA	cis	rs1371614	0.635	rs34803465	ENSG00000272148.1	RP11-195B17.1	-3.95	9.07e-05	0.00717	-0.17	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26915417	chr2:27062428~27062907:-
THCA	cis	rs801193	0.66	rs974239	ENSG00000230189.5	GS1-124K5.2	3.95	9.07e-05	0.00717	0.12	0.18	Aortic root size;	chr7:66748504	chr7:66409143~66490059:-
THCA	cis	rs7959452	0.535	rs7135092	ENSG00000274979.1	RP11-1143G9.5	-3.95	9.07e-05	0.00717	-0.19	-0.18	Blood protein levels;	chr12:69264550	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.535	rs7308481	ENSG00000274979.1	RP11-1143G9.5	-3.95	9.07e-05	0.00717	-0.19	-0.18	Blood protein levels;	chr12:69265519	chr12:69326574~69331882:-
THCA	cis	rs11220082	0.666	rs35203305	ENSG00000254671.2	STT3A-AS1	-3.95	9.07e-05	0.00717	-0.21	-0.18	Schizophrenia;	chr11:125468987	chr11:125570284~125592568:-
THCA	cis	rs6933660	0.646	rs9397051	ENSG00000219395.2	HSPA8P15	-3.95	9.07e-05	0.00718	-0.16	-0.18	Menarche (age at onset);	chr6:151457190	chr6:151411259~151413945:-
THCA	cis	rs7615952	0.688	rs4422259	ENSG00000272840.1	RP11-379B18.6	3.95	9.07e-05	0.00718	0.27	0.18	Blood pressure (smoking interaction);	chr3:125826988	chr3:125774714~125797953:+
THCA	cis	rs7551222	0.752	rs1380576	ENSG00000240219.1	RP11-430C7.5	3.95	9.07e-05	0.00718	0.17	0.18	Schizophrenia;	chr1:204519150	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.716	rs12041075	ENSG00000240219.1	RP11-430C7.5	3.95	9.07e-05	0.00718	0.17	0.18	Schizophrenia;	chr1:204523025	chr1:204626775~204629712:+
THCA	cis	rs7598759	1	rs7598759	ENSG00000181798.2	LINC00471	-3.95	9.07e-05	0.00718	-0.2	-0.18	Noise-induced hearing loss;	chr2:231457245	chr2:231508426~231514339:-
THCA	cis	rs12234571	1	rs4391357	ENSG00000214293.7	APTR	3.95	9.07e-05	0.00718	0.22	0.18	Obesity-related traits;	chr7:77776304	chr7:77657660~77696265:-
THCA	cis	rs3812831	0.695	rs913526	ENSG00000264539.1	MIR548AR	3.95	9.08e-05	0.00718	0.19	0.18	Schizophrenia;	chr13:114163471	chr13:114244505~114244561:+
THCA	cis	rs6496044	0.568	rs6496040	ENSG00000259630.2	CTD-2262B20.1	-3.95	9.08e-05	0.00718	-0.19	-0.18	Interstitial lung disease;	chr15:85520898	chr15:85415228~85415633:+
THCA	cis	rs6496044	0.568	rs11855789	ENSG00000259630.2	CTD-2262B20.1	-3.95	9.08e-05	0.00718	-0.19	-0.18	Interstitial lung disease;	chr15:85523172	chr15:85415228~85415633:+
THCA	cis	rs2839186	0.619	rs55689527	ENSG00000228137.1	AP001469.7	3.95	9.08e-05	0.00718	0.18	0.18	Testicular germ cell tumor;	chr21:46202813	chr21:46246890~46247682:+
THCA	cis	rs4792901	0.722	rs7220615	ENSG00000267151.3	RP11-100E5.2	3.95	9.08e-05	0.00718	0.2	0.18	Dupuytren's disease;	chr17:43463276	chr17:43444707~43451200:+
THCA	cis	rs4664293	0.631	rs13019272	ENSG00000230783.1	AC009961.2	-3.95	9.08e-05	0.00718	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159802352	chr2:159689217~159690291:-
THCA	cis	rs55726902	1	rs73107993	ENSG00000257488.4	RP5-1057I20.2	3.95	9.08e-05	0.00718	0.3	0.18	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47826854~47837898:+
THCA	cis	rs150992	0.587	rs4448016	ENSG00000246763.5	RGMB-AS1	3.95	9.08e-05	0.00718	0.19	0.18	Body mass index;	chr5:99037904	chr5:98769618~98773469:-
THCA	cis	rs17286411	0.671	rs2036338	ENSG00000260185.1	RP11-432I5.6	3.95	9.08e-05	0.00718	0.25	0.18	Blood protein levels;	chr16:71754927	chr16:71655027~71664212:+
THCA	cis	rs642803	0.527	rs1647570	ENSG00000255557.1	RP11-770G2.2	-3.95	9.08e-05	0.00718	-0.21	-0.18	Urate levels;	chr11:65800785	chr11:65745729~65771585:+
THCA	cis	rs6828577	0.862	rs298991	ENSG00000248280.1	RP11-33B1.2	3.95	9.08e-05	0.00719	0.16	0.18	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118724845	chr4:119440561~119450157:-
THCA	cis	rs962856	0.619	rs1842958	ENSG00000236780.4	AC078941.1	3.95	9.08e-05	0.00719	0.24	0.18	Pancreatic cancer;	chr2:67349427	chr2:67123357~67215319:-
THCA	cis	rs962856	0.592	rs6546296	ENSG00000236780.4	AC078941.1	3.95	9.08e-05	0.00719	0.24	0.18	Pancreatic cancer;	chr2:67351290	chr2:67123357~67215319:-
THCA	cis	rs72829446	0.505	rs62059826	ENSG00000266824.1	RP11-599B13.7	3.95	9.08e-05	0.00719	0.27	0.18	Androgen levels;	chr17:7582265	chr17:8176812~8182812:+
THCA	cis	rs34421088	0.531	rs2245232	ENSG00000255046.1	RP11-297N6.4	3.95	9.08e-05	0.00719	0.19	0.18	Neuroticism;	chr8:11543435	chr8:11797928~11802568:-
THCA	cis	rs4761470	0.577	rs35129588	ENSG00000258172.1	RP11-1105G2.4	-3.95	9.09e-05	0.00719	-0.24	-0.18	Estradiol plasma levels (breast cancer);	chr12:94297780	chr12:94272150~94277195:-
THCA	cis	rs7246967	0.673	rs6511383	ENSG00000198153.8	ZNF849P	-3.95	9.09e-05	0.00719	-0.28	-0.18	Bronchopulmonary dysplasia;	chr19:22774098	chr19:22685167~22686732:+
THCA	cis	rs724818	0.661	rs1588524	ENSG00000251609.2	SETP12	3.95	9.09e-05	0.00719	0.5	0.18	Monobrow thickness;	chr4:120845514	chr4:120895494~120897083:-
THCA	cis	rs6121246	0.954	rs7266148	ENSG00000224628.2	RP5-854E16.2	-3.95	9.09e-05	0.00719	-0.25	-0.18	Mean corpuscular hemoglobin;	chr20:31843267	chr20:31285317~31286835:-
THCA	cis	rs9925964	0.804	rs4889606	ENSG00000260911.2	RP11-196G11.2	3.95	9.09e-05	0.00719	0.15	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30999862	chr16:31043150~31049868:+
THCA	cis	rs9863	0.861	rs7973683	ENSG00000270061.1	RP11-214K3.19	-3.95	9.09e-05	0.00719	-0.23	-0.18	White blood cell count;	chr12:123964676	chr12:123969990~123970344:-
THCA	cis	rs858239	0.899	rs10085838	ENSG00000226816.2	AC005082.12	3.95	9.09e-05	0.00719	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23206013~23208045:+
THCA	cis	rs3758911	1	rs10789615	ENSG00000255353.1	RP11-382M14.1	-3.95	9.09e-05	0.00719	-0.22	-0.18	Coronary artery disease;	chr11:107318088	chr11:107176286~107177530:+
THCA	cis	rs11649653	0.502	rs11864054	ENSG00000279196.1	RP11-1072A3.3	3.95	9.09e-05	0.00719	0.18	0.18	Triglycerides;	chr16:30834813	chr16:30984630~30988270:-
THCA	cis	rs2015599	0.549	rs7311081	ENSG00000275476.1	RP11-996F15.4	3.95	9.09e-05	0.00719	0.17	0.18	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.517	rs7295212	ENSG00000275476.1	RP11-996F15.4	3.95	9.09e-05	0.00719	0.17	0.18	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29277397~29277882:-
THCA	cis	rs6137726	0.508	rs975525	ENSG00000237396.1	LINC01384	3.95	9.09e-05	0.00719	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22659774	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.508	rs2145058	ENSG00000237396.1	LINC01384	3.95	9.09e-05	0.00719	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22660132	chr20:22587522~22607517:-
THCA	cis	rs2841277	0.646	rs2819419	ENSG00000258701.1	LINC00638	3.95	9.09e-05	0.00719	0.19	0.18	Rheumatoid arthritis;	chr14:104939901	chr14:104821201~104823718:+
THCA	cis	rs11239930	0.538	rs4950362	ENSG00000278811.3	LINC00624	3.95	9.09e-05	0.00719	0.21	0.18	AIDS progression;	chr1:147088336	chr1:147258885~147517875:-
THCA	cis	rs1577917	0.958	rs1545376	ENSG00000220563.1	PKMP3	3.95	9.09e-05	0.00719	0.14	0.18	Response to antipsychotic treatment;	chr6:85794864	chr6:85659892~85660606:-
THCA	cis	rs55692468	0.539	rs4664110	ENSG00000213197.3	AC012066.1	-3.95	9.09e-05	0.00719	-0.23	-0.18	Intraocular pressure;	chr2:152461900	chr2:152389937~152390630:+
THCA	cis	rs7572733	0.935	rs771010	ENSG00000231621.1	AC013264.2	3.95	9.09e-05	0.00719	0.17	0.18	Dermatomyositis;	chr2:197826282	chr2:197197991~197199273:+
THCA	cis	rs1552244	0.554	rs3732964	ENSG00000269982.1	RP11-1020A11.2	3.95	9.09e-05	0.00719	0.13	0.18	Alzheimer's disease;	chr3:10007155	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs3732963	ENSG00000269982.1	RP11-1020A11.2	3.95	9.09e-05	0.00719	0.13	0.18	Alzheimer's disease;	chr3:10007201	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.608	rs3732962	ENSG00000269982.1	RP11-1020A11.2	3.95	9.09e-05	0.00719	0.13	0.18	Alzheimer's disease;	chr3:10007267	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs2272118	ENSG00000269982.1	RP11-1020A11.2	3.95	9.09e-05	0.00719	0.13	0.18	Alzheimer's disease;	chr3:10007603	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs58020561	ENSG00000269982.1	RP11-1020A11.2	3.95	9.09e-05	0.00719	0.13	0.18	Alzheimer's disease;	chr3:10012998	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs13081079	ENSG00000269982.1	RP11-1020A11.2	3.95	9.09e-05	0.00719	0.13	0.18	Alzheimer's disease;	chr3:10014664	chr3:9958717~9962539:+
THCA	cis	rs7511006	0.798	rs11703673	ENSG00000273137.1	RP3-402G11.28	3.95	9.09e-05	0.00719	0.13	0.18	Obesity-related traits;	chr22:50213998	chr22:50208461~50209542:-
THCA	cis	rs2408955	0.522	rs3997	ENSG00000257735.1	RP11-370I10.6	-3.95	9.1e-05	0.00719	-0.21	-0.18	Glycated hemoglobin levels;	chr12:48087804	chr12:48350945~48442411:+
THCA	cis	rs61160187	0.583	rs6449503	ENSG00000215032.2	GNL3LP1	-3.95	9.1e-05	0.0072	-0.22	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60891935~60893577:-
THCA	cis	rs17685	0.712	rs6976236	ENSG00000227038.2	AC005077.12	3.95	9.1e-05	0.0072	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76111769	chr7:76090431~76108779:-
THCA	cis	rs758324	0.687	rs156057	ENSG00000224431.1	AC063976.7	-3.95	9.1e-05	0.0072	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132142341	chr5:132199456~132203487:+
THCA	cis	rs962856	0.506	rs6546306	ENSG00000236780.4	AC078941.1	3.95	9.1e-05	0.0072	0.25	0.18	Pancreatic cancer;	chr2:67413977	chr2:67123357~67215319:-
THCA	cis	rs10833905	1	rs1863627	ENSG00000246225.5	RP11-17A1.3	-3.95	9.1e-05	0.0072	-0.25	-0.18	Sudden cardiac arrest;	chr11:23044317	chr11:22829380~22945393:+
THCA	cis	rs3105593	1	rs3109878	ENSG00000242737.1	RP11-562A8.1	3.95	9.1e-05	0.0072	0.22	0.18	QT interval;	chr15:50544046	chr15:50466738~50467096:+
THCA	cis	rs7520050	0.966	rs9429183	ENSG00000281133.1	AL355480.3	3.95	9.1e-05	0.0072	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45580892~45580996:-
THCA	cis	rs10761482	0.861	rs2393625	ENSG00000254271.1	RP11-131N11.4	-3.95	9.1e-05	0.0072	-0.24	-0.18	Schizophrenia;	chr10:60359448	chr10:60734342~60741828:+
THCA	cis	rs7829975	0.714	rs60315134	ENSG00000233609.3	RP11-62H7.2	3.95	9.1e-05	0.0072	0.17	0.18	Mood instability;	chr8:8813089	chr8:8961200~8979025:+
THCA	cis	rs7267979	0.966	rs454723	ENSG00000276952.1	RP5-965G21.6	3.95	9.1e-05	0.0072	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25284915~25285588:-
THCA	cis	rs10029851	0.56	rs3910459	ENSG00000234492.4	RPL34-AS1	3.95	9.1e-05	0.0072	0.17	0.18	Amyotrophic lateral sclerosis (sporadic);	chr4:108691132	chr4:108538190~108620460:-
THCA	cis	rs7940646	0.812	rs4910165	ENSG00000254554.1	RP11-351I24.1	-3.95	9.1e-05	0.0072	-0.21	-0.18	Platelet aggregation;	chr11:10652497	chr11:10302657~10303704:-
THCA	cis	rs4470077	1	rs4470077	ENSG00000258413.1	RP11-665C16.6	-3.95	9.1e-05	0.0072	-0.31	-0.18	Platelet count;	chr14:55430820	chr14:55262767~55272075:-
THCA	cis	rs4470077	1	rs10146352	ENSG00000258413.1	RP11-665C16.6	-3.95	9.1e-05	0.0072	-0.31	-0.18	Platelet count;	chr14:55430871	chr14:55262767~55272075:-
THCA	cis	rs9925964	0.933	rs9939417	ENSG00000279196.1	RP11-1072A3.3	-3.95	9.1e-05	0.0072	-0.17	-0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042146	chr16:30984630~30988270:-
THCA	cis	rs1541160	0.879	rs2065950	ENSG00000239494.2	RN7SL333P	3.95	9.1e-05	0.0072	0.18	0.18	Amyotrophic lateral sclerosis;	chr1:170046125	chr1:169859756~169860052:+
THCA	cis	rs10090774	0.71	rs10103745	ENSG00000279766.1	RP11-642A1.2	-3.95	9.1e-05	0.0072	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140680544	chr8:140572142~140572812:-
THCA	cis	rs1404100	0.51	rs2341683	ENSG00000249274.1	PDLIM1P4	3.95	9.1e-05	0.0072	0.18	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99069807	chr3:98782188~98783193:+
THCA	cis	rs9291059	0.737	rs12494647	ENSG00000236297.1	RP11-175P19.2	3.95	9.1e-05	0.0072	0.39	0.18	Depressive symptoms (multi-trait analysis);	chr3:193668868	chr3:193578812~193593090:-
THCA	cis	rs9923856	0.616	rs876476	ENSG00000263033.2	RP11-396B14.2	-3.95	9.11e-05	0.0072	-0.16	-0.18	Atopic dermatitis;Adult asthma;	chr16:11056391	chr16:11196177~11224969:+
THCA	cis	rs17801127	0.818	rs17744655	ENSG00000231969.1	AC144449.1	3.95	9.11e-05	0.0072	0.38	0.18	Liver enzyme levels (alanine transaminase);	chr2:149709805	chr2:149587196~149848233:+
THCA	cis	rs6142618	0.583	rs6119771	ENSG00000224452.1	RSL24D1P6	3.95	9.11e-05	0.0072	0.21	0.18	Inflammatory bowel disease;	chr20:32182572	chr20:32170390~32170790:-
THCA	cis	rs5758659	0.652	rs133336	ENSG00000270083.1	RP1-257I20.14	3.95	9.11e-05	0.0072	0.19	0.18	Cognitive function;	chr22:42020299	chr22:42089630~42090028:-
THCA	cis	rs10435719	0.773	rs7842810	ENSG00000254948.1	OR7E158P	-3.95	9.11e-05	0.0072	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:11919900~11920809:-
THCA	cis	rs875971	0.502	rs2946580	ENSG00000273024.4	INTS4P2	3.95	9.11e-05	0.0072	0.23	0.18	Aortic root size;	chr7:66066855	chr7:65647864~65715661:+
THCA	cis	rs559928	0.597	rs2096706	ENSG00000236935.1	AP003774.1	3.95	9.11e-05	0.0072	0.26	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64156974	chr11:64325050~64329504:-
THCA	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	3.95	9.11e-05	0.0072	0.16	0.18	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
THCA	cis	rs2436845	0.554	rs647313	ENSG00000253320.4	KB-1507C5.2	-3.95	9.11e-05	0.0072	-0.15	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102904426	chr8:102864300~102977876:+
THCA	cis	rs7927592	0.513	rs653056	ENSG00000160172.9	FAM86C2P	3.95	9.11e-05	0.0072	0.17	0.18	Total body bone mineral density;	chr11:68436157	chr11:67791648~67805336:-
THCA	cis	rs6504108	0.624	rs2021752	ENSG00000264920.1	RP11-6N17.4	3.95	9.11e-05	0.0072	0.15	0.18	Body mass index;	chr17:48162901	chr17:47891255~47895812:-
THCA	cis	rs337161	0.719	rs337147	ENSG00000221571.3	RNU6ATAC35P	-3.95	9.11e-05	0.00721	-0.2	-0.18	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220767069	chr1:220825620~220826063:+
THCA	cis	rs4950322	1	rs72694750	ENSG00000226015.2	CCT8P1	3.95	9.11e-05	0.00721	0.22	0.18	Protein quantitative trait loci;	chr1:147396856	chr1:147203276~147204932:-
THCA	cis	rs4950322	1	rs1986987	ENSG00000226015.2	CCT8P1	3.95	9.11e-05	0.00721	0.22	0.18	Protein quantitative trait loci;	chr1:147397553	chr1:147203276~147204932:-
THCA	cis	rs4950322	1	rs61230354	ENSG00000226015.2	CCT8P1	3.95	9.11e-05	0.00721	0.22	0.18	Protein quantitative trait loci;	chr1:147398161	chr1:147203276~147204932:-
THCA	cis	rs4950322	1	rs4950429	ENSG00000226015.2	CCT8P1	3.95	9.11e-05	0.00721	0.22	0.18	Protein quantitative trait loci;	chr1:147400227	chr1:147203276~147204932:-
THCA	cis	rs4950322	1	rs59498179	ENSG00000226015.2	CCT8P1	3.95	9.11e-05	0.00721	0.22	0.18	Protein quantitative trait loci;	chr1:147400417	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.947	rs58671552	ENSG00000226015.2	CCT8P1	3.95	9.11e-05	0.00721	0.22	0.18	Protein quantitative trait loci;	chr1:147409534	chr1:147203276~147204932:-
THCA	cis	rs9863	0.794	rs7133378	ENSG00000270061.1	RP11-214K3.19	-3.95	9.11e-05	0.00721	-0.24	-0.18	White blood cell count;	chr12:123924955	chr12:123969990~123970344:-
THCA	cis	rs1348850	0.597	rs13014417	ENSG00000280374.1	RP11-337N6.3	-3.95	9.11e-05	0.00721	-0.28	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177553107	chr2:177317715~177318471:-
THCA	cis	rs10861661	0.963	rs12424054	ENSG00000260329.1	RP11-412D9.4	3.95	9.11e-05	0.00721	0.21	0.18	Triglyceride levels;	chr12:106792969	chr12:106954029~106955497:-
THCA	cis	rs686320	0.748	rs673753	ENSG00000254614.2	AP003068.23	-3.95	9.11e-05	0.00721	-0.33	-0.18	Hip circumference adjusted for BMI;	chr11:65438546	chr11:65177606~65181834:-
THCA	cis	rs910316	1	rs10146482	ENSG00000259138.1	RP11-950C14.7	3.95	9.11e-05	0.00721	0.16	0.18	Height;	chr14:75107384	chr14:75127153~75136930:+
THCA	cis	rs61160187	0.75	rs1807017	ENSG00000215032.2	GNL3LP1	3.95	9.12e-05	0.00721	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:60891935~60893577:-
THCA	cis	rs17597773	0.638	rs11118615	ENSG00000272823.1	RP11-295M18.6	-3.95	9.12e-05	0.00721	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220823271	chr1:220828676~220829211:-
THCA	cis	rs5758659	0.569	rs133293	ENSG00000273366.1	CTA-989H11.1	-3.95	9.12e-05	0.00721	-0.22	-0.18	Cognitive function;	chr22:41986793	chr22:42278188~42278846:+
THCA	cis	rs7726839	1	rs7726839	ENSG00000225138.6	CTD-2228K2.7	3.95	9.12e-05	0.00721	0.18	0.18	Obesity-related traits;	chr5:618471	chr5:473236~480884:+
THCA	cis	rs13118159	0.55	rs28522910	ENSG00000254094.1	AC078852.1	-3.95	9.12e-05	0.00721	-0.21	-0.18	Longevity;	chr4:1380986	chr4:1356581~1358075:+
THCA	cis	rs36093844	0.752	rs7950738	ENSG00000279742.1	RP11-700A24.1	-3.95	9.12e-05	0.00721	-0.28	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85841715	chr11:85852557~85854943:-
THCA	cis	rs9400467	0.7	rs55812705	ENSG00000219773.1	RP11-506B6.3	-3.95	9.12e-05	0.00721	-0.24	-0.18	Amino acid levels;Blood metabolite levels;	chr6:111417590	chr6:112355841~112356714:-
THCA	cis	rs6494488	0.5	rs72741307	ENSG00000259635.1	AC100830.3	-3.95	9.12e-05	0.00721	-0.46	-0.18	Coronary artery disease;	chr15:64408024	chr15:64701248~64719602:+
THCA	cis	rs2414856	0.51	rs77109323	ENSG00000259635.1	AC100830.3	-3.95	9.12e-05	0.00721	-0.46	-0.18	Pulse pressure;Systolic blood pressure;	chr15:64412742	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs34758599	ENSG00000259635.1	AC100830.3	-3.95	9.12e-05	0.00721	-0.46	-0.18	Coronary artery disease;	chr15:64414133	chr15:64701248~64719602:+
THCA	cis	rs42648	0.748	rs12673914	ENSG00000225498.1	AC002064.5	3.95	9.12e-05	0.00721	0.19	0.18	Homocysteine levels;	chr7:90314075	chr7:90312496~90322592:+
THCA	cis	rs2191566	0.664	rs55958002	ENSG00000266921.1	RP11-15A1.7	-3.95	9.12e-05	0.00721	-0.17	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44039635	chr19:43996896~44002836:-
THCA	cis	rs17685	0.753	rs10262501	ENSG00000230882.1	AC005077.14	-3.95	9.12e-05	0.00721	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76038854	chr7:76071469~76074963:-
THCA	cis	rs9393777	0.764	rs35565446	ENSG00000220721.1	OR1F12	3.95	9.12e-05	0.00721	0.41	0.18	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28073316~28074233:+
THCA	cis	rs13118159	0.509	rs10023473	ENSG00000254094.1	AC078852.1	-3.95	9.12e-05	0.00721	-0.21	-0.18	Longevity;	chr4:1381497	chr4:1356581~1358075:+
THCA	cis	rs7760535	0.597	rs9320368	ENSG00000271789.1	RP5-1112D6.7	-3.95	9.12e-05	0.00721	-0.17	-0.18	Metabolic traits;	chr6:111583534	chr6:111297126~111298510:+
THCA	cis	rs7809615	0.748	rs10215854	ENSG00000244219.5	GS1-259H13.2	-3.95	9.12e-05	0.00721	-0.3	-0.18	Blood metabolite ratios;	chr7:99439297	chr7:99598066~99610813:+
THCA	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	3.95	9.12e-05	0.00721	0.2	0.18	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
THCA	cis	rs12681366	0.734	rs716770	ENSG00000261437.1	RP11-22C11.2	3.95	9.13e-05	0.00721	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94378693	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.734	rs10504936	ENSG00000261437.1	RP11-22C11.2	3.95	9.13e-05	0.00721	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94379827	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.734	rs10112606	ENSG00000261437.1	RP11-22C11.2	3.95	9.13e-05	0.00721	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94383838	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.708	rs12680029	ENSG00000261437.1	RP11-22C11.2	3.95	9.13e-05	0.00721	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94392418	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.647	rs12545262	ENSG00000261437.1	RP11-22C11.2	3.95	9.13e-05	0.00721	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94392813	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.734	rs28641679	ENSG00000261437.1	RP11-22C11.2	3.95	9.13e-05	0.00721	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94394465	chr8:94637285~94639467:-
THCA	cis	rs786425	0.711	rs12819746	ENSG00000278112.1	RP11-972P1.11	3.95	9.13e-05	0.00721	0.17	0.18	Pubertal anthropometrics;	chr12:123709027	chr12:123519390~123519856:-
THCA	cis	rs17221829	0.703	rs1962258	ENSG00000280385.1	AP000648.5	-3.95	9.13e-05	0.00722	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89647519	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.673	rs1962257	ENSG00000280385.1	AP000648.5	-3.95	9.13e-05	0.00722	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89647569	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs12421371	ENSG00000280385.1	AP000648.5	-3.95	9.13e-05	0.00722	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89647840	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs12421374	ENSG00000280385.1	AP000648.5	-3.95	9.13e-05	0.00722	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89647899	chr11:90193614~90198120:+
THCA	cis	rs13434995	0.513	rs62303730	ENSG00000249700.7	SRD5A3-AS1	-3.95	9.13e-05	0.00722	-0.26	-0.18	Adiponectin levels;	chr4:55498948	chr4:55363971~55395847:-
THCA	cis	rs758324	0.947	rs11948962	ENSG00000237714.1	P4HA2-AS1	3.95	9.13e-05	0.00722	0.26	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131778137	chr5:132184876~132192808:+
THCA	cis	rs7179456	0.567	rs72745027	ENSG00000245975.2	RP11-30K9.6	-3.95	9.13e-05	0.00722	-0.17	-0.18	Asperger disorder;	chr15:58802130	chr15:58768072~58770974:-
THCA	cis	rs4759375	1	rs10773005	ENSG00000256092.2	RP13-942N8.1	-3.95	9.14e-05	0.00722	-0.2	-0.18	HDL cholesterol;	chr12:123305460	chr12:123363868~123366113:+
THCA	cis	rs12105510	0.626	rs35500968	ENSG00000270696.1	RP11-342K6.1	-3.95	9.14e-05	0.00722	-0.18	-0.18	Response to platinum-based chemotherapy (cisplatin);	chr2:75637534	chr2:75660462~75662208:+
THCA	cis	rs2286503	0.752	rs59538378	ENSG00000226329.2	AC005682.6	3.95	9.14e-05	0.00722	0.22	0.18	Fibrinogen;	chr7:22837478	chr7:22863874~22881350:-
THCA	cis	rs11955398	0.502	rs10052649	ENSG00000272308.1	RP11-231G3.1	3.95	9.14e-05	0.00722	0.19	0.18	Intelligence (multi-trait analysis);	chr5:60859157	chr5:60866457~60866935:-
THCA	cis	rs7178909	0.835	rs8035374	ENSG00000259677.1	RP11-493E3.1	3.95	9.14e-05	0.00722	0.21	0.18	Common traits (Other);	chr15:89851966	chr15:89876540~89877285:+
THCA	cis	rs1850744	0.51	rs1996335	ENSG00000250942.1	ENPP7P11	3.95	9.14e-05	0.00722	0.24	0.18	Economic and political preferences;	chr4:9824190	chr4:9677308~9677934:+
THCA	cis	rs1908814	0.516	rs10113062	ENSG00000254948.1	OR7E158P	-3.95	9.14e-05	0.00722	-0.22	-0.18	Neuroticism;	chr8:11935740	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.516	rs10113145	ENSG00000254948.1	OR7E158P	-3.95	9.14e-05	0.00722	-0.22	-0.18	Neuroticism;	chr8:11935786	chr8:11919900~11920809:-
THCA	cis	rs10266483	0.96	rs679883	ENSG00000271550.1	BNIP3P11	-3.95	9.14e-05	0.00722	-0.22	-0.18	Response to statin therapy;	chr7:64289990	chr7:64678954~64687393:-
THCA	cis	rs4272720	0.666	rs17011744	ENSG00000234736.4	FAM170B-AS1	-3.95	9.14e-05	0.00722	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49072989	chr10:49121839~49151547:+
THCA	cis	rs9660180	0.967	rs9660106	ENSG00000215914.4	MMP23A	-3.95	9.14e-05	0.00722	-0.24	-0.18	Body mass index;	chr1:1866508	chr1:1699942~1701782:+
THCA	cis	rs9309473	1	rs3738848	ENSG00000273245.1	RP11-434P11.2	3.95	9.14e-05	0.00722	0.24	0.18	Metabolite levels;	chr2:73534754	chr2:73750256~73750786:-
THCA	cis	rs6921919	0.638	rs2108926	ENSG00000176933.5	TOB2P1	-3.95	9.14e-05	0.00722	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28217643~28218634:-
THCA	cis	rs41342147	0.66	rs7559564	ENSG00000223374.1	AC005104.3	3.95	9.14e-05	0.00723	0.16	0.18	Vitiligo;	chr2:241300503	chr2:241351340~241353104:-
THCA	cis	rs2692947	0.74	rs11695514	ENSG00000232931.4	LINC00342	3.95	9.14e-05	0.00723	0.15	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95882320	chr2:95807118~95816215:-
THCA	cis	rs4925386	0.759	rs2427293	ENSG00000275437.1	RP5-908M14.10	-3.95	9.15e-05	0.00723	-0.18	-0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62402236~62405935:-
THCA	cis	rs7259376	0.807	rs7254434	ENSG00000269345.1	VN1R85P	3.95	9.15e-05	0.00723	0.19	0.18	Menopause (age at onset);	chr19:22317231	chr19:22174766~22175191:-
THCA	cis	rs7208859	0.673	rs216418	ENSG00000280069.1	CTD-2349P21.3	-3.95	9.15e-05	0.00723	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs216423	ENSG00000280069.1	CTD-2349P21.3	-3.95	9.15e-05	0.00723	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30738182~30740275:+
THCA	cis	rs1577917	0.71	rs9342041	ENSG00000220563.1	PKMP3	3.95	9.15e-05	0.00723	0.13	0.18	Response to antipsychotic treatment;	chr6:85571157	chr6:85659892~85660606:-
THCA	cis	rs6504108	0.577	rs2109982	ENSG00000264920.1	RP11-6N17.4	-3.95	9.15e-05	0.00723	-0.15	-0.18	Body mass index;	chr17:48167407	chr17:47891255~47895812:-
THCA	cis	rs1985732	1	rs1985732	ENSG00000124549.13	BTN2A3P	-3.95	9.15e-05	0.00723	-0.19	-0.18	Depressive symptoms (multi-trait analysis);	chr6:26375933	chr6:26421391~26432383:+
THCA	cis	rs1861628	0.512	rs10932677	ENSG00000237930.1	AC007563.4	-3.95	9.15e-05	0.00723	-0.28	-0.18	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216762427	chr2:216785774~216786144:-
THCA	cis	rs860295	1	rs822527	ENSG00000160766.13	GBAP1	3.95	9.15e-05	0.00723	0.2	0.18	Body mass index;	chr1:155768262	chr1:155213821~155227422:-
THCA	cis	rs10875746	0.669	rs11168499	ENSG00000258273.1	RP11-370I10.4	3.95	9.15e-05	0.00723	0.26	0.18	Longevity (90 years and older);	chr12:48268887	chr12:48333755~48333901:-
THCA	cis	rs2836974	0.899	rs34433511	ENSG00000255568.3	BRWD1-AS2	3.95	9.15e-05	0.00723	0.16	0.18	Cognitive function;	chr21:39246957	chr21:39313935~39314962:+
THCA	cis	rs3738443	0.52	rs6699577	ENSG00000259865.1	RP11-488L18.10	3.95	9.15e-05	0.00723	0.16	0.18	Alcohol dependence;	chr1:247224152	chr1:247187281~247188526:-
THCA	cis	rs748404	0.533	rs2139651	ENSG00000249839.1	AC011330.5	3.95	9.16e-05	0.00724	0.21	0.18	Lung cancer;	chr15:43126560	chr15:43663654~43684339:-
THCA	cis	rs4908760	0.868	rs12131864	ENSG00000270282.1	RP5-1115A15.2	3.95	9.16e-05	0.00724	0.21	0.18	Vitiligo;	chr1:8531103	chr1:8512653~8513021:+
THCA	cis	rs9393777	0.778	rs4452638	ENSG00000280107.1	AL022393.9	3.95	9.16e-05	0.00724	0.3	0.18	Intelligence (multi-trait analysis);	chr6:27261486	chr6:28170845~28172521:+
THCA	cis	rs465969	1	rs13208890	ENSG00000272356.1	RP5-1112D6.8	3.95	9.16e-05	0.00724	0.26	0.18	Psoriasis;	chr6:111500620	chr6:111309203~111313517:+
THCA	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	3.95	9.16e-05	0.00724	0.16	0.18	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
THCA	cis	rs11758351	0.866	rs75091077	ENSG00000216331.1	HIST1H1PS1	3.95	9.16e-05	0.00724	0.28	0.18	Renal underexcretion gout;Gout;	chr6:26207318	chr6:26195566~26195771:+
THCA	cis	rs2281636	0.754	rs7092699	ENSG00000233690.1	EBAG9P1	3.95	9.16e-05	0.00724	0.17	0.18	Obesity-related traits;	chr10:99605545	chr10:99697407~99697949:-
THCA	cis	rs150992	0.593	rs34497	ENSG00000246763.5	RGMB-AS1	3.95	9.16e-05	0.00724	0.18	0.18	Body mass index;	chr5:98962885	chr5:98769618~98773469:-
THCA	cis	rs150992	0.593	rs34496	ENSG00000246763.5	RGMB-AS1	3.95	9.16e-05	0.00724	0.18	0.18	Body mass index;	chr5:98963812	chr5:98769618~98773469:-
THCA	cis	rs150992	0.632	rs326493	ENSG00000246763.5	RGMB-AS1	3.95	9.16e-05	0.00724	0.18	0.18	Body mass index;	chr5:98966251	chr5:98769618~98773469:-
THCA	cis	rs867186	1	rs17092215	ENSG00000126005.14	MMP24-AS1	-3.95	9.16e-05	0.00724	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35008110	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs8117847	ENSG00000126005.14	MMP24-AS1	-3.95	9.16e-05	0.00724	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35054677	chr20:35216462~35278131:-
THCA	cis	rs17695224	0.585	rs721890	ENSG00000275055.1	CTC-471J1.11	-3.95	9.16e-05	0.00724	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51837808	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.701	rs721889	ENSG00000275055.1	CTC-471J1.11	-3.95	9.16e-05	0.00724	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51837996	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.701	rs1468642	ENSG00000275055.1	CTC-471J1.11	-3.95	9.16e-05	0.00724	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51838504	chr19:52049007~52049754:+
THCA	cis	rs6696239	0.955	rs12084072	ENSG00000227711.2	RP11-275O4.5	-3.95	9.16e-05	0.00724	-0.25	-0.18	Height;	chr1:227539883	chr1:227509028~227520477:-
THCA	cis	rs7829975	0.626	rs907183	ENSG00000253981.4	ALG1L13P	-3.95	9.16e-05	0.00724	-0.17	-0.18	Mood instability;	chr8:8872251	chr8:8236003~8244667:-
THCA	cis	rs9650657	0.645	rs9969657	ENSG00000261451.1	RP11-981G7.1	3.95	9.16e-05	0.00724	0.21	0.18	Neuroticism;	chr8:10657768	chr8:10433672~10438312:+
THCA	cis	rs1045529	0.524	rs34251783	ENSG00000233609.3	RP11-62H7.2	-3.95	9.16e-05	0.00724	-0.17	-0.18	Myopia (pathological);Myopia;	chr8:9033866	chr8:8961200~8979025:+
THCA	cis	rs4908768	0.906	rs55860300	ENSG00000232912.4	RP5-1115A15.1	-3.95	9.16e-05	0.00724	-0.22	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536276	chr1:8424645~8434838:+
THCA	cis	rs4141404	0.818	rs5997897	ENSG00000235573.2	RP3-412A9.12	3.95	9.17e-05	0.00724	0.19	0.18	Paclitaxel-induced neuropathy;	chr22:31174450	chr22:31113017~31113396:+
THCA	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-3.95	9.17e-05	0.00724	-0.21	-0.18	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
THCA	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-3.95	9.17e-05	0.00724	-0.21	-0.18	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
THCA	cis	rs911555	0.723	rs6575986	ENSG00000269940.1	RP11-73M18.7	3.95	9.17e-05	0.00724	0.18	0.18	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103694560~103695170:+
THCA	cis	rs150992	0.678	rs161950	ENSG00000246763.5	RGMB-AS1	-3.95	9.17e-05	0.00724	-0.19	-0.18	Body mass index;	chr5:98924533	chr5:98769618~98773469:-
THCA	cis	rs9425766	0.85	rs9425755	ENSG00000270084.1	GAS5-AS1	-3.95	9.17e-05	0.00724	-0.18	-0.18	Life satisfaction;	chr1:173843501	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.85	rs1322770	ENSG00000270084.1	GAS5-AS1	-3.95	9.17e-05	0.00724	-0.18	-0.18	Life satisfaction;	chr1:173863198	chr1:173863248~173863941:+
THCA	cis	rs9595908	0.669	rs9596205	ENSG00000212293.1	SNORA16	-3.95	9.17e-05	0.00724	-0.22	-0.18	Body mass index;	chr13:32754487	chr13:32420390~32420516:-
THCA	cis	rs12497850	0.864	rs4513485	ENSG00000228638.1	FCF1P2	-3.95	9.17e-05	0.00724	-0.19	-0.18	Parkinson's disease;	chr3:49102533	chr3:48290793~48291375:-
THCA	cis	rs7838490	0.504	rs11997591	ENSG00000253553.4	RP11-586K2.1	3.95	9.17e-05	0.00724	0.19	0.18	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88520503	chr8:88326836~88737134:+
THCA	cis	rs321358	0.895	rs6589210	ENSG00000271390.1	RP11-89C3.3	3.95	9.17e-05	0.00725	0.28	0.18	Body mass index;	chr11:111088408	chr11:111089870~111090368:-
THCA	cis	rs12753569	0.934	rs6593523	ENSG00000272855.1	RP5-1102E8.3	3.95	9.17e-05	0.00725	0.23	0.18	Personality dimensions;	chr1:76021223	chr1:76636877~76637339:+
THCA	cis	rs6504108	0.624	rs3805363	ENSG00000264920.1	RP11-6N17.4	-3.95	9.17e-05	0.00725	-0.15	-0.18	Body mass index;	chr17:48164260	chr17:47891255~47895812:-
THCA	cis	rs1541160	1	rs6668310	ENSG00000239494.2	RN7SL333P	3.95	9.18e-05	0.00725	0.18	0.18	Amyotrophic lateral sclerosis;	chr1:170062713	chr1:169859756~169860052:+
THCA	cis	rs2033711	0.87	rs11669741	ENSG00000232098.3	CTD-2619J13.14	-3.95	9.18e-05	0.00725	-0.16	-0.18	Uric acid clearance;	chr19:58449114	chr19:58404238~58408484:-
THCA	cis	rs321358	1	rs321352	ENSG00000271390.1	RP11-89C3.3	3.95	9.18e-05	0.00725	0.3	0.18	Body mass index;	chr11:111123001	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs167683	ENSG00000271390.1	RP11-89C3.3	3.95	9.18e-05	0.00725	0.3	0.18	Body mass index;	chr11:111123131	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321355	ENSG00000271390.1	RP11-89C3.3	3.95	9.18e-05	0.00725	0.3	0.18	Body mass index;	chr11:111124273	chr11:111089870~111090368:-
THCA	cis	rs9425766	0.927	rs9425757	ENSG00000270084.1	GAS5-AS1	-3.95	9.18e-05	0.00725	-0.18	-0.18	Life satisfaction;	chr1:173855675	chr1:173863248~173863941:+
THCA	cis	rs13434995	0.513	rs7665286	ENSG00000249700.7	SRD5A3-AS1	3.95	9.18e-05	0.00725	0.26	0.18	Adiponectin levels;	chr4:55578765	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs7683997	ENSG00000249700.7	SRD5A3-AS1	3.95	9.18e-05	0.00725	0.26	0.18	Adiponectin levels;	chr4:55581272	chr4:55363971~55395847:-
THCA	cis	rs16975963	0.644	rs112666969	ENSG00000276846.1	CTD-3220F14.3	-3.95	9.18e-05	0.00725	-0.17	-0.18	Longevity;	chr19:37556743	chr19:37314868~37315620:-
THCA	cis	rs897984	0.76	rs11076	ENSG00000275263.1	RP11-1072A3.4	3.95	9.18e-05	0.00725	0.21	0.18	Dementia with Lewy bodies;	chr16:30984207	chr16:30956872~30957199:-
THCA	cis	rs6832769	0.767	rs11133394	ENSG00000223305.1	RN7SKP30	3.95	9.18e-05	0.00726	0.23	0.18	Personality dimensions;	chr4:55517071	chr4:55540502~55540835:-
THCA	cis	rs17292804	0.527	rs12887734	ENSG00000244691.1	RPL10AP1	-3.95	9.18e-05	0.00726	-0.25	-0.18	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103412119~103412761:-
THCA	cis	rs7294478	0.738	rs11050917	ENSG00000205885.6	C1RL-AS1	3.95	9.19e-05	0.00726	0.13	0.18	Neuritic plaque;	chr12:7111810	chr12:7108052~7122501:+
THCA	cis	rs741677	1	rs741677	ENSG00000231784.7	DBIL5P	-3.95	9.19e-05	0.00726	-0.19	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:560603	chr17:752660~755336:+
THCA	cis	rs10129255	1	rs4612959	ENSG00000211972.2	IGHV3-66	3.95	9.19e-05	0.00726	0.11	0.18	Kawasaki disease;	chr14:106767055	chr14:106675017~106675544:-
THCA	cis	rs10129255	1	rs10129407	ENSG00000211972.2	IGHV3-66	3.95	9.19e-05	0.00726	0.11	0.18	Kawasaki disease;	chr14:106767956	chr14:106675017~106675544:-
THCA	cis	rs6487679	1	rs7298108	ENSG00000245105.2	A2M-AS1	-3.95	9.19e-05	0.00726	-0.16	-0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9065177~9068060:+
THCA	cis	rs950169	0.922	rs12912934	ENSG00000275120.1	RP11-182J1.17	3.95	9.19e-05	0.00726	0.21	0.18	Schizophrenia;	chr15:84571216	chr15:84599434~84606463:-
THCA	cis	rs950169	0.922	rs62021167	ENSG00000275120.1	RP11-182J1.17	3.95	9.19e-05	0.00726	0.21	0.18	Schizophrenia;	chr15:84574820	chr15:84599434~84606463:-
THCA	cis	rs16852403	0.619	rs10913509	ENSG00000224687.1	RASAL2-AS1	3.95	9.19e-05	0.00726	0.29	0.18	Childhood ear infection;	chr1:178153649	chr1:178091508~178093984:-
THCA	cis	rs1204798	0.636	rs62414141	ENSG00000237021.2	RP3-486I3.7	-3.95	9.19e-05	0.00726	-0.22	-0.18	Dental caries;	chr6:116179264	chr6:116254207~116256743:+
THCA	cis	rs4947019	0.609	rs752260	ENSG00000223537.2	RP5-919F19.5	-3.95	9.19e-05	0.00726	-0.33	-0.18	Hematological parameters;	chr6:109449605	chr6:109487906~109506800:+
THCA	cis	rs62495153	0.744	rs62498736	ENSG00000254153.1	CTA-398F10.2	-3.95	9.19e-05	0.00726	-0.43	-0.18	Hippocampal volume;	chr8:8470175	chr8:8456909~8461337:-
THCA	cis	rs62495153	0.744	rs62498737	ENSG00000254153.1	CTA-398F10.2	-3.95	9.19e-05	0.00726	-0.43	-0.18	Hippocampal volume;	chr8:8470568	chr8:8456909~8461337:-
THCA	cis	rs150992	0.525	rs331930	ENSG00000241597.2	CTD-2007H13.1	-3.95	9.19e-05	0.00726	-0.23	-0.18	Body mass index;	chr5:98833559	chr5:98954394~98954972:+
THCA	cis	rs2120243	0.572	rs6803628	ENSG00000241770.1	RP11-555M1.3	-3.95	9.19e-05	0.00726	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157407795	chr3:157163452~157169133:+
THCA	cis	rs7616559	0.82	rs1482856	ENSG00000244515.1	KRT18P34	-3.95	9.19e-05	0.00726	-0.22	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157036652	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.82	rs1482859	ENSG00000244515.1	KRT18P34	-3.95	9.19e-05	0.00726	-0.22	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157036877	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.789	rs9818500	ENSG00000244515.1	KRT18P34	-3.95	9.19e-05	0.00726	-0.22	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157042350	chr3:157162663~157163932:-
THCA	cis	rs478304	0.934	rs574483	ENSG00000255557.1	RP11-770G2.2	-3.95	9.2e-05	0.00726	-0.19	-0.18	Acne (severe);	chr11:65747806	chr11:65745729~65771585:+
THCA	cis	rs478304	0.934	rs474483	ENSG00000255557.1	RP11-770G2.2	-3.95	9.2e-05	0.00726	-0.19	-0.18	Acne (severe);	chr11:65752589	chr11:65745729~65771585:+
THCA	cis	rs478304	0.9	rs502468	ENSG00000255557.1	RP11-770G2.2	-3.95	9.2e-05	0.00726	-0.19	-0.18	Acne (severe);	chr11:65757648	chr11:65745729~65771585:+
THCA	cis	rs478304	0.934	rs517115	ENSG00000255557.1	RP11-770G2.2	-3.95	9.2e-05	0.00726	-0.19	-0.18	Acne (severe);	chr11:65759517	chr11:65745729~65771585:+
THCA	cis	rs478304	0.934	rs498354	ENSG00000255557.1	RP11-770G2.2	-3.95	9.2e-05	0.00726	-0.19	-0.18	Acne (severe);	chr11:65760742	chr11:65745729~65771585:+
THCA	cis	rs2474937	0.535	rs4659080	ENSG00000231365.4	RP11-418J17.1	3.95	9.2e-05	0.00726	0.18	0.18	Congenital heart malformation;	chr1:118380446	chr1:119140396~119275973:+
THCA	cis	rs4879656	0.835	rs1332096	ENSG00000225693.1	LAGE3P1	-3.95	9.2e-05	0.00726	-0.19	-0.18	Menopause (age at onset);	chr9:32936041	chr9:33019682~33020165:-
THCA	cis	rs9611565	0.592	rs4822046	ENSG00000237037.8	NDUFA6-AS1	3.94	9.2e-05	0.00726	0.18	0.18	Vitiligo;	chr22:41591539	chr22:42090931~42137742:+
THCA	cis	rs150992	0.673	rs331549	ENSG00000241597.2	CTD-2007H13.1	3.94	9.2e-05	0.00726	0.23	0.18	Body mass index;	chr5:98805731	chr5:98954394~98954972:+
THCA	cis	rs150992	0.673	rs992775	ENSG00000241597.2	CTD-2007H13.1	3.94	9.2e-05	0.00726	0.23	0.18	Body mass index;	chr5:98807754	chr5:98954394~98954972:+
THCA	cis	rs6762	0.748	rs1130719	ENSG00000255142.1	AP006621.6	3.94	9.2e-05	0.00727	0.13	0.18	Mean platelet volume;	chr11:838760	chr11:781645~782105:+
THCA	cis	rs6546886	0.913	rs12713805	ENSG00000235499.1	AC073046.25	3.94	9.2e-05	0.00727	0.17	0.18	Dialysis-related mortality;	chr2:74016253	chr2:73985132~73986343:+
THCA	cis	rs12493885	0.654	rs61792350	ENSG00000243069.6	ARHGEF26-AS1	-3.94	9.2e-05	0.00727	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:153995170	chr3:154024401~154121332:-
THCA	cis	rs2836974	0.931	rs13047663	ENSG00000255568.3	BRWD1-AS2	3.94	9.2e-05	0.00727	0.16	0.18	Cognitive function;	chr21:39336892	chr21:39313935~39314962:+
THCA	cis	rs2223471	0.967	rs2281158	ENSG00000060303.5	RPS17P5	-3.94	9.2e-05	0.00727	-0.21	-0.18	Subcutaneous adipose tissue;	chr6:50763022	chr6:50857255~50857662:-
THCA	cis	rs877819	0.583	rs2620880	ENSG00000228403.1	RP11-563N6.6	3.94	9.2e-05	0.00727	0.19	0.18	Systemic lupus erythematosus;	chr10:48877383	chr10:48878022~48878649:+
THCA	cis	rs10861661	0.856	rs4964190	ENSG00000260329.1	RP11-412D9.4	-3.94	9.21e-05	0.00727	-0.18	-0.18	Triglyceride levels;	chr12:106822581	chr12:106954029~106955497:-
THCA	cis	rs564343	0.563	rs1642958	ENSG00000255320.1	RP11-755F10.1	-3.94	9.21e-05	0.00727	-0.22	-0.18	Obesity (early onset extreme);	chr11:66054502	chr11:66244840~66246239:-
THCA	cis	rs853679	0.76	rs9357067	ENSG00000273712.1	RP5-874C20.7	3.94	9.21e-05	0.00727	0.25	0.18	Depression;	chr6:28242515	chr6:28315613~28315883:-
THCA	cis	rs853679	0.76	rs967005	ENSG00000273712.1	RP5-874C20.7	3.94	9.21e-05	0.00727	0.25	0.18	Depression;	chr6:28242910	chr6:28315613~28315883:-
THCA	cis	rs964611	0.786	rs10519169	ENSG00000259488.2	RP11-154J22.1	-3.94	9.21e-05	0.00727	-0.16	-0.18	Metabolite levels (Pyroglutamine);	chr15:48372829	chr15:48312353~48331856:-
THCA	cis	rs2562456	0.876	rs62110202	ENSG00000268658.4	LINC00664	3.94	9.21e-05	0.00727	0.26	0.18	Pain;	chr19:21571799	chr19:21483374~21503238:+
THCA	cis	rs5753037	0.869	rs5752973	ENSG00000279699.1	RP1-102K2.9	3.94	9.21e-05	0.00727	0.17	0.18	Type 1 diabetes;	chr22:29868285	chr22:30275215~30276951:-
THCA	cis	rs7200543	1	rs1121	ENSG00000188599.16	NPIPP1	-3.94	9.21e-05	0.00727	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:15104312~15123498:-
THCA	cis	rs728616	0.558	rs35547640	ENSG00000225484.5	NUTM2B-AS1	-3.94	9.21e-05	0.00727	-0.32	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80379394	chr10:79663088~79826594:-
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000220721.1	OR1F12	3.94	9.21e-05	0.00727	0.2	0.18	Pubertal anthropometrics;	chr6:28259100	chr6:28073316~28074233:+
THCA	cis	rs7227401	0.927	rs1030110	ENSG00000264365.1	RP11-621L6.2	3.94	9.21e-05	0.00727	0.22	0.18	Osteoporosis-related phenotypes;	chr18:24357057	chr18:24364787~24367984:+
THCA	cis	rs2214442	0.934	rs1023522	ENSG00000271133.4	CTA-293F17.1	-3.94	9.21e-05	0.00727	-0.18	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20373967	chr7:20328299~20331747:-
THCA	cis	rs9843304	0.565	rs9857136	ENSG00000243885.1	RP11-278L15.2	-3.94	9.21e-05	0.00727	-0.2	-0.18	Gallstone disease;	chr3:149492066	chr3:149384179~149385800:-
THCA	cis	rs2836974	0.8	rs73221174	ENSG00000255568.3	BRWD1-AS2	3.94	9.21e-05	0.00727	0.16	0.18	Cognitive function;	chr21:39169013	chr21:39313935~39314962:+
THCA	cis	rs7572733	0.84	rs700655	ENSG00000231621.1	AC013264.2	-3.94	9.21e-05	0.00727	-0.17	-0.18	Dermatomyositis;	chr2:197778907	chr2:197197991~197199273:+
THCA	cis	rs875971	0.895	rs12698520	ENSG00000230189.5	GS1-124K5.2	3.94	9.21e-05	0.00727	0.12	0.18	Aortic root size;	chr7:66453720	chr7:66409143~66490059:-
THCA	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	3.94	9.22e-05	0.00728	0.2	0.18	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
THCA	cis	rs5758659	0.714	rs6002626	ENSG00000273366.1	CTA-989H11.1	3.94	9.22e-05	0.00728	0.21	0.18	Cognitive function;	chr22:42121985	chr22:42278188~42278846:+
THCA	cis	rs2562456	0.754	rs112195516	ENSG00000268278.1	RP11-420K14.1	3.94	9.22e-05	0.00728	0.25	0.18	Pain;	chr19:21410849	chr19:21637974~21656300:+
THCA	cis	rs28510890	0.72	rs17704001	ENSG00000258676.4	RP11-386M24.3	3.94	9.22e-05	0.00728	0.17	0.18	Lung cancer in ever smokers;	chr15:92583935	chr15:92580829~92600545:+
THCA	cis	rs8002861	0.664	rs9525873	ENSG00000274001.1	RP11-5G9.5	3.94	9.22e-05	0.00728	0.22	0.18	Leprosy;	chr13:43908068	chr13:43877715~43878163:-
THCA	cis	rs12478296	1	rs73007138	ENSG00000261186.2	RP11-341N2.1	-3.94	9.22e-05	0.00728	-0.32	-0.18	Obesity-related traits;	chr2:242064890	chr2:242087351~242088457:-
THCA	cis	rs13118159	0.55	rs28614045	ENSG00000254094.1	AC078852.1	-3.94	9.22e-05	0.00728	-0.21	-0.18	Longevity;	chr4:1380907	chr4:1356581~1358075:+
THCA	cis	rs9810089	0.708	rs619605	ENSG00000273455.1	RP11-305O4.3	3.94	9.22e-05	0.00728	0.23	0.18	Gestational age at birth (child effect);	chr3:136368170	chr3:136087475~136087913:-
THCA	cis	rs11088226	0.681	rs8131384	ENSG00000186842.4	LINC00846	-3.94	9.22e-05	0.00728	-0.27	-0.18	Gastritis;	chr21:32571817	chr21:32572238~32575881:-
THCA	cis	rs9341808	0.667	rs742833	ENSG00000272129.1	RP11-250B2.6	3.94	9.22e-05	0.00728	0.22	0.18	Sitting height ratio;	chr6:80211729	chr6:80355424~80356859:+
THCA	cis	rs2180341	0.695	rs6569487	ENSG00000220522.2	RP1-177A13.1	-3.94	9.22e-05	0.00728	-0.21	-0.18	Breast cancer;	chr6:127405051	chr6:127416535~127416952:-
THCA	cis	rs2652834	0.904	rs2729826	ENSG00000259459.4	RP11-321G12.1	3.94	9.22e-05	0.00728	0.18	0.18	HDL cholesterol;	chr15:63068247	chr15:63390136~63438320:+
THCA	cis	rs9309473	0.519	rs12991161	ENSG00000273245.1	RP11-434P11.2	-3.94	9.23e-05	0.00728	-0.21	-0.18	Metabolite levels;	chr2:73644244	chr2:73750256~73750786:-
THCA	cis	rs4742903	0.935	rs4742907	ENSG00000270332.1	SMC2-AS1	3.94	9.23e-05	0.00728	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104205945	chr9:104080024~104093073:-
THCA	cis	rs3002142	1	rs3002142	ENSG00000272750.1	RP11-378J18.8	-3.94	9.23e-05	0.00728	-0.24	-0.18	LDL peak particle diameter (total fat intake interaction);	chr1:222614720	chr1:222658867~222661512:-
THCA	cis	rs17092148	0.836	rs4911157	ENSG00000276073.1	RP5-1125A11.7	-3.94	9.23e-05	0.00728	-0.22	-0.18	Neuroticism;	chr20:34579271	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.887	rs932542	ENSG00000276073.1	RP5-1125A11.7	-3.94	9.23e-05	0.00728	-0.22	-0.18	Neuroticism;	chr20:34583564	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.887	rs6059931	ENSG00000276073.1	RP5-1125A11.7	-3.94	9.23e-05	0.00728	-0.22	-0.18	Neuroticism;	chr20:34587534	chr20:33985617~33988989:-
THCA	cis	rs34779708	0.733	rs11010146	ENSG00000233200.1	RP11-324I22.2	3.94	9.23e-05	0.00728	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs7086715	ENSG00000233200.1	RP11-324I22.2	3.94	9.23e-05	0.00728	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.702	rs7087150	ENSG00000233200.1	RP11-324I22.2	3.94	9.23e-05	0.00728	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs60553075	ENSG00000233200.1	RP11-324I22.2	3.94	9.23e-05	0.00728	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.733	rs12249814	ENSG00000233200.1	RP11-324I22.2	3.94	9.23e-05	0.00728	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35219894~35230598:-
THCA	cis	rs9307551	0.744	rs10004226	ENSG00000249646.2	OR7E94P	-3.94	9.23e-05	0.00729	-0.23	-0.18	Refractive error;	chr4:79569654	chr4:79587302~79588130:-
THCA	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-3.94	9.23e-05	0.00729	-0.17	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
THCA	cis	rs61677309	1	rs4938494	ENSG00000278376.1	RP11-158I9.8	3.94	9.23e-05	0.00729	0.14	0.18	Lung cancer in ever smokers;	chr11:118280020	chr11:118791254~118793137:+
THCA	cis	rs8113308	0.515	rs56343029	ENSG00000269483.1	AC006272.1	3.94	9.23e-05	0.00729	0.37	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960184	chr19:51839924~51843324:-
THCA	cis	rs9650657	0.771	rs6601513	ENSG00000255310.2	AF131215.2	-3.94	9.23e-05	0.00729	-0.15	-0.18	Neuroticism;	chr8:10737333	chr8:11107788~11109726:-
THCA	cis	rs867186	1	rs73905041	ENSG00000126005.14	MMP24-AS1	-3.94	9.23e-05	0.00729	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35004345	chr20:35216462~35278131:-
THCA	cis	rs10761482	0.861	rs1350633	ENSG00000254271.1	RP11-131N11.4	3.94	9.24e-05	0.00729	0.24	0.18	Schizophrenia;	chr10:60352152	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.813	rs10740026	ENSG00000254271.1	RP11-131N11.4	3.94	9.24e-05	0.00729	0.24	0.18	Schizophrenia;	chr10:60353084	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs4948410	ENSG00000254271.1	RP11-131N11.4	3.94	9.24e-05	0.00729	0.24	0.18	Schizophrenia;	chr10:60356289	chr10:60734342~60741828:+
THCA	cis	rs4763879	0.634	rs2098298	ENSG00000214776.8	RP11-726G1.1	-3.94	9.24e-05	0.00729	-0.22	-0.18	Type 1 diabetes;	chr12:9707473	chr12:9467552~9576275:+
THCA	cis	rs17685	0.753	rs1104879	ENSG00000227038.2	AC005077.12	3.94	9.24e-05	0.00729	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76056250	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs7804598	ENSG00000227038.2	AC005077.12	3.94	9.24e-05	0.00729	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76073260	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs59659102	ENSG00000227038.2	AC005077.12	3.94	9.24e-05	0.00729	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76080796	chr7:76090431~76108779:-
THCA	cis	rs17685	0.725	rs6467993	ENSG00000227038.2	AC005077.12	3.94	9.24e-05	0.00729	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76090032	chr7:76090431~76108779:-
THCA	cis	rs17685	0.725	rs7795291	ENSG00000227038.2	AC005077.12	3.94	9.24e-05	0.00729	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76095888	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs6954569	ENSG00000227038.2	AC005077.12	3.94	9.24e-05	0.00729	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76109567	chr7:76090431~76108779:-
THCA	cis	rs6560517	1	rs10869773	ENSG00000234618.1	RPSAP9	-3.94	9.24e-05	0.00729	-0.2	-0.18	Dialysis-related mortality;	chr9:76420431	chr9:76398699~76399586:+
THCA	cis	rs6560517	0.915	rs7849239	ENSG00000234618.1	RPSAP9	-3.94	9.24e-05	0.00729	-0.2	-0.18	Dialysis-related mortality;	chr9:76420676	chr9:76398699~76399586:+
THCA	cis	rs6921919	0.789	rs1119211	ENSG00000219392.1	RP1-265C24.5	3.94	9.24e-05	0.00729	0.22	0.18	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28115628~28116551:+
THCA	cis	rs12893668	0.703	rs4906335	ENSG00000244691.1	RPL10AP1	-3.94	9.24e-05	0.00729	-0.26	-0.18	Reticulocyte count;	chr14:103554804	chr14:103412119~103412761:-
THCA	cis	rs62158800	0.638	rs1400116	ENSG00000237880.1	AC096669.2	3.94	9.24e-05	0.00729	0.18	0.18	Facial morphology (factor 22);	chr2:107677765	chr2:107385632~107542649:-
THCA	cis	rs7658584	0.592	rs56892189	ENSG00000246375.2	RP11-10L7.1	3.94	9.24e-05	0.00729	0.28	0.18	Squamous cell lung carcinoma;	chr4:88188491	chr4:88284942~88331421:+
THCA	cis	rs1823874	0.581	rs9920347	ENSG00000254744.3	CTD-3076O17.1	3.94	9.24e-05	0.00729	0.21	0.18	IgG glycosylation;	chr15:99799126	chr15:99970215~99974010:+
THCA	cis	rs10847980	1	rs10847980	ENSG00000256092.2	RP13-942N8.1	3.94	9.24e-05	0.00729	0.21	0.18	Adiponectin levels;	chr12:122903375	chr12:123363868~123366113:+
THCA	cis	rs10540	0.908	rs1044707	ENSG00000279672.1	CMB9-55F22.1	-3.94	9.24e-05	0.00729	-0.35	-0.18	Body mass index;	chr11:491334	chr11:779617~780755:+
THCA	cis	rs564799	0.966	rs545143	ENSG00000244040.4	IL12A-AS1	-3.94	9.24e-05	0.00729	-0.23	-0.18	Systemic lupus erythematosus;	chr3:160014208	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs545232	ENSG00000244040.4	IL12A-AS1	3.94	9.24e-05	0.00729	0.23	0.18	Systemic lupus erythematosus;	chr3:160014244	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs547875	ENSG00000244040.4	IL12A-AS1	3.94	9.24e-05	0.00729	0.23	0.18	Systemic lupus erythematosus;	chr3:160014513	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs548018	ENSG00000244040.4	IL12A-AS1	3.94	9.24e-05	0.00729	0.23	0.18	Systemic lupus erythematosus;	chr3:160014558	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs6441289	ENSG00000244040.4	IL12A-AS1	3.94	9.24e-05	0.00729	0.23	0.18	Systemic lupus erythematosus;	chr3:160015095	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs6441290	ENSG00000244040.4	IL12A-AS1	3.94	9.24e-05	0.00729	0.23	0.18	Systemic lupus erythematosus;	chr3:160015105	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs574808	ENSG00000244040.4	IL12A-AS1	3.94	9.24e-05	0.00729	0.23	0.18	Systemic lupus erythematosus;	chr3:160015196	chr3:159913400~160225299:-
THCA	cis	rs564799	0.933	rs589545	ENSG00000244040.4	IL12A-AS1	3.94	9.24e-05	0.00729	0.23	0.18	Systemic lupus erythematosus;	chr3:160015813	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs491966	ENSG00000244040.4	IL12A-AS1	3.94	9.24e-05	0.00729	0.23	0.18	Systemic lupus erythematosus;	chr3:160015905	chr3:159913400~160225299:-
THCA	cis	rs34217772	0.509	rs61990509	ENSG00000258636.1	CTD-2298J14.2	3.94	9.24e-05	0.00729	0.31	0.18	Myopia;	chr14:41973482	chr14:41587861~41604856:-
THCA	cis	rs9457247	0.508	rs9459874	ENSG00000235272.1	FAM103A2P	-3.94	9.24e-05	0.00729	-0.24	-0.18	Crohn's disease;	chr6:167090639	chr6:166586124~166586477:-
THCA	cis	rs9608946	1	rs13750	ENSG00000279699.1	RP1-102K2.9	3.94	9.24e-05	0.00729	0.21	0.18	Red cell distribution width;	chr22:30489113	chr22:30275215~30276951:-
THCA	cis	rs28735056	1	rs59183289	ENSG00000261126.6	RP11-795F19.1	-3.94	9.24e-05	0.00729	-0.14	-0.18	Schizophrenia;	chr18:79871198	chr18:80046900~80095482:+
THCA	cis	rs9843304	0.5	rs34358037	ENSG00000240541.2	TM4SF1-AS1	3.94	9.24e-05	0.00729	0.16	0.18	Gallstone disease;	chr3:149483497	chr3:149377778~149386583:+
THCA	cis	rs9400467	0.568	rs9320364	ENSG00000255389.1	C6orf3	3.94	9.24e-05	0.00729	0.2	0.18	Amino acid levels;Blood metabolite levels;	chr6:111490719	chr6:111599875~111602295:+
THCA	cis	rs67478160	0.583	rs12879612	ENSG00000258534.1	CTD-2134A5.4	-3.94	9.24e-05	0.0073	-0.18	-0.18	Schizophrenia;	chr14:103767281	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs4900594	ENSG00000258534.1	CTD-2134A5.4	-3.94	9.24e-05	0.0073	-0.18	-0.18	Schizophrenia;	chr14:103784669	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs3742369	ENSG00000258534.1	CTD-2134A5.4	-3.94	9.24e-05	0.0073	-0.18	-0.18	Schizophrenia;	chr14:103784939	chr14:103854366~103880111:-
THCA	cis	rs5006884	0.585	rs12804310	ENSG00000167355.6	AC104389.28	-3.94	9.25e-05	0.0073	-0.31	-0.18	Fetal hemoglobin levels;	chr11:5436959	chr11:5304976~5505652:-
THCA	cis	rs4434872	0.536	rs12023578	ENSG00000223599.1	RP11-216N14.7	-3.94	9.25e-05	0.0073	-0.32	-0.18	Conduct disorder (symptom count);	chr1:153909072	chr1:153852106~153853414:-
THCA	cis	rs7274963	0.685	rs2300821	ENSG00000236474.1	GCNT1P1	3.94	9.25e-05	0.0073	0.24	0.18	Body mass index;	chr20:18308536	chr20:18420160~18421454:-
THCA	cis	rs9291683	0.551	rs2276961	ENSG00000261490.1	RP11-448G15.3	3.94	9.25e-05	0.0073	0.11	0.18	Bone mineral density;	chr4:10021357	chr4:10068089~10073019:-
THCA	cis	rs755249	0.761	rs61781390	ENSG00000237624.1	OXCT2P1	3.94	9.25e-05	0.0073	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39514956~39516490:+
THCA	cis	rs9611565	0.512	rs139560	ENSG00000237037.8	NDUFA6-AS1	3.94	9.25e-05	0.0073	0.17	0.18	Vitiligo;	chr22:41798958	chr22:42090931~42137742:+
THCA	cis	rs12753569	1	rs12753569	ENSG00000272855.1	RP5-1102E8.3	3.94	9.25e-05	0.0073	0.22	0.18	Personality dimensions;	chr1:76018329	chr1:76636877~76637339:+
THCA	cis	rs1908814	0.516	rs13281077	ENSG00000254948.1	OR7E158P	-3.94	9.25e-05	0.0073	-0.22	-0.18	Neuroticism;	chr8:11937305	chr8:11919900~11920809:-
THCA	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	3.94	9.25e-05	0.0073	0.2	0.18	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	3.94	9.25e-05	0.0073	0.2	0.18	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	3.94	9.25e-05	0.0073	0.2	0.18	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	3.94	9.25e-05	0.0073	0.2	0.18	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	3.94	9.25e-05	0.0073	0.2	0.18	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	3.94	9.25e-05	0.0073	0.2	0.18	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
THCA	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	3.94	9.25e-05	0.0073	0.2	0.18	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
THCA	cis	rs786425	0.711	rs1060639	ENSG00000278112.1	RP11-972P1.11	3.94	9.25e-05	0.0073	0.18	0.18	Pubertal anthropometrics;	chr12:123625441	chr12:123519390~123519856:-
THCA	cis	rs6137726	0.508	rs2424457	ENSG00000237396.1	LINC01384	3.94	9.25e-05	0.0073	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22664411	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.508	rs2424458	ENSG00000237396.1	LINC01384	3.94	9.25e-05	0.0073	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22664505	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.508	rs2145059	ENSG00000237396.1	LINC01384	3.94	9.25e-05	0.0073	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22664889	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.508	rs2145060	ENSG00000237396.1	LINC01384	3.94	9.25e-05	0.0073	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22664994	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.508	rs2145061	ENSG00000237396.1	LINC01384	3.94	9.25e-05	0.0073	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22665097	chr20:22587522~22607517:-
THCA	cis	rs4767841	0.594	rs203364	ENSG00000252886.1	RN7SKP197	-3.94	9.25e-05	0.0073	-0.17	-0.18	Urgency urinary incontinence;	chr12:119777265	chr12:119631090~119631386:-
THCA	cis	rs42648	0.633	rs11563909	ENSG00000225498.1	AC002064.5	3.94	9.25e-05	0.0073	0.19	0.18	Homocysteine levels;	chr7:90306390	chr7:90312496~90322592:+
THCA	cis	rs17092148	1	rs7271289	ENSG00000276073.1	RP5-1125A11.7	3.94	9.25e-05	0.0073	0.21	0.18	Neuroticism;	chr20:34809500	chr20:33985617~33988989:-
THCA	cis	rs4321325	0.733	rs111245735	ENSG00000236682.1	AC068282.3	-3.94	9.25e-05	0.0073	-0.38	-0.18	Protein C levels;	chr2:127184946	chr2:127389130~127400580:+
THCA	cis	rs4321325	0.733	rs74707659	ENSG00000236682.1	AC068282.3	-3.94	9.25e-05	0.0073	-0.38	-0.18	Protein C levels;	chr2:127187893	chr2:127389130~127400580:+
THCA	cis	rs4321325	0.733	rs78593261	ENSG00000236682.1	AC068282.3	-3.94	9.25e-05	0.0073	-0.38	-0.18	Protein C levels;	chr2:127189468	chr2:127389130~127400580:+
THCA	cis	rs4321325	0.733	rs75834205	ENSG00000236682.1	AC068282.3	-3.94	9.25e-05	0.0073	-0.38	-0.18	Protein C levels;	chr2:127189661	chr2:127389130~127400580:+
THCA	cis	rs6453278	0.559	rs4418080	ENSG00000250802.5	ZBED3-AS1	-3.94	9.25e-05	0.0073	-0.17	-0.18	Autism;	chr5:77099359	chr5:77086740~77166909:+
THCA	cis	rs11992162	0.967	rs4840601	ENSG00000255046.1	RP11-297N6.4	-3.94	9.26e-05	0.0073	-0.19	-0.18	Monocyte count;	chr8:11971221	chr8:11797928~11802568:-
THCA	cis	rs1865760	0.516	rs9379818	ENSG00000272810.1	U91328.22	-3.94	9.26e-05	0.0073	-0.14	-0.18	Height;	chr6:26022978	chr6:26013241~26013757:+
THCA	cis	rs959260	0.858	rs2053156	ENSG00000263843.1	RP11-649A18.12	3.94	9.26e-05	0.0073	0.19	0.18	Systemic lupus erythematosus;	chr17:75382359	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs7211915	ENSG00000263843.1	RP11-649A18.12	3.94	9.26e-05	0.0073	0.19	0.18	Systemic lupus erythematosus;	chr17:75383791	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs4789183	ENSG00000263843.1	RP11-649A18.12	3.94	9.26e-05	0.0073	0.19	0.18	Systemic lupus erythematosus;	chr17:75384140	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs9900002	ENSG00000263843.1	RP11-649A18.12	3.94	9.26e-05	0.0073	0.19	0.18	Systemic lupus erythematosus;	chr17:75385937	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs4789184	ENSG00000263843.1	RP11-649A18.12	3.94	9.26e-05	0.0073	0.19	0.18	Systemic lupus erythematosus;	chr17:75387233	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs4789185	ENSG00000263843.1	RP11-649A18.12	3.94	9.26e-05	0.0073	0.19	0.18	Systemic lupus erythematosus;	chr17:75387287	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs9909076	ENSG00000263843.1	RP11-649A18.12	3.94	9.26e-05	0.0073	0.19	0.18	Systemic lupus erythematosus;	chr17:75388728	chr17:75271369~75273895:+
THCA	cis	rs1371614	0.531	rs77562583	ENSG00000229122.1	AGBL5-IT1	3.94	9.26e-05	0.0073	0.13	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928775	chr2:27061038~27061815:+
THCA	cis	rs9868809	0.505	rs11708786	ENSG00000270441.1	RP11-694I15.7	3.94	9.26e-05	0.0073	0.23	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48715221	chr3:49140086~49160851:-
THCA	cis	rs1198872	0.892	rs1198868	ENSG00000272275.1	RP11-791G15.2	-3.94	9.26e-05	0.0073	-0.21	-0.18	Cardiac Troponin-T levels;	chr2:10762287	chr2:10767875~10770058:-
THCA	cis	rs7956611	0.564	rs7294455	ENSG00000213343.5	RPL21P18	-3.94	9.26e-05	0.0073	-0.2	-0.18	Age of smoking initiation;	chr12:66520606	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs4144463	ENSG00000213343.5	RPL21P18	-3.94	9.26e-05	0.0073	-0.2	-0.18	Age of smoking initiation;	chr12:66520743	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs7973517	ENSG00000213343.5	RPL21P18	-3.94	9.26e-05	0.0073	-0.2	-0.18	Age of smoking initiation;	chr12:66525192	chr12:66037235~66037714:+
THCA	cis	rs8067354	0.872	rs2645466	ENSG00000266701.1	AC005702.4	3.94	9.26e-05	0.0073	0.25	0.18	Hemoglobin concentration;	chr17:59775853	chr17:60042546~60042627:-
THCA	cis	rs12893668	0.697	rs67899457	ENSG00000252469.1	RNU7-160P	3.94	9.26e-05	0.0073	0.21	0.18	Reticulocyte count;	chr14:103593729	chr14:103550345~103550406:+
THCA	cis	rs7956611	0.564	rs7960316	ENSG00000213343.5	RPL21P18	-3.94	9.26e-05	0.00731	-0.21	-0.18	Age of smoking initiation;	chr12:66511438	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs28513666	ENSG00000213343.5	RPL21P18	-3.94	9.26e-05	0.00731	-0.21	-0.18	Age of smoking initiation;	chr12:66511898	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs11176239	ENSG00000213343.5	RPL21P18	-3.94	9.26e-05	0.00731	-0.21	-0.18	Age of smoking initiation;	chr12:66513748	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs10506485	ENSG00000213343.5	RPL21P18	-3.94	9.26e-05	0.00731	-0.21	-0.18	Age of smoking initiation;	chr12:66513880	chr12:66037235~66037714:+
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000280069.1	CTD-2349P21.3	-3.94	9.26e-05	0.00731	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30738182~30740275:+
THCA	cis	rs7208859	0.623	rs8082537	ENSG00000265443.1	CTD-2349P21.6	-3.94	9.27e-05	0.00731	-0.29	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30726305~30727564:-
THCA	cis	rs8062405	0.625	rs8060365	ENSG00000270424.1	RP11-1348G14.6	-3.94	9.27e-05	0.00731	-0.22	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28749959~28750595:-
THCA	cis	rs12440869	0.959	rs4374116	ENSG00000270964.1	RP11-502I4.3	-3.94	9.27e-05	0.00731	-0.16	-0.18	Peak velocity of the mitral A-wave;	chr15:67330799	chr15:67541072~67542604:-
THCA	cis	rs3845817	0.671	rs840785	ENSG00000237979.1	AC007389.1	3.94	9.27e-05	0.00731	0.2	0.18	Bipolar disorder;	chr2:65541842	chr2:65500993~65502138:-
THCA	cis	rs3845817	0.703	rs702915	ENSG00000237979.1	AC007389.1	3.94	9.27e-05	0.00731	0.2	0.18	Bipolar disorder;	chr2:65543462	chr2:65500993~65502138:-
THCA	cis	rs3845817	0.703	rs1673457	ENSG00000237979.1	AC007389.1	3.94	9.27e-05	0.00731	0.2	0.18	Bipolar disorder;	chr2:65544511	chr2:65500993~65502138:-
THCA	cis	rs3845817	0.703	rs1673458	ENSG00000237979.1	AC007389.1	3.94	9.27e-05	0.00731	0.2	0.18	Bipolar disorder;	chr2:65544512	chr2:65500993~65502138:-
THCA	cis	rs7179228	1	rs4777037	ENSG00000260657.2	RP11-315D16.4	3.94	9.27e-05	0.00731	0.27	0.18	Systolic blood pressure;	chr15:68327798	chr15:68267792~68277994:-
THCA	cis	rs4130590	0.934	rs7041940	ENSG00000271833.1	RP11-356B19.11	-3.94	9.27e-05	0.00731	-0.19	-0.18	Bipolar disorder;	chr9:127347467	chr9:127366770~127367397:+
THCA	cis	rs4130590	0.966	rs6478770	ENSG00000271833.1	RP11-356B19.11	-3.94	9.27e-05	0.00731	-0.19	-0.18	Bipolar disorder;	chr9:127349952	chr9:127366770~127367397:+
THCA	cis	rs11822910	0.953	rs11827928	ENSG00000265566.2	RN7SL605P	3.94	9.27e-05	0.00731	0.31	0.18	Platelet distribution width;	chr11:57430417	chr11:57528085~57528365:-
THCA	cis	rs9307551	0.817	rs12507160	ENSG00000249646.2	OR7E94P	-3.94	9.27e-05	0.00731	-0.23	-0.18	Refractive error;	chr4:79573647	chr4:79587302~79588130:-
THCA	cis	rs2380205	0.935	rs907689	ENSG00000232807.2	RP11-536K7.3	3.94	9.27e-05	0.00731	0.17	0.18	Breast cancer;	chr10:5859010	chr10:5934270~5945900:-
THCA	cis	rs9410380	0.935	rs10780209	ENSG00000225385.3	RP11-350E12.4	-3.94	9.27e-05	0.00731	-0.18	-0.18	Monocyte count;	chr9:88857212	chr9:88066915~88068037:+
THCA	cis	rs7200786	0.607	rs7184431	ENSG00000274038.1	RP11-66H6.4	-3.94	9.27e-05	0.00731	-0.22	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11041529	chr16:11056556~11057034:+
THCA	cis	rs970548	0.954	rs12243153	ENSG00000230869.1	CTGLF10P	3.94	9.27e-05	0.00732	0.22	0.18	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45506612	chr10:45678692~45700532:+
THCA	cis	rs4742903	0.935	rs7872034	ENSG00000270332.1	SMC2-AS1	3.94	9.28e-05	0.00732	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104134528	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.901	rs10122512	ENSG00000270332.1	SMC2-AS1	3.94	9.28e-05	0.00732	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104136129	chr9:104080024~104093073:-
THCA	cis	rs4792901	0.959	rs2293015	ENSG00000267151.3	RP11-100E5.2	3.94	9.28e-05	0.00732	0.19	0.18	Dupuytren's disease;	chr17:43544631	chr17:43444707~43451200:+
THCA	cis	rs4268898	0.76	rs11676939	ENSG00000242628.4	AC009228.1	-3.94	9.28e-05	0.00732	-0.21	-0.18	Asthma;	chr2:24256188	chr2:24214381~24221516:+
THCA	cis	rs394563	0.591	rs6570963	ENSG00000231760.4	RP11-350J20.5	-3.94	9.28e-05	0.00732	-0.22	-0.18	Dupuytren's disease;	chr6:149370219	chr6:149796151~149826294:-
THCA	cis	rs394563	0.591	rs6570964	ENSG00000231760.4	RP11-350J20.5	-3.94	9.28e-05	0.00732	-0.22	-0.18	Dupuytren's disease;	chr6:149370723	chr6:149796151~149826294:-
THCA	cis	rs4950322	0.802	rs72694705	ENSG00000180867.10	PDIA3P1	3.94	9.28e-05	0.00732	0.18	0.18	Protein quantitative trait loci;	chr1:147362313	chr1:147178113~147179622:+
THCA	cis	rs7560272	0.501	rs12615807	ENSG00000273245.1	RP11-434P11.2	-3.94	9.28e-05	0.00732	-0.2	-0.18	Schizophrenia;	chr2:73720456	chr2:73750256~73750786:-
THCA	cis	rs7927592	0.956	rs7102273	ENSG00000160172.9	FAM86C2P	3.94	9.28e-05	0.00732	0.17	0.18	Total body bone mineral density;	chr11:68618111	chr11:67791648~67805336:-
THCA	cis	rs875971	0.662	rs448725	ENSG00000229886.1	RP5-1132H15.3	3.94	9.28e-05	0.00732	0.19	0.18	Aortic root size;	chr7:66049641	chr7:66025126~66031544:-
THCA	cis	rs6545883	0.562	rs777588	ENSG00000270820.4	RP11-355B11.2	3.94	9.28e-05	0.00732	0.14	0.18	Tuberculosis;	chr2:61199685	chr2:61471188~61484130:+
THCA	cis	rs2180341	0.782	rs6912006	ENSG00000220522.2	RP1-177A13.1	3.94	9.28e-05	0.00732	0.2	0.18	Breast cancer;	chr6:127401486	chr6:127416535~127416952:-
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	3.94	9.28e-05	0.00732	0.22	0.18	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
THCA	cis	rs472402	0.54	rs3776431	ENSG00000250056.4	LINC01018	-3.94	9.28e-05	0.00732	-0.21	-0.18	Response to amphetamines;	chr5:6618643	chr5:6582136~6588499:+
THCA	cis	rs7598759	0.966	rs6754426	ENSG00000281035.1	AC017104.3	-3.94	9.29e-05	0.00732	-0.19	-0.18	Noise-induced hearing loss;	chr2:231458068	chr2:231456417~231456557:-
THCA	cis	rs7674212	0.865	rs1481279	ENSG00000248971.2	KRT8P46	3.94	9.29e-05	0.00733	0.22	0.18	Type 2 diabetes;	chr4:103056781	chr4:102728746~102730171:-
THCA	cis	rs1009077	0.67	rs28566610	ENSG00000260091.1	RP11-33B1.4	-3.94	9.29e-05	0.00733	-0.17	-0.18	Endometriosis;	chr4:119613767	chr4:119409333~119410233:+
THCA	cis	rs9392556	0.734	rs648900	ENSG00000272248.1	RP3-406P24.4	3.94	9.29e-05	0.00733	0.22	0.18	Blood metabolite levels;	chr6:4109188	chr6:4018713~4019202:+
THCA	cis	rs1404100	0.51	rs6768480	ENSG00000240476.1	LINC00973	-3.94	9.29e-05	0.00733	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99070070	chr3:98981058~98983096:+
THCA	cis	rs4218	0.681	rs4531679	ENSG00000277144.1	RP11-59H7.4	-3.94	9.29e-05	0.00733	-0.25	-0.18	Social communication problems;	chr15:59083246	chr15:59115547~59116089:-
THCA	cis	rs875971	0.545	rs73378304	ENSG00000273142.1	RP11-458F8.4	3.94	9.29e-05	0.00733	0.16	0.18	Aortic root size;	chr7:66175760	chr7:66902857~66906297:+
THCA	cis	rs12803635	0.557	rs10896172	ENSG00000255306.1	RP5-901A4.1	3.94	9.29e-05	0.00733	0.32	0.18	Mean corpuscular volume;	chr11:67408221	chr11:68024809~68030461:-
THCA	cis	rs9435732	0.778	rs56047197	ENSG00000235241.1	RP11-108M9.5	3.94	9.3e-05	0.00733	0.2	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17011965	chr1:16889095~16889602:+
THCA	cis	rs6546886	0.912	rs13014576	ENSG00000235499.1	AC073046.25	3.94	9.3e-05	0.00733	0.17	0.18	Dialysis-related mortality;	chr2:74082274	chr2:73985132~73986343:+
THCA	cis	rs568617	0.716	rs111953392	ENSG00000245156.1	RP11-867G23.3	-3.94	9.3e-05	0.00733	-0.22	-0.18	Crohn's disease;	chr11:65828226	chr11:66269832~66278525:-
THCA	cis	rs13083990	0.881	rs13085674	ENSG00000272758.4	RP11-299J3.8	-3.94	9.3e-05	0.00733	-0.17	-0.18	Cardiac Troponin-T levels;	chr3:122292504	chr3:122416207~122443180:+
THCA	cis	rs860295	0.65	rs28662267	ENSG00000160766.13	GBAP1	-3.94	9.3e-05	0.00733	-0.21	-0.18	Body mass index;	chr1:155710658	chr1:155213821~155227422:-
THCA	cis	rs4906332	1	rs35862113	ENSG00000252469.1	RNU7-160P	3.94	9.3e-05	0.00733	0.19	0.18	Coronary artery disease;	chr14:103390892	chr14:103550345~103550406:+
THCA	cis	rs4906332	0.84	rs34161327	ENSG00000252469.1	RNU7-160P	3.94	9.3e-05	0.00733	0.19	0.18	Coronary artery disease;	chr14:103390988	chr14:103550345~103550406:+
THCA	cis	rs9435732	0.778	rs6662202	ENSG00000235241.1	RP11-108M9.5	3.94	9.3e-05	0.00733	0.23	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17009758	chr1:16889095~16889602:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000275400.1	RP4-756H11.5	-3.94	9.3e-05	0.00733	-0.17	-0.18	Aortic root size;	chr7:66008093	chr7:66553805~66554199:-
THCA	cis	rs17412738	0.651	rs11914615	ENSG00000248724.5	NPHP3-AS1	-3.94	9.3e-05	0.00733	-0.33	-0.18	Blood protein levels;	chr3:132404638	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.589	rs76621798	ENSG00000248724.5	NPHP3-AS1	-3.94	9.3e-05	0.00733	-0.33	-0.18	Red cell distribution width;	chr3:132405352	chr3:132721750~132874223:+
THCA	cis	rs854765	0.583	rs4244602	ENSG00000281749.1	Y_RNA	3.94	9.3e-05	0.00734	0.23	0.18	Total body bone mineral density;	chr17:17938142	chr17:18001101~18001195:-
THCA	cis	rs2790457	0.771	rs2800737	ENSG00000254635.4	WAC-AS1	-3.94	9.3e-05	0.00734	-0.18	-0.18	Multiple myeloma;	chr10:28654143	chr10:28522652~28532743:-
THCA	cis	rs12541437	0.617	rs2921734	ENSG00000253327.2	RAD21-AS1	3.94	9.3e-05	0.00734	0.21	0.18	Gut microbiome composition (winter);	chr8:116922111	chr8:116874424~116876868:+
THCA	cis	rs11673344	0.67	rs73039188	ENSG00000267260.1	CTD-2162K18.4	-3.94	9.31e-05	0.00734	-0.24	-0.18	Obesity-related traits;	chr19:36922449	chr19:36773153~36777078:+
THCA	cis	rs7829975	0.628	rs1109618	ENSG00000254340.1	RP11-10A14.3	-3.94	9.31e-05	0.00734	-0.21	-0.18	Mood instability;	chr8:8713854	chr8:9141424~9145435:+
THCA	cis	rs10911902	0.643	rs6678193	ENSG00000233196.2	GS1-304P7.1	-3.94	9.31e-05	0.00734	-0.29	-0.18	Schizophrenia;	chr1:186413607	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.602	rs79668124	ENSG00000233196.2	GS1-304P7.1	-3.94	9.31e-05	0.00734	-0.29	-0.18	Schizophrenia;	chr1:186415103	chr1:186580515~186581191:-
THCA	cis	rs6822297	0.875	rs10939144	ENSG00000240005.4	RP11-293A21.1	-3.94	9.31e-05	0.00734	-0.19	-0.18	Obesity-related traits;	chr4:26965284	chr4:26859806~26860599:-
THCA	cis	rs7727544	0.684	rs272874	ENSG00000224431.1	AC063976.7	-3.94	9.31e-05	0.00734	-0.16	-0.18	Blood metabolite levels;	chr5:132339353	chr5:132199456~132203487:+
THCA	cis	rs12612619	0.732	rs13032059	ENSG00000272148.1	RP11-195B17.1	3.94	9.31e-05	0.00734	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010921	chr2:27062428~27062907:-
THCA	cis	rs12612619	0.732	rs13032100	ENSG00000272148.1	RP11-195B17.1	3.94	9.31e-05	0.00734	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010991	chr2:27062428~27062907:-
THCA	cis	rs7737355	0.947	rs7706785	ENSG00000237714.1	P4HA2-AS1	3.94	9.31e-05	0.00734	0.26	0.18	Life satisfaction;	chr5:131619167	chr5:132184876~132192808:+
THCA	cis	rs7897654	0.571	rs12771681	ENSG00000272912.1	RP11-724N1.1	-3.94	9.31e-05	0.00734	-0.23	-0.18	Schizophrenia;	chr10:102875863	chr10:102914585~102915404:+
THCA	cis	rs12612619	0.64	rs7560633	ENSG00000272148.1	RP11-195B17.1	-3.94	9.31e-05	0.00734	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27119199	chr2:27062428~27062907:-
THCA	cis	rs2732480	0.967	rs2732469	ENSG00000275228.1	RP11-370I10.10	-3.94	9.32e-05	0.00734	-0.19	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48327942~48328472:-
THCA	cis	rs1612141	0.901	rs1112504	ENSG00000251363.2	RP11-129M6.1	-3.94	9.32e-05	0.00734	-0.24	-0.18	QT interval (drug interaction);	chr14:41240508	chr14:40954898~40975877:+
THCA	cis	rs7959452	0.535	rs1350166	ENSG00000274979.1	RP11-1143G9.5	-3.94	9.32e-05	0.00734	-0.19	-0.18	Blood protein levels;	chr12:69242534	chr12:69326574~69331882:-
THCA	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-3.94	9.32e-05	0.00735	-0.19	-0.18	Asthma;	chr2:102399682	chr2:102438713~102440475:+
THCA	cis	rs2839186	0.564	rs4819215	ENSG00000215424.8	MCM3AP-AS1	3.94	9.32e-05	0.00735	0.1	0.18	Testicular germ cell tumor;	chr21:46203659	chr21:46229217~46259390:+
THCA	cis	rs465969	0.744	rs34659678	ENSG00000272356.1	RP5-1112D6.8	3.94	9.32e-05	0.00735	0.29	0.18	Psoriasis;	chr6:111567337	chr6:111309203~111313517:+
THCA	cis	rs4934494	0.768	rs34993776	ENSG00000240996.1	RP11-80H5.7	-3.94	9.32e-05	0.00735	-0.22	-0.18	Red blood cell count;	chr10:89681932	chr10:89694295~89697928:-
THCA	cis	rs1048886	0.938	rs2691496	ENSG00000271967.1	RP11-134K13.4	-3.94	9.32e-05	0.00735	-0.19	-0.18	Type 2 diabetes;	chr6:70582470	chr6:70596438~70596980:+
THCA	cis	rs10540	0.73	rs61876338	ENSG00000279672.1	CMB9-55F22.1	3.94	9.32e-05	0.00735	0.35	0.18	Body mass index;	chr11:493730	chr11:779617~780755:+
THCA	cis	rs2839627	0.638	rs73366794	ENSG00000225218.1	AP001628.6	3.94	9.32e-05	0.00735	0.3	0.18	Information processing speed;	chr21:42849070	chr21:42831040~42836477:-
THCA	cis	rs5758511	0.68	rs17002902	ENSG00000237037.8	NDUFA6-AS1	-3.94	9.32e-05	0.00735	-0.17	-0.18	Birth weight;	chr22:42229503	chr22:42090931~42137742:+
THCA	cis	rs7131987	0.65	rs10843377	ENSG00000273680.1	RP11-996F15.6	-3.94	9.32e-05	0.00735	-0.25	-0.18	QT interval;	chr12:29284120	chr12:29332733~29333383:-
THCA	cis	rs7166081	1	rs10152973	ENSG00000270964.1	RP11-502I4.3	-3.94	9.32e-05	0.00735	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67354880	chr15:67541072~67542604:-
THCA	cis	rs12544026	0.515	rs481545	ENSG00000253669.3	KB-1732A1.1	-3.94	9.32e-05	0.00735	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101877091	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.581	rs495636	ENSG00000253669.3	KB-1732A1.1	-3.94	9.32e-05	0.00735	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101877996	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.581	rs540459	ENSG00000253669.3	KB-1732A1.1	-3.94	9.32e-05	0.00735	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101878969	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.625	rs566315	ENSG00000253669.3	KB-1732A1.1	-3.94	9.32e-05	0.00735	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101879561	chr8:102805517~102809971:+
THCA	cis	rs9402743	0.632	rs6570028	ENSG00000272189.1	RP3-325F22.5	3.94	9.32e-05	0.00735	0.17	0.18	Systemic lupus erythematosus;	chr6:135754784	chr6:136550661~136552554:+
THCA	cis	rs7572644	0.64	rs11127126	ENSG00000223522.1	AC093690.1	-3.94	9.32e-05	0.00735	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27800417	chr2:28307691~28310459:-
THCA	cis	rs4819052	1	rs9306123	ENSG00000273796.1	LL21NC02-21A1.1	-3.94	9.32e-05	0.00735	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45403809~45404369:-
THCA	cis	rs5758659	0.714	rs5751216	ENSG00000205702.9	CYP2D7	-3.94	9.33e-05	0.00735	-0.13	-0.18	Cognitive function;	chr22:42112933	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.714	rs5758589	ENSG00000205702.9	CYP2D7	-3.94	9.33e-05	0.00735	-0.13	-0.18	Cognitive function;	chr22:42122378	chr22:42140203~42144577:-
THCA	cis	rs741677	0.893	rs1978963	ENSG00000231784.7	DBIL5P	3.94	9.33e-05	0.00735	0.2	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:580592	chr17:752660~755336:+
THCA	cis	rs2380205	0.689	rs11255602	ENSG00000232807.2	RP11-536K7.3	3.94	9.33e-05	0.00735	0.17	0.18	Breast cancer;	chr10:5861754	chr10:5934270~5945900:-
THCA	cis	rs2692947	0.589	rs810057	ENSG00000235584.2	AC008268.1	-3.94	9.33e-05	0.00735	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96349335	chr2:95666084~95668715:+
THCA	cis	rs8031584	0.723	rs11632229	ENSG00000270015.1	RP11-540B6.6	3.94	9.33e-05	0.00735	0.13	0.18	Huntington's disease progression;	chr15:30887331	chr15:30926514~30928407:+
THCA	cis	rs16957091	0.528	rs12910799	ENSG00000205771.5	CATSPER2P1	3.94	9.33e-05	0.00735	0.26	0.18	MGMT methylation in smokers;	chr15:42982666	chr15:43726918~43747094:-
THCA	cis	rs7131987	0.65	rs6487808	ENSG00000273680.1	RP11-996F15.6	-3.94	9.33e-05	0.00735	-0.25	-0.18	QT interval;	chr12:29310426	chr12:29332733~29333383:-
THCA	cis	rs2692947	0.644	rs1168968	ENSG00000235584.2	AC008268.1	-3.94	9.33e-05	0.00735	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96159625	chr2:95666084~95668715:+
THCA	cis	rs950169	0.922	rs4338765	ENSG00000275120.1	RP11-182J1.17	3.94	9.33e-05	0.00735	0.21	0.18	Schizophrenia;	chr15:84248084	chr15:84599434~84606463:-
THCA	cis	rs2806561	0.765	rs2806557	ENSG00000249087.5	ZNF436-AS1	-3.94	9.33e-05	0.00736	-0.12	-0.18	Height;	chr1:23176879	chr1:23368997~23371839:+
THCA	cis	rs7403037	0.642	rs1976758	ENSG00000260760.1	PWRN3	3.94	9.33e-05	0.00736	0.2	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24180614	chr15:24441127~24447967:+
THCA	cis	rs7560272	0.512	rs2421677	ENSG00000163016.8	ALMS1P	-3.94	9.33e-05	0.00736	-0.22	-0.18	Schizophrenia;	chr2:73738790	chr2:73644919~73685576:+
THCA	cis	rs6921919	0.887	rs16894116	ENSG00000219392.1	RP1-265C24.5	-3.94	9.33e-05	0.00736	-0.24	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28115628~28116551:+
THCA	cis	rs11175194	0.655	rs68047317	ENSG00000255642.1	PABPC1P4	3.94	9.34e-05	0.00736	0.38	0.18	Epithelial ovarian cancer;	chr12:63871384	chr12:63822021~63823895:+
THCA	cis	rs7219021	0.705	rs962273	ENSG00000248278.1	SUMO2P17	3.94	9.34e-05	0.00736	0.23	0.18	Schizophrenia or bipolar disorder;	chr17:48900991	chr17:48874860~48908983:-
THCA	cis	rs6938	0.534	rs11072512	ENSG00000260269.4	CTD-2323K18.1	-3.94	9.34e-05	0.00736	-0.26	-0.18	Breast cancer;	chr15:74911685	chr15:75527150~75601205:-
THCA	cis	rs6938	0.534	rs12907898	ENSG00000260269.4	CTD-2323K18.1	-3.94	9.34e-05	0.00736	-0.26	-0.18	Breast cancer;	chr15:74915531	chr15:75527150~75601205:-
THCA	cis	rs7246657	0.524	rs35080624	ENSG00000276846.1	CTD-3220F14.3	3.94	9.34e-05	0.00736	0.22	0.18	Coronary artery calcification;	chr19:36965680	chr19:37314868~37315620:-
THCA	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	3.94	9.34e-05	0.00736	0.21	0.18	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	3.94	9.34e-05	0.00736	0.21	0.18	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
THCA	cis	rs9959145	1	rs28815517	ENSG00000267199.1	RP11-861E21.2	3.94	9.34e-05	0.00736	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12558747	chr18:12438890~12448205:+
THCA	cis	rs7615952	0.673	rs34072288	ENSG00000248787.1	RP11-666A20.4	-3.94	9.34e-05	0.00736	-0.37	-0.18	Blood pressure (smoking interaction);	chr3:125825186	chr3:125908005~125910272:-
THCA	cis	rs2074409	0.572	rs8079671	ENSG00000277501.1	RP11-697E22.2	-3.94	9.34e-05	0.00736	-0.26	-0.18	Response to angiotensin II receptor blocker therapy;	chr17:37606931	chr17:37642947~37684252:+
THCA	cis	rs12893668	0.667	rs71417869	ENSG00000252469.1	RNU7-160P	3.94	9.34e-05	0.00736	0.21	0.18	Reticulocyte count;	chr14:103611097	chr14:103550345~103550406:+
THCA	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	3.94	9.34e-05	0.00736	0.16	0.18	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	3.94	9.34e-05	0.00736	0.16	0.18	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	3.94	9.34e-05	0.00736	0.16	0.18	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
THCA	cis	rs7074356	0.688	rs34894697	ENSG00000278616.1	BEND3P3	3.94	9.35e-05	0.00736	0.16	0.18	Borderline personality disorder;	chr10:80410132	chr10:79682997~79685436:+
THCA	cis	rs150992	0.57	rs398436	ENSG00000246763.5	RGMB-AS1	3.94	9.35e-05	0.00736	0.18	0.18	Body mass index;	chr5:98991352	chr5:98769618~98773469:-
THCA	cis	rs3764021	0.87	rs10492166	ENSG00000214776.8	RP11-726G1.1	3.94	9.35e-05	0.00736	0.22	0.18	Type 1 diabetes;	chr12:9733403	chr12:9467552~9576275:+
THCA	cis	rs7824557	0.872	rs6601577	ENSG00000154316.13	TDH	-3.94	9.35e-05	0.00736	-0.13	-0.18	Retinal vascular caliber;	chr8:11245173	chr8:11339637~11368452:+
THCA	cis	rs4699052	1	rs6533059	ENSG00000246560.2	RP11-10L12.4	3.94	9.35e-05	0.00737	0.21	0.18	Testicular germ cell tumor;	chr4:103212219	chr4:102828055~102844075:+
THCA	cis	rs7824557	0.569	rs10106207	ENSG00000206014.6	OR7E161P	3.94	9.35e-05	0.00737	0.21	0.18	Retinal vascular caliber;	chr8:11157828	chr8:11928597~11929563:-
THCA	cis	rs745109	0.504	rs76526816	ENSG00000273080.1	RP11-301O19.1	3.94	9.35e-05	0.00737	0.32	0.18	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86370509	chr2:86195590~86196049:+
THCA	cis	rs67981189	0.896	rs17108967	ENSG00000269927.1	RP6-91H8.3	3.94	9.35e-05	0.00737	0.2	0.18	Schizophrenia;	chr14:71075451	chr14:71141125~71143253:-
THCA	cis	rs7166081	1	rs12595736	ENSG00000270964.1	RP11-502I4.3	-3.94	9.36e-05	0.00737	-0.17	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67290264	chr15:67541072~67542604:-
THCA	cis	rs7828089	0.715	rs11136029	ENSG00000248738.5	RP11-87E22.2	3.94	9.36e-05	0.00737	0.18	0.18	Verbal declarative memory;	chr8:22395972	chr8:22877972~22888022:+
THCA	cis	rs6547705	1	rs6743139	ENSG00000231259.4	AC125232.1	-3.94	9.36e-05	0.00737	-0.24	-0.18	Progressive supranuclear palsy;	chr2:86791329	chr2:87031815~87053069:-
THCA	cis	rs4218	0.636	rs4775116	ENSG00000259732.1	RP11-59H7.3	3.94	9.36e-05	0.00737	0.25	0.18	Social communication problems;	chr15:59135608	chr15:59121034~59133250:+
THCA	cis	rs9608946	1	rs8138759	ENSG00000279699.1	RP1-102K2.9	3.94	9.36e-05	0.00737	0.21	0.18	Red cell distribution width;	chr22:30488440	chr22:30275215~30276951:-
THCA	cis	rs853679	0.607	rs34788973	ENSG00000272009.1	RP1-313I6.12	-3.94	9.36e-05	0.00737	-0.34	-0.18	Depression;	chr6:27911422	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs61742093	ENSG00000272009.1	RP1-313I6.12	-3.94	9.36e-05	0.00737	-0.34	-0.18	Depression;	chr6:27912204	chr6:28078792~28081130:-
THCA	cis	rs7914558	0.966	rs12571568	ENSG00000213061.2	PFN1P11	3.94	9.36e-05	0.00737	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs12766205	ENSG00000213061.2	PFN1P11	3.94	9.36e-05	0.00737	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs10883837	ENSG00000213061.2	PFN1P11	3.94	9.36e-05	0.00737	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs746293	ENSG00000213061.2	PFN1P11	3.94	9.36e-05	0.00737	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs11191577	ENSG00000213061.2	PFN1P11	3.94	9.36e-05	0.00737	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:102838011~102845473:-
THCA	cis	rs877819	0.583	rs1904595	ENSG00000228403.1	RP11-563N6.6	3.94	9.36e-05	0.00737	0.19	0.18	Systemic lupus erythematosus;	chr10:48877222	chr10:48878022~48878649:+
THCA	cis	rs2033711	0.87	rs6510152	ENSG00000232098.3	CTD-2619J13.14	3.94	9.36e-05	0.00737	0.16	0.18	Uric acid clearance;	chr19:58441952	chr19:58404238~58408484:-
THCA	cis	rs9380516	0.581	rs3798345	ENSG00000228559.1	RP3-340B19.3	-3.94	9.36e-05	0.00737	-0.23	-0.18	Hepatitis C induced liver fibrosis;	chr6:35594694	chr6:35544632~35545669:+
THCA	cis	rs1056107	0.572	rs10817334	ENSG00000230185.4	C9orf147	3.94	9.36e-05	0.00738	0.16	0.18	Colorectal cancer;	chr9:112401777	chr9:112433816~112487204:-
THCA	cis	rs3742597	0.84	rs10148907	ENSG00000276116.2	FUT8-AS1	3.94	9.36e-05	0.00738	0.2	0.18	N-glycan levels;	chr14:65366654	chr14:65411170~65412690:-
THCA	cis	rs4743820	0.503	rs10820835	ENSG00000235641.4	LINC00484	-3.94	9.36e-05	0.00738	-0.22	-0.18	Ulcerative colitis;Inflammatory bowel disease;	chr9:91158945	chr9:91159573~91165658:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000275400.1	RP4-756H11.5	-3.94	9.36e-05	0.00738	-0.17	-0.18	Aortic root size;	chr7:66008701	chr7:66553805~66554199:-
THCA	cis	rs4713118	0.955	rs9468201	ENSG00000261839.1	RP1-265C24.8	3.94	9.36e-05	0.00738	0.2	0.18	Parkinson's disease;	chr6:27719256	chr6:28136849~28139678:+
THCA	cis	rs2076295	0.503	rs3778338	ENSG00000261189.1	RP3-512B11.3	-3.94	9.36e-05	0.00738	-0.18	-0.18	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7565935	chr6:7540451~7541338:-
THCA	cis	rs5752326	0.558	rs737801	ENSG00000261188.1	CTA-445C9.14	3.94	9.36e-05	0.00738	0.19	0.18	Ischemic stroke;	chr22:26467673	chr22:26512537~26514568:+
THCA	cis	rs7162943	0.887	rs11858280	ENSG00000260123.1	RP11-326A19.4	-3.94	9.36e-05	0.00738	-0.23	-0.18	Mean platelet volume;	chr15:89069059	chr15:89041223~89082819:+
THCA	cis	rs1552244	0.608	rs6764807	ENSG00000269982.1	RP11-1020A11.2	3.94	9.37e-05	0.00738	0.13	0.18	Alzheimer's disease;	chr3:9957119	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs34391585	ENSG00000269982.1	RP11-1020A11.2	3.94	9.37e-05	0.00738	0.13	0.18	Alzheimer's disease;	chr3:9957524	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.515	rs7613004	ENSG00000269982.1	RP11-1020A11.2	3.94	9.37e-05	0.00738	0.13	0.18	Alzheimer's disease;	chr3:9958229	chr3:9958717~9962539:+
THCA	cis	rs7616559	0.962	rs4574238	ENSG00000244515.1	KRT18P34	-3.94	9.37e-05	0.00738	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157008474	chr3:157162663~157163932:-
THCA	cis	rs17253792	0.822	rs8013831	ENSG00000186615.9	KTN1-AS1	-3.94	9.37e-05	0.00738	-0.28	-0.18	Putamen volume;	chr14:55706180	chr14:55499278~55580110:-
THCA	cis	rs1075265	0.584	rs1862121	ENSG00000272156.1	RP11-477N3.1	3.94	9.37e-05	0.00738	0.18	0.18	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54082554~54085066:+
THCA	cis	rs3738443	0.951	rs41315860	ENSG00000259865.1	RP11-488L18.10	3.94	9.37e-05	0.00738	0.19	0.18	Alcohol dependence;	chr1:247212558	chr1:247187281~247188526:-
THCA	cis	rs6840360	0.573	rs4696250	ENSG00000251611.1	RP11-610P16.1	-3.94	9.37e-05	0.00738	-0.13	-0.18	Intelligence (multi-trait analysis);	chr4:151345169	chr4:151407551~151408835:-
THCA	cis	rs962856	0.619	rs7564335	ENSG00000236780.4	AC078941.1	3.94	9.37e-05	0.00738	0.24	0.18	Pancreatic cancer;	chr2:67352835	chr2:67123357~67215319:-
THCA	cis	rs962856	0.619	rs6546298	ENSG00000236780.4	AC078941.1	3.94	9.37e-05	0.00738	0.24	0.18	Pancreatic cancer;	chr2:67354721	chr2:67123357~67215319:-
THCA	cis	rs7937	0.693	rs12973666	ENSG00000279108.1	CTC-490E21.11	3.94	9.37e-05	0.00738	0.19	0.18	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40783492	chr19:40840159~40842039:+
THCA	cis	rs786425	0.77	rs7306549	ENSG00000278112.1	RP11-972P1.11	3.94	9.37e-05	0.00738	0.17	0.18	Pubertal anthropometrics;	chr12:123672350	chr12:123519390~123519856:-
THCA	cis	rs7550636	0.797	rs10921283	ENSG00000276735.1	Metazoa_SRP	3.94	9.37e-05	0.00738	0.22	0.18	Coronary artery calcification;	chr1:192901339	chr1:193236794~193237107:-
THCA	cis	rs752590	0.666	rs67081417	ENSG00000227359.1	AC017074.2	3.94	9.37e-05	0.00738	0.28	0.18	Mucinous ovarian carcinoma;	chr2:113244868	chr2:113677702~113704078:-
THCA	cis	rs14027	0.843	rs6469849	ENSG00000245330.4	KB-1471A8.1	3.94	9.38e-05	0.00739	0.18	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119867419~119874488:-
THCA	cis	rs793571	0.822	rs2013117	ENSG00000245975.2	RP11-30K9.6	-3.94	9.38e-05	0.00739	-0.2	-0.18	Schizophrenia;	chr15:58881111	chr15:58768072~58770974:-
THCA	cis	rs17221829	0.702	rs2075536	ENSG00000280385.1	AP000648.5	3.94	9.38e-05	0.00739	0.17	0.18	Anxiety in major depressive disorder;	chr11:89674223	chr11:90193614~90198120:+
THCA	cis	rs34779708	0.733	rs12240638	ENSG00000233200.1	RP11-324I22.2	3.94	9.38e-05	0.00739	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35219894~35230598:-
THCA	cis	rs860295	0.836	rs1360554	ENSG00000160766.13	GBAP1	3.94	9.38e-05	0.00739	0.2	0.18	Body mass index;	chr1:155503565	chr1:155213821~155227422:-
THCA	cis	rs5752326	0.51	rs5752325	ENSG00000261188.1	CTA-445C9.14	3.94	9.38e-05	0.00739	0.18	0.18	Ischemic stroke;	chr22:26446852	chr22:26512537~26514568:+
THCA	cis	rs6012564	0.793	rs6067007	ENSG00000230758.1	SNAP23P	3.94	9.38e-05	0.00739	0.22	0.18	Anger;	chr20:49204492	chr20:49038357~49038602:-
THCA	cis	rs285757	0.895	rs12443091	ENSG00000259064.2	RP11-386M24.5	-3.94	9.38e-05	0.00739	-0.26	-0.18	HIV-1 susceptibility;	chr15:92649782	chr15:92627073~92627414:+
THCA	cis	rs9611565	0.512	rs139562	ENSG00000237037.8	NDUFA6-AS1	3.94	9.39e-05	0.00739	0.17	0.18	Vitiligo;	chr22:41800680	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.512	rs139566	ENSG00000237037.8	NDUFA6-AS1	3.94	9.39e-05	0.00739	0.17	0.18	Vitiligo;	chr22:41803273	chr22:42090931~42137742:+
THCA	cis	rs9532669	0.89	rs2324738	ENSG00000229473.2	RGS17P1	3.94	9.39e-05	0.00739	0.22	0.18	Cervical cancer;	chr13:40925242	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.963	rs2324739	ENSG00000229473.2	RGS17P1	3.94	9.39e-05	0.00739	0.22	0.18	Cervical cancer;	chr13:40925479	chr13:40992779~40993331:-
THCA	cis	rs9810089	0.814	rs10804640	ENSG00000273455.1	RP11-305O4.3	3.94	9.39e-05	0.00739	0.23	0.18	Gestational age at birth (child effect);	chr3:136446853	chr3:136087475~136087913:-
THCA	cis	rs9608946	1	rs9606735	ENSG00000279699.1	RP1-102K2.9	3.94	9.39e-05	0.00739	0.21	0.18	Red cell distribution width;	chr22:30488844	chr22:30275215~30276951:-
THCA	cis	rs6067053	0.646	rs3818066	ENSG00000230758.1	SNAP23P	3.94	9.39e-05	0.00739	0.22	0.18	Intelligence (multi-trait analysis);	chr20:49278429	chr20:49038357~49038602:-
THCA	cis	rs6067053	0.671	rs6067035	ENSG00000230758.1	SNAP23P	3.94	9.39e-05	0.00739	0.22	0.18	Intelligence (multi-trait analysis);	chr20:49291253	chr20:49038357~49038602:-
THCA	cis	rs6756513	0.5	rs4420721	ENSG00000231024.1	AC092431.3	3.94	9.39e-05	0.00739	0.27	0.18	Breast cancer;Platelet count;	chr2:69836395	chr2:69700192~69713847:-
THCA	cis	rs9309473	1	rs6736866	ENSG00000273245.1	RP11-434P11.2	3.94	9.39e-05	0.00739	0.25	0.18	Metabolite levels;	chr2:73434858	chr2:73750256~73750786:-
THCA	cis	rs9650657	0.812	rs11250072	ENSG00000255310.2	AF131215.2	-3.94	9.39e-05	0.00739	-0.15	-0.18	Neuroticism;	chr8:10774611	chr8:11107788~11109726:-
THCA	cis	rs2677744	1	rs4773	ENSG00000214432.8	AC068831.10	-3.94	9.39e-05	0.00739	-0.18	-0.18	Attention deficit hyperactivity disorder;	chr15:90920612	chr15:91022619~91036611:+
THCA	cis	rs4761638	0.765	rs4373996	ENSG00000241556.1	RP11-490G8.1	-3.94	9.39e-05	0.0074	-0.2	-0.18	Insulin disposition index;	chr12:94602145	chr12:95467397~95467861:-
THCA	cis	rs7777677	0.963	rs4726550	ENSG00000211750.2	TRBV24-1	-3.94	9.39e-05	0.0074	-0.18	-0.18	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142656701~142657213:+
THCA	cis	rs2235642	0.787	rs2235646	ENSG00000260989.1	LA16c-395F10.2	-3.94	9.39e-05	0.0074	-0.19	-0.18	Coronary artery disease;	chr16:1551286	chr16:1580527~1610328:+
THCA	cis	rs9905704	0.647	rs9901655	ENSG00000224738.1	AC099850.1	3.94	9.39e-05	0.0074	0.22	0.18	Testicular germ cell tumor;	chr17:58909781	chr17:59106598~59118267:+
THCA	cis	rs11710088	0.895	rs4482615	ENSG00000240541.2	TM4SF1-AS1	3.94	9.39e-05	0.0074	0.17	0.18	QRS duration;	chr3:149480894	chr3:149377778~149386583:+
THCA	cis	rs728616	0.681	rs117420340	ENSG00000225484.5	NUTM2B-AS1	-3.94	9.4e-05	0.0074	-0.31	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406739	chr10:79663088~79826594:-
THCA	cis	rs2692947	0.644	rs3821051	ENSG00000235584.2	AC008268.1	3.94	9.4e-05	0.0074	0.18	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96247049	chr2:95666084~95668715:+
THCA	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	3.94	9.4e-05	0.0074	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	3.94	9.4e-05	0.0074	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	3.94	9.4e-05	0.0074	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	3.94	9.4e-05	0.0074	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	3.94	9.4e-05	0.0074	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
THCA	cis	rs6545883	0.783	rs12713442	ENSG00000271889.1	RP11-493E12.1	3.94	9.4e-05	0.0074	0.17	0.18	Tuberculosis;	chr2:61620943	chr2:61151433~61162105:-
THCA	cis	rs854765	0.583	rs7503334	ENSG00000281749.1	Y_RNA	-3.94	9.4e-05	0.0074	-0.23	-0.18	Total body bone mineral density;	chr17:17876144	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs6502619	ENSG00000281749.1	Y_RNA	-3.94	9.4e-05	0.0074	-0.23	-0.18	Total body bone mineral density;	chr17:17876390	chr17:18001101~18001195:-
THCA	cis	rs6688613	0.685	rs11579987	ENSG00000225171.2	DUTP6	3.94	9.4e-05	0.0074	0.26	0.18	Refractive astigmatism;	chr1:166920127	chr1:166868748~166869209:+
THCA	cis	rs2281603	0.62	rs9323450	ENSG00000272909.1	CTD-2555O16.4	-3.94	9.4e-05	0.0074	-0.2	-0.18	Lymphocyte counts;	chr14:64461249	chr14:64440369~64442238:-
THCA	cis	rs7849973	0.532	rs10965507	ENSG00000234840.1	LINC01239	-3.94	9.4e-05	0.0074	-0.2	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22902232	chr9:22646200~22824213:+
THCA	cis	rs950169	0.8	rs4842847	ENSG00000275120.1	RP11-182J1.17	3.94	9.4e-05	0.0074	0.21	0.18	Schizophrenia;	chr15:84262447	chr15:84599434~84606463:-
THCA	cis	rs17074492	1	rs55743985	ENSG00000214182.5	PTMAP5	3.94	9.4e-05	0.0074	0.21	0.18	Sjögren's syndrome;	chr13:81598191	chr13:81689911~81691072:+
THCA	cis	rs4767841	0.874	rs7294387	ENSG00000252886.1	RN7SKP197	-3.94	9.4e-05	0.0074	-0.18	-0.18	Urgency urinary incontinence;	chr12:119769607	chr12:119631090~119631386:-
THCA	cis	rs10875746	0.669	rs10875792	ENSG00000226413.2	OR8T1P	3.94	9.4e-05	0.0074	0.26	0.18	Longevity (90 years and older);	chr12:48303640	chr12:48442030~48442947:-
THCA	cis	rs10875746	0.623	rs10875793	ENSG00000226413.2	OR8T1P	3.94	9.4e-05	0.0074	0.26	0.18	Longevity (90 years and older);	chr12:48303647	chr12:48442030~48442947:-
THCA	cis	rs6940638	0.688	rs9295730	ENSG00000220721.1	OR1F12	3.94	9.41e-05	0.0074	0.21	0.18	Intelligence (multi-trait analysis);	chr6:27161027	chr6:28073316~28074233:+
THCA	cis	rs1908814	0.516	rs35391955	ENSG00000254948.1	OR7E158P	-3.94	9.41e-05	0.0074	-0.22	-0.18	Neuroticism;	chr8:11939219	chr8:11919900~11920809:-
THCA	cis	rs7259376	0.871	rs34187872	ENSG00000269138.1	ZNF209P	-3.94	9.41e-05	0.00741	-0.18	-0.18	Menopause (age at onset);	chr19:22425081	chr19:22463922~22473036:+
THCA	cis	rs755249	0.532	rs2296173	ENSG00000182109.6	RP11-69E11.4	3.94	9.41e-05	0.00741	0.2	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39522280~39546187:-
THCA	cis	rs12313068	0.656	rs41436646	ENSG00000249094.2	RP1-7G5.6	3.94	9.41e-05	0.00741	0.28	0.18	Intelligence (multi-trait analysis);	chr12:110057366	chr12:109880676~109888467:+
THCA	cis	rs11671005	0.779	rs3794970	ENSG00000252334.1	RNU6-1337P	-3.94	9.41e-05	0.00741	-0.27	-0.18	Mean platelet volume;	chr19:58474893	chr19:58483749~58483843:-
THCA	cis	rs2880765	0.527	rs35184622	ENSG00000259630.2	CTD-2262B20.1	-3.94	9.41e-05	0.00741	-0.23	-0.18	Coronary artery disease;	chr15:85529804	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.527	rs1483578	ENSG00000259630.2	CTD-2262B20.1	-3.94	9.41e-05	0.00741	-0.23	-0.18	Coronary artery disease;	chr15:85532186	chr15:85415228~85415633:+
THCA	cis	rs11634944	0.593	rs12050838	ENSG00000251896.1	SNORD116-27	-3.94	9.41e-05	0.00741	-0.2	-0.18	Interleukin-8 levels;	chr15:24972464	chr15:25101575~25101666:+
THCA	cis	rs394563	0.559	rs7753269	ENSG00000231760.4	RP11-350J20.5	-3.94	9.41e-05	0.00741	-0.22	-0.18	Dupuytren's disease;	chr6:149350224	chr6:149796151~149826294:-
THCA	cis	rs2120243	0.572	rs2305620	ENSG00000241770.1	RP11-555M1.3	-3.94	9.41e-05	0.00741	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157409797	chr3:157163452~157169133:+
THCA	cis	rs4713118	0.868	rs35069907	ENSG00000261839.1	RP1-265C24.8	3.94	9.41e-05	0.00741	0.21	0.18	Parkinson's disease;	chr6:27778913	chr6:28136849~28139678:+
THCA	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	3.94	9.41e-05	0.00741	0.21	0.18	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
THCA	cis	rs76382185	0.756	rs12740106	ENSG00000233184.5	RP11-421L21.3	3.94	9.42e-05	0.00741	0.27	0.18	Lymphocyte counts;	chr1:101135193	chr1:101025878~101087268:+
THCA	cis	rs2129782	0.558	rs1601816	ENSG00000253553.4	RP11-586K2.1	3.94	9.42e-05	0.00741	0.26	0.18	Electrodermal activity;	chr8:88462069	chr8:88326836~88737134:+
THCA	cis	rs2028299	0.92	rs2043880	ENSG00000259677.1	RP11-493E3.1	3.94	9.42e-05	0.00741	0.24	0.18	Type 2 diabetes;	chr15:89889294	chr15:89876540~89877285:+
THCA	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	3.94	9.42e-05	0.00741	0.21	0.18	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
THCA	cis	rs28735056	0.967	rs11660941	ENSG00000261126.6	RP11-795F19.1	-3.94	9.42e-05	0.00741	-0.15	-0.18	Schizophrenia;	chr18:79870600	chr18:80046900~80095482:+
THCA	cis	rs28510890	0.754	rs8033582	ENSG00000258676.4	RP11-386M24.3	3.94	9.42e-05	0.00741	0.17	0.18	Lung cancer in ever smokers;	chr15:92582658	chr15:92580829~92600545:+
THCA	cis	rs6546886	0.956	rs6755711	ENSG00000235499.1	AC073046.25	3.94	9.42e-05	0.00741	0.16	0.18	Dialysis-related mortality;	chr2:74074713	chr2:73985132~73986343:+
THCA	cis	rs7119038	0.818	rs7942535	ENSG00000255422.1	AP002954.4	-3.94	9.42e-05	0.00742	-0.22	-0.18	Sjögren's syndrome;	chr11:118810755	chr11:118704607~118750263:+
THCA	cis	rs4950322	0.576	rs2353979	ENSG00000226015.2	CCT8P1	-3.94	9.42e-05	0.00742	-0.19	-0.18	Protein quantitative trait loci;	chr1:147368185	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.576	rs2353980	ENSG00000226015.2	CCT8P1	-3.94	9.42e-05	0.00742	-0.19	-0.18	Protein quantitative trait loci;	chr1:147368274	chr1:147203276~147204932:-
THCA	cis	rs758324	0.645	rs156033	ENSG00000224431.1	AC063976.7	-3.94	9.42e-05	0.00742	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132191628	chr5:132199456~132203487:+
THCA	cis	rs7259376	0.902	rs11669356	ENSG00000269138.1	ZNF209P	-3.94	9.42e-05	0.00742	-0.18	-0.18	Menopause (age at onset);	chr19:22422318	chr19:22463922~22473036:+
THCA	cis	rs71520386	0.796	rs71530697	ENSG00000228649.7	AC005682.5	-3.94	9.42e-05	0.00742	-0.29	-0.18	Fibrinogen levels;	chr7:22799134	chr7:22854178~22861579:+
THCA	cis	rs2334880	0.587	rs8058188	ENSG00000260185.1	RP11-432I5.6	-3.94	9.42e-05	0.00742	-0.25	-0.18	Malaria;	chr16:71641233	chr16:71655027~71664212:+
THCA	cis	rs12022452	1	rs12031278	ENSG00000237899.1	RP4-739H11.3	-3.94	9.43e-05	0.00742	-0.29	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40669089~40687588:-
THCA	cis	rs4671400	0.543	rs2290324	ENSG00000271889.1	RP11-493E12.1	-3.94	9.43e-05	0.00742	-0.19	-0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61221641	chr2:61151433~61162105:-
THCA	cis	rs2334880	0.836	rs9934715	ENSG00000260593.1	RP11-432I5.2	-3.94	9.43e-05	0.00742	-0.28	-0.18	Malaria;	chr16:71723484	chr16:71623708~71626816:-
THCA	cis	rs881375	0.678	rs10760125	ENSG00000270917.1	RP11-27I1.6	-3.94	9.43e-05	0.00742	-0.24	-0.18	Rheumatoid arthritis;	chr9:120900312	chr9:120812475~120812845:-
THCA	cis	rs881375	0.678	rs9886724	ENSG00000270917.1	RP11-27I1.6	-3.94	9.43e-05	0.00742	-0.24	-0.18	Rheumatoid arthritis;	chr9:120902741	chr9:120812475~120812845:-
THCA	cis	rs881375	0.631	rs10739577	ENSG00000270917.1	RP11-27I1.6	-3.94	9.43e-05	0.00742	-0.24	-0.18	Rheumatoid arthritis;	chr9:120906576	chr9:120812475~120812845:-
THCA	cis	rs6499755	0.87	rs31074	ENSG00000260135.5	RP11-212I21.2	-3.94	9.43e-05	0.00742	-0.2	-0.18	Hypospadias;	chr16:55323258	chr16:55426797~55462297:-
THCA	cis	rs7829975	0.774	rs35431455	ENSG00000253981.4	ALG1L13P	3.94	9.43e-05	0.00742	0.17	0.18	Mood instability;	chr8:8816226	chr8:8236003~8244667:-
THCA	cis	rs6954895	0.574	rs73086839	ENSG00000271122.1	RP11-379H18.1	3.94	9.43e-05	0.00742	0.15	0.18	Anger;	chr7:35572704	chr7:35695214~35699413:+
THCA	cis	rs7551222	0.752	rs10793766	ENSG00000240219.1	RP11-430C7.5	3.94	9.43e-05	0.00742	0.17	0.18	Schizophrenia;	chr1:204580368	chr1:204626775~204629712:+
THCA	cis	rs6477918	0.544	rs10981382	ENSG00000230185.4	C9orf147	-3.94	9.43e-05	0.00742	-0.19	-0.18	Obstetric antiphospholipid syndrome;	chr9:112392218	chr9:112433816~112487204:-
THCA	cis	rs5758511	0.596	rs55644935	ENSG00000230107.1	CTA-126B4.7	-3.94	9.43e-05	0.00742	-0.21	-0.18	Birth weight;	chr22:42270063	chr22:42438023~42446195:+
THCA	cis	rs786425	0.707	rs2250026	ENSG00000270095.1	RP11-214K3.18	-3.94	9.43e-05	0.00742	-0.21	-0.18	Pubertal anthropometrics;	chr12:123713858	chr12:123971457~123971714:-
THCA	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	3.94	9.44e-05	0.00742	0.2	0.18	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	3.94	9.44e-05	0.00742	0.2	0.18	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
THCA	cis	rs1389724	0.648	rs12030728	ENSG00000259834.1	RP11-284N8.3	3.94	9.44e-05	0.00742	0.15	0.18	Schizophrenia;	chr1:110773461	chr1:110653560~110657040:-
THCA	cis	rs1389724	0.648	rs1160413	ENSG00000259834.1	RP11-284N8.3	-3.94	9.44e-05	0.00742	-0.15	-0.18	Schizophrenia;	chr1:110773072	chr1:110653560~110657040:-
THCA	cis	rs6881280	1	rs59494239	ENSG00000249996.1	RP11-359P5.1	-3.94	9.44e-05	0.00743	-0.29	-0.18	Self-reported allergy;	chr5:123296394	chr5:123036271~123054667:+
THCA	cis	rs13434995	0.513	rs4336288	ENSG00000249700.7	SRD5A3-AS1	3.94	9.44e-05	0.00743	0.26	0.18	Adiponectin levels;	chr4:55584088	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs9993599	ENSG00000249700.7	SRD5A3-AS1	3.94	9.44e-05	0.00743	0.26	0.18	Adiponectin levels;	chr4:55586798	chr4:55363971~55395847:-
THCA	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-3.94	9.44e-05	0.00743	-0.16	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
THCA	cis	rs9291683	0.53	rs35908990	ENSG00000250413.1	RP11-448G15.1	-3.94	9.44e-05	0.00743	-0.17	-0.18	Bone mineral density;	chr4:9974481	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.551	rs62295971	ENSG00000250413.1	RP11-448G15.1	-3.94	9.44e-05	0.00743	-0.17	-0.18	Bone mineral density;	chr4:9976518	chr4:10006482~10009725:+
THCA	cis	rs1510272	0.889	rs2063352	ENSG00000243926.1	TIPARP-AS1	-3.94	9.44e-05	0.00743	-0.19	-0.18	Testicular germ cell tumor;	chr3:156610691	chr3:156671862~156674378:-
THCA	cis	rs8077577	1	rs62073605	ENSG00000273018.4	CTD-2303H24.2	-3.94	9.44e-05	0.00743	-0.3	-0.18	Obesity-related traits;	chr17:18163477	chr17:18511221~18551705:-
THCA	cis	rs8077577	1	rs62073606	ENSG00000273018.4	CTD-2303H24.2	-3.94	9.44e-05	0.00743	-0.3	-0.18	Obesity-related traits;	chr17:18165828	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.945	rs62073611	ENSG00000273018.4	CTD-2303H24.2	-3.94	9.44e-05	0.00743	-0.3	-0.18	Obesity-related traits;	chr17:18168647	chr17:18511221~18551705:-
THCA	cis	rs599083	0.53	rs2508834	ENSG00000212093.1	AP000807.1	-3.94	9.44e-05	0.00743	-0.2	-0.18	Bone mineral density (spine);	chr11:68407886	chr11:68506083~68506166:-
THCA	cis	rs10435719	0.902	rs7459545	ENSG00000206014.6	OR7E161P	-3.94	9.44e-05	0.00743	-0.21	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:11928597~11929563:-
THCA	cis	rs3790606	1	rs12136566	ENSG00000273483.1	RP4-671G15.2	3.94	9.44e-05	0.00743	0.19	0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr1:112508452	chr1:112517799~112518441:-
THCA	cis	rs1204798	0.947	rs1210355	ENSG00000237021.2	RP3-486I3.7	-3.94	9.45e-05	0.00743	-0.19	-0.18	Dental caries;	chr6:116205754	chr6:116254207~116256743:+
THCA	cis	rs1383484	0.761	rs10906981	ENSG00000225151.9	GOLGA2P7	3.94	9.45e-05	0.00743	0.25	0.18	Height;	chr15:83853807	chr15:84199311~84230136:-
THCA	cis	rs7824557	0.527	rs2572449	ENSG00000261451.1	RP11-981G7.1	3.94	9.45e-05	0.00743	0.22	0.18	Retinal vascular caliber;	chr8:11381628	chr8:10433672~10438312:+
THCA	cis	rs9425766	0.962	rs9425430	ENSG00000270084.1	GAS5-AS1	-3.94	9.45e-05	0.00743	-0.18	-0.18	Life satisfaction;	chr1:173888145	chr1:173863248~173863941:+
THCA	cis	rs11673344	0.704	rs571340	ENSG00000267260.1	CTD-2162K18.4	-3.94	9.45e-05	0.00743	-0.22	-0.18	Obesity-related traits;	chr19:36933981	chr19:36773153~36777078:+
THCA	cis	rs16975963	0.843	rs17249047	ENSG00000226686.6	LINC01535	-3.94	9.45e-05	0.00744	-0.24	-0.18	Longevity;	chr19:37845923	chr19:37251912~37265535:+
THCA	cis	rs728616	0.681	rs12413174	ENSG00000278616.1	BEND3P3	3.94	9.45e-05	0.00744	0.19	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80302648	chr10:79682997~79685436:+
THCA	cis	rs7312933	0.645	rs12049942	ENSG00000257225.1	RP11-328C8.4	-3.94	9.45e-05	0.00744	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42193250	chr12:42459366~42466128:+
THCA	cis	rs1842579	0.767	rs12136023	ENSG00000272691.1	RP11-290M5.4	-3.94	9.46e-05	0.00744	-0.18	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85874579	chr1:85578500~85578742:-
THCA	cis	rs7430456	0.874	rs7428501	ENSG00000231574.4	RP11-91K9.1	-3.94	9.46e-05	0.00744	-0.24	-0.18	Breast cancer;	chr3:177751974	chr3:177816865~177899224:+
THCA	cis	rs12807809	0.588	rs3830078	ENSG00000245498.5	RP11-677M14.7	3.94	9.46e-05	0.00744	0.24	0.18	Schizophrenia;	chr11:124737639	chr11:124800450~124834487:+
THCA	cis	rs1383484	0.798	rs28544951	ENSG00000225151.9	GOLGA2P7	3.94	9.46e-05	0.00744	0.25	0.18	Height;	chr15:83850088	chr15:84199311~84230136:-
THCA	cis	rs9329221	0.617	rs615632	ENSG00000248538.5	RP11-10A14.5	3.94	9.46e-05	0.00744	0.23	0.18	Neuroticism;	chr8:9938811	chr8:9189011~9202854:+
THCA	cis	rs7312933	0.67	rs2406568	ENSG00000257225.1	RP11-328C8.4	-3.94	9.46e-05	0.00744	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42158495	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.703	rs1059360	ENSG00000257225.1	RP11-328C8.4	-3.94	9.46e-05	0.00744	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42160703	chr12:42459366~42466128:+
THCA	cis	rs7200543	1	rs6498540	ENSG00000188599.16	NPIPP1	-3.94	9.46e-05	0.00744	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:15104312~15123498:-
THCA	cis	rs73076966	0.891	rs7271240	ENSG00000274269.1	RP4-545L17.12	3.94	9.46e-05	0.00744	0.28	0.18	Plateletcrit;	chr20:1536260	chr20:1186092~1207036:+
THCA	cis	rs1023500	0.505	rs2143139	ENSG00000273366.1	CTA-989H11.1	-3.94	9.46e-05	0.00744	-0.22	-0.18	Schizophrenia;	chr22:42218395	chr22:42278188~42278846:+
THCA	cis	rs3096299	0.692	rs4785565	ENSG00000261118.1	RP11-104N10.1	3.94	9.46e-05	0.00744	0.15	0.18	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89492017~89504460:-
THCA	cis	rs4664304	0.62	rs11895141	ENSG00000226266.5	AC009961.3	-3.94	9.46e-05	0.00744	-0.21	-0.18	Crohn's disease;Inflammatory bowel disease;	chr2:159859938	chr2:159670708~159712435:-
THCA	cis	rs2221894	0.922	rs9792190	ENSG00000251191.6	LINC00589	-3.94	9.46e-05	0.00744	-0.21	-0.18	Obesity-related traits;	chr8:28970874	chr8:29673922~29748109:-
THCA	cis	rs11992162	0.967	rs10108320	ENSG00000270154.1	RP11-419I17.1	-3.94	9.46e-05	0.00744	-0.22	-0.18	Monocyte count;	chr8:11974754	chr8:12476462~12477122:+
THCA	cis	rs6939532	0.761	rs3799378	ENSG00000124549.13	BTN2A3P	3.94	9.46e-05	0.00744	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:26404146	chr6:26421391~26432383:+
THCA	cis	rs151234	0.676	rs231970	ENSG00000259982.1	CDC37P1	-3.94	9.47e-05	0.00745	-0.36	-0.18	Platelet distribution width;	chr16:28555683	chr16:28700294~28701540:-
THCA	cis	rs2337406	0.714	rs7150993	ENSG00000211974.3	IGHV2-70	-3.94	9.47e-05	0.00745	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106818515	chr14:106723574~106724093:-
THCA	cis	rs4578769	0.879	rs7235234	ENSG00000265939.1	UBE2CP2	3.94	9.47e-05	0.00745	0.22	0.18	Eosinophil percentage of white cells;	chr18:22864239	chr18:22900486~22900995:-
THCA	cis	rs6586163	1	rs3824729	ENSG00000261438.1	RP11-399O19.9	3.94	9.47e-05	0.00745	0.14	0.18	Chronic lymphocytic leukemia;	chr10:88992859	chr10:89015836~89017059:+
THCA	cis	rs6586163	0.967	rs10887877	ENSG00000261438.1	RP11-399O19.9	3.94	9.47e-05	0.00745	0.14	0.18	Chronic lymphocytic leukemia;	chr10:88993281	chr10:89015836~89017059:+
THCA	cis	rs7551222	0.681	rs2045623	ENSG00000240219.1	RP11-430C7.5	3.94	9.47e-05	0.00745	0.17	0.18	Schizophrenia;	chr1:204528285	chr1:204626775~204629712:+
THCA	cis	rs394563	0.559	rs7752555	ENSG00000231760.4	RP11-350J20.5	-3.94	9.47e-05	0.00745	-0.22	-0.18	Dupuytren's disease;	chr6:149349980	chr6:149796151~149826294:-
THCA	cis	rs9307551	0.817	rs12500146	ENSG00000249646.2	OR7E94P	-3.94	9.47e-05	0.00745	-0.22	-0.18	Refractive error;	chr4:79580002	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.817	rs1031004	ENSG00000249646.2	OR7E94P	-3.94	9.47e-05	0.00745	-0.23	-0.18	Refractive error;	chr4:79595695	chr4:79587302~79588130:-
THCA	cis	rs1580019	0.844	rs1584615	ENSG00000231952.3	DPY19L1P2	-3.94	9.47e-05	0.00745	-0.23	-0.18	Cognitive ability;	chr7:32463646	chr7:32812757~32838570:+
THCA	cis	rs11710088	0.931	rs34659397	ENSG00000244503.1	RP11-278L15.6	3.94	9.47e-05	0.00745	0.23	0.18	QRS duration;	chr3:149482575	chr3:149494660~149495995:+
THCA	cis	rs9291683	0.597	rs11723016	ENSG00000261490.1	RP11-448G15.3	-3.94	9.47e-05	0.00745	-0.11	-0.18	Bone mineral density;	chr4:10124565	chr4:10068089~10073019:-
THCA	cis	rs860295	0.665	rs11264393	ENSG00000236675.1	MTX1P1	-3.94	9.47e-05	0.00745	-0.18	-0.18	Body mass index;	chr1:155604680	chr1:155230975~155234325:+
THCA	cis	rs11633886	0.585	rs1949575	ENSG00000259200.1	RP11-718O11.1	3.94	9.47e-05	0.00745	0.22	0.18	Diisocyanate-induced asthma;	chr15:45784002	chr15:45705078~45931069:+
THCA	cis	rs875971	0.545	rs4718348	ENSG00000232559.3	GS1-124K5.12	3.94	9.47e-05	0.00745	0.2	0.18	Aortic root size;	chr7:66441589	chr7:66554588~66576923:-
THCA	cis	rs7112925	0.738	rs11227673	ENSG00000255517.5	CTD-3074O7.5	3.94	9.47e-05	0.00745	0.13	0.18	Height;	chr11:67065057	chr11:66473490~66480233:-
THCA	cis	rs4245128	0.862	rs10891470	ENSG00000247416.2	RP11-629G13.1	3.94	9.47e-05	0.00745	0.17	0.18	Life satisfaction;	chr11:112915724	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.862	rs10891471	ENSG00000247416.2	RP11-629G13.1	3.94	9.47e-05	0.00745	0.17	0.18	Life satisfaction;	chr11:112915726	chr11:112959279~112963460:-
THCA	cis	rs2980439	0.557	rs2976876	ENSG00000253981.4	ALG1L13P	3.94	9.47e-05	0.00745	0.17	0.18	Neuroticism;	chr8:8461340	chr8:8236003~8244667:-
THCA	cis	rs6121246	0.954	rs6060989	ENSG00000230613.1	HM13-AS1	3.94	9.48e-05	0.00745	0.19	0.18	Mean corpuscular hemoglobin;	chr20:31841960	chr20:31567707~31573263:-
THCA	cis	rs988712	0.607	rs11030084	ENSG00000245573.6	BDNF-AS	-3.94	9.48e-05	0.00745	-0.19	-0.18	Obesity;	chr11:27622178	chr11:27506838~27698174:+
THCA	cis	rs58950470	0.521	rs7950197	ENSG00000255557.1	RP11-770G2.2	3.94	9.48e-05	0.00745	0.2	0.18	Schizophrenia;	chr11:65678655	chr11:65745729~65771585:+
THCA	cis	rs6142618	0.84	rs6119834	ENSG00000224452.1	RSL24D1P6	-3.94	9.48e-05	0.00745	-0.22	-0.18	Inflammatory bowel disease;	chr20:32348944	chr20:32170390~32170790:-
THCA	cis	rs11710088	0.895	rs4482615	ENSG00000244503.1	RP11-278L15.6	3.94	9.48e-05	0.00745	0.23	0.18	QRS duration;	chr3:149480894	chr3:149494660~149495995:+
THCA	cis	rs7781557	0.64	rs73714541	ENSG00000170629.13	DPY19L2P2	-3.94	9.48e-05	0.00745	-0.23	-0.18	Colorectal adenoma (advanced);	chr7:102982217	chr7:103175133~103280410:-
THCA	cis	rs7824557	0.505	rs2572440	ENSG00000261451.1	RP11-981G7.1	3.94	9.48e-05	0.00745	0.22	0.18	Retinal vascular caliber;	chr8:11391501	chr8:10433672~10438312:+
THCA	cis	rs150992	0.64	rs326485	ENSG00000246763.5	RGMB-AS1	3.94	9.48e-05	0.00746	0.19	0.18	Body mass index;	chr5:98845717	chr5:98769618~98773469:-
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000280069.1	CTD-2349P21.3	-3.94	9.48e-05	0.00746	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30738182~30740275:+
THCA	cis	rs3177980	1	rs1131498	ENSG00000239494.2	RN7SL333P	-3.94	9.48e-05	0.00746	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:169707345	chr1:169859756~169860052:+
THCA	cis	rs36093844	0.626	rs11234517	ENSG00000279742.1	RP11-700A24.1	3.94	9.48e-05	0.00746	0.24	0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86020533	chr11:85852557~85854943:-
THCA	cis	rs35740288	0.694	rs17618909	ENSG00000259295.5	CSPG4P12	3.94	9.48e-05	0.00746	0.28	0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85552231	chr15:85191438~85213905:+
THCA	cis	rs7737355	0.947	rs32113	ENSG00000237714.1	P4HA2-AS1	-3.94	9.48e-05	0.00746	-0.25	-0.18	Life satisfaction;	chr5:131713892	chr5:132184876~132192808:+
THCA	cis	rs10155981	1	rs10155987	ENSG00000179428.2	AC073072.5	-3.94	9.49e-05	0.00746	-0.29	-0.18	Bilirubin levels;	chr7:22716917	chr7:22725395~22727620:-
THCA	cis	rs72627123	1	rs72627117	ENSG00000259065.1	RP5-1021I20.1	-3.94	9.49e-05	0.00746	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73888530	chr14:73787360~73803270:+
THCA	cis	rs7112925	0.738	rs12803688	ENSG00000255517.5	CTD-3074O7.5	3.94	9.49e-05	0.00746	0.13	0.18	Height;	chr11:67065794	chr11:66473490~66480233:-
THCA	cis	rs9330264	0.508	rs7364869	ENSG00000225855.5	RUSC1-AS1	3.94	9.49e-05	0.00746	0.12	0.18	1,5-anhydroglucitol levels;	chr1:155114712	chr1:155316863~155324176:-
THCA	cis	rs8062405	1	rs2008514	ENSG00000270424.1	RP11-1348G14.6	-3.94	9.49e-05	0.00746	-0.21	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28749959~28750595:-
THCA	cis	rs3845817	0.703	rs702904	ENSG00000237979.1	AC007389.1	3.94	9.49e-05	0.00746	0.2	0.18	Bipolar disorder;	chr2:65538960	chr2:65500993~65502138:-
THCA	cis	rs6696239	0.911	rs12129213	ENSG00000227711.2	RP11-275O4.5	-3.94	9.49e-05	0.00746	-0.24	-0.18	Height;	chr1:227698506	chr1:227509028~227520477:-
THCA	cis	rs7824557	0.545	rs34482136	ENSG00000255495.1	AC145124.2	-3.94	9.49e-05	0.00746	-0.21	-0.18	Retinal vascular caliber;	chr8:11370376	chr8:12194467~12196280:+
THCA	cis	rs453301	0.506	rs476845	ENSG00000233609.3	RP11-62H7.2	-3.94	9.49e-05	0.00746	-0.17	-0.18	Joint mobility (Beighton score);	chr8:8765367	chr8:8961200~8979025:+
THCA	cis	rs4713118	0.505	rs276371	ENSG00000176933.5	TOB2P1	-3.94	9.49e-05	0.00746	-0.2	-0.18	Parkinson's disease;	chr6:27942930	chr6:28217643~28218634:-
THCA	cis	rs13113518	0.51	rs10049561	ENSG00000273257.1	RP11-177J6.1	3.94	9.49e-05	0.00746	0.24	0.18	Height;	chr4:55426623	chr4:55387949~55388271:+
THCA	cis	rs7166081	1	rs35151633	ENSG00000270964.1	RP11-502I4.3	-3.94	9.5e-05	0.00747	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67275927	chr15:67541072~67542604:-
THCA	cis	rs10489167	1	rs823676	ENSG00000237899.1	RP4-739H11.3	3.94	9.5e-05	0.00747	0.32	0.18	Depressive and manic episodes in bipolar disorder;	chr1:40773456	chr1:40669089~40687588:-
THCA	cis	rs13256369	0.708	rs9644772	ENSG00000254153.1	CTA-398F10.2	-3.94	9.5e-05	0.00747	-0.21	-0.18	Obesity-related traits;	chr8:8700175	chr8:8456909~8461337:-
THCA	cis	rs10256972	0.521	rs7811577	ENSG00000225146.1	AC073957.15	3.94	9.5e-05	0.00747	0.19	0.18	Endometriosis;Longevity;	chr7:1063193	chr7:1029025~1043891:+
THCA	cis	rs2562456	0.958	rs2562508	ENSG00000268278.1	RP11-420K14.1	-3.94	9.5e-05	0.00747	-0.21	-0.18	Pain;	chr19:21543479	chr19:21637974~21656300:+
THCA	cis	rs2821260	0.703	rs2821239	ENSG00000227207.2	RPL31P12	3.94	9.5e-05	0.00747	0.2	0.18	Intelligence (multi-trait analysis);	chr1:72124510	chr1:72301472~72301829:+
THCA	cis	rs2821260	0.703	rs2630406	ENSG00000227207.2	RPL31P12	3.94	9.5e-05	0.00747	0.2	0.18	Intelligence (multi-trait analysis);	chr1:72125182	chr1:72301472~72301829:+
THCA	cis	rs957448	0.561	rs71532325	ENSG00000253175.1	RP11-267M23.6	3.94	9.5e-05	0.00747	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94565036~94565715:+
THCA	cis	rs9329221	0.618	rs4314693	ENSG00000261451.1	RP11-981G7.1	-3.94	9.5e-05	0.00747	-0.22	-0.18	Neuroticism;	chr8:10401422	chr8:10433672~10438312:+
THCA	cis	rs875971	0.545	rs6460276	ENSG00000232559.3	GS1-124K5.12	3.94	9.5e-05	0.00747	0.19	0.18	Aortic root size;	chr7:66182290	chr7:66554588~66576923:-
THCA	cis	rs13113518	0.513	rs13132085	ENSG00000272969.1	RP11-528I4.2	-3.94	9.5e-05	0.00747	-0.21	-0.18	Height;	chr4:55593918	chr4:55547112~55547889:+
THCA	cis	rs7829975	0.774	rs13259216	ENSG00000233609.3	RP11-62H7.2	3.94	9.5e-05	0.00747	0.17	0.18	Mood instability;	chr8:8816091	chr8:8961200~8979025:+
THCA	cis	rs7760535	0.656	rs1883136	ENSG00000255389.1	C6orf3	-3.94	9.5e-05	0.00747	-0.17	-0.18	Metabolic traits;	chr6:111585820	chr6:111599875~111602295:+
THCA	cis	rs12544026	0.549	rs494352	ENSG00000253669.3	KB-1732A1.1	-3.94	9.5e-05	0.00747	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101865115	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.581	rs577756	ENSG00000253669.3	KB-1732A1.1	-3.94	9.5e-05	0.00747	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101866234	chr8:102805517~102809971:+
THCA	cis	rs4788570	0.615	rs2032918	ENSG00000260593.1	RP11-432I5.2	-3.94	9.51e-05	0.00747	-0.28	-0.18	Intelligence (multi-trait analysis);	chr16:71669533	chr16:71623708~71626816:-
THCA	cis	rs4788570	0.584	rs11075898	ENSG00000260593.1	RP11-432I5.2	-3.94	9.51e-05	0.00747	-0.28	-0.18	Intelligence (multi-trait analysis);	chr16:71671312	chr16:71623708~71626816:-
THCA	cis	rs875971	0.545	rs73378304	ENSG00000273024.4	INTS4P2	-3.94	9.51e-05	0.00747	-0.22	-0.18	Aortic root size;	chr7:66175760	chr7:65647864~65715661:+
THCA	cis	rs73173548	0.502	rs10505857	ENSG00000247828.6	TMEM161B-AS1	3.94	9.51e-05	0.00748	0.16	0.18	Macular telangiectasia type 2;	chr5:88420376	chr5:88268895~88436685:+
THCA	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	3.94	9.51e-05	0.00748	0.21	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
THCA	cis	rs11671005	0.737	rs11673101	ENSG00000252334.1	RNU6-1337P	3.94	9.51e-05	0.00748	0.28	0.18	Mean platelet volume;	chr19:58483686	chr19:58483749~58483843:-
THCA	cis	rs7829975	0.871	rs7829826	ENSG00000233609.3	RP11-62H7.2	-3.94	9.51e-05	0.00748	-0.17	-0.18	Mood instability;	chr8:8720610	chr8:8961200~8979025:+
THCA	cis	rs7178424	0.742	rs12916268	ENSG00000259251.2	RP11-643M14.1	-3.94	9.51e-05	0.00748	-0.18	-0.18	Height;	chr15:61883443	chr15:62060503~62062434:+
THCA	cis	rs7824557	0.737	rs10481445	ENSG00000255495.1	AC145124.2	-3.94	9.51e-05	0.00748	-0.2	-0.18	Retinal vascular caliber;	chr8:11251760	chr8:12194467~12196280:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000229180.5	GS1-124K5.11	3.94	9.51e-05	0.00748	0.12	0.18	Calcium levels;	chr7:65996954	chr7:66526088~66542624:-
THCA	cis	rs2562456	0.561	rs12610883	ENSG00000268278.1	RP11-420K14.1	3.94	9.52e-05	0.00748	0.21	0.18	Pain;	chr19:21567257	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs7259708	ENSG00000268278.1	RP11-420K14.1	3.94	9.52e-05	0.00748	0.21	0.18	Pain;	chr19:21567846	chr19:21637974~21656300:+
THCA	cis	rs1122401	0.576	rs2247901	ENSG00000280159.1	CTD-2591A1.1	3.94	9.52e-05	0.00748	0.2	0.18	Smoking initiation;	chr5:54569777	chr5:54643557~54645987:+
THCA	cis	rs1122401	0.576	rs2098714	ENSG00000280159.1	CTD-2591A1.1	3.94	9.52e-05	0.00748	0.2	0.18	Smoking initiation;	chr5:54570291	chr5:54643557~54645987:+
THCA	cis	rs9796	0.621	rs2899013	ENSG00000247556.5	OIP5-AS1	3.94	9.52e-05	0.00748	0.14	0.18	Menopause (age at onset);	chr15:41200085	chr15:41283990~41309737:+
THCA	cis	rs879500	0.961	rs8094944	ENSG00000227279.1	AC015933.2	3.94	9.52e-05	0.00748	0.2	0.18	Lung function (FVC);	chr18:28533879	chr18:27954519~27963687:+
THCA	cis	rs879500	0.961	rs72892341	ENSG00000227279.1	AC015933.2	3.94	9.52e-05	0.00748	0.2	0.18	Lung function (FVC);	chr18:28534285	chr18:27954519~27963687:+
THCA	cis	rs10266483	0.739	rs679966	ENSG00000234338.1	RP11-797H7.1	3.94	9.52e-05	0.00748	0.13	0.18	Response to statin therapy;	chr7:64306688	chr7:64835280~64836882:-
THCA	cis	rs2239547	0.657	rs3755803	ENSG00000243224.1	RP5-1157M23.2	-3.94	9.52e-05	0.00748	-0.21	-0.18	Schizophrenia;	chr3:52832141	chr3:52239258~52241097:+
THCA	cis	rs13098911	0.54	rs71327021	ENSG00000226074.4	PRSS44	-3.94	9.52e-05	0.00748	-0.34	-0.18	Celiac disease;	chr3:46079025	chr3:46809359~46812558:-
THCA	cis	rs13325613	0.517	rs13091868	ENSG00000226074.4	PRSS44	-3.94	9.52e-05	0.00748	-0.34	-0.18	Monocyte count;	chr3:46081551	chr3:46809359~46812558:-
THCA	cis	rs13325613	0.585	rs13092030	ENSG00000226074.4	PRSS44	-3.94	9.52e-05	0.00748	-0.34	-0.18	Monocyte count;	chr3:46081563	chr3:46809359~46812558:-
THCA	cis	rs4742903	0.904	rs1605448	ENSG00000270332.1	SMC2-AS1	3.94	9.52e-05	0.00748	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104214124	chr9:104080024~104093073:-
THCA	cis	rs853679	0.527	rs853683	ENSG00000176933.5	TOB2P1	-3.94	9.52e-05	0.00748	-0.2	-0.18	Depression;	chr6:28327262	chr6:28217643~28218634:-
THCA	cis	rs6921919	0.945	rs7765989	ENSG00000280107.1	AL022393.9	-3.94	9.52e-05	0.00748	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28170845~28172521:+
THCA	cis	rs17695224	0.611	rs10420568	ENSG00000275055.1	CTC-471J1.11	-3.94	9.52e-05	0.00748	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51835662	chr19:52049007~52049754:+
THCA	cis	rs9650657	0.812	rs6993841	ENSG00000255310.2	AF131215.2	-3.94	9.52e-05	0.00748	-0.15	-0.18	Neuroticism;	chr8:10775174	chr8:11107788~11109726:-
THCA	cis	rs1560104	0.709	rs2903042	ENSG00000259876.1	CTD-3037G24.4	3.94	9.52e-05	0.00748	0.21	0.18	Obesity-related traits;	chr16:12604249	chr16:12556353~12557694:-
THCA	cis	rs3845817	0.703	rs702919	ENSG00000237979.1	AC007389.1	3.94	9.52e-05	0.00748	0.2	0.18	Bipolar disorder;	chr2:65545157	chr2:65500993~65502138:-
THCA	cis	rs9810089	0.903	rs7427564	ENSG00000273455.1	RP11-305O4.3	3.94	9.52e-05	0.00749	0.24	0.18	Gestational age at birth (child effect);	chr3:136555593	chr3:136087475~136087913:-
THCA	cis	rs513088	0.718	rs562914	ENSG00000225171.2	DUTP6	3.94	9.52e-05	0.00749	0.27	0.18	Schizophrenia;	chr1:166702692	chr1:166868748~166869209:+
THCA	cis	rs1501911	0.53	rs162473	ENSG00000241597.2	CTD-2007H13.1	3.94	9.53e-05	0.00749	0.23	0.18	Lung function (FEV1/FVC);	chr5:98805276	chr5:98954394~98954972:+
THCA	cis	rs2562456	0.833	rs1626404	ENSG00000268278.1	RP11-420K14.1	3.94	9.53e-05	0.00749	0.25	0.18	Pain;	chr19:21300986	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs1781867	ENSG00000268278.1	RP11-420K14.1	3.94	9.53e-05	0.00749	0.25	0.18	Pain;	chr19:21304368	chr19:21637974~21656300:+
THCA	cis	rs11951515	0.508	rs6860493	ENSG00000248240.1	RP11-159F24.5	-3.94	9.53e-05	0.00749	-0.19	-0.18	Metabolite levels  (X-11787);	chr5:43602611	chr5:43515274~43525310:+
THCA	cis	rs8083427	0.867	rs2298593	ENSG00000275805.1	RP11-349H17.2	3.94	9.53e-05	0.00749	0.39	0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr18:26543103	chr18:26565723~26575626:-
THCA	cis	rs6939532	0.522	rs4712980	ENSG00000124549.13	BTN2A3P	3.94	9.53e-05	0.00749	0.19	0.18	Autism spectrum disorder or schizophrenia;	chr6:26355530	chr6:26421391~26432383:+
THCA	cis	rs4788570	0.615	rs7195059	ENSG00000260185.1	RP11-432I5.6	-3.94	9.53e-05	0.00749	-0.33	-0.18	Intelligence (multi-trait analysis);	chr16:71684463	chr16:71655027~71664212:+
THCA	cis	rs6724465	0.636	rs61574393	ENSG00000272644.1	RP11-33O4.1	3.94	9.53e-05	0.00749	0.26	0.18	Height;	chr2:219129545	chr2:219069354~219069809:-
THCA	cis	rs10186029	0.509	rs62187850	ENSG00000270659.1	RP11-105N14.1	3.94	9.53e-05	0.00749	0.15	0.18	Systemic sclerosis;	chr2:213072878	chr2:213152970~213153659:+
THCA	cis	rs4906332	0.782	rs12891288	ENSG00000269940.1	RP11-73M18.7	3.94	9.53e-05	0.00749	0.19	0.18	Coronary artery disease;	chr14:103533413	chr14:103694560~103695170:+
THCA	cis	rs4906332	0.811	rs2756138	ENSG00000244691.1	RPL10AP1	3.94	9.53e-05	0.00749	0.25	0.18	Coronary artery disease;	chr14:103530396	chr14:103412119~103412761:-
THCA	cis	rs8083427	0.867	rs2298594	ENSG00000275805.1	RP11-349H17.2	3.94	9.53e-05	0.00749	0.39	0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr18:26543503	chr18:26565723~26575626:-
THCA	cis	rs4915077	0.773	rs55711603	ENSG00000230489.1	VAV3-AS1	3.94	9.53e-05	0.00749	0.29	0.18	Hypothyroidism;	chr1:107731595	chr1:107964443~107994607:+
THCA	cis	rs5758511	0.596	rs55644935	ENSG00000270083.1	RP1-257I20.14	-3.94	9.54e-05	0.00749	-0.23	-0.18	Birth weight;	chr22:42270063	chr22:42089630~42090028:-
THCA	cis	rs853679	1	rs9986596	ENSG00000273712.1	RP5-874C20.7	3.94	9.54e-05	0.00749	0.29	0.18	Depression;	chr6:28251883	chr6:28315613~28315883:-
THCA	cis	rs7674212	0.57	rs2711899	ENSG00000230069.3	LRRC37A15P	-3.94	9.54e-05	0.00749	-0.18	-0.18	Type 2 diabetes;	chr4:103141257	chr4:102727274~102730721:-
THCA	cis	rs925255	0.678	rs6547853	ENSG00000270210.1	RP11-373D23.3	3.94	9.54e-05	0.00749	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr2:28423934	chr2:28425945~28426719:+
THCA	cis	rs4705962	0.878	rs11242127	ENSG00000230612.2	AC004237.1	-3.94	9.54e-05	0.00749	-0.22	-0.18	Atopic dermatitis;	chr5:132719812	chr5:132688681~132723725:+
THCA	cis	rs853679	1	rs2799077	ENSG00000273712.1	RP5-874C20.7	3.94	9.54e-05	0.00749	0.28	0.18	Depression;	chr6:28266819	chr6:28315613~28315883:-
THCA	cis	rs2933343	0.649	rs789216	ENSG00000231305.3	RP11-723O4.2	3.94	9.54e-05	0.0075	0.19	0.18	IgG glycosylation;	chr3:128875660	chr3:128861313~128871540:-
THCA	cis	rs420259	0.516	rs10153059	ENSG00000260136.4	CTD-2270L9.4	-3.94	9.54e-05	0.0075	-0.14	-0.18	Bipolar disorder;	chr16:23501062	chr16:23452758~23457606:+
THCA	cis	rs7804306	0.522	rs2882015	ENSG00000233264.2	AC006042.8	3.94	9.54e-05	0.0075	0.24	0.18	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8029247	chr7:7980312~7982228:+
THCA	cis	rs4792901	0.802	rs28532791	ENSG00000279602.1	CTD-3014M21.1	-3.94	9.54e-05	0.0075	-0.23	-0.18	Dupuytren's disease;	chr17:43512111	chr17:43360041~43361361:-
THCA	cis	rs7798970	0.606	rs4466326	ENSG00000225498.1	AC002064.5	-3.94	9.54e-05	0.0075	-0.19	-0.18	Inflammatory skin disease;	chr7:90015759	chr7:90312496~90322592:+
THCA	cis	rs17122278	1	rs17122278	ENSG00000255239.1	AP002954.6	3.94	9.54e-05	0.0075	0.32	0.18	Total cholesterol levels;	chr11:118578655	chr11:118688039~118690600:-
THCA	cis	rs853679	0.556	rs45509595	ENSG00000272009.1	RP1-313I6.12	-3.94	9.54e-05	0.0075	-0.35	-0.18	Depression;	chr6:27873148	chr6:28078792~28081130:-
THCA	cis	rs11089937	0.616	rs7286793	ENSG00000211639.2	IGLV4-60	3.94	9.55e-05	0.0075	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22162199~22162681:+
THCA	cis	rs1023500	0.505	rs134874	ENSG00000273366.1	CTA-989H11.1	-3.94	9.55e-05	0.0075	-0.22	-0.18	Schizophrenia;	chr22:42265138	chr22:42278188~42278846:+
THCA	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	3.94	9.55e-05	0.0075	0.16	0.18	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	3.94	9.55e-05	0.0075	0.16	0.18	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	3.94	9.55e-05	0.0075	0.16	0.18	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	3.94	9.55e-05	0.0075	0.16	0.18	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	3.94	9.55e-05	0.0075	0.16	0.18	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	3.94	9.55e-05	0.0075	0.16	0.18	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
THCA	cis	rs10090774	0.71	rs11780289	ENSG00000279766.1	RP11-642A1.2	-3.94	9.55e-05	0.0075	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140679315	chr8:140572142~140572812:-
THCA	cis	rs7849973	0.7	rs7865016	ENSG00000234840.1	LINC01239	-3.94	9.55e-05	0.0075	-0.21	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22819408	chr9:22646200~22824213:+
THCA	cis	rs6504108	0.624	rs2278868	ENSG00000264920.1	RP11-6N17.4	-3.94	9.55e-05	0.0075	-0.15	-0.18	Body mass index;	chr17:48184809	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs11079814	ENSG00000264920.1	RP11-6N17.4	-3.94	9.55e-05	0.0075	-0.15	-0.18	Body mass index;	chr17:48191077	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.602	rs11872095	ENSG00000264920.1	RP11-6N17.4	-3.94	9.55e-05	0.0075	-0.15	-0.18	Body mass index;	chr17:48193810	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs12452956	ENSG00000264920.1	RP11-6N17.4	-3.94	9.55e-05	0.0075	-0.15	-0.18	Body mass index;	chr17:48196575	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs8075270	ENSG00000264920.1	RP11-6N17.4	-3.94	9.55e-05	0.0075	-0.15	-0.18	Body mass index;	chr17:48197648	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs8072282	ENSG00000264920.1	RP11-6N17.4	-3.94	9.55e-05	0.0075	-0.15	-0.18	Body mass index;	chr17:48199496	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs8069064	ENSG00000264920.1	RP11-6N17.4	-3.94	9.55e-05	0.0075	-0.15	-0.18	Body mass index;	chr17:48203301	chr17:47891255~47895812:-
THCA	cis	rs365302	1	rs433308	ENSG00000235086.1	FNDC1-IT1	-3.94	9.55e-05	0.0075	-0.25	-0.18	Coronary heart disease;	chr6:159198834	chr6:159240786~159243329:+
THCA	cis	rs944289	0.562	rs12431566	ENSG00000258844.1	RP11-259K15.2	-3.94	9.55e-05	0.0075	-0.16	-0.18	Thyroid cancer;	chr14:36051211	chr14:36214607~36235608:+
THCA	cis	rs12142240	0.698	rs61519400	ENSG00000232022.5	FAAHP1	-3.94	9.55e-05	0.0075	-0.2	-0.18	Menopause (age at onset);	chr1:46389626	chr1:46432129~46445521:+
THCA	cis	rs11601239	0.646	rs10791773	ENSG00000254750.1	CASP1P2	-3.94	9.55e-05	0.00751	-0.14	-0.18	Refractive error;	chr11:105760552	chr11:105063345~105071541:-
THCA	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-3.94	9.55e-05	0.00751	-0.19	-0.18	Asthma;	chr2:102377873	chr2:102438713~102440475:+
THCA	cis	rs4268898	0.722	rs11691212	ENSG00000242628.4	AC009228.1	-3.94	9.55e-05	0.00751	-0.22	-0.18	Asthma;	chr2:24181864	chr2:24214381~24221516:+
THCA	cis	rs13434995	0.513	rs62310862	ENSG00000249700.7	SRD5A3-AS1	-3.94	9.55e-05	0.00751	-0.25	-0.18	Adiponectin levels;	chr4:55572594	chr4:55363971~55395847:-
THCA	cis	rs11673344	0.555	rs502546	ENSG00000268499.1	CTB-102L5.8	3.94	9.55e-05	0.00751	0.19	0.18	Obesity-related traits;	chr19:37361788	chr19:38199836~38200934:+
THCA	cis	rs1005277	0.505	rs7917943	ENSG00000275858.1	RP11-291L22.8	-3.94	9.55e-05	0.00751	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38450738~38451069:-
THCA	cis	rs881375	0.669	rs73541868	ENSG00000270917.1	RP11-27I1.6	-3.94	9.55e-05	0.00751	-0.24	-0.18	Rheumatoid arthritis;	chr9:120876986	chr9:120812475~120812845:-
THCA	cis	rs4218	0.681	rs58335303	ENSG00000277144.1	RP11-59H7.4	-3.94	9.55e-05	0.00751	-0.25	-0.18	Social communication problems;	chr15:59073206	chr15:59115547~59116089:-
THCA	cis	rs4792901	0.802	rs9901586	ENSG00000267151.3	RP11-100E5.2	3.94	9.56e-05	0.00751	0.2	0.18	Dupuytren's disease;	chr17:43503523	chr17:43444707~43451200:+
THCA	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	3.94	9.56e-05	0.00751	0.16	0.18	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
THCA	cis	rs10421328	0.784	rs28635562	ENSG00000271283.1	CTC-412M14.6	3.94	9.56e-05	0.00751	0.24	0.18	Parental longevity (combined parental age at death);	chr19:19658881	chr19:19699203~19699409:-
THCA	cis	rs8020441	0.945	rs61410944	ENSG00000269906.1	RP11-248J18.2	3.94	9.56e-05	0.00751	0.26	0.18	Cognitive performance;	chr14:50700018	chr14:50662511~50663178:-
THCA	cis	rs3892630	1	rs3892630	ENSG00000267475.1	CTD-2538C1.2	3.94	9.56e-05	0.00751	0.26	0.18	Red blood cell traits;	chr19:32690578	chr19:32687089~32691750:-
THCA	cis	rs9435732	0.832	rs2076602	ENSG00000268869.4	ESPNP	3.94	9.56e-05	0.00751	0.21	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16996703	chr1:16687339~16720157:-
THCA	cis	rs3177980	0.749	rs4987358	ENSG00000239494.2	RN7SL333P	3.94	9.56e-05	0.00751	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:169696410	chr1:169859756~169860052:+
THCA	cis	rs17092148	0.895	rs4417778	ENSG00000276073.1	RP5-1125A11.7	-3.94	9.56e-05	0.00751	-0.21	-0.18	Neuroticism;	chr20:34763184	chr20:33985617~33988989:-
THCA	cis	rs2836974	0.899	rs2836957	ENSG00000255568.3	BRWD1-AS2	3.94	9.56e-05	0.00751	0.16	0.18	Cognitive function;	chr21:39251208	chr21:39313935~39314962:+
THCA	cis	rs758324	0.606	rs247276	ENSG00000224431.1	AC063976.7	-3.94	9.56e-05	0.00751	-0.17	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132133311	chr5:132199456~132203487:+
THCA	cis	rs9393813	0.967	rs764284	ENSG00000204789.4	ZNF204P	3.94	9.56e-05	0.00751	0.14	0.18	Bipolar disorder;	chr6:27344299	chr6:27357825~27360221:-
THCA	cis	rs2236521	0.617	rs113604626	ENSG00000226332.2	RP11-157P1.4	3.94	9.57e-05	0.00751	0.16	0.18	Pelvic organ prolapse;	chr20:62318450	chr20:62305432~62306325:-
THCA	cis	rs875971	0.619	rs12533585	ENSG00000229180.5	GS1-124K5.11	3.94	9.57e-05	0.00752	0.12	0.18	Aortic root size;	chr7:66519618	chr7:66526088~66542624:-
THCA	cis	rs6782029	0.55	rs17778035	ENSG00000225026.1	AC091492.2	-3.94	9.57e-05	0.00752	-0.3	-0.18	Anorexia nervosa;	chr3:11636221	chr3:12328003~12328274:+
THCA	cis	rs853679	0.76	rs9393910	ENSG00000273712.1	RP5-874C20.7	3.94	9.57e-05	0.00752	0.25	0.18	Depression;	chr6:28240414	chr6:28315613~28315883:-
THCA	cis	rs853679	0.76	rs9368563	ENSG00000273712.1	RP5-874C20.7	3.94	9.57e-05	0.00752	0.25	0.18	Depression;	chr6:28240780	chr6:28315613~28315883:-
THCA	cis	rs853679	0.76	rs9295768	ENSG00000273712.1	RP5-874C20.7	3.94	9.57e-05	0.00752	0.25	0.18	Depression;	chr6:28241324	chr6:28315613~28315883:-
THCA	cis	rs9487605	1	rs9487605	ENSG00000255389.1	C6orf3	3.94	9.57e-05	0.00752	0.18	0.18	Inflammatory skin disease;	chr6:111261682	chr6:111599875~111602295:+
THCA	cis	rs4561483	0.603	rs11544193	ENSG00000263307.1	RP11-166B2.8	-3.94	9.57e-05	0.00752	-0.19	-0.18	Testicular germ cell tumor;	chr16:11915447	chr16:11851649~11895611:+
THCA	cis	rs7243790	0.805	rs12458588	ENSG00000277324.1	RP11-850A17.1	-3.94	9.57e-05	0.00752	-0.18	-0.18	Diastolic blood pressure;	chr18:54377323	chr18:54268346~54270028:-
THCA	cis	rs6088580	0.524	rs6088560	ENSG00000126005.14	MMP24-AS1	3.94	9.57e-05	0.00752	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34640745	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.524	rs7269596	ENSG00000126005.14	MMP24-AS1	3.94	9.57e-05	0.00752	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34641259	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.524	rs6087612	ENSG00000126005.14	MMP24-AS1	3.94	9.57e-05	0.00752	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34643018	chr20:35216462~35278131:-
THCA	cis	rs4073416	0.542	rs11158603	ENSG00000276116.2	FUT8-AS1	3.94	9.57e-05	0.00752	0.2	0.18	N-glycan levels;	chr14:65605322	chr14:65411170~65412690:-
THCA	cis	rs11638352	1	rs4924728	ENSG00000166763.7	STRCP1	-3.93	9.58e-05	0.00752	-0.35	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43997755	chr15:43699488~43718184:-
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000182586.6	LINC00334	-3.93	9.58e-05	0.00752	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45234340~45258730:+
THCA	cis	rs12681288	0.55	rs76893867	ENSG00000260721.1	AF067845.1	3.93	9.58e-05	0.00752	0.22	0.18	Schizophrenia;	chr8:1012618	chr8:1368642~1369833:-
THCA	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-3.93	9.58e-05	0.00752	-0.19	-0.18	Asthma;	chr2:102401592	chr2:102438713~102440475:+
THCA	cis	rs4262150	0.883	rs72799143	ENSG00000253921.1	CTB-113P19.3	3.93	9.58e-05	0.00753	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152721189	chr5:151753992~151767247:+
THCA	cis	rs10833905	1	rs2114466	ENSG00000246225.5	RP11-17A1.3	-3.93	9.58e-05	0.00753	-0.25	-0.18	Sudden cardiac arrest;	chr11:23014841	chr11:22829380~22945393:+
THCA	cis	rs10875746	0.625	rs2898065	ENSG00000258273.1	RP11-370I10.4	3.93	9.59e-05	0.00753	0.25	0.18	Longevity (90 years and older);	chr12:48250836	chr12:48333755~48333901:-
THCA	cis	rs72634501	0.542	rs2134472	ENSG00000228060.1	RP11-69E11.8	3.93	9.59e-05	0.00753	0.17	0.18	HDL cholesterol;	chr1:39137542	chr1:39565160~39573203:+
THCA	cis	rs2980439	0.557	rs2921056	ENSG00000253981.4	ALG1L13P	3.93	9.59e-05	0.00753	0.17	0.18	Neuroticism;	chr8:8461672	chr8:8236003~8244667:-
THCA	cis	rs34421088	0.576	rs2572432	ENSG00000255046.1	RP11-297N6.4	3.93	9.59e-05	0.00753	0.2	0.18	Neuroticism;	chr8:11244214	chr8:11797928~11802568:-
THCA	cis	rs4742903	0.935	rs1889284	ENSG00000270332.1	SMC2-AS1	3.93	9.59e-05	0.00753	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104164699	chr9:104080024~104093073:-
THCA	cis	rs911555	0.755	rs9671414	ENSG00000269958.1	RP11-73M18.8	-3.93	9.59e-05	0.00753	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103500962	chr14:103696353~103697163:+
THCA	cis	rs2006933	0.625	rs2125846	ENSG00000267644.1	CTD-2008P7.10	3.93	9.59e-05	0.00753	0.24	0.18	Amyotrophic lateral sclerosis;	chr17:28171022	chr17:28219285~28220005:+
THCA	cis	rs17597773	0.674	rs984676	ENSG00000238078.1	LINC01352	3.93	9.6e-05	0.00753	0.25	0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220835080	chr1:220829255~220832429:+
THCA	cis	rs10266483	0.739	rs682662	ENSG00000234338.1	RP11-797H7.1	3.93	9.6e-05	0.00754	0.13	0.18	Response to statin therapy;	chr7:64306107	chr7:64835280~64836882:-
THCA	cis	rs6693017	1	rs11590678	ENSG00000272823.1	RP11-295M18.6	-3.93	9.6e-05	0.00754	-0.28	-0.18	Monocyte early outgrowth colony forming units;	chr1:220808107	chr1:220828676~220829211:-
THCA	cis	rs5758511	0.68	rs5758662	ENSG00000237037.8	NDUFA6-AS1	-3.93	9.6e-05	0.00754	-0.17	-0.18	Birth weight;	chr22:42232082	chr22:42090931~42137742:+
THCA	cis	rs9902453	0.933	rs9303628	ENSG00000263370.1	RP11-68I3.5	3.93	9.6e-05	0.00754	0.23	0.18	Coffee consumption (cups per day);	chr17:30200210	chr17:29639627~29640825:+
THCA	cis	rs638893	1	rs636736	ENSG00000255422.1	AP002954.4	-3.93	9.6e-05	0.00754	-0.26	-0.18	Vitiligo;	chr11:118834436	chr11:118704607~118750263:+
THCA	cis	rs11633886	0.842	rs4774748	ENSG00000259200.1	RP11-718O11.1	3.93	9.6e-05	0.00754	0.22	0.18	Diisocyanate-induced asthma;	chr15:45778142	chr15:45705078~45931069:+
THCA	cis	rs6088590	1	rs6088595	ENSG00000269202.1	RP4-614O4.12	-3.93	9.6e-05	0.00754	-0.17	-0.18	Coronary artery disease;	chr20:34770696	chr20:35201747~35203288:-
THCA	cis	rs12364620	1	rs12364620	ENSG00000160172.9	FAM86C2P	3.93	9.6e-05	0.00754	0.18	0.18	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:67791648~67805336:-
THCA	cis	rs8067354	0.958	rs8081468	ENSG00000266701.1	AC005702.4	3.93	9.6e-05	0.00754	0.25	0.18	Hemoglobin concentration;	chr17:59759563	chr17:60042546~60042627:-
THCA	cis	rs8067354	0.958	rs2333563	ENSG00000266701.1	AC005702.4	3.93	9.6e-05	0.00754	0.25	0.18	Hemoglobin concentration;	chr17:59762207	chr17:60042546~60042627:-
THCA	cis	rs8067354	0.872	rs2645483	ENSG00000266701.1	AC005702.4	3.93	9.6e-05	0.00754	0.25	0.18	Hemoglobin concentration;	chr17:59770823	chr17:60042546~60042627:-
THCA	cis	rs2115630	0.691	rs8040066	ENSG00000259295.5	CSPG4P12	-3.93	9.6e-05	0.00754	-0.24	-0.18	P wave terminal force;	chr15:84633234	chr15:85191438~85213905:+
THCA	cis	rs2153535	0.585	rs6597343	ENSG00000230939.1	RP11-314C16.1	-3.93	9.6e-05	0.00754	-0.19	-0.18	Motion sickness;	chr6:8620270	chr6:8784178~8785445:+
THCA	cis	rs6929812	1	rs6929812	ENSG00000216915.2	RP1-97D16.1	3.93	9.61e-05	0.00754	0.23	0.18	Neuroticism (multi-trait analysis);	chr6:27416741	chr6:27737000~27738494:-
THCA	cis	rs10833905	1	rs11026932	ENSG00000246225.5	RP11-17A1.3	-3.93	9.61e-05	0.00754	-0.25	-0.18	Sudden cardiac arrest;	chr11:23043853	chr11:22829380~22945393:+
THCA	cis	rs2243123	0.602	rs2243149	ENSG00000244040.4	IL12A-AS1	3.93	9.61e-05	0.00754	0.24	0.18	Multiple sclerosis;	chr3:159997925	chr3:159913400~160225299:-
THCA	cis	rs4601821	0.965	rs10891543	ENSG00000270179.1	RP11-159N11.4	-3.93	9.61e-05	0.00754	-0.18	-0.18	Alcoholic chronic pancreatitis;	chr11:113385173	chr11:113368478~113369117:+
THCA	cis	rs17599629	0.502	rs2055975	ENSG00000231073.1	RP11-316M1.3	-3.93	9.61e-05	0.00754	-0.23	-0.18	Prostate cancer;	chr1:150646156	chr1:150973123~150975534:+
THCA	cis	rs7474896	0.832	rs35954589	ENSG00000263064.2	RP11-291L22.7	3.93	9.61e-05	0.00755	0.3	0.18	Obesity (extreme);	chr10:37637455	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.778	rs11011310	ENSG00000263064.2	RP11-291L22.7	3.93	9.61e-05	0.00755	0.3	0.18	Obesity (extreme);	chr10:37652983	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.832	rs61857921	ENSG00000263064.2	RP11-291L22.7	3.93	9.61e-05	0.00755	0.3	0.18	Obesity (extreme);	chr10:37672109	chr10:38448689~38448949:+
THCA	cis	rs7637701	0.713	rs9867857	ENSG00000243926.1	TIPARP-AS1	3.93	9.61e-05	0.00755	0.18	0.18	Breast cancer;	chr3:156773371	chr3:156671862~156674378:-
THCA	cis	rs7798970	0.645	rs4313085	ENSG00000225498.1	AC002064.5	-3.93	9.61e-05	0.00755	-0.19	-0.18	Inflammatory skin disease;	chr7:90009379	chr7:90312496~90322592:+
THCA	cis	rs9467773	0.62	rs1027203	ENSG00000261353.1	CTA-14H9.5	-3.93	9.61e-05	0.00755	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26527063~26527404:+
THCA	cis	rs11175834	0.655	rs4631931	ENSG00000250748.5	RP11-230G5.2	3.93	9.61e-05	0.00755	0.3	0.18	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65572195	chr12:65466820~65642372:-
THCA	cis	rs150992	0.79	rs45931	ENSG00000246763.5	RGMB-AS1	3.93	9.62e-05	0.00755	0.18	0.18	Body mass index;	chr5:98978344	chr5:98769618~98773469:-
THCA	cis	rs1005277	0.505	rs1208689	ENSG00000275858.1	RP11-291L22.8	3.93	9.62e-05	0.00755	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38450738~38451069:-
THCA	cis	rs7267979	1	rs6115153	ENSG00000276952.1	RP5-965G21.6	-3.93	9.62e-05	0.00755	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs7268053	ENSG00000276952.1	RP5-965G21.6	-3.93	9.62e-05	0.00755	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6083809	ENSG00000276952.1	RP5-965G21.6	-3.93	9.62e-05	0.00755	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25284915~25285588:-
THCA	cis	rs2153535	0.518	rs9328485	ENSG00000230939.1	RP11-314C16.1	-3.93	9.62e-05	0.00755	-0.19	-0.18	Motion sickness;	chr6:8524831	chr6:8784178~8785445:+
THCA	cis	rs858239	0.867	rs10250602	ENSG00000226816.2	AC005082.12	3.93	9.62e-05	0.00755	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23206013~23208045:+
THCA	cis	rs5769765	0.773	rs138834	ENSG00000260613.1	RP3-522J7.6	-3.93	9.62e-05	0.00755	-0.23	-0.18	Schizophrenia;	chr22:49786849	chr22:49832616~49837786:-
THCA	cis	rs7824557	0.527	rs2409756	ENSG00000227888.4	FAM66A	-3.93	9.63e-05	0.00756	-0.23	-0.18	Retinal vascular caliber;	chr8:11384516	chr8:12362019~12388296:+
THCA	cis	rs8177876	0.749	rs2602407	ENSG00000261838.4	RP11-303E16.6	-3.93	9.63e-05	0.00756	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059141	chr16:81069854~81076598:+
THCA	cis	rs836788	0.535	rs6151840	ENSG00000251221.1	LINC01337	-3.93	9.63e-05	0.00756	-0.19	-0.18	Glomerular filtration rate (creatinine);	chr5:80791435	chr5:80608623~80622524:-
THCA	cis	rs10875746	0.669	rs11168496	ENSG00000258273.1	RP11-370I10.4	3.93	9.63e-05	0.00756	0.25	0.18	Longevity (90 years and older);	chr12:48257072	chr12:48333755~48333901:-
THCA	cis	rs7829975	0.522	rs6601689	ENSG00000248538.5	RP11-10A14.5	-3.93	9.63e-05	0.00756	-0.23	-0.18	Mood instability;	chr8:8314761	chr8:9189011~9202854:+
THCA	cis	rs6921919	1	rs35875412	ENSG00000280107.1	AL022393.9	-3.93	9.63e-05	0.00756	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28170845~28172521:+
THCA	cis	rs17221829	0.733	rs35757457	ENSG00000280385.1	AP000648.5	-3.93	9.63e-05	0.00756	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89625082	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.703	rs11018680	ENSG00000280385.1	AP000648.5	-3.93	9.63e-05	0.00756	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89630843	chr11:90193614~90198120:+
THCA	cis	rs6688613	0.685	rs10918599	ENSG00000225171.2	DUTP6	-3.93	9.64e-05	0.00756	-0.26	-0.18	Refractive astigmatism;	chr1:166949549	chr1:166868748~166869209:+
THCA	cis	rs513088	0.645	rs526834	ENSG00000225171.2	DUTP6	3.93	9.64e-05	0.00756	0.26	0.18	Schizophrenia;	chr1:166726549	chr1:166868748~166869209:+
THCA	cis	rs10090774	0.965	rs13276704	ENSG00000280303.2	ERICD	-3.93	9.64e-05	0.00756	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140983597	chr8:140636281~140638283:+
THCA	cis	rs9595908	0.709	rs1924606	ENSG00000212293.1	SNORA16	3.93	9.64e-05	0.00756	0.21	0.18	Body mass index;	chr13:32759230	chr13:32420390~32420516:-
THCA	cis	rs6600671	0.934	rs11249348	ENSG00000275585.1	CH17-118O6.3	-3.93	9.64e-05	0.00756	-0.21	-0.18	Hip geometry;	chr1:121446444	chr1:120985692~121052167:-
THCA	cis	rs34421088	0.56	rs2245250	ENSG00000206014.6	OR7E161P	3.93	9.64e-05	0.00757	0.21	0.18	Neuroticism;	chr8:11543171	chr8:11928597~11929563:-
THCA	cis	rs293748	0.825	rs468022	ENSG00000250155.1	CTD-2353F22.1	-3.93	9.64e-05	0.00757	-0.25	-0.18	Obesity-related traits;	chr5:36988150	chr5:36666214~36725195:-
THCA	cis	rs7089973	0.604	rs7095816	ENSG00000228169.3	PPIAP19	3.93	9.64e-05	0.00757	0.21	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114825350	chr10:114690143~114690634:-
THCA	cis	rs1198872	0.892	rs1198864	ENSG00000272275.1	RP11-791G15.2	-3.93	9.64e-05	0.00757	-0.21	-0.18	Cardiac Troponin-T levels;	chr2:10760869	chr2:10767875~10770058:-
THCA	cis	rs1577917	0.958	rs1414199	ENSG00000220563.1	PKMP3	-3.93	9.64e-05	0.00757	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85812652	chr6:85659892~85660606:-
THCA	cis	rs854765	0.583	rs11078404	ENSG00000281749.1	Y_RNA	3.93	9.64e-05	0.00757	0.22	0.18	Total body bone mineral density;	chr17:17917173	chr17:18001101~18001195:-
THCA	cis	rs74233809	1	rs77787671	ENSG00000272912.1	RP11-724N1.1	-3.93	9.65e-05	0.00757	-0.32	-0.18	Birth weight;	chr10:103016448	chr10:102914585~102915404:+
THCA	cis	rs9863	0.827	rs12823740	ENSG00000270061.1	RP11-214K3.19	-3.93	9.65e-05	0.00757	-0.23	-0.18	White blood cell count;	chr12:123973455	chr12:123969990~123970344:-
THCA	cis	rs758324	0.732	rs156034	ENSG00000224431.1	AC063976.7	-3.93	9.65e-05	0.00757	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132192021	chr5:132199456~132203487:+
THCA	cis	rs7819412	0.715	rs35223712	ENSG00000255046.1	RP11-297N6.4	3.93	9.65e-05	0.00757	0.19	0.18	Triglycerides;	chr8:11186417	chr8:11797928~11802568:-
THCA	cis	rs12612619	0.668	rs2304682	ENSG00000272148.1	RP11-195B17.1	3.93	9.65e-05	0.00757	0.17	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27084901	chr2:27062428~27062907:-
THCA	cis	rs4950322	0.58	rs4950371	ENSG00000271721.1	RP11-337C18.9	3.93	9.65e-05	0.00757	0.2	0.18	Protein quantitative trait loci;	chr1:147114243	chr1:147175602~147177740:+
THCA	cis	rs944289	0.617	rs1958617	ENSG00000258844.1	RP11-259K15.2	3.93	9.65e-05	0.00757	0.17	0.18	Thyroid cancer;	chr14:36118418	chr14:36214607~36235608:+
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000182586.6	LINC00334	3.93	9.65e-05	0.00757	0.19	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45234340~45258730:+
THCA	cis	rs10090774	0.965	rs7840381	ENSG00000279766.1	RP11-642A1.2	3.93	9.65e-05	0.00757	0.22	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140764183	chr8:140572142~140572812:-
THCA	cis	rs2749592	0.918	rs1208653	ENSG00000120555.12	SEPT7P9	-3.93	9.65e-05	0.00757	-0.21	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37964898	chr10:38383069~38402916:-
THCA	cis	rs67478160	0.619	rs28698555	ENSG00000269940.1	RP11-73M18.7	-3.93	9.65e-05	0.00757	-0.17	-0.18	Schizophrenia;	chr14:103850149	chr14:103694560~103695170:+
THCA	cis	rs4908768	0.501	rs12061328	ENSG00000270282.1	RP5-1115A15.2	3.93	9.65e-05	0.00757	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs6577488	ENSG00000270282.1	RP5-1115A15.2	3.93	9.65e-05	0.00757	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs4351668	ENSG00000270282.1	RP5-1115A15.2	3.93	9.65e-05	0.00757	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs7551849	ENSG00000270282.1	RP5-1115A15.2	3.93	9.65e-05	0.00757	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8512653~8513021:+
THCA	cis	rs8040855	0.894	rs6496770	ENSG00000225151.9	GOLGA2P7	3.93	9.65e-05	0.00758	0.24	0.18	Bulimia nervosa;	chr15:85161890	chr15:84199311~84230136:-
THCA	cis	rs2115630	1	rs2879828	ENSG00000275120.1	RP11-182J1.17	-3.93	9.65e-05	0.00758	-0.18	-0.18	P wave terminal force;	chr15:84818746	chr15:84599434~84606463:-
THCA	cis	rs858239	1	rs156407	ENSG00000230042.1	AK3P3	-3.93	9.66e-05	0.00758	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23129178~23129841:+
THCA	cis	rs6978712	0.505	rs6949899	ENSG00000226770.1	AC000124.1	-3.93	9.66e-05	0.00758	-0.23	-0.18	Medication adherence in chronic diseases;	chr7:127505669	chr7:127476883~127485804:+
THCA	cis	rs786425	0.71	rs11057326	ENSG00000278112.1	RP11-972P1.11	3.93	9.66e-05	0.00758	0.17	0.18	Pubertal anthropometrics;	chr12:123663931	chr12:123519390~123519856:-
THCA	cis	rs2120243	0.539	rs6441128	ENSG00000241770.1	RP11-555M1.3	-3.93	9.66e-05	0.00758	-0.24	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157403469	chr3:157163452~157169133:+
THCA	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102374753	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102379885	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102381819	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102382514	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102382943	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102388870	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102389644	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102389988	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102394452	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102399227	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102402540	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102402571	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102403325	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	3.93	9.66e-05	0.00758	0.19	0.18	Asthma;	chr2:102403679	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-3.93	9.66e-05	0.00758	-0.19	-0.18	Asthma;	chr2:102374328	chr2:102438713~102440475:+
THCA	cis	rs3096299	0.719	rs2911262	ENSG00000261118.1	RP11-104N10.1	3.93	9.66e-05	0.00758	0.15	0.18	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89492017~89504460:-
THCA	cis	rs7615952	0.611	rs9681518	ENSG00000272840.1	RP11-379B18.6	3.93	9.66e-05	0.00758	0.34	0.18	Blood pressure (smoking interaction);	chr3:125896287	chr3:125774714~125797953:+
THCA	cis	rs7904321	1	rs10740103	ENSG00000232075.1	MRPL35P2	-3.93	9.66e-05	0.00758	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63074319	chr10:63634317~63634827:-
THCA	cis	rs2749592	0.918	rs1208653	ENSG00000226578.1	RP11-258F22.1	3.93	9.66e-05	0.00758	0.22	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37964898	chr10:37775371~37784131:-
THCA	cis	rs894638	1	rs79821348	ENSG00000263327.5	TAPT1-AS1	-3.93	9.67e-05	0.00758	-0.22	-0.18	Glomerular filtration rate in chronic kidney disease;	chr4:16114594	chr4:16226685~16320140:+
THCA	cis	rs9291683	1	rs9291683	ENSG00000261490.1	RP11-448G15.3	3.93	9.67e-05	0.00758	0.11	0.18	Bone mineral density;	chr4:10322536	chr4:10068089~10073019:-
THCA	cis	rs853679	0.699	rs9468318	ENSG00000273712.1	RP5-874C20.7	3.93	9.67e-05	0.00759	0.25	0.18	Depression;	chr6:28241753	chr6:28315613~28315883:-
THCA	cis	rs7089973	0.604	rs17663387	ENSG00000228169.3	PPIAP19	3.93	9.67e-05	0.00759	0.21	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114828301	chr10:114690143~114690634:-
THCA	cis	rs10435719	0.902	rs12681142	ENSG00000206014.6	OR7E161P	-3.93	9.67e-05	0.00759	-0.21	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:11928597~11929563:-
THCA	cis	rs755249	0.567	rs72637906	ENSG00000182109.6	RP11-69E11.4	3.93	9.67e-05	0.00759	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs67886352	ENSG00000182109.6	RP11-69E11.4	3.93	9.67e-05	0.00759	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs60323161	ENSG00000182109.6	RP11-69E11.4	3.93	9.67e-05	0.00759	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs66727439	ENSG00000182109.6	RP11-69E11.4	3.93	9.67e-05	0.00759	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39522280~39546187:-
THCA	cis	rs854765	0.583	rs9913724	ENSG00000281749.1	Y_RNA	3.93	9.67e-05	0.00759	0.22	0.18	Total body bone mineral density;	chr17:17915787	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs7207043	ENSG00000281749.1	Y_RNA	3.93	9.67e-05	0.00759	0.22	0.18	Total body bone mineral density;	chr17:17915874	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs6502622	ENSG00000281749.1	Y_RNA	3.93	9.67e-05	0.00759	0.22	0.18	Total body bone mineral density;	chr17:17931377	chr17:18001101~18001195:-
THCA	cis	rs4742903	0.935	rs10991186	ENSG00000270332.1	SMC2-AS1	-3.93	9.67e-05	0.00759	-0.17	-0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104233872	chr9:104080024~104093073:-
THCA	cis	rs1552244	0.572	rs6785976	ENSG00000180385.7	EMC3-AS1	3.93	9.67e-05	0.00759	0.22	0.18	Alzheimer's disease;	chr3:10126963	chr3:9986893~10006990:+
THCA	cis	rs7111546	0.565	rs56379609	ENSG00000246225.5	RP11-17A1.3	3.93	9.68e-05	0.00759	0.32	0.18	Dialysis-related mortality;	chr11:22945736	chr11:22829380~22945393:+
THCA	cis	rs1075232	0.826	rs16956738	ENSG00000215302.7	CTD-3092A11.1	3.93	9.68e-05	0.00759	0.37	0.18	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30470779~30507623:+
THCA	cis	rs453301	0.631	rs17700611	ENSG00000233609.3	RP11-62H7.2	-3.93	9.68e-05	0.00759	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8936144	chr8:8961200~8979025:+
THCA	cis	rs878939	0.625	rs1035209	ENSG00000233690.1	EBAG9P1	3.93	9.68e-05	0.00759	0.23	0.18	Warfarin maintenance dose;	chr10:99585609	chr10:99697407~99697949:-
THCA	cis	rs4792901	0.729	rs12603059	ENSG00000267151.3	RP11-100E5.2	3.93	9.68e-05	0.00759	0.19	0.18	Dupuytren's disease;	chr17:43461078	chr17:43444707~43451200:+
THCA	cis	rs2980439	0.607	rs2980419	ENSG00000233609.3	RP11-62H7.2	3.93	9.68e-05	0.00759	0.17	0.18	Neuroticism;	chr8:8256619	chr8:8961200~8979025:+
THCA	cis	rs427394	0.632	rs377137	ENSG00000248677.1	CTD-2044J15.1	3.93	9.68e-05	0.0076	0.17	0.18	Menopause (age at onset);	chr5:6740355	chr5:6686325~6707711:-
THCA	cis	rs2898290	0.592	rs2736342	ENSG00000254527.1	ENPP7P12	-3.93	9.68e-05	0.0076	-0.22	-0.18	Systolic blood pressure;	chr8:11489780	chr8:12205759~12206389:-
THCA	cis	rs72928364	0.86	rs13085839	ENSG00000256628.3	ZBTB11-AS1	3.93	9.69e-05	0.0076	0.3	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101078390	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.86	rs17219986	ENSG00000256628.3	ZBTB11-AS1	3.93	9.69e-05	0.0076	0.3	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101080826	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.86	rs16843225	ENSG00000256628.3	ZBTB11-AS1	3.93	9.69e-05	0.0076	0.3	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101082413	chr3:101676475~101679217:+
THCA	cis	rs2777491	1	rs316609	ENSG00000247556.5	OIP5-AS1	3.93	9.69e-05	0.0076	0.15	0.18	Ulcerative colitis;	chr15:41451630	chr15:41283990~41309737:+
THCA	cis	rs7577696	0.671	rs55877106	ENSG00000276334.1	AL133243.1	3.93	9.69e-05	0.0076	0.19	0.18	Inflammatory biomarkers;	chr2:32205732	chr2:32521927~32523547:+
THCA	cis	rs7819412	0.715	rs2409727	ENSG00000254839.1	AF131215.6	3.93	9.69e-05	0.0076	0.19	0.18	Triglycerides;	chr8:11185727	chr8:11062647~11067089:-
THCA	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	3.93	9.69e-05	0.0076	0.19	0.18	Asthma;	chr2:102404807	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	3.93	9.69e-05	0.0076	0.19	0.18	Asthma;	chr2:102407218	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	3.93	9.69e-05	0.0076	0.19	0.18	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	3.93	9.69e-05	0.0076	0.19	0.18	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	3.93	9.69e-05	0.0076	0.19	0.18	Asthma;	chr2:102423587	chr2:102438713~102440475:+
THCA	cis	rs9905704	0.647	rs11659035	ENSG00000224738.1	AC099850.1	3.93	9.69e-05	0.0076	0.21	0.18	Testicular germ cell tumor;	chr17:58888691	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.647	rs11650809	ENSG00000224738.1	AC099850.1	3.93	9.69e-05	0.0076	0.21	0.18	Testicular germ cell tumor;	chr17:58895380	chr17:59106598~59118267:+
THCA	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	3.93	9.69e-05	0.0076	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
THCA	cis	rs7798970	0.645	rs6969996	ENSG00000225498.1	AC002064.5	-3.93	9.69e-05	0.0076	-0.18	-0.18	Inflammatory skin disease;	chr7:90020089	chr7:90312496~90322592:+
THCA	cis	rs420259	0.516	rs152455	ENSG00000260136.4	CTD-2270L9.4	3.93	9.69e-05	0.0076	0.14	0.18	Bipolar disorder;	chr16:23571752	chr16:23452758~23457606:+
THCA	cis	rs9467773	0.549	rs9461273	ENSG00000228223.2	HCG11	3.93	9.69e-05	0.0076	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26523450~26526579:+
THCA	cis	rs2333021	1	rs2333021	ENSG00000258376.2	RP4-647C14.2	-3.93	9.69e-05	0.0076	-0.21	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73017676	chr14:73242651~73245979:-
THCA	cis	rs71520386	0.632	rs9691076	ENSG00000226329.2	AC005682.6	-3.93	9.7e-05	0.0076	-0.23	-0.18	Fibrinogen levels;	chr7:22829742	chr7:22863874~22881350:-
THCA	cis	rs11069062	1	rs10851022	ENSG00000270482.1	RP11-131L12.2	3.93	9.7e-05	0.0076	0.14	0.18	Obesity-related traits;	chr12:118730679	chr12:118375350~118376275:-
THCA	cis	rs6067053	0.671	rs6067024	ENSG00000230758.1	SNAP23P	3.93	9.7e-05	0.0076	0.22	0.18	Intelligence (multi-trait analysis);	chr20:49226609	chr20:49038357~49038602:-
THCA	cis	rs765787	0.53	rs3759895	ENSG00000259932.1	CTD-2651B20.7	3.93	9.7e-05	0.00761	0.22	0.18	Uric acid levels;	chr15:45251672	chr15:45198517~45199139:-
THCA	cis	rs7142002	0.73	rs58803878	ENSG00000271780.1	RP11-1017G21.5	-3.93	9.7e-05	0.00761	-0.23	-0.18	Autism;	chr14:101924770	chr14:101948347~101949425:+
THCA	cis	rs357618	0.531	rs165333	ENSG00000260581.1	CTB-113P19.4	3.93	9.7e-05	0.00761	0.28	0.18	Basophil percentage of white cells;	chr5:151497586	chr5:151652275~151655449:+
THCA	cis	rs1577917	0.771	rs7762321	ENSG00000220563.1	PKMP3	3.93	9.7e-05	0.00761	0.13	0.18	Response to antipsychotic treatment;	chr6:85702428	chr6:85659892~85660606:-
THCA	cis	rs2898290	0.622	rs1382567	ENSG00000206014.6	OR7E161P	3.93	9.7e-05	0.00761	0.21	0.18	Systolic blood pressure;	chr8:11493390	chr8:11928597~11929563:-
THCA	cis	rs2251260	1	rs1092095	ENSG00000232774.6	FLJ22447	3.93	9.7e-05	0.00761	0.27	0.18	Yeast infection;	chr14:61551574	chr14:61570540~61658696:+
THCA	cis	rs11673344	0.764	rs519551	ENSG00000267260.1	CTD-2162K18.4	-3.93	9.7e-05	0.00761	-0.22	-0.18	Obesity-related traits;	chr19:36965046	chr19:36773153~36777078:+
THCA	cis	rs1232027	0.588	rs245331	ENSG00000249655.1	CTC-325J23.2	3.93	9.7e-05	0.00761	0.21	0.18	Huntington's disease progression;	chr5:80730558	chr5:80630313~80631590:-
THCA	cis	rs9425766	0.962	rs1322780	ENSG00000270084.1	GAS5-AS1	-3.93	9.71e-05	0.00761	-0.18	-0.18	Life satisfaction;	chr1:173896448	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.962	rs9425435	ENSG00000270084.1	GAS5-AS1	-3.93	9.71e-05	0.00761	-0.18	-0.18	Life satisfaction;	chr1:173896936	chr1:173863248~173863941:+
THCA	cis	rs726288	1	rs12259284	ENSG00000230091.5	TMEM254-AS1	3.93	9.71e-05	0.00761	0.45	0.18	Rheumatoid arthritis;	chr10:79927652	chr10:80046860~80078912:-
THCA	cis	rs7760535	0.711	rs240965	ENSG00000255389.1	C6orf3	-3.93	9.71e-05	0.00761	-0.18	-0.18	Metabolic traits;	chr6:111323321	chr6:111599875~111602295:+
THCA	cis	rs189798	0.807	rs330912	ENSG00000233609.3	RP11-62H7.2	3.93	9.71e-05	0.00761	0.18	0.18	Myopia (pathological);	chr8:9138784	chr8:8961200~8979025:+
THCA	cis	rs9309473	0.519	rs13017182	ENSG00000273245.1	RP11-434P11.2	-3.93	9.71e-05	0.00761	-0.21	-0.18	Metabolite levels;	chr2:73663877	chr2:73750256~73750786:-
THCA	cis	rs1048886	0.938	rs9294868	ENSG00000271967.1	RP11-134K13.4	-3.93	9.71e-05	0.00761	-0.19	-0.18	Type 2 diabetes;	chr6:70415806	chr6:70596438~70596980:+
THCA	cis	rs6479891	0.818	rs59215788	ENSG00000272767.1	JMJD1C-AS1	3.93	9.71e-05	0.00761	0.25	0.18	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs59246603	ENSG00000272767.1	JMJD1C-AS1	3.93	9.71e-05	0.00761	0.25	0.18	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs4746138	ENSG00000272767.1	JMJD1C-AS1	3.93	9.71e-05	0.00761	0.25	0.18	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63465229~63466563:+
THCA	cis	rs2141079	0.686	rs12568524	ENSG00000230728.1	RP11-240D10.4	-3.93	9.71e-05	0.00761	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr1:53656303	chr1:54621477~54628438:-
THCA	cis	rs4356203	0.87	rs214922	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215576	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214921	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215914	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.811	rs214920	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17216402	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214919	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17217157	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214918	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17218302	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214916	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220102	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214915	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220226	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214914	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220345	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.84	rs214911	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220691	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214910	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221242	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214909	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221731	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.905	rs618331	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17225789	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs7949699	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17226161	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs10832745	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228128	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs11024204	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228258	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs10832747	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228472	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs10832748	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17230184	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs2171615	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231094	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs10741724	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231604	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.783	rs7113964	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17234374	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs10766381	ENSG00000272034.1	SNORD14A	-3.93	9.71e-05	0.00761	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17235498	chr11:17074654~17074744:-
THCA	cis	rs76878669	0.583	rs8187658	ENSG00000255320.1	RP11-755F10.1	3.93	9.71e-05	0.00761	0.26	0.18	Educational attainment (years of education);	chr11:66366614	chr11:66244840~66246239:-
THCA	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-3.93	9.72e-05	0.00762	-0.21	-0.18	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
THCA	cis	rs42648	0.748	rs6972119	ENSG00000225498.1	AC002064.5	3.93	9.72e-05	0.00762	0.19	0.18	Homocysteine levels;	chr7:90264694	chr7:90312496~90322592:+
THCA	cis	rs62158800	0.789	rs1913987	ENSG00000237880.1	AC096669.2	3.93	9.72e-05	0.00762	0.18	0.18	Facial morphology (factor 22);	chr2:107600164	chr2:107385632~107542649:-
THCA	cis	rs1908814	0.516	rs7825529	ENSG00000255495.1	AC145124.2	3.93	9.72e-05	0.00762	0.21	0.18	Neuroticism;	chr8:11936935	chr8:12194467~12196280:+
THCA	cis	rs9905704	0.624	rs11652761	ENSG00000224738.1	AC099850.1	3.93	9.72e-05	0.00762	0.21	0.18	Testicular germ cell tumor;	chr17:58908734	chr17:59106598~59118267:+
THCA	cis	rs801193	1	rs7782320	ENSG00000223473.2	GS1-124K5.3	3.93	9.72e-05	0.00762	0.12	0.18	Aortic root size;	chr7:66712111	chr7:66491049~66493566:-
THCA	cis	rs1204798	1	rs7770203	ENSG00000237021.2	RP3-486I3.7	-3.93	9.72e-05	0.00762	-0.19	-0.18	Dental caries;	chr6:116205246	chr6:116254207~116256743:+
THCA	cis	rs867371	0.82	rs7164362	ENSG00000255769.6	GOLGA2P10	-3.93	9.72e-05	0.00762	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472993~82513950:-
THCA	cis	rs13064773	0.546	rs340270	ENSG00000279311.1	RP11-170K4.2	3.93	9.73e-05	0.00762	0.23	0.18	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158876262	chr3:158869898~158871821:+
THCA	cis	rs1930961	0.558	rs12160908	ENSG00000272977.1	CTA-390C10.10	-3.93	9.73e-05	0.00762	-0.28	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25476218~25479971:+
THCA	cis	rs7824557	0.603	rs2250028	ENSG00000206014.6	OR7E161P	-3.93	9.73e-05	0.00762	-0.21	-0.18	Retinal vascular caliber;	chr8:11356080	chr8:11928597~11929563:-
THCA	cis	rs5753037	0.869	rs2301402	ENSG00000279699.1	RP1-102K2.9	3.93	9.73e-05	0.00762	0.19	0.18	Type 1 diabetes;	chr22:29838056	chr22:30275215~30276951:-
THCA	cis	rs601999	1	rs601999	ENSG00000267185.1	PTP4A2P1	-3.93	9.73e-05	0.00762	-0.24	-0.18	Parkinson's disease;	chr17:42546140	chr17:42533532~42534009:+
THCA	cis	rs2777491	0.957	rs316614	ENSG00000247556.5	OIP5-AS1	3.93	9.73e-05	0.00762	0.15	0.18	Ulcerative colitis;	chr15:41454427	chr15:41283990~41309737:+
THCA	cis	rs2839186	0.934	rs13049797	ENSG00000215424.8	MCM3AP-AS1	3.93	9.73e-05	0.00762	0.1	0.18	Testicular germ cell tumor;	chr21:46287668	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.732	rs55904887	ENSG00000215424.8	MCM3AP-AS1	3.93	9.73e-05	0.00762	0.1	0.18	Testicular germ cell tumor;	chr21:46287897	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.934	rs2839197	ENSG00000215424.8	MCM3AP-AS1	3.93	9.73e-05	0.00762	0.1	0.18	Testicular germ cell tumor;	chr21:46288219	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.868	rs2839199	ENSG00000215424.8	MCM3AP-AS1	3.93	9.73e-05	0.00762	0.1	0.18	Testicular germ cell tumor;	chr21:46288355	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.933	rs4818832	ENSG00000215424.8	MCM3AP-AS1	3.93	9.73e-05	0.00762	0.1	0.18	Testicular germ cell tumor;	chr21:46288720	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.9	rs59828751	ENSG00000215424.8	MCM3AP-AS1	3.93	9.73e-05	0.00762	0.1	0.18	Testicular germ cell tumor;	chr21:46289004	chr21:46229217~46259390:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000272831.1	RP11-792A8.4	-3.93	9.73e-05	0.00763	-0.12	-0.18	Aortic root size;	chr7:66597493	chr7:66739829~66740385:-
THCA	cis	rs34421088	0.531	rs2245232	ENSG00000206014.6	OR7E161P	3.93	9.73e-05	0.00763	0.21	0.18	Neuroticism;	chr8:11543435	chr8:11928597~11929563:-
THCA	cis	rs495337	0.72	rs6067274	ENSG00000229222.1	KRT18P4	-3.93	9.73e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49927849	chr20:49956745~49958032:+
THCA	cis	rs495337	0.72	rs6125819	ENSG00000229222.1	KRT18P4	-3.93	9.73e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49929173	chr20:49956745~49958032:+
THCA	cis	rs495337	0.786	rs6125820	ENSG00000229222.1	KRT18P4	-3.93	9.73e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49929294	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs6067275	ENSG00000229222.1	KRT18P4	-3.93	9.73e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49929336	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs6122845	ENSG00000229222.1	KRT18P4	-3.93	9.73e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49929737	chr20:49956745~49958032:+
THCA	cis	rs495337	0.721	rs11696404	ENSG00000229222.1	KRT18P4	-3.93	9.73e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49931743	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs11696437	ENSG00000229222.1	KRT18P4	-3.93	9.73e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49931781	chr20:49956745~49958032:+
THCA	cis	rs495337	0.721	rs6125822	ENSG00000229222.1	KRT18P4	-3.93	9.73e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49932229	chr20:49956745~49958032:+
THCA	cis	rs6498068	0.594	rs12996	ENSG00000260468.1	LINC01290	-3.93	9.73e-05	0.00763	-0.23	-0.18	Metabolite levels (MHPG);	chr16:10529447	chr16:10514842~10528202:-
THCA	cis	rs2839186	0.9	rs2839200	ENSG00000215424.8	MCM3AP-AS1	3.93	9.73e-05	0.00763	0.1	0.18	Testicular germ cell tumor;	chr21:46289181	chr21:46229217~46259390:+
THCA	cis	rs7551222	0.662	rs4951399	ENSG00000240219.1	RP11-430C7.5	3.93	9.73e-05	0.00763	0.17	0.18	Schizophrenia;	chr1:204564127	chr1:204626775~204629712:+
THCA	cis	rs736408	0.608	rs2239547	ENSG00000243224.1	RP5-1157M23.2	-3.93	9.73e-05	0.00763	-0.21	-0.18	Bipolar disorder;	chr3:52821213	chr3:52239258~52241097:+
THCA	cis	rs67981189	0.896	rs12883437	ENSG00000269927.1	RP6-91H8.3	3.93	9.73e-05	0.00763	0.2	0.18	Schizophrenia;	chr14:70998064	chr14:71141125~71143253:-
THCA	cis	rs7583236	1	rs12617061	ENSG00000179818.12	PCBP1-AS1	-3.93	9.73e-05	0.00763	-0.18	-0.18	Obesity-related traits;	chr2:69955206	chr2:69962263~70103220:-
THCA	cis	rs7121800	0.632	rs7114662	ENSG00000242353.1	RP4-710M3.1	-3.93	9.74e-05	0.00763	-0.16	-0.18	Pit-and-Fissure caries;	chr11:30507967	chr11:30368148~30368646:+
THCA	cis	rs4666002	0.956	rs34502053	ENSG00000234072.1	AC074117.10	3.93	9.74e-05	0.00763	0.15	0.18	Phospholipid levels (plasma);	chr2:27631657	chr2:27356246~27367622:+
THCA	cis	rs7521902	0.617	rs7412010	ENSG00000228397.1	RP1-224A6.3	-3.93	9.74e-05	0.00763	-0.32	-0.18	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22109953	chr1:22023994~22024968:-
THCA	cis	rs6012953	1	rs6020560	ENSG00000231715.1	COX6CP2	3.93	9.74e-05	0.00763	0.19	0.18	Vitiligo;	chr20:50502882	chr20:50479767~50479991:+
THCA	cis	rs2549003	1	rs13170412	ENSG00000237714.1	P4HA2-AS1	-3.93	9.74e-05	0.00763	-0.23	-0.18	Asthma (sex interaction);	chr5:132487827	chr5:132184876~132192808:+
THCA	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-3.93	9.74e-05	0.00763	-0.16	-0.18	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
THCA	cis	rs7243790	0.805	rs7243441	ENSG00000277324.1	RP11-850A17.1	-3.93	9.74e-05	0.00763	-0.18	-0.18	Diastolic blood pressure;	chr18:54391363	chr18:54268346~54270028:-
THCA	cis	rs495337	0.965	rs6122848	ENSG00000229222.1	KRT18P4	-3.93	9.74e-05	0.00763	-0.22	-0.18	Psoriasis;	chr20:49930020	chr20:49956745~49958032:+
THCA	cis	rs9608946	1	rs9608936	ENSG00000279699.1	RP1-102K2.9	3.93	9.74e-05	0.00763	0.21	0.18	Red cell distribution width;	chr22:30485258	chr22:30275215~30276951:-
THCA	cis	rs950169	0.887	rs3860265	ENSG00000275120.1	RP11-182J1.17	3.93	9.74e-05	0.00763	0.21	0.18	Schizophrenia;	chr15:84390487	chr15:84599434~84606463:-
THCA	cis	rs950169	0.724	rs11632668	ENSG00000275120.1	RP11-182J1.17	3.93	9.74e-05	0.00763	0.21	0.18	Schizophrenia;	chr15:84393989	chr15:84599434~84606463:-
THCA	cis	rs950169	0.881	rs34591918	ENSG00000275120.1	RP11-182J1.17	3.93	9.74e-05	0.00763	0.21	0.18	Schizophrenia;	chr15:84396135	chr15:84599434~84606463:-
THCA	cis	rs10090774	0.965	rs12680723	ENSG00000279766.1	RP11-642A1.2	-3.93	9.75e-05	0.00764	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140984704	chr8:140572142~140572812:-
THCA	cis	rs9400467	1	rs6938986	ENSG00000271789.1	RP5-1112D6.7	-3.93	9.75e-05	0.00764	-0.18	-0.18	Amino acid levels;Blood metabolite levels;	chr6:111115249	chr6:111297126~111298510:+
THCA	cis	rs10181042	0.565	rs62150982	ENSG00000270820.4	RP11-355B11.2	-3.93	9.75e-05	0.00764	-0.14	-0.18	Crohn's disease;	chr2:61053540	chr2:61471188~61484130:+
THCA	cis	rs36093844	0.626	rs72961111	ENSG00000279742.1	RP11-700A24.1	-3.93	9.75e-05	0.00764	-0.23	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86008770	chr11:85852557~85854943:-
THCA	cis	rs4272720	0.639	rs7085823	ENSG00000234736.4	FAM170B-AS1	-3.93	9.75e-05	0.00764	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49076600	chr10:49121839~49151547:+
THCA	cis	rs12440869	1	rs8025186	ENSG00000270964.1	RP11-502I4.3	-3.93	9.75e-05	0.00764	-0.17	-0.18	Peak velocity of the mitral A-wave;	chr15:67349216	chr15:67541072~67542604:-
THCA	cis	rs2980439	0.525	rs2980508	ENSG00000254153.1	CTA-398F10.2	-3.93	9.75e-05	0.00764	-0.18	-0.18	Neuroticism;	chr8:8314210	chr8:8456909~8461337:-
THCA	cis	rs10435719	0.718	rs7813935	ENSG00000254948.1	OR7E158P	-3.93	9.75e-05	0.00764	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:11919900~11920809:-
THCA	cis	rs1908814	0.504	rs7830734	ENSG00000254948.1	OR7E158P	-3.93	9.75e-05	0.00764	-0.22	-0.18	Neuroticism;	chr8:11938130	chr8:11919900~11920809:-
THCA	cis	rs12681963	0.614	rs4409367	ENSG00000248159.1	HSPA8P11	3.93	9.75e-05	0.00764	0.35	0.18	Migraine;	chr8:30243112	chr8:30237382~30240997:+
THCA	cis	rs12681963	0.614	rs4626556	ENSG00000248159.1	HSPA8P11	3.93	9.75e-05	0.00764	0.35	0.18	Migraine;	chr8:30243325	chr8:30237382~30240997:+
THCA	cis	rs62458065	0.64	rs10271491	ENSG00000231952.3	DPY19L1P2	3.93	9.76e-05	0.00764	0.31	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32491053	chr7:32812757~32838570:+
THCA	cis	rs950169	0.922	rs11638445	ENSG00000275120.1	RP11-182J1.17	3.93	9.76e-05	0.00764	0.21	0.18	Schizophrenia;	chr15:84594463	chr15:84599434~84606463:-
THCA	cis	rs11971779	0.941	rs7802779	ENSG00000252332.1	RNU6-911P	-3.93	9.76e-05	0.00764	-0.22	-0.18	Diisocyanate-induced asthma;	chr7:139437833	chr7:139448740~139448843:+
THCA	cis	rs17695224	0.675	rs56177367	ENSG00000275055.1	CTC-471J1.11	-3.93	9.76e-05	0.00764	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51835343	chr19:52049007~52049754:+
THCA	cis	rs911555	0.723	rs12894652	ENSG00000269910.1	RP11-73M18.10	-3.93	9.76e-05	0.00764	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103694516~103695050:-
THCA	cis	rs12022452	1	rs75936657	ENSG00000237899.1	RP4-739H11.3	-3.93	9.76e-05	0.00764	-0.29	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40669089~40687588:-
THCA	cis	rs7617480	0.756	rs990211	ENSG00000228638.1	FCF1P2	-3.93	9.76e-05	0.00764	-0.23	-0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48683607	chr3:48290793~48291375:-
THCA	cis	rs7166081	1	rs4776908	ENSG00000270964.1	RP11-502I4.3	-3.93	9.76e-05	0.00764	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67247749	chr15:67541072~67542604:-
THCA	cis	rs2904524	0.737	rs79376393	ENSG00000257815.4	RP11-611E13.2	-3.93	9.76e-05	0.00764	-0.25	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70403676	chr12:69904033~70243360:-
THCA	cis	rs5758659	0.714	rs5751220	ENSG00000273366.1	CTA-989H11.1	3.93	9.76e-05	0.00764	0.21	0.18	Cognitive function;	chr22:42120201	chr22:42278188~42278846:+
THCA	cis	rs495337	0.76	rs2769978	ENSG00000229222.1	KRT18P4	-3.93	9.76e-05	0.00764	-0.22	-0.18	Psoriasis;	chr20:49910886	chr20:49956745~49958032:+
THCA	cis	rs12681366	0.734	rs4735288	ENSG00000261437.1	RP11-22C11.2	3.93	9.76e-05	0.00765	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94354316	chr8:94637285~94639467:-
THCA	cis	rs55661361	0.708	rs7113041	ENSG00000255045.1	RP11-677M14.2	-3.93	9.76e-05	0.00765	-0.16	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124742695	chr11:124744634~124746337:-
THCA	cis	rs6430585	0.591	rs12476135	ENSG00000231890.6	DARS-AS1	-3.93	9.76e-05	0.00765	-0.22	-0.18	Corneal structure;	chr2:135728770	chr2:135985176~136022593:+
THCA	cis	rs9733	0.687	rs12410050	ENSG00000231073.1	RP11-316M1.3	-3.93	9.76e-05	0.00765	-0.21	-0.18	Tonsillectomy;	chr1:150884665	chr1:150973123~150975534:+
THCA	cis	rs4660214	0.666	rs1537818	ENSG00000182109.6	RP11-69E11.4	-3.93	9.76e-05	0.00765	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181366	chr1:39522280~39546187:-
THCA	cis	rs858239	0.806	rs10268610	ENSG00000230042.1	AK3P3	-3.93	9.76e-05	0.00765	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23129178~23129841:+
THCA	cis	rs13098911	0.54	rs13074382	ENSG00000226074.4	PRSS44	-3.93	9.76e-05	0.00765	-0.32	-0.18	Celiac disease;	chr3:46020348	chr3:46809359~46812558:-
THCA	cis	rs453301	0.686	rs6748	ENSG00000233609.3	RP11-62H7.2	-3.93	9.77e-05	0.00765	-0.17	-0.18	Joint mobility (Beighton score);	chr8:9033292	chr8:8961200~8979025:+
THCA	cis	rs2898290	0.622	rs13272061	ENSG00000254527.1	ENPP7P12	-3.93	9.77e-05	0.00765	-0.23	-0.18	Systolic blood pressure;	chr8:11494752	chr8:12205759~12206389:-
THCA	cis	rs6138458	0.626	rs6050259	ENSG00000274173.1	RP4-568C11.4	3.93	9.77e-05	0.00765	0.15	0.18	Blood protein levels;	chr20:25030787	chr20:24931840~24932983:+
THCA	cis	rs7819412	0.745	rs2898260	ENSG00000254948.1	OR7E158P	3.93	9.77e-05	0.00765	0.22	0.18	Triglycerides;	chr8:11081980	chr8:11919900~11920809:-
THCA	cis	rs7829975	0.593	rs2921061	ENSG00000233609.3	RP11-62H7.2	3.93	9.77e-05	0.00765	0.18	0.18	Mood instability;	chr8:8460105	chr8:8961200~8979025:+
THCA	cis	rs654950	0.84	rs2810551	ENSG00000230638.4	RP11-486B10.4	3.93	9.77e-05	0.00765	0.2	0.18	Airway imaging phenotypes;	chr1:41529731	chr1:41542069~41544310:+
THCA	cis	rs9329221	0.741	rs9650622	ENSG00000233609.3	RP11-62H7.2	-3.93	9.77e-05	0.00765	-0.18	-0.18	Neuroticism;	chr8:9946782	chr8:8961200~8979025:+
THCA	cis	rs7131987	0.675	rs3847678	ENSG00000275476.1	RP11-996F15.4	3.93	9.77e-05	0.00765	0.18	0.18	QT interval;	chr12:29398627	chr12:29277397~29277882:-
THCA	cis	rs12493885	0.725	rs11718315	ENSG00000243069.6	ARHGEF26-AS1	-3.93	9.77e-05	0.00765	-0.29	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154006408	chr3:154024401~154121332:-
THCA	cis	rs1499614	1	rs2659913	ENSG00000237310.1	GS1-124K5.4	3.93	9.77e-05	0.00765	0.21	0.18	Gout;	chr7:66692349	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs2659911	ENSG00000237310.1	GS1-124K5.4	3.93	9.77e-05	0.00765	0.21	0.18	Gout;	chr7:66693433	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs2707838	ENSG00000237310.1	GS1-124K5.4	3.93	9.77e-05	0.00765	0.21	0.18	Gout;	chr7:66694214	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs60326618	ENSG00000237310.1	GS1-124K5.4	3.93	9.77e-05	0.00765	0.21	0.18	Gout;	chr7:66701371	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs2707830	ENSG00000237310.1	GS1-124K5.4	3.93	9.77e-05	0.00765	0.21	0.18	Gout;	chr7:66702658	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs2707828	ENSG00000237310.1	GS1-124K5.4	3.93	9.77e-05	0.00765	0.21	0.18	Gout;	chr7:66706390	chr7:66493706~66495474:+
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000237310.1	GS1-124K5.4	3.93	9.77e-05	0.00765	0.21	0.18	Gout;	chr7:66710076	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs2659903	ENSG00000237310.1	GS1-124K5.4	3.93	9.77e-05	0.00765	0.21	0.18	Gout;	chr7:66715944	chr7:66493706~66495474:+
THCA	cis	rs365302	1	rs374973	ENSG00000235086.1	FNDC1-IT1	3.93	9.77e-05	0.00766	0.25	0.18	Coronary heart disease;	chr6:159224530	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs432598	ENSG00000235086.1	FNDC1-IT1	3.93	9.77e-05	0.00766	0.25	0.18	Coronary heart disease;	chr6:159224723	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs401578	ENSG00000235086.1	FNDC1-IT1	3.93	9.77e-05	0.00766	0.25	0.18	Coronary heart disease;	chr6:159224751	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs445227	ENSG00000235086.1	FNDC1-IT1	3.93	9.77e-05	0.00766	0.25	0.18	Coronary heart disease;	chr6:159224856	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs378194	ENSG00000235086.1	FNDC1-IT1	3.93	9.77e-05	0.00766	0.25	0.18	Coronary heart disease;	chr6:159225291	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs375512	ENSG00000235086.1	FNDC1-IT1	3.93	9.77e-05	0.00766	0.25	0.18	Coronary heart disease;	chr6:159225418	chr6:159240786~159243329:+
THCA	cis	rs755249	0.917	rs61781392	ENSG00000237624.1	OXCT2P1	3.93	9.77e-05	0.00766	0.25	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39514956~39516490:+
THCA	cis	rs755249	0.917	rs61232586	ENSG00000237624.1	OXCT2P1	3.93	9.77e-05	0.00766	0.25	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39514956~39516490:+
THCA	cis	rs755249	0.917	rs61781393	ENSG00000237624.1	OXCT2P1	3.93	9.77e-05	0.00766	0.25	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39514956~39516490:+
THCA	cis	rs11242704	0.662	rs12201506	ENSG00000272279.1	RP11-157J24.2	-3.93	9.78e-05	0.00766	-0.29	-0.18	Response to hepatitis C treatment;	chr6:1536205	chr6:1528364~1528911:-
THCA	cis	rs1908814	0.503	rs34657250	ENSG00000254948.1	OR7E158P	3.93	9.78e-05	0.00766	0.23	0.18	Neuroticism;	chr8:11937864	chr8:11919900~11920809:-
THCA	cis	rs7829975	0.582	rs6982832	ENSG00000254340.1	RP11-10A14.3	-3.93	9.78e-05	0.00766	-0.2	-0.18	Mood instability;	chr8:8934707	chr8:9141424~9145435:+
THCA	cis	rs9926296	0.527	rs1800335	ENSG00000274627.1	RP11-104N10.2	-3.93	9.78e-05	0.00766	-0.18	-0.18	Vitiligo;	chr16:89779787	chr16:89516797~89522217:+
THCA	cis	rs6929812	0.639	rs7754724	ENSG00000271755.1	RP1-153G14.4	3.93	9.78e-05	0.00766	0.21	0.18	Neuroticism (multi-trait analysis);	chr6:27483018	chr6:27404010~27406964:-
THCA	cis	rs73198271	0.71	rs3827808	ENSG00000253893.2	FAM85B	3.93	9.78e-05	0.00766	0.24	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821847	chr8:8167819~8226614:-
THCA	cis	rs17092148	1	rs57131731	ENSG00000276073.1	RP5-1125A11.7	3.93	9.78e-05	0.00766	0.21	0.18	Neuroticism;	chr20:34804936	chr20:33985617~33988989:-
THCA	cis	rs6517329	0.538	rs879893	ENSG00000230212.5	AP000688.14	-3.93	9.78e-05	0.00766	-0.22	-0.18	Schizophrenia;	chr21:36136489	chr21:36069642~36126640:-
THCA	cis	rs10435719	0.867	rs35778860	ENSG00000254948.1	OR7E158P	-3.93	9.79e-05	0.00766	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:11919900~11920809:-
THCA	cis	rs4218	0.681	rs1867757	ENSG00000259732.1	RP11-59H7.3	-3.93	9.79e-05	0.00766	-0.24	-0.18	Social communication problems;	chr15:59072315	chr15:59121034~59133250:+
THCA	cis	rs7551222	0.752	rs12032733	ENSG00000240219.1	RP11-430C7.5	3.93	9.79e-05	0.00766	0.17	0.18	Schizophrenia;	chr1:204512081	chr1:204626775~204629712:+
THCA	cis	rs11153306	0.818	rs7764009	ENSG00000231889.6	TRAF3IP2-AS1	-3.93	9.79e-05	0.00766	-0.15	-0.18	Tonsillectomy;	chr6:111623393	chr6:111483511~111598302:+
THCA	cis	rs56104184	0.779	rs2131093	ENSG00000243829.1	CTB-33G10.1	-3.93	9.79e-05	0.00767	-0.23	-0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48847436	chr19:49719498~49720081:-
THCA	cis	rs1005277	0.505	rs200910	ENSG00000275858.1	RP11-291L22.8	3.93	9.79e-05	0.00767	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38450738~38451069:-
THCA	cis	rs35146811	0.696	rs1727124	ENSG00000078319.8	PMS2P1	-3.93	9.79e-05	0.00767	-0.22	-0.18	Coronary artery disease;	chr7:100206481	chr7:100320992~100341908:-
THCA	cis	rs9925964	0.622	rs8046707	ENSG00000279196.1	RP11-1072A3.3	-3.93	9.79e-05	0.00767	-0.17	-0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30904912	chr16:30984630~30988270:-
THCA	cis	rs6453278	0.768	rs4703726	ENSG00000250802.5	ZBED3-AS1	3.93	9.79e-05	0.00767	0.18	0.18	Autism;	chr5:77108413	chr5:77086740~77166909:+
THCA	cis	rs4950322	0.57	rs11800580	ENSG00000180867.10	PDIA3P1	-3.93	9.8e-05	0.00767	-0.18	-0.18	Protein quantitative trait loci;	chr1:147261053	chr1:147178113~147179622:+
THCA	cis	rs6696239	0.869	rs34421331	ENSG00000227711.2	RP11-275O4.5	-3.93	9.8e-05	0.00767	-0.24	-0.18	Height;	chr1:227690927	chr1:227509028~227520477:-
THCA	cis	rs9309473	0.948	rs10183818	ENSG00000273245.1	RP11-434P11.2	3.93	9.8e-05	0.00767	0.25	0.18	Metabolite levels;	chr2:73487429	chr2:73750256~73750786:-
THCA	cis	rs12541437	0.617	rs2921736	ENSG00000253327.2	RAD21-AS1	3.93	9.8e-05	0.00767	0.21	0.18	Gut microbiome composition (winter);	chr8:116919448	chr8:116874424~116876868:+
THCA	cis	rs12541437	0.617	rs2921735	ENSG00000253327.2	RAD21-AS1	3.93	9.8e-05	0.00767	0.21	0.18	Gut microbiome composition (winter);	chr8:116921277	chr8:116874424~116876868:+
THCA	cis	rs234720	0.55	rs234731	ENSG00000233754.1	AP001628.7	3.93	9.8e-05	0.00767	0.21	0.18	Cognitive performance;	chr21:43029279	chr21:42781074~42782233:-
THCA	cis	rs9302635	0.513	rs7184169	ENSG00000260886.1	TAT-AS1	3.93	9.8e-05	0.00767	0.23	0.18	Blood protein levels;	chr16:72119034	chr16:71565789~71578187:+
THCA	cis	rs10089	1	rs4836368	ENSG00000245937.6	LINC01184	3.93	9.8e-05	0.00767	0.2	0.18	Ileal carcinoids;	chr5:128150638	chr5:127940426~128083172:-
THCA	cis	rs4906332	1	rs17617307	ENSG00000252469.1	RNU7-160P	3.93	9.8e-05	0.00767	0.19	0.18	Coronary artery disease;	chr14:103438628	chr14:103550345~103550406:+
THCA	cis	rs13113518	0.812	rs12500686	ENSG00000272969.1	RP11-528I4.2	3.93	9.8e-05	0.00767	0.22	0.18	Height;	chr4:55457922	chr4:55547112~55547889:+
THCA	cis	rs7178424	0.742	rs2414755	ENSG00000259251.2	RP11-643M14.1	-3.93	9.8e-05	0.00768	-0.18	-0.18	Height;	chr15:61880230	chr15:62060503~62062434:+
THCA	cis	rs2015599	0.525	rs10743656	ENSG00000273680.1	RP11-996F15.6	-3.93	9.8e-05	0.00768	-0.25	-0.18	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29332733~29333383:-
THCA	cis	rs67981189	0.896	rs34049963	ENSG00000269927.1	RP6-91H8.3	3.93	9.8e-05	0.00768	0.2	0.18	Schizophrenia;	chr14:70974029	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs3814871	ENSG00000269927.1	RP6-91H8.3	3.93	9.8e-05	0.00768	0.2	0.18	Schizophrenia;	chr14:70978071	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs17108822	ENSG00000269927.1	RP6-91H8.3	3.93	9.8e-05	0.00768	0.2	0.18	Schizophrenia;	chr14:70979189	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs8012728	ENSG00000269927.1	RP6-91H8.3	3.93	9.8e-05	0.00768	0.2	0.18	Schizophrenia;	chr14:70981231	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs34731365	ENSG00000269927.1	RP6-91H8.3	3.93	9.8e-05	0.00768	0.2	0.18	Schizophrenia;	chr14:70982877	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs7157250	ENSG00000269927.1	RP6-91H8.3	3.93	9.8e-05	0.00768	0.2	0.18	Schizophrenia;	chr14:70991112	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs4132849	ENSG00000269927.1	RP6-91H8.3	3.93	9.8e-05	0.00768	0.2	0.18	Schizophrenia;	chr14:70992806	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.821	rs56021283	ENSG00000269927.1	RP6-91H8.3	3.93	9.8e-05	0.00768	0.2	0.18	Schizophrenia;	chr14:70996042	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.806	rs2810107	ENSG00000269927.1	RP6-91H8.3	-3.93	9.8e-05	0.00768	-0.2	-0.18	Schizophrenia;	chr14:70954340	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs2526890	ENSG00000269927.1	RP6-91H8.3	-3.93	9.8e-05	0.00768	-0.2	-0.18	Schizophrenia;	chr14:70963410	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs2810100	ENSG00000269927.1	RP6-91H8.3	-3.93	9.8e-05	0.00768	-0.2	-0.18	Schizophrenia;	chr14:70965455	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs2526877	ENSG00000269927.1	RP6-91H8.3	-3.93	9.8e-05	0.00768	-0.2	-0.18	Schizophrenia;	chr14:70966605	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs2810098	ENSG00000269927.1	RP6-91H8.3	-3.93	9.8e-05	0.00768	-0.2	-0.18	Schizophrenia;	chr14:70967194	chr14:71141125~71143253:-
THCA	cis	rs9868809	0.881	rs2276852	ENSG00000270441.1	RP11-694I15.7	3.93	9.81e-05	0.00768	0.22	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629490	chr3:49140086~49160851:-
THCA	cis	rs7111546	0.565	rs7127052	ENSG00000246225.5	RP11-17A1.3	3.93	9.81e-05	0.00768	0.32	0.18	Dialysis-related mortality;	chr11:22942091	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.565	rs4525237	ENSG00000246225.5	RP11-17A1.3	3.93	9.81e-05	0.00768	0.32	0.18	Dialysis-related mortality;	chr11:22942429	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.565	rs112702692	ENSG00000246225.5	RP11-17A1.3	3.93	9.81e-05	0.00768	0.32	0.18	Dialysis-related mortality;	chr11:22942823	chr11:22829380~22945393:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000229180.5	GS1-124K5.11	-3.93	9.81e-05	0.00768	-0.12	-0.18	Aortic root size;	chr7:66619753	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs28698552	ENSG00000229180.5	GS1-124K5.11	3.93	9.81e-05	0.00768	0.12	0.18	Aortic root size;	chr7:66540031	chr7:66526088~66542624:-
THCA	cis	rs6933660	0.646	rs9383899	ENSG00000219395.2	HSPA8P15	-3.93	9.81e-05	0.00768	-0.16	-0.18	Menarche (age at onset);	chr6:151459887	chr6:151411259~151413945:-
THCA	cis	rs71520386	0.632	rs28526185	ENSG00000226329.2	AC005682.6	-3.93	9.81e-05	0.00768	-0.23	-0.18	Fibrinogen levels;	chr7:22831699	chr7:22863874~22881350:-
THCA	cis	rs6724465	0.673	rs7596389	ENSG00000272644.1	RP11-33O4.1	-3.93	9.81e-05	0.00768	-0.24	-0.18	Height;	chr2:219150495	chr2:219069354~219069809:-
THCA	cis	rs2058059	0.551	rs4473912	ENSG00000205578.5	POM121B	-3.93	9.81e-05	0.00768	-0.29	-0.18	Subcutaneous adipose tissue;	chr7:72600851	chr7:73293497~73301161:+
THCA	cis	rs16944613	0.541	rs6496690	ENSG00000259212.1	CTD-3065B20.2	3.93	9.81e-05	0.00768	0.28	0.18	Colorectal cancer;	chr15:90554169	chr15:90595840~90596447:-
THCA	cis	rs6517329	0.513	rs2187300	ENSG00000236830.5	CBR3-AS1	3.93	9.81e-05	0.00768	0.17	0.18	Schizophrenia;	chr21:36165173	chr21:36131767~36175815:-
THCA	cis	rs853679	0.517	rs17711344	ENSG00000219891.2	ZSCAN12P1	-3.93	9.81e-05	0.00768	-0.25	-0.18	Depression;	chr6:28109824	chr6:28091154~28093664:+
THCA	cis	rs11771526	0.901	rs7791914	ENSG00000272905.1	RP11-265E18.1	3.93	9.81e-05	0.00768	0.23	0.18	Body mass index;	chr7:32257142	chr7:32845394~32846061:+
THCA	cis	rs709400	0.93	rs2274268	ENSG00000258735.1	LINC00637	3.93	9.82e-05	0.00768	0.23	0.18	Body mass index;	chr14:103563041	chr14:103847721~103858049:+
THCA	cis	rs1039766	1	rs268853	ENSG00000204929.10	AC074391.1	3.93	9.82e-05	0.00768	0.29	0.18	Lung adenocarcinoma;Lung cancer;	chr2:65250869	chr2:65436711~66084639:+
THCA	cis	rs1580019	0.813	rs2044839	ENSG00000231952.3	DPY19L1P2	-3.93	9.82e-05	0.00768	-0.23	-0.18	Cognitive ability;	chr7:32461193	chr7:32812757~32838570:+
THCA	cis	rs4245128	0.707	rs7102945	ENSG00000227487.3	NCAM1-AS1	3.93	9.82e-05	0.00769	0.18	0.18	Life satisfaction;	chr11:112934740	chr11:113269532~113273901:-
THCA	cis	rs17286411	0.671	rs2278031	ENSG00000260185.1	RP11-432I5.6	-3.93	9.82e-05	0.00769	-0.24	-0.18	Blood protein levels;	chr16:71734597	chr16:71655027~71664212:+
THCA	cis	rs17092148	0.636	rs2295096	ENSG00000276073.1	RP5-1125A11.7	3.93	9.82e-05	0.00769	0.19	0.18	Neuroticism;	chr20:34876907	chr20:33985617~33988989:-
THCA	cis	rs1577917	0.958	rs36042496	ENSG00000220563.1	PKMP3	-3.93	9.82e-05	0.00769	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85814496	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.917	rs1584273	ENSG00000220563.1	PKMP3	-3.93	9.82e-05	0.00769	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85814859	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs12198971	ENSG00000220563.1	PKMP3	-3.93	9.82e-05	0.00769	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85815727	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs34230196	ENSG00000220563.1	PKMP3	-3.93	9.82e-05	0.00769	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85816304	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.917	rs4707226	ENSG00000220563.1	PKMP3	-3.93	9.82e-05	0.00769	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85818110	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.917	rs13213603	ENSG00000220563.1	PKMP3	-3.93	9.82e-05	0.00769	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85825040	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs2324839	ENSG00000220563.1	PKMP3	-3.93	9.82e-05	0.00769	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85827224	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs3900313	ENSG00000220563.1	PKMP3	-3.93	9.82e-05	0.00769	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85827436	chr6:85659892~85660606:-
THCA	cis	rs12234571	1	rs6975196	ENSG00000214293.7	APTR	3.93	9.82e-05	0.00769	0.22	0.18	Obesity-related traits;	chr7:77804898	chr7:77657660~77696265:-
THCA	cis	rs12967678	1	rs12967678	ENSG00000260302.1	RP11-973H7.1	3.93	9.82e-05	0.00769	0.35	0.18	Selective IgA deficiency;	chr18:12805389	chr18:12774651~12775923:-
THCA	cis	rs875971	0.545	rs13311962	ENSG00000232559.3	GS1-124K5.12	-3.93	9.82e-05	0.00769	-0.19	-0.18	Aortic root size;	chr7:66603142	chr7:66554588~66576923:-
THCA	cis	rs4916588	0.697	rs2054200	ENSG00000270170.1	NCBP2-AS2	3.93	9.83e-05	0.00769	0.14	0.18	Night sleep phenotypes;	chr3:196927665	chr3:196942623~196943540:+
THCA	cis	rs3740713	1	rs78549183	ENSG00000256464.1	YWHABP2	3.93	9.83e-05	0.00769	0.32	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr11:18490243~18490955:-
THCA	cis	rs972578	0.791	rs738383	ENSG00000230319.1	AL022476.2	3.93	9.83e-05	0.00769	0.19	0.18	Mean platelet volume;	chr22:42919387	chr22:43038585~43052366:+
THCA	cis	rs7737355	0.947	rs10067982	ENSG00000237714.1	P4HA2-AS1	3.93	9.83e-05	0.00769	0.25	0.18	Life satisfaction;	chr5:131500247	chr5:132184876~132192808:+
THCA	cis	rs4879656	0.762	rs7868944	ENSG00000225693.1	LAGE3P1	3.93	9.83e-05	0.00769	0.19	0.18	Menopause (age at onset);	chr9:32938861	chr9:33019682~33020165:-
THCA	cis	rs7178424	0.742	rs963024	ENSG00000259251.2	RP11-643M14.1	3.93	9.83e-05	0.00769	0.18	0.18	Height;	chr15:61919251	chr15:62060503~62062434:+
THCA	cis	rs9316337	1	rs9316337	ENSG00000236953.1	ZDHHC20-IT1	-3.93	9.83e-05	0.00769	-0.19	-0.18	Schizophrenia;	chr13:21388068	chr13:21376977~21377874:-
THCA	cis	rs875971	0.66	rs801192	ENSG00000229180.5	GS1-124K5.11	-3.93	9.83e-05	0.00769	-0.12	-0.18	Aortic root size;	chr7:66566965	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs801190	ENSG00000229180.5	GS1-124K5.11	-3.93	9.83e-05	0.00769	-0.12	-0.18	Aortic root size;	chr7:66568046	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs3857686	ENSG00000229180.5	GS1-124K5.11	-3.93	9.83e-05	0.00769	-0.12	-0.18	Aortic root size;	chr7:66571204	chr7:66526088~66542624:-
THCA	cis	rs875971	0.638	rs6460305	ENSG00000229180.5	GS1-124K5.11	-3.93	9.83e-05	0.00769	-0.12	-0.18	Aortic root size;	chr7:66595421	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs10272357	ENSG00000229180.5	GS1-124K5.11	-3.93	9.83e-05	0.00769	-0.12	-0.18	Aortic root size;	chr7:66598087	chr7:66526088~66542624:-
THCA	cis	rs2033711	0.783	rs11671113	ENSG00000232098.3	CTD-2619J13.14	3.93	9.83e-05	0.00769	0.16	0.18	Uric acid clearance;	chr19:58446720	chr19:58404238~58408484:-
THCA	cis	rs7131987	0.565	rs7968883	ENSG00000257176.2	RP11-996F15.2	3.93	9.83e-05	0.0077	0.18	0.18	QT interval;	chr12:29241258	chr12:29280418~29317848:-
THCA	cis	rs875971	0.642	rs35526611	ENSG00000229180.5	GS1-124K5.11	-3.93	9.83e-05	0.0077	-0.12	-0.18	Aortic root size;	chr7:66629021	chr7:66526088~66542624:-
THCA	cis	rs150992	0.587	rs13179812	ENSG00000246763.5	RGMB-AS1	-3.93	9.84e-05	0.0077	-0.18	-0.18	Body mass index;	chr5:99021029	chr5:98769618~98773469:-
THCA	cis	rs854765	0.724	rs2955371	ENSG00000281749.1	Y_RNA	-3.93	9.84e-05	0.0077	-0.23	-0.18	Total body bone mineral density;	chr17:18064083	chr17:18001101~18001195:-
THCA	cis	rs1048886	0.872	rs2691486	ENSG00000271967.1	RP11-134K13.4	-3.93	9.84e-05	0.0077	-0.19	-0.18	Type 2 diabetes;	chr6:70576722	chr6:70596438~70596980:+
THCA	cis	rs1923626	0.93	rs10913418	ENSG00000224968.1	RP1-35C21.1	-3.93	9.84e-05	0.0077	-0.2	-0.18	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr1:177786164	chr1:177351586~177366272:+
THCA	cis	rs214785	1	rs214781	ENSG00000226644.4	RP11-128M1.1	-3.93	9.84e-05	0.0077	-0.18	-0.18	Basal cell carcinoma;	chr20:2300638	chr20:2207217~2213151:+
THCA	cis	rs3808502	0.525	rs13280813	ENSG00000255046.1	RP11-297N6.4	3.93	9.84e-05	0.0077	0.19	0.18	Neuroticism;	chr8:11567596	chr8:11797928~11802568:-
THCA	cis	rs4792901	0.765	rs9913605	ENSG00000267151.3	RP11-100E5.2	3.93	9.84e-05	0.0077	0.2	0.18	Dupuytren's disease;	chr17:43515142	chr17:43444707~43451200:+
THCA	cis	rs7119	0.635	rs938090	ENSG00000259362.2	RP11-307C19.1	3.93	9.84e-05	0.0077	0.23	0.18	Type 2 diabetes;	chr15:77587633	chr15:77525540~77534110:+
THCA	cis	rs72627123	1	rs45559033	ENSG00000259065.1	RP5-1021I20.1	-3.93	9.84e-05	0.0077	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73874421	chr14:73787360~73803270:+
THCA	cis	rs27419	0.57	rs4631137	ENSG00000272123.1	CTD-2366F13.2	-3.93	9.84e-05	0.0077	-0.2	-0.18	Schizophrenia;	chr5:53124615	chr5:53089016~53089468:-
THCA	cis	rs7212590	0.655	rs16943969	ENSG00000267302.4	RP11-178C3.2	3.93	9.84e-05	0.0077	0.33	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59953792	chr17:59964832~59996972:+
THCA	cis	rs79481398	0.616	rs76501864	ENSG00000276772.1	CTD-2515H24.2	-3.93	9.84e-05	0.0077	-0.23	-0.18	Facial morphology (factor 19);	chr15:57496455	chr15:57553955~57555680:+
THCA	cis	rs9992966	0.677	rs35256693	ENSG00000213331.4	RP11-713C19.2	-3.93	9.84e-05	0.0077	-0.49	-0.18	Trans fatty acid levels;	chr4:187673684	chr4:187970273~187971284:+
THCA	cis	rs10492201	0.529	rs10878724	ENSG00000255733.4	IFNG-AS1	-3.93	9.84e-05	0.0077	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006091	chr12:67989445~68234686:+
THCA	cis	rs875971	0.66	rs79009421	ENSG00000229180.5	GS1-124K5.11	-3.93	9.84e-05	0.0077	-0.12	-0.18	Aortic root size;	chr7:66603522	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs7807944	ENSG00000229180.5	GS1-124K5.11	-3.93	9.84e-05	0.0077	-0.12	-0.18	Aortic root size;	chr7:66622208	chr7:66526088~66542624:-
THCA	cis	rs875971	0.638	rs35986979	ENSG00000229180.5	GS1-124K5.11	-3.93	9.84e-05	0.0077	-0.12	-0.18	Aortic root size;	chr7:66624003	chr7:66526088~66542624:-
THCA	cis	rs16944613	0.588	rs6496698	ENSG00000259212.1	CTD-3065B20.2	3.93	9.84e-05	0.0077	0.28	0.18	Colorectal cancer;	chr15:90592326	chr15:90595840~90596447:-
THCA	cis	rs5758511	0.68	rs17002902	ENSG00000230107.1	CTA-126B4.7	-3.93	9.85e-05	0.0077	-0.22	-0.18	Birth weight;	chr22:42229503	chr22:42438023~42446195:+
THCA	cis	rs3849570	0.588	rs57623955	ENSG00000241593.4	RP11-520D19.2	-3.93	9.85e-05	0.0077	-0.24	-0.18	Waist circumference;Body mass index;	chr3:81549839	chr3:81246579~81297345:-
THCA	cis	rs1232027	1	rs865646	ENSG00000249655.1	CTC-325J23.2	3.93	9.85e-05	0.0077	0.2	0.18	Huntington's disease progression;	chr5:80646538	chr5:80630313~80631590:-
THCA	cis	rs9329221	0.741	rs13264066	ENSG00000233609.3	RP11-62H7.2	-3.93	9.85e-05	0.0077	-0.18	-0.18	Neuroticism;	chr8:9946565	chr8:8961200~8979025:+
THCA	cis	rs440932	0.887	rs398801	ENSG00000248538.5	RP11-10A14.5	3.93	9.85e-05	0.0077	0.22	0.18	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:9189011~9202854:+
THCA	cis	rs1577917	0.917	rs2218594	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85834048	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs2197648	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85834169	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs2100109	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85835208	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs1447160	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85836405	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs12198061	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85841267	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs1838955	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85855731	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs2084294	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85856225	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.876	rs11752223	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85863676	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs12660846	ENSG00000220563.1	PKMP3	-3.93	9.85e-05	0.00771	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85864091	chr6:85659892~85660606:-
THCA	cis	rs6479891	1	rs2893922	ENSG00000272767.1	JMJD1C-AS1	-3.93	9.85e-05	0.00771	-0.24	-0.18	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63465229~63466563:+
THCA	cis	rs10833905	0.818	rs4430508	ENSG00000246225.5	RP11-17A1.3	-3.93	9.85e-05	0.00771	-0.25	-0.18	Sudden cardiac arrest;	chr11:23045957	chr11:22829380~22945393:+
THCA	cis	rs11583043	0.546	rs35363849	ENSG00000233184.5	RP11-421L21.3	3.93	9.85e-05	0.00771	0.19	0.18	Inflammatory bowel disease;Ulcerative colitis;	chr1:101125737	chr1:101025878~101087268:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000230295.1	RP11-458F8.2	3.93	9.85e-05	0.00771	0.14	0.18	Aortic root size;	chr7:66589419	chr7:66880708~66882981:+
THCA	cis	rs901683	1	rs35047800	ENSG00000230869.1	CTGLF10P	-3.93	9.85e-05	0.00771	-0.42	-0.18	Mean corpuscular volume;Red blood cell traits;	chr10:45593599	chr10:45678692~45700532:+
THCA	cis	rs7927592	0.513	rs7950129	ENSG00000160172.9	FAM86C2P	3.93	9.85e-05	0.00771	0.17	0.18	Total body bone mineral density;	chr11:68435435	chr11:67791648~67805336:-
THCA	cis	rs13256369	0.951	rs10503394	ENSG00000254153.1	CTA-398F10.2	-3.93	9.85e-05	0.00771	-0.2	-0.18	Obesity-related traits;	chr8:8708265	chr8:8456909~8461337:-
THCA	cis	rs57709857	0.915	rs11777067	ENSG00000272092.1	RP11-350N15.5	3.93	9.85e-05	0.00771	0.19	0.18	Autism spectrum disorder or schizophrenia;	chr8:38441129	chr8:38382364~38383461:+
THCA	cis	rs11681884	0.786	rs28928270	ENSG00000272563.1	RP11-480C16.1	-3.93	9.85e-05	0.00771	-0.4	-0.18	Stroke;	chr2:113068646	chr2:113432600~113436042:+
THCA	cis	rs4950322	0.58	rs7514970	ENSG00000180867.10	PDIA3P1	3.93	9.85e-05	0.00771	0.17	0.18	Protein quantitative trait loci;	chr1:147120516	chr1:147178113~147179622:+
THCA	cis	rs7264396	0.887	rs2236159	ENSG00000088340.14	FER1L4	3.93	9.85e-05	0.00771	0.16	0.18	Total cholesterol levels;	chr20:35514360	chr20:35558737~35607562:-
THCA	cis	rs9435732	1	rs2076600	ENSG00000235241.1	RP11-108M9.5	3.93	9.85e-05	0.00771	0.2	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17010896	chr1:16889095~16889602:+
THCA	cis	rs7914558	0.646	rs7897654	ENSG00000213277.3	MARCKSL1P1	3.93	9.86e-05	0.00771	0.19	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902701	chr10:103175554~103176094:+
THCA	cis	rs17695224	0.675	rs10405314	ENSG00000275055.1	CTC-471J1.11	-3.93	9.86e-05	0.00771	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51839450	chr19:52049007~52049754:+
THCA	cis	rs3105593	0.933	rs3109882	ENSG00000242737.1	RP11-562A8.1	3.93	9.86e-05	0.00771	0.22	0.18	QT interval;	chr15:50547860	chr15:50466738~50467096:+
THCA	cis	rs151234	0.676	rs508022	ENSG00000259982.1	CDC37P1	-3.93	9.86e-05	0.00771	-0.36	-0.18	Platelet distribution width;	chr16:28562642	chr16:28700294~28701540:-
THCA	cis	rs7772697	0.508	rs9498197	ENSG00000223701.3	RAET1E-AS1	-3.93	9.86e-05	0.00771	-0.26	-0.18	Diabetic retinopathy;	chr6:149042549	chr6:149884431~149919508:+
THCA	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	3.93	9.86e-05	0.00771	0.19	0.18	Asthma;	chr2:102423717	chr2:102438713~102440475:+
THCA	cis	rs453301	0.653	rs7853	ENSG00000253981.4	ALG1L13P	3.93	9.86e-05	0.00771	0.16	0.18	Joint mobility (Beighton score);	chr8:9033304	chr8:8236003~8244667:-
THCA	cis	rs2933343	0.7	rs1680778	ENSG00000231305.3	RP11-723O4.2	3.93	9.86e-05	0.00771	0.19	0.18	IgG glycosylation;	chr3:128895342	chr3:128861313~128871540:-
THCA	cis	rs894638	1	rs78136291	ENSG00000263327.5	TAPT1-AS1	-3.93	9.86e-05	0.00771	-0.22	-0.18	Glomerular filtration rate in chronic kidney disease;	chr4:16114213	chr4:16226685~16320140:+
THCA	cis	rs7824557	0.527	rs11785394	ENSG00000154316.13	TDH	3.93	9.86e-05	0.00771	0.13	0.18	Retinal vascular caliber;	chr8:11380520	chr8:11339637~11368452:+
THCA	cis	rs1150668	0.699	rs13408	ENSG00000280107.1	AL022393.9	-3.93	9.86e-05	0.00771	-0.17	-0.18	Pubertal anthropometrics;	chr6:28244970	chr6:28170845~28172521:+
THCA	cis	rs765787	0.505	rs1648302	ENSG00000259539.1	CTD-2651B20.1	3.93	9.86e-05	0.00772	0.22	0.18	Uric acid levels;	chr15:45202040	chr15:45152664~45167526:-
THCA	cis	rs7267979	0.706	rs6138542	ENSG00000274973.1	RP13-401N8.7	-3.93	9.86e-05	0.00772	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25845497~25845862:+
THCA	cis	rs12681366	0.708	rs1011249	ENSG00000261437.1	RP11-22C11.2	3.93	9.86e-05	0.00772	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94425833	chr8:94637285~94639467:-
THCA	cis	rs3824488	0.79	rs28372566	ENSG00000271155.1	RP11-435O5.5	-3.93	9.87e-05	0.00772	-0.28	-0.18	Neuroticism;	chr9:95482696	chr9:95506235~95507636:+
THCA	cis	rs804280	1	rs804280	ENSG00000206014.6	OR7E161P	-3.93	9.87e-05	0.00772	-0.21	-0.18	Myopia (pathological);	chr8:11755189	chr8:11928597~11929563:-
THCA	cis	rs7911264	0.739	rs4933734	ENSG00000236493.2	EIF2S2P3	3.93	9.87e-05	0.00772	0.19	0.18	Inflammatory bowel disease;	chr10:92654810	chr10:92668745~92669743:-
THCA	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	3.93	9.87e-05	0.00772	0.21	0.18	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
THCA	cis	rs7552393	0.93	rs761405	ENSG00000233008.4	RP11-475O6.1	-3.93	9.87e-05	0.00772	-0.19	-0.18	Select biomarker traits;	chr1:83799892	chr1:83575776~83861023:-
THCA	cis	rs10802047	0.509	rs1779414	ENSG00000231365.4	RP11-418J17.1	3.93	9.87e-05	0.00772	0.18	0.18	Relative hand skill in reading disability;	chr1:118839604	chr1:119140396~119275973:+
THCA	cis	rs1908814	0.516	rs7812563	ENSG00000254948.1	OR7E158P	-3.93	9.87e-05	0.00772	-0.22	-0.18	Neuroticism;	chr8:11936979	chr8:11919900~11920809:-
THCA	cis	rs7819412	0.875	rs11250121	ENSG00000261451.1	RP11-981G7.1	-3.93	9.87e-05	0.00772	-0.23	-0.18	Triglycerides;	chr8:11202802	chr8:10433672~10438312:+
THCA	cis	rs2191566	0.639	rs7260075	ENSG00000266921.1	RP11-15A1.7	-3.93	9.87e-05	0.00772	-0.17	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44062613	chr19:43996896~44002836:-
THCA	cis	rs4845570	0.92	rs10788809	ENSG00000249602.1	RP11-98D18.3	3.93	9.87e-05	0.00772	0.26	0.18	Coronary artery disease;	chr1:151788316	chr1:151763384~151769501:-
THCA	cis	rs7617480	0.616	rs7429596	ENSG00000229759.1	MRPS18AP1	3.93	9.87e-05	0.00772	0.28	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48771098	chr3:48256350~48256938:-
THCA	cis	rs9611565	0.571	rs2050032	ENSG00000237037.8	NDUFA6-AS1	-3.93	9.87e-05	0.00772	-0.16	-0.18	Vitiligo;	chr22:41756425	chr22:42090931~42137742:+
THCA	cis	rs12612619	0.689	rs6711384	ENSG00000229122.1	AGBL5-IT1	3.93	9.87e-05	0.00772	0.14	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057224	chr2:27061038~27061815:+
THCA	cis	rs448720	1	rs448720	ENSG00000260657.2	RP11-315D16.4	-3.93	9.87e-05	0.00772	-0.22	-0.18	Cognitive performance;	chr15:67906573	chr15:68267792~68277994:-
THCA	cis	rs42648	0.748	rs10227385	ENSG00000225498.1	AC002064.5	3.93	9.87e-05	0.00772	0.19	0.18	Homocysteine levels;	chr7:90261054	chr7:90312496~90322592:+
THCA	cis	rs2732480	0.557	rs2732441	ENSG00000257735.1	RP11-370I10.6	3.93	9.88e-05	0.00772	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.577	rs2732448	ENSG00000257735.1	RP11-370I10.6	3.93	9.88e-05	0.00772	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.577	rs2732466	ENSG00000257735.1	RP11-370I10.6	3.93	9.88e-05	0.00772	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.557	rs2634682	ENSG00000257735.1	RP11-370I10.6	3.93	9.88e-05	0.00772	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48350945~48442411:+
THCA	cis	rs5751614	1	rs5759664	ENSG00000240160.3	RN7SL263P	3.93	9.88e-05	0.00772	0.2	0.18	Height;	chr22:23249536	chr22:23261782~23262071:-
THCA	cis	rs1923539	0.713	rs2265960	ENSG00000225484.5	NUTM2B-AS1	3.93	9.88e-05	0.00772	0.22	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969830	chr10:79663088~79826594:-
THCA	cis	rs1371614	0.655	rs4665927	ENSG00000229122.1	AGBL5-IT1	-3.93	9.88e-05	0.00773	-0.13	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26926498	chr2:27061038~27061815:+
THCA	cis	rs6993244	1	rs6993244	ENSG00000233609.3	RP11-62H7.2	3.93	9.88e-05	0.00773	0.17	0.18	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8961200~8979025:+
THCA	cis	rs550448	0.853	rs849329	ENSG00000234336.5	JAZF1-AS1	-3.93	9.88e-05	0.00773	-0.29	-0.18	Type 1 diabetes;	chr7:28194980	chr7:28180322~28243917:+
THCA	cis	rs56309584	0.715	rs74252612	ENSG00000271002.1	RP11-599B13.8	-3.93	9.88e-05	0.00773	-0.28	-0.18	Initial pursuit acceleration;	chr17:8238782	chr17:8199123~8199437:-
THCA	cis	rs1005277	0.505	rs10827836	ENSG00000120555.12	SEPT7P9	-3.93	9.88e-05	0.00773	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38383069~38402916:-
THCA	cis	rs6416877	0.921	rs8069990	ENSG00000277491.1	RP11-676J12.9	-3.93	9.88e-05	0.00773	-0.22	-0.18	Myeloid white cell count;	chr17:1428090	chr17:795306~795794:+
THCA	cis	rs62244186	0.683	rs6766334	ENSG00000214820.3	MPRIPP1	3.93	9.89e-05	0.00773	0.19	0.18	Depressive symptoms;	chr3:44525573	chr3:44579938~44581026:-
THCA	cis	rs2974760	0.606	rs6600143	ENSG00000268836.1	LA16c-OS12.2	-3.93	9.89e-05	0.00773	-0.18	-0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151390	chr16:185748~186294:-
THCA	cis	rs6479891	0.73	rs16918600	ENSG00000272767.1	JMJD1C-AS1	3.93	9.89e-05	0.00773	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63465229~63466563:+
THCA	cis	rs6479891	0.915	rs11812934	ENSG00000272767.1	JMJD1C-AS1	3.93	9.89e-05	0.00773	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63465229~63466563:+
THCA	cis	rs7855088	0.789	rs10116946	ENSG00000236130.1	PTCSC2	-3.93	9.89e-05	0.00773	-0.15	-0.18	Serum thyroid-stimulating hormone levels;	chr9:97977551	chr9:97805935~97810008:-
THCA	cis	rs7131987	0.903	rs11050163	ENSG00000275476.1	RP11-996F15.4	-3.93	9.89e-05	0.00773	-0.17	-0.18	QT interval;	chr12:29267465	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.903	rs10843373	ENSG00000275476.1	RP11-996F15.4	-3.93	9.89e-05	0.00773	-0.17	-0.18	QT interval;	chr12:29267675	chr12:29277397~29277882:-
THCA	cis	rs962856	0.619	rs7592026	ENSG00000236780.4	AC078941.1	-3.93	9.89e-05	0.00773	-0.24	-0.18	Pancreatic cancer;	chr2:67368007	chr2:67123357~67215319:-
THCA	cis	rs9393813	0.528	rs6899950	ENSG00000271755.1	RP1-153G14.4	3.93	9.89e-05	0.00773	0.21	0.18	Bipolar disorder;	chr6:27466216	chr6:27404010~27406964:-
THCA	cis	rs7432375	0.901	rs4408829	ENSG00000273455.1	RP11-305O4.3	-3.93	9.89e-05	0.00773	-0.24	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136685841	chr3:136087475~136087913:-
THCA	cis	rs7551222	0.634	rs12139477	ENSG00000240219.1	RP11-430C7.5	3.93	9.89e-05	0.00773	0.17	0.18	Schizophrenia;	chr1:204583976	chr1:204626775~204629712:+
THCA	cis	rs1040393	0.556	rs7520099	ENSG00000225171.2	DUTP6	-3.93	9.89e-05	0.00773	-0.29	-0.18	Schizophrenia;	chr1:167007646	chr1:166868748~166869209:+
THCA	cis	rs3015497	0.587	rs1353204	ENSG00000270062.1	RP11-248J18.3	3.93	9.89e-05	0.00773	0.2	0.18	Mean platelet volume;	chr14:50614797	chr14:50723777~50724272:-
THCA	cis	rs801193	1	rs4717319	ENSG00000275400.1	RP4-756H11.5	-3.93	9.89e-05	0.00773	-0.17	-0.18	Aortic root size;	chr7:66777606	chr7:66553805~66554199:-
THCA	cis	rs801193	0.904	rs4718403	ENSG00000275400.1	RP4-756H11.5	-3.93	9.89e-05	0.00773	-0.17	-0.18	Aortic root size;	chr7:66777742	chr7:66553805~66554199:-
THCA	cis	rs7809950	0.678	rs2107317	ENSG00000272072.1	CTA-363E19.2	3.93	9.89e-05	0.00774	0.19	0.18	Coronary artery disease;	chr7:107259240	chr7:107192559~107193300:-
THCA	cis	rs758324	0.661	rs27349	ENSG00000224431.1	AC063976.7	-3.93	9.89e-05	0.00774	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132078029	chr5:132199456~132203487:+
THCA	cis	rs3096299	0.667	rs2965947	ENSG00000261118.1	RP11-104N10.1	3.93	9.89e-05	0.00774	0.15	0.18	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89492017~89504460:-
THCA	cis	rs321358	1	rs73019214	ENSG00000271390.1	RP11-89C3.3	3.93	9.89e-05	0.00774	0.3	0.18	Body mass index;	chr11:111131680	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs419633	ENSG00000271390.1	RP11-89C3.3	3.93	9.89e-05	0.00774	0.3	0.18	Body mass index;	chr11:111132187	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs429803	ENSG00000271390.1	RP11-89C3.3	3.93	9.89e-05	0.00774	0.3	0.18	Body mass index;	chr11:111132263	chr11:111089870~111090368:-
THCA	cis	rs321358	0.943	rs402820	ENSG00000271390.1	RP11-89C3.3	3.93	9.89e-05	0.00774	0.3	0.18	Body mass index;	chr11:111132480	chr11:111089870~111090368:-
THCA	cis	rs7580717	0.54	rs62197320	ENSG00000224376.1	AC017104.6	3.93	9.89e-05	0.00774	0.18	0.18	Multiple myeloma;	chr2:231195652	chr2:231388976~231394991:+
THCA	cis	rs7824557	0.688	rs2572397	ENSG00000261451.1	RP11-981G7.1	3.93	9.9e-05	0.00774	0.22	0.18	Retinal vascular caliber;	chr8:11318894	chr8:10433672~10438312:+
THCA	cis	rs4272720	0.666	rs7896344	ENSG00000234736.4	FAM170B-AS1	-3.93	9.9e-05	0.00774	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49052831	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.666	rs9804403	ENSG00000234736.4	FAM170B-AS1	-3.93	9.9e-05	0.00774	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49054099	chr10:49121839~49151547:+
THCA	cis	rs8031584	0.958	rs34909055	ENSG00000178081.11	ULK4P3	3.93	9.9e-05	0.00774	0.23	0.18	Huntington's disease progression;	chr15:30991967	chr15:30103720~30131757:+
THCA	cis	rs4908768	0.859	rs12131717	ENSG00000232912.4	RP5-1115A15.1	-3.93	9.9e-05	0.00774	-0.21	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8658026	chr1:8424645~8434838:+
THCA	cis	rs5758659	0.714	rs5758574	ENSG00000205702.9	CYP2D7	-3.93	9.9e-05	0.00774	-0.13	-0.18	Cognitive function;	chr22:42085396	chr22:42140203~42144577:-
THCA	cis	rs7616559	0.924	rs1482860	ENSG00000244515.1	KRT18P34	-3.93	9.9e-05	0.00774	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157012960	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.962	rs1482863	ENSG00000244515.1	KRT18P34	-3.93	9.9e-05	0.00774	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157013855	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.962	rs9840284	ENSG00000244515.1	KRT18P34	-3.93	9.9e-05	0.00774	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157016430	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.924	rs6779199	ENSG00000244515.1	KRT18P34	-3.93	9.9e-05	0.00774	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157019112	chr3:157162663~157163932:-
THCA	cis	rs7616559	0.962	rs9839037	ENSG00000244515.1	KRT18P34	-3.93	9.9e-05	0.00774	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157021636	chr3:157162663~157163932:-
THCA	cis	rs3738443	0.951	rs61840467	ENSG00000259865.1	RP11-488L18.10	3.93	9.9e-05	0.00774	0.19	0.18	Alcohol dependence;	chr1:247216936	chr1:247187281~247188526:-
THCA	cis	rs71520386	0.632	rs1029738	ENSG00000226329.2	AC005682.6	-3.93	9.9e-05	0.00774	-0.23	-0.18	Fibrinogen levels;	chr7:22834428	chr7:22863874~22881350:-
THCA	cis	rs2549003	1	rs2548999	ENSG00000237714.1	P4HA2-AS1	3.93	9.9e-05	0.00774	0.22	0.18	Asthma (sex interaction);	chr5:132495366	chr5:132184876~132192808:+
THCA	cis	rs11771526	0.901	rs10252303	ENSG00000272905.1	RP11-265E18.1	3.93	9.9e-05	0.00774	0.24	0.18	Body mass index;	chr7:32264826	chr7:32845394~32846061:+
THCA	cis	rs564799	0.871	rs1874886	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160011868	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs587422	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160012018	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs483714	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160012090	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs484600	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160012174	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs600519	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160012630	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs6808498	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160012892	chr3:159913400~160225299:-
THCA	cis	rs564799	0.931	rs6771363	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160012895	chr3:159913400~160225299:-
THCA	cis	rs564799	0.931	rs6808518	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160012951	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs2914116	ENSG00000244040.4	IL12A-AS1	3.93	9.9e-05	0.00774	0.23	0.18	Systemic lupus erythematosus;	chr3:160013513	chr3:159913400~160225299:-
THCA	cis	rs2692947	0.77	rs11689832	ENSG00000235584.2	AC008268.1	-3.93	9.91e-05	0.00775	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95889103	chr2:95666084~95668715:+
THCA	cis	rs1440072	0.702	rs11690197	ENSG00000228802.1	AC073641.2	-3.93	9.91e-05	0.00775	-0.37	-0.18	Waist circumference;Body mass index;	chr2:223031844	chr2:223965701~223967706:-
THCA	cis	rs858239	0.665	rs6964665	ENSG00000230042.1	AK3P3	-3.93	9.91e-05	0.00775	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23129178~23129841:+
THCA	cis	rs6840360	0.571	rs12650655	ENSG00000251611.1	RP11-610P16.1	-3.93	9.91e-05	0.00775	-0.14	-0.18	Intelligence (multi-trait analysis);	chr4:151634923	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs7685697	ENSG00000251611.1	RP11-610P16.1	-3.93	9.91e-05	0.00775	-0.14	-0.18	Intelligence (multi-trait analysis);	chr4:151637697	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.593	rs10022023	ENSG00000251611.1	RP11-610P16.1	-3.93	9.91e-05	0.00775	-0.14	-0.18	Intelligence (multi-trait analysis);	chr4:151639579	chr4:151407551~151408835:-
THCA	cis	rs875971	0.545	rs4718325	ENSG00000273142.1	RP11-458F8.4	3.93	9.91e-05	0.00775	0.17	0.18	Aortic root size;	chr7:66215323	chr7:66902857~66906297:+
THCA	cis	rs2380205	0.517	rs12781700	ENSG00000232807.2	RP11-536K7.3	3.93	9.91e-05	0.00775	0.18	0.18	Breast cancer;	chr10:5894462	chr10:5934270~5945900:-
THCA	cis	rs61677309	1	rs12577045	ENSG00000278376.1	RP11-158I9.8	3.93	9.91e-05	0.00775	0.14	0.18	Lung cancer in ever smokers;	chr11:118280731	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs67774926	ENSG00000278376.1	RP11-158I9.8	3.93	9.91e-05	0.00775	0.14	0.18	Lung cancer in ever smokers;	chr11:118286908	chr11:118791254~118793137:+
THCA	cis	rs56104184	0.83	rs17272645	ENSG00000243829.1	CTB-33G10.1	3.93	9.91e-05	0.00775	0.22	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48839109	chr19:49719498~49720081:-
THCA	cis	rs6832769	0.767	rs6850524	ENSG00000223305.1	RN7SKP30	3.93	9.91e-05	0.00775	0.23	0.18	Personality dimensions;	chr4:55515830	chr4:55540502~55540835:-
THCA	cis	rs6847067	0.929	rs1484660	ENSG00000180769.7	WDFY3-AS2	3.93	9.91e-05	0.00775	0.13	0.18	Oropharynx cancer;	chr4:84861028	chr4:84965682~85011277:+
THCA	cis	rs214785	1	rs214784	ENSG00000226644.4	RP11-128M1.1	3.93	9.91e-05	0.00775	0.18	0.18	Basal cell carcinoma;	chr20:2302019	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214785	ENSG00000226644.4	RP11-128M1.1	3.93	9.91e-05	0.00775	0.18	0.18	Basal cell carcinoma;	chr20:2302811	chr20:2207217~2213151:+
THCA	cis	rs74233809	1	rs11191580	ENSG00000272912.1	RP11-724N1.1	3.93	9.91e-05	0.00775	0.33	0.18	Birth weight;	chr10:103146454	chr10:102914585~102915404:+
THCA	cis	rs150992	0.609	rs393697	ENSG00000246763.5	RGMB-AS1	3.93	9.91e-05	0.00775	0.18	0.18	Body mass index;	chr5:98991357	chr5:98769618~98773469:-
THCA	cis	rs7474896	0.515	rs2738203	ENSG00000120555.12	SEPT7P9	-3.93	9.91e-05	0.00775	-0.24	-0.18	Obesity (extreme);	chr10:37988668	chr10:38383069~38402916:-
THCA	cis	rs11673344	0.582	rs114437741	ENSG00000267260.1	CTD-2162K18.4	-3.93	9.91e-05	0.00775	-0.22	-0.18	Obesity-related traits;	chr19:36955379	chr19:36773153~36777078:+
THCA	cis	rs962856	0.866	rs13387185	ENSG00000236780.4	AC078941.1	3.93	9.92e-05	0.00775	0.22	0.18	Pancreatic cancer;	chr2:67401517	chr2:67123357~67215319:-
THCA	cis	rs875971	0.545	rs316328	ENSG00000232559.3	GS1-124K5.12	-3.93	9.92e-05	0.00775	-0.18	-0.18	Aortic root size;	chr7:66143851	chr7:66554588~66576923:-
THCA	cis	rs1153858	1	rs59889118	ENSG00000275672.1	GATM-AS1	-3.93	9.92e-05	0.00775	-0.19	-0.18	Homoarginine levels;	chr15:45326532	chr15:45378700~45380123:+
THCA	cis	rs9796	0.621	rs9972349	ENSG00000247556.5	OIP5-AS1	3.93	9.92e-05	0.00775	0.14	0.18	Menopause (age at onset);	chr15:41199458	chr15:41283990~41309737:+
THCA	cis	rs34421088	0.56	rs11780851	ENSG00000206014.6	OR7E161P	3.93	9.92e-05	0.00775	0.21	0.18	Neuroticism;	chr8:11543607	chr8:11928597~11929563:-
THCA	cis	rs10938353	0.68	rs12645110	ENSG00000273369.1	RP11-700J17.1	3.93	9.92e-05	0.00775	0.21	0.18	Body mass index;	chr4:44667706	chr4:44693946~44694386:-
THCA	cis	rs11971779	0.68	rs10271297	ENSG00000252332.1	RNU6-911P	-3.93	9.92e-05	0.00775	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139367564	chr7:139448740~139448843:+
THCA	cis	rs893363	0.621	rs14165	ENSG00000271916.1	RP11-884K10.6	-3.93	9.92e-05	0.00775	-0.21	-0.18	Axial length;	chr3:53813381	chr3:53797764~53798019:-
THCA	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-3.93	9.92e-05	0.00776	-0.2	-0.18	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-3.93	9.92e-05	0.00776	-0.2	-0.18	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
THCA	cis	rs4780401	0.933	rs7203803	ENSG00000274038.1	RP11-66H6.4	3.93	9.92e-05	0.00776	0.21	0.18	Rheumatoid arthritis;	chr16:11718435	chr16:11056556~11057034:+
THCA	cis	rs17095355	1	rs734165	ENSG00000203876.8	ADD3-AS1	-3.93	9.92e-05	0.00776	-0.2	-0.18	Biliary atresia;	chr10:109938031	chr10:109940104~110008381:-
THCA	cis	rs11992162	0.55	rs61426048	ENSG00000254948.1	OR7E158P	3.93	9.92e-05	0.00776	0.22	0.18	Monocyte count;	chr8:11927447	chr8:11919900~11920809:-
THCA	cis	rs9634489	0.502	rs7336870	ENSG00000247400.3	DNAJC3-AS1	-3.93	9.93e-05	0.00776	-0.12	-0.18	Body mass index;	chr13:96432423	chr13:95648733~95676925:-
THCA	cis	rs2919009	0.602	rs7906342	ENSG00000271670.1	RP11-95I16.4	3.93	9.93e-05	0.00776	0.19	0.18	Obesity-related traits;	chr10:120923654	chr10:120879256~120880667:-
THCA	cis	rs752590	0.666	rs6542125	ENSG00000227359.1	AC017074.2	3.93	9.93e-05	0.00776	0.27	0.18	Mucinous ovarian carcinoma;	chr2:113261249	chr2:113677702~113704078:-
THCA	cis	rs752590	0.614	rs6758928	ENSG00000227359.1	AC017074.2	3.93	9.93e-05	0.00776	0.27	0.18	Mucinous ovarian carcinoma;	chr2:113261773	chr2:113677702~113704078:-
THCA	cis	rs8070624	0.543	rs7219320	ENSG00000281749.1	Y_RNA	3.93	9.93e-05	0.00776	0.23	0.18	Total body bone mineral density;	chr17:17977563	chr17:18001101~18001195:-
THCA	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-3.93	9.93e-05	0.00776	-0.2	-0.18	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
THCA	cis	rs1267303	0.6	rs57100184	ENSG00000232022.5	FAAHP1	3.93	9.93e-05	0.00776	0.22	0.18	Monobrow;	chr1:46539038	chr1:46432129~46445521:+
THCA	cis	rs3845817	0.67	rs840787	ENSG00000237979.1	AC007389.1	3.93	9.93e-05	0.00776	0.21	0.18	Bipolar disorder;	chr2:65548756	chr2:65500993~65502138:-
THCA	cis	rs3742597	0.84	rs60488013	ENSG00000276116.2	FUT8-AS1	-3.93	9.93e-05	0.00776	-0.21	-0.18	N-glycan levels;	chr14:65359136	chr14:65411170~65412690:-
THCA	cis	rs6995541	0.606	rs7829089	ENSG00000248896.2	CTD-2135J3.3	-3.93	9.94e-05	0.00777	-0.22	-0.18	Triglyceride levels;	chr8:10826629	chr8:10729314~10771392:+
THCA	cis	rs1005277	0.505	rs13503	ENSG00000120555.12	SEPT7P9	-3.93	9.94e-05	0.00777	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38383069~38402916:-
THCA	cis	rs6472827	0.953	rs2936686	ENSG00000253983.2	RP1-16A9.1	3.93	9.94e-05	0.00777	0.3	0.18	Uterine fibroids;	chr8:74203974	chr8:74199396~74208441:+
THCA	cis	rs2562456	0.917	rs2562466	ENSG00000268278.1	RP11-420K14.1	-3.93	9.94e-05	0.00777	-0.21	-0.18	Pain;	chr19:21531402	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.917	rs2562468	ENSG00000268278.1	RP11-420K14.1	-3.93	9.94e-05	0.00777	-0.21	-0.18	Pain;	chr19:21532048	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.917	rs2562471	ENSG00000268278.1	RP11-420K14.1	-3.93	9.94e-05	0.00777	-0.21	-0.18	Pain;	chr19:21533017	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.917	rs2681377	ENSG00000268278.1	RP11-420K14.1	-3.93	9.94e-05	0.00777	-0.21	-0.18	Pain;	chr19:21533718	chr19:21637974~21656300:+
THCA	cis	rs1979679	0.766	rs7299798	ENSG00000278733.1	RP11-425D17.1	-3.93	9.94e-05	0.00777	-0.18	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28559224	chr12:28185625~28186190:-
THCA	cis	rs1979679	0.766	rs10843202	ENSG00000278733.1	RP11-425D17.1	-3.93	9.94e-05	0.00777	-0.18	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28563111	chr12:28185625~28186190:-
THCA	cis	rs1389724	0.632	rs4839566	ENSG00000259834.1	RP11-284N8.3	3.93	9.94e-05	0.00777	0.15	0.18	Schizophrenia;	chr1:110788378	chr1:110653560~110657040:-
THCA	cis	rs4262150	0.883	rs72799157	ENSG00000253921.1	CTB-113P19.3	3.93	9.94e-05	0.00777	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152739856	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.846	rs72799160	ENSG00000253921.1	CTB-113P19.3	3.93	9.94e-05	0.00777	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152749963	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.846	rs72799161	ENSG00000253921.1	CTB-113P19.3	3.93	9.94e-05	0.00777	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152750047	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.846	rs72799163	ENSG00000253921.1	CTB-113P19.3	3.93	9.94e-05	0.00777	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152752557	chr5:151753992~151767247:+
THCA	cis	rs3782089	0.744	rs11545200	ENSG00000214659.4	KRT8P26	-3.93	9.94e-05	0.00777	-0.32	-0.18	Height;	chr11:65552280	chr11:65726939~65728214:+
THCA	cis	rs321358	0.895	rs73015151	ENSG00000271390.1	RP11-89C3.3	3.93	9.94e-05	0.00777	0.28	0.18	Body mass index;	chr11:111084669	chr11:111089870~111090368:-
THCA	cis	rs321358	0.895	rs17535886	ENSG00000271390.1	RP11-89C3.3	3.93	9.94e-05	0.00777	0.28	0.18	Body mass index;	chr11:111084852	chr11:111089870~111090368:-
THCA	cis	rs964611	1	rs964611	ENSG00000259488.2	RP11-154J22.1	-3.93	9.94e-05	0.00777	-0.18	-0.18	Metabolite levels (Pyroglutamine);	chr15:48305317	chr15:48312353~48331856:-
THCA	cis	rs1336149	0.527	rs72700743	ENSG00000211581.1	MIR765	3.93	9.94e-05	0.00777	0.23	0.18	Chin dimples;	chr1:157045172	chr1:156936131~156936244:-
THCA	cis	rs17818399	0.51	rs12105801	ENSG00000279254.1	RP11-536C12.1	-3.93	9.94e-05	0.00777	-0.17	-0.18	Height;	chr2:46572204	chr2:46668870~46670778:+
THCA	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	3.93	9.94e-05	0.00777	0.21	0.18	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
THCA	cis	rs7772486	0.79	rs9497431	ENSG00000270638.1	RP3-466P17.1	-3.93	9.94e-05	0.00777	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.79	rs7753092	ENSG00000270638.1	RP3-466P17.1	-3.93	9.94e-05	0.00777	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145735570~145737218:+
THCA	cis	rs4792901	0.765	rs35557239	ENSG00000267151.3	RP11-100E5.2	3.93	9.94e-05	0.00777	0.2	0.18	Dupuytren's disease;	chr17:43470907	chr17:43444707~43451200:+
THCA	cis	rs548181	0.736	rs540436	ENSG00000254671.2	STT3A-AS1	-3.93	9.94e-05	0.00777	-0.33	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125642724	chr11:125570284~125592568:-
THCA	cis	rs801193	1	rs1553610	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66732246	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs2707845	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66733811	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs2707850	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66738883	chr7:66553805~66554199:-
THCA	cis	rs801193	0.967	rs1110414	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66740595	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs7783924	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66744070	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs7789184	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66745208	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs2707854	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66747610	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs3800812	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66758474	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs4279493	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66761633	chr7:66553805~66554199:-
THCA	cis	rs801193	0.761	rs2659888	ENSG00000275400.1	RP4-756H11.5	-3.93	9.94e-05	0.00777	-0.17	-0.18	Aortic root size;	chr7:66765184	chr7:66553805~66554199:-
THCA	cis	rs1842579	0.93	rs12760458	ENSG00000272691.1	RP11-290M5.4	-3.93	9.95e-05	0.00777	-0.17	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85834762	chr1:85578500~85578742:-
THCA	cis	rs1842579	1	rs12077825	ENSG00000272691.1	RP11-290M5.4	-3.93	9.95e-05	0.00777	-0.17	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85834845	chr1:85578500~85578742:-
THCA	cis	rs1842579	1	rs12098168	ENSG00000272691.1	RP11-290M5.4	-3.93	9.95e-05	0.00777	-0.17	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85834894	chr1:85578500~85578742:-
THCA	cis	rs7968440	1	rs7307815	ENSG00000272368.2	RP4-605O3.4	3.93	9.95e-05	0.00777	0.11	0.18	Fibrinogen;	chr12:50528927	chr12:50112197~50165618:+
THCA	cis	rs7924176	0.521	rs10762599	ENSG00000232342.6	RP11-46O21.2	3.93	9.95e-05	0.00777	0.23	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:74506081~74530553:-
THCA	cis	rs755249	0.508	rs6703800	ENSG00000228060.1	RP11-69E11.8	3.93	9.95e-05	0.00777	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39160970	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.724	rs12117785	ENSG00000228060.1	RP11-69E11.8	3.93	9.95e-05	0.00777	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39162739	chr1:39565160~39573203:+
THCA	cis	rs2289700	1	rs16970287	ENSG00000252061.1	RNU6-415P	-3.93	9.95e-05	0.00777	-0.35	-0.18	Bipolar disorder;	chr15:78935915	chr15:78898840~78898936:-
THCA	cis	rs800160	0.545	rs2521289	ENSG00000236264.4	RPL26P30	3.93	9.95e-05	0.00777	0.24	0.18	Bacteremia;	chr11:2321786	chr11:2335132~2335776:-
THCA	cis	rs2676071	0.638	rs2251110	ENSG00000259721.1	RP11-758N13.1	3.93	9.95e-05	0.00778	0.2	0.18	Periodontitis (Mean PAL);	chr15:33306336	chr15:32717270~32719007:-
THCA	cis	rs737008	0.96	rs34764020	ENSG00000263080.1	RP11-485G7.5	-3.93	9.95e-05	0.00778	-0.21	-0.18	Obesity-related traits;	chr16:11284502	chr16:11341809~11345211:-
THCA	cis	rs4578769	0.569	rs3851822	ENSG00000273232.1	RP11-370A5.2	-3.93	9.95e-05	0.00778	-0.24	-0.18	Eosinophil percentage of white cells;	chr18:22882829	chr18:22882825~22883357:-
THCA	cis	rs4443100	0.916	rs2078727	ENSG00000230701.2	FBXW4P1	3.93	9.95e-05	0.00778	0.21	0.18	Serum parathyroid hormone levels;	chr22:23042844	chr22:23262767~23265005:+
THCA	cis	rs4443100	0.916	rs2078728	ENSG00000230701.2	FBXW4P1	3.93	9.95e-05	0.00778	0.21	0.18	Serum parathyroid hormone levels;	chr22:23042944	chr22:23262767~23265005:+
THCA	cis	rs453301	0.653	rs7005133	ENSG00000253981.4	ALG1L13P	3.93	9.96e-05	0.00778	0.16	0.18	Joint mobility (Beighton score);	chr8:9043712	chr8:8236003~8244667:-
THCA	cis	rs71520386	0.607	rs4308627	ENSG00000226329.2	AC005682.6	-3.93	9.96e-05	0.00778	-0.23	-0.18	Fibrinogen levels;	chr7:22840285	chr7:22863874~22881350:-
THCA	cis	rs10090774	0.687	rs13268978	ENSG00000279766.1	RP11-642A1.2	-3.93	9.96e-05	0.00778	-0.21	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140669286	chr8:140572142~140572812:-
THCA	cis	rs10435719	0.902	rs7459983	ENSG00000206014.6	OR7E161P	-3.93	9.96e-05	0.00778	-0.21	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:11928597~11929563:-
THCA	cis	rs7129556	0.702	rs650171	ENSG00000254459.1	RP11-91P24.7	3.93	9.96e-05	0.00778	0.22	0.18	Weight loss (gastric bypass surgery);	chr11:77787440	chr11:77829654~77872262:-
THCA	cis	rs2880765	0.835	rs7178991	ENSG00000218052.5	ADAMTS7P4	-3.93	9.96e-05	0.00778	-0.2	-0.18	Coronary artery disease;	chr15:85507713	chr15:85255369~85330334:-
THCA	cis	rs728616	0.558	rs34268041	ENSG00000278616.1	BEND3P3	3.93	9.96e-05	0.00778	0.18	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80388883	chr10:79682997~79685436:+
THCA	cis	rs7259376	0.905	rs11879791	ENSG00000269345.1	VN1R85P	3.93	9.96e-05	0.00778	0.19	0.18	Menopause (age at onset);	chr19:22354137	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs59598661	ENSG00000269345.1	VN1R85P	3.93	9.96e-05	0.00778	0.19	0.18	Menopause (age at onset);	chr19:22354227	chr19:22174766~22175191:-
THCA	cis	rs4845875	0.542	rs7533315	ENSG00000242349.4	NPPA-AS1	3.93	9.96e-05	0.00778	0.2	0.18	Midregional pro atrial natriuretic peptide levels;	chr1:11800626	chr1:11841017~11848079:+
THCA	cis	rs2562456	0.755	rs2914646	ENSG00000268658.4	LINC00664	-3.93	9.96e-05	0.00778	-0.26	-0.18	Pain;	chr19:21454359	chr19:21483374~21503238:+
THCA	cis	rs10875746	0.768	rs12305182	ENSG00000269514.1	RP11-370I10.12	3.93	9.96e-05	0.00778	0.17	0.18	Longevity (90 years and older);	chr12:48027624	chr12:48198387~48202031:+
THCA	cis	rs2692947	0.655	rs2315668	ENSG00000235584.2	AC008268.1	-3.93	9.97e-05	0.00779	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95763814	chr2:95666084~95668715:+
THCA	cis	rs786425	0.677	rs11834141	ENSG00000278112.1	RP11-972P1.11	3.93	9.97e-05	0.00779	0.18	0.18	Pubertal anthropometrics;	chr12:123666149	chr12:123519390~123519856:-
THCA	cis	rs786425	0.59	rs7296804	ENSG00000278112.1	RP11-972P1.11	3.93	9.97e-05	0.00779	0.18	0.18	Pubertal anthropometrics;	chr12:123669316	chr12:123519390~123519856:-
THCA	cis	rs8003054	0.589	rs4465523	ENSG00000258515.1	RP11-203M5.7	3.92	9.97e-05	0.00779	0.12	0.18	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445364	chr14:20451305~20451918:+
THCA	cis	rs9902453	0.817	rs12941382	ENSG00000263370.1	RP11-68I3.5	-3.92	9.97e-05	0.00779	-0.23	-0.18	Coffee consumption (cups per day);	chr17:30083106	chr17:29639627~29640825:+
THCA	cis	rs9928842	0.882	rs6564241	ENSG00000261783.1	RP11-252K23.2	3.92	9.97e-05	0.00779	0.35	0.18	Alcoholic chronic pancreatitis;	chr16:75230076	chr16:75379818~75381260:-
THCA	cis	rs11317778	1	rs11317778	ENSG00000241597.2	CTD-2007H13.1	-3.92	9.97e-05	0.00779	-0.23	-0.18	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98954394~98954972:+
THCA	cis	rs7578199	0.576	rs10191488	ENSG00000223374.1	AC005104.3	-3.92	9.97e-05	0.00779	-0.13	-0.18	Chronic lymphocytic leukemia;	chr2:241464720	chr2:241351340~241353104:-
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000229212.6	RP11-561C5.4	3.92	9.97e-05	0.00779	0.23	0.18	P wave terminal force;	chr15:84654022	chr15:85205440~85234795:-
THCA	cis	rs11069062	0.866	rs2030411	ENSG00000270482.1	RP11-131L12.2	3.92	9.97e-05	0.00779	0.15	0.18	Obesity-related traits;	chr12:118707294	chr12:118375350~118376275:-
THCA	cis	rs12142240	0.698	rs66847432	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46366341	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.659	rs67547686	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46366557	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.659	rs17361873	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46367014	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs72677599	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46368579	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs56049453	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46369796	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs67200518	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46370105	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs67941619	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46372547	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs66483119	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46372717	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.698	rs68012736	ENSG00000232022.5	FAAHP1	-3.92	9.98e-05	0.00779	-0.2	-0.18	Menopause (age at onset);	chr1:46373838	chr1:46432129~46445521:+
THCA	cis	rs6088580	0.524	rs6088567	ENSG00000126005.14	MMP24-AS1	3.92	9.98e-05	0.00779	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34676068	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.524	rs6088568	ENSG00000126005.14	MMP24-AS1	3.92	9.98e-05	0.00779	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34678167	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.524	rs1321306	ENSG00000126005.14	MMP24-AS1	3.92	9.98e-05	0.00779	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34678575	chr20:35216462~35278131:-
THCA	cis	rs7727544	0.604	rs2069803	ENSG00000263597.1	MIR3936	3.92	9.98e-05	0.00779	0.18	0.18	Blood metabolite levels;	chr5:132064740	chr5:132365490~132365599:-
THCA	cis	rs1908814	0.516	rs4840597	ENSG00000255495.1	AC145124.2	3.92	9.98e-05	0.00779	0.21	0.18	Neuroticism;	chr8:11938559	chr8:12194467~12196280:+
THCA	cis	rs804280	0.509	rs4841639	ENSG00000255495.1	AC145124.2	3.92	9.98e-05	0.00779	0.21	0.18	Myopia (pathological);	chr8:11938584	chr8:12194467~12196280:+
THCA	cis	rs11771526	0.681	rs79578813	ENSG00000272905.1	RP11-265E18.1	3.92	9.98e-05	0.00779	0.24	0.18	Body mass index;	chr7:32269255	chr7:32845394~32846061:+
THCA	cis	rs1979679	0.801	rs6487686	ENSG00000278733.1	RP11-425D17.1	-3.92	9.98e-05	0.00779	-0.18	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28548362	chr12:28185625~28186190:-
THCA	cis	rs7829975	0.627	rs876954	ENSG00000233609.3	RP11-62H7.2	3.92	9.98e-05	0.00779	0.18	0.18	Mood instability;	chr8:8453413	chr8:8961200~8979025:+
THCA	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	3.92	9.98e-05	0.00779	0.16	0.18	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
THCA	cis	rs7267979	0.545	rs6050426	ENSG00000277938.1	RP5-965G21.3	3.92	9.98e-05	0.00779	0.15	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25197629	chr20:25229150~25231933:+
THCA	cis	rs9291683	0.595	rs35501905	ENSG00000250413.1	RP11-448G15.1	-3.92	9.98e-05	0.0078	-0.17	-0.18	Bone mineral density;	chr4:10051807	chr4:10006482~10009725:+
THCA	cis	rs7267979	0.873	rs6132822	ENSG00000274973.1	RP13-401N8.7	-3.92	9.98e-05	0.0078	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25845497~25845862:+
THCA	cis	rs13113518	1	rs7660980	ENSG00000272969.1	RP11-528I4.2	-3.92	9.98e-05	0.0078	-0.21	-0.18	Height;	chr4:55542948	chr4:55547112~55547889:+
THCA	cis	rs2732480	0.5	rs1387257	ENSG00000257735.1	RP11-370I10.6	3.92	9.98e-05	0.0078	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48350945~48442411:+
THCA	cis	rs17597773	0.638	rs6668666	ENSG00000272823.1	RP11-295M18.6	-3.92	9.99e-05	0.0078	-0.23	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826069	chr1:220828676~220829211:-
THCA	cis	rs7312933	0.703	rs10880268	ENSG00000257225.1	RP11-328C8.4	-3.92	9.99e-05	0.0078	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42205320	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.703	rs12370778	ENSG00000257225.1	RP11-328C8.4	-3.92	9.99e-05	0.0078	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42205894	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.703	rs11181378	ENSG00000257225.1	RP11-328C8.4	-3.92	9.99e-05	0.0078	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42206856	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.67	rs10880269	ENSG00000257225.1	RP11-328C8.4	-3.92	9.99e-05	0.0078	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42212333	chr12:42459366~42466128:+
THCA	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	-3.92	9.99e-05	0.0078	-0.09	-0.18	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
THCA	cis	rs786425	0.804	rs11057320	ENSG00000278112.1	RP11-972P1.11	3.92	9.99e-05	0.0078	0.17	0.18	Pubertal anthropometrics;	chr12:123656815	chr12:123519390~123519856:-
THCA	cis	rs4268898	0.76	rs11125535	ENSG00000242628.4	AC009228.1	-3.92	9.99e-05	0.0078	-0.21	-0.18	Asthma;	chr2:24305245	chr2:24214381~24221516:+
THCA	cis	rs5758659	0.569	rs133293	ENSG00000270083.1	RP1-257I20.14	3.92	9.99e-05	0.0078	0.19	0.18	Cognitive function;	chr22:41986793	chr22:42089630~42090028:-
THCA	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	3.92	9.99e-05	0.0078	0.16	0.18	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	3.92	9.99e-05	0.0078	0.16	0.18	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
THCA	cis	rs1560104	0.709	rs8062074	ENSG00000259876.1	CTD-3037G24.4	3.92	9.99e-05	0.0078	0.21	0.18	Obesity-related traits;	chr16:12609691	chr16:12556353~12557694:-
THCA	cis	rs16944613	0.541	rs10852135	ENSG00000259212.1	CTD-3065B20.2	3.92	9.99e-05	0.0078	0.28	0.18	Colorectal cancer;	chr15:90563180	chr15:90595840~90596447:-
THCA	cis	rs61160187	0.582	rs7737276	ENSG00000272308.1	RP11-231G3.1	-3.92	9.99e-05	0.0078	-0.17	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60866457~60866935:-
THCA	cis	rs2115630	0.967	rs8028490	ENSG00000259295.5	CSPG4P12	-3.92	1e-04	0.00781	-0.24	-0.18	P wave terminal force;	chr15:84734657	chr15:85191438~85213905:+
THCA	cis	rs858239	0.965	rs156429	ENSG00000230042.1	AK3P3	-3.92	1e-04	0.00781	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23129178~23129841:+
THCA	cis	rs4245128	0.93	rs10750011	ENSG00000247416.2	RP11-629G13.1	3.92	1e-04	0.00781	0.17	0.18	Life satisfaction;	chr11:112916119	chr11:112959279~112963460:-
THCA	cis	rs62158800	0.683	rs1516201	ENSG00000237880.1	AC096669.2	3.92	1e-04	0.00781	0.19	0.18	Facial morphology (factor 22);	chr2:107686571	chr2:107385632~107542649:-
THCA	cis	rs4356203	0.678	rs1125737	ENSG00000272034.1	SNORD14A	-3.92	1e-04	0.00781	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17242386	chr11:17074654~17074744:-
THCA	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-3.92	1e-04	0.00781	-0.14	-0.18	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
THCA	cis	rs6083	0.512	rs17269397	ENSG00000245975.2	RP11-30K9.6	-3.92	1e-04	0.00781	-0.16	-0.18	Schizophrenia;	chr15:58565179	chr15:58768072~58770974:-
THCA	cis	rs2836974	0.899	rs114399588	ENSG00000255568.3	BRWD1-AS2	3.92	1e-04	0.00781	0.16	0.18	Cognitive function;	chr21:39282032	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.965	rs8131126	ENSG00000255568.3	BRWD1-AS2	3.92	1e-04	0.00781	0.16	0.18	Cognitive function;	chr21:39283828	chr21:39313935~39314962:+
THCA	cis	rs1005277	0.505	rs7069702	ENSG00000120555.12	SEPT7P9	-3.92	1e-04	0.00781	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38383069~38402916:-
THCA	cis	rs2436845	0.554	rs667927	ENSG00000253320.4	KB-1507C5.2	-3.92	1e-04	0.00781	-0.15	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102900186	chr8:102864300~102977876:+
THCA	cis	rs4792901	0.802	rs9898286	ENSG00000267151.3	RP11-100E5.2	3.92	1e-04	0.00781	0.2	0.18	Dupuytren's disease;	chr17:43485174	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs79934399	ENSG00000267151.3	RP11-100E5.2	3.92	1e-04	0.00781	0.2	0.18	Dupuytren's disease;	chr17:43494593	chr17:43444707~43451200:+
THCA	cis	rs881375	0.678	rs2269060	ENSG00000270917.1	RP11-27I1.6	-3.92	1e-04	0.00781	-0.23	-0.18	Rheumatoid arthritis;	chr9:120921291	chr9:120812475~120812845:-
THCA	cis	rs6142618	1	rs6142618	ENSG00000224452.1	RSL24D1P6	-3.92	1e-04	0.00781	-0.22	-0.18	Inflammatory bowel disease;	chr20:32137845	chr20:32170390~32170790:-
THCA	cis	rs6600671	1	rs2319969	ENSG00000275585.1	CH17-118O6.3	-3.92	1e-04	0.00781	-0.22	-0.18	Hip geometry;	chr1:121465481	chr1:120985692~121052167:-
THCA	cis	rs9287719	0.837	rs4233882	ENSG00000243819.4	RN7SL832P	3.92	1e-04	0.00781	0.14	0.18	Prostate cancer;	chr2:10615438	chr2:10690344~10692099:+
THCA	cis	rs7927592	0.913	rs12272917	ENSG00000160172.9	FAM86C2P	3.92	1e-04	0.00781	0.17	0.18	Total body bone mineral density;	chr11:68495902	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs66752716	ENSG00000160172.9	FAM86C2P	3.92	1e-04	0.00781	0.17	0.18	Total body bone mineral density;	chr11:68506158	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs11228262	ENSG00000160172.9	FAM86C2P	3.92	1e-04	0.00781	0.17	0.18	Total body bone mineral density;	chr11:68507439	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs55883802	ENSG00000160172.9	FAM86C2P	3.92	1e-04	0.00781	0.17	0.18	Total body bone mineral density;	chr11:68511361	chr11:67791648~67805336:-
THCA	cis	rs5751901	0.614	rs4820599	ENSG00000128262.7	POM121L9P	-3.92	1e-04	0.00781	-0.18	-0.18	Protein quantitative trait loci;	chr22:24594246	chr22:24251828~24265525:+
THCA	cis	rs4533267	0.843	rs4074097	ENSG00000189419.6	SPATA41	3.92	1e-04	0.00781	0.24	0.18	Height;	chr15:100255300	chr15:100344457~100349655:-
THCA	cis	rs11220082	0.666	rs7103665	ENSG00000254671.2	STT3A-AS1	-3.92	1e-04	0.00781	-0.21	-0.18	Schizophrenia;	chr11:125472998	chr11:125570284~125592568:-
THCA	cis	rs11220082	0.644	rs61917855	ENSG00000254671.2	STT3A-AS1	-3.92	1e-04	0.00781	-0.21	-0.18	Schizophrenia;	chr11:125473652	chr11:125570284~125592568:-
THCA	cis	rs7259376	0.936	rs11085524	ENSG00000269345.1	VN1R85P	3.92	1e-04	0.00781	0.19	0.18	Menopause (age at onset);	chr19:22353620	chr19:22174766~22175191:-
THCA	cis	rs7520050	0.898	rs785502	ENSG00000281133.1	AL355480.3	3.92	1e-04	0.00781	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45580892~45580996:-
THCA	cis	rs7818688	0.614	rs73271148	ENSG00000253528.2	RP11-347C18.4	-3.92	1e-04	0.00782	-0.26	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94864317	chr8:94974573~94974853:-
THCA	cis	rs42648	0.567	rs12669304	ENSG00000225498.1	AC002064.5	3.92	1e-04	0.00782	0.19	0.18	Homocysteine levels;	chr7:90261726	chr7:90312496~90322592:+
THCA	cis	rs10496034	0.541	rs10169328	ENSG00000237887.1	AC092839.1	-3.92	1e-04	0.00782	-0.36	-0.18	Refractive astigmatism;	chr2:54711338	chr2:54529343~54529801:+
THCA	cis	rs5753037	0.774	rs140118	ENSG00000279699.1	RP1-102K2.9	3.92	1e-04	0.00782	0.18	0.18	Type 1 diabetes;	chr22:29739817	chr22:30275215~30276951:-
THCA	cis	rs714027	0.534	rs140124	ENSG00000279699.1	RP1-102K2.9	3.92	1e-04	0.00782	0.18	0.18	Lymphocyte counts;	chr22:29747704	chr22:30275215~30276951:-
THCA	cis	rs80130819	1	rs80130819	ENSG00000257735.1	RP11-370I10.6	-3.92	1e-04	0.00782	-0.38	-0.18	Prostate cancer;	chr12:48025835	chr12:48350945~48442411:+
THCA	cis	rs7246657	0.722	rs11083432	ENSG00000226686.6	LINC01535	3.92	1e-04	0.00782	0.25	0.18	Coronary artery calcification;	chr19:37691732	chr19:37251912~37265535:+
THCA	cis	rs801193	1	rs62466793	ENSG00000275400.1	RP4-756H11.5	-3.92	1e-04	0.00782	-0.17	-0.18	Aortic root size;	chr7:66726530	chr7:66553805~66554199:-
THCA	cis	rs9611565	0.659	rs9607815	ENSG00000237037.8	NDUFA6-AS1	3.92	1e-04	0.00782	0.17	0.18	Vitiligo;	chr22:41554667	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.659	rs12484175	ENSG00000237037.8	NDUFA6-AS1	3.92	1e-04	0.00782	0.17	0.18	Vitiligo;	chr22:41557735	chr22:42090931~42137742:+
THCA	cis	rs6903823	0.508	rs1150718	ENSG00000220721.1	OR1F12	3.92	1e-04	0.00782	0.2	0.18	Pulmonary function;	chr6:28289170	chr6:28073316~28074233:+
THCA	cis	rs13182402	1	rs71586101	ENSG00000230929.5	RP11-395C3.1	-3.92	1e-04	0.00783	-0.36	-0.18	Osteoporosis;	chr5:126572894	chr5:126628019~126628319:-
THCA	cis	rs13182402	1	rs67308532	ENSG00000230929.5	RP11-395C3.1	-3.92	1e-04	0.00783	-0.36	-0.18	Osteoporosis;	chr5:126572907	chr5:126628019~126628319:-
THCA	cis	rs11064837	0.504	rs2393522	ENSG00000248636.5	RP11-768F21.1	3.92	1e-04	0.00783	0.2	0.18	Schizophrenia;	chr12:119617552	chr12:119387987~119668079:-
THCA	cis	rs3764021	0.87	rs10743819	ENSG00000214776.8	RP11-726G1.1	3.92	1e-04	0.00783	0.21	0.18	Type 1 diabetes;	chr12:9724172	chr12:9467552~9576275:+
THCA	cis	rs61160187	0.582	rs1526896	ENSG00000272308.1	RP11-231G3.1	-3.92	1e-04	0.00783	-0.17	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60866457~60866935:-
THCA	cis	rs7088591	0.867	rs10509082	ENSG00000276818.1	AC026393.1	3.92	1e-04	0.00783	0.36	0.18	Blood pressure;	chr10:57982693	chr10:57095699~57095781:+
THCA	cis	rs172166	0.516	rs2622322	ENSG00000261839.1	RP1-265C24.8	3.92	1e-04	0.00783	0.17	0.18	Cardiac Troponin-T levels;	chr6:28149665	chr6:28136849~28139678:+
THCA	cis	rs4947019	0.609	rs4946968	ENSG00000223537.2	RP5-919F19.5	-3.92	1e-04	0.00783	-0.33	-0.18	Hematological parameters;	chr6:109357907	chr6:109487906~109506800:+
THCA	cis	rs9902453	0.845	rs7222842	ENSG00000263370.1	RP11-68I3.5	3.92	1e-04	0.00783	0.24	0.18	Coffee consumption (cups per day);	chr17:29919925	chr17:29639627~29640825:+
THCA	cis	rs962856	0.619	rs1601529	ENSG00000236780.4	AC078941.1	-3.92	1e-04	0.00783	-0.24	-0.18	Pancreatic cancer;	chr2:67367705	chr2:67123357~67215319:-
THCA	cis	rs11073619	0.803	rs7180895	ENSG00000259728.4	LINC00933	3.92	1e-04	0.00783	0.32	0.18	Positive affect;	chr15:84614489	chr15:84570649~84580175:+
THCA	cis	rs4321325	0.733	rs78238478	ENSG00000236682.1	AC068282.3	-3.92	1e-04	0.00783	-0.37	-0.18	Protein C levels;	chr2:127178730	chr2:127389130~127400580:+
THCA	cis	rs11671005	0.656	rs11672609	ENSG00000269600.1	AC016629.3	-3.92	1e-04	0.00783	-0.28	-0.18	Mean platelet volume;	chr19:58495557	chr19:58593896~58599355:-
THCA	cis	rs9549260	0.561	rs61963209	ENSG00000239827.7	SUGT1P3	-3.92	1e-04	0.00783	-0.23	-0.18	Red blood cell count;	chr13:40928452	chr13:40908159~40921774:-
THCA	cis	rs1908814	0.516	rs13281077	ENSG00000255495.1	AC145124.2	3.92	1e-04	0.00783	0.21	0.18	Neuroticism;	chr8:11937305	chr8:12194467~12196280:+
THCA	cis	rs2657294	0.861	rs6480769	ENSG00000233313.2	HMGA1P5	-3.92	1e-04	0.00783	-0.24	-0.18	Pneumonia;	chr10:75091745	chr10:75276376~75276646:-
THCA	cis	rs927833	0.502	rs2424408	ENSG00000214535.3	RPS15AP1	3.92	1e-04	0.00784	0.26	0.18	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr20:21943535	chr20:21166206~21166596:-
THCA	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-3.92	1e-04	0.00784	-0.16	-0.18	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
THCA	cis	rs7772697	0.632	rs1316534	ENSG00000223701.3	RAET1E-AS1	-3.92	1e-04	0.00784	-0.25	-0.18	Diabetic retinopathy;	chr6:149096407	chr6:149884431~149919508:+
THCA	cis	rs453301	0.686	rs6987107	ENSG00000254340.1	RP11-10A14.3	-3.92	1e-04	0.00784	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9036071	chr8:9141424~9145435:+
THCA	cis	rs12681366	0.683	rs2445721	ENSG00000261437.1	RP11-22C11.2	-3.92	1e-04	0.00784	-0.16	-0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94377083	chr8:94637285~94639467:-
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000182586.6	LINC00334	-3.92	1e-04	0.00784	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45234340~45258730:+
THCA	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	3.92	1e-04	0.00784	0.21	0.18	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
THCA	cis	rs7158359	0.955	rs4904510	ENSG00000222990.1	RNU4-22P	-3.92	1e-04	0.00784	-0.24	-0.18	Weight loss (gastric bypass surgery);	chr14:89126669	chr14:88513498~88513663:+
THCA	cis	rs7824557	0.564	rs55758514	ENSG00000255495.1	AC145124.2	-3.92	1e-04	0.00784	-0.2	-0.18	Retinal vascular caliber;	chr8:11372750	chr8:12194467~12196280:+
THCA	cis	rs7819412	0.537	rs2127127	ENSG00000255046.1	RP11-297N6.4	3.92	1e-04	0.00784	0.19	0.18	Triglycerides;	chr8:11577283	chr8:11797928~11802568:-
THCA	cis	rs12188164	0.525	rs1114665	ENSG00000188242.4	PP7080	-3.92	1e-04	0.00784	-0.16	-0.18	Cystic fibrosis severity;	chr5:452132	chr5:466124~473098:-
THCA	cis	rs8103033	0.676	rs1988274	ENSG00000226025.8	LGALS17A	-3.92	1e-04	0.00784	-0.16	-0.18	Obesity-related traits;	chr19:39664258	chr19:39679374~39686373:+
THCA	cis	rs453301	0.506	rs476845	ENSG00000254340.1	RP11-10A14.3	-3.92	1e-04	0.00784	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8765367	chr8:9141424~9145435:+
THCA	cis	rs11123170	0.529	rs1015753	ENSG00000274877.1	RP11-65I12.1	3.92	0.000101	0.00784	0.1	0.18	Renal function-related traits (BUN);	chr2:113211226	chr2:113237595~113240825:+
THCA	cis	rs7927592	0.913	rs11228292	ENSG00000160172.9	FAM86C2P	3.92	0.000101	0.00784	0.18	0.18	Total body bone mineral density;	chr11:68612304	chr11:67791648~67805336:-
THCA	cis	rs13063635	0.915	rs35855315	ENSG00000226074.4	PRSS44	-3.92	0.000101	0.00784	-0.33	-0.18	Eosinophil percentage of granulocytes;	chr3:45964747	chr3:46809359~46812558:-
THCA	cis	rs10090774	0.841	rs4562374	ENSG00000280303.2	ERICD	-3.92	0.000101	0.00784	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140722145	chr8:140636281~140638283:+
THCA	cis	rs1124769	0.748	rs7170455	ENSG00000259378.1	DCAF13P3	-3.92	0.000101	0.00784	-0.27	-0.18	Cognitive performance;	chr15:51077543	chr15:50944663~50945996:+
THCA	cis	rs7131987	0.565	rs766445	ENSG00000275476.1	RP11-996F15.4	3.92	0.000101	0.00785	0.18	0.18	QT interval;	chr12:29260560	chr12:29277397~29277882:-
THCA	cis	rs1924981	0.509	rs612564	ENSG00000261485.1	PAN3-AS1	-3.92	0.000101	0.00785	-0.13	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr13:28489506	chr13:28136843~28138193:-
THCA	cis	rs875971	0.522	rs2949690	ENSG00000275400.1	RP4-756H11.5	3.92	0.000101	0.00785	0.17	0.18	Aortic root size;	chr7:66018255	chr7:66553805~66554199:-
THCA	cis	rs13108904	0.905	rs1680074	ENSG00000254094.1	AC078852.1	3.92	0.000101	0.00785	0.2	0.18	Obesity-related traits;	chr4:1285833	chr4:1356581~1358075:+
THCA	cis	rs2919009	0.537	rs11199650	ENSG00000271670.1	RP11-95I16.4	3.92	0.000101	0.00785	0.19	0.18	Obesity-related traits;	chr10:120923297	chr10:120879256~120880667:-
THCA	cis	rs1541160	0.957	rs6694304	ENSG00000239494.2	RN7SL333P	3.92	0.000101	0.00785	0.18	0.18	Amyotrophic lateral sclerosis;	chr1:170040496	chr1:169859756~169860052:+
THCA	cis	rs72928364	0.929	rs10511182	ENSG00000256628.3	ZBTB11-AS1	3.92	0.000101	0.00785	0.3	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101053991	chr3:101676475~101679217:+
THCA	cis	rs10802047	0.566	rs10923683	ENSG00000231365.4	RP11-418J17.1	-3.92	0.000101	0.00785	-0.18	-0.18	Relative hand skill in reading disability;	chr1:118797424	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.566	rs7416374	ENSG00000231365.4	RP11-418J17.1	-3.92	0.000101	0.00785	-0.18	-0.18	Relative hand skill in reading disability;	chr1:118798001	chr1:119140396~119275973:+
THCA	cis	rs4906332	1	rs8004780	ENSG00000259775.1	RP11-45P15.4	-3.92	0.000101	0.00785	-0.15	-0.18	Coronary artery disease;	chr14:103387023	chr14:103331674~103332367:-
THCA	cis	rs1383484	0.506	rs899927	ENSG00000259728.4	LINC00933	-3.92	0.000101	0.00785	-0.22	-0.18	Height;	chr15:83893127	chr15:84570649~84580175:+
THCA	cis	rs12612619	0.732	rs11680032	ENSG00000272148.1	RP11-195B17.1	3.92	0.000101	0.00785	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26975280	chr2:27062428~27062907:-
THCA	cis	rs10833905	1	rs10833902	ENSG00000246225.5	RP11-17A1.3	-3.92	0.000101	0.00785	-0.25	-0.18	Sudden cardiac arrest;	chr11:23013647	chr11:22829380~22945393:+
THCA	cis	rs2153535	0.518	rs926533	ENSG00000230939.1	RP11-314C16.1	-3.92	0.000101	0.00785	-0.19	-0.18	Motion sickness;	chr6:8556529	chr6:8784178~8785445:+
THCA	cis	rs2221894	1	rs6985217	ENSG00000251191.6	LINC00589	-3.92	0.000101	0.00785	-0.21	-0.18	Obesity-related traits;	chr8:28955638	chr8:29673922~29748109:-
THCA	cis	rs853679	0.567	rs3799499	ENSG00000273712.1	RP5-874C20.7	3.92	0.000101	0.00786	0.21	0.18	Depression;	chr6:28386473	chr6:28315613~28315883:-
THCA	cis	rs853679	0.567	rs2232427	ENSG00000273712.1	RP5-874C20.7	3.92	0.000101	0.00786	0.21	0.18	Depression;	chr6:28391932	chr6:28315613~28315883:-
THCA	cis	rs2412819	0.571	rs8038068	ENSG00000166763.7	STRCP1	3.92	0.000101	0.00786	0.25	0.18	Lung cancer;	chr15:43622175	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs56246169	ENSG00000166763.7	STRCP1	3.92	0.000101	0.00786	0.25	0.18	Lung cancer;	chr15:43628358	chr15:43699488~43718184:-
THCA	cis	rs7111546	0.565	rs74485461	ENSG00000246225.5	RP11-17A1.3	3.92	0.000101	0.00786	0.31	0.18	Dialysis-related mortality;	chr11:22945017	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.565	rs1160275	ENSG00000246225.5	RP11-17A1.3	3.92	0.000101	0.00786	0.31	0.18	Dialysis-related mortality;	chr11:22945134	chr11:22829380~22945393:+
THCA	cis	rs7111546	0.52	rs55962216	ENSG00000246225.5	RP11-17A1.3	3.92	0.000101	0.00786	0.31	0.18	Dialysis-related mortality;	chr11:22945897	chr11:22829380~22945393:+
THCA	cis	rs61160187	0.673	rs4353980	ENSG00000251279.1	CTC-436P18.1	3.92	0.000101	0.00786	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60779501	chr5:61162070~61232040:+
THCA	cis	rs11822910	1	rs11822910	ENSG00000265566.2	RN7SL605P	3.92	0.000101	0.00786	0.31	0.18	Platelet distribution width;	chr11:57428444	chr11:57528085~57528365:-
THCA	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	3.92	0.000101	0.00786	0.2	0.18	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
THCA	cis	rs9287719	0.774	rs4997811	ENSG00000243819.4	RN7SL832P	3.92	0.000101	0.00786	0.14	0.18	Prostate cancer;	chr2:10615412	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.745	rs4997810	ENSG00000243819.4	RN7SL832P	3.92	0.000101	0.00786	0.14	0.18	Prostate cancer;	chr2:10615414	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.745	rs4997809	ENSG00000243819.4	RN7SL832P	3.92	0.000101	0.00786	0.14	0.18	Prostate cancer;	chr2:10615416	chr2:10690344~10692099:+
THCA	cis	rs3781264	0.595	rs7084988	ENSG00000273450.1	RP11-76P2.4	3.92	0.000101	0.00786	0.22	0.18	Esophageal cancer and gastric cancer;	chr10:94349085	chr10:94314907~94315327:-
THCA	cis	rs3781264	0.595	rs7085378	ENSG00000273450.1	RP11-76P2.4	3.92	0.000101	0.00786	0.22	0.18	Esophageal cancer and gastric cancer;	chr10:94349568	chr10:94314907~94315327:-
THCA	cis	rs12681366	0.708	rs2930962	ENSG00000261437.1	RP11-22C11.2	3.92	0.000101	0.00786	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94433277	chr8:94637285~94639467:-
THCA	cis	rs4356203	0.87	rs603618	ENSG00000272034.1	SNORD14A	-3.92	0.000101	0.00786	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17224815	chr11:17074654~17074744:-
THCA	cis	rs7951911	0.915	rs12289360	ENSG00000254427.1	RP11-430H10.1	3.92	0.000101	0.00786	0.33	0.18	IgG glycosylation;	chr11:45074259	chr11:45355371~45366121:+
THCA	cis	rs11633886	0.677	rs4774198	ENSG00000259200.1	RP11-718O11.1	-3.92	0.000101	0.00786	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45754347	chr15:45705078~45931069:+
THCA	cis	rs7520050	0.902	rs4626927	ENSG00000281133.1	AL355480.3	3.92	0.000101	0.00786	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.902	rs7514192	ENSG00000281133.1	AL355480.3	3.92	0.000101	0.00786	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45580892~45580996:-
THCA	cis	rs11168936	0.637	rs3858587	ENSG00000258017.1	RP11-386G11.10	-3.92	0.000101	0.00786	-0.24	-0.18	Cancer (pleiotropy);	chr12:49276650	chr12:49127782~49147869:+
THCA	cis	rs7829975	0.66	rs10093926	ENSG00000253981.4	ALG1L13P	-3.92	0.000101	0.00786	-0.17	-0.18	Mood instability;	chr8:8691510	chr8:8236003~8244667:-
THCA	cis	rs6921919	0.583	rs9468370	ENSG00000273712.1	RP5-874C20.7	3.92	0.000101	0.00786	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28315613~28315883:-
THCA	cis	rs7178375	1	rs9806159	ENSG00000215302.7	CTD-3092A11.1	-3.92	0.000101	0.00786	-0.24	-0.18	Hypertriglyceridemia;	chr15:30917451	chr15:30470779~30507623:+
THCA	cis	rs7551222	0.716	rs11240751	ENSG00000240219.1	RP11-430C7.5	3.92	0.000101	0.00786	0.17	0.18	Schizophrenia;	chr1:204492922	chr1:204626775~204629712:+
THCA	cis	rs1204798	1	rs742930	ENSG00000237021.2	RP3-486I3.7	3.92	0.000101	0.00786	0.19	0.18	Dental caries;	chr6:116201452	chr6:116254207~116256743:+
THCA	cis	rs2223471	0.967	rs760899	ENSG00000060303.5	RPS17P5	-3.92	0.000101	0.00786	-0.22	-0.18	Subcutaneous adipose tissue;	chr6:50725894	chr6:50857255~50857662:-
THCA	cis	rs2076295	0.503	rs3778337	ENSG00000261189.1	RP3-512B11.3	-3.92	0.000101	0.00786	-0.17	-0.18	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7565652	chr6:7540451~7541338:-
THCA	cis	rs9510787	0.538	rs12585977	ENSG00000205861.10	C1QTNF9B-AS1	3.92	0.000101	0.00786	0.22	0.18	Nasopharyngeal carcinoma;	chr13:23666012	chr13:23888889~23897263:+
THCA	cis	rs7824557	0.564	rs34964435	ENSG00000227888.4	FAM66A	-3.92	0.000101	0.00787	-0.23	-0.18	Retinal vascular caliber;	chr8:11372697	chr8:12362019~12388296:+
THCA	cis	rs513088	0.628	rs547863	ENSG00000225171.2	DUTP6	3.92	0.000101	0.00787	0.26	0.18	Schizophrenia;	chr1:166733136	chr1:166868748~166869209:+
THCA	cis	rs1923243	0.749	rs7519995	ENSG00000223479.3	RP4-788P17.1	3.92	0.000101	0.00787	0.19	0.18	Migraine;	chr1:73062569	chr1:73635216~73715214:+
THCA	cis	rs7111546	1	rs16910180	ENSG00000246225.5	RP11-17A1.3	3.92	0.000101	0.00787	0.31	0.18	Dialysis-related mortality;	chr11:22800297	chr11:22829380~22945393:+
THCA	cis	rs18122	0.846	rs11885548	ENSG00000236780.4	AC078941.1	3.92	0.000101	0.00787	0.24	0.18	Waist-to-hip ratio adjusted for body mass index;	chr2:67401461	chr2:67123357~67215319:-
THCA	cis	rs735539	0.521	rs574139	ENSG00000278291.1	RP11-172H24.4	3.92	0.000101	0.00787	0.24	0.18	Dental caries;	chr13:20851677	chr13:20699307~20703718:-
THCA	cis	rs735539	0.521	rs513795	ENSG00000278291.1	RP11-172H24.4	3.92	0.000101	0.00787	0.24	0.18	Dental caries;	chr13:20853309	chr13:20699307~20703718:-
THCA	cis	rs735539	0.521	rs9550672	ENSG00000278291.1	RP11-172H24.4	3.92	0.000101	0.00787	0.24	0.18	Dental caries;	chr13:20854241	chr13:20699307~20703718:-
THCA	cis	rs564343	0.583	rs2430978	ENSG00000255320.1	RP11-755F10.1	-3.92	0.000101	0.00787	-0.22	-0.18	Obesity (early onset extreme);	chr11:66049185	chr11:66244840~66246239:-
THCA	cis	rs6696239	0.911	rs56950588	ENSG00000227711.2	RP11-275O4.5	-3.92	0.000101	0.00787	-0.24	-0.18	Height;	chr1:227680773	chr1:227509028~227520477:-
THCA	cis	rs791590	0.941	rs12722515	ENSG00000225948.2	RP11-554I8.1	3.92	0.000101	0.00787	0.28	0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:6039267	chr10:6618716~6625346:+
THCA	cis	rs1560104	0.584	rs12921820	ENSG00000259876.1	CTD-3037G24.4	3.92	0.000101	0.00787	0.21	0.18	Obesity-related traits;	chr16:12606775	chr16:12556353~12557694:-
THCA	cis	rs346923	1	rs73248642	ENSG00000226950.5	DANCR	3.92	0.000101	0.00787	0.21	0.18	Biochemical measures;	chr4:52494892	chr4:52712404~52720351:+
THCA	cis	rs7621025	0.755	rs1017881	ENSG00000239213.4	NCK1-AS1	3.92	0.000101	0.00787	0.16	0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136638851	chr3:136841726~136862054:-
THCA	cis	rs4805272	1	rs1422213	ENSG00000267799.1	MAN1A2P1	3.92	0.000101	0.00787	0.2	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28839227	chr19:28790812~28792871:-
THCA	cis	rs801193	1	rs10252765	ENSG00000272831.1	RP11-792A8.4	3.92	0.000101	0.00787	0.11	0.18	Aortic root size;	chr7:66763745	chr7:66739829~66740385:-
THCA	cis	rs4578769	0.55	rs8087501	ENSG00000273232.1	RP11-370A5.2	3.92	0.000101	0.00787	0.24	0.18	Eosinophil percentage of white cells;	chr18:22970711	chr18:22882825~22883357:-
THCA	cis	rs420259	0.516	rs722069	ENSG00000260136.4	CTD-2270L9.4	3.92	0.000101	0.00788	0.14	0.18	Bipolar disorder;	chr16:23495619	chr16:23452758~23457606:+
THCA	cis	rs7829975	0.628	rs1109618	ENSG00000253981.4	ALG1L13P	-3.92	0.000101	0.00788	-0.18	-0.18	Mood instability;	chr8:8713854	chr8:8236003~8244667:-
THCA	cis	rs10089	0.953	rs6875982	ENSG00000245937.6	LINC01184	3.92	0.000101	0.00788	0.19	0.18	Ileal carcinoids;	chr5:128193505	chr5:127940426~128083172:-
THCA	cis	rs2380205	0.517	rs12785055	ENSG00000232807.2	RP11-536K7.3	3.92	0.000101	0.00788	0.18	0.18	Breast cancer;	chr10:5899167	chr10:5934270~5945900:-
THCA	cis	rs2076295	0.503	rs55938083	ENSG00000261189.1	RP3-512B11.3	-3.92	0.000101	0.00788	-0.17	-0.18	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7565143	chr6:7540451~7541338:-
THCA	cis	rs11671005	0.656	rs11671092	ENSG00000252334.1	RNU6-1337P	3.92	0.000101	0.00788	0.28	0.18	Mean platelet volume;	chr19:58497742	chr19:58483749~58483843:-
THCA	cis	rs11671005	0.656	rs55928441	ENSG00000252334.1	RNU6-1337P	3.92	0.000101	0.00788	0.28	0.18	Mean platelet volume;	chr19:58498307	chr19:58483749~58483843:-
THCA	cis	rs11758351	0.789	rs2069020	ENSG00000216331.1	HIST1H1PS1	3.92	0.000101	0.00788	0.28	0.18	Renal underexcretion gout;Gout;	chr6:26205272	chr6:26195566~26195771:+
THCA	cis	rs7577696	0.613	rs212752	ENSG00000276334.1	AL133243.1	3.92	0.000101	0.00788	0.19	0.18	Inflammatory biomarkers;	chr2:32194834	chr2:32521927~32523547:+
THCA	cis	rs4699052	0.963	rs6533066	ENSG00000246560.2	RP11-10L12.4	3.92	0.000101	0.00788	0.21	0.18	Testicular germ cell tumor;	chr4:103242450	chr4:102828055~102844075:+
THCA	cis	rs2120243	0.592	rs4640513	ENSG00000241770.1	RP11-555M1.3	-3.92	0.000101	0.00788	-0.22	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157398161	chr3:157163452~157169133:+
THCA	cis	rs11950562	0.54	rs157577	ENSG00000233006.5	AC034220.3	3.92	0.000101	0.00788	0.16	0.18	Mean platelet volume;Blood metabolite levels;	chr5:132227878	chr5:132311285~132369916:-
THCA	cis	rs71520386	0.634	rs13240023	ENSG00000226329.2	AC005682.6	-3.92	0.000101	0.00788	-0.23	-0.18	Fibrinogen levels;	chr7:22827874	chr7:22863874~22881350:-
THCA	cis	rs2033711	0.783	rs11671113	ENSG00000269054.1	CTD-2619J13.3	-3.92	0.000101	0.00788	-0.14	-0.18	Uric acid clearance;	chr19:58446720	chr19:58362585~58366591:+
THCA	cis	rs564799	0.842	rs480913	ENSG00000244040.4	IL12A-AS1	3.92	0.000101	0.00788	0.23	0.18	Systemic lupus erythematosus;	chr3:160011793	chr3:159913400~160225299:-
THCA	cis	rs17504106	0.643	rs10080084	ENSG00000254373.1	RP11-34P1.2	-3.92	0.000101	0.00788	-0.21	-0.18	Post-traumatic stress disorder;	chr5:161069570	chr5:160258253~160258585:+
THCA	cis	rs6546886	0.912	rs4331526	ENSG00000235499.1	AC073046.25	3.92	0.000101	0.00788	0.17	0.18	Dialysis-related mortality;	chr2:74067322	chr2:73985132~73986343:+
THCA	cis	rs6929812	0.702	rs4713101	ENSG00000271755.1	RP1-153G14.4	3.92	0.000101	0.00789	0.2	0.18	Neuroticism (multi-trait analysis);	chr6:27440019	chr6:27404010~27406964:-
THCA	cis	rs7089973	0.565	rs7082836	ENSG00000228169.3	PPIAP19	3.92	0.000101	0.00789	0.21	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114886478	chr10:114690143~114690634:-
THCA	cis	rs12612619	0.621	rs4665943	ENSG00000272148.1	RP11-195B17.1	-3.92	0.000101	0.00789	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27073017	chr2:27062428~27062907:-
THCA	cis	rs17382723	0.775	rs2302042	ENSG00000225521.1	AC005237.4	3.92	0.000101	0.00789	0.23	0.18	Height;	chr2:241081108	chr2:241015599~241064116:-
THCA	cis	rs2033711	0.811	rs9304814	ENSG00000232098.3	CTD-2619J13.14	3.92	0.000101	0.00789	0.16	0.18	Uric acid clearance;	chr19:58440444	chr19:58404238~58408484:-
THCA	cis	rs875971	0.628	rs6974355	ENSG00000229180.5	GS1-124K5.11	3.92	0.000101	0.00789	0.12	0.18	Aortic root size;	chr7:66376994	chr7:66526088~66542624:-
THCA	cis	rs879500	1	rs7242659	ENSG00000227279.1	AC015933.2	3.92	0.000101	0.00789	0.2	0.18	Lung function (FVC);	chr18:28546829	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs7232841	ENSG00000227279.1	AC015933.2	3.92	0.000101	0.00789	0.2	0.18	Lung function (FVC);	chr18:28547316	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs17677456	ENSG00000227279.1	AC015933.2	3.92	0.000101	0.00789	0.2	0.18	Lung function (FVC);	chr18:28547605	chr18:27954519~27963687:+
THCA	cis	rs793571	0.59	rs347115	ENSG00000245975.2	RP11-30K9.6	3.92	0.000101	0.00789	0.16	0.18	Schizophrenia;	chr15:58790760	chr15:58768072~58770974:-
THCA	cis	rs7819412	0.936	rs7814499	ENSG00000255046.1	RP11-297N6.4	3.92	0.000101	0.00789	0.19	0.18	Triglycerides;	chr8:11183138	chr8:11797928~11802568:-
THCA	cis	rs12544026	0.581	rs529684	ENSG00000253669.3	KB-1732A1.1	3.92	0.000101	0.00789	0.2	0.18	Major depression and alcohol dependence;	chr8:101869499	chr8:102805517~102809971:+
THCA	cis	rs897984	0.762	rs11150601	ENSG00000275263.1	RP11-1072A3.4	3.92	0.000101	0.00789	0.21	0.18	Dementia with Lewy bodies;	chr16:30966478	chr16:30956872~30957199:-
THCA	cis	rs897984	0.721	rs4889525	ENSG00000275263.1	RP11-1072A3.4	3.92	0.000101	0.00789	0.21	0.18	Dementia with Lewy bodies;	chr16:30978537	chr16:30956872~30957199:-
THCA	cis	rs7919656	0.782	rs1904596	ENSG00000228403.1	RP11-563N6.6	3.92	0.000101	0.00789	0.2	0.18	Clinically amyopathic dermatomyositis;	chr10:48872266	chr10:48878022~48878649:+
THCA	cis	rs372883	0.624	rs1153286	ENSG00000176054.6	RPL23P2	-3.92	0.000101	0.00789	-0.15	-0.18	Pancreatic cancer;	chr21:29312062	chr21:28997613~28998033:-
THCA	cis	rs4803480	0.72	rs4141218	ENSG00000270164.1	LINC01480	-3.92	0.000101	0.00789	-0.18	-0.18	Schizophrenia;	chr19:41575555	chr19:41535183~41536904:+
THCA	cis	rs9834970	0.588	rs4296548	ENSG00000281100.1	RP11-640L9.2	-3.92	0.000101	0.00789	-0.19	-0.18	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36874323	chr3:36823151~36825158:-
THCA	cis	rs9595908	0.785	rs9591261	ENSG00000212293.1	SNORA16	3.92	0.000101	0.00789	0.2	0.18	Body mass index;	chr13:32710989	chr13:32420390~32420516:-
THCA	cis	rs7131987	0.675	rs1436322	ENSG00000275476.1	RP11-996F15.4	3.92	0.000101	0.00789	0.17	0.18	QT interval;	chr12:29401872	chr12:29277397~29277882:-
THCA	cis	rs11633886	0.967	rs884305	ENSG00000273972.1	CTD-2306A12.1	-3.92	0.000101	0.0079	-0.19	-0.18	Diisocyanate-induced asthma;	chr15:45783116	chr15:45702640~45703183:+
THCA	cis	rs720064	0.555	rs7244601	ENSG00000264745.1	TTC39C-AS1	3.92	0.000101	0.0079	0.19	0.18	Strep throat;	chr18:23929704	chr18:23994213~24015339:-
THCA	cis	rs5758659	0.652	rs5751195	ENSG00000205702.9	CYP2D7	3.92	0.000101	0.0079	0.13	0.18	Cognitive function;	chr22:41983997	chr22:42140203~42144577:-
THCA	cis	rs5751901	0.614	rs2070477	ENSG00000128262.7	POM121L9P	-3.92	0.000101	0.0079	-0.18	-0.18	Protein quantitative trait loci;	chr22:24594949	chr22:24251828~24265525:+
THCA	cis	rs12410462	0.502	rs75429875	ENSG00000227711.2	RP11-275O4.5	-3.92	0.000101	0.0079	-0.33	-0.18	Major depressive disorder;	chr1:227769499	chr1:227509028~227520477:-
THCA	cis	rs9488822	0.596	rs13206506	ENSG00000237021.2	RP3-486I3.7	3.92	0.000101	0.0079	0.2	0.18	LDL cholesterol;Cholesterol, total;	chr6:116003297	chr6:116254207~116256743:+
THCA	cis	rs854765	0.724	rs62072049	ENSG00000281749.1	Y_RNA	3.92	0.000101	0.0079	0.24	0.18	Total body bone mineral density;	chr17:18003206	chr17:18001101~18001195:-
THCA	cis	rs7520050	0.966	rs12409773	ENSG00000281133.1	AL355480.3	3.92	0.000101	0.0079	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45580892~45580996:-
THCA	cis	rs4788570	0.578	rs4788553	ENSG00000260593.1	RP11-432I5.2	-3.92	0.000101	0.0079	-0.28	-0.18	Intelligence (multi-trait analysis);	chr16:71746374	chr16:71623708~71626816:-
THCA	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-3.92	0.000101	0.0079	-0.15	-0.18	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
THCA	cis	rs9810089	0.758	rs12492510	ENSG00000273455.1	RP11-305O4.3	3.92	0.000101	0.0079	0.24	0.18	Gestational age at birth (child effect);	chr3:136432789	chr3:136087475~136087913:-
THCA	cis	rs17597773	0.638	rs4143773	ENSG00000272823.1	RP11-295M18.6	-3.92	0.000101	0.0079	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220814900	chr1:220828676~220829211:-
THCA	cis	rs1908814	0.541	rs7824267	ENSG00000255495.1	AC145124.2	3.92	0.000101	0.0079	0.21	0.18	Neuroticism;	chr8:11936770	chr8:12194467~12196280:+
THCA	cis	rs755249	0.876	rs61781391	ENSG00000237624.1	OXCT2P1	3.92	0.000101	0.00791	0.25	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39514956~39516490:+
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000265443.1	CTD-2349P21.6	-3.92	0.000101	0.00791	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000265443.1	CTD-2349P21.6	-3.92	0.000101	0.00791	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000265443.1	CTD-2349P21.6	-3.92	0.000101	0.00791	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30726305~30727564:-
THCA	cis	rs12544026	0.547	rs568194	ENSG00000253669.3	KB-1732A1.1	-3.92	0.000101	0.00791	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101861899	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.581	rs566392	ENSG00000253669.3	KB-1732A1.1	-3.92	0.000101	0.00791	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101862073	chr8:102805517~102809971:+
THCA	cis	rs875971	0.545	rs221986	ENSG00000273024.4	INTS4P2	3.92	0.000101	0.00791	0.22	0.18	Aortic root size;	chr7:66105323	chr7:65647864~65715661:+
THCA	cis	rs736408	0.509	rs3774349	ENSG00000243224.1	RP5-1157M23.2	-3.92	0.000101	0.00791	-0.18	-0.18	Bipolar disorder;	chr3:52688319	chr3:52239258~52241097:+
THCA	cis	rs2806561	0.765	rs679591	ENSG00000249087.5	ZNF436-AS1	-3.92	0.000101	0.00791	-0.12	-0.18	Height;	chr1:23173423	chr1:23368997~23371839:+
THCA	cis	rs9595908	0.785	rs9652200	ENSG00000212293.1	SNORA16	3.92	0.000101	0.00791	0.21	0.18	Body mass index;	chr13:32715613	chr13:32420390~32420516:-
THCA	cis	rs2676071	0.654	rs1567847	ENSG00000259721.1	RP11-758N13.1	-3.92	0.000101	0.00791	-0.21	-0.18	Periodontitis (Mean PAL);	chr15:33315243	chr15:32717270~32719007:-
THCA	cis	rs6121246	0.909	rs6058463	ENSG00000224628.2	RP5-854E16.2	-3.92	0.000101	0.00791	-0.24	-0.18	Mean corpuscular hemoglobin;	chr20:31797389	chr20:31285317~31286835:-
THCA	cis	rs3845817	0.733	rs702906	ENSG00000237979.1	AC007389.1	3.92	0.000101	0.00791	0.2	0.18	Bipolar disorder;	chr2:65539745	chr2:65500993~65502138:-
THCA	cis	rs613391	0.536	rs554191	ENSG00000234840.1	LINC01239	-3.92	0.000101	0.00791	-0.2	-0.18	Quantitative traits;	chr9:22720123	chr9:22646200~22824213:+
THCA	cis	rs613391	0.561	rs694541	ENSG00000234840.1	LINC01239	-3.92	0.000101	0.00791	-0.2	-0.18	Quantitative traits;	chr9:22722357	chr9:22646200~22824213:+
THCA	cis	rs613391	0.578	rs7874257	ENSG00000234840.1	LINC01239	-3.92	0.000101	0.00791	-0.2	-0.18	Quantitative traits;	chr9:22723026	chr9:22646200~22824213:+
THCA	cis	rs7824557	0.564	rs55758514	ENSG00000227888.4	FAM66A	-3.92	0.000101	0.00791	-0.23	-0.18	Retinal vascular caliber;	chr8:11372750	chr8:12362019~12388296:+
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000189316.3	RP11-797H7.5	-3.92	0.000101	0.00791	-0.19	-0.18	Calcium levels;	chr7:65806798	chr7:64888527~64890100:-
THCA	cis	rs1560104	0.709	rs3919630	ENSG00000259876.1	CTD-3037G24.4	3.92	0.000102	0.00791	0.21	0.18	Obesity-related traits;	chr16:12607086	chr16:12556353~12557694:-
THCA	cis	rs11800820	0.555	rs12565947	ENSG00000227953.5	LINC01341	-3.92	0.000102	0.00791	-0.16	-0.18	Obesity-related traits;	chr1:246486923	chr1:246776013~246792385:+
THCA	cis	rs12612619	0.732	rs3754734	ENSG00000272148.1	RP11-195B17.1	3.92	0.000102	0.00791	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27076730	chr2:27062428~27062907:-
THCA	cis	rs1580019	0.562	rs4720064	ENSG00000273014.1	RP11-225B17.2	3.92	0.000102	0.00791	0.18	0.18	Cognitive ability;	chr7:32520026	chr7:32758882~32759353:+
THCA	cis	rs709400	0.93	rs57447494	ENSG00000258735.1	LINC00637	3.92	0.000102	0.00791	0.23	0.18	Body mass index;	chr14:103568232	chr14:103847721~103858049:+
THCA	cis	rs76382185	0.756	rs7547030	ENSG00000233184.5	RP11-421L21.3	3.92	0.000102	0.00791	0.26	0.18	Lymphocyte counts;	chr1:101129201	chr1:101025878~101087268:+
THCA	cis	rs912593	0.872	rs12428409	ENSG00000225179.1	LINC00457	3.92	0.000102	0.00791	0.23	0.18	Cancer;	chr13:34474390	chr13:34435450~34640685:-
THCA	cis	rs7267979	0.714	rs1555329	ENSG00000274973.1	RP13-401N8.7	-3.92	0.000102	0.00791	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.714	rs3787082	ENSG00000274973.1	RP13-401N8.7	-3.92	0.000102	0.00791	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.714	rs6115107	ENSG00000274973.1	RP13-401N8.7	-3.92	0.000102	0.00791	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25845497~25845862:+
THCA	cis	rs860295	0.627	rs11264410	ENSG00000236675.1	MTX1P1	-3.92	0.000102	0.00791	-0.18	-0.18	Body mass index;	chr1:155775558	chr1:155230975~155234325:+
THCA	cis	rs10090774	0.687	rs11995049	ENSG00000279766.1	RP11-642A1.2	-3.92	0.000102	0.00792	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140682990	chr8:140572142~140572812:-
THCA	cis	rs4268898	1	rs4268898	ENSG00000242628.4	AC009228.1	-3.92	0.000102	0.00792	-0.22	-0.18	Asthma;	chr2:24267544	chr2:24214381~24221516:+
THCA	cis	rs4742903	0.904	rs1507514	ENSG00000270332.1	SMC2-AS1	3.92	0.000102	0.00792	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104223833	chr9:104080024~104093073:-
THCA	cis	rs28735056	0.818	rs7235615	ENSG00000261126.6	RP11-795F19.1	3.92	0.000102	0.00792	0.15	0.18	Schizophrenia;	chr18:79884742	chr18:80046900~80095482:+
THCA	cis	rs853679	0.657	rs1778483	ENSG00000280107.1	AL022393.9	-3.92	0.000102	0.00792	-0.18	-0.18	Depression;	chr6:28273214	chr6:28170845~28172521:+
THCA	cis	rs853679	0.657	rs1778482	ENSG00000280107.1	AL022393.9	-3.92	0.000102	0.00792	-0.18	-0.18	Depression;	chr6:28273215	chr6:28170845~28172521:+
THCA	cis	rs10895987	0.531	rs7943007	ENSG00000197847.11	SLC22A20	3.92	0.000102	0.00792	0.19	0.18	Blood protein levels;	chr11:65089626	chr11:65213840~65242757:+
THCA	cis	rs12101261	0.813	rs58266067	ENSG00000259167.2	NMNAT1P1	3.92	0.000102	0.00792	0.21	0.18	Graves' disease;	chr14:81002132	chr14:81032529~81033404:+
THCA	cis	rs13178541	0.577	rs67655763	ENSG00000250378.1	RP11-119J18.1	-3.92	0.000102	0.00792	-0.2	-0.18	IgG glycosylation;	chr5:135789541	chr5:135812667~135826582:+
THCA	cis	rs67340775	0.834	rs13218875	ENSG00000272009.1	RP1-313I6.12	-3.92	0.000102	0.00792	-0.34	-0.18	Lung cancer in ever smokers;	chr6:27916234	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs67040724	ENSG00000272009.1	RP1-313I6.12	-3.92	0.000102	0.00792	-0.34	-0.18	Depression;	chr6:27937731	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs67662114	ENSG00000272009.1	RP1-313I6.12	-3.92	0.000102	0.00792	-0.34	-0.18	Depression;	chr6:27964523	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13216117	ENSG00000272009.1	RP1-313I6.12	-3.92	0.000102	0.00792	-0.34	-0.18	Depression;	chr6:27970706	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs36101351	ENSG00000272009.1	RP1-313I6.12	-3.92	0.000102	0.00792	-0.34	-0.18	Depression;	chr6:27975591	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs28360499	ENSG00000272009.1	RP1-313I6.12	-3.92	0.000102	0.00792	-0.34	-0.18	Depression;	chr6:27977618	chr6:28078792~28081130:-
THCA	cis	rs854765	0.583	rs950966	ENSG00000281749.1	Y_RNA	-3.92	0.000102	0.00792	-0.23	-0.18	Total body bone mineral density;	chr17:17880434	chr17:18001101~18001195:-
THCA	cis	rs8105895	1	rs8104559	ENSG00000269345.1	VN1R85P	3.92	0.000102	0.00792	0.24	0.18	Body mass index (change over time);	chr19:22022365	chr19:22174766~22175191:-
THCA	cis	rs7951911	1	rs1386669	ENSG00000254427.1	RP11-430H10.1	3.92	0.000102	0.00792	0.28	0.18	IgG glycosylation;	chr11:45083255	chr11:45355371~45366121:+
THCA	cis	rs2933343	0.621	rs6764682	ENSG00000261159.1	RP11-723O4.9	-3.92	0.000102	0.00793	-0.19	-0.18	IgG glycosylation;	chr3:128849540	chr3:128859716~128860526:-
THCA	cis	rs950169	0.922	rs11633075	ENSG00000275120.1	RP11-182J1.17	3.92	0.000102	0.00793	0.21	0.18	Schizophrenia;	chr15:84570741	chr15:84599434~84606463:-
THCA	cis	rs8177876	0.749	rs804885	ENSG00000261838.4	RP11-303E16.6	-3.92	0.000102	0.00793	-0.28	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061758	chr16:81069854~81076598:+
THCA	cis	rs321358	0.945	rs73015199	ENSG00000271390.1	RP11-89C3.3	3.92	0.000102	0.00793	0.29	0.18	Body mass index;	chr11:111104952	chr11:111089870~111090368:-
THCA	cis	rs1499614	1	rs2141924	ENSG00000237310.1	GS1-124K5.4	3.92	0.000102	0.00793	0.21	0.18	Gout;	chr7:66721259	chr7:66493706~66495474:+
THCA	cis	rs2688608	0.647	rs2227575	ENSG00000271816.1	BMS1P4	3.92	0.000102	0.00793	0.18	0.18	Inflammatory bowel disease;	chr10:73918082	chr10:73699151~73730487:-
THCA	cis	rs3935996	0.965	rs6663328	ENSG00000233147.1	RP11-90C4.1	-3.92	0.000102	0.00793	-0.15	-0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55852201	chr1:55823807~55868248:+
THCA	cis	rs7617480	0.648	rs4974083	ENSG00000229759.1	MRPS18AP1	3.92	0.000102	0.00793	0.28	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48963193	chr3:48256350~48256938:-
THCA	cis	rs10043228	0.702	rs62384474	ENSG00000250015.1	CTC-339F2.2	3.92	0.000102	0.00793	0.22	0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116298321	chr5:116302354~116304134:-
THCA	cis	rs8062405	0.789	rs28676837	ENSG00000261766.1	RP11-22P6.2	3.92	0.000102	0.00793	0.18	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28862166~28863340:-
THCA	cis	rs427394	0.659	rs419128	ENSG00000248677.1	CTD-2044J15.1	3.92	0.000102	0.00793	0.17	0.18	Menopause (age at onset);	chr5:6739678	chr5:6686325~6707711:-
THCA	cis	rs3809566	0.963	rs12148057	ENSG00000259459.4	RP11-321G12.1	-3.92	0.000102	0.00793	-0.15	-0.18	Platelet count;	chr15:63039310	chr15:63390136~63438320:+
THCA	cis	rs3809566	0.963	rs4775608	ENSG00000259459.4	RP11-321G12.1	-3.92	0.000102	0.00793	-0.15	-0.18	Platelet count;	chr15:63039741	chr15:63390136~63438320:+
THCA	cis	rs7520050	0.966	rs11211208	ENSG00000281133.1	AL355480.3	3.92	0.000102	0.00793	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45580892~45580996:-
THCA	cis	rs1383484	0.958	rs5006997	ENSG00000225151.9	GOLGA2P7	3.92	0.000102	0.00793	0.24	0.18	Height;	chr15:83849268	chr15:84199311~84230136:-
THCA	cis	rs394563	0.619	rs4895787	ENSG00000231760.4	RP11-350J20.5	-3.92	0.000102	0.00793	-0.22	-0.18	Dupuytren's disease;	chr6:149325364	chr6:149796151~149826294:-
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000229212.6	RP11-561C5.4	3.92	0.000102	0.00794	0.23	0.18	P wave terminal force;	chr15:84635039	chr15:85205440~85234795:-
THCA	cis	rs1124609	1	rs111705530	ENSG00000244879.4	GABPB1-AS1	3.92	0.000102	0.00794	0.27	0.18	Subjective well-being;	chr15:50186235	chr15:50354959~50372202:+
THCA	cis	rs1124609	1	rs1124609	ENSG00000244879.4	GABPB1-AS1	3.92	0.000102	0.00794	0.27	0.18	Subjective well-being;	chr15:50193820	chr15:50354959~50372202:+
THCA	cis	rs4748857	0.853	rs7095016	ENSG00000224215.1	RP11-371A19.2	3.92	0.000102	0.00794	0.19	0.18	Systemic lupus erythematosus;	chr10:23321343	chr10:23343957~23345181:+
THCA	cis	rs11671005	0.779	rs731259	ENSG00000252334.1	RNU6-1337P	3.92	0.000102	0.00794	0.28	0.18	Mean platelet volume;	chr19:58478057	chr19:58483749~58483843:-
THCA	cis	rs9926296	0.546	rs7187436	ENSG00000274627.1	RP11-104N10.2	-3.92	0.000102	0.00794	-0.18	-0.18	Vitiligo;	chr16:89778702	chr16:89516797~89522217:+
THCA	cis	rs34526934	0.566	rs1374325	ENSG00000226363.3	HAGLROS	3.92	0.000102	0.00794	0.23	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179243	chr2:176177717~176179008:+
THCA	cis	rs937213	0.781	rs28515996	ENSG00000275636.1	RP11-521C20.5	3.92	0.000102	0.00794	0.2	0.18	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40005018	chr15:40078892~40079347:+
THCA	cis	rs801193	0.935	rs11772264	ENSG00000229180.5	GS1-124K5.11	3.92	0.000102	0.00794	0.12	0.18	Aortic root size;	chr7:66711400	chr7:66526088~66542624:-
THCA	cis	rs2919009	0.6	rs55706145	ENSG00000271670.1	RP11-95I16.4	3.92	0.000102	0.00794	0.21	0.18	Obesity-related traits;	chr10:120790581	chr10:120879256~120880667:-
THCA	cis	rs7200543	1	rs4500751	ENSG00000188599.16	NPIPP1	-3.92	0.000102	0.00794	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:15104312~15123498:-
THCA	cis	rs7432375	0.901	rs4521165	ENSG00000273455.1	RP11-305O4.3	-3.92	0.000102	0.00794	-0.23	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136650868	chr3:136087475~136087913:-
THCA	cis	rs7432375	0.901	rs7618518	ENSG00000273455.1	RP11-305O4.3	-3.92	0.000102	0.00794	-0.23	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136651250	chr3:136087475~136087913:-
THCA	cis	rs7432375	0.901	rs1017882	ENSG00000273455.1	RP11-305O4.3	3.92	0.000102	0.00794	0.23	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136638863	chr3:136087475~136087913:-
THCA	cis	rs4267450	0.69	rs10422617	ENSG00000261770.1	CTC-459F4.1	3.92	0.000102	0.00794	0.32	0.18	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28371341	chr19:27757184~27760849:-
THCA	cis	rs13108904	0.901	rs12641735	ENSG00000254094.1	AC078852.1	-3.92	0.000102	0.00794	-0.2	-0.18	Obesity-related traits;	chr4:1310646	chr4:1356581~1358075:+
THCA	cis	rs564799	0.931	rs1651081	ENSG00000244040.4	IL12A-AS1	3.92	0.000102	0.00794	0.23	0.18	Systemic lupus erythematosus;	chr3:160014715	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs571099	ENSG00000244040.4	IL12A-AS1	3.92	0.000102	0.00794	0.23	0.18	Systemic lupus erythematosus;	chr3:160014777	chr3:159913400~160225299:-
THCA	cis	rs2562456	0.682	rs11085464	ENSG00000268278.1	RP11-420K14.1	3.92	0.000102	0.00794	0.21	0.18	Pain;	chr19:21568976	chr19:21637974~21656300:+
THCA	cis	rs875971	0.545	rs17138149	ENSG00000232559.3	GS1-124K5.12	3.92	0.000102	0.00794	0.19	0.18	Aortic root size;	chr7:66228193	chr7:66554588~66576923:-
THCA	cis	rs62434120	0.677	rs9322280	ENSG00000273132.1	RP11-350J20.12	3.92	0.000102	0.00795	0.22	0.18	Blood pressure traits (multi-trait analysis);Diastolic blood pressure;Systolic blood pressure;	chr6:150724529	chr6:149852462~149853192:+
THCA	cis	rs11633886	0.707	rs11070472	ENSG00000273972.1	CTD-2306A12.1	-3.92	0.000102	0.00795	-0.2	-0.18	Diisocyanate-induced asthma;	chr15:45744031	chr15:45702640~45703183:+
THCA	cis	rs9813712	0.585	rs10934929	ENSG00000253540.4	FAM86HP	3.92	0.000102	0.00795	0.25	0.18	Response to amphetamines;	chr3:130225231	chr3:130099092~130111472:-
THCA	cis	rs1124609	1	rs78224090	ENSG00000244879.4	GABPB1-AS1	3.92	0.000102	0.00795	0.27	0.18	Subjective well-being;	chr15:50182032	chr15:50354959~50372202:+
THCA	cis	rs854765	0.505	rs4924832	ENSG00000281749.1	Y_RNA	3.92	0.000102	0.00795	0.23	0.18	Total body bone mineral density;	chr17:17994425	chr17:18001101~18001195:-
THCA	cis	rs7973719	0.868	rs7315553	ENSG00000205885.6	C1RL-AS1	3.92	0.000102	0.00795	0.13	0.18	IgG glycosylation;	chr12:7201242	chr12:7108052~7122501:+
THCA	cis	rs11971779	0.715	rs7781459	ENSG00000252332.1	RNU6-911P	-3.92	0.000102	0.00795	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139409136	chr7:139448740~139448843:+
THCA	cis	rs1436955	0.754	rs7167881	ENSG00000259251.2	RP11-643M14.1	-3.92	0.000102	0.00795	-0.22	-0.18	Type 2 diabetes;	chr15:62103999	chr15:62060503~62062434:+
THCA	cis	rs479105	0.563	rs3825343	ENSG00000278356.1	RP11-372B4.3	3.92	0.000102	0.00795	0.18	0.18	Gut microbiota (bacterial taxa);	chr12:3256260	chr12:2885819~2886329:+
THCA	cis	rs685782	0.786	rs581757	ENSG00000200201.1	Y_RNA	-3.92	0.000102	0.00795	-0.27	-0.18	Metabolite levels (Dihydroxy docosatrienoic acid);	chr11:3717324	chr11:3665164~3665259:-
THCA	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-3.92	0.000102	0.00795	-0.16	-0.18	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
THCA	cis	rs4879656	0.564	rs1197774	ENSG00000225693.1	LAGE3P1	-3.92	0.000102	0.00795	-0.19	-0.18	Menopause (age at onset);	chr9:33001451	chr9:33019682~33020165:-
THCA	cis	rs9693857	0.505	rs2085640	ENSG00000254153.1	CTA-398F10.2	-3.92	0.000102	0.00795	-0.19	-0.18	Systolic blood pressure;	chr8:9407954	chr8:8456909~8461337:-
THCA	cis	rs7119	0.634	rs2667782	ENSG00000259362.2	RP11-307C19.1	3.92	0.000102	0.00795	0.25	0.18	Type 2 diabetes;	chr15:77569954	chr15:77525540~77534110:+
THCA	cis	rs7119	0.604	rs2667783	ENSG00000259362.2	RP11-307C19.1	3.92	0.000102	0.00795	0.25	0.18	Type 2 diabetes;	chr15:77570187	chr15:77525540~77534110:+
THCA	cis	rs7119	0.604	rs2458035	ENSG00000259362.2	RP11-307C19.1	3.92	0.000102	0.00795	0.25	0.18	Type 2 diabetes;	chr15:77570464	chr15:77525540~77534110:+
THCA	cis	rs7656342	1	rs7656342	ENSG00000242034.1	RP11-1396O13.1	3.92	0.000102	0.00795	0.21	0.18	Gut microbiota (bacterial taxa);	chr4:9816492	chr4:9553614~9553985:-
THCA	cis	rs9291683	0.53	rs4235346	ENSG00000250413.1	RP11-448G15.1	3.92	0.000102	0.00795	0.17	0.18	Bone mineral density;	chr4:9943672	chr4:10006482~10009725:+
THCA	cis	rs10435719	0.805	rs13269417	ENSG00000206014.6	OR7E161P	-3.92	0.000102	0.00795	-0.21	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:11928597~11929563:-
THCA	cis	rs4578769	0.877	rs7232963	ENSG00000265939.1	UBE2CP2	3.92	0.000102	0.00795	0.22	0.18	Eosinophil percentage of white cells;	chr18:23011231	chr18:22900486~22900995:-
THCA	cis	rs3796352	1	rs3097417	ENSG00000280417.1	RP11-5O17.1	3.92	0.000102	0.00795	0.26	0.18	Immune reponse to smallpox (secreted IL-2);	chr3:53054585	chr3:53046166~53048122:+
THCA	cis	rs4533267	0.843	rs4074098	ENSG00000189419.6	SPATA41	3.92	0.000102	0.00795	0.23	0.18	Height;	chr15:100255199	chr15:100344457~100349655:-
THCA	cis	rs2227564	0.729	rs2688611	ENSG00000271816.1	BMS1P4	3.92	0.000102	0.00795	0.19	0.18	Crohn's disease;Inflammatory bowel disease;	chr10:73893614	chr10:73699151~73730487:-
THCA	cis	rs150992	0.673	rs692832	ENSG00000241597.2	CTD-2007H13.1	-3.92	0.000102	0.00795	-0.23	-0.18	Body mass index;	chr5:98856761	chr5:98954394~98954972:+
THCA	cis	rs2279440	0.585	rs7651326	ENSG00000254485.4	RP11-380O24.1	3.92	0.000102	0.00795	0.25	0.18	Glucose homeostasis traits;	chr3:9459629	chr3:9292588~9363303:-
THCA	cis	rs13178541	0.641	rs62364708	ENSG00000250378.1	RP11-119J18.1	-3.92	0.000102	0.00795	-0.2	-0.18	IgG glycosylation;	chr5:135796164	chr5:135812667~135826582:+
THCA	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	3.92	0.000102	0.00795	0.21	0.18	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
THCA	cis	rs10186029	0.509	rs6726540	ENSG00000270659.1	RP11-105N14.1	3.92	0.000102	0.00795	0.16	0.18	Systemic sclerosis;	chr2:213079030	chr2:213152970~213153659:+
THCA	cis	rs9368481	0.524	rs9393768	ENSG00000261353.1	CTA-14H9.5	-3.92	0.000102	0.00796	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26527063~26527404:+
THCA	cis	rs11123170	0.543	rs12472361	ENSG00000274877.1	RP11-65I12.1	3.92	0.000102	0.00796	0.1	0.18	Renal function-related traits (BUN);	chr2:113223068	chr2:113237595~113240825:+
THCA	cis	rs4792901	0.802	rs9901586	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000102	0.00796	-0.23	-0.18	Dupuytren's disease;	chr17:43503523	chr17:43360041~43361361:-
THCA	cis	rs1836229	1	rs1836227	ENSG00000225706.1	PTPRD-AS1	-3.92	0.000102	0.00796	-0.21	-0.18	Restless legs syndrome;	chr9:8819454	chr9:8858130~8862255:+
THCA	cis	rs1577917	0.876	rs12212808	ENSG00000220563.1	PKMP3	-3.92	0.000102	0.00796	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85824254	chr6:85659892~85660606:-
THCA	cis	rs735539	0.555	rs2762990	ENSG00000278291.1	RP11-172H24.4	3.92	0.000102	0.00796	0.24	0.18	Dental caries;	chr13:20797288	chr13:20699307~20703718:-
THCA	cis	rs9500256	0.967	rs4928431	ENSG00000239650.4	GUSBP4	-3.92	0.000102	0.00796	-0.17	-0.18	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57919784~57930291:-
THCA	cis	rs7560272	0.538	rs6732812	ENSG00000273245.1	RP11-434P11.2	-3.92	0.000102	0.00796	-0.2	-0.18	Schizophrenia;	chr2:73695348	chr2:73750256~73750786:-
THCA	cis	rs2806561	0.765	rs1738470	ENSG00000249087.5	ZNF436-AS1	-3.92	0.000102	0.00796	-0.11	-0.18	Height;	chr1:23185418	chr1:23368997~23371839:+
THCA	cis	rs2803122	0.501	rs10811140	ENSG00000272842.1	RP11-513M16.7	-3.92	0.000102	0.00796	-0.22	-0.18	Pulse pressure;	chr9:19230401	chr9:19371386~19371945:-
THCA	cis	rs2015599	0.525	rs7959145	ENSG00000273680.1	RP11-996F15.6	-3.92	0.000102	0.00796	-0.25	-0.18	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29332733~29333383:-
THCA	cis	rs2015599	0.525	rs7961943	ENSG00000273680.1	RP11-996F15.6	-3.92	0.000102	0.00796	-0.25	-0.18	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29332733~29333383:-
THCA	cis	rs17221829	0.645	rs11018705	ENSG00000280385.1	AP000648.5	-3.92	0.000102	0.00796	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89649532	chr11:90193614~90198120:+
THCA	cis	rs3105593	1	rs3105593	ENSG00000242737.1	RP11-562A8.1	3.92	0.000102	0.00796	0.22	0.18	QT interval;	chr15:50552821	chr15:50466738~50467096:+
THCA	cis	rs349045	0.56	rs11083725	ENSG00000268601.1	AC115522.3	3.92	0.000102	0.00796	0.22	0.18	Reading or mathematical ability;	chr19:43796424	chr19:43794309~43795658:-
THCA	cis	rs10090774	0.672	rs11784581	ENSG00000279766.1	RP11-642A1.2	-3.92	0.000102	0.00796	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140657122	chr8:140572142~140572812:-
THCA	cis	rs13434995	0.513	rs73236153	ENSG00000249700.7	SRD5A3-AS1	-3.92	0.000102	0.00796	-0.26	-0.18	Adiponectin levels;	chr4:55585600	chr4:55363971~55395847:-
THCA	cis	rs2836974	0.897	rs13047678	ENSG00000255568.3	BRWD1-AS2	3.92	0.000102	0.00796	0.16	0.18	Cognitive function;	chr21:39336927	chr21:39313935~39314962:+
THCA	cis	rs7829975	0.774	rs35039922	ENSG00000254340.1	RP11-10A14.3	3.92	0.000102	0.00796	0.19	0.18	Mood instability;	chr8:8817815	chr8:9141424~9145435:+
THCA	cis	rs2474937	0.545	rs55722937	ENSG00000231365.4	RP11-418J17.1	3.92	0.000102	0.00796	0.18	0.18	Congenital heart malformation;	chr1:118361571	chr1:119140396~119275973:+
THCA	cis	rs2153535	0.518	rs4959493	ENSG00000230939.1	RP11-314C16.1	-3.92	0.000102	0.00797	-0.19	-0.18	Motion sickness;	chr6:8588503	chr6:8784178~8785445:+
THCA	cis	rs8179	1	rs42031	ENSG00000230927.2	TMBIM7P	3.92	0.000102	0.00797	0.28	0.18	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92608082	chr7:92412976~92439562:-
THCA	cis	rs9863	0.827	rs7305864	ENSG00000270061.1	RP11-214K3.19	-3.92	0.000102	0.00797	-0.23	-0.18	White blood cell count;	chr12:123957333	chr12:123969990~123970344:-
THCA	cis	rs9291683	0.53	rs10939620	ENSG00000250413.1	RP11-448G15.1	3.92	0.000102	0.00797	0.17	0.18	Bone mineral density;	chr4:9944508	chr4:10006482~10009725:+
THCA	cis	rs853679	0.882	rs3757188	ENSG00000273712.1	RP5-874C20.7	3.92	0.000102	0.00797	0.31	0.18	Depression;	chr6:28139579	chr6:28315613~28315883:-
THCA	cis	rs6546886	0.912	rs7584777	ENSG00000235499.1	AC073046.25	3.92	0.000102	0.00797	0.17	0.18	Dialysis-related mortality;	chr2:74090620	chr2:73985132~73986343:+
THCA	cis	rs875971	0.545	rs1547529	ENSG00000232559.3	GS1-124K5.12	3.92	0.000102	0.00797	0.19	0.18	Aortic root size;	chr7:66258859	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs7783889	ENSG00000232559.3	GS1-124K5.12	3.92	0.000102	0.00797	0.19	0.18	Aortic root size;	chr7:66283366	chr7:66554588~66576923:-
THCA	cis	rs9878978	1	rs9878978	ENSG00000227588.2	CNTN4-AS2	3.92	0.000102	0.00797	0.2	0.18	Blood pressure (smoking interaction);	chr3:2444285	chr3:2110409~2144241:-
THCA	cis	rs7829975	0.617	rs4841072	ENSG00000254340.1	RP11-10A14.3	-3.92	0.000102	0.00797	-0.2	-0.18	Mood instability;	chr8:8933743	chr8:9141424~9145435:+
THCA	cis	rs7520050	0.933	rs12045165	ENSG00000280836.1	AL355480.1	3.92	0.000102	0.00797	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45581219~45581321:-
THCA	cis	rs71520386	0.632	rs71520387	ENSG00000226329.2	AC005682.6	-3.92	0.000102	0.00797	-0.23	-0.18	Fibrinogen levels;	chr7:22830057	chr7:22863874~22881350:-
THCA	cis	rs71520386	0.632	rs10224244	ENSG00000226329.2	AC005682.6	-3.92	0.000102	0.00797	-0.23	-0.18	Fibrinogen levels;	chr7:22830455	chr7:22863874~22881350:-
THCA	cis	rs1501911	0.53	rs193072	ENSG00000241597.2	CTD-2007H13.1	-3.92	0.000102	0.00797	-0.23	-0.18	Lung function (FEV1/FVC);	chr5:98822171	chr5:98954394~98954972:+
THCA	cis	rs9693857	0.52	rs13267391	ENSG00000248538.5	RP11-10A14.5	-3.92	0.000102	0.00797	-0.23	-0.18	Systolic blood pressure;	chr8:9499204	chr8:9189011~9202854:+
THCA	cis	rs453301	0.686	rs1045527	ENSG00000254340.1	RP11-10A14.3	-3.92	0.000102	0.00797	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9032531	chr8:9141424~9145435:+
THCA	cis	rs2662776	0.521	rs10799902	ENSG00000232995.6	RGS5	3.92	0.000102	0.00797	0.15	0.18	Lead levels in blood;	chr1:163189892	chr1:163244505~163321894:-
THCA	cis	rs4906332	1	rs35224956	ENSG00000252469.1	RNU7-160P	3.92	0.000102	0.00797	0.19	0.18	Coronary artery disease;	chr14:103434144	chr14:103550345~103550406:+
THCA	cis	rs11148252	0.508	rs6561671	ENSG00000273784.3	RP11-78J21.7	-3.92	0.000102	0.00797	-0.18	-0.18	Lewy body disease;	chr13:52608179	chr13:52600042~52642542:+
THCA	cis	rs7959452	0.535	rs2305641	ENSG00000274979.1	RP11-1143G9.5	-3.92	0.000102	0.00797	-0.19	-0.18	Blood protein levels;	chr12:69253134	chr12:69326574~69331882:-
THCA	cis	rs613391	0.702	rs976731	ENSG00000234840.1	LINC01239	-3.92	0.000102	0.00797	-0.21	-0.18	Quantitative traits;	chr9:22695594	chr9:22646200~22824213:+
THCA	cis	rs12901789	1	rs12901789	ENSG00000270964.1	RP11-502I4.3	-3.92	0.000102	0.00797	-0.16	-0.18	Total body bone mineral density;	chr15:67269876	chr15:67541072~67542604:-
THCA	cis	rs448720	1	rs1606524	ENSG00000260657.2	RP11-315D16.4	3.92	0.000102	0.00798	0.22	0.18	Cognitive performance;	chr15:67902830	chr15:68267792~68277994:-
THCA	cis	rs3764021	0.87	rs10743819	ENSG00000256594.6	RP11-705C15.2	3.92	0.000102	0.00798	0.14	0.18	Type 1 diabetes;	chr12:9724172	chr12:9633419~9658412:+
THCA	cis	rs17853159	1	rs17853159	ENSG00000281912.1	LINC01144	-3.92	0.000102	0.00798	-0.24	-0.18	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45345193	chr1:45303910~45305619:+
THCA	cis	rs12121840	0.573	rs927844	ENSG00000237463.4	RP11-280O1.2	3.92	0.000102	0.00798	0.15	0.18	Interleukin-1-receptor antagonist levels;	chr1:165541075	chr1:165476841~165582155:-
THCA	cis	rs61677309	1	rs2120269	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118280420	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.964	rs55798741	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118283399	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs58520343	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118284285	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.964	rs55815657	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118284359	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs67462512	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118284621	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs1074459	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118285282	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs1074457	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118285402	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs56938099	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118285973	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs61390396	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118286003	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs66832804	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118286334	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs12576947	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118287340	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs12576100	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118287566	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.964	rs12576118	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118287725	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.929	rs12576119	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118287726	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs56357739	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118287792	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs55899310	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118287987	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs56224295	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118291176	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs55806415	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.00798	0.14	0.18	Lung cancer in ever smokers;	chr11:118292147	chr11:118791254~118793137:+
THCA	cis	rs7707921	0.881	rs4391141	ENSG00000251374.1	RPS23P5	3.92	0.000102	0.00798	0.26	0.18	Breast cancer;	chr5:81967703	chr5:82265157~82265259:-
THCA	cis	rs4700393	0.517	rs17332108	ENSG00000272308.1	RP11-231G3.1	-3.92	0.000102	0.00798	-0.22	-0.18	Intelligence (multi-trait analysis);	chr5:60836057	chr5:60866457~60866935:-
THCA	cis	rs494526	0.769	rs530409	ENSG00000229272.1	RP11-498J9.2	3.92	0.000103	0.00798	0.2	0.18	Alcoholic chronic pancreatitis;	chr10:119048962	chr10:119003536~119003884:-
THCA	cis	rs897984	0.645	rs9938550	ENSG00000275263.1	RP11-1072A3.4	3.92	0.000103	0.00798	0.21	0.18	Dementia with Lewy bodies;	chr16:30987821	chr16:30956872~30957199:-
THCA	cis	rs28830936	0.966	rs2241522	ENSG00000250379.1	RP11-23P13.4	3.92	0.000103	0.00798	0.2	0.18	Diastolic blood pressure;	chr15:41835536	chr15:41825099~41827936:-
THCA	cis	rs6546886	0.912	rs13021880	ENSG00000235499.1	AC073046.25	3.92	0.000103	0.00798	0.16	0.18	Dialysis-related mortality;	chr2:74083660	chr2:73985132~73986343:+
THCA	cis	rs7927592	0.956	rs2510384	ENSG00000160172.9	FAM86C2P	3.92	0.000103	0.00798	0.18	0.18	Total body bone mineral density;	chr11:68624369	chr11:67791648~67805336:-
THCA	cis	rs1371614	0.632	rs3820823	ENSG00000272148.1	RP11-195B17.1	3.92	0.000103	0.00798	0.16	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26941938	chr2:27062428~27062907:-
THCA	cis	rs2154427	0.872	rs76474418	ENSG00000238197.4	PAXBP1-AS1	3.92	0.000103	0.00798	0.18	0.18	Bilirubin levels;	chr21:32677803	chr21:32728115~32743122:+
THCA	cis	rs2058059	0.551	rs72608543	ENSG00000205578.5	POM121B	-3.92	0.000103	0.00798	-0.3	-0.18	Subcutaneous adipose tissue;	chr7:72597693	chr7:73293497~73301161:+
THCA	cis	rs4780401	0.933	rs1579258	ENSG00000274038.1	RP11-66H6.4	-3.92	0.000103	0.00798	-0.21	-0.18	Rheumatoid arthritis;	chr16:11731047	chr16:11056556~11057034:+
THCA	cis	rs7246967	0.673	rs2112610	ENSG00000198153.8	ZNF849P	-3.92	0.000103	0.00798	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22734049	chr19:22685167~22686732:+
THCA	cis	rs559555	0.568	rs546935	ENSG00000276517.1	AL133243.2	-3.92	0.000103	0.00798	-0.17	-0.18	Blood metabolite ratios;Blood metabolite levels;	chr2:31628605	chr2:32526504~32529507:+
THCA	cis	rs6903823	0.508	rs1150724	ENSG00000176933.5	TOB2P1	-3.92	0.000103	0.00798	-0.2	-0.18	Pulmonary function;	chr6:28282459	chr6:28217643~28218634:-
THCA	cis	rs4785204	1	rs55707752	ENSG00000279356.1	RP11-429P3.8	-3.92	0.000103	0.00798	-0.36	-0.18	Esophageal cancer (squamous cell);	chr16:50099659	chr16:50072862~50074986:+
THCA	cis	rs7772486	0.79	rs10223507	ENSG00000270638.1	RP3-466P17.1	-3.92	0.000103	0.00799	-0.14	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145735570~145737218:+
THCA	cis	rs12682352	0.535	rs12677550	ENSG00000253981.4	ALG1L13P	-3.92	0.000103	0.00799	-0.17	-0.18	Neuroticism;	chr8:8786812	chr8:8236003~8244667:-
THCA	cis	rs1113500	0.787	rs2336126	ENSG00000230489.1	VAV3-AS1	-3.92	0.000103	0.00799	-0.15	-0.18	Growth-regulated protein alpha levels;	chr1:108098283	chr1:107964443~107994607:+
THCA	cis	rs962856	0.964	rs11890812	ENSG00000236780.4	AC078941.1	3.92	0.000103	0.00799	0.22	0.18	Pancreatic cancer;	chr2:67392883	chr2:67123357~67215319:-
THCA	cis	rs875971	0.545	rs17138156	ENSG00000232559.3	GS1-124K5.12	3.92	0.000103	0.00799	0.19	0.18	Aortic root size;	chr7:66249708	chr7:66554588~66576923:-
THCA	cis	rs16976116	0.53	rs508482	ENSG00000279145.1	RP11-547D13.1	-3.92	0.000103	0.00799	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55118309	chr15:55171972~55178175:-
THCA	cis	rs1009077	0.627	rs7681796	ENSG00000260091.1	RP11-33B1.4	-3.92	0.000103	0.00799	-0.17	-0.18	Endometriosis;	chr4:119611992	chr4:119409333~119410233:+
THCA	cis	rs1009077	0.587	rs12502511	ENSG00000260091.1	RP11-33B1.4	-3.92	0.000103	0.00799	-0.17	-0.18	Endometriosis;	chr4:119614560	chr4:119409333~119410233:+
THCA	cis	rs1009077	0.627	rs4833622	ENSG00000260091.1	RP11-33B1.4	-3.92	0.000103	0.00799	-0.17	-0.18	Endometriosis;	chr4:119625504	chr4:119409333~119410233:+
THCA	cis	rs7074356	0.915	rs17617970	ENSG00000278616.1	BEND3P3	-3.92	0.000103	0.00799	-0.19	-0.18	Borderline personality disorder;	chr10:80447136	chr10:79682997~79685436:+
THCA	cis	rs875971	0.545	rs11767262	ENSG00000232559.3	GS1-124K5.12	3.92	0.000103	0.00799	0.19	0.18	Aortic root size;	chr7:66302237	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs66594357	ENSG00000232559.3	GS1-124K5.12	3.92	0.000103	0.00799	0.19	0.18	Aortic root size;	chr7:66327797	chr7:66554588~66576923:-
THCA	cis	rs11583043	0.546	rs6688545	ENSG00000233184.5	RP11-421L21.3	3.92	0.000103	0.008	0.19	0.18	Inflammatory bowel disease;Ulcerative colitis;	chr1:101124779	chr1:101025878~101087268:+
THCA	cis	rs11971779	0.648	rs6974099	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139413820	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs10261557	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139414291	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.553	rs11973507	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139414715	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs10265718	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139415322	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.553	rs10085770	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139415603	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs2355788	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139417151	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.618	rs3778931	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139417744	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs10278377	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139418325	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.618	rs13068	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139419395	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.648	rs6946113	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139421380	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6946393	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139421423	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.553	rs10269108	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139421586	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs9683	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139422993	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs10085901	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139424243	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs10085902	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139424359	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.617	rs66652773	ENSG00000252332.1	RNU6-911P	-3.92	0.000103	0.008	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139424827	chr7:139448740~139448843:+
THCA	cis	rs6586163	1	rs6586163	ENSG00000261438.1	RP11-399O19.9	3.92	0.000103	0.008	0.14	0.18	Chronic lymphocytic leukemia;	chr10:88992261	chr10:89015836~89017059:+
THCA	cis	rs1612141	1	rs1779541	ENSG00000251363.2	RP11-129M6.1	-3.92	0.000103	0.008	-0.26	-0.18	QT interval (drug interaction);	chr14:41215623	chr14:40954898~40975877:+
THCA	cis	rs1612141	1	rs1627768	ENSG00000251363.2	RP11-129M6.1	-3.92	0.000103	0.008	-0.26	-0.18	QT interval (drug interaction);	chr14:41215985	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.947	rs1782174	ENSG00000251363.2	RP11-129M6.1	-3.92	0.000103	0.008	-0.26	-0.18	QT interval (drug interaction);	chr14:41217273	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.947	rs1779540	ENSG00000251363.2	RP11-129M6.1	-3.92	0.000103	0.008	-0.26	-0.18	QT interval (drug interaction);	chr14:41217319	chr14:40954898~40975877:+
THCA	cis	rs1612141	1	rs1778373	ENSG00000251363.2	RP11-129M6.1	-3.92	0.000103	0.008	-0.26	-0.18	QT interval (drug interaction);	chr14:41219552	chr14:40954898~40975877:+
THCA	cis	rs758324	0.732	rs152055	ENSG00000224431.1	AC063976.7	-3.92	0.000103	0.008	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132183150	chr5:132199456~132203487:+
THCA	cis	rs758324	0.582	rs152054	ENSG00000224431.1	AC063976.7	-3.92	0.000103	0.008	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132183847	chr5:132199456~132203487:+
THCA	cis	rs2289700	1	rs10152868	ENSG00000252061.1	RNU6-415P	3.92	0.000103	0.008	0.36	0.18	Bipolar disorder;	chr15:78938627	chr15:78898840~78898936:-
THCA	cis	rs9393777	0.844	rs28360634	ENSG00000220721.1	OR1F12	3.92	0.000103	0.008	0.37	0.18	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28073316~28074233:+
THCA	cis	rs11633886	0.748	rs949491	ENSG00000259200.1	RP11-718O11.1	-3.92	0.000103	0.008	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45767977	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.72	rs4408481	ENSG00000259200.1	RP11-718O11.1	-3.92	0.000103	0.008	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45768871	chr15:45705078~45931069:+
THCA	cis	rs4915077	0.773	rs12565046	ENSG00000230489.1	VAV3-AS1	3.92	0.000103	0.008	0.29	0.18	Hypothyroidism;	chr1:107740654	chr1:107964443~107994607:+
THCA	cis	rs9926296	0.528	rs4785721	ENSG00000274627.1	RP11-104N10.2	-3.92	0.000103	0.008	-0.18	-0.18	Vitiligo;	chr16:89773589	chr16:89516797~89522217:+
THCA	cis	rs9435732	0.725	rs10437047	ENSG00000268869.4	ESPNP	3.92	0.000103	0.008	0.21	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16994933	chr1:16687339~16720157:-
THCA	cis	rs586688	0.696	rs1256457	ENSG00000224536.1	RP11-134G8.7	-3.92	0.000103	0.008	-0.27	-0.18	Obesity-related traits;	chr1:201690611	chr1:201507241~201533608:+
THCA	cis	rs7259376	0.875	rs4932755	ENSG00000269345.1	VN1R85P	3.92	0.000103	0.008	0.19	0.18	Menopause (age at onset);	chr19:22312014	chr19:22174766~22175191:-
THCA	cis	rs11633886	0.842	rs7183858	ENSG00000259200.1	RP11-718O11.1	-3.92	0.000103	0.00801	-0.22	-0.18	Diisocyanate-induced asthma;	chr15:45747950	chr15:45705078~45931069:+
THCA	cis	rs889398	0.934	rs12923231	ENSG00000226232.7	RP11-419C5.2	3.92	0.000103	0.00801	0.18	0.18	Body mass index;	chr16:69538989	chr16:69976388~69996188:-
THCA	cis	rs7182948	0.957	rs1354918	ENSG00000259531.2	RP11-295H24.3	3.92	0.000103	0.00801	0.23	0.18	Lung adenocarcinoma;	chr15:49559052	chr15:49365124~49366685:-
THCA	cis	rs7200543	0.961	rs3803573	ENSG00000188599.16	NPIPP1	-3.92	0.000103	0.00801	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:15104312~15123498:-
THCA	cis	rs6586163	1	rs6586164	ENSG00000261438.1	RP11-399O19.9	3.92	0.000103	0.00801	0.14	0.18	Chronic lymphocytic leukemia;	chr10:88992274	chr10:89015836~89017059:+
THCA	cis	rs55702914	0.712	rs12619296	ENSG00000231621.1	AC013264.2	3.92	0.000103	0.00801	0.17	0.18	Major depression and alcohol dependence;	chr2:197284043	chr2:197197991~197199273:+
THCA	cis	rs7131987	0.934	rs2216854	ENSG00000275476.1	RP11-996F15.4	-3.92	0.000103	0.00801	-0.17	-0.18	QT interval;	chr12:29270527	chr12:29277397~29277882:-
THCA	cis	rs7824557	0.564	rs2043508	ENSG00000255495.1	AC145124.2	-3.92	0.000103	0.00801	-0.2	-0.18	Retinal vascular caliber;	chr8:11369897	chr8:12194467~12196280:+
THCA	cis	rs6517329	0.513	rs2835289	ENSG00000236830.5	CBR3-AS1	3.92	0.000103	0.00801	0.17	0.18	Schizophrenia;	chr21:36163599	chr21:36131767~36175815:-
THCA	cis	rs453301	0.597	rs7001187	ENSG00000233609.3	RP11-62H7.2	-3.92	0.000103	0.00801	-0.19	-0.18	Joint mobility (Beighton score);	chr8:8935272	chr8:8961200~8979025:+
THCA	cis	rs1979679	0.808	rs10843115	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000103	0.00801	-0.17	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28154784	chr12:28163298~28190738:-
THCA	cis	rs763121	0.853	rs5757187	ENSG00000273076.1	RP3-508I15.22	-3.92	0.000103	0.00801	-0.17	-0.18	Menopause (age at onset);	chr22:38625517	chr22:38743495~38743910:+
THCA	cis	rs4792901	0.759	rs60442473	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000103	0.00801	-0.23	-0.18	Dupuytren's disease;	chr17:43501919	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs76971300	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000103	0.00801	-0.23	-0.18	Dupuytren's disease;	chr17:43503220	chr17:43360041~43361361:-
THCA	cis	rs302972	0.826	rs303010	ENSG00000168405.13	CMAHP	-3.92	0.000103	0.00801	-0.38	-0.18	Creatinine levels in ischemic stroke;	chr6:25081877	chr6:25081068~25166555:-
THCA	cis	rs9558942	0.564	rs1927755	ENSG00000277863.1	RP11-282A11.4	-3.92	0.000103	0.00801	-0.22	-0.18	Obesity-related traits;	chr13:107063626	chr13:106903150~106904099:-
THCA	cis	rs2163813	1	rs12986120	ENSG00000271499.1	CTC-559E9.9	-3.92	0.000103	0.00802	-0.22	-0.18	Toenail selenium levels;	chr19:19709330	chr19:19750618~19752544:+
THCA	cis	rs657075	0.595	rs2292260	ENSG00000237714.1	P4HA2-AS1	-3.92	0.000103	0.00802	-0.37	-0.18	Rheumatoid arthritis;	chr5:132271243	chr5:132184876~132192808:+
THCA	cis	rs7829975	0.714	rs60315134	ENSG00000254340.1	RP11-10A14.3	3.92	0.000103	0.00802	0.19	0.18	Mood instability;	chr8:8813089	chr8:9141424~9145435:+
THCA	cis	rs9876781	0.872	rs11797	ENSG00000199476.1	Y_RNA	-3.92	0.000103	0.00802	-0.23	-0.18	Longevity;	chr3:48467186	chr3:48288587~48288694:+
THCA	cis	rs10496034	0.541	rs13398208	ENSG00000237887.1	AC092839.1	-3.92	0.000103	0.00802	-0.35	-0.18	Refractive astigmatism;	chr2:54714573	chr2:54529343~54529801:+
THCA	cis	rs657075	0.54	rs25883	ENSG00000224431.1	AC063976.7	-3.92	0.000103	0.00802	-0.17	-0.18	Rheumatoid arthritis;	chr5:132076239	chr5:132199456~132203487:+
THCA	cis	rs10090774	0.965	rs11777839	ENSG00000280303.2	ERICD	-3.92	0.000103	0.00802	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140907795	chr8:140636281~140638283:+
THCA	cis	rs7918232	1	rs6482595	ENSG00000262412.1	RP11-85G18.6	-3.92	0.000103	0.00802	-0.25	-0.18	Breast cancer;	chr10:27091332	chr10:27243130~27250804:+
THCA	cis	rs735539	0.593	rs35584557	ENSG00000278291.1	RP11-172H24.4	3.92	0.000103	0.00802	0.24	0.18	Dental caries;	chr13:20792418	chr13:20699307~20703718:-
THCA	cis	rs4886920	0.822	rs8026203	ENSG00000260776.4	RP11-114H24.2	-3.92	0.000103	0.00802	-0.21	-0.18	Neuroticism;	chr15:77813366	chr15:77914217~77926846:-
THCA	cis	rs10741243	1	rs10741243	ENSG00000230098.1	TCERG1L-AS1	3.92	0.000103	0.00802	0.24	0.18	Type 2 diabetes;	chr10:131149699	chr10:131095218~131095777:+
THCA	cis	rs10741243	1	rs7094311	ENSG00000230098.1	TCERG1L-AS1	3.92	0.000103	0.00802	0.24	0.18	Type 2 diabetes;	chr10:131150422	chr10:131095218~131095777:+
THCA	cis	rs10741243	1	rs7081792	ENSG00000230098.1	TCERG1L-AS1	3.92	0.000103	0.00802	0.24	0.18	Type 2 diabetes;	chr10:131150577	chr10:131095218~131095777:+
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000184274.3	LINC00315	-3.92	0.000103	0.00802	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45300245~45305257:-
THCA	cis	rs2839186	0.9	rs56840278	ENSG00000215424.8	MCM3AP-AS1	3.92	0.000103	0.00802	0.1	0.18	Testicular germ cell tumor;	chr21:46289019	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.933	rs56955294	ENSG00000215424.8	MCM3AP-AS1	3.92	0.000103	0.00802	0.1	0.18	Testicular germ cell tumor;	chr21:46289039	chr21:46229217~46259390:+
THCA	cis	rs11073619	0.616	rs34602083	ENSG00000259728.4	LINC00933	-3.92	0.000103	0.00802	-0.34	-0.18	Positive affect;	chr15:84397156	chr15:84570649~84580175:+
THCA	cis	rs6600671	1	rs4844607	ENSG00000275585.1	CH17-118O6.3	3.92	0.000103	0.00802	0.21	0.18	Hip geometry;	chr1:121442201	chr1:120985692~121052167:-
THCA	cis	rs875971	0.8	rs427557	ENSG00000229886.1	RP5-1132H15.3	3.92	0.000103	0.00802	0.19	0.18	Aortic root size;	chr7:66054263	chr7:66025126~66031544:-
THCA	cis	rs3824488	0.92	rs28446116	ENSG00000271155.1	RP11-435O5.5	-3.92	0.000103	0.00802	-0.27	-0.18	Neuroticism;	chr9:95481103	chr9:95506235~95507636:+
THCA	cis	rs3748656	1	rs12030612	ENSG00000273483.1	RP4-671G15.2	3.92	0.000103	0.00802	0.2	0.18	Hip circumference adjusted for BMI;	chr1:112673015	chr1:112517799~112518441:-
THCA	cis	rs3748656	1	rs12030641	ENSG00000273483.1	RP4-671G15.2	3.92	0.000103	0.00802	0.2	0.18	Hip circumference adjusted for BMI;	chr1:112673095	chr1:112517799~112518441:-
THCA	cis	rs793571	0.59	rs442495	ENSG00000245975.2	RP11-30K9.6	3.92	0.000103	0.00802	0.16	0.18	Schizophrenia;	chr15:58730416	chr15:58768072~58770974:-
THCA	cis	rs7586085	0.868	rs1968293	ENSG00000232411.1	AC009495.3	-3.92	0.000103	0.00802	-0.19	-0.18	Total body bone mineral density;	chr2:165761147	chr2:165833048~165839098:-
THCA	cis	rs2562784	0.638	rs2730100	ENSG00000225151.9	GOLGA2P7	-3.92	0.000103	0.00803	-0.32	-0.18	Height;	chr15:83630141	chr15:84199311~84230136:-
THCA	cis	rs700651	0.789	rs1976772	ENSG00000231621.1	AC013264.2	-3.92	0.000103	0.00803	-0.19	-0.18	Intracranial aneurysm;	chr2:198003477	chr2:197197991~197199273:+
THCA	cis	rs4218	0.681	rs12913177	ENSG00000259732.1	RP11-59H7.3	3.92	0.000103	0.00803	0.24	0.18	Social communication problems;	chr15:59066273	chr15:59121034~59133250:+
THCA	cis	rs9532669	0.926	rs6560963	ENSG00000229473.2	RGS17P1	3.92	0.000103	0.00803	0.23	0.18	Cervical cancer;	chr13:40871126	chr13:40992779~40993331:-
THCA	cis	rs1023500	0.505	rs134885	ENSG00000182057.4	OGFRP1	3.92	0.000103	0.00803	0.2	0.18	Schizophrenia;	chr22:42277805	chr22:42269753~42275196:+
THCA	cis	rs9543976	0.623	rs4611344	ENSG00000261105.4	LMO7-AS1	3.92	0.000103	0.00803	0.25	0.18	Diabetic retinopathy;	chr13:75601192	chr13:75604700~75635994:-
THCA	cis	rs7818688	1	rs61596977	ENSG00000253528.2	RP11-347C18.4	-3.92	0.000103	0.00803	-0.3	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94984937	chr8:94974573~94974853:-
THCA	cis	rs2076295	0.503	rs1358904	ENSG00000261189.1	RP3-512B11.3	-3.92	0.000103	0.00803	-0.17	-0.18	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7564228	chr6:7540451~7541338:-
THCA	cis	rs763121	0.889	rs2267390	ENSG00000228274.3	RP3-508I15.9	-3.92	0.000103	0.00803	-0.19	-0.18	Menopause (age at onset);	chr22:38493652	chr22:38667585~38681820:-
THCA	cis	rs7267979	1	rs6050555	ENSG00000276952.1	RP5-965G21.6	-3.92	0.000103	0.00803	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25284915~25285588:-
THCA	cis	rs1122401	0.576	rs2962549	ENSG00000280159.1	CTD-2591A1.1	-3.92	0.000103	0.00803	-0.2	-0.18	Smoking initiation;	chr5:54574653	chr5:54643557~54645987:+
THCA	cis	rs10090774	0.965	rs13258420	ENSG00000280303.2	ERICD	-3.92	0.000103	0.00803	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140895513	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs11783743	ENSG00000280303.2	ERICD	-3.92	0.000103	0.00803	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140897118	chr8:140636281~140638283:+
THCA	cis	rs4819052	0.851	rs2255774	ENSG00000182586.6	LINC00334	-3.92	0.000103	0.00803	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45234340~45258730:+
THCA	cis	rs4713118	0.869	rs2056925	ENSG00000261839.1	RP1-265C24.8	3.92	0.000103	0.00803	0.2	0.18	Parkinson's disease;	chr6:27723126	chr6:28136849~28139678:+
THCA	cis	rs875971	0.558	rs4433015	ENSG00000272831.1	RP11-792A8.4	-3.92	0.000103	0.00803	-0.11	-0.18	Aortic root size;	chr7:66174736	chr7:66739829~66740385:-
THCA	cis	rs15676	0.947	rs2977999	ENSG00000234771.3	SLC25A25-AS1	3.92	0.000103	0.00803	0.15	0.18	Blood metabolite levels;	chr9:128817528	chr9:128108581~128118693:-
THCA	cis	rs4934494	0.677	rs11185760	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000103	0.00803	-0.21	-0.18	Red blood cell count;	chr10:89571547	chr10:89694295~89697928:-
THCA	cis	rs4144027	0.967	rs10133399	ENSG00000269940.1	RP11-73M18.7	3.92	0.000103	0.00804	0.17	0.18	Blood metabolite levels;	chr14:103895506	chr14:103694560~103695170:+
THCA	cis	rs6728642	0.519	rs7589232	ENSG00000230606.9	AC159540.1	3.92	0.000103	0.00804	0.22	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900411	chr2:97416165~97433527:-
THCA	cis	rs875971	0.545	rs10950029	ENSG00000232559.3	GS1-124K5.12	3.92	0.000103	0.00804	0.19	0.18	Aortic root size;	chr7:66169334	chr7:66554588~66576923:-
THCA	cis	rs453301	0.686	rs7017868	ENSG00000254340.1	RP11-10A14.3	-3.92	0.000103	0.00804	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9015783	chr8:9141424~9145435:+
THCA	cis	rs453301	0.686	rs3895823	ENSG00000254340.1	RP11-10A14.3	-3.92	0.000103	0.00804	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9016136	chr8:9141424~9145435:+
THCA	cis	rs10090774	0.965	rs9324537	ENSG00000280303.2	ERICD	-3.92	0.000103	0.00804	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140964035	chr8:140636281~140638283:+
THCA	cis	rs4869313	0.694	rs1820149	ENSG00000247121.5	CTD-2260A17.2	-3.92	0.000103	0.00804	-0.13	-0.18	Pediatric autoimmune diseases;	chr5:96971454	chr5:96814028~96935809:-
THCA	cis	rs7216064	1	rs4271626	ENSG00000265055.1	AC145343.2	3.92	0.000103	0.00804	0.25	0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934017	chr17:68096046~68101474:-
THCA	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	3.92	0.000103	0.00804	0.21	0.18	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
THCA	cis	rs4561483	0.624	rs2215928	ENSG00000263307.1	RP11-166B2.8	3.92	0.000103	0.00804	0.18	0.18	Testicular germ cell tumor;	chr16:11834061	chr16:11851649~11895611:+
THCA	cis	rs2692947	0.77	rs72823920	ENSG00000235584.2	AC008268.1	-3.92	0.000103	0.00804	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95765128	chr2:95666084~95668715:+
THCA	cis	rs950169	0.922	rs12915832	ENSG00000275120.1	RP11-182J1.17	3.92	0.000103	0.00804	0.21	0.18	Schizophrenia;	chr15:84568226	chr15:84599434~84606463:-
THCA	cis	rs12313068	0.709	rs11064912	ENSG00000249094.2	RP1-7G5.6	-3.92	0.000103	0.00804	-0.28	-0.18	Intelligence (multi-trait analysis);	chr12:110067894	chr12:109880676~109888467:+
THCA	cis	rs877819	0.583	rs2663033	ENSG00000228403.1	RP11-563N6.6	-3.92	0.000103	0.00804	-0.19	-0.18	Systemic lupus erythematosus;	chr10:48876623	chr10:48878022~48878649:+
THCA	cis	rs17286411	0.671	rs34764568	ENSG00000260185.1	RP11-432I5.6	-3.92	0.000103	0.00804	-0.24	-0.18	Blood protein levels;	chr16:71623702	chr16:71655027~71664212:+
THCA	cis	rs10940346	0.506	rs12187591	ENSG00000271752.1	RP11-269M20.3	3.92	0.000103	0.00804	0.18	0.18	Schizophrenia;	chr5:50586789	chr5:50662859~50663266:-
THCA	cis	rs1560104	0.597	rs12162081	ENSG00000260601.1	RP11-552C15.1	-3.92	0.000103	0.00805	-0.21	-0.18	Obesity-related traits;	chr16:12616425	chr16:12545482~12546684:+
THCA	cis	rs765787	0.53	rs3759895	ENSG00000259539.1	CTD-2651B20.1	3.92	0.000104	0.00805	0.22	0.18	Uric acid levels;	chr15:45251672	chr15:45152664~45167526:-
THCA	cis	rs4218	0.635	rs10431792	ENSG00000277144.1	RP11-59H7.4	-3.92	0.000104	0.00805	-0.25	-0.18	Social communication problems;	chr15:59066181	chr15:59115547~59116089:-
THCA	cis	rs858239	0.899	rs2268745	ENSG00000226816.2	AC005082.12	3.92	0.000104	0.00805	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23206013~23208045:+
THCA	cis	rs56804039	0.524	rs7016459	ENSG00000254153.1	CTA-398F10.2	3.92	0.000104	0.00805	0.3	0.18	Cervical cancer;	chr8:8509006	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs7001071	ENSG00000254153.1	CTA-398F10.2	3.92	0.000104	0.00805	0.3	0.18	Cervical cancer;	chr8:8509011	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs55669645	ENSG00000254153.1	CTA-398F10.2	3.92	0.000104	0.00805	0.3	0.18	Cervical cancer;	chr8:8509849	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs66989459	ENSG00000254153.1	CTA-398F10.2	3.92	0.000104	0.00805	0.3	0.18	Cervical cancer;	chr8:8510401	chr8:8456909~8461337:-
THCA	cis	rs8177876	0.822	rs4889225	ENSG00000261838.4	RP11-303E16.6	-3.92	0.000104	0.00805	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr16:81069854~81076598:+
THCA	cis	rs7798970	0.645	rs6953653	ENSG00000225498.1	AC002064.5	3.92	0.000104	0.00805	0.18	0.18	Inflammatory skin disease;	chr7:90007703	chr7:90312496~90322592:+
THCA	cis	rs4780355	0.918	rs243318	ENSG00000263080.1	RP11-485G7.5	3.92	0.000104	0.00805	0.22	0.18	Crohn's disease and psoriasis;	chr16:11264161	chr16:11341809~11345211:-
THCA	cis	rs5758511	0.633	rs5758690	ENSG00000270083.1	RP1-257I20.14	-3.92	0.000104	0.00805	-0.22	-0.18	Birth weight;	chr22:42272289	chr22:42089630~42090028:-
THCA	cis	rs4853525	0.62	rs6751868	ENSG00000235852.1	AC005540.3	3.92	0.000104	0.00805	0.19	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190877222	chr2:190880797~190882059:-
THCA	cis	rs2638953	0.853	rs11049670	ENSG00000247934.4	RP11-967K21.1	3.92	0.000104	0.00805	0.18	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28499342	chr12:28163298~28190738:-
THCA	cis	rs2080501	0.628	rs28542020	ENSG00000275155.1	CTD-2595P9.4	-3.92	0.000104	0.00805	-0.17	-0.18	IgG glycosylation;	chr16:49626677	chr16:49847018~49847632:-
THCA	cis	rs7577696	0.695	rs62134021	ENSG00000276334.1	AL133243.1	3.92	0.000104	0.00805	0.19	0.18	Inflammatory biomarkers;	chr2:32189905	chr2:32521927~32523547:+
THCA	cis	rs7927592	0.956	rs7944870	ENSG00000160172.9	FAM86C2P	3.92	0.000104	0.00805	0.18	0.18	Total body bone mineral density;	chr11:68541640	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.513	rs607887	ENSG00000160172.9	FAM86C2P	3.92	0.000104	0.00805	0.16	0.18	Total body bone mineral density;	chr11:68429493	chr11:67791648~67805336:-
THCA	cis	rs897984	0.762	rs897986	ENSG00000275263.1	RP11-1072A3.4	3.92	0.000104	0.00805	0.21	0.18	Dementia with Lewy bodies;	chr16:30969581	chr16:30956872~30957199:-
THCA	cis	rs897984	0.721	rs28360557	ENSG00000275263.1	RP11-1072A3.4	3.92	0.000104	0.00805	0.21	0.18	Dementia with Lewy bodies;	chr16:30971939	chr16:30956872~30957199:-
THCA	cis	rs897984	0.684	rs6950	ENSG00000275263.1	RP11-1072A3.4	3.92	0.000104	0.00805	0.21	0.18	Dementia with Lewy bodies;	chr16:30984348	chr16:30956872~30957199:-
THCA	cis	rs897984	0.762	rs2305880	ENSG00000275263.1	RP11-1072A3.4	3.92	0.000104	0.00805	0.21	0.18	Dementia with Lewy bodies;	chr16:30988141	chr16:30956872~30957199:-
THCA	cis	rs9393813	0.528	rs4713108	ENSG00000271755.1	RP1-153G14.4	3.92	0.000104	0.00805	0.2	0.18	Bipolar disorder;	chr6:27490234	chr6:27404010~27406964:-
THCA	cis	rs9840812	0.535	rs695983	ENSG00000239213.4	NCK1-AS1	3.92	0.000104	0.00806	0.16	0.18	Fibrinogen levels;	chr3:136345705	chr3:136841726~136862054:-
THCA	cis	rs4266290	0.671	rs12651314	ENSG00000214846.4	RP11-115L11.1	3.92	0.000104	0.00806	0.25	0.18	Parkinson's disease;	chr4:15751947	chr4:15730962~15731627:-
THCA	cis	rs6473252	0.966	rs10957986	ENSG00000254162.1	RP11-48B3.3	-3.92	0.000104	0.00806	-0.15	-0.18	Breast cancer;	chr8:80902544	chr8:80535006~80539135:-
THCA	cis	rs9650657	0.812	rs11250074	ENSG00000255310.2	AF131215.2	-3.92	0.000104	0.00806	-0.15	-0.18	Neuroticism;	chr8:10774749	chr8:11107788~11109726:-
THCA	cis	rs8105895	0.935	rs62110986	ENSG00000269345.1	VN1R85P	3.92	0.000104	0.00806	0.25	0.18	Body mass index (change over time);	chr19:22073969	chr19:22174766~22175191:-
THCA	cis	rs7829975	0.572	rs7005000	ENSG00000254340.1	RP11-10A14.3	-3.92	0.000104	0.00806	-0.2	-0.18	Mood instability;	chr8:8939092	chr8:9141424~9145435:+
THCA	cis	rs18122	0.871	rs4671802	ENSG00000236780.4	AC078941.1	3.92	0.000104	0.00806	0.24	0.18	Waist-to-hip ratio adjusted for body mass index;	chr2:67420299	chr2:67123357~67215319:-
THCA	cis	rs913655	1	rs913655	ENSG00000240291.1	RP11-499P20.2	3.92	0.000104	0.00806	0.13	0.18	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18801883	chr10:18513115~18545651:-
THCA	cis	rs1541160	1	rs11584929	ENSG00000239494.2	RN7SL333P	-3.92	0.000104	0.00806	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:170062276	chr1:169859756~169860052:+
THCA	cis	rs2408955	0.522	rs4760679	ENSG00000257735.1	RP11-370I10.6	-3.92	0.000104	0.00806	-0.2	-0.18	Glycated hemoglobin levels;	chr12:48067852	chr12:48350945~48442411:+
THCA	cis	rs3738443	0.904	rs61840474	ENSG00000259865.1	RP11-488L18.10	3.92	0.000104	0.00806	0.19	0.18	Alcohol dependence;	chr1:247225109	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.904	rs61840475	ENSG00000259865.1	RP11-488L18.10	3.92	0.000104	0.00806	0.19	0.18	Alcohol dependence;	chr1:247225818	chr1:247187281~247188526:-
THCA	cis	rs804280	0.509	rs9886639	ENSG00000254948.1	OR7E158P	-3.92	0.000104	0.00806	-0.22	-0.18	Myopia (pathological);	chr8:11927020	chr8:11919900~11920809:-
THCA	cis	rs2281636	0.894	rs2297446	ENSG00000233690.1	EBAG9P1	3.92	0.000104	0.00806	0.17	0.18	Obesity-related traits;	chr10:99610258	chr10:99697407~99697949:-
THCA	cis	rs13256369	0.802	rs35382339	ENSG00000254153.1	CTA-398F10.2	-3.91	0.000104	0.00807	-0.2	-0.18	Obesity-related traits;	chr8:8701745	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.802	rs11781257	ENSG00000254153.1	CTA-398F10.2	-3.91	0.000104	0.00807	-0.2	-0.18	Obesity-related traits;	chr8:8702153	chr8:8456909~8461337:-
THCA	cis	rs10419113	0.701	rs10403317	ENSG00000268545.1	VN1R107P	3.91	0.000104	0.00807	0.21	0.18	Pediatric bone mineral density (spine);	chr19:57680115	chr19:57459912~57460120:+
THCA	cis	rs2243123	0.602	rs2133310	ENSG00000244040.4	IL12A-AS1	-3.91	0.000104	0.00807	-0.22	-0.18	Multiple sclerosis;	chr3:159998565	chr3:159913400~160225299:-
THCA	cis	rs8070624	0.543	rs8068175	ENSG00000281749.1	Y_RNA	3.91	0.000104	0.00807	0.23	0.18	Total body bone mineral density;	chr17:17971172	chr17:18001101~18001195:-
THCA	cis	rs8070624	0.543	rs57728924	ENSG00000281749.1	Y_RNA	3.91	0.000104	0.00807	0.23	0.18	Total body bone mineral density;	chr17:17972028	chr17:18001101~18001195:-
THCA	cis	rs8070128	0.688	rs59304093	ENSG00000281749.1	Y_RNA	3.91	0.000104	0.00807	0.23	0.18	Total body bone mineral density;	chr17:17972093	chr17:18001101~18001195:-
THCA	cis	rs11971779	0.68	rs7805767	ENSG00000252332.1	RNU6-911P	-3.91	0.000104	0.00807	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139426669	chr7:139448740~139448843:+
THCA	cis	rs7904321	1	rs10761697	ENSG00000232075.1	MRPL35P2	-3.91	0.000104	0.00807	-0.23	-0.18	Intelligence (multi-trait analysis);	chr10:63077534	chr10:63634317~63634827:-
THCA	cis	rs8099594	0.541	rs4939574	ENSG00000266696.1	RP11-30L3.2	3.91	0.000104	0.00807	0.22	0.18	Height;	chr18:49238453	chr18:49205912~49208781:+
THCA	cis	rs7824557	0.564	rs13274106	ENSG00000154316.13	TDH	3.91	0.000104	0.00807	0.13	0.18	Retinal vascular caliber;	chr8:11376449	chr8:11339637~11368452:+
THCA	cis	rs4950322	1	rs72694750	ENSG00000271721.1	RP11-337C18.9	3.91	0.000104	0.00807	0.21	0.18	Protein quantitative trait loci;	chr1:147396856	chr1:147175602~147177740:+
THCA	cis	rs4950322	1	rs1986987	ENSG00000271721.1	RP11-337C18.9	3.91	0.000104	0.00807	0.21	0.18	Protein quantitative trait loci;	chr1:147397553	chr1:147175602~147177740:+
THCA	cis	rs4950322	1	rs61230354	ENSG00000271721.1	RP11-337C18.9	3.91	0.000104	0.00807	0.21	0.18	Protein quantitative trait loci;	chr1:147398161	chr1:147175602~147177740:+
THCA	cis	rs4950322	1	rs4950429	ENSG00000271721.1	RP11-337C18.9	3.91	0.000104	0.00807	0.21	0.18	Protein quantitative trait loci;	chr1:147400227	chr1:147175602~147177740:+
THCA	cis	rs4950322	1	rs59498179	ENSG00000271721.1	RP11-337C18.9	3.91	0.000104	0.00807	0.21	0.18	Protein quantitative trait loci;	chr1:147400417	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.947	rs58671552	ENSG00000271721.1	RP11-337C18.9	3.91	0.000104	0.00807	0.21	0.18	Protein quantitative trait loci;	chr1:147409534	chr1:147175602~147177740:+
THCA	cis	rs7818688	0.697	rs28399553	ENSG00000253528.2	RP11-347C18.4	-3.91	0.000104	0.00807	-0.27	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94894566	chr8:94974573~94974853:-
THCA	cis	rs12368653	0.534	rs923828	ENSG00000270039.1	RP11-571M6.17	3.91	0.000104	0.00807	0.19	0.18	Multiple sclerosis;	chr12:57621711	chr12:57803838~57804415:+
THCA	cis	rs10875746	0.669	rs10875770	ENSG00000258273.1	RP11-370I10.4	3.91	0.000104	0.00807	0.25	0.18	Longevity (90 years and older);	chr12:48206737	chr12:48333755~48333901:-
THCA	cis	rs17597773	0.598	rs11118616	ENSG00000272823.1	RP11-295M18.6	-3.91	0.000104	0.00807	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220832314	chr1:220828676~220829211:-
THCA	cis	rs7829975	0.539	rs883647	ENSG00000253981.4	ALG1L13P	-3.91	0.000104	0.00807	-0.18	-0.18	Mood instability;	chr8:8712214	chr8:8236003~8244667:-
THCA	cis	rs758747	0.531	rs8058233	ENSG00000276754.1	RP11-461A8.5	-3.91	0.000104	0.00807	-0.16	-0.18	Body mass index;	chr16:3588808	chr16:3686998~3687380:+
THCA	cis	rs12440869	1	rs66517624	ENSG00000270964.1	RP11-502I4.3	3.91	0.000104	0.00808	0.16	0.18	Peak velocity of the mitral A-wave;	chr15:67209828	chr15:67541072~67542604:-
THCA	cis	rs2115630	1	rs58581703	ENSG00000259295.5	CSPG4P12	-3.91	0.000104	0.00808	-0.23	-0.18	P wave terminal force;	chr15:84733704	chr15:85191438~85213905:+
THCA	cis	rs1005277	0.529	rs1780125	ENSG00000120555.12	SEPT7P9	3.91	0.000104	0.00808	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38383069~38402916:-
THCA	cis	rs293748	0.771	rs158792	ENSG00000250155.1	CTD-2353F22.1	-3.91	0.000104	0.00808	-0.23	-0.18	Obesity-related traits;	chr5:36889068	chr5:36666214~36725195:-
THCA	cis	rs559928	0.597	rs2186572	ENSG00000236935.1	AP003774.1	3.91	0.000104	0.00808	0.26	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64128415	chr11:64325050~64329504:-
THCA	cis	rs559928	0.557	rs7122408	ENSG00000236935.1	AP003774.1	3.91	0.000104	0.00808	0.26	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64131354	chr11:64325050~64329504:-
THCA	cis	rs12681366	0.537	rs6999976	ENSG00000261437.1	RP11-22C11.2	3.91	0.000104	0.00808	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94470194	chr8:94637285~94639467:-
THCA	cis	rs9923856	0.614	rs7203459	ENSG00000263033.2	RP11-396B14.2	-3.91	0.000104	0.00808	-0.17	-0.18	Atopic dermatitis;Adult asthma;	chr16:11136846	chr16:11196177~11224969:+
THCA	cis	rs4808779	0.924	rs1075403	ENSG00000268650.3	AC068499.10	-3.91	0.000104	0.00808	-0.18	-0.18	Granulocyte percentage of myeloid white cells;	chr19:18274140	chr19:18204730~18220480:+
THCA	cis	rs9481169	0.557	rs2179070	ENSG00000272356.1	RP5-1112D6.8	3.91	0.000104	0.00808	0.28	0.18	Inflammatory skin disease;	chr6:111564549	chr6:111309203~111313517:+
THCA	cis	rs6496044	0.507	rs2467096	ENSG00000259276.1	RP11-815J21.3	3.91	0.000104	0.00808	0.2	0.18	Interstitial lung disease;	chr15:85667447	chr15:85621264~85627689:-
THCA	cis	rs17695224	0.675	rs1468641	ENSG00000275055.1	CTC-471J1.11	-3.91	0.000104	0.00808	-0.14	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51838366	chr19:52049007~52049754:+
THCA	cis	rs12472274	0.817	rs12621791	ENSG00000186235.9	AC016757.3	3.91	0.000104	0.00808	0.25	0.18	Phospholipid levels (plasma);	chr2:238195420	chr2:238224552~238231677:-
THCA	cis	rs12472274	0.941	rs4663861	ENSG00000186235.9	AC016757.3	3.91	0.000104	0.00808	0.25	0.18	Phospholipid levels (plasma);	chr2:238196562	chr2:238224552~238231677:-
THCA	cis	rs728616	0.681	rs55899456	ENSG00000278616.1	BEND3P3	3.91	0.000104	0.00809	0.18	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80290890	chr10:79682997~79685436:+
THCA	cis	rs1062753	0.771	rs5751245	ENSG00000270083.1	RP1-257I20.14	-3.91	0.000104	0.00809	-0.21	-0.18	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42224934	chr22:42089630~42090028:-
THCA	cis	rs34792	0.821	rs153809	ENSG00000207425.1	Y_RNA	3.91	0.000104	0.00809	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464514	chr16:14915457~14915556:-
THCA	cis	rs780094	0.5	rs12467476	ENSG00000234072.1	AC074117.10	3.91	0.000104	0.00809	0.14	0.18	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27602848	chr2:27356246~27367622:+
THCA	cis	rs780094	0.5	rs12464616	ENSG00000234072.1	AC074117.10	3.91	0.000104	0.00809	0.14	0.18	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27604225	chr2:27356246~27367622:+
THCA	cis	rs7809950	0.678	rs62482507	ENSG00000272072.1	CTA-363E19.2	3.91	0.000104	0.00809	0.19	0.18	Coronary artery disease;	chr7:107384043	chr7:107192559~107193300:-
THCA	cis	rs9467773	0.511	rs17278688	ENSG00000124549.13	BTN2A3P	3.91	0.000104	0.00809	0.17	0.18	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26421391~26432383:+
THCA	cis	rs11030122	0.959	rs11030176	ENSG00000230593.3	AC090804.1	3.91	0.000104	0.00809	0.23	0.18	Mean platelet volume;Platelet distribution width;	chr11:3891574	chr11:3892398~3892887:-
THCA	cis	rs780094	0.5	rs4666002	ENSG00000234072.1	AC074117.10	3.91	0.000104	0.00809	0.14	0.18	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27617773	chr2:27356246~27367622:+
THCA	cis	rs7616559	0.962	rs1905208	ENSG00000244515.1	KRT18P34	-3.91	0.000104	0.00809	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157034698	chr3:157162663~157163932:-
THCA	cis	rs3893377	0.848	rs3893376	ENSG00000214846.4	RP11-115L11.1	3.91	0.000104	0.00809	0.24	0.18	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15740451	chr4:15730962~15731627:-
THCA	cis	rs7824557	0.564	rs34964435	ENSG00000255495.1	AC145124.2	-3.91	0.000104	0.00809	-0.2	-0.18	Retinal vascular caliber;	chr8:11372697	chr8:12194467~12196280:+
THCA	cis	rs2191566	0.576	rs405763	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43989395	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs370809	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43989678	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs382255	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43990004	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs381628	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43990181	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs395803	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43990542	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs420584	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43991105	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs381091	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43991163	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs420355	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43991173	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs419839	ENSG00000277806.1	RP11-15A1.8	3.91	0.000104	0.00809	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43991446	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs381759	ENSG00000277806.1	RP11-15A1.8	-3.91	0.000104	0.00809	-0.18	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:43990993	chr19:43976815~43977448:+
THCA	cis	rs4788570	0.615	rs9888756	ENSG00000260185.1	RP11-432I5.6	-3.91	0.000104	0.00809	-0.32	-0.18	Intelligence (multi-trait analysis);	chr16:71706574	chr16:71655027~71664212:+
THCA	cis	rs4460629	0.71	rs11264318	ENSG00000225855.5	RUSC1-AS1	3.91	0.000104	0.00809	0.12	0.18	Serum magnesium levels;	chr1:155111241	chr1:155316863~155324176:-
THCA	cis	rs4295623	0.559	rs4841600	ENSG00000254866.2	DEFB109P3	-3.91	0.000104	0.00809	-0.24	-0.18	Morning vs. evening chronotype;	chr8:11830639	chr8:12150895~12151134:-
THCA	cis	rs2380205	0.875	rs4282898	ENSG00000232807.2	RP11-536K7.3	3.91	0.000104	0.00809	0.17	0.18	Breast cancer;	chr10:5857324	chr10:5934270~5945900:-
THCA	cis	rs896854	0.516	rs12679044	ENSG00000253528.2	RP11-347C18.4	3.91	0.000104	0.00809	0.2	0.18	Type 2 diabetes;	chr8:94879128	chr8:94974573~94974853:-
THCA	cis	rs9402682	0.592	rs1569534	ENSG00000232876.1	CTA-212D2.2	-3.91	0.000104	0.00809	-0.25	-0.18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135130442	chr6:135055033~135060550:+
THCA	cis	rs2562456	0.917	rs2681376	ENSG00000268278.1	RP11-420K14.1	-3.91	0.000104	0.0081	-0.21	-0.18	Pain;	chr19:21532723	chr19:21637974~21656300:+
THCA	cis	rs9316337	0.582	rs2146401	ENSG00000236953.1	ZDHHC20-IT1	-3.91	0.000104	0.0081	-0.2	-0.18	Schizophrenia;	chr13:21444511	chr13:21376977~21377874:-
THCA	cis	rs2154427	0.872	rs76446596	ENSG00000238197.4	PAXBP1-AS1	3.91	0.000104	0.0081	0.18	0.18	Bilirubin levels;	chr21:32726080	chr21:32728115~32743122:+
THCA	cis	rs7924176	0.502	rs1874151	ENSG00000213731.2	RAB5CP1	-3.91	0.000104	0.0081	-0.21	-0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107856	chr10:74423435~74424014:-
THCA	cis	rs10875746	0.624	rs10875777	ENSG00000258273.1	RP11-370I10.4	3.91	0.000104	0.0081	0.24	0.18	Longevity (90 years and older);	chr12:48228288	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.669	rs61941006	ENSG00000258273.1	RP11-370I10.4	3.91	0.000104	0.0081	0.24	0.18	Longevity (90 years and older);	chr12:48237350	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.669	rs1021313	ENSG00000258273.1	RP11-370I10.4	3.91	0.000104	0.0081	0.24	0.18	Longevity (90 years and older);	chr12:48244258	chr12:48333755~48333901:-
THCA	cis	rs75504410	0.579	rs2637713	ENSG00000231160.8	KLF3-AS1	3.91	0.000104	0.0081	0.13	0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38625716	chr4:38612701~38664883:-
THCA	cis	rs2919009	0.664	rs2289337	ENSG00000271670.1	RP11-95I16.4	3.91	0.000104	0.0081	0.2	0.18	Obesity-related traits;	chr10:120889970	chr10:120879256~120880667:-
THCA	cis	rs150992	0.79	rs40075	ENSG00000246763.5	RGMB-AS1	3.91	0.000104	0.0081	0.18	0.18	Body mass index;	chr5:98976743	chr5:98769618~98773469:-
THCA	cis	rs8081395	0.576	rs1292032	ENSG00000267302.4	RP11-178C3.2	3.91	0.000104	0.0081	0.21	0.18	White blood cell count;	chr17:59914982	chr17:59964832~59996972:+
THCA	cis	rs2692947	0.655	rs60090597	ENSG00000235584.2	AC008268.1	-3.91	0.000104	0.0081	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95740518	chr2:95666084~95668715:+
THCA	cis	rs151234	0.612	rs11641853	ENSG00000259982.1	CDC37P1	-3.91	0.000104	0.0081	-0.36	-0.18	Platelet distribution width;	chr16:28578398	chr16:28700294~28701540:-
THCA	cis	rs9863	0.828	rs7307277	ENSG00000270028.1	RP11-380L11.4	3.91	0.000104	0.0081	0.19	0.18	White blood cell count;	chr12:123990609	chr12:123925461~123926083:-
THCA	cis	rs9863	0.828	rs71458830	ENSG00000270028.1	RP11-380L11.4	3.91	0.000104	0.0081	0.19	0.18	White blood cell count;	chr12:123992014	chr12:123925461~123926083:-
THCA	cis	rs9863	0.828	rs12809473	ENSG00000270028.1	RP11-380L11.4	3.91	0.000104	0.0081	0.19	0.18	White blood cell count;	chr12:123992052	chr12:123925461~123926083:-
THCA	cis	rs9863	0.828	rs12827409	ENSG00000270028.1	RP11-380L11.4	3.91	0.000104	0.0081	0.19	0.18	White blood cell count;	chr12:123992159	chr12:123925461~123926083:-
THCA	cis	rs9863	0.828	rs7135314	ENSG00000270028.1	RP11-380L11.4	3.91	0.000104	0.0081	0.19	0.18	White blood cell count;	chr12:123994019	chr12:123925461~123926083:-
THCA	cis	rs9863	0.828	rs56041971	ENSG00000270028.1	RP11-380L11.4	3.91	0.000104	0.0081	0.19	0.18	White blood cell count;	chr12:123996319	chr12:123925461~123926083:-
THCA	cis	rs6504108	0.624	rs17620033	ENSG00000264920.1	RP11-6N17.4	-3.91	0.000104	0.0081	-0.15	-0.18	Body mass index;	chr17:48214052	chr17:47891255~47895812:-
THCA	cis	rs7583236	1	rs11126253	ENSG00000179818.12	PCBP1-AS1	-3.91	0.000104	0.0081	-0.19	-0.18	Obesity-related traits;	chr2:69954186	chr2:69962263~70103220:-
THCA	cis	rs4742903	0.935	rs4587392	ENSG00000270332.1	SMC2-AS1	3.91	0.000104	0.0081	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104210227	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs1413341	ENSG00000270332.1	SMC2-AS1	3.91	0.000104	0.0081	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104210732	chr9:104080024~104093073:-
THCA	cis	rs7798970	0.645	rs7799411	ENSG00000225498.1	AC002064.5	-3.91	0.000104	0.0081	-0.18	-0.18	Inflammatory skin disease;	chr7:90007090	chr7:90312496~90322592:+
THCA	cis	rs2039553	0.583	rs9545191	ENSG00000227354.5	RBM26-AS1	-3.91	0.000104	0.0081	-0.17	-0.18	Pancreatic cancer;	chr13:79762725	chr13:79406309~79424328:+
THCA	cis	rs10771431	0.597	rs10843142	ENSG00000256427.1	RP11-118B22.4	3.91	0.000104	0.0081	0.2	0.18	Breast size;	chr12:9204906	chr12:9246497~9257960:+
THCA	cis	rs9510787	0.649	rs9510793	ENSG00000205861.10	C1QTNF9B-AS1	-3.91	0.000104	0.0081	-0.23	-0.18	Nasopharyngeal carcinoma;	chr13:23638981	chr13:23888889~23897263:+
THCA	cis	rs9510787	0.649	rs7989882	ENSG00000205861.10	C1QTNF9B-AS1	-3.91	0.000104	0.0081	-0.23	-0.18	Nasopharyngeal carcinoma;	chr13:23640464	chr13:23888889~23897263:+
THCA	cis	rs962856	0.575	rs3770655	ENSG00000236780.4	AC078941.1	3.91	0.000104	0.0081	0.24	0.18	Pancreatic cancer;	chr2:67404993	chr2:67123357~67215319:-
THCA	cis	rs11168618	1	rs10875830	ENSG00000240399.1	RP1-228P16.1	3.91	0.000104	0.0081	0.18	0.18	Adiponectin levels;	chr12:48543727	chr12:48054813~48055591:-
THCA	cis	rs9840812	0.769	rs606725	ENSG00000239213.4	NCK1-AS1	-3.91	0.000104	0.0081	-0.16	-0.18	Fibrinogen levels;	chr3:136267245	chr3:136841726~136862054:-
THCA	cis	rs7727544	0.625	rs4705916	ENSG00000263597.1	MIR3936	3.91	0.000104	0.00811	0.18	0.18	Blood metabolite levels;	chr5:132071800	chr5:132365490~132365599:-
THCA	cis	rs4272720	0.639	rs12244748	ENSG00000234736.4	FAM170B-AS1	-3.91	0.000104	0.00811	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49062418	chr10:49121839~49151547:+
THCA	cis	rs1005277	0.579	rs2008449	ENSG00000120555.12	SEPT7P9	-3.91	0.000104	0.00811	-0.19	-0.18	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38383069~38402916:-
THCA	cis	rs4906332	1	rs12147655	ENSG00000244691.1	RPL10AP1	-3.91	0.000104	0.00811	-0.23	-0.18	Coronary artery disease;	chr14:103384569	chr14:103412119~103412761:-
THCA	cis	rs1124769	0.598	rs1438921	ENSG00000259378.1	DCAF13P3	-3.91	0.000104	0.00811	-0.27	-0.18	Cognitive performance;	chr15:51165905	chr15:50944663~50945996:+
THCA	cis	rs804280	0.525	rs17153755	ENSG00000255046.1	RP11-297N6.4	-3.91	0.000104	0.00811	-0.18	-0.18	Myopia (pathological);	chr8:11753991	chr8:11797928~11802568:-
THCA	cis	rs754133	0.963	rs12319419	ENSG00000257534.1	RP11-834C11.10	3.91	0.000104	0.00811	0.22	0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026992	chr12:54162065~54164452:-
THCA	cis	rs10435719	0.773	rs7842810	ENSG00000255495.1	AC145124.2	3.91	0.000104	0.00811	0.21	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:12194467~12196280:+
THCA	cis	rs61160187	0.667	rs7722373	ENSG00000215032.2	GNL3LP1	3.91	0.000104	0.00811	0.21	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60891935~60893577:-
THCA	cis	rs7973719	0.868	rs6486910	ENSG00000205885.6	C1RL-AS1	3.91	0.000104	0.00811	0.13	0.18	IgG glycosylation;	chr12:7203883	chr12:7108052~7122501:+
THCA	cis	rs7973719	0.773	rs6486911	ENSG00000205885.6	C1RL-AS1	3.91	0.000104	0.00811	0.13	0.18	IgG glycosylation;	chr12:7203898	chr12:7108052~7122501:+
THCA	cis	rs7973719	0.833	rs7970916	ENSG00000205885.6	C1RL-AS1	3.91	0.000104	0.00811	0.13	0.18	IgG glycosylation;	chr12:7205150	chr12:7108052~7122501:+
THCA	cis	rs11633886	0.528	rs2460632	ENSG00000259200.1	RP11-718O11.1	3.91	0.000104	0.00811	0.22	0.18	Diisocyanate-induced asthma;	chr15:45803763	chr15:45705078~45931069:+
THCA	cis	rs17685	0.712	rs28456330	ENSG00000230882.1	AC005077.14	3.91	0.000104	0.00811	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76181224	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs10235086	ENSG00000230882.1	AC005077.14	3.91	0.000104	0.00811	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76203820	chr7:76071469~76074963:-
THCA	cis	rs9309473	0.851	rs6546850	ENSG00000273245.1	RP11-434P11.2	3.91	0.000104	0.00811	0.24	0.18	Metabolite levels;	chr2:73604020	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.898	rs6546852	ENSG00000273245.1	RP11-434P11.2	3.91	0.000104	0.00811	0.24	0.18	Metabolite levels;	chr2:73606304	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.95	rs6546853	ENSG00000273245.1	RP11-434P11.2	3.91	0.000104	0.00811	0.24	0.18	Metabolite levels;	chr2:73606612	chr2:73750256~73750786:-
THCA	cis	rs360071	0.528	rs360097	ENSG00000242861.1	RP11-285F7.2	-3.91	0.000105	0.00811	-0.16	-0.18	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);	chr1:225878055	chr1:225840883~225846522:-
THCA	cis	rs17221829	0.733	rs11018699	ENSG00000280385.1	AP000648.5	-3.91	0.000105	0.00811	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89646794	chr11:90193614~90198120:+
THCA	cis	rs950169	0.686	rs12906474	ENSG00000275120.1	RP11-182J1.17	3.91	0.000105	0.00811	0.21	0.18	Schizophrenia;	chr15:84566006	chr15:84599434~84606463:-
THCA	cis	rs950169	0.81	rs2879976	ENSG00000275120.1	RP11-182J1.17	3.91	0.000105	0.00811	0.21	0.18	Schizophrenia;	chr15:84566347	chr15:84599434~84606463:-
THCA	cis	rs748404	0.533	rs2139651	ENSG00000166763.7	STRCP1	-3.91	0.000105	0.00811	-0.19	-0.18	Lung cancer;	chr15:43126560	chr15:43699488~43718184:-
THCA	cis	rs7824557	0.713	rs9286062	ENSG00000255310.2	AF131215.2	-3.91	0.000105	0.00811	-0.15	-0.18	Retinal vascular caliber;	chr8:11261018	chr8:11107788~11109726:-
THCA	cis	rs12188164	1	rs72717410	ENSG00000225138.6	CTD-2228K2.7	3.91	0.000105	0.00811	0.19	0.18	Cystic fibrosis severity;	chr5:428670	chr5:473236~480884:+
THCA	cis	rs4218	0.689	rs34338282	ENSG00000259732.1	RP11-59H7.3	-3.91	0.000105	0.00811	-0.25	-0.18	Social communication problems;	chr15:59096897	chr15:59121034~59133250:+
THCA	cis	rs860295	0.871	rs12724079	ENSG00000160766.13	GBAP1	3.91	0.000105	0.00812	0.19	0.18	Body mass index;	chr1:155464151	chr1:155213821~155227422:-
THCA	cis	rs12073837	0.784	rs61830288	ENSG00000238078.1	LINC01352	-3.91	0.000105	0.00812	-0.23	-0.18	F-cell distribution;	chr1:220815399	chr1:220829255~220832429:+
THCA	cis	rs12073837	0.784	rs61830289	ENSG00000238078.1	LINC01352	-3.91	0.000105	0.00812	-0.23	-0.18	F-cell distribution;	chr1:220815400	chr1:220829255~220832429:+
THCA	cis	rs12073837	0.784	rs35730037	ENSG00000238078.1	LINC01352	-3.91	0.000105	0.00812	-0.23	-0.18	F-cell distribution;	chr1:220815403	chr1:220829255~220832429:+
THCA	cis	rs17597773	0.638	rs7530074	ENSG00000238078.1	LINC01352	-3.91	0.000105	0.00812	-0.23	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815924	chr1:220829255~220832429:+
THCA	cis	rs17597773	0.638	rs7530176	ENSG00000238078.1	LINC01352	-3.91	0.000105	0.00812	-0.23	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816040	chr1:220829255~220832429:+
THCA	cis	rs17597773	0.638	rs7553447	ENSG00000238078.1	LINC01352	-3.91	0.000105	0.00812	-0.23	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816192	chr1:220829255~220832429:+
THCA	cis	rs1913185	0.787	rs67671074	ENSG00000261051.1	RP11-274H2.5	-3.91	0.000105	0.00812	-0.24	-0.18	Obesity-related traits;	chr3:146085476	chr3:146059585~146061679:-
THCA	cis	rs17286411	0.671	rs12597065	ENSG00000260185.1	RP11-432I5.6	-3.91	0.000105	0.00812	-0.24	-0.18	Blood protein levels;	chr16:71707721	chr16:71655027~71664212:+
THCA	cis	rs854765	0.583	rs8065563	ENSG00000281749.1	Y_RNA	3.91	0.000105	0.00812	0.23	0.18	Total body bone mineral density;	chr17:17879090	chr17:18001101~18001195:-
THCA	cis	rs9650657	0.812	rs11250073	ENSG00000255310.2	AF131215.2	-3.91	0.000105	0.00812	-0.15	-0.18	Neuroticism;	chr8:10774726	chr8:11107788~11109726:-
THCA	cis	rs4245128	0.93	rs9666469	ENSG00000247416.2	RP11-629G13.1	3.91	0.000105	0.00812	0.17	0.18	Life satisfaction;	chr11:112916973	chr11:112959279~112963460:-
THCA	cis	rs4722166	0.532	rs6461662	ENSG00000225541.1	AC002480.5	-3.91	0.000105	0.00812	-0.2	-0.18	Lung cancer;	chr7:22717470	chr7:22571607~22661792:-
THCA	cis	rs1580019	0.587	rs10951338	ENSG00000273014.1	RP11-225B17.2	3.91	0.000105	0.00812	0.18	0.18	Cognitive ability;	chr7:32520477	chr7:32758882~32759353:+
THCA	cis	rs2337406	0.714	rs7145254	ENSG00000211974.3	IGHV2-70	-3.91	0.000105	0.00812	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106817783	chr14:106723574~106724093:-
THCA	cis	rs6570726	0.935	rs416987	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.00812	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.905	rs452770	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.00812	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs442254	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.00812	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs441575	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.00812	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs436212	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.00812	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs414222	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.00812	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs415590	ENSG00000270638.1	RP3-466P17.1	3.91	0.000105	0.00812	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145735570~145737218:+
THCA	cis	rs757282	0.607	rs7485961	ENSG00000268069.2	RP5-1057I20.4	-3.91	0.000105	0.00812	-0.29	-0.18	Optic nerve measurement (cup-to-disc ratio);	chr12:47764148	chr12:47784923~47786002:+
THCA	cis	rs10435719	0.867	rs6999030	ENSG00000255495.1	AC145124.2	3.91	0.000105	0.00812	0.21	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.834	rs6985792	ENSG00000255495.1	AC145124.2	3.91	0.000105	0.00812	0.21	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:12194467~12196280:+
THCA	cis	rs801193	1	rs3778909	ENSG00000275400.1	RP4-756H11.5	-3.91	0.000105	0.00812	-0.17	-0.18	Aortic root size;	chr7:66790659	chr7:66553805~66554199:-
THCA	cis	rs944289	0.53	rs2780308	ENSG00000258844.1	RP11-259K15.2	-3.91	0.000105	0.00812	-0.16	-0.18	Thyroid cancer;	chr14:36050062	chr14:36214607~36235608:+
THCA	cis	rs7727544	0.508	rs10900804	ENSG00000263597.1	MIR3936	3.91	0.000105	0.00813	0.18	0.18	Blood metabolite levels;	chr5:132066152	chr5:132365490~132365599:-
THCA	cis	rs3738443	0.904	rs12562191	ENSG00000259865.1	RP11-488L18.10	3.91	0.000105	0.00813	0.19	0.18	Alcohol dependence;	chr1:247234227	chr1:247187281~247188526:-
THCA	cis	rs3738443	0.904	rs12569090	ENSG00000259865.1	RP11-488L18.10	3.91	0.000105	0.00813	0.19	0.18	Alcohol dependence;	chr1:247234370	chr1:247187281~247188526:-
THCA	cis	rs12612619	0.732	rs1866655	ENSG00000272148.1	RP11-195B17.1	-3.91	0.000105	0.00813	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26985999	chr2:27062428~27062907:-
THCA	cis	rs12216545	0.765	rs9986804	ENSG00000241134.3	BET1P1	-3.91	0.000105	0.00813	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150559323	chr7:150749736~150750094:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000272831.1	RP11-792A8.4	-3.91	0.000105	0.00813	-0.11	-0.18	Aortic root size;	chr7:66120784	chr7:66739829~66740385:-
THCA	cis	rs10129255	1	rs10129255	ENSG00000211972.2	IGHV3-66	-3.91	0.000105	0.00813	-0.11	-0.18	Kawasaki disease;	chr14:106767970	chr14:106675017~106675544:-
THCA	cis	rs4879656	0.797	rs2297218	ENSG00000225693.1	LAGE3P1	-3.91	0.000105	0.00813	-0.19	-0.18	Menopause (age at onset);	chr9:33025253	chr9:33019682~33020165:-
THCA	cis	rs35146811	0.735	rs1727138	ENSG00000078319.8	PMS2P1	-3.91	0.000105	0.00813	-0.22	-0.18	Coronary artery disease;	chr7:100217624	chr7:100320992~100341908:-
THCA	cis	rs13325613	0.504	rs71325101	ENSG00000226074.4	PRSS44	-3.91	0.000105	0.00813	-0.33	-0.18	Monocyte count;	chr3:45974077	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs71325102	ENSG00000226074.4	PRSS44	-3.91	0.000105	0.00813	-0.33	-0.18	Celiac disease;	chr3:45974441	chr3:46809359~46812558:-
THCA	cis	rs12216545	0.662	rs6972770	ENSG00000241134.3	BET1P1	-3.91	0.000105	0.00813	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150543696	chr7:150749736~150750094:+
THCA	cis	rs2836974	0.966	rs7283420	ENSG00000255568.3	BRWD1-AS2	3.91	0.000105	0.00813	0.16	0.18	Cognitive function;	chr21:39294939	chr21:39313935~39314962:+
THCA	cis	rs12681366	0.734	rs2919672	ENSG00000261437.1	RP11-22C11.2	3.91	0.000105	0.00813	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94424919	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.708	rs2930958	ENSG00000261437.1	RP11-22C11.2	3.91	0.000105	0.00813	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94428325	chr8:94637285~94639467:-
THCA	cis	rs13323323	0.691	rs9815769	ENSG00000214820.3	MPRIPP1	3.91	0.000105	0.00813	0.21	0.18	IgG glycosylation;	chr3:44621522	chr3:44579938~44581026:-
THCA	cis	rs3764021	0.506	rs11052372	ENSG00000256069.6	A2MP1	-3.91	0.000105	0.00813	-0.21	-0.18	Type 1 diabetes;	chr12:9679363	chr12:9228533~9275817:-
THCA	cis	rs10089	0.953	rs72794400	ENSG00000245937.6	LINC01184	3.91	0.000105	0.00814	0.2	0.18	Ileal carcinoids;	chr5:128180336	chr5:127940426~128083172:-
THCA	cis	rs12493885	0.725	rs4679728	ENSG00000243069.6	ARHGEF26-AS1	-3.91	0.000105	0.00814	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154014972	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.725	rs61791468	ENSG00000243069.6	ARHGEF26-AS1	-3.91	0.000105	0.00814	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154021731	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.725	rs11718646	ENSG00000243069.6	ARHGEF26-AS1	-3.91	0.000105	0.00814	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154024207	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.725	rs11707232	ENSG00000243069.6	ARHGEF26-AS1	-3.91	0.000105	0.00814	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154024288	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.725	rs61791493	ENSG00000243069.6	ARHGEF26-AS1	-3.91	0.000105	0.00814	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154025784	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.769	rs61791507	ENSG00000243069.6	ARHGEF26-AS1	-3.91	0.000105	0.00814	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154031097	chr3:154024401~154121332:-
THCA	cis	rs3748656	1	rs1106287	ENSG00000273483.1	RP4-671G15.2	3.91	0.000105	0.00814	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112699500	chr1:112517799~112518441:-
THCA	cis	rs74233809	1	rs11191560	ENSG00000272912.1	RP11-724N1.1	-3.91	0.000105	0.00814	-0.32	-0.18	Birth weight;	chr10:103109281	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs12413046	ENSG00000272912.1	RP11-724N1.1	-3.91	0.000105	0.00814	-0.32	-0.18	Birth weight;	chr10:103111447	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs10883832	ENSG00000272912.1	RP11-724N1.1	-3.91	0.000105	0.00814	-0.32	-0.18	Birth weight;	chr10:103111522	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs79082900	ENSG00000272912.1	RP11-724N1.1	-3.91	0.000105	0.00814	-0.32	-0.18	Birth weight;	chr10:103117545	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs12220375	ENSG00000272912.1	RP11-724N1.1	-3.91	0.000105	0.00814	-0.32	-0.18	Birth weight;	chr10:103141734	chr10:102914585~102915404:+
THCA	cis	rs9435732	0.778	rs6662202	ENSG00000268869.4	ESPNP	3.91	0.000105	0.00814	0.21	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17009758	chr1:16687339~16720157:-
THCA	cis	rs9309473	0.519	rs7606947	ENSG00000273245.1	RP11-434P11.2	3.91	0.000105	0.00814	0.2	0.18	Metabolite levels;	chr2:73682691	chr2:73750256~73750786:-
THCA	cis	rs12368653	0.591	rs1038914	ENSG00000270039.1	RP11-571M6.17	-3.91	0.000105	0.00814	-0.19	-0.18	Multiple sclerosis;	chr12:57617283	chr12:57803838~57804415:+
THCA	cis	rs11220082	0.761	rs11220065	ENSG00000254671.2	STT3A-AS1	-3.91	0.000105	0.00814	-0.22	-0.18	Schizophrenia;	chr11:125425343	chr11:125570284~125592568:-
THCA	cis	rs6546886	1	rs12988533	ENSG00000235499.1	AC073046.25	3.91	0.000105	0.00814	0.17	0.18	Dialysis-related mortality;	chr2:74015907	chr2:73985132~73986343:+
THCA	cis	rs910873	0.505	rs2378249	ENSG00000276073.1	RP5-1125A11.7	-3.91	0.000105	0.00814	-0.21	-0.18	Melanoma;	chr20:34630286	chr20:33985617~33988989:-
THCA	cis	rs7121800	0.632	rs7944883	ENSG00000242353.1	RP4-710M3.1	-3.91	0.000105	0.00814	-0.16	-0.18	Pit-and-Fissure caries;	chr11:30509936	chr11:30368148~30368646:+
THCA	cis	rs900400	0.696	rs9822326	ENSG00000244515.1	KRT18P34	-3.91	0.000105	0.00814	-0.2	-0.18	circulating leptin levels adjusted for BMI;Birth weight;Menarche (age at onset);Adiponectin levels in pregnancy;circulating leptin levels;	chr3:157085776	chr3:157162663~157163932:-
THCA	cis	rs56318008	0.681	rs61778045	ENSG00000228397.1	RP1-224A6.3	-3.91	0.000105	0.00814	-0.31	-0.18	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22032102	chr1:22023994~22024968:-
THCA	cis	rs56318008	0.68	rs61778046	ENSG00000228397.1	RP1-224A6.3	-3.91	0.000105	0.00814	-0.31	-0.18	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22032296	chr1:22023994~22024968:-
THCA	cis	rs56318008	0.738	rs72665313	ENSG00000228397.1	RP1-224A6.3	-3.91	0.000105	0.00814	-0.31	-0.18	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22033346	chr1:22023994~22024968:-
THCA	cis	rs56313388	0.505	rs9923472	ENSG00000246379.5	RP11-461O7.1	-3.91	0.000105	0.00814	-0.19	-0.18	Pulse pressure;	chr16:56247842	chr16:56092987~56191094:-
THCA	cis	rs591584	0.73	rs11020847	ENSG00000255893.1	RP11-685N10.1	3.91	0.000105	0.00814	0.21	0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94590746	chr11:94472908~94473570:-
THCA	cis	rs7746199	0.736	rs13202295	ENSG00000272009.1	RP1-313I6.12	-3.91	0.000105	0.00814	-0.35	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28078792~28081130:-
THCA	cis	rs8062405	0.698	rs10499	ENSG00000270424.1	RP11-1348G14.6	-3.91	0.000105	0.00814	-0.22	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28749959~28750595:-
THCA	cis	rs11881751	0.876	rs34889187	ENSG00000267011.4	CTB-50L17.16	3.91	0.000105	0.00814	0.26	0.18	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr19:5018948	chr19:4457962~4471493:-
THCA	cis	rs11881751	0.876	rs34009962	ENSG00000267011.4	CTB-50L17.16	3.91	0.000105	0.00814	0.26	0.18	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr19:5020463	chr19:4457962~4471493:-
THCA	cis	rs11881751	0.829	rs67614507	ENSG00000267011.4	CTB-50L17.16	3.91	0.000105	0.00814	0.26	0.18	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr19:5022846	chr19:4457962~4471493:-
THCA	cis	rs559928	0.597	rs11600667	ENSG00000236935.1	AP003774.1	3.91	0.000105	0.00815	0.26	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64208711	chr11:64325050~64329504:-
THCA	cis	rs875971	0.638	rs10249404	ENSG00000275400.1	RP4-756H11.5	3.91	0.000105	0.00815	0.17	0.18	Aortic root size;	chr7:66581737	chr7:66553805~66554199:-
THCA	cis	rs2298450	0.717	rs62232368	ENSG00000214867.3	SRSF9P1	3.91	0.000105	0.00815	0.26	0.18	Schizophrenia;	chr21:36253713	chr21:36295173~36295702:-
THCA	cis	rs7131987	0.903	rs2194520	ENSG00000275476.1	RP11-996F15.4	-3.91	0.000105	0.00815	-0.17	-0.18	QT interval;	chr12:29270779	chr12:29277397~29277882:-
THCA	cis	rs9467773	1	rs9467787	ENSG00000228223.2	HCG11	-3.91	0.000105	0.00815	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26523450~26526579:+
THCA	cis	rs801193	1	rs2707836	ENSG00000275400.1	RP4-756H11.5	-3.91	0.000105	0.00815	-0.17	-0.18	Aortic root size;	chr7:66695448	chr7:66553805~66554199:-
THCA	cis	rs801193	0.844	rs7779971	ENSG00000275400.1	RP4-756H11.5	-3.91	0.000105	0.00815	-0.17	-0.18	Aortic root size;	chr7:66696803	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs2659906	ENSG00000275400.1	RP4-756H11.5	-3.91	0.000105	0.00815	-0.17	-0.18	Aortic root size;	chr7:66700323	chr7:66553805~66554199:-
THCA	cis	rs878939	0.625	rs17578367	ENSG00000233690.1	EBAG9P1	3.91	0.000105	0.00815	0.23	0.18	Warfarin maintenance dose;	chr10:99584410	chr10:99697407~99697949:-
THCA	cis	rs4443100	0.916	rs6003494	ENSG00000230701.2	FBXW4P1	3.91	0.000105	0.00815	0.22	0.18	Serum parathyroid hormone levels;	chr22:23057283	chr22:23262767~23265005:+
THCA	cis	rs911555	0.755	rs8016676	ENSG00000269958.1	RP11-73M18.8	-3.91	0.000105	0.00815	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103696353~103697163:+
THCA	cis	rs9595908	0.869	rs9591185	ENSG00000212293.1	SNORA16	3.91	0.000105	0.00815	0.21	0.18	Body mass index;	chr13:32627829	chr13:32420390~32420516:-
THCA	cis	rs7267979	0.932	rs417130	ENSG00000276952.1	RP5-965G21.6	3.91	0.000105	0.00815	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.932	rs372678	ENSG00000276952.1	RP5-965G21.6	3.91	0.000105	0.00815	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25284915~25285588:-
THCA	cis	rs7973719	0.868	rs12825629	ENSG00000205885.6	C1RL-AS1	3.91	0.000105	0.00815	0.13	0.18	IgG glycosylation;	chr12:7202987	chr12:7108052~7122501:+
THCA	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	3.91	0.000105	0.00815	0.2	0.18	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	3.91	0.000105	0.00815	0.2	0.18	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	3.91	0.000105	0.00815	0.2	0.18	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
THCA	cis	rs7826238	0.623	rs2976893	ENSG00000254153.1	CTA-398F10.2	3.91	0.000105	0.00815	0.2	0.18	Systolic blood pressure;	chr8:8480709	chr8:8456909~8461337:-
THCA	cis	rs854765	0.506	rs7210400	ENSG00000281749.1	Y_RNA	-3.91	0.000105	0.00815	-0.23	-0.18	Total body bone mineral density;	chr17:18046643	chr17:18001101~18001195:-
THCA	cis	rs7577696	0.671	rs13427170	ENSG00000276334.1	AL133243.1	-3.91	0.000105	0.00816	-0.19	-0.18	Inflammatory biomarkers;	chr2:32173041	chr2:32521927~32523547:+
THCA	cis	rs2657294	0.895	rs4746262	ENSG00000226051.5	ZNF503-AS1	-3.91	0.000105	0.00816	-0.25	-0.18	Pneumonia;	chr10:75093631	chr10:75269819~75373500:+
THCA	cis	rs1499614	1	rs2707840	ENSG00000237310.1	GS1-124K5.4	3.91	0.000105	0.00816	0.21	0.18	Gout;	chr7:66693028	chr7:66493706~66495474:+
THCA	cis	rs7615952	0.604	rs9837847	ENSG00000248787.1	RP11-666A20.4	-3.91	0.000105	0.00816	-0.35	-0.18	Blood pressure (smoking interaction);	chr3:125905076	chr3:125908005~125910272:-
THCA	cis	rs2408955	0.561	rs9971924	ENSG00000257735.1	RP11-370I10.6	-3.91	0.000105	0.00816	-0.2	-0.18	Glycated hemoglobin levels;	chr12:48086049	chr12:48350945~48442411:+
THCA	cis	rs2408955	0.522	rs7139330	ENSG00000257735.1	RP11-370I10.6	-3.91	0.000105	0.00816	-0.2	-0.18	Glycated hemoglobin levels;	chr12:48089701	chr12:48350945~48442411:+
THCA	cis	rs2408955	0.522	rs2051851	ENSG00000257735.1	RP11-370I10.6	-3.91	0.000105	0.00816	-0.2	-0.18	Glycated hemoglobin levels;	chr12:48092157	chr12:48350945~48442411:+
THCA	cis	rs2135507	0.817	rs28391520	ENSG00000270480.1	RP11-57B24.1	3.91	0.000105	0.00816	0.24	0.18	Juvenile osteochondritis dissecans;	chr4:82664000	chr4:82691737~82692468:+
THCA	cis	rs2135507	0.817	rs28418575	ENSG00000270480.1	RP11-57B24.1	3.91	0.000105	0.00816	0.24	0.18	Juvenile osteochondritis dissecans;	chr4:82664069	chr4:82691737~82692468:+
THCA	cis	rs1383484	0.798	rs59355989	ENSG00000225151.9	GOLGA2P7	3.91	0.000105	0.00816	0.25	0.18	Height;	chr15:83841979	chr15:84199311~84230136:-
THCA	cis	rs4356203	0.87	rs7342262	ENSG00000272034.1	SNORD14A	-3.91	0.000105	0.00816	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17264260	chr11:17074654~17074744:-
THCA	cis	rs6163	0.588	rs10786706	ENSG00000236937.2	PTGES3P4	3.91	0.000105	0.00816	0.22	0.18	Waist circumference;Hip circumference;	chr10:102740902	chr10:102845595~102845950:+
THCA	cis	rs6163	0.588	rs3818708	ENSG00000236937.2	PTGES3P4	3.91	0.000105	0.00816	0.22	0.18	Waist circumference;Hip circumference;	chr10:102743827	chr10:102845595~102845950:+
THCA	cis	rs17122278	0.722	rs60837962	ENSG00000255239.1	AP002954.6	-3.91	0.000105	0.00816	-0.33	-0.18	Total cholesterol levels;	chr11:118567733	chr11:118688039~118690600:-
THCA	cis	rs9926296	0.533	rs7190823	ENSG00000274627.1	RP11-104N10.2	-3.91	0.000105	0.00816	-0.18	-0.18	Vitiligo;	chr16:89799635	chr16:89516797~89522217:+
THCA	cis	rs6494488	0.5	rs72742966	ENSG00000259635.1	AC100830.3	-3.91	0.000105	0.00816	-0.44	-0.18	Coronary artery disease;	chr15:64626980	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742968	ENSG00000259635.1	AC100830.3	-3.91	0.000105	0.00816	-0.44	-0.18	Coronary artery disease;	chr15:64627721	chr15:64701248~64719602:+
THCA	cis	rs2562456	0.724	rs58001930	ENSG00000268278.1	RP11-420K14.1	3.91	0.000105	0.00817	0.21	0.18	Pain;	chr19:21560061	chr19:21637974~21656300:+
THCA	cis	rs13083990	0.8	rs13061727	ENSG00000272758.4	RP11-299J3.8	3.91	0.000105	0.00817	0.17	0.18	Cardiac Troponin-T levels;	chr3:122288504	chr3:122416207~122443180:+
THCA	cis	rs150992	0.57	rs10050423	ENSG00000246763.5	RGMB-AS1	-3.91	0.000105	0.00817	-0.18	-0.18	Body mass index;	chr5:99006312	chr5:98769618~98773469:-
THCA	cis	rs9467773	0.967	rs6941022	ENSG00000228223.2	HCG11	-3.91	0.000105	0.00817	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs2224380	ENSG00000228223.2	HCG11	-3.91	0.000105	0.00817	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9461271	ENSG00000228223.2	HCG11	-3.91	0.000105	0.00817	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26523450~26526579:+
THCA	cis	rs7131987	0.903	rs67150462	ENSG00000275476.1	RP11-996F15.4	-3.91	0.000105	0.00817	-0.18	-0.18	QT interval;	chr12:29240392	chr12:29277397~29277882:-
THCA	cis	rs959260	0.688	rs4789173	ENSG00000263843.1	RP11-649A18.12	3.91	0.000105	0.00817	0.2	0.18	Systemic lupus erythematosus;	chr17:75353416	chr17:75271369~75273895:+
THCA	cis	rs7914558	0.966	rs11191471	ENSG00000213061.2	PFN1P11	3.91	0.000105	0.00817	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102942293	chr10:102838011~102845473:-
THCA	cis	rs11671005	0.779	rs3794970	ENSG00000269600.1	AC016629.3	3.91	0.000105	0.00817	0.26	0.18	Mean platelet volume;	chr19:58474893	chr19:58593896~58599355:-
THCA	cis	rs922182	0.692	rs7162147	ENSG00000275785.1	RP11-111E14.2	3.91	0.000105	0.00817	0.2	0.18	Blood protein levels;	chr15:63999301	chr15:63890030~63890317:+
THCA	cis	rs6473252	0.966	rs4739760	ENSG00000254162.1	RP11-48B3.3	-3.91	0.000105	0.00817	-0.15	-0.18	Breast cancer;	chr8:80899077	chr8:80535006~80539135:-
THCA	cis	rs6473252	0.966	rs4739761	ENSG00000254162.1	RP11-48B3.3	-3.91	0.000105	0.00817	-0.15	-0.18	Breast cancer;	chr8:80899206	chr8:80535006~80539135:-
THCA	cis	rs6473252	0.966	rs2084088	ENSG00000254162.1	RP11-48B3.3	-3.91	0.000105	0.00817	-0.15	-0.18	Breast cancer;	chr8:80899670	chr8:80535006~80539135:-
THCA	cis	rs6473252	0.966	rs55690008	ENSG00000254162.1	RP11-48B3.3	-3.91	0.000105	0.00817	-0.15	-0.18	Breast cancer;	chr8:80900278	chr8:80535006~80539135:-
THCA	cis	rs6473252	0.966	rs12546179	ENSG00000254162.1	RP11-48B3.3	-3.91	0.000105	0.00817	-0.15	-0.18	Breast cancer;	chr8:80901849	chr8:80535006~80539135:-
THCA	cis	rs1908814	0.516	rs11250178	ENSG00000206014.6	OR7E161P	-3.91	0.000105	0.00817	-0.21	-0.18	Neuroticism;	chr8:11942725	chr8:11928597~11929563:-
THCA	cis	rs925946	0.518	rs12419462	ENSG00000245573.6	BDNF-AS	-3.91	0.000105	0.00817	-0.17	-0.18	Weight;Body mass index;	chr11:27601762	chr11:27506838~27698174:+
THCA	cis	rs2278702	1	rs75809369	ENSG00000259495.2	RP11-210M15.2	-3.91	0.000105	0.00817	-0.26	-0.18	Bipolar disorder;	chr15:80406225	chr15:80344853~80403575:-
THCA	cis	rs4780355	0.918	rs243323	ENSG00000263080.1	RP11-485G7.5	3.91	0.000105	0.00817	0.22	0.18	Crohn's disease and psoriasis;	chr16:11267345	chr16:11341809~11345211:-
THCA	cis	rs1348850	0.645	rs13431091	ENSG00000280374.1	RP11-337N6.3	-3.91	0.000105	0.00817	-0.28	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177569887	chr2:177317715~177318471:-
THCA	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	3.91	0.000105	0.00818	0.23	0.18	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
THCA	cis	rs6756513	0.5	rs33992437	ENSG00000231024.1	AC092431.3	-3.91	0.000105	0.00818	-0.26	-0.18	Breast cancer;Platelet count;	chr2:69828039	chr2:69700192~69713847:-
THCA	cis	rs34779708	0.801	rs12246600	ENSG00000233200.1	RP11-324I22.2	3.91	0.000105	0.00818	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.801	rs12098720	ENSG00000233200.1	RP11-324I22.2	3.91	0.000105	0.00818	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.801	rs34592588	ENSG00000233200.1	RP11-324I22.2	3.91	0.000105	0.00818	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35219894~35230598:-
THCA	cis	rs28374715	0.532	rs28897479	ENSG00000247556.5	OIP5-AS1	3.91	0.000105	0.00818	0.18	0.18	Ulcerative colitis;	chr15:41398653	chr15:41283990~41309737:+
THCA	cis	rs365302	0.904	rs409843	ENSG00000235086.1	FNDC1-IT1	3.91	0.000105	0.00818	0.25	0.18	Coronary heart disease;	chr6:159227800	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs418902	ENSG00000235086.1	FNDC1-IT1	3.91	0.000105	0.00818	0.25	0.18	Coronary heart disease;	chr6:159227832	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs418901	ENSG00000235086.1	FNDC1-IT1	3.91	0.000105	0.00818	0.25	0.18	Coronary heart disease;	chr6:159227837	chr6:159240786~159243329:+
THCA	cis	rs2120243	0.572	rs3816528	ENSG00000241770.1	RP11-555M1.3	3.91	0.000105	0.00818	0.23	0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157409501	chr3:157163452~157169133:+
THCA	cis	rs853679	0.517	rs2273564	ENSG00000219891.2	ZSCAN12P1	3.91	0.000105	0.00818	0.25	0.18	Depression;	chr6:28089816	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000219891.2	ZSCAN12P1	3.91	0.000105	0.00818	0.25	0.18	Depression;	chr6:28090857	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000219891.2	ZSCAN12P1	3.91	0.000105	0.00818	0.25	0.18	Depression;	chr6:28091439	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000219891.2	ZSCAN12P1	3.91	0.000105	0.00818	0.25	0.18	Depression;	chr6:28092227	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000219891.2	ZSCAN12P1	3.91	0.000105	0.00818	0.25	0.18	Depression;	chr6:28093966	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000219891.2	ZSCAN12P1	3.91	0.000105	0.00818	0.25	0.18	Depression;	chr6:28094014	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000219891.2	ZSCAN12P1	3.91	0.000105	0.00818	0.25	0.18	Depression;	chr6:28096077	chr6:28091154~28093664:+
THCA	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-3.91	0.000105	0.00818	-0.19	-0.18	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
THCA	cis	rs959260	0.748	rs4789178	ENSG00000263843.1	RP11-649A18.12	3.91	0.000106	0.00818	0.19	0.18	Systemic lupus erythematosus;	chr17:75372161	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs2117562	ENSG00000263843.1	RP11-649A18.12	3.91	0.000106	0.00818	0.19	0.18	Systemic lupus erythematosus;	chr17:75372919	chr17:75271369~75273895:+
THCA	cis	rs7432375	0.901	rs11919030	ENSG00000273455.1	RP11-305O4.3	3.91	0.000106	0.00818	0.23	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136629757	chr3:136087475~136087913:-
THCA	cis	rs9425766	0.962	rs2065171	ENSG00000270084.1	GAS5-AS1	-3.91	0.000106	0.00818	-0.18	-0.18	Life satisfaction;	chr1:173876972	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.962	rs4652229	ENSG00000270084.1	GAS5-AS1	-3.91	0.000106	0.00818	-0.18	-0.18	Life satisfaction;	chr1:173877452	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.927	rs9425765	ENSG00000270084.1	GAS5-AS1	-3.91	0.000106	0.00818	-0.18	-0.18	Life satisfaction;	chr1:173878871	chr1:173863248~173863941:+
THCA	cis	rs1577917	0.916	rs12206726	ENSG00000220563.1	PKMP3	-3.91	0.000106	0.00818	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85789998	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs12209259	ENSG00000220563.1	PKMP3	-3.91	0.000106	0.00818	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85792630	chr6:85659892~85660606:-
THCA	cis	rs875971	0.54	rs4717275	ENSG00000229180.5	GS1-124K5.11	-3.91	0.000106	0.00818	-0.12	-0.18	Aortic root size;	chr7:65800193	chr7:66526088~66542624:-
THCA	cis	rs944289	0.53	rs2755193	ENSG00000258844.1	RP11-259K15.2	-3.91	0.000106	0.00818	-0.16	-0.18	Thyroid cancer;	chr14:36049416	chr14:36214607~36235608:+
THCA	cis	rs1612141	1	rs1782143	ENSG00000251363.2	RP11-129M6.1	-3.91	0.000106	0.00818	-0.26	-0.18	QT interval (drug interaction);	chr14:41258531	chr14:40954898~40975877:+
THCA	cis	rs854765	0.693	rs8080061	ENSG00000281749.1	Y_RNA	-3.91	0.000106	0.00818	-0.22	-0.18	Total body bone mineral density;	chr17:17873075	chr17:18001101~18001195:-
THCA	cis	rs17504106	0.666	rs10075958	ENSG00000254373.1	RP11-34P1.2	3.91	0.000106	0.00818	0.21	0.18	Post-traumatic stress disorder;	chr5:161067752	chr5:160258253~160258585:+
THCA	cis	rs513088	0.681	rs556498	ENSG00000225171.2	DUTP6	3.91	0.000106	0.00818	0.26	0.18	Schizophrenia;	chr1:166719963	chr1:166868748~166869209:+
THCA	cis	rs1404100	0.531	rs1038271	ENSG00000240476.1	LINC00973	-3.91	0.000106	0.00818	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067399	chr3:98981058~98983096:+
THCA	cis	rs7615304	0.617	rs343994	ENSG00000243926.1	TIPARP-AS1	-3.91	0.000106	0.00819	-0.17	-0.18	Interleukin-2 levels;	chr3:156787575	chr3:156671862~156674378:-
THCA	cis	rs7829975	0.742	rs1533058	ENSG00000254340.1	RP11-10A14.3	3.91	0.000106	0.00819	0.2	0.18	Mood instability;	chr8:8827680	chr8:9141424~9145435:+
THCA	cis	rs3015497	0.789	rs2934688	ENSG00000270062.1	RP11-248J18.3	3.91	0.000106	0.00819	0.2	0.18	Mean platelet volume;	chr14:50645642	chr14:50723777~50724272:-
THCA	cis	rs7267979	0.745	rs6132845	ENSG00000274973.1	RP13-401N8.7	-3.91	0.000106	0.00819	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25845497~25845862:+
THCA	cis	rs9316337	0.582	rs9316380	ENSG00000236953.1	ZDHHC20-IT1	-3.91	0.000106	0.00819	-0.2	-0.18	Schizophrenia;	chr13:21449475	chr13:21376977~21377874:-
THCA	cis	rs2732480	0.577	rs2634693	ENSG00000257735.1	RP11-370I10.6	3.91	0.000106	0.00819	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.577	rs2634691	ENSG00000257735.1	RP11-370I10.6	3.91	0.000106	0.00819	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48350945~48442411:+
THCA	cis	rs9868809	0.772	rs73078349	ENSG00000270441.1	RP11-694I15.7	3.91	0.000106	0.00819	0.27	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48650681	chr3:49140086~49160851:-
THCA	cis	rs6696239	0.823	rs12124388	ENSG00000227711.2	RP11-275O4.5	-3.91	0.000106	0.00819	-0.24	-0.18	Height;	chr1:227683125	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.866	rs7536661	ENSG00000227711.2	RP11-275O4.5	-3.91	0.000106	0.00819	-0.24	-0.18	Height;	chr1:227683846	chr1:227509028~227520477:-
THCA	cis	rs6918586	1	rs6918586	ENSG00000272462.2	U91328.19	3.91	0.000106	0.00819	0.14	0.18	Schizophrenia;	chr6:26097156	chr6:25992662~26001775:+
THCA	cis	rs962856	0.619	rs1601530	ENSG00000236780.4	AC078941.1	3.91	0.000106	0.00819	0.24	0.18	Pancreatic cancer;	chr2:67367784	chr2:67123357~67215319:-
THCA	cis	rs7819412	0.745	rs6601569	ENSG00000261451.1	RP11-981G7.1	-3.91	0.000106	0.00819	-0.22	-0.18	Triglycerides;	chr8:11216069	chr8:10433672~10438312:+
THCA	cis	rs11069062	0.866	rs10851021	ENSG00000270482.1	RP11-131L12.2	3.91	0.000106	0.00819	0.14	0.18	Obesity-related traits;	chr12:118721158	chr12:118375350~118376275:-
THCA	cis	rs11069062	0.866	rs1829564	ENSG00000270482.1	RP11-131L12.2	3.91	0.000106	0.00819	0.14	0.18	Obesity-related traits;	chr12:118724144	chr12:118375350~118376275:-
THCA	cis	rs12893668	0.703	rs34026011	ENSG00000244691.1	RPL10AP1	-3.91	0.000106	0.00819	-0.25	-0.18	Reticulocyte count;	chr14:103584546	chr14:103412119~103412761:-
THCA	cis	rs28510890	0.547	rs10152637	ENSG00000258676.4	RP11-386M24.3	3.91	0.000106	0.0082	0.2	0.18	Lung cancer in ever smokers;	chr15:92602409	chr15:92580829~92600545:+
THCA	cis	rs214785	1	rs214794	ENSG00000226644.4	RP11-128M1.1	3.91	0.000106	0.0082	0.18	0.18	Basal cell carcinoma;	chr20:2305411	chr20:2207217~2213151:+
THCA	cis	rs875971	0.545	rs73152714	ENSG00000273024.4	INTS4P2	-3.91	0.000106	0.0082	-0.22	-0.18	Aortic root size;	chr7:66534641	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000273024.4	INTS4P2	-3.91	0.000106	0.0082	-0.22	-0.18	Aortic root size;	chr7:66536353	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000273024.4	INTS4P2	3.91	0.000106	0.0082	0.22	0.18	Aortic root size;	chr7:66560286	chr7:65647864~65715661:+
THCA	cis	rs73193808	0.639	rs2832242	ENSG00000176054.6	RPL23P2	3.91	0.000106	0.0082	0.16	0.18	Coronary artery disease;	chr21:29179864	chr21:28997613~28998033:-
THCA	cis	rs7819412	0.669	rs6601568	ENSG00000255495.1	AC145124.2	-3.91	0.000106	0.0082	-0.21	-0.18	Triglycerides;	chr8:11215893	chr8:12194467~12196280:+
THCA	cis	rs875971	0.862	rs709609	ENSG00000229886.1	RP5-1132H15.3	-3.91	0.000106	0.0082	-0.19	-0.18	Aortic root size;	chr7:66095574	chr7:66025126~66031544:-
THCA	cis	rs11242704	0.962	rs12200039	ENSG00000272279.1	RP11-157J24.2	-3.91	0.000106	0.0082	-0.29	-0.18	Response to hepatitis C treatment;	chr6:1536150	chr6:1528364~1528911:-
THCA	cis	rs10833905	0.938	rs10833931	ENSG00000246225.5	RP11-17A1.3	3.91	0.000106	0.0082	0.26	0.18	Sudden cardiac arrest;	chr11:23075707	chr11:22829380~22945393:+
THCA	cis	rs16852403	0.619	rs10913513	ENSG00000224687.1	RASAL2-AS1	3.91	0.000106	0.0082	0.29	0.18	Childhood ear infection;	chr1:178166806	chr1:178091508~178093984:-
THCA	cis	rs16852403	0.571	rs11800119	ENSG00000224687.1	RASAL2-AS1	3.91	0.000106	0.0082	0.29	0.18	Childhood ear infection;	chr1:178175838	chr1:178091508~178093984:-
THCA	cis	rs12780845	0.54	rs11254406	ENSG00000234961.1	RP11-124N14.3	3.91	0.000106	0.0082	0.19	0.18	Homocysteine levels;	chr10:17149693	chr10:17233325~17234833:-
THCA	cis	rs6517329	0.899	rs2835281	ENSG00000236830.5	CBR3-AS1	-3.91	0.000106	0.0082	-0.16	-0.18	Schizophrenia;	chr21:36117592	chr21:36131767~36175815:-
THCA	cis	rs4950322	0.58	rs4950308	ENSG00000180867.10	PDIA3P1	3.91	0.000106	0.0082	0.17	0.18	Protein quantitative trait loci;	chr1:147120092	chr1:147178113~147179622:+
THCA	cis	rs962856	0.575	rs6732641	ENSG00000236780.4	AC078941.1	3.91	0.000106	0.00821	0.24	0.18	Pancreatic cancer;	chr2:67381453	chr2:67123357~67215319:-
THCA	cis	rs962856	0.575	rs7579385	ENSG00000236780.4	AC078941.1	3.91	0.000106	0.00821	0.24	0.18	Pancreatic cancer;	chr2:67384140	chr2:67123357~67215319:-
THCA	cis	rs12681366	0.801	rs12549544	ENSG00000261437.1	RP11-22C11.2	3.91	0.000106	0.00821	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94637285~94639467:-
THCA	cis	rs9368481	0.569	rs6907403	ENSG00000261353.1	CTA-14H9.5	-3.91	0.000106	0.00821	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26527063~26527404:+
THCA	cis	rs9368481	0.502	rs3933232	ENSG00000261353.1	CTA-14H9.5	-3.91	0.000106	0.00821	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26527063~26527404:+
THCA	cis	rs4792901	0.959	rs9899005	ENSG00000267151.3	RP11-100E5.2	3.91	0.000106	0.00821	0.18	0.18	Dupuytren's disease;	chr17:43565500	chr17:43444707~43451200:+
THCA	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-3.91	0.000106	0.00821	-0.17	-0.18	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-3.91	0.000106	0.00821	-0.17	-0.18	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
THCA	cis	rs10411161	0.58	rs10409620	ENSG00000275055.1	CTC-471J1.11	-3.91	0.000106	0.00821	-0.15	-0.18	Breast cancer;	chr19:51867923	chr19:52049007~52049754:+
THCA	cis	rs2474937	0.561	rs6428745	ENSG00000231365.4	RP11-418J17.1	3.91	0.000106	0.00821	0.18	0.18	Congenital heart malformation;	chr1:118382831	chr1:119140396~119275973:+
THCA	cis	rs17301013	0.896	rs13375788	ENSG00000270084.1	GAS5-AS1	-3.91	0.000106	0.00821	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174524207	chr1:173863248~173863941:+
THCA	cis	rs150992	0.548	rs12109067	ENSG00000246763.5	RGMB-AS1	3.91	0.000106	0.00821	0.18	0.18	Body mass index;	chr5:99038928	chr5:98769618~98773469:-
THCA	cis	rs10484434	1	rs62394540	ENSG00000272462.2	U91328.19	3.91	0.000106	0.00821	0.2	0.18	HIV-1 viral setpoint;	chr6:25970946	chr6:25992662~26001775:+
THCA	cis	rs1979679	0.573	rs4931087	ENSG00000247934.4	RP11-967K21.1	-3.91	0.000106	0.00821	-0.18	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582158	chr12:28163298~28190738:-
THCA	cis	rs1383484	0.958	rs5016012	ENSG00000259728.4	LINC00933	-3.91	0.000106	0.00822	-0.22	-0.18	Height;	chr15:83843253	chr15:84570649~84580175:+
THCA	cis	rs4916588	0.697	rs4916586	ENSG00000270170.1	NCBP2-AS2	3.91	0.000106	0.00822	0.14	0.18	Night sleep phenotypes;	chr3:196933949	chr3:196942623~196943540:+
THCA	cis	rs5758511	0.68	rs5758652	ENSG00000237037.8	NDUFA6-AS1	-3.91	0.000106	0.00822	-0.17	-0.18	Birth weight;	chr22:42216402	chr22:42090931~42137742:+
THCA	cis	rs5758511	0.68	rs1033460	ENSG00000237037.8	NDUFA6-AS1	-3.91	0.000106	0.00822	-0.17	-0.18	Birth weight;	chr22:42223302	chr22:42090931~42137742:+
THCA	cis	rs5758511	0.679	rs55867855	ENSG00000237037.8	NDUFA6-AS1	-3.91	0.000106	0.00822	-0.17	-0.18	Birth weight;	chr22:42227252	chr22:42090931~42137742:+
THCA	cis	rs2839186	0.872	rs2250213	ENSG00000228137.1	AP001469.7	3.91	0.000106	0.00822	0.18	0.18	Testicular germ cell tumor;	chr21:46254361	chr21:46246890~46247682:+
THCA	cis	rs2239815	0.576	rs10427628	ENSG00000272858.1	CTA-292E10.8	-3.91	0.000106	0.00822	-0.21	-0.18	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28843778	chr22:28814914~28815662:+
THCA	cis	rs13118159	0.527	rs6599309	ENSG00000254094.1	AC078852.1	-3.91	0.000106	0.00822	-0.22	-0.18	Longevity;	chr4:1394327	chr4:1356581~1358075:+
THCA	cis	rs6088580	0.524	rs6088569	ENSG00000126005.14	MMP24-AS1	3.91	0.000106	0.00822	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34680395	chr20:35216462~35278131:-
THCA	cis	rs7824557	0.564	rs2736290	ENSG00000154316.13	TDH	3.91	0.000106	0.00822	0.13	0.18	Retinal vascular caliber;	chr8:11376789	chr8:11339637~11368452:+
THCA	cis	rs2839186	0.814	rs13052376	ENSG00000215424.8	MCM3AP-AS1	3.91	0.000106	0.00822	0.1	0.18	Testicular germ cell tumor;	chr21:46287489	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.934	rs13046494	ENSG00000215424.8	MCM3AP-AS1	3.91	0.000106	0.00822	0.1	0.18	Testicular germ cell tumor;	chr21:46287516	chr21:46229217~46259390:+
THCA	cis	rs2839186	0.872	rs13052495	ENSG00000215424.8	MCM3AP-AS1	3.91	0.000106	0.00822	0.1	0.18	Testicular germ cell tumor;	chr21:46287560	chr21:46229217~46259390:+
THCA	cis	rs1864585	0.806	rs73209947	ENSG00000280294.1	RP11-177H2.1	3.91	0.000106	0.00822	0.19	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10891938	chr8:10856085~10859436:-
THCA	cis	rs801193	0.935	rs11772264	ENSG00000223473.2	GS1-124K5.3	3.91	0.000106	0.00822	0.12	0.18	Aortic root size;	chr7:66711400	chr7:66491049~66493566:-
THCA	cis	rs7216064	1	rs62085993	ENSG00000265055.1	AC145343.2	3.91	0.000106	0.00822	0.25	0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67927036	chr17:68096046~68101474:-
THCA	cis	rs782212	0.592	rs4649955	ENSG00000227207.2	RPL31P12	3.91	0.000106	0.00822	0.3	0.18	Depression;	chr1:72422971	chr1:72301472~72301829:+
THCA	cis	rs4791641	0.756	rs2313286	ENSG00000178977.3	LINC00324	3.91	0.000106	0.00822	0.2	0.18	Red blood cell count;LDL cholesterol;Hematocrit;Hemoglobin concentration;LDL cholesterol levels;	chr17:8275010	chr17:8220642~8224043:-
THCA	cis	rs13434995	0.513	rs62303728	ENSG00000249700.7	SRD5A3-AS1	-3.91	0.000106	0.00822	-0.25	-0.18	Adiponectin levels;	chr4:55495762	chr4:55363971~55395847:-
THCA	cis	rs8177876	0.597	rs1048194	ENSG00000261838.4	RP11-303E16.6	-3.91	0.000106	0.00822	-0.37	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81069854~81076598:+
THCA	cis	rs6893300	0.785	rs11738720	ENSG00000225051.5	HMGB3P22	3.91	0.000106	0.00823	0.18	0.18	Resting heart rate;	chr5:179727997	chr5:179679032~179694768:+
THCA	cis	rs4742903	0.935	rs1580014	ENSG00000270332.1	SMC2-AS1	3.91	0.000106	0.00823	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104171344	chr9:104080024~104093073:-
THCA	cis	rs17711722	0.523	rs313812	ENSG00000272831.1	RP11-792A8.4	-3.91	0.000106	0.00823	-0.11	-0.18	Calcium levels;	chr7:66040056	chr7:66739829~66740385:-
THCA	cis	rs763121	0.813	rs2179143	ENSG00000225450.1	RP3-508I15.14	-3.91	0.000106	0.00823	-0.14	-0.18	Menopause (age at onset);	chr22:38641979	chr22:38739003~38749041:+
THCA	cis	rs7616559	0.649	rs35626159	ENSG00000244515.1	KRT18P34	-3.91	0.000106	0.00823	-0.21	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157015087	chr3:157162663~157163932:-
THCA	cis	rs4144027	0.967	rs72712857	ENSG00000269958.1	RP11-73M18.8	3.91	0.000106	0.00823	0.16	0.18	Blood metabolite levels;	chr14:103896336	chr14:103696353~103697163:+
THCA	cis	rs11601239	0.668	rs10750733	ENSG00000254750.1	CASP1P2	-3.91	0.000106	0.00823	-0.14	-0.18	Refractive error;	chr11:105768630	chr11:105063345~105071541:-
THCA	cis	rs5758511	0.596	rs55644935	ENSG00000205702.9	CYP2D7	3.91	0.000106	0.00823	0.16	0.18	Birth weight;	chr22:42270063	chr22:42140203~42144577:-
THCA	cis	rs11239930	0.538	rs59064267	ENSG00000278811.3	LINC00624	3.91	0.000106	0.00823	0.21	0.18	AIDS progression;	chr1:147089146	chr1:147258885~147517875:-
THCA	cis	rs9813712	0.953	rs9847910	ENSG00000253540.4	FAM86HP	3.91	0.000106	0.00823	0.22	0.18	Response to amphetamines;	chr3:130248174	chr3:130099092~130111472:-
THCA	cis	rs2221894	1	rs10111019	ENSG00000251191.6	LINC00589	-3.91	0.000106	0.00823	-0.21	-0.18	Obesity-related traits;	chr8:28972783	chr8:29673922~29748109:-
THCA	cis	rs12893668	0.703	rs35498576	ENSG00000244691.1	RPL10AP1	-3.91	0.000106	0.00823	-0.25	-0.18	Reticulocyte count;	chr14:103559556	chr14:103412119~103412761:-
THCA	cis	rs6687821	0.515	rs56291917	ENSG00000261737.1	RP4-612B15.3	-3.91	0.000106	0.00823	-0.27	-0.18	Yeast infection;	chr1:86934926	chr1:86703502~86704462:-
THCA	cis	rs3740713	0.592	rs73434674	ENSG00000256464.1	YWHABP2	3.91	0.000106	0.00823	0.29	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr11:18490243~18490955:-
THCA	cis	rs4272720	0.639	rs7088718	ENSG00000234736.4	FAM170B-AS1	-3.91	0.000106	0.00823	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49061639	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.639	rs7073208	ENSG00000234736.4	FAM170B-AS1	-3.91	0.000106	0.00823	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49061668	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.639	rs12244666	ENSG00000234736.4	FAM170B-AS1	-3.91	0.000106	0.00823	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49062332	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.639	rs4402204	ENSG00000234736.4	FAM170B-AS1	-3.91	0.000106	0.00823	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49063812	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.587	rs12253426	ENSG00000234736.4	FAM170B-AS1	-3.91	0.000106	0.00823	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49067014	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.639	rs35462783	ENSG00000234736.4	FAM170B-AS1	-3.91	0.000106	0.00823	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49068780	chr10:49121839~49151547:+
THCA	cis	rs4713118	0.539	rs200988	ENSG00000226314.6	ZNF192P1	-3.91	0.000106	0.00823	-0.21	-0.18	Parkinson's disease;	chr6:27851575	chr6:28161781~28169594:+
THCA	cis	rs200986	1	rs200986	ENSG00000226314.6	ZNF192P1	-3.91	0.000106	0.00823	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28161781~28169594:+
THCA	cis	rs7010876	0.632	rs1915024	ENSG00000253553.4	RP11-586K2.1	-3.91	0.000106	0.00823	-0.19	-0.18	Schizophrenia;	chr8:88282725	chr8:88326836~88737134:+
THCA	cis	rs1008126	0.8	rs2711853	ENSG00000234715.1	CTB-107G13.1	-3.91	0.000106	0.00823	-0.21	-0.18	Metabolite levels (Pyroglutamine);	chr7:103520843	chr7:103445207~103514007:+
THCA	cis	rs6756513	0.5	rs2290452	ENSG00000231024.1	AC092431.3	-3.91	0.000106	0.00824	-0.27	-0.18	Breast cancer;Platelet count;	chr2:69820512	chr2:69700192~69713847:-
THCA	cis	rs79478560	0.518	rs7978781	ENSG00000270061.1	RP11-214K3.19	-3.91	0.000106	0.00824	-0.23	-0.18	Lymphocyte counts;	chr12:123903490	chr12:123969990~123970344:-
THCA	cis	rs10484434	0.818	rs11755492	ENSG00000272810.1	U91328.22	3.91	0.000106	0.00824	0.19	0.18	HIV-1 viral setpoint;	chr6:26045930	chr6:26013241~26013757:+
THCA	cis	rs2832191	0.716	rs8132085	ENSG00000176054.6	RPL23P2	-3.91	0.000106	0.00824	-0.15	-0.18	Dental caries;	chr21:29129068	chr21:28997613~28998033:-
THCA	cis	rs7904321	1	rs2036791	ENSG00000232075.1	MRPL35P2	-3.91	0.000106	0.00824	-0.23	-0.18	Intelligence (multi-trait analysis);	chr10:63074592	chr10:63634317~63634827:-
THCA	cis	rs879500	0.961	rs11083288	ENSG00000227279.1	AC015933.2	-3.91	0.000106	0.00824	-0.2	-0.18	Lung function (FVC);	chr18:28530995	chr18:27954519~27963687:+
THCA	cis	rs3845817	0.868	rs702890	ENSG00000281920.1	RP11-418H16.1	3.91	0.000106	0.00824	0.22	0.18	Bipolar disorder;	chr2:65530517	chr2:65623272~65628424:+
THCA	cis	rs2275906	0.557	rs1408269	ENSG00000272462.2	U91328.19	3.91	0.000106	0.00824	0.16	0.18	Urate levels in lean individuals;	chr6:25879795	chr6:25992662~26001775:+
THCA	cis	rs4671400	0.571	rs2421116	ENSG00000271889.1	RP11-493E12.1	-3.91	0.000106	0.00824	-0.19	-0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61261276	chr2:61151433~61162105:-
THCA	cis	rs10129255	0.957	rs10142918	ENSG00000211972.2	IGHV3-66	3.91	0.000106	0.00824	0.1	0.18	Kawasaki disease;	chr14:106782206	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs10142859	ENSG00000211972.2	IGHV3-66	3.91	0.000106	0.00824	0.1	0.18	Kawasaki disease;	chr14:106782238	chr14:106675017~106675544:-
THCA	cis	rs4706831	0.647	rs9350847	ENSG00000260645.1	RP11-250B2.5	3.91	0.000106	0.00824	0.15	0.18	Joint mobility (Beighton score);	chr6:80179300	chr6:80466958~80469080:+
THCA	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-3.91	0.000106	0.00824	-0.17	-0.18	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
THCA	cis	rs2657294	0.895	rs3088142	ENSG00000233313.2	HMGA1P5	-3.91	0.000106	0.00824	-0.24	-0.18	Pneumonia;	chr10:75094806	chr10:75276376~75276646:-
THCA	cis	rs853679	0.607	rs68188794	ENSG00000220721.1	OR1F12	3.91	0.000106	0.00824	0.4	0.18	Depression;	chr6:28112999	chr6:28073316~28074233:+
THCA	cis	rs12497850	0.864	rs4955410	ENSG00000228638.1	FCF1P2	-3.91	0.000106	0.00824	-0.19	-0.18	Parkinson's disease;	chr3:49143785	chr3:48290793~48291375:-
THCA	cis	rs12760731	0.511	rs12758980	ENSG00000213057.5	C1orf220	3.91	0.000106	0.00824	0.18	0.18	Obesity-related traits;	chr1:178642498	chr1:178542752~178548889:+
THCA	cis	rs2562456	0.876	rs11085467	ENSG00000268278.1	RP11-420K14.1	3.91	0.000106	0.00825	0.21	0.18	Pain;	chr19:21569041	chr19:21637974~21656300:+
THCA	cis	rs11971779	0.648	rs6467852	ENSG00000252332.1	RNU6-911P	-3.91	0.000106	0.00825	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139427845	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.616	rs7779314	ENSG00000252332.1	RNU6-911P	-3.91	0.000106	0.00825	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139427950	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.715	rs7779390	ENSG00000252332.1	RNU6-911P	-3.91	0.000106	0.00825	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139428207	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.584	rs34762928	ENSG00000252332.1	RNU6-911P	-3.91	0.000106	0.00825	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139428422	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs11760420	ENSG00000252332.1	RNU6-911P	-3.91	0.000106	0.00825	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139430022	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.553	rs10228643	ENSG00000252332.1	RNU6-911P	-3.91	0.000106	0.00825	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139430674	chr7:139448740~139448843:+
THCA	cis	rs4700393	0.52	rs5012862	ENSG00000251279.1	CTC-436P18.1	-3.91	0.000107	0.00825	-0.24	-0.18	Intelligence (multi-trait analysis);	chr5:60588926	chr5:61162070~61232040:+
THCA	cis	rs3813567	0.759	rs7163204	ENSG00000261143.1	ADAMTS7P3	-3.91	0.000107	0.00825	-0.27	-0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78661398	chr15:77976042~77993057:+
THCA	cis	rs3813567	0.702	rs7164665	ENSG00000261143.1	ADAMTS7P3	-3.91	0.000107	0.00825	-0.27	-0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78661577	chr15:77976042~77993057:+
THCA	cis	rs9291683	0.53	rs4697698	ENSG00000250413.1	RP11-448G15.1	-3.91	0.000107	0.00825	-0.17	-0.18	Bone mineral density;	chr4:9940953	chr4:10006482~10009725:+
THCA	cis	rs240993	0.595	rs1040383	ENSG00000271789.1	RP5-1112D6.7	3.91	0.000107	0.00825	0.19	0.18	Inflammatory skin disease;Psoriasis;	chr6:111580985	chr6:111297126~111298510:+
THCA	cis	rs7824557	0.564	rs12550129	ENSG00000154316.13	TDH	3.91	0.000107	0.00825	0.13	0.18	Retinal vascular caliber;	chr8:11376408	chr8:11339637~11368452:+
THCA	cis	rs4950322	0.576	rs4950427	ENSG00000180867.10	PDIA3P1	-3.91	0.000107	0.00825	-0.16	-0.18	Protein quantitative trait loci;	chr1:147391175	chr1:147178113~147179622:+
THCA	cis	rs1923243	0.814	rs11210139	ENSG00000223479.3	RP4-788P17.1	-3.91	0.000107	0.00825	-0.19	-0.18	Migraine;	chr1:73130808	chr1:73635216~73715214:+
THCA	cis	rs78153629	1	rs8033938	ENSG00000259330.1	INAFM2	-3.91	0.000107	0.00825	-0.21	-0.18	Heschl's gyrus morphology;	chr15:40410915	chr15:40325216~40326715:+
THCA	cis	rs4705962	0.878	rs2299003	ENSG00000230612.2	AC004237.1	3.91	0.000107	0.00825	0.22	0.18	Atopic dermatitis;	chr5:132722604	chr5:132688681~132723725:+
THCA	cis	rs7911264	0.765	rs2421941	ENSG00000236493.2	EIF2S2P3	3.91	0.000107	0.00825	0.19	0.18	Inflammatory bowel disease;	chr10:92586152	chr10:92668745~92669743:-
THCA	cis	rs9368481	0.524	rs12530345	ENSG00000261353.1	CTA-14H9.5	-3.91	0.000107	0.00825	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26527063~26527404:+
THCA	cis	rs10419113	0.668	rs10403851	ENSG00000268545.1	VN1R107P	-3.91	0.000107	0.00825	-0.21	-0.18	Pediatric bone mineral density (spine);	chr19:57667866	chr19:57459912~57460120:+
THCA	cis	rs804280	1	rs804281	ENSG00000254948.1	OR7E158P	-3.91	0.000107	0.00825	-0.22	-0.18	Myopia (pathological);	chr8:11754356	chr8:11919900~11920809:-
THCA	cis	rs13064411	0.66	rs11916690	ENSG00000243849.1	CFAP44-AS1	3.91	0.000107	0.00825	0.28	0.18	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113293496	chr3:113403991~113433992:+
THCA	cis	rs448720	1	rs8035326	ENSG00000260657.2	RP11-315D16.4	-3.91	0.000107	0.00825	-0.22	-0.18	Cognitive performance;	chr15:67916195	chr15:68267792~68277994:-
THCA	cis	rs7528684	1	rs7528684	ENSG00000236731.1	RP4-801G22.2	3.91	0.000107	0.00826	0.18	0.18	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157701026	chr1:157629939~157630728:-
THCA	cis	rs9844666	0.512	rs13322891	ENSG00000273486.1	RP11-731C17.2	3.91	0.000107	0.00826	0.16	0.18	Height;	chr3:135914683	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9877722	ENSG00000273486.1	RP11-731C17.2	3.91	0.000107	0.00826	0.16	0.18	Height;	chr3:135916626	chr3:136837338~136839021:-
THCA	cis	rs4819052	0.84	rs914217	ENSG00000273796.1	LL21NC02-21A1.1	-3.91	0.000107	0.00826	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45403809~45404369:-
THCA	cis	rs9368481	0.547	rs2093303	ENSG00000261353.1	CTA-14H9.5	-3.91	0.000107	0.00826	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26527063~26527404:+
THCA	cis	rs6600671	1	rs11249351	ENSG00000275585.1	CH17-118O6.3	-3.91	0.000107	0.00826	-0.21	-0.18	Hip geometry;	chr1:121430082	chr1:120985692~121052167:-
THCA	cis	rs6893300	0.776	rs55868831	ENSG00000225051.5	HMGB3P22	3.91	0.000107	0.00826	0.18	0.18	Resting heart rate;	chr5:179730295	chr5:179679032~179694768:+
THCA	cis	rs6893300	0.776	rs56396231	ENSG00000225051.5	HMGB3P22	3.91	0.000107	0.00826	0.18	0.18	Resting heart rate;	chr5:179730297	chr5:179679032~179694768:+
THCA	cis	rs708224	0.558	rs161981	ENSG00000277342.1	RP11-843B15.4	-3.91	0.000107	0.00826	-0.22	-0.18	Pancreatic cancer;	chr12:32265317	chr12:32109076~32109602:+
THCA	cis	rs75920871	0.66	rs12271161	ENSG00000254851.1	RP11-109L13.1	3.91	0.000107	0.00826	0.28	0.18	Subjective well-being;	chr11:117109195	chr11:117135528~117138582:+
THCA	cis	rs10771431	0.81	rs10771418	ENSG00000256427.1	RP11-118B22.4	3.91	0.000107	0.00826	0.2	0.18	Breast size;	chr12:9206399	chr12:9246497~9257960:+
THCA	cis	rs2562456	0.755	rs1879234	ENSG00000268278.1	RP11-420K14.1	-3.91	0.000107	0.00826	-0.21	-0.18	Pain;	chr19:21521677	chr19:21637974~21656300:+
THCA	cis	rs962856	0.619	rs1027000	ENSG00000236780.4	AC078941.1	3.91	0.000107	0.00826	0.24	0.18	Pancreatic cancer;	chr2:67373657	chr2:67123357~67215319:-
THCA	cis	rs962856	0.619	rs1032158	ENSG00000236780.4	AC078941.1	3.91	0.000107	0.00826	0.24	0.18	Pancreatic cancer;	chr2:67373896	chr2:67123357~67215319:-
THCA	cis	rs308403	0.509	rs9990804	ENSG00000224786.1	CETN4P	3.91	0.000107	0.00826	0.18	0.18	Blood protein levels;	chr4:122750829	chr4:122730548~122732193:-
THCA	cis	rs156299	0.513	rs2079199	ENSG00000234286.1	AC006026.13	3.91	0.000107	0.00826	0.23	0.18	Vitamin D levels;	chr7:24169350	chr7:23680195~23680786:-
THCA	cis	rs7166081	1	rs12324222	ENSG00000270964.1	RP11-502I4.3	-3.91	0.000107	0.00827	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67288944	chr15:67541072~67542604:-
THCA	cis	rs801193	0.66	rs10950049	ENSG00000230189.5	GS1-124K5.2	3.91	0.000107	0.00827	0.12	0.18	Aortic root size;	chr7:66765873	chr7:66409143~66490059:-
THCA	cis	rs4950322	0.857	rs72693002	ENSG00000180867.10	PDIA3P1	3.91	0.000107	0.00827	0.18	0.18	Protein quantitative trait loci;	chr1:147357593	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.857	rs72694703	ENSG00000180867.10	PDIA3P1	3.91	0.000107	0.00827	0.18	0.18	Protein quantitative trait loci;	chr1:147358427	chr1:147178113~147179622:+
THCA	cis	rs11673344	0.764	rs472226	ENSG00000267260.1	CTD-2162K18.4	-3.91	0.000107	0.00827	-0.22	-0.18	Obesity-related traits;	chr19:36967811	chr19:36773153~36777078:+
THCA	cis	rs889312	0.5	rs33323	ENSG00000271828.1	CTD-2310F14.1	-3.91	0.000107	0.00827	-0.24	-0.18	Breast cancer (early onset);Breast cancer;	chr5:56879739	chr5:56927874~56929573:+
THCA	cis	rs11069062	0.819	rs12311037	ENSG00000270482.1	RP11-131L12.2	3.91	0.000107	0.00827	0.14	0.18	Obesity-related traits;	chr12:118715386	chr12:118375350~118376275:-
THCA	cis	rs72482608	0.716	rs10919470	ENSG00000271811.1	RP1-79C4.4	3.91	0.000107	0.00827	0.23	0.18	Emphysema imaging phenotypes;	chr1:170793539	chr1:170667381~170669425:+
THCA	cis	rs5758659	0.714	rs2284087	ENSG00000205702.9	CYP2D7	-3.91	0.000107	0.00827	-0.13	-0.18	Cognitive function;	chr22:42089667	chr22:42140203~42144577:-
THCA	cis	rs9333290	0.897	rs1839124	ENSG00000259915.2	RP11-410E4.1	-3.91	0.000107	0.00827	-0.21	-0.18	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186661887	chr2:186354570~186356773:-
THCA	cis	rs7577696	0.626	rs13431540	ENSG00000276334.1	AL133243.1	3.91	0.000107	0.00827	0.19	0.18	Inflammatory biomarkers;	chr2:32109784	chr2:32521927~32523547:+
THCA	cis	rs11638352	0.661	rs2733213	ENSG00000166763.7	STRCP1	3.91	0.000107	0.00827	0.35	0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44170756	chr15:43699488~43718184:-
THCA	cis	rs7216064	1	rs56393562	ENSG00000265055.1	AC145343.2	3.91	0.000107	0.00827	0.25	0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67937802	chr17:68096046~68101474:-
THCA	cis	rs2115630	0.967	rs11073702	ENSG00000259295.5	CSPG4P12	-3.91	0.000107	0.00827	-0.24	-0.18	P wave terminal force;	chr15:84766840	chr15:85191438~85213905:+
THCA	cis	rs11064837	0.504	rs7310536	ENSG00000248636.5	RP11-768F21.1	3.91	0.000107	0.00827	0.2	0.18	Schizophrenia;	chr12:119616268	chr12:119387987~119668079:-
THCA	cis	rs13325613	0.834	rs13092160	ENSG00000223552.1	RP11-24F11.2	-3.91	0.000107	0.00827	-0.29	-0.18	Monocyte count;	chr3:46213300	chr3:46364955~46407059:-
THCA	cis	rs7432375	0.901	rs4038587	ENSG00000273455.1	RP11-305O4.3	-3.91	0.000107	0.00827	-0.23	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136662526	chr3:136087475~136087913:-
THCA	cis	rs7432375	0.901	rs9836231	ENSG00000273455.1	RP11-305O4.3	-3.91	0.000107	0.00827	-0.23	-0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136695479	chr3:136087475~136087913:-
THCA	cis	rs1015362	0.503	rs1883708	ENSG00000275784.1	RP5-1125A11.6	-3.91	0.000107	0.00828	-0.21	-0.18	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33989480~33991818:-
THCA	cis	rs7246967	0.608	rs428613	ENSG00000198153.8	ZNF849P	-3.91	0.000107	0.00828	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22827117	chr19:22685167~22686732:+
THCA	cis	rs151234	0.741	rs151230	ENSG00000259982.1	CDC37P1	-3.91	0.000107	0.00828	-0.36	-0.18	Platelet distribution width;	chr16:28571894	chr16:28700294~28701540:-
THCA	cis	rs5751614	0.517	rs928780	ENSG00000236611.1	AP000343.2	-3.91	0.000107	0.00828	-0.23	-0.18	Height;	chr22:23257682	chr22:23326616~23328493:+
THCA	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	3.91	0.000107	0.00828	0.19	0.18	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
THCA	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	3.91	0.000107	0.00828	0.2	0.18	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
THCA	cis	rs4886920	0.887	rs7161954	ENSG00000260776.4	RP11-114H24.2	-3.91	0.000107	0.00828	-0.22	-0.18	Neuroticism;	chr15:77826613	chr15:77914217~77926846:-
THCA	cis	rs7829975	0.606	rs6422352	ENSG00000254340.1	RP11-10A14.3	-3.91	0.000107	0.00828	-0.2	-0.18	Mood instability;	chr8:8936683	chr8:9141424~9145435:+
THCA	cis	rs7829975	0.606	rs891570	ENSG00000254340.1	RP11-10A14.3	-3.91	0.000107	0.00828	-0.2	-0.18	Mood instability;	chr8:8936944	chr8:9141424~9145435:+
THCA	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-3.91	0.000107	0.00828	-0.17	-0.18	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
THCA	cis	rs2279440	0.759	rs17050392	ENSG00000254485.4	RP11-380O24.1	3.91	0.000107	0.00828	0.21	0.18	Glucose homeostasis traits;	chr3:9481610	chr3:9292588~9363303:-
THCA	cis	rs9923856	0.614	rs62026377	ENSG00000263033.2	RP11-396B14.2	-3.91	0.000107	0.00828	-0.16	-0.18	Atopic dermatitis;Adult asthma;	chr16:11135271	chr16:11196177~11224969:+
THCA	cis	rs6453278	0.768	rs13358038	ENSG00000250802.5	ZBED3-AS1	3.91	0.000107	0.00828	0.18	0.18	Autism;	chr5:77108226	chr5:77086740~77166909:+
THCA	cis	rs7727544	0.505	rs721121	ENSG00000263597.1	MIR3936	3.91	0.000107	0.00828	0.17	0.18	Blood metabolite levels;	chr5:132070740	chr5:132365490~132365599:-
THCA	cis	rs11771526	0.579	rs77818421	ENSG00000272905.1	RP11-265E18.1	3.91	0.000107	0.00828	0.27	0.18	Body mass index;	chr7:32335517	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.786	rs11768955	ENSG00000272905.1	RP11-265E18.1	3.91	0.000107	0.00828	0.27	0.18	Body mass index;	chr7:32339094	chr7:32845394~32846061:+
THCA	cis	rs2919009	0.544	rs2901280	ENSG00000271670.1	RP11-95I16.4	-3.91	0.000107	0.00829	-0.19	-0.18	Obesity-related traits;	chr10:120895865	chr10:120879256~120880667:-
THCA	cis	rs2163813	0.959	rs2315285	ENSG00000271499.1	CTC-559E9.9	-3.91	0.000107	0.00829	-0.22	-0.18	Toenail selenium levels;	chr19:19715039	chr19:19750618~19752544:+
THCA	cis	rs2163813	1	rs2163813	ENSG00000271499.1	CTC-559E9.9	-3.91	0.000107	0.00829	-0.22	-0.18	Toenail selenium levels;	chr19:19718292	chr19:19750618~19752544:+
THCA	cis	rs704	0.585	rs3093680	ENSG00000237575.4	PYY2	3.91	0.000107	0.00829	0.21	0.18	Osteoprotegerin levels;	chr17:28337780	chr17:28226563~28228065:+
THCA	cis	rs7798970	0.607	rs10952980	ENSG00000225498.1	AC002064.5	-3.91	0.000107	0.00829	-0.19	-0.18	Inflammatory skin disease;	chr7:90013788	chr7:90312496~90322592:+
THCA	cis	rs3845817	0.832	rs702950	ENSG00000281920.1	RP11-418H16.1	-3.91	0.000107	0.00829	-0.22	-0.18	Bipolar disorder;	chr2:65537776	chr2:65623272~65628424:+
THCA	cis	rs6688613	0.729	rs2072742	ENSG00000225171.2	DUTP6	-3.91	0.000107	0.00829	-0.26	-0.18	Refractive astigmatism;	chr1:166960436	chr1:166868748~166869209:+
THCA	cis	rs6688613	0.729	rs10918603	ENSG00000225171.2	DUTP6	-3.91	0.000107	0.00829	-0.26	-0.18	Refractive astigmatism;	chr1:166967266	chr1:166868748~166869209:+
THCA	cis	rs6688613	0.729	rs7545806	ENSG00000225171.2	DUTP6	-3.91	0.000107	0.00829	-0.26	-0.18	Refractive astigmatism;	chr1:166969318	chr1:166868748~166869209:+
THCA	cis	rs6570726	0.935	rs421268	ENSG00000270638.1	RP3-466P17.1	3.91	0.000107	0.00829	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs384519	ENSG00000270638.1	RP3-466P17.1	3.91	0.000107	0.00829	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs454370	ENSG00000270638.1	RP3-466P17.1	3.91	0.000107	0.00829	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145735570~145737218:+
THCA	cis	rs17741873	0.779	rs10509346	ENSG00000271848.1	RP11-464F9.21	3.91	0.000107	0.00829	0.22	0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73836256	chr10:73654039~73674719:+
THCA	cis	rs2033711	0.87	rs7409473	ENSG00000269867.1	CTD-2583A14.8	-3.91	0.000107	0.00829	-0.14	-0.18	Uric acid clearance;	chr19:58427798	chr19:57867038~57868172:-
THCA	cis	rs2033711	0.87	rs7408188	ENSG00000269867.1	CTD-2583A14.8	-3.91	0.000107	0.00829	-0.14	-0.18	Uric acid clearance;	chr19:58428022	chr19:57867038~57868172:-
THCA	cis	rs2033711	0.87	rs1051500	ENSG00000269867.1	CTD-2583A14.8	-3.91	0.000107	0.00829	-0.14	-0.18	Uric acid clearance;	chr19:58433035	chr19:57867038~57868172:-
THCA	cis	rs6456156	1	rs6911766	ENSG00000235272.1	FAM103A2P	-3.91	0.000107	0.00829	-0.24	-0.18	Primary biliary cholangitis;	chr6:167109682	chr6:166586124~166586477:-
THCA	cis	rs7578199	0.576	rs4675947	ENSG00000223374.1	AC005104.3	-3.91	0.000107	0.00829	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241484695	chr2:241351340~241353104:-
THCA	cis	rs7578199	0.576	rs34505866	ENSG00000223374.1	AC005104.3	-3.91	0.000107	0.00829	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241486170	chr2:241351340~241353104:-
THCA	cis	rs6479891	0.908	rs61853655	ENSG00000272767.1	JMJD1C-AS1	3.91	0.000107	0.00829	0.27	0.18	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63465229~63466563:+
THCA	cis	rs10484434	0.792	rs7757646	ENSG00000272462.2	U91328.19	3.91	0.000107	0.00829	0.19	0.18	HIV-1 viral setpoint;	chr6:26064151	chr6:25992662~26001775:+
THCA	cis	rs10484434	0.818	rs62394555	ENSG00000272462.2	U91328.19	3.91	0.000107	0.00829	0.19	0.18	HIV-1 viral setpoint;	chr6:26071861	chr6:25992662~26001775:+
THCA	cis	rs10771431	0.967	rs7137443	ENSG00000256427.1	RP11-118B22.4	3.91	0.000107	0.00829	0.2	0.18	Breast size;	chr12:9219433	chr12:9246497~9257960:+
THCA	cis	rs10771431	0.935	rs1988852	ENSG00000256427.1	RP11-118B22.4	3.91	0.000107	0.00829	0.2	0.18	Breast size;	chr12:9220266	chr12:9246497~9257960:+
THCA	cis	rs4267450	0.793	rs73021318	ENSG00000261770.1	CTC-459F4.1	3.91	0.000107	0.00829	0.32	0.18	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28357972	chr19:27757184~27760849:-
THCA	cis	rs3740713	0.669	rs78098319	ENSG00000256464.1	YWHABP2	3.91	0.000107	0.00829	0.29	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr11:18490243~18490955:-
THCA	cis	rs7824557	0.583	rs2263512	ENSG00000255495.1	AC145124.2	-3.91	0.000107	0.00829	-0.2	-0.18	Retinal vascular caliber;	chr8:11375910	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.583	rs6601585	ENSG00000255495.1	AC145124.2	-3.91	0.000107	0.00829	-0.2	-0.18	Retinal vascular caliber;	chr8:11376150	chr8:12194467~12196280:+
THCA	cis	rs10833905	1	rs1426849	ENSG00000246225.5	RP11-17A1.3	-3.91	0.000107	0.00829	-0.25	-0.18	Sudden cardiac arrest;	chr11:23026393	chr11:22829380~22945393:+
THCA	cis	rs950169	0.526	rs698620	ENSG00000259295.5	CSPG4P12	-3.91	0.000107	0.00829	-0.23	-0.18	Schizophrenia;	chr15:84633977	chr15:85191438~85213905:+
THCA	cis	rs2436845	0.521	rs2679742	ENSG00000253320.4	KB-1507C5.2	-3.91	0.000107	0.00829	-0.15	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102867569	chr8:102864300~102977876:+
THCA	cis	rs944289	0.503	rs4999746	ENSG00000258844.1	RP11-259K15.2	3.91	0.000107	0.00829	0.17	0.18	Thyroid cancer;	chr14:36190730	chr14:36214607~36235608:+
THCA	cis	rs6517329	0.6	rs2835279	ENSG00000230212.5	AP000688.14	-3.91	0.000107	0.00829	-0.22	-0.18	Schizophrenia;	chr21:36112905	chr21:36069642~36126640:-
THCA	cis	rs62380364	0.87	rs57055575	ENSG00000247828.6	TMEM161B-AS1	-3.91	0.000107	0.0083	-0.13	-0.18	Intelligence (multi-trait analysis);	chr5:88855175	chr5:88268895~88436685:+
THCA	cis	rs9733	0.818	rs4970926	ENSG00000231073.1	RP11-316M1.3	-3.91	0.000107	0.0083	-0.21	-0.18	Tonsillectomy;	chr1:150701208	chr1:150973123~150975534:+
THCA	cis	rs9733	0.818	rs12403609	ENSG00000231073.1	RP11-316M1.3	-3.91	0.000107	0.0083	-0.21	-0.18	Tonsillectomy;	chr1:150704009	chr1:150973123~150975534:+
THCA	cis	rs9733	0.818	rs6694531	ENSG00000231073.1	RP11-316M1.3	-3.91	0.000107	0.0083	-0.21	-0.18	Tonsillectomy;	chr1:150711036	chr1:150973123~150975534:+
THCA	cis	rs9733	0.818	rs10888388	ENSG00000231073.1	RP11-316M1.3	-3.91	0.000107	0.0083	-0.21	-0.18	Tonsillectomy;	chr1:150714820	chr1:150973123~150975534:+
THCA	cis	rs9733	0.818	rs12130363	ENSG00000231073.1	RP11-316M1.3	-3.91	0.000107	0.0083	-0.21	-0.18	Tonsillectomy;	chr1:150716120	chr1:150973123~150975534:+
THCA	cis	rs4671400	0.516	rs1809028	ENSG00000271889.1	RP11-493E12.1	3.91	0.000107	0.0083	0.19	0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61186588	chr2:61151433~61162105:-
THCA	cis	rs1371614	0.635	rs10196691	ENSG00000272148.1	RP11-195B17.1	-3.91	0.000107	0.0083	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918491	chr2:27062428~27062907:-
THCA	cis	rs12612619	0.732	rs12616092	ENSG00000272148.1	RP11-195B17.1	3.91	0.000107	0.0083	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26994360	chr2:27062428~27062907:-
THCA	cis	rs9510787	0.649	rs12429900	ENSG00000205861.10	C1QTNF9B-AS1	-3.91	0.000107	0.0083	-0.23	-0.18	Nasopharyngeal carcinoma;	chr13:23638214	chr13:23888889~23897263:+
THCA	cis	rs28643277	0.671	rs1105180	ENSG00000237470.3	DCLRE1CP1	3.91	0.000107	0.0083	0.23	0.18	Periodontitis (CDC/AAP);	chr10:15498723	chr10:15015370~15021863:-
THCA	cis	rs2898290	0.622	rs7822109	ENSG00000206014.6	OR7E161P	3.91	0.000107	0.0083	0.21	0.18	Systolic blood pressure;	chr8:11491638	chr8:11928597~11929563:-
THCA	cis	rs2820315	0.867	rs2819346	ENSG00000223774.4	RP11-307B6.3	3.91	0.000107	0.0083	0.19	0.18	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201912959	chr1:201893842~201899978:+
THCA	cis	rs11758351	1	rs11758351	ENSG00000216331.1	HIST1H1PS1	3.91	0.000107	0.0083	0.28	0.18	Renal underexcretion gout;Gout;	chr6:26203682	chr6:26195566~26195771:+
THCA	cis	rs875971	0.545	rs10950036	ENSG00000232559.3	GS1-124K5.12	3.91	0.000107	0.0083	0.19	0.18	Aortic root size;	chr7:66353241	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs73148639	ENSG00000232559.3	GS1-124K5.12	3.91	0.000107	0.0083	0.19	0.18	Aortic root size;	chr7:66390342	chr7:66554588~66576923:-
THCA	cis	rs7674212	0.581	rs10516496	ENSG00000248971.2	KRT8P46	-3.91	0.000107	0.0083	-0.22	-0.18	Type 2 diabetes;	chr4:103021008	chr4:102728746~102730171:-
THCA	cis	rs7520050	0.966	rs6661910	ENSG00000281133.1	AL355480.3	3.91	0.000107	0.0083	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45580892~45580996:-
THCA	cis	rs6942407	0.649	rs6952384	ENSG00000224046.1	AC005076.5	-3.91	0.000107	0.00831	-0.17	-0.18	Food allergy;	chr7:87230235	chr7:87151423~87152420:-
THCA	cis	rs10768122	0.524	rs7116432	ENSG00000251194.2	RP1-68D18.2	3.91	0.000107	0.00831	0.16	0.18	Vitiligo;	chr11:35222511	chr11:35212550~35214007:+
THCA	cis	rs721917	0.526	rs2256574	ENSG00000244733.5	RP11-506M13.3	-3.91	0.000107	0.00831	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79660891~79677996:+
THCA	cis	rs5006884	0.627	rs9666787	ENSG00000167355.6	AC104389.28	-3.91	0.000107	0.00831	-0.3	-0.18	Fetal hemoglobin levels;	chr11:5425227	chr11:5304976~5505652:-
THCA	cis	rs950169	0.922	rs12906983	ENSG00000275120.1	RP11-182J1.17	3.91	0.000107	0.00831	0.21	0.18	Schizophrenia;	chr15:84262270	chr15:84599434~84606463:-
THCA	cis	rs9393777	0.92	rs34071253	ENSG00000226314.6	ZNF192P1	-3.91	0.000107	0.00831	-0.33	-0.18	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28161781~28169594:+
THCA	cis	rs160451	0.84	rs216990	ENSG00000251136.7	RP11-37B2.1	3.91	0.000107	0.00831	0.17	0.18	Leprosy;	chr8:89664572	chr8:89609409~89757727:-
THCA	cis	rs7829975	0.539	rs883647	ENSG00000254153.1	CTA-398F10.2	3.91	0.000107	0.00831	0.21	0.18	Mood instability;	chr8:8712214	chr8:8456909~8461337:-
THCA	cis	rs12493885	0.769	rs61791509	ENSG00000243069.6	ARHGEF26-AS1	-3.91	0.000107	0.00831	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154035389	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.769	rs61791510	ENSG00000243069.6	ARHGEF26-AS1	-3.91	0.000107	0.00831	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154036877	chr3:154024401~154121332:-
THCA	cis	rs172166	0.516	rs1225710	ENSG00000261839.1	RP1-265C24.8	-3.91	0.000107	0.00831	-0.17	-0.18	Cardiac Troponin-T levels;	chr6:28132862	chr6:28136849~28139678:+
THCA	cis	rs2898290	0.617	rs13273172	ENSG00000255046.1	RP11-297N6.4	3.91	0.000107	0.00831	0.19	0.18	Systolic blood pressure;	chr8:11603602	chr8:11797928~11802568:-
THCA	cis	rs6496044	0.963	rs6496050	ENSG00000259295.5	CSPG4P12	3.91	0.000108	0.00832	0.23	0.18	Interstitial lung disease;	chr15:85526019	chr15:85191438~85213905:+
THCA	cis	rs853679	0.723	rs9366718	ENSG00000273712.1	RP5-874C20.7	3.91	0.000108	0.00832	0.25	0.18	Depression;	chr6:28237724	chr6:28315613~28315883:-
THCA	cis	rs12722605	0.54	rs35612087	ENSG00000229664.1	RP11-536K7.5	3.91	0.000108	0.00832	0.24	0.18	Inflammatory biomarkers;	chr10:5993712	chr10:6025978~6036427:+
THCA	cis	rs7614311	0.594	rs66473811	ENSG00000271843.1	RP11-245J9.5	-3.91	0.000108	0.00832	-0.29	-0.18	Lung function (FVC);Lung function (FEV1);	chr3:64014788	chr3:64008082~64008692:-
THCA	cis	rs3738443	0.545	rs12566906	ENSG00000259865.1	RP11-488L18.10	3.91	0.000108	0.00832	0.16	0.18	Alcohol dependence;	chr1:247224904	chr1:247187281~247188526:-
THCA	cis	rs17286411	0.671	rs3751817	ENSG00000260185.1	RP11-432I5.6	-3.91	0.000108	0.00832	-0.24	-0.18	Blood protein levels;	chr16:71730931	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs4788551	ENSG00000260185.1	RP11-432I5.6	-3.91	0.000108	0.00832	-0.24	-0.18	Blood protein levels;	chr16:71733758	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs4788552	ENSG00000260185.1	RP11-432I5.6	-3.91	0.000108	0.00832	-0.24	-0.18	Blood protein levels;	chr16:71733933	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.669	rs8052999	ENSG00000260185.1	RP11-432I5.6	-3.91	0.000108	0.00832	-0.24	-0.18	Blood protein levels;	chr16:71736933	chr16:71655027~71664212:+
THCA	cis	rs2333194	0.844	rs17182286	ENSG00000258695.2	RP3-414A15.2	-3.91	0.000108	0.00832	-0.23	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr14:73282200	chr14:73522878~73530610:+
THCA	cis	rs7267979	0.753	rs400357	ENSG00000277938.1	RP5-965G21.3	3.91	0.000108	0.00832	0.14	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25229150~25231933:+
THCA	cis	rs36093844	0.626	rs17817919	ENSG00000279742.1	RP11-700A24.1	3.91	0.000108	0.00832	0.24	0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86043679	chr11:85852557~85854943:-
THCA	cis	rs786425	0.77	rs66647364	ENSG00000278112.1	RP11-972P1.11	3.91	0.000108	0.00832	0.17	0.18	Pubertal anthropometrics;	chr12:123712733	chr12:123519390~123519856:-
THCA	cis	rs959260	0.688	rs1435093	ENSG00000263843.1	RP11-649A18.12	3.91	0.000108	0.00832	0.2	0.18	Systemic lupus erythematosus;	chr17:75361505	chr17:75271369~75273895:+
THCA	cis	rs959260	0.688	rs9899687	ENSG00000263843.1	RP11-649A18.12	3.91	0.000108	0.00832	0.2	0.18	Systemic lupus erythematosus;	chr17:75362178	chr17:75271369~75273895:+
THCA	cis	rs959260	0.688	rs9302990	ENSG00000263843.1	RP11-649A18.12	3.91	0.000108	0.00832	0.2	0.18	Systemic lupus erythematosus;	chr17:75363365	chr17:75271369~75273895:+
THCA	cis	rs6792584	0.861	rs7616397	ENSG00000241316.5	SUCLG2-AS1	3.91	0.000108	0.00832	0.17	0.18	Corneal astigmatism;	chr3:67466857	chr3:67654697~67947713:+
THCA	cis	rs786425	0.77	rs7298831	ENSG00000278112.1	RP11-972P1.11	3.91	0.000108	0.00833	0.17	0.18	Pubertal anthropometrics;	chr12:123688008	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs11829958	ENSG00000278112.1	RP11-972P1.11	3.91	0.000108	0.00833	0.17	0.18	Pubertal anthropometrics;	chr12:123688458	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs35114195	ENSG00000278112.1	RP11-972P1.11	3.91	0.000108	0.00833	0.17	0.18	Pubertal anthropometrics;	chr12:123691466	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs12828633	ENSG00000278112.1	RP11-972P1.11	3.91	0.000108	0.00833	0.17	0.18	Pubertal anthropometrics;	chr12:123695073	chr12:123519390~123519856:-
THCA	cis	rs3824488	0.92	rs2282040	ENSG00000237857.2	RP11-435O5.2	-3.91	0.000108	0.00833	-0.31	-0.18	Neuroticism;	chr9:95486046	chr9:95414834~95426796:-
THCA	cis	rs7989336	0.562	rs1925100	ENSG00000247400.3	DNAJC3-AS1	-3.91	0.000108	0.00833	-0.12	-0.18	Obesity;	chr13:96371896	chr13:95648733~95676925:-
THCA	cis	rs7989336	0.562	rs1925099	ENSG00000247400.3	DNAJC3-AS1	-3.91	0.000108	0.00833	-0.12	-0.18	Obesity;	chr13:96372044	chr13:95648733~95676925:-
THCA	cis	rs9527	0.571	rs12765337	ENSG00000272912.1	RP11-724N1.1	-3.91	0.000108	0.00833	-0.21	-0.18	Arsenic metabolism;	chr10:102875587	chr10:102914585~102915404:+
THCA	cis	rs944289	0.646	rs8003253	ENSG00000258844.1	RP11-259K15.2	3.91	0.000108	0.00833	0.16	0.18	Thyroid cancer;	chr14:36088485	chr14:36214607~36235608:+
THCA	cis	rs74233809	1	rs12411886	ENSG00000272912.1	RP11-724N1.1	-3.91	0.000108	0.00833	-0.33	-0.18	Birth weight;	chr10:102925542	chr10:102914585~102915404:+
THCA	cis	rs67478160	0.572	rs8016014	ENSG00000258534.1	CTD-2134A5.4	-3.91	0.000108	0.00833	-0.18	-0.18	Schizophrenia;	chr14:103827461	chr14:103854366~103880111:-
THCA	cis	rs654950	0.934	rs641974	ENSG00000230638.4	RP11-486B10.4	3.91	0.000108	0.00833	0.22	0.18	Airway imaging phenotypes;	chr1:41536466	chr1:41542069~41544310:+
THCA	cis	rs654950	0.934	rs654220	ENSG00000230638.4	RP11-486B10.4	3.91	0.000108	0.00833	0.22	0.18	Airway imaging phenotypes;	chr1:41536885	chr1:41542069~41544310:+
THCA	cis	rs7143963	0.609	rs11846158	ENSG00000272444.1	RP11-1017G21.6	3.91	0.000108	0.00833	0.16	0.18	Body mass index;	chr14:102826622	chr14:101952416~101953063:+
THCA	cis	rs9595908	0.669	rs9596218	ENSG00000212293.1	SNORA16	3.91	0.000108	0.00833	0.21	0.18	Body mass index;	chr13:32764222	chr13:32420390~32420516:-
THCA	cis	rs11971779	0.648	rs6967836	ENSG00000252332.1	RNU6-911P	-3.91	0.000108	0.00833	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139395198	chr7:139448740~139448843:+
THCA	cis	rs1707322	0.638	rs9429095	ENSG00000280836.1	AL355480.1	3.91	0.000108	0.00833	0.23	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45581219~45581321:-
THCA	cis	rs9863	0.828	rs12303933	ENSG00000270028.1	RP11-380L11.4	3.91	0.000108	0.00833	0.19	0.18	White blood cell count;	chr12:123997709	chr12:123925461~123926083:-
THCA	cis	rs6600671	1	rs12145080	ENSG00000275585.1	CH17-118O6.3	3.91	0.000108	0.00833	0.21	0.18	Hip geometry;	chr1:121443673	chr1:120985692~121052167:-
THCA	cis	rs4746818	1	rs906218	ENSG00000229001.1	ACTBP14	-3.91	0.000108	0.00834	-0.29	-0.18	Left atrial antero-posterior diameter;	chr10:69201157	chr10:69022778~69023866:+
THCA	cis	rs1009077	0.627	rs6534146	ENSG00000260091.1	RP11-33B1.4	-3.91	0.000108	0.00834	-0.17	-0.18	Endometriosis;	chr4:119617668	chr4:119409333~119410233:+
THCA	cis	rs3733585	0.806	rs7375599	ENSG00000250413.1	RP11-448G15.1	-3.91	0.000108	0.00834	-0.17	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9953294	chr4:10006482~10009725:+
THCA	cis	rs17194490	0.665	rs10510233	ENSG00000237990.3	CNTN4-AS1	3.91	0.000108	0.00834	0.25	0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2526646	chr3:3039033~3069242:-
THCA	cis	rs2015599	0.525	rs7298031	ENSG00000273680.1	RP11-996F15.6	-3.91	0.000108	0.00834	-0.25	-0.18	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29332733~29333383:-
THCA	cis	rs2015599	0.525	rs2016832	ENSG00000273680.1	RP11-996F15.6	-3.91	0.000108	0.00834	-0.25	-0.18	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29332733~29333383:-
THCA	cis	rs6067053	0.621	rs11696801	ENSG00000230758.1	SNAP23P	3.91	0.000108	0.00834	0.22	0.18	Intelligence (multi-trait analysis);	chr20:49251062	chr20:49038357~49038602:-
THCA	cis	rs6067053	0.671	rs6125600	ENSG00000230758.1	SNAP23P	3.91	0.000108	0.00834	0.22	0.18	Intelligence (multi-trait analysis);	chr20:49256363	chr20:49038357~49038602:-
THCA	cis	rs791590	0.941	rs12722489	ENSG00000225948.2	RP11-554I8.1	3.91	0.000108	0.00834	0.28	0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:6060049	chr10:6618716~6625346:+
THCA	cis	rs8062405	0.698	rs8046545	ENSG00000270424.1	RP11-1348G14.6	-3.91	0.000108	0.00834	-0.22	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28749959~28750595:-
THCA	cis	rs13401620	0.745	rs67730315	ENSG00000231013.1	AC013275.2	-3.91	0.000108	0.00834	-0.21	-0.18	Breast size;	chr2:119715194	chr2:119476448~119487346:+
THCA	cis	rs9309473	0.95	rs6546849	ENSG00000273245.1	RP11-434P11.2	3.91	0.000108	0.00834	0.24	0.18	Metabolite levels;	chr2:73603910	chr2:73750256~73750786:-
THCA	cis	rs11971779	0.68	rs17613690	ENSG00000252332.1	RNU6-911P	3.91	0.000108	0.00834	0.2	0.18	Diisocyanate-induced asthma;	chr7:139403655	chr7:139448740~139448843:+
THCA	cis	rs7927592	0.913	rs7109294	ENSG00000160172.9	FAM86C2P	3.91	0.000108	0.00834	0.17	0.18	Total body bone mineral density;	chr11:68564625	chr11:67791648~67805336:-
THCA	cis	rs1876905	0.68	rs354527	ENSG00000271789.1	RP5-1112D6.7	-3.91	0.000108	0.00834	-0.23	-0.18	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111297126~111298510:+
THCA	cis	rs10761482	0.701	rs12411733	ENSG00000254271.1	RP11-131N11.4	3.91	0.000108	0.00835	0.22	0.18	Schizophrenia;	chr10:60363288	chr10:60734342~60741828:+
THCA	cis	rs2446066	0.872	rs3741651	ENSG00000257379.1	RP11-793H13.8	3.91	0.000108	0.00835	0.26	0.18	Red blood cell count;	chr12:53383387	chr12:53441741~53467528:+
THCA	cis	rs5769765	0.865	rs9616369	ENSG00000260613.1	RP3-522J7.6	-3.91	0.000108	0.00835	-0.22	-0.18	Schizophrenia;	chr22:49910943	chr22:49832616~49837786:-
THCA	cis	rs308403	0.509	rs13117125	ENSG00000224786.1	CETN4P	3.91	0.000108	0.00835	0.18	0.18	Blood protein levels;	chr4:122749669	chr4:122730548~122732193:-
THCA	cis	rs2721195	0.845	rs3757966	ENSG00000265393.1	CTD-2517M22.17	-3.91	0.000108	0.00835	-0.22	-0.18	Age at first birth;	chr8:144519234	chr8:144512567~144513672:+
THCA	cis	rs6573604	1	rs6573602	ENSG00000276116.2	FUT8-AS1	-3.9	0.000108	0.00835	-0.22	-0.18	N-glycan levels;	chr14:65317892	chr14:65411170~65412690:-
THCA	cis	rs875971	0.545	rs67775320	ENSG00000232559.3	GS1-124K5.12	3.9	0.000108	0.00835	0.19	0.18	Aortic root size;	chr7:66193792	chr7:66554588~66576923:-
THCA	cis	rs4578769	0.513	rs2034933	ENSG00000273232.1	RP11-370A5.2	3.9	0.000108	0.00835	0.24	0.18	Eosinophil percentage of white cells;	chr18:22918788	chr18:22882825~22883357:-
THCA	cis	rs964611	0.786	rs5020564	ENSG00000259488.2	RP11-154J22.1	-3.9	0.000108	0.00835	-0.17	-0.18	Metabolite levels (Pyroglutamine);	chr15:48372356	chr15:48312353~48331856:-
THCA	cis	rs2191566	0.576	rs402785	ENSG00000277806.1	RP11-15A1.8	3.9	0.000108	0.00835	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43988084	chr19:43976815~43977448:+
THCA	cis	rs2191566	0.576	rs414402	ENSG00000277806.1	RP11-15A1.8	3.9	0.000108	0.00835	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43988416	chr19:43976815~43977448:+
THCA	cis	rs7312933	0.67	rs10880258	ENSG00000257225.1	RP11-328C8.4	-3.9	0.000108	0.00835	-0.18	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42153729	chr12:42459366~42466128:+
THCA	cis	rs669446	0.528	rs7538463	ENSG00000237950.1	RP11-7O11.3	3.9	0.000108	0.00835	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43730745	chr1:43944370~43946551:-
THCA	cis	rs7737355	0.947	rs10041744	ENSG00000237714.1	P4HA2-AS1	3.9	0.000108	0.00835	0.25	0.18	Life satisfaction;	chr5:131525159	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs244739	ENSG00000237714.1	P4HA2-AS1	-3.9	0.000108	0.00835	-0.25	-0.18	Life satisfaction;	chr5:131471181	chr5:132184876~132192808:+
THCA	cis	rs2221894	0.959	rs1487969	ENSG00000251191.6	LINC00589	3.9	0.000108	0.00835	0.22	0.18	Obesity-related traits;	chr8:29028144	chr8:29673922~29748109:-
THCA	cis	rs12724450	1	rs12724450	ENSG00000228126.1	FALEC	3.9	0.000108	0.00836	0.36	0.18	Blood protein levels;	chr1:150508095	chr1:150515757~150518032:+
THCA	cis	rs704	0.585	rs1007398	ENSG00000237575.4	PYY2	3.9	0.000108	0.00836	0.21	0.18	Osteoprotegerin levels;	chr17:28338622	chr17:28226563~28228065:+
THCA	cis	rs912593	0.872	rs5027695	ENSG00000225179.1	LINC00457	-3.9	0.000108	0.00836	-0.23	-0.18	Cancer;	chr13:34477546	chr13:34435450~34640685:-
THCA	cis	rs6012953	0.967	rs6020585	ENSG00000231715.1	COX6CP2	3.9	0.000108	0.00836	0.18	0.18	Vitiligo;	chr20:50530955	chr20:50479767~50479991:+
THCA	cis	rs6546886	0.912	rs60279245	ENSG00000235499.1	AC073046.25	3.9	0.000108	0.00836	0.16	0.18	Dialysis-related mortality;	chr2:74085616	chr2:73985132~73986343:+
THCA	cis	rs6494488	0.5	rs72742909	ENSG00000259635.1	AC100830.3	-3.9	0.000108	0.00836	-0.45	-0.18	Coronary artery disease;	chr15:64549241	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742910	ENSG00000259635.1	AC100830.3	-3.9	0.000108	0.00836	-0.45	-0.18	Coronary artery disease;	chr15:64549635	chr15:64701248~64719602:+
THCA	cis	rs4389656	0.625	rs274681	ENSG00000248677.1	CTD-2044J15.1	3.9	0.000108	0.00836	0.18	0.18	Coronary artery disease;	chr5:6748546	chr5:6686325~6707711:-
THCA	cis	rs3764021	0.509	rs10772074	ENSG00000214776.8	RP11-726G1.1	3.9	0.000108	0.00836	0.23	0.18	Type 1 diabetes;	chr12:9717686	chr12:9467552~9576275:+
THCA	cis	rs2732480	0.5	rs2450986	ENSG00000257735.1	RP11-370I10.6	3.9	0.000108	0.00836	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48350945~48442411:+
THCA	cis	rs17597773	0.638	rs12145674	ENSG00000272823.1	RP11-295M18.6	3.9	0.000108	0.00836	0.23	0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826931	chr1:220828676~220829211:-
THCA	cis	rs7829975	0.774	rs11249893	ENSG00000248538.5	RP11-10A14.5	-3.9	0.000108	0.00836	-0.23	-0.18	Mood instability;	chr8:8843341	chr8:9189011~9202854:+
THCA	cis	rs7085104	0.727	rs12773892	ENSG00000272912.1	RP11-724N1.1	-3.9	0.000108	0.00836	-0.23	-0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102871420	chr10:102914585~102915404:+
THCA	cis	rs7897654	0.571	rs12767543	ENSG00000272912.1	RP11-724N1.1	-3.9	0.000108	0.00836	-0.23	-0.18	Schizophrenia;	chr10:102871906	chr10:102914585~102915404:+
THCA	cis	rs1039766	1	rs10116	ENSG00000204929.10	AC074391.1	3.9	0.000108	0.00836	0.29	0.18	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr2:65436711~66084639:+
THCA	cis	rs1039766	1	rs268878	ENSG00000204929.10	AC074391.1	3.9	0.000108	0.00836	0.29	0.18	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr2:65436711~66084639:+
THCA	cis	rs1039766	0.929	rs268881	ENSG00000204929.10	AC074391.1	3.9	0.000108	0.00836	0.29	0.18	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr2:65436711~66084639:+
THCA	cis	rs1923626	0.93	rs10913419	ENSG00000224968.1	RP1-35C21.1	-3.9	0.000108	0.00836	-0.2	-0.18	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr1:177786329	chr1:177351586~177366272:+
THCA	cis	rs736408	0.812	rs2240920	ENSG00000243224.1	RP5-1157M23.2	3.9	0.000108	0.00836	0.2	0.18	Bipolar disorder;	chr3:52796993	chr3:52239258~52241097:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000229180.5	GS1-124K5.11	-3.9	0.000108	0.00836	-0.12	-0.18	Aortic root size;	chr7:66120784	chr7:66526088~66542624:-
THCA	cis	rs240993	0.548	rs1040382	ENSG00000271789.1	RP5-1112D6.7	3.9	0.000108	0.00836	0.19	0.18	Inflammatory skin disease;Psoriasis;	chr6:111580876	chr6:111297126~111298510:+
THCA	cis	rs763121	0.853	rs1569492	ENSG00000228274.3	RP3-508I15.9	3.9	0.000108	0.00836	0.18	0.18	Menopause (age at onset);	chr22:38579506	chr22:38667585~38681820:-
THCA	cis	rs2836974	0.897	rs8132568	ENSG00000255568.3	BRWD1-AS2	3.9	0.000108	0.00836	0.15	0.18	Cognitive function;	chr21:39155990	chr21:39313935~39314962:+
THCA	cis	rs9863	0.931	rs4765335	ENSG00000270061.1	RP11-214K3.19	-3.9	0.000108	0.00837	-0.23	-0.18	White blood cell count;	chr12:123946265	chr12:123969990~123970344:-
THCA	cis	rs7737355	0.947	rs3776004	ENSG00000237714.1	P4HA2-AS1	3.9	0.000108	0.00837	0.25	0.18	Life satisfaction;	chr5:131543738	chr5:132184876~132192808:+
THCA	cis	rs2380205	0.517	rs6602330	ENSG00000232807.2	RP11-536K7.3	3.9	0.000108	0.00837	0.18	0.18	Breast cancer;	chr10:5902270	chr10:5934270~5945900:-
THCA	cis	rs10833905	1	rs10833904	ENSG00000246225.5	RP11-17A1.3	3.9	0.000108	0.00837	0.25	0.18	Sudden cardiac arrest;	chr11:23018465	chr11:22829380~22945393:+
THCA	cis	rs3758911	1	rs10789618	ENSG00000255353.1	RP11-382M14.1	-3.9	0.000108	0.00837	-0.22	-0.18	Coronary artery disease;	chr11:107319003	chr11:107176286~107177530:+
THCA	cis	rs17711722	0.523	rs365896	ENSG00000272831.1	RP11-792A8.4	-3.9	0.000108	0.00837	-0.11	-0.18	Calcium levels;	chr7:66045710	chr7:66739829~66740385:-
THCA	cis	rs2692947	0.673	rs3111873	ENSG00000235584.2	AC008268.1	3.9	0.000108	0.00837	0.18	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96116247	chr2:95666084~95668715:+
THCA	cis	rs9283706	1	rs9283706	ENSG00000229666.1	MAST4-AS1	-3.9	0.000108	0.00837	-0.25	-0.18	Coronary artery disease;	chr5:66987692	chr5:67001383~67003953:-
THCA	cis	rs812925	0.512	rs1177309	ENSG00000270820.4	RP11-355B11.2	3.9	0.000108	0.00837	0.15	0.18	Immature fraction of reticulocytes;	chr2:61158113	chr2:61471188~61484130:+
THCA	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-3.9	0.000108	0.00837	-0.2	-0.18	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
THCA	cis	rs1048886	0.938	rs2842081	ENSG00000271967.1	RP11-134K13.4	-3.9	0.000108	0.00837	-0.19	-0.18	Type 2 diabetes;	chr6:70578541	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs2691490	ENSG00000271967.1	RP11-134K13.4	-3.9	0.000108	0.00837	-0.19	-0.18	Type 2 diabetes;	chr6:70578856	chr6:70596438~70596980:+
THCA	cis	rs564799	0.842	rs480134	ENSG00000244040.4	IL12A-AS1	3.9	0.000108	0.00837	0.23	0.18	Systemic lupus erythematosus;	chr3:160011745	chr3:159913400~160225299:-
THCA	cis	rs564799	0.842	rs586094	ENSG00000244040.4	IL12A-AS1	3.9	0.000108	0.00837	0.23	0.18	Systemic lupus erythematosus;	chr3:160011761	chr3:159913400~160225299:-
THCA	cis	rs4792901	0.802	rs28532791	ENSG00000267151.3	RP11-100E5.2	3.9	0.000108	0.00837	0.2	0.18	Dupuytren's disease;	chr17:43512111	chr17:43444707~43451200:+
THCA	cis	rs7192750	0.586	rs2335714	ENSG00000260886.1	TAT-AS1	3.9	0.000108	0.00837	0.26	0.18	Total cholesterol levels;LDL cholesterol levels;	chr16:71864023	chr16:71565789~71578187:+
THCA	cis	rs9650657	0.535	rs7011756	ENSG00000206014.6	OR7E161P	3.9	0.000108	0.00837	0.2	0.18	Neuroticism;	chr8:11162068	chr8:11928597~11929563:-
THCA	cis	rs7267979	0.932	rs2387891	ENSG00000276952.1	RP5-965G21.6	3.9	0.000108	0.00837	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25284915~25285588:-
THCA	cis	rs11089937	0.584	rs6001213	ENSG00000211639.2	IGLV4-60	3.9	0.000108	0.00837	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22182108	chr22:22162199~22162681:+
THCA	cis	rs7709377	0.671	rs6866454	ENSG00000250015.1	CTC-339F2.2	3.9	0.000108	0.00837	0.18	0.18	Metabolite levels  (X-11787);	chr5:116121394	chr5:116302354~116304134:-
THCA	cis	rs867371	0.896	rs6495647	ENSG00000278603.1	RP13-608F4.5	3.9	0.000108	0.00837	0.22	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472203~82472426:+
THCA	cis	rs12755164	0.742	rs6424496	ENSG00000223479.3	RP4-788P17.1	-3.9	0.000108	0.00838	-0.19	-0.18	Schizophrenia;	chr1:72866265	chr1:73635216~73715214:+
THCA	cis	rs13113518	0.812	rs11133385	ENSG00000223305.1	RN7SKP30	3.9	0.000109	0.00838	0.23	0.18	Height;	chr4:55460485	chr4:55540502~55540835:-
THCA	cis	rs3015497	0.789	rs3015502	ENSG00000270062.1	RP11-248J18.3	3.9	0.000109	0.00838	0.2	0.18	Mean platelet volume;	chr14:50641709	chr14:50723777~50724272:-
THCA	cis	rs3015497	0.789	rs3015500	ENSG00000270062.1	RP11-248J18.3	3.9	0.000109	0.00838	0.2	0.18	Mean platelet volume;	chr14:50642159	chr14:50723777~50724272:-
THCA	cis	rs3015497	0.789	rs3015498	ENSG00000270062.1	RP11-248J18.3	3.9	0.000109	0.00838	0.2	0.18	Mean platelet volume;	chr14:50646106	chr14:50723777~50724272:-
THCA	cis	rs3015497	0.789	rs3015496	ENSG00000270062.1	RP11-248J18.3	3.9	0.000109	0.00838	0.2	0.18	Mean platelet volume;	chr14:50647333	chr14:50723777~50724272:-
THCA	cis	rs9733	0.818	rs11204702	ENSG00000231073.1	RP11-316M1.3	-3.9	0.000109	0.00838	-0.21	-0.18	Tonsillectomy;	chr1:150691031	chr1:150973123~150975534:+
THCA	cis	rs4792901	0.877	rs9912927	ENSG00000267151.3	RP11-100E5.2	3.9	0.000109	0.00838	0.19	0.18	Dupuytren's disease;	chr17:43542667	chr17:43444707~43451200:+
THCA	cis	rs9905704	0.918	rs302868	ENSG00000224738.1	AC099850.1	3.9	0.000109	0.00839	0.24	0.18	Testicular germ cell tumor;	chr17:58674762	chr17:59106598~59118267:+
THCA	cis	rs12168402	0.51	rs1076116	ENSG00000273076.1	RP3-508I15.22	3.9	0.000109	0.00839	0.17	0.18	Subjective well-being;	chr22:38841832	chr22:38743495~38743910:+
THCA	cis	rs12216545	0.765	rs10238068	ENSG00000241134.3	BET1P1	-3.9	0.000109	0.00839	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552670	chr7:150749736~150750094:+
THCA	cis	rs8077577	0.945	rs11871039	ENSG00000273018.4	CTD-2303H24.2	-3.9	0.000109	0.00839	-0.3	-0.18	Obesity-related traits;	chr17:18175590	chr17:18511221~18551705:-
THCA	cis	rs9467773	0.869	rs1796521	ENSG00000261353.1	CTA-14H9.5	3.9	0.000109	0.00839	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26527063~26527404:+
THCA	cis	rs875971	0.545	rs10950036	ENSG00000273024.4	INTS4P2	-3.9	0.000109	0.00839	-0.22	-0.18	Aortic root size;	chr7:66353241	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000273024.4	INTS4P2	-3.9	0.000109	0.00839	-0.22	-0.18	Aortic root size;	chr7:66390342	chr7:65647864~65715661:+
THCA	cis	rs9733	0.744	rs2039590	ENSG00000231073.1	RP11-316M1.3	-3.9	0.000109	0.00839	-0.21	-0.18	Tonsillectomy;	chr1:150840839	chr1:150973123~150975534:+
THCA	cis	rs2839186	0.619	rs55689527	ENSG00000215424.8	MCM3AP-AS1	3.9	0.000109	0.00839	0.1	0.18	Testicular germ cell tumor;	chr21:46202813	chr21:46229217~46259390:+
THCA	cis	rs4908768	0.501	rs12756257	ENSG00000270282.1	RP5-1115A15.2	3.9	0.000109	0.00839	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8512653~8513021:+
THCA	cis	rs12681288	0.523	rs73176528	ENSG00000260721.1	AF067845.1	3.9	0.000109	0.00839	0.22	0.18	Schizophrenia;	chr8:1011962	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.55	rs58295701	ENSG00000260721.1	AF067845.1	3.9	0.000109	0.00839	0.22	0.18	Schizophrenia;	chr8:1012136	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.55	rs73176529	ENSG00000260721.1	AF067845.1	3.9	0.000109	0.00839	0.22	0.18	Schizophrenia;	chr8:1012283	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.55	rs59004371	ENSG00000260721.1	AF067845.1	3.9	0.000109	0.00839	0.22	0.18	Schizophrenia;	chr8:1012393	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.523	rs111782857	ENSG00000260721.1	AF067845.1	3.9	0.000109	0.00839	0.22	0.18	Schizophrenia;	chr8:1012486	chr8:1368642~1369833:-
THCA	cis	rs11601239	0.646	rs7934866	ENSG00000254750.1	CASP1P2	3.9	0.000109	0.00839	0.14	0.18	Refractive error;	chr11:105790514	chr11:105063345~105071541:-
THCA	cis	rs3733585	0.781	rs4292328	ENSG00000250413.1	RP11-448G15.1	3.9	0.000109	0.00839	0.17	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9969338	chr4:10006482~10009725:+
THCA	cis	rs9693857	0.52	rs4557706	ENSG00000248538.5	RP11-10A14.5	-3.9	0.000109	0.00839	-0.23	-0.18	Systolic blood pressure;	chr8:9499859	chr8:9189011~9202854:+
THCA	cis	rs321358	1	rs321359	ENSG00000271390.1	RP11-89C3.3	3.9	0.000109	0.00839	0.3	0.18	Body mass index;	chr11:111125257	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321360	ENSG00000271390.1	RP11-89C3.3	3.9	0.000109	0.00839	0.3	0.18	Body mass index;	chr11:111125346	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321361	ENSG00000271390.1	RP11-89C3.3	3.9	0.000109	0.00839	0.3	0.18	Body mass index;	chr11:111125495	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321362	ENSG00000271390.1	RP11-89C3.3	3.9	0.000109	0.00839	0.3	0.18	Body mass index;	chr11:111125754	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321363	ENSG00000271390.1	RP11-89C3.3	3.9	0.000109	0.00839	0.3	0.18	Body mass index;	chr11:111125929	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321366	ENSG00000271390.1	RP11-89C3.3	3.9	0.000109	0.00839	0.3	0.18	Body mass index;	chr11:111128003	chr11:111089870~111090368:-
THCA	cis	rs853679	0.517	rs6932109	ENSG00000219891.2	ZSCAN12P1	-3.9	0.000109	0.00839	-0.25	-0.18	Depression;	chr6:28110525	chr6:28091154~28093664:+
THCA	cis	rs4262150	0.883	rs72799148	ENSG00000253921.1	CTB-113P19.3	3.9	0.000109	0.00839	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152727548	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.883	rs72799150	ENSG00000253921.1	CTB-113P19.3	3.9	0.000109	0.00839	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152731126	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.883	rs72799151	ENSG00000253921.1	CTB-113P19.3	3.9	0.000109	0.00839	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152731277	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.883	rs72799153	ENSG00000253921.1	CTB-113P19.3	3.9	0.000109	0.00839	0.23	0.18	Bipolar disorder and schizophrenia;	chr5:152733298	chr5:151753992~151767247:+
THCA	cis	rs6933660	0.76	rs3806982	ENSG00000219395.2	HSPA8P15	-3.9	0.000109	0.00839	-0.15	-0.18	Menarche (age at onset);	chr6:151453781	chr6:151411259~151413945:-
THCA	cis	rs1383484	0.958	rs5006997	ENSG00000259728.4	LINC00933	-3.9	0.000109	0.00839	-0.22	-0.18	Height;	chr15:83849268	chr15:84570649~84580175:+
THCA	cis	rs7615952	0.512	rs2979351	ENSG00000248787.1	RP11-666A20.4	-3.9	0.000109	0.00839	-0.27	-0.18	Blood pressure (smoking interaction);	chr3:125644755	chr3:125908005~125910272:-
THCA	cis	rs5758659	0.652	rs133326	ENSG00000270083.1	RP1-257I20.14	3.9	0.000109	0.00839	0.19	0.18	Cognitive function;	chr22:42010881	chr22:42089630~42090028:-
THCA	cis	rs7897654	0.571	rs12765002	ENSG00000272912.1	RP11-724N1.1	-3.9	0.000109	0.00839	-0.23	-0.18	Schizophrenia;	chr10:102875591	chr10:102914585~102915404:+
THCA	cis	rs6806253	0.73	rs4857855	ENSG00000239405.1	TMED10P2	3.9	0.000109	0.0084	0.28	0.18	Pit-and-Fissure caries;	chr3:128541707	chr3:128538020~128538631:+
THCA	cis	rs10435719	0.899	rs7815595	ENSG00000255495.1	AC145124.2	3.9	0.000109	0.0084	0.21	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.834	rs11250176	ENSG00000255495.1	AC145124.2	3.9	0.000109	0.0084	0.21	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.516	rs4367597	ENSG00000255495.1	AC145124.2	3.9	0.000109	0.0084	0.21	0.18	Neuroticism;	chr8:11936020	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.899	rs9329251	ENSG00000255495.1	AC145124.2	3.9	0.000109	0.0084	0.21	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:12194467~12196280:+
THCA	cis	rs6442522	1	rs9841038	ENSG00000249786.6	EAF1-AS1	3.9	0.000109	0.0084	0.19	0.18	Uric acid levels;	chr3:15412479	chr3:15436171~15455940:-
THCA	cis	rs10496034	0.541	rs75654812	ENSG00000237887.1	AC092839.1	-3.9	0.000109	0.0084	-0.32	-0.18	Refractive astigmatism;	chr2:54684831	chr2:54529343~54529801:+
THCA	cis	rs1030877	0.889	rs2576746	ENSG00000235319.1	AC012360.4	-3.9	0.000109	0.0084	-0.2	-0.18	Obesity-related traits;	chr2:105293102	chr2:105324210~105330529:+
THCA	cis	rs9863	0.828	rs4765541	ENSG00000270061.1	RP11-214K3.19	-3.9	0.000109	0.0084	-0.23	-0.18	White blood cell count;	chr12:123981448	chr12:123969990~123970344:-
THCA	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	3.9	0.000109	0.0084	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	3.9	0.000109	0.0084	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
THCA	cis	rs12126655	0.685	rs6677889	ENSG00000230489.1	VAV3-AS1	-3.9	0.000109	0.0084	-0.16	-0.18	Plasma thyroid-stimulating hormone levels;	chr1:107864204	chr1:107964443~107994607:+
THCA	cis	rs13083990	0.919	rs13095172	ENSG00000272758.4	RP11-299J3.8	3.9	0.000109	0.0084	0.17	0.18	Cardiac Troponin-T levels;	chr3:122271410	chr3:122416207~122443180:+
THCA	cis	rs5997397	0.933	rs5762783	ENSG00000226471.5	CTA-292E10.6	-3.9	0.000109	0.0084	-0.15	-0.18	Red cell distribution width;	chr22:28769537	chr22:28800683~28848559:+
THCA	cis	rs12681366	0.62	rs2930968	ENSG00000261437.1	RP11-22C11.2	3.9	0.000109	0.0084	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94450467	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.663	rs2930970	ENSG00000261437.1	RP11-22C11.2	3.9	0.000109	0.0084	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94452109	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.663	rs2921389	ENSG00000261437.1	RP11-22C11.2	3.9	0.000109	0.0084	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94454138	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.663	rs2043987	ENSG00000261437.1	RP11-22C11.2	3.9	0.000109	0.0084	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94457465	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.663	rs2919662	ENSG00000261437.1	RP11-22C11.2	3.9	0.000109	0.0084	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94458044	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.663	rs2919660	ENSG00000261437.1	RP11-22C11.2	3.9	0.000109	0.0084	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94458469	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.663	rs1561648	ENSG00000261437.1	RP11-22C11.2	3.9	0.000109	0.0084	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94462209	chr8:94637285~94639467:-
THCA	cis	rs911555	0.755	rs2756132	ENSG00000269910.1	RP11-73M18.10	-3.9	0.000109	0.0084	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103694516~103695050:-
THCA	cis	rs7267979	0.816	rs443009	ENSG00000277938.1	RP5-965G21.3	-3.9	0.000109	0.0084	-0.15	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25229150~25231933:+
THCA	cis	rs6546886	0.912	rs13006301	ENSG00000235499.1	AC073046.25	3.9	0.000109	0.0084	0.16	0.18	Dialysis-related mortality;	chr2:74063888	chr2:73985132~73986343:+
THCA	cis	rs2191566	0.576	rs393195	ENSG00000277806.1	RP11-15A1.8	3.9	0.000109	0.0084	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43988990	chr19:43976815~43977448:+
THCA	cis	rs875971	0.545	rs67775320	ENSG00000273024.4	INTS4P2	-3.9	0.000109	0.0084	-0.22	-0.18	Aortic root size;	chr7:66193792	chr7:65647864~65715661:+
THCA	cis	rs5758511	0.68	rs5758657	ENSG00000237037.8	NDUFA6-AS1	-3.9	0.000109	0.0084	-0.17	-0.18	Birth weight;	chr22:42222663	chr22:42090931~42137742:+
THCA	cis	rs5758511	0.68	rs1033459	ENSG00000237037.8	NDUFA6-AS1	-3.9	0.000109	0.0084	-0.17	-0.18	Birth weight;	chr22:42223061	chr22:42090931~42137742:+
THCA	cis	rs5758659	0.714	rs5758578	ENSG00000205702.9	CYP2D7	-3.9	0.000109	0.0084	-0.13	-0.18	Cognitive function;	chr22:42094288	chr22:42140203~42144577:-
THCA	cis	rs1005277	0.579	rs1621040	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780136	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780138	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780139	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.602	rs1780141	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.541	rs1740741	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.528	rs2057228	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1740742	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.602	rs1740743	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1740745	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1740747	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1740749	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780115	ENSG00000120555.12	SEPT7P9	3.9	0.000109	0.00841	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38383069~38402916:-
THCA	cis	rs950169	0.84	rs12905223	ENSG00000275120.1	RP11-182J1.17	3.9	0.000109	0.00841	0.21	0.18	Schizophrenia;	chr15:84571037	chr15:84599434~84606463:-
THCA	cis	rs72928364	0.86	rs62274067	ENSG00000256628.3	ZBTB11-AS1	3.9	0.000109	0.00841	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101084630	chr3:101676475~101679217:+
THCA	cis	rs13118159	0.801	rs13147602	ENSG00000254094.1	AC078852.1	-3.9	0.000109	0.00841	-0.2	-0.18	Longevity;	chr4:1338387	chr4:1356581~1358075:+
THCA	cis	rs758324	0.732	rs152056	ENSG00000224431.1	AC063976.7	-3.9	0.000109	0.00841	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132181789	chr5:132199456~132203487:+
THCA	cis	rs9926296	0.643	rs2159114	ENSG00000274627.1	RP11-104N10.2	-3.9	0.000109	0.00841	-0.18	-0.18	Vitiligo;	chr16:89765433	chr16:89516797~89522217:+
THCA	cis	rs7914558	1	rs7077291	ENSG00000213061.2	PFN1P11	3.9	0.000109	0.00841	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185994	chr10:102838011~102845473:-
THCA	cis	rs5769765	0.773	rs4075331	ENSG00000260613.1	RP3-522J7.6	-3.9	0.000109	0.00841	-0.22	-0.18	Schizophrenia;	chr22:49909202	chr22:49832616~49837786:-
THCA	cis	rs1334894	0.584	rs3798344	ENSG00000228559.1	RP3-340B19.3	-3.9	0.000109	0.00841	-0.28	-0.18	Coronary artery disease;	chr6:35499123	chr6:35544632~35545669:+
THCA	cis	rs944289	0.53	rs2780309	ENSG00000258844.1	RP11-259K15.2	-3.9	0.000109	0.00841	-0.16	-0.18	Thyroid cancer;	chr14:36050646	chr14:36214607~36235608:+
THCA	cis	rs6443245	0.611	rs2648585	ENSG00000227110.5	LMCD1-AS1	-3.9	0.000109	0.00841	-0.21	-0.18	Daytime sleep phenotypes;	chr3:9588574	chr3:7952805~8611924:-
THCA	cis	rs6443245	0.532	rs2648584	ENSG00000227110.5	LMCD1-AS1	-3.9	0.000109	0.00841	-0.21	-0.18	Daytime sleep phenotypes;	chr3:9588662	chr3:7952805~8611924:-
THCA	cis	rs6487679	0.526	rs7305336	ENSG00000256069.6	A2MP1	3.9	0.000109	0.00841	0.21	0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9222493	chr12:9228533~9275817:-
THCA	cis	rs10771511	1	rs10771511	ENSG00000257599.1	OVCH1-AS1	-3.9	0.000109	0.00841	-0.21	-0.18	Platelet distribution width;	chr12:29284284	chr12:29389294~29487488:+
THCA	cis	rs5758511	0.68	rs739147	ENSG00000230107.1	CTA-126B4.7	-3.9	0.000109	0.00841	-0.21	-0.18	Birth weight;	chr22:42275060	chr22:42438023~42446195:+
THCA	cis	rs3764021	0.868	rs7306304	ENSG00000214776.8	RP11-726G1.1	3.9	0.000109	0.00841	0.21	0.18	Type 1 diabetes;	chr12:9724600	chr12:9467552~9576275:+
THCA	cis	rs3764021	0.837	rs7306557	ENSG00000214776.8	RP11-726G1.1	3.9	0.000109	0.00841	0.21	0.18	Type 1 diabetes;	chr12:9724760	chr12:9467552~9576275:+
THCA	cis	rs6940638	0.688	rs2022272	ENSG00000220721.1	OR1F12	3.9	0.000109	0.00841	0.21	0.18	Intelligence (multi-trait analysis);	chr6:27135801	chr6:28073316~28074233:+
THCA	cis	rs12544026	0.719	rs9297313	ENSG00000253669.3	KB-1732A1.1	-3.9	0.000109	0.00841	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101837973	chr8:102805517~102809971:+
THCA	cis	rs2434529	0.747	rs95397	ENSG00000245275.6	SAP30L-AS1	3.9	0.000109	0.00841	0.18	0.18	Autism spectrum disorder or schizophrenia;	chr5:154272755	chr5:154329437~154445850:-
THCA	cis	rs683250	0.629	rs532258	ENSG00000254551.1	RP11-727A23.7	-3.9	0.000109	0.00841	-0.22	-0.18	Subcortical brain region volumes;	chr11:83222565	chr11:83209431~83213379:-
THCA	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	3.9	0.000109	0.00841	0.25	0.18	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
THCA	cis	rs6995541	0.631	rs7829201	ENSG00000248896.2	CTD-2135J3.3	-3.9	0.000109	0.00841	-0.22	-0.18	Triglyceride levels;	chr8:10826673	chr8:10729314~10771392:+
THCA	cis	rs6995541	0.647	rs6984388	ENSG00000248896.2	CTD-2135J3.3	-3.9	0.000109	0.00841	-0.22	-0.18	Triglyceride levels;	chr8:10828159	chr8:10729314~10771392:+
THCA	cis	rs4788570	0.51	rs9931074	ENSG00000260593.1	RP11-432I5.2	-3.9	0.000109	0.00842	-0.28	-0.18	Intelligence (multi-trait analysis);	chr16:71633777	chr16:71623708~71626816:-
THCA	cis	rs2836326	1	rs9975835	ENSG00000226012.1	AP001434.2	3.9	0.000109	0.00842	0.26	0.18	Metabolite levels (HVA);	chr21:38339020	chr21:38237217~38238201:-
THCA	cis	rs564799	0.966	rs522127	ENSG00000244040.4	IL12A-AS1	3.9	0.000109	0.00842	0.23	0.18	Systemic lupus erythematosus;	chr3:160016881	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs523886	ENSG00000244040.4	IL12A-AS1	3.9	0.000109	0.00842	0.23	0.18	Systemic lupus erythematosus;	chr3:160017071	chr3:159913400~160225299:-
THCA	cis	rs564799	0.931	rs2366643	ENSG00000244040.4	IL12A-AS1	3.9	0.000109	0.00842	0.23	0.18	Systemic lupus erythematosus;	chr3:160018698	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs2366644	ENSG00000244040.4	IL12A-AS1	3.9	0.000109	0.00842	0.23	0.18	Systemic lupus erythematosus;	chr3:160018785	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs2647930	ENSG00000244040.4	IL12A-AS1	3.9	0.000109	0.00842	0.23	0.18	Systemic lupus erythematosus;	chr3:160019106	chr3:159913400~160225299:-
THCA	cis	rs564799	0.966	rs2647931	ENSG00000244040.4	IL12A-AS1	3.9	0.000109	0.00842	0.23	0.18	Systemic lupus erythematosus;	chr3:160019289	chr3:159913400~160225299:-
THCA	cis	rs17818399	0.788	rs13013245	ENSG00000279254.1	RP11-536C12.1	-3.9	0.000109	0.00842	-0.19	-0.18	Height;	chr2:46578947	chr2:46668870~46670778:+
THCA	cis	rs2806561	0.765	rs1738469	ENSG00000249087.5	ZNF436-AS1	-3.9	0.000109	0.00842	-0.11	-0.18	Height;	chr1:23184914	chr1:23368997~23371839:+
THCA	cis	rs9291683	0.595	rs10939665	ENSG00000250413.1	RP11-448G15.1	-3.9	0.000109	0.00842	-0.17	-0.18	Bone mineral density;	chr4:10036004	chr4:10006482~10009725:+
THCA	cis	rs4268898	0.686	rs2042468	ENSG00000242628.4	AC009228.1	-3.9	0.000109	0.00842	-0.22	-0.18	Asthma;	chr2:24175577	chr2:24214381~24221516:+
THCA	cis	rs7267979	1	rs2856	ENSG00000276952.1	RP5-965G21.6	3.9	0.000109	0.00842	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25284915~25285588:-
THCA	cis	rs7243790	0.805	rs12458280	ENSG00000277324.1	RP11-850A17.1	-3.9	0.000109	0.00842	-0.18	-0.18	Diastolic blood pressure;	chr18:54386772	chr18:54268346~54270028:-
THCA	cis	rs4268898	0.722	rs6723257	ENSG00000242628.4	AC009228.1	-3.9	0.000109	0.00842	-0.22	-0.18	Asthma;	chr2:24168260	chr2:24214381~24221516:+
THCA	cis	rs7121800	0.603	rs2085612	ENSG00000242353.1	RP4-710M3.1	-3.9	0.000109	0.00842	-0.16	-0.18	Pit-and-Fissure caries;	chr11:30522875	chr11:30368148~30368646:+
THCA	cis	rs7178424	0.711	rs11635569	ENSG00000259251.2	RP11-643M14.1	-3.9	0.000109	0.00842	-0.18	-0.18	Height;	chr15:61921398	chr15:62060503~62062434:+
THCA	cis	rs2858942	0.527	rs7185345	ENSG00000206168.1	Z69890.1	-3.9	0.000109	0.00843	-0.19	-0.18	Mean corpuscular hemoglobin;	chr16:192771	chr16:231134~231472:+
THCA	cis	rs12935229	0.756	rs7192536	ENSG00000260922.1	RP11-538I12.3	-3.9	0.000109	0.00843	-0.26	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77267112	chr16:77234877~77290934:+
THCA	cis	rs73198271	0.737	rs506960	ENSG00000253981.4	ALG1L13P	-3.9	0.000109	0.00843	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8236003~8244667:-
THCA	cis	rs7131987	0.565	rs766445	ENSG00000257176.2	RP11-996F15.2	3.9	0.000109	0.00843	0.18	0.18	QT interval;	chr12:29260560	chr12:29280418~29317848:-
THCA	cis	rs13434995	0.513	rs13133077	ENSG00000249700.7	SRD5A3-AS1	3.9	0.000109	0.00843	0.25	0.18	Adiponectin levels;	chr4:55577642	chr4:55363971~55395847:-
THCA	cis	rs9527	0.518	rs7899608	ENSG00000236937.2	PTGES3P4	3.9	0.000109	0.00843	0.32	0.18	Arsenic metabolism;	chr10:102967547	chr10:102845595~102845950:+
THCA	cis	rs6894268	0.685	rs28685239	ENSG00000273549.1	Metazoa_SRP	-3.9	0.000109	0.00843	-0.22	-0.18	Eating disorders;	chr5:179594981	chr5:179629151~179629410:+
THCA	cis	rs10860794	0.634	rs10860805	ENSG00000274560.1	RP11-285E23.2	-3.9	0.000109	0.00843	-0.12	-0.18	Blood protein levels;	chr12:101876558	chr12:101696002~101696450:-
THCA	cis	rs10860794	0.667	rs7312044	ENSG00000274560.1	RP11-285E23.2	-3.9	0.000109	0.00843	-0.12	-0.18	Blood protein levels;	chr12:101880741	chr12:101696002~101696450:-
THCA	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	3.9	0.000109	0.00843	0.16	0.18	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
THCA	cis	rs10938353	0.638	rs6813425	ENSG00000273369.1	RP11-700J17.1	3.9	0.000109	0.00843	0.21	0.18	Body mass index;	chr4:44659503	chr4:44693946~44694386:-
THCA	cis	rs10938353	0.68	rs72624165	ENSG00000273369.1	RP11-700J17.1	3.9	0.000109	0.00843	0.21	0.18	Body mass index;	chr4:44662457	chr4:44693946~44694386:-
THCA	cis	rs1923243	0.617	rs6667756	ENSG00000223479.3	RP4-788P17.1	-3.9	0.000109	0.00843	-0.19	-0.18	Migraine;	chr1:72980284	chr1:73635216~73715214:+
THCA	cis	rs6878727	0.552	rs181931	ENSG00000253807.4	LINC01170	3.9	0.000109	0.00843	0.18	0.18	Breast cancer;	chr5:124351038	chr5:124059794~124405079:-
THCA	cis	rs9926296	0.581	rs12598477	ENSG00000274627.1	RP11-104N10.2	-3.9	0.000109	0.00843	-0.18	-0.18	Vitiligo;	chr16:89836074	chr16:89516797~89522217:+
THCA	cis	rs2806561	0.765	rs2806556	ENSG00000249087.5	ZNF436-AS1	-3.9	0.000109	0.00843	-0.11	-0.18	Height;	chr1:23176357	chr1:23368997~23371839:+
THCA	cis	rs2341260	0.541	rs4650219	ENSG00000223479.3	RP4-788P17.1	-3.9	0.000109	0.00843	-0.23	-0.18	Cardiac Troponin-T levels;	chr1:73611467	chr1:73635216~73715214:+
THCA	cis	rs6600671	0.967	rs12069545	ENSG00000275585.1	CH17-118O6.3	-3.9	0.000109	0.00844	-0.21	-0.18	Hip geometry;	chr1:121430343	chr1:120985692~121052167:-
THCA	cis	rs62385074	1	rs62385074	ENSG00000250274.1	CTB-114C7.4	3.9	0.000109	0.00844	0.31	0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr5:170304613	chr5:170308701~170312716:-
THCA	cis	rs9905704	0.846	rs302863	ENSG00000224738.1	AC099850.1	-3.9	0.000109	0.00844	-0.23	-0.18	Testicular germ cell tumor;	chr17:58621466	chr17:59106598~59118267:+
THCA	cis	rs12149074	0.901	rs7187382	ENSG00000260876.4	LINC01229	3.9	0.000109	0.00844	0.18	0.18	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80077245	chr16:79676108~79807922:+
THCA	cis	rs2522056	0.808	rs7704457	ENSG00000237714.1	P4HA2-AS1	3.9	0.000109	0.00844	0.26	0.18	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132184876~132192808:+
THCA	cis	rs2640806	0.505	rs13262091	ENSG00000253105.4	KB-1448A5.1	3.9	0.000109	0.00844	0.21	0.18	Obesity-related traits;	chr8:96352945	chr8:96371865~96387438:-
THCA	cis	rs7824557	0.583	rs2263511	ENSG00000255495.1	AC145124.2	-3.9	0.000109	0.00844	-0.2	-0.18	Retinal vascular caliber;	chr8:11375809	chr8:12194467~12196280:+
THCA	cis	rs755249	0.567	rs61783378	ENSG00000182109.6	RP11-69E11.4	3.9	0.000109	0.00844	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39522280~39546187:-
THCA	cis	rs2839186	0.558	rs2968	ENSG00000228137.1	AP001469.7	-3.9	0.000109	0.00844	-0.18	-0.18	Testicular germ cell tumor;	chr21:46188666	chr21:46246890~46247682:+
THCA	cis	rs12497850	0.765	rs12487580	ENSG00000228638.1	FCF1P2	-3.9	0.000109	0.00844	-0.19	-0.18	Parkinson's disease;	chr3:49145499	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.797	rs61583136	ENSG00000228638.1	FCF1P2	-3.9	0.000109	0.00844	-0.19	-0.18	Parkinson's disease;	chr3:49151762	chr3:48290793~48291375:-
THCA	cis	rs67079557	1	rs67079557	ENSG00000260274.1	RP11-817O13.8	3.9	0.000109	0.00844	0.13	0.18	Breast cancer;	chr15:75637966	chr15:75368155~75369584:+
THCA	cis	rs9896933	0.614	rs3785511	ENSG00000262410.1	RP11-388C12.8	3.9	0.000109	0.00844	0.23	0.18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82928440	chr17:82745068~82745709:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000230189.5	GS1-124K5.2	3.9	0.000109	0.00844	0.12	0.18	Aortic root size;	chr7:66749580	chr7:66409143~66490059:-
THCA	cis	rs801193	0.66	rs4610622	ENSG00000230189.5	GS1-124K5.2	3.9	0.000109	0.00844	0.12	0.18	Aortic root size;	chr7:66759510	chr7:66409143~66490059:-
THCA	cis	rs7904321	1	rs10761691	ENSG00000232075.1	MRPL35P2	-3.9	0.000109	0.00844	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63073349	chr10:63634317~63634827:-
THCA	cis	rs1150668	0.799	rs1150707	ENSG00000280107.1	AL022393.9	-3.9	0.000109	0.00844	-0.17	-0.18	Pubertal anthropometrics;	chr6:28229827	chr6:28170845~28172521:+
THCA	cis	rs7259376	0.936	rs1865074	ENSG00000269345.1	VN1R85P	3.9	0.000109	0.00844	0.19	0.18	Menopause (age at onset);	chr19:22372147	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs1865073	ENSG00000269345.1	VN1R85P	3.9	0.000109	0.00844	0.19	0.18	Menopause (age at onset);	chr19:22372178	chr19:22174766~22175191:-
THCA	cis	rs867371	0.82	rs12443224	ENSG00000278603.1	RP13-608F4.5	3.9	0.000109	0.00844	0.23	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82472203~82472426:+
THCA	cis	rs2455799	0.533	rs2470550	ENSG00000270409.1	RP11-44D5.1	-3.9	0.000109	0.00844	-0.19	-0.18	Mean platelet volume;	chr3:15702214	chr3:15732252~15733470:+
THCA	cis	rs3764021	0.87	rs7307111	ENSG00000214776.8	RP11-726G1.1	3.9	0.000109	0.00844	0.21	0.18	Type 1 diabetes;	chr12:9725227	chr12:9467552~9576275:+
THCA	cis	rs2657294	0.895	rs3088142	ENSG00000226051.5	ZNF503-AS1	-3.9	0.000109	0.00845	-0.25	-0.18	Pneumonia;	chr10:75094806	chr10:75269819~75373500:+
THCA	cis	rs7824557	0.547	rs2409745	ENSG00000255495.1	AC145124.2	3.9	0.000109	0.00845	0.2	0.18	Retinal vascular caliber;	chr8:11219126	chr8:12194467~12196280:+
THCA	cis	rs2652822	0.525	rs3784671	ENSG00000259459.4	RP11-321G12.1	-3.9	0.00011	0.00845	-0.14	-0.18	Metabolic traits;	chr15:63276985	chr15:63390136~63438320:+
THCA	cis	rs4788570	0.584	rs9934301	ENSG00000260593.1	RP11-432I5.2	-3.9	0.00011	0.00845	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71722942	chr16:71623708~71626816:-
THCA	cis	rs6724465	0.636	rs72951774	ENSG00000272644.1	RP11-33O4.1	3.9	0.00011	0.00845	0.26	0.18	Height;	chr2:219127334	chr2:219069354~219069809:-
THCA	cis	rs10090774	0.687	rs11995049	ENSG00000280303.2	ERICD	-3.9	0.00011	0.00845	-0.16	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140682990	chr8:140636281~140638283:+
THCA	cis	rs4713118	0.628	rs9295740	ENSG00000220721.1	OR1F12	3.9	0.00011	0.00845	0.24	0.18	Parkinson's disease;	chr6:27721723	chr6:28073316~28074233:+
THCA	cis	rs7777677	0.925	rs6956269	ENSG00000211750.2	TRBV24-1	-3.9	0.00011	0.00845	-0.18	-0.18	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142656701~142657213:+
THCA	cis	rs7267979	1	rs4815411	ENSG00000276952.1	RP5-965G21.6	-3.9	0.00011	0.00845	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25284915~25285588:-
THCA	cis	rs2692947	0.63	rs1168966	ENSG00000232931.4	LINC00342	3.9	0.00011	0.00845	0.14	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96132771	chr2:95807118~95816215:-
THCA	cis	rs5769765	0.908	rs9627788	ENSG00000260613.1	RP3-522J7.6	-3.9	0.00011	0.00845	-0.22	-0.18	Schizophrenia;	chr22:49906790	chr22:49832616~49837786:-
THCA	cis	rs7511006	1	rs7511006	ENSG00000273137.1	RP3-402G11.28	-3.9	0.00011	0.00845	-0.12	-0.18	Obesity-related traits;	chr22:50237830	chr22:50208461~50209542:-
THCA	cis	rs7511006	1	rs7290710	ENSG00000273137.1	RP3-402G11.28	-3.9	0.00011	0.00845	-0.12	-0.18	Obesity-related traits;	chr22:50239025	chr22:50208461~50209542:-
THCA	cis	rs7904321	1	rs4746865	ENSG00000232075.1	MRPL35P2	-3.9	0.00011	0.00845	-0.23	-0.18	Intelligence (multi-trait analysis);	chr10:63074413	chr10:63634317~63634827:-
THCA	cis	rs7772697	0.508	rs12200909	ENSG00000223701.3	RAET1E-AS1	-3.9	0.00011	0.00845	-0.26	-0.18	Diabetic retinopathy;	chr6:149044291	chr6:149884431~149919508:+
THCA	cis	rs17685	0.796	rs3757594	ENSG00000227038.2	AC005077.12	-3.9	0.00011	0.00846	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76049326	chr7:76090431~76108779:-
THCA	cis	rs1853665	0.669	rs4368824	ENSG00000231760.4	RP11-350J20.5	3.9	0.00011	0.00846	0.34	0.18	Radiation response;	chr6:149948163	chr6:149796151~149826294:-
THCA	cis	rs1204798	0.685	rs1204812	ENSG00000237021.2	RP3-486I3.7	-3.9	0.00011	0.00846	-0.2	-0.18	Dental caries;	chr6:116231933	chr6:116254207~116256743:+
THCA	cis	rs7829975	0.593	rs2921051	ENSG00000233609.3	RP11-62H7.2	3.9	0.00011	0.00846	0.17	0.18	Mood instability;	chr8:8462594	chr8:8961200~8979025:+
THCA	cis	rs7546	0.504	rs2075636	ENSG00000267077.1	RP11-127I20.5	-3.9	0.00011	0.00846	-0.2	-0.18	Cancer;	chr16:4888320	chr16:4795265~4796532:-
THCA	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	3.9	0.00011	0.00846	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	3.9	0.00011	0.00846	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	3.9	0.00011	0.00846	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	3.9	0.00011	0.00846	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
THCA	cis	rs613391	0.508	rs10965431	ENSG00000234840.1	LINC01239	-3.9	0.00011	0.00846	-0.2	-0.18	Quantitative traits;	chr9:22725850	chr9:22646200~22824213:+
THCA	cis	rs72627123	1	rs58204112	ENSG00000259065.1	RP5-1021I20.1	-3.9	0.00011	0.00846	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73892714	chr14:73787360~73803270:+
THCA	cis	rs9309473	0.519	rs35421685	ENSG00000273245.1	RP11-434P11.2	-3.9	0.00011	0.00846	-0.2	-0.18	Metabolite levels;	chr2:73683011	chr2:73750256~73750786:-
THCA	cis	rs17221829	0.617	rs11018677	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89629652	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs11018679	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89629701	chr11:90193614~90198120:+
THCA	cis	rs10540	1	rs12794284	ENSG00000279672.1	CMB9-55F22.1	3.9	0.00011	0.00846	0.35	0.18	Body mass index;	chr11:477623	chr11:779617~780755:+
THCA	cis	rs7170668	0.896	rs4374121	ENSG00000259134.4	LINC00924	3.9	0.00011	0.00846	0.23	0.18	Motion sickness;	chr15:95490170	chr15:95433095~95507847:+
THCA	cis	rs494526	0.767	rs904977	ENSG00000229272.1	RP11-498J9.2	-3.9	0.00011	0.00846	-0.2	-0.18	Alcoholic chronic pancreatitis;	chr10:119023819	chr10:119003536~119003884:-
THCA	cis	rs34975555	0.892	rs13274246	ENSG00000253671.1	RP11-806O11.1	-3.9	0.00011	0.00846	-0.29	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17959172	chr8:17808941~17820868:+
THCA	cis	rs78487399	0.808	rs10180005	ENSG00000234936.1	AC010883.5	3.9	0.00011	0.00846	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43510326	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs13405776	ENSG00000234936.1	AC010883.5	3.9	0.00011	0.00846	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43511982	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs13419380	ENSG00000234936.1	AC010883.5	3.9	0.00011	0.00846	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43512045	chr2:43229573~43233394:+
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000265443.1	CTD-2349P21.6	-3.9	0.00011	0.00846	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30726305~30727564:-
THCA	cis	rs1862618	0.853	rs1423621	ENSG00000234553.1	AC022431.3	-3.9	0.00011	0.00846	-0.2	-0.18	Initial pursuit acceleration;	chr5:56805208	chr5:56536583~56537826:-
THCA	cis	rs912593	1	rs9599169	ENSG00000225179.1	LINC00457	3.9	0.00011	0.00846	0.23	0.18	Cancer;	chr13:34465736	chr13:34435450~34640685:-
THCA	cis	rs7200543	0.883	rs4985148	ENSG00000188599.16	NPIPP1	-3.9	0.00011	0.00846	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:15104312~15123498:-
THCA	cis	rs17221829	0.702	rs72969198	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89624439	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs72971005	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89625244	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs11600976	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89627674	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.6	rs3881248	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89629028	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.702	rs72971023	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89630766	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.703	rs11018682	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89631283	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.733	rs11018684	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00846	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89631695	chr11:90193614~90198120:+
THCA	cis	rs2074409	0.571	rs67499664	ENSG00000276054.1	RP11-378E13.3	3.9	0.00011	0.00846	0.28	0.18	Response to angiotensin II receptor blocker therapy;	chr17:37533543	chr17:37386886~37387926:+
THCA	cis	rs9959145	1	rs79998152	ENSG00000267199.1	RP11-861E21.2	3.9	0.00011	0.00847	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12567413	chr18:12438890~12448205:+
THCA	cis	rs9959145	0.778	rs77764901	ENSG00000267199.1	RP11-861E21.2	3.9	0.00011	0.00847	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12567459	chr18:12438890~12448205:+
THCA	cis	rs7737355	0.704	rs984616	ENSG00000237714.1	P4HA2-AS1	3.9	0.00011	0.00847	0.24	0.18	Life satisfaction;	chr5:131555408	chr5:132184876~132192808:+
THCA	cis	rs75059851	1	rs75059851	ENSG00000280237.1	MIR4697HG	3.9	0.00011	0.00847	0.21	0.18	Schizophrenia;	chr11:133952674	chr11:133896438~133901601:-
THCA	cis	rs7688540	0.8	rs11731285	ENSG00000250892.1	RP11-1365D11.1	3.9	0.00011	0.00847	0.25	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:201409~205009:-
THCA	cis	rs2836974	0.863	rs8132333	ENSG00000255568.3	BRWD1-AS2	3.9	0.00011	0.00847	0.15	0.18	Cognitive function;	chr21:39155974	chr21:39313935~39314962:+
THCA	cis	rs11168351	0.833	rs6580652	ENSG00000257735.1	RP11-370I10.6	-3.9	0.00011	0.00847	-0.2	-0.18	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48350945~48442411:+
THCA	cis	rs7044106	0.887	rs1359328	ENSG00000238181.2	AHCYP2	-3.9	0.00011	0.00847	-0.25	-0.18	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120720673~120721972:+
THCA	cis	rs17074492	1	rs17291274	ENSG00000214182.5	PTMAP5	3.9	0.00011	0.00847	0.21	0.18	Sjögren's syndrome;	chr13:81593807	chr13:81689911~81691072:+
THCA	cis	rs17597773	0.638	rs6668666	ENSG00000238078.1	LINC01352	-3.9	0.00011	0.00847	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826069	chr1:220829255~220832429:+
THCA	cis	rs10175706	0.965	rs13412368	ENSG00000256637.5	RP11-76I14.1	-3.9	0.00011	0.00847	-0.16	-0.18	Chin dimples;	chr2:104005336	chr2:103874310~104077778:+
THCA	cis	rs603446	0.967	rs180350	ENSG00000254851.1	RP11-109L13.1	-3.9	0.00011	0.00847	-0.23	-0.18	Triglycerides;	chr11:116739332	chr11:117135528~117138582:+
THCA	cis	rs8014204	0.816	rs28426374	ENSG00000279594.1	RP11-950C14.10	-3.9	0.00011	0.00847	-0.17	-0.18	Caffeine consumption;	chr14:74880037	chr14:75011269~75012851:-
THCA	cis	rs9863	0.827	rs7305864	ENSG00000269938.1	RP11-214K3.20	-3.9	0.00011	0.00847	-0.2	-0.18	White blood cell count;	chr12:123957333	chr12:123968023~123968579:-
THCA	cis	rs2886497	1	rs59375773	ENSG00000224215.1	RP11-371A19.2	-3.9	0.00011	0.00847	-0.23	-0.18	Major depression and alcohol dependence;	chr10:23380362	chr10:23343957~23345181:+
THCA	cis	rs10090774	0.813	rs11787221	ENSG00000280303.2	ERICD	-3.9	0.00011	0.00847	-0.16	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708995	chr8:140636281~140638283:+
THCA	cis	rs1005277	0.505	rs10827835	ENSG00000275858.1	RP11-291L22.8	-3.9	0.00011	0.00847	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38450738~38451069:-
THCA	cis	rs1580019	0.522	rs10951340	ENSG00000273014.1	RP11-225B17.2	3.9	0.00011	0.00848	0.18	0.18	Cognitive ability;	chr7:32522796	chr7:32758882~32759353:+
THCA	cis	rs17027633	1	rs80017784	ENSG00000260948.1	RP11-552M11.8	-3.9	0.00011	0.00848	-0.39	-0.18	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405657	chr1:111431046~111433068:-
THCA	cis	rs17027633	1	rs74935221	ENSG00000260948.1	RP11-552M11.8	-3.9	0.00011	0.00848	-0.39	-0.18	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405676	chr1:111431046~111433068:-
THCA	cis	rs17027633	1	rs79696376	ENSG00000260948.1	RP11-552M11.8	-3.9	0.00011	0.00848	-0.39	-0.18	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405708	chr1:111431046~111433068:-
THCA	cis	rs17027633	1	rs76747944	ENSG00000260948.1	RP11-552M11.8	-3.9	0.00011	0.00848	-0.39	-0.18	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405727	chr1:111431046~111433068:-
THCA	cis	rs17027633	1	rs74226038	ENSG00000260948.1	RP11-552M11.8	-3.9	0.00011	0.00848	-0.39	-0.18	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405985	chr1:111431046~111433068:-
THCA	cis	rs2191566	0.664	rs7254261	ENSG00000266921.1	RP11-15A1.7	-3.9	0.00011	0.00848	-0.17	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44061274	chr19:43996896~44002836:-
THCA	cis	rs2736337	0.53	rs2003422	ENSG00000154316.13	TDH	-3.9	0.00011	0.00848	-0.13	-0.18	Rheumatoid arthritis;	chr8:11445628	chr8:11339637~11368452:+
THCA	cis	rs9677476	0.517	rs55970645	ENSG00000224376.1	AC017104.6	3.9	0.00011	0.00848	0.18	0.18	Food antigen IgG levels;	chr2:231187780	chr2:231388976~231394991:+
THCA	cis	rs9534288	0.83	rs940	ENSG00000235903.6	CPB2-AS1	3.9	0.00011	0.00848	0.25	0.18	Blood protein levels;	chr13:46053345	chr13:46052806~46113332:+
THCA	cis	rs513088	0.589	rs502594	ENSG00000225171.2	DUTP6	3.9	0.00011	0.00848	0.26	0.18	Schizophrenia;	chr1:166721246	chr1:166868748~166869209:+
THCA	cis	rs17221829	0.673	rs11018676	ENSG00000280385.1	AP000648.5	-3.9	0.00011	0.00848	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89629560	chr11:90193614~90198120:+
THCA	cis	rs763121	0.962	rs2071887	ENSG00000225450.1	RP3-508I15.14	-3.9	0.00011	0.00848	-0.13	-0.18	Menopause (age at onset);	chr22:38483005	chr22:38739003~38749041:+
THCA	cis	rs2039553	0.583	rs2329138	ENSG00000227354.5	RBM26-AS1	-3.9	0.00011	0.00848	-0.17	-0.18	Pancreatic cancer;	chr13:79763571	chr13:79406309~79424328:+
THCA	cis	rs748404	0.55	rs12912505	ENSG00000166763.7	STRCP1	3.9	0.00011	0.00848	0.24	0.18	Lung cancer;	chr15:43525206	chr15:43699488~43718184:-
THCA	cis	rs3748656	0.887	rs3737136	ENSG00000273483.1	RP4-671G15.2	3.9	0.00011	0.00848	0.2	0.18	Hip circumference adjusted for BMI;	chr1:112517810	chr1:112517799~112518441:-
THCA	cis	rs2221894	0.881	rs2035644	ENSG00000251191.6	LINC00589	3.9	0.00011	0.00848	0.21	0.18	Obesity-related traits;	chr8:29042180	chr8:29673922~29748109:-
THCA	cis	rs308403	0.509	rs7690133	ENSG00000224786.1	CETN4P	3.9	0.00011	0.00848	0.18	0.18	Blood protein levels;	chr4:122752654	chr4:122730548~122732193:-
THCA	cis	rs9329221	0.648	rs4512422	ENSG00000261451.1	RP11-981G7.1	-3.9	0.00011	0.00848	-0.22	-0.18	Neuroticism;	chr8:10401379	chr8:10433672~10438312:+
THCA	cis	rs17597773	0.638	rs12139139	ENSG00000272823.1	RP11-295M18.6	-3.9	0.00011	0.00848	-0.23	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220827284	chr1:220828676~220829211:-
THCA	cis	rs9307551	0.817	rs1975399	ENSG00000249646.2	OR7E94P	-3.9	0.00011	0.00848	-0.22	-0.18	Refractive error;	chr4:79582612	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.779	rs1440854	ENSG00000249646.2	OR7E94P	-3.9	0.00011	0.00848	-0.22	-0.18	Refractive error;	chr4:79585580	chr4:79587302~79588130:-
THCA	cis	rs5758511	0.634	rs1001587	ENSG00000230107.1	CTA-126B4.7	-3.9	0.00011	0.00848	-0.21	-0.18	Birth weight;	chr22:42274105	chr22:42438023~42446195:+
THCA	cis	rs459571	0.92	rs2520094	ENSG00000235106.7	LINC00094	3.9	0.00011	0.00848	0.16	0.18	Platelet distribution width;	chr9:134054863	chr9:134025439~134034666:+
THCA	cis	rs9926296	0.656	rs11861084	ENSG00000274627.1	RP11-104N10.2	3.9	0.00011	0.00848	0.18	0.18	Vitiligo;	chr16:89809302	chr16:89516797~89522217:+
THCA	cis	rs2135507	0.817	rs28647824	ENSG00000270480.1	RP11-57B24.1	3.9	0.00011	0.00848	0.24	0.18	Juvenile osteochondritis dissecans;	chr4:82663909	chr4:82691737~82692468:+
THCA	cis	rs4759375	1	rs10444439	ENSG00000256092.2	RP13-942N8.1	-3.9	0.00011	0.00849	-0.19	-0.18	HDL cholesterol;	chr12:123281890	chr12:123363868~123366113:+
THCA	cis	rs727563	0.569	rs73178647	ENSG00000237037.8	NDUFA6-AS1	3.9	0.00011	0.00849	0.17	0.18	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr22:42090931~42137742:+
THCA	cis	rs7968440	0.707	rs1109726	ENSG00000272368.2	RP4-605O3.4	3.9	0.00011	0.00849	0.11	0.18	Fibrinogen;	chr12:50764765	chr12:50112197~50165618:+
THCA	cis	rs7178424	0.742	rs1981916	ENSG00000259251.2	RP11-643M14.1	-3.9	0.00011	0.00849	-0.18	-0.18	Height;	chr15:61879280	chr15:62060503~62062434:+
THCA	cis	rs4646450	0.636	rs2003499	ENSG00000244219.5	GS1-259H13.2	-3.9	0.00011	0.00849	-0.26	-0.18	Blood metabolite levels;	chr7:99417361	chr7:99598066~99610813:+
THCA	cis	rs755249	0.508	rs624971	ENSG00000228060.1	RP11-69E11.8	-3.9	0.00011	0.00849	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39565160~39573203:+
THCA	cis	rs9316337	0.549	rs9509714	ENSG00000236953.1	ZDHHC20-IT1	-3.9	0.00011	0.00849	-0.2	-0.18	Schizophrenia;	chr13:21442477	chr13:21376977~21377874:-
THCA	cis	rs9316337	0.582	rs7329073	ENSG00000236953.1	ZDHHC20-IT1	-3.9	0.00011	0.00849	-0.2	-0.18	Schizophrenia;	chr13:21443751	chr13:21376977~21377874:-
THCA	cis	rs8070624	0.543	rs4299203	ENSG00000281749.1	Y_RNA	3.9	0.00011	0.00849	0.23	0.18	Total body bone mineral density;	chr17:17974845	chr17:18001101~18001195:-
THCA	cis	rs478304	0.654	rs7115734	ENSG00000255557.1	RP11-770G2.2	3.9	0.00011	0.00849	0.21	0.18	Acne (severe);	chr11:65691493	chr11:65745729~65771585:+
THCA	cis	rs478304	0.654	rs10896032	ENSG00000255557.1	RP11-770G2.2	3.9	0.00011	0.00849	0.21	0.18	Acne (severe);	chr11:65691948	chr11:65745729~65771585:+
THCA	cis	rs478304	0.654	rs6591187	ENSG00000255557.1	RP11-770G2.2	3.9	0.00011	0.00849	0.21	0.18	Acne (severe);	chr11:65692615	chr11:65745729~65771585:+
THCA	cis	rs478304	0.654	rs10896034	ENSG00000255557.1	RP11-770G2.2	3.9	0.00011	0.00849	0.21	0.18	Acne (severe);	chr11:65693312	chr11:65745729~65771585:+
THCA	cis	rs12216545	0.737	rs6962143	ENSG00000241134.3	BET1P1	-3.9	0.00011	0.00849	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150548846	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs6962518	ENSG00000241134.3	BET1P1	-3.9	0.00011	0.00849	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150548850	chr7:150749736~150750094:+
THCA	cis	rs3758911	0.861	rs10789621	ENSG00000255353.1	RP11-382M14.1	3.9	0.00011	0.00849	0.22	0.18	Coronary artery disease;	chr11:107388345	chr11:107176286~107177530:+
THCA	cis	rs1577917	0.958	rs11758508	ENSG00000220563.1	PKMP3	3.9	0.00011	0.00849	0.14	0.18	Response to antipsychotic treatment;	chr6:85797160	chr6:85659892~85660606:-
THCA	cis	rs6933660	0.8	rs13201167	ENSG00000219395.2	HSPA8P15	-3.9	0.00011	0.00849	-0.15	-0.18	Menarche (age at onset);	chr6:151452369	chr6:151411259~151413945:-
THCA	cis	rs8179	1	rs4272	ENSG00000230927.2	TMBIM7P	-3.9	0.00011	0.00849	-0.26	-0.18	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92607515	chr7:92412976~92439562:-
THCA	cis	rs2820315	0.867	rs2820322	ENSG00000223774.4	RP11-307B6.3	3.9	0.00011	0.0085	0.19	0.18	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201911172	chr1:201893842~201899978:+
THCA	cis	rs2721195	0.719	rs4925811	ENSG00000265393.1	CTD-2517M22.17	3.9	0.00011	0.0085	0.21	0.18	Age at first birth;	chr8:144577063	chr8:144512567~144513672:+
THCA	cis	rs7829975	0.508	rs4841006	ENSG00000233609.3	RP11-62H7.2	-3.9	0.00011	0.0085	-0.16	-0.18	Mood instability;	chr8:8643964	chr8:8961200~8979025:+
THCA	cis	rs7824557	0.547	rs2409749	ENSG00000254866.2	DEFB109P3	3.9	0.00011	0.0085	0.25	0.18	Retinal vascular caliber;	chr8:11221440	chr8:12150895~12151134:-
THCA	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	3.9	0.00011	0.0085	0.17	0.18	Height;	chr5:36941665	chr5:36666214~36725195:-
THCA	cis	rs9863	0.861	rs3802999	ENSG00000270028.1	RP11-380L11.4	3.9	0.00011	0.0085	0.19	0.18	White blood cell count;	chr12:123929551	chr12:123925461~123926083:-
THCA	cis	rs472402	0.56	rs10037161	ENSG00000250056.4	LINC01018	-3.9	0.00011	0.0085	-0.21	-0.18	Response to amphetamines;	chr5:6624181	chr5:6582136~6588499:+
THCA	cis	rs4742903	0.904	rs7029970	ENSG00000270332.1	SMC2-AS1	3.9	0.00011	0.0085	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104244284	chr9:104080024~104093073:-
THCA	cis	rs10911902	0.643	rs16825335	ENSG00000233196.2	GS1-304P7.1	-3.9	0.00011	0.0085	-0.27	-0.18	Schizophrenia;	chr1:186418612	chr1:186580515~186581191:-
THCA	cis	rs74233809	1	rs11191472	ENSG00000272912.1	RP11-724N1.1	-3.9	0.00011	0.0085	-0.33	-0.18	Birth weight;	chr10:102947259	chr10:102914585~102915404:+
THCA	cis	rs7267979	1	rs6050598	ENSG00000276952.1	RP5-965G21.6	3.9	0.00011	0.0085	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25284915~25285588:-
THCA	cis	rs4788570	0.578	rs8062188	ENSG00000260593.1	RP11-432I5.2	-3.9	0.00011	0.0085	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71695922	chr16:71623708~71626816:-
THCA	cis	rs964611	0.625	rs1843144	ENSG00000259488.2	RP11-154J22.1	3.9	0.00011	0.0085	0.16	0.18	Metabolite levels (Pyroglutamine);	chr15:48232325	chr15:48312353~48331856:-
THCA	cis	rs10186029	0.509	rs1122846	ENSG00000270659.1	RP11-105N14.1	-3.9	0.00011	0.0085	-0.15	-0.18	Systemic sclerosis;	chr2:213074630	chr2:213152970~213153659:+
THCA	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	3.9	0.00011	0.0085	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
THCA	cis	rs2120243	0.592	rs1869857	ENSG00000241770.1	RP11-555M1.3	3.9	0.00011	0.0085	0.22	0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157405568	chr3:157163452~157169133:+
THCA	cis	rs10741243	0.558	rs4341449	ENSG00000230098.1	TCERG1L-AS1	3.9	0.00011	0.0085	0.24	0.18	Type 2 diabetes;	chr10:131151472	chr10:131095218~131095777:+
THCA	cis	rs2033711	0.902	rs4801589	ENSG00000269054.1	CTD-2619J13.3	-3.9	0.00011	0.00851	-0.14	-0.18	Uric acid clearance;	chr19:58442031	chr19:58362585~58366591:+
THCA	cis	rs4763879	0.739	rs2895988	ENSG00000214776.8	RP11-726G1.1	-3.9	0.00011	0.00851	-0.21	-0.18	Type 1 diabetes;	chr12:9675831	chr12:9467552~9576275:+
THCA	cis	rs614226	0.938	rs787824	ENSG00000278344.1	RP11-18C24.8	-3.9	0.00011	0.00851	-0.23	-0.18	Type 1 diabetes nephropathy;	chr12:120486835	chr12:120500735~120501090:-
THCA	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	3.9	0.00011	0.00851	0.2	0.18	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
THCA	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	3.9	0.00011	0.00851	0.23	0.18	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
THCA	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	3.9	0.00011	0.00851	0.23	0.18	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
THCA	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	3.9	0.00011	0.00851	0.23	0.18	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
THCA	cis	rs7615952	0.558	rs7641353	ENSG00000248787.1	RP11-666A20.4	-3.9	0.00011	0.00851	-0.27	-0.18	Blood pressure (smoking interaction);	chr3:125621035	chr3:125908005~125910272:-
THCA	cis	rs6012953	0.874	rs734589	ENSG00000231715.1	COX6CP2	-3.9	0.00011	0.00851	-0.18	-0.18	Vitiligo;	chr20:50562384	chr20:50479767~50479991:+
THCA	cis	rs2252521	0.583	rs317732	ENSG00000272568.4	CTB-113D17.1	3.9	0.00011	0.00851	0.2	0.18	Cognitive performance;	chr7:29049567	chr7:28979967~29013367:+
THCA	cis	rs4971059	0.629	rs12904	ENSG00000225855.5	RUSC1-AS1	3.9	0.00011	0.00851	0.11	0.18	Breast cancer;	chr1:155134221	chr1:155316863~155324176:-
THCA	cis	rs10875746	0.729	rs11168355	ENSG00000258234.1	RP11-370I10.2	-3.9	0.00011	0.00851	-0.2	-0.18	Longevity (90 years and older);	chr12:48017195	chr12:48231098~48284210:-
THCA	cis	rs4660214	0.666	rs2490946	ENSG00000228060.1	RP11-69E11.8	-3.9	0.00011	0.00851	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39565160~39573203:+
THCA	cis	rs755249	0.51	rs1184716	ENSG00000228060.1	RP11-69E11.8	-3.9	0.00011	0.00851	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39565160~39573203:+
THCA	cis	rs9611565	0.659	rs12484228	ENSG00000237037.8	NDUFA6-AS1	3.9	0.00011	0.00851	0.16	0.18	Vitiligo;	chr22:41543735	chr22:42090931~42137742:+
THCA	cis	rs854765	0.583	rs4553680	ENSG00000281749.1	Y_RNA	3.9	0.000111	0.00851	0.23	0.18	Total body bone mineral density;	chr17:17954408	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs8080823	ENSG00000281749.1	Y_RNA	3.9	0.000111	0.00851	0.23	0.18	Total body bone mineral density;	chr17:17960734	chr17:18001101~18001195:-
THCA	cis	rs34421088	0.559	rs12386974	ENSG00000206014.6	OR7E161P	-3.9	0.000111	0.00851	-0.21	-0.18	Neuroticism;	chr8:11543119	chr8:11928597~11929563:-
THCA	cis	rs6540731	0.905	rs11119883	ENSG00000226251.4	RP11-15I11.3	-3.9	0.000111	0.00851	-0.21	-0.18	Intelligence (childhood);	chr1:212213918	chr1:212225278~212238977:-
THCA	cis	rs72765298	0.79	rs72767017	ENSG00000235332.2	RP11-366O20.5	3.9	0.000111	0.00851	0.27	0.18	Pulse pressure;	chr9:125188076	chr9:125194649~125195821:-
THCA	cis	rs7824557	0.583	rs2736292	ENSG00000154316.13	TDH	-3.9	0.000111	0.00851	-0.13	-0.18	Retinal vascular caliber;	chr8:11376991	chr8:11339637~11368452:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66364510	chr7:66409143~66490059:-
THCA	cis	rs875971	0.929	rs778712	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66384991	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs778710	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66389847	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs778708	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66391332	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs778696	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66405826	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs778694	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66406571	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs4718344	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66409394	chr7:66409143~66490059:-
THCA	cis	rs875971	0.737	rs7803424	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66415618	chr7:66409143~66490059:-
THCA	cis	rs875971	0.83	rs7799834	ENSG00000230189.5	GS1-124K5.2	3.9	0.000111	0.00852	0.12	0.18	Aortic root size;	chr7:66415707	chr7:66409143~66490059:-
THCA	cis	rs293748	0.771	rs158797	ENSG00000250155.1	CTD-2353F22.1	-3.9	0.000111	0.00852	-0.23	-0.18	Obesity-related traits;	chr5:36870318	chr5:36666214~36725195:-
THCA	cis	rs3806843	0.576	rs155363	ENSG00000202515.1	VTRNA1-3	-3.9	0.000111	0.00852	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140921958	chr5:140726158~140726246:+
THCA	cis	rs4742903	0.935	rs975253	ENSG00000270332.1	SMC2-AS1	3.9	0.000111	0.00852	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104165979	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.904	rs971969	ENSG00000270332.1	SMC2-AS1	3.9	0.000111	0.00852	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104167517	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs7875929	ENSG00000270332.1	SMC2-AS1	3.9	0.000111	0.00852	0.17	0.18	Breast cancer;High-grade serous ovarian cancer;	chr9:104169127	chr9:104080024~104093073:-
THCA	cis	rs1385374	0.764	rs35299112	ENSG00000274695.1	RP11-21K12.3	3.9	0.000111	0.00852	0.39	0.18	Systemic lupus erythematosus;	chr12:128840385	chr12:128826836~128827579:+
THCA	cis	rs7193541	0.965	rs7199068	ENSG00000262904.1	TMPOP2	-3.9	0.000111	0.00852	-0.21	-0.18	Multiple myeloma;	chr16:74664365	chr16:74667506~74668706:+
THCA	cis	rs2055729	0.557	rs7000542	ENSG00000248538.5	RP11-10A14.5	-3.9	0.000111	0.00852	-0.22	-0.18	Multiple myeloma (hyperdiploidy);	chr8:10023625	chr8:9189011~9202854:+
THCA	cis	rs858239	0.899	rs28458177	ENSG00000230042.1	AK3P3	-3.9	0.000111	0.00852	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23129178~23129841:+
THCA	cis	rs12476592	0.571	rs2176415	ENSG00000242412.1	DBIL5P2	3.9	0.000111	0.00852	0.23	0.18	Childhood ear infection;	chr2:63409433	chr2:63117851~63119542:-
THCA	cis	rs7956611	0.564	rs7488693	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66512403	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs7977592	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66512545	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs7977856	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66512806	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs11613276	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66513378	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs7965031	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66514853	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs12581953	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66515028	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs6581702	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66516786	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs7976246	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66517362	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs35666435	ENSG00000213343.5	RPL21P18	-3.9	0.000111	0.00852	-0.2	-0.18	Age of smoking initiation;	chr12:66517605	chr12:66037235~66037714:+
THCA	cis	rs2442825	0.508	rs2648545	ENSG00000206573.7	THUMPD3-AS1	-3.9	0.000111	0.00852	-0.1	-0.18	Cerebrospinal fluid clusterin levels;	chr3:9347539	chr3:9349689~9398579:-
THCA	cis	rs240993	0.909	rs240991	ENSG00000255389.1	C6orf3	3.9	0.000111	0.00852	0.18	0.18	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111599875~111602295:+
THCA	cis	rs240993	1	rs240993	ENSG00000255389.1	C6orf3	3.9	0.000111	0.00852	0.18	0.18	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111599875~111602295:+
THCA	cis	rs860295	0.702	rs11264375	ENSG00000236675.1	MTX1P1	3.9	0.000111	0.00852	0.18	0.18	Body mass index;	chr1:155454274	chr1:155230975~155234325:+
THCA	cis	rs13256369	0.802	rs11249884	ENSG00000254153.1	CTA-398F10.2	3.9	0.000111	0.00852	0.2	0.18	Obesity-related traits;	chr8:8704042	chr8:8456909~8461337:-
THCA	cis	rs17597773	0.635	rs1494368	ENSG00000272823.1	RP11-295M18.6	-3.9	0.000111	0.00853	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220830826	chr1:220828676~220829211:-
THCA	cis	rs758324	0.617	rs246842	ENSG00000224431.1	AC063976.7	-3.9	0.000111	0.00853	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132066108	chr5:132199456~132203487:+
THCA	cis	rs7647973	0.771	rs9865051	ENSG00000228638.1	FCF1P2	-3.9	0.000111	0.00853	-0.22	-0.18	Menarche (age at onset);	chr3:49128636	chr3:48290793~48291375:-
THCA	cis	rs1125355	0.964	rs78599894	ENSG00000243792.1	OR7E89P	-3.9	0.000111	0.00853	-0.26	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158817912	chr2:158853755~158854576:+
THCA	cis	rs6088580	0.524	rs6088564	ENSG00000126005.14	MMP24-AS1	3.9	0.000111	0.00853	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34661640	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.524	rs11167241	ENSG00000126005.14	MMP24-AS1	3.9	0.000111	0.00853	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34663031	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.505	rs6142219	ENSG00000126005.14	MMP24-AS1	3.9	0.000111	0.00853	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34668541	chr20:35216462~35278131:-
THCA	cis	rs944289	0.561	rs371191	ENSG00000258844.1	RP11-259K15.2	-3.9	0.000111	0.00853	-0.16	-0.18	Thyroid cancer;	chr14:36064000	chr14:36214607~36235608:+
THCA	cis	rs7615952	0.611	rs2947646	ENSG00000248787.1	RP11-666A20.4	3.9	0.000111	0.00853	0.34	0.18	Blood pressure (smoking interaction);	chr3:125874759	chr3:125908005~125910272:-
THCA	cis	rs62244186	0.748	rs12635624	ENSG00000214820.3	MPRIPP1	3.9	0.000111	0.00853	0.19	0.18	Depressive symptoms;	chr3:44637006	chr3:44579938~44581026:-
THCA	cis	rs9733	0.791	rs11800059	ENSG00000231073.1	RP11-316M1.3	-3.9	0.000111	0.00853	-0.21	-0.18	Tonsillectomy;	chr1:150678699	chr1:150973123~150975534:+
THCA	cis	rs9733	0.818	rs11204695	ENSG00000231073.1	RP11-316M1.3	-3.9	0.000111	0.00853	-0.21	-0.18	Tonsillectomy;	chr1:150684535	chr1:150973123~150975534:+
THCA	cis	rs12313068	0.709	rs10849698	ENSG00000249094.2	RP1-7G5.6	3.9	0.000111	0.00853	0.28	0.18	Intelligence (multi-trait analysis);	chr12:110066993	chr12:109880676~109888467:+
THCA	cis	rs3105593	0.933	rs7176874	ENSG00000242737.1	RP11-562A8.1	3.9	0.000111	0.00853	0.22	0.18	QT interval;	chr15:50537783	chr15:50466738~50467096:+
THCA	cis	rs2549003	0.966	rs2706385	ENSG00000237714.1	P4HA2-AS1	3.9	0.000111	0.00853	0.22	0.18	Asthma (sex interaction);	chr5:132496074	chr5:132184876~132192808:+
THCA	cis	rs3758911	0.788	rs10890704	ENSG00000255353.1	RP11-382M14.1	-3.9	0.000111	0.00853	-0.23	-0.18	Coronary artery disease;	chr11:107312779	chr11:107176286~107177530:+
THCA	cis	rs7520050	1	rs785511	ENSG00000281133.1	AL355480.3	3.9	0.000111	0.00853	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs809775	ENSG00000281133.1	AL355480.3	3.9	0.000111	0.00853	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45580892~45580996:-
THCA	cis	rs7296418	0.552	rs7312955	ENSG00000256092.2	RP13-942N8.1	3.9	0.000111	0.00853	0.17	0.18	Platelet count;	chr12:123263236	chr12:123363868~123366113:+
THCA	cis	rs2380220	1	rs9632496	ENSG00000261366.1	MANEA-AS1	-3.9	0.000111	0.00854	-0.2	-0.18	Behavioural disinhibition (generation interaction);	chr6:95528574	chr6:95575183~95577450:-
THCA	cis	rs1005277	0.505	rs200936	ENSG00000275858.1	RP11-291L22.8	3.9	0.000111	0.00854	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.505	rs200937	ENSG00000275858.1	RP11-291L22.8	3.9	0.000111	0.00854	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38450738~38451069:-
THCA	cis	rs669446	0.533	rs4660261	ENSG00000237950.1	RP11-7O11.3	3.9	0.000111	0.00854	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43763926	chr1:43944370~43946551:-
THCA	cis	rs4906332	0.834	rs12882130	ENSG00000269910.1	RP11-73M18.10	3.9	0.000111	0.00854	0.15	0.18	Coronary artery disease;	chr14:103412437	chr14:103694516~103695050:-
THCA	cis	rs2692947	0.727	rs749459	ENSG00000232931.4	LINC00342	3.9	0.000111	0.00854	0.14	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129975	chr2:95807118~95816215:-
THCA	cis	rs4561483	0.583	rs11645213	ENSG00000263307.1	RP11-166B2.8	-3.9	0.000111	0.00854	-0.18	-0.18	Testicular germ cell tumor;	chr16:11849067	chr16:11851649~11895611:+
THCA	cis	rs3782089	1	rs11602375	ENSG00000245532.5	NEAT1	3.9	0.000111	0.00854	0.24	0.18	Height;	chr11:65529069	chr11:65422774~65445540:+
THCA	cis	rs3782089	1	rs11600543	ENSG00000245532.5	NEAT1	3.9	0.000111	0.00854	0.24	0.18	Height;	chr11:65531468	chr11:65422774~65445540:+
THCA	cis	rs10256972	0.786	rs3735686	ENSG00000199023.2	MIR339	-3.9	0.000111	0.00854	-0.18	-0.18	Endometriosis;Longevity;	chr7:1022891	chr7:1022935~1023045:-
THCA	cis	rs2412819	0.571	rs66903736	ENSG00000166763.7	STRCP1	3.9	0.000111	0.00854	0.25	0.18	Lung cancer;	chr15:43619435	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.571	rs66749753	ENSG00000166763.7	STRCP1	3.9	0.000111	0.00854	0.25	0.18	Lung cancer;	chr15:43619601	chr15:43699488~43718184:-
THCA	cis	rs7804306	0.579	rs13245462	ENSG00000233264.2	AC006042.8	3.9	0.000111	0.00854	0.24	0.18	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8034978	chr7:7980312~7982228:+
THCA	cis	rs879324	0.74	rs58084688	ENSG00000280092.1	AC002044.3	3.9	0.000111	0.00854	0.26	0.18	Stroke (ischemic);	chr16:73007953	chr16:73005601~73006141:-
THCA	cis	rs1612141	1	rs1778375	ENSG00000251363.2	RP11-129M6.1	-3.9	0.000111	0.00854	-0.26	-0.18	QT interval (drug interaction);	chr14:41222178	chr14:40954898~40975877:+
THCA	cis	rs1612141	1	rs1778376	ENSG00000251363.2	RP11-129M6.1	-3.9	0.000111	0.00854	-0.26	-0.18	QT interval (drug interaction);	chr14:41222193	chr14:40954898~40975877:+
THCA	cis	rs867186	0.92	rs8119351	ENSG00000126005.14	MMP24-AS1	-3.9	0.000111	0.00855	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35166602	chr20:35216462~35278131:-
THCA	cis	rs733592	0.965	rs1978161	ENSG00000269514.1	RP11-370I10.12	3.9	0.000111	0.00855	0.15	0.18	Plateletcrit;	chr12:48073938	chr12:48198387~48202031:+
THCA	cis	rs7403037	0.55	rs61993575	ENSG00000260760.1	PWRN3	3.9	0.000111	0.00855	0.26	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24399038	chr15:24441127~24447967:+
THCA	cis	rs700651	0.757	rs6748683	ENSG00000231621.1	AC013264.2	-3.9	0.000111	0.00855	-0.19	-0.18	Intracranial aneurysm;	chr2:198013284	chr2:197197991~197199273:+
THCA	cis	rs67981189	0.865	rs2810115	ENSG00000269927.1	RP6-91H8.3	-3.9	0.000111	0.00855	-0.2	-0.18	Schizophrenia;	chr14:70928070	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs917065	ENSG00000269927.1	RP6-91H8.3	-3.9	0.000111	0.00855	-0.2	-0.18	Schizophrenia;	chr14:70931129	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.896	rs1018977	ENSG00000269927.1	RP6-91H8.3	-3.9	0.000111	0.00855	-0.2	-0.18	Schizophrenia;	chr14:70933936	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.752	rs2332477	ENSG00000269927.1	RP6-91H8.3	-3.9	0.000111	0.00855	-0.2	-0.18	Schizophrenia;	chr14:70936594	chr14:71141125~71143253:-
THCA	cis	rs1714507	0.533	rs1620229	ENSG00000272247.1	RP11-379F4.9	-3.9	0.000111	0.00855	-0.17	-0.18	Subjective well-being;	chr3:158575469	chr3:158801257~158801935:-
THCA	cis	rs6473252	1	rs4739763	ENSG00000254162.1	RP11-48B3.3	-3.9	0.000111	0.00855	-0.15	-0.18	Breast cancer;	chr8:80906113	chr8:80535006~80539135:-
THCA	cis	rs10129255	1	rs10137758	ENSG00000211972.2	IGHV3-66	3.9	0.000111	0.00855	0.11	0.18	Kawasaki disease;	chr14:106697673	chr14:106675017~106675544:-
THCA	cis	rs3935996	0.965	rs11206668	ENSG00000233147.1	RP11-90C4.1	-3.9	0.000111	0.00855	-0.15	-0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55854067	chr1:55823807~55868248:+
THCA	cis	rs17741873	0.779	rs10458656	ENSG00000271848.1	RP11-464F9.21	-3.9	0.000111	0.00855	-0.22	-0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73832904	chr10:73654039~73674719:+
THCA	cis	rs3748656	1	rs12126971	ENSG00000273483.1	RP4-671G15.2	3.9	0.000111	0.00855	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112688664	chr1:112517799~112518441:-
THCA	cis	rs959260	0.688	rs4789176	ENSG00000263843.1	RP11-649A18.12	3.9	0.000111	0.00855	0.2	0.18	Systemic lupus erythematosus;	chr17:75356787	chr17:75271369~75273895:+
THCA	cis	rs3820928	0.605	rs4675124	ENSG00000212391.1	SNORA48	-3.9	0.000111	0.00855	-0.19	-0.18	Pulmonary function;	chr2:226937638	chr2:226968989~226969122:-
THCA	cis	rs11971779	0.68	rs4732370	ENSG00000252332.1	RNU6-911P	3.9	0.000111	0.00855	0.2	0.18	Diisocyanate-induced asthma;	chr7:139392494	chr7:139448740~139448843:+
THCA	cis	rs7560272	0.501	rs2006997	ENSG00000273245.1	RP11-434P11.2	-3.9	0.000111	0.00855	-0.2	-0.18	Schizophrenia;	chr2:73720719	chr2:73750256~73750786:-
THCA	cis	rs11771526	0.551	rs1008652	ENSG00000272905.1	RP11-265E18.1	-3.9	0.000111	0.00855	-0.22	-0.18	Body mass index;	chr7:32214791	chr7:32845394~32846061:+
THCA	cis	rs685782	0.786	rs17190886	ENSG00000200201.1	Y_RNA	-3.9	0.000111	0.00855	-0.25	-0.18	Metabolite levels (Dihydroxy docosatrienoic acid);	chr11:3787137	chr11:3665164~3665259:-
THCA	cis	rs17253792	0.822	rs10137885	ENSG00000186615.9	KTN1-AS1	-3.9	0.000111	0.00855	-0.28	-0.18	Putamen volume;	chr14:55706872	chr14:55499278~55580110:-
THCA	cis	rs1923539	0.822	rs1923536	ENSG00000242600.5	MBL1P	-3.9	0.000111	0.00856	-0.18	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950053	chr10:79904898~79950336:+
THCA	cis	rs250585	0.736	rs540719	ENSG00000260136.4	CTD-2270L9.4	3.9	0.000111	0.00856	0.14	0.18	Egg allergy;	chr16:23445257	chr16:23452758~23457606:+
THCA	cis	rs1510272	0.889	rs6441086	ENSG00000243926.1	TIPARP-AS1	-3.9	0.000111	0.00856	-0.19	-0.18	Testicular germ cell tumor;	chr3:156607834	chr3:156671862~156674378:-
THCA	cis	rs1510272	0.847	rs6802056	ENSG00000243926.1	TIPARP-AS1	-3.9	0.000111	0.00856	-0.19	-0.18	Testicular germ cell tumor;	chr3:156608112	chr3:156671862~156674378:-
THCA	cis	rs11950562	0.54	rs157577	ENSG00000224431.1	AC063976.7	3.9	0.000111	0.00856	0.17	0.18	Mean platelet volume;Blood metabolite levels;	chr5:132227878	chr5:132199456~132203487:+
THCA	cis	rs13108904	0.521	rs4974609	ENSG00000254094.1	AC078852.1	3.9	0.000111	0.00856	0.2	0.18	Obesity-related traits;	chr4:1363136	chr4:1356581~1358075:+
THCA	cis	rs10833905	1	rs10833905	ENSG00000246225.5	RP11-17A1.3	3.9	0.000111	0.00856	0.25	0.18	Sudden cardiac arrest;	chr11:23023046	chr11:22829380~22945393:+
THCA	cis	rs10833905	1	rs57275726	ENSG00000246225.5	RP11-17A1.3	-3.9	0.000111	0.00856	-0.25	-0.18	Sudden cardiac arrest;	chr11:23024166	chr11:22829380~22945393:+
THCA	cis	rs427691	0.625	rs845735	ENSG00000249476.1	CTD-2587M2.1	-3.9	0.000111	0.00856	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr5:109688170	chr5:109237120~109326369:-
THCA	cis	rs6724465	0.929	rs7585868	ENSG00000272644.1	RP11-33O4.1	3.9	0.000111	0.00856	0.26	0.18	Height;	chr2:219117942	chr2:219069354~219069809:-
THCA	cis	rs9341808	0.754	rs6907729	ENSG00000260645.1	RP11-250B2.5	-3.9	0.000111	0.00856	-0.15	-0.18	Sitting height ratio;	chr6:80295205	chr6:80466958~80469080:+
THCA	cis	rs9926296	0.607	rs2079672	ENSG00000274627.1	RP11-104N10.2	3.9	0.000111	0.00856	0.17	0.18	Vitiligo;	chr16:89818509	chr16:89516797~89522217:+
THCA	cis	rs6163	0.588	rs67506723	ENSG00000236937.2	PTGES3P4	3.9	0.000111	0.00856	0.22	0.18	Waist circumference;Hip circumference;	chr10:102749307	chr10:102845595~102845950:+
THCA	cis	rs12493885	0.818	rs11928425	ENSG00000243069.6	ARHGEF26-AS1	-3.9	0.000111	0.00856	-0.3	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154055776	chr3:154024401~154121332:-
THCA	cis	rs2289681	0.524	rs111271177	ENSG00000280022.1	RP11-707O23.1	3.9	0.000111	0.00856	0.37	0.18	Cognitive function;	chr17:44814497	chr17:45592621~45593369:+
THCA	cis	rs3758911	0.861	rs2161965	ENSG00000255353.1	RP11-382M14.1	-3.9	0.000111	0.00856	-0.22	-0.18	Coronary artery disease;	chr11:107397123	chr11:107176286~107177530:+
THCA	cis	rs2455799	0.573	rs2470523	ENSG00000270409.1	RP11-44D5.1	-3.9	0.000111	0.00856	-0.19	-0.18	Mean platelet volume;	chr3:15726584	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.553	rs2262664	ENSG00000270409.1	RP11-44D5.1	-3.9	0.000111	0.00856	-0.19	-0.18	Mean platelet volume;	chr3:15726590	chr3:15732252~15733470:+
THCA	cis	rs877529	0.966	rs5995688	ENSG00000279833.1	RP4-742C19.13	-3.9	0.000111	0.00856	-0.12	-0.18	Multiple myeloma;	chr22:39152022	chr22:39133090~39136760:+
THCA	cis	rs12612619	0.732	rs1440044	ENSG00000272148.1	RP11-195B17.1	3.9	0.000111	0.00857	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004086	chr2:27062428~27062907:-
THCA	cis	rs4879656	0.741	rs10813942	ENSG00000225693.1	LAGE3P1	-3.9	0.000111	0.00857	-0.21	-0.18	Menopause (age at onset);	chr9:33092837	chr9:33019682~33020165:-
THCA	cis	rs7737355	0.947	rs6859469	ENSG00000237714.1	P4HA2-AS1	3.9	0.000111	0.00857	0.25	0.18	Life satisfaction;	chr5:131626853	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs13174006	ENSG00000237714.1	P4HA2-AS1	3.9	0.000111	0.00857	0.25	0.18	Life satisfaction;	chr5:131627780	chr5:132184876~132192808:+
THCA	cis	rs8020441	0.838	rs72681662	ENSG00000269906.1	RP11-248J18.2	3.9	0.000111	0.00857	0.25	0.18	Cognitive performance;	chr14:50697166	chr14:50662511~50663178:-
THCA	cis	rs6995541	0.647	rs11776767	ENSG00000248896.2	CTD-2135J3.3	-3.9	0.000111	0.00857	-0.22	-0.18	Triglyceride levels;	chr8:10826419	chr8:10729314~10771392:+
THCA	cis	rs4819052	1	rs13047688	ENSG00000184274.3	LINC00315	-3.9	0.000111	0.00857	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45300245~45305257:-
THCA	cis	rs7178424	0.742	rs12915825	ENSG00000259251.2	RP11-643M14.1	-3.9	0.000111	0.00857	-0.18	-0.18	Height;	chr15:61883437	chr15:62060503~62062434:+
THCA	cis	rs763121	0.813	rs4821807	ENSG00000235209.1	CTA-150C2.13	3.9	0.000111	0.00857	0.23	0.18	Menopause (age at onset);	chr22:38669577	chr22:38921227~38924708:+
THCA	cis	rs13434995	0.513	rs2101476	ENSG00000249700.7	SRD5A3-AS1	-3.9	0.000111	0.00857	-0.26	-0.18	Adiponectin levels;	chr4:55578961	chr4:55363971~55395847:-
THCA	cis	rs2549003	1	rs2549007	ENSG00000237714.1	P4HA2-AS1	3.9	0.000111	0.00857	0.23	0.18	Asthma (sex interaction);	chr5:132491183	chr5:132184876~132192808:+
THCA	cis	rs2549003	1	rs2706384	ENSG00000237714.1	P4HA2-AS1	3.9	0.000111	0.00857	0.23	0.18	Asthma (sex interaction);	chr5:132491188	chr5:132184876~132192808:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000223473.2	GS1-124K5.3	3.9	0.000111	0.00857	0.12	0.18	Aortic root size;	chr7:66376994	chr7:66491049~66493566:-
THCA	cis	rs12476592	0.602	rs6546007	ENSG00000242412.1	DBIL5P2	3.9	0.000111	0.00857	0.23	0.18	Childhood ear infection;	chr2:63497661	chr2:63117851~63119542:-
THCA	cis	rs6832769	0.643	rs1488939	ENSG00000272969.1	RP11-528I4.2	-3.9	0.000111	0.00857	-0.21	-0.18	Personality dimensions;	chr4:55652977	chr4:55547112~55547889:+
THCA	cis	rs656319	0.605	rs60278284	ENSG00000261451.1	RP11-981G7.1	-3.9	0.000111	0.00858	-0.23	-0.18	Myopia (pathological);	chr8:10145700	chr8:10433672~10438312:+
THCA	cis	rs6939532	0.522	rs9366652	ENSG00000124549.13	BTN2A3P	-3.9	0.000111	0.00858	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26353991	chr6:26421391~26432383:+
THCA	cis	rs10917151	1	rs10917151	ENSG00000228397.1	RP1-224A6.3	-3.9	0.000111	0.00858	-0.33	-0.18	Endometriosis;	chr1:22096228	chr1:22023994~22024968:-
THCA	cis	rs34792	0.599	rs153791	ENSG00000207425.1	Y_RNA	-3.9	0.000111	0.00858	-0.19	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15453224	chr16:14915457~14915556:-
THCA	cis	rs881375	0.715	rs10818482	ENSG00000270917.1	RP11-27I1.6	3.9	0.000111	0.00858	0.23	0.18	Rheumatoid arthritis;	chr9:120885807	chr9:120812475~120812845:-
THCA	cis	rs3105593	0.933	rs3105592	ENSG00000242737.1	RP11-562A8.1	-3.9	0.000111	0.00858	-0.22	-0.18	QT interval;	chr15:50578074	chr15:50466738~50467096:+
THCA	cis	rs62158800	0.789	rs116799836	ENSG00000224568.1	AC096669.3	3.9	0.000111	0.00858	0.34	0.18	Facial morphology (factor 22);	chr2:107676150	chr2:107529487~107556326:+
THCA	cis	rs62158800	0.789	rs2138473	ENSG00000224568.1	AC096669.3	3.9	0.000111	0.00858	0.34	0.18	Facial morphology (factor 22);	chr2:107678290	chr2:107529487~107556326:+
THCA	cis	rs7940646	0.812	rs11042906	ENSG00000254554.1	RP11-351I24.1	3.9	0.000111	0.00858	0.22	0.18	Platelet aggregation;	chr11:10643688	chr11:10302657~10303704:-
THCA	cis	rs6088590	0.735	rs6060003	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000111	0.00858	-0.15	-0.18	Coronary artery disease;	chr20:34707141	chr20:33985617~33988989:-
THCA	cis	rs447735	0.507	rs11645271	ENSG00000274627.1	RP11-104N10.2	-3.9	0.000111	0.00858	-0.18	-0.18	Hemoglobin concentration;	chr16:89662717	chr16:89516797~89522217:+
THCA	cis	rs1371614	0.635	rs10175737	ENSG00000272148.1	RP11-195B17.1	-3.9	0.000111	0.00858	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916879	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.635	rs877273	ENSG00000272148.1	RP11-195B17.1	-3.9	0.000111	0.00858	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917154	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.577	rs877274	ENSG00000272148.1	RP11-195B17.1	-3.9	0.000111	0.00858	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917231	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.635	rs6706127	ENSG00000272148.1	RP11-195B17.1	-3.9	0.000111	0.00858	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917873	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.635	rs9309558	ENSG00000272148.1	RP11-195B17.1	-3.9	0.000111	0.00858	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918636	chr2:27062428~27062907:-
THCA	cis	rs9307551	0.857	rs2218212	ENSG00000249646.2	OR7E94P	-3.9	0.000111	0.00858	-0.22	-0.18	Refractive error;	chr4:79614887	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.857	rs2218213	ENSG00000249646.2	OR7E94P	-3.9	0.000111	0.00858	-0.22	-0.18	Refractive error;	chr4:79614890	chr4:79587302~79588130:-
THCA	cis	rs9595908	0.733	rs9315175	ENSG00000212293.1	SNORA16	3.9	0.000111	0.00858	0.2	0.18	Body mass index;	chr13:32649581	chr13:32420390~32420516:-
THCA	cis	rs11758351	1	rs16891405	ENSG00000216331.1	HIST1H1PS1	3.9	0.000111	0.00858	0.28	0.18	Renal underexcretion gout;Gout;	chr6:26204278	chr6:26195566~26195771:+
THCA	cis	rs755249	0.567	rs16826000	ENSG00000182109.6	RP11-69E11.4	3.9	0.000112	0.00858	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs16826009	ENSG00000182109.6	RP11-69E11.4	3.9	0.000112	0.00858	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39522280~39546187:-
THCA	cis	rs854765	0.583	rs4925129	ENSG00000281749.1	Y_RNA	3.9	0.000112	0.00858	0.23	0.18	Total body bone mineral density;	chr17:17903872	chr17:18001101~18001195:-
THCA	cis	rs28735056	0.904	rs9967107	ENSG00000261126.6	RP11-795F19.1	3.9	0.000112	0.00858	0.14	0.18	Schizophrenia;	chr18:79873343	chr18:80046900~80095482:+
THCA	cis	rs17695224	0.63	rs4802879	ENSG00000275055.1	CTC-471J1.11	-3.9	0.000112	0.00858	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51837122	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.611	rs4802880	ENSG00000275055.1	CTC-471J1.11	-3.9	0.000112	0.00858	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51837123	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.675	rs2109656	ENSG00000275055.1	CTC-471J1.11	-3.9	0.000112	0.00858	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51837424	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.675	rs3948650	ENSG00000275055.1	CTC-471J1.11	-3.9	0.000112	0.00858	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51837446	chr19:52049007~52049754:+
THCA	cis	rs10861661	0.963	rs3782707	ENSG00000260329.1	RP11-412D9.4	-3.9	0.000112	0.00858	-0.2	-0.18	Triglyceride levels;	chr12:106791409	chr12:106954029~106955497:-
THCA	cis	rs7502499	0.581	rs4477768	ENSG00000253730.1	RP11-893F2.13	3.9	0.000112	0.00858	0.22	0.18	Cancer;Coronary artery disease;	chr17:49433211	chr17:50158333~50161276:-
THCA	cis	rs854765	0.587	rs12936927	ENSG00000281749.1	Y_RNA	-3.9	0.000112	0.00858	-0.23	-0.18	Total body bone mineral density;	chr17:17823651	chr17:18001101~18001195:-
THCA	cis	rs17597773	0.638	rs881995	ENSG00000238078.1	LINC01352	-3.9	0.000112	0.00858	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220811152	chr1:220829255~220832429:+
THCA	cis	rs7394190	0.935	rs6480708	ENSG00000272140.2	RP11-574K11.29	-3.9	0.000112	0.00858	-0.16	-0.18	Incident atrial fibrillation;	chr10:73660356	chr10:73703735~73713581:-
THCA	cis	rs713587	0.713	rs11125884	ENSG00000224165.4	DNAJC27-AS1	-3.9	0.000112	0.00859	-0.1	-0.18	Body mass index in non-asthmatics;	chr2:25016395	chr2:24971390~25039694:+
THCA	cis	rs7520050	0.966	rs1085243	ENSG00000281133.1	AL355480.3	3.9	0.000112	0.00859	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs1768803	ENSG00000281133.1	AL355480.3	3.9	0.000112	0.00859	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs1707333	ENSG00000281133.1	AL355480.3	3.9	0.000112	0.00859	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs4660910	ENSG00000281133.1	AL355480.3	3.9	0.000112	0.00859	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs785481	ENSG00000281133.1	AL355480.3	3.9	0.000112	0.00859	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6675726	ENSG00000281133.1	AL355480.3	3.9	0.000112	0.00859	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs785520	ENSG00000281133.1	AL355480.3	3.9	0.000112	0.00859	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45580892~45580996:-
THCA	cis	rs453301	0.686	rs17702602	ENSG00000254340.1	RP11-10A14.3	-3.9	0.000112	0.00859	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9051086	chr8:9141424~9145435:+
THCA	cis	rs11073619	0.616	rs113031444	ENSG00000259728.4	LINC00933	-3.9	0.000112	0.00859	-0.36	-0.18	Positive affect;	chr15:84391590	chr15:84570649~84580175:+
THCA	cis	rs1348850	0.645	rs4893963	ENSG00000280374.1	RP11-337N6.3	3.9	0.000112	0.00859	0.27	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177566019	chr2:177317715~177318471:-
THCA	cis	rs5758659	0.652	rs133301	ENSG00000281538.1	RP4-669P10.20	3.9	0.000112	0.00859	0.16	0.18	Cognitive function;	chr22:41994089	chr22:42138060~42139726:+
THCA	cis	rs3015497	0.789	rs2356457	ENSG00000270062.1	RP11-248J18.3	3.9	0.000112	0.00859	0.2	0.18	Mean platelet volume;	chr14:50650145	chr14:50723777~50724272:-
THCA	cis	rs755249	0.508	rs10888688	ENSG00000228060.1	RP11-69E11.8	3.9	0.000112	0.00859	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39171633	chr1:39565160~39573203:+
THCA	cis	rs7818688	0.653	rs11776687	ENSG00000253528.2	RP11-347C18.4	-3.9	0.000112	0.00859	-0.26	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94824079	chr8:94974573~94974853:-
THCA	cis	rs7809615	0.748	rs28602855	ENSG00000244219.5	GS1-259H13.2	-3.9	0.000112	0.00859	-0.29	-0.18	Blood metabolite ratios;	chr7:99468363	chr7:99598066~99610813:+
THCA	cis	rs7809615	0.748	rs10808112	ENSG00000244219.5	GS1-259H13.2	-3.9	0.000112	0.00859	-0.29	-0.18	Blood metabolite ratios;	chr7:99473365	chr7:99598066~99610813:+
THCA	cis	rs11710088	0.599	rs4681509	ENSG00000240541.2	TM4SF1-AS1	3.9	0.000112	0.00859	0.16	0.18	QRS duration;	chr3:149483657	chr3:149377778~149386583:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000275400.1	RP4-756H11.5	3.9	0.000112	0.00859	0.17	0.18	Aortic root size;	chr7:65950660	chr7:66553805~66554199:-
THCA	cis	rs1371614	0.635	rs4665923	ENSG00000272148.1	RP11-195B17.1	3.9	0.000112	0.00859	0.16	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916043	chr2:27062428~27062907:-
THCA	cis	rs2163813	1	rs2013561	ENSG00000271499.1	CTC-559E9.9	-3.9	0.000112	0.00859	-0.22	-0.18	Toenail selenium levels;	chr19:19715368	chr19:19750618~19752544:+
THCA	cis	rs2163813	0.959	rs12984272	ENSG00000271499.1	CTC-559E9.9	-3.9	0.000112	0.00859	-0.22	-0.18	Toenail selenium levels;	chr19:19716071	chr19:19750618~19752544:+
THCA	cis	rs2163813	1	rs36006965	ENSG00000271499.1	CTC-559E9.9	-3.9	0.000112	0.00859	-0.22	-0.18	Toenail selenium levels;	chr19:19719242	chr19:19750618~19752544:+
THCA	cis	rs2163813	1	rs12982273	ENSG00000271499.1	CTC-559E9.9	-3.9	0.000112	0.00859	-0.22	-0.18	Toenail selenium levels;	chr19:19719335	chr19:19750618~19752544:+
THCA	cis	rs4906332	1	rs12879663	ENSG00000252469.1	RNU7-160P	3.9	0.000112	0.00859	0.19	0.18	Coronary artery disease;	chr14:103407878	chr14:103550345~103550406:+
THCA	cis	rs875971	0.929	rs4122249	ENSG00000230189.5	GS1-124K5.2	3.9	0.000112	0.00859	0.11	0.18	Aortic root size;	chr7:66455949	chr7:66409143~66490059:-
THCA	cis	rs2692947	0.74	rs11695514	ENSG00000235584.2	AC008268.1	-3.9	0.000112	0.0086	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95882320	chr2:95666084~95668715:+
THCA	cis	rs7688540	0.8	rs7694325	ENSG00000250892.1	RP11-1365D11.1	3.9	0.000112	0.0086	0.25	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:201409~205009:-
THCA	cis	rs448720	1	rs410554	ENSG00000260657.2	RP11-315D16.4	-3.9	0.000112	0.0086	-0.22	-0.18	Cognitive performance;	chr15:67906161	chr15:68267792~68277994:-
THCA	cis	rs765787	0.53	rs1648289	ENSG00000259932.1	CTD-2651B20.7	3.9	0.000112	0.0086	0.22	0.18	Uric acid levels;	chr15:45224296	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs1648287	ENSG00000259932.1	CTD-2651B20.7	3.9	0.000112	0.0086	0.22	0.18	Uric acid levels;	chr15:45224758	chr15:45198517~45199139:-
THCA	cis	rs2836974	0.932	rs2836953	ENSG00000255568.3	BRWD1-AS2	3.9	0.000112	0.0086	0.16	0.18	Cognitive function;	chr21:39245557	chr21:39313935~39314962:+
THCA	cis	rs16918636	0.504	rs673073	ENSG00000249867.4	RP11-115J23.1	-3.9	0.000112	0.0086	-0.19	-0.18	Menarche (age at onset);	chr11:29160355	chr11:28702615~29063821:+
THCA	cis	rs67340775	0.541	rs200979	ENSG00000220721.1	OR1F12	3.9	0.000112	0.0086	0.27	0.18	Lung cancer in ever smokers;	chr6:27884579	chr6:28073316~28074233:+
THCA	cis	rs150992	0.525	rs331930	ENSG00000246763.5	RGMB-AS1	3.9	0.000112	0.0086	0.19	0.18	Body mass index;	chr5:98833559	chr5:98769618~98773469:-
THCA	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	3.9	0.000112	0.0086	0.21	0.18	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
THCA	cis	rs10090774	0.664	rs28605671	ENSG00000279766.1	RP11-642A1.2	-3.9	0.000112	0.0086	-0.22	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140645013	chr8:140572142~140572812:-
THCA	cis	rs4245128	0.965	rs7122417	ENSG00000247416.2	RP11-629G13.1	3.9	0.000112	0.0086	0.17	0.18	Life satisfaction;	chr11:112890203	chr11:112959279~112963460:-
THCA	cis	rs4743820	0.503	rs10991791	ENSG00000229694.5	RP11-305L7.6	3.9	0.000112	0.0086	0.21	0.18	Ulcerative colitis;Inflammatory bowel disease;	chr9:91159223	chr9:91119062~91182762:+
THCA	cis	rs713587	0.626	rs62140636	ENSG00000224165.4	DNAJC27-AS1	3.9	0.000112	0.0086	0.1	0.18	Body mass index in non-asthmatics;	chr2:25010942	chr2:24971390~25039694:+
THCA	cis	rs13178541	0.542	rs10900837	ENSG00000250378.1	RP11-119J18.1	-3.9	0.000112	0.0086	-0.2	-0.18	IgG glycosylation;	chr5:135790074	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.577	rs10900838	ENSG00000250378.1	RP11-119J18.1	-3.9	0.000112	0.0086	-0.2	-0.18	IgG glycosylation;	chr5:135790078	chr5:135812667~135826582:+
THCA	cis	rs964611	0.872	rs17350938	ENSG00000259488.2	RP11-154J22.1	-3.9	0.000112	0.0086	-0.2	-0.18	Metabolite levels (Pyroglutamine);	chr15:48297784	chr15:48312353~48331856:-
THCA	cis	rs685782	0.786	rs619479	ENSG00000200201.1	Y_RNA	-3.9	0.000112	0.00861	-0.27	-0.18	Metabolite levels (Dihydroxy docosatrienoic acid);	chr11:3716168	chr11:3665164~3665259:-
THCA	cis	rs1044573	0.514	rs2268879	ENSG00000274973.1	RP13-401N8.7	3.9	0.000112	0.00861	0.2	0.18	Allergic rhinitis;	chr20:25197169	chr20:25845497~25845862:+
THCA	cis	rs832187	0.594	rs832197	ENSG00000224479.4	AC136289.1	-3.9	0.000112	0.00861	-0.22	-0.18	Schizophrenia;	chr3:63898616	chr3:63742293~63827445:-
THCA	cis	rs4144027	0.967	rs72712857	ENSG00000269940.1	RP11-73M18.7	3.9	0.000112	0.00861	0.18	0.18	Blood metabolite levels;	chr14:103896336	chr14:103694560~103695170:+
THCA	cis	rs8115854	0.922	rs62206533	ENSG00000269846.1	RP4-621N11.2	-3.9	0.000112	0.00861	-0.23	-0.18	Hippocampal atrophy;	chr20:37149199	chr20:37095785~37097178:+
THCA	cis	rs2455799	0.552	rs2470519	ENSG00000270409.1	RP11-44D5.1	-3.9	0.000112	0.00861	-0.19	-0.18	Mean platelet volume;	chr3:15721340	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.573	rs2470520	ENSG00000270409.1	RP11-44D5.1	-3.9	0.000112	0.00861	-0.19	-0.18	Mean platelet volume;	chr3:15721413	chr3:15732252~15733470:+
THCA	cis	rs7973719	0.833	rs7962563	ENSG00000205885.6	C1RL-AS1	3.9	0.000112	0.00861	0.13	0.18	IgG glycosylation;	chr12:7200918	chr12:7108052~7122501:+
THCA	cis	rs7615952	0.599	rs66532274	ENSG00000241288.6	RP11-379B18.5	-3.9	0.000112	0.00861	-0.19	-0.18	Blood pressure (smoking interaction);	chr3:126013002	chr3:125827238~125916384:-
THCA	cis	rs11648785	0.546	rs7199280	ENSG00000222019.6	URAHP	3.9	0.000112	0.00861	0.15	0.18	Tanning;	chr16:90039332	chr16:90039761~90047773:-
THCA	cis	rs801193	0.901	rs4273746	ENSG00000272831.1	RP11-792A8.4	-3.9	0.000112	0.00861	-0.11	-0.18	Aortic root size;	chr7:66836124	chr7:66739829~66740385:-
THCA	cis	rs7824557	0.737	rs10481445	ENSG00000206014.6	OR7E161P	3.9	0.000112	0.00861	0.2	0.18	Retinal vascular caliber;	chr8:11251760	chr8:11928597~11929563:-
THCA	cis	rs6696239	0.956	rs7540382	ENSG00000227711.2	RP11-275O4.5	-3.9	0.000112	0.00861	-0.24	-0.18	Height;	chr1:227692595	chr1:227509028~227520477:-
THCA	cis	rs448720	1	rs12900710	ENSG00000260657.2	RP11-315D16.4	-3.9	0.000112	0.00861	-0.22	-0.18	Cognitive performance;	chr15:67904997	chr15:68267792~68277994:-
THCA	cis	rs2191566	0.576	rs381888	ENSG00000277806.1	RP11-15A1.8	3.9	0.000112	0.00861	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43988853	chr19:43976815~43977448:+
THCA	cis	rs293748	0.771	rs292181	ENSG00000250155.1	CTD-2353F22.1	-3.9	0.000112	0.00861	-0.23	-0.18	Obesity-related traits;	chr5:36952474	chr5:36666214~36725195:-
THCA	cis	rs293748	0.771	rs292186	ENSG00000250155.1	CTD-2353F22.1	-3.9	0.000112	0.00861	-0.23	-0.18	Obesity-related traits;	chr5:36967320	chr5:36666214~36725195:-
THCA	cis	rs293748	0.771	rs294695	ENSG00000250155.1	CTD-2353F22.1	-3.9	0.000112	0.00861	-0.23	-0.18	Obesity-related traits;	chr5:36986586	chr5:36666214~36725195:-
THCA	cis	rs365302	1	rs444708	ENSG00000235086.1	FNDC1-IT1	3.9	0.000112	0.00861	0.25	0.18	Coronary heart disease;	chr6:159223798	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs411814	ENSG00000235086.1	FNDC1-IT1	3.9	0.000112	0.00861	0.25	0.18	Coronary heart disease;	chr6:159223811	chr6:159240786~159243329:+
THCA	cis	rs9634489	0.59	rs1927785	ENSG00000247400.3	DNAJC3-AS1	-3.9	0.000112	0.00861	-0.11	-0.18	Body mass index;	chr13:96279194	chr13:95648733~95676925:-
THCA	cis	rs8177876	0.731	rs4889235	ENSG00000261838.4	RP11-303E16.6	-3.9	0.000112	0.00861	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81110033	chr16:81069854~81076598:+
THCA	cis	rs7617480	0.61	rs10865954	ENSG00000229759.1	MRPS18AP1	3.9	0.000112	0.00861	0.23	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chr3:48256350~48256938:-
THCA	cis	rs6977955	1	rs2189965	ENSG00000234336.5	JAZF1-AS1	-3.9	0.000112	0.00861	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr7:28132395	chr7:28180322~28243917:+
THCA	cis	rs877529	0.683	rs139379	ENSG00000279833.1	RP4-742C19.13	3.9	0.000112	0.00862	0.12	0.18	Multiple myeloma;	chr22:39129786	chr22:39133090~39136760:+
THCA	cis	rs2505675	0.631	rs234913	ENSG00000272465.1	RP1-136B1.1	-3.9	0.000112	0.00862	-0.24	-0.18	Tuberculosis;	chr6:2209776	chr6:2437549~2438249:+
THCA	cis	rs12544026	0.647	rs7829693	ENSG00000253669.3	KB-1732A1.1	-3.9	0.000112	0.00862	-0.19	-0.18	Major depression and alcohol dependence;	chr8:101830644	chr8:102805517~102809971:+
THCA	cis	rs2115630	0.846	rs8024538	ENSG00000259728.4	LINC00933	-3.9	0.000112	0.00862	-0.21	-0.18	P wave terminal force;	chr15:84825188	chr15:84570649~84580175:+
THCA	cis	rs7829975	0.714	rs11777085	ENSG00000253981.4	ALG1L13P	3.9	0.000112	0.00862	0.17	0.18	Mood instability;	chr8:8814919	chr8:8236003~8244667:-
THCA	cis	rs10181042	0.528	rs2564118	ENSG00000232713.2	AC010733.5	3.9	0.000112	0.00862	0.16	0.18	Crohn's disease;	chr2:61006154	chr2:60938204~60938604:-
THCA	cis	rs42648	0.596	rs194520	ENSG00000225498.1	AC002064.5	3.9	0.000112	0.00862	0.19	0.18	Homocysteine levels;	chr7:90225132	chr7:90312496~90322592:+
THCA	cis	rs2288884	0.505	rs12459170	ENSG00000260160.1	CTC-471J1.2	-3.9	0.000112	0.00862	-0.2	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51955005	chr19:52058490~52063703:-
THCA	cis	rs962856	0.619	rs6714988	ENSG00000236780.4	AC078941.1	3.9	0.000112	0.00862	0.24	0.18	Pancreatic cancer;	chr2:67368657	chr2:67123357~67215319:-
THCA	cis	rs8062405	0.691	rs11646653	ENSG00000270424.1	RP11-1348G14.6	-3.9	0.000112	0.00862	-0.21	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28749959~28750595:-
THCA	cis	rs2275848	0.866	rs13284731	ENSG00000203364.2	RP11-370F5.4	3.9	0.000112	0.00862	0.24	0.18	Obesity (early onset extreme);	chr9:93117970	chr9:93147040~93148556:+
THCA	cis	rs7267979	0.933	rs2424708	ENSG00000276952.1	RP5-965G21.6	3.9	0.000112	0.00862	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs884613	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000112	0.00862	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs1888998	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000112	0.00862	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2500433	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000112	0.00862	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2482948	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000112	0.00862	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2482919	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000112	0.00862	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6037086	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000112	0.00862	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2482923	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000112	0.00862	-0.19	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25284915~25285588:-
THCA	cis	rs1552244	0.572	rs7645667	ENSG00000180385.7	EMC3-AS1	3.9	0.000112	0.00863	0.23	0.18	Alzheimer's disease;	chr3:10115653	chr3:9986893~10006990:+
THCA	cis	rs9868809	0.656	rs73078362	ENSG00000270441.1	RP11-694I15.7	3.9	0.000112	0.00863	0.27	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48666484	chr3:49140086~49160851:-
THCA	cis	rs7956611	0.564	rs7138741	ENSG00000213343.5	RPL21P18	-3.9	0.000112	0.00863	-0.2	-0.18	Age of smoking initiation;	chr12:66519949	chr12:66037235~66037714:+
THCA	cis	rs12129938	0.911	rs76009896	ENSG00000231940.1	RPS7P3	3.9	0.000112	0.00863	0.23	0.18	Thyroid cancer;	chr1:233266290	chr1:233288868~233289447:-
THCA	cis	rs12129938	0.911	rs74982670	ENSG00000231940.1	RPS7P3	3.9	0.000112	0.00863	0.23	0.18	Thyroid cancer;	chr1:233266291	chr1:233288868~233289447:-
THCA	cis	rs3824488	0.599	rs16909859	ENSG00000271155.1	RP11-435O5.5	-3.9	0.000112	0.00863	-0.27	-0.18	Neuroticism;	chr9:95442510	chr9:95506235~95507636:+
THCA	cis	rs60695258	1	rs2035403	ENSG00000251411.1	RP11-397E7.4	-3.9	0.000112	0.00863	-0.16	-0.18	Hematocrit;	chr4:87097839	chr4:86913266~86914817:-
THCA	cis	rs10760158	0.736	rs10760168	ENSG00000235865.2	GSN-AS1	3.9	0.000112	0.00863	0.15	0.18	Pulse pressure;	chr9:121286449	chr9:121280768~121285530:-
THCA	cis	rs9929218	0.608	rs35158985	ENSG00000274698.1	RP11-71L14.4	-3.9	0.000112	0.00863	-0.22	-0.18	Colorectal cancer;	chr16:68762843	chr16:68450283~68452318:+
THCA	cis	rs150992	0.711	rs2617507	ENSG00000241597.2	CTD-2007H13.1	-3.9	0.000112	0.00863	-0.23	-0.18	Body mass index;	chr5:98912548	chr5:98954394~98954972:+
THCA	cis	rs5758659	0.714	rs6002607	ENSG00000273366.1	CTA-989H11.1	3.9	0.000112	0.00863	0.21	0.18	Cognitive function;	chr22:42100502	chr22:42278188~42278846:+
THCA	cis	rs9309473	0.898	rs10170786	ENSG00000273245.1	RP11-434P11.2	3.9	0.000112	0.00863	0.23	0.18	Metabolite levels;	chr2:73585861	chr2:73750256~73750786:-
THCA	cis	rs2070074	0.591	rs7037232	ENSG00000230074.1	RP11-195F19.9	-3.9	0.000112	0.00863	-0.32	-0.18	CTACK levels;	chr9:34587487	chr9:34665665~34681298:+
THCA	cis	rs801193	1	rs10234018	ENSG00000272831.1	RP11-792A8.4	-3.9	0.000112	0.00863	-0.11	-0.18	Aortic root size;	chr7:66681297	chr7:66739829~66740385:-
THCA	cis	rs4272720	0.639	rs2264847	ENSG00000234736.4	FAM170B-AS1	3.9	0.000112	0.00864	0.19	0.18	Platelet count;Plateletcrit;	chr10:49046221	chr10:49121839~49151547:+
THCA	cis	rs1005277	0.579	rs2103938	ENSG00000120555.12	SEPT7P9	3.9	0.000112	0.00864	0.2	0.18	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38383069~38402916:-
THCA	cis	rs760794	0.666	rs7773816	ENSG00000228412.5	RP4-625H18.2	3.9	0.000112	0.00864	0.23	0.18	Endometriosis;	chr6:19823201	chr6:19802164~19804752:-
THCA	cis	rs494526	0.735	rs658352	ENSG00000229272.1	RP11-498J9.2	3.9	0.000112	0.00864	0.2	0.18	Alcoholic chronic pancreatitis;	chr10:119044276	chr10:119003536~119003884:-
THCA	cis	rs6442522	0.533	rs2100545	ENSG00000249786.6	EAF1-AS1	3.9	0.000112	0.00864	0.18	0.18	Uric acid levels;	chr3:15480112	chr3:15436171~15455940:-
THCA	cis	rs7430456	0.87	rs9864169	ENSG00000231574.4	RP11-91K9.1	-3.9	0.000112	0.00864	-0.23	-0.18	Breast cancer;	chr3:177746841	chr3:177816865~177899224:+
THCA	cis	rs7430456	0.901	rs12696448	ENSG00000231574.4	RP11-91K9.1	-3.9	0.000112	0.00864	-0.23	-0.18	Breast cancer;	chr3:177746860	chr3:177816865~177899224:+
THCA	cis	rs12118280	0.513	rs6702877	ENSG00000280186.1	RP11-483I13.6	3.9	0.000112	0.00864	0.15	0.18	Myeloid white cell count;	chr1:108212812	chr1:108200413~108202743:+
THCA	cis	rs878939	0.625	rs35564340	ENSG00000233690.1	EBAG9P1	3.9	0.000112	0.00864	0.23	0.18	Warfarin maintenance dose;	chr10:99584506	chr10:99697407~99697949:-
THCA	cis	rs3104964	0.646	rs3134245	ENSG00000253773.2	C8orf37-AS1	3.9	0.000112	0.00864	0.23	0.18	Colorectal cancer;	chr8:95584521	chr8:95204456~95810136:+
THCA	cis	rs3104964	0.668	rs3134246	ENSG00000253773.2	C8orf37-AS1	3.9	0.000112	0.00864	0.23	0.18	Colorectal cancer;	chr8:95584524	chr8:95204456~95810136:+
THCA	cis	rs9309473	0.5	rs7608328	ENSG00000273245.1	RP11-434P11.2	-3.9	0.000112	0.00864	-0.21	-0.18	Metabolite levels;	chr2:73686892	chr2:73750256~73750786:-
THCA	cis	rs4700393	0.517	rs12516248	ENSG00000272308.1	RP11-231G3.1	3.9	0.000112	0.00864	0.21	0.18	Intelligence (multi-trait analysis);	chr5:60835824	chr5:60866457~60866935:-
THCA	cis	rs2281603	0.951	rs1982440	ENSG00000258824.2	CTD-2555O16.2	-3.9	0.000112	0.00864	-0.18	-0.18	Lymphocyte counts;	chr14:64494049	chr14:64422935~64448557:-
THCA	cis	rs9510787	0.649	rs12429914	ENSG00000205861.10	C1QTNF9B-AS1	-3.9	0.000112	0.00864	-0.22	-0.18	Nasopharyngeal carcinoma;	chr13:23638347	chr13:23888889~23897263:+
THCA	cis	rs4388249	0.696	rs31600	ENSG00000271849.1	CTC-332L22.1	3.9	0.000112	0.00864	0.24	0.18	Schizophrenia;	chr5:109670675	chr5:109687802~109688329:-
THCA	cis	rs7658584	0.592	rs13147650	ENSG00000246375.2	RP11-10L7.1	3.9	0.000112	0.00864	0.27	0.18	Squamous cell lung carcinoma;	chr4:88188244	chr4:88284942~88331421:+
THCA	cis	rs7658584	0.624	rs13152371	ENSG00000246375.2	RP11-10L7.1	3.9	0.000112	0.00864	0.27	0.18	Squamous cell lung carcinoma;	chr4:88192345	chr4:88284942~88331421:+
THCA	cis	rs765787	0.53	rs1648289	ENSG00000259539.1	CTD-2651B20.1	3.89	0.000112	0.00864	0.22	0.18	Uric acid levels;	chr15:45224296	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs1648287	ENSG00000259539.1	CTD-2651B20.1	3.89	0.000112	0.00864	0.22	0.18	Uric acid levels;	chr15:45224758	chr15:45152664~45167526:-
THCA	cis	rs10875746	0.951	rs2269935	ENSG00000258234.1	RP11-370I10.2	3.89	0.000112	0.00864	0.21	0.18	Longevity (90 years and older);	chr12:48122681	chr12:48231098~48284210:-
THCA	cis	rs1198872	0.812	rs1198867	ENSG00000272275.1	RP11-791G15.2	-3.89	0.000112	0.00864	-0.21	-0.18	Cardiac Troponin-T levels;	chr2:10762281	chr2:10767875~10770058:-
THCA	cis	rs1198872	0.892	rs1198869	ENSG00000272275.1	RP11-791G15.2	-3.89	0.000112	0.00864	-0.21	-0.18	Cardiac Troponin-T levels;	chr2:10762319	chr2:10767875~10770058:-
THCA	cis	rs8062405	1	rs1987472	ENSG00000270424.1	RP11-1348G14.6	3.89	0.000112	0.00865	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28749959~28750595:-
THCA	cis	rs4081724	0.63	rs41344151	ENSG00000267296.2	CEBPA-AS1	3.89	0.000112	0.00865	0.28	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33304803	chr19:33302857~33305054:+
THCA	cis	rs7578199	0.59	rs905660	ENSG00000223374.1	AC005104.3	-3.89	0.000112	0.00865	-0.12	-0.18	Chronic lymphocytic leukemia;	chr2:241505343	chr2:241351340~241353104:-
THCA	cis	rs1113500	0.575	rs1781067	ENSG00000230489.1	VAV3-AS1	-3.89	0.000113	0.00865	-0.17	-0.18	Growth-regulated protein alpha levels;	chr1:108025389	chr1:107964443~107994607:+
THCA	cis	rs10824037	0.673	rs11000789	ENSG00000271848.1	RP11-464F9.21	-3.89	0.000113	0.00865	-0.22	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr10:73835468	chr10:73654039~73674719:+
THCA	cis	rs11069062	0.819	rs10774985	ENSG00000270482.1	RP11-131L12.2	3.89	0.000113	0.00865	0.15	0.18	Obesity-related traits;	chr12:118704642	chr12:118375350~118376275:-
THCA	cis	rs62344088	1	rs7716917	ENSG00000277812.1	AC021087.1	3.89	0.000113	0.00865	0.45	0.18	Asthma (childhood onset);	chr5:93272	chr5:262769~262881:+
THCA	cis	rs9309473	0.528	rs79799178	ENSG00000273245.1	RP11-434P11.2	3.89	0.000113	0.00865	0.28	0.18	Metabolite levels;	chr2:73564108	chr2:73750256~73750786:-
THCA	cis	rs78487399	0.808	rs76851696	ENSG00000234936.1	AC010883.5	3.89	0.000113	0.00865	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43518923	chr2:43229573~43233394:+
THCA	cis	rs2154427	1	rs2154427	ENSG00000238197.4	PAXBP1-AS1	3.89	0.000113	0.00865	0.18	0.18	Bilirubin levels;	chr21:32796263	chr21:32728115~32743122:+
THCA	cis	rs7259376	0.902	rs7248242	ENSG00000269138.1	ZNF209P	-3.89	0.000113	0.00865	-0.18	-0.18	Menopause (age at onset);	chr19:22393192	chr19:22463922~22473036:+
THCA	cis	rs7665090	0.728	rs227275	ENSG00000248971.2	KRT8P46	3.89	0.000113	0.00865	0.21	0.18	Primary biliary cholangitis;	chr4:102672741	chr4:102728746~102730171:-
THCA	cis	rs7824557	0.564	rs7828263	ENSG00000227888.4	FAM66A	-3.89	0.000113	0.00865	-0.23	-0.18	Retinal vascular caliber;	chr8:11374377	chr8:12362019~12388296:+
THCA	cis	rs74233809	1	rs12217501	ENSG00000272912.1	RP11-724N1.1	-3.89	0.000113	0.00865	-0.32	-0.18	Birth weight;	chr10:103092132	chr10:102914585~102915404:+
THCA	cis	rs8062405	0.69	rs762634	ENSG00000270424.1	RP11-1348G14.6	3.89	0.000113	0.00865	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28749959~28750595:-
THCA	cis	rs62034325	0.697	rs710410	ENSG00000270424.1	RP11-1348G14.6	3.89	0.000113	0.00865	0.22	0.18	Body mass index;	chr16:28592021	chr16:28749959~28750595:-
THCA	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	3.89	0.000113	0.00865	0.23	0.18	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
THCA	cis	rs4767841	0.935	rs2952403	ENSG00000252886.1	RN7SKP197	-3.89	0.000113	0.00865	-0.18	-0.18	Urgency urinary incontinence;	chr12:119738080	chr12:119631090~119631386:-
THCA	cis	rs9309473	1	rs13421462	ENSG00000273245.1	RP11-434P11.2	3.89	0.000113	0.00865	0.24	0.18	Metabolite levels;	chr2:73492748	chr2:73750256~73750786:-
THCA	cis	rs12134133	1	rs6668683	ENSG00000237074.1	RP11-6J21.2	3.89	0.000113	0.00865	0.18	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs10494889	ENSG00000237074.1	RP11-6J21.2	3.89	0.000113	0.00865	0.18	0.18	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207249067~207309121:+
THCA	cis	rs10792320	0.508	rs56182543	ENSG00000279491.1	RP11-810P12.7	-3.89	0.000113	0.00865	-0.21	-0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:62000440	chr11:61967794~61969490:+
THCA	cis	rs1075265	0.836	rs10208233	ENSG00000235937.1	AC008280.1	3.89	0.000113	0.00865	0.21	0.18	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54029552~54030682:-
THCA	cis	rs7824557	0.569	rs2409718	ENSG00000206014.6	OR7E161P	3.89	0.000113	0.00865	0.2	0.18	Retinal vascular caliber;	chr8:11155467	chr8:11928597~11929563:-
THCA	cis	rs13325613	0.834	rs13075270	ENSG00000223552.1	RP11-24F11.2	-3.89	0.000113	0.00866	-0.26	-0.18	Monocyte count;	chr3:46212298	chr3:46364955~46407059:-
THCA	cis	rs2640806	0.544	rs11997526	ENSG00000253105.4	KB-1448A5.1	3.89	0.000113	0.00866	0.21	0.18	Obesity-related traits;	chr8:96353691	chr8:96371865~96387438:-
THCA	cis	rs2640806	0.505	rs11990371	ENSG00000253105.4	KB-1448A5.1	3.89	0.000113	0.00866	0.21	0.18	Obesity-related traits;	chr8:96353700	chr8:96371865~96387438:-
THCA	cis	rs2474937	0.561	rs10923561	ENSG00000231365.4	RP11-418J17.1	3.89	0.000113	0.00866	0.18	0.18	Congenital heart malformation;	chr1:118391276	chr1:119140396~119275973:+
THCA	cis	rs785830	1	rs785830	ENSG00000231808.2	LINC01388	-3.89	0.000113	0.00866	-0.2	-0.18	Platelet distribution width;	chr9:246357	chr9:112713~113754:-
THCA	cis	rs150992	0.574	rs2927655	ENSG00000241597.2	CTD-2007H13.1	-3.89	0.000113	0.00866	-0.23	-0.18	Body mass index;	chr5:98839049	chr5:98954394~98954972:+
THCA	cis	rs4908769	0.775	rs4995074	ENSG00000232912.4	RP5-1115A15.1	3.89	0.000113	0.00866	0.19	0.18	Allergy;	chr1:8475104	chr1:8424645~8434838:+
THCA	cis	rs4788570	0.647	rs904764	ENSG00000260185.1	RP11-432I5.6	-3.89	0.000113	0.00866	-0.33	-0.18	Intelligence (multi-trait analysis);	chr16:71738892	chr16:71655027~71664212:+
THCA	cis	rs4883201	0.536	rs7961355	ENSG00000245105.2	A2M-AS1	3.89	0.000113	0.00866	0.17	0.18	Total cholesterol levels;Cholesterol, total;	chr12:8962035	chr12:9065177~9068060:+
THCA	cis	rs4660214	0.666	rs7414381	ENSG00000228060.1	RP11-69E11.8	3.89	0.000113	0.00866	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs3116387	ENSG00000228060.1	RP11-69E11.8	3.89	0.000113	0.00866	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.614	rs1537815	ENSG00000228060.1	RP11-69E11.8	3.89	0.000113	0.00866	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.789	rs1984142	ENSG00000228060.1	RP11-69E11.8	3.89	0.000113	0.00866	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs2275188	ENSG00000228060.1	RP11-69E11.8	3.89	0.000113	0.00866	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39565160~39573203:+
THCA	cis	rs2562456	0.837	rs62110205	ENSG00000268278.1	RP11-420K14.1	3.89	0.000113	0.00866	0.21	0.18	Pain;	chr19:21577269	chr19:21637974~21656300:+
THCA	cis	rs9595908	0.869	rs9591189	ENSG00000212293.1	SNORA16	3.89	0.000113	0.00866	0.2	0.18	Body mass index;	chr13:32632514	chr13:32420390~32420516:-
THCA	cis	rs1387259	0.929	rs2634666	ENSG00000257735.1	RP11-370I10.6	3.89	0.000113	0.00866	0.2	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48350945~48442411:+
THCA	cis	rs1387259	0.929	rs2956703	ENSG00000257735.1	RP11-370I10.6	3.89	0.000113	0.00866	0.2	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48350945~48442411:+
THCA	cis	rs1387259	0.931	rs1107654	ENSG00000257735.1	RP11-370I10.6	3.89	0.000113	0.00866	0.2	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48350945~48442411:+
THCA	cis	rs67478160	0.643	rs11628332	ENSG00000258534.1	CTD-2134A5.4	-3.89	0.000113	0.00866	-0.17	-0.18	Schizophrenia;	chr14:103774804	chr14:103854366~103880111:-
THCA	cis	rs16944613	0.588	rs6416553	ENSG00000259212.1	CTD-3065B20.2	-3.89	0.000113	0.00866	-0.27	-0.18	Colorectal cancer;	chr15:90592179	chr15:90595840~90596447:-
THCA	cis	rs4272720	0.639	rs2264846	ENSG00000234736.4	FAM170B-AS1	3.89	0.000113	0.00866	0.19	0.18	Platelet count;Plateletcrit;	chr10:49045142	chr10:49121839~49151547:+
THCA	cis	rs2640806	0.505	rs11997620	ENSG00000253105.4	KB-1448A5.1	3.89	0.000113	0.00866	0.21	0.18	Obesity-related traits;	chr8:96353911	chr8:96371865~96387438:-
THCA	cis	rs76382185	0.808	rs34864335	ENSG00000233184.5	RP11-421L21.3	3.89	0.000113	0.00867	0.26	0.18	Lymphocyte counts;	chr1:101115171	chr1:101025878~101087268:+
THCA	cis	rs7927592	0.83	rs10896339	ENSG00000160172.9	FAM86C2P	3.89	0.000113	0.00867	0.17	0.18	Total body bone mineral density;	chr11:68535378	chr11:67791648~67805336:-
THCA	cis	rs9926296	0.572	rs2376878	ENSG00000274627.1	RP11-104N10.2	-3.89	0.000113	0.00867	-0.17	-0.18	Vitiligo;	chr16:89818753	chr16:89516797~89522217:+
THCA	cis	rs793571	0.544	rs383902	ENSG00000245975.2	RP11-30K9.6	3.89	0.000113	0.00867	0.16	0.18	Schizophrenia;	chr15:58741975	chr15:58768072~58770974:-
THCA	cis	rs2251381	0.75	rs8129616	ENSG00000176054.6	RPL23P2	-3.89	0.000113	0.00867	-0.16	-0.18	Selective IgA deficiency;	chr21:29147764	chr21:28997613~28998033:-
THCA	cis	rs7259376	0.934	rs7253315	ENSG00000269138.1	ZNF209P	-3.89	0.000113	0.00867	-0.18	-0.18	Menopause (age at onset);	chr19:22411637	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs6511350	ENSG00000269138.1	ZNF209P	-3.89	0.000113	0.00867	-0.18	-0.18	Menopause (age at onset);	chr19:22411895	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs10423736	ENSG00000269138.1	ZNF209P	-3.89	0.000113	0.00867	-0.18	-0.18	Menopause (age at onset);	chr19:22413330	chr19:22463922~22473036:+
THCA	cis	rs786425	0.655	rs114208992	ENSG00000278112.1	RP11-972P1.11	3.89	0.000113	0.00867	0.17	0.18	Pubertal anthropometrics;	chr12:123684695	chr12:123519390~123519856:-
THCA	cis	rs3809566	1	rs4775612	ENSG00000259459.4	RP11-321G12.1	-3.89	0.000113	0.00867	-0.15	-0.18	Platelet count;	chr15:63039958	chr15:63390136~63438320:+
THCA	cis	rs3809566	1	rs4775610	ENSG00000259459.4	RP11-321G12.1	3.89	0.000113	0.00867	0.15	0.18	Platelet count;	chr15:63039858	chr15:63390136~63438320:+
THCA	cis	rs3809566	1	rs4774471	ENSG00000259459.4	RP11-321G12.1	3.89	0.000113	0.00867	0.15	0.18	Platelet count;	chr15:63040446	chr15:63390136~63438320:+
THCA	cis	rs10484434	0.892	rs62394556	ENSG00000272462.2	U91328.19	3.89	0.000113	0.00867	0.19	0.18	HIV-1 viral setpoint;	chr6:26072668	chr6:25992662~26001775:+
THCA	cis	rs6801044	0.789	rs823526	ENSG00000223711.1	AC091633.3	3.89	0.000113	0.00867	0.24	0.18	Creatinine levels in ischemic stroke;	chr3:195551478	chr3:195544048~195550581:+
THCA	cis	rs690037	0.773	rs689779	ENSG00000272529.1	RP11-415F23.4	3.89	0.000113	0.00867	0.16	0.18	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16351804	chr3:16345126~16346440:+
THCA	cis	rs1336149	0.545	rs1094565	ENSG00000211581.1	MIR765	3.89	0.000113	0.00868	0.23	0.18	Chin dimples;	chr1:157057475	chr1:156936131~156936244:-
THCA	cis	rs7658584	0.592	rs6854688	ENSG00000246375.2	RP11-10L7.1	-3.89	0.000113	0.00868	-0.27	-0.18	Squamous cell lung carcinoma;	chr4:88191681	chr4:88284942~88331421:+
THCA	cis	rs17666538	0.585	rs4448252	ENSG00000254207.1	RP11-43A14.1	3.89	0.000113	0.00868	0.34	0.18	IgG glycosylation;	chr8:665597	chr8:725188~725877:-
THCA	cis	rs17666538	0.535	rs4338080	ENSG00000254207.1	RP11-43A14.1	3.89	0.000113	0.00868	0.34	0.18	IgG glycosylation;	chr8:665598	chr8:725188~725877:-
THCA	cis	rs2806561	0.765	rs681395	ENSG00000249087.5	ZNF436-AS1	-3.89	0.000113	0.00868	-0.11	-0.18	Height;	chr1:23173821	chr1:23368997~23371839:+
THCA	cis	rs2905347	0.895	rs2961280	ENSG00000232949.1	AC002480.4	-3.89	0.000113	0.00868	-0.22	-0.18	Major depression and alcohol dependence;	chr7:22600098	chr7:22589705~22591622:+
THCA	cis	rs4908768	0.501	rs7527389	ENSG00000270282.1	RP5-1115A15.2	3.89	0.000113	0.00868	0.21	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8512653~8513021:+
THCA	cis	rs7131987	0.565	rs4412790	ENSG00000257176.2	RP11-996F15.2	3.89	0.000113	0.00868	0.18	0.18	QT interval;	chr12:29253828	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.565	rs10743651	ENSG00000257176.2	RP11-996F15.2	3.89	0.000113	0.00868	0.18	0.18	QT interval;	chr12:29255006	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.546	rs7299648	ENSG00000257176.2	RP11-996F15.2	3.89	0.000113	0.00868	0.18	0.18	QT interval;	chr12:29256797	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.547	rs4370971	ENSG00000257176.2	RP11-996F15.2	3.89	0.000113	0.00868	0.18	0.18	QT interval;	chr12:29257066	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.565	rs7316026	ENSG00000257176.2	RP11-996F15.2	3.89	0.000113	0.00868	0.18	0.18	QT interval;	chr12:29258881	chr12:29280418~29317848:-
THCA	cis	rs11678584	0.686	rs72785601	ENSG00000276517.1	AL133243.2	-3.89	0.000113	0.00868	-0.3	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32575455	chr2:32526504~32529507:+
THCA	cis	rs17597773	0.638	rs12139139	ENSG00000238078.1	LINC01352	-3.89	0.000113	0.00868	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220827284	chr1:220829255~220832429:+
THCA	cis	rs7914558	1	rs10748838	ENSG00000213061.2	PFN1P11	3.89	0.000113	0.00868	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184229	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs3758543	ENSG00000213061.2	PFN1P11	3.89	0.000113	0.00868	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184987	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs4917997	ENSG00000213061.2	PFN1P11	3.89	0.000113	0.00868	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185456	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs7077097	ENSG00000213061.2	PFN1P11	3.89	0.000113	0.00868	0.22	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185706	chr10:102838011~102845473:-
THCA	cis	rs6479891	1	rs11817689	ENSG00000272767.1	JMJD1C-AS1	-3.89	0.000113	0.00868	-0.24	-0.18	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63465229~63466563:+
THCA	cis	rs78487399	0.808	rs79271345	ENSG00000234936.1	AC010883.5	3.89	0.000113	0.00868	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43518955	chr2:43229573~43233394:+
THCA	cis	rs6479891	0.908	rs16918638	ENSG00000272767.1	JMJD1C-AS1	3.89	0.000113	0.00868	0.26	0.18	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63465229~63466563:+
THCA	cis	rs2179367	0.632	rs9485389	ENSG00000216906.2	RP11-350J20.9	-3.89	0.000113	0.00868	-0.22	-0.18	Dupuytren's disease;	chr6:149420078	chr6:149904243~149906418:+
THCA	cis	rs6453278	0.592	rs13154602	ENSG00000250802.5	ZBED3-AS1	-3.89	0.000113	0.00868	-0.17	-0.18	Autism;	chr5:77100092	chr5:77086740~77166909:+
THCA	cis	rs11671005	0.737	rs11673101	ENSG00000269600.1	AC016629.3	-3.89	0.000113	0.00869	-0.27	-0.18	Mean platelet volume;	chr19:58483686	chr19:58593896~58599355:-
THCA	cis	rs6121246	0.954	rs6121245	ENSG00000230613.1	HM13-AS1	3.89	0.000113	0.00869	0.19	0.18	Mean corpuscular hemoglobin;	chr20:31844257	chr20:31567707~31573263:-
THCA	cis	rs4780401	0.933	rs4780395	ENSG00000274038.1	RP11-66H6.4	-3.89	0.000113	0.00869	-0.21	-0.18	Rheumatoid arthritis;	chr16:11716084	chr16:11056556~11057034:+
THCA	cis	rs17092148	1	rs7265992	ENSG00000276073.1	RP5-1125A11.7	3.89	0.000113	0.00869	0.21	0.18	Neuroticism;	chr20:34937604	chr20:33985617~33988989:-
THCA	cis	rs61677309	0.964	rs112753655	ENSG00000278376.1	RP11-158I9.8	3.89	0.000113	0.00869	0.14	0.18	Lung cancer in ever smokers;	chr11:118284080	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.964	rs113145584	ENSG00000278376.1	RP11-158I9.8	3.89	0.000113	0.00869	0.14	0.18	Lung cancer in ever smokers;	chr11:118284083	chr11:118791254~118793137:+
THCA	cis	rs875971	0.522	rs1880556	ENSG00000234585.5	CCT6P3	3.89	0.000113	0.00869	0.16	0.18	Aortic root size;	chr7:65967557	chr7:65038354~65074713:+
THCA	cis	rs7259376	0.777	rs7247735	ENSG00000270947.1	AC025811.3	-3.89	0.000113	0.00869	-0.19	-0.18	Menopause (age at onset);	chr19:22392686	chr19:22455988~22456459:+
THCA	cis	rs704	0.605	rs2227736	ENSG00000237575.4	PYY2	3.89	0.000113	0.00869	0.21	0.18	Osteoprotegerin levels;	chr17:28366210	chr17:28226563~28228065:+
THCA	cis	rs704	0.585	rs2227735	ENSG00000237575.4	PYY2	3.89	0.000113	0.00869	0.21	0.18	Osteoprotegerin levels;	chr17:28366237	chr17:28226563~28228065:+
THCA	cis	rs796395	0.967	rs623356	ENSG00000232480.1	TGFB2-AS1	3.89	0.000113	0.00869	0.2	0.18	Post bronchodilator FEV1/FVC ratio;	chr1:218474044	chr1:218344196~218345678:-
THCA	cis	rs11064837	0.504	rs7972445	ENSG00000248636.5	RP11-768F21.1	3.89	0.000113	0.0087	0.2	0.18	Schizophrenia;	chr12:119617604	chr12:119387987~119668079:-
THCA	cis	rs6546886	0.956	rs6546885	ENSG00000235499.1	AC073046.25	3.89	0.000113	0.0087	0.16	0.18	Dialysis-related mortality;	chr2:74018365	chr2:73985132~73986343:+
THCA	cis	rs791590	1	rs791590	ENSG00000225948.2	RP11-554I8.1	3.89	0.000113	0.0087	0.28	0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:6048359	chr10:6618716~6625346:+
THCA	cis	rs317865	1	rs1625980	ENSG00000263327.5	TAPT1-AS1	-3.89	0.000113	0.0087	-0.27	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr4:16151236	chr4:16226685~16320140:+
THCA	cis	rs9309473	0.95	rs13408433	ENSG00000273245.1	RP11-434P11.2	3.89	0.000113	0.0087	0.25	0.18	Metabolite levels;	chr2:73655945	chr2:73750256~73750786:-
THCA	cis	rs11614913	0.509	rs12300425	ENSG00000248265.1	FLJ12825	3.89	0.000113	0.0087	0.2	0.18	Waist circumference adjusted for body mass index;	chr12:54001298	chr12:54058254~54122234:+
THCA	cis	rs2625529	0.824	rs2306488	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000113	0.0087	-0.25	-0.18	Red blood cell count;	chr15:71999774	chr15:71818396~71823384:+
THCA	cis	rs950169	0.881	rs150965	ENSG00000188388.10	GOLGA6L3	3.89	0.000113	0.0087	0.24	0.18	Schizophrenia;	chr15:84537296	chr15:85240472~85247170:+
THCA	cis	rs6963495	0.818	rs73192141	ENSG00000272604.1	RP11-251G23.5	3.89	0.000113	0.0087	0.23	0.18	Bipolar disorder (body mass index interaction);	chr7:105560682	chr7:105571083~105573660:+
THCA	cis	rs295490	0.748	rs3772876	ENSG00000272656.1	RP11-219D15.3	3.89	0.000113	0.0087	0.33	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469035	chr3:139349024~139349371:-
THCA	cis	rs7798970	0.645	rs10263109	ENSG00000225498.1	AC002064.5	3.89	0.000113	0.0087	0.18	0.18	Inflammatory skin disease;	chr7:90016190	chr7:90312496~90322592:+
THCA	cis	rs7259376	0.875	rs9304996	ENSG00000269345.1	VN1R85P	3.89	0.000113	0.0087	0.19	0.18	Menopause (age at onset);	chr19:22303733	chr19:22174766~22175191:-
THCA	cis	rs9905704	0.647	rs6503888	ENSG00000224738.1	AC099850.1	3.89	0.000113	0.0087	0.21	0.18	Testicular germ cell tumor;	chr17:58950765	chr17:59106598~59118267:+
THCA	cis	rs6570726	0.818	rs412350	ENSG00000270638.1	RP3-466P17.1	3.89	0.000113	0.0087	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145735570~145737218:+
THCA	cis	rs12887734	0.524	rs12888002	ENSG00000258534.1	CTD-2134A5.4	-3.89	0.000113	0.0087	-0.19	-0.18	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103854366~103880111:-
THCA	cis	rs6121246	0.909	rs3203770	ENSG00000224628.2	RP5-854E16.2	-3.89	0.000113	0.0087	-0.24	-0.18	Mean corpuscular hemoglobin;	chr20:31794512	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6119725	ENSG00000224628.2	RP5-854E16.2	-3.89	0.000113	0.0087	-0.24	-0.18	Mean corpuscular hemoglobin;	chr20:31797754	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs1075698	ENSG00000224628.2	RP5-854E16.2	-3.89	0.000113	0.0087	-0.24	-0.18	Mean corpuscular hemoglobin;	chr20:31800189	chr20:31285317~31286835:-
THCA	cis	rs56804039	0.524	rs6988990	ENSG00000254153.1	CTA-398F10.2	3.89	0.000113	0.0087	0.29	0.18	Cervical cancer;	chr8:8510890	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs7011761	ENSG00000254153.1	CTA-398F10.2	3.89	0.000113	0.0087	0.29	0.18	Cervical cancer;	chr8:8511045	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs7016788	ENSG00000254153.1	CTA-398F10.2	3.89	0.000113	0.0087	0.29	0.18	Cervical cancer;	chr8:8511226	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs7012227	ENSG00000254153.1	CTA-398F10.2	3.89	0.000113	0.0087	0.29	0.18	Cervical cancer;	chr8:8511280	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs6995198	ENSG00000254153.1	CTA-398F10.2	3.89	0.000113	0.0087	0.29	0.18	Cervical cancer;	chr8:8512445	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs6985671	ENSG00000254153.1	CTA-398F10.2	3.89	0.000113	0.0087	0.29	0.18	Cervical cancer;	chr8:8512494	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs6993658	ENSG00000254153.1	CTA-398F10.2	3.89	0.000113	0.0087	0.29	0.18	Cervical cancer;	chr8:8512842	chr8:8456909~8461337:-
THCA	cis	rs56804039	0.524	rs6998450	ENSG00000254153.1	CTA-398F10.2	3.89	0.000113	0.0087	0.29	0.18	Cervical cancer;	chr8:8512843	chr8:8456909~8461337:-
THCA	cis	rs7824557	0.545	rs34482136	ENSG00000154316.13	TDH	3.89	0.000113	0.0087	0.13	0.18	Retinal vascular caliber;	chr8:11370376	chr8:11339637~11368452:+
THCA	cis	rs7474896	0.515	rs688608	ENSG00000120555.12	SEPT7P9	-3.89	0.000113	0.0087	-0.24	-0.18	Obesity (extreme);	chr10:38042696	chr10:38383069~38402916:-
THCA	cis	rs1035144	0.654	rs3783951	ENSG00000258915.1	BHLHB9P1	-3.89	0.000113	0.0087	-0.19	-0.18	Male sexual orientation;	chr14:80981752	chr14:80981988~80983638:+
THCA	cis	rs1035144	0.679	rs4903959	ENSG00000258915.1	BHLHB9P1	-3.89	0.000113	0.0087	-0.19	-0.18	Male sexual orientation;	chr14:80982276	chr14:80981988~80983638:+
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000182586.6	LINC00334	-3.89	0.000113	0.0087	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45234340~45258730:+
THCA	cis	rs8115854	0.922	rs8115763	ENSG00000269846.1	RP4-621N11.2	3.89	0.000113	0.0087	0.23	0.18	Hippocampal atrophy;	chr20:37179804	chr20:37095785~37097178:+
THCA	cis	rs73198271	0.737	rs565203	ENSG00000253981.4	ALG1L13P	-3.89	0.000113	0.0087	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8775447	chr8:8236003~8244667:-
THCA	cis	rs9902453	0.868	rs8066602	ENSG00000263370.1	RP11-68I3.5	3.89	0.000113	0.00871	0.23	0.18	Coffee consumption (cups per day);	chr17:30196067	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.868	rs8066731	ENSG00000263370.1	RP11-68I3.5	3.89	0.000113	0.00871	0.23	0.18	Coffee consumption (cups per day);	chr17:30196103	chr17:29639627~29640825:+
THCA	cis	rs11247915	0.501	rs34209692	ENSG00000236782.4	RP11-96L14.7	-3.89	0.000113	0.00871	-0.21	-0.18	Obesity-related traits;	chr1:26282291	chr1:26169947~26171821:-
THCA	cis	rs17741873	0.779	rs3812635	ENSG00000271848.1	RP11-464F9.21	-3.89	0.000113	0.00871	-0.22	-0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73834544	chr10:73654039~73674719:+
THCA	cis	rs17741873	0.779	rs3812634	ENSG00000271848.1	RP11-464F9.21	-3.89	0.000113	0.00871	-0.22	-0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73834728	chr10:73654039~73674719:+
THCA	cis	rs17741873	0.779	rs2242255	ENSG00000271848.1	RP11-464F9.21	-3.89	0.000113	0.00871	-0.22	-0.18	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73837531	chr10:73654039~73674719:+
THCA	cis	rs150992	0.711	rs2617507	ENSG00000246763.5	RGMB-AS1	3.89	0.000113	0.00871	0.19	0.18	Body mass index;	chr5:98912548	chr5:98769618~98773469:-
THCA	cis	rs7216064	0.954	rs9907491	ENSG00000265055.1	AC145343.2	-3.89	0.000113	0.00871	-0.25	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67953877	chr17:68096046~68101474:-
THCA	cis	rs7216064	0.954	rs4790974	ENSG00000265055.1	AC145343.2	-3.89	0.000113	0.00871	-0.25	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67954991	chr17:68096046~68101474:-
THCA	cis	rs9341808	0.727	rs4706834	ENSG00000260645.1	RP11-250B2.5	3.89	0.000113	0.00871	0.15	0.18	Sitting height ratio;	chr6:80302888	chr6:80466958~80469080:+
THCA	cis	rs793571	0.543	rs4775087	ENSG00000245975.2	RP11-30K9.6	3.89	0.000113	0.00871	0.16	0.18	Schizophrenia;	chr15:58682705	chr15:58768072~58770974:-
THCA	cis	rs9329221	0.712	rs1962073	ENSG00000154316.13	TDH	3.89	0.000113	0.00871	0.12	0.18	Neuroticism;	chr8:10403043	chr8:11339637~11368452:+
THCA	cis	rs10875746	0.68	rs4760610	ENSG00000269514.1	RP11-370I10.12	3.89	0.000113	0.00871	0.17	0.18	Longevity (90 years and older);	chr12:48024442	chr12:48198387~48202031:+
THCA	cis	rs11633886	0.565	rs1402164	ENSG00000273972.1	CTD-2306A12.1	3.89	0.000113	0.00871	0.2	0.18	Diisocyanate-induced asthma;	chr15:45779974	chr15:45702640~45703183:+
THCA	cis	rs9863	0.828	rs4765562	ENSG00000270061.1	RP11-214K3.19	-3.89	0.000113	0.00871	-0.23	-0.18	White blood cell count;	chr12:123988024	chr12:123969990~123970344:-
THCA	cis	rs964611	0.706	rs11070638	ENSG00000259488.2	RP11-154J22.1	3.89	0.000113	0.00871	0.16	0.18	Metabolite levels (Pyroglutamine);	chr15:48371906	chr15:48312353~48331856:-
THCA	cis	rs972578	1	rs2267480	ENSG00000274717.1	RP1-47A17.1	-3.89	0.000113	0.00871	-0.19	-0.18	Mean platelet volume;	chr22:42966970	chr22:42791814~42794313:-
THCA	cis	rs7182948	1	rs4774539	ENSG00000259531.2	RP11-295H24.3	-3.89	0.000113	0.00871	-0.21	-0.18	Lung adenocarcinoma;	chr15:49526775	chr15:49365124~49366685:-
THCA	cis	rs6449502	1	rs6876346	ENSG00000251279.1	CTC-436P18.1	-3.89	0.000113	0.00871	-0.28	-0.18	Mean platelet volume;	chr5:60796009	chr5:61162070~61232040:+
THCA	cis	rs6449502	1	rs6877849	ENSG00000251279.1	CTC-436P18.1	3.89	0.000113	0.00871	0.28	0.18	Mean platelet volume;	chr5:60792792	chr5:61162070~61232040:+
THCA	cis	rs6449502	1	rs7712473	ENSG00000251279.1	CTC-436P18.1	3.89	0.000113	0.00871	0.28	0.18	Mean platelet volume;	chr5:60812643	chr5:61162070~61232040:+
THCA	cis	rs685782	0.678	rs66480520	ENSG00000200201.1	Y_RNA	-3.89	0.000113	0.00871	-0.26	-0.18	Metabolite levels (Dihydroxy docosatrienoic acid);	chr11:3741564	chr11:3665164~3665259:-
THCA	cis	rs6921919	0.789	rs6912584	ENSG00000219392.1	RP1-265C24.5	-3.89	0.000113	0.00871	-0.22	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28115628~28116551:+
THCA	cis	rs2732480	0.5	rs2932093	ENSG00000257735.1	RP11-370I10.6	3.89	0.000113	0.00871	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48350945~48442411:+
THCA	cis	rs959260	0.688	rs9302989	ENSG00000263843.1	RP11-649A18.12	3.89	0.000113	0.00871	0.2	0.18	Systemic lupus erythematosus;	chr17:75363189	chr17:75271369~75273895:+
THCA	cis	rs7264396	0.635	rs6121073	ENSG00000088340.14	FER1L4	3.89	0.000113	0.00871	0.18	0.18	Total cholesterol levels;	chr20:35869591	chr20:35558737~35607562:-
THCA	cis	rs6696239	0.956	rs1995019	ENSG00000227711.2	RP11-275O4.5	-3.89	0.000114	0.00872	-0.25	-0.18	Height;	chr1:227580096	chr1:227509028~227520477:-
THCA	cis	rs763121	0.853	rs5750621	ENSG00000273076.1	RP3-508I15.22	3.89	0.000114	0.00872	0.18	0.18	Menopause (age at onset);	chr22:38560161	chr22:38743495~38743910:+
THCA	cis	rs763121	0.744	rs5757140	ENSG00000273076.1	RP3-508I15.22	3.89	0.000114	0.00872	0.18	0.18	Menopause (age at onset);	chr22:38561008	chr22:38743495~38743910:+
THCA	cis	rs7914558	0.966	rs4532960	ENSG00000213061.2	PFN1P11	3.89	0.000114	0.00872	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102907649	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs10786724	ENSG00000213061.2	PFN1P11	3.89	0.000114	0.00872	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102909185	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs2297786	ENSG00000213061.2	PFN1P11	3.89	0.000114	0.00872	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102920221	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs10786725	ENSG00000213061.2	PFN1P11	3.89	0.000114	0.00872	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102922600	chr10:102838011~102845473:-
THCA	cis	rs7170668	0.831	rs8023322	ENSG00000259134.4	LINC00924	3.89	0.000114	0.00872	0.21	0.18	Motion sickness;	chr15:95483744	chr15:95433095~95507847:+
THCA	cis	rs6988985	0.678	rs28710914	ENSG00000253741.1	CTD-2292P10.4	-3.89	0.000114	0.00872	-0.22	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921874	chr8:142702252~142726973:-
THCA	cis	rs35176054	0.558	rs71471298	ENSG00000280693.1	SH3PXD2A-AS1	-3.89	0.000114	0.00872	-0.34	-0.18	Atrial fibrillation;	chr10:103747387	chr10:103745966~103755423:+
THCA	cis	rs4218	0.531	rs6494065	ENSG00000277144.1	RP11-59H7.4	3.89	0.000114	0.00872	0.23	0.18	Social communication problems;	chr15:59053249	chr15:59115547~59116089:-
THCA	cis	rs755249	0.567	rs4660214	ENSG00000182109.6	RP11-69E11.4	3.89	0.000114	0.00872	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39522280~39546187:-
THCA	cis	rs7760951	0.747	rs7746850	ENSG00000228559.1	RP3-340B19.3	-3.89	0.000114	0.00872	-0.26	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr6:35636868	chr6:35544632~35545669:+
THCA	cis	rs964611	0.808	rs2279369	ENSG00000259488.2	RP11-154J22.1	-3.89	0.000114	0.00872	-0.19	-0.18	Metabolite levels (Pyroglutamine);	chr15:48250133	chr15:48312353~48331856:-
THCA	cis	rs9287719	0.967	rs7355649	ENSG00000243819.4	RN7SL832P	3.89	0.000114	0.00872	0.14	0.18	Prostate cancer;	chr2:10607968	chr2:10690344~10692099:+
THCA	cis	rs7267979	1	rs453329	ENSG00000276952.1	RP5-965G21.6	3.89	0.000114	0.00873	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25284915~25285588:-
THCA	cis	rs1862618	0.853	rs2432195	ENSG00000234553.1	AC022431.3	-3.89	0.000114	0.00873	-0.2	-0.18	Initial pursuit acceleration;	chr5:56824586	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs252916	ENSG00000234553.1	AC022431.3	-3.89	0.000114	0.00873	-0.2	-0.18	Initial pursuit acceleration;	chr5:56825961	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.802	rs832560	ENSG00000234553.1	AC022431.3	-3.89	0.000114	0.00873	-0.2	-0.18	Initial pursuit acceleration;	chr5:56828596	chr5:56536583~56537826:-
THCA	cis	rs755249	0.567	rs41270807	ENSG00000182109.6	RP11-69E11.4	3.89	0.000114	0.00873	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39522280~39546187:-
THCA	cis	rs3758911	0.861	rs11212114	ENSG00000255353.1	RP11-382M14.1	3.89	0.000114	0.00873	0.23	0.18	Coronary artery disease;	chr11:107274940	chr11:107176286~107177530:+
THCA	cis	rs151227923	1	rs151227923	ENSG00000273117.1	AC144652.1	3.89	0.000114	0.00873	0.23	0.18	Stem cell growth factor beta levels;	chr7:155314854	chr7:155295918~155297541:-
THCA	cis	rs140365914	1	rs140365914	ENSG00000273117.1	AC144652.1	3.89	0.000114	0.00873	0.23	0.18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr7:155314860	chr7:155295918~155297541:-
THCA	cis	rs354225	0.785	rs2567834	ENSG00000162997.14	PRORSD1P	-3.89	0.000114	0.00873	-0.19	-0.18	Schizophrenia;	chr2:54706232	chr2:55282319~55284522:+
THCA	cis	rs6723108	0.66	rs655472	ENSG00000224043.6	CCNT2-AS1	-3.89	0.000114	0.00873	-0.19	-0.18	Type 2 diabetes;	chr2:134532650	chr2:134735464~134918710:-
THCA	cis	rs600231	0.623	rs587080	ENSG00000254614.2	AP003068.23	3.89	0.000114	0.00873	0.23	0.18	Bone mineral density;	chr11:65486329	chr11:65177606~65181834:-
THCA	cis	rs972578	0.791	rs4822243	ENSG00000230319.1	AL022476.2	3.89	0.000114	0.00873	0.19	0.18	Mean platelet volume;	chr22:42987497	chr22:43038585~43052366:+
THCA	cis	rs972578	0.936	rs2267486	ENSG00000230319.1	AL022476.2	3.89	0.000114	0.00873	0.19	0.18	Mean platelet volume;	chr22:42988011	chr22:43038585~43052366:+
THCA	cis	rs10484434	0.901	rs17531978	ENSG00000272462.2	U91328.19	3.89	0.000114	0.00873	0.2	0.18	HIV-1 viral setpoint;	chr6:26129164	chr6:25992662~26001775:+
THCA	cis	rs7829975	0.535	rs4841005	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000114	0.00874	-0.16	-0.18	Mood instability;	chr8:8643720	chr8:8961200~8979025:+
THCA	cis	rs1371614	0.611	rs877272	ENSG00000272148.1	RP11-195B17.1	3.89	0.000114	0.00874	0.16	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917020	chr2:27062428~27062907:-
THCA	cis	rs875971	0.83	rs587360	ENSG00000229886.1	RP5-1132H15.3	3.89	0.000114	0.00874	0.19	0.18	Aortic root size;	chr7:66057711	chr7:66025126~66031544:-
THCA	cis	rs7615952	0.546	rs2979333	ENSG00000272840.1	RP11-379B18.6	3.89	0.000114	0.00874	0.28	0.18	Blood pressure (smoking interaction);	chr3:125641499	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.546	rs111812401	ENSG00000272840.1	RP11-379B18.6	3.89	0.000114	0.00874	0.28	0.18	Blood pressure (smoking interaction);	chr3:125642651	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.546	rs2979350	ENSG00000272840.1	RP11-379B18.6	3.89	0.000114	0.00874	0.28	0.18	Blood pressure (smoking interaction);	chr3:125643371	chr3:125774714~125797953:+
THCA	cis	rs41308713	0.681	rs8116426	ENSG00000196756.10	SNHG17	-3.89	0.000114	0.00874	-0.4	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38405996	chr20:38420588~38435353:-
THCA	cis	rs41308713	0.786	rs8116471	ENSG00000196756.10	SNHG17	-3.89	0.000114	0.00874	-0.4	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38406047	chr20:38420588~38435353:-
THCA	cis	rs2676071	0.767	rs2676077	ENSG00000259721.1	RP11-758N13.1	-3.89	0.000114	0.00874	-0.21	-0.18	Periodontitis (Mean PAL);	chr15:33313100	chr15:32717270~32719007:-
THCA	cis	rs875971	0.545	rs4718348	ENSG00000273142.1	RP11-458F8.4	3.89	0.000114	0.00874	0.17	0.18	Aortic root size;	chr7:66441589	chr7:66902857~66906297:+
THCA	cis	rs12216545	0.765	rs6949018	ENSG00000241134.3	BET1P1	-3.89	0.000114	0.00874	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150558495	chr7:150749736~150750094:+
THCA	cis	rs9595908	0.629	rs962454	ENSG00000212293.1	SNORA16	3.89	0.000114	0.00874	0.21	0.18	Body mass index;	chr13:32719131	chr13:32420390~32420516:-
THCA	cis	rs2281603	1	rs11849530	ENSG00000258824.2	CTD-2555O16.2	-3.89	0.000114	0.00874	-0.18	-0.18	Lymphocyte counts;	chr14:64451694	chr14:64422935~64448557:-
THCA	cis	rs4965006	0.915	rs7969545	ENSG00000273568.1	RP11-417L19.6	3.89	0.000114	0.00874	0.28	0.18	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934612	chr12:131934642~131934928:+
THCA	cis	rs7259376	0.84	rs8106611	ENSG00000269345.1	VN1R85P	3.89	0.000114	0.00874	0.19	0.18	Menopause (age at onset);	chr19:22386816	chr19:22174766~22175191:-
THCA	cis	rs745109	0.504	rs113679164	ENSG00000273080.1	RP11-301O19.1	3.89	0.000114	0.00874	0.32	0.18	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86411479	chr2:86195590~86196049:+
THCA	cis	rs6568686	0.735	rs7762054	ENSG00000255389.1	C6orf3	3.89	0.000114	0.00874	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111549539	chr6:111599875~111602295:+
THCA	cis	rs875971	0.862	rs1167408	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000114	0.00874	-0.19	-0.18	Aortic root size;	chr7:66091121	chr7:66025126~66031544:-
THCA	cis	rs875971	0.83	rs1167406	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000114	0.00874	-0.19	-0.18	Aortic root size;	chr7:66091949	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs1167399	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000114	0.00874	-0.19	-0.18	Aortic root size;	chr7:66096890	chr7:66025126~66031544:-
THCA	cis	rs875971	0.862	rs57866200	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000114	0.00874	-0.19	-0.18	Aortic root size;	chr7:66100405	chr7:66025126~66031544:-
THCA	cis	rs5753037	0.869	rs6006300	ENSG00000279699.1	RP1-102K2.9	3.89	0.000114	0.00874	0.17	0.18	Type 1 diabetes;	chr22:29906164	chr22:30275215~30276951:-
THCA	cis	rs10540	1	rs117339389	ENSG00000279672.1	CMB9-55F22.1	3.89	0.000114	0.00874	0.35	0.18	Body mass index;	chr11:505025	chr11:779617~780755:+
THCA	cis	rs6453278	0.559	rs3934501	ENSG00000250802.5	ZBED3-AS1	-3.89	0.000114	0.00874	-0.17	-0.18	Autism;	chr5:77097859	chr5:77086740~77166909:+
THCA	cis	rs7772697	0.508	rs6570924	ENSG00000223701.3	RAET1E-AS1	-3.89	0.000114	0.00875	-0.25	-0.18	Diabetic retinopathy;	chr6:149043914	chr6:149884431~149919508:+
THCA	cis	rs8099594	0.565	rs7240563	ENSG00000266696.1	RP11-30L3.2	3.89	0.000114	0.00875	0.22	0.18	Height;	chr18:49236812	chr18:49205912~49208781:+
THCA	cis	rs858239	0.539	rs10270695	ENSG00000230042.1	AK3P3	3.89	0.000114	0.00875	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23129178~23129841:+
THCA	cis	rs8028182	0.501	rs11072553	ENSG00000260274.1	RP11-817O13.8	3.89	0.000114	0.00875	0.13	0.18	Sudden cardiac arrest;	chr15:75640436	chr15:75368155~75369584:+
THCA	cis	rs1555322	0.929	rs2247828	ENSG00000279253.1	RP4-614O4.13	3.89	0.000114	0.00875	0.23	0.18	Attention deficit hyperactivity disorder;	chr20:35252136	chr20:35262727~35264187:-
THCA	cis	rs3177980	0.521	rs527261	ENSG00000239494.2	RN7SL333P	3.89	0.000114	0.00875	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:169976022	chr1:169859756~169860052:+
THCA	cis	rs67981189	0.865	rs2810117	ENSG00000269927.1	RP6-91H8.3	-3.89	0.000114	0.00875	-0.2	-0.18	Schizophrenia;	chr14:70924308	chr14:71141125~71143253:-
THCA	cis	rs7829975	0.523	rs9644774	ENSG00000254153.1	CTA-398F10.2	3.89	0.000114	0.00875	0.21	0.18	Mood instability;	chr8:8702322	chr8:8456909~8461337:-
THCA	cis	rs12022452	1	rs12034162	ENSG00000237899.1	RP4-739H11.3	-3.89	0.000114	0.00875	-0.28	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40669089~40687588:-
THCA	cis	rs2562456	0.876	rs11085468	ENSG00000268658.4	LINC00664	3.89	0.000114	0.00875	0.26	0.18	Pain;	chr19:21569087	chr19:21483374~21503238:+
THCA	cis	rs11247915	0.561	rs12750420	ENSG00000236782.4	RP11-96L14.7	-3.89	0.000114	0.00876	-0.21	-0.18	Obesity-related traits;	chr1:26282158	chr1:26169947~26171821:-
THCA	cis	rs6494488	0.5	rs11854894	ENSG00000259635.1	AC100830.3	-3.89	0.000114	0.00876	-0.43	-0.18	Coronary artery disease;	chr15:64728046	chr15:64701248~64719602:+
THCA	cis	rs875971	0.706	rs1643374	ENSG00000232546.1	RP11-458F8.1	-3.89	0.000114	0.00876	-0.15	-0.18	Aortic root size;	chr7:66407695	chr7:66848496~66858136:+
THCA	cis	rs6028446	0.608	rs6124134	ENSG00000224635.1	RP4-564F22.5	-3.89	0.000114	0.00876	-0.22	-0.18	Chin dimples;	chr20:39287621	chr20:38406011~38416797:-
THCA	cis	rs6101567	0.517	rs4812371	ENSG00000224635.1	RP4-564F22.5	-3.89	0.000114	0.00876	-0.22	-0.18	Nose size;	chr20:39287714	chr20:38406011~38416797:-
THCA	cis	rs4648045	0.647	rs3774938	ENSG00000246560.2	RP11-10L12.4	3.89	0.000114	0.00876	0.22	0.18	Lymphocyte percentage of white cells;	chr4:102517282	chr4:102828055~102844075:+
THCA	cis	rs6494488	0.5	rs72742926	ENSG00000259635.1	AC100830.3	-3.89	0.000114	0.00876	-0.45	-0.18	Coronary artery disease;	chr15:64572262	chr15:64701248~64719602:+
THCA	cis	rs950169	0.887	rs71395453	ENSG00000275120.1	RP11-182J1.17	3.89	0.000114	0.00876	0.21	0.18	Schizophrenia;	chr15:84570259	chr15:84599434~84606463:-
THCA	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	3.89	0.000114	0.00876	0.21	0.18	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
THCA	cis	rs728616	0.614	rs61859199	ENSG00000225484.5	NUTM2B-AS1	-3.89	0.000114	0.00876	-0.31	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs1538818	ENSG00000225484.5	NUTM2B-AS1	-3.89	0.000114	0.00876	-0.31	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80363037	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs61859209	ENSG00000225484.5	NUTM2B-AS1	-3.89	0.000114	0.00876	-0.31	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr10:79663088~79826594:-
THCA	cis	rs728616	0.614	rs61859210	ENSG00000225484.5	NUTM2B-AS1	-3.89	0.000114	0.00876	-0.31	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80371712	chr10:79663088~79826594:-
THCA	cis	rs34975555	0.616	rs58657358	ENSG00000253671.1	RP11-806O11.1	-3.89	0.000114	0.00876	-0.25	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17942278	chr8:17808941~17820868:+
THCA	cis	rs6997458	0.785	rs1389247	ENSG00000253549.4	RP11-317J10.2	3.89	0.000114	0.00876	0.18	0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85410354	chr8:85441851~85464915:-
THCA	cis	rs5758511	0.68	rs5758662	ENSG00000230107.1	CTA-126B4.7	-3.89	0.000114	0.00876	-0.22	-0.18	Birth weight;	chr22:42232082	chr22:42438023~42446195:+
THCA	cis	rs78487399	0.808	rs6746058	ENSG00000234936.1	AC010883.5	3.89	0.000114	0.00876	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43460403	chr2:43229573~43233394:+
THCA	cis	rs5758511	0.68	rs5758688	ENSG00000270083.1	RP1-257I20.14	-3.89	0.000114	0.00876	-0.23	-0.18	Birth weight;	chr22:42266495	chr22:42089630~42090028:-
THCA	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	3.89	0.000114	0.00876	0.31	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
THCA	cis	rs372883	0.6	rs407712	ENSG00000176054.6	RPL23P2	-3.89	0.000114	0.00876	-0.16	-0.18	Pancreatic cancer;	chr21:29350210	chr21:28997613~28998033:-
THCA	cis	rs7178424	0.875	rs8029942	ENSG00000259251.2	RP11-643M14.1	-3.89	0.000114	0.00876	-0.18	-0.18	Height;	chr15:62061259	chr15:62060503~62062434:+
THCA	cis	rs721917	0.525	rs2246111	ENSG00000244733.5	RP11-506M13.3	-3.89	0.000114	0.00876	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79660891~79677996:+
THCA	cis	rs11583043	1	rs35445887	ENSG00000233184.5	RP11-421L21.3	3.89	0.000114	0.00876	0.19	0.18	Inflammatory bowel disease;Ulcerative colitis;	chr1:101058083	chr1:101025878~101087268:+
THCA	cis	rs2287838	1	rs2287838	ENSG00000267370.1	CTD-2623N2.3	3.89	0.000114	0.00876	0.17	0.18	Sleep duration;	chr19:9848338	chr19:9756152~9756863:-
THCA	cis	rs867186	1	rs11907438	ENSG00000126005.14	MMP24-AS1	-3.89	0.000114	0.00877	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35053417	chr20:35216462~35278131:-
THCA	cis	rs4780401	0.933	rs1592572	ENSG00000274038.1	RP11-66H6.4	-3.89	0.000114	0.00877	-0.21	-0.18	Rheumatoid arthritis;	chr16:11716526	chr16:11056556~11057034:+
THCA	cis	rs6472827	0.762	rs2936687	ENSG00000253983.2	RP1-16A9.1	3.89	0.000114	0.00877	0.29	0.18	Uterine fibroids;	chr8:74205136	chr8:74199396~74208441:+
THCA	cis	rs6472827	0.762	rs77058572	ENSG00000253983.2	RP1-16A9.1	3.89	0.000114	0.00877	0.29	0.18	Uterine fibroids;	chr8:74205137	chr8:74199396~74208441:+
THCA	cis	rs308403	0.509	rs6811183	ENSG00000224786.1	CETN4P	3.89	0.000114	0.00877	0.18	0.18	Blood protein levels;	chr4:122750396	chr4:122730548~122732193:-
THCA	cis	rs4759375	0.915	rs7954704	ENSG00000256092.2	RP13-942N8.1	3.89	0.000114	0.00877	0.19	0.18	HDL cholesterol;	chr12:123326824	chr12:123363868~123366113:+
THCA	cis	rs12216545	0.765	rs2140140	ENSG00000241134.3	BET1P1	-3.89	0.000114	0.00877	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552266	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs2373807	ENSG00000241134.3	BET1P1	-3.89	0.000114	0.00877	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552282	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs2373808	ENSG00000241134.3	BET1P1	-3.89	0.000114	0.00877	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552303	chr7:150749736~150750094:+
THCA	cis	rs2135507	0.817	rs34782288	ENSG00000270480.1	RP11-57B24.1	3.89	0.000114	0.00877	0.24	0.18	Juvenile osteochondritis dissecans;	chr4:82663279	chr4:82691737~82692468:+
THCA	cis	rs2135507	0.817	rs11947465	ENSG00000270480.1	RP11-57B24.1	3.89	0.000114	0.00877	0.24	0.18	Juvenile osteochondritis dissecans;	chr4:82663564	chr4:82691737~82692468:+
THCA	cis	rs6801044	0.741	rs823517	ENSG00000223711.1	AC091633.3	3.89	0.000114	0.00877	0.24	0.18	Creatinine levels in ischemic stroke;	chr3:195541837	chr3:195544048~195550581:+
THCA	cis	rs2625529	0.824	rs4445848	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000114	0.00877	-0.25	-0.18	Red blood cell count;	chr15:72062257	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs4131630	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000114	0.00877	-0.25	-0.18	Red blood cell count;	chr15:72063057	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.775	rs35673773	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000114	0.00877	-0.25	-0.18	Red blood cell count;	chr15:72107545	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs11072346	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000114	0.00877	-0.25	-0.18	Red blood cell count;	chr15:72108093	chr15:71818396~71823384:+
THCA	cis	rs3169166	0.546	rs1519819	ENSG00000259562.2	RP11-762H8.2	-3.89	0.000114	0.00877	-0.11	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78249427	chr15:78290527~78291221:-
THCA	cis	rs2191566	0.576	rs396148	ENSG00000277806.1	RP11-15A1.8	3.89	0.000114	0.00877	0.18	0.18	Acute lymphoblastic leukemia (childhood);	chr19:43990396	chr19:43976815~43977448:+
THCA	cis	rs7824557	0.724	rs2251473	ENSG00000261451.1	RP11-981G7.1	3.89	0.000114	0.00877	0.22	0.18	Retinal vascular caliber;	chr8:11319617	chr8:10433672~10438312:+
THCA	cis	rs67340775	0.541	rs200975	ENSG00000220721.1	OR1F12	3.89	0.000114	0.00877	0.27	0.18	Lung cancer in ever smokers;	chr6:27887847	chr6:28073316~28074233:+
THCA	cis	rs67340775	0.541	rs200974	ENSG00000220721.1	OR1F12	3.89	0.000114	0.00877	0.27	0.18	Lung cancer in ever smokers;	chr6:27888067	chr6:28073316~28074233:+
THCA	cis	rs9309473	1	rs7604682	ENSG00000273245.1	RP11-434P11.2	3.89	0.000114	0.00877	0.24	0.18	Metabolite levels;	chr2:73560899	chr2:73750256~73750786:-
THCA	cis	rs321358	0.945	rs10502129	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111107405	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs10502130	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111107437	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs73017109	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111108484	chr11:111089870~111090368:-
THCA	cis	rs321358	0.887	rs1470537	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111109328	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs12421769	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111109500	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs73017114	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111111582	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs17458493	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111112156	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs17458541	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111113182	chr11:111089870~111090368:-
THCA	cis	rs321358	0.836	rs17458597	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111113599	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs73017176	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111113879	chr11:111089870~111090368:-
THCA	cis	rs321358	0.887	rs80221187	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111113977	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs73017177	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111114034	chr11:111089870~111090368:-
THCA	cis	rs321358	0.895	rs73017179	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111114037	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs1356411	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111115371	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs12420595	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111115871	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs17537360	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111116921	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs17537367	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111117008	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs17458885	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111117222	chr11:111089870~111090368:-
THCA	cis	rs321358	0.945	rs7931995	ENSG00000271390.1	RP11-89C3.3	3.89	0.000114	0.00877	0.29	0.18	Body mass index;	chr11:111117691	chr11:111089870~111090368:-
THCA	cis	rs181553	0.664	rs7241593	ENSG00000266696.1	RP11-30L3.2	3.89	0.000114	0.00877	0.22	0.18	Hip circumference adjusted for BMI;	chr18:49173711	chr18:49205912~49208781:+
THCA	cis	rs12760731	0.511	rs10429849	ENSG00000213057.5	C1orf220	3.89	0.000114	0.00878	0.18	0.18	Obesity-related traits;	chr1:178642798	chr1:178542752~178548889:+
THCA	cis	rs2253762	0.54	rs12249581	ENSG00000226864.1	ATE1-AS1	3.89	0.000114	0.00878	0.28	0.18	Breast cancer;	chr10:122013486	chr10:121928312~121951965:+
THCA	cis	rs7259376	0.936	rs4932759	ENSG00000270947.1	AC025811.3	3.89	0.000115	0.00878	0.19	0.18	Menopause (age at onset);	chr19:22357303	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs12608491	ENSG00000270947.1	AC025811.3	3.89	0.000115	0.00878	0.19	0.18	Menopause (age at onset);	chr19:22358825	chr19:22455988~22456459:+
THCA	cis	rs7312933	0.737	rs10880261	ENSG00000257225.1	RP11-328C8.4	-3.89	0.000115	0.00878	-0.18	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42180020	chr12:42459366~42466128:+
THCA	cis	rs1153858	1	rs4775895	ENSG00000275672.1	GATM-AS1	-3.89	0.000115	0.00878	-0.18	-0.18	Homoarginine levels;	chr15:45325759	chr15:45378700~45380123:+
THCA	cis	rs2455799	0.613	rs11128760	ENSG00000270409.1	RP11-44D5.1	-3.89	0.000115	0.00878	-0.19	-0.18	Mean platelet volume;	chr3:15831900	chr3:15732252~15733470:+
THCA	cis	rs7577696	0.72	rs12465124	ENSG00000276334.1	AL133243.1	3.89	0.000115	0.00878	0.19	0.18	Inflammatory biomarkers;	chr2:32111610	chr2:32521927~32523547:+
THCA	cis	rs7647973	0.769	rs11130181	ENSG00000228638.1	FCF1P2	-3.89	0.000115	0.00878	-0.21	-0.18	Menarche (age at onset);	chr3:49072486	chr3:48290793~48291375:-
THCA	cis	rs2904524	1	rs17107924	ENSG00000257815.4	RP11-611E13.2	3.89	0.000115	0.00879	0.17	0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70280875	chr12:69904033~70243360:-
THCA	cis	rs2882667	0.931	rs7720150	ENSG00000249593.5	CTB-46B19.2	3.89	0.000115	0.00879	0.21	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:139012647~139051203:+
THCA	cis	rs4081724	0.638	rs61397480	ENSG00000267296.2	CEBPA-AS1	3.89	0.000115	0.00879	0.22	0.18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33355166	chr19:33302857~33305054:+
THCA	cis	rs4245128	0.93	rs2360954	ENSG00000247416.2	RP11-629G13.1	3.89	0.000115	0.00879	0.17	0.18	Life satisfaction;	chr11:112895027	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.965	rs994493	ENSG00000247416.2	RP11-629G13.1	3.89	0.000115	0.00879	0.17	0.18	Life satisfaction;	chr11:112900759	chr11:112959279~112963460:-
THCA	cis	rs453301	0.631	rs13250781	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000115	0.00879	-0.18	-0.18	Joint mobility (Beighton score);	chr8:8935833	chr8:8961200~8979025:+
THCA	cis	rs4950322	1	rs72694720	ENSG00000271721.1	RP11-337C18.9	3.89	0.000115	0.00879	0.22	0.18	Protein quantitative trait loci;	chr1:147371939	chr1:147175602~147177740:+
THCA	cis	rs448720	1	rs383168	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000115	0.00879	-0.22	-0.18	Cognitive performance;	chr15:67912656	chr15:68267792~68277994:-
THCA	cis	rs448720	1	rs388675	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000115	0.00879	-0.22	-0.18	Cognitive performance;	chr15:67913409	chr15:68267792~68277994:-
THCA	cis	rs448720	1	rs12323989	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000115	0.00879	-0.22	-0.18	Cognitive performance;	chr15:67913692	chr15:68267792~68277994:-
THCA	cis	rs448720	1	rs372644	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000115	0.00879	-0.22	-0.18	Cognitive performance;	chr15:67914240	chr15:68267792~68277994:-
THCA	cis	rs448720	1	rs449761	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000115	0.00879	-0.22	-0.18	Cognitive performance;	chr15:67918241	chr15:68267792~68277994:-
THCA	cis	rs7621025	0.586	rs12330725	ENSG00000239213.4	NCK1-AS1	-3.89	0.000115	0.00879	-0.16	-0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136693738	chr3:136841726~136862054:-
THCA	cis	rs4500972	1	rs4500972	ENSG00000273245.1	RP11-434P11.2	3.89	0.000115	0.00879	0.24	0.18	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73750256~73750786:-
THCA	cis	rs301901	0.686	rs158795	ENSG00000250155.1	CTD-2353F22.1	-3.89	0.000115	0.00879	-0.2	-0.18	Height;	chr5:36882886	chr5:36666214~36725195:-
THCA	cis	rs6442522	0.673	rs7628975	ENSG00000249786.6	EAF1-AS1	-3.89	0.000115	0.00879	-0.18	-0.18	Uric acid levels;	chr3:15460623	chr3:15436171~15455940:-
THCA	cis	rs6430538	0.621	rs6430540	ENSG00000224043.6	CCNT2-AS1	-3.89	0.000115	0.00879	-0.19	-0.18	Parkinson's disease;	chr2:134793993	chr2:134735464~134918710:-
THCA	cis	rs4730276	0.674	rs2237685	ENSG00000241764.3	AC002467.7	3.89	0.000115	0.00879	0.15	0.18	Ulcerative colitis;	chr7:107934339	chr7:107742817~107744581:-
THCA	cis	rs1560104	0.709	rs8062074	ENSG00000262801.4	U91319.1	3.89	0.000115	0.00879	0.21	0.18	Obesity-related traits;	chr16:12609691	chr16:13246316~13562918:+
THCA	cis	rs7267979	0.789	rs9927	ENSG00000274973.1	RP13-401N8.7	-3.89	0.000115	0.00879	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25845497~25845862:+
THCA	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	3.89	0.000115	0.00879	0.16	0.18	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
THCA	cis	rs12493885	0.725	rs73158447	ENSG00000243069.6	ARHGEF26-AS1	-3.89	0.000115	0.00879	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154012003	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.654	rs61793488	ENSG00000243069.6	ARHGEF26-AS1	-3.89	0.000115	0.00879	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154012762	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.725	rs61793489	ENSG00000243069.6	ARHGEF26-AS1	-3.89	0.000115	0.00879	-0.33	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154013367	chr3:154024401~154121332:-
THCA	cis	rs3736485	0.716	rs1080394	ENSG00000259709.1	CTD-2184D3.7	3.89	0.000115	0.00879	0.18	0.18	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51465424	chr15:52124561~52140246:+
THCA	cis	rs931608	0.789	rs903937	ENSG00000269138.1	ZNF209P	-3.89	0.000115	0.0088	-0.25	-0.18	Response to statins (LDL cholesterol change);Dental caries;	chr19:22427186	chr19:22463922~22473036:+
THCA	cis	rs36093844	0.626	rs10501603	ENSG00000279742.1	RP11-700A24.1	-3.89	0.000115	0.0088	-0.24	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85970873	chr11:85852557~85854943:-
THCA	cis	rs853679	0.517	rs3734573	ENSG00000219891.2	ZSCAN12P1	3.89	0.000115	0.0088	0.25	0.18	Depression;	chr6:28091659	chr6:28091154~28093664:+
THCA	cis	rs7818688	0.546	rs13250762	ENSG00000253528.2	RP11-347C18.4	-3.89	0.000115	0.0088	-0.27	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975342	chr8:94974573~94974853:-
THCA	cis	rs17689437	0.874	rs72785112	ENSG00000275383.1	RP11-615I2.6	3.89	0.000115	0.0088	0.31	0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68579398	chr16:68591382~68594424:+
THCA	cis	rs459571	1	rs467387	ENSG00000235106.7	LINC00094	3.89	0.000115	0.0088	0.16	0.18	Platelet distribution width;	chr9:134041883	chr9:134025439~134034666:+
THCA	cis	rs7178424	0.742	rs1981917	ENSG00000259251.2	RP11-643M14.1	-3.89	0.000115	0.0088	-0.18	-0.18	Height;	chr15:61879707	chr15:62060503~62062434:+
THCA	cis	rs13048019	0.744	rs10854349	ENSG00000237594.2	AP000251.3	3.89	0.000115	0.0088	0.22	0.18	Amyotrophic lateral sclerosis;	chr21:31532807	chr21:31559245~31560487:+
THCA	cis	rs337161	0.81	rs61830265	ENSG00000221571.3	RNU6ATAC35P	-3.89	0.000115	0.0088	-0.2	-0.18	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220790074	chr1:220825620~220826063:+
THCA	cis	rs2677744	0.534	rs6496739	ENSG00000214432.8	AC068831.10	-3.89	0.000115	0.0088	-0.22	-0.18	Attention deficit hyperactivity disorder;	chr15:90951200	chr15:91022619~91036611:+
THCA	cis	rs7985	1	rs5761672	ENSG00000244625.4	MIATNB	3.89	0.000115	0.0088	0.2	0.18	Electroencephalogram traits;	chr22:26673476	chr22:26672767~26780207:+
THCA	cis	rs4869313	0.642	rs1216565	ENSG00000247121.5	CTD-2260A17.2	-3.89	0.000115	0.0088	-0.13	-0.18	Pediatric autoimmune diseases;	chr5:96930175	chr5:96814028~96935809:-
THCA	cis	rs61677309	1	rs61706007	ENSG00000278376.1	RP11-158I9.8	3.89	0.000115	0.0088	0.13	0.18	Lung cancer in ever smokers;	chr11:118296563	chr11:118791254~118793137:+
THCA	cis	rs6921919	1	rs6921919	ENSG00000219392.1	RP1-265C24.5	-3.89	0.000115	0.0088	-0.23	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28115628~28116551:+
THCA	cis	rs7264396	0.887	rs224370	ENSG00000088340.14	FER1L4	3.89	0.000115	0.00881	0.16	0.18	Total cholesterol levels;	chr20:35485555	chr20:35558737~35607562:-
THCA	cis	rs1577917	0.687	rs1470531	ENSG00000220563.1	PKMP3	-3.89	0.000115	0.00881	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85797651	chr6:85659892~85660606:-
THCA	cis	rs4763879	0.739	rs2114871	ENSG00000214776.8	RP11-726G1.1	-3.89	0.000115	0.00881	-0.21	-0.18	Type 1 diabetes;	chr12:9676842	chr12:9467552~9576275:+
THCA	cis	rs860295	0.557	rs12037177	ENSG00000236675.1	MTX1P1	3.89	0.000115	0.00881	0.18	0.18	Body mass index;	chr1:155907238	chr1:155230975~155234325:+
THCA	cis	rs10984970	0.826	rs62578018	ENSG00000238181.2	AHCYP2	3.89	0.000115	0.00881	0.46	0.18	Lung cancer;	chr9:120697596	chr9:120720673~120721972:+
THCA	cis	rs17597773	0.638	rs4143773	ENSG00000238078.1	LINC01352	-3.89	0.000115	0.00881	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220814900	chr1:220829255~220832429:+
THCA	cis	rs7615952	0.673	rs35955861	ENSG00000248787.1	RP11-666A20.4	-3.89	0.000115	0.00881	-0.34	-0.18	Blood pressure (smoking interaction);	chr3:125907358	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.673	rs35001498	ENSG00000248787.1	RP11-666A20.4	-3.89	0.000115	0.00881	-0.34	-0.18	Blood pressure (smoking interaction);	chr3:125909801	chr3:125908005~125910272:-
THCA	cis	rs4245128	0.775	rs1155027	ENSG00000227487.3	NCAM1-AS1	3.89	0.000115	0.00881	0.18	0.18	Life satisfaction;	chr11:112944365	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.745	rs10789928	ENSG00000227487.3	NCAM1-AS1	3.89	0.000115	0.00881	0.18	0.18	Life satisfaction;	chr11:112945464	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.736	rs7105571	ENSG00000227487.3	NCAM1-AS1	3.89	0.000115	0.00881	0.18	0.18	Life satisfaction;	chr11:112946325	chr11:113269532~113273901:-
THCA	cis	rs57502260	0.704	rs41478448	ENSG00000212093.1	AP000807.1	3.89	0.000115	0.00881	0.23	0.18	Total body bone mineral density (age 45-60);	chr11:68414153	chr11:68506083~68506166:-
THCA	cis	rs7208859	0.673	rs216409	ENSG00000280069.1	CTD-2349P21.3	3.89	0.000115	0.00881	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30738182~30740275:+
THCA	cis	rs7616559	0.627	rs4263246	ENSG00000244515.1	KRT18P34	-3.89	0.000115	0.00881	-0.2	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157008885	chr3:157162663~157163932:-
THCA	cis	rs7615952	0.599	rs6438953	ENSG00000241288.6	RP11-379B18.5	-3.89	0.000115	0.00881	-0.19	-0.18	Blood pressure (smoking interaction);	chr3:126006108	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.599	rs1044215	ENSG00000241288.6	RP11-379B18.5	-3.89	0.000115	0.00881	-0.19	-0.18	Blood pressure (smoking interaction);	chr3:126006716	chr3:125827238~125916384:-
THCA	cis	rs757110	0.77	rs4439492	ENSG00000260196.1	RP1-239B22.5	3.89	0.000115	0.00881	0.2	0.18	Type 2 diabetes;	chr11:17365186	chr11:17380649~17383531:+
THCA	cis	rs2153535	0.518	rs2183113	ENSG00000230939.1	RP11-314C16.1	-3.89	0.000115	0.00881	-0.19	-0.18	Motion sickness;	chr6:8528305	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.539	rs4960436	ENSG00000230939.1	RP11-314C16.1	-3.89	0.000115	0.00881	-0.19	-0.18	Motion sickness;	chr6:8532237	chr6:8784178~8785445:+
THCA	cis	rs9902453	0.542	rs3809789	ENSG00000264290.1	RP11-68I3.4	3.89	0.000115	0.00881	0.13	0.18	Coffee consumption (cups per day);	chr17:29628743	chr17:29569580~29570519:+
THCA	cis	rs11601239	0.593	rs1954761	ENSG00000254750.1	CASP1P2	3.89	0.000115	0.00881	0.14	0.18	Refractive error;	chr11:105726159	chr11:105063345~105071541:-
THCA	cis	rs150992	0.632	rs34489	ENSG00000246763.5	RGMB-AS1	-3.89	0.000115	0.00881	-0.18	-0.18	Body mass index;	chr5:98977180	chr5:98769618~98773469:-
THCA	cis	rs738144	0.648	rs14040	ENSG00000235209.1	CTA-150C2.13	-3.89	0.000115	0.00881	-0.26	-0.18	IgG glycosylation;	chr22:38779262	chr22:38921227~38924708:+
THCA	cis	rs11252926	0.673	rs816620	ENSG00000276662.1	RP11-631M21.7	-3.89	0.000115	0.00882	-0.19	-0.18	Psychosis in Alzheimer's disease;	chr10:599976	chr10:147820~148751:-
THCA	cis	rs1923539	0.571	rs911887	ENSG00000244733.5	RP11-506M13.3	-3.89	0.000115	0.00882	-0.19	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79941767	chr10:79660891~79677996:+
THCA	cis	rs2290416	0.892	rs3793372	ENSG00000253931.1	RP11-909N17.2	3.89	0.000115	0.00882	0.36	0.18	Attention deficit hyperactivity disorder;	chr8:143582063	chr8:143412749~143417054:+
THCA	cis	rs4409675	0.912	rs11247730	ENSG00000227050.1	RP11-460I13.2	3.89	0.000115	0.00882	0.24	0.18	Corneal astigmatism;	chr1:27944226	chr1:27938875~27960193:-
THCA	cis	rs9788721	0.868	rs17486278	ENSG00000261762.1	RP11-650L12.2	-3.89	0.000115	0.00882	-0.22	-0.18	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78575140	chr15:78589123~78591276:-
THCA	cis	rs1125355	0.964	rs72943123	ENSG00000243792.1	OR7E89P	-3.89	0.000115	0.00882	-0.26	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158818711	chr2:158853755~158854576:+
THCA	cis	rs1125355	0.964	rs74556943	ENSG00000243792.1	OR7E89P	-3.89	0.000115	0.00882	-0.26	-0.18	Alzheimer's disease in APOE e4+ carriers;	chr2:158819211	chr2:158853755~158854576:+
THCA	cis	rs471756	0.523	rs575307	ENSG00000231808.2	LINC01388	-3.89	0.000115	0.00882	-0.2	-0.18	Mean platelet volume;	chr9:219774	chr9:112713~113754:-
THCA	cis	rs471756	0.523	rs574399	ENSG00000231808.2	LINC01388	-3.89	0.000115	0.00882	-0.2	-0.18	Mean platelet volume;	chr9:219875	chr9:112713~113754:-
THCA	cis	rs7829975	0.846	rs11779061	ENSG00000253981.4	ALG1L13P	-3.89	0.000115	0.00882	-0.17	-0.18	Mood instability;	chr8:8691922	chr8:8236003~8244667:-
THCA	cis	rs3743162	1	rs3743161	ENSG00000275120.1	RP11-182J1.17	3.89	0.000115	0.00882	0.21	0.18	Alzheimer's disease (age of onset);	chr15:84887607	chr15:84599434~84606463:-
THCA	cis	rs11671005	0.656	rs11672609	ENSG00000265272.2	RN7SL693P	3.89	0.000115	0.00882	0.26	0.18	Mean platelet volume;	chr19:58495557	chr19:58490797~58491075:+
THCA	cis	rs3015497	0.575	rs8023035	ENSG00000270062.1	RP11-248J18.3	3.89	0.000115	0.00882	0.21	0.18	Mean platelet volume;	chr14:50695701	chr14:50723777~50724272:-
THCA	cis	rs2638953	0.815	rs10843186	ENSG00000247934.4	RP11-967K21.1	-3.89	0.000115	0.00882	-0.18	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482921	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.815	rs1511551	ENSG00000247934.4	RP11-967K21.1	-3.89	0.000115	0.00882	-0.18	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483897	chr12:28163298~28190738:-
THCA	cis	rs7829975	0.846	rs1879957	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000115	0.00882	-0.17	-0.18	Mood instability;	chr8:8687298	chr8:8961200~8979025:+
THCA	cis	rs7216064	1	rs7216064	ENSG00000265055.1	AC145343.2	3.89	0.000115	0.00882	0.25	0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67902693	chr17:68096046~68101474:-
THCA	cis	rs8031584	0.651	rs28664821	ENSG00000178081.11	ULK4P3	-3.89	0.000115	0.00882	-0.22	-0.18	Huntington's disease progression;	chr15:30880120	chr15:30103720~30131757:+
THCA	cis	rs1923243	0.681	rs7516446	ENSG00000223479.3	RP4-788P17.1	-3.89	0.000115	0.00882	-0.19	-0.18	Migraine;	chr1:73001114	chr1:73635216~73715214:+
THCA	cis	rs6137726	0.613	rs1884742	ENSG00000237396.1	LINC01384	3.89	0.000115	0.00882	0.17	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22647875	chr20:22587522~22607517:-
THCA	cis	rs1961102	0.521	rs613559	ENSG00000253320.4	KB-1507C5.2	-3.89	0.000115	0.00883	-0.15	-0.18	QT interval;	chr8:102918952	chr8:102864300~102977876:+
THCA	cis	rs6449502	0.92	rs162240	ENSG00000251279.1	CTC-436P18.1	-3.89	0.000115	0.00883	-0.29	-0.18	Mean platelet volume;	chr5:61003517	chr5:61162070~61232040:+
THCA	cis	rs3096299	0.685	rs12935112	ENSG00000261118.1	RP11-104N10.1	-3.89	0.000115	0.00883	-0.15	-0.18	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89492017~89504460:-
THCA	cis	rs934734	0.532	rs7557569	ENSG00000214533.3	KRT18P33	-3.89	0.000115	0.00883	-0.22	-0.18	Rheumatoid arthritis;	chr2:65417427	chr2:65666695~65667737:+
THCA	cis	rs7918232	0.83	rs10764672	ENSG00000262412.1	RP11-85G18.6	-3.89	0.000115	0.00883	-0.26	-0.18	Breast cancer;	chr10:27103612	chr10:27243130~27250804:+
THCA	cis	rs7914558	0.966	rs10450373	ENSG00000213061.2	PFN1P11	3.89	0.000115	0.00883	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102968859	chr10:102838011~102845473:-
THCA	cis	rs8130944	1	rs10154056	ENSG00000225731.1	AP001627.1	3.89	0.000115	0.00883	0.21	0.18	Perceived unattractiveness to mosquitoes;	chr21:42717774	chr21:42733594~42741758:-
THCA	cis	rs8130944	0.897	rs4919996	ENSG00000225731.1	AP001627.1	3.89	0.000115	0.00883	0.21	0.18	Perceived unattractiveness to mosquitoes;	chr21:42717943	chr21:42733594~42741758:-
THCA	cis	rs8130944	0.808	rs4919997	ENSG00000225731.1	AP001627.1	3.89	0.000115	0.00883	0.21	0.18	Perceived unattractiveness to mosquitoes;	chr21:42718065	chr21:42733594~42741758:-
THCA	cis	rs8130944	1	rs7281614	ENSG00000225731.1	AP001627.1	3.89	0.000115	0.00883	0.21	0.18	Perceived unattractiveness to mosquitoes;	chr21:42718374	chr21:42733594~42741758:-
THCA	cis	rs8130944	0.93	rs7278005	ENSG00000225731.1	AP001627.1	3.89	0.000115	0.00883	0.21	0.18	Perceived unattractiveness to mosquitoes;	chr21:42718510	chr21:42733594~42741758:-
THCA	cis	rs8130944	0.964	rs4920135	ENSG00000225731.1	AP001627.1	3.89	0.000115	0.00883	0.21	0.18	Perceived unattractiveness to mosquitoes;	chr21:42719198	chr21:42733594~42741758:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000275400.1	RP4-756H11.5	3.89	0.000115	0.00883	0.17	0.18	Aortic root size;	chr7:66642265	chr7:66553805~66554199:-
THCA	cis	rs3755605	0.519	rs34710333	ENSG00000242578.1	RP11-469J4.3	3.89	0.000115	0.00883	0.2	0.18	Testicular germ cell tumor;	chr3:170212674	chr3:170410512~170418615:+
THCA	cis	rs911555	0.574	rs34251103	ENSG00000269958.1	RP11-73M18.8	-3.89	0.000115	0.00883	-0.17	-0.18	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103696353~103697163:+
THCA	cis	rs6142618	0.967	rs6058527	ENSG00000224452.1	RSL24D1P6	3.89	0.000115	0.00883	0.22	0.18	Inflammatory bowel disease;	chr20:32121088	chr20:32170390~32170790:-
THCA	cis	rs7264396	0.887	rs2236161	ENSG00000088340.14	FER1L4	3.89	0.000115	0.00883	0.16	0.18	Total cholesterol levels;	chr20:35513802	chr20:35558737~35607562:-
THCA	cis	rs6546886	1	rs6546886	ENSG00000235499.1	AC073046.25	3.89	0.000115	0.00883	0.17	0.18	Dialysis-related mortality;	chr2:74018650	chr2:73985132~73986343:+
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000237310.1	GS1-124K5.4	3.89	0.000115	0.00883	0.21	0.18	Gout;	chr7:66732812	chr7:66493706~66495474:+
THCA	cis	rs2562456	0.755	rs2914646	ENSG00000268278.1	RP11-420K14.1	-3.89	0.000115	0.00884	-0.22	-0.18	Pain;	chr19:21454359	chr19:21637974~21656300:+
THCA	cis	rs7551222	0.752	rs4252685	ENSG00000240219.1	RP11-430C7.5	3.89	0.000115	0.00884	0.16	0.18	Schizophrenia;	chr1:204527728	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.681	rs4252686	ENSG00000240219.1	RP11-430C7.5	3.89	0.000115	0.00884	0.16	0.18	Schizophrenia;	chr1:204527767	chr1:204626775~204629712:+
THCA	cis	rs2341260	0.573	rs11210306	ENSG00000223479.3	RP4-788P17.1	-3.89	0.000115	0.00884	-0.23	-0.18	Cardiac Troponin-T levels;	chr1:73610845	chr1:73635216~73715214:+
THCA	cis	rs1113500	0.636	rs3853493	ENSG00000230489.1	VAV3-AS1	-3.89	0.000115	0.00884	-0.16	-0.18	Growth-regulated protein alpha levels;	chr1:108094571	chr1:107964443~107994607:+
THCA	cis	rs10496034	0.542	rs72797538	ENSG00000162997.14	PRORSD1P	3.89	0.000115	0.00884	0.29	0.18	Refractive astigmatism;	chr2:55150974	chr2:55282319~55284522:+
THCA	cis	rs1635	0.826	rs115041649	ENSG00000216901.1	AL022393.7	3.89	0.000115	0.00884	0.4	0.18	Schizophrenia;	chr6:28306876	chr6:28176188~28176674:+
THCA	cis	rs7819412	0.538	rs4523214	ENSG00000206014.6	OR7E161P	3.89	0.000115	0.00884	0.21	0.18	Triglycerides;	chr8:11113263	chr8:11928597~11929563:-
THCA	cis	rs7131987	0.565	rs6487792	ENSG00000257176.2	RP11-996F15.2	3.89	0.000115	0.00884	0.17	0.18	QT interval;	chr12:29259743	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.585	rs2194517	ENSG00000257176.2	RP11-996F15.2	3.89	0.000115	0.00884	0.17	0.18	QT interval;	chr12:29260002	chr12:29280418~29317848:-
THCA	cis	rs78487399	0.908	rs11889803	ENSG00000234936.1	AC010883.5	3.89	0.000115	0.00884	0.22	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43622892	chr2:43229573~43233394:+
THCA	cis	rs495337	0.76	rs6067282	ENSG00000229222.1	KRT18P4	-3.89	0.000115	0.00884	-0.22	-0.18	Psoriasis;	chr20:49952741	chr20:49956745~49958032:+
THCA	cis	rs7809799	0.571	rs67934834	ENSG00000244219.5	GS1-259H13.2	-3.89	0.000115	0.00884	-0.39	-0.18	Ulcerative colitis;	chr7:99301841	chr7:99598066~99610813:+
THCA	cis	rs11190604	1	rs3750720	ENSG00000273030.1	RP11-285F16.1	3.89	0.000115	0.00885	0.21	0.18	Palmitoleic acid (16:1n-7) levels;	chr10:100489127	chr10:100412934~100413421:+
THCA	cis	rs71537559	1	rs71537559	ENSG00000220721.1	OR1F12	3.89	0.000116	0.00885	0.36	0.18	Squamous cell lung carcinoma;	chr6:27342000	chr6:28073316~28074233:+
THCA	cis	rs7824557	0.583	rs4448232	ENSG00000154316.13	TDH	-3.89	0.000116	0.00885	-0.13	-0.18	Retinal vascular caliber;	chr8:11373845	chr8:11339637~11368452:+
THCA	cis	rs4698048	0.51	rs12509714	ENSG00000261490.1	RP11-448G15.3	3.89	0.000116	0.00885	0.11	0.18	Skin aging (microtopography measurement);	chr4:10105467	chr4:10068089~10073019:-
THCA	cis	rs7737355	0.947	rs7725220	ENSG00000237714.1	P4HA2-AS1	3.89	0.000116	0.00885	0.25	0.18	Life satisfaction;	chr5:131541308	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs6596027	ENSG00000237714.1	P4HA2-AS1	3.89	0.000116	0.00885	0.25	0.18	Life satisfaction;	chr5:131543854	chr5:132184876~132192808:+
THCA	cis	rs6756513	0.5	rs56168154	ENSG00000231024.1	AC092431.3	-3.89	0.000116	0.00885	-0.26	-0.18	Breast cancer;Platelet count;	chr2:69863781	chr2:69700192~69713847:-
THCA	cis	rs2235642	0.893	rs2076445	ENSG00000260989.1	LA16c-395F10.2	-3.89	0.000116	0.00885	-0.18	-0.18	Coronary artery disease;	chr16:1542265	chr16:1580527~1610328:+
THCA	cis	rs9558942	0.564	rs12585896	ENSG00000277863.1	RP11-282A11.4	-3.89	0.000116	0.00885	-0.22	-0.18	Obesity-related traits;	chr13:107070981	chr13:106903150~106904099:-
THCA	cis	rs7973719	0.509	rs7969751	ENSG00000205885.6	C1RL-AS1	-3.89	0.000116	0.00885	-0.14	-0.18	IgG glycosylation;	chr12:7218106	chr12:7108052~7122501:+
THCA	cis	rs9650657	0.812	rs7834466	ENSG00000255310.2	AF131215.2	-3.89	0.000116	0.00885	-0.15	-0.18	Neuroticism;	chr8:10777295	chr8:11107788~11109726:-
THCA	cis	rs7552393	0.965	rs2389652	ENSG00000233008.4	RP11-475O6.1	-3.89	0.000116	0.00885	-0.19	-0.18	Select biomarker traits;	chr1:83785751	chr1:83575776~83861023:-
THCA	cis	rs250585	0.736	rs727238	ENSG00000260136.4	CTD-2270L9.4	-3.89	0.000116	0.00885	-0.14	-0.18	Egg allergy;	chr16:23509745	chr16:23452758~23457606:+
THCA	cis	rs42648	0.596	rs194518	ENSG00000225498.1	AC002064.5	3.89	0.000116	0.00885	0.19	0.18	Homocysteine levels;	chr7:90223835	chr7:90312496~90322592:+
THCA	cis	rs1204798	0.588	rs9488873	ENSG00000237021.2	RP3-486I3.7	-3.89	0.000116	0.00885	-0.21	-0.18	Dental caries;	chr6:116226077	chr6:116254207~116256743:+
THCA	cis	rs11601239	0.63	rs1938957	ENSG00000254750.1	CASP1P2	3.89	0.000116	0.00885	0.14	0.18	Refractive error;	chr11:105769742	chr11:105063345~105071541:-
THCA	cis	rs448720	0.967	rs338357	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000116	0.00886	-0.22	-0.18	Cognitive performance;	chr15:67902334	chr15:68267792~68277994:-
THCA	cis	rs7267979	1	rs1888999	ENSG00000276952.1	RP5-965G21.6	3.89	0.000116	0.00886	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25284915~25285588:-
THCA	cis	rs4788570	0.615	rs889568	ENSG00000260185.1	RP11-432I5.6	-3.89	0.000116	0.00886	-0.33	-0.18	Intelligence (multi-trait analysis);	chr16:71738496	chr16:71655027~71664212:+
THCA	cis	rs4713118	0.506	rs9366697	ENSG00000220721.1	OR1F12	3.89	0.000116	0.00886	0.2	0.18	Parkinson's disease;	chr6:27665239	chr6:28073316~28074233:+
THCA	cis	rs875971	0.83	rs427575	ENSG00000229886.1	RP5-1132H15.3	3.89	0.000116	0.00886	0.19	0.18	Aortic root size;	chr7:66054232	chr7:66025126~66031544:-
THCA	cis	rs589448	0.867	rs623853	ENSG00000274979.1	RP11-1143G9.5	-3.89	0.000116	0.00886	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69360050	chr12:69326574~69331882:-
THCA	cis	rs589448	0.934	rs554591	ENSG00000274979.1	RP11-1143G9.5	-3.89	0.000116	0.00886	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69360067	chr12:69326574~69331882:-
THCA	cis	rs9595908	0.709	rs7318563	ENSG00000212293.1	SNORA16	3.89	0.000116	0.00886	0.21	0.18	Body mass index;	chr13:32749348	chr13:32420390~32420516:-
THCA	cis	rs4713118	0.868	rs7756968	ENSG00000261839.1	RP1-265C24.8	3.89	0.000116	0.00886	0.21	0.18	Parkinson's disease;	chr6:27767175	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.826	rs2893929	ENSG00000261839.1	RP1-265C24.8	3.89	0.000116	0.00886	0.21	0.18	Parkinson's disease;	chr6:27770953	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.666	rs4140646	ENSG00000261839.1	RP1-265C24.8	3.89	0.000116	0.00886	0.21	0.18	Parkinson's disease;	chr6:27771022	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.666	rs2893930	ENSG00000261839.1	RP1-265C24.8	3.89	0.000116	0.00886	0.21	0.18	Parkinson's disease;	chr6:27771027	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.868	rs742047	ENSG00000261839.1	RP1-265C24.8	3.89	0.000116	0.00886	0.21	0.18	Parkinson's disease;	chr6:27771601	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.868	rs760587	ENSG00000261839.1	RP1-265C24.8	3.89	0.000116	0.00886	0.21	0.18	Parkinson's disease;	chr6:27772521	chr6:28136849~28139678:+
THCA	cis	rs3105593	0.933	rs3098202	ENSG00000242737.1	RP11-562A8.1	3.89	0.000116	0.00886	0.22	0.18	QT interval;	chr15:50546039	chr15:50466738~50467096:+
THCA	cis	rs9788721	1	rs55781567	ENSG00000261762.1	RP11-650L12.2	-3.89	0.000116	0.00886	-0.24	-0.18	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78565644	chr15:78589123~78591276:-
THCA	cis	rs10792320	0.565	rs77709427	ENSG00000279491.1	RP11-810P12.7	-3.89	0.000116	0.00886	-0.22	-0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61968663	chr11:61967794~61969490:+
THCA	cis	rs12476592	0.602	rs10865337	ENSG00000242412.1	DBIL5P2	3.89	0.000116	0.00886	0.23	0.18	Childhood ear infection;	chr2:63493772	chr2:63117851~63119542:-
THCA	cis	rs1371614	0.592	rs12613534	ENSG00000272148.1	RP11-195B17.1	-3.89	0.000116	0.00886	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26915726	chr2:27062428~27062907:-
THCA	cis	rs17286411	0.641	rs28582831	ENSG00000260185.1	RP11-432I5.6	-3.89	0.000116	0.00886	-0.24	-0.18	Blood protein levels;	chr16:71692838	chr16:71655027~71664212:+
THCA	cis	rs589448	0.967	rs634512	ENSG00000274979.1	RP11-1143G9.5	-3.89	0.000116	0.00886	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69360232	chr12:69326574~69331882:-
THCA	cis	rs7200543	1	rs4985154	ENSG00000188599.16	NPIPP1	-3.89	0.000116	0.00886	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:15104312~15123498:-
THCA	cis	rs7200543	1	rs34614532	ENSG00000188599.16	NPIPP1	-3.89	0.000116	0.00886	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:15104312~15123498:-
THCA	cis	rs16975963	0.843	rs7254809	ENSG00000226686.6	LINC01535	-3.89	0.000116	0.00886	-0.23	-0.18	Longevity;	chr19:37875055	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.843	rs11672163	ENSG00000226686.6	LINC01535	-3.89	0.000116	0.00886	-0.23	-0.18	Longevity;	chr19:37883216	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.843	rs73027451	ENSG00000226686.6	LINC01535	-3.89	0.000116	0.00886	-0.23	-0.18	Longevity;	chr19:37885026	chr19:37251912~37265535:+
THCA	cis	rs448720	1	rs12441572	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000116	0.00886	-0.22	-0.18	Cognitive performance;	chr15:67898921	chr15:68267792~68277994:-
THCA	cis	rs448720	1	rs338352	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000116	0.00886	-0.22	-0.18	Cognitive performance;	chr15:67900931	chr15:68267792~68277994:-
THCA	cis	rs448720	1	rs338354	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000116	0.00886	-0.22	-0.18	Cognitive performance;	chr15:67901279	chr15:68267792~68277994:-
THCA	cis	rs7632954	0.605	rs6790631	ENSG00000227110.5	LMCD1-AS1	3.89	0.000116	0.00886	0.22	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8479919	chr3:7952805~8611924:-
THCA	cis	rs9595908	0.669	rs2032508	ENSG00000212293.1	SNORA16	3.89	0.000116	0.00887	0.21	0.18	Body mass index;	chr13:32779332	chr13:32420390~32420516:-
THCA	cis	rs804280	0.509	rs35626932	ENSG00000206014.6	OR7E161P	-3.89	0.000116	0.00887	-0.21	-0.18	Myopia (pathological);	chr8:11929423	chr8:11928597~11929563:-
THCA	cis	rs2299587	0.554	rs3739404	ENSG00000253671.1	RP11-806O11.1	-3.89	0.000116	0.00887	-0.2	-0.18	Economic and political preferences;	chr8:17882334	chr8:17808941~17820868:+
THCA	cis	rs308403	0.509	rs10016979	ENSG00000224786.1	CETN4P	3.89	0.000116	0.00887	0.18	0.18	Blood protein levels;	chr4:122752037	chr4:122730548~122732193:-
THCA	cis	rs1520333	0.574	rs12681308	ENSG00000254352.1	RP11-578O24.2	-3.89	0.000116	0.00887	-0.2	-0.18	Multiple sclerosis;	chr8:78492658	chr8:78723796~78724136:-
THCA	cis	rs1850744	0.609	rs6448959	ENSG00000163612.10	FAM86KP	-3.89	0.000116	0.00887	-0.39	-0.18	Economic and political preferences;	chr4:9682303	chr4:9153296~9165451:+
THCA	cis	rs7924176	0.521	rs11000999	ENSG00000232342.6	RP11-46O21.2	3.89	0.000116	0.00887	0.22	0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:74506081~74530553:-
THCA	cis	rs795484	0.633	rs904662	ENSG00000275759.1	RP11-131L12.3	-3.89	0.000116	0.00887	-0.17	-0.18	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118144028	chr12:118428281~118428870:+
THCA	cis	rs9425766	0.886	rs9661233	ENSG00000270084.1	GAS5-AS1	-3.89	0.000116	0.00887	-0.18	-0.18	Life satisfaction;	chr1:173874913	chr1:173863248~173863941:+
THCA	cis	rs17685	0.712	rs10271413	ENSG00000227038.2	AC005077.12	3.89	0.000116	0.00887	0.18	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76125540	chr7:76090431~76108779:-
THCA	cis	rs4723738	1	rs4723733	ENSG00000227191.5	TRGC2	3.89	0.000116	0.00887	0.13	0.18	Treatment response for severe sepsis;	chr7:38184011	chr7:38239580~38368091:-
THCA	cis	rs613391	0.712	rs523296	ENSG00000234840.1	LINC01239	-3.89	0.000116	0.00887	-0.21	-0.18	Quantitative traits;	chr9:22688211	chr9:22646200~22824213:+
THCA	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	3.89	0.000116	0.00887	0.16	0.18	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
THCA	cis	rs17666538	0.585	rs1669615	ENSG00000254207.1	RP11-43A14.1	3.89	0.000116	0.00887	0.34	0.18	IgG glycosylation;	chr8:666665	chr8:725188~725877:-
THCA	cis	rs17666538	0.535	rs896522	ENSG00000254207.1	RP11-43A14.1	3.89	0.000116	0.00887	0.34	0.18	IgG glycosylation;	chr8:666991	chr8:725188~725877:-
THCA	cis	rs17666538	0.535	rs1669613	ENSG00000254207.1	RP11-43A14.1	3.89	0.000116	0.00887	0.34	0.18	IgG glycosylation;	chr8:667565	chr8:725188~725877:-
THCA	cis	rs17666538	0.585	rs1037393	ENSG00000254207.1	RP11-43A14.1	3.89	0.000116	0.00887	0.34	0.18	IgG glycosylation;	chr8:672634	chr8:725188~725877:-
THCA	cis	rs17666538	0.585	rs6559064	ENSG00000254207.1	RP11-43A14.1	3.89	0.000116	0.00887	0.34	0.18	IgG glycosylation;	chr8:673061	chr8:725188~725877:-
THCA	cis	rs17666538	0.585	rs6559065	ENSG00000254207.1	RP11-43A14.1	3.89	0.000116	0.00887	0.34	0.18	IgG glycosylation;	chr8:673156	chr8:725188~725877:-
THCA	cis	rs4908768	0.859	rs4908770	ENSG00000232912.4	RP5-1115A15.1	-3.89	0.000116	0.00888	-0.21	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8651313	chr1:8424645~8434838:+
THCA	cis	rs478304	0.654	rs10896035	ENSG00000255557.1	RP11-770G2.2	3.89	0.000116	0.00888	0.21	0.18	Acne (severe);	chr11:65693689	chr11:65745729~65771585:+
THCA	cis	rs875971	0.545	rs2707851	ENSG00000232559.3	GS1-124K5.12	-3.89	0.000116	0.00888	-0.19	-0.18	Aortic root size;	chr7:66624178	chr7:66554588~66576923:-
THCA	cis	rs36093844	0.527	rs17817588	ENSG00000279742.1	RP11-700A24.1	-3.89	0.000116	0.00888	-0.23	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85965788	chr11:85852557~85854943:-
THCA	cis	rs11105298	0.891	rs4842661	ENSG00000266347.2	AC068641.1	3.89	0.000116	0.00888	0.23	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89592833~89592927:+
THCA	cis	rs4460629	0.68	rs10796938	ENSG00000225855.5	RUSC1-AS1	3.89	0.000116	0.00888	0.12	0.18	Serum magnesium levels;	chr1:155099579	chr1:155316863~155324176:-
THCA	cis	rs6430585	0.591	rs4585083	ENSG00000231890.6	DARS-AS1	-3.89	0.000116	0.00888	-0.21	-0.18	Corneal structure;	chr2:135728772	chr2:135985176~136022593:+
THCA	cis	rs61677309	1	rs61677309	ENSG00000278376.1	RP11-158I9.8	3.89	0.000116	0.00888	0.14	0.18	Lung cancer in ever smokers;	chr11:118297371	chr11:118791254~118793137:+
THCA	cis	rs9309473	0.948	rs7566385	ENSG00000273245.1	RP11-434P11.2	3.89	0.000116	0.00888	0.24	0.18	Metabolite levels;	chr2:73529690	chr2:73750256~73750786:-
THCA	cis	rs9926296	0.581	rs2108838	ENSG00000274627.1	RP11-104N10.2	-3.89	0.000116	0.00888	-0.18	-0.18	Vitiligo;	chr16:89838018	chr16:89516797~89522217:+
THCA	cis	rs4713118	0.868	rs7756968	ENSG00000272009.1	RP1-313I6.12	-3.89	0.000116	0.00888	-0.21	-0.18	Parkinson's disease;	chr6:27767175	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.826	rs2893929	ENSG00000272009.1	RP1-313I6.12	-3.89	0.000116	0.00888	-0.21	-0.18	Parkinson's disease;	chr6:27770953	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.666	rs4140646	ENSG00000272009.1	RP1-313I6.12	-3.89	0.000116	0.00888	-0.21	-0.18	Parkinson's disease;	chr6:27771022	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.666	rs2893930	ENSG00000272009.1	RP1-313I6.12	-3.89	0.000116	0.00888	-0.21	-0.18	Parkinson's disease;	chr6:27771027	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.868	rs742047	ENSG00000272009.1	RP1-313I6.12	-3.89	0.000116	0.00888	-0.21	-0.18	Parkinson's disease;	chr6:27771601	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.868	rs760587	ENSG00000272009.1	RP1-313I6.12	-3.89	0.000116	0.00888	-0.21	-0.18	Parkinson's disease;	chr6:27772521	chr6:28078792~28081130:-
THCA	cis	rs2649	0.542	rs8023506	ENSG00000259459.4	RP11-321G12.1	-3.89	0.000116	0.00888	-0.15	-0.18	Aortic root size;	chr15:63592263	chr15:63390136~63438320:+
THCA	cis	rs17221829	0.699	rs7118152	ENSG00000280385.1	AP000648.5	-3.89	0.000116	0.00888	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89650486	chr11:90193614~90198120:+
THCA	cis	rs1383484	1	rs4465575	ENSG00000259728.4	LINC00933	-3.89	0.000116	0.00889	-0.22	-0.18	Height;	chr15:83844160	chr15:84570649~84580175:+
THCA	cis	rs214785	1	rs214755	ENSG00000226644.4	RP11-128M1.1	3.89	0.000116	0.00889	0.18	0.18	Basal cell carcinoma;	chr20:2293341	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214756	ENSG00000226644.4	RP11-128M1.1	3.89	0.000116	0.00889	0.18	0.18	Basal cell carcinoma;	chr20:2293735	chr20:2207217~2213151:+
THCA	cis	rs927821	0.941	rs12776002	ENSG00000203886.4	CYP17A1-AS1	3.89	0.000116	0.00889	0.23	0.18	Social autistic-like traits;	chr10:102439867	chr10:102832721~102834516:+
THCA	cis	rs13034020	0.947	rs35742507	ENSG00000271889.1	RP11-493E12.1	-3.89	0.000116	0.00889	-0.25	-0.18	Hodgkin's lymphoma;	chr2:60829509	chr2:61151433~61162105:-
THCA	cis	rs34975555	0.892	rs6586673	ENSG00000253671.1	RP11-806O11.1	-3.89	0.000116	0.00889	-0.28	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17946157	chr8:17808941~17820868:+
THCA	cis	rs2882667	0.931	rs1433009	ENSG00000249593.5	CTB-46B19.2	3.89	0.000116	0.00889	0.21	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:139012647~139051203:+
THCA	cis	rs4788570	0.584	rs7204608	ENSG00000260593.1	RP11-432I5.2	3.89	0.000116	0.00889	0.27	0.18	Intelligence (multi-trait analysis);	chr16:71644776	chr16:71623708~71626816:-
THCA	cis	rs1501911	0.53	rs751878	ENSG00000246763.5	RGMB-AS1	3.89	0.000116	0.00889	0.19	0.18	Lung function (FEV1/FVC);	chr5:98827240	chr5:98769618~98773469:-
THCA	cis	rs1501911	0.53	rs331926	ENSG00000246763.5	RGMB-AS1	3.89	0.000116	0.00889	0.19	0.18	Lung function (FEV1/FVC);	chr5:98828697	chr5:98769618~98773469:-
THCA	cis	rs8033133	0.56	rs1549478	ENSG00000251896.1	SNORD116-27	-3.89	0.000116	0.00889	-0.2	-0.18	Blood osmolality (transformed sodium);	chr15:25087053	chr15:25101575~25101666:+
THCA	cis	rs8177876	0.822	rs7206814	ENSG00000261838.4	RP11-303E16.6	-3.89	0.000116	0.00889	-0.28	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81069854~81076598:+
THCA	cis	rs2806561	0.765	rs643492	ENSG00000249087.5	ZNF436-AS1	3.89	0.000116	0.00889	0.11	0.18	Height;	chr1:23174861	chr1:23368997~23371839:+
THCA	cis	rs1635	0.826	rs4711167	ENSG00000216901.1	AL022393.7	-3.89	0.000116	0.0089	-0.39	-0.18	Schizophrenia;	chr6:28327111	chr6:28176188~28176674:+
THCA	cis	rs12612619	0.732	rs11688708	ENSG00000272148.1	RP11-195B17.1	3.89	0.000116	0.0089	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976740	chr2:27062428~27062907:-
THCA	cis	rs7359257	0.576	rs9652480	ENSG00000260657.2	RP11-315D16.4	3.89	0.000116	0.0089	0.24	0.18	Menarche (age at onset);	chr15:67554979	chr15:68267792~68277994:-
THCA	cis	rs1124609	1	rs78284414	ENSG00000244879.4	GABPB1-AS1	3.89	0.000116	0.0089	0.27	0.18	Subjective well-being;	chr15:50178205	chr15:50354959~50372202:+
THCA	cis	rs12234571	1	rs61100223	ENSG00000214293.7	APTR	3.89	0.000116	0.0089	0.22	0.18	Obesity-related traits;	chr7:77808959	chr7:77657660~77696265:-
THCA	cis	rs893363	0.61	rs920252	ENSG00000271916.1	RP11-884K10.6	-3.89	0.000116	0.0089	-0.21	-0.18	Axial length;	chr3:53814645	chr3:53797764~53798019:-
THCA	cis	rs4144027	1	rs4144027	ENSG00000269958.1	RP11-73M18.8	3.89	0.000116	0.0089	0.17	0.18	Blood metabolite levels;	chr14:103891301	chr14:103696353~103697163:+
THCA	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-3.89	0.000116	0.0089	-0.21	-0.18	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
THCA	cis	rs1009077	0.627	rs6847164	ENSG00000260091.1	RP11-33B1.4	-3.89	0.000116	0.0089	-0.16	-0.18	Endometriosis;	chr4:119613579	chr4:119409333~119410233:+
THCA	cis	rs7819412	0.505	rs17782554	ENSG00000261451.1	RP11-981G7.1	-3.89	0.000116	0.0089	-0.23	-0.18	Triglycerides;	chr8:11164596	chr8:10433672~10438312:+
THCA	cis	rs7259376	0.902	rs11669179	ENSG00000269138.1	ZNF209P	-3.89	0.000116	0.0089	-0.18	-0.18	Menopause (age at onset);	chr19:22421927	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.902	rs11669270	ENSG00000269138.1	ZNF209P	-3.89	0.000116	0.0089	-0.18	-0.18	Menopause (age at onset);	chr19:22422014	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.902	rs11669353	ENSG00000269138.1	ZNF209P	-3.89	0.000116	0.0089	-0.18	-0.18	Menopause (age at onset);	chr19:22422301	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.902	rs11879678	ENSG00000269138.1	ZNF209P	-3.89	0.000116	0.0089	-0.18	-0.18	Menopause (age at onset);	chr19:22424510	chr19:22463922~22473036:+
THCA	cis	rs10129255	0.957	rs12590735	ENSG00000280411.1	IGHV1-69-2	-3.89	0.000116	0.0089	-0.11	-0.18	Kawasaki disease;	chr14:106779660	chr14:106762092~106762588:-
THCA	cis	rs656319	0.513	rs34990153	ENSG00000261451.1	RP11-981G7.1	-3.89	0.000116	0.0089	-0.22	-0.18	Myopia (pathological);	chr8:10138879	chr8:10433672~10438312:+
THCA	cis	rs964611	0.882	rs4775746	ENSG00000259488.2	RP11-154J22.1	3.89	0.000116	0.00891	0.17	0.18	Metabolite levels (Pyroglutamine);	chr15:48346050	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs4775748	ENSG00000259488.2	RP11-154J22.1	3.89	0.000116	0.00891	0.17	0.18	Metabolite levels (Pyroglutamine);	chr15:48346598	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs12917438	ENSG00000259488.2	RP11-154J22.1	3.89	0.000116	0.00891	0.17	0.18	Metabolite levels (Pyroglutamine);	chr15:48347540	chr15:48312353~48331856:-
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000184274.3	LINC00315	-3.89	0.000116	0.00891	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45300245~45305257:-
THCA	cis	rs7176527	0.796	rs1057946	ENSG00000229212.6	RP11-561C5.4	3.89	0.000116	0.00891	0.31	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85205440~85234795:-
THCA	cis	rs2640806	0.505	rs11997560	ENSG00000253105.4	KB-1448A5.1	-3.89	0.000116	0.00891	-0.21	-0.18	Obesity-related traits;	chr8:96353778	chr8:96371865~96387438:-
THCA	cis	rs2898290	0.592	rs2736342	ENSG00000251402.3	FAM90A25P	-3.89	0.000116	0.00891	-0.22	-0.18	Systolic blood pressure;	chr8:11489780	chr8:12415080~12418090:-
THCA	cis	rs7520050	1	rs12410070	ENSG00000281133.1	AL355480.3	3.89	0.000116	0.00891	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs12410071	ENSG00000281133.1	AL355480.3	3.89	0.000116	0.00891	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45580892~45580996:-
THCA	cis	rs7829975	0.807	rs519019	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000116	0.00891	-0.17	-0.18	Mood instability;	chr8:8737594	chr8:8961200~8979025:+
THCA	cis	rs5769765	1	rs2295408	ENSG00000260613.1	RP3-522J7.6	3.89	0.000116	0.00891	0.23	0.18	Schizophrenia;	chr22:49867403	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs2295409	ENSG00000260613.1	RP3-522J7.6	3.89	0.000116	0.00891	0.23	0.18	Schizophrenia;	chr22:49867412	chr22:49832616~49837786:-
THCA	cis	rs11069062	0.826	rs10774988	ENSG00000270482.1	RP11-131L12.2	3.89	0.000116	0.00891	0.14	0.18	Obesity-related traits;	chr12:118718042	chr12:118375350~118376275:-
THCA	cis	rs13113518	0.812	rs2412648	ENSG00000223305.1	RN7SKP30	3.89	0.000116	0.00891	0.23	0.18	Height;	chr4:55454900	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs12512737	ENSG00000223305.1	RN7SKP30	3.89	0.000116	0.00891	0.23	0.18	Height;	chr4:55454938	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs13125984	ENSG00000223305.1	RN7SKP30	3.89	0.000116	0.00891	0.23	0.18	Height;	chr4:55455102	chr4:55540502~55540835:-
THCA	cis	rs9840812	0.656	rs4678437	ENSG00000239213.4	NCK1-AS1	3.89	0.000116	0.00891	0.16	0.18	Fibrinogen levels;	chr3:136598823	chr3:136841726~136862054:-
THCA	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	3.89	0.000116	0.00891	0.16	0.18	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
THCA	cis	rs6504108	1	rs6504108	ENSG00000264920.1	RP11-6N17.4	-3.89	0.000117	0.00891	-0.16	-0.18	Body mass index;	chr17:48215561	chr17:47891255~47895812:-
THCA	cis	rs6788895	0.661	rs73010956	ENSG00000244265.1	SIAH2-AS1	3.89	0.000117	0.00891	0.39	0.18	Breast cancer;	chr3:150774937	chr3:150761937~150762538:+
THCA	cis	rs6788895	0.661	rs60259684	ENSG00000244265.1	SIAH2-AS1	3.89	0.000117	0.00891	0.39	0.18	Breast cancer;	chr3:150777164	chr3:150761937~150762538:+
THCA	cis	rs3824488	0.79	rs28520225	ENSG00000271155.1	RP11-435O5.5	-3.89	0.000117	0.00891	-0.27	-0.18	Neuroticism;	chr9:95480905	chr9:95506235~95507636:+
THCA	cis	rs10435719	0.902	rs6601633	ENSG00000255495.1	AC145124.2	-3.89	0.000117	0.00891	-0.21	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:12194467~12196280:+
THCA	cis	rs9309473	1	rs11901272	ENSG00000273245.1	RP11-434P11.2	3.89	0.000117	0.00892	0.24	0.18	Metabolite levels;	chr2:73493317	chr2:73750256~73750786:-
THCA	cis	rs9905704	0.846	rs302878	ENSG00000224738.1	AC099850.1	3.89	0.000117	0.00892	0.23	0.18	Testicular germ cell tumor;	chr17:58685603	chr17:59106598~59118267:+
THCA	cis	rs1362756	1	rs1420993	ENSG00000260057.4	LINC01571	-3.89	0.000117	0.00892	-0.19	-0.18	Optic disc parameters;Optic disc area;	chr16:51430987	chr16:51762519~51773173:+
THCA	cis	rs1046896	0.562	rs9912684	ENSG00000263063.1	RP11-388C12.1	-3.89	0.000117	0.00892	-0.23	-0.18	Glycated hemoglobin levels;	chr17:82915191	chr17:82713908~82716255:-
THCA	cis	rs2695743	0.592	rs1438060	ENSG00000222043.2	AC079305.10	3.89	0.000117	0.00892	0.16	0.18	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177819246	chr2:177264359~177265515:+
THCA	cis	rs72996113	0.702	rs11224351	ENSG00000248027.1	CTD-2383M3.1	-3.89	0.000117	0.00892	-0.31	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100643299	chr11:100684162~100687955:-
THCA	cis	rs12126655	0.961	rs12128738	ENSG00000230489.1	VAV3-AS1	3.89	0.000117	0.00892	0.18	0.18	Plasma thyroid-stimulating hormone levels;	chr1:107816192	chr1:107964443~107994607:+
THCA	cis	rs7665090	0.87	rs228615	ENSG00000230069.3	LRRC37A15P	3.89	0.000117	0.00892	0.18	0.18	Primary biliary cholangitis;	chr4:102658303	chr4:102727274~102730721:-
THCA	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	3.89	0.000117	0.00892	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	3.89	0.000117	0.00892	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	3.89	0.000117	0.00892	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	3.89	0.000117	0.00892	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	3.89	0.000117	0.00892	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	3.89	0.000117	0.00892	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	3.89	0.000117	0.00892	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
THCA	cis	rs1204798	0.636	rs62414128	ENSG00000237021.2	RP3-486I3.7	-3.89	0.000117	0.00892	-0.22	-0.18	Dental caries;	chr6:116143069	chr6:116254207~116256743:+
THCA	cis	rs7182948	1	rs8040716	ENSG00000259531.2	RP11-295H24.3	3.89	0.000117	0.00892	0.23	0.18	Lung adenocarcinoma;	chr15:49482228	chr15:49365124~49366685:-
THCA	cis	rs4950322	0.512	rs4625342	ENSG00000226015.2	CCT8P1	-3.89	0.000117	0.00893	-0.18	-0.18	Protein quantitative trait loci;	chr1:147369887	chr1:147203276~147204932:-
THCA	cis	rs9863	0.804	rs80270210	ENSG00000270028.1	RP11-380L11.4	3.89	0.000117	0.00893	0.19	0.18	White blood cell count;	chr12:123962850	chr12:123925461~123926083:-
THCA	cis	rs853679	0.585	rs201004	ENSG00000220721.1	OR1F12	3.89	0.000117	0.00893	0.25	0.18	Depression;	chr6:27837156	chr6:28073316~28074233:+
THCA	cis	rs11719291	0.833	rs73080361	ENSG00000229759.1	MRPS18AP1	-3.89	0.000117	0.00893	-0.4	-0.18	Cognitive function;	chr3:48794713	chr3:48256350~48256938:-
THCA	cis	rs10875746	0.729	rs1990028	ENSG00000258273.1	RP11-370I10.4	3.89	0.000117	0.00893	0.25	0.18	Longevity (90 years and older);	chr12:48014230	chr12:48333755~48333901:-
THCA	cis	rs1913185	0.787	rs58874363	ENSG00000261051.1	RP11-274H2.5	-3.89	0.000117	0.00893	-0.24	-0.18	Obesity-related traits;	chr3:146126725	chr3:146059585~146061679:-
THCA	cis	rs7208859	0.562	rs216408	ENSG00000280069.1	CTD-2349P21.3	3.89	0.000117	0.00893	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30738182~30740275:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000230189.5	GS1-124K5.2	3.89	0.000117	0.00893	0.11	0.18	Aortic root size;	chr7:66473171	chr7:66409143~66490059:-
THCA	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-3.89	0.000117	0.00893	-0.2	-0.18	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
THCA	cis	rs17221829	0.699	rs7129641	ENSG00000280385.1	AP000648.5	-3.89	0.000117	0.00893	-0.18	-0.18	Anxiety in major depressive disorder;	chr11:89650538	chr11:90193614~90198120:+
THCA	cis	rs73173548	0.502	rs13180798	ENSG00000247828.6	TMEM161B-AS1	3.89	0.000117	0.00893	0.16	0.18	Macular telangiectasia type 2;	chr5:88425633	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs13163266	ENSG00000247828.6	TMEM161B-AS1	3.89	0.000117	0.00893	0.16	0.18	Macular telangiectasia type 2;	chr5:88425703	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs13180932	ENSG00000247828.6	TMEM161B-AS1	3.89	0.000117	0.00893	0.16	0.18	Macular telangiectasia type 2;	chr5:88425720	chr5:88268895~88436685:+
THCA	cis	rs4660214	0.724	rs11205695	ENSG00000228060.1	RP11-69E11.8	3.89	0.000117	0.00893	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155285	chr1:39565160~39573203:+
THCA	cis	rs972578	1	rs738379	ENSG00000274717.1	RP1-47A17.1	3.89	0.000117	0.00893	0.18	0.18	Mean platelet volume;	chr22:43004758	chr22:42791814~42794313:-
THCA	cis	rs9527	0.525	rs12770034	ENSG00000272912.1	RP11-724N1.1	-3.89	0.000117	0.00893	-0.21	-0.18	Arsenic metabolism;	chr10:102875838	chr10:102914585~102915404:+
THCA	cis	rs4273100	0.79	rs60166680	ENSG00000263934.3	SNORD3A	3.89	0.000117	0.00893	0.27	0.18	Schizophrenia;	chr17:19374231	chr17:19188016~19188714:+
THCA	cis	rs9291683	0.679	rs13137795	ENSG00000261490.1	RP11-448G15.3	3.89	0.000117	0.00893	0.11	0.18	Bone mineral density;	chr4:10049882	chr4:10068089~10073019:-
THCA	cis	rs7818688	0.614	rs11784299	ENSG00000253528.2	RP11-347C18.4	-3.89	0.000117	0.00893	-0.26	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94837695	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.614	rs10956927	ENSG00000253528.2	RP11-347C18.4	-3.89	0.000117	0.00893	-0.26	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94838715	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.614	rs11781429	ENSG00000253528.2	RP11-347C18.4	-3.89	0.000117	0.00893	-0.26	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94843706	chr8:94974573~94974853:-
THCA	cis	rs860295	0.871	rs6688636	ENSG00000160766.13	GBAP1	3.89	0.000117	0.00893	0.2	0.18	Body mass index;	chr1:155509106	chr1:155213821~155227422:-
THCA	cis	rs13178541	0.577	rs67427688	ENSG00000250378.1	RP11-119J18.1	-3.89	0.000117	0.00894	-0.2	-0.18	IgG glycosylation;	chr5:135789248	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.542	rs35475457	ENSG00000250378.1	RP11-119J18.1	-3.89	0.000117	0.00894	-0.2	-0.18	IgG glycosylation;	chr5:135789389	chr5:135812667~135826582:+
THCA	cis	rs4906332	0.966	rs12894275	ENSG00000252469.1	RNU7-160P	-3.89	0.000117	0.00894	-0.19	-0.18	Coronary artery disease;	chr14:103435087	chr14:103550345~103550406:+
THCA	cis	rs4074961	0.669	rs4652964	ENSG00000233621.1	LINC01137	-3.89	0.000117	0.00894	-0.18	-0.18	Axial length;	chr1:37612628	chr1:37454879~37474411:-
THCA	cis	rs4879656	0.831	rs13289835	ENSG00000225693.1	LAGE3P1	-3.89	0.000117	0.00894	-0.19	-0.18	Menopause (age at onset);	chr9:33069183	chr9:33019682~33020165:-
THCA	cis	rs6517329	0.538	rs4816521	ENSG00000230212.5	AP000688.14	-3.89	0.000117	0.00894	-0.22	-0.18	Schizophrenia;	chr21:36138440	chr21:36069642~36126640:-
THCA	cis	rs4915077	0.773	rs12564672	ENSG00000230489.1	VAV3-AS1	3.89	0.000117	0.00894	0.3	0.18	Hypothyroidism;	chr1:107744406	chr1:107964443~107994607:+
THCA	cis	rs2299587	0.61	rs7001974	ENSG00000253671.1	RP11-806O11.1	-3.89	0.000117	0.00894	-0.21	-0.18	Economic and political preferences;	chr8:17915786	chr8:17808941~17820868:+
THCA	cis	rs2299587	0.61	rs6987474	ENSG00000253671.1	RP11-806O11.1	-3.89	0.000117	0.00894	-0.21	-0.18	Economic and political preferences;	chr8:17915789	chr8:17808941~17820868:+
THCA	cis	rs73108077	0.915	rs73116254	ENSG00000277112.2	RP11-755J8.1	-3.89	0.000117	0.00894	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31453983	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs5022146	ENSG00000277112.2	RP11-755J8.1	-3.89	0.000117	0.00894	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31454603	chr20:30681825~30723932:-
THCA	cis	rs13126694	0.65	rs6536287	ENSG00000248429.4	RP11-597D13.9	-3.89	0.000117	0.00894	-0.19	-0.18	Blood osmolality (transformed sodium);	chr4:157921400	chr4:158170752~158202877:+
THCA	cis	rs17286411	0.671	rs9940217	ENSG00000260185.1	RP11-432I5.6	-3.89	0.000117	0.00894	-0.24	-0.18	Blood protein levels;	chr16:71687610	chr16:71655027~71664212:+
THCA	cis	rs2320614	0.648	rs1382661	ENSG00000250027.1	RP11-563E2.2	-3.89	0.000117	0.00894	-0.16	-0.18	Lung adenocarcinoma;	chr4:163182938	chr4:163108785~163119965:+
THCA	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-3.89	0.000117	0.00894	-0.11	-0.18	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
THCA	cis	rs6921919	0.562	rs13198809	ENSG00000272009.1	RP1-313I6.12	-3.89	0.000117	0.00895	-0.33	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs35353359	ENSG00000272009.1	RP1-313I6.12	-3.89	0.000117	0.00895	-0.33	-0.18	Depression;	chr6:28356601	chr6:28078792~28081130:-
THCA	cis	rs9863	0.861	rs11057396	ENSG00000270028.1	RP11-380L11.4	3.88	0.000117	0.00895	0.19	0.18	White blood cell count;	chr12:123934515	chr12:123925461~123926083:-
THCA	cis	rs7615952	0.932	rs11922218	ENSG00000272840.1	RP11-379B18.6	3.88	0.000117	0.00895	0.29	0.18	Blood pressure (smoking interaction);	chr3:125912446	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.866	rs11922276	ENSG00000272840.1	RP11-379B18.6	3.88	0.000117	0.00895	0.29	0.18	Blood pressure (smoking interaction);	chr3:125912483	chr3:125774714~125797953:+
THCA	cis	rs858239	0.669	rs12539467	ENSG00000230042.1	AK3P3	-3.88	0.000117	0.00895	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23129178~23129841:+
THCA	cis	rs2427308	0.607	rs1741635	ENSG00000275437.1	RP5-908M14.10	-3.88	0.000117	0.00895	-0.18	-0.18	Colorectal cancer;	chr20:62363141	chr20:62402236~62405935:-
THCA	cis	rs6517329	0.538	rs8126939	ENSG00000230212.5	AP000688.14	-3.88	0.000117	0.00895	-0.22	-0.18	Schizophrenia;	chr21:36140649	chr21:36069642~36126640:-
THCA	cis	rs6517329	0.538	rs4817781	ENSG00000230212.5	AP000688.14	-3.88	0.000117	0.00895	-0.22	-0.18	Schizophrenia;	chr21:36141298	chr21:36069642~36126640:-
THCA	cis	rs6517329	0.538	rs4817782	ENSG00000230212.5	AP000688.14	-3.88	0.000117	0.00895	-0.22	-0.18	Schizophrenia;	chr21:36141449	chr21:36069642~36126640:-
THCA	cis	rs2191566	0.639	rs7257749	ENSG00000266921.1	RP11-15A1.7	-3.88	0.000117	0.00896	-0.16	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44044513	chr19:43996896~44002836:-
THCA	cis	rs2191566	0.691	rs59086054	ENSG00000266921.1	RP11-15A1.7	-3.88	0.000117	0.00896	-0.16	-0.18	Acute lymphoblastic leukemia (childhood);	chr19:44044943	chr19:43996896~44002836:-
THCA	cis	rs9291683	0.595	rs3733585	ENSG00000250413.1	RP11-448G15.1	-3.88	0.000117	0.00896	-0.17	-0.18	Bone mineral density;	chr4:10034715	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.561	rs3733584	ENSG00000250413.1	RP11-448G15.1	-3.88	0.000117	0.00896	-0.17	-0.18	Bone mineral density;	chr4:10034882	chr4:10006482~10009725:+
THCA	cis	rs2163813	1	rs56093876	ENSG00000271499.1	CTC-559E9.9	-3.88	0.000117	0.00896	-0.22	-0.18	Toenail selenium levels;	chr19:19708306	chr19:19750618~19752544:+
THCA	cis	rs2163813	1	rs1061270	ENSG00000271499.1	CTC-559E9.9	-3.88	0.000117	0.00896	-0.22	-0.18	Toenail selenium levels;	chr19:19710558	chr19:19750618~19752544:+
THCA	cis	rs34638686	1	rs34638686	ENSG00000270441.1	RP11-694I15.7	3.88	0.000117	0.00896	0.24	0.18	Educational attainment (years of education);	chr3:48645225	chr3:49140086~49160851:-
THCA	cis	rs950169	0.922	rs2033284	ENSG00000275120.1	RP11-182J1.17	3.88	0.000117	0.00896	0.21	0.18	Schizophrenia;	chr15:84391575	chr15:84599434~84606463:-
THCA	cis	rs17826219	0.789	rs4794873	ENSG00000214719.10	AC005562.1	-3.88	0.000117	0.00896	-0.23	-0.18	Body mass index;	chr17:30421334	chr17:30576464~30672789:+
THCA	cis	rs9309473	0.5	rs10189578	ENSG00000273245.1	RP11-434P11.2	3.88	0.000117	0.00896	0.21	0.18	Metabolite levels;	chr2:73501482	chr2:73750256~73750786:-
THCA	cis	rs11633886	1	rs2413792	ENSG00000259200.1	RP11-718O11.1	-3.88	0.000117	0.00896	-0.21	-0.18	Diisocyanate-induced asthma;	chr15:45801469	chr15:45705078~45931069:+
THCA	cis	rs6012953	1	rs6020563	ENSG00000231715.1	COX6CP2	3.88	0.000117	0.00896	0.19	0.18	Vitiligo;	chr20:50503858	chr20:50479767~50479991:+
THCA	cis	rs1555322	0.932	rs6060321	ENSG00000269202.1	RP4-614O4.12	-3.88	0.000117	0.00896	-0.21	-0.18	Attention deficit hyperactivity disorder;	chr20:35245978	chr20:35201747~35203288:-
THCA	cis	rs4932397	1	rs4932397	ENSG00000173867.8	RP11-97O12.7	3.88	0.000117	0.00896	0.19	0.18	Familial hepatitis B virus-related hepatocellular carcinoma;	chr15:88493060	chr15:88459717~88512529:-
THCA	cis	rs875971	0.505	rs2462573	ENSG00000230295.1	RP11-458F8.2	3.88	0.000117	0.00896	0.14	0.18	Aortic root size;	chr7:66042405	chr7:66880708~66882981:+
THCA	cis	rs7200786	0.583	rs7185202	ENSG00000274038.1	RP11-66H6.4	-3.88	0.000117	0.00896	-0.22	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11041207	chr16:11056556~11057034:+
THCA	cis	rs7616559	0.924	rs6774012	ENSG00000244515.1	KRT18P34	-3.88	0.000117	0.00896	-0.24	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157029804	chr3:157162663~157163932:-
THCA	cis	rs17695224	0.545	rs7252805	ENSG00000275055.1	CTC-471J1.11	-3.88	0.000117	0.00896	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51840169	chr19:52049007~52049754:+
THCA	cis	rs10043228	1	rs10062350	ENSG00000248445.4	SEMA6A-AS1	-3.88	0.000117	0.00896	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116117800	chr5:116447547~116508276:+
THCA	cis	rs7403037	1	rs28715816	ENSG00000260760.1	PWRN3	3.88	0.000117	0.00896	0.2	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24579361	chr15:24441127~24447967:+
THCA	cis	rs7403037	1	rs28456975	ENSG00000260760.1	PWRN3	3.88	0.000117	0.00896	0.2	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24579582	chr15:24441127~24447967:+
THCA	cis	rs763121	0.853	rs5750673	ENSG00000235209.1	CTA-150C2.13	3.88	0.000117	0.00897	0.24	0.18	Menopause (age at onset);	chr22:38714119	chr22:38921227~38924708:+
THCA	cis	rs714027	0.546	rs5997549	ENSG00000279699.1	RP1-102K2.9	3.88	0.000117	0.00897	0.18	0.18	Lymphocyte counts;	chr22:29869355	chr22:30275215~30276951:-
THCA	cis	rs2562456	0.917	rs2681392	ENSG00000268278.1	RP11-420K14.1	-3.88	0.000117	0.00897	-0.21	-0.18	Pain;	chr19:21513185	chr19:21637974~21656300:+
THCA	cis	rs916888	0.821	rs199505	ENSG00000260075.1	NSFP1	3.88	0.000117	0.00897	0.28	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46372855~46487141:+
THCA	cis	rs916888	0.821	rs70602	ENSG00000260075.1	NSFP1	3.88	0.000117	0.00897	0.28	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46372855~46487141:+
THCA	cis	rs34421088	0.56	rs2248325	ENSG00000227888.4	FAM66A	-3.88	0.000117	0.00897	-0.23	-0.18	Neuroticism;	chr8:11539365	chr8:12362019~12388296:+
THCA	cis	rs34421088	0.56	rs2248316	ENSG00000227888.4	FAM66A	-3.88	0.000117	0.00897	-0.23	-0.18	Neuroticism;	chr8:11539564	chr8:12362019~12388296:+
THCA	cis	rs34421088	0.56	rs2248315	ENSG00000227888.4	FAM66A	-3.88	0.000117	0.00897	-0.23	-0.18	Neuroticism;	chr8:11539577	chr8:12362019~12388296:+
THCA	cis	rs3845817	0.808	rs702895	ENSG00000281920.1	RP11-418H16.1	-3.88	0.000117	0.00897	-0.21	-0.18	Bipolar disorder;	chr2:65534933	chr2:65623272~65628424:+
THCA	cis	rs3845817	0.868	rs702896	ENSG00000281920.1	RP11-418H16.1	-3.88	0.000117	0.00897	-0.21	-0.18	Bipolar disorder;	chr2:65535089	chr2:65623272~65628424:+
THCA	cis	rs4950322	0.748	rs17360812	ENSG00000180867.10	PDIA3P1	-3.88	0.000117	0.00897	-0.18	-0.18	Protein quantitative trait loci;	chr1:147355010	chr1:147178113~147179622:+
THCA	cis	rs7829975	0.688	rs6995407	ENSG00000233609.3	RP11-62H7.2	3.88	0.000117	0.00897	0.18	0.18	Mood instability;	chr8:8527137	chr8:8961200~8979025:+
THCA	cis	rs7474896	0.895	rs2749559	ENSG00000276805.1	RP11-291L22.6	-3.88	0.000117	0.00897	-0.27	-0.18	Obesity (extreme);	chr10:37922494	chr10:38451030~38451785:+
THCA	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	3.88	0.000117	0.00897	0.1	0.18	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
THCA	cis	rs7560272	0.501	rs12713798	ENSG00000163016.8	ALMS1P	-3.88	0.000117	0.00898	-0.22	-0.18	Schizophrenia;	chr2:73759294	chr2:73644919~73685576:+
THCA	cis	rs11105298	0.891	rs10858869	ENSG00000266347.2	AC068641.1	3.88	0.000117	0.00898	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs10858871	ENSG00000266347.2	AC068641.1	3.88	0.000117	0.00898	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89592833~89592927:+
THCA	cis	rs2839186	0.814	rs2276257	ENSG00000228137.1	AP001469.7	3.88	0.000117	0.00898	0.17	0.18	Testicular germ cell tumor;	chr21:46291315	chr21:46246890~46247682:+
THCA	cis	rs10266483	0.774	rs56055804	ENSG00000234338.1	RP11-797H7.1	-3.88	0.000117	0.00898	-0.14	-0.18	Response to statin therapy;	chr7:64410423	chr7:64835280~64836882:-
THCA	cis	rs12681366	0.839	rs3019278	ENSG00000261437.1	RP11-22C11.2	3.88	0.000118	0.00898	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.839	rs2930964	ENSG00000261437.1	RP11-22C11.2	3.88	0.000118	0.00898	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94637285~94639467:-
THCA	cis	rs7176527	0.5	rs895571	ENSG00000259570.1	RP11-671M22.4	-3.88	0.000118	0.00898	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:84394512~84395514:+
THCA	cis	rs7259376	0.936	rs2195965	ENSG00000270947.1	AC025811.3	3.88	0.000118	0.00898	0.19	0.18	Menopause (age at onset);	chr19:22355309	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs2195964	ENSG00000270947.1	AC025811.3	3.88	0.000118	0.00898	0.19	0.18	Menopause (age at onset);	chr19:22355536	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.905	rs2082480	ENSG00000270947.1	AC025811.3	3.88	0.000118	0.00898	0.19	0.18	Menopause (age at onset);	chr19:22355848	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs58170323	ENSG00000270947.1	AC025811.3	3.88	0.000118	0.00898	0.19	0.18	Menopause (age at onset);	chr19:22356313	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs2099354	ENSG00000270947.1	AC025811.3	3.88	0.000118	0.00898	0.19	0.18	Menopause (age at onset);	chr19:22356730	chr19:22455988~22456459:+
THCA	cis	rs7927592	0.913	rs11228268	ENSG00000160172.9	FAM86C2P	3.88	0.000118	0.00898	0.17	0.18	Total body bone mineral density;	chr11:68519979	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs4084149	ENSG00000160172.9	FAM86C2P	3.88	0.000118	0.00898	0.17	0.18	Total body bone mineral density;	chr11:68521099	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs7925275	ENSG00000160172.9	FAM86C2P	3.88	0.000118	0.00898	0.17	0.18	Total body bone mineral density;	chr11:68522965	chr11:67791648~67805336:-
THCA	cis	rs6449502	0.623	rs7731760	ENSG00000251279.1	CTC-436P18.1	-3.88	0.000118	0.00898	-0.27	-0.18	Mean platelet volume;	chr5:60841341	chr5:61162070~61232040:+
THCA	cis	rs1612141	1	rs1778371	ENSG00000251363.2	RP11-129M6.1	-3.88	0.000118	0.00898	-0.26	-0.18	QT interval (drug interaction);	chr14:41201856	chr14:40954898~40975877:+
THCA	cis	rs7824557	0.527	rs2572448	ENSG00000261451.1	RP11-981G7.1	-3.88	0.000118	0.00898	-0.22	-0.18	Retinal vascular caliber;	chr8:11381843	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.527	rs2572447	ENSG00000261451.1	RP11-981G7.1	-3.88	0.000118	0.00898	-0.22	-0.18	Retinal vascular caliber;	chr8:11382001	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.527	rs2572446	ENSG00000261451.1	RP11-981G7.1	-3.88	0.000118	0.00898	-0.22	-0.18	Retinal vascular caliber;	chr8:11382056	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.527	rs10109537	ENSG00000261451.1	RP11-981G7.1	-3.88	0.000118	0.00898	-0.22	-0.18	Retinal vascular caliber;	chr8:11382131	chr8:10433672~10438312:+
THCA	cis	rs13178541	0.688	rs12189128	ENSG00000250378.1	RP11-119J18.1	-3.88	0.000118	0.00898	-0.21	-0.18	IgG glycosylation;	chr5:135770662	chr5:135812667~135826582:+
THCA	cis	rs1612141	1	rs1618852	ENSG00000251363.2	RP11-129M6.1	-3.88	0.000118	0.00898	-0.26	-0.18	QT interval (drug interaction);	chr14:41265322	chr14:40954898~40975877:+
THCA	cis	rs9584850	1	rs9584850	ENSG00000231194.1	FARP1-AS1	3.88	0.000118	0.00898	0.22	0.18	Neuroticism;	chr13:98449172	chr13:98435405~98435840:-
THCA	cis	rs34421088	0.559	rs12386974	ENSG00000255046.1	RP11-297N6.4	-3.88	0.000118	0.00898	-0.19	-0.18	Neuroticism;	chr8:11543119	chr8:11797928~11802568:-
THCA	cis	rs854765	0.547	rs9894138	ENSG00000281749.1	Y_RNA	-3.88	0.000118	0.00899	-0.22	-0.18	Total body bone mineral density;	chr17:18061031	chr17:18001101~18001195:-
THCA	cis	rs9450351	0.744	rs9450299	ENSG00000203875.9	SNHG5	-3.88	0.000118	0.00899	-0.36	-0.18	Interferon gamma-induced protein 10 levels;	chr6:85562103	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs6930543	ENSG00000203875.9	SNHG5	-3.88	0.000118	0.00899	-0.36	-0.18	Interferon gamma-induced protein 10 levels;	chr6:85562658	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	3.88	0.000118	0.00899	0.16	0.18	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	3.88	0.000118	0.00899	0.16	0.18	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
THCA	cis	rs9650657	0.812	rs4240669	ENSG00000255310.2	AF131215.2	-3.88	0.000118	0.00899	-0.15	-0.18	Neuroticism;	chr8:10772477	chr8:11107788~11109726:-
THCA	cis	rs11673344	0.583	rs10421436	ENSG00000267422.1	CTD-2554C21.1	-3.88	0.000118	0.00899	-0.16	-0.18	Obesity-related traits;	chr19:37394601	chr19:37779686~37792865:+
THCA	cis	rs925946	0.518	rs7481311	ENSG00000245573.6	BDNF-AS	3.88	0.000118	0.00899	0.17	0.18	Weight;Body mass index;	chr11:27561582	chr11:27506838~27698174:+
THCA	cis	rs7521902	0.617	rs12037376	ENSG00000228397.1	RP1-224A6.3	-3.88	0.000118	0.00899	-0.33	-0.18	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22135618	chr1:22023994~22024968:-
THCA	cis	rs733592	0.894	rs886589	ENSG00000258273.1	RP11-370I10.4	3.88	0.000118	0.00899	0.21	0.18	Plateletcrit;	chr12:48083414	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.859	rs2054905	ENSG00000257735.1	RP11-370I10.6	3.88	0.000118	0.00899	0.2	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.5	rs2732461	ENSG00000257735.1	RP11-370I10.6	3.88	0.000118	0.00899	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48350945~48442411:+
THCA	cis	rs73198271	0.737	rs535094	ENSG00000253981.4	ALG1L13P	-3.88	0.000118	0.00899	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776418	chr8:8236003~8244667:-
THCA	cis	rs73198271	0.765	rs534103	ENSG00000253981.4	ALG1L13P	-3.88	0.000118	0.00899	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776559	chr8:8236003~8244667:-
THCA	cis	rs62380364	0.774	rs2362108	ENSG00000247828.6	TMEM161B-AS1	-3.88	0.000118	0.009	-0.13	-0.18	Intelligence (multi-trait analysis);	chr5:88851954	chr5:88268895~88436685:+
THCA	cis	rs2320614	0.679	rs72631678	ENSG00000250027.1	RP11-563E2.2	-3.88	0.000118	0.009	-0.16	-0.18	Lung adenocarcinoma;	chr4:163181563	chr4:163108785~163119965:+
THCA	cis	rs4356203	0.87	rs7937176	ENSG00000272034.1	SNORD14A	-3.88	0.000118	0.009	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17258198	chr11:17074654~17074744:-
THCA	cis	rs1823874	0.581	rs12910401	ENSG00000254744.3	CTD-3076O17.1	-3.88	0.000118	0.009	-0.21	-0.18	IgG glycosylation;	chr15:99799692	chr15:99970215~99974010:+
THCA	cis	rs4561483	0.743	rs28653099	ENSG00000263307.1	RP11-166B2.8	-3.88	0.000118	0.009	-0.18	-0.18	Testicular germ cell tumor;	chr16:11915293	chr16:11851649~11895611:+
THCA	cis	rs9467773	1	rs10484442	ENSG00000228223.2	HCG11	-3.88	0.000118	0.009	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26523450~26526579:+
THCA	cis	rs3806843	0.576	rs155361	ENSG00000202515.1	VTRNA1-3	-3.88	0.000118	0.009	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140927699	chr5:140726158~140726246:+
THCA	cis	rs9650657	0.769	rs2116093	ENSG00000255310.2	AF131215.2	-3.88	0.000118	0.009	-0.15	-0.18	Neuroticism;	chr8:10755789	chr8:11107788~11109726:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000230295.1	RP11-458F8.2	3.88	0.000118	0.009	0.14	0.18	Aortic root size;	chr7:66048109	chr7:66880708~66882981:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000230295.1	RP11-458F8.2	3.88	0.000118	0.009	0.14	0.18	Aortic root size;	chr7:66048321	chr7:66880708~66882981:+
THCA	cis	rs962856	0.619	rs6546297	ENSG00000236780.4	AC078941.1	3.88	0.000118	0.009	0.24	0.18	Pancreatic cancer;	chr2:67353388	chr2:67123357~67215319:-
THCA	cis	rs62292953	0.79	rs76381165	ENSG00000248724.5	NPHP3-AS1	-3.88	0.000118	0.009	-0.34	-0.18	Red cell distribution width;	chr3:132466808	chr3:132721750~132874223:+
THCA	cis	rs1371614	0.635	rs9309559	ENSG00000229122.1	AGBL5-IT1	3.88	0.000118	0.009	0.13	0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918647	chr2:27061038~27061815:+
THCA	cis	rs12681366	0.636	rs2515155	ENSG00000261437.1	RP11-22C11.2	-3.88	0.000118	0.009	-0.16	-0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94376469	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.593	rs2515154	ENSG00000261437.1	RP11-22C11.2	-3.88	0.000118	0.009	-0.16	-0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94376675	chr8:94637285~94639467:-
THCA	cis	rs10090774	0.965	rs10106750	ENSG00000280303.2	ERICD	-3.88	0.000118	0.009	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994810	chr8:140636281~140638283:+
THCA	cis	rs12681366	0.801	rs12682524	ENSG00000261437.1	RP11-22C11.2	3.88	0.000118	0.00901	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94637285~94639467:-
THCA	cis	rs11758351	0.866	rs2069019	ENSG00000216331.1	HIST1H1PS1	3.88	0.000118	0.00901	0.28	0.18	Renal underexcretion gout;Gout;	chr6:26205376	chr6:26195566~26195771:+
THCA	cis	rs11758351	0.866	rs2069018	ENSG00000216331.1	HIST1H1PS1	3.88	0.000118	0.00901	0.28	0.18	Renal underexcretion gout;Gout;	chr6:26205490	chr6:26195566~26195771:+
THCA	cis	rs944289	0.646	rs396043	ENSG00000258844.1	RP11-259K15.2	-3.88	0.000118	0.00901	-0.16	-0.18	Thyroid cancer;	chr14:36071815	chr14:36214607~36235608:+
THCA	cis	rs4822983	0.516	rs715517	ENSG00000272858.1	CTA-292E10.8	-3.88	0.000118	0.00901	-0.19	-0.18	Esophageal cancer (squamous cell);	chr22:28247468	chr22:28814914~28815662:+
THCA	cis	rs1204798	1	rs1204848	ENSG00000237021.2	RP3-486I3.7	-3.88	0.000118	0.00901	-0.19	-0.18	Dental caries;	chr6:116203100	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1204851	ENSG00000237021.2	RP3-486I3.7	-3.88	0.000118	0.00901	-0.19	-0.18	Dental caries;	chr6:116205957	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1209221	ENSG00000237021.2	RP3-486I3.7	-3.88	0.000118	0.00901	-0.19	-0.18	Dental caries;	chr6:116207816	chr6:116254207~116256743:+
THCA	cis	rs1404100	0.51	rs1038273	ENSG00000240476.1	LINC00973	-3.88	0.000118	0.00901	-0.19	-0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067757	chr3:98981058~98983096:+
THCA	cis	rs13098911	0.54	rs71327023	ENSG00000226074.4	PRSS44	-3.88	0.000118	0.00901	-0.34	-0.18	Celiac disease;	chr3:46089733	chr3:46809359~46812558:-
THCA	cis	rs5758511	0.68	rs739147	ENSG00000270083.1	RP1-257I20.14	-3.88	0.000118	0.00901	-0.22	-0.18	Birth weight;	chr22:42275060	chr22:42089630~42090028:-
THCA	cis	rs2408955	0.522	rs4760612	ENSG00000257735.1	RP11-370I10.6	-3.88	0.000118	0.00901	-0.21	-0.18	Glycated hemoglobin levels;	chr12:48028073	chr12:48350945~48442411:+
THCA	cis	rs61270009	1	rs61270009	ENSG00000247828.6	TMEM161B-AS1	3.88	0.000118	0.00901	0.16	0.18	Depressive symptoms;	chr5:88280322	chr5:88268895~88436685:+
THCA	cis	rs10833905	1	rs10430910	ENSG00000246225.5	RP11-17A1.3	-3.88	0.000118	0.00901	-0.25	-0.18	Sudden cardiac arrest;	chr11:23015273	chr11:22829380~22945393:+
THCA	cis	rs150992	0.632	rs34490	ENSG00000246763.5	RGMB-AS1	3.88	0.000118	0.00901	0.18	0.18	Body mass index;	chr5:98974967	chr5:98769618~98773469:-
THCA	cis	rs73108077	1	rs73116264	ENSG00000277112.2	RP11-755J8.1	-3.88	0.000118	0.00901	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31456926	chr20:30681825~30723932:-
THCA	cis	rs11105298	0.891	rs11105299	ENSG00000266347.2	AC068641.1	3.88	0.000118	0.00902	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs1008764	ENSG00000266347.2	AC068641.1	3.88	0.000118	0.00902	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89592833~89592927:+
THCA	cis	rs6494488	0.5	rs72742916	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64558476	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs55990268	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64562105	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742921	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64563357	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742923	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64563497	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742925	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64571104	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742927	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64574106	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742928	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64576281	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742930	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64578145	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742931	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64579797	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742934	ENSG00000259635.1	AC100830.3	-3.88	0.000118	0.00902	-0.45	-0.18	Coronary artery disease;	chr15:64583524	chr15:64701248~64719602:+
THCA	cis	rs7259376	0.871	rs2360622	ENSG00000270947.1	AC025811.3	3.88	0.000118	0.00902	0.19	0.18	Menopause (age at onset);	chr19:22387820	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.837	rs16999542	ENSG00000270947.1	AC025811.3	3.88	0.000118	0.00902	0.19	0.18	Menopause (age at onset);	chr19:22390290	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.902	rs10408428	ENSG00000270947.1	AC025811.3	-3.88	0.000118	0.00902	-0.19	-0.18	Menopause (age at onset);	chr19:22395221	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.694	rs75653200	ENSG00000270947.1	AC025811.3	-3.88	0.000118	0.00902	-0.19	-0.18	Menopause (age at onset);	chr19:22396701	chr19:22455988~22456459:+
THCA	cis	rs10484434	0.792	rs9689245	ENSG00000272462.2	U91328.19	3.88	0.000118	0.00902	0.19	0.18	HIV-1 viral setpoint;	chr6:26050617	chr6:25992662~26001775:+
THCA	cis	rs295490	0.748	rs61680644	ENSG00000272656.1	RP11-219D15.3	3.88	0.000118	0.00902	0.33	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139455729	chr3:139349024~139349371:-
THCA	cis	rs295490	0.667	rs79829464	ENSG00000272656.1	RP11-219D15.3	3.88	0.000118	0.00902	0.33	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456842	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs77347345	ENSG00000272656.1	RP11-219D15.3	3.88	0.000118	0.00902	0.33	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139459863	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs17560106	ENSG00000272656.1	RP11-219D15.3	3.88	0.000118	0.00902	0.33	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139461388	chr3:139349024~139349371:-
THCA	cis	rs295490	0.667	rs2289350	ENSG00000272656.1	RP11-219D15.3	3.88	0.000118	0.00902	0.33	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139462436	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs80323892	ENSG00000272656.1	RP11-219D15.3	3.88	0.000118	0.00902	0.33	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139464658	chr3:139349024~139349371:-
THCA	cis	rs11673344	0.734	rs1667343	ENSG00000267260.1	CTD-2162K18.4	-3.88	0.000118	0.00902	-0.22	-0.18	Obesity-related traits;	chr19:36978196	chr19:36773153~36777078:+
THCA	cis	rs5753037	0.653	rs140129	ENSG00000279699.1	RP1-102K2.9	3.88	0.000118	0.00902	0.17	0.18	Type 1 diabetes;	chr22:29754560	chr22:30275215~30276951:-
THCA	cis	rs7572733	0.515	rs1836234	ENSG00000231621.1	AC013264.2	-3.88	0.000118	0.00902	-0.19	-0.18	Dermatomyositis;	chr2:198018149	chr2:197197991~197199273:+
THCA	cis	rs700651	0.789	rs116165148	ENSG00000231621.1	AC013264.2	-3.88	0.000118	0.00902	-0.19	-0.18	Intracranial aneurysm;	chr2:198023623	chr2:197197991~197199273:+
THCA	cis	rs700651	0.789	rs1978889	ENSG00000231621.1	AC013264.2	-3.88	0.000118	0.00902	-0.19	-0.18	Intracranial aneurysm;	chr2:198024642	chr2:197197991~197199273:+
THCA	cis	rs700651	0.789	rs10184395	ENSG00000231621.1	AC013264.2	-3.88	0.000118	0.00902	-0.19	-0.18	Intracranial aneurysm;	chr2:198029561	chr2:197197991~197199273:+
THCA	cis	rs17286411	0.671	rs9923679	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000118	0.00902	-0.24	-0.18	Blood protein levels;	chr16:71713945	chr16:71655027~71664212:+
THCA	cis	rs6496044	0.568	rs12708554	ENSG00000259407.1	RP11-158M2.3	-3.88	0.000118	0.00902	-0.18	-0.18	Interstitial lung disease;	chr15:85531066	chr15:85744109~85750281:-
THCA	cis	rs964611	0.751	rs2291340	ENSG00000259488.2	RP11-154J22.1	-3.88	0.000118	0.00903	-0.15	-0.18	Metabolite levels (Pyroglutamine);	chr15:48255779	chr15:48312353~48331856:-
THCA	cis	rs2692947	0.726	rs13019188	ENSG00000232931.4	LINC00342	-3.88	0.000118	0.00903	-0.14	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96108451	chr2:95807118~95816215:-
THCA	cis	rs6012953	0.538	rs2426156	ENSG00000231715.1	COX6CP2	3.88	0.000118	0.00903	0.2	0.18	Vitiligo;	chr20:50518762	chr20:50479767~50479991:+
THCA	cis	rs12476592	0.602	rs2421952	ENSG00000242412.1	DBIL5P2	3.88	0.000118	0.00903	0.23	0.18	Childhood ear infection;	chr2:63522699	chr2:63117851~63119542:-
THCA	cis	rs79481398	0.616	rs79413113	ENSG00000276772.1	CTD-2515H24.2	-3.88	0.000118	0.00903	-0.23	-0.18	Facial morphology (factor 19);	chr15:57496542	chr15:57553955~57555680:+
THCA	cis	rs72949976	0.966	rs6752061	ENSG00000270659.1	RP11-105N14.1	3.88	0.000118	0.00903	0.14	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213163094	chr2:213152970~213153659:+
THCA	cis	rs4819052	1	rs4818769	ENSG00000182586.6	LINC00334	-3.88	0.000118	0.00903	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45234340~45258730:+
THCA	cis	rs875971	0.545	rs1796217	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000118	0.00903	-0.19	-0.18	Aortic root size;	chr7:66620931	chr7:66554588~66576923:-
THCA	cis	rs7615952	0.641	rs4490307	ENSG00000241288.6	RP11-379B18.5	-3.88	0.000118	0.00903	-0.19	-0.18	Blood pressure (smoking interaction);	chr3:125993833	chr3:125827238~125916384:-
THCA	cis	rs8046148	1	rs2058813	ENSG00000279356.1	RP11-429P3.8	-3.88	0.000118	0.00903	-0.24	-0.18	Testicular germ cell tumor;	chr16:50095543	chr16:50072862~50074986:+
THCA	cis	rs10089	1	rs11957052	ENSG00000245937.6	LINC01184	3.88	0.000118	0.00903	0.19	0.18	Ileal carcinoids;	chr5:128188363	chr5:127940426~128083172:-
THCA	cis	rs67478160	0.654	rs4906365	ENSG00000269940.1	RP11-73M18.7	3.88	0.000118	0.00903	0.17	0.18	Schizophrenia;	chr14:103762893	chr14:103694560~103695170:+
THCA	cis	rs2436845	0.554	rs567395	ENSG00000253320.4	KB-1507C5.2	-3.88	0.000118	0.00903	-0.15	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102902262	chr8:102864300~102977876:+
THCA	cis	rs354225	0.584	rs7591231	ENSG00000212175.1	SNORA12	-3.88	0.000118	0.00904	-0.22	-0.18	Schizophrenia;	chr2:54602459	chr2:55565703~55565850:+
THCA	cis	rs6498142	0.569	rs9926433	ENSG00000263033.2	RP11-396B14.2	3.88	0.000118	0.00904	0.17	0.18	Immunoglobulin A;	chr16:10986729	chr16:11196177~11224969:+
THCA	cis	rs589448	0.9	rs588493	ENSG00000274979.1	RP11-1143G9.5	-3.88	0.000118	0.00904	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69358206	chr12:69326574~69331882:-
THCA	cis	rs589448	1	rs589448	ENSG00000274979.1	RP11-1143G9.5	-3.88	0.000118	0.00904	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69358420	chr12:69326574~69331882:-
THCA	cis	rs589448	0.933	rs523398	ENSG00000274979.1	RP11-1143G9.5	-3.88	0.000118	0.00904	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69358995	chr12:69326574~69331882:-
THCA	cis	rs7119	0.604	rs907383	ENSG00000259362.2	RP11-307C19.1	3.88	0.000118	0.00904	0.25	0.18	Type 2 diabetes;	chr15:77578304	chr15:77525540~77534110:+
THCA	cis	rs12368653	0.789	rs17852479	ENSG00000270039.1	RP11-571M6.17	3.88	0.000118	0.00904	0.2	0.18	Multiple sclerosis;	chr12:57732451	chr12:57803838~57804415:+
THCA	cis	rs7845219	0.597	rs7002058	ENSG00000253528.2	RP11-347C18.4	3.88	0.000118	0.00904	0.2	0.18	Type 2 diabetes;	chr8:94861765	chr8:94974573~94974853:-
THCA	cis	rs6137726	0.524	rs2424440	ENSG00000237396.1	LINC01384	3.88	0.000118	0.00904	0.17	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22643338	chr20:22587522~22607517:-
THCA	cis	rs4915077	0.686	rs17019843	ENSG00000230489.1	VAV3-AS1	3.88	0.000118	0.00904	0.29	0.18	Hypothyroidism;	chr1:107730651	chr1:107964443~107994607:+
THCA	cis	rs6997458	0.869	rs11261474	ENSG00000253549.4	RP11-317J10.2	3.88	0.000118	0.00904	0.17	0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85382421	chr8:85441851~85464915:-
THCA	cis	rs4295623	0.559	rs2409836	ENSG00000254866.2	DEFB109P3	-3.88	0.000118	0.00904	-0.24	-0.18	Morning vs. evening chronotype;	chr8:11831719	chr8:12150895~12151134:-
THCA	cis	rs4767841	0.509	rs7300010	ENSG00000248636.5	RP11-768F21.1	-3.88	0.000118	0.00904	-0.18	-0.18	Urgency urinary incontinence;	chr12:119796572	chr12:119387987~119668079:-
THCA	cis	rs7474896	0.778	rs35215319	ENSG00000263064.2	RP11-291L22.7	3.88	0.000118	0.00904	0.3	0.18	Obesity (extreme);	chr10:37620071	chr10:38448689~38448949:+
THCA	cis	rs7474896	0.887	rs12570864	ENSG00000263064.2	RP11-291L22.7	3.88	0.000118	0.00904	0.3	0.18	Obesity (extreme);	chr10:37648365	chr10:38448689~38448949:+
THCA	cis	rs17801127	0.579	rs61198982	ENSG00000231969.1	AC144449.1	3.88	0.000118	0.00904	0.37	0.18	Liver enzyme levels (alanine transaminase);	chr2:149756549	chr2:149587196~149848233:+
THCA	cis	rs17801127	0.688	rs35224448	ENSG00000231969.1	AC144449.1	3.88	0.000118	0.00904	0.37	0.18	Liver enzyme levels (alanine transaminase);	chr2:149762838	chr2:149587196~149848233:+
THCA	cis	rs589448	0.967	rs2617834	ENSG00000274979.1	RP11-1143G9.5	-3.88	0.000119	0.00905	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69359585	chr12:69326574~69331882:-
THCA	cis	rs589448	0.967	rs2617835	ENSG00000274979.1	RP11-1143G9.5	-3.88	0.000119	0.00905	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69359640	chr12:69326574~69331882:-
THCA	cis	rs589448	0.933	rs2249093	ENSG00000274979.1	RP11-1143G9.5	-3.88	0.000119	0.00905	-0.19	-0.18	Cerebrospinal fluid biomarker levels;	chr12:69359732	chr12:69326574~69331882:-
THCA	cis	rs72627123	1	rs72627126	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000119	0.00905	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73903321	chr14:73787360~73803270:+
THCA	cis	rs10771431	0.597	rs10771412	ENSG00000256427.1	RP11-118B22.4	3.88	0.000119	0.00905	0.2	0.18	Breast size;	chr12:9201757	chr12:9246497~9257960:+
THCA	cis	rs10771431	0.597	rs10771413	ENSG00000256427.1	RP11-118B22.4	3.88	0.000119	0.00905	0.2	0.18	Breast size;	chr12:9201817	chr12:9246497~9257960:+
THCA	cis	rs7914558	1	rs8139	ENSG00000272912.1	RP11-724N1.1	-3.88	0.000119	0.00905	-0.2	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:102914585~102915404:+
THCA	cis	rs4073416	0.542	rs4902399	ENSG00000276116.2	FUT8-AS1	-3.88	0.000119	0.00905	-0.2	-0.18	N-glycan levels;	chr14:65490179	chr14:65411170~65412690:-
THCA	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	3.88	0.000119	0.00905	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	3.88	0.000119	0.00905	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	3.88	0.000119	0.00905	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	3.88	0.000119	0.00905	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-3.88	0.000119	0.00905	-0.19	-0.18	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	3.88	0.000119	0.00905	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
THCA	cis	rs6494488	0.5	rs56095421	ENSG00000259635.1	AC100830.3	-3.88	0.000119	0.00905	-0.44	-0.18	Coronary artery disease;	chr15:64619206	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs112226132	ENSG00000259635.1	AC100830.3	-3.88	0.000119	0.00905	-0.44	-0.18	Coronary artery disease;	chr15:64619276	chr15:64701248~64719602:+
THCA	cis	rs1150668	0.799	rs7206	ENSG00000280107.1	AL022393.9	-3.88	0.000119	0.00905	-0.17	-0.18	Pubertal anthropometrics;	chr6:28233360	chr6:28170845~28172521:+
THCA	cis	rs17286411	0.671	rs11645467	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71740487	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs11646635	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71740794	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.642	rs11646748	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71741177	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs951453	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71742241	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs4788442	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71743545	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs35173463	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71744737	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs2270832	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71746582	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs2270831	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71746696	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs2270830	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71748541	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs11075900	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00905	-0.24	-0.18	Blood protein levels;	chr16:71749470	chr16:71655027~71664212:+
THCA	cis	rs4746818	0.688	rs951718	ENSG00000229001.1	ACTBP14	-3.88	0.000119	0.00905	-0.28	-0.18	Left atrial antero-posterior diameter;	chr10:69168288	chr10:69022778~69023866:+
THCA	cis	rs7819412	0.669	rs35499486	ENSG00000255495.1	AC145124.2	-3.88	0.000119	0.00905	-0.21	-0.18	Triglycerides;	chr8:11216527	chr8:12194467~12196280:+
THCA	cis	rs9905704	0.801	rs302847	ENSG00000224738.1	AC099850.1	3.88	0.000119	0.00905	0.23	0.18	Testicular germ cell tumor;	chr17:58610120	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.881	rs302846	ENSG00000224738.1	AC099850.1	3.88	0.000119	0.00905	0.23	0.18	Testicular germ cell tumor;	chr17:58610175	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.756	rs302860	ENSG00000224738.1	AC099850.1	3.88	0.000119	0.00905	0.23	0.18	Testicular germ cell tumor;	chr17:58617647	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.846	rs302861	ENSG00000224738.1	AC099850.1	3.88	0.000119	0.00905	0.23	0.18	Testicular germ cell tumor;	chr17:58619679	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.846	rs372648	ENSG00000224738.1	AC099850.1	3.88	0.000119	0.00905	0.23	0.18	Testicular germ cell tumor;	chr17:58659424	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.708	rs304263	ENSG00000224738.1	AC099850.1	3.88	0.000119	0.00905	0.23	0.18	Testicular germ cell tumor;	chr17:58672580	chr17:59106598~59118267:+
THCA	cis	rs858239	0.899	rs2268747	ENSG00000226816.2	AC005082.12	3.88	0.000119	0.00905	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23206013~23208045:+
THCA	cis	rs1577917	0.696	rs10806334	ENSG00000220563.1	PKMP3	-3.88	0.000119	0.00906	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85729611	chr6:85659892~85660606:-
THCA	cis	rs6878727	0.552	rs1904462	ENSG00000253807.4	LINC01170	3.88	0.000119	0.00906	0.18	0.18	Breast cancer;	chr5:124355050	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.552	rs1904463	ENSG00000253807.4	LINC01170	3.88	0.000119	0.00906	0.18	0.18	Breast cancer;	chr5:124355190	chr5:124059794~124405079:-
THCA	cis	rs494526	0.739	rs565922	ENSG00000229272.1	RP11-498J9.2	3.88	0.000119	0.00906	0.2	0.18	Alcoholic chronic pancreatitis;	chr10:119043923	chr10:119003536~119003884:-
THCA	cis	rs427394	0.659	rs175594	ENSG00000248677.1	CTD-2044J15.1	3.88	0.000119	0.00906	0.17	0.18	Menopause (age at onset);	chr5:6729772	chr5:6686325~6707711:-
THCA	cis	rs427394	0.593	rs880993	ENSG00000248677.1	CTD-2044J15.1	3.88	0.000119	0.00906	0.17	0.18	Menopause (age at onset);	chr5:6732007	chr5:6686325~6707711:-
THCA	cis	rs427394	0.659	rs274695	ENSG00000248677.1	CTD-2044J15.1	3.88	0.000119	0.00906	0.17	0.18	Menopause (age at onset);	chr5:6732139	chr5:6686325~6707711:-
THCA	cis	rs34421088	0.506	rs2409755	ENSG00000154316.13	TDH	-3.88	0.000119	0.00906	-0.13	-0.18	Neuroticism;	chr8:11312474	chr8:11339637~11368452:+
THCA	cis	rs72996113	0.938	rs76021287	ENSG00000248027.1	CTD-2383M3.1	-3.88	0.000119	0.00906	-0.33	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100630882	chr11:100684162~100687955:-
THCA	cis	rs72996113	0.938	rs11224334	ENSG00000248027.1	CTD-2383M3.1	-3.88	0.000119	0.00906	-0.33	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100632301	chr11:100684162~100687955:-
THCA	cis	rs7826238	0.524	rs2921055	ENSG00000253981.4	ALG1L13P	3.88	0.000119	0.00906	0.17	0.18	Systolic blood pressure;	chr8:8461832	chr8:8236003~8244667:-
THCA	cis	rs62292953	0.79	rs11920734	ENSG00000248724.5	NPHP3-AS1	-3.88	0.000119	0.00906	-0.34	-0.18	Red cell distribution width;	chr3:132475446	chr3:132721750~132874223:+
THCA	cis	rs5758659	0.622	rs5758527	ENSG00000270083.1	RP1-257I20.14	3.88	0.000119	0.00906	0.19	0.18	Cognitive function;	chr22:41979757	chr22:42089630~42090028:-
THCA	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	3.88	0.000119	0.00906	0.2	0.18	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
THCA	cis	rs7707921	0.881	rs7733122	ENSG00000251374.1	RPS23P5	3.88	0.000119	0.00907	0.26	0.18	Breast cancer;	chr5:82055624	chr5:82265157~82265259:-
THCA	cis	rs7430456	1	rs7430456	ENSG00000231574.4	RP11-91K9.1	3.88	0.000119	0.00907	0.22	0.18	Breast cancer;	chr3:177768082	chr3:177816865~177899224:+
THCA	cis	rs1552244	0.515	rs6768768	ENSG00000180385.7	EMC3-AS1	3.88	0.000119	0.00907	0.22	0.18	Alzheimer's disease;	chr3:10135969	chr3:9986893~10006990:+
THCA	cis	rs13168506	0.56	rs7729550	ENSG00000271824.1	AC009014.3	-3.88	0.000119	0.00907	-0.18	-0.18	Stroke;	chr5:136209249	chr5:136191468~136193134:-
THCA	cis	rs3015497	0.752	rs6572682	ENSG00000270062.1	RP11-248J18.3	3.88	0.000119	0.00907	0.2	0.18	Mean platelet volume;	chr14:50678082	chr14:50723777~50724272:-
THCA	cis	rs9611565	0.659	rs4822036	ENSG00000237037.8	NDUFA6-AS1	3.88	0.000119	0.00907	0.16	0.18	Vitiligo;	chr22:41540015	chr22:42090931~42137742:+
THCA	cis	rs728616	0.681	rs55838345	ENSG00000278616.1	BEND3P3	3.88	0.000119	0.00907	0.18	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80325364	chr10:79682997~79685436:+
THCA	cis	rs728616	0.614	rs61859191	ENSG00000278616.1	BEND3P3	3.88	0.000119	0.00907	0.18	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80331271	chr10:79682997~79685436:+
THCA	cis	rs728616	0.614	rs17678338	ENSG00000278616.1	BEND3P3	3.88	0.000119	0.00907	0.18	0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80338390	chr10:79682997~79685436:+
THCA	cis	rs910873	0.505	rs6087607	ENSG00000276073.1	RP5-1125A11.7	-3.88	0.000119	0.00908	-0.22	-0.18	Melanoma;	chr20:34609685	chr20:33985617~33988989:-
THCA	cis	rs1842579	0.622	rs7539262	ENSG00000272691.1	RP11-290M5.4	-3.88	0.000119	0.00908	-0.17	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85791883	chr1:85578500~85578742:-
THCA	cis	rs1075265	0.836	rs1421622	ENSG00000235937.1	AC008280.1	-3.88	0.000119	0.00908	-0.2	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54029552~54030682:-
THCA	cis	rs9925964	0.967	rs2855475	ENSG00000260911.2	RP11-196G11.2	3.88	0.000119	0.00908	0.14	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31136227	chr16:31043150~31049868:+
THCA	cis	rs17689437	0.881	rs1069286	ENSG00000260084.1	RP11-615I2.1	3.88	0.000119	0.00908	0.26	0.18	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68523371	chr16:68573782~68589512:-
THCA	cis	rs7520050	0.778	rs3014238	ENSG00000281133.1	AL355480.3	3.88	0.000119	0.00908	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45580892~45580996:-
THCA	cis	rs8064024	0.538	rs12446456	ENSG00000267077.1	RP11-127I20.5	3.88	0.000119	0.00908	0.2	0.18	Cancer;	chr16:4872200	chr16:4795265~4796532:-
THCA	cis	rs4321325	0.733	rs79208542	ENSG00000236682.1	AC068282.3	-3.88	0.000119	0.00908	-0.36	-0.18	Protein C levels;	chr2:127178110	chr2:127389130~127400580:+
THCA	cis	rs6691738	0.959	rs7521390	ENSG00000227373.4	RP11-160H22.5	-3.88	0.000119	0.00908	-0.24	-0.18	Asthma;	chr1:173172821	chr1:174115300~174160004:-
THCA	cis	rs7142002	0.73	rs58803878	ENSG00000272444.1	RP11-1017G21.6	-3.88	0.000119	0.00908	-0.22	-0.18	Autism;	chr14:101924770	chr14:101952416~101953063:+
THCA	cis	rs10129255	0.957	rs11846893	ENSG00000280411.1	IGHV1-69-2	-3.88	0.000119	0.00908	-0.11	-0.18	Kawasaki disease;	chr14:106779068	chr14:106762092~106762588:-
THCA	cis	rs12493885	0.818	rs7641039	ENSG00000243069.6	ARHGEF26-AS1	3.88	0.000119	0.00908	0.29	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154050849	chr3:154024401~154121332:-
THCA	cis	rs74233809	0.636	rs284851	ENSG00000213277.3	MARCKSL1P1	3.88	0.000119	0.00908	0.24	0.18	Birth weight;	chr10:102818774	chr10:103175554~103176094:+
THCA	cis	rs2289681	1	rs2289681	ENSG00000280022.1	RP11-707O23.1	3.88	0.000119	0.00908	0.26	0.18	Cognitive function;	chr17:44911720	chr17:45592621~45593369:+
THCA	cis	rs7246657	0.525	rs1667351	ENSG00000276846.1	CTD-3220F14.3	3.88	0.000119	0.00908	0.16	0.18	Coronary artery calcification;	chr19:36987125	chr19:37314868~37315620:-
THCA	cis	rs7178572	0.789	rs4886869	ENSG00000259362.2	RP11-307C19.1	-3.88	0.000119	0.00908	-0.22	-0.18	Type 2 diabetes;	chr15:77507315	chr15:77525540~77534110:+
THCA	cis	rs1556032	0.63	rs10046853	ENSG00000225472.1	RP11-120J1.1	-3.88	0.000119	0.00908	-0.17	-0.18	AIDS;	chr9:14456933	chr9:14317085~14357908:+
THCA	cis	rs4759375	0.667	rs11057242	ENSG00000256092.2	RP13-942N8.1	-3.88	0.000119	0.00909	-0.19	-0.18	HDL cholesterol;	chr12:123285815	chr12:123363868~123366113:+
THCA	cis	rs6546886	0.75	rs71406850	ENSG00000257800.1	FNBP1P1	-3.88	0.000119	0.00909	-0.18	-0.18	Dialysis-related mortality;	chr2:74016131	chr2:74120680~74123218:+
THCA	cis	rs9959145	1	rs78908311	ENSG00000267199.1	RP11-861E21.2	3.88	0.000119	0.00909	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12688279	chr18:12438890~12448205:+
THCA	cis	rs7264396	0.623	rs6119609	ENSG00000088340.14	FER1L4	3.88	0.000119	0.00909	0.16	0.18	Total cholesterol levels;	chr20:35451572	chr20:35558737~35607562:-
THCA	cis	rs12476592	0.602	rs6708804	ENSG00000242412.1	DBIL5P2	3.88	0.000119	0.00909	0.22	0.18	Childhood ear infection;	chr2:63580135	chr2:63117851~63119542:-
THCA	cis	rs72928364	0.789	rs36082674	ENSG00000256628.3	ZBTB11-AS1	3.88	0.000119	0.00909	0.32	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101084906	chr3:101676475~101679217:+
THCA	cis	rs1979679	0.686	rs4348940	ENSG00000247934.4	RP11-967K21.1	3.88	0.000119	0.00909	0.19	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28437804	chr12:28163298~28190738:-
THCA	cis	rs4819052	1	rs733738	ENSG00000182586.6	LINC00334	3.88	0.000119	0.00909	0.2	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45234340~45258730:+
THCA	cis	rs4886920	0.862	rs34549121	ENSG00000260776.4	RP11-114H24.2	-3.88	0.000119	0.00909	-0.2	-0.18	Neuroticism;	chr15:77831644	chr15:77914217~77926846:-
THCA	cis	rs858239	0.899	rs858271	ENSG00000226816.2	AC005082.12	3.88	0.000119	0.00909	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23206013~23208045:+
THCA	cis	rs6517329	0.538	rs1056892	ENSG00000230212.5	AP000688.14	-3.88	0.000119	0.0091	-0.22	-0.18	Schizophrenia;	chr21:36146408	chr21:36069642~36126640:-
THCA	cis	rs6580649	0.882	rs2286022	ENSG00000273765.1	RP11-370I10.11	-3.88	0.000119	0.0091	-0.2	-0.18	Lung cancer;	chr12:48042864	chr12:48360920~48361377:+
THCA	cis	rs4803480	0.529	rs4803481	ENSG00000270164.1	LINC01480	-3.88	0.000119	0.0091	-0.15	-0.18	Schizophrenia;	chr19:41560186	chr19:41535183~41536904:+
THCA	cis	rs453301	0.624	rs2288673	ENSG00000254340.1	RP11-10A14.3	3.88	0.000119	0.0091	0.19	0.18	Joint mobility (Beighton score);	chr8:9002766	chr8:9141424~9145435:+
THCA	cis	rs7829975	0.774	rs13259216	ENSG00000253981.4	ALG1L13P	3.88	0.000119	0.0091	0.17	0.18	Mood instability;	chr8:8816091	chr8:8236003~8244667:-
THCA	cis	rs17286411	0.671	rs1035545	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.0091	-0.24	-0.18	Blood protein levels;	chr16:71663849	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs11648674	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.0091	-0.24	-0.18	Blood protein levels;	chr16:71669826	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.641	rs3925658	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.0091	-0.24	-0.18	Blood protein levels;	chr16:71675264	chr16:71655027~71664212:+
THCA	cis	rs12681366	0.761	rs2197003	ENSG00000253175.1	RP11-267M23.6	3.88	0.000119	0.0091	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94444758	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.801	rs2921386	ENSG00000253175.1	RP11-267M23.6	3.88	0.000119	0.0091	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94446672	chr8:94565036~94565715:+
THCA	cis	rs73193808	0.639	rs2832242	ENSG00000231125.2	AF129075.5	-3.88	0.000119	0.0091	-0.17	-0.18	Coronary artery disease;	chr21:29179864	chr21:29058073~29060095:-
THCA	cis	rs1560104	0.709	rs7194367	ENSG00000259876.1	CTD-3037G24.4	3.88	0.000119	0.0091	0.2	0.18	Obesity-related traits;	chr16:12604376	chr16:12556353~12557694:-
THCA	cis	rs2115630	0.691	rs61322921	ENSG00000259295.5	CSPG4P12	-3.88	0.000119	0.0091	-0.24	-0.18	P wave terminal force;	chr15:84620407	chr15:85191438~85213905:+
THCA	cis	rs559555	0.511	rs614173	ENSG00000276517.1	AL133243.2	-3.88	0.000119	0.0091	-0.17	-0.18	Blood metabolite ratios;Blood metabolite levels;	chr2:31628133	chr2:32526504~32529507:+
THCA	cis	rs6430585	0.878	rs9677760	ENSG00000231890.6	DARS-AS1	3.88	0.000119	0.0091	0.2	0.18	Corneal structure;	chr2:135781369	chr2:135985176~136022593:+
THCA	cis	rs7220401	0.512	rs71371126	ENSG00000264290.1	RP11-68I3.4	-3.88	0.000119	0.0091	-0.15	-0.18	Coronary artery disease;	chr17:29675624	chr17:29569580~29570519:+
THCA	cis	rs12200782	0.649	rs3757142	ENSG00000124549.13	BTN2A3P	-3.88	0.000119	0.0091	-0.21	-0.18	Small cell lung carcinoma;	chr6:26380317	chr6:26421391~26432383:+
THCA	cis	rs2777491	0.574	rs11635906	ENSG00000247556.5	OIP5-AS1	3.88	0.000119	0.00911	0.17	0.18	Ulcerative colitis;	chr15:41487062	chr15:41283990~41309737:+
THCA	cis	rs11157436	1	rs2293731	ENSG00000211812.1	TRAV26-2	-3.88	0.000119	0.00911	-0.17	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22202583~22203368:+
THCA	cis	rs13113518	0.812	rs6849474	ENSG00000223305.1	RN7SKP30	3.88	0.000119	0.00911	0.22	0.18	Height;	chr4:55452295	chr4:55540502~55540835:-
THCA	cis	rs2980439	0.525	rs2980508	ENSG00000253981.4	ALG1L13P	3.88	0.000119	0.00911	0.16	0.18	Neuroticism;	chr8:8314210	chr8:8236003~8244667:-
THCA	cis	rs12216545	0.737	rs1916010	ENSG00000241134.3	BET1P1	-3.88	0.000119	0.00911	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150536963	chr7:150749736~150750094:+
THCA	cis	rs793571	0.779	rs8035628	ENSG00000245975.2	RP11-30K9.6	-3.88	0.000119	0.00911	-0.19	-0.18	Schizophrenia;	chr15:58885201	chr15:58768072~58770974:-
THCA	cis	rs73108077	1	rs73116233	ENSG00000277112.2	RP11-755J8.1	-3.88	0.000119	0.00911	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31448538	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs73116235	ENSG00000277112.2	RP11-755J8.1	-3.88	0.000119	0.00911	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31449052	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs75231340	ENSG00000277112.2	RP11-755J8.1	-3.88	0.000119	0.00911	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31449114	chr20:30681825~30723932:-
THCA	cis	rs73108077	0.92	rs45520534	ENSG00000277112.2	RP11-755J8.1	-3.88	0.000119	0.00911	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31450235	chr20:30681825~30723932:-
THCA	cis	rs959260	0.8	rs8081778	ENSG00000263843.1	RP11-649A18.12	3.88	0.000119	0.00911	0.2	0.18	Systemic lupus erythematosus;	chr17:75316191	chr17:75271369~75273895:+
THCA	cis	rs10954779	0.764	rs2162071	ENSG00000127589.4	TUBBP1	3.88	0.000119	0.00911	0.21	0.18	Intelligence (multi-trait analysis);	chr8:31163739	chr8:30351873~30353518:+
THCA	cis	rs17286411	0.671	rs28704189	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000119	0.00911	-0.25	-0.18	Blood protein levels;	chr16:71792095	chr16:71655027~71664212:+
THCA	cis	rs10875746	0.669	rs11168508	ENSG00000258273.1	RP11-370I10.4	3.88	0.000119	0.00911	0.24	0.18	Longevity (90 years and older);	chr12:48289728	chr12:48333755~48333901:-
THCA	cis	rs8077577	0.671	rs4925177	ENSG00000273018.4	CTD-2303H24.2	-3.88	0.000119	0.00911	-0.25	-0.18	Obesity-related traits;	chr17:18349554	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.671	rs4925178	ENSG00000273018.4	CTD-2303H24.2	-3.88	0.000119	0.00911	-0.25	-0.18	Obesity-related traits;	chr17:18349597	chr17:18511221~18551705:-
THCA	cis	rs8077577	0.671	rs12450760	ENSG00000273018.4	CTD-2303H24.2	-3.88	0.000119	0.00911	-0.25	-0.18	Obesity-related traits;	chr17:18350508	chr17:18511221~18551705:-
THCA	cis	rs4819052	1	rs9984901	ENSG00000182586.6	LINC00334	-3.88	0.000119	0.00911	-0.2	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45234340~45258730:+
THCA	cis	rs4792901	0.959	rs55955027	ENSG00000267151.3	RP11-100E5.2	3.88	0.000119	0.00911	0.18	0.18	Dupuytren's disease;	chr17:43543788	chr17:43444707~43451200:+
THCA	cis	rs6860806	0.695	rs11952099	ENSG00000263597.1	MIR3936	3.88	0.000119	0.00911	0.17	0.18	Breast cancer;	chr5:132241079	chr5:132365490~132365599:-
THCA	cis	rs6860806	0.661	rs2136187	ENSG00000263597.1	MIR3936	3.88	0.000119	0.00911	0.17	0.18	Breast cancer;	chr5:132242201	chr5:132365490~132365599:-
THCA	cis	rs10833905	0.877	rs11026924	ENSG00000246225.5	RP11-17A1.3	-3.88	0.000119	0.00911	-0.25	-0.18	Sudden cardiac arrest;	chr11:23034626	chr11:22829380~22945393:+
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000254414.1	RP11-182J1.1	-3.88	0.00012	0.00911	-0.21	-0.18	P wave terminal force;	chr15:84631400	chr15:84631898~84633987:-
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000254414.1	RP11-182J1.1	-3.88	0.00012	0.00911	-0.21	-0.18	P wave terminal force;	chr15:84631524	chr15:84631898~84633987:-
THCA	cis	rs10792320	1	rs2028062	ENSG00000279491.1	RP11-810P12.7	3.88	0.00012	0.00912	0.18	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61978481	chr11:61967794~61969490:+
THCA	cis	rs2562456	0.792	rs2562398	ENSG00000268278.1	RP11-420K14.1	-3.88	0.00012	0.00912	-0.21	-0.18	Pain;	chr19:21540147	chr19:21637974~21656300:+
THCA	cis	rs2153535	0.518	rs6597336	ENSG00000230939.1	RP11-314C16.1	-3.88	0.00012	0.00912	-0.19	-0.18	Motion sickness;	chr6:8530663	chr6:8784178~8785445:+
THCA	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	3.88	0.00012	0.00912	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
THCA	cis	rs7089973	0.604	rs10885618	ENSG00000228169.3	PPIAP19	3.88	0.00012	0.00912	0.2	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114857959	chr10:114690143~114690634:-
THCA	cis	rs4460629	0.742	rs6693477	ENSG00000225855.5	RUSC1-AS1	3.88	0.00012	0.00912	0.11	0.18	Serum magnesium levels;	chr1:155109464	chr1:155316863~155324176:-
THCA	cis	rs548181	0.609	rs511822	ENSG00000254671.2	STT3A-AS1	-3.88	0.00012	0.00912	-0.33	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125664220	chr11:125570284~125592568:-
THCA	cis	rs6878727	0.552	rs256609	ENSG00000253807.4	LINC01170	3.88	0.00012	0.00912	0.18	0.18	Breast cancer;	chr5:124348319	chr5:124059794~124405079:-
THCA	cis	rs1035144	0.704	rs5002906	ENSG00000259167.2	NMNAT1P1	3.88	0.00012	0.00912	0.22	0.18	Male sexual orientation;	chr14:80978955	chr14:81032529~81033404:+
THCA	cis	rs10411161	0.657	rs67462252	ENSG00000275055.1	CTC-471J1.11	-3.88	0.00012	0.00912	-0.17	-0.18	Breast cancer;	chr19:51879598	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs8110073	ENSG00000275055.1	CTC-471J1.11	-3.88	0.00012	0.00912	-0.17	-0.18	Breast cancer;	chr19:51879870	chr19:52049007~52049754:+
THCA	cis	rs5758511	0.68	rs5758682	ENSG00000230107.1	CTA-126B4.7	-3.88	0.00012	0.00912	-0.22	-0.18	Birth weight;	chr22:42249196	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.68	rs34107327	ENSG00000230107.1	CTA-126B4.7	-3.88	0.00012	0.00912	-0.22	-0.18	Birth weight;	chr22:42252347	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.68	rs5758684	ENSG00000230107.1	CTA-126B4.7	-3.88	0.00012	0.00912	-0.22	-0.18	Birth weight;	chr22:42253503	chr22:42438023~42446195:+
THCA	cis	rs2692947	0.696	rs2576437	ENSG00000232931.4	LINC00342	3.88	0.00012	0.00912	0.14	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96134678	chr2:95807118~95816215:-
THCA	cis	rs800160	0.777	rs2521284	ENSG00000199550.1	Y_RNA	-3.88	0.00012	0.00912	-0.27	-0.18	Bacteremia;	chr11:2320447	chr11:2372638~2372750:+
THCA	cis	rs7089973	0.604	rs7923693	ENSG00000228169.3	PPIAP19	3.88	0.00012	0.00912	0.2	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114859807	chr10:114690143~114690634:-
THCA	cis	rs7089973	0.604	rs7895830	ENSG00000228169.3	PPIAP19	3.88	0.00012	0.00912	0.2	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114866017	chr10:114690143~114690634:-
THCA	cis	rs7819412	0.875	rs11250121	ENSG00000255495.1	AC145124.2	-3.88	0.00012	0.00912	-0.2	-0.18	Triglycerides;	chr8:11202802	chr8:12194467~12196280:+
THCA	cis	rs738722	0.539	rs2346397	ENSG00000272858.1	CTA-292E10.8	3.88	0.00012	0.00912	0.17	0.18	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28490817	chr22:28814914~28815662:+
THCA	cis	rs2243480	1	rs2533288	ENSG00000237310.1	GS1-124K5.4	3.88	0.00012	0.00913	0.21	0.18	Diabetic kidney disease;	chr7:66591724	chr7:66493706~66495474:+
THCA	cis	rs13325613	0.915	rs3136668	ENSG00000223552.1	RP11-24F11.2	-3.88	0.00012	0.00913	-0.31	-0.18	Monocyte count;	chr3:46202789	chr3:46364955~46407059:-
THCA	cis	rs875971	0.54	rs1723268	ENSG00000229180.5	GS1-124K5.11	3.88	0.00012	0.00913	0.12	0.18	Aortic root size;	chr7:66008093	chr7:66526088~66542624:-
THCA	cis	rs7838490	0.504	rs10504862	ENSG00000253553.4	RP11-586K2.1	3.88	0.00012	0.00913	0.19	0.18	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88535666	chr8:88326836~88737134:+
THCA	cis	rs7824557	0.545	rs2572450	ENSG00000227888.4	FAM66A	-3.88	0.00012	0.00913	-0.23	-0.18	Retinal vascular caliber;	chr8:11372129	chr8:12362019~12388296:+
THCA	cis	rs7142002	0.568	rs56139445	ENSG00000272444.1	RP11-1017G21.6	-3.88	0.00012	0.00913	-0.21	-0.18	Autism;	chr14:101919432	chr14:101952416~101953063:+
THCA	cis	rs7074356	0.915	rs17680103	ENSG00000278616.1	BEND3P3	3.88	0.00012	0.00913	0.18	0.18	Borderline personality disorder;	chr10:80447862	chr10:79682997~79685436:+
THCA	cis	rs9863	0.828	rs7311969	ENSG00000269997.1	RP11-214K3.21	3.88	0.00012	0.00913	0.21	0.18	White blood cell count;	chr12:123985786	chr12:123966077~123966629:-
THCA	cis	rs7259376	0.936	rs7256749	ENSG00000269138.1	ZNF209P	-3.88	0.00012	0.00913	-0.18	-0.18	Menopause (age at onset);	chr19:22409487	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.869	rs11673228	ENSG00000269138.1	ZNF209P	-3.88	0.00012	0.00913	-0.18	-0.18	Menopause (age at onset);	chr19:22413282	chr19:22463922~22473036:+
THCA	cis	rs2135507	0.817	rs11947382	ENSG00000270480.1	RP11-57B24.1	3.88	0.00012	0.00913	0.24	0.18	Juvenile osteochondritis dissecans;	chr4:82663408	chr4:82691737~82692468:+
THCA	cis	rs7142002	0.527	rs4906164	ENSG00000272444.1	RP11-1017G21.6	-3.88	0.00012	0.00913	-0.21	-0.18	Autism;	chr14:101920694	chr14:101952416~101953063:+
THCA	cis	rs1153858	1	rs28679834	ENSG00000275672.1	GATM-AS1	-3.88	0.00012	0.00913	-0.18	-0.18	Homoarginine levels;	chr15:45324008	chr15:45378700~45380123:+
THCA	cis	rs13118159	0.836	rs2293630	ENSG00000254094.1	AC078852.1	-3.88	0.00012	0.00913	-0.2	-0.18	Longevity;	chr4:1348733	chr4:1356581~1358075:+
THCA	cis	rs6494488	0.5	rs117686856	ENSG00000259635.1	AC100830.3	-3.88	0.00012	0.00913	-0.45	-0.18	Coronary artery disease;	chr15:64593046	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742943	ENSG00000259635.1	AC100830.3	-3.88	0.00012	0.00913	-0.45	-0.18	Coronary artery disease;	chr15:64597264	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72742950	ENSG00000259635.1	AC100830.3	-3.88	0.00012	0.00913	-0.45	-0.18	Coronary artery disease;	chr15:64604198	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs118175183	ENSG00000259635.1	AC100830.3	-3.88	0.00012	0.00913	-0.45	-0.18	Coronary artery disease;	chr15:64607142	chr15:64701248~64719602:+
THCA	cis	rs13113518	0.678	rs7663650	ENSG00000223305.1	RN7SKP30	-3.88	0.00012	0.00913	-0.22	-0.18	Height;	chr4:55364952	chr4:55540502~55540835:-
THCA	cis	rs12681288	0.578	rs56702775	ENSG00000260721.1	AF067845.1	3.88	0.00012	0.00913	0.22	0.18	Schizophrenia;	chr8:1018860	chr8:1368642~1369833:-
THCA	cis	rs4705962	0.878	rs10074523	ENSG00000230612.2	AC004237.1	3.88	0.00012	0.00913	0.22	0.18	Atopic dermatitis;	chr5:132724891	chr5:132688681~132723725:+
THCA	cis	rs11126435	0.844	rs363691	ENSG00000234521.1	AC005041.11	-3.88	0.00012	0.00913	-0.27	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr2:74614442	chr2:74413020~74413481:-
THCA	cis	rs202072	1	rs202073	ENSG00000272379.1	RP1-257A7.5	-3.88	0.00012	0.00914	-0.26	-0.18	HIV-1 viral setpoint;	chr6:13268373	chr6:13290018~13290490:-
THCA	cis	rs853679	0.546	rs13195291	ENSG00000272009.1	RP1-313I6.12	-3.88	0.00012	0.00914	-0.34	-0.18	Depression;	chr6:28201463	chr6:28078792~28081130:-
THCA	cis	rs853679	0.556	rs13197633	ENSG00000272009.1	RP1-313I6.12	-3.88	0.00012	0.00914	-0.34	-0.18	Depression;	chr6:28206979	chr6:28078792~28081130:-
THCA	cis	rs11168618	0.567	rs56354789	ENSG00000240399.1	RP1-228P16.1	3.88	0.00012	0.00914	0.18	0.18	Adiponectin levels;	chr12:48410160	chr12:48054813~48055591:-
THCA	cis	rs7772486	0.774	rs2748503	ENSG00000270638.1	RP3-466P17.1	3.88	0.00012	0.00914	0.14	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145973906	chr6:145735570~145737218:+
THCA	cis	rs564799	0.966	rs4679867	ENSG00000244040.4	IL12A-AS1	-3.88	0.00012	0.00914	-0.23	-0.18	Systemic lupus erythematosus;	chr3:160006116	chr3:159913400~160225299:-
THCA	cis	rs4792901	0.759	rs12948043	ENSG00000267151.3	RP11-100E5.2	3.88	0.00012	0.00914	0.19	0.18	Dupuytren's disease;	chr17:43538462	chr17:43444707~43451200:+
THCA	cis	rs2904524	0.541	rs10784840	ENSG00000257815.4	RP11-611E13.2	-3.88	0.00012	0.00914	-0.14	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70388944	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.5	rs11178214	ENSG00000257815.4	RP11-611E13.2	-3.88	0.00012	0.00914	-0.14	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70389327	chr12:69904033~70243360:-
THCA	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-3.88	0.00012	0.00914	-0.15	-0.18	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-3.88	0.00012	0.00914	-0.15	-0.18	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
THCA	cis	rs11638352	0.661	rs2733209	ENSG00000166763.7	STRCP1	-3.88	0.00012	0.00914	-0.35	-0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44158298	chr15:43699488~43718184:-
THCA	cis	rs2033711	0.728	rs4801586	ENSG00000268049.1	CTD-2619J13.9	-3.88	0.00012	0.00914	-0.22	-0.18	Uric acid clearance;	chr19:58423161	chr19:58357999~58359603:+
THCA	cis	rs5753037	0.653	rs131272	ENSG00000279699.1	RP1-102K2.9	3.88	0.00012	0.00914	0.17	0.18	Type 1 diabetes;	chr22:29757666	chr22:30275215~30276951:-
THCA	cis	rs7829975	1	rs7829975	ENSG00000253981.4	ALG1L13P	-3.88	0.00012	0.00914	-0.17	-0.18	Mood instability;	chr8:8690607	chr8:8236003~8244667:-
THCA	cis	rs2562456	0.833	rs8106025	ENSG00000268278.1	RP11-420K14.1	-3.88	0.00012	0.00914	-0.22	-0.18	Pain;	chr19:21451922	chr19:21637974~21656300:+
THCA	cis	rs950169	0.881	rs4842852	ENSG00000275120.1	RP11-182J1.17	3.88	0.00012	0.00914	0.21	0.18	Schizophrenia;	chr15:84387263	chr15:84599434~84606463:-
THCA	cis	rs950169	0.84	rs4842853	ENSG00000275120.1	RP11-182J1.17	3.88	0.00012	0.00914	0.21	0.18	Schizophrenia;	chr15:84387606	chr15:84599434~84606463:-
THCA	cis	rs950169	0.922	rs4842946	ENSG00000275120.1	RP11-182J1.17	3.88	0.00012	0.00914	0.21	0.18	Schizophrenia;	chr15:84387633	chr15:84599434~84606463:-
THCA	cis	rs950169	0.84	rs4842854	ENSG00000275120.1	RP11-182J1.17	3.88	0.00012	0.00914	0.21	0.18	Schizophrenia;	chr15:84387641	chr15:84599434~84606463:-
THCA	cis	rs4906332	1	rs11541718	ENSG00000259775.1	RP11-45P15.4	-3.88	0.00012	0.00915	-0.15	-0.18	Coronary artery disease;	chr14:103385827	chr14:103331674~103332367:-
THCA	cis	rs9905704	0.647	rs2036730	ENSG00000224738.1	AC099850.1	3.88	0.00012	0.00915	0.21	0.18	Testicular germ cell tumor;	chr17:58960921	chr17:59106598~59118267:+
THCA	cis	rs4834770	0.746	rs2389747	ENSG00000248280.1	RP11-33B1.2	3.88	0.00012	0.00915	0.15	0.18	Blood protein levels;	chr4:119314947	chr4:119440561~119450157:-
THCA	cis	rs4834770	0.717	rs1022146	ENSG00000248280.1	RP11-33B1.2	3.88	0.00012	0.00915	0.15	0.18	Blood protein levels;	chr4:119314948	chr4:119440561~119450157:-
THCA	cis	rs2455799	0.613	rs1532767	ENSG00000270409.1	RP11-44D5.1	-3.88	0.00012	0.00915	-0.18	-0.18	Mean platelet volume;	chr3:15692093	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs2470548	ENSG00000270409.1	RP11-44D5.1	-3.88	0.00012	0.00915	-0.18	-0.18	Mean platelet volume;	chr3:15696182	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs6772879	ENSG00000270409.1	RP11-44D5.1	-3.88	0.00012	0.00915	-0.18	-0.18	Mean platelet volume;	chr3:15700286	chr3:15732252~15733470:+
THCA	cis	rs2749592	0.531	rs1208559	ENSG00000099251.13	HSD17B7P2	-3.88	0.00012	0.00915	-0.15	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38356380~38378505:+
THCA	cis	rs5762752	0.677	rs2145161	ENSG00000272858.1	CTA-292E10.8	-3.88	0.00012	0.00915	-0.17	-0.18	Optic disc area;	chr22:28648372	chr22:28814914~28815662:+
THCA	cis	rs1035144	0.679	rs4903957	ENSG00000258915.1	BHLHB9P1	-3.88	0.00012	0.00915	-0.19	-0.18	Male sexual orientation;	chr14:80982167	chr14:80981988~80983638:+
THCA	cis	rs4767841	0.552	rs4767833	ENSG00000252886.1	RN7SKP197	-3.88	0.00012	0.00915	-0.18	-0.18	Urgency urinary incontinence;	chr12:119613165	chr12:119631090~119631386:-
THCA	cis	rs13098911	0.54	rs71327010	ENSG00000226074.4	PRSS44	-3.88	0.00012	0.00915	-0.34	-0.18	Celiac disease;	chr3:46027343	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34562820	ENSG00000226074.4	PRSS44	-3.88	0.00012	0.00915	-0.34	-0.18	Celiac disease;	chr3:46029589	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34619093	ENSG00000226074.4	PRSS44	-3.88	0.00012	0.00915	-0.34	-0.18	Celiac disease;	chr3:46031027	chr3:46809359~46812558:-
THCA	cis	rs2836974	0.831	rs4375956	ENSG00000255568.3	BRWD1-AS2	3.88	0.00012	0.00915	0.15	0.18	Cognitive function;	chr21:39149862	chr21:39313935~39314962:+
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000265443.1	CTD-2349P21.6	-3.88	0.00012	0.00915	-0.29	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30726305~30727564:-
THCA	cis	rs10200159	1	rs6739788	ENSG00000272606.1	RP11-554J4.1	3.88	0.00012	0.00915	0.34	0.18	Vitiligo;	chr2:55635220	chr2:55617909~55618373:+
THCA	cis	rs5758659	0.652	rs133340	ENSG00000270083.1	RP1-257I20.14	-3.88	0.00012	0.00916	-0.19	-0.18	Cognitive function;	chr22:42021683	chr22:42089630~42090028:-
THCA	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	3.88	0.00012	0.00916	0.23	0.18	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
THCA	cis	rs9291683	0.507	rs6849273	ENSG00000261490.1	RP11-448G15.3	3.88	0.00012	0.00916	0.11	0.18	Bone mineral density;	chr4:10019971	chr4:10068089~10073019:-
THCA	cis	rs4938303	0.788	rs61906112	ENSG00000254851.1	RP11-109L13.1	3.88	0.00012	0.00916	0.27	0.18	Triglycerides;	chr11:116685049	chr11:117135528~117138582:+
THCA	cis	rs6499188	0.522	rs8046299	ENSG00000274698.1	RP11-71L14.4	3.88	0.00012	0.00916	0.24	0.18	Ulcerative colitis;	chr16:68638443	chr16:68450283~68452318:+
THCA	cis	rs853679	0.666	rs200956	ENSG00000261839.1	RP1-265C24.8	3.88	0.00012	0.00916	0.22	0.18	Depression;	chr6:27871968	chr6:28136849~28139678:+
THCA	cis	rs9291683	0.588	rs35866697	ENSG00000261490.1	RP11-448G15.3	3.88	0.00012	0.00916	0.11	0.18	Bone mineral density;	chr4:10016980	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.588	rs35099040	ENSG00000261490.1	RP11-448G15.3	3.88	0.00012	0.00916	0.11	0.18	Bone mineral density;	chr4:10017215	chr4:10068089~10073019:-
THCA	cis	rs7045881	0.8	rs73433937	ENSG00000254396.1	RP11-56F10.3	3.88	0.00012	0.00916	0.3	0.18	Schizophrenia;	chr9:26941606	chr9:27102630~27104728:+
THCA	cis	rs4788570	0.615	rs2334880	ENSG00000260185.1	RP11-432I5.6	-3.88	0.00012	0.00916	-0.33	-0.18	Intelligence (multi-trait analysis);	chr16:71619734	chr16:71655027~71664212:+
THCA	cis	rs10421328	0.95	rs55831814	ENSG00000271283.1	CTC-412M14.6	3.88	0.00012	0.00916	0.26	0.18	Parental longevity (combined parental age at death);	chr19:19666835	chr19:19699203~19699409:-
THCA	cis	rs9863	0.828	rs7311969	ENSG00000270061.1	RP11-214K3.19	3.88	0.00012	0.00916	0.23	0.18	White blood cell count;	chr12:123985786	chr12:123969990~123970344:-
THCA	cis	rs1612141	0.843	rs1782146	ENSG00000251363.2	RP11-129M6.1	-3.88	0.00012	0.00916	-0.26	-0.18	QT interval (drug interaction);	chr14:41262374	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.947	rs1778402	ENSG00000251363.2	RP11-129M6.1	-3.88	0.00012	0.00916	-0.26	-0.18	QT interval (drug interaction);	chr14:41263057	chr14:40954898~40975877:+
THCA	cis	rs1612141	1	rs1782149	ENSG00000251363.2	RP11-129M6.1	-3.88	0.00012	0.00916	-0.26	-0.18	QT interval (drug interaction);	chr14:41265861	chr14:40954898~40975877:+
THCA	cis	rs1612141	1	rs1779512	ENSG00000251363.2	RP11-129M6.1	-3.88	0.00012	0.00916	-0.26	-0.18	QT interval (drug interaction);	chr14:41270730	chr14:40954898~40975877:+
THCA	cis	rs6756513	0.5	rs58819073	ENSG00000231024.1	AC092431.3	-3.88	0.00012	0.00916	-0.26	-0.18	Breast cancer;Platelet count;	chr2:69822090	chr2:69700192~69713847:-
THCA	cis	rs2458413	0.935	rs2514667	ENSG00000253477.4	RP11-1C8.4	-3.88	0.00012	0.00916	-0.19	-0.18	Paget's disease;	chr8:104346362	chr8:103483398~103501676:-
THCA	cis	rs6121246	0.909	rs6089071	ENSG00000224628.2	RP5-854E16.2	-3.88	0.00012	0.00916	-0.24	-0.18	Mean corpuscular hemoglobin;	chr20:31790581	chr20:31285317~31286835:-
THCA	cis	rs6573604	1	rs17102598	ENSG00000276116.2	FUT8-AS1	3.88	0.00012	0.00916	0.21	0.18	N-glycan levels;	chr14:65318142	chr14:65411170~65412690:-
THCA	cis	rs9595908	0.832	rs13378546	ENSG00000212293.1	SNORA16	3.88	0.00012	0.00916	0.21	0.18	Body mass index;	chr13:32631522	chr13:32420390~32420516:-
THCA	cis	rs3892630	0.824	rs34425841	ENSG00000267475.1	CTD-2538C1.2	-3.88	0.00012	0.00917	-0.27	-0.18	Red blood cell traits;	chr19:32740713	chr19:32687089~32691750:-
THCA	cis	rs13113518	0.783	rs13111128	ENSG00000223305.1	RN7SKP30	3.88	0.00012	0.00917	0.23	0.18	Height;	chr4:55578154	chr4:55540502~55540835:-
THCA	cis	rs12699921	0.933	rs6942635	ENSG00000279048.1	RP11-511H23.2	3.88	0.00012	0.00917	0.11	0.18	Fibrinogen levels;	chr7:17948242	chr7:17940503~17942922:+
THCA	cis	rs67981189	0.896	rs7145484	ENSG00000269927.1	RP6-91H8.3	3.88	0.00012	0.00917	0.2	0.18	Schizophrenia;	chr14:71006820	chr14:71141125~71143253:-
THCA	cis	rs3865444	1	rs3865444	ENSG00000171101.12	SIGLEC17P	3.88	0.00012	0.00917	0.2	0.18	Alzheimer's disease (late onset);Platelet count;White blood cell count;	chr19:51224706	chr19:51167328~51173524:+
THCA	cis	rs8002861	0.515	rs9525846	ENSG00000274001.1	RP11-5G9.5	-3.88	0.00012	0.00917	-0.21	-0.18	Leprosy;	chr13:43816721	chr13:43877715~43878163:-
THCA	cis	rs35740288	0.822	rs11629690	ENSG00000259407.1	RP11-158M2.3	-3.88	0.00012	0.00917	-0.22	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744493	chr15:85744109~85750281:-
THCA	cis	rs4273100	0.834	rs59415593	ENSG00000263934.3	SNORD3A	3.88	0.00012	0.00917	0.27	0.18	Schizophrenia;	chr17:19319911	chr17:19188016~19188714:+
THCA	cis	rs6881634	0.501	rs3952231	ENSG00000245556.2	SCAMP1-AS1	-3.88	0.00012	0.00917	-0.12	-0.18	Hippocampal atrophy;	chr5:78444003	chr5:78342365~78360507:-
THCA	cis	rs4268898	0.722	rs7564420	ENSG00000242628.4	AC009228.1	3.88	0.00012	0.00917	0.21	0.18	Asthma;	chr2:24191133	chr2:24214381~24221516:+
THCA	cis	rs6756513	0.5	rs2054046	ENSG00000231024.1	AC092431.3	3.88	0.00012	0.00917	0.26	0.18	Breast cancer;Platelet count;	chr2:69889942	chr2:69700192~69713847:-
THCA	cis	rs308403	0.509	rs1849431	ENSG00000224786.1	CETN4P	3.88	0.00012	0.00917	0.18	0.18	Blood protein levels;	chr4:122753607	chr4:122730548~122732193:-
THCA	cis	rs7826238	0.601	rs2976907	ENSG00000254340.1	RP11-10A14.3	3.88	0.00012	0.00917	0.2	0.18	Systolic blood pressure;	chr8:8487658	chr8:9141424~9145435:+
THCA	cis	rs911555	0.755	rs8014013	ENSG00000269958.1	RP11-73M18.8	-3.88	0.00012	0.00917	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103696353~103697163:+
THCA	cis	rs13113518	0.683	rs9761521	ENSG00000223305.1	RN7SKP30	3.88	0.00012	0.00917	0.23	0.18	Height;	chr4:55363436	chr4:55540502~55540835:-
THCA	cis	rs763121	0.853	rs5750630	ENSG00000273076.1	RP3-508I15.22	3.88	0.00012	0.00918	0.18	0.18	Menopause (age at onset);	chr22:38589813	chr22:38743495~38743910:+
THCA	cis	rs7089973	0.61	rs12774597	ENSG00000236799.1	RP11-383C6.2	-3.88	0.00012	0.00918	-0.22	-0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114995923	chr10:114994657~114996593:+
THCA	cis	rs7089973	0.61	rs34453431	ENSG00000236799.1	RP11-383C6.2	-3.88	0.00012	0.00918	-0.22	-0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114999924	chr10:114994657~114996593:+
THCA	cis	rs73230612	1	rs980944	ENSG00000242767.1	ZBTB20-AS4	-3.88	0.00012	0.00918	-0.23	-0.18	Type 2 diabetes;	chr3:115210665	chr3:115100423~115103061:+
THCA	cis	rs494526	0.769	rs608790	ENSG00000229272.1	RP11-498J9.2	3.88	0.00012	0.00918	0.2	0.18	Alcoholic chronic pancreatitis;	chr10:119046651	chr10:119003536~119003884:-
THCA	cis	rs17286411	0.671	rs11075902	ENSG00000260185.1	RP11-432I5.6	-3.88	0.000121	0.00918	-0.24	-0.18	Blood protein levels;	chr16:71775185	chr16:71655027~71664212:+
THCA	cis	rs3812831	0.599	rs428637	ENSG00000264539.1	MIR548AR	3.88	0.000121	0.00918	0.19	0.18	Schizophrenia;	chr13:114161664	chr13:114244505~114244561:+
THCA	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-3.88	0.000121	0.00918	-0.19	-0.18	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	3.88	0.000121	0.00918	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
THCA	cis	rs7707921	0.881	rs73134722	ENSG00000251374.1	RPS23P5	3.88	0.000121	0.00918	0.26	0.18	Breast cancer;	chr5:82030803	chr5:82265157~82265259:-
THCA	cis	rs4759375	1	rs28410096	ENSG00000256092.2	RP13-942N8.1	3.88	0.000121	0.00918	0.19	0.18	HDL cholesterol;	chr12:123396315	chr12:123363868~123366113:+
THCA	cis	rs7819412	0.669	rs2409743	ENSG00000255495.1	AC145124.2	-3.88	0.000121	0.00918	-0.2	-0.18	Triglycerides;	chr8:11212851	chr8:12194467~12196280:+
THCA	cis	rs6012953	0.618	rs3787345	ENSG00000231715.1	COX6CP2	-3.88	0.000121	0.00918	-0.19	-0.18	Vitiligo;	chr20:50568886	chr20:50479767~50479991:+
THCA	cis	rs7829975	0.56	rs17154599	ENSG00000254153.1	CTA-398F10.2	3.88	0.000121	0.00918	0.2	0.18	Mood instability;	chr8:8693908	chr8:8456909~8461337:-
THCA	cis	rs1383484	1	rs7172049	ENSG00000259728.4	LINC00933	-3.88	0.000121	0.00918	-0.22	-0.18	Height;	chr15:83834559	chr15:84570649~84580175:+
THCA	cis	rs4759375	0.748	rs596940	ENSG00000256092.2	RP13-942N8.1	-3.88	0.000121	0.00918	-0.23	-0.18	HDL cholesterol;	chr12:123076184	chr12:123363868~123366113:+
THCA	cis	rs1404100	0.531	rs1038271	ENSG00000249274.1	PDLIM1P4	3.88	0.000121	0.00918	0.18	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067399	chr3:98782188~98783193:+
THCA	cis	rs7184046	0.797	rs13737	ENSG00000260274.1	RP11-817O13.8	3.88	0.000121	0.00919	0.13	0.18	Height;	chr15:75639788	chr15:75368155~75369584:+
THCA	cis	rs2562456	0.833	rs1781872	ENSG00000268278.1	RP11-420K14.1	3.88	0.000121	0.00919	0.25	0.18	Pain;	chr19:21294601	chr19:21637974~21656300:+
THCA	cis	rs72627123	1	rs72627120	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73896777	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs72627122	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73901533	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs72627123	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73901628	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs72627124	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73902425	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs72627125	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73902920	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs72627127	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73903395	chr14:73787360~73803270:+
THCA	cis	rs72627123	0.737	rs2240632	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73904463	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs72627129	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73908102	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs72627130	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73908194	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs59363432	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73930842	chr14:73787360~73803270:+
THCA	cis	rs72627123	0.867	rs17094076	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73933789	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs72627138	ENSG00000259065.1	RP5-1021I20.1	-3.88	0.000121	0.00919	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73935197	chr14:73787360~73803270:+
THCA	cis	rs6494488	0.5	rs16948187	ENSG00000259635.1	AC100830.3	-3.88	0.000121	0.00919	-0.39	-0.18	Coronary artery disease;	chr15:64696783	chr15:64701248~64719602:+
THCA	cis	rs13098911	0.54	rs56332428	ENSG00000226074.4	PRSS44	-3.88	0.000121	0.00919	-0.32	-0.18	Celiac disease;	chr3:45948381	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34381952	ENSG00000226074.4	PRSS44	-3.88	0.000121	0.00919	-0.32	-0.18	Celiac disease;	chr3:45954256	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs41289616	ENSG00000226074.4	PRSS44	-3.88	0.000121	0.00919	-0.32	-0.18	Eosinophil percentage of granulocytes;	chr3:45955771	chr3:46809359~46812558:-
THCA	cis	rs4237845	0.78	rs3751331	ENSG00000270039.1	RP11-571M6.17	-3.88	0.000121	0.00919	-0.19	-0.18	Intelligence (multi-trait analysis);	chr12:57896495	chr12:57803838~57804415:+
THCA	cis	rs2635047	0.875	rs2635040	ENSG00000280212.1	RP11-49K24.3	-3.88	0.000121	0.00919	-0.17	-0.18	Educational attainment;	chr18:47114601	chr18:47076117~47076594:+
THCA	cis	rs4245128	0.736	rs7938406	ENSG00000227487.3	NCAM1-AS1	-3.88	0.000121	0.00919	-0.17	-0.18	Life satisfaction;	chr11:112952072	chr11:113269532~113273901:-
THCA	cis	rs3812831	0.695	rs8000778	ENSG00000264539.1	MIR548AR	3.88	0.000121	0.00919	0.19	0.18	Schizophrenia;	chr13:114178835	chr13:114244505~114244561:+
THCA	cis	rs8033133	0.602	rs1549477	ENSG00000251896.1	SNORD116-27	-3.88	0.000121	0.00919	-0.2	-0.18	Blood osmolality (transformed sodium);	chr15:25086971	chr15:25101575~25101666:+
THCA	cis	rs1923243	0.749	rs10889999	ENSG00000223479.3	RP4-788P17.1	-3.88	0.000121	0.00919	-0.19	-0.18	Migraine;	chr1:73043384	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.722	rs11210108	ENSG00000223479.3	RP4-788P17.1	-3.88	0.000121	0.00919	-0.19	-0.18	Migraine;	chr1:73048103	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.749	rs6690611	ENSG00000223479.3	RP4-788P17.1	-3.88	0.000121	0.00919	-0.19	-0.18	Migraine;	chr1:73057185	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.749	rs12021955	ENSG00000223479.3	RP4-788P17.1	-3.88	0.000121	0.00919	-0.19	-0.18	Migraine;	chr1:73058542	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.749	rs11210114	ENSG00000223479.3	RP4-788P17.1	-3.88	0.000121	0.00919	-0.19	-0.18	Migraine;	chr1:73061950	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.749	rs7554291	ENSG00000223479.3	RP4-788P17.1	-3.88	0.000121	0.00919	-0.19	-0.18	Migraine;	chr1:73062067	chr1:73635216~73715214:+
THCA	cis	rs877819	0.583	rs2663029	ENSG00000228403.1	RP11-563N6.6	3.88	0.000121	0.00919	0.19	0.18	Systemic lupus erythematosus;	chr10:48878956	chr10:48878022~48878649:+
THCA	cis	rs7402982	0.625	rs4966008	ENSG00000259424.1	RP11-35O15.1	-3.88	0.000121	0.00919	-0.18	-0.18	Birth weight;	chr15:98660216	chr15:98646951~98647371:-
THCA	cis	rs2732480	0.5	rs12829841	ENSG00000257735.1	RP11-370I10.6	3.88	0.000121	0.00919	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.523	rs34286639	ENSG00000257735.1	RP11-370I10.6	3.88	0.000121	0.00919	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48350945~48442411:+
THCA	cis	rs1387259	0.929	rs11168484	ENSG00000257735.1	RP11-370I10.6	3.88	0.000121	0.00919	0.2	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48350945~48442411:+
THCA	cis	rs6472827	0.856	rs7841382	ENSG00000253983.2	RP1-16A9.1	-3.88	0.000121	0.00919	-0.3	-0.18	Uterine fibroids;	chr8:74212381	chr8:74199396~74208441:+
THCA	cis	rs55702914	0.712	rs12616329	ENSG00000231621.1	AC013264.2	3.88	0.000121	0.00919	0.17	0.18	Major depression and alcohol dependence;	chr2:197283905	chr2:197197991~197199273:+
THCA	cis	rs11633886	0.528	rs2248216	ENSG00000259200.1	RP11-718O11.1	3.88	0.000121	0.00919	0.21	0.18	Diisocyanate-induced asthma;	chr15:45809383	chr15:45705078~45931069:+
THCA	cis	rs16915157	0.557	rs17818833	ENSG00000254271.1	RP11-131N11.4	-3.88	0.000121	0.00919	-0.38	-0.18	Schizophrenia;	chr10:60571001	chr10:60734342~60741828:+
THCA	cis	rs7246967	0.673	rs34671960	ENSG00000198153.8	ZNF849P	-3.88	0.000121	0.00919	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22765891	chr19:22685167~22686732:+
THCA	cis	rs7829975	0.714	rs4840362	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000121	0.00919	-0.19	-0.18	Mood instability;	chr8:8812572	chr8:9141424~9145435:+
THCA	cis	rs7819412	0.74	rs11250119	ENSG00000280294.1	RP11-177H2.1	3.88	0.000121	0.00919	0.15	0.18	Triglycerides;	chr8:11179525	chr8:10856085~10859436:-
THCA	cis	rs724818	0.661	rs17051254	ENSG00000251609.2	SETP12	-3.88	0.000121	0.00919	-0.49	-0.18	Monobrow thickness;	chr4:120782627	chr4:120895494~120897083:-
THCA	cis	rs875971	0.964	rs160635	ENSG00000229886.1	RP5-1132H15.3	3.88	0.000121	0.0092	0.19	0.18	Aortic root size;	chr7:66063931	chr7:66025126~66031544:-
THCA	cis	rs17772222	0.511	rs10150833	ENSG00000258983.2	RP11-507K2.2	3.88	0.000121	0.0092	0.19	0.18	Coronary artery calcification;	chr14:88843296	chr14:88499334~88515502:+
THCA	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	3.88	0.000121	0.0092	0.2	0.18	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	3.88	0.000121	0.0092	0.2	0.18	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
THCA	cis	rs3824488	0.599	rs16909856	ENSG00000271155.1	RP11-435O5.5	-3.88	0.000121	0.0092	-0.27	-0.18	Neuroticism;	chr9:95442211	chr9:95506235~95507636:+
THCA	cis	rs2682471	0.605	rs10772275	ENSG00000245648.1	RP11-277P12.20	3.88	0.000121	0.0092	0.18	0.18	Macrophage inflammatory protein 1a levels;	chr12:10410993	chr12:10363769~10398506:+
THCA	cis	rs7809950	0.773	rs2237668	ENSG00000272072.1	CTA-363E19.2	3.88	0.000121	0.0092	0.19	0.18	Coronary artery disease;	chr7:107409764	chr7:107192559~107193300:-
THCA	cis	rs9393777	0.72	rs56401801	ENSG00000220721.1	OR1F12	3.88	0.000121	0.0092	0.36	0.18	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28073316~28074233:+
THCA	cis	rs7088591	1	rs16911377	ENSG00000276818.1	AC026393.1	-3.88	0.000121	0.0092	-0.36	-0.18	Blood pressure;	chr10:57964350	chr10:57095699~57095781:+
THCA	cis	rs9905704	0.918	rs12949138	ENSG00000224738.1	AC099850.1	3.88	0.000121	0.0092	0.24	0.18	Testicular germ cell tumor;	chr17:58857504	chr17:59106598~59118267:+
THCA	cis	rs150992	0.587	rs4703052	ENSG00000246763.5	RGMB-AS1	-3.88	0.000121	0.0092	-0.18	-0.18	Body mass index;	chr5:99008818	chr5:98769618~98773469:-
THCA	cis	rs150992	0.517	rs326464	ENSG00000241597.2	CTD-2007H13.1	-3.88	0.000121	0.0092	-0.23	-0.18	Body mass index;	chr5:98906499	chr5:98954394~98954972:+
THCA	cis	rs1501911	0.53	rs162150	ENSG00000241597.2	CTD-2007H13.1	-3.88	0.000121	0.0092	-0.23	-0.18	Lung function (FEV1/FVC);	chr5:98913909	chr5:98954394~98954972:+
THCA	cis	rs4915077	0.773	rs17019773	ENSG00000226822.1	RP11-356N1.2	3.88	0.000121	0.0092	0.32	0.18	Hypothyroidism;	chr1:107721390	chr1:108071482~108074519:+
THCA	cis	rs4792901	0.802	rs58141510	ENSG00000267151.3	RP11-100E5.2	3.88	0.000121	0.0092	0.2	0.18	Dupuytren's disease;	chr17:43509107	chr17:43444707~43451200:+
THCA	cis	rs7737355	0.853	rs26005	ENSG00000237714.1	P4HA2-AS1	3.88	0.000121	0.0092	0.25	0.18	Life satisfaction;	chr5:131652336	chr5:132184876~132192808:+
THCA	cis	rs6881280	1	rs78997522	ENSG00000249996.1	RP11-359P5.1	-3.88	0.000121	0.0092	-0.29	-0.18	Self-reported allergy;	chr5:123299904	chr5:123036271~123054667:+
THCA	cis	rs2120243	0.504	rs1824058	ENSG00000241770.1	RP11-555M1.3	-3.88	0.000121	0.00921	-0.23	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157406991	chr3:157163452~157169133:+
THCA	cis	rs2732480	0.5	rs7315820	ENSG00000257735.1	RP11-370I10.6	3.88	0.000121	0.00921	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48350945~48442411:+
THCA	cis	rs6494488	0.5	rs72744707	ENSG00000259635.1	AC100830.3	-3.88	0.000121	0.00921	-0.43	-0.18	Coronary artery disease;	chr15:64719801	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744709	ENSG00000259635.1	AC100830.3	-3.88	0.000121	0.00921	-0.43	-0.18	Coronary artery disease;	chr15:64721011	chr15:64701248~64719602:+
THCA	cis	rs2120243	0.625	rs4482625	ENSG00000241770.1	RP11-555M1.3	-3.88	0.000121	0.00921	-0.22	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr3:157378220	chr3:157163452~157169133:+
THCA	cis	rs875971	0.545	rs75840613	ENSG00000232559.3	GS1-124K5.12	3.88	0.000121	0.00921	0.19	0.18	Aortic root size;	chr7:66376399	chr7:66554588~66576923:-
THCA	cis	rs1019173	0.901	rs62480049	ENSG00000261455.1	LINC01003	-3.88	0.000121	0.00921	-0.17	-0.18	Kidney function decline traits;	chr7:152010396	chr7:152463786~152465549:+
THCA	cis	rs56046484	0.956	rs35204319	ENSG00000259630.2	CTD-2262B20.1	-3.88	0.000121	0.00921	-0.26	-0.18	Testicular germ cell tumor;	chr15:85107246	chr15:85415228~85415633:+
THCA	cis	rs9392556	0.6	rs2326408	ENSG00000272248.1	RP3-406P24.4	3.88	0.000121	0.00921	0.22	0.18	Blood metabolite levels;	chr6:4119282	chr6:4018713~4019202:+
THCA	cis	rs793571	0.523	rs7161889	ENSG00000245975.2	RP11-30K9.6	3.88	0.000121	0.00921	0.16	0.18	Schizophrenia;	chr15:58691226	chr15:58768072~58770974:-
THCA	cis	rs7267979	0.966	rs6083818	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4815409	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs6107031	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6115159	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4813562	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6037099	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs4815414	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6083825	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs34645895	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6115168	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6037105	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2387880	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2387882	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2387884	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00921	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25284915~25285588:-
THCA	cis	rs4660214	0.666	rs636083	ENSG00000228060.1	RP11-69E11.8	-3.88	0.000121	0.00921	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39565160~39573203:+
THCA	cis	rs9309711	0.544	rs9309712	ENSG00000271868.1	RP11-1293J14.1	-3.88	0.000121	0.00921	-0.23	-0.18	Neurofibrillary tangles;	chr2:3487556	chr2:3496956~3497428:+
THCA	cis	rs2839186	0.903	rs61182475	ENSG00000228137.1	AP001469.7	3.88	0.000121	0.00921	0.18	0.18	Testicular germ cell tumor;	chr21:46287136	chr21:46246890~46247682:+
THCA	cis	rs9307551	0.817	rs13142610	ENSG00000249646.2	OR7E94P	-3.88	0.000121	0.00922	-0.22	-0.18	Refractive error;	chr4:79602297	chr4:79587302~79588130:-
THCA	cis	rs7829975	0.714	rs4841040	ENSG00000254340.1	RP11-10A14.3	3.88	0.000121	0.00922	0.19	0.18	Mood instability;	chr8:8797017	chr8:9141424~9145435:+
THCA	cis	rs7819412	1	rs7819412	ENSG00000254839.1	AF131215.6	-3.88	0.000121	0.00922	-0.18	-0.18	Triglycerides;	chr8:11187652	chr8:11062647~11067089:-
THCA	cis	rs1039766	1	rs12104748	ENSG00000204929.10	AC074391.1	-3.88	0.000121	0.00922	-0.29	-0.18	Lung adenocarcinoma;Lung cancer;	chr2:65290112	chr2:65436711~66084639:+
THCA	cis	rs6754311	0.517	rs1865452	ENSG00000231890.6	DARS-AS1	-3.88	0.000121	0.00922	-0.2	-0.18	Mosquito bite size;	chr2:135781760	chr2:135985176~136022593:+
THCA	cis	rs4906332	1	rs12147655	ENSG00000259775.1	RP11-45P15.4	-3.88	0.000121	0.00922	-0.15	-0.18	Coronary artery disease;	chr14:103384569	chr14:103331674~103332367:-
THCA	cis	rs875971	0.545	rs1267814	ENSG00000273024.4	INTS4P2	3.88	0.000121	0.00922	0.22	0.18	Aortic root size;	chr7:66579422	chr7:65647864~65715661:+
THCA	cis	rs1577917	0.958	rs12213431	ENSG00000220563.1	PKMP3	-3.88	0.000121	0.00922	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85791238	chr6:85659892~85660606:-
THCA	cis	rs7914558	1	rs11191541	ENSG00000272912.1	RP11-724N1.1	-3.88	0.000121	0.00922	-0.21	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102914585~102915404:+
THCA	cis	rs2154427	0.938	rs2833967	ENSG00000238197.4	PAXBP1-AS1	3.88	0.000121	0.00922	0.18	0.18	Bilirubin levels;	chr21:32818998	chr21:32728115~32743122:+
THCA	cis	rs7089973	0.584	rs4752322	ENSG00000228169.3	PPIAP19	3.88	0.000121	0.00922	0.2	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114853499	chr10:114690143~114690634:-
THCA	cis	rs7312933	0.558	rs11181483	ENSG00000257225.1	RP11-328C8.4	-3.88	0.000121	0.00922	-0.18	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42404582	chr12:42459366~42466128:+
THCA	cis	rs3783637	0.5	rs17128077	ENSG00000258413.1	RP11-665C16.6	-3.88	0.000121	0.00922	-0.33	-0.18	Rheumatoid arthritis;Obesity-related traits;	chr14:54919316	chr14:55262767~55272075:-
THCA	cis	rs4950322	1	rs4448568	ENSG00000271721.1	RP11-337C18.9	3.88	0.000121	0.00922	0.21	0.18	Protein quantitative trait loci;	chr1:147377296	chr1:147175602~147177740:+
THCA	cis	rs2243123	0.557	rs2243138	ENSG00000244040.4	IL12A-AS1	3.88	0.000121	0.00922	0.24	0.18	Multiple sclerosis;	chr3:159996563	chr3:159913400~160225299:-
THCA	cis	rs9291683	0.595	rs13145442	ENSG00000250413.1	RP11-448G15.1	-3.88	0.000121	0.00922	-0.17	-0.18	Bone mineral density;	chr4:10035637	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.595	rs11731110	ENSG00000250413.1	RP11-448G15.1	-3.88	0.000121	0.00922	-0.17	-0.18	Bone mineral density;	chr4:10035722	chr4:10006482~10009725:+
THCA	cis	rs11634944	0.63	rs705	ENSG00000257151.1	PWAR6	3.88	0.000121	0.00922	0.13	0.18	Interleukin-8 levels;	chr15:24974365	chr15:25031873~25036490:+
THCA	cis	rs9309473	0.95	rs7596773	ENSG00000273245.1	RP11-434P11.2	3.88	0.000121	0.00922	0.25	0.18	Metabolite levels;	chr2:73618873	chr2:73750256~73750786:-
THCA	cis	rs867186	1	rs11907594	ENSG00000126005.14	MMP24-AS1	-3.88	0.000121	0.00923	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35086040	chr20:35216462~35278131:-
THCA	cis	rs7927592	0.913	rs59056571	ENSG00000160172.9	FAM86C2P	3.88	0.000121	0.00923	0.17	0.18	Total body bone mineral density;	chr11:68505505	chr11:67791648~67805336:-
THCA	cis	rs7737355	0.947	rs7724769	ENSG00000237714.1	P4HA2-AS1	3.88	0.000121	0.00923	0.25	0.18	Life satisfaction;	chr5:131619250	chr5:132184876~132192808:+
THCA	cis	rs67981189	0.896	rs12892739	ENSG00000269927.1	RP6-91H8.3	3.88	0.000121	0.00923	0.2	0.18	Schizophrenia;	chr14:70983891	chr14:71141125~71143253:-
THCA	cis	rs448720	1	rs11071969	ENSG00000260657.2	RP11-315D16.4	3.88	0.000121	0.00923	0.22	0.18	Cognitive performance;	chr15:67903240	chr15:68267792~68277994:-
THCA	cis	rs7267979	1	rs6050561	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00923	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6083813	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00923	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4815406	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00923	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs6083817	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00923	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050564	ENSG00000276952.1	RP5-965G21.6	-3.88	0.000121	0.00923	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25284915~25285588:-
THCA	cis	rs61677309	1	rs4938499	ENSG00000278376.1	RP11-158I9.8	3.88	0.000121	0.00923	0.14	0.18	Lung cancer in ever smokers;	chr11:118291781	chr11:118791254~118793137:+
THCA	cis	rs8023401	0.507	rs16961062	ENSG00000259705.1	RP11-227D13.1	3.88	0.000121	0.00923	0.21	0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48511722	chr15:48645951~48652016:+
THCA	cis	rs17286411	0.639	rs8062441	ENSG00000260185.1	RP11-432I5.6	3.88	0.000121	0.00923	0.25	0.18	Blood protein levels;	chr16:71770011	chr16:71655027~71664212:+
THCA	cis	rs35176054	0.73	rs35696766	ENSG00000280693.1	SH3PXD2A-AS1	-3.88	0.000121	0.00923	-0.33	-0.18	Atrial fibrillation;	chr10:103776904	chr10:103745966~103755423:+
THCA	cis	rs1823874	0.581	rs12905599	ENSG00000254744.3	CTD-3076O17.1	-3.88	0.000121	0.00923	-0.2	-0.18	IgG glycosylation;	chr15:99799733	chr15:99970215~99974010:+
THCA	cis	rs7200786	0.618	rs7185491	ENSG00000274038.1	RP11-66H6.4	-3.88	0.000121	0.00923	-0.22	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11040807	chr16:11056556~11057034:+
THCA	cis	rs6878727	0.665	rs154210	ENSG00000253807.4	LINC01170	3.88	0.000121	0.00923	0.16	0.18	Breast cancer;	chr5:124349229	chr5:124059794~124405079:-
THCA	cis	rs9844666	0.512	rs9837855	ENSG00000273486.1	RP11-731C17.2	3.88	0.000121	0.00923	0.16	0.18	Height;	chr3:135905980	chr3:136837338~136839021:-
THCA	cis	rs9309473	1	rs6546837	ENSG00000273245.1	RP11-434P11.2	3.88	0.000121	0.00923	0.23	0.18	Metabolite levels;	chr2:73450771	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs6756987	ENSG00000273245.1	RP11-434P11.2	3.88	0.000121	0.00923	0.23	0.18	Metabolite levels;	chr2:73459950	chr2:73750256~73750786:-
THCA	cis	rs964611	0.882	rs3784619	ENSG00000259488.2	RP11-154J22.1	3.88	0.000121	0.00924	0.17	0.18	Metabolite levels (Pyroglutamine);	chr15:48333741	chr15:48312353~48331856:-
THCA	cis	rs972578	0.967	rs8138930	ENSG00000230319.1	AL022476.2	3.88	0.000121	0.00924	0.18	0.18	Mean platelet volume;	chr22:42940722	chr22:43038585~43052366:+
THCA	cis	rs12935229	0.756	rs9936614	ENSG00000260922.1	RP11-538I12.3	-3.88	0.000121	0.00924	-0.26	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77261685	chr16:77234877~77290934:+
THCA	cis	rs3812831	0.643	rs7322339	ENSG00000264539.1	MIR548AR	3.88	0.000121	0.00924	0.19	0.18	Schizophrenia;	chr13:114164251	chr13:114244505~114244561:+
THCA	cis	rs17331151	0.573	rs11626	ENSG00000242142.1	SERBP1P3	-3.88	0.000121	0.00924	-0.29	-0.18	Immune reponse to smallpox (secreted IL-2);	chr3:52839968	chr3:53064283~53065091:-
THCA	cis	rs1336149	0.527	rs1750802	ENSG00000211581.1	MIR765	-3.88	0.000121	0.00924	-0.23	-0.18	Chin dimples;	chr1:157035362	chr1:156936131~156936244:-
THCA	cis	rs7927592	0.956	rs2155730	ENSG00000160172.9	FAM86C2P	3.88	0.000121	0.00924	0.17	0.18	Total body bone mineral density;	chr11:68562006	chr11:67791648~67805336:-
THCA	cis	rs4268898	0.722	rs10445893	ENSG00000242628.4	AC009228.1	-3.88	0.000121	0.00924	-0.21	-0.18	Asthma;	chr2:24184259	chr2:24214381~24221516:+
THCA	cis	rs427943	0.864	rs367986	ENSG00000223768.1	LINC00205	3.88	0.000121	0.00924	0.16	0.18	Body mass index;	chr21:45168189	chr21:45293285~45297354:+
THCA	cis	rs4660214	0.666	rs587404	ENSG00000228060.1	RP11-69E11.8	-3.88	0.000121	0.00924	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39565160~39573203:+
THCA	cis	rs12681366	0.762	rs10109060	ENSG00000261437.1	RP11-22C11.2	3.88	0.000121	0.00924	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94365140	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.762	rs1598713	ENSG00000261437.1	RP11-22C11.2	3.88	0.000121	0.00924	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94369061	chr8:94637285~94639467:-
THCA	cis	rs10256972	0.521	rs10280960	ENSG00000225146.1	AC073957.15	3.88	0.000122	0.00924	0.18	0.18	Endometriosis;Longevity;	chr7:1064061	chr7:1029025~1043891:+
THCA	cis	rs7707921	0.881	rs112413913	ENSG00000251374.1	RPS23P5	3.88	0.000122	0.00924	0.26	0.18	Breast cancer;	chr5:82063890	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.881	rs73134739	ENSG00000251374.1	RPS23P5	3.88	0.000122	0.00924	0.26	0.18	Breast cancer;	chr5:82074941	chr5:82265157~82265259:-
THCA	cis	rs4666002	0.636	rs2272406	ENSG00000234072.1	AC074117.10	3.88	0.000122	0.00924	0.16	0.18	Phospholipid levels (plasma);	chr2:27669156	chr2:27356246~27367622:+
THCA	cis	rs494526	0.739	rs67487722	ENSG00000229272.1	RP11-498J9.2	3.88	0.000122	0.00924	0.2	0.18	Alcoholic chronic pancreatitis;	chr10:119044922	chr10:119003536~119003884:-
THCA	cis	rs2033711	0.783	rs8113810	ENSG00000268049.1	CTD-2619J13.9	-3.88	0.000122	0.00925	-0.22	-0.18	Uric acid clearance;	chr19:58420739	chr19:58357999~58359603:+
THCA	cis	rs2033711	0.87	rs4801270	ENSG00000268049.1	CTD-2619J13.9	-3.88	0.000122	0.00925	-0.22	-0.18	Uric acid clearance;	chr19:58421395	chr19:58357999~58359603:+
THCA	cis	rs755249	0.567	rs16825887	ENSG00000182109.6	RP11-69E11.4	-3.88	0.000122	0.00925	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39522280~39546187:-
THCA	cis	rs854765	0.624	rs4925116	ENSG00000281749.1	Y_RNA	-3.88	0.000122	0.00925	-0.23	-0.18	Total body bone mineral density;	chr17:17827886	chr17:18001101~18001195:-
THCA	cis	rs7956611	0.564	rs7316113	ENSG00000213343.5	RPL21P18	-3.88	0.000122	0.00925	-0.2	-0.18	Age of smoking initiation;	chr12:66509292	chr12:66037235~66037714:+
THCA	cis	rs12780845	0.54	rs11254435	ENSG00000234961.1	RP11-124N14.3	-3.88	0.000122	0.00925	-0.18	-0.18	Homocysteine levels;	chr10:17182427	chr10:17233325~17234833:-
THCA	cis	rs3767627	0.505	rs3767628	ENSG00000203819.6	HIST2H2BC	3.88	0.000122	0.00925	0.22	0.18	Height;	chr1:149966820	chr1:149850193~149850772:-
THCA	cis	rs6121246	1	rs6121246	ENSG00000224628.2	RP5-854E16.2	-3.88	0.000122	0.00925	-0.24	-0.18	Mean corpuscular hemoglobin;	chr20:31845549	chr20:31285317~31286835:-
THCA	cis	rs1009077	0.627	rs35526209	ENSG00000245958.5	RP11-33B1.1	3.88	0.000122	0.00926	0.24	0.18	Endometriosis;	chr4:119675251	chr4:119454791~119552025:+
THCA	cis	rs17092148	0.848	rs6060030	ENSG00000276073.1	RP5-1125A11.7	-3.88	0.000122	0.00926	-0.2	-0.18	Neuroticism;	chr20:34752510	chr20:33985617~33988989:-
THCA	cis	rs7166081	1	rs12443279	ENSG00000270964.1	RP11-502I4.3	-3.88	0.000122	0.00926	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67269017	chr15:67541072~67542604:-
THCA	cis	rs4245128	0.93	rs1447479	ENSG00000247416.2	RP11-629G13.1	3.88	0.000122	0.00926	0.17	0.18	Life satisfaction;	chr11:112906576	chr11:112959279~112963460:-
THCA	cis	rs9834970	1	rs9834970	ENSG00000281100.1	RP11-640L9.2	3.88	0.000122	0.00926	0.18	0.18	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36814539	chr3:36823151~36825158:-
THCA	cis	rs478304	0.593	rs4645927	ENSG00000255557.1	RP11-770G2.2	3.88	0.000122	0.00926	0.21	0.18	Acne (severe);	chr11:65715356	chr11:65745729~65771585:+
THCA	cis	rs11089937	0.926	rs5750601	ENSG00000263366.2	LL22NC03-33B6.4	-3.88	0.000122	0.00926	-0.22	-0.18	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22114844~22118005:-
THCA	cis	rs2380205	0.583	rs7919425	ENSG00000232807.2	RP11-536K7.3	3.88	0.000122	0.00926	0.17	0.18	Breast cancer;	chr10:5926122	chr10:5934270~5945900:-
THCA	cis	rs4295623	0.556	rs10903343	ENSG00000206014.6	OR7E161P	-3.88	0.000122	0.00926	-0.2	-0.18	Morning vs. evening chronotype;	chr8:11838363	chr8:11928597~11929563:-
THCA	cis	rs10411262	0.935	rs314661	ENSG00000245598.5	DACT3-AS1	-3.88	0.000122	0.00926	-0.2	-0.18	Tonsillectomy;	chr19:46669216	chr19:46660364~46677447:+
THCA	cis	rs4321325	0.733	rs78516281	ENSG00000236682.1	AC068282.3	-3.88	0.000122	0.00926	-0.37	-0.18	Protein C levels;	chr2:127186988	chr2:127389130~127400580:+
THCA	cis	rs7819412	0.505	rs17782536	ENSG00000261451.1	RP11-981G7.1	-3.88	0.000122	0.00926	-0.23	-0.18	Triglycerides;	chr8:11164172	chr8:10433672~10438312:+
THCA	cis	rs4906332	1	rs35366629	ENSG00000252469.1	RNU7-160P	3.87	0.000122	0.00926	0.19	0.18	Coronary artery disease;	chr14:103436717	chr14:103550345~103550406:+
THCA	cis	rs2135507	0.817	rs6850132	ENSG00000270480.1	RP11-57B24.1	3.87	0.000122	0.00926	0.24	0.18	Juvenile osteochondritis dissecans;	chr4:82656082	chr4:82691737~82692468:+
THCA	cis	rs2135507	0.817	rs6830284	ENSG00000270480.1	RP11-57B24.1	3.87	0.000122	0.00926	0.24	0.18	Juvenile osteochondritis dissecans;	chr4:82656255	chr4:82691737~82692468:+
THCA	cis	rs1383484	0.798	rs59355989	ENSG00000259728.4	LINC00933	-3.87	0.000122	0.00926	-0.23	-0.18	Height;	chr15:83841979	chr15:84570649~84580175:+
THCA	cis	rs3018712	0.532	rs2510396	ENSG00000212093.1	AP000807.1	-3.87	0.000122	0.00926	-0.23	-0.18	Total body bone mineral density;	chr11:68650184	chr11:68506083~68506166:-
THCA	cis	rs10129255	0.957	rs8009073	ENSG00000280411.1	IGHV1-69-2	-3.87	0.000122	0.00926	-0.11	-0.18	Kawasaki disease;	chr14:106777278	chr14:106762092~106762588:-
THCA	cis	rs959260	1	rs2117563	ENSG00000263843.1	RP11-649A18.12	3.87	0.000122	0.00926	0.19	0.18	Systemic lupus erythematosus;	chr17:75372904	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs959260	ENSG00000263843.1	RP11-649A18.12	3.87	0.000122	0.00926	0.19	0.18	Systemic lupus erythematosus;	chr17:75373341	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs7226070	ENSG00000263843.1	RP11-649A18.12	3.87	0.000122	0.00926	0.19	0.18	Systemic lupus erythematosus;	chr17:75376730	chr17:75271369~75273895:+
THCA	cis	rs564799	0.966	rs629209	ENSG00000244040.4	IL12A-AS1	3.87	0.000122	0.00927	0.23	0.18	Systemic lupus erythematosus;	chr3:160010926	chr3:159913400~160225299:-
THCA	cis	rs6687821	0.515	rs2753275	ENSG00000261737.1	RP4-612B15.3	-3.87	0.000122	0.00927	-0.27	-0.18	Yeast infection;	chr1:86956377	chr1:86703502~86704462:-
THCA	cis	rs11971779	0.688	rs8137	ENSG00000252332.1	RNU6-911P	3.87	0.000122	0.00927	0.2	0.18	Diisocyanate-induced asthma;	chr7:139419715	chr7:139448740~139448843:+
THCA	cis	rs3770081	0.59	rs79771503	ENSG00000273080.1	RP11-301O19.1	-3.87	0.000122	0.00927	-0.44	-0.18	Facial emotion recognition (sad faces);	chr2:86239616	chr2:86195590~86196049:+
THCA	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00927	0.18	0.18	Asthma;	chr2:102411180	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00927	0.18	0.18	Asthma;	chr2:102411191	chr2:102438713~102440475:+
THCA	cis	rs2933343	0.621	rs4927921	ENSG00000261159.1	RP11-723O4.9	-3.87	0.000122	0.00927	-0.18	-0.18	IgG glycosylation;	chr3:128850025	chr3:128859716~128860526:-
THCA	cis	rs4245128	0.862	rs7951929	ENSG00000247416.2	RP11-629G13.1	3.87	0.000122	0.00927	0.17	0.18	Life satisfaction;	chr11:112892072	chr11:112959279~112963460:-
THCA	cis	rs12755164	0.51	rs12137963	ENSG00000223479.3	RP4-788P17.1	3.87	0.000122	0.00927	0.2	0.18	Schizophrenia;	chr1:72832194	chr1:73635216~73715214:+
THCA	cis	rs685782	0.73	rs2957867	ENSG00000200201.1	Y_RNA	-3.87	0.000122	0.00927	-0.26	-0.18	Metabolite levels (Dihydroxy docosatrienoic acid);	chr11:3772593	chr11:3665164~3665259:-
THCA	cis	rs337161	0.765	rs365398	ENSG00000221571.3	RNU6ATAC35P	-3.87	0.000122	0.00927	-0.2	-0.18	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220764886	chr1:220825620~220826063:+
THCA	cis	rs337161	0.765	rs425473	ENSG00000221571.3	RNU6ATAC35P	-3.87	0.000122	0.00927	-0.2	-0.18	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220765226	chr1:220825620~220826063:+
THCA	cis	rs1541160	0.956	rs72715936	ENSG00000239494.2	RN7SL333P	-3.87	0.000122	0.00927	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:170014706	chr1:169859756~169860052:+
THCA	cis	rs10089	0.904	rs3087889	ENSG00000245937.6	LINC01184	3.87	0.000122	0.00927	0.19	0.18	Ileal carcinoids;	chr5:128189252	chr5:127940426~128083172:-
THCA	cis	rs854765	0.551	rs6502626	ENSG00000281749.1	Y_RNA	3.87	0.000122	0.00927	0.22	0.18	Total body bone mineral density;	chr17:17946136	chr17:18001101~18001195:-
THCA	cis	rs6696239	0.956	rs1390401	ENSG00000227711.2	RP11-275O4.5	-3.87	0.000122	0.00927	-0.24	-0.18	Height;	chr1:227610249	chr1:227509028~227520477:-
THCA	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	3.87	0.000122	0.00927	0.19	0.18	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
THCA	cis	rs7551222	0.752	rs4252677	ENSG00000240219.1	RP11-430C7.5	3.87	0.000122	0.00927	0.16	0.18	Schizophrenia;	chr1:204526125	chr1:204626775~204629712:+
THCA	cis	rs875971	0.545	rs6460281	ENSG00000232559.3	GS1-124K5.12	3.87	0.000122	0.00927	0.19	0.18	Aortic root size;	chr7:66216128	chr7:66554588~66576923:-
THCA	cis	rs1850744	0.702	rs13104360	ENSG00000163612.10	FAM86KP	-3.87	0.000122	0.00927	-0.39	-0.18	Economic and political preferences;	chr4:9683180	chr4:9153296~9165451:+
THCA	cis	rs1577917	0.559	rs7763210	ENSG00000220563.1	PKMP3	-3.87	0.000122	0.00927	-0.13	-0.18	Response to antipsychotic treatment;	chr6:86098900	chr6:85659892~85660606:-
THCA	cis	rs708224	0.513	rs792474	ENSG00000277342.1	RP11-843B15.4	3.87	0.000122	0.00928	0.23	0.18	Pancreatic cancer;	chr12:32281787	chr12:32109076~32109602:+
THCA	cis	rs7411387	1	rs7411387	ENSG00000203878.10	CHIAP2	3.87	0.000122	0.00928	0.19	0.18	Interferon alpha levels in systemic lupus erythematosus;	chr1:111294513	chr1:111280059~111286116:+
THCA	cis	rs7824557	0.527	rs11785394	ENSG00000227888.4	FAM66A	-3.87	0.000122	0.00928	-0.22	-0.18	Retinal vascular caliber;	chr8:11380520	chr8:12362019~12388296:+
THCA	cis	rs12022452	1	rs2184877	ENSG00000272145.1	NFYC-AS1	3.87	0.000122	0.00928	0.14	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40690380~40692066:-
THCA	cis	rs9309473	1	rs6724782	ENSG00000273245.1	RP11-434P11.2	3.87	0.000122	0.00928	0.23	0.18	Metabolite levels;	chr2:73452863	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs6546839	ENSG00000273245.1	RP11-434P11.2	3.87	0.000122	0.00928	0.23	0.18	Metabolite levels;	chr2:73453381	chr2:73750256~73750786:-
THCA	cis	rs7809950	0.723	rs62483633	ENSG00000272072.1	CTA-363E19.2	3.87	0.000122	0.00928	0.19	0.18	Coronary artery disease;	chr7:107236199	chr7:107192559~107193300:-
THCA	cis	rs7985	1	rs1894720	ENSG00000244625.4	MIATNB	3.87	0.000122	0.00928	0.2	0.18	Electroencephalogram traits;	chr22:26671261	chr22:26672767~26780207:+
THCA	cis	rs1113500	0.787	rs4571989	ENSG00000230489.1	VAV3-AS1	-3.87	0.000122	0.00928	-0.16	-0.18	Growth-regulated protein alpha levels;	chr1:108088722	chr1:107964443~107994607:+
THCA	cis	rs17881320	0.51	rs7221385	ENSG00000108785.7	HSD17B1P1	3.87	0.000122	0.00928	0.33	0.18	Atopic dermatitis;	chr17:42410063	chr17:42546764~42548706:+
THCA	cis	rs10954779	0.764	rs2737339	ENSG00000127589.4	TUBBP1	-3.87	0.000122	0.00928	-0.21	-0.18	Intelligence (multi-trait analysis);	chr8:31155954	chr8:30351873~30353518:+
THCA	cis	rs4671400	0.543	rs10178135	ENSG00000271889.1	RP11-493E12.1	-3.87	0.000122	0.00928	-0.18	-0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258132	chr2:61151433~61162105:-
THCA	cis	rs881375	0.967	rs7034653	ENSG00000270917.1	RP11-27I1.6	-3.87	0.000122	0.00928	-0.24	-0.18	Rheumatoid arthritis;	chr9:120925094	chr9:120812475~120812845:-
THCA	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	3.87	0.000122	0.00928	0.23	0.18	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
THCA	cis	rs10761482	0.775	rs1459725	ENSG00000254271.1	RP11-131N11.4	3.87	0.000122	0.00928	0.24	0.18	Schizophrenia;	chr10:60378850	chr10:60734342~60741828:+
THCA	cis	rs11678584	0.513	rs4435504	ENSG00000276517.1	AL133243.2	-3.87	0.000122	0.00928	-0.25	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32534801	chr2:32526504~32529507:+
THCA	cis	rs9425766	0.886	rs1322775	ENSG00000270084.1	GAS5-AS1	-3.87	0.000122	0.00928	-0.18	-0.18	Life satisfaction;	chr1:173886160	chr1:173863248~173863941:+
THCA	cis	rs11583043	0.575	rs12727971	ENSG00000233184.5	RP11-421L21.3	3.87	0.000122	0.00928	0.19	0.18	Inflammatory bowel disease;Ulcerative colitis;	chr1:101123619	chr1:101025878~101087268:+
THCA	cis	rs1577917	0.958	rs34994386	ENSG00000220563.1	PKMP3	-3.87	0.000122	0.00929	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85814417	chr6:85659892~85660606:-
THCA	cis	rs78153629	0.841	rs17733008	ENSG00000259330.1	INAFM2	-3.87	0.000122	0.00929	-0.21	-0.18	Heschl's gyrus morphology;	chr15:40382719	chr15:40325216~40326715:+
THCA	cis	rs78153629	1	rs7164132	ENSG00000259330.1	INAFM2	-3.87	0.000122	0.00929	-0.21	-0.18	Heschl's gyrus morphology;	chr15:40382954	chr15:40325216~40326715:+
THCA	cis	rs5752773	0.514	rs2223370	ENSG00000272858.1	CTA-292E10.8	-3.87	0.000122	0.00929	-0.2	-0.18	Vertical cup-disc ratio;	chr22:28273167	chr22:28814914~28815662:+
THCA	cis	rs7737355	0.898	rs3775999	ENSG00000237714.1	P4HA2-AS1	3.87	0.000122	0.00929	0.26	0.18	Life satisfaction;	chr5:131634397	chr5:132184876~132192808:+
THCA	cis	rs206548	1	rs206559	ENSG00000266891.1	RP11-692N5.2	-3.87	0.000122	0.00929	-0.22	-0.18	Serum protein levels (sST2);	chr18:10380477	chr18:9734882~9735602:-
THCA	cis	rs6477918	0.598	rs34120702	ENSG00000230185.4	C9orf147	-3.87	0.000122	0.00929	-0.18	-0.18	Obstetric antiphospholipid syndrome;	chr9:112397239	chr9:112433816~112487204:-
THCA	cis	rs6477918	0.598	rs34080807	ENSG00000230185.4	C9orf147	-3.87	0.000122	0.00929	-0.18	-0.18	Obstetric antiphospholipid syndrome;	chr9:112398261	chr9:112433816~112487204:-
THCA	cis	rs6477918	0.598	rs7046534	ENSG00000230185.4	C9orf147	-3.87	0.000122	0.00929	-0.18	-0.18	Obstetric antiphospholipid syndrome;	chr9:112399269	chr9:112433816~112487204:-
THCA	cis	rs6762	0.748	rs3059	ENSG00000255142.1	AP006621.6	3.87	0.000122	0.00929	0.13	0.18	Mean platelet volume;	chr11:840319	chr11:781645~782105:+
THCA	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00929	0.18	0.18	Asthma;	chr2:102381261	chr2:102438713~102440475:+
THCA	cis	rs9467773	0.596	rs62396201	ENSG00000228223.2	HCG11	-3.87	0.000122	0.00929	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26523450~26526579:+
THCA	cis	rs1035144	0.679	rs2110696	ENSG00000259167.2	NMNAT1P1	3.87	0.000122	0.00929	0.23	0.18	Male sexual orientation;	chr14:80977024	chr14:81032529~81033404:+
THCA	cis	rs6580649	0.825	rs4760611	ENSG00000273765.1	RP11-370I10.11	3.87	0.000122	0.00929	0.19	0.18	Lung cancer;	chr12:48027666	chr12:48360920~48361377:+
THCA	cis	rs453301	0.506	rs476845	ENSG00000253981.4	ALG1L13P	-3.87	0.000122	0.00929	-0.16	-0.18	Joint mobility (Beighton score);	chr8:8765367	chr8:8236003~8244667:-
THCA	cis	rs1930961	1	rs5996946	ENSG00000272942.1	CTA-246H3.12	-3.87	0.000122	0.00929	-0.3	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25434324~25435070:-
THCA	cis	rs2898279	0.815	rs4581006	ENSG00000242296.2	DEFB109P1	-3.87	0.000122	0.00929	-0.23	-0.18	Small cell lung carcinoma;	chr8:11447856	chr8:12393209~12400366:-
THCA	cis	rs2239547	0.657	rs4687554	ENSG00000243224.1	RP5-1157M23.2	-3.87	0.000122	0.00929	-0.21	-0.18	Schizophrenia;	chr3:52830119	chr3:52239258~52241097:+
THCA	cis	rs58235267	0.564	rs360808	ENSG00000242412.1	DBIL5P2	3.87	0.000122	0.00929	0.21	0.18	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:62700340	chr2:63117851~63119542:-
THCA	cis	rs6696239	1	rs6698409	ENSG00000227711.2	RP11-275O4.5	-3.87	0.000122	0.00929	-0.25	-0.18	Height;	chr1:227580657	chr1:227509028~227520477:-
THCA	cis	rs9840812	0.592	rs900048	ENSG00000239213.4	NCK1-AS1	3.87	0.000122	0.00929	0.16	0.18	Fibrinogen levels;	chr3:136500088	chr3:136841726~136862054:-
THCA	cis	rs2279440	0.85	rs3872707	ENSG00000254485.4	RP11-380O24.1	3.87	0.000122	0.00929	0.22	0.18	Glucose homeostasis traits;	chr3:9472332	chr3:9292588~9363303:-
THCA	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	3.87	0.000122	0.00929	0.28	0.18	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
THCA	cis	rs2380205	0.517	rs7082434	ENSG00000232807.2	RP11-536K7.3	3.87	0.000122	0.00929	0.18	0.18	Breast cancer;	chr10:5906675	chr10:5934270~5945900:-
THCA	cis	rs4792901	0.765	rs12601607	ENSG00000279602.1	CTD-3014M21.1	-3.87	0.000122	0.00929	-0.23	-0.18	Dupuytren's disease;	chr17:43461415	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.729	rs12603131	ENSG00000279602.1	CTD-3014M21.1	-3.87	0.000122	0.00929	-0.23	-0.18	Dupuytren's disease;	chr17:43461471	chr17:43360041~43361361:-
THCA	cis	rs9911578	1	rs12449365	ENSG00000224738.1	AC099850.1	-3.87	0.000122	0.00929	-0.2	-0.18	Intelligence (multi-trait analysis);	chr17:58523299	chr17:59106598~59118267:+
THCA	cis	rs529866	0.519	rs4451969	ENSG00000263080.1	RP11-485G7.5	-3.87	0.000122	0.0093	-0.21	-0.18	Inflammatory bowel disease;Crohn's disease;	chr16:11289662	chr16:11341809~11345211:-
THCA	cis	rs5758511	0.68	rs56111723	ENSG00000270083.1	RP1-257I20.14	-3.87	0.000122	0.0093	-0.22	-0.18	Birth weight;	chr22:42268877	chr22:42089630~42090028:-
THCA	cis	rs15676	0.947	rs2997922	ENSG00000234771.3	SLC25A25-AS1	3.87	0.000122	0.0093	0.14	0.18	Blood metabolite levels;	chr9:128818465	chr9:128108581~128118693:-
THCA	cis	rs10129255	0.517	rs11625572	ENSG00000224373.3	IGHV4-59	3.87	0.000122	0.0093	0.11	0.18	Kawasaki disease;	chr14:106656426	chr14:106627249~106627825:-
THCA	cis	rs1404100	0.51	rs6768480	ENSG00000249274.1	PDLIM1P4	3.87	0.000122	0.0093	0.18	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99070070	chr3:98782188~98783193:+
THCA	cis	rs6477918	0.598	rs7019195	ENSG00000230185.4	C9orf147	-3.87	0.000122	0.0093	-0.18	-0.18	Obstetric antiphospholipid syndrome;	chr9:112399502	chr9:112433816~112487204:-
THCA	cis	rs7674212	0.51	rs2720468	ENSG00000230069.3	LRRC37A15P	-3.87	0.000122	0.0093	-0.18	-0.18	Type 2 diabetes;	chr4:103163996	chr4:102727274~102730721:-
THCA	cis	rs5758659	0.652	rs133321	ENSG00000281538.1	RP4-669P10.20	3.87	0.000122	0.0093	0.16	0.18	Cognitive function;	chr22:42009318	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.652	rs133323	ENSG00000281538.1	RP4-669P10.20	3.87	0.000122	0.0093	0.16	0.18	Cognitive function;	chr22:42009918	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.652	rs133327	ENSG00000281538.1	RP4-669P10.20	3.87	0.000122	0.0093	0.16	0.18	Cognitive function;	chr22:42011685	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.652	rs133330	ENSG00000281538.1	RP4-669P10.20	3.87	0.000122	0.0093	0.16	0.18	Cognitive function;	chr22:42013452	chr22:42138060~42139726:+
THCA	cis	rs13053817	1	rs34305567	ENSG00000279159.1	RP3-394A18.1	3.87	0.000122	0.0093	0.18	0.18	Carotid atherosclerosis in HIV infection;	chr22:29457573	chr22:29978950~30028236:-
THCA	cis	rs7267979	0.586	rs11087505	ENSG00000274973.1	RP13-401N8.7	-3.87	0.000122	0.0093	-0.2	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:25845497~25845862:+
THCA	cis	rs3748682	0.861	rs28625842	ENSG00000252448.1	SNORA63	-3.87	0.000122	0.0093	-0.22	-0.18	Hypothyroidism;	chr1:37845114	chr1:37884237~37884317:+
THCA	cis	rs2640806	0.505	rs11996832	ENSG00000253105.4	KB-1448A5.1	3.87	0.000122	0.0093	0.21	0.18	Obesity-related traits;	chr8:96353584	chr8:96371865~96387438:-
THCA	cis	rs786425	0.77	rs12825800	ENSG00000278112.1	RP11-972P1.11	3.87	0.000122	0.0093	0.17	0.18	Pubertal anthropometrics;	chr12:123709119	chr12:123519390~123519856:-
THCA	cis	rs786425	0.77	rs6488897	ENSG00000278112.1	RP11-972P1.11	3.87	0.000122	0.0093	0.17	0.18	Pubertal anthropometrics;	chr12:123710936	chr12:123519390~123519856:-
THCA	cis	rs7200543	1	rs72774845	ENSG00000188599.16	NPIPP1	-3.87	0.000122	0.0093	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:15104312~15123498:-
THCA	cis	rs4803480	0.507	rs11083627	ENSG00000270164.1	LINC01480	-3.87	0.000122	0.0093	-0.15	-0.18	Schizophrenia;	chr19:41563530	chr19:41535183~41536904:+
THCA	cis	rs6449502	0.702	rs1867597	ENSG00000251279.1	CTC-436P18.1	-3.87	0.000122	0.0093	-0.27	-0.18	Mean platelet volume;	chr5:60842003	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.702	rs13189346	ENSG00000251279.1	CTC-436P18.1	-3.87	0.000122	0.0093	-0.27	-0.18	Mean platelet volume;	chr5:60842032	chr5:61162070~61232040:+
THCA	cis	rs721917	0.506	rs1923540	ENSG00000244733.5	RP11-506M13.3	-3.87	0.000122	0.0093	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79660891~79677996:+
THCA	cis	rs5758659	0.652	rs133324	ENSG00000281538.1	RP4-669P10.20	3.87	0.000122	0.0093	0.16	0.18	Cognitive function;	chr22:42010367	chr22:42138060~42139726:+
THCA	cis	rs10860794	0.667	rs11111069	ENSG00000274560.1	RP11-285E23.2	-3.87	0.000122	0.0093	-0.12	-0.18	Blood protein levels;	chr12:101878184	chr12:101696002~101696450:-
THCA	cis	rs7674212	0.541	rs4699050	ENSG00000230069.3	LRRC37A15P	-3.87	0.000122	0.00931	-0.18	-0.18	Type 2 diabetes;	chr4:103193140	chr4:102727274~102730721:-
THCA	cis	rs7674212	0.541	rs17217473	ENSG00000230069.3	LRRC37A15P	-3.87	0.000122	0.00931	-0.18	-0.18	Type 2 diabetes;	chr4:103193585	chr4:102727274~102730721:-
THCA	cis	rs6860806	0.661	rs2136188	ENSG00000263597.1	MIR3936	-3.87	0.000122	0.00931	-0.17	-0.18	Breast cancer;	chr5:132241821	chr5:132365490~132365599:-
THCA	cis	rs2221894	0.881	rs6994074	ENSG00000251191.6	LINC00589	3.87	0.000122	0.00931	0.21	0.18	Obesity-related traits;	chr8:29035376	chr8:29673922~29748109:-
THCA	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma;	chr2:102415109	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma;	chr2:102415289	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma;	chr2:102417501	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma;	chr2:102418383	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma;	chr2:102419319	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma;	chr2:102419875	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
THCA	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	3.87	0.000122	0.00931	0.18	0.18	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
THCA	cis	rs7849973	0.581	rs62574662	ENSG00000234840.1	LINC01239	-3.87	0.000122	0.00931	-0.22	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22812202	chr9:22646200~22824213:+
THCA	cis	rs758324	0.588	rs421377	ENSG00000237714.1	P4HA2-AS1	3.87	0.000122	0.00931	0.25	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131991464	chr5:132184876~132192808:+
THCA	cis	rs6046396	1	rs6046396	ENSG00000233895.1	RP1-122P22.2	3.87	0.000122	0.00931	0.15	0.18	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19757708~19809675:+
THCA	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	3.87	0.000122	0.00931	0.19	0.18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
THCA	cis	rs4722166	0.532	rs6963591	ENSG00000225541.1	AC002480.5	3.87	0.000123	0.00931	0.19	0.18	Lung cancer;	chr7:22717651	chr7:22571607~22661792:-
THCA	cis	rs2898290	0.5	rs11998678	ENSG00000255046.1	RP11-297N6.4	3.87	0.000123	0.00931	0.19	0.18	Systolic blood pressure;	chr8:11972641	chr8:11797928~11802568:-
THCA	cis	rs55702914	0.712	rs6730590	ENSG00000231621.1	AC013264.2	3.87	0.000123	0.00931	0.17	0.18	Major depression and alcohol dependence;	chr2:197283360	chr2:197197991~197199273:+
THCA	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	3.87	0.000123	0.00931	0.18	0.18	Asthma;	chr2:102410644	chr2:102438713~102440475:+
THCA	cis	rs7243790	0.777	rs3826583	ENSG00000277324.1	RP11-850A17.1	-3.87	0.000123	0.00931	-0.19	-0.18	Diastolic blood pressure;	chr18:54406621	chr18:54268346~54270028:-
THCA	cis	rs4930561	0.765	rs4930229	ENSG00000184795.9	UNC93B5	-3.87	0.000123	0.00931	-0.2	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68176613	chr11:67711702~67716005:-
THCA	cis	rs7927592	0.913	rs6591340	ENSG00000160172.9	FAM86C2P	3.87	0.000123	0.00931	0.17	0.18	Total body bone mineral density;	chr11:68530168	chr11:67791648~67805336:-
THCA	cis	rs6788895	0.661	rs16862837	ENSG00000244265.1	SIAH2-AS1	-3.87	0.000123	0.00931	-0.39	-0.18	Breast cancer;	chr3:150752071	chr3:150761937~150762538:+
THCA	cis	rs6968419	1	rs2402053	ENSG00000237870.5	AC073130.1	3.87	0.000123	0.00931	0.18	0.18	Intraocular pressure;	chr7:116196743	chr7:116275606~116286734:-
THCA	cis	rs7824557	0.737	rs10481445	ENSG00000154316.13	TDH	3.87	0.000123	0.00931	0.13	0.18	Retinal vascular caliber;	chr8:11251760	chr8:11339637~11368452:+
THCA	cis	rs8115854	0.922	rs3748457	ENSG00000269846.1	RP4-621N11.2	-3.87	0.000123	0.00932	-0.23	-0.18	Hippocampal atrophy;	chr20:37158243	chr20:37095785~37097178:+
THCA	cis	rs4443100	0.916	rs6003495	ENSG00000230701.2	FBXW4P1	3.87	0.000123	0.00932	0.21	0.18	Serum parathyroid hormone levels;	chr22:23057565	chr22:23262767~23265005:+
THCA	cis	rs2625529	0.824	rs12906711	ENSG00000260037.4	CTD-2524L6.3	-3.87	0.000123	0.00932	-0.25	-0.18	Red blood cell count;	chr15:71922724	chr15:71818396~71823384:+
THCA	cis	rs2221894	0.922	rs11136055	ENSG00000251191.6	LINC00589	-3.87	0.000123	0.00932	-0.21	-0.18	Obesity-related traits;	chr8:28998009	chr8:29673922~29748109:-
THCA	cis	rs2221894	0.922	rs11136056	ENSG00000251191.6	LINC00589	-3.87	0.000123	0.00932	-0.21	-0.18	Obesity-related traits;	chr8:29006558	chr8:29673922~29748109:-
THCA	cis	rs6997458	0.785	rs2548281	ENSG00000253549.4	RP11-317J10.2	3.87	0.000123	0.00932	0.18	0.18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85398547	chr8:85441851~85464915:-
THCA	cis	rs116175783	0.793	rs3769956	ENSG00000227403.1	AC009299.3	-3.87	0.000123	0.00932	-0.38	-0.18	Intelligence (multi-trait analysis);	chr2:161420790	chr2:161244739~161249050:+
THCA	cis	rs4913250	1	rs4913250	ENSG00000256077.4	RP11-335O4.1	3.87	0.000123	0.00932	0.21	0.18	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr12:67534444	chr12:67571197~67589987:-
THCA	cis	rs6500602	0.964	rs2896893	ENSG00000280063.1	RP11-295D4.3	3.87	0.000123	0.00932	0.1	0.18	Schizophrenia;	chr16:4428558	chr16:4346694~4348648:-
THCA	cis	rs7707921	0.881	rs112355050	ENSG00000251374.1	RPS23P5	3.87	0.000123	0.00932	0.26	0.18	Breast cancer;	chr5:82090216	chr5:82265157~82265259:-
THCA	cis	rs763121	0.815	rs4821799	ENSG00000228274.3	RP3-508I15.9	-3.87	0.000123	0.00932	-0.18	-0.18	Menopause (age at onset);	chr22:38625321	chr22:38667585~38681820:-
THCA	cis	rs988712	0.622	rs7103411	ENSG00000245573.6	BDNF-AS	3.87	0.000123	0.00932	0.17	0.18	Obesity;	chr11:27678578	chr11:27506838~27698174:+
THCA	cis	rs13098911	0.598	rs13089554	ENSG00000226074.4	PRSS44	-3.87	0.000123	0.00932	-0.34	-0.18	Celiac disease;	chr3:46086065	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13095717	ENSG00000226074.4	PRSS44	-3.87	0.000123	0.00932	-0.34	-0.18	Celiac disease;	chr3:46087050	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13075528	ENSG00000226074.4	PRSS44	-3.87	0.000123	0.00932	-0.34	-0.18	Celiac disease;	chr3:46087217	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13095602	ENSG00000226074.4	PRSS44	-3.87	0.000123	0.00932	-0.34	-0.18	Celiac disease;	chr3:46087221	chr3:46809359~46812558:-
THCA	cis	rs2071852	1	rs2071852	ENSG00000280383.1	CTA-941F9.10	3.87	0.000123	0.00932	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr22:45718364	chr22:45657019~45680130:+
THCA	cis	rs7737355	0.947	rs1422081	ENSG00000237714.1	P4HA2-AS1	3.87	0.000123	0.00932	0.25	0.18	Life satisfaction;	chr5:131440360	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs12656936	ENSG00000237714.1	P4HA2-AS1	-3.87	0.000123	0.00932	-0.25	-0.18	Life satisfaction;	chr5:131452949	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs3776028	ENSG00000237714.1	P4HA2-AS1	-3.87	0.000123	0.00932	-0.25	-0.18	Life satisfaction;	chr5:131454057	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs739952	ENSG00000237714.1	P4HA2-AS1	-3.87	0.000123	0.00932	-0.25	-0.18	Life satisfaction;	chr5:131460875	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs58895212	ENSG00000237714.1	P4HA2-AS1	-3.87	0.000123	0.00932	-0.25	-0.18	Life satisfaction;	chr5:131461364	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs12659474	ENSG00000237714.1	P4HA2-AS1	-3.87	0.000123	0.00932	-0.25	-0.18	Life satisfaction;	chr5:131465611	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs1468303	ENSG00000237714.1	P4HA2-AS1	-3.87	0.000123	0.00932	-0.25	-0.18	Life satisfaction;	chr5:131468707	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs42264	ENSG00000237714.1	P4HA2-AS1	3.87	0.000123	0.00932	0.25	0.18	Life satisfaction;	chr5:131474335	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs13163091	ENSG00000237714.1	P4HA2-AS1	-3.87	0.000123	0.00932	-0.25	-0.18	Life satisfaction;	chr5:131500348	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs7720339	ENSG00000237714.1	P4HA2-AS1	3.87	0.000123	0.00932	0.25	0.18	Life satisfaction;	chr5:131501441	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs6882552	ENSG00000237714.1	P4HA2-AS1	3.87	0.000123	0.00932	0.25	0.18	Life satisfaction;	chr5:131505800	chr5:132184876~132192808:+
THCA	cis	rs875971	0.564	rs313804	ENSG00000272831.1	RP11-792A8.4	3.87	0.000123	0.00932	0.12	0.18	Aortic root size;	chr7:66049635	chr7:66739829~66740385:-
THCA	cis	rs1908814	0.516	rs13281315	ENSG00000255495.1	AC145124.2	3.87	0.000123	0.00932	0.2	0.18	Neuroticism;	chr8:11937346	chr8:12194467~12196280:+
THCA	cis	rs6546886	0.956	rs10168408	ENSG00000235499.1	AC073046.25	3.87	0.000123	0.00933	0.16	0.18	Dialysis-related mortality;	chr2:74016469	chr2:73985132~73986343:+
THCA	cis	rs1387259	0.929	rs11168460	ENSG00000257735.1	RP11-370I10.6	3.87	0.000123	0.00933	0.2	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.5	rs7297824	ENSG00000257735.1	RP11-370I10.6	3.87	0.000123	0.00933	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48350945~48442411:+
THCA	cis	rs1414896	1	rs4146667	ENSG00000226026.4	RP11-57H12.3	3.87	0.000123	0.00933	0.17	0.18	Non-alcoholic fatty liver disease histology (AST);	chr1:95238041	chr1:95163219~95233982:-
THCA	cis	rs1580019	0.587	rs7806941	ENSG00000273014.1	RP11-225B17.2	3.87	0.000123	0.00933	0.18	0.18	Cognitive ability;	chr7:32513707	chr7:32758882~32759353:+
THCA	cis	rs7737355	0.947	rs10477736	ENSG00000237714.1	P4HA2-AS1	3.87	0.000123	0.00933	0.25	0.18	Life satisfaction;	chr5:131586432	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs6890784	ENSG00000237714.1	P4HA2-AS1	3.87	0.000123	0.00933	0.25	0.18	Life satisfaction;	chr5:131603847	chr5:132184876~132192808:+
THCA	cis	rs6967414	0.681	rs2881352	ENSG00000187953.9	PMS2CL	-3.87	0.000123	0.00933	-0.25	-0.18	Hematocrit;Hemoglobin concentration;	chr7:6713880	chr7:6710128~6753862:+
THCA	cis	rs6517329	0.538	rs4510305	ENSG00000230212.5	AP000688.14	-3.87	0.000123	0.00933	-0.22	-0.18	Schizophrenia;	chr21:36148374	chr21:36069642~36126640:-
THCA	cis	rs6012953	0.874	rs6063534	ENSG00000231715.1	COX6CP2	3.87	0.000123	0.00933	0.19	0.18	Vitiligo;	chr20:50572631	chr20:50479767~50479991:+
THCA	cis	rs2885805	0.596	rs343763	ENSG00000259834.1	RP11-284N8.3	-3.87	0.000123	0.00933	-0.18	-0.18	Cytomegalovirus antibody response;	chr1:110810039	chr1:110653560~110657040:-
THCA	cis	rs10270805	1	rs10270805	ENSG00000272537.1	GS1-166A23.1	-3.87	0.000123	0.00933	-0.35	-0.18	Response to statin therapy;	chr7:16460517	chr7:16471184~16471373:+
THCA	cis	rs7829975	0.593	rs2979241	ENSG00000254340.1	RP11-10A14.3	3.87	0.000123	0.00933	0.19	0.18	Mood instability;	chr8:8445843	chr8:9141424~9145435:+
THCA	cis	rs7772697	0.508	rs4441968	ENSG00000223701.3	RAET1E-AS1	-3.87	0.000123	0.00933	-0.25	-0.18	Diabetic retinopathy;	chr6:149042818	chr6:149884431~149919508:+
THCA	cis	rs12544026	0.548	rs542208	ENSG00000253669.3	KB-1732A1.1	-3.87	0.000123	0.00934	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101888623	chr8:102805517~102809971:+
THCA	cis	rs11710088	0.895	rs13067320	ENSG00000244503.1	RP11-278L15.6	3.87	0.000123	0.00934	0.22	0.18	QRS duration;	chr3:149481805	chr3:149494660~149495995:+
THCA	cis	rs2154427	0.872	rs2230766	ENSG00000238197.4	PAXBP1-AS1	3.87	0.000123	0.00934	0.19	0.18	Bilirubin levels;	chr21:32639102	chr21:32728115~32743122:+
THCA	cis	rs7911264	0.765	rs7092522	ENSG00000236493.2	EIF2S2P3	3.87	0.000123	0.00934	0.19	0.18	Inflammatory bowel disease;	chr10:92583226	chr10:92668745~92669743:-
THCA	cis	rs6496044	0.568	rs4842888	ENSG00000259630.2	CTD-2262B20.1	3.87	0.000123	0.00934	0.19	0.18	Interstitial lung disease;	chr15:85519902	chr15:85415228~85415633:+
THCA	cis	rs62292953	0.79	rs11925701	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132469814	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs62292944	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132472285	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs62292945	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132473630	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs11916613	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132475238	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs77189509	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132475781	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs79623295	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132476042	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs62292948	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132476719	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.722	rs76569691	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132476993	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.656	rs62292949	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132477517	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.79	rs62292951	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000123	0.00934	-0.33	-0.18	Red cell distribution width;	chr3:132479312	chr3:132721750~132874223:+
THCA	cis	rs754466	0.606	rs11002308	ENSG00000213514.2	RP11-428P16.2	3.87	0.000123	0.00934	0.19	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77835038	chr10:77730766~77734769:+
THCA	cis	rs7615952	0.673	rs9821905	ENSG00000248787.1	RP11-666A20.4	3.87	0.000123	0.00934	0.35	0.18	Blood pressure (smoking interaction);	chr3:125902007	chr3:125908005~125910272:-
THCA	cis	rs10875746	0.903	rs989144	ENSG00000258234.1	RP11-370I10.2	3.87	0.000123	0.00934	0.21	0.18	Longevity (90 years and older);	chr12:48090190	chr12:48231098~48284210:-
THCA	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	3.87	0.000123	0.00934	0.18	0.18	Asthma;	chr2:102412435	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	3.87	0.000123	0.00934	0.18	0.18	Asthma;	chr2:102412461	chr2:102438713~102440475:+
THCA	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	3.87	0.000123	0.00934	0.18	0.18	Asthma;	chr2:102412524	chr2:102438713~102440475:+
THCA	cis	rs6546886	0.912	rs4853009	ENSG00000235499.1	AC073046.25	3.87	0.000123	0.00934	0.16	0.18	Dialysis-related mortality;	chr2:74069284	chr2:73985132~73986343:+
THCA	cis	rs7819412	0.668	rs2409721	ENSG00000255046.1	RP11-297N6.4	3.87	0.000123	0.00934	0.19	0.18	Triglycerides;	chr8:11180735	chr8:11797928~11802568:-
THCA	cis	rs11771526	0.901	rs17161086	ENSG00000272905.1	RP11-265E18.1	-3.87	0.000123	0.00934	-0.23	-0.18	Body mass index;	chr7:32254642	chr7:32845394~32846061:+
THCA	cis	rs10761482	0.701	rs7087958	ENSG00000254271.1	RP11-131N11.4	3.87	0.000123	0.00934	0.22	0.18	Schizophrenia;	chr10:60362133	chr10:60734342~60741828:+
THCA	cis	rs7267979	0.899	rs2179459	ENSG00000276952.1	RP5-965G21.6	3.87	0.000123	0.00935	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25284915~25285588:-
THCA	cis	rs8105895	1	rs62112907	ENSG00000269345.1	VN1R85P	3.87	0.000123	0.00935	0.24	0.18	Body mass index (change over time);	chr19:22026767	chr19:22174766~22175191:-
THCA	cis	rs12935229	0.866	rs17769870	ENSG00000260922.1	RP11-538I12.3	3.87	0.000123	0.00935	0.29	0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77302582	chr16:77234877~77290934:+
THCA	cis	rs7586085	0.845	rs3791848	ENSG00000232411.1	AC009495.3	3.87	0.000123	0.00935	0.19	0.18	Total body bone mineral density;	chr2:165756733	chr2:165833048~165839098:-
THCA	cis	rs5758511	0.68	rs5758651	ENSG00000237037.8	NDUFA6-AS1	-3.87	0.000123	0.00935	-0.17	-0.18	Birth weight;	chr22:42213142	chr22:42090931~42137742:+
THCA	cis	rs6504108	0.624	rs4794505	ENSG00000264920.1	RP11-6N17.4	-3.87	0.000123	0.00935	-0.15	-0.18	Body mass index;	chr17:48205944	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.647	rs12150533	ENSG00000264920.1	RP11-6N17.4	-3.87	0.000123	0.00935	-0.15	-0.18	Body mass index;	chr17:48210179	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs4794517	ENSG00000264920.1	RP11-6N17.4	-3.87	0.000123	0.00935	-0.15	-0.18	Body mass index;	chr17:48214491	chr17:47891255~47895812:-
THCA	cis	rs2455799	0.613	rs2455813	ENSG00000270409.1	RP11-44D5.1	-3.87	0.000123	0.00935	-0.18	-0.18	Mean platelet volume;	chr3:15693544	chr3:15732252~15733470:+
THCA	cis	rs9905704	0.836	rs170024	ENSG00000224738.1	AC099850.1	3.87	0.000123	0.00935	0.23	0.18	Testicular germ cell tumor;	chr17:58754526	chr17:59106598~59118267:+
THCA	cis	rs7927592	0.913	rs10896329	ENSG00000160172.9	FAM86C2P	3.87	0.000123	0.00935	0.17	0.18	Total body bone mineral density;	chr11:68482561	chr11:67791648~67805336:-
THCA	cis	rs494526	0.609	rs10886383	ENSG00000229272.1	RP11-498J9.2	-3.87	0.000123	0.00935	-0.2	-0.18	Alcoholic chronic pancreatitis;	chr10:119104715	chr10:119003536~119003884:-
THCA	cis	rs1580019	0.885	rs1610141	ENSG00000231952.3	DPY19L1P2	-3.87	0.000123	0.00935	-0.23	-0.18	Cognitive ability;	chr7:32458823	chr7:32812757~32838570:+
THCA	cis	rs1371614	0.611	rs4665920	ENSG00000272148.1	RP11-195B17.1	-3.87	0.000123	0.00935	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26905966	chr2:27062428~27062907:-
THCA	cis	rs548181	0.673	rs12288034	ENSG00000254671.2	STT3A-AS1	3.87	0.000123	0.00935	0.33	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125701046	chr11:125570284~125592568:-
THCA	cis	rs13118159	0.55	rs1137789	ENSG00000254094.1	AC078852.1	-3.87	0.000123	0.00935	-0.21	-0.18	Longevity;	chr4:1388010	chr4:1356581~1358075:+
THCA	cis	rs1842579	0.767	rs1564515	ENSG00000272691.1	RP11-290M5.4	-3.87	0.000123	0.00935	-0.17	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85875197	chr1:85578500~85578742:-
THCA	cis	rs1842579	0.767	rs12122234	ENSG00000272691.1	RP11-290M5.4	-3.87	0.000123	0.00935	-0.17	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85875470	chr1:85578500~85578742:-
THCA	cis	rs527616	0.793	rs675150	ENSG00000260372.5	AQP4-AS1	3.87	0.000123	0.00935	0.19	0.18	Breast cancer;	chr18:26759755	chr18:26655742~27190698:+
THCA	cis	rs786425	0.835	rs7966867	ENSG00000270095.1	RP11-214K3.18	3.87	0.000123	0.00935	0.2	0.18	Pubertal anthropometrics;	chr12:123694870	chr12:123971457~123971714:-
THCA	cis	rs6586163	1	rs1324551	ENSG00000261438.1	RP11-399O19.9	3.87	0.000123	0.00936	0.14	0.18	Chronic lymphocytic leukemia;	chr10:88991759	chr10:89015836~89017059:+
THCA	cis	rs17767294	0.612	rs9461425	ENSG00000272009.1	RP1-313I6.12	-3.87	0.000123	0.00936	-0.27	-0.18	Parkinson's disease;	chr6:27951910	chr6:28078792~28081130:-
THCA	cis	rs936229	0.626	rs3765066	ENSG00000260269.4	CTD-2323K18.1	-3.87	0.000123	0.00936	-0.24	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr15:74848513	chr15:75527150~75601205:-
THCA	cis	rs4718428	1	rs4718428	ENSG00000275400.1	RP4-756H11.5	-3.87	0.000123	0.00936	-0.17	-0.18	Corneal structure;	chr7:66956459	chr7:66553805~66554199:-
THCA	cis	rs4460629	0.742	rs7365544	ENSG00000225855.5	RUSC1-AS1	3.87	0.000123	0.00936	0.12	0.18	Serum magnesium levels;	chr1:155096272	chr1:155316863~155324176:-
THCA	cis	rs4460629	0.804	rs56112907	ENSG00000225855.5	RUSC1-AS1	3.87	0.000123	0.00936	0.12	0.18	Serum magnesium levels;	chr1:155098386	chr1:155316863~155324176:-
THCA	cis	rs67981189	1	rs67981189	ENSG00000269927.1	RP6-91H8.3	3.87	0.000123	0.00936	0.2	0.18	Schizophrenia;	chr14:71005509	chr14:71141125~71143253:-
THCA	cis	rs6449502	1	rs6871557	ENSG00000251279.1	CTC-436P18.1	-3.87	0.000123	0.00936	-0.28	-0.18	Mean platelet volume;	chr5:60821679	chr5:61162070~61232040:+
THCA	cis	rs561341	1	rs56903735	ENSG00000265798.5	RP11-271K11.5	3.87	0.000123	0.00936	0.25	0.18	Hip circumference adjusted for BMI;	chr17:31927374	chr17:31038575~31059121:-
THCA	cis	rs447735	0.587	rs11647958	ENSG00000274627.1	RP11-104N10.2	3.87	0.000123	0.00936	0.18	0.18	Hemoglobin concentration;	chr16:89654501	chr16:89516797~89522217:+
THCA	cis	rs1979679	0.682	rs4359252	ENSG00000247934.4	RP11-967K21.1	3.87	0.000123	0.00936	0.19	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28434298	chr12:28163298~28190738:-
THCA	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	3.87	0.000123	0.00936	0.23	0.18	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
THCA	cis	rs10435719	0.902	rs4840599	ENSG00000255495.1	AC145124.2	-3.87	0.000123	0.00936	-0.21	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:12194467~12196280:+
THCA	cis	rs12142240	0.698	rs6684274	ENSG00000232022.5	FAAHP1	3.87	0.000123	0.00937	0.2	0.18	Menopause (age at onset);	chr1:46345170	chr1:46432129~46445521:+
THCA	cis	rs6498068	0.594	rs1875929	ENSG00000260468.1	LINC01290	-3.87	0.000123	0.00937	-0.22	-0.18	Metabolite levels (MHPG);	chr16:10528202	chr16:10514842~10528202:-
THCA	cis	rs34864796	0.547	rs200476	ENSG00000226314.6	ZNF192P1	-3.87	0.000123	0.00937	-0.24	-0.18	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28161781~28169594:+
THCA	cis	rs6710503	0.711	rs62140562	ENSG00000271936.1	RP11-443B20.1	-3.87	0.000123	0.00937	-0.2	-0.18	Lung cancer in ever smokers;Breast cancer;	chr2:24798168	chr2:24825610~24826717:+
THCA	cis	rs11671005	0.611	rs56026876	ENSG00000269600.1	AC016629.3	-3.87	0.000123	0.00937	-0.26	-0.18	Mean platelet volume;	chr19:58494790	chr19:58593896~58599355:-
THCA	cis	rs6473252	1	rs6994674	ENSG00000254162.1	RP11-48B3.3	-3.87	0.000123	0.00937	-0.15	-0.18	Breast cancer;	chr8:80878351	chr8:80535006~80539135:-
THCA	cis	rs1541160	1	rs973015	ENSG00000239494.2	RN7SL333P	3.87	0.000123	0.00937	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170063476	chr1:169859756~169860052:+
THCA	cis	rs3177980	0.528	rs6427232	ENSG00000239494.2	RN7SL333P	3.87	0.000123	0.00937	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170072580	chr1:169859756~169860052:+
THCA	cis	rs1541160	1	rs522444	ENSG00000239494.2	RN7SL333P	3.87	0.000123	0.00937	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170074763	chr1:169859756~169860052:+
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000184274.3	LINC00315	-3.87	0.000123	0.00937	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45300245~45305257:-
THCA	cis	rs804280	0.662	rs810738	ENSG00000254948.1	OR7E158P	-3.87	0.000123	0.00937	-0.24	-0.18	Myopia (pathological);	chr8:11753697	chr8:11919900~11920809:-
THCA	cis	rs654950	0.875	rs4660544	ENSG00000230638.4	RP11-486B10.4	3.87	0.000123	0.00937	0.2	0.18	Airway imaging phenotypes;	chr1:41531200	chr1:41542069~41544310:+
THCA	cis	rs151234	0.676	rs151320	ENSG00000259982.1	CDC37P1	3.87	0.000123	0.00937	0.34	0.18	Platelet distribution width;	chr16:28557357	chr16:28700294~28701540:-
THCA	cis	rs6496932	0.909	rs74024818	ENSG00000259630.2	CTD-2262B20.1	3.87	0.000123	0.00937	0.25	0.18	Central corneal thickness;Corneal structure;	chr15:85339299	chr15:85415228~85415633:+
THCA	cis	rs3748656	0.943	rs12756815	ENSG00000273483.1	RP4-671G15.2	3.87	0.000123	0.00937	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112664621	chr1:112517799~112518441:-
THCA	cis	rs7819412	0.703	rs2409713	ENSG00000261451.1	RP11-981G7.1	-3.87	0.000123	0.00937	-0.23	-0.18	Triglycerides;	chr8:11152287	chr8:10433672~10438312:+
THCA	cis	rs875971	0.545	rs1796222	ENSG00000273024.4	INTS4P2	3.87	0.000123	0.00937	0.22	0.18	Aortic root size;	chr7:66592167	chr7:65647864~65715661:+
THCA	cis	rs669446	0.562	rs10890275	ENSG00000237950.1	RP11-7O11.3	3.87	0.000123	0.00937	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43728545	chr1:43944370~43946551:-
THCA	cis	rs9467773	0.935	rs1056668	ENSG00000228223.2	HCG11	-3.87	0.000123	0.00937	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26510377	chr6:26523450~26526579:+
THCA	cis	rs8177876	0.822	rs56198248	ENSG00000261838.4	RP11-303E16.6	3.87	0.000123	0.00937	0.38	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074869	chr16:81069854~81076598:+
THCA	cis	rs150992	0.609	rs366353	ENSG00000246763.5	RGMB-AS1	-3.87	0.000124	0.00937	-0.18	-0.18	Body mass index;	chr5:98995663	chr5:98769618~98773469:-
THCA	cis	rs4713118	0.868	rs35069907	ENSG00000272009.1	RP1-313I6.12	-3.87	0.000124	0.00938	-0.21	-0.18	Parkinson's disease;	chr6:27778913	chr6:28078792~28081130:-
THCA	cis	rs73222236	0.787	rs6783337	ENSG00000273486.1	RP11-731C17.2	3.87	0.000124	0.00938	0.16	0.18	Coronary artery disease;	chr3:136333895	chr3:136837338~136839021:-
THCA	cis	rs4578769	0.836	rs3844227	ENSG00000265939.1	UBE2CP2	3.87	0.000124	0.00938	0.22	0.18	Eosinophil percentage of white cells;	chr18:22871067	chr18:22900486~22900995:-
THCA	cis	rs669446	0.562	rs6429636	ENSG00000237950.1	RP11-7O11.3	3.87	0.000124	0.00938	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43717869	chr1:43944370~43946551:-
THCA	cis	rs669446	0.562	rs10890273	ENSG00000237950.1	RP11-7O11.3	3.87	0.000124	0.00938	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43720773	chr1:43944370~43946551:-
THCA	cis	rs669446	0.562	rs11210907	ENSG00000237950.1	RP11-7O11.3	3.87	0.000124	0.00938	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43726088	chr1:43944370~43946551:-
THCA	cis	rs1635	0.826	rs79567170	ENSG00000216901.1	AL022393.7	3.87	0.000124	0.00938	0.4	0.18	Schizophrenia;	chr6:28312280	chr6:28176188~28176674:+
THCA	cis	rs1635	0.826	rs4713159	ENSG00000216901.1	AL022393.7	3.87	0.000124	0.00938	0.4	0.18	Schizophrenia;	chr6:28315995	chr6:28176188~28176674:+
THCA	cis	rs9863	0.828	rs1187415	ENSG00000270061.1	RP11-214K3.19	3.87	0.000124	0.00938	0.22	0.18	White blood cell count;	chr12:124006982	chr12:123969990~123970344:-
THCA	cis	rs9863	0.828	rs7975482	ENSG00000270028.1	RP11-380L11.4	3.87	0.000124	0.00938	0.19	0.18	White blood cell count;	chr12:123997143	chr12:123925461~123926083:-
THCA	cis	rs4218	0.648	rs8042896	ENSG00000259732.1	RP11-59H7.3	-3.87	0.000124	0.00938	-0.24	-0.18	Social communication problems;	chr15:59067727	chr15:59121034~59133250:+
THCA	cis	rs4792901	0.802	rs9903373	ENSG00000267151.3	RP11-100E5.2	3.87	0.000124	0.00938	0.19	0.18	Dupuytren's disease;	chr17:43480606	chr17:43444707~43451200:+
THCA	cis	rs1871744	0.746	rs6857600	ENSG00000246375.2	RP11-10L7.1	-3.87	0.000124	0.00938	-0.28	-0.18	Renal underexcretion gout;	chr4:88144923	chr4:88284942~88331421:+
THCA	cis	rs79478560	0.518	rs10846573	ENSG00000270061.1	RP11-214K3.19	-3.87	0.000124	0.00938	-0.23	-0.18	Lymphocyte counts;	chr12:123898141	chr12:123969990~123970344:-
THCA	cis	rs7259376	0.936	rs4932760	ENSG00000270947.1	AC025811.3	3.87	0.000124	0.00938	0.19	0.18	Menopause (age at onset);	chr19:22357653	chr19:22455988~22456459:+
THCA	cis	rs5758659	0.652	rs133313	ENSG00000281538.1	RP4-669P10.20	3.87	0.000124	0.00939	0.16	0.18	Cognitive function;	chr22:42005745	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.652	rs133314	ENSG00000281538.1	RP4-669P10.20	3.87	0.000124	0.00939	0.16	0.18	Cognitive function;	chr22:42005837	chr22:42138060~42139726:+
THCA	cis	rs2717559	0.541	rs12549240	ENSG00000253741.1	CTD-2292P10.4	3.87	0.000124	0.00939	0.22	0.18	Urinary tract infection frequency;	chr8:142799964	chr8:142702252~142726973:-
THCA	cis	rs6933660	0.8	rs9383900	ENSG00000219395.2	HSPA8P15	-3.87	0.000124	0.00939	-0.15	-0.18	Menarche (age at onset);	chr6:151461681	chr6:151411259~151413945:-
THCA	cis	rs17818399	0.51	rs1451153	ENSG00000279254.1	RP11-536C12.1	-3.87	0.000124	0.00939	-0.17	-0.18	Height;	chr2:46572713	chr2:46668870~46670778:+
THCA	cis	rs1501911	0.53	rs161933	ENSG00000241597.2	CTD-2007H13.1	-3.87	0.000124	0.00939	-0.23	-0.18	Lung function (FEV1/FVC);	chr5:98874643	chr5:98954394~98954972:+
THCA	cis	rs1501911	0.53	rs161938	ENSG00000241597.2	CTD-2007H13.1	-3.87	0.000124	0.00939	-0.23	-0.18	Lung function (FEV1/FVC);	chr5:98875501	chr5:98954394~98954972:+
THCA	cis	rs55702914	0.65	rs6715690	ENSG00000231621.1	AC013264.2	3.87	0.000124	0.00939	0.17	0.18	Major depression and alcohol dependence;	chr2:197283647	chr2:197197991~197199273:+
THCA	cis	rs2380205	0.517	rs56369297	ENSG00000232807.2	RP11-536K7.3	3.87	0.000124	0.00939	0.18	0.18	Breast cancer;	chr10:5904680	chr10:5934270~5945900:-
THCA	cis	rs10875746	0.859	rs4760622	ENSG00000258273.1	RP11-370I10.4	3.87	0.000124	0.00939	0.25	0.18	Longevity (90 years and older);	chr12:48198177	chr12:48333755~48333901:-
THCA	cis	rs9478638	0.592	rs162982	ENSG00000235381.1	RP11-477D19.2	3.87	0.000124	0.00939	0.14	0.18	Electroencephalogram traits;	chr6:155313480	chr6:155253139~155256724:-
THCA	cis	rs7111546	1	rs1055321	ENSG00000246225.5	RP11-17A1.3	3.87	0.000124	0.00939	0.33	0.18	Dialysis-related mortality;	chr11:22812856	chr11:22829380~22945393:+
THCA	cis	rs12476592	0.602	rs11898615	ENSG00000242412.1	DBIL5P2	3.87	0.000124	0.0094	0.22	0.18	Childhood ear infection;	chr2:63521150	chr2:63117851~63119542:-
THCA	cis	rs875971	0.638	rs6960778	ENSG00000229180.5	GS1-124K5.11	-3.87	0.000124	0.0094	-0.12	-0.18	Aortic root size;	chr7:66606610	chr7:66526088~66542624:-
THCA	cis	rs780094	0.5	rs12987055	ENSG00000234072.1	AC074117.10	3.87	0.000124	0.0094	0.14	0.18	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27611285	chr2:27356246~27367622:+
THCA	cis	rs4666002	0.956	rs13020949	ENSG00000234072.1	AC074117.10	3.87	0.000124	0.0094	0.14	0.18	Phospholipid levels (plasma);	chr2:27613738	chr2:27356246~27367622:+
THCA	cis	rs2455799	0.634	rs11128765	ENSG00000270409.1	RP11-44D5.1	-3.87	0.000124	0.0094	-0.19	-0.18	Mean platelet volume;	chr3:15861824	chr3:15732252~15733470:+
THCA	cis	rs800160	0.925	rs708153	ENSG00000199550.1	Y_RNA	3.87	0.000124	0.0094	0.25	0.18	Bacteremia;	chr11:2363262	chr11:2372638~2372750:+
THCA	cis	rs9402682	0.629	rs1320959	ENSG00000232876.1	CTA-212D2.2	-3.87	0.000124	0.0094	-0.23	-0.18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135116248	chr6:135055033~135060550:+
THCA	cis	rs7335046	0.536	rs61970284	ENSG00000234005.3	GAPDHP22	-3.87	0.000124	0.0094	-0.22	-0.18	Basal cell carcinoma;	chr13:99266517	chr13:99190579~99190991:-
THCA	cis	rs12681963	0.688	rs2958746	ENSG00000248159.1	HSPA8P11	-3.87	0.000124	0.0094	-0.31	-0.18	Migraine;	chr8:30231554	chr8:30237382~30240997:+
THCA	cis	rs911555	0.603	rs8016326	ENSG00000269940.1	RP11-73M18.7	3.87	0.000124	0.0094	0.18	0.18	Intelligence (multi-trait analysis);	chr14:103380379	chr14:103694560~103695170:+
THCA	cis	rs875971	0.545	rs316306	ENSG00000273024.4	INTS4P2	3.87	0.000124	0.0094	0.22	0.18	Aortic root size;	chr7:66153687	chr7:65647864~65715661:+
THCA	cis	rs4819052	0.851	rs2838866	ENSG00000184274.3	LINC00315	-3.87	0.000124	0.0094	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45300245~45305257:-
THCA	cis	rs7914558	1	rs4917996	ENSG00000213061.2	PFN1P11	3.87	0.000124	0.0094	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103166072	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs6584540	ENSG00000213061.2	PFN1P11	3.87	0.000124	0.0094	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103167877	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs7081075	ENSG00000213061.2	PFN1P11	3.87	0.000124	0.0094	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103169434	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs10786740	ENSG00000213061.2	PFN1P11	3.87	0.000124	0.0094	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103175836	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.901	rs35525740	ENSG00000213061.2	PFN1P11	3.87	0.000124	0.0094	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181355	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.869	rs10883842	ENSG00000213061.2	PFN1P11	3.87	0.000124	0.0094	0.21	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181832	chr10:102838011~102845473:-
THCA	cis	rs1153858	1	rs1980288	ENSG00000275672.1	GATM-AS1	-3.87	0.000124	0.0094	-0.18	-0.18	Homoarginine levels;	chr15:45328414	chr15:45378700~45380123:+
THCA	cis	rs442309	0.687	rs10822052	ENSG00000238280.1	RP11-436D10.3	3.87	0.000124	0.0094	0.22	0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62696010	chr10:62793562~62805887:-
THCA	cis	rs4268898	0.697	rs6714652	ENSG00000242628.4	AC009228.1	-3.87	0.000124	0.0094	-0.22	-0.18	Asthma;	chr2:24160189	chr2:24214381~24221516:+
THCA	cis	rs7819412	0.634	rs6987767	ENSG00000206014.6	OR7E161P	-3.87	0.000124	0.0094	-0.2	-0.18	Triglycerides;	chr8:11052556	chr8:11928597~11929563:-
THCA	cis	rs17286411	0.639	rs10500559	ENSG00000260185.1	RP11-432I5.6	-3.87	0.000124	0.0094	-0.25	-0.18	Blood protein levels;	chr16:71659190	chr16:71655027~71664212:+
THCA	cis	rs11971779	0.648	rs6947309	ENSG00000252332.1	RNU6-911P	-3.87	0.000124	0.0094	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139351084	chr7:139448740~139448843:+
THCA	cis	rs853679	0.546	rs71537572	ENSG00000272009.1	RP1-313I6.12	-3.87	0.000124	0.00941	-0.34	-0.18	Depression;	chr6:28002937	chr6:28078792~28081130:-
THCA	cis	rs733592	0.507	rs7299704	ENSG00000258273.1	RP11-370I10.4	-3.87	0.000124	0.00941	-0.21	-0.18	Plateletcrit;	chr12:48050705	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.669	rs11168496	ENSG00000226413.2	OR8T1P	3.87	0.000124	0.00941	0.24	0.18	Longevity (90 years and older);	chr12:48257072	chr12:48442030~48442947:-
THCA	cis	rs793571	0.502	rs688756	ENSG00000245975.2	RP11-30K9.6	3.87	0.000124	0.00941	0.17	0.18	Schizophrenia;	chr15:58784073	chr15:58768072~58770974:-
THCA	cis	rs12216545	0.737	rs7808866	ENSG00000241134.3	BET1P1	-3.87	0.000124	0.00941	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150526894	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs7788188	ENSG00000241134.3	BET1P1	-3.87	0.000124	0.00941	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150529581	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs7801447	ENSG00000241134.3	BET1P1	-3.87	0.000124	0.00941	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150530193	chr7:150749736~150750094:+
THCA	cis	rs947583	0.588	rs12204523	ENSG00000272189.1	RP3-325F22.5	3.87	0.000124	0.00941	0.18	0.18	Phosphorus levels;	chr6:135753856	chr6:136550661~136552554:+
THCA	cis	rs7824557	0.564	rs2736288	ENSG00000255495.1	AC145124.2	-3.87	0.000124	0.00941	-0.2	-0.18	Retinal vascular caliber;	chr8:11370591	chr8:12194467~12196280:+
THCA	cis	rs1005277	0.505	rs719569	ENSG00000120555.12	SEPT7P9	-3.87	0.000124	0.00941	-0.19	-0.18	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.505	rs7099777	ENSG00000120555.12	SEPT7P9	-3.87	0.000124	0.00941	-0.19	-0.18	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.522	rs200943	ENSG00000120555.12	SEPT7P9	3.87	0.000124	0.00941	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38383069~38402916:-
THCA	cis	rs654950	0.792	rs625448	ENSG00000230638.4	RP11-486B10.4	-3.87	0.000124	0.00941	-0.19	-0.18	Airway imaging phenotypes;	chr1:41522870	chr1:41542069~41544310:+
THCA	cis	rs1504749	0.569	rs11991964	ENSG00000254142.2	RP11-53M11.3	-3.87	0.000124	0.00941	-0.27	-0.18	Intracranial aneurysm;	chr8:54394531	chr8:54554361~54561927:+
THCA	cis	rs1510272	0.728	rs4680287	ENSG00000243926.1	TIPARP-AS1	-3.87	0.000124	0.00941	-0.19	-0.18	Testicular germ cell tumor;	chr3:156611391	chr3:156671862~156674378:-
THCA	cis	rs13118159	0.651	rs4974599	ENSG00000254094.1	AC078852.1	-3.87	0.000124	0.00941	-0.2	-0.18	Longevity;	chr4:1320642	chr4:1356581~1358075:+
THCA	cis	rs858239	0.899	rs7794684	ENSG00000226816.2	AC005082.12	3.87	0.000124	0.00941	0.26	0.18	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23206013~23208045:+
THCA	cis	rs2239547	0.657	rs7620706	ENSG00000243224.1	RP5-1157M23.2	-3.87	0.000124	0.00941	-0.21	-0.18	Schizophrenia;	chr3:52857740	chr3:52239258~52241097:+
THCA	cis	rs10858047	0.831	rs7530191	ENSG00000231128.4	RP5-1073O3.2	-3.87	0.000124	0.00941	-0.26	-0.18	Autism;	chr1:114641211	chr1:113812379~113829171:+
THCA	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	3.87	0.000124	0.00941	0.25	0.18	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
THCA	cis	rs56309584	0.874	rs7503199	ENSG00000271002.1	RP11-599B13.8	-3.87	0.000124	0.00941	-0.24	-0.18	Initial pursuit acceleration;	chr17:8230957	chr17:8199123~8199437:-
THCA	cis	rs4578769	0.55	rs930909	ENSG00000273232.1	RP11-370A5.2	3.87	0.000124	0.00942	0.24	0.18	Eosinophil percentage of white cells;	chr18:22976361	chr18:22882825~22883357:-
THCA	cis	rs6088813	0.885	rs224331	ENSG00000279253.1	RP4-614O4.13	-3.87	0.000124	0.00942	-0.17	-0.18	Height;	chr20:35434589	chr20:35262727~35264187:-
THCA	cis	rs867186	1	rs8121957	ENSG00000126005.14	MMP24-AS1	-3.87	0.000124	0.00942	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35088306	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs11905354	ENSG00000126005.14	MMP24-AS1	-3.87	0.000124	0.00942	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35089361	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs73903009	ENSG00000126005.14	MMP24-AS1	-3.87	0.000124	0.00942	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35090929	chr20:35216462~35278131:-
THCA	cis	rs10760158	0.832	rs3827678	ENSG00000226752.6	PSMD5-AS1	-3.87	0.000124	0.00942	-0.21	-0.18	Pulse pressure;	chr9:121284444	chr9:120824828~120854385:+
THCA	cis	rs12554020	0.504	rs10992845	ENSG00000227603.1	RP11-165J3.6	3.87	0.000124	0.00942	0.29	0.18	Schizophrenia;	chr9:93671148	chr9:93435332~93437121:-
THCA	cis	rs295490	0.748	rs41399544	ENSG00000272656.1	RP11-219D15.3	3.87	0.000124	0.00942	0.34	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356303	chr3:139349024~139349371:-
THCA	cis	rs2736345	0.788	rs998683	ENSG00000254527.1	ENPP7P12	-3.87	0.000124	0.00942	-0.23	-0.18	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:12205759~12206389:-
THCA	cis	rs7131987	0.903	rs7974221	ENSG00000257599.1	OVCH1-AS1	-3.87	0.000124	0.00942	-0.21	-0.18	QT interval;	chr12:29246515	chr12:29389294~29487488:+
THCA	cis	rs7131987	0.868	rs11050151	ENSG00000257599.1	OVCH1-AS1	-3.87	0.000124	0.00942	-0.21	-0.18	QT interval;	chr12:29250075	chr12:29389294~29487488:+
THCA	cis	rs2235642	0.928	rs2076435	ENSG00000260989.1	LA16c-395F10.2	-3.87	0.000124	0.00942	-0.18	-0.18	Coronary artery disease;	chr16:1557573	chr16:1580527~1610328:+
THCA	cis	rs7246967	0.673	rs4933027	ENSG00000198153.8	ZNF849P	3.87	0.000124	0.00942	0.27	0.18	Bronchopulmonary dysplasia;	chr19:22721170	chr19:22685167~22686732:+
THCA	cis	rs1056107	0.541	rs10739349	ENSG00000230185.4	C9orf147	3.87	0.000124	0.00942	0.16	0.18	Colorectal cancer;	chr9:112415749	chr9:112433816~112487204:-
THCA	cis	rs10792665	0.844	rs10898058	ENSG00000255503.1	RP11-113K21.4	-3.87	0.000124	0.00942	-0.18	-0.18	Obesity-related traits;	chr11:82946817	chr11:83072402~83097196:-
THCA	cis	rs56804039	0.524	rs11785096	ENSG00000254153.1	CTA-398F10.2	3.87	0.000124	0.00942	0.29	0.18	Cervical cancer;	chr8:8515304	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.742	rs1533058	ENSG00000253981.4	ALG1L13P	3.87	0.000124	0.00942	0.17	0.18	Mood instability;	chr8:8827680	chr8:8236003~8244667:-
THCA	cis	rs11758351	0.929	rs6906367	ENSG00000216331.1	HIST1H1PS1	3.87	0.000124	0.00942	0.24	0.18	Renal underexcretion gout;Gout;	chr6:26186897	chr6:26195566~26195771:+
THCA	cis	rs950169	0.84	rs62029595	ENSG00000188388.10	GOLGA6L3	3.87	0.000124	0.00942	0.24	0.18	Schizophrenia;	chr15:84400603	chr15:85240472~85247170:+
THCA	cis	rs1959947	0.876	rs72676040	ENSG00000251363.2	RP11-129M6.1	-3.87	0.000124	0.00942	-0.23	-0.18	Hemostatic factors and hematological phenotypes;	chr14:41046819	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs10134247	ENSG00000251363.2	RP11-129M6.1	-3.87	0.000124	0.00942	-0.23	-0.18	Hemostatic factors and hematological phenotypes;	chr14:41048176	chr14:40954898~40975877:+
THCA	cis	rs6456156	0.586	rs9459853	ENSG00000235272.1	FAM103A2P	3.87	0.000124	0.00942	0.24	0.18	Primary biliary cholangitis;	chr6:167052286	chr6:166586124~166586477:-
THCA	cis	rs4950322	1	rs4950322	ENSG00000271721.1	RP11-337C18.9	-3.87	0.000124	0.00942	-0.21	-0.18	Protein quantitative trait loci;	chr1:147383114	chr1:147175602~147177740:+
THCA	cis	rs4763879	0.502	rs11052552	ENSG00000278635.1	CTD-2318O12.1	-3.87	0.000124	0.00942	-0.18	-0.18	Type 1 diabetes;	chr12:9703362	chr12:9415641~9416718:+
THCA	cis	rs9467773	0.967	rs7753565	ENSG00000228223.2	HCG11	-3.87	0.000124	0.00943	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26523450~26526579:+
THCA	cis	rs879500	1	rs7238333	ENSG00000227279.1	AC015933.2	3.87	0.000124	0.00943	0.2	0.18	Lung function (FVC);	chr18:28542380	chr18:27954519~27963687:+
THCA	cis	rs879500	0.96	rs7239100	ENSG00000227279.1	AC015933.2	3.87	0.000124	0.00943	0.2	0.18	Lung function (FVC);	chr18:28542839	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs879500	ENSG00000227279.1	AC015933.2	3.87	0.000124	0.00943	0.2	0.18	Lung function (FVC);	chr18:28544724	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs1476300	ENSG00000227279.1	AC015933.2	3.87	0.000124	0.00943	0.2	0.18	Lung function (FVC);	chr18:28544980	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs879501	ENSG00000227279.1	AC015933.2	3.87	0.000124	0.00943	0.2	0.18	Lung function (FVC);	chr18:28545744	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs1476299	ENSG00000227279.1	AC015933.2	3.87	0.000124	0.00943	0.2	0.18	Lung function (FVC);	chr18:28545989	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs7243217	ENSG00000227279.1	AC015933.2	3.87	0.000124	0.00943	0.2	0.18	Lung function (FVC);	chr18:28546794	chr18:27954519~27963687:+
THCA	cis	rs9860428	0.844	rs9878913	ENSG00000243795.1	RP11-572M11.3	3.87	0.000124	0.00943	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866272	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs2399442	ENSG00000243795.1	RP11-572M11.3	3.87	0.000124	0.00943	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866426	chr3:113142350~113167819:-
THCA	cis	rs13113518	0.783	rs34534635	ENSG00000272969.1	RP11-528I4.2	3.87	0.000124	0.00943	0.21	0.18	Height;	chr4:55573424	chr4:55547112~55547889:+
THCA	cis	rs13182402	1	rs62391527	ENSG00000230929.5	RP11-395C3.1	-3.87	0.000124	0.00943	-0.35	-0.18	Osteoporosis;	chr5:126569278	chr5:126628019~126628319:-
THCA	cis	rs2011503	0.782	rs8113006	ENSG00000271283.1	CTC-412M14.6	-3.87	0.000124	0.00943	-0.26	-0.18	Bipolar disorder;	chr19:19558632	chr19:19699203~19699409:-
THCA	cis	rs2836974	0.932	rs8129416	ENSG00000255568.3	BRWD1-AS2	3.87	0.000124	0.00943	0.16	0.18	Cognitive function;	chr21:39245219	chr21:39313935~39314962:+
THCA	cis	rs34779708	0.733	rs7087099	ENSG00000233200.1	RP11-324I22.2	3.87	0.000124	0.00943	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35219894~35230598:-
THCA	cis	rs9595908	0.671	rs12428598	ENSG00000212293.1	SNORA16	3.87	0.000124	0.00943	0.21	0.18	Body mass index;	chr13:32684839	chr13:32420390~32420516:-
THCA	cis	rs656319	0.702	rs587328	ENSG00000248538.5	RP11-10A14.5	3.87	0.000124	0.00943	0.23	0.18	Myopia (pathological);	chr8:9952212	chr8:9189011~9202854:+
THCA	cis	rs2287838	1	rs12609594	ENSG00000267370.1	CTD-2623N2.3	-3.87	0.000124	0.00943	-0.17	-0.18	Sleep duration;	chr19:9861741	chr19:9756152~9756863:-
THCA	cis	rs4792901	0.918	rs12603164	ENSG00000267151.3	RP11-100E5.2	3.87	0.000124	0.00943	0.18	0.18	Dupuytren's disease;	chr17:43541198	chr17:43444707~43451200:+
THCA	cis	rs8031584	0.678	rs35098644	ENSG00000178081.11	ULK4P3	3.87	0.000124	0.00943	0.23	0.18	Huntington's disease progression;	chr15:30853237	chr15:30103720~30131757:+
THCA	cis	rs7259376	0.714	rs4358065	ENSG00000269345.1	VN1R85P	3.87	0.000124	0.00943	0.19	0.18	Menopause (age at onset);	chr19:22338330	chr19:22174766~22175191:-
THCA	cis	rs12760731	0.843	rs12023718	ENSG00000213057.5	C1orf220	-3.87	0.000124	0.00943	-0.21	-0.18	Obesity-related traits;	chr1:178522744	chr1:178542752~178548889:+
THCA	cis	rs7182948	0.957	rs28647709	ENSG00000259531.2	RP11-295H24.3	3.87	0.000124	0.00944	0.23	0.18	Lung adenocarcinoma;	chr15:49518778	chr15:49365124~49366685:-
THCA	cis	rs7873102	0.564	rs1928245	ENSG00000213839.4	TMX2P1	3.87	0.000124	0.00944	0.15	0.18	Brain structure;	chr9:38063605	chr9:37885683~37886390:+
THCA	cis	rs2271404	0.506	rs12989775	ENSG00000227992.1	AC108463.2	3.87	0.000124	0.00944	0.24	0.18	Atopic dermatitis;	chr2:111241250	chr2:111203964~111206215:-
THCA	cis	rs13401620	0.702	rs55954706	ENSG00000231013.1	AC013275.2	-3.87	0.000124	0.00944	-0.21	-0.18	Breast size;	chr2:119705883	chr2:119476448~119487346:+
THCA	cis	rs1876449	0.838	rs4797922	ENSG00000266171.1	RP11-769O8.1	3.87	0.000124	0.00944	0.19	0.18	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr18:1474979	chr18:735746~737459:+
THCA	cis	rs4950322	1	rs1806618	ENSG00000271721.1	RP11-337C18.9	3.87	0.000124	0.00944	0.21	0.18	Protein quantitative trait loci;	chr1:147377075	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.895	rs17356735	ENSG00000271721.1	RP11-337C18.9	3.87	0.000124	0.00944	0.21	0.18	Protein quantitative trait loci;	chr1:147378328	chr1:147175602~147177740:+
THCA	cis	rs9467773	0.836	rs1624440	ENSG00000261353.1	CTA-14H9.5	3.87	0.000124	0.00944	0.18	0.18	Intelligence (multi-trait analysis);	chr6:26433101	chr6:26527063~26527404:+
THCA	cis	rs2692947	0.616	rs2301707	ENSG00000235584.2	AC008268.1	-3.87	0.000124	0.00944	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96266108	chr2:95666084~95668715:+
THCA	cis	rs881375	0.967	rs1014529	ENSG00000270917.1	RP11-27I1.6	-3.87	0.000125	0.00944	-0.25	-0.18	Rheumatoid arthritis;	chr9:120922665	chr9:120812475~120812845:-
THCA	cis	rs62292953	0.79	rs62292952	ENSG00000248724.5	NPHP3-AS1	-3.87	0.000125	0.00944	-0.33	-0.18	Red cell distribution width;	chr3:132481875	chr3:132721750~132874223:+
THCA	cis	rs1005277	0.579	rs932538	ENSG00000120555.12	SEPT7P9	3.87	0.000125	0.00944	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.541	rs2472177	ENSG00000120555.12	SEPT7P9	3.87	0.000125	0.00944	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2472178	ENSG00000120555.12	SEPT7P9	3.87	0.000125	0.00944	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474572	ENSG00000120555.12	SEPT7P9	3.87	0.000125	0.00944	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2505198	ENSG00000120555.12	SEPT7P9	3.87	0.000125	0.00944	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38383069~38402916:-
THCA	cis	rs7951911	0.915	rs11038291	ENSG00000254427.1	RP11-430H10.1	3.87	0.000125	0.00944	0.32	0.18	IgG glycosylation;	chr11:45079747	chr11:45355371~45366121:+
THCA	cis	rs7572644	0.62	rs6547816	ENSG00000223522.1	AC093690.1	3.87	0.000125	0.00944	0.23	0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27946730	chr2:28307691~28310459:-
THCA	cis	rs4272720	0.666	rs7070387	ENSG00000234736.4	FAM170B-AS1	-3.87	0.000125	0.00944	-0.19	-0.18	Platelet count;Plateletcrit;	chr10:49058244	chr10:49121839~49151547:+
THCA	cis	rs6546886	0.912	rs13027288	ENSG00000235499.1	AC073046.25	3.87	0.000125	0.00944	0.16	0.18	Dialysis-related mortality;	chr2:74083938	chr2:73985132~73986343:+
THCA	cis	rs6693388	0.56	rs13320	ENSG00000203288.3	RP11-98D18.9	3.87	0.000125	0.00944	0.14	0.18	Blood metabolite ratios;	chr1:151874041	chr1:151790804~151794402:+
THCA	cis	rs804280	0.638	rs36038176	ENSG00000270154.1	RP11-419I17.1	-3.87	0.000125	0.00944	-0.26	-0.18	Myopia (pathological);	chr8:11752486	chr8:12476462~12477122:+
THCA	cis	rs10457838	0.549	rs2500536	ENSG00000231760.4	RP11-350J20.5	-3.87	0.000125	0.00944	-0.23	-0.18	Post-traumatic stress disorder;	chr6:149008353	chr6:149796151~149826294:-
THCA	cis	rs4950322	0.515	rs11239954	ENSG00000271721.1	RP11-337C18.9	3.87	0.000125	0.00945	0.19	0.18	Protein quantitative trait loci;	chr1:147246045	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.515	rs76327075	ENSG00000271721.1	RP11-337C18.9	3.87	0.000125	0.00945	0.19	0.18	Protein quantitative trait loci;	chr1:147246319	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.515	rs11239958	ENSG00000271721.1	RP11-337C18.9	3.87	0.000125	0.00945	0.19	0.18	Protein quantitative trait loci;	chr1:147247454	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.515	rs12060046	ENSG00000271721.1	RP11-337C18.9	3.87	0.000125	0.00945	0.19	0.18	Protein quantitative trait loci;	chr1:147249278	chr1:147175602~147177740:+
THCA	cis	rs4869313	0.66	rs12716486	ENSG00000247121.5	CTD-2260A17.2	-3.87	0.000125	0.00945	-0.13	-0.18	Pediatric autoimmune diseases;	chr5:96971932	chr5:96814028~96935809:-
THCA	cis	rs2058059	0.511	rs66624667	ENSG00000205578.5	POM121B	-3.87	0.000125	0.00945	-0.29	-0.18	Subcutaneous adipose tissue;	chr7:72565634	chr7:73293497~73301161:+
THCA	cis	rs2058059	0.551	rs58608277	ENSG00000205578.5	POM121B	-3.87	0.000125	0.00945	-0.29	-0.18	Subcutaneous adipose tissue;	chr7:72567083	chr7:73293497~73301161:+
THCA	cis	rs12694997	0.508	rs4503983	ENSG00000223374.1	AC005104.3	-3.87	0.000125	0.00945	-0.12	-0.18	Height;	chr2:241471654	chr2:241351340~241353104:-
THCA	cis	rs12694997	0.543	rs5016140	ENSG00000223374.1	AC005104.3	-3.87	0.000125	0.00945	-0.12	-0.18	Height;	chr2:241471656	chr2:241351340~241353104:-
THCA	cis	rs372883	0.648	rs1153292	ENSG00000176054.6	RPL23P2	-3.87	0.000125	0.00945	-0.15	-0.18	Pancreatic cancer;	chr21:29316874	chr21:28997613~28998033:-
THCA	cis	rs758324	0.732	rs1983246	ENSG00000224431.1	AC063976.7	-3.87	0.000125	0.00945	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132190188	chr5:132199456~132203487:+
THCA	cis	rs758324	0.633	rs2667737	ENSG00000224431.1	AC063976.7	-3.87	0.000125	0.00945	-0.18	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132190190	chr5:132199456~132203487:+
THCA	cis	rs448720	1	rs12438699	ENSG00000260657.2	RP11-315D16.4	-3.87	0.000125	0.00945	-0.22	-0.18	Cognitive performance;	chr15:67898919	chr15:68267792~68277994:-
THCA	cis	rs17695224	0.675	rs10422421	ENSG00000275055.1	CTC-471J1.11	-3.87	0.000125	0.00945	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51836479	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.675	rs10422984	ENSG00000275055.1	CTC-471J1.11	-3.87	0.000125	0.00945	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51836492	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.675	rs10422606	ENSG00000275055.1	CTC-471J1.11	-3.87	0.000125	0.00945	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51836494	chr19:52049007~52049754:+
THCA	cis	rs758324	0.588	rs253945	ENSG00000237714.1	P4HA2-AS1	3.87	0.000125	0.00945	0.25	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131994465	chr5:132184876~132192808:+
THCA	cis	rs3096299	0.685	rs2911244	ENSG00000261118.1	RP11-104N10.1	3.87	0.000125	0.00945	0.15	0.18	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89492017~89504460:-
THCA	cis	rs669446	0.562	rs4660260	ENSG00000237950.1	RP11-7O11.3	3.87	0.000125	0.00945	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43729682	chr1:43944370~43946551:-
THCA	cis	rs9652601	0.691	rs7198004	ENSG00000263033.2	RP11-396B14.2	-3.87	0.000125	0.00945	-0.14	-0.18	Systemic lupus erythematosus;	chr16:11113760	chr16:11196177~11224969:+
THCA	cis	rs9300255	0.543	rs1617156	ENSG00000235423.7	RP11-282O18.3	3.87	0.000125	0.00945	0.18	0.18	Neutrophil percentage of white cells;	chr12:123105618	chr12:123252030~123261483:-
THCA	cis	rs911555	0.547	rs8006994	ENSG00000269940.1	RP11-73M18.7	3.87	0.000125	0.00945	0.18	0.18	Intelligence (multi-trait analysis);	chr14:103374959	chr14:103694560~103695170:+
THCA	cis	rs7949566	0.614	rs11220473	ENSG00000255062.1	RP11-712L6.5	-3.87	0.000125	0.00945	-0.19	-0.18	Platelet distribution width;Mean platelet volume;	chr11:126401743	chr11:126294298~126304318:-
THCA	cis	rs7481311	0.917	rs11030067	ENSG00000245573.6	BDNF-AS	-3.87	0.000125	0.00945	-0.17	-0.18	Weight;Body mass index;	chr11:27599385	chr11:27506838~27698174:+
THCA	cis	rs1552244	0.554	rs6800204	ENSG00000269982.1	RP11-1020A11.2	3.87	0.000125	0.00945	0.12	0.18	Alzheimer's disease;	chr3:9953720	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs6762594	ENSG00000269982.1	RP11-1020A11.2	3.87	0.000125	0.00945	0.12	0.18	Alzheimer's disease;	chr3:9953832	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs3846167	ENSG00000269982.1	RP11-1020A11.2	3.87	0.000125	0.00945	0.12	0.18	Alzheimer's disease;	chr3:9954742	chr3:9958717~9962539:+
THCA	cis	rs2080501	0.628	rs1861656	ENSG00000275155.1	CTD-2595P9.4	3.87	0.000125	0.00945	0.16	0.18	IgG glycosylation;	chr16:49629108	chr16:49847018~49847632:-
THCA	cis	rs7267979	1	rs6076345	ENSG00000276952.1	RP5-965G21.6	-3.87	0.000125	0.00946	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4815418	ENSG00000276952.1	RP5-965G21.6	-3.87	0.000125	0.00946	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4813566	ENSG00000276952.1	RP5-965G21.6	-3.87	0.000125	0.00946	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4815421	ENSG00000276952.1	RP5-965G21.6	-3.87	0.000125	0.00946	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25284915~25285588:-
THCA	cis	rs4763879	0.739	rs12582584	ENSG00000214776.8	RP11-726G1.1	-3.87	0.000125	0.00946	-0.21	-0.18	Type 1 diabetes;	chr12:9671542	chr12:9467552~9576275:+
THCA	cis	rs17772222	0.511	rs12879875	ENSG00000258983.2	RP11-507K2.2	3.87	0.000125	0.00946	0.19	0.18	Coronary artery calcification;	chr14:88840206	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.511	rs17124903	ENSG00000258983.2	RP11-507K2.2	3.87	0.000125	0.00946	0.19	0.18	Coronary artery calcification;	chr14:88842934	chr14:88499334~88515502:+
THCA	cis	rs7394190	0.935	rs4746140	ENSG00000272140.2	RP11-574K11.29	-3.87	0.000125	0.00946	-0.16	-0.18	Incident atrial fibrillation;	chr10:73657491	chr10:73703735~73713581:-
THCA	cis	rs12291225	0.679	rs11023178	ENSG00000251991.1	RNU7-49P	3.87	0.000125	0.00946	0.21	0.18	Sense of smell;	chr11:14288736	chr11:14478892~14478953:+
THCA	cis	rs2832191	0.716	rs1888439	ENSG00000176054.6	RPL23P2	3.87	0.000125	0.00946	0.15	0.18	Dental caries;	chr21:29082136	chr21:28997613~28998033:-
THCA	cis	rs2455799	0.613	rs13080145	ENSG00000270409.1	RP11-44D5.1	-3.87	0.000125	0.00946	-0.19	-0.18	Mean platelet volume;	chr3:15838553	chr3:15732252~15733470:+
THCA	cis	rs964611	0.751	rs8032420	ENSG00000259488.2	RP11-154J22.1	-3.87	0.000125	0.00946	-0.15	-0.18	Metabolite levels (Pyroglutamine);	chr15:48253184	chr15:48312353~48331856:-
THCA	cis	rs4788570	0.615	rs10852502	ENSG00000260593.1	RP11-432I5.2	-3.87	0.000125	0.00946	-0.29	-0.18	Intelligence (multi-trait analysis);	chr16:71618169	chr16:71623708~71626816:-
THCA	cis	rs2732480	0.5	rs12828309	ENSG00000257735.1	RP11-370I10.6	3.87	0.000125	0.00946	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48350945~48442411:+
THCA	cis	rs34286592	0.929	rs1057452	ENSG00000214725.6	CDIPT-AS1	3.87	0.000125	0.00946	0.32	0.18	Multiple sclerosis;	chr16:29822393	chr16:29863593~29868053:+
THCA	cis	rs7267979	1	rs6050590	ENSG00000276952.1	RP5-965G21.6	-3.87	0.000125	0.00946	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25284915~25285588:-
THCA	cis	rs4601821	1	rs877138	ENSG00000270179.1	RP11-159N11.4	3.87	0.000125	0.00946	0.18	0.18	Alcoholic chronic pancreatitis;	chr11:113385786	chr11:113368478~113369117:+
THCA	cis	rs879500	1	rs7243947	ENSG00000227279.1	AC015933.2	-3.87	0.000125	0.00947	-0.2	-0.18	Lung function (FVC);	chr18:28543531	chr18:27954519~27963687:+
THCA	cis	rs17622252	0.722	rs17695594	ENSG00000280989.1	LINC00581	3.87	0.000125	0.00947	0.33	0.18	Bipolar disorder;	chr6:21352150	chr6:21486061~21511895:-
THCA	cis	rs17622252	0.722	rs75435452	ENSG00000280989.1	LINC00581	3.87	0.000125	0.00947	0.33	0.18	Bipolar disorder;	chr6:21353431	chr6:21486061~21511895:-
THCA	cis	rs6847067	1	rs6847067	ENSG00000180769.7	WDFY3-AS2	3.87	0.000125	0.00947	0.13	0.18	Oropharynx cancer;	chr4:84811016	chr4:84965682~85011277:+
THCA	cis	rs2228479	0.717	rs11649210	ENSG00000274627.1	RP11-104N10.2	-3.87	0.000125	0.00947	-0.27	-0.18	Skin colour saturation;	chr16:89740825	chr16:89516797~89522217:+
THCA	cis	rs11673344	0.764	rs826304	ENSG00000267260.1	CTD-2162K18.4	-3.87	0.000125	0.00947	-0.22	-0.18	Obesity-related traits;	chr19:36952681	chr19:36773153~36777078:+
THCA	cis	rs7727544	0.514	rs3846728	ENSG00000263597.1	MIR3936	3.87	0.000125	0.00947	0.16	0.18	Blood metabolite levels;	chr5:132100524	chr5:132365490~132365599:-
THCA	cis	rs12493885	0.769	rs61791540	ENSG00000243069.6	ARHGEF26-AS1	-3.87	0.000125	0.00947	-0.32	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154039252	chr3:154024401~154121332:-
THCA	cis	rs1414896	1	rs10874910	ENSG00000226026.4	RP11-57H12.3	3.87	0.000125	0.00947	0.17	0.18	Non-alcoholic fatty liver disease histology (AST);	chr1:95242011	chr1:95163219~95233982:-
THCA	cis	rs7572733	0.935	rs700669	ENSG00000231621.1	AC013264.2	-3.87	0.000125	0.00947	-0.16	-0.18	Dermatomyositis;	chr2:197819743	chr2:197197991~197199273:+
THCA	cis	rs1035144	0.679	rs2110696	ENSG00000258915.1	BHLHB9P1	-3.87	0.000125	0.00947	-0.19	-0.18	Male sexual orientation;	chr14:80977024	chr14:80981988~80983638:+
THCA	cis	rs586688	0.625	rs672696	ENSG00000224536.1	RP11-134G8.7	3.87	0.000125	0.00947	0.27	0.18	Obesity-related traits;	chr1:201709952	chr1:201507241~201533608:+
THCA	cis	rs1411478	0.967	rs57113693	ENSG00000243155.1	RP11-46A10.5	3.87	0.000125	0.00947	0.19	0.18	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180983158	chr1:180944042~180976482:-
THCA	cis	rs2455799	0.634	rs1345160	ENSG00000270409.1	RP11-44D5.1	-3.87	0.000125	0.00947	-0.19	-0.18	Mean platelet volume;	chr3:15820519	chr3:15732252~15733470:+
THCA	cis	rs916888	0.821	rs199504	ENSG00000260075.1	NSFP1	3.87	0.000125	0.00947	0.28	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46372855~46487141:+
THCA	cis	rs1124769	0.748	rs12442459	ENSG00000259378.1	DCAF13P3	3.87	0.000125	0.00947	0.28	0.18	Cognitive performance;	chr15:51074518	chr15:50944663~50945996:+
THCA	cis	rs13034020	0.641	rs35852308	ENSG00000271889.1	RP11-493E12.1	-3.87	0.000125	0.00947	-0.25	-0.18	Hodgkin's lymphoma;	chr2:60998428	chr2:61151433~61162105:-
THCA	cis	rs4295623	0.553	rs34962960	ENSG00000270154.1	RP11-419I17.1	-3.87	0.000125	0.00947	-0.21	-0.18	Morning vs. evening chronotype;	chr8:11737088	chr8:12476462~12477122:+
THCA	cis	rs2275906	0.557	rs62394317	ENSG00000272462.2	U91328.19	3.87	0.000125	0.00948	0.17	0.18	Urate levels in lean individuals;	chr6:25882749	chr6:25992662~26001775:+
THCA	cis	rs17074492	1	rs59810375	ENSG00000214182.5	PTMAP5	3.87	0.000125	0.00948	0.2	0.18	Sjögren's syndrome;	chr13:81601851	chr13:81689911~81691072:+
THCA	cis	rs1538970	0.884	rs781232	ENSG00000234329.1	RP11-767N6.2	-3.87	0.000125	0.00948	-0.18	-0.18	Platelet count;	chr1:45424727	chr1:45651039~45651826:-
THCA	cis	rs8030605	0.778	rs1579370	ENSG00000277245.1	RP11-48G14.3	-3.87	0.000125	0.00948	-0.3	-0.18	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56292669	chr15:56447120~56447697:+
THCA	cis	rs2289700	1	rs78813423	ENSG00000252061.1	RNU6-415P	-3.87	0.000125	0.00948	-0.36	-0.18	Bipolar disorder;	chr15:78938663	chr15:78898840~78898936:-
THCA	cis	rs71520386	0.632	rs9654968	ENSG00000226329.2	AC005682.6	-3.87	0.000125	0.00948	-0.23	-0.18	Fibrinogen levels;	chr7:22836697	chr7:22863874~22881350:-
THCA	cis	rs4356203	0.87	rs11024208	ENSG00000272034.1	SNORD14A	-3.87	0.000125	0.00948	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17238432	chr11:17074654~17074744:-
THCA	cis	rs7264396	0.887	rs224343	ENSG00000088340.14	FER1L4	3.87	0.000125	0.00948	0.16	0.18	Total cholesterol levels;	chr20:35448887	chr20:35558737~35607562:-
THCA	cis	rs6952407	1	rs6952407	ENSG00000230295.1	RP11-458F8.2	3.87	0.000125	0.00948	0.13	0.18	Cotinine glucuronidation;	chr7:66580525	chr7:66880708~66882981:+
THCA	cis	rs9595908	0.869	rs9591191	ENSG00000212293.1	SNORA16	3.87	0.000125	0.00948	0.2	0.18	Body mass index;	chr13:32633397	chr13:32420390~32420516:-
THCA	cis	rs4971059	0.629	rs12904	ENSG00000236675.1	MTX1P1	-3.87	0.000125	0.00948	-0.17	-0.18	Breast cancer;	chr1:155134221	chr1:155230975~155234325:+
THCA	cis	rs7647973	0.771	rs9865051	ENSG00000229759.1	MRPS18AP1	3.87	0.000125	0.00948	0.27	0.18	Menarche (age at onset);	chr3:49128636	chr3:48256350~48256938:-
THCA	cis	rs488400	0.558	rs361163	ENSG00000251377.1	RP11-18H21.3	3.87	0.000125	0.00948	0.18	0.18	Trans fatty acid levels;	chr4:151878731	chr4:152207421~152225870:-
THCA	cis	rs5769765	0.913	rs2319462	ENSG00000260613.1	RP3-522J7.6	3.87	0.000125	0.00949	0.22	0.18	Schizophrenia;	chr22:49869722	chr22:49832616~49837786:-
THCA	cis	rs7956611	0.564	rs12099510	ENSG00000213343.5	RPL21P18	-3.87	0.000125	0.00949	-0.2	-0.18	Age of smoking initiation;	chr12:66513855	chr12:66037235~66037714:+
THCA	cis	rs4713118	0.513	rs2294480	ENSG00000216915.2	RP1-97D16.1	-3.87	0.000125	0.00949	-0.23	-0.18	Parkinson's disease;	chr6:27616182	chr6:27737000~27738494:-
THCA	cis	rs7508	0.546	rs382752	ENSG00000253671.1	RP11-806O11.1	3.87	0.000125	0.00949	0.22	0.18	Atrial fibrillation;	chr8:18040874	chr8:17808941~17820868:+
THCA	cis	rs875971	0.545	rs4718348	ENSG00000273024.4	INTS4P2	-3.87	0.000125	0.00949	-0.23	-0.18	Aortic root size;	chr7:66441589	chr7:65647864~65715661:+
THCA	cis	rs7586085	0.868	rs3762552	ENSG00000232411.1	AC009495.3	-3.87	0.000125	0.00949	-0.19	-0.18	Total body bone mineral density;	chr2:165758269	chr2:165833048~165839098:-
THCA	cis	rs2348418	0.765	rs4931734	ENSG00000278733.1	RP11-425D17.1	3.87	0.000125	0.00949	0.15	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28185625~28186190:-
THCA	cis	rs2348418	0.733	rs1824769	ENSG00000278733.1	RP11-425D17.1	3.87	0.000125	0.00949	0.15	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28185625~28186190:-
THCA	cis	rs2348418	0.671	rs2169753	ENSG00000278733.1	RP11-425D17.1	3.87	0.000125	0.00949	0.15	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28185625~28186190:-
THCA	cis	rs12681366	0.839	rs3019282	ENSG00000261437.1	RP11-22C11.2	3.87	0.000125	0.00949	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94439898	chr8:94637285~94639467:-
THCA	cis	rs5758659	0.819	rs134871	ENSG00000227370.1	RP4-669P10.19	-3.87	0.000125	0.00949	-0.16	-0.18	Cognitive function;	chr22:42256710	chr22:42132543~42132998:+
THCA	cis	rs8031584	0.672	rs17227989	ENSG00000178081.11	ULK4P3	3.87	0.000125	0.00949	0.26	0.18	Huntington's disease progression;	chr15:31001571	chr15:30103720~30131757:+
THCA	cis	rs9959145	0.929	rs113240057	ENSG00000267199.1	RP11-861E21.2	3.87	0.000125	0.00949	0.23	0.18	Immune response to smallpox vaccine (IL-6);	chr18:12693707	chr18:12438890~12448205:+
THCA	cis	rs3087591	0.683	rs7502556	ENSG00000263535.1	AK4P1	3.87	0.000125	0.00949	0.21	0.18	Hip circumference;	chr17:31315412	chr17:31345521~31346187:+
THCA	cis	rs7259376	0.777	rs7247735	ENSG00000269345.1	VN1R85P	-3.87	0.000125	0.00949	-0.19	-0.18	Menopause (age at onset);	chr19:22392686	chr19:22174766~22175191:-
THCA	cis	rs804280	0.525	rs1004712	ENSG00000255046.1	RP11-297N6.4	-3.87	0.000125	0.00949	-0.18	-0.18	Myopia (pathological);	chr8:11764784	chr8:11797928~11802568:-
THCA	cis	rs853679	0.517	rs9393887	ENSG00000219891.2	ZSCAN12P1	3.87	0.000125	0.00949	0.25	0.18	Depression;	chr6:28091242	chr6:28091154~28093664:+
THCA	cis	rs7178375	1	rs12907055	ENSG00000215302.7	CTD-3092A11.1	-3.87	0.000125	0.0095	-0.24	-0.18	Hypertriglyceridemia;	chr15:30912091	chr15:30470779~30507623:+
THCA	cis	rs2717559	0.541	rs11774054	ENSG00000253741.1	CTD-2292P10.4	3.87	0.000125	0.0095	0.23	0.18	Urinary tract infection frequency;	chr8:142800560	chr8:142702252~142726973:-
THCA	cis	rs539096	0.692	rs6686238	ENSG00000237950.1	RP11-7O11.3	3.87	0.000125	0.0095	0.15	0.18	Intelligence (multi-trait analysis);	chr1:43744582	chr1:43944370~43946551:-
THCA	cis	rs2235642	0.859	rs12599207	ENSG00000260989.1	LA16c-395F10.2	-3.87	0.000125	0.0095	-0.18	-0.18	Coronary artery disease;	chr16:1556444	chr16:1580527~1610328:+
THCA	cis	rs12544026	0.825	rs1264933	ENSG00000253669.3	KB-1732A1.1	3.87	0.000125	0.0095	0.2	0.18	Major depression and alcohol dependence;	chr8:101840061	chr8:102805517~102809971:+
THCA	cis	rs867186	1	rs7274866	ENSG00000126005.14	MMP24-AS1	-3.87	0.000125	0.0095	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35020813	chr20:35216462~35278131:-
THCA	cis	rs867186	0.92	rs75383229	ENSG00000126005.14	MMP24-AS1	-3.87	0.000125	0.0095	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35025848	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs55946144	ENSG00000126005.14	MMP24-AS1	-3.87	0.000125	0.0095	-0.28	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35041807	chr20:35216462~35278131:-
THCA	cis	rs4915077	0.892	rs17020086	ENSG00000226822.1	RP11-356N1.2	3.87	0.000125	0.0095	0.29	0.18	Hypothyroidism;	chr1:107809179	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs17020088	ENSG00000226822.1	RP11-356N1.2	3.87	0.000125	0.0095	0.29	0.18	Hypothyroidism;	chr1:107809190	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs6691039	ENSG00000226822.1	RP11-356N1.2	3.87	0.000125	0.0095	0.29	0.18	Hypothyroidism;	chr1:107809270	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs6703923	ENSG00000226822.1	RP11-356N1.2	3.87	0.000125	0.0095	0.29	0.18	Hypothyroidism;	chr1:107809630	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs4914962	ENSG00000226822.1	RP11-356N1.2	3.87	0.000125	0.0095	0.29	0.18	Hypothyroidism;	chr1:107809974	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs17020100	ENSG00000226822.1	RP11-356N1.2	3.87	0.000125	0.0095	0.29	0.18	Hypothyroidism;	chr1:107810229	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs17020103	ENSG00000226822.1	RP11-356N1.2	3.87	0.000125	0.0095	0.29	0.18	Hypothyroidism;	chr1:107810405	chr1:108071482~108074519:+
THCA	cis	rs1232027	0.545	rs1650742	ENSG00000251050.1	RP11-168A11.4	3.87	0.000125	0.0095	0.15	0.18	Huntington's disease progression;	chr5:80695064	chr5:80019609~80019920:+
THCA	cis	rs7829975	0.742	rs12547493	ENSG00000233609.3	RP11-62H7.2	-3.87	0.000125	0.0095	-0.17	-0.18	Mood instability;	chr8:8804024	chr8:8961200~8979025:+
THCA	cis	rs5753037	0.615	rs131279	ENSG00000279699.1	RP1-102K2.9	3.87	0.000125	0.00951	0.17	0.18	Type 1 diabetes;	chr22:29759262	chr22:30275215~30276951:-
THCA	cis	rs875971	0.66	rs12698534	ENSG00000230295.1	RP11-458F8.2	-3.87	0.000125	0.00951	-0.13	-0.18	Aortic root size;	chr7:66521858	chr7:66880708~66882981:+
THCA	cis	rs13053817	1	rs12484859	ENSG00000279159.1	RP3-394A18.1	3.87	0.000125	0.00951	0.18	0.18	Carotid atherosclerosis in HIV infection;	chr22:29448895	chr22:29978950~30028236:-
THCA	cis	rs365302	1	rs419281	ENSG00000235086.1	FNDC1-IT1	3.87	0.000125	0.00951	0.25	0.18	Coronary heart disease;	chr6:159221828	chr6:159240786~159243329:+
THCA	cis	rs7809950	0.678	rs2395868	ENSG00000272072.1	CTA-363E19.2	-3.87	0.000126	0.00951	-0.19	-0.18	Coronary artery disease;	chr7:107257055	chr7:107192559~107193300:-
THCA	cis	rs17301013	0.932	rs10912807	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00951	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174547228	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.9	rs56347239	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00951	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174564476	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs7542389	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00951	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174565104	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs12074753	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00951	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174565768	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs1016466	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00951	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174570652	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs10753086	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00951	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174580802	chr1:173863248~173863941:+
THCA	cis	rs4950322	0.947	rs72694723	ENSG00000271721.1	RP11-337C18.9	3.87	0.000126	0.00951	0.21	0.18	Protein quantitative trait loci;	chr1:147373174	chr1:147175602~147177740:+
THCA	cis	rs7616559	0.649	rs9811993	ENSG00000244515.1	KRT18P34	-3.87	0.000126	0.00951	-0.2	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157007284	chr3:157162663~157163932:-
THCA	cis	rs78487399	0.908	rs11901680	ENSG00000234936.1	AC010883.5	3.87	0.000126	0.00951	0.22	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43623218	chr2:43229573~43233394:+
THCA	cis	rs7829975	0.533	rs13274028	ENSG00000254340.1	RP11-10A14.3	3.87	0.000126	0.00951	0.19	0.18	Mood instability;	chr8:8871683	chr8:9141424~9145435:+
THCA	cis	rs9650657	0.645	rs4841408	ENSG00000261451.1	RP11-981G7.1	-3.87	0.000126	0.00951	-0.21	-0.18	Neuroticism;	chr8:10658826	chr8:10433672~10438312:+
THCA	cis	rs13063635	0.915	rs34338823	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00951	-0.34	-0.18	Eosinophil percentage of granulocytes;	chr3:45887277	chr3:46809359~46812558:-
THCA	cis	rs912593	0.935	rs5027700	ENSG00000225179.1	LINC00457	3.87	0.000126	0.00951	0.23	0.18	Cancer;	chr13:34477340	chr13:34435450~34640685:-
THCA	cis	rs912593	0.748	rs5027699	ENSG00000225179.1	LINC00457	3.87	0.000126	0.00951	0.23	0.18	Cancer;	chr13:34477354	chr13:34435450~34640685:-
THCA	cis	rs912593	0.748	rs5027698	ENSG00000225179.1	LINC00457	3.87	0.000126	0.00951	0.23	0.18	Cancer;	chr13:34477357	chr13:34435450~34640685:-
THCA	cis	rs13178541	0.511	rs11744702	ENSG00000250378.1	RP11-119J18.1	-3.87	0.000126	0.00951	-0.2	-0.18	IgG glycosylation;	chr5:135789114	chr5:135812667~135826582:+
THCA	cis	rs5758659	0.714	rs133376	ENSG00000273366.1	CTA-989H11.1	-3.87	0.000126	0.00951	-0.21	-0.18	Cognitive function;	chr22:42070901	chr22:42278188~42278846:+
THCA	cis	rs3105593	0.933	rs11633404	ENSG00000242737.1	RP11-562A8.1	3.87	0.000126	0.00951	0.22	0.18	QT interval;	chr15:50607112	chr15:50466738~50467096:+
THCA	cis	rs3105593	0.933	rs4775894	ENSG00000242737.1	RP11-562A8.1	3.87	0.000126	0.00951	0.22	0.18	QT interval;	chr15:50611403	chr15:50466738~50467096:+
THCA	cis	rs853679	0.607	rs34243448	ENSG00000272009.1	RP1-313I6.12	-3.87	0.000126	0.00951	-0.33	-0.18	Depression;	chr6:28225324	chr6:28078792~28081130:-
THCA	cis	rs6878727	0.526	rs149445	ENSG00000253807.4	LINC01170	3.87	0.000126	0.00951	0.17	0.18	Breast cancer;	chr5:124345005	chr5:124059794~124405079:-
THCA	cis	rs9393777	0.72	rs56401801	ENSG00000226314.6	ZNF192P1	-3.87	0.000126	0.00951	-0.35	-0.18	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28161781~28169594:+
THCA	cis	rs559555	1	rs559555	ENSG00000276517.1	AL133243.2	-3.87	0.000126	0.00951	-0.16	-0.18	Blood metabolite ratios;Blood metabolite levels;	chr2:31585905	chr2:32526504~32529507:+
THCA	cis	rs7927592	0.913	rs10896338	ENSG00000160172.9	FAM86C2P	3.87	0.000126	0.00951	0.17	0.18	Total body bone mineral density;	chr11:68531892	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs7115374	ENSG00000160172.9	FAM86C2P	3.87	0.000126	0.00951	0.17	0.18	Total body bone mineral density;	chr11:68532608	chr11:67791648~67805336:-
THCA	cis	rs8105895	1	rs2359820	ENSG00000269345.1	VN1R85P	3.87	0.000126	0.00952	0.24	0.18	Body mass index (change over time);	chr19:22025312	chr19:22174766~22175191:-
THCA	cis	rs17685	0.712	rs9800948	ENSG00000230882.1	AC005077.14	3.87	0.000126	0.00952	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76181155	chr7:76071469~76074963:-
THCA	cis	rs4660214	0.639	rs6699928	ENSG00000228060.1	RP11-69E11.8	3.87	0.000126	0.00952	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39267827	chr1:39565160~39573203:+
THCA	cis	rs17301013	0.932	rs727279	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00952	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174496026	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.794	rs6425283	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00952	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174499853	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs2072760	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00952	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174510186	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs10912797	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00952	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174511225	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs6668053	ENSG00000270084.1	GAS5-AS1	-3.87	0.000126	0.00952	-0.18	-0.18	Systemic lupus erythematosus;	chr1:174515139	chr1:173863248~173863941:+
THCA	cis	rs6499755	0.841	rs31082	ENSG00000260135.5	RP11-212I21.2	-3.87	0.000126	0.00952	-0.19	-0.18	Hypospadias;	chr16:55327581	chr16:55426797~55462297:-
THCA	cis	rs17095355	1	rs7073969	ENSG00000203876.8	ADD3-AS1	-3.87	0.000126	0.00952	-0.22	-0.18	Biliary atresia;	chr10:109994040	chr10:109940104~110008381:-
THCA	cis	rs786425	0.628	rs118004082	ENSG00000278112.1	RP11-972P1.11	3.87	0.000126	0.00952	0.17	0.18	Pubertal anthropometrics;	chr12:123684693	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs35416308	ENSG00000278112.1	RP11-972P1.11	3.87	0.000126	0.00952	0.17	0.18	Pubertal anthropometrics;	chr12:123684914	chr12:123519390~123519856:-
THCA	cis	rs796395	0.901	rs3009947	ENSG00000232480.1	TGFB2-AS1	-3.87	0.000126	0.00952	-0.19	-0.18	Post bronchodilator FEV1/FVC ratio;	chr1:218515813	chr1:218344196~218345678:-
THCA	cis	rs34638952	0.523	rs56220857	ENSG00000240531.1	RPL21P123	3.87	0.000126	0.00952	0.24	0.18	Sitting height ratio;	chr17:29175479	chr17:29716279~29716685:-
THCA	cis	rs4906332	0.782	rs12891288	ENSG00000269958.1	RP11-73M18.8	3.87	0.000126	0.00952	0.17	0.18	Coronary artery disease;	chr14:103533413	chr14:103696353~103697163:+
THCA	cis	rs61160187	0.61	rs4700397	ENSG00000251279.1	CTC-436P18.1	3.87	0.000126	0.00952	0.21	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:61162070~61232040:+
THCA	cis	rs2274136	0.779	rs6899967	ENSG00000272269.1	RP11-500C11.3	3.87	0.000126	0.00952	0.21	0.18	Obesity-related traits;	chr6:17708584	chr6:17706257~17707344:+
THCA	cis	rs3790515	1	rs3790515	ENSG00000203288.3	RP11-98D18.9	3.87	0.000126	0.00952	0.21	0.18	Depressive symptoms (SSRI exposure interaction);	chr1:151813896	chr1:151790804~151794402:+
THCA	cis	rs1198872	0.812	rs1198867	ENSG00000243819.4	RN7SL832P	3.87	0.000126	0.00952	0.14	0.18	Cardiac Troponin-T levels;	chr2:10762281	chr2:10690344~10692099:+
THCA	cis	rs1198872	0.892	rs1198869	ENSG00000243819.4	RN7SL832P	3.87	0.000126	0.00952	0.14	0.18	Cardiac Troponin-T levels;	chr2:10762319	chr2:10690344~10692099:+
THCA	cis	rs448720	1	rs12593295	ENSG00000260657.2	RP11-315D16.4	3.87	0.000126	0.00952	0.22	0.18	Cognitive performance;	chr15:67916439	chr15:68267792~68277994:-
THCA	cis	rs4713118	0.699	rs200969	ENSG00000272009.1	RP1-313I6.12	-3.87	0.000126	0.00952	-0.2	-0.18	Parkinson's disease;	chr6:27891675	chr6:28078792~28081130:-
THCA	cis	rs2562456	1	rs2359155	ENSG00000268658.4	LINC00664	-3.87	0.000126	0.00953	-0.25	-0.18	Pain;	chr19:21489067	chr19:21483374~21503238:+
THCA	cis	rs2015599	0.525	rs10771514	ENSG00000273680.1	RP11-996F15.6	-3.87	0.000126	0.00953	-0.24	-0.18	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29332733~29333383:-
THCA	cis	rs17286411	0.642	rs9927336	ENSG00000260185.1	RP11-432I5.6	-3.87	0.000126	0.00953	-0.24	-0.18	Blood protein levels;	chr16:71678418	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.641	rs9927437	ENSG00000260185.1	RP11-432I5.6	-3.87	0.000126	0.00953	-0.24	-0.18	Blood protein levels;	chr16:71678559	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs4788826	ENSG00000260185.1	RP11-432I5.6	-3.87	0.000126	0.00953	-0.24	-0.18	Blood protein levels;	chr16:71687117	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs4788827	ENSG00000260185.1	RP11-432I5.6	-3.87	0.000126	0.00953	-0.24	-0.18	Blood protein levels;	chr16:71687129	chr16:71655027~71664212:+
THCA	cis	rs12893668	0.638	rs11851616	ENSG00000252469.1	RNU7-160P	3.87	0.000126	0.00953	0.21	0.18	Reticulocyte count;	chr14:103599263	chr14:103550345~103550406:+
THCA	cis	rs12893668	0.667	rs11844466	ENSG00000252469.1	RNU7-160P	3.87	0.000126	0.00953	0.21	0.18	Reticulocyte count;	chr14:103600085	chr14:103550345~103550406:+
THCA	cis	rs12893668	0.637	rs12892038	ENSG00000252469.1	RNU7-160P	3.87	0.000126	0.00953	0.21	0.18	Reticulocyte count;	chr14:103602292	chr14:103550345~103550406:+
THCA	cis	rs12893668	0.637	rs4525427	ENSG00000252469.1	RNU7-160P	3.87	0.000126	0.00953	0.21	0.18	Reticulocyte count;	chr14:103606456	chr14:103550345~103550406:+
THCA	cis	rs10266483	0.656	rs670966	ENSG00000234338.1	RP11-797H7.1	3.87	0.000126	0.00953	0.12	0.18	Response to statin therapy;	chr7:64302521	chr7:64835280~64836882:-
THCA	cis	rs2904524	0.541	rs11178215	ENSG00000257815.4	RP11-611E13.2	-3.87	0.000126	0.00953	-0.14	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70390913	chr12:69904033~70243360:-
THCA	cis	rs804280	0.544	rs804276	ENSG00000255046.1	RP11-297N6.4	-3.87	0.000126	0.00953	-0.18	-0.18	Myopia (pathological);	chr8:11767499	chr8:11797928~11802568:-
THCA	cis	rs5769765	1	rs5770728	ENSG00000260613.1	RP3-522J7.6	3.87	0.000126	0.00953	0.22	0.18	Schizophrenia;	chr22:49866336	chr22:49832616~49837786:-
THCA	cis	rs894638	1	rs79594692	ENSG00000263327.5	TAPT1-AS1	-3.87	0.000126	0.00953	-0.22	-0.18	Glomerular filtration rate in chronic kidney disease;	chr4:16112324	chr4:16226685~16320140:+
THCA	cis	rs713587	0.713	rs12466350	ENSG00000224165.4	DNAJC27-AS1	-3.87	0.000126	0.00953	-0.1	-0.18	Body mass index in non-asthmatics;	chr2:25017100	chr2:24971390~25039694:+
THCA	cis	rs7937	0.693	rs17726276	ENSG00000279108.1	CTC-490E21.11	3.87	0.000126	0.00953	0.18	0.18	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40785214	chr19:40840159~40842039:+
THCA	cis	rs13098911	0.54	rs35159820	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46026981	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13090194	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46028081	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs59166269	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Eosinophil percentage of granulocytes;	chr3:46028845	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs57437758	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Eosinophil percentage of granulocytes;	chr3:46028861	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13082697	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46030271	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13060287	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46030376	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs68087193	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46031138	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.748	rs2102056	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Eosinophil percentage of granulocytes;	chr3:46031276	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs2088690	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46031347	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.92	rs34774687	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Eosinophil percentage of granulocytes;	chr3:46031822	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs35814488	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46032431	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs6790866	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46033219	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs6791016	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46033366	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs6780028	ENSG00000226074.4	PRSS44	-3.87	0.000126	0.00953	-0.31	-0.18	Celiac disease;	chr3:46033598	chr3:46809359~46812558:-
THCA	cis	rs3796352	0.527	rs11716506	ENSG00000242142.1	SERBP1P3	-3.87	0.000126	0.00954	-0.3	-0.18	Immune reponse to smallpox (secreted IL-2);	chr3:52910312	chr3:53064283~53065091:-
THCA	cis	rs7259376	0.84	rs8106611	ENSG00000270947.1	AC025811.3	3.87	0.000126	0.00954	0.19	0.18	Menopause (age at onset);	chr19:22386816	chr19:22455988~22456459:+
THCA	cis	rs6724465	1	rs7598980	ENSG00000272644.1	RP11-33O4.1	3.87	0.000126	0.00954	0.26	0.18	Height;	chr2:219103700	chr2:219069354~219069809:-
THCA	cis	rs6933660	0.76	rs1825368	ENSG00000219395.2	HSPA8P15	-3.87	0.000126	0.00954	-0.15	-0.18	Menarche (age at onset);	chr6:151454124	chr6:151411259~151413945:-
THCA	cis	rs4713118	0.629	rs203890	ENSG00000219891.2	ZSCAN12P1	3.87	0.000126	0.00954	0.24	0.18	Parkinson's disease;	chr6:28054470	chr6:28091154~28093664:+
THCA	cis	rs4356203	0.818	rs214927	ENSG00000272034.1	SNORD14A	-3.87	0.000126	0.00954	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17209698	chr11:17074654~17074744:-
THCA	cis	rs4356203	0.87	rs214926	ENSG00000272034.1	SNORD14A	-3.87	0.000126	0.00954	-0.18	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17210255	chr11:17074654~17074744:-
THCA	cis	rs879500	0.961	rs7239162	ENSG00000227279.1	AC015933.2	3.87	0.000126	0.00954	0.2	0.18	Lung function (FVC);	chr18:28523020	chr18:27954519~27963687:+
THCA	cis	rs150992	0.711	rs161735	ENSG00000241597.2	CTD-2007H13.1	-3.87	0.000126	0.00954	-0.23	-0.18	Body mass index;	chr5:98862026	chr5:98954394~98954972:+
THCA	cis	rs9393777	0.92	rs35716472	ENSG00000226314.6	ZNF192P1	-3.87	0.000126	0.00954	-0.33	-0.18	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28161781~28169594:+
THCA	cis	rs10043228	1	rs12520568	ENSG00000248445.4	SEMA6A-AS1	-3.87	0.000126	0.00954	-0.24	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116285808	chr5:116447547~116508276:+
THCA	cis	rs4443100	0.832	rs4434089	ENSG00000230701.2	FBXW4P1	-3.87	0.000126	0.00954	-0.21	-0.18	Serum parathyroid hormone levels;	chr22:23041683	chr22:23262767~23265005:+
THCA	cis	rs2115630	0.967	rs11073731	ENSG00000275120.1	RP11-182J1.17	-3.87	0.000126	0.00954	-0.18	-0.18	P wave terminal force;	chr15:84811882	chr15:84599434~84606463:-
THCA	cis	rs2115630	1	rs8037423	ENSG00000275120.1	RP11-182J1.17	-3.87	0.000126	0.00954	-0.18	-0.18	P wave terminal force;	chr15:84812263	chr15:84599434~84606463:-
THCA	cis	rs459571	0.916	rs109536	ENSG00000235106.7	LINC00094	3.87	0.000126	0.00954	0.15	0.18	Platelet distribution width;	chr9:134024865	chr9:134025439~134034666:+
THCA	cis	rs72949976	1	rs6747328	ENSG00000270659.1	RP11-105N14.1	3.87	0.000126	0.00954	0.14	0.18	Squamous cell lung carcinoma;Lung cancer;	chr2:213167432	chr2:213152970~213153659:+
THCA	cis	rs6494488	0.5	rs72742913	ENSG00000259635.1	AC100830.3	-3.87	0.000126	0.00955	-0.45	-0.18	Coronary artery disease;	chr15:64554511	chr15:64701248~64719602:+
THCA	cis	rs2281636	0.723	rs11190245	ENSG00000260475.1	RP11-85A1.3	3.87	0.000126	0.00955	0.18	0.18	Obesity-related traits;	chr10:99691502	chr10:99621055~99621918:+
THCA	cis	rs1555322	0.745	rs2425017	ENSG00000269202.1	RP4-614O4.12	-3.87	0.000126	0.00955	-0.21	-0.18	Attention deficit hyperactivity disorder;	chr20:35229835	chr20:35201747~35203288:-
THCA	cis	rs72627123	0.749	rs72627104	ENSG00000259065.1	RP5-1021I20.1	-3.87	0.000126	0.00955	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73839245	chr14:73787360~73803270:+
THCA	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	3.87	0.000126	0.00955	0.2	0.18	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
THCA	cis	rs8062405	0.691	rs743590	ENSG00000270424.1	RP11-1348G14.6	3.87	0.000126	0.00955	0.22	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28749959~28750595:-
THCA	cis	rs1371614	0.611	rs4665922	ENSG00000272148.1	RP11-195B17.1	-3.87	0.000126	0.00955	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26911066	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.635	rs12714002	ENSG00000272148.1	RP11-195B17.1	-3.87	0.000126	0.00955	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26912057	chr2:27062428~27062907:-
THCA	cis	rs4470077	1	rs8003684	ENSG00000258413.1	RP11-665C16.6	-3.87	0.000126	0.00955	-0.3	-0.18	Platelet count;	chr14:55425320	chr14:55262767~55272075:-
THCA	cis	rs7267979	0.966	rs2424715	ENSG00000276952.1	RP5-965G21.6	3.87	0.000126	0.00955	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25284915~25285588:-
THCA	cis	rs56309584	0.715	rs11651199	ENSG00000271002.1	RP11-599B13.8	-3.87	0.000126	0.00955	-0.27	-0.18	Initial pursuit acceleration;	chr17:8239326	chr17:8199123~8199437:-
THCA	cis	rs6121246	0.909	rs6060821	ENSG00000224628.2	RP5-854E16.2	-3.87	0.000126	0.00955	-0.24	-0.18	Mean corpuscular hemoglobin;	chr20:31706231	chr20:31285317~31286835:-
THCA	cis	rs9309473	0.5	rs12997018	ENSG00000273245.1	RP11-434P11.2	-3.87	0.000126	0.00955	-0.21	-0.18	Metabolite levels;	chr2:73685772	chr2:73750256~73750786:-
THCA	cis	rs6728642	0.519	rs6721921	ENSG00000230606.9	AC159540.1	3.87	0.000126	0.00955	0.22	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900764	chr2:97416165~97433527:-
THCA	cis	rs6728642	0.519	rs59131346	ENSG00000230606.9	AC159540.1	3.87	0.000126	0.00955	0.22	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96901031	chr2:97416165~97433527:-
THCA	cis	rs7520050	0.902	rs9429088	ENSG00000281133.1	AL355480.3	3.87	0.000126	0.00955	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45580892~45580996:-
THCA	cis	rs67981189	0.766	rs2526852	ENSG00000269927.1	RP6-91H8.3	-3.87	0.000126	0.00955	-0.2	-0.18	Schizophrenia;	chr14:70949450	chr14:71141125~71143253:-
THCA	cis	rs4714902	0.564	rs2206964	ENSG00000231769.2	RP1-8B1.4	-3.87	0.000126	0.00955	-0.17	-0.18	Colonoscopy-negative controls vs population controls;	chr6:46177810	chr6:46097093~46129706:-
THCA	cis	rs721917	0.525	rs2819106	ENSG00000244733.5	RP11-506M13.3	-3.87	0.000126	0.00956	-0.2	-0.18	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79660891~79677996:+
THCA	cis	rs6494488	0.5	rs72744713	ENSG00000259635.1	AC100830.3	-3.87	0.000126	0.00956	-0.43	-0.18	Coronary artery disease;	chr15:64723335	chr15:64701248~64719602:+
THCA	cis	rs1501911	0.53	rs161942	ENSG00000246763.5	RGMB-AS1	3.87	0.000126	0.00956	0.18	0.18	Lung function (FEV1/FVC);	chr5:98868016	chr5:98769618~98773469:-
THCA	cis	rs35740288	0.822	rs2241268	ENSG00000259407.1	RP11-158M2.3	-3.87	0.000126	0.00956	-0.22	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85735078	chr15:85744109~85750281:-
THCA	cis	rs62458065	0.568	rs62466415	ENSG00000231952.3	DPY19L1P2	3.87	0.000126	0.00956	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32478642	chr7:32812757~32838570:+
THCA	cis	rs73198271	0.562	rs17154743	ENSG00000253893.2	FAM85B	3.87	0.000126	0.00956	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793277	chr8:8167819~8226614:-
THCA	cis	rs6938	0.534	rs59945415	ENSG00000260269.4	CTD-2323K18.1	-3.87	0.000126	0.00956	-0.26	-0.18	Breast cancer;	chr15:74936086	chr15:75527150~75601205:-
THCA	cis	rs11673344	0.764	rs513406	ENSG00000267260.1	CTD-2162K18.4	-3.87	0.000126	0.00956	-0.22	-0.18	Obesity-related traits;	chr19:36948245	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.734	rs496872	ENSG00000267260.1	CTD-2162K18.4	-3.87	0.000126	0.00956	-0.22	-0.18	Obesity-related traits;	chr19:36948579	chr19:36773153~36777078:+
THCA	cis	rs7873102	0.669	rs10973654	ENSG00000213839.4	TMX2P1	3.87	0.000126	0.00956	0.14	0.18	Brain structure;	chr9:38055922	chr9:37885683~37886390:+
THCA	cis	rs9911578	0.839	rs7208505	ENSG00000224738.1	AC099850.1	3.87	0.000126	0.00956	0.2	0.18	Intelligence (multi-trait analysis);	chr17:59110368	chr17:59106598~59118267:+
THCA	cis	rs60180747	0.909	rs76549445	ENSG00000261318.1	RP11-653J6.1	3.87	0.000126	0.00956	0.25	0.18	Testicular germ cell tumor;	chr15:66534560	chr15:66278498~66293357:-
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000275400.1	RP4-756H11.5	-3.87	0.000126	0.00956	-0.17	-0.18	Calcium levels;	chr7:65967580	chr7:66553805~66554199:-
THCA	cis	rs875971	0.545	rs316316	ENSG00000273024.4	INTS4P2	3.87	0.000126	0.00956	0.22	0.18	Aortic root size;	chr7:66149270	chr7:65647864~65715661:+
THCA	cis	rs1005277	0.505	rs1208689	ENSG00000120555.12	SEPT7P9	3.87	0.000126	0.00956	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38383069~38402916:-
THCA	cis	rs1862618	0.853	rs252922	ENSG00000234553.1	AC022431.3	-3.87	0.000126	0.00956	-0.2	-0.18	Initial pursuit acceleration;	chr5:56840516	chr5:56536583~56537826:-
THCA	cis	rs7259376	0.902	rs10409947	ENSG00000269345.1	VN1R85P	3.87	0.000126	0.00956	0.19	0.18	Menopause (age at onset);	chr19:22329716	chr19:22174766~22175191:-
THCA	cis	rs1411478	1	rs7553330	ENSG00000243155.1	RP11-46A10.5	3.87	0.000126	0.00956	0.19	0.18	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180986879	chr1:180944042~180976482:-
THCA	cis	rs427943	0.83	rs914206	ENSG00000223768.1	LINC00205	-3.87	0.000126	0.00956	-0.16	-0.18	Body mass index;	chr21:45181262	chr21:45293285~45297354:+
THCA	cis	rs9902453	0.868	rs12944395	ENSG00000263370.1	RP11-68I3.5	-3.87	0.000126	0.00956	-0.23	-0.18	Coffee consumption (cups per day);	chr17:29996481	chr17:29639627~29640825:+
THCA	cis	rs13113518	0.783	rs12510400	ENSG00000223305.1	RN7SKP30	3.87	0.000126	0.00956	0.23	0.18	Height;	chr4:55577294	chr4:55540502~55540835:-
THCA	cis	rs7711186	0.786	rs12654185	ENSG00000252464.1	RN7SKP70	3.87	0.000126	0.00956	0.2	0.18	Urate levels in obese individuals;	chr5:178650458	chr5:178619728~178619998:-
THCA	cis	rs7711186	0.786	rs73353883	ENSG00000252464.1	RN7SKP70	3.87	0.000126	0.00956	0.2	0.18	Urate levels in obese individuals;	chr5:178650495	chr5:178619728~178619998:-
THCA	cis	rs9510787	0.538	rs12430043	ENSG00000205861.10	C1QTNF9B-AS1	-3.87	0.000126	0.00956	-0.22	-0.18	Nasopharyngeal carcinoma;	chr13:23682221	chr13:23888889~23897263:+
THCA	cis	rs6441975	0.506	rs1001007	ENSG00000223552.1	RP11-24F11.2	3.87	0.000126	0.00956	0.15	0.18	AIDS progression;	chr3:46387167	chr3:46364955~46407059:-
THCA	cis	rs7838490	0.504	rs12681181	ENSG00000253553.4	RP11-586K2.1	3.87	0.000126	0.00956	0.18	0.18	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88564753	chr8:88326836~88737134:+
THCA	cis	rs13256369	0.802	rs12153	ENSG00000254153.1	CTA-398F10.2	-3.87	0.000126	0.00956	-0.2	-0.18	Obesity-related traits;	chr8:8703399	chr8:8456909~8461337:-
THCA	cis	rs6049003	0.599	rs6114233	ENSG00000270001.1	RP11-218C14.8	-3.87	0.000126	0.00956	-0.2	-0.18	Cerebrospinal fluid biomarker levels;	chr20:23710245	chr20:23631826~23632316:-
THCA	cis	rs372883	0.613	rs1153290	ENSG00000176054.6	RPL23P2	-3.87	0.000126	0.00956	-0.15	-0.18	Pancreatic cancer;	chr21:29315083	chr21:28997613~28998033:-
THCA	cis	rs758324	0.755	rs25886	ENSG00000237714.1	P4HA2-AS1	-3.87	0.000126	0.00956	-0.25	-0.18	Alzheimer's disease in APOE e4- carriers;	chr5:132079373	chr5:132184876~132192808:+
THCA	cis	rs12612619	0.658	rs112794902	ENSG00000229122.1	AGBL5-IT1	3.87	0.000126	0.00957	0.13	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26928718	chr2:27061038~27061815:+
THCA	cis	rs12612619	0.658	rs77920959	ENSG00000229122.1	AGBL5-IT1	3.87	0.000126	0.00957	0.13	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26928722	chr2:27061038~27061815:+
THCA	cis	rs4575098	0.681	rs6779	ENSG00000227741.1	RP11-536C5.7	3.87	0.000126	0.00957	0.2	0.18	Monocyte percentage of white cells;	chr1:161171642	chr1:160202199~160208869:-
THCA	cis	rs957448	0.507	rs1984711	ENSG00000253175.1	RP11-267M23.6	3.87	0.000126	0.00957	0.21	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94565036~94565715:+
THCA	cis	rs881375	0.933	rs1548784	ENSG00000270917.1	RP11-27I1.6	-3.87	0.000126	0.00957	-0.24	-0.18	Rheumatoid arthritis;	chr9:120923002	chr9:120812475~120812845:-
THCA	cis	rs12928939	0.517	rs9940234	ENSG00000260886.1	TAT-AS1	3.87	0.000126	0.00957	0.24	0.18	Post bronchodilator FEV1;	chr16:71930902	chr16:71565789~71578187:+
THCA	cis	rs1385374	0.563	rs12299194	ENSG00000274695.1	RP11-21K12.3	3.87	0.000127	0.00957	0.32	0.18	Systemic lupus erythematosus;	chr12:128780293	chr12:128826836~128827579:+
THCA	cis	rs7399018	0.739	rs6580811	ENSG00000278126.1	RP11-454E5.4	3.87	0.000127	0.00957	0.21	0.18	Cisplatin-induced ototoxicity;	chr12:51218717	chr12:51201684~51202581:-
THCA	cis	rs9876781	0.559	rs1903144	ENSG00000244380.1	RP11-24C3.2	3.87	0.000127	0.00957	0.21	0.18	Longevity;	chr3:48364907	chr3:48440352~48446656:-
THCA	cis	rs2039553	0.681	rs2802638	ENSG00000227354.5	RBM26-AS1	3.87	0.000127	0.00958	0.16	0.18	Pancreatic cancer;	chr13:79738511	chr13:79406309~79424328:+
THCA	cis	rs409045	0.84	rs404765	ENSG00000271874.1	CTD-2024P10.2	3.87	0.000127	0.00958	0.23	0.18	Left ventricular mass;	chr5:34640033	chr5:34651457~34651888:-
THCA	cis	rs11603020	0.95	rs28362951	ENSG00000254602.1	AP000662.4	-3.87	0.000127	0.00958	-0.2	-0.18	Blood protein levels;	chr11:57605053	chr11:57638024~57652790:+
THCA	cis	rs4713118	0.539	rs200967	ENSG00000226314.6	ZNF192P1	-3.87	0.000127	0.00958	-0.21	-0.18	Parkinson's disease;	chr6:27894349	chr6:28161781~28169594:+
THCA	cis	rs420259	0.51	rs12921516	ENSG00000260136.4	CTD-2270L9.4	-3.87	0.000127	0.00958	-0.14	-0.18	Bipolar disorder;	chr16:23510082	chr16:23452758~23457606:+
THCA	cis	rs7131987	0.903	rs7970390	ENSG00000257599.1	OVCH1-AS1	-3.87	0.000127	0.00958	-0.21	-0.18	QT interval;	chr12:29245722	chr12:29389294~29487488:+
THCA	cis	rs6762	0.692	rs5030778	ENSG00000255142.1	AP006621.6	3.87	0.000127	0.00958	0.13	0.18	Mean platelet volume;	chr11:836008	chr11:781645~782105:+
THCA	cis	rs651907	0.64	rs771578	ENSG00000256628.3	ZBTB11-AS1	3.87	0.000127	0.00958	0.2	0.18	Colorectal cancer;	chr3:101894590	chr3:101676475~101679217:+
THCA	cis	rs10090774	0.965	rs7831770	ENSG00000280303.2	ERICD	-3.87	0.000127	0.00958	-0.17	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140990088	chr8:140636281~140638283:+
THCA	cis	rs9660180	1	rs3737628	ENSG00000215914.4	MMP23A	-3.87	0.000127	0.00958	-0.23	-0.18	Body mass index;	chr1:1791493	chr1:1699942~1701782:+
THCA	cis	rs2933343	0.621	rs883843	ENSG00000261159.1	RP11-723O4.9	-3.87	0.000127	0.00958	-0.19	-0.18	IgG glycosylation;	chr3:128848540	chr3:128859716~128860526:-
THCA	cis	rs4792901	0.765	rs3809751	ENSG00000267151.3	RP11-100E5.2	3.87	0.000127	0.00958	0.2	0.18	Dupuytren's disease;	chr17:43482417	chr17:43444707~43451200:+
THCA	cis	rs17597773	0.674	rs12073837	ENSG00000272823.1	RP11-295M18.6	-3.87	0.000127	0.00958	-0.23	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220836863	chr1:220828676~220829211:-
THCA	cis	rs17597773	0.674	rs11118619	ENSG00000272823.1	RP11-295M18.6	-3.87	0.000127	0.00958	-0.23	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220838921	chr1:220828676~220829211:-
THCA	cis	rs6498068	0.564	rs4780938	ENSG00000260468.1	LINC01290	-3.87	0.000127	0.00958	-0.23	-0.18	Metabolite levels (MHPG);	chr16:10527228	chr16:10514842~10528202:-
THCA	cis	rs875971	0.638	rs801205	ENSG00000230295.1	RP11-458F8.2	3.87	0.000127	0.00958	0.13	0.18	Aortic root size;	chr7:66557157	chr7:66880708~66882981:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000230295.1	RP11-458F8.2	3.87	0.000127	0.00958	0.13	0.18	Aortic root size;	chr7:66557902	chr7:66880708~66882981:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000230295.1	RP11-458F8.2	3.87	0.000127	0.00958	0.13	0.18	Aortic root size;	chr7:66571411	chr7:66880708~66882981:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000230295.1	RP11-458F8.2	3.87	0.000127	0.00958	0.13	0.18	Aortic root size;	chr7:66572000	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000230295.1	RP11-458F8.2	3.87	0.000127	0.00958	0.13	0.18	Aortic root size;	chr7:66577454	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000230295.1	RP11-458F8.2	3.87	0.000127	0.00958	0.13	0.18	Aortic root size;	chr7:66577989	chr7:66880708~66882981:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000230295.1	RP11-458F8.2	3.87	0.000127	0.00958	0.13	0.18	Aortic root size;	chr7:66591816	chr7:66880708~66882981:+
THCA	cis	rs3812831	0.695	rs7983872	ENSG00000264539.1	MIR548AR	3.86	0.000127	0.00958	0.19	0.18	Schizophrenia;	chr13:114179306	chr13:114244505~114244561:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000127	0.00958	-0.14	-0.18	Aortic root size;	chr7:66376994	chr7:66848496~66858136:+
THCA	cis	rs3799378	0.579	rs9348715	ENSG00000124549.13	BTN2A3P	-3.86	0.000127	0.00958	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26375414	chr6:26421391~26432383:+
THCA	cis	rs7819412	0.875	rs6981523	ENSG00000206014.6	OR7E161P	3.86	0.000127	0.00959	0.2	0.18	Triglycerides;	chr8:11204283	chr8:11928597~11929563:-
THCA	cis	rs669446	0.533	rs2158956	ENSG00000237950.1	RP11-7O11.3	3.86	0.000127	0.00959	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43746026	chr1:43944370~43946551:-
THCA	cis	rs61142792	1	rs28510818	ENSG00000272459.1	RP11-1277A3.3	3.86	0.000127	0.00959	0.39	0.18	Alzheimer disease and age of onset;	chr5:177555661	chr5:177554824~177555364:+
THCA	cis	rs360071	0.528	rs360100	ENSG00000242861.1	RP11-285F7.2	-3.86	0.000127	0.00959	-0.16	-0.18	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);	chr1:225879682	chr1:225840883~225846522:-
THCA	cis	rs763121	0.889	rs9610971	ENSG00000228274.3	RP3-508I15.9	-3.86	0.000127	0.00959	-0.19	-0.18	Menopause (age at onset);	chr22:38514805	chr22:38667585~38681820:-
THCA	cis	rs2562456	0.833	rs2562487	ENSG00000268278.1	RP11-420K14.1	3.86	0.000127	0.00959	0.21	0.18	Pain;	chr19:21468580	chr19:21637974~21656300:+
THCA	cis	rs6137726	0.529	rs910957	ENSG00000237396.1	LINC01384	3.86	0.000127	0.00959	0.17	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22653216	chr20:22587522~22607517:-
THCA	cis	rs875971	0.619	rs10278371	ENSG00000229180.5	GS1-124K5.11	-3.86	0.000127	0.00959	-0.12	-0.18	Aortic root size;	chr7:66586553	chr7:66526088~66542624:-
THCA	cis	rs13108904	0.901	rs12509700	ENSG00000254094.1	AC078852.1	-3.86	0.000127	0.00959	-0.2	-0.18	Obesity-related traits;	chr4:1302533	chr4:1356581~1358075:+
THCA	cis	rs13325613	0.915	rs3774630	ENSG00000223552.1	RP11-24F11.2	-3.86	0.000127	0.00959	-0.31	-0.18	Monocyte count;	chr3:46202782	chr3:46364955~46407059:-
THCA	cis	rs10090774	0.687	rs13268978	ENSG00000280303.2	ERICD	-3.86	0.000127	0.00959	-0.16	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140669286	chr8:140636281~140638283:+
THCA	cis	rs9309473	0.95	rs10206899	ENSG00000273245.1	RP11-434P11.2	3.86	0.000127	0.00959	0.25	0.18	Metabolite levels;	chr2:73673773	chr2:73750256~73750786:-
THCA	cis	rs912593	1	rs9315298	ENSG00000225179.1	LINC00457	3.86	0.000127	0.00959	0.23	0.18	Cancer;	chr13:34466616	chr13:34435450~34640685:-
THCA	cis	rs10895987	0.531	rs11227118	ENSG00000197847.11	SLC22A20	-3.86	0.000127	0.00959	-0.18	-0.18	Blood protein levels;	chr11:65093183	chr11:65213840~65242757:+
THCA	cis	rs494526	1	rs7905458	ENSG00000229272.1	RP11-498J9.2	-3.86	0.000127	0.00959	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr10:119026042	chr10:119003536~119003884:-
THCA	cis	rs634537	0.559	rs643319	ENSG00000229298.1	TUBB8P1	3.86	0.000127	0.00959	0.19	0.18	Glioma;Non-glioblastoma glioma;Glioblastoma;	chr9:22017837	chr9:21811621~21812347:-
THCA	cis	rs7727544	0.513	rs10065787	ENSG00000263597.1	MIR3936	3.86	0.000127	0.00959	0.17	0.18	Blood metabolite levels;	chr5:132100793	chr5:132365490~132365599:-
THCA	cis	rs38055	0.519	rs10069631	ENSG00000247796.2	CTD-2366F13.1	3.86	0.000127	0.0096	0.19	0.18	Acne (severe);	chr5:53126169	chr5:53109842~53115126:+
THCA	cis	rs7616559	0.627	rs11715321	ENSG00000244515.1	KRT18P34	-3.86	0.000127	0.0096	-0.2	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157024986	chr3:157162663~157163932:-
THCA	cis	rs2692947	0.537	rs72821437	ENSG00000168992.4	OR7E102P	3.86	0.000127	0.0096	0.22	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95535051	chr2:95546531~95547545:+
THCA	cis	rs12681366	0.881	rs2931631	ENSG00000261437.1	RP11-22C11.2	3.86	0.000127	0.0096	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94401415	chr8:94637285~94639467:-
THCA	cis	rs10496034	0.541	rs77334206	ENSG00000237887.1	AC092839.1	-3.86	0.000127	0.0096	-0.32	-0.18	Refractive astigmatism;	chr2:54688190	chr2:54529343~54529801:+
THCA	cis	rs6477918	0.598	rs10981381	ENSG00000230185.4	C9orf147	-3.86	0.000127	0.0096	-0.19	-0.18	Obstetric antiphospholipid syndrome;	chr9:112390704	chr9:112433816~112487204:-
THCA	cis	rs17286411	0.671	rs951939	ENSG00000260185.1	RP11-432I5.6	-3.86	0.000127	0.0096	-0.24	-0.18	Blood protein levels;	chr16:71775631	chr16:71655027~71664212:+
THCA	cis	rs7216064	0.734	rs12942774	ENSG00000237854.3	LINC00674	-3.86	0.000127	0.0096	-0.18	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971446	chr17:68101908~68115518:+
THCA	cis	rs7267979	1	rs6115182	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000127	0.0096	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25284915~25285588:-
THCA	cis	rs2692947	0.77	rs12471925	ENSG00000235584.2	AC008268.1	-3.86	0.000127	0.0096	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95889774	chr2:95666084~95668715:+
THCA	cis	rs1923243	0.749	rs12097442	ENSG00000223479.3	RP4-788P17.1	-3.86	0.000127	0.0096	-0.19	-0.18	Migraine;	chr1:73018343	chr1:73635216~73715214:+
THCA	cis	rs9810089	0.814	rs2688600	ENSG00000273455.1	RP11-305O4.3	3.86	0.000127	0.00961	0.23	0.18	Gestational age at birth (child effect);	chr3:136533754	chr3:136087475~136087913:-
THCA	cis	rs9810089	0.777	rs2688601	ENSG00000273455.1	RP11-305O4.3	3.86	0.000127	0.00961	0.23	0.18	Gestational age at birth (child effect);	chr3:136533759	chr3:136087475~136087913:-
THCA	cis	rs15676	1	rs15676	ENSG00000234771.3	SLC25A25-AS1	-3.86	0.000127	0.00961	-0.15	-0.18	Blood metabolite levels;	chr9:128809748	chr9:128108581~128118693:-
THCA	cis	rs308403	0.509	rs1849430	ENSG00000224786.1	CETN4P	3.86	0.000127	0.00961	0.18	0.18	Blood protein levels;	chr4:122753546	chr4:122730548~122732193:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000230295.1	RP11-458F8.2	-3.86	0.000127	0.00961	-0.13	-0.18	Aortic root size;	chr7:66540165	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000230295.1	RP11-458F8.2	-3.86	0.000127	0.00961	-0.13	-0.18	Aortic root size;	chr7:66542376	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000230295.1	RP11-458F8.2	3.86	0.000127	0.00961	0.13	0.18	Aortic root size;	chr7:66545590	chr7:66880708~66882981:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000230295.1	RP11-458F8.2	3.86	0.000127	0.00961	0.13	0.18	Aortic root size;	chr7:66546680	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000230295.1	RP11-458F8.2	3.86	0.000127	0.00961	0.13	0.18	Aortic root size;	chr7:66550702	chr7:66880708~66882981:+
THCA	cis	rs7432375	1	rs940174	ENSG00000273455.1	RP11-305O4.3	3.86	0.000127	0.00961	0.23	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136590868	chr3:136087475~136087913:-
THCA	cis	rs10875746	0.669	rs10875772	ENSG00000258273.1	RP11-370I10.4	3.86	0.000127	0.00961	0.25	0.18	Longevity (90 years and older);	chr12:48215770	chr12:48333755~48333901:-
THCA	cis	rs735539	0.521	rs2585901	ENSG00000278291.1	RP11-172H24.4	3.86	0.000127	0.00961	0.24	0.18	Dental caries;	chr13:20846132	chr13:20699307~20703718:-
THCA	cis	rs9543976	0.623	rs6562914	ENSG00000261105.4	LMO7-AS1	3.86	0.000127	0.00961	0.24	0.18	Diabetic retinopathy;	chr13:75593401	chr13:75604700~75635994:-
THCA	cis	rs722599	0.961	rs2359239	ENSG00000279594.1	RP11-950C14.10	-3.86	0.000127	0.00961	-0.17	-0.18	IgG glycosylation;	chr14:74860068	chr14:75011269~75012851:-
THCA	cis	rs722599	1	rs722599	ENSG00000279594.1	RP11-950C14.10	-3.86	0.000127	0.00961	-0.17	-0.18	IgG glycosylation;	chr14:74860740	chr14:75011269~75012851:-
THCA	cis	rs494526	0.735	rs4751694	ENSG00000229272.1	RP11-498J9.2	-3.86	0.000127	0.00961	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr10:119095945	chr10:119003536~119003884:-
THCA	cis	rs748404	1	rs12911132	ENSG00000166763.7	STRCP1	3.86	0.000127	0.00961	0.21	0.18	Lung cancer;	chr15:43268238	chr15:43699488~43718184:-
THCA	cis	rs7178909	0.835	rs7169019	ENSG00000259677.1	RP11-493E3.1	3.86	0.000127	0.00961	0.21	0.18	Common traits (Other);	chr15:89857132	chr15:89876540~89877285:+
THCA	cis	rs6504108	0.624	rs4794525	ENSG00000264920.1	RP11-6N17.4	-3.86	0.000127	0.00961	-0.15	-0.18	Body mass index;	chr17:48220996	chr17:47891255~47895812:-
THCA	cis	rs7927592	0.956	rs948315	ENSG00000160172.9	FAM86C2P	3.86	0.000127	0.00961	0.17	0.18	Total body bone mineral density;	chr11:68541672	chr11:67791648~67805336:-
THCA	cis	rs1538970	0.924	rs12097497	ENSG00000234329.1	RP11-767N6.2	3.86	0.000127	0.00961	0.18	0.18	Platelet count;	chr1:45414997	chr1:45651039~45651826:-
THCA	cis	rs13182402	1	rs73343333	ENSG00000230929.5	RP11-395C3.1	-3.86	0.000127	0.00961	-0.33	-0.18	Osteoporosis;	chr5:126577868	chr5:126628019~126628319:-
THCA	cis	rs13182402	0.901	rs113394196	ENSG00000230929.5	RP11-395C3.1	-3.86	0.000127	0.00961	-0.33	-0.18	Osteoporosis;	chr5:126577999	chr5:126628019~126628319:-
THCA	cis	rs1065852	0.51	rs5758666	ENSG00000270083.1	RP1-257I20.14	-3.86	0.000127	0.00962	-0.21	-0.18	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42236827	chr22:42089630~42090028:-
THCA	cis	rs1161098	1	rs2700565	ENSG00000256037.1	MRPL40P1	-3.86	0.000127	0.00962	-0.26	-0.18	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67464073	chr12:67351436~67352039:+
THCA	cis	rs755249	0.567	rs66531516	ENSG00000182109.6	RP11-69E11.4	3.86	0.000127	0.00962	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39522280~39546187:-
THCA	cis	rs4650994	0.525	rs10913567	ENSG00000213057.5	C1orf220	-3.86	0.000127	0.00962	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr1:178542806	chr1:178542752~178548889:+
THCA	cis	rs4650994	0.507	rs12405456	ENSG00000213057.5	C1orf220	-3.86	0.000127	0.00962	-0.13	-0.18	HDL cholesterol;HDL cholesterol levels;	chr1:178543196	chr1:178542752~178548889:+
THCA	cis	rs12121840	0.79	rs16847110	ENSG00000237463.4	RP11-280O1.2	3.86	0.000127	0.00962	0.16	0.18	Interleukin-1-receptor antagonist levels;	chr1:165568020	chr1:165476841~165582155:-
THCA	cis	rs7621025	0.662	rs3856637	ENSG00000239213.4	NCK1-AS1	3.86	0.000127	0.00962	0.16	0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136672353	chr3:136841726~136862054:-
THCA	cis	rs10083777	0.551	rs79378252	ENSG00000261838.4	RP11-303E16.6	3.86	0.000127	0.00962	0.4	0.18	Metabolite levels (small molecules and protein measures);	chr16:81014554	chr16:81069854~81076598:+
THCA	cis	rs911555	0.755	rs17841064	ENSG00000269958.1	RP11-73M18.8	3.86	0.000127	0.00962	0.16	0.18	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103696353~103697163:+
THCA	cis	rs6546886	0.869	rs13013211	ENSG00000235499.1	AC073046.25	3.86	0.000127	0.00962	0.17	0.18	Dialysis-related mortality;	chr2:74087634	chr2:73985132~73986343:+
THCA	cis	rs4886920	0.894	rs4886930	ENSG00000260776.4	RP11-114H24.2	-3.86	0.000127	0.00962	-0.2	-0.18	Neuroticism;	chr15:77835064	chr15:77914217~77926846:-
THCA	cis	rs875971	0.666	rs13242072	ENSG00000229180.5	GS1-124K5.11	-3.86	0.000127	0.00962	-0.12	-0.18	Aortic root size;	chr7:66301001	chr7:66526088~66542624:-
THCA	cis	rs340849	0.935	rs340846	ENSG00000274895.1	RP11-478J18.2	3.86	0.000127	0.00963	0.15	0.18	Alzheimer's disease;	chr1:213947753	chr1:213983793~213986419:-
THCA	cis	rs340849	0.901	rs340841	ENSG00000274895.1	RP11-478J18.2	3.86	0.000127	0.00963	0.15	0.18	Alzheimer's disease;	chr1:213951127	chr1:213983793~213986419:-
THCA	cis	rs4819052	1	rs733738	ENSG00000184274.3	LINC00315	3.86	0.000127	0.00963	0.24	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45300245~45305257:-
THCA	cis	rs62244186	0.659	rs6441844	ENSG00000214820.3	MPRIPP1	3.86	0.000127	0.00963	0.19	0.18	Depressive symptoms;	chr3:44462087	chr3:44579938~44581026:-
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000255052.4	FAM66D	3.86	0.000127	0.00963	0.23	0.18	Neuroticism;	chr8:11986249	chr8:12115782~12177550:+
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000184274.3	LINC00315	-3.86	0.000127	0.00963	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45300245~45305257:-
THCA	cis	rs3748656	0.895	rs11102498	ENSG00000273483.1	RP4-671G15.2	3.86	0.000127	0.00963	0.19	0.18	Hip circumference adjusted for BMI;	chr1:112576820	chr1:112517799~112518441:-
THCA	cis	rs17597773	0.638	rs7544735	ENSG00000272823.1	RP11-295M18.6	3.86	0.000127	0.00963	0.23	0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220825571	chr1:220828676~220829211:-
THCA	cis	rs2919009	0.723	rs7071661	ENSG00000271670.1	RP11-95I16.4	3.86	0.000127	0.00963	0.19	0.18	Obesity-related traits;	chr10:120810472	chr10:120879256~120880667:-
THCA	cis	rs6762	0.692	rs7928925	ENSG00000255142.1	AP006621.6	3.86	0.000127	0.00963	0.13	0.18	Mean platelet volume;	chr11:839155	chr11:781645~782105:+
THCA	cis	rs6762	0.719	rs7936806	ENSG00000255142.1	AP006621.6	3.86	0.000127	0.00963	0.13	0.18	Mean platelet volume;	chr11:839186	chr11:781645~782105:+
THCA	cis	rs11089937	0.651	rs6001216	ENSG00000211639.2	IGLV4-60	3.86	0.000127	0.00963	0.12	0.18	Periodontitis (PAL4Q3);	chr22:22183755	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.651	rs6001217	ENSG00000211639.2	IGLV4-60	3.86	0.000127	0.00963	0.12	0.18	Periodontitis (PAL4Q3);	chr22:22183804	chr22:22162199~22162681:+
THCA	cis	rs11089937	0.521	rs6001221	ENSG00000211639.2	IGLV4-60	3.86	0.000127	0.00963	0.12	0.18	Periodontitis (PAL4Q3);	chr22:22185176	chr22:22162199~22162681:+
THCA	cis	rs13434995	0.513	rs62309729	ENSG00000249700.7	SRD5A3-AS1	-3.86	0.000127	0.00963	-0.25	-0.18	Adiponectin levels;	chr4:55536679	chr4:55363971~55395847:-
THCA	cis	rs9905704	0.918	rs34430710	ENSG00000224738.1	AC099850.1	3.86	0.000127	0.00963	0.24	0.18	Testicular germ cell tumor;	chr17:58799266	chr17:59106598~59118267:+
THCA	cis	rs654950	0.875	rs2810550	ENSG00000230638.4	RP11-486B10.4	3.86	0.000127	0.00963	0.2	0.18	Airway imaging phenotypes;	chr1:41529668	chr1:41542069~41544310:+
THCA	cis	rs9309473	0.519	rs1881246	ENSG00000273245.1	RP11-434P11.2	-3.86	0.000127	0.00963	-0.21	-0.18	Metabolite levels;	chr2:73422994	chr2:73750256~73750786:-
THCA	cis	rs6894268	0.751	rs11741546	ENSG00000273549.1	Metazoa_SRP	-3.86	0.000127	0.00964	-0.22	-0.18	Eating disorders;	chr5:179599908	chr5:179629151~179629410:+
THCA	cis	rs7074356	0.915	rs1870146	ENSG00000278616.1	BEND3P3	-3.86	0.000127	0.00964	-0.18	-0.18	Borderline personality disorder;	chr10:80450623	chr10:79682997~79685436:+
THCA	cis	rs5758659	0.904	rs5758653	ENSG00000273366.1	CTA-989H11.1	-3.86	0.000127	0.00964	-0.21	-0.18	Cognitive function;	chr22:42217479	chr22:42278188~42278846:+
THCA	cis	rs9660180	0.967	rs6603802	ENSG00000215914.4	MMP23A	-3.86	0.000128	0.00964	-0.23	-0.18	Body mass index;	chr1:1881082	chr1:1699942~1701782:+
THCA	cis	rs853679	0.585	rs201001	ENSG00000220721.1	OR1F12	3.86	0.000128	0.00964	0.25	0.18	Depression;	chr6:27841121	chr6:28073316~28074233:+
THCA	cis	rs853679	0.585	rs201000	ENSG00000220721.1	OR1F12	3.86	0.000128	0.00964	0.25	0.18	Depression;	chr6:27841381	chr6:28073316~28074233:+
THCA	cis	rs7586085	1	rs12185719	ENSG00000232411.1	AC009495.3	-3.86	0.000128	0.00964	-0.19	-0.18	Total body bone mineral density;	chr2:165718973	chr2:165833048~165839098:-
THCA	cis	rs12544026	0.548	rs482023	ENSG00000253669.3	KB-1732A1.1	-3.86	0.000128	0.00964	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101897779	chr8:102805517~102809971:+
THCA	cis	rs7166081	1	rs12899051	ENSG00000270964.1	RP11-502I4.3	-3.86	0.000128	0.00964	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67281403	chr15:67541072~67542604:-
THCA	cis	rs9353324	1	rs78362791	ENSG00000203875.9	SNHG5	-3.86	0.000128	0.00964	-0.4	-0.18	Interferon gamma-induced protein 10 levels;	chr6:86032858	chr6:85660950~85678736:-
THCA	cis	rs8115854	0.961	rs11906766	ENSG00000269846.1	RP4-621N11.2	-3.86	0.000128	0.00964	-0.24	-0.18	Hippocampal atrophy;	chr20:37147639	chr20:37095785~37097178:+
THCA	cis	rs9291683	0.62	rs4444830	ENSG00000261490.1	RP11-448G15.3	-3.86	0.000128	0.00964	-0.12	-0.18	Bone mineral density;	chr4:10123195	chr4:10068089~10073019:-
THCA	cis	rs734999	0.588	rs4648652	ENSG00000225931.3	RP3-395M20.7	3.86	0.000128	0.00964	0.21	0.18	Ulcerative colitis;	chr1:2604319	chr1:2566410~2569888:+
THCA	cis	rs1577330	0.846	rs2095405	ENSG00000254396.1	RP11-56F10.3	3.86	0.000128	0.00964	0.21	0.18	IgG glycosylation;	chr9:27073652	chr9:27102630~27104728:+
THCA	cis	rs12681366	0.734	rs1872889	ENSG00000261437.1	RP11-22C11.2	3.86	0.000128	0.00965	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94406193	chr8:94637285~94639467:-
THCA	cis	rs8007846	0.685	rs11623920	ENSG00000276116.2	FUT8-AS1	3.86	0.000128	0.00965	0.18	0.18	Multiple sclerosis--Brain Glutamate Levels;	chr14:65352596	chr14:65411170~65412690:-
THCA	cis	rs4295623	0.553	rs34962960	ENSG00000255046.1	RP11-297N6.4	3.86	0.000128	0.00965	0.18	0.18	Morning vs. evening chronotype;	chr8:11737088	chr8:11797928~11802568:-
THCA	cis	rs9880211	0.613	rs6439629	ENSG00000273486.1	RP11-731C17.2	3.86	0.000128	0.00965	0.17	0.18	Height;Body mass index;	chr3:136182428	chr3:136837338~136839021:-
THCA	cis	rs7259376	0.875	rs1991830	ENSG00000269345.1	VN1R85P	3.86	0.000128	0.00965	0.19	0.18	Menopause (age at onset);	chr19:22331928	chr19:22174766~22175191:-
THCA	cis	rs9435732	1	rs9435732	ENSG00000186301.8	MST1P2	-3.86	0.000128	0.00965	-0.15	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16981663	chr1:16645622~16650289:+
THCA	cis	rs7829975	0.5	rs7841082	ENSG00000248538.5	RP11-10A14.5	3.86	0.000128	0.00965	0.23	0.18	Mood instability;	chr8:8311465	chr8:9189011~9202854:+
THCA	cis	rs7267979	1	rs6050609	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000128	0.00965	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2424712	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2424714	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050617	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.933	rs2387887	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050626	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6037121	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs1047171	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050629	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050630	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050632	ENSG00000276952.1	RP5-965G21.6	3.86	0.000128	0.00965	0.18	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25284915~25285588:-
THCA	cis	rs1371614	0.635	rs4316900	ENSG00000272148.1	RP11-195B17.1	-3.86	0.000128	0.00965	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917474	chr2:27062428~27062907:-
THCA	cis	rs10089	1	rs3805606	ENSG00000245937.6	LINC01184	-3.86	0.000128	0.00965	-0.2	-0.18	Ileal carcinoids;	chr5:128135121	chr5:127940426~128083172:-
THCA	cis	rs2299587	0.56	rs11987695	ENSG00000253671.1	RP11-806O11.1	-3.86	0.000128	0.00965	-0.21	-0.18	Economic and political preferences;	chr8:17923576	chr8:17808941~17820868:+
THCA	cis	rs16957091	0.528	rs66932813	ENSG00000205771.5	CATSPER2P1	3.86	0.000128	0.00965	0.25	0.18	MGMT methylation in smokers;	chr15:42796424	chr15:43726918~43747094:-
THCA	cis	rs12893668	0.581	rs34843146	ENSG00000252469.1	RNU7-160P	3.86	0.000128	0.00965	0.21	0.18	Reticulocyte count;	chr14:103613527	chr14:103550345~103550406:+
THCA	cis	rs6787172	0.811	rs4510417	ENSG00000272087.1	RP11-379F4.7	-3.86	0.000128	0.00965	-0.16	-0.18	Subjective well-being;	chr3:158491764	chr3:158693120~158693768:-
THCA	cis	rs4879656	0.872	rs10758180	ENSG00000225693.1	LAGE3P1	3.86	0.000128	0.00965	0.18	0.18	Menopause (age at onset);	chr9:33045149	chr9:33019682~33020165:-
THCA	cis	rs3824488	0.834	rs79057214	ENSG00000271155.1	RP11-435O5.5	-3.86	0.000128	0.00965	-0.31	-0.18	Neuroticism;	chr9:95488392	chr9:95506235~95507636:+
THCA	cis	rs72996113	0.818	rs11224335	ENSG00000248027.1	CTD-2383M3.1	-3.86	0.000128	0.00965	-0.33	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100632623	chr11:100684162~100687955:-
THCA	cis	rs72996113	0.938	rs11224336	ENSG00000248027.1	CTD-2383M3.1	-3.86	0.000128	0.00965	-0.33	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100632801	chr11:100684162~100687955:-
THCA	cis	rs4237845	0.844	rs4630335	ENSG00000270039.1	RP11-571M6.17	-3.86	0.000128	0.00965	-0.19	-0.18	Intelligence (multi-trait analysis);	chr12:57908475	chr12:57803838~57804415:+
THCA	cis	rs712419	0.667	rs712417	ENSG00000258998.1	RP11-398E10.1	-3.86	0.000128	0.00965	-0.24	-0.18	Body mass index (change over time) in lung cancer;	chr14:44733511	chr14:44763157~44782829:-
THCA	cis	rs7246967	0.551	rs387675	ENSG00000236312.3	RPL34P34	-3.86	0.000128	0.00965	-0.36	-0.18	Bronchopulmonary dysplasia;	chr19:22810431	chr19:22368599~22368952:-
THCA	cis	rs234720	0.55	rs234722	ENSG00000233754.1	AP001628.7	3.86	0.000128	0.00966	0.2	0.18	Cognitive performance;	chr21:43026818	chr21:42781074~42782233:-
THCA	cis	rs9926296	0.681	rs12923946	ENSG00000274627.1	RP11-104N10.2	-3.86	0.000128	0.00966	-0.18	-0.18	Vitiligo;	chr16:89754672	chr16:89516797~89522217:+
THCA	cis	rs1876905	0.68	rs9400468	ENSG00000271789.1	RP5-1112D6.7	-3.86	0.000128	0.00966	-0.22	-0.18	Mean corpuscular hemoglobin;	chr6:111138766	chr6:111297126~111298510:+
THCA	cis	rs6137726	0.524	rs2208168	ENSG00000237396.1	LINC01384	3.86	0.000128	0.00966	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22642628	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.568	rs2424442	ENSG00000237396.1	LINC01384	3.86	0.000128	0.00966	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22644151	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs6082762	ENSG00000237396.1	LINC01384	3.86	0.000128	0.00966	0.16	0.18	Amyotrophic lateral sclerosis (sporadic);	chr20:22644378	chr20:22587522~22607517:-
THCA	cis	rs1371614	0.632	rs4665929	ENSG00000272148.1	RP11-195B17.1	-3.86	0.000128	0.00966	-0.16	-0.18	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26932981	chr2:27062428~27062907:-
THCA	cis	rs10875746	0.768	rs4760676	ENSG00000269514.1	RP11-370I10.12	3.86	0.000128	0.00966	0.17	0.18	Longevity (90 years and older);	chr12:48027880	chr12:48198387~48202031:+
THCA	cis	rs12216545	0.737	rs10226860	ENSG00000241134.3	BET1P1	-3.86	0.000128	0.00966	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150537661	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.711	rs2090955	ENSG00000241134.3	BET1P1	-3.86	0.000128	0.00966	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150538398	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs1522595	ENSG00000241134.3	BET1P1	-3.86	0.000128	0.00966	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150538747	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs4725910	ENSG00000241134.3	BET1P1	-3.86	0.000128	0.00966	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150540180	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs4725911	ENSG00000241134.3	BET1P1	-3.86	0.000128	0.00966	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150540240	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.737	rs1568628	ENSG00000241134.3	BET1P1	-3.86	0.000128	0.00966	-0.21	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150542198	chr7:150749736~150750094:+
THCA	cis	rs9307551	0.817	rs17003985	ENSG00000249646.2	OR7E94P	-3.86	0.000128	0.00966	-0.22	-0.18	Refractive error;	chr4:79602561	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.817	rs35487709	ENSG00000249646.2	OR7E94P	-3.86	0.000128	0.00966	-0.22	-0.18	Refractive error;	chr4:79603180	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.817	rs35631270	ENSG00000249646.2	OR7E94P	-3.86	0.000128	0.00966	-0.22	-0.18	Refractive error;	chr4:79603194	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.817	rs1348086	ENSG00000249646.2	OR7E94P	-3.86	0.000128	0.00966	-0.22	-0.18	Refractive error;	chr4:79605078	chr4:79587302~79588130:-
THCA	cis	rs4791641	0.967	rs8078338	ENSG00000178977.3	LINC00324	3.86	0.000128	0.00966	0.2	0.18	Red blood cell count;LDL cholesterol;Hematocrit;Hemoglobin concentration;LDL cholesterol levels;	chr17:8225842	chr17:8220642~8224043:-
THCA	cis	rs2235642	0.507	rs2235643	ENSG00000260989.1	LA16c-395F10.2	3.86	0.000128	0.00967	0.2	0.18	Coronary artery disease;	chr16:1535114	chr16:1580527~1610328:+
THCA	cis	rs11971779	0.793	rs11764426	ENSG00000252332.1	RNU6-911P	-3.86	0.000128	0.00967	-0.21	-0.18	Diisocyanate-induced asthma;	chr7:139339304	chr7:139448740~139448843:+
THCA	cis	rs2190422	0.551	rs11971743	ENSG00000234715.1	CTB-107G13.1	-3.86	0.000128	0.00967	-0.25	-0.18	Morning vs. evening chronotype;	chr7:103519711	chr7:103445207~103514007:+
THCA	cis	rs7560272	0.723	rs6744697	ENSG00000273245.1	RP11-434P11.2	3.86	0.000128	0.00967	0.21	0.18	Schizophrenia;	chr2:73538311	chr2:73750256~73750786:-
THCA	cis	rs4916588	0.767	rs111544824	ENSG00000270170.1	NCBP2-AS2	3.86	0.000128	0.00967	0.14	0.18	Night sleep phenotypes;	chr3:196928993	chr3:196942623~196943540:+
THCA	cis	rs2351088	0.572	rs138152	ENSG00000280383.1	CTA-941F9.10	3.86	0.000128	0.00967	0.19	0.18	Tonsillectomy;	chr22:45710794	chr22:45657019~45680130:+
THCA	cis	rs9650657	0.504	rs10093053	ENSG00000255046.1	RP11-297N6.4	3.86	0.000128	0.00967	0.18	0.18	Neuroticism;	chr8:11179678	chr8:11797928~11802568:-
THCA	cis	rs3733585	0.753	rs12500805	ENSG00000261490.1	RP11-448G15.3	3.86	0.000128	0.00967	0.11	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10016355	chr4:10068089~10073019:-
THCA	cis	rs786425	0.682	rs7399224	ENSG00000278112.1	RP11-972P1.11	3.86	0.000128	0.00967	0.17	0.18	Pubertal anthropometrics;	chr12:123711309	chr12:123519390~123519856:-
THCA	cis	rs9608946	1	rs9606736	ENSG00000279699.1	RP1-102K2.9	3.86	0.000128	0.00967	0.21	0.18	Red cell distribution width;	chr22:30490590	chr22:30275215~30276951:-
THCA	cis	rs854765	0.583	rs9890341	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17919861	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs11869536	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17923214	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs62064158	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17923621	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs28428991	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17924335	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs67253360	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17925659	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs9904163	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17927239	chr17:18001101~18001195:-
THCA	cis	rs854765	0.587	rs4077828	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17930330	chr17:18001101~18001195:-
THCA	cis	rs854765	0.618	rs8068820	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17930805	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs4077198	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17931249	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs11656840	ENSG00000281749.1	Y_RNA	3.86	0.000128	0.00967	0.22	0.18	Total body bone mineral density;	chr17:17934040	chr17:18001101~18001195:-
THCA	cis	rs111326718	1	rs111326718	ENSG00000213061.2	PFN1P11	3.86	0.000128	0.00967	0.21	0.18	Reticulocyte count;	chr10:103011454	chr10:102838011~102845473:-
THCA	cis	rs36093844	0.626	rs11234513	ENSG00000279742.1	RP11-700A24.1	-3.86	0.000128	0.00967	-0.23	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86012084	chr11:85852557~85854943:-
THCA	cis	rs75504410	1	rs113157781	ENSG00000231160.8	KLF3-AS1	-3.86	0.000128	0.00967	-0.2	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38650155	chr4:38612701~38664883:-
THCA	cis	rs5758511	0.689	rs5758691	ENSG00000270083.1	RP1-257I20.14	-3.86	0.000128	0.00967	-0.22	-0.18	Birth weight;	chr22:42272498	chr22:42089630~42090028:-
THCA	cis	rs5758511	0.68	rs1001586	ENSG00000270083.1	RP1-257I20.14	-3.86	0.000128	0.00967	-0.22	-0.18	Birth weight;	chr22:42274287	chr22:42089630~42090028:-
THCA	cis	rs10089	0.953	rs2016015	ENSG00000245937.6	LINC01184	3.86	0.000128	0.00967	0.19	0.18	Ileal carcinoids;	chr5:128191561	chr5:127940426~128083172:-
THCA	cis	rs9291683	0.588	rs12647117	ENSG00000261490.1	RP11-448G15.3	3.86	0.000128	0.00967	0.11	0.18	Bone mineral density;	chr4:10020435	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.588	rs12506364	ENSG00000261490.1	RP11-448G15.3	3.86	0.000128	0.00967	0.11	0.18	Bone mineral density;	chr4:10021824	chr4:10068089~10073019:-
THCA	cis	rs7403037	0.55	rs12185097	ENSG00000260760.1	PWRN3	3.86	0.000128	0.00967	0.26	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24404457	chr15:24441127~24447967:+
THCA	cis	rs683250	0.66	rs509144	ENSG00000254551.1	RP11-727A23.7	3.86	0.000128	0.00967	0.22	0.18	Subcortical brain region volumes;	chr11:83275553	chr11:83209431~83213379:-
THCA	cis	rs11088226	0.681	rs2833903	ENSG00000186842.4	LINC00846	-3.86	0.000128	0.00967	-0.26	-0.18	Gastritis;	chr21:32568509	chr21:32572238~32575881:-
THCA	cis	rs7264396	0.887	rs224344	ENSG00000088340.14	FER1L4	3.86	0.000128	0.00968	0.16	0.18	Total cholesterol levels;	chr20:35449053	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs224347	ENSG00000088340.14	FER1L4	3.86	0.000128	0.00968	0.16	0.18	Total cholesterol levels;	chr20:35449712	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.832	rs224349	ENSG00000088340.14	FER1L4	3.86	0.000128	0.00968	0.16	0.18	Total cholesterol levels;	chr20:35457571	chr20:35558737~35607562:-
THCA	cis	rs17597773	0.674	rs12089958	ENSG00000272823.1	RP11-295M18.6	-3.86	0.000128	0.00968	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828021	chr1:220828676~220829211:-
THCA	cis	rs9291683	0.552	rs10939656	ENSG00000261490.1	RP11-448G15.3	3.86	0.000128	0.00968	0.11	0.18	Bone mineral density;	chr4:10013022	chr4:10068089~10073019:-
THCA	cis	rs2408955	0.522	rs6580650	ENSG00000257735.1	RP11-370I10.6	-3.86	0.000128	0.00968	-0.21	-0.18	Glycated hemoglobin levels;	chr12:48024773	chr12:48350945~48442411:+
THCA	cis	rs10484434	0.901	rs62396160	ENSG00000272462.2	U91328.19	3.86	0.000128	0.00968	0.19	0.18	HIV-1 viral setpoint;	chr6:26075165	chr6:25992662~26001775:+
THCA	cis	rs1864585	0.52	rs73208789	ENSG00000280294.1	RP11-177H2.1	3.86	0.000128	0.00968	0.18	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10821677	chr8:10856085~10859436:-
THCA	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	3.86	0.000128	0.00968	0.25	0.18	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
THCA	cis	rs970548	0.909	rs55665473	ENSG00000230869.1	CTGLF10P	3.86	0.000128	0.00968	0.22	0.18	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45526557	chr10:45678692~45700532:+
THCA	cis	rs2455799	0.613	rs10510443	ENSG00000270409.1	RP11-44D5.1	-3.86	0.000128	0.00968	-0.19	-0.18	Mean platelet volume;	chr3:15787620	chr3:15732252~15733470:+
THCA	cis	rs67478160	0.529	rs12880413	ENSG00000258534.1	CTD-2134A5.4	-3.86	0.000128	0.00968	-0.17	-0.18	Schizophrenia;	chr14:103801070	chr14:103854366~103880111:-
THCA	cis	rs7824557	0.564	rs34389419	ENSG00000255495.1	AC145124.2	-3.86	0.000128	0.00968	-0.2	-0.18	Retinal vascular caliber;	chr8:11371810	chr8:12194467~12196280:+
THCA	cis	rs11763147	1	rs11763147	ENSG00000275400.1	RP4-756H11.5	3.86	0.000128	0.00968	0.17	0.18	Corneal structure;	chr7:65861834	chr7:66553805~66554199:-
THCA	cis	rs72627123	1	rs17093141	ENSG00000259065.1	RP5-1021I20.1	-3.86	0.000128	0.00968	-0.27	-0.18	Morning vs. evening chronotype;	chr14:73860200	chr14:73787360~73803270:+
THCA	cis	rs7212590	0.748	rs7211208	ENSG00000267302.4	RP11-178C3.2	3.86	0.000128	0.00968	0.32	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59879748	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.655	rs8070039	ENSG00000267302.4	RP11-178C3.2	3.86	0.000128	0.00968	0.32	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59896224	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.655	rs56198517	ENSG00000267302.4	RP11-178C3.2	3.86	0.000128	0.00968	0.32	0.18	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59899221	chr17:59964832~59996972:+
THCA	cis	rs7818688	0.578	rs11786451	ENSG00000253528.2	RP11-347C18.4	-3.86	0.000128	0.00968	-0.26	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94884803	chr8:94974573~94974853:-
THCA	cis	rs733175	0.855	rs10023068	ENSG00000261490.1	RP11-448G15.3	-3.86	0.000128	0.00969	-0.13	-0.18	Psychosis and Alzheimer's disease;	chr4:10003208	chr4:10068089~10073019:-
THCA	cis	rs733175	0.855	rs10018666	ENSG00000261490.1	RP11-448G15.3	3.86	0.000128	0.00969	0.13	0.18	Psychosis and Alzheimer's disease;	chr4:10003181	chr4:10068089~10073019:-
THCA	cis	rs7707921	0.957	rs226205	ENSG00000251374.1	RPS23P5	-3.86	0.000128	0.00969	-0.27	-0.18	Breast cancer;	chr5:82297835	chr5:82265157~82265259:-
THCA	cis	rs7973719	0.509	rs7969508	ENSG00000205885.6	C1RL-AS1	-3.86	0.000128	0.00969	-0.14	-0.18	IgG glycosylation;	chr12:7217906	chr12:7108052~7122501:+
THCA	cis	rs7973719	0.509	rs7969635	ENSG00000205885.6	C1RL-AS1	-3.86	0.000128	0.00969	-0.14	-0.18	IgG glycosylation;	chr12:7218016	chr12:7108052~7122501:+
THCA	cis	rs11242704	0.925	rs2816295	ENSG00000218027.2	RP11-157J24.1	3.86	0.000128	0.00969	0.23	0.18	Response to hepatitis C treatment;	chr6:1538703	chr6:1513698~1515289:-
THCA	cis	rs13178541	0.542	rs12653449	ENSG00000250378.1	RP11-119J18.1	-3.86	0.000128	0.00969	-0.2	-0.18	IgG glycosylation;	chr5:135789750	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.577	rs12653452	ENSG00000250378.1	RP11-119J18.1	-3.86	0.000128	0.00969	-0.2	-0.18	IgG glycosylation;	chr5:135789785	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.577	rs12653438	ENSG00000250378.1	RP11-119J18.1	-3.86	0.000128	0.00969	-0.2	-0.18	IgG glycosylation;	chr5:135789834	chr5:135812667~135826582:+
THCA	cis	rs5769765	0.955	rs7511159	ENSG00000260613.1	RP3-522J7.6	-3.86	0.000128	0.00969	-0.22	-0.18	Schizophrenia;	chr22:49914248	chr22:49832616~49837786:-
THCA	cis	rs10438797	0.77	rs9906043	ENSG00000276995.1	RP11-321A17.6	-3.86	0.000128	0.00969	-0.17	-0.18	Night sleep phenotypes;	chr17:29177903	chr17:29071124~29071594:-
THCA	cis	rs1880529	0.966	rs13113625	ENSG00000206820.1	RNU1-138P	-3.86	0.000128	0.00969	-0.2	-0.18	White matter integrity (bipolar disorder risk interaction);	chr4:113472588	chr4:113420323~113420486:+
THCA	cis	rs13217239	0.646	rs9379956	ENSG00000261353.1	CTA-14H9.5	3.86	0.000128	0.00969	0.18	0.18	Schizophrenia;	chr6:27065956	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs7747454	ENSG00000261353.1	CTA-14H9.5	3.86	0.000128	0.00969	0.18	0.18	Schizophrenia;	chr6:27066474	chr6:26527063~26527404:+
THCA	cis	rs3758911	1	rs1046095	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000128	0.00969	-0.22	-0.18	Coronary artery disease;	chr11:107326509	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs3758911	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000128	0.00969	-0.22	-0.18	Coronary artery disease;	chr11:107326914	chr11:107176286~107177530:+
THCA	cis	rs7829975	0.582	rs11783950	ENSG00000233609.3	RP11-62H7.2	-3.86	0.000128	0.00969	-0.18	-0.18	Mood instability;	chr8:8740321	chr8:8961200~8979025:+
THCA	cis	rs9291683	0.588	rs4280729	ENSG00000261490.1	RP11-448G15.3	3.86	0.000128	0.00969	0.11	0.18	Bone mineral density;	chr4:10012237	chr4:10068089~10073019:-
THCA	cis	rs7200543	1	rs1121	ENSG00000260735.1	RP11-72I8.1	-3.86	0.000128	0.00969	-0.2	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:15094411~15109197:+
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000189316.3	RP11-797H7.5	-3.86	0.000128	0.00969	-0.19	-0.18	Calcium levels;	chr7:65751755	chr7:64888527~64890100:-
THCA	cis	rs6981523	0.566	rs34162231	ENSG00000261451.1	RP11-981G7.1	-3.86	0.000128	0.00969	-0.23	-0.18	Neuroticism;	chr8:11145578	chr8:10433672~10438312:+
THCA	cis	rs13063635	0.831	rs13433997	ENSG00000226074.4	PRSS44	-3.86	0.000128	0.00969	-0.31	-0.18	Eosinophil percentage of granulocytes;	chr3:46008273	chr3:46809359~46812558:-
THCA	cis	rs2692947	0.537	rs1345917	ENSG00000168992.4	OR7E102P	3.86	0.000128	0.00969	0.22	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95534855	chr2:95546531~95547545:+
THCA	cis	rs10483853	0.689	rs11623977	ENSG00000258695.2	RP3-414A15.2	-3.86	0.000128	0.0097	-0.26	-0.18	Coronary artery calcification;	chr14:73370662	chr14:73522878~73530610:+
THCA	cis	rs10043228	1	rs6876972	ENSG00000248445.4	SEMA6A-AS1	-3.86	0.000128	0.0097	-0.23	-0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116306822	chr5:116447547~116508276:+
THCA	cis	rs875971	0.619	rs12533585	ENSG00000230295.1	RP11-458F8.2	-3.86	0.000128	0.0097	-0.13	-0.18	Aortic root size;	chr7:66519618	chr7:66880708~66882981:+
THCA	cis	rs12803635	0.557	rs35121740	ENSG00000255306.1	RP5-901A4.1	3.86	0.000128	0.0097	0.31	0.18	Mean corpuscular volume;	chr11:67407878	chr11:68024809~68030461:-
THCA	cis	rs10090774	0.965	rs7815898	ENSG00000280303.2	ERICD	3.86	0.000128	0.0097	0.16	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140866442	chr8:140636281~140638283:+
THCA	cis	rs8046148	0.951	rs2356837	ENSG00000279356.1	RP11-429P3.8	3.86	0.000128	0.0097	0.24	0.18	Testicular germ cell tumor;	chr16:50086982	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.865	rs11076512	ENSG00000279356.1	RP11-429P3.8	3.86	0.000128	0.0097	0.24	0.18	Testicular germ cell tumor;	chr16:50097943	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.951	rs11642579	ENSG00000279356.1	RP11-429P3.8	3.86	0.000128	0.0097	0.24	0.18	Testicular germ cell tumor;	chr16:50098169	chr16:50072862~50074986:+
THCA	cis	rs7637701	0.818	rs10936038	ENSG00000241544.1	RP11-6F2.5	-3.86	0.000128	0.0097	-0.21	-0.18	Breast cancer;	chr3:156814877	chr3:157081841~157088547:+
THCA	cis	rs7637701	0.818	rs11711674	ENSG00000241544.1	RP11-6F2.5	-3.86	0.000128	0.0097	-0.21	-0.18	Breast cancer;	chr3:156815164	chr3:157081841~157088547:+
THCA	cis	rs7637701	0.818	rs1560415	ENSG00000241544.1	RP11-6F2.5	-3.86	0.000128	0.0097	-0.21	-0.18	Breast cancer;	chr3:156819569	chr3:157081841~157088547:+
THCA	cis	rs7637701	0.818	rs1560416	ENSG00000241544.1	RP11-6F2.5	-3.86	0.000128	0.0097	-0.21	-0.18	Breast cancer;	chr3:156819630	chr3:157081841~157088547:+
THCA	cis	rs7637701	0.818	rs9837271	ENSG00000241544.1	RP11-6F2.5	-3.86	0.000128	0.0097	-0.21	-0.18	Breast cancer;	chr3:156820949	chr3:157081841~157088547:+
THCA	cis	rs330071	0.686	rs10087406	ENSG00000254153.1	CTA-398F10.2	3.86	0.000128	0.0097	0.19	0.18	Acne (severe);	chr8:9389088	chr8:8456909~8461337:-
THCA	cis	rs13113518	0.812	rs12505880	ENSG00000272969.1	RP11-528I4.2	3.86	0.000129	0.0097	0.21	0.18	Height;	chr4:55440988	chr4:55547112~55547889:+
THCA	cis	rs58235267	0.656	rs13410889	ENSG00000242412.1	DBIL5P2	-3.86	0.000129	0.00971	-0.2	-0.18	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:62860643	chr2:63117851~63119542:-
THCA	cis	rs9876781	0.563	rs4858821	ENSG00000244380.1	RP11-24C3.2	-3.86	0.000129	0.00971	-0.22	-0.18	Longevity;	chr3:48512515	chr3:48440352~48446656:-
THCA	cis	rs3806843	0.576	rs246008	ENSG00000202515.1	VTRNA1-3	-3.86	0.000129	0.00971	-0.2	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140958900	chr5:140726158~140726246:+
THCA	cis	rs7166081	1	rs8030620	ENSG00000270964.1	RP11-502I4.3	-3.86	0.000129	0.00971	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67328327	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs35722009	ENSG00000270964.1	RP11-502I4.3	-3.86	0.000129	0.00971	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67333195	chr15:67541072~67542604:-
THCA	cis	rs9393777	0.92	rs35716472	ENSG00000272009.1	RP1-313I6.12	-3.86	0.000129	0.00971	-0.29	-0.18	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28078792~28081130:-
THCA	cis	rs11673344	0.73	rs475026	ENSG00000267260.1	CTD-2162K18.4	-3.86	0.000129	0.00971	-0.22	-0.18	Obesity-related traits;	chr19:36968115	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.734	rs1644638	ENSG00000267260.1	CTD-2162K18.4	-3.86	0.000129	0.00971	-0.22	-0.18	Obesity-related traits;	chr19:36970513	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.764	rs1644643	ENSG00000267260.1	CTD-2162K18.4	-3.86	0.000129	0.00971	-0.22	-0.18	Obesity-related traits;	chr19:36972269	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.764	rs1644645	ENSG00000267260.1	CTD-2162K18.4	-3.86	0.000129	0.00971	-0.22	-0.18	Obesity-related traits;	chr19:36972528	chr19:36773153~36777078:+
THCA	cis	rs62244186	0.659	rs7649834	ENSG00000214820.3	MPRIPP1	3.86	0.000129	0.00971	0.19	0.18	Depressive symptoms;	chr3:44462240	chr3:44579938~44581026:-
THCA	cis	rs1876905	0.68	rs7767302	ENSG00000271789.1	RP5-1112D6.7	3.86	0.000129	0.00971	0.22	0.18	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111297126~111298510:+
THCA	cis	rs11098499	0.73	rs12505735	ENSG00000249244.1	RP11-548H18.2	3.86	0.000129	0.00971	0.2	0.18	Corneal astigmatism;	chr4:119611801	chr4:119391831~119395335:-
THCA	cis	rs9437689	0.714	rs6675668	ENSG00000235501.4	RP4-639F20.1	3.86	0.000129	0.00972	0.2	0.18	Phospholipid levels (plasma);	chr1:95050081	chr1:94927566~94963270:+
THCA	cis	rs13063635	0.915	rs35525815	ENSG00000226074.4	PRSS44	-3.86	0.000129	0.00972	-0.32	-0.18	Eosinophil percentage of granulocytes;	chr3:45964777	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.748	rs17280623	ENSG00000226074.4	PRSS44	-3.86	0.000129	0.00972	-0.32	-0.18	Eosinophil percentage of granulocytes;	chr3:45964849	chr3:46809359~46812558:-
THCA	cis	rs962856	0.604	rs2035566	ENSG00000236780.4	AC078941.1	3.86	0.000129	0.00972	0.24	0.18	Pancreatic cancer;	chr2:67389141	chr2:67123357~67215319:-
THCA	cis	rs18122	0.881	rs7585530	ENSG00000236780.4	AC078941.1	3.86	0.000129	0.00972	0.24	0.18	Waist-to-hip ratio adjusted for body mass index;	chr2:67391124	chr2:67123357~67215319:-
THCA	cis	rs9393777	0.92	rs72839445	ENSG00000272009.1	RP1-313I6.12	-3.86	0.000129	0.00972	-0.35	-0.18	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28078792~28081130:-
THCA	cis	rs16975963	0.644	rs12462505	ENSG00000276846.1	CTD-3220F14.3	-3.86	0.000129	0.00972	-0.16	-0.18	Longevity;	chr19:37647224	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.644	rs11083430	ENSG00000276846.1	CTD-3220F14.3	-3.86	0.000129	0.00972	-0.16	-0.18	Longevity;	chr19:37648587	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.644	rs73035158	ENSG00000276846.1	CTD-3220F14.3	-3.86	0.000129	0.00972	-0.16	-0.18	Longevity;	chr19:37650979	chr19:37314868~37315620:-
THCA	cis	rs875971	0.545	rs2420456	ENSG00000232559.3	GS1-124K5.12	3.86	0.000129	0.00972	0.19	0.18	Aortic root size;	chr7:66280619	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs697970	ENSG00000229886.1	RP5-1132H15.3	-3.86	0.000129	0.00972	-0.19	-0.18	Aortic root size;	chr7:66095065	chr7:66025126~66031544:-
THCA	cis	rs1005277	0.505	rs200910	ENSG00000120555.12	SEPT7P9	3.86	0.000129	0.00972	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38383069~38402916:-
THCA	cis	rs6067053	0.671	rs1130146	ENSG00000230758.1	SNAP23P	3.86	0.000129	0.00972	0.22	0.18	Intelligence (multi-trait analysis);	chr20:49242680	chr20:49038357~49038602:-
THCA	cis	rs3806843	0.576	rs251368	ENSG00000278901.1	AC005609.17	-3.86	0.000129	0.00972	-0.2	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140861442	chr5:140878073~140882642:-
THCA	cis	rs12544026	0.581	rs569787	ENSG00000253669.3	KB-1732A1.1	-3.86	0.000129	0.00972	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101863593	chr8:102805517~102809971:+
THCA	cis	rs200895692	1	rs200895692	ENSG00000228452.1	RP5-994D16.9	3.86	0.000129	0.00972	0.25	0.18	Monocyte count;	chr1:42956299	chr1:42775813~42776790:-
THCA	cis	rs1499614	0.522	rs13247442	ENSG00000237310.1	GS1-124K5.4	3.86	0.000129	0.00972	0.26	0.18	Gout;	chr7:66723871	chr7:66493706~66495474:+
THCA	cis	rs2836974	0.863	rs12483216	ENSG00000255568.3	BRWD1-AS2	3.86	0.000129	0.00972	0.15	0.18	Cognitive function;	chr21:39167688	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.863	rs6517519	ENSG00000255568.3	BRWD1-AS2	3.86	0.000129	0.00972	0.15	0.18	Cognitive function;	chr21:39168319	chr21:39313935~39314962:+
THCA	cis	rs3018712	0.532	rs948861	ENSG00000212093.1	AP000807.1	-3.86	0.000129	0.00972	-0.23	-0.18	Total body bone mineral density;	chr11:68653154	chr11:68506083~68506166:-
THCA	cis	rs1404100	0.51	rs1038273	ENSG00000249274.1	PDLIM1P4	3.86	0.000129	0.00973	0.18	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067757	chr3:98782188~98783193:+
THCA	cis	rs3770081	1	rs3770082	ENSG00000273080.1	RP11-301O19.1	-3.86	0.000129	0.00973	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86053799	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs3770081	ENSG00000273080.1	RP11-301O19.1	-3.86	0.000129	0.00973	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86053802	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs2278087	ENSG00000273080.1	RP11-301O19.1	-3.86	0.000129	0.00973	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86054823	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs60649958	ENSG00000273080.1	RP11-301O19.1	-3.86	0.000129	0.00973	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86055877	chr2:86195590~86196049:+
THCA	cis	rs9650657	0.504	rs2409724	ENSG00000255046.1	RP11-297N6.4	3.86	0.000129	0.00973	0.18	0.18	Neuroticism;	chr8:11184133	chr8:11797928~11802568:-
THCA	cis	rs7809950	0.678	rs62483641	ENSG00000272072.1	CTA-363E19.2	3.86	0.000129	0.00973	0.19	0.18	Coronary artery disease;	chr7:107261296	chr7:107192559~107193300:-
THCA	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-3.86	0.000129	0.00973	-0.17	-0.18	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
THCA	cis	rs13113518	0.783	rs12510400	ENSG00000272969.1	RP11-528I4.2	3.86	0.000129	0.00973	0.21	0.18	Height;	chr4:55577294	chr4:55547112~55547889:+
THCA	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-3.86	0.000129	0.00973	-0.2	-0.18	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
THCA	cis	rs2080501	0.51	rs1420676	ENSG00000275155.1	CTD-2595P9.4	-3.86	0.000129	0.00973	-0.17	-0.18	IgG glycosylation;	chr16:49632652	chr16:49847018~49847632:-
THCA	cis	rs944289	0.504	rs107196	ENSG00000258844.1	RP11-259K15.2	-3.86	0.000129	0.00973	-0.16	-0.18	Thyroid cancer;	chr14:36054892	chr14:36214607~36235608:+
THCA	cis	rs12476592	0.602	rs6546004	ENSG00000242412.1	DBIL5P2	3.86	0.000129	0.00973	0.23	0.18	Childhood ear infection;	chr2:63412394	chr2:63117851~63119542:-
THCA	cis	rs11971779	0.68	rs10274480	ENSG00000252332.1	RNU6-911P	-3.86	0.000129	0.00973	-0.2	-0.18	Diisocyanate-induced asthma;	chr7:139367682	chr7:139448740~139448843:+
THCA	cis	rs17382723	0.887	rs2302047	ENSG00000225521.1	AC005237.4	3.86	0.000129	0.00973	0.22	0.18	Height;	chr2:241094355	chr2:241015599~241064116:-
THCA	cis	rs5758659	0.716	rs5758661	ENSG00000227370.1	RP4-669P10.19	-3.86	0.000129	0.00974	-0.16	-0.18	Cognitive function;	chr22:42228439	chr22:42132543~42132998:+
THCA	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	3.86	0.000129	0.00974	0.21	0.18	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
THCA	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	3.86	0.000129	0.00974	0.21	0.18	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	3.86	0.000129	0.00974	0.21	0.18	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	3.86	0.000129	0.00974	0.21	0.18	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
THCA	cis	rs6881280	1	rs1549624	ENSG00000249996.1	RP11-359P5.1	3.86	0.000129	0.00974	0.28	0.18	Self-reported allergy;	chr5:123297547	chr5:123036271~123054667:+
THCA	cis	rs4808779	0.924	rs12608504	ENSG00000268650.3	AC068499.10	-3.86	0.000129	0.00974	-0.18	-0.18	Granulocyte percentage of myeloid white cells;	chr19:18278325	chr19:18204730~18220480:+
THCA	cis	rs7777677	0.925	rs2156964	ENSG00000211750.2	TRBV24-1	-3.86	0.000129	0.00974	-0.18	-0.18	Alcoholic chronic pancreatitis;	chr7:142664755	chr7:142656701~142657213:+
THCA	cis	rs62244186	0.659	rs4431151	ENSG00000214820.3	MPRIPP1	3.86	0.000129	0.00974	0.19	0.18	Depressive symptoms;	chr3:44469414	chr3:44579938~44581026:-
THCA	cis	rs62244186	0.608	rs2888390	ENSG00000214820.3	MPRIPP1	3.86	0.000129	0.00974	0.19	0.18	Depressive symptoms;	chr3:44469913	chr3:44579938~44581026:-
THCA	cis	rs73173548	0.502	rs4144466	ENSG00000247828.6	TMEM161B-AS1	3.86	0.000129	0.00974	0.15	0.18	Macular telangiectasia type 2;	chr5:88412379	chr5:88268895~88436685:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000275400.1	RP4-756H11.5	3.86	0.000129	0.00974	0.16	0.18	Aortic root size;	chr7:66633495	chr7:66553805~66554199:-
THCA	cis	rs875971	0.66	rs1860470	ENSG00000275400.1	RP4-756H11.5	3.86	0.000129	0.00974	0.16	0.18	Aortic root size;	chr7:66638707	chr7:66553805~66554199:-
THCA	cis	rs11678584	0.609	rs72787504	ENSG00000276517.1	AL133243.2	-3.86	0.000129	0.00974	-0.3	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32580249	chr2:32526504~32529507:+
THCA	cis	rs724818	0.661	rs3827584	ENSG00000251609.2	SETP12	-3.86	0.000129	0.00974	-0.49	-0.18	Monobrow thickness;	chr4:120782322	chr4:120895494~120897083:-
THCA	cis	rs959260	0.688	rs1369299	ENSG00000263843.1	RP11-649A18.12	3.86	0.000129	0.00974	0.19	0.18	Systemic lupus erythematosus;	chr17:75351244	chr17:75271369~75273895:+
THCA	cis	rs959260	0.61	rs9906825	ENSG00000263843.1	RP11-649A18.12	3.86	0.000129	0.00974	0.19	0.18	Systemic lupus erythematosus;	chr17:75354499	chr17:75271369~75273895:+
THCA	cis	rs7403037	0.601	rs4778420	ENSG00000260760.1	PWRN3	3.86	0.000129	0.00974	0.21	0.18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24193994	chr15:24441127~24447967:+
THCA	cis	rs12681366	0.708	rs3019154	ENSG00000261437.1	RP11-22C11.2	3.86	0.000129	0.00974	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94434280	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.708	rs3019279	ENSG00000261437.1	RP11-22C11.2	3.86	0.000129	0.00974	0.16	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94435677	chr8:94637285~94639467:-
THCA	cis	rs4601821	1	rs4601821	ENSG00000270179.1	RP11-159N11.4	-3.86	0.000129	0.00974	-0.18	-0.18	Alcoholic chronic pancreatitis;	chr11:113379624	chr11:113368478~113369117:+
THCA	cis	rs9634489	0.59	rs1927791	ENSG00000247400.3	DNAJC3-AS1	-3.86	0.000129	0.00974	-0.11	-0.18	Body mass index;	chr13:96269166	chr13:95648733~95676925:-
THCA	cis	rs7894407	0.629	rs11598702	ENSG00000272912.1	RP11-724N1.1	3.86	0.000129	0.00974	0.22	0.18	White matter hyperintensity burden;	chr10:103138228	chr10:102914585~102915404:+
THCA	cis	rs3169166	0.546	rs4887029	ENSG00000259562.2	RP11-762H8.2	3.86	0.000129	0.00974	0.11	0.18	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78299168	chr15:78290527~78291221:-
THCA	cis	rs6142618	0.905	rs6121352	ENSG00000224452.1	RSL24D1P6	-3.86	0.000129	0.00974	-0.22	-0.18	Inflammatory bowel disease;	chr20:32127894	chr20:32170390~32170790:-
THCA	cis	rs4950322	0.518	rs61838951	ENSG00000180867.10	PDIA3P1	3.86	0.000129	0.00974	0.17	0.18	Protein quantitative trait loci;	chr1:147116081	chr1:147178113~147179622:+
THCA	cis	rs12476592	0.516	rs4671503	ENSG00000242412.1	DBIL5P2	3.86	0.000129	0.00974	0.23	0.18	Childhood ear infection;	chr2:63409956	chr2:63117851~63119542:-
THCA	cis	rs420259	0.516	rs9302410	ENSG00000260136.4	CTD-2270L9.4	-3.86	0.000129	0.00974	-0.13	-0.18	Bipolar disorder;	chr16:23500051	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs9933261	ENSG00000260136.4	CTD-2270L9.4	-3.86	0.000129	0.00974	-0.13	-0.18	Bipolar disorder;	chr16:23504631	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs9931842	ENSG00000260136.4	CTD-2270L9.4	-3.86	0.000129	0.00974	-0.13	-0.18	Bipolar disorder;	chr16:23513237	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs2040573	ENSG00000260136.4	CTD-2270L9.4	-3.86	0.000129	0.00974	-0.13	-0.18	Bipolar disorder;	chr16:23518411	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs11074565	ENSG00000260136.4	CTD-2270L9.4	-3.86	0.000129	0.00974	-0.13	-0.18	Bipolar disorder;	chr16:23521687	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs2072061	ENSG00000260136.4	CTD-2270L9.4	-3.86	0.000129	0.00974	-0.13	-0.18	Bipolar disorder;	chr16:23529902	chr16:23452758~23457606:+
THCA	cis	rs2640806	0.505	rs6997311	ENSG00000253105.4	KB-1448A5.1	-3.86	0.000129	0.00974	-0.21	-0.18	Obesity-related traits;	chr8:96354178	chr8:96371865~96387438:-
THCA	cis	rs3818717	0.538	rs752579	ENSG00000281749.1	Y_RNA	-3.86	0.000129	0.00975	-0.22	-0.18	Lymphocyte counts;	chr17:17757033	chr17:18001101~18001195:-
THCA	cis	rs2562456	0.839	rs2562411	ENSG00000268521.1	VN1R83P	3.86	0.000129	0.00975	0.17	0.18	Pain;	chr19:21419181	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.876	rs2562413	ENSG00000268521.1	VN1R83P	3.86	0.000129	0.00975	0.17	0.18	Pain;	chr19:21420084	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.916	rs1967182	ENSG00000268521.1	VN1R83P	3.86	0.000129	0.00975	0.17	0.18	Pain;	chr19:21420337	chr19:21289554~21289998:-
THCA	cis	rs9650657	0.801	rs718741	ENSG00000255310.2	AF131215.2	-3.86	0.000129	0.00975	-0.15	-0.18	Neuroticism;	chr8:10756874	chr8:11107788~11109726:-
THCA	cis	rs7267979	0.932	rs6115214	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000129	0.00975	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25284915~25285588:-
THCA	cis	rs701145	0.585	rs1727882	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000129	0.00975	0.34	0.18	Coronary artery disease;	chr3:154119457	chr3:154024401~154121332:-
THCA	cis	rs708224	0.513	rs708226	ENSG00000277342.1	RP11-843B15.4	3.86	0.000129	0.00975	0.23	0.18	Pancreatic cancer;	chr12:32283563	chr12:32109076~32109602:+
THCA	cis	rs8007846	0.555	rs12895337	ENSG00000276116.2	FUT8-AS1	3.86	0.000129	0.00975	0.19	0.18	Multiple sclerosis--Brain Glutamate Levels;	chr14:65340724	chr14:65411170~65412690:-
THCA	cis	rs11621121	0.699	rs7143666	ENSG00000276116.2	FUT8-AS1	3.86	0.000129	0.00975	0.19	0.18	N-glycan levels;	chr14:65343259	chr14:65411170~65412690:-
THCA	cis	rs2836974	0.836	rs1041440	ENSG00000255568.3	BRWD1-AS2	3.86	0.000129	0.00975	0.15	0.18	Cognitive function;	chr21:39255399	chr21:39313935~39314962:+
THCA	cis	rs10181042	0.535	rs2441465	ENSG00000270820.4	RP11-355B11.2	3.86	0.000129	0.00975	0.14	0.18	Crohn's disease;	chr2:61084052	chr2:61471188~61484130:+
THCA	cis	rs4671400	0.571	rs28480287	ENSG00000271889.1	RP11-493E12.1	-3.86	0.000129	0.00975	-0.18	-0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61262154	chr2:61151433~61162105:-
THCA	cis	rs7520050	0.966	rs1707304	ENSG00000281133.1	AL355480.3	3.86	0.000129	0.00975	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45580892~45580996:-
THCA	cis	rs1842579	1	rs1325260	ENSG00000272691.1	RP11-290M5.4	-3.86	0.000129	0.00975	-0.17	-0.18	Coronary artery aneurysm in Kawasaki disease;	chr1:85835767	chr1:85578500~85578742:-
THCA	cis	rs1577917	0.682	rs6909767	ENSG00000220563.1	PKMP3	3.86	0.000129	0.00975	0.13	0.18	Response to antipsychotic treatment;	chr6:85518391	chr6:85659892~85660606:-
THCA	cis	rs62158800	0.852	rs7422236	ENSG00000224568.1	AC096669.3	3.86	0.000129	0.00975	0.31	0.18	Facial morphology (factor 22);	chr2:107687092	chr2:107529487~107556326:+
THCA	cis	rs9650657	0.836	rs891556	ENSG00000255310.2	AF131215.2	-3.86	0.000129	0.00975	-0.15	-0.18	Neuroticism;	chr8:10766123	chr8:11107788~11109726:-
THCA	cis	rs12935418	0.616	rs12446053	ENSG00000278985.1	RP11-303E16.9	-3.86	0.000129	0.00975	-0.21	-0.18	Mean corpuscular volume;	chr16:80930234	chr16:80982319~80984094:-
THCA	cis	rs73198271	0.562	rs11774860	ENSG00000253893.2	FAM85B	3.86	0.000129	0.00975	0.29	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794369	chr8:8167819~8226614:-
THCA	cis	rs5758511	0.68	rs5758657	ENSG00000230107.1	CTA-126B4.7	-3.86	0.000129	0.00976	-0.22	-0.18	Birth weight;	chr22:42222663	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.68	rs1033459	ENSG00000230107.1	CTA-126B4.7	-3.86	0.000129	0.00976	-0.22	-0.18	Birth weight;	chr22:42223061	chr22:42438023~42446195:+
THCA	cis	rs1056107	0.572	rs10981396	ENSG00000230185.4	C9orf147	-3.86	0.000129	0.00976	-0.16	-0.18	Colorectal cancer;	chr9:112407993	chr9:112433816~112487204:-
THCA	cis	rs7182948	0.958	rs28430272	ENSG00000259531.2	RP11-295H24.3	3.86	0.000129	0.00976	0.23	0.18	Lung adenocarcinoma;	chr15:49462254	chr15:49365124~49366685:-
THCA	cis	rs7182948	1	rs28393768	ENSG00000259531.2	RP11-295H24.3	3.86	0.000129	0.00976	0.23	0.18	Lung adenocarcinoma;	chr15:49474054	chr15:49365124~49366685:-
THCA	cis	rs651907	1	rs651907	ENSG00000256628.3	ZBTB11-AS1	3.86	0.000129	0.00976	0.18	0.18	Colorectal cancer;	chr3:101881880	chr3:101676475~101679217:+
THCA	cis	rs4693089	0.604	rs6826913	ENSG00000213608.5	SLC25A14P1	3.86	0.000129	0.00976	0.2	0.18	Menopause (age at onset);	chr4:83428434	chr4:83477524~83478424:+
THCA	cis	rs6022858	0.909	rs6123328	ENSG00000236352.1	AC005220.3	3.86	0.000129	0.00976	0.26	0.18	Red cell distribution width;	chr20:53939438	chr20:53940160~53942508:+
THCA	cis	rs6494488	0.5	rs72742982	ENSG00000259635.1	AC100830.3	-3.86	0.000129	0.00976	-0.45	-0.18	Coronary artery disease;	chr15:64684856	chr15:64701248~64719602:+
THCA	cis	rs2414856	0.504	rs72742986	ENSG00000259635.1	AC100830.3	-3.86	0.000129	0.00976	-0.45	-0.18	Pulse pressure;Systolic blood pressure;	chr15:64695030	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs1133357	ENSG00000259635.1	AC100830.3	-3.86	0.000129	0.00976	-0.45	-0.18	Coronary artery disease;	chr15:64695371	chr15:64701248~64719602:+
THCA	cis	rs73198271	0.531	rs17154756	ENSG00000253893.2	FAM85B	3.86	0.000129	0.00976	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794884	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.531	rs11985640	ENSG00000253893.2	FAM85B	3.86	0.000129	0.00976	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794994	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.531	rs56100346	ENSG00000253893.2	FAM85B	3.86	0.000129	0.00976	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8795334	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.531	rs17154758	ENSG00000253893.2	FAM85B	3.86	0.000129	0.00976	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8795833	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.53	rs113160067	ENSG00000253893.2	FAM85B	3.86	0.000129	0.00976	0.28	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797011	chr8:8167819~8226614:-
THCA	cis	rs7312933	0.703	rs10459290	ENSG00000257225.1	RP11-328C8.4	-3.86	0.000129	0.00976	-0.18	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42219488	chr12:42459366~42466128:+
THCA	cis	rs7200543	1	rs55727637	ENSG00000188599.16	NPIPP1	-3.86	0.000129	0.00976	-0.14	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:15104312~15123498:-
THCA	cis	rs713587	0.967	rs6752378	ENSG00000224165.4	DNAJC27-AS1	-3.86	0.000129	0.00976	-0.1	-0.18	Body mass index in non-asthmatics;	chr2:24927247	chr2:24971390~25039694:+
THCA	cis	rs7707921	0.881	rs73134747	ENSG00000251374.1	RPS23P5	3.86	0.000129	0.00976	0.26	0.18	Breast cancer;	chr5:82082475	chr5:82265157~82265259:-
THCA	cis	rs271738	0.582	rs271770	ENSG00000231768.1	LINC01354	-3.86	0.000129	0.00976	-0.2	-0.18	Bipolar disorder;	chr1:234540168	chr1:234527891~234531779:-
THCA	cis	rs911555	0.692	rs60235428	ENSG00000269958.1	RP11-73M18.8	-3.86	0.000129	0.00976	-0.16	-0.18	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103696353~103697163:+
THCA	cis	rs62244186	0.748	rs4682987	ENSG00000214820.3	MPRIPP1	3.86	0.000129	0.00976	0.18	0.18	Depressive symptoms;	chr3:44633504	chr3:44579938~44581026:-
THCA	cis	rs7804306	1	rs34059590	ENSG00000233264.2	AC006042.8	3.86	0.000129	0.00976	0.31	0.18	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8026584	chr7:7980312~7982228:+
THCA	cis	rs2239547	0.618	rs3733047	ENSG00000243224.1	RP5-1157M23.2	3.86	0.000129	0.00976	0.21	0.18	Schizophrenia;	chr3:52837913	chr3:52239258~52241097:+
THCA	cis	rs4886920	0.862	rs7179211	ENSG00000260776.4	RP11-114H24.2	-3.86	0.000129	0.00976	-0.2	-0.18	Neuroticism;	chr15:77843589	chr15:77914217~77926846:-
THCA	cis	rs34792	0.853	rs1684546	ENSG00000207425.1	Y_RNA	3.86	0.000129	0.00976	0.19	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15466568	chr16:14915457~14915556:-
THCA	cis	rs889312	0.5	rs11960484	ENSG00000271828.1	CTD-2310F14.1	3.86	0.00013	0.00977	0.24	0.18	Breast cancer (early onset);Breast cancer;	chr5:56813327	chr5:56927874~56929573:+
THCA	cis	rs10489167	0.92	rs12121412	ENSG00000237899.1	RP4-739H11.3	3.86	0.00013	0.00977	0.32	0.18	Depressive and manic episodes in bipolar disorder;	chr1:40699160	chr1:40669089~40687588:-
THCA	cis	rs10489167	1	rs12118374	ENSG00000237899.1	RP4-739H11.3	3.86	0.00013	0.00977	0.32	0.18	Depressive and manic episodes in bipolar disorder;	chr1:40699871	chr1:40669089~40687588:-
THCA	cis	rs2348418	0.733	rs1904386	ENSG00000278733.1	RP11-425D17.1	3.86	0.00013	0.00977	0.15	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28185625~28186190:-
THCA	cis	rs36715	1	rs36715	ENSG00000245937.6	LINC01184	3.86	0.00013	0.00977	0.18	0.18	Breast cancer;	chr5:128227188	chr5:127940426~128083172:-
THCA	cis	rs7267979	0.833	rs4619688	ENSG00000276952.1	RP5-965G21.6	3.86	0.00013	0.00977	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25284915~25285588:-
THCA	cis	rs465969	0.744	rs36007392	ENSG00000272356.1	RP5-1112D6.8	3.86	0.00013	0.00977	0.25	0.18	Psoriasis;	chr6:111509287	chr6:111309203~111313517:+
THCA	cis	rs465969	1	rs13197107	ENSG00000272356.1	RP5-1112D6.8	3.86	0.00013	0.00977	0.25	0.18	Psoriasis;	chr6:111512031	chr6:111309203~111313517:+
THCA	cis	rs9500256	0.966	rs1322446	ENSG00000239650.4	GUSBP4	3.86	0.00013	0.00977	0.17	0.18	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57919784~57930291:-
THCA	cis	rs7665090	0.806	rs434644	ENSG00000248971.2	KRT8P46	3.86	0.00013	0.00977	0.21	0.18	Primary biliary cholangitis;	chr4:102662032	chr4:102728746~102730171:-
THCA	cis	rs13178541	0.542	rs11748092	ENSG00000250378.1	RP11-119J18.1	-3.86	0.00013	0.00977	-0.2	-0.18	IgG glycosylation;	chr5:135789035	chr5:135812667~135826582:+
THCA	cis	rs972578	1	rs3819677	ENSG00000230319.1	AL022476.2	3.86	0.00013	0.00977	0.18	0.18	Mean platelet volume;	chr22:42990685	chr22:43038585~43052366:+
THCA	cis	rs12681288	1	rs2336696	ENSG00000260721.1	AF067845.1	3.86	0.00013	0.00977	0.21	0.18	Schizophrenia;	chr8:1083802	chr8:1368642~1369833:-
THCA	cis	rs4578769	0.55	rs12958492	ENSG00000273232.1	RP11-370A5.2	3.86	0.00013	0.00977	0.23	0.18	Eosinophil percentage of white cells;	chr18:22988974	chr18:22882825~22883357:-
THCA	cis	rs3758911	0.861	rs10890710	ENSG00000255353.1	RP11-382M14.1	-3.86	0.00013	0.00977	-0.22	-0.18	Coronary artery disease;	chr11:107317423	chr11:107176286~107177530:+
THCA	cis	rs7259376	0.902	rs7248242	ENSG00000269345.1	VN1R85P	-3.86	0.00013	0.00977	-0.19	-0.18	Menopause (age at onset);	chr19:22393192	chr19:22174766~22175191:-
THCA	cis	rs7267979	0.903	rs2474766	ENSG00000276952.1	RP5-965G21.6	3.86	0.00013	0.00978	0.19	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25284915~25285588:-
THCA	cis	rs4705952	0.557	rs2548990	ENSG00000233006.5	AC034220.3	3.86	0.00013	0.00978	0.14	0.18	C-reactive protein levels;	chr5:132525954	chr5:132311285~132369916:-
THCA	cis	rs962856	0.521	rs6749629	ENSG00000236780.4	AC078941.1	3.86	0.00013	0.00978	0.24	0.18	Pancreatic cancer;	chr2:67412414	chr2:67123357~67215319:-
THCA	cis	rs2439831	0.541	rs12440854	ENSG00000275601.1	AC011330.13	-3.86	0.00013	0.00978	-0.3	-0.18	Lung cancer in ever smokers;	chr15:43318474	chr15:43642389~43643023:-
THCA	cis	rs10954779	0.764	rs2725363	ENSG00000127589.4	TUBBP1	3.86	0.00013	0.00978	0.21	0.18	Intelligence (multi-trait analysis);	chr8:31141878	chr8:30351873~30353518:+
THCA	cis	rs4434872	1	rs4567311	ENSG00000223599.1	RP11-216N14.7	3.86	0.00013	0.00978	0.3	0.18	Conduct disorder (symptom count);	chr1:153802207	chr1:153852106~153853414:-
THCA	cis	rs9402682	0.592	rs9385716	ENSG00000232876.1	CTA-212D2.2	-3.86	0.00013	0.00978	-0.25	-0.18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135134191	chr6:135055033~135060550:+
THCA	cis	rs911555	0.673	rs7144271	ENSG00000269940.1	RP11-73M18.7	3.86	0.00013	0.00978	0.18	0.18	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs10148970	ENSG00000269940.1	RP11-73M18.7	3.86	0.00013	0.00978	0.18	0.18	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103694560~103695170:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000230295.1	RP11-458F8.2	3.86	0.00013	0.00978	0.13	0.18	Aortic root size;	chr7:66566965	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000230295.1	RP11-458F8.2	3.86	0.00013	0.00978	0.13	0.18	Aortic root size;	chr7:66568046	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000230295.1	RP11-458F8.2	3.86	0.00013	0.00978	0.13	0.18	Aortic root size;	chr7:66571204	chr7:66880708~66882981:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000230295.1	RP11-458F8.2	3.86	0.00013	0.00978	0.13	0.18	Aortic root size;	chr7:66595421	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000230295.1	RP11-458F8.2	3.86	0.00013	0.00978	0.13	0.18	Aortic root size;	chr7:66598087	chr7:66880708~66882981:+
THCA	cis	rs754466	0.606	rs11002309	ENSG00000213514.2	RP11-428P16.2	3.86	0.00013	0.00978	0.19	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77835173	chr10:77730766~77734769:+
THCA	cis	rs7615952	0.736	rs9866347	ENSG00000272840.1	RP11-379B18.6	3.86	0.00013	0.00978	0.31	0.18	Blood pressure (smoking interaction);	chr3:125951082	chr3:125774714~125797953:+
THCA	cis	rs7182948	0.768	rs17482833	ENSG00000259531.2	RP11-295H24.3	-3.86	0.00013	0.00978	-0.21	-0.18	Lung adenocarcinoma;	chr15:49679298	chr15:49365124~49366685:-
THCA	cis	rs1124769	0.57	rs4142324	ENSG00000273674.3	CTD-2378E12.1	3.86	0.00013	0.00978	0.23	0.18	Cognitive performance;	chr15:50871860	chr15:50839875~50908599:-
THCA	cis	rs6443245	0.611	rs2648371	ENSG00000227110.5	LMCD1-AS1	3.86	0.00013	0.00978	0.21	0.18	Daytime sleep phenotypes;	chr3:9586691	chr3:7952805~8611924:-
THCA	cis	rs7772697	0.635	rs9498210	ENSG00000223701.3	RAET1E-AS1	-3.86	0.00013	0.00978	-0.24	-0.18	Diabetic retinopathy;	chr6:149088996	chr6:149884431~149919508:+
THCA	cis	rs10043228	1	rs6876972	ENSG00000250015.1	CTC-339F2.2	3.86	0.00013	0.00978	0.26	0.18	Asthma or chronic obstructive pulmonary disease;	chr5:116306822	chr5:116302354~116304134:-
THCA	cis	rs2692947	0.644	rs772154	ENSG00000235584.2	AC008268.1	-3.86	0.00013	0.00978	-0.18	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96355926	chr2:95666084~95668715:+
THCA	cis	rs2836974	0.565	rs2836939	ENSG00000255568.3	BRWD1-AS2	3.86	0.00013	0.00978	0.19	0.18	Cognitive function;	chr21:39206620	chr21:39313935~39314962:+
THCA	cis	rs10875746	0.587	rs9788082	ENSG00000258273.1	RP11-370I10.4	3.86	0.00013	0.00978	0.26	0.18	Longevity (90 years and older);	chr12:48358273	chr12:48333755~48333901:-
THCA	cis	rs972578	0.967	rs4822235	ENSG00000230319.1	AL022476.2	3.86	0.00013	0.00978	0.18	0.18	Mean platelet volume;	chr22:42942084	chr22:43038585~43052366:+
THCA	cis	rs3104964	1	rs12675322	ENSG00000253773.2	C8orf37-AS1	3.86	0.00013	0.00978	0.23	0.18	Colorectal cancer;	chr8:95601560	chr8:95204456~95810136:+
THCA	cis	rs7737355	0.947	rs9327619	ENSG00000237714.1	P4HA2-AS1	3.86	0.00013	0.00978	0.25	0.18	Life satisfaction;	chr5:131586088	chr5:132184876~132192808:+
THCA	cis	rs6546550	0.901	rs34586537	ENSG00000179818.12	PCBP1-AS1	3.86	0.00013	0.00979	0.14	0.18	Prevalent atrial fibrillation;	chr2:69936184	chr2:69962263~70103220:-
THCA	cis	rs295490	0.748	rs78490940	ENSG00000272656.1	RP11-219D15.3	3.86	0.00013	0.00979	0.34	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139370333	chr3:139349024~139349371:-
THCA	cis	rs6600671	1	rs10903161	ENSG00000275585.1	CH17-118O6.3	-3.86	0.00013	0.00979	-0.21	-0.18	Hip geometry;	chr1:121436882	chr1:120985692~121052167:-
THCA	cis	rs11237982	0.543	rs7129676	ENSG00000255345.1	CTD-2337I7.1	-3.86	0.00013	0.00979	-0.29	-0.18	Verbal declarative memory;	chr11:79700847	chr11:79092848~79098003:+
THCA	cis	rs4819052	0.851	rs2838864	ENSG00000182586.6	LINC00334	3.86	0.00013	0.00979	0.18	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45234340~45258730:+
THCA	cis	rs10940346	0.506	rs10454829	ENSG00000271752.1	RP11-269M20.3	3.86	0.00013	0.00979	0.18	0.18	Schizophrenia;	chr5:50585120	chr5:50662859~50663266:-
THCA	cis	rs9860428	0.844	rs2399441	ENSG00000243795.1	RP11-572M11.3	3.86	0.00013	0.00979	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868165	chr3:113142350~113167819:-
THCA	cis	rs6487679	0.543	rs4883222	ENSG00000245105.2	A2M-AS1	3.86	0.00013	0.00979	0.22	0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9223819	chr12:9065177~9068060:+
THCA	cis	rs12291225	0.679	rs11369	ENSG00000251991.1	RNU7-49P	3.86	0.00013	0.00979	0.21	0.18	Sense of smell;	chr11:14266550	chr11:14478892~14478953:+
THCA	cis	rs669446	0.533	rs28833034	ENSG00000237950.1	RP11-7O11.3	3.86	0.00013	0.00979	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43747271	chr1:43944370~43946551:-
THCA	cis	rs62344088	1	rs6880143	ENSG00000277812.1	AC021087.1	3.86	0.00013	0.00979	0.44	0.18	Asthma (childhood onset);	chr5:137401	chr5:262769~262881:+
THCA	cis	rs4947019	0.534	rs10080925	ENSG00000223537.2	RP5-919F19.5	-3.86	0.00013	0.0098	-0.33	-0.18	Hematological parameters;	chr6:109339389	chr6:109487906~109506800:+
THCA	cis	rs3808502	0.563	rs12549144	ENSG00000255046.1	RP11-297N6.4	-3.86	0.00013	0.0098	-0.18	-0.18	Neuroticism;	chr8:11565352	chr8:11797928~11802568:-
THCA	cis	rs9611565	0.512	rs5758439	ENSG00000237037.8	NDUFA6-AS1	-3.86	0.00013	0.0098	-0.17	-0.18	Vitiligo;	chr22:41735758	chr22:42090931~42137742:+
THCA	cis	rs4660214	0.724	rs3931300	ENSG00000228060.1	RP11-69E11.8	3.86	0.00013	0.0098	0.16	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39195175	chr1:39565160~39573203:+
THCA	cis	rs758747	0.514	rs8054140	ENSG00000276754.1	RP11-461A8.5	-3.86	0.00013	0.0098	-0.17	-0.18	Body mass index;	chr16:3522694	chr16:3686998~3687380:+
THCA	cis	rs34779708	0.766	rs7913451	ENSG00000233200.1	RP11-324I22.2	3.86	0.00013	0.0098	0.22	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35219894~35230598:-
THCA	cis	rs6441286	0.964	rs9852519	ENSG00000244040.4	IL12A-AS1	-3.86	0.00013	0.0098	-0.22	-0.18	Primary biliary cholangitis;	chr3:160002841	chr3:159913400~160225299:-
THCA	cis	rs10129255	0.834	rs10139893	ENSG00000280411.1	IGHV1-69-2	-3.86	0.00013	0.0098	-0.11	-0.18	Kawasaki disease;	chr14:106711377	chr14:106762092~106762588:-
THCA	cis	rs875971	0.66	rs28698552	ENSG00000230295.1	RP11-458F8.2	-3.86	0.00013	0.00981	-0.13	-0.18	Aortic root size;	chr7:66540031	chr7:66880708~66882981:+
THCA	cis	rs1348850	0.645	rs11887886	ENSG00000280374.1	RP11-337N6.3	-3.86	0.00013	0.00981	-0.28	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177561002	chr2:177317715~177318471:-
THCA	cis	rs17685	0.697	rs28689051	ENSG00000227038.2	AC005077.12	3.86	0.00013	0.00981	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76134306	chr7:76090431~76108779:-
THCA	cis	rs4699052	0.787	rs2169508	ENSG00000230069.3	LRRC37A15P	-3.86	0.00013	0.00981	-0.17	-0.18	Testicular germ cell tumor;	chr4:103145733	chr4:102727274~102730721:-
THCA	cis	rs42648	0.748	rs10226014	ENSG00000225498.1	AC002064.5	-3.86	0.00013	0.00981	-0.19	-0.18	Homocysteine levels;	chr7:90273219	chr7:90312496~90322592:+
THCA	cis	rs9307551	0.817	rs2903640	ENSG00000249646.2	OR7E94P	-3.86	0.00013	0.00981	-0.22	-0.18	Refractive error;	chr4:79610171	chr4:79587302~79588130:-
THCA	cis	rs3806843	0.576	rs155359	ENSG00000202515.1	VTRNA1-3	-3.86	0.00013	0.00981	-0.21	-0.18	Depressive symptoms (multi-trait analysis);	chr5:140935840	chr5:140726158~140726246:+
THCA	cis	rs7166081	1	rs2289262	ENSG00000270964.1	RP11-502I4.3	-3.86	0.00013	0.00981	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67208695	chr15:67541072~67542604:-
THCA	cis	rs9532679	0.747	rs61963226	ENSG00000239827.7	SUGT1P3	-3.86	0.00013	0.00981	-0.22	-0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr13:40961273	chr13:40908159~40921774:-
THCA	cis	rs9810089	0.843	rs834304	ENSG00000273455.1	RP11-305O4.3	3.86	0.00013	0.00981	0.23	0.18	Gestational age at birth (child effect);	chr3:136392816	chr3:136087475~136087913:-
THCA	cis	rs11633886	0.585	rs1949575	ENSG00000273972.1	CTD-2306A12.1	3.86	0.00013	0.00981	0.2	0.18	Diisocyanate-induced asthma;	chr15:45784002	chr15:45702640~45703183:+
THCA	cis	rs15676	0.947	rs2977994	ENSG00000234771.3	SLC25A25-AS1	3.86	0.00013	0.00982	0.14	0.18	Blood metabolite levels;	chr9:128822937	chr9:128108581~128118693:-
THCA	cis	rs6432852	0.516	rs12477613	ENSG00000235192.1	AC009495.2	3.86	0.00013	0.00982	0.22	0.18	Diabetic kidney disease;	chr2:165860674	chr2:165794851~165810010:+
THCA	cis	rs13098911	0.54	rs13063527	ENSG00000226074.4	PRSS44	-3.86	0.00013	0.00982	-0.34	-0.18	Celiac disease;	chr3:46094198	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs1491950	ENSG00000226074.4	PRSS44	-3.86	0.00013	0.00982	-0.34	-0.18	Celiac disease;	chr3:46096615	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs4373103	ENSG00000226074.4	PRSS44	-3.86	0.00013	0.00982	-0.34	-0.18	Celiac disease;	chr3:46096963	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34492478	ENSG00000226074.4	PRSS44	-3.86	0.00013	0.00982	-0.34	-0.18	Celiac disease;	chr3:46097350	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs71327024	ENSG00000226074.4	PRSS44	-3.86	0.00013	0.00982	-0.34	-0.18	Celiac disease;	chr3:46098581	chr3:46809359~46812558:-
THCA	cis	rs9307551	0.817	rs12507375	ENSG00000249646.2	OR7E94P	-3.86	0.00013	0.00982	-0.22	-0.18	Refractive error;	chr4:79575206	chr4:79587302~79588130:-
THCA	cis	rs67340775	0.541	rs200973	ENSG00000220721.1	OR1F12	3.86	0.00013	0.00982	0.27	0.18	Lung cancer in ever smokers;	chr6:27890643	chr6:28073316~28074233:+
THCA	cis	rs9863	0.862	rs6488912	ENSG00000270061.1	RP11-214K3.19	-3.86	0.00013	0.00982	-0.23	-0.18	White blood cell count;	chr12:123958205	chr12:123969990~123970344:-
THCA	cis	rs7089973	0.604	rs1924034	ENSG00000228169.3	PPIAP19	3.86	0.00013	0.00982	0.2	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114818780	chr10:114690143~114690634:-
THCA	cis	rs7674212	0.541	rs2045746	ENSG00000230069.3	LRRC37A15P	3.86	0.00013	0.00982	0.18	0.18	Type 2 diabetes;	chr4:103162421	chr4:102727274~102730721:-
THCA	cis	rs12722605	0.54	rs35869582	ENSG00000229664.1	RP11-536K7.5	3.86	0.00013	0.00982	0.24	0.18	Inflammatory biomarkers;	chr10:5993956	chr10:6025978~6036427:+
THCA	cis	rs75828804	1	rs16945871	ENSG00000260922.1	RP11-538I12.3	-3.86	0.00013	0.00982	-0.36	-0.18	Intraocular pressure;	chr16:77536583	chr16:77234877~77290934:+
THCA	cis	rs3824488	0.92	rs80155616	ENSG00000271155.1	RP11-435O5.5	-3.86	0.00013	0.00982	-0.31	-0.18	Neuroticism;	chr9:95481586	chr9:95506235~95507636:+
THCA	cis	rs3824488	0.92	rs28510415	ENSG00000271155.1	RP11-435O5.5	-3.86	0.00013	0.00982	-0.31	-0.18	Neuroticism;	chr9:95482744	chr9:95506235~95507636:+
THCA	cis	rs1971762	0.545	rs10747676	ENSG00000270175.1	RP11-793H13.11	-3.86	0.00013	0.00983	-0.11	-0.18	Height;	chr12:53656146	chr12:53500162~53500936:-
THCA	cis	rs12681366	0.762	rs67639046	ENSG00000261437.1	RP11-22C11.2	3.86	0.00013	0.00983	0.17	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94373552	chr8:94637285~94639467:-
THCA	cis	rs11242704	0.962	rs4959138	ENSG00000218027.2	RP11-157J24.1	3.86	0.00013	0.00983	0.23	0.18	Response to hepatitis C treatment;	chr6:1539496	chr6:1513698~1515289:-
THCA	cis	rs7819412	0.875	rs6981523	ENSG00000261451.1	RP11-981G7.1	-3.86	0.00013	0.00983	-0.22	-0.18	Triglycerides;	chr8:11204283	chr8:10433672~10438312:+
THCA	cis	rs4819052	1	rs13052356	ENSG00000184274.3	LINC00315	-3.86	0.00013	0.00983	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45300245~45305257:-
THCA	cis	rs733175	0.83	rs6834555	ENSG00000261490.1	RP11-448G15.3	3.86	0.00013	0.00983	0.13	0.18	Psychosis and Alzheimer's disease;	chr4:10060702	chr4:10068089~10073019:-
THCA	cis	rs6121246	0.633	rs6060986	ENSG00000230613.1	HM13-AS1	3.86	0.00013	0.00983	0.17	0.18	Mean corpuscular hemoglobin;	chr20:31838494	chr20:31567707~31573263:-
THCA	cis	rs4792901	0.918	rs12603189	ENSG00000267151.3	RP11-100E5.2	-3.86	0.000131	0.00983	-0.18	-0.18	Dupuytren's disease;	chr17:43541309	chr17:43444707~43451200:+
THCA	cis	rs564343	0.545	rs576836	ENSG00000255320.1	RP11-755F10.1	-3.86	0.000131	0.00983	-0.22	-0.18	Obesity (early onset extreme);	chr11:66056098	chr11:66244840~66246239:-
THCA	cis	rs10833905	1	rs12417226	ENSG00000246225.5	RP11-17A1.3	-3.86	0.000131	0.00984	-0.25	-0.18	Sudden cardiac arrest;	chr11:23017289	chr11:22829380~22945393:+
THCA	cis	rs7267979	1	rs6050599	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000131	0.00984	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050602	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000131	0.00984	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs6083855	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000131	0.00984	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4815426	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000131	0.00984	-0.18	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25284915~25285588:-
THCA	cis	rs1009077	1	rs2714959	ENSG00000245958.5	RP11-33B1.1	-3.86	0.000131	0.00984	-0.21	-0.18	Endometriosis;	chr4:119710354	chr4:119454791~119552025:+
THCA	cis	rs7924176	0.521	rs7899920	ENSG00000232342.6	RP11-46O21.2	-3.86	0.000131	0.00984	-0.22	-0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:74506081~74530553:-
THCA	cis	rs6496667	1	rs7178663	ENSG00000259262.1	NDUFA3P4	3.86	0.000131	0.00984	0.24	0.18	Rheumatoid arthritis;	chr15:90353826	chr15:90385814~90386063:+
THCA	cis	rs6496667	1	rs7177486	ENSG00000259262.1	NDUFA3P4	3.86	0.000131	0.00984	0.24	0.18	Rheumatoid arthritis;	chr15:90353877	chr15:90385814~90386063:+
THCA	cis	rs6496667	0.821	rs77731392	ENSG00000259262.1	NDUFA3P4	3.86	0.000131	0.00984	0.24	0.18	Rheumatoid arthritis;	chr15:90354218	chr15:90385814~90386063:+
THCA	cis	rs6496667	1	rs7162175	ENSG00000259262.1	NDUFA3P4	3.86	0.000131	0.00984	0.24	0.18	Rheumatoid arthritis;	chr15:90354241	chr15:90385814~90386063:+
THCA	cis	rs10461617	0.617	rs1423623	ENSG00000234553.1	AC022431.3	3.86	0.000131	0.00984	0.18	0.18	Type 2 diabetes;	chr5:56769748	chr5:56536583~56537826:-
THCA	cis	rs9527	0.501	rs12244388	ENSG00000272912.1	RP11-724N1.1	-3.86	0.000131	0.00984	-0.21	-0.18	Arsenic metabolism;	chr10:102880295	chr10:102914585~102915404:+
THCA	cis	rs1204798	0.685	rs1204802	ENSG00000237021.2	RP3-486I3.7	-3.86	0.000131	0.00984	-0.2	-0.18	Dental caries;	chr6:116225119	chr6:116254207~116256743:+
THCA	cis	rs1204798	0.685	rs1204805	ENSG00000237021.2	RP3-486I3.7	-3.86	0.000131	0.00984	-0.2	-0.18	Dental caries;	chr6:116227728	chr6:116254207~116256743:+
THCA	cis	rs1204798	0.588	rs1204806	ENSG00000237021.2	RP3-486I3.7	-3.86	0.000131	0.00984	-0.2	-0.18	Dental caries;	chr6:116227781	chr6:116254207~116256743:+
THCA	cis	rs3733585	0.753	rs1122141	ENSG00000261490.1	RP11-448G15.3	-3.86	0.000131	0.00984	-0.11	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9945654	chr4:10068089~10073019:-
THCA	cis	rs7020830	0.898	rs13290794	ENSG00000260100.1	RP11-220I1.5	-3.86	0.000131	0.00985	-0.21	-0.18	Schizophrenia;	chr9:37183631	chr9:37078813~37079776:-
THCA	cis	rs8003054	0.537	rs11160711	ENSG00000258515.1	RP11-203M5.7	-3.86	0.000131	0.00985	-0.12	-0.18	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445837	chr14:20451305~20451918:+
THCA	cis	rs972578	1	rs4140554	ENSG00000230319.1	AL022476.2	-3.86	0.000131	0.00985	-0.18	-0.18	Mean platelet volume;	chr22:42959250	chr22:43038585~43052366:+
THCA	cis	rs56309584	0.715	rs3027246	ENSG00000271002.1	RP11-599B13.8	-3.86	0.000131	0.00985	-0.27	-0.18	Initial pursuit acceleration;	chr17:8227905	chr17:8199123~8199437:-
THCA	cis	rs2281603	0.857	rs3783722	ENSG00000258824.2	CTD-2555O16.2	-3.86	0.000131	0.00985	-0.18	-0.18	Lymphocyte counts;	chr14:64531248	chr14:64422935~64448557:-
THCA	cis	rs1510272	1	rs1510272	ENSG00000243926.1	TIPARP-AS1	-3.86	0.000131	0.00985	-0.18	-0.18	Testicular germ cell tumor;	chr3:156582935	chr3:156671862~156674378:-
THCA	cis	rs11239930	0.517	rs556976	ENSG00000180867.10	PDIA3P1	3.86	0.000131	0.00985	0.17	0.18	AIDS progression;	chr1:147073643	chr1:147178113~147179622:+
THCA	cis	rs758324	0.561	rs253946	ENSG00000237714.1	P4HA2-AS1	3.86	0.000131	0.00985	0.25	0.18	Alzheimer's disease in APOE e4- carriers;	chr5:131994768	chr5:132184876~132192808:+
THCA	cis	rs4792901	0.877	rs34454760	ENSG00000267151.3	RP11-100E5.2	3.86	0.000131	0.00985	0.18	0.18	Dupuytren's disease;	chr17:43564878	chr17:43444707~43451200:+
THCA	cis	rs80168506	0.748	rs12694298	ENSG00000234308.2	AC093381.2	3.86	0.000131	0.00985	0.21	0.18	Selective IgA deficiency;	chr2:213197183	chr2:212795331~212819264:+
THCA	cis	rs1552244	0.572	rs41464050	ENSG00000180385.7	EMC3-AS1	3.86	0.000131	0.00985	0.22	0.18	Alzheimer's disease;	chr3:10116709	chr3:9986893~10006990:+
THCA	cis	rs4073416	0.542	rs7150094	ENSG00000276116.2	FUT8-AS1	3.86	0.000131	0.00985	0.2	0.18	N-glycan levels;	chr14:65469643	chr14:65411170~65412690:-
THCA	cis	rs7615952	0.673	rs34072288	ENSG00000272840.1	RP11-379B18.6	3.86	0.000131	0.00985	0.35	0.18	Blood pressure (smoking interaction);	chr3:125825186	chr3:125774714~125797953:+
THCA	cis	rs12755164	0.505	rs7544848	ENSG00000223479.3	RP4-788P17.1	3.86	0.000131	0.00985	0.2	0.18	Schizophrenia;	chr1:72823250	chr1:73635216~73715214:+
THCA	cis	rs2011503	0.739	rs4808973	ENSG00000271283.1	CTC-412M14.6	-3.86	0.000131	0.00986	-0.26	-0.18	Bipolar disorder;	chr19:19614647	chr19:19699203~19699409:-
THCA	cis	rs17382723	0.887	rs78834190	ENSG00000225521.1	AC005237.4	3.86	0.000131	0.00986	0.22	0.18	Height;	chr2:241093979	chr2:241015599~241064116:-
THCA	cis	rs7818688	1	rs2340536	ENSG00000253528.2	RP11-347C18.4	-3.86	0.000131	0.00986	-0.3	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94998207	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs11781619	ENSG00000253528.2	RP11-347C18.4	-3.86	0.000131	0.00986	-0.3	-0.18	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95005095	chr8:94974573~94974853:-
THCA	cis	rs4879656	0.872	rs7876033	ENSG00000225693.1	LAGE3P1	-3.86	0.000131	0.00986	-0.18	-0.18	Menopause (age at onset);	chr9:33058561	chr9:33019682~33020165:-
THCA	cis	rs4879656	0.8	rs1537041	ENSG00000225693.1	LAGE3P1	-3.86	0.000131	0.00986	-0.18	-0.18	Menopause (age at onset);	chr9:33060418	chr9:33019682~33020165:-
THCA	cis	rs11671005	0.779	rs55875034	ENSG00000268912.1	CTD-2619J13.17	-3.86	0.000131	0.00986	-0.17	-0.18	Mean platelet volume;	chr19:58472191	chr19:58428632~58431148:-
THCA	cis	rs7824557	0.724	rs2251473	ENSG00000254866.2	DEFB109P3	-3.86	0.000131	0.00986	-0.24	-0.18	Retinal vascular caliber;	chr8:11319617	chr8:12150895~12151134:-
THCA	cis	rs2836974	0.931	rs12151994	ENSG00000255568.3	BRWD1-AS2	3.86	0.000131	0.00986	0.15	0.18	Cognitive function;	chr21:39318471	chr21:39313935~39314962:+
THCA	cis	rs1560104	0.675	rs8063669	ENSG00000259876.1	CTD-3037G24.4	3.86	0.000131	0.00986	0.2	0.18	Obesity-related traits;	chr16:12603379	chr16:12556353~12557694:-
THCA	cis	rs2839627	0.638	rs8133179	ENSG00000225218.1	AP001628.6	3.86	0.000131	0.00986	0.3	0.18	Information processing speed;	chr21:42852217	chr21:42831040~42836477:-
THCA	cis	rs2436845	0.531	rs1806299	ENSG00000253320.4	KB-1507C5.2	-3.86	0.000131	0.00986	-0.15	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102886303	chr8:102864300~102977876:+
THCA	cis	rs2436845	0.554	rs10104704	ENSG00000253320.4	KB-1507C5.2	-3.86	0.000131	0.00986	-0.15	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102888657	chr8:102864300~102977876:+
THCA	cis	rs2436845	0.554	rs491770	ENSG00000253320.4	KB-1507C5.2	-3.86	0.000131	0.00986	-0.15	-0.18	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102895800	chr8:102864300~102977876:+
THCA	cis	rs6546886	0.912	rs12713808	ENSG00000235499.1	AC073046.25	3.86	0.000131	0.00986	0.16	0.18	Dialysis-related mortality;	chr2:74065652	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.912	rs4241260	ENSG00000235499.1	AC073046.25	3.86	0.000131	0.00986	0.16	0.18	Dialysis-related mortality;	chr2:74066268	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.912	rs13387010	ENSG00000235499.1	AC073046.25	3.86	0.000131	0.00986	0.16	0.18	Dialysis-related mortality;	chr2:74067527	chr2:73985132~73986343:+
THCA	cis	rs7264396	0.887	rs224351	ENSG00000088340.14	FER1L4	3.86	0.000131	0.00986	0.16	0.18	Total cholesterol levels;	chr20:35464448	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs224354	ENSG00000088340.14	FER1L4	3.86	0.000131	0.00986	0.16	0.18	Total cholesterol levels;	chr20:35466784	chr20:35558737~35607562:-
THCA	cis	rs889398	0.771	rs11075732	ENSG00000226232.7	RP11-419C5.2	3.86	0.000131	0.00986	0.17	0.18	Body mass index;	chr16:69732135	chr16:69976388~69996188:-
THCA	cis	rs754466	0.58	rs1054608	ENSG00000213514.2	RP11-428P16.2	3.86	0.000131	0.00986	0.19	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77783550	chr10:77730766~77734769:+
THCA	cis	rs7578199	0.576	rs4675945	ENSG00000223374.1	AC005104.3	3.86	0.000131	0.00986	0.12	0.18	Chronic lymphocytic leukemia;	chr2:241489394	chr2:241351340~241353104:-
THCA	cis	rs2439831	0.681	rs28594657	ENSG00000275601.1	AC011330.13	-3.86	0.000131	0.00986	-0.31	-0.18	Lung cancer in ever smokers;	chr15:43296690	chr15:43642389~43643023:-
THCA	cis	rs7264396	0.887	rs224362	ENSG00000088340.14	FER1L4	3.86	0.000131	0.00987	0.16	0.18	Total cholesterol levels;	chr20:35474817	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.887	rs224364	ENSG00000088340.14	FER1L4	3.86	0.000131	0.00987	0.16	0.18	Total cholesterol levels;	chr20:35476040	chr20:35558737~35607562:-
THCA	cis	rs5758659	0.569	rs133293	ENSG00000281538.1	RP4-669P10.20	3.86	0.000131	0.00987	0.16	0.18	Cognitive function;	chr22:41986793	chr22:42138060~42139726:+
THCA	cis	rs9650657	0.836	rs4841438	ENSG00000255310.2	AF131215.2	-3.86	0.000131	0.00987	-0.15	-0.18	Neuroticism;	chr8:10749246	chr8:11107788~11109726:-
THCA	cis	rs9650657	0.836	rs11250067	ENSG00000255310.2	AF131215.2	-3.86	0.000131	0.00987	-0.15	-0.18	Neuroticism;	chr8:10749444	chr8:11107788~11109726:-
THCA	cis	rs669446	0.562	rs4660259	ENSG00000237950.1	RP11-7O11.3	3.86	0.000131	0.00987	0.15	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43728863	chr1:43944370~43946551:-
THCA	cis	rs13113518	0.783	rs6843722	ENSG00000223305.1	RN7SKP30	3.86	0.000131	0.00987	0.23	0.18	Height;	chr4:55465165	chr4:55540502~55540835:-
THCA	cis	rs10186029	0.509	rs13417355	ENSG00000270659.1	RP11-105N14.1	3.86	0.000131	0.00987	0.15	0.18	Systemic sclerosis;	chr2:213078306	chr2:213152970~213153659:+
THCA	cis	rs253959	0.633	rs10477554	ENSG00000272265.1	CTD-2287O16.4	-3.86	0.000131	0.00987	-0.19	-0.18	Bipolar disorder and schizophrenia;	chr5:116390094	chr5:116078110~116078570:-
THCA	cis	rs9291683	0.609	rs12507050	ENSG00000261490.1	RP11-448G15.3	3.86	0.000131	0.00987	0.11	0.18	Bone mineral density;	chr4:10005681	chr4:10068089~10073019:-
THCA	cis	rs875971	0.66	rs10229345	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000131	0.00987	-0.15	-0.18	Aortic root size;	chr7:66517181	chr7:66848496~66858136:+
THCA	cis	rs11708578	0.554	rs67971733	ENSG00000237990.3	CNTN4-AS1	3.86	0.000131	0.00987	0.22	0.18	Schizophrenia;	chr3:2389810	chr3:3039033~3069242:-
THCA	cis	rs11708578	0.554	rs67583614	ENSG00000237990.3	CNTN4-AS1	3.86	0.000131	0.00987	0.22	0.18	Schizophrenia;	chr3:2389815	chr3:3039033~3069242:-
THCA	cis	rs11708578	0.522	rs66695130	ENSG00000237990.3	CNTN4-AS1	3.86	0.000131	0.00987	0.22	0.18	Schizophrenia;	chr3:2389958	chr3:3039033~3069242:-
THCA	cis	rs11708578	0.554	rs67607715	ENSG00000237990.3	CNTN4-AS1	3.86	0.000131	0.00987	0.22	0.18	Schizophrenia;	chr3:2390010	chr3:3039033~3069242:-
THCA	cis	rs11708578	0.554	rs13070802	ENSG00000237990.3	CNTN4-AS1	3.86	0.000131	0.00987	0.22	0.18	Schizophrenia;	chr3:2390386	chr3:3039033~3069242:-
THCA	cis	rs2904524	0.737	rs77753073	ENSG00000257815.4	RP11-611E13.2	-3.86	0.000131	0.00987	-0.24	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70417911	chr12:69904033~70243360:-
THCA	cis	rs2904524	0.737	rs77612206	ENSG00000257815.4	RP11-611E13.2	-3.86	0.000131	0.00987	-0.24	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70419630	chr12:69904033~70243360:-
THCA	cis	rs9333290	0.93	rs3816386	ENSG00000259915.2	RP11-410E4.1	3.86	0.000131	0.00988	0.21	0.18	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186663908	chr2:186354570~186356773:-
THCA	cis	rs13434995	0.513	rs1979605	ENSG00000249700.7	SRD5A3-AS1	3.86	0.000131	0.00988	0.25	0.18	Adiponectin levels;	chr4:55552706	chr4:55363971~55395847:-
THCA	cis	rs7737355	0.947	rs11242081	ENSG00000237714.1	P4HA2-AS1	3.86	0.000131	0.00988	0.25	0.18	Life satisfaction;	chr5:131572442	chr5:132184876~132192808:+
THCA	cis	rs4780401	0.933	rs8058003	ENSG00000274038.1	RP11-66H6.4	-3.86	0.000131	0.00988	-0.21	-0.18	Rheumatoid arthritis;	chr16:11721322	chr16:11056556~11057034:+
THCA	cis	rs12554020	0.582	rs2001609	ENSG00000227603.1	RP11-165J3.6	3.86	0.000131	0.00988	0.34	0.18	Schizophrenia;	chr9:93633081	chr9:93435332~93437121:-
THCA	cis	rs13178541	0.552	rs6881599	ENSG00000250167.1	CTC-321K16.1	-3.86	0.000131	0.00988	-0.18	-0.18	IgG glycosylation;	chr5:135705961	chr5:135559577~135634874:+
THCA	cis	rs2692947	0.727	rs893173	ENSG00000232931.4	LINC00342	3.86	0.000131	0.00988	0.14	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96124048	chr2:95807118~95816215:-
THCA	cis	rs6801044	0.789	rs823525	ENSG00000223711.1	AC091633.3	3.86	0.000131	0.00988	0.23	0.18	Creatinine levels in ischemic stroke;	chr3:195552301	chr3:195544048~195550581:+
THCA	cis	rs6762	0.748	rs7928935	ENSG00000255142.1	AP006621.6	3.86	0.000131	0.00988	0.13	0.18	Mean platelet volume;	chr11:839127	chr11:781645~782105:+
THCA	cis	rs701145	0.585	rs1713839	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154111316	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs2060622	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154116073	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727879	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154118030	chr3:154024401~154121332:-
THCA	cis	rs701145	0.537	rs1713832	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154118044	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727880	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154118183	chr3:154024401~154121332:-
THCA	cis	rs701145	0.537	rs1713831	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154118510	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727884	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154120579	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713828	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154120764	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727887	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154121676	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs12493885	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154122077	chr3:154024401~154121332:-
THCA	cis	rs701145	0.537	rs1713855	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154130044	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713854	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154130241	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727893	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154132077	chr3:154024401~154121332:-
THCA	cis	rs701145	0.643	rs7647694	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154133746	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs6769099	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154134653	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs921318	ENSG00000243069.6	ARHGEF26-AS1	3.86	0.000131	0.00988	0.33	0.18	Coronary artery disease;	chr3:154138986	chr3:154024401~154121332:-
THCA	cis	rs12493885	0.818	rs60023390	ENSG00000243069.6	ARHGEF26-AS1	-3.86	0.000131	0.00988	-0.29	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154053267	chr3:154024401~154121332:-
THCA	cis	rs786425	0.833	rs7313628	ENSG00000270095.1	RP11-214K3.18	-3.86	0.000131	0.00988	-0.2	-0.18	Pubertal anthropometrics;	chr12:123622468	chr12:123971457~123971714:-
THCA	cis	rs875971	0.522	rs2949690	ENSG00000229180.5	GS1-124K5.11	-3.86	0.000131	0.00988	-0.12	-0.18	Aortic root size;	chr7:66018255	chr7:66526088~66542624:-
THCA	cis	rs10256972	0.804	rs10275585	ENSG00000225146.1	AC073957.15	3.86	0.000131	0.00988	0.19	0.18	Endometriosis;Longevity;	chr7:977703	chr7:1029025~1043891:+
THCA	cis	rs1864585	0.52	rs73208790	ENSG00000280294.1	RP11-177H2.1	3.86	0.000131	0.00988	0.18	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10822515	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs73208791	ENSG00000280294.1	RP11-177H2.1	3.86	0.000131	0.00988	0.18	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10822828	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.505	rs73208792	ENSG00000280294.1	RP11-177H2.1	3.86	0.000131	0.00988	0.18	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10822961	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs73208793	ENSG00000280294.1	RP11-177H2.1	3.86	0.000131	0.00988	0.18	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10823275	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.552	rs73208794	ENSG00000280294.1	RP11-177H2.1	3.86	0.000131	0.00988	0.18	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10823738	chr8:10856085~10859436:-
THCA	cis	rs7615952	0.673	rs9821905	ENSG00000272840.1	RP11-379B18.6	-3.86	0.000131	0.00988	-0.33	-0.18	Blood pressure (smoking interaction);	chr3:125902007	chr3:125774714~125797953:+
THCA	cis	rs11317778	1	rs11317778	ENSG00000246763.5	RGMB-AS1	3.86	0.000131	0.00988	0.18	0.18	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98769618~98773469:-
THCA	cis	rs11960179	0.892	rs78714449	ENSG00000250066.1	RP11-141O11.1	-3.86	0.000131	0.00989	-0.32	-0.18	Glomerular filtration rate (creatinine);	chr5:68506927	chr5:68963246~68967845:+
THCA	cis	rs11960179	0.892	rs2161529	ENSG00000250066.1	RP11-141O11.1	-3.86	0.000131	0.00989	-0.32	-0.18	Glomerular filtration rate (creatinine);	chr5:68507526	chr5:68963246~68967845:+
THCA	cis	rs9307551	0.697	rs7691918	ENSG00000250334.4	LINC00989	-3.86	0.000131	0.00989	-0.23	-0.18	Refractive error;	chr4:79495337	chr4:79492416~79576460:+
THCA	cis	rs2839186	0.872	rs13052233	ENSG00000215424.8	MCM3AP-AS1	3.86	0.000131	0.00989	0.1	0.18	Testicular germ cell tumor;	chr21:46287370	chr21:46229217~46259390:+
THCA	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	3.86	0.000131	0.00989	0.2	0.18	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
THCA	cis	rs12410462	1	rs12410462	ENSG00000227711.2	RP11-275O4.5	3.86	0.000131	0.00989	0.27	0.18	Major depressive disorder;	chr1:227480089	chr1:227509028~227520477:-
THCA	cis	rs9926296	0.632	rs1800286	ENSG00000274627.1	RP11-104N10.2	-3.86	0.000131	0.00989	-0.18	-0.18	Vitiligo;	chr16:89803353	chr16:89516797~89522217:+
THCA	cis	rs875971	0.545	rs1796219	ENSG00000232559.3	GS1-124K5.12	-3.86	0.000131	0.00989	-0.19	-0.18	Aortic root size;	chr7:66645977	chr7:66554588~66576923:-
THCA	cis	rs13006863	0.509	rs1667605	ENSG00000225439.2	BOLA3-AS1	3.86	0.000131	0.00989	0.21	0.18	Immune reponse to smallpox (secreted TNF-alpha);Post-traumatic stress disorder (asjusted for relatedness);	chr2:74147757	chr2:74148009~74150061:+
THCA	cis	rs12544026	0.819	rs6468801	ENSG00000253669.3	KB-1732A1.1	-3.86	0.000131	0.00989	-0.2	-0.18	Major depression and alcohol dependence;	chr8:101828445	chr8:102805517~102809971:+
THCA	cis	rs6500602	0.929	rs9926114	ENSG00000280063.1	RP11-295D4.3	3.86	0.000131	0.0099	0.1	0.18	Schizophrenia;	chr16:4428321	chr16:4346694~4348648:-
THCA	cis	rs9314614	0.933	rs2741098	ENSG00000245857.2	GS1-24F4.2	-3.86	0.000131	0.0099	-0.23	-0.18	White blood cell count (basophil);IgA nephropathy;	chr8:6832754	chr8:6835554~6885276:+
THCA	cis	rs11708578	0.554	rs13076097	ENSG00000237990.3	CNTN4-AS1	3.86	0.000132	0.0099	0.22	0.18	Schizophrenia;	chr3:2390755	chr3:3039033~3069242:-
THCA	cis	rs7260598	0.502	rs6511585	ENSG00000268442.1	CTD-2027I19.2	-3.86	0.000132	0.0099	-0.26	-0.18	Response to taxane treatment (placlitaxel);	chr19:23820470	chr19:24162370~24163425:-
THCA	cis	rs889312	0.5	rs866223	ENSG00000271828.1	CTD-2310F14.1	-3.86	0.000132	0.0099	-0.24	-0.18	Breast cancer (early onset);Breast cancer;	chr5:56829526	chr5:56927874~56929573:+
THCA	cis	rs12142240	0.698	rs56130131	ENSG00000232022.5	FAAHP1	-3.86	0.000132	0.0099	-0.2	-0.18	Menopause (age at onset);	chr1:46395634	chr1:46432129~46445521:+
THCA	cis	rs71520386	0.846	rs17778126	ENSG00000228649.7	AC005682.5	-3.86	0.000132	0.0099	-0.28	-0.18	Fibrinogen levels;	chr7:22779340	chr7:22854178~22861579:+
THCA	cis	rs6920965	0.583	rs9388456	ENSG00000226409.1	RP11-735G4.1	-3.86	0.000132	0.0099	-0.21	-0.18	High light scatter reticulocyte count;	chr6:125826051	chr6:125370211~125374324:-
THCA	cis	rs3935740	1	rs6495564	ENSG00000271983.1	RP11-28H5.2	3.86	0.000132	0.0099	0.22	0.18	Parkinson's disease;	chr15:81335106	chr15:80693216~80693707:-
THCA	cis	rs1501911	0.53	rs751878	ENSG00000241597.2	CTD-2007H13.1	-3.86	0.000132	0.0099	-0.23	-0.18	Lung function (FEV1/FVC);	chr5:98827240	chr5:98954394~98954972:+
THCA	cis	rs1501911	0.53	rs331926	ENSG00000241597.2	CTD-2007H13.1	-3.86	0.000132	0.0099	-0.23	-0.18	Lung function (FEV1/FVC);	chr5:98828697	chr5:98954394~98954972:+
THCA	cis	rs4950322	0.58	rs1813002	ENSG00000226015.2	CCT8P1	3.86	0.000132	0.0099	0.2	0.18	Protein quantitative trait loci;	chr1:147112579	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.518	rs4950304	ENSG00000226015.2	CCT8P1	3.86	0.000132	0.0099	0.2	0.18	Protein quantitative trait loci;	chr1:147116685	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.518	rs4950305	ENSG00000226015.2	CCT8P1	3.86	0.000132	0.0099	0.2	0.18	Protein quantitative trait loci;	chr1:147117711	chr1:147203276~147204932:-
THCA	cis	rs4671400	0.571	rs4672429	ENSG00000271889.1	RP11-493E12.1	-3.86	0.000132	0.0099	-0.19	-0.18	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61268334	chr2:61151433~61162105:-
THCA	cis	rs944289	0.533	rs2780313	ENSG00000258844.1	RP11-259K15.2	-3.86	0.000132	0.0099	-0.16	-0.18	Thyroid cancer;	chr14:36059216	chr14:36214607~36235608:+
THCA	cis	rs6929812	0.967	rs7509	ENSG00000216915.2	RP1-97D16.1	3.86	0.000132	0.0099	0.23	0.18	Neuroticism (multi-trait analysis);	chr6:27451068	chr6:27737000~27738494:-
THCA	cis	rs7166081	1	rs12594229	ENSG00000270964.1	RP11-502I4.3	-3.86	0.000132	0.0099	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67303746	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs4776917	ENSG00000270964.1	RP11-502I4.3	-3.86	0.000132	0.0099	-0.16	-0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67308006	chr15:67541072~67542604:-
THCA	cis	rs78487399	0.808	rs10169346	ENSG00000234936.1	AC010883.5	3.86	0.000132	0.0099	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43513966	chr2:43229573~43233394:+
THCA	cis	rs12476592	0.516	rs6706123	ENSG00000242412.1	DBIL5P2	3.86	0.000132	0.00991	0.22	0.18	Childhood ear infection;	chr2:63574388	chr2:63117851~63119542:-
THCA	cis	rs2562456	0.958	rs2562508	ENSG00000268658.4	LINC00664	-3.86	0.000132	0.00991	-0.25	-0.18	Pain;	chr19:21543479	chr19:21483374~21503238:+
THCA	cis	rs7956611	0.564	rs7313182	ENSG00000213343.5	RPL21P18	-3.86	0.000132	0.00991	-0.2	-0.18	Age of smoking initiation;	chr12:66505246	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs7299018	ENSG00000213343.5	RPL21P18	-3.86	0.000132	0.00991	-0.2	-0.18	Age of smoking initiation;	chr12:66505458	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs7313809	ENSG00000213343.5	RPL21P18	-3.86	0.000132	0.00991	-0.2	-0.18	Age of smoking initiation;	chr12:66505601	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs61925948	ENSG00000213343.5	RPL21P18	-3.86	0.000132	0.00991	-0.2	-0.18	Age of smoking initiation;	chr12:66506073	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs56243809	ENSG00000213343.5	RPL21P18	-3.86	0.000132	0.00991	-0.2	-0.18	Age of smoking initiation;	chr12:66506349	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs34583648	ENSG00000213343.5	RPL21P18	-3.86	0.000132	0.00991	-0.2	-0.18	Age of smoking initiation;	chr12:66506525	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs1493490	ENSG00000213343.5	RPL21P18	-3.86	0.000132	0.00991	-0.2	-0.18	Age of smoking initiation;	chr12:66508044	chr12:66037235~66037714:+
THCA	cis	rs867186	1	rs8124662	ENSG00000126005.14	MMP24-AS1	-3.86	0.000132	0.00991	-0.27	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35051453	chr20:35216462~35278131:-
THCA	cis	rs867186	0.92	rs11905081	ENSG00000126005.14	MMP24-AS1	-3.86	0.000132	0.00991	-0.27	-0.18	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35053117	chr20:35216462~35278131:-
THCA	cis	rs11242704	0.89	rs2816289	ENSG00000218027.2	RP11-157J24.1	3.86	0.000132	0.00991	0.23	0.18	Response to hepatitis C treatment;	chr6:1537065	chr6:1513698~1515289:-
THCA	cis	rs4700393	0.517	rs71592686	ENSG00000272308.1	RP11-231G3.1	3.86	0.000132	0.00991	0.2	0.18	Intelligence (multi-trait analysis);	chr5:60825444	chr5:60866457~60866935:-
THCA	cis	rs10435719	0.718	rs7813935	ENSG00000255495.1	AC145124.2	3.86	0.000132	0.00991	0.21	0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.504	rs7830734	ENSG00000255495.1	AC145124.2	3.86	0.000132	0.00991	0.21	0.18	Neuroticism;	chr8:11938130	chr8:12194467~12196280:+
THCA	cis	rs42648	0.935	rs7803012	ENSG00000225498.1	AC002064.5	-3.86	0.000132	0.00991	-0.18	-0.18	Homocysteine levels;	chr7:90396852	chr7:90312496~90322592:+
THCA	cis	rs12478296	0.792	rs57482298	ENSG00000220804.7	AC093642.5	3.86	0.000132	0.00991	0.2	0.18	Obesity-related traits;	chr2:242068997	chr2:242088633~242160153:+
THCA	cis	rs2638953	0.815	rs11049658	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000132	0.00991	-0.18	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481930	chr12:28163298~28190738:-
THCA	cis	rs1005277	0.579	rs1740732	ENSG00000120555.12	SEPT7P9	3.86	0.000132	0.00991	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38383069~38402916:-
THCA	cis	rs786425	0.682	rs7302649	ENSG00000278112.1	RP11-972P1.11	3.86	0.000132	0.00991	0.17	0.18	Pubertal anthropometrics;	chr12:123675219	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs34534928	ENSG00000278112.1	RP11-972P1.11	3.86	0.000132	0.00991	0.17	0.18	Pubertal anthropometrics;	chr12:123676287	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs12820195	ENSG00000278112.1	RP11-972P1.11	3.86	0.000132	0.00991	0.17	0.18	Pubertal anthropometrics;	chr12:123677500	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7973695	ENSG00000278112.1	RP11-972P1.11	3.86	0.000132	0.00991	0.17	0.18	Pubertal anthropometrics;	chr12:123677930	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7959553	ENSG00000278112.1	RP11-972P1.11	3.86	0.000132	0.00991	0.17	0.18	Pubertal anthropometrics;	chr12:123678158	chr12:123519390~123519856:-
THCA	cis	rs786425	0.711	rs66690784	ENSG00000278112.1	RP11-972P1.11	3.86	0.000132	0.00991	0.17	0.18	Pubertal anthropometrics;	chr12:123681130	chr12:123519390~123519856:-
THCA	cis	rs786425	0.711	rs7963968	ENSG00000278112.1	RP11-972P1.11	3.86	0.000132	0.00991	0.17	0.18	Pubertal anthropometrics;	chr12:123681494	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7302788	ENSG00000278112.1	RP11-972P1.11	3.86	0.000132	0.00991	0.17	0.18	Pubertal anthropometrics;	chr12:123682474	chr12:123519390~123519856:-
THCA	cis	rs10208649	0.522	rs7594400	ENSG00000272156.1	RP11-477N3.1	-3.86	0.000132	0.00991	-0.36	-0.18	Body mass index;	chr2:54176970	chr2:54082554~54085066:+
THCA	cis	rs7176527	0.579	rs366717	ENSG00000176700.18	SCAND2P	3.86	0.000132	0.00991	0.13	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84631451~84647478:+
THCA	cis	rs10844154	0.543	rs2650125	ENSG00000277342.1	RP11-843B15.4	3.86	0.000132	0.00992	0.23	0.18	Emphysema-related traits;Weight;	chr12:32255074	chr12:32109076~32109602:+
THCA	cis	rs6756513	0.5	rs2278932	ENSG00000231024.1	AC092431.3	-3.86	0.000132	0.00992	-0.26	-0.18	Breast cancer;Platelet count;	chr2:69828984	chr2:69700192~69713847:-
THCA	cis	rs67981189	0.835	rs2526855	ENSG00000269927.1	RP6-91H8.3	-3.86	0.000132	0.00992	-0.2	-0.18	Schizophrenia;	chr14:70946629	chr14:71141125~71143253:-
THCA	cis	rs4460629	0.742	rs11581730	ENSG00000225855.5	RUSC1-AS1	3.85	0.000132	0.00992	0.11	0.18	Serum magnesium levels;	chr1:155109682	chr1:155316863~155324176:-
THCA	cis	rs4460629	0.742	rs7548955	ENSG00000225855.5	RUSC1-AS1	3.85	0.000132	0.00992	0.11	0.18	Serum magnesium levels;	chr1:155109822	chr1:155316863~155324176:-
THCA	cis	rs7572644	0.64	rs7593136	ENSG00000223522.1	AC093690.1	-3.85	0.000132	0.00992	-0.21	-0.18	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27794925	chr2:28307691~28310459:-
THCA	cis	rs1510552	0.816	rs13032246	ENSG00000270659.1	RP11-105N14.1	3.85	0.000132	0.00992	0.16	0.18	Contrast sensitivity;	chr2:214136502	chr2:213152970~213153659:+
THCA	cis	rs1204798	0.945	rs1204791	ENSG00000237021.2	RP3-486I3.7	-3.85	0.000132	0.00992	-0.2	-0.18	Dental caries;	chr6:116217923	chr6:116254207~116256743:+
THCA	cis	rs58235267	0.656	rs12713469	ENSG00000242412.1	DBIL5P2	3.85	0.000132	0.00992	0.2	0.18	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:62832792	chr2:63117851~63119542:-
THCA	cis	rs9863	0.828	rs11057409	ENSG00000270028.1	RP11-380L11.4	-3.85	0.000132	0.00992	-0.19	-0.18	White blood cell count;	chr12:123994784	chr12:123925461~123926083:-
THCA	cis	rs73108077	1	rs73116268	ENSG00000277112.2	RP11-755J8.1	-3.85	0.000132	0.00992	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31461103	chr20:30681825~30723932:-
THCA	cis	rs73108077	1	rs75774213	ENSG00000277112.2	RP11-755J8.1	-3.85	0.000132	0.00992	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31462439	chr20:30681825~30723932:-
THCA	cis	rs9309711	0.643	rs10188449	ENSG00000271868.1	RP11-1293J14.1	-3.85	0.000132	0.00992	-0.23	-0.18	Neurofibrillary tangles;	chr2:3476595	chr2:3496956~3497428:+
THCA	cis	rs3734729	1	rs17079521	ENSG00000218358.2	RAET1K	3.85	0.000132	0.00992	0.51	0.18	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150255514	chr6:149998019~150005157:-
THCA	cis	rs61677309	1	rs56140791	ENSG00000278376.1	RP11-158I9.8	3.85	0.000132	0.00992	0.13	0.18	Lung cancer in ever smokers;	chr11:118296475	chr11:118791254~118793137:+
THCA	cis	rs9926296	0.508	rs1558184	ENSG00000274627.1	RP11-104N10.2	-3.85	0.000132	0.00992	-0.18	-0.18	Vitiligo;	chr16:89775966	chr16:89516797~89522217:+
THCA	cis	rs4761470	0.577	rs4761602	ENSG00000258365.1	RP11-1105G2.3	-3.85	0.000132	0.00993	-0.2	-0.18	Estradiol plasma levels (breast cancer);	chr12:94291262	chr12:94277758~94282844:-
THCA	cis	rs1008126	0.609	rs6465920	ENSG00000234715.1	CTB-107G13.1	-3.85	0.000132	0.00993	-0.21	-0.18	Metabolite levels (Pyroglutamine);	chr7:103444323	chr7:103445207~103514007:+
THCA	cis	rs12681288	0.523	rs6983944	ENSG00000260721.1	AF067845.1	3.85	0.000132	0.00993	0.21	0.18	Schizophrenia;	chr8:1005147	chr8:1368642~1369833:-
THCA	cis	rs6500602	0.739	rs4786502	ENSG00000280063.1	RP11-295D4.3	3.85	0.000132	0.00993	0.09	0.18	Schizophrenia;	chr16:4487103	chr16:4346694~4348648:-
THCA	cis	rs6756513	0.5	rs72839869	ENSG00000231024.1	AC092431.3	-3.85	0.000132	0.00993	-0.26	-0.18	Breast cancer;Platelet count;	chr2:69814049	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs72839870	ENSG00000231024.1	AC092431.3	-3.85	0.000132	0.00993	-0.26	-0.18	Breast cancer;Platelet count;	chr2:69815783	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs3771535	ENSG00000231024.1	AC092431.3	-3.85	0.000132	0.00993	-0.26	-0.18	Breast cancer;Platelet count;	chr2:69816643	chr2:69700192~69713847:-
THCA	cis	rs6938	0.618	rs62029167	ENSG00000260269.4	CTD-2323K18.1	-3.85	0.000132	0.00993	-0.26	-0.18	Breast cancer;	chr15:74936009	chr15:75527150~75601205:-
THCA	cis	rs17685	0.753	rs11972240	ENSG00000227038.2	AC005077.12	3.85	0.000132	0.00993	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76064761	chr7:76090431~76108779:-
THCA	cis	rs1198872	0.892	rs1198868	ENSG00000243819.4	RN7SL832P	3.85	0.000132	0.00993	0.14	0.18	Cardiac Troponin-T levels;	chr2:10762287	chr2:10690344~10692099:+
THCA	cis	rs3770081	1	rs6724025	ENSG00000273080.1	RP11-301O19.1	-3.85	0.000132	0.00993	-0.37	-0.18	Facial emotion recognition (sad faces);	chr2:85973712	chr2:86195590~86196049:+
THCA	cis	rs7819412	0.74	rs11250119	ENSG00000254839.1	AF131215.6	3.85	0.000132	0.00993	0.18	0.18	Triglycerides;	chr8:11179525	chr8:11062647~11067089:-
THCA	cis	rs10911902	0.602	rs74370445	ENSG00000233196.2	GS1-304P7.1	-3.85	0.000132	0.00994	-0.27	-0.18	Schizophrenia;	chr1:186380327	chr1:186580515~186581191:-
THCA	cis	rs2360027	0.662	rs1911166	ENSG00000231365.4	RP11-418J17.1	-3.85	0.000132	0.00994	-0.17	-0.18	Tonsillectomy;	chr1:118583708	chr1:119140396~119275973:+
THCA	cis	rs7819412	0.774	rs34208825	ENSG00000206014.6	OR7E161P	3.85	0.000132	0.00994	0.2	0.18	Triglycerides;	chr8:11157106	chr8:11928597~11929563:-
THCA	cis	rs7824557	0.564	rs2572400	ENSG00000154316.13	TDH	3.85	0.000132	0.00994	0.13	0.18	Retinal vascular caliber;	chr8:11376858	chr8:11339637~11368452:+
THCA	cis	rs308403	0.532	rs309386	ENSG00000224786.1	CETN4P	3.85	0.000132	0.00994	0.18	0.18	Blood protein levels;	chr4:122744836	chr4:122730548~122732193:-
THCA	cis	rs67340775	0.541	rs200966	ENSG00000220721.1	OR1F12	3.85	0.000132	0.00994	0.27	0.18	Lung cancer in ever smokers;	chr6:27894374	chr6:28073316~28074233:+
THCA	cis	rs7829975	0.606	rs10112585	ENSG00000254340.1	RP11-10A14.3	-3.85	0.000132	0.00994	-0.19	-0.18	Mood instability;	chr8:8937520	chr8:9141424~9145435:+
THCA	cis	rs6993270	0.602	rs74693645	ENSG00000245330.4	KB-1471A8.1	-3.85	0.000132	0.00994	-0.3	-0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119900867	chr8:119867419~119874488:-
THCA	cis	rs7089973	0.604	rs765173	ENSG00000228169.3	PPIAP19	3.85	0.000132	0.00994	0.2	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114841916	chr10:114690143~114690634:-
THCA	cis	rs2179367	0.632	rs997682	ENSG00000216906.2	RP11-350J20.9	-3.85	0.000132	0.00994	-0.22	-0.18	Dupuytren's disease;	chr6:149345484	chr6:149904243~149906418:+
THCA	cis	rs10050311	0.698	rs3775238	ENSG00000251411.1	RP11-397E7.4	-3.85	0.000132	0.00994	-0.21	-0.18	Insulin-related traits;	chr4:86712231	chr4:86913266~86914817:-
THCA	cis	rs7737355	0.947	rs193458	ENSG00000237714.1	P4HA2-AS1	3.85	0.000132	0.00994	0.25	0.18	Life satisfaction;	chr5:131480591	chr5:132184876~132192808:+
THCA	cis	rs2223471	1	rs6928000	ENSG00000060303.5	RPS17P5	-3.85	0.000132	0.00994	-0.21	-0.18	Subcutaneous adipose tissue;	chr6:50774448	chr6:50857255~50857662:-
THCA	cis	rs9287719	0.967	rs10206225	ENSG00000243819.4	RN7SL832P	3.85	0.000132	0.00995	0.14	0.18	Prostate cancer;	chr2:10618531	chr2:10690344~10692099:+
THCA	cis	rs1510272	1	rs1510273	ENSG00000243926.1	TIPARP-AS1	-3.85	0.000132	0.00995	-0.18	-0.18	Testicular germ cell tumor;	chr3:156583033	chr3:156671862~156674378:-
THCA	cis	rs752590	0.614	rs67626501	ENSG00000227359.1	AC017074.2	3.85	0.000132	0.00995	0.26	0.18	Mucinous ovarian carcinoma;	chr2:113262802	chr2:113677702~113704078:-
THCA	cis	rs7160336	0.713	rs7161293	ENSG00000259065.1	RP5-1021I20.1	3.85	0.000132	0.00995	0.21	0.18	Blood protein levels;	chr14:74031655	chr14:73787360~73803270:+
THCA	cis	rs734999	0.545	rs10910111	ENSG00000225931.3	RP3-395M20.7	3.85	0.000132	0.00995	0.21	0.18	Ulcerative colitis;	chr1:2611214	chr1:2566410~2569888:+
THCA	cis	rs2360027	0.662	rs12129804	ENSG00000231365.4	RP11-418J17.1	-3.85	0.000132	0.00995	-0.17	-0.18	Tonsillectomy;	chr1:118592566	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.662	rs12045512	ENSG00000231365.4	RP11-418J17.1	-3.85	0.000132	0.00995	-0.17	-0.18	Tonsillectomy;	chr1:118593514	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.662	rs4659105	ENSG00000231365.4	RP11-418J17.1	-3.85	0.000132	0.00995	-0.17	-0.18	Tonsillectomy;	chr1:118595604	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.662	rs12138163	ENSG00000231365.4	RP11-418J17.1	-3.85	0.000132	0.00995	-0.17	-0.18	Tonsillectomy;	chr1:118597074	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.662	rs4658990	ENSG00000231365.4	RP11-418J17.1	-3.85	0.000132	0.00995	-0.17	-0.18	Tonsillectomy;	chr1:118597765	chr1:119140396~119275973:+
THCA	cis	rs10256972	0.626	rs62433138	ENSG00000225146.1	AC073957.15	3.85	0.000132	0.00995	0.19	0.18	Endometriosis;Longevity;	chr7:1011241	chr7:1029025~1043891:+
THCA	cis	rs12022452	0.506	rs12569328	ENSG00000237899.1	RP4-739H11.3	-3.85	0.000132	0.00995	-0.26	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40669089~40687588:-
THCA	cis	rs11105298	1	rs11105298	ENSG00000266347.2	AC068641.1	-3.85	0.000132	0.00995	-0.22	-0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89592833~89592927:+
THCA	cis	rs10254284	1	rs6962289	ENSG00000234336.5	JAZF1-AS1	3.85	0.000132	0.00995	0.18	0.18	Systemic lupus erythematosus;Lymphocyte percentage of white cells;	chr7:28121760	chr7:28180322~28243917:+
THCA	cis	rs10191559	0.638	rs6732354	ENSG00000236153.1	AC104076.3	3.85	0.000132	0.00995	0.19	0.18	Red blood cell count;	chr2:180992142	chr2:180979427~180980090:-
THCA	cis	rs2276314	1	rs9304153	ENSG00000267627.4	RP11-905K4.1	-3.85	0.000132	0.00995	-0.22	-0.18	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35951803~35966118:-
THCA	cis	rs13098911	0.54	rs13068570	ENSG00000226074.4	PRSS44	-3.85	0.000132	0.00995	-0.34	-0.18	Celiac disease;	chr3:46094946	chr3:46809359~46812558:-
THCA	cis	rs17695224	0.675	rs2109658	ENSG00000275055.1	CTC-471J1.11	3.85	0.000132	0.00995	0.14	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51838871	chr19:52049007~52049754:+
THCA	cis	rs13113518	0.51	rs6828454	ENSG00000273257.1	RP11-177J6.1	3.85	0.000132	0.00995	0.23	0.18	Height;	chr4:55424329	chr4:55387949~55388271:+
THCA	cis	rs321358	0.895	rs17536059	ENSG00000271390.1	RP11-89C3.3	-3.85	0.000132	0.00996	-0.27	-0.18	Body mass index;	chr11:111086611	chr11:111089870~111090368:-
THCA	cis	rs10435719	0.61	rs76311455	ENSG00000206014.6	OR7E161P	-3.85	0.000132	0.00996	-0.21	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933017	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.61	rs80269926	ENSG00000206014.6	OR7E161P	-3.85	0.000132	0.00996	-0.21	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933018	chr8:11928597~11929563:-
THCA	cis	rs13113518	0.812	rs12500456	ENSG00000272969.1	RP11-528I4.2	3.85	0.000132	0.00996	0.21	0.18	Height;	chr4:55561053	chr4:55547112~55547889:+
THCA	cis	rs9314614	0.714	rs2980949	ENSG00000245857.2	GS1-24F4.2	3.85	0.000132	0.00996	0.23	0.18	White blood cell count (basophil);IgA nephropathy;	chr8:6855728	chr8:6835554~6885276:+
THCA	cis	rs4664304	0.62	rs1828480	ENSG00000226266.5	AC009961.3	-3.85	0.000132	0.00996	-0.2	-0.18	Crohn's disease;Inflammatory bowel disease;	chr2:159863873	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.62	rs1397717	ENSG00000226266.5	AC009961.3	-3.85	0.000132	0.00996	-0.2	-0.18	Crohn's disease;Inflammatory bowel disease;	chr2:159863933	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.62	rs10929958	ENSG00000226266.5	AC009961.3	-3.85	0.000132	0.00996	-0.2	-0.18	Crohn's disease;Inflammatory bowel disease;	chr2:159864027	chr2:159670708~159712435:-
THCA	cis	rs17685	0.753	rs4732595	ENSG00000227038.2	AC005077.12	3.85	0.000132	0.00996	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76125821	chr7:76090431~76108779:-
THCA	cis	rs724818	0.661	rs28488919	ENSG00000251609.2	SETP12	-3.85	0.000132	0.00996	-0.49	-0.18	Monobrow thickness;	chr4:120796586	chr4:120895494~120897083:-
THCA	cis	rs2688608	0.592	rs7923045	ENSG00000272140.2	RP11-574K11.29	3.85	0.000133	0.00996	0.15	0.18	Inflammatory bowel disease;	chr10:73727740	chr10:73703735~73713581:-
THCA	cis	rs12681366	0.843	rs3019156	ENSG00000261437.1	RP11-22C11.2	3.85	0.000133	0.00996	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94409552	chr8:94637285~94639467:-
THCA	cis	rs7552393	1	rs7552393	ENSG00000233008.4	RP11-475O6.1	-3.85	0.000133	0.00996	-0.19	-0.18	Select biomarker traits;	chr1:83788868	chr1:83575776~83861023:-
THCA	cis	rs13108904	0.901	rs6826029	ENSG00000254094.1	AC078852.1	-3.85	0.000133	0.00996	-0.19	-0.18	Obesity-related traits;	chr4:1313901	chr4:1356581~1358075:+
THCA	cis	rs12681366	0.801	rs12549544	ENSG00000253175.1	RP11-267M23.6	3.85	0.000133	0.00997	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94565036~94565715:+
THCA	cis	rs17286411	0.671	rs9925069	ENSG00000260185.1	RP11-432I5.6	-3.85	0.000133	0.00997	-0.24	-0.18	Blood protein levels;	chr16:71790268	chr16:71655027~71664212:+
THCA	cis	rs12681366	0.761	rs2930963	ENSG00000261437.1	RP11-22C11.2	3.85	0.000133	0.00997	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94637285~94639467:-
THCA	cis	rs2692947	0.537	rs72821435	ENSG00000168992.4	OR7E102P	3.85	0.000133	0.00997	0.22	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95522187	chr2:95546531~95547545:+
THCA	cis	rs2692947	0.537	rs12468117	ENSG00000168992.4	OR7E102P	3.85	0.000133	0.00997	0.22	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95528835	chr2:95546531~95547545:+
THCA	cis	rs10540	1	rs61876323	ENSG00000279672.1	CMB9-55F22.1	3.85	0.000133	0.00997	0.34	0.18	Body mass index;	chr11:462855	chr11:779617~780755:+
THCA	cis	rs10540	1	rs79808876	ENSG00000279672.1	CMB9-55F22.1	3.85	0.000133	0.00997	0.34	0.18	Body mass index;	chr11:465763	chr11:779617~780755:+
THCA	cis	rs10540	1	rs35068485	ENSG00000279672.1	CMB9-55F22.1	3.85	0.000133	0.00997	0.34	0.18	Body mass index;	chr11:466032	chr11:779617~780755:+
THCA	cis	rs10540	1	rs61876326	ENSG00000279672.1	CMB9-55F22.1	3.85	0.000133	0.00997	0.34	0.18	Body mass index;	chr11:467368	chr11:779617~780755:+
THCA	cis	rs10771431	0.597	rs3759275	ENSG00000256427.1	RP11-118B22.4	3.85	0.000133	0.00997	0.2	0.18	Breast size;	chr12:9201232	chr12:9246497~9257960:+
THCA	cis	rs10771431	0.597	rs3759274	ENSG00000256427.1	RP11-118B22.4	3.85	0.000133	0.00997	0.2	0.18	Breast size;	chr12:9201279	chr12:9246497~9257960:+
THCA	cis	rs7264396	0.832	rs224361	ENSG00000088340.14	FER1L4	3.85	0.000133	0.00997	0.16	0.18	Total cholesterol levels;	chr20:35473753	chr20:35558737~35607562:-
THCA	cis	rs35176054	0.73	rs11596085	ENSG00000280693.1	SH3PXD2A-AS1	-3.85	0.000133	0.00997	-0.33	-0.18	Atrial fibrillation;	chr10:103769902	chr10:103745966~103755423:+
THCA	cis	rs7560272	0.723	rs6729468	ENSG00000273245.1	RP11-434P11.2	3.85	0.000133	0.00997	0.21	0.18	Schizophrenia;	chr2:73538126	chr2:73750256~73750786:-
THCA	cis	rs11158026	0.501	rs2057368	ENSG00000258413.1	RP11-665C16.6	-3.85	0.000133	0.00997	-0.27	-0.18	Parkinson's disease;	chr14:54837291	chr14:55262767~55272075:-
THCA	cis	rs1577917	0.917	rs1414201	ENSG00000220563.1	PKMP3	-3.85	0.000133	0.00997	-0.13	-0.18	Response to antipsychotic treatment;	chr6:85790598	chr6:85659892~85660606:-
THCA	cis	rs2839186	0.559	rs2277826	ENSG00000228137.1	AP001469.7	-3.85	0.000133	0.00997	-0.18	-0.18	Testicular germ cell tumor;	chr21:46219578	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.587	rs35679325	ENSG00000228137.1	AP001469.7	-3.85	0.000133	0.00997	-0.18	-0.18	Testicular germ cell tumor;	chr21:46221066	chr21:46246890~46247682:+
THCA	cis	rs12444979	0.515	rs8046628	ENSG00000261195.1	CTD-2380F24.1	-3.85	0.000133	0.00997	-0.28	-0.18	Body mass index;	chr16:19770638	chr16:19761172~19766099:-
THCA	cis	rs875971	0.545	rs6961853	ENSG00000273024.4	INTS4P2	-3.85	0.000133	0.00997	-0.22	-0.18	Aortic root size;	chr7:66537035	chr7:65647864~65715661:+
THCA	cis	rs763121	0.853	rs5757193	ENSG00000273076.1	RP3-508I15.22	-3.85	0.000133	0.00997	-0.18	-0.18	Menopause (age at onset);	chr22:38638862	chr22:38743495~38743910:+
THCA	cis	rs13256369	0.708	rs11783670	ENSG00000254153.1	CTA-398F10.2	-3.85	0.000133	0.00997	-0.2	-0.18	Obesity-related traits;	chr8:8701884	chr8:8456909~8461337:-
THCA	cis	rs7656342	0.535	rs4575993	ENSG00000250342.1	SNRPCP16	-3.85	0.000133	0.00997	-0.23	-0.18	Gut microbiota (bacterial taxa);	chr4:9857120	chr4:9051842~9052051:-
THCA	cis	rs4713118	0.55	rs9368527	ENSG00000261839.1	RP1-265C24.8	3.85	0.000133	0.00997	0.17	0.18	Parkinson's disease;	chr6:27711666	chr6:28136849~28139678:+
THCA	cis	rs2836974	0.867	rs77959119	ENSG00000255568.3	BRWD1-AS2	3.85	0.000133	0.00998	0.16	0.17	Cognitive function;	chr21:39170842	chr21:39313935~39314962:+
THCA	cis	rs2239547	0.618	rs4687658	ENSG00000243224.1	RP5-1157M23.2	-3.85	0.000133	0.00998	-0.21	-0.17	Schizophrenia;	chr3:52826350	chr3:52239258~52241097:+
THCA	cis	rs2239547	0.657	rs2276817	ENSG00000243224.1	RP5-1157M23.2	-3.85	0.000133	0.00998	-0.21	-0.17	Schizophrenia;	chr3:52826920	chr3:52239258~52241097:+
THCA	cis	rs2239547	0.657	rs13072536	ENSG00000243224.1	RP5-1157M23.2	-3.85	0.000133	0.00998	-0.21	-0.17	Schizophrenia;	chr3:52827195	chr3:52239258~52241097:+
THCA	cis	rs2239547	0.657	rs12488303	ENSG00000243224.1	RP5-1157M23.2	-3.85	0.000133	0.00998	-0.21	-0.17	Schizophrenia;	chr3:52827987	chr3:52239258~52241097:+
THCA	cis	rs2239547	0.657	rs2072391	ENSG00000243224.1	RP5-1157M23.2	-3.85	0.000133	0.00998	-0.21	-0.17	Schizophrenia;	chr3:52828184	chr3:52239258~52241097:+
THCA	cis	rs786425	0.538	rs786452	ENSG00000270095.1	RP11-214K3.18	3.85	0.000133	0.00998	0.19	0.17	Pubertal anthropometrics;	chr12:123572622	chr12:123971457~123971714:-
THCA	cis	rs10090774	0.71	rs13274713	ENSG00000279766.1	RP11-642A1.2	-3.85	0.000133	0.00998	-0.21	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655098	chr8:140572142~140572812:-
THCA	cis	rs11601239	0.646	rs2000523	ENSG00000254750.1	CASP1P2	3.85	0.000133	0.00998	0.14	0.17	Refractive error;	chr11:105761638	chr11:105063345~105071541:-
THCA	cis	rs9925964	0.933	rs12448321	ENSG00000279196.1	RP11-1072A3.3	-3.85	0.000133	0.00998	-0.17	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036959	chr16:30984630~30988270:-
THCA	cis	rs7772697	0.635	rs6570932	ENSG00000223701.3	RAET1E-AS1	-3.85	0.000133	0.00998	-0.24	-0.17	Diabetic retinopathy;	chr6:149090197	chr6:149884431~149919508:+
THCA	cis	rs931608	0.64	rs12460715	ENSG00000269138.1	ZNF209P	3.85	0.000133	0.00998	0.25	0.17	Response to statins (LDL cholesterol change);Dental caries;	chr19:22340502	chr19:22463922~22473036:+
THCA	cis	rs7111546	0.515	rs7926598	ENSG00000246225.5	RP11-17A1.3	3.85	0.000133	0.00998	0.32	0.17	Dialysis-related mortality;	chr11:22916855	chr11:22829380~22945393:+
THCA	cis	rs10927875	0.632	rs10927863	ENSG00000179743.3	FLJ37453	-3.85	0.000133	0.00998	-0.12	-0.17	Dilated cardiomyopathy;	chr1:15838752	chr1:15834479~15848147:-
THCA	cis	rs10927875	0.632	rs10927864	ENSG00000179743.3	FLJ37453	-3.85	0.000133	0.00998	-0.12	-0.17	Dilated cardiomyopathy;	chr1:15839166	chr1:15834479~15848147:-
THCA	cis	rs150992	0.711	rs170734	ENSG00000246763.5	RGMB-AS1	3.85	0.000133	0.00998	0.19	0.17	Body mass index;	chr5:98811337	chr5:98769618~98773469:-
THCA	cis	rs17382723	0.887	rs61234509	ENSG00000225521.1	AC005237.4	3.85	0.000133	0.00998	0.22	0.17	Height;	chr2:241090322	chr2:241015599~241064116:-
THCA	cis	rs2442825	0.693	rs2258768	ENSG00000254485.4	RP11-380O24.1	-3.85	0.000133	0.00998	-0.16	-0.17	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9292588~9363303:-
THCA	cis	rs11648785	0.546	rs7198372	ENSG00000222019.6	URAHP	3.85	0.000133	0.00999	0.15	0.17	Tanning;	chr16:90039254	chr16:90039761~90047773:-
THCA	cis	rs7191700	1	rs7191700	ENSG00000263080.1	RP11-485G7.5	3.85	0.000133	0.00999	0.23	0.17	Multiple sclerosis;	chr16:11312946	chr16:11341809~11345211:-
THCA	cis	rs9296095	0.796	rs3846855	ENSG00000197251.3	LINC00336	-3.85	0.000133	0.00999	-0.22	-0.17	Platelet count;	chr6:33588100	chr6:33586106~33593338:-
THCA	cis	rs6847067	0.929	rs6835046	ENSG00000180769.7	WDFY3-AS2	-3.85	0.000133	0.00999	-0.13	-0.17	Oropharynx cancer;	chr4:84833791	chr4:84965682~85011277:+
THCA	cis	rs10954779	0.764	rs2725361	ENSG00000127589.4	TUBBP1	3.85	0.000133	0.00999	0.21	0.17	Intelligence (multi-trait analysis);	chr8:31139810	chr8:30351873~30353518:+
THCA	cis	rs12149695	0.872	rs4787415	ENSG00000259940.2	CTD-3203P2.1	3.85	0.000133	0.00999	0.19	0.17	Gut microbiota (bacterial taxa);	chr16:27239885	chr16:27213308~27214993:-
THCA	cis	rs5769765	0.862	rs9616774	ENSG00000260613.1	RP3-522J7.6	-3.85	0.000133	0.00999	-0.22	-0.17	Schizophrenia;	chr22:49896951	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs8138941	ENSG00000260613.1	RP3-522J7.6	-3.85	0.000133	0.00999	-0.22	-0.17	Schizophrenia;	chr22:49897030	chr22:49832616~49837786:-
THCA	cis	rs912593	0.935	rs12428795	ENSG00000225179.1	LINC00457	3.85	0.000133	0.00999	0.22	0.17	Cancer;	chr13:34477122	chr13:34435450~34640685:-
THCA	cis	rs6724465	1	rs55838820	ENSG00000272644.1	RP11-33O4.1	3.85	0.000133	0.00999	0.29	0.17	Height;	chr2:219082963	chr2:219069354~219069809:-
THCA	cis	rs1908814	0.51	rs57655799	ENSG00000255495.1	AC145124.2	3.85	0.000133	0.00999	0.2	0.17	Neuroticism;	chr8:11924908	chr8:12194467~12196280:+
THCA	cis	rs8105895	0.8	rs62112872	ENSG00000269345.1	VN1R85P	3.85	0.000133	0.00999	0.24	0.17	Body mass index (change over time);	chr19:22009623	chr19:22174766~22175191:-
THCA	cis	rs6500602	0.927	rs7200817	ENSG00000280063.1	RP11-295D4.3	3.85	0.000133	0.00999	0.1	0.17	Schizophrenia;	chr16:4430597	chr16:4346694~4348648:-
THCA	cis	rs7737355	0.947	rs6883034	ENSG00000237714.1	P4HA2-AS1	3.85	0.000133	0.00999	0.25	0.17	Life satisfaction;	chr5:131584722	chr5:132184876~132192808:+
THCA	cis	rs964611	0.938	rs1820494	ENSG00000259488.2	RP11-154J22.1	3.85	0.000133	0.00999	0.16	0.17	Metabolite levels (Pyroglutamine);	chr15:48310977	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs1820491	ENSG00000259488.2	RP11-154J22.1	3.85	0.000133	0.00999	0.16	0.17	Metabolite levels (Pyroglutamine);	chr15:48311245	chr15:48312353~48331856:-
THCA	cis	rs753778	0.629	rs2278447	ENSG00000253210.1	RP11-809O17.1	-3.85	0.000133	0.00999	-0.21	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141196806	chr8:141126044~141129961:-
THCA	cis	rs12906542	0.544	rs35472584	ENSG00000259792.1	RP11-114H24.6	-3.85	0.000133	0.00999	-0.24	-0.17	Breast cancer;	chr15:77974385	chr15:77993405~77995289:+
THCA	cis	rs9911578	0.902	rs12948746	ENSG00000224738.1	AC099850.1	3.85	0.000133	0.00999	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58994531	chr17:59106598~59118267:+
THCA	cis	rs11992162	0.551	rs35010200	ENSG00000254948.1	OR7E158P	3.85	0.000133	0.00999	0.22	0.17	Monocyte count;	chr8:11928146	chr8:11919900~11920809:-
THCA	cis	rs5758511	0.68	rs5758686	ENSG00000230107.1	CTA-126B4.7	-3.85	0.000133	0.00999	-0.21	-0.17	Birth weight;	chr22:42259371	chr22:42438023~42446195:+
THCA	cis	rs8035452	0.929	rs12592161	ENSG00000273674.3	CTD-2378E12.1	3.85	0.000133	0.01	0.23	0.17	Alzheimer's disease (late onset);	chr15:50699212	chr15:50839875~50908599:-
THCA	cis	rs9810089	0.814	rs73226190	ENSG00000273455.1	RP11-305O4.3	3.85	0.000133	0.01	0.23	0.17	Gestational age at birth (child effect);	chr3:136494468	chr3:136087475~136087913:-
THCA	cis	rs7914558	0.966	rs3977751	ENSG00000272912.1	RP11-724N1.1	-3.85	0.000133	0.01	-0.21	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:102914585~102915404:+
THCA	cis	rs4578769	0.879	rs6417086	ENSG00000265939.1	UBE2CP2	3.85	0.000133	0.01	0.22	0.17	Eosinophil percentage of white cells;	chr18:23041751	chr18:22900486~22900995:-
THCA	cis	rs62184315	0.938	rs7563391	ENSG00000253559.1	OSGEPL1-AS1	-3.85	0.000133	0.01	-0.24	-0.17	Alcohol dependence (age at onset);	chr2:189915077	chr2:189762704~189765556:+
THCA	cis	rs16957091	0.647	rs35298309	ENSG00000205771.5	CATSPER2P1	3.85	0.000133	0.01	0.24	0.17	MGMT methylation in smokers;	chr15:42784803	chr15:43726918~43747094:-
THCA	cis	rs7572733	0.555	rs6434954	ENSG00000231621.1	AC013264.2	-3.85	0.000133	0.01	-0.19	-0.17	Dermatomyositis;	chr2:198064992	chr2:197197991~197199273:+
THCA	cis	rs7555523	0.832	rs7524755	ENSG00000224358.1	RP11-466F5.8	-3.85	0.000133	0.01	-0.26	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165725660	chr1:165768929~165775176:+
THCA	cis	rs6929812	0.546	rs2393962	ENSG00000204789.4	ZNF204P	-3.85	0.000133	0.01	-0.14	-0.17	Neuroticism (multi-trait analysis);	chr6:27495045	chr6:27357825~27360221:-
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000184274.3	LINC00315	-3.85	0.000133	0.01	-0.22	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45300245~45305257:-
THCA	cis	rs9660180	0.967	rs10907191	ENSG00000215914.4	MMP23A	-3.85	0.000133	0.01	-0.23	-0.17	Body mass index;	chr1:1843381	chr1:1699942~1701782:+
THCA	cis	rs8053891	0.507	rs34150651	ENSG00000279206.1	RP5-991G20.6	3.85	0.000133	0.01	0.19	0.17	Coronary artery disease;	chr16:71994213	chr16:72772673~72773272:+
THCA	cis	rs35146811	0.7	rs2950520	ENSG00000078319.8	PMS2P1	-3.85	0.000133	0.01	-0.22	-0.17	Coronary artery disease;	chr7:100229525	chr7:100320992~100341908:-
THCA	cis	rs9291683	0.53	rs6449196	ENSG00000250413.1	RP11-448G15.1	3.85	0.000133	0.01	0.17	0.17	Bone mineral density;	chr4:9972036	chr4:10006482~10009725:+
THCA	cis	rs17221829	0.549	rs9666894	ENSG00000280385.1	AP000648.5	-3.85	0.000133	0.01	-0.17	-0.17	Anxiety in major depressive disorder;	chr11:89625191	chr11:90193614~90198120:+
THCA	cis	rs62244186	0.659	rs4682745	ENSG00000214820.3	MPRIPP1	3.85	0.000133	0.01	0.19	0.17	Depressive symptoms;	chr3:44467475	chr3:44579938~44581026:-
THCA	cis	rs7212590	0.581	rs57812342	ENSG00000267302.4	RP11-178C3.2	3.85	0.000133	0.01	0.33	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59749793	chr17:59964832~59996972:+
THCA	cis	rs2904297	1	rs1001158	ENSG00000261490.1	RP11-448G15.3	-3.85	0.000133	0.01	-0.12	-0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11036832	chr4:10068089~10073019:-
THCA	cis	rs1436955	0.712	rs76744825	ENSG00000259251.2	RP11-643M14.1	-3.85	0.000133	0.01	-0.23	-0.17	Type 2 diabetes;	chr15:62097500	chr15:62060503~62062434:+
THCA	cis	rs755249	0.567	rs4660208	ENSG00000182109.6	RP11-69E11.4	3.85	0.000133	0.01	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39522280~39546187:-
THCA	cis	rs28735056	1	rs28735056	ENSG00000261126.6	RP11-795F19.1	-3.85	0.000133	0.01	-0.14	-0.17	Schizophrenia;	chr18:79862879	chr18:80046900~80095482:+
THCA	cis	rs3169166	0.546	rs1519818	ENSG00000259562.2	RP11-762H8.2	-3.85	0.000133	0.01	-0.11	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78249403	chr15:78290527~78291221:-
THCA	cis	rs2898290	0.622	rs4840567	ENSG00000206014.6	OR7E161P	3.85	0.000133	0.01	0.21	0.17	Systolic blood pressure;	chr8:11490116	chr8:11928597~11929563:-
THCA	cis	rs867186	0.698	rs17406518	ENSG00000126005.14	MMP24-AS1	-3.85	0.000133	0.01	-0.28	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35211373	chr20:35216462~35278131:-
THCA	cis	rs9908552	0.72	rs2131431	ENSG00000277491.1	RP11-676J12.9	-3.85	0.000133	0.01	-0.21	-0.17	Schizophrenia;	chr17:1391601	chr17:795306~795794:+
THCA	cis	rs6696239	0.911	rs10916166	ENSG00000227711.2	RP11-275O4.5	-3.85	0.000133	0.01	-0.24	-0.17	Height;	chr1:227569367	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.955	rs10916167	ENSG00000227711.2	RP11-275O4.5	-3.85	0.000133	0.01	-0.24	-0.17	Height;	chr1:227573431	chr1:227509028~227520477:-
THCA	cis	rs3755605	0.728	rs6444895	ENSG00000242578.1	RP11-469J4.3	3.85	0.000133	0.01	0.2	0.17	Testicular germ cell tumor;	chr3:170083870	chr3:170410512~170418615:+
THCA	cis	rs8192917	0.573	rs17257110	ENSG00000258744.1	RP11-80A15.1	-3.85	0.000133	0.01	-0.28	-0.17	Vitiligo;	chr14:24638317	chr14:24501594~24508688:+
THCA	cis	rs397969	0.573	rs203475	ENSG00000261033.1	RP11-209D14.2	-3.85	0.000133	0.01	-0.26	-0.17	Platelet count;	chr17:19947662	chr17:20008051~20009234:-
THCA	cis	rs9309473	1	rs7576245	ENSG00000273245.1	RP11-434P11.2	3.85	0.000133	0.01	0.23	0.17	Metabolite levels;	chr2:73602551	chr2:73750256~73750786:-
THCA	cis	rs1853665	1	rs9383993	ENSG00000218358.2	RAET1K	3.85	0.000133	0.01	0.28	0.17	Radiation response;	chr6:149978163	chr6:149998019~150005157:-
THCA	cis	rs2360027	0.599	rs12128952	ENSG00000231365.4	RP11-418J17.1	-3.85	0.000133	0.01	-0.18	-0.17	Tonsillectomy;	chr1:118565003	chr1:119140396~119275973:+
THCA	cis	rs2836950	0.545	rs11700449	ENSG00000235701.1	PCBP2P1	-3.85	0.000133	0.01	-0.19	-0.17	Menarche (age at onset);	chr21:39150493	chr21:39171130~39172106:-
THCA	cis	rs8031584	0.781	rs4779498	ENSG00000270015.1	RP11-540B6.6	-3.85	0.000133	0.01	-0.13	-0.17	Huntington's disease progression;	chr15:30885273	chr15:30926514~30928407:+
THCA	cis	rs7737355	0.628	rs75544080	ENSG00000237714.1	P4HA2-AS1	-3.85	0.000133	0.01	-0.37	-0.17	Life satisfaction;	chr5:131549822	chr5:132184876~132192808:+
THCA	cis	rs2455799	0.573	rs2470546	ENSG00000270409.1	RP11-44D5.1	-3.85	0.000133	0.01	-0.18	-0.17	Mean platelet volume;	chr3:15692390	chr3:15732252~15733470:+
THCA	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	3.85	0.000133	0.01	0.2	0.17	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
THCA	cis	rs12544026	0.617	rs7828175	ENSG00000253669.3	KB-1732A1.1	3.85	0.000133	0.01	0.2	0.17	Major depression and alcohol dependence;	chr8:101829133	chr8:102805517~102809971:+
THCA	cis	rs2290416	0.892	rs76108894	ENSG00000253931.1	RP11-909N17.2	3.85	0.000133	0.01	0.35	0.17	Attention deficit hyperactivity disorder;	chr8:143591363	chr8:143412749~143417054:+
THCA	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	3.85	0.000133	0.01	0.2	0.17	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
THCA	cis	rs763121	0.889	rs1837988	ENSG00000228274.3	RP3-508I15.9	-3.85	0.000133	0.01	-0.19	-0.17	Menopause (age at onset);	chr22:38505089	chr22:38667585~38681820:-
THCA	cis	rs72627123	1	rs2302138	ENSG00000259065.1	RP5-1021I20.1	-3.85	0.000133	0.01	-0.27	-0.17	Morning vs. evening chronotype;	chr14:73896602	chr14:73787360~73803270:+
THCA	cis	rs7166081	1	rs9806377	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000133	0.01	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67319724	chr15:67541072~67542604:-
THCA	cis	rs2223471	1	rs2223471	ENSG00000060303.5	RPS17P5	-3.85	0.000133	0.01	-0.21	-0.17	Subcutaneous adipose tissue;	chr6:50765935	chr6:50857255~50857662:-
THCA	cis	rs453301	0.653	rs11784393	ENSG00000253981.4	ALG1L13P	3.85	0.000133	0.01	0.16	0.17	Joint mobility (Beighton score);	chr8:9045624	chr8:8236003~8244667:-
THCA	cis	rs17301013	0.932	rs6664764	ENSG00000270084.1	GAS5-AS1	-3.85	0.000133	0.01	-0.18	-0.17	Systemic lupus erythematosus;	chr1:174443402	chr1:173863248~173863941:+
THCA	cis	rs6860806	0.661	rs1588263	ENSG00000263597.1	MIR3936	3.85	0.000133	0.01	0.17	0.17	Breast cancer;	chr5:132241465	chr5:132365490~132365599:-
THCA	cis	rs1510272	0.69	rs62275573	ENSG00000243926.1	TIPARP-AS1	-3.85	0.000134	0.01	-0.19	-0.17	Testicular germ cell tumor;	chr3:156607915	chr3:156671862~156674378:-
THCA	cis	rs7818688	0.614	rs12056808	ENSG00000253528.2	RP11-347C18.4	-3.85	0.000134	0.01	-0.25	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94864640	chr8:94974573~94974853:-
THCA	cis	rs9341808	0.754	rs3805885	ENSG00000260645.1	RP11-250B2.5	-3.85	0.000134	0.01	-0.15	-0.17	Sitting height ratio;	chr6:80287034	chr6:80466958~80469080:+
THCA	cis	rs2028299	0.919	rs7174878	ENSG00000259677.1	RP11-493E3.1	3.85	0.000134	0.01	0.23	0.17	Type 2 diabetes;	chr15:89891656	chr15:89876540~89877285:+
THCA	cis	rs12493885	0.818	rs10935970	ENSG00000243069.6	ARHGEF26-AS1	-3.85	0.000134	0.01	-0.29	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154052448	chr3:154024401~154121332:-
THCA	cis	rs10256972	0.713	rs10435026	ENSG00000199023.2	MIR339	-3.85	0.000134	0.01	-0.18	-0.17	Endometriosis;Longevity;	chr7:1026312	chr7:1022935~1023045:-
THCA	cis	rs2299587	0.521	rs3739406	ENSG00000253671.1	RP11-806O11.1	-3.85	0.000134	0.01	-0.2	-0.17	Economic and political preferences;	chr8:17882029	chr8:17808941~17820868:+
THCA	cis	rs9863	0.828	rs75989601	ENSG00000270028.1	RP11-380L11.4	3.85	0.000134	0.01	0.19	0.17	White blood cell count;	chr12:123982176	chr12:123925461~123926083:-
THCA	cis	rs9863	0.828	rs35099862	ENSG00000270028.1	RP11-380L11.4	3.85	0.000134	0.01	0.19	0.17	White blood cell count;	chr12:123982657	chr12:123925461~123926083:-
THCA	cis	rs13256369	0.802	rs2280560	ENSG00000254153.1	CTA-398F10.2	-3.85	0.000134	0.01	-0.2	-0.17	Obesity-related traits;	chr8:8703092	chr8:8456909~8461337:-
THCA	cis	rs4742903	0.875	rs7037174	ENSG00000270332.1	SMC2-AS1	3.85	0.000134	0.01	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104162590	chr9:104080024~104093073:-
THCA	cis	rs1865760	0.663	rs9348704	ENSG00000272810.1	U91328.22	-3.85	0.000134	0.01	-0.13	-0.17	Height;	chr6:26000165	chr6:26013241~26013757:+
THCA	cis	rs4245128	0.798	rs11214414	ENSG00000247416.2	RP11-629G13.1	3.85	0.000134	0.01	0.16	0.17	Life satisfaction;	chr11:112904101	chr11:112959279~112963460:-
THCA	cis	rs6724465	1	rs13419740	ENSG00000272644.1	RP11-33O4.1	3.85	0.000134	0.01	0.26	0.17	Height;	chr2:219104375	chr2:219069354~219069809:-
THCA	cis	rs763121	0.889	rs1043402	ENSG00000228274.3	RP3-508I15.9	-3.85	0.000134	0.01	-0.19	-0.17	Menopause (age at onset);	chr22:38483683	chr22:38667585~38681820:-
THCA	cis	rs9291683	0.53	rs11723970	ENSG00000250413.1	RP11-448G15.1	-3.85	0.000134	0.01	-0.17	-0.17	Bone mineral density;	chr4:9978838	chr4:10006482~10009725:+
THCA	cis	rs3733585	0.805	rs882222	ENSG00000250413.1	RP11-448G15.1	-3.85	0.000134	0.01	-0.17	-0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9979670	chr4:10006482~10009725:+
THCA	cis	rs2549003	0.966	rs10213701	ENSG00000237714.1	P4HA2-AS1	-3.85	0.000134	0.01	-0.23	-0.17	Asthma (sex interaction);	chr5:132488372	chr5:132184876~132192808:+
THCA	cis	rs2692947	0.637	rs72492201	ENSG00000235584.2	AC008268.1	-3.85	0.000134	0.01	-0.17	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95964453	chr2:95666084~95668715:+
THCA	cis	rs2243480	1	rs709607	ENSG00000164669.11	INTS4P1	-3.85	0.000134	0.01	-0.34	-0.17	Diabetic kidney disease;	chr7:65984554	chr7:65141225~65234216:+
THCA	cis	rs7572733	0.935	rs10198606	ENSG00000231621.1	AC013264.2	3.85	0.000134	0.01	0.16	0.17	Dermatomyositis;	chr2:197905015	chr2:197197991~197199273:+
THCA	cis	rs28829049	0.508	rs4578242	ENSG00000270728.1	RP4-657E11.10	-3.85	0.000134	0.01	-0.13	-0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19065071	chr1:19297080~19297903:+
THCA	cis	rs4245128	0.862	rs1892978	ENSG00000247416.2	RP11-629G13.1	3.85	0.000134	0.01	0.16	0.17	Life satisfaction;	chr11:112925288	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.896	rs2197687	ENSG00000247416.2	RP11-629G13.1	3.85	0.000134	0.01	0.16	0.17	Life satisfaction;	chr11:112925388	chr11:112959279~112963460:-
THCA	cis	rs4879656	0.835	rs13290323	ENSG00000225693.1	LAGE3P1	-3.85	0.000134	0.01	-0.18	-0.17	Menopause (age at onset);	chr9:33062293	chr9:33019682~33020165:-
THCA	cis	rs4660214	0.724	rs7554301	ENSG00000228060.1	RP11-69E11.8	3.85	0.000134	0.01	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177792	chr1:39565160~39573203:+
THCA	cis	rs11073619	0.616	rs2401427	ENSG00000259728.4	LINC00933	-3.85	0.000134	0.01	-0.33	-0.17	Positive affect;	chr15:84402427	chr15:84570649~84580175:+
THCA	cis	rs1404100	0.51	rs1038272	ENSG00000249274.1	PDLIM1P4	3.85	0.000134	0.01	0.18	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067685	chr3:98782188~98783193:+
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000219891.2	ZSCAN12P1	3.85	0.000134	0.01	0.24	0.17	Parkinson's disease;	chr6:28066257	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000219891.2	ZSCAN12P1	3.85	0.000134	0.01	0.24	0.17	Parkinson's disease;	chr6:28066263	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000219891.2	ZSCAN12P1	3.85	0.000134	0.01	0.24	0.17	Parkinson's disease;	chr6:28066343	chr6:28091154~28093664:+
THCA	cis	rs6088580	0.524	rs7274854	ENSG00000126005.14	MMP24-AS1	-3.85	0.000134	0.01	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34640868	chr20:35216462~35278131:-
THCA	cis	rs11601239	0.646	rs1938958	ENSG00000254750.1	CASP1P2	3.85	0.000134	0.01	0.14	0.17	Refractive error;	chr11:105771255	chr11:105063345~105071541:-
THCA	cis	rs11018874	0.532	rs11018867	ENSG00000280367.1	RP11-121L10.2	3.85	0.000134	0.0101	0.21	0.17	White blood cell types;	chr11:90129177	chr11:90223153~90226538:+
THCA	cis	rs7927592	0.83	rs7120635	ENSG00000160172.9	FAM86C2P	3.85	0.000134	0.0101	0.17	0.17	Total body bone mineral density;	chr11:68493825	chr11:67791648~67805336:-
THCA	cis	rs548181	0.611	rs609200	ENSG00000254671.2	STT3A-AS1	3.85	0.000134	0.0101	0.35	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125513912	chr11:125570284~125592568:-
THCA	cis	rs6724465	1	rs17655003	ENSG00000272644.1	RP11-33O4.1	3.85	0.000134	0.0101	0.26	0.17	Height;	chr2:219065759	chr2:219069354~219069809:-
THCA	cis	rs9911578	0.967	rs8182277	ENSG00000224738.1	AC099850.1	3.85	0.000134	0.0101	0.2	0.17	Intelligence (multi-trait analysis);	chr17:59067006	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs6503893	ENSG00000224738.1	AC099850.1	3.85	0.000134	0.0101	0.2	0.17	Intelligence (multi-trait analysis);	chr17:59072334	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.933	rs74370218	ENSG00000224738.1	AC099850.1	-3.85	0.000134	0.0101	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:59017851	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.803	rs8069033	ENSG00000224738.1	AC099850.1	-3.85	0.000134	0.0101	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:59054220	chr17:59106598~59118267:+
THCA	cis	rs7560272	0.588	rs4852965	ENSG00000273245.1	RP11-434P11.2	-3.85	0.000134	0.0101	-0.2	-0.17	Schizophrenia;	chr2:73684042	chr2:73750256~73750786:-
THCA	cis	rs2033711	0.87	rs1465789	ENSG00000232098.3	CTD-2619J13.14	3.85	0.000134	0.0101	0.16	0.17	Uric acid clearance;	chr19:58434689	chr19:58404238~58408484:-
THCA	cis	rs13113518	0.51	rs6858749	ENSG00000273257.1	RP11-177J6.1	3.85	0.000134	0.0101	0.23	0.17	Height;	chr4:55424270	chr4:55387949~55388271:+
THCA	cis	rs13113518	0.51	rs11732723	ENSG00000273257.1	RP11-177J6.1	-3.85	0.000134	0.0101	-0.23	-0.17	Height;	chr4:55424391	chr4:55387949~55388271:+
THCA	cis	rs11673344	0.536	rs62108291	ENSG00000267640.4	CTD-2554C21.2	3.85	0.000134	0.0101	0.13	0.17	Obesity-related traits;	chr19:37659457	chr19:37817359~37826638:+
THCA	cis	rs1635	0.655	rs16893929	ENSG00000216901.1	AL022393.7	3.85	0.000134	0.0101	0.39	0.17	Schizophrenia;	chr6:28303040	chr6:28176188~28176674:+
THCA	cis	rs2474937	0.561	rs1885011	ENSG00000231365.4	RP11-418J17.1	3.85	0.000134	0.0101	0.18	0.17	Congenital heart malformation;	chr1:118380128	chr1:119140396~119275973:+
THCA	cis	rs1862618	0.511	rs2591952	ENSG00000234553.1	AC022431.3	-3.85	0.000134	0.0101	-0.2	-0.17	Initial pursuit acceleration;	chr5:56824942	chr5:56536583~56537826:-
THCA	cis	rs7829975	0.714	rs59046059	ENSG00000233609.3	RP11-62H7.2	3.85	0.000134	0.0101	0.17	0.17	Mood instability;	chr8:8813226	chr8:8961200~8979025:+
THCA	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	3.85	0.000134	0.0101	0.2	0.17	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	3.85	0.000134	0.0101	0.2	0.17	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
THCA	cis	rs786425	0.601	rs7138209	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123672505	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs12822546	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123672700	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7975119	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123673127	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7975233	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123673198	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7978447	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123673533	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7953596	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123673903	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7953599	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123673908	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7963498	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123673955	chr12:123519390~123519856:-
THCA	cis	rs786425	0.74	rs7133543	ENSG00000278112.1	RP11-972P1.11	3.85	0.000134	0.0101	0.17	0.17	Pubertal anthropometrics;	chr12:123674864	chr12:123519390~123519856:-
THCA	cis	rs7737355	0.645	rs184950	ENSG00000237714.1	P4HA2-AS1	3.85	0.000134	0.0101	0.25	0.17	Life satisfaction;	chr5:131517154	chr5:132184876~132192808:+
THCA	cis	rs713587	0.967	rs10182458	ENSG00000224165.4	DNAJC27-AS1	-3.85	0.000134	0.0101	-0.1	-0.17	Body mass index in non-asthmatics;	chr2:24927772	chr2:24971390~25039694:+
THCA	cis	rs8077577	0.895	rs735960	ENSG00000273018.4	CTD-2303H24.2	-3.85	0.000134	0.0101	-0.29	-0.17	Obesity-related traits;	chr17:18153987	chr17:18511221~18551705:-
THCA	cis	rs9427116	0.502	rs9427100	ENSG00000236675.1	MTX1P1	-3.85	0.000134	0.0101	-0.16	-0.17	Blood protein levels;	chr1:154611286	chr1:155230975~155234325:+
THCA	cis	rs2115630	1	rs6496441	ENSG00000275120.1	RP11-182J1.17	-3.85	0.000134	0.0101	-0.18	-0.17	P wave terminal force;	chr15:84820117	chr15:84599434~84606463:-
THCA	cis	rs1790761	0.967	rs7110021	ENSG00000255318.1	RP11-655M14.13	-3.85	0.000134	0.0101	-0.19	-0.17	Mean corpuscular volume;	chr11:67486093	chr11:67618279~67627304:-
THCA	cis	rs867186	1	rs11167254	ENSG00000126005.14	MMP24-AS1	-3.85	0.000134	0.0101	-0.27	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35066781	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs78202808	ENSG00000126005.14	MMP24-AS1	-3.85	0.000134	0.0101	-0.27	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35079621	chr20:35216462~35278131:-
THCA	cis	rs2239815	0.515	rs5762839	ENSG00000272858.1	CTA-292E10.8	-3.85	0.000134	0.0101	-0.23	-0.17	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;	chr22:28835459	chr22:28814914~28815662:+
THCA	cis	rs74233809	1	rs12221064	ENSG00000272912.1	RP11-724N1.1	-3.85	0.000134	0.0101	-0.32	-0.17	Birth weight;	chr10:102917369	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs77602510	ENSG00000272912.1	RP11-724N1.1	-3.85	0.000134	0.0101	-0.32	-0.17	Birth weight;	chr10:102922845	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs78821730	ENSG00000272912.1	RP11-724N1.1	-3.85	0.000134	0.0101	-0.32	-0.17	Birth weight;	chr10:102924787	chr10:102914585~102915404:+
THCA	cis	rs78487399	0.808	rs13414140	ENSG00000234936.1	AC010883.5	3.85	0.000134	0.0101	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43444037	chr2:43229573~43233394:+
THCA	cis	rs7166081	1	rs4776350	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000134	0.0101	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67249841	chr15:67541072~67542604:-
THCA	cis	rs874628	0.703	rs72999449	ENSG00000268650.3	AC068499.10	3.85	0.000134	0.0101	0.21	0.17	Multiple sclerosis;	chr19:18126240	chr19:18204730~18220480:+
THCA	cis	rs6479901	0.557	rs4746125	ENSG00000272767.1	JMJD1C-AS1	3.85	0.000134	0.0101	0.24	0.17	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63465229~63466563:+
THCA	cis	rs758324	0.54	rs31481	ENSG00000237714.1	P4HA2-AS1	3.85	0.000134	0.0101	0.26	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132061509	chr5:132184876~132192808:+
THCA	cis	rs1580019	0.587	rs7804457	ENSG00000273014.1	RP11-225B17.2	3.85	0.000134	0.0101	0.18	0.17	Cognitive ability;	chr7:32518369	chr7:32758882~32759353:+
THCA	cis	rs78944489	0.867	rs28494633	ENSG00000217702.2	RP11-287D1.4	-3.85	0.000134	0.0101	-0.44	-0.17	Schizophrenia;	chr2:73215060	chr2:74130583~74135395:+
THCA	cis	rs720064	0.558	rs7245197	ENSG00000264745.1	TTC39C-AS1	3.85	0.000134	0.0101	0.19	0.17	Strep throat;	chr18:23926339	chr18:23994213~24015339:-
THCA	cis	rs720064	0.586	rs12958287	ENSG00000264745.1	TTC39C-AS1	3.85	0.000134	0.0101	0.19	0.17	Strep throat;	chr18:23927465	chr18:23994213~24015339:-
THCA	cis	rs16944613	0.636	rs6416552	ENSG00000259212.1	CTD-3065B20.2	3.85	0.000134	0.0101	0.26	0.17	Colorectal cancer;	chr15:90588879	chr15:90595840~90596447:-
THCA	cis	rs7615952	0.932	rs13065725	ENSG00000248787.1	RP11-666A20.4	-3.85	0.000134	0.0101	-0.31	-0.17	Blood pressure (smoking interaction);	chr3:125913446	chr3:125908005~125910272:-
THCA	cis	rs17286411	0.671	rs12926987	ENSG00000260185.1	RP11-432I5.6	-3.85	0.000134	0.0101	-0.24	-0.17	Blood protein levels;	chr16:71698892	chr16:71655027~71664212:+
THCA	cis	rs55692468	0.771	rs6744391	ENSG00000213197.3	AC012066.1	-3.85	0.000134	0.0101	-0.23	-0.17	Intraocular pressure;	chr2:152478100	chr2:152389937~152390630:+
THCA	cis	rs61677309	1	rs7110019	ENSG00000278376.1	RP11-158I9.8	3.85	0.000134	0.0101	0.13	0.17	Lung cancer in ever smokers;	chr11:118297902	chr11:118791254~118793137:+
THCA	cis	rs372883	0.6	rs2832291	ENSG00000176054.6	RPL23P2	3.85	0.000134	0.0101	0.16	0.17	Pancreatic cancer;	chr21:29362067	chr21:28997613~28998033:-
THCA	cis	rs711244	0.532	rs4670181	ENSG00000279519.1	RP11-288C18.1	3.85	0.000134	0.0101	0.14	0.17	Mean platelet volume;	chr2:36999760	chr2:36839922~36842539:-
THCA	cis	rs4742903	0.584	rs10217250	ENSG00000270332.1	SMC2-AS1	3.85	0.000134	0.0101	0.17	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104149352	chr9:104080024~104093073:-
THCA	cis	rs250585	0.736	rs250584	ENSG00000260136.4	CTD-2270L9.4	3.85	0.000134	0.0101	0.14	0.17	Egg allergy;	chr16:23391710	chr16:23452758~23457606:+
THCA	cis	rs6840360	0.567	rs6844259	ENSG00000251611.1	RP11-610P16.1	-3.85	0.000134	0.0101	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151370032	chr4:151407551~151408835:-
THCA	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	3.85	0.000134	0.0101	0.2	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
THCA	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-3.85	0.000134	0.0101	-0.2	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
THCA	cis	rs5758511	0.68	rs5758687	ENSG00000270083.1	RP1-257I20.14	-3.85	0.000134	0.0101	-0.23	-0.17	Birth weight;	chr22:42260582	chr22:42089630~42090028:-
THCA	cis	rs1075265	0.935	rs6545384	ENSG00000235937.1	AC008280.1	3.85	0.000134	0.0101	0.2	0.17	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54029552~54030682:-
THCA	cis	rs12073837	0.5	rs11118610	ENSG00000221571.3	RNU6ATAC35P	-3.85	0.000134	0.0101	-0.16	-0.17	F-cell distribution;	chr1:220816744	chr1:220825620~220826063:+
THCA	cis	rs138249	1	rs138209	ENSG00000273253.2	RP3-402G11.26	-3.85	0.000134	0.0101	-0.17	-0.17	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50100984	chr22:50199090~50200837:-
THCA	cis	rs2836974	0.965	rs8134733	ENSG00000255568.3	BRWD1-AS2	3.85	0.000134	0.0101	0.16	0.17	Cognitive function;	chr21:39311533	chr21:39313935~39314962:+
THCA	cis	rs4081724	0.638	rs17529948	ENSG00000267296.2	CEBPA-AS1	3.85	0.000134	0.0101	0.22	0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33354692	chr19:33302857~33305054:+
THCA	cis	rs16944613	0.541	rs13313427	ENSG00000259212.1	CTD-3065B20.2	3.85	0.000134	0.0101	0.27	0.17	Colorectal cancer;	chr15:90547536	chr15:90595840~90596447:-
THCA	cis	rs4883201	0.656	rs10129061	ENSG00000245105.2	A2M-AS1	3.85	0.000134	0.0101	0.17	0.17	Total cholesterol levels;Cholesterol, total;	chr12:8953239	chr12:9065177~9068060:+
THCA	cis	rs11633886	0.546	rs1033167	ENSG00000259200.1	RP11-718O11.1	-3.85	0.000134	0.0101	-0.22	-0.17	Diisocyanate-induced asthma;	chr15:45747340	chr15:45705078~45931069:+
THCA	cis	rs1577917	0.545	rs9294338	ENSG00000220563.1	PKMP3	3.85	0.000134	0.0101	0.12	0.17	Response to antipsychotic treatment;	chr6:85764650	chr6:85659892~85660606:-
THCA	cis	rs2904524	0.737	rs17108097	ENSG00000257815.4	RP11-611E13.2	-3.85	0.000134	0.0101	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70395620	chr12:69904033~70243360:-
THCA	cis	rs4713118	0.699	rs573179	ENSG00000272009.1	RP1-313I6.12	-3.85	0.000134	0.0101	-0.2	-0.17	Parkinson's disease;	chr6:27881898	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.699	rs200978	ENSG00000272009.1	RP1-313I6.12	-3.85	0.000134	0.0101	-0.2	-0.17	Parkinson's disease;	chr6:27885390	chr6:28078792~28081130:-
THCA	cis	rs7572644	0.64	rs11891769	ENSG00000223522.1	AC093690.1	-3.85	0.000134	0.0101	-0.2	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27802713	chr2:28307691~28310459:-
THCA	cis	rs683250	0.6	rs566703	ENSG00000254551.1	RP11-727A23.7	3.85	0.000134	0.0101	0.22	0.17	Subcortical brain region volumes;	chr11:83282141	chr11:83209431~83213379:-
THCA	cis	rs733592	0.507	rs7138917	ENSG00000258273.1	RP11-370I10.4	3.85	0.000134	0.0101	0.21	0.17	Plateletcrit;	chr12:48061472	chr12:48333755~48333901:-
THCA	cis	rs7819412	0.806	rs2898256	ENSG00000261451.1	RP11-981G7.1	-3.85	0.000134	0.0101	-0.22	-0.17	Triglycerides;	chr8:11075185	chr8:10433672~10438312:+
THCA	cis	rs6456156	0.586	rs4710176	ENSG00000235272.1	FAM103A2P	3.85	0.000134	0.0101	0.24	0.17	Primary biliary cholangitis;	chr6:167078151	chr6:166586124~166586477:-
THCA	cis	rs860295	0.651	rs6692183	ENSG00000236675.1	MTX1P1	-3.85	0.000134	0.0101	-0.18	-0.17	Body mass index;	chr1:155334536	chr1:155230975~155234325:+
THCA	cis	rs9307551	0.817	rs1440864	ENSG00000249646.2	OR7E94P	-3.85	0.000134	0.0101	-0.22	-0.17	Refractive error;	chr4:79571830	chr4:79587302~79588130:-
THCA	cis	rs11048434	0.518	rs11048496	ENSG00000256720.1	RP11-436I9.6	-3.85	0.000134	0.0101	-0.19	-0.17	Sjögren's syndrome;	chr12:9019825	chr12:9135084~9135591:+
THCA	cis	rs738144	0.533	rs8140217	ENSG00000235209.1	CTA-150C2.13	3.85	0.000134	0.0101	0.28	0.17	IgG glycosylation;	chr22:38821996	chr22:38921227~38924708:+
THCA	cis	rs1850744	0.623	rs1878277	ENSG00000250942.1	ENPP7P11	3.85	0.000134	0.0101	0.23	0.17	Economic and political preferences;	chr4:9823519	chr4:9677308~9677934:+
THCA	cis	rs7166081	1	rs7166081	ENSG00000270964.1	RP11-502I4.3	3.85	0.000134	0.0101	0.16	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67199963	chr15:67541072~67542604:-
THCA	cis	rs12134133	1	rs6660557	ENSG00000237074.1	RP11-6J21.2	3.85	0.000134	0.0101	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs7521457	ENSG00000237074.1	RP11-6J21.2	3.85	0.000134	0.0101	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs7553157	ENSG00000237074.1	RP11-6J21.2	3.85	0.000134	0.0101	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207249067~207309121:+
THCA	cis	rs12134133	1	rs7553339	ENSG00000237074.1	RP11-6J21.2	3.85	0.000134	0.0101	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207249067~207309121:+
THCA	cis	rs7572733	0.935	rs2060489	ENSG00000231621.1	AC013264.2	-3.85	0.000134	0.0101	-0.16	-0.17	Dermatomyositis;	chr2:197887562	chr2:197197991~197199273:+
THCA	cis	rs2980439	0.556	rs2921059	ENSG00000253981.4	ALG1L13P	3.85	0.000134	0.0101	0.17	0.17	Neuroticism;	chr8:8460377	chr8:8236003~8244667:-
THCA	cis	rs1019173	0.966	rs17557000	ENSG00000261455.1	LINC01003	-3.85	0.000134	0.0101	-0.17	-0.17	Kidney function decline traits;	chr7:152010808	chr7:152463786~152465549:+
THCA	cis	rs9494145	0.638	rs6569992	ENSG00000232876.1	CTA-212D2.2	-3.85	0.000134	0.0101	-0.27	-0.17	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135131014	chr6:135055033~135060550:+
THCA	cis	rs10435719	0.744	rs11250175	ENSG00000255495.1	AC145124.2	3.85	0.000134	0.0101	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.516	rs13252853	ENSG00000255495.1	AC145124.2	3.85	0.000134	0.0101	0.2	0.17	Neuroticism;	chr8:11935465	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.516	rs13252854	ENSG00000255495.1	AC145124.2	3.85	0.000134	0.0101	0.2	0.17	Neuroticism;	chr8:11935469	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.516	rs13279577	ENSG00000255495.1	AC145124.2	3.85	0.000134	0.0101	0.2	0.17	Neuroticism;	chr8:11935587	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.516	rs10112958	ENSG00000255495.1	AC145124.2	3.85	0.000134	0.0101	0.2	0.17	Neuroticism;	chr8:11935631	chr8:12194467~12196280:+
THCA	cis	rs700651	0.685	rs976180	ENSG00000231621.1	AC013264.2	3.85	0.000135	0.0101	0.19	0.17	Intracranial aneurysm;	chr2:198015719	chr2:197197991~197199273:+
THCA	cis	rs964611	0.622	rs12593807	ENSG00000259488.2	RP11-154J22.1	-3.85	0.000135	0.0101	-0.17	-0.17	Metabolite levels (Pyroglutamine);	chr15:48254530	chr15:48312353~48331856:-
THCA	cis	rs9693857	0.52	rs6997629	ENSG00000248538.5	RP11-10A14.5	-3.85	0.000135	0.0101	-0.24	-0.17	Systolic blood pressure;	chr8:9496355	chr8:9189011~9202854:+
THCA	cis	rs4792901	0.625	rs112302569	ENSG00000279602.1	CTD-3014M21.1	-3.85	0.000135	0.0101	-0.23	-0.17	Dupuytren's disease;	chr17:43459623	chr17:43360041~43361361:-
THCA	cis	rs4713118	0.615	rs9348772	ENSG00000216915.2	RP1-97D16.1	-3.85	0.000135	0.0101	-0.23	-0.17	Parkinson's disease;	chr6:27688311	chr6:27737000~27738494:-
THCA	cis	rs11992162	0.905	rs7836953	ENSG00000255046.1	RP11-297N6.4	-3.85	0.000135	0.0101	-0.18	-0.17	Monocyte count;	chr8:11978203	chr8:11797928~11802568:-
THCA	cis	rs67478160	0.704	rs12894254	ENSG00000258534.1	CTD-2134A5.4	-3.85	0.000135	0.0101	-0.17	-0.17	Schizophrenia;	chr14:103824612	chr14:103854366~103880111:-
THCA	cis	rs3758911	0.828	rs10890701	ENSG00000255353.1	RP11-382M14.1	-3.85	0.000135	0.0101	-0.23	-0.17	Coronary artery disease;	chr11:107309216	chr11:107176286~107177530:+
THCA	cis	rs5758511	0.633	rs5758690	ENSG00000230107.1	CTA-126B4.7	-3.85	0.000135	0.0101	-0.21	-0.17	Birth weight;	chr22:42272289	chr22:42438023~42446195:+
THCA	cis	rs1799922	0.708	rs339046	ENSG00000273270.1	RP11-212P7.2	-3.85	0.000135	0.0101	-0.19	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128750509	chr7:128524016~128531069:-
THCA	cis	rs7182948	0.958	rs28669217	ENSG00000259531.2	RP11-295H24.3	3.85	0.000135	0.0101	0.23	0.17	Lung adenocarcinoma;	chr15:49487591	chr15:49365124~49366685:-
THCA	cis	rs879500	0.961	rs57670954	ENSG00000227279.1	AC015933.2	3.85	0.000135	0.0101	0.2	0.17	Lung function (FVC);	chr18:28525243	chr18:27954519~27963687:+
THCA	cis	rs12476592	0.602	rs4671508	ENSG00000242412.1	DBIL5P2	3.85	0.000135	0.0101	0.23	0.17	Childhood ear infection;	chr2:63427006	chr2:63117851~63119542:-
THCA	cis	rs17345786	0.52	rs1476123	ENSG00000256628.3	ZBTB11-AS1	3.85	0.000135	0.0101	0.19	0.17	Colonoscopy-negative controls vs population controls;	chr3:101594569	chr3:101676475~101679217:+
THCA	cis	rs2732480	0.5	rs1552550	ENSG00000257735.1	RP11-370I10.6	3.85	0.000135	0.0101	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.5	rs2450991	ENSG00000257735.1	RP11-370I10.6	3.85	0.000135	0.0101	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48350945~48442411:+
THCA	cis	rs7829975	0.714	rs6994038	ENSG00000254340.1	RP11-10A14.3	3.85	0.000135	0.0101	0.19	0.17	Mood instability;	chr8:8803028	chr8:9141424~9145435:+
THCA	cis	rs420259	0.516	rs717998	ENSG00000260136.4	CTD-2270L9.4	-3.85	0.000135	0.0101	-0.13	-0.17	Bipolar disorder;	chr16:23549450	chr16:23452758~23457606:+
THCA	cis	rs4144027	0.935	rs8008020	ENSG00000269940.1	RP11-73M18.7	-3.85	0.000135	0.0101	-0.17	-0.17	Blood metabolite levels;	chr14:103889546	chr14:103694560~103695170:+
THCA	cis	rs7616559	0.584	rs11719102	ENSG00000240875.4	LINC00886	-3.85	0.000135	0.0101	-0.14	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157068755	chr3:156747346~156817062:-
THCA	cis	rs1959947	0.837	rs72676042	ENSG00000251363.2	RP11-129M6.1	-3.85	0.000135	0.0101	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41047068	chr14:40954898~40975877:+
THCA	cis	rs2625529	0.761	rs8028532	ENSG00000260037.4	CTD-2524L6.3	-3.85	0.000135	0.0101	-0.24	-0.17	Red blood cell count;	chr15:72055713	chr15:71818396~71823384:+
THCA	cis	rs74233809	1	rs35125602	ENSG00000272912.1	RP11-724N1.1	-3.85	0.000135	0.0101	-0.32	-0.17	Birth weight;	chr10:102896282	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs11191453	ENSG00000272912.1	RP11-724N1.1	-3.85	0.000135	0.0101	-0.32	-0.17	Birth weight;	chr10:102900095	chr10:102914585~102915404:+
THCA	cis	rs3813567	0.759	rs12148319	ENSG00000261143.1	ADAMTS7P3	-3.85	0.000135	0.0101	-0.26	-0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78663850	chr15:77976042~77993057:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000232546.1	RP11-458F8.1	3.85	0.000135	0.0101	0.14	0.17	Aortic root size;	chr7:66682114	chr7:66848496~66858136:+
THCA	cis	rs758324	0.716	rs27348	ENSG00000237714.1	P4HA2-AS1	-3.85	0.000135	0.0101	-0.25	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132071446	chr5:132184876~132192808:+
THCA	cis	rs9450351	0.744	rs76569085	ENSG00000203875.9	SNHG5	-3.85	0.000135	0.0101	-0.4	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85971523	chr6:85660950~85678736:-
THCA	cis	rs2288884	0.505	rs2278414	ENSG00000260160.1	CTC-471J1.2	-3.85	0.000135	0.0101	-0.21	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964569	chr19:52058490~52063703:-
THCA	cis	rs10254284	0.921	rs2391591	ENSG00000234336.5	JAZF1-AS1	3.85	0.000135	0.0101	0.18	0.17	Systemic lupus erythematosus;Lymphocyte percentage of white cells;	chr7:28118045	chr7:28180322~28243917:+
THCA	cis	rs5758511	0.68	rs5758652	ENSG00000230107.1	CTA-126B4.7	-3.85	0.000135	0.0101	-0.22	-0.17	Birth weight;	chr22:42216402	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.68	rs1033460	ENSG00000230107.1	CTA-126B4.7	-3.85	0.000135	0.0101	-0.22	-0.17	Birth weight;	chr22:42223302	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.679	rs55867855	ENSG00000230107.1	CTA-126B4.7	-3.85	0.000135	0.0101	-0.22	-0.17	Birth weight;	chr22:42227252	chr22:42438023~42446195:+
THCA	cis	rs9611565	0.512	rs4822052	ENSG00000237037.8	NDUFA6-AS1	3.85	0.000135	0.0101	0.16	0.17	Vitiligo;	chr22:41797737	chr22:42090931~42137742:+
THCA	cis	rs2455799	0.533	rs2470513	ENSG00000270409.1	RP11-44D5.1	-3.85	0.000135	0.0101	-0.18	-0.17	Mean platelet volume;	chr3:15708549	chr3:15732252~15733470:+
THCA	cis	rs440932	0.717	rs330944	ENSG00000248538.5	RP11-10A14.5	-3.85	0.000135	0.0101	-0.22	-0.17	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:9189011~9202854:+
THCA	cis	rs7849973	1	rs7849973	ENSG00000234840.1	LINC01239	3.85	0.000135	0.0101	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22819577	chr9:22646200~22824213:+
THCA	cis	rs6088580	0.524	rs6142210	ENSG00000126005.14	MMP24-AS1	3.85	0.000135	0.0101	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34635208	chr20:35216462~35278131:-
THCA	cis	rs2657294	0.861	rs6480769	ENSG00000226051.5	ZNF503-AS1	-3.85	0.000135	0.0101	-0.25	-0.17	Pneumonia;	chr10:75091745	chr10:75269819~75373500:+
THCA	cis	rs7089973	0.604	rs11196942	ENSG00000228169.3	PPIAP19	3.85	0.000135	0.0101	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114837113	chr10:114690143~114690634:-
THCA	cis	rs599083	0.53	rs491347	ENSG00000212093.1	AP000807.1	-3.85	0.000135	0.0101	-0.19	-0.17	Bone mineral density (spine);	chr11:68402220	chr11:68506083~68506166:-
THCA	cis	rs6137726	0.524	rs1203922	ENSG00000237396.1	LINC01384	3.85	0.000135	0.0101	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22605062	chr20:22587522~22607517:-
THCA	cis	rs56309584	0.715	rs74506939	ENSG00000271002.1	RP11-599B13.8	-3.85	0.000135	0.0101	-0.27	-0.17	Initial pursuit acceleration;	chr17:8236145	chr17:8199123~8199437:-
THCA	cis	rs3781264	0.848	rs10509670	ENSG00000273450.1	RP11-76P2.4	-3.85	0.000135	0.0101	-0.21	-0.17	Esophageal cancer and gastric cancer;	chr10:94308190	chr10:94314907~94315327:-
THCA	cis	rs10266483	0.739	rs55747800	ENSG00000234338.1	RP11-797H7.1	-3.85	0.000135	0.0101	-0.14	-0.17	Response to statin therapy;	chr7:64410105	chr7:64835280~64836882:-
THCA	cis	rs748404	0.518	rs2176870	ENSG00000166763.7	STRCP1	-3.85	0.000135	0.0101	-0.2	-0.17	Lung cancer;	chr15:43144212	chr15:43699488~43718184:-
THCA	cis	rs6001482	0.702	rs5757581	ENSG00000272779.1	LL22NC03-80A10.6	3.85	0.000135	0.0101	0.19	0.17	Diastolic blood pressure;	chr22:22234220	chr22:22303224~22310401:+
THCA	cis	rs877529	1	rs139404	ENSG00000279833.1	RP4-742C19.13	-3.85	0.000135	0.0101	-0.12	-0.17	Multiple myeloma;	chr22:39151196	chr22:39133090~39136760:+
THCA	cis	rs17772222	0.696	rs28666030	ENSG00000222990.1	RNU4-22P	3.85	0.000135	0.0101	0.22	0.17	Coronary artery calcification;	chr14:88511463	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.74	rs28493481	ENSG00000222990.1	RNU4-22P	3.85	0.000135	0.0101	0.22	0.17	Coronary artery calcification;	chr14:88511491	chr14:88513498~88513663:+
THCA	cis	rs3748682	0.861	rs12563037	ENSG00000252448.1	SNORA63	3.85	0.000135	0.0101	0.22	0.17	Hypothyroidism;	chr1:37792972	chr1:37884237~37884317:+
THCA	cis	rs950169	0.922	rs12910334	ENSG00000275120.1	RP11-182J1.17	3.85	0.000135	0.0101	0.21	0.17	Schizophrenia;	chr15:84403620	chr15:84599434~84606463:-
THCA	cis	rs6696239	0.911	rs7538206	ENSG00000227711.2	RP11-275O4.5	-3.85	0.000135	0.0101	-0.24	-0.17	Height;	chr1:227689081	chr1:227509028~227520477:-
THCA	cis	rs2033711	0.87	rs4801583	ENSG00000269867.1	CTD-2583A14.8	-3.85	0.000135	0.0101	-0.14	-0.17	Uric acid clearance;	chr19:58407038	chr19:57867038~57868172:-
THCA	cis	rs1993293	0.636	rs2924776	ENSG00000254744.3	CTD-3076O17.1	3.85	0.000135	0.0101	0.2	0.17	Coronary artery calcification;	chr15:99755973	chr15:99970215~99974010:+
THCA	cis	rs12612619	0.732	rs920433	ENSG00000272148.1	RP11-195B17.1	3.85	0.000135	0.0101	0.16	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989658	chr2:27062428~27062907:-
THCA	cis	rs2337406	0.714	rs2337463	ENSG00000211974.3	IGHV2-70	-3.85	0.000135	0.0101	-0.17	-0.17	Alzheimer's disease (late onset);	chr14:106816066	chr14:106723574~106724093:-
THCA	cis	rs6121246	0.908	rs17093657	ENSG00000230613.1	HM13-AS1	3.85	0.000135	0.0101	0.19	0.17	Mean corpuscular hemoglobin;	chr20:31841091	chr20:31567707~31573263:-
THCA	cis	rs6121246	0.954	rs6060992	ENSG00000230613.1	HM13-AS1	3.85	0.000135	0.0101	0.19	0.17	Mean corpuscular hemoglobin;	chr20:31843452	chr20:31567707~31573263:-
THCA	cis	rs4906332	1	rs3783398	ENSG00000252469.1	RNU7-160P	-3.85	0.000135	0.0101	-0.19	-0.17	Coronary artery disease;	chr14:103483041	chr14:103550345~103550406:+
THCA	cis	rs8001976	0.517	rs7982622	ENSG00000227848.1	SUCLA2-AS1	-3.85	0.000135	0.0101	-0.16	-0.17	Aging (time to event);	chr13:47699622	chr13:48001389~48002552:+
THCA	cis	rs7772486	0.79	rs7753696	ENSG00000270638.1	RP3-466P17.1	-3.85	0.000135	0.0101	-0.14	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145735570~145737218:+
THCA	cis	rs7572644	0.766	rs12165240	ENSG00000223522.1	AC093690.1	3.85	0.000135	0.0101	0.23	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27949258	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.766	rs7587180	ENSG00000223522.1	AC093690.1	3.85	0.000135	0.0101	0.23	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27953242	chr2:28307691~28310459:-
THCA	cis	rs7089973	0.585	rs7907837	ENSG00000228169.3	PPIAP19	3.85	0.000135	0.0101	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114850931	chr10:114690143~114690634:-
THCA	cis	rs7089973	0.584	rs7908665	ENSG00000228169.3	PPIAP19	3.85	0.000135	0.0101	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114851578	chr10:114690143~114690634:-
THCA	cis	rs1005277	0.579	rs1780133	ENSG00000120555.12	SEPT7P9	3.85	0.000135	0.0101	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38383069~38402916:-
THCA	cis	rs12149074	0.933	rs1382387	ENSG00000260876.4	LINC01229	3.85	0.000135	0.0101	0.17	0.17	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80072464	chr16:79676108~79807922:+
THCA	cis	rs10496034	0.618	rs10170283	ENSG00000237887.1	AC092839.1	-3.85	0.000135	0.0101	-0.35	-0.17	Refractive astigmatism;	chr2:54729429	chr2:54529343~54529801:+
THCA	cis	rs14027	0.921	rs3812463	ENSG00000245330.4	KB-1471A8.1	3.85	0.000135	0.0101	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119867419~119874488:-
THCA	cis	rs1389724	0.648	rs1160414	ENSG00000259834.1	RP11-284N8.3	3.85	0.000135	0.0101	0.15	0.17	Schizophrenia;	chr1:110772939	chr1:110653560~110657040:-
THCA	cis	rs9868809	0.881	rs6773261	ENSG00000270441.1	RP11-694I15.7	3.85	0.000135	0.0101	0.23	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48637631	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.881	rs13096357	ENSG00000270441.1	RP11-694I15.7	3.85	0.000135	0.0101	0.23	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48638423	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.881	rs13076269	ENSG00000270441.1	RP11-694I15.7	3.85	0.000135	0.0101	0.23	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48638492	chr3:49140086~49160851:-
THCA	cis	rs12410462	0.688	rs35582095	ENSG00000227711.2	RP11-275O4.5	-3.85	0.000135	0.0101	-0.22	-0.17	Major depressive disorder;	chr1:227771505	chr1:227509028~227520477:-
THCA	cis	rs2625529	0.761	rs16956444	ENSG00000260037.4	CTD-2524L6.3	-3.85	0.000135	0.0101	-0.24	-0.17	Red blood cell count;	chr15:71978894	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.816	rs8025504	ENSG00000260037.4	CTD-2524L6.3	-3.85	0.000135	0.0101	-0.24	-0.17	Red blood cell count;	chr15:72002416	chr15:71818396~71823384:+
THCA	cis	rs7826238	0.653	rs2979202	ENSG00000254153.1	CTA-398F10.2	-3.85	0.000135	0.0101	-0.2	-0.17	Systolic blood pressure;	chr8:8486617	chr8:8456909~8461337:-
THCA	cis	rs9911578	0.967	rs11079368	ENSG00000224738.1	AC099850.1	-3.85	0.000135	0.0101	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:59009112	chr17:59106598~59118267:+
THCA	cis	rs9650657	0.812	rs10089615	ENSG00000255310.2	AF131215.2	-3.85	0.000135	0.0101	-0.15	-0.17	Neuroticism;	chr8:10776622	chr8:11107788~11109726:-
THCA	cis	rs10540	0.908	rs35608427	ENSG00000279672.1	CMB9-55F22.1	3.85	0.000135	0.0101	0.34	0.17	Body mass index;	chr11:498976	chr11:779617~780755:+
THCA	cis	rs13168506	0.552	rs889010	ENSG00000271824.1	AC009014.3	-3.85	0.000135	0.0101	-0.18	-0.17	Stroke;	chr5:136237222	chr5:136191468~136193134:-
THCA	cis	rs765787	0.53	rs28526629	ENSG00000259932.1	CTD-2651B20.7	3.85	0.000135	0.0101	0.21	0.17	Uric acid levels;	chr15:45248264	chr15:45198517~45199139:-
THCA	cis	rs6724465	0.636	rs72951773	ENSG00000272644.1	RP11-33O4.1	3.85	0.000135	0.0101	0.25	0.17	Height;	chr2:219126435	chr2:219069354~219069809:-
THCA	cis	rs4356203	0.87	rs1979603	ENSG00000272034.1	SNORD14A	-3.85	0.000135	0.0101	-0.18	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17261839	chr11:17074654~17074744:-
THCA	cis	rs56318008	0.773	rs2268179	ENSG00000228397.1	RP1-224A6.3	-3.85	0.000135	0.0101	-0.31	-0.17	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22088292	chr1:22023994~22024968:-
THCA	cis	rs11219769	0.729	rs4337053	ENSG00000255045.1	RP11-677M14.2	-3.85	0.000135	0.0101	-0.18	-0.17	Blood protein levels;	chr11:124732967	chr11:124744634~124746337:-
THCA	cis	rs448720	1	rs7162089	ENSG00000260657.2	RP11-315D16.4	3.85	0.000135	0.0101	0.22	0.17	Cognitive performance;	chr15:67914114	chr15:68267792~68277994:-
THCA	cis	rs448720	1	rs8025791	ENSG00000260657.2	RP11-315D16.4	3.85	0.000135	0.0101	0.22	0.17	Cognitive performance;	chr15:67917807	chr15:68267792~68277994:-
THCA	cis	rs721917	0.506	rs2819097	ENSG00000244733.5	RP11-506M13.3	-3.85	0.000135	0.0101	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79660891~79677996:+
THCA	cis	rs793571	0.523	rs7163162	ENSG00000245975.2	RP11-30K9.6	3.85	0.000135	0.0101	0.16	0.17	Schizophrenia;	chr15:58691389	chr15:58768072~58770974:-
THCA	cis	rs9911578	0.967	rs12603238	ENSG00000224738.1	AC099850.1	-3.85	0.000135	0.0101	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:59053424	chr17:59106598~59118267:+
THCA	cis	rs7264396	0.887	rs224392	ENSG00000088340.14	FER1L4	3.85	0.000135	0.0101	0.16	0.17	Total cholesterol levels;	chr20:35520128	chr20:35558737~35607562:-
THCA	cis	rs293748	0.771	rs167146	ENSG00000250155.1	CTD-2353F22.1	-3.85	0.000135	0.0101	-0.23	-0.17	Obesity-related traits;	chr5:36922204	chr5:36666214~36725195:-
THCA	cis	rs7914558	1	rs12255047	ENSG00000213061.2	PFN1P11	3.85	0.000135	0.0101	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103000995	chr10:102838011~102845473:-
THCA	cis	rs10090774	0.93	rs6982216	ENSG00000280303.2	ERICD	-3.85	0.000135	0.0101	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140838142	chr8:140636281~140638283:+
THCA	cis	rs13098911	0.54	rs71327009	ENSG00000226074.4	PRSS44	-3.85	0.000135	0.0101	-0.34	-0.17	Celiac disease;	chr3:46023134	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs35161099	ENSG00000226074.4	PRSS44	-3.85	0.000135	0.0101	-0.34	-0.17	Celiac disease;	chr3:46026015	chr3:46809359~46812558:-
THCA	cis	rs4268898	0.76	rs4665675	ENSG00000242628.4	AC009228.1	3.85	0.000135	0.0101	0.2	0.17	Asthma;	chr2:24245263	chr2:24214381~24221516:+
THCA	cis	rs2732480	0.538	rs1387260	ENSG00000257735.1	RP11-370I10.6	3.85	0.000135	0.0101	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48350945~48442411:+
THCA	cis	rs2562456	0.917	rs2681389	ENSG00000268278.1	RP11-420K14.1	-3.85	0.000135	0.0102	-0.21	-0.17	Pain;	chr19:21509773	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.917	rs6511256	ENSG00000268278.1	RP11-420K14.1	-3.85	0.000135	0.0102	-0.21	-0.17	Pain;	chr19:21510513	chr19:21637974~21656300:+
THCA	cis	rs854765	0.583	rs9912895	ENSG00000281749.1	Y_RNA	-3.85	0.000135	0.0102	-0.22	-0.17	Total body bone mineral density;	chr17:17922706	chr17:18001101~18001195:-
THCA	cis	rs2676071	0.767	rs2670942	ENSG00000259721.1	RP11-758N13.1	-3.85	0.000135	0.0102	-0.21	-0.17	Periodontitis (Mean PAL);	chr15:33312126	chr15:32717270~32719007:-
THCA	cis	rs9291683	0.595	rs13150928	ENSG00000250413.1	RP11-448G15.1	-3.85	0.000135	0.0102	-0.17	-0.17	Bone mineral density;	chr4:10051337	chr4:10006482~10009725:+
THCA	cis	rs11065706	0.699	rs11065612	ENSG00000278993.1	RP3-424M6.4	3.85	0.000135	0.0102	0.27	0.17	Heart rate;	chr12:110270728	chr12:110501614~110503441:+
THCA	cis	rs8024893	1	rs7180114	ENSG00000215302.7	CTD-3092A11.1	3.85	0.000135	0.0102	0.26	0.17	Red cell distribution width;	chr15:31247976	chr15:30470779~30507623:+
THCA	cis	rs13272623	0.502	rs268562	ENSG00000246366.5	RP11-382J12.1	-3.85	0.000135	0.0102	-0.21	-0.17	IgG glycosylation;	chr8:70582545	chr8:70608577~70663279:+
THCA	cis	rs12681366	0.881	rs12682038	ENSG00000261437.1	RP11-22C11.2	3.85	0.000135	0.0102	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94393252	chr8:94637285~94639467:-
THCA	cis	rs250585	0.736	rs250581	ENSG00000260136.4	CTD-2270L9.4	3.85	0.000135	0.0102	0.13	0.17	Egg allergy;	chr16:23400516	chr16:23452758~23457606:+
THCA	cis	rs1005277	0.505	rs200939	ENSG00000120555.12	SEPT7P9	3.85	0.000136	0.0102	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38383069~38402916:-
THCA	cis	rs13098911	0.54	rs71327025	ENSG00000226074.4	PRSS44	-3.85	0.000136	0.0102	-0.34	-0.17	Celiac disease;	chr3:46106012	chr3:46809359~46812558:-
THCA	cis	rs7267979	0.773	rs6132821	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000136	0.0102	-0.2	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.844	rs1555330	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000136	0.0102	-0.2	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.844	rs6107017	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000136	0.0102	-0.2	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.844	rs6132824	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000136	0.0102	-0.2	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25845497~25845862:+
THCA	cis	rs7914558	1	rs3740387	ENSG00000272912.1	RP11-724N1.1	-3.85	0.000136	0.0102	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:102914585~102915404:+
THCA	cis	rs2128382	0.556	rs34983967	ENSG00000253720.1	RP11-473O4.3	-3.85	0.000136	0.0102	-0.26	-0.17	Colorectal cancer;	chr8:129842824	chr8:129939856~129949394:+
THCA	cis	rs2434529	1	rs17552639	ENSG00000245275.6	SAP30L-AS1	-3.85	0.000136	0.0102	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr5:154271899	chr5:154329437~154445850:-
THCA	cis	rs7819412	0.715	rs2409727	ENSG00000255046.1	RP11-297N6.4	3.85	0.000136	0.0102	0.19	0.17	Triglycerides;	chr8:11185727	chr8:11797928~11802568:-
THCA	cis	rs4965006	1	rs4965006	ENSG00000273568.1	RP11-417L19.6	3.85	0.000136	0.0102	0.28	0.17	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934988	chr12:131934642~131934928:+
THCA	cis	rs448720	1	rs7163687	ENSG00000260657.2	RP11-315D16.4	3.85	0.000136	0.0102	0.21	0.17	Cognitive performance;	chr15:67901611	chr15:68267792~68277994:-
THCA	cis	rs12073359	0.509	rs66649150	ENSG00000253047.1	SNORA40	-3.85	0.000136	0.0102	-0.29	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150204998	chr1:150600539~150600659:-
THCA	cis	rs12073359	0.509	rs67880399	ENSG00000253047.1	SNORA40	-3.85	0.000136	0.0102	-0.29	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150211804	chr1:150600539~150600659:-
THCA	cis	rs7711186	0.786	rs4079112	ENSG00000252464.1	RN7SKP70	3.85	0.000136	0.0102	0.19	0.17	Urate levels in obese individuals;	chr5:178645501	chr5:178619728~178619998:-
THCA	cis	rs7711186	0.786	rs4301240	ENSG00000252464.1	RN7SKP70	3.85	0.000136	0.0102	0.19	0.17	Urate levels in obese individuals;	chr5:178645662	chr5:178619728~178619998:-
THCA	cis	rs10984970	0.59	rs62577998	ENSG00000226752.6	PSMD5-AS1	3.85	0.000136	0.0102	0.45	0.17	Lung cancer;	chr9:120535807	chr9:120824828~120854385:+
THCA	cis	rs72759215	1	rs72759215	ENSG00000272308.1	RP11-231G3.1	-3.85	0.000136	0.0102	-0.17	-0.17	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60866457~60866935:-
THCA	cis	rs9650657	0.571	rs4240673	ENSG00000269899.1	RP11-589N15.2	3.85	0.000136	0.0102	0.19	0.17	Neuroticism;	chr8:10930102	chr8:11846154~11846391:-
THCA	cis	rs7616559	0.586	rs28564228	ENSG00000244515.1	KRT18P34	-3.85	0.000136	0.0102	-0.2	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157022281	chr3:157162663~157163932:-
THCA	cis	rs965513	0.524	rs1443432	ENSG00000214417.4	KRT18P13	-3.85	0.000136	0.0102	-0.16	-0.17	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97820913	chr9:97698922~97700734:+
THCA	cis	rs74233809	1	rs11191454	ENSG00000272912.1	RP11-724N1.1	-3.85	0.000136	0.0102	-0.32	-0.17	Birth weight;	chr10:102900247	chr10:102914585~102915404:+
THCA	cis	rs881375	0.715	rs7858209	ENSG00000238181.2	AHCYP2	-3.85	0.000136	0.0102	-0.21	-0.17	Rheumatoid arthritis;	chr9:120883482	chr9:120720673~120721972:+
THCA	cis	rs881375	0.715	rs10760119	ENSG00000238181.2	AHCYP2	-3.85	0.000136	0.0102	-0.21	-0.17	Rheumatoid arthritis;	chr9:120883782	chr9:120720673~120721972:+
THCA	cis	rs7111546	0.565	rs4565895	ENSG00000246225.5	RP11-17A1.3	3.85	0.000136	0.0102	0.3	0.17	Dialysis-related mortality;	chr11:22936935	chr11:22829380~22945393:+
THCA	cis	rs7267979	0.932	rs449370	ENSG00000276952.1	RP5-965G21.6	-3.85	0.000136	0.0102	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25284915~25285588:-
THCA	cis	rs17286411	0.671	rs9925228	ENSG00000260185.1	RP11-432I5.6	-3.85	0.000136	0.0102	-0.24	-0.17	Blood protein levels;	chr16:71725461	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs918721	ENSG00000260185.1	RP11-432I5.6	-3.85	0.000136	0.0102	-0.24	-0.17	Blood protein levels;	chr16:71726708	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs1392487	ENSG00000260185.1	RP11-432I5.6	-3.85	0.000136	0.0102	-0.24	-0.17	Blood protein levels;	chr16:71727085	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.705	rs9921270	ENSG00000260185.1	RP11-432I5.6	-3.85	0.000136	0.0102	-0.24	-0.17	Blood protein levels;	chr16:71727158	chr16:71655027~71664212:+
THCA	cis	rs13178541	0.577	rs11748103	ENSG00000250378.1	RP11-119J18.1	-3.85	0.000136	0.0102	-0.2	-0.17	IgG glycosylation;	chr5:135789066	chr5:135812667~135826582:+
THCA	cis	rs1062753	0.731	rs11090065	ENSG00000273366.1	CTA-989H11.1	3.85	0.000136	0.0102	0.22	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41988167	chr22:42278188~42278846:+
THCA	cis	rs9309473	0.95	rs10207264	ENSG00000273245.1	RP11-434P11.2	3.85	0.000136	0.0102	0.24	0.17	Metabolite levels;	chr2:73486970	chr2:73750256~73750786:-
THCA	cis	rs2692947	0.537	rs12471472	ENSG00000168992.4	OR7E102P	3.85	0.000136	0.0102	0.22	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95539707	chr2:95546531~95547545:+
THCA	cis	rs61160187	0.582	rs56025209	ENSG00000272308.1	RP11-231G3.1	-3.85	0.000136	0.0102	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs2049579	ENSG00000272308.1	RP11-231G3.1	-3.85	0.000136	0.0102	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60866457~60866935:-
THCA	cis	rs9911578	0.967	rs11656413	ENSG00000224738.1	AC099850.1	-3.85	0.000136	0.0102	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:59004652	chr17:59106598~59118267:+
THCA	cis	rs7264396	0.836	rs4911183	ENSG00000088340.14	FER1L4	-3.85	0.000136	0.0102	-0.18	-0.17	Total cholesterol levels;	chr20:35593631	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs6058297	ENSG00000088340.14	FER1L4	3.85	0.000136	0.0102	0.18	0.17	Total cholesterol levels;	chr20:35683939	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs11697903	ENSG00000088340.14	FER1L4	3.85	0.000136	0.0102	0.18	0.17	Total cholesterol levels;	chr20:35684302	chr20:35558737~35607562:-
THCA	cis	rs10089	1	rs10478803	ENSG00000245937.6	LINC01184	3.85	0.000136	0.0102	0.2	0.17	Ileal carcinoids;	chr5:128153163	chr5:127940426~128083172:-
THCA	cis	rs7737355	0.947	rs56228197	ENSG00000237714.1	P4HA2-AS1	-3.85	0.000136	0.0102	-0.25	-0.17	Life satisfaction;	chr5:131469782	chr5:132184876~132192808:+
THCA	cis	rs10911902	0.643	rs17491733	ENSG00000233196.2	GS1-304P7.1	-3.85	0.000136	0.0102	-0.28	-0.17	Schizophrenia;	chr1:186402168	chr1:186580515~186581191:-
THCA	cis	rs2836974	0.932	rs2150415	ENSG00000255568.3	BRWD1-AS2	3.85	0.000136	0.0102	0.15	0.17	Cognitive function;	chr21:39243441	chr21:39313935~39314962:+
THCA	cis	rs13256369	0.802	rs11995449	ENSG00000254153.1	CTA-398F10.2	-3.85	0.000136	0.0102	-0.2	-0.17	Obesity-related traits;	chr8:8702388	chr8:8456909~8461337:-
THCA	cis	rs6137726	0.569	rs2180553	ENSG00000237396.1	LINC01384	3.85	0.000136	0.0102	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22651781	chr20:22587522~22607517:-
THCA	cis	rs2403221	0.656	rs11042498	ENSG00000246273.5	SBF2-AS1	-3.85	0.000136	0.0102	-0.21	-0.17	Smoking initiation;	chr11:9793879	chr11:9758292~9811319:+
THCA	cis	rs877819	0.583	rs1993985	ENSG00000228403.1	RP11-563N6.6	-3.85	0.000136	0.0102	-0.19	-0.17	Systemic lupus erythematosus;	chr10:48850986	chr10:48878022~48878649:+
THCA	cis	rs4081724	0.63	rs73024219	ENSG00000267296.2	CEBPA-AS1	3.85	0.000136	0.0102	0.3	0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33295906	chr19:33302857~33305054:+
THCA	cis	rs9467773	1	rs1078679	ENSG00000228223.2	HCG11	-3.85	0.000136	0.0102	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6932156	ENSG00000228223.2	HCG11	-3.85	0.000136	0.0102	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6924838	ENSG00000228223.2	HCG11	-3.85	0.000136	0.0102	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs6925895	ENSG00000228223.2	HCG11	-3.85	0.000136	0.0102	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26523450~26526579:+
THCA	cis	rs61160187	0.582	rs888799	ENSG00000272308.1	RP11-231G3.1	-3.85	0.000136	0.0102	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.548	rs1983484	ENSG00000272308.1	RP11-231G3.1	-3.85	0.000136	0.0102	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60866457~60866935:-
THCA	cis	rs7166081	1	rs35524716	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000136	0.0102	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67286649	chr15:67541072~67542604:-
THCA	cis	rs5769765	0.955	rs8135963	ENSG00000260613.1	RP3-522J7.6	-3.85	0.000136	0.0102	-0.22	-0.17	Schizophrenia;	chr22:49907828	chr22:49832616~49837786:-
THCA	cis	rs12499086	0.642	rs11733400	ENSG00000251175.4	RP11-45L9.1	3.85	0.000136	0.0102	0.22	0.17	Economic and political preferences (time);	chr4:105490016	chr4:105746245~105827172:-
THCA	cis	rs12499086	0.607	rs1076215	ENSG00000251175.4	RP11-45L9.1	3.85	0.000136	0.0102	0.22	0.17	Economic and political preferences (time);	chr4:105491094	chr4:105746245~105827172:-
THCA	cis	rs12499086	0.642	rs1076216	ENSG00000251175.4	RP11-45L9.1	3.85	0.000136	0.0102	0.22	0.17	Economic and political preferences (time);	chr4:105491253	chr4:105746245~105827172:-
THCA	cis	rs11009175	0.725	rs11009195	ENSG00000273038.2	RP11-479G22.8	-3.85	0.000136	0.0102	-0.22	-0.17	Depression (quantitative trait);	chr10:33045345	chr10:32887255~32889311:-
THCA	cis	rs7586085	0.967	rs13009598	ENSG00000232411.1	AC009495.3	-3.85	0.000136	0.0102	-0.19	-0.17	Total body bone mineral density;	chr2:165703536	chr2:165833048~165839098:-
THCA	cis	rs6443245	0.591	rs2648381	ENSG00000227110.5	LMCD1-AS1	-3.85	0.000136	0.0102	-0.2	-0.17	Daytime sleep phenotypes;	chr3:9580993	chr3:7952805~8611924:-
THCA	cis	rs7166081	1	rs72625777	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000136	0.0102	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67211470	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs2033783	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000136	0.0102	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67215430	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs8026870	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000136	0.0102	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67219051	chr15:67541072~67542604:-
THCA	cis	rs7166081	0.95	rs35322464	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000136	0.0102	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67219152	chr15:67541072~67542604:-
THCA	cis	rs6671200	0.831	rs35949014	ENSG00000235501.4	RP4-639F20.1	-3.85	0.000136	0.0102	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95139279	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs35098538	ENSG00000235501.4	RP4-639F20.1	-3.85	0.000136	0.0102	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95139890	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs35013306	ENSG00000235501.4	RP4-639F20.1	-3.85	0.000136	0.0102	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95140216	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs77817666	ENSG00000235501.4	RP4-639F20.1	-3.85	0.000136	0.0102	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95140496	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs78629196	ENSG00000235501.4	RP4-639F20.1	-3.85	0.000136	0.0102	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95140514	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs13376185	ENSG00000235501.4	RP4-639F20.1	-3.85	0.000136	0.0102	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95140722	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs13376187	ENSG00000235501.4	RP4-639F20.1	-3.85	0.000136	0.0102	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95140814	chr1:94927566~94963270:+
THCA	cis	rs950169	0.887	rs12903946	ENSG00000275120.1	RP11-182J1.17	3.85	0.000136	0.0102	0.21	0.17	Schizophrenia;	chr15:84399732	chr15:84599434~84606463:-
THCA	cis	rs950169	0.887	rs62029593	ENSG00000275120.1	RP11-182J1.17	3.85	0.000136	0.0102	0.21	0.17	Schizophrenia;	chr15:84400482	chr15:84599434~84606463:-
THCA	cis	rs950169	0.81	rs62029594	ENSG00000275120.1	RP11-182J1.17	3.85	0.000136	0.0102	0.21	0.17	Schizophrenia;	chr15:84400554	chr15:84599434~84606463:-
THCA	cis	rs950169	0.881	rs62029596	ENSG00000275120.1	RP11-182J1.17	3.85	0.000136	0.0102	0.21	0.17	Schizophrenia;	chr15:84400736	chr15:84599434~84606463:-
THCA	cis	rs950169	0.881	rs4081123	ENSG00000275120.1	RP11-182J1.17	3.85	0.000136	0.0102	0.21	0.17	Schizophrenia;	chr15:84401537	chr15:84599434~84606463:-
THCA	cis	rs950169	0.881	rs62029599	ENSG00000275120.1	RP11-182J1.17	3.85	0.000136	0.0102	0.21	0.17	Schizophrenia;	chr15:84401867	chr15:84599434~84606463:-
THCA	cis	rs950169	0.8	rs4099846	ENSG00000275120.1	RP11-182J1.17	3.85	0.000136	0.0102	0.21	0.17	Schizophrenia;	chr15:84402196	chr15:84599434~84606463:-
THCA	cis	rs72627123	0.881	rs17094011	ENSG00000259065.1	RP5-1021I20.1	-3.85	0.000136	0.0102	-0.27	-0.17	Morning vs. evening chronotype;	chr14:73925425	chr14:73787360~73803270:+
THCA	cis	rs72627123	1	rs7148538	ENSG00000259065.1	RP5-1021I20.1	-3.85	0.000136	0.0102	-0.27	-0.17	Morning vs. evening chronotype;	chr14:73925639	chr14:73787360~73803270:+
THCA	cis	rs7737355	0.947	rs11242078	ENSG00000237714.1	P4HA2-AS1	-3.85	0.000136	0.0102	-0.25	-0.17	Life satisfaction;	chr5:131456342	chr5:132184876~132192808:+
THCA	cis	rs6687821	0.593	rs797947	ENSG00000261737.1	RP4-612B15.3	-3.85	0.000136	0.0102	-0.27	-0.17	Yeast infection;	chr1:86844606	chr1:86703502~86704462:-
THCA	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	3.85	0.000136	0.0102	0.2	0.17	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
THCA	cis	rs12681366	0.623	rs10106494	ENSG00000261437.1	RP11-22C11.2	3.85	0.000136	0.0102	0.17	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94471226	chr8:94637285~94639467:-
THCA	cis	rs7259376	0.905	rs2082479	ENSG00000270947.1	AC025811.3	3.85	0.000136	0.0102	0.18	0.17	Menopause (age at onset);	chr19:22357045	chr19:22455988~22456459:+
THCA	cis	rs13064411	0.66	rs3829889	ENSG00000243849.1	CFAP44-AS1	3.85	0.000136	0.0102	0.28	0.17	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113296617	chr3:113403991~113433992:+
THCA	cis	rs17695224	0.74	rs10407041	ENSG00000275055.1	CTC-471J1.11	-3.85	0.000136	0.0102	-0.14	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51839416	chr19:52049007~52049754:+
THCA	cis	rs755249	0.567	rs1126313	ENSG00000182109.6	RP11-69E11.4	-3.85	0.000136	0.0102	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs112672438	ENSG00000182109.6	RP11-69E11.4	3.85	0.000136	0.0102	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs16825921	ENSG00000182109.6	RP11-69E11.4	3.85	0.000136	0.0102	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs16825939	ENSG00000182109.6	RP11-69E11.4	3.85	0.000136	0.0102	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs16825942	ENSG00000182109.6	RP11-69E11.4	3.85	0.000136	0.0102	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs72661927	ENSG00000182109.6	RP11-69E11.4	3.85	0.000136	0.0102	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs2036463	ENSG00000182109.6	RP11-69E11.4	3.85	0.000136	0.0102	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs2036464	ENSG00000182109.6	RP11-69E11.4	3.85	0.000136	0.0102	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs905381	ENSG00000182109.6	RP11-69E11.4	3.85	0.000136	0.0102	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39522280~39546187:-
THCA	cis	rs6968419	0.963	rs940471	ENSG00000237870.5	AC073130.1	3.85	0.000136	0.0102	0.18	0.17	Intraocular pressure;	chr7:116201154	chr7:116275606~116286734:-
THCA	cis	rs7554547	0.622	rs4846067	ENSG00000199347.1	RNU5E-1	-3.85	0.000136	0.0102	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11880209	chr1:11908152~11908271:+
THCA	cis	rs420259	0.556	rs7187920	ENSG00000260136.4	CTD-2270L9.4	-3.85	0.000136	0.0102	-0.13	-0.17	Bipolar disorder;	chr16:23552180	chr16:23452758~23457606:+
THCA	cis	rs6847067	0.965	rs17009247	ENSG00000180769.7	WDFY3-AS2	3.85	0.000136	0.0102	0.13	0.17	Oropharynx cancer;	chr4:84746519	chr4:84965682~85011277:+
THCA	cis	rs59918340	0.934	rs7001864	ENSG00000253307.1	RP11-10J21.4	-3.85	0.000136	0.0102	-0.24	-0.17	Immature fraction of reticulocytes;	chr8:141225898	chr8:141252286~141253292:-
THCA	cis	rs853679	0.607	rs35001169	ENSG00000272009.1	RP1-313I6.12	-3.85	0.000136	0.0102	-0.34	-0.17	Depression;	chr6:28219854	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs35656932	ENSG00000272009.1	RP1-313I6.12	-3.85	0.000136	0.0102	-0.34	-0.17	Depression;	chr6:28223510	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13208096	ENSG00000272009.1	RP1-313I6.12	-3.85	0.000136	0.0102	-0.34	-0.17	Depression;	chr6:28257533	chr6:28078792~28081130:-
THCA	cis	rs4578769	0.879	rs12963622	ENSG00000265939.1	UBE2CP2	3.85	0.000136	0.0102	0.21	0.17	Eosinophil percentage of white cells;	chr18:22859594	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.879	rs7241050	ENSG00000265939.1	UBE2CP2	3.85	0.000136	0.0102	0.21	0.17	Eosinophil percentage of white cells;	chr18:22860300	chr18:22900486~22900995:-
THCA	cis	rs10484434	0.818	rs3799374	ENSG00000272462.2	U91328.19	3.85	0.000136	0.0102	0.19	0.17	HIV-1 viral setpoint;	chr6:26088179	chr6:25992662~26001775:+
THCA	cis	rs7166081	1	rs4776909	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000136	0.0102	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67250011	chr15:67541072~67542604:-
THCA	cis	rs4794202	0.609	rs4794318	ENSG00000264920.1	RP11-6N17.4	-3.85	0.000136	0.0102	-0.22	-0.17	Alzheimer's disease (cognitive decline);	chr17:47950705	chr17:47891255~47895812:-
THCA	cis	rs1580019	0.844	rs1901202	ENSG00000231952.3	DPY19L1P2	-3.85	0.000136	0.0102	-0.23	-0.17	Cognitive ability;	chr7:32464112	chr7:32812757~32838570:+
THCA	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-3.85	0.000136	0.0102	-0.2	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
THCA	cis	rs10927875	0.632	rs4661667	ENSG00000179743.3	FLJ37453	-3.85	0.000136	0.0102	-0.12	-0.17	Dilated cardiomyopathy;	chr1:15836236	chr1:15834479~15848147:-
THCA	cis	rs6546886	0.869	rs4853007	ENSG00000235499.1	AC073046.25	3.85	0.000136	0.0102	0.16	0.17	Dialysis-related mortality;	chr2:74045130	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.912	rs4852326	ENSG00000235499.1	AC073046.25	3.85	0.000136	0.0102	0.16	0.17	Dialysis-related mortality;	chr2:74045291	chr2:73985132~73986343:+
THCA	cis	rs6443245	0.611	rs67854857	ENSG00000227110.5	LMCD1-AS1	-3.85	0.000136	0.0102	-0.2	-0.17	Daytime sleep phenotypes;	chr3:9585850	chr3:7952805~8611924:-
THCA	cis	rs10510102	0.516	rs2420976	ENSG00000226864.1	ATE1-AS1	-3.85	0.000136	0.0102	-0.29	-0.17	Breast cancer;	chr10:121986932	chr10:121928312~121951965:+
THCA	cis	rs4713118	0.581	rs200504	ENSG00000220721.1	OR1F12	3.85	0.000136	0.0102	0.25	0.17	Parkinson's disease;	chr6:27818042	chr6:28073316~28074233:+
THCA	cis	rs765787	0.53	rs28526629	ENSG00000259539.1	CTD-2651B20.1	3.85	0.000136	0.0102	0.21	0.17	Uric acid levels;	chr15:45248264	chr15:45152664~45167526:-
THCA	cis	rs67981189	0.858	rs17108877	ENSG00000269927.1	RP6-91H8.3	3.85	0.000136	0.0102	0.2	0.17	Schizophrenia;	chr14:71007092	chr14:71141125~71143253:-
THCA	cis	rs1005277	0.505	rs200935	ENSG00000120555.12	SEPT7P9	3.85	0.000136	0.0102	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38383069~38402916:-
THCA	cis	rs210648	0.692	rs210610	ENSG00000230202.1	RP11-632C17__A.1	-3.85	0.000137	0.0102	-0.18	-0.17	Economic and political preferences;	chr6:117513281	chr6:117998975~117999448:+
THCA	cis	rs293748	0.882	rs245588	ENSG00000250155.1	CTD-2353F22.1	-3.85	0.000137	0.0102	-0.24	-0.17	Obesity-related traits;	chr5:36923108	chr5:36666214~36725195:-
THCA	cis	rs11088226	0.681	rs2833897	ENSG00000186842.4	LINC00846	-3.85	0.000137	0.0102	-0.26	-0.17	Gastritis;	chr21:32559482	chr21:32572238~32575881:-
THCA	cis	rs6137726	0.524	rs1203925	ENSG00000237396.1	LINC01384	3.85	0.000137	0.0102	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22608135	chr20:22587522~22607517:-
THCA	cis	rs9902453	0.689	rs56788338	ENSG00000263370.1	RP11-68I3.5	3.85	0.000137	0.0102	0.23	0.17	Coffee consumption (cups per day);	chr17:29859539	chr17:29639627~29640825:+
THCA	cis	rs3755605	0.728	rs61672237	ENSG00000242578.1	RP11-469J4.3	3.85	0.000137	0.0102	0.2	0.17	Testicular germ cell tumor;	chr3:170086549	chr3:170410512~170418615:+
THCA	cis	rs10208649	0.611	rs61740458	ENSG00000233266.1	HMGB1P31	3.85	0.000137	0.0102	0.31	0.17	Body mass index;	chr2:54065503	chr2:54051334~54051760:+
THCA	cis	rs2033711	0.503	rs7254299	ENSG00000268895.4	A1BG-AS1	-3.85	0.000137	0.0102	-0.21	-0.17	Uric acid clearance;	chr19:58373598	chr19:58347751~58355183:+
THCA	cis	rs7927592	0.913	rs67605986	ENSG00000160172.9	FAM86C2P	3.85	0.000137	0.0102	0.17	0.17	Total body bone mineral density;	chr11:68533487	chr11:67791648~67805336:-
THCA	cis	rs11148252	0.5	rs342768	ENSG00000273784.3	RP11-78J21.7	-3.85	0.000137	0.0102	-0.18	-0.17	Lewy body disease;	chr13:52634747	chr13:52600042~52642542:+
THCA	cis	rs6560517	0.607	rs785936	ENSG00000234618.1	RPSAP9	-3.85	0.000137	0.0102	-0.18	-0.17	Dialysis-related mortality;	chr9:76478748	chr9:76398699~76399586:+
THCA	cis	rs853679	0.713	rs200991	ENSG00000220721.1	OR1F12	-3.85	0.000137	0.0102	-0.26	-0.17	Depression;	chr6:27847716	chr6:28073316~28074233:+
THCA	cis	rs13113518	0.513	rs13147861	ENSG00000272969.1	RP11-528I4.2	3.85	0.000137	0.0102	0.21	0.17	Height;	chr4:55611014	chr4:55547112~55547889:+
THCA	cis	rs10954779	0.764	rs2725364	ENSG00000127589.4	TUBBP1	3.85	0.000137	0.0102	0.21	0.17	Intelligence (multi-trait analysis);	chr8:31142496	chr8:30351873~30353518:+
THCA	cis	rs7727544	0.564	rs3852206	ENSG00000263597.1	MIR3936	3.85	0.000137	0.0102	0.18	0.17	Blood metabolite levels;	chr5:132079743	chr5:132365490~132365599:-
THCA	cis	rs875971	0.638	rs10249404	ENSG00000229180.5	GS1-124K5.11	-3.85	0.000137	0.0102	-0.12	-0.17	Aortic root size;	chr7:66581737	chr7:66526088~66542624:-
THCA	cis	rs58605417	0.509	rs7837253	ENSG00000253553.4	RP11-586K2.1	3.85	0.000137	0.0102	0.18	0.17	Schizophrenia;	chr8:88557557	chr8:88326836~88737134:+
THCA	cis	rs9341808	0.5	rs2223873	ENSG00000260645.1	RP11-250B2.5	3.85	0.000137	0.0102	0.14	0.17	Sitting height ratio;	chr6:80338571	chr6:80466958~80469080:+
THCA	cis	rs17685	0.753	rs1574107	ENSG00000230882.1	AC005077.14	3.85	0.000137	0.0102	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76055729	chr7:76071469~76074963:-
THCA	cis	rs889312	0.923	rs1862625	ENSG00000271828.1	CTD-2310F14.1	-3.85	0.000137	0.0102	-0.25	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56736892	chr5:56927874~56929573:+
THCA	cis	rs2562456	0.874	rs9304986	ENSG00000268278.1	RP11-420K14.1	-3.85	0.000137	0.0102	-0.21	-0.17	Pain;	chr19:21499260	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.917	rs2650805	ENSG00000268278.1	RP11-420K14.1	-3.85	0.000137	0.0102	-0.21	-0.17	Pain;	chr19:21505137	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.917	rs10420016	ENSG00000268278.1	RP11-420K14.1	-3.85	0.000137	0.0102	-0.21	-0.17	Pain;	chr19:21505800	chr19:21637974~21656300:+
THCA	cis	rs9291683	0.588	rs2240721	ENSG00000261490.1	RP11-448G15.3	3.85	0.000137	0.0102	0.11	0.17	Bone mineral density;	chr4:10018940	chr4:10068089~10073019:-
THCA	cis	rs4803480	0.554	rs12150975	ENSG00000270164.1	LINC01480	-3.85	0.000137	0.0102	-0.15	-0.17	Schizophrenia;	chr19:41563990	chr19:41535183~41536904:+
THCA	cis	rs4803480	0.554	rs12983999	ENSG00000270164.1	LINC01480	-3.85	0.000137	0.0102	-0.15	-0.17	Schizophrenia;	chr19:41564158	chr19:41535183~41536904:+
THCA	cis	rs4713118	0.866	rs9468217	ENSG00000272009.1	RP1-313I6.12	-3.85	0.000137	0.0102	-0.2	-0.17	Parkinson's disease;	chr6:27758688	chr6:28078792~28081130:-
THCA	cis	rs7246967	0.608	rs2569728	ENSG00000198153.8	ZNF849P	-3.85	0.000137	0.0102	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22831202	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.608	rs453175	ENSG00000198153.8	ZNF849P	-3.85	0.000137	0.0102	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22831285	chr19:22685167~22686732:+
THCA	cis	rs6967414	0.681	rs11979878	ENSG00000187953.9	PMS2CL	-3.85	0.000137	0.0102	-0.25	-0.17	Hematocrit;Hemoglobin concentration;	chr7:6714172	chr7:6710128~6753862:+
THCA	cis	rs6995541	0.647	rs6987200	ENSG00000248896.2	CTD-2135J3.3	-3.85	0.000137	0.0102	-0.21	-0.17	Triglyceride levels;	chr8:10831156	chr8:10729314~10771392:+
THCA	cis	rs8115854	0.922	rs8120307	ENSG00000269846.1	RP4-621N11.2	-3.85	0.000137	0.0102	-0.23	-0.17	Hippocampal atrophy;	chr20:37174785	chr20:37095785~37097178:+
THCA	cis	rs8115854	0.922	rs6031843	ENSG00000269846.1	RP4-621N11.2	-3.85	0.000137	0.0102	-0.23	-0.17	Hippocampal atrophy;	chr20:37174900	chr20:37095785~37097178:+
THCA	cis	rs8115854	0.922	rs8122715	ENSG00000269846.1	RP4-621N11.2	-3.85	0.000137	0.0102	-0.23	-0.17	Hippocampal atrophy;	chr20:37177464	chr20:37095785~37097178:+
THCA	cis	rs10792320	0.592	rs71490344	ENSG00000279491.1	RP11-810P12.7	-3.85	0.000137	0.0102	-0.21	-0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61979546	chr11:61967794~61969490:+
THCA	cis	rs7665090	1	rs3733202	ENSG00000251288.2	RP11-10L12.2	-3.85	0.000137	0.0102	-0.22	-0.17	Primary biliary cholangitis;	chr4:102635704	chr4:102751401~102752641:+
THCA	cis	rs6903823	0.508	rs1778484	ENSG00000220721.1	OR1F12	3.85	0.000137	0.0102	0.2	0.17	Pulmonary function;	chr6:28273021	chr6:28073316~28074233:+
THCA	cis	rs4915077	0.773	rs72705622	ENSG00000230489.1	VAV3-AS1	3.85	0.000137	0.0102	0.27	0.17	Hypothyroidism;	chr1:107709929	chr1:107964443~107994607:+
THCA	cis	rs3812831	0.695	rs7995986	ENSG00000264539.1	MIR548AR	3.85	0.000137	0.0102	0.18	0.17	Schizophrenia;	chr13:114173327	chr13:114244505~114244561:+
THCA	cis	rs494526	0.868	rs10749286	ENSG00000229272.1	RP11-498J9.2	-3.85	0.000137	0.0102	-0.19	-0.17	Alcoholic chronic pancreatitis;	chr10:119085108	chr10:119003536~119003884:-
THCA	cis	rs858239	0.669	rs56400441	ENSG00000230042.1	AK3P3	-3.85	0.000137	0.0102	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23129178~23129841:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000232559.3	GS1-124K5.12	3.85	0.000137	0.0102	0.19	0.17	Aortic root size;	chr7:66164012	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs12673308	ENSG00000232559.3	GS1-124K5.12	3.85	0.000137	0.0102	0.19	0.17	Aortic root size;	chr7:66166374	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs67397473	ENSG00000232559.3	GS1-124K5.12	3.85	0.000137	0.0102	0.19	0.17	Aortic root size;	chr7:66168318	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs10950027	ENSG00000232559.3	GS1-124K5.12	3.85	0.000137	0.0102	0.19	0.17	Aortic root size;	chr7:66169164	chr7:66554588~66576923:-
THCA	cis	rs10992797	0.563	rs10992795	ENSG00000227603.1	RP11-165J3.6	-3.85	0.000137	0.0102	-0.18	-0.17	Intelligence (multi-trait analysis);	chr9:93597226	chr9:93435332~93437121:-
THCA	cis	rs7267979	0.833	rs6138556	ENSG00000276952.1	RP5-965G21.6	3.85	0.000137	0.0102	0.19	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25284915~25285588:-
THCA	cis	rs7660883	1	rs3775217	ENSG00000251411.1	RP11-397E7.4	3.85	0.000137	0.0102	0.17	0.17	HDL cholesterol levels;	chr4:87098315	chr4:86913266~86914817:-
THCA	cis	rs62073968	1	rs62073968	ENSG00000228782.6	CTD-2026D20.3	3.85	0.000137	0.0102	0.23	0.17	Mean platelet volume;	chr17:47531904	chr17:47450568~47492492:-
THCA	cis	rs7746199	0.736	rs35037868	ENSG00000272009.1	RP1-313I6.12	-3.85	0.000137	0.0102	-0.34	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28078792~28081130:-
THCA	cis	rs1035144	0.679	rs4903957	ENSG00000259167.2	NMNAT1P1	3.85	0.000137	0.0102	0.22	0.17	Male sexual orientation;	chr14:80982167	chr14:81032529~81033404:+
THCA	cis	rs2732480	0.5	rs11168464	ENSG00000257735.1	RP11-370I10.6	3.85	0.000137	0.0102	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48350945~48442411:+
THCA	cis	rs7829975	0.742	rs1533058	ENSG00000233609.3	RP11-62H7.2	3.85	0.000137	0.0102	0.17	0.17	Mood instability;	chr8:8827680	chr8:8961200~8979025:+
THCA	cis	rs6504108	0.647	rs7210149	ENSG00000264920.1	RP11-6N17.4	-3.85	0.000137	0.0102	-0.15	-0.17	Body mass index;	chr17:48220260	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.602	rs1452667	ENSG00000264920.1	RP11-6N17.4	-3.85	0.000137	0.0102	-0.15	-0.17	Body mass index;	chr17:48225053	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs4793779	ENSG00000264920.1	RP11-6N17.4	-3.85	0.000137	0.0102	-0.15	-0.17	Body mass index;	chr17:48229235	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs1452666	ENSG00000264920.1	RP11-6N17.4	-3.85	0.000137	0.0102	-0.15	-0.17	Body mass index;	chr17:48230388	chr17:47891255~47895812:-
THCA	cis	rs6504108	0.624	rs1377201	ENSG00000264920.1	RP11-6N17.4	-3.85	0.000137	0.0102	-0.15	-0.17	Body mass index;	chr17:48234766	chr17:47891255~47895812:-
THCA	cis	rs10760158	0.832	rs3810942	ENSG00000226752.6	PSMD5-AS1	-3.85	0.000137	0.0102	-0.21	-0.17	Pulse pressure;	chr9:121282717	chr9:120824828~120854385:+
THCA	cis	rs13178541	0.577	rs67621798	ENSG00000250378.1	RP11-119J18.1	-3.85	0.000137	0.0102	-0.2	-0.17	IgG glycosylation;	chr5:135789568	chr5:135812667~135826582:+
THCA	cis	rs11822910	0.911	rs2250887	ENSG00000265566.2	RN7SL605P	3.85	0.000137	0.0102	0.28	0.17	Platelet distribution width;	chr11:57434711	chr11:57528085~57528365:-
THCA	cis	rs9510787	0.51	rs28634443	ENSG00000205861.10	C1QTNF9B-AS1	-3.85	0.000137	0.0102	-0.24	-0.17	Nasopharyngeal carcinoma;	chr13:23673046	chr13:23888889~23897263:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000184274.3	LINC00315	-3.85	0.000137	0.0102	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45300245~45305257:-
THCA	cis	rs763121	0.815	rs9306328	ENSG00000225450.1	RP3-508I15.14	-3.85	0.000137	0.0102	-0.13	-0.17	Menopause (age at onset);	chr22:38632908	chr22:38739003~38749041:+
THCA	cis	rs10129255	0.957	rs2007467	ENSG00000211972.2	IGHV3-66	-3.85	0.000137	0.0102	-0.11	-0.17	Kawasaki disease;	chr14:106771605	chr14:106675017~106675544:-
THCA	cis	rs6847067	0.931	rs7685537	ENSG00000180769.7	WDFY3-AS2	3.85	0.000137	0.0102	0.13	0.17	Oropharynx cancer;	chr4:84757471	chr4:84965682~85011277:+
THCA	cis	rs559555	0.553	rs522638	ENSG00000276517.1	AL133243.2	-3.85	0.000137	0.0102	-0.17	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31580605	chr2:32526504~32529507:+
THCA	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-3.85	0.000137	0.0102	-0.15	-0.17	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
THCA	cis	rs4908768	0.501	rs11121199	ENSG00000270282.1	RP5-1115A15.2	3.85	0.000137	0.0102	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8512653~8513021:+
THCA	cis	rs5760842	0.51	rs733117	ENSG00000203280.4	CTA-221G9.12	-3.85	0.000137	0.0103	-0.15	-0.17	Recurrent major depressive disorder;	chr22:25099860	chr22:25102433~25112692:-
THCA	cis	rs1959947	0.876	rs66945183	ENSG00000251363.2	RP11-129M6.1	-3.85	0.000137	0.0103	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41047227	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs72676043	ENSG00000251363.2	RP11-129M6.1	-3.85	0.000137	0.0103	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41047234	chr14:40954898~40975877:+
THCA	cis	rs66887589	0.66	rs4833613	ENSG00000249244.1	RP11-548H18.2	-3.85	0.000137	0.0103	-0.18	-0.17	Diastolic blood pressure;	chr4:119229001	chr4:119391831~119395335:-
THCA	cis	rs853679	0.517	rs9380047	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28070115	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28071237	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28074687	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28076559	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28076704	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28078391	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28080757	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28080760	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28082231	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28082261	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Parkinson's disease;	chr6:28082269	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28082984	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28083994	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28084025	chr6:28091154~28093664:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28085319	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28096855	chr6:28091154~28093664:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28099759	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Parkinson's disease;	chr6:28100173	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28100648	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28104824	chr6:28091154~28093664:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28107222	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28108492	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000219891.2	ZSCAN12P1	3.85	0.000137	0.0103	0.25	0.17	Depression;	chr6:28110254	chr6:28091154~28093664:+
THCA	cis	rs4759375	1	rs28592032	ENSG00000256092.2	RP13-942N8.1	3.85	0.000137	0.0103	0.19	0.17	HDL cholesterol;	chr12:123394898	chr12:123363868~123366113:+
THCA	cis	rs3845817	0.798	rs702952	ENSG00000281920.1	RP11-418H16.1	-3.85	0.000137	0.0103	-0.21	-0.17	Bipolar disorder;	chr2:65537915	chr2:65623272~65628424:+
THCA	cis	rs4245128	0.93	rs4245127	ENSG00000247416.2	RP11-629G13.1	3.85	0.000137	0.0103	0.16	0.17	Life satisfaction;	chr11:112921141	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.93	rs4936212	ENSG00000247416.2	RP11-629G13.1	3.85	0.000137	0.0103	0.16	0.17	Life satisfaction;	chr11:112924113	chr11:112959279~112963460:-
THCA	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	3.85	0.000137	0.0103	0.36	0.17	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	3.85	0.000137	0.0103	0.36	0.17	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	3.85	0.000137	0.0103	0.36	0.17	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	3.85	0.000137	0.0103	0.36	0.17	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
THCA	cis	rs8054556	0.74	rs3924855	ENSG00000273724.1	RP11-347C12.12	-3.85	0.000137	0.0103	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29943634	chr16:30336400~30343336:+
THCA	cis	rs763121	0.853	rs9610986	ENSG00000273076.1	RP3-508I15.22	3.85	0.000137	0.0103	0.17	0.17	Menopause (age at onset);	chr22:38629272	chr22:38743495~38743910:+
THCA	cis	rs2436845	0.521	rs7833202	ENSG00000253320.4	KB-1507C5.2	-3.85	0.000137	0.0103	-0.15	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102909325	chr8:102864300~102977876:+
THCA	cis	rs11242704	0.962	rs2816284	ENSG00000218027.2	RP11-157J24.1	3.85	0.000137	0.0103	0.23	0.17	Response to hepatitis C treatment;	chr6:1536467	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.962	rs2816285	ENSG00000218027.2	RP11-157J24.1	3.85	0.000137	0.0103	0.23	0.17	Response to hepatitis C treatment;	chr6:1536553	chr6:1513698~1515289:-
THCA	cis	rs31251	0.803	rs3756295	ENSG00000237714.1	P4HA2-AS1	-3.85	0.000137	0.0103	-0.22	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr5:131357147	chr5:132184876~132192808:+
THCA	cis	rs910316	0.763	rs175047	ENSG00000259138.1	RP11-950C14.7	-3.85	0.000137	0.0103	-0.15	-0.17	Height;	chr14:75012336	chr14:75127153~75136930:+
THCA	cis	rs28829049	0.895	rs2313061	ENSG00000270728.1	RP4-657E11.10	-3.85	0.000137	0.0103	-0.13	-0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19033799	chr1:19297080~19297903:+
THCA	cis	rs1880529	0.831	rs13145771	ENSG00000206820.1	RNU1-138P	-3.85	0.000137	0.0103	-0.2	-0.17	White matter integrity (bipolar disorder risk interaction);	chr4:113481762	chr4:113420323~113420486:+
THCA	cis	rs1387259	0.839	rs7486941	ENSG00000257735.1	RP11-370I10.6	-3.84	0.000137	0.0103	-0.19	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48350945~48442411:+
THCA	cis	rs17604090	1	rs28591682	ENSG00000227855.3	DPY19L2P3	3.84	0.000137	0.0103	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29651195	chr7:29650227~29742594:+
THCA	cis	rs4879656	0.872	rs1537039	ENSG00000225693.1	LAGE3P1	-3.84	0.000137	0.0103	-0.18	-0.17	Menopause (age at onset);	chr9:33061718	chr9:33019682~33020165:-
THCA	cis	rs2806561	0.765	rs623988	ENSG00000249087.5	ZNF436-AS1	-3.84	0.000137	0.0103	-0.11	-0.17	Height;	chr1:23192984	chr1:23368997~23371839:+
THCA	cis	rs7200786	0.583	rs2302557	ENSG00000274038.1	RP11-66H6.4	-3.84	0.000137	0.0103	-0.22	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11042191	chr16:11056556~11057034:+
THCA	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-3.84	0.000137	0.0103	-0.24	-0.17	Depression;	chr6:28422360	chr6:28943877~28944537:+
THCA	cis	rs912593	1	rs1575636	ENSG00000225179.1	LINC00457	3.84	0.000137	0.0103	0.22	0.17	Cancer;	chr13:34456306	chr13:34435450~34640685:-
THCA	cis	rs796395	0.905	rs10047116	ENSG00000232480.1	TGFB2-AS1	3.84	0.000137	0.0103	0.2	0.17	Post bronchodilator FEV1/FVC ratio;	chr1:218464949	chr1:218344196~218345678:-
THCA	cis	rs9911578	0.934	rs8081967	ENSG00000224738.1	AC099850.1	3.84	0.000137	0.0103	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58995340	chr17:59106598~59118267:+
THCA	cis	rs10090774	0.769	rs56352956	ENSG00000280303.2	ERICD	3.84	0.000137	0.0103	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140730167	chr8:140636281~140638283:+
THCA	cis	rs11671005	0.696	rs73066211	ENSG00000269600.1	AC016629.3	-3.84	0.000137	0.0103	-0.27	-0.17	Mean platelet volume;	chr19:58485712	chr19:58593896~58599355:-
THCA	cis	rs1005277	0.638	rs1005278	ENSG00000120555.12	SEPT7P9	-3.84	0.000137	0.0103	-0.2	-0.17	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:38383069~38402916:-
THCA	cis	rs9309473	0.95	rs6756885	ENSG00000273245.1	RP11-434P11.2	3.84	0.000137	0.0103	0.24	0.17	Metabolite levels;	chr2:73578045	chr2:73750256~73750786:-
THCA	cis	rs2562456	0.833	rs2562507	ENSG00000268278.1	RP11-420K14.1	-3.84	0.000137	0.0103	-0.21	-0.17	Pain;	chr19:21543535	chr19:21637974~21656300:+
THCA	cis	rs860295	0.756	rs7546258	ENSG00000236675.1	MTX1P1	-3.84	0.000137	0.0103	-0.18	-0.17	Body mass index;	chr1:155728854	chr1:155230975~155234325:+
THCA	cis	rs6494488	0.5	rs72758943	ENSG00000259635.1	AC100830.3	-3.84	0.000137	0.0103	-0.45	-0.17	Coronary artery disease;	chr15:64386502	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72758946	ENSG00000259635.1	AC100830.3	-3.84	0.000137	0.0103	-0.45	-0.17	Coronary artery disease;	chr15:64387164	chr15:64701248~64719602:+
THCA	cis	rs765787	0.53	rs4514617	ENSG00000259539.1	CTD-2651B20.1	3.84	0.000137	0.0103	0.21	0.17	Uric acid levels;	chr15:45243241	chr15:45152664~45167526:-
THCA	cis	rs7572644	0.665	rs4233716	ENSG00000223522.1	AC093690.1	-3.84	0.000137	0.0103	-0.22	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27811517	chr2:28307691~28310459:-
THCA	cis	rs55702914	0.625	rs787989	ENSG00000231621.1	AC013264.2	3.84	0.000137	0.0103	0.17	0.17	Major depression and alcohol dependence;	chr2:197335399	chr2:197197991~197199273:+
THCA	cis	rs10435719	0.902	rs7006538	ENSG00000206014.6	OR7E161P	-3.84	0.000137	0.0103	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:11928597~11929563:-
THCA	cis	rs34421088	0.56	rs2248699	ENSG00000206014.6	OR7E161P	3.84	0.000137	0.0103	0.21	0.17	Neuroticism;	chr8:11536255	chr8:11928597~11929563:-
THCA	cis	rs75504410	0.85	rs61140521	ENSG00000231160.8	KLF3-AS1	-3.84	0.000137	0.0103	-0.2	-0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38642059	chr4:38612701~38664883:-
THCA	cis	rs9611565	0.659	rs56319767	ENSG00000237037.8	NDUFA6-AS1	3.84	0.000137	0.0103	0.16	0.17	Vitiligo;	chr22:41537833	chr22:42090931~42137742:+
THCA	cis	rs3177980	0.958	rs10800468	ENSG00000239494.2	RN7SL333P	-3.84	0.000137	0.0103	-0.18	-0.17	Amyotrophic lateral sclerosis;	chr1:169736270	chr1:169859756~169860052:+
THCA	cis	rs3177980	0.958	rs12084893	ENSG00000239494.2	RN7SL333P	-3.84	0.000137	0.0103	-0.18	-0.17	Amyotrophic lateral sclerosis;	chr1:169739245	chr1:169859756~169860052:+
THCA	cis	rs7129556	0.69	rs588217	ENSG00000254459.1	RP11-91P24.7	-3.84	0.000137	0.0103	-0.22	-0.17	Weight loss (gastric bypass surgery);	chr11:77872330	chr11:77829654~77872262:-
THCA	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	3.84	0.000137	0.0103	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
THCA	cis	rs2243123	0.602	rs2243135	ENSG00000244040.4	IL12A-AS1	3.84	0.000137	0.0103	0.24	0.17	Multiple sclerosis;	chr3:159995206	chr3:159913400~160225299:-
THCA	cis	rs4575098	0.681	rs11589567	ENSG00000227741.1	RP11-536C5.7	3.84	0.000137	0.0103	0.19	0.17	Monocyte percentage of white cells;	chr1:161146232	chr1:160202199~160208869:-
THCA	cis	rs453301	0.686	rs11785819	ENSG00000254340.1	RP11-10A14.3	-3.84	0.000137	0.0103	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9012868	chr8:9141424~9145435:+
THCA	cis	rs4915077	0.892	rs79566197	ENSG00000226822.1	RP11-356N1.2	3.84	0.000137	0.0103	0.34	0.17	Hypothyroidism;	chr1:107860073	chr1:108071482~108074519:+
THCA	cis	rs10871290	0.507	rs3851731	ENSG00000207525.1	Y_RNA	-3.84	0.000137	0.0103	-0.21	-0.17	Breast cancer;	chr16:74451890	chr16:74463888~74463988:-
THCA	cis	rs9863	0.861	rs77020228	ENSG00000270028.1	RP11-380L11.4	3.84	0.000137	0.0103	0.19	0.17	White blood cell count;	chr12:123933925	chr12:123925461~123926083:-
THCA	cis	rs6449502	0.925	rs35006499	ENSG00000251279.1	CTC-436P18.1	-3.84	0.000138	0.0103	-0.28	-0.17	Mean platelet volume;	chr5:60816122	chr5:61162070~61232040:+
THCA	cis	rs6715284	1	rs16837131	ENSG00000238829.1	RNU7-45P	3.84	0.000138	0.0103	0.39	0.17	Rheumatoid arthritis;	chr2:201309089	chr2:201141904~201141966:+
THCA	cis	rs4780401	0.933	rs4439779	ENSG00000274038.1	RP11-66H6.4	-3.84	0.000138	0.0103	-0.21	-0.17	Rheumatoid arthritis;	chr16:11732985	chr16:11056556~11057034:+
THCA	cis	rs875971	0.545	rs35459055	ENSG00000232559.3	GS1-124K5.12	3.84	0.000138	0.0103	0.19	0.17	Aortic root size;	chr7:66479399	chr7:66554588~66576923:-
THCA	cis	rs74233809	1	rs5011520	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.32	-0.17	Birth weight;	chr10:102937759	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs10883808	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.32	-0.17	Birth weight;	chr10:102961369	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs11191479	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.32	-0.17	Birth weight;	chr10:102963863	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs10883815	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.32	-0.17	Birth weight;	chr10:102979422	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs112390216	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.32	-0.17	Birth weight;	chr10:102981274	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs11191502	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.32	-0.17	Birth weight;	chr10:103005737	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs74444347	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.32	-0.17	Birth weight;	chr10:103009518	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs12221335	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.32	-0.17	Birth weight;	chr10:103009635	chr10:102914585~102915404:+
THCA	cis	rs285757	1	rs285755	ENSG00000259064.2	RP11-386M24.5	-3.84	0.000138	0.0103	-0.27	-0.17	HIV-1 susceptibility;	chr15:92634985	chr15:92627073~92627414:+
THCA	cis	rs285757	1	rs285757	ENSG00000259064.2	RP11-386M24.5	-3.84	0.000138	0.0103	-0.27	-0.17	HIV-1 susceptibility;	chr15:92635945	chr15:92627073~92627414:+
THCA	cis	rs494003	1	rs578056	ENSG00000214659.4	KRT8P26	3.84	0.000138	0.0103	0.19	0.17	Systemic lupus erythematosus;	chr11:65747403	chr11:65726939~65728214:+
THCA	cis	rs9584850	0.794	rs9630321	ENSG00000231194.1	FARP1-AS1	3.84	0.000138	0.0103	0.21	0.17	Neuroticism;	chr13:98454725	chr13:98435405~98435840:-
THCA	cis	rs669446	0.533	rs7543520	ENSG00000237950.1	RP11-7O11.3	3.84	0.000138	0.0103	0.15	0.17	Amyotrophic lateral sclerosis (age of onset);	chr1:43778195	chr1:43944370~43946551:-
THCA	cis	rs5758659	0.653	rs133383	ENSG00000273366.1	CTA-989H11.1	-3.84	0.000138	0.0103	-0.21	-0.17	Cognitive function;	chr22:42077599	chr22:42278188~42278846:+
THCA	cis	rs10457678	0.534	rs72987060	ENSG00000225415.2	RP3-509I19.1	-3.84	0.000138	0.0103	-0.24	-0.17	Colorectal or endometrial cancer;	chr6:138832754	chr6:138822747~138823799:+
THCA	cis	rs4761470	0.577	rs4761602	ENSG00000258172.1	RP11-1105G2.4	-3.84	0.000138	0.0103	-0.24	-0.17	Estradiol plasma levels (breast cancer);	chr12:94291262	chr12:94272150~94277195:-
THCA	cis	rs2039553	0.591	rs12019641	ENSG00000227354.5	RBM26-AS1	-3.84	0.000138	0.0103	-0.17	-0.17	Pancreatic cancer;	chr13:79800893	chr13:79406309~79424328:+
THCA	cis	rs875971	0.528	rs801213	ENSG00000273024.4	INTS4P2	3.84	0.000138	0.0103	0.22	0.17	Aortic root size;	chr7:66549931	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000273024.4	INTS4P2	3.84	0.000138	0.0103	0.22	0.17	Aortic root size;	chr7:66550643	chr7:65647864~65715661:+
THCA	cis	rs9410380	1	rs1502715	ENSG00000225385.3	RP11-350E12.4	3.84	0.000138	0.0103	0.17	0.17	Monocyte count;	chr9:88846852	chr9:88066915~88068037:+
THCA	cis	rs9410380	0.935	rs2799699	ENSG00000225385.3	RP11-350E12.4	3.84	0.000138	0.0103	0.17	0.17	Monocyte count;	chr9:88847580	chr9:88066915~88068037:+
THCA	cis	rs2320614	1	rs6845885	ENSG00000250027.1	RP11-563E2.2	-3.84	0.000138	0.0103	-0.16	-0.17	Lung adenocarcinoma;	chr4:163114954	chr4:163108785~163119965:+
THCA	cis	rs709400	0.827	rs2274269	ENSG00000258735.1	LINC00637	3.84	0.000138	0.0103	0.23	0.17	Body mass index;	chr14:103562909	chr14:103847721~103858049:+
THCA	cis	rs7798970	0.645	rs6952141	ENSG00000225498.1	AC002064.5	3.84	0.000138	0.0103	0.18	0.17	Inflammatory skin disease;	chr7:90020021	chr7:90312496~90322592:+
THCA	cis	rs950169	0.881	rs72750843	ENSG00000275120.1	RP11-182J1.17	3.84	0.000138	0.0103	0.21	0.17	Schizophrenia;	chr15:84592552	chr15:84599434~84606463:-
THCA	cis	rs3736986	0.908	rs10814354	ENSG00000215283.3	HMGB3P24	-3.84	0.000138	0.0103	-0.32	-0.17	Bipolar disorder (inflammation and infection response interaction);	chr9:36185193	chr9:36303499~36304924:-
THCA	cis	rs1555322	1	rs1555322	ENSG00000279253.1	RP4-614O4.13	-3.84	0.000138	0.0103	-0.24	-0.17	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35262727~35264187:-
THCA	cis	rs7542375	0.524	rs2807869	ENSG00000238078.1	LINC01352	-3.84	0.000138	0.0103	-0.21	-0.17	Obesity-related traits;	chr1:220920726	chr1:220829255~220832429:+
THCA	cis	rs7542375	0.507	rs2484697	ENSG00000238078.1	LINC01352	-3.84	0.000138	0.0103	-0.21	-0.17	Obesity-related traits;	chr1:220921376	chr1:220829255~220832429:+
THCA	cis	rs9309473	0.519	rs6730785	ENSG00000273245.1	RP11-434P11.2	-3.84	0.000138	0.0103	-0.21	-0.17	Metabolite levels;	chr2:73415275	chr2:73750256~73750786:-
THCA	cis	rs1153858	1	rs12909158	ENSG00000275672.1	GATM-AS1	-3.84	0.000138	0.0103	-0.18	-0.17	Homoarginine levels;	chr15:45328976	chr15:45378700~45380123:+
THCA	cis	rs1362756	0.958	rs8055396	ENSG00000260057.4	LINC01571	-3.84	0.000138	0.0103	-0.19	-0.17	Optic disc parameters;Optic disc area;	chr16:51432229	chr16:51762519~51773173:+
THCA	cis	rs73173548	0.502	rs10505855	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000138	0.0103	0.16	0.17	Macular telangiectasia type 2;	chr5:88440962	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs4129235	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000138	0.0103	0.16	0.17	Macular telangiectasia type 2;	chr5:88441465	chr5:88268895~88436685:+
THCA	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	3.84	0.000138	0.0103	0.19	0.17	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
THCA	cis	rs7927592	0.513	rs608343	ENSG00000160172.9	FAM86C2P	3.84	0.000138	0.0103	0.16	0.17	Total body bone mineral density;	chr11:68429362	chr11:67791648~67805336:-
THCA	cis	rs1790761	0.587	rs4930431	ENSG00000255318.1	RP11-655M14.13	-3.84	0.000138	0.0103	-0.19	-0.17	Mean corpuscular volume;	chr11:67526837	chr11:67618279~67627304:-
THCA	cis	rs10435719	0.902	rs7459983	ENSG00000255495.1	AC145124.2	3.84	0.000138	0.0103	0.21	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:12194467~12196280:+
THCA	cis	rs7578199	0.504	rs10182982	ENSG00000223374.1	AC005104.3	-3.84	0.000138	0.0103	-0.12	-0.17	Chronic lymphocytic leukemia;	chr2:241464506	chr2:241351340~241353104:-
THCA	cis	rs2657294	0.895	rs2002023	ENSG00000233313.2	HMGA1P5	-3.84	0.000138	0.0103	-0.23	-0.17	Pneumonia;	chr10:75088766	chr10:75276376~75276646:-
THCA	cis	rs548181	0.611	rs2849225	ENSG00000254671.2	STT3A-AS1	-3.84	0.000138	0.0103	-0.35	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125546040	chr11:125570284~125592568:-
THCA	cis	rs11971779	0.68	rs4732379	ENSG00000252332.1	RNU6-911P	-3.84	0.000138	0.0103	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139438068	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.68	rs6978680	ENSG00000252332.1	RNU6-911P	3.84	0.000138	0.0103	0.2	0.17	Diisocyanate-induced asthma;	chr7:139427302	chr7:139448740~139448843:+
THCA	cis	rs75059851	1	rs73036063	ENSG00000280237.1	MIR4697HG	3.84	0.000138	0.0103	0.2	0.17	Schizophrenia;	chr11:133958863	chr11:133896438~133901601:-
THCA	cis	rs832187	0.64	rs704367	ENSG00000224479.4	AC136289.1	-3.84	0.000138	0.0103	-0.22	-0.17	Schizophrenia;	chr3:63883101	chr3:63742293~63827445:-
THCA	cis	rs8130944	1	rs10154056	ENSG00000235772.1	AP001625.6	3.84	0.000138	0.0103	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42717774	chr21:42560374~42561934:-
THCA	cis	rs8130944	0.897	rs4919996	ENSG00000235772.1	AP001625.6	3.84	0.000138	0.0103	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42717943	chr21:42560374~42561934:-
THCA	cis	rs8130944	0.808	rs4919997	ENSG00000235772.1	AP001625.6	3.84	0.000138	0.0103	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42718065	chr21:42560374~42561934:-
THCA	cis	rs8130944	1	rs7281614	ENSG00000235772.1	AP001625.6	3.84	0.000138	0.0103	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42718374	chr21:42560374~42561934:-
THCA	cis	rs8130944	0.93	rs7278005	ENSG00000235772.1	AP001625.6	3.84	0.000138	0.0103	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42718510	chr21:42560374~42561934:-
THCA	cis	rs8130944	0.964	rs4920135	ENSG00000235772.1	AP001625.6	3.84	0.000138	0.0103	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42719198	chr21:42560374~42561934:-
THCA	cis	rs7819412	0.806	rs17723229	ENSG00000261451.1	RP11-981G7.1	-3.84	0.000138	0.0103	-0.22	-0.17	Triglycerides;	chr8:11072559	chr8:10433672~10438312:+
THCA	cis	rs73173548	0.502	rs6865869	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000138	0.0103	0.16	0.17	Macular telangiectasia type 2;	chr5:88449645	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.738	rs12659772	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000138	0.0103	0.16	0.17	Depressive symptoms;	chr5:88451917	chr5:88268895~88436685:+
THCA	cis	rs365302	1	rs433171	ENSG00000235086.1	FNDC1-IT1	3.84	0.000138	0.0103	0.24	0.17	Coronary heart disease;	chr6:159224346	chr6:159240786~159243329:+
THCA	cis	rs970548	1	rs970548	ENSG00000230869.1	CTGLF10P	3.84	0.000138	0.0103	0.21	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45517829	chr10:45678692~45700532:+
THCA	cis	rs346923	1	rs73248639	ENSG00000226950.5	DANCR	3.84	0.000138	0.0103	0.2	0.17	Biochemical measures;	chr4:52484595	chr4:52712404~52720351:+
THCA	cis	rs346923	1	rs73248641	ENSG00000226950.5	DANCR	3.84	0.000138	0.0103	0.2	0.17	Biochemical measures;	chr4:52492080	chr4:52712404~52720351:+
THCA	cis	rs7615952	0.558	rs7641353	ENSG00000272840.1	RP11-379B18.6	3.84	0.000138	0.0103	0.25	0.17	Blood pressure (smoking interaction);	chr3:125621035	chr3:125774714~125797953:+
THCA	cis	rs4321325	0.733	rs13421996	ENSG00000236682.1	AC068282.3	-3.84	0.000138	0.0103	-0.35	-0.17	Protein C levels;	chr2:127177236	chr2:127389130~127400580:+
THCA	cis	rs4763879	0.778	rs7977940	ENSG00000214776.8	RP11-726G1.1	-3.84	0.000138	0.0103	-0.21	-0.17	Type 1 diabetes;	chr12:9686320	chr12:9467552~9576275:+
THCA	cis	rs17356983	1	rs17356983	ENSG00000233325.3	MIPEPP3	3.84	0.000138	0.0103	0.2	0.17	Obesity-related traits;	chr13:21340975	chr13:21298139~21306373:+
THCA	cis	rs11030122	0.959	rs7118295	ENSG00000230593.3	AC090804.1	3.84	0.000138	0.0103	0.23	0.17	Mean platelet volume;Platelet distribution width;	chr11:3881873	chr11:3892398~3892887:-
THCA	cis	rs9291683	0.552	rs11736410	ENSG00000261490.1	RP11-448G15.3	3.84	0.000138	0.0103	0.11	0.17	Bone mineral density;	chr4:10015617	chr4:10068089~10073019:-
THCA	cis	rs9510787	0.649	rs9507128	ENSG00000205861.10	C1QTNF9B-AS1	3.84	0.000138	0.0103	0.22	0.17	Nasopharyngeal carcinoma;	chr13:23642953	chr13:23888889~23897263:+
THCA	cis	rs6847067	1	rs6858666	ENSG00000180769.7	WDFY3-AS2	3.84	0.000138	0.0103	0.13	0.17	Oropharynx cancer;	chr4:84808783	chr4:84965682~85011277:+
THCA	cis	rs6847067	1	rs6531775	ENSG00000180769.7	WDFY3-AS2	3.84	0.000138	0.0103	0.13	0.17	Oropharynx cancer;	chr4:84809761	chr4:84965682~85011277:+
THCA	cis	rs4664304	0.62	rs2136977	ENSG00000226266.5	AC009961.3	-3.84	0.000138	0.0103	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159866339	chr2:159670708~159712435:-
THCA	cis	rs9843304	0.546	rs9847773	ENSG00000243885.1	RP11-278L15.2	-3.84	0.000138	0.0103	-0.19	-0.17	Gallstone disease;	chr3:149500029	chr3:149384179~149385800:-
THCA	cis	rs9843304	0.509	rs6798061	ENSG00000243885.1	RP11-278L15.2	-3.84	0.000138	0.0103	-0.19	-0.17	Gallstone disease;	chr3:149500683	chr3:149384179~149385800:-
THCA	cis	rs7166081	1	rs12900758	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000138	0.0103	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67230705	chr15:67541072~67542604:-
THCA	cis	rs7166081	0.95	rs28645602	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000138	0.0103	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67238985	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs2289789	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000138	0.0103	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67240045	chr15:67541072~67542604:-
THCA	cis	rs1580019	0.961	rs958217	ENSG00000231952.3	DPY19L1P2	-3.84	0.000138	0.0103	-0.22	-0.17	Cognitive ability;	chr7:32453805	chr7:32812757~32838570:+
THCA	cis	rs420259	0.516	rs2106458	ENSG00000260136.4	CTD-2270L9.4	-3.84	0.000138	0.0103	-0.13	-0.17	Bipolar disorder;	chr16:23520110	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs2369009	ENSG00000260136.4	CTD-2270L9.4	-3.84	0.000138	0.0103	-0.13	-0.17	Bipolar disorder;	chr16:23544405	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs11642395	ENSG00000260136.4	CTD-2270L9.4	-3.84	0.000138	0.0103	-0.13	-0.17	Bipolar disorder;	chr16:23545240	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs2106454	ENSG00000260136.4	CTD-2270L9.4	-3.84	0.000138	0.0103	-0.13	-0.17	Bipolar disorder;	chr16:23549077	chr16:23452758~23457606:+
THCA	cis	rs9410380	1	rs2174057	ENSG00000225385.3	RP11-350E12.4	3.84	0.000138	0.0103	0.17	0.17	Monocyte count;	chr9:88845333	chr9:88066915~88068037:+
THCA	cis	rs10090774	0.965	rs61661433	ENSG00000279766.1	RP11-642A1.2	3.84	0.000138	0.0103	0.21	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140976296	chr8:140572142~140572812:-
THCA	cis	rs3018712	0.532	rs2513281	ENSG00000212093.1	AP000807.1	-3.84	0.000138	0.0103	-0.23	-0.17	Total body bone mineral density;	chr11:68649626	chr11:68506083~68506166:-
THCA	cis	rs11771526	0.901	rs62456038	ENSG00000272905.1	RP11-265E18.1	3.84	0.000138	0.0103	0.24	0.17	Body mass index;	chr7:32249051	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.686	rs62457463	ENSG00000272905.1	RP11-265E18.1	3.84	0.000138	0.0103	0.24	0.17	Body mass index;	chr7:32250244	chr7:32845394~32846061:+
THCA	cis	rs2281603	0.57	rs28766386	ENSG00000258824.2	CTD-2555O16.2	-3.84	0.000138	0.0103	-0.15	-0.17	Lymphocyte counts;	chr14:64479679	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs10133848	ENSG00000258824.2	CTD-2555O16.2	-3.84	0.000138	0.0103	-0.15	-0.17	Lymphocyte counts;	chr14:64481771	chr14:64422935~64448557:-
THCA	cis	rs2221894	0.922	rs1858462	ENSG00000251191.6	LINC00589	-3.84	0.000138	0.0103	-0.21	-0.17	Obesity-related traits;	chr8:28903220	chr8:29673922~29748109:-
THCA	cis	rs9987353	0.793	rs9329182	ENSG00000248538.5	RP11-10A14.5	3.84	0.000138	0.0103	0.24	0.17	Recombination measurement;	chr8:9253679	chr8:9189011~9202854:+
THCA	cis	rs854765	0.663	rs12941550	ENSG00000281749.1	Y_RNA	-3.84	0.000138	0.0103	-0.22	-0.17	Total body bone mineral density;	chr17:17850514	chr17:18001101~18001195:-
THCA	cis	rs8115854	0.883	rs62206557	ENSG00000269846.1	RP4-621N11.2	-3.84	0.000138	0.0103	-0.23	-0.17	Hippocampal atrophy;	chr20:37180220	chr20:37095785~37097178:+
THCA	cis	rs12230172	0.557	rs1290030	ENSG00000258245.1	RP11-114H23.3	-3.84	0.000138	0.0103	-0.18	-0.17	Glioma;Non-glioblastoma glioma;	chr12:75818804	chr12:75688794~75689096:-
THCA	cis	rs7897654	0.571	rs12764049	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000138	0.0103	-0.23	-0.17	Schizophrenia;	chr10:102875199	chr10:102914585~102915404:+
THCA	cis	rs791590	0.941	rs12722553	ENSG00000229664.1	RP11-536K7.5	3.84	0.000138	0.0103	0.28	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6029321	chr10:6025978~6036427:+
THCA	cis	rs1913185	0.787	rs59384952	ENSG00000261051.1	RP11-274H2.5	-3.84	0.000138	0.0103	-0.24	-0.17	Obesity-related traits;	chr3:146060012	chr3:146059585~146061679:-
THCA	cis	rs6061231	0.624	rs8668	ENSG00000228812.6	LAMA5-AS1	3.84	0.000138	0.0103	0.18	0.17	Colorectal cancer;	chr20:62389008	chr20:62352995~62356480:+
THCA	cis	rs1334894	0.901	rs16877540	ENSG00000228559.1	RP3-340B19.3	3.84	0.000138	0.0103	0.35	0.17	Coronary artery disease;	chr6:35538954	chr6:35544632~35545669:+
THCA	cis	rs789859	0.611	rs1077729	ENSG00000272707.1	RP11-534C12.1	3.84	0.000138	0.0103	0.19	0.17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr3:194697397	chr3:194637505~194637664:-
THCA	cis	rs6847067	1	rs2170935	ENSG00000180769.7	WDFY3-AS2	3.84	0.000138	0.0103	0.13	0.17	Oropharynx cancer;	chr4:84797795	chr4:84965682~85011277:+
THCA	cis	rs9860428	0.844	rs9852286	ENSG00000243795.1	RP11-572M11.3	3.84	0.000138	0.0103	0.2	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896161	chr3:113142350~113167819:-
THCA	cis	rs7560272	0.501	rs10191988	ENSG00000273245.1	RP11-434P11.2	-3.84	0.000138	0.0103	-0.2	-0.17	Schizophrenia;	chr2:73720660	chr2:73750256~73750786:-
THCA	cis	rs3789045	0.615	rs11240748	ENSG00000235363.1	SNRPGP10	-3.84	0.000138	0.0103	-0.25	-0.17	Educational attainment (college completion);	chr1:204484192	chr1:205351247~205351471:+
THCA	cis	rs9634489	0.632	rs7332928	ENSG00000247400.3	DNAJC3-AS1	3.84	0.000138	0.0103	0.12	0.17	Body mass index;	chr13:96396705	chr13:95648733~95676925:-
THCA	cis	rs614226	0.872	rs787827	ENSG00000278344.1	RP11-18C24.8	3.84	0.000138	0.0103	0.23	0.17	Type 1 diabetes nephropathy;	chr12:120499991	chr12:120500735~120501090:-
THCA	cis	rs4950322	0.518	rs61838951	ENSG00000271721.1	RP11-337C18.9	3.84	0.000138	0.0103	0.19	0.17	Protein quantitative trait loci;	chr1:147116081	chr1:147175602~147177740:+
THCA	cis	rs7335046	0.505	rs6491493	ENSG00000234005.3	GAPDHP22	-3.84	0.000138	0.0103	-0.22	-0.17	Basal cell carcinoma;	chr13:99248166	chr13:99190579~99190991:-
THCA	cis	rs593531	0.513	rs7930193	ENSG00000255440.1	RP11-632K5.2	-3.84	0.000138	0.0103	-0.21	-0.17	Neuroticism;	chr11:74320512	chr11:74409060~74416379:+
THCA	cis	rs13113518	0.812	rs13140173	ENSG00000223305.1	RN7SKP30	3.84	0.000138	0.0103	0.22	0.17	Height;	chr4:55527164	chr4:55540502~55540835:-
THCA	cis	rs7900823	0.528	rs10826435	ENSG00000230500.1	MKX-AS1	3.84	0.000138	0.0103	0.24	0.17	Lung cancer;	chr10:28251731	chr10:27744786~27767794:+
THCA	cis	rs8077577	0.671	rs9910090	ENSG00000273018.4	CTD-2303H24.2	-3.84	0.000138	0.0103	-0.25	-0.17	Obesity-related traits;	chr17:18347085	chr17:18511221~18551705:-
THCA	cis	rs9309473	1	rs10496193	ENSG00000273245.1	RP11-434P11.2	3.84	0.000139	0.0103	0.24	0.17	Metabolite levels;	chr2:73546376	chr2:73750256~73750786:-
THCA	cis	rs481331	0.866	rs2505893	ENSG00000215146.4	RP11-313J2.1	-3.84	0.000139	0.0103	-0.3	-0.17	Systemic juvenile idiopathic arthritis;	chr10:42709533	chr10:42331866~42367974:-
THCA	cis	rs9911578	1	rs391370	ENSG00000224738.1	AC099850.1	3.84	0.000139	0.0104	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58597689	chr17:59106598~59118267:+
THCA	cis	rs12134133	1	rs6658718	ENSG00000237074.1	RP11-6J21.2	3.84	0.000139	0.0104	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207249067~207309121:+
THCA	cis	rs2281603	0.57	rs3742606	ENSG00000258824.2	CTD-2555O16.2	-3.84	0.000139	0.0104	-0.15	-0.17	Lymphocyte counts;	chr14:64478371	chr14:64422935~64448557:-
THCA	cis	rs9863	0.861	rs4930725	ENSG00000269938.1	RP11-214K3.20	-3.84	0.000139	0.0104	-0.2	-0.17	White blood cell count;	chr12:123943615	chr12:123968023~123968579:-
THCA	cis	rs897984	0.759	rs13708	ENSG00000275263.1	RP11-1072A3.4	3.84	0.000139	0.0104	0.21	0.17	Dementia with Lewy bodies;	chr16:30989488	chr16:30956872~30957199:-
THCA	cis	rs5758659	0.652	rs1063392	ENSG00000205702.9	CYP2D7	-3.84	0.000139	0.0104	-0.13	-0.17	Cognitive function;	chr22:42058946	chr22:42140203~42144577:-
THCA	cis	rs1612141	1	rs1779543	ENSG00000251363.2	RP11-129M6.1	-3.84	0.000139	0.0104	-0.25	-0.17	QT interval (drug interaction);	chr14:41207934	chr14:40954898~40975877:+
THCA	cis	rs1612141	1	rs1779542	ENSG00000251363.2	RP11-129M6.1	-3.84	0.000139	0.0104	-0.25	-0.17	QT interval (drug interaction);	chr14:41208976	chr14:40954898~40975877:+
THCA	cis	rs1612141	1	rs1778372	ENSG00000251363.2	RP11-129M6.1	-3.84	0.000139	0.0104	-0.25	-0.17	QT interval (drug interaction);	chr14:41209263	chr14:40954898~40975877:+
THCA	cis	rs17122278	1	rs1047079	ENSG00000255239.1	AP002954.6	-3.84	0.000139	0.0104	-0.32	-0.17	Total cholesterol levels;	chr11:118602516	chr11:118688039~118690600:-
THCA	cis	rs6995541	0.647	rs2271357	ENSG00000248896.2	CTD-2135J3.3	-3.84	0.000139	0.0104	-0.21	-0.17	Triglyceride levels;	chr8:10826113	chr8:10729314~10771392:+
THCA	cis	rs2361718	0.603	rs12951255	ENSG00000279259.1	RP11-334C17.3	3.84	0.000139	0.0104	0.16	0.17	Yeast infection;	chr17:80111798	chr17:80147250~80148596:+
THCA	cis	rs2640806	0.505	rs11984998	ENSG00000253105.4	KB-1448A5.1	3.84	0.000139	0.0104	0.21	0.17	Obesity-related traits;	chr8:96351786	chr8:96371865~96387438:-
THCA	cis	rs765787	0.53	rs2554456	ENSG00000259932.1	CTD-2651B20.7	3.84	0.000139	0.0104	0.21	0.17	Uric acid levels;	chr15:45228940	chr15:45198517~45199139:-
THCA	cis	rs516805	0.924	rs809770	ENSG00000279114.1	RP3-425C14.5	-3.84	0.000139	0.0104	-0.17	-0.17	Lymphocyte counts;	chr6:122440061	chr6:122471923~122484161:+
THCA	cis	rs516805	0.924	rs476215	ENSG00000279114.1	RP3-425C14.5	-3.84	0.000139	0.0104	-0.17	-0.17	Lymphocyte counts;	chr6:122440739	chr6:122471923~122484161:+
THCA	cis	rs786425	0.717	rs12817757	ENSG00000278112.1	RP11-972P1.11	3.84	0.000139	0.0104	0.17	0.17	Pubertal anthropometrics;	chr12:123671940	chr12:123519390~123519856:-
THCA	cis	rs7833787	0.501	rs1492288	ENSG00000278886.1	RP11-108A14.1	-3.84	0.000139	0.0104	-0.25	-0.17	Obesity-related traits;	chr8:18827383	chr8:18864681~18865247:-
THCA	cis	rs6453278	0.732	rs4703727	ENSG00000250802.5	ZBED3-AS1	-3.84	0.000139	0.0104	-0.17	-0.17	Autism;	chr5:77111752	chr5:77086740~77166909:+
THCA	cis	rs858239	0.806	rs10268610	ENSG00000226816.2	AC005082.12	3.84	0.000139	0.0104	0.26	0.17	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23206013~23208045:+
THCA	cis	rs6487679	1	rs7298108	ENSG00000256069.6	A2MP1	-3.84	0.000139	0.0104	-0.23	-0.17	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9228533~9275817:-
THCA	cis	rs7259376	0.902	rs4932763	ENSG00000269138.1	ZNF209P	-3.84	0.000139	0.0104	-0.18	-0.17	Menopause (age at onset);	chr19:22421120	chr19:22463922~22473036:+
THCA	cis	rs755249	0.567	rs4660546	ENSG00000182109.6	RP11-69E11.4	3.84	0.000139	0.0104	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39522280~39546187:-
THCA	cis	rs835154	1	rs835154	ENSG00000272057.1	CTB-40H15.4	-3.84	0.000139	0.0104	-0.17	-0.17	Blood metabolite levels;	chr5:14876460	chr5:14872332~14872713:+
THCA	cis	rs453301	0.658	rs6986044	ENSG00000254340.1	RP11-10A14.3	-3.84	0.000139	0.0104	-0.2	-0.17	Joint mobility (Beighton score);	chr8:9017276	chr8:9141424~9145435:+
THCA	cis	rs2933343	0.649	rs1683786	ENSG00000231305.3	RP11-723O4.2	3.84	0.000139	0.0104	0.19	0.17	IgG glycosylation;	chr3:128908109	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.7	rs876754	ENSG00000231305.3	RP11-723O4.2	3.84	0.000139	0.0104	0.19	0.17	IgG glycosylation;	chr3:128908910	chr3:128861313~128871540:-
THCA	cis	rs7166081	0.951	rs67872952	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000139	0.0104	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67269260	chr15:67541072~67542604:-
THCA	cis	rs651907	0.64	rs1091664	ENSG00000256628.3	ZBTB11-AS1	3.84	0.000139	0.0104	0.2	0.17	Colorectal cancer;	chr3:101899846	chr3:101676475~101679217:+
THCA	cis	rs7824557	0.544	rs1865521	ENSG00000255495.1	AC145124.2	3.84	0.000139	0.0104	0.2	0.17	Retinal vascular caliber;	chr8:11373740	chr8:12194467~12196280:+
THCA	cis	rs878939	0.625	rs35137159	ENSG00000233690.1	EBAG9P1	3.84	0.000139	0.0104	0.22	0.17	Warfarin maintenance dose;	chr10:99584492	chr10:99697407~99697949:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000229180.5	GS1-124K5.11	-3.84	0.000139	0.0104	-0.12	-0.17	Aortic root size;	chr7:66032447	chr7:66526088~66542624:-
THCA	cis	rs4971059	0.617	rs12127609	ENSG00000225855.5	RUSC1-AS1	3.84	0.000139	0.0104	0.11	0.17	Breast cancer;	chr1:155161015	chr1:155316863~155324176:-
THCA	cis	rs853679	0.546	rs13195291	ENSG00000220721.1	OR1F12	3.84	0.000139	0.0104	0.39	0.17	Depression;	chr6:28201463	chr6:28073316~28074233:+
THCA	cis	rs853679	0.556	rs13197633	ENSG00000220721.1	OR1F12	3.84	0.000139	0.0104	0.39	0.17	Depression;	chr6:28206979	chr6:28073316~28074233:+
THCA	cis	rs4785204	1	rs9925215	ENSG00000279356.1	RP11-429P3.8	3.84	0.000139	0.0104	0.31	0.17	Esophageal cancer (squamous cell);	chr16:50062219	chr16:50072862~50074986:+
THCA	cis	rs1048886	0.872	rs12525538	ENSG00000271967.1	RP11-134K13.4	-3.84	0.000139	0.0104	-0.2	-0.17	Type 2 diabetes;	chr6:70575198	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs34246525	ENSG00000271967.1	RP11-134K13.4	-3.84	0.000139	0.0104	-0.2	-0.17	Type 2 diabetes;	chr6:70575239	chr6:70596438~70596980:+
THCA	cis	rs7772697	0.635	rs1316376	ENSG00000223701.3	RAET1E-AS1	-3.84	0.000139	0.0104	-0.24	-0.17	Diabetic retinopathy;	chr6:149089413	chr6:149884431~149919508:+
THCA	cis	rs13063635	0.764	rs7653372	ENSG00000226074.4	PRSS44	-3.84	0.000139	0.0104	-0.31	-0.17	Eosinophil percentage of granulocytes;	chr3:45886267	chr3:46809359~46812558:-
THCA	cis	rs73230612	1	rs16823508	ENSG00000242767.1	ZBTB20-AS4	3.84	0.000139	0.0104	0.23	0.17	Type 2 diabetes;	chr3:115117295	chr3:115100423~115103061:+
THCA	cis	rs73230612	1	rs12639377	ENSG00000242767.1	ZBTB20-AS4	3.84	0.000139	0.0104	0.23	0.17	Type 2 diabetes;	chr3:115117849	chr3:115100423~115103061:+
THCA	cis	rs73230612	1	rs13323268	ENSG00000242767.1	ZBTB20-AS4	3.84	0.000139	0.0104	0.23	0.17	Type 2 diabetes;	chr3:115129134	chr3:115100423~115103061:+
THCA	cis	rs73230612	1	rs12632241	ENSG00000242767.1	ZBTB20-AS4	3.84	0.000139	0.0104	0.23	0.17	Type 2 diabetes;	chr3:115131135	chr3:115100423~115103061:+
THCA	cis	rs73230612	1	rs73230612	ENSG00000242767.1	ZBTB20-AS4	3.84	0.000139	0.0104	0.23	0.17	Type 2 diabetes;	chr3:115131989	chr3:115100423~115103061:+
THCA	cis	rs2299587	0.554	rs2073562	ENSG00000253671.1	RP11-806O11.1	-3.84	0.000139	0.0104	-0.2	-0.17	Economic and political preferences;	chr8:17885420	chr8:17808941~17820868:+
THCA	cis	rs950776	0.667	rs57728226	ENSG00000261762.1	RP11-650L12.2	3.84	0.000139	0.0104	0.24	0.17	Sudden cardiac arrest;	chr15:78637008	chr15:78589123~78591276:-
THCA	cis	rs950776	0.745	rs36045869	ENSG00000261762.1	RP11-650L12.2	3.84	0.000139	0.0104	0.24	0.17	Sudden cardiac arrest;	chr15:78637156	chr15:78589123~78591276:-
THCA	cis	rs67981189	0.858	rs2526862	ENSG00000269927.1	RP6-91H8.3	-3.84	0.000139	0.0104	-0.2	-0.17	Schizophrenia;	chr14:70942897	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.788	rs2526860	ENSG00000269927.1	RP6-91H8.3	-3.84	0.000139	0.0104	-0.2	-0.17	Schizophrenia;	chr14:70945161	chr14:71141125~71143253:-
THCA	cis	rs7824557	0.564	rs1435275	ENSG00000154316.13	TDH	3.84	0.000139	0.0104	0.13	0.17	Retinal vascular caliber;	chr8:11378226	chr8:11339637~11368452:+
THCA	cis	rs4767841	0.565	rs393773	ENSG00000252886.1	RN7SKP197	-3.84	0.000139	0.0104	-0.17	-0.17	Urgency urinary incontinence;	chr12:119782242	chr12:119631090~119631386:-
THCA	cis	rs1577917	1	rs2816815	ENSG00000220563.1	PKMP3	-3.84	0.000139	0.0104	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85981938	chr6:85659892~85660606:-
THCA	cis	rs6504622	0.818	rs11079742	ENSG00000238419.1	RNU7-186P	-3.84	0.000139	0.0104	-0.19	-0.17	Orofacial clefts;	chr17:46942762	chr17:47259358~47259420:-
THCA	cis	rs755249	0.567	rs67020650	ENSG00000182109.6	RP11-69E11.4	3.84	0.000139	0.0104	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs72661925	ENSG00000182109.6	RP11-69E11.4	3.84	0.000139	0.0104	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39522280~39546187:-
THCA	cis	rs2839186	0.656	rs4819226	ENSG00000228137.1	AP001469.7	3.84	0.000139	0.0104	0.18	0.17	Testicular germ cell tumor;	chr21:46292498	chr21:46246890~46247682:+
THCA	cis	rs7617480	0.61	rs4955420	ENSG00000229759.1	MRPS18AP1	3.84	0.000139	0.0104	0.23	0.17	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:48256350~48256938:-
THCA	cis	rs73173548	0.502	rs4451795	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000139	0.0104	0.15	0.17	Macular telangiectasia type 2;	chr5:88422879	chr5:88268895~88436685:+
THCA	cis	rs4601821	1	rs6589375	ENSG00000270179.1	RP11-159N11.4	-3.84	0.000139	0.0104	-0.18	-0.17	Alcoholic chronic pancreatitis;	chr11:113384389	chr11:113368478~113369117:+
THCA	cis	rs6142618	0.935	rs6061183	ENSG00000224452.1	RSL24D1P6	3.84	0.000139	0.0104	0.22	0.17	Inflammatory bowel disease;	chr20:32140133	chr20:32170390~32170790:-
THCA	cis	rs4792901	0.722	rs8074904	ENSG00000279602.1	CTD-3014M21.1	-3.84	0.000139	0.0104	-0.22	-0.17	Dupuytren's disease;	chr17:43494209	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.759	rs75491854	ENSG00000279602.1	CTD-3014M21.1	-3.84	0.000139	0.0104	-0.22	-0.17	Dupuytren's disease;	chr17:43497282	chr17:43360041~43361361:-
THCA	cis	rs2625529	0.642	rs2200056	ENSG00000260037.4	CTD-2524L6.3	-3.84	0.000139	0.0104	-0.24	-0.17	Red blood cell count;	chr15:72010326	chr15:71818396~71823384:+
THCA	cis	rs7131987	0.565	rs4412790	ENSG00000275476.1	RP11-996F15.4	3.84	0.000139	0.0104	0.17	0.17	QT interval;	chr12:29253828	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.565	rs10743651	ENSG00000275476.1	RP11-996F15.4	3.84	0.000139	0.0104	0.17	0.17	QT interval;	chr12:29255006	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.546	rs7299648	ENSG00000275476.1	RP11-996F15.4	3.84	0.000139	0.0104	0.17	0.17	QT interval;	chr12:29256797	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.547	rs4370971	ENSG00000275476.1	RP11-996F15.4	3.84	0.000139	0.0104	0.17	0.17	QT interval;	chr12:29257066	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.565	rs7316026	ENSG00000275476.1	RP11-996F15.4	3.84	0.000139	0.0104	0.17	0.17	QT interval;	chr12:29258881	chr12:29277397~29277882:-
THCA	cis	rs17286411	0.639	rs12447856	ENSG00000260185.1	RP11-432I5.6	3.84	0.000139	0.0104	0.24	0.17	Blood protein levels;	chr16:71756770	chr16:71655027~71664212:+
THCA	cis	rs35123781	0.654	rs356443	ENSG00000253404.1	AC034243.1	-3.84	0.000139	0.0104	-0.22	-0.17	Schizophrenia;	chr5:139698244	chr5:138744434~138753309:-
THCA	cis	rs12295638	0.73	rs7127915	ENSG00000254862.4	RP11-159H22.2	-3.84	0.000139	0.0104	-0.23	-0.17	Obesity (extreme);	chr11:26631415	chr11:27471729~27482433:+
THCA	cis	rs2933343	0.553	rs35076317	ENSG00000231305.3	RP11-723O4.2	3.84	0.000139	0.0104	0.19	0.17	IgG glycosylation;	chr3:128996692	chr3:128861313~128871540:-
THCA	cis	rs214785	0.858	rs214787	ENSG00000226644.4	RP11-128M1.1	3.84	0.000139	0.0104	0.18	0.17	Basal cell carcinoma;	chr20:2303021	chr20:2207217~2213151:+
THCA	cis	rs214785	0.929	rs214789	ENSG00000226644.4	RP11-128M1.1	3.84	0.000139	0.0104	0.18	0.17	Basal cell carcinoma;	chr20:2303618	chr20:2207217~2213151:+
THCA	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	3.84	0.000139	0.0104	0.2	0.17	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
THCA	cis	rs7212590	0.581	rs8069418	ENSG00000267302.4	RP11-178C3.2	3.84	0.000139	0.0104	0.33	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59740852	chr17:59964832~59996972:+
THCA	cis	rs910316	0.726	rs175040	ENSG00000259138.1	RP11-950C14.7	-3.84	0.000139	0.0104	-0.15	-0.17	Height;	chr14:75002852	chr14:75127153~75136930:+
THCA	cis	rs931608	1	rs11085534	ENSG00000269138.1	ZNF209P	-3.84	0.000139	0.0104	-0.24	-0.17	Response to statins (LDL cholesterol change);Dental caries;	chr19:22430427	chr19:22463922~22473036:+
THCA	cis	rs9309473	1	rs2056486	ENSG00000273245.1	RP11-434P11.2	3.84	0.000139	0.0104	0.23	0.17	Metabolite levels;	chr2:73490440	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs10193972	ENSG00000273245.1	RP11-434P11.2	3.84	0.000139	0.0104	0.23	0.17	Metabolite levels;	chr2:73490529	chr2:73750256~73750786:-
THCA	cis	rs6995541	0.606	rs6990055	ENSG00000248896.2	CTD-2135J3.3	-3.84	0.000139	0.0104	-0.21	-0.17	Triglyceride levels;	chr8:10828739	chr8:10729314~10771392:+
THCA	cis	rs10186029	0.509	rs6733869	ENSG00000270659.1	RP11-105N14.1	3.84	0.000139	0.0104	0.15	0.17	Systemic sclerosis;	chr2:213084349	chr2:213152970~213153659:+
THCA	cis	rs3925158	0.51	rs60945224	ENSG00000229589.1	ACVR2B-AS1	-3.84	0.000139	0.0104	-0.35	-0.17	Gut microbiota (bacterial taxa);	chr3:38203189	chr3:38451027~38454820:-
THCA	cis	rs6847067	0.86	rs6853486	ENSG00000180769.7	WDFY3-AS2	3.84	0.000139	0.0104	0.13	0.17	Oropharynx cancer;	chr4:84619661	chr4:84965682~85011277:+
THCA	cis	rs74233809	1	rs74233809	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000139	0.0104	-0.31	-0.17	Birth weight;	chr10:103154183	chr10:102914585~102915404:+
THCA	cis	rs9911578	0.935	rs420878	ENSG00000224738.1	AC099850.1	3.84	0.000139	0.0104	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58631716	chr17:59106598~59118267:+
THCA	cis	rs4971059	0.654	rs4971073	ENSG00000236675.1	MTX1P1	-3.84	0.000139	0.0104	-0.16	-0.17	Breast cancer;	chr1:155140628	chr1:155230975~155234325:+
THCA	cis	rs6560517	0.747	rs7871849	ENSG00000234618.1	RPSAP9	-3.84	0.000139	0.0104	-0.2	-0.17	Dialysis-related mortality;	chr9:76474194	chr9:76398699~76399586:+
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000219891.2	ZSCAN12P1	3.84	0.000139	0.0104	0.24	0.17	Parkinson's disease;	chr6:28065618	chr6:28091154~28093664:+
THCA	cis	rs6121246	0.909	rs6060679	ENSG00000224628.2	RP5-854E16.2	3.84	0.000139	0.0104	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31682969	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs7272062	ENSG00000224628.2	RP5-854E16.2	-3.84	0.000139	0.0104	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31671342	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6119651	ENSG00000224628.2	RP5-854E16.2	-3.84	0.000139	0.0104	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31671443	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs2376992	ENSG00000224628.2	RP5-854E16.2	-3.84	0.000139	0.0104	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31675615	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6060644	ENSG00000224628.2	RP5-854E16.2	-3.84	0.000139	0.0104	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31677849	chr20:31285317~31286835:-
THCA	cis	rs3812831	0.661	rs2987458	ENSG00000264539.1	MIR548AR	3.84	0.000139	0.0104	0.18	0.17	Schizophrenia;	chr13:114154360	chr13:114244505~114244561:+
THCA	cis	rs13434995	0.513	rs17722979	ENSG00000249700.7	SRD5A3-AS1	-3.84	0.000139	0.0104	-0.24	-0.17	Adiponectin levels;	chr4:55480244	chr4:55363971~55395847:-
THCA	cis	rs7089973	0.604	rs10885620	ENSG00000228169.3	PPIAP19	3.84	0.000139	0.0104	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114870289	chr10:114690143~114690634:-
THCA	cis	rs2692947	0.673	rs584811	ENSG00000235584.2	AC008268.1	3.84	0.000139	0.0104	0.17	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96404141	chr2:95666084~95668715:+
THCA	cis	rs13256369	0.802	rs1060107	ENSG00000254153.1	CTA-398F10.2	-3.84	0.000139	0.0104	-0.2	-0.17	Obesity-related traits;	chr8:8703889	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.802	rs4840350	ENSG00000254153.1	CTA-398F10.2	-3.84	0.000139	0.0104	-0.2	-0.17	Obesity-related traits;	chr8:8703932	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.802	rs1060106	ENSG00000254153.1	CTA-398F10.2	-3.84	0.000139	0.0104	-0.2	-0.17	Obesity-related traits;	chr8:8703942	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.802	rs11249883	ENSG00000254153.1	CTA-398F10.2	-3.84	0.000139	0.0104	-0.2	-0.17	Obesity-related traits;	chr8:8704027	chr8:8456909~8461337:-
THCA	cis	rs12478296	1	rs55777943	ENSG00000220804.7	AC093642.5	3.84	0.000139	0.0104	0.2	0.17	Obesity-related traits;	chr2:242098535	chr2:242088633~242160153:+
THCA	cis	rs1023500	0.573	rs133380	ENSG00000227370.1	RP4-669P10.19	-3.84	0.000139	0.0104	-0.17	-0.17	Schizophrenia;	chr22:42072906	chr22:42132543~42132998:+
THCA	cis	rs714027	0.565	rs9614099	ENSG00000279699.1	RP1-102K2.9	3.84	0.00014	0.0104	0.18	0.17	Lymphocyte counts;	chr22:29892349	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.813	rs9614100	ENSG00000279699.1	RP1-102K2.9	3.84	0.00014	0.0104	0.18	0.17	Type 1 diabetes;	chr22:29892350	chr22:30275215~30276951:-
THCA	cis	rs340849	0.617	rs17710847	ENSG00000274895.1	RP11-478J18.2	-3.84	0.00014	0.0104	-0.15	-0.17	Alzheimer's disease;	chr1:213929776	chr1:213983793~213986419:-
THCA	cis	rs11971779	0.68	rs11768023	ENSG00000252332.1	RNU6-911P	-3.84	0.00014	0.0104	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139369649	chr7:139448740~139448843:+
THCA	cis	rs12681288	1	rs2167505	ENSG00000260721.1	AF067845.1	3.84	0.00014	0.0104	0.21	0.17	Schizophrenia;	chr8:1083877	chr8:1368642~1369833:-
THCA	cis	rs7487075	0.93	rs4076248	ENSG00000257261.4	RP11-96H19.1	3.84	0.00014	0.0104	0.14	0.17	Itch intensity from mosquito bite;	chr12:46439822	chr12:46383679~46876159:+
THCA	cis	rs6696239	0.956	rs2172936	ENSG00000227711.2	RP11-275O4.5	-3.84	0.00014	0.0104	-0.24	-0.17	Height;	chr1:227596547	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.956	rs9726691	ENSG00000227711.2	RP11-275O4.5	-3.84	0.00014	0.0104	-0.24	-0.17	Height;	chr1:227597923	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.956	rs10916173	ENSG00000227711.2	RP11-275O4.5	-3.84	0.00014	0.0104	-0.24	-0.17	Height;	chr1:227605545	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.911	rs10753436	ENSG00000227711.2	RP11-275O4.5	-3.84	0.00014	0.0104	-0.24	-0.17	Height;	chr1:227609163	chr1:227509028~227520477:-
THCA	cis	rs6918586	1	rs198811	ENSG00000272462.2	U91328.19	3.84	0.00014	0.0104	0.14	0.17	Schizophrenia;	chr6:26128218	chr6:25992662~26001775:+
THCA	cis	rs877819	0.552	rs2127586	ENSG00000228403.1	RP11-563N6.6	-3.84	0.00014	0.0104	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48871605	chr10:48878022~48878649:+
THCA	cis	rs12476592	0.571	rs6546005	ENSG00000242412.1	DBIL5P2	3.84	0.00014	0.0104	0.22	0.17	Childhood ear infection;	chr2:63444937	chr2:63117851~63119542:-
THCA	cis	rs7166081	1	rs58074225	ENSG00000270964.1	RP11-502I4.3	-3.84	0.00014	0.0104	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67253554	chr15:67541072~67542604:-
THCA	cis	rs2153535	0.518	rs9406187	ENSG00000230939.1	RP11-314C16.1	-3.84	0.00014	0.0104	-0.19	-0.17	Motion sickness;	chr6:8654376	chr6:8784178~8785445:+
THCA	cis	rs11673344	0.73	rs1644641	ENSG00000267260.1	CTD-2162K18.4	-3.84	0.00014	0.0104	-0.22	-0.17	Obesity-related traits;	chr19:36971237	chr19:36773153~36777078:+
THCA	cis	rs62244186	0.659	rs56234157	ENSG00000214820.3	MPRIPP1	3.84	0.00014	0.0104	0.19	0.17	Depressive symptoms;	chr3:44474729	chr3:44579938~44581026:-
THCA	cis	rs6756513	0.5	rs2278933	ENSG00000231024.1	AC092431.3	-3.84	0.00014	0.0104	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69829233	chr2:69700192~69713847:-
THCA	cis	rs724818	0.661	rs17051259	ENSG00000251609.2	SETP12	-3.84	0.00014	0.0104	-0.49	-0.17	Monobrow thickness;	chr4:120792103	chr4:120895494~120897083:-
THCA	cis	rs13098911	0.54	rs2230322	ENSG00000226074.4	PRSS44	-3.84	0.00014	0.0104	-0.31	-0.17	Celiac disease;	chr3:46021837	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs876668	ENSG00000226074.4	PRSS44	-3.84	0.00014	0.0104	-0.31	-0.17	Celiac disease;	chr3:46022261	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs60019065	ENSG00000226074.4	PRSS44	-3.84	0.00014	0.0104	-0.31	-0.17	Celiac disease;	chr3:46023126	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs35930050	ENSG00000226074.4	PRSS44	-3.84	0.00014	0.0104	-0.31	-0.17	Celiac disease;	chr3:46024271	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs34584867	ENSG00000226074.4	PRSS44	-3.84	0.00014	0.0104	-0.31	-0.17	Eosinophil percentage of granulocytes;	chr3:46024471	chr3:46809359~46812558:-
THCA	cis	rs4950322	0.58	rs4950371	ENSG00000180867.10	PDIA3P1	3.84	0.00014	0.0104	0.17	0.17	Protein quantitative trait loci;	chr1:147114243	chr1:147178113~147179622:+
THCA	cis	rs4808779	0.924	rs1469024	ENSG00000268650.3	AC068499.10	-3.84	0.00014	0.0104	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr19:18273734	chr19:18204730~18220480:+
THCA	cis	rs10185424	0.521	rs4851529	ENSG00000281162.1	LINC01127	-3.84	0.00014	0.0104	-0.14	-0.17	Crohn's disease;Ulcerative colitis;	chr2:102030838	chr2:101962056~101987167:+
THCA	cis	rs17741873	0.779	rs4746153	ENSG00000271848.1	RP11-464F9.21	-3.84	0.00014	0.0104	-0.22	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73838524	chr10:73654039~73674719:+
THCA	cis	rs13256369	0.802	rs12681925	ENSG00000254153.1	CTA-398F10.2	-3.84	0.00014	0.0104	-0.2	-0.17	Obesity-related traits;	chr8:8704139	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.802	rs12680019	ENSG00000254153.1	CTA-398F10.2	-3.84	0.00014	0.0104	-0.2	-0.17	Obesity-related traits;	chr8:8704188	chr8:8456909~8461337:-
THCA	cis	rs2762353	0.639	rs566530	ENSG00000272462.2	U91328.19	-3.84	0.00014	0.0104	-0.14	-0.17	Blood metabolite levels;	chr6:25878133	chr6:25992662~26001775:+
THCA	cis	rs3758141	0.858	rs6983992	ENSG00000278886.1	RP11-108A14.1	3.84	0.00014	0.0104	0.28	0.17	Body mass index (change over time) in gastrointestinal cancer;	chr8:18871125	chr8:18864681~18865247:-
THCA	cis	rs10266483	0.739	rs2692104	ENSG00000234338.1	RP11-797H7.1	3.84	0.00014	0.0104	0.12	0.17	Response to statin therapy;	chr7:64300577	chr7:64835280~64836882:-
THCA	cis	rs12476592	0.602	rs6546009	ENSG00000242412.1	DBIL5P2	3.84	0.00014	0.0104	0.22	0.17	Childhood ear infection;	chr2:63518608	chr2:63117851~63119542:-
THCA	cis	rs12554020	0.686	rs12553775	ENSG00000227603.1	RP11-165J3.6	3.84	0.00014	0.0104	0.35	0.17	Schizophrenia;	chr9:93630107	chr9:93435332~93437121:-
THCA	cis	rs7819412	0.645	rs4841508	ENSG00000261451.1	RP11-981G7.1	-3.84	0.00014	0.0104	-0.22	-0.17	Triglycerides;	chr8:11207494	chr8:10433672~10438312:+
THCA	cis	rs740750	1	rs740750	ENSG00000254333.1	CTC-367J11.1	3.84	0.00014	0.0104	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr5:150135511	chr5:150475531~150485968:-
THCA	cis	rs17193922	0.876	rs55813797	ENSG00000279344.1	RP11-44F14.7	3.84	0.00014	0.0104	0.2	0.17	Hip circumference adjusted for BMI;	chr16:53517398	chr16:53478957~53481550:-
THCA	cis	rs3824488	0.599	rs357523	ENSG00000271155.1	RP11-435O5.5	-3.84	0.00014	0.0104	-0.29	-0.17	Neuroticism;	chr9:95427053	chr9:95506235~95507636:+
THCA	cis	rs2179367	0.632	rs9498344	ENSG00000216906.2	RP11-350J20.9	3.84	0.00014	0.0104	0.22	0.17	Dupuytren's disease;	chr6:149401053	chr6:149904243~149906418:+
THCA	cis	rs2579519	0.547	rs11683523	ENSG00000235584.2	AC008268.1	-3.84	0.00014	0.0104	-0.18	-0.17	Diastolic blood pressure;	chr2:95879107	chr2:95666084~95668715:+
THCA	cis	rs11601239	0.646	rs495498	ENSG00000254750.1	CASP1P2	3.84	0.00014	0.0104	0.14	0.17	Refractive error;	chr11:105705048	chr11:105063345~105071541:-
THCA	cis	rs1348850	0.567	rs2222711	ENSG00000271996.1	RP11-337N6.1	3.84	0.00014	0.0104	0.23	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177669382	chr2:177306373~177310572:+
THCA	cis	rs853679	0.607	rs13217984	ENSG00000220721.1	OR1F12	3.84	0.00014	0.0104	0.41	0.17	Depression;	chr6:28171932	chr6:28073316~28074233:+
THCA	cis	rs853679	0.556	rs67297533	ENSG00000220721.1	OR1F12	3.84	0.00014	0.0104	0.41	0.17	Depression;	chr6:28173475	chr6:28073316~28074233:+
THCA	cis	rs853679	0.505	rs35781323	ENSG00000220721.1	OR1F12	3.84	0.00014	0.0104	0.41	0.17	Depression;	chr6:28177054	chr6:28073316~28074233:+
THCA	cis	rs13098911	0.54	rs13071283	ENSG00000226074.4	PRSS44	-3.84	0.00014	0.0104	-0.32	-0.17	Celiac disease;	chr3:45968515	chr3:46809359~46812558:-
THCA	cis	rs11105298	0.891	rs12369685	ENSG00000266347.2	AC068641.1	3.84	0.00014	0.0104	0.23	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89592833~89592927:+
THCA	cis	rs2562456	0.876	rs2359144	ENSG00000268521.1	VN1R83P	3.84	0.00014	0.0104	0.17	0.17	Pain;	chr19:21407834	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.876	rs4638726	ENSG00000268521.1	VN1R83P	3.84	0.00014	0.0104	0.17	0.17	Pain;	chr19:21409710	chr19:21289554~21289998:-
THCA	cis	rs9467773	0.595	rs7767847	ENSG00000228223.2	HCG11	-3.84	0.00014	0.0104	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs3800303	ENSG00000228223.2	HCG11	-3.84	0.00014	0.0104	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26523450~26526579:+
THCA	cis	rs7131987	1	rs7131987	ENSG00000257599.1	OVCH1-AS1	-3.84	0.00014	0.0104	-0.21	-0.17	QT interval;	chr12:29253555	chr12:29389294~29487488:+
THCA	cis	rs7127129	0.777	rs3781656	ENSG00000246889.2	AP000487.5	-3.84	0.00014	0.0104	-0.18	-0.17	Aortic root size;	chr11:70162549	chr11:70372246~70398488:-
THCA	cis	rs10938353	0.68	rs1491313	ENSG00000273369.1	RP11-700J17.1	3.84	0.00014	0.0104	0.21	0.17	Body mass index;	chr4:44783372	chr4:44693946~44694386:-
THCA	cis	rs9595908	0.669	rs4057298	ENSG00000212293.1	SNORA16	3.84	0.00014	0.0104	0.21	0.17	Body mass index;	chr13:32734227	chr13:32420390~32420516:-
THCA	cis	rs2806561	0.765	rs605367	ENSG00000249087.5	ZNF436-AS1	-3.84	0.00014	0.0104	-0.11	-0.17	Height;	chr1:23192031	chr1:23368997~23371839:+
THCA	cis	rs3755605	0.728	rs6788549	ENSG00000242578.1	RP11-469J4.3	3.84	0.00014	0.0104	0.2	0.17	Testicular germ cell tumor;	chr3:170107417	chr3:170410512~170418615:+
THCA	cis	rs6443245	0.611	rs2648379	ENSG00000227110.5	LMCD1-AS1	-3.84	0.00014	0.0104	-0.2	-0.17	Daytime sleep phenotypes;	chr3:9583458	chr3:7952805~8611924:-
THCA	cis	rs12681366	0.881	rs12674614	ENSG00000261437.1	RP11-22C11.2	3.84	0.00014	0.0104	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94396605	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.881	rs3019155	ENSG00000261437.1	RP11-22C11.2	3.84	0.00014	0.0104	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94405359	chr8:94637285~94639467:-
THCA	cis	rs1015362	0.504	rs6059552	ENSG00000275784.1	RP5-1125A11.6	-3.84	0.00014	0.0104	-0.2	-0.17	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33989480~33991818:-
THCA	cis	rs4908768	0.871	rs4908508	ENSG00000232912.4	RP5-1115A15.1	-3.84	0.00014	0.0104	-0.2	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8740721	chr1:8424645~8434838:+
THCA	cis	rs4767841	0.935	rs2952444	ENSG00000252886.1	RN7SKP197	-3.84	0.00014	0.0104	-0.18	-0.17	Urgency urinary incontinence;	chr12:119737986	chr12:119631090~119631386:-
THCA	cis	rs12476592	0.602	rs10168545	ENSG00000242412.1	DBIL5P2	3.84	0.00014	0.0104	0.22	0.17	Childhood ear infection;	chr2:63507150	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs7576316	ENSG00000242412.1	DBIL5P2	3.84	0.00014	0.0104	0.22	0.17	Childhood ear infection;	chr2:63513988	chr2:63117851~63119542:-
THCA	cis	rs683250	0.629	rs682713	ENSG00000254551.1	RP11-727A23.7	-3.84	0.00014	0.0105	-0.22	-0.17	Subcortical brain region volumes;	chr11:83223343	chr11:83209431~83213379:-
THCA	cis	rs150992	0.711	rs170734	ENSG00000241597.2	CTD-2007H13.1	-3.84	0.00014	0.0105	-0.23	-0.17	Body mass index;	chr5:98811337	chr5:98954394~98954972:+
THCA	cis	rs6012564	0.819	rs1467417	ENSG00000230758.1	SNAP23P	-3.84	0.00014	0.0105	-0.22	-0.17	Anger;	chr20:48917118	chr20:49038357~49038602:-
THCA	cis	rs7586085	0.874	rs62174820	ENSG00000232411.1	AC009495.3	-3.84	0.00014	0.0105	-0.19	-0.17	Total body bone mineral density;	chr2:165760157	chr2:165833048~165839098:-
THCA	cis	rs11710088	0.931	rs11920457	ENSG00000244503.1	RP11-278L15.6	3.84	0.00014	0.0105	0.22	0.17	QRS duration;	chr3:149482082	chr3:149494660~149495995:+
THCA	cis	rs11710088	0.931	rs66482463	ENSG00000244503.1	RP11-278L15.6	3.84	0.00014	0.0105	0.22	0.17	QRS duration;	chr3:149482293	chr3:149494660~149495995:+
THCA	cis	rs7829975	0.714	rs4840362	ENSG00000233609.3	RP11-62H7.2	-3.84	0.00014	0.0105	-0.17	-0.17	Mood instability;	chr8:8812572	chr8:8961200~8979025:+
THCA	cis	rs7688540	0.771	rs7669892	ENSG00000211553.1	AC253576.2	3.84	0.00014	0.0105	0.22	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:315464	chr4:136461~136568:+
THCA	cis	rs9291683	0.551	rs2240720	ENSG00000261490.1	RP11-448G15.3	3.84	0.00014	0.0105	0.11	0.17	Bone mineral density;	chr4:10018856	chr4:10068089~10073019:-
THCA	cis	rs56318008	0.773	rs3754496	ENSG00000228397.1	RP1-224A6.3	-3.84	0.00014	0.0105	-0.31	-0.17	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22052387	chr1:22023994~22024968:-
THCA	cis	rs4791641	0.756	rs4791663	ENSG00000178977.3	LINC00324	3.84	0.00014	0.0105	0.2	0.17	Red blood cell count;LDL cholesterol;Hematocrit;Hemoglobin concentration;LDL cholesterol levels;	chr17:8282584	chr17:8220642~8224043:-
THCA	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-3.84	0.00014	0.0105	-0.17	-0.17	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
THCA	cis	rs6546550	0.835	rs3755389	ENSG00000179818.12	PCBP1-AS1	-3.84	0.00014	0.0105	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69892337	chr2:69962263~70103220:-
THCA	cis	rs1125355	0.893	rs114932236	ENSG00000243792.1	OR7E89P	-3.84	0.00014	0.0105	-0.27	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158827375	chr2:158853755~158854576:+
THCA	cis	rs801193	0.904	rs4718405	ENSG00000272831.1	RP11-792A8.4	3.84	0.00014	0.0105	0.11	0.17	Aortic root size;	chr7:66789659	chr7:66739829~66740385:-
THCA	cis	rs58904263	1	rs58904263	ENSG00000224628.2	RP5-854E16.2	-3.84	0.00014	0.0105	-0.23	-0.17	Monocyte count;	chr20:31813603	chr20:31285317~31286835:-
THCA	cis	rs656319	0.58	rs17690549	ENSG00000248538.5	RP11-10A14.5	3.84	0.00014	0.0105	0.23	0.17	Myopia (pathological);	chr8:10141028	chr8:9189011~9202854:+
THCA	cis	rs2288884	0.579	rs6509609	ENSG00000260160.1	CTC-471J1.2	-3.84	0.00014	0.0105	-0.18	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51970353	chr19:52058490~52063703:-
THCA	cis	rs9925964	0.933	rs10871454	ENSG00000279196.1	RP11-1072A3.3	-3.84	0.00014	0.0105	-0.17	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036758	chr16:30984630~30988270:-
THCA	cis	rs911555	0.713	rs10162425	ENSG00000269940.1	RP11-73M18.7	3.84	0.00014	0.0105	0.18	0.17	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103694560~103695170:+
THCA	cis	rs9911578	1	rs437732	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58598500	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs302854	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58606251	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs302859	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58615771	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs9898626	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58620858	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs2611782	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58640595	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs302843	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58650625	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs302842	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58650741	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.935	rs2567912	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58653909	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs1631237	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58657334	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs2567911	ENSG00000224738.1	AC099850.1	3.84	0.00014	0.0105	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58657616	chr17:59106598~59118267:+
THCA	cis	rs8062405	1	rs12325113	ENSG00000270424.1	RP11-1348G14.6	3.84	0.00014	0.0105	0.21	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28749959~28750595:-
THCA	cis	rs56163509	1	rs56163509	ENSG00000270424.1	RP11-1348G14.6	3.84	0.00014	0.0105	0.21	0.17	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs62037369	ENSG00000270424.1	RP11-1348G14.6	3.84	0.00014	0.0105	0.21	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28749959~28750595:-
THCA	cis	rs8062405	0.965	rs7359397	ENSG00000270424.1	RP11-1348G14.6	3.84	0.00014	0.0105	0.21	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28749959~28750595:-
THCA	cis	rs7546	0.504	rs2075637	ENSG00000267077.1	RP11-127I20.5	-3.84	0.00014	0.0105	-0.2	-0.17	Cancer;	chr16:4888279	chr16:4795265~4796532:-
THCA	cis	rs10090774	0.93	rs9886378	ENSG00000280303.2	ERICD	-3.84	0.00014	0.0105	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140910738	chr8:140636281~140638283:+
THCA	cis	rs1923539	0.549	rs2250360	ENSG00000225484.5	NUTM2B-AS1	3.84	0.00014	0.0105	0.22	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79905258	chr10:79663088~79826594:-
THCA	cis	rs2836974	1	rs2836974	ENSG00000255568.3	BRWD1-AS2	-3.84	0.00014	0.0105	-0.15	-0.17	Cognitive function;	chr21:39291255	chr21:39313935~39314962:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000229180.5	GS1-124K5.11	3.84	0.00014	0.0105	0.12	0.17	Aortic root size;	chr7:66521858	chr7:66526088~66542624:-
THCA	cis	rs9309473	1	rs10187416	ENSG00000273245.1	RP11-434P11.2	3.84	0.00014	0.0105	0.24	0.17	Metabolite levels;	chr2:73486614	chr2:73750256~73750786:-
THCA	cis	rs765787	0.53	rs11636395	ENSG00000259539.1	CTD-2651B20.1	3.84	0.000141	0.0105	0.22	0.17	Uric acid levels;	chr15:45243486	chr15:45152664~45167526:-
THCA	cis	rs6968419	1	rs6967663	ENSG00000237870.5	AC073130.1	3.84	0.000141	0.0105	0.18	0.17	Intraocular pressure;	chr7:116195756	chr7:116275606~116286734:-
THCA	cis	rs755249	0.567	rs3818806	ENSG00000182109.6	RP11-69E11.4	3.84	0.000141	0.0105	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39522280~39546187:-
THCA	cis	rs12291225	0.645	rs3763950	ENSG00000251991.1	RNU7-49P	3.84	0.000141	0.0105	0.21	0.17	Sense of smell;	chr11:14256503	chr11:14478892~14478953:+
THCA	cis	rs7960884	0.655	rs979063	ENSG00000177359.16	RP11-551L14.1	3.84	0.000141	0.0105	0.2	0.17	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31229812	chr12:31111652~31206154:-
THCA	cis	rs9739640	1	rs9739640	ENSG00000257379.1	RP11-793H13.8	3.84	0.000141	0.0105	0.26	0.17	Reticulocyte count;	chr12:53389390	chr12:53441741~53467528:+
THCA	cis	rs1577330	0.699	rs1577328	ENSG00000254396.1	RP11-56F10.3	-3.84	0.000141	0.0105	-0.21	-0.17	IgG glycosylation;	chr9:27101038	chr9:27102630~27104728:+
THCA	cis	rs972578	0.74	rs737782	ENSG00000274717.1	RP1-47A17.1	-3.84	0.000141	0.0105	-0.18	-0.17	Mean platelet volume;	chr22:43001557	chr22:42791814~42794313:-
THCA	cis	rs4073416	0.508	rs7146993	ENSG00000276116.2	FUT8-AS1	-3.84	0.000141	0.0105	-0.19	-0.17	N-glycan levels;	chr14:65582154	chr14:65411170~65412690:-
THCA	cis	rs7129556	0.737	rs10899404	ENSG00000254459.1	RP11-91P24.7	3.84	0.000141	0.0105	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77751747	chr11:77829654~77872262:-
THCA	cis	rs6012953	1	rs6012953	ENSG00000231715.1	COX6CP2	3.84	0.000141	0.0105	0.19	0.17	Vitiligo;	chr20:50506506	chr20:50479767~50479991:+
THCA	cis	rs6479891	0.908	rs61853639	ENSG00000272767.1	JMJD1C-AS1	3.84	0.000141	0.0105	0.25	0.17	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63465229~63466563:+
THCA	cis	rs9863	0.828	rs952632	ENSG00000270028.1	RP11-380L11.4	3.84	0.000141	0.0105	0.19	0.17	White blood cell count;	chr12:123985191	chr12:123925461~123926083:-
THCA	cis	rs9863	0.694	rs11837287	ENSG00000270028.1	RP11-380L11.4	3.84	0.000141	0.0105	0.19	0.17	White blood cell count;	chr12:123985512	chr12:123925461~123926083:-
THCA	cis	rs2590942	0.838	rs2613500	ENSG00000227207.2	RPL31P12	-3.84	0.000141	0.0105	-0.29	-0.17	Childhood body mass index;	chr1:72354201	chr1:72301472~72301829:+
THCA	cis	rs1122401	0.538	rs2962547	ENSG00000280159.1	CTD-2591A1.1	3.84	0.000141	0.0105	0.19	0.17	Smoking initiation;	chr5:54568774	chr5:54643557~54645987:+
THCA	cis	rs7824557	0.525	rs12682349	ENSG00000227888.4	FAM66A	3.84	0.000141	0.0105	0.22	0.17	Retinal vascular caliber;	chr8:11387794	chr8:12362019~12388296:+
THCA	cis	rs11694172	1	rs11675723	ENSG00000273456.1	RP11-686O6.2	3.84	0.000141	0.0105	0.16	0.17	Cholesterol, total;	chr2:202682150	chr2:202374932~202375604:-
THCA	cis	rs733175	0.794	rs7678211	ENSG00000261490.1	RP11-448G15.3	3.84	0.000141	0.0105	0.13	0.17	Psychosis and Alzheimer's disease;	chr4:10055959	chr4:10068089~10073019:-
THCA	cis	rs733175	0.83	rs6812851	ENSG00000261490.1	RP11-448G15.3	3.84	0.000141	0.0105	0.13	0.17	Psychosis and Alzheimer's disease;	chr4:10057079	chr4:10068089~10073019:-
THCA	cis	rs733175	0.83	rs714873	ENSG00000261490.1	RP11-448G15.3	3.84	0.000141	0.0105	0.13	0.17	Psychosis and Alzheimer's disease;	chr4:10057994	chr4:10068089~10073019:-
THCA	cis	rs733175	0.83	rs714871	ENSG00000261490.1	RP11-448G15.3	3.84	0.000141	0.0105	0.13	0.17	Psychosis and Alzheimer's disease;	chr4:10058007	chr4:10068089~10073019:-
THCA	cis	rs733175	0.83	rs6813650	ENSG00000261490.1	RP11-448G15.3	3.84	0.000141	0.0105	0.13	0.17	Psychosis and Alzheimer's disease;	chr4:10059436	chr4:10068089~10073019:-
THCA	cis	rs733175	0.83	rs10004571	ENSG00000261490.1	RP11-448G15.3	3.84	0.000141	0.0105	0.13	0.17	Psychosis and Alzheimer's disease;	chr4:10061341	chr4:10068089~10073019:-
THCA	cis	rs7552393	0.965	rs6699405	ENSG00000233008.4	RP11-475O6.1	-3.84	0.000141	0.0105	-0.19	-0.17	Select biomarker traits;	chr1:83792926	chr1:83575776~83861023:-
THCA	cis	rs74233809	1	rs12221193	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000141	0.0105	-0.32	-0.17	Birth weight;	chr10:102905510	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs77180047	ENSG00000272912.1	RP11-724N1.1	-3.84	0.000141	0.0105	-0.32	-0.17	Birth weight;	chr10:102907000	chr10:102914585~102915404:+
THCA	cis	rs6847067	0.965	rs67045782	ENSG00000180769.7	WDFY3-AS2	3.84	0.000141	0.0105	0.13	0.17	Oropharynx cancer;	chr4:84859429	chr4:84965682~85011277:+
THCA	cis	rs17604090	1	rs10272065	ENSG00000227855.3	DPY19L2P3	3.84	0.000141	0.0105	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29654620	chr7:29650227~29742594:+
THCA	cis	rs6012953	0.56	rs13041704	ENSG00000231715.1	COX6CP2	3.84	0.000141	0.0105	0.19	0.17	Vitiligo;	chr20:50527746	chr20:50479767~50479991:+
THCA	cis	rs7246967	0.673	rs16999519	ENSG00000198153.8	ZNF849P	3.84	0.000141	0.0105	0.26	0.17	Bronchopulmonary dysplasia;	chr19:22631274	chr19:22685167~22686732:+
THCA	cis	rs9291683	0.62	rs4383618	ENSG00000261490.1	RP11-448G15.3	-3.84	0.000141	0.0105	-0.11	-0.17	Bone mineral density;	chr4:10123527	chr4:10068089~10073019:-
THCA	cis	rs7520050	0.778	rs2088102	ENSG00000281133.1	AL355480.3	3.84	0.000141	0.0105	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45580892~45580996:-
THCA	cis	rs2006933	0.625	rs62065057	ENSG00000267644.1	CTD-2008P7.10	3.84	0.000141	0.0105	0.23	0.17	Amyotrophic lateral sclerosis;	chr17:28114259	chr17:28219285~28220005:+
THCA	cis	rs1580019	0.534	rs13237495	ENSG00000273014.1	RP11-225B17.2	3.84	0.000141	0.0105	0.18	0.17	Cognitive ability;	chr7:32521075	chr7:32758882~32759353:+
THCA	cis	rs12549025	0.838	rs35195642	ENSG00000253390.1	CTC-756D1.2	-3.84	0.000141	0.0105	-0.3	-0.17	Reticulocyte fraction of red cells;	chr8:23537158	chr8:23458601~23484971:+
THCA	cis	rs8024893	1	rs8038787	ENSG00000215302.7	CTD-3092A11.1	3.84	0.000141	0.0105	0.26	0.17	Red cell distribution width;	chr15:31246171	chr15:30470779~30507623:+
THCA	cis	rs6981523	0.553	rs11783890	ENSG00000205879.4	FAM90A2P	-3.84	0.000141	0.0105	-0.22	-0.17	Neuroticism;	chr8:11198879	chr8:12172202~12178575:-
THCA	cis	rs7520050	0.966	rs785488	ENSG00000281133.1	AL355480.3	3.84	0.000141	0.0105	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs785489	ENSG00000281133.1	AL355480.3	3.84	0.000141	0.0105	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45580892~45580996:-
THCA	cis	rs763121	0.853	rs1569492	ENSG00000225450.1	RP3-508I15.14	3.84	0.000141	0.0105	0.13	0.17	Menopause (age at onset);	chr22:38579506	chr22:38739003~38749041:+
THCA	cis	rs875971	0.638	rs10249404	ENSG00000232546.1	RP11-458F8.1	3.84	0.000141	0.0105	0.14	0.17	Aortic root size;	chr7:66581737	chr7:66848496~66858136:+
THCA	cis	rs17123764	0.892	rs12317778	ENSG00000257464.1	RP11-161H23.8	-3.84	0.000141	0.0105	-0.32	-0.17	Intelligence (multi-trait analysis);	chr12:49711854	chr12:49442424~49442652:-
THCA	cis	rs4950322	0.547	rs61838945	ENSG00000180867.10	PDIA3P1	3.84	0.000141	0.0105	0.17	0.17	Protein quantitative trait loci;	chr1:147111477	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.563	rs6686480	ENSG00000180867.10	PDIA3P1	3.84	0.000141	0.0105	0.17	0.17	Protein quantitative trait loci;	chr1:147111986	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.563	rs6700783	ENSG00000180867.10	PDIA3P1	3.84	0.000141	0.0105	0.17	0.17	Protein quantitative trait loci;	chr1:147111987	chr1:147178113~147179622:+
THCA	cis	rs62158800	0.598	rs1516215	ENSG00000237880.1	AC096669.2	3.84	0.000141	0.0105	0.18	0.17	Facial morphology (factor 22);	chr2:107676325	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs6542730	ENSG00000237880.1	AC096669.2	3.84	0.000141	0.0105	0.18	0.17	Facial morphology (factor 22);	chr2:107676927	chr2:107385632~107542649:-
THCA	cis	rs62158800	0.598	rs1588950	ENSG00000237880.1	AC096669.2	3.84	0.000141	0.0105	0.18	0.17	Facial morphology (factor 22);	chr2:107681369	chr2:107385632~107542649:-
THCA	cis	rs62292953	0.589	rs10490862	ENSG00000248724.5	NPHP3-AS1	-3.84	0.000141	0.0105	-0.31	-0.17	Red cell distribution width;	chr3:132441869	chr3:132721750~132874223:+
THCA	cis	rs4971059	0.629	rs9297	ENSG00000236675.1	MTX1P1	-3.84	0.000141	0.0105	-0.16	-0.17	Breast cancer;	chr1:155134074	chr1:155230975~155234325:+
THCA	cis	rs875971	0.619	rs10278371	ENSG00000230295.1	RP11-458F8.2	3.84	0.000141	0.0105	0.13	0.17	Aortic root size;	chr7:66586553	chr7:66880708~66882981:+
THCA	cis	rs6929812	1	rs6456785	ENSG00000216915.2	RP1-97D16.1	3.84	0.000141	0.0105	0.23	0.17	Neuroticism (multi-trait analysis);	chr6:27422620	chr6:27737000~27738494:-
THCA	cis	rs17597773	0.674	rs2279638	ENSG00000272823.1	RP11-295M18.6	-3.84	0.000141	0.0105	-0.23	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828445	chr1:220828676~220829211:-
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000265443.1	CTD-2349P21.6	-3.84	0.000141	0.0105	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30726305~30727564:-
THCA	cis	rs7259376	0.936	rs7259586	ENSG00000269138.1	ZNF209P	3.84	0.000141	0.0105	0.17	0.17	Menopause (age at onset);	chr19:22355060	chr19:22463922~22473036:+
THCA	cis	rs6921919	0.848	rs56131013	ENSG00000176933.5	TOB2P1	-3.84	0.000141	0.0105	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28217643~28218634:-
THCA	cis	rs711244	0.532	rs12104444	ENSG00000279519.1	RP11-288C18.1	3.84	0.000141	0.0105	0.14	0.17	Mean platelet volume;	chr2:37026290	chr2:36839922~36842539:-
THCA	cis	rs9532669	0.963	rs1056835	ENSG00000229473.2	RGS17P1	3.84	0.000141	0.0105	0.22	0.17	Cervical cancer;	chr13:40932585	chr13:40992779~40993331:-
THCA	cis	rs4568518	0.74	rs11535159	ENSG00000279048.1	RP11-511H23.2	3.84	0.000141	0.0105	0.11	0.17	Measles;	chr7:17970686	chr7:17940503~17942922:+
THCA	cis	rs925946	0.518	rs12361806	ENSG00000245573.6	BDNF-AS	-3.84	0.000141	0.0105	-0.17	-0.17	Weight;Body mass index;	chr11:27598022	chr11:27506838~27698174:+
THCA	cis	rs13217239	0.608	rs6930508	ENSG00000261353.1	CTA-14H9.5	3.84	0.000141	0.0105	0.18	0.17	Schizophrenia;	chr6:27085363	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs2142685	ENSG00000261353.1	CTA-14H9.5	3.84	0.000141	0.0105	0.18	0.17	Schizophrenia;	chr6:27086718	chr6:26527063~26527404:+
THCA	cis	rs472402	0.623	rs8192130	ENSG00000250056.4	LINC01018	-3.84	0.000141	0.0105	-0.21	-0.17	Response to amphetamines;	chr5:6636337	chr5:6582136~6588499:+
THCA	cis	rs2154427	0.935	rs2833953	ENSG00000238197.4	PAXBP1-AS1	3.84	0.000141	0.0105	0.17	0.17	Bilirubin levels;	chr21:32790008	chr21:32728115~32743122:+
THCA	cis	rs13108904	0.935	rs1732102	ENSG00000254094.1	AC078852.1	3.84	0.000141	0.0105	0.2	0.17	Obesity-related traits;	chr4:1284136	chr4:1356581~1358075:+
THCA	cis	rs10191559	0.638	rs10205700	ENSG00000236153.1	AC104076.3	3.84	0.000141	0.0105	0.18	0.17	Red blood cell count;	chr2:181097894	chr2:180979427~180980090:-
THCA	cis	rs12681963	0.688	rs4733396	ENSG00000248159.1	HSPA8P11	-3.84	0.000141	0.0105	-0.31	-0.17	Migraine;	chr8:30145889	chr8:30237382~30240997:+
THCA	cis	rs2442825	0.691	rs2600182	ENSG00000254485.4	RP11-380O24.1	-3.84	0.000141	0.0105	-0.17	-0.17	Cerebrospinal fluid clusterin levels;	chr3:9396376	chr3:9292588~9363303:-
THCA	cis	rs1541160	1	rs614044	ENSG00000239494.2	RN7SL333P	-3.84	0.000141	0.0105	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr1:169993945	chr1:169859756~169860052:+
THCA	cis	rs1541160	1	rs628436	ENSG00000239494.2	RN7SL333P	-3.84	0.000141	0.0105	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr1:169994869	chr1:169859756~169860052:+
THCA	cis	rs1541160	1	rs541896	ENSG00000239494.2	RN7SL333P	-3.84	0.000141	0.0105	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr1:169999279	chr1:169859756~169860052:+
THCA	cis	rs7916697	0.52	rs12246624	ENSG00000233590.1	RP11-153K11.3	-3.84	0.000141	0.0105	-0.23	-0.17	Optic disc area;	chr10:68276805	chr10:68233251~68242379:-
THCA	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-3.84	0.000141	0.0105	-0.23	-0.17	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
THCA	cis	rs4845570	0.834	rs1196467	ENSG00000249602.1	RP11-98D18.3	3.84	0.000141	0.0105	0.28	0.17	Coronary artery disease;	chr1:151737562	chr1:151763384~151769501:-
THCA	cis	rs295490	0.748	rs78681436	ENSG00000272656.1	RP11-219D15.3	3.84	0.000141	0.0105	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139510715	chr3:139349024~139349371:-
THCA	cis	rs2736345	0.747	rs1478901	ENSG00000254527.1	ENPP7P12	3.84	0.000141	0.0105	0.24	0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11490324	chr8:12205759~12206389:-
THCA	cis	rs877529	0.603	rs5995689	ENSG00000279833.1	RP4-742C19.13	-3.84	0.000141	0.0105	-0.13	-0.17	Multiple myeloma;	chr22:39165474	chr22:39133090~39136760:+
THCA	cis	rs7927592	0.913	rs11228287	ENSG00000160172.9	FAM86C2P	3.84	0.000141	0.0105	0.17	0.17	Total body bone mineral density;	chr11:68582286	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs10896346	ENSG00000160172.9	FAM86C2P	3.84	0.000141	0.0105	0.17	0.17	Total body bone mineral density;	chr11:68585203	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs10896347	ENSG00000160172.9	FAM86C2P	3.84	0.000141	0.0105	0.17	0.17	Total body bone mineral density;	chr11:68585659	chr11:67791648~67805336:-
THCA	cis	rs1501911	0.53	rs161933	ENSG00000246763.5	RGMB-AS1	3.84	0.000141	0.0105	0.18	0.17	Lung function (FEV1/FVC);	chr5:98874643	chr5:98769618~98773469:-
THCA	cis	rs1501911	0.53	rs161938	ENSG00000246763.5	RGMB-AS1	3.84	0.000141	0.0105	0.18	0.17	Lung function (FEV1/FVC);	chr5:98875501	chr5:98769618~98773469:-
THCA	cis	rs9844666	0.512	rs55678980	ENSG00000273486.1	RP11-731C17.2	3.84	0.000141	0.0105	0.16	0.17	Height;	chr3:135911376	chr3:136837338~136839021:-
THCA	cis	rs8077577	0.671	rs9901707	ENSG00000273018.4	CTD-2303H24.2	-3.84	0.000141	0.0105	-0.25	-0.17	Obesity-related traits;	chr17:18356566	chr17:18511221~18551705:-
THCA	cis	rs150992	0.517	rs326464	ENSG00000246763.5	RGMB-AS1	3.84	0.000141	0.0105	0.18	0.17	Body mass index;	chr5:98906499	chr5:98769618~98773469:-
THCA	cis	rs1501911	0.53	rs162150	ENSG00000246763.5	RGMB-AS1	3.84	0.000141	0.0105	0.18	0.17	Lung function (FEV1/FVC);	chr5:98913909	chr5:98769618~98773469:-
THCA	cis	rs9291683	0.595	rs13150928	ENSG00000261490.1	RP11-448G15.3	3.84	0.000141	0.0105	0.11	0.17	Bone mineral density;	chr4:10051337	chr4:10068089~10073019:-
THCA	cis	rs10969557	0.744	rs10969094	ENSG00000231808.2	LINC01388	3.84	0.000141	0.0105	0.19	0.17	Lung cancer;	chr9:303396	chr9:112713~113754:-
THCA	cis	rs2832191	0.729	rs2832201	ENSG00000176054.6	RPL23P2	-3.84	0.000141	0.0105	-0.15	-0.17	Dental caries;	chr21:29127520	chr21:28997613~28998033:-
THCA	cis	rs13064773	0.51	rs340277	ENSG00000279311.1	RP11-170K4.2	3.84	0.000141	0.0105	0.24	0.17	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158869942	chr3:158869898~158871821:+
THCA	cis	rs875971	0.545	rs2707851	ENSG00000273024.4	INTS4P2	3.84	0.000141	0.0105	0.22	0.17	Aortic root size;	chr7:66624178	chr7:65647864~65715661:+
THCA	cis	rs2281603	0.951	rs60908674	ENSG00000258824.2	CTD-2555O16.2	-3.84	0.000141	0.0105	-0.18	-0.17	Lymphocyte counts;	chr14:64514181	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.904	rs59440409	ENSG00000258824.2	CTD-2555O16.2	-3.84	0.000141	0.0105	-0.18	-0.17	Lymphocyte counts;	chr14:64514249	chr14:64422935~64448557:-
THCA	cis	rs7707921	0.881	rs57621982	ENSG00000251374.1	RPS23P5	3.84	0.000142	0.0105	0.25	0.17	Breast cancer;	chr5:82110951	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.881	rs60733727	ENSG00000251374.1	RPS23P5	3.84	0.000142	0.0105	0.25	0.17	Breast cancer;	chr5:82152464	chr5:82265157~82265259:-
THCA	cis	rs10484434	0.901	rs62396167	ENSG00000272462.2	U91328.19	3.84	0.000142	0.0105	0.2	0.17	HIV-1 viral setpoint;	chr6:26113314	chr6:25992662~26001775:+
THCA	cis	rs17597773	0.674	rs903319	ENSG00000272823.1	RP11-295M18.6	-3.84	0.000142	0.0105	-0.24	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812469	chr1:220828676~220829211:-
THCA	cis	rs2613964	0.504	rs3995917	ENSG00000243795.1	RP11-572M11.3	-3.84	0.000142	0.0105	-0.2	-0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133767	chr3:113142350~113167819:-
THCA	cis	rs642858	0.747	rs629778	ENSG00000234147.1	RP3-460G2.2	3.84	0.000142	0.0105	0.2	0.17	Type 2 diabetes;	chr6:139892400	chr6:140845958~140852924:-
THCA	cis	rs2692947	0.537	rs11677429	ENSG00000168992.4	OR7E102P	3.84	0.000142	0.0105	0.22	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95527313	chr2:95546531~95547545:+
THCA	cis	rs2692947	0.508	rs2216793	ENSG00000168992.4	OR7E102P	3.84	0.000142	0.0105	0.22	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95530574	chr2:95546531~95547545:+
THCA	cis	rs9928842	0.823	rs2870472	ENSG00000261783.1	RP11-252K23.2	3.84	0.000142	0.0105	0.33	0.17	Alcoholic chronic pancreatitis;	chr16:75244943	chr16:75379818~75381260:-
THCA	cis	rs4869313	0.668	rs251344	ENSG00000247121.5	CTD-2260A17.2	-3.84	0.000142	0.0106	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96923223	chr5:96814028~96935809:-
THCA	cis	rs877819	0.583	rs2663034	ENSG00000228403.1	RP11-563N6.6	-3.84	0.000142	0.0106	-0.19	-0.17	Systemic lupus erythematosus;	chr10:48876711	chr10:48878022~48878649:+
THCA	cis	rs10090774	0.71	rs13278258	ENSG00000279766.1	RP11-642A1.2	-3.84	0.000142	0.0106	-0.21	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140675675	chr8:140572142~140572812:-
THCA	cis	rs7615952	0.932	rs13325495	ENSG00000248787.1	RP11-666A20.4	-3.84	0.000142	0.0106	-0.31	-0.17	Blood pressure (smoking interaction);	chr3:125918573	chr3:125908005~125910272:-
THCA	cis	rs12694997	0.503	rs3771588	ENSG00000223374.1	AC005104.3	-3.84	0.000142	0.0106	-0.12	-0.17	Height;	chr2:241472694	chr2:241351340~241353104:-
THCA	cis	rs881375	0.967	rs7034492	ENSG00000270917.1	RP11-27I1.6	-3.84	0.000142	0.0106	-0.24	-0.17	Rheumatoid arthritis;	chr9:120924933	chr9:120812475~120812845:-
THCA	cis	rs1541160	1	rs476269	ENSG00000239494.2	RN7SL333P	-3.84	0.000142	0.0106	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr1:169974145	chr1:169859756~169860052:+
THCA	cis	rs7737355	0.755	rs12519233	ENSG00000237714.1	P4HA2-AS1	3.84	0.000142	0.0106	0.25	0.17	Life satisfaction;	chr5:131624400	chr5:132184876~132192808:+
THCA	cis	rs8031584	1	rs11638409	ENSG00000178081.11	ULK4P3	3.84	0.000142	0.0106	0.24	0.17	Huntington's disease progression;	chr15:30995987	chr15:30103720~30131757:+
THCA	cis	rs5758511	0.68	rs1107553	ENSG00000270083.1	RP1-257I20.14	-3.84	0.000142	0.0106	-0.22	-0.17	Birth weight;	chr22:42271467	chr22:42089630~42090028:-
THCA	cis	rs12549025	0.945	rs11783469	ENSG00000253390.1	CTC-756D1.2	-3.84	0.000142	0.0106	-0.3	-0.17	Reticulocyte fraction of red cells;	chr8:23543882	chr8:23458601~23484971:+
THCA	cis	rs7647973	0.769	rs6446204	ENSG00000229759.1	MRPS18AP1	3.84	0.000142	0.0106	0.27	0.17	Menarche (age at onset);	chr3:48997446	chr3:48256350~48256938:-
THCA	cis	rs7089973	0.584	rs6585300	ENSG00000228169.3	PPIAP19	3.84	0.000142	0.0106	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114880130	chr10:114690143~114690634:-
THCA	cis	rs150992	0.861	rs151102	ENSG00000246763.5	RGMB-AS1	-3.84	0.000142	0.0106	-0.18	-0.17	Body mass index;	chr5:98947626	chr5:98769618~98773469:-
THCA	cis	rs793571	0.669	rs714696	ENSG00000245975.2	RP11-30K9.6	3.84	0.000142	0.0106	0.16	0.17	Schizophrenia;	chr15:58670788	chr15:58768072~58770974:-
THCA	cis	rs875971	0.545	rs4718325	ENSG00000273024.4	INTS4P2	-3.84	0.000142	0.0106	-0.22	-0.17	Aortic root size;	chr7:66215323	chr7:65647864~65715661:+
THCA	cis	rs1383484	0.798	rs12438269	ENSG00000225151.9	GOLGA2P7	3.84	0.000142	0.0106	0.25	0.17	Height;	chr15:83833797	chr15:84199311~84230136:-
THCA	cis	rs73173548	0.502	rs76393802	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000142	0.0106	0.16	0.17	Macular telangiectasia type 2;	chr5:88455311	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs10942532	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000142	0.0106	0.16	0.17	Macular telangiectasia type 2;	chr5:88462015	chr5:88268895~88436685:+
THCA	cis	rs2836974	0.966	rs7283516	ENSG00000255568.3	BRWD1-AS2	3.84	0.000142	0.0106	0.15	0.17	Cognitive function;	chr21:39318611	chr21:39313935~39314962:+
THCA	cis	rs6921919	0.789	rs6456814	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000142	0.0106	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28115628~28116551:+
THCA	cis	rs4266290	0.818	rs10008644	ENSG00000273133.1	RP11-799M12.2	-3.84	0.000142	0.0106	-0.23	-0.17	Parkinson's disease;	chr4:15718347	chr4:15563698~15564253:-
THCA	cis	rs721917	0.506	rs2244451	ENSG00000244733.5	RP11-506M13.3	-3.84	0.000142	0.0106	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79885234	chr10:79660891~79677996:+
THCA	cis	rs13083990	0.881	rs12635478	ENSG00000272758.4	RP11-299J3.8	3.84	0.000142	0.0106	0.17	0.17	Cardiac Troponin-T levels;	chr3:122289706	chr3:122416207~122443180:+
THCA	cis	rs7264396	0.832	rs224378	ENSG00000088340.14	FER1L4	3.84	0.000142	0.0106	0.16	0.17	Total cholesterol levels;	chr20:35500935	chr20:35558737~35607562:-
THCA	cis	rs62244186	0.659	rs1806579	ENSG00000214820.3	MPRIPP1	3.84	0.000142	0.0106	0.19	0.17	Depressive symptoms;	chr3:44467789	chr3:44579938~44581026:-
THCA	cis	rs4218	0.638	rs8042516	ENSG00000259732.1	RP11-59H7.3	-3.84	0.000142	0.0106	-0.24	-0.17	Social communication problems;	chr15:59067525	chr15:59121034~59133250:+
THCA	cis	rs453301	0.686	rs10217044	ENSG00000233609.3	RP11-62H7.2	-3.84	0.000142	0.0106	-0.17	-0.17	Joint mobility (Beighton score);	chr8:9037242	chr8:8961200~8979025:+
THCA	cis	rs10191559	0.613	rs2368196	ENSG00000236153.1	AC104076.3	3.84	0.000142	0.0106	0.18	0.17	Red blood cell count;	chr2:181102348	chr2:180979427~180980090:-
THCA	cis	rs6982240	1	rs6982240	ENSG00000253307.1	RP11-10J21.4	3.84	0.000142	0.0106	0.24	0.17	Tonsillectomy;	chr8:141247279	chr8:141252286~141253292:-
THCA	cis	rs987724	0.515	rs1320011	ENSG00000243926.1	TIPARP-AS1	3.84	0.000142	0.0106	0.21	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156899993	chr3:156671862~156674378:-
THCA	cis	rs7179228	0.819	rs7171871	ENSG00000260657.2	RP11-315D16.4	3.84	0.000142	0.0106	0.23	0.17	Systolic blood pressure;	chr15:68323316	chr15:68267792~68277994:-
THCA	cis	rs6997458	0.904	rs725605	ENSG00000253549.4	RP11-317J10.2	3.84	0.000142	0.0106	0.17	0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85354657	chr8:85441851~85464915:-
THCA	cis	rs6997458	0.904	rs1532424	ENSG00000253549.4	RP11-317J10.2	3.84	0.000142	0.0106	0.17	0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85355963	chr8:85441851~85464915:-
THCA	cis	rs3764021	0.87	rs10466829	ENSG00000214776.8	RP11-726G1.1	3.84	0.000142	0.0106	0.21	0.17	Type 1 diabetes;	chr12:9723495	chr12:9467552~9576275:+
THCA	cis	rs206548	1	rs206548	ENSG00000266891.1	RP11-692N5.2	-3.84	0.000142	0.0106	-0.22	-0.17	Serum protein levels (sST2);	chr18:10382886	chr18:9734882~9735602:-
THCA	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	3.84	0.000142	0.0106	0.2	0.17	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000234585.5	CCT6P3	3.84	0.000142	0.0106	0.16	0.17	Aortic root size;	chr7:65960907	chr7:65038354~65074713:+
THCA	cis	rs2455799	0.634	rs4685266	ENSG00000270409.1	RP11-44D5.1	-3.84	0.000142	0.0106	-0.18	-0.17	Mean platelet volume;	chr3:15867259	chr3:15732252~15733470:+
THCA	cis	rs7089973	0.604	rs7915943	ENSG00000228169.3	PPIAP19	3.84	0.000142	0.0106	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114858318	chr10:114690143~114690634:-
THCA	cis	rs2898290	0.622	rs1478890	ENSG00000206014.6	OR7E161P	3.84	0.000142	0.0106	0.21	0.17	Systolic blood pressure;	chr8:11498093	chr8:11928597~11929563:-
THCA	cis	rs453301	0.624	rs2915251	ENSG00000233609.3	RP11-62H7.2	3.84	0.000142	0.0106	0.17	0.17	Joint mobility (Beighton score);	chr8:9009901	chr8:8961200~8979025:+
THCA	cis	rs701145	0.585	rs12497267	ENSG00000243069.6	ARHGEF26-AS1	3.84	0.000142	0.0106	0.33	0.17	Coronary artery disease;	chr3:154122171	chr3:154024401~154121332:-
THCA	cis	rs753778	0.57	rs6578154	ENSG00000253210.1	RP11-809O17.1	-3.84	0.000142	0.0106	-0.21	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141199958	chr8:141126044~141129961:-
THCA	cis	rs6840360	0.593	rs4696103	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000142	0.0106	-0.14	-0.17	Intelligence (multi-trait analysis);	chr4:151643459	chr4:151407551~151408835:-
THCA	cis	rs7520050	0.966	rs10890363	ENSG00000281133.1	AL355480.3	-3.84	0.000142	0.0106	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45890476	chr1:45580892~45580996:-
THCA	cis	rs757110	0.74	rs10832776	ENSG00000260196.1	RP1-239B22.5	3.84	0.000142	0.0106	0.2	0.17	Type 2 diabetes;	chr11:17363677	chr11:17380649~17383531:+
THCA	cis	rs1501911	0.53	rs162149	ENSG00000241597.2	CTD-2007H13.1	-3.84	0.000142	0.0106	-0.22	-0.17	Lung function (FEV1/FVC);	chr5:98913851	chr5:98954394~98954972:+
THCA	cis	rs6121246	0.909	rs1994251	ENSG00000224628.2	RP5-854E16.2	-3.84	0.000142	0.0106	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31699525	chr20:31285317~31286835:-
THCA	cis	rs757110	0.705	rs10832778	ENSG00000260196.1	RP1-239B22.5	3.84	0.000142	0.0106	0.2	0.17	Type 2 diabetes;	chr11:17372526	chr11:17380649~17383531:+
THCA	cis	rs757110	0.77	rs11024271	ENSG00000260196.1	RP1-239B22.5	3.84	0.000142	0.0106	0.2	0.17	Type 2 diabetes;	chr11:17373993	chr11:17380649~17383531:+
THCA	cis	rs6840360	0.615	rs9884167	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000142	0.0106	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151549647	chr4:151407551~151408835:-
THCA	cis	rs2033711	0.87	rs7409473	ENSG00000232098.3	CTD-2619J13.14	3.84	0.000142	0.0106	0.15	0.17	Uric acid clearance;	chr19:58427798	chr19:58404238~58408484:-
THCA	cis	rs2033711	0.87	rs7408188	ENSG00000232098.3	CTD-2619J13.14	3.84	0.000142	0.0106	0.15	0.17	Uric acid clearance;	chr19:58428022	chr19:58404238~58408484:-
THCA	cis	rs2033711	0.87	rs1051500	ENSG00000232098.3	CTD-2619J13.14	3.84	0.000142	0.0106	0.15	0.17	Uric acid clearance;	chr19:58433035	chr19:58404238~58408484:-
THCA	cis	rs13113518	0.51	rs3749473	ENSG00000273257.1	RP11-177J6.1	3.84	0.000142	0.0106	0.23	0.17	Height;	chr4:55428461	chr4:55387949~55388271:+
THCA	cis	rs3808502	0.527	rs2736389	ENSG00000154316.13	TDH	-3.84	0.000142	0.0106	-0.14	-0.17	Neuroticism;	chr8:11303801	chr8:11339637~11368452:+
THCA	cis	rs1908814	0.516	rs11250178	ENSG00000255495.1	AC145124.2	3.84	0.000142	0.0106	0.21	0.17	Neuroticism;	chr8:11942725	chr8:12194467~12196280:+
THCA	cis	rs17666538	1	rs17666538	ENSG00000254207.1	RP11-43A14.1	-3.84	0.000142	0.0106	-0.41	-0.17	IgG glycosylation;	chr8:616207	chr8:725188~725877:-
THCA	cis	rs11089937	0.963	rs2073454	ENSG00000263366.2	LL22NC03-33B6.4	-3.84	0.000142	0.0106	-0.22	-0.17	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22114844~22118005:-
THCA	cis	rs7674212	0.541	rs11727498	ENSG00000230069.3	LRRC37A15P	-3.84	0.000142	0.0106	-0.18	-0.17	Type 2 diabetes;	chr4:103179830	chr4:102727274~102730721:-
THCA	cis	rs4865169	0.783	rs7668814	ENSG00000269949.1	RP11-738E22.3	3.84	0.000142	0.0106	0.2	0.17	Breast cancer;	chr4:56959024	chr4:56960927~56961373:-
THCA	cis	rs9863	0.861	rs7312404	ENSG00000270028.1	RP11-380L11.4	3.84	0.000142	0.0106	0.18	0.17	White blood cell count;	chr12:123962181	chr12:123925461~123926083:-
THCA	cis	rs9863	0.827	rs7134121	ENSG00000270028.1	RP11-380L11.4	3.84	0.000142	0.0106	0.18	0.17	White blood cell count;	chr12:123962799	chr12:123925461~123926083:-
THCA	cis	rs757110	0.648	rs12146443	ENSG00000260196.1	RP1-239B22.5	3.84	0.000142	0.0106	0.19	0.17	Type 2 diabetes;	chr11:17362951	chr11:17380649~17383531:+
THCA	cis	rs7914558	0.966	rs7096269	ENSG00000213061.2	PFN1P11	3.84	0.000142	0.0106	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102976964	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.933	rs10883814	ENSG00000213061.2	PFN1P11	3.84	0.000142	0.0106	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102977647	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs1971589	ENSG00000213061.2	PFN1P11	3.84	0.000142	0.0106	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102984649	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs1890185	ENSG00000213061.2	PFN1P11	3.84	0.000142	0.0106	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102838011~102845473:-
THCA	cis	rs10875746	0.669	rs9634261	ENSG00000258273.1	RP11-370I10.4	3.84	0.000142	0.0106	0.24	0.17	Longevity (90 years and older);	chr12:48293088	chr12:48333755~48333901:-
THCA	cis	rs78487399	0.665	rs6753942	ENSG00000234936.1	AC010883.5	3.84	0.000142	0.0106	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43522297	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.665	rs17030980	ENSG00000234936.1	AC010883.5	3.84	0.000142	0.0106	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43524341	chr2:43229573~43233394:+
THCA	cis	rs7665090	1	rs4013	ENSG00000248971.2	KRT8P46	-3.84	0.000142	0.0106	-0.2	-0.17	Primary biliary cholangitis;	chr4:102631656	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.967	rs4019	ENSG00000248971.2	KRT8P46	-3.84	0.000142	0.0106	-0.2	-0.17	Primary biliary cholangitis;	chr4:102631673	chr4:102728746~102730171:-
THCA	cis	rs1913185	0.891	rs67325724	ENSG00000240032.1	RP11-274H2.3	-3.84	0.000142	0.0106	-0.28	-0.17	Obesity-related traits;	chr3:146156940	chr3:146066344~146069185:-
THCA	cis	rs2839186	0.749	rs62226488	ENSG00000228137.1	AP001469.7	3.84	0.000142	0.0106	0.17	0.17	Testicular germ cell tumor;	chr21:46290603	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.749	rs62226489	ENSG00000228137.1	AP001469.7	3.84	0.000142	0.0106	0.17	0.17	Testicular germ cell tumor;	chr21:46290605	chr21:46246890~46247682:+
THCA	cis	rs4819052	1	rs4819052	ENSG00000273796.1	LL21NC02-21A1.1	-3.84	0.000142	0.0106	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45403809~45404369:-
THCA	cis	rs3806843	0.612	rs246075	ENSG00000202515.1	VTRNA1-3	-3.84	0.000142	0.0106	-0.21	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140920972	chr5:140726158~140726246:+
THCA	cis	rs6546886	0.912	rs7601526	ENSG00000235499.1	AC073046.25	3.84	0.000142	0.0106	0.16	0.17	Dialysis-related mortality;	chr2:74051354	chr2:73985132~73986343:+
THCA	cis	rs9926296	0.568	rs4420527	ENSG00000274627.1	RP11-104N10.2	3.84	0.000142	0.0106	0.18	0.17	Vitiligo;	chr16:89747780	chr16:89516797~89522217:+
THCA	cis	rs4268898	0.722	rs7563958	ENSG00000242628.4	AC009228.1	-3.84	0.000142	0.0106	-0.21	-0.17	Asthma;	chr2:24199512	chr2:24214381~24221516:+
THCA	cis	rs10435719	0.647	rs10092605	ENSG00000255495.1	AC145124.2	3.84	0.000142	0.0106	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:12194467~12196280:+
THCA	cis	rs6942407	0.592	rs56327053	ENSG00000224046.1	AC005076.5	-3.84	0.000142	0.0106	-0.16	-0.17	Food allergy;	chr7:87119223	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.592	rs17766011	ENSG00000224046.1	AC005076.5	-3.84	0.000142	0.0106	-0.16	-0.17	Food allergy;	chr7:87119853	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.64	rs17698411	ENSG00000224046.1	AC005076.5	-3.84	0.000142	0.0106	-0.16	-0.17	Food allergy;	chr7:87119881	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.592	rs6465092	ENSG00000224046.1	AC005076.5	-3.84	0.000142	0.0106	-0.16	-0.17	Food allergy;	chr7:87121609	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.592	rs6958626	ENSG00000224046.1	AC005076.5	-3.84	0.000142	0.0106	-0.16	-0.17	Food allergy;	chr7:87122209	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.592	rs6959152	ENSG00000224046.1	AC005076.5	-3.84	0.000142	0.0106	-0.16	-0.17	Food allergy;	chr7:87122291	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.542	rs6958797	ENSG00000224046.1	AC005076.5	-3.84	0.000142	0.0106	-0.16	-0.17	Food allergy;	chr7:87122352	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.592	rs2373389	ENSG00000224046.1	AC005076.5	-3.84	0.000142	0.0106	-0.16	-0.17	Food allergy;	chr7:87122461	chr7:87151423~87152420:-
THCA	cis	rs854765	0.552	rs11078407	ENSG00000281749.1	Y_RNA	3.84	0.000143	0.0106	0.22	0.17	Total body bone mineral density;	chr17:17937769	chr17:18001101~18001195:-
THCA	cis	rs4879656	0.797	rs7872744	ENSG00000225693.1	LAGE3P1	-3.84	0.000143	0.0106	-0.18	-0.17	Menopause (age at onset);	chr9:33054164	chr9:33019682~33020165:-
THCA	cis	rs478304	0.619	rs10896028	ENSG00000255557.1	RP11-770G2.2	3.84	0.000143	0.0106	0.21	0.17	Acne (severe);	chr11:65664716	chr11:65745729~65771585:+
THCA	cis	rs12497850	0.764	rs6784111	ENSG00000228638.1	FCF1P2	-3.84	0.000143	0.0106	-0.19	-0.17	Parkinson's disease;	chr3:49141413	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.864	rs12493001	ENSG00000228638.1	FCF1P2	-3.84	0.000143	0.0106	-0.19	-0.17	Parkinson's disease;	chr3:49144452	chr3:48290793~48291375:-
THCA	cis	rs12497850	0.829	rs12636030	ENSG00000228638.1	FCF1P2	-3.84	0.000143	0.0106	-0.19	-0.17	Parkinson's disease;	chr3:49144804	chr3:48290793~48291375:-
THCA	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-3.84	0.000143	0.0106	-0.17	-0.17	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
THCA	cis	rs4971059	0.629	rs9297	ENSG00000225855.5	RUSC1-AS1	3.84	0.000143	0.0106	0.11	0.17	Breast cancer;	chr1:155134074	chr1:155316863~155324176:-
THCA	cis	rs6686643	0.63	rs7554034	ENSG00000236206.1	RP11-306I1.2	3.84	0.000143	0.0106	0.26	0.17	Total ventricular volume;	chr1:165641227	chr1:165598463~165623331:+
THCA	cis	rs4948275	0.597	rs2251482	ENSG00000237233.2	TMEM26-AS1	3.84	0.000143	0.0106	0.23	0.17	Night sleep phenotypes;	chr10:61606156	chr10:61452639~61481956:+
THCA	cis	rs3018712	0.532	rs2513282	ENSG00000212093.1	AP000807.1	-3.84	0.000143	0.0106	-0.23	-0.17	Total body bone mineral density;	chr11:68650843	chr11:68506083~68506166:-
THCA	cis	rs10844154	0.508	rs2728801	ENSG00000277342.1	RP11-843B15.4	3.84	0.000143	0.0106	0.23	0.17	Emphysema-related traits;Weight;	chr12:32255286	chr12:32109076~32109602:+
THCA	cis	rs11158609	0.526	rs34304067	ENSG00000278784.1	RP11-468E2.11	3.84	0.000143	0.0106	0.17	0.17	Systolic blood pressure (cigarette smoking interaction);	chr14:24201552	chr14:24201612~24202811:-
THCA	cis	rs853679	0.657	rs1778483	ENSG00000273712.1	RP5-874C20.7	3.84	0.000143	0.0106	0.2	0.17	Depression;	chr6:28273214	chr6:28315613~28315883:-
THCA	cis	rs853679	0.657	rs1778482	ENSG00000273712.1	RP5-874C20.7	3.84	0.000143	0.0106	0.2	0.17	Depression;	chr6:28273215	chr6:28315613~28315883:-
THCA	cis	rs9926296	0.512	rs11076626	ENSG00000274627.1	RP11-104N10.2	-3.84	0.000143	0.0106	-0.18	-0.17	Vitiligo;	chr16:89798695	chr16:89516797~89522217:+
THCA	cis	rs9926296	0.533	rs10852623	ENSG00000274627.1	RP11-104N10.2	-3.84	0.000143	0.0106	-0.18	-0.17	Vitiligo;	chr16:89798834	chr16:89516797~89522217:+
THCA	cis	rs67981189	0.896	rs2526846	ENSG00000269927.1	RP6-91H8.3	-3.84	0.000143	0.0106	-0.2	-0.17	Schizophrenia;	chr14:70957538	chr14:71141125~71143253:-
THCA	cis	rs6801044	0.695	rs823514	ENSG00000223711.1	AC091633.3	3.84	0.000143	0.0106	0.23	0.17	Creatinine levels in ischemic stroke;	chr3:195537858	chr3:195544048~195550581:+
THCA	cis	rs836788	0.633	rs245013	ENSG00000251221.1	LINC01337	-3.84	0.000143	0.0106	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr5:80751257	chr5:80608623~80622524:-
THCA	cis	rs453301	0.598	rs1025395	ENSG00000253981.4	ALG1L13P	3.84	0.000143	0.0106	0.16	0.17	Joint mobility (Beighton score);	chr8:8979093	chr8:8236003~8244667:-
THCA	cis	rs877529	0.967	rs139385	ENSG00000279833.1	RP4-742C19.13	-3.84	0.000143	0.0106	-0.12	-0.17	Multiple myeloma;	chr22:39134127	chr22:39133090~39136760:+
THCA	cis	rs877529	0.967	rs139386	ENSG00000279833.1	RP4-742C19.13	-3.84	0.000143	0.0106	-0.12	-0.17	Multiple myeloma;	chr22:39134854	chr22:39133090~39136760:+
THCA	cis	rs7615952	0.515	rs4267608	ENSG00000250012.1	RP11-124N2.1	-3.84	0.000143	0.0106	-0.17	-0.17	Blood pressure (smoking interaction);	chr3:125961657	chr3:126084220~126095349:+
THCA	cis	rs2179367	0.632	rs7349921	ENSG00000216906.2	RP11-350J20.9	3.83	0.000143	0.0106	0.22	0.17	Dupuytren's disease;	chr6:149392727	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs60153446	ENSG00000216906.2	RP11-350J20.9	3.83	0.000143	0.0106	0.22	0.17	Dupuytren's disease;	chr6:149393186	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs61259243	ENSG00000216906.2	RP11-350J20.9	3.83	0.000143	0.0106	0.22	0.17	Dupuytren's disease;	chr6:149393457	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs62426115	ENSG00000216906.2	RP11-350J20.9	3.83	0.000143	0.0106	0.22	0.17	Dupuytren's disease;	chr6:149393718	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs68080376	ENSG00000216906.2	RP11-350J20.9	3.83	0.000143	0.0106	0.22	0.17	Dupuytren's disease;	chr6:149393873	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs763590	ENSG00000216906.2	RP11-350J20.9	3.83	0.000143	0.0106	0.22	0.17	Dupuytren's disease;	chr6:149398831	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs17506789	ENSG00000216906.2	RP11-350J20.9	3.83	0.000143	0.0106	0.22	0.17	Dupuytren's disease;	chr6:149399710	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.586	rs34097428	ENSG00000216906.2	RP11-350J20.9	3.83	0.000143	0.0106	0.22	0.17	Dupuytren's disease;	chr6:149399822	chr6:149904243~149906418:+
THCA	cis	rs793571	0.59	rs474875	ENSG00000245975.2	RP11-30K9.6	3.83	0.000143	0.0106	0.16	0.17	Schizophrenia;	chr15:58794504	chr15:58768072~58770974:-
THCA	cis	rs1383484	0.798	rs28544951	ENSG00000259728.4	LINC00933	-3.83	0.000143	0.0106	-0.22	-0.17	Height;	chr15:83850088	chr15:84570649~84580175:+
THCA	cis	rs755249	0.642	rs28788506	ENSG00000237624.1	OXCT2P1	3.83	0.000143	0.0106	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39514956~39516490:+
THCA	cis	rs755249	0.669	rs4660311	ENSG00000237624.1	OXCT2P1	3.83	0.000143	0.0106	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39514956~39516490:+
THCA	cis	rs9450351	0.744	rs1447157	ENSG00000203875.9	SNHG5	-3.83	0.000143	0.0106	-0.35	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85879434	chr6:85660950~85678736:-
THCA	cis	rs11073619	0.616	rs3994408	ENSG00000259728.4	LINC00933	-3.83	0.000143	0.0106	-0.33	-0.17	Positive affect;	chr15:84390854	chr15:84570649~84580175:+
THCA	cis	rs7911264	0.739	rs6583827	ENSG00000236493.2	EIF2S2P3	3.83	0.000143	0.0106	0.19	0.17	Inflammatory bowel disease;	chr10:92598266	chr10:92668745~92669743:-
THCA	cis	rs7911264	0.739	rs7096101	ENSG00000236493.2	EIF2S2P3	3.83	0.000143	0.0106	0.19	0.17	Inflammatory bowel disease;	chr10:92603171	chr10:92668745~92669743:-
THCA	cis	rs7911264	0.739	rs10786050	ENSG00000236493.2	EIF2S2P3	3.83	0.000143	0.0106	0.19	0.17	Inflammatory bowel disease;	chr10:92607473	chr10:92668745~92669743:-
THCA	cis	rs11771526	0.901	rs11767695	ENSG00000272905.1	RP11-265E18.1	3.83	0.000143	0.0106	0.24	0.17	Body mass index;	chr7:32276348	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.792	rs62457499	ENSG00000272905.1	RP11-265E18.1	3.83	0.000143	0.0106	0.24	0.17	Body mass index;	chr7:32279585	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs17161137	ENSG00000272905.1	RP11-265E18.1	3.83	0.000143	0.0106	0.24	0.17	Body mass index;	chr7:32284187	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.818	rs17161140	ENSG00000272905.1	RP11-265E18.1	3.83	0.000143	0.0106	0.24	0.17	Body mass index;	chr7:32284587	chr7:32845394~32846061:+
THCA	cis	rs1113500	0.787	rs11185266	ENSG00000230489.1	VAV3-AS1	-3.83	0.000143	0.0106	-0.16	-0.17	Growth-regulated protein alpha levels;	chr1:108100042	chr1:107964443~107994607:+
THCA	cis	rs6479891	1	rs16918575	ENSG00000272767.1	JMJD1C-AS1	-3.83	0.000143	0.0106	-0.25	-0.17	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63465229~63466563:+
THCA	cis	rs877819	0.583	rs2620881	ENSG00000228403.1	RP11-563N6.6	-3.83	0.000143	0.0106	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48875066	chr10:48878022~48878649:+
THCA	cis	rs875971	0.545	rs6460298	ENSG00000232559.3	GS1-124K5.12	3.83	0.000143	0.0106	0.19	0.17	Aortic root size;	chr7:66442783	chr7:66554588~66576923:-
THCA	cis	rs962856	0.575	rs6740919	ENSG00000236780.4	AC078941.1	-3.83	0.000143	0.0106	-0.22	-0.17	Pancreatic cancer;	chr2:67392923	chr2:67123357~67215319:-
THCA	cis	rs2806561	0.734	rs667211	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000143	0.0106	-0.11	-0.17	Height;	chr1:23189649	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs682766	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000143	0.0106	-0.11	-0.17	Height;	chr1:23189904	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs4333826	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000143	0.0106	-0.11	-0.17	Height;	chr1:23191021	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.828	rs604030	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000143	0.0106	-0.11	-0.17	Height;	chr1:23191734	chr1:23368997~23371839:+
THCA	cis	rs950169	0.84	rs62029595	ENSG00000275120.1	RP11-182J1.17	3.83	0.000143	0.0106	0.21	0.17	Schizophrenia;	chr15:84400603	chr15:84599434~84606463:-
THCA	cis	rs2235649	0.588	rs11863172	ENSG00000260541.1	LA16c-429E7.1	3.83	0.000143	0.0106	0.24	0.17	Blood metabolite levels;	chr16:1859082	chr16:1841020~1843547:-
THCA	cis	rs7665090	1	rs735404	ENSG00000248971.2	KRT8P46	-3.83	0.000143	0.0106	-0.2	-0.17	Primary biliary cholangitis;	chr4:102632508	chr4:102728746~102730171:-
THCA	cis	rs2635047	0.905	rs7504798	ENSG00000280212.1	RP11-49K24.3	-3.83	0.000143	0.0106	-0.17	-0.17	Educational attainment;	chr18:47084508	chr18:47076117~47076594:+
THCA	cis	rs1362756	1	rs8050675	ENSG00000260057.4	LINC01571	3.83	0.000143	0.0106	0.18	0.17	Optic disc parameters;Optic disc area;	chr16:51432461	chr16:51762519~51773173:+
THCA	cis	rs5758511	0.633	rs5751258	ENSG00000270083.1	RP1-257I20.14	-3.83	0.000143	0.0106	-0.23	-0.17	Birth weight;	chr22:42267865	chr22:42089630~42090028:-
THCA	cis	rs2736345	0.502	rs12680762	ENSG00000269899.1	RP11-589N15.2	3.83	0.000143	0.0106	0.21	0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11474517	chr8:11846154~11846391:-
THCA	cis	rs11089937	0.651	rs1543779	ENSG00000211639.2	IGLV4-60	-3.83	0.000143	0.0106	-0.13	-0.17	Periodontitis (PAL4Q3);	chr22:22194092	chr22:22162199~22162681:+
THCA	cis	rs7927592	0.913	rs12285993	ENSG00000160172.9	FAM86C2P	3.83	0.000143	0.0106	0.17	0.17	Total body bone mineral density;	chr11:68535070	chr11:67791648~67805336:-
THCA	cis	rs9467773	0.935	rs11752946	ENSG00000228223.2	HCG11	-3.83	0.000143	0.0106	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26523450~26526579:+
THCA	cis	rs7894407	0.623	rs10883846	ENSG00000272912.1	RP11-724N1.1	3.83	0.000143	0.0106	0.22	0.17	White matter hyperintensity burden;	chr10:103198487	chr10:102914585~102915404:+
THCA	cis	rs7129556	0.954	rs11237220	ENSG00000254459.1	RP11-91P24.7	3.83	0.000143	0.0106	0.23	0.17	Weight loss (gastric bypass surgery);	chr11:77557415	chr11:77829654~77872262:-
THCA	cis	rs893363	0.61	rs893362	ENSG00000271916.1	RP11-884K10.6	-3.83	0.000143	0.0106	-0.21	-0.17	Axial length;	chr3:53813767	chr3:53797764~53798019:-
THCA	cis	rs2243123	0.602	rs2243151	ENSG00000244040.4	IL12A-AS1	3.83	0.000143	0.0106	0.23	0.17	Multiple sclerosis;	chr3:159998234	chr3:159913400~160225299:-
THCA	cis	rs2434529	1	rs17628118	ENSG00000245275.6	SAP30L-AS1	-3.83	0.000143	0.0106	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr5:154267701	chr5:154329437~154445850:-
THCA	cis	rs11673344	0.764	rs547483	ENSG00000267260.1	CTD-2162K18.4	3.83	0.000143	0.0106	0.22	0.17	Obesity-related traits;	chr19:36950463	chr19:36773153~36777078:+
THCA	cis	rs2721195	1	rs11542372	ENSG00000265393.1	CTD-2517M22.17	3.83	0.000143	0.0106	0.21	0.17	Age at first birth;	chr8:144451706	chr8:144512567~144513672:+
THCA	cis	rs2721195	1	rs6599530	ENSG00000265393.1	CTD-2517M22.17	3.83	0.000143	0.0106	0.21	0.17	Age at first birth;	chr8:144452035	chr8:144512567~144513672:+
THCA	cis	rs6504108	0.602	rs7219967	ENSG00000264920.1	RP11-6N17.4	-3.83	0.000143	0.0106	-0.15	-0.17	Body mass index;	chr17:48216712	chr17:47891255~47895812:-
THCA	cis	rs6142618	0.783	rs6058619	ENSG00000224452.1	RSL24D1P6	3.83	0.000143	0.0106	0.22	0.17	Inflammatory bowel disease;	chr20:32293549	chr20:32170390~32170790:-
THCA	cis	rs34792	0.525	rs12923446	ENSG00000275910.1	RP11-680G24.6	3.83	0.000143	0.0106	0.2	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15509723	chr16:15015828~15016390:-
THCA	cis	rs12612619	0.689	rs10181551	ENSG00000229122.1	AGBL5-IT1	-3.83	0.000143	0.0106	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27054406	chr2:27061038~27061815:+
THCA	cis	rs34783982	0.529	rs6496536	ENSG00000259699.2	HMGB1P8	-3.83	0.000143	0.0106	-0.24	-0.17	Squamous cell lung carcinoma;	chr15:88936744	chr15:89135547~89136495:-
THCA	cis	rs7246967	0.611	rs35355374	ENSG00000236312.3	RPL34P34	-3.83	0.000143	0.0106	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22654899	chr19:22368599~22368952:-
THCA	cis	rs7246967	0.551	rs34563787	ENSG00000236312.3	RPL34P34	-3.83	0.000143	0.0106	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22654934	chr19:22368599~22368952:-
THCA	cis	rs9367716	0.956	rs7757492	ENSG00000276576.1	MRPL30P1	3.83	0.000143	0.0106	0.22	0.17	Coronary artery disease;	chr6:57255780	chr6:57029521~57029988:+
THCA	cis	rs3733585	0.806	rs11723382	ENSG00000250413.1	RP11-448G15.1	3.83	0.000143	0.0106	0.17	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9953036	chr4:10006482~10009725:+
THCA	cis	rs3733585	0.674	rs7375643	ENSG00000250413.1	RP11-448G15.1	3.83	0.000143	0.0106	0.17	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9953615	chr4:10006482~10009725:+
THCA	cis	rs853679	0.607	rs13204012	ENSG00000220721.1	OR1F12	3.83	0.000143	0.0106	0.39	0.17	Depression;	chr6:28233753	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13205211	ENSG00000220721.1	OR1F12	3.83	0.000143	0.0106	0.39	0.17	Depression;	chr6:28235278	chr6:28073316~28074233:+
THCA	cis	rs11992162	0.597	rs7011924	ENSG00000254948.1	OR7E158P	3.83	0.000143	0.0106	0.22	0.17	Monocyte count;	chr8:11923084	chr8:11919900~11920809:-
THCA	cis	rs7430456	0.839	rs9824506	ENSG00000231574.4	RP11-91K9.1	3.83	0.000143	0.0106	0.23	0.17	Breast cancer;	chr3:177751431	chr3:177816865~177899224:+
THCA	cis	rs3924048	0.559	rs4580	ENSG00000276830.1	MIR6730	-3.83	0.000143	0.0106	-0.17	-0.17	Optic cup area;	chr1:12568159	chr1:12578957~12579023:-
THCA	cis	rs8006682	0.507	rs1884811	ENSG00000259038.1	CTD-2325P2.4	3.83	0.000143	0.0106	0.19	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68654947	chr14:68627166~68628445:-
THCA	cis	rs7176527	0.519	rs12148368	ENSG00000259570.1	RP11-671M22.4	-3.83	0.000143	0.0106	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84394512~84395514:+
THCA	cis	rs4915077	0.773	rs17484367	ENSG00000230489.1	VAV3-AS1	3.83	0.000143	0.0106	0.29	0.17	Hypothyroidism;	chr1:107727031	chr1:107964443~107994607:+
THCA	cis	rs12493885	0.818	rs6800048	ENSG00000243069.6	ARHGEF26-AS1	-3.83	0.000143	0.0107	-0.29	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154048392	chr3:154024401~154121332:-
THCA	cis	rs6696239	0.876	rs4379651	ENSG00000227711.2	RP11-275O4.5	3.83	0.000143	0.0107	0.24	0.17	Height;	chr1:227579238	chr1:227509028~227520477:-
THCA	cis	rs11694172	1	rs72928909	ENSG00000273456.1	RP11-686O6.2	3.83	0.000143	0.0107	0.16	0.17	Cholesterol, total;	chr2:202676931	chr2:202374932~202375604:-
THCA	cis	rs12476592	0.571	rs4671505	ENSG00000242412.1	DBIL5P2	3.83	0.000143	0.0107	0.23	0.17	Childhood ear infection;	chr2:63417168	chr2:63117851~63119542:-
THCA	cis	rs7583236	1	rs7583236	ENSG00000179818.12	PCBP1-AS1	-3.83	0.000143	0.0107	-0.18	-0.17	Obesity-related traits;	chr2:69955673	chr2:69962263~70103220:-
THCA	cis	rs5758659	0.729	rs134866	ENSG00000227370.1	RP4-669P10.19	-3.83	0.000143	0.0107	-0.16	-0.17	Cognitive function;	chr22:42254657	chr22:42132543~42132998:+
THCA	cis	rs1039766	1	rs268882	ENSG00000204929.10	AC074391.1	-3.83	0.000143	0.0107	-0.27	-0.17	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr2:65436711~66084639:+
THCA	cis	rs763512	0.532	rs1416	ENSG00000276054.1	RP11-378E13.3	3.83	0.000143	0.0107	0.28	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37534709	chr17:37386886~37387926:+
THCA	cis	rs9717605	0.908	rs56122767	ENSG00000226445.1	XXyac-YX65C7_A.2	3.83	0.000143	0.0107	0.21	0.17	Left atrial antero-posterior diameter;	chr6:169250070	chr6:169213254~169239565:+
THCA	cis	rs9717605	1	rs56255660	ENSG00000226445.1	XXyac-YX65C7_A.2	3.83	0.000143	0.0107	0.21	0.17	Left atrial antero-posterior diameter;	chr6:169250071	chr6:169213254~169239565:+
THCA	cis	rs12216545	0.765	rs6464078	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150551308	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs2140142	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150551980	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs2140141	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150551991	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs2373809	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552377	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs10237569	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552439	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs12538768	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552912	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.711	rs6960291	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150553489	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs6980388	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150553621	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs1916002	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150553806	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.686	rs2373811	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150554563	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs4725915	ENSG00000241134.3	BET1P1	-3.83	0.000143	0.0107	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150554664	chr7:150749736~150750094:+
THCA	cis	rs875971	0.545	rs1796217	ENSG00000273024.4	INTS4P2	3.83	0.000143	0.0107	0.22	0.17	Aortic root size;	chr7:66620931	chr7:65647864~65715661:+
THCA	cis	rs1048257	0.553	rs2819421	ENSG00000258701.1	LINC00638	3.83	0.000143	0.0107	0.19	0.17	Systemic lupus erythematosus;	chr14:104942474	chr14:104821201~104823718:+
THCA	cis	rs7243790	0.774	rs62091573	ENSG00000277324.1	RP11-850A17.1	-3.83	0.000143	0.0107	-0.18	-0.17	Diastolic blood pressure;	chr18:54412685	chr18:54268346~54270028:-
THCA	cis	rs7243790	0.805	rs62091574	ENSG00000277324.1	RP11-850A17.1	-3.83	0.000143	0.0107	-0.18	-0.17	Diastolic blood pressure;	chr18:54412693	chr18:54268346~54270028:-
THCA	cis	rs1552244	0.554	rs4488814	ENSG00000269982.1	RP11-1020A11.2	-3.83	0.000143	0.0107	-0.12	-0.17	Alzheimer's disease;	chr3:9960716	chr3:9958717~9962539:+
THCA	cis	rs357618	0.581	rs165363	ENSG00000260581.1	CTB-113P19.4	3.83	0.000143	0.0107	0.27	0.17	Basophil percentage of white cells;	chr5:151486257	chr5:151652275~151655449:+
THCA	cis	rs875971	0.666	rs13242072	ENSG00000230295.1	RP11-458F8.2	3.83	0.000143	0.0107	0.13	0.17	Aortic root size;	chr7:66301001	chr7:66880708~66882981:+
THCA	cis	rs3808502	0.527	rs56177149	ENSG00000261451.1	RP11-981G7.1	3.83	0.000143	0.0107	0.23	0.17	Neuroticism;	chr8:11389789	chr8:10433672~10438312:+
THCA	cis	rs7131987	0.565	rs6487792	ENSG00000275476.1	RP11-996F15.4	3.83	0.000144	0.0107	0.17	0.17	QT interval;	chr12:29259743	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.585	rs2194517	ENSG00000275476.1	RP11-996F15.4	3.83	0.000144	0.0107	0.17	0.17	QT interval;	chr12:29260002	chr12:29277397~29277882:-
THCA	cis	rs7845127	0.53	rs950118	ENSG00000253671.1	RP11-806O11.1	3.83	0.000144	0.0107	0.2	0.17	Night sleep phenotypes;	chr8:18264077	chr8:17808941~17820868:+
THCA	cis	rs4660214	0.666	rs1775656	ENSG00000228060.1	RP11-69E11.8	-3.83	0.000144	0.0107	-0.17	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39565160~39573203:+
THCA	cis	rs9987353	0.589	rs1053036	ENSG00000253981.4	ALG1L13P	-3.83	0.000144	0.0107	-0.17	-0.17	Recombination measurement;	chr8:9202567	chr8:8236003~8244667:-
THCA	cis	rs6088580	0.524	rs2378251	ENSG00000126005.14	MMP24-AS1	3.83	0.000144	0.0107	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34688946	chr20:35216462~35278131:-
THCA	cis	rs708224	0.587	rs184469	ENSG00000274964.1	RP11-817I4.1	3.83	0.000144	0.0107	0.19	0.17	Pancreatic cancer;	chr12:32247364	chr12:32339368~32340724:+
THCA	cis	rs6088580	0.543	rs13042351	ENSG00000126005.14	MMP24-AS1	3.83	0.000144	0.0107	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34650769	chr20:35216462~35278131:-
THCA	cis	rs9309473	1	rs7585004	ENSG00000273245.1	RP11-434P11.2	3.83	0.000144	0.0107	0.24	0.17	Metabolite levels;	chr2:73439517	chr2:73750256~73750786:-
THCA	cis	rs5758511	0.573	rs139558	ENSG00000230107.1	CTA-126B4.7	3.83	0.000144	0.0107	0.19	0.17	Birth weight;	chr22:41793547	chr22:42438023~42446195:+
THCA	cis	rs7089973	0.61	rs12779231	ENSG00000236799.1	RP11-383C6.2	-3.83	0.000144	0.0107	-0.21	-0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:115000335	chr10:114994657~114996593:+
THCA	cis	rs9810089	1	rs9810089	ENSG00000273455.1	RP11-305O4.3	-3.83	0.000144	0.0107	-0.23	-0.17	Gestational age at birth (child effect);	chr3:136088767	chr3:136087475~136087913:-
THCA	cis	rs9959145	0.929	rs113231666	ENSG00000267199.1	RP11-861E21.2	3.83	0.000144	0.0107	0.23	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12574011	chr18:12438890~12448205:+
THCA	cis	rs7520050	0.966	rs785491	ENSG00000281133.1	AL355480.3	3.83	0.000144	0.0107	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs785503	ENSG00000281133.1	AL355480.3	3.83	0.000144	0.0107	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45580892~45580996:-
THCA	cis	rs9303029	1	rs9898723	ENSG00000265458.1	RP13-20L14.6	3.83	0.000144	0.0107	0.21	0.17	Protein quantitative trait loci;	chr17:82482031	chr17:82454273~82458521:-
THCA	cis	rs6696239	0.956	rs6694427	ENSG00000227711.2	RP11-275O4.5	-3.83	0.000144	0.0107	-0.24	-0.17	Height;	chr1:227619885	chr1:227509028~227520477:-
THCA	cis	rs12478296	0.901	rs7603560	ENSG00000220804.7	AC093642.5	3.83	0.000144	0.0107	0.2	0.17	Obesity-related traits;	chr2:242101105	chr2:242088633~242160153:+
THCA	cis	rs12234571	0.546	rs12671323	ENSG00000214293.7	APTR	3.83	0.000144	0.0107	0.23	0.17	Obesity-related traits;	chr7:77485548	chr7:77657660~77696265:-
THCA	cis	rs6120849	0.708	rs6087659	ENSG00000269202.1	RP4-614O4.12	-3.83	0.000144	0.0107	-0.19	-0.17	Protein C levels;	chr20:35018580	chr20:35201747~35203288:-
THCA	cis	rs6496044	0.611	rs8026938	ENSG00000259630.2	CTD-2262B20.1	3.83	0.000144	0.0107	0.19	0.17	Interstitial lung disease;	chr15:85525887	chr15:85415228~85415633:+
THCA	cis	rs7259376	0.905	rs8112246	ENSG00000269345.1	VN1R85P	3.83	0.000144	0.0107	0.19	0.17	Menopause (age at onset);	chr19:22384645	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.846	rs4024624	ENSG00000269345.1	VN1R85P	3.83	0.000144	0.0107	0.19	0.17	Menopause (age at onset);	chr19:22385462	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.846	rs5014503	ENSG00000269345.1	VN1R85P	3.83	0.000144	0.0107	0.19	0.17	Menopause (age at onset);	chr19:22385538	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.818	rs8101997	ENSG00000269345.1	VN1R85P	3.83	0.000144	0.0107	0.19	0.17	Menopause (age at onset);	chr19:22385630	chr19:22174766~22175191:-
THCA	cis	rs1923243	0.749	rs4559446	ENSG00000223479.3	RP4-788P17.1	-3.83	0.000144	0.0107	-0.19	-0.17	Migraine;	chr1:73041665	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.749	rs6424508	ENSG00000223479.3	RP4-788P17.1	-3.83	0.000144	0.0107	-0.19	-0.17	Migraine;	chr1:73042018	chr1:73635216~73715214:+
THCA	cis	rs6101567	0.517	rs12625060	ENSG00000224635.1	RP4-564F22.5	-3.83	0.000144	0.0107	-0.22	-0.17	Nose size;	chr20:39282124	chr20:38406011~38416797:-
THCA	cis	rs12753569	0.934	rs6676370	ENSG00000272855.1	RP5-1102E8.3	3.83	0.000144	0.0107	0.22	0.17	Personality dimensions;	chr1:76024500	chr1:76636877~76637339:+
THCA	cis	rs6138458	0.828	rs6138466	ENSG00000274173.1	RP4-568C11.4	3.83	0.000144	0.0107	0.16	0.17	Blood protein levels;	chr20:25016501	chr20:24931840~24932983:+
THCA	cis	rs12887734	0.546	rs66676135	ENSG00000258534.1	CTD-2134A5.4	-3.83	0.000144	0.0107	-0.19	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103854366~103880111:-
THCA	cis	rs875971	0.66	rs801217	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66545590	chr7:66526088~66542624:-
THCA	cis	rs875971	0.638	rs801216	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66546680	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs801211	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66550702	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000229180.5	GS1-124K5.11	3.83	0.000144	0.0107	0.12	0.17	Aortic root size;	chr7:66540165	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs13224319	ENSG00000229180.5	GS1-124K5.11	3.83	0.000144	0.0107	0.12	0.17	Aortic root size;	chr7:66542376	chr7:66526088~66542624:-
THCA	cis	rs2694917	0.68	rs73114872	ENSG00000257576.1	RP11-153M3.1	3.83	0.000144	0.0107	0.27	0.17	Blood metabolite ratios;	chr12:56467250	chr12:56511002~56512703:+
THCA	cis	rs11633886	1	rs11633886	ENSG00000273972.1	CTD-2306A12.1	-3.83	0.000144	0.0107	-0.19	-0.17	Diisocyanate-induced asthma;	chr15:45786109	chr15:45702640~45703183:+
THCA	cis	rs9611565	0.512	rs768414	ENSG00000237037.8	NDUFA6-AS1	-3.83	0.000144	0.0107	-0.17	-0.17	Vitiligo;	chr22:41739747	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.512	rs8141103	ENSG00000237037.8	NDUFA6-AS1	-3.83	0.000144	0.0107	-0.17	-0.17	Vitiligo;	chr22:41740926	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.512	rs5751148	ENSG00000237037.8	NDUFA6-AS1	-3.83	0.000144	0.0107	-0.17	-0.17	Vitiligo;	chr22:41743074	chr22:42090931~42137742:+
THCA	cis	rs727563	0.635	rs5751149	ENSG00000237037.8	NDUFA6-AS1	-3.83	0.000144	0.0107	-0.17	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr22:42090931~42137742:+
THCA	cis	rs4245128	0.896	rs10891473	ENSG00000247416.2	RP11-629G13.1	3.83	0.000144	0.0107	0.16	0.17	Life satisfaction;	chr11:112926936	chr11:112959279~112963460:-
THCA	cis	rs12544026	0.581	rs502334	ENSG00000253669.3	KB-1732A1.1	-3.83	0.000144	0.0107	-0.2	-0.17	Major depression and alcohol dependence;	chr8:101868814	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.581	rs576173	ENSG00000253669.3	KB-1732A1.1	-3.83	0.000144	0.0107	-0.2	-0.17	Major depression and alcohol dependence;	chr8:101869016	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.581	rs531624	ENSG00000253669.3	KB-1732A1.1	-3.83	0.000144	0.0107	-0.2	-0.17	Major depression and alcohol dependence;	chr8:101869711	chr8:102805517~102809971:+
THCA	cis	rs61142792	1	rs335480	ENSG00000272459.1	RP11-1277A3.3	3.83	0.000144	0.0107	0.39	0.17	Alzheimer disease and age of onset;	chr5:177560723	chr5:177554824~177555364:+
THCA	cis	rs11069062	0.866	rs1846598	ENSG00000270482.1	RP11-131L12.2	3.83	0.000144	0.0107	0.14	0.17	Obesity-related traits;	chr12:118710900	chr12:118375350~118376275:-
THCA	cis	rs368187	0.721	rs1759760	ENSG00000258844.1	RP11-259K15.2	-3.83	0.000144	0.0107	-0.16	-0.17	Thyroid cancer;	chr14:36052560	chr14:36214607~36235608:+
THCA	cis	rs7403037	1	rs7180201	ENSG00000260760.1	PWRN3	-3.83	0.000144	0.0107	-0.2	-0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24587524	chr15:24441127~24447967:+
THCA	cis	rs2625529	0.73	rs8182011	ENSG00000260037.4	CTD-2524L6.3	3.83	0.000144	0.0107	0.23	0.17	Red blood cell count;	chr15:72097607	chr15:71818396~71823384:+
THCA	cis	rs2806561	0.796	rs1738467	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000144	0.0107	-0.11	-0.17	Height;	chr1:23180028	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.734	rs2806564	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000144	0.0107	-0.11	-0.17	Height;	chr1:23180192	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs2806565	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000144	0.0107	-0.11	-0.17	Height;	chr1:23180575	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.704	rs2868573	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000144	0.0107	-0.11	-0.17	Height;	chr1:23181760	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs9426692	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000144	0.0107	-0.11	-0.17	Height;	chr1:23181933	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.704	rs1757039	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000144	0.0107	-0.11	-0.17	Height;	chr1:23182164	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs1612905	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000144	0.0107	-0.11	-0.17	Height;	chr1:23183530	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs1738468	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000144	0.0107	-0.11	-0.17	Height;	chr1:23184357	chr1:23368997~23371839:+
THCA	cis	rs6762	0.748	rs28735718	ENSG00000255142.1	AP006621.6	3.83	0.000144	0.0107	0.12	0.17	Mean platelet volume;	chr11:839629	chr11:781645~782105:+
THCA	cis	rs2039553	0.552	rs1414110	ENSG00000227354.5	RBM26-AS1	-3.83	0.000144	0.0107	-0.16	-0.17	Pancreatic cancer;	chr13:79750788	chr13:79406309~79424328:+
THCA	cis	rs12803635	0.557	rs1558257	ENSG00000255306.1	RP5-901A4.1	3.83	0.000144	0.0107	0.3	0.17	Mean corpuscular volume;	chr11:67412554	chr11:68024809~68030461:-
THCA	cis	rs4792901	0.592	rs57462570	ENSG00000267151.3	RP11-100E5.2	3.83	0.000144	0.0107	0.19	0.17	Dupuytren's disease;	chr17:43530611	chr17:43444707~43451200:+
THCA	cis	rs6430538	0.621	rs12465725	ENSG00000224043.6	CCNT2-AS1	-3.83	0.000144	0.0107	-0.19	-0.17	Parkinson's disease;	chr2:134792516	chr2:134735464~134918710:-
THCA	cis	rs9532669	0.926	rs4600337	ENSG00000229473.2	RGS17P1	3.83	0.000144	0.0107	0.22	0.17	Cervical cancer;	chr13:40879564	chr13:40992779~40993331:-
THCA	cis	rs2251260	0.685	rs1088673	ENSG00000250548.5	RP11-47I22.2	-3.83	0.000144	0.0107	-0.27	-0.17	Yeast infection;	chr14:61538930	chr14:61556313~61570653:-
THCA	cis	rs1039766	1	rs1039766	ENSG00000204929.10	AC074391.1	-3.83	0.000144	0.0107	-0.28	-0.17	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr2:65436711~66084639:+
THCA	cis	rs2836974	0.897	rs8132295	ENSG00000255568.3	BRWD1-AS2	-3.83	0.000144	0.0107	-0.15	-0.17	Cognitive function;	chr21:39155848	chr21:39313935~39314962:+
THCA	cis	rs6496932	0.865	rs10520600	ENSG00000259630.2	CTD-2262B20.1	3.83	0.000144	0.0107	0.25	0.17	Central corneal thickness;Corneal structure;	chr15:85365171	chr15:85415228~85415633:+
THCA	cis	rs2180341	0.781	rs7760652	ENSG00000220522.2	RP1-177A13.1	3.83	0.000144	0.0107	0.21	0.17	Breast cancer;	chr6:127250951	chr6:127416535~127416952:-
THCA	cis	rs875971	1	rs6460296	ENSG00000230189.5	GS1-124K5.2	3.83	0.000144	0.0107	0.11	0.17	Aortic root size;	chr7:66430152	chr7:66409143~66490059:-
THCA	cis	rs875971	0.895	rs4718349	ENSG00000230189.5	GS1-124K5.2	3.83	0.000144	0.0107	0.11	0.17	Aortic root size;	chr7:66444024	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs2042133	ENSG00000230189.5	GS1-124K5.2	3.83	0.000144	0.0107	0.11	0.17	Aortic root size;	chr7:66466935	chr7:66409143~66490059:-
THCA	cis	rs875971	0.964	rs2161065	ENSG00000230189.5	GS1-124K5.2	3.83	0.000144	0.0107	0.11	0.17	Aortic root size;	chr7:66467918	chr7:66409143~66490059:-
THCA	cis	rs875971	0.862	rs12698521	ENSG00000230189.5	GS1-124K5.2	3.83	0.000144	0.0107	0.11	0.17	Aortic root size;	chr7:66474502	chr7:66409143~66490059:-
THCA	cis	rs7927592	0.513	rs689075	ENSG00000160172.9	FAM86C2P	3.83	0.000144	0.0107	0.16	0.17	Total body bone mineral density;	chr11:68426964	chr11:67791648~67805336:-
THCA	cis	rs875971	0.638	rs801205	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66557157	chr7:66526088~66542624:-
THCA	cis	rs875971	0.617	rs810400	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66557902	chr7:66526088~66542624:-
THCA	cis	rs875971	0.638	rs3898855	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66571411	chr7:66526088~66542624:-
THCA	cis	rs875971	0.638	rs10278816	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66572000	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs10281080	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66577454	chr7:66526088~66542624:-
THCA	cis	rs875971	0.66	rs10950044	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66577989	chr7:66526088~66542624:-
THCA	cis	rs875971	0.522	rs1968127	ENSG00000229180.5	GS1-124K5.11	-3.83	0.000144	0.0107	-0.12	-0.17	Aortic root size;	chr7:66591816	chr7:66526088~66542624:-
THCA	cis	rs7818688	0.614	rs11777353	ENSG00000253528.2	RP11-347C18.4	-3.83	0.000144	0.0107	-0.26	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94846955	chr8:94974573~94974853:-
THCA	cis	rs9928842	0.771	rs4888363	ENSG00000261783.1	RP11-252K23.2	3.83	0.000144	0.0107	0.31	0.17	Alcoholic chronic pancreatitis;	chr16:75243446	chr16:75379818~75381260:-
THCA	cis	rs9467773	1	rs1884949	ENSG00000228223.2	HCG11	-3.83	0.000144	0.0107	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26523450~26526579:+
THCA	cis	rs3845817	0.832	rs702945	ENSG00000281920.1	RP11-418H16.1	-3.83	0.000144	0.0107	-0.21	-0.17	Bipolar disorder;	chr2:65534098	chr2:65623272~65628424:+
THCA	cis	rs12755164	0.771	rs940917	ENSG00000223479.3	RP4-788P17.1	-3.83	0.000144	0.0107	-0.19	-0.17	Schizophrenia;	chr1:72844455	chr1:73635216~73715214:+
THCA	cis	rs1876905	0.524	rs1084639	ENSG00000271789.1	RP5-1112D6.7	-3.83	0.000144	0.0107	-0.22	-0.17	Mean corpuscular hemoglobin;	chr6:111165240	chr6:111297126~111298510:+
THCA	cis	rs62385074	1	rs17648477	ENSG00000250274.1	CTB-114C7.4	3.83	0.000144	0.0107	0.29	0.17	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr5:170304854	chr5:170308701~170312716:-
THCA	cis	rs16975963	0.644	rs73033139	ENSG00000276846.1	CTD-3220F14.3	-3.83	0.000144	0.0107	-0.16	-0.17	Longevity;	chr19:37600784	chr19:37314868~37315620:-
THCA	cis	rs13434995	0.513	rs41324951	ENSG00000249700.7	SRD5A3-AS1	3.83	0.000144	0.0107	0.25	0.17	Adiponectin levels;	chr4:55422576	chr4:55363971~55395847:-
THCA	cis	rs733592	0.965	rs1978161	ENSG00000258273.1	RP11-370I10.4	3.83	0.000144	0.0107	0.21	0.17	Plateletcrit;	chr12:48073938	chr12:48333755~48333901:-
THCA	cis	rs346923	1	rs28606562	ENSG00000226950.5	DANCR	3.83	0.000144	0.0107	0.2	0.17	Biochemical measures;	chr4:52499233	chr4:52712404~52720351:+
THCA	cis	rs2013441	0.866	rs2703773	ENSG00000261033.1	RP11-209D14.2	3.83	0.000144	0.0107	0.25	0.17	Obesity-related traits;	chr17:20228501	chr17:20008051~20009234:-
THCA	cis	rs786425	1	rs786425	ENSG00000270095.1	RP11-214K3.18	3.83	0.000144	0.0107	0.2	0.17	Pubertal anthropometrics;	chr12:123600955	chr12:123971457~123971714:-
THCA	cis	rs5752326	0.558	rs1023495	ENSG00000261188.1	CTA-445C9.14	3.83	0.000144	0.0107	0.18	0.17	Ischemic stroke;	chr22:26469088	chr22:26512537~26514568:+
THCA	cis	rs62292953	0.79	rs62292897	ENSG00000248724.5	NPHP3-AS1	-3.83	0.000144	0.0107	-0.33	-0.17	Red cell distribution width;	chr3:132468966	chr3:132721750~132874223:+
THCA	cis	rs42648	0.596	rs194524	ENSG00000225498.1	AC002064.5	3.83	0.000144	0.0107	0.18	0.17	Homocysteine levels;	chr7:90232518	chr7:90312496~90322592:+
THCA	cis	rs56114371	0.568	rs200468	ENSG00000226314.6	ZNF192P1	-3.83	0.000144	0.0107	-0.24	-0.17	Breast cancer;	chr6:27790076	chr6:28161781~28169594:+
THCA	cis	rs1371614	0.55	rs2384508	ENSG00000229122.1	AGBL5-IT1	3.83	0.000144	0.0107	0.12	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26920188	chr2:27061038~27061815:+
THCA	cis	rs9863	0.861	rs12298484	ENSG00000270028.1	RP11-380L11.4	3.83	0.000144	0.0107	0.2	0.17	White blood cell count;	chr12:123934127	chr12:123925461~123926083:-
THCA	cis	rs5769765	0.908	rs2319464	ENSG00000260613.1	RP3-522J7.6	3.83	0.000144	0.0107	0.22	0.17	Schizophrenia;	chr22:49872129	chr22:49832616~49837786:-
THCA	cis	rs2067615	0.896	rs2589266	ENSG00000260329.1	RP11-412D9.4	-3.83	0.000144	0.0107	-0.16	-0.17	Heart rate;	chr12:106862208	chr12:106954029~106955497:-
THCA	cis	rs7772486	0.811	rs2777475	ENSG00000270638.1	RP3-466P17.1	3.83	0.000144	0.0107	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145983467	chr6:145735570~145737218:+
THCA	cis	rs6442522	0.678	rs2345106	ENSG00000249786.6	EAF1-AS1	3.83	0.000144	0.0107	0.18	0.17	Uric acid levels;	chr3:15467521	chr3:15436171~15455940:-
THCA	cis	rs6442522	0.678	rs878946	ENSG00000249786.6	EAF1-AS1	3.83	0.000144	0.0107	0.18	0.17	Uric acid levels;	chr3:15467705	chr3:15436171~15455940:-
THCA	cis	rs6442522	0.678	rs878945	ENSG00000249786.6	EAF1-AS1	3.83	0.000144	0.0107	0.18	0.17	Uric acid levels;	chr3:15467820	chr3:15436171~15455940:-
THCA	cis	rs6442522	0.678	rs3773452	ENSG00000249786.6	EAF1-AS1	3.83	0.000144	0.0107	0.18	0.17	Uric acid levels;	chr3:15468447	chr3:15436171~15455940:-
THCA	cis	rs10927875	0.632	rs4661666	ENSG00000179743.3	FLJ37453	-3.83	0.000144	0.0107	-0.13	-0.17	Dilated cardiomyopathy;	chr1:15835976	chr1:15834479~15848147:-
THCA	cis	rs1971762	0.509	rs784567	ENSG00000270175.1	RP11-793H13.11	3.83	0.000144	0.0107	0.12	0.17	Height;	chr12:53500681	chr12:53500162~53500936:-
THCA	cis	rs34102591	0.826	rs12322694	ENSG00000270028.1	RP11-380L11.4	3.83	0.000144	0.0107	0.23	0.17	Schizophrenia;	chr12:123922745	chr12:123925461~123926083:-
THCA	cis	rs4930561	0.765	rs7931502	ENSG00000184795.9	UNC93B5	3.83	0.000144	0.0107	0.2	0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68192140	chr11:67711702~67716005:-
THCA	cis	rs735539	0.521	rs693489	ENSG00000278291.1	RP11-172H24.4	3.83	0.000145	0.0107	0.24	0.17	Dental caries;	chr13:20848866	chr13:20699307~20703718:-
THCA	cis	rs867186	1	rs8118005	ENSG00000126005.14	MMP24-AS1	-3.83	0.000145	0.0107	-0.27	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35048416	chr20:35216462~35278131:-
THCA	cis	rs758324	0.797	rs71970	ENSG00000237714.1	P4HA2-AS1	3.83	0.000145	0.0107	0.26	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131988426	chr5:132184876~132192808:+
THCA	cis	rs7399018	0.739	rs10747608	ENSG00000278126.1	RP11-454E5.4	3.83	0.000145	0.0107	0.19	0.17	Cisplatin-induced ototoxicity;	chr12:51222798	chr12:51201684~51202581:-
THCA	cis	rs6860806	0.661	rs4705927	ENSG00000263597.1	MIR3936	3.83	0.000145	0.0107	0.17	0.17	Breast cancer;	chr5:132242915	chr5:132365490~132365599:-
THCA	cis	rs35740288	0.857	rs11632034	ENSG00000259407.1	RP11-158M2.3	-3.83	0.000145	0.0107	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85740841	chr15:85744109~85750281:-
THCA	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	3.83	0.000145	0.0107	0.2	0.17	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
THCA	cis	rs12887734	0.524	rs12588797	ENSG00000258534.1	CTD-2134A5.4	3.83	0.000145	0.0107	0.19	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103854366~103880111:-
THCA	cis	rs295490	0.748	rs79854429	ENSG00000272656.1	RP11-219D15.3	3.83	0.000145	0.0107	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139512550	chr3:139349024~139349371:-
THCA	cis	rs3758911	1	rs11212160	ENSG00000255353.1	RP11-382M14.1	-3.83	0.000145	0.0107	-0.22	-0.17	Coronary artery disease;	chr11:107326192	chr11:107176286~107177530:+
THCA	cis	rs7903847	0.62	rs10882904	ENSG00000225850.3	RP11-452K12.4	3.83	0.000145	0.0107	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97355926	chr10:97334564~97343203:+
THCA	cis	rs17685	0.753	rs10085567	ENSG00000227038.2	AC005077.12	3.83	0.000145	0.0107	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76104888	chr7:76090431~76108779:-
THCA	cis	rs4245128	0.93	rs10488742	ENSG00000247416.2	RP11-629G13.1	3.83	0.000145	0.0107	0.16	0.17	Life satisfaction;	chr11:112912614	chr11:112959279~112963460:-
THCA	cis	rs11633886	0.585	rs11070473	ENSG00000273972.1	CTD-2306A12.1	-3.83	0.000145	0.0107	-0.2	-0.17	Diisocyanate-induced asthma;	chr15:45789560	chr15:45702640~45703183:+
THCA	cis	rs9450351	0.744	rs9450383	ENSG00000280232.1	RP11-321N4.4	3.83	0.000145	0.0107	0.38	0.17	Interferon gamma-induced protein 10 levels;	chr6:86073540	chr6:85498441~85499058:-
THCA	cis	rs12476592	0.602	rs2028887	ENSG00000242412.1	DBIL5P2	3.83	0.000145	0.0107	0.22	0.17	Childhood ear infection;	chr2:63489089	chr2:63117851~63119542:-
THCA	cis	rs791590	0.941	rs12722523	ENSG00000225948.2	RP11-554I8.1	3.83	0.000145	0.0107	0.28	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6036427	chr10:6618716~6625346:+
THCA	cis	rs1411478	1	rs3747957	ENSG00000243155.1	RP11-46A10.5	3.83	0.000145	0.0107	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984717	chr1:180944042~180976482:-
THCA	cis	rs17622252	0.722	rs12524874	ENSG00000280989.1	LINC00581	3.83	0.000145	0.0107	0.33	0.17	Bipolar disorder;	chr6:21355968	chr6:21486061~21511895:-
THCA	cis	rs4272720	0.562	rs4644582	ENSG00000234736.4	FAM170B-AS1	-3.83	0.000145	0.0107	-0.18	-0.17	Platelet count;Plateletcrit;	chr10:49113949	chr10:49121839~49151547:+
THCA	cis	rs55966801	0.898	rs56312618	ENSG00000277290.1	RP11-326C3.16	-3.83	0.000145	0.0107	-0.23	-0.17	Plateletcrit;	chr11:237209	chr11:243099~243483:-
THCA	cis	rs55966801	0.898	rs939915	ENSG00000277290.1	RP11-326C3.16	-3.83	0.000145	0.0107	-0.23	-0.17	Plateletcrit;	chr11:237737	chr11:243099~243483:-
THCA	cis	rs55966801	0.842	rs72865313	ENSG00000277290.1	RP11-326C3.16	-3.83	0.000145	0.0107	-0.23	-0.17	Plateletcrit;	chr11:240754	chr11:243099~243483:-
THCA	cis	rs55781332	1	rs55781332	ENSG00000277290.1	RP11-326C3.16	-3.83	0.000145	0.0107	-0.23	-0.17	Total body bone mineral density (age 30-45);Total body bone mineral density;	chr11:242859	chr11:243099~243483:-
THCA	cis	rs6095360	0.546	rs8119308	ENSG00000227431.4	CSE1L-AS1	-3.83	0.000145	0.0107	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48918572	chr20:49040463~49046044:-
THCA	cis	rs2820315	0.867	rs2644121	ENSG00000223774.4	RP11-307B6.3	3.83	0.000145	0.0107	0.19	0.17	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201912156	chr1:201893842~201899978:+
THCA	cis	rs7259376	0.807	rs6511348	ENSG00000269138.1	ZNF209P	3.83	0.000145	0.0107	0.18	0.17	Menopause (age at onset);	chr19:22374572	chr19:22463922~22473036:+
THCA	cis	rs853679	0.882	rs9468300	ENSG00000261839.1	RP1-265C24.8	3.83	0.000145	0.0107	0.26	0.17	Depression;	chr6:28159062	chr6:28136849~28139678:+
THCA	cis	rs642803	1	rs642803	ENSG00000255120.4	OVOL1-AS1	3.83	0.000145	0.0107	0.21	0.17	Urate levels;	chr11:65793149	chr11:65789051~65790868:-
THCA	cis	rs2190422	0.551	rs11976900	ENSG00000234715.1	CTB-107G13.1	-3.83	0.000145	0.0107	-0.24	-0.17	Morning vs. evening chronotype;	chr7:103521822	chr7:103445207~103514007:+
THCA	cis	rs2190422	0.551	rs10282605	ENSG00000234715.1	CTB-107G13.1	3.83	0.000145	0.0107	0.24	0.17	Morning vs. evening chronotype;	chr7:103521923	chr7:103445207~103514007:+
THCA	cis	rs7914558	1	rs4917994	ENSG00000272912.1	RP11-724N1.1	-3.83	0.000145	0.0108	-0.21	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs2275271	ENSG00000272912.1	RP11-724N1.1	-3.83	0.000145	0.0108	-0.21	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs11191539	ENSG00000272912.1	RP11-724N1.1	-3.83	0.000145	0.0108	-0.21	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs943038	ENSG00000272912.1	RP11-724N1.1	-3.83	0.000145	0.0108	-0.21	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:102914585~102915404:+
THCA	cis	rs3748656	0.887	rs35147679	ENSG00000273483.1	RP4-671G15.2	3.83	0.000145	0.0108	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112525955	chr1:112517799~112518441:-
THCA	cis	rs7226408	0.6	rs1147759	ENSG00000267707.2	RP11-95O2.5	-3.83	0.000145	0.0108	-0.17	-0.17	Obesity-related traits;	chr18:36820503	chr18:37243776~37247506:+
THCA	cis	rs7226408	0.6	rs1147761	ENSG00000267707.2	RP11-95O2.5	-3.83	0.000145	0.0108	-0.17	-0.17	Obesity-related traits;	chr18:36821197	chr18:37243776~37247506:+
THCA	cis	rs4262150	0.689	rs11167584	ENSG00000253921.1	CTB-113P19.3	3.83	0.000145	0.0108	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152625167	chr5:151753992~151767247:+
THCA	cis	rs910316	1	rs876402	ENSG00000259138.1	RP11-950C14.7	-3.83	0.000145	0.0108	-0.15	-0.17	Height;	chr14:75135159	chr14:75127153~75136930:+
THCA	cis	rs7259376	0.936	rs55983151	ENSG00000270947.1	AC025811.3	3.83	0.000145	0.0108	0.18	0.17	Menopause (age at onset);	chr19:22370134	chr19:22455988~22456459:+
THCA	cis	rs12499086	0.642	rs9996658	ENSG00000251175.4	RP11-45L9.1	3.83	0.000145	0.0108	0.22	0.17	Economic and political preferences (time);	chr4:105494403	chr4:105746245~105827172:-
THCA	cis	rs1127311	0.905	rs6702449	ENSG00000236675.1	MTX1P1	-3.83	0.000145	0.0108	-0.16	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154610734	chr1:155230975~155234325:+
THCA	cis	rs7899106	1	rs12412597	ENSG00000270002.1	RP11-93H12.4	3.83	0.000145	0.0108	0.3	0.17	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85579500	chr10:85644073~85648066:+
THCA	cis	rs7200543	0.583	rs4985149	ENSG00000188599.16	NPIPP1	-3.83	0.000145	0.0108	-0.13	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:15104312~15123498:-
THCA	cis	rs9733	0.791	rs11204693	ENSG00000231073.1	RP11-316M1.3	-3.83	0.000145	0.0108	-0.21	-0.17	Tonsillectomy;	chr1:150675511	chr1:150973123~150975534:+
THCA	cis	rs11633886	0.528	rs2247958	ENSG00000259200.1	RP11-718O11.1	3.83	0.000145	0.0108	0.21	0.17	Diisocyanate-induced asthma;	chr15:45807336	chr15:45705078~45931069:+
THCA	cis	rs6546550	0.901	rs13028508	ENSG00000179818.12	PCBP1-AS1	3.83	0.000145	0.0108	0.14	0.17	Prevalent atrial fibrillation;	chr2:69891295	chr2:69962263~70103220:-
THCA	cis	rs10489167	1	rs10489167	ENSG00000237899.1	RP4-739H11.3	-3.83	0.000145	0.0108	-0.31	-0.17	Depressive and manic episodes in bipolar disorder;	chr1:40710794	chr1:40669089~40687588:-
THCA	cis	rs765787	0.53	rs4774542	ENSG00000259539.1	CTD-2651B20.1	-3.83	0.000145	0.0108	-0.22	-0.17	Uric acid levels;	chr15:45233828	chr15:45152664~45167526:-
THCA	cis	rs910316	1	rs10140851	ENSG00000259138.1	RP11-950C14.7	3.83	0.000145	0.0108	0.15	0.17	Height;	chr14:75045909	chr14:75127153~75136930:+
THCA	cis	rs1046896	1	rs1046896	ENSG00000263063.1	RP11-388C12.1	3.83	0.000145	0.0108	0.21	0.17	Glycated hemoglobin levels;	chr17:82727657	chr17:82713908~82716255:-
THCA	cis	rs6142618	0.811	rs4243971	ENSG00000224452.1	RSL24D1P6	3.83	0.000145	0.0108	0.22	0.17	Inflammatory bowel disease;	chr20:32261714	chr20:32170390~32170790:-
THCA	cis	rs10191559	0.619	rs1401130	ENSG00000236153.1	AC104076.3	3.83	0.000145	0.0108	0.19	0.17	Red blood cell count;	chr2:181029486	chr2:180979427~180980090:-
THCA	cis	rs9660180	0.967	rs2272908	ENSG00000215914.4	MMP23A	3.83	0.000145	0.0108	0.23	0.17	Body mass index;	chr1:1790040	chr1:1699942~1701782:+
THCA	cis	rs2749592	0.55	rs7081464	ENSG00000120555.12	SEPT7P9	-3.83	0.000145	0.0108	-0.19	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38383069~38402916:-
THCA	cis	rs4819052	1	rs3746980	ENSG00000184274.3	LINC00315	-3.83	0.000145	0.0108	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45300245~45305257:-
THCA	cis	rs7259376	0.902	rs10414591	ENSG00000269138.1	ZNF209P	-3.83	0.000145	0.0108	-0.17	-0.17	Menopause (age at onset);	chr19:22417320	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.902	rs10420380	ENSG00000269138.1	ZNF209P	-3.83	0.000145	0.0108	-0.17	-0.17	Menopause (age at onset);	chr19:22417822	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.869	rs10402396	ENSG00000269138.1	ZNF209P	-3.83	0.000145	0.0108	-0.17	-0.17	Menopause (age at onset);	chr19:22419007	chr19:22463922~22473036:+
THCA	cis	rs11168618	0.846	rs7974213	ENSG00000240399.1	RP1-228P16.1	-3.83	0.000145	0.0108	-0.17	-0.17	Adiponectin levels;	chr12:48487709	chr12:48054813~48055591:-
THCA	cis	rs7178375	1	rs35162264	ENSG00000215302.7	CTD-3092A11.1	-3.83	0.000145	0.0108	-0.24	-0.17	Hypertriglyceridemia;	chr15:30908480	chr15:30470779~30507623:+
THCA	cis	rs875971	0.545	rs10950029	ENSG00000273024.4	INTS4P2	-3.83	0.000145	0.0108	-0.21	-0.17	Aortic root size;	chr7:66169334	chr7:65647864~65715661:+
THCA	cis	rs757978	1	rs7601738	ENSG00000235351.1	AC114730.11	3.83	0.000145	0.0108	0.17	0.17	Chronic lymphocytic leukemia;	chr2:241436398	chr2:241724615~241725693:-
THCA	cis	rs2442825	0.693	rs2728949	ENSG00000254485.4	RP11-380O24.1	-3.83	0.000145	0.0108	-0.16	-0.17	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9292588~9363303:-
THCA	cis	rs2357982	0.525	rs197273	ENSG00000227403.1	AC009299.3	-3.83	0.000145	0.0108	-0.2	-0.17	Presence of antiphospholipid antibodies;	chr2:161038152	chr2:161244739~161249050:+
THCA	cis	rs7903847	0.642	rs7092499	ENSG00000225850.3	RP11-452K12.4	3.83	0.000145	0.0108	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97380556	chr10:97334564~97343203:+
THCA	cis	rs454217	0.714	rs395142	ENSG00000277851.1	RP11-756G20.1	-3.83	0.000145	0.0108	-0.17	-0.17	Smoking quantity;	chr12:92341860	chr12:92247756~92363832:-
THCA	cis	rs9500256	1	rs9500256	ENSG00000239650.4	GUSBP4	3.83	0.000145	0.0108	0.17	0.17	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57919784~57930291:-
THCA	cis	rs6599077	0.573	rs7644914	ENSG00000223797.4	ENTPD3-AS1	-3.83	0.000145	0.0108	-0.16	-0.17	Sleep-related phenotypes;	chr3:40153552	chr3:40313802~40453329:-
THCA	cis	rs10761482	0.954	rs10443926	ENSG00000254271.1	RP11-131N11.4	3.83	0.000145	0.0108	0.23	0.17	Schizophrenia;	chr10:60306235	chr10:60734342~60741828:+
THCA	cis	rs13108904	0.87	rs4974541	ENSG00000254094.1	AC078852.1	-3.83	0.000145	0.0108	-0.2	-0.17	Obesity-related traits;	chr4:1250249	chr4:1356581~1358075:+
THCA	cis	rs6095360	0.546	rs6019525	ENSG00000227431.4	CSE1L-AS1	-3.83	0.000145	0.0108	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48917419	chr20:49040463~49046044:-
THCA	cis	rs1510272	1	rs4679778	ENSG00000243926.1	TIPARP-AS1	-3.83	0.000145	0.0108	-0.18	-0.17	Testicular germ cell tumor;	chr3:156578150	chr3:156671862~156674378:-
THCA	cis	rs7209700	0.862	rs2015729	ENSG00000262879.4	RP11-156P1.3	3.83	0.000145	0.0108	0.16	0.17	IgG glycosylation;	chr17:47277127	chr17:46984045~47100323:-
THCA	cis	rs17604090	1	rs17603986	ENSG00000227855.3	DPY19L2P3	3.83	0.000145	0.0108	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29650873	chr7:29650227~29742594:+
THCA	cis	rs7772486	0.79	rs9376970	ENSG00000270638.1	RP3-466P17.1	-3.83	0.000145	0.0108	-0.14	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145735570~145737218:+
THCA	cis	rs56046484	1	rs12911330	ENSG00000259630.2	CTD-2262B20.1	-3.83	0.000145	0.0108	-0.25	-0.17	Testicular germ cell tumor;	chr15:85087103	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.956	rs34919315	ENSG00000259630.2	CTD-2262B20.1	-3.83	0.000145	0.0108	-0.25	-0.17	Testicular germ cell tumor;	chr15:85088675	chr15:85415228~85415633:+
THCA	cis	rs6142618	0.811	rs6057547	ENSG00000224452.1	RSL24D1P6	3.83	0.000145	0.0108	0.22	0.17	Inflammatory bowel disease;	chr20:32257534	chr20:32170390~32170790:-
THCA	cis	rs9905704	0.918	rs302852	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58607853	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs302857	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58615026	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs186221	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58618606	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.831	rs12949598	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58629884	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs430973	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58631845	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs68139131	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58639888	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs581903	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58641836	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs654743	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58659129	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.874	rs304265	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58671937	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs302880	ENSG00000224738.1	AC099850.1	3.83	0.000145	0.0108	0.23	0.17	Testicular germ cell tumor;	chr17:58684050	chr17:59106598~59118267:+
THCA	cis	rs7914558	0.966	rs7908280	ENSG00000272912.1	RP11-724N1.1	-3.83	0.000145	0.0108	-0.21	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102914585~102915404:+
THCA	cis	rs1923539	0.549	rs2250135	ENSG00000225484.5	NUTM2B-AS1	3.83	0.000145	0.0108	0.22	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79907567	chr10:79663088~79826594:-
THCA	cis	rs10090774	0.71	rs13249806	ENSG00000279766.1	RP11-642A1.2	-3.83	0.000145	0.0108	-0.21	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140675407	chr8:140572142~140572812:-
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000184274.3	LINC00315	-3.83	0.000145	0.0108	-0.22	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45300245~45305257:-
THCA	cis	rs7819412	0.668	rs2409721	ENSG00000261451.1	RP11-981G7.1	-3.83	0.000145	0.0108	-0.22	-0.17	Triglycerides;	chr8:11180735	chr8:10433672~10438312:+
THCA	cis	rs1635	0.826	rs3800324	ENSG00000216901.1	AL022393.7	3.83	0.000145	0.0108	0.39	0.17	Schizophrenia;	chr6:28296904	chr6:28176188~28176674:+
THCA	cis	rs712419	0.667	rs712414	ENSG00000258998.1	RP11-398E10.1	3.83	0.000145	0.0108	0.24	0.17	Body mass index (change over time) in lung cancer;	chr14:44732150	chr14:44763157~44782829:-
THCA	cis	rs2064219	0.554	rs6914846	ENSG00000271755.1	RP1-153G14.4	3.83	0.000145	0.0108	0.2	0.17	Depressive symptoms;Depressive symptoms (multi-trait analysis);	chr6:27442900	chr6:27404010~27406964:-
THCA	cis	rs34526934	0.566	rs62624470	ENSG00000226363.3	HAGLROS	3.83	0.000145	0.0108	0.23	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176176179	chr2:176177717~176179008:+
THCA	cis	rs17685	0.672	rs1639623	ENSG00000227038.2	AC005077.12	3.83	0.000145	0.0108	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76078633	chr7:76090431~76108779:-
THCA	cis	rs34421088	0.548	rs2618443	ENSG00000255046.1	RP11-297N6.4	3.83	0.000145	0.0108	0.18	0.17	Neuroticism;	chr8:11527047	chr8:11797928~11802568:-
THCA	cis	rs7726839	0.561	rs6555357	ENSG00000225138.6	CTD-2228K2.7	3.83	0.000145	0.0108	0.2	0.17	Obesity-related traits;	chr5:560808	chr5:473236~480884:+
THCA	cis	rs1046896	0.731	rs9906115	ENSG00000263063.1	RP11-388C12.1	-3.83	0.000145	0.0108	-0.24	-0.17	Glycated hemoglobin levels;	chr17:82833593	chr17:82713908~82716255:-
THCA	cis	rs1204798	1	rs1204841	ENSG00000237021.2	RP3-486I3.7	-3.83	0.000145	0.0108	-0.19	-0.17	Dental caries;	chr6:116198477	chr6:116254207~116256743:+
THCA	cis	rs1204798	1	rs1204843	ENSG00000237021.2	RP3-486I3.7	-3.83	0.000145	0.0108	-0.19	-0.17	Dental caries;	chr6:116199822	chr6:116254207~116256743:+
THCA	cis	rs7819412	0.806	rs10113808	ENSG00000206014.6	OR7E161P	3.83	0.000145	0.0108	0.2	0.17	Triglycerides;	chr8:11069382	chr8:11928597~11929563:-
THCA	cis	rs2153535	0.518	rs1998265	ENSG00000230939.1	RP11-314C16.1	-3.83	0.000145	0.0108	-0.19	-0.17	Motion sickness;	chr6:8651929	chr6:8784178~8785445:+
THCA	cis	rs60180747	0.909	rs112095287	ENSG00000261318.1	RP11-653J6.1	3.83	0.000145	0.0108	0.25	0.17	Testicular germ cell tumor;	chr15:66499749	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.909	rs74956204	ENSG00000261318.1	RP11-653J6.1	3.83	0.000145	0.0108	0.25	0.17	Testicular germ cell tumor;	chr15:66502014	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.909	rs28684409	ENSG00000261318.1	RP11-653J6.1	3.83	0.000145	0.0108	0.25	0.17	Testicular germ cell tumor;	chr15:66502368	chr15:66278498~66293357:-
THCA	cis	rs60180747	0.909	rs79981875	ENSG00000261318.1	RP11-653J6.1	3.83	0.000145	0.0108	0.25	0.17	Testicular germ cell tumor;	chr15:66509324	chr15:66278498~66293357:-
THCA	cis	rs1501911	0.53	rs161942	ENSG00000241597.2	CTD-2007H13.1	-3.83	0.000145	0.0108	-0.22	-0.17	Lung function (FEV1/FVC);	chr5:98868016	chr5:98954394~98954972:+
THCA	cis	rs1853665	0.895	rs9478311	ENSG00000231760.4	RP11-350J20.5	3.83	0.000145	0.0108	0.26	0.17	Radiation response;	chr6:149965999	chr6:149796151~149826294:-
THCA	cis	rs7707921	0.881	rs73136777	ENSG00000251374.1	RPS23P5	3.83	0.000145	0.0108	0.25	0.17	Breast cancer;	chr5:82138660	chr5:82265157~82265259:-
THCA	cis	rs758324	0.588	rs253944	ENSG00000237714.1	P4HA2-AS1	3.83	0.000145	0.0108	0.24	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131994361	chr5:132184876~132192808:+
THCA	cis	rs67981189	0.896	rs7153237	ENSG00000269927.1	RP6-91H8.3	3.83	0.000145	0.0108	0.2	0.17	Schizophrenia;	chr14:71021937	chr14:71141125~71143253:-
THCA	cis	rs7951911	0.915	rs7131423	ENSG00000254427.1	RP11-430H10.1	3.83	0.000146	0.0108	0.32	0.17	IgG glycosylation;	chr11:45077084	chr11:45355371~45366121:+
THCA	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	3.83	0.000146	0.0108	0.24	0.17	Depression;	chr6:28407125	chr6:28943877~28944537:+
THCA	cis	rs9309473	1	rs10175180	ENSG00000273245.1	RP11-434P11.2	3.83	0.000146	0.0108	0.23	0.17	Metabolite levels;	chr2:73445995	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs10496191	ENSG00000273245.1	RP11-434P11.2	3.83	0.000146	0.0108	0.23	0.17	Metabolite levels;	chr2:73446670	chr2:73750256~73750786:-
THCA	cis	rs765787	0.53	rs1706834	ENSG00000259539.1	CTD-2651B20.1	3.83	0.000146	0.0108	0.21	0.17	Uric acid levels;	chr15:45225656	chr15:45152664~45167526:-
THCA	cis	rs4588572	0.644	rs1159930	ENSG00000245556.2	SCAMP1-AS1	3.83	0.000146	0.0108	0.14	0.17	Triglycerides;	chr5:78473120	chr5:78342365~78360507:-
THCA	cis	rs12451471	0.559	rs12452263	ENSG00000279259.1	RP11-334C17.3	-3.83	0.000146	0.0108	-0.18	-0.17	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80105511	chr17:80147250~80148596:+
THCA	cis	rs13063635	0.915	rs1994491	ENSG00000226074.4	PRSS44	-3.83	0.000146	0.0108	-0.32	-0.17	Eosinophil percentage of granulocytes;	chr3:45918928	chr3:46809359~46812558:-
THCA	cis	rs12681366	0.839	rs3019280	ENSG00000261437.1	RP11-22C11.2	3.83	0.000146	0.0108	0.17	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.839	rs3019281	ENSG00000261437.1	RP11-22C11.2	3.83	0.000146	0.0108	0.17	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94637285~94639467:-
THCA	cis	rs1577917	0.958	rs12195776	ENSG00000220563.1	PKMP3	-3.83	0.000146	0.0108	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85778881	chr6:85659892~85660606:-
THCA	cis	rs800160	0.777	rs962902	ENSG00000199550.1	Y_RNA	3.83	0.000146	0.0108	0.26	0.17	Bacteremia;	chr11:2330995	chr11:2372638~2372750:+
THCA	cis	rs2058059	0.551	rs13225871	ENSG00000205578.5	POM121B	-3.83	0.000146	0.0108	-0.28	-0.17	Subcutaneous adipose tissue;	chr7:72573203	chr7:73293497~73301161:+
THCA	cis	rs1150668	0.796	rs213236	ENSG00000220721.1	OR1F12	3.83	0.000146	0.0108	0.19	0.17	Pubertal anthropometrics;	chr6:28356620	chr6:28073316~28074233:+
THCA	cis	rs13182402	0.901	rs13188450	ENSG00000230929.5	RP11-395C3.1	-3.83	0.000146	0.0108	-0.33	-0.17	Osteoporosis;	chr5:126583668	chr5:126628019~126628319:-
THCA	cis	rs6657613	0.503	rs9435739	ENSG00000186301.8	MST1P2	-3.83	0.000146	0.0108	-0.15	-0.17	Hip circumference adjusted for BMI;	chr1:17016429	chr1:16645622~16650289:+
THCA	cis	rs9309473	1	rs3813227	ENSG00000273245.1	RP11-434P11.2	-3.83	0.000146	0.0108	-0.23	-0.17	Metabolite levels;	chr2:73424839	chr2:73750256~73750786:-
THCA	cis	rs10208649	1	rs10208649	ENSG00000233266.1	HMGB1P31	-3.83	0.000146	0.0108	-0.39	-0.17	Body mass index;	chr2:53934226	chr2:54051334~54051760:+
THCA	cis	rs17286411	0.671	rs7185997	ENSG00000260185.1	RP11-432I5.6	-3.83	0.000146	0.0108	-0.24	-0.17	Blood protein levels;	chr16:71758305	chr16:71655027~71664212:+
THCA	cis	rs10090774	0.87	rs12234950	ENSG00000280303.2	ERICD	3.83	0.000146	0.0108	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140746229	chr8:140636281~140638283:+
THCA	cis	rs12410462	0.591	rs3748806	ENSG00000227711.2	RP11-275O4.5	3.83	0.000146	0.0108	0.21	0.17	Major depressive disorder;	chr1:227563411	chr1:227509028~227520477:-
THCA	cis	rs8115854	0.961	rs8120336	ENSG00000269846.1	RP4-621N11.2	-3.83	0.000146	0.0108	-0.22	-0.17	Hippocampal atrophy;	chr20:37120676	chr20:37095785~37097178:+
THCA	cis	rs13098911	0.54	rs13059238	ENSG00000226074.4	PRSS44	-3.83	0.000146	0.0108	-0.32	-0.17	Celiac disease;	chr3:45966333	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs17214952	ENSG00000226074.4	PRSS44	-3.83	0.000146	0.0108	-0.32	-0.17	Celiac disease;	chr3:45969944	chr3:46809359~46812558:-
THCA	cis	rs875971	0.545	rs6979636	ENSG00000273024.4	INTS4P2	-3.83	0.000146	0.0108	-0.22	-0.17	Aortic root size;	chr7:66276638	chr7:65647864~65715661:+
THCA	cis	rs3770081	1	rs12620810	ENSG00000273080.1	RP11-301O19.1	-3.83	0.000146	0.0108	-0.38	-0.17	Facial emotion recognition (sad faces);	chr2:86164358	chr2:86195590~86196049:+
THCA	cis	rs2562456	0.92	rs2650784	ENSG00000268658.4	LINC00664	-3.83	0.000146	0.0108	-0.25	-0.17	Pain;	chr19:21483795	chr19:21483374~21503238:+
THCA	cis	rs1008126	0.8	rs2528862	ENSG00000234715.1	CTB-107G13.1	-3.83	0.000146	0.0108	-0.2	-0.17	Metabolite levels (Pyroglutamine);	chr7:103515497	chr7:103445207~103514007:+
THCA	cis	rs71520386	0.807	rs10263435	ENSG00000228649.7	AC005682.5	-3.83	0.000146	0.0108	-0.26	-0.17	Fibrinogen levels;	chr7:22790243	chr7:22854178~22861579:+
THCA	cis	rs41313321	0.92	rs73672491	ENSG00000272696.1	RP11-339B21.13	3.83	0.000146	0.0108	0.15	0.17	Coenzyme Q10 levels;	chr9:128294423	chr9:128316337~128316909:+
THCA	cis	rs7945705	0.837	rs10769966	ENSG00000254860.4	TMEM9B-AS1	-3.83	0.000146	0.0108	-0.19	-0.17	Hemoglobin concentration;	chr11:8825494	chr11:8964675~8977527:+
THCA	cis	rs6687821	0.515	rs10873806	ENSG00000261737.1	RP4-612B15.3	3.83	0.000146	0.0108	0.26	0.17	Yeast infection;	chr1:86974915	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs11161914	ENSG00000261737.1	RP4-612B15.3	3.83	0.000146	0.0108	0.26	0.17	Yeast infection;	chr1:86977846	chr1:86703502~86704462:-
THCA	cis	rs9925964	0.591	rs11649653	ENSG00000279196.1	RP11-1072A3.3	-3.83	0.000146	0.0108	-0.16	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30907166	chr16:30984630~30988270:-
THCA	cis	rs2676071	1	rs2676071	ENSG00000259721.1	RP11-758N13.1	-3.83	0.000146	0.0108	-0.2	-0.17	Periodontitis (Mean PAL);	chr15:33304875	chr15:32717270~32719007:-
THCA	cis	rs6968419	1	rs6979486	ENSG00000237870.5	AC073130.1	3.83	0.000146	0.0108	0.18	0.17	Intraocular pressure;	chr7:116192384	chr7:116275606~116286734:-
THCA	cis	rs9532669	0.89	rs9525417	ENSG00000229473.2	RGS17P1	3.83	0.000146	0.0108	0.22	0.17	Cervical cancer;	chr13:40878431	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs9532638	ENSG00000229473.2	RGS17P1	3.83	0.000146	0.0108	0.22	0.17	Cervical cancer;	chr13:40878471	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7997536	ENSG00000229473.2	RGS17P1	3.83	0.000146	0.0108	0.22	0.17	Cervical cancer;	chr13:40878685	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7997560	ENSG00000229473.2	RGS17P1	3.83	0.000146	0.0108	0.22	0.17	Cervical cancer;	chr13:40878723	chr13:40992779~40993331:-
THCA	cis	rs9309473	0.948	rs13392691	ENSG00000273245.1	RP11-434P11.2	3.83	0.000146	0.0108	0.25	0.17	Metabolite levels;	chr2:73521853	chr2:73750256~73750786:-
THCA	cis	rs13098911	0.54	rs71325095	ENSG00000226074.4	PRSS44	-3.83	0.000146	0.0108	-0.32	-0.17	Celiac disease;	chr3:45948429	chr3:46809359~46812558:-
THCA	cis	rs17382723	0.887	rs1062748	ENSG00000225521.1	AC005237.4	3.83	0.000146	0.0108	0.22	0.17	Height;	chr2:241089326	chr2:241015599~241064116:-
THCA	cis	rs4356203	0.87	rs10832751	ENSG00000272034.1	SNORD14A	-3.83	0.000146	0.0108	-0.17	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17252469	chr11:17074654~17074744:-
THCA	cis	rs7216064	0.532	rs3890640	ENSG00000267023.4	LRRC37A16P	3.83	0.000146	0.0108	0.13	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68125777~68152468:-
THCA	cis	rs7216064	0.589	rs8072723	ENSG00000267023.4	LRRC37A16P	3.83	0.000146	0.0108	0.13	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68125777~68152468:-
THCA	cis	rs330048	0.561	rs4840401	ENSG00000248538.5	RP11-10A14.5	3.83	0.000146	0.0108	0.23	0.17	Systemic lupus erythematosus;	chr8:9290615	chr8:9189011~9202854:+
THCA	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	3.83	0.000146	0.0108	0.22	0.17	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
THCA	cis	rs73198271	0.53	rs11778326	ENSG00000253893.2	FAM85B	3.83	0.000146	0.0108	0.28	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794056	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.562	rs113730597	ENSG00000253893.2	FAM85B	3.83	0.000146	0.0108	0.28	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794063	chr8:8167819~8226614:-
THCA	cis	rs10089	1	rs883074	ENSG00000245937.6	LINC01184	-3.83	0.000146	0.0108	-0.19	-0.17	Ileal carcinoids;	chr5:128110131	chr5:127940426~128083172:-
THCA	cis	rs9810089	0.967	rs7372313	ENSG00000273455.1	RP11-305O4.3	3.83	0.000146	0.0108	0.23	0.17	Gestational age at birth (child effect);	chr3:136154116	chr3:136087475~136087913:-
THCA	cis	rs5769765	0.704	rs138837	ENSG00000260613.1	RP3-522J7.6	-3.83	0.000146	0.0108	-0.21	-0.17	Schizophrenia;	chr22:49787066	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.671	rs138841	ENSG00000260613.1	RP3-522J7.6	-3.83	0.000146	0.0108	-0.21	-0.17	Schizophrenia;	chr22:49788312	chr22:49832616~49837786:-
THCA	cis	rs4950322	0.518	rs56151278	ENSG00000180867.10	PDIA3P1	3.83	0.000146	0.0108	0.17	0.17	Protein quantitative trait loci;	chr1:147117421	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.518	rs4950306	ENSG00000180867.10	PDIA3P1	3.83	0.000146	0.0108	0.17	0.17	Protein quantitative trait loci;	chr1:147117838	chr1:147178113~147179622:+
THCA	cis	rs793571	0.744	rs4775097	ENSG00000245975.2	RP11-30K9.6	-3.83	0.000146	0.0108	-0.17	-0.17	Schizophrenia;	chr15:58848602	chr15:58768072~58770974:-
THCA	cis	rs7572733	0.875	rs771018	ENSG00000231621.1	AC013264.2	-3.83	0.000146	0.0108	-0.16	-0.17	Dermatomyositis;	chr2:197785535	chr2:197197991~197199273:+
THCA	cis	rs9573569	1	rs9573569	ENSG00000228444.2	RP11-173B14.4	-3.83	0.000146	0.0108	-0.17	-0.17	Mean platelet volume;	chr13:75484835	chr13:75631271~75632135:+
THCA	cis	rs11678825	0.789	rs13398456	ENSG00000272663.1	RP11-191L17.1	-3.83	0.000146	0.0108	-0.24	-0.17	Reticulocyte fraction of red cells;	chr2:48391888	chr2:48440043~48440597:-
THCA	cis	rs2051773	0.539	rs6486345	ENSG00000184669.7	OR7E14P	-3.83	0.000146	0.0108	-0.24	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17017230	chr11:17013998~17053024:+
THCA	cis	rs8033133	0.56	rs12441340	ENSG00000251896.1	SNORD116-27	-3.83	0.000146	0.0108	-0.19	-0.17	Blood osmolality (transformed sodium);	chr15:25078817	chr15:25101575~25101666:+
THCA	cis	rs10875746	0.729	rs11168357	ENSG00000258234.1	RP11-370I10.2	3.83	0.000146	0.0108	0.2	0.17	Longevity (90 years and older);	chr12:48018355	chr12:48231098~48284210:-
THCA	cis	rs2455799	0.613	rs6802048	ENSG00000270409.1	RP11-44D5.1	-3.83	0.000146	0.0108	-0.18	-0.17	Mean platelet volume;	chr3:15842426	chr3:15732252~15733470:+
THCA	cis	rs755249	0.501	rs4660669	ENSG00000182109.6	RP11-69E11.4	-3.83	0.000146	0.0108	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39522280~39546187:-
THCA	cis	rs7598759	0.966	rs6754426	ENSG00000181798.2	LINC00471	-3.83	0.000146	0.0108	-0.2	-0.17	Noise-induced hearing loss;	chr2:231458068	chr2:231508426~231514339:-
THCA	cis	rs950169	0.96	rs12905475	ENSG00000275120.1	RP11-182J1.17	3.83	0.000146	0.0108	0.22	0.17	Schizophrenia;	chr15:84131743	chr15:84599434~84606463:-
THCA	cis	rs13113518	0.812	rs12649507	ENSG00000272969.1	RP11-528I4.2	-3.83	0.000146	0.0108	-0.21	-0.17	Height;	chr4:55514317	chr4:55547112~55547889:+
THCA	cis	rs1635	0.655	rs16893917	ENSG00000216901.1	AL022393.7	3.83	0.000146	0.0108	0.39	0.17	Schizophrenia;	chr6:28301630	chr6:28176188~28176674:+
THCA	cis	rs2360027	0.965	rs4106949	ENSG00000231365.4	RP11-418J17.1	-3.83	0.000146	0.0108	-0.17	-0.17	Tonsillectomy;	chr1:118597180	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.831	rs1911178	ENSG00000231365.4	RP11-418J17.1	-3.83	0.000146	0.0108	-0.17	-0.17	Tonsillectomy;	chr1:118597439	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.929	rs10923626	ENSG00000231365.4	RP11-418J17.1	-3.83	0.000146	0.0108	-0.17	-0.17	Tonsillectomy;	chr1:118598579	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.929	rs10923627	ENSG00000231365.4	RP11-418J17.1	-3.83	0.000146	0.0108	-0.17	-0.17	Tonsillectomy;	chr1:118598712	chr1:119140396~119275973:+
THCA	cis	rs7264396	0.57	rs1970576	ENSG00000088340.14	FER1L4	3.83	0.000146	0.0108	0.17	0.17	Total cholesterol levels;	chr20:35748798	chr20:35558737~35607562:-
THCA	cis	rs2058059	0.551	rs1954708	ENSG00000205578.5	POM121B	-3.83	0.000146	0.0108	-0.28	-0.17	Subcutaneous adipose tissue;	chr7:72621134	chr7:73293497~73301161:+
THCA	cis	rs11088226	0.645	rs2833917	ENSG00000186842.4	LINC00846	-3.83	0.000146	0.0108	-0.27	-0.17	Gastritis;	chr21:32585234	chr21:32572238~32575881:-
THCA	cis	rs17221829	0.644	rs7943100	ENSG00000280385.1	AP000648.5	-3.83	0.000146	0.0108	-0.18	-0.17	Anxiety in major depressive disorder;	chr11:89648869	chr11:90193614~90198120:+
THCA	cis	rs11881751	0.868	rs33938520	ENSG00000267011.4	CTB-50L17.16	-3.83	0.000146	0.0108	-0.25	-0.17	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr19:4984577	chr19:4457962~4471493:-
THCA	cis	rs911555	0.519	rs8014069	ENSG00000244691.1	RPL10AP1	-3.83	0.000146	0.0108	-0.25	-0.17	Intelligence (multi-trait analysis);	chr14:103537974	chr14:103412119~103412761:-
THCA	cis	rs2236231	0.55	rs4902496	ENSG00000259502.1	RP11-643G16.3	-3.83	0.000146	0.0108	-0.21	-0.17	Plasma kynurenine levels in major depressive disorder;	chr14:67588896	chr14:67610986~67613864:+
THCA	cis	rs1865760	0.551	rs9461230	ENSG00000272810.1	U91328.22	-3.83	0.000146	0.0108	-0.14	-0.17	Height;	chr6:26019012	chr6:26013241~26013757:+
THCA	cis	rs2303282	0.664	rs2617846	ENSG00000274031.1	RP11-413H22.3	-3.83	0.000146	0.0108	-0.2	-0.17	Breast cancer;	chr16:56363241	chr16:56465642~56466162:-
THCA	cis	rs2303282	0.664	rs899242	ENSG00000274031.1	RP11-413H22.3	-3.83	0.000146	0.0108	-0.2	-0.17	Breast cancer;	chr16:56364673	chr16:56465642~56466162:-
THCA	cis	rs10875746	0.669	rs2279464	ENSG00000258273.1	RP11-370I10.4	3.83	0.000146	0.0108	0.25	0.17	Longevity (90 years and older);	chr12:48296626	chr12:48333755~48333901:-
THCA	cis	rs758324	0.588	rs253947	ENSG00000237714.1	P4HA2-AS1	3.83	0.000146	0.0108	0.24	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131994822	chr5:132184876~132192808:+
THCA	cis	rs13256369	0.802	rs34762800	ENSG00000254153.1	CTA-398F10.2	-3.83	0.000146	0.0108	-0.2	-0.17	Obesity-related traits;	chr8:8701784	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.777	rs6989926	ENSG00000233609.3	RP11-62H7.2	-3.83	0.000146	0.0108	-0.17	-0.17	Mood instability;	chr8:8689803	chr8:8961200~8979025:+
THCA	cis	rs2455826	0.5	rs2455852	ENSG00000270409.1	RP11-44D5.1	-3.83	0.000146	0.0108	-0.19	-0.17	Inflammatory skin disease;	chr3:15647181	chr3:15732252~15733470:+
THCA	cis	rs12681288	0.578	rs73176535	ENSG00000260721.1	AF067845.1	3.83	0.000146	0.0108	0.21	0.17	Schizophrenia;	chr8:1021916	chr8:1368642~1369833:-
THCA	cis	rs910316	0.967	rs11159116	ENSG00000259138.1	RP11-950C14.7	3.83	0.000146	0.0108	0.15	0.17	Height;	chr14:75083881	chr14:75127153~75136930:+
THCA	cis	rs7637701	0.713	rs9818780	ENSG00000243926.1	TIPARP-AS1	3.83	0.000146	0.0108	0.18	0.17	Breast cancer;	chr3:156774969	chr3:156671862~156674378:-
THCA	cis	rs7637701	0.713	rs9878566	ENSG00000243926.1	TIPARP-AS1	3.83	0.000146	0.0108	0.18	0.17	Breast cancer;	chr3:156775424	chr3:156671862~156674378:-
THCA	cis	rs9309473	1	rs6546838	ENSG00000273245.1	RP11-434P11.2	3.83	0.000146	0.0108	0.23	0.17	Metabolite levels;	chr2:73452153	chr2:73750256~73750786:-
THCA	cis	rs4965006	0.915	rs4965004	ENSG00000273568.1	RP11-417L19.6	-3.83	0.000146	0.0108	-0.28	-0.17	Posterior cortical atrophy and Alzheimer's disease;	chr12:131940155	chr12:131934642~131934928:+
THCA	cis	rs6600671	0.693	rs1853731	ENSG00000226067.5	CH17-118O6.2	3.83	0.000146	0.0108	0.18	0.17	Hip geometry;	chr1:121510262	chr1:120913275~121009291:+
THCA	cis	rs9467773	0.649	rs2145318	ENSG00000228223.2	HCG11	-3.83	0.000146	0.0108	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26496375	chr6:26523450~26526579:+
THCA	cis	rs2051773	0.567	rs7934608	ENSG00000184669.7	OR7E14P	-3.83	0.000146	0.0108	-0.24	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17017370	chr11:17013998~17053024:+
THCA	cis	rs4906332	1	rs4900574	ENSG00000259775.1	RP11-45P15.4	3.83	0.000146	0.0109	0.15	0.17	Coronary artery disease;	chr14:103412687	chr14:103331674~103332367:-
THCA	cis	rs7312933	0.607	rs7965392	ENSG00000257225.1	RP11-328C8.4	-3.83	0.000146	0.0109	-0.18	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42146478	chr12:42459366~42466128:+
THCA	cis	rs9402682	0.592	rs9385717	ENSG00000232876.1	CTA-212D2.2	-3.83	0.000146	0.0109	-0.24	-0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135137285	chr6:135055033~135060550:+
THCA	cis	rs10043228	1	rs78465528	ENSG00000248445.4	SEMA6A-AS1	-3.83	0.000146	0.0109	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116138709	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs62385219	ENSG00000248445.4	SEMA6A-AS1	-3.83	0.000146	0.0109	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116162791	chr5:116447547~116508276:+
THCA	cis	rs14027	0.921	rs2136374	ENSG00000279347.1	RP11-85I17.2	-3.83	0.000146	0.0109	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119838736~119840385:-
THCA	cis	rs14027	0.881	rs4871578	ENSG00000279347.1	RP11-85I17.2	-3.83	0.000146	0.0109	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs10110601	ENSG00000279347.1	RP11-85I17.2	-3.83	0.000146	0.0109	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119838736~119840385:-
THCA	cis	rs74233809	1	rs77860422	ENSG00000272912.1	RP11-724N1.1	-3.83	0.000146	0.0109	-0.31	-0.17	Birth weight;	chr10:102988252	chr10:102914585~102915404:+
THCA	cis	rs7959452	0.535	rs10784771	ENSG00000274979.1	RP11-1143G9.5	-3.83	0.000146	0.0109	-0.19	-0.17	Blood protein levels;	chr12:69227484	chr12:69326574~69331882:-
THCA	cis	rs853679	0.607	rs35001169	ENSG00000220721.1	OR1F12	3.83	0.000146	0.0109	0.39	0.17	Depression;	chr6:28219854	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs35656932	ENSG00000220721.1	OR1F12	3.83	0.000146	0.0109	0.39	0.17	Depression;	chr6:28223510	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13208096	ENSG00000220721.1	OR1F12	3.83	0.000146	0.0109	0.39	0.17	Depression;	chr6:28257533	chr6:28073316~28074233:+
THCA	cis	rs17772222	0.682	rs2297129	ENSG00000222990.1	RNU4-22P	3.83	0.000146	0.0109	0.21	0.17	Coronary artery calcification;	chr14:88469581	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.682	rs61542857	ENSG00000222990.1	RNU4-22P	3.83	0.000146	0.0109	0.21	0.17	Coronary artery calcification;	chr14:88470358	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.682	rs3783889	ENSG00000222990.1	RNU4-22P	3.83	0.000146	0.0109	0.21	0.17	Coronary artery calcification;	chr14:88475637	chr14:88513498~88513663:+
THCA	cis	rs758324	0.704	rs587759	ENSG00000224431.1	AC063976.7	-3.83	0.000147	0.0109	-0.17	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132056787	chr5:132199456~132203487:+
THCA	cis	rs801193	1	rs2659915	ENSG00000230295.1	RP11-458F8.2	-3.83	0.000147	0.0109	-0.13	-0.17	Aortic root size;	chr7:66688114	chr7:66880708~66882981:+
THCA	cis	rs9980	0.803	rs56259873	ENSG00000226232.7	RP11-419C5.2	-3.83	0.000147	0.0109	-0.27	-0.17	Blood osmolality (transformed sodium);	chr16:69755293	chr16:69976388~69996188:-
THCA	cis	rs2688608	0.592	rs7080579	ENSG00000272140.2	RP11-574K11.29	3.83	0.000147	0.0109	0.15	0.17	Inflammatory bowel disease;	chr10:73744271	chr10:73703735~73713581:-
THCA	cis	rs7208859	0.673	rs1347360	ENSG00000280069.1	CTD-2349P21.3	-3.83	0.000147	0.0109	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30738182~30740275:+
THCA	cis	rs67340775	0.541	rs169287	ENSG00000220721.1	OR1F12	3.83	0.000147	0.0109	0.27	0.17	Lung cancer in ever smokers;	chr6:27886982	chr6:28073316~28074233:+
THCA	cis	rs2688608	0.592	rs10762559	ENSG00000272140.2	RP11-574K11.29	3.83	0.000147	0.0109	0.15	0.17	Inflammatory bowel disease;	chr10:73726695	chr10:73703735~73713581:-
THCA	cis	rs6570726	0.818	rs398812	ENSG00000270638.1	RP3-466P17.1	3.83	0.000147	0.0109	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145735570~145737218:+
THCA	cis	rs10871290	0.65	rs12600126	ENSG00000207525.1	Y_RNA	3.83	0.000147	0.0109	0.21	0.17	Breast cancer;	chr16:74455834	chr16:74463888~74463988:-
THCA	cis	rs964611	0.882	rs6493317	ENSG00000259488.2	RP11-154J22.1	-3.83	0.000147	0.0109	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48275959	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs6493318	ENSG00000259488.2	RP11-154J22.1	-3.83	0.000147	0.0109	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48276062	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs6493319	ENSG00000259488.2	RP11-154J22.1	-3.83	0.000147	0.0109	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48276071	chr15:48312353~48331856:-
THCA	cis	rs340849	0.703	rs17762192	ENSG00000274895.1	RP11-478J18.2	-3.83	0.000147	0.0109	-0.15	-0.17	Alzheimer's disease;	chr1:213951784	chr1:213983793~213986419:-
THCA	cis	rs10954779	0.764	rs2737338	ENSG00000127589.4	TUBBP1	3.83	0.000147	0.0109	0.21	0.17	Intelligence (multi-trait analysis);	chr8:31155614	chr8:30351873~30353518:+
THCA	cis	rs10954779	0.764	rs2737341	ENSG00000127589.4	TUBBP1	3.83	0.000147	0.0109	0.21	0.17	Intelligence (multi-trait analysis);	chr8:31156409	chr8:30351873~30353518:+
THCA	cis	rs11992162	0.967	rs7836456	ENSG00000270154.1	RP11-419I17.1	3.83	0.000147	0.0109	0.22	0.17	Monocyte count;	chr8:11971666	chr8:12476462~12477122:+
THCA	cis	rs7246760	0.737	rs57296518	ENSG00000267106.4	ZNF561-AS1	3.83	0.000147	0.0109	0.3	0.17	Pursuit maintenance gain;	chr19:9709274	chr19:9621291~9645896:+
THCA	cis	rs10927875	0.562	rs10803401	ENSG00000179743.3	FLJ37453	-3.83	0.000147	0.0109	-0.13	-0.17	Dilated cardiomyopathy;	chr1:15820882	chr1:15834479~15848147:-
THCA	cis	rs10927875	0.632	rs6677321	ENSG00000179743.3	FLJ37453	-3.83	0.000147	0.0109	-0.13	-0.17	Dilated cardiomyopathy;	chr1:15822806	chr1:15834479~15848147:-
THCA	cis	rs3105593	0.901	rs3098200	ENSG00000242737.1	RP11-562A8.1	3.83	0.000147	0.0109	0.22	0.17	QT interval;	chr15:50529748	chr15:50466738~50467096:+
THCA	cis	rs4245128	0.93	rs10789925	ENSG00000247416.2	RP11-629G13.1	3.83	0.000147	0.0109	0.17	0.17	Life satisfaction;	chr11:112915970	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.965	rs7114179	ENSG00000247416.2	RP11-629G13.1	3.83	0.000147	0.0109	0.17	0.17	Life satisfaction;	chr11:112918207	chr11:112959279~112963460:-
THCA	cis	rs708224	0.513	rs813785	ENSG00000277342.1	RP11-843B15.4	3.83	0.000147	0.0109	0.23	0.17	Pancreatic cancer;	chr12:32283852	chr12:32109076~32109602:+
THCA	cis	rs643506	0.874	rs618031	ENSG00000230911.1	PPIHP1	-3.83	0.000147	0.0109	-0.23	-0.17	Breast cancer;	chr11:111778139	chr11:112029858~112030367:-
THCA	cis	rs910316	1	rs3742780	ENSG00000259138.1	RP11-950C14.7	3.83	0.000147	0.0109	0.15	0.17	Height;	chr14:75038305	chr14:75127153~75136930:+
THCA	cis	rs854765	0.583	rs8070128	ENSG00000281749.1	Y_RNA	-3.83	0.000147	0.0109	-0.22	-0.17	Total body bone mineral density;	chr17:17901411	chr17:18001101~18001195:-
THCA	cis	rs2455799	0.574	rs2455798	ENSG00000270409.1	RP11-44D5.1	-3.83	0.000147	0.0109	-0.18	-0.17	Mean platelet volume;	chr3:15658998	chr3:15732252~15733470:+
THCA	cis	rs4746818	1	rs7909631	ENSG00000229001.1	ACTBP14	-3.83	0.000147	0.0109	-0.28	-0.17	Left atrial antero-posterior diameter;	chr10:69158920	chr10:69022778~69023866:+
THCA	cis	rs6477918	0.598	rs7019216	ENSG00000230185.4	C9orf147	3.83	0.000147	0.0109	0.18	0.17	Obstetric antiphospholipid syndrome;	chr9:112399568	chr9:112433816~112487204:-
THCA	cis	rs9532669	0.963	rs9562238	ENSG00000229473.2	RGS17P1	3.83	0.000147	0.0109	0.22	0.17	Cervical cancer;	chr13:40924785	chr13:40992779~40993331:-
THCA	cis	rs2115630	0.653	rs61394864	ENSG00000259295.5	CSPG4P12	-3.83	0.000147	0.0109	-0.23	-0.17	P wave terminal force;	chr15:84626943	chr15:85191438~85213905:+
THCA	cis	rs5769765	0.955	rs61136468	ENSG00000260613.1	RP3-522J7.6	-3.83	0.000147	0.0109	-0.22	-0.17	Schizophrenia;	chr22:49919031	chr22:49832616~49837786:-
THCA	cis	rs12681366	0.881	rs16916760	ENSG00000261437.1	RP11-22C11.2	3.83	0.000147	0.0109	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94356881	chr8:94637285~94639467:-
THCA	cis	rs1923243	0.749	rs11210111	ENSG00000223479.3	RP4-788P17.1	-3.83	0.000147	0.0109	-0.19	-0.17	Migraine;	chr1:73050889	chr1:73635216~73715214:+
THCA	cis	rs9368481	0.569	rs10946868	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000147	0.0109	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26527063~26527404:+
THCA	cis	rs4073582	0.576	rs556595	ENSG00000245156.1	RP11-867G23.3	3.83	0.000147	0.0109	0.15	0.17	Gout;	chr11:66290611	chr11:66269832~66278525:-
THCA	cis	rs7919656	0.662	rs2928404	ENSG00000228403.1	RP11-563N6.6	-3.83	0.000147	0.0109	-0.18	-0.17	Clinically amyopathic dermatomyositis;	chr10:48870956	chr10:48878022~48878649:+
THCA	cis	rs964611	0.882	rs4257154	ENSG00000259488.2	RP11-154J22.1	3.83	0.000147	0.0109	0.16	0.17	Metabolite levels (Pyroglutamine);	chr15:48362879	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs12438457	ENSG00000259488.2	RP11-154J22.1	3.83	0.000147	0.0109	0.16	0.17	Metabolite levels (Pyroglutamine);	chr15:48364246	chr15:48312353~48331856:-
THCA	cis	rs12544026	0.516	rs487987	ENSG00000253669.3	KB-1732A1.1	-3.83	0.000147	0.0109	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101890769	chr8:102805517~102809971:+
THCA	cis	rs2236176	0.588	rs62217895	ENSG00000275457.1	RP1-198K11.5	3.83	0.000147	0.0109	0.29	0.17	Body mass index;	chr20:21264640	chr20:21302731~21303704:-
THCA	cis	rs3924048	0.547	rs6678689	ENSG00000272482.1	RP11-474O21.5	-3.83	0.000147	0.0109	-0.16	-0.17	Optic cup area;	chr1:12559874	chr1:12618900~12619244:-
THCA	cis	rs7727544	0.625	rs3091338	ENSG00000263597.1	MIR3936	3.83	0.000147	0.0109	0.17	0.17	Blood metabolite levels;	chr5:132067045	chr5:132365490~132365599:-
THCA	cis	rs478304	0.654	rs11601509	ENSG00000255557.1	RP11-770G2.2	3.83	0.000147	0.0109	0.21	0.17	Acne (severe);	chr11:65689393	chr11:65745729~65771585:+
THCA	cis	rs9410380	1	rs10780207	ENSG00000225385.3	RP11-350E12.4	-3.83	0.000147	0.0109	-0.17	-0.17	Monocyte count;	chr9:88855818	chr9:88066915~88068037:+
THCA	cis	rs12544026	0.521	rs558772	ENSG00000253669.3	KB-1732A1.1	-3.83	0.000147	0.0109	-0.2	-0.17	Major depression and alcohol dependence;	chr8:101880274	chr8:102805517~102809971:+
THCA	cis	rs7824557	0.564	rs13274106	ENSG00000227888.4	FAM66A	-3.83	0.000147	0.0109	-0.22	-0.17	Retinal vascular caliber;	chr8:11376449	chr8:12362019~12388296:+
THCA	cis	rs465969	1	rs9387010	ENSG00000272356.1	RP5-1112D6.8	-3.83	0.000147	0.0109	-0.26	-0.17	Psoriasis;	chr6:111384741	chr6:111309203~111313517:+
THCA	cis	rs7829975	0.742	rs12547493	ENSG00000254340.1	RP11-10A14.3	-3.83	0.000147	0.0109	-0.19	-0.17	Mood instability;	chr8:8804024	chr8:9141424~9145435:+
THCA	cis	rs7520050	0.966	rs785494	ENSG00000281133.1	AL355480.3	3.83	0.000147	0.0109	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45580892~45580996:-
THCA	cis	rs73198271	0.562	rs964772	ENSG00000253893.2	FAM85B	3.83	0.000147	0.0109	0.28	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793796	chr8:8167819~8226614:-
THCA	cis	rs73198271	0.562	rs964773	ENSG00000253893.2	FAM85B	3.83	0.000147	0.0109	0.28	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793804	chr8:8167819~8226614:-
THCA	cis	rs11583043	1	rs7535068	ENSG00000233184.5	RP11-421L21.3	3.83	0.000147	0.0109	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101024773	chr1:101025878~101087268:+
THCA	cis	rs11583043	1	rs12750667	ENSG00000233184.5	RP11-421L21.3	3.83	0.000147	0.0109	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101033126	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.957	rs6577223	ENSG00000233184.5	RP11-421L21.3	3.83	0.000147	0.0109	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101034194	chr1:101025878~101087268:+
THCA	cis	rs447735	0.537	rs7190341	ENSG00000274627.1	RP11-104N10.2	-3.83	0.000147	0.0109	-0.18	-0.17	Hemoglobin concentration;	chr16:89851129	chr16:89516797~89522217:+
THCA	cis	rs2281603	0.951	rs73267743	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64511424	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs73267744	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64511461	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs61985707	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64512846	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs12586212	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64513329	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs61615397	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64514346	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs10133243	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64514807	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs12589947	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64515453	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs3783724	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64516759	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs3783723	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64516821	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs12587136	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64518570	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs58893738	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64519093	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs28626711	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64521561	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs10133411	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64522206	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs17101896	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64526205	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs59512674	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64526295	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs61985711	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64526540	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs10142835	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64526733	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs10143170	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64527045	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs10138256	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64528494	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs10149286	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64528518	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs1453009	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64528976	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs11158544	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64529769	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs12588886	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64530226	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.951	rs1453004	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000147	0.0109	-0.18	-0.17	Lymphocyte counts;	chr14:64530237	chr14:64422935~64448557:-
THCA	cis	rs875971	0.66	rs3764903	ENSG00000230295.1	RP11-458F8.2	3.83	0.000147	0.0109	0.13	0.17	Aortic root size;	chr7:66633495	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000230295.1	RP11-458F8.2	3.83	0.000147	0.0109	0.13	0.17	Aortic root size;	chr7:66638707	chr7:66880708~66882981:+
THCA	cis	rs735539	0.521	rs716480	ENSG00000278291.1	RP11-172H24.4	3.83	0.000147	0.0109	0.23	0.17	Dental caries;	chr13:20843955	chr13:20699307~20703718:-
THCA	cis	rs7980687	0.638	rs7299943	ENSG00000235423.7	RP11-282O18.3	3.83	0.000147	0.0109	0.18	0.17	Head circumference (infant);Educational attainment;Height;	chr12:123108938	chr12:123252030~123261483:-
THCA	cis	rs5758659	0.652	rs133335	ENSG00000205702.9	CYP2D7	-3.83	0.000147	0.0109	-0.13	-0.17	Cognitive function;	chr22:42020052	chr22:42140203~42144577:-
THCA	cis	rs6724465	0.929	rs13410177	ENSG00000272644.1	RP11-33O4.1	3.83	0.000147	0.0109	0.26	0.17	Height;	chr2:219110130	chr2:219069354~219069809:-
THCA	cis	rs1577917	0.74	rs9344533	ENSG00000220563.1	PKMP3	3.83	0.000147	0.0109	0.13	0.17	Response to antipsychotic treatment;	chr6:85526470	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.74	rs7775864	ENSG00000220563.1	PKMP3	3.83	0.000147	0.0109	0.13	0.17	Response to antipsychotic treatment;	chr6:85538041	chr6:85659892~85660606:-
THCA	cis	rs16975963	0.843	rs241935	ENSG00000226686.6	LINC01535	3.83	0.000147	0.0109	0.23	0.17	Longevity;	chr19:37803323	chr19:37251912~37265535:+
THCA	cis	rs2483519	0.511	rs1968122	ENSG00000228169.3	PPIAP19	3.83	0.000147	0.0109	0.2	0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114704223	chr10:114690143~114690634:-
THCA	cis	rs6995541	0.647	rs6987199	ENSG00000248896.2	CTD-2135J3.3	-3.83	0.000147	0.0109	-0.21	-0.17	Triglyceride levels;	chr8:10831151	chr8:10729314~10771392:+
THCA	cis	rs4785204	0.867	rs7188083	ENSG00000279356.1	RP11-429P3.8	-3.83	0.000147	0.0109	-0.33	-0.17	Esophageal cancer (squamous cell);	chr16:50104083	chr16:50072862~50074986:+
THCA	cis	rs17772222	0.63	rs12433739	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000147	0.0109	-0.18	-0.17	Coronary artery calcification;	chr14:88331704	chr14:88551597~88552493:+
THCA	cis	rs854765	0.624	rs12938501	ENSG00000281749.1	Y_RNA	-3.83	0.000147	0.0109	-0.23	-0.17	Total body bone mineral density;	chr17:17833944	chr17:18001101~18001195:-
THCA	cis	rs9959145	0.778	rs2186906	ENSG00000267199.1	RP11-861E21.2	3.83	0.000147	0.0109	0.22	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12572196	chr18:12438890~12448205:+
THCA	cis	rs748404	0.666	rs12906017	ENSG00000166763.7	STRCP1	3.83	0.000147	0.0109	0.23	0.17	Lung cancer;	chr15:43504710	chr15:43699488~43718184:-
THCA	cis	rs7914558	0.966	rs2065977	ENSG00000213061.2	PFN1P11	3.83	0.000147	0.0109	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs12569617	ENSG00000213061.2	PFN1P11	3.83	0.000147	0.0109	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102970239	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.933	rs1538204	ENSG00000213061.2	PFN1P11	3.83	0.000147	0.0109	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102838011~102845473:-
THCA	cis	rs2280018	0.609	rs2941253	ENSG00000207425.1	Y_RNA	3.83	0.000147	0.0109	0.2	0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:14915457~14915556:-
THCA	cis	rs656319	0.513	rs1484641	ENSG00000261451.1	RP11-981G7.1	3.83	0.000147	0.0109	0.22	0.17	Myopia (pathological);	chr8:10129014	chr8:10433672~10438312:+
THCA	cis	rs911555	0.755	rs8018400	ENSG00000269958.1	RP11-73M18.8	-3.83	0.000147	0.0109	-0.16	-0.17	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103696353~103697163:+
THCA	cis	rs76382185	0.808	rs6687105	ENSG00000233184.5	RP11-421L21.3	3.83	0.000147	0.0109	0.25	0.17	Lymphocyte counts;	chr1:101111822	chr1:101025878~101087268:+
THCA	cis	rs76382185	0.808	rs6699619	ENSG00000233184.5	RP11-421L21.3	-3.83	0.000147	0.0109	-0.25	-0.17	Lymphocyte counts;	chr1:101111728	chr1:101025878~101087268:+
THCA	cis	rs7904321	0.932	rs1396967	ENSG00000232075.1	MRPL35P2	-3.83	0.000147	0.0109	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63080060	chr10:63634317~63634827:-
THCA	cis	rs7259376	0.875	rs2116919	ENSG00000269345.1	VN1R85P	3.83	0.000147	0.0109	0.19	0.17	Menopause (age at onset);	chr19:22308904	chr19:22174766~22175191:-
THCA	cis	rs7619708	1	rs7619708	ENSG00000273009.1	RP11-352G9.1	3.83	0.000147	0.0109	0.23	0.17	Red cell distribution width;	chr3:196083316	chr3:195913078~195913683:-
THCA	cis	rs2058059	0.551	rs2960920	ENSG00000205578.5	POM121B	3.83	0.000147	0.0109	0.28	0.17	Subcutaneous adipose tissue;	chr7:72618762	chr7:73293497~73301161:+
THCA	cis	rs6942407	0.592	rs1859125	ENSG00000224046.1	AC005076.5	-3.83	0.000147	0.0109	-0.16	-0.17	Food allergy;	chr7:87122758	chr7:87151423~87152420:-
THCA	cis	rs1476587	0.527	rs1859126	ENSG00000224046.1	AC005076.5	-3.83	0.000147	0.0109	-0.16	-0.17	Brachial circumference;	chr7:87122818	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.592	rs1859128	ENSG00000224046.1	AC005076.5	-3.83	0.000147	0.0109	-0.16	-0.17	Food allergy;	chr7:87122855	chr7:87151423~87152420:-
THCA	cis	rs6762	0.719	rs28655651	ENSG00000255142.1	AP006621.6	3.83	0.000147	0.0109	0.12	0.17	Mean platelet volume;	chr11:837121	chr11:781645~782105:+
THCA	cis	rs6762	0.748	rs1130663	ENSG00000255142.1	AP006621.6	3.83	0.000147	0.0109	0.12	0.17	Mean platelet volume;	chr11:837582	chr11:781645~782105:+
THCA	cis	rs11633886	0.585	rs2460628	ENSG00000273972.1	CTD-2306A12.1	3.83	0.000147	0.0109	0.2	0.17	Diisocyanate-induced asthma;	chr15:45795754	chr15:45702640~45703183:+
THCA	cis	rs12188164	0.762	rs11745923	ENSG00000225138.6	CTD-2228K2.7	3.83	0.000147	0.0109	0.19	0.17	Cystic fibrosis severity;	chr5:475293	chr5:473236~480884:+
THCA	cis	rs2562456	0.874	rs2562408	ENSG00000268278.1	RP11-420K14.1	-3.83	0.000147	0.0109	-0.21	-0.17	Pain;	chr19:21527079	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.874	rs2562417	ENSG00000268278.1	RP11-420K14.1	-3.83	0.000147	0.0109	-0.21	-0.17	Pain;	chr19:21528400	chr19:21637974~21656300:+
THCA	cis	rs10875746	0.768	rs10875724	ENSG00000269514.1	RP11-370I10.12	3.83	0.000147	0.0109	0.17	0.17	Longevity (90 years and older);	chr12:48026470	chr12:48198387~48202031:+
THCA	cis	rs3105593	0.933	rs3131588	ENSG00000242737.1	RP11-562A8.1	3.83	0.000147	0.0109	0.22	0.17	QT interval;	chr15:50549855	chr15:50466738~50467096:+
THCA	cis	rs6142618	0.84	rs2424879	ENSG00000224452.1	RSL24D1P6	-3.83	0.000147	0.0109	-0.21	-0.17	Inflammatory bowel disease;	chr20:32371901	chr20:32170390~32170790:-
THCA	cis	rs7614311	1	rs2637983	ENSG00000271843.1	RP11-245J9.5	-3.83	0.000147	0.0109	-0.25	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:63835956	chr3:64008082~64008692:-
THCA	cis	rs721917	0.525	rs2758545	ENSG00000244733.5	RP11-506M13.3	-3.83	0.000147	0.0109	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79660891~79677996:+
THCA	cis	rs1865760	0.602	rs2157050	ENSG00000272810.1	U91328.22	-3.83	0.000147	0.0109	-0.13	-0.17	Height;	chr6:26020203	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.602	rs9467662	ENSG00000272810.1	U91328.22	-3.83	0.000147	0.0109	-0.13	-0.17	Height;	chr6:26021099	chr6:26013241~26013757:+
THCA	cis	rs11088226	0.645	rs2833904	ENSG00000186842.4	LINC00846	-3.83	0.000147	0.0109	-0.25	-0.17	Gastritis;	chr21:32568779	chr21:32572238~32575881:-
THCA	cis	rs17695224	0.675	rs7252671	ENSG00000275055.1	CTC-471J1.11	-3.83	0.000147	0.0109	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51834830	chr19:52049007~52049754:+
THCA	cis	rs972578	1	rs2284097	ENSG00000274717.1	RP1-47A17.1	-3.83	0.000147	0.0109	-0.18	-0.17	Mean platelet volume;	chr22:43004000	chr22:42791814~42794313:-
THCA	cis	rs7829975	0.617	rs4841071	ENSG00000254340.1	RP11-10A14.3	3.83	0.000147	0.0109	0.19	0.17	Mood instability;	chr8:8933634	chr8:9141424~9145435:+
THCA	cis	rs6494488	0.5	rs16948170	ENSG00000259635.1	AC100830.3	-3.83	0.000147	0.0109	-0.4	-0.17	Coronary artery disease;	chr15:64675455	chr15:64701248~64719602:+
THCA	cis	rs34779708	0.733	rs3853672	ENSG00000233200.1	RP11-324I22.2	3.83	0.000147	0.0109	0.21	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35219894~35230598:-
THCA	cis	rs11671005	0.779	rs731259	ENSG00000269600.1	AC016629.3	-3.83	0.000148	0.0109	-0.26	-0.17	Mean platelet volume;	chr19:58478057	chr19:58593896~58599355:-
THCA	cis	rs6724465	1	rs1052483	ENSG00000272644.1	RP11-33O4.1	-3.83	0.000148	0.0109	-0.25	-0.17	Height;	chr2:219069626	chr2:219069354~219069809:-
THCA	cis	rs6940638	0.688	rs9393791	ENSG00000220721.1	OR1F12	3.83	0.000148	0.0109	0.21	0.17	Intelligence (multi-trait analysis);	chr6:27164750	chr6:28073316~28074233:+
THCA	cis	rs2239547	0.657	rs12496077	ENSG00000243224.1	RP5-1157M23.2	-3.83	0.000148	0.0109	-0.2	-0.17	Schizophrenia;	chr3:52852225	chr3:52239258~52241097:+
THCA	cis	rs2692947	0.673	rs2229169	ENSG00000235584.2	AC008268.1	3.83	0.000148	0.0109	0.18	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96114968	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.673	rs2692894	ENSG00000235584.2	AC008268.1	3.83	0.000148	0.0109	0.18	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96119195	chr2:95666084~95668715:+
THCA	cis	rs1371614	0.501	rs6745807	ENSG00000229122.1	AGBL5-IT1	3.83	0.000148	0.0109	0.13	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26962449	chr2:27061038~27061815:+
THCA	cis	rs8113308	0.515	rs113082012	ENSG00000269483.1	AC006272.1	3.83	0.000148	0.0109	0.37	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960980	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.515	rs73066986	ENSG00000269483.1	AC006272.1	3.83	0.000148	0.0109	0.37	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51962805	chr19:51839924~51843324:-
THCA	cis	rs8113308	0.515	rs4986770	ENSG00000269483.1	AC006272.1	3.83	0.000148	0.0109	0.37	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51964781	chr19:51839924~51843324:-
THCA	cis	rs11671005	0.735	rs11671591	ENSG00000269600.1	AC016629.3	3.83	0.000148	0.0109	0.26	0.17	Mean platelet volume;	chr19:58406970	chr19:58593896~58599355:-
THCA	cis	rs7572644	0.766	rs10168171	ENSG00000223522.1	AC093690.1	-3.83	0.000148	0.0109	-0.22	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28009220	chr2:28307691~28310459:-
THCA	cis	rs10761482	0.954	rs10740022	ENSG00000254271.1	RP11-131N11.4	-3.83	0.000148	0.0109	-0.23	-0.17	Schizophrenia;	chr10:60302928	chr10:60734342~60741828:+
THCA	cis	rs7919656	0.662	rs2663069	ENSG00000228403.1	RP11-563N6.6	-3.83	0.000148	0.0109	-0.18	-0.17	Clinically amyopathic dermatomyositis;	chr10:48873077	chr10:48878022~48878649:+
THCA	cis	rs2904524	1	rs58974570	ENSG00000257815.4	RP11-611E13.2	-3.83	0.000148	0.0109	-0.16	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70363568	chr12:69904033~70243360:-
THCA	cis	rs6494488	0.5	rs72741338	ENSG00000259635.1	AC100830.3	-3.83	0.000148	0.0109	-0.43	-0.17	Coronary artery disease;	chr15:64468888	chr15:64701248~64719602:+
THCA	cis	rs10090774	0.965	rs13253989	ENSG00000280303.2	ERICD	-3.83	0.000148	0.0109	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140922363	chr8:140636281~140638283:+
THCA	cis	rs5769765	0.728	rs6520064	ENSG00000260613.1	RP3-522J7.6	-3.83	0.000148	0.0109	-0.21	-0.17	Schizophrenia;	chr22:49900821	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.773	rs6520065	ENSG00000260613.1	RP3-522J7.6	-3.83	0.000148	0.0109	-0.21	-0.17	Schizophrenia;	chr22:49900822	chr22:49832616~49837786:-
THCA	cis	rs4819052	1	rs9306123	ENSG00000184274.3	LINC00315	-3.83	0.000148	0.0109	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45300245~45305257:-
THCA	cis	rs3925158	0.51	rs4955397	ENSG00000229589.1	ACVR2B-AS1	-3.83	0.000148	0.0109	-0.35	-0.17	Gut microbiota (bacterial taxa);	chr3:38260646	chr3:38451027~38454820:-
THCA	cis	rs853679	0.527	rs853693	ENSG00000176933.5	TOB2P1	-3.83	0.000148	0.0109	-0.2	-0.17	Depression;	chr6:28314871	chr6:28217643~28218634:-
THCA	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	3.83	0.000148	0.0109	0.24	0.17	Depression;	chr6:28428413	chr6:28943877~28944537:+
THCA	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	3.83	0.000148	0.0109	0.24	0.17	Depression;	chr6:28430971	chr6:28943877~28944537:+
THCA	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	3.83	0.000148	0.0109	0.24	0.17	Depression;	chr6:28431469	chr6:28943877~28944537:+
THCA	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	3.83	0.000148	0.0109	0.24	0.17	Depression;	chr6:28432562	chr6:28943877~28944537:+
THCA	cis	rs7914558	1	rs7067970	ENSG00000213061.2	PFN1P11	3.83	0.000148	0.0109	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:102838011~102845473:-
THCA	cis	rs9393777	0.841	rs13191474	ENSG00000226314.6	ZNF192P1	-3.83	0.000148	0.0109	-0.34	-0.17	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28161781~28169594:+
THCA	cis	rs9393777	0.92	rs41269265	ENSG00000226314.6	ZNF192P1	-3.83	0.000148	0.0109	-0.34	-0.17	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28161781~28169594:+
THCA	cis	rs7178909	0.872	rs3867167	ENSG00000259677.1	RP11-493E3.1	3.83	0.000148	0.0109	0.21	0.17	Common traits (Other);	chr15:89890558	chr15:89876540~89877285:+
THCA	cis	rs722864	0.503	rs11677913	ENSG00000238133.5	MLK7-AS1	3.83	0.000148	0.0109	0.23	0.17	Lung cancer;	chr2:173216806	chr2:173166446~173282036:-
THCA	cis	rs7403037	1	rs8024039	ENSG00000260760.1	PWRN3	3.83	0.000148	0.0109	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24581198	chr15:24441127~24447967:+
THCA	cis	rs7264396	0.79	rs3787168	ENSG00000088340.14	FER1L4	3.83	0.000148	0.0109	0.17	0.17	Total cholesterol levels;	chr20:35645356	chr20:35558737~35607562:-
THCA	cis	rs78153629	1	rs11541642	ENSG00000259330.1	INAFM2	-3.83	0.000148	0.0109	-0.24	-0.17	Heschl's gyrus morphology;	chr15:40391501	chr15:40325216~40326715:+
THCA	cis	rs970548	1	rs11239545	ENSG00000230869.1	CTGLF10P	-3.83	0.000148	0.0109	-0.21	-0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45516797	chr10:45678692~45700532:+
THCA	cis	rs3806843	0.576	rs246066	ENSG00000202515.1	VTRNA1-3	-3.83	0.000148	0.0109	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140943562	chr5:140726158~140726246:+
THCA	cis	rs3767627	1	rs12026500	ENSG00000203819.6	HIST2H2BC	3.83	0.000148	0.0109	0.25	0.17	Height;	chr1:149973630	chr1:149850193~149850772:-
THCA	cis	rs3767627	0.929	rs11205310	ENSG00000203819.6	HIST2H2BC	3.83	0.000148	0.0109	0.25	0.17	Height;	chr1:149993226	chr1:149850193~149850772:-
THCA	cis	rs721917	0.586	rs2758550	ENSG00000244733.5	RP11-506M13.3	-3.83	0.000148	0.0109	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79660891~79677996:+
THCA	cis	rs5758511	0.68	rs1107554	ENSG00000227370.1	RP4-669P10.19	3.83	0.000148	0.0109	0.19	0.17	Birth weight;	chr22:42271588	chr22:42132543~42132998:+
THCA	cis	rs2214442	0.605	rs34134267	ENSG00000271133.4	CTA-293F17.1	3.83	0.000148	0.0109	0.18	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20377411	chr7:20328299~20331747:-
THCA	cis	rs8130944	1	rs2269152	ENSG00000225731.1	AP001627.1	3.83	0.000148	0.0109	0.21	0.17	Perceived unattractiveness to mosquitoes;	chr21:42724534	chr21:42733594~42741758:-
THCA	cis	rs944289	0.615	rs1333312	ENSG00000257520.1	RP11-896J10.3	3.83	0.000148	0.0109	0.18	0.17	Thyroid cancer;	chr14:36093396	chr14:36473207~36519521:-
THCA	cis	rs5758659	0.716	rs86669	ENSG00000227370.1	RP4-669P10.19	-3.83	0.000148	0.0109	-0.15	-0.17	Cognitive function;	chr22:42284794	chr22:42132543~42132998:+
THCA	cis	rs9905704	0.846	rs304262	ENSG00000224738.1	AC099850.1	3.83	0.000148	0.0109	0.22	0.17	Testicular germ cell tumor;	chr17:58737095	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.846	rs304298	ENSG00000224738.1	AC099850.1	3.83	0.000148	0.0109	0.22	0.17	Testicular germ cell tumor;	chr17:58762328	chr17:59106598~59118267:+
THCA	cis	rs12681366	0.683	rs2046665	ENSG00000261437.1	RP11-22C11.2	-3.83	0.000148	0.0109	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94375731	chr8:94637285~94639467:-
THCA	cis	rs285757	1	rs366789	ENSG00000259064.2	RP11-386M24.5	-3.83	0.000148	0.0109	-0.27	-0.17	HIV-1 susceptibility;	chr15:92646299	chr15:92627073~92627414:+
THCA	cis	rs2522056	0.808	rs1016988	ENSG00000237714.1	P4HA2-AS1	-3.83	0.000148	0.011	-0.25	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132408882	chr5:132184876~132192808:+
THCA	cis	rs35740288	0.822	rs11630179	ENSG00000259407.1	RP11-158M2.3	-3.83	0.000148	0.011	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85739703	chr15:85744109~85750281:-
THCA	cis	rs9532669	0.926	rs11147824	ENSG00000229473.2	RGS17P1	3.83	0.000148	0.011	0.22	0.17	Cervical cancer;	chr13:40878183	chr13:40992779~40993331:-
THCA	cis	rs75504410	1	rs114706726	ENSG00000231160.8	KLF3-AS1	-3.83	0.000148	0.011	-0.2	-0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38653658	chr4:38612701~38664883:-
THCA	cis	rs793571	0.59	rs673813	ENSG00000245975.2	RP11-30K9.6	3.83	0.000148	0.011	0.16	0.17	Schizophrenia;	chr15:58784972	chr15:58768072~58770974:-
THCA	cis	rs3758141	0.929	rs6997057	ENSG00000278886.1	RP11-108A14.1	-3.83	0.000148	0.011	-0.28	-0.17	Body mass index (change over time) in gastrointestinal cancer;	chr8:18871048	chr8:18864681~18865247:-
THCA	cis	rs6565180	0.632	rs8050812	ENSG00000274653.1	RP11-347C12.11	3.83	0.000148	0.011	0.18	0.17	Tonsillectomy;	chr16:30374516	chr16:30359825~30360336:+
THCA	cis	rs559555	0.512	rs481344	ENSG00000276517.1	AL133243.2	-3.83	0.000148	0.011	-0.17	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31634850	chr2:32526504~32529507:+
THCA	cis	rs1065852	0.526	rs7290907	ENSG00000227370.1	RP4-669P10.19	3.83	0.000148	0.011	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994205	chr22:42132543~42132998:+
THCA	cis	rs1065852	0.526	rs7290655	ENSG00000227370.1	RP4-669P10.19	3.83	0.000148	0.011	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994221	chr22:42132543~42132998:+
THCA	cis	rs2688608	0.592	rs10762560	ENSG00000272140.2	RP11-574K11.29	3.83	0.000148	0.011	0.15	0.17	Inflammatory bowel disease;	chr10:73735647	chr10:73703735~73713581:-
THCA	cis	rs564799	0.966	rs669003	ENSG00000244040.4	IL12A-AS1	-3.83	0.000148	0.011	-0.22	-0.17	Systemic lupus erythematosus;	chr3:160014098	chr3:159913400~160225299:-
THCA	cis	rs10191559	0.663	rs10167839	ENSG00000236153.1	AC104076.3	3.83	0.000148	0.011	0.19	0.17	Red blood cell count;	chr2:181018152	chr2:180979427~180980090:-
THCA	cis	rs4980532	1	rs4980532	ENSG00000256280.1	RP11-466C23.5	-3.83	0.000148	0.011	-0.18	-0.17	Pulse pressure;	chr11:63913247	chr11:63834667~63834943:-
THCA	cis	rs2806561	0.704	rs667330	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000148	0.011	-0.11	-0.17	Height;	chr1:23188764	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs668234	ENSG00000249087.5	ZNF436-AS1	-3.83	0.000148	0.011	-0.11	-0.17	Height;	chr1:23188974	chr1:23368997~23371839:+
THCA	cis	rs6771316	0.504	rs6796822	ENSG00000277855.1	RP11-154H23.4	-3.83	0.000148	0.011	-0.22	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr3:72091558	chr3:71581721~71628558:+
THCA	cis	rs875971	0.545	rs1909508	ENSG00000232559.3	GS1-124K5.12	3.83	0.000148	0.011	0.19	0.17	Aortic root size;	chr7:66301366	chr7:66554588~66576923:-
THCA	cis	rs786425	0.77	rs7138503	ENSG00000278112.1	RP11-972P1.11	3.83	0.000148	0.011	0.17	0.17	Pubertal anthropometrics;	chr12:123699280	chr12:123519390~123519856:-
THCA	cis	rs6498068	0.677	rs2279871	ENSG00000260468.1	LINC01290	3.83	0.000148	0.011	0.24	0.17	Metabolite levels (MHPG);	chr16:10538518	chr16:10514842~10528202:-
THCA	cis	rs3858145	0.5	rs4633337	ENSG00000233590.1	RP11-153K11.3	3.83	0.000148	0.011	0.25	0.17	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285970	chr10:68233251~68242379:-
THCA	cis	rs4950322	0.58	rs17355419	ENSG00000180867.10	PDIA3P1	3.83	0.000148	0.011	0.17	0.17	Protein quantitative trait loci;	chr1:147110094	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.58	rs72706428	ENSG00000180867.10	PDIA3P1	3.83	0.000148	0.011	0.17	0.17	Protein quantitative trait loci;	chr1:147110219	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.563	rs61838944	ENSG00000180867.10	PDIA3P1	3.83	0.000148	0.011	0.17	0.17	Protein quantitative trait loci;	chr1:147110275	chr1:147178113~147179622:+
THCA	cis	rs728616	0.681	rs11815284	ENSG00000242600.5	MBL1P	3.83	0.000148	0.011	0.2	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80263386	chr10:79904898~79950336:+
THCA	cis	rs740750	1	rs2304058	ENSG00000254333.1	CTC-367J11.1	-3.83	0.000148	0.011	-0.21	-0.17	Cerebrospinal fluid biomarker levels;	chr5:150128981	chr5:150475531~150485968:-
THCA	cis	rs9467773	1	rs9467796	ENSG00000228223.2	HCG11	-3.83	0.000148	0.011	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26523450~26526579:+
THCA	cis	rs9467773	1	rs9467797	ENSG00000228223.2	HCG11	-3.83	0.000148	0.011	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26523450~26526579:+
THCA	cis	rs1039766	1	rs72822431	ENSG00000204929.10	AC074391.1	-3.83	0.000148	0.011	-0.28	-0.17	Lung adenocarcinoma;Lung cancer;	chr2:65294682	chr2:65436711~66084639:+
THCA	cis	rs910316	0.763	rs175036	ENSG00000259138.1	RP11-950C14.7	-3.83	0.000148	0.011	-0.15	-0.17	Height;	chr14:74997592	chr14:75127153~75136930:+
THCA	cis	rs910316	0.712	rs175037	ENSG00000259138.1	RP11-950C14.7	-3.83	0.000148	0.011	-0.15	-0.17	Height;	chr14:74998335	chr14:75127153~75136930:+
THCA	cis	rs9990333	0.562	rs56038600	ENSG00000207650.1	MIR570	3.83	0.000148	0.011	0.19	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195699401~195699497:+
THCA	cis	rs71520386	0.846	rs35247857	ENSG00000228649.7	AC005682.5	-3.83	0.000148	0.011	-0.27	-0.17	Fibrinogen levels;	chr7:22780901	chr7:22854178~22861579:+
THCA	cis	rs7777677	0.925	rs4726547	ENSG00000211750.2	TRBV24-1	-3.83	0.000148	0.011	-0.18	-0.17	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142656701~142657213:+
THCA	cis	rs7818688	0.614	rs6989591	ENSG00000253528.2	RP11-347C18.4	-3.83	0.000148	0.011	-0.25	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94862352	chr8:94974573~94974853:-
THCA	cis	rs7647973	0.807	rs4955416	ENSG00000229759.1	MRPS18AP1	3.83	0.000148	0.011	0.26	0.17	Menarche (age at onset);	chr3:49070995	chr3:48256350~48256938:-
THCA	cis	rs642858	0.866	rs4243464	ENSG00000234147.1	RP3-460G2.2	-3.83	0.000148	0.011	-0.22	-0.17	Type 2 diabetes;	chr6:140032527	chr6:140845958~140852924:-
THCA	cis	rs2436845	0.521	rs601588	ENSG00000253320.4	KB-1507C5.2	-3.83	0.000148	0.011	-0.15	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102902518	chr8:102864300~102977876:+
THCA	cis	rs2574985	0.54	rs11005937	ENSG00000279863.1	RP11-521C22.2	3.83	0.000148	0.011	0.2	0.17	Subjective well-being;	chr10:50495587	chr10:50334538~50336123:+
THCA	cis	rs1959947	0.876	rs12891904	ENSG00000251363.2	RP11-129M6.1	-3.83	0.000148	0.011	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41054597	chr14:40954898~40975877:+
THCA	cis	rs9911578	0.933	rs11868348	ENSG00000224738.1	AC099850.1	3.83	0.000148	0.011	0.2	0.17	Intelligence (multi-trait analysis);	chr17:59101877	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.9	rs8067264	ENSG00000224738.1	AC099850.1	3.83	0.000148	0.011	0.2	0.17	Intelligence (multi-trait analysis);	chr17:59105432	chr17:59106598~59118267:+
THCA	cis	rs34792	0.76	rs153808	ENSG00000207425.1	Y_RNA	3.83	0.000148	0.011	0.19	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464485	chr16:14915457~14915556:-
THCA	cis	rs7088591	0.867	rs117555401	ENSG00000276818.1	AC026393.1	3.83	0.000148	0.011	0.37	0.17	Blood pressure;	chr10:58018451	chr10:57095699~57095781:+
THCA	cis	rs17221829	0.673	rs11018700	ENSG00000280385.1	AP000648.5	-3.83	0.000148	0.011	-0.18	-0.17	Anxiety in major depressive disorder;	chr11:89648898	chr11:90193614~90198120:+
THCA	cis	rs7359257	0.576	rs11638507	ENSG00000260657.2	RP11-315D16.4	3.83	0.000148	0.011	0.24	0.17	Menarche (age at onset);	chr15:67581707	chr15:68267792~68277994:-
THCA	cis	rs10411161	0.702	rs11879319	ENSG00000275055.1	CTC-471J1.11	-3.83	0.000148	0.011	-0.17	-0.17	Breast cancer;	chr19:51886339	chr19:52049007~52049754:+
THCA	cis	rs9905704	0.846	rs2567894	ENSG00000224738.1	AC099850.1	3.83	0.000148	0.011	0.22	0.17	Testicular germ cell tumor;	chr17:58716754	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.846	rs28363318	ENSG00000224738.1	AC099850.1	3.83	0.000148	0.011	0.22	0.17	Testicular germ cell tumor;	chr17:58720846	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.846	rs304267	ENSG00000224738.1	AC099850.1	3.83	0.000148	0.011	0.22	0.17	Testicular germ cell tumor;	chr17:58722019	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.846	rs304268	ENSG00000224738.1	AC099850.1	3.83	0.000148	0.011	0.22	0.17	Testicular germ cell tumor;	chr17:58722546	chr17:59106598~59118267:+
THCA	cis	rs4852324	0.541	rs7568898	ENSG00000217702.2	RP11-287D1.4	3.83	0.000148	0.011	0.36	0.17	Systemic lupus erythematosus;	chr2:74044450	chr2:74130583~74135395:+
THCA	cis	rs1800795	0.599	rs1546762	ENSG00000225541.1	AC002480.5	-3.83	0.000148	0.011	-0.19	-0.17	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22717884	chr7:22571607~22661792:-
THCA	cis	rs4722166	0.532	rs1546763	ENSG00000225541.1	AC002480.5	-3.83	0.000148	0.011	-0.19	-0.17	Lung cancer;	chr7:22718224	chr7:22571607~22661792:-
THCA	cis	rs4237845	0.537	rs4237844	ENSG00000270039.1	RP11-571M6.17	3.83	0.000148	0.011	0.2	0.17	Intelligence (multi-trait analysis);	chr12:57874204	chr12:57803838~57804415:+
THCA	cis	rs4245128	0.896	rs11214417	ENSG00000247416.2	RP11-629G13.1	3.82	0.000148	0.011	0.16	0.17	Life satisfaction;	chr11:112912326	chr11:112959279~112963460:-
THCA	cis	rs8062405	0.691	rs11646653	ENSG00000278665.1	RP11-666O2.4	-3.82	0.000148	0.011	-0.2	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28599241~28601881:-
THCA	cis	rs7665090	1	rs1054029	ENSG00000248971.2	KRT8P46	-3.82	0.000148	0.011	-0.2	-0.17	Primary biliary cholangitis;	chr4:102631896	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs3194585	ENSG00000248971.2	KRT8P46	-3.82	0.000148	0.011	-0.2	-0.17	Primary biliary cholangitis;	chr4:102631933	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs735405	ENSG00000248971.2	KRT8P46	-3.82	0.000148	0.011	-0.2	-0.17	Primary biliary cholangitis;	chr4:102632759	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs1077358	ENSG00000248971.2	KRT8P46	-3.82	0.000148	0.011	-0.2	-0.17	Primary biliary cholangitis;	chr4:102632769	chr4:102728746~102730171:-
THCA	cis	rs7216064	1	rs7209675	ENSG00000278740.1	RP11-147L13.14	3.82	0.000148	0.011	0.2	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67835142	chr17:68188547~68189165:+
THCA	cis	rs420259	0.516	rs9927961	ENSG00000260136.4	CTD-2270L9.4	-3.82	0.000148	0.011	-0.13	-0.17	Bipolar disorder;	chr16:23503204	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs2097662	ENSG00000260136.4	CTD-2270L9.4	-3.82	0.000148	0.011	-0.13	-0.17	Bipolar disorder;	chr16:23512024	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs7405145	ENSG00000260136.4	CTD-2270L9.4	-3.82	0.000148	0.011	-0.13	-0.17	Bipolar disorder;	chr16:23526451	chr16:23452758~23457606:+
THCA	cis	rs6724465	1	rs6724465	ENSG00000272644.1	RP11-33O4.1	3.82	0.000148	0.011	0.26	0.17	Height;	chr2:219079124	chr2:219069354~219069809:-
THCA	cis	rs10489167	1	rs12134020	ENSG00000237899.1	RP4-739H11.3	3.82	0.000148	0.011	0.32	0.17	Depressive and manic episodes in bipolar disorder;	chr1:40740803	chr1:40669089~40687588:-
THCA	cis	rs2688608	0.592	rs12253482	ENSG00000272140.2	RP11-574K11.29	3.82	0.000148	0.011	0.15	0.17	Inflammatory bowel disease;	chr10:73736372	chr10:73703735~73713581:-
THCA	cis	rs6828577	0.909	rs298987	ENSG00000281731.1	RP11-384K6.8	-3.82	0.000149	0.011	-0.2	-0.17	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118727489	chr4:118664087~118685341:-
THCA	cis	rs4788570	0.615	rs7190487	ENSG00000260593.1	RP11-432I5.2	-3.82	0.000149	0.011	-0.28	-0.17	Intelligence (multi-trait analysis);	chr16:71614714	chr16:71623708~71626816:-
THCA	cis	rs301800	0.526	rs1325920	ENSG00000230679.1	ENO1-AS1	3.82	0.000149	0.011	0.17	0.17	Educational attainment (years of education);	chr1:8879783	chr1:8878835~8879894:+
THCA	cis	rs3817198	0.927	rs112907808	ENSG00000226416.1	MRPL23-AS1	-3.82	0.000149	0.011	-0.22	-0.17	Breast cancer;Mammographic density (dense area);	chr11:1886380	chr11:1983237~1989920:-
THCA	cis	rs10435719	0.902	rs7459545	ENSG00000255495.1	AC145124.2	3.82	0.000149	0.011	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:12194467~12196280:+
THCA	cis	rs875971	0.825	rs59466412	ENSG00000229886.1	RP5-1132H15.3	-3.82	0.000149	0.011	-0.19	-0.17	Aortic root size;	chr7:66100371	chr7:66025126~66031544:-
THCA	cis	rs7824557	0.583	rs4448232	ENSG00000255495.1	AC145124.2	3.82	0.000149	0.011	0.2	0.17	Retinal vascular caliber;	chr8:11373845	chr8:12194467~12196280:+
THCA	cis	rs7985	0.901	rs736690	ENSG00000244625.4	MIATNB	3.82	0.000149	0.011	0.21	0.17	Electroencephalogram traits;	chr22:26678805	chr22:26672767~26780207:+
THCA	cis	rs2163813	1	rs12973901	ENSG00000271499.1	CTC-559E9.9	-3.82	0.000149	0.011	-0.21	-0.17	Toenail selenium levels;	chr19:19712461	chr19:19750618~19752544:+
THCA	cis	rs160451	0.782	rs218892	ENSG00000251136.7	RP11-37B2.1	3.82	0.000149	0.011	0.16	0.17	Leprosy;	chr8:89685582	chr8:89609409~89757727:-
THCA	cis	rs459571	0.715	rs401826	ENSG00000235106.7	LINC00094	3.82	0.000149	0.011	0.16	0.17	Platelet distribution width;	chr9:134025469	chr9:134025439~134034666:+
THCA	cis	rs17122278	0.613	rs572126	ENSG00000243431.1	RPL5P30	-3.82	0.000149	0.011	-0.15	-0.17	Total cholesterol levels;	chr11:118488446	chr11:118560690~118561580:+
THCA	cis	rs6546886	0.912	rs7592749	ENSG00000235499.1	AC073046.25	3.82	0.000149	0.011	0.16	0.17	Dialysis-related mortality;	chr2:74071905	chr2:73985132~73986343:+
THCA	cis	rs793571	0.523	rs12439457	ENSG00000245975.2	RP11-30K9.6	3.82	0.000149	0.011	0.16	0.17	Schizophrenia;	chr15:58690191	chr15:58768072~58770974:-
THCA	cis	rs34792	0.528	rs153804	ENSG00000255277.3	ABCC6P2	3.82	0.000149	0.011	0.18	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15459197	chr16:14820792~14824702:-
THCA	cis	rs9921222	0.521	rs11649255	ENSG00000268836.1	LA16c-OS12.2	3.82	0.000149	0.011	0.17	0.17	Bone mineral density (spine);Bone mineral density;	chr16:307140	chr16:185748~186294:-
THCA	cis	rs7259376	0.871	rs2360622	ENSG00000269345.1	VN1R85P	3.82	0.000149	0.011	0.19	0.17	Menopause (age at onset);	chr19:22387820	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.837	rs16999542	ENSG00000269345.1	VN1R85P	3.82	0.000149	0.011	0.19	0.17	Menopause (age at onset);	chr19:22390290	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.902	rs10408428	ENSG00000269345.1	VN1R85P	-3.82	0.000149	0.011	-0.19	-0.17	Menopause (age at onset);	chr19:22395221	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.694	rs75653200	ENSG00000269345.1	VN1R85P	-3.82	0.000149	0.011	-0.19	-0.17	Menopause (age at onset);	chr19:22396701	chr19:22174766~22175191:-
THCA	cis	rs7142002	0.568	rs4906163	ENSG00000272444.1	RP11-1017G21.6	-3.82	0.000149	0.011	-0.21	-0.17	Autism;	chr14:101920229	chr14:101952416~101953063:+
THCA	cis	rs7142002	0.568	rs4900520	ENSG00000272444.1	RP11-1017G21.6	-3.82	0.000149	0.011	-0.21	-0.17	Autism;	chr14:101920320	chr14:101952416~101953063:+
THCA	cis	rs7142002	0.568	rs4900521	ENSG00000272444.1	RP11-1017G21.6	-3.82	0.000149	0.011	-0.21	-0.17	Autism;	chr14:101920357	chr14:101952416~101953063:+
THCA	cis	rs35791980	0.627	rs10273411	ENSG00000273341.1	RP5-899E9.1	3.82	0.000149	0.011	0.18	0.17	Pursuit maintenance gain;	chr7:77298694	chr7:77416673~77425443:+
THCA	cis	rs72996113	0.702	rs74788811	ENSG00000248027.1	CTD-2383M3.1	-3.82	0.000149	0.011	-0.31	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100642783	chr11:100684162~100687955:-
THCA	cis	rs79478560	0.518	rs10846572	ENSG00000270061.1	RP11-214K3.19	-3.82	0.000149	0.011	-0.22	-0.17	Lymphocyte counts;	chr12:123898053	chr12:123969990~123970344:-
THCA	cis	rs1005277	0.522	rs289649	ENSG00000275858.1	RP11-291L22.8	3.82	0.000149	0.011	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38450738~38451069:-
THCA	cis	rs2898290	0.617	rs13278965	ENSG00000255310.2	AF131215.2	3.82	0.000149	0.011	0.15	0.17	Systolic blood pressure;	chr8:11609236	chr8:11107788~11109726:-
THCA	cis	rs150992	0.592	rs10038192	ENSG00000246763.5	RGMB-AS1	3.82	0.000149	0.011	0.18	0.17	Body mass index;	chr5:98989755	chr5:98769618~98773469:-
THCA	cis	rs150992	0.571	rs10045959	ENSG00000246763.5	RGMB-AS1	3.82	0.000149	0.011	0.18	0.17	Body mass index;	chr5:98989767	chr5:98769618~98773469:-
THCA	cis	rs150992	0.571	rs10037147	ENSG00000246763.5	RGMB-AS1	3.82	0.000149	0.011	0.18	0.17	Body mass index;	chr5:98989768	chr5:98769618~98773469:-
THCA	cis	rs6968419	0.788	rs7459377	ENSG00000237870.5	AC073130.1	3.82	0.000149	0.011	0.19	0.17	Intraocular pressure;	chr7:116185554	chr7:116275606~116286734:-
THCA	cis	rs9959145	1	rs79692970	ENSG00000267199.1	RP11-861E21.2	3.82	0.000149	0.011	0.23	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12580218	chr18:12438890~12448205:+
THCA	cis	rs7897654	0.571	rs7920697	ENSG00000272912.1	RP11-724N1.1	-3.82	0.000149	0.011	-0.22	-0.17	Schizophrenia;	chr10:102873580	chr10:102914585~102915404:+
THCA	cis	rs2235642	0.821	rs8051895	ENSG00000260989.1	LA16c-395F10.2	-3.82	0.000149	0.011	-0.18	-0.17	Coronary artery disease;	chr16:1552810	chr16:1580527~1610328:+
THCA	cis	rs2235642	0.691	rs2281235	ENSG00000260989.1	LA16c-395F10.2	-3.82	0.000149	0.011	-0.18	-0.17	Coronary artery disease;	chr16:1553534	chr16:1580527~1610328:+
THCA	cis	rs1400745	0.756	rs761924	ENSG00000258738.1	RP11-73E17.2	-3.82	0.000149	0.011	-0.21	-0.17	Monocyte count;	chr14:34864077	chr14:34874343~34876459:+
THCA	cis	rs2721195	0.781	rs10110962	ENSG00000265393.1	CTD-2517M22.17	-3.82	0.000149	0.011	-0.21	-0.17	Age at first birth;	chr8:144554939	chr8:144512567~144513672:+
THCA	cis	rs4808779	0.924	rs10416600	ENSG00000268650.3	AC068499.10	-3.82	0.000149	0.011	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr19:18275253	chr19:18204730~18220480:+
THCA	cis	rs4947019	1	rs4947015	ENSG00000260273.1	RP11-425D10.10	3.82	0.000149	0.011	0.31	0.17	Hematological parameters;	chr6:109731312	chr6:109382795~109383666:+
THCA	cis	rs7572644	0.766	rs13399709	ENSG00000223522.1	AC093690.1	3.82	0.000149	0.011	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27944583	chr2:28307691~28310459:-
THCA	cis	rs6442522	0.533	rs2100544	ENSG00000249786.6	EAF1-AS1	3.82	0.000149	0.011	0.18	0.17	Uric acid levels;	chr3:15480158	chr3:15436171~15455940:-
THCA	cis	rs7551222	0.752	rs10793765	ENSG00000240219.1	RP11-430C7.5	3.82	0.000149	0.011	0.16	0.17	Schizophrenia;	chr1:204580247	chr1:204626775~204629712:+
THCA	cis	rs7614311	0.681	rs6776209	ENSG00000271843.1	RP11-245J9.5	-3.82	0.000149	0.011	-0.29	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:63872957	chr3:64008082~64008692:-
THCA	cis	rs4819052	1	rs28628220	ENSG00000184274.3	LINC00315	-3.82	0.000149	0.011	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45300245~45305257:-
THCA	cis	rs4819052	1	rs2838830	ENSG00000184274.3	LINC00315	-3.82	0.000149	0.011	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45300245~45305257:-
THCA	cis	rs7709377	0.516	rs13362436	ENSG00000271918.1	CTD-2287O16.5	3.82	0.000149	0.011	0.17	0.17	Metabolite levels  (X-11787);	chr5:116207285	chr5:116083807~116085416:-
THCA	cis	rs11018904	0.636	rs61903695	ENSG00000280367.1	RP11-121L10.2	3.82	0.000149	0.011	0.21	0.17	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90223153~90226538:+
THCA	cis	rs8062405	1	rs7498555	ENSG00000270424.1	RP11-1348G14.6	3.82	0.000149	0.011	0.21	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28749959~28750595:-
THCA	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	3.82	0.000149	0.011	0.16	0.17	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
THCA	cis	rs4578769	0.55	rs9949333	ENSG00000273232.1	RP11-370A5.2	3.82	0.000149	0.011	0.24	0.17	Eosinophil percentage of white cells;	chr18:22815080	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs9962620	ENSG00000273232.1	RP11-370A5.2	3.82	0.000149	0.011	0.24	0.17	Eosinophil percentage of white cells;	chr18:22815811	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs4800433	ENSG00000273232.1	RP11-370A5.2	3.82	0.000149	0.011	0.24	0.17	Eosinophil percentage of white cells;	chr18:22816691	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs11082155	ENSG00000273232.1	RP11-370A5.2	3.82	0.000149	0.011	0.24	0.17	Eosinophil percentage of white cells;	chr18:22824527	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs4289091	ENSG00000273232.1	RP11-370A5.2	3.82	0.000149	0.011	0.24	0.17	Eosinophil percentage of white cells;	chr18:22825856	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.589	rs12606787	ENSG00000273232.1	RP11-370A5.2	3.82	0.000149	0.011	0.24	0.17	Eosinophil percentage of white cells;	chr18:22830392	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs12956367	ENSG00000273232.1	RP11-370A5.2	3.82	0.000149	0.011	0.24	0.17	Eosinophil percentage of white cells;	chr18:22833742	chr18:22882825~22883357:-
THCA	cis	rs11190604	1	rs11190569	ENSG00000273030.1	RP11-285F16.1	3.82	0.000149	0.011	0.2	0.17	Palmitoleic acid (16:1n-7) levels;	chr10:100467652	chr10:100412934~100413421:+
THCA	cis	rs8177876	0.915	rs73597252	ENSG00000261838.4	RP11-303E16.6	3.82	0.000149	0.011	0.37	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81069854~81076598:+
THCA	cis	rs7824557	0.843	rs2572418	ENSG00000255495.1	AC145124.2	-3.82	0.000149	0.011	-0.19	-0.17	Retinal vascular caliber;	chr8:11255580	chr8:12194467~12196280:+
THCA	cis	rs911555	0.755	rs7148567	ENSG00000269940.1	RP11-73M18.7	3.82	0.000149	0.011	0.18	0.17	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs10144051	ENSG00000269940.1	RP11-73M18.7	3.82	0.000149	0.011	0.18	0.17	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103694560~103695170:+
THCA	cis	rs214785	1	rs214778	ENSG00000226644.4	RP11-128M1.1	3.82	0.000149	0.011	0.18	0.17	Basal cell carcinoma;	chr20:2299969	chr20:2207217~2213151:+
THCA	cis	rs17604090	0.648	rs823384	ENSG00000225264.3	ZNRF2P2	3.82	0.000149	0.011	0.21	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29617999	chr7:29598795~29685255:-
THCA	cis	rs4883201	0.656	rs10743568	ENSG00000245105.2	A2M-AS1	3.82	0.000149	0.011	0.17	0.17	Total cholesterol levels;Cholesterol, total;	chr12:8958196	chr12:9065177~9068060:+
THCA	cis	rs11708578	0.554	rs13077123	ENSG00000237990.3	CNTN4-AS1	3.82	0.000149	0.011	0.22	0.17	Schizophrenia;	chr3:2391491	chr3:3039033~3069242:-
THCA	cis	rs11708578	0.554	rs13098123	ENSG00000237990.3	CNTN4-AS1	3.82	0.000149	0.011	0.22	0.17	Schizophrenia;	chr3:2391577	chr3:3039033~3069242:-
THCA	cis	rs7927592	0.956	rs6591341	ENSG00000160172.9	FAM86C2P	3.82	0.000149	0.011	0.17	0.17	Total body bone mineral density;	chr11:68568010	chr11:67791648~67805336:-
THCA	cis	rs10129255	0.872	rs1858683	ENSG00000280411.1	IGHV1-69-2	-3.82	0.000149	0.011	-0.11	-0.17	Kawasaki disease;	chr14:106670217	chr14:106762092~106762588:-
THCA	cis	rs494003	1	rs494003	ENSG00000214659.4	KRT8P26	3.82	0.000149	0.011	0.19	0.17	Systemic lupus erythematosus;	chr11:65774827	chr11:65726939~65728214:+
THCA	cis	rs7824557	0.724	rs2572398	ENSG00000261451.1	RP11-981G7.1	3.82	0.000149	0.011	0.22	0.17	Retinal vascular caliber;	chr8:11320584	chr8:10433672~10438312:+
THCA	cis	rs72949976	0.898	rs6732233	ENSG00000270659.1	RP11-105N14.1	3.82	0.000149	0.011	0.14	0.17	Squamous cell lung carcinoma;Lung cancer;	chr2:213158110	chr2:213152970~213153659:+
THCA	cis	rs17213965	0.561	rs9929598	ENSG00000207425.1	Y_RNA	-3.82	0.000149	0.011	-0.22	-0.17	Waist-hip ratio;	chr16:15786153	chr16:14915457~14915556:-
THCA	cis	rs4713118	0.539	rs200988	ENSG00000216915.2	RP1-97D16.1	-3.82	0.000149	0.011	-0.25	-0.17	Parkinson's disease;	chr6:27851575	chr6:27737000~27738494:-
THCA	cis	rs200986	1	rs200986	ENSG00000216915.2	RP1-97D16.1	-3.82	0.000149	0.011	-0.25	-0.17	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:27737000~27738494:-
THCA	cis	rs3796352	0.527	rs11715498	ENSG00000242142.1	SERBP1P3	-3.82	0.000149	0.011	-0.3	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:52909535	chr3:53064283~53065091:-
THCA	cis	rs11633886	0.528	rs2248207	ENSG00000259200.1	RP11-718O11.1	3.82	0.000149	0.011	0.21	0.17	Diisocyanate-induced asthma;	chr15:45809215	chr15:45705078~45931069:+
THCA	cis	rs1913185	0.837	rs67154251	ENSG00000261051.1	RP11-274H2.5	-3.82	0.000149	0.011	-0.25	-0.17	Obesity-related traits;	chr3:146157193	chr3:146059585~146061679:-
THCA	cis	rs539096	0.692	rs6669157	ENSG00000237950.1	RP11-7O11.3	3.82	0.000149	0.011	0.15	0.17	Intelligence (multi-trait analysis);	chr1:43751205	chr1:43944370~43946551:-
THCA	cis	rs669446	0.533	rs3791042	ENSG00000237950.1	RP11-7O11.3	3.82	0.000149	0.011	0.15	0.17	Amyotrophic lateral sclerosis (age of onset);	chr1:43753604	chr1:43944370~43946551:-
THCA	cis	rs9990333	0.521	rs3862281	ENSG00000207650.1	MIR570	3.82	0.000149	0.011	0.19	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195699401~195699497:+
THCA	cis	rs8023401	0.507	rs714290	ENSG00000259705.1	RP11-227D13.1	3.82	0.000149	0.011	0.21	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48459132	chr15:48645951~48652016:+
THCA	cis	rs6479891	1	rs12411988	ENSG00000272767.1	JMJD1C-AS1	-3.82	0.000149	0.011	-0.25	-0.17	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63465229~63466563:+
THCA	cis	rs7131987	0.834	rs12228468	ENSG00000273680.1	RP11-996F15.6	-3.82	0.000149	0.011	-0.24	-0.17	QT interval;	chr12:29300677	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.903	rs11050153	ENSG00000257599.1	OVCH1-AS1	-3.82	0.000149	0.011	-0.21	-0.17	QT interval;	chr12:29252215	chr12:29389294~29487488:+
THCA	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	3.82	0.000149	0.011	0.16	0.17	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
THCA	cis	rs7259376	0.837	rs1368476	ENSG00000269345.1	VN1R85P	-3.82	0.000149	0.011	-0.19	-0.17	Menopause (age at onset);	chr19:22403390	chr19:22174766~22175191:-
THCA	cis	rs10858047	1	rs10858047	ENSG00000231128.4	RP5-1073O3.2	-3.82	0.000149	0.011	-0.24	-0.17	Autism;	chr1:114531255	chr1:113812379~113829171:+
THCA	cis	rs7069191	0.668	rs10994497	ENSG00000254271.1	RP11-131N11.4	3.82	0.000149	0.011	0.27	0.17	Pediatric bone mineral density (spine);	chr10:60754509	chr10:60734342~60741828:+
THCA	cis	rs7829975	0.51	rs332037	ENSG00000253981.4	ALG1L13P	3.82	0.000149	0.011	0.17	0.17	Mood instability;	chr8:8865165	chr8:8236003~8244667:-
THCA	cis	rs9840812	0.683	rs8045	ENSG00000239213.4	NCK1-AS1	-3.82	0.000149	0.011	-0.19	-0.17	Fibrinogen levels;	chr3:136336617	chr3:136841726~136862054:-
THCA	cis	rs10761482	0.813	rs10509130	ENSG00000254271.1	RP11-131N11.4	3.82	0.000149	0.011	0.23	0.17	Schizophrenia;	chr10:60361354	chr10:60734342~60741828:+
THCA	cis	rs4908769	0.775	rs12759741	ENSG00000232912.4	RP5-1115A15.1	3.82	0.000149	0.011	0.18	0.17	Allergy;	chr1:8499600	chr1:8424645~8434838:+
THCA	cis	rs6568686	0.786	rs6911772	ENSG00000255389.1	C6orf3	-3.82	0.000149	0.011	-0.24	-0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111536435	chr6:111599875~111602295:+
THCA	cis	rs9959145	1	rs17595746	ENSG00000267199.1	RP11-861E21.2	3.82	0.000149	0.011	0.23	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12707859	chr18:12438890~12448205:+
THCA	cis	rs26528	0.584	rs153103	ENSG00000270424.1	RP11-1348G14.6	-3.82	0.000149	0.011	-0.2	-0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28749959~28750595:-
THCA	cis	rs208520	0.955	rs12216176	ENSG00000218890.1	NUFIP1P	3.82	0.000149	0.011	0.29	0.17	Exhaled nitric oxide output;	chr6:66295237	chr6:66093431~66094909:-
THCA	cis	rs4660214	0.666	rs588326	ENSG00000228060.1	RP11-69E11.8	-3.82	0.000149	0.011	-0.17	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39443054	chr1:39565160~39573203:+
THCA	cis	rs67478160	0.619	rs8018062	ENSG00000258534.1	CTD-2134A5.4	-3.82	0.000149	0.011	-0.17	-0.17	Schizophrenia;	chr14:103815617	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs2223937	ENSG00000258534.1	CTD-2134A5.4	-3.82	0.000149	0.011	-0.17	-0.17	Schizophrenia;	chr14:103820043	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs4900600	ENSG00000258534.1	CTD-2134A5.4	-3.82	0.000149	0.011	-0.17	-0.17	Schizophrenia;	chr14:103825502	chr14:103854366~103880111:-
THCA	cis	rs950169	0.922	rs11630760	ENSG00000275120.1	RP11-182J1.17	3.82	0.000149	0.011	0.21	0.17	Schizophrenia;	chr15:84570106	chr15:84599434~84606463:-
THCA	cis	rs603446	0.583	rs180377	ENSG00000254851.1	RP11-109L13.1	-3.82	0.000149	0.011	-0.22	-0.17	Triglycerides;	chr11:116718411	chr11:117135528~117138582:+
THCA	cis	rs17286411	0.671	rs8203	ENSG00000260185.1	RP11-432I5.6	-3.82	0.000149	0.011	-0.24	-0.17	Blood protein levels;	chr16:71645029	chr16:71655027~71664212:+
THCA	cis	rs4819052	0.766	rs4819035	ENSG00000273796.1	LL21NC02-21A1.1	-3.82	0.000149	0.011	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45403809~45404369:-
THCA	cis	rs12780845	0.54	rs2273735	ENSG00000234961.1	RP11-124N14.3	-3.82	0.000149	0.011	-0.18	-0.17	Homocysteine levels;	chr10:17174420	chr10:17233325~17234833:-
THCA	cis	rs6494488	0.5	rs56239505	ENSG00000259635.1	AC100830.3	-3.82	0.000149	0.011	-0.45	-0.17	Coronary artery disease;	chr15:64383223	chr15:64701248~64719602:+
THCA	cis	rs1713985	0.508	rs1713951	ENSG00000269949.1	RP11-738E22.3	-3.82	0.000149	0.011	-0.36	-0.17	Age-related macular degeneration;	chr4:56994951	chr4:56960927~56961373:-
THCA	cis	rs2806561	0.765	rs1997866	ENSG00000249087.5	ZNF436-AS1	-3.82	0.000149	0.011	-0.11	-0.17	Height;	chr1:23186031	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs641808	ENSG00000249087.5	ZNF436-AS1	-3.82	0.000149	0.011	-0.11	-0.17	Height;	chr1:23187630	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs652706	ENSG00000249087.5	ZNF436-AS1	-3.82	0.000149	0.011	-0.11	-0.17	Height;	chr1:23187753	chr1:23368997~23371839:+
THCA	cis	rs2806561	0.765	rs652783	ENSG00000249087.5	ZNF436-AS1	-3.82	0.000149	0.011	-0.11	-0.17	Height;	chr1:23187820	chr1:23368997~23371839:+
THCA	cis	rs1908814	0.516	rs11996277	ENSG00000206014.6	OR7E161P	-3.82	0.000149	0.011	-0.21	-0.17	Neuroticism;	chr8:11942522	chr8:11928597~11929563:-
THCA	cis	rs10435719	0.902	rs11250179	ENSG00000206014.6	OR7E161P	-3.82	0.000149	0.011	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:11928597~11929563:-
THCA	cis	rs4792901	0.659	rs8073121	ENSG00000267151.3	RP11-100E5.2	3.82	0.000149	0.0111	0.19	0.17	Dupuytren's disease;	chr17:43465554	chr17:43444707~43451200:+
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000265443.1	CTD-2349P21.6	-3.82	0.000149	0.0111	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000265443.1	CTD-2349P21.6	-3.82	0.000149	0.0111	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30726305~30727564:-
THCA	cis	rs5753618	0.583	rs5753632	ENSG00000214076.3	CPSF1P1	-3.82	0.000149	0.0111	-0.23	-0.17	Colorectal cancer;	chr22:31467111	chr22:32269381~32273110:+
THCA	cis	rs2338	1	rs2745571	ENSG00000272279.1	RP11-157J24.2	-3.82	0.00015	0.0111	-0.23	-0.17	Response to platinum-based agents;	chr6:1568635	chr6:1528364~1528911:-
THCA	cis	rs7142002	0.568	rs60184724	ENSG00000272444.1	RP11-1017G21.6	-3.82	0.00015	0.0111	-0.21	-0.17	Autism;	chr14:101919601	chr14:101952416~101953063:+
THCA	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	3.82	0.00015	0.0111	0.2	0.17	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
THCA	cis	rs12134133	1	rs12134133	ENSG00000237074.1	RP11-6J21.2	3.82	0.00015	0.0111	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207249067~207309121:+
THCA	cis	rs8067354	0.789	rs1292068	ENSG00000266701.1	AC005702.4	3.82	0.00015	0.0111	0.24	0.17	Hemoglobin concentration;	chr17:59851958	chr17:60042546~60042627:-
THCA	cis	rs3740713	0.719	rs78515595	ENSG00000256464.1	YWHABP2	3.82	0.00015	0.0111	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18409830	chr11:18490243~18490955:-
THCA	cis	rs2455799	0.613	rs2345736	ENSG00000270409.1	RP11-44D5.1	-3.82	0.00015	0.0111	-0.19	-0.17	Mean platelet volume;	chr3:15783353	chr3:15732252~15733470:+
THCA	cis	rs1371614	0.523	rs4233714	ENSG00000272148.1	RP11-195B17.1	-3.82	0.00015	0.0111	-0.16	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26958586	chr2:27062428~27062907:-
THCA	cis	rs12493885	0.818	rs61791544	ENSG00000243069.6	ARHGEF26-AS1	-3.82	0.00015	0.0111	-0.29	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154049715	chr3:154024401~154121332:-
THCA	cis	rs7267979	1	rs6107033	ENSG00000276952.1	RP5-965G21.6	-3.82	0.00015	0.0111	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25284915~25285588:-
THCA	cis	rs34779708	0.733	rs3936503	ENSG00000233200.1	RP11-324I22.2	-3.82	0.00015	0.0111	-0.21	-0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35219894~35230598:-
THCA	cis	rs6929812	0.665	rs7754678	ENSG00000271755.1	RP1-153G14.4	3.82	0.00015	0.0111	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27444951	chr6:27404010~27406964:-
THCA	cis	rs854765	0.624	rs9902941	ENSG00000281749.1	Y_RNA	-3.82	0.00015	0.0111	-0.23	-0.17	Total body bone mineral density;	chr17:17830446	chr17:18001101~18001195:-
THCA	cis	rs4726279	0.516	rs11767432	ENSG00000020219.9	CCT8L1P	-3.82	0.00015	0.0111	-0.25	-0.17	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr7:153357617	chr7:152445477~152447150:+
THCA	cis	rs2836974	0.777	rs34038277	ENSG00000255568.3	BRWD1-AS2	3.82	0.00015	0.0111	0.15	0.17	Cognitive function;	chr21:39327921	chr21:39313935~39314962:+
THCA	cis	rs9810089	1	rs1278493	ENSG00000273455.1	RP11-305O4.3	-3.82	0.00015	0.0111	-0.23	-0.17	Gestational age at birth (child effect);	chr3:136095167	chr3:136087475~136087913:-
THCA	cis	rs4794202	0.629	rs7214694	ENSG00000264920.1	RP11-6N17.4	-3.82	0.00015	0.0111	-0.21	-0.17	Alzheimer's disease (cognitive decline);	chr17:47817987	chr17:47891255~47895812:-
THCA	cis	rs6942407	0.592	rs739711	ENSG00000224046.1	AC005076.5	-3.82	0.00015	0.0111	-0.16	-0.17	Food allergy;	chr7:87117425	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.543	rs739712	ENSG00000224046.1	AC005076.5	-3.82	0.00015	0.0111	-0.16	-0.17	Food allergy;	chr7:87117482	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.542	rs744136	ENSG00000224046.1	AC005076.5	-3.82	0.00015	0.0111	-0.16	-0.17	Food allergy;	chr7:87117765	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.542	rs1981535	ENSG00000224046.1	AC005076.5	-3.82	0.00015	0.0111	-0.16	-0.17	Food allergy;	chr7:87118059	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.592	rs1981536	ENSG00000224046.1	AC005076.5	-3.82	0.00015	0.0111	-0.16	-0.17	Food allergy;	chr7:87118573	chr7:87151423~87152420:-
THCA	cis	rs10256972	0.647	rs10233430	ENSG00000225146.1	AC073957.15	3.82	0.00015	0.0111	0.19	0.17	Endometriosis;Longevity;	chr7:1012028	chr7:1029025~1043891:+
THCA	cis	rs440932	1	rs365309	ENSG00000248538.5	RP11-10A14.5	3.82	0.00015	0.0111	0.21	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9189011~9202854:+
THCA	cis	rs7264396	0.79	rs6060539	ENSG00000088340.14	FER1L4	3.82	0.00015	0.0111	0.17	0.17	Total cholesterol levels;	chr20:35651460	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.747	rs6058291	ENSG00000088340.14	FER1L4	3.82	0.00015	0.0111	0.17	0.17	Total cholesterol levels;	chr20:35659847	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs6060541	ENSG00000088340.14	FER1L4	3.82	0.00015	0.0111	0.17	0.17	Total cholesterol levels;	chr20:35660144	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs6058293	ENSG00000088340.14	FER1L4	3.82	0.00015	0.0111	0.17	0.17	Total cholesterol levels;	chr20:35660969	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs6121018	ENSG00000088340.14	FER1L4	3.82	0.00015	0.0111	0.17	0.17	Total cholesterol levels;	chr20:35661138	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs6060542	ENSG00000088340.14	FER1L4	3.82	0.00015	0.0111	0.17	0.17	Total cholesterol levels;	chr20:35661139	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs6121020	ENSG00000088340.14	FER1L4	3.82	0.00015	0.0111	0.17	0.17	Total cholesterol levels;	chr20:35664084	chr20:35558737~35607562:-
THCA	cis	rs7829975	0.714	rs6994038	ENSG00000233609.3	RP11-62H7.2	3.82	0.00015	0.0111	0.17	0.17	Mood instability;	chr8:8803028	chr8:8961200~8979025:+
THCA	cis	rs6860806	0.661	rs6890009	ENSG00000263597.1	MIR3936	3.82	0.00015	0.0111	0.17	0.17	Breast cancer;	chr5:132244340	chr5:132365490~132365599:-
THCA	cis	rs7818688	0.653	rs11786088	ENSG00000253528.2	RP11-347C18.4	-3.82	0.00015	0.0111	-0.26	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94823912	chr8:94974573~94974853:-
THCA	cis	rs140174	0.763	rs131421	ENSG00000278655.1	KB-1572G7.5	3.82	0.00015	0.0111	0.2	0.17	Migraine;	chr22:23579015	chr22:23607041~23608407:+
THCA	cis	rs854765	0.547	rs2955378	ENSG00000281749.1	Y_RNA	3.82	0.00015	0.0111	0.22	0.17	Total body bone mineral density;	chr17:18026939	chr17:18001101~18001195:-
THCA	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-3.82	0.00015	0.0111	-0.18	-0.17	Asthma;	chr2:102393077	chr2:102438713~102440475:+
THCA	cis	rs910316	0.763	rs13712	ENSG00000259138.1	RP11-950C14.7	3.82	0.00015	0.0111	0.15	0.17	Height;	chr14:75017109	chr14:75127153~75136930:+
THCA	cis	rs2299587	0.585	rs2073569	ENSG00000253671.1	RP11-806O11.1	-3.82	0.00015	0.0111	-0.21	-0.17	Economic and political preferences;	chr8:17924649	chr8:17808941~17820868:+
THCA	cis	rs2239557	0.539	rs2302117	ENSG00000259065.1	RP5-1021I20.1	-3.82	0.00015	0.0111	-0.26	-0.17	Common traits (Other);	chr14:73988110	chr14:73787360~73803270:+
THCA	cis	rs2239557	0.539	rs62005063	ENSG00000259065.1	RP5-1021I20.1	-3.82	0.00015	0.0111	-0.26	-0.17	Common traits (Other);	chr14:73989276	chr14:73787360~73803270:+
THCA	cis	rs2281636	0.723	rs11190255	ENSG00000260475.1	RP11-85A1.3	3.82	0.00015	0.0111	0.18	0.17	Obesity-related traits;	chr10:99714742	chr10:99621055~99621918:+
THCA	cis	rs62380364	0.837	rs17487515	ENSG00000247828.6	TMEM161B-AS1	-3.82	0.00015	0.0111	-0.13	-0.17	Intelligence (multi-trait analysis);	chr5:88853474	chr5:88268895~88436685:+
THCA	cis	rs62380364	0.87	rs17559709	ENSG00000247828.6	TMEM161B-AS1	-3.82	0.00015	0.0111	-0.13	-0.17	Intelligence (multi-trait analysis);	chr5:88853509	chr5:88268895~88436685:+
THCA	cis	rs62380364	0.87	rs4145738	ENSG00000247828.6	TMEM161B-AS1	-3.82	0.00015	0.0111	-0.13	-0.17	Intelligence (multi-trait analysis);	chr5:88854472	chr5:88268895~88436685:+
THCA	cis	rs7819412	0.669	rs7823349	ENSG00000255046.1	RP11-297N6.4	3.82	0.00015	0.0111	0.19	0.17	Triglycerides;	chr8:11141120	chr8:11797928~11802568:-
THCA	cis	rs7819412	0.669	rs4840549	ENSG00000255046.1	RP11-297N6.4	3.82	0.00015	0.0111	0.19	0.17	Triglycerides;	chr8:11141445	chr8:11797928~11802568:-
THCA	cis	rs4908768	0.501	rs4908761	ENSG00000270282.1	RP5-1115A15.2	3.82	0.00015	0.0111	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8512653~8513021:+
THCA	cis	rs57709857	0.957	rs7012844	ENSG00000272092.1	RP11-350N15.5	-3.82	0.00015	0.0111	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38389244	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs2016875	ENSG00000272092.1	RP11-350N15.5	-3.82	0.00015	0.0111	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38401517	chr8:38382364~38383461:+
THCA	cis	rs9329221	0.655	rs656319	ENSG00000261451.1	RP11-981G7.1	-3.82	0.00015	0.0111	-0.22	-0.17	Neuroticism;	chr8:9956901	chr8:10433672~10438312:+
THCA	cis	rs763121	0.853	rs8140617	ENSG00000273076.1	RP3-508I15.22	-3.82	0.00015	0.0111	-0.17	-0.17	Menopause (age at onset);	chr22:38574434	chr22:38743495~38743910:+
THCA	cis	rs9309473	0.519	rs12618600	ENSG00000273245.1	RP11-434P11.2	-3.82	0.00015	0.0111	-0.21	-0.17	Metabolite levels;	chr2:73663555	chr2:73750256~73750786:-
THCA	cis	rs6860806	0.507	rs169256	ENSG00000237714.1	P4HA2-AS1	3.82	0.00015	0.0111	0.27	0.17	Breast cancer;	chr5:132352840	chr5:132184876~132192808:+
THCA	cis	rs801193	1	rs7782320	ENSG00000229180.5	GS1-124K5.11	3.82	0.00015	0.0111	0.12	0.17	Aortic root size;	chr7:66712111	chr7:66526088~66542624:-
THCA	cis	rs6696239	0.956	rs12131114	ENSG00000227711.2	RP11-275O4.5	-3.82	0.00015	0.0111	-0.24	-0.17	Height;	chr1:227590926	chr1:227509028~227520477:-
THCA	cis	rs9402682	0.592	rs9385715	ENSG00000232876.1	CTA-212D2.2	-3.82	0.00015	0.0111	-0.24	-0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135133247	chr6:135055033~135060550:+
THCA	cis	rs12472274	1	rs12472274	ENSG00000186235.9	AC016757.3	3.82	0.00015	0.0111	0.24	0.17	Phospholipid levels (plasma);	chr2:238186781	chr2:238224552~238231677:-
THCA	cis	rs13108904	0.87	rs1564508	ENSG00000254094.1	AC078852.1	-3.82	0.00015	0.0111	-0.2	-0.17	Obesity-related traits;	chr4:1251091	chr4:1356581~1358075:+
THCA	cis	rs6723108	0.654	rs669759	ENSG00000224043.6	CCNT2-AS1	-3.82	0.00015	0.0111	-0.2	-0.17	Type 2 diabetes;	chr2:134533564	chr2:134735464~134918710:-
THCA	cis	rs6499188	1	rs6499188	ENSG00000274698.1	RP11-71L14.4	3.82	0.00015	0.0111	0.24	0.17	Ulcerative colitis;	chr16:68640885	chr16:68450283~68452318:+
THCA	cis	rs7162943	0.887	rs11858077	ENSG00000260123.1	RP11-326A19.4	-3.82	0.00015	0.0111	-0.22	-0.17	Mean platelet volume;	chr15:89068326	chr15:89041223~89082819:+
THCA	cis	rs6546550	0.835	rs13002091	ENSG00000179818.12	PCBP1-AS1	-3.82	0.00015	0.0111	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69891256	chr2:69962263~70103220:-
THCA	cis	rs4273100	1	rs16960499	ENSG00000263934.3	SNORD3A	3.82	0.00015	0.0111	0.27	0.17	Schizophrenia;	chr17:19299719	chr17:19188016~19188714:+
THCA	cis	rs72858496	0.59	rs11888238	ENSG00000238057.7	ZEB2-AS1	3.82	0.00015	0.0111	0.33	0.17	Renal cell carcinoma;	chr2:144394668	chr2:144518097~144521477:+
THCA	cis	rs7131987	0.565	rs7300032	ENSG00000257176.2	RP11-996F15.2	3.82	0.00015	0.0111	0.17	0.17	QT interval;	chr12:29256859	chr12:29280418~29317848:-
THCA	cis	rs6903823	0.508	rs1150721	ENSG00000220721.1	OR1F12	3.82	0.00015	0.0111	0.2	0.17	Pulmonary function;	chr6:28287263	chr6:28073316~28074233:+
THCA	cis	rs6903823	0.508	rs1233660	ENSG00000220721.1	OR1F12	3.82	0.00015	0.0111	0.2	0.17	Pulmonary function;	chr6:28292472	chr6:28073316~28074233:+
THCA	cis	rs10844706	0.699	rs2401390	ENSG00000214776.8	RP11-726G1.1	3.82	0.00015	0.0111	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9719218	chr12:9467552~9576275:+
THCA	cis	rs340849	1	rs1008431	ENSG00000274895.1	RP11-478J18.2	3.82	0.00015	0.0111	0.14	0.17	Alzheimer's disease;	chr1:213935953	chr1:213983793~213986419:-
THCA	cis	rs2436845	0.521	rs1714399	ENSG00000253320.4	KB-1507C5.2	-3.82	0.00015	0.0111	-0.15	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102892525	chr8:102864300~102977876:+
THCA	cis	rs9921338	0.509	rs7190050	ENSG00000262636.1	CTD-3088G3.4	-3.82	0.00015	0.0111	-0.23	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348225	chr16:11380859~11381118:-
THCA	cis	rs1385374	0.764	rs61944982	ENSG00000274695.1	RP11-21K12.3	3.82	0.00015	0.0111	0.38	0.17	Systemic lupus erythematosus;	chr12:128840939	chr12:128826836~128827579:+
THCA	cis	rs28735056	0.904	rs11520415	ENSG00000261126.6	RP11-795F19.1	3.82	0.00015	0.0111	0.14	0.17	Schizophrenia;	chr18:79860620	chr18:80046900~80095482:+
THCA	cis	rs4568518	0.74	rs10429191	ENSG00000279048.1	RP11-511H23.2	3.82	0.00015	0.0111	0.11	0.17	Measles;	chr7:17969474	chr7:17940503~17942922:+
THCA	cis	rs9796	0.87	rs4923890	ENSG00000247556.5	OIP5-AS1	-3.82	0.00015	0.0111	-0.14	-0.17	Menopause (age at onset);	chr15:40966792	chr15:41283990~41309737:+
THCA	cis	rs2688608	0.647	rs2461863	ENSG00000271816.1	BMS1P4	3.82	0.00015	0.0111	0.17	0.17	Inflammatory bowel disease;	chr10:73920478	chr10:73699151~73730487:-
THCA	cis	rs150992	0.512	rs161954	ENSG00000246763.5	RGMB-AS1	3.82	0.00015	0.0111	0.18	0.17	Body mass index;	chr5:98920833	chr5:98769618~98773469:-
THCA	cis	rs73173548	0.502	rs71639111	ENSG00000247828.6	TMEM161B-AS1	3.82	0.00015	0.0111	0.16	0.17	Macular telangiectasia type 2;	chr5:88428788	chr5:88268895~88436685:+
THCA	cis	rs4660214	0.666	rs598415	ENSG00000228060.1	RP11-69E11.8	-3.82	0.00015	0.0111	-0.17	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39565160~39573203:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000273024.4	INTS4P2	-3.82	0.00015	0.0111	-0.21	-0.17	Aortic root size;	chr7:66158946	chr7:65647864~65715661:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000273024.4	INTS4P2	-3.82	0.00015	0.0111	-0.21	-0.17	Aortic root size;	chr7:66160135	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000273024.4	INTS4P2	-3.82	0.00015	0.0111	-0.21	-0.17	Aortic root size;	chr7:66161064	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs316324	ENSG00000273024.4	INTS4P2	3.82	0.00015	0.0111	0.21	0.17	Aortic root size;	chr7:66145627	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000273024.4	INTS4P2	3.82	0.00015	0.0111	0.21	0.17	Aortic root size;	chr7:66146002	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000273024.4	INTS4P2	3.82	0.00015	0.0111	0.21	0.17	Aortic root size;	chr7:66152984	chr7:65647864~65715661:+
THCA	cis	rs1371614	0.632	rs6738528	ENSG00000229122.1	AGBL5-IT1	-3.82	0.00015	0.0111	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26926390	chr2:27061038~27061815:+
THCA	cis	rs1113500	0.787	rs12047429	ENSG00000230489.1	VAV3-AS1	-3.82	0.00015	0.0111	-0.16	-0.17	Growth-regulated protein alpha levels;	chr1:108090617	chr1:107964443~107994607:+
THCA	cis	rs1520333	0.54	rs9643737	ENSG00000254352.1	RP11-578O24.2	-3.82	0.00015	0.0111	-0.2	-0.17	Multiple sclerosis;	chr8:78484955	chr8:78723796~78724136:-
THCA	cis	rs34421088	0.56	rs2618434	ENSG00000227888.4	FAM66A	-3.82	0.00015	0.0111	-0.22	-0.17	Neuroticism;	chr8:11541356	chr8:12362019~12388296:+
THCA	cis	rs755249	0.53	rs16826087	ENSG00000182109.6	RP11-69E11.4	3.82	0.00015	0.0111	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39522280~39546187:-
THCA	cis	rs2505675	0.961	rs2450300	ENSG00000250903.7	GMDS-AS1	-3.82	0.00015	0.0111	-0.15	-0.17	Tuberculosis;	chr6:2322220	chr6:2245748~2482022:+
THCA	cis	rs2235642	0.928	rs9932984	ENSG00000260989.1	LA16c-395F10.2	-3.82	0.00015	0.0111	-0.18	-0.17	Coronary artery disease;	chr16:1555050	chr16:1580527~1610328:+
THCA	cis	rs6088590	0.603	rs6579186	ENSG00000276073.1	RP5-1125A11.7	-3.82	0.00015	0.0111	-0.15	-0.17	Coronary artery disease;	chr20:34694394	chr20:33985617~33988989:-
THCA	cis	rs4073582	0.595	rs801739	ENSG00000245156.1	RP11-867G23.3	3.82	0.00015	0.0111	0.14	0.17	Gout;	chr11:66155118	chr11:66269832~66278525:-
THCA	cis	rs2645424	0.671	rs2294138	ENSG00000255046.1	RP11-297N6.4	3.82	0.00015	0.0111	0.19	0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847630	chr8:11797928~11802568:-
THCA	cis	rs4073405	0.503	rs7102123	ENSG00000205106.4	DKFZp779M0652	-3.82	0.00015	0.0111	-0.17	-0.17	Schizophrenia;	chr11:45297636	chr11:45771432~45772358:+
THCA	cis	rs2251188	0.609	rs2253869	ENSG00000187953.9	PMS2CL	-3.82	0.00015	0.0111	-0.18	-0.17	Sum basophil neutrophil counts;Neutrophil count;	chr7:6643823	chr7:6710128~6753862:+
THCA	cis	rs9527	0.571	rs3740400	ENSG00000272912.1	RP11-724N1.1	-3.82	0.00015	0.0111	-0.21	-0.17	Arsenic metabolism;	chr10:102869708	chr10:102914585~102915404:+
THCA	cis	rs9527	0.571	rs7904113	ENSG00000272912.1	RP11-724N1.1	-3.82	0.00015	0.0111	-0.21	-0.17	Arsenic metabolism;	chr10:102873357	chr10:102914585~102915404:+
THCA	cis	rs1144333	0.655	rs7521538	ENSG00000272855.1	RP5-1102E8.3	-3.82	0.00015	0.0111	-0.37	-0.17	Attention function in attention deficit hyperactive disorder;	chr1:75954755	chr1:76636877~76637339:+
THCA	cis	rs12291225	0.679	rs34238445	ENSG00000251991.1	RNU7-49P	3.82	0.00015	0.0111	0.21	0.17	Sense of smell;	chr11:14294369	chr11:14478892~14478953:+
THCA	cis	rs9611565	0.512	rs9607842	ENSG00000237037.8	NDUFA6-AS1	3.82	0.00015	0.0111	0.17	0.17	Vitiligo;	chr22:41796718	chr22:42090931~42137742:+
THCA	cis	rs6121246	0.909	rs6060812	ENSG00000224628.2	RP5-854E16.2	-3.82	0.00015	0.0111	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31705000	chr20:31285317~31286835:-
THCA	cis	rs2275906	0.557	rs6456704	ENSG00000272462.2	U91328.19	3.82	0.00015	0.0111	0.16	0.17	Urate levels in lean individuals;	chr6:25880137	chr6:25992662~26001775:+
THCA	cis	rs907612	0.638	rs907613	ENSG00000226416.1	MRPL23-AS1	3.82	0.00015	0.0111	0.21	0.17	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Monocyte count;	chr11:1853062	chr11:1983237~1989920:-
THCA	cis	rs12188164	0.965	rs56346498	ENSG00000225138.6	CTD-2228K2.7	3.82	0.00015	0.0111	0.18	0.17	Cystic fibrosis severity;	chr5:423480	chr5:473236~480884:+
THCA	cis	rs2336384	0.929	rs56243319	ENSG00000199347.1	RNU5E-1	-3.82	0.00015	0.0111	-0.22	-0.17	Platelet count;	chr1:11988538	chr1:11908152~11908271:+
THCA	cis	rs73173548	0.502	rs6865693	ENSG00000247828.6	TMEM161B-AS1	3.82	0.00015	0.0111	0.15	0.17	Macular telangiectasia type 2;	chr5:88419422	chr5:88268895~88436685:+
THCA	cis	rs12234571	1	rs73374135	ENSG00000214293.7	APTR	3.82	0.00015	0.0111	0.22	0.17	Obesity-related traits;	chr7:77753938	chr7:77657660~77696265:-
THCA	cis	rs11671005	0.779	rs11670125	ENSG00000252334.1	RNU6-1337P	3.82	0.00015	0.0111	0.27	0.17	Mean platelet volume;	chr19:58476023	chr19:58483749~58483843:-
THCA	cis	rs868036	0.609	rs28742003	ENSG00000270964.1	RP11-502I4.3	-3.82	0.00015	0.0111	-0.17	-0.17	Restless legs syndrome;	chr15:67835431	chr15:67541072~67542604:-
THCA	cis	rs10840133	1	rs10840133	ENSG00000254860.4	TMEM9B-AS1	-3.82	0.000151	0.0111	-0.19	-0.17	Reticulocyte fraction of red cells;	chr11:8824822	chr11:8964675~8977527:+
THCA	cis	rs7914558	1	rs11191541	ENSG00000213061.2	PFN1P11	3.82	0.000151	0.0111	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102838011~102845473:-
THCA	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	3.82	0.000151	0.0111	0.21	0.17	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
THCA	cis	rs4915077	0.892	rs17020107	ENSG00000226822.1	RP11-356N1.2	3.82	0.000151	0.0111	0.28	0.17	Hypothyroidism;	chr1:107811226	chr1:108071482~108074519:+
THCA	cis	rs10090774	0.965	rs9324540	ENSG00000280303.2	ERICD	-3.82	0.000151	0.0111	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140980322	chr8:140636281~140638283:+
THCA	cis	rs11971779	0.648	rs59791374	ENSG00000252332.1	RNU6-911P	-3.82	0.000151	0.0111	-0.19	-0.17	Diisocyanate-induced asthma;	chr7:139432216	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.59	rs59602547	ENSG00000252332.1	RNU6-911P	-3.82	0.000151	0.0111	-0.19	-0.17	Diisocyanate-induced asthma;	chr7:139432277	chr7:139448740~139448843:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000275400.1	RP4-756H11.5	-3.82	0.000151	0.0111	-0.16	-0.17	Aortic root size;	chr7:65832759	chr7:66553805~66554199:-
THCA	cis	rs875971	0.522	rs10807697	ENSG00000275400.1	RP4-756H11.5	-3.82	0.000151	0.0111	-0.16	-0.17	Aortic root size;	chr7:65951183	chr7:66553805~66554199:-
THCA	cis	rs11601239	0.668	rs1938961	ENSG00000254750.1	CASP1P2	-3.82	0.000151	0.0111	-0.14	-0.17	Refractive error;	chr11:105742383	chr11:105063345~105071541:-
THCA	cis	rs10089	1	rs10057122	ENSG00000245937.6	LINC01184	3.82	0.000151	0.0111	0.19	0.17	Ileal carcinoids;	chr5:128176371	chr5:127940426~128083172:-
THCA	cis	rs17122278	1	rs73022042	ENSG00000243431.1	RPL5P30	3.82	0.000151	0.0111	0.17	0.17	Total cholesterol levels;	chr11:118538178	chr11:118560690~118561580:+
THCA	cis	rs3892630	0.619	rs61062732	ENSG00000267567.1	CTD-2538C1.3	3.82	0.000151	0.0111	0.25	0.17	Red blood cell traits;	chr19:32813811	chr19:32718298~32719595:-
THCA	cis	rs875971	0.619	rs2302918	ENSG00000229180.5	GS1-124K5.11	3.82	0.000151	0.0111	0.12	0.17	Aortic root size;	chr7:66535945	chr7:66526088~66542624:-
THCA	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	3.82	0.000151	0.0111	0.18	0.17	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
THCA	cis	rs62380364	0.805	rs2362109	ENSG00000247828.6	TMEM161B-AS1	-3.82	0.000151	0.0111	-0.13	-0.17	Intelligence (multi-trait analysis);	chr5:88852224	chr5:88268895~88436685:+
THCA	cis	rs12612619	0.732	rs893790	ENSG00000272148.1	RP11-195B17.1	-3.82	0.000151	0.0111	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26978989	chr2:27062428~27062907:-
THCA	cis	rs7577696	0.568	rs410469	ENSG00000276334.1	AL133243.1	-3.82	0.000151	0.0111	-0.2	-0.17	Inflammatory biomarkers;	chr2:32251923	chr2:32521927~32523547:+
THCA	cis	rs8031584	0.781	rs4779498	ENSG00000259845.1	HERC2P10	3.82	0.000151	0.0111	0.24	0.17	Huntington's disease progression;	chr15:30885273	chr15:30815271~30844153:+
THCA	cis	rs875971	0.545	rs4441996	ENSG00000232559.3	GS1-124K5.12	-3.82	0.000151	0.0111	-0.19	-0.17	Aortic root size;	chr7:66123233	chr7:66554588~66576923:-
THCA	cis	rs7616559	0.637	rs4266145	ENSG00000240875.4	LINC00886	-3.82	0.000151	0.0111	-0.16	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157059596	chr3:156747346~156817062:-
THCA	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	3.82	0.000151	0.0111	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
THCA	cis	rs721917	0.506	rs4320898	ENSG00000244733.5	RP11-506M13.3	-3.82	0.000151	0.0111	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs4322333	ENSG00000244733.5	RP11-506M13.3	-3.82	0.000151	0.0111	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79660891~79677996:+
THCA	cis	rs972578	1	rs5751410	ENSG00000230319.1	AL022476.2	3.82	0.000151	0.0111	0.18	0.17	Mean platelet volume;	chr22:42997979	chr22:43038585~43052366:+
THCA	cis	rs2179367	0.552	rs11155652	ENSG00000216906.2	RP11-350J20.9	3.82	0.000151	0.0111	0.22	0.17	Dupuytren's disease;	chr6:149417849	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12209364	ENSG00000216906.2	RP11-350J20.9	3.82	0.000151	0.0111	0.22	0.17	Dupuytren's disease;	chr6:149418062	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9322179	ENSG00000216906.2	RP11-350J20.9	3.82	0.000151	0.0111	0.22	0.17	Dupuytren's disease;	chr6:149418664	chr6:149904243~149906418:+
THCA	cis	rs7829975	0.902	rs485107	ENSG00000233609.3	RP11-62H7.2	-3.82	0.000151	0.0111	-0.17	-0.17	Mood instability;	chr8:8723898	chr8:8961200~8979025:+
THCA	cis	rs1127311	1	rs9427094	ENSG00000236675.1	MTX1P1	-3.82	0.000151	0.0111	-0.16	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154585209	chr1:155230975~155234325:+
THCA	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-3.82	0.000151	0.0111	-0.19	-0.17	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
THCA	cis	rs6088590	0.735	rs6088618	ENSG00000276073.1	RP5-1125A11.7	-3.82	0.000151	0.0111	-0.15	-0.17	Coronary artery disease;	chr20:34821547	chr20:33985617~33988989:-
THCA	cis	rs11867129	1	rs4786271	ENSG00000260778.3	RP11-304L19.13	3.82	0.000151	0.0111	0.17	0.17	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2318141	chr16:2268155~2273418:+
THCA	cis	rs9911578	0.967	rs2429369	ENSG00000224738.1	AC099850.1	3.82	0.000151	0.0111	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58424059	chr17:59106598~59118267:+
THCA	cis	rs2235642	0.928	rs1057610	ENSG00000260989.1	LA16c-395F10.2	-3.82	0.000151	0.0111	-0.18	-0.17	Coronary artery disease;	chr16:1555536	chr16:1580527~1610328:+
THCA	cis	rs6995541	0.647	rs6991499	ENSG00000248896.2	CTD-2135J3.3	3.82	0.000151	0.0111	0.21	0.17	Triglyceride levels;	chr8:10831487	chr8:10729314~10771392:+
THCA	cis	rs113835537	0.627	rs4630309	ENSG00000255517.5	CTD-3074O7.5	3.82	0.000151	0.0111	0.18	0.17	Airway imaging phenotypes;	chr11:66565601	chr11:66473490~66480233:-
THCA	cis	rs6088590	0.735	rs6060001	ENSG00000276073.1	RP5-1125A11.7	3.82	0.000151	0.0111	0.15	0.17	Coronary artery disease;	chr20:34706549	chr20:33985617~33988989:-
THCA	cis	rs9926296	0.605	rs6500449	ENSG00000274627.1	RP11-104N10.2	-3.82	0.000151	0.0111	-0.17	-0.17	Vitiligo;	chr16:89789985	chr16:89516797~89522217:+
THCA	cis	rs9532669	0.926	rs2875421	ENSG00000229473.2	RGS17P1	3.82	0.000151	0.0111	0.22	0.17	Cervical cancer;	chr13:40936536	chr13:40992779~40993331:-
THCA	cis	rs7307902	1	rs11168141	ENSG00000280054.1	RP1-197B17.7	-3.82	0.000151	0.0111	-0.2	-0.17	Obesity-related traits;	chr12:47534290	chr12:47728151~47730598:-
THCA	cis	rs7819412	0.74	rs7844536	ENSG00000206014.6	OR7E161P	3.82	0.000151	0.0111	0.2	0.17	Triglycerides;	chr8:11176519	chr8:11928597~11929563:-
THCA	cis	rs2455799	0.613	rs9848007	ENSG00000270409.1	RP11-44D5.1	-3.82	0.000151	0.0112	-0.18	-0.17	Mean platelet volume;	chr3:15811086	chr3:15732252~15733470:+
THCA	cis	rs2635047	0.837	rs2571009	ENSG00000280212.1	RP11-49K24.3	-3.82	0.000151	0.0112	-0.17	-0.17	Educational attainment;	chr18:47123908	chr18:47076117~47076594:+
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000232559.3	GS1-124K5.12	3.82	0.000151	0.0112	0.3	0.17	Diabetic kidney disease;	chr7:66009932	chr7:66554588~66576923:-
THCA	cis	rs12476592	0.602	rs9789351	ENSG00000242412.1	DBIL5P2	3.82	0.000151	0.0112	0.22	0.17	Childhood ear infection;	chr2:63513480	chr2:63117851~63119542:-
THCA	cis	rs8044868	0.861	rs9936642	ENSG00000260886.1	TAT-AS1	-3.82	0.000151	0.0112	-0.2	-0.17	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72175620	chr16:71565789~71578187:+
THCA	cis	rs12893668	0.703	rs4906338	ENSG00000244691.1	RPL10AP1	-3.82	0.000151	0.0112	-0.24	-0.17	Reticulocyte count;	chr14:103584020	chr14:103412119~103412761:-
THCA	cis	rs7665090	1	rs2866406	ENSG00000248971.2	KRT8P46	-3.82	0.000151	0.0112	-0.2	-0.17	Primary biliary cholangitis;	chr4:102632862	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs2866407	ENSG00000248971.2	KRT8P46	-3.82	0.000151	0.0112	-0.2	-0.17	Primary biliary cholangitis;	chr4:102632951	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs2866408	ENSG00000248971.2	KRT8P46	-3.82	0.000151	0.0112	-0.2	-0.17	Primary biliary cholangitis;	chr4:102632956	chr4:102728746~102730171:-
THCA	cis	rs5769765	0.955	rs8139758	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49867475	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.955	rs5769761	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49869993	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.954	rs5769762	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49870394	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.955	rs2319465	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49872136	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs34774661	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49873860	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs4824106	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49874174	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.954	rs5770739	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49874366	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs5770741	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49876567	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs5770742	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49876661	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs4597652	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49876922	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs5769764	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49877136	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs5769765	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49877528	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.865	rs4824108	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49877780	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.908	rs4824109	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49877812	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.837	rs4824110	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49877983	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.955	rs5769767	ENSG00000260613.1	RP3-522J7.6	3.82	0.000151	0.0112	0.22	0.17	Schizophrenia;	chr22:49883261	chr22:49832616~49837786:-
THCA	cis	rs11671005	0.571	rs56243535	ENSG00000269600.1	AC016629.3	-3.82	0.000151	0.0112	-0.26	-0.17	Mean platelet volume;	chr19:58494783	chr19:58593896~58599355:-
THCA	cis	rs6499755	0.932	rs31075	ENSG00000260135.5	RP11-212I21.2	-3.82	0.000151	0.0112	-0.19	-0.17	Hypospadias;	chr16:55323326	chr16:55426797~55462297:-
THCA	cis	rs7819412	0.74	rs28633434	ENSG00000261451.1	RP11-981G7.1	-3.82	0.000151	0.0112	-0.22	-0.17	Triglycerides;	chr8:11196413	chr8:10433672~10438312:+
THCA	cis	rs10457838	0.755	rs11755147	ENSG00000268592.3	RAET1E-AS1	-3.82	0.000151	0.0112	-0.26	-0.17	Post-traumatic stress disorder;	chr6:149090029	chr6:149863494~149919507:+
THCA	cis	rs2688608	0.587	rs2894040	ENSG00000272140.2	RP11-574K11.29	3.82	0.000151	0.0112	0.15	0.17	Inflammatory bowel disease;	chr10:73718401	chr10:73703735~73713581:-
THCA	cis	rs2688608	0.592	rs3849967	ENSG00000272140.2	RP11-574K11.29	3.82	0.000151	0.0112	0.15	0.17	Inflammatory bowel disease;	chr10:73723608	chr10:73703735~73713581:-
THCA	cis	rs2688608	0.592	rs7909802	ENSG00000272140.2	RP11-574K11.29	3.82	0.000151	0.0112	0.15	0.17	Inflammatory bowel disease;	chr10:73724428	chr10:73703735~73713581:-
THCA	cis	rs4389656	0.625	rs274682	ENSG00000248677.1	CTD-2044J15.1	3.82	0.000151	0.0112	0.17	0.17	Coronary artery disease;	chr5:6748405	chr5:6686325~6707711:-
THCA	cis	rs10861661	0.963	rs10444533	ENSG00000260329.1	RP11-412D9.4	3.82	0.000151	0.0112	0.19	0.17	Triglyceride levels;	chr12:106835927	chr12:106954029~106955497:-
THCA	cis	rs7911264	0.739	rs10736069	ENSG00000236493.2	EIF2S2P3	3.82	0.000151	0.0112	0.19	0.17	Inflammatory bowel disease;	chr10:92635636	chr10:92668745~92669743:-
THCA	cis	rs7911264	0.739	rs7900689	ENSG00000236493.2	EIF2S2P3	3.82	0.000151	0.0112	0.19	0.17	Inflammatory bowel disease;	chr10:92635991	chr10:92668745~92669743:-
THCA	cis	rs7911264	0.739	rs6583830	ENSG00000236493.2	EIF2S2P3	3.82	0.000151	0.0112	0.19	0.17	Inflammatory bowel disease;	chr10:92638361	chr10:92668745~92669743:-
THCA	cis	rs10927875	0.632	rs6699394	ENSG00000179743.3	FLJ37453	-3.82	0.000151	0.0112	-0.12	-0.17	Dilated cardiomyopathy;	chr1:15818648	chr1:15834479~15848147:-
THCA	cis	rs10266483	1	rs1960321	ENSG00000228653.2	HNRNPCP7	-3.82	0.000151	0.0112	-0.15	-0.17	Response to statin therapy;	chr7:64270906	chr7:64500825~64501729:+
THCA	cis	rs2842346	0.628	rs2842338	ENSG00000258623.1	CTD-2325P2.3	-3.82	0.000151	0.0112	-0.22	-0.17	Breast cancer;	chr14:68524569	chr14:68683411~68685565:-
THCA	cis	rs7656342	0.964	rs13141706	ENSG00000242034.1	RP11-1396O13.1	-3.82	0.000151	0.0112	-0.2	-0.17	Gut microbiota (bacterial taxa);	chr4:9816721	chr4:9553614~9553985:-
THCA	cis	rs875971	0.706	rs1643374	ENSG00000229180.5	GS1-124K5.11	3.82	0.000151	0.0112	0.12	0.17	Aortic root size;	chr7:66407695	chr7:66526088~66542624:-
THCA	cis	rs17286411	0.641	rs9939455	ENSG00000260185.1	RP11-432I5.6	-3.82	0.000151	0.0112	-0.24	-0.17	Blood protein levels;	chr16:71757895	chr16:71655027~71664212:+
THCA	cis	rs9316337	0.843	rs9509683	ENSG00000236953.1	ZDHHC20-IT1	-3.82	0.000151	0.0112	-0.18	-0.17	Schizophrenia;	chr13:21403673	chr13:21376977~21377874:-
THCA	cis	rs5015933	0.736	rs10125995	ENSG00000232630.1	PRPS1P2	-3.82	0.000151	0.0112	-0.12	-0.17	Body mass index;	chr9:125383663	chr9:125150653~125151589:+
THCA	cis	rs12234571	1	rs17156706	ENSG00000214293.7	APTR	3.82	0.000151	0.0112	0.22	0.17	Obesity-related traits;	chr7:77708119	chr7:77657660~77696265:-
THCA	cis	rs17853159	0.558	rs1938298	ENSG00000281912.1	LINC01144	-3.82	0.000151	0.0112	-0.19	-0.17	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45278854	chr1:45303910~45305619:+
THCA	cis	rs7824557	0.527	rs2572376	ENSG00000227888.4	FAM66A	-3.82	0.000151	0.0112	-0.22	-0.17	Retinal vascular caliber;	chr8:11380247	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.527	rs2736305	ENSG00000227888.4	FAM66A	-3.82	0.000151	0.0112	-0.22	-0.17	Retinal vascular caliber;	chr8:11380264	chr8:12362019~12388296:+
THCA	cis	rs6477918	0.544	rs6477927	ENSG00000230185.4	C9orf147	-3.82	0.000151	0.0112	-0.18	-0.17	Obstetric antiphospholipid syndrome;	chr9:112393041	chr9:112433816~112487204:-
THCA	cis	rs879500	1	rs1504116	ENSG00000227279.1	AC015933.2	3.82	0.000151	0.0112	0.2	0.17	Lung function (FVC);	chr18:28539096	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs1566819	ENSG00000227279.1	AC015933.2	3.82	0.000151	0.0112	0.2	0.17	Lung function (FVC);	chr18:28540773	chr18:27954519~27963687:+
THCA	cis	rs765787	0.53	rs2433229	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45223037	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4331289	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45223140	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2433228	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45223173	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11854690	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45223818	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs28733848	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45223849	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11854689	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45223854	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs1706830	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45224031	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs1706831	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45224032	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2433227	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45224921	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2668751	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45225095	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs1648286	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45225188	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs1648285	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45225307	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs1706835	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45225686	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs1631533	ENSG00000259932.1	CTD-2651B20.7	3.82	0.000151	0.0112	0.21	0.17	Uric acid levels;	chr15:45226430	chr15:45198517~45199139:-
THCA	cis	rs5758659	0.653	rs133383	ENSG00000205702.9	CYP2D7	3.82	0.000151	0.0112	0.13	0.17	Cognitive function;	chr22:42077599	chr22:42140203~42144577:-
THCA	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	3.82	0.000151	0.0112	0.2	0.17	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
THCA	cis	rs10129255	1	rs10137758	ENSG00000274576.2	IGHV2-70	3.82	0.000151	0.0112	0.12	0.17	Kawasaki disease;	chr14:106697673	chr14:106770577~106771020:-
THCA	cis	rs6600671	1	rs1856572	ENSG00000226067.5	CH17-118O6.2	3.82	0.000151	0.0112	0.17	0.17	Hip geometry;	chr1:121427719	chr1:120913275~121009291:+
THCA	cis	rs7403037	0.55	rs61993572	ENSG00000260760.1	PWRN3	3.82	0.000152	0.0112	0.25	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24395005	chr15:24441127~24447967:+
THCA	cis	rs2221894	0.922	rs4407834	ENSG00000251191.6	LINC00589	-3.82	0.000152	0.0112	-0.21	-0.17	Obesity-related traits;	chr8:28984304	chr8:29673922~29748109:-
THCA	cis	rs72627123	0.881	rs28548133	ENSG00000259065.1	RP5-1021I20.1	3.82	0.000152	0.0112	0.27	0.17	Morning vs. evening chronotype;	chr14:73842451	chr14:73787360~73803270:+
THCA	cis	rs365302	0.953	rs389041	ENSG00000235086.1	FNDC1-IT1	3.82	0.000152	0.0112	0.24	0.17	Coronary heart disease;	chr6:159225821	chr6:159240786~159243329:+
THCA	cis	rs17685	0.753	rs869804	ENSG00000230882.1	AC005077.14	3.82	0.000152	0.0112	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76059636	chr7:76071469~76074963:-
THCA	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	3.82	0.000152	0.0112	0.2	0.17	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	3.82	0.000152	0.0112	0.2	0.17	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
THCA	cis	rs6443245	0.611	rs2648380	ENSG00000227110.5	LMCD1-AS1	-3.82	0.000152	0.0112	-0.2	-0.17	Daytime sleep phenotypes;	chr3:9583370	chr3:7952805~8611924:-
THCA	cis	rs13098911	0.54	rs13097556	ENSG00000226074.4	PRSS44	-3.82	0.000152	0.0112	-0.31	-0.17	Celiac disease;	chr3:46020505	chr3:46809359~46812558:-
THCA	cis	rs757110	0.77	rs1557765	ENSG00000260196.1	RP1-239B22.5	3.82	0.000152	0.0112	0.19	0.17	Type 2 diabetes;	chr11:17382092	chr11:17380649~17383531:+
THCA	cis	rs875971	0.545	rs11767262	ENSG00000273024.4	INTS4P2	-3.82	0.000152	0.0112	-0.22	-0.17	Aortic root size;	chr7:66302237	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000273024.4	INTS4P2	-3.82	0.000152	0.0112	-0.22	-0.17	Aortic root size;	chr7:66327797	chr7:65647864~65715661:+
THCA	cis	rs2625529	0.938	rs2625530	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000152	0.0112	-0.25	-0.17	Red blood cell count;	chr15:71833693	chr15:71818396~71823384:+
THCA	cis	rs8179	1	rs42033	ENSG00000230927.2	TMBIM7P	3.82	0.000152	0.0112	0.27	0.17	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92608219	chr7:92412976~92439562:-
THCA	cis	rs763121	0.853	rs5750672	ENSG00000272669.1	RP3-508I15.21	3.82	0.000152	0.0112	0.12	0.17	Menopause (age at onset);	chr22:38708163	chr22:38742625~38743115:+
THCA	cis	rs17286411	0.671	rs9922054	ENSG00000260185.1	RP11-432I5.6	-3.82	0.000152	0.0112	-0.24	-0.17	Blood protein levels;	chr16:71779848	chr16:71655027~71664212:+
THCA	cis	rs7474896	0.616	rs2474561	ENSG00000275858.1	RP11-291L22.8	3.82	0.000152	0.0112	0.25	0.17	Obesity (extreme);	chr10:38084616	chr10:38450738~38451069:-
THCA	cis	rs42648	0.596	rs194511	ENSG00000225498.1	AC002064.5	3.82	0.000152	0.0112	0.19	0.17	Homocysteine levels;	chr7:90217413	chr7:90312496~90322592:+
THCA	cis	rs61160187	0.582	rs4700404	ENSG00000272308.1	RP11-231G3.1	-3.82	0.000152	0.0112	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60866457~60866935:-
THCA	cis	rs10895987	0.531	rs11227120	ENSG00000197847.11	SLC22A20	-3.82	0.000152	0.0112	-0.18	-0.17	Blood protein levels;	chr11:65097387	chr11:65213840~65242757:+
THCA	cis	rs71520386	0.861	rs35841035	ENSG00000228649.7	AC005682.5	-3.82	0.000152	0.0112	-0.27	-0.17	Fibrinogen levels;	chr7:22822987	chr7:22854178~22861579:+
THCA	cis	rs7142002	0.649	rs2150539	ENSG00000272444.1	RP11-1017G21.6	-3.82	0.000152	0.0112	-0.25	-0.17	Autism;	chr14:102205004	chr14:101952416~101953063:+
THCA	cis	rs910316	1	rs7156105	ENSG00000259138.1	RP11-950C14.7	3.82	0.000152	0.0112	0.15	0.17	Height;	chr14:75075251	chr14:75127153~75136930:+
THCA	cis	rs9309473	1	rs2901438	ENSG00000273245.1	RP11-434P11.2	3.82	0.000152	0.0112	0.23	0.17	Metabolite levels;	chr2:73438528	chr2:73750256~73750786:-
THCA	cis	rs7572733	0.576	rs1368989	ENSG00000231621.1	AC013264.2	-3.82	0.000152	0.0112	-0.19	-0.17	Dermatomyositis;	chr2:198072358	chr2:197197991~197199273:+
THCA	cis	rs10266483	0.774	rs10253630	ENSG00000271550.1	BNIP3P11	-3.82	0.000152	0.0112	-0.23	-0.17	Response to statin therapy;	chr7:64366962	chr7:64678954~64687393:-
THCA	cis	rs10090774	0.965	rs11775840	ENSG00000280303.2	ERICD	-3.82	0.000152	0.0112	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140873134	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs4074812	ENSG00000280303.2	ERICD	-3.82	0.000152	0.0112	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140873430	chr8:140636281~140638283:+
THCA	cis	rs964611	0.882	rs1905612	ENSG00000259488.2	RP11-154J22.1	3.82	0.000152	0.0112	0.17	0.17	Metabolite levels (Pyroglutamine);	chr15:48363720	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs971952	ENSG00000259488.2	RP11-154J22.1	3.82	0.000152	0.0112	0.17	0.17	Metabolite levels (Pyroglutamine);	chr15:48363743	chr15:48312353~48331856:-
THCA	cis	rs2721195	0.967	rs11777703	ENSG00000265393.1	CTD-2517M22.17	3.82	0.000152	0.0112	0.21	0.17	Age at first birth;	chr8:144478125	chr8:144512567~144513672:+
THCA	cis	rs7259376	0.936	rs10454118	ENSG00000270947.1	AC025811.3	-3.82	0.000152	0.0112	-0.18	-0.17	Menopause (age at onset);	chr19:22376803	chr19:22455988~22456459:+
THCA	cis	rs8053891	0.507	rs66553600	ENSG00000279206.1	RP5-991G20.6	3.82	0.000152	0.0112	0.18	0.17	Coronary artery disease;	chr16:71994299	chr16:72772673~72773272:+
THCA	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	3.82	0.000152	0.0112	0.16	0.17	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
THCA	cis	rs7824557	0.603	rs2736278	ENSG00000227888.4	FAM66A	3.82	0.000152	0.0112	0.22	0.17	Retinal vascular caliber;	chr8:11362272	chr8:12362019~12388296:+
THCA	cis	rs748404	0.589	rs62020616	ENSG00000166763.7	STRCP1	3.82	0.000152	0.0112	0.22	0.17	Lung cancer;	chr15:43558554	chr15:43699488~43718184:-
THCA	cis	rs748404	0.626	rs60367691	ENSG00000166763.7	STRCP1	3.82	0.000152	0.0112	0.22	0.17	Lung cancer;	chr15:43559201	chr15:43699488~43718184:-
THCA	cis	rs6012953	1	rs3787334	ENSG00000231715.1	COX6CP2	3.82	0.000152	0.0112	0.19	0.17	Vitiligo;	chr20:50511483	chr20:50479767~50479991:+
THCA	cis	rs1799922	1	rs4509261	ENSG00000271553.1	RP11-274B21.10	-3.82	0.000152	0.0112	-0.15	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128742231	chr7:128667043~128668156:+
THCA	cis	rs2436845	0.521	rs2570948	ENSG00000253320.4	KB-1507C5.2	-3.82	0.000152	0.0112	-0.15	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102870430	chr8:102864300~102977876:+
THCA	cis	rs13113518	0.841	rs7699867	ENSG00000272969.1	RP11-528I4.2	3.82	0.000152	0.0112	0.21	0.17	Height;	chr4:55483718	chr4:55547112~55547889:+
THCA	cis	rs123509	0.687	rs6865	ENSG00000173811.9	CCDC13-AS1	-3.82	0.000152	0.0112	-0.2	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42784549	chr3:42732575~42746768:+
THCA	cis	rs343092	1	rs343092	ENSG00000241749.4	RPSAP52	-3.82	0.000152	0.0112	-0.2	-0.17	Type 2 diabetes;	chr12:65857160	chr12:65758020~65826997:-
THCA	cis	rs11239930	0.517	rs3011809	ENSG00000278811.3	LINC00624	3.82	0.000152	0.0112	0.2	0.17	AIDS progression;	chr1:147077593	chr1:147258885~147517875:-
THCA	cis	rs10089	1	rs1864922	ENSG00000245937.6	LINC01184	3.82	0.000152	0.0112	0.2	0.17	Ileal carcinoids;	chr5:128085008	chr5:127940426~128083172:-
THCA	cis	rs10089	0.951	rs1864923	ENSG00000245937.6	LINC01184	3.82	0.000152	0.0112	0.2	0.17	Ileal carcinoids;	chr5:128085151	chr5:127940426~128083172:-
THCA	cis	rs2253762	0.54	rs11200324	ENSG00000226864.1	ATE1-AS1	-3.82	0.000152	0.0112	-0.27	-0.17	Breast cancer;	chr10:122009999	chr10:121928312~121951965:+
THCA	cis	rs295490	0.748	rs77016755	ENSG00000272656.1	RP11-219D15.3	3.82	0.000152	0.0112	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139392125	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs61034702	ENSG00000272656.1	RP11-219D15.3	3.82	0.000152	0.0112	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139395105	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs115177972	ENSG00000272656.1	RP11-219D15.3	3.82	0.000152	0.0112	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139410696	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs77876369	ENSG00000272656.1	RP11-219D15.3	3.82	0.000152	0.0112	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139412070	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs77131232	ENSG00000272656.1	RP11-219D15.3	3.82	0.000152	0.0112	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139415468	chr3:139349024~139349371:-
THCA	cis	rs295490	0.588	rs75694829	ENSG00000272656.1	RP11-219D15.3	3.82	0.000152	0.0112	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139416582	chr3:139349024~139349371:-
THCA	cis	rs7873102	0.647	rs56225059	ENSG00000213839.4	TMX2P1	3.82	0.000152	0.0112	0.14	0.17	Brain structure;	chr9:38058581	chr9:37885683~37886390:+
THCA	cis	rs9911578	0.967	rs8082544	ENSG00000224738.1	AC099850.1	-3.82	0.000152	0.0112	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:59108446	chr17:59106598~59118267:+
THCA	cis	rs791590	0.941	rs12722527	ENSG00000225948.2	RP11-554I8.1	3.82	0.000152	0.0112	0.28	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6035365	chr10:6618716~6625346:+
THCA	cis	rs9911578	1	rs2531729	ENSG00000224738.1	AC099850.1	3.82	0.000152	0.0112	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58462529	chr17:59106598~59118267:+
THCA	cis	rs2549794	0.526	rs6876611	ENSG00000247121.5	CTD-2260A17.2	3.82	0.000152	0.0112	0.13	0.17	Crohn's disease;	chr5:96907894	chr5:96814028~96935809:-
THCA	cis	rs7824557	0.527	rs2409756	ENSG00000261451.1	RP11-981G7.1	-3.82	0.000152	0.0112	-0.22	-0.17	Retinal vascular caliber;	chr8:11384516	chr8:10433672~10438312:+
THCA	cis	rs6439699	1	rs35361620	ENSG00000273486.1	RP11-731C17.2	3.82	0.000152	0.0112	0.18	0.17	Intelligence (multi-trait analysis);	chr3:137291095	chr3:136837338~136839021:-
THCA	cis	rs6439699	1	rs58088387	ENSG00000273486.1	RP11-731C17.2	3.82	0.000152	0.0112	0.18	0.17	Intelligence (multi-trait analysis);	chr3:137291160	chr3:136837338~136839021:-
THCA	cis	rs6439699	1	rs1478325	ENSG00000273486.1	RP11-731C17.2	3.82	0.000152	0.0112	0.18	0.17	Intelligence (multi-trait analysis);	chr3:137294864	chr3:136837338~136839021:-
THCA	cis	rs9905704	0.846	rs7212271	ENSG00000224738.1	AC099850.1	3.82	0.000152	0.0112	0.22	0.17	Testicular germ cell tumor;	chr17:58786557	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.846	rs11079356	ENSG00000224738.1	AC099850.1	3.82	0.000152	0.0112	0.22	0.17	Testicular germ cell tumor;	chr17:58786881	chr17:59106598~59118267:+
THCA	cis	rs2692947	0.727	rs2692950	ENSG00000235584.2	AC008268.1	-3.82	0.000152	0.0112	-0.17	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007776	chr2:95666084~95668715:+
THCA	cis	rs56104184	0.779	rs17272666	ENSG00000243829.1	CTB-33G10.1	-3.82	0.000152	0.0112	-0.22	-0.17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48853037	chr19:49719498~49720081:-
THCA	cis	rs7798970	0.594	rs4728859	ENSG00000225498.1	AC002064.5	-3.82	0.000152	0.0112	-0.18	-0.17	Inflammatory skin disease;	chr7:90042986	chr7:90312496~90322592:+
THCA	cis	rs7759001	0.744	rs6650992	ENSG00000271755.1	RP1-153G14.4	3.82	0.000152	0.0112	0.21	0.17	Glomerular filtration rate (creatinine);	chr6:27494606	chr6:27404010~27406964:-
THCA	cis	rs7010267	0.773	rs4876869	ENSG00000254278.1	RP11-278I4.2	3.82	0.000152	0.0112	0.22	0.17	Total body bone mineral density (age 45-60);	chr8:118929038	chr8:119062942~119068782:-
THCA	cis	rs10875746	0.903	rs11168401	ENSG00000258234.1	RP11-370I10.2	3.82	0.000152	0.0112	0.21	0.17	Longevity (90 years and older);	chr12:48087736	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs12304476	ENSG00000258234.1	RP11-370I10.2	3.82	0.000152	0.0112	0.21	0.17	Longevity (90 years and older);	chr12:48088370	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs3782911	ENSG00000258234.1	RP11-370I10.2	3.82	0.000152	0.0112	0.21	0.17	Longevity (90 years and older);	chr12:48089709	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.859	rs3782910	ENSG00000258234.1	RP11-370I10.2	3.82	0.000152	0.0112	0.21	0.17	Longevity (90 years and older);	chr12:48089724	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs61918806	ENSG00000258234.1	RP11-370I10.2	3.82	0.000152	0.0112	0.21	0.17	Longevity (90 years and older);	chr12:48090650	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs11168403	ENSG00000258234.1	RP11-370I10.2	3.82	0.000152	0.0112	0.21	0.17	Longevity (90 years and older);	chr12:48091175	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs10875740	ENSG00000258234.1	RP11-370I10.2	3.82	0.000152	0.0112	0.21	0.17	Longevity (90 years and older);	chr12:48095334	chr12:48231098~48284210:-
THCA	cis	rs6894216	0.627	rs12654296	ENSG00000248610.1	HSPA8P4	-3.82	0.000152	0.0112	-0.21	-0.17	Response to amphetamines;	chr5:130355167	chr5:130140031~130141950:+
THCA	cis	rs2688608	0.56	rs10128354	ENSG00000272140.2	RP11-574K11.29	3.82	0.000152	0.0112	0.15	0.17	Inflammatory bowel disease;	chr10:73710287	chr10:73703735~73713581:-
THCA	cis	rs7572733	0.935	rs696814	ENSG00000231621.1	AC013264.2	-3.82	0.000152	0.0112	-0.16	-0.17	Dermatomyositis;	chr2:197823175	chr2:197197991~197199273:+
THCA	cis	rs72829446	0.505	rs10852891	ENSG00000266824.1	RP11-599B13.7	3.82	0.000152	0.0112	0.27	0.17	Androgen levels;	chr17:7587492	chr17:8176812~8182812:+
THCA	cis	rs9329221	0.651	rs2975648	ENSG00000261451.1	RP11-981G7.1	-3.82	0.000152	0.0112	-0.21	-0.17	Neuroticism;	chr8:10278466	chr8:10433672~10438312:+
THCA	cis	rs6982240	0.514	rs7002268	ENSG00000253307.1	RP11-10J21.4	3.82	0.000152	0.0112	0.25	0.17	Tonsillectomy;	chr8:141267241	chr8:141252286~141253292:-
THCA	cis	rs4722166	0.532	rs4719711	ENSG00000225541.1	AC002480.5	3.82	0.000152	0.0112	0.19	0.17	Lung cancer;	chr7:22716069	chr7:22571607~22661792:-
THCA	cis	rs10256972	0.63	rs10282584	ENSG00000199023.2	MIR339	-3.82	0.000152	0.0112	-0.19	-0.17	Endometriosis;Longevity;	chr7:1041806	chr7:1022935~1023045:-
THCA	cis	rs17092148	0.636	rs7273470	ENSG00000276073.1	RP5-1125A11.7	3.82	0.000152	0.0112	0.19	0.17	Neuroticism;	chr20:34869118	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.579	rs7265109	ENSG00000276073.1	RP5-1125A11.7	3.82	0.000152	0.0112	0.19	0.17	Neuroticism;	chr20:34871551	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.636	rs11697978	ENSG00000276073.1	RP5-1125A11.7	3.82	0.000152	0.0112	0.19	0.17	Neuroticism;	chr20:34872563	chr20:33985617~33988989:-
THCA	cis	rs2832191	0.692	rs2776240	ENSG00000176054.6	RPL23P2	3.82	0.000152	0.0112	0.15	0.17	Dental caries;	chr21:28938317	chr21:28997613~28998033:-
THCA	cis	rs6121246	0.821	rs3181073	ENSG00000224628.2	RP5-854E16.2	3.82	0.000152	0.0112	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31719396	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs1994250	ENSG00000224628.2	RP5-854E16.2	-3.82	0.000152	0.0112	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31699691	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs1994249	ENSG00000224628.2	RP5-854E16.2	-3.82	0.000152	0.0112	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31699790	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.865	rs6058421	ENSG00000224628.2	RP5-854E16.2	-3.82	0.000152	0.0112	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31707210	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.909	rs6060870	ENSG00000224628.2	RP5-854E16.2	-3.82	0.000152	0.0112	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31715496	chr20:31285317~31286835:-
THCA	cis	rs4819052	1	rs2297286	ENSG00000184274.3	LINC00315	-3.82	0.000152	0.0112	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45300245~45305257:-
THCA	cis	rs4767841	0.874	rs10129003	ENSG00000252886.1	RN7SKP197	-3.82	0.000152	0.0112	-0.17	-0.17	Urgency urinary incontinence;	chr12:119759912	chr12:119631090~119631386:-
THCA	cis	rs1501911	0.53	rs326468	ENSG00000241597.2	CTD-2007H13.1	-3.82	0.000152	0.0112	-0.22	-0.17	Lung function (FEV1/FVC);	chr5:98897105	chr5:98954394~98954972:+
THCA	cis	rs453301	0.686	rs7814328	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000152	0.0112	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9018719	chr8:9141424~9145435:+
THCA	cis	rs7572644	0.64	rs4666014	ENSG00000223522.1	AC093690.1	3.82	0.000152	0.0112	0.21	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27796308	chr2:28307691~28310459:-
THCA	cis	rs4950322	0.58	rs4950308	ENSG00000226015.2	CCT8P1	3.82	0.000152	0.0112	0.2	0.17	Protein quantitative trait loci;	chr1:147120092	chr1:147203276~147204932:-
THCA	cis	rs9303542	0.729	rs12952824	ENSG00000278765.1	RP5-890E16.5	-3.82	0.000152	0.0112	-0.23	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48400833	chr17:48066704~48067293:-
THCA	cis	rs739310	1	rs739310	ENSG00000235271.4	RP1-90L6.3	-3.82	0.000152	0.0112	-0.26	-0.17	Obesity-related traits;	chr22:26655335	chr22:26903292~26920611:+
THCA	cis	rs427394	0.659	rs274678	ENSG00000248677.1	CTD-2044J15.1	-3.82	0.000152	0.0112	-0.17	-0.17	Menopause (age at onset);	chr5:6752272	chr5:6686325~6707711:-
THCA	cis	rs7129556	0.69	rs947841	ENSG00000254459.1	RP11-91P24.7	3.82	0.000152	0.0112	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77881863	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.69	rs695046	ENSG00000254459.1	RP11-91P24.7	3.82	0.000152	0.0112	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77883308	chr11:77829654~77872262:-
THCA	cis	rs2562456	0.876	rs62110163	ENSG00000268278.1	RP11-420K14.1	3.82	0.000152	0.0112	0.21	0.17	Pain;	chr19:21546020	chr19:21637974~21656300:+
THCA	cis	rs7826238	0.72	rs12546760	ENSG00000254153.1	CTA-398F10.2	3.82	0.000152	0.0112	0.19	0.17	Systolic blood pressure;	chr8:8517326	chr8:8456909~8461337:-
THCA	cis	rs10089	1	rs77086350	ENSG00000245937.6	LINC01184	3.82	0.000152	0.0112	0.19	0.17	Ileal carcinoids;	chr5:128158739	chr5:127940426~128083172:-
THCA	cis	rs2357982	0.556	rs16845495	ENSG00000232320.6	AC009299.5	-3.82	0.000152	0.0112	-0.24	-0.17	Presence of antiphospholipid antibodies;	chr2:161042627	chr2:161340816~161341326:-
THCA	cis	rs9314614	0.901	rs2978902	ENSG00000245857.2	GS1-24F4.2	-3.82	0.000152	0.0112	-0.22	-0.17	White blood cell count (basophil);IgA nephropathy;	chr8:6832651	chr8:6835554~6885276:+
THCA	cis	rs39841	1	rs39841	ENSG00000272109.1	CTD-2260A17.3	-3.82	0.000152	0.0112	-0.23	-0.17	Inflammatory skin disease;	chr5:96784466	chr5:96804353~96806105:+
THCA	cis	rs30380	0.734	rs30376	ENSG00000272109.1	CTD-2260A17.3	-3.82	0.000152	0.0112	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96804353~96806105:+
THCA	cis	rs7737355	0.947	rs17167760	ENSG00000237714.1	P4HA2-AS1	-3.82	0.000152	0.0112	-0.24	-0.17	Life satisfaction;	chr5:131447006	chr5:132184876~132192808:+
THCA	cis	rs10760158	0.769	rs10760170	ENSG00000235865.2	GSN-AS1	3.82	0.000152	0.0112	0.15	0.17	Pulse pressure;	chr9:121295935	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs1865542	ENSG00000235865.2	GSN-AS1	3.82	0.000152	0.0112	0.15	0.17	Pulse pressure;	chr9:121296521	chr9:121280768~121285530:-
THCA	cis	rs453301	0.658	rs9650616	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000152	0.0112	-0.2	-0.17	Joint mobility (Beighton score);	chr8:9011689	chr8:9141424~9145435:+
THCA	cis	rs4759375	1	rs9669295	ENSG00000256092.2	RP13-942N8.1	3.82	0.000152	0.0112	0.19	0.17	HDL cholesterol;	chr12:123358123	chr12:123363868~123366113:+
THCA	cis	rs4759375	0.92	rs28786830	ENSG00000256092.2	RP13-942N8.1	3.82	0.000152	0.0112	0.19	0.17	HDL cholesterol;	chr12:123375925	chr12:123363868~123366113:+
THCA	cis	rs4759375	0.85	rs28503862	ENSG00000256092.2	RP13-942N8.1	3.82	0.000152	0.0112	0.19	0.17	HDL cholesterol;	chr12:123382559	chr12:123363868~123366113:+
THCA	cis	rs7615952	0.551	rs6438945	ENSG00000248787.1	RP11-666A20.4	-3.82	0.000152	0.0112	-0.3	-0.17	Blood pressure (smoking interaction);	chr3:125915630	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.673	rs7632557	ENSG00000248787.1	RP11-666A20.4	-3.82	0.000152	0.0112	-0.3	-0.17	Blood pressure (smoking interaction);	chr3:125916038	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.932	rs9841157	ENSG00000248787.1	RP11-666A20.4	-3.82	0.000152	0.0112	-0.3	-0.17	Blood pressure (smoking interaction);	chr3:125916812	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.551	rs12695470	ENSG00000248787.1	RP11-666A20.4	-3.82	0.000152	0.0112	-0.3	-0.17	Blood pressure (smoking interaction);	chr3:125916875	chr3:125908005~125910272:-
THCA	cis	rs1023500	0.505	rs134901	ENSG00000237037.8	NDUFA6-AS1	-3.82	0.000152	0.0112	-0.14	-0.17	Schizophrenia;	chr22:42287514	chr22:42090931~42137742:+
THCA	cis	rs1433188	0.847	rs10091818	ENSG00000253582.1	RP11-649G15.2	3.82	0.000153	0.0112	0.2	0.17	Subjective well-being;	chr8:107432173	chr8:106520474~106657548:-
THCA	cis	rs972578	0.967	rs1883314	ENSG00000230319.1	AL022476.2	3.82	0.000153	0.0112	0.18	0.17	Mean platelet volume;	chr22:42978801	chr22:43038585~43052366:+
THCA	cis	rs944289	0.557	rs8016147	ENSG00000258844.1	RP11-259K15.2	3.82	0.000153	0.0112	0.17	0.17	Thyroid cancer;	chr14:36111685	chr14:36214607~36235608:+
THCA	cis	rs17695224	0.545	rs10500309	ENSG00000275055.1	CTC-471J1.11	-3.82	0.000153	0.0112	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51829123	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.545	rs8111469	ENSG00000275055.1	CTC-471J1.11	-3.82	0.000153	0.0112	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51829272	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.565	rs61681419	ENSG00000275055.1	CTC-471J1.11	-3.82	0.000153	0.0112	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51830726	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.545	rs13346095	ENSG00000275055.1	CTC-471J1.11	-3.82	0.000153	0.0112	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51831092	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.5	rs13346104	ENSG00000275055.1	CTC-471J1.11	-3.82	0.000153	0.0112	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51831173	chr19:52049007~52049754:+
THCA	cis	rs4950322	0.58	rs17355419	ENSG00000271721.1	RP11-337C18.9	3.82	0.000153	0.0112	0.19	0.17	Protein quantitative trait loci;	chr1:147110094	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.58	rs72706428	ENSG00000271721.1	RP11-337C18.9	3.82	0.000153	0.0112	0.19	0.17	Protein quantitative trait loci;	chr1:147110219	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.563	rs61838944	ENSG00000271721.1	RP11-337C18.9	3.82	0.000153	0.0112	0.19	0.17	Protein quantitative trait loci;	chr1:147110275	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.518	rs11811023	ENSG00000226015.2	CCT8P1	-3.82	0.000153	0.0112	-0.2	-0.17	Protein quantitative trait loci;	chr1:147109536	chr1:147203276~147204932:-
THCA	cis	rs9291683	0.53	rs998675	ENSG00000261490.1	RP11-448G15.3	3.82	0.000153	0.0112	0.11	0.17	Bone mineral density;	chr4:9947205	chr4:10068089~10073019:-
THCA	cis	rs453301	0.719	rs34004903	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000153	0.0112	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9035094	chr8:9141424~9145435:+
THCA	cis	rs7267979	0.873	rs6037062	ENSG00000276952.1	RP5-965G21.6	3.82	0.000153	0.0112	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25284915~25285588:-
THCA	cis	rs740160	0.681	rs10275381	ENSG00000244219.5	GS1-259H13.2	-3.82	0.000153	0.0112	-0.31	-0.17	Dehydroepiandrosterone sulphate levels;	chr7:99406836	chr7:99598066~99610813:+
THCA	cis	rs62289301	0.571	rs13104095	ENSG00000273133.1	RP11-799M12.2	3.82	0.000153	0.0112	0.21	0.17	Joint mobility (Beighton score);	chr4:15444387	chr4:15563698~15564253:-
THCA	cis	rs786425	0.833	rs7313628	ENSG00000278112.1	RP11-972P1.11	3.82	0.000153	0.0112	0.16	0.17	Pubertal anthropometrics;	chr12:123622468	chr12:123519390~123519856:-
THCA	cis	rs6088590	0.687	rs13044899	ENSG00000276073.1	RP5-1125A11.7	-3.82	0.000153	0.0112	-0.15	-0.17	Coronary artery disease;	chr20:34699274	chr20:33985617~33988989:-
THCA	cis	rs12023718	0.588	rs12042226	ENSG00000213057.5	C1orf220	3.82	0.000153	0.0112	0.18	0.17	Obesity-related traits;	chr1:178619970	chr1:178542752~178548889:+
THCA	cis	rs12023718	0.588	rs6674606	ENSG00000213057.5	C1orf220	3.82	0.000153	0.0112	0.18	0.17	Obesity-related traits;	chr1:178629882	chr1:178542752~178548889:+
THCA	cis	rs9291683	0.527	rs3822247	ENSG00000261490.1	RP11-448G15.3	-3.82	0.000153	0.0112	-0.11	-0.17	Bone mineral density;	chr4:10093047	chr4:10068089~10073019:-
THCA	cis	rs972578	0.837	rs7364152	ENSG00000230319.1	AL022476.2	3.82	0.000153	0.0112	0.19	0.17	Mean platelet volume;	chr22:42920661	chr22:43038585~43052366:+
THCA	cis	rs1577330	0.528	rs62542708	ENSG00000234676.1	IFT74-AS1	-3.82	0.000153	0.0112	-0.36	-0.17	IgG glycosylation;	chr9:27072430	chr9:26955780~26956295:-
THCA	cis	rs7095607	0.967	rs7916821	ENSG00000274008.1	Metazoa_SRP	3.82	0.000153	0.0112	0.19	0.17	Lung function (FVC);	chr10:68174212	chr10:69098496~69098794:+
THCA	cis	rs453301	0.653	rs1045529	ENSG00000253981.4	ALG1L13P	-3.82	0.000153	0.0112	-0.16	-0.17	Joint mobility (Beighton score);	chr8:9032588	chr8:8236003~8244667:-
THCA	cis	rs7818688	0.653	rs11775475	ENSG00000253528.2	RP11-347C18.4	-3.82	0.000153	0.0113	-0.27	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94893261	chr8:94974573~94974853:-
THCA	cis	rs3820928	0.605	rs6718767	ENSG00000212391.1	SNORA48	-3.82	0.000153	0.0113	-0.19	-0.17	Pulmonary function;	chr2:226936060	chr2:226968989~226969122:-
THCA	cis	rs3820928	0.605	rs13410141	ENSG00000212391.1	SNORA48	-3.82	0.000153	0.0113	-0.19	-0.17	Pulmonary function;	chr2:226940813	chr2:226968989~226969122:-
THCA	cis	rs765787	0.53	rs13329228	ENSG00000259539.1	CTD-2651B20.1	3.82	0.000153	0.0113	0.21	0.17	Uric acid levels;	chr15:45240819	chr15:45152664~45167526:-
THCA	cis	rs17122278	0.613	rs572126	ENSG00000255239.1	AP002954.6	3.82	0.000153	0.0113	0.26	0.17	Total cholesterol levels;	chr11:118488446	chr11:118688039~118690600:-
THCA	cis	rs7838490	0.504	rs1844054	ENSG00000253553.4	RP11-586K2.1	-3.82	0.000153	0.0113	-0.18	-0.17	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88551272	chr8:88326836~88737134:+
THCA	cis	rs7737355	0.947	rs31240	ENSG00000237714.1	P4HA2-AS1	3.82	0.000153	0.0113	0.24	0.17	Life satisfaction;	chr5:131475453	chr5:132184876~132192808:+
THCA	cis	rs6997458	1	rs6997458	ENSG00000253549.4	RP11-317J10.2	3.82	0.000153	0.0113	0.17	0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85361801	chr8:85441851~85464915:-
THCA	cis	rs10760158	0.832	rs4240466	ENSG00000226752.6	PSMD5-AS1	-3.82	0.000153	0.0113	-0.2	-0.17	Pulse pressure;	chr9:121277456	chr9:120824828~120854385:+
THCA	cis	rs71520386	0.898	rs12536144	ENSG00000228649.7	AC005682.5	-3.82	0.000153	0.0113	-0.27	-0.17	Fibrinogen levels;	chr7:22782890	chr7:22854178~22861579:+
THCA	cis	rs16976116	0.53	rs559069	ENSG00000279145.1	RP11-547D13.1	-3.82	0.000153	0.0113	-0.18	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55116264	chr15:55171972~55178175:-
THCA	cis	rs73193808	0.59	rs9981735	ENSG00000176054.6	RPL23P2	3.82	0.000153	0.0113	0.16	0.17	Coronary artery disease;	chr21:29195543	chr21:28997613~28998033:-
THCA	cis	rs73193808	0.59	rs9982010	ENSG00000176054.6	RPL23P2	3.82	0.000153	0.0113	0.16	0.17	Coronary artery disease;	chr21:29195855	chr21:28997613~28998033:-
THCA	cis	rs11960179	0.892	rs113341114	ENSG00000250066.1	RP11-141O11.1	-3.82	0.000153	0.0113	-0.32	-0.17	Glomerular filtration rate (creatinine);	chr5:68513450	chr5:68963246~68967845:+
THCA	cis	rs1005277	0.522	rs1208681	ENSG00000275858.1	RP11-291L22.8	3.82	0.000153	0.0113	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38450738~38451069:-
THCA	cis	rs2732480	0.5	rs11168468	ENSG00000257735.1	RP11-370I10.6	3.82	0.000153	0.0113	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48350945~48442411:+
THCA	cis	rs2898290	0.622	rs1478890	ENSG00000254527.1	ENPP7P12	-3.82	0.000153	0.0113	-0.22	-0.17	Systolic blood pressure;	chr8:11498093	chr8:12205759~12206389:-
THCA	cis	rs10435719	0.899	rs11250177	ENSG00000255495.1	AC145124.2	3.82	0.000153	0.0113	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:12194467~12196280:+
THCA	cis	rs7829975	0.66	rs10093926	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000153	0.0113	-0.19	-0.17	Mood instability;	chr8:8691510	chr8:9141424~9145435:+
THCA	cis	rs6570726	0.935	rs12663204	ENSG00000270638.1	RP3-466P17.1	3.82	0.000153	0.0113	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs12663205	ENSG00000270638.1	RP3-466P17.1	3.82	0.000153	0.0113	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs12663211	ENSG00000270638.1	RP3-466P17.1	3.82	0.000153	0.0113	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs422540	ENSG00000270638.1	RP3-466P17.1	3.82	0.000153	0.0113	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs409121	ENSG00000270638.1	RP3-466P17.1	3.82	0.000153	0.0113	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145735570~145737218:+
THCA	cis	rs71007656	1	rs71007656	ENSG00000275858.1	RP11-291L22.8	3.82	0.000153	0.0113	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.522	rs289648	ENSG00000275858.1	RP11-291L22.8	3.82	0.000153	0.0113	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38450738~38451069:-
THCA	cis	rs7166081	1	rs12900708	ENSG00000270964.1	RP11-502I4.3	-3.82	0.000153	0.0113	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67243102	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs12910062	ENSG00000270964.1	RP11-502I4.3	-3.82	0.000153	0.0113	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67244872	chr15:67541072~67542604:-
THCA	cis	rs6430585	0.941	rs7589832	ENSG00000231890.6	DARS-AS1	-3.82	0.000153	0.0113	-0.2	-0.17	Corneal structure;	chr2:135746531	chr2:135985176~136022593:+
THCA	cis	rs13053817	1	rs71324766	ENSG00000279159.1	RP3-394A18.1	3.82	0.000153	0.0113	0.17	0.17	Carotid atherosclerosis in HIV infection;	chr22:29443670	chr22:29978950~30028236:-
THCA	cis	rs12478296	1	rs11899408	ENSG00000261186.2	RP11-341N2.1	-3.82	0.000153	0.0113	-0.28	-0.17	Obesity-related traits;	chr2:242072479	chr2:242087351~242088457:-
THCA	cis	rs11105298	0.891	rs10858890	ENSG00000266347.2	AC068641.1	3.82	0.000153	0.0113	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89592833~89592927:+
THCA	cis	rs737008	1	rs737008	ENSG00000263080.1	RP11-485G7.5	-3.82	0.000153	0.0113	-0.21	-0.17	Obesity-related traits;	chr16:11281009	chr16:11341809~11345211:-
THCA	cis	rs4915077	0.773	rs4915069	ENSG00000226822.1	RP11-356N1.2	3.82	0.000153	0.0113	0.31	0.17	Hypothyroidism;	chr1:107722714	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.773	rs17019787	ENSG00000226822.1	RP11-356N1.2	3.82	0.000153	0.0113	0.31	0.17	Hypothyroidism;	chr1:107723344	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.773	rs17019790	ENSG00000226822.1	RP11-356N1.2	3.82	0.000153	0.0113	0.31	0.17	Hypothyroidism;	chr1:107723977	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.773	rs17019798	ENSG00000226822.1	RP11-356N1.2	3.82	0.000153	0.0113	0.31	0.17	Hypothyroidism;	chr1:107724593	chr1:108071482~108074519:+
THCA	cis	rs4886920	0.536	rs11857840	ENSG00000214646.7	RP11-114H24.4	-3.82	0.000153	0.0113	-0.22	-0.17	Neuroticism;	chr15:77864411	chr15:77941442~77944582:-
THCA	cis	rs5758659	0.569	rs133294	ENSG00000281538.1	RP4-669P10.20	3.82	0.000153	0.0113	0.16	0.17	Cognitive function;	chr22:41986801	chr22:42138060~42139726:+
THCA	cis	rs7176527	0.848	rs72630462	ENSG00000230373.7	GOLGA6L5P	3.82	0.000153	0.0113	0.25	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:84507885~84516814:-
THCA	cis	rs71520386	0.846	rs76474740	ENSG00000228649.7	AC005682.5	-3.82	0.000153	0.0113	-0.27	-0.17	Fibrinogen levels;	chr7:22775741	chr7:22854178~22861579:+
THCA	cis	rs71520386	0.846	rs77741999	ENSG00000228649.7	AC005682.5	-3.82	0.000153	0.0113	-0.27	-0.17	Fibrinogen levels;	chr7:22775785	chr7:22854178~22861579:+
THCA	cis	rs71520386	0.796	rs71520381	ENSG00000228649.7	AC005682.5	-3.82	0.000153	0.0113	-0.27	-0.17	Fibrinogen levels;	chr7:22776388	chr7:22854178~22861579:+
THCA	cis	rs4660456	0.913	rs545218	ENSG00000272145.1	NFYC-AS1	-3.82	0.000153	0.0113	-0.13	-0.17	Platelet count;	chr1:40675313	chr1:40690380~40692066:-
THCA	cis	rs10938353	0.678	rs60018658	ENSG00000273369.1	RP11-700J17.1	3.82	0.000153	0.0113	0.21	0.17	Body mass index;	chr4:44800149	chr4:44693946~44694386:-
THCA	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	3.82	0.000153	0.0113	0.19	0.17	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
THCA	cis	rs12940923	0.938	rs2680691	ENSG00000264672.4	SEPT4-AS1	-3.82	0.000153	0.0113	-0.24	-0.17	Circulating myeloperoxidase levels (plasma);	chr17:58328497	chr17:58519837~58556977:+
THCA	cis	rs6806253	0.73	rs56954786	ENSG00000239405.1	TMED10P2	3.82	0.000153	0.0113	0.27	0.17	Pit-and-Fissure caries;	chr3:128540870	chr3:128538020~128538631:+
THCA	cis	rs6806253	0.689	rs59420157	ENSG00000239405.1	TMED10P2	3.82	0.000153	0.0113	0.27	0.17	Pit-and-Fissure caries;	chr3:128540981	chr3:128538020~128538631:+
THCA	cis	rs41313321	1	rs41313321	ENSG00000272696.1	RP11-339B21.13	3.82	0.000153	0.0113	0.15	0.17	Coenzyme Q10 levels;	chr9:128289037	chr9:128316337~128316909:+
THCA	cis	rs6430585	0.941	rs60963894	ENSG00000231890.6	DARS-AS1	-3.82	0.000153	0.0113	-0.2	-0.17	Corneal structure;	chr2:135782100	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.941	rs10496737	ENSG00000231890.6	DARS-AS1	-3.82	0.000153	0.0113	-0.2	-0.17	Corneal structure;	chr2:135782513	chr2:135985176~136022593:+
THCA	cis	rs4660456	0.529	rs61779237	ENSG00000238287.1	RP11-656D10.3	3.82	0.000153	0.0113	0.21	0.17	Platelet count;	chr1:40685300	chr1:40493157~40508661:-
THCA	cis	rs8028182	1	rs8028182	ENSG00000260269.4	CTD-2323K18.1	-3.82	0.000153	0.0113	-0.27	-0.17	Sudden cardiac arrest;	chr15:75426328	chr15:75527150~75601205:-
THCA	cis	rs55692468	0.804	rs1579050	ENSG00000213197.3	AC012066.1	3.82	0.000153	0.0113	0.23	0.17	Intraocular pressure;	chr2:152508013	chr2:152389937~152390630:+
THCA	cis	rs4262150	0.883	rs11167589	ENSG00000253921.1	CTB-113P19.3	3.82	0.000153	0.0113	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152719145	chr5:151753992~151767247:+
THCA	cis	rs10805346	1	rs10805346	ENSG00000261490.1	RP11-448G15.3	-3.82	0.000153	0.0113	-0.11	-0.17	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:9918723	chr4:10068089~10073019:-
THCA	cis	rs6545883	0.868	rs7594191	ENSG00000212978.6	AC016747.3	-3.82	0.000153	0.0113	-0.18	-0.17	Tuberculosis;	chr2:61612883	chr2:61141592~61144969:-
THCA	cis	rs7819412	0.875	rs6981523	ENSG00000255495.1	AC145124.2	-3.82	0.000153	0.0113	-0.2	-0.17	Triglycerides;	chr8:11204283	chr8:12194467~12196280:+
THCA	cis	rs41342147	0.529	rs6718952	ENSG00000223374.1	AC005104.3	3.82	0.000153	0.0113	0.15	0.17	Vitiligo;	chr2:241279935	chr2:241351340~241353104:-
THCA	cis	rs12612619	0.704	rs11680633	ENSG00000272148.1	RP11-195B17.1	3.82	0.000153	0.0113	0.16	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27001341	chr2:27062428~27062907:-
THCA	cis	rs7267979	0.868	rs6138550	ENSG00000276952.1	RP5-965G21.6	3.82	0.000153	0.0113	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.903	rs6050481	ENSG00000276952.1	RP5-965G21.6	3.82	0.000153	0.0113	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.834	rs6115100	ENSG00000276952.1	RP5-965G21.6	3.82	0.000153	0.0113	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25284915~25285588:-
THCA	cis	rs17382723	0.83	rs113198353	ENSG00000229996.1	AC093585.6	3.82	0.000153	0.0113	0.23	0.17	Height;	chr2:241095059	chr2:241010045~241010744:-
THCA	cis	rs3758911	1	rs11212159	ENSG00000255353.1	RP11-382M14.1	-3.82	0.000153	0.0113	-0.22	-0.17	Coronary artery disease;	chr11:107326003	chr11:107176286~107177530:+
THCA	cis	rs12681366	0.881	rs2381793	ENSG00000261437.1	RP11-22C11.2	3.82	0.000153	0.0113	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94388167	chr8:94637285~94639467:-
THCA	cis	rs9796	0.621	rs12324159	ENSG00000247556.5	OIP5-AS1	3.82	0.000153	0.0113	0.14	0.17	Menopause (age at onset);	chr15:41170270	chr15:41283990~41309737:+
THCA	cis	rs7089973	0.61	rs12761122	ENSG00000236799.1	RP11-383C6.2	-3.82	0.000153	0.0113	-0.21	-0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114993789	chr10:114994657~114996593:+
THCA	cis	rs737008	0.922	rs1559394	ENSG00000263080.1	RP11-485G7.5	-3.82	0.000153	0.0113	-0.21	-0.17	Obesity-related traits;	chr16:11275348	chr16:11341809~11345211:-
THCA	cis	rs1908814	0.516	rs7812563	ENSG00000255495.1	AC145124.2	3.82	0.000153	0.0113	0.2	0.17	Neuroticism;	chr8:11936979	chr8:12194467~12196280:+
THCA	cis	rs153852	0.715	rs36729	ENSG00000243806.1	RPL7P18	-3.82	0.000153	0.0113	-0.23	-0.17	Cancer;	chr5:94827001	chr5:94825961~94826694:-
THCA	cis	rs6496044	0.634	rs4843066	ENSG00000259630.2	CTD-2262B20.1	-3.82	0.000153	0.0113	-0.19	-0.17	Interstitial lung disease;	chr15:85519680	chr15:85415228~85415633:+
THCA	cis	rs11771526	0.551	rs2392053	ENSG00000272905.1	RP11-265E18.1	-3.82	0.000153	0.0113	-0.22	-0.17	Body mass index;	chr7:32219444	chr7:32845394~32846061:+
THCA	cis	rs9926296	0.605	rs12448860	ENSG00000274627.1	RP11-104N10.2	-3.82	0.000153	0.0113	-0.17	-0.17	Vitiligo;	chr16:89783221	chr16:89516797~89522217:+
THCA	cis	rs4389656	0.826	rs395939	ENSG00000248677.1	CTD-2044J15.1	3.82	0.000153	0.0113	0.17	0.17	Coronary artery disease;	chr5:6734132	chr5:6686325~6707711:-
THCA	cis	rs9863	0.828	rs4765127	ENSG00000269938.1	RP11-214K3.20	-3.82	0.000153	0.0113	-0.2	-0.17	White blood cell count;	chr12:123975620	chr12:123968023~123968579:-
THCA	cis	rs13325613	0.834	rs36010446	ENSG00000223552.1	RP11-24F11.2	-3.82	0.000153	0.0113	-0.3	-0.17	Monocyte count;	chr3:46185233	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs17282797	ENSG00000223552.1	RP11-24F11.2	-3.82	0.000153	0.0113	-0.3	-0.17	Monocyte count;	chr3:46191273	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13080979	ENSG00000223552.1	RP11-24F11.2	-3.82	0.000153	0.0113	-0.3	-0.17	Monocyte count;	chr3:46192198	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13097666	ENSG00000223552.1	RP11-24F11.2	-3.82	0.000153	0.0113	-0.3	-0.17	Monocyte count;	chr3:46192975	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13098911	ENSG00000223552.1	RP11-24F11.2	-3.82	0.000153	0.0113	-0.3	-0.17	Monocyte count;	chr3:46193709	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34378541	ENSG00000223552.1	RP11-24F11.2	-3.82	0.000153	0.0113	-0.3	-0.17	Monocyte count;	chr3:46198157	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs17282922	ENSG00000223552.1	RP11-24F11.2	-3.82	0.000153	0.0113	-0.3	-0.17	Monocyte count;	chr3:46198680	chr3:46364955~46407059:-
THCA	cis	rs13108904	0.87	rs2279281	ENSG00000254094.1	AC078852.1	-3.82	0.000153	0.0113	-0.2	-0.17	Obesity-related traits;	chr4:1251489	chr4:1356581~1358075:+
THCA	cis	rs4237845	0.816	rs61935769	ENSG00000270039.1	RP11-571M6.17	-3.82	0.000153	0.0113	-0.19	-0.17	Intelligence (multi-trait analysis);	chr12:57900561	chr12:57803838~57804415:+
THCA	cis	rs7336933	0.866	rs4941411	ENSG00000278338.3	VWA8-AS1	-3.82	0.000153	0.0113	-0.31	-0.17	Calcium levels;	chr13:41897362	chr13:41955808~41981565:+
THCA	cis	rs7296418	0.699	rs1109559	ENSG00000256092.2	RP13-942N8.1	3.82	0.000154	0.0113	0.13	0.17	Platelet count;	chr12:123273314	chr12:123363868~123366113:+
THCA	cis	rs1923539	0.549	rs1923542	ENSG00000225484.5	NUTM2B-AS1	3.82	0.000154	0.0113	0.22	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79909470	chr10:79663088~79826594:-
THCA	cis	rs5758511	0.68	rs5758681	ENSG00000270083.1	RP1-257I20.14	-3.82	0.000154	0.0113	-0.22	-0.17	Birth weight;	chr22:42249085	chr22:42089630~42090028:-
THCA	cis	rs7267979	0.866	rs2424698	ENSG00000276952.1	RP5-965G21.6	3.82	0.000154	0.0113	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25284915~25285588:-
THCA	cis	rs78487399	0.808	rs74608713	ENSG00000234936.1	AC010883.5	3.82	0.000154	0.0113	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536400	chr2:43229573~43233394:+
THCA	cis	rs875971	0.545	rs4441996	ENSG00000273024.4	INTS4P2	3.82	0.000154	0.0113	0.21	0.17	Aortic root size;	chr7:66123233	chr7:65647864~65715661:+
THCA	cis	rs4713118	0.868	rs2893928	ENSG00000261839.1	RP1-265C24.8	3.82	0.000154	0.0113	0.21	0.17	Parkinson's disease;	chr6:27770651	chr6:28136849~28139678:+
THCA	cis	rs6600671	0.691	rs6600662	ENSG00000226067.5	CH17-118O6.2	3.82	0.000154	0.0113	0.18	0.17	Hip geometry;	chr1:121488992	chr1:120913275~121009291:+
THCA	cis	rs6019512	1	rs6019512	ENSG00000227431.4	CSE1L-AS1	-3.82	0.000154	0.0113	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48909470	chr20:49040463~49046044:-
THCA	cis	rs13113518	0.812	rs6830409	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55522229	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs2035692	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55528801	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs4507426	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55529387	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs2035691	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55529786	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.756	rs11939652	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55532542	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs13107810	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55542243	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs7667741	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55544621	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs13140590	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55548666	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs13116035	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55561218	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.783	rs2171618	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55564241	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.783	rs7690837	ENSG00000223305.1	RN7SKP30	3.82	0.000154	0.0113	0.22	0.17	Height;	chr4:55575856	chr4:55540502~55540835:-
THCA	cis	rs6472827	0.811	rs7841494	ENSG00000253983.2	RP1-16A9.1	-3.82	0.000154	0.0113	-0.29	-0.17	Uterine fibroids;	chr8:74212425	chr8:74199396~74208441:+
THCA	cis	rs1411478	1	rs4652547	ENSG00000243155.1	RP11-46A10.5	3.82	0.000154	0.0113	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984953	chr1:180944042~180976482:-
THCA	cis	rs1411478	1	rs4652548	ENSG00000243155.1	RP11-46A10.5	3.82	0.000154	0.0113	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984994	chr1:180944042~180976482:-
THCA	cis	rs2688608	0.592	rs11000758	ENSG00000272140.2	RP11-574K11.29	3.82	0.000154	0.0113	0.15	0.17	Inflammatory bowel disease;	chr10:73733852	chr10:73703735~73713581:-
THCA	cis	rs67478160	0.619	rs12885018	ENSG00000258534.1	CTD-2134A5.4	-3.82	0.000154	0.0113	-0.17	-0.17	Schizophrenia;	chr14:103807475	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs12891175	ENSG00000258534.1	CTD-2134A5.4	-3.82	0.000154	0.0113	-0.17	-0.17	Schizophrenia;	chr14:103807829	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.595	rs12889993	ENSG00000258534.1	CTD-2134A5.4	-3.82	0.000154	0.0113	-0.17	-0.17	Schizophrenia;	chr14:103807957	chr14:103854366~103880111:-
THCA	cis	rs285757	0.842	rs285772	ENSG00000259064.2	RP11-386M24.5	-3.82	0.000154	0.0113	-0.27	-0.17	HIV-1 susceptibility;	chr15:92648520	chr15:92627073~92627414:+
THCA	cis	rs459571	0.92	rs460154	ENSG00000235106.7	LINC00094	3.82	0.000154	0.0113	0.15	0.17	Platelet distribution width;	chr9:134044187	chr9:134025439~134034666:+
THCA	cis	rs4578769	0.569	rs9948922	ENSG00000273232.1	RP11-370A5.2	3.82	0.000154	0.0113	0.24	0.17	Eosinophil percentage of white cells;	chr18:22930198	chr18:22882825~22883357:-
THCA	cis	rs944289	0.561	rs395660	ENSG00000258844.1	RP11-259K15.2	-3.82	0.000154	0.0113	-0.16	-0.17	Thyroid cancer;	chr14:36063593	chr14:36214607~36235608:+
THCA	cis	rs10454142	0.7	rs11690845	ENSG00000202227.1	RNU6-282P	-3.82	0.000154	0.0113	-0.21	-0.17	Sex hormone-binding globulin levels;	chr2:48357687	chr2:48501922~48502024:-
THCA	cis	rs2180341	0.781	rs6913350	ENSG00000220522.2	RP1-177A13.1	3.82	0.000154	0.0113	0.21	0.17	Breast cancer;	chr6:127249415	chr6:127416535~127416952:-
THCA	cis	rs10089	1	rs10061367	ENSG00000245937.6	LINC01184	3.82	0.000154	0.0113	0.2	0.17	Ileal carcinoids;	chr5:128113329	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs3816006	ENSG00000245937.6	LINC01184	3.82	0.000154	0.0113	0.2	0.17	Ileal carcinoids;	chr5:128114889	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs4835943	ENSG00000245937.6	LINC01184	3.82	0.000154	0.0113	0.2	0.17	Ileal carcinoids;	chr5:128121877	chr5:127940426~128083172:-
THCA	cis	rs10089	0.857	rs7718286	ENSG00000245937.6	LINC01184	3.82	0.000154	0.0113	0.2	0.17	Ileal carcinoids;	chr5:128123722	chr5:127940426~128083172:-
THCA	cis	rs3808502	0.527	rs56177149	ENSG00000206014.6	OR7E161P	-3.82	0.000154	0.0113	-0.21	-0.17	Neuroticism;	chr8:11389789	chr8:11928597~11929563:-
THCA	cis	rs6142618	0.811	rs4911207	ENSG00000224452.1	RSL24D1P6	3.82	0.000154	0.0113	0.22	0.17	Inflammatory bowel disease;	chr20:32258714	chr20:32170390~32170790:-
THCA	cis	rs321358	1	rs321353	ENSG00000271390.1	RP11-89C3.3	-3.82	0.000154	0.0113	-0.29	-0.17	Body mass index;	chr11:111123841	chr11:111089870~111090368:-
THCA	cis	rs321358	1	rs321358	ENSG00000271390.1	RP11-89C3.3	3.82	0.000154	0.0113	0.29	0.17	Body mass index;	chr11:111125247	chr11:111089870~111090368:-
THCA	cis	rs14027	0.921	rs16893140	ENSG00000279347.1	RP11-85I17.2	-3.82	0.000154	0.0113	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767007	chr8:119838736~119840385:-
THCA	cis	rs12476592	0.602	rs7570031	ENSG00000242412.1	DBIL5P2	3.82	0.000154	0.0113	0.22	0.17	Childhood ear infection;	chr2:63565131	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.543	rs12105140	ENSG00000242412.1	DBIL5P2	3.82	0.000154	0.0113	0.22	0.17	Childhood ear infection;	chr2:63570084	chr2:63117851~63119542:-
THCA	cis	rs56046484	0.956	rs17541572	ENSG00000259630.2	CTD-2262B20.1	3.82	0.000154	0.0113	0.26	0.17	Testicular germ cell tumor;	chr15:85122016	chr15:85415228~85415633:+
THCA	cis	rs1005277	0.54	rs2145487	ENSG00000275858.1	RP11-291L22.8	3.82	0.000154	0.0113	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38450738~38451069:-
THCA	cis	rs459571	0.959	rs455381	ENSG00000235106.7	LINC00094	3.82	0.000154	0.0113	0.15	0.17	Platelet distribution width;	chr9:134040455	chr9:134025439~134034666:+
THCA	cis	rs9473147	0.843	rs6904933	ENSG00000270761.1	RP11-385F7.1	-3.82	0.000154	0.0113	-0.14	-0.17	Platelet distribution width;Mean platelet volume;	chr6:47660822	chr6:47477243~47477572:-
THCA	cis	rs1876905	0.764	rs4947106	ENSG00000272356.1	RP5-1112D6.8	3.82	0.000154	0.0113	0.17	0.17	Mean corpuscular hemoglobin;	chr6:111100163	chr6:111309203~111313517:+
THCA	cis	rs2408955	0.542	rs7975632	ENSG00000257735.1	RP11-370I10.6	3.82	0.000154	0.0113	0.2	0.17	Glycated hemoglobin levels;	chr12:48049265	chr12:48350945~48442411:+
THCA	cis	rs6545883	0.783	rs7579651	ENSG00000212978.6	AC016747.3	3.82	0.000154	0.0113	0.19	0.17	Tuberculosis;	chr2:61573144	chr2:61141592~61144969:-
THCA	cis	rs948562	1	rs11229535	ENSG00000280010.1	AP001350.4	3.82	0.000154	0.0113	0.27	0.17	Lymphoma;	chr11:58580913	chr11:58627435~58628528:+
THCA	cis	rs14027	0.921	rs7813651	ENSG00000245330.4	KB-1471A8.1	3.82	0.000154	0.0113	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs35496588	ENSG00000245330.4	KB-1471A8.1	-3.82	0.000154	0.0113	-0.18	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119867419~119874488:-
THCA	cis	rs910316	1	rs3742778	ENSG00000259138.1	RP11-950C14.7	-3.82	0.000154	0.0113	-0.15	-0.17	Height;	chr14:75071514	chr14:75127153~75136930:+
THCA	cis	rs4074961	0.604	rs4411102	ENSG00000233621.1	LINC01137	-3.82	0.000154	0.0113	-0.18	-0.17	Axial length;	chr1:37597823	chr1:37454879~37474411:-
THCA	cis	rs10954779	0.764	rs2553280	ENSG00000127589.4	TUBBP1	3.82	0.000154	0.0113	0.2	0.17	Intelligence (multi-trait analysis);	chr8:31137345	chr8:30351873~30353518:+
THCA	cis	rs6957923	0.967	rs10950947	ENSG00000234286.1	AC006026.13	3.82	0.000154	0.0113	0.23	0.17	Height;	chr7:23464135	chr7:23680195~23680786:-
THCA	cis	rs12681366	0.683	rs1379246	ENSG00000261437.1	RP11-22C11.2	-3.82	0.000154	0.0113	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94361073	chr8:94637285~94639467:-
THCA	cis	rs7632954	0.669	rs7642129	ENSG00000227110.5	LMCD1-AS1	3.82	0.000154	0.0113	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8489062	chr3:7952805~8611924:-
THCA	cis	rs1005277	0.54	rs4934907	ENSG00000275858.1	RP11-291L22.8	3.82	0.000154	0.0113	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.54	rs11011351	ENSG00000275858.1	RP11-291L22.8	3.82	0.000154	0.0113	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38450738~38451069:-
THCA	cis	rs4604234	0.901	rs112709609	ENSG00000260645.1	RP11-250B2.5	-3.82	0.000154	0.0113	-0.32	-0.17	Cancer;	chr6:80388244	chr6:80466958~80469080:+
THCA	cis	rs7665090	1	rs11727546	ENSG00000251288.2	RP11-10L12.2	-3.82	0.000154	0.0113	-0.22	-0.17	Primary biliary cholangitis;	chr4:102636507	chr4:102751401~102752641:+
THCA	cis	rs11105298	0.891	rs3741898	ENSG00000266347.2	AC068641.1	3.82	0.000154	0.0113	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs3741899	ENSG00000266347.2	AC068641.1	3.82	0.000154	0.0113	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs10858906	ENSG00000266347.2	AC068641.1	3.82	0.000154	0.0113	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89592833~89592927:+
THCA	cis	rs2625529	0.701	rs12911154	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000154	0.0113	-0.24	-0.17	Red blood cell count;	chr15:71920312	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs7170754	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000154	0.0113	-0.24	-0.17	Red blood cell count;	chr15:71926253	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs7170461	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000154	0.0113	-0.24	-0.17	Red blood cell count;	chr15:71926258	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs12917428	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000154	0.0113	-0.24	-0.17	Red blood cell count;	chr15:71929657	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.701	rs2306490	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000154	0.0113	-0.24	-0.17	Red blood cell count;	chr15:71935496	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.701	rs62025574	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000154	0.0113	-0.24	-0.17	Red blood cell count;	chr15:71943734	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.878	rs71395051	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000154	0.0113	-0.24	-0.17	Red blood cell count;	chr15:71947448	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs11072339	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000154	0.0113	-0.24	-0.17	Red blood cell count;	chr15:71954849	chr15:71818396~71823384:+
THCA	cis	rs12681366	0.623	rs10106494	ENSG00000253175.1	RP11-267M23.6	3.82	0.000154	0.0113	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94471226	chr8:94565036~94565715:+
THCA	cis	rs6894268	0.751	rs28410430	ENSG00000273549.1	Metazoa_SRP	-3.82	0.000154	0.0113	-0.22	-0.17	Eating disorders;	chr5:179595112	chr5:179629151~179629410:+
THCA	cis	rs9467773	0.511	rs11755443	ENSG00000124549.13	BTN2A3P	3.82	0.000154	0.0113	0.16	0.17	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26421391~26432383:+
THCA	cis	rs4792901	0.802	rs2279191	ENSG00000267151.3	RP11-100E5.2	3.82	0.000154	0.0113	0.19	0.17	Dupuytren's disease;	chr17:43493059	chr17:43444707~43451200:+
THCA	cis	rs874628	0.686	rs885683	ENSG00000268650.3	AC068499.10	-3.82	0.000154	0.0113	-0.2	-0.17	Multiple sclerosis;	chr19:18133880	chr19:18204730~18220480:+
THCA	cis	rs7707921	0.881	rs12108833	ENSG00000251374.1	RPS23P5	3.82	0.000154	0.0113	0.25	0.17	Breast cancer;	chr5:82075936	chr5:82265157~82265259:-
THCA	cis	rs2039553	0.639	rs9530958	ENSG00000227354.5	RBM26-AS1	-3.82	0.000154	0.0113	-0.17	-0.17	Pancreatic cancer;	chr13:79780752	chr13:79406309~79424328:+
THCA	cis	rs11030122	0.959	rs7120336	ENSG00000230593.3	AC090804.1	3.82	0.000154	0.0113	0.23	0.17	Mean platelet volume;Platelet distribution width;	chr11:3880048	chr11:3892398~3892887:-
THCA	cis	rs2290416	0.892	rs58774517	ENSG00000253931.1	RP11-909N17.2	3.82	0.000154	0.0113	0.36	0.17	Attention deficit hyperactivity disorder;	chr8:143574594	chr8:143412749~143417054:+
THCA	cis	rs9379850	0.528	rs67575965	ENSG00000216331.1	HIST1H1PS1	3.82	0.000154	0.0113	0.25	0.17	Intelligence (multi-trait analysis);	chr6:26196365	chr6:26195566~26195771:+
THCA	cis	rs4767841	0.775	rs203330	ENSG00000248636.5	RP11-768F21.1	-3.82	0.000154	0.0113	-0.18	-0.17	Urgency urinary incontinence;	chr12:119771954	chr12:119387987~119668079:-
THCA	cis	rs7826238	0.517	rs35144760	ENSG00000254153.1	CTA-398F10.2	3.82	0.000154	0.0113	0.22	0.17	Systolic blood pressure;	chr8:8504213	chr8:8456909~8461337:-
THCA	cis	rs2836974	0.965	rs2836965	ENSG00000255568.3	BRWD1-AS2	-3.82	0.000154	0.0113	-0.15	-0.17	Cognitive function;	chr21:39261705	chr21:39313935~39314962:+
THCA	cis	rs944289	0.646	rs367883	ENSG00000258844.1	RP11-259K15.2	-3.82	0.000154	0.0113	-0.15	-0.17	Thyroid cancer;	chr14:36063400	chr14:36214607~36235608:+
THCA	cis	rs944289	0.646	rs368181	ENSG00000258844.1	RP11-259K15.2	-3.82	0.000154	0.0113	-0.15	-0.17	Thyroid cancer;	chr14:36065621	chr14:36214607~36235608:+
THCA	cis	rs13108904	0.901	rs7673398	ENSG00000254094.1	AC078852.1	-3.82	0.000154	0.0113	-0.19	-0.17	Obesity-related traits;	chr4:1306289	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.901	rs7668661	ENSG00000254094.1	AC078852.1	-3.82	0.000154	0.0113	-0.19	-0.17	Obesity-related traits;	chr4:1306384	chr4:1356581~1358075:+
THCA	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	3.82	0.000154	0.0113	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
THCA	cis	rs1577917	1	rs6923148	ENSG00000220563.1	PKMP3	3.82	0.000154	0.0113	0.13	0.17	Response to antipsychotic treatment;	chr6:86058068	chr6:85659892~85660606:-
THCA	cis	rs6724465	0.673	rs77397607	ENSG00000272644.1	RP11-33O4.1	3.82	0.000154	0.0113	0.24	0.17	Height;	chr2:219157074	chr2:219069354~219069809:-
THCA	cis	rs2562456	0.516	rs56072098	ENSG00000268658.4	LINC00664	-3.82	0.000154	0.0113	-0.25	-0.17	Pain;	chr19:21469158	chr19:21483374~21503238:+
THCA	cis	rs7819412	0.775	rs34094119	ENSG00000254948.1	OR7E158P	3.82	0.000154	0.0113	0.21	0.17	Triglycerides;	chr8:11078388	chr8:11919900~11920809:-
THCA	cis	rs189798	0.807	rs330905	ENSG00000233609.3	RP11-62H7.2	3.82	0.000154	0.0114	0.17	0.17	Myopia (pathological);	chr8:9136041	chr8:8961200~8979025:+
THCA	cis	rs73242632	0.5	rs11726321	ENSG00000269949.1	RP11-738E22.3	-3.82	0.000154	0.0114	-0.3	-0.17	Congenital heart disease (maternal effect);	chr4:57054738	chr4:56960927~56961373:-
THCA	cis	rs73242632	0.5	rs1718873	ENSG00000269949.1	RP11-738E22.3	-3.82	0.000154	0.0114	-0.3	-0.17	Congenital heart disease (maternal effect);	chr4:57054933	chr4:56960927~56961373:-
THCA	cis	rs73242632	0.5	rs1718874	ENSG00000269949.1	RP11-738E22.3	-3.82	0.000154	0.0114	-0.3	-0.17	Congenital heart disease (maternal effect);	chr4:57054967	chr4:56960927~56961373:-
THCA	cis	rs854765	0.583	rs11078405	ENSG00000281749.1	Y_RNA	3.82	0.000154	0.0114	0.22	0.17	Total body bone mineral density;	chr17:17921664	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs11871899	ENSG00000281749.1	Y_RNA	3.82	0.000154	0.0114	0.22	0.17	Total body bone mineral density;	chr17:17923434	chr17:18001101~18001195:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000275400.1	RP4-756H11.5	-3.82	0.000154	0.0114	-0.16	-0.17	Calcium levels;	chr7:65941231	chr7:66553805~66554199:-
THCA	cis	rs17122278	1	rs17122269	ENSG00000255239.1	AP002954.6	-3.82	0.000154	0.0114	-0.32	-0.17	Total cholesterol levels;	chr11:118574560	chr11:118688039~118690600:-
THCA	cis	rs17412738	0.51	rs78208917	ENSG00000248724.5	NPHP3-AS1	-3.82	0.000154	0.0114	-0.38	-0.17	Blood protein levels;	chr3:132510864	chr3:132721750~132874223:+
THCA	cis	rs418053	0.694	rs412970	ENSG00000272209.1	RP3-500L14.2	3.82	0.000154	0.0114	0.19	0.17	Breast cancer;	chr6:13719441	chr6:13825432~13826574:+
THCA	cis	rs7829975	0.56	rs6994131	ENSG00000254153.1	CTA-398F10.2	3.82	0.000154	0.0114	0.2	0.17	Mood instability;	chr8:8693448	chr8:8456909~8461337:-
THCA	cis	rs7927592	0.513	rs630225	ENSG00000160172.9	FAM86C2P	3.82	0.000154	0.0114	0.16	0.17	Total body bone mineral density;	chr11:68427143	chr11:67791648~67805336:-
THCA	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-3.82	0.000154	0.0114	-0.18	-0.17	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000261839.1	RP1-265C24.8	3.82	0.000154	0.0114	0.17	0.17	Cardiac Troponin-T levels;	chr6:28164978	chr6:28136849~28139678:+
THCA	cis	rs62244186	0.659	rs9819766	ENSG00000214820.3	MPRIPP1	3.82	0.000154	0.0114	0.18	0.17	Depressive symptoms;	chr3:44479488	chr3:44579938~44581026:-
THCA	cis	rs1383484	0.761	rs28401196	ENSG00000225151.9	GOLGA2P7	3.82	0.000154	0.0114	0.24	0.17	Height;	chr15:83878609	chr15:84199311~84230136:-
THCA	cis	rs28735056	0.875	rs4239346	ENSG00000261126.6	RP11-795F19.1	3.82	0.000154	0.0114	0.14	0.17	Schizophrenia;	chr18:79881226	chr18:80046900~80095482:+
THCA	cis	rs7709377	0.516	rs10519444	ENSG00000271918.1	CTD-2287O16.5	3.82	0.000154	0.0114	0.17	0.17	Metabolite levels  (X-11787);	chr5:116137726	chr5:116083807~116085416:-
THCA	cis	rs1371614	0.61	rs3820822	ENSG00000272148.1	RP11-195B17.1	-3.81	0.000154	0.0114	-0.16	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26932994	chr2:27062428~27062907:-
THCA	cis	rs7088591	1	rs61028733	ENSG00000276818.1	AC026393.1	3.81	0.000154	0.0114	0.35	0.17	Blood pressure;	chr10:57965666	chr10:57095699~57095781:+
THCA	cis	rs11756659	0.505	rs16891142	ENSG00000272810.1	U91328.22	3.81	0.000154	0.0114	0.15	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25898911	chr6:26013241~26013757:+
THCA	cis	rs5753037	0.676	rs737945	ENSG00000279699.1	RP1-102K2.9	3.81	0.000154	0.0114	0.16	0.17	Type 1 diabetes;	chr22:29806785	chr22:30275215~30276951:-
THCA	cis	rs7259376	0.84	rs1985135	ENSG00000269345.1	VN1R85P	3.81	0.000154	0.0114	0.19	0.17	Menopause (age at onset);	chr19:22340776	chr19:22174766~22175191:-
THCA	cis	rs1502337	0.532	rs6606684	ENSG00000278993.1	RP3-424M6.4	-3.81	0.000154	0.0114	-0.27	-0.17	Body mass index;	chr12:110362361	chr12:110501614~110503441:+
THCA	cis	rs7089973	0.604	rs2181563	ENSG00000228169.3	PPIAP19	3.81	0.000154	0.0114	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114844585	chr10:114690143~114690634:-
THCA	cis	rs9905704	0.918	rs369184	ENSG00000224738.1	AC099850.1	3.81	0.000154	0.0114	0.23	0.17	Testicular germ cell tumor;	chr17:58631725	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs444393	ENSG00000224738.1	AC099850.1	3.81	0.000154	0.0114	0.23	0.17	Testicular germ cell tumor;	chr17:58631861	chr17:59106598~59118267:+
THCA	cis	rs1106529	0.515	rs10923697	ENSG00000231365.4	RP11-418J17.1	3.81	0.000154	0.0114	0.23	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118913367	chr1:119140396~119275973:+
THCA	cis	rs12935229	0.756	rs2077814	ENSG00000260922.1	RP11-538I12.3	-3.81	0.000154	0.0114	-0.26	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77269914	chr16:77234877~77290934:+
THCA	cis	rs10266483	1	rs10266483	ENSG00000228653.2	HNRNPCP7	-3.81	0.000154	0.0114	-0.15	-0.17	Response to statin therapy;	chr7:64272953	chr7:64500825~64501729:+
THCA	cis	rs2076295	0.503	rs34533690	ENSG00000261189.1	RP3-512B11.3	-3.81	0.000155	0.0114	-0.17	-0.17	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7564652	chr6:7540451~7541338:-
THCA	cis	rs34792	0.513	rs255002	ENSG00000207425.1	Y_RNA	-3.81	0.000155	0.0114	-0.19	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15484406	chr16:14915457~14915556:-
THCA	cis	rs1853665	1	rs1951931	ENSG00000218358.2	RAET1K	-3.81	0.000155	0.0114	-0.29	-0.17	Radiation response;	chr6:149975762	chr6:149998019~150005157:-
THCA	cis	rs7259376	0.905	rs8112246	ENSG00000270947.1	AC025811.3	3.81	0.000155	0.0114	0.18	0.17	Menopause (age at onset);	chr19:22384645	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.846	rs4024624	ENSG00000270947.1	AC025811.3	3.81	0.000155	0.0114	0.18	0.17	Menopause (age at onset);	chr19:22385462	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.846	rs5014503	ENSG00000270947.1	AC025811.3	3.81	0.000155	0.0114	0.18	0.17	Menopause (age at onset);	chr19:22385538	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.818	rs8101997	ENSG00000270947.1	AC025811.3	3.81	0.000155	0.0114	0.18	0.17	Menopause (age at onset);	chr19:22385630	chr19:22455988~22456459:+
THCA	cis	rs7294478	0.664	rs10843440	ENSG00000205885.6	C1RL-AS1	3.81	0.000155	0.0114	0.12	0.17	Neuritic plaque;	chr12:7110842	chr12:7108052~7122501:+
THCA	cis	rs11105298	0.891	rs4842662	ENSG00000266347.2	AC068641.1	3.81	0.000155	0.0114	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs3825330	ENSG00000266347.2	AC068641.1	3.81	0.000155	0.0114	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89592833~89592927:+
THCA	cis	rs6088590	0.648	rs6058105	ENSG00000269202.1	RP4-614O4.12	-3.81	0.000155	0.0114	-0.14	-0.17	Coronary artery disease;	chr20:34683915	chr20:35201747~35203288:-
THCA	cis	rs1411478	1	rs12744212	ENSG00000243155.1	RP11-46A10.5	3.81	0.000155	0.0114	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180983380	chr1:180944042~180976482:-
THCA	cis	rs7818688	0.614	rs16917082	ENSG00000253528.2	RP11-347C18.4	-3.81	0.000155	0.0114	-0.25	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94849597	chr8:94974573~94974853:-
THCA	cis	rs9911578	0.967	rs3826353	ENSG00000224738.1	AC099850.1	3.81	0.000155	0.0114	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58997938	chr17:59106598~59118267:+
THCA	cis	rs1267303	0.537	rs59935547	ENSG00000232022.5	FAAHP1	3.81	0.000155	0.0114	0.2	0.17	Monobrow;	chr1:46535751	chr1:46432129~46445521:+
THCA	cis	rs7656342	0.651	rs13127001	ENSG00000242034.1	RP11-1396O13.1	3.81	0.000155	0.0114	0.2	0.17	Gut microbiota (bacterial taxa);	chr4:9729591	chr4:9553614~9553985:-
THCA	cis	rs67478160	0.679	rs8011109	ENSG00000258534.1	CTD-2134A5.4	-3.81	0.000155	0.0114	-0.17	-0.17	Schizophrenia;	chr14:103813637	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.655	rs4900598	ENSG00000258534.1	CTD-2134A5.4	-3.81	0.000155	0.0114	-0.17	-0.17	Schizophrenia;	chr14:103815204	chr14:103854366~103880111:-
THCA	cis	rs910316	1	rs7142235	ENSG00000259138.1	RP11-950C14.7	3.81	0.000155	0.0114	0.15	0.17	Height;	chr14:75093260	chr14:75127153~75136930:+
THCA	cis	rs28830936	0.966	rs3179542	ENSG00000250379.1	RP11-23P13.4	3.81	0.000155	0.0114	0.2	0.17	Diastolic blood pressure;	chr15:41825925	chr15:41825099~41827936:-
THCA	cis	rs875971	0.545	rs12670811	ENSG00000232559.3	GS1-124K5.12	3.81	0.000155	0.0114	0.19	0.17	Aortic root size;	chr7:66358032	chr7:66554588~66576923:-
THCA	cis	rs2455799	0.613	rs11128762	ENSG00000270409.1	RP11-44D5.1	-3.81	0.000155	0.0114	-0.19	-0.17	Mean platelet volume;	chr3:15841932	chr3:15732252~15733470:+
THCA	cis	rs1667255	1	rs7243588	ENSG00000266521.1	RP11-650P15.1	3.81	0.000155	0.0114	0.22	0.17	Retinol levels;	chr18:31580649	chr18:31496645~31497195:-
THCA	cis	rs853679	0.607	rs13204012	ENSG00000272009.1	RP1-313I6.12	-3.81	0.000155	0.0114	-0.33	-0.17	Depression;	chr6:28233753	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13205211	ENSG00000272009.1	RP1-313I6.12	-3.81	0.000155	0.0114	-0.33	-0.17	Depression;	chr6:28235278	chr6:28078792~28081130:-
THCA	cis	rs4791641	1	rs4791641	ENSG00000178977.3	LINC00324	3.81	0.000155	0.0114	0.19	0.17	Red blood cell count;LDL cholesterol;Hematocrit;Hemoglobin concentration;LDL cholesterol levels;	chr17:8257831	chr17:8220642~8224043:-
THCA	cis	rs9905704	0.836	rs12952429	ENSG00000224738.1	AC099850.1	3.81	0.000155	0.0114	0.22	0.17	Testicular germ cell tumor;	chr17:58765709	chr17:59106598~59118267:+
THCA	cis	rs4763879	0.634	rs917913	ENSG00000214776.8	RP11-726G1.1	-3.81	0.000155	0.0114	-0.21	-0.17	Type 1 diabetes;	chr12:9707040	chr12:9467552~9576275:+
THCA	cis	rs2886497	0.624	rs10828441	ENSG00000224215.1	RP11-371A19.2	-3.81	0.000155	0.0114	-0.2	-0.17	Major depression and alcohol dependence;	chr10:23396527	chr10:23343957~23345181:+
THCA	cis	rs73173548	0.502	rs6867204	ENSG00000247828.6	TMEM161B-AS1	3.81	0.000155	0.0114	0.16	0.17	Macular telangiectasia type 2;	chr5:88446423	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs34933255	ENSG00000247828.6	TMEM161B-AS1	3.81	0.000155	0.0114	0.16	0.17	Macular telangiectasia type 2;	chr5:88446492	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs12188494	ENSG00000247828.6	TMEM161B-AS1	3.81	0.000155	0.0114	0.16	0.17	Macular telangiectasia type 2;	chr5:88447747	chr5:88268895~88436685:+
THCA	cis	rs9532669	0.89	rs12865032	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40873801	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs34123829	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40873808	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4488324	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40873864	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4288867	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40873880	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4415896	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40874001	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs4415897	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40874035	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4389021	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40874209	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.824	rs4628828	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40874369	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.737	rs34354179	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40874424	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9594445	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40874859	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9594446	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40874863	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4402423	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40875010	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.963	rs9532628	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40875172	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532629	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40875193	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7491149	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40875216	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532630	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40875472	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs4306385	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40875641	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4406939	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40876108	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4628824	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40876217	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532632	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40876309	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532633	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40876332	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532634	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40876369	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532635	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40876397	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs12428959	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40876638	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.895	rs4942009	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40877243	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4334153	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40877737	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4309270	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40877827	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4270044	ENSG00000229473.2	RGS17P1	3.81	0.000155	0.0114	0.22	0.17	Cervical cancer;	chr13:40877923	chr13:40992779~40993331:-
THCA	cis	rs2625529	0.824	rs12899485	ENSG00000260037.4	CTD-2524L6.3	3.81	0.000155	0.0114	0.24	0.17	Red blood cell count;	chr15:71850874	chr15:71818396~71823384:+
THCA	cis	rs934734	0.509	rs12185577	ENSG00000214533.3	KRT18P33	-3.81	0.000155	0.0114	-0.21	-0.17	Rheumatoid arthritis;	chr2:65432354	chr2:65666695~65667737:+
THCA	cis	rs13113518	0.783	rs11133389	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55486718	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs4865001	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55490176	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs4864543	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55490228	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs6825774	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55491150	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs3805153	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55493557	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.756	rs7658446	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55495262	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.776	rs13124436	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55502504	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.783	rs6843997	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55508982	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.783	rs12508367	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55509442	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs2272073	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55510177	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs4865003	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0114	0.21	0.17	Height;	chr4:55514802	chr4:55547112~55547889:+
THCA	cis	rs11672691	0.756	rs8107333	ENSG00000268355.1	AC006129.1	-3.81	0.000155	0.0114	-0.22	-0.17	Prostate cancer;	chr19:41481965	chr19:41531206~41532174:+
THCA	cis	rs1576263	0.504	rs1854411	ENSG00000230939.1	RP11-314C16.1	-3.81	0.000155	0.0114	-0.19	-0.17	Photic sneeze reflex;	chr6:8545771	chr6:8784178~8785445:+
THCA	cis	rs4879656	0.564	rs7864363	ENSG00000225693.1	LAGE3P1	3.81	0.000155	0.0114	0.18	0.17	Menopause (age at onset);	chr9:33022002	chr9:33019682~33020165:-
THCA	cis	rs714027	0.585	rs3958027	ENSG00000279699.1	RP1-102K2.9	3.81	0.000155	0.0114	0.18	0.17	Lymphocyte counts;	chr22:29848846	chr22:30275215~30276951:-
THCA	cis	rs714027	0.585	rs9614077	ENSG00000279699.1	RP1-102K2.9	3.81	0.000155	0.0114	0.18	0.17	Lymphocyte counts;	chr22:29848960	chr22:30275215~30276951:-
THCA	cis	rs3748682	0.821	rs12030690	ENSG00000252448.1	SNORA63	-3.81	0.000155	0.0114	-0.22	-0.17	Hypothyroidism;	chr1:37792335	chr1:37884237~37884317:+
THCA	cis	rs6568686	0.73	rs4526232	ENSG00000255389.1	C6orf3	-3.81	0.000155	0.0114	-0.24	-0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111535842	chr6:111599875~111602295:+
THCA	cis	rs11088226	0.681	rs2833901	ENSG00000186842.4	LINC00846	-3.81	0.000155	0.0114	-0.26	-0.17	Gastritis;	chr21:32567008	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.681	rs16989507	ENSG00000186842.4	LINC00846	-3.81	0.000155	0.0114	-0.26	-0.17	Gastritis;	chr21:32567199	chr21:32572238~32575881:-
THCA	cis	rs7727544	0.582	rs6896703	ENSG00000263597.1	MIR3936	-3.81	0.000155	0.0114	-0.16	-0.17	Blood metabolite levels;	chr5:132185602	chr5:132365490~132365599:-
THCA	cis	rs12935229	1	rs71396107	ENSG00000260922.1	RP11-538I12.3	-3.81	0.000155	0.0114	-0.29	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77302659	chr16:77234877~77290934:+
THCA	cis	rs12476592	0.602	rs262488	ENSG00000242412.1	DBIL5P2	3.81	0.000155	0.0114	0.22	0.17	Childhood ear infection;	chr2:63655045	chr2:63117851~63119542:-
THCA	cis	rs5753037	0.653	rs131286	ENSG00000279699.1	RP1-102K2.9	3.81	0.000155	0.0114	0.17	0.17	Type 1 diabetes;	chr22:29762362	chr22:30275215~30276951:-
THCA	cis	rs758324	0.797	rs82125	ENSG00000237714.1	P4HA2-AS1	-3.81	0.000155	0.0114	-0.26	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131986548	chr5:132184876~132192808:+
THCA	cis	rs2806561	0.765	rs641032	ENSG00000249087.5	ZNF436-AS1	3.81	0.000155	0.0114	0.11	0.17	Height;	chr1:23187487	chr1:23368997~23371839:+
THCA	cis	rs13126694	0.744	rs6843728	ENSG00000248429.4	RP11-597D13.9	-3.81	0.000155	0.0114	-0.19	-0.17	Blood osmolality (transformed sodium);	chr4:158093947	chr4:158170752~158202877:+
THCA	cis	rs2348418	0.733	rs2169752	ENSG00000278733.1	RP11-425D17.1	3.81	0.000155	0.0114	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28185625~28186190:-
THCA	cis	rs948562	0.947	rs1938601	ENSG00000280010.1	AP001350.4	3.81	0.000155	0.0114	0.28	0.17	Lymphoma;	chr11:58646988	chr11:58627435~58628528:+
THCA	cis	rs683250	0.629	rs2846424	ENSG00000254551.1	RP11-727A23.7	3.81	0.000155	0.0114	0.22	0.17	Subcortical brain region volumes;	chr11:83278123	chr11:83209431~83213379:-
THCA	cis	rs7737355	0.947	rs79018835	ENSG00000237714.1	P4HA2-AS1	-3.81	0.000155	0.0114	-0.25	-0.17	Life satisfaction;	chr5:131462768	chr5:132184876~132192808:+
THCA	cis	rs651907	0.617	rs797776	ENSG00000256628.3	ZBTB11-AS1	3.81	0.000155	0.0114	0.18	0.17	Colorectal cancer;	chr3:101891399	chr3:101676475~101679217:+
THCA	cis	rs6933660	0.646	rs6911456	ENSG00000219395.2	HSPA8P15	-3.81	0.000155	0.0114	-0.15	-0.17	Menarche (age at onset);	chr6:151457799	chr6:151411259~151413945:-
THCA	cis	rs3177980	1	rs17525350	ENSG00000239494.2	RN7SL333P	-3.81	0.000155	0.0114	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr1:169700674	chr1:169859756~169860052:+
THCA	cis	rs2688608	0.592	rs11000760	ENSG00000272140.2	RP11-574K11.29	3.81	0.000155	0.0114	0.15	0.17	Inflammatory bowel disease;	chr10:73733976	chr10:73703735~73713581:-
THCA	cis	rs9611565	0.659	rs1810461	ENSG00000237037.8	NDUFA6-AS1	3.81	0.000155	0.0114	0.16	0.17	Vitiligo;	chr22:41531816	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.659	rs73178626	ENSG00000237037.8	NDUFA6-AS1	3.81	0.000155	0.0114	0.16	0.17	Vitiligo;	chr22:41532367	chr22:42090931~42137742:+
THCA	cis	rs6453278	0.553	rs11958651	ENSG00000250802.5	ZBED3-AS1	-3.81	0.000155	0.0114	-0.17	-0.17	Autism;	chr5:77097734	chr5:77086740~77166909:+
THCA	cis	rs4845570	0.831	rs11588634	ENSG00000249602.1	RP11-98D18.3	-3.81	0.000155	0.0114	-0.27	-0.17	Coronary artery disease;	chr1:151808210	chr1:151763384~151769501:-
THCA	cis	rs10908458	0.584	rs10908455	ENSG00000160766.13	GBAP1	3.81	0.000155	0.0114	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155094807	chr1:155213821~155227422:-
THCA	cis	rs7089973	0.604	rs17095662	ENSG00000228169.3	PPIAP19	3.81	0.000155	0.0114	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114836312	chr10:114690143~114690634:-
THCA	cis	rs9911578	0.967	rs6416932	ENSG00000224738.1	AC099850.1	3.81	0.000155	0.0114	0.2	0.17	Intelligence (multi-trait analysis);	chr17:59071630	chr17:59106598~59118267:+
THCA	cis	rs7129556	0.737	rs7950873	ENSG00000254459.1	RP11-91P24.7	3.81	0.000155	0.0114	0.23	0.17	Weight loss (gastric bypass surgery);	chr11:77701806	chr11:77829654~77872262:-
THCA	cis	rs17122278	1	rs11216891	ENSG00000243431.1	RPL5P30	3.81	0.000155	0.0114	0.17	0.17	Total cholesterol levels;	chr11:118551519	chr11:118560690~118561580:+
THCA	cis	rs9527	0.551	rs28606370	ENSG00000272912.1	RP11-724N1.1	-3.81	0.000155	0.0114	-0.21	-0.17	Arsenic metabolism;	chr10:102911075	chr10:102914585~102915404:+
THCA	cis	rs10984970	1	rs10984970	ENSG00000226752.6	PSMD5-AS1	3.81	0.000155	0.0114	0.45	0.17	Lung cancer;	chr9:120638143	chr9:120824828~120854385:+
THCA	cis	rs3824488	0.92	rs113154802	ENSG00000237857.2	RP11-435O5.2	-3.81	0.000155	0.0114	-0.34	-0.17	Neuroticism;	chr9:95516131	chr9:95414834~95426796:-
THCA	cis	rs12681366	0.734	rs2931633	ENSG00000261437.1	RP11-22C11.2	3.81	0.000155	0.0114	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94410492	chr8:94637285~94639467:-
THCA	cis	rs9309473	0.95	rs1918863	ENSG00000273245.1	RP11-434P11.2	3.81	0.000155	0.0114	0.23	0.17	Metabolite levels;	chr2:73417353	chr2:73750256~73750786:-
THCA	cis	rs4713118	0.568	rs9468213	ENSG00000220721.1	OR1F12	3.81	0.000155	0.0114	0.2	0.17	Parkinson's disease;	chr6:27738401	chr6:28073316~28074233:+
THCA	cis	rs3782089	0.744	rs11545200	ENSG00000245532.5	NEAT1	3.81	0.000155	0.0114	0.24	0.17	Height;	chr11:65552280	chr11:65422774~65445540:+
THCA	cis	rs11971779	0.878	rs4732378	ENSG00000252332.1	RNU6-911P	-3.81	0.000155	0.0114	-0.22	-0.17	Diisocyanate-induced asthma;	chr7:139435649	chr7:139448740~139448843:+
THCA	cis	rs4578769	0.55	rs4800435	ENSG00000273232.1	RP11-370A5.2	3.81	0.000155	0.0114	0.24	0.17	Eosinophil percentage of white cells;	chr18:22862923	chr18:22882825~22883357:-
THCA	cis	rs2380205	0.689	rs907690	ENSG00000232807.2	RP11-536K7.3	3.81	0.000155	0.0114	0.17	0.17	Breast cancer;	chr10:5859404	chr10:5934270~5945900:-
THCA	cis	rs4950322	0.547	rs61838945	ENSG00000271721.1	RP11-337C18.9	3.81	0.000155	0.0114	0.19	0.17	Protein quantitative trait loci;	chr1:147111477	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.563	rs6686480	ENSG00000271721.1	RP11-337C18.9	3.81	0.000155	0.0114	0.19	0.17	Protein quantitative trait loci;	chr1:147111986	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.563	rs6700783	ENSG00000271721.1	RP11-337C18.9	3.81	0.000155	0.0114	0.19	0.17	Protein quantitative trait loci;	chr1:147111987	chr1:147175602~147177740:+
THCA	cis	rs71520386	0.607	rs28660425	ENSG00000226329.2	AC005682.6	-3.81	0.000155	0.0114	-0.23	-0.17	Fibrinogen levels;	chr7:22818532	chr7:22863874~22881350:-
THCA	cis	rs7572733	0.935	rs6742782	ENSG00000231621.1	AC013264.2	-3.81	0.000155	0.0114	-0.16	-0.17	Dermatomyositis;	chr2:197890297	chr2:197197991~197199273:+
THCA	cis	rs60180747	1	rs11637556	ENSG00000261318.1	RP11-653J6.1	3.81	0.000155	0.0114	0.23	0.17	Testicular germ cell tumor;	chr15:66436613	chr15:66278498~66293357:-
THCA	cis	rs60180747	1	rs11636809	ENSG00000261318.1	RP11-653J6.1	3.81	0.000155	0.0114	0.23	0.17	Testicular germ cell tumor;	chr15:66437589	chr15:66278498~66293357:-
THCA	cis	rs804280	0.565	rs2645453	ENSG00000270154.1	RP11-419I17.1	3.81	0.000155	0.0114	0.2	0.17	Myopia (pathological);	chr8:11764492	chr8:12476462~12477122:+
THCA	cis	rs17286411	0.671	rs9937280	ENSG00000260185.1	RP11-432I5.6	-3.81	0.000155	0.0114	-0.24	-0.17	Blood protein levels;	chr16:71693959	chr16:71655027~71664212:+
THCA	cis	rs12612619	0.695	rs11126806	ENSG00000272148.1	RP11-195B17.1	-3.81	0.000155	0.0114	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27002276	chr2:27062428~27062907:-
THCA	cis	rs4767841	0.552	rs2893796	ENSG00000252886.1	RN7SKP197	-3.81	0.000155	0.0114	-0.18	-0.17	Urgency urinary incontinence;	chr12:119613464	chr12:119631090~119631386:-
THCA	cis	rs7267979	0.668	rs2387977	ENSG00000125804.12	FAM182A	3.81	0.000155	0.0114	0.22	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:26054655~26086917:+
THCA	cis	rs6871536	0.951	rs2706401	ENSG00000233006.5	AC034220.3	-3.81	0.000155	0.0114	-0.16	-0.17	Asthma (childhood onset);	chr5:132545913	chr5:132311285~132369916:-
THCA	cis	rs7826238	0.564	rs2921053	ENSG00000253981.4	ALG1L13P	3.81	0.000155	0.0114	0.17	0.17	Systolic blood pressure;	chr8:8462453	chr8:8236003~8244667:-
THCA	cis	rs6995541	0.647	rs7833128	ENSG00000248896.2	CTD-2135J3.3	-3.81	0.000155	0.0114	-0.21	-0.17	Triglyceride levels;	chr8:10826912	chr8:10729314~10771392:+
THCA	cis	rs11960179	0.892	rs17256961	ENSG00000250066.1	RP11-141O11.1	-3.81	0.000155	0.0114	-0.31	-0.17	Glomerular filtration rate (creatinine);	chr5:68480708	chr5:68963246~68967845:+
THCA	cis	rs6600671	1	rs6600671	ENSG00000275585.1	CH17-118O6.3	3.81	0.000155	0.0114	0.22	0.17	Hip geometry;	chr1:121458637	chr1:120985692~121052167:-
THCA	cis	rs72482608	0.835	rs12044001	ENSG00000271811.1	RP1-79C4.4	3.81	0.000155	0.0114	0.21	0.17	Emphysema imaging phenotypes;	chr1:170778324	chr1:170667381~170669425:+
THCA	cis	rs3105593	0.933	rs3131595	ENSG00000242737.1	RP11-562A8.1	3.81	0.000155	0.0114	0.21	0.17	QT interval;	chr15:50585386	chr15:50466738~50467096:+
THCA	cis	rs3105593	0.933	rs874665	ENSG00000242737.1	RP11-562A8.1	3.81	0.000155	0.0114	0.21	0.17	QT interval;	chr15:50585795	chr15:50466738~50467096:+
THCA	cis	rs7572733	0.905	rs6718039	ENSG00000231621.1	AC013264.2	-3.81	0.000155	0.0114	-0.16	-0.17	Dermatomyositis;	chr2:197896918	chr2:197197991~197199273:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000273024.4	INTS4P2	-3.81	0.000155	0.0114	-0.22	-0.17	Aortic root size;	chr7:66221293	chr7:65647864~65715661:+
THCA	cis	rs7528684	0.966	rs2317230	ENSG00000236731.1	RP4-801G22.2	3.81	0.000155	0.0114	0.19	0.17	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157705207	chr1:157629939~157630728:-
THCA	cis	rs7259376	0.936	rs12151261	ENSG00000270947.1	AC025811.3	-3.81	0.000155	0.0114	-0.18	-0.17	Menopause (age at onset);	chr19:22405127	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs8111665	ENSG00000270947.1	AC025811.3	-3.81	0.000155	0.0114	-0.18	-0.17	Menopause (age at onset);	chr19:22405757	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs7247220	ENSG00000270947.1	AC025811.3	-3.81	0.000155	0.0114	-0.18	-0.17	Menopause (age at onset);	chr19:22406687	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs12983542	ENSG00000270947.1	AC025811.3	-3.81	0.000155	0.0114	-0.18	-0.17	Menopause (age at onset);	chr19:22407783	chr19:22455988~22456459:+
THCA	cis	rs10043228	0.826	rs62384691	ENSG00000248445.4	SEMA6A-AS1	-3.81	0.000155	0.0114	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116096846	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs62384692	ENSG00000248445.4	SEMA6A-AS1	-3.81	0.000155	0.0114	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116097513	chr5:116447547~116508276:+
THCA	cis	rs10043228	0.826	rs62384695	ENSG00000248445.4	SEMA6A-AS1	-3.81	0.000155	0.0114	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116099200	chr5:116447547~116508276:+
THCA	cis	rs10043228	1	rs62384714	ENSG00000248445.4	SEMA6A-AS1	-3.81	0.000155	0.0114	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116116900	chr5:116447547~116508276:+
THCA	cis	rs1045529	0.524	rs34251783	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000156	0.0114	-0.19	-0.17	Myopia (pathological);Myopia;	chr8:9033866	chr8:9141424~9145435:+
THCA	cis	rs4869313	0.643	rs1423568	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96903590	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.617	rs2161658	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96903941	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2548531	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96904009	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2549786	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96904010	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2549788	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96904682	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.607	rs2549789	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96906566	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2549790	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96906708	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.617	rs33934033	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96907162	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs17087165	ENSG00000247121.5	CTD-2260A17.2	3.81	0.000156	0.0114	0.13	0.17	Pediatric autoimmune diseases;	chr5:96907277	chr5:96814028~96935809:-
THCA	cis	rs3758911	0.894	rs10502087	ENSG00000255353.1	RP11-382M14.1	-3.81	0.000156	0.0114	-0.22	-0.17	Coronary artery disease;	chr11:107381482	chr11:107176286~107177530:+
THCA	cis	rs2729354	0.768	rs2729384	ENSG00000254602.1	AP000662.4	-3.81	0.000156	0.0114	-0.22	-0.17	Blood protein levels;	chr11:57491144	chr11:57638024~57652790:+
THCA	cis	rs7216064	1	rs9915591	ENSG00000278740.1	RP11-147L13.14	3.81	0.000156	0.0114	0.2	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829974	chr17:68188547~68189165:+
THCA	cis	rs7170668	0.896	rs1424740	ENSG00000259134.4	LINC00924	3.81	0.000156	0.0114	0.23	0.17	Motion sickness;	chr15:95489447	chr15:95433095~95507847:+
THCA	cis	rs6792584	0.598	rs7624455	ENSG00000241316.5	SUCLG2-AS1	3.81	0.000156	0.0114	0.16	0.17	Corneal astigmatism;	chr3:67519279	chr3:67654697~67947713:+
THCA	cis	rs2625529	0.641	rs11852789	ENSG00000260037.4	CTD-2524L6.3	-3.81	0.000156	0.0114	-0.24	-0.17	Red blood cell count;	chr15:71973153	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.775	rs4777477	ENSG00000260037.4	CTD-2524L6.3	-3.81	0.000156	0.0114	-0.24	-0.17	Red blood cell count;	chr15:71977271	chr15:71818396~71823384:+
THCA	cis	rs1979679	0.65	rs3963302	ENSG00000278733.1	RP11-425D17.1	3.81	0.000156	0.0114	0.2	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28367813	chr12:28185625~28186190:-
THCA	cis	rs9925964	0.744	rs12716979	ENSG00000279196.1	RP11-1072A3.3	-3.81	0.000156	0.0114	-0.17	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31000500	chr16:30984630~30988270:-
THCA	cis	rs10771431	0.597	rs10843144	ENSG00000256427.1	RP11-118B22.4	3.81	0.000156	0.0114	0.2	0.17	Breast size;	chr12:9204981	chr12:9246497~9257960:+
THCA	cis	rs12410462	0.551	rs12070539	ENSG00000227711.2	RP11-275O4.5	-3.81	0.000156	0.0114	-0.21	-0.17	Major depressive disorder;	chr1:227677615	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.551	rs753541	ENSG00000227711.2	RP11-275O4.5	-3.81	0.000156	0.0114	-0.21	-0.17	Major depressive disorder;	chr1:227678782	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.551	rs4384237	ENSG00000227711.2	RP11-275O4.5	-3.81	0.000156	0.0114	-0.21	-0.17	Major depressive disorder;	chr1:227680853	chr1:227509028~227520477:-
THCA	cis	rs11867129	1	rs13332547	ENSG00000260778.3	RP11-304L19.13	3.81	0.000156	0.0114	0.17	0.17	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2317423	chr16:2268155~2273418:+
THCA	cis	rs3743162	1	rs12917429	ENSG00000225151.9	GOLGA2P7	3.81	0.000156	0.0114	0.26	0.17	Alzheimer's disease (age of onset);	chr15:84881866	chr15:84199311~84230136:-
THCA	cis	rs4819052	1	rs4819052	ENSG00000184274.3	LINC00315	-3.81	0.000156	0.0114	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45300245~45305257:-
THCA	cis	rs9925964	0.933	rs11150604	ENSG00000279196.1	RP11-1072A3.3	-3.81	0.000156	0.0114	-0.17	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31025699	chr16:30984630~30988270:-
THCA	cis	rs796395	0.967	rs1764705	ENSG00000232480.1	TGFB2-AS1	-3.81	0.000156	0.0114	-0.19	-0.17	Post bronchodilator FEV1/FVC ratio;	chr1:218475214	chr1:218344196~218345678:-
THCA	cis	rs7127129	0.842	rs7127005	ENSG00000246889.2	AP000487.5	-3.81	0.000156	0.0114	-0.18	-0.17	Aortic root size;	chr11:70170816	chr11:70372246~70398488:-
THCA	cis	rs295490	0.748	rs2289348	ENSG00000272656.1	RP11-219D15.3	3.81	0.000156	0.0114	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139445424	chr3:139349024~139349371:-
THCA	cis	rs4792901	0.802	rs2279191	ENSG00000279602.1	CTD-3014M21.1	-3.81	0.000156	0.0115	-0.22	-0.17	Dupuytren's disease;	chr17:43493059	chr17:43360041~43361361:-
THCA	cis	rs3015497	0.753	rs12881776	ENSG00000270062.1	RP11-248J18.3	3.81	0.000156	0.0115	0.2	0.17	Mean platelet volume;	chr14:50669612	chr14:50723777~50724272:-
THCA	cis	rs6012953	1	rs932420	ENSG00000231715.1	COX6CP2	3.81	0.000156	0.0115	0.19	0.17	Vitiligo;	chr20:50516532	chr20:50479767~50479991:+
THCA	cis	rs10875746	0.903	rs12306451	ENSG00000258234.1	RP11-370I10.2	3.81	0.000156	0.0115	0.21	0.17	Longevity (90 years and older);	chr12:48089458	chr12:48231098~48284210:-
THCA	cis	rs4295623	0.507	rs2256241	ENSG00000255046.1	RP11-297N6.4	3.81	0.000156	0.0115	0.17	0.17	Morning vs. evening chronotype;	chr8:11637148	chr8:11797928~11802568:-
THCA	cis	rs1556032	0.504	rs4741378	ENSG00000225472.1	RP11-120J1.1	-3.81	0.000156	0.0115	-0.16	-0.17	AIDS;	chr9:14456740	chr9:14317085~14357908:+
THCA	cis	rs1387259	0.899	rs7307566	ENSG00000257735.1	RP11-370I10.6	3.81	0.000156	0.0115	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48350945~48442411:+
THCA	cis	rs6137726	0.613	rs754855	ENSG00000237396.1	LINC01384	-3.81	0.000156	0.0115	-0.17	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22653005	chr20:22587522~22607517:-
THCA	cis	rs4908768	0.501	rs11121201	ENSG00000270282.1	RP5-1115A15.2	3.81	0.000156	0.0115	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8512653~8513021:+
THCA	cis	rs61160187	0.75	rs1807017	ENSG00000272308.1	RP11-231G3.1	-3.81	0.000156	0.0115	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:60866457~60866935:-
THCA	cis	rs9611565	0.625	rs73178625	ENSG00000237037.8	NDUFA6-AS1	3.81	0.000156	0.0115	0.16	0.17	Vitiligo;	chr22:41532316	chr22:42090931~42137742:+
THCA	cis	rs13113518	0.756	rs12510275	ENSG00000223305.1	RN7SKP30	3.81	0.000156	0.0115	0.22	0.17	Height;	chr4:55516548	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs12510327	ENSG00000223305.1	RN7SKP30	3.81	0.000156	0.0115	0.22	0.17	Height;	chr4:55516744	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs11939580	ENSG00000223305.1	RN7SKP30	3.81	0.000156	0.0115	0.22	0.17	Height;	chr4:55517185	chr4:55540502~55540835:-
THCA	cis	rs9329221	0.621	rs522483	ENSG00000261451.1	RP11-981G7.1	-3.81	0.000156	0.0115	-0.22	-0.17	Neuroticism;	chr8:9955459	chr8:10433672~10438312:+
THCA	cis	rs700651	0.789	rs1813106	ENSG00000231621.1	AC013264.2	-3.81	0.000156	0.0115	-0.18	-0.17	Intracranial aneurysm;	chr2:198015865	chr2:197197991~197199273:+
THCA	cis	rs2299587	0.545	rs28603021	ENSG00000253671.1	RP11-806O11.1	-3.81	0.000156	0.0115	-0.2	-0.17	Economic and political preferences;	chr8:17903245	chr8:17808941~17820868:+
THCA	cis	rs7560272	0.512	rs4530394	ENSG00000273245.1	RP11-434P11.2	-3.81	0.000156	0.0115	-0.2	-0.17	Schizophrenia;	chr2:73702523	chr2:73750256~73750786:-
THCA	cis	rs11512640	0.677	rs75863651	ENSG00000254671.2	STT3A-AS1	3.81	0.000156	0.0115	0.5	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125428271	chr11:125570284~125592568:-
THCA	cis	rs4767841	1	rs4766947	ENSG00000252886.1	RN7SKP197	-3.81	0.000156	0.0115	-0.17	-0.17	Urgency urinary incontinence;	chr12:119723596	chr12:119631090~119631386:-
THCA	cis	rs7586085	0.837	rs13429321	ENSG00000232411.1	AC009495.3	-3.81	0.000156	0.0115	-0.19	-0.17	Total body bone mineral density;	chr2:165748500	chr2:165833048~165839098:-
THCA	cis	rs7586085	0.874	rs2303393	ENSG00000232411.1	AC009495.3	-3.81	0.000156	0.0115	-0.19	-0.17	Total body bone mineral density;	chr2:165749290	chr2:165833048~165839098:-
THCA	cis	rs7586085	0.837	rs2303394	ENSG00000232411.1	AC009495.3	-3.81	0.000156	0.0115	-0.19	-0.17	Total body bone mineral density;	chr2:165749417	chr2:165833048~165839098:-
THCA	cis	rs479105	0.583	rs1860436	ENSG00000278356.1	RP11-372B4.3	3.81	0.000156	0.0115	0.17	0.17	Gut microbiota (bacterial taxa);	chr12:3260008	chr12:2885819~2886329:+
THCA	cis	rs2574985	0.53	rs2144862	ENSG00000279863.1	RP11-521C22.2	-3.81	0.000156	0.0115	-0.19	-0.17	Subjective well-being;	chr10:50500638	chr10:50334538~50336123:+
THCA	cis	rs752590	0.623	rs13405033	ENSG00000227359.1	AC017074.2	3.81	0.000156	0.0115	0.28	0.17	Mucinous ovarian carcinoma;	chr2:113237018	chr2:113677702~113704078:-
THCA	cis	rs911555	0.755	rs34411783	ENSG00000269958.1	RP11-73M18.8	-3.81	0.000156	0.0115	-0.16	-0.17	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103696353~103697163:+
THCA	cis	rs7119	0.666	rs2516302	ENSG00000259362.2	RP11-307C19.1	3.81	0.000156	0.0115	0.23	0.17	Type 2 diabetes;	chr15:77587500	chr15:77525540~77534110:+
THCA	cis	rs12681366	0.537	rs10956914	ENSG00000261437.1	RP11-22C11.2	-3.81	0.000156	0.0115	-0.17	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94471495	chr8:94637285~94639467:-
THCA	cis	rs7560272	0.512	rs2421677	ENSG00000273245.1	RP11-434P11.2	-3.81	0.000156	0.0115	-0.2	-0.17	Schizophrenia;	chr2:73738790	chr2:73750256~73750786:-
THCA	cis	rs12544026	0.581	rs480570	ENSG00000253669.3	KB-1732A1.1	-3.81	0.000156	0.0115	-0.2	-0.17	Major depression and alcohol dependence;	chr8:101870493	chr8:102805517~102809971:+
THCA	cis	rs6688613	0.685	rs2142615	ENSG00000225171.2	DUTP6	-3.81	0.000156	0.0115	-0.25	-0.17	Refractive astigmatism;	chr1:166953494	chr1:166868748~166869209:+
THCA	cis	rs7551222	0.716	rs4245738	ENSG00000240219.1	RP11-430C7.5	3.81	0.000156	0.0115	0.16	0.17	Schizophrenia;	chr1:204536979	chr1:204626775~204629712:+
THCA	cis	rs2221894	0.959	rs8180944	ENSG00000251191.6	LINC00589	3.81	0.000156	0.0115	0.21	0.17	Obesity-related traits;	chr8:29046569	chr8:29673922~29748109:-
THCA	cis	rs2338	1	rs62390564	ENSG00000272279.1	RP11-157J24.2	-3.81	0.000156	0.0115	-0.23	-0.17	Response to platinum-based agents;	chr6:1570127	chr6:1528364~1528911:-
THCA	cis	rs4780355	0.877	rs243317	ENSG00000263080.1	RP11-485G7.5	-3.81	0.000156	0.0115	-0.21	-0.17	Crohn's disease and psoriasis;	chr16:11263474	chr16:11341809~11345211:-
THCA	cis	rs6570726	0.935	rs906774	ENSG00000270638.1	RP3-466P17.1	3.81	0.000156	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs366308	ENSG00000270638.1	RP3-466P17.1	3.81	0.000156	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs384806	ENSG00000270638.1	RP3-466P17.1	3.81	0.000156	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs385185	ENSG00000270638.1	RP3-466P17.1	3.81	0.000156	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs384453	ENSG00000270638.1	RP3-466P17.1	3.81	0.000156	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs372378	ENSG00000270638.1	RP3-466P17.1	3.81	0.000156	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.905	rs388728	ENSG00000270638.1	RP3-466P17.1	3.81	0.000156	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145735570~145737218:+
THCA	cis	rs4915077	0.892	rs17019881	ENSG00000230489.1	VAV3-AS1	3.81	0.000156	0.0115	0.3	0.17	Hypothyroidism;	chr1:107747241	chr1:107964443~107994607:+
THCA	cis	rs950169	0.84	rs72748702	ENSG00000188388.10	GOLGA6L3	3.81	0.000156	0.0115	0.23	0.17	Schizophrenia;	chr15:84246494	chr15:85240472~85247170:+
THCA	cis	rs6991838	0.593	rs7011464	ENSG00000272010.1	CTD-3025N20.3	-3.81	0.000156	0.0115	-0.17	-0.17	Intelligence (multi-trait analysis);	chr8:65723052	chr8:65591850~65592472:-
THCA	cis	rs6893300	0.784	rs62404347	ENSG00000225051.5	HMGB3P22	3.81	0.000156	0.0115	0.18	0.17	Resting heart rate;	chr5:179718130	chr5:179679032~179694768:+
THCA	cis	rs3755605	0.728	rs60284850	ENSG00000242578.1	RP11-469J4.3	3.81	0.000156	0.0115	0.19	0.17	Testicular germ cell tumor;	chr3:170082613	chr3:170410512~170418615:+
THCA	cis	rs525592	1	rs525592	ENSG00000160172.9	FAM86C2P	3.81	0.000156	0.0115	0.16	0.17	Bone mineral density;	chr11:68427636	chr11:67791648~67805336:-
THCA	cis	rs9810089	0.843	rs11717954	ENSG00000273455.1	RP11-305O4.3	3.81	0.000156	0.0115	0.23	0.17	Gestational age at birth (child effect);	chr3:136393267	chr3:136087475~136087913:-
THCA	cis	rs17853159	0.558	rs3121768	ENSG00000281912.1	LINC01144	-3.81	0.000156	0.0115	-0.19	-0.17	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45273023	chr1:45303910~45305619:+
THCA	cis	rs1204798	0.588	rs1204792	ENSG00000237021.2	RP3-486I3.7	-3.81	0.000156	0.0115	-0.21	-0.17	Dental caries;	chr6:116218228	chr6:116254207~116256743:+
THCA	cis	rs73222236	0.783	rs67214626	ENSG00000273486.1	RP11-731C17.2	3.81	0.000156	0.0115	0.16	0.17	Coronary artery disease;	chr3:136270534	chr3:136837338~136839021:-
THCA	cis	rs7572644	0.766	rs2337372	ENSG00000223522.1	AC093690.1	-3.81	0.000156	0.0115	-0.23	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27917482	chr2:28307691~28310459:-
THCA	cis	rs2898290	0.622	rs7829381	ENSG00000206014.6	OR7E161P	3.81	0.000156	0.0115	0.21	0.17	Systolic blood pressure;	chr8:11487064	chr8:11928597~11929563:-
THCA	cis	rs2898290	0.622	rs11250140	ENSG00000206014.6	OR7E161P	3.81	0.000156	0.0115	0.21	0.17	Systolic blood pressure;	chr8:11489083	chr8:11928597~11929563:-
THCA	cis	rs6696239	0.956	rs12081818	ENSG00000227711.2	RP11-275O4.5	-3.81	0.000156	0.0115	-0.24	-0.17	Height;	chr1:227632673	chr1:227509028~227520477:-
THCA	cis	rs2239547	0.657	rs6445538	ENSG00000243224.1	RP5-1157M23.2	-3.81	0.000156	0.0115	-0.2	-0.17	Schizophrenia;	chr3:52840272	chr3:52239258~52241097:+
THCA	cis	rs10090774	0.93	rs9324539	ENSG00000280303.2	ERICD	-3.81	0.000156	0.0115	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140966898	chr8:140636281~140638283:+
THCA	cis	rs62458065	0.513	rs10245103	ENSG00000231952.3	DPY19L1P2	3.81	0.000156	0.0115	0.28	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32495217	chr7:32812757~32838570:+
THCA	cis	rs752590	0.65	rs6751201	ENSG00000227359.1	AC017074.2	-3.81	0.000156	0.0115	-0.21	-0.17	Mucinous ovarian carcinoma;	chr2:113195122	chr2:113677702~113704078:-
THCA	cis	rs1127311	1	rs1127313	ENSG00000236675.1	MTX1P1	3.81	0.000156	0.0115	0.16	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154583949	chr1:155230975~155234325:+
THCA	cis	rs10421328	1	rs10421328	ENSG00000271283.1	CTC-412M14.6	3.81	0.000156	0.0115	0.26	0.17	Parental longevity (combined parental age at death);	chr19:19666005	chr19:19699203~19699409:-
THCA	cis	rs513088	0.681	rs543408	ENSG00000225171.2	DUTP6	3.81	0.000156	0.0115	0.25	0.17	Schizophrenia;	chr1:166717580	chr1:166868748~166869209:+
THCA	cis	rs2298450	1	rs2298450	ENSG00000214867.3	SRSF9P1	3.81	0.000156	0.0115	0.24	0.17	Schizophrenia;	chr21:36251149	chr21:36295173~36295702:-
THCA	cis	rs9329221	0.623	rs7825778	ENSG00000154316.13	TDH	3.81	0.000156	0.0115	0.12	0.17	Neuroticism;	chr8:10403500	chr8:11339637~11368452:+
THCA	cis	rs4950322	0.547	rs56864370	ENSG00000226015.2	CCT8P1	3.81	0.000156	0.0115	0.2	0.17	Protein quantitative trait loci;	chr1:147111847	chr1:147203276~147204932:-
THCA	cis	rs6938	0.534	rs1127796	ENSG00000260269.4	CTD-2323K18.1	3.81	0.000156	0.0115	0.25	0.17	Breast cancer;	chr15:74900663	chr15:75527150~75601205:-
THCA	cis	rs13126694	0.65	rs10028808	ENSG00000248429.4	RP11-597D13.9	3.81	0.000156	0.0115	0.18	0.17	Blood osmolality (transformed sodium);	chr4:157939488	chr4:158170752~158202877:+
THCA	cis	rs9532669	0.857	rs9525427	ENSG00000229473.2	RGS17P1	3.81	0.000156	0.0115	0.21	0.17	Cervical cancer;	chr13:40918029	chr13:40992779~40993331:-
THCA	cis	rs10090774	0.965	rs11775023	ENSG00000280303.2	ERICD	-3.81	0.000156	0.0115	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959246	chr8:140636281~140638283:+
THCA	cis	rs7824557	0.547	rs4512344	ENSG00000206014.6	OR7E161P	3.81	0.000156	0.0115	0.21	0.17	Retinal vascular caliber;	chr8:11221272	chr8:11928597~11929563:-
THCA	cis	rs9980	1	rs244422	ENSG00000226232.7	RP11-419C5.2	-3.81	0.000156	0.0115	-0.26	-0.17	Blood osmolality (transformed sodium);	chr16:69583610	chr16:69976388~69996188:-
THCA	cis	rs9481169	0.557	rs13194006	ENSG00000272356.1	RP5-1112D6.8	3.81	0.000156	0.0115	0.28	0.17	Inflammatory skin disease;	chr6:111575051	chr6:111309203~111313517:+
THCA	cis	rs9450351	0.744	rs9344570	ENSG00000203875.9	SNHG5	-3.81	0.000156	0.0115	-0.35	-0.17	Interferon gamma-induced protein 10 levels;	chr6:86084062	chr6:85660950~85678736:-
THCA	cis	rs7707921	0.667	rs111549985	ENSG00000251374.1	RPS23P5	3.81	0.000156	0.0115	0.25	0.17	Breast cancer;	chr5:81972251	chr5:82265157~82265259:-
THCA	cis	rs10090774	1	rs7001591	ENSG00000280303.2	ERICD	3.81	0.000156	0.0115	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140823901	chr8:140636281~140638283:+
THCA	cis	rs721917	0.506	rs2265961	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000156	0.0115	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs7088752	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000156	0.0115	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs7078242	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000156	0.0115	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79660891~79677996:+
THCA	cis	rs721917	0.525	rs2244001	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000156	0.0115	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs1811886	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000156	0.0115	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2819113	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000156	0.0115	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79660891~79677996:+
THCA	cis	rs3748656	0.945	rs12724928	ENSG00000273483.1	RP4-671G15.2	3.81	0.000156	0.0115	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112586309	chr1:112517799~112518441:-
THCA	cis	rs875971	0.545	rs1267814	ENSG00000232559.3	GS1-124K5.12	-3.81	0.000156	0.0115	-0.19	-0.17	Aortic root size;	chr7:66579422	chr7:66554588~66576923:-
THCA	cis	rs1560104	0.709	rs7200211	ENSG00000259876.1	CTD-3037G24.4	3.81	0.000156	0.0115	0.2	0.17	Obesity-related traits;	chr16:12605083	chr16:12556353~12557694:-
THCA	cis	rs6439699	0.825	rs77090835	ENSG00000273486.1	RP11-731C17.2	3.81	0.000156	0.0115	0.19	0.17	Intelligence (multi-trait analysis);	chr3:137381778	chr3:136837338~136839021:-
THCA	cis	rs7259376	0.875	rs1975175	ENSG00000269345.1	VN1R85P	3.81	0.000157	0.0115	0.19	0.17	Menopause (age at onset);	chr19:22332437	chr19:22174766~22175191:-
THCA	cis	rs10270805	0.73	rs9791629	ENSG00000272537.1	GS1-166A23.1	3.81	0.000157	0.0115	0.35	0.17	Response to statin therapy;	chr7:16460784	chr7:16471184~16471373:+
THCA	cis	rs4666002	0.957	rs1919128	ENSG00000234072.1	AC074117.10	3.81	0.000157	0.0115	0.14	0.17	Phospholipid levels (plasma);	chr2:27578892	chr2:27356246~27367622:+
THCA	cis	rs9467773	1	rs6930120	ENSG00000228223.2	HCG11	-3.81	0.000157	0.0115	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26523450~26526579:+
THCA	cis	rs66486766	1	rs66486766	ENSG00000275120.1	RP11-182J1.17	3.81	0.000157	0.0115	0.22	0.17	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84599434~84606463:-
THCA	cis	rs172166	0.516	rs1225715	ENSG00000280107.1	AL022393.9	3.81	0.000157	0.0115	0.17	0.17	Cardiac Troponin-T levels;	chr6:28145595	chr6:28170845~28172521:+
THCA	cis	rs3781264	0.595	rs6583937	ENSG00000273450.1	RP11-76P2.4	3.81	0.000157	0.0115	0.22	0.17	Esophageal cancer and gastric cancer;	chr10:94323695	chr10:94314907~94315327:-
THCA	cis	rs755249	0.567	rs41270799	ENSG00000182109.6	RP11-69E11.4	3.81	0.000157	0.0115	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39522280~39546187:-
THCA	cis	rs72634501	0.54	rs16826036	ENSG00000182109.6	RP11-69E11.4	3.81	0.000157	0.0115	0.19	0.17	HDL cholesterol;	chr1:39292127	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs16826038	ENSG00000182109.6	RP11-69E11.4	3.81	0.000157	0.0115	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs61782157	ENSG00000182109.6	RP11-69E11.4	3.81	0.000157	0.0115	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs41270803	ENSG00000182109.6	RP11-69E11.4	3.81	0.000157	0.0115	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs61783376	ENSG00000182109.6	RP11-69E11.4	3.81	0.000157	0.0115	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs4660636	ENSG00000182109.6	RP11-69E11.4	3.81	0.000157	0.0115	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39522280~39546187:-
THCA	cis	rs7259376	0.936	rs8108630	ENSG00000269345.1	VN1R85P	3.81	0.000157	0.0115	0.19	0.17	Menopause (age at onset);	chr19:22352375	chr19:22174766~22175191:-
THCA	cis	rs7267979	0.903	rs6115118	ENSG00000276952.1	RP5-965G21.6	3.81	0.000157	0.0115	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.903	rs1118963	ENSG00000276952.1	RP5-965G21.6	3.81	0.000157	0.0115	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25284915~25285588:-
THCA	cis	rs701145	0.585	rs62276839	ENSG00000243069.6	ARHGEF26-AS1	-3.81	0.000157	0.0115	-0.32	-0.17	Coronary artery disease;	chr3:154062618	chr3:154024401~154121332:-
THCA	cis	rs881375	0.654	rs10760126	ENSG00000270917.1	RP11-27I1.6	-3.81	0.000157	0.0115	-0.23	-0.17	Rheumatoid arthritis;	chr9:120900340	chr9:120812475~120812845:-
THCA	cis	rs881375	0.678	rs4836834	ENSG00000270917.1	RP11-27I1.6	-3.81	0.000157	0.0115	-0.23	-0.17	Rheumatoid arthritis;	chr9:120903623	chr9:120812475~120812845:-
THCA	cis	rs2373000	1	rs2373000	ENSG00000225402.1	AC010878.3	-3.81	0.000157	0.0115	-0.19	-0.17	Schizophrenia;	chr2:37365485	chr2:37816915~37817961:+
THCA	cis	rs9329221	0.537	rs13264586	ENSG00000261451.1	RP11-981G7.1	3.81	0.000157	0.0115	0.21	0.17	Neuroticism;	chr8:10121875	chr8:10433672~10438312:+
THCA	cis	rs6942407	0.546	rs2190424	ENSG00000224046.1	AC005076.5	-3.81	0.000157	0.0115	-0.17	-0.17	Food allergy;	chr7:87212655	chr7:87151423~87152420:-
THCA	cis	rs7246760	1	rs12462027	ENSG00000267106.4	ZNF561-AS1	3.81	0.000157	0.0115	0.32	0.17	Pursuit maintenance gain;	chr19:9816184	chr19:9621291~9645896:+
THCA	cis	rs27419	0.593	rs3915696	ENSG00000272123.1	CTD-2366F13.2	-3.81	0.000157	0.0115	-0.19	-0.17	Schizophrenia;	chr5:53124593	chr5:53089016~53089468:-
THCA	cis	rs2562456	0.876	rs10424079	ENSG00000268521.1	VN1R83P	3.81	0.000157	0.0115	0.17	0.17	Pain;	chr19:21406377	chr19:21289554~21289998:-
THCA	cis	rs4785204	1	rs13339262	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50057472	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs7193487	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50059495	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs9939710	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50060040	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs8064107	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50060412	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs8064089	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50060571	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs9924629	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50061595	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs4785202	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50062084	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs4785203	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50062154	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs8056208	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50063193	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs7186983	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50064941	chr16:50072862~50074986:+
THCA	cis	rs4785204	1	rs7187350	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000157	0.0115	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50065125	chr16:50072862~50074986:+
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000214533.3	KRT18P33	-3.81	0.000157	0.0115	-0.21	-0.17	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65666695~65667737:+
THCA	cis	rs4076555	0.558	rs12279351	ENSG00000251364.5	CTD-2516F10.2	3.81	0.000157	0.0115	0.16	0.17	IgG glycosylation;	chr11:7454551	chr11:7427266~7512515:-
THCA	cis	rs11252926	0.604	rs12359454	ENSG00000232656.6	IDI2-AS1	-3.81	0.000157	0.0115	-0.22	-0.17	Psychosis in Alzheimer's disease;	chr10:522141	chr10:1022666~1044201:+
THCA	cis	rs520525	1	rs520525	ENSG00000271811.1	RP1-79C4.4	3.81	0.000157	0.0115	0.22	0.17	Atrial fibrillation;	chr1:170669192	chr1:170667381~170669425:+
THCA	cis	rs6456156	0.774	rs1556413	ENSG00000235272.1	FAM103A2P	-3.81	0.000157	0.0115	-0.23	-0.17	Primary biliary cholangitis;	chr6:167111255	chr6:166586124~166586477:-
THCA	cis	rs495337	0.76	rs1056200	ENSG00000229222.1	KRT18P4	-3.81	0.000157	0.0115	-0.22	-0.17	Psoriasis;	chr20:49939711	chr20:49956745~49958032:+
THCA	cis	rs9481169	0.557	rs73534579	ENSG00000272356.1	RP5-1112D6.8	3.81	0.000157	0.0115	0.28	0.17	Inflammatory skin disease;	chr6:111589486	chr6:111309203~111313517:+
THCA	cis	rs1005277	0.502	rs2800484	ENSG00000120555.12	SEPT7P9	3.81	0.000157	0.0115	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38383069~38402916:-
THCA	cis	rs11239930	0.517	rs492243	ENSG00000278811.3	LINC00624	3.81	0.000157	0.0115	0.2	0.17	AIDS progression;	chr1:147077930	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.517	rs493000	ENSG00000278811.3	LINC00624	3.81	0.000157	0.0115	0.2	0.17	AIDS progression;	chr1:147077979	chr1:147258885~147517875:-
THCA	cis	rs13113518	0.812	rs1522114	ENSG00000272969.1	RP11-528I4.2	3.81	0.000157	0.0115	0.21	0.17	Height;	chr4:55489895	chr4:55547112~55547889:+
THCA	cis	rs10435719	0.902	rs12681142	ENSG00000255495.1	AC145124.2	3.81	0.000157	0.0115	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:12194467~12196280:+
THCA	cis	rs495337	0.76	rs6125830	ENSG00000229222.1	KRT18P4	-3.81	0.000157	0.0115	-0.22	-0.17	Psoriasis;	chr20:49955125	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs4810995	ENSG00000229222.1	KRT18P4	-3.81	0.000157	0.0115	-0.22	-0.17	Psoriasis;	chr20:49955265	chr20:49956745~49958032:+
THCA	cis	rs9291683	0.53	rs882223	ENSG00000250413.1	RP11-448G15.1	-3.81	0.000157	0.0115	-0.17	-0.17	Bone mineral density;	chr4:9980001	chr4:10006482~10009725:+
THCA	cis	rs2836326	1	rs2836326	ENSG00000226012.1	AP001434.2	3.81	0.000157	0.0115	0.25	0.17	Metabolite levels (HVA);	chr21:38349842	chr21:38237217~38238201:-
THCA	cis	rs10863936	0.5	rs2105162	ENSG00000198468.6	FLVCR1-AS1	-3.81	0.000157	0.0115	-0.2	-0.17	Height;	chr1:211931984	chr1:212852108~212858088:-
THCA	cis	rs1065852	0.526	rs12166549	ENSG00000227370.1	RP4-669P10.19	3.81	0.000157	0.0115	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014415	chr22:42132543~42132998:+
THCA	cis	rs1065852	0.526	rs9611711	ENSG00000227370.1	RP4-669P10.19	3.81	0.000157	0.0115	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014691	chr22:42132543~42132998:+
THCA	cis	rs5753037	0.869	rs5997546	ENSG00000279699.1	RP1-102K2.9	3.81	0.000157	0.0115	0.17	0.17	Type 1 diabetes;	chr22:29863353	chr22:30275215~30276951:-
THCA	cis	rs2190422	0.509	rs2237622	ENSG00000234715.1	CTB-107G13.1	3.81	0.000157	0.0115	0.25	0.17	Morning vs. evening chronotype;	chr7:103529323	chr7:103445207~103514007:+
THCA	cis	rs2013441	0.606	rs12942179	ENSG00000261033.1	RP11-209D14.2	-3.81	0.000157	0.0115	-0.21	-0.17	Obesity-related traits;	chr17:20096468	chr17:20008051~20009234:-
THCA	cis	rs2281603	0.521	rs3742608	ENSG00000258824.2	CTD-2555O16.2	-3.81	0.000157	0.0115	-0.15	-0.17	Lymphocyte counts;	chr14:64470315	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs2045024	ENSG00000258824.2	CTD-2555O16.2	-3.81	0.000157	0.0115	-0.15	-0.17	Lymphocyte counts;	chr14:64470634	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs10131416	ENSG00000258824.2	CTD-2555O16.2	-3.81	0.000157	0.0115	-0.15	-0.17	Lymphocyte counts;	chr14:64477555	chr14:64422935~64448557:-
THCA	cis	rs13113518	0.812	rs12500456	ENSG00000223305.1	RN7SKP30	3.81	0.000157	0.0115	0.22	0.17	Height;	chr4:55561053	chr4:55540502~55540835:-
THCA	cis	rs13108904	0.935	rs2293633	ENSG00000254094.1	AC078852.1	-3.81	0.000157	0.0115	-0.2	-0.17	Obesity-related traits;	chr4:1297852	chr4:1356581~1358075:+
THCA	cis	rs7824557	0.507	rs7010590	ENSG00000261451.1	RP11-981G7.1	3.81	0.000157	0.0115	0.22	0.17	Retinal vascular caliber;	chr8:11205373	chr8:10433672~10438312:+
THCA	cis	rs1961102	0.521	rs613049	ENSG00000253320.4	KB-1507C5.2	-3.81	0.000157	0.0115	-0.15	-0.17	QT interval;	chr8:102919081	chr8:102864300~102977876:+
THCA	cis	rs6847067	0.616	rs10446678	ENSG00000180769.7	WDFY3-AS2	3.81	0.000157	0.0115	0.13	0.17	Oropharynx cancer;	chr4:84613006	chr4:84965682~85011277:+
THCA	cis	rs9925964	0.744	rs12716979	ENSG00000260911.2	RP11-196G11.2	-3.81	0.000157	0.0115	-0.14	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31000500	chr16:31043150~31049868:+
THCA	cis	rs4906332	1	rs7155822	ENSG00000259775.1	RP11-45P15.4	-3.81	0.000157	0.0115	-0.15	-0.17	Coronary artery disease;	chr14:103456053	chr14:103331674~103332367:-
THCA	cis	rs4845570	0.831	rs11588258	ENSG00000249602.1	RP11-98D18.3	-3.81	0.000157	0.0115	-0.27	-0.17	Coronary artery disease;	chr1:151808252	chr1:151763384~151769501:-
THCA	cis	rs10540	0.915	rs35389167	ENSG00000279672.1	CMB9-55F22.1	3.81	0.000157	0.0115	0.33	0.17	Body mass index;	chr11:460765	chr11:779617~780755:+
THCA	cis	rs13434995	0.513	rs6851971	ENSG00000249700.7	SRD5A3-AS1	3.81	0.000157	0.0115	0.24	0.17	Adiponectin levels;	chr4:55561897	chr4:55363971~55395847:-
THCA	cis	rs10875746	0.669	rs10467101	ENSG00000258273.1	RP11-370I10.4	3.81	0.000157	0.0115	0.24	0.17	Longevity (90 years and older);	chr12:48213954	chr12:48333755~48333901:-
THCA	cis	rs7520050	0.966	rs6661910	ENSG00000280836.1	AL355480.1	3.81	0.000157	0.0115	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45581219~45581321:-
THCA	cis	rs67478160	0.625	rs7141473	ENSG00000269940.1	RP11-73M18.7	-3.81	0.000157	0.0115	-0.16	-0.17	Schizophrenia;	chr14:103849718	chr14:103694560~103695170:+
THCA	cis	rs8077577	0.671	rs4500798	ENSG00000273018.4	CTD-2303H24.2	-3.81	0.000157	0.0115	-0.25	-0.17	Obesity-related traits;	chr17:18351765	chr17:18511221~18551705:-
THCA	cis	rs524281	1	rs489337	ENSG00000255120.4	OVOL1-AS1	3.81	0.000157	0.0115	0.25	0.17	Electroencephalogram traits;	chr11:66087090	chr11:65789051~65790868:-
THCA	cis	rs2303282	0.7	rs35626903	ENSG00000274031.1	RP11-413H22.3	-3.81	0.000157	0.0115	-0.2	-0.17	Breast cancer;	chr16:56397701	chr16:56465642~56466162:-
THCA	cis	rs2640806	0.505	rs6997446	ENSG00000253105.4	KB-1448A5.1	3.81	0.000157	0.0115	0.21	0.17	Obesity-related traits;	chr8:96354230	chr8:96371865~96387438:-
THCA	cis	rs12032381	1	rs6674252	ENSG00000238042.4	RP11-815M8.1	3.81	0.000157	0.0115	0.16	0.17	Dupuytren's disease;	chr1:221444228	chr1:221880981~221978523:-
THCA	cis	rs2640806	0.505	rs11988031	ENSG00000253105.4	KB-1448A5.1	3.81	0.000157	0.0115	0.21	0.17	Obesity-related traits;	chr8:96354631	chr8:96371865~96387438:-
THCA	cis	rs465969	0.655	rs13203984	ENSG00000272356.1	RP5-1112D6.8	3.81	0.000157	0.0115	0.26	0.17	Psoriasis;	chr6:111388538	chr6:111309203~111313517:+
THCA	cis	rs858239	0.932	rs858272	ENSG00000230042.1	AK3P3	-3.81	0.000157	0.0115	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23129178~23129841:+
THCA	cis	rs7824557	0.564	rs2572379	ENSG00000255495.1	AC145124.2	-3.81	0.000157	0.0115	-0.2	-0.17	Retinal vascular caliber;	chr8:11379971	chr8:12194467~12196280:+
THCA	cis	rs11971779	0.793	rs4728464	ENSG00000252332.1	RNU6-911P	3.81	0.000157	0.0115	0.21	0.17	Diisocyanate-induced asthma;	chr7:139332924	chr7:139448740~139448843:+
THCA	cis	rs2905347	0.895	rs2961282	ENSG00000232949.1	AC002480.4	-3.81	0.000157	0.0115	-0.22	-0.17	Major depression and alcohol dependence;	chr7:22600770	chr7:22589705~22591622:+
THCA	cis	rs11064837	0.525	rs739422	ENSG00000248636.5	RP11-768F21.1	3.81	0.000157	0.0115	0.2	0.17	Schizophrenia;	chr12:119604701	chr12:119387987~119668079:-
THCA	cis	rs1577917	0.916	rs7759727	ENSG00000220563.1	PKMP3	-3.81	0.000157	0.0115	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85809160	chr6:85659892~85660606:-
THCA	cis	rs9660180	0.836	rs72634845	ENSG00000215914.4	MMP23A	-3.81	0.000157	0.0115	-0.23	-0.17	Body mass index;	chr1:1773460	chr1:1699942~1701782:+
THCA	cis	rs9660180	0.868	rs72634846	ENSG00000215914.4	MMP23A	-3.81	0.000157	0.0115	-0.23	-0.17	Body mass index;	chr1:1773476	chr1:1699942~1701782:+
THCA	cis	rs9309473	0.615	rs62149774	ENSG00000273245.1	RP11-434P11.2	3.81	0.000157	0.0115	0.28	0.17	Metabolite levels;	chr2:73560525	chr2:73750256~73750786:-
THCA	cis	rs153852	0.859	rs36732	ENSG00000243806.1	RPL7P18	-3.81	0.000157	0.0115	-0.23	-0.17	Cancer;	chr5:94829386	chr5:94825961~94826694:-
THCA	cis	rs7216064	1	rs2052187	ENSG00000278740.1	RP11-147L13.14	3.81	0.000157	0.0115	0.2	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67838621	chr17:68188547~68189165:+
THCA	cis	rs11971779	0.616	rs10269683	ENSG00000252332.1	RNU6-911P	-3.81	0.000157	0.0115	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139416122	chr7:139448740~139448843:+
THCA	cis	rs6137726	0.524	rs1203929	ENSG00000237396.1	LINC01384	3.81	0.000157	0.0115	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22609266	chr20:22587522~22607517:-
THCA	cis	rs6570726	0.934	rs430003	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs395948	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs452552	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs451349	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.905	rs406799	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs1883406	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.87	rs370653	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs391524	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs429306	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs428659	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs419847	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs419850	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs411641	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs376991	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs379164	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs401888	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs414646	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs454614	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.846	rs411468	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs425731	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs421690	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs399169	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs377130	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs408723	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs425717	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs424263	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.905	rs419575	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs409725	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs386823	ENSG00000270638.1	RP3-466P17.1	3.81	0.000157	0.0115	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145735570~145737218:+
THCA	cis	rs11185790	0.784	rs10881612	ENSG00000232936.4	RP11-80H5.2	3.81	0.000157	0.0115	0.22	0.17	Metabolic traits;	chr10:89627031	chr10:89645282~89650667:+
THCA	cis	rs9926296	0.546	rs9935541	ENSG00000274627.1	RP11-104N10.2	-3.81	0.000157	0.0115	-0.18	-0.17	Vitiligo;	chr16:89839517	chr16:89516797~89522217:+
THCA	cis	rs752590	0.623	rs66775912	ENSG00000227359.1	AC017074.2	3.81	0.000157	0.0116	0.28	0.17	Mucinous ovarian carcinoma;	chr2:113231152	chr2:113677702~113704078:-
THCA	cis	rs9467773	0.869	rs742090	ENSG00000261353.1	CTA-14H9.5	3.81	0.000157	0.0116	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26415409	chr6:26527063~26527404:+
THCA	cis	rs10483853	0.806	rs12435797	ENSG00000258695.2	RP3-414A15.2	3.81	0.000157	0.0116	0.24	0.17	Coronary artery calcification;	chr14:73330961	chr14:73522878~73530610:+
THCA	cis	rs9287719	0.967	rs6744599	ENSG00000243819.4	RN7SL832P	-3.81	0.000157	0.0116	-0.14	-0.17	Prostate cancer;	chr2:10606887	chr2:10690344~10692099:+
THCA	cis	rs5758511	0.68	rs5758681	ENSG00000230107.1	CTA-126B4.7	-3.81	0.000157	0.0116	-0.21	-0.17	Birth weight;	chr22:42249085	chr22:42438023~42446195:+
THCA	cis	rs559555	0.861	rs6749019	ENSG00000276517.1	AL133243.2	-3.81	0.000157	0.0116	-0.16	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31572741	chr2:32526504~32529507:+
THCA	cis	rs1908814	0.516	rs7825529	ENSG00000254948.1	OR7E158P	-3.81	0.000157	0.0116	-0.22	-0.17	Neuroticism;	chr8:11936935	chr8:11919900~11920809:-
THCA	cis	rs9341808	0.727	rs10943697	ENSG00000260645.1	RP11-250B2.5	3.81	0.000158	0.0116	0.15	0.17	Sitting height ratio;	chr6:80221789	chr6:80466958~80469080:+
THCA	cis	rs4763879	0.778	rs11052497	ENSG00000214776.8	RP11-726G1.1	-3.81	0.000158	0.0116	-0.21	-0.17	Type 1 diabetes;	chr12:9696679	chr12:9467552~9576275:+
THCA	cis	rs2625529	0.824	rs4776581	ENSG00000260037.4	CTD-2524L6.3	-3.81	0.000158	0.0116	-0.24	-0.17	Red blood cell count;	chr15:71914730	chr15:71818396~71823384:+
THCA	cis	rs11242704	0.962	rs2816286	ENSG00000218027.2	RP11-157J24.1	-3.81	0.000158	0.0116	-0.23	-0.17	Response to hepatitis C treatment;	chr6:1536661	chr6:1513698~1515289:-
THCA	cis	rs4908768	0.501	rs6577502	ENSG00000270282.1	RP5-1115A15.2	3.81	0.000158	0.0116	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs1473420	ENSG00000270282.1	RP5-1115A15.2	3.81	0.000158	0.0116	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8512653~8513021:+
THCA	cis	rs7824557	0.778	rs6601572	ENSG00000255046.1	RP11-297N6.4	3.81	0.000158	0.0116	0.17	0.17	Retinal vascular caliber;	chr8:11235828	chr8:11797928~11802568:-
THCA	cis	rs3770081	1	rs73947314	ENSG00000273080.1	RP11-301O19.1	-3.81	0.000158	0.0116	-0.39	-0.17	Facial emotion recognition (sad faces);	chr2:86045993	chr2:86195590~86196049:+
THCA	cis	rs10419113	0.628	rs9304795	ENSG00000268545.1	VN1R107P	3.81	0.000158	0.0116	0.2	0.17	Pediatric bone mineral density (spine);	chr19:57666177	chr19:57459912~57460120:+
THCA	cis	rs494003	1	rs11227288	ENSG00000214659.4	KRT8P26	3.81	0.000158	0.0116	0.19	0.17	Systemic lupus erythematosus;	chr11:65749117	chr11:65726939~65728214:+
THCA	cis	rs12129938	0.868	rs7534800	ENSG00000231940.1	RPS7P3	-3.81	0.000158	0.0116	-0.24	-0.17	Thyroid cancer;	chr1:233286440	chr1:233288868~233289447:-
THCA	cis	rs7259376	0.837	rs1368476	ENSG00000270947.1	AC025811.3	-3.81	0.000158	0.0116	-0.18	-0.17	Menopause (age at onset);	chr19:22403390	chr19:22455988~22456459:+
THCA	cis	rs9527	0.518	rs11191487	ENSG00000236937.2	PTGES3P4	3.81	0.000158	0.0116	0.32	0.17	Arsenic metabolism;	chr10:102974866	chr10:102845595~102845950:+
THCA	cis	rs4578769	0.569	rs1379805	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22914589	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs1031652	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22916035	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs9967326	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22916787	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs9946660	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22917007	chr18:22882825~22883357:-
THCA	cis	rs12962334	0.568	rs2034932	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Breast cancer;	chr18:22918727	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs4800438	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22920482	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.55	rs721578	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22922719	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs7229422	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22923157	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs12960915	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22924013	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.589	rs9964726	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22925516	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs9958831	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22926050	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs11659166	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22926143	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.569	rs12957183	ENSG00000273232.1	RP11-370A5.2	3.81	0.000158	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22927124	chr18:22882825~22883357:-
THCA	cis	rs1580019	0.961	rs11768506	ENSG00000231952.3	DPY19L1P2	-3.81	0.000158	0.0116	-0.22	-0.17	Cognitive ability;	chr7:32455176	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs11765387	ENSG00000231952.3	DPY19L1P2	-3.81	0.000158	0.0116	-0.22	-0.17	Cognitive ability;	chr7:32455178	chr7:32812757~32838570:+
THCA	cis	rs6491750	1	rs6491750	ENSG00000276957.1	RP11-29B2.6	3.81	0.000158	0.0116	0.3	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103491262	chr13:102593338~102593873:-
THCA	cis	rs721917	0.506	rs2758556	ENSG00000244733.5	RP11-506M13.3	3.81	0.000158	0.0116	0.2	0.17	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79660891~79677996:+
THCA	cis	rs10256972	0.524	rs6945202	ENSG00000225146.1	AC073957.15	3.81	0.000158	0.0116	0.19	0.17	Endometriosis;Longevity;	chr7:1076922	chr7:1029025~1043891:+
THCA	cis	rs2562456	0.833	rs2562507	ENSG00000268658.4	LINC00664	-3.81	0.000158	0.0116	-0.25	-0.17	Pain;	chr19:21543535	chr19:21483374~21503238:+
THCA	cis	rs724818	0.661	rs12506109	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.49	-0.17	Monobrow thickness;	chr4:120769028	chr4:120895494~120897083:-
THCA	cis	rs724818	1	rs12507367	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.49	-0.17	Monobrow thickness;	chr4:120770445	chr4:120895494~120897083:-
THCA	cis	rs4356203	0.87	rs10832746	ENSG00000272034.1	SNORD14A	-3.81	0.000158	0.0116	-0.17	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228406	chr11:17074654~17074744:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.000158	0.0116	-0.18	-0.17	Aortic root size;	chr7:66093491	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs1182882	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.000158	0.0116	-0.18	-0.17	Aortic root size;	chr7:66097076	chr7:66025126~66031544:-
THCA	cis	rs4714902	0.564	rs2143745	ENSG00000231769.2	RP1-8B1.4	-3.81	0.000158	0.0116	-0.17	-0.17	Colonoscopy-negative controls vs population controls;	chr6:46179075	chr6:46097093~46129706:-
THCA	cis	rs67340775	0.834	rs13218875	ENSG00000220721.1	OR1F12	3.81	0.000158	0.0116	0.39	0.17	Lung cancer in ever smokers;	chr6:27916234	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs67040724	ENSG00000220721.1	OR1F12	3.81	0.000158	0.0116	0.39	0.17	Depression;	chr6:27937731	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs67662114	ENSG00000220721.1	OR1F12	3.81	0.000158	0.0116	0.39	0.17	Depression;	chr6:27964523	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13216117	ENSG00000220721.1	OR1F12	3.81	0.000158	0.0116	0.39	0.17	Depression;	chr6:27970706	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs36101351	ENSG00000220721.1	OR1F12	3.81	0.000158	0.0116	0.39	0.17	Depression;	chr6:27975591	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs28360499	ENSG00000220721.1	OR1F12	3.81	0.000158	0.0116	0.39	0.17	Depression;	chr6:27977618	chr6:28073316~28074233:+
THCA	cis	rs4533267	0.748	rs4450381	ENSG00000189419.6	SPATA41	-3.81	0.000158	0.0116	-0.22	-0.17	Height;	chr15:100246043	chr15:100344457~100349655:-
THCA	cis	rs1127311	1	rs1127311	ENSG00000236675.1	MTX1P1	-3.81	0.000158	0.0116	-0.16	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154584187	chr1:155230975~155234325:+
THCA	cis	rs2562456	0.793	rs2650819	ENSG00000268278.1	RP11-420K14.1	-3.81	0.000158	0.0116	-0.21	-0.17	Pain;	chr19:21456071	chr19:21637974~21656300:+
THCA	cis	rs2522056	0.808	rs17771891	ENSG00000237714.1	P4HA2-AS1	3.81	0.000158	0.0116	0.25	0.17	Fibrinogen;Lymphocyte counts;	chr5:132408510	chr5:132184876~132192808:+
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000184274.3	LINC00315	-3.81	0.000158	0.0116	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45300245~45305257:-
THCA	cis	rs1371614	0.566	rs10184824	ENSG00000272148.1	RP11-195B17.1	-3.81	0.000158	0.0116	-0.16	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26955084	chr2:27062428~27062907:-
THCA	cis	rs16957091	0.528	rs72721511	ENSG00000205771.5	CATSPER2P1	3.81	0.000158	0.0116	0.25	0.17	MGMT methylation in smokers;	chr15:42994161	chr15:43726918~43747094:-
THCA	cis	rs786425	0.74	rs7397160	ENSG00000278112.1	RP11-972P1.11	3.81	0.000158	0.0116	0.17	0.17	Pubertal anthropometrics;	chr12:123711672	chr12:123519390~123519856:-
THCA	cis	rs786425	0.601	rs67178535	ENSG00000278112.1	RP11-972P1.11	3.81	0.000158	0.0116	0.17	0.17	Pubertal anthropometrics;	chr12:123711752	chr12:123519390~123519856:-
THCA	cis	rs3806843	0.576	rs246072	ENSG00000202515.1	VTRNA1-3	-3.81	0.000158	0.0116	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140940841	chr5:140726158~140726246:+
THCA	cis	rs2360027	0.965	rs1911176	ENSG00000231365.4	RP11-418J17.1	-3.81	0.000158	0.0116	-0.17	-0.17	Tonsillectomy;	chr1:118592291	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.929	rs4659106	ENSG00000231365.4	RP11-418J17.1	-3.81	0.000158	0.0116	-0.17	-0.17	Tonsillectomy;	chr1:118596767	chr1:119140396~119275973:+
THCA	cis	rs2729354	0.729	rs2848634	ENSG00000254602.1	AP000662.4	-3.81	0.000158	0.0116	-0.22	-0.17	Blood protein levels;	chr11:57484855	chr11:57638024~57652790:+
THCA	cis	rs7737355	1	rs2158428	ENSG00000237714.1	P4HA2-AS1	-3.81	0.000158	0.0116	-0.25	-0.17	Life satisfaction;	chr5:131415788	chr5:132184876~132192808:+
THCA	cis	rs724818	0.661	rs12644850	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120807996	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs72678335	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120808726	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs28810489	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120808906	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs1397771	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120813150	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs171068	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120820723	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs343185	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120820992	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs168226	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120821615	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs343182	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120822691	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs1809075	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120825675	chr4:120895494~120897083:-
THCA	cis	rs724818	0.661	rs2667171	ENSG00000251609.2	SETP12	-3.81	0.000158	0.0116	-0.48	-0.17	Monobrow thickness;	chr4:120828122	chr4:120895494~120897083:-
THCA	cis	rs3747767	1	rs9352736	ENSG00000233967.5	RP11-250B2.3	3.81	0.000158	0.0116	0.3	0.17	Hoarding;	chr6:79468303	chr6:80443344~80465927:+
THCA	cis	rs755249	1	rs755249	ENSG00000237624.1	OXCT2P1	3.81	0.000158	0.0116	0.23	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39514956~39516490:+
THCA	cis	rs791590	1	rs2246031	ENSG00000225948.2	RP11-554I8.1	-3.81	0.000158	0.0116	-0.26	-0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6050247	chr10:6618716~6625346:+
THCA	cis	rs6546886	0.912	rs13006407	ENSG00000235499.1	AC073046.25	3.81	0.000158	0.0116	0.16	0.17	Dialysis-related mortality;	chr2:74053148	chr2:73985132~73986343:+
THCA	cis	rs2629751	0.962	rs2583230	ENSG00000214198.6	RP11-642P15.1	-3.81	0.000158	0.0116	-0.14	-0.17	Hepatitis C induced liver fibrosis;	chr12:104013663	chr12:103843749~103930211:-
THCA	cis	rs2044029	0.504	rs1372214	ENSG00000243568.2	RP11-2I17.1	-3.81	0.000158	0.0116	-0.24	-0.17	Airflow obstruction;	chr15:71363085	chr15:72134641~72135436:+
THCA	cis	rs6690583	0.623	rs898036	ENSG00000226970.2	RP11-82H13.2	3.81	0.000158	0.0116	0.3	0.17	Serum sulfate level;	chr1:85056221	chr1:84244334~84244577:+
THCA	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	-3.81	0.000158	0.0116	-0.08	-0.17	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
THCA	cis	rs4767841	0.565	rs432718	ENSG00000248636.5	RP11-768F21.1	-3.81	0.000158	0.0116	-0.18	-0.17	Urgency urinary incontinence;	chr12:119790740	chr12:119387987~119668079:-
THCA	cis	rs7829975	0.711	rs1039916	ENSG00000254340.1	RP11-10A14.3	3.81	0.000158	0.0116	0.19	0.17	Mood instability;	chr8:8828344	chr8:9141424~9145435:+
THCA	cis	rs4906332	0.966	rs12588705	ENSG00000259775.1	RP11-45P15.4	-3.81	0.000158	0.0116	-0.15	-0.17	Coronary artery disease;	chr14:103399140	chr14:103331674~103332367:-
THCA	cis	rs4906332	0.966	rs59858038	ENSG00000259775.1	RP11-45P15.4	-3.81	0.000158	0.0116	-0.15	-0.17	Coronary artery disease;	chr14:103400765	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs12889703	ENSG00000259775.1	RP11-45P15.4	-3.81	0.000158	0.0116	-0.15	-0.17	Coronary artery disease;	chr14:103406614	chr14:103331674~103332367:-
THCA	cis	rs758324	0.588	rs426991	ENSG00000237714.1	P4HA2-AS1	3.81	0.000158	0.0116	0.24	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131991652	chr5:132184876~132192808:+
THCA	cis	rs2562456	0.833	rs62110428	ENSG00000268278.1	RP11-420K14.1	3.81	0.000158	0.0116	0.24	0.17	Pain;	chr19:21430854	chr19:21637974~21656300:+
THCA	cis	rs9818758	0.556	rs9813813	ENSG00000229759.1	MRPS18AP1	-3.81	0.000158	0.0116	-0.37	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49169660	chr3:48256350~48256938:-
THCA	cis	rs13098911	0.54	rs13066062	ENSG00000226074.4	PRSS44	-3.81	0.000158	0.0116	-0.33	-0.17	Celiac disease;	chr3:45976852	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs36122610	ENSG00000226074.4	PRSS44	-3.81	0.000158	0.0116	-0.33	-0.17	Celiac disease;	chr3:45981341	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34442130	ENSG00000226074.4	PRSS44	-3.81	0.000158	0.0116	-0.33	-0.17	Celiac disease;	chr3:45983037	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13075758	ENSG00000226074.4	PRSS44	-3.81	0.000158	0.0116	-0.33	-0.17	Celiac disease;	chr3:45983556	chr3:46809359~46812558:-
THCA	cis	rs61160187	0.549	rs62367879	ENSG00000272308.1	RP11-231G3.1	-3.81	0.000158	0.0116	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60866457~60866935:-
THCA	cis	rs1150668	1	rs1150668	ENSG00000280107.1	AL022393.9	-3.81	0.000158	0.0116	-0.17	-0.17	Pubertal anthropometrics;	chr6:28162011	chr6:28170845~28172521:+
THCA	cis	rs1005277	0.54	rs289638	ENSG00000275858.1	RP11-291L22.8	3.81	0.000158	0.0116	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38450738~38451069:-
THCA	cis	rs9450351	0.744	rs9362248	ENSG00000203875.9	SNHG5	-3.81	0.000158	0.0116	-0.33	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85847249	chr6:85660950~85678736:-
THCA	cis	rs35146811	0.7	rs866500	ENSG00000078319.8	PMS2P1	-3.81	0.000158	0.0116	-0.23	-0.17	Coronary artery disease;	chr7:100242838	chr7:100320992~100341908:-
THCA	cis	rs7088591	0.702	rs77854825	ENSG00000276818.1	AC026393.1	3.81	0.000158	0.0116	0.36	0.17	Blood pressure;	chr10:57999772	chr10:57095699~57095781:+
THCA	cis	rs4683346	0.656	rs11129979	ENSG00000273328.4	RP11-141M3.6	-3.81	0.000158	0.0116	-0.21	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42849239	chr3:42809414~42908105:+
THCA	cis	rs867186	1	rs117249133	ENSG00000126005.14	MMP24-AS1	-3.81	0.000158	0.0116	-0.28	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35185827	chr20:35216462~35278131:-
THCA	cis	rs2033711	0.755	rs4801587	ENSG00000268049.1	CTD-2619J13.9	-3.81	0.000158	0.0116	-0.22	-0.17	Uric acid clearance;	chr19:58425312	chr19:58357999~58359603:+
THCA	cis	rs10027350	0.714	rs3796791	ENSG00000281501.1	SEPSECS-AS1	3.81	0.000158	0.0116	0.19	0.17	Childhood ear infection;	chr4:25132423	chr4:25160641~25201440:+
THCA	cis	rs2237234	0.542	rs7755997	ENSG00000124549.13	BTN2A3P	3.81	0.000158	0.0116	0.17	0.17	Autism spectrum disorder or schizophrenia;	chr6:26482820	chr6:26421391~26432383:+
THCA	cis	rs3806843	0.576	rs246002	ENSG00000202515.1	VTRNA1-3	-3.81	0.000158	0.0116	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140961519	chr5:140726158~140726246:+
THCA	cis	rs796395	0.934	rs1690791	ENSG00000232480.1	TGFB2-AS1	-3.81	0.000158	0.0116	-0.19	-0.17	Post bronchodilator FEV1/FVC ratio;	chr1:218471980	chr1:218344196~218345678:-
THCA	cis	rs9309473	0.519	rs2421670	ENSG00000273245.1	RP11-434P11.2	-3.81	0.000158	0.0116	-0.21	-0.17	Metabolite levels;	chr2:73659534	chr2:73750256~73750786:-
THCA	cis	rs17772222	0.682	rs1864744	ENSG00000222990.1	RNU4-22P	-3.81	0.000158	0.0116	-0.21	-0.17	Coronary artery calcification;	chr14:88484662	chr14:88513498~88513663:+
THCA	cis	rs13217239	0.646	rs10946898	ENSG00000124549.13	BTN2A3P	3.81	0.000158	0.0116	0.16	0.17	Schizophrenia;	chr6:27036105	chr6:26421391~26432383:+
THCA	cis	rs6762	0.642	rs28692469	ENSG00000255142.1	AP006621.6	3.81	0.000158	0.0116	0.12	0.17	Mean platelet volume;	chr11:839675	chr11:781645~782105:+
THCA	cis	rs4713118	0.539	rs200967	ENSG00000273712.1	RP5-874C20.7	3.81	0.000158	0.0116	0.21	0.17	Parkinson's disease;	chr6:27894349	chr6:28315613~28315883:-
THCA	cis	rs2832191	0.703	rs2853827	ENSG00000176054.6	RPL23P2	3.81	0.000158	0.0116	0.15	0.17	Dental caries;	chr21:29071275	chr21:28997613~28998033:-
THCA	cis	rs9291683	0.609	rs36084205	ENSG00000261490.1	RP11-448G15.3	3.81	0.000158	0.0116	0.11	0.17	Bone mineral density;	chr4:10027054	chr4:10068089~10073019:-
THCA	cis	rs7520050	0.966	rs785485	ENSG00000281133.1	AL355480.3	3.81	0.000158	0.0116	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45580892~45580996:-
THCA	cis	rs6500602	0.964	rs2304633	ENSG00000280063.1	RP11-295D4.3	3.81	0.000158	0.0116	0.1	0.17	Schizophrenia;	chr16:4446972	chr16:4346694~4348648:-
THCA	cis	rs7551222	0.752	rs4951389	ENSG00000240219.1	RP11-430C7.5	3.81	0.000158	0.0116	0.16	0.17	Schizophrenia;	chr1:204506706	chr1:204626775~204629712:+
THCA	cis	rs9693857	0.52	rs7830572	ENSG00000248538.5	RP11-10A14.5	-3.81	0.000158	0.0116	-0.23	-0.17	Systolic blood pressure;	chr8:9499292	chr8:9189011~9202854:+
THCA	cis	rs4819052	0.655	rs2330103	ENSG00000273796.1	LL21NC02-21A1.1	-3.81	0.000158	0.0116	-0.18	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45403809~45404369:-
THCA	cis	rs2562456	0.917	rs11085463	ENSG00000268658.4	LINC00664	3.81	0.000159	0.0116	0.25	0.17	Pain;	chr19:21568500	chr19:21483374~21503238:+
THCA	cis	rs1959947	0.837	rs4904218	ENSG00000251363.2	RP11-129M6.1	-3.81	0.000159	0.0116	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41056931	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.793	rs2185995	ENSG00000251363.2	RP11-129M6.1	-3.81	0.000159	0.0116	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41057343	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs2154105	ENSG00000251363.2	RP11-129M6.1	-3.81	0.000159	0.0116	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41057676	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs2154106	ENSG00000251363.2	RP11-129M6.1	-3.81	0.000159	0.0116	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41057681	chr14:40954898~40975877:+
THCA	cis	rs758324	0.54	rs31481	ENSG00000224431.1	AC063976.7	3.81	0.000159	0.0116	0.17	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132061509	chr5:132199456~132203487:+
THCA	cis	rs6847067	0.794	rs6531782	ENSG00000180769.7	WDFY3-AS2	-3.81	0.000159	0.0116	-0.13	-0.17	Oropharynx cancer;	chr4:85007246	chr4:84965682~85011277:+
THCA	cis	rs1204798	0.588	rs9488849	ENSG00000237021.2	RP3-486I3.7	-3.81	0.000159	0.0116	-0.21	-0.17	Dental caries;	chr6:116142155	chr6:116254207~116256743:+
THCA	cis	rs8130944	0.964	rs7280645	ENSG00000235772.1	AP001625.6	3.81	0.000159	0.0116	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42716515	chr21:42560374~42561934:-
THCA	cis	rs2522056	1	rs62385693	ENSG00000237714.1	P4HA2-AS1	-3.81	0.000159	0.0116	-0.25	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132437982	chr5:132184876~132192808:+
THCA	cis	rs17122278	1	rs2277291	ENSG00000243431.1	RPL5P30	3.81	0.000159	0.0116	0.19	0.17	Total cholesterol levels;	chr11:118565041	chr11:118560690~118561580:+
THCA	cis	rs4915077	0.892	rs17020105	ENSG00000226822.1	RP11-356N1.2	3.81	0.000159	0.0116	0.28	0.17	Hypothyroidism;	chr1:107811106	chr1:108071482~108074519:+
THCA	cis	rs2153535	0.518	rs1328868	ENSG00000230939.1	RP11-314C16.1	-3.81	0.000159	0.0116	-0.19	-0.17	Motion sickness;	chr6:8652345	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.518	rs9505510	ENSG00000230939.1	RP11-314C16.1	-3.81	0.000159	0.0116	-0.19	-0.17	Motion sickness;	chr6:8657603	chr6:8784178~8785445:+
THCA	cis	rs7829975	0.84	rs555617	ENSG00000253981.4	ALG1L13P	-3.81	0.000159	0.0116	-0.16	-0.17	Mood instability;	chr8:8735335	chr8:8236003~8244667:-
THCA	cis	rs7586085	0.874	rs13422985	ENSG00000232411.1	AC009495.3	3.81	0.000159	0.0116	0.19	0.17	Total body bone mineral density;	chr2:165764126	chr2:165833048~165839098:-
THCA	cis	rs7403037	1	rs28786136	ENSG00000260760.1	PWRN3	3.81	0.000159	0.0116	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24586967	chr15:24441127~24447967:+
THCA	cis	rs7403037	1	rs28625349	ENSG00000260760.1	PWRN3	3.81	0.000159	0.0116	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24587326	chr15:24441127~24447967:+
THCA	cis	rs4761470	0.577	rs57925369	ENSG00000258172.1	RP11-1105G2.4	-3.81	0.000159	0.0116	-0.23	-0.17	Estradiol plasma levels (breast cancer);	chr12:94295732	chr12:94272150~94277195:-
THCA	cis	rs2562456	0.752	rs279809	ENSG00000268278.1	RP11-420K14.1	3.81	0.000159	0.0116	0.25	0.17	Pain;	chr19:21284729	chr19:21637974~21656300:+
THCA	cis	rs12681366	0.659	rs2470735	ENSG00000261437.1	RP11-22C11.2	-3.81	0.000159	0.0116	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94403670	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.636	rs2246066	ENSG00000261437.1	RP11-22C11.2	-3.81	0.000159	0.0116	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94406927	chr8:94637285~94639467:-
THCA	cis	rs4443100	0.916	rs875602	ENSG00000230701.2	FBXW4P1	3.81	0.000159	0.0116	0.2	0.17	Serum parathyroid hormone levels;	chr22:23053506	chr22:23262767~23265005:+
THCA	cis	rs6570726	0.818	rs399516	ENSG00000270638.1	RP3-466P17.1	3.81	0.000159	0.0116	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145735570~145737218:+
THCA	cis	rs9863	0.931	rs4575361	ENSG00000270028.1	RP11-380L11.4	3.81	0.000159	0.0116	0.19	0.17	White blood cell count;	chr12:123925982	chr12:123925461~123926083:-
THCA	cis	rs10435719	0.902	rs7459545	ENSG00000254948.1	OR7E158P	-3.81	0.000159	0.0116	-0.22	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:11919900~11920809:-
THCA	cis	rs74233809	1	rs74233296	ENSG00000272912.1	RP11-724N1.1	-3.81	0.000159	0.0116	-0.31	-0.17	Birth weight;	chr10:102895593	chr10:102914585~102915404:+
THCA	cis	rs758324	0.947	rs600661	ENSG00000237714.1	P4HA2-AS1	-3.81	0.000159	0.0116	-0.25	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131955201	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs615305	ENSG00000237714.1	P4HA2-AS1	-3.81	0.000159	0.0116	-0.25	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131956163	chr5:132184876~132192808:+
THCA	cis	rs7131987	0.868	rs7958210	ENSG00000257599.1	OVCH1-AS1	-3.81	0.000159	0.0116	-0.21	-0.17	QT interval;	chr12:29242248	chr12:29389294~29487488:+
THCA	cis	rs520525	0.963	rs524877	ENSG00000271811.1	RP1-79C4.4	3.81	0.000159	0.0116	0.22	0.17	Atrial fibrillation;	chr1:170659294	chr1:170667381~170669425:+
THCA	cis	rs733175	0.794	rs10033088	ENSG00000261490.1	RP11-448G15.3	3.81	0.000159	0.0116	0.13	0.17	Psychosis and Alzheimer's disease;	chr4:10056088	chr4:10068089~10073019:-
THCA	cis	rs683250	0.629	rs669290	ENSG00000254551.1	RP11-727A23.7	3.81	0.000159	0.0116	0.21	0.17	Subcortical brain region volumes;	chr11:83238015	chr11:83209431~83213379:-
THCA	cis	rs17741873	0.632	rs56756262	ENSG00000271848.1	RP11-464F9.21	-3.81	0.000159	0.0116	-0.22	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73829735	chr10:73654039~73674719:+
THCA	cis	rs6487679	0.543	rs34363	ENSG00000111788.10	RP11-22B23.1	-3.81	0.000159	0.0116	-0.29	-0.17	Non-alcoholic fatty liver disease histology (AST);	chr12:9238261	chr12:9277235~9313241:+
THCA	cis	rs7176527	0.848	rs72630461	ENSG00000230373.7	GOLGA6L5P	3.81	0.000159	0.0116	0.25	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84696913	chr15:84507885~84516814:-
THCA	cis	rs2797160	0.508	rs9375404	ENSG00000237742.5	RP11-624M8.1	-3.81	0.000159	0.0116	-0.16	-0.17	Endometrial cancer;	chr6:125606749	chr6:125578558~125749190:-
THCA	cis	rs7560272	0.501	rs12713793	ENSG00000163016.8	ALMS1P	-3.81	0.000159	0.0116	-0.21	-0.17	Schizophrenia;	chr2:73728987	chr2:73644919~73685576:+
THCA	cis	rs2732480	0.557	rs2409004	ENSG00000257735.1	RP11-370I10.6	3.81	0.000159	0.0116	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48350945~48442411:+
THCA	cis	rs2732480	0.577	rs2450994	ENSG00000257735.1	RP11-370I10.6	3.81	0.000159	0.0116	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48350945~48442411:+
THCA	cis	rs3845817	0.868	rs702891	ENSG00000281920.1	RP11-418H16.1	3.81	0.000159	0.0116	0.21	0.17	Bipolar disorder;	chr2:65531316	chr2:65623272~65628424:+
THCA	cis	rs11105298	0.891	rs10858899	ENSG00000266347.2	AC068641.1	3.81	0.000159	0.0116	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs10858900	ENSG00000266347.2	AC068641.1	3.81	0.000159	0.0116	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs11105316	ENSG00000266347.2	AC068641.1	3.81	0.000159	0.0116	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89592833~89592927:+
THCA	cis	rs9291683	0.53	rs10939620	ENSG00000261490.1	RP11-448G15.3	-3.81	0.000159	0.0116	-0.11	-0.17	Bone mineral density;	chr4:9944508	chr4:10068089~10073019:-
THCA	cis	rs7259376	0.902	rs12610462	ENSG00000269345.1	VN1R85P	3.81	0.000159	0.0116	0.19	0.17	Menopause (age at onset);	chr19:22368660	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs16999064	ENSG00000269345.1	VN1R85P	3.81	0.000159	0.0116	0.19	0.17	Menopause (age at onset);	chr19:22369800	chr19:22174766~22175191:-
THCA	cis	rs4218	0.689	rs2121237	ENSG00000259732.1	RP11-59H7.3	-3.81	0.000159	0.0116	-0.24	-0.17	Social communication problems;	chr15:59091888	chr15:59121034~59133250:+
THCA	cis	rs61160187	0.61	rs4700399	ENSG00000251279.1	CTC-436P18.1	-3.81	0.000159	0.0116	-0.21	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:61162070~61232040:+
THCA	cis	rs160451	0.782	rs10956226	ENSG00000251136.7	RP11-37B2.1	3.81	0.000159	0.0116	0.16	0.17	Leprosy;	chr8:89687131	chr8:89609409~89757727:-
THCA	cis	rs17345786	0.52	rs12638134	ENSG00000256628.3	ZBTB11-AS1	3.81	0.000159	0.0116	0.18	0.17	Colonoscopy-negative controls vs population controls;	chr3:101615765	chr3:101676475~101679217:+
THCA	cis	rs75059851	1	rs3802924	ENSG00000280237.1	MIR4697HG	3.81	0.000159	0.0116	0.2	0.17	Schizophrenia;	chr11:133957838	chr11:133896438~133901601:-
THCA	cis	rs3924048	0.547	rs6678689	ENSG00000276830.1	MIR6730	-3.81	0.000159	0.0116	-0.18	-0.17	Optic cup area;	chr1:12559874	chr1:12578957~12579023:-
THCA	cis	rs453301	0.686	rs6748	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000159	0.0116	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9033292	chr8:9141424~9145435:+
THCA	cis	rs7119038	0.818	rs11217040	ENSG00000255422.1	AP002954.4	3.81	0.000159	0.0116	0.22	0.17	Sjögren's syndrome;	chr11:118809939	chr11:118704607~118750263:+
THCA	cis	rs3743162	1	rs12917429	ENSG00000275120.1	RP11-182J1.17	-3.81	0.000159	0.0116	-0.21	-0.17	Alzheimer's disease (age of onset);	chr15:84881866	chr15:84599434~84606463:-
THCA	cis	rs4578769	0.524	rs9956919	ENSG00000273232.1	RP11-370A5.2	3.81	0.000159	0.0116	0.24	0.17	Eosinophil percentage of white cells;	chr18:22896538	chr18:22882825~22883357:-
THCA	cis	rs1005277	0.522	rs1208767	ENSG00000275858.1	RP11-291L22.8	3.81	0.000159	0.0116	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38450738~38451069:-
THCA	cis	rs9634489	0.559	rs7334728	ENSG00000247400.3	DNAJC3-AS1	-3.81	0.000159	0.0116	-0.11	-0.17	Body mass index;	chr13:96289299	chr13:95648733~95676925:-
THCA	cis	rs11168249	0.819	rs2525051	ENSG00000276691.1	RP5-1057I20.5	3.81	0.000159	0.0116	0.17	0.17	Lymphocyte counts;Inflammatory bowel disease;Ulcerative colitis;	chr12:47802156	chr12:47788426~47788971:+
THCA	cis	rs4578769	0.55	rs11082182	ENSG00000273232.1	RP11-370A5.2	3.81	0.000159	0.0116	0.23	0.17	Eosinophil percentage of white cells;	chr18:22872136	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.531	rs11082183	ENSG00000273232.1	RP11-370A5.2	3.81	0.000159	0.0116	0.23	0.17	Eosinophil percentage of white cells;	chr18:22872137	chr18:22882825~22883357:-
THCA	cis	rs11971779	0.68	rs7779900	ENSG00000252332.1	RNU6-911P	-3.81	0.000159	0.0116	-0.19	-0.17	Diisocyanate-induced asthma;	chr7:139398241	chr7:139448740~139448843:+
THCA	cis	rs13063635	0.831	rs35209528	ENSG00000226074.4	PRSS44	-3.81	0.000159	0.0116	-0.33	-0.17	Eosinophil percentage of granulocytes;	chr3:45962004	chr3:46809359~46812558:-
THCA	cis	rs970548	0.954	rs10466245	ENSG00000230869.1	CTGLF10P	3.81	0.000159	0.0116	0.21	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45536299	chr10:45678692~45700532:+
THCA	cis	rs34421088	0.56	rs2245250	ENSG00000227888.4	FAM66A	-3.81	0.000159	0.0116	-0.22	-0.17	Neuroticism;	chr8:11543171	chr8:12362019~12388296:+
THCA	cis	rs13434995	0.513	rs972446	ENSG00000249700.7	SRD5A3-AS1	3.81	0.000159	0.0116	0.24	0.17	Adiponectin levels;	chr4:55569581	chr4:55363971~55395847:-
THCA	cis	rs13434995	0.513	rs11732481	ENSG00000249700.7	SRD5A3-AS1	3.81	0.000159	0.0116	0.24	0.17	Adiponectin levels;	chr4:55570212	chr4:55363971~55395847:-
THCA	cis	rs6724465	0.852	rs7561119	ENSG00000272644.1	RP11-33O4.1	3.81	0.000159	0.0116	0.25	0.17	Height;	chr2:219121531	chr2:219069354~219069809:-
THCA	cis	rs7616559	0.566	rs2046269	ENSG00000244515.1	KRT18P34	-3.81	0.000159	0.0116	-0.2	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157011765	chr3:157162663~157163932:-
THCA	cis	rs11242704	0.962	rs2816287	ENSG00000218027.2	RP11-157J24.1	-3.81	0.000159	0.0116	-0.22	-0.17	Response to hepatitis C treatment;	chr6:1536909	chr6:1513698~1515289:-
THCA	cis	rs420259	0.516	rs2072062	ENSG00000260136.4	CTD-2270L9.4	-3.81	0.000159	0.0116	-0.13	-0.17	Bipolar disorder;	chr16:23529477	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs7199108	ENSG00000260136.4	CTD-2270L9.4	-3.81	0.000159	0.0116	-0.13	-0.17	Bipolar disorder;	chr16:23537480	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs2106456	ENSG00000260136.4	CTD-2270L9.4	-3.81	0.000159	0.0116	-0.13	-0.17	Bipolar disorder;	chr16:23539610	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs11643602	ENSG00000260136.4	CTD-2270L9.4	-3.81	0.000159	0.0116	-0.13	-0.17	Bipolar disorder;	chr16:23545588	chr16:23452758~23457606:+
THCA	cis	rs420259	0.516	rs4968019	ENSG00000260136.4	CTD-2270L9.4	-3.81	0.000159	0.0116	-0.13	-0.17	Bipolar disorder;	chr16:23546469	chr16:23452758~23457606:+
THCA	cis	rs2842346	0.568	rs2525521	ENSG00000258623.1	CTD-2325P2.3	-3.81	0.000159	0.0116	-0.22	-0.17	Breast cancer;	chr14:68536600	chr14:68683411~68685565:-
THCA	cis	rs7203193	0.966	rs9932957	ENSG00000241641.1	RPS23P6	3.81	0.000159	0.0116	0.17	0.17	LDL cholesterol;	chr16:11539171	chr16:12081237~12081902:+
THCA	cis	rs494526	0.641	rs11198770	ENSG00000229272.1	RP11-498J9.2	-3.81	0.000159	0.0116	-0.19	-0.17	Alcoholic chronic pancreatitis;	chr10:119098232	chr10:119003536~119003884:-
THCA	cis	rs7259376	0.875	rs6511345	ENSG00000270947.1	AC025811.3	3.81	0.000159	0.0116	0.18	0.17	Menopause (age at onset);	chr19:22354634	chr19:22455988~22456459:+
THCA	cis	rs34102591	0.744	rs35981630	ENSG00000270028.1	RP11-380L11.4	3.81	0.000159	0.0116	0.27	0.17	Schizophrenia;	chr12:123978731	chr12:123925461~123926083:-
THCA	cis	rs12499086	0.611	rs6817372	ENSG00000251175.4	RP11-45L9.1	3.81	0.000159	0.0116	0.22	0.17	Economic and political preferences (time);	chr4:105503381	chr4:105746245~105827172:-
THCA	cis	rs3740713	0.669	rs113003553	ENSG00000256464.1	YWHABP2	3.81	0.000159	0.0117	0.28	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr11:18490243~18490955:-
THCA	cis	rs7737355	0.947	rs6895841	ENSG00000237714.1	P4HA2-AS1	3.81	0.000159	0.0117	0.25	0.17	Life satisfaction;	chr5:131437841	chr5:132184876~132192808:+
THCA	cis	rs7818688	0.745	rs16917117	ENSG00000253528.2	RP11-347C18.4	3.81	0.000159	0.0117	0.27	0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94897270	chr8:94974573~94974853:-
THCA	cis	rs200972	1	rs200972	ENSG00000273712.1	RP5-874C20.7	3.81	0.000159	0.0117	0.2	0.17	Urinary tract infection frequency;	chr6:27891059	chr6:28315613~28315883:-
THCA	cis	rs8007846	0.685	rs7157006	ENSG00000276116.2	FUT8-AS1	3.81	0.000159	0.0117	0.18	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr14:65361489	chr14:65411170~65412690:-
THCA	cis	rs8007846	0.685	rs7158347	ENSG00000276116.2	FUT8-AS1	3.81	0.000159	0.0117	0.18	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr14:65362237	chr14:65411170~65412690:-
THCA	cis	rs4883201	0.656	rs4883203	ENSG00000245105.2	A2M-AS1	3.81	0.000159	0.0117	0.17	0.17	Total cholesterol levels;Cholesterol, total;	chr12:8959201	chr12:9065177~9068060:+
THCA	cis	rs4268898	0.862	rs11125549	ENSG00000242628.4	AC009228.1	-3.81	0.000159	0.0117	-0.21	-0.17	Asthma;	chr2:24353371	chr2:24214381~24221516:+
THCA	cis	rs73173548	0.528	rs34182576	ENSG00000247828.6	TMEM161B-AS1	3.81	0.000159	0.0117	0.16	0.17	Macular telangiectasia type 2;	chr5:88438321	chr5:88268895~88436685:+
THCA	cis	rs721917	0.506	rs2758555	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000159	0.0117	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs1923538	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000159	0.0117	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79660891~79677996:+
THCA	cis	rs721917	0.507	rs2819101	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000159	0.0117	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2819100	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000159	0.0117	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2758547	ENSG00000244733.5	RP11-506M13.3	-3.81	0.000159	0.0117	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79660891~79677996:+
THCA	cis	rs4785204	1	rs9932240	ENSG00000279356.1	RP11-429P3.8	-3.81	0.000159	0.0117	-0.31	-0.17	Esophageal cancer (squamous cell);	chr16:50060316	chr16:50072862~50074986:+
THCA	cis	rs1267303	0.642	rs6696219	ENSG00000232022.5	FAAHP1	3.81	0.000159	0.0117	0.2	0.17	Monobrow;	chr1:46534736	chr1:46432129~46445521:+
THCA	cis	rs6490294	0.747	rs632650	ENSG00000226469.1	ADAM1B	3.81	0.000159	0.0117	0.22	0.17	Mean platelet volume;	chr12:111693894	chr12:111927018~111929017:+
THCA	cis	rs1005277	0.522	rs9417256	ENSG00000275858.1	RP11-291L22.8	3.81	0.000159	0.0117	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38450738~38451069:-
THCA	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-3.81	0.000159	0.0117	-0.19	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
THCA	cis	rs14027	0.883	rs35449013	ENSG00000245330.4	KB-1471A8.1	3.81	0.000159	0.0117	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119867419~119874488:-
THCA	cis	rs9928842	0.824	rs889515	ENSG00000261783.1	RP11-252K23.2	3.81	0.000159	0.0117	0.33	0.17	Alcoholic chronic pancreatitis;	chr16:75217401	chr16:75379818~75381260:-
THCA	cis	rs1009077	0.627	rs28625289	ENSG00000248280.1	RP11-33B1.2	-3.81	0.000159	0.0117	-0.19	-0.17	Endometriosis;	chr4:119601850	chr4:119440561~119450157:-
THCA	cis	rs4950322	1	rs72694750	ENSG00000180867.10	PDIA3P1	3.81	0.000159	0.0117	0.18	0.17	Protein quantitative trait loci;	chr1:147396856	chr1:147178113~147179622:+
THCA	cis	rs4950322	1	rs1986987	ENSG00000180867.10	PDIA3P1	3.81	0.000159	0.0117	0.18	0.17	Protein quantitative trait loci;	chr1:147397553	chr1:147178113~147179622:+
THCA	cis	rs4950322	1	rs61230354	ENSG00000180867.10	PDIA3P1	3.81	0.000159	0.0117	0.18	0.17	Protein quantitative trait loci;	chr1:147398161	chr1:147178113~147179622:+
THCA	cis	rs4950322	1	rs4950429	ENSG00000180867.10	PDIA3P1	3.81	0.000159	0.0117	0.18	0.17	Protein quantitative trait loci;	chr1:147400227	chr1:147178113~147179622:+
THCA	cis	rs4950322	1	rs59498179	ENSG00000180867.10	PDIA3P1	3.81	0.000159	0.0117	0.18	0.17	Protein quantitative trait loci;	chr1:147400417	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.947	rs58671552	ENSG00000180867.10	PDIA3P1	3.81	0.000159	0.0117	0.18	0.17	Protein quantitative trait loci;	chr1:147409534	chr1:147178113~147179622:+
THCA	cis	rs9959145	0.706	rs117416781	ENSG00000267199.1	RP11-861E21.2	3.81	0.000159	0.0117	0.22	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12684925	chr18:12438890~12448205:+
THCA	cis	rs9959145	1	rs78421903	ENSG00000267199.1	RP11-861E21.2	3.81	0.000159	0.0117	0.22	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12688701	chr18:12438890~12448205:+
THCA	cis	rs2625529	0.824	rs12595228	ENSG00000260037.4	CTD-2524L6.3	-3.81	0.000159	0.0117	-0.24	-0.17	Red blood cell count;	chr15:71974874	chr15:71818396~71823384:+
THCA	cis	rs4759375	0.92	rs7972811	ENSG00000256092.2	RP13-942N8.1	3.81	0.000159	0.0117	0.19	0.17	HDL cholesterol;	chr12:123336233	chr12:123363868~123366113:+
THCA	cis	rs295490	0.748	rs79654016	ENSG00000272656.1	RP11-219D15.3	3.81	0.000159	0.0117	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139374644	chr3:139349024~139349371:-
THCA	cis	rs757081	0.506	rs11529609	ENSG00000272034.1	SNORD14A	-3.81	0.000159	0.0117	-0.2	-0.17	Systolic blood pressure;	chr11:17042243	chr11:17074654~17074744:-
THCA	cis	rs786425	0.682	rs7309528	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123687111	chr12:123519390~123519856:-
THCA	cis	rs786425	0.69	rs6488892	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123687279	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs6488893	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123687356	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs12829984	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123687760	chr12:123519390~123519856:-
THCA	cis	rs786425	0.654	rs7307343	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123689818	chr12:123519390~123519856:-
THCA	cis	rs786425	0.654	rs7310918	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123690109	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs11833604	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123691925	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs35946281	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123692469	chr12:123519390~123519856:-
THCA	cis	rs786425	0.655	rs12821242	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123693782	chr12:123519390~123519856:-
THCA	cis	rs786425	0.711	rs12831081	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123695192	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7298440	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123696502	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7979528	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123697273	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7968029	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123697573	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs11613632	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123699518	chr12:123519390~123519856:-
THCA	cis	rs786425	0.575	rs73219037	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123699935	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7398152	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123700092	chr12:123519390~123519856:-
THCA	cis	rs786425	0.655	rs7973155	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123701401	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs34586028	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123702535	chr12:123519390~123519856:-
THCA	cis	rs786425	0.655	rs11612030	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123703517	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs12827074	ENSG00000278112.1	RP11-972P1.11	3.81	0.000159	0.0117	0.17	0.17	Pubertal anthropometrics;	chr12:123706289	chr12:123519390~123519856:-
THCA	cis	rs12497850	0.644	rs11928552	ENSG00000228638.1	FCF1P2	-3.81	0.000159	0.0117	-0.18	-0.17	Parkinson's disease;	chr3:48702450	chr3:48290793~48291375:-
THCA	cis	rs7824557	0.564	rs12547100	ENSG00000255046.1	RP11-297N6.4	3.81	0.000159	0.0117	0.18	0.17	Retinal vascular caliber;	chr8:11385123	chr8:11797928~11802568:-
THCA	cis	rs13113518	0.756	rs12510275	ENSG00000272969.1	RP11-528I4.2	3.81	0.000159	0.0117	0.2	0.17	Height;	chr4:55516548	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs12510327	ENSG00000272969.1	RP11-528I4.2	3.81	0.000159	0.0117	0.2	0.17	Height;	chr4:55516744	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs11939580	ENSG00000272969.1	RP11-528I4.2	3.81	0.000159	0.0117	0.2	0.17	Height;	chr4:55517185	chr4:55547112~55547889:+
THCA	cis	rs889312	0.5	rs252905	ENSG00000271828.1	CTD-2310F14.1	-3.81	0.000159	0.0117	-0.24	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56823048	chr5:56927874~56929573:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000223473.2	GS1-124K5.3	-3.81	0.000159	0.0117	-0.12	-0.17	Aortic root size;	chr7:66836124	chr7:66491049~66493566:-
THCA	cis	rs1023500	0.573	rs133380	ENSG00000273366.1	CTA-989H11.1	-3.81	0.000159	0.0117	-0.21	-0.17	Schizophrenia;	chr22:42072906	chr22:42278188~42278846:+
THCA	cis	rs34421088	0.56	rs2245357	ENSG00000227888.4	FAM66A	-3.81	0.000159	0.0117	-0.22	-0.17	Neuroticism;	chr8:11541975	chr8:12362019~12388296:+
THCA	cis	rs17597773	0.638	rs11118609	ENSG00000238078.1	LINC01352	3.81	0.000159	0.0117	0.23	0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815148	chr1:220829255~220832429:+
THCA	cis	rs6560517	0.519	rs11144933	ENSG00000234618.1	RPSAP9	-3.81	0.000159	0.0117	-0.2	-0.17	Dialysis-related mortality;	chr9:76508799	chr9:76398699~76399586:+
THCA	cis	rs6012953	1	rs6091173	ENSG00000231715.1	COX6CP2	3.81	0.000159	0.0117	0.18	0.17	Vitiligo;	chr20:50517562	chr20:50479767~50479991:+
THCA	cis	rs17286411	0.641	rs4788549	ENSG00000260185.1	RP11-432I5.6	-3.81	0.000159	0.0117	-0.24	-0.17	Blood protein levels;	chr16:71680216	chr16:71655027~71664212:+
THCA	cis	rs12817211	0.658	rs35031884	ENSG00000272368.2	RP4-605O3.4	-3.81	0.000159	0.0117	-0.14	-0.17	Colorectal or endometrial cancer;	chr12:50383790	chr12:50112197~50165618:+
THCA	cis	rs12817211	0.699	rs61926184	ENSG00000272368.2	RP4-605O3.4	-3.81	0.000159	0.0117	-0.14	-0.17	Colorectal or endometrial cancer;	chr12:50384521	chr12:50112197~50165618:+
THCA	cis	rs6142618	0.811	rs6058611	ENSG00000224452.1	RSL24D1P6	3.81	0.000159	0.0117	0.22	0.17	Inflammatory bowel disease;	chr20:32273297	chr20:32170390~32170790:-
THCA	cis	rs7520050	0.966	rs7556436	ENSG00000281133.1	AL355480.3	-3.81	0.000159	0.0117	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45580892~45580996:-
THCA	cis	rs2115630	1	rs10220733	ENSG00000259295.5	CSPG4P12	-3.81	0.00016	0.0117	-0.23	-0.17	P wave terminal force;	chr15:84737633	chr15:85191438~85213905:+
THCA	cis	rs2115630	1	rs1030863	ENSG00000259295.5	CSPG4P12	-3.81	0.00016	0.0117	-0.23	-0.17	P wave terminal force;	chr15:84739404	chr15:85191438~85213905:+
THCA	cis	rs7264396	0.733	rs6058305	ENSG00000088340.14	FER1L4	3.81	0.00016	0.0117	0.17	0.17	Total cholesterol levels;	chr20:35722835	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.733	rs2425105	ENSG00000088340.14	FER1L4	3.81	0.00016	0.0117	0.17	0.17	Total cholesterol levels;	chr20:35724912	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.747	rs2425112	ENSG00000088340.14	FER1L4	3.81	0.00016	0.0117	0.17	0.17	Total cholesterol levels;	chr20:35731853	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs2425115	ENSG00000088340.14	FER1L4	3.81	0.00016	0.0117	0.17	0.17	Total cholesterol levels;	chr20:35734496	chr20:35558737~35607562:-
THCA	cis	rs858239	0.899	rs1881203	ENSG00000226816.2	AC005082.12	3.81	0.00016	0.0117	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23206013~23208045:+
THCA	cis	rs7577696	0.649	rs56208031	ENSG00000276334.1	AL133243.1	3.81	0.00016	0.0117	0.19	0.17	Inflammatory biomarkers;	chr2:32120494	chr2:32521927~32523547:+
THCA	cis	rs453301	0.624	rs2288671	ENSG00000254340.1	RP11-10A14.3	3.81	0.00016	0.0117	0.18	0.17	Joint mobility (Beighton score);	chr8:9003384	chr8:9141424~9145435:+
THCA	cis	rs6929812	0.702	rs7753569	ENSG00000271755.1	RP1-153G14.4	3.81	0.00016	0.0117	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27421371	chr6:27404010~27406964:-
THCA	cis	rs3738443	0.672	rs6691539	ENSG00000259865.1	RP11-488L18.10	3.81	0.00016	0.0117	0.15	0.17	Alcohol dependence;	chr1:247209370	chr1:247187281~247188526:-
THCA	cis	rs4470077	1	rs12879078	ENSG00000258413.1	RP11-665C16.6	-3.81	0.00016	0.0117	-0.3	-0.17	Platelet count;	chr14:55432697	chr14:55262767~55272075:-
THCA	cis	rs7178424	0.742	rs12906423	ENSG00000259251.2	RP11-643M14.1	-3.81	0.00016	0.0117	-0.17	-0.17	Height;	chr15:61911685	chr15:62060503~62062434:+
THCA	cis	rs7615952	0.546	rs2922194	ENSG00000241278.1	ENPP7P4	3.81	0.00016	0.0117	0.25	0.17	Blood pressure (smoking interaction);	chr3:125613419	chr3:125848223~125909372:+
THCA	cis	rs755249	0.883	rs12035330	ENSG00000182109.6	RP11-69E11.4	3.81	0.00016	0.0117	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39522280~39546187:-
THCA	cis	rs9863	0.827	rs6488913	ENSG00000270028.1	RP11-380L11.4	-3.81	0.00016	0.0117	-0.18	-0.17	White blood cell count;	chr12:123961022	chr12:123925461~123926083:-
THCA	cis	rs10090774	0.932	rs9644449	ENSG00000280303.2	ERICD	-3.81	0.00016	0.0117	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140937186	chr8:140636281~140638283:+
THCA	cis	rs5997397	0.934	rs6005864	ENSG00000226471.5	CTA-292E10.6	3.81	0.00016	0.0117	0.14	0.17	Red cell distribution width;	chr22:28761499	chr22:28800683~28848559:+
THCA	cis	rs10911902	0.601	rs16825279	ENSG00000228238.1	GS1-304P7.2	-3.81	0.00016	0.0117	-0.29	-0.17	Schizophrenia;	chr1:186385523	chr1:186578279~186579299:+
THCA	cis	rs1200921	0.898	rs1148259	ENSG00000272983.1	RP11-508N22.12	-3.81	0.00016	0.0117	-0.15	-0.17	Breast cancer;	chr10:37219522	chr10:38137337~38144399:+
THCA	cis	rs1005277	0.505	rs200936	ENSG00000120555.12	SEPT7P9	3.81	0.00016	0.0117	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.505	rs200937	ENSG00000120555.12	SEPT7P9	3.81	0.00016	0.0117	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38383069~38402916:-
THCA	cis	rs1383484	1	rs12443111	ENSG00000225151.9	GOLGA2P7	3.81	0.00016	0.0117	0.23	0.17	Height;	chr15:83835727	chr15:84199311~84230136:-
THCA	cis	rs1040	0.674	rs7381269	ENSG00000261039.2	RP11-417E7.2	-3.81	0.00016	0.0117	-0.19	-0.17	Joint mobility (Beighton score);	chr6:169200066	chr6:169175304~169182740:-
THCA	cis	rs1040	0.674	rs9393166	ENSG00000261039.2	RP11-417E7.2	-3.81	0.00016	0.0117	-0.19	-0.17	Joint mobility (Beighton score);	chr6:169200760	chr6:169175304~169182740:-
THCA	cis	rs471756	0.523	rs605001	ENSG00000231808.2	LINC01388	-3.81	0.00016	0.0117	-0.2	-0.17	Mean platelet volume;	chr9:223843	chr9:112713~113754:-
THCA	cis	rs181553	0.664	rs1838962	ENSG00000266696.1	RP11-30L3.2	3.81	0.00016	0.0117	0.22	0.17	Hip circumference adjusted for BMI;	chr18:49153529	chr18:49205912~49208781:+
THCA	cis	rs613391	0.561	rs496615	ENSG00000234840.1	LINC01239	-3.81	0.00016	0.0117	-0.2	-0.17	Quantitative traits;	chr9:22718466	chr9:22646200~22824213:+
THCA	cis	rs853679	1	rs7740487	ENSG00000261839.1	RP1-265C24.8	3.81	0.00016	0.0117	0.24	0.17	Depression;	chr6:28248708	chr6:28136849~28139678:+
THCA	cis	rs853679	1	rs68141011	ENSG00000261839.1	RP1-265C24.8	3.81	0.00016	0.0117	0.24	0.17	Depression;	chr6:28250019	chr6:28136849~28139678:+
THCA	cis	rs853679	1	rs13200462	ENSG00000261839.1	RP1-265C24.8	3.81	0.00016	0.0117	0.24	0.17	Depression;	chr6:28250421	chr6:28136849~28139678:+
THCA	cis	rs7824557	0.564	rs12550129	ENSG00000227888.4	FAM66A	-3.81	0.00016	0.0117	-0.22	-0.17	Retinal vascular caliber;	chr8:11376408	chr8:12362019~12388296:+
THCA	cis	rs2191566	0.576	rs431509	ENSG00000277806.1	RP11-15A1.8	3.81	0.00016	0.0117	0.18	0.17	Acute lymphoblastic leukemia (childhood);	chr19:43991918	chr19:43976815~43977448:+
THCA	cis	rs17695224	0.545	rs7252508	ENSG00000275055.1	CTC-471J1.11	-3.81	0.00016	0.0117	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51831530	chr19:52049007~52049754:+
THCA	cis	rs72827839	1	rs72827899	ENSG00000228782.6	CTD-2026D20.3	3.81	0.00016	0.0117	0.22	0.17	Ease of getting up in the morning;	chr17:48474504	chr17:47450568~47492492:-
THCA	cis	rs8007846	0.65	rs12881911	ENSG00000276116.2	FUT8-AS1	3.81	0.00016	0.0117	0.18	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr14:65364503	chr14:65411170~65412690:-
THCA	cis	rs7833790	0.929	rs28464834	ENSG00000254689.1	RP11-354A14.1	-3.81	0.00016	0.0117	-0.22	-0.17	Diastolic blood pressure;	chr8:81885121	chr8:81885377~81923193:+
THCA	cis	rs927833	0.502	rs2424420	ENSG00000214535.3	RPS15AP1	-3.81	0.00016	0.0117	-0.25	-0.17	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr20:21982410	chr20:21166206~21166596:-
THCA	cis	rs875971	0.522	rs4502988	ENSG00000182722.5	SEPHS1P1	-3.81	0.00016	0.0117	-0.2	-0.17	Aortic root size;	chr7:65832759	chr7:64852397~64853354:-
THCA	cis	rs10559647	1	rs10559647	ENSG00000273038.2	RP11-479G22.8	-3.81	0.00016	0.0117	-0.2	-0.17	Platelet distribution width;	chr10:32380146	chr10:32887255~32889311:-
THCA	cis	rs11633886	0.585	rs12915174	ENSG00000273972.1	CTD-2306A12.1	3.81	0.00016	0.0117	0.2	0.17	Diisocyanate-induced asthma;	chr15:45787505	chr15:45702640~45703183:+
THCA	cis	rs10844706	0.669	rs10772108	ENSG00000214776.8	RP11-726G1.1	3.81	0.00016	0.0117	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9746454	chr12:9467552~9576275:+
THCA	cis	rs2688608	0.592	rs11814282	ENSG00000272140.2	RP11-574K11.29	3.81	0.00016	0.0117	0.15	0.17	Inflammatory bowel disease;	chr10:73730459	chr10:73703735~73713581:-
THCA	cis	rs6995541	0.647	rs6982769	ENSG00000248896.2	CTD-2135J3.3	-3.81	0.00016	0.0117	-0.21	-0.17	Triglyceride levels;	chr8:10830890	chr8:10729314~10771392:+
THCA	cis	rs7949566	0.614	rs10790801	ENSG00000255062.1	RP11-712L6.5	-3.81	0.00016	0.0117	-0.18	-0.17	Platelet distribution width;Mean platelet volume;	chr11:126402917	chr11:126294298~126304318:-
THCA	cis	rs7178375	0.843	rs3794596	ENSG00000215302.7	CTD-3092A11.1	-3.81	0.00016	0.0117	-0.23	-0.17	Hypertriglyceridemia;	chr15:30930823	chr15:30470779~30507623:+
THCA	cis	rs988712	1	rs988712	ENSG00000245573.6	BDNF-AS	3.81	0.00016	0.0117	0.16	0.17	Obesity;	chr11:27541835	chr11:27506838~27698174:+
THCA	cis	rs791590	0.752	rs62626317	ENSG00000225948.2	RP11-554I8.1	3.81	0.00016	0.0117	0.25	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6068962	chr10:6618716~6625346:+
THCA	cis	rs9660180	0.934	rs12729990	ENSG00000215914.4	MMP23A	-3.81	0.00016	0.0117	-0.23	-0.17	Body mass index;	chr1:1880596	chr1:1699942~1701782:+
THCA	cis	rs4869313	0.66	rs2549800	ENSG00000247121.5	CTD-2260A17.2	3.81	0.00016	0.0117	0.13	0.17	Pediatric autoimmune diseases;	chr5:96913930	chr5:96814028~96935809:-
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000229180.5	GS1-124K5.11	3.81	0.00016	0.0117	0.17	0.17	Diabetic kidney disease;	chr7:65988305	chr7:66526088~66542624:-
THCA	cis	rs17695224	0.606	rs10411054	ENSG00000275055.1	CTC-471J1.11	-3.81	0.00016	0.0117	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51831208	chr19:52049007~52049754:+
THCA	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	3.81	0.00016	0.0117	0.19	0.17	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
THCA	cis	rs4808779	1	rs4808779	ENSG00000268650.3	AC068499.10	-3.81	0.00016	0.0117	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr19:18294126	chr19:18204730~18220480:+
THCA	cis	rs1124769	0.654	rs35779980	ENSG00000259378.1	DCAF13P3	3.81	0.00016	0.0117	0.27	0.17	Cognitive performance;	chr15:51194301	chr15:50944663~50945996:+
THCA	cis	rs9595908	0.709	rs17594677	ENSG00000212293.1	SNORA16	3.81	0.00016	0.0117	0.2	0.17	Body mass index;	chr13:32734875	chr13:32420390~32420516:-
THCA	cis	rs1501911	0.53	rs162149	ENSG00000246763.5	RGMB-AS1	3.81	0.00016	0.0117	0.18	0.17	Lung function (FEV1/FVC);	chr5:98913851	chr5:98769618~98773469:-
THCA	cis	rs7829975	0.742	rs12547493	ENSG00000253981.4	ALG1L13P	-3.81	0.00016	0.0117	-0.17	-0.17	Mood instability;	chr8:8804024	chr8:8236003~8244667:-
THCA	cis	rs9905704	0.56	rs2526375	ENSG00000265148.4	BZRAP1-AS1	3.81	0.00016	0.0117	0.19	0.17	Testicular germ cell tumor;	chr17:58351733	chr17:58325450~58415766:+
THCA	cis	rs10129255	0.913	rs10140943	ENSG00000211972.2	IGHV3-66	3.81	0.00016	0.0117	0.1	0.17	Kawasaki disease;	chr14:106767441	chr14:106675017~106675544:-
THCA	cis	rs7615952	0.546	rs11718647	ENSG00000272840.1	RP11-379B18.6	3.81	0.00016	0.0117	0.28	0.17	Blood pressure (smoking interaction);	chr3:125633178	chr3:125774714~125797953:+
THCA	cis	rs35176054	1	rs35176054	ENSG00000280693.1	SH3PXD2A-AS1	-3.81	0.00016	0.0117	-0.32	-0.17	Atrial fibrillation;	chr10:103720629	chr10:103745966~103755423:+
THCA	cis	rs11649653	0.502	rs4889490	ENSG00000279196.1	RP11-1072A3.3	3.81	0.00016	0.0117	0.17	0.17	Triglycerides;	chr16:30811726	chr16:30984630~30988270:-
THCA	cis	rs10266483	0.774	rs11765812	ENSG00000271550.1	BNIP3P11	-3.81	0.00016	0.0117	-0.24	-0.17	Response to statin therapy;	chr7:64385366	chr7:64678954~64687393:-
THCA	cis	rs7826238	0.535	rs2979179	ENSG00000253981.4	ALG1L13P	3.81	0.00016	0.0117	0.16	0.17	Systolic blood pressure;	chr8:8462519	chr8:8236003~8244667:-
THCA	cis	rs427394	0.659	rs274693	ENSG00000248677.1	CTD-2044J15.1	3.81	0.00016	0.0117	0.17	0.17	Menopause (age at onset);	chr5:6734049	chr5:6686325~6707711:-
THCA	cis	rs427394	0.632	rs169285	ENSG00000248677.1	CTD-2044J15.1	3.81	0.00016	0.0117	0.17	0.17	Menopause (age at onset);	chr5:6736474	chr5:6686325~6707711:-
THCA	cis	rs1371614	0.632	rs3739088	ENSG00000272148.1	RP11-195B17.1	-3.81	0.00016	0.0117	-0.16	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944916	chr2:27062428~27062907:-
THCA	cis	rs1371614	0.632	rs3769135	ENSG00000272148.1	RP11-195B17.1	-3.81	0.00016	0.0117	-0.16	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26945543	chr2:27062428~27062907:-
THCA	cis	rs293748	0.771	rs66868318	ENSG00000250155.1	CTD-2353F22.1	-3.81	0.00016	0.0117	-0.23	-0.17	Obesity-related traits;	chr5:36826119	chr5:36666214~36725195:-
THCA	cis	rs2919009	0.544	rs7920943	ENSG00000271670.1	RP11-95I16.4	3.81	0.00016	0.0117	0.19	0.17	Obesity-related traits;	chr10:120923456	chr10:120879256~120880667:-
THCA	cis	rs34421088	0.548	rs2618443	ENSG00000227888.4	FAM66A	-3.81	0.00016	0.0117	-0.22	-0.17	Neuroticism;	chr8:11527047	chr8:12362019~12388296:+
THCA	cis	rs2625529	0.824	rs4411469	ENSG00000260037.4	CTD-2524L6.3	-3.81	0.00016	0.0117	-0.24	-0.17	Red blood cell count;	chr15:72129348	chr15:71818396~71823384:+
THCA	cis	rs250585	0.736	rs3096175	ENSG00000260136.4	CTD-2270L9.4	3.81	0.00016	0.0117	0.13	0.17	Egg allergy;	chr16:23446262	chr16:23452758~23457606:+
THCA	cis	rs34421088	0.576	rs2572437	ENSG00000255046.1	RP11-297N6.4	3.81	0.00016	0.0117	0.2	0.17	Neuroticism;	chr8:11240932	chr8:11797928~11802568:-
THCA	cis	rs796395	0.967	rs575544	ENSG00000232480.1	TGFB2-AS1	-3.81	0.00016	0.0117	-0.19	-0.17	Post bronchodilator FEV1/FVC ratio;	chr1:218469799	chr1:218344196~218345678:-
THCA	cis	rs7551222	0.752	rs12039454	ENSG00000240219.1	RP11-430C7.5	-3.81	0.00016	0.0117	-0.16	-0.17	Schizophrenia;	chr1:204573452	chr1:204626775~204629712:+
THCA	cis	rs6940638	0.744	rs858964	ENSG00000220721.1	OR1F12	-3.81	0.00016	0.0117	-0.21	-0.17	Intelligence (multi-trait analysis);	chr6:27174835	chr6:28073316~28074233:+
THCA	cis	rs1009077	1	rs2892875	ENSG00000245958.5	RP11-33B1.1	3.81	0.00016	0.0117	0.22	0.17	Endometriosis;	chr4:119695038	chr4:119454791~119552025:+
THCA	cis	rs420259	0.516	rs2239951	ENSG00000260136.4	CTD-2270L9.4	-3.81	0.00016	0.0117	-0.13	-0.17	Bipolar disorder;	chr16:23493672	chr16:23452758~23457606:+
THCA	cis	rs4713118	0.619	rs200486	ENSG00000220721.1	OR1F12	3.81	0.00016	0.0117	0.24	0.17	Parkinson's disease;	chr6:27811728	chr6:28073316~28074233:+
THCA	cis	rs56046484	0.912	rs12914674	ENSG00000259630.2	CTD-2262B20.1	-3.81	0.00016	0.0117	-0.25	-0.17	Testicular germ cell tumor;	chr15:85119829	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.956	rs34889576	ENSG00000259630.2	CTD-2262B20.1	-3.81	0.00016	0.0117	-0.25	-0.17	Testicular germ cell tumor;	chr15:85121445	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.956	rs34076898	ENSG00000259630.2	CTD-2262B20.1	-3.81	0.00016	0.0117	-0.25	-0.17	Testicular germ cell tumor;	chr15:85121569	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.956	rs35533990	ENSG00000259630.2	CTD-2262B20.1	-3.81	0.00016	0.0117	-0.25	-0.17	Testicular germ cell tumor;	chr15:85121590	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.956	rs35045545	ENSG00000259630.2	CTD-2262B20.1	-3.81	0.00016	0.0117	-0.25	-0.17	Testicular germ cell tumor;	chr15:85121720	chr15:85415228~85415633:+
THCA	cis	rs11971779	0.68	rs7785903	ENSG00000252332.1	RNU6-911P	-3.81	0.00016	0.0117	-0.19	-0.17	Diisocyanate-induced asthma;	chr7:139437897	chr7:139448740~139448843:+
THCA	cis	rs7819412	0.765	rs17783634	ENSG00000261451.1	RP11-981G7.1	-3.81	0.00016	0.0117	-0.22	-0.17	Triglycerides;	chr8:11196588	chr8:10433672~10438312:+
THCA	cis	rs7911264	0.739	rs6583827	ENSG00000232709.1	MARK2P9	-3.81	0.00016	0.0117	-0.21	-0.17	Inflammatory bowel disease;	chr10:92598266	chr10:92418667~92420875:+
THCA	cis	rs7911264	0.739	rs7096101	ENSG00000232709.1	MARK2P9	-3.81	0.00016	0.0117	-0.21	-0.17	Inflammatory bowel disease;	chr10:92603171	chr10:92418667~92420875:+
THCA	cis	rs7911264	0.739	rs10786050	ENSG00000232709.1	MARK2P9	-3.81	0.00016	0.0117	-0.21	-0.17	Inflammatory bowel disease;	chr10:92607473	chr10:92418667~92420875:+
THCA	cis	rs714027	0.585	rs960987	ENSG00000279699.1	RP1-102K2.9	3.81	0.00016	0.0117	0.18	0.17	Lymphocyte counts;	chr22:29947488	chr22:30275215~30276951:-
THCA	cis	rs7520050	0.966	rs10890361	ENSG00000234329.1	RP11-767N6.2	-3.81	0.00016	0.0117	-0.16	-0.17	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:45651039~45651826:-
THCA	cis	rs9467773	0.869	rs1796520	ENSG00000261353.1	CTA-14H9.5	3.81	0.00016	0.0117	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26410572	chr6:26527063~26527404:+
THCA	cis	rs295490	0.667	rs76728176	ENSG00000272656.1	RP11-219D15.3	3.81	0.000161	0.0117	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441574	chr3:139349024~139349371:-
THCA	cis	rs7819412	0.668	rs2409714	ENSG00000261451.1	RP11-981G7.1	-3.81	0.000161	0.0117	-0.22	-0.17	Triglycerides;	chr8:11152608	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.547	rs2409745	ENSG00000206014.6	OR7E161P	-3.81	0.000161	0.0117	-0.2	-0.17	Retinal vascular caliber;	chr8:11219126	chr8:11928597~11929563:-
THCA	cis	rs4087296	0.736	rs2967364	ENSG00000261235.1	RP11-510J16.5	-3.8	0.000161	0.0117	-0.22	-0.17	Bone mineral density;	chr16:82321149	chr16:82044336~82139631:-
THCA	cis	rs9959145	1	rs78543731	ENSG00000267199.1	RP11-861E21.2	3.8	0.000161	0.0117	0.22	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12665565	chr18:12438890~12448205:+
THCA	cis	rs494526	0.769	rs12264824	ENSG00000229272.1	RP11-498J9.2	3.8	0.000161	0.0117	0.2	0.17	Alcoholic chronic pancreatitis;	chr10:119076264	chr10:119003536~119003884:-
THCA	cis	rs1799922	1	rs1043550	ENSG00000271553.1	RP11-274B21.10	-3.8	0.000161	0.0117	-0.15	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128769171	chr7:128667043~128668156:+
THCA	cis	rs4664304	0.62	rs10929956	ENSG00000226266.5	AC009961.3	-3.8	0.000161	0.0117	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159858104	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.62	rs10186586	ENSG00000226266.5	AC009961.3	-3.8	0.000161	0.0117	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159858823	chr2:159670708~159712435:-
THCA	cis	rs2299587	0.545	rs13264911	ENSG00000253671.1	RP11-806O11.1	-3.8	0.000161	0.0117	-0.2	-0.17	Economic and political preferences;	chr8:17902247	chr8:17808941~17820868:+
THCA	cis	rs7927592	0.913	rs3740631	ENSG00000160172.9	FAM86C2P	3.8	0.000161	0.0117	0.17	0.17	Total body bone mineral density;	chr11:68574254	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs3824850	ENSG00000160172.9	FAM86C2P	3.8	0.000161	0.0117	0.17	0.17	Total body bone mineral density;	chr11:68574405	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs3740629	ENSG00000160172.9	FAM86C2P	3.8	0.000161	0.0117	0.17	0.17	Total body bone mineral density;	chr11:68576125	chr11:67791648~67805336:-
THCA	cis	rs1009077	0.518	rs28382361	ENSG00000248280.1	RP11-33B1.2	-3.8	0.000161	0.0117	-0.19	-0.17	Endometriosis;	chr4:119601926	chr4:119440561~119450157:-
THCA	cis	rs7819412	0.875	rs11250121	ENSG00000254839.1	AF131215.6	3.8	0.000161	0.0117	0.18	0.17	Triglycerides;	chr8:11202802	chr8:11062647~11067089:-
THCA	cis	rs757282	0.569	rs3759408	ENSG00000268069.2	RP5-1057I20.4	3.8	0.000161	0.0117	0.27	0.17	Optic nerve measurement (cup-to-disc ratio);	chr12:47779438	chr12:47784923~47786002:+
THCA	cis	rs2455799	0.594	rs11128769	ENSG00000270409.1	RP11-44D5.1	-3.8	0.000161	0.0117	-0.18	-0.17	Mean platelet volume;	chr3:15884723	chr3:15732252~15733470:+
THCA	cis	rs765787	0.53	rs2433229	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45223037	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4331289	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45223140	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2433228	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45223173	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11854690	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45223818	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs28733848	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45223849	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11854689	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45223854	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs1706830	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45224031	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs1706831	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45224032	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2433227	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45224921	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2668751	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45225095	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs1648286	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45225188	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs1648285	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45225307	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs1706835	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45225686	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs1631533	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000161	0.0117	0.21	0.17	Uric acid levels;	chr15:45226430	chr15:45152664~45167526:-
THCA	cis	rs7267979	0.966	rs6037083	ENSG00000276952.1	RP5-965G21.6	-3.8	0.000161	0.0117	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25284915~25285588:-
THCA	cis	rs10954779	0.728	rs2725359	ENSG00000127589.4	TUBBP1	3.8	0.000161	0.0118	0.2	0.17	Intelligence (multi-trait analysis);	chr8:31134232	chr8:30351873~30353518:+
THCA	cis	rs2882667	0.898	rs4380651	ENSG00000249593.5	CTB-46B19.2	3.8	0.000161	0.0118	0.21	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:139012647~139051203:+
THCA	cis	rs4869313	0.668	rs1363977	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96913003	chr5:96814028~96935809:-
THCA	cis	rs2039553	0.608	rs12428029	ENSG00000227354.5	RBM26-AS1	3.8	0.000161	0.0118	0.16	0.17	Pancreatic cancer;	chr13:79768177	chr13:79406309~79424328:+
THCA	cis	rs12544026	0.647	rs28623673	ENSG00000253669.3	KB-1732A1.1	-3.8	0.000161	0.0118	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101830683	chr8:102805517~102809971:+
THCA	cis	rs12548874	0.607	rs12543492	ENSG00000253528.2	RP11-347C18.4	3.8	0.000161	0.0118	0.2	0.17	Hemoglobin concentration;	chr8:94879615	chr8:94974573~94974853:-
THCA	cis	rs853679	0.607	rs13217984	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000161	0.0118	-0.34	-0.17	Depression;	chr6:28171932	chr6:28078792~28081130:-
THCA	cis	rs853679	0.556	rs67297533	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000161	0.0118	-0.34	-0.17	Depression;	chr6:28173475	chr6:28078792~28081130:-
THCA	cis	rs853679	0.505	rs35781323	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000161	0.0118	-0.34	-0.17	Depression;	chr6:28177054	chr6:28078792~28081130:-
THCA	cis	rs1478897	0.575	rs12679960	ENSG00000227888.4	FAM66A	3.8	0.000161	0.0118	0.23	0.17	Systemic lupus erythematosus;	chr8:11573481	chr8:12362019~12388296:+
THCA	cis	rs67478160	0.643	rs12434686	ENSG00000269940.1	RP11-73M18.7	-3.8	0.000161	0.0118	-0.16	-0.17	Schizophrenia;	chr14:103849696	chr14:103694560~103695170:+
THCA	cis	rs651907	0.712	rs796410	ENSG00000256628.3	ZBTB11-AS1	3.8	0.000161	0.0118	0.18	0.17	Colorectal cancer;	chr3:101891345	chr3:101676475~101679217:+
THCA	cis	rs8059260	0.541	rs35126143	ENSG00000274038.1	RP11-66H6.4	-3.8	0.000161	0.0118	-0.38	-0.17	Alcohol consumption over the past year;	chr16:11070455	chr16:11056556~11057034:+
THCA	cis	rs17607347	0.505	rs76220403	ENSG00000247324.2	RP11-510M2.2	-3.8	0.000161	0.0118	-0.34	-0.17	Intelligence (multi-trait analysis);	chr16:72306706	chr16:71462278~71465941:+
THCA	cis	rs4578769	0.788	rs12962334	ENSG00000273232.1	RP11-370A5.2	3.8	0.000161	0.0118	0.24	0.17	Eosinophil percentage of white cells;	chr18:22897971	chr18:22882825~22883357:-
THCA	cis	rs548181	0.668	rs540555	ENSG00000254671.2	STT3A-AS1	-3.8	0.000161	0.0118	-0.32	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125616953	chr11:125570284~125592568:-
THCA	cis	rs548181	0.736	rs540723	ENSG00000254671.2	STT3A-AS1	-3.8	0.000161	0.0118	-0.32	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125619726	chr11:125570284~125592568:-
THCA	cis	rs2032366	0.606	rs1377171	ENSG00000267316.4	RP11-879F14.3	-3.8	0.000161	0.0118	-0.19	-0.17	Obesity-related traits;	chr18:61606810	chr18:61571342~61579456:-
THCA	cis	rs6724465	0.673	rs6751232	ENSG00000272644.1	RP11-33O4.1	3.8	0.000161	0.0118	0.23	0.17	Height;	chr2:219151208	chr2:219069354~219069809:-
THCA	cis	rs9863	0.828	rs11057408	ENSG00000270028.1	RP11-380L11.4	3.8	0.000161	0.0118	0.19	0.17	White blood cell count;	chr12:123980289	chr12:123925461~123926083:-
THCA	cis	rs17807624	0.702	rs7815172	ENSG00000227888.4	FAM66A	3.8	0.000161	0.0118	0.21	0.17	Systemic lupus erythematosus;	chr8:11596162	chr8:12362019~12388296:+
THCA	cis	rs11638352	1	rs7174819	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0118	-0.32	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44223666	chr15:43699488~43718184:-
THCA	cis	rs752590	0.51	rs13431315	ENSG00000227359.1	AC017074.2	3.8	0.000161	0.0118	0.28	0.17	Mucinous ovarian carcinoma;	chr2:113239717	chr2:113677702~113704078:-
THCA	cis	rs172166	0.61	rs276369	ENSG00000176933.5	TOB2P1	-3.8	0.000161	0.0118	-0.19	-0.17	Cardiac Troponin-T levels;	chr6:27951465	chr6:28217643~28218634:-
THCA	cis	rs3736986	0.908	rs10972783	ENSG00000215283.3	HMGB3P24	-3.8	0.000161	0.0118	-0.32	-0.17	Bipolar disorder (inflammation and infection response interaction);	chr9:36185471	chr9:36303499~36304924:-
THCA	cis	rs4869313	0.668	rs2549795	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96908934	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2548526	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96909913	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.642	rs2548525	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96910188	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2549798	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96910199	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2549799	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96910206	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2113191	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96910634	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.694	rs2548524	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96910897	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2548523	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96911236	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.617	rs1363975	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96913182	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2255546	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96913411	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2255633	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96913619	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.642	rs2255634	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96913647	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2255637	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96913674	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2548521	ENSG00000247121.5	CTD-2260A17.2	3.8	0.000161	0.0118	0.13	0.17	Pediatric autoimmune diseases;	chr5:96915224	chr5:96814028~96935809:-
THCA	cis	rs10938353	0.871	rs7677605	ENSG00000273369.1	RP11-700J17.1	-3.8	0.000161	0.0118	-0.19	-0.17	Body mass index;	chr4:44592074	chr4:44693946~44694386:-
THCA	cis	rs7520050	0.966	rs12139630	ENSG00000281133.1	AL355480.3	3.8	0.000161	0.0118	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs12144263	ENSG00000281133.1	AL355480.3	3.8	0.000161	0.0118	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6668284	ENSG00000281133.1	AL355480.3	3.8	0.000161	0.0118	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs4660321	ENSG00000281133.1	AL355480.3	3.8	0.000161	0.0118	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45580892~45580996:-
THCA	cis	rs4792901	0.802	rs55989313	ENSG00000267151.3	RP11-100E5.2	3.8	0.000161	0.0118	0.19	0.17	Dupuytren's disease;	chr17:43528880	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs28581728	ENSG00000267151.3	RP11-100E5.2	3.8	0.000161	0.0118	0.19	0.17	Dupuytren's disease;	chr17:43531968	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs28608935	ENSG00000267151.3	RP11-100E5.2	3.8	0.000161	0.0118	0.19	0.17	Dupuytren's disease;	chr17:43532102	chr17:43444707~43451200:+
THCA	cis	rs4788570	0.615	rs4788822	ENSG00000260593.1	RP11-432I5.2	-3.8	0.000161	0.0118	-0.27	-0.17	Intelligence (multi-trait analysis);	chr16:71647612	chr16:71623708~71626816:-
THCA	cis	rs10875746	0.68	rs4760610	ENSG00000258234.1	RP11-370I10.2	3.8	0.000161	0.0118	0.2	0.17	Longevity (90 years and older);	chr12:48024442	chr12:48231098~48284210:-
THCA	cis	rs13064773	0.51	rs340315	ENSG00000279311.1	RP11-170K4.2	3.8	0.000161	0.0118	0.23	0.17	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158857800	chr3:158869898~158871821:+
THCA	cis	rs757978	0.81	rs2055569	ENSG00000235351.1	AC114730.11	-3.8	0.000161	0.0118	-0.16	-0.17	Chronic lymphocytic leukemia;	chr2:241462024	chr2:241724615~241725693:-
THCA	cis	rs8177876	0.658	rs16954505	ENSG00000261061.1	RP11-303E16.2	-3.8	0.000161	0.0118	-0.26	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81040555	chr16:81030770~81031485:+
THCA	cis	rs10540	0.818	rs12806089	ENSG00000279672.1	CMB9-55F22.1	3.8	0.000161	0.0118	0.34	0.17	Body mass index;	chr11:501468	chr11:779617~780755:+
THCA	cis	rs10540	1	rs12419716	ENSG00000279672.1	CMB9-55F22.1	3.8	0.000161	0.0118	0.34	0.17	Body mass index;	chr11:503385	chr11:779617~780755:+
THCA	cis	rs10540	1	rs12419766	ENSG00000279672.1	CMB9-55F22.1	3.8	0.000161	0.0118	0.34	0.17	Body mass index;	chr11:503710	chr11:779617~780755:+
THCA	cis	rs10540	1	rs12421457	ENSG00000279672.1	CMB9-55F22.1	3.8	0.000161	0.0118	0.34	0.17	Body mass index;	chr11:505780	chr11:779617~780755:+
THCA	cis	rs10540	1	rs12786555	ENSG00000279672.1	CMB9-55F22.1	3.8	0.000161	0.0118	0.34	0.17	Body mass index;	chr11:506229	chr11:779617~780755:+
THCA	cis	rs10540	1	rs35874808	ENSG00000279672.1	CMB9-55F22.1	3.8	0.000161	0.0118	0.34	0.17	Body mass index;	chr11:506442	chr11:779617~780755:+
THCA	cis	rs10540	1	rs61877760	ENSG00000279672.1	CMB9-55F22.1	3.8	0.000161	0.0118	0.34	0.17	Body mass index;	chr11:506596	chr11:779617~780755:+
THCA	cis	rs4869313	0.502	rs1230381	ENSG00000247121.5	CTD-2260A17.2	-3.8	0.000161	0.0118	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96918505	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs1230382	ENSG00000247121.5	CTD-2260A17.2	-3.8	0.000161	0.0118	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96918650	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.642	rs1019503	ENSG00000247121.5	CTD-2260A17.2	-3.8	0.000161	0.0118	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96919113	chr5:96814028~96935809:-
THCA	cis	rs1411478	0.84	rs11586493	ENSG00000243155.1	RP11-46A10.5	3.8	0.000161	0.0118	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180992109	chr1:180944042~180976482:-
THCA	cis	rs13113518	0.783	rs34534635	ENSG00000223305.1	RN7SKP30	3.8	0.000161	0.0118	0.22	0.17	Height;	chr4:55573424	chr4:55540502~55540835:-
THCA	cis	rs10090774	0.932	rs11786859	ENSG00000280303.2	ERICD	-3.8	0.000161	0.0118	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140974782	chr8:140636281~140638283:+
THCA	cis	rs55966801	0.732	rs117558678	ENSG00000277290.1	RP11-326C3.16	-3.8	0.000161	0.0118	-0.22	-0.17	Plateletcrit;	chr11:270330	chr11:243099~243483:-
THCA	cis	rs7259811	0.54	rs2191436	ENSG00000279405.1	AC098795.1	-3.8	0.000161	0.0118	-0.18	-0.17	Western dietary pattern;	chr19:56706592	chr19:56480397~56483977:-
THCA	cis	rs9291683	0.595	rs3733585	ENSG00000261490.1	RP11-448G15.3	3.8	0.000161	0.0118	0.11	0.17	Bone mineral density;	chr4:10034715	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.561	rs3733584	ENSG00000261490.1	RP11-448G15.3	3.8	0.000161	0.0118	0.11	0.17	Bone mineral density;	chr4:10034882	chr4:10068089~10073019:-
THCA	cis	rs2015599	0.549	rs7956305	ENSG00000273680.1	RP11-996F15.6	-3.8	0.000161	0.0118	-0.24	-0.17	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29332733~29333383:-
THCA	cis	rs2015599	0.543	rs6487807	ENSG00000273680.1	RP11-996F15.6	-3.8	0.000161	0.0118	-0.24	-0.17	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29332733~29333383:-
THCA	cis	rs11638352	1	rs2615297	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0118	-0.39	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44113823	chr15:43699488~43718184:-
THCA	cis	rs2733201	1	rs2733201	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0118	-0.39	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44116203	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs2615294	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0118	-0.39	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44120422	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs2555380	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0118	-0.39	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44120437	chr15:43699488~43718184:-
THCA	cis	rs11638352	1	rs2706471	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0118	-0.39	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44122172	chr15:43699488~43718184:-
THCA	cis	rs5758511	0.633	rs5758690	ENSG00000205702.9	CYP2D7	3.8	0.000161	0.0118	0.15	0.17	Birth weight;	chr22:42272289	chr22:42140203~42144577:-
THCA	cis	rs7267979	0.966	rs4813557	ENSG00000276952.1	RP5-965G21.6	-3.8	0.000161	0.0118	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25284915~25285588:-
THCA	cis	rs1923243	0.749	rs6657470	ENSG00000223479.3	RP4-788P17.1	-3.8	0.000161	0.0118	-0.19	-0.17	Migraine;	chr1:73057573	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.749	rs12022006	ENSG00000223479.3	RP4-788P17.1	-3.8	0.000161	0.0118	-0.19	-0.17	Migraine;	chr1:73058668	chr1:73635216~73715214:+
THCA	cis	rs1864585	0.52	rs7817252	ENSG00000280294.1	RP11-177H2.1	3.8	0.000161	0.0118	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10828422	chr8:10856085~10859436:-
THCA	cis	rs559555	0.597	rs676033	ENSG00000276517.1	AL133243.2	-3.8	0.000161	0.0118	-0.17	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31583901	chr2:32526504~32529507:+
THCA	cis	rs10897473	0.529	rs10751006	ENSG00000236935.1	AP003774.1	-3.8	0.000161	0.0118	-0.19	-0.17	Immature fraction of reticulocytes;	chr11:64084722	chr11:64325050~64329504:-
THCA	cis	rs6137726	0.524	rs6075931	ENSG00000237396.1	LINC01384	3.8	0.000161	0.0118	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22644757	chr20:22587522~22607517:-
THCA	cis	rs9325081	1	rs9325081	ENSG00000247199.3	RP11-373N22.3	-3.8	0.000161	0.0118	-0.41	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;	chr5:148171783	chr5:148268307~148383783:-
THCA	cis	rs10896135	0.526	rs12795774	ENSG00000255320.1	RP11-755F10.1	-3.8	0.000161	0.0118	-0.23	-0.17	Bipolar disorder;	chr11:66614046	chr11:66244840~66246239:-
THCA	cis	rs13064773	0.51	rs340302	ENSG00000279311.1	RP11-170K4.2	3.8	0.000161	0.0118	0.23	0.17	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158854764	chr3:158869898~158871821:+
THCA	cis	rs13098911	0.54	rs4388012	ENSG00000226074.4	PRSS44	-3.8	0.000161	0.0118	-0.32	-0.17	Celiac disease;	chr3:45955009	chr3:46809359~46812558:-
THCA	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	3.8	0.000161	0.0118	0.2	0.17	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
THCA	cis	rs1005277	0.54	rs1987431	ENSG00000275858.1	RP11-291L22.8	3.8	0.000161	0.0118	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38450738~38451069:-
THCA	cis	rs4869313	0.668	rs1981846	ENSG00000247121.5	CTD-2260A17.2	-3.8	0.000161	0.0118	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96933158	chr5:96814028~96935809:-
THCA	cis	rs78487399	0.731	rs6747229	ENSG00000234936.1	AC010883.5	3.8	0.000161	0.0118	0.24	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43485471	chr2:43229573~43233394:+
THCA	cis	rs79419269	0.572	rs7812088	ENSG00000265810.1	MIR3907	3.8	0.000161	0.0118	0.22	0.17	Immunoglobulin light chain (AL) amyloidosis;	chr7:151222743	chr7:151433489~151433639:-
THCA	cis	rs13178541	0.511	rs28373574	ENSG00000250378.1	RP11-119J18.1	-3.8	0.000161	0.0118	-0.2	-0.17	IgG glycosylation;	chr5:135789626	chr5:135812667~135826582:+
THCA	cis	rs4538475	0.556	rs4263397	ENSG00000273133.1	RP11-799M12.2	3.8	0.000161	0.0118	0.23	0.17	Parkinson's disease;	chr4:15737767	chr4:15563698~15564253:-
THCA	cis	rs9611565	0.659	rs73178641	ENSG00000237037.8	NDUFA6-AS1	3.8	0.000161	0.0118	0.16	0.17	Vitiligo;	chr22:41556071	chr22:42090931~42137742:+
THCA	cis	rs13098911	0.54	rs34438204	ENSG00000226074.4	PRSS44	-3.8	0.000161	0.0118	-0.33	-0.17	Celiac disease;	chr3:46039814	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13063033	ENSG00000226074.4	PRSS44	-3.8	0.000161	0.0118	-0.33	-0.17	Celiac disease;	chr3:46040989	chr3:46809359~46812558:-
THCA	cis	rs12681366	0.708	rs2470718	ENSG00000261437.1	RP11-22C11.2	-3.8	0.000161	0.0118	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94346849	chr8:94637285~94639467:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000275400.1	RP4-756H11.5	-3.8	0.000161	0.0118	-0.16	-0.17	Aortic root size;	chr7:65964026	chr7:66553805~66554199:-
THCA	cis	rs7819412	0.745	rs7017567	ENSG00000254948.1	OR7E158P	3.8	0.000161	0.0118	0.21	0.17	Triglycerides;	chr8:11076189	chr8:11919900~11920809:-
THCA	cis	rs471756	0.523	rs604470	ENSG00000231808.2	LINC01388	-3.8	0.000161	0.0118	-0.2	-0.17	Mean platelet volume;	chr9:223979	chr9:112713~113754:-
THCA	cis	rs11673344	0.523	rs36096221	ENSG00000233527.7	ZNF529-AS1	3.8	0.000161	0.0118	0.15	0.17	Obesity-related traits;	chr19:37060838	chr19:36573070~36594708:+
THCA	cis	rs9309473	1	rs11893881	ENSG00000273245.1	RP11-434P11.2	3.8	0.000162	0.0118	0.24	0.17	Metabolite levels;	chr2:73597246	chr2:73750256~73750786:-
THCA	cis	rs7665090	0.905	rs2866410	ENSG00000251288.2	RP11-10L12.2	-3.8	0.000162	0.0118	-0.22	-0.17	Primary biliary cholangitis;	chr4:102633178	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.936	rs2866411	ENSG00000251288.2	RP11-10L12.2	-3.8	0.000162	0.0118	-0.22	-0.17	Primary biliary cholangitis;	chr4:102633183	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.936	rs2866412	ENSG00000251288.2	RP11-10L12.2	-3.8	0.000162	0.0118	-0.22	-0.17	Primary biliary cholangitis;	chr4:102633193	chr4:102751401~102752641:+
THCA	cis	rs10090774	0.965	rs13258775	ENSG00000280303.2	ERICD	-3.8	0.000162	0.0118	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140984141	chr8:140636281~140638283:+
THCA	cis	rs1062753	0.922	rs9611712	ENSG00000227370.1	RP4-669P10.19	3.8	0.000162	0.0118	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014989	chr22:42132543~42132998:+
THCA	cis	rs11971779	0.68	rs4728465	ENSG00000252332.1	RNU6-911P	-3.8	0.000162	0.0118	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139384315	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.715	rs55714903	ENSG00000252332.1	RNU6-911P	-3.8	0.000162	0.0118	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139389844	chr7:139448740~139448843:+
THCA	cis	rs10090774	0.664	rs11774042	ENSG00000279766.1	RP11-642A1.2	-3.8	0.000162	0.0118	-0.21	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140657279	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.71	rs7460	ENSG00000279766.1	RP11-642A1.2	-3.8	0.000162	0.0118	-0.21	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140658761	chr8:140572142~140572812:-
THCA	cis	rs2336384	0.896	rs11121847	ENSG00000199347.1	RNU5E-1	-3.8	0.000162	0.0118	-0.22	-0.17	Platelet count;	chr1:12002450	chr1:11908152~11908271:+
THCA	cis	rs741677	0.964	rs8077122	ENSG00000231784.7	DBIL5P	-3.8	0.000162	0.0118	-0.19	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:592282	chr17:752660~755336:+
THCA	cis	rs34421088	0.678	rs35726503	ENSG00000270154.1	RP11-419I17.1	-3.8	0.000162	0.0118	-0.2	-0.17	Neuroticism;	chr8:11734407	chr8:12476462~12477122:+
THCA	cis	rs1541160	0.879	rs2474708	ENSG00000239494.2	RN7SL333P	3.8	0.000162	0.0118	0.17	0.17	Amyotrophic lateral sclerosis;	chr1:170007222	chr1:169859756~169860052:+
THCA	cis	rs1541160	1	rs7539241	ENSG00000239494.2	RN7SL333P	3.8	0.000162	0.0118	0.17	0.17	Amyotrophic lateral sclerosis;	chr1:170010174	chr1:169859756~169860052:+
THCA	cis	rs1541160	1	rs28441321	ENSG00000239494.2	RN7SL333P	3.8	0.000162	0.0118	0.17	0.17	Amyotrophic lateral sclerosis;	chr1:170020827	chr1:169859756~169860052:+
THCA	cis	rs9287719	0.901	rs55861579	ENSG00000243819.4	RN7SL832P	3.8	0.000162	0.0118	0.14	0.17	Prostate cancer;	chr2:10623214	chr2:10690344~10692099:+
THCA	cis	rs10090774	0.932	rs7816620	ENSG00000280303.2	ERICD	-3.8	0.000162	0.0118	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994015	chr8:140636281~140638283:+
THCA	cis	rs4906332	1	rs35862113	ENSG00000259775.1	RP11-45P15.4	-3.8	0.000162	0.0118	-0.15	-0.17	Coronary artery disease;	chr14:103390892	chr14:103331674~103332367:-
THCA	cis	rs4906332	0.84	rs34161327	ENSG00000259775.1	RP11-45P15.4	-3.8	0.000162	0.0118	-0.15	-0.17	Coronary artery disease;	chr14:103390988	chr14:103331674~103332367:-
THCA	cis	rs308403	0.509	rs309357	ENSG00000224786.1	CETN4P	3.8	0.000162	0.0118	0.18	0.17	Blood protein levels;	chr4:122732421	chr4:122730548~122732193:-
THCA	cis	rs4460629	0.742	rs11264312	ENSG00000225855.5	RUSC1-AS1	3.8	0.000162	0.0118	0.11	0.17	Serum magnesium levels;	chr1:155103412	chr1:155316863~155324176:-
THCA	cis	rs4460629	0.742	rs4625273	ENSG00000225855.5	RUSC1-AS1	3.8	0.000162	0.0118	0.11	0.17	Serum magnesium levels;	chr1:155103567	chr1:155316863~155324176:-
THCA	cis	rs4460629	0.742	rs7366355	ENSG00000225855.5	RUSC1-AS1	3.8	0.000162	0.0118	0.11	0.17	Serum magnesium levels;	chr1:155104258	chr1:155316863~155324176:-
THCA	cis	rs7267979	1	rs4815420	ENSG00000276952.1	RP5-965G21.6	-3.8	0.000162	0.0118	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25284915~25285588:-
THCA	cis	rs36093844	0.626	rs72963077	ENSG00000279742.1	RP11-700A24.1	-3.8	0.000162	0.0118	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86026023	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.527	rs111309964	ENSG00000279742.1	RP11-700A24.1	-3.8	0.000162	0.0118	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86027529	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.576	rs17745236	ENSG00000279742.1	RP11-700A24.1	-3.8	0.000162	0.0118	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86035580	chr11:85852557~85854943:-
THCA	cis	rs6677524	0.516	rs7525154	ENSG00000227887.1	RPS26P13	3.8	0.000162	0.0118	0.24	0.17	Inflammatory bowel disease;	chr1:208360316	chr1:208697369~208697698:-
THCA	cis	rs9660180	0.839	rs12040826	ENSG00000215914.4	MMP23A	-3.8	0.000162	0.0118	-0.23	-0.17	Body mass index;	chr1:1773848	chr1:1699942~1701782:+
THCA	cis	rs9475752	0.688	rs6941401	ENSG00000231441.1	RP11-472M19.2	3.8	0.000162	0.0118	0.18	0.17	Menarche (age at onset);	chr6:56919898	chr6:56844002~56864078:+
THCA	cis	rs4648045	0.647	rs1598857	ENSG00000246560.2	RP11-10L12.4	3.8	0.000162	0.0118	0.21	0.17	Lymphocyte percentage of white cells;	chr4:102518268	chr4:102828055~102844075:+
THCA	cis	rs57709857	0.957	rs59498392	ENSG00000272092.1	RP11-350N15.5	-3.8	0.000162	0.0118	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38402915	chr8:38382364~38383461:+
THCA	cis	rs860295	0.65	rs28662267	ENSG00000236675.1	MTX1P1	-3.8	0.000162	0.0118	-0.18	-0.17	Body mass index;	chr1:155710658	chr1:155230975~155234325:+
THCA	cis	rs7089973	0.61	rs72836518	ENSG00000236799.1	RP11-383C6.2	-3.8	0.000162	0.0118	-0.21	-0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:115004225	chr10:114994657~114996593:+
THCA	cis	rs7560272	0.682	rs2421546	ENSG00000273245.1	RP11-434P11.2	-3.8	0.000162	0.0118	-0.2	-0.17	Schizophrenia;	chr2:73413949	chr2:73750256~73750786:-
THCA	cis	rs6095357	1	rs6095357	ENSG00000227431.4	CSE1L-AS1	-3.8	0.000162	0.0118	-0.22	-0.17	Schizophrenia;	chr20:48907328	chr20:49040463~49046044:-
THCA	cis	rs6012564	0.859	rs1997851	ENSG00000227431.4	CSE1L-AS1	-3.8	0.000162	0.0118	-0.22	-0.17	Anger;	chr20:48909956	chr20:49040463~49046044:-
THCA	cis	rs2736345	0.788	rs2618476	ENSG00000254527.1	ENPP7P12	3.8	0.000162	0.0118	0.23	0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:12205759~12206389:-
THCA	cis	rs42648	0.935	rs42659	ENSG00000225498.1	AC002064.5	3.8	0.000162	0.0118	0.18	0.17	Homocysteine levels;	chr7:90352644	chr7:90312496~90322592:+
THCA	cis	rs7959452	0.503	rs7300266	ENSG00000274979.1	RP11-1143G9.5	-3.8	0.000162	0.0118	-0.18	-0.17	Blood protein levels;	chr12:69260407	chr12:69326574~69331882:-
THCA	cis	rs73222236	0.825	rs6776841	ENSG00000273486.1	RP11-731C17.2	3.8	0.000162	0.0118	0.16	0.17	Coronary artery disease;	chr3:136323322	chr3:136837338~136839021:-
THCA	cis	rs853679	0.607	rs67340775	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000162	0.0118	-0.33	-0.17	Depression;	chr6:28336607	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs35030260	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000162	0.0118	-0.33	-0.17	Depression;	chr6:28337731	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13217619	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000162	0.0118	-0.33	-0.17	Depression;	chr6:28338894	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs35016036	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000162	0.0118	-0.33	-0.17	Depression;	chr6:28347103	chr6:28078792~28081130:-
THCA	cis	rs853679	0.546	rs35744819	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000162	0.0118	-0.33	-0.17	Depression;	chr6:28350554	chr6:28078792~28081130:-
THCA	cis	rs6560517	0.519	rs3808903	ENSG00000234618.1	RPSAP9	-3.8	0.000162	0.0118	-0.2	-0.17	Dialysis-related mortality;	chr9:76500813	chr9:76398699~76399586:+
THCA	cis	rs12681366	1	rs2930971	ENSG00000261437.1	RP11-22C11.2	3.8	0.000162	0.0118	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94420319	chr8:94637285~94639467:-
THCA	cis	rs17685	0.672	rs6465011	ENSG00000230882.1	AC005077.14	3.8	0.000162	0.0118	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76181979	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs11764119	ENSG00000230882.1	AC005077.14	3.8	0.000162	0.0118	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76183040	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs2158867	ENSG00000230882.1	AC005077.14	3.8	0.000162	0.0118	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76185823	chr7:76071469~76074963:-
THCA	cis	rs17685	0.712	rs1859794	ENSG00000230882.1	AC005077.14	3.8	0.000162	0.0118	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76192226	chr7:76071469~76074963:-
THCA	cis	rs17428076	0.836	rs57718990	ENSG00000228389.1	AC068039.4	-3.8	0.000162	0.0118	-0.2	-0.17	Myopia;	chr2:171806104	chr2:171773482~171775844:+
THCA	cis	rs6121246	0.954	rs6060978	ENSG00000224628.2	RP5-854E16.2	-3.8	0.000162	0.0118	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31829090	chr20:31285317~31286835:-
THCA	cis	rs12493885	0.769	rs11711982	ENSG00000243069.6	ARHGEF26-AS1	-3.8	0.000162	0.0118	-0.3	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154039078	chr3:154024401~154121332:-
THCA	cis	rs12681366	0.806	rs72672679	ENSG00000261437.1	RP11-22C11.2	3.8	0.000162	0.0118	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94368956	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.881	rs12675415	ENSG00000261437.1	RP11-22C11.2	3.8	0.000162	0.0118	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94371332	chr8:94637285~94639467:-
THCA	cis	rs10419113	0.668	rs2360535	ENSG00000268545.1	VN1R107P	3.8	0.000162	0.0118	0.2	0.17	Pediatric bone mineral density (spine);	chr19:57668813	chr19:57459912~57460120:+
THCA	cis	rs795484	0.926	rs708867	ENSG00000275409.1	RP11-131L12.4	-3.8	0.000162	0.0118	-0.14	-0.17	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118191894	chr12:118430147~118430699:+
THCA	cis	rs10484434	1	rs10484434	ENSG00000272810.1	U91328.22	-3.8	0.000162	0.0118	-0.18	-0.17	HIV-1 viral setpoint;	chr6:26031385	chr6:26013241~26013757:+
THCA	cis	rs10484434	0.818	rs62000984	ENSG00000272810.1	U91328.22	3.8	0.000162	0.0118	0.18	0.17	HIV-1 viral setpoint;	chr6:26017447	chr6:26013241~26013757:+
THCA	cis	rs31251	0.835	rs2420148	ENSG00000237714.1	P4HA2-AS1	-3.8	0.000162	0.0118	-0.22	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr5:131259715	chr5:132184876~132192808:+
THCA	cis	rs804280	0.509	rs13268030	ENSG00000255495.1	AC145124.2	3.8	0.000162	0.0118	0.2	0.17	Myopia (pathological);	chr8:11925564	chr8:12194467~12196280:+
THCA	cis	rs6456156	0.875	rs55802221	ENSG00000235272.1	FAM103A2P	-3.8	0.000162	0.0118	-0.24	-0.17	Primary biliary cholangitis;	chr6:167103832	chr6:166586124~166586477:-
THCA	cis	rs13113518	0.812	rs2048564	ENSG00000272969.1	RP11-528I4.2	3.8	0.000162	0.0118	0.2	0.17	Height;	chr4:55407965	chr4:55547112~55547889:+
THCA	cis	rs12681288	0.963	rs35220148	ENSG00000260721.1	AF067845.1	3.8	0.000162	0.0118	0.21	0.17	Schizophrenia;	chr8:1077602	chr8:1368642~1369833:-
THCA	cis	rs35771425	0.5	rs3738199	ENSG00000153363.11	LINC00467	-3.8	0.000162	0.0118	-0.13	-0.17	Educational attainment (years of education);	chr1:211372002	chr1:211382803~211435333:+
THCA	cis	rs4759375	1	rs7312145	ENSG00000256092.2	RP13-942N8.1	3.8	0.000162	0.0118	0.19	0.17	HDL cholesterol;	chr12:123340792	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs7315453	ENSG00000256092.2	RP13-942N8.1	3.8	0.000162	0.0118	0.19	0.17	HDL cholesterol;	chr12:123340842	chr12:123363868~123366113:+
THCA	cis	rs4759375	0.92	rs7298909	ENSG00000256092.2	RP13-942N8.1	3.8	0.000162	0.0118	0.19	0.17	HDL cholesterol;	chr12:123346392	chr12:123363868~123366113:+
THCA	cis	rs4759375	0.79	rs9739171	ENSG00000256092.2	RP13-942N8.1	3.8	0.000162	0.0118	0.19	0.17	HDL cholesterol;	chr12:123356447	chr12:123363868~123366113:+
THCA	cis	rs4759375	0.915	rs11503021	ENSG00000256092.2	RP13-942N8.1	3.8	0.000162	0.0118	0.19	0.17	HDL cholesterol;	chr12:123360011	chr12:123363868~123366113:+
THCA	cis	rs894638	1	rs11933542	ENSG00000263327.5	TAPT1-AS1	-3.8	0.000162	0.0118	-0.21	-0.17	Glomerular filtration rate in chronic kidney disease;	chr4:16114359	chr4:16226685~16320140:+
THCA	cis	rs970548	0.955	rs10900223	ENSG00000230869.1	CTGLF10P	3.8	0.000162	0.0118	0.21	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45526183	chr10:45678692~45700532:+
THCA	cis	rs13064773	0.528	rs340268	ENSG00000279311.1	RP11-170K4.2	3.8	0.000162	0.0118	0.22	0.17	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158876867	chr3:158869898~158871821:+
THCA	cis	rs12544026	0.581	rs569015	ENSG00000253669.3	KB-1732A1.1	-3.8	0.000162	0.0118	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101879228	chr8:102805517~102809971:+
THCA	cis	rs1580019	0.961	rs2392056	ENSG00000231952.3	DPY19L1P2	-3.8	0.000162	0.0118	-0.22	-0.17	Cognitive ability;	chr7:32459341	chr7:32812757~32838570:+
THCA	cis	rs6546886	0.912	rs7587991	ENSG00000235499.1	AC073046.25	3.8	0.000162	0.0118	0.16	0.17	Dialysis-related mortality;	chr2:74070161	chr2:73985132~73986343:+
THCA	cis	rs2562456	0.876	rs7252585	ENSG00000268658.4	LINC00664	-3.8	0.000162	0.0118	-0.25	-0.17	Pain;	chr19:21475141	chr19:21483374~21503238:+
THCA	cis	rs4660214	0.789	rs1180375	ENSG00000228060.1	RP11-69E11.8	-3.8	0.000162	0.0118	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415368	chr1:39565160~39573203:+
THCA	cis	rs11098499	0.866	rs3756156	ENSG00000249244.1	RP11-548H18.2	3.8	0.000162	0.0118	0.2	0.17	Corneal astigmatism;	chr4:119603686	chr4:119391831~119395335:-
THCA	cis	rs4699052	0.963	rs6816055	ENSG00000246560.2	RP11-10L12.4	3.8	0.000162	0.0118	0.2	0.17	Testicular germ cell tumor;	chr4:103222003	chr4:102828055~102844075:+
THCA	cis	rs4699052	0.963	rs11097801	ENSG00000246560.2	RP11-10L12.4	3.8	0.000162	0.0118	0.2	0.17	Testicular germ cell tumor;	chr4:103229166	chr4:102828055~102844075:+
THCA	cis	rs4699052	0.963	rs56144793	ENSG00000246560.2	RP11-10L12.4	3.8	0.000162	0.0118	0.2	0.17	Testicular germ cell tumor;	chr4:103229496	chr4:102828055~102844075:+
THCA	cis	rs71520386	1	rs71520386	ENSG00000228649.7	AC005682.5	-3.8	0.000162	0.0118	-0.27	-0.17	Fibrinogen levels;	chr7:22813902	chr7:22854178~22861579:+
THCA	cis	rs172166	0.516	rs1150670	ENSG00000261839.1	RP1-265C24.8	3.8	0.000162	0.0118	0.16	0.17	Cardiac Troponin-T levels;	chr6:28162781	chr6:28136849~28139678:+
THCA	cis	rs7560272	0.501	rs7210	ENSG00000163016.8	ALMS1P	-3.8	0.000162	0.0118	-0.21	-0.17	Schizophrenia;	chr2:73729997	chr2:73644919~73685576:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000219891.2	ZSCAN12P1	3.8	0.000162	0.0118	0.24	0.17	Depression;	chr6:28079011	chr6:28091154~28093664:+
THCA	cis	rs2191566	0.648	rs4803675	ENSG00000266921.1	RP11-15A1.7	3.8	0.000162	0.0119	0.16	0.17	Acute lymphoblastic leukemia (childhood);	chr19:44085563	chr19:43996896~44002836:-
THCA	cis	rs7264396	0.79	rs6060565	ENSG00000088340.14	FER1L4	3.8	0.000162	0.0119	0.17	0.17	Total cholesterol levels;	chr20:35697520	chr20:35558737~35607562:-
THCA	cis	rs745109	0.504	rs17027169	ENSG00000273080.1	RP11-301O19.1	3.8	0.000162	0.0119	0.31	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86368710	chr2:86195590~86196049:+
THCA	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	3.8	0.000162	0.0119	0.22	0.17	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
THCA	cis	rs172166	0.516	rs2791333	ENSG00000261839.1	RP1-265C24.8	3.8	0.000162	0.0119	0.17	0.17	Cardiac Troponin-T levels;	chr6:28143336	chr6:28136849~28139678:+
THCA	cis	rs372883	0.648	rs1003772	ENSG00000176054.6	RPL23P2	3.8	0.000162	0.0119	0.16	0.17	Pancreatic cancer;	chr21:29363824	chr21:28997613~28998033:-
THCA	cis	rs56046484	0.956	rs2174218	ENSG00000218052.5	ADAMTS7P4	3.8	0.000162	0.0119	0.26	0.17	Testicular germ cell tumor;	chr15:85081425	chr15:85255369~85330334:-
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000229212.6	RP11-561C5.4	-3.8	0.000162	0.0119	-0.22	-0.17	P wave terminal force;	chr15:84655131	chr15:85205440~85234795:-
THCA	cis	rs7927592	0.913	rs12283755	ENSG00000160172.9	FAM86C2P	3.8	0.000162	0.0119	0.17	0.17	Total body bone mineral density;	chr11:68604190	chr11:67791648~67805336:-
THCA	cis	rs7819412	0.669	rs6601568	ENSG00000254866.2	DEFB109P3	3.8	0.000162	0.0119	0.24	0.17	Triglycerides;	chr8:11215893	chr8:12150895~12151134:-
THCA	cis	rs6137726	0.524	rs6137704	ENSG00000237396.1	LINC01384	3.8	0.000162	0.0119	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22639060	chr20:22587522~22607517:-
THCA	cis	rs17597773	0.674	rs2378425	ENSG00000272823.1	RP11-295M18.6	-3.8	0.000162	0.0119	-0.23	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220842716	chr1:220828676~220829211:-
THCA	cis	rs6995541	0.647	rs6991526	ENSG00000248896.2	CTD-2135J3.3	-3.8	0.000162	0.0119	-0.21	-0.17	Triglyceride levels;	chr8:10831540	chr8:10729314~10771392:+
THCA	cis	rs2039553	0.553	rs7322877	ENSG00000227354.5	RBM26-AS1	3.8	0.000162	0.0119	0.16	0.17	Pancreatic cancer;	chr13:79811497	chr13:79406309~79424328:+
THCA	cis	rs7873102	0.654	rs7033326	ENSG00000213839.4	TMX2P1	-3.8	0.000162	0.0119	-0.13	-0.17	Brain structure;	chr9:37962802	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.654	rs7033327	ENSG00000213839.4	TMX2P1	-3.8	0.000162	0.0119	-0.13	-0.17	Brain structure;	chr9:37962804	chr9:37885683~37886390:+
THCA	cis	rs7824557	0.564	rs2736295	ENSG00000255495.1	AC145124.2	3.8	0.000162	0.0119	0.2	0.17	Retinal vascular caliber;	chr8:11377271	chr8:12194467~12196280:+
THCA	cis	rs614226	0.938	rs12857	ENSG00000278344.1	RP11-18C24.8	3.8	0.000162	0.0119	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120496143	chr12:120500735~120501090:-
THCA	cis	rs2919009	0.664	rs17591472	ENSG00000271670.1	RP11-95I16.4	3.8	0.000162	0.0119	0.2	0.17	Obesity-related traits;	chr10:120785735	chr10:120879256~120880667:-
THCA	cis	rs7560272	0.501	rs2272178	ENSG00000163016.8	ALMS1P	-3.8	0.000162	0.0119	-0.21	-0.17	Schizophrenia;	chr2:73750482	chr2:73644919~73685576:+
THCA	cis	rs13325613	0.834	rs13089543	ENSG00000223552.1	RP11-24F11.2	-3.8	0.000162	0.0119	-0.28	-0.17	Monocyte count;	chr3:46142068	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13089544	ENSG00000223552.1	RP11-24F11.2	-3.8	0.000162	0.0119	-0.28	-0.17	Monocyte count;	chr3:46142069	chr3:46364955~46407059:-
THCA	cis	rs881375	0.678	rs10118357	ENSG00000270917.1	RP11-27I1.6	-3.8	0.000162	0.0119	-0.23	-0.17	Rheumatoid arthritis;	chr9:120917790	chr9:120812475~120812845:-
THCA	cis	rs6500602	0.647	rs4785967	ENSG00000280063.1	RP11-295D4.3	3.8	0.000162	0.0119	0.09	0.17	Schizophrenia;	chr16:4473207	chr16:4346694~4348648:-
THCA	cis	rs786425	0.655	rs7398298	ENSG00000278112.1	RP11-972P1.11	3.8	0.000162	0.0119	0.17	0.17	Pubertal anthropometrics;	chr12:123708181	chr12:123519390~123519856:-
THCA	cis	rs786425	0.654	rs7305838	ENSG00000278112.1	RP11-972P1.11	3.8	0.000162	0.0119	0.17	0.17	Pubertal anthropometrics;	chr12:123708924	chr12:123519390~123519856:-
THCA	cis	rs7069191	0.877	rs920644	ENSG00000254271.1	RP11-131N11.4	3.8	0.000163	0.0119	0.26	0.17	Pediatric bone mineral density (spine);	chr10:60681798	chr10:60734342~60741828:+
THCA	cis	rs2911280	0.764	rs77531223	ENSG00000278985.1	RP11-303E16.9	-3.8	0.000163	0.0119	-0.32	-0.17	Dehydroepiandrosterone sulphate levels;	chr16:81532913	chr16:80982319~80984094:-
THCA	cis	rs2135507	0.681	rs7683727	ENSG00000270480.1	RP11-57B24.1	3.8	0.000163	0.0119	0.23	0.17	Juvenile osteochondritis dissecans;	chr4:82654197	chr4:82691737~82692468:+
THCA	cis	rs832540	0.866	rs832579	ENSG00000271828.1	CTD-2310F14.1	-3.8	0.000163	0.0119	-0.23	-0.17	Coronary artery disease;	chr5:56869116	chr5:56927874~56929573:+
THCA	cis	rs889312	0.5	rs832580	ENSG00000271828.1	CTD-2310F14.1	-3.8	0.000163	0.0119	-0.23	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56876819	chr5:56927874~56929573:+
THCA	cis	rs7403037	0.583	rs61993131	ENSG00000260760.1	PWRN3	3.8	0.000163	0.0119	0.24	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24541287	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.652	rs61993134	ENSG00000260760.1	PWRN3	3.8	0.000163	0.0119	0.24	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24544682	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.583	rs34466529	ENSG00000260760.1	PWRN3	3.8	0.000163	0.0119	0.24	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24554698	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.571	rs34414719	ENSG00000260760.1	PWRN3	3.8	0.000163	0.0119	0.24	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24555095	chr15:24441127~24447967:+
THCA	cis	rs7403037	0.687	rs36080197	ENSG00000260760.1	PWRN3	3.8	0.000163	0.0119	0.24	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24561951	chr15:24441127~24447967:+
THCA	cis	rs2851391	0.501	rs732672	ENSG00000233754.1	AP001628.7	-3.8	0.000163	0.0119	-0.18	-0.17	Homocysteine levels;Blood metabolite levels;Obesity-related traits;	chr21:43043924	chr21:42781074~42782233:-
THCA	cis	rs2039553	0.792	rs915260	ENSG00000227354.5	RBM26-AS1	3.8	0.000163	0.0119	0.17	0.17	Pancreatic cancer;	chr13:79723931	chr13:79406309~79424328:+
THCA	cis	rs748404	0.511	rs12442190	ENSG00000166763.7	STRCP1	-3.8	0.000163	0.0119	-0.18	-0.17	Lung cancer;	chr15:43153107	chr15:43699488~43718184:-
THCA	cis	rs2412819	0.545	rs654276	ENSG00000166763.7	STRCP1	-3.8	0.000163	0.0119	-0.25	-0.17	Lung cancer;	chr15:43798656	chr15:43699488~43718184:-
THCA	cis	rs7836436	0.686	rs6986364	ENSG00000245330.4	KB-1471A8.1	-3.8	0.000163	0.0119	-0.27	-0.17	HIV-1 viral setpoint;	chr8:119933200	chr8:119867419~119874488:-
THCA	cis	rs2221894	1	rs4559202	ENSG00000251191.6	LINC00589	-3.8	0.000163	0.0119	-0.21	-0.17	Obesity-related traits;	chr8:28959335	chr8:29673922~29748109:-
THCA	cis	rs854765	0.583	rs11650890	ENSG00000281749.1	Y_RNA	-3.8	0.000163	0.0119	-0.22	-0.17	Total body bone mineral density;	chr17:17887568	chr17:18001101~18001195:-
THCA	cis	rs860295	0.966	rs821551	ENSG00000236675.1	MTX1P1	-3.8	0.000163	0.0119	-0.17	-0.17	Body mass index;	chr1:155718789	chr1:155230975~155234325:+
THCA	cis	rs860295	0.58	rs7528441	ENSG00000236675.1	MTX1P1	-3.8	0.000163	0.0119	-0.18	-0.17	Body mass index;	chr1:155873465	chr1:155230975~155234325:+
THCA	cis	rs889512	0.642	rs8048529	ENSG00000261783.1	RP11-252K23.2	3.8	0.000163	0.0119	0.35	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75241732	chr16:75379818~75381260:-
THCA	cis	rs2455799	0.573	rs2455836	ENSG00000270409.1	RP11-44D5.1	-3.8	0.000163	0.0119	-0.18	-0.17	Mean platelet volume;	chr3:15713031	chr3:15732252~15733470:+
THCA	cis	rs6860806	1	rs6860806	ENSG00000263597.1	MIR3936	-3.8	0.000163	0.0119	-0.16	-0.17	Breast cancer;	chr5:132304843	chr5:132365490~132365599:-
THCA	cis	rs214785	1	rs214758	ENSG00000226644.4	RP11-128M1.1	-3.8	0.000163	0.0119	-0.17	-0.17	Basal cell carcinoma;	chr20:2294882	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214776	ENSG00000226644.4	RP11-128M1.1	-3.8	0.000163	0.0119	-0.17	-0.17	Basal cell carcinoma;	chr20:2299745	chr20:2207217~2213151:+
THCA	cis	rs214785	0.932	rs214760	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2295330	chr20:2207217~2213151:+
THCA	cis	rs214785	0.932	rs214762	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2297246	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214763	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2297382	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214768	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2298346	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214769	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2298435	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214772	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2299248	chr20:2207217~2213151:+
THCA	cis	rs214785	0.872	rs214773	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2299263	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214774	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2299654	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214775	ENSG00000226644.4	RP11-128M1.1	3.8	0.000163	0.0119	0.17	0.17	Basal cell carcinoma;	chr20:2299709	chr20:2207217~2213151:+
THCA	cis	rs7759001	0.711	rs10946921	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27464076	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.652	rs6920010	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27466057	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs12213598	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27468466	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs11970336	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27469245	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs2049944	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27470852	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs2049945	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27470869	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.652	rs7741031	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27470962	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.652	rs7745380	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27471142	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs2179154	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27471152	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs2142705	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27471346	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs7750795	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27472225	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.652	rs2272815	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27472763	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.6	rs2272816	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27472766	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.652	rs7756216	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27473153	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs62401365	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27473751	chr6:27404010~27406964:-
THCA	cis	rs7264396	0.79	rs2425097	ENSG00000088340.14	FER1L4	3.8	0.000163	0.0119	0.17	0.17	Total cholesterol levels;	chr20:35721004	chr20:35558737~35607562:-
THCA	cis	rs17122278	1	rs1047079	ENSG00000243431.1	RPL5P30	3.8	0.000163	0.0119	0.18	0.17	Total cholesterol levels;	chr11:118602516	chr11:118560690~118561580:+
THCA	cis	rs2692947	0.655	rs2315668	ENSG00000232931.4	LINC00342	3.8	0.000163	0.0119	0.14	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95763814	chr2:95807118~95816215:-
THCA	cis	rs6012953	0.817	rs16995294	ENSG00000231715.1	COX6CP2	-3.8	0.000163	0.0119	-0.18	-0.17	Vitiligo;	chr20:50564808	chr20:50479767~50479991:+
THCA	cis	rs7131987	0.565	rs7300032	ENSG00000275476.1	RP11-996F15.4	3.8	0.000163	0.0119	0.17	0.17	QT interval;	chr12:29256859	chr12:29277397~29277882:-
THCA	cis	rs6600671	0.764	rs6600673	ENSG00000226067.5	CH17-118O6.2	3.8	0.000163	0.0119	0.18	0.17	Hip geometry;	chr1:121426988	chr1:120913275~121009291:+
THCA	cis	rs10857712	0.95	rs7906765	ENSG00000214279.11	SCART1	-3.8	0.000163	0.0119	-0.14	-0.17	Systemic lupus erythematosus;	chr10:133411956	chr10:133453928~133523558:+
THCA	cis	rs17286411	0.671	rs4788558	ENSG00000260185.1	RP11-432I5.6	-3.8	0.000163	0.0119	-0.24	-0.17	Blood protein levels;	chr16:71787474	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs1392483	ENSG00000260185.1	RP11-432I5.6	-3.8	0.000163	0.0119	-0.24	-0.17	Blood protein levels;	chr16:71788328	chr16:71655027~71664212:+
THCA	cis	rs9611565	0.512	rs5751147	ENSG00000237037.8	NDUFA6-AS1	-3.8	0.000163	0.0119	-0.16	-0.17	Vitiligo;	chr22:41743050	chr22:42090931~42137742:+
THCA	cis	rs889512	0.642	rs13337397	ENSG00000261783.1	RP11-252K23.2	3.8	0.000163	0.0119	0.34	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75261741	chr16:75379818~75381260:-
THCA	cis	rs1411478	0.967	rs59145927	ENSG00000243155.1	RP11-46A10.5	3.8	0.000163	0.0119	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180983159	chr1:180944042~180976482:-
THCA	cis	rs8014204	0.816	rs10083386	ENSG00000279594.1	RP11-950C14.10	-3.8	0.000163	0.0119	-0.16	-0.17	Caffeine consumption;	chr14:74880882	chr14:75011269~75012851:-
THCA	cis	rs9291683	0.538	rs11727199	ENSG00000261490.1	RP11-448G15.3	3.8	0.000163	0.0119	0.11	0.17	Bone mineral density;	chr4:10034566	chr4:10068089~10073019:-
THCA	cis	rs4389656	0.743	rs34681760	ENSG00000248677.1	CTD-2044J15.1	3.8	0.000163	0.0119	0.17	0.17	Coronary artery disease;	chr5:6712721	chr5:6686325~6707711:-
THCA	cis	rs2115630	0.905	rs6496401	ENSG00000259295.5	CSPG4P12	-3.8	0.000163	0.0119	-0.23	-0.17	P wave terminal force;	chr15:84754562	chr15:85191438~85213905:+
THCA	cis	rs7759001	0.744	rs13220155	ENSG00000271755.1	RP1-153G14.4	3.8	0.000163	0.0119	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27483331	chr6:27404010~27406964:-
THCA	cis	rs11212260	0.655	rs689199	ENSG00000261098.1	RP11-819C21.1	-3.8	0.000163	0.0119	-0.34	-0.17	IgG glycosylation;	chr11:107518083	chr11:107312132~107316271:-
THCA	cis	rs11212260	0.85	rs515555	ENSG00000261098.1	RP11-819C21.1	3.8	0.000163	0.0119	0.34	0.17	IgG glycosylation;	chr11:107520297	chr11:107312132~107316271:-
THCA	cis	rs13113518	0.812	rs6830409	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55522229	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs2035692	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55528801	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs4507426	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55529387	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs2035691	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55529786	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.756	rs11939652	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55532542	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs13107810	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55542243	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs7667741	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55544621	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs13140590	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55548666	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs13116035	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55561218	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.783	rs2171618	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55564241	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.783	rs7690837	ENSG00000272969.1	RP11-528I4.2	3.8	0.000163	0.0119	0.2	0.17	Height;	chr4:55575856	chr4:55547112~55547889:+
THCA	cis	rs372883	0.613	rs1153289	ENSG00000176054.6	RPL23P2	-3.8	0.000163	0.0119	-0.15	-0.17	Pancreatic cancer;	chr21:29313891	chr21:28997613~28998033:-
THCA	cis	rs804280	0.517	rs7815179	ENSG00000255495.1	AC145124.2	3.8	0.000163	0.0119	0.2	0.17	Myopia (pathological);	chr8:11934539	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.871	rs7815186	ENSG00000255495.1	AC145124.2	3.8	0.000163	0.0119	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.516	rs7833079	ENSG00000255495.1	AC145124.2	3.8	0.000163	0.0119	0.2	0.17	Neuroticism;	chr8:11934620	chr8:12194467~12196280:+
THCA	cis	rs11030122	0.959	rs1869084	ENSG00000230593.3	AC090804.1	3.8	0.000163	0.0119	0.23	0.17	Mean platelet volume;Platelet distribution width;	chr11:3888056	chr11:3892398~3892887:-
THCA	cis	rs12291225	0.679	rs4756786	ENSG00000251991.1	RNU7-49P	3.8	0.000163	0.0119	0.21	0.17	Sense of smell;	chr11:14264354	chr11:14478892~14478953:+
THCA	cis	rs8130944	1	rs8130333	ENSG00000235772.1	AP001625.6	3.8	0.000163	0.0119	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42716342	chr21:42560374~42561934:-
THCA	cis	rs7873102	0.654	rs6476666	ENSG00000213839.4	TMX2P1	-3.8	0.000163	0.0119	-0.13	-0.17	Brain structure;	chr9:37963050	chr9:37885683~37886390:+
THCA	cis	rs4218	0.689	rs35555888	ENSG00000259732.1	RP11-59H7.3	-3.8	0.000163	0.0119	-0.24	-0.17	Social communication problems;	chr15:59093935	chr15:59121034~59133250:+
THCA	cis	rs6933660	0.721	rs2128945	ENSG00000219395.2	HSPA8P15	-3.8	0.000163	0.0119	-0.15	-0.17	Menarche (age at onset);	chr6:151446772	chr6:151411259~151413945:-
THCA	cis	rs9291683	0.588	rs3733586	ENSG00000250413.1	RP11-448G15.1	-3.8	0.000163	0.0119	-0.16	-0.17	Bone mineral density;	chr4:9995910	chr4:10006482~10009725:+
THCA	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	3.8	0.000163	0.0119	0.19	0.17	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
THCA	cis	rs755249	0.917	rs61779330	ENSG00000182109.6	RP11-69E11.4	3.8	0.000163	0.0119	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39522280~39546187:-
THCA	cis	rs755249	0.876	rs72662001	ENSG00000182109.6	RP11-69E11.4	3.8	0.000163	0.0119	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39522280~39546187:-
THCA	cis	rs6687821	0.515	rs10489917	ENSG00000261737.1	RP4-612B15.3	-3.8	0.000163	0.0119	-0.26	-0.17	Yeast infection;	chr1:86932105	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs12072434	ENSG00000261737.1	RP4-612B15.3	-3.8	0.000163	0.0119	-0.26	-0.17	Yeast infection;	chr1:86935026	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs1923144	ENSG00000261737.1	RP4-612B15.3	-3.8	0.000163	0.0119	-0.26	-0.17	Yeast infection;	chr1:86938548	chr1:86703502~86704462:-
THCA	cis	rs9880211	1	rs6805316	ENSG00000239213.4	NCK1-AS1	3.8	0.000163	0.0119	0.19	0.17	Height;Body mass index;	chr3:136233270	chr3:136841726~136862054:-
THCA	cis	rs1862618	0.853	rs832553	ENSG00000234553.1	AC022431.3	-3.8	0.000163	0.0119	-0.2	-0.17	Initial pursuit acceleration;	chr5:56818959	chr5:56536583~56537826:-
THCA	cis	rs1387259	0.79	rs2732445	ENSG00000257735.1	RP11-370I10.6	3.8	0.000163	0.0119	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48350945~48442411:+
THCA	cis	rs2832077	0.943	rs2832094	ENSG00000232855.5	AF131217.1	3.8	0.000163	0.0119	0.21	0.17	Cognitive test performance;	chr21:28793588	chr21:28439346~28674848:-
THCA	cis	rs5006884	1	rs7113817	ENSG00000167355.6	AC104389.28	-3.8	0.000163	0.0119	-0.24	-0.17	Fetal hemoglobin levels;	chr11:5365842	chr11:5304976~5505652:-
THCA	cis	rs1923243	0.775	rs12133935	ENSG00000223479.3	RP4-788P17.1	-3.8	0.000163	0.0119	-0.19	-0.17	Migraine;	chr1:73182117	chr1:73635216~73715214:+
THCA	cis	rs786425	0.682	rs7307008	ENSG00000278112.1	RP11-972P1.11	-3.8	0.000163	0.0119	-0.17	-0.17	Pubertal anthropometrics;	chr12:123675474	chr12:123519390~123519856:-
THCA	cis	rs2236231	0.522	rs4902490	ENSG00000259502.1	RP11-643G16.3	3.8	0.000163	0.0119	0.17	0.17	Plasma kynurenine levels in major depressive disorder;	chr14:67575538	chr14:67610986~67613864:+
THCA	cis	rs17741873	0.779	rs12573092	ENSG00000271848.1	RP11-464F9.21	-3.8	0.000163	0.0119	-0.21	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73840258	chr10:73654039~73674719:+
THCA	cis	rs9813712	0.953	rs9871734	ENSG00000253540.4	FAM86HP	3.8	0.000163	0.0119	0.21	0.17	Response to amphetamines;	chr3:130240756	chr3:130099092~130111472:-
THCA	cis	rs7819412	0.525	rs10086521	ENSG00000280294.1	RP11-177H2.1	3.8	0.000163	0.0119	0.14	0.17	Triglycerides;	chr8:10926259	chr8:10856085~10859436:-
THCA	cis	rs4869313	0.694	rs7722694	ENSG00000247121.5	CTD-2260A17.2	-3.8	0.000163	0.0119	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96983787	chr5:96814028~96935809:-
THCA	cis	rs62292953	0.719	rs11920676	ENSG00000248724.5	NPHP3-AS1	-3.8	0.000163	0.0119	-0.31	-0.17	Red cell distribution width;	chr3:132447161	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.719	rs11917172	ENSG00000248724.5	NPHP3-AS1	-3.8	0.000163	0.0119	-0.31	-0.17	Red cell distribution width;	chr3:132447422	chr3:132721750~132874223:+
THCA	cis	rs2187895	1	rs2187895	ENSG00000271811.1	RP1-79C4.4	3.8	0.000163	0.0119	0.26	0.17	Tonsillectomy;	chr1:170715290	chr1:170667381~170669425:+
THCA	cis	rs9980	0.762	rs62050038	ENSG00000226232.7	RP11-419C5.2	-3.8	0.000163	0.0119	-0.26	-0.17	Blood osmolality (transformed sodium);	chr16:69768962	chr16:69976388~69996188:-
THCA	cis	rs4578769	0.569	rs8094359	ENSG00000273232.1	RP11-370A5.2	3.8	0.000163	0.0119	0.23	0.17	Eosinophil percentage of white cells;	chr18:22907743	chr18:22882825~22883357:-
THCA	cis	rs7819412	0.807	rs4840542	ENSG00000254948.1	OR7E158P	3.8	0.000163	0.0119	0.21	0.17	Triglycerides;	chr8:11087299	chr8:11919900~11920809:-
THCA	cis	rs11992162	0.613	rs56094399	ENSG00000227888.4	FAM66A	-3.8	0.000163	0.0119	-0.23	-0.17	Monocyte count;	chr8:11939961	chr8:12362019~12388296:+
THCA	cis	rs9316337	0.582	rs4770158	ENSG00000236953.1	ZDHHC20-IT1	-3.8	0.000163	0.0119	-0.2	-0.17	Schizophrenia;	chr13:21449610	chr13:21376977~21377874:-
THCA	cis	rs7166081	1	rs4432221	ENSG00000270964.1	RP11-502I4.3	3.8	0.000163	0.0119	0.16	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67342524	chr15:67541072~67542604:-
THCA	cis	rs5752326	0.764	rs5997093	ENSG00000244625.4	MIATNB	-3.8	0.000163	0.0119	-0.28	-0.17	Ischemic stroke;	chr22:26455862	chr22:26672767~26780207:+
THCA	cis	rs3824488	0.85	rs2282041	ENSG00000271155.1	RP11-435O5.5	-3.8	0.000163	0.0119	-0.26	-0.17	Neuroticism;	chr9:95486105	chr9:95506235~95507636:+
THCA	cis	rs12440869	1	rs4312262	ENSG00000270964.1	RP11-502I4.3	-3.8	0.000163	0.0119	-0.15	-0.17	Peak velocity of the mitral A-wave;	chr15:67365172	chr15:67541072~67542604:-
THCA	cis	rs4578769	0.879	rs9950650	ENSG00000265939.1	UBE2CP2	3.8	0.000163	0.0119	0.21	0.17	Eosinophil percentage of white cells;	chr18:22864537	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.879	rs7244549	ENSG00000265939.1	UBE2CP2	3.8	0.000163	0.0119	0.21	0.17	Eosinophil percentage of white cells;	chr18:22866052	chr18:22900486~22900995:-
THCA	cis	rs13098911	0.54	rs2088692	ENSG00000226074.4	PRSS44	-3.8	0.000163	0.0119	-0.31	-0.17	Celiac disease;	chr3:46035840	chr3:46809359~46812558:-
THCA	cis	rs10435719	0.867	rs62493601	ENSG00000255495.1	AC145124.2	3.8	0.000163	0.0119	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:12194467~12196280:+
THCA	cis	rs804280	0.509	rs35626932	ENSG00000254948.1	OR7E158P	-3.8	0.000163	0.0119	-0.22	-0.17	Myopia (pathological);	chr8:11929423	chr8:11919900~11920809:-
THCA	cis	rs12681366	0.595	rs2450580	ENSG00000261437.1	RP11-22C11.2	-3.8	0.000163	0.0119	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94351548	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.708	rs2515165	ENSG00000261437.1	RP11-22C11.2	-3.8	0.000163	0.0119	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94352616	chr8:94637285~94639467:-
THCA	cis	rs948562	0.947	rs7482383	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0119	0.28	0.17	Lymphoma;	chr11:58602225	chr11:58627435~58628528:+
THCA	cis	rs948562	0.947	rs76985515	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0119	0.28	0.17	Lymphoma;	chr11:58604321	chr11:58627435~58628528:+
THCA	cis	rs948562	0.947	rs78176302	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0119	0.28	0.17	Lymphoma;	chr11:58615176	chr11:58627435~58628528:+
THCA	cis	rs948562	0.947	rs11541682	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0119	0.28	0.17	Lymphoma;	chr11:58618279	chr11:58627435~58628528:+
THCA	cis	rs948562	0.947	rs17489568	ENSG00000280010.1	AP001350.4	3.8	0.000163	0.0119	0.28	0.17	Lymphoma;	chr11:58622534	chr11:58627435~58628528:+
THCA	cis	rs5753037	0.869	rs4287865	ENSG00000279699.1	RP1-102K2.9	3.8	0.000163	0.0119	0.17	0.17	Type 1 diabetes;	chr22:29911569	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.869	rs737939	ENSG00000279699.1	RP1-102K2.9	3.8	0.000163	0.0119	0.17	0.17	Type 1 diabetes;	chr22:29919427	chr22:30275215~30276951:-
THCA	cis	rs479105	0.603	rs3782774	ENSG00000278356.1	RP11-372B4.3	3.8	0.000163	0.0119	0.17	0.17	Gut microbiota (bacterial taxa);	chr12:3262065	chr12:2885819~2886329:+
THCA	cis	rs796395	0.934	rs622912	ENSG00000232480.1	TGFB2-AS1	-3.8	0.000163	0.0119	-0.2	-0.17	Post bronchodilator FEV1/FVC ratio;	chr1:218497015	chr1:218344196~218345678:-
THCA	cis	rs1959947	0.876	rs1959946	ENSG00000251363.2	RP11-129M6.1	-3.8	0.000163	0.0119	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41049902	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs8004166	ENSG00000251363.2	RP11-129M6.1	-3.8	0.000163	0.0119	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41050664	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs10438077	ENSG00000251363.2	RP11-129M6.1	-3.8	0.000163	0.0119	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41050791	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.837	rs8018684	ENSG00000251363.2	RP11-129M6.1	-3.8	0.000163	0.0119	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41050852	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.837	rs10150415	ENSG00000251363.2	RP11-129M6.1	-3.8	0.000163	0.0119	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41051717	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs28546760	ENSG00000251363.2	RP11-129M6.1	-3.8	0.000163	0.0119	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41052564	chr14:40954898~40975877:+
THCA	cis	rs1865760	0.625	rs9393681	ENSG00000272810.1	U91328.22	-3.8	0.000163	0.0119	-0.13	-0.17	Height;	chr6:26008032	chr6:26013241~26013757:+
THCA	cis	rs8081395	0.775	rs2526355	ENSG00000267302.4	RP11-178C3.2	3.8	0.000163	0.0119	0.2	0.17	White blood cell count;	chr17:59875872	chr17:59964832~59996972:+
THCA	cis	rs875971	0.964	rs6945019	ENSG00000272831.1	RP11-792A8.4	3.8	0.000163	0.0119	0.11	0.17	Aortic root size;	chr7:66457471	chr7:66739829~66740385:-
THCA	cis	rs4713118	0.868	rs10484401	ENSG00000272009.1	RP1-313I6.12	3.8	0.000163	0.0119	0.2	0.17	Parkinson's disease;	chr6:27778811	chr6:28078792~28081130:-
THCA	cis	rs6453278	0.559	rs13170206	ENSG00000250802.5	ZBED3-AS1	3.8	0.000163	0.0119	0.17	0.17	Autism;	chr5:77099990	chr5:77086740~77166909:+
THCA	cis	rs988712	0.705	rs4923460	ENSG00000245573.6	BDNF-AS	3.8	0.000163	0.0119	0.17	0.17	Obesity;	chr11:27635242	chr11:27506838~27698174:+
THCA	cis	rs9450351	0.744	rs6900270	ENSG00000203875.9	SNHG5	-3.8	0.000163	0.0119	-0.34	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85504789	chr6:85660950~85678736:-
THCA	cis	rs16976116	0.643	rs12440420	ENSG00000279145.1	RP11-547D13.1	-3.8	0.000163	0.0119	-0.16	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55225234	chr15:55171972~55178175:-
THCA	cis	rs16975963	0.644	rs11665759	ENSG00000276846.1	CTD-3220F14.3	-3.8	0.000163	0.0119	-0.16	-0.17	Longevity;	chr19:37548773	chr19:37314868~37315620:-
THCA	cis	rs6472235	0.656	rs57683289	ENSG00000272192.1	CTD-2532N20.1	3.8	0.000163	0.0119	0.18	0.17	Plateletcrit;Myopia (pathological);	chr8:65973204	chr8:65842752~65843331:+
THCA	cis	rs11971779	0.68	rs6960876	ENSG00000252332.1	RNU6-911P	3.8	0.000163	0.0119	0.2	0.17	Diisocyanate-induced asthma;	chr7:139427430	chr7:139448740~139448843:+
THCA	cis	rs889512	0.642	rs8046145	ENSG00000261783.1	RP11-252K23.2	3.8	0.000163	0.0119	0.34	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75261123	chr16:75379818~75381260:-
THCA	cis	rs10484434	0.901	rs41266783	ENSG00000272810.1	U91328.22	3.8	0.000163	0.0119	0.18	0.17	HIV-1 viral setpoint;	chr6:26032200	chr6:26013241~26013757:+
THCA	cis	rs7927592	0.956	rs11228277	ENSG00000160172.9	FAM86C2P	3.8	0.000163	0.0119	0.17	0.17	Total body bone mineral density;	chr11:68540856	chr11:67791648~67805336:-
THCA	cis	rs4262150	0.846	rs113655983	ENSG00000253921.1	CTB-113P19.3	3.8	0.000164	0.0119	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152748533	chr5:151753992~151767247:+
THCA	cis	rs5753037	0.869	rs5763646	ENSG00000279699.1	RP1-102K2.9	3.8	0.000164	0.0119	0.17	0.17	Type 1 diabetes;	chr22:29963421	chr22:30275215~30276951:-
THCA	cis	rs7520050	0.966	rs7524495	ENSG00000281133.1	AL355480.3	3.8	0.000164	0.0119	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45580892~45580996:-
THCA	cis	rs11098499	0.913	rs67073020	ENSG00000249244.1	RP11-548H18.2	3.8	0.000164	0.0119	0.2	0.17	Corneal astigmatism;	chr4:119231402	chr4:119391831~119395335:-
THCA	cis	rs7824557	0.544	rs1865521	ENSG00000154316.13	TDH	-3.8	0.000164	0.0119	-0.13	-0.17	Retinal vascular caliber;	chr8:11373740	chr8:11339637~11368452:+
THCA	cis	rs1577917	0.816	rs9353349	ENSG00000220563.1	PKMP3	3.8	0.000164	0.0119	0.13	0.17	Response to antipsychotic treatment;	chr6:85998007	chr6:85659892~85660606:-
THCA	cis	rs2019137	0.905	rs2276561	ENSG00000234997.1	AC016745.3	-3.8	0.000164	0.0119	-0.17	-0.17	Lymphocyte counts;	chr2:113198794	chr2:113424495~113425324:+
THCA	cis	rs2019137	0.936	rs2305133	ENSG00000234997.1	AC016745.3	-3.8	0.000164	0.0119	-0.17	-0.17	Lymphocyte counts;	chr2:113199244	chr2:113424495~113425324:+
THCA	cis	rs2019137	0.936	rs12612729	ENSG00000234997.1	AC016745.3	-3.8	0.000164	0.0119	-0.17	-0.17	Lymphocyte counts;	chr2:113199471	chr2:113424495~113425324:+
THCA	cis	rs2019137	0.936	rs731834	ENSG00000234997.1	AC016745.3	-3.8	0.000164	0.0119	-0.17	-0.17	Lymphocyte counts;	chr2:113199621	chr2:113424495~113425324:+
THCA	cis	rs13256369	0.708	rs11249886	ENSG00000254153.1	CTA-398F10.2	-3.8	0.000164	0.0119	-0.2	-0.17	Obesity-related traits;	chr8:8704511	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.802	rs11249887	ENSG00000254153.1	CTA-398F10.2	-3.8	0.000164	0.0119	-0.2	-0.17	Obesity-related traits;	chr8:8704674	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.755	rs12550057	ENSG00000254153.1	CTA-398F10.2	-3.8	0.000164	0.0119	-0.2	-0.17	Obesity-related traits;	chr8:8704758	chr8:8456909~8461337:-
THCA	cis	rs6724465	1	rs13386793	ENSG00000272644.1	RP11-33O4.1	3.8	0.000164	0.0119	0.25	0.17	Height;	chr2:219107852	chr2:219069354~219069809:-
THCA	cis	rs6724465	0.929	rs12104660	ENSG00000272644.1	RP11-33O4.1	3.8	0.000164	0.0119	0.25	0.17	Height;	chr2:219108262	chr2:219069354~219069809:-
THCA	cis	rs67478160	0.572	rs8015603	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000164	0.0119	-0.17	-0.17	Schizophrenia;	chr14:103827341	chr14:103854366~103880111:-
THCA	cis	rs9309473	1	rs7584575	ENSG00000273245.1	RP11-434P11.2	3.8	0.000164	0.0119	0.23	0.17	Metabolite levels;	chr2:73439274	chr2:73750256~73750786:-
THCA	cis	rs11098499	0.863	rs13136462	ENSG00000249244.1	RP11-548H18.2	3.8	0.000164	0.0119	0.2	0.17	Corneal astigmatism;	chr4:119622018	chr4:119391831~119395335:-
THCA	cis	rs12476592	0.602	rs4671509	ENSG00000242412.1	DBIL5P2	3.8	0.000164	0.0119	0.22	0.17	Childhood ear infection;	chr2:63458870	chr2:63117851~63119542:-
THCA	cis	rs614226	0.516	rs1794748	ENSG00000278344.1	RP11-18C24.8	3.8	0.000164	0.0119	0.23	0.17	Type 1 diabetes nephropathy;	chr12:120515955	chr12:120500735~120501090:-
THCA	cis	rs4325129	0.677	rs10797035	ENSG00000272668.1	RP11-190A12.8	3.8	0.000164	0.0119	0.2	0.17	Obesity-related traits;	chr1:159474855	chr1:159866954~159867685:+
THCA	cis	rs11756659	0.653	rs11757088	ENSG00000272462.2	U91328.19	3.8	0.000164	0.0119	0.17	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25948230	chr6:25992662~26001775:+
THCA	cis	rs4073582	0.894	rs801733	ENSG00000255320.1	RP11-755F10.1	-3.8	0.000164	0.0119	-0.23	-0.17	Gout;	chr11:66167078	chr11:66244840~66246239:-
THCA	cis	rs15676	0.783	rs10988119	ENSG00000234771.3	SLC25A25-AS1	-3.8	0.000164	0.0119	-0.15	-0.17	Blood metabolite levels;	chr9:128802306	chr9:128108581~128118693:-
THCA	cis	rs15676	0.783	rs10988120	ENSG00000234771.3	SLC25A25-AS1	-3.8	0.000164	0.0119	-0.15	-0.17	Blood metabolite levels;	chr9:128802416	chr9:128108581~128118693:-
THCA	cis	rs15676	0.783	rs10819442	ENSG00000234771.3	SLC25A25-AS1	-3.8	0.000164	0.0119	-0.15	-0.17	Blood metabolite levels;	chr9:128802471	chr9:128108581~128118693:-
THCA	cis	rs15676	0.783	rs10988121	ENSG00000234771.3	SLC25A25-AS1	-3.8	0.000164	0.0119	-0.15	-0.17	Blood metabolite levels;	chr9:128802647	chr9:128108581~128118693:-
THCA	cis	rs15676	0.783	rs7044955	ENSG00000234771.3	SLC25A25-AS1	-3.8	0.000164	0.0119	-0.15	-0.17	Blood metabolite levels;	chr9:128804873	chr9:128108581~128118693:-
THCA	cis	rs494526	0.835	rs11198741	ENSG00000229272.1	RP11-498J9.2	3.8	0.000164	0.0119	0.2	0.17	Alcoholic chronic pancreatitis;	chr10:119029218	chr10:119003536~119003884:-
THCA	cis	rs7394190	0.935	rs12570126	ENSG00000272140.2	RP11-574K11.29	3.8	0.000164	0.0119	0.16	0.17	Incident atrial fibrillation;	chr10:73657031	chr10:73703735~73713581:-
THCA	cis	rs1417770	0.931	rs12564025	ENSG00000260971.3	RP11-504A18.1	-3.8	0.000164	0.0119	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr1:56250420	chr1:56248294~56258571:-
THCA	cis	rs9303542	0.729	rs56146024	ENSG00000278765.1	RP5-890E16.5	-3.8	0.000164	0.0119	-0.23	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48395087	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs35533148	ENSG00000278765.1	RP5-890E16.5	-3.8	0.000164	0.0119	-0.23	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48410238	chr17:48066704~48067293:-
THCA	cis	rs2933343	0.553	rs71331686	ENSG00000231305.3	RP11-723O4.2	3.8	0.000164	0.0119	0.19	0.17	IgG glycosylation;	chr3:128992585	chr3:128861313~128871540:-
THCA	cis	rs4713118	0.505	rs156740	ENSG00000261839.1	RP1-265C24.8	3.8	0.000164	0.0119	0.16	0.17	Parkinson's disease;	chr6:27992657	chr6:28136849~28139678:+
THCA	cis	rs6560517	0.707	rs12237420	ENSG00000234618.1	RPSAP9	-3.8	0.000164	0.0119	-0.2	-0.17	Dialysis-related mortality;	chr9:76473048	chr9:76398699~76399586:+
THCA	cis	rs804280	0.662	rs810738	ENSG00000270154.1	RP11-419I17.1	3.8	0.000164	0.0119	0.24	0.17	Myopia (pathological);	chr8:11753697	chr8:12476462~12477122:+
THCA	cis	rs9788721	0.967	rs55853698	ENSG00000261762.1	RP11-650L12.2	-3.8	0.000164	0.0119	-0.23	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78565597	chr15:78589123~78591276:-
THCA	cis	rs6935502	1	rs6935502	ENSG00000224984.1	RP11-524H19.2	-3.8	0.000164	0.0119	-0.2	-0.17	Subjective well-being;	chr6:54788742	chr6:54840118~54840855:-
THCA	cis	rs453301	0.506	rs686189	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000164	0.012	-0.19	-0.17	Joint mobility (Beighton score);	chr8:8766127	chr8:9141424~9145435:+
THCA	cis	rs7819412	0.74	rs11250119	ENSG00000206014.6	OR7E161P	3.8	0.000164	0.012	0.2	0.17	Triglycerides;	chr8:11179525	chr8:11928597~11929563:-
THCA	cis	rs2562456	0.72	rs6511250	ENSG00000268278.1	RP11-420K14.1	-3.8	0.000164	0.012	-0.21	-0.17	Pain;	chr19:21473244	chr19:21637974~21656300:+
THCA	cis	rs494526	0.899	rs10886379	ENSG00000229272.1	RP11-498J9.2	-3.8	0.000164	0.012	-0.19	-0.17	Alcoholic chronic pancreatitis;	chr10:119087544	chr10:119003536~119003884:-
THCA	cis	rs755249	0.501	rs2455648	ENSG00000182109.6	RP11-69E11.4	3.8	0.000164	0.012	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39522280~39546187:-
THCA	cis	rs4947019	0.609	rs9487074	ENSG00000223537.2	RP5-919F19.5	-3.8	0.000164	0.012	-0.32	-0.17	Hematological parameters;	chr6:109368478	chr6:109487906~109506800:+
THCA	cis	rs10760158	0.832	rs4837834	ENSG00000235865.2	GSN-AS1	3.8	0.000164	0.012	0.15	0.17	Pulse pressure;	chr9:121296899	chr9:121280768~121285530:-
THCA	cis	rs67478160	0.643	rs2887282	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000164	0.012	-0.17	-0.17	Schizophrenia;	chr14:103814397	chr14:103854366~103880111:-
THCA	cis	rs3755605	0.728	rs1352204	ENSG00000242578.1	RP11-469J4.3	3.8	0.000164	0.012	0.19	0.17	Testicular germ cell tumor;	chr3:170098722	chr3:170410512~170418615:+
THCA	cis	rs11105298	0.786	rs10858897	ENSG00000266347.2	AC068641.1	3.8	0.000164	0.012	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89592833~89592927:+
THCA	cis	rs9400467	0.922	rs1216019	ENSG00000271789.1	RP5-1112D6.7	-3.8	0.000164	0.012	-0.17	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111181991	chr6:111297126~111298510:+
THCA	cis	rs2348418	0.733	rs2169754	ENSG00000278733.1	RP11-425D17.1	3.8	0.000164	0.012	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28185625~28186190:-
THCA	cis	rs10760158	0.832	rs10760169	ENSG00000226752.6	PSMD5-AS1	-3.8	0.000164	0.012	-0.21	-0.17	Pulse pressure;	chr9:121295404	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs10760171	ENSG00000226752.6	PSMD5-AS1	-3.8	0.000164	0.012	-0.21	-0.17	Pulse pressure;	chr9:121296081	chr9:120824828~120854385:+
THCA	cis	rs7246657	0.638	rs7246461	ENSG00000226686.6	LINC01535	3.8	0.000164	0.012	0.24	0.17	Coronary artery calcification;	chr19:37705680	chr19:37251912~37265535:+
THCA	cis	rs42648	0.806	rs6951894	ENSG00000225498.1	AC002064.5	3.8	0.000164	0.012	0.18	0.17	Homocysteine levels;	chr7:90264631	chr7:90312496~90322592:+
THCA	cis	rs964611	0.751	rs58922278	ENSG00000259488.2	RP11-154J22.1	-3.8	0.000164	0.012	-0.16	-0.17	Metabolite levels (Pyroglutamine);	chr15:48257357	chr15:48312353~48331856:-
THCA	cis	rs4240897	0.935	rs1474868	ENSG00000201801.1	RNU5E-4P	-3.8	0.000164	0.012	-0.2	-0.17	Tuberculosis;	chr1:11984107	chr1:11909808~11909927:-
THCA	cis	rs9878978	1	rs17194392	ENSG00000227588.2	CNTN4-AS2	3.8	0.000164	0.012	0.21	0.17	Blood pressure (smoking interaction);	chr3:2445591	chr3:2110409~2144241:-
THCA	cis	rs1023500	0.505	rs134886	ENSG00000182057.4	OGFRP1	-3.8	0.000164	0.012	-0.2	-0.17	Schizophrenia;	chr22:42277850	chr22:42269753~42275196:+
THCA	cis	rs1383484	0.798	rs2086441	ENSG00000259728.4	LINC00933	-3.8	0.000164	0.012	-0.22	-0.17	Height;	chr15:83881728	chr15:84570649~84580175:+
THCA	cis	rs4950322	0.576	rs4950427	ENSG00000226015.2	CCT8P1	-3.8	0.000164	0.012	-0.18	-0.17	Protein quantitative trait loci;	chr1:147391175	chr1:147203276~147204932:-
THCA	cis	rs11992162	0.529	rs6995037	ENSG00000254948.1	OR7E158P	3.8	0.000164	0.012	0.22	0.17	Monocyte count;	chr8:11923378	chr8:11919900~11920809:-
THCA	cis	rs8033133	0.56	rs1549478	ENSG00000270523.1	RP11-145P16.3	3.8	0.000164	0.012	0.17	0.17	Blood osmolality (transformed sodium);	chr15:25087053	chr15:25130978~25131337:+
THCA	cis	rs5753037	0.653	rs131285	ENSG00000279699.1	RP1-102K2.9	3.8	0.000164	0.012	0.17	0.17	Type 1 diabetes;	chr22:29761951	chr22:30275215~30276951:-
THCA	cis	rs6088580	0.543	rs4911158	ENSG00000126005.14	MMP24-AS1	3.8	0.000164	0.012	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34651708	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.524	rs1853056	ENSG00000126005.14	MMP24-AS1	3.8	0.000164	0.012	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34674254	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.524	rs6087616	ENSG00000126005.14	MMP24-AS1	3.8	0.000164	0.012	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34675229	chr20:35216462~35278131:-
THCA	cis	rs7520050	0.966	rs12409773	ENSG00000280836.1	AL355480.1	3.8	0.000164	0.012	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45581219~45581321:-
THCA	cis	rs13325613	0.834	rs34340501	ENSG00000223552.1	RP11-24F11.2	-3.8	0.000164	0.012	-0.3	-0.17	Monocyte count;	chr3:46183724	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs71327038	ENSG00000223552.1	RP11-24F11.2	-3.8	0.000164	0.012	-0.3	-0.17	Monocyte count;	chr3:46184503	chr3:46364955~46407059:-
THCA	cis	rs4908768	0.539	rs7526171	ENSG00000270282.1	RP5-1115A15.2	3.8	0.000164	0.012	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8590126	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.539	rs6675443	ENSG00000270282.1	RP5-1115A15.2	3.8	0.000164	0.012	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8591523	chr1:8512653~8513021:+
THCA	cis	rs4930838	1	rs11049924	ENSG00000274315.1	RP11-996F15.5	3.8	0.000164	0.012	0.32	0.17	Facial emotion recognition (angry faces);	chr12:28933226	chr12:29331434~29331936:-
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000265443.1	CTD-2349P21.6	-3.8	0.000164	0.012	-0.29	-0.17	Body mass index;	chr17:30806554	chr17:30726305~30727564:-
THCA	cis	rs41342147	0.66	rs77807882	ENSG00000223374.1	AC005104.3	3.8	0.000164	0.012	0.15	0.17	Vitiligo;	chr2:241302766	chr2:241351340~241353104:-
THCA	cis	rs1908814	0.516	rs10113062	ENSG00000255495.1	AC145124.2	3.8	0.000164	0.012	0.2	0.17	Neuroticism;	chr8:11935740	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.516	rs10113145	ENSG00000255495.1	AC145124.2	3.8	0.000164	0.012	0.2	0.17	Neuroticism;	chr8:11935786	chr8:12194467~12196280:+
THCA	cis	rs12234571	1	rs73374165	ENSG00000214293.7	APTR	3.8	0.000164	0.012	0.21	0.17	Obesity-related traits;	chr7:77787712	chr7:77657660~77696265:-
THCA	cis	rs9341808	0.718	rs1324123	ENSG00000260645.1	RP11-250B2.5	3.8	0.000164	0.012	0.15	0.17	Sitting height ratio;	chr6:80223177	chr6:80466958~80469080:+
THCA	cis	rs8062405	1	rs72793811	ENSG00000270424.1	RP11-1348G14.6	3.8	0.000164	0.012	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs72793812	ENSG00000270424.1	RP11-1348G14.6	3.8	0.000164	0.012	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28749959~28750595:-
THCA	cis	rs10419113	0.668	rs2360530	ENSG00000268545.1	VN1R107P	3.8	0.000164	0.012	0.2	0.17	Pediatric bone mineral density (spine);	chr19:57669785	chr19:57459912~57460120:+
THCA	cis	rs950169	0.887	rs12903946	ENSG00000188388.10	GOLGA6L3	3.8	0.000164	0.012	0.23	0.17	Schizophrenia;	chr15:84399732	chr15:85240472~85247170:+
THCA	cis	rs950169	0.887	rs62029593	ENSG00000188388.10	GOLGA6L3	3.8	0.000164	0.012	0.23	0.17	Schizophrenia;	chr15:84400482	chr15:85240472~85247170:+
THCA	cis	rs950169	0.81	rs62029594	ENSG00000188388.10	GOLGA6L3	3.8	0.000164	0.012	0.23	0.17	Schizophrenia;	chr15:84400554	chr15:85240472~85247170:+
THCA	cis	rs950169	0.881	rs62029596	ENSG00000188388.10	GOLGA6L3	3.8	0.000164	0.012	0.23	0.17	Schizophrenia;	chr15:84400736	chr15:85240472~85247170:+
THCA	cis	rs950169	0.881	rs4081123	ENSG00000188388.10	GOLGA6L3	3.8	0.000164	0.012	0.23	0.17	Schizophrenia;	chr15:84401537	chr15:85240472~85247170:+
THCA	cis	rs950169	0.881	rs62029599	ENSG00000188388.10	GOLGA6L3	3.8	0.000164	0.012	0.23	0.17	Schizophrenia;	chr15:84401867	chr15:85240472~85247170:+
THCA	cis	rs950169	0.8	rs4099846	ENSG00000188388.10	GOLGA6L3	3.8	0.000164	0.012	0.23	0.17	Schizophrenia;	chr15:84402196	chr15:85240472~85247170:+
THCA	cis	rs2688608	0.672	rs4065	ENSG00000271816.1	BMS1P4	3.8	0.000164	0.012	0.17	0.17	Inflammatory bowel disease;	chr10:73916706	chr10:73699151~73730487:-
THCA	cis	rs10954779	0.738	rs2737347	ENSG00000127589.4	TUBBP1	3.8	0.000164	0.012	0.21	0.17	Intelligence (multi-trait analysis);	chr8:31164475	chr8:30351873~30353518:+
THCA	cis	rs2640806	0.505	rs6981384	ENSG00000253105.4	KB-1448A5.1	3.8	0.000164	0.012	0.2	0.17	Obesity-related traits;	chr8:96349502	chr8:96371865~96387438:-
THCA	cis	rs757978	0.543	rs12477089	ENSG00000223374.1	AC005104.3	3.8	0.000164	0.012	0.15	0.17	Chronic lymphocytic leukemia;	chr2:241325898	chr2:241351340~241353104:-
THCA	cis	rs758324	0.561	rs407204	ENSG00000237714.1	P4HA2-AS1	3.8	0.000164	0.012	0.24	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131991772	chr5:132184876~132192808:+
THCA	cis	rs3767627	1	rs3767627	ENSG00000203819.6	HIST2H2BC	3.8	0.000164	0.012	0.25	0.17	Height;	chr1:149966973	chr1:149850193~149850772:-
THCA	cis	rs6496044	0.507	rs410522	ENSG00000259276.1	RP11-815J21.3	3.8	0.000165	0.012	0.2	0.17	Interstitial lung disease;	chr15:85663813	chr15:85621264~85627689:-
THCA	cis	rs4144027	1	rs4144027	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000165	0.012	-0.19	-0.17	Blood metabolite levels;	chr14:103891301	chr14:103854366~103880111:-
THCA	cis	rs4561483	0.583	rs1019813	ENSG00000263307.1	RP11-166B2.8	-3.8	0.000165	0.012	-0.18	-0.17	Testicular germ cell tumor;	chr16:11846972	chr16:11851649~11895611:+
THCA	cis	rs4713118	0.539	rs200951	ENSG00000216915.2	RP1-97D16.1	-3.8	0.000165	0.012	-0.25	-0.17	Parkinson's disease;	chr6:27868152	chr6:27737000~27738494:-
THCA	cis	rs16975963	0.843	rs241955	ENSG00000276846.1	CTD-3220F14.3	-3.8	0.000165	0.012	-0.16	-0.17	Longevity;	chr19:37788037	chr19:37314868~37315620:-
THCA	cis	rs9863	0.861	rs75321546	ENSG00000270028.1	RP11-380L11.4	3.8	0.000165	0.012	0.18	0.17	White blood cell count;	chr12:123962918	chr12:123925461~123926083:-
THCA	cis	rs9863	0.861	rs55990776	ENSG00000270028.1	RP11-380L11.4	3.8	0.000165	0.012	0.18	0.17	White blood cell count;	chr12:123962919	chr12:123925461~123926083:-
THCA	cis	rs6498068	0.594	rs3087620	ENSG00000260468.1	LINC01290	-3.8	0.000165	0.012	-0.22	-0.17	Metabolite levels (MHPG);	chr16:10529475	chr16:10514842~10528202:-
THCA	cis	rs2933343	0.7	rs883602	ENSG00000231305.3	RP11-723O4.2	3.8	0.000165	0.012	0.19	0.17	IgG glycosylation;	chr3:128935109	chr3:128861313~128871540:-
THCA	cis	rs10050311	0.698	rs4693780	ENSG00000251411.1	RP11-397E7.4	3.8	0.000165	0.012	0.2	0.17	Insulin-related traits;	chr4:86720066	chr4:86913266~86914817:-
THCA	cis	rs6840360	0.55	rs6535806	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151562754	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.53	rs6839802	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151564682	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs7695866	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151566958	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs7674244	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151567150	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.55	rs6836343	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151576412	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696270	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151577137	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.593	rs28602726	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151578636	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs28608620	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151583639	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs11099823	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151589413	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.55	rs62327267	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151597601	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs28454076	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151598931	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs1822346	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151604151	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs1822347	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151604167	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696272	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151607077	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs2407069	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151612049	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs10026670	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151618060	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs2406976	ENSG00000251611.1	RP11-610P16.1	-3.8	0.000165	0.012	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151619904	chr4:151407551~151408835:-
THCA	cis	rs9813712	0.717	rs9835466	ENSG00000253540.4	FAM86HP	3.8	0.000165	0.012	0.24	0.17	Response to amphetamines;	chr3:130258530	chr3:130099092~130111472:-
THCA	cis	rs10185424	0.521	rs4851531	ENSG00000281162.1	LINC01127	-3.8	0.000165	0.012	-0.14	-0.17	Crohn's disease;Ulcerative colitis;	chr2:102032147	chr2:101962056~101987167:+
THCA	cis	rs7819412	0.775	rs11773990	ENSG00000254948.1	OR7E158P	3.8	0.000165	0.012	0.21	0.17	Triglycerides;	chr8:11077572	chr8:11919900~11920809:-
THCA	cis	rs7819412	0.775	rs4545055	ENSG00000254948.1	OR7E158P	3.8	0.000165	0.012	0.21	0.17	Triglycerides;	chr8:11077856	chr8:11919900~11920809:-
THCA	cis	rs7819412	0.775	rs2898257	ENSG00000254948.1	OR7E158P	3.8	0.000165	0.012	0.21	0.17	Triglycerides;	chr8:11077858	chr8:11919900~11920809:-
THCA	cis	rs1292048	1	rs1292048	ENSG00000267302.4	RP11-178C3.2	3.8	0.000165	0.012	0.2	0.17	Red cell distribution width;	chr17:59877710	chr17:59964832~59996972:+
THCA	cis	rs4808199	0.948	rs2074300	ENSG00000267481.1	CTC-559E9.5	-3.8	0.000165	0.012	-0.18	-0.17	Nonalcoholic fatty liver disease;	chr19:19270187	chr19:19788755~19790531:-
THCA	cis	rs4808199	0.948	rs2074301	ENSG00000267481.1	CTC-559E9.5	-3.8	0.000165	0.012	-0.18	-0.17	Nonalcoholic fatty liver disease;	chr19:19270906	chr19:19788755~19790531:-
THCA	cis	rs12681366	0.708	rs2470731	ENSG00000261437.1	RP11-22C11.2	-3.8	0.000165	0.012	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94363146	chr8:94637285~94639467:-
THCA	cis	rs832187	0.603	rs7615475	ENSG00000224479.4	AC136289.1	3.8	0.000165	0.012	0.21	0.17	Schizophrenia;	chr3:63940985	chr3:63742293~63827445:-
THCA	cis	rs56309584	0.883	rs9897627	ENSG00000271002.1	RP11-599B13.8	-3.8	0.000165	0.012	-0.23	-0.17	Initial pursuit acceleration;	chr17:8258528	chr17:8199123~8199437:-
THCA	cis	rs1541160	0.956	rs541655	ENSG00000239494.2	RN7SL333P	-3.8	0.000165	0.012	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr1:169971617	chr1:169859756~169860052:+
THCA	cis	rs7772697	0.508	rs9498201	ENSG00000223701.3	RAET1E-AS1	3.8	0.000165	0.012	0.24	0.17	Diabetic retinopathy;	chr6:149060690	chr6:149884431~149919508:+
THCA	cis	rs1555322	1	rs2425027	ENSG00000126005.14	MMP24-AS1	-3.8	0.000165	0.012	-0.25	-0.17	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35216462~35278131:-
THCA	cis	rs9309473	0.5	rs2421582	ENSG00000273245.1	RP11-434P11.2	-3.8	0.000165	0.012	-0.21	-0.17	Metabolite levels;	chr2:73671293	chr2:73750256~73750786:-
THCA	cis	rs17695224	0.565	rs7248523	ENSG00000275055.1	CTC-471J1.11	-3.8	0.000165	0.012	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51833888	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.585	rs10406893	ENSG00000275055.1	CTC-471J1.11	-3.8	0.000165	0.012	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51833901	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.545	rs10406732	ENSG00000275055.1	CTC-471J1.11	-3.8	0.000165	0.012	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51833974	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.519	rs2159654	ENSG00000275055.1	CTC-471J1.11	-3.8	0.000165	0.012	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51834004	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.5	rs2159655	ENSG00000275055.1	CTC-471J1.11	-3.8	0.000165	0.012	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51834006	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.527	rs2903546	ENSG00000275055.1	CTC-471J1.11	-3.8	0.000165	0.012	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51834082	chr19:52049007~52049754:+
THCA	cis	rs858239	0.899	rs28458177	ENSG00000226816.2	AC005082.12	3.8	0.000165	0.012	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23206013~23208045:+
THCA	cis	rs6893300	0.857	rs6860716	ENSG00000225051.5	HMGB3P22	3.8	0.000165	0.012	0.18	0.17	Resting heart rate;	chr5:179735839	chr5:179679032~179694768:+
THCA	cis	rs9796	0.654	rs2947489	ENSG00000247556.5	OIP5-AS1	-3.8	0.000165	0.012	-0.14	-0.17	Menopause (age at onset);	chr15:41167378	chr15:41283990~41309737:+
THCA	cis	rs12681366	0.683	rs2515161	ENSG00000261437.1	RP11-22C11.2	-3.8	0.000165	0.012	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94358690	chr8:94637285~94639467:-
THCA	cis	rs6570726	0.818	rs437978	ENSG00000270638.1	RP3-466P17.1	3.8	0.000165	0.012	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145735570~145737218:+
THCA	cis	rs9840812	0.728	rs12635723	ENSG00000239213.4	NCK1-AS1	3.8	0.000165	0.012	0.16	0.17	Fibrinogen levels;	chr3:136581890	chr3:136841726~136862054:-
THCA	cis	rs910316	1	rs7303	ENSG00000259138.1	RP11-950C14.7	3.8	0.000165	0.012	0.15	0.17	Height;	chr14:75053362	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs10143132	ENSG00000259138.1	RP11-950C14.7	3.8	0.000165	0.012	0.15	0.17	Height;	chr14:75059147	chr14:75127153~75136930:+
THCA	cis	rs2360027	0.579	rs10802044	ENSG00000231365.4	RP11-418J17.1	-3.8	0.000165	0.012	-0.17	-0.17	Tonsillectomy;	chr1:118574966	chr1:119140396~119275973:+
THCA	cis	rs11242704	0.962	rs2816293	ENSG00000218027.2	RP11-157J24.1	3.8	0.000165	0.012	0.22	0.17	Response to hepatitis C treatment;	chr6:1538065	chr6:1513698~1515289:-
THCA	cis	rs4038782	0.653	rs872297	ENSG00000277440.1	RP11-295D4.5	3.8	0.000165	0.012	0.21	0.17	Cancer;	chr16:4915784	chr16:4430522~4431103:+
THCA	cis	rs2652822	0.525	rs11071738	ENSG00000259459.4	RP11-321G12.1	-3.8	0.000165	0.012	-0.14	-0.17	Metabolic traits;	chr15:63287956	chr15:63390136~63438320:+
THCA	cis	rs2613964	0.504	rs2399465	ENSG00000243795.1	RP11-572M11.3	3.8	0.000165	0.012	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129145	chr3:113142350~113167819:-
THCA	cis	rs2613964	0.504	rs2399466	ENSG00000243795.1	RP11-572M11.3	3.8	0.000165	0.012	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129190	chr3:113142350~113167819:-
THCA	cis	rs2236521	0.659	rs72487383	ENSG00000226332.2	RP11-157P1.4	3.8	0.000165	0.012	0.14	0.17	Pelvic organ prolapse;	chr20:62314257	chr20:62305432~62306325:-
THCA	cis	rs1865760	0.588	rs9467658	ENSG00000272810.1	U91328.22	-3.8	0.000165	0.012	-0.13	-0.17	Height;	chr6:26010653	chr6:26013241~26013757:+
THCA	cis	rs6570726	0.935	rs413916	ENSG00000270638.1	RP3-466P17.1	3.8	0.000165	0.012	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145735570~145737218:+
THCA	cis	rs7660883	1	rs2045592	ENSG00000251411.1	RP11-397E7.4	-3.8	0.000165	0.012	-0.16	-0.17	HDL cholesterol levels;	chr4:87093194	chr4:86913266~86914817:-
THCA	cis	rs17685	0.736	rs4732594	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76123955	chr7:76090431~76108779:-
THCA	cis	rs17685	0.671	rs60303271	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76130690	chr7:76090431~76108779:-
THCA	cis	rs17685	0.735	rs11763339	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76132223	chr7:76090431~76108779:-
THCA	cis	rs17685	0.775	rs11761172	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76132229	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs11764129	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76132572	chr7:76090431~76108779:-
THCA	cis	rs17685	0.816	rs11763076	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76136645	chr7:76090431~76108779:-
THCA	cis	rs17685	0.623	rs7782808	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76139327	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs6953665	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76139731	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs7778735	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76140919	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs10275521	ENSG00000227038.2	AC005077.12	3.8	0.000165	0.012	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76141654	chr7:76090431~76108779:-
THCA	cis	rs11673344	0.583	rs7254411	ENSG00000267260.1	CTD-2162K18.4	-3.8	0.000165	0.012	-0.21	-0.17	Obesity-related traits;	chr19:37034969	chr19:36773153~36777078:+
THCA	cis	rs1371614	0.635	rs12618836	ENSG00000272148.1	RP11-195B17.1	3.8	0.000165	0.012	0.16	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914748	chr2:27062428~27062907:-
THCA	cis	rs7520050	0.933	rs12045165	ENSG00000281133.1	AL355480.3	3.8	0.000165	0.012	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45580892~45580996:-
THCA	cis	rs7777677	0.925	rs4726544	ENSG00000211750.2	TRBV24-1	-3.8	0.000165	0.012	-0.18	-0.17	Alcoholic chronic pancreatitis;	chr7:142659616	chr7:142656701~142657213:+
THCA	cis	rs2625529	0.824	rs1074330	ENSG00000260037.4	CTD-2524L6.3	-3.8	0.000165	0.012	-0.24	-0.17	Red blood cell count;	chr15:71958400	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs12902006	ENSG00000260037.4	CTD-2524L6.3	-3.8	0.000165	0.012	-0.24	-0.17	Red blood cell count;	chr15:71960655	chr15:71818396~71823384:+
THCA	cis	rs7707921	0.958	rs4703870	ENSG00000251374.1	RPS23P5	-3.8	0.000165	0.012	-0.25	-0.17	Breast cancer;	chr5:82196824	chr5:82265157~82265259:-
THCA	cis	rs11088226	0.681	rs1134747	ENSG00000186842.4	LINC00846	-3.8	0.000165	0.012	-0.25	-0.17	Gastritis;	chr21:32566701	chr21:32572238~32575881:-
THCA	cis	rs1005277	0.522	rs7090858	ENSG00000275858.1	RP11-291L22.8	-3.8	0.000165	0.012	-0.2	-0.17	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38450738~38451069:-
THCA	cis	rs9450351	0.744	rs9344570	ENSG00000280232.1	RP11-321N4.4	3.8	0.000165	0.012	0.38	0.17	Interferon gamma-induced protein 10 levels;	chr6:86084062	chr6:85498441~85499058:-
THCA	cis	rs4578769	0.569	rs12605341	ENSG00000273232.1	RP11-370A5.2	-3.8	0.000165	0.012	-0.24	-0.17	Eosinophil percentage of white cells;	chr18:22803011	chr18:22882825~22883357:-
THCA	cis	rs12440869	0.959	rs7161879	ENSG00000270964.1	RP11-502I4.3	-3.8	0.000165	0.012	-0.15	-0.17	Peak velocity of the mitral A-wave;	chr15:67282102	chr15:67541072~67542604:-
THCA	cis	rs9660180	0.934	rs34849348	ENSG00000215914.4	MMP23A	-3.8	0.000165	0.012	-0.23	-0.17	Body mass index;	chr1:1831318	chr1:1699942~1701782:+
THCA	cis	rs2919009	0.607	rs72826623	ENSG00000271670.1	RP11-95I16.4	3.8	0.000165	0.012	0.2	0.17	Obesity-related traits;	chr10:120952843	chr10:120879256~120880667:-
THCA	cis	rs67478160	0.643	rs34813623	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000165	0.012	-0.17	-0.17	Schizophrenia;	chr14:103796957	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.608	rs34066659	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000165	0.012	-0.17	-0.17	Schizophrenia;	chr14:103797090	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs7147171	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000165	0.012	-0.17	-0.17	Schizophrenia;	chr14:103798520	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.619	rs11623546	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000165	0.012	-0.17	-0.17	Schizophrenia;	chr14:103802761	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.619	rs55824307	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000165	0.012	-0.17	-0.17	Schizophrenia;	chr14:103804870	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.595	rs12879501	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000165	0.012	-0.17	-0.17	Schizophrenia;	chr14:103806297	chr14:103854366~103880111:-
THCA	cis	rs6696239	0.956	rs3942992	ENSG00000227711.2	RP11-275O4.5	3.8	0.000165	0.012	0.24	0.17	Height;	chr1:227584695	chr1:227509028~227520477:-
THCA	cis	rs10491083	0.661	rs55748285	ENSG00000261996.1	CTC-281F24.1	3.8	0.000165	0.012	0.34	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6654010	chr17:6653464~6655009:-
THCA	cis	rs3026101	0.671	rs3026109	ENSG00000234327.6	AC012146.7	3.8	0.000165	0.012	0.14	0.17	Body mass index;	chr17:5381185	chr17:5111468~5115004:+
THCA	cis	rs7131987	0.565	rs7971296	ENSG00000275476.1	RP11-996F15.4	3.8	0.000165	0.012	0.17	0.17	QT interval;	chr12:29263297	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.605	rs1120528	ENSG00000275476.1	RP11-996F15.4	3.8	0.000165	0.012	0.17	0.17	QT interval;	chr12:29264237	chr12:29277397~29277882:-
THCA	cis	rs9926296	0.585	rs6500441	ENSG00000274627.1	RP11-104N10.2	-3.8	0.000165	0.012	-0.18	-0.17	Vitiligo;	chr16:89762261	chr16:89516797~89522217:+
THCA	cis	rs2933343	0.7	rs6787833	ENSG00000231305.3	RP11-723O4.2	3.8	0.000165	0.012	0.18	0.17	IgG glycosylation;	chr3:128937341	chr3:128861313~128871540:-
THCA	cis	rs1005277	0.579	rs2800485	ENSG00000120555.12	SEPT7P9	3.8	0.000165	0.012	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38383069~38402916:-
THCA	cis	rs1411478	1	rs3789364	ENSG00000243155.1	RP11-46A10.5	3.8	0.000165	0.012	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180981907	chr1:180944042~180976482:-
THCA	cis	rs11212260	0.85	rs641946	ENSG00000261098.1	RP11-819C21.1	-3.8	0.000165	0.012	-0.34	-0.17	IgG glycosylation;	chr11:107511389	chr11:107312132~107316271:-
THCA	cis	rs6687821	0.515	rs12025384	ENSG00000261737.1	RP4-612B15.3	3.8	0.000165	0.012	0.26	0.17	Yeast infection;	chr1:86972227	chr1:86703502~86704462:-
THCA	cis	rs964611	0.882	rs11070635	ENSG00000259488.2	RP11-154J22.1	3.8	0.000165	0.012	0.16	0.17	Metabolite levels (Pyroglutamine);	chr15:48361928	chr15:48312353~48331856:-
THCA	cis	rs10181042	0.528	rs2564118	ENSG00000270820.4	RP11-355B11.2	3.8	0.000165	0.012	0.14	0.17	Crohn's disease;	chr2:61006154	chr2:61471188~61484130:+
THCA	cis	rs10090774	0.965	rs11167005	ENSG00000280303.2	ERICD	3.8	0.000165	0.012	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140873057	chr8:140636281~140638283:+
THCA	cis	rs267567	0.626	rs267543	ENSG00000235257.7	ITGA9-AS1	3.8	0.000165	0.012	0.14	0.17	PR interval;	chr3:37537997	chr3:37745432~37861780:-
THCA	cis	rs394563	0.601	rs431978	ENSG00000223701.3	RAET1E-AS1	-3.8	0.000165	0.012	-0.23	-0.17	Dupuytren's disease;	chr6:149471864	chr6:149884431~149919508:+
THCA	cis	rs1923243	0.617	rs12409116	ENSG00000223479.3	RP4-788P17.1	3.8	0.000165	0.012	0.19	0.17	Migraine;	chr1:73075117	chr1:73635216~73715214:+
THCA	cis	rs2919009	0.712	rs2241847	ENSG00000271670.1	RP11-95I16.4	3.8	0.000165	0.012	0.19	0.17	Obesity-related traits;	chr10:120858159	chr10:120879256~120880667:-
THCA	cis	rs17023223	0.537	rs10923767	ENSG00000227056.2	RPL6P2	-3.8	0.000165	0.012	-0.23	-0.17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119219314~119220096:-
THCA	cis	rs7259376	0.875	rs10409520	ENSG00000269345.1	VN1R85P	3.8	0.000165	0.012	0.19	0.17	Menopause (age at onset);	chr19:22329675	chr19:22174766~22175191:-
THCA	cis	rs2099527	0.504	rs1548256	ENSG00000279863.1	RP11-521C22.2	3.8	0.000165	0.012	0.19	0.17	Life satisfaction;	chr10:50508812	chr10:50334538~50336123:+
THCA	cis	rs6496044	0.568	rs2880764	ENSG00000259407.1	RP11-158M2.3	-3.8	0.000165	0.012	-0.18	-0.17	Interstitial lung disease;	chr15:85513177	chr15:85744109~85750281:-
THCA	cis	rs7246657	0.722	rs12979640	ENSG00000226686.6	LINC01535	3.8	0.000165	0.012	0.25	0.17	Coronary artery calcification;	chr19:37688255	chr19:37251912~37265535:+
THCA	cis	rs17741873	0.779	rs12572101	ENSG00000271848.1	RP11-464F9.21	-3.8	0.000165	0.012	-0.22	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73840893	chr10:73654039~73674719:+
THCA	cis	rs6545883	0.868	rs6545887	ENSG00000212978.6	AC016747.3	3.8	0.000165	0.012	0.19	0.17	Tuberculosis;	chr2:61601683	chr2:61141592~61144969:-
THCA	cis	rs5758511	0.68	rs5758699	ENSG00000270083.1	RP1-257I20.14	-3.8	0.000165	0.012	-0.21	-0.17	Birth weight;	chr22:42292028	chr22:42089630~42090028:-
THCA	cis	rs700651	0.789	rs6715070	ENSG00000231621.1	AC013264.2	3.8	0.000165	0.012	0.18	0.17	Intracranial aneurysm;	chr2:198033541	chr2:197197991~197199273:+
THCA	cis	rs2882667	0.931	rs12719518	ENSG00000249593.5	CTB-46B19.2	3.8	0.000165	0.012	0.2	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:139012647~139051203:+
THCA	cis	rs6012953	0.874	rs1885176	ENSG00000231715.1	COX6CP2	-3.8	0.000165	0.012	-0.18	-0.17	Vitiligo;	chr20:50558752	chr20:50479767~50479991:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000232559.3	GS1-124K5.12	3.8	0.000165	0.012	0.19	0.17	Aortic root size;	chr7:66221293	chr7:66554588~66576923:-
THCA	cis	rs2810114	0.517	rs61988697	ENSG00000269927.1	RP6-91H8.3	3.8	0.000165	0.012	0.27	0.17	Alcohol dependence;	chr14:70926344	chr14:71141125~71143253:-
THCA	cis	rs2652834	0.519	rs4075584	ENSG00000259459.4	RP11-321G12.1	-3.8	0.000165	0.012	-0.18	-0.17	HDL cholesterol;	chr15:63048093	chr15:63390136~63438320:+
THCA	cis	rs10090774	0.687	rs11784281	ENSG00000279766.1	RP11-642A1.2	-3.8	0.000165	0.012	-0.21	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655911	chr8:140572142~140572812:-
THCA	cis	rs1876905	0.62	rs377716	ENSG00000271789.1	RP5-1112D6.7	-3.8	0.000166	0.012	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111181705	chr6:111297126~111298510:+
THCA	cis	rs7586085	0.934	rs2113843	ENSG00000232411.1	AC009495.3	-3.8	0.000166	0.0121	-0.18	-0.17	Total body bone mineral density;	chr2:165695242	chr2:165833048~165839098:-
THCA	cis	rs12681366	0.843	rs3019147	ENSG00000261437.1	RP11-22C11.2	3.8	0.000166	0.0121	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94412804	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.881	rs3019149	ENSG00000261437.1	RP11-22C11.2	3.8	0.000166	0.0121	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94418351	chr8:94637285~94639467:-
THCA	cis	rs907612	0.638	rs907611	ENSG00000226416.1	MRPL23-AS1	3.8	0.000166	0.0121	0.21	0.17	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Monocyte count;	chr11:1852842	chr11:1983237~1989920:-
THCA	cis	rs10043228	0.793	rs62384477	ENSG00000250015.1	CTC-339F2.2	3.8	0.000166	0.0121	0.26	0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116313868	chr5:116302354~116304134:-
THCA	cis	rs10771431	0.597	rs7976807	ENSG00000256427.1	RP11-118B22.4	3.8	0.000166	0.0121	0.2	0.17	Breast size;	chr12:9199863	chr12:9246497~9257960:+
THCA	cis	rs9475752	0.744	rs9464407	ENSG00000231441.1	RP11-472M19.2	3.8	0.000166	0.0121	0.18	0.17	Menarche (age at onset);	chr6:56914772	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.744	rs6459174	ENSG00000231441.1	RP11-472M19.2	3.8	0.000166	0.0121	0.18	0.17	Menarche (age at onset);	chr6:56921257	chr6:56844002~56864078:+
THCA	cis	rs7586085	0.563	rs994296	ENSG00000232411.1	AC009495.3	-3.8	0.000166	0.0121	-0.19	-0.17	Total body bone mineral density;	chr2:165632290	chr2:165833048~165839098:-
THCA	cis	rs62184315	1	rs62184315	ENSG00000253559.1	OSGEPL1-AS1	-3.8	0.000166	0.0121	-0.24	-0.17	Alcohol dependence (age at onset);	chr2:189907219	chr2:189762704~189765556:+
THCA	cis	rs7216064	0.953	rs62086044	ENSG00000278740.1	RP11-147L13.14	3.8	0.000166	0.0121	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67974721	chr17:68188547~68189165:+
THCA	cis	rs9309473	1	rs10189574	ENSG00000273245.1	RP11-434P11.2	3.8	0.000166	0.0121	0.23	0.17	Metabolite levels;	chr2:73471391	chr2:73750256~73750786:-
THCA	cis	rs7520050	0.933	rs11211203	ENSG00000281133.1	AL355480.3	3.8	0.000166	0.0121	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs4660317	ENSG00000281133.1	AL355480.3	3.8	0.000166	0.0121	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs10749860	ENSG00000281133.1	AL355480.3	3.8	0.000166	0.0121	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs6688365	ENSG00000281133.1	AL355480.3	3.8	0.000166	0.0121	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6656992	ENSG00000281133.1	AL355480.3	3.8	0.000166	0.0121	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs61783220	ENSG00000281133.1	AL355480.3	3.8	0.000166	0.0121	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45580892~45580996:-
THCA	cis	rs7919656	0.72	rs2943244	ENSG00000228403.1	RP11-563N6.6	3.8	0.000166	0.0121	0.19	0.17	Clinically amyopathic dermatomyositis;	chr10:48892844	chr10:48878022~48878649:+
THCA	cis	rs4919087	0.532	rs56189004	ENSG00000237169.1	RP11-452K12.3	3.8	0.000166	0.0121	0.23	0.17	Monocyte count;	chr10:97326875	chr10:97309138~97309958:-
THCA	cis	rs10875746	0.859	rs11168371	ENSG00000258234.1	RP11-370I10.2	3.8	0.000166	0.0121	0.21	0.17	Longevity (90 years and older);	chr12:48043903	chr12:48231098~48284210:-
THCA	cis	rs28510890	0.536	rs8032832	ENSG00000258647.4	LINC00930	-3.8	0.000166	0.0121	-0.19	-0.17	Lung cancer in ever smokers;	chr15:92614865	chr15:92567818~92572042:-
THCA	cis	rs1417770	1	rs1417770	ENSG00000260971.3	RP11-504A18.1	-3.8	0.000166	0.0121	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr1:56255862	chr1:56248294~56258571:-
THCA	cis	rs2898290	0.512	rs899366	ENSG00000255046.1	RP11-297N6.4	-3.8	0.000166	0.0121	-0.19	-0.17	Systolic blood pressure;	chr8:11572976	chr8:11797928~11802568:-
THCA	cis	rs875971	1	rs2220626	ENSG00000229886.1	RP5-1132H15.3	-3.8	0.000166	0.0121	-0.18	-0.17	Aortic root size;	chr7:66081075	chr7:66025126~66031544:-
THCA	cis	rs867186	1	rs117616040	ENSG00000126005.14	MMP24-AS1	-3.8	0.000166	0.0121	-0.29	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34977725	chr20:35216462~35278131:-
THCA	cis	rs17689437	0.522	rs2862780	ENSG00000260084.1	RP11-615I2.1	3.8	0.000166	0.0121	0.2	0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68605435	chr16:68573782~68589512:-
THCA	cis	rs900400	0.931	rs9817452	ENSG00000244515.1	KRT18P34	-3.8	0.000166	0.0121	-0.2	-0.17	circulating leptin levels adjusted for BMI;Birth weight;Menarche (age at onset);Adiponectin levels in pregnancy;circulating leptin levels;	chr3:157077625	chr3:157162663~157163932:-
THCA	cis	rs7759001	0.711	rs10946929	ENSG00000271755.1	RP1-153G14.4	3.8	0.000166	0.0121	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27488027	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs10946931	ENSG00000271755.1	RP1-153G14.4	3.8	0.000166	0.0121	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27494167	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs10452601	ENSG00000271755.1	RP1-153G14.4	3.8	0.000166	0.0121	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27494437	chr6:27404010~27406964:-
THCA	cis	rs7819412	0.654	rs4840550	ENSG00000255046.1	RP11-297N6.4	3.8	0.000166	0.0121	0.18	0.17	Triglycerides;	chr8:11171520	chr8:11797928~11802568:-
THCA	cis	rs4561483	0.645	rs2192645	ENSG00000263307.1	RP11-166B2.8	3.8	0.000166	0.0121	0.18	0.17	Testicular germ cell tumor;	chr16:11834162	chr16:11851649~11895611:+
THCA	cis	rs9607412	0.536	rs130624	ENSG00000279738.1	RP5-1014D13.2	3.8	0.000166	0.0121	0.15	0.17	Mean corpuscular volume;	chr22:37042611	chr22:37876148~37895563:+
THCA	cis	rs741738	1	rs741738	ENSG00000254910.1	RP11-326C3.7	3.8	0.000166	0.0121	0.21	0.17	Granulocyte percentage of myeloid white cells;	chr11:309508	chr11:310139~311141:-
THCA	cis	rs875971	0.505	rs1723275	ENSG00000230295.1	RP11-458F8.2	3.8	0.000166	0.0121	0.13	0.17	Aortic root size;	chr7:66039646	chr7:66880708~66882981:+
THCA	cis	rs8130944	0.964	rs7280645	ENSG00000225731.1	AP001627.1	3.8	0.000166	0.0121	0.21	0.17	Perceived unattractiveness to mosquitoes;	chr21:42716515	chr21:42733594~42741758:-
THCA	cis	rs754133	1	rs754133	ENSG00000257534.1	RP11-834C11.10	3.8	0.000166	0.0121	0.21	0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54025136	chr12:54162065~54164452:-
THCA	cis	rs7924176	0.564	rs34868542	ENSG00000232342.6	RP11-46O21.2	3.8	0.000166	0.0121	0.22	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226399	chr10:74506081~74530553:-
THCA	cis	rs754466	0.58	rs12357670	ENSG00000213514.2	RP11-428P16.2	3.8	0.000166	0.0121	0.19	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77798422	chr10:77730766~77734769:+
THCA	cis	rs6901152	0.869	rs7454731	ENSG00000217648.1	RP1-95L4.4	-3.8	0.000166	0.0121	-0.18	-0.17	Acute lymphoblastic leukemia (childhood);	chr6:143340963	chr6:143342246~143343383:+
THCA	cis	rs4512344	0.509	rs2409784	ENSG00000255046.1	RP11-297N6.4	3.8	0.000166	0.0121	0.18	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11797928~11802568:-
THCA	cis	rs927833	0.502	rs78894318	ENSG00000214535.3	RPS15AP1	-3.8	0.000166	0.0121	-0.26	-0.17	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr20:21963987	chr20:21166206~21166596:-
THCA	cis	rs1113500	0.933	rs1414674	ENSG00000226822.1	RP11-356N1.2	3.8	0.000166	0.0121	0.18	0.17	Growth-regulated protein alpha levels;	chr1:108083325	chr1:108071482~108074519:+
THCA	cis	rs6921919	0.887	rs16894116	ENSG00000280107.1	AL022393.9	-3.8	0.000166	0.0121	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28170845~28172521:+
THCA	cis	rs524281	1	rs547087	ENSG00000255120.4	OVOL1-AS1	3.8	0.000166	0.0121	0.24	0.17	Electroencephalogram traits;	chr11:66078793	chr11:65789051~65790868:-
THCA	cis	rs5751901	0.575	rs2154611	ENSG00000128262.7	POM121L9P	-3.8	0.000166	0.0121	-0.18	-0.17	Protein quantitative trait loci;	chr22:24593953	chr22:24251828~24265525:+
THCA	cis	rs1005277	0.505	rs7917943	ENSG00000120555.12	SEPT7P9	-3.8	0.000166	0.0121	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38383069~38402916:-
THCA	cis	rs7412746	0.611	rs7532045	ENSG00000224800.1	RP11-235D19.2	-3.8	0.000166	0.0121	-0.23	-0.17	Melanoma;	chr1:150849371	chr1:150881236~150881683:-
THCA	cis	rs9437689	0.566	rs1146465	ENSG00000235501.4	RP4-639F20.1	-3.8	0.000166	0.0121	-0.19	-0.17	Phospholipid levels (plasma);	chr1:94936057	chr1:94927566~94963270:+
THCA	cis	rs10129255	0.872	rs10133674	ENSG00000280411.1	IGHV1-69-2	-3.8	0.000166	0.0121	-0.11	-0.17	Kawasaki disease;	chr14:106692788	chr14:106762092~106762588:-
THCA	cis	rs17685	0.672	rs55807301	ENSG00000230882.1	AC005077.14	3.8	0.000166	0.0121	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76178083	chr7:76071469~76074963:-
THCA	cis	rs6545883	0.831	rs2592356	ENSG00000212978.6	AC016747.3	3.8	0.000166	0.0121	0.19	0.17	Tuberculosis;	chr2:61583293	chr2:61141592~61144969:-
THCA	cis	rs11841001	0.556	rs1470273	ENSG00000261105.4	LMO7-AS1	-3.8	0.000166	0.0121	-0.25	-0.17	Corneal astigmatism;	chr13:75768241	chr13:75604700~75635994:-
THCA	cis	rs3853824	0.668	rs1040261	ENSG00000263089.1	RP11-166P13.4	3.8	0.000166	0.0121	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr17:56836210	chr17:57092145~57096425:-
THCA	cis	rs17801127	0.901	rs1526285	ENSG00000231969.1	AC144449.1	3.8	0.000166	0.0121	0.32	0.17	Liver enzyme levels (alanine transaminase);	chr2:149652011	chr2:149587196~149848233:+
THCA	cis	rs1124769	0.619	rs12904435	ENSG00000259378.1	DCAF13P3	3.8	0.000166	0.0121	0.26	0.17	Cognitive performance;	chr15:50818006	chr15:50944663~50945996:+
THCA	cis	rs765787	0.53	rs2413775	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000166	0.0121	0.22	0.17	Uric acid levels;	chr15:45252090	chr15:45152664~45167526:-
THCA	cis	rs16975963	0.644	rs11083428	ENSG00000276846.1	CTD-3220F14.3	-3.8	0.000166	0.0121	-0.16	-0.17	Longevity;	chr19:37593066	chr19:37314868~37315620:-
THCA	cis	rs9911578	0.967	rs7503190	ENSG00000224738.1	AC099850.1	3.8	0.000166	0.0121	0.2	0.17	Intelligence (multi-trait analysis);	chr17:59106801	chr17:59106598~59118267:+
THCA	cis	rs17092148	0.636	rs17122844	ENSG00000276073.1	RP5-1125A11.7	3.8	0.000166	0.0121	0.19	0.17	Neuroticism;	chr20:34864797	chr20:33985617~33988989:-
THCA	cis	rs17092148	0.579	rs62212082	ENSG00000276073.1	RP5-1125A11.7	3.8	0.000166	0.0121	0.19	0.17	Neuroticism;	chr20:34866438	chr20:33985617~33988989:-
THCA	cis	rs765787	0.53	rs2554457	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000166	0.0121	0.21	0.17	Uric acid levels;	chr15:45228728	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs10467979	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000166	0.0121	0.21	0.17	Uric acid levels;	chr15:45229072	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2554455	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000166	0.0121	0.21	0.17	Uric acid levels;	chr15:45229106	chr15:45152664~45167526:-
THCA	cis	rs17772222	0.682	rs28371093	ENSG00000222990.1	RNU4-22P	3.8	0.000166	0.0121	0.21	0.17	Coronary artery calcification;	chr14:88486112	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.655	rs10150594	ENSG00000222990.1	RNU4-22P	3.8	0.000166	0.0121	0.21	0.17	Coronary artery calcification;	chr14:88489613	chr14:88513498~88513663:+
THCA	cis	rs875971	1	rs6945843	ENSG00000230189.5	GS1-124K5.2	-3.8	0.000166	0.0121	-0.11	-0.17	Aortic root size;	chr7:66269796	chr7:66409143~66490059:-
THCA	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	3.8	0.000166	0.0121	0.19	0.17	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-3.8	0.000166	0.0121	-0.19	-0.17	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
THCA	cis	rs295490	0.748	rs75472377	ENSG00000272656.1	RP11-219D15.3	3.8	0.000166	0.0121	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139439365	chr3:139349024~139349371:-
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000270154.1	RP11-419I17.1	3.8	0.000166	0.0121	0.21	0.17	Neuroticism;	chr8:11989569	chr8:12476462~12477122:+
THCA	cis	rs4792901	0.802	rs58141510	ENSG00000279602.1	CTD-3014M21.1	-3.8	0.000166	0.0121	-0.22	-0.17	Dupuytren's disease;	chr17:43509107	chr17:43360041~43361361:-
THCA	cis	rs586716	0.506	rs72697760	ENSG00000224549.1	RP11-370B11.3	3.8	0.000166	0.0121	0.21	0.17	Tuberculosis;	chr9:22517762	chr9:22767175~22768316:+
THCA	cis	rs2688608	0.588	rs10128205	ENSG00000272140.2	RP11-574K11.29	3.8	0.000166	0.0121	0.15	0.17	Inflammatory bowel disease;	chr10:73709890	chr10:73703735~73713581:-
THCA	cis	rs1065852	0.526	rs9607869	ENSG00000227370.1	RP4-669P10.19	3.8	0.000166	0.0121	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42022106	chr22:42132543~42132998:+
THCA	cis	rs4578769	0.531	rs12964304	ENSG00000273232.1	RP11-370A5.2	3.8	0.000166	0.0121	0.24	0.17	Eosinophil percentage of white cells;	chr18:22928641	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.531	rs12968784	ENSG00000273232.1	RP11-370A5.2	3.8	0.000166	0.0121	0.24	0.17	Eosinophil percentage of white cells;	chr18:22928645	chr18:22882825~22883357:-
THCA	cis	rs7160336	0.728	rs4899488	ENSG00000258586.1	RP5-1021I20.2	3.8	0.000166	0.0121	0.23	0.17	Blood protein levels;	chr14:74008147	chr14:73822559~73830135:-
THCA	cis	rs62244186	0.659	rs56231820	ENSG00000214820.3	MPRIPP1	3.8	0.000166	0.0121	0.18	0.17	Depressive symptoms;	chr3:44488837	chr3:44579938~44581026:-
THCA	cis	rs4780401	0.933	rs4584833	ENSG00000274038.1	RP11-66H6.4	-3.8	0.000166	0.0121	-0.2	-0.17	Rheumatoid arthritis;	chr16:11704902	chr16:11056556~11057034:+
THCA	cis	rs548181	0.736	rs497344	ENSG00000254671.2	STT3A-AS1	-3.8	0.000166	0.0121	-0.32	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125600629	chr11:125570284~125592568:-
THCA	cis	rs12291225	0.679	rs11023172	ENSG00000251991.1	RNU7-49P	3.8	0.000166	0.0121	0.2	0.17	Sense of smell;	chr11:14273821	chr11:14478892~14478953:+
THCA	cis	rs12291225	0.679	rs4757245	ENSG00000251991.1	RNU7-49P	3.8	0.000166	0.0121	0.2	0.17	Sense of smell;	chr11:14276326	chr11:14478892~14478953:+
THCA	cis	rs9660180	0.935	rs9786942	ENSG00000215914.4	MMP23A	-3.8	0.000166	0.0121	-0.23	-0.17	Body mass index;	chr1:1827774	chr1:1699942~1701782:+
THCA	cis	rs13113518	0.783	rs11133389	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55486718	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs4865001	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55490176	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs4864543	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55490228	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs6825774	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55491150	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs3805153	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55493557	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.756	rs7658446	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55495262	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.776	rs13124436	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55502504	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.783	rs6843997	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55508982	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.783	rs12508367	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55509442	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs2272073	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55510177	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs4865003	ENSG00000223305.1	RN7SKP30	3.8	0.000166	0.0121	0.22	0.17	Height;	chr4:55514802	chr4:55540502~55540835:-
THCA	cis	rs2562456	0.754	rs11666213	ENSG00000268278.1	RP11-420K14.1	3.8	0.000166	0.0121	0.24	0.17	Pain;	chr19:21422843	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62110429	ENSG00000268278.1	RP11-420K14.1	3.8	0.000166	0.0121	0.24	0.17	Pain;	chr19:21430984	chr19:21637974~21656300:+
THCA	cis	rs7520050	0.931	rs6698247	ENSG00000280836.1	AL355480.1	3.8	0.000166	0.0121	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6675946	ENSG00000280836.1	AL355480.1	3.8	0.000166	0.0121	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs7526678	ENSG00000280836.1	AL355480.1	3.8	0.000166	0.0121	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs6686134	ENSG00000280836.1	AL355480.1	3.8	0.000166	0.0121	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45581219~45581321:-
THCA	cis	rs12612619	0.732	rs6547355	ENSG00000272148.1	RP11-195B17.1	3.8	0.000166	0.0121	0.16	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26987337	chr2:27062428~27062907:-
THCA	cis	rs860295	0.729	rs11264369	ENSG00000236675.1	MTX1P1	3.8	0.000166	0.0121	0.18	0.17	Body mass index;	chr1:155390039	chr1:155230975~155234325:+
THCA	cis	rs9788721	0.934	rs55676755	ENSG00000261762.1	RP11-650L12.2	-3.8	0.000166	0.0121	-0.23	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78606590	chr15:78589123~78591276:-
THCA	cis	rs147144681	1	rs147144681	ENSG00000261762.1	RP11-650L12.2	-3.8	0.000166	0.0121	-0.23	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78608566	chr15:78589123~78591276:-
THCA	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	3.8	0.000166	0.0121	0.31	0.17	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
THCA	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	3.8	0.000166	0.0121	0.31	0.17	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
THCA	cis	rs10911902	0.643	rs111828305	ENSG00000233196.2	GS1-304P7.1	-3.8	0.000166	0.0121	-0.28	-0.17	Schizophrenia;	chr1:186393069	chr1:186580515~186581191:-
THCA	cis	rs875971	0.522	rs1701760	ENSG00000229180.5	GS1-124K5.11	3.8	0.000166	0.0121	0.12	0.17	Aortic root size;	chr7:66008701	chr7:66526088~66542624:-
THCA	cis	rs2733201	1	rs11635948	ENSG00000166763.7	STRCP1	-3.8	0.000166	0.0121	-0.33	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43993896	chr15:43699488~43718184:-
THCA	cis	rs2904297	0.958	rs1506790	ENSG00000261490.1	RP11-448G15.3	-3.8	0.000166	0.0121	-0.12	-0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11031512	chr4:10068089~10073019:-
THCA	cis	rs4705952	0.524	rs2406543	ENSG00000233006.5	AC034220.3	3.8	0.000166	0.0121	0.14	0.17	C-reactive protein levels;	chr5:132524628	chr5:132311285~132369916:-
THCA	cis	rs7829975	0.593	rs2921061	ENSG00000248538.5	RP11-10A14.5	-3.8	0.000166	0.0121	-0.22	-0.17	Mood instability;	chr8:8460105	chr8:9189011~9202854:+
THCA	cis	rs6921919	0.638	rs9468344	ENSG00000273712.1	RP5-874C20.7	3.8	0.000166	0.0121	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28315613~28315883:-
THCA	cis	rs875971	0.545	rs6950988	ENSG00000232559.3	GS1-124K5.12	3.8	0.000166	0.0121	0.19	0.17	Aortic root size;	chr7:66511428	chr7:66554588~66576923:-
THCA	cis	rs7772486	0.79	rs4896852	ENSG00000270638.1	RP3-466P17.1	-3.8	0.000166	0.0121	-0.14	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145735570~145737218:+
THCA	cis	rs7181230	1	rs28534747	ENSG00000275636.1	RP11-521C20.5	3.8	0.000166	0.0121	0.18	0.17	Dehydroepiandrosterone sulphate levels;	chr15:40082068	chr15:40078892~40079347:+
THCA	cis	rs9367716	0.912	rs9382695	ENSG00000276576.1	MRPL30P1	-3.8	0.000166	0.0121	-0.22	-0.17	Coronary artery disease;	chr6:57245256	chr6:57029521~57029988:+
THCA	cis	rs910316	1	rs7156328	ENSG00000259138.1	RP11-950C14.7	3.8	0.000166	0.0121	0.15	0.17	Height;	chr14:75066238	chr14:75127153~75136930:+
THCA	cis	rs9951026	0.933	rs3786249	ENSG00000267674.1	RP11-813F20.2	-3.8	0.000166	0.0121	-0.16	-0.17	Testicular germ cell tumor;	chr18:49571119	chr18:49739823~49742063:-
THCA	cis	rs36093844	0.626	rs11234492	ENSG00000279742.1	RP11-700A24.1	-3.8	0.000166	0.0121	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85953768	chr11:85852557~85854943:-
THCA	cis	rs3770081	1	rs80304739	ENSG00000272564.1	RP11-548P2.2	-3.8	0.000166	0.0121	-0.33	-0.17	Facial emotion recognition (sad faces);	chr2:85915416	chr2:85904279~85904727:+
THCA	cis	rs9860428	0.844	rs10804505	ENSG00000243795.1	RP11-572M11.3	-3.8	0.000166	0.0121	-0.21	-0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112855409	chr3:113142350~113167819:-
THCA	cis	rs17741873	0.779	rs10824037	ENSG00000271848.1	RP11-464F9.21	-3.8	0.000166	0.0121	-0.22	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73829120	chr10:73654039~73674719:+
THCA	cis	rs17695224	0.527	rs7250063	ENSG00000275055.1	CTC-471J1.11	-3.8	0.000166	0.0121	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51834447	chr19:52049007~52049754:+
THCA	cis	rs2019137	0.936	rs902696	ENSG00000234997.1	AC016745.3	3.8	0.000166	0.0121	0.17	0.17	Lymphocyte counts;	chr2:113197302	chr2:113424495~113425324:+
THCA	cis	rs13108904	0.535	rs1250101	ENSG00000254094.1	AC078852.1	3.8	0.000166	0.0121	0.21	0.17	Obesity-related traits;	chr4:1242323	chr4:1356581~1358075:+
THCA	cis	rs1035144	0.704	rs5002906	ENSG00000258915.1	BHLHB9P1	-3.8	0.000166	0.0121	-0.19	-0.17	Male sexual orientation;	chr14:80978955	chr14:80981988~80983638:+
THCA	cis	rs708224	0.557	rs261874	ENSG00000277342.1	RP11-843B15.4	3.8	0.000166	0.0121	0.23	0.17	Pancreatic cancer;	chr12:32291829	chr12:32109076~32109602:+
THCA	cis	rs75828804	1	rs75673420	ENSG00000260922.1	RP11-538I12.3	-3.8	0.000166	0.0121	-0.37	-0.17	Intraocular pressure;	chr16:77519893	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs75218508	ENSG00000260922.1	RP11-538I12.3	-3.8	0.000166	0.0121	-0.37	-0.17	Intraocular pressure;	chr16:77519898	chr16:77234877~77290934:+
THCA	cis	rs2692947	0.8	rs2692948	ENSG00000232931.4	LINC00342	3.8	0.000166	0.0121	0.14	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007817	chr2:95807118~95816215:-
THCA	cis	rs11894081	0.528	rs11689040	ENSG00000232835.1	AC107057.1	3.8	0.000167	0.0121	0.22	0.17	Crohn's disease;	chr2:5523807	chr2:5549780~5556031:-
THCA	cis	rs9860428	0.844	rs11711087	ENSG00000243795.1	RP11-572M11.3	3.8	0.000167	0.0121	0.2	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868702	chr3:113142350~113167819:-
THCA	cis	rs8009147	1	rs8009147	ENSG00000258534.1	CTD-2134A5.4	-3.8	0.000167	0.0121	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr14:103798325	chr14:103854366~103880111:-
THCA	cis	rs6142618	0.806	rs2424878	ENSG00000224452.1	RSL24D1P6	-3.8	0.000167	0.0121	-0.21	-0.17	Inflammatory bowel disease;	chr20:32368305	chr20:32170390~32170790:-
THCA	cis	rs6121246	0.909	rs6060793	ENSG00000224628.2	RP5-854E16.2	-3.8	0.000167	0.0121	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31701027	chr20:31285317~31286835:-
THCA	cis	rs6788895	1	rs1444197	ENSG00000244265.1	SIAH2-AS1	3.8	0.000167	0.0121	0.43	0.17	Breast cancer;	chr3:150762270	chr3:150761937~150762538:+
THCA	cis	rs7818688	0.578	rs75025610	ENSG00000253528.2	RP11-347C18.4	-3.8	0.000167	0.0121	-0.25	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94826075	chr8:94974573~94974853:-
THCA	cis	rs7131987	0.565	rs7971296	ENSG00000257176.2	RP11-996F15.2	3.8	0.000167	0.0121	0.17	0.17	QT interval;	chr12:29263297	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.605	rs1120528	ENSG00000257176.2	RP11-996F15.2	3.8	0.000167	0.0121	0.17	0.17	QT interval;	chr12:29264237	chr12:29280418~29317848:-
THCA	cis	rs150992	0.711	rs161735	ENSG00000246763.5	RGMB-AS1	3.8	0.000167	0.0121	0.18	0.17	Body mass index;	chr5:98862026	chr5:98769618~98773469:-
THCA	cis	rs10760158	0.62	rs10739596	ENSG00000226752.6	PSMD5-AS1	-3.8	0.000167	0.0121	-0.22	-0.17	Pulse pressure;	chr9:121327845	chr9:120824828~120854385:+
THCA	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	3.8	0.000167	0.0121	0.22	0.17	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
THCA	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	3.8	0.000167	0.0121	0.22	0.17	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
THCA	cis	rs6871536	0.951	rs12652920	ENSG00000233006.5	AC034220.3	-3.8	0.000167	0.0121	-0.16	-0.17	Asthma (childhood onset);	chr5:132549548	chr5:132311285~132369916:-
THCA	cis	rs912593	0.935	rs12427741	ENSG00000225179.1	LINC00457	3.8	0.000167	0.0121	0.22	0.17	Cancer;	chr13:34476875	chr13:34435450~34640685:-
THCA	cis	rs912593	0.935	rs12429710	ENSG00000225179.1	LINC00457	3.8	0.000167	0.0121	0.22	0.17	Cancer;	chr13:34476893	chr13:34435450~34640685:-
THCA	cis	rs912593	0.935	rs12429711	ENSG00000225179.1	LINC00457	3.8	0.000167	0.0121	0.22	0.17	Cancer;	chr13:34476897	chr13:34435450~34640685:-
THCA	cis	rs2562784	0.638	rs2585044	ENSG00000225151.9	GOLGA2P7	-3.8	0.000167	0.0121	-0.31	-0.17	Height;	chr15:83637194	chr15:84199311~84230136:-
THCA	cis	rs763121	0.889	rs9607557	ENSG00000225450.1	RP3-508I15.14	-3.8	0.000167	0.0121	-0.13	-0.17	Menopause (age at onset);	chr22:38644274	chr22:38739003~38749041:+
THCA	cis	rs7560272	0.538	rs4241257	ENSG00000273245.1	RP11-434P11.2	-3.8	0.000167	0.0121	-0.2	-0.17	Schizophrenia;	chr2:73711480	chr2:73750256~73750786:-
THCA	cis	rs4743820	0.503	rs4437763	ENSG00000229694.5	RP11-305L7.6	3.8	0.000167	0.0121	0.2	0.17	Ulcerative colitis;Inflammatory bowel disease;	chr9:91151297	chr9:91119062~91182762:+
THCA	cis	rs853679	0.599	rs149990	ENSG00000272009.1	RP1-313I6.12	-3.8	0.000167	0.0121	-0.24	-0.17	Depression;	chr6:28030480	chr6:28078792~28081130:-
THCA	cis	rs78487399	0.908	rs17031106	ENSG00000234936.1	AC010883.5	3.8	0.000167	0.0121	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43601917	chr2:43229573~43233394:+
THCA	cis	rs7166081	1	rs3743349	ENSG00000270964.1	RP11-502I4.3	-3.8	0.000167	0.0121	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67359759	chr15:67541072~67542604:-
THCA	cis	rs2348418	0.703	rs10843122	ENSG00000278733.1	RP11-425D17.1	3.8	0.000167	0.0121	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28185625~28186190:-
THCA	cis	rs2348418	0.765	rs2078016	ENSG00000278733.1	RP11-425D17.1	3.8	0.000167	0.0121	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28185625~28186190:-
THCA	cis	rs343092	1	rs2583930	ENSG00000241749.4	RPSAP52	3.8	0.000167	0.0121	0.19	0.17	Type 2 diabetes;	chr12:65852401	chr12:65758020~65826997:-
THCA	cis	rs2729354	0.817	rs2250673	ENSG00000254602.1	AP000662.4	-3.8	0.000167	0.0121	-0.22	-0.17	Blood protein levels;	chr11:57500697	chr11:57638024~57652790:+
THCA	cis	rs3015497	0.616	rs7154131	ENSG00000270062.1	RP11-248J18.3	3.8	0.000167	0.0121	0.19	0.17	Mean platelet volume;	chr14:50579808	chr14:50723777~50724272:-
THCA	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	3.8	0.000167	0.0121	0.18	0.17	Asthma;	chr2:102418659	chr2:102438713~102440475:+
THCA	cis	rs10540	1	rs61876342	ENSG00000279672.1	CMB9-55F22.1	3.8	0.000167	0.0121	0.34	0.17	Body mass index;	chr11:496193	chr11:779617~780755:+
THCA	cis	rs12216545	0.765	rs2204130	ENSG00000241134.3	BET1P1	-3.8	0.000167	0.0121	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150554348	chr7:150749736~150750094:+
THCA	cis	rs285757	0.947	rs2254142	ENSG00000259064.2	RP11-386M24.5	-3.8	0.000167	0.0121	-0.27	-0.17	HIV-1 susceptibility;	chr15:92643499	chr15:92627073~92627414:+
THCA	cis	rs77147124	0.959	rs2792703	ENSG00000225292.2	RP11-57H14.3	-3.8	0.000167	0.0121	-0.23	-0.17	HDL cholesterol;	chr10:112171932	chr10:112888735~112906111:+
THCA	cis	rs7829975	0.523	rs9644774	ENSG00000253981.4	ALG1L13P	-3.8	0.000167	0.0121	-0.18	-0.17	Mood instability;	chr8:8702322	chr8:8236003~8244667:-
THCA	cis	rs13178541	0.641	rs11242294	ENSG00000250378.1	RP11-119J18.1	-3.79	0.000167	0.0121	-0.2	-0.17	IgG glycosylation;	chr5:135797027	chr5:135812667~135826582:+
THCA	cis	rs757081	0.533	rs7949405	ENSG00000272034.1	SNORD14A	-3.79	0.000167	0.0121	-0.2	-0.17	Systolic blood pressure;	chr11:17063645	chr11:17074654~17074744:-
THCA	cis	rs12478296	1	rs57603292	ENSG00000220804.7	AC093642.5	3.79	0.000167	0.0121	0.2	0.17	Obesity-related traits;	chr2:242086386	chr2:242088633~242160153:+
THCA	cis	rs9402682	0.557	rs55889993	ENSG00000232876.1	CTA-212D2.2	-3.79	0.000167	0.0121	-0.24	-0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135137457	chr6:135055033~135060550:+
THCA	cis	rs17685	0.753	rs1637039	ENSG00000227038.2	AC005077.12	3.79	0.000167	0.0121	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76063691	chr7:76090431~76108779:-
THCA	cis	rs11673344	0.543	rs8108429	ENSG00000267260.1	CTD-2162K18.4	-3.79	0.000167	0.0121	-0.21	-0.17	Obesity-related traits;	chr19:37145874	chr19:36773153~36777078:+
THCA	cis	rs9329221	0.618	rs73197281	ENSG00000261451.1	RP11-981G7.1	-3.79	0.000167	0.0121	-0.21	-0.17	Neuroticism;	chr8:10405772	chr8:10433672~10438312:+
THCA	cis	rs61677309	1	rs56318049	ENSG00000278376.1	RP11-158I9.8	3.79	0.000167	0.0121	0.13	0.17	Lung cancer in ever smokers;	chr11:118295893	chr11:118791254~118793137:+
THCA	cis	rs7259376	0.936	rs8110854	ENSG00000270947.1	AC025811.3	3.79	0.000167	0.0121	0.18	0.17	Menopause (age at onset);	chr19:22366651	chr19:22455988~22456459:+
THCA	cis	rs9788682	0.694	rs3825845	ENSG00000261143.1	ADAMTS7P3	-3.79	0.000167	0.0121	-0.25	-0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78617916	chr15:77976042~77993057:+
THCA	cis	rs6546550	0.901	rs7573442	ENSG00000179818.12	PCBP1-AS1	-3.79	0.000167	0.0121	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69926905	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.868	rs12713682	ENSG00000179818.12	PCBP1-AS1	-3.79	0.000167	0.0121	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69927002	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs11893500	ENSG00000179818.12	PCBP1-AS1	-3.79	0.000167	0.0121	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69927055	chr2:69962263~70103220:-
THCA	cis	rs2562784	0.638	rs2585046	ENSG00000225151.9	GOLGA2P7	-3.79	0.000167	0.0121	-0.31	-0.17	Height;	chr15:83640221	chr15:84199311~84230136:-
THCA	cis	rs6095360	0.546	rs6012562	ENSG00000227431.4	CSE1L-AS1	3.79	0.000167	0.0122	0.22	0.17	Intelligence (multi-trait analysis);	chr20:48918724	chr20:49040463~49046044:-
THCA	cis	rs3758911	0.929	rs1843	ENSG00000255353.1	RP11-382M14.1	-3.79	0.000167	0.0122	-0.22	-0.17	Coronary artery disease;	chr11:107312219	chr11:107176286~107177530:+
THCA	cis	rs757110	0.745	rs10734252	ENSG00000260196.1	RP1-239B22.5	3.79	0.000167	0.0122	0.19	0.17	Type 2 diabetes;	chr11:17383292	chr11:17380649~17383531:+
THCA	cis	rs4073416	0.542	rs3825639	ENSG00000276116.2	FUT8-AS1	3.79	0.000167	0.0122	0.19	0.17	N-glycan levels;	chr14:65561787	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.542	rs12433597	ENSG00000276116.2	FUT8-AS1	3.79	0.000167	0.0122	0.19	0.17	N-glycan levels;	chr14:65562129	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.542	rs9323461	ENSG00000276116.2	FUT8-AS1	3.79	0.000167	0.0122	0.19	0.17	N-glycan levels;	chr14:65564687	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.534	rs7147002	ENSG00000276116.2	FUT8-AS1	3.79	0.000167	0.0122	0.19	0.17	N-glycan levels;	chr14:65565828	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.542	rs2183277	ENSG00000276116.2	FUT8-AS1	3.79	0.000167	0.0122	0.19	0.17	N-glycan levels;	chr14:65568711	chr14:65411170~65412690:-
THCA	cis	rs925946	0.518	rs10767646	ENSG00000245573.6	BDNF-AS	3.79	0.000167	0.0122	0.16	0.17	Weight;Body mass index;	chr11:27538197	chr11:27506838~27698174:+
THCA	cis	rs7267979	0.868	rs6138553	ENSG00000276952.1	RP5-965G21.6	3.79	0.000167	0.0122	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.903	rs6115109	ENSG00000276952.1	RP5-965G21.6	3.79	0.000167	0.0122	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25284915~25285588:-
THCA	cis	rs9810089	0.967	rs10935177	ENSG00000273455.1	RP11-305O4.3	-3.79	0.000167	0.0122	-0.22	-0.17	Gestational age at birth (child effect);	chr3:136132235	chr3:136087475~136087913:-
THCA	cis	rs2455799	0.574	rs2455801	ENSG00000270409.1	RP11-44D5.1	-3.79	0.000167	0.0122	-0.18	-0.17	Mean platelet volume;	chr3:15660350	chr3:15732252~15733470:+
THCA	cis	rs1348850	0.567	rs7605609	ENSG00000271996.1	RP11-337N6.1	3.79	0.000167	0.0122	0.23	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177670214	chr2:177306373~177310572:+
THCA	cis	rs875971	1	rs1167612	ENSG00000272831.1	RP11-792A8.4	-3.79	0.000167	0.0122	-0.11	-0.17	Aortic root size;	chr7:66102989	chr7:66739829~66740385:-
THCA	cis	rs6938	0.534	rs11854704	ENSG00000260269.4	CTD-2323K18.1	-3.79	0.000167	0.0122	-0.25	-0.17	Breast cancer;	chr15:74928674	chr15:75527150~75601205:-
THCA	cis	rs4950322	0.518	rs61838938	ENSG00000271721.1	RP11-337C18.9	3.79	0.000167	0.0122	0.19	0.17	Protein quantitative trait loci;	chr1:147105943	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.529	rs11809327	ENSG00000271721.1	RP11-337C18.9	3.79	0.000167	0.0122	0.19	0.17	Protein quantitative trait loci;	chr1:147106679	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.563	rs11809328	ENSG00000271721.1	RP11-337C18.9	3.79	0.000167	0.0122	0.19	0.17	Protein quantitative trait loci;	chr1:147106681	chr1:147175602~147177740:+
THCA	cis	rs875971	0.895	rs4145009	ENSG00000222364.1	RNU6-96P	3.79	0.000167	0.0122	0.2	0.17	Aortic root size;	chr7:66261628	chr7:66395191~66395286:+
THCA	cis	rs308403	0.509	rs309382	ENSG00000224786.1	CETN4P	3.79	0.000167	0.0122	0.18	0.17	Blood protein levels;	chr4:122748617	chr4:122730548~122732193:-
THCA	cis	rs6847067	0.631	rs2120091	ENSG00000180769.7	WDFY3-AS2	3.79	0.000167	0.0122	0.13	0.17	Oropharynx cancer;	chr4:84616672	chr4:84965682~85011277:+
THCA	cis	rs73193808	0.614	rs2245023	ENSG00000176054.6	RPL23P2	3.79	0.000167	0.0122	0.15	0.17	Coronary artery disease;	chr21:29174539	chr21:28997613~28998033:-
THCA	cis	rs17092148	0.636	rs59030726	ENSG00000276073.1	RP5-1125A11.7	3.79	0.000167	0.0122	0.19	0.17	Neuroticism;	chr20:34866314	chr20:33985617~33988989:-
THCA	cis	rs765787	0.53	rs11636395	ENSG00000259932.1	CTD-2651B20.7	3.79	0.000167	0.0122	0.21	0.17	Uric acid levels;	chr15:45243486	chr15:45198517~45199139:-
THCA	cis	rs875971	0.545	rs6460276	ENSG00000273024.4	INTS4P2	-3.79	0.000167	0.0122	-0.21	-0.17	Aortic root size;	chr7:66182290	chr7:65647864~65715661:+
THCA	cis	rs9392556	0.6	rs664299	ENSG00000272248.1	RP3-406P24.4	3.79	0.000167	0.0122	0.22	0.17	Blood metabolite levels;	chr6:4112007	chr6:4018713~4019202:+
THCA	cis	rs9392556	0.533	rs619439	ENSG00000272248.1	RP3-406P24.4	3.79	0.000167	0.0122	0.22	0.17	Blood metabolite levels;	chr6:4113695	chr6:4018713~4019202:+
THCA	cis	rs2455799	0.552	rs2470540	ENSG00000270409.1	RP11-44D5.1	-3.79	0.000167	0.0122	-0.18	-0.17	Mean platelet volume;	chr3:15677145	chr3:15732252~15733470:+
THCA	cis	rs5753037	0.653	rs131271	ENSG00000273350.1	RP4-539M6.20	-3.79	0.000167	0.0122	-0.19	-0.17	Type 1 diabetes;	chr22:29755593	chr22:30420512~30420912:+
THCA	cis	rs5753037	0.653	rs140133	ENSG00000273350.1	RP4-539M6.20	-3.79	0.000167	0.0122	-0.19	-0.17	Type 1 diabetes;	chr22:29756533	chr22:30420512~30420912:+
THCA	cis	rs3758911	0.828	rs17106875	ENSG00000255353.1	RP11-382M14.1	-3.79	0.000167	0.0122	-0.22	-0.17	Coronary artery disease;	chr11:107407957	chr11:107176286~107177530:+
THCA	cis	rs879500	1	rs57937009	ENSG00000227279.1	AC015933.2	3.79	0.000167	0.0122	0.2	0.17	Lung function (FVC);	chr18:28549058	chr18:27954519~27963687:+
THCA	cis	rs17382723	0.83	rs113198353	ENSG00000225521.1	AC005237.4	3.79	0.000167	0.0122	0.22	0.17	Height;	chr2:241095059	chr2:241015599~241064116:-
THCA	cis	rs10844706	0.669	rs10772102	ENSG00000214776.8	RP11-726G1.1	3.79	0.000168	0.0122	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9744357	chr12:9467552~9576275:+
THCA	cis	rs721917	0.506	rs2819098	ENSG00000244733.5	RP11-506M13.3	-3.79	0.000168	0.0122	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79660891~79677996:+
THCA	cis	rs67981189	0.896	rs17108804	ENSG00000269927.1	RP6-91H8.3	-3.79	0.000168	0.0122	-0.19	-0.17	Schizophrenia;	chr14:70974807	chr14:71141125~71143253:-
THCA	cis	rs4648045	0.647	rs3774933	ENSG00000246560.2	RP11-10L12.4	3.79	0.000168	0.0122	0.21	0.17	Lymphocyte percentage of white cells;	chr4:102505182	chr4:102828055~102844075:+
THCA	cis	rs412658	0.504	rs369128	ENSG00000269845.1	RP11-420K14.6	-3.79	0.000168	0.0122	-0.2	-0.17	Telomere length;	chr19:21925064	chr19:21750747~21753438:+
THCA	cis	rs412658	0.504	rs17769372	ENSG00000269845.1	RP11-420K14.6	-3.79	0.000168	0.0122	-0.2	-0.17	Telomere length;	chr19:21931902	chr19:21750747~21753438:+
THCA	cis	rs4908768	0.539	rs922366	ENSG00000270282.1	RP5-1115A15.2	3.79	0.000168	0.0122	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8512653~8513021:+
THCA	cis	rs9911578	0.933	rs2531725	ENSG00000224738.1	AC099850.1	3.79	0.000168	0.0122	0.2	0.17	Intelligence (multi-trait analysis);	chr17:58440601	chr17:59106598~59118267:+
THCA	cis	rs285757	0.843	rs434826	ENSG00000259064.2	RP11-386M24.5	-3.79	0.000168	0.0122	-0.26	-0.17	HIV-1 susceptibility;	chr15:92663579	chr15:92627073~92627414:+
THCA	cis	rs758324	0.533	rs25884	ENSG00000224431.1	AC063976.7	-3.79	0.000168	0.0122	-0.16	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132076545	chr5:132199456~132203487:+
THCA	cis	rs2179367	0.632	rs9498348	ENSG00000216906.2	RP11-350J20.9	3.79	0.000168	0.0122	0.22	0.17	Dupuytren's disease;	chr6:149418352	chr6:149904243~149906418:+
THCA	cis	rs7089973	0.641	rs17795104	ENSG00000236799.1	RP11-383C6.2	-3.79	0.000168	0.0122	-0.21	-0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114979772	chr10:114994657~114996593:+
THCA	cis	rs2562456	0.516	rs56072098	ENSG00000268278.1	RP11-420K14.1	-3.79	0.000168	0.0122	-0.21	-0.17	Pain;	chr19:21469158	chr19:21637974~21656300:+
THCA	cis	rs3745672	0.59	rs10407094	ENSG00000219665.7	CTD-2006C1.2	-3.79	0.000168	0.0122	-0.33	-0.17	Multiple sclerosis;	chr19:11968463	chr19:11987617~12046275:+
THCA	cis	rs11601239	0.607	rs11226857	ENSG00000254750.1	CASP1P2	-3.79	0.000168	0.0122	-0.14	-0.17	Refractive error;	chr11:105828874	chr11:105063345~105071541:-
THCA	cis	rs13217239	0.646	rs11756275	ENSG00000124549.13	BTN2A3P	-3.79	0.000168	0.0122	-0.16	-0.17	Schizophrenia;	chr6:27039334	chr6:26421391~26432383:+
THCA	cis	rs9926296	0.609	rs4785709	ENSG00000274627.1	RP11-104N10.2	3.79	0.000168	0.0122	0.18	0.17	Vitiligo;	chr16:89730257	chr16:89516797~89522217:+
THCA	cis	rs11583043	1	rs3861734	ENSG00000233184.5	RP11-421L21.3	3.79	0.000168	0.0122	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101023905	chr1:101025878~101087268:+
THCA	cis	rs11583043	1	rs2391573	ENSG00000233184.5	RP11-421L21.3	3.79	0.000168	0.0122	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101024142	chr1:101025878~101087268:+
THCA	cis	rs2562456	0.833	rs4429400	ENSG00000268278.1	RP11-420K14.1	3.79	0.000168	0.0122	0.25	0.17	Pain;	chr19:21338163	chr19:21637974~21656300:+
THCA	cis	rs6570726	0.935	rs447247	ENSG00000270638.1	RP3-466P17.1	3.79	0.000168	0.0122	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145735570~145737218:+
THCA	cis	rs6570726	0.935	rs369458	ENSG00000270638.1	RP3-466P17.1	3.79	0.000168	0.0122	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145735570~145737218:+
THCA	cis	rs6545883	0.868	rs2427885	ENSG00000212978.6	AC016747.3	3.79	0.000168	0.0122	0.19	0.17	Tuberculosis;	chr2:61589642	chr2:61141592~61144969:-
THCA	cis	rs2688608	0.934	rs2675679	ENSG00000271816.1	BMS1P4	3.79	0.000168	0.0122	0.17	0.17	Inflammatory bowel disease;	chr10:73898823	chr10:73699151~73730487:-
THCA	cis	rs7809950	0.678	rs17153981	ENSG00000272072.1	CTA-363E19.2	3.79	0.000168	0.0122	0.19	0.17	Coronary artery disease;	chr7:107281661	chr7:107192559~107193300:-
THCA	cis	rs7178375	1	rs7169064	ENSG00000215302.7	CTD-3092A11.1	-3.79	0.000168	0.0122	-0.24	-0.17	Hypertriglyceridemia;	chr15:30918659	chr15:30470779~30507623:+
THCA	cis	rs1005277	0.54	rs2474598	ENSG00000120555.12	SEPT7P9	-3.79	0.000168	0.0122	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38383069~38402916:-
THCA	cis	rs7616559	0.649	rs1842840	ENSG00000244515.1	KRT18P34	-3.79	0.000168	0.0122	-0.2	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157010268	chr3:157162663~157163932:-
THCA	cis	rs34792	0.604	rs12148985	ENSG00000207425.1	Y_RNA	-3.79	0.000168	0.0122	-0.19	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15493052	chr16:14915457~14915556:-
THCA	cis	rs10129255	1	rs10134517	ENSG00000211972.2	IGHV3-66	3.79	0.000168	0.0122	0.1	0.17	Kawasaki disease;	chr14:106718498	chr14:106675017~106675544:-
THCA	cis	rs73108077	0.517	rs111795036	ENSG00000277112.2	RP11-755J8.1	-3.79	0.000168	0.0122	-0.33	-0.17	Red blood cell density in sickle cell anemia;	chr20:31448767	chr20:30681825~30723932:-
THCA	cis	rs727563	0.635	rs5758444	ENSG00000237037.8	NDUFA6-AS1	-3.79	0.000168	0.0122	-0.16	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr22:42090931~42137742:+
THCA	cis	rs4742903	0.935	rs4743694	ENSG00000270332.1	SMC2-AS1	3.79	0.000168	0.0122	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104170882	chr9:104080024~104093073:-
THCA	cis	rs2039553	0.553	rs9545203	ENSG00000227354.5	RBM26-AS1	-3.79	0.000168	0.0122	-0.16	-0.17	Pancreatic cancer;	chr13:79808902	chr13:79406309~79424328:+
THCA	cis	rs754133	0.964	rs4759318	ENSG00000257534.1	RP11-834C11.10	3.79	0.000168	0.0122	0.21	0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026314	chr12:54162065~54164452:-
THCA	cis	rs9863	1	rs9863	ENSG00000269938.1	RP11-214K3.20	-3.79	0.000168	0.0122	-0.21	-0.17	White blood cell count;	chr12:123936906	chr12:123968023~123968579:-
THCA	cis	rs7809950	0.678	rs13230144	ENSG00000272072.1	CTA-363E19.2	3.79	0.000168	0.0122	0.18	0.17	Coronary artery disease;	chr7:107268727	chr7:107192559~107193300:-
THCA	cis	rs2820315	1	rs903678	ENSG00000223774.4	RP11-307B6.3	3.79	0.000168	0.0122	0.19	0.17	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201840790	chr1:201893842~201899978:+
THCA	cis	rs7824557	0.564	rs2572389	ENSG00000255495.1	AC145124.2	-3.79	0.000168	0.0122	-0.2	-0.17	Retinal vascular caliber;	chr8:11378883	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs2736301	ENSG00000255495.1	AC145124.2	-3.79	0.000168	0.0122	-0.2	-0.17	Retinal vascular caliber;	chr8:11378904	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs2736302	ENSG00000255495.1	AC145124.2	-3.79	0.000168	0.0122	-0.2	-0.17	Retinal vascular caliber;	chr8:11378910	chr8:12194467~12196280:+
THCA	cis	rs3808502	0.647	rs7821302	ENSG00000255495.1	AC145124.2	-3.79	0.000168	0.0122	-0.2	-0.17	Neuroticism;	chr8:11379063	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs7821459	ENSG00000255495.1	AC145124.2	-3.79	0.000168	0.0122	-0.2	-0.17	Retinal vascular caliber;	chr8:11379172	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs7834572	ENSG00000255495.1	AC145124.2	-3.79	0.000168	0.0122	-0.2	-0.17	Retinal vascular caliber;	chr8:11379176	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs4631424	ENSG00000255495.1	AC145124.2	-3.79	0.000168	0.0122	-0.2	-0.17	Retinal vascular caliber;	chr8:11379300	chr8:12194467~12196280:+
THCA	cis	rs735539	0.593	rs4463942	ENSG00000278291.1	RP11-172H24.4	3.79	0.000168	0.0122	0.23	0.17	Dental caries;	chr13:20793295	chr13:20699307~20703718:-
THCA	cis	rs735539	0.593	rs2818997	ENSG00000278291.1	RP11-172H24.4	3.79	0.000168	0.0122	0.23	0.17	Dental caries;	chr13:20795176	chr13:20699307~20703718:-
THCA	cis	rs7660883	0.929	rs28432336	ENSG00000251411.1	RP11-397E7.4	3.79	0.000168	0.0122	0.17	0.17	HDL cholesterol levels;	chr4:87063179	chr4:86913266~86914817:-
THCA	cis	rs7824557	0.564	rs35009431	ENSG00000227888.4	FAM66A	-3.79	0.000168	0.0122	-0.22	-0.17	Retinal vascular caliber;	chr8:11375279	chr8:12362019~12388296:+
THCA	cis	rs2221894	0.922	rs11136054	ENSG00000251191.6	LINC00589	-3.79	0.000168	0.0122	-0.21	-0.17	Obesity-related traits;	chr8:28997585	chr8:29673922~29748109:-
THCA	cis	rs10844706	0.666	rs10844609	ENSG00000214776.8	RP11-726G1.1	3.79	0.000168	0.0122	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9723909	chr12:9467552~9576275:+
THCA	cis	rs11633886	0.904	rs11636751	ENSG00000259200.1	RP11-718O11.1	-3.79	0.000168	0.0122	-0.2	-0.17	Diisocyanate-induced asthma;	chr15:45811225	chr15:45705078~45931069:+
THCA	cis	rs3748656	0.945	rs56135413	ENSG00000273483.1	RP4-671G15.2	3.79	0.000168	0.0122	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112550284	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.887	rs11102496	ENSG00000273483.1	RP4-671G15.2	3.79	0.000168	0.0122	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112565842	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.945	rs10857967	ENSG00000273483.1	RP4-671G15.2	3.79	0.000168	0.0122	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112577971	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.945	rs12140506	ENSG00000273483.1	RP4-671G15.2	3.79	0.000168	0.0122	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112584808	chr1:112517799~112518441:-
THCA	cis	rs2179367	0.632	rs12154153	ENSG00000216906.2	RP11-350J20.9	3.79	0.000168	0.0122	0.22	0.17	Dupuytren's disease;	chr6:149401686	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs11155649	ENSG00000216906.2	RP11-350J20.9	3.79	0.000168	0.0122	0.22	0.17	Dupuytren's disease;	chr6:149405830	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs11155650	ENSG00000216906.2	RP11-350J20.9	3.79	0.000168	0.0122	0.22	0.17	Dupuytren's disease;	chr6:149407613	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs11155651	ENSG00000216906.2	RP11-350J20.9	3.79	0.000168	0.0122	0.22	0.17	Dupuytren's disease;	chr6:149408146	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs7896	ENSG00000216906.2	RP11-350J20.9	3.79	0.000168	0.0122	0.22	0.17	Dupuytren's disease;	chr6:149410340	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12196750	ENSG00000216906.2	RP11-350J20.9	3.79	0.000168	0.0122	0.22	0.17	Dupuytren's disease;	chr6:149413335	chr6:149904243~149906418:+
THCA	cis	rs4245128	0.931	rs10750012	ENSG00000247416.2	RP11-629G13.1	3.79	0.000168	0.0122	0.16	0.17	Life satisfaction;	chr11:112916186	chr11:112959279~112963460:-
THCA	cis	rs2299587	0.519	rs3850746	ENSG00000253671.1	RP11-806O11.1	3.79	0.000168	0.0122	0.21	0.17	Economic and political preferences;	chr8:17930027	chr8:17808941~17820868:+
THCA	cis	rs9858542	0.537	rs9874474	ENSG00000270441.1	RP11-694I15.7	3.79	0.000168	0.0122	0.19	0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49288745	chr3:49140086~49160851:-
THCA	cis	rs420259	0.516	rs4968008	ENSG00000260136.4	CTD-2270L9.4	3.79	0.000168	0.0122	0.13	0.17	Bipolar disorder;	chr16:23479032	chr16:23452758~23457606:+
THCA	cis	rs793571	0.822	rs17302045	ENSG00000245975.2	RP11-30K9.6	-3.79	0.000168	0.0122	-0.19	-0.17	Schizophrenia;	chr15:58907738	chr15:58768072~58770974:-
THCA	cis	rs7819412	0.66	rs7462931	ENSG00000206014.6	OR7E161P	3.79	0.000168	0.0122	0.2	0.17	Triglycerides;	chr8:11052833	chr8:11928597~11929563:-
THCA	cis	rs7200543	1	rs1135999	ENSG00000260735.1	RP11-72I8.1	-3.79	0.000168	0.0122	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:15094411~15109197:+
THCA	cis	rs7200543	1	rs1136001	ENSG00000260735.1	RP11-72I8.1	-3.79	0.000168	0.0122	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:15094411~15109197:+
THCA	cis	rs7200543	1	rs2740	ENSG00000260735.1	RP11-72I8.1	-3.79	0.000168	0.0122	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:15094411~15109197:+
THCA	cis	rs2839186	0.807	rs2032226	ENSG00000228137.1	AP001469.7	3.79	0.000168	0.0122	0.17	0.17	Testicular germ cell tumor;	chr21:46260438	chr21:46246890~46247682:+
THCA	cis	rs2380205	0.538	rs11255774	ENSG00000232807.2	RP11-536K7.3	3.79	0.000168	0.0122	0.17	0.17	Breast cancer;	chr10:5897096	chr10:5934270~5945900:-
THCA	cis	rs3764021	0.509	rs10772071	ENSG00000214776.8	RP11-726G1.1	3.79	0.000168	0.0122	0.22	0.17	Type 1 diabetes;	chr12:9717324	chr12:9467552~9576275:+
THCA	cis	rs3764021	0.509	rs10772072	ENSG00000214776.8	RP11-726G1.1	3.79	0.000168	0.0122	0.22	0.17	Type 1 diabetes;	chr12:9717335	chr12:9467552~9576275:+
THCA	cis	rs7520050	0.966	rs7515491	ENSG00000281133.1	AL355480.3	3.79	0.000168	0.0122	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45889407	chr1:45580892~45580996:-
THCA	cis	rs2692947	0.759	rs1917890	ENSG00000235584.2	AC008268.1	-3.79	0.000168	0.0122	-0.17	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96006253	chr2:95666084~95668715:+
THCA	cis	rs2191566	0.664	rs7255512	ENSG00000266921.1	RP11-15A1.7	-3.79	0.000168	0.0122	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:44070547	chr19:43996896~44002836:-
THCA	cis	rs4819052	1	rs4818769	ENSG00000184274.3	LINC00315	-3.79	0.000168	0.0122	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45300245~45305257:-
THCA	cis	rs6674176	0.542	rs2906468	ENSG00000237950.1	RP11-7O11.3	3.79	0.000168	0.0122	0.16	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43853335	chr1:43944370~43946551:-
THCA	cis	rs6674176	0.542	rs3011225	ENSG00000237950.1	RP11-7O11.3	3.79	0.000168	0.0122	0.16	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43853701	chr1:43944370~43946551:-
THCA	cis	rs354225	0.597	rs4347868	ENSG00000212175.1	SNORA12	-3.79	0.000168	0.0122	-0.21	-0.17	Schizophrenia;	chr2:54603479	chr2:55565703~55565850:+
THCA	cis	rs6449502	1	rs6449502	ENSG00000251279.1	CTC-436P18.1	3.79	0.000168	0.0122	0.28	0.17	Mean platelet volume;	chr5:60797268	chr5:61162070~61232040:+
THCA	cis	rs12544026	0.617	rs2155939	ENSG00000253669.3	KB-1732A1.1	-3.79	0.000168	0.0122	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101834974	chr8:102805517~102809971:+
THCA	cis	rs7956611	0.521	rs17102578	ENSG00000213343.5	RPL21P18	-3.79	0.000168	0.0122	-0.2	-0.17	Age of smoking initiation;	chr12:66508686	chr12:66037235~66037714:+
THCA	cis	rs964611	0.935	rs3784618	ENSG00000259488.2	RP11-154J22.1	-3.79	0.000168	0.0122	-0.19	-0.17	Metabolite levels (Pyroglutamine);	chr15:48284184	chr15:48312353~48331856:-
THCA	cis	rs786425	0.682	rs11611354	ENSG00000278112.1	RP11-972P1.11	3.79	0.000168	0.0122	0.17	0.17	Pubertal anthropometrics;	chr12:123669092	chr12:123519390~123519856:-
THCA	cis	rs9393777	0.844	rs72839477	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000168	0.0122	-0.34	-0.17	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28078792~28081130:-
THCA	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	3.79	0.000168	0.0122	0.22	0.17	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
THCA	cis	rs889312	0.5	rs832585	ENSG00000271828.1	CTD-2310F14.1	-3.79	0.000168	0.0122	-0.24	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56830077	chr5:56927874~56929573:+
THCA	cis	rs7829975	0.846	rs6601724	ENSG00000233609.3	RP11-62H7.2	-3.79	0.000169	0.0122	-0.16	-0.17	Mood instability;	chr8:8687362	chr8:8961200~8979025:+
THCA	cis	rs11671005	0.571	rs56243535	ENSG00000268912.1	CTD-2619J13.17	-3.79	0.000169	0.0122	-0.16	-0.17	Mean platelet volume;	chr19:58494783	chr19:58428632~58431148:-
THCA	cis	rs804280	0.509	rs10109241	ENSG00000255495.1	AC145124.2	3.79	0.000169	0.0122	0.2	0.17	Myopia (pathological);	chr8:11927476	chr8:12194467~12196280:+
THCA	cis	rs8003054	0.572	rs11626277	ENSG00000258515.1	RP11-203M5.7	3.79	0.000169	0.0122	0.12	0.17	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445990	chr14:20451305~20451918:+
THCA	cis	rs853679	0.546	rs71537572	ENSG00000220721.1	OR1F12	3.79	0.000169	0.0122	0.39	0.17	Depression;	chr6:28002937	chr6:28073316~28074233:+
THCA	cis	rs10421328	0.821	rs2288867	ENSG00000271283.1	CTC-412M14.6	3.79	0.000169	0.0122	0.24	0.17	Parental longevity (combined parental age at death);	chr19:19654759	chr19:19699203~19699409:-
THCA	cis	rs4906332	0.811	rs2756138	ENSG00000269910.1	RP11-73M18.10	-3.79	0.000169	0.0122	-0.16	-0.17	Coronary artery disease;	chr14:103530396	chr14:103694516~103695050:-
THCA	cis	rs2613964	0.504	rs7617193	ENSG00000243795.1	RP11-572M11.3	3.79	0.000169	0.0122	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130004	chr3:113142350~113167819:-
THCA	cis	rs804280	0.504	rs2645457	ENSG00000254948.1	OR7E158P	3.79	0.000169	0.0123	0.22	0.17	Myopia (pathological);	chr8:11756603	chr8:11919900~11920809:-
THCA	cis	rs1499614	1	rs2707832	ENSG00000237310.1	GS1-124K5.4	3.79	0.000169	0.0123	0.2	0.17	Gout;	chr7:66671562	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-3.79	0.000169	0.0123	-0.16	-0.17	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
THCA	cis	rs288326	0.561	rs17265824	ENSG00000272800.1	RP11-438L19.1	3.79	0.000169	0.0123	0.31	0.17	Blood protein levels;	chr2:182847242	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs79908577	ENSG00000272800.1	RP11-438L19.1	3.79	0.000169	0.0123	0.31	0.17	Blood protein levels;	chr2:182847444	chr2:183214319~183215400:+
THCA	cis	rs10492096	0.945	rs1045546	ENSG00000276718.1	RP1-102E24.10	-3.79	0.000169	0.0123	-0.22	-0.17	Hip geometry;	chr12:6458741	chr12:6466537~6467135:+
THCA	cis	rs7487637	0.529	rs11168245	ENSG00000257488.4	RP5-1057I20.2	3.79	0.000169	0.0123	0.29	0.17	Mononucleosis;	chr12:47810716	chr12:47826854~47837898:+
THCA	cis	rs10875746	0.855	rs10875730	ENSG00000258234.1	RP11-370I10.2	3.79	0.000169	0.0123	0.21	0.17	Longevity (90 years and older);	chr12:48034092	chr12:48231098~48284210:-
THCA	cis	rs11723261	0.582	rs4634177	ENSG00000250892.1	RP11-1365D11.1	3.79	0.000169	0.0123	0.25	0.17	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:201409~205009:-
THCA	cis	rs7010267	0.776	rs4407910	ENSG00000254278.1	RP11-278I4.2	3.79	0.000169	0.0123	0.22	0.17	Total body bone mineral density (age 45-60);	chr8:118904878	chr8:119062942~119068782:-
THCA	cis	rs1876905	0.62	rs354530	ENSG00000271789.1	RP5-1112D6.7	-3.79	0.000169	0.0123	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111297126~111298510:+
THCA	cis	rs755249	0.501	rs661316	ENSG00000182109.6	RP11-69E11.4	3.79	0.000169	0.0123	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39522280~39546187:-
THCA	cis	rs13053817	1	rs13055259	ENSG00000279159.1	RP3-394A18.1	3.79	0.000169	0.0123	0.17	0.17	Carotid atherosclerosis in HIV infection;	chr22:29460903	chr22:29978950~30028236:-
THCA	cis	rs1577917	0.545	rs1335443	ENSG00000220563.1	PKMP3	-3.79	0.000169	0.0123	-0.12	-0.17	Response to antipsychotic treatment;	chr6:85769019	chr6:85659892~85660606:-
THCA	cis	rs7267979	1	rs6050565	ENSG00000276952.1	RP5-965G21.6	-3.79	0.000169	0.0123	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25284915~25285588:-
THCA	cis	rs112537273	1	rs112537273	ENSG00000272092.1	RP11-350N15.5	-3.79	0.000169	0.0123	-0.18	-0.17	Schizophrenia;	chr8:38390788	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs7816998	ENSG00000272092.1	RP11-350N15.5	-3.79	0.000169	0.0123	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38399988	chr8:38382364~38383461:+
THCA	cis	rs17331151	0.573	rs79664140	ENSG00000242142.1	SERBP1P3	-3.79	0.000169	0.0123	-0.28	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:52832920	chr3:53064283~53065091:-
THCA	cis	rs17331151	0.573	rs76029595	ENSG00000242142.1	SERBP1P3	-3.79	0.000169	0.0123	-0.28	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:52834507	chr3:53064283~53065091:-
THCA	cis	rs9467773	0.595	rs12525810	ENSG00000228223.2	HCG11	-3.79	0.000169	0.0123	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26523450~26526579:+
THCA	cis	rs3748656	1	rs12120956	ENSG00000273483.1	RP4-671G15.2	3.79	0.000169	0.0123	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112659949	chr1:112517799~112518441:-
THCA	cis	rs7520050	0.808	rs11211195	ENSG00000281133.1	AL355480.3	3.79	0.000169	0.0123	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.808	rs11211196	ENSG00000281133.1	AL355480.3	3.79	0.000169	0.0123	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45580892~45580996:-
THCA	cis	rs2120019	0.567	rs8025170	ENSG00000274515.1	CTD-2026K11.5	3.79	0.000169	0.0123	0.2	0.17	Blood trace element (Zn levels);	chr15:74878642	chr15:75645020~75645442:+
THCA	cis	rs67478160	0.644	rs7159810	ENSG00000258534.1	CTD-2134A5.4	-3.79	0.000169	0.0123	-0.17	-0.17	Schizophrenia;	chr14:103827780	chr14:103854366~103880111:-
THCA	cis	rs875971	0.706	rs1643374	ENSG00000230295.1	RP11-458F8.2	-3.79	0.000169	0.0123	-0.13	-0.17	Aortic root size;	chr7:66407695	chr7:66880708~66882981:+
THCA	cis	rs2736340	0.539	rs9644687	ENSG00000254527.1	ENPP7P12	-3.79	0.000169	0.0123	-0.22	-0.17	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465516	chr8:12205759~12206389:-
THCA	cis	rs13113518	0.783	rs13111128	ENSG00000272969.1	RP11-528I4.2	3.79	0.000169	0.0123	0.2	0.17	Height;	chr4:55578154	chr4:55547112~55547889:+
THCA	cis	rs2235642	0.826	rs8053605	ENSG00000260989.1	LA16c-395F10.2	-3.79	0.000169	0.0123	-0.18	-0.17	Coronary artery disease;	chr16:1544157	chr16:1580527~1610328:+
THCA	cis	rs17221829	0.669	rs7128681	ENSG00000280385.1	AP000648.5	-3.79	0.000169	0.0123	-0.17	-0.17	Anxiety in major depressive disorder;	chr11:89650476	chr11:90193614~90198120:+
THCA	cis	rs4578769	0.55	rs8092358	ENSG00000273232.1	RP11-370A5.2	3.79	0.000169	0.0123	0.23	0.17	Eosinophil percentage of white cells;	chr18:22911835	chr18:22882825~22883357:-
THCA	cis	rs7551222	0.752	rs10793767	ENSG00000240219.1	RP11-430C7.5	3.79	0.000169	0.0123	0.16	0.17	Schizophrenia;	chr1:204580436	chr1:204626775~204629712:+
THCA	cis	rs6430585	0.527	rs76380759	ENSG00000231890.6	DARS-AS1	-3.79	0.000169	0.0123	-0.2	-0.17	Corneal structure;	chr2:135680947	chr2:135985176~136022593:+
THCA	cis	rs4819052	1	rs733739	ENSG00000182586.6	LINC00334	-3.79	0.000169	0.0123	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45234340~45258730:+
THCA	cis	rs10946940	0.632	rs9366698	ENSG00000220721.1	OR1F12	3.79	0.000169	0.0123	0.21	0.17	Systemic lupus erythematosus;	chr6:27704256	chr6:28073316~28074233:+
THCA	cis	rs2692947	0.637	rs1168967	ENSG00000232931.4	LINC00342	3.79	0.000169	0.0123	0.14	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96160278	chr2:95807118~95816215:-
THCA	cis	rs854765	0.624	rs12952723	ENSG00000281749.1	Y_RNA	-3.79	0.000169	0.0123	-0.22	-0.17	Total body bone mineral density;	chr17:17828337	chr17:18001101~18001195:-
THCA	cis	rs11574514	1	rs28679372	ENSG00000280214.1	CTD-2012K14.5	3.79	0.000169	0.0123	0.28	0.17	Crohn's disease;	chr16:67849029	chr16:67550815~67552935:-
THCA	cis	rs1144333	0.655	rs76992868	ENSG00000272855.1	RP5-1102E8.3	-3.79	0.000169	0.0123	-0.37	-0.17	Attention function in attention deficit hyperactive disorder;	chr1:75953231	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs58722308	ENSG00000272855.1	RP5-1102E8.3	-3.79	0.000169	0.0123	-0.37	-0.17	Attention function in attention deficit hyperactive disorder;	chr1:75957840	chr1:76636877~76637339:+
THCA	cis	rs3743266	0.613	rs12442393	ENSG00000240163.1	RP11-745A24.1	-3.79	0.000169	0.0123	-0.2	-0.17	Menarche (age at onset);	chr15:60442261	chr15:60390371~60390682:+
THCA	cis	rs4218	0.648	rs35460138	ENSG00000259732.1	RP11-59H7.3	-3.79	0.000169	0.0123	-0.23	-0.17	Social communication problems;	chr15:59093200	chr15:59121034~59133250:+
THCA	cis	rs7772486	0.79	rs4280983	ENSG00000270638.1	RP3-466P17.1	-3.79	0.000169	0.0123	-0.14	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145735570~145737218:+
THCA	cis	rs62434120	0.571	rs5025711	ENSG00000273132.1	RP11-350J20.12	3.79	0.000169	0.0123	0.21	0.17	Blood pressure traits (multi-trait analysis);Diastolic blood pressure;Systolic blood pressure;	chr6:150730918	chr6:149852462~149853192:+
THCA	cis	rs683250	0.629	rs647030	ENSG00000254551.1	RP11-727A23.7	3.79	0.000169	0.0123	0.21	0.17	Subcortical brain region volumes;	chr11:83277674	chr11:83209431~83213379:-
THCA	cis	rs12893668	0.703	rs2403197	ENSG00000244691.1	RPL10AP1	-3.79	0.000169	0.0123	-0.24	-0.17	Reticulocyte count;	chr14:103587427	chr14:103412119~103412761:-
THCA	cis	rs34421088	0.548	rs2618443	ENSG00000255495.1	AC145124.2	-3.79	0.000169	0.0123	-0.2	-0.17	Neuroticism;	chr8:11527047	chr8:12194467~12196280:+
THCA	cis	rs836788	0.608	rs863221	ENSG00000251221.1	LINC01337	-3.79	0.000169	0.0123	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr5:80746456	chr5:80608623~80622524:-
THCA	cis	rs875971	0.545	rs1638724	ENSG00000273024.4	INTS4P2	3.79	0.000169	0.0123	0.21	0.17	Aortic root size;	chr7:66575494	chr7:65647864~65715661:+
THCA	cis	rs785830	0.655	rs588412	ENSG00000231808.2	LINC01388	3.79	0.000169	0.0123	0.2	0.17	Platelet distribution width;	chr9:249391	chr9:112713~113754:-
THCA	cis	rs1979679	0.553	rs10459088	ENSG00000247934.4	RP11-967K21.1	-3.79	0.000169	0.0123	-0.17	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28115920	chr12:28163298~28190738:-
THCA	cis	rs11756659	0.505	rs16891146	ENSG00000272810.1	U91328.22	-3.79	0.000169	0.0123	-0.14	-0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25903080	chr6:26013241~26013757:+
THCA	cis	rs2051773	0.51	rs11024129	ENSG00000272034.1	SNORD14A	-3.79	0.000169	0.0123	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17034870	chr11:17074654~17074744:-
THCA	cis	rs2051773	0.51	rs11024130	ENSG00000272034.1	SNORD14A	-3.79	0.000169	0.0123	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17034878	chr11:17074654~17074744:-
THCA	cis	rs2051773	0.51	rs11024131	ENSG00000272034.1	SNORD14A	-3.79	0.000169	0.0123	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17034893	chr11:17074654~17074744:-
THCA	cis	rs2051773	0.567	rs6486348	ENSG00000272034.1	SNORD14A	-3.79	0.000169	0.0123	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17036227	chr11:17074654~17074744:-
THCA	cis	rs2692947	0.55	rs4613327	ENSG00000235959.1	AC009237.17	-3.79	0.000169	0.0123	-0.2	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95918075	chr2:95640181~95640604:-
THCA	cis	rs4671400	0.571	rs12615222	ENSG00000271889.1	RP11-493E12.1	-3.79	0.000169	0.0123	-0.19	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267760	chr2:61151433~61162105:-
THCA	cis	rs4671400	0.543	rs62152274	ENSG00000271889.1	RP11-493E12.1	-3.79	0.000169	0.0123	-0.19	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61272453	chr2:61151433~61162105:-
THCA	cis	rs4671400	0.571	rs62152275	ENSG00000271889.1	RP11-493E12.1	-3.79	0.000169	0.0123	-0.19	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61275103	chr2:61151433~61162105:-
THCA	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	3.79	0.000169	0.0123	0.19	0.17	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
THCA	cis	rs6890695	1	rs6890695	ENSG00000237714.1	P4HA2-AS1	3.79	0.000169	0.0123	0.24	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131552731	chr5:132184876~132192808:+
THCA	cis	rs832187	0.629	rs59971314	ENSG00000224479.4	AC136289.1	3.79	0.000169	0.0123	0.21	0.17	Schizophrenia;	chr3:63928942	chr3:63742293~63827445:-
THCA	cis	rs4925386	0.765	rs6142737	ENSG00000275437.1	RP5-908M14.10	3.79	0.000169	0.0123	0.17	0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62402236~62405935:-
THCA	cis	rs875971	0.628	rs6974355	ENSG00000230295.1	RP11-458F8.2	-3.79	0.000169	0.0123	-0.13	-0.17	Aortic root size;	chr7:66376994	chr7:66880708~66882981:+
THCA	cis	rs931608	0.64	rs7253033	ENSG00000269138.1	ZNF209P	3.79	0.000169	0.0123	0.25	0.17	Response to statins (LDL cholesterol change);Dental caries;	chr19:22320401	chr19:22463922~22473036:+
THCA	cis	rs16904179	0.71	rs80134279	ENSG00000280543.1	ASAP1-IT2	3.79	0.000169	0.0123	0.33	0.17	Post-traumatic stress disorder (asjusted for relatedness);	chr8:129950911	chr8:130082738~130084768:-
THCA	cis	rs853679	0.769	rs7752608	ENSG00000204709.4	LINC01556	3.79	0.000169	0.0123	0.39	0.17	Depression;	chr6:28333418	chr6:28943877~28944537:+
THCA	cis	rs16982689	1	rs16982689	ENSG00000278196.1	IGLV2-8	3.79	0.000169	0.0123	0.2	0.17	Attention function in attention deficit hyperactive disorder;	chr22:22081907	chr22:22822658~22823293:+
THCA	cis	rs4925386	0.84	rs6143035	ENSG00000275437.1	RP5-908M14.10	-3.79	0.000169	0.0123	-0.17	-0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62402236~62405935:-
THCA	cis	rs6545883	0.868	rs6748003	ENSG00000212978.6	AC016747.3	3.79	0.000169	0.0123	0.19	0.17	Tuberculosis;	chr2:61579565	chr2:61141592~61144969:-
THCA	cis	rs12472274	0.941	rs11677230	ENSG00000186235.9	AC016757.3	3.79	0.000169	0.0123	0.24	0.17	Phospholipid levels (plasma);	chr2:238183413	chr2:238224552~238231677:-
THCA	cis	rs7166081	1	rs877177	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67213622	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs35997299	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67215252	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs16950776	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67218266	chr15:67541072~67542604:-
THCA	cis	rs7166081	0.951	rs34590589	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67221852	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs34296414	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67222071	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs9806590	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67224003	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs11071942	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67224610	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs4776906	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67228279	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs78553942	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000169	0.0123	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67229472	chr15:67541072~67542604:-
THCA	cis	rs11637445	0.589	rs4776989	ENSG00000260657.2	RP11-315D16.4	-3.79	0.000169	0.0123	-0.23	-0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67838346	chr15:68267792~68277994:-
THCA	cis	rs7772486	0.777	rs1546966	ENSG00000270638.1	RP3-466P17.1	3.79	0.000169	0.0123	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146064882	chr6:145735570~145737218:+
THCA	cis	rs6546550	0.901	rs6716937	ENSG00000179818.12	PCBP1-AS1	-3.79	0.000169	0.0123	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69900097	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.867	rs1048266	ENSG00000179818.12	PCBP1-AS1	-3.79	0.000169	0.0123	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69905544	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.867	rs6738174	ENSG00000179818.12	PCBP1-AS1	-3.79	0.000169	0.0123	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69923083	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs6725425	ENSG00000179818.12	PCBP1-AS1	-3.79	0.000169	0.0123	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69923542	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.867	rs726920	ENSG00000179818.12	PCBP1-AS1	-3.79	0.000169	0.0123	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69924895	chr2:69962263~70103220:-
THCA	cis	rs10109025	0.67	rs7825690	ENSG00000269918.1	AF131215.9	-3.79	0.000169	0.0123	-0.18	-0.17	Joint mobility (Beighton score);	chr8:11000747	chr8:11104691~11106704:-
THCA	cis	rs7560272	0.501	rs2421676	ENSG00000273245.1	RP11-434P11.2	-3.79	0.000169	0.0123	-0.2	-0.17	Schizophrenia;	chr2:73738960	chr2:73750256~73750786:-
THCA	cis	rs5753037	0.653	rs131271	ENSG00000279699.1	RP1-102K2.9	3.79	0.000169	0.0123	0.17	0.17	Type 1 diabetes;	chr22:29755593	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.653	rs140133	ENSG00000279699.1	RP1-102K2.9	3.79	0.000169	0.0123	0.17	0.17	Type 1 diabetes;	chr22:29756533	chr22:30275215~30276951:-
THCA	cis	rs4916588	0.697	rs73080424	ENSG00000270170.1	NCBP2-AS2	3.79	0.00017	0.0123	0.14	0.17	Night sleep phenotypes;	chr3:196929209	chr3:196942623~196943540:+
THCA	cis	rs2205829	0.563	rs4413607	ENSG00000204789.4	ZNF204P	-3.79	0.00017	0.0123	-0.14	-0.17	Bipolar disorder;	chr6:27507341	chr6:27357825~27360221:-
THCA	cis	rs1850744	0.702	rs7434744	ENSG00000163612.10	FAM86KP	-3.79	0.00017	0.0123	-0.36	-0.17	Economic and political preferences;	chr4:9671064	chr4:9153296~9165451:+
THCA	cis	rs11148252	0.711	rs61957304	ENSG00000273784.3	RP11-78J21.7	-3.79	0.00017	0.0123	-0.19	-0.17	Lewy body disease;	chr13:52224288	chr13:52600042~52642542:+
THCA	cis	rs11242704	0.962	rs2569827	ENSG00000218027.2	RP11-157J24.1	3.79	0.00017	0.0123	0.22	0.17	Response to hepatitis C treatment;	chr6:1537828	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.962	rs2569828	ENSG00000218027.2	RP11-157J24.1	3.79	0.00017	0.0123	0.22	0.17	Response to hepatitis C treatment;	chr6:1538010	chr6:1513698~1515289:-
THCA	cis	rs6921919	0.848	rs6903652	ENSG00000176933.5	TOB2P1	-3.79	0.00017	0.0123	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28217643~28218634:-
THCA	cis	rs9467773	0.838	rs3734540	ENSG00000228223.2	HCG11	-3.79	0.00017	0.0123	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26463093	chr6:26523450~26526579:+
THCA	cis	rs758324	0.898	rs510434	ENSG00000237714.1	P4HA2-AS1	-3.79	0.00017	0.0123	-0.24	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131956810	chr5:132184876~132192808:+
THCA	cis	rs9863	0.861	rs10846580	ENSG00000269938.1	RP11-214K3.20	-3.79	0.00017	0.0123	-0.2	-0.17	White blood cell count;	chr12:123930906	chr12:123968023~123968579:-
THCA	cis	rs61677309	0.964	rs56292628	ENSG00000278376.1	RP11-158I9.8	3.79	0.00017	0.0123	0.13	0.17	Lung cancer in ever smokers;	chr11:118293157	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs55940627	ENSG00000278376.1	RP11-158I9.8	3.79	0.00017	0.0123	0.13	0.17	Lung cancer in ever smokers;	chr11:118293205	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs12577820	ENSG00000278376.1	RP11-158I9.8	3.79	0.00017	0.0123	0.13	0.17	Lung cancer in ever smokers;	chr11:118293518	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs59450866	ENSG00000278376.1	RP11-158I9.8	3.79	0.00017	0.0123	0.13	0.17	Lung cancer in ever smokers;	chr11:118296992	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs58093803	ENSG00000278376.1	RP11-158I9.8	3.79	0.00017	0.0123	0.13	0.17	Lung cancer in ever smokers;	chr11:118297441	chr11:118791254~118793137:+
THCA	cis	rs13053817	0.948	rs13058415	ENSG00000279159.1	RP3-394A18.1	3.79	0.00017	0.0123	0.17	0.17	Carotid atherosclerosis in HIV infection;	chr22:29452492	chr22:29978950~30028236:-
THCA	cis	rs7267979	0.966	rs6037097	ENSG00000276952.1	RP5-965G21.6	3.79	0.00017	0.0123	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25284915~25285588:-
THCA	cis	rs11603020	0.95	rs28362947	ENSG00000254602.1	AP000662.4	-3.79	0.00017	0.0123	-0.2	-0.17	Blood protein levels;	chr11:57601535	chr11:57638024~57652790:+
THCA	cis	rs11603020	0.95	rs28362948	ENSG00000254602.1	AP000662.4	-3.79	0.00017	0.0123	-0.2	-0.17	Blood protein levels;	chr11:57601540	chr11:57638024~57652790:+
THCA	cis	rs295490	0.748	rs76520271	ENSG00000272656.1	RP11-219D15.3	3.79	0.00017	0.0123	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139422441	chr3:139349024~139349371:-
THCA	cis	rs4705962	0.658	rs11949166	ENSG00000230612.2	AC004237.1	3.79	0.00017	0.0123	0.22	0.17	Atopic dermatitis;	chr5:132691989	chr5:132688681~132723725:+
THCA	cis	rs7200543	1	rs14347	ENSG00000188599.16	NPIPP1	-3.79	0.00017	0.0123	-0.13	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:15104312~15123498:-
THCA	cis	rs7546	0.505	rs760118	ENSG00000267077.1	RP11-127I20.5	-3.79	0.00017	0.0123	-0.19	-0.17	Cancer;	chr16:4890993	chr16:4795265~4796532:-
THCA	cis	rs7737355	0.947	rs244736	ENSG00000237714.1	P4HA2-AS1	3.79	0.00017	0.0123	0.25	0.17	Life satisfaction;	chr5:131480485	chr5:132184876~132192808:+
THCA	cis	rs4218	0.56	rs8039514	ENSG00000259732.1	RP11-59H7.3	-3.79	0.00017	0.0123	-0.23	-0.17	Social communication problems;	chr15:59114382	chr15:59121034~59133250:+
THCA	cis	rs7216064	1	rs3206817	ENSG00000265055.1	AC145343.2	3.79	0.00017	0.0123	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896718	chr17:68096046~68101474:-
THCA	cis	rs7833787	0.501	rs6586768	ENSG00000278886.1	RP11-108A14.1	-3.79	0.00017	0.0123	-0.25	-0.17	Obesity-related traits;	chr8:18829083	chr8:18864681~18865247:-
THCA	cis	rs854765	0.693	rs9907287	ENSG00000281749.1	Y_RNA	-3.79	0.00017	0.0123	-0.21	-0.17	Total body bone mineral density;	chr17:17870804	chr17:18001101~18001195:-
THCA	cis	rs10089	1	rs7703634	ENSG00000245937.6	LINC01184	3.79	0.00017	0.0123	0.19	0.17	Ileal carcinoids;	chr5:128173531	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs1559263	ENSG00000245937.6	LINC01184	3.79	0.00017	0.0123	0.19	0.17	Ileal carcinoids;	chr5:128177181	chr5:127940426~128083172:-
THCA	cis	rs3806843	0.547	rs246065	ENSG00000202515.1	VTRNA1-3	-3.79	0.00017	0.0123	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140944053	chr5:140726158~140726246:+
THCA	cis	rs11633886	0.565	rs1356881	ENSG00000273972.1	CTD-2306A12.1	3.79	0.00017	0.0123	0.19	0.17	Diisocyanate-induced asthma;	chr15:45781261	chr15:45702640~45703183:+
THCA	cis	rs6957923	0.81	rs7779665	ENSG00000234286.1	AC006026.13	-3.79	0.00017	0.0123	-0.23	-0.17	Height;	chr7:23481344	chr7:23680195~23680786:-
THCA	cis	rs295490	0.748	rs56993164	ENSG00000272656.1	RP11-219D15.3	3.79	0.00017	0.0123	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139388391	chr3:139349024~139349371:-
THCA	cis	rs854765	0.547	rs2955372	ENSG00000281749.1	Y_RNA	-3.79	0.00017	0.0123	-0.22	-0.17	Total body bone mineral density;	chr17:18066915	chr17:18001101~18001195:-
THCA	cis	rs7759001	0.681	rs7756377	ENSG00000271755.1	RP1-153G14.4	3.79	0.00017	0.0123	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27513882	chr6:27404010~27406964:-
THCA	cis	rs4722585	0.533	rs2049843	ENSG00000273237.1	CTB-119C2.1	-3.79	0.00017	0.0123	-0.16	-0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26157343	chr7:26173533~26174945:-
THCA	cis	rs4568518	0.74	rs10428925	ENSG00000279048.1	RP11-511H23.2	3.79	0.00017	0.0123	0.11	0.17	Measles;	chr7:17969582	chr7:17940503~17942922:+
THCA	cis	rs7809950	0.731	rs4730238	ENSG00000272072.1	CTA-363E19.2	3.79	0.00017	0.0123	0.18	0.17	Coronary artery disease;	chr7:107414342	chr7:107192559~107193300:-
THCA	cis	rs72627123	1	rs2302139	ENSG00000259065.1	RP5-1021I20.1	-3.79	0.00017	0.0123	-0.26	-0.17	Morning vs. evening chronotype;	chr14:73896232	chr14:73787360~73803270:+
THCA	cis	rs6756513	0.5	rs12613917	ENSG00000231024.1	AC092431.3	-3.79	0.00017	0.0123	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69838970	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs11888098	ENSG00000231024.1	AC092431.3	-3.79	0.00017	0.0123	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69839759	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs11888102	ENSG00000231024.1	AC092431.3	-3.79	0.00017	0.0123	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69839790	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs3771533	ENSG00000231024.1	AC092431.3	-3.79	0.00017	0.0123	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69840925	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs2872076	ENSG00000231024.1	AC092431.3	-3.79	0.00017	0.0123	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69841623	chr2:69700192~69713847:-
THCA	cis	rs494526	0.709	rs7088698	ENSG00000229272.1	RP11-498J9.2	-3.79	0.00017	0.0123	-0.19	-0.17	Alcoholic chronic pancreatitis;	chr10:119093114	chr10:119003536~119003884:-
THCA	cis	rs7200543	1	rs14347	ENSG00000260735.1	RP11-72I8.1	-3.79	0.00017	0.0123	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:15094411~15109197:+
THCA	cis	rs13006863	0.509	rs1667605	ENSG00000217702.2	RP11-287D1.4	-3.79	0.00017	0.0123	-0.21	-0.17	Immune reponse to smallpox (secreted TNF-alpha);Post-traumatic stress disorder (asjusted for relatedness);	chr2:74147757	chr2:74130583~74135395:+
THCA	cis	rs13217239	0.572	rs9379958	ENSG00000261353.1	CTA-14H9.5	3.79	0.00017	0.0123	0.18	0.17	Schizophrenia;	chr6:27098384	chr6:26527063~26527404:+
THCA	cis	rs2115630	0.875	rs8039472	ENSG00000259728.4	LINC00933	-3.79	0.00017	0.0123	-0.2	-0.17	P wave terminal force;	chr15:84818413	chr15:84570649~84580175:+
THCA	cis	rs860295	0.871	rs6696888	ENSG00000160766.13	GBAP1	3.79	0.00017	0.0123	0.19	0.17	Body mass index;	chr1:155539091	chr1:155213821~155227422:-
THCA	cis	rs10927875	0.597	rs61782184	ENSG00000179743.3	FLJ37453	-3.79	0.00017	0.0123	-0.12	-0.17	Dilated cardiomyopathy;	chr1:15824481	chr1:15834479~15848147:-
THCA	cis	rs6439699	0.825	rs1116726	ENSG00000273486.1	RP11-731C17.2	3.79	0.00017	0.0123	0.19	0.17	Intelligence (multi-trait analysis);	chr3:137367026	chr3:136837338~136839021:-
THCA	cis	rs6439699	0.709	rs34931689	ENSG00000273486.1	RP11-731C17.2	3.79	0.00017	0.0123	0.19	0.17	Intelligence (multi-trait analysis);	chr3:137377914	chr3:136837338~136839021:-
THCA	cis	rs61784830	0.71	rs61783251	ENSG00000234329.1	RP11-767N6.2	3.79	0.00017	0.0123	0.25	0.17	Iron status biomarkers (total iron binding capacity);	chr1:45902415	chr1:45651039~45651826:-
THCA	cis	rs2439831	0.681	rs28578454	ENSG00000166763.7	STRCP1	3.79	0.00017	0.0123	0.25	0.17	Lung cancer in ever smokers;	chr15:43310834	chr15:43699488~43718184:-
THCA	cis	rs867186	1	rs9941751	ENSG00000126005.14	MMP24-AS1	-3.79	0.00017	0.0123	-0.27	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35057906	chr20:35216462~35278131:-
THCA	cis	rs3806843	0.551	rs184996	ENSG00000202515.1	VTRNA1-3	-3.79	0.00017	0.0123	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140944188	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246064	ENSG00000202515.1	VTRNA1-3	-3.79	0.00017	0.0123	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140944724	chr5:140726158~140726246:+
THCA	cis	rs9905704	0.918	rs12942969	ENSG00000224738.1	AC099850.1	3.79	0.00017	0.0123	0.23	0.17	Testicular germ cell tumor;	chr17:58815511	chr17:59106598~59118267:+
THCA	cis	rs2562456	0.761	rs35008138	ENSG00000268278.1	RP11-420K14.1	3.79	0.00017	0.0123	0.21	0.17	Pain;	chr19:21548822	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs2681388	ENSG00000268278.1	RP11-420K14.1	3.79	0.00017	0.0123	0.21	0.17	Pain;	chr19:21549451	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.876	rs2681370	ENSG00000268278.1	RP11-420K14.1	3.79	0.00017	0.0123	0.21	0.17	Pain;	chr19:21554036	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.876	rs11668606	ENSG00000268278.1	RP11-420K14.1	3.79	0.00017	0.0123	0.21	0.17	Pain;	chr19:21554618	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.876	rs2681395	ENSG00000268278.1	RP11-420K14.1	3.79	0.00017	0.0123	0.21	0.17	Pain;	chr19:21555338	chr19:21637974~21656300:+
THCA	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	3.79	0.00017	0.0123	0.18	0.17	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
THCA	cis	rs2652822	0.525	rs7176591	ENSG00000259459.4	RP11-321G12.1	-3.79	0.00017	0.0123	-0.14	-0.17	Metabolic traits;	chr15:63288397	chr15:63390136~63438320:+
THCA	cis	rs972578	1	rs5759070	ENSG00000230319.1	AL022476.2	3.79	0.00017	0.0123	0.18	0.17	Mean platelet volume;	chr22:42979695	chr22:43038585~43052366:+
THCA	cis	rs6894268	1	rs6894268	ENSG00000273549.1	Metazoa_SRP	-3.79	0.00017	0.0123	-0.21	-0.17	Eating disorders;	chr5:179605487	chr5:179629151~179629410:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000232559.3	GS1-124K5.12	3.79	0.00017	0.0123	0.19	0.17	Aortic root size;	chr7:66158946	chr7:66554588~66576923:-
THCA	cis	rs875971	0.52	rs12666485	ENSG00000232559.3	GS1-124K5.12	3.79	0.00017	0.0123	0.19	0.17	Aortic root size;	chr7:66160135	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs67688847	ENSG00000232559.3	GS1-124K5.12	3.79	0.00017	0.0123	0.19	0.17	Aortic root size;	chr7:66161064	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs316324	ENSG00000232559.3	GS1-124K5.12	-3.79	0.00017	0.0123	-0.19	-0.17	Aortic root size;	chr7:66145627	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs316323	ENSG00000232559.3	GS1-124K5.12	-3.79	0.00017	0.0123	-0.19	-0.17	Aortic root size;	chr7:66146002	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs316305	ENSG00000232559.3	GS1-124K5.12	-3.79	0.00017	0.0123	-0.19	-0.17	Aortic root size;	chr7:66152984	chr7:66554588~66576923:-
THCA	cis	rs10129255	0.957	rs10140904	ENSG00000280411.1	IGHV1-69-2	-3.79	0.00017	0.0123	-0.11	-0.17	Kawasaki disease;	chr14:106776558	chr14:106762092~106762588:-
THCA	cis	rs7819412	0.643	rs7829396	ENSG00000255046.1	RP11-297N6.4	3.79	0.00017	0.0123	0.19	0.17	Triglycerides;	chr8:11142073	chr8:11797928~11802568:-
THCA	cis	rs295490	0.748	rs116416768	ENSG00000272656.1	RP11-219D15.3	3.79	0.00017	0.0123	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139382294	chr3:139349024~139349371:-
THCA	cis	rs755249	0.642	rs28788506	ENSG00000228060.1	RP11-69E11.8	-3.79	0.00017	0.0123	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39565160~39573203:+
THCA	cis	rs755249	0.669	rs4660311	ENSG00000228060.1	RP11-69E11.8	-3.79	0.00017	0.0123	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39565160~39573203:+
THCA	cis	rs4906332	1	rs12896612	ENSG00000259775.1	RP11-45P15.4	-3.79	0.00017	0.0123	-0.15	-0.17	Coronary artery disease;	chr14:103411531	chr14:103331674~103332367:-
THCA	cis	rs2729354	0.768	rs2584856	ENSG00000254602.1	AP000662.4	-3.79	0.00017	0.0123	-0.22	-0.17	Blood protein levels;	chr11:57499839	chr11:57638024~57652790:+
THCA	cis	rs3743266	0.613	rs1063100	ENSG00000240163.1	RP11-745A24.1	-3.79	0.00017	0.0123	-0.2	-0.17	Menarche (age at onset);	chr15:60442498	chr15:60390371~60390682:+
THCA	cis	rs795484	0.889	rs708868	ENSG00000275409.1	RP11-131L12.4	-3.79	0.00017	0.0123	-0.14	-0.17	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118191964	chr12:118430147~118430699:+
THCA	cis	rs795484	0.926	rs383371	ENSG00000275409.1	RP11-131L12.4	3.79	0.00017	0.0123	0.14	0.17	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118187446	chr12:118430147~118430699:+
THCA	cis	rs7131987	0.565	rs1991113	ENSG00000257176.2	RP11-996F15.2	-3.79	0.00017	0.0123	-0.17	-0.17	QT interval;	chr12:29239070	chr12:29280418~29317848:-
THCA	cis	rs7737355	0.898	rs4706030	ENSG00000237714.1	P4HA2-AS1	3.79	0.00017	0.0123	0.25	0.17	Life satisfaction;	chr5:131621793	chr5:132184876~132192808:+
THCA	cis	rs654950	0.783	rs640688	ENSG00000230638.4	RP11-486B10.4	3.79	0.00017	0.0123	0.19	0.17	Airway imaging phenotypes;	chr1:41536160	chr1:41542069~41544310:+
THCA	cis	rs62246343	0.572	rs62246311	ENSG00000254485.4	RP11-380O24.1	3.79	0.00017	0.0123	0.28	0.17	Fibrinogen levels;	chr3:9456459	chr3:9292588~9363303:-
THCA	cis	rs62246343	0.572	rs111979419	ENSG00000254485.4	RP11-380O24.1	3.79	0.00017	0.0123	0.28	0.17	Fibrinogen levels;	chr3:9457372	chr3:9292588~9363303:-
THCA	cis	rs3763267	0.649	rs73040144	ENSG00000226445.1	XXyac-YX65C7_A.2	3.79	0.00017	0.0123	0.33	0.17	Blood protein levels;	chr6:169191343	chr6:169213254~169239565:+
THCA	cis	rs2652822	0.555	rs77171305	ENSG00000259459.4	RP11-321G12.1	-3.79	0.00017	0.0123	-0.14	-0.17	Metabolic traits;	chr15:63244031	chr15:63390136~63438320:+
THCA	cis	rs5758511	0.68	rs58654759	ENSG00000230107.1	CTA-126B4.7	-3.79	0.00017	0.0123	-0.21	-0.17	Birth weight;	chr22:42246570	chr22:42438023~42446195:+
THCA	cis	rs2882667	0.931	rs11955952	ENSG00000249593.5	CTB-46B19.2	3.79	0.00017	0.0123	0.21	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:139012647~139051203:+
THCA	cis	rs12612619	0.732	rs4665366	ENSG00000272148.1	RP11-195B17.1	-3.79	0.00017	0.0123	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989728	chr2:27062428~27062907:-
THCA	cis	rs57784326	1	rs57784326	ENSG00000276593.1	RP11-295H24.5	-3.79	0.00017	0.0123	-0.2	-0.17	Bacterial meningitis;	chr15:49504433	chr15:49353485~49354034:+
THCA	cis	rs61160187	0.582	rs12516995	ENSG00000272308.1	RP11-231G3.1	-3.79	0.00017	0.0123	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60866457~60866935:-
THCA	cis	rs8030605	0.778	rs76712141	ENSG00000277245.1	RP11-48G14.3	3.79	0.00017	0.0124	0.32	0.17	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56208936	chr15:56447120~56447697:+
THCA	cis	rs1501911	0.509	rs330421	ENSG00000241597.2	CTD-2007H13.1	-3.79	0.00017	0.0124	-0.22	-0.17	Lung function (FEV1/FVC);	chr5:98859077	chr5:98954394~98954972:+
THCA	cis	rs765787	0.53	rs2668737	ENSG00000259932.1	CTD-2651B20.7	3.79	0.00017	0.0124	0.21	0.17	Uric acid levels;	chr15:45230601	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs1706764	ENSG00000259932.1	CTD-2651B20.7	3.79	0.00017	0.0124	0.21	0.17	Uric acid levels;	chr15:45232058	chr15:45198517~45199139:-
THCA	cis	rs17685	0.753	rs4728550	ENSG00000227038.2	AC005077.12	-3.79	0.00017	0.0124	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76041670	chr7:76090431~76108779:-
THCA	cis	rs7560272	0.501	rs2421675	ENSG00000163016.8	ALMS1P	-3.79	0.00017	0.0124	-0.21	-0.17	Schizophrenia;	chr2:73728174	chr2:73644919~73685576:+
THCA	cis	rs7656342	0.964	rs13141706	ENSG00000249866.1	OR7E83P	-3.79	0.00017	0.0124	-0.19	-0.17	Gut microbiota (bacterial taxa);	chr4:9816721	chr4:9512905~9513874:+
THCA	cis	rs1520333	0.54	rs13282207	ENSG00000254352.1	RP11-578O24.2	-3.79	0.00017	0.0124	-0.2	-0.17	Multiple sclerosis;	chr8:78466812	chr8:78723796~78724136:-
THCA	cis	rs6546886	0.917	rs12713803	ENSG00000235499.1	AC073046.25	3.79	0.00017	0.0124	0.16	0.17	Dialysis-related mortality;	chr2:74011554	chr2:73985132~73986343:+
THCA	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	3.79	0.000171	0.0124	0.16	0.17	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
THCA	cis	rs6137726	0.524	rs1203947	ENSG00000237396.1	LINC01384	3.79	0.000171	0.0124	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22621725	chr20:22587522~22607517:-
THCA	cis	rs7259376	0.936	rs10454118	ENSG00000269345.1	VN1R85P	-3.79	0.000171	0.0124	-0.19	-0.17	Menopause (age at onset);	chr19:22376803	chr19:22174766~22175191:-
THCA	cis	rs7166081	1	rs16953610	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000171	0.0124	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67209254	chr15:67541072~67542604:-
THCA	cis	rs10954779	0.702	rs2725351	ENSG00000127589.4	TUBBP1	3.79	0.000171	0.0124	0.21	0.17	Intelligence (multi-trait analysis);	chr8:31119930	chr8:30351873~30353518:+
THCA	cis	rs9435732	0.778	rs2076604	ENSG00000186301.8	MST1P2	-3.79	0.000171	0.0124	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16991570	chr1:16645622~16650289:+
THCA	cis	rs478304	0.654	rs10896029	ENSG00000255557.1	RP11-770G2.2	3.79	0.000171	0.0124	0.21	0.17	Acne (severe);	chr11:65685481	chr11:65745729~65771585:+
THCA	cis	rs478304	0.627	rs11227254	ENSG00000255557.1	RP11-770G2.2	3.79	0.000171	0.0124	0.21	0.17	Acne (severe);	chr11:65686529	chr11:65745729~65771585:+
THCA	cis	rs478304	0.637	rs11227255	ENSG00000255557.1	RP11-770G2.2	3.79	0.000171	0.0124	0.21	0.17	Acne (severe);	chr11:65686573	chr11:65745729~65771585:+
THCA	cis	rs478304	0.627	rs1073602	ENSG00000255557.1	RP11-770G2.2	3.79	0.000171	0.0124	0.21	0.17	Acne (severe);	chr11:65687915	chr11:65745729~65771585:+
THCA	cis	rs478304	0.654	rs6591185	ENSG00000255557.1	RP11-770G2.2	3.79	0.000171	0.0124	0.21	0.17	Acne (severe);	chr11:65688271	chr11:65745729~65771585:+
THCA	cis	rs7727544	0.617	rs3843503	ENSG00000263597.1	MIR3936	3.79	0.000171	0.0124	0.17	0.17	Blood metabolite levels;	chr5:132130936	chr5:132365490~132365599:-
THCA	cis	rs9393777	0.92	rs13195040	ENSG00000272009.1	RP1-313I6.12	3.79	0.000171	0.0124	0.29	0.17	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28078792~28081130:-
THCA	cis	rs3845817	0.703	rs702909	ENSG00000237979.1	AC007389.1	-3.79	0.000171	0.0124	-0.19	-0.17	Bipolar disorder;	chr2:65540113	chr2:65500993~65502138:-
THCA	cis	rs7246760	1	rs73014068	ENSG00000267106.4	ZNF561-AS1	3.79	0.000171	0.0124	0.33	0.17	Pursuit maintenance gain;	chr19:9812107	chr19:9621291~9645896:+
THCA	cis	rs6546886	0.957	rs12713806	ENSG00000235499.1	AC073046.25	3.79	0.000171	0.0124	0.16	0.17	Dialysis-related mortality;	chr2:74031009	chr2:73985132~73986343:+
THCA	cis	rs6840360	0.615	rs4696267	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151543348	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs4696268	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151543571	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs10021407	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151543850	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs58977077	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151549087	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.554	rs62329088	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151550137	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs66852535	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151551075	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.593	rs10033405	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151553337	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs4696096	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151554235	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs1962910	ENSG00000251611.1	RP11-610P16.1	-3.79	0.000171	0.0124	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151558240	chr4:151407551~151408835:-
THCA	cis	rs9500256	0.967	rs1012500	ENSG00000239650.4	GUSBP4	3.79	0.000171	0.0124	0.16	0.17	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57919784~57930291:-
THCA	cis	rs763121	0.853	rs2072794	ENSG00000228274.3	RP3-508I15.9	-3.79	0.000171	0.0124	-0.2	-0.17	Menopause (age at onset);	chr22:38754538	chr22:38667585~38681820:-
THCA	cis	rs4578769	0.569	rs1448769	ENSG00000273232.1	RP11-370A5.2	3.79	0.000171	0.0124	0.24	0.17	Eosinophil percentage of white cells;	chr18:22838322	chr18:22882825~22883357:-
THCA	cis	rs10857712	0.754	rs1052582	ENSG00000214279.11	SCART1	-3.79	0.000171	0.0124	-0.14	-0.17	Systemic lupus erythematosus;	chr10:133420336	chr10:133453928~133523558:+
THCA	cis	rs9368481	0.546	rs12664610	ENSG00000261353.1	CTA-14H9.5	-3.79	0.000171	0.0124	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26527063~26527404:+
THCA	cis	rs520525	0.963	rs627848	ENSG00000271811.1	RP1-79C4.4	3.79	0.000171	0.0124	0.22	0.17	Atrial fibrillation;	chr1:170662279	chr1:170667381~170669425:+
THCA	cis	rs3733585	0.783	rs13148371	ENSG00000261490.1	RP11-448G15.3	3.79	0.000171	0.0124	0.11	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10068089~10073019:-
THCA	cis	rs832540	0.864	rs252908	ENSG00000271828.1	CTD-2310F14.1	-3.79	0.000171	0.0124	-0.24	-0.17	Coronary artery disease;	chr5:56824859	chr5:56927874~56929573:+
THCA	cis	rs6903823	0.508	rs1778484	ENSG00000176933.5	TOB2P1	-3.79	0.000171	0.0124	-0.19	-0.17	Pulmonary function;	chr6:28273021	chr6:28217643~28218634:-
THCA	cis	rs7551222	0.752	rs12133735	ENSG00000240219.1	RP11-430C7.5	3.79	0.000171	0.0124	0.16	0.17	Schizophrenia;	chr1:204587708	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.752	rs12566957	ENSG00000240219.1	RP11-430C7.5	3.79	0.000171	0.0124	0.16	0.17	Schizophrenia;	chr1:204587830	chr1:204626775~204629712:+
THCA	cis	rs481331	0.799	rs210269	ENSG00000215146.4	RP11-313J2.1	-3.79	0.000171	0.0124	-0.3	-0.17	Systemic juvenile idiopathic arthritis;	chr10:42505999	chr10:42331866~42367974:-
THCA	cis	rs10886471	0.579	rs12254134	ENSG00000228485.1	GRK5-IT1	-3.79	0.000171	0.0124	-0.18	-0.17	Type 2 diabetes;	chr10:119412370	chr10:119208531~119211760:+
THCA	cis	rs10808739	0.8	rs78533583	ENSG00000254006.4	RP11-1D12.2	-3.79	0.000171	0.0124	-0.23	-0.17	HIV-1 susceptibility;	chr8:64828770	chr8:64801236~64817573:-
THCA	cis	rs149737732	1	rs149737732	ENSG00000272319.1	AL022345.7	3.79	0.000171	0.0124	0.45	0.17	Pediatric bone mineral content (radius);	chr10:42741770	chr10:42579724~42582772:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000273024.4	INTS4P2	3.79	0.000171	0.0124	0.22	0.17	Aortic root size;	chr7:66112359	chr7:65647864~65715661:+
THCA	cis	rs889312	0.5	rs702691	ENSG00000271828.1	CTD-2310F14.1	-3.79	0.000171	0.0124	-0.24	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56818699	chr5:56927874~56929573:+
THCA	cis	rs12451471	0.559	rs34746710	ENSG00000279259.1	RP11-334C17.3	-3.79	0.000171	0.0124	-0.18	-0.17	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80105425	chr17:80147250~80148596:+
THCA	cis	rs2351088	0.572	rs58401605	ENSG00000231711.2	LINC00899	3.79	0.000171	0.0124	0.22	0.17	Tonsillectomy;	chr22:45794080	chr22:46039907~46044853:-
THCA	cis	rs7111546	0.514	rs1346251	ENSG00000246225.5	RP11-17A1.3	3.79	0.000171	0.0124	0.3	0.17	Dialysis-related mortality;	chr11:22974736	chr11:22829380~22945393:+
THCA	cis	rs6441286	0.964	rs9881959	ENSG00000244040.4	IL12A-AS1	-3.79	0.000171	0.0124	-0.22	-0.17	Primary biliary cholangitis;	chr3:160004060	chr3:159913400~160225299:-
THCA	cis	rs2340727	0.66	rs2340725	ENSG00000229808.1	RP11-456P18.2	-3.79	0.000171	0.0124	-0.24	-0.17	White blood cell count;Hematology traits;	chr1:161973844	chr1:161890833~161892196:+
THCA	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	3.79	0.000171	0.0124	0.23	0.17	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
THCA	cis	rs11708578	0.554	rs1995209	ENSG00000237990.3	CNTN4-AS1	3.79	0.000171	0.0124	0.21	0.17	Schizophrenia;	chr3:2390928	chr3:3039033~3069242:-
THCA	cis	rs11708578	0.554	rs1995210	ENSG00000237990.3	CNTN4-AS1	3.79	0.000171	0.0124	0.21	0.17	Schizophrenia;	chr3:2391127	chr3:3039033~3069242:-
THCA	cis	rs9467773	0.62	rs9461276	ENSG00000228223.2	HCG11	-3.79	0.000171	0.0124	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26523450~26526579:+
THCA	cis	rs7236492	0.872	rs74569193	ENSG00000267655.1	CTD-2286N8.2	3.79	0.000171	0.0124	0.39	0.17	Inflammatory bowel disease;Crohn's disease;	chr18:79472698	chr18:79117207~79117920:+
THCA	cis	rs7927592	0.913	rs7107622	ENSG00000160172.9	FAM86C2P	3.79	0.000171	0.0124	0.17	0.17	Total body bone mineral density;	chr11:68606715	chr11:67791648~67805336:-
THCA	cis	rs7264396	1	rs6060479	ENSG00000088340.14	FER1L4	-3.79	0.000171	0.0124	-0.17	-0.17	Total cholesterol levels;	chr20:35577801	chr20:35558737~35607562:-
THCA	cis	rs2629751	0.962	rs2629798	ENSG00000214198.6	RP11-642P15.1	-3.79	0.000171	0.0124	-0.14	-0.17	Hepatitis C induced liver fibrosis;	chr12:104016318	chr12:103843749~103930211:-
THCA	cis	rs10858047	0.883	rs2137365	ENSG00000231128.4	RP5-1073O3.2	-3.79	0.000171	0.0124	-0.24	-0.17	Autism;	chr1:114536064	chr1:113812379~113829171:+
THCA	cis	rs858239	0.738	rs13225593	ENSG00000230042.1	AK3P3	-3.79	0.000171	0.0124	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23129178~23129841:+
THCA	cis	rs752590	0.623	rs67776659	ENSG00000227359.1	AC017074.2	3.79	0.000171	0.0124	0.28	0.17	Mucinous ovarian carcinoma;	chr2:113227017	chr2:113677702~113704078:-
THCA	cis	rs7246760	0.867	rs8102257	ENSG00000267106.4	ZNF561-AS1	3.79	0.000171	0.0124	0.32	0.17	Pursuit maintenance gain;	chr19:9720119	chr19:9621291~9645896:+
THCA	cis	rs6121246	0.909	rs6089070	ENSG00000224628.2	RP5-854E16.2	3.79	0.000171	0.0124	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31789970	chr20:31285317~31286835:-
THCA	cis	rs1612141	1	rs1782185	ENSG00000251363.2	RP11-129M6.1	-3.79	0.000171	0.0124	-0.25	-0.17	QT interval (drug interaction);	chr14:41232098	chr14:40954898~40975877:+
THCA	cis	rs10875746	0.537	rs4760625	ENSG00000226413.2	OR8T1P	3.79	0.000171	0.0124	0.24	0.17	Longevity (90 years and older);	chr12:48279960	chr12:48442030~48442947:-
THCA	cis	rs2562456	0.833	rs2968076	ENSG00000268278.1	RP11-420K14.1	-3.79	0.000171	0.0124	-0.21	-0.17	Pain;	chr19:21454299	chr19:21637974~21656300:+
THCA	cis	rs735539	0.636	rs9579928	ENSG00000238286.1	SLC35E1P1	3.79	0.000171	0.0124	0.19	0.17	Dental caries;	chr13:20700668	chr13:20607268~20608131:+
THCA	cis	rs3845817	0.832	rs702883	ENSG00000281920.1	RP11-418H16.1	-3.79	0.000171	0.0124	-0.21	-0.17	Bipolar disorder;	chr2:65524951	chr2:65623272~65628424:+
THCA	cis	rs3845817	0.838	rs702886	ENSG00000281920.1	RP11-418H16.1	-3.79	0.000171	0.0124	-0.21	-0.17	Bipolar disorder;	chr2:65526176	chr2:65623272~65628424:+
THCA	cis	rs7665090	0.665	rs227277	ENSG00000230069.3	LRRC37A15P	3.79	0.000171	0.0124	0.18	0.17	Primary biliary cholangitis;	chr4:102673781	chr4:102727274~102730721:-
THCA	cis	rs875971	0.545	rs4718325	ENSG00000232559.3	GS1-124K5.12	3.79	0.000171	0.0124	0.19	0.17	Aortic root size;	chr7:66215323	chr7:66554588~66576923:-
THCA	cis	rs6012564	0.893	rs6012555	ENSG00000227431.4	CSE1L-AS1	-3.79	0.000171	0.0124	-0.22	-0.17	Anger;	chr20:48911205	chr20:49040463~49046044:-
THCA	cis	rs6142618	0.84	rs6119232	ENSG00000224452.1	RSL24D1P6	3.79	0.000171	0.0124	0.21	0.17	Inflammatory bowel disease;	chr20:32282536	chr20:32170390~32170790:-
THCA	cis	rs2013441	0.866	rs2703784	ENSG00000261033.1	RP11-209D14.2	3.79	0.000171	0.0124	0.24	0.17	Obesity-related traits;	chr17:20248007	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs2526471	ENSG00000261033.1	RP11-209D14.2	3.79	0.000171	0.0124	0.24	0.17	Obesity-related traits;	chr17:20248360	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs2526470	ENSG00000261033.1	RP11-209D14.2	3.79	0.000171	0.0124	0.24	0.17	Obesity-related traits;	chr17:20256957	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.761	rs2526468	ENSG00000261033.1	RP11-209D14.2	3.79	0.000171	0.0124	0.24	0.17	Obesity-related traits;	chr17:20259759	chr17:20008051~20009234:-
THCA	cis	rs613391	0.522	rs1992926	ENSG00000234840.1	LINC01239	-3.79	0.000171	0.0124	-0.2	-0.17	Quantitative traits;	chr9:22730294	chr9:22646200~22824213:+
THCA	cis	rs613391	0.522	rs1667083	ENSG00000234840.1	LINC01239	-3.79	0.000171	0.0124	-0.2	-0.17	Quantitative traits;	chr9:22730548	chr9:22646200~22824213:+
THCA	cis	rs613391	0.522	rs1470616	ENSG00000234840.1	LINC01239	-3.79	0.000171	0.0124	-0.2	-0.17	Quantitative traits;	chr9:22730733	chr9:22646200~22824213:+
THCA	cis	rs613391	0.522	rs491563	ENSG00000234840.1	LINC01239	-3.79	0.000171	0.0124	-0.2	-0.17	Quantitative traits;	chr9:22730788	chr9:22646200~22824213:+
THCA	cis	rs266717	0.816	rs266753	ENSG00000234197.1	ETV5-AS1	-3.79	0.000171	0.0124	-0.14	-0.17	Adiponectin levels;	chr3:186791270	chr3:186079170~186080947:+
THCA	cis	rs266717	0.816	rs266752	ENSG00000234197.1	ETV5-AS1	-3.79	0.000171	0.0124	-0.14	-0.17	Adiponectin levels;	chr3:186791290	chr3:186079170~186080947:+
THCA	cis	rs2239547	0.657	rs4687672	ENSG00000243224.1	RP5-1157M23.2	-3.79	0.000171	0.0124	-0.2	-0.17	Schizophrenia;	chr3:52846527	chr3:52239258~52241097:+
THCA	cis	rs4578769	0.569	rs12966840	ENSG00000273232.1	RP11-370A5.2	-3.79	0.000171	0.0124	-0.24	-0.17	Eosinophil percentage of white cells;	chr18:22856911	chr18:22882825~22883357:-
THCA	cis	rs3782464	0.585	rs73201491	ENSG00000257517.1	RP4-601P9.1	-3.79	0.000171	0.0124	-0.24	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr12:114356398	chr12:114768674~114771851:+
THCA	cis	rs1993293	1	rs1993293	ENSG00000254744.3	CTD-3076O17.1	3.79	0.000171	0.0124	0.18	0.17	Coronary artery calcification;	chr15:99757458	chr15:99970215~99974010:+
THCA	cis	rs11710088	0.895	rs66609533	ENSG00000240541.2	TM4SF1-AS1	3.79	0.000171	0.0124	0.16	0.17	QRS duration;	chr3:149482345	chr3:149377778~149386583:+
THCA	cis	rs11673344	0.765	rs826296	ENSG00000267260.1	CTD-2162K18.4	-3.79	0.000171	0.0124	-0.22	-0.17	Obesity-related traits;	chr19:36947384	chr19:36773153~36777078:+
THCA	cis	rs1005277	0.54	rs7903942	ENSG00000275858.1	RP11-291L22.8	-3.79	0.000171	0.0124	-0.2	-0.17	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38450738~38451069:-
THCA	cis	rs7829975	0.811	rs7011229	ENSG00000233609.3	RP11-62H7.2	-3.79	0.000171	0.0124	-0.16	-0.17	Mood instability;	chr8:8685814	chr8:8961200~8979025:+
THCA	cis	rs2882667	0.931	rs10074461	ENSG00000249593.5	CTB-46B19.2	3.79	0.000171	0.0124	0.21	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:139012647~139051203:+
THCA	cis	rs10875746	0.537	rs4760625	ENSG00000258273.1	RP11-370I10.4	3.79	0.000171	0.0124	0.25	0.17	Longevity (90 years and older);	chr12:48279960	chr12:48333755~48333901:-
THCA	cis	rs2562456	0.682	rs11085464	ENSG00000268658.4	LINC00664	3.79	0.000171	0.0124	0.25	0.17	Pain;	chr19:21568976	chr19:21483374~21503238:+
THCA	cis	rs4819052	0.84	rs914217	ENSG00000184274.3	LINC00315	-3.79	0.000171	0.0124	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45300245~45305257:-
THCA	cis	rs6121246	1	rs6121246	ENSG00000230613.1	HM13-AS1	3.79	0.000171	0.0124	0.19	0.17	Mean corpuscular hemoglobin;	chr20:31845549	chr20:31567707~31573263:-
THCA	cis	rs62289301	0.637	rs16891934	ENSG00000273133.1	RP11-799M12.2	3.79	0.000171	0.0124	0.22	0.17	Joint mobility (Beighton score);	chr4:15424919	chr4:15563698~15564253:-
THCA	cis	rs17122278	1	rs11216887	ENSG00000243431.1	RPL5P30	3.79	0.000171	0.0124	0.17	0.17	Total cholesterol levels;	chr11:118550021	chr11:118560690~118561580:+
THCA	cis	rs4819052	1	rs733739	ENSG00000184274.3	LINC00315	-3.79	0.000171	0.0124	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45300245~45305257:-
THCA	cis	rs5758511	0.68	rs1107554	ENSG00000270083.1	RP1-257I20.14	-3.79	0.000171	0.0124	-0.21	-0.17	Birth weight;	chr22:42271588	chr22:42089630~42090028:-
THCA	cis	rs56309584	0.715	rs78286057	ENSG00000271002.1	RP11-599B13.8	-3.79	0.000171	0.0124	-0.27	-0.17	Initial pursuit acceleration;	chr17:8248721	chr17:8199123~8199437:-
THCA	cis	rs12887734	0.524	rs722637	ENSG00000258534.1	CTD-2134A5.4	3.79	0.000171	0.0124	0.18	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103854366~103880111:-
THCA	cis	rs4742903	0.935	rs17236663	ENSG00000270332.1	SMC2-AS1	3.79	0.000171	0.0124	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104166121	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs12351370	ENSG00000270332.1	SMC2-AS1	3.79	0.000171	0.0124	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104166659	chr9:104080024~104093073:-
THCA	cis	rs427943	0.798	rs1537122	ENSG00000223768.1	LINC00205	-3.79	0.000171	0.0124	-0.15	-0.17	Body mass index;	chr21:45178591	chr21:45293285~45297354:+
THCA	cis	rs7586085	1	rs6710388	ENSG00000232411.1	AC009495.3	-3.79	0.000171	0.0124	-0.18	-0.17	Total body bone mineral density;	chr2:165726631	chr2:165833048~165839098:-
THCA	cis	rs42648	1	rs42649	ENSG00000225498.1	AC002064.5	3.79	0.000171	0.0124	0.18	0.17	Homocysteine levels;	chr7:90348475	chr7:90312496~90322592:+
THCA	cis	rs539096	0.692	rs7549094	ENSG00000237950.1	RP11-7O11.3	3.79	0.000171	0.0124	0.15	0.17	Intelligence (multi-trait analysis);	chr1:43747507	chr1:43944370~43946551:-
THCA	cis	rs9435732	0.778	rs2076604	ENSG00000268869.4	ESPNP	3.79	0.000171	0.0124	0.21	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16991570	chr1:16687339~16720157:-
THCA	cis	rs72634501	0.531	rs67758468	ENSG00000182109.6	RP11-69E11.4	3.79	0.000171	0.0124	0.18	0.17	HDL cholesterol;	chr1:39156916	chr1:39522280~39546187:-
THCA	cis	rs5758659	0.594	rs739292	ENSG00000205702.9	CYP2D7	3.79	0.000171	0.0124	0.13	0.17	Cognitive function;	chr22:41972853	chr22:42140203~42144577:-
THCA	cis	rs7259376	0.869	rs8110636	ENSG00000269138.1	ZNF209P	-3.79	0.000171	0.0124	-0.17	-0.17	Menopause (age at onset);	chr19:22418025	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.902	rs8100087	ENSG00000269138.1	ZNF209P	-3.79	0.000171	0.0124	-0.17	-0.17	Menopause (age at onset);	chr19:22418557	chr19:22463922~22473036:+
THCA	cis	rs4965593	0.526	rs10902566	ENSG00000278456.1	RP11-66B24.9	-3.79	0.000172	0.0124	-0.22	-0.17	Height;	chr15:100264277	chr15:100888472~100889106:-
THCA	cis	rs765787	0.53	rs1706834	ENSG00000259932.1	CTD-2651B20.7	3.79	0.000172	0.0124	0.21	0.17	Uric acid levels;	chr15:45225656	chr15:45198517~45199139:-
THCA	cis	rs3790515	1	rs3790515	ENSG00000268288.1	RP11-98D18.16	3.79	0.000172	0.0124	0.27	0.17	Depressive symptoms (SSRI exposure interaction);	chr1:151813896	chr1:151766486~151767000:-
THCA	cis	rs3026445	0.519	rs75013764	ENSG00000278993.1	RP3-424M6.4	3.79	0.000172	0.0124	0.26	0.17	QT interval;	chr12:110290196	chr12:110501614~110503441:+
THCA	cis	rs6120849	0.95	rs6088732	ENSG00000269202.1	RP4-614O4.12	3.79	0.000172	0.0124	0.18	0.17	Protein C levels;	chr20:35156331	chr20:35201747~35203288:-
THCA	cis	rs4947019	0.609	rs2177092	ENSG00000223537.2	RP5-919F19.5	-3.79	0.000172	0.0124	-0.31	-0.17	Hematological parameters;	chr6:109365466	chr6:109487906~109506800:+
THCA	cis	rs4947019	0.609	rs2275649	ENSG00000223537.2	RP5-919F19.5	-3.79	0.000172	0.0124	-0.31	-0.17	Hematological parameters;	chr6:109370125	chr6:109487906~109506800:+
THCA	cis	rs7819412	0.775	rs4841490	ENSG00000254948.1	OR7E158P	3.79	0.000172	0.0124	0.21	0.17	Triglycerides;	chr8:11079381	chr8:11919900~11920809:-
THCA	cis	rs12493885	0.725	rs73158427	ENSG00000243069.6	ARHGEF26-AS1	-3.79	0.000172	0.0124	-0.28	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154003704	chr3:154024401~154121332:-
THCA	cis	rs11168351	0.517	rs10875754	ENSG00000258273.1	RP11-370I10.4	-3.79	0.000172	0.0124	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48333755~48333901:-
THCA	cis	rs7713065	0.531	rs2522051	ENSG00000263597.1	MIR3936	3.79	0.000172	0.0124	0.16	0.17	Lung function (FEV1/FVC);	chr5:132461886	chr5:132365490~132365599:-
THCA	cis	rs2191566	0.576	rs397683	ENSG00000277806.1	RP11-15A1.8	3.79	0.000172	0.0124	0.18	0.17	Acute lymphoblastic leukemia (childhood);	chr19:43989902	chr19:43976815~43977448:+
THCA	cis	rs6121246	0.58	rs6121016	ENSG00000224628.2	RP5-854E16.2	-3.79	0.000172	0.0124	-0.25	-0.17	Mean corpuscular hemoglobin;	chr20:31657436	chr20:31285317~31286835:-
THCA	cis	rs7829975	0.502	rs11785183	ENSG00000254153.1	CTA-398F10.2	3.79	0.000172	0.0124	0.2	0.17	Mood instability;	chr8:8708447	chr8:8456909~8461337:-
THCA	cis	rs520525	0.963	rs501680	ENSG00000271811.1	RP1-79C4.4	3.79	0.000172	0.0124	0.21	0.17	Atrial fibrillation;	chr1:170656726	chr1:170667381~170669425:+
THCA	cis	rs8177876	0.57	rs11863158	ENSG00000261838.4	RP11-303E16.6	3.79	0.000172	0.0124	0.29	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr16:81069854~81076598:+
THCA	cis	rs9425766	0.962	rs6663875	ENSG00000270084.1	GAS5-AS1	-3.79	0.000172	0.0124	-0.17	-0.17	Life satisfaction;	chr1:173894071	chr1:173863248~173863941:+
THCA	cis	rs4144027	0.935	rs8008020	ENSG00000269958.1	RP11-73M18.8	-3.79	0.000172	0.0124	-0.16	-0.17	Blood metabolite levels;	chr14:103889546	chr14:103696353~103697163:+
THCA	cis	rs478304	0.934	rs509206	ENSG00000255557.1	RP11-770G2.2	-3.79	0.000172	0.0124	-0.19	-0.17	Acne (severe);	chr11:65726336	chr11:65745729~65771585:+
THCA	cis	rs7829975	0.626	rs332040	ENSG00000253981.4	ALG1L13P	3.79	0.000172	0.0124	0.17	0.17	Mood instability;	chr8:8872978	chr8:8236003~8244667:-
THCA	cis	rs4908768	0.501	rs6577492	ENSG00000270282.1	RP5-1115A15.2	3.79	0.000172	0.0124	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8515005	chr1:8512653~8513021:+
THCA	cis	rs7166081	1	rs12898685	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000172	0.0124	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67233434	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs4776348	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000172	0.0124	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67240966	chr15:67541072~67542604:-
THCA	cis	rs4660214	0.694	rs16866216	ENSG00000228060.1	RP11-69E11.8	3.79	0.000172	0.0124	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39208916	chr1:39565160~39573203:+
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000184274.3	LINC00315	-3.79	0.000172	0.0124	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45300245~45305257:-
THCA	cis	rs17507216	0.718	rs4779033	ENSG00000255769.6	GOLGA2P10	3.79	0.000172	0.0124	0.27	0.17	Excessive daytime sleepiness;	chr15:82576634	chr15:82472993~82513950:-
THCA	cis	rs4272720	0.507	rs4128908	ENSG00000234736.4	FAM170B-AS1	-3.79	0.000172	0.0124	-0.18	-0.17	Platelet count;Plateletcrit;	chr10:49061496	chr10:49121839~49151547:+
THCA	cis	rs763121	0.889	rs1043402	ENSG00000273076.1	RP3-508I15.22	3.79	0.000172	0.0124	0.17	0.17	Menopause (age at onset);	chr22:38483683	chr22:38743495~38743910:+
THCA	cis	rs9660180	0.967	rs12034740	ENSG00000215914.4	MMP23A	-3.79	0.000172	0.0124	-0.22	-0.17	Body mass index;	chr1:1797530	chr1:1699942~1701782:+
THCA	cis	rs2408955	0.504	rs11168441	ENSG00000257735.1	RP11-370I10.6	3.79	0.000172	0.0124	0.2	0.17	Glycated hemoglobin levels;	chr12:48182271	chr12:48350945~48442411:+
THCA	cis	rs854765	0.583	rs7207395	ENSG00000281749.1	Y_RNA	3.79	0.000172	0.0124	0.22	0.17	Total body bone mineral density;	chr17:17916021	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs4341796	ENSG00000281749.1	Y_RNA	3.79	0.000172	0.0124	0.22	0.17	Total body bone mineral density;	chr17:17935710	chr17:18001101~18001195:-
THCA	cis	rs6546886	0.957	rs11885172	ENSG00000235499.1	AC073046.25	3.79	0.000172	0.0124	0.16	0.17	Dialysis-related mortality;	chr2:74029967	chr2:73985132~73986343:+
THCA	cis	rs7572644	0.766	rs10188108	ENSG00000223522.1	AC093690.1	3.79	0.000172	0.0124	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27969688	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.713	rs1458397	ENSG00000223522.1	AC093690.1	3.79	0.000172	0.0124	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27996741	chr2:28307691~28310459:-
THCA	cis	rs1577917	0.57	rs114854865	ENSG00000220563.1	PKMP3	-3.79	0.000172	0.0124	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85844518	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.916	rs4706252	ENSG00000220563.1	PKMP3	-3.79	0.000172	0.0124	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85845462	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs2324840	ENSG00000220563.1	PKMP3	-3.79	0.000172	0.0124	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85847902	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs12202188	ENSG00000220563.1	PKMP3	-3.79	0.000172	0.0124	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85852982	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs36035797	ENSG00000220563.1	PKMP3	-3.79	0.000172	0.0124	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85853162	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.917	rs2084293	ENSG00000220563.1	PKMP3	-3.79	0.000172	0.0124	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85856284	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs12209668	ENSG00000220563.1	PKMP3	-3.79	0.000172	0.0124	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85856799	chr6:85659892~85660606:-
THCA	cis	rs2880765	0.835	rs7162502	ENSG00000218052.5	ADAMTS7P4	-3.79	0.000172	0.0124	-0.2	-0.17	Coronary artery disease;	chr15:85501242	chr15:85255369~85330334:-
THCA	cis	rs11583043	0.958	rs12746722	ENSG00000233184.5	RP11-421L21.3	3.79	0.000172	0.0124	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:100999233	chr1:101025878~101087268:+
THCA	cis	rs11583043	1	rs11583043	ENSG00000233184.5	RP11-421L21.3	3.79	0.000172	0.0124	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101000498	chr1:101025878~101087268:+
THCA	cis	rs11583043	1	rs6682873	ENSG00000233184.5	RP11-421L21.3	3.79	0.000172	0.0124	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101005350	chr1:101025878~101087268:+
THCA	cis	rs11583043	1	rs7521424	ENSG00000233184.5	RP11-421L21.3	3.79	0.000172	0.0124	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101010345	chr1:101025878~101087268:+
THCA	cis	rs11583043	1	rs11584222	ENSG00000233184.5	RP11-421L21.3	3.79	0.000172	0.0124	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101014554	chr1:101025878~101087268:+
THCA	cis	rs6101567	0.517	rs2073311	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000172	0.0124	-0.21	-0.17	Nose size;	chr20:39272048	chr20:38406011~38416797:-
THCA	cis	rs934734	0.532	rs62141075	ENSG00000214533.3	KRT18P33	-3.79	0.000172	0.0125	-0.21	-0.17	Rheumatoid arthritis;	chr2:65417482	chr2:65666695~65667737:+
THCA	cis	rs1389724	0.648	rs1494316	ENSG00000259834.1	RP11-284N8.3	-3.79	0.000172	0.0125	-0.15	-0.17	Schizophrenia;	chr1:110777033	chr1:110653560~110657040:-
THCA	cis	rs4925386	0.84	rs6142738	ENSG00000275437.1	RP5-908M14.10	-3.79	0.000172	0.0125	-0.17	-0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62402236~62405935:-
THCA	cis	rs2880765	0.714	rs6497187	ENSG00000218052.5	ADAMTS7P4	-3.79	0.000172	0.0125	-0.19	-0.17	Coronary artery disease;	chr15:85468119	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.743	rs6497191	ENSG00000218052.5	ADAMTS7P4	-3.79	0.000172	0.0125	-0.19	-0.17	Coronary artery disease;	chr15:85468270	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.743	rs6416598	ENSG00000218052.5	ADAMTS7P4	-3.79	0.000172	0.0125	-0.19	-0.17	Coronary artery disease;	chr15:85468617	chr15:85255369~85330334:-
THCA	cis	rs701145	0.585	rs1713810	ENSG00000243069.6	ARHGEF26-AS1	-3.79	0.000172	0.0125	-0.3	-0.17	Coronary artery disease;	chr3:154159037	chr3:154024401~154121332:-
THCA	cis	rs11158609	0.878	rs7160883	ENSG00000278784.1	RP11-468E2.11	3.79	0.000172	0.0125	0.16	0.17	Systolic blood pressure (cigarette smoking interaction);	chr14:24204769	chr14:24201612~24202811:-
THCA	cis	rs6012953	1	rs6020572	ENSG00000231715.1	COX6CP2	3.79	0.000172	0.0125	0.19	0.17	Vitiligo;	chr20:50511703	chr20:50479767~50479991:+
THCA	cis	rs28830936	0.966	rs28451764	ENSG00000250379.1	RP11-23P13.4	3.79	0.000172	0.0125	0.2	0.17	Diastolic blood pressure;	chr15:41834385	chr15:41825099~41827936:-
THCA	cis	rs28830936	0.966	rs28373318	ENSG00000250379.1	RP11-23P13.4	3.79	0.000172	0.0125	0.2	0.17	Diastolic blood pressure;	chr15:41834527	chr15:41825099~41827936:-
THCA	cis	rs9487094	0.689	rs4636056	ENSG00000223537.2	RP5-919F19.5	-3.79	0.000172	0.0125	-0.17	-0.17	Height;	chr6:109409679	chr6:109487906~109506800:+
THCA	cis	rs2055375	0.666	rs159544	ENSG00000251279.1	CTC-436P18.1	-3.79	0.000172	0.0125	-0.22	-0.17	Intelligence (multi-trait analysis);	chr5:61193420	chr5:61162070~61232040:+
THCA	cis	rs603446	0.967	rs180346	ENSG00000254851.1	RP11-109L13.1	-3.79	0.000172	0.0125	-0.23	-0.17	Triglycerides;	chr11:116741943	chr11:117135528~117138582:+
THCA	cis	rs5758511	0.68	rs5758651	ENSG00000230107.1	CTA-126B4.7	-3.79	0.000172	0.0125	-0.21	-0.17	Birth weight;	chr22:42213142	chr22:42438023~42446195:+
THCA	cis	rs62158800	0.598	rs11123670	ENSG00000224568.1	AC096669.3	3.79	0.000172	0.0125	0.21	0.17	Facial morphology (factor 22);	chr2:107674278	chr2:107529487~107556326:+
THCA	cis	rs12480732	1	rs12480732	ENSG00000175730.8	BAK1P1	3.79	0.000172	0.0125	0.24	0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:32603213	chr20:32690180~32690815:-
THCA	cis	rs6847067	0.965	rs4529041	ENSG00000180769.7	WDFY3-AS2	3.79	0.000172	0.0125	0.12	0.17	Oropharynx cancer;	chr4:84700259	chr4:84965682~85011277:+
THCA	cis	rs9291683	0.595	rs11722930	ENSG00000261490.1	RP11-448G15.3	3.79	0.000172	0.0125	0.11	0.17	Bone mineral density;	chr4:10033830	chr4:10068089~10073019:-
THCA	cis	rs793571	0.714	rs972801	ENSG00000245975.2	RP11-30K9.6	-3.79	0.000172	0.0125	-0.16	-0.17	Schizophrenia;	chr15:58628999	chr15:58768072~58770974:-
THCA	cis	rs9467773	0.511	rs11755443	ENSG00000261353.1	CTA-14H9.5	-3.79	0.000172	0.0125	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26527063~26527404:+
THCA	cis	rs748404	0.533	rs7165861	ENSG00000166763.7	STRCP1	-3.79	0.000172	0.0125	-0.18	-0.17	Lung cancer;	chr15:43131129	chr15:43699488~43718184:-
THCA	cis	rs854765	0.654	rs11078400	ENSG00000281749.1	Y_RNA	-3.79	0.000172	0.0125	-0.21	-0.17	Total body bone mineral density;	chr17:17854414	chr17:18001101~18001195:-
THCA	cis	rs854765	0.654	rs9911281	ENSG00000281749.1	Y_RNA	-3.79	0.000172	0.0125	-0.21	-0.17	Total body bone mineral density;	chr17:17859143	chr17:18001101~18001195:-
THCA	cis	rs854765	0.693	rs4924823	ENSG00000281749.1	Y_RNA	-3.79	0.000172	0.0125	-0.21	-0.17	Total body bone mineral density;	chr17:17861188	chr17:18001101~18001195:-
THCA	cis	rs60180747	1	rs79065844	ENSG00000261318.1	RP11-653J6.1	3.79	0.000172	0.0125	0.23	0.17	Testicular germ cell tumor;	chr15:66397773	chr15:66278498~66293357:-
THCA	cis	rs2574985	0.548	rs12356922	ENSG00000279863.1	RP11-521C22.2	3.79	0.000172	0.0125	0.19	0.17	Subjective well-being;	chr10:50453610	chr10:50334538~50336123:+
THCA	cis	rs9990333	0.687	rs62285383	ENSG00000231464.1	AC024937.4	3.79	0.000172	0.0125	0.21	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196087052	chr3:195996738~195998233:+
THCA	cis	rs7520050	0.931	rs11211189	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs12411269	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs11211198	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs10890352	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6700597	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6695809	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs11211199	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs4376778	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6672898	ENSG00000281133.1	AL355480.3	3.79	0.000172	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45580892~45580996:-
THCA	cis	rs9611565	0.659	rs12483998	ENSG00000237037.8	NDUFA6-AS1	3.79	0.000172	0.0125	0.16	0.17	Vitiligo;	chr22:41539358	chr22:42090931~42137742:+
THCA	cis	rs2574985	0.586	rs1569963	ENSG00000279863.1	RP11-521C22.2	3.79	0.000172	0.0125	0.19	0.17	Subjective well-being;	chr10:50496623	chr10:50334538~50336123:+
THCA	cis	rs11681884	0.786	rs17042750	ENSG00000272563.1	RP11-480C16.1	-3.79	0.000172	0.0125	-0.38	-0.17	Stroke;	chr2:113065574	chr2:113432600~113436042:+
THCA	cis	rs4906332	1	rs3783397	ENSG00000259775.1	RP11-45P15.4	-3.79	0.000172	0.0125	-0.15	-0.17	Coronary artery disease;	chr14:103480952	chr14:103331674~103332367:-
THCA	cis	rs4699052	1	rs7661702	ENSG00000246560.2	RP11-10L12.4	3.79	0.000172	0.0125	0.2	0.17	Testicular germ cell tumor;	chr4:103218972	chr4:102828055~102844075:+
THCA	cis	rs4699052	0.928	rs2126473	ENSG00000246560.2	RP11-10L12.4	3.79	0.000172	0.0125	0.2	0.17	Testicular germ cell tumor;	chr4:103220376	chr4:102828055~102844075:+
THCA	cis	rs755249	0.508	rs12023553	ENSG00000228060.1	RP11-69E11.8	3.79	0.000172	0.0125	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39205820	chr1:39565160~39573203:+
THCA	cis	rs875971	0.545	rs75577046	ENSG00000232559.3	GS1-124K5.12	3.79	0.000172	0.0125	0.19	0.17	Aortic root size;	chr7:66493729	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs3735147	ENSG00000232559.3	GS1-124K5.12	3.79	0.000172	0.0125	0.19	0.17	Aortic root size;	chr7:66505541	chr7:66554588~66576923:-
THCA	cis	rs1124769	0.654	rs28591334	ENSG00000259378.1	DCAF13P3	3.79	0.000172	0.0125	0.26	0.17	Cognitive performance;	chr15:51187393	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.654	rs12904291	ENSG00000259378.1	DCAF13P3	3.79	0.000172	0.0125	0.26	0.17	Cognitive performance;	chr15:51187708	chr15:50944663~50945996:+
THCA	cis	rs1510272	0.921	rs2202965	ENSG00000243926.1	TIPARP-AS1	-3.79	0.000172	0.0125	-0.18	-0.17	Testicular germ cell tumor;	chr3:156568927	chr3:156671862~156674378:-
THCA	cis	rs3935996	0.965	rs4540693	ENSG00000233147.1	RP11-90C4.1	-3.79	0.000172	0.0125	-0.15	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55860284	chr1:55823807~55868248:+
THCA	cis	rs9309473	0.615	rs74523560	ENSG00000273245.1	RP11-434P11.2	3.79	0.000172	0.0125	0.28	0.17	Metabolite levels;	chr2:73537058	chr2:73750256~73750786:-
THCA	cis	rs7216064	0.954	rs9907491	ENSG00000278740.1	RP11-147L13.14	-3.79	0.000172	0.0125	-0.19	-0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67953877	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.954	rs4790974	ENSG00000278740.1	RP11-147L13.14	-3.79	0.000172	0.0125	-0.19	-0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67954991	chr17:68188547~68189165:+
THCA	cis	rs6733301	0.529	rs56784950	ENSG00000224165.4	DNAJC27-AS1	3.79	0.000172	0.0125	0.12	0.17	Height;	chr2:24970039	chr2:24971390~25039694:+
THCA	cis	rs7212590	0.618	rs35806089	ENSG00000267302.4	RP11-178C3.2	3.79	0.000172	0.0125	0.32	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59866545	chr17:59964832~59996972:+
THCA	cis	rs2898290	0.622	rs978803	ENSG00000206014.6	OR7E161P	-3.79	0.000172	0.0125	-0.21	-0.17	Systolic blood pressure;	chr8:11485966	chr8:11928597~11929563:-
THCA	cis	rs875971	0.706	rs1643374	ENSG00000223473.2	GS1-124K5.3	3.79	0.000173	0.0125	0.11	0.17	Aortic root size;	chr7:66407695	chr7:66491049~66493566:-
THCA	cis	rs5015933	0.801	rs11999662	ENSG00000232630.1	PRPS1P2	-3.79	0.000173	0.0125	-0.12	-0.17	Body mass index;	chr9:125381649	chr9:125150653~125151589:+
THCA	cis	rs11658311	1	rs8074981	ENSG00000232344.2	AC087163.2	3.79	0.000173	0.0125	0.22	0.17	Obsessive-compulsive symptoms;	chr17:17631540	chr17:18010643~18011822:+
THCA	cis	rs11658311	1	rs56177028	ENSG00000232344.2	AC087163.2	3.79	0.000173	0.0125	0.22	0.17	Obsessive-compulsive symptoms;	chr17:17631675	chr17:18010643~18011822:+
THCA	cis	rs11658311	1	rs57638011	ENSG00000232344.2	AC087163.2	3.79	0.000173	0.0125	0.22	0.17	Obsessive-compulsive symptoms;	chr17:17631963	chr17:18010643~18011822:+
THCA	cis	rs11658311	1	rs28715719	ENSG00000232344.2	AC087163.2	3.79	0.000173	0.0125	0.22	0.17	Obsessive-compulsive symptoms;	chr17:17632122	chr17:18010643~18011822:+
THCA	cis	rs4713118	0.869	rs6914924	ENSG00000261839.1	RP1-265C24.8	3.79	0.000173	0.0125	0.19	0.17	Parkinson's disease;	chr6:27743751	chr6:28136849~28139678:+
THCA	cis	rs5758511	0.68	rs5758686	ENSG00000270083.1	RP1-257I20.14	-3.79	0.000173	0.0125	-0.23	-0.17	Birth weight;	chr22:42259371	chr22:42089630~42090028:-
THCA	cis	rs9291683	0.609	rs12500810	ENSG00000261490.1	RP11-448G15.3	3.79	0.000173	0.0125	0.11	0.17	Bone mineral density;	chr4:10029444	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.525	rs12506455	ENSG00000261490.1	RP11-448G15.3	3.79	0.000173	0.0125	0.11	0.17	Bone mineral density;	chr4:10029945	chr4:10068089~10073019:-
THCA	cis	rs5769765	0.817	rs8142561	ENSG00000260613.1	RP3-522J7.6	-3.79	0.000173	0.0125	-0.21	-0.17	Schizophrenia;	chr22:49898102	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.955	rs8138687	ENSG00000260613.1	RP3-522J7.6	-3.79	0.000173	0.0125	-0.21	-0.17	Schizophrenia;	chr22:49898221	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.955	rs8135816	ENSG00000260613.1	RP3-522J7.6	-3.79	0.000173	0.0125	-0.21	-0.17	Schizophrenia;	chr22:49898328	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.818	rs8140681	ENSG00000260613.1	RP3-522J7.6	-3.79	0.000173	0.0125	-0.21	-0.17	Schizophrenia;	chr22:49898433	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.825	rs9616780	ENSG00000260613.1	RP3-522J7.6	-3.79	0.000173	0.0125	-0.21	-0.17	Schizophrenia;	chr22:49899115	chr22:49832616~49837786:-
THCA	cis	rs875971	0.545	rs1547529	ENSG00000273024.4	INTS4P2	-3.79	0.000173	0.0125	-0.21	-0.17	Aortic root size;	chr7:66258859	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000273024.4	INTS4P2	-3.79	0.000173	0.0125	-0.21	-0.17	Aortic root size;	chr7:66283366	chr7:65647864~65715661:+
THCA	cis	rs853679	0.607	rs13211507	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28289600	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34691223	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28290431	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13207345	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28297795	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs72854513	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28298177	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs56189111	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28304196	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34950484	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28310911	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs35072899	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28313764	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34661125	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28314117	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13190888	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28318208	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs56075693	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28322551	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34218844	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000173	0.0125	-0.33	-0.17	Depression;	chr6:28322870	chr6:28078792~28081130:-
THCA	cis	rs7520050	0.933	rs6680211	ENSG00000281133.1	AL355480.3	3.79	0.000173	0.0125	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45580892~45580996:-
THCA	cis	rs765787	0.53	rs2668737	ENSG00000259539.1	CTD-2651B20.1	3.79	0.000173	0.0125	0.21	0.17	Uric acid levels;	chr15:45230601	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs1706764	ENSG00000259539.1	CTD-2651B20.1	3.79	0.000173	0.0125	0.21	0.17	Uric acid levels;	chr15:45232058	chr15:45152664~45167526:-
THCA	cis	rs12681366	0.708	rs2445699	ENSG00000261437.1	RP11-22C11.2	-3.79	0.000173	0.0125	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94334289	chr8:94637285~94639467:-
THCA	cis	rs4763879	0.778	rs2895989	ENSG00000214776.8	RP11-726G1.1	-3.79	0.000173	0.0125	-0.21	-0.17	Type 1 diabetes;	chr12:9688735	chr12:9467552~9576275:+
THCA	cis	rs6500602	0.929	rs6500603	ENSG00000280063.1	RP11-295D4.3	3.79	0.000173	0.0125	0.09	0.17	Schizophrenia;	chr16:4447536	chr16:4346694~4348648:-
THCA	cis	rs1555322	1	rs2425041	ENSG00000126005.14	MMP24-AS1	-3.79	0.000173	0.0125	-0.25	-0.17	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35216462~35278131:-
THCA	cis	rs6787172	0.622	rs12636560	ENSG00000272087.1	RP11-379F4.7	3.79	0.000173	0.0125	0.16	0.17	Subjective well-being;	chr3:158453665	chr3:158693120~158693768:-
THCA	cis	rs7819412	0.617	rs10087081	ENSG00000255310.2	AF131215.2	-3.79	0.000173	0.0125	-0.16	-0.17	Triglycerides;	chr8:11117407	chr8:11107788~11109726:-
THCA	cis	rs6487679	0.543	rs7956661	ENSG00000111788.10	RP11-22B23.1	3.79	0.000173	0.0125	0.28	0.17	Non-alcoholic fatty liver disease histology (AST);	chr12:9201988	chr12:9277235~9313241:+
THCA	cis	rs13053817	1	rs13053758	ENSG00000279159.1	RP3-394A18.1	3.79	0.000173	0.0125	0.17	0.17	Carotid atherosclerosis in HIV infection;	chr22:29459500	chr22:29978950~30028236:-
THCA	cis	rs3824488	0.92	rs75614054	ENSG00000237857.2	RP11-435O5.2	-3.79	0.000173	0.0125	-0.34	-0.17	Neuroticism;	chr9:95513507	chr9:95414834~95426796:-
THCA	cis	rs12286929	0.59	rs4936322	ENSG00000255580.1	AP000462.2	3.79	0.000173	0.0125	0.16	0.17	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;	chr11:115190813	chr11:115363629~115377931:+
THCA	cis	rs61160187	0.582	rs12652830	ENSG00000272308.1	RP11-231G3.1	-3.79	0.000173	0.0125	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60866457~60866935:-
THCA	cis	rs9911578	0.967	rs7502208	ENSG00000224738.1	AC099850.1	3.79	0.000173	0.0125	0.2	0.17	Intelligence (multi-trait analysis);	chr17:59087736	chr17:59106598~59118267:+
THCA	cis	rs6570726	0.935	rs453609	ENSG00000270638.1	RP3-466P17.1	3.79	0.000173	0.0125	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145735570~145737218:+
THCA	cis	rs944289	0.589	rs63360860	ENSG00000258844.1	RP11-259K15.2	-3.79	0.000173	0.0125	-0.16	-0.17	Thyroid cancer;	chr14:36068846	chr14:36214607~36235608:+
THCA	cis	rs9467773	0.534	rs34453863	ENSG00000228223.2	HCG11	-3.79	0.000173	0.0125	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26523450~26526579:+
THCA	cis	rs2153535	0.518	rs9328473	ENSG00000230939.1	RP11-314C16.1	-3.79	0.000173	0.0125	-0.19	-0.17	Motion sickness;	chr6:8487092	chr6:8784178~8785445:+
THCA	cis	rs7542375	0.655	rs55703860	ENSG00000238078.1	LINC01352	-3.79	0.000173	0.0125	-0.24	-0.17	Obesity-related traits;	chr1:220907797	chr1:220829255~220832429:+
THCA	cis	rs858239	1	rs199347	ENSG00000230042.1	AK3P3	-3.79	0.000173	0.0125	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23129178~23129841:+
THCA	cis	rs7551222	0.752	rs35270244	ENSG00000240219.1	RP11-430C7.5	3.79	0.000173	0.0125	0.16	0.17	Schizophrenia;	chr1:204579288	chr1:204626775~204629712:+
THCA	cis	rs2688608	0.618	rs28553894	ENSG00000272140.2	RP11-574K11.29	3.79	0.000173	0.0125	0.15	0.17	Inflammatory bowel disease;	chr10:73730085	chr10:73703735~73713581:-
THCA	cis	rs2688608	0.618	rs28718766	ENSG00000272140.2	RP11-574K11.29	3.79	0.000173	0.0125	0.15	0.17	Inflammatory bowel disease;	chr10:73730086	chr10:73703735~73713581:-
THCA	cis	rs16975963	0.843	rs241954	ENSG00000276846.1	CTD-3220F14.3	-3.79	0.000173	0.0125	-0.16	-0.17	Longevity;	chr19:37786890	chr19:37314868~37315620:-
THCA	cis	rs7737355	1	rs12517604	ENSG00000237714.1	P4HA2-AS1	-3.79	0.000173	0.0125	-0.25	-0.17	Life satisfaction;	chr5:131412807	chr5:132184876~132192808:+
THCA	cis	rs2180341	0.68	rs9388554	ENSG00000220522.2	RP1-177A13.1	3.79	0.000173	0.0125	0.21	0.17	Breast cancer;	chr6:127255089	chr6:127416535~127416952:-
THCA	cis	rs853679	1	rs7740487	ENSG00000273712.1	RP5-874C20.7	3.79	0.000173	0.0125	0.28	0.17	Depression;	chr6:28248708	chr6:28315613~28315883:-
THCA	cis	rs853679	1	rs68141011	ENSG00000273712.1	RP5-874C20.7	3.79	0.000173	0.0125	0.28	0.17	Depression;	chr6:28250019	chr6:28315613~28315883:-
THCA	cis	rs853679	1	rs13200462	ENSG00000273712.1	RP5-874C20.7	3.79	0.000173	0.0125	0.28	0.17	Depression;	chr6:28250421	chr6:28315613~28315883:-
THCA	cis	rs11105298	0.891	rs11105313	ENSG00000266347.2	AC068641.1	-3.79	0.000173	0.0125	-0.22	-0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89592833~89592927:+
THCA	cis	rs7759001	0.744	rs2893917	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27462962	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.711	rs10807025	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27464049	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs4358616	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27465069	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs13201443	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27465634	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs13201965	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27465816	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs6920408	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27466441	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs6920733	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27466608	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs6921071	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27466663	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs4713104	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27467000	chr6:27404010~27406964:-
THCA	cis	rs7759001	0.744	rs2272814	ENSG00000271755.1	RP1-153G14.4	3.79	0.000173	0.0125	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27467928	chr6:27404010~27406964:-
THCA	cis	rs7914558	1	rs7071373	ENSG00000213061.2	PFN1P11	3.79	0.000173	0.0125	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103012165	chr10:102838011~102845473:-
THCA	cis	rs7259376	0.704	rs1897613	ENSG00000269345.1	VN1R85P	3.79	0.000173	0.0125	0.19	0.17	Menopause (age at onset);	chr19:22390773	chr19:22174766~22175191:-
THCA	cis	rs343604	1	rs343604	ENSG00000232811.1	RP11-96K19.2	-3.79	0.000173	0.0125	-0.33	-0.17	Acute lymphoblastic leukemia (childhood);	chr1:110716148	chr1:110943467~110952848:+
THCA	cis	rs2360027	0.965	rs2798444	ENSG00000231365.4	RP11-418J17.1	3.79	0.000173	0.0125	0.16	0.17	Tonsillectomy;	chr1:118586619	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.965	rs2798445	ENSG00000231365.4	RP11-418J17.1	3.79	0.000173	0.0125	0.16	0.17	Tonsillectomy;	chr1:118587191	chr1:119140396~119275973:+
THCA	cis	rs10411195	0.661	rs61692909	ENSG00000267419.1	CTC-559E9.6	-3.79	0.000173	0.0125	-0.3	-0.17	Smoking behavior;	chr19:19858880	chr19:19776602~19834927:+
THCA	cis	rs12476592	0.602	rs989527	ENSG00000242412.1	DBIL5P2	3.79	0.000173	0.0125	0.22	0.17	Childhood ear infection;	chr2:63499657	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs1867849	ENSG00000242412.1	DBIL5P2	3.79	0.000173	0.0125	0.22	0.17	Childhood ear infection;	chr2:63499798	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.571	rs1446565	ENSG00000242412.1	DBIL5P2	3.79	0.000173	0.0125	0.22	0.17	Childhood ear infection;	chr2:63504441	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs1446564	ENSG00000242412.1	DBIL5P2	3.79	0.000173	0.0125	0.22	0.17	Childhood ear infection;	chr2:63504548	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs10865338	ENSG00000242412.1	DBIL5P2	3.79	0.000173	0.0125	0.22	0.17	Childhood ear infection;	chr2:63505375	chr2:63117851~63119542:-
THCA	cis	rs9693857	0.52	rs7814570	ENSG00000248538.5	RP11-10A14.5	-3.79	0.000173	0.0125	-0.23	-0.17	Systolic blood pressure;	chr8:9508802	chr8:9189011~9202854:+
THCA	cis	rs6545883	0.54	rs11687956	ENSG00000270820.4	RP11-355B11.2	-3.79	0.000173	0.0125	-0.14	-0.17	Tuberculosis;	chr2:61624207	chr2:61471188~61484130:+
THCA	cis	rs9911578	1	rs654778	ENSG00000224738.1	AC099850.1	3.79	0.000173	0.0125	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58659112	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs368186	ENSG00000224738.1	AC099850.1	3.79	0.000173	0.0125	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58659298	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs2643124	ENSG00000224738.1	AC099850.1	3.79	0.000173	0.0125	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58664311	chr17:59106598~59118267:+
THCA	cis	rs9925964	0.933	rs749671	ENSG00000279196.1	RP11-1072A3.3	-3.79	0.000173	0.0125	-0.17	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077026	chr16:30984630~30988270:-
THCA	cis	rs9467773	0.595	rs13207371	ENSG00000228223.2	HCG11	-3.79	0.000173	0.0125	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26523450~26526579:+
THCA	cis	rs804280	0.662	rs11250164	ENSG00000270154.1	RP11-419I17.1	-3.79	0.000173	0.0125	-0.23	-0.17	Myopia (pathological);	chr8:11753177	chr8:12476462~12477122:+
THCA	cis	rs2688608	0.672	rs2633321	ENSG00000271816.1	BMS1P4	3.79	0.000173	0.0125	0.17	0.17	Inflammatory bowel disease;	chr10:73933937	chr10:73699151~73730487:-
THCA	cis	rs7777677	0.925	rs4726540	ENSG00000211750.2	TRBV24-1	-3.79	0.000173	0.0125	-0.18	-0.17	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142656701~142657213:+
THCA	cis	rs73230612	0.929	rs114072304	ENSG00000242767.1	ZBTB20-AS4	3.79	0.000173	0.0125	0.23	0.17	Type 2 diabetes;	chr3:115184885	chr3:115100423~115103061:+
THCA	cis	rs7122539	0.576	rs3741194	ENSG00000275484.1	CTC-1337H24.4	-3.79	0.000173	0.0125	-0.15	-0.17	HIV-1 susceptibility;	chr11:66858763	chr11:67374416~67374932:+
THCA	cis	rs1005277	0.522	rs7090858	ENSG00000120555.12	SEPT7P9	-3.79	0.000173	0.0125	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38383069~38402916:-
THCA	cis	rs459571	0.916	rs467303	ENSG00000235106.7	LINC00094	3.79	0.000173	0.0125	0.15	0.17	Platelet distribution width;	chr9:134039713	chr9:134025439~134034666:+
THCA	cis	rs9844666	0.512	rs870812	ENSG00000273486.1	RP11-731C17.2	3.79	0.000173	0.0125	0.16	0.17	Height;	chr3:135928225	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs908825	ENSG00000273486.1	RP11-731C17.2	3.79	0.000173	0.0125	0.16	0.17	Height;	chr3:135928695	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs1568350	ENSG00000273486.1	RP11-731C17.2	3.79	0.000173	0.0125	0.16	0.17	Height;	chr3:135929843	chr3:136837338~136839021:-
THCA	cis	rs9291683	0.588	rs35438220	ENSG00000250413.1	RP11-448G15.1	-3.79	0.000173	0.0125	-0.16	-0.17	Bone mineral density;	chr4:9997774	chr4:10006482~10009725:+
THCA	cis	rs708224	0.513	rs2594000	ENSG00000277342.1	RP11-843B15.4	3.79	0.000173	0.0125	0.23	0.17	Pancreatic cancer;	chr12:32285786	chr12:32109076~32109602:+
THCA	cis	rs7737355	1	rs27708	ENSG00000237714.1	P4HA2-AS1	-3.79	0.000173	0.0125	-0.24	-0.17	Life satisfaction;	chr5:131407848	chr5:132184876~132192808:+
THCA	cis	rs972578	0.837	rs5758957	ENSG00000230319.1	AL022476.2	3.79	0.000173	0.0125	0.18	0.17	Mean platelet volume;	chr22:42822457	chr22:43038585~43052366:+
THCA	cis	rs16975963	0.644	rs73033117	ENSG00000276846.1	CTD-3220F14.3	-3.79	0.000173	0.0125	-0.16	-0.17	Longevity;	chr19:37582245	chr19:37314868~37315620:-
THCA	cis	rs2446066	0.872	rs10876455	ENSG00000257379.1	RP11-793H13.8	3.79	0.000173	0.0125	0.26	0.17	Red blood cell count;	chr12:53431541	chr12:53441741~53467528:+
THCA	cis	rs4919087	0.748	rs11189131	ENSG00000237169.1	RP11-452K12.3	3.79	0.000173	0.0125	0.22	0.17	Monocyte count;	chr10:97326078	chr10:97309138~97309958:-
THCA	cis	rs7824557	0.843	rs2736375	ENSG00000255310.2	AF131215.2	-3.79	0.000173	0.0125	-0.14	-0.17	Retinal vascular caliber;	chr8:11258240	chr8:11107788~11109726:-
THCA	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	3.79	0.000173	0.0125	0.19	0.17	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	3.79	0.000173	0.0125	0.19	0.17	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	3.79	0.000173	0.0125	0.19	0.17	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
THCA	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	3.79	0.000173	0.0125	0.19	0.17	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
THCA	cis	rs12410462	1	rs12410243	ENSG00000227711.2	RP11-275O4.5	-3.79	0.000173	0.0125	-0.27	-0.17	Major depressive disorder;	chr1:227481773	chr1:227509028~227520477:-
THCA	cis	rs214785	1	rs214790	ENSG00000226644.4	RP11-128M1.1	3.79	0.000173	0.0125	0.17	0.17	Basal cell carcinoma;	chr20:2304260	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214791	ENSG00000226644.4	RP11-128M1.1	3.79	0.000173	0.0125	0.17	0.17	Basal cell carcinoma;	chr20:2304328	chr20:2207217~2213151:+
THCA	cis	rs214785	1	rs214792	ENSG00000226644.4	RP11-128M1.1	3.79	0.000173	0.0125	0.17	0.17	Basal cell carcinoma;	chr20:2304389	chr20:2207217~2213151:+
THCA	cis	rs214785	0.932	rs214793	ENSG00000226644.4	RP11-128M1.1	3.79	0.000173	0.0125	0.17	0.17	Basal cell carcinoma;	chr20:2305059	chr20:2207217~2213151:+
THCA	cis	rs214785	0.932	rs214795	ENSG00000226644.4	RP11-128M1.1	3.79	0.000173	0.0125	0.17	0.17	Basal cell carcinoma;	chr20:2305545	chr20:2207217~2213151:+
THCA	cis	rs654950	0.875	rs687766	ENSG00000230638.4	RP11-486B10.4	-3.79	0.000173	0.0125	-0.19	-0.17	Airway imaging phenotypes;	chr1:41533178	chr1:41542069~41544310:+
THCA	cis	rs654950	0.875	rs687835	ENSG00000230638.4	RP11-486B10.4	-3.79	0.000173	0.0125	-0.19	-0.17	Airway imaging phenotypes;	chr1:41533233	chr1:41542069~41544310:+
THCA	cis	rs11061269	1	rs11061268	ENSG00000280002.1	RP11-76C10.6	-3.79	0.000173	0.0125	-0.35	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr12:130971887	chr12:130988312~130990028:-
THCA	cis	rs4699052	1	rs4699055	ENSG00000246560.2	RP11-10L12.4	3.79	0.000173	0.0125	0.2	0.17	Testicular germ cell tumor;	chr4:103233343	chr4:102828055~102844075:+
THCA	cis	rs295490	0.667	rs79661321	ENSG00000272656.1	RP11-219D15.3	3.79	0.000173	0.0125	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139434762	chr3:139349024~139349371:-
THCA	cis	rs343829	1	rs343829	ENSG00000268333.1	RP4-806M20.3	3.79	0.000173	0.0125	0.43	0.17	Platelet distribution width;	chr20:58978449	chr20:58833809~58836529:-
THCA	cis	rs1039766	1	rs7558347	ENSG00000204929.10	AC074391.1	3.79	0.000173	0.0125	0.28	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65245666	chr2:65436711~66084639:+
THCA	cis	rs1005277	0.522	rs9418276	ENSG00000275858.1	RP11-291L22.8	3.79	0.000173	0.0125	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38450738~38451069:-
THCA	cis	rs1005277	0.522	rs7072977	ENSG00000275858.1	RP11-291L22.8	3.79	0.000173	0.0125	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38450738~38451069:-
THCA	cis	rs67478160	0.643	rs6575999	ENSG00000258534.1	CTD-2134A5.4	-3.79	0.000173	0.0125	-0.17	-0.17	Schizophrenia;	chr14:103784272	chr14:103854366~103880111:-
THCA	cis	rs10083777	0.551	rs111889995	ENSG00000261838.4	RP11-303E16.6	3.79	0.000173	0.0125	0.39	0.17	Metabolite levels (small molecules and protein measures);	chr16:81000166	chr16:81069854~81076598:+
THCA	cis	rs6901004	0.803	rs9400470	ENSG00000271789.1	RP5-1112D6.7	-3.79	0.000173	0.0125	-0.16	-0.17	Blood metabolite levels;	chr6:111156928	chr6:111297126~111298510:+
THCA	cis	rs17695224	0.5	rs4801897	ENSG00000275055.1	CTC-471J1.11	-3.79	0.000173	0.0125	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51831942	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.5	rs4802876	ENSG00000275055.1	CTC-471J1.11	-3.79	0.000173	0.0125	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51831964	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.5	rs4802877	ENSG00000275055.1	CTC-471J1.11	-3.79	0.000173	0.0125	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51831991	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.52	rs4801898	ENSG00000275055.1	CTC-471J1.11	-3.79	0.000173	0.0125	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51832064	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.545	rs17761960	ENSG00000275055.1	CTC-471J1.11	-3.79	0.000173	0.0125	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51832275	chr19:52049007~52049754:+
THCA	cis	rs295490	0.748	rs78103472	ENSG00000272656.1	RP11-219D15.3	3.79	0.000174	0.0125	0.34	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139433304	chr3:139349024~139349371:-
THCA	cis	rs9291683	0.595	rs13145442	ENSG00000261490.1	RP11-448G15.3	3.79	0.000174	0.0125	0.11	0.17	Bone mineral density;	chr4:10035637	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.595	rs11731110	ENSG00000261490.1	RP11-448G15.3	3.79	0.000174	0.0125	0.11	0.17	Bone mineral density;	chr4:10035722	chr4:10068089~10073019:-
THCA	cis	rs959260	0.688	rs9894206	ENSG00000263843.1	RP11-649A18.12	3.79	0.000174	0.0125	0.19	0.17	Systemic lupus erythematosus;	chr17:75364073	chr17:75271369~75273895:+
THCA	cis	rs150992	0.711	rs1069182	ENSG00000246763.5	RGMB-AS1	-3.79	0.000174	0.0125	-0.18	-0.17	Body mass index;	chr5:98806512	chr5:98769618~98773469:-
THCA	cis	rs150992	0.673	rs992773	ENSG00000246763.5	RGMB-AS1	-3.79	0.000174	0.0125	-0.18	-0.17	Body mass index;	chr5:98808169	chr5:98769618~98773469:-
THCA	cis	rs6504622	0.577	rs197925	ENSG00000263142.4	LRRC37A17P	3.79	0.000174	0.0125	0.12	0.17	Orofacial clefts;	chr17:46933355	chr17:46978481~47054569:+
THCA	cis	rs5758659	0.714	rs2413668	ENSG00000205702.9	CYP2D7	-3.79	0.000174	0.0125	-0.13	-0.17	Cognitive function;	chr22:42109837	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.657	rs5758587	ENSG00000205702.9	CYP2D7	-3.79	0.000174	0.0125	-0.13	-0.17	Cognitive function;	chr22:42121632	chr22:42140203~42144577:-
THCA	cis	rs7940646	0.812	rs10840453	ENSG00000254554.1	RP11-351I24.1	3.79	0.000174	0.0125	0.22	0.17	Platelet aggregation;	chr11:10643354	chr11:10302657~10303704:-
THCA	cis	rs9660180	1	rs9660180	ENSG00000215914.4	MMP23A	-3.79	0.000174	0.0126	-0.22	-0.17	Body mass index;	chr1:1791592	chr1:1699942~1701782:+
THCA	cis	rs57709857	0.794	rs56322953	ENSG00000272092.1	RP11-350N15.5	-3.79	0.000174	0.0126	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38385709	chr8:38382364~38383461:+
THCA	cis	rs1864585	0.52	rs17776946	ENSG00000280294.1	RP11-177H2.1	3.78	0.000174	0.0126	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10825164	chr8:10856085~10859436:-
THCA	cis	rs4578769	0.531	rs9951973	ENSG00000273232.1	RP11-370A5.2	-3.78	0.000174	0.0126	-0.24	-0.17	Eosinophil percentage of white cells;	chr18:22974353	chr18:22882825~22883357:-
THCA	cis	rs10421328	0.717	rs2288865	ENSG00000271283.1	CTC-412M14.6	3.78	0.000174	0.0126	0.25	0.17	Parental longevity (combined parental age at death);	chr19:19652826	chr19:19699203~19699409:-
THCA	cis	rs2562456	0.833	rs1932087	ENSG00000268278.1	RP11-420K14.1	3.78	0.000174	0.0126	0.25	0.17	Pain;	chr19:21338625	chr19:21637974~21656300:+
THCA	cis	rs7829975	0.846	rs11779061	ENSG00000254340.1	RP11-10A14.3	-3.78	0.000174	0.0126	-0.19	-0.17	Mood instability;	chr8:8691922	chr8:9141424~9145435:+
THCA	cis	rs7973719	0.899	rs12424618	ENSG00000205885.6	C1RL-AS1	3.78	0.000174	0.0126	0.13	0.17	IgG glycosylation;	chr12:7192206	chr12:7108052~7122501:+
THCA	cis	rs7264396	0.832	rs224381	ENSG00000088340.14	FER1L4	3.78	0.000174	0.0126	0.16	0.17	Total cholesterol levels;	chr20:35509307	chr20:35558737~35607562:-
THCA	cis	rs13108904	0.87	rs3733338	ENSG00000254094.1	AC078852.1	-3.78	0.000174	0.0126	-0.2	-0.17	Obesity-related traits;	chr4:1247684	chr4:1356581~1358075:+
THCA	cis	rs7554547	0.69	rs4314892	ENSG00000199347.1	RNU5E-1	-3.78	0.000174	0.0126	-0.24	-0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11889780	chr1:11908152~11908271:+
THCA	cis	rs13437751	0.881	rs1877650	ENSG00000223558.1	TRIM60P17	3.78	0.000174	0.0126	0.38	0.17	QT interval (drug interaction);	chr7:63927975	chr7:64085560~64086576:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000232559.3	GS1-124K5.12	3.78	0.000174	0.0126	0.19	0.17	Aortic root size;	chr7:66376216	chr7:66554588~66576923:-
THCA	cis	rs987724	0.515	rs9870137	ENSG00000243926.1	TIPARP-AS1	3.78	0.000174	0.0126	0.21	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898867	chr3:156671862~156674378:-
THCA	cis	rs17270561	0.636	rs2070642	ENSG00000272462.2	U91328.19	-3.78	0.000174	0.0126	-0.14	-0.17	Iron status biomarkers;	chr6:25830984	chr6:25992662~26001775:+
THCA	cis	rs4915077	0.773	rs17019845	ENSG00000230489.1	VAV3-AS1	3.78	0.000174	0.0126	0.29	0.17	Hypothyroidism;	chr1:107731203	chr1:107964443~107994607:+
THCA	cis	rs4915077	0.773	rs17019846	ENSG00000230489.1	VAV3-AS1	3.78	0.000174	0.0126	0.29	0.17	Hypothyroidism;	chr1:107732010	chr1:107964443~107994607:+
THCA	cis	rs795484	0.963	rs795475	ENSG00000275409.1	RP11-131L12.4	-3.78	0.000174	0.0126	-0.14	-0.17	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118159851	chr12:118430147~118430699:+
THCA	cis	rs12681366	0.592	rs2450556	ENSG00000261437.1	RP11-22C11.2	-3.78	0.000174	0.0126	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94318104	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.592	rs2445728	ENSG00000261437.1	RP11-22C11.2	-3.78	0.000174	0.0126	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94318458	chr8:94637285~94639467:-
THCA	cis	rs4268898	0.722	rs35520052	ENSG00000242628.4	AC009228.1	-3.78	0.000174	0.0126	-0.21	-0.17	Asthma;	chr2:24192408	chr2:24214381~24221516:+
THCA	cis	rs7658584	0.562	rs1580353	ENSG00000246375.2	RP11-10L7.1	3.78	0.000174	0.0126	0.27	0.17	Squamous cell lung carcinoma;	chr4:88184764	chr4:88284942~88331421:+
THCA	cis	rs2380205	0.689	rs12359234	ENSG00000232807.2	RP11-536K7.3	-3.78	0.000174	0.0126	-0.16	-0.17	Breast cancer;	chr10:5860748	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.517	rs7067928	ENSG00000232807.2	RP11-536K7.3	3.78	0.000174	0.0126	0.18	0.17	Breast cancer;	chr10:5910891	chr10:5934270~5945900:-
THCA	cis	rs2522056	0.808	rs1016988	ENSG00000263597.1	MIR3936	-3.78	0.000174	0.0126	-0.19	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132408882	chr5:132365490~132365599:-
THCA	cis	rs1580019	0.587	rs7806113	ENSG00000273014.1	RP11-225B17.2	3.78	0.000174	0.0126	0.18	0.17	Cognitive ability;	chr7:32513472	chr7:32758882~32759353:+
THCA	cis	rs8099594	0.524	rs12961466	ENSG00000266696.1	RP11-30L3.2	3.78	0.000174	0.0126	0.22	0.17	Height;	chr18:49212792	chr18:49205912~49208781:+
THCA	cis	rs7264396	0.943	rs224395	ENSG00000088340.14	FER1L4	3.78	0.000174	0.0126	0.16	0.17	Total cholesterol levels;	chr20:35521599	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.943	rs1810742	ENSG00000088340.14	FER1L4	3.78	0.000174	0.0126	0.16	0.17	Total cholesterol levels;	chr20:35521890	chr20:35558737~35607562:-
THCA	cis	rs1003719	0.591	rs9636914	ENSG00000270116.1	AP001429.1	-3.78	0.000174	0.0126	-0.2	-0.17	Eye color traits;	chr21:37217431	chr21:37100814~37101343:+
THCA	cis	rs17092148	1	rs60789653	ENSG00000276073.1	RP5-1125A11.7	3.78	0.000174	0.0126	0.2	0.17	Neuroticism;	chr20:34859359	chr20:33985617~33988989:-
THCA	cis	rs910873	0.505	rs67260051	ENSG00000276073.1	RP5-1125A11.7	3.78	0.000174	0.0126	0.2	0.17	Melanoma;	chr20:34860614	chr20:33985617~33988989:-
THCA	cis	rs1950832	0.723	rs1447579	ENSG00000258636.1	CTD-2298J14.2	-3.78	0.000174	0.0126	-0.23	-0.17	Urate levels in obese individuals;	chr14:41656478	chr14:41587861~41604856:-
THCA	cis	rs804280	0.509	rs9886639	ENSG00000255495.1	AC145124.2	3.78	0.000174	0.0126	0.2	0.17	Myopia (pathological);	chr8:11927020	chr8:12194467~12196280:+
THCA	cis	rs699371	0.564	rs56992115	ENSG00000270000.1	RP3-449M8.9	3.78	0.000174	0.0126	0.17	0.17	Height;	chr14:74442708	chr14:74471930~74472360:-
THCA	cis	rs4759375	1	rs28581850	ENSG00000256092.2	RP13-942N8.1	3.78	0.000174	0.0126	0.19	0.17	HDL cholesterol;	chr12:123387170	chr12:123363868~123366113:+
THCA	cis	rs4759375	1	rs28660993	ENSG00000256092.2	RP13-942N8.1	3.78	0.000174	0.0126	0.19	0.17	HDL cholesterol;	chr12:123390847	chr12:123363868~123366113:+
THCA	cis	rs1005277	0.579	rs176838	ENSG00000120555.12	SEPT7P9	-3.78	0.000174	0.0126	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38383069~38402916:-
THCA	cis	rs2099527	0.504	rs10763529	ENSG00000279863.1	RP11-521C22.2	3.78	0.000174	0.0126	0.2	0.17	Life satisfaction;	chr10:50523144	chr10:50334538~50336123:+
THCA	cis	rs3763267	0.649	rs73040115	ENSG00000226445.1	XXyac-YX65C7_A.2	3.78	0.000174	0.0126	0.33	0.17	Blood protein levels;	chr6:169183699	chr6:169213254~169239565:+
THCA	cis	rs2320614	1	rs4691894	ENSG00000250027.1	RP11-563E2.2	-3.78	0.000174	0.0126	-0.16	-0.17	Lung adenocarcinoma;	chr4:163126203	chr4:163108785~163119965:+
THCA	cis	rs2039553	0.568	rs1335288	ENSG00000227354.5	RBM26-AS1	-3.78	0.000174	0.0126	-0.16	-0.17	Pancreatic cancer;	chr13:79801287	chr13:79406309~79424328:+
THCA	cis	rs478304	0.718	rs61744384	ENSG00000245532.5	NEAT1	-3.78	0.000174	0.0126	-0.12	-0.17	Acne (severe);	chr11:65619907	chr11:65422774~65445540:+
THCA	cis	rs17689437	0.813	rs11644787	ENSG00000260084.1	RP11-615I2.1	-3.78	0.000174	0.0126	-0.25	-0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68634949	chr16:68573782~68589512:-
THCA	cis	rs2214442	0.79	rs3807949	ENSG00000271133.4	CTA-293F17.1	-3.78	0.000174	0.0126	-0.18	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20396896	chr7:20328299~20331747:-
THCA	cis	rs17345786	0.798	rs1609159	ENSG00000244119.1	PDCL3P4	3.78	0.000174	0.0126	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr3:101557058	chr3:101712472~101713191:+
THCA	cis	rs150992	0.632	rs162341	ENSG00000246763.5	RGMB-AS1	3.78	0.000174	0.0126	0.18	0.17	Body mass index;	chr5:98967230	chr5:98769618~98773469:-
THCA	cis	rs1046896	1	rs1046917	ENSG00000263063.1	RP11-388C12.1	3.78	0.000174	0.0126	0.2	0.17	Glycated hemoglobin levels;	chr17:82727779	chr17:82713908~82716255:-
THCA	cis	rs1046896	0.503	rs12947062	ENSG00000263063.1	RP11-388C12.1	3.78	0.000174	0.0126	0.2	0.17	Glycated hemoglobin levels;	chr17:82728494	chr17:82713908~82716255:-
THCA	cis	rs2832191	0.716	rs1984012	ENSG00000176054.6	RPL23P2	3.78	0.000174	0.0126	0.15	0.17	Dental caries;	chr21:29020151	chr21:28997613~28998033:-
THCA	cis	rs8031584	1	rs11634216	ENSG00000178081.11	ULK4P3	3.78	0.000174	0.0126	0.23	0.17	Huntington's disease progression;	chr15:30996467	chr15:30103720~30131757:+
THCA	cis	rs2549003	1	rs2549009	ENSG00000237714.1	P4HA2-AS1	3.78	0.000174	0.0126	0.22	0.17	Asthma (sex interaction);	chr5:132491073	chr5:132184876~132192808:+
THCA	cis	rs17221829	0.549	rs72969202	ENSG00000280385.1	AP000648.5	-3.78	0.000174	0.0126	-0.17	-0.17	Anxiety in major depressive disorder;	chr11:89625187	chr11:90193614~90198120:+
THCA	cis	rs172166	0.61	rs156737	ENSG00000176933.5	TOB2P1	-3.78	0.000174	0.0126	-0.19	-0.17	Cardiac Troponin-T levels;	chr6:27927435	chr6:28217643~28218634:-
THCA	cis	rs853679	0.517	rs9393891	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Depression;	chr6:28111382	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Depression;	chr6:28111650	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Parkinson's disease;	chr6:28112168	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Depression;	chr6:28112175	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Depression;	chr6:28113851	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Depression;	chr6:28114487	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Depression;	chr6:28114933	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Depression;	chr6:28115743	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Depression;	chr6:28116411	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Parkinson's disease;	chr6:28118700	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Parkinson's disease;	chr6:28118701	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000219891.2	ZSCAN12P1	3.78	0.000174	0.0126	0.24	0.17	Parkinson's disease;	chr6:28119896	chr6:28091154~28093664:+
THCA	cis	rs7960884	0.629	rs979062	ENSG00000177359.16	RP11-551L14.1	3.78	0.000174	0.0126	0.19	0.17	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31229755	chr12:31111652~31206154:-
THCA	cis	rs7960884	0.655	rs979064	ENSG00000177359.16	RP11-551L14.1	3.78	0.000174	0.0126	0.19	0.17	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31229824	chr12:31111652~31206154:-
THCA	cis	rs12285276	0.504	rs7120278	ENSG00000205106.4	DKFZp779M0652	3.78	0.000174	0.0126	0.19	0.17	Visceral fat;	chr11:45796560	chr11:45771432~45772358:+
THCA	cis	rs9393813	1	rs1011665	ENSG00000204789.4	ZNF204P	3.78	0.000174	0.0126	0.14	0.17	Bipolar disorder;	chr6:27364519	chr6:27357825~27360221:-
THCA	cis	rs2286503	0.78	rs929464	ENSG00000228649.7	AC005682.5	3.78	0.000174	0.0126	0.21	0.17	Fibrinogen;	chr7:22835151	chr7:22854178~22861579:+
THCA	cis	rs748404	0.589	rs3862138	ENSG00000166763.7	STRCP1	3.78	0.000174	0.0126	0.23	0.17	Lung cancer;	chr15:43523801	chr15:43699488~43718184:-
THCA	cis	rs12612619	0.689	rs6721395	ENSG00000272148.1	RP11-195B17.1	3.78	0.000174	0.0126	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057259	chr2:27062428~27062907:-
THCA	cis	rs4699052	1	rs4699052	ENSG00000246560.2	RP11-10L12.4	3.78	0.000174	0.0126	0.2	0.17	Testicular germ cell tumor;	chr4:103216633	chr4:102828055~102844075:+
THCA	cis	rs17666538	1	rs57896286	ENSG00000254207.1	RP11-43A14.1	-3.78	0.000174	0.0126	-0.41	-0.17	IgG glycosylation;	chr8:621479	chr8:725188~725877:-
THCA	cis	rs1577917	1	rs4706254	ENSG00000220563.1	PKMP3	-3.78	0.000174	0.0126	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85893095	chr6:85659892~85660606:-
THCA	cis	rs881375	0.678	rs2416804	ENSG00000270917.1	RP11-27I1.6	3.78	0.000174	0.0126	0.23	0.17	Rheumatoid arthritis;	chr9:120914118	chr9:120812475~120812845:-
THCA	cis	rs6921919	0.789	rs6912584	ENSG00000176933.5	TOB2P1	-3.78	0.000174	0.0126	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28217643~28218634:-
THCA	cis	rs7208859	0.623	rs426434	ENSG00000280069.1	CTD-2349P21.3	-3.78	0.000174	0.0126	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30738182~30740275:+
THCA	cis	rs2749592	0.918	rs4934590	ENSG00000120555.12	SEPT7P9	-3.78	0.000174	0.0126	-0.21	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37588641	chr10:38383069~38402916:-
THCA	cis	rs1559040	0.79	rs11687470	ENSG00000272156.1	RP11-477N3.1	-3.78	0.000174	0.0126	-0.31	-0.17	Sudden cardiac arrest;	chr2:54009666	chr2:54082554~54085066:+
THCA	cis	rs2562152	0.654	rs216600	ENSG00000226942.2	IL9RP3	-3.78	0.000174	0.0126	-0.24	-0.17	Glioblastoma;	chr16:60167	chr16:29336~38321:-
THCA	cis	rs7216064	1	rs60432293	ENSG00000278740.1	RP11-147L13.14	3.78	0.000174	0.0126	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864291	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.953	rs4790905	ENSG00000278740.1	RP11-147L13.14	3.78	0.000174	0.0126	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867234	chr17:68188547~68189165:+
THCA	cis	rs894638	1	rs79263701	ENSG00000263327.5	TAPT1-AS1	-3.78	0.000174	0.0126	-0.22	-0.17	Glomerular filtration rate in chronic kidney disease;	chr4:16114631	chr4:16226685~16320140:+
THCA	cis	rs4906332	1	rs12885234	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000174	0.0126	-0.15	-0.17	Coronary artery disease;	chr14:103422844	chr14:103331674~103332367:-
THCA	cis	rs4906332	0.966	rs35799018	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000174	0.0126	-0.15	-0.17	Coronary artery disease;	chr14:103427138	chr14:103331674~103332367:-
THCA	cis	rs1577917	0.958	rs9647601	ENSG00000220563.1	PKMP3	-3.78	0.000174	0.0126	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85740109	chr6:85659892~85660606:-
THCA	cis	rs7900823	0.528	rs1870098	ENSG00000230500.1	MKX-AS1	-3.78	0.000174	0.0126	-0.23	-0.17	Lung cancer;	chr10:28252467	chr10:27744786~27767794:+
THCA	cis	rs78487399	0.808	rs1388387	ENSG00000234936.1	AC010883.5	3.78	0.000175	0.0126	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43509830	chr2:43229573~43233394:+
THCA	cis	rs9905704	0.881	rs12942879	ENSG00000224738.1	AC099850.1	3.78	0.000175	0.0126	0.23	0.17	Testicular germ cell tumor;	chr17:58783892	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs72828707	ENSG00000224738.1	AC099850.1	3.78	0.000175	0.0126	0.23	0.17	Testicular germ cell tumor;	chr17:58805875	chr17:59106598~59118267:+
THCA	cis	rs7267979	1	rs6050547	ENSG00000276952.1	RP5-965G21.6	-3.78	0.000175	0.0126	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25284915~25285588:-
THCA	cis	rs6942407	0.546	rs2108271	ENSG00000224046.1	AC005076.5	-3.78	0.000175	0.0126	-0.16	-0.17	Food allergy;	chr7:87176056	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.546	rs7810647	ENSG00000224046.1	AC005076.5	-3.78	0.000175	0.0126	-0.16	-0.17	Food allergy;	chr7:87176645	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.546	rs4728686	ENSG00000224046.1	AC005076.5	-3.78	0.000175	0.0126	-0.16	-0.17	Food allergy;	chr7:87185468	chr7:87151423~87152420:-
THCA	cis	rs2455799	0.613	rs1969095	ENSG00000270409.1	RP11-44D5.1	-3.78	0.000175	0.0126	-0.18	-0.17	Mean platelet volume;	chr3:15692045	chr3:15732252~15733470:+
THCA	cis	rs478304	0.934	rs509206	ENSG00000214659.4	KRT8P26	-3.78	0.000175	0.0126	-0.15	-0.17	Acne (severe);	chr11:65726336	chr11:65726939~65728214:+
THCA	cis	rs13217239	0.646	rs4269366	ENSG00000261353.1	CTA-14H9.5	-3.78	0.000175	0.0126	-0.18	-0.17	Schizophrenia;	chr6:27048634	chr6:26527063~26527404:+
THCA	cis	rs9876781	0.967	rs7618883	ENSG00000199476.1	Y_RNA	-3.78	0.000175	0.0126	-0.22	-0.17	Longevity;	chr3:48457056	chr3:48288587~48288694:+
THCA	cis	rs860295	0.812	rs11264413	ENSG00000203761.5	MSTO2P	-3.78	0.000175	0.0126	-0.14	-0.17	Body mass index;	chr1:155818865	chr1:155745829~155750137:+
THCA	cis	rs1799922	0.896	rs56184882	ENSG00000271553.1	RP11-274B21.10	-3.78	0.000175	0.0126	-0.15	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128743532	chr7:128667043~128668156:+
THCA	cis	rs193541	0.509	rs7720862	ENSG00000260686.1	CTB-36H16.2	-3.78	0.000175	0.0126	-0.16	-0.17	Glucose homeostasis traits;	chr5:122832420	chr5:122832356~122834533:+
THCA	cis	rs10875746	0.624	rs11168498	ENSG00000258273.1	RP11-370I10.4	3.78	0.000175	0.0126	0.25	0.17	Longevity (90 years and older);	chr12:48261305	chr12:48333755~48333901:-
THCA	cis	rs72819454	0.522	rs55760245	ENSG00000280693.1	SH3PXD2A-AS1	-3.78	0.000175	0.0126	-0.35	-0.17	Interleukin-9 levels;	chr10:103763262	chr10:103745966~103755423:+
THCA	cis	rs12681366	0.801	rs12682524	ENSG00000253175.1	RP11-267M23.6	3.78	0.000175	0.0126	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94565036~94565715:+
THCA	cis	rs3087591	0.683	rs4368212	ENSG00000263535.1	AK4P1	3.78	0.000175	0.0126	0.21	0.17	Hip circumference;	chr17:31312245	chr17:31345521~31346187:+
THCA	cis	rs758324	0.661	rs27748	ENSG00000224431.1	AC063976.7	-3.78	0.000175	0.0126	-0.18	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132079679	chr5:132199456~132203487:+
THCA	cis	rs10792665	0.844	rs7130899	ENSG00000255503.1	RP11-113K21.4	-3.78	0.000175	0.0126	-0.18	-0.17	Obesity-related traits;	chr11:82933862	chr11:83072402~83097196:-
THCA	cis	rs1153858	0.943	rs12439575	ENSG00000275672.1	GATM-AS1	-3.78	0.000175	0.0126	-0.18	-0.17	Homoarginine levels;	chr15:45392618	chr15:45378700~45380123:+
THCA	cis	rs10761482	0.684	rs898328	ENSG00000254271.1	RP11-131N11.4	3.78	0.000175	0.0126	0.23	0.17	Schizophrenia;	chr10:60287836	chr10:60734342~60741828:+
THCA	cis	rs2562456	0.561	rs12610883	ENSG00000268658.4	LINC00664	3.78	0.000175	0.0126	0.25	0.17	Pain;	chr19:21567257	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.793	rs7259708	ENSG00000268658.4	LINC00664	3.78	0.000175	0.0126	0.25	0.17	Pain;	chr19:21567846	chr19:21483374~21503238:+
THCA	cis	rs7259376	0.84	rs1808668	ENSG00000269345.1	VN1R85P	3.78	0.000175	0.0126	0.19	0.17	Menopause (age at onset);	chr19:22335855	chr19:22174766~22175191:-
THCA	cis	rs972578	0.666	rs3827362	ENSG00000274717.1	RP1-47A17.1	-3.78	0.000175	0.0126	-0.18	-0.17	Mean platelet volume;	chr22:42931573	chr22:42791814~42794313:-
THCA	cis	rs2522056	1	rs2106854	ENSG00000237714.1	P4HA2-AS1	-3.78	0.000175	0.0126	-0.25	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132433482	chr5:132184876~132192808:+
THCA	cis	rs7246760	0.867	rs67539464	ENSG00000267106.4	ZNF561-AS1	3.78	0.000175	0.0126	0.31	0.17	Pursuit maintenance gain;	chr19:9721748	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs73011937	ENSG00000267106.4	ZNF561-AS1	3.78	0.000175	0.0126	0.31	0.17	Pursuit maintenance gain;	chr19:9721854	chr19:9621291~9645896:+
THCA	cis	rs2692947	0.666	rs7566050	ENSG00000235584.2	AC008268.1	-3.78	0.000175	0.0126	-0.17	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95960282	chr2:95666084~95668715:+
THCA	cis	rs4763879	0.752	rs10772083	ENSG00000214776.8	RP11-726G1.1	3.78	0.000175	0.0126	0.21	0.17	Type 1 diabetes;	chr12:9722302	chr12:9467552~9576275:+
THCA	cis	rs4578769	0.836	rs3936488	ENSG00000265939.1	UBE2CP2	3.78	0.000175	0.0126	0.21	0.17	Eosinophil percentage of white cells;	chr18:22874459	chr18:22900486~22900995:-
THCA	cis	rs6088580	0.524	rs6088552	ENSG00000126005.14	MMP24-AS1	3.78	0.000175	0.0126	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34638687	chr20:35216462~35278131:-
THCA	cis	rs7737355	0.898	rs4706024	ENSG00000237714.1	P4HA2-AS1	3.78	0.000175	0.0126	0.24	0.17	Life satisfaction;	chr5:131568470	chr5:132184876~132192808:+
THCA	cis	rs1577917	0.958	rs12196230	ENSG00000220563.1	PKMP3	-3.78	0.000175	0.0126	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85810242	chr6:85659892~85660606:-
THCA	cis	rs3770081	1	rs56104203	ENSG00000273080.1	RP11-301O19.1	-3.78	0.000175	0.0126	-0.38	-0.17	Facial emotion recognition (sad faces);	chr2:86109133	chr2:86195590~86196049:+
THCA	cis	rs12476592	0.602	rs262501	ENSG00000242412.1	DBIL5P2	-3.78	0.000175	0.0126	-0.2	-0.17	Childhood ear infection;	chr2:63631523	chr2:63117851~63119542:-
THCA	cis	rs2832191	0.967	rs3787660	ENSG00000232855.5	AF131217.1	-3.78	0.000175	0.0126	-0.18	-0.17	Dental caries;	chr21:29148586	chr21:28439346~28674848:-
THCA	cis	rs2625529	0.816	rs4777467	ENSG00000260037.4	CTD-2524L6.3	-3.78	0.000175	0.0126	-0.24	-0.17	Red blood cell count;	chr15:71846137	chr15:71818396~71823384:+
THCA	cis	rs10129255	0.744	rs28517388	ENSG00000211972.2	IGHV3-66	3.78	0.000175	0.0126	0.11	0.17	Kawasaki disease;	chr14:106704323	chr14:106675017~106675544:-
THCA	cis	rs559555	0.574	rs632148	ENSG00000276517.1	AL133243.2	-3.78	0.000175	0.0126	-0.17	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31580962	chr2:32526504~32529507:+
THCA	cis	rs7521902	0.66	rs2235529	ENSG00000228397.1	RP1-224A6.3	-3.78	0.000175	0.0126	-0.31	-0.17	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22123994	chr1:22023994~22024968:-
THCA	cis	rs9911578	0.967	rs8072712	ENSG00000224738.1	AC099850.1	3.78	0.000175	0.0126	0.2	0.17	Intelligence (multi-trait analysis);	chr17:59085103	chr17:59106598~59118267:+
THCA	cis	rs6762	0.748	rs5030780	ENSG00000255284.1	AP006621.5	3.78	0.000175	0.0126	0.12	0.17	Mean platelet volume;	chr11:838110	chr11:777578~784297:+
THCA	cis	rs11220082	0.627	rs34912904	ENSG00000254671.2	STT3A-AS1	-3.78	0.000175	0.0126	-0.2	-0.17	Schizophrenia;	chr11:125475460	chr11:125570284~125592568:-
THCA	cis	rs7737355	0.898	rs1468328	ENSG00000224431.1	AC063976.7	3.78	0.000175	0.0126	0.16	0.17	Life satisfaction;	chr5:131276007	chr5:132199456~132203487:+
THCA	cis	rs5758511	0.68	rs1107553	ENSG00000227370.1	RP4-669P10.19	3.78	0.000175	0.0126	0.19	0.17	Birth weight;	chr22:42271467	chr22:42132543~42132998:+
THCA	cis	rs7819412	0.807	rs10105315	ENSG00000261451.1	RP11-981G7.1	-3.78	0.000175	0.0126	-0.22	-0.17	Triglycerides;	chr8:11074693	chr8:10433672~10438312:+
THCA	cis	rs1387259	0.64	rs10783243	ENSG00000240399.1	RP1-228P16.1	-3.78	0.000175	0.0126	-0.16	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48054813~48055591:-
THCA	cis	rs931127	0.502	rs1466462	ENSG00000245532.5	NEAT1	3.78	0.000175	0.0126	0.12	0.17	Systemic lupus erythematosus;	chr11:65651893	chr11:65422774~65445540:+
THCA	cis	rs7989336	0.562	rs9554349	ENSG00000247400.3	DNAJC3-AS1	-3.78	0.000175	0.0126	-0.11	-0.17	Obesity;	chr13:96371575	chr13:95648733~95676925:-
THCA	cis	rs7989336	0.562	rs7995352	ENSG00000247400.3	DNAJC3-AS1	-3.78	0.000175	0.0126	-0.11	-0.17	Obesity;	chr13:96371579	chr13:95648733~95676925:-
THCA	cis	rs7824557	0.564	rs1435275	ENSG00000255495.1	AC145124.2	-3.78	0.000175	0.0126	-0.2	-0.17	Retinal vascular caliber;	chr8:11378226	chr8:12194467~12196280:+
THCA	cis	rs912593	1	rs9315299	ENSG00000225179.1	LINC00457	3.78	0.000175	0.0126	0.22	0.17	Cancer;	chr13:34467019	chr13:34435450~34640685:-
THCA	cis	rs7927592	0.513	rs531163	ENSG00000160172.9	FAM86C2P	3.78	0.000175	0.0126	0.16	0.17	Total body bone mineral density;	chr11:68427028	chr11:67791648~67805336:-
THCA	cis	rs7572733	0.905	rs6434945	ENSG00000231621.1	AC013264.2	-3.78	0.000175	0.0126	-0.16	-0.17	Dermatomyositis;	chr2:197933236	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs10207433	ENSG00000231621.1	AC013264.2	-3.78	0.000175	0.0126	-0.16	-0.17	Dermatomyositis;	chr2:197941206	chr2:197197991~197199273:+
THCA	cis	rs2281636	0.66	rs7072263	ENSG00000260475.1	RP11-85A1.3	3.78	0.000175	0.0126	0.18	0.17	Obesity-related traits;	chr10:99607888	chr10:99621055~99621918:+
THCA	cis	rs372883	0.6	rs1312254	ENSG00000176054.6	RPL23P2	-3.78	0.000175	0.0126	-0.15	-0.17	Pancreatic cancer;	chr21:29323080	chr21:28997613~28998033:-
THCA	cis	rs2303282	0.664	rs4924	ENSG00000274031.1	RP11-413H22.3	-3.78	0.000175	0.0126	-0.2	-0.17	Breast cancer;	chr16:56362574	chr16:56465642~56466162:-
THCA	cis	rs4218	0.543	rs8027536	ENSG00000259732.1	RP11-59H7.3	-3.78	0.000175	0.0126	-0.23	-0.17	Social communication problems;	chr15:59022364	chr15:59121034~59133250:+
THCA	cis	rs9863	0.861	rs11057397	ENSG00000270028.1	RP11-380L11.4	3.78	0.000175	0.0126	0.19	0.17	White blood cell count;	chr12:123935181	chr12:123925461~123926083:-
THCA	cis	rs14027	0.921	rs2048239	ENSG00000245330.4	KB-1471A8.1	3.78	0.000175	0.0126	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119867419~119874488:-
THCA	cis	rs71327718	1	rs71327718	ENSG00000248787.1	RP11-666A20.4	-3.78	0.000175	0.0126	-0.34	-0.17	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125908005~125910272:-
THCA	cis	rs6942407	0.546	rs4140847	ENSG00000224046.1	AC005076.5	-3.78	0.000175	0.0126	-0.16	-0.17	Food allergy;	chr7:87153947	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.546	rs3789251	ENSG00000224046.1	AC005076.5	-3.78	0.000175	0.0126	-0.16	-0.17	Food allergy;	chr7:87163987	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.546	rs3789252	ENSG00000224046.1	AC005076.5	-3.78	0.000175	0.0126	-0.16	-0.17	Food allergy;	chr7:87164046	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.546	rs2074757	ENSG00000224046.1	AC005076.5	-3.78	0.000175	0.0126	-0.16	-0.17	Food allergy;	chr7:87164805	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.546	rs765968	ENSG00000224046.1	AC005076.5	-3.78	0.000175	0.0126	-0.16	-0.17	Food allergy;	chr7:87165408	chr7:87151423~87152420:-
THCA	cis	rs8099594	0.565	rs1893527	ENSG00000266696.1	RP11-30L3.2	-3.78	0.000175	0.0126	-0.21	-0.17	Height;	chr18:49185738	chr18:49205912~49208781:+
THCA	cis	rs11601239	0.668	rs2155040	ENSG00000254750.1	CASP1P2	3.78	0.000175	0.0126	0.14	0.17	Refractive error;	chr11:105770794	chr11:105063345~105071541:-
THCA	cis	rs13325613	0.834	rs13083881	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46143128	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.585	rs17216717	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46144831	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13075836	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46145146	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13096325	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46145346	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13097340	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46145626	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.764	rs3091314	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46147261	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34693386	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46153910	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34101673	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46155794	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34409248	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46156579	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34996127	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46156681	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34897745	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46156884	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35853141	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46156896	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13069467	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46160383	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34567015	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46160720	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs78124692	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46160745	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs80007414	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46160746	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35685805	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46161286	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35162796	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46162887	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs35942803	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46167291	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35288652	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46167935	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35566550	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46169020	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.749	rs79948053	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46169568	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35919278	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46172102	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34523728	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46178341	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34570200	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46179008	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.666	rs35560301	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46179014	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34134191	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46180039	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13069750	ENSG00000223552.1	RP11-24F11.2	-3.78	0.000175	0.0126	-0.3	-0.17	Monocyte count;	chr3:46183358	chr3:46364955~46407059:-
THCA	cis	rs6696239	1	rs12140848	ENSG00000227711.2	RP11-275O4.5	-3.78	0.000175	0.0127	-0.24	-0.17	Height;	chr1:227589241	chr1:227509028~227520477:-
THCA	cis	rs6696239	0.955	rs12129894	ENSG00000227711.2	RP11-275O4.5	-3.78	0.000175	0.0127	-0.24	-0.17	Height;	chr1:227589287	chr1:227509028~227520477:-
THCA	cis	rs9878978	0.722	rs34160306	ENSG00000227588.2	CNTN4-AS2	3.78	0.000175	0.0127	0.23	0.17	Blood pressure (smoking interaction);	chr3:2456443	chr3:2110409~2144241:-
THCA	cis	rs6012564	0.893	rs6066909	ENSG00000230758.1	SNAP23P	3.78	0.000175	0.0127	0.22	0.17	Anger;	chr20:48913376	chr20:49038357~49038602:-
THCA	cis	rs929354	0.629	rs6950739	ENSG00000224629.1	RP5-1142J19.2	-3.78	0.000175	0.0127	-0.17	-0.17	Body mass index;	chr7:157189756	chr7:157263022~157263229:-
THCA	cis	rs2898290	0.617	rs13278965	ENSG00000255046.1	RP11-297N6.4	-3.78	0.000175	0.0127	-0.18	-0.17	Systolic blood pressure;	chr8:11609236	chr8:11797928~11802568:-
THCA	cis	rs6494488	0.5	rs7165925	ENSG00000259635.1	AC100830.3	3.78	0.000175	0.0127	0.39	0.17	Coronary artery disease;	chr15:64693405	chr15:64701248~64719602:+
THCA	cis	rs1555322	0.53	rs2250205	ENSG00000269202.1	RP4-614O4.12	-3.78	0.000175	0.0127	-0.18	-0.17	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35201747~35203288:-
THCA	cis	rs295490	0.748	rs77343695	ENSG00000272656.1	RP11-219D15.3	3.78	0.000175	0.0127	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139430617	chr3:139349024~139349371:-
THCA	cis	rs854765	0.583	rs8073001	ENSG00000281749.1	Y_RNA	-3.78	0.000175	0.0127	-0.21	-0.17	Total body bone mineral density;	chr17:17928402	chr17:18001101~18001195:-
THCA	cis	rs14027	0.705	rs13265683	ENSG00000245330.4	KB-1471A8.1	3.78	0.000175	0.0127	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119867419~119874488:-
THCA	cis	rs7259376	0.936	rs7255829	ENSG00000269345.1	VN1R85P	3.78	0.000175	0.0127	0.19	0.17	Menopause (age at onset);	chr19:22354509	chr19:22174766~22175191:-
THCA	cis	rs2749592	0.55	rs7917262	ENSG00000120555.12	SEPT7P9	-3.78	0.000175	0.0127	-0.19	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38383069~38402916:-
THCA	cis	rs2749592	0.55	rs9733309	ENSG00000120555.12	SEPT7P9	-3.78	0.000175	0.0127	-0.19	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38383069~38402916:-
THCA	cis	rs11601239	0.668	rs10791771	ENSG00000254750.1	CASP1P2	3.78	0.000175	0.0127	0.14	0.17	Refractive error;	chr11:105746328	chr11:105063345~105071541:-
THCA	cis	rs7871764	0.881	rs35017035	ENSG00000281128.1	PTENP1-AS	3.78	0.000175	0.0127	0.27	0.17	Height;	chr9:34072896	chr9:33677268~33688011:+
THCA	cis	rs62289301	0.5	rs34400909	ENSG00000273133.1	RP11-799M12.2	3.78	0.000175	0.0127	0.21	0.17	Joint mobility (Beighton score);	chr4:15438190	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.571	rs71601477	ENSG00000273133.1	RP11-799M12.2	3.78	0.000175	0.0127	0.21	0.17	Joint mobility (Beighton score);	chr4:15438306	chr4:15563698~15564253:-
THCA	cis	rs7919656	0.662	rs2620882	ENSG00000228403.1	RP11-563N6.6	-3.78	0.000175	0.0127	-0.18	-0.17	Clinically amyopathic dermatomyositis;	chr10:48873187	chr10:48878022~48878649:+
THCA	cis	rs6671200	0.85	rs259345	ENSG00000235501.4	RP4-639F20.1	3.78	0.000175	0.0127	0.34	0.17	Stearic acid (18:0) levels;	chr1:95264093	chr1:94927566~94963270:+
THCA	cis	rs3806843	0.576	rs246063	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140944907	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246062	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140944995	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.521	rs246061	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140945071	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.607	rs246060	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140945164	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246059	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140945425	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.548	rs246058	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140945549	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.548	rs246057	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140945998	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.548	rs246055	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140946077	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.547	rs246054	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140946574	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.548	rs246052	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140946828	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.52	rs246051	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140946879	chr5:140726158~140726246:+
THCA	cis	rs31872	0.521	rs246050	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Visceral adipose tissue adjusted for BMI;	chr5:140947275	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246049	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140948005	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246047	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140948752	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246046	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140949679	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246045	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140950299	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246043	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140951339	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.608	rs246042	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140951382	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246041	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140951543	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.548	rs246038	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140952114	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246037	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140952261	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246036	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140952301	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246034	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140952479	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.547	rs246033	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140952530	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246032	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140952962	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.517	rs246031	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140953522	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246030	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140953569	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246029	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140953641	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246028	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140953928	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246027	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140954016	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246024	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140954367	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.546	rs246023	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140954405	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246021	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140954919	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246020	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140955186	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.551	rs246018	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140955458	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.518	rs173471	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140955641	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.549	rs246012	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140956692	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246011	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140956820	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.547	rs246010	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140957050	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246007	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140959163	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246006	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140959643	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246005	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140960299	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.576	rs246003	ENSG00000202515.1	VTRNA1-3	-3.78	0.000175	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140961280	chr5:140726158~140726246:+
THCA	cis	rs2692947	0.683	rs62153700	ENSG00000232931.4	LINC00342	3.78	0.000175	0.0127	0.15	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95915590	chr2:95807118~95816215:-
THCA	cis	rs721917	0.506	rs2758539	ENSG00000244733.5	RP11-506M13.3	-3.78	0.000175	0.0127	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79894680	chr10:79660891~79677996:+
THCA	cis	rs721917	0.525	rs2758541	ENSG00000244733.5	RP11-506M13.3	-3.78	0.000175	0.0127	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79895801	chr10:79660891~79677996:+
THCA	cis	rs12544026	0.547	rs526533	ENSG00000253669.3	KB-1732A1.1	-3.78	0.000175	0.0127	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101879005	chr8:102805517~102809971:+
THCA	cis	rs2408955	0.561	rs11168365	ENSG00000273765.1	RP11-370I10.11	-3.78	0.000175	0.0127	-0.17	-0.17	Glycated hemoglobin levels;	chr12:48027989	chr12:48360920~48361377:+
THCA	cis	rs1501138	0.688	rs1121630	ENSG00000263327.5	TAPT1-AS1	-3.78	0.000175	0.0127	-0.28	-0.17	Systemic juvenile idiopathic arthritis;	chr4:16285117	chr4:16226685~16320140:+
THCA	cis	rs9650657	0.513	rs7005884	ENSG00000269899.1	RP11-589N15.2	3.78	0.000175	0.0127	0.19	0.17	Neuroticism;	chr8:10938962	chr8:11846154~11846391:-
THCA	cis	rs10792665	0.844	rs7930200	ENSG00000255503.1	RP11-113K21.4	-3.78	0.000175	0.0127	-0.18	-0.17	Obesity-related traits;	chr11:82938838	chr11:83072402~83097196:-
THCA	cis	rs7259376	0.775	rs2360621	ENSG00000269138.1	ZNF209P	3.78	0.000175	0.0127	0.18	0.17	Menopause (age at onset);	chr19:22365867	chr19:22463922~22473036:+
THCA	cis	rs9595908	0.709	rs7331632	ENSG00000212293.1	SNORA16	3.78	0.000175	0.0127	0.2	0.17	Body mass index;	chr13:32753864	chr13:32420390~32420516:-
THCA	cis	rs12459419	1	rs12459419	ENSG00000171101.12	SIGLEC17P	3.78	0.000176	0.0127	0.2	0.17	Plateletcrit;Blood protein levels;	chr19:51225221	chr19:51167328~51173524:+
THCA	cis	rs6546550	0.901	rs13015457	ENSG00000179818.12	PCBP1-AS1	-3.78	0.000176	0.0127	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69898631	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs7598283	ENSG00000179818.12	PCBP1-AS1	-3.78	0.000176	0.0127	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69901585	chr2:69962263~70103220:-
THCA	cis	rs75828804	1	rs75881525	ENSG00000260922.1	RP11-538I12.3	-3.78	0.000176	0.0127	-0.37	-0.17	Intraocular pressure;	chr16:77547870	chr16:77234877~77290934:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000273142.1	RP11-458F8.4	-3.78	0.000176	0.0127	-0.15	-0.17	Aortic root size;	chr7:66087510	chr7:66902857~66906297:+
THCA	cis	rs9863	0.896	rs12311114	ENSG00000269938.1	RP11-214K3.20	3.78	0.000176	0.0127	0.2	0.17	White blood cell count;	chr12:123976156	chr12:123968023~123968579:-
THCA	cis	rs12129938	0.911	rs6697791	ENSG00000231940.1	RPS7P3	-3.78	0.000176	0.0127	-0.22	-0.17	Thyroid cancer;	chr1:233276132	chr1:233288868~233289447:-
THCA	cis	rs758324	0.947	rs6886188	ENSG00000237714.1	P4HA2-AS1	3.78	0.000176	0.0127	0.25	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131842559	chr5:132184876~132192808:+
THCA	cis	rs2821260	0.782	rs1486094	ENSG00000227207.2	RPL31P12	3.78	0.000176	0.0127	0.19	0.17	Intelligence (multi-trait analysis);	chr1:72107749	chr1:72301472~72301829:+
THCA	cis	rs757282	0.569	rs73105899	ENSG00000268069.2	RP5-1057I20.4	3.78	0.000176	0.0127	0.27	0.17	Optic nerve measurement (cup-to-disc ratio);	chr12:47778995	chr12:47784923~47786002:+
THCA	cis	rs6142618	0.967	rs6061182	ENSG00000224452.1	RSL24D1P6	3.78	0.000176	0.0127	0.21	0.17	Inflammatory bowel disease;	chr20:32139433	chr20:32170390~32170790:-
THCA	cis	rs5753037	0.585	rs249396	ENSG00000279699.1	RP1-102K2.9	3.78	0.000176	0.0127	0.16	0.17	Type 1 diabetes;	chr22:29817983	chr22:30275215~30276951:-
THCA	cis	rs9987353	0.519	rs13276350	ENSG00000253981.4	ALG1L13P	-3.78	0.000176	0.0127	-0.17	-0.17	Recombination measurement;	chr8:9205647	chr8:8236003~8244667:-
THCA	cis	rs7259376	1	rs2163846	ENSG00000269345.1	VN1R85P	3.78	0.000176	0.0127	0.19	0.17	Menopause (age at onset);	chr19:22323042	chr19:22174766~22175191:-
THCA	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	3.78	0.000176	0.0127	0.15	0.17	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
THCA	cis	rs10540	1	rs61876336	ENSG00000279672.1	CMB9-55F22.1	3.78	0.000176	0.0127	0.34	0.17	Body mass index;	chr11:489537	chr11:779617~780755:+
THCA	cis	rs7760535	1	rs7760535	ENSG00000255389.1	C6orf3	3.78	0.000176	0.0127	0.17	0.17	Metabolic traits;	chr6:111425880	chr6:111599875~111602295:+
THCA	cis	rs9878978	0.722	rs17194427	ENSG00000227588.2	CNTN4-AS2	3.78	0.000176	0.0127	0.23	0.17	Blood pressure (smoking interaction);	chr3:2453518	chr3:2110409~2144241:-
THCA	cis	rs7578199	0.576	rs2279846	ENSG00000223374.1	AC005104.3	-3.78	0.000176	0.0127	-0.12	-0.17	Chronic lymphocytic leukemia;	chr2:241499656	chr2:241351340~241353104:-
THCA	cis	rs1577917	0.655	rs9359658	ENSG00000220563.1	PKMP3	3.78	0.000176	0.0127	0.12	0.17	Response to antipsychotic treatment;	chr6:85596051	chr6:85659892~85660606:-
THCA	cis	rs16966142	0.581	rs17177912	ENSG00000260259.1	RP11-368I7.4	3.78	0.000176	0.0127	0.29	0.17	Caffeine consumption;	chr16:89843021	chr16:89682620~89686569:-
THCA	cis	rs964611	1	rs1820492	ENSG00000259488.2	RP11-154J22.1	3.78	0.000176	0.0127	0.16	0.17	Metabolite levels (Pyroglutamine);	chr15:48311230	chr15:48312353~48331856:-
THCA	cis	rs1577330	0.948	rs1591355	ENSG00000254396.1	RP11-56F10.3	3.78	0.000176	0.0127	0.21	0.17	IgG glycosylation;	chr9:27075885	chr9:27102630~27104728:+
THCA	cis	rs4727027	0.704	rs12537763	ENSG00000244560.5	RP4-800G7.2	-3.78	0.000176	0.0127	-0.1	-0.17	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149206892	chr7:149285281~149297312:+
THCA	cis	rs4879656	0.872	rs1537040	ENSG00000225693.1	LAGE3P1	-3.78	0.000176	0.0127	-0.18	-0.17	Menopause (age at onset);	chr9:33061442	chr9:33019682~33020165:-
THCA	cis	rs16957091	0.528	rs12911334	ENSG00000205771.5	CATSPER2P1	3.78	0.000176	0.0127	0.25	0.17	MGMT methylation in smokers;	chr15:43013055	chr15:43726918~43747094:-
THCA	cis	rs41411047	0.826	rs57335608	ENSG00000252172.1	RNU6-720P	3.78	0.000176	0.0127	0.36	0.17	Myocardial infarction;	chr3:149935899	chr3:149917342~149917449:-
THCA	cis	rs7178424	0.743	rs8032681	ENSG00000259251.2	RP11-643M14.1	-3.78	0.000176	0.0127	-0.17	-0.17	Height;	chr15:61870044	chr15:62060503~62062434:+
THCA	cis	rs7178424	0.742	rs12908081	ENSG00000259251.2	RP11-643M14.1	-3.78	0.000176	0.0127	-0.17	-0.17	Height;	chr15:61870065	chr15:62060503~62062434:+
THCA	cis	rs12681366	0.801	rs1372048	ENSG00000253175.1	RP11-267M23.6	3.78	0.000176	0.0127	0.22	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94565036~94565715:+
THCA	cis	rs12476592	0.602	rs4671068	ENSG00000242412.1	DBIL5P2	3.78	0.000176	0.0127	0.22	0.17	Childhood ear infection;	chr2:63571199	chr2:63117851~63119542:-
THCA	cis	rs9911578	0.935	rs2302189	ENSG00000224738.1	AC099850.1	-3.78	0.000176	0.0127	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:58506844	chr17:59106598~59118267:+
THCA	cis	rs1127311	0.905	rs6699729	ENSG00000236675.1	MTX1P1	-3.78	0.000176	0.0127	-0.16	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154610420	chr1:155230975~155234325:+
THCA	cis	rs9427116	0.502	rs6699825	ENSG00000236675.1	MTX1P1	-3.78	0.000176	0.0127	-0.16	-0.17	Blood protein levels;	chr1:154610494	chr1:155230975~155234325:+
THCA	cis	rs1035144	0.679	rs4903958	ENSG00000258915.1	BHLHB9P1	3.78	0.000176	0.0127	0.19	0.17	Male sexual orientation;	chr14:80982258	chr14:80981988~80983638:+
THCA	cis	rs7178424	0.777	rs2042608	ENSG00000259251.2	RP11-643M14.1	-3.78	0.000176	0.0127	-0.17	-0.17	Height;	chr15:61940181	chr15:62060503~62062434:+
THCA	cis	rs181553	0.504	rs7230541	ENSG00000266696.1	RP11-30L3.2	-3.78	0.000176	0.0127	-0.25	-0.17	Hip circumference adjusted for BMI;	chr18:49439070	chr18:49205912~49208781:+
THCA	cis	rs11642862	1	rs11642603	ENSG00000275263.1	RP11-1072A3.4	-3.78	0.000176	0.0127	-0.38	-0.17	Tonsillectomy;	chr16:30874900	chr16:30956872~30957199:-
THCA	cis	rs1538970	0.924	rs6657284	ENSG00000234329.1	RP11-767N6.2	3.78	0.000176	0.0127	0.17	0.17	Platelet count;	chr1:45413416	chr1:45651039~45651826:-
THCA	cis	rs7727544	0.647	rs7721882	ENSG00000263597.1	MIR3936	3.78	0.000176	0.0127	0.17	0.17	Blood metabolite levels;	chr5:132083255	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.625	rs3864277	ENSG00000263597.1	MIR3936	3.78	0.000176	0.0127	0.17	0.17	Blood metabolite levels;	chr5:132084556	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.647	rs6898270	ENSG00000263597.1	MIR3936	3.78	0.000176	0.0127	0.17	0.17	Blood metabolite levels;	chr5:132085497	chr5:132365490~132365599:-
THCA	cis	rs6940638	0.688	rs9393795	ENSG00000224843.5	LINC00240	3.78	0.000176	0.0127	0.16	0.17	Intelligence (multi-trait analysis);	chr6:27249940	chr6:26956992~27023924:+
THCA	cis	rs804280	0.542	rs36100659	ENSG00000255495.1	AC145124.2	3.78	0.000176	0.0127	0.2	0.17	Myopia (pathological);	chr8:11934144	chr8:12194467~12196280:+
THCA	cis	rs5769765	1	rs8184990	ENSG00000260613.1	RP3-522J7.6	3.78	0.000176	0.0127	0.22	0.17	Schizophrenia;	chr22:49879526	chr22:49832616~49837786:-
THCA	cis	rs11751172	0.651	rs35611098	ENSG00000271857.1	RP1-244F24.1	3.78	0.000176	0.0127	0.11	0.17	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45571683	chr6:45421079~45422005:-
THCA	cis	rs6921919	0.848	rs9468350	ENSG00000219392.1	RP1-265C24.5	-3.78	0.000176	0.0127	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28115628~28116551:+
THCA	cis	rs10165862	0.537	rs17009372	ENSG00000273245.1	RP11-434P11.2	-3.78	0.000176	0.0127	-0.23	-0.17	Intelligence (multi-trait analysis);	chr2:73728444	chr2:73750256~73750786:-
THCA	cis	rs1383484	1	rs4438273	ENSG00000259728.4	LINC00933	-3.78	0.000176	0.0127	-0.21	-0.17	Height;	chr15:83832524	chr15:84570649~84580175:+
THCA	cis	rs9316337	0.548	rs9506682	ENSG00000236953.1	ZDHHC20-IT1	-3.78	0.000176	0.0127	-0.2	-0.17	Schizophrenia;	chr13:21449931	chr13:21376977~21377874:-
THCA	cis	rs11168351	0.864	rs12228750	ENSG00000257735.1	RP11-370I10.6	-3.78	0.000176	0.0127	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48350945~48442411:+
THCA	cis	rs11168351	0.864	rs10875743	ENSG00000257735.1	RP11-370I10.6	-3.78	0.000176	0.0127	-0.2	-0.17	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48350945~48442411:+
THCA	cis	rs397969	0.646	rs203478	ENSG00000261033.1	RP11-209D14.2	-3.78	0.000176	0.0127	-0.26	-0.17	Platelet count;	chr17:19926529	chr17:20008051~20009234:-
THCA	cis	rs752590	0.623	rs67802835	ENSG00000227359.1	AC017074.2	3.78	0.000176	0.0127	0.28	0.17	Mucinous ovarian carcinoma;	chr2:113221583	chr2:113677702~113704078:-
THCA	cis	rs801193	0.901	rs4273746	ENSG00000229180.5	GS1-124K5.11	-3.78	0.000176	0.0127	-0.12	-0.17	Aortic root size;	chr7:66836124	chr7:66526088~66542624:-
THCA	cis	rs2832191	0.716	rs2249028	ENSG00000176054.6	RPL23P2	3.78	0.000176	0.0127	0.15	0.17	Dental caries;	chr21:28993001	chr21:28997613~28998033:-
THCA	cis	rs2832191	0.716	rs2297252	ENSG00000176054.6	RPL23P2	3.78	0.000176	0.0127	0.15	0.17	Dental caries;	chr21:29004783	chr21:28997613~28998033:-
THCA	cis	rs12478296	1	rs7603984	ENSG00000220804.7	AC093642.5	3.78	0.000176	0.0127	0.2	0.17	Obesity-related traits;	chr2:242105143	chr2:242088633~242160153:+
THCA	cis	rs765787	0.53	rs28524974	ENSG00000259539.1	CTD-2651B20.1	3.78	0.000176	0.0127	0.21	0.17	Uric acid levels;	chr15:45251330	chr15:45152664~45167526:-
THCA	cis	rs6121246	0.779	rs6060763	ENSG00000224628.2	RP5-854E16.2	-3.78	0.000176	0.0127	-0.23	-0.17	Mean corpuscular hemoglobin;	chr20:31694420	chr20:31285317~31286835:-
THCA	cis	rs9500256	0.669	rs7770369	ENSG00000215190.7	LINC00680	3.78	0.000176	0.0127	0.2	0.17	Eosinophilic esophagitis (pediatric);	chr6:58021043	chr6:57946074~57961501:-
THCA	cis	rs7511006	1	rs5771109	ENSG00000273137.1	RP3-402G11.28	-3.78	0.000176	0.0127	-0.12	-0.17	Obesity-related traits;	chr22:50240142	chr22:50208461~50209542:-
THCA	cis	rs295490	0.748	rs76522909	ENSG00000272656.1	RP11-219D15.3	3.78	0.000176	0.0127	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139444006	chr3:139349024~139349371:-
THCA	cis	rs2839186	0.5	rs13052701	ENSG00000215424.8	MCM3AP-AS1	3.78	0.000176	0.0127	0.11	0.17	Testicular germ cell tumor;	chr21:46240131	chr21:46229217~46259390:+
THCA	cis	rs875971	0.66	rs10229345	ENSG00000223473.2	GS1-124K5.3	3.78	0.000176	0.0127	0.11	0.17	Aortic root size;	chr7:66517181	chr7:66491049~66493566:-
THCA	cis	rs12149074	0.901	rs9319549	ENSG00000260876.4	LINC01229	3.78	0.000176	0.0127	0.17	0.17	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80076285	chr16:79676108~79807922:+
THCA	cis	rs10090774	0.965	rs13255947	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140901346	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10089610	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140911514	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13254151	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140915211	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13273095	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140916839	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11778436	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140920047	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11785722	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140923414	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10103265	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140924839	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.841	rs11781072	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140928040	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs11786423	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140929471	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11784127	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140931408	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.813	rs11774672	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140931433	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13279233	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140936375	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs11775547	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140938349	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs11777476	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140940276	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11774024	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140940435	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11167010	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140944111	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs10102796	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140945576	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10093049	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140947405	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs2166869	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140950479	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13269453	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140951078	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10088980	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140953591	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10092810	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955055	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11992645	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955298	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs55827446	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959173	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11775885	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959895	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10089966	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140962443	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13265704	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140963053	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs727944	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140965089	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.901	rs9324538	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140966639	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10104187	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140968361	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.87	rs10087115	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140968731	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13278775	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140971830	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.87	rs10099696	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140980411	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11990541	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140987915	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11167017	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140989972	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10110937	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992419	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs1397380	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992955	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11167018	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0127	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140993212	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs7843337	ENSG00000280303.2	ERICD	3.78	0.000176	0.0127	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140952543	chr8:140636281~140638283:+
THCA	cis	rs15676	0.783	rs3829057	ENSG00000234771.3	SLC25A25-AS1	3.78	0.000176	0.0127	0.15	0.17	Blood metabolite levels;	chr9:128805703	chr9:128108581~128118693:-
THCA	cis	rs6487679	0.543	rs34363	ENSG00000245105.2	A2M-AS1	-3.78	0.000176	0.0127	-0.23	-0.17	Non-alcoholic fatty liver disease histology (AST);	chr12:9238261	chr12:9065177~9068060:+
THCA	cis	rs2434529	0.823	rs153437	ENSG00000245275.6	SAP30L-AS1	3.78	0.000176	0.0127	0.18	0.17	Autism spectrum disorder or schizophrenia;	chr5:154273176	chr5:154329437~154445850:-
THCA	cis	rs10435719	0.902	rs4840599	ENSG00000254948.1	OR7E158P	3.78	0.000176	0.0127	0.22	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11919900~11920809:-
THCA	cis	rs6546886	0.912	rs7589915	ENSG00000235499.1	AC073046.25	3.78	0.000176	0.0127	0.16	0.17	Dialysis-related mortality;	chr2:74055003	chr2:73985132~73986343:+
THCA	cis	rs6088590	0.71	rs6059992	ENSG00000276073.1	RP5-1125A11.7	-3.78	0.000176	0.0127	-0.15	-0.17	Coronary artery disease;	chr20:34694471	chr20:33985617~33988989:-
THCA	cis	rs4325129	0.677	rs4233352	ENSG00000272668.1	RP11-190A12.8	3.78	0.000176	0.0127	0.2	0.17	Obesity-related traits;	chr1:159476920	chr1:159866954~159867685:+
THCA	cis	rs4908768	0.539	rs7547411	ENSG00000270282.1	RP5-1115A15.2	3.78	0.000176	0.0127	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8512653~8513021:+
THCA	cis	rs6942407	0.546	rs10228392	ENSG00000224046.1	AC005076.5	-3.78	0.000177	0.0127	-0.16	-0.17	Food allergy;	chr7:87170357	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.546	rs10257953	ENSG00000224046.1	AC005076.5	-3.78	0.000177	0.0127	-0.16	-0.17	Food allergy;	chr7:87170410	chr7:87151423~87152420:-
THCA	cis	rs181553	0.629	rs12232591	ENSG00000266696.1	RP11-30L3.2	3.78	0.000177	0.0127	0.21	0.17	Hip circumference adjusted for BMI;	chr18:49164091	chr18:49205912~49208781:+
THCA	cis	rs862034	0.531	rs11159084	ENSG00000270000.1	RP3-449M8.9	3.78	0.000177	0.0127	0.17	0.17	Height;	chr14:74458441	chr14:74471930~74472360:-
THCA	cis	rs7045881	0.8	rs62544368	ENSG00000254396.1	RP11-56F10.3	3.78	0.000177	0.0127	0.32	0.17	Schizophrenia;	chr9:26812094	chr9:27102630~27104728:+
THCA	cis	rs17428076	0.793	rs56275355	ENSG00000228389.1	AC068039.4	-3.78	0.000177	0.0127	-0.2	-0.17	Myopia;	chr2:171853670	chr2:171773482~171775844:+
THCA	cis	rs7520050	0.966	rs7539932	ENSG00000281133.1	AL355480.3	3.78	0.000177	0.0127	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs61783200	ENSG00000281133.1	AL355480.3	3.78	0.000177	0.0127	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6680380	ENSG00000281133.1	AL355480.3	3.78	0.000177	0.0127	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs10890354	ENSG00000281133.1	AL355480.3	3.78	0.000177	0.0127	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs6697557	ENSG00000281133.1	AL355480.3	3.78	0.000177	0.0127	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6701614	ENSG00000281133.1	AL355480.3	3.78	0.000177	0.0127	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45580892~45580996:-
THCA	cis	rs57590327	0.503	rs6800295	ENSG00000241593.4	RP11-520D19.2	-3.78	0.000177	0.0127	-0.22	-0.17	Extraversion;	chr3:81543860	chr3:81246579~81297345:-
THCA	cis	rs7511006	0.895	rs5771270	ENSG00000273137.1	RP3-402G11.28	-3.78	0.000177	0.0127	-0.12	-0.17	Obesity-related traits;	chr22:50244436	chr22:50208461~50209542:-
THCA	cis	rs288326	0.561	rs75466155	ENSG00000272800.1	RP11-438L19.1	3.78	0.000177	0.0127	0.32	0.17	Blood protein levels;	chr2:182842076	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs79804181	ENSG00000272800.1	RP11-438L19.1	3.78	0.000177	0.0127	0.32	0.17	Blood protein levels;	chr2:182846170	chr2:183214319~183215400:+
THCA	cis	rs2857891	0.537	rs10839666	ENSG00000241678.1	RP11-732A19.1	3.78	0.000177	0.0127	0.21	0.17	Response to cytadine analogues (cytosine arabinoside);	chr11:6948748	chr11:6685891~6686369:-
THCA	cis	rs9368481	0.594	rs7768643	ENSG00000261353.1	CTA-14H9.5	-3.78	0.000177	0.0127	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26527063~26527404:+
THCA	cis	rs9368481	0.594	rs7768814	ENSG00000261353.1	CTA-14H9.5	-3.78	0.000177	0.0127	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26527063~26527404:+
THCA	cis	rs6088580	0.609	rs6059844	ENSG00000126005.14	MMP24-AS1	-3.78	0.000177	0.0127	-0.16	-0.17	Glomerular filtration rate (creatinine);	chr20:34448677	chr20:35216462~35278131:-
THCA	cis	rs56309584	0.715	rs3027234	ENSG00000271002.1	RP11-599B13.8	-3.78	0.000177	0.0127	-0.27	-0.17	Initial pursuit acceleration;	chr17:8232774	chr17:8199123~8199437:-
THCA	cis	rs7578199	0.552	rs2279845	ENSG00000223374.1	AC005104.3	-3.78	0.000177	0.0127	-0.12	-0.17	Chronic lymphocytic leukemia;	chr2:241501248	chr2:241351340~241353104:-
THCA	cis	rs3806843	0.576	rs246074	ENSG00000202515.1	VTRNA1-3	-3.78	0.000177	0.0127	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140928384	chr5:140726158~140726246:+
THCA	cis	rs7520050	1	rs12410070	ENSG00000280836.1	AL355480.1	3.78	0.000177	0.0127	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs12410071	ENSG00000280836.1	AL355480.1	3.78	0.000177	0.0127	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45581219~45581321:-
THCA	cis	rs854765	0.583	rs11650649	ENSG00000281749.1	Y_RNA	-3.78	0.000177	0.0127	-0.22	-0.17	Total body bone mineral density;	chr17:17887005	chr17:18001101~18001195:-
THCA	cis	rs173896	1	rs173896	ENSG00000246859.2	STARD4-AS1	-3.78	0.000177	0.0127	-0.23	-0.17	Bipolar disorder and schizophrenia;	chr5:111771418	chr5:111512226~111739726:+
THCA	cis	rs7727544	0.684	rs272874	ENSG00000263597.1	MIR3936	-3.78	0.000177	0.0128	-0.17	-0.17	Blood metabolite levels;	chr5:132339353	chr5:132365490~132365599:-
THCA	cis	rs9926296	0.605	rs12709094	ENSG00000274627.1	RP11-104N10.2	-3.78	0.000177	0.0128	-0.17	-0.17	Vitiligo;	chr16:89786609	chr16:89516797~89522217:+
THCA	cis	rs10802047	0.632	rs489076	ENSG00000231365.4	RP11-418J17.1	-3.78	0.000177	0.0128	-0.18	-0.17	Relative hand skill in reading disability;	chr1:118689902	chr1:119140396~119275973:+
THCA	cis	rs9291683	0.588	rs11732054	ENSG00000250413.1	RP11-448G15.1	-3.78	0.000177	0.0128	-0.16	-0.17	Bone mineral density;	chr4:9998253	chr4:10006482~10009725:+
THCA	cis	rs9308731	0.591	rs938095	ENSG00000227992.1	AC108463.2	3.78	0.000177	0.0128	0.2	0.17	Chronic lymphocytic leukemia;	chr2:111191232	chr2:111203964~111206215:-
THCA	cis	rs62244186	0.659	rs9850129	ENSG00000214820.3	MPRIPP1	3.78	0.000177	0.0128	0.18	0.17	Depressive symptoms;	chr3:44490555	chr3:44579938~44581026:-
THCA	cis	rs6903823	0.508	rs1150726	ENSG00000176933.5	TOB2P1	-3.78	0.000177	0.0128	-0.19	-0.17	Pulmonary function;	chr6:28275265	chr6:28217643~28218634:-
THCA	cis	rs3758911	0.894	rs11212154	ENSG00000255353.1	RP11-382M14.1	-3.78	0.000177	0.0128	-0.22	-0.17	Coronary artery disease;	chr11:107319238	chr11:107176286~107177530:+
THCA	cis	rs9625935	0.797	rs1076137	ENSG00000279159.1	RP3-394A18.1	3.78	0.000177	0.0128	0.14	0.17	Tonsillectomy;	chr22:29828002	chr22:29978950~30028236:-
THCA	cis	rs17092148	1	rs6088579	ENSG00000276073.1	RP5-1125A11.7	-3.78	0.000177	0.0128	-0.21	-0.17	Neuroticism;	chr20:34696820	chr20:33985617~33988989:-
THCA	cis	rs6560517	0.519	rs2147266	ENSG00000234618.1	RPSAP9	3.78	0.000177	0.0128	0.21	0.17	Dialysis-related mortality;	chr9:76508074	chr9:76398699~76399586:+
THCA	cis	rs889512	0.642	rs28595463	ENSG00000261783.1	RP11-252K23.2	3.78	0.000177	0.0128	0.34	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75247337	chr16:75379818~75381260:-
THCA	cis	rs267567	0.647	rs267559	ENSG00000235257.7	ITGA9-AS1	3.78	0.000177	0.0128	0.14	0.17	PR interval;	chr3:37533779	chr3:37745432~37861780:-
THCA	cis	rs295490	0.748	rs59628512	ENSG00000272656.1	RP11-219D15.3	3.78	0.000177	0.0128	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139472550	chr3:139349024~139349371:-
THCA	cis	rs4763879	0.502	rs11052552	ENSG00000256673.1	RP11-599J14.2	-3.78	0.000177	0.0128	-0.2	-0.17	Type 1 diabetes;	chr12:9703362	chr12:9398355~9414851:-
THCA	cis	rs17286411	0.671	rs3752681	ENSG00000260185.1	RP11-432I5.6	3.78	0.000177	0.0128	0.23	0.17	Blood protein levels;	chr16:71644760	chr16:71655027~71664212:+
THCA	cis	rs72482608	0.835	rs6679313	ENSG00000271811.1	RP1-79C4.4	3.78	0.000177	0.0128	0.21	0.17	Emphysema imaging phenotypes;	chr1:170745969	chr1:170667381~170669425:+
THCA	cis	rs11168249	0.819	rs2525051	ENSG00000257488.4	RP5-1057I20.2	3.78	0.000177	0.0128	0.22	0.17	Lymphocyte counts;Inflammatory bowel disease;Ulcerative colitis;	chr12:47802156	chr12:47826854~47837898:+
THCA	cis	rs8067545	0.603	rs10083830	ENSG00000261033.1	RP11-209D14.2	-3.78	0.000177	0.0128	-0.22	-0.17	Schizophrenia;	chr17:20062570	chr17:20008051~20009234:-
THCA	cis	rs801193	0.967	rs3800823	ENSG00000223473.2	GS1-124K5.3	-3.78	0.000177	0.0128	-0.11	-0.17	Aortic root size;	chr7:66682123	chr7:66491049~66493566:-
THCA	cis	rs804280	0.662	rs804283	ENSG00000270154.1	RP11-419I17.1	3.78	0.000177	0.0128	0.24	0.17	Myopia (pathological);	chr8:11753534	chr8:12476462~12477122:+
THCA	cis	rs5167	0.539	rs4803783	ENSG00000186019.10	AC084219.4	3.78	0.000177	0.0128	0.2	0.17	Blood protein levels;	chr19:44967201	chr19:44105463~44113145:-
THCA	cis	rs2074409	0.53	rs7224979	ENSG00000276054.1	RP11-378E13.3	-3.78	0.000177	0.0128	-0.26	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37593525	chr17:37386886~37387926:+
THCA	cis	rs6137726	0.524	rs1203924	ENSG00000237396.1	LINC01384	3.78	0.000177	0.0128	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22605670	chr20:22587522~22607517:-
THCA	cis	rs796395	0.701	rs2000220	ENSG00000228208.5	C1orf143	3.78	0.000177	0.0128	0.21	0.17	Post bronchodilator FEV1/FVC ratio;	chr1:218414294	chr1:218510096~218525978:+
THCA	cis	rs4869313	0.668	rs7736466	ENSG00000247121.5	CTD-2260A17.2	-3.78	0.000177	0.0128	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96954007	chr5:96814028~96935809:-
THCA	cis	rs13063635	0.915	rs17714228	ENSG00000226074.4	PRSS44	-3.78	0.000177	0.0128	-0.34	-0.17	Eosinophil percentage of granulocytes;	chr3:45903640	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs71325092	ENSG00000226074.4	PRSS44	-3.78	0.000177	0.0128	-0.34	-0.17	Eosinophil percentage of granulocytes;	chr3:45905526	chr3:46809359~46812558:-
THCA	cis	rs2276314	1	rs2276314	ENSG00000267627.4	RP11-905K4.1	3.78	0.000177	0.0128	0.22	0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35951803~35966118:-
THCA	cis	rs6893300	0.745	rs6639	ENSG00000225051.5	HMGB3P22	3.78	0.000177	0.0128	0.18	0.17	Resting heart rate;	chr5:179729781	chr5:179679032~179694768:+
THCA	cis	rs2836974	0.796	rs77153312	ENSG00000255568.3	BRWD1-AS2	3.78	0.000177	0.0128	0.15	0.17	Cognitive function;	chr21:39323573	chr21:39313935~39314962:+
THCA	cis	rs656900	0.74	rs1675181	ENSG00000261229.4	MTHFS	3.78	0.000177	0.0128	0.18	0.17	Cerebrospinal P-tau181p levels;	chr15:79819296	chr15:79843547~79897285:-
THCA	cis	rs12681366	0.881	rs2960121	ENSG00000253175.1	RP11-267M23.6	3.78	0.000177	0.0128	0.22	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94417678	chr8:94565036~94565715:+
THCA	cis	rs10911902	0.643	rs78088787	ENSG00000233196.2	GS1-304P7.1	-3.78	0.000177	0.0128	-0.26	-0.17	Schizophrenia;	chr1:186364550	chr1:186580515~186581191:-
THCA	cis	rs6756513	0.5	rs1048130	ENSG00000231024.1	AC092431.3	-3.78	0.000177	0.0128	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69904452	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs11126249	ENSG00000231024.1	AC092431.3	-3.78	0.000177	0.0128	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69909485	chr2:69700192~69713847:-
THCA	cis	rs2688608	0.592	rs7076585	ENSG00000272140.2	RP11-574K11.29	3.78	0.000177	0.0128	0.15	0.17	Inflammatory bowel disease;	chr10:73743934	chr10:73703735~73713581:-
THCA	cis	rs58327846	1	rs58327846	ENSG00000279434.1	RP11-85K15.3	-3.78	0.000177	0.0128	-0.16	-0.17	Breast cancer;	chr14:35130485	chr14:35086035~35088059:+
THCA	cis	rs8115854	0.885	rs6513954	ENSG00000269846.1	RP4-621N11.2	-3.78	0.000177	0.0128	-0.22	-0.17	Hippocampal atrophy;	chr20:37176567	chr20:37095785~37097178:+
THCA	cis	rs614226	0.938	rs7963543	ENSG00000278344.1	RP11-18C24.8	3.78	0.000177	0.0128	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120486145	chr12:120500735~120501090:-
THCA	cis	rs62158800	0.683	rs1516201	ENSG00000224568.1	AC096669.3	3.78	0.000177	0.0128	0.22	0.17	Facial morphology (factor 22);	chr2:107686571	chr2:107529487~107556326:+
THCA	cis	rs12612619	0.732	rs722911	ENSG00000272148.1	RP11-195B17.1	3.78	0.000177	0.0128	0.16	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26988344	chr2:27062428~27062907:-
THCA	cis	rs494003	1	rs10896043	ENSG00000214659.4	KRT8P26	-3.78	0.000177	0.0128	-0.19	-0.17	Systemic lupus erythematosus;	chr11:65776356	chr11:65726939~65728214:+
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000184274.3	LINC00315	-3.78	0.000177	0.0128	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45300245~45305257:-
THCA	cis	rs911555	0.755	rs6575988	ENSG00000269958.1	RP11-73M18.8	-3.78	0.000177	0.0128	-0.16	-0.17	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103696353~103697163:+
THCA	cis	rs6088580	0.524	rs6088570	ENSG00000126005.14	MMP24-AS1	3.78	0.000177	0.0128	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34680491	chr20:35216462~35278131:-
THCA	cis	rs9693857	0.52	rs11249928	ENSG00000248538.5	RP11-10A14.5	-3.78	0.000177	0.0128	-0.23	-0.17	Systolic blood pressure;	chr8:9505750	chr8:9189011~9202854:+
THCA	cis	rs853679	0.599	rs149943	ENSG00000272009.1	RP1-313I6.12	-3.78	0.000177	0.0128	-0.24	-0.17	Depression;	chr6:28034610	chr6:28078792~28081130:-
THCA	cis	rs4742903	0.967	rs10991119	ENSG00000270332.1	SMC2-AS1	-3.78	0.000177	0.0128	-0.16	-0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104142996	chr9:104080024~104093073:-
THCA	cis	rs7551222	0.663	rs1563828	ENSG00000240219.1	RP11-430C7.5	3.78	0.000177	0.0128	0.16	0.17	Schizophrenia;	chr1:204547449	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.752	rs4951398	ENSG00000240219.1	RP11-430C7.5	3.78	0.000177	0.0128	0.16	0.17	Schizophrenia;	chr1:204562748	chr1:204626775~204629712:+
THCA	cis	rs73198271	0.74	rs10092720	ENSG00000254153.1	CTA-398F10.2	3.78	0.000177	0.0128	0.21	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8456909~8461337:-
THCA	cis	rs2179367	0.959	rs9377212	ENSG00000223701.3	RAET1E-AS1	3.78	0.000177	0.0128	0.22	0.17	Dupuytren's disease;	chr6:149383765	chr6:149884431~149919508:+
THCA	cis	rs988712	0.921	rs4922788	ENSG00000245573.6	BDNF-AS	-3.78	0.000177	0.0128	-0.15	-0.17	Obesity;	chr11:27589482	chr11:27506838~27698174:+
THCA	cis	rs4389656	0.775	rs274668	ENSG00000248677.1	CTD-2044J15.1	3.78	0.000177	0.0128	0.17	0.17	Coronary artery disease;	chr5:6711517	chr5:6686325~6707711:-
THCA	cis	rs10435719	0.805	rs13269417	ENSG00000254948.1	OR7E158P	-3.78	0.000177	0.0128	-0.22	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:11919900~11920809:-
THCA	cis	rs748404	0.533	rs11632120	ENSG00000166763.7	STRCP1	-3.78	0.000177	0.0128	-0.18	-0.17	Lung cancer;	chr15:43123175	chr15:43699488~43718184:-
THCA	cis	rs7829975	0.633	rs2979181	ENSG00000233609.3	RP11-62H7.2	3.78	0.000177	0.0128	0.17	0.17	Mood instability;	chr8:8465578	chr8:8961200~8979025:+
THCA	cis	rs7956611	0.564	rs7964266	ENSG00000213343.5	RPL21P18	-3.78	0.000177	0.0128	-0.2	-0.17	Age of smoking initiation;	chr12:66521455	chr12:66037235~66037714:+
THCA	cis	rs4865169	0.623	rs6838975	ENSG00000269949.1	RP11-738E22.3	-3.78	0.000177	0.0128	-0.22	-0.17	Breast cancer;	chr4:56873650	chr4:56960927~56961373:-
THCA	cis	rs708547	0.541	rs6554392	ENSG00000269949.1	RP11-738E22.3	-3.78	0.000177	0.0128	-0.22	-0.17	Response to bleomycin (chromatid breaks);	chr4:56873782	chr4:56960927~56961373:-
THCA	cis	rs12549025	0.945	rs11785620	ENSG00000253390.1	CTC-756D1.2	-3.78	0.000177	0.0128	-0.3	-0.17	Reticulocyte fraction of red cells;	chr8:23541442	chr8:23458601~23484971:+
THCA	cis	rs12549025	1	rs12549025	ENSG00000253390.1	CTC-756D1.2	-3.78	0.000177	0.0128	-0.3	-0.17	Reticulocyte fraction of red cells;	chr8:23542024	chr8:23458601~23484971:+
THCA	cis	rs12549025	0.945	rs35617675	ENSG00000253390.1	CTC-756D1.2	-3.78	0.000177	0.0128	-0.3	-0.17	Reticulocyte fraction of red cells;	chr8:23547196	chr8:23458601~23484971:+
THCA	cis	rs12549025	0.945	rs11787200	ENSG00000253390.1	CTC-756D1.2	-3.78	0.000177	0.0128	-0.3	-0.17	Reticulocyte fraction of red cells;	chr8:23547610	chr8:23458601~23484971:+
THCA	cis	rs9595908	0.63	rs4057297	ENSG00000212293.1	SNORA16	3.78	0.000177	0.0128	0.2	0.17	Body mass index;	chr13:32731612	chr13:32420390~32420516:-
THCA	cis	rs9595908	0.63	rs1929939	ENSG00000212293.1	SNORA16	3.78	0.000177	0.0128	0.2	0.17	Body mass index;	chr13:32733547	chr13:32420390~32420516:-
THCA	cis	rs7119038	0.865	rs7117261	ENSG00000255239.1	AP002954.6	3.78	0.000177	0.0128	0.27	0.17	Sjögren's syndrome;	chr11:118870448	chr11:118688039~118690600:-
THCA	cis	rs832540	0.83	rs252907	ENSG00000271828.1	CTD-2310F14.1	-3.78	0.000177	0.0128	-0.24	-0.17	Coronary artery disease;	chr5:56824819	chr5:56927874~56929573:+
THCA	cis	rs10090774	0.965	rs61661433	ENSG00000280303.2	ERICD	3.78	0.000177	0.0128	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140976296	chr8:140636281~140638283:+
THCA	cis	rs7914558	1	rs4917380	ENSG00000213061.2	PFN1P11	3.78	0.000177	0.0128	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103015578	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs7914558	ENSG00000213061.2	PFN1P11	3.78	0.000177	0.0128	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103016151	chr10:102838011~102845473:-
THCA	cis	rs9487094	0.666	rs9480956	ENSG00000223537.2	RP5-919F19.5	-3.78	0.000177	0.0128	-0.17	-0.17	Height;	chr6:109424305	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.689	rs12214147	ENSG00000223537.2	RP5-919F19.5	-3.78	0.000177	0.0128	-0.17	-0.17	Height;	chr6:109425054	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.689	rs17070591	ENSG00000223537.2	RP5-919F19.5	-3.78	0.000177	0.0128	-0.17	-0.17	Height;	chr6:109426518	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.666	rs7751582	ENSG00000223537.2	RP5-919F19.5	-3.78	0.000177	0.0128	-0.17	-0.17	Height;	chr6:109427644	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.689	rs9487103	ENSG00000223537.2	RP5-919F19.5	-3.78	0.000177	0.0128	-0.17	-0.17	Height;	chr6:109430292	chr6:109487906~109506800:+
THCA	cis	rs3812831	0.543	rs389108	ENSG00000264539.1	MIR548AR	3.78	0.000178	0.0128	0.18	0.17	Schizophrenia;	chr13:114159914	chr13:114244505~114244561:+
THCA	cis	rs804280	0.543	rs13261205	ENSG00000255495.1	AC145124.2	3.78	0.000178	0.0128	0.2	0.17	Myopia (pathological);	chr8:11933707	chr8:12194467~12196280:+
THCA	cis	rs804280	0.518	rs34266352	ENSG00000255495.1	AC145124.2	3.78	0.000178	0.0128	0.2	0.17	Myopia (pathological);	chr8:11933953	chr8:12194467~12196280:+
THCA	cis	rs804280	0.542	rs34117651	ENSG00000255495.1	AC145124.2	3.78	0.000178	0.0128	0.2	0.17	Myopia (pathological);	chr8:11934108	chr8:12194467~12196280:+
THCA	cis	rs17301013	0.896	rs6425287	ENSG00000270084.1	GAS5-AS1	-3.78	0.000178	0.0128	-0.18	-0.17	Systemic lupus erythematosus;	chr1:174566264	chr1:173863248~173863941:+
THCA	cis	rs4879656	0.843	rs10813918	ENSG00000225693.1	LAGE3P1	3.78	0.000178	0.0128	0.18	0.17	Menopause (age at onset);	chr9:32996372	chr9:33019682~33020165:-
THCA	cis	rs6441286	0.929	rs13065738	ENSG00000244040.4	IL12A-AS1	-3.78	0.000178	0.0128	-0.22	-0.17	Primary biliary cholangitis;	chr3:160002772	chr3:159913400~160225299:-
THCA	cis	rs490608	0.628	rs678157	ENSG00000203761.5	MSTO2P	-3.78	0.000178	0.0128	-0.14	-0.17	Inflammatory bowel disease;	chr1:155688550	chr1:155745829~155750137:+
THCA	cis	rs10090774	0.71	rs10107434	ENSG00000279766.1	RP11-642A1.2	-3.78	0.000178	0.0128	-0.21	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140662466	chr8:140572142~140572812:-
THCA	cis	rs786425	0.682	rs7135660	ENSG00000278112.1	RP11-972P1.11	3.78	0.000178	0.0128	0.17	0.17	Pubertal anthropometrics;	chr12:123689687	chr12:123519390~123519856:-
THCA	cis	rs875971	0.545	rs2279757	ENSG00000232559.3	GS1-124K5.12	3.78	0.000178	0.0128	0.19	0.17	Aortic root size;	chr7:66363676	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs11766183	ENSG00000232559.3	GS1-124K5.12	3.78	0.000178	0.0128	0.19	0.17	Aortic root size;	chr7:66374173	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs7811204	ENSG00000232559.3	GS1-124K5.12	3.78	0.000178	0.0128	0.19	0.17	Aortic root size;	chr7:66387213	chr7:66554588~66576923:-
THCA	cis	rs8023401	0.529	rs3929051	ENSG00000259705.1	RP11-227D13.1	-3.78	0.000178	0.0128	-0.21	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48428074	chr15:48645951~48652016:+
THCA	cis	rs372883	0.648	rs15092	ENSG00000176054.6	RPL23P2	-3.78	0.000178	0.0128	-0.15	-0.17	Pancreatic cancer;	chr21:29345880	chr21:28997613~28998033:-
THCA	cis	rs11671005	0.735	rs3826682	ENSG00000269600.1	AC016629.3	-3.78	0.000178	0.0128	-0.25	-0.17	Mean platelet volume;	chr19:58407381	chr19:58593896~58599355:-
THCA	cis	rs854765	0.547	rs4584886	ENSG00000281749.1	Y_RNA	3.78	0.000178	0.0128	0.22	0.17	Total body bone mineral density;	chr17:17992891	chr17:18001101~18001195:-
THCA	cis	rs6500602	0.727	rs55939215	ENSG00000280063.1	RP11-295D4.3	3.78	0.000178	0.0128	0.09	0.17	Schizophrenia;	chr16:4491389	chr16:4346694~4348648:-
THCA	cis	rs7403037	0.687	rs61993107	ENSG00000260760.1	PWRN3	3.78	0.000178	0.0128	0.24	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24537990	chr15:24441127~24447967:+
THCA	cis	rs17685	0.712	rs60721456	ENSG00000227038.2	AC005077.12	3.78	0.000178	0.0128	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76114502	chr7:76090431~76108779:-
THCA	cis	rs763121	0.925	rs5757251	ENSG00000225450.1	RP3-508I15.14	-3.78	0.000178	0.0128	-0.13	-0.17	Menopause (age at onset);	chr22:38704123	chr22:38739003~38749041:+
THCA	cis	rs3781264	0.6	rs10882416	ENSG00000273450.1	RP11-76P2.4	-3.78	0.000178	0.0128	-0.21	-0.17	Esophageal cancer and gastric cancer;	chr10:94285297	chr10:94314907~94315327:-
THCA	cis	rs12682352	0.602	rs4841044	ENSG00000248538.5	RP11-10A14.5	3.78	0.000178	0.0128	0.22	0.17	Neuroticism;	chr8:8807430	chr8:9189011~9202854:+
THCA	cis	rs2307022	0.541	rs10775303	ENSG00000274698.1	RP11-71L14.4	3.78	0.000178	0.0128	0.21	0.17	Body mass index;	chr16:68327011	chr16:68450283~68452318:+
THCA	cis	rs6747488	0.504	rs644103	ENSG00000276517.1	AL133243.2	-3.78	0.000178	0.0128	-0.16	-0.17	Interleukin-18 levels;	chr2:31630252	chr2:32526504~32529507:+
THCA	cis	rs12681366	0.614	rs3099397	ENSG00000261437.1	RP11-22C11.2	3.78	0.000178	0.0128	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94467091	chr8:94637285~94639467:-
THCA	cis	rs2080501	0.54	rs7184732	ENSG00000275155.1	CTD-2595P9.4	3.78	0.000178	0.0128	0.15	0.17	IgG glycosylation;	chr16:49652075	chr16:49847018~49847632:-
THCA	cis	rs9291683	0.526	rs7695555	ENSG00000250413.1	RP11-448G15.1	-3.78	0.000178	0.0128	-0.17	-0.17	Bone mineral density;	chr4:10000032	chr4:10006482~10009725:+
THCA	cis	rs17286411	0.613	rs60881203	ENSG00000260185.1	RP11-432I5.6	-3.78	0.000178	0.0128	-0.23	-0.17	Blood protein levels;	chr16:71703756	chr16:71655027~71664212:+
THCA	cis	rs9911578	1	rs2531732	ENSG00000224738.1	AC099850.1	-3.78	0.000178	0.0128	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58471059	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs2531734	ENSG00000224738.1	AC099850.1	-3.78	0.000178	0.0128	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58473443	chr17:59106598~59118267:+
THCA	cis	rs9291683	0.588	rs3756238	ENSG00000261490.1	RP11-448G15.3	3.78	0.000178	0.0128	0.1	0.17	Bone mineral density;	chr4:10011578	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.552	rs10939655	ENSG00000261490.1	RP11-448G15.3	3.78	0.000178	0.0128	0.1	0.17	Bone mineral density;	chr4:10013018	chr4:10068089~10073019:-
THCA	cis	rs11971779	0.68	rs11764236	ENSG00000252332.1	RNU6-911P	-3.78	0.000178	0.0128	-0.19	-0.17	Diisocyanate-induced asthma;	chr7:139433768	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.648	rs66463279	ENSG00000252332.1	RNU6-911P	-3.78	0.000178	0.0128	-0.19	-0.17	Diisocyanate-induced asthma;	chr7:139433915	chr7:139448740~139448843:+
THCA	cis	rs2640806	0.505	rs7007009	ENSG00000253105.4	KB-1448A5.1	3.78	0.000178	0.0128	0.2	0.17	Obesity-related traits;	chr8:96352492	chr8:96371865~96387438:-
THCA	cis	rs150992	0.655	rs327807	ENSG00000246763.5	RGMB-AS1	-3.78	0.000178	0.0128	-0.18	-0.17	Body mass index;	chr5:98942448	chr5:98769618~98773469:-
THCA	cis	rs6479891	0.591	rs4598556	ENSG00000232075.1	MRPL35P2	3.78	0.000178	0.0128	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63097283	chr10:63634317~63634827:-
THCA	cis	rs1075265	0.791	rs1833498	ENSG00000235937.1	AC008280.1	3.78	0.000178	0.0128	0.2	0.17	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54029552~54030682:-
THCA	cis	rs2115630	0.641	rs11073613	ENSG00000259728.4	LINC00933	-3.78	0.000178	0.0128	-0.21	-0.17	P wave terminal force;	chr15:84642662	chr15:84570649~84580175:+
THCA	cis	rs6500637	0.931	rs79338890	ENSG00000267077.1	RP11-127I20.5	3.78	0.000178	0.0128	0.21	0.17	Cancer;	chr16:4855126	chr16:4795265~4796532:-
THCA	cis	rs11671005	0.695	rs8106061	ENSG00000269600.1	AC016629.3	-3.78	0.000178	0.0128	-0.25	-0.17	Mean platelet volume;	chr19:58406623	chr19:58593896~58599355:-
THCA	cis	rs7520050	0.778	rs12404197	ENSG00000281133.1	AL355480.3	3.78	0.000178	0.0128	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.801	rs6703960	ENSG00000281133.1	AL355480.3	3.78	0.000178	0.0128	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45580892~45580996:-
THCA	cis	rs11975235	0.782	rs1029550	ENSG00000272905.1	RP11-265E18.1	-3.78	0.000178	0.0128	-0.14	-0.17	Presence of antiphospholipid antibodies;	chr7:32147157	chr7:32845394~32846061:+
THCA	cis	rs7903847	0.62	rs10882907	ENSG00000225850.3	RP11-452K12.4	-3.78	0.000178	0.0128	-0.17	-0.17	Granulocyte percentage of myeloid white cells;	chr10:97366031	chr10:97334564~97343203:+
THCA	cis	rs6546886	0.912	rs10168410	ENSG00000235499.1	AC073046.25	3.78	0.000178	0.0128	0.16	0.17	Dialysis-related mortality;	chr2:74066983	chr2:73985132~73986343:+
THCA	cis	rs4908768	0.871	rs11121221	ENSG00000232912.4	RP5-1115A15.1	-3.78	0.000178	0.0128	-0.2	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8707470	chr1:8424645~8434838:+
THCA	cis	rs1005277	0.683	rs7923868	ENSG00000275858.1	RP11-291L22.8	3.78	0.000178	0.0128	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38450738~38451069:-
THCA	cis	rs2933343	0.553	rs789212	ENSG00000231305.3	RP11-723O4.2	3.78	0.000178	0.0128	0.19	0.17	IgG glycosylation;	chr3:128968069	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.553	rs35979399	ENSG00000231305.3	RP11-723O4.2	3.78	0.000178	0.0128	0.19	0.17	IgG glycosylation;	chr3:128978470	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.533	rs11915889	ENSG00000231305.3	RP11-723O4.2	3.78	0.000178	0.0128	0.19	0.17	IgG glycosylation;	chr3:128982023	chr3:128861313~128871540:-
THCA	cis	rs12188164	0.543	rs2672722	ENSG00000188242.4	PP7080	-3.78	0.000178	0.0128	-0.15	-0.17	Cystic fibrosis severity;	chr5:453452	chr5:466124~473098:-
THCA	cis	rs12188164	0.543	rs2672757	ENSG00000188242.4	PP7080	-3.78	0.000178	0.0128	-0.15	-0.17	Cystic fibrosis severity;	chr5:454617	chr5:466124~473098:-
THCA	cis	rs11239930	0.517	rs584107	ENSG00000278811.3	LINC00624	-3.78	0.000178	0.0128	-0.2	-0.17	AIDS progression;	chr1:147075862	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.517	rs685741	ENSG00000278811.3	LINC00624	3.78	0.000178	0.0128	0.2	0.17	AIDS progression;	chr1:147074503	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.517	rs678111	ENSG00000278811.3	LINC00624	3.78	0.000178	0.0128	0.2	0.17	AIDS progression;	chr1:147076613	chr1:147258885~147517875:-
THCA	cis	rs11239930	0.517	rs535827	ENSG00000278811.3	LINC00624	3.78	0.000178	0.0128	0.2	0.17	AIDS progression;	chr1:147076642	chr1:147258885~147517875:-
THCA	cis	rs56309584	0.521	rs11651599	ENSG00000271002.1	RP11-599B13.8	-3.78	0.000178	0.0128	-0.27	-0.17	Initial pursuit acceleration;	chr17:8276194	chr17:8199123~8199437:-
THCA	cis	rs6088580	0.505	rs6141503	ENSG00000126005.14	MMP24-AS1	3.78	0.000178	0.0128	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34686665	chr20:35216462~35278131:-
THCA	cis	rs9291683	0.588	rs3756237	ENSG00000261490.1	RP11-448G15.3	3.78	0.000178	0.0128	0.1	0.17	Bone mineral density;	chr4:10011754	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.588	rs3756236	ENSG00000261490.1	RP11-448G15.3	3.78	0.000178	0.0128	0.1	0.17	Bone mineral density;	chr4:10011839	chr4:10068089~10073019:-
THCA	cis	rs8023401	0.507	rs2306352	ENSG00000259705.1	RP11-227D13.1	3.78	0.000178	0.0128	0.21	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48513440	chr15:48645951~48652016:+
THCA	cis	rs6840360	0.571	rs11736116	ENSG00000251611.1	RP11-610P16.1	-3.78	0.000178	0.0128	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151610664	chr4:151407551~151408835:-
THCA	cis	rs6747488	0.55	rs223621	ENSG00000276334.1	AL133243.1	3.78	0.000178	0.0128	0.19	0.17	Interleukin-18 levels;	chr2:31805423	chr2:32521927~32523547:+
THCA	cis	rs2033711	0.87	rs7409473	ENSG00000268049.1	CTD-2619J13.9	-3.78	0.000178	0.0128	-0.21	-0.17	Uric acid clearance;	chr19:58427798	chr19:58357999~58359603:+
THCA	cis	rs2033711	0.87	rs7408188	ENSG00000268049.1	CTD-2619J13.9	-3.78	0.000178	0.0128	-0.21	-0.17	Uric acid clearance;	chr19:58428022	chr19:58357999~58359603:+
THCA	cis	rs2033711	0.87	rs1051500	ENSG00000268049.1	CTD-2619J13.9	-3.78	0.000178	0.0128	-0.21	-0.17	Uric acid clearance;	chr19:58433035	chr19:58357999~58359603:+
THCA	cis	rs9425766	0.626	rs6691053	ENSG00000227373.4	RP11-160H22.5	3.78	0.000178	0.0128	0.25	0.17	Life satisfaction;	chr1:173899817	chr1:174115300~174160004:-
THCA	cis	rs7616559	0.627	rs11720579	ENSG00000244515.1	KRT18P34	-3.78	0.000178	0.0128	-0.2	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157025689	chr3:157162663~157163932:-
THCA	cis	rs17122278	1	rs73022038	ENSG00000243431.1	RPL5P30	3.78	0.000178	0.0128	0.17	0.17	Total cholesterol levels;	chr11:118537756	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs73022041	ENSG00000243431.1	RPL5P30	3.78	0.000178	0.0128	0.17	0.17	Total cholesterol levels;	chr11:118538074	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs7128587	ENSG00000243431.1	RPL5P30	3.78	0.000178	0.0128	0.17	0.17	Total cholesterol levels;	chr11:118538587	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs11216883	ENSG00000243431.1	RPL5P30	3.78	0.000178	0.0128	0.17	0.17	Total cholesterol levels;	chr11:118539753	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs11216884	ENSG00000243431.1	RPL5P30	3.78	0.000178	0.0128	0.17	0.17	Total cholesterol levels;	chr11:118539773	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs11216886	ENSG00000243431.1	RPL5P30	3.78	0.000178	0.0128	0.17	0.17	Total cholesterol levels;	chr11:118540709	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs61290697	ENSG00000243431.1	RPL5P30	3.78	0.000178	0.0128	0.17	0.17	Total cholesterol levels;	chr11:118541643	chr11:118560690~118561580:+
THCA	cis	rs4604234	0.614	rs11962441	ENSG00000260645.1	RP11-250B2.5	-3.78	0.000178	0.0128	-0.28	-0.17	Cancer;	chr6:80155705	chr6:80466958~80469080:+
THCA	cis	rs9532669	0.926	rs4555012	ENSG00000229473.2	RGS17P1	3.78	0.000178	0.0128	0.22	0.17	Cervical cancer;	chr13:40879997	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs12871420	ENSG00000229473.2	RGS17P1	3.78	0.000178	0.0128	0.22	0.17	Cervical cancer;	chr13:40880034	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs12871735	ENSG00000229473.2	RGS17P1	3.78	0.000178	0.0128	0.22	0.17	Cervical cancer;	chr13:40880169	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs12871895	ENSG00000229473.2	RGS17P1	3.78	0.000178	0.0128	0.22	0.17	Cervical cancer;	chr13:40880189	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs12872288	ENSG00000229473.2	RGS17P1	3.78	0.000178	0.0128	0.22	0.17	Cervical cancer;	chr13:40880268	chr13:40992779~40993331:-
THCA	cis	rs1959947	0.837	rs10133953	ENSG00000251363.2	RP11-129M6.1	-3.78	0.000178	0.0128	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41047806	chr14:40954898~40975877:+
THCA	cis	rs12612619	0.732	rs714513	ENSG00000272148.1	RP11-195B17.1	3.78	0.000178	0.0128	0.16	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26983606	chr2:27062428~27062907:-
THCA	cis	rs1436955	0.959	rs8030240	ENSG00000259251.2	RP11-643M14.1	3.78	0.000178	0.0128	0.19	0.17	Type 2 diabetes;	chr15:62107365	chr15:62060503~62062434:+
THCA	cis	rs4788570	0.547	rs6499538	ENSG00000260593.1	RP11-432I5.2	-3.78	0.000178	0.0128	-0.28	-0.17	Intelligence (multi-trait analysis);	chr16:71728382	chr16:71623708~71626816:-
THCA	cis	rs16957091	0.647	rs35088691	ENSG00000205771.5	CATSPER2P1	3.78	0.000178	0.0128	0.23	0.17	MGMT methylation in smokers;	chr15:42772565	chr15:43726918~43747094:-
THCA	cis	rs801193	1	rs13239306	ENSG00000236529.1	RP13-254B10.1	-3.78	0.000178	0.0128	-0.2	-0.17	Aortic root size;	chr7:66671030	chr7:65840212~65840596:+
THCA	cis	rs7713065	1	rs3857440	ENSG00000237714.1	P4HA2-AS1	-3.78	0.000178	0.0128	-0.26	-0.17	Lung function (FEV1/FVC);	chr5:132458377	chr5:132184876~132192808:+
THCA	cis	rs2274273	0.84	rs943590	ENSG00000258469.1	CHMP4BP1	3.78	0.000178	0.0129	0.15	0.17	Protein biomarker;	chr14:55271878	chr14:55298644~55299231:+
THCA	cis	rs7727544	0.582	rs4361509	ENSG00000263597.1	MIR3936	-3.78	0.000178	0.0129	-0.16	-0.17	Blood metabolite levels;	chr5:132201060	chr5:132365490~132365599:-
THCA	cis	rs714027	0.585	rs73162764	ENSG00000279699.1	RP1-102K2.9	3.78	0.000178	0.0129	0.17	0.17	Lymphocyte counts;	chr22:29962756	chr22:30275215~30276951:-
THCA	cis	rs2115630	0.967	rs12595786	ENSG00000275120.1	RP11-182J1.17	-3.78	0.000178	0.0129	-0.18	-0.17	P wave terminal force;	chr15:84793439	chr15:84599434~84606463:-
THCA	cis	rs860295	0.557	rs11264372	ENSG00000236675.1	MTX1P1	-3.78	0.000179	0.0129	-0.18	-0.17	Body mass index;	chr1:155443139	chr1:155230975~155234325:+
THCA	cis	rs964611	0.872	rs2279366	ENSG00000259488.2	RP11-154J22.1	-3.78	0.000179	0.0129	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48249830	chr15:48312353~48331856:-
THCA	cis	rs7264396	0.836	rs6058275	ENSG00000088340.14	FER1L4	3.78	0.000179	0.0129	0.17	0.17	Total cholesterol levels;	chr20:35598409	chr20:35558737~35607562:-
THCA	cis	rs854765	0.663	rs4925120	ENSG00000281749.1	Y_RNA	-3.78	0.000179	0.0129	-0.22	-0.17	Total body bone mineral density;	chr17:17851319	chr17:18001101~18001195:-
THCA	cis	rs397969	0.621	rs203480	ENSG00000261033.1	RP11-209D14.2	-3.78	0.000179	0.0129	-0.26	-0.17	Platelet count;	chr17:19925646	chr17:20008051~20009234:-
THCA	cis	rs1642645	1	rs1642645	ENSG00000228452.1	RP5-994D16.9	-3.78	0.000179	0.0129	-0.22	-0.17	Left ventricular obstructive tract defect (maternal effect);	chr1:42036610	chr1:42775813~42776790:-
THCA	cis	rs1908814	0.516	rs35391955	ENSG00000255495.1	AC145124.2	3.78	0.000179	0.0129	0.2	0.17	Neuroticism;	chr8:11939219	chr8:12194467~12196280:+
THCA	cis	rs2163813	0.959	rs247770	ENSG00000271499.1	CTC-559E9.9	3.78	0.000179	0.0129	0.21	0.17	Toenail selenium levels;	chr19:19737995	chr19:19750618~19752544:+
THCA	cis	rs5758511	0.68	rs5758682	ENSG00000270083.1	RP1-257I20.14	-3.78	0.000179	0.0129	-0.22	-0.17	Birth weight;	chr22:42249196	chr22:42089630~42090028:-
THCA	cis	rs5758511	0.68	rs34107327	ENSG00000270083.1	RP1-257I20.14	-3.78	0.000179	0.0129	-0.22	-0.17	Birth weight;	chr22:42252347	chr22:42089630~42090028:-
THCA	cis	rs5758511	0.68	rs5758684	ENSG00000270083.1	RP1-257I20.14	-3.78	0.000179	0.0129	-0.22	-0.17	Birth weight;	chr22:42253503	chr22:42089630~42090028:-
THCA	cis	rs12681366	0.614	rs2921387	ENSG00000261437.1	RP11-22C11.2	3.78	0.000179	0.0129	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94446109	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.614	rs935052	ENSG00000261437.1	RP11-22C11.2	3.78	0.000179	0.0129	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94449718	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.614	rs2930969	ENSG00000261437.1	RP11-22C11.2	3.78	0.000179	0.0129	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94451857	chr8:94637285~94639467:-
THCA	cis	rs62289301	0.637	rs62289290	ENSG00000273133.1	RP11-799M12.2	3.78	0.000179	0.0129	0.22	0.17	Joint mobility (Beighton score);	chr4:15423317	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs16891929	ENSG00000273133.1	RP11-799M12.2	3.78	0.000179	0.0129	0.22	0.17	Joint mobility (Beighton score);	chr4:15423573	chr4:15563698~15564253:-
THCA	cis	rs3817198	1	rs3817198	ENSG00000226416.1	MRPL23-AS1	-3.78	0.000179	0.0129	-0.21	-0.17	Breast cancer;Mammographic density (dense area);	chr11:1887776	chr11:1983237~1989920:-
THCA	cis	rs2880765	0.835	rs4526974	ENSG00000259407.1	RP11-158M2.3	-3.78	0.000179	0.0129	-0.17	-0.17	Coronary artery disease;	chr15:85481053	chr15:85744109~85750281:-
THCA	cis	rs4906332	0.966	rs2065016	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103413319	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs34479426	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103415486	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs8012127	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103476425	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs78316803	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103476526	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs17617832	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103476803	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs11625172	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103478575	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs17617935	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103486549	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs17680085	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103486817	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs12896919	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103490376	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs35126287	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103493095	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs55930273	ENSG00000259775.1	RP11-45P15.4	-3.78	0.000179	0.0129	-0.15	-0.17	Coronary artery disease;	chr14:103493961	chr14:103331674~103332367:-
THCA	cis	rs62025270	1	rs62025270	ENSG00000259295.5	CSPG4P12	-3.78	0.000179	0.0129	-0.28	-0.17	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85191438~85213905:+
THCA	cis	rs11089937	0.616	rs4145537	ENSG00000211639.2	IGLV4-60	-3.78	0.000179	0.0129	-0.12	-0.17	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22162199~22162681:+
THCA	cis	rs1125355	0.655	rs1515924	ENSG00000243792.1	OR7E89P	3.78	0.000179	0.0129	0.25	0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158792828	chr2:158853755~158854576:+
THCA	cis	rs11250098	0.562	rs6987134	ENSG00000261451.1	RP11-981G7.1	-3.78	0.000179	0.0129	-0.22	-0.17	Morning vs. evening chronotype;	chr8:10947396	chr8:10433672~10438312:+
THCA	cis	rs4764124	0.571	rs11830399	ENSG00000261324.2	RP11-174G6.5	-3.78	0.000179	0.0129	-0.13	-0.17	Pubertal anthropometrics;	chr12:14803998	chr12:14762504~14767931:-
THCA	cis	rs4073416	0.508	rs11844682	ENSG00000276116.2	FUT8-AS1	3.78	0.000179	0.0129	0.19	0.17	N-glycan levels;	chr14:65444126	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.504	rs6573612	ENSG00000276116.2	FUT8-AS1	3.78	0.000179	0.0129	0.19	0.17	N-glycan levels;	chr14:65446111	chr14:65411170~65412690:-
THCA	cis	rs1127311	0.901	rs11264223	ENSG00000236675.1	MTX1P1	-3.78	0.000179	0.0129	-0.16	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154593043	chr1:155230975~155234325:+
THCA	cis	rs34975555	0.803	rs4570198	ENSG00000253671.1	RP11-806O11.1	-3.78	0.000179	0.0129	-0.28	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17958196	chr8:17808941~17820868:+
THCA	cis	rs2694917	0.68	rs2638314	ENSG00000257576.1	RP11-153M3.1	3.78	0.000179	0.0129	0.27	0.17	Blood metabolite ratios;	chr12:56472550	chr12:56511002~56512703:+
THCA	cis	rs4578769	0.918	rs6507457	ENSG00000265939.1	UBE2CP2	-3.78	0.000179	0.0129	-0.21	-0.17	Eosinophil percentage of white cells;	chr18:23046473	chr18:22900486~22900995:-
THCA	cis	rs1862618	0.853	rs10461617	ENSG00000234553.1	AC022431.3	-3.78	0.000179	0.0129	-0.2	-0.17	Initial pursuit acceleration;	chr5:56808481	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.756	rs9292125	ENSG00000234553.1	AC022431.3	-3.78	0.000179	0.0129	-0.2	-0.17	Initial pursuit acceleration;	chr5:56811373	chr5:56536583~56537826:-
THCA	cis	rs9341808	0.754	rs3805907	ENSG00000260645.1	RP11-250B2.5	-3.78	0.000179	0.0129	-0.15	-0.17	Sitting height ratio;	chr6:80263948	chr6:80466958~80469080:+
THCA	cis	rs7119038	0.818	rs2155433	ENSG00000255422.1	AP002954.4	3.78	0.000179	0.0129	0.21	0.17	Sjögren's syndrome;	chr11:118742212	chr11:118704607~118750263:+
THCA	cis	rs13064411	0.696	rs11921931	ENSG00000243849.1	CFAP44-AS1	3.78	0.000179	0.0129	0.28	0.17	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113296244	chr3:113403991~113433992:+
THCA	cis	rs7824557	0.51	rs1435274	ENSG00000227888.4	FAM66A	-3.78	0.000179	0.0129	-0.22	-0.17	Retinal vascular caliber;	chr8:11378401	chr8:12362019~12388296:+
THCA	cis	rs12073837	0.5	rs4143772	ENSG00000272823.1	RP11-295M18.6	-3.78	0.000179	0.0129	-0.2	-0.17	F-cell distribution;	chr1:220815004	chr1:220828676~220829211:-
THCA	cis	rs9910055	0.573	rs228768	ENSG00000267080.4	ASB16-AS1	-3.78	0.000179	0.0129	-0.15	-0.17	Total body bone mineral density;	chr17:44114525	chr17:44175973~44186717:-
THCA	cis	rs685782	0.529	rs276898	ENSG00000200201.1	Y_RNA	-3.78	0.000179	0.0129	-0.24	-0.17	Metabolite levels (Dihydroxy docosatrienoic acid);	chr11:3762282	chr11:3665164~3665259:-
THCA	cis	rs3893429	0.522	rs12486037	ENSG00000248724.5	NPHP3-AS1	-3.78	0.000179	0.0129	-0.2	-0.17	Aggressiveness in attention deficit hyperactivity disorder;	chr3:132155752	chr3:132721750~132874223:+
THCA	cis	rs36093844	0.527	rs72951266	ENSG00000279742.1	RP11-700A24.1	-3.78	0.000179	0.0129	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85983565	chr11:85852557~85854943:-
THCA	cis	rs10540	1	rs35255804	ENSG00000279672.1	CMB9-55F22.1	3.78	0.000179	0.0129	0.34	0.17	Body mass index;	chr11:492617	chr11:779617~780755:+
THCA	cis	rs308403	0.533	rs12644866	ENSG00000224786.1	CETN4P	3.78	0.000179	0.0129	0.18	0.17	Blood protein levels;	chr4:122746449	chr4:122730548~122732193:-
THCA	cis	rs372883	0.6	rs2832295	ENSG00000176054.6	RPL23P2	3.78	0.000179	0.0129	0.15	0.17	Pancreatic cancer;	chr21:29367522	chr21:28997613~28998033:-
THCA	cis	rs12681366	0.683	rs2470739	ENSG00000261437.1	RP11-22C11.2	-3.78	0.000179	0.0129	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94389694	chr8:94637285~94639467:-
THCA	cis	rs9987353	0.522	rs2929466	ENSG00000254153.1	CTA-398F10.2	3.78	0.000179	0.0129	0.19	0.17	Recombination measurement;	chr8:9206389	chr8:8456909~8461337:-
THCA	cis	rs13217239	0.646	rs9393789	ENSG00000261353.1	CTA-14H9.5	3.78	0.000179	0.0129	0.18	0.17	Schizophrenia;	chr6:27099249	chr6:26527063~26527404:+
THCA	cis	rs7809950	0.678	rs7803151	ENSG00000272072.1	CTA-363E19.2	3.78	0.000179	0.0129	0.19	0.17	Coronary artery disease;	chr7:107293801	chr7:107192559~107193300:-
THCA	cis	rs7403037	1	rs7495122	ENSG00000260760.1	PWRN3	3.78	0.000179	0.0129	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24588464	chr15:24441127~24447967:+
THCA	cis	rs7403037	1	rs7494918	ENSG00000260760.1	PWRN3	3.78	0.000179	0.0129	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24588477	chr15:24441127~24447967:+
THCA	cis	rs7844233	0.649	rs6996367	ENSG00000254023.1	PKMP4	3.78	0.000179	0.0129	0.28	0.17	Breast cancer;	chr8:75677970	chr8:75376709~75377014:+
THCA	cis	rs7829975	0.686	rs907180	ENSG00000254340.1	RP11-10A14.3	3.78	0.000179	0.0129	0.18	0.17	Mood instability;	chr8:8845317	chr8:9141424~9145435:+
THCA	cis	rs2929278	0.561	rs3099045	ENSG00000275601.1	AC011330.13	-3.78	0.000179	0.0129	-0.21	-0.17	Schizophrenia;	chr15:43631757	chr15:43642389~43643023:-
THCA	cis	rs9435732	0.594	rs2647166	ENSG00000268869.4	ESPNP	-3.78	0.000179	0.0129	-0.18	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17016240	chr1:16687339~16720157:-
THCA	cis	rs34421088	0.576	rs2572436	ENSG00000255046.1	RP11-297N6.4	3.78	0.000179	0.0129	0.2	0.17	Neuroticism;	chr8:11241700	chr8:11797928~11802568:-
THCA	cis	rs34526934	0.672	rs6710142	ENSG00000226363.3	HAGLROS	3.78	0.000179	0.0129	0.24	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176190041	chr2:176177717~176179008:+
THCA	cis	rs172166	0.561	rs149971	ENSG00000261839.1	RP1-265C24.8	3.78	0.000179	0.0129	0.16	0.17	Cardiac Troponin-T levels;	chr6:28014374	chr6:28136849~28139678:+
THCA	cis	rs9980	0.817	rs1972658	ENSG00000226232.7	RP11-419C5.2	3.78	0.00018	0.0129	0.26	0.17	Blood osmolality (transformed sodium);	chr16:69557380	chr16:69976388~69996188:-
THCA	cis	rs1842579	1	rs6693669	ENSG00000272691.1	RP11-290M5.4	-3.78	0.00018	0.0129	-0.17	-0.17	Coronary artery aneurysm in Kawasaki disease;	chr1:85821897	chr1:85578500~85578742:-
THCA	cis	rs1842579	1	rs1481199	ENSG00000272691.1	RP11-290M5.4	-3.78	0.00018	0.0129	-0.17	-0.17	Coronary artery aneurysm in Kawasaki disease;	chr1:85822883	chr1:85578500~85578742:-
THCA	cis	rs11671005	0.779	rs11670125	ENSG00000269600.1	AC016629.3	-3.78	0.00018	0.0129	-0.26	-0.17	Mean platelet volume;	chr19:58476023	chr19:58593896~58599355:-
THCA	cis	rs7487637	0.566	rs875023	ENSG00000257488.4	RP5-1057I20.2	-3.78	0.00018	0.0129	-0.29	-0.17	Mononucleosis;	chr12:47800652	chr12:47826854~47837898:+
THCA	cis	rs11633886	0.967	rs7165191	ENSG00000273972.1	CTD-2306A12.1	3.78	0.00018	0.0129	0.19	0.17	Diisocyanate-induced asthma;	chr15:45783735	chr15:45702640~45703183:+
THCA	cis	rs13178541	0.574	rs11242292	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135793829	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.574	rs11242293	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135793846	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs11954354	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135793998	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs11955110	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135794353	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.606	rs11958506	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135794373	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.574	rs11958557	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135794527	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs11948583	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135794589	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.574	rs55798589	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135794616	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.574	rs11748719	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135794979	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.574	rs11745326	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135795200	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs10053928	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135795501	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs10069265	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135795700	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs10077045	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135795798	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs62364709	ENSG00000250378.1	RP11-119J18.1	-3.78	0.00018	0.0129	-0.2	-0.17	IgG glycosylation;	chr5:135796257	chr5:135812667~135826582:+
THCA	cis	rs972578	0.84	rs8138151	ENSG00000230319.1	AL022476.2	3.78	0.00018	0.0129	0.18	0.17	Mean platelet volume;	chr22:42989997	chr22:43038585~43052366:+
THCA	cis	rs765787	0.53	rs11636404	ENSG00000259539.1	CTD-2651B20.1	3.78	0.00018	0.0129	0.21	0.17	Uric acid levels;	chr15:45243663	chr15:45152664~45167526:-
THCA	cis	rs2562456	0.724	rs58001930	ENSG00000268658.4	LINC00664	3.78	0.00018	0.0129	0.25	0.17	Pain;	chr19:21560061	chr19:21483374~21503238:+
THCA	cis	rs4906332	0.811	rs2296487	ENSG00000269940.1	RP11-73M18.7	3.78	0.00018	0.0129	0.19	0.17	Coronary artery disease;	chr14:103529868	chr14:103694560~103695170:+
THCA	cis	rs9902453	0.845	rs62068583	ENSG00000264290.1	RP11-68I3.4	3.78	0.00018	0.0129	0.13	0.17	Coffee consumption (cups per day);	chr17:29674464	chr17:29569580~29570519:+
THCA	cis	rs301901	0.861	rs217797	ENSG00000250155.1	CTD-2353F22.1	-3.78	0.00018	0.0129	-0.17	-0.17	Height;	chr5:37318193	chr5:36666214~36725195:-
THCA	cis	rs7264396	0.79	rs2425096	ENSG00000088340.14	FER1L4	3.78	0.00018	0.0129	0.17	0.17	Total cholesterol levels;	chr20:35720666	chr20:35558737~35607562:-
THCA	cis	rs10435719	0.902	rs7459983	ENSG00000254948.1	OR7E158P	-3.78	0.00018	0.0129	-0.22	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:11919900~11920809:-
THCA	cis	rs1580019	0.587	rs9638880	ENSG00000273014.1	RP11-225B17.2	3.78	0.00018	0.0129	0.18	0.17	Cognitive ability;	chr7:32512789	chr7:32758882~32759353:+
THCA	cis	rs1023500	0.505	rs134899	ENSG00000237037.8	NDUFA6-AS1	-3.78	0.00018	0.0129	-0.14	-0.17	Schizophrenia;	chr22:42287024	chr22:42090931~42137742:+
THCA	cis	rs2904524	1	rs17108038	ENSG00000257815.4	RP11-611E13.2	-3.78	0.00018	0.0129	-0.16	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70347828	chr12:69904033~70243360:-
THCA	cis	rs7520050	0.933	rs6694340	ENSG00000281133.1	AL355480.3	3.78	0.00018	0.0129	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45580892~45580996:-
THCA	cis	rs7551222	0.721	rs4951402	ENSG00000240219.1	RP11-430C7.5	3.78	0.00018	0.0129	0.16	0.17	Schizophrenia;	chr1:204569994	chr1:204626775~204629712:+
THCA	cis	rs10875746	0.669	rs61941003	ENSG00000258273.1	RP11-370I10.4	3.78	0.00018	0.0129	0.25	0.17	Longevity (90 years and older);	chr12:48225842	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.579	rs10875778	ENSG00000258273.1	RP11-370I10.4	3.78	0.00018	0.0129	0.25	0.17	Longevity (90 years and older);	chr12:48230872	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.669	rs10875779	ENSG00000258273.1	RP11-370I10.4	3.78	0.00018	0.0129	0.25	0.17	Longevity (90 years and older);	chr12:48236086	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.669	rs11168487	ENSG00000258273.1	RP11-370I10.4	3.78	0.00018	0.0129	0.25	0.17	Longevity (90 years and older);	chr12:48246926	chr12:48333755~48333901:-
THCA	cis	rs5758659	0.622	rs5758527	ENSG00000205702.9	CYP2D7	3.78	0.00018	0.0129	0.13	0.17	Cognitive function;	chr22:41979757	chr22:42140203~42144577:-
THCA	cis	rs9595908	0.609	rs733487	ENSG00000212293.1	SNORA16	3.78	0.00018	0.0129	0.2	0.17	Body mass index;	chr13:32741068	chr13:32420390~32420516:-
THCA	cis	rs1154275	0.537	rs9832885	ENSG00000272844.1	RP11-484K9.4	3.78	0.00018	0.0129	0.14	0.17	Takotsubo syndrome;	chr3:112799612	chr3:112990447~112991153:-
THCA	cis	rs13053817	1	rs13057815	ENSG00000279159.1	RP3-394A18.1	3.78	0.00018	0.0129	0.17	0.17	Carotid atherosclerosis in HIV infection;	chr22:29457537	chr22:29978950~30028236:-
THCA	cis	rs7274963	1	rs7274963	ENSG00000236474.1	GCNT1P1	3.78	0.00018	0.0129	0.22	0.17	Body mass index;	chr20:18310335	chr20:18420160~18421454:-
THCA	cis	rs2919009	0.664	rs7906521	ENSG00000271670.1	RP11-95I16.4	3.78	0.00018	0.0129	0.19	0.17	Obesity-related traits;	chr10:120927034	chr10:120879256~120880667:-
THCA	cis	rs9309473	0.66	rs17349321	ENSG00000273245.1	RP11-434P11.2	3.78	0.00018	0.0129	0.27	0.17	Metabolite levels;	chr2:73416625	chr2:73750256~73750786:-
THCA	cis	rs9341808	0.528	rs2322753	ENSG00000260645.1	RP11-250B2.5	3.78	0.00018	0.0129	0.14	0.17	Sitting height ratio;	chr6:80333148	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.556	rs2223875	ENSG00000260645.1	RP11-250B2.5	3.78	0.00018	0.0129	0.14	0.17	Sitting height ratio;	chr6:80335735	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.587	rs3805859	ENSG00000260645.1	RP11-250B2.5	3.78	0.00018	0.0129	0.14	0.17	Sitting height ratio;	chr6:80339229	chr6:80466958~80469080:+
THCA	cis	rs16957091	0.528	rs34474101	ENSG00000205771.5	CATSPER2P1	3.78	0.00018	0.0129	0.25	0.17	MGMT methylation in smokers;	chr15:42895262	chr15:43726918~43747094:-
THCA	cis	rs4272720	0.51	rs4445564	ENSG00000234736.4	FAM170B-AS1	-3.78	0.00018	0.0129	-0.18	-0.17	Platelet count;Plateletcrit;	chr10:49088577	chr10:49121839~49151547:+
THCA	cis	rs703842	0.616	rs7489290	ENSG00000270039.1	RP11-571M6.17	-3.78	0.00018	0.0129	-0.2	-0.17	Multiple sclerosis;	chr12:57834805	chr12:57803838~57804415:+
THCA	cis	rs3770081	1	rs17027011	ENSG00000273080.1	RP11-301O19.1	-3.78	0.00018	0.0129	-0.33	-0.17	Facial emotion recognition (sad faces);	chr2:86179433	chr2:86195590~86196049:+
THCA	cis	rs656900	0.74	rs644315	ENSG00000261229.4	MTHFS	3.78	0.00018	0.0129	0.18	0.17	Cerebrospinal P-tau181p levels;	chr15:79821207	chr15:79843547~79897285:-
THCA	cis	rs3758911	0.861	rs11212197	ENSG00000255353.1	RP11-382M14.1	-3.78	0.00018	0.0129	-0.22	-0.17	Coronary artery disease;	chr11:107391784	chr11:107176286~107177530:+
THCA	cis	rs7520050	0.966	rs4545281	ENSG00000281133.1	AL355480.3	3.78	0.00018	0.0129	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45894382	chr1:45580892~45580996:-
THCA	cis	rs11601239	0.607	rs11226858	ENSG00000254750.1	CASP1P2	-3.78	0.00018	0.0129	-0.14	-0.17	Refractive error;	chr11:105828951	chr11:105063345~105071541:-
THCA	cis	rs950169	0.84	rs2896002	ENSG00000275120.1	RP11-182J1.17	3.78	0.00018	0.0129	0.21	0.17	Schizophrenia;	chr15:84390423	chr15:84599434~84606463:-
THCA	cis	rs1959947	0.876	rs4904224	ENSG00000251363.2	RP11-129M6.1	-3.78	0.00018	0.0129	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41059025	chr14:40954898~40975877:+
THCA	cis	rs9475752	0.744	rs35301163	ENSG00000231441.1	RP11-472M19.2	3.78	0.00018	0.0129	0.18	0.17	Menarche (age at onset);	chr6:56924105	chr6:56844002~56864078:+
THCA	cis	rs12681366	0.801	rs72674819	ENSG00000253175.1	RP11-267M23.6	3.78	0.00018	0.0129	0.22	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94468072	chr8:94565036~94565715:+
THCA	cis	rs56114371	0.53	rs169262	ENSG00000226314.6	ZNF192P1	-3.78	0.00018	0.0129	-0.23	-0.17	Breast cancer;	chr6:27803112	chr6:28161781~28169594:+
THCA	cis	rs2675662	0.525	rs12264025	ENSG00000272140.2	RP11-574K11.29	3.78	0.00018	0.0129	0.15	0.17	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73703735~73713581:-
THCA	cis	rs2688608	0.592	rs12253429	ENSG00000272140.2	RP11-574K11.29	3.78	0.00018	0.0129	0.15	0.17	Inflammatory bowel disease;	chr10:73736403	chr10:73703735~73713581:-
THCA	cis	rs656319	0.58	rs13279701	ENSG00000261451.1	RP11-981G7.1	-3.78	0.00018	0.0129	-0.22	-0.17	Myopia (pathological);	chr8:10111940	chr8:10433672~10438312:+
THCA	cis	rs8007846	0.631	rs8014475	ENSG00000276116.2	FUT8-AS1	3.78	0.00018	0.0129	0.18	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr14:65344819	chr14:65411170~65412690:-
THCA	cis	rs7665090	0.934	rs35112949	ENSG00000248971.2	KRT8P46	-3.78	0.00018	0.0129	-0.2	-0.17	Primary biliary cholangitis;	chr4:102638473	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.87	rs34349956	ENSG00000248971.2	KRT8P46	-3.78	0.00018	0.0129	-0.2	-0.17	Primary biliary cholangitis;	chr4:102638476	chr4:102728746~102730171:-
THCA	cis	rs3748656	0.945	rs11102501	ENSG00000273483.1	RP4-671G15.2	3.78	0.00018	0.0129	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112585332	chr1:112517799~112518441:-
THCA	cis	rs2341873	0.524	rs4849255	ENSG00000204588.5	LINC01123	-3.78	0.00018	0.0129	-0.19	-0.17	Neutrophil percentage of white cells;	chr2:110928212	chr2:109987063~109996140:+
THCA	cis	rs10435719	0.902	rs7006538	ENSG00000255495.1	AC145124.2	3.78	0.00018	0.0129	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:12194467~12196280:+
THCA	cis	rs295490	0.748	rs77995988	ENSG00000272656.1	RP11-219D15.3	3.78	0.00018	0.0129	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456686	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs79361389	ENSG00000272656.1	RP11-219D15.3	3.78	0.00018	0.0129	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139458517	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs78251555	ENSG00000272656.1	RP11-219D15.3	3.78	0.00018	0.0129	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139460159	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs17494356	ENSG00000272656.1	RP11-219D15.3	3.78	0.00018	0.0129	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139465126	chr3:139349024~139349371:-
THCA	cis	rs2904297	0.916	rs6846529	ENSG00000261490.1	RP11-448G15.3	-3.78	0.00018	0.0129	-0.12	-0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11023507	chr4:10068089~10073019:-
THCA	cis	rs12681366	0.881	rs10464877	ENSG00000261437.1	RP11-22C11.2	3.78	0.00018	0.0129	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94385615	chr8:94637285~94639467:-
THCA	cis	rs17122278	1	rs7932700	ENSG00000243431.1	RPL5P30	3.78	0.00018	0.013	0.17	0.17	Total cholesterol levels;	chr11:118540998	chr11:118560690~118561580:+
THCA	cis	rs2832191	0.716	rs9983051	ENSG00000176054.6	RPL23P2	3.78	0.00018	0.013	0.15	0.17	Dental caries;	chr21:28999569	chr21:28997613~28998033:-
THCA	cis	rs7760535	0.597	rs9320368	ENSG00000231889.6	TRAF3IP2-AS1	3.78	0.00018	0.013	0.15	0.17	Metabolic traits;	chr6:111583534	chr6:111483511~111598302:+
THCA	cis	rs9650657	0.769	rs1968400	ENSG00000255310.2	AF131215.2	-3.78	0.00018	0.013	-0.14	-0.17	Neuroticism;	chr8:10757921	chr8:11107788~11109726:-
THCA	cis	rs9905704	0.918	rs302862	ENSG00000224738.1	AC099850.1	3.78	0.00018	0.013	0.23	0.17	Testicular germ cell tumor;	chr17:58620083	chr17:59106598~59118267:+
THCA	cis	rs7220401	0.512	rs2289629	ENSG00000264290.1	RP11-68I3.4	3.78	0.00018	0.013	0.14	0.17	Coronary artery disease;	chr17:29632885	chr17:29569580~29570519:+
THCA	cis	rs34779708	0.706	rs36027395	ENSG00000233200.1	RP11-324I22.2	3.78	0.00018	0.013	0.21	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35219894~35230598:-
THCA	cis	rs9291683	0.588	rs6844329	ENSG00000261490.1	RP11-448G15.3	3.78	0.00018	0.013	0.1	0.17	Bone mineral density;	chr4:10016920	chr4:10068089~10073019:-
THCA	cis	rs7520050	0.966	rs10890363	ENSG00000280836.1	AL355480.1	-3.78	0.00018	0.013	-0.21	-0.17	Reticulocyte count;Red blood cell count;	chr1:45890476	chr1:45581219~45581321:-
THCA	cis	rs4908768	0.501	rs6577499	ENSG00000270282.1	RP5-1115A15.2	-3.78	0.00018	0.013	-0.2	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8512653~8513021:+
THCA	cis	rs17134212	0.565	rs12658467	ENSG00000251187.4	CTC-459M5.2	3.78	0.00018	0.013	0.16	0.17	Common carotid intima-media thickness in HIV negative individuals;	chr5:112205253	chr5:112192020~112210139:+
THCA	cis	rs7243790	0.967	rs62091589	ENSG00000277324.1	RP11-850A17.1	-3.78	0.00018	0.013	-0.18	-0.17	Diastolic blood pressure;	chr18:54425327	chr18:54268346~54270028:-
THCA	cis	rs12499086	0.574	rs13144832	ENSG00000251175.4	RP11-45L9.1	3.78	0.00018	0.013	0.21	0.17	Economic and political preferences (time);	chr4:105498361	chr4:105746245~105827172:-
THCA	cis	rs372883	0.563	rs1153293	ENSG00000176054.6	RPL23P2	3.78	0.00018	0.013	0.15	0.17	Pancreatic cancer;	chr21:29319004	chr21:28997613~28998033:-
THCA	cis	rs2474937	0.536	rs67180520	ENSG00000231365.4	RP11-418J17.1	3.78	0.00018	0.013	0.17	0.17	Congenital heart malformation;	chr1:118387238	chr1:119140396~119275973:+
THCA	cis	rs1065852	0.526	rs56234624	ENSG00000232710.1	RP4-669P10.16	-3.78	0.00018	0.013	-0.21	-0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41992822	chr22:42136433~42139927:-
THCA	cis	rs2919009	0.664	rs61872418	ENSG00000271670.1	RP11-95I16.4	3.78	0.00018	0.013	0.2	0.17	Obesity-related traits;	chr10:120785859	chr10:120879256~120880667:-
THCA	cis	rs8177876	0.749	rs935942	ENSG00000261838.4	RP11-303E16.6	-3.78	0.00018	0.013	-0.28	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81069854~81076598:+
THCA	cis	rs1836229	0.835	rs10815961	ENSG00000225706.1	PTPRD-AS1	-3.78	0.00018	0.013	-0.2	-0.17	Restless legs syndrome;	chr9:8818758	chr9:8858130~8862255:+
THCA	cis	rs10760158	0.8	rs10739595	ENSG00000226752.6	PSMD5-AS1	-3.78	0.00018	0.013	-0.21	-0.17	Pulse pressure;	chr9:121293743	chr9:120824828~120854385:+
THCA	cis	rs17122278	1	rs2277292	ENSG00000243431.1	RPL5P30	3.78	0.00018	0.013	0.17	0.17	Total cholesterol levels;	chr11:118554704	chr11:118560690~118561580:+
THCA	cis	rs2721195	1	rs2721195	ENSG00000265393.1	CTD-2517M22.17	3.78	0.00018	0.013	0.21	0.17	Age at first birth;	chr8:144451628	chr8:144512567~144513672:+
THCA	cis	rs74233809	1	rs11191499	ENSG00000272912.1	RP11-724N1.1	-3.78	0.00018	0.013	-0.31	-0.17	Birth weight;	chr10:103004514	chr10:102914585~102915404:+
THCA	cis	rs4578769	0.55	rs4473296	ENSG00000273232.1	RP11-370A5.2	-3.78	0.00018	0.013	-0.23	-0.17	Eosinophil percentage of white cells;	chr18:22986421	chr18:22882825~22883357:-
THCA	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	3.78	0.00018	0.013	0.18	0.17	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
THCA	cis	rs7824557	0.815	rs958648	ENSG00000255310.2	AF131215.2	-3.78	0.00018	0.013	-0.14	-0.17	Retinal vascular caliber;	chr8:11246386	chr8:11107788~11109726:-
THCA	cis	rs3808502	0.503	rs2061830	ENSG00000227888.4	FAM66A	3.77	0.000181	0.013	0.22	0.17	Neuroticism;	chr8:11539948	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.592	rs920044	ENSG00000206014.6	OR7E161P	-3.77	0.000181	0.013	-0.2	-0.17	Retinal vascular caliber;	chr8:11366804	chr8:11928597~11929563:-
THCA	cis	rs7616559	0.962	rs1600976	ENSG00000244515.1	KRT18P34	-3.77	0.000181	0.013	-0.23	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157033705	chr3:157162663~157163932:-
THCA	cis	rs6142618	0.935	rs6061184	ENSG00000224452.1	RSL24D1P6	3.77	0.000181	0.013	0.21	0.17	Inflammatory bowel disease;	chr20:32142435	chr20:32170390~32170790:-
THCA	cis	rs481331	0.866	rs499558	ENSG00000215146.4	RP11-313J2.1	3.77	0.000181	0.013	0.3	0.17	Systemic juvenile idiopathic arthritis;	chr10:42716583	chr10:42331866~42367974:-
THCA	cis	rs6500602	0.963	rs7201012	ENSG00000280063.1	RP11-295D4.3	3.77	0.000181	0.013	0.1	0.17	Schizophrenia;	chr16:4430681	chr16:4346694~4348648:-
THCA	cis	rs1923243	0.714	rs11210121	ENSG00000223479.3	RP4-788P17.1	3.77	0.000181	0.013	0.19	0.17	Migraine;	chr1:73075388	chr1:73635216~73715214:+
THCA	cis	rs62244186	0.715	rs11130032	ENSG00000214820.3	MPRIPP1	3.77	0.000181	0.013	0.18	0.17	Depressive symptoms;	chr3:44662591	chr3:44579938~44581026:-
THCA	cis	rs10200159	0.793	rs12615063	ENSG00000206964.1	Y_RNA	-3.77	0.000181	0.013	-0.39	-0.17	Vitiligo;	chr2:55680347	chr2:55286018~55286128:+
THCA	cis	rs6570726	0.935	rs446242	ENSG00000270638.1	RP3-466P17.1	3.77	0.000181	0.013	0.14	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145735570~145737218:+
THCA	cis	rs2688608	0.672	rs2688621	ENSG00000271816.1	BMS1P4	3.77	0.000181	0.013	0.17	0.17	Inflammatory bowel disease;	chr10:73928091	chr10:73699151~73730487:-
THCA	cis	rs8017455	0.656	rs2241119	ENSG00000259167.2	NMNAT1P1	-3.77	0.000181	0.013	-0.25	-0.17	Hair morphology;	chr14:81092621	chr14:81032529~81033404:+
THCA	cis	rs7089973	0.604	rs11819372	ENSG00000228169.3	PPIAP19	3.77	0.000181	0.013	0.2	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114835175	chr10:114690143~114690634:-
THCA	cis	rs801193	0.935	rs2659899	ENSG00000275400.1	RP4-756H11.5	-3.77	0.000181	0.013	-0.16	-0.17	Aortic root size;	chr7:66721734	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs1553609	ENSG00000275400.1	RP4-756H11.5	-3.77	0.000181	0.013	-0.16	-0.17	Aortic root size;	chr7:66732152	chr7:66553805~66554199:-
THCA	cis	rs801193	0.967	rs2707853	ENSG00000275400.1	RP4-756H11.5	-3.77	0.000181	0.013	-0.16	-0.17	Aortic root size;	chr7:66749023	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs2659889	ENSG00000275400.1	RP4-756H11.5	-3.77	0.000181	0.013	-0.16	-0.17	Aortic root size;	chr7:66752125	chr7:66553805~66554199:-
THCA	cis	rs17382723	0.887	rs60134249	ENSG00000225521.1	AC005237.4	3.77	0.000181	0.013	0.22	0.17	Height;	chr2:241103233	chr2:241015599~241064116:-
THCA	cis	rs17382723	0.887	rs58343802	ENSG00000225521.1	AC005237.4	3.77	0.000181	0.013	0.22	0.17	Height;	chr2:241103398	chr2:241015599~241064116:-
THCA	cis	rs854765	0.583	rs11078406	ENSG00000281749.1	Y_RNA	3.77	0.000181	0.013	0.21	0.17	Total body bone mineral density;	chr17:17937509	chr17:18001101~18001195:-
THCA	cis	rs17772222	0.637	rs7161660	ENSG00000222990.1	RNU4-22P	3.77	0.000181	0.013	0.21	0.17	Coronary artery calcification;	chr14:88471832	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.682	rs7141363	ENSG00000222990.1	RNU4-22P	3.77	0.000181	0.013	0.21	0.17	Coronary artery calcification;	chr14:88471879	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.637	rs879932	ENSG00000222990.1	RNU4-22P	3.77	0.000181	0.013	0.21	0.17	Coronary artery calcification;	chr14:88479247	chr14:88513498~88513663:+
THCA	cis	rs2692947	0.759	rs2949885	ENSG00000235584.2	AC008268.1	-3.77	0.000181	0.013	-0.17	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95996667	chr2:95666084~95668715:+
THCA	cis	rs6012953	0.73	rs6020562	ENSG00000231715.1	COX6CP2	3.77	0.000181	0.013	0.18	0.17	Vitiligo;	chr20:50503069	chr20:50479767~50479991:+
THCA	cis	rs5751614	0.557	rs5759666	ENSG00000236611.1	AP000343.2	-3.77	0.000181	0.013	-0.23	-0.17	Height;	chr22:23260155	chr22:23326616~23328493:+
THCA	cis	rs860295	0.812	rs10908481	ENSG00000236675.1	MTX1P1	-3.77	0.000181	0.013	-0.18	-0.17	Body mass index;	chr1:155743859	chr1:155230975~155234325:+
THCA	cis	rs6921919	0.789	rs11970439	ENSG00000219392.1	RP1-265C24.5	-3.77	0.000181	0.013	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28115628~28116551:+
THCA	cis	rs804280	0.703	rs745379	ENSG00000270154.1	RP11-419I17.1	-3.77	0.000181	0.013	-0.21	-0.17	Myopia (pathological);	chr8:11758186	chr8:12476462~12477122:+
THCA	cis	rs2455799	0.613	rs7633542	ENSG00000270409.1	RP11-44D5.1	-3.77	0.000181	0.013	-0.18	-0.17	Mean platelet volume;	chr3:15774819	chr3:15732252~15733470:+
THCA	cis	rs9611565	0.659	rs73178632	ENSG00000237037.8	NDUFA6-AS1	3.77	0.000181	0.013	0.16	0.17	Vitiligo;	chr22:41538569	chr22:42090931~42137742:+
THCA	cis	rs11190604	0.767	rs10883477	ENSG00000273030.1	RP11-285F16.1	3.77	0.000181	0.013	0.2	0.17	Palmitoleic acid (16:1n-7) levels;	chr10:100401639	chr10:100412934~100413421:+
THCA	cis	rs3015497	0.626	rs7150204	ENSG00000270062.1	RP11-248J18.3	3.77	0.000181	0.013	0.2	0.17	Mean platelet volume;	chr14:50670637	chr14:50723777~50724272:-
THCA	cis	rs10875746	0.855	rs2269936	ENSG00000258234.1	RP11-370I10.2	3.77	0.000181	0.013	0.21	0.17	Longevity (90 years and older);	chr12:48031452	chr12:48231098~48284210:-
THCA	cis	rs74233809	1	rs11191514	ENSG00000272912.1	RP11-724N1.1	-3.77	0.000181	0.013	-0.31	-0.17	Birth weight;	chr10:103013607	chr10:102914585~102915404:+
THCA	cis	rs9650657	0.746	rs4841441	ENSG00000255310.2	AF131215.2	-3.77	0.000181	0.013	-0.14	-0.17	Neuroticism;	chr8:10773388	chr8:11107788~11109726:-
THCA	cis	rs6982240	0.514	rs1865247	ENSG00000253307.1	RP11-10J21.4	3.77	0.000181	0.013	0.25	0.17	Tonsillectomy;	chr8:141264555	chr8:141252286~141253292:-
THCA	cis	rs6982240	0.514	rs10481414	ENSG00000253307.1	RP11-10J21.4	3.77	0.000181	0.013	0.25	0.17	Tonsillectomy;	chr8:141265227	chr8:141252286~141253292:-
THCA	cis	rs6982240	0.514	rs9324543	ENSG00000253307.1	RP11-10J21.4	3.77	0.000181	0.013	0.25	0.17	Tonsillectomy;	chr8:141265563	chr8:141252286~141253292:-
THCA	cis	rs6982240	0.514	rs10088801	ENSG00000253307.1	RP11-10J21.4	3.77	0.000181	0.013	0.25	0.17	Tonsillectomy;	chr8:141265702	chr8:141252286~141253292:-
THCA	cis	rs2274089	0.649	rs3804103	ENSG00000272810.1	U91328.22	-3.77	0.000181	0.013	-0.24	-0.17	Iron status biomarkers;	chr6:25617063	chr6:26013241~26013757:+
THCA	cis	rs765787	0.53	rs13329228	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000181	0.013	0.21	0.17	Uric acid levels;	chr15:45240819	chr15:45198517~45199139:-
THCA	cis	rs10181042	0.565	rs1177233	ENSG00000232713.2	AC010733.5	-3.77	0.000181	0.013	-0.16	-0.17	Crohn's disease;	chr2:61034999	chr2:60938204~60938604:-
THCA	cis	rs7616559	0.649	rs12636394	ENSG00000244515.1	KRT18P34	-3.77	0.000181	0.013	-0.2	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157018893	chr3:157162663~157163932:-
THCA	cis	rs4460629	0.742	rs7368345	ENSG00000225855.5	RUSC1-AS1	-3.77	0.000181	0.013	-0.11	-0.17	Serum magnesium levels;	chr1:155107614	chr1:155316863~155324176:-
THCA	cis	rs9475677	0.953	rs9986501	ENSG00000231441.1	RP11-472M19.2	3.77	0.000181	0.013	0.21	0.17	Gut microbiota (functional units);	chr6:56352304	chr6:56844002~56864078:+
THCA	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	3.77	0.000181	0.013	0.2	0.17	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
THCA	cis	rs12612619	0.732	rs12613822	ENSG00000272148.1	RP11-195B17.1	3.77	0.000181	0.013	0.16	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26994234	chr2:27062428~27062907:-
THCA	cis	rs2688608	0.62	rs12253408	ENSG00000272140.2	RP11-574K11.29	3.77	0.000181	0.013	0.15	0.17	Inflammatory bowel disease;	chr10:73736198	chr10:73703735~73713581:-
THCA	cis	rs858239	0.863	rs274054	ENSG00000230042.1	AK3P3	-3.77	0.000181	0.013	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23129178~23129841:+
THCA	cis	rs4908768	0.52	rs6681362	ENSG00000270282.1	RP5-1115A15.2	3.77	0.000181	0.013	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598468	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.539	rs1318218	ENSG00000270282.1	RP5-1115A15.2	3.77	0.000181	0.013	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598653	chr1:8512653~8513021:+
THCA	cis	rs6083	0.549	rs11858020	ENSG00000245975.2	RP11-30K9.6	3.77	0.000181	0.013	0.15	0.17	Schizophrenia;	chr15:58560223	chr15:58768072~58770974:-
THCA	cis	rs4819052	0.679	rs2255761	ENSG00000273796.1	LL21NC02-21A1.1	-3.77	0.000181	0.013	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45403809~45404369:-
THCA	cis	rs17685	0.702	rs6960598	ENSG00000227038.2	AC005077.12	3.77	0.000181	0.013	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76143673	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs10235738	ENSG00000227038.2	AC005077.12	3.77	0.000181	0.013	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76144142	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs6953342	ENSG00000227038.2	AC005077.12	3.77	0.000181	0.013	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76147435	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs10952842	ENSG00000227038.2	AC005077.12	3.77	0.000181	0.013	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76151095	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs6464994	ENSG00000227038.2	AC005077.12	3.77	0.000181	0.013	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76155350	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs7794454	ENSG00000227038.2	AC005077.12	-3.77	0.000181	0.013	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76146692	chr7:76090431~76108779:-
THCA	cis	rs1401543	0.891	rs6414336	ENSG00000239213.4	NCK1-AS1	-3.77	0.000181	0.013	-0.19	-0.17	Anticoagulant levels;	chr3:135887193	chr3:136841726~136862054:-
THCA	cis	rs763121	0.853	rs2076028	ENSG00000228274.3	RP3-508I15.9	-3.77	0.000181	0.013	-0.2	-0.17	Menopause (age at onset);	chr22:38754445	chr22:38667585~38681820:-
THCA	cis	rs4767841	0.565	rs2240309	ENSG00000252886.1	RN7SKP197	3.77	0.000181	0.013	0.17	0.17	Urgency urinary incontinence;	chr12:119783648	chr12:119631090~119631386:-
THCA	cis	rs12681366	0.537	rs10095298	ENSG00000253175.1	RP11-267M23.6	3.77	0.000181	0.013	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94472353	chr8:94565036~94565715:+
THCA	cis	rs9309473	1	rs6740223	ENSG00000273245.1	RP11-434P11.2	3.77	0.000181	0.013	0.23	0.17	Metabolite levels;	chr2:73426204	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs6707722	ENSG00000273245.1	RP11-434P11.2	3.77	0.000181	0.013	0.23	0.17	Metabolite levels;	chr2:73427235	chr2:73750256~73750786:-
THCA	cis	rs3892630	0.588	rs1976501	ENSG00000267475.1	CTD-2538C1.2	-3.77	0.000181	0.013	-0.24	-0.17	Red blood cell traits;	chr19:32717249	chr19:32687089~32691750:-
THCA	cis	rs12188164	0.525	rs2561665	ENSG00000188242.4	PP7080	-3.77	0.000181	0.013	-0.15	-0.17	Cystic fibrosis severity;	chr5:460020	chr5:466124~473098:-
THCA	cis	rs3020264	0.586	rs3020265	ENSG00000271743.1	CTD-2541M15.3	3.77	0.000181	0.013	0.21	0.17	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631400	chr8:6615604~6617198:-
THCA	cis	rs2797160	0.515	rs4897149	ENSG00000226409.1	RP11-735G4.1	3.77	0.000181	0.013	0.22	0.17	Endometrial cancer;	chr6:125658872	chr6:125370211~125374324:-
THCA	cis	rs17428076	0.793	rs72881938	ENSG00000228389.1	AC068039.4	-3.77	0.000181	0.013	-0.2	-0.17	Myopia;	chr2:171772242	chr2:171773482~171775844:+
THCA	cis	rs3748682	0.861	rs28420383	ENSG00000252448.1	SNORA63	-3.77	0.000181	0.013	-0.22	-0.17	Hypothyroidism;	chr1:37880733	chr1:37884237~37884317:+
THCA	cis	rs9309473	0.5	rs4286298	ENSG00000273245.1	RP11-434P11.2	-3.77	0.000181	0.013	-0.21	-0.17	Metabolite levels;	chr2:73654981	chr2:73750256~73750786:-
THCA	cis	rs721917	0.506	rs927452	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000181	0.013	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79660891~79677996:+
THCA	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	3.77	0.000181	0.013	0.18	0.17	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
THCA	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	3.77	0.000181	0.013	0.18	0.17	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
THCA	cis	rs1035144	0.679	rs72693068	ENSG00000258915.1	BHLHB9P1	-3.77	0.000181	0.013	-0.19	-0.17	Male sexual orientation;	chr14:80979394	chr14:80981988~80983638:+
THCA	cis	rs1035144	0.679	rs72693070	ENSG00000258915.1	BHLHB9P1	-3.77	0.000181	0.013	-0.19	-0.17	Male sexual orientation;	chr14:80979587	chr14:80981988~80983638:+
THCA	cis	rs1035144	0.679	rs72693073	ENSG00000258915.1	BHLHB9P1	-3.77	0.000181	0.013	-0.19	-0.17	Male sexual orientation;	chr14:80980213	chr14:80981988~80983638:+
THCA	cis	rs7711186	0.708	rs11742564	ENSG00000252464.1	RN7SKP70	3.77	0.000181	0.013	0.18	0.17	Urate levels in obese individuals;	chr5:178636335	chr5:178619728~178619998:-
THCA	cis	rs12440869	1	rs4776354	ENSG00000270964.1	RP11-502I4.3	3.77	0.000181	0.013	0.15	0.17	Peak velocity of the mitral A-wave;	chr15:67365943	chr15:67541072~67542604:-
THCA	cis	rs12440869	0.959	rs4776923	ENSG00000270964.1	RP11-502I4.3	3.77	0.000181	0.013	0.15	0.17	Peak velocity of the mitral A-wave;	chr15:67366040	chr15:67541072~67542604:-
THCA	cis	rs1501911	0.53	rs193072	ENSG00000246763.5	RGMB-AS1	3.77	0.000181	0.013	0.18	0.17	Lung function (FEV1/FVC);	chr5:98822171	chr5:98769618~98773469:-
THCA	cis	rs17194490	0.665	rs10510234	ENSG00000237990.3	CNTN4-AS1	3.77	0.000181	0.013	0.26	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2532599	chr3:3039033~3069242:-
THCA	cis	rs2221894	0.96	rs1877501	ENSG00000251191.6	LINC00589	-3.77	0.000181	0.013	-0.2	-0.17	Obesity-related traits;	chr8:28952434	chr8:29673922~29748109:-
THCA	cis	rs1862618	0.756	rs13356762	ENSG00000234553.1	AC022431.3	-3.77	0.000181	0.013	-0.2	-0.17	Initial pursuit acceleration;	chr5:56815165	chr5:56536583~56537826:-
THCA	cis	rs6545883	0.868	rs7608483	ENSG00000212978.6	AC016747.3	3.77	0.000181	0.013	0.18	0.17	Tuberculosis;	chr2:61609100	chr2:61141592~61144969:-
THCA	cis	rs3758911	0.828	rs11212173	ENSG00000255353.1	RP11-382M14.1	-3.77	0.000181	0.013	-0.22	-0.17	Coronary artery disease;	chr11:107343881	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.894	rs11212179	ENSG00000255353.1	RP11-382M14.1	-3.77	0.000181	0.013	-0.22	-0.17	Coronary artery disease;	chr11:107357254	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.856	rs11212180	ENSG00000255353.1	RP11-382M14.1	-3.77	0.000181	0.013	-0.22	-0.17	Coronary artery disease;	chr11:107358630	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.856	rs11212181	ENSG00000255353.1	RP11-382M14.1	-3.77	0.000181	0.013	-0.22	-0.17	Coronary artery disease;	chr11:107360169	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.894	rs11212182	ENSG00000255353.1	RP11-382M14.1	-3.77	0.000181	0.013	-0.22	-0.17	Coronary artery disease;	chr11:107360879	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.894	rs11607304	ENSG00000255353.1	RP11-382M14.1	-3.77	0.000181	0.013	-0.22	-0.17	Coronary artery disease;	chr11:107361870	chr11:107176286~107177530:+
THCA	cis	rs1913185	0.837	rs67154251	ENSG00000240032.1	RP11-274H2.3	-3.77	0.000181	0.013	-0.28	-0.17	Obesity-related traits;	chr3:146157193	chr3:146066344~146069185:-
THCA	cis	rs1862618	0.802	rs986049	ENSG00000234553.1	AC022431.3	-3.77	0.000182	0.013	-0.2	-0.17	Initial pursuit acceleration;	chr5:56814406	chr5:56536583~56537826:-
THCA	cis	rs7927592	0.913	rs12363722	ENSG00000160172.9	FAM86C2P	3.77	0.000182	0.013	0.17	0.17	Total body bone mineral density;	chr11:68468823	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.871	rs12360903	ENSG00000160172.9	FAM86C2P	3.77	0.000182	0.013	0.17	0.17	Total body bone mineral density;	chr11:68468846	chr11:67791648~67805336:-
THCA	cis	rs1065656	0.581	rs2575351	ENSG00000261123.1	RP11-304L19.3	3.77	0.000182	0.013	0.23	0.17	Insulin-like growth factors;	chr16:1786708	chr16:2094830~2097026:-
THCA	cis	rs9595908	0.669	rs17516382	ENSG00000212293.1	SNORA16	3.77	0.000182	0.013	0.21	0.17	Body mass index;	chr13:32735426	chr13:32420390~32420516:-
THCA	cis	rs9309473	0.898	rs9807961	ENSG00000273245.1	RP11-434P11.2	3.77	0.000182	0.013	0.23	0.17	Metabolite levels;	chr2:73466916	chr2:73750256~73750786:-
THCA	cis	rs3818717	0.538	rs4925108	ENSG00000281749.1	Y_RNA	-3.77	0.000182	0.013	-0.22	-0.17	Lymphocyte counts;	chr17:17746109	chr17:18001101~18001195:-
THCA	cis	rs3818717	0.507	rs12940675	ENSG00000281749.1	Y_RNA	-3.77	0.000182	0.013	-0.22	-0.17	Lymphocyte counts;	chr17:17747900	chr17:18001101~18001195:-
THCA	cis	rs12681366	0.614	rs2919663	ENSG00000261437.1	RP11-22C11.2	3.77	0.000182	0.013	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94457918	chr8:94637285~94639467:-
THCA	cis	rs2625529	0.824	rs12903484	ENSG00000260037.4	CTD-2524L6.3	-3.77	0.000182	0.013	-0.23	-0.17	Red blood cell count;	chr15:72007140	chr15:71818396~71823384:+
THCA	cis	rs7829975	0.51	rs332037	ENSG00000233609.3	RP11-62H7.2	3.77	0.000182	0.013	0.18	0.17	Mood instability;	chr8:8865165	chr8:8961200~8979025:+
THCA	cis	rs763121	0.853	rs5750622	ENSG00000273076.1	RP3-508I15.22	3.77	0.000182	0.013	0.17	0.17	Menopause (age at onset);	chr22:38560459	chr22:38743495~38743910:+
THCA	cis	rs453301	0.686	rs28482034	ENSG00000254340.1	RP11-10A14.3	-3.77	0.000182	0.013	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9012154	chr8:9141424~9145435:+
THCA	cis	rs288326	0.561	rs75473200	ENSG00000272800.1	RP11-438L19.1	3.77	0.000182	0.0131	0.32	0.17	Blood protein levels;	chr2:182897437	chr2:183214319~183215400:+
THCA	cis	rs7707921	0.752	rs2406910	ENSG00000251374.1	RPS23P5	-3.77	0.000182	0.0131	-0.23	-0.17	Breast cancer;	chr5:82012900	chr5:82265157~82265259:-
THCA	cis	rs950169	0.763	rs35372971	ENSG00000275120.1	RP11-182J1.17	3.77	0.000182	0.0131	0.2	0.17	Schizophrenia;	chr15:84387097	chr15:84599434~84606463:-
THCA	cis	rs9291059	1	rs9291059	ENSG00000236297.1	RP11-175P19.2	3.77	0.000182	0.0131	0.36	0.17	Depressive symptoms (multi-trait analysis);	chr3:193627166	chr3:193578812~193593090:-
THCA	cis	rs3770081	1	rs57083584	ENSG00000273080.1	RP11-301O19.1	-3.77	0.000182	0.0131	-0.43	-0.17	Facial emotion recognition (sad faces);	chr2:86056525	chr2:86195590~86196049:+
THCA	cis	rs13113518	0.812	rs2048564	ENSG00000223305.1	RN7SKP30	3.77	0.000182	0.0131	0.22	0.17	Height;	chr4:55407965	chr4:55540502~55540835:-
THCA	cis	rs9527	0.571	rs12219246	ENSG00000272912.1	RP11-724N1.1	-3.77	0.000182	0.0131	-0.2	-0.17	Arsenic metabolism;	chr10:102853598	chr10:102914585~102915404:+
THCA	cis	rs801193	1	rs62466794	ENSG00000275400.1	RP4-756H11.5	-3.77	0.000182	0.0131	-0.16	-0.17	Aortic root size;	chr7:66726592	chr7:66553805~66554199:-
THCA	cis	rs295490	0.748	rs77869711	ENSG00000272656.1	RP11-219D15.3	3.77	0.000182	0.0131	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139348416	chr3:139349024~139349371:-
THCA	cis	rs172166	0.56	rs203878	ENSG00000261839.1	RP1-265C24.8	3.77	0.000182	0.0131	0.16	0.17	Cardiac Troponin-T levels;	chr6:28081218	chr6:28136849~28139678:+
THCA	cis	rs765787	0.53	rs11636440	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45243784	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs28414644	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45244523	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs28396110	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45244711	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4775834	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45245313	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4775835	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45245355	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4775836	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45245466	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4775837	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45245486	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs12917187	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45246099	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11639403	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45246152	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2413782	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45246292	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2413780	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45246668	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11636018	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45246939	chr15:45198517~45199139:-
THCA	cis	rs765787	0.556	rs2413778	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45247199	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs28756676	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45248162	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs55771002	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45249368	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs55920042	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45249379	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4238376	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45249689	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4238377	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45249783	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4775844	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45249850	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs3759893	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45250752	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs16941017	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45251083	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2413776	ENSG00000259932.1	CTD-2651B20.7	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45251972	chr15:45198517~45199139:-
THCA	cis	rs72819454	0.522	rs9665617	ENSG00000280693.1	SH3PXD2A-AS1	-3.77	0.000182	0.0131	-0.35	-0.17	Interleukin-9 levels;	chr10:103764487	chr10:103745966~103755423:+
THCA	cis	rs6430585	0.591	rs72970243	ENSG00000231890.6	DARS-AS1	-3.77	0.000182	0.0131	-0.19	-0.17	Corneal structure;	chr2:135726662	chr2:135985176~136022593:+
THCA	cis	rs354225	0.512	rs9917248	ENSG00000162997.14	PRORSD1P	-3.77	0.000182	0.0131	-0.23	-0.17	Schizophrenia;	chr2:54697326	chr2:55282319~55284522:+
THCA	cis	rs295490	0.748	rs80249265	ENSG00000272656.1	RP11-219D15.3	3.77	0.000182	0.0131	0.34	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139371856	chr3:139349024~139349371:-
THCA	cis	rs7914558	1	rs4917994	ENSG00000213061.2	PFN1P11	3.77	0.000182	0.0131	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs2275271	ENSG00000213061.2	PFN1P11	3.77	0.000182	0.0131	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs11191539	ENSG00000213061.2	PFN1P11	3.77	0.000182	0.0131	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs943038	ENSG00000213061.2	PFN1P11	3.77	0.000182	0.0131	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:102838011~102845473:-
THCA	cis	rs1560104	1	rs4780465	ENSG00000259876.1	CTD-3037G24.4	3.77	0.000182	0.0131	0.2	0.17	Obesity-related traits;	chr16:12613666	chr16:12556353~12557694:-
THCA	cis	rs7927592	0.83	rs11228240	ENSG00000160172.9	FAM86C2P	3.77	0.000182	0.0131	0.17	0.17	Total body bone mineral density;	chr11:68450822	chr11:67791648~67805336:-
THCA	cis	rs2540949	0.538	rs2540970	ENSG00000237979.1	AC007389.1	3.77	0.000182	0.0131	0.21	0.17	Atrial fibrillation;	chr2:65027965	chr2:65500993~65502138:-
THCA	cis	rs959260	1	rs2033607	ENSG00000263843.1	RP11-649A18.12	3.77	0.000182	0.0131	0.18	0.17	Systemic lupus erythematosus;	chr17:75371207	chr17:75271369~75273895:+
THCA	cis	rs7737355	0.645	rs7731071	ENSG00000237714.1	P4HA2-AS1	3.77	0.000182	0.0131	0.25	0.17	Life satisfaction;	chr5:131637790	chr5:132184876~132192808:+
THCA	cis	rs4785204	1	rs1968186	ENSG00000279356.1	RP11-429P3.8	3.77	0.000182	0.0131	0.33	0.17	Esophageal cancer (squamous cell);	chr16:50091601	chr16:50072862~50074986:+
THCA	cis	rs4886920	0.894	rs11637937	ENSG00000260776.4	RP11-114H24.2	-3.77	0.000182	0.0131	-0.2	-0.17	Neuroticism;	chr15:77827488	chr15:77914217~77926846:-
THCA	cis	rs12368653	0.693	rs2640610	ENSG00000270039.1	RP11-571M6.17	3.77	0.000182	0.0131	0.18	0.17	Multiple sclerosis;	chr12:57643652	chr12:57803838~57804415:+
THCA	cis	rs728616	0.558	rs2880599	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000182	0.0131	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80404679	chr10:79663088~79826594:-
THCA	cis	rs613391	0.614	rs518534	ENSG00000224549.1	RP11-370B11.3	-3.77	0.000182	0.0131	-0.2	-0.17	Quantitative traits;	chr9:22666185	chr9:22767175~22768316:+
THCA	cis	rs34975555	0.616	rs35195847	ENSG00000253671.1	RP11-806O11.1	-3.77	0.000182	0.0131	-0.25	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17962488	chr8:17808941~17820868:+
THCA	cis	rs853679	0.607	rs35902873	ENSG00000220721.1	OR1F12	3.77	0.000182	0.0131	0.39	0.17	Depression;	chr6:28091171	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13197574	ENSG00000220721.1	OR1F12	3.77	0.000182	0.0131	0.39	0.17	Depression;	chr6:28092461	chr6:28073316~28074233:+
THCA	cis	rs11069062	0.866	rs745872	ENSG00000270482.1	RP11-131L12.2	3.77	0.000182	0.0131	0.14	0.17	Obesity-related traits;	chr12:118713895	chr12:118375350~118376275:-
THCA	cis	rs9393813	0.529	rs12526864	ENSG00000204789.4	ZNF204P	3.77	0.000182	0.0131	0.14	0.17	Bipolar disorder;	chr6:27488463	chr6:27357825~27360221:-
THCA	cis	rs295490	0.667	rs59960641	ENSG00000272656.1	RP11-219D15.3	3.77	0.000182	0.0131	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139346587	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs80248005	ENSG00000272656.1	RP11-219D15.3	3.77	0.000182	0.0131	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139347834	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs17394620	ENSG00000272656.1	RP11-219D15.3	3.77	0.000182	0.0131	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139348541	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs17316181	ENSG00000272656.1	RP11-219D15.3	3.77	0.000182	0.0131	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139350851	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs61613889	ENSG00000272656.1	RP11-219D15.3	3.77	0.000182	0.0131	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139352279	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs59958973	ENSG00000272656.1	RP11-219D15.3	3.77	0.000182	0.0131	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139352385	chr3:139349024~139349371:-
THCA	cis	rs765787	0.53	rs11636367	ENSG00000259539.1	CTD-2651B20.1	3.77	0.000182	0.0131	0.21	0.17	Uric acid levels;	chr15:45243664	chr15:45152664~45167526:-
THCA	cis	rs758324	0.588	rs687429	ENSG00000237714.1	P4HA2-AS1	3.77	0.000182	0.0131	0.24	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131992830	chr5:132184876~132192808:+
THCA	cis	rs7927592	0.871	rs55953412	ENSG00000160172.9	FAM86C2P	3.77	0.000182	0.0131	0.17	0.17	Total body bone mineral density;	chr11:68560815	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs7102898	ENSG00000160172.9	FAM86C2P	3.77	0.000182	0.0131	0.17	0.17	Total body bone mineral density;	chr11:68561402	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs2282563	ENSG00000160172.9	FAM86C2P	3.77	0.000182	0.0131	0.17	0.17	Total body bone mineral density;	chr11:68565732	chr11:67791648~67805336:-
THCA	cis	rs6968419	0.788	rs4276607	ENSG00000237870.5	AC073130.1	3.77	0.000182	0.0131	0.19	0.17	Intraocular pressure;	chr7:116181554	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.788	rs67915501	ENSG00000237870.5	AC073130.1	3.77	0.000182	0.0131	0.19	0.17	Intraocular pressure;	chr7:116181982	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.788	rs60671526	ENSG00000237870.5	AC073130.1	3.77	0.000182	0.0131	0.19	0.17	Intraocular pressure;	chr7:116183015	chr7:116275606~116286734:-
THCA	cis	rs7707921	0.958	rs6452447	ENSG00000251374.1	RPS23P5	-3.77	0.000182	0.0131	-0.25	-0.17	Breast cancer;	chr5:82186703	chr5:82265157~82265259:-
THCA	cis	rs4742903	0.904	rs4743691	ENSG00000270332.1	SMC2-AS1	3.77	0.000182	0.0131	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104169260	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs4743692	ENSG00000270332.1	SMC2-AS1	3.77	0.000182	0.0131	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104169609	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs1450681	ENSG00000270332.1	SMC2-AS1	3.77	0.000182	0.0131	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104170154	chr9:104080024~104093073:-
THCA	cis	rs701145	0.585	rs17817774	ENSG00000243069.6	ARHGEF26-AS1	-3.77	0.000182	0.0131	-0.3	-0.17	Coronary artery disease;	chr3:154062079	chr3:154024401~154121332:-
THCA	cis	rs2239547	0.657	rs6445539	ENSG00000243224.1	RP5-1157M23.2	-3.77	0.000182	0.0131	-0.2	-0.17	Schizophrenia;	chr3:52840280	chr3:52239258~52241097:+
THCA	cis	rs2239547	0.657	rs7638524	ENSG00000243224.1	RP5-1157M23.2	-3.77	0.000182	0.0131	-0.2	-0.17	Schizophrenia;	chr3:52840845	chr3:52239258~52241097:+
THCA	cis	rs4218	0.593	rs8040456	ENSG00000277144.1	RP11-59H7.4	-3.77	0.000182	0.0131	-0.24	-0.17	Social communication problems;	chr15:59063904	chr15:59115547~59116089:-
THCA	cis	rs1502337	0.532	rs6606687	ENSG00000278993.1	RP3-424M6.4	-3.77	0.000182	0.0131	-0.26	-0.17	Body mass index;	chr12:110501616	chr12:110501614~110503441:+
THCA	cis	rs10090774	0.965	rs13250232	ENSG00000280303.2	ERICD	-3.77	0.000182	0.0131	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140927107	chr8:140636281~140638283:+
THCA	cis	rs11992162	0.591	rs4240678	ENSG00000270154.1	RP11-419I17.1	-3.77	0.000182	0.0131	-0.21	-0.17	Monocyte count;	chr8:11944917	chr8:12476462~12477122:+
THCA	cis	rs8030605	0.778	rs4392004	ENSG00000277245.1	RP11-48G14.3	3.77	0.000182	0.0131	0.28	0.17	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56256724	chr15:56447120~56447697:+
THCA	cis	rs721917	0.506	rs2493722	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79896989	chr10:79660891~79677996:+
THCA	cis	rs721917	0.545	rs2758542	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79897946	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs7914360	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898002	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2493725	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898126	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2254025	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898457	chr10:79660891~79677996:+
THCA	cis	rs721917	0.525	rs2254017	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898635	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2254016	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898668	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2254013	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898692	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2253875	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79899446	chr10:79660891~79677996:+
THCA	cis	rs721917	0.544	rs9325567	ENSG00000244733.5	RP11-506M13.3	-3.77	0.000182	0.0131	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79899822	chr10:79660891~79677996:+
THCA	cis	rs9611565	0.512	rs139561	ENSG00000237037.8	NDUFA6-AS1	-3.77	0.000182	0.0131	-0.16	-0.17	Vitiligo;	chr22:41799406	chr22:42090931~42137742:+
THCA	cis	rs2455799	0.613	rs2470537	ENSG00000270409.1	RP11-44D5.1	-3.77	0.000182	0.0131	-0.18	-0.17	Mean platelet volume;	chr3:15675391	chr3:15732252~15733470:+
THCA	cis	rs6137726	0.569	rs6082765	ENSG00000237396.1	LINC01384	3.77	0.000182	0.0131	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22651338	chr20:22587522~22607517:-
THCA	cis	rs2243123	0.602	rs2243143	ENSG00000244040.4	IL12A-AS1	3.77	0.000182	0.0131	0.23	0.17	Multiple sclerosis;	chr3:159997015	chr3:159913400~160225299:-
THCA	cis	rs2243123	0.602	rs2243147	ENSG00000244040.4	IL12A-AS1	3.77	0.000182	0.0131	0.23	0.17	Multiple sclerosis;	chr3:159997599	chr3:159913400~160225299:-
THCA	cis	rs7267979	1	rs6083844	ENSG00000276952.1	RP5-965G21.6	-3.77	0.000182	0.0131	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25284915~25285588:-
THCA	cis	rs2688608	0.592	rs3933085	ENSG00000272140.2	RP11-574K11.29	3.77	0.000182	0.0131	0.15	0.17	Inflammatory bowel disease;	chr10:73723573	chr10:73703735~73713581:-
THCA	cis	rs2688608	0.592	rs7909544	ENSG00000272140.2	RP11-574K11.29	3.77	0.000182	0.0131	0.15	0.17	Inflammatory bowel disease;	chr10:73724246	chr10:73703735~73713581:-
THCA	cis	rs4268898	1	rs10165445	ENSG00000242628.4	AC009228.1	-3.77	0.000182	0.0131	-0.21	-0.17	Asthma;	chr2:24218829	chr2:24214381~24221516:+
THCA	cis	rs4268898	1	rs6707781	ENSG00000242628.4	AC009228.1	-3.77	0.000182	0.0131	-0.21	-0.17	Asthma;	chr2:24219014	chr2:24214381~24221516:+
THCA	cis	rs4268898	1	rs1203	ENSG00000242628.4	AC009228.1	-3.77	0.000182	0.0131	-0.21	-0.17	Asthma;	chr2:24220461	chr2:24214381~24221516:+
THCA	cis	rs4268898	0.965	rs4665673	ENSG00000242628.4	AC009228.1	-3.77	0.000182	0.0131	-0.21	-0.17	Asthma;	chr2:24236868	chr2:24214381~24221516:+
THCA	cis	rs13098911	0.54	rs13078739	ENSG00000226074.4	PRSS44	-3.77	0.000183	0.0131	-0.31	-0.17	Celiac disease;	chr3:45965996	chr3:46809359~46812558:-
THCA	cis	rs867186	0.698	rs11699306	ENSG00000279253.1	RP4-614O4.13	-3.77	0.000183	0.0131	-0.26	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35213480	chr20:35262727~35264187:-
THCA	cis	rs4578769	0.918	rs12458661	ENSG00000265939.1	UBE2CP2	-3.77	0.000183	0.0131	-0.21	-0.17	Eosinophil percentage of white cells;	chr18:23004284	chr18:22900486~22900995:-
THCA	cis	rs1050631	1	rs3110564	ENSG00000260552.1	RP11-49I11.1	-3.77	0.000183	0.0131	-0.21	-0.17	Esophageal squamous cell cancer (length of survival);	chr18:36121626	chr18:36179996~36187448:-
THCA	cis	rs4833079	0.562	rs11944291	ENSG00000231160.8	KLF3-AS1	-3.77	0.000183	0.0131	-0.09	-0.17	Body mass index;	chr4:38629999	chr4:38612701~38664883:-
THCA	cis	rs9309711	0.643	rs4264589	ENSG00000271868.1	RP11-1293J14.1	-3.77	0.000183	0.0131	-0.22	-0.17	Neurofibrillary tangles;	chr2:3477327	chr2:3496956~3497428:+
THCA	cis	rs740160	0.558	rs17161669	ENSG00000244219.5	GS1-259H13.2	-3.77	0.000183	0.0131	-0.27	-0.17	Dehydroepiandrosterone sulphate levels;	chr7:99311040	chr7:99598066~99610813:+
THCA	cis	rs7632954	0.669	rs9879912	ENSG00000227110.5	LMCD1-AS1	3.77	0.000183	0.0131	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8486115	chr3:7952805~8611924:-
THCA	cis	rs12546962	0.544	rs17149791	ENSG00000254153.1	CTA-398F10.2	3.77	0.000183	0.0131	0.2	0.17	Body mass index;	chr8:9330609	chr8:8456909~8461337:-
THCA	cis	rs6504108	0.602	rs2938483	ENSG00000264920.1	RP11-6N17.4	-3.77	0.000183	0.0131	-0.15	-0.17	Body mass index;	chr17:48240642	chr17:47891255~47895812:-
THCA	cis	rs2777491	0.707	rs1757456	ENSG00000247556.5	OIP5-AS1	3.77	0.000183	0.0131	0.15	0.17	Ulcerative colitis;	chr15:41501296	chr15:41283990~41309737:+
THCA	cis	rs5758659	0.714	rs5751220	ENSG00000205702.9	CYP2D7	-3.77	0.000183	0.0131	-0.13	-0.17	Cognitive function;	chr22:42120201	chr22:42140203~42144577:-
THCA	cis	rs740363	0.805	rs10886014	ENSG00000225302.2	RP11-539I5.1	3.77	0.000183	0.0131	0.13	0.17	Heart failure;	chr10:116843717	chr10:116828761~116850205:-
THCA	cis	rs1959947	0.876	rs4904223	ENSG00000251363.2	RP11-129M6.1	-3.77	0.000183	0.0131	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41058890	chr14:40954898~40975877:+
THCA	cis	rs16975963	0.594	rs73039018	ENSG00000276846.1	CTD-3220F14.3	-3.77	0.000183	0.0131	-0.16	-0.17	Longevity;	chr19:37726993	chr19:37314868~37315620:-
THCA	cis	rs372883	0.6	rs2832294	ENSG00000176054.6	RPL23P2	3.77	0.000183	0.0131	0.15	0.17	Pancreatic cancer;	chr21:29367350	chr21:28997613~28998033:-
THCA	cis	rs7647973	0.58	rs12637576	ENSG00000228638.1	FCF1P2	-3.77	0.000183	0.0131	-0.18	-0.17	Menarche (age at onset);	chr3:49199901	chr3:48290793~48291375:-
THCA	cis	rs2613964	0.548	rs9870733	ENSG00000240057.4	RP11-572M11.4	3.77	0.000183	0.0131	0.16	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130407	chr3:113019532~113183301:+
THCA	cis	rs11633886	0.842	rs2175840	ENSG00000259200.1	RP11-718O11.1	-3.77	0.000183	0.0131	-0.21	-0.17	Diisocyanate-induced asthma;	chr15:45750036	chr15:45705078~45931069:+
THCA	cis	rs861409	0.771	rs2022003	ENSG00000227295.2	ELL2P1	3.77	0.000183	0.0131	0.2	0.17	Red cell distribution width;	chr1:158617176	chr1:158175850~158177755:-
THCA	cis	rs11123170	0.529	rs35606997	ENSG00000274877.1	RP11-65I12.1	3.77	0.000183	0.0131	0.1	0.17	Renal function-related traits (BUN);	chr2:113215773	chr2:113237595~113240825:+
THCA	cis	rs7246967	0.608	rs370734	ENSG00000198153.8	ZNF849P	-3.77	0.000183	0.0131	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22829784	chr19:22685167~22686732:+
THCA	cis	rs9425766	0.85	rs7349095	ENSG00000270084.1	GAS5-AS1	-3.77	0.000183	0.0131	-0.17	-0.17	Life satisfaction;	chr1:173887899	chr1:173863248~173863941:+
THCA	cis	rs548181	0.668	rs579661	ENSG00000254671.2	STT3A-AS1	-3.77	0.000183	0.0131	-0.32	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125604871	chr11:125570284~125592568:-
THCA	cis	rs724818	0.661	rs72680418	ENSG00000251609.2	SETP12	-3.77	0.000183	0.0131	-0.48	-0.17	Monobrow thickness;	chr4:120834056	chr4:120895494~120897083:-
THCA	cis	rs17685	0.593	rs56265719	ENSG00000227038.2	AC005077.12	3.77	0.000183	0.0131	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76166951	chr7:76090431~76108779:-
THCA	cis	rs17221829	0.733	rs12421173	ENSG00000280385.1	AP000648.5	-3.77	0.000183	0.0131	-0.17	-0.17	Anxiety in major depressive disorder;	chr11:89651320	chr11:90193614~90198120:+
THCA	cis	rs7200543	0.961	rs1741	ENSG00000188599.16	NPIPP1	-3.77	0.000183	0.0131	-0.13	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:15104312~15123498:-
THCA	cis	rs11088226	0.681	rs2833902	ENSG00000186842.4	LINC00846	-3.77	0.000183	0.0131	-0.25	-0.17	Gastritis;	chr21:32568148	chr21:32572238~32575881:-
THCA	cis	rs2638953	0.853	rs10843180	ENSG00000247934.4	RP11-967K21.1	-3.77	0.000183	0.0131	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462221	chr12:28163298~28190738:-
THCA	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	3.77	0.000183	0.0131	0.22	0.17	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
THCA	cis	rs972578	0.806	rs8137128	ENSG00000230319.1	AL022476.2	3.77	0.000183	0.0131	0.18	0.17	Mean platelet volume;	chr22:42989990	chr22:43038585~43052366:+
THCA	cis	rs970548	0.954	rs11239571	ENSG00000230869.1	CTGLF10P	-3.77	0.000183	0.0131	-0.21	-0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45592444	chr10:45678692~45700532:+
THCA	cis	rs4792901	0.729	rs12603059	ENSG00000279602.1	CTD-3014M21.1	-3.77	0.000183	0.0131	-0.22	-0.17	Dupuytren's disease;	chr17:43461078	chr17:43360041~43361361:-
THCA	cis	rs7520050	0.902	rs1355642	ENSG00000234329.1	RP11-767N6.2	-3.77	0.000183	0.0131	-0.15	-0.17	Reticulocyte count;Red blood cell count;	chr1:46133231	chr1:45651039~45651826:-
THCA	cis	rs2836974	0.965	rs2836967	ENSG00000255568.3	BRWD1-AS2	3.77	0.000183	0.0131	0.15	0.17	Cognitive function;	chr21:39267176	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.965	rs8130984	ENSG00000255568.3	BRWD1-AS2	3.77	0.000183	0.0131	0.15	0.17	Cognitive function;	chr21:39268040	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.965	rs6517538	ENSG00000255568.3	BRWD1-AS2	3.77	0.000183	0.0131	0.15	0.17	Cognitive function;	chr21:39284316	chr21:39313935~39314962:+
THCA	cis	rs7956611	0.564	rs12099548	ENSG00000213343.5	RPL21P18	-3.77	0.000183	0.0131	-0.2	-0.17	Age of smoking initiation;	chr12:66512496	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs7979740	ENSG00000213343.5	RPL21P18	-3.77	0.000183	0.0131	-0.2	-0.17	Age of smoking initiation;	chr12:66514758	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.564	rs6581701	ENSG00000213343.5	RPL21P18	-3.77	0.000183	0.0131	-0.2	-0.17	Age of smoking initiation;	chr12:66516759	chr12:66037235~66037714:+
THCA	cis	rs494526	0.674	rs2420491	ENSG00000229272.1	RP11-498J9.2	-3.77	0.000183	0.0131	-0.2	-0.17	Alcoholic chronic pancreatitis;	chr10:119092299	chr10:119003536~119003884:-
THCA	cis	rs2276314	1	rs56050783	ENSG00000267627.4	RP11-905K4.1	-3.77	0.000183	0.0131	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35951803~35966118:-
THCA	cis	rs2276314	1	rs58054756	ENSG00000267627.4	RP11-905K4.1	-3.77	0.000183	0.0131	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35951803~35966118:-
THCA	cis	rs2276314	1	rs1540042	ENSG00000267627.4	RP11-905K4.1	-3.77	0.000183	0.0131	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35951803~35966118:-
THCA	cis	rs740363	0.936	rs2291316	ENSG00000225302.2	RP11-539I5.1	3.77	0.000183	0.0131	0.12	0.17	Heart failure;	chr10:116834778	chr10:116828761~116850205:-
THCA	cis	rs6940638	0.688	rs9393795	ENSG00000219392.1	RP1-265C24.5	-3.77	0.000183	0.0131	-0.21	-0.17	Intelligence (multi-trait analysis);	chr6:27249940	chr6:28115628~28116551:+
THCA	cis	rs12472274	0.941	rs2880131	ENSG00000186235.9	AC016757.3	3.77	0.000183	0.0131	0.24	0.17	Phospholipid levels (plasma);	chr2:238180510	chr2:238224552~238231677:-
THCA	cis	rs6138458	0.828	rs6132785	ENSG00000274173.1	RP4-568C11.4	3.77	0.000183	0.0131	0.15	0.17	Blood protein levels;	chr20:25012778	chr20:24931840~24932983:+
THCA	cis	rs2657294	0.895	rs2002023	ENSG00000226051.5	ZNF503-AS1	-3.77	0.000183	0.0131	-0.24	-0.17	Pneumonia;	chr10:75088766	chr10:75269819~75373500:+
THCA	cis	rs1959947	0.876	rs2799785	ENSG00000251363.2	RP11-129M6.1	-3.77	0.000183	0.0131	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41060923	chr14:40954898~40975877:+
THCA	cis	rs10256972	0.527	rs2949170	ENSG00000225146.1	AC073957.15	3.77	0.000183	0.0131	0.19	0.17	Endometriosis;Longevity;	chr7:1176802	chr7:1029025~1043891:+
THCA	cis	rs4650994	0.544	rs6682815	ENSG00000213057.5	C1orf220	-3.77	0.000183	0.0131	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178531974	chr1:178542752~178548889:+
THCA	cis	rs34421088	0.559	rs12386974	ENSG00000270154.1	RP11-419I17.1	3.77	0.000183	0.0131	0.21	0.17	Neuroticism;	chr8:11543119	chr8:12476462~12477122:+
THCA	cis	rs348196	0.767	rs12744132	ENSG00000160766.13	GBAP1	-3.77	0.000183	0.0131	-0.21	-0.17	Breast cancer;	chr1:155693535	chr1:155213821~155227422:-
THCA	cis	rs8113308	0.515	rs56343029	ENSG00000260160.1	CTC-471J1.2	3.77	0.000183	0.0131	0.26	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960184	chr19:52058490~52063703:-
THCA	cis	rs10875746	0.669	rs11168459	ENSG00000258273.1	RP11-370I10.4	3.77	0.000183	0.0132	0.24	0.17	Longevity (90 years and older);	chr12:48202458	chr12:48333755~48333901:-
THCA	cis	rs13217239	0.646	rs6456767	ENSG00000261353.1	CTA-14H9.5	3.77	0.000183	0.0132	0.18	0.17	Schizophrenia;	chr6:27102764	chr6:26527063~26527404:+
THCA	cis	rs4664293	1	rs4665083	ENSG00000230783.1	AC009961.2	3.77	0.000183	0.0132	0.21	0.17	Monocyte percentage of white cells;	chr2:159573616	chr2:159689217~159690291:-
THCA	cis	rs7914558	0.966	rs11191518	ENSG00000213061.2	PFN1P11	3.77	0.000183	0.0132	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:102838011~102845473:-
THCA	cis	rs17122278	0.722	rs60837962	ENSG00000243431.1	RPL5P30	3.77	0.000183	0.0132	0.18	0.17	Total cholesterol levels;	chr11:118567733	chr11:118560690~118561580:+
THCA	cis	rs7208859	0.778	rs6505219	ENSG00000266490.1	CTD-2349P21.9	3.77	0.000183	0.0132	0.2	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30792372~30792833:+
THCA	cis	rs854765	0.583	rs8078583	ENSG00000281749.1	Y_RNA	3.77	0.000183	0.0132	0.22	0.17	Total body bone mineral density;	chr17:17908151	chr17:18001101~18001195:-
THCA	cis	rs2832077	1	rs2832065	ENSG00000232855.5	AF131217.1	3.77	0.000183	0.0132	0.21	0.17	Cognitive test performance;	chr21:28763040	chr21:28439346~28674848:-
THCA	cis	rs2255336	0.706	rs4492900	ENSG00000245648.1	RP11-277P12.20	-3.77	0.000183	0.0132	-0.18	-0.17	Blood protein levels;	chr12:10447980	chr12:10363769~10398506:+
THCA	cis	rs7520050	0.931	rs6698247	ENSG00000281133.1	AL355480.3	3.77	0.000184	0.0132	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6675946	ENSG00000281133.1	AL355480.3	3.77	0.000184	0.0132	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs7526678	ENSG00000281133.1	AL355480.3	3.77	0.000184	0.0132	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs6686134	ENSG00000281133.1	AL355480.3	3.77	0.000184	0.0132	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45580892~45580996:-
THCA	cis	rs7259376	0.902	rs11669356	ENSG00000270947.1	AC025811.3	-3.77	0.000184	0.0132	-0.19	-0.17	Menopause (age at onset);	chr19:22422318	chr19:22455988~22456459:+
THCA	cis	rs877529	0.934	rs79503	ENSG00000279833.1	RP4-742C19.13	-3.77	0.000184	0.0132	-0.11	-0.17	Multiple myeloma;	chr22:39132435	chr22:39133090~39136760:+
THCA	cis	rs35740288	0.857	rs11630274	ENSG00000259407.1	RP11-158M2.3	-3.77	0.000184	0.0132	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85745156	chr15:85744109~85750281:-
THCA	cis	rs7178909	0.902	rs8034116	ENSG00000259677.1	RP11-493E3.1	3.77	0.000184	0.0132	0.21	0.17	Common traits (Other);	chr15:89898336	chr15:89876540~89877285:+
THCA	cis	rs57709857	0.957	rs16887378	ENSG00000272092.1	RP11-350N15.5	-3.77	0.000184	0.0132	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38438225	chr8:38382364~38383461:+
THCA	cis	rs950169	0.887	rs35986397	ENSG00000275120.1	RP11-182J1.17	3.77	0.000184	0.0132	0.21	0.17	Schizophrenia;	chr15:84400409	chr15:84599434~84606463:-
THCA	cis	rs1510272	0.96	rs9864425	ENSG00000243926.1	TIPARP-AS1	-3.77	0.000184	0.0132	-0.18	-0.17	Testicular germ cell tumor;	chr3:156568301	chr3:156671862~156674378:-
THCA	cis	rs2228479	0.85	rs17233497	ENSG00000274627.1	RP11-104N10.2	-3.77	0.000184	0.0132	-0.36	-0.17	Skin colour saturation;	chr16:89748744	chr16:89516797~89522217:+
THCA	cis	rs10938353	0.68	rs17654223	ENSG00000273369.1	RP11-700J17.1	3.77	0.000184	0.0132	0.2	0.17	Body mass index;	chr4:44741551	chr4:44693946~44694386:-
THCA	cis	rs42648	0.738	rs10248104	ENSG00000225498.1	AC002064.5	3.77	0.000184	0.0132	0.19	0.17	Homocysteine levels;	chr7:90265948	chr7:90312496~90322592:+
THCA	cis	rs10844706	0.699	rs741199	ENSG00000214776.8	RP11-726G1.1	3.77	0.000184	0.0132	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9720769	chr12:9467552~9576275:+
THCA	cis	rs2221894	0.922	rs7837237	ENSG00000251191.6	LINC00589	3.77	0.000184	0.0132	0.2	0.17	Obesity-related traits;	chr8:29018704	chr8:29673922~29748109:-
THCA	cis	rs853679	0.556	rs13200214	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.38	0.17	Depression;	chr6:28049472	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs71559070	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.38	0.17	Depression;	chr6:28071151	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34166054	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.38	0.17	Depression;	chr6:28098023	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34662244	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.38	0.17	Depression;	chr6:28106103	chr6:28073316~28074233:+
THCA	cis	rs35952432	1	rs35952432	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.38	0.17	Lung cancer;	chr6:28107123	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13203816	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.38	0.17	Depression;	chr6:28111820	chr6:28073316~28074233:+
THCA	cis	rs853679	0.556	rs34588114	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.38	0.17	Depression;	chr6:28112850	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs34371502	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.38	0.17	Depression;	chr6:28113980	chr6:28073316~28074233:+
THCA	cis	rs727563	0.638	rs4820443	ENSG00000237037.8	NDUFA6-AS1	3.77	0.000184	0.0132	0.16	0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr22:42090931~42137742:+
THCA	cis	rs214785	1	rs214799	ENSG00000226644.4	RP11-128M1.1	3.77	0.000184	0.0132	0.17	0.17	Basal cell carcinoma;	chr20:2306058	chr20:2207217~2213151:+
THCA	cis	rs2348418	0.733	rs4931078	ENSG00000278733.1	RP11-425D17.1	3.77	0.000184	0.0132	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28215067	chr12:28185625~28186190:-
THCA	cis	rs7176527	1	rs3762168	ENSG00000259683.1	RP11-182J1.14	3.77	0.000184	0.0132	0.24	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:84389729~84395903:+
THCA	cis	rs12291225	0.679	rs10832240	ENSG00000251991.1	RNU7-49P	3.77	0.000184	0.0132	0.2	0.17	Sense of smell;	chr11:14283198	chr11:14478892~14478953:+
THCA	cis	rs12291225	0.679	rs7934671	ENSG00000251991.1	RNU7-49P	3.77	0.000184	0.0132	0.2	0.17	Sense of smell;	chr11:14283555	chr11:14478892~14478953:+
THCA	cis	rs4664304	0.62	rs2048437	ENSG00000226266.5	AC009961.3	-3.77	0.000184	0.0132	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159855554	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.62	rs2048436	ENSG00000226266.5	AC009961.3	-3.77	0.000184	0.0132	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159855608	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.62	rs11675085	ENSG00000226266.5	AC009961.3	-3.77	0.000184	0.0132	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159856841	chr2:159670708~159712435:-
THCA	cis	rs267567	0.647	rs267546	ENSG00000235257.7	ITGA9-AS1	3.77	0.000184	0.0132	0.14	0.17	PR interval;	chr3:37537363	chr3:37745432~37861780:-
THCA	cis	rs3758911	1	rs11212164	ENSG00000255353.1	RP11-382M14.1	-3.77	0.000184	0.0132	-0.21	-0.17	Coronary artery disease;	chr11:107328113	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs6588965	ENSG00000255353.1	RP11-382M14.1	-3.77	0.000184	0.0132	-0.21	-0.17	Coronary artery disease;	chr11:107330963	chr11:107176286~107177530:+
THCA	cis	rs9611565	0.512	rs9611667	ENSG00000237037.8	NDUFA6-AS1	3.77	0.000184	0.0132	0.17	0.17	Vitiligo;	chr22:41791011	chr22:42090931~42137742:+
THCA	cis	rs7520050	0.933	rs12565042	ENSG00000281133.1	AL355480.3	3.77	0.000184	0.0132	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs10789475	ENSG00000281133.1	AL355480.3	3.77	0.000184	0.0132	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.933	rs6666743	ENSG00000281133.1	AL355480.3	3.77	0.000184	0.0132	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.933	rs9787208	ENSG00000281133.1	AL355480.3	3.77	0.000184	0.0132	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45580892~45580996:-
THCA	cis	rs1113500	0.787	rs10881502	ENSG00000230489.1	VAV3-AS1	3.77	0.000184	0.0132	0.15	0.17	Growth-regulated protein alpha levels;	chr1:108099197	chr1:107964443~107994607:+
THCA	cis	rs7395662	1	rs11039745	ENSG00000200090.1	Y_RNA	-3.77	0.000184	0.0132	-0.12	-0.17	HDL cholesterol;	chr11:48442259	chr11:47726894~47726992:-
THCA	cis	rs7395662	0.926	rs10742848	ENSG00000200090.1	Y_RNA	-3.77	0.000184	0.0132	-0.12	-0.17	HDL cholesterol;	chr11:48447236	chr11:47726894~47726992:-
THCA	cis	rs4879656	0.966	rs10758181	ENSG00000225693.1	LAGE3P1	-3.77	0.000184	0.0132	-0.19	-0.17	Menopause (age at onset);	chr9:33045163	chr9:33019682~33020165:-
THCA	cis	rs12681366	0.708	rs1813167	ENSG00000261437.1	RP11-22C11.2	-3.77	0.000184	0.0132	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94336525	chr8:94637285~94639467:-
THCA	cis	rs832187	0.704	rs704364	ENSG00000224479.4	AC136289.1	-3.77	0.000184	0.0132	-0.21	-0.17	Schizophrenia;	chr3:63889058	chr3:63742293~63827445:-
THCA	cis	rs295490	0.748	rs74877536	ENSG00000272656.1	RP11-219D15.3	3.77	0.000184	0.0132	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139344277	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs1602628	ENSG00000272656.1	RP11-219D15.3	3.77	0.000184	0.0132	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139345532	chr3:139349024~139349371:-
THCA	cis	rs2334880	0.836	rs9934715	ENSG00000260185.1	RP11-432I5.6	-3.77	0.000184	0.0132	-0.32	-0.17	Malaria;	chr16:71723484	chr16:71655027~71664212:+
THCA	cis	rs7819412	0.775	rs4841489	ENSG00000254948.1	OR7E158P	3.77	0.000184	0.0132	0.2	0.17	Triglycerides;	chr8:11079301	chr8:11919900~11920809:-
THCA	cis	rs6500602	1	rs12447826	ENSG00000280063.1	RP11-295D4.3	3.77	0.000184	0.0132	0.1	0.17	Schizophrenia;	chr16:4414616	chr16:4346694~4348648:-
THCA	cis	rs2688608	0.592	rs11000757	ENSG00000272140.2	RP11-574K11.29	3.77	0.000184	0.0132	0.15	0.17	Inflammatory bowel disease;	chr10:73727057	chr10:73703735~73713581:-
THCA	cis	rs4908760	0.792	rs11121215	ENSG00000270282.1	RP5-1115A15.2	3.77	0.000184	0.0132	0.2	0.17	Vitiligo;	chr1:8673069	chr1:8512653~8513021:+
THCA	cis	rs4664293	0.541	rs12692551	ENSG00000230783.1	AC009961.2	3.77	0.000184	0.0132	0.21	0.17	Monocyte percentage of white cells;	chr2:159501263	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.541	rs2113859	ENSG00000230783.1	AC009961.2	3.77	0.000184	0.0132	0.21	0.17	Monocyte percentage of white cells;	chr2:159502199	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.541	rs62173243	ENSG00000230783.1	AC009961.2	3.77	0.000184	0.0132	0.21	0.17	Monocyte percentage of white cells;	chr2:159502693	chr2:159689217~159690291:-
THCA	cis	rs10090774	0.71	rs4413752	ENSG00000279766.1	RP11-642A1.2	-3.77	0.000184	0.0132	-0.21	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140678873	chr8:140572142~140572812:-
THCA	cis	rs748404	0.56	rs689797	ENSG00000275601.1	AC011330.13	-3.77	0.000184	0.0132	-0.2	-0.17	Lung cancer;	chr15:43534359	chr15:43642389~43643023:-
THCA	cis	rs748404	0.56	rs2255663	ENSG00000275601.1	AC011330.13	3.77	0.000184	0.0132	0.2	0.17	Lung cancer;	chr15:43536810	chr15:43642389~43643023:-
THCA	cis	rs708224	0.513	rs806784	ENSG00000277342.1	RP11-843B15.4	3.77	0.000184	0.0132	0.23	0.17	Pancreatic cancer;	chr12:32285255	chr12:32109076~32109602:+
THCA	cis	rs2880765	0.743	rs7168345	ENSG00000218052.5	ADAMTS7P4	3.77	0.000184	0.0132	0.19	0.17	Coronary artery disease;	chr15:85470370	chr15:85255369~85330334:-
THCA	cis	rs8040855	0.93	rs6496767	ENSG00000225151.9	GOLGA2P7	3.77	0.000184	0.0132	0.23	0.17	Bulimia nervosa;	chr15:85159522	chr15:84199311~84230136:-
THCA	cis	rs6472235	0.681	rs67768803	ENSG00000272192.1	CTD-2532N20.1	3.77	0.000184	0.0132	0.18	0.17	Plateletcrit;Myopia (pathological);	chr8:65955957	chr8:65842752~65843331:+
THCA	cis	rs7551222	0.752	rs10900599	ENSG00000240219.1	RP11-430C7.5	3.77	0.000184	0.0132	0.16	0.17	Schizophrenia;	chr1:204572815	chr1:204626775~204629712:+
THCA	cis	rs7572733	0.935	rs1369512	ENSG00000231621.1	AC013264.2	-3.77	0.000184	0.0132	-0.16	-0.17	Dermatomyositis;	chr2:197902408	chr2:197197991~197199273:+
THCA	cis	rs3935996	0.965	rs7546553	ENSG00000233147.1	RP11-90C4.1	-3.77	0.000184	0.0132	-0.15	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55867514	chr1:55823807~55868248:+
THCA	cis	rs13401620	0.702	rs11123532	ENSG00000231013.1	AC013275.2	-3.77	0.000184	0.0132	-0.2	-0.17	Breast size;	chr2:119703189	chr2:119476448~119487346:+
THCA	cis	rs867186	0.92	rs6579216	ENSG00000126005.14	MMP24-AS1	-3.77	0.000184	0.0132	-0.27	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35080494	chr20:35216462~35278131:-
THCA	cis	rs12291225	0.753	rs1431374	ENSG00000251991.1	RNU7-49P	3.77	0.000184	0.0132	0.2	0.17	Sense of smell;	chr11:14282429	chr11:14478892~14478953:+
THCA	cis	rs11867129	0.908	rs13332514	ENSG00000260778.3	RP11-304L19.13	3.77	0.000184	0.0132	0.17	0.17	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2317335	chr16:2268155~2273418:+
THCA	cis	rs9309473	1	rs10186501	ENSG00000273245.1	RP11-434P11.2	3.77	0.000184	0.0132	0.23	0.17	Metabolite levels;	chr2:73470717	chr2:73750256~73750786:-
THCA	cis	rs9987353	0.518	rs4841110	ENSG00000254153.1	CTA-398F10.2	-3.77	0.000184	0.0132	-0.19	-0.17	Recombination measurement;	chr8:9228513	chr8:8456909~8461337:-
THCA	cis	rs964611	0.504	rs12909283	ENSG00000259488.2	RP11-154J22.1	3.77	0.000184	0.0132	0.15	0.17	Metabolite levels (Pyroglutamine);	chr15:48231689	chr15:48312353~48331856:-
THCA	cis	rs713587	0.967	rs6749422	ENSG00000224165.4	DNAJC27-AS1	-3.77	0.000184	0.0132	-0.1	-0.17	Body mass index in non-asthmatics;	chr2:24927142	chr2:24971390~25039694:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000230189.5	GS1-124K5.2	-3.77	0.000184	0.0132	-0.11	-0.17	Aortic root size;	chr7:66120784	chr7:66409143~66490059:-
THCA	cis	rs959260	1	rs7216423	ENSG00000263843.1	RP11-649A18.12	3.77	0.000184	0.0132	0.18	0.17	Systemic lupus erythematosus;	chr17:75369590	chr17:75271369~75273895:+
THCA	cis	rs959260	1	rs2033609	ENSG00000263843.1	RP11-649A18.12	3.77	0.000184	0.0132	0.18	0.17	Systemic lupus erythematosus;	chr17:75370940	chr17:75271369~75273895:+
THCA	cis	rs773506	0.72	rs3914139	ENSG00000235641.4	LINC00484	3.77	0.000184	0.0132	0.22	0.17	Type 2 diabetes nephropathy;	chr9:91200908	chr9:91159573~91165658:+
THCA	cis	rs773506	0.72	rs7035931	ENSG00000235641.4	LINC00484	3.77	0.000184	0.0132	0.22	0.17	Type 2 diabetes nephropathy;	chr9:91203994	chr9:91159573~91165658:+
THCA	cis	rs773506	0.72	rs7020997	ENSG00000235641.4	LINC00484	3.77	0.000184	0.0132	0.22	0.17	Type 2 diabetes nephropathy;	chr9:91204070	chr9:91159573~91165658:+
THCA	cis	rs773506	0.72	rs3884186	ENSG00000235641.4	LINC00484	3.77	0.000184	0.0132	0.22	0.17	Type 2 diabetes nephropathy;	chr9:91204751	chr9:91159573~91165658:+
THCA	cis	rs9393777	0.778	rs66841633	ENSG00000220721.1	OR1F12	3.77	0.000184	0.0132	0.35	0.17	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28073316~28074233:+
THCA	cis	rs7508	0.511	rs438818	ENSG00000253671.1	RP11-806O11.1	-3.77	0.000184	0.0132	-0.21	-0.17	Atrial fibrillation;	chr8:18042052	chr8:17808941~17820868:+
THCA	cis	rs2821260	0.644	rs2630395	ENSG00000227207.2	RPL31P12	3.77	0.000184	0.0132	0.19	0.17	Intelligence (multi-trait analysis);	chr1:72111494	chr1:72301472~72301829:+
THCA	cis	rs7824557	0.545	rs2572450	ENSG00000255495.1	AC145124.2	-3.77	0.000184	0.0132	-0.2	-0.17	Retinal vascular caliber;	chr8:11372129	chr8:12194467~12196280:+
THCA	cis	rs786425	0.711	rs1060637	ENSG00000278112.1	RP11-972P1.11	3.77	0.000184	0.0132	0.17	0.17	Pubertal anthropometrics;	chr12:123625575	chr12:123519390~123519856:-
THCA	cis	rs60695258	1	rs60695258	ENSG00000251411.1	RP11-397E7.4	-3.77	0.000184	0.0132	-0.16	-0.17	Hematocrit;	chr4:87101557	chr4:86913266~86914817:-
THCA	cis	rs10200159	0.793	rs13420929	ENSG00000206964.1	Y_RNA	-3.77	0.000185	0.0132	-0.39	-0.17	Vitiligo;	chr2:55692185	chr2:55286018~55286128:+
THCA	cis	rs10200159	0.793	rs7586115	ENSG00000206964.1	Y_RNA	-3.77	0.000185	0.0132	-0.39	-0.17	Vitiligo;	chr2:55692501	chr2:55286018~55286128:+
THCA	cis	rs9595908	0.709	rs4942892	ENSG00000212293.1	SNORA16	-3.77	0.000185	0.0132	-0.2	-0.17	Body mass index;	chr13:32754269	chr13:32420390~32420516:-
THCA	cis	rs7927592	0.913	rs6591344	ENSG00000160172.9	FAM86C2P	3.77	0.000185	0.0132	0.17	0.17	Total body bone mineral density;	chr11:68593405	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs7127948	ENSG00000160172.9	FAM86C2P	3.77	0.000185	0.0132	0.17	0.17	Total body bone mineral density;	chr11:68595594	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs7106010	ENSG00000160172.9	FAM86C2P	3.77	0.000185	0.0132	0.17	0.17	Total body bone mineral density;	chr11:68597744	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs3758643	ENSG00000160172.9	FAM86C2P	3.77	0.000185	0.0132	0.17	0.17	Total body bone mineral density;	chr11:68599725	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.871	rs17603185	ENSG00000160172.9	FAM86C2P	3.77	0.000185	0.0132	0.17	0.17	Total body bone mineral density;	chr11:68608773	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs4988291	ENSG00000160172.9	FAM86C2P	3.77	0.000185	0.0132	0.17	0.17	Total body bone mineral density;	chr11:68614139	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.871	rs12941	ENSG00000160172.9	FAM86C2P	3.77	0.000185	0.0132	0.17	0.17	Total body bone mineral density;	chr11:68614725	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs11228293	ENSG00000160172.9	FAM86C2P	3.77	0.000185	0.0132	0.17	0.17	Total body bone mineral density;	chr11:68617178	chr11:67791648~67805336:-
THCA	cis	rs757978	0.733	rs41342147	ENSG00000235351.1	AC114730.11	-3.77	0.000185	0.0132	-0.16	-0.17	Chronic lymphocytic leukemia;	chr2:241468173	chr2:241724615~241725693:-
THCA	cis	rs7395662	0.745	rs10838830	ENSG00000200090.1	Y_RNA	3.77	0.000185	0.0132	0.12	0.17	HDL cholesterol;	chr11:48212380	chr11:47726894~47726992:-
THCA	cis	rs1056107	0.541	rs2150258	ENSG00000230185.4	C9orf147	3.77	0.000185	0.0132	0.16	0.17	Colorectal cancer;	chr9:112412328	chr9:112433816~112487204:-
THCA	cis	rs76382185	0.756	rs12727382	ENSG00000233184.5	RP11-421L21.3	3.77	0.000185	0.0132	0.24	0.17	Lymphocyte counts;	chr1:101123098	chr1:101025878~101087268:+
THCA	cis	rs7665090	1	rs6821119	ENSG00000248971.2	KRT8P46	-3.77	0.000185	0.0132	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634076	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.934	rs6844332	ENSG00000248971.2	KRT8P46	-3.77	0.000185	0.0132	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634095	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.967	rs6821133	ENSG00000248971.2	KRT8P46	-3.77	0.000185	0.0132	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634096	chr4:102728746~102730171:-
THCA	cis	rs9905704	0.918	rs2567901	ENSG00000224738.1	AC099850.1	3.77	0.000185	0.0132	0.23	0.17	Testicular germ cell tumor;	chr17:58705894	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs304283	ENSG00000224738.1	AC099850.1	3.77	0.000185	0.0132	0.23	0.17	Testicular germ cell tumor;	chr17:58708364	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs304271	ENSG00000224738.1	AC099850.1	3.77	0.000185	0.0132	0.23	0.17	Testicular germ cell tumor;	chr17:58725097	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs304272	ENSG00000224738.1	AC099850.1	3.77	0.000185	0.0132	0.23	0.17	Testicular germ cell tumor;	chr17:58725667	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs2611783	ENSG00000224738.1	AC099850.1	3.77	0.000185	0.0132	0.23	0.17	Testicular germ cell tumor;	chr17:58731169	chr17:59106598~59118267:+
THCA	cis	rs5753037	0.653	rs140129	ENSG00000273350.1	RP4-539M6.20	-3.77	0.000185	0.0132	-0.19	-0.17	Type 1 diabetes;	chr22:29754560	chr22:30420512~30420912:+
THCA	cis	rs9595908	0.63	rs79837633	ENSG00000212293.1	SNORA16	3.77	0.000185	0.0132	0.2	0.17	Body mass index;	chr13:32754590	chr13:32420390~32420516:-
THCA	cis	rs1865760	0.566	rs3752419	ENSG00000272810.1	U91328.22	-3.77	0.000185	0.0132	-0.14	-0.17	Height;	chr6:26027205	chr6:26013241~26013757:+
THCA	cis	rs111756027	0.593	rs12449219	ENSG00000260922.1	RP11-538I12.3	3.77	0.000185	0.0132	0.29	0.17	Bone mineral density (Ward's triangle area);	chr16:77228046	chr16:77234877~77290934:+
THCA	cis	rs36093844	0.527	rs17817690	ENSG00000279742.1	RP11-700A24.1	-3.77	0.000185	0.0132	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85981018	chr11:85852557~85854943:-
THCA	cis	rs7824557	0.564	rs2736288	ENSG00000154316.13	TDH	3.77	0.000185	0.0132	0.13	0.17	Retinal vascular caliber;	chr8:11370591	chr8:11339637~11368452:+
THCA	cis	rs4908768	0.911	rs12567592	ENSG00000232912.4	RP5-1115A15.1	-3.77	0.000185	0.0132	-0.2	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8728848	chr1:8424645~8434838:+
THCA	cis	rs7264396	0.887	rs6060435	ENSG00000088340.14	FER1L4	-3.77	0.000185	0.0132	-0.16	-0.17	Total cholesterol levels;	chr20:35481545	chr20:35558737~35607562:-
THCA	cis	rs6491750	1	rs57141409	ENSG00000276957.1	RP11-29B2.6	-3.77	0.000185	0.0132	-0.29	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103495261	chr13:102593338~102593873:-
THCA	cis	rs2688608	0.647	rs2633319	ENSG00000271816.1	BMS1P4	3.77	0.000185	0.0132	0.17	0.17	Inflammatory bowel disease;	chr10:73931489	chr10:73699151~73730487:-
THCA	cis	rs6942407	0.545	rs6465101	ENSG00000224046.1	AC005076.5	-3.77	0.000185	0.0132	-0.17	-0.17	Food allergy;	chr7:87229749	chr7:87151423~87152420:-
THCA	cis	rs1864585	0.806	rs12156345	ENSG00000280294.1	RP11-177H2.1	3.77	0.000185	0.0132	0.19	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10895027	chr8:10856085~10859436:-
THCA	cis	rs4575098	0.652	rs11576058	ENSG00000227741.1	RP11-536C5.7	3.77	0.000185	0.0132	0.19	0.17	Monocyte percentage of white cells;	chr1:161141656	chr1:160202199~160208869:-
THCA	cis	rs4575098	0.681	rs10908824	ENSG00000227741.1	RP11-536C5.7	3.77	0.000185	0.0132	0.19	0.17	Monocyte percentage of white cells;	chr1:161142141	chr1:160202199~160208869:-
THCA	cis	rs9309473	1	rs6546836	ENSG00000273245.1	RP11-434P11.2	3.77	0.000185	0.0132	0.23	0.17	Metabolite levels;	chr2:73450706	chr2:73750256~73750786:-
THCA	cis	rs7551222	0.752	rs16853958	ENSG00000240219.1	RP11-430C7.5	3.77	0.000185	0.0132	0.16	0.17	Schizophrenia;	chr1:204559216	chr1:204626775~204629712:+
THCA	cis	rs4434872	0.525	rs6671009	ENSG00000223599.1	RP11-216N14.7	-3.77	0.000185	0.0132	-0.33	-0.17	Conduct disorder (symptom count);	chr1:154047902	chr1:153852106~153853414:-
THCA	cis	rs8023401	0.507	rs7164277	ENSG00000259705.1	RP11-227D13.1	3.77	0.000185	0.0132	0.21	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48507151	chr15:48645951~48652016:+
THCA	cis	rs8023401	0.507	rs9806163	ENSG00000259705.1	RP11-227D13.1	3.77	0.000185	0.0132	0.21	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48511642	chr15:48645951~48652016:+
THCA	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	3.77	0.000185	0.0132	0.15	0.17	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
THCA	cis	rs6142618	0.846	rs11907716	ENSG00000224452.1	RSL24D1P6	3.77	0.000185	0.0132	0.21	0.17	Inflammatory bowel disease;	chr20:32189997	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.846	rs11907235	ENSG00000224452.1	RSL24D1P6	3.77	0.000185	0.0132	0.21	0.17	Inflammatory bowel disease;	chr20:32190057	chr20:32170390~32170790:-
THCA	cis	rs11710088	0.931	rs4320033	ENSG00000240541.2	TM4SF1-AS1	3.77	0.000185	0.0132	0.16	0.17	QRS duration;	chr3:149481468	chr3:149377778~149386583:+
THCA	cis	rs4906332	0.834	rs12882130	ENSG00000244691.1	RPL10AP1	-3.77	0.000185	0.0132	-0.21	-0.17	Coronary artery disease;	chr14:103412437	chr14:103412119~103412761:-
THCA	cis	rs11105298	0.891	rs10858896	ENSG00000266347.2	AC068641.1	3.77	0.000185	0.0132	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs11105312	ENSG00000266347.2	AC068641.1	3.77	0.000185	0.0132	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs10777185	ENSG00000266347.2	AC068641.1	3.77	0.000185	0.0132	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.786	rs10777186	ENSG00000266347.2	AC068641.1	3.77	0.000185	0.0132	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89592833~89592927:+
THCA	cis	rs7554547	0.644	rs57077193	ENSG00000199347.1	RNU5E-1	3.77	0.000185	0.0132	0.24	0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11878154	chr1:11908152~11908271:+
THCA	cis	rs683257	1	rs117661682	ENSG00000234147.1	RP3-460G2.2	-3.77	0.000185	0.0132	-0.33	-0.17	Facial emotion recognition (angry faces);	chr6:140832838	chr6:140845958~140852924:-
THCA	cis	rs6671200	0.831	rs71654411	ENSG00000235501.4	RP4-639F20.1	-3.77	0.000185	0.0133	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95135466	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs34136988	ENSG00000235501.4	RP4-639F20.1	-3.77	0.000185	0.0133	-0.35	-0.17	Stearic acid (18:0) levels;	chr1:95135520	chr1:94927566~94963270:+
THCA	cis	rs801193	1	rs10252765	ENSG00000229180.5	GS1-124K5.11	3.77	0.000185	0.0133	0.12	0.17	Aortic root size;	chr7:66763745	chr7:66526088~66542624:-
THCA	cis	rs7621331	0.817	rs1403769	ENSG00000273486.1	RP11-731C17.2	3.77	0.000185	0.0133	0.15	0.17	Waist circumference adjusted for body mass index;	chr3:135949506	chr3:136837338~136839021:-
THCA	cis	rs2919009	0.664	rs10510083	ENSG00000271670.1	RP11-95I16.4	3.77	0.000185	0.0133	0.19	0.17	Obesity-related traits;	chr10:120925013	chr10:120879256~120880667:-
THCA	cis	rs7616559	0.962	rs1552194	ENSG00000244515.1	KRT18P34	3.77	0.000185	0.0133	0.23	0.17	Carotid artery intima media thickness (sex interaction);	chr3:157002377	chr3:157162663~157163932:-
THCA	cis	rs4648045	0.565	rs62327181	ENSG00000251288.2	RP11-10L12.2	-3.77	0.000185	0.0133	-0.23	-0.17	Lymphocyte percentage of white cells;	chr4:102624981	chr4:102751401~102752641:+
THCA	cis	rs9308731	0.583	rs4848406	ENSG00000227992.1	AC108463.2	-3.77	0.000185	0.0133	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111176181	chr2:111203964~111206215:-
THCA	cis	rs12549025	0.891	rs33963055	ENSG00000253390.1	CTC-756D1.2	-3.77	0.000185	0.0133	-0.29	-0.17	Reticulocyte fraction of red cells;	chr8:23549665	chr8:23458601~23484971:+
THCA	cis	rs2882667	0.931	rs7706391	ENSG00000249593.5	CTB-46B19.2	3.77	0.000185	0.0133	0.21	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:139012647~139051203:+
THCA	cis	rs9843304	0.546	rs56303133	ENSG00000243885.1	RP11-278L15.2	-3.77	0.000185	0.0133	-0.19	-0.17	Gallstone disease;	chr3:149494692	chr3:149384179~149385800:-
THCA	cis	rs10129255	0.834	rs10139893	ENSG00000211972.2	IGHV3-66	3.77	0.000185	0.0133	0.1	0.17	Kawasaki disease;	chr14:106711377	chr14:106675017~106675544:-
THCA	cis	rs13178541	0.641	rs2345447	ENSG00000250378.1	RP11-119J18.1	-3.77	0.000185	0.0133	-0.2	-0.17	IgG glycosylation;	chr5:135804058	chr5:135812667~135826582:+
THCA	cis	rs9291683	0.609	rs55959894	ENSG00000261490.1	RP11-448G15.3	3.77	0.000185	0.0133	0.1	0.17	Bone mineral density;	chr4:10024956	chr4:10068089~10073019:-
THCA	cis	rs2562456	0.793	rs2562474	ENSG00000268278.1	RP11-420K14.1	-3.77	0.000185	0.0133	-0.21	-0.17	Pain;	chr19:21463480	chr19:21637974~21656300:+
THCA	cis	rs6012953	0.934	rs2904269	ENSG00000231715.1	COX6CP2	3.77	0.000185	0.0133	0.18	0.17	Vitiligo;	chr20:50539794	chr20:50479767~50479991:+
THCA	cis	rs10911902	0.643	rs3766705	ENSG00000233196.2	GS1-304P7.1	-3.77	0.000185	0.0133	-0.27	-0.17	Schizophrenia;	chr1:186342680	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs16825201	ENSG00000233196.2	GS1-304P7.1	-3.77	0.000185	0.0133	-0.27	-0.17	Schizophrenia;	chr1:186344698	chr1:186580515~186581191:-
THCA	cis	rs1927790	0.648	rs2389631	ENSG00000247400.3	DNAJC3-AS1	-3.77	0.000185	0.0133	-0.11	-0.17	Body mass index;	chr13:96280614	chr13:95648733~95676925:-
THCA	cis	rs5758511	0.68	rs739146	ENSG00000237037.8	NDUFA6-AS1	-3.77	0.000185	0.0133	-0.16	-0.17	Birth weight;	chr22:42264408	chr22:42090931~42137742:+
THCA	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	3.77	0.000185	0.0133	0.15	0.17	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	3.77	0.000185	0.0133	0.15	0.17	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
THCA	cis	rs1383484	1	rs1383484	ENSG00000259728.4	LINC00933	-3.77	0.000185	0.0133	-0.21	-0.17	Height;	chr15:83854003	chr15:84570649~84580175:+
THCA	cis	rs7737355	0.812	rs798413	ENSG00000224431.1	AC063976.7	3.77	0.000185	0.0133	0.16	0.17	Life satisfaction;	chr5:131360893	chr5:132199456~132203487:+
THCA	cis	rs875971	0.545	rs316316	ENSG00000232559.3	GS1-124K5.12	-3.77	0.000185	0.0133	-0.18	-0.17	Aortic root size;	chr7:66149270	chr7:66554588~66576923:-
THCA	cis	rs74233809	1	rs17115213	ENSG00000272912.1	RP11-724N1.1	-3.77	0.000185	0.0133	-0.31	-0.17	Birth weight;	chr10:102921386	chr10:102914585~102915404:+
THCA	cis	rs11069062	0.866	rs12303035	ENSG00000270482.1	RP11-131L12.2	3.77	0.000185	0.0133	0.14	0.17	Obesity-related traits;	chr12:118712715	chr12:118375350~118376275:-
THCA	cis	rs5758659	0.652	rs6519301	ENSG00000273366.1	CTA-989H11.1	-3.77	0.000185	0.0133	-0.2	-0.17	Cognitive function;	chr22:41989963	chr22:42278188~42278846:+
THCA	cis	rs758324	0.717	rs7720910	ENSG00000224431.1	AC063976.7	3.77	0.000185	0.0133	0.18	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132024654	chr5:132199456~132203487:+
THCA	cis	rs150992	0.821	rs326480	ENSG00000246763.5	RGMB-AS1	3.77	0.000185	0.0133	0.18	0.17	Body mass index;	chr5:98949263	chr5:98769618~98773469:-
THCA	cis	rs13113518	0.812	rs6849474	ENSG00000272969.1	RP11-528I4.2	3.77	0.000185	0.0133	0.2	0.17	Height;	chr4:55452295	chr4:55547112~55547889:+
THCA	cis	rs7916697	0.52	rs4745957	ENSG00000233590.1	RP11-153K11.3	3.77	0.000185	0.0133	0.23	0.17	Optic disc area;	chr10:68284945	chr10:68233251~68242379:-
THCA	cis	rs10181042	0.565	rs3108630	ENSG00000232713.2	AC010733.5	-3.77	0.000185	0.0133	-0.15	-0.17	Crohn's disease;	chr2:61041025	chr2:60938204~60938604:-
THCA	cis	rs2348418	0.703	rs12368149	ENSG00000278733.1	RP11-425D17.1	3.77	0.000185	0.0133	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28168625	chr12:28185625~28186190:-
THCA	cis	rs5751901	0.614	rs5760489	ENSG00000128262.7	POM121L9P	-3.77	0.000185	0.0133	-0.17	-0.17	Protein quantitative trait loci;	chr22:24594679	chr22:24251828~24265525:+
THCA	cis	rs6715284	1	rs6711941	ENSG00000238829.1	RNU7-45P	-3.77	0.000185	0.0133	-0.38	-0.17	Rheumatoid arthritis;	chr2:201313407	chr2:201141904~201141966:+
THCA	cis	rs2832191	0.626	rs2254796	ENSG00000176054.6	RPL23P2	-3.77	0.000185	0.0133	-0.15	-0.17	Dental caries;	chr21:28969569	chr21:28997613~28998033:-
THCA	cis	rs889398	0.594	rs3790085	ENSG00000226232.7	RP11-419C5.2	-3.77	0.000185	0.0133	-0.17	-0.17	Body mass index;	chr16:69853817	chr16:69976388~69996188:-
THCA	cis	rs12935229	0.808	rs60918167	ENSG00000260922.1	RP11-538I12.3	-3.77	0.000185	0.0133	-0.29	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77265230	chr16:77234877~77290934:+
THCA	cis	rs9326246	0.545	rs485638	ENSG00000254851.1	RP11-109L13.1	3.77	0.000186	0.0133	0.39	0.17	Coronary artery disease;	chr11:116652656	chr11:117135528~117138582:+
THCA	cis	rs1836229	0.874	rs6477358	ENSG00000225706.1	PTPRD-AS1	-3.77	0.000186	0.0133	-0.21	-0.17	Restless legs syndrome;	chr9:8832394	chr9:8858130~8862255:+
THCA	cis	rs293748	0.771	rs159140	ENSG00000250155.1	CTD-2353F22.1	-3.77	0.000186	0.0133	-0.23	-0.17	Obesity-related traits;	chr5:36925903	chr5:36666214~36725195:-
THCA	cis	rs3885907	0.546	rs3935645	ENSG00000224511.1	LINC00365	3.77	0.000186	0.0133	0.22	0.17	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);	chr13:30763421	chr13:30103178~30108875:-
THCA	cis	rs6995541	0.744	rs10109416	ENSG00000248896.2	CTD-2135J3.3	-3.77	0.000186	0.0133	-0.22	-0.17	Triglyceride levels;	chr8:10827245	chr8:10729314~10771392:+
THCA	cis	rs1387259	0.698	rs4579969	ENSG00000240399.1	RP1-228P16.1	-3.77	0.000186	0.0133	-0.17	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48054813~48055591:-
THCA	cis	rs1371614	0.611	rs3843322	ENSG00000272148.1	RP11-195B17.1	3.77	0.000186	0.0133	0.16	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908981	chr2:27062428~27062907:-
THCA	cis	rs17301013	0.932	rs6425280	ENSG00000270084.1	GAS5-AS1	-3.77	0.000186	0.0133	-0.18	-0.17	Systemic lupus erythematosus;	chr1:174422186	chr1:173863248~173863941:+
THCA	cis	rs524281	0.692	rs10791845	ENSG00000255120.4	OVOL1-AS1	3.77	0.000186	0.0133	0.24	0.17	Electroencephalogram traits;	chr11:66066869	chr11:65789051~65790868:-
THCA	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	3.77	0.000186	0.0133	0.16	0.17	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	3.77	0.000186	0.0133	0.16	0.17	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
THCA	cis	rs6137726	0.524	rs1203953	ENSG00000237396.1	LINC01384	3.77	0.000186	0.0133	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22635505	chr20:22587522~22607517:-
THCA	cis	rs5752773	0.513	rs695439	ENSG00000272858.1	CTA-292E10.8	-3.77	0.000186	0.0133	-0.18	-0.17	Vertical cup-disc ratio;	chr22:28459035	chr22:28814914~28815662:+
THCA	cis	rs2688608	0.592	rs10762563	ENSG00000272140.2	RP11-574K11.29	3.77	0.000186	0.0133	0.14	0.17	Inflammatory bowel disease;	chr10:73765044	chr10:73703735~73713581:-
THCA	cis	rs7824557	0.564	rs2572386	ENSG00000255495.1	AC145124.2	-3.77	0.000186	0.0133	-0.19	-0.17	Retinal vascular caliber;	chr8:11379466	chr8:12194467~12196280:+
THCA	cis	rs7246760	1	rs113915533	ENSG00000267106.4	ZNF561-AS1	3.77	0.000186	0.0133	0.33	0.17	Pursuit maintenance gain;	chr19:9770703	chr19:9621291~9645896:+
THCA	cis	rs7246760	1	rs7246772	ENSG00000267106.4	ZNF561-AS1	3.77	0.000186	0.0133	0.33	0.17	Pursuit maintenance gain;	chr19:9775607	chr19:9621291~9645896:+
THCA	cis	rs7246760	1	rs73507215	ENSG00000267106.4	ZNF561-AS1	3.77	0.000186	0.0133	0.33	0.17	Pursuit maintenance gain;	chr19:9776636	chr19:9621291~9645896:+
THCA	cis	rs13217239	0.646	rs10946897	ENSG00000261353.1	CTA-14H9.5	-3.77	0.000186	0.0133	-0.18	-0.17	Schizophrenia;	chr6:27027472	chr6:26527063~26527404:+
THCA	cis	rs4819052	1	rs2838847	ENSG00000184274.3	LINC00315	-3.77	0.000186	0.0133	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45300245~45305257:-
THCA	cis	rs1908814	0.516	rs60176945	ENSG00000255495.1	AC145124.2	3.77	0.000186	0.0133	0.2	0.17	Neuroticism;	chr8:11939165	chr8:12194467~12196280:+
THCA	cis	rs1908814	0.516	rs56102998	ENSG00000255495.1	AC145124.2	3.77	0.000186	0.0133	0.2	0.17	Neuroticism;	chr8:11939166	chr8:12194467~12196280:+
THCA	cis	rs8058578	0.832	rs35969813	ENSG00000260911.2	RP11-196G11.2	3.77	0.000186	0.0133	0.15	0.17	Multiple myeloma;	chr16:30703096	chr16:31043150~31049868:+
THCA	cis	rs11030122	0.959	rs10767685	ENSG00000230593.3	AC090804.1	3.77	0.000186	0.0133	0.22	0.17	Mean platelet volume;Platelet distribution width;	chr11:3892803	chr11:3892398~3892887:-
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000280107.1	AL022393.9	-3.77	0.000186	0.0133	-0.17	-0.17	Pubertal anthropometrics;	chr6:28271903	chr6:28170845~28172521:+
THCA	cis	rs9427116	0.502	rs7531982	ENSG00000236675.1	MTX1P1	-3.77	0.000186	0.0133	-0.15	-0.17	Blood protein levels;	chr1:154623646	chr1:155230975~155234325:+
THCA	cis	rs17345786	0.906	rs58835747	ENSG00000244119.1	PDCL3P4	3.77	0.000186	0.0133	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr3:101524790	chr3:101712472~101713191:+
THCA	cis	rs13437751	0.881	rs73123099	ENSG00000223558.1	TRIM60P17	3.77	0.000186	0.0133	0.37	0.17	QT interval (drug interaction);	chr7:63934897	chr7:64085560~64086576:+
THCA	cis	rs1577917	0.958	rs11752180	ENSG00000220563.1	PKMP3	-3.77	0.000186	0.0133	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85863447	chr6:85659892~85660606:-
THCA	cis	rs17826219	0.561	rs4794869	ENSG00000264538.5	SUZ12P1	-3.77	0.000186	0.0133	-0.26	-0.17	Body mass index;	chr17:30364082	chr17:30709299~30790908:+
THCA	cis	rs427394	0.659	rs274725	ENSG00000248677.1	CTD-2044J15.1	3.77	0.000186	0.0133	0.17	0.17	Menopause (age at onset);	chr5:6717295	chr5:6686325~6707711:-
THCA	cis	rs7824557	0.545	rs2572380	ENSG00000255495.1	AC145124.2	-3.77	0.000186	0.0133	-0.19	-0.17	Retinal vascular caliber;	chr8:11379968	chr8:12194467~12196280:+
THCA	cis	rs4273100	1	rs4924986	ENSG00000263934.3	SNORD3A	-3.77	0.000186	0.0133	-0.27	-0.17	Schizophrenia;	chr17:19339154	chr17:19188016~19188714:+
THCA	cis	rs11583043	1	rs34915449	ENSG00000233184.5	RP11-421L21.3	3.77	0.000186	0.0133	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101011230	chr1:101025878~101087268:+
THCA	cis	rs11583043	1	rs17123612	ENSG00000233184.5	RP11-421L21.3	3.77	0.000186	0.0133	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101011258	chr1:101025878~101087268:+
THCA	cis	rs7824557	0.592	rs2736280	ENSG00000206014.6	OR7E161P	-3.77	0.000186	0.0133	-0.2	-0.17	Retinal vascular caliber;	chr8:11365513	chr8:11928597~11929563:-
THCA	cis	rs7259376	0.807	rs11669254	ENSG00000269138.1	ZNF209P	3.77	0.000186	0.0133	0.18	0.17	Menopause (age at onset);	chr19:22362003	chr19:22463922~22473036:+
THCA	cis	rs9840812	0.577	rs503973	ENSG00000239213.4	NCK1-AS1	-3.77	0.000186	0.0133	-0.18	-0.17	Fibrinogen levels;	chr3:136340695	chr3:136841726~136862054:-
THCA	cis	rs6121246	0.697	rs8118150	ENSG00000224628.2	RP5-854E16.2	-3.77	0.000186	0.0133	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31848285	chr20:31285317~31286835:-
THCA	cis	rs2562784	0.638	rs12437593	ENSG00000225151.9	GOLGA2P7	-3.77	0.000186	0.0133	-0.32	-0.17	Height;	chr15:83594945	chr15:84199311~84230136:-
THCA	cis	rs2625529	0.824	rs16956328	ENSG00000260037.4	CTD-2524L6.3	-3.77	0.000186	0.0133	-0.24	-0.17	Red blood cell count;	chr15:71851514	chr15:71818396~71823384:+
THCA	cis	rs7829975	0.811	rs7011229	ENSG00000253981.4	ALG1L13P	-3.77	0.000186	0.0133	-0.16	-0.17	Mood instability;	chr8:8685814	chr8:8236003~8244667:-
THCA	cis	rs3806843	0.583	rs408652	ENSG00000202515.1	VTRNA1-3	-3.77	0.000186	0.0133	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140950428	chr5:140726158~140726246:+
THCA	cis	rs733592	1	rs733592	ENSG00000258273.1	RP11-370I10.4	3.77	0.000186	0.0133	0.2	0.17	Plateletcrit;	chr12:48035993	chr12:48333755~48333901:-
THCA	cis	rs875971	0.825	rs59466412	ENSG00000222364.1	RNU6-96P	3.77	0.000186	0.0133	0.2	0.17	Aortic root size;	chr7:66100371	chr7:66395191~66395286:+
THCA	cis	rs7216064	1	rs8071463	ENSG00000265055.1	AC145343.2	-3.77	0.000186	0.0133	-0.24	-0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942539	chr17:68096046~68101474:-
THCA	cis	rs7824557	0.544	rs1865521	ENSG00000227888.4	FAM66A	3.77	0.000186	0.0133	0.22	0.17	Retinal vascular caliber;	chr8:11373740	chr8:12362019~12388296:+
THCA	cis	rs11601239	0.646	rs630880	ENSG00000254750.1	CASP1P2	3.77	0.000186	0.0133	0.14	0.17	Refractive error;	chr11:105802378	chr11:105063345~105071541:-
THCA	cis	rs4389656	0.857	rs274677	ENSG00000248677.1	CTD-2044J15.1	3.77	0.000186	0.0133	0.17	0.17	Coronary artery disease;	chr5:6754289	chr5:6686325~6707711:-
THCA	cis	rs6921919	0.638	rs1416920	ENSG00000176933.5	TOB2P1	-3.77	0.000186	0.0133	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28217643~28218634:-
THCA	cis	rs6921919	0.525	rs1361386	ENSG00000176933.5	TOB2P1	-3.77	0.000186	0.0133	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28217643~28218634:-
THCA	cis	rs6921919	0.638	rs6456815	ENSG00000176933.5	TOB2P1	-3.77	0.000186	0.0133	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28217643~28218634:-
THCA	cis	rs4853525	0.59	rs6740086	ENSG00000235852.1	AC005540.3	3.77	0.000186	0.0133	0.19	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190871204	chr2:190880797~190882059:-
THCA	cis	rs7551222	0.752	rs10900597	ENSG00000240219.1	RP11-430C7.5	3.77	0.000186	0.0133	0.16	0.17	Schizophrenia;	chr1:204553361	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.752	rs12741351	ENSG00000240219.1	RP11-430C7.5	3.77	0.000186	0.0133	0.16	0.17	Schizophrenia;	chr1:204559128	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.721	rs4951080	ENSG00000240219.1	RP11-430C7.5	3.77	0.000186	0.0133	0.16	0.17	Schizophrenia;	chr1:204564156	chr1:204626775~204629712:+
THCA	cis	rs7551222	0.752	rs4951400	ENSG00000240219.1	RP11-430C7.5	3.77	0.000186	0.0133	0.16	0.17	Schizophrenia;	chr1:204565443	chr1:204626775~204629712:+
THCA	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	3.77	0.000186	0.0133	0.16	0.17	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
THCA	cis	rs111756027	0.593	rs9924848	ENSG00000260922.1	RP11-538I12.3	3.77	0.000186	0.0133	0.26	0.17	Bone mineral density (Ward's triangle area);	chr16:77212074	chr16:77234877~77290934:+
THCA	cis	rs10844706	0.669	rs10844682	ENSG00000214776.8	RP11-726G1.1	-3.77	0.000186	0.0133	-0.21	-0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9747028	chr12:9467552~9576275:+
THCA	cis	rs7200543	1	rs16966952	ENSG00000188599.16	NPIPP1	-3.77	0.000186	0.0133	-0.13	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:15104312~15123498:-
THCA	cis	rs1383484	1	rs11259921	ENSG00000225151.9	GOLGA2P7	3.77	0.000186	0.0133	0.22	0.17	Height;	chr15:83836734	chr15:84199311~84230136:-
THCA	cis	rs4648045	0.647	rs1599961	ENSG00000246560.2	RP11-10L12.4	3.77	0.000186	0.0133	0.21	0.17	Lymphocyte percentage of white cells;	chr4:102522412	chr4:102828055~102844075:+
THCA	cis	rs1923243	0.617	rs7516673	ENSG00000223479.3	RP4-788P17.1	-3.77	0.000186	0.0133	-0.18	-0.17	Migraine;	chr1:72964170	chr1:73635216~73715214:+
THCA	cis	rs2163813	1	rs247771	ENSG00000271283.1	CTC-412M14.6	-3.77	0.000186	0.0133	-0.24	-0.17	Toenail selenium levels;	chr19:19737073	chr19:19699203~19699409:-
THCA	cis	rs7572644	0.766	rs1350481	ENSG00000223522.1	AC093690.1	3.77	0.000186	0.0133	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27962941	chr2:28307691~28310459:-
THCA	cis	rs7117932	0.935	rs10790964	ENSG00000270160.1	RP11-264E20.2	3.77	0.000186	0.0133	0.2	0.17	Obesity-related traits;	chr11:128575954	chr11:128614340~128615236:-
THCA	cis	rs2613964	0.504	rs1903431	ENSG00000243795.1	RP11-572M11.3	3.77	0.000186	0.0133	0.19	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133810	chr3:113142350~113167819:-
THCA	cis	rs7829975	0.511	rs2921028	ENSG00000253981.4	ALG1L13P	3.77	0.000186	0.0133	0.17	0.17	Mood instability;	chr8:8482967	chr8:8236003~8244667:-
THCA	cis	rs7617480	0.519	rs6790914	ENSG00000229759.1	MRPS18AP1	3.77	0.000186	0.0133	0.22	0.17	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:48256350~48256938:-
THCA	cis	rs1577917	0.958	rs7739241	ENSG00000220563.1	PKMP3	-3.77	0.000186	0.0133	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85866078	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs12202712	ENSG00000220563.1	PKMP3	-3.77	0.000186	0.0133	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85868823	chr6:85659892~85660606:-
THCA	cis	rs7200543	0.961	rs1741	ENSG00000260735.1	RP11-72I8.1	-3.77	0.000186	0.0133	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:15094411~15109197:+
THCA	cis	rs7326068	0.61	rs8000601	ENSG00000278291.1	RP11-172H24.4	3.77	0.000186	0.0133	0.23	0.17	Schizophrenia, bipolar disorder and depression (combined);	chr13:20765245	chr13:20699307~20703718:-
THCA	cis	rs7326068	0.51	rs4432108	ENSG00000278291.1	RP11-172H24.4	3.77	0.000186	0.0133	0.23	0.17	Schizophrenia, bipolar disorder and depression (combined);	chr13:20768012	chr13:20699307~20703718:-
THCA	cis	rs7191700	0.509	rs415595	ENSG00000263179.1	HNRNPCP4	-3.77	0.000186	0.0133	-0.21	-0.17	Multiple sclerosis;	chr16:11269835	chr16:11242653~11243552:+
THCA	cis	rs7191700	0.509	rs416603	ENSG00000263179.1	HNRNPCP4	3.77	0.000186	0.0133	0.21	0.17	Multiple sclerosis;	chr16:11270222	chr16:11242653~11243552:+
THCA	cis	rs9368481	0.729	rs10946881	ENSG00000228223.2	HCG11	-3.77	0.000186	0.0133	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26523450~26526579:+
THCA	cis	rs62402013	1	rs62402013	ENSG00000228223.2	HCG11	-3.77	0.000186	0.0133	-0.19	-0.17	Schizophrenia;	chr6:26947221	chr6:26523450~26526579:+
THCA	cis	rs7216064	0.589	rs7213585	ENSG00000267023.4	LRRC37A16P	-3.77	0.000186	0.0133	-0.13	-0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68066200	chr17:68125777~68152468:-
THCA	cis	rs12612619	0.732	rs7585410	ENSG00000272148.1	RP11-195B17.1	3.77	0.000186	0.0133	0.16	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26979252	chr2:27062428~27062907:-
THCA	cis	rs832187	0.665	rs7627690	ENSG00000224479.4	AC136289.1	3.77	0.000186	0.0133	0.21	0.17	Schizophrenia;	chr3:63914801	chr3:63742293~63827445:-
THCA	cis	rs7307902	1	rs11168143	ENSG00000280054.1	RP1-197B17.7	-3.77	0.000186	0.0133	-0.2	-0.17	Obesity-related traits;	chr12:47534397	chr12:47728151~47730598:-
THCA	cis	rs7307902	1	rs10875657	ENSG00000280054.1	RP1-197B17.7	-3.77	0.000186	0.0133	-0.2	-0.17	Obesity-related traits;	chr12:47534538	chr12:47728151~47730598:-
THCA	cis	rs7307902	1	rs10875658	ENSG00000280054.1	RP1-197B17.7	-3.77	0.000186	0.0133	-0.2	-0.17	Obesity-related traits;	chr12:47534587	chr12:47728151~47730598:-
THCA	cis	rs7074356	0.915	rs1870146	ENSG00000225484.5	NUTM2B-AS1	3.77	0.000186	0.0133	0.31	0.17	Borderline personality disorder;	chr10:80450623	chr10:79663088~79826594:-
THCA	cis	rs758324	0.947	rs380182	ENSG00000237714.1	P4HA2-AS1	-3.77	0.000187	0.0133	-0.24	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131983343	chr5:132184876~132192808:+
THCA	cis	rs854765	0.583	rs7222480	ENSG00000281749.1	Y_RNA	3.77	0.000187	0.0133	0.22	0.17	Total body bone mineral density;	chr17:17915503	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs62064156	ENSG00000281749.1	Y_RNA	3.77	0.000187	0.0133	0.22	0.17	Total body bone mineral density;	chr17:17919166	chr17:18001101~18001195:-
THCA	cis	rs854765	0.551	rs56886154	ENSG00000281749.1	Y_RNA	3.77	0.000187	0.0133	0.22	0.17	Total body bone mineral density;	chr17:17928159	chr17:18001101~18001195:-
THCA	cis	rs2033711	0.84	rs4801590	ENSG00000232098.3	CTD-2619J13.14	3.77	0.000187	0.0133	0.15	0.17	Uric acid clearance;	chr19:58450446	chr19:58404238~58408484:-
THCA	cis	rs4742903	0.875	rs2122581	ENSG00000270332.1	SMC2-AS1	3.77	0.000187	0.0133	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104246530	chr9:104080024~104093073:-
THCA	cis	rs911555	0.755	rs11627446	ENSG00000269958.1	RP11-73M18.8	3.77	0.000187	0.0134	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103696353~103697163:+
THCA	cis	rs7665090	0.905	rs2866410	ENSG00000248971.2	KRT8P46	-3.77	0.000187	0.0134	-0.2	-0.17	Primary biliary cholangitis;	chr4:102633178	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.936	rs2866411	ENSG00000248971.2	KRT8P46	-3.77	0.000187	0.0134	-0.2	-0.17	Primary biliary cholangitis;	chr4:102633183	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.936	rs2866412	ENSG00000248971.2	KRT8P46	-3.77	0.000187	0.0134	-0.2	-0.17	Primary biliary cholangitis;	chr4:102633193	chr4:102728746~102730171:-
THCA	cis	rs2898290	0.622	rs978803	ENSG00000270154.1	RP11-419I17.1	3.77	0.000187	0.0134	0.22	0.17	Systolic blood pressure;	chr8:11485966	chr8:12476462~12477122:+
THCA	cis	rs6138458	0.626	rs6132789	ENSG00000274173.1	RP4-568C11.4	-3.77	0.000187	0.0134	-0.15	-0.17	Blood protein levels;	chr20:25032173	chr20:24931840~24932983:+
THCA	cis	rs17301013	0.932	rs12077622	ENSG00000270084.1	GAS5-AS1	-3.77	0.000187	0.0134	-0.18	-0.17	Systemic lupus erythematosus;	chr1:174442507	chr1:173863248~173863941:+
THCA	cis	rs6733301	0.554	rs7593864	ENSG00000224165.4	DNAJC27-AS1	3.77	0.000187	0.0134	0.12	0.17	Height;	chr2:24971872	chr2:24971390~25039694:+
THCA	cis	rs860295	0.557	rs11264372	ENSG00000160766.13	GBAP1	-3.77	0.000187	0.0134	-0.21	-0.17	Body mass index;	chr1:155443139	chr1:155213821~155227422:-
THCA	cis	rs7829975	0.774	rs35039922	ENSG00000253981.4	ALG1L13P	3.77	0.000187	0.0134	0.16	0.17	Mood instability;	chr8:8817815	chr8:8236003~8244667:-
THCA	cis	rs4699052	0.963	rs11733615	ENSG00000230069.3	LRRC37A15P	-3.77	0.000187	0.0134	-0.17	-0.17	Testicular germ cell tumor;	chr4:103236007	chr4:102727274~102730721:-
THCA	cis	rs786425	0.711	rs36018806	ENSG00000278112.1	RP11-972P1.11	3.77	0.000187	0.0134	0.17	0.17	Pubertal anthropometrics;	chr12:123630005	chr12:123519390~123519856:-
THCA	cis	rs62344088	1	rs28409618	ENSG00000277812.1	AC021087.1	3.77	0.000187	0.0134	0.43	0.17	Asthma (childhood onset);	chr5:160174	chr5:262769~262881:+
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000280107.1	AL022393.9	-3.77	0.000187	0.0134	-0.17	-0.17	Pubertal anthropometrics;	chr6:28259100	chr6:28170845~28172521:+
THCA	cis	rs11634944	0.506	rs765438	ENSG00000251896.1	SNORD116-27	-3.77	0.000187	0.0134	-0.19	-0.17	Interleukin-8 levels;	chr15:24990981	chr15:25101575~25101666:+
THCA	cis	rs6472235	0.656	rs11994927	ENSG00000272192.1	CTD-2532N20.1	3.77	0.000187	0.0134	0.18	0.17	Plateletcrit;Myopia (pathological);	chr8:65970615	chr8:65842752~65843331:+
THCA	cis	rs2013441	0.866	rs2526492	ENSG00000261033.1	RP11-209D14.2	3.77	0.000187	0.0134	0.24	0.17	Obesity-related traits;	chr17:20192302	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.835	rs2526491	ENSG00000261033.1	RP11-209D14.2	3.77	0.000187	0.0134	0.24	0.17	Obesity-related traits;	chr17:20194149	chr17:20008051~20009234:-
THCA	cis	rs4819052	0.679	rs2838860	ENSG00000273796.1	LL21NC02-21A1.1	-3.77	0.000187	0.0134	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45403809~45404369:-
THCA	cis	rs7580658	0.614	rs7585198	ENSG00000213236.3	YWHAZP2	-3.77	0.000187	0.0134	-0.17	-0.17	Protein C levels;	chr2:127205059	chr2:126557435~126558162:-
THCA	cis	rs860295	0.812	rs12024257	ENSG00000203761.5	MSTO2P	-3.77	0.000187	0.0134	-0.13	-0.17	Body mass index;	chr1:155810745	chr1:155745829~155750137:+
THCA	cis	rs860295	0.812	rs6657670	ENSG00000203761.5	MSTO2P	-3.77	0.000187	0.0134	-0.13	-0.17	Body mass index;	chr1:155818076	chr1:155745829~155750137:+
THCA	cis	rs5753037	0.653	rs140131	ENSG00000273350.1	RP4-539M6.20	-3.77	0.000187	0.0134	-0.19	-0.17	Type 1 diabetes;	chr22:29755727	chr22:30420512~30420912:+
THCA	cis	rs875971	0.66	rs801193	ENSG00000230295.1	RP11-458F8.2	3.77	0.000187	0.0134	0.13	0.17	Aortic root size;	chr7:66565625	chr7:66880708~66882981:+
THCA	cis	rs7615952	0.673	rs115942855	ENSG00000272840.1	RP11-379B18.6	3.77	0.000187	0.0134	0.33	0.17	Blood pressure (smoking interaction);	chr3:125883117	chr3:125774714~125797953:+
THCA	cis	rs267567	0.626	rs2844360	ENSG00000235257.7	ITGA9-AS1	3.77	0.000187	0.0134	0.14	0.17	PR interval;	chr3:37529687	chr3:37745432~37861780:-
THCA	cis	rs267567	0.647	rs2844362	ENSG00000235257.7	ITGA9-AS1	3.77	0.000187	0.0134	0.14	0.17	PR interval;	chr3:37529787	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs525731	ENSG00000235257.7	ITGA9-AS1	3.77	0.000187	0.0134	0.14	0.17	PR interval;	chr3:37530336	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs487036	ENSG00000235257.7	ITGA9-AS1	3.77	0.000187	0.0134	0.14	0.17	PR interval;	chr3:37530508	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs183845	ENSG00000235257.7	ITGA9-AS1	3.77	0.000187	0.0134	0.14	0.17	PR interval;	chr3:37531088	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs2434131	ENSG00000235257.7	ITGA9-AS1	3.77	0.000187	0.0134	0.14	0.17	PR interval;	chr3:37531164	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs2434130	ENSG00000235257.7	ITGA9-AS1	3.77	0.000187	0.0134	0.14	0.17	PR interval;	chr3:37531199	chr3:37745432~37861780:-
THCA	cis	rs4915077	0.773	rs61471569	ENSG00000226822.1	RP11-356N1.2	3.77	0.000187	0.0134	0.31	0.17	Hypothyroidism;	chr1:107716445	chr1:108071482~108074519:+
THCA	cis	rs755249	0.642	rs11206430	ENSG00000237624.1	OXCT2P1	3.77	0.000187	0.0134	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39609695	chr1:39514956~39516490:+
THCA	cis	rs7572733	0.84	rs700640	ENSG00000231621.1	AC013264.2	-3.77	0.000187	0.0134	-0.16	-0.17	Dermatomyositis;	chr2:197726162	chr2:197197991~197199273:+
THCA	cis	rs1580019	0.844	rs4723159	ENSG00000231952.3	DPY19L1P2	-3.77	0.000187	0.0134	-0.23	-0.17	Cognitive ability;	chr7:32473192	chr7:32812757~32838570:+
THCA	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	3.77	0.000187	0.0134	0.2	0.17	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
THCA	cis	rs7819412	0.806	rs2898256	ENSG00000254948.1	OR7E158P	3.77	0.000187	0.0134	0.21	0.17	Triglycerides;	chr8:11075185	chr8:11919900~11920809:-
THCA	cis	rs12476592	0.571	rs7606045	ENSG00000242412.1	DBIL5P2	3.77	0.000187	0.0134	0.21	0.17	Childhood ear infection;	chr2:63599394	chr2:63117851~63119542:-
THCA	cis	rs141413113	1	rs141413113	ENSG00000273328.4	RP11-141M3.6	3.77	0.000187	0.0134	0.23	0.17	Lymphocyte percentage of white cells;	chr3:42865919	chr3:42809414~42908105:+
THCA	cis	rs2688608	0.592	rs11000759	ENSG00000272140.2	RP11-574K11.29	3.77	0.000187	0.0134	0.15	0.17	Inflammatory bowel disease;	chr10:73733968	chr10:73703735~73713581:-
THCA	cis	rs3748656	0.945	rs10857964	ENSG00000273483.1	RP4-671G15.2	3.77	0.000187	0.0134	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112555011	chr1:112517799~112518441:-
THCA	cis	rs6920965	0.561	rs9401851	ENSG00000226409.1	RP11-735G4.1	-3.77	0.000187	0.0134	-0.21	-0.17	High light scatter reticulocyte count;	chr6:125860810	chr6:125370211~125374324:-
THCA	cis	rs2070488	0.965	rs2284819	ENSG00000229589.1	ACVR2B-AS1	3.77	0.000187	0.0134	0.16	0.17	Electrocardiographic conduction measures;	chr3:38515670	chr3:38451027~38454820:-
THCA	cis	rs765787	0.53	rs1706832	ENSG00000259539.1	CTD-2651B20.1	3.77	0.000187	0.0134	0.21	0.17	Uric acid levels;	chr15:45224975	chr15:45152664~45167526:-
THCA	cis	rs6496667	1	rs6496668	ENSG00000259262.1	NDUFA3P4	3.77	0.000187	0.0134	0.23	0.17	Rheumatoid arthritis;	chr15:90350472	chr15:90385814~90386063:+
THCA	cis	rs6696239	0.956	rs6659349	ENSG00000227711.2	RP11-275O4.5	-3.77	0.000187	0.0134	-0.24	-0.17	Height;	chr1:227623754	chr1:227509028~227520477:-
THCA	cis	rs934734	0.532	rs10166100	ENSG00000214533.3	KRT18P33	-3.77	0.000187	0.0134	-0.21	-0.17	Rheumatoid arthritis;	chr2:65418616	chr2:65666695~65667737:+
THCA	cis	rs2434529	1	rs10051799	ENSG00000245275.6	SAP30L-AS1	3.77	0.000187	0.0134	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154268910	chr5:154329437~154445850:-
THCA	cis	rs9450351	0.744	rs9362225	ENSG00000203875.9	SNHG5	-3.77	0.000187	0.0134	-0.34	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85500713	chr6:85660950~85678736:-
THCA	cis	rs1023500	0.505	rs134874	ENSG00000233903.2	Z83851.4	3.77	0.000187	0.0134	0.21	0.17	Schizophrenia;	chr22:42265138	chr22:42276355~42277052:+
THCA	cis	rs7680126	0.58	rs6827401	ENSG00000261490.1	RP11-448G15.3	3.77	0.000187	0.0134	0.17	0.17	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10029442	chr4:10068089~10073019:-
THCA	cis	rs17772222	0.682	rs8017689	ENSG00000222990.1	RNU4-22P	3.77	0.000187	0.0134	0.21	0.17	Coronary artery calcification;	chr14:88483442	chr14:88513498~88513663:+
THCA	cis	rs2688608	0.53	rs71507081	ENSG00000272140.2	RP11-574K11.29	3.77	0.000187	0.0134	0.15	0.17	Inflammatory bowel disease;	chr10:73733378	chr10:73703735~73713581:-
THCA	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-3.77	0.000187	0.0134	-0.16	-0.17	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
THCA	cis	rs6732426	0.524	rs10166054	ENSG00000234936.1	AC010883.5	3.77	0.000187	0.0134	0.14	0.17	Hair morphology;	chr2:43391901	chr2:43229573~43233394:+
THCA	cis	rs7259376	0.905	rs12608842	ENSG00000270947.1	AC025811.3	-3.77	0.000187	0.0134	-0.18	-0.17	Menopause (age at onset);	chr19:22365211	chr19:22455988~22456459:+
THCA	cis	rs12476592	0.571	rs190519	ENSG00000242412.1	DBIL5P2	3.77	0.000187	0.0134	0.22	0.17	Childhood ear infection;	chr2:63631291	chr2:63117851~63119542:-
THCA	cis	rs6762	0.719	rs28620453	ENSG00000255142.1	AP006621.6	3.77	0.000187	0.0134	0.12	0.17	Mean platelet volume;	chr11:836971	chr11:781645~782105:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000273024.4	INTS4P2	-3.77	0.000187	0.0134	-0.21	-0.17	Aortic root size;	chr7:66164012	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000273024.4	INTS4P2	-3.77	0.000187	0.0134	-0.21	-0.17	Aortic root size;	chr7:66166374	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000273024.4	INTS4P2	-3.77	0.000187	0.0134	-0.21	-0.17	Aortic root size;	chr7:66168318	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000273024.4	INTS4P2	-3.77	0.000187	0.0134	-0.21	-0.17	Aortic root size;	chr7:66169164	chr7:65647864~65715661:+
THCA	cis	rs875971	0.965	rs7794930	ENSG00000272831.1	RP11-792A8.4	-3.77	0.000187	0.0134	-0.11	-0.17	Aortic root size;	chr7:66313559	chr7:66739829~66740385:-
THCA	cis	rs412658	0.504	rs10404322	ENSG00000269845.1	RP11-420K14.6	-3.77	0.000187	0.0134	-0.2	-0.17	Telomere length;	chr19:21927867	chr19:21750747~21753438:+
THCA	cis	rs858239	1	rs199347	ENSG00000226816.2	AC005082.12	3.77	0.000187	0.0134	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23206013~23208045:+
THCA	cis	rs728616	0.558	rs34268041	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000187	0.0134	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80388883	chr10:79663088~79826594:-
THCA	cis	rs10844706	0.699	rs10772079	ENSG00000214776.8	RP11-726G1.1	3.77	0.000187	0.0134	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721798	chr12:9467552~9576275:+
THCA	cis	rs7737355	0.898	rs4706025	ENSG00000237714.1	P4HA2-AS1	3.77	0.000187	0.0134	0.24	0.17	Life satisfaction;	chr5:131578095	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.812	rs250888	ENSG00000237714.1	P4HA2-AS1	-3.77	0.000187	0.0134	-0.24	-0.17	Life satisfaction;	chr5:131679653	chr5:132184876~132192808:+
THCA	cis	rs12195230	0.592	rs1933459	ENSG00000233797.1	UFL1-AS1	-3.77	0.000187	0.0134	-0.26	-0.17	Blood pressure;	chr6:96990413	chr6:96358374~96521669:-
THCA	cis	rs10995505	0.589	rs10822140	ENSG00000272767.1	JMJD1C-AS1	-3.77	0.000187	0.0134	-0.2	-0.17	Intelligence (multi-trait analysis);	chr10:63123267	chr10:63465229~63466563:+
THCA	cis	rs10995505	0.589	rs2896496	ENSG00000272767.1	JMJD1C-AS1	-3.77	0.000187	0.0134	-0.2	-0.17	Intelligence (multi-trait analysis);	chr10:63123622	chr10:63465229~63466563:+
THCA	cis	rs4925386	0.84	rs6143036	ENSG00000275437.1	RP5-908M14.10	3.77	0.000187	0.0134	0.17	0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62402236~62405935:-
THCA	cis	rs853679	0.527	rs853683	ENSG00000220721.1	OR1F12	3.77	0.000187	0.0134	0.19	0.17	Depression;	chr6:28327262	chr6:28073316~28074233:+
THCA	cis	rs9905704	0.813	rs304269	ENSG00000224738.1	AC099850.1	-3.77	0.000187	0.0134	-0.22	-0.17	Testicular germ cell tumor;	chr17:58724698	chr17:59106598~59118267:+
THCA	cis	rs2799081	1	rs2799081	ENSG00000220721.1	OR1F12	3.77	0.000187	0.0134	0.2	0.17	Myopia;	chr6:28302807	chr6:28073316~28074233:+
THCA	cis	rs6871536	1	rs12187537	ENSG00000233006.5	AC034220.3	-3.77	0.000187	0.0134	-0.16	-0.17	Asthma (childhood onset);	chr5:132604212	chr5:132311285~132369916:-
THCA	cis	rs12216545	0.765	rs4725916	ENSG00000241134.3	BET1P1	-3.77	0.000187	0.0134	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150554772	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs2373813	ENSG00000241134.3	BET1P1	-3.77	0.000187	0.0134	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150554849	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs2888666	ENSG00000241134.3	BET1P1	-3.77	0.000187	0.0134	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150555262	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs4725347	ENSG00000241134.3	BET1P1	-3.77	0.000187	0.0134	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150555485	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.711	rs1403221	ENSG00000241134.3	BET1P1	-3.77	0.000187	0.0134	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150556548	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.765	rs1403222	ENSG00000241134.3	BET1P1	3.77	0.000187	0.0134	0.2	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150556825	chr7:150749736~150750094:+
THCA	cis	rs4906332	1	rs17617307	ENSG00000259775.1	RP11-45P15.4	-3.77	0.000188	0.0134	-0.15	-0.17	Coronary artery disease;	chr14:103438628	chr14:103331674~103332367:-
THCA	cis	rs4746818	1	rs10762263	ENSG00000229001.1	ACTBP14	-3.77	0.000188	0.0134	-0.28	-0.17	Left atrial antero-posterior diameter;	chr10:69210422	chr10:69022778~69023866:+
THCA	cis	rs7264396	0.887	rs224419	ENSG00000088340.14	FER1L4	3.77	0.000188	0.0134	0.16	0.17	Total cholesterol levels;	chr20:35555321	chr20:35558737~35607562:-
THCA	cis	rs875971	0.571	rs78668714	ENSG00000232559.3	GS1-124K5.12	3.77	0.000188	0.0134	0.19	0.17	Aortic root size;	chr7:66474464	chr7:66554588~66576923:-
THCA	cis	rs17772222	0.727	rs3179969	ENSG00000222990.1	RNU4-22P	3.77	0.000188	0.0134	0.21	0.17	Coronary artery calcification;	chr14:88396185	chr14:88513498~88513663:+
THCA	cis	rs10090774	0.965	rs4961288	ENSG00000280303.2	ERICD	3.77	0.000188	0.0134	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140731369	chr8:140636281~140638283:+
THCA	cis	rs172166	0.516	rs1225618	ENSG00000261839.1	RP1-265C24.8	3.77	0.000188	0.0134	0.16	0.17	Cardiac Troponin-T levels;	chr6:28161935	chr6:28136849~28139678:+
THCA	cis	rs875971	0.502	rs6460311	ENSG00000230295.1	RP11-458F8.2	-3.77	0.000188	0.0134	-0.15	-0.17	Aortic root size;	chr7:66646886	chr7:66880708~66882981:+
THCA	cis	rs7074356	0.915	rs17680103	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000188	0.0134	-0.31	-0.17	Borderline personality disorder;	chr10:80447862	chr10:79663088~79826594:-
THCA	cis	rs5751901	0.929	rs2330805	ENSG00000225098.1	BCRP1	3.77	0.000188	0.0134	0.21	0.17	Protein quantitative trait loci;	chr22:24602652	chr22:24259929~24263764:-
THCA	cis	rs13113518	0.783	rs6843722	ENSG00000272969.1	RP11-528I4.2	3.76	0.000188	0.0134	0.2	0.17	Height;	chr4:55465165	chr4:55547112~55547889:+
THCA	cis	rs7665090	1	rs2866409	ENSG00000248971.2	KRT8P46	-3.76	0.000188	0.0134	-0.2	-0.17	Primary biliary cholangitis;	chr4:102633104	chr4:102728746~102730171:-
THCA	cis	rs2562456	0.834	rs13346641	ENSG00000268521.1	VN1R83P	3.76	0.000188	0.0134	0.17	0.17	Pain;	chr19:21409481	chr19:21289554~21289998:-
THCA	cis	rs6756513	0.5	rs72839877	ENSG00000231024.1	AC092431.3	-3.76	0.000188	0.0134	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69832475	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs72839879	ENSG00000231024.1	AC092431.3	-3.76	0.000188	0.0134	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69835144	chr2:69700192~69713847:-
THCA	cis	rs721917	0.506	rs7073842	ENSG00000244733.5	RP11-506M13.3	-3.76	0.000188	0.0134	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79660891~79677996:+
THCA	cis	rs2235642	0.601	rs2235647	ENSG00000260989.1	LA16c-395F10.2	-3.76	0.000188	0.0134	-0.19	-0.17	Coronary artery disease;	chr16:1551330	chr16:1580527~1610328:+
THCA	cis	rs6416877	0.679	rs11651209	ENSG00000277491.1	RP11-676J12.9	3.76	0.000188	0.0134	0.18	0.17	Myeloid white cell count;	chr17:1461602	chr17:795306~795794:+
THCA	cis	rs2562784	0.638	rs2730098	ENSG00000225151.9	GOLGA2P7	-3.76	0.000188	0.0134	-0.31	-0.17	Height;	chr15:83613166	chr15:84199311~84230136:-
THCA	cis	rs2408955	0.501	rs8716	ENSG00000257735.1	RP11-370I10.6	3.76	0.000188	0.0134	0.2	0.17	Glycated hemoglobin levels;	chr12:48145699	chr12:48350945~48442411:+
THCA	cis	rs7259376	0.84	rs3862494	ENSG00000269345.1	VN1R85P	3.76	0.000188	0.0134	0.19	0.17	Menopause (age at onset);	chr19:22336720	chr19:22174766~22175191:-
THCA	cis	rs61160187	0.582	rs12655209	ENSG00000272308.1	RP11-231G3.1	3.76	0.000188	0.0134	0.16	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60866457~60866935:-
THCA	cis	rs1029738	0.535	rs10262258	ENSG00000228649.7	AC005682.5	3.76	0.000188	0.0134	0.19	0.17	Fibrinogen levels;	chr7:22802700	chr7:22854178~22861579:+
THCA	cis	rs10484434	0.71	rs34956419	ENSG00000272462.2	U91328.19	3.76	0.000188	0.0134	0.18	0.17	HIV-1 viral setpoint;	chr6:26077646	chr6:25992662~26001775:+
THCA	cis	rs2191566	0.691	rs4803673	ENSG00000266921.1	RP11-15A1.7	-3.76	0.000188	0.0134	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:44080403	chr19:43996896~44002836:-
THCA	cis	rs7713065	0.802	rs10036896	ENSG00000263597.1	MIR3936	-3.76	0.000188	0.0134	-0.22	-0.17	Lung function (FEV1/FVC);	chr5:132449486	chr5:132365490~132365599:-
THCA	cis	rs7178909	0.831	rs1910587	ENSG00000259677.1	RP11-493E3.1	3.76	0.000188	0.0134	0.21	0.17	Common traits (Other);	chr15:89897255	chr15:89876540~89877285:+
THCA	cis	rs7178909	0.797	rs1910586	ENSG00000259677.1	RP11-493E3.1	3.76	0.000188	0.0134	0.21	0.17	Common traits (Other);	chr15:89897257	chr15:89876540~89877285:+
THCA	cis	rs3748656	0.831	rs11102509	ENSG00000273483.1	RP4-671G15.2	3.76	0.000188	0.0134	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112598596	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.887	rs12728311	ENSG00000273483.1	RP4-671G15.2	3.76	0.000188	0.0134	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112601817	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.945	rs9308256	ENSG00000273483.1	RP4-671G15.2	3.76	0.000188	0.0134	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112611742	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.945	rs12122980	ENSG00000273483.1	RP4-671G15.2	3.76	0.000188	0.0134	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112614559	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.895	rs11102513	ENSG00000273483.1	RP4-671G15.2	3.76	0.000188	0.0134	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112617548	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.945	rs11102514	ENSG00000273483.1	RP4-671G15.2	3.76	0.000188	0.0134	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112617797	chr1:112517799~112518441:-
THCA	cis	rs72996113	0.702	rs75986749	ENSG00000248027.1	CTD-2383M3.1	-3.76	0.000188	0.0134	-0.3	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100642702	chr11:100684162~100687955:-
THCA	cis	rs1876905	0.68	rs783085	ENSG00000271789.1	RP5-1112D6.7	-3.76	0.000188	0.0134	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111155482	chr6:111297126~111298510:+
THCA	cis	rs4906332	1	rs28711288	ENSG00000259775.1	RP11-45P15.4	-3.76	0.000188	0.0134	-0.15	-0.17	Coronary artery disease;	chr14:103439789	chr14:103331674~103332367:-
THCA	cis	rs10090774	0.901	rs11997937	ENSG00000280303.2	ERICD	-3.76	0.000188	0.0134	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140957252	chr8:140636281~140638283:+
THCA	cis	rs758324	0.891	rs635164	ENSG00000237714.1	P4HA2-AS1	-3.76	0.000188	0.0134	-0.24	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131977181	chr5:132184876~132192808:+
THCA	cis	rs478304	0.651	rs11600918	ENSG00000255320.1	RP11-755F10.1	3.76	0.000188	0.0134	0.22	0.17	Acne (severe);	chr11:65744494	chr11:66244840~66246239:-
THCA	cis	rs721917	0.506	rs2819102	ENSG00000244733.5	RP11-506M13.3	-3.76	0.000188	0.0134	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79660891~79677996:+
THCA	cis	rs9843304	0.9	rs6774253	ENSG00000240541.2	TM4SF1-AS1	-3.76	0.000188	0.0134	-0.16	-0.17	Gallstone disease;	chr3:149494110	chr3:149377778~149386583:+
THCA	cis	rs3026445	0.519	rs11065209	ENSG00000278993.1	RP3-424M6.4	3.76	0.000188	0.0134	0.26	0.17	QT interval;	chr12:110156465	chr12:110501614~110503441:+
THCA	cis	rs7560272	0.723	rs62153184	ENSG00000273245.1	RP11-434P11.2	3.76	0.000188	0.0134	0.21	0.17	Schizophrenia;	chr2:73546742	chr2:73750256~73750786:-
THCA	cis	rs9911578	0.967	rs4932693	ENSG00000224738.1	AC099850.1	-3.76	0.000188	0.0134	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:59032966	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.934	rs58092632	ENSG00000224738.1	AC099850.1	-3.76	0.000188	0.0134	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:59033740	chr17:59106598~59118267:+
THCA	cis	rs1799922	0.684	rs339095	ENSG00000273270.1	RP11-212P7.2	-3.76	0.000188	0.0134	-0.18	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128765993	chr7:128524016~128531069:-
THCA	cis	rs748404	0.56	rs570933	ENSG00000275601.1	AC011330.13	-3.76	0.000188	0.0134	-0.2	-0.17	Lung cancer;	chr15:43531832	chr15:43642389~43643023:-
THCA	cis	rs12544026	0.548	rs561603	ENSG00000253669.3	KB-1732A1.1	-3.76	0.000188	0.0134	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101902513	chr8:102805517~102809971:+
THCA	cis	rs6995541	0.557	rs7841093	ENSG00000248896.2	CTD-2135J3.3	-3.76	0.000188	0.0134	-0.22	-0.17	Triglyceride levels;	chr8:10825823	chr8:10729314~10771392:+
THCA	cis	rs6442522	0.644	rs6783160	ENSG00000249786.6	EAF1-AS1	3.76	0.000188	0.0134	0.18	0.17	Uric acid levels;	chr3:15467511	chr3:15436171~15455940:-
THCA	cis	rs1501911	0.53	rs326468	ENSG00000246763.5	RGMB-AS1	3.76	0.000188	0.0134	0.18	0.17	Lung function (FEV1/FVC);	chr5:98897105	chr5:98769618~98773469:-
THCA	cis	rs1383484	0.506	rs4414460	ENSG00000259728.4	LINC00933	-3.76	0.000188	0.0134	-0.21	-0.17	Height;	chr15:83893988	chr15:84570649~84580175:+
THCA	cis	rs2904297	0.837	rs4373155	ENSG00000261490.1	RP11-448G15.3	3.76	0.000188	0.0134	0.12	0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11021175	chr4:10068089~10073019:-
THCA	cis	rs10438797	0.838	rs6505112	ENSG00000276995.1	RP11-321A17.6	-3.76	0.000188	0.0134	-0.16	-0.17	Night sleep phenotypes;	chr17:29165615	chr17:29071124~29071594:-
THCA	cis	rs57709857	0.957	rs12056642	ENSG00000272092.1	RP11-350N15.5	-3.76	0.000188	0.0134	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38307554	chr8:38382364~38383461:+
THCA	cis	rs4245128	0.689	rs10891474	ENSG00000227487.3	NCAM1-AS1	3.76	0.000188	0.0134	0.17	0.17	Life satisfaction;	chr11:112930167	chr11:113269532~113273901:-
THCA	cis	rs11708578	0.53	rs35806602	ENSG00000237990.3	CNTN4-AS1	3.76	0.000188	0.0134	0.21	0.17	Schizophrenia;	chr3:2388671	chr3:3039033~3069242:-
THCA	cis	rs11708578	0.554	rs35675781	ENSG00000237990.3	CNTN4-AS1	3.76	0.000188	0.0134	0.21	0.17	Schizophrenia;	chr3:2388682	chr3:3039033~3069242:-
THCA	cis	rs10083777	0.551	rs79623059	ENSG00000261838.4	RP11-303E16.6	3.76	0.000188	0.0134	0.39	0.17	Metabolite levels (small molecules and protein measures);	chr16:80973348	chr16:81069854~81076598:+
THCA	cis	rs7583236	0.929	rs3821276	ENSG00000179818.12	PCBP1-AS1	3.76	0.000188	0.0135	0.17	0.17	Obesity-related traits;	chr2:69960041	chr2:69962263~70103220:-
THCA	cis	rs911555	0.723	rs11160751	ENSG00000269940.1	RP11-73M18.7	3.76	0.000188	0.0135	0.17	0.17	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103694560~103695170:+
THCA	cis	rs2839186	0.771	rs13046451	ENSG00000228137.1	AP001469.7	-3.76	0.000188	0.0135	-0.17	-0.17	Testicular germ cell tumor;	chr21:46221459	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.77	rs2280956	ENSG00000228137.1	AP001469.7	-3.76	0.000188	0.0135	-0.17	-0.17	Testicular germ cell tumor;	chr21:46222409	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.771	rs2839155	ENSG00000228137.1	AP001469.7	3.76	0.000188	0.0135	0.17	0.17	Testicular germ cell tumor;	chr21:46220078	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.771	rs2280959	ENSG00000228137.1	AP001469.7	3.76	0.000188	0.0135	0.17	0.17	Testicular germ cell tumor;	chr21:46222082	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.739	rs2280958	ENSG00000228137.1	AP001469.7	3.76	0.000188	0.0135	0.17	0.17	Testicular germ cell tumor;	chr21:46222102	chr21:46246890~46247682:+
THCA	cis	rs6969780	0.673	rs2301721	ENSG00000233429.8	HOTAIRM1	-3.76	0.000188	0.0135	-0.21	-0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156494	chr7:27095647~27100265:+
THCA	cis	rs7560272	0.501	rs2421674	ENSG00000163016.8	ALMS1P	-3.76	0.000188	0.0135	-0.21	-0.17	Schizophrenia;	chr2:73728305	chr2:73644919~73685576:+
THCA	cis	rs78487399	0.808	rs7601039	ENSG00000234936.1	AC010883.5	3.76	0.000188	0.0135	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43601498	chr2:43229573~43233394:+
THCA	cis	rs7829975	0.511	rs2980423	ENSG00000233609.3	RP11-62H7.2	3.76	0.000188	0.0135	0.17	0.17	Mood instability;	chr8:8285053	chr8:8961200~8979025:+
THCA	cis	rs4764124	0.646	rs2075268	ENSG00000261324.2	RP11-174G6.5	-3.76	0.000188	0.0135	-0.13	-0.17	Pubertal anthropometrics;	chr12:14803542	chr12:14762504~14767931:-
THCA	cis	rs2163813	1	rs247772	ENSG00000271283.1	CTC-412M14.6	-3.76	0.000188	0.0135	-0.23	-0.17	Toenail selenium levels;	chr19:19735649	chr19:19699203~19699409:-
THCA	cis	rs12428035	0.764	rs565898	ENSG00000247400.3	DNAJC3-AS1	3.76	0.000188	0.0135	0.16	0.17	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96019324	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs565297	ENSG00000247400.3	DNAJC3-AS1	3.76	0.000188	0.0135	0.16	0.17	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96027176	chr13:95648733~95676925:-
THCA	cis	rs321358	0.945	rs17458235	ENSG00000271390.1	RP11-89C3.3	-3.76	0.000188	0.0135	-0.29	-0.17	Body mass index;	chr11:111106114	chr11:111089870~111090368:-
THCA	cis	rs4489787	0.568	rs2731065	ENSG00000273765.1	RP11-370I10.11	3.76	0.000188	0.0135	0.19	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48499140	chr12:48360920~48361377:+
THCA	cis	rs17801127	0.818	rs16827307	ENSG00000231969.1	AC144449.1	-3.76	0.000188	0.0135	-0.3	-0.17	Liver enzyme levels (alanine transaminase);	chr2:149663444	chr2:149587196~149848233:+
THCA	cis	rs10897473	0.554	rs7115071	ENSG00000236935.1	AP003774.1	-3.76	0.000188	0.0135	-0.18	-0.17	Immature fraction of reticulocytes;	chr11:64084161	chr11:64325050~64329504:-
THCA	cis	rs7188697	0.922	rs173475	ENSG00000276259.1	RP11-481J2.4	-3.76	0.000188	0.0135	-0.12	-0.17	QT interval;	chr16:58546626	chr16:58522970~58523842:+
THCA	cis	rs758324	0.947	rs173812	ENSG00000237714.1	P4HA2-AS1	-3.76	0.000188	0.0135	-0.24	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131983767	chr5:132184876~132192808:+
THCA	cis	rs763121	0.925	rs5750654	ENSG00000225450.1	RP3-508I15.14	-3.76	0.000188	0.0135	-0.13	-0.17	Menopause (age at onset);	chr22:38655423	chr22:38739003~38749041:+
THCA	cis	rs150992	0.673	rs330419	ENSG00000241597.2	CTD-2007H13.1	3.76	0.000188	0.0135	0.22	0.17	Body mass index;	chr5:98857460	chr5:98954394~98954972:+
THCA	cis	rs656319	0.58	rs17690549	ENSG00000261451.1	RP11-981G7.1	-3.76	0.000188	0.0135	-0.22	-0.17	Myopia (pathological);	chr8:10141028	chr8:10433672~10438312:+
THCA	cis	rs28643277	0.671	rs10906910	ENSG00000237470.3	DCLRE1CP1	3.76	0.000188	0.0135	0.22	0.17	Periodontitis (CDC/AAP);	chr10:15500586	chr10:15015370~15021863:-
THCA	cis	rs7246657	0.943	rs2081096	ENSG00000268499.1	CTB-102L5.8	3.76	0.000189	0.0135	0.22	0.17	Coronary artery calcification;	chr19:37473798	chr19:38199836~38200934:+
THCA	cis	rs2836974	0.8	rs12482857	ENSG00000255568.3	BRWD1-AS2	3.76	0.000189	0.0135	0.15	0.17	Cognitive function;	chr21:39142935	chr21:39313935~39314962:+
THCA	cis	rs2235649	0.704	rs1742425	ENSG00000260541.1	LA16c-429E7.1	3.76	0.000189	0.0135	0.23	0.17	Blood metabolite levels;	chr16:1854523	chr16:1841020~1843547:-
THCA	cis	rs972578	0.837	rs3788600	ENSG00000274717.1	RP1-47A17.1	-3.76	0.000189	0.0135	-0.18	-0.17	Mean platelet volume;	chr22:42931310	chr22:42791814~42794313:-
THCA	cis	rs7267979	0.604	rs242130	ENSG00000274973.1	RP13-401N8.7	3.76	0.000189	0.0135	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:25845497~25845862:+
THCA	cis	rs959260	1	rs2385264	ENSG00000263843.1	RP11-649A18.12	3.76	0.000189	0.0135	0.18	0.17	Systemic lupus erythematosus;	chr17:75368911	chr17:75271369~75273895:+
THCA	cis	rs9329221	0.537	rs12678797	ENSG00000261451.1	RP11-981G7.1	-3.76	0.000189	0.0135	-0.2	-0.17	Neuroticism;	chr8:10121409	chr8:10433672~10438312:+
THCA	cis	rs10435719	0.809	rs77601743	ENSG00000255495.1	AC145124.2	3.76	0.000189	0.0135	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933060	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.678	rs74724594	ENSG00000255495.1	AC145124.2	3.76	0.000189	0.0135	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933067	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.702	rs77055881	ENSG00000255495.1	AC145124.2	3.76	0.000189	0.0135	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933072	chr8:12194467~12196280:+
THCA	cis	rs10043228	1	rs17139265	ENSG00000248445.4	SEMA6A-AS1	-3.76	0.000189	0.0135	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116243113	chr5:116447547~116508276:+
THCA	cis	rs10888838	0.567	rs3766453	ENSG00000198711.5	SSBP3-AS1	3.76	0.000189	0.0135	0.18	0.17	Mitochondrial DNA levels;	chr1:54237196	chr1:54236440~54239063:+
THCA	cis	rs12472274	0.941	rs6748440	ENSG00000186235.9	AC016757.3	3.76	0.000189	0.0135	0.24	0.17	Phospholipid levels (plasma);	chr2:238191734	chr2:238224552~238231677:-
THCA	cis	rs7394190	1	rs10824026	ENSG00000272140.2	RP11-574K11.29	-3.76	0.000189	0.0135	-0.16	-0.17	Incident atrial fibrillation;	chr10:73661450	chr10:73703735~73713581:-
THCA	cis	rs227932	1	rs227932	ENSG00000234286.1	AC006026.13	-3.76	0.000189	0.0135	-0.34	-0.17	Schizophrenia;	chr7:23584856	chr7:23680195~23680786:-
THCA	cis	rs9987353	0.62	rs34455383	ENSG00000254340.1	RP11-10A14.3	-3.76	0.000189	0.0135	-0.21	-0.17	Recombination measurement;	chr8:9208948	chr8:9141424~9145435:+
THCA	cis	rs7551222	0.752	rs12130686	ENSG00000240219.1	RP11-430C7.5	3.76	0.000189	0.0135	0.16	0.17	Schizophrenia;	chr1:204584929	chr1:204626775~204629712:+
THCA	cis	rs7737355	0.947	rs3776027	ENSG00000237714.1	P4HA2-AS1	-3.76	0.000189	0.0135	-0.24	-0.17	Life satisfaction;	chr5:131467277	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs31254	ENSG00000237714.1	P4HA2-AS1	3.76	0.000189	0.0135	0.24	0.17	Life satisfaction;	chr5:131493711	chr5:132184876~132192808:+
THCA	cis	rs7542375	0.655	rs4846670	ENSG00000238078.1	LINC01352	-3.76	0.000189	0.0135	-0.24	-0.17	Obesity-related traits;	chr1:220895675	chr1:220829255~220832429:+
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000261839.1	RP1-265C24.8	3.76	0.000189	0.0135	0.16	0.17	Pubertal anthropometrics;	chr6:28175232	chr6:28136849~28139678:+
THCA	cis	rs412658	0.704	rs8105767	ENSG00000269345.1	VN1R85P	3.76	0.000189	0.0135	0.19	0.17	Telomere length;	chr19:22032639	chr19:22174766~22175191:-
THCA	cis	rs1383484	0.761	rs28401196	ENSG00000259728.4	LINC00933	-3.76	0.000189	0.0135	-0.22	-0.17	Height;	chr15:83878609	chr15:84570649~84580175:+
THCA	cis	rs7259376	0.645	rs7245650	ENSG00000269345.1	VN1R85P	3.76	0.000189	0.0135	0.19	0.17	Menopause (age at onset);	chr19:22300893	chr19:22174766~22175191:-
THCA	cis	rs7980687	0.506	rs1611973	ENSG00000256092.2	RP13-942N8.1	3.76	0.000189	0.0135	0.12	0.17	Head circumference (infant);Educational attainment;Height;	chr12:123138184	chr12:123363868~123366113:+
THCA	cis	rs12549025	0.505	rs11984487	ENSG00000253390.1	CTC-756D1.2	-3.76	0.000189	0.0135	-0.26	-0.17	Reticulocyte fraction of red cells;	chr8:23543772	chr8:23458601~23484971:+
THCA	cis	rs745109	0.504	rs75610186	ENSG00000273080.1	RP11-301O19.1	3.76	0.000189	0.0135	0.31	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86372933	chr2:86195590~86196049:+
THCA	cis	rs7112925	0.932	rs12287978	ENSG00000255517.5	CTD-3074O7.5	3.76	0.000189	0.0135	0.13	0.17	Height;	chr11:67065856	chr11:66473490~66480233:-
THCA	cis	rs6121246	0.909	rs6060633	ENSG00000224628.2	RP5-854E16.2	-3.76	0.000189	0.0135	-0.23	-0.17	Mean corpuscular hemoglobin;	chr20:31675514	chr20:31285317~31286835:-
THCA	cis	rs4713118	0.506	rs9366697	ENSG00000261839.1	RP1-265C24.8	3.76	0.000189	0.0135	0.17	0.17	Parkinson's disease;	chr6:27665239	chr6:28136849~28139678:+
THCA	cis	rs13113518	0.812	rs11932712	ENSG00000223305.1	RN7SKP30	3.76	0.000189	0.0135	0.22	0.17	Height;	chr4:55436423	chr4:55540502~55540835:-
THCA	cis	rs13113518	0.812	rs12501746	ENSG00000223305.1	RN7SKP30	3.76	0.000189	0.0135	0.22	0.17	Height;	chr4:55437438	chr4:55540502~55540835:-
THCA	cis	rs2067615	0.826	rs2731359	ENSG00000260329.1	RP11-412D9.4	-3.76	0.000189	0.0135	-0.15	-0.17	Heart rate;	chr12:106861769	chr12:106954029~106955497:-
THCA	cis	rs3806843	0.576	rs251370	ENSG00000278901.1	AC005609.17	-3.76	0.000189	0.0135	-0.19	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140866702	chr5:140878073~140882642:-
THCA	cis	rs7737355	0.898	rs3775998	ENSG00000237714.1	P4HA2-AS1	3.76	0.000189	0.0135	0.25	0.17	Life satisfaction;	chr5:131643639	chr5:132184876~132192808:+
THCA	cis	rs16975963	0.644	rs73031322	ENSG00000276846.1	CTD-3220F14.3	-3.76	0.000189	0.0135	-0.16	-0.17	Longevity;	chr19:37549977	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.644	rs73031326	ENSG00000276846.1	CTD-3220F14.3	-3.76	0.000189	0.0135	-0.16	-0.17	Longevity;	chr19:37552120	chr19:37314868~37315620:-
THCA	cis	rs846111	1	rs846111	ENSG00000226944.1	RP1-120G22.11	3.76	0.000189	0.0135	0.21	0.17	QT interval;	chr1:6219310	chr1:6204840~6205780:-
THCA	cis	rs4561483	0.549	rs33659	ENSG00000263307.1	RP11-166B2.8	3.76	0.000189	0.0135	0.17	0.17	Testicular germ cell tumor;	chr16:11869504	chr16:11851649~11895611:+
THCA	cis	rs2832191	0.935	rs11910316	ENSG00000232855.5	AF131217.1	3.76	0.000189	0.0135	0.18	0.17	Dental caries;	chr21:29147408	chr21:28439346~28674848:-
THCA	cis	rs12549025	0.796	rs7015818	ENSG00000253390.1	CTC-756D1.2	3.76	0.000189	0.0135	0.27	0.17	Reticulocyte fraction of red cells;	chr8:23544557	chr8:23458601~23484971:+
THCA	cis	rs1913185	0.891	rs67325724	ENSG00000261051.1	RP11-274H2.5	-3.76	0.000189	0.0135	-0.25	-0.17	Obesity-related traits;	chr3:146156940	chr3:146059585~146061679:-
THCA	cis	rs62045849	0.557	rs6500533	ENSG00000259877.2	RP11-46C24.7	3.76	0.000189	0.0135	0.19	0.17	Red blood cell count;	chr16:89123657	chr16:89215211~89217653:-
THCA	cis	rs1560104	0.709	rs8063664	ENSG00000259876.1	CTD-3037G24.4	3.76	0.000189	0.0135	0.2	0.17	Obesity-related traits;	chr16:12603354	chr16:12556353~12557694:-
THCA	cis	rs1417770	0.931	rs778409	ENSG00000260971.3	RP11-504A18.1	3.76	0.000189	0.0135	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr1:56239197	chr1:56248294~56258571:-
THCA	cis	rs708224	0.587	rs184469	ENSG00000277342.1	RP11-843B15.4	3.76	0.000189	0.0135	0.22	0.17	Pancreatic cancer;	chr12:32247364	chr12:32109076~32109602:+
THCA	cis	rs7824557	0.564	rs2572386	ENSG00000227888.4	FAM66A	-3.76	0.000189	0.0135	-0.22	-0.17	Retinal vascular caliber;	chr8:11379466	chr8:12362019~12388296:+
THCA	cis	rs285757	1	rs285758	ENSG00000259064.2	RP11-386M24.5	-3.76	0.000189	0.0135	-0.26	-0.17	HIV-1 susceptibility;	chr15:92636354	chr15:92627073~92627414:+
THCA	cis	rs6901152	1	rs1863137	ENSG00000217648.1	RP1-95L4.4	-3.76	0.000189	0.0135	-0.18	-0.17	Acute lymphoblastic leukemia (childhood);	chr6:143332585	chr6:143342246~143343383:+
THCA	cis	rs911555	0.755	rs11620897	ENSG00000269958.1	RP11-73M18.8	3.76	0.000189	0.0135	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103696353~103697163:+
THCA	cis	rs2522056	0.808	rs7704457	ENSG00000263597.1	MIR3936	3.76	0.000189	0.0135	0.18	0.17	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132365490~132365599:-
THCA	cis	rs453301	0.686	rs28665409	ENSG00000254340.1	RP11-10A14.3	-3.76	0.000189	0.0135	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9011767	chr8:9141424~9145435:+
THCA	cis	rs57709857	1	rs2411256	ENSG00000272092.1	RP11-350N15.5	-3.76	0.000189	0.0135	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38435945	chr8:38382364~38383461:+
THCA	cis	rs11212260	0.85	rs1728908	ENSG00000261098.1	RP11-819C21.1	-3.76	0.000189	0.0135	-0.33	-0.17	IgG glycosylation;	chr11:107501748	chr11:107312132~107316271:-
THCA	cis	rs13063635	0.915	rs17764980	ENSG00000226074.4	PRSS44	-3.76	0.000189	0.0135	-0.33	-0.17	Eosinophil percentage of granulocytes;	chr3:45897524	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs17714101	ENSG00000226074.4	PRSS44	-3.76	0.000189	0.0135	-0.33	-0.17	Eosinophil percentage of granulocytes;	chr3:45898310	chr3:46809359~46812558:-
THCA	cis	rs2640806	0.505	rs7837495	ENSG00000253105.4	KB-1448A5.1	3.76	0.000189	0.0135	0.2	0.17	Obesity-related traits;	chr8:96347280	chr8:96371865~96387438:-
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000254414.1	RP11-182J1.1	-3.76	0.000189	0.0135	-0.21	-0.17	P wave terminal force;	chr15:84635039	chr15:84631898~84633987:-
THCA	cis	rs2179367	0.632	rs55836833	ENSG00000216906.2	RP11-350J20.9	3.76	0.000189	0.0135	0.22	0.17	Dupuytren's disease;	chr6:149403736	chr6:149904243~149906418:+
THCA	cis	rs1023500	0.573	rs133381	ENSG00000270083.1	RP1-257I20.14	3.76	0.000189	0.0135	0.2	0.17	Schizophrenia;	chr22:42074604	chr22:42089630~42090028:-
THCA	cis	rs8070128	0.568	rs3935506	ENSG00000281749.1	Y_RNA	3.76	0.000189	0.0135	0.22	0.17	Total body bone mineral density;	chr17:17978745	chr17:18001101~18001195:-
THCA	cis	rs714027	0.585	rs5763670	ENSG00000279699.1	RP1-102K2.9	3.76	0.000189	0.0135	0.17	0.17	Lymphocyte counts;	chr22:29987769	chr22:30275215~30276951:-
THCA	cis	rs714027	0.565	rs2285667	ENSG00000279699.1	RP1-102K2.9	3.76	0.000189	0.0135	0.17	0.17	Lymphocyte counts;	chr22:29988115	chr22:30275215~30276951:-
THCA	cis	rs714027	0.585	rs2007446	ENSG00000279699.1	RP1-102K2.9	3.76	0.000189	0.0135	0.17	0.17	Lymphocyte counts;	chr22:29992612	chr22:30275215~30276951:-
THCA	cis	rs875971	0.528	rs801213	ENSG00000232559.3	GS1-124K5.12	-3.76	0.000189	0.0135	-0.19	-0.17	Aortic root size;	chr7:66549931	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs801212	ENSG00000232559.3	GS1-124K5.12	-3.76	0.000189	0.0135	-0.19	-0.17	Aortic root size;	chr7:66550643	chr7:66554588~66576923:-
THCA	cis	rs7246760	1	rs17849496	ENSG00000267106.4	ZNF561-AS1	3.76	0.000189	0.0135	0.32	0.17	Pursuit maintenance gain;	chr19:9811547	chr19:9621291~9645896:+
THCA	cis	rs6568686	0.786	rs6910340	ENSG00000255389.1	C6orf3	-3.76	0.000189	0.0135	-0.24	-0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111541861	chr6:111599875~111602295:+
THCA	cis	rs12681366	0.564	rs2165405	ENSG00000253175.1	RP11-267M23.6	3.76	0.000189	0.0135	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94442079	chr8:94565036~94565715:+
THCA	cis	rs4950322	0.512	rs4625342	ENSG00000180867.10	PDIA3P1	-3.76	0.000189	0.0135	-0.15	-0.17	Protein quantitative trait loci;	chr1:147369887	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.518	rs61838938	ENSG00000180867.10	PDIA3P1	3.76	0.000189	0.0135	0.17	0.17	Protein quantitative trait loci;	chr1:147105943	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.529	rs11809327	ENSG00000180867.10	PDIA3P1	3.76	0.000189	0.0135	0.17	0.17	Protein quantitative trait loci;	chr1:147106679	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.563	rs11809328	ENSG00000180867.10	PDIA3P1	3.76	0.000189	0.0135	0.17	0.17	Protein quantitative trait loci;	chr1:147106681	chr1:147178113~147179622:+
THCA	cis	rs17604090	0.816	rs10248839	ENSG00000227855.3	DPY19L2P3	3.76	0.000189	0.0135	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29657637	chr7:29650227~29742594:+
THCA	cis	rs7166081	1	rs4776905	ENSG00000270964.1	RP11-502I4.3	-3.76	0.000189	0.0135	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67207992	chr15:67541072~67542604:-
THCA	cis	rs295490	0.748	rs2291555	ENSG00000272656.1	RP11-219D15.3	3.76	0.000189	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139355352	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs17335312	ENSG00000272656.1	RP11-219D15.3	3.76	0.000189	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356544	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs58060926	ENSG00000272656.1	RP11-219D15.3	3.76	0.000189	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356577	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs78116750	ENSG00000272656.1	RP11-219D15.3	3.76	0.000189	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356886	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs74365525	ENSG00000272656.1	RP11-219D15.3	3.76	0.000189	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357107	chr3:139349024~139349371:-
THCA	cis	rs295490	0.667	rs80049554	ENSG00000272656.1	RP11-219D15.3	3.76	0.000189	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357161	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs2307031	ENSG00000272656.1	RP11-219D15.3	3.76	0.000189	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357978	chr3:139349024~139349371:-
THCA	cis	rs295490	0.915	rs79695313	ENSG00000272656.1	RP11-219D15.3	3.76	0.000189	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139358335	chr3:139349024~139349371:-
THCA	cis	rs1501911	0.53	rs161941	ENSG00000246763.5	RGMB-AS1	-3.76	0.00019	0.0135	-0.18	-0.17	Lung function (FEV1/FVC);	chr5:98863500	chr5:98769618~98773469:-
THCA	cis	rs6921919	0.848	rs6903652	ENSG00000219392.1	RP1-265C24.5	-3.76	0.00019	0.0135	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28115628~28116551:+
THCA	cis	rs9911578	0.9	rs717828	ENSG00000224738.1	AC099850.1	3.76	0.00019	0.0135	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58458571	chr17:59106598~59118267:+
THCA	cis	rs17092148	0.697	rs13037664	ENSG00000269202.1	RP4-614O4.12	3.76	0.00019	0.0135	0.18	0.17	Neuroticism;	chr20:34709184	chr20:35201747~35203288:-
THCA	cis	rs2732480	0.557	rs923397	ENSG00000257735.1	RP11-370I10.6	3.76	0.00019	0.0135	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48350945~48442411:+
THCA	cis	rs7216064	1	rs9912084	ENSG00000278740.1	RP11-147L13.14	3.76	0.00019	0.0135	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871919	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs9912770	ENSG00000278740.1	RP11-147L13.14	3.76	0.00019	0.0135	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872117	chr17:68188547~68189165:+
THCA	cis	rs10129255	0.785	rs10150044	ENSG00000280411.1	IGHV1-69-2	-3.76	0.00019	0.0135	-0.11	-0.17	Kawasaki disease;	chr14:106775695	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs10137980	ENSG00000280411.1	IGHV1-69-2	-3.76	0.00019	0.0135	-0.11	-0.17	Kawasaki disease;	chr14:106775735	chr14:106762092~106762588:-
THCA	cis	rs11992162	0.569	rs11786149	ENSG00000270154.1	RP11-419I17.1	-3.76	0.00019	0.0135	-0.22	-0.17	Monocyte count;	chr8:11943309	chr8:12476462~12477122:+
THCA	cis	rs4722585	0.533	rs6964215	ENSG00000273237.1	CTB-119C2.1	-3.76	0.00019	0.0135	-0.16	-0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26157199	chr7:26173533~26174945:-
THCA	cis	rs7809950	0.817	rs17154091	ENSG00000272072.1	CTA-363E19.2	3.76	0.00019	0.0135	0.18	0.17	Coronary artery disease;	chr7:107444345	chr7:107192559~107193300:-
THCA	cis	rs910316	1	rs12590452	ENSG00000259138.1	RP11-950C14.7	3.76	0.00019	0.0135	0.15	0.17	Height;	chr14:75082053	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs1043674	ENSG00000259138.1	RP11-950C14.7	3.76	0.00019	0.0135	0.15	0.17	Height;	chr14:75082667	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs10142865	ENSG00000259138.1	RP11-950C14.7	3.76	0.00019	0.0135	0.15	0.17	Height;	chr14:75088921	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs10142626	ENSG00000259138.1	RP11-950C14.7	3.76	0.00019	0.0135	0.15	0.17	Height;	chr14:75088933	chr14:75127153~75136930:+
THCA	cis	rs910316	0.967	rs2010678	ENSG00000259138.1	RP11-950C14.7	3.76	0.00019	0.0135	0.15	0.17	Height;	chr14:75100475	chr14:75127153~75136930:+
THCA	cis	rs910316	0.967	rs4899545	ENSG00000259138.1	RP11-950C14.7	3.76	0.00019	0.0135	0.15	0.17	Height;	chr14:75101435	chr14:75127153~75136930:+
THCA	cis	rs295490	0.748	rs77327267	ENSG00000272656.1	RP11-219D15.3	3.76	0.00019	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341667	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs77705963	ENSG00000272656.1	RP11-219D15.3	3.76	0.00019	0.0135	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341843	chr3:139349024~139349371:-
THCA	cis	rs804280	0.544	rs804276	ENSG00000270154.1	RP11-419I17.1	3.76	0.00019	0.0135	0.2	0.17	Myopia (pathological);	chr8:11767499	chr8:12476462~12477122:+
THCA	cis	rs9693857	0.518	rs13279136	ENSG00000254153.1	CTA-398F10.2	3.76	0.00019	0.0135	0.21	0.17	Systolic blood pressure;	chr8:9421436	chr8:8456909~8461337:-
THCA	cis	rs12549025	0.796	rs10503727	ENSG00000253390.1	CTC-756D1.2	-3.76	0.00019	0.0135	-0.27	-0.17	Reticulocyte fraction of red cells;	chr8:23540164	chr8:23458601~23484971:+
THCA	cis	rs1612141	1	rs1779539	ENSG00000251363.2	RP11-129M6.1	-3.76	0.00019	0.0135	-0.25	-0.17	QT interval (drug interaction);	chr14:41225860	chr14:40954898~40975877:+
THCA	cis	rs74233809	1	rs10509759	ENSG00000272912.1	RP11-724N1.1	-3.76	0.00019	0.0135	-0.31	-0.17	Birth weight;	chr10:102929908	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs10883806	ENSG00000272912.1	RP11-724N1.1	-3.76	0.00019	0.0135	-0.31	-0.17	Birth weight;	chr10:102953319	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs78260931	ENSG00000272912.1	RP11-724N1.1	-3.76	0.00019	0.0135	-0.31	-0.17	Birth weight;	chr10:102962205	chr10:102914585~102915404:+
THCA	cis	rs74233809	1	rs11191505	ENSG00000272912.1	RP11-724N1.1	-3.76	0.00019	0.0135	-0.31	-0.17	Birth weight;	chr10:103007134	chr10:102914585~102915404:+
THCA	cis	rs2880765	0.835	rs2170736	ENSG00000259407.1	RP11-158M2.3	-3.76	0.00019	0.0135	-0.17	-0.17	Coronary artery disease;	chr15:85500167	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.835	rs4340287	ENSG00000259407.1	RP11-158M2.3	-3.76	0.00019	0.0135	-0.17	-0.17	Coronary artery disease;	chr15:85500506	chr15:85744109~85750281:-
THCA	cis	rs4919694	0.536	rs12414777	ENSG00000213277.3	MARCKSL1P1	3.76	0.00019	0.0135	0.22	0.17	Arsenic metabolism;	chr10:102938024	chr10:103175554~103176094:+
THCA	cis	rs489332	0.532	rs498313	ENSG00000234618.1	RPSAP9	-3.76	0.00019	0.0135	-0.18	-0.17	Schizophrenia;	chr9:75419253	chr9:76398699~76399586:+
THCA	cis	rs9303542	0.694	rs6504135	ENSG00000278765.1	RP5-890E16.5	-3.76	0.00019	0.0135	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48255303	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs6504145	ENSG00000278765.1	RP5-890E16.5	-3.76	0.00019	0.0135	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48263229	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs17621199	ENSG00000278765.1	RP5-890E16.5	-3.76	0.00019	0.0135	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48264913	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs17621297	ENSG00000278765.1	RP5-890E16.5	-3.76	0.00019	0.0135	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48269125	chr17:48066704~48067293:-
THCA	cis	rs753778	0.57	rs6985866	ENSG00000253210.1	RP11-809O17.1	3.76	0.00019	0.0135	0.21	0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141200237	chr8:141126044~141129961:-
THCA	cis	rs11678825	0.631	rs113596710	ENSG00000272663.1	RP11-191L17.1	-3.76	0.00019	0.0135	-0.24	-0.17	Reticulocyte fraction of red cells;	chr2:48385573	chr2:48440043~48440597:-
THCA	cis	rs9611565	0.659	rs12483786	ENSG00000237037.8	NDUFA6-AS1	3.76	0.00019	0.0135	0.16	0.17	Vitiligo;	chr22:41542532	chr22:42090931~42137742:+
THCA	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	3.76	0.00019	0.0135	0.1	0.17	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
THCA	cis	rs10435719	0.78	rs9692662	ENSG00000255495.1	AC145124.2	3.76	0.00019	0.0135	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.899	rs9693925	ENSG00000255495.1	AC145124.2	3.76	0.00019	0.0135	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:12194467~12196280:+
THCA	cis	rs755249	0.567	rs3118014	ENSG00000182109.6	RP11-69E11.4	3.76	0.00019	0.0135	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39522280~39546187:-
THCA	cis	rs4761638	1	rs4761638	ENSG00000241556.1	RP11-490G8.1	-3.76	0.00019	0.0135	-0.19	-0.17	Insulin disposition index;	chr12:94600873	chr12:95467397~95467861:-
THCA	cis	rs9435732	0.697	rs9435671	ENSG00000186301.8	MST1P2	-3.76	0.00019	0.0135	-0.14	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17013444	chr1:16645622~16650289:+
THCA	cis	rs1113500	0.575	rs1781067	ENSG00000226822.1	RP11-356N1.2	3.76	0.00019	0.0135	0.18	0.17	Growth-regulated protein alpha levels;	chr1:108025389	chr1:108071482~108074519:+
THCA	cis	rs9303542	0.729	rs7218848	ENSG00000278765.1	RP5-890E16.5	3.76	0.00019	0.0135	0.22	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48341227	chr17:48066704~48067293:-
THCA	cis	rs755249	0.874	rs61779310	ENSG00000182109.6	RP11-69E11.4	3.76	0.00019	0.0135	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39522280~39546187:-
THCA	cis	rs6449502	0.92	rs295556	ENSG00000251279.1	CTC-436P18.1	3.76	0.00019	0.0135	0.28	0.17	Mean platelet volume;	chr5:61106383	chr5:61162070~61232040:+
THCA	cis	rs1876905	0.68	rs354528	ENSG00000271789.1	RP5-1112D6.7	-3.76	0.00019	0.0135	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111184068	chr6:111297126~111298510:+
THCA	cis	rs1864585	0.52	rs17776404	ENSG00000280294.1	RP11-177H2.1	3.76	0.00019	0.0136	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10815319	chr8:10856085~10859436:-
THCA	cis	rs4763879	0.865	rs4763840	ENSG00000256673.1	RP11-599J14.2	3.76	0.00019	0.0136	0.21	0.17	Type 1 diabetes;	chr12:9731814	chr12:9398355~9414851:-
THCA	cis	rs4578769	0.55	rs4474794	ENSG00000273232.1	RP11-370A5.2	3.76	0.00019	0.0136	0.23	0.17	Eosinophil percentage of white cells;	chr18:22987010	chr18:22882825~22883357:-
THCA	cis	rs9908102	0.9	rs62058145	ENSG00000277621.1	RP11-597M12.2	-3.76	0.00019	0.0136	-0.18	-0.17	Schizophrenia;	chr17:13010173	chr17:12982613~12983002:-
THCA	cis	rs2243480	0.522	rs431168	ENSG00000232559.3	GS1-124K5.12	3.76	0.00019	0.0136	0.3	0.17	Diabetic kidney disease;	chr7:66046617	chr7:66554588~66576923:-
THCA	cis	rs2625529	0.824	rs7183749	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.00019	0.0136	-0.24	-0.17	Red blood cell count;	chr15:72084937	chr15:71818396~71823384:+
THCA	cis	rs804280	0.662	rs11784764	ENSG00000254948.1	OR7E158P	3.76	0.00019	0.0136	0.24	0.17	Myopia (pathological);	chr8:11753365	chr8:11919900~11920809:-
THCA	cis	rs12291225	0.637	rs8570	ENSG00000251991.1	RNU7-49P	3.76	0.00019	0.0136	0.2	0.17	Sense of smell;	chr11:14279213	chr11:14478892~14478953:+
THCA	cis	rs2904297	0.958	rs10939105	ENSG00000261490.1	RP11-448G15.3	-3.76	0.00019	0.0136	-0.11	-0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11022058	chr4:10068089~10073019:-
THCA	cis	rs801193	1	rs4717310	ENSG00000275400.1	RP4-756H11.5	-3.76	0.00019	0.0136	-0.16	-0.17	Aortic root size;	chr7:66696020	chr7:66553805~66554199:-
THCA	cis	rs875971	1	rs1167411	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.00019	0.0136	-0.18	-0.17	Aortic root size;	chr7:66074277	chr7:66025126~66031544:-
THCA	cis	rs3858145	0.546	rs7912806	ENSG00000233590.1	RP11-153K11.3	3.76	0.00019	0.0136	0.24	0.17	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68296578	chr10:68233251~68242379:-
THCA	cis	rs9980	0.947	rs72783112	ENSG00000226232.7	RP11-419C5.2	-3.76	0.00019	0.0136	-0.26	-0.17	Blood osmolality (transformed sodium);	chr16:69663712	chr16:69976388~69996188:-
THCA	cis	rs2911280	0.764	rs7196069	ENSG00000278985.1	RP11-303E16.9	-3.76	0.00019	0.0136	-0.3	-0.17	Dehydroepiandrosterone sulphate levels;	chr16:81527851	chr16:80982319~80984094:-
THCA	cis	rs10875746	0.904	rs11168422	ENSG00000258234.1	RP11-370I10.2	3.76	0.00019	0.0136	0.2	0.17	Longevity (90 years and older);	chr12:48125722	chr12:48231098~48284210:-
THCA	cis	rs2190422	0.551	rs2256517	ENSG00000234715.1	CTB-107G13.1	3.76	0.00019	0.0136	0.25	0.17	Morning vs. evening chronotype;	chr7:103525814	chr7:103445207~103514007:+
THCA	cis	rs11601239	0.607	rs11226856	ENSG00000254750.1	CASP1P2	-3.76	0.00019	0.0136	-0.14	-0.17	Refractive error;	chr11:105828322	chr11:105063345~105071541:-
THCA	cis	rs7786410	1	rs7786410	ENSG00000273720.1	RP11-613E4.4	3.76	0.00019	0.0136	0.3	0.17	Age-related hearing impairment;	chr7:55854630	chr7:55743073~55743457:+
THCA	cis	rs9307551	0.817	rs13146986	ENSG00000249646.2	OR7E94P	-3.76	0.00019	0.0136	-0.22	-0.17	Refractive error;	chr4:79591074	chr4:79587302~79588130:-
THCA	cis	rs2070488	0.965	rs3749386	ENSG00000229589.1	ACVR2B-AS1	3.76	0.00019	0.0136	0.16	0.17	Electrocardiographic conduction measures;	chr3:38454574	chr3:38451027~38454820:-
THCA	cis	rs683250	0.598	rs625102	ENSG00000254551.1	RP11-727A23.7	3.76	0.00019	0.0136	0.21	0.17	Subcortical brain region volumes;	chr11:83241066	chr11:83209431~83213379:-
THCA	cis	rs17666538	1	rs57255985	ENSG00000254207.1	RP11-43A14.1	-3.76	0.00019	0.0136	-0.41	-0.17	IgG glycosylation;	chr8:624131	chr8:725188~725877:-
THCA	cis	rs12478296	0.591	rs12468297	ENSG00000261186.2	RP11-341N2.1	-3.76	0.00019	0.0136	-0.22	-0.17	Obesity-related traits;	chr2:242054323	chr2:242087351~242088457:-
THCA	cis	rs2058059	0.51	rs61567992	ENSG00000205578.5	POM121B	-3.76	0.00019	0.0136	-0.29	-0.17	Subcutaneous adipose tissue;	chr7:72576332	chr7:73293497~73301161:+
THCA	cis	rs8062405	1	rs12443881	ENSG00000270424.1	RP11-1348G14.6	3.76	0.00019	0.0136	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28749959~28750595:-
THCA	cis	rs2880765	0.835	rs2170735	ENSG00000259407.1	RP11-158M2.3	-3.76	0.00019	0.0136	-0.17	-0.17	Coronary artery disease;	chr15:85500254	chr15:85744109~85750281:-
THCA	cis	rs7665090	1	rs7664828	ENSG00000248971.2	KRT8P46	-3.76	0.00019	0.0136	-0.2	-0.17	Primary biliary cholangitis;	chr4:102630219	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.967	rs7690123	ENSG00000248971.2	KRT8P46	-3.76	0.00019	0.0136	-0.2	-0.17	Primary biliary cholangitis;	chr4:102630602	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs7665659	ENSG00000248971.2	KRT8P46	-3.76	0.00019	0.0136	-0.2	-0.17	Primary biliary cholangitis;	chr4:102630661	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs7665854	ENSG00000248971.2	KRT8P46	-3.76	0.00019	0.0136	-0.2	-0.17	Primary biliary cholangitis;	chr4:102630752	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.846	rs7690700	ENSG00000248971.2	KRT8P46	-3.76	0.00019	0.0136	-0.2	-0.17	Primary biliary cholangitis;	chr4:102630911	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs13112557	ENSG00000248971.2	KRT8P46	-3.76	0.00019	0.0136	-0.2	-0.17	Primary biliary cholangitis;	chr4:102631096	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs12644381	ENSG00000248971.2	KRT8P46	-3.76	0.00019	0.0136	-0.2	-0.17	Primary biliary cholangitis;	chr4:102631273	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs1054037	ENSG00000248971.2	KRT8P46	-3.76	0.00019	0.0136	-0.2	-0.17	Primary biliary cholangitis;	chr4:102631552	chr4:102728746~102730171:-
THCA	cis	rs6828577	0.774	rs7697022	ENSG00000281731.1	RP11-384K6.8	-3.76	0.00019	0.0136	-0.2	-0.17	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118734522	chr4:118664087~118685341:-
THCA	cis	rs6500602	0.727	rs12443748	ENSG00000280063.1	RP11-295D4.3	3.76	0.00019	0.0136	0.09	0.17	Schizophrenia;	chr16:4491830	chr16:4346694~4348648:-
THCA	cis	rs7577696	0.671	rs467523	ENSG00000276334.1	AL133243.1	-3.76	0.00019	0.0136	-0.19	-0.17	Inflammatory biomarkers;	chr2:32076562	chr2:32521927~32523547:+
THCA	cis	rs9291683	0.588	rs2240722	ENSG00000261490.1	RP11-448G15.3	3.76	0.000191	0.0136	0.1	0.17	Bone mineral density;	chr4:10019133	chr4:10068089~10073019:-
THCA	cis	rs7737355	0.947	rs32110	ENSG00000237714.1	P4HA2-AS1	3.76	0.000191	0.0136	0.25	0.17	Life satisfaction;	chr5:131710142	chr5:132184876~132192808:+
THCA	cis	rs11800820	0.537	rs3124111	ENSG00000231612.1	RP11-522M21.3	3.76	0.000191	0.0136	0.23	0.17	Obesity-related traits;	chr1:246542528	chr1:245673732~245676478:-
THCA	cis	rs55702914	0.935	rs56116936	ENSG00000231621.1	AC013264.2	-3.76	0.000191	0.0136	-0.17	-0.17	Major depression and alcohol dependence;	chr2:197354493	chr2:197197991~197199273:+
THCA	cis	rs13113518	0.812	rs11133385	ENSG00000272969.1	RP11-528I4.2	3.76	0.000191	0.0136	0.2	0.17	Height;	chr4:55460485	chr4:55547112~55547889:+
THCA	cis	rs4144027	0.967	rs56126771	ENSG00000258534.1	CTD-2134A5.4	-3.76	0.000191	0.0136	-0.18	-0.17	Blood metabolite levels;	chr14:103894806	chr14:103854366~103880111:-
THCA	cis	rs1612141	0.948	rs3866732	ENSG00000251363.2	RP11-129M6.1	3.76	0.000191	0.0136	0.25	0.17	QT interval (drug interaction);	chr14:41287209	chr14:40954898~40975877:+
THCA	cis	rs11694172	1	rs72928921	ENSG00000273456.1	RP11-686O6.2	3.76	0.000191	0.0136	0.16	0.17	Cholesterol, total;	chr2:202685302	chr2:202374932~202375604:-
THCA	cis	rs11694172	1	rs62194137	ENSG00000273456.1	RP11-686O6.2	3.76	0.000191	0.0136	0.16	0.17	Cholesterol, total;	chr2:202686822	chr2:202374932~202375604:-
THCA	cis	rs9863	0.794	rs7978610	ENSG00000270028.1	RP11-380L11.4	-3.76	0.000191	0.0136	-0.18	-0.17	White blood cell count;	chr12:123984025	chr12:123925461~123926083:-
THCA	cis	rs3087591	0.615	rs12943365	ENSG00000263535.1	AK4P1	3.76	0.000191	0.0136	0.21	0.17	Hip circumference;	chr17:31353508	chr17:31345521~31346187:+
THCA	cis	rs2018683	0.6	rs717891	ENSG00000228421.2	AC005013.5	3.76	0.000191	0.0136	0.21	0.17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28960758	chr7:28957667~28959345:+
THCA	cis	rs1842579	0.597	rs12746325	ENSG00000272691.1	RP11-290M5.4	-3.76	0.000191	0.0136	-0.17	-0.17	Coronary artery aneurysm in Kawasaki disease;	chr1:85786342	chr1:85578500~85578742:-
THCA	cis	rs6828577	0.909	rs298987	ENSG00000248280.1	RP11-33B1.2	3.76	0.000191	0.0136	0.15	0.17	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118727489	chr4:119440561~119450157:-
THCA	cis	rs10954779	0.642	rs2737345	ENSG00000127589.4	TUBBP1	3.76	0.000191	0.0136	0.2	0.17	Intelligence (multi-trait analysis);	chr8:31160915	chr8:30351873~30353518:+
THCA	cis	rs6963495	0.818	rs73192113	ENSG00000272604.1	RP11-251G23.5	3.76	0.000191	0.0136	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105529156	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73192115	ENSG00000272604.1	RP11-251G23.5	3.76	0.000191	0.0136	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105529158	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs6973263	ENSG00000272604.1	RP11-251G23.5	3.76	0.000191	0.0136	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105529846	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs6955796	ENSG00000272604.1	RP11-251G23.5	3.76	0.000191	0.0136	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105529874	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs6973974	ENSG00000272604.1	RP11-251G23.5	3.76	0.000191	0.0136	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105530182	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs55983796	ENSG00000272604.1	RP11-251G23.5	3.76	0.000191	0.0136	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105530494	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73192120	ENSG00000272604.1	RP11-251G23.5	3.76	0.000191	0.0136	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105530709	chr7:105571083~105573660:+
THCA	cis	rs2076295	0.503	rs1358903	ENSG00000261189.1	RP3-512B11.3	-3.76	0.000191	0.0136	-0.17	-0.17	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7563906	chr6:7540451~7541338:-
THCA	cis	rs7927592	0.913	rs7123564	ENSG00000160172.9	FAM86C2P	3.76	0.000191	0.0136	0.17	0.17	Total body bone mineral density;	chr11:68594696	chr11:67791648~67805336:-
THCA	cis	rs11971779	0.715	rs6467856	ENSG00000252332.1	RNU6-911P	-3.76	0.000191	0.0136	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139442553	chr7:139448740~139448843:+
THCA	cis	rs7737355	0.947	rs2215190	ENSG00000237714.1	P4HA2-AS1	3.76	0.000191	0.0136	0.24	0.17	Life satisfaction;	chr5:131585973	chr5:132184876~132192808:+
THCA	cis	rs4722166	0.532	rs4719712	ENSG00000225541.1	AC002480.5	-3.76	0.000191	0.0136	-0.19	-0.17	Lung cancer;	chr7:22716188	chr7:22571607~22661792:-
THCA	cis	rs889312	0.5	rs3099460	ENSG00000271828.1	CTD-2310F14.1	-3.76	0.000191	0.0136	-0.23	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56837921	chr5:56927874~56929573:+
THCA	cis	rs16975963	0.644	rs73033129	ENSG00000276846.1	CTD-3220F14.3	-3.76	0.000191	0.0136	-0.16	-0.17	Longevity;	chr19:37589634	chr19:37314868~37315620:-
THCA	cis	rs2625529	0.824	rs4777470	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000191	0.0136	-0.24	-0.17	Red blood cell count;	chr15:71915177	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.761	rs4776582	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000191	0.0136	-0.24	-0.17	Red blood cell count;	chr15:71915179	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.762	rs1384007	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000191	0.0136	-0.24	-0.17	Red blood cell count;	chr15:71937193	chr15:71818396~71823384:+
THCA	cis	rs10911902	0.643	rs76991105	ENSG00000233196.2	GS1-304P7.1	-3.76	0.000191	0.0136	-0.28	-0.17	Schizophrenia;	chr1:186376920	chr1:186580515~186581191:-
THCA	cis	rs2455799	0.573	rs924753	ENSG00000270409.1	RP11-44D5.1	-3.76	0.000191	0.0136	-0.18	-0.17	Mean platelet volume;	chr3:15664617	chr3:15732252~15733470:+
THCA	cis	rs9450351	0.744	rs2229524	ENSG00000203875.9	SNHG5	-3.76	0.000191	0.0136	-0.33	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85489525	chr6:85660950~85678736:-
THCA	cis	rs944289	0.617	rs1958614	ENSG00000258844.1	RP11-259K15.2	3.76	0.000191	0.0136	0.16	0.17	Thyroid cancer;	chr14:36118107	chr14:36214607~36235608:+
THCA	cis	rs1577917	0.958	rs12192033	ENSG00000220563.1	PKMP3	-3.76	0.000191	0.0136	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85762841	chr6:85659892~85660606:-
THCA	cis	rs780094	0.5	rs4665991	ENSG00000234072.1	AC074117.10	3.76	0.000191	0.0136	0.14	0.17	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27543417	chr2:27356246~27367622:+
THCA	cis	rs780094	0.5	rs12995461	ENSG00000234072.1	AC074117.10	3.76	0.000191	0.0136	0.14	0.17	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27555300	chr2:27356246~27367622:+
THCA	cis	rs780094	0.5	rs4665382	ENSG00000234072.1	AC074117.10	3.76	0.000191	0.0136	0.14	0.17	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27560934	chr2:27356246~27367622:+
THCA	cis	rs4819052	1	rs9984901	ENSG00000184274.3	LINC00315	-3.76	0.000191	0.0136	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45300245~45305257:-
THCA	cis	rs2806561	0.577	rs488438	ENSG00000249087.5	ZNF436-AS1	-3.76	0.000191	0.0136	-0.11	-0.17	Height;	chr1:23172506	chr1:23368997~23371839:+
THCA	cis	rs988712	0.921	rs1114029	ENSG00000245573.6	BDNF-AS	3.76	0.000191	0.0136	0.15	0.17	Obesity;	chr11:27574434	chr11:27506838~27698174:+
THCA	cis	rs7927592	0.871	rs113020558	ENSG00000160172.9	FAM86C2P	3.76	0.000191	0.0136	0.17	0.17	Total body bone mineral density;	chr11:68529364	chr11:67791648~67805336:-
THCA	cis	rs4484658	0.778	rs1465914	ENSG00000253773.2	C8orf37-AS1	-3.76	0.000191	0.0136	-0.31	-0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:95203035	chr8:95204456~95810136:+
THCA	cis	rs153852	0.892	rs36731	ENSG00000243806.1	RPL7P18	-3.76	0.000191	0.0136	-0.23	-0.17	Cancer;	chr5:94827967	chr5:94825961~94826694:-
THCA	cis	rs7474896	0.832	rs12357256	ENSG00000263064.2	RP11-291L22.7	3.76	0.000191	0.0136	0.28	0.17	Obesity (extreme);	chr10:38070573	chr10:38448689~38448949:+
THCA	cis	rs9532669	0.889	rs9549302	ENSG00000229473.2	RGS17P1	3.76	0.000191	0.0136	0.22	0.17	Cervical cancer;	chr13:40843278	chr13:40992779~40993331:-
THCA	cis	rs9959145	1	rs9967026	ENSG00000267199.1	RP11-861E21.2	3.76	0.000191	0.0136	0.22	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12566484	chr18:12438890~12448205:+
THCA	cis	rs17074492	1	rs17074492	ENSG00000214182.5	PTMAP5	3.76	0.000191	0.0136	0.19	0.17	Sjögren's syndrome;	chr13:81587764	chr13:81689911~81691072:+
THCA	cis	rs875971	1	rs6956179	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000191	0.0136	-0.18	-0.17	Aortic root size;	chr7:66341672	chr7:66025126~66031544:-
THCA	cis	rs4268898	0.76	rs7597919	ENSG00000242628.4	AC009228.1	-3.76	0.000191	0.0136	-0.2	-0.17	Asthma;	chr2:24340777	chr2:24214381~24221516:+
THCA	cis	rs965513	0.524	rs6478413	ENSG00000214417.4	KRT18P13	-3.76	0.000191	0.0136	-0.16	-0.17	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97819742	chr9:97698922~97700734:+
THCA	cis	rs34421088	0.678	rs35928010	ENSG00000270154.1	RP11-419I17.1	-3.76	0.000191	0.0136	-0.2	-0.17	Neuroticism;	chr8:11734367	chr8:12476462~12477122:+
THCA	cis	rs6012953	0.874	rs1885177	ENSG00000231715.1	COX6CP2	-3.76	0.000191	0.0136	-0.18	-0.17	Vitiligo;	chr20:50574691	chr20:50479767~50479991:+
THCA	cis	rs7520050	0.966	rs7550746	ENSG00000280836.1	AL355480.1	3.76	0.000191	0.0136	0.21	0.17	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45581219~45581321:-
THCA	cis	rs8062405	0.964	rs7187333	ENSG00000270424.1	RP11-1348G14.6	3.76	0.000191	0.0136	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28749959~28750595:-
THCA	cis	rs8062405	1	rs12446589	ENSG00000270424.1	RP11-1348G14.6	3.76	0.000191	0.0136	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28749959~28750595:-
THCA	cis	rs11971779	0.68	rs66491565	ENSG00000252332.1	RNU6-911P	-3.76	0.000191	0.0136	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139404231	chr7:139448740~139448843:+
THCA	cis	rs9911578	1	rs8071916	ENSG00000224738.1	AC099850.1	3.76	0.000191	0.0136	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58582918	chr17:59106598~59118267:+
THCA	cis	rs7246657	0.722	rs1291	ENSG00000226686.6	LINC01535	3.76	0.000191	0.0136	0.24	0.17	Coronary artery calcification;	chr19:37738477	chr19:37251912~37265535:+
THCA	cis	rs7829975	0.593	rs2921051	ENSG00000253130.1	CTD-3023L14.2	-3.76	0.000191	0.0136	-0.18	-0.17	Mood instability;	chr8:8462594	chr8:8561391~8569688:+
THCA	cis	rs1908814	0.516	rs11996277	ENSG00000254948.1	OR7E158P	-3.76	0.000191	0.0136	-0.22	-0.17	Neuroticism;	chr8:11942522	chr8:11919900~11920809:-
THCA	cis	rs755249	0.917	rs72663503	ENSG00000182109.6	RP11-69E11.4	3.76	0.000191	0.0136	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39522280~39546187:-
THCA	cis	rs755249	0.917	rs61779331	ENSG00000182109.6	RP11-69E11.4	3.76	0.000191	0.0136	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39522280~39546187:-
THCA	cis	rs77580281	1	rs2157728	ENSG00000185065.6	AC000068.5	-3.76	0.000191	0.0136	-0.19	-0.17	Pediatric bone mineral density (hip);	chr22:19551004	chr22:19447893~19450105:+
THCA	cis	rs6696239	0.956	rs11590390	ENSG00000227711.2	RP11-275O4.5	-3.76	0.000191	0.0136	-0.25	-0.17	Height;	chr1:227545335	chr1:227509028~227520477:-
THCA	cis	rs1046896	1	rs1046875	ENSG00000263063.1	RP11-388C12.1	3.76	0.000191	0.0136	0.2	0.17	Glycated hemoglobin levels;	chr17:82727550	chr17:82713908~82716255:-
THCA	cis	rs13113518	0.812	rs11932712	ENSG00000272969.1	RP11-528I4.2	3.76	0.000191	0.0136	0.2	0.17	Height;	chr4:55436423	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs12501746	ENSG00000272969.1	RP11-528I4.2	3.76	0.000191	0.0136	0.2	0.17	Height;	chr4:55437438	chr4:55547112~55547889:+
THCA	cis	rs3812831	0.669	rs7327370	ENSG00000264539.1	MIR548AR	3.76	0.000191	0.0136	0.18	0.17	Schizophrenia;	chr13:114181383	chr13:114244505~114244561:+
THCA	cis	rs12887734	0.524	rs4906364	ENSG00000258735.1	LINC00637	-3.76	0.000191	0.0136	-0.22	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103847721~103858049:+
THCA	cis	rs372883	0.648	rs1153288	ENSG00000176054.6	RPL23P2	3.76	0.000191	0.0136	0.15	0.17	Pancreatic cancer;	chr21:29313770	chr21:28997613~28998033:-
THCA	cis	rs3809566	1	rs3809566	ENSG00000259459.4	RP11-321G12.1	-3.76	0.000191	0.0136	-0.14	-0.17	Platelet count;	chr15:63041525	chr15:63390136~63438320:+
THCA	cis	rs17772222	0.839	rs2274735	ENSG00000222990.1	RNU4-22P	3.76	0.000191	0.0136	0.2	0.17	Coronary artery calcification;	chr14:88505414	chr14:88513498~88513663:+
THCA	cis	rs9309473	0.95	rs11689588	ENSG00000273245.1	RP11-434P11.2	3.76	0.000191	0.0136	0.24	0.17	Metabolite levels;	chr2:73546564	chr2:73750256~73750786:-
THCA	cis	rs9425766	0.924	rs5877	ENSG00000270084.1	GAS5-AS1	-3.76	0.000191	0.0136	-0.17	-0.17	Life satisfaction;	chr1:173909724	chr1:173863248~173863941:+
THCA	cis	rs12188164	0.543	rs890972	ENSG00000188242.4	PP7080	-3.76	0.000191	0.0136	-0.15	-0.17	Cystic fibrosis severity;	chr5:462350	chr5:466124~473098:-
THCA	cis	rs12188164	0.543	rs2434694	ENSG00000188242.4	PP7080	-3.76	0.000191	0.0136	-0.15	-0.17	Cystic fibrosis severity;	chr5:462619	chr5:466124~473098:-
THCA	cis	rs9584850	0.874	rs3742137	ENSG00000231194.1	FARP1-AS1	3.76	0.000191	0.0136	0.21	0.17	Neuroticism;	chr13:98450195	chr13:98435405~98435840:-
THCA	cis	rs916888	0.779	rs199528	ENSG00000260075.1	NSFP1	-3.76	0.000191	0.0136	-0.28	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46372855~46487141:+
THCA	cis	rs916888	0.821	rs199525	ENSG00000260075.1	NSFP1	-3.76	0.000191	0.0136	-0.28	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46372855~46487141:+
THCA	cis	rs7111546	1	rs3763947	ENSG00000246225.5	RP11-17A1.3	-3.76	0.000191	0.0136	-0.31	-0.17	Dialysis-related mortality;	chr11:22813523	chr11:22829380~22945393:+
THCA	cis	rs6456156	0.766	rs150112	ENSG00000235272.1	FAM103A2P	-3.76	0.000191	0.0136	-0.23	-0.17	Primary biliary cholangitis;	chr6:167096390	chr6:166586124~166586477:-
THCA	cis	rs13113518	0.783	rs11943206	ENSG00000272969.1	RP11-528I4.2	3.76	0.000191	0.0136	0.2	0.17	Height;	chr4:55570843	chr4:55547112~55547889:+
THCA	cis	rs10504130	0.696	rs113323463	ENSG00000272024.1	RP11-546K22.3	-3.76	0.000191	0.0136	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51912737	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs111926180	ENSG00000272024.1	RP11-546K22.3	-3.76	0.000191	0.0136	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51913101	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs78238505	ENSG00000272024.1	RP11-546K22.3	-3.76	0.000191	0.0136	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51915578	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs76649327	ENSG00000272024.1	RP11-546K22.3	-3.76	0.000191	0.0136	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51917219	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs76717135	ENSG00000272024.1	RP11-546K22.3	-3.76	0.000191	0.0136	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51917672	chr8:51950284~51950690:+
THCA	cis	rs7737355	0.947	rs31585	ENSG00000237714.1	P4HA2-AS1	3.76	0.000191	0.0136	0.25	0.17	Life satisfaction;	chr5:131663389	chr5:132184876~132192808:+
THCA	cis	rs12681366	0.708	rs2515156	ENSG00000261437.1	RP11-22C11.2	-3.76	0.000191	0.0136	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94366958	chr8:94637285~94639467:-
THCA	cis	rs13178541	0.606	rs9637922	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135791514	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.671	rs9637923	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135791532	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs11242290	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135791660	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs12654633	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135791677	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs12656771	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135791696	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs10060930	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135791965	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.606	rs10069058	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135792227	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs4499826	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135792619	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.574	rs9637925	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135792982	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs12153181	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135793126	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.671	rs12153176	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135793155	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs12153182	ENSG00000250378.1	RP11-119J18.1	-3.76	0.000191	0.0136	-0.2	-0.17	IgG glycosylation;	chr5:135793165	chr5:135812667~135826582:+
THCA	cis	rs11771526	0.901	rs11761481	ENSG00000272905.1	RP11-265E18.1	3.76	0.000191	0.0136	0.22	0.17	Body mass index;	chr7:32254382	chr7:32845394~32846061:+
THCA	cis	rs2228479	0.717	rs17226274	ENSG00000274627.1	RP11-104N10.2	-3.76	0.000191	0.0136	-0.29	-0.17	Skin colour saturation;	chr16:89783762	chr16:89516797~89522217:+
THCA	cis	rs13098911	0.54	rs35464221	ENSG00000226074.4	PRSS44	-3.76	0.000191	0.0136	-0.33	-0.17	Celiac disease;	chr3:46127548	chr3:46809359~46812558:-
THCA	cis	rs1943345	0.556	rs528703	ENSG00000254551.1	RP11-727A23.7	3.76	0.000192	0.0136	0.21	0.17	Obesity-related traits;	chr11:83214993	chr11:83209431~83213379:-
THCA	cis	rs1577917	0.654	rs9450284	ENSG00000220563.1	PKMP3	3.76	0.000192	0.0136	0.13	0.17	Response to antipsychotic treatment;	chr6:85489611	chr6:85659892~85660606:-
THCA	cis	rs12681366	0.614	rs2921385	ENSG00000261437.1	RP11-22C11.2	-3.76	0.000192	0.0136	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94447120	chr8:94637285~94639467:-
THCA	cis	rs926937	0.622	rs6005500	ENSG00000235954.5	TTC28-AS1	-3.76	0.000192	0.0136	-0.24	-0.17	Age-related cataracts;	chr22:27529117	chr22:27919376~28008581:+
THCA	cis	rs972578	1	rs972578	ENSG00000230319.1	AL022476.2	3.76	0.000192	0.0137	0.18	0.17	Mean platelet volume;	chr22:42991689	chr22:43038585~43052366:+
THCA	cis	rs2736345	0.672	rs2618473	ENSG00000254527.1	ENPP7P12	3.76	0.000192	0.0137	0.23	0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486618	chr8:12205759~12206389:-
THCA	cis	rs17382723	1	rs17382723	ENSG00000225521.1	AC005237.4	3.76	0.000192	0.0137	0.21	0.17	Height;	chr2:241114131	chr2:241015599~241064116:-
THCA	cis	rs1005277	0.522	rs11011343	ENSG00000275858.1	RP11-291L22.8	3.76	0.000192	0.0137	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38450738~38451069:-
THCA	cis	rs7522061	0.546	rs2785664	ENSG00000236731.1	RP4-801G22.2	-3.76	0.000192	0.0137	-0.17	-0.17	Blood protein levels;	chr1:157651445	chr1:157629939~157630728:-
THCA	cis	rs775227	0.636	rs3773697	ENSG00000243849.1	CFAP44-AS1	3.76	0.000192	0.0137	0.31	0.17	Dental caries;	chr3:113304662	chr3:113403991~113433992:+
THCA	cis	rs755249	0.727	rs12028034	ENSG00000182109.6	RP11-69E11.4	-3.76	0.000192	0.0137	-0.17	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39522280~39546187:-
THCA	cis	rs9902453	0.845	rs72823935	ENSG00000264290.1	RP11-68I3.4	3.76	0.000192	0.0137	0.13	0.17	Coffee consumption (cups per day);	chr17:29681577	chr17:29569580~29570519:+
THCA	cis	rs7474896	1	rs11492508	ENSG00000276805.1	RP11-291L22.6	3.76	0.000192	0.0137	0.27	0.17	Obesity (extreme);	chr10:37809208	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs2891586	ENSG00000276805.1	RP11-291L22.6	3.76	0.000192	0.0137	0.27	0.17	Obesity (extreme);	chr10:37812715	chr10:38451030~38451785:+
THCA	cis	rs2625529	0.824	rs4777480	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000192	0.0137	-0.23	-0.17	Red blood cell count;	chr15:72036656	chr15:71818396~71823384:+
THCA	cis	rs76439304	1	rs76439304	ENSG00000247903.1	RP11-421F16.3	-3.76	0.000192	0.0137	-0.28	-0.17	Mean corpuscular volume;	chr12:26880537	chr12:26971586~26979582:+
THCA	cis	rs7267979	0.932	rs928121	ENSG00000276952.1	RP5-965G21.6	3.76	0.000192	0.0137	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25284915~25285588:-
THCA	cis	rs6920965	0.507	rs12203025	ENSG00000226409.1	RP11-735G4.1	-3.76	0.000192	0.0137	-0.21	-0.17	High light scatter reticulocyte count;	chr6:125870888	chr6:125370211~125374324:-
THCA	cis	rs812925	0.511	rs11886950	ENSG00000270820.4	RP11-355B11.2	3.76	0.000192	0.0137	0.14	0.17	Immature fraction of reticulocytes;	chr2:61172182	chr2:61471188~61484130:+
THCA	cis	rs2562456	0.72	rs6511250	ENSG00000268658.4	LINC00664	-3.76	0.000192	0.0137	-0.25	-0.17	Pain;	chr19:21473244	chr19:21483374~21503238:+
THCA	cis	rs1371614	0.635	rs10196691	ENSG00000229122.1	AGBL5-IT1	-3.76	0.000192	0.0137	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918491	chr2:27061038~27061815:+
THCA	cis	rs7973719	0.833	rs3825405	ENSG00000205885.6	C1RL-AS1	3.76	0.000192	0.0137	0.13	0.17	IgG glycosylation;	chr12:7207547	chr12:7108052~7122501:+
THCA	cis	rs2348418	0.8	rs6487667	ENSG00000278733.1	RP11-425D17.1	3.76	0.000192	0.0137	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28195643	chr12:28185625~28186190:-
THCA	cis	rs2348418	0.701	rs6487670	ENSG00000278733.1	RP11-425D17.1	3.76	0.000192	0.0137	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28210856	chr12:28185625~28186190:-
THCA	cis	rs755249	0.833	rs61779313	ENSG00000182109.6	RP11-69E11.4	3.76	0.000192	0.0137	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39522280~39546187:-
THCA	cis	rs950169	0.84	rs2896002	ENSG00000188388.10	GOLGA6L3	3.76	0.000192	0.0137	0.23	0.17	Schizophrenia;	chr15:84390423	chr15:85240472~85247170:+
THCA	cis	rs9291683	0.609	rs4622999	ENSG00000261490.1	RP11-448G15.3	3.76	0.000192	0.0137	0.1	0.17	Bone mineral density;	chr4:10001771	chr4:10068089~10073019:-
THCA	cis	rs7819412	0.618	rs10105377	ENSG00000255310.2	AF131215.2	-3.76	0.000192	0.0137	-0.15	-0.17	Triglycerides;	chr8:11118223	chr8:11107788~11109726:-
THCA	cis	rs10090774	0.965	rs1868280	ENSG00000280303.2	ERICD	3.76	0.000192	0.0137	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140886155	chr8:140636281~140638283:+
THCA	cis	rs9595908	0.669	rs9591303	ENSG00000212293.1	SNORA16	3.76	0.000192	0.0137	0.2	0.17	Body mass index;	chr13:32748278	chr13:32420390~32420516:-
THCA	cis	rs41411047	0.826	rs73155079	ENSG00000252172.1	RNU6-720P	3.76	0.000192	0.0137	0.36	0.17	Myocardial infarction;	chr3:149858673	chr3:149917342~149917449:-
THCA	cis	rs11665867	0.816	rs66599479	ENSG00000279108.1	CTC-490E21.11	-3.76	0.000192	0.0137	-0.26	-0.17	Hematocrit;	chr19:40742950	chr19:40840159~40842039:+
THCA	cis	rs12753569	0.934	rs10430051	ENSG00000272855.1	RP5-1102E8.3	3.76	0.000192	0.0137	0.22	0.17	Personality dimensions;	chr1:76025943	chr1:76636877~76637339:+
THCA	cis	rs5758659	0.714	rs6002626	ENSG00000205702.9	CYP2D7	-3.76	0.000192	0.0137	-0.13	-0.17	Cognitive function;	chr22:42121985	chr22:42140203~42144577:-
THCA	cis	rs11992162	0.597	rs7016320	ENSG00000227888.4	FAM66A	-3.76	0.000192	0.0137	-0.22	-0.17	Monocyte count;	chr8:11923543	chr8:12362019~12388296:+
THCA	cis	rs13401620	0.742	rs56414520	ENSG00000236878.1	AC012363.7	-3.76	0.000192	0.0137	-0.21	-0.17	Breast size;	chr2:119795531	chr2:120211054~120211715:+
THCA	cis	rs9584850	0.915	rs7983438	ENSG00000231194.1	FARP1-AS1	3.76	0.000192	0.0137	0.21	0.17	Neuroticism;	chr13:98451063	chr13:98435405~98435840:-
THCA	cis	rs13102973	0.64	rs13151892	ENSG00000250144.1	RP11-553P9.1	-3.76	0.000192	0.0137	-0.12	-0.17	Subjective well-being;	chr4:134910220	chr4:135045464~135046850:+
THCA	cis	rs55692468	0.771	rs10191361	ENSG00000213197.3	AC012066.1	-3.76	0.000192	0.0137	-0.22	-0.17	Intraocular pressure;	chr2:152484334	chr2:152389937~152390630:+
THCA	cis	rs55692468	0.848	rs3811574	ENSG00000213197.3	AC012066.1	-3.76	0.000192	0.0137	-0.22	-0.17	Intraocular pressure;	chr2:152490331	chr2:152389937~152390630:+
THCA	cis	rs7824557	0.564	rs11782430	ENSG00000255495.1	AC145124.2	-3.76	0.000192	0.0137	-0.2	-0.17	Retinal vascular caliber;	chr8:11368562	chr8:12194467~12196280:+
THCA	cis	rs397969	0.596	rs7209653	ENSG00000261033.1	RP11-209D14.2	-3.76	0.000192	0.0137	-0.23	-0.17	Platelet count;	chr17:19978771	chr17:20008051~20009234:-
THCA	cis	rs9840812	0.598	rs1145101	ENSG00000273486.1	RP11-731C17.2	3.76	0.000192	0.0137	0.18	0.17	Fibrinogen levels;	chr3:136350444	chr3:136837338~136839021:-
THCA	cis	rs62289301	0.571	rs35539860	ENSG00000273133.1	RP11-799M12.2	3.76	0.000192	0.0137	0.21	0.17	Joint mobility (Beighton score);	chr4:15448893	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.592	rs68012715	ENSG00000273133.1	RP11-799M12.2	3.76	0.000192	0.0137	0.21	0.17	Joint mobility (Beighton score);	chr4:15449239	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.571	rs17469724	ENSG00000273133.1	RP11-799M12.2	3.76	0.000192	0.0137	0.21	0.17	Joint mobility (Beighton score);	chr4:15450457	chr4:15563698~15564253:-
THCA	cis	rs765787	0.53	rs2554457	ENSG00000259932.1	CTD-2651B20.7	3.76	0.000192	0.0137	0.21	0.17	Uric acid levels;	chr15:45228728	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs10467979	ENSG00000259932.1	CTD-2651B20.7	3.76	0.000192	0.0137	0.21	0.17	Uric acid levels;	chr15:45229072	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2554455	ENSG00000259932.1	CTD-2651B20.7	3.76	0.000192	0.0137	0.21	0.17	Uric acid levels;	chr15:45229106	chr15:45198517~45199139:-
THCA	cis	rs7647973	0.58	rs2117938	ENSG00000228638.1	FCF1P2	3.76	0.000192	0.0137	0.17	0.17	Menarche (age at onset);	chr3:49226417	chr3:48290793~48291375:-
THCA	cis	rs10489167	1	rs2744803	ENSG00000237899.1	RP4-739H11.3	3.76	0.000192	0.0137	0.3	0.17	Depressive and manic episodes in bipolar disorder;	chr1:40717433	chr1:40669089~40687588:-
THCA	cis	rs5758659	0.652	rs133303	ENSG00000270083.1	RP1-257I20.14	3.76	0.000192	0.0137	0.18	0.17	Cognitive function;	chr22:41999238	chr22:42089630~42090028:-
THCA	cis	rs9818758	0.607	rs73082362	ENSG00000229759.1	MRPS18AP1	-3.76	0.000192	0.0137	-0.39	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076296	chr3:48256350~48256938:-
THCA	cis	rs12681366	0.708	rs2470732	ENSG00000261437.1	RP11-22C11.2	-3.76	0.000192	0.0137	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94364719	chr8:94637285~94639467:-
THCA	cis	rs11088226	0.681	rs2833899	ENSG00000186842.4	LINC00846	-3.76	0.000192	0.0137	-0.25	-0.17	Gastritis;	chr21:32560953	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.645	rs78172258	ENSG00000186842.4	LINC00846	-3.76	0.000192	0.0137	-0.25	-0.17	Gastritis;	chr21:32564229	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.681	rs11702499	ENSG00000186842.4	LINC00846	-3.76	0.000192	0.0137	-0.25	-0.17	Gastritis;	chr21:32566255	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.681	rs11700670	ENSG00000186842.4	LINC00846	-3.76	0.000192	0.0137	-0.25	-0.17	Gastritis;	chr21:32566305	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.681	rs11700671	ENSG00000186842.4	LINC00846	-3.76	0.000192	0.0137	-0.25	-0.17	Gastritis;	chr21:32566311	chr21:32572238~32575881:-
THCA	cis	rs10815468	0.553	rs67176627	ENSG00000229611.1	RP11-390F4.10	3.76	0.000192	0.0137	0.19	0.17	Bipolar disorder and schizophrenia;	chr9:6790982	chr9:6704471~6707780:+
THCA	cis	rs2239557	0.539	rs35864336	ENSG00000259065.1	RP5-1021I20.1	-3.76	0.000192	0.0137	-0.26	-0.17	Common traits (Other);	chr14:73987492	chr14:73787360~73803270:+
THCA	cis	rs916888	0.773	rs199533	ENSG00000260075.1	NSFP1	-3.76	0.000192	0.0137	-0.28	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46372855~46487141:+
THCA	cis	rs308403	0.509	rs309379	ENSG00000224786.1	CETN4P	3.76	0.000192	0.0137	0.17	0.17	Blood protein levels;	chr4:122750301	chr4:122730548~122732193:-
THCA	cis	rs2120243	0.641	rs7639254	ENSG00000241770.1	RP11-555M1.3	-3.76	0.000192	0.0137	-0.22	-0.17	Hepatocellular carcinoma in hepatitis B infection;	chr3:157423252	chr3:157163452~157169133:+
THCA	cis	rs9611565	0.512	rs5996063	ENSG00000237037.8	NDUFA6-AS1	-3.76	0.000192	0.0137	-0.16	-0.17	Vitiligo;	chr22:41772763	chr22:42090931~42137742:+
THCA	cis	rs2886497	0.947	rs11013430	ENSG00000224215.1	RP11-371A19.2	-3.76	0.000192	0.0137	-0.22	-0.17	Major depression and alcohol dependence;	chr10:23382437	chr10:23343957~23345181:+
THCA	cis	rs34779708	0.733	rs12254018	ENSG00000233200.1	RP11-324I22.2	3.76	0.000192	0.0137	0.21	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35219894~35230598:-
THCA	cis	rs7819412	0.806	rs17723229	ENSG00000254948.1	OR7E158P	3.76	0.000192	0.0137	0.21	0.17	Triglycerides;	chr8:11072559	chr8:11919900~11920809:-
THCA	cis	rs12681366	1	rs2960122	ENSG00000261437.1	RP11-22C11.2	3.76	0.000192	0.0137	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94419858	chr8:94637285~94639467:-
THCA	cis	rs2006933	0.625	rs56692730	ENSG00000267644.1	CTD-2008P7.10	3.76	0.000192	0.0137	0.23	0.17	Amyotrophic lateral sclerosis;	chr17:28111201	chr17:28219285~28220005:+
THCA	cis	rs853679	0.825	rs8180562	ENSG00000261839.1	RP1-265C24.8	3.76	0.000192	0.0137	0.26	0.17	Depression;	chr6:28173682	chr6:28136849~28139678:+
THCA	cis	rs853679	0.882	rs9380064	ENSG00000261839.1	RP1-265C24.8	3.76	0.000192	0.0137	0.26	0.17	Depression;	chr6:28175340	chr6:28136849~28139678:+
THCA	cis	rs72829446	0.505	rs9901673	ENSG00000266824.1	RP11-599B13.7	3.76	0.000192	0.0137	0.26	0.17	Androgen levels;	chr17:7580783	chr17:8176812~8182812:+
THCA	cis	rs478304	0.53	rs11568300	ENSG00000255557.1	RP11-770G2.2	3.76	0.000192	0.0137	0.2	0.17	Acne (severe);	chr11:65657696	chr11:65745729~65771585:+
THCA	cis	rs11971779	0.68	rs6965212	ENSG00000252332.1	RNU6-911P	-3.76	0.000192	0.0137	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139341719	chr7:139448740~139448843:+
THCA	cis	rs12188164	0.561	rs2721010	ENSG00000188242.4	PP7080	-3.76	0.000192	0.0137	-0.15	-0.17	Cystic fibrosis severity;	chr5:456800	chr5:466124~473098:-
THCA	cis	rs8081395	0.729	rs12453125	ENSG00000267302.4	RP11-178C3.2	-3.76	0.000192	0.0137	-0.2	-0.17	White blood cell count;	chr17:59968715	chr17:59964832~59996972:+
THCA	cis	rs7824557	0.547	rs6601570	ENSG00000254866.2	DEFB109P3	3.76	0.000192	0.0137	0.24	0.17	Retinal vascular caliber;	chr8:11221858	chr8:12150895~12151134:-
THCA	cis	rs7824557	0.545	rs34482136	ENSG00000227888.4	FAM66A	-3.76	0.000192	0.0137	-0.22	-0.17	Retinal vascular caliber;	chr8:11370376	chr8:12362019~12388296:+
THCA	cis	rs6860806	0.603	rs112300250	ENSG00000263597.1	MIR3936	3.76	0.000192	0.0137	0.16	0.17	Breast cancer;	chr5:132247599	chr5:132365490~132365599:-
THCA	cis	rs5758659	0.652	rs133340	ENSG00000234009.1	RPL5P34	3.76	0.000192	0.0137	0.16	0.17	Cognitive function;	chr22:42021683	chr22:42776406~42777296:-
THCA	cis	rs6840360	0.615	rs113052419	ENSG00000251611.1	RP11-610P16.1	-3.76	0.000193	0.0137	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151551856	chr4:151407551~151408835:-
THCA	cis	rs7045881	0.558	rs4463511	ENSG00000254396.1	RP11-56F10.3	3.76	0.000193	0.0137	0.21	0.17	Schizophrenia;	chr9:27063177	chr9:27102630~27104728:+
THCA	cis	rs6696239	0.869	rs12129704	ENSG00000227711.2	RP11-275O4.5	-3.76	0.000193	0.0137	-0.24	-0.17	Height;	chr1:227635447	chr1:227509028~227520477:-
THCA	cis	rs11105298	0.891	rs12369195	ENSG00000266347.2	AC068641.1	3.76	0.000193	0.0137	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89592833~89592927:+
THCA	cis	rs2231884	0.697	rs11227332	ENSG00000245156.1	RP11-867G23.3	-3.76	0.000193	0.0137	-0.2	-0.17	Inflammatory bowel disease;	chr11:65856268	chr11:66269832~66278525:-
THCA	cis	rs6942407	0.592	rs757961	ENSG00000224046.1	AC005076.5	-3.76	0.000193	0.0137	-0.17	-0.17	Food allergy;	chr7:87220194	chr7:87151423~87152420:-
THCA	cis	rs1560104	0.597	rs4781300	ENSG00000260601.1	RP11-552C15.1	-3.76	0.000193	0.0137	-0.21	-0.17	Obesity-related traits;	chr16:12613866	chr16:12545482~12546684:+
THCA	cis	rs858239	0.669	rs1006709	ENSG00000230042.1	AK3P3	-3.76	0.000193	0.0137	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23129178~23129841:+
THCA	cis	rs11175834	0.557	rs4444128	ENSG00000213344.2	PCNPP3	3.76	0.000193	0.0137	0.29	0.17	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65571793	chr12:65645992~65646462:-
THCA	cis	rs12368653	0.651	rs2307097	ENSG00000270039.1	RP11-571M6.17	3.76	0.000193	0.0137	0.19	0.17	Multiple sclerosis;	chr12:57802018	chr12:57803838~57804415:+
THCA	cis	rs643506	0.817	rs1940392	ENSG00000230911.1	PPIHP1	-3.76	0.000193	0.0137	-0.23	-0.17	Breast cancer;	chr11:111906122	chr11:112029858~112030367:-
THCA	cis	rs7613875	0.58	rs12634780	ENSG00000281691.1	RBM5-AS1	-3.76	0.000193	0.0137	-0.15	-0.17	Body mass index;	chr3:50005908	chr3:50099603~50100988:-
THCA	cis	rs11153306	0.515	rs3213575	ENSG00000271789.1	RP5-1112D6.7	-3.76	0.000193	0.0137	-0.16	-0.17	Tonsillectomy;	chr6:111598068	chr6:111297126~111298510:+
THCA	cis	rs2039553	0.507	rs9545205	ENSG00000227354.5	RBM26-AS1	-3.76	0.000193	0.0137	-0.16	-0.17	Pancreatic cancer;	chr13:79809755	chr13:79406309~79424328:+
THCA	cis	rs1635	0.826	rs742107	ENSG00000216901.1	AL022393.7	3.76	0.000193	0.0137	0.37	0.17	Schizophrenia;	chr6:28322937	chr6:28176188~28176674:+
THCA	cis	rs12935418	0.733	rs35115578	ENSG00000278985.1	RP11-303E16.9	3.76	0.000193	0.0137	0.24	0.17	Mean corpuscular volume;	chr16:80946392	chr16:80982319~80984094:-
THCA	cis	rs6598955	0.67	rs4659366	ENSG00000236782.4	RP11-96L14.7	-3.76	0.000193	0.0137	-0.21	-0.17	Obesity-related traits;	chr1:26216081	chr1:26169947~26171821:-
THCA	cis	rs4869313	0.694	rs38035	ENSG00000247121.5	CTD-2260A17.2	-3.76	0.000193	0.0137	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96987576	chr5:96814028~96935809:-
THCA	cis	rs6940638	1	rs12204280	ENSG00000224843.5	LINC00240	3.76	0.000193	0.0137	0.19	0.17	Intelligence (multi-trait analysis);	chr6:27065325	chr6:26956992~27023924:+
THCA	cis	rs755249	0.529	rs4660732	ENSG00000182109.6	RP11-69E11.4	3.76	0.000193	0.0137	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs61779285	ENSG00000182109.6	RP11-69E11.4	3.76	0.000193	0.0137	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs3768301	ENSG00000182109.6	RP11-69E11.4	3.76	0.000193	0.0137	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs113214136	ENSG00000182109.6	RP11-69E11.4	3.76	0.000193	0.0137	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs3768302	ENSG00000182109.6	RP11-69E11.4	3.76	0.000193	0.0137	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39522280~39546187:-
THCA	cis	rs755249	0.532	rs17343193	ENSG00000182109.6	RP11-69E11.4	3.76	0.000193	0.0137	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs61779300	ENSG00000182109.6	RP11-69E11.4	3.76	0.000193	0.0137	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39522280~39546187:-
THCA	cis	rs8062405	0.964	rs11860513	ENSG00000270424.1	RP11-1348G14.6	3.76	0.000193	0.0137	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28749959~28750595:-
THCA	cis	rs2979489	0.812	rs2915618	ENSG00000254152.1	CTD-3107M8.2	3.76	0.000193	0.0137	0.22	0.17	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Mean corpuscular hemoglobin;Plateletcrit;Sum neutrophil eosinophil counts;Mean corpuscular volume;	chr8:30414121	chr8:30349866~30350347:-
THCA	cis	rs4218	0.543	rs8027536	ENSG00000277144.1	RP11-59H7.4	-3.76	0.000193	0.0137	-0.23	-0.17	Social communication problems;	chr15:59022364	chr15:59115547~59116089:-
THCA	cis	rs7200543	1	rs16966953	ENSG00000188599.16	NPIPP1	-3.76	0.000193	0.0137	-0.13	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15104312~15123498:-
THCA	cis	rs7326068	0.61	rs4769134	ENSG00000278291.1	RP11-172H24.4	3.76	0.000193	0.0137	0.23	0.17	Schizophrenia, bipolar disorder and depression (combined);	chr13:20864732	chr13:20699307~20703718:-
THCA	cis	rs3126085	0.935	rs10888471	ENSG00000237975.5	FLG-AS1	3.76	0.000193	0.0137	0.27	0.17	Atopic dermatitis;	chr1:152228373	chr1:152168125~152445456:+
THCA	cis	rs12549025	0.891	rs35482451	ENSG00000253390.1	CTC-756D1.2	-3.76	0.000193	0.0137	-0.3	-0.17	Reticulocyte fraction of red cells;	chr8:23542753	chr8:23458601~23484971:+
THCA	cis	rs66887589	0.627	rs3872807	ENSG00000249244.1	RP11-548H18.2	3.76	0.000193	0.0137	0.17	0.17	Diastolic blood pressure;	chr4:119439096	chr4:119391831~119395335:-
THCA	cis	rs66887589	0.56	rs9684327	ENSG00000249244.1	RP11-548H18.2	3.76	0.000193	0.0137	0.17	0.17	Diastolic blood pressure;	chr4:119444286	chr4:119391831~119395335:-
THCA	cis	rs7737355	0.947	rs6596009	ENSG00000224431.1	AC063976.7	3.76	0.000193	0.0137	0.19	0.17	Life satisfaction;	chr5:131272400	chr5:132199456~132203487:+
THCA	cis	rs9393777	0.92	rs13212562	ENSG00000272009.1	RP1-313I6.12	-3.76	0.000193	0.0137	-0.23	-0.17	Intelligence (multi-trait analysis);	chr6:27332531	chr6:28078792~28081130:-
THCA	cis	rs8035452	0.857	rs3098190	ENSG00000273674.3	CTD-2378E12.1	-3.76	0.000193	0.0137	-0.22	-0.17	Alzheimer's disease (late onset);	chr15:50520702	chr15:50839875~50908599:-
THCA	cis	rs11073619	0.616	rs17597076	ENSG00000259728.4	LINC00933	-3.76	0.000193	0.0137	-0.33	-0.17	Positive affect;	chr15:84572704	chr15:84570649~84580175:+
THCA	cis	rs11018874	0.597	rs4393275	ENSG00000280367.1	RP11-121L10.2	3.76	0.000193	0.0137	0.2	0.17	White blood cell types;	chr11:90153229	chr11:90223153~90226538:+
THCA	cis	rs3743162	0.955	rs12442557	ENSG00000275120.1	RP11-182J1.17	3.76	0.000193	0.0137	0.21	0.17	Alzheimer's disease (age of onset);	chr15:84887913	chr15:84599434~84606463:-
THCA	cis	rs5770872	0.521	rs7511047	ENSG00000273253.2	RP3-402G11.26	3.76	0.000193	0.0137	0.18	0.17	Tonsillectomy;	chr22:50378190	chr22:50199090~50200837:-
THCA	cis	rs964611	0.816	rs8029997	ENSG00000259488.2	RP11-154J22.1	-3.76	0.000193	0.0137	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48248596	chr15:48312353~48331856:-
THCA	cis	rs7176527	0.848	rs3748374	ENSG00000225151.9	GOLGA2P7	3.76	0.000193	0.0137	0.3	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:84199311~84230136:-
THCA	cis	rs12200782	0.649	rs9467735	ENSG00000124549.13	BTN2A3P	-3.76	0.000193	0.0137	-0.21	-0.17	Small cell lung carcinoma;	chr6:26379586	chr6:26421391~26432383:+
THCA	cis	rs7264396	0.79	rs2425125	ENSG00000088340.14	FER1L4	-3.76	0.000193	0.0137	-0.17	-0.17	Total cholesterol levels;	chr20:35743032	chr20:35558737~35607562:-
THCA	cis	rs1510272	0.961	rs1510275	ENSG00000243926.1	TIPARP-AS1	-3.76	0.000193	0.0137	-0.17	-0.17	Testicular germ cell tumor;	chr3:156586611	chr3:156671862~156674378:-
THCA	cis	rs7824557	0.564	rs2043508	ENSG00000154316.13	TDH	3.76	0.000193	0.0137	0.13	0.17	Retinal vascular caliber;	chr8:11369897	chr8:11339637~11368452:+
THCA	cis	rs6688613	0.721	rs2312675	ENSG00000225171.2	DUTP6	-3.76	0.000193	0.0137	-0.25	-0.17	Refractive astigmatism;	chr1:166953296	chr1:166868748~166869209:+
THCA	cis	rs875971	0.545	rs1909508	ENSG00000273024.4	INTS4P2	-3.76	0.000193	0.0137	-0.21	-0.17	Aortic root size;	chr7:66301366	chr7:65647864~65715661:+
THCA	cis	rs56046484	0.871	rs71397837	ENSG00000218052.5	ADAMTS7P4	-3.76	0.000193	0.0137	-0.28	-0.17	Testicular germ cell tumor;	chr15:85020330	chr15:85255369~85330334:-
THCA	cis	rs9309473	0.5	rs1528169	ENSG00000273245.1	RP11-434P11.2	-3.76	0.000193	0.0137	-0.2	-0.17	Metabolite levels;	chr2:73442058	chr2:73750256~73750786:-
THCA	cis	rs2625529	0.824	rs12592364	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000193	0.0137	-0.24	-0.17	Red blood cell count;	chr15:71992306	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs12595464	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000193	0.0137	-0.24	-0.17	Red blood cell count;	chr15:72002057	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs12916694	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000193	0.0137	-0.24	-0.17	Red blood cell count;	chr15:72005799	chr15:71818396~71823384:+
THCA	cis	rs773506	0.72	rs12236714	ENSG00000235641.4	LINC00484	3.76	0.000193	0.0138	0.22	0.17	Type 2 diabetes nephropathy;	chr9:91199045	chr9:91159573~91165658:+
THCA	cis	rs10181042	0.565	rs1177234	ENSG00000232713.2	AC010733.5	3.76	0.000193	0.0138	0.15	0.17	Crohn's disease;	chr2:61032928	chr2:60938204~60938604:-
THCA	cis	rs17685	0.753	rs10476	ENSG00000227038.2	AC005077.12	-3.76	0.000193	0.0138	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76067102	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs1104878	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76056275	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs869805	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76059278	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs869806	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76059305	chr7:76090431~76108779:-
THCA	cis	rs17685	0.672	rs1639618	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76072669	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs1637044	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76074426	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs1639620	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76074772	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs4552844	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76088777	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs4732578	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76092214	chr7:76090431~76108779:-
THCA	cis	rs17685	0.625	rs1639630	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76101181	chr7:76090431~76108779:-
THCA	cis	rs17685	0.784	rs1613890	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76105719	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs10245584	ENSG00000227038.2	AC005077.12	3.76	0.000193	0.0138	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76116548	chr7:76090431~76108779:-
THCA	cis	rs1371614	0.523	rs12991124	ENSG00000272148.1	RP11-195B17.1	-3.76	0.000193	0.0138	-0.16	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956624	chr2:27062428~27062907:-
THCA	cis	rs56046484	0.871	rs62021203	ENSG00000218052.5	ADAMTS7P4	-3.76	0.000193	0.0138	-0.28	-0.17	Testicular germ cell tumor;	chr15:85020846	chr15:85255369~85330334:-
THCA	cis	rs7829975	0.54	rs2976909	ENSG00000254153.1	CTA-398F10.2	3.76	0.000193	0.0138	0.19	0.17	Mood instability;	chr8:8489180	chr8:8456909~8461337:-
THCA	cis	rs10181042	0.565	rs2564117	ENSG00000232713.2	AC010733.5	3.76	0.000193	0.0138	0.16	0.17	Crohn's disease;	chr2:61005887	chr2:60938204~60938604:-
THCA	cis	rs34975555	0.557	rs11990384	ENSG00000253671.1	RP11-806O11.1	-3.76	0.000193	0.0138	-0.26	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17930926	chr8:17808941~17820868:+
THCA	cis	rs17597773	0.674	rs1494371	ENSG00000272823.1	RP11-295M18.6	-3.76	0.000193	0.0138	-0.23	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841256	chr1:220828676~220829211:-
THCA	cis	rs765787	0.53	rs11636440	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45243784	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs28414644	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45244523	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs28396110	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45244711	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4775834	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45245313	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4775835	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45245355	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4775836	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45245466	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4775837	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45245486	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs12917187	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45246099	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11639403	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45246152	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2413782	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45246292	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2413780	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45246668	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11636018	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45246939	chr15:45152664~45167526:-
THCA	cis	rs765787	0.556	rs2413778	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45247199	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs28756676	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45248162	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs55771002	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45249368	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs55920042	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45249379	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4238376	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45249689	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4238377	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45249783	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4775844	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45249850	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs3759893	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45250752	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs16941017	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45251083	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2413776	ENSG00000259539.1	CTD-2651B20.1	3.76	0.000193	0.0138	0.21	0.17	Uric acid levels;	chr15:45251972	chr15:45152664~45167526:-
THCA	cis	rs17286411	0.671	rs2303225	ENSG00000260185.1	RP11-432I5.6	-3.76	0.000193	0.0138	-0.23	-0.17	Blood protein levels;	chr16:71640979	chr16:71655027~71664212:+
THCA	cis	rs11239930	0.538	rs604716	ENSG00000278811.3	LINC00624	3.76	0.000193	0.0138	0.2	0.17	AIDS progression;	chr1:147073173	chr1:147258885~147517875:-
THCA	cis	rs9543976	0.623	rs974373	ENSG00000261105.4	LMO7-AS1	3.76	0.000193	0.0138	0.24	0.17	Diabetic retinopathy;	chr13:75589660	chr13:75604700~75635994:-
THCA	cis	rs9402682	0.592	rs2078213	ENSG00000232876.1	CTA-212D2.2	-3.76	0.000193	0.0138	-0.24	-0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135136933	chr6:135055033~135060550:+
THCA	cis	rs927821	1	rs7086205	ENSG00000203886.4	CYP17A1-AS1	3.76	0.000193	0.0138	0.22	0.17	Social autistic-like traits;	chr10:102442972	chr10:102832721~102834516:+
THCA	cis	rs12681366	0.762	rs3019148	ENSG00000261437.1	RP11-22C11.2	3.76	0.000193	0.0138	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94417407	chr8:94637285~94639467:-
THCA	cis	rs12410462	0.591	rs903695	ENSG00000227711.2	RP11-275O4.5	-3.76	0.000194	0.0138	-0.21	-0.17	Major depressive disorder;	chr1:227545368	chr1:227509028~227520477:-
THCA	cis	rs7528684	0.934	rs2317231	ENSG00000236731.1	RP4-801G22.2	3.76	0.000194	0.0138	0.18	0.17	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157716547	chr1:157629939~157630728:-
THCA	cis	rs6723226	0.75	rs10182170	ENSG00000276517.1	AL133243.2	-3.76	0.000194	0.0138	-0.16	-0.17	Intelligence (multi-trait analysis);	chr2:32479118	chr2:32526504~32529507:+
THCA	cis	rs34421088	0.56	rs11780851	ENSG00000227888.4	FAM66A	-3.76	0.000194	0.0138	-0.22	-0.17	Neuroticism;	chr8:11543607	chr8:12362019~12388296:+
THCA	cis	rs193541	0.509	rs12109789	ENSG00000260686.1	CTB-36H16.2	-3.76	0.000194	0.0138	-0.16	-0.17	Glucose homeostasis traits;	chr5:122810924	chr5:122832356~122834533:+
THCA	cis	rs1923243	0.743	rs4622012	ENSG00000223479.3	RP4-788P17.1	3.76	0.000194	0.0138	0.18	0.17	Migraine;	chr1:73115751	chr1:73635216~73715214:+
THCA	cis	rs13098911	0.54	rs71327017	ENSG00000226074.4	PRSS44	-3.76	0.000194	0.0138	-0.33	-0.17	Celiac disease;	chr3:46069721	chr3:46809359~46812558:-
THCA	cis	rs4578769	0.918	rs1902920	ENSG00000265939.1	UBE2CP2	3.76	0.000194	0.0138	0.21	0.17	Eosinophil percentage of white cells;	chr18:22964688	chr18:22900486~22900995:-
THCA	cis	rs153852	0.811	rs36727	ENSG00000243806.1	RPL7P18	-3.76	0.000194	0.0138	-0.23	-0.17	Cancer;	chr5:94824464	chr5:94825961~94826694:-
THCA	cis	rs1612141	1	rs1778381	ENSG00000251363.2	RP11-129M6.1	-3.76	0.000194	0.0138	-0.25	-0.17	QT interval (drug interaction);	chr14:41233328	chr14:40954898~40975877:+
THCA	cis	rs1005277	0.579	rs2505194	ENSG00000120555.12	SEPT7P9	3.76	0.000194	0.0138	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38383069~38402916:-
THCA	cis	rs36093844	0.576	rs57125313	ENSG00000279742.1	RP11-700A24.1	-3.76	0.000194	0.0138	-0.22	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85962793	chr11:85852557~85854943:-
THCA	cis	rs9291683	0.609	rs13141233	ENSG00000261490.1	RP11-448G15.3	3.76	0.000194	0.0138	0.1	0.17	Bone mineral density;	chr4:10027105	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.609	rs34709913	ENSG00000261490.1	RP11-448G15.3	3.76	0.000194	0.0138	0.1	0.17	Bone mineral density;	chr4:10027331	chr4:10068089~10073019:-
THCA	cis	rs4819052	1	rs3746980	ENSG00000182586.6	LINC00334	-3.76	0.000194	0.0138	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45234340~45258730:+
THCA	cis	rs1908814	0.516	rs58869268	ENSG00000255495.1	AC145124.2	3.76	0.000194	0.0138	0.2	0.17	Neuroticism;	chr8:11939586	chr8:12194467~12196280:+
THCA	cis	rs3748656	0.945	rs34107138	ENSG00000273483.1	RP4-671G15.2	3.76	0.000194	0.0138	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112594948	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.945	rs12049572	ENSG00000273483.1	RP4-671G15.2	3.76	0.000194	0.0138	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112597961	chr1:112517799~112518441:-
THCA	cis	rs310333	1	rs310333	ENSG00000260185.1	RP11-432I5.6	3.76	0.000194	0.0138	0.24	0.17	Intelligence (multi-trait analysis);	chr16:71545764	chr16:71655027~71664212:+
THCA	cis	rs791590	0.715	rs7093069	ENSG00000225948.2	RP11-554I8.1	3.76	0.000194	0.0138	0.23	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6021356	chr10:6618716~6625346:+
THCA	cis	rs17194490	0.665	rs13072786	ENSG00000237990.3	CNTN4-AS1	3.76	0.000194	0.0138	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2530907	chr3:3039033~3069242:-
THCA	cis	rs12681366	0.801	rs2919658	ENSG00000253175.1	RP11-267M23.6	3.76	0.000194	0.0138	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:94565036~94565715:+
THCA	cis	rs150992	0.673	rs161953	ENSG00000241597.2	CTD-2007H13.1	-3.76	0.000194	0.0138	-0.22	-0.17	Body mass index;	chr5:98921201	chr5:98954394~98954972:+
THCA	cis	rs150992	0.673	rs161952	ENSG00000241597.2	CTD-2007H13.1	-3.76	0.000194	0.0138	-0.22	-0.17	Body mass index;	chr5:98921665	chr5:98954394~98954972:+
THCA	cis	rs7520050	0.807	rs28844317	ENSG00000281133.1	AL355480.3	-3.76	0.000194	0.0138	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.807	rs6429576	ENSG00000281133.1	AL355480.3	-3.76	0.000194	0.0138	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45580892~45580996:-
THCA	cis	rs1580019	0.537	rs7804609	ENSG00000273014.1	RP11-225B17.2	3.76	0.000194	0.0138	0.18	0.17	Cognitive ability;	chr7:32518482	chr7:32758882~32759353:+
THCA	cis	rs6598955	0.67	rs10794525	ENSG00000236782.4	RP11-96L14.7	-3.76	0.000194	0.0138	-0.21	-0.17	Obesity-related traits;	chr1:26210702	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.67	rs6676619	ENSG00000236782.4	RP11-96L14.7	-3.76	0.000194	0.0138	-0.21	-0.17	Obesity-related traits;	chr1:26212544	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.67	rs7531518	ENSG00000236782.4	RP11-96L14.7	-3.76	0.000194	0.0138	-0.21	-0.17	Obesity-related traits;	chr1:26213258	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.67	rs12733645	ENSG00000236782.4	RP11-96L14.7	-3.76	0.000194	0.0138	-0.21	-0.17	Obesity-related traits;	chr1:26213865	chr1:26169947~26171821:-
THCA	cis	rs1059312	1	rs3825180	ENSG00000279500.1	RP11-21K12.2	3.76	0.000194	0.0138	0.11	0.17	Systemic lupus erythematosus;	chr12:128794697	chr12:128813186~128814750:-
THCA	cis	rs4965593	0.526	rs4965298	ENSG00000278456.1	RP11-66B24.9	-3.76	0.000194	0.0138	-0.23	-0.17	Height;	chr15:100262561	chr15:100888472~100889106:-
THCA	cis	rs9467773	0.62	rs9467810	ENSG00000228223.2	HCG11	-3.76	0.000194	0.0138	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26523450~26526579:+
THCA	cis	rs60180747	0.909	rs78921612	ENSG00000261318.1	RP11-653J6.1	3.76	0.000194	0.0138	0.24	0.17	Testicular germ cell tumor;	chr15:66533699	chr15:66278498~66293357:-
THCA	cis	rs13108904	0.935	rs1620928	ENSG00000254094.1	AC078852.1	3.76	0.000194	0.0138	0.19	0.17	Obesity-related traits;	chr4:1285336	chr4:1356581~1358075:+
THCA	cis	rs9425766	0.962	rs1322777	ENSG00000270084.1	GAS5-AS1	-3.76	0.000194	0.0138	-0.17	-0.17	Life satisfaction;	chr1:173889962	chr1:173863248~173863941:+
THCA	cis	rs7927592	0.913	rs7106339	ENSG00000160172.9	FAM86C2P	3.76	0.000194	0.0138	0.17	0.17	Total body bone mineral density;	chr11:68472773	chr11:67791648~67805336:-
THCA	cis	rs889398	0.904	rs6499244	ENSG00000226232.7	RP11-419C5.2	-3.76	0.000194	0.0138	-0.16	-0.17	Body mass index;	chr16:69701368	chr16:69976388~69996188:-
THCA	cis	rs13113518	0.678	rs13149568	ENSG00000223305.1	RN7SKP30	3.76	0.000194	0.0138	0.22	0.17	Height;	chr4:55370412	chr4:55540502~55540835:-
THCA	cis	rs10540	1	rs35898083	ENSG00000279672.1	CMB9-55F22.1	3.76	0.000194	0.0138	0.34	0.17	Body mass index;	chr11:484469	chr11:779617~780755:+
THCA	cis	rs10540	0.908	rs71487293	ENSG00000279672.1	CMB9-55F22.1	3.76	0.000194	0.0138	0.34	0.17	Body mass index;	chr11:486414	chr11:779617~780755:+
THCA	cis	rs10540	1	rs61876332	ENSG00000279672.1	CMB9-55F22.1	3.76	0.000194	0.0138	0.34	0.17	Body mass index;	chr11:487101	chr11:779617~780755:+
THCA	cis	rs9316337	0.549	rs4769165	ENSG00000236953.1	ZDHHC20-IT1	-3.76	0.000194	0.0138	-0.19	-0.17	Schizophrenia;	chr13:21435947	chr13:21376977~21377874:-
THCA	cis	rs17604090	0.823	rs28415620	ENSG00000227855.3	DPY19L2P3	3.76	0.000194	0.0138	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29661488	chr7:29650227~29742594:+
THCA	cis	rs17604090	0.878	rs4457221	ENSG00000227855.3	DPY19L2P3	3.76	0.000194	0.0138	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29662158	chr7:29650227~29742594:+
THCA	cis	rs17604090	0.878	rs10262227	ENSG00000227855.3	DPY19L2P3	3.76	0.000194	0.0138	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29664457	chr7:29650227~29742594:+
THCA	cis	rs2842346	0.549	rs1859302	ENSG00000258623.1	CTD-2325P2.3	-3.76	0.000194	0.0138	-0.22	-0.17	Breast cancer;	chr14:68539468	chr14:68683411~68685565:-
THCA	cis	rs875971	1	rs1144895	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000194	0.0138	-0.18	-0.17	Aortic root size;	chr7:66076320	chr7:66025126~66031544:-
THCA	cis	rs12188164	0.543	rs7728027	ENSG00000188242.4	PP7080	-3.76	0.000194	0.0138	-0.15	-0.17	Cystic fibrosis severity;	chr5:459828	chr5:466124~473098:-
THCA	cis	rs7412746	0.563	rs3768013	ENSG00000224800.1	RP11-235D19.2	-3.76	0.000194	0.0138	-0.23	-0.17	Melanoma;	chr1:150842935	chr1:150881236~150881683:-
THCA	cis	rs4950322	0.947	rs72694723	ENSG00000180867.10	PDIA3P1	3.76	0.000194	0.0138	0.18	0.17	Protein quantitative trait loci;	chr1:147373174	chr1:147178113~147179622:+
THCA	cis	rs4262150	0.726	rs4958568	ENSG00000253921.1	CTB-113P19.3	3.76	0.000194	0.0138	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152636533	chr5:151753992~151767247:+
THCA	cis	rs295490	0.748	rs77036655	ENSG00000272656.1	RP11-219D15.3	3.76	0.000194	0.0138	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139436231	chr3:139349024~139349371:-
THCA	cis	rs3087591	0.708	rs2525568	ENSG00000263535.1	AK4P1	3.76	0.000194	0.0138	0.2	0.17	Hip circumference;	chr17:31348860	chr17:31345521~31346187:+
THCA	cis	rs7200543	1	rs4985154	ENSG00000260735.1	RP11-72I8.1	-3.76	0.000194	0.0138	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:15094411~15109197:+
THCA	cis	rs7200543	1	rs34614532	ENSG00000260735.1	RP11-72I8.1	-3.76	0.000194	0.0138	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:15094411~15109197:+
THCA	cis	rs6142618	0.84	rs2424882	ENSG00000224452.1	RSL24D1P6	-3.76	0.000194	0.0138	-0.21	-0.17	Inflammatory bowel disease;	chr20:32391408	chr20:32170390~32170790:-
THCA	cis	rs5758659	0.652	rs133336	ENSG00000234009.1	RPL5P34	-3.76	0.000194	0.0138	-0.16	-0.17	Cognitive function;	chr22:42020299	chr22:42776406~42777296:-
THCA	cis	rs478304	0.754	rs2004649	ENSG00000245532.5	NEAT1	-3.76	0.000194	0.0138	-0.12	-0.17	Acne (severe);	chr11:65613445	chr11:65422774~65445540:+
THCA	cis	rs11758351	0.925	rs2183948	ENSG00000216331.1	HIST1H1PS1	3.76	0.000194	0.0138	0.28	0.17	Renal underexcretion gout;Gout;	chr6:26180104	chr6:26195566~26195771:+
THCA	cis	rs1023500	0.505	rs2143139	ENSG00000182057.4	OGFRP1	3.76	0.000194	0.0138	0.2	0.17	Schizophrenia;	chr22:42218395	chr22:42269753~42275196:+
THCA	cis	rs6496044	0.568	rs1351196	ENSG00000259630.2	CTD-2262B20.1	-3.76	0.000194	0.0138	-0.18	-0.17	Interstitial lung disease;	chr15:85534173	chr15:85415228~85415633:+
THCA	cis	rs1913185	0.787	rs2864794	ENSG00000240032.1	RP11-274H2.3	-3.76	0.000194	0.0138	-0.26	-0.17	Obesity-related traits;	chr3:146148583	chr3:146066344~146069185:-
THCA	cis	rs10090774	0.965	rs7840381	ENSG00000280303.2	ERICD	3.76	0.000194	0.0138	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140764183	chr8:140636281~140638283:+
THCA	cis	rs10419113	0.668	rs2360533	ENSG00000268545.1	VN1R107P	3.76	0.000194	0.0138	0.2	0.17	Pediatric bone mineral density (spine);	chr19:57668907	chr19:57459912~57460120:+
THCA	cis	rs57709857	0.957	rs1488936	ENSG00000272092.1	RP11-350N15.5	-3.76	0.000194	0.0138	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38356221	chr8:38382364~38383461:+
THCA	cis	rs2436845	0.772	rs3018952	ENSG00000253669.3	KB-1732A1.1	-3.76	0.000194	0.0138	-0.18	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102803270	chr8:102805517~102809971:+
THCA	cis	rs2153535	0.585	rs7762631	ENSG00000230939.1	RP11-314C16.1	3.76	0.000194	0.0138	0.18	0.17	Motion sickness;	chr6:8635339	chr6:8784178~8785445:+
THCA	cis	rs11673344	0.523	rs10420330	ENSG00000267260.1	CTD-2162K18.4	-3.76	0.000194	0.0138	-0.2	-0.17	Obesity-related traits;	chr19:37111269	chr19:36773153~36777078:+
THCA	cis	rs718433	0.585	rs4982491	ENSG00000211778.2	TRAV4	-3.76	0.000194	0.0138	-0.13	-0.17	Intraocular pressure;	chr14:21742958	chr14:21736152~21736982:+
THCA	cis	rs7772697	0.508	rs4332004	ENSG00000223701.3	RAET1E-AS1	-3.76	0.000194	0.0138	-0.24	-0.17	Diabetic retinopathy;	chr6:149050476	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.508	rs6930713	ENSG00000223701.3	RAET1E-AS1	-3.76	0.000194	0.0138	-0.24	-0.17	Diabetic retinopathy;	chr6:149056474	chr6:149884431~149919508:+
THCA	cis	rs7665090	0.967	rs6533022	ENSG00000248971.2	KRT8P46	-3.76	0.000194	0.0138	-0.2	-0.17	Primary biliary cholangitis;	chr4:102637794	chr4:102728746~102730171:-
THCA	cis	rs61160187	0.788	rs12519587	ENSG00000251279.1	CTC-436P18.1	-3.76	0.000194	0.0138	-0.21	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60791073	chr5:61162070~61232040:+
THCA	cis	rs3768792	0.731	rs2371788	ENSG00000196096.3	AC079610.2	-3.76	0.000194	0.0138	-0.24	-0.17	Systemic lupus erythematosus;	chr2:212988479	chr2:213276552~213284205:-
THCA	cis	rs3768792	0.665	rs62187817	ENSG00000196096.3	AC079610.2	-3.76	0.000194	0.0138	-0.24	-0.17	Systemic lupus erythematosus;	chr2:212991174	chr2:213276552~213284205:-
THCA	cis	rs9611565	0.659	rs56364401	ENSG00000237037.8	NDUFA6-AS1	3.76	0.000195	0.0138	0.16	0.17	Vitiligo;	chr22:41555239	chr22:42090931~42137742:+
THCA	cis	rs6504622	0.818	rs9303532	ENSG00000238419.1	RNU7-186P	-3.76	0.000195	0.0138	-0.19	-0.17	Orofacial clefts;	chr17:46956636	chr17:47259358~47259420:-
THCA	cis	rs6504622	0.818	rs9910899	ENSG00000238419.1	RNU7-186P	3.76	0.000195	0.0138	0.19	0.17	Orofacial clefts;	chr17:46956976	chr17:47259358~47259420:-
THCA	cis	rs6504622	0.818	rs9912794	ENSG00000238419.1	RNU7-186P	3.76	0.000195	0.0138	0.19	0.17	Orofacial clefts;	chr17:46957075	chr17:47259358~47259420:-
THCA	cis	rs6504622	0.818	rs9898527	ENSG00000238419.1	RNU7-186P	3.76	0.000195	0.0138	0.19	0.17	Orofacial clefts;	chr17:46958844	chr17:47259358~47259420:-
THCA	cis	rs6504622	0.791	rs61671555	ENSG00000238419.1	RNU7-186P	3.76	0.000195	0.0138	0.19	0.17	Orofacial clefts;	chr17:46960491	chr17:47259358~47259420:-
THCA	cis	rs9291683	0.609	rs13149985	ENSG00000261490.1	RP11-448G15.3	3.76	0.000195	0.0138	0.1	0.17	Bone mineral density;	chr4:10026766	chr4:10068089~10073019:-
THCA	cis	rs11233413	1	rs2127361	ENSG00000246067.6	RAB30-AS1	-3.76	0.000195	0.0138	-0.17	-0.17	Economic and political preferences (feminism/equality);	chr11:83005476	chr11:83072066~83106719:+
THCA	cis	rs72775230	0.755	rs11816084	ENSG00000233990.1	RP11-401E9.3	3.76	0.000195	0.0138	0.28	0.17	Conotruncal heart defects (inherited effects);	chr10:8519464	chr10:7833618~7833957:-
THCA	cis	rs4869313	0.668	rs2549787	ENSG00000247121.5	CTD-2260A17.2	3.76	0.000195	0.0138	0.13	0.17	Pediatric autoimmune diseases;	chr5:96904133	chr5:96814028~96935809:-
THCA	cis	rs4950322	0.512	rs2353981	ENSG00000271721.1	RP11-337C18.9	-3.76	0.000195	0.0138	-0.18	-0.17	Protein quantitative trait loci;	chr1:147368365	chr1:147175602~147177740:+
THCA	cis	rs2562456	0.833	rs2968078	ENSG00000268278.1	RP11-420K14.1	-3.76	0.000195	0.0138	-0.21	-0.17	Pain;	chr19:21458942	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.755	rs2650773	ENSG00000268278.1	RP11-420K14.1	-3.76	0.000195	0.0138	-0.21	-0.17	Pain;	chr19:21461286	chr19:21637974~21656300:+
THCA	cis	rs875971	0.545	rs73376401	ENSG00000273024.4	INTS4P2	-3.76	0.000195	0.0138	-0.21	-0.17	Aortic root size;	chr7:66174841	chr7:65647864~65715661:+
THCA	cis	rs3758911	0.964	rs11212158	ENSG00000255353.1	RP11-382M14.1	-3.76	0.000195	0.0138	-0.21	-0.17	Coronary artery disease;	chr11:107325745	chr11:107176286~107177530:+
THCA	cis	rs7296418	0.517	rs73231928	ENSG00000256092.2	RP13-942N8.1	3.76	0.000195	0.0138	0.12	0.17	Platelet count;	chr12:123239778	chr12:123363868~123366113:+
THCA	cis	rs3743772	0.881	rs62048523	ENSG00000279344.1	RP11-44F14.7	3.76	0.000195	0.0138	0.3	0.17	Depressive symptoms (SSRI exposure interaction);	chr16:53471465	chr16:53478957~53481550:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000230295.1	RP11-458F8.2	3.76	0.000195	0.0138	0.13	0.17	Aortic root size;	chr7:66642265	chr7:66880708~66882981:+
THCA	cis	rs11640533	0.901	rs2908792	ENSG00000279344.1	RP11-44F14.7	3.76	0.000195	0.0138	0.17	0.17	Intelligence (multi-trait analysis);	chr16:53378507	chr16:53478957~53481550:-
THCA	cis	rs1440410	0.835	rs4594668	ENSG00000250326.1	RP11-284M14.1	3.76	0.000195	0.0138	0.15	0.17	Ischemic stroke;	chr4:143129293	chr4:142933195~143184861:-
THCA	cis	rs12291225	0.679	rs11605531	ENSG00000251991.1	RNU7-49P	3.76	0.000195	0.0138	0.2	0.17	Sense of smell;	chr11:14270048	chr11:14478892~14478953:+
THCA	cis	rs12291225	0.639	rs61883858	ENSG00000251991.1	RNU7-49P	3.76	0.000195	0.0138	0.2	0.17	Sense of smell;	chr11:14273162	chr11:14478892~14478953:+
THCA	cis	rs12291225	0.679	rs11023170	ENSG00000251991.1	RNU7-49P	3.76	0.000195	0.0138	0.2	0.17	Sense of smell;	chr11:14273363	chr11:14478892~14478953:+
THCA	cis	rs7178375	1	rs10163148	ENSG00000269930.1	RP11-932O9.9	-3.76	0.000195	0.0138	-0.24	-0.17	Hypertriglyceridemia;	chr15:30920481	chr15:30616958~30617749:+
THCA	cis	rs1383484	0.575	rs986118	ENSG00000259728.4	LINC00933	-3.76	0.000195	0.0138	-0.21	-0.17	Height;	chr15:83946437	chr15:84570649~84580175:+
THCA	cis	rs295490	0.748	rs17395611	ENSG00000272656.1	RP11-219D15.3	-3.76	0.000195	0.0138	-0.32	-0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139425773	chr3:139349024~139349371:-
THCA	cis	rs10903027	0.963	rs10903028	ENSG00000224183.1	SDHDP6	3.76	0.000195	0.0138	0.23	0.17	IgG glycosylation;	chr1:25076700	chr1:25294164~25294643:-
THCA	cis	rs11098499	0.69	rs34818745	ENSG00000249244.1	RP11-548H18.2	3.76	0.000195	0.0139	0.2	0.17	Corneal astigmatism;	chr4:119335900	chr4:119391831~119395335:-
THCA	cis	rs559555	0.512	rs655548	ENSG00000276517.1	AL133243.2	-3.76	0.000195	0.0139	-0.16	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31611589	chr2:32526504~32529507:+
THCA	cis	rs1520333	0.54	rs13282611	ENSG00000254352.1	RP11-578O24.2	-3.76	0.000195	0.0139	-0.19	-0.17	Multiple sclerosis;	chr8:78452661	chr8:78723796~78724136:-
THCA	cis	rs10090774	0.87	rs11782305	ENSG00000280303.2	ERICD	-3.76	0.000195	0.0139	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140995572	chr8:140636281~140638283:+
THCA	cis	rs3864261	0.836	rs34648	ENSG00000249085.1	CTD-2631K10.1	-3.76	0.000195	0.0139	-0.27	-0.17	Discordance in emotional problems in monozygotic twins;	chr5:72816594	chr5:72794405~72816565:-
THCA	cis	rs56046484	0.871	rs35000527	ENSG00000218052.5	ADAMTS7P4	-3.76	0.000195	0.0139	-0.28	-0.17	Testicular germ cell tumor;	chr15:85010550	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.826	rs35816571	ENSG00000218052.5	ADAMTS7P4	-3.76	0.000195	0.0139	-0.28	-0.17	Testicular germ cell tumor;	chr15:85010891	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.871	rs12900736	ENSG00000218052.5	ADAMTS7P4	-3.76	0.000195	0.0139	-0.28	-0.17	Testicular germ cell tumor;	chr15:85014909	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.871	rs12904958	ENSG00000218052.5	ADAMTS7P4	-3.76	0.000195	0.0139	-0.28	-0.17	Testicular germ cell tumor;	chr15:85014956	chr15:85255369~85330334:-
THCA	cis	rs9863	0.536	rs4765568	ENSG00000270061.1	RP11-214K3.19	3.76	0.000195	0.0139	0.26	0.17	White blood cell count;	chr12:123994614	chr12:123969990~123970344:-
THCA	cis	rs17092148	0.666	rs62212084	ENSG00000276073.1	RP5-1125A11.7	3.76	0.000195	0.0139	0.19	0.17	Neuroticism;	chr20:34871048	chr20:33985617~33988989:-
THCA	cis	rs113817606	1	rs113817606	ENSG00000250999.1	RP11-1379J22.5	-3.76	0.000195	0.0139	-0.36	-0.17	Daytime sleep phenotypes;	chr5:179629159	chr5:179657762~179664432:+
THCA	cis	rs7267979	0.932	rs4280527	ENSG00000276952.1	RP5-965G21.6	3.76	0.000195	0.0139	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25284915~25285588:-
THCA	cis	rs12332430	1	rs12332430	ENSG00000247199.3	RP11-373N22.3	-3.76	0.000195	0.0139	-0.39	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;	chr5:148170734	chr5:148268307~148383783:-
THCA	cis	rs56804039	1	rs17616779	ENSG00000254153.1	CTA-398F10.2	-3.76	0.000195	0.0139	-0.21	-0.17	Cervical cancer;	chr8:8524864	chr8:8456909~8461337:-
THCA	cis	rs9393813	0.516	rs4711152	ENSG00000216915.2	RP1-97D16.1	-3.76	0.000195	0.0139	-0.23	-0.17	Bipolar disorder;	chr6:27412423	chr6:27737000~27738494:-
THCA	cis	rs7267979	0.789	rs9927	ENSG00000276952.1	RP5-965G21.6	3.75	0.000195	0.0139	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25284915~25285588:-
THCA	cis	rs10090774	0.965	rs11780030	ENSG00000280303.2	ERICD	-3.75	0.000195	0.0139	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140997644	chr8:140636281~140638283:+
THCA	cis	rs12234571	1	rs17157676	ENSG00000214293.7	APTR	3.75	0.000195	0.0139	0.21	0.17	Obesity-related traits;	chr7:77778063	chr7:77657660~77696265:-
THCA	cis	rs12234571	1	rs3814468	ENSG00000214293.7	APTR	3.75	0.000195	0.0139	0.21	0.17	Obesity-related traits;	chr7:77782409	chr7:77657660~77696265:-
THCA	cis	rs10496034	0.542	rs72797538	ENSG00000240401.7	AC012358.8	3.75	0.000195	0.0139	0.34	0.17	Refractive astigmatism;	chr2:55150974	chr2:55282350~55346049:+
THCA	cis	rs61160187	0.582	rs4700402	ENSG00000272308.1	RP11-231G3.1	-3.75	0.000195	0.0139	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.549	rs61017995	ENSG00000272308.1	RP11-231G3.1	-3.75	0.000195	0.0139	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.556	rs62367862	ENSG00000272308.1	RP11-231G3.1	-3.75	0.000195	0.0139	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs2898309	ENSG00000272308.1	RP11-231G3.1	-3.75	0.000195	0.0139	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.576	rs10805374	ENSG00000272308.1	RP11-231G3.1	-3.75	0.000195	0.0139	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60866457~60866935:-
THCA	cis	rs9970334	0.596	rs709209	ENSG00000225077.2	LINC00337	-3.75	0.000195	0.0139	-0.22	-0.17	Resting heart rate;	chr1:6218354	chr1:6236240~6239444:+
THCA	cis	rs6942407	0.592	rs886787	ENSG00000224046.1	AC005076.5	-3.75	0.000195	0.0139	-0.17	-0.17	Food allergy;	chr7:87220894	chr7:87151423~87152420:-
THCA	cis	rs4489787	0.568	rs2731065	ENSG00000240399.1	RP1-228P16.1	3.75	0.000195	0.0139	0.19	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48499140	chr12:48054813~48055591:-
THCA	cis	rs1959947	0.876	rs28493104	ENSG00000251363.2	RP11-129M6.1	-3.75	0.000195	0.0139	-0.23	-0.17	Hemostatic factors and hematological phenotypes;	chr14:41049241	chr14:40954898~40975877:+
THCA	cis	rs7336933	0.74	rs1331038	ENSG00000278338.3	VWA8-AS1	-3.75	0.000195	0.0139	-0.28	-0.17	Calcium levels;	chr13:41835707	chr13:41955808~41981565:+
THCA	cis	rs2562456	0.837	rs11085462	ENSG00000268658.4	LINC00664	3.75	0.000195	0.0139	0.25	0.17	Pain;	chr19:21567449	chr19:21483374~21503238:+
THCA	cis	rs11658311	0.85	rs7215055	ENSG00000226478.3	UPF3AP1	-3.75	0.000195	0.0139	-0.42	-0.17	Obsessive-compulsive symptoms;	chr17:17555039	chr17:16745636~16746761:-
THCA	cis	rs7520050	0.807	rs28647556	ENSG00000281133.1	AL355480.3	-3.75	0.000195	0.0139	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.807	rs4274104	ENSG00000281133.1	AL355480.3	-3.75	0.000195	0.0139	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45580892~45580996:-
THCA	cis	rs10760158	0.8	rs4837829	ENSG00000235865.2	GSN-AS1	3.75	0.000195	0.0139	0.15	0.17	Pulse pressure;	chr9:121283680	chr9:121280768~121285530:-
THCA	cis	rs755249	0.567	rs4660603	ENSG00000182109.6	RP11-69E11.4	-3.75	0.000195	0.0139	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39522280~39546187:-
THCA	cis	rs7208859	0.673	rs216424	ENSG00000265443.1	CTD-2349P21.6	-3.75	0.000195	0.0139	-0.27	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30726305~30727564:-
THCA	cis	rs7259376	0.503	rs1704013	ENSG00000269138.1	ZNF209P	3.75	0.000195	0.0139	0.16	0.17	Menopause (age at onset);	chr19:22455584	chr19:22463922~22473036:+
THCA	cis	rs354225	0.539	rs10169439	ENSG00000162997.14	PRORSD1P	-3.75	0.000195	0.0139	-0.2	-0.17	Schizophrenia;	chr2:54732553	chr2:55282319~55284522:+
THCA	cis	rs1864585	0.52	rs17720365	ENSG00000280294.1	RP11-177H2.1	-3.75	0.000195	0.0139	-0.17	-0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10821989	chr8:10856085~10859436:-
THCA	cis	rs832540	0.902	rs194059	ENSG00000271828.1	CTD-2310F14.1	-3.75	0.000195	0.0139	-0.23	-0.17	Coronary artery disease;	chr5:56901589	chr5:56927874~56929573:+
THCA	cis	rs1962772	0.505	rs6586608	ENSG00000279903.1	RP11-349F21.5	3.75	0.000195	0.0139	0.21	0.17	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17512143	chr8:17500012~17500605:+
THCA	cis	rs2694917	0.632	rs2638315	ENSG00000257576.1	RP11-153M3.1	3.75	0.000195	0.0139	0.26	0.17	Blood metabolite ratios;	chr12:56471272	chr12:56511002~56512703:+
THCA	cis	rs10129255	0.872	rs8015406	ENSG00000280411.1	IGHV1-69-2	-3.75	0.000196	0.0139	-0.11	-0.17	Kawasaki disease;	chr14:106670611	chr14:106762092~106762588:-
THCA	cis	rs16975963	0.793	rs59616348	ENSG00000226686.6	LINC01535	-3.75	0.000196	0.0139	-0.23	-0.17	Longevity;	chr19:37957113	chr19:37251912~37265535:+
THCA	cis	rs3748656	1	rs12130243	ENSG00000273483.1	RP4-671G15.2	3.75	0.000196	0.0139	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112627045	chr1:112517799~112518441:-
THCA	cis	rs3748656	1	rs12040988	ENSG00000273483.1	RP4-671G15.2	3.75	0.000196	0.0139	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112631182	chr1:112517799~112518441:-
THCA	cis	rs4950322	0.547	rs61838945	ENSG00000226015.2	CCT8P1	3.75	0.000196	0.0139	0.19	0.17	Protein quantitative trait loci;	chr1:147111477	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.563	rs6686480	ENSG00000226015.2	CCT8P1	3.75	0.000196	0.0139	0.19	0.17	Protein quantitative trait loci;	chr1:147111986	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.563	rs6700783	ENSG00000226015.2	CCT8P1	3.75	0.000196	0.0139	0.19	0.17	Protein quantitative trait loci;	chr1:147111987	chr1:147203276~147204932:-
THCA	cis	rs721048	0.79	rs62180323	ENSG00000242412.1	DBIL5P2	-3.75	0.000196	0.0139	-0.23	-0.17	Prostate cancer;	chr2:63185154	chr2:63117851~63119542:-
THCA	cis	rs1050846	0.603	rs1050847	ENSG00000269901.1	RP11-178L8.9	3.75	0.000196	0.0139	0.2	0.17	Neuroticism;	chr16:87410128	chr16:87362536~87367476:+
THCA	cis	rs17689437	0.958	rs11075683	ENSG00000275383.1	RP11-615I2.6	3.75	0.000196	0.0139	0.27	0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68547574	chr16:68591382~68594424:+
THCA	cis	rs972578	1	rs2267480	ENSG00000230319.1	AL022476.2	3.75	0.000196	0.0139	0.18	0.17	Mean platelet volume;	chr22:42966970	chr22:43038585~43052366:+
THCA	cis	rs10875746	0.855	rs12296244	ENSG00000258234.1	RP11-370I10.2	3.75	0.000196	0.0139	0.2	0.17	Longevity (90 years and older);	chr12:48047696	chr12:48231098~48284210:-
THCA	cis	rs6545883	0.868	rs28749199	ENSG00000212978.6	AC016747.3	3.75	0.000196	0.0139	0.19	0.17	Tuberculosis;	chr2:61599917	chr2:61141592~61144969:-
THCA	cis	rs4588572	0.688	rs11743511	ENSG00000245556.2	SCAMP1-AS1	-3.75	0.000196	0.0139	-0.13	-0.17	Triglycerides;	chr5:78396995	chr5:78342365~78360507:-
THCA	cis	rs1865760	0.532	rs1061482	ENSG00000272810.1	U91328.22	-3.75	0.000196	0.0139	-0.13	-0.17	Height;	chr6:26086471	chr6:26013241~26013757:+
THCA	cis	rs9880211	0.679	rs9818740	ENSG00000239213.4	NCK1-AS1	3.75	0.000196	0.0139	0.18	0.17	Height;Body mass index;	chr3:136220744	chr3:136841726~136862054:-
THCA	cis	rs10540	1	rs61876334	ENSG00000279672.1	CMB9-55F22.1	3.75	0.000196	0.0139	0.34	0.17	Body mass index;	chr11:487201	chr11:779617~780755:+
THCA	cis	rs9329221	0.662	rs13254942	ENSG00000253641.4	RP11-981G7.2	-3.75	0.000196	0.0139	-0.17	-0.17	Neuroticism;	chr8:10400168	chr8:10474565~10481974:+
THCA	cis	rs12681366	0.571	rs2919654	ENSG00000261437.1	RP11-22C11.2	3.75	0.000196	0.0139	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94464045	chr8:94637285~94639467:-
THCA	cis	rs927833	0.502	rs2424409	ENSG00000214535.3	RPS15AP1	-3.75	0.000196	0.0139	-0.26	-0.17	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr20:21948413	chr20:21166206~21166596:-
THCA	cis	rs7264396	0.887	rs10359	ENSG00000088340.14	FER1L4	3.75	0.000196	0.0139	0.16	0.17	Total cholesterol levels;	chr20:35511960	chr20:35558737~35607562:-
THCA	cis	rs9393777	0.778	rs13212921	ENSG00000220721.1	OR1F12	3.75	0.000196	0.0139	0.33	0.17	Intelligence (multi-trait analysis);	chr6:27237643	chr6:28073316~28074233:+
THCA	cis	rs7900823	0.528	rs2085471	ENSG00000230500.1	MKX-AS1	3.75	0.000196	0.0139	0.23	0.17	Lung cancer;	chr10:28253194	chr10:27744786~27767794:+
THCA	cis	rs10266483	0.921	rs624257	ENSG00000271550.1	BNIP3P11	-3.75	0.000196	0.0139	-0.2	-0.17	Response to statin therapy;	chr7:64284848	chr7:64678954~64687393:-
THCA	cis	rs2692947	0.667	rs4144055	ENSG00000235584.2	AC008268.1	-3.75	0.000196	0.0139	-0.17	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95982108	chr2:95666084~95668715:+
THCA	cis	rs2625529	0.824	rs12592044	ENSG00000260037.4	CTD-2524L6.3	-3.75	0.000196	0.0139	-0.24	-0.17	Red blood cell count;	chr15:72126774	chr15:71818396~71823384:+
THCA	cis	rs321358	0.895	rs73015171	ENSG00000271390.1	RP11-89C3.3	3.75	0.000196	0.0139	0.27	0.17	Body mass index;	chr11:111087535	chr11:111089870~111090368:-
THCA	cis	rs875971	0.66	rs6460308	ENSG00000230295.1	RP11-458F8.2	3.75	0.000196	0.0139	0.13	0.17	Aortic root size;	chr7:66619753	chr7:66880708~66882981:+
THCA	cis	rs853679	0.567	rs16894091	ENSG00000220721.1	OR1F12	-3.75	0.000196	0.0139	-0.21	-0.17	Depression;	chr6:28422360	chr6:28073316~28074233:+
THCA	cis	rs5758659	0.622	rs6519298	ENSG00000273366.1	CTA-989H11.1	-3.75	0.000196	0.0139	-0.21	-0.17	Cognitive function;	chr22:41968993	chr22:42278188~42278846:+
THCA	cis	rs10411161	0.702	rs1433081	ENSG00000275055.1	CTC-471J1.11	-3.75	0.000196	0.0139	-0.17	-0.17	Breast cancer;	chr19:51887457	chr19:52049007~52049754:+
THCA	cis	rs7127129	0.842	rs11235473	ENSG00000246889.2	AP000487.5	-3.75	0.000196	0.0139	-0.17	-0.17	Aortic root size;	chr11:70171328	chr11:70372246~70398488:-
THCA	cis	rs7829975	0.564	rs2921057	ENSG00000248538.5	RP11-10A14.5	-3.75	0.000196	0.0139	-0.22	-0.17	Mood instability;	chr8:8461157	chr8:9189011~9202854:+
THCA	cis	rs7819412	1	rs7819412	ENSG00000255046.1	RP11-297N6.4	-3.75	0.000196	0.0139	-0.18	-0.17	Triglycerides;	chr8:11187652	chr8:11797928~11802568:-
THCA	cis	rs11583043	0.575	rs7528842	ENSG00000233184.5	RP11-421L21.3	-3.75	0.000196	0.0139	-0.18	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101118107	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.575	rs56403901	ENSG00000233184.5	RP11-421L21.3	3.75	0.000196	0.0139	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101120491	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.575	rs12759611	ENSG00000233184.5	RP11-421L21.3	3.75	0.000196	0.0139	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101121589	chr1:101025878~101087268:+
THCA	cis	rs57709857	0.957	rs60558877	ENSG00000272092.1	RP11-350N15.5	-3.75	0.000196	0.0139	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38382980	chr8:38382364~38383461:+
THCA	cis	rs9926296	0.586	rs1800359	ENSG00000274627.1	RP11-104N10.2	-3.75	0.000196	0.0139	-0.18	-0.17	Vitiligo;	chr16:89738853	chr16:89516797~89522217:+
THCA	cis	rs8192917	0.573	rs12323930	ENSG00000258744.1	RP11-80A15.1	-3.75	0.000196	0.0139	-0.27	-0.17	Vitiligo;	chr14:24643627	chr14:24501594~24508688:+
THCA	cis	rs80130819	0.686	rs78239819	ENSG00000257735.1	RP11-370I10.6	-3.75	0.000196	0.0139	-0.34	-0.17	Prostate cancer;	chr12:48018767	chr12:48350945~48442411:+
THCA	cis	rs11633886	0.528	rs3914852	ENSG00000259200.1	RP11-718O11.1	3.75	0.000196	0.0139	0.21	0.17	Diisocyanate-induced asthma;	chr15:45808853	chr15:45705078~45931069:+
THCA	cis	rs6756513	0.505	rs17037076	ENSG00000231024.1	AC092431.3	-3.75	0.000196	0.0139	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69806517	chr2:69700192~69713847:-
THCA	cis	rs427394	0.582	rs274665	ENSG00000248677.1	CTD-2044J15.1	3.75	0.000196	0.0139	0.17	0.17	Menopause (age at onset);	chr5:6707868	chr5:6686325~6707711:-
THCA	cis	rs4460629	0.742	rs6427158	ENSG00000225855.5	RUSC1-AS1	3.75	0.000196	0.0139	0.11	0.17	Serum magnesium levels;	chr1:155102427	chr1:155316863~155324176:-
THCA	cis	rs7824557	0.564	rs2572395	ENSG00000255495.1	AC145124.2	-3.75	0.000196	0.0139	-0.19	-0.17	Retinal vascular caliber;	chr8:11377851	chr8:12194467~12196280:+
THCA	cis	rs9527	0.518	rs12771834	ENSG00000236937.2	PTGES3P4	3.75	0.000196	0.0139	0.31	0.17	Arsenic metabolism;	chr10:102895662	chr10:102845595~102845950:+
THCA	cis	rs586688	0.625	rs609396	ENSG00000224536.1	RP11-134G8.7	-3.75	0.000196	0.0139	-0.26	-0.17	Obesity-related traits;	chr1:201686105	chr1:201507241~201533608:+
THCA	cis	rs5753037	0.585	rs36572	ENSG00000279699.1	RP1-102K2.9	3.75	0.000196	0.0139	0.16	0.17	Type 1 diabetes;	chr22:29804947	chr22:30275215~30276951:-
THCA	cis	rs7824557	0.583	rs4448232	ENSG00000227888.4	FAM66A	3.75	0.000196	0.0139	0.22	0.17	Retinal vascular caliber;	chr8:11373845	chr8:12362019~12388296:+
THCA	cis	rs7665090	1	rs12498722	ENSG00000248971.2	KRT8P46	-3.75	0.000196	0.0139	-0.2	-0.17	Primary biliary cholangitis;	chr4:102633365	chr4:102728746~102730171:-
THCA	cis	rs2380205	0.517	rs17319759	ENSG00000232807.2	RP11-536K7.3	3.75	0.000196	0.0139	0.17	0.17	Breast cancer;	chr10:5920927	chr10:5934270~5945900:-
THCA	cis	rs9980	1	rs9980	ENSG00000226232.7	RP11-419C5.2	-3.75	0.000196	0.0139	-0.26	-0.17	Blood osmolality (transformed sodium);	chr16:69703565	chr16:69976388~69996188:-
THCA	cis	rs9980	1	rs1043470	ENSG00000226232.7	RP11-419C5.2	-3.75	0.000196	0.0139	-0.26	-0.17	Blood osmolality (transformed sodium);	chr16:69704005	chr16:69976388~69996188:-
THCA	cis	rs2562456	0.833	rs62107540	ENSG00000268278.1	RP11-420K14.1	3.75	0.000196	0.0139	0.24	0.17	Pain;	chr19:21335693	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62107541	ENSG00000268278.1	RP11-420K14.1	3.75	0.000196	0.0139	0.24	0.17	Pain;	chr19:21335733	chr19:21637974~21656300:+
THCA	cis	rs2898279	0.872	rs7830445	ENSG00000242296.2	DEFB109P1	-3.75	0.000196	0.0139	-0.23	-0.17	Small cell lung carcinoma;	chr8:11444552	chr8:12393209~12400366:-
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000182586.6	LINC00334	-3.75	0.000196	0.0139	-0.18	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45234340~45258730:+
THCA	cis	rs881375	0.967	rs2416806	ENSG00000270917.1	RP11-27I1.6	-3.75	0.000196	0.0139	-0.24	-0.17	Rheumatoid arthritis;	chr9:120928014	chr9:120812475~120812845:-
THCA	cis	rs881375	0.933	rs7028641	ENSG00000270917.1	RP11-27I1.6	-3.75	0.000196	0.0139	-0.24	-0.17	Rheumatoid arthritis;	chr9:120928863	chr9:120812475~120812845:-
THCA	cis	rs7824557	0.564	rs2572394	ENSG00000255495.1	AC145124.2	-3.75	0.000196	0.0139	-0.19	-0.17	Retinal vascular caliber;	chr8:11377884	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs2437152	ENSG00000255495.1	AC145124.2	-3.75	0.000196	0.0139	-0.19	-0.17	Retinal vascular caliber;	chr8:11377988	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs2736300	ENSG00000255495.1	AC145124.2	-3.75	0.000196	0.0139	-0.19	-0.17	Retinal vascular caliber;	chr8:11378070	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs2572392	ENSG00000255495.1	AC145124.2	-3.75	0.000196	0.0139	-0.19	-0.17	Retinal vascular caliber;	chr8:11378096	chr8:12194467~12196280:+
THCA	cis	rs10875746	0.556	rs4760619	ENSG00000258273.1	RP11-370I10.4	3.75	0.000196	0.0139	0.27	0.17	Longevity (90 years and older);	chr12:48106148	chr12:48333755~48333901:-
THCA	cis	rs7395662	0.889	rs11039754	ENSG00000200090.1	Y_RNA	-3.75	0.000196	0.0139	-0.12	-0.17	HDL cholesterol;	chr11:48453661	chr11:47726894~47726992:-
THCA	cis	rs55966801	0.841	rs11607019	ENSG00000277290.1	RP11-326C3.16	-3.75	0.000196	0.0139	-0.23	-0.17	Plateletcrit;	chr11:234349	chr11:243099~243483:-
THCA	cis	rs7665090	0.934	rs35112949	ENSG00000251288.2	RP11-10L12.2	-3.75	0.000196	0.0139	-0.22	-0.17	Primary biliary cholangitis;	chr4:102638473	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.87	rs34349956	ENSG00000251288.2	RP11-10L12.2	-3.75	0.000196	0.0139	-0.22	-0.17	Primary biliary cholangitis;	chr4:102638476	chr4:102751401~102752641:+
THCA	cis	rs12129938	0.911	rs1857004	ENSG00000231940.1	RPS7P3	-3.75	0.000196	0.0139	-0.22	-0.17	Thyroid cancer;	chr1:233287016	chr1:233288868~233289447:-
THCA	cis	rs753778	0.559	rs2288997	ENSG00000253210.1	RP11-809O17.1	3.75	0.000196	0.0139	0.22	0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141190632	chr8:141126044~141129961:-
THCA	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	3.75	0.000196	0.0139	0.22	0.17	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
THCA	cis	rs11992186	0.505	rs7845203	ENSG00000233609.3	RP11-62H7.2	3.75	0.000196	0.0139	0.17	0.17	Neuroticism;	chr8:8287918	chr8:8961200~8979025:+
THCA	cis	rs2235642	0.891	rs2281231	ENSG00000260989.1	LA16c-395F10.2	-3.75	0.000196	0.0139	-0.18	-0.17	Coronary artery disease;	chr16:1551878	chr16:1580527~1610328:+
THCA	cis	rs9796	0.689	rs13329537	ENSG00000247556.5	OIP5-AS1	-3.75	0.000196	0.0139	-0.14	-0.17	Menopause (age at onset);	chr15:41157013	chr15:41283990~41309737:+
THCA	cis	rs9905704	0.918	rs302858	ENSG00000224738.1	AC099850.1	3.75	0.000196	0.0139	0.23	0.17	Testicular germ cell tumor;	chr17:58615439	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs694720	ENSG00000224738.1	AC099850.1	3.75	0.000196	0.0139	0.23	0.17	Testicular germ cell tumor;	chr17:58630658	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs385793	ENSG00000224738.1	AC099850.1	3.75	0.000196	0.0139	0.23	0.17	Testicular germ cell tumor;	chr17:58653232	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.874	rs2643126	ENSG00000224738.1	AC099850.1	3.75	0.000196	0.0139	0.23	0.17	Testicular germ cell tumor;	chr17:58660404	chr17:59106598~59118267:+
THCA	cis	rs2797160	0.935	rs1739379	ENSG00000226409.1	RP11-735G4.1	3.75	0.000196	0.0139	0.2	0.17	Endometrial cancer;	chr6:125691447	chr6:125370211~125374324:-
THCA	cis	rs11960179	0.892	rs77858646	ENSG00000250066.1	RP11-141O11.1	-3.75	0.000196	0.0139	-0.31	-0.17	Glomerular filtration rate (creatinine);	chr5:68513838	chr5:68963246~68967845:+
THCA	cis	rs1023500	0.505	rs134888	ENSG00000273366.1	CTA-989H11.1	-3.75	0.000196	0.0139	-0.21	-0.17	Schizophrenia;	chr22:42278275	chr22:42278188~42278846:+
THCA	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
THCA	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	3.75	0.000196	0.0139	0.35	0.17	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
THCA	cis	rs10504130	0.696	rs17212214	ENSG00000272024.1	RP11-546K22.3	3.75	0.000196	0.0139	0.19	0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51950284~51950690:+
THCA	cis	rs13256369	0.802	rs13256404	ENSG00000254153.1	CTA-398F10.2	-3.75	0.000196	0.0139	-0.2	-0.17	Obesity-related traits;	chr8:8705464	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.756	rs13280759	ENSG00000254153.1	CTA-398F10.2	-3.75	0.000196	0.0139	-0.2	-0.17	Obesity-related traits;	chr8:8705485	chr8:8456909~8461337:-
THCA	cis	rs10090774	0.932	rs11998619	ENSG00000280303.2	ERICD	-3.75	0.000196	0.0139	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140885597	chr8:140636281~140638283:+
THCA	cis	rs6969780	0.63	rs3735530	ENSG00000233429.8	HOTAIRM1	-3.75	0.000196	0.0139	-0.21	-0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150363	chr7:27095647~27100265:+
THCA	cis	rs6969780	0.722	rs4722666	ENSG00000233429.8	HOTAIRM1	-3.75	0.000196	0.0139	-0.21	-0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27157982	chr7:27095647~27100265:+
THCA	cis	rs11992162	0.597	rs7824564	ENSG00000254948.1	OR7E158P	3.75	0.000196	0.014	0.21	0.17	Monocyte count;	chr8:11922671	chr8:11919900~11920809:-
THCA	cis	rs7088591	0.867	rs79789486	ENSG00000276818.1	AC026393.1	3.75	0.000196	0.014	0.35	0.17	Blood pressure;	chr10:57991459	chr10:57095699~57095781:+
THCA	cis	rs879324	0.74	rs719354	ENSG00000280092.1	AC002044.3	3.75	0.000196	0.014	0.25	0.17	Stroke (ischemic);	chr16:73009030	chr16:73005601~73006141:-
THCA	cis	rs860295	0.557	rs12035524	ENSG00000160766.13	GBAP1	-3.75	0.000197	0.014	-0.21	-0.17	Body mass index;	chr1:155697311	chr1:155213821~155227422:-
THCA	cis	rs7819412	0.715	rs2409727	ENSG00000261451.1	RP11-981G7.1	-3.75	0.000197	0.014	-0.22	-0.17	Triglycerides;	chr8:11185727	chr8:10433672~10438312:+
THCA	cis	rs4561483	0.583	rs1019814	ENSG00000263307.1	RP11-166B2.8	-3.75	0.000197	0.014	-0.18	-0.17	Testicular germ cell tumor;	chr16:11846907	chr16:11851649~11895611:+
THCA	cis	rs13325613	0.764	rs4493469	ENSG00000223552.1	RP11-24F11.2	-3.75	0.000197	0.014	-0.28	-0.17	Monocyte count;	chr3:46136500	chr3:46364955~46407059:-
THCA	cis	rs14027	0.921	rs7833112	ENSG00000245330.4	KB-1471A8.1	3.75	0.000197	0.014	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119867419~119874488:-
THCA	cis	rs11771526	0.901	rs41519845	ENSG00000272905.1	RP11-265E18.1	3.75	0.000197	0.014	0.24	0.17	Body mass index;	chr7:32275831	chr7:32845394~32846061:+
THCA	cis	rs577676	0.524	rs601938	ENSG00000271811.1	RP1-79C4.4	3.75	0.000197	0.014	0.21	0.17	Prevalent atrial fibrillation;	chr1:170661118	chr1:170667381~170669425:+
THCA	cis	rs4722166	0.532	rs4719713	ENSG00000225541.1	AC002480.5	-3.75	0.000197	0.014	-0.19	-0.17	Lung cancer;	chr7:22719192	chr7:22571607~22661792:-
THCA	cis	rs3748682	0.808	rs12728438	ENSG00000252448.1	SNORA63	-3.75	0.000197	0.014	-0.22	-0.17	Hypothyroidism;	chr1:37883728	chr1:37884237~37884317:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000273024.4	INTS4P2	-3.75	0.000197	0.014	-0.22	-0.17	Aortic root size;	chr7:66376216	chr7:65647864~65715661:+
THCA	cis	rs1577917	1	rs13199006	ENSG00000220563.1	PKMP3	-3.75	0.000197	0.014	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85898990	chr6:85659892~85660606:-
THCA	cis	rs1577917	1	rs7766645	ENSG00000220563.1	PKMP3	-3.75	0.000197	0.014	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85912520	chr6:85659892~85660606:-
THCA	cis	rs1577917	1	rs9647603	ENSG00000220563.1	PKMP3	-3.75	0.000197	0.014	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85929623	chr6:85659892~85660606:-
THCA	cis	rs1577917	1	rs7747824	ENSG00000220563.1	PKMP3	-3.75	0.000197	0.014	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85937388	chr6:85659892~85660606:-
THCA	cis	rs1577917	1	rs35385043	ENSG00000220563.1	PKMP3	-3.75	0.000197	0.014	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85938828	chr6:85659892~85660606:-
THCA	cis	rs1577917	1	rs35760725	ENSG00000220563.1	PKMP3	-3.75	0.000197	0.014	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85939267	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs2660576	ENSG00000220563.1	PKMP3	-3.75	0.000197	0.014	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85941885	chr6:85659892~85660606:-
THCA	cis	rs1577917	1	rs6914463	ENSG00000220563.1	PKMP3	-3.75	0.000197	0.014	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85943697	chr6:85659892~85660606:-
THCA	cis	rs9843304	0.507	rs56242998	ENSG00000243885.1	RP11-278L15.2	-3.75	0.000197	0.014	-0.19	-0.17	Gallstone disease;	chr3:149496693	chr3:149384179~149385800:-
THCA	cis	rs7568498	1	rs13387779	ENSG00000235724.7	AC009299.2	3.75	0.000197	0.014	0.25	0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161082846	chr2:161222785~161308303:-
THCA	cis	rs2334880	0.836	rs9939458	ENSG00000260593.1	RP11-432I5.2	-3.75	0.000197	0.014	-0.27	-0.17	Malaria;	chr16:71633228	chr16:71623708~71626816:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000230295.1	RP11-458F8.2	3.75	0.000197	0.014	0.13	0.17	Aortic root size;	chr7:66603522	chr7:66880708~66882981:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000230295.1	RP11-458F8.2	3.75	0.000197	0.014	0.13	0.17	Aortic root size;	chr7:66622208	chr7:66880708~66882981:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000230295.1	RP11-458F8.2	3.75	0.000197	0.014	0.13	0.17	Aortic root size;	chr7:66624003	chr7:66880708~66882981:+
THCA	cis	rs7312933	0.558	rs11181463	ENSG00000257225.1	RP11-328C8.4	-3.75	0.000197	0.014	-0.18	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42369834	chr12:42459366~42466128:+
THCA	cis	rs12544026	0.581	rs1313944	ENSG00000253669.3	KB-1732A1.1	-3.75	0.000197	0.014	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101874833	chr8:102805517~102809971:+
THCA	cis	rs972578	0.967	rs972579	ENSG00000230319.1	AL022476.2	3.75	0.000197	0.014	0.18	0.17	Mean platelet volume;	chr22:42991705	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs4820502	ENSG00000230319.1	AL022476.2	3.75	0.000197	0.014	0.18	0.17	Mean platelet volume;	chr22:42991909	chr22:43038585~43052366:+
THCA	cis	rs6860806	0.695	rs6867282	ENSG00000263597.1	MIR3936	3.75	0.000197	0.014	0.16	0.17	Breast cancer;	chr5:132247427	chr5:132365490~132365599:-
THCA	cis	rs765787	0.505	rs11630884	ENSG00000259539.1	CTD-2651B20.1	3.75	0.000197	0.014	0.21	0.17	Uric acid levels;	chr15:45240048	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11634794	ENSG00000259539.1	CTD-2651B20.1	3.75	0.000197	0.014	0.21	0.17	Uric acid levels;	chr15:45242294	chr15:45152664~45167526:-
THCA	cis	rs181553	0.699	rs12970381	ENSG00000266696.1	RP11-30L3.2	3.75	0.000197	0.014	0.21	0.17	Hip circumference adjusted for BMI;	chr18:49167450	chr18:49205912~49208781:+
THCA	cis	rs8099594	0.51	rs7233575	ENSG00000266696.1	RP11-30L3.2	3.75	0.000197	0.014	0.21	0.17	Height;	chr18:49168712	chr18:49205912~49208781:+
THCA	cis	rs8099594	0.51	rs1893528	ENSG00000266696.1	RP11-30L3.2	3.75	0.000197	0.014	0.21	0.17	Height;	chr18:49169720	chr18:49205912~49208781:+
THCA	cis	rs1962772	0.502	rs2720492	ENSG00000279271.1	RP11-349F21.3	-3.75	0.000197	0.014	-0.2	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17526130	chr8:17498647~17499238:-
THCA	cis	rs2154427	0.752	rs79114597	ENSG00000238197.4	PAXBP1-AS1	3.75	0.000197	0.014	0.17	0.17	Bilirubin levels;	chr21:32828420	chr21:32728115~32743122:+
THCA	cis	rs10090774	0.932	rs1448226	ENSG00000280303.2	ERICD	-3.75	0.000197	0.014	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140894289	chr8:140636281~140638283:+
THCA	cis	rs2436845	1	rs2679752	ENSG00000253669.3	KB-1732A1.1	-3.75	0.000197	0.014	-0.18	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102851890	chr8:102805517~102809971:+
THCA	cis	rs3748656	0.945	rs12137269	ENSG00000273483.1	RP4-671G15.2	3.75	0.000197	0.014	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112564011	chr1:112517799~112518441:-
THCA	cis	rs17597773	0.674	rs1494372	ENSG00000272823.1	RP11-295M18.6	-3.75	0.000197	0.014	-0.23	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841279	chr1:220828676~220829211:-
THCA	cis	rs440932	1	rs378974	ENSG00000254153.1	CTA-398F10.2	-3.75	0.000197	0.014	-0.18	-0.17	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8456909~8461337:-
THCA	cis	rs765787	0.53	rs1706832	ENSG00000259932.1	CTD-2651B20.7	3.75	0.000197	0.014	0.21	0.17	Uric acid levels;	chr15:45224975	chr15:45198517~45199139:-
THCA	cis	rs10191559	0.81	rs4362519	ENSG00000236153.1	AC104076.3	3.75	0.000197	0.014	0.18	0.17	Red blood cell count;	chr2:181024335	chr2:180979427~180980090:-
THCA	cis	rs7264396	0.79	rs2425083	ENSG00000088340.14	FER1L4	3.75	0.000197	0.014	0.17	0.17	Total cholesterol levels;	chr20:35712534	chr20:35558737~35607562:-
THCA	cis	rs61677309	0.929	rs58983315	ENSG00000278376.1	RP11-158I9.8	3.75	0.000197	0.014	0.13	0.17	Lung cancer in ever smokers;	chr11:118297044	chr11:118791254~118793137:+
THCA	cis	rs3758911	1	rs10789616	ENSG00000255353.1	RP11-382M14.1	-3.75	0.000197	0.014	-0.21	-0.17	Coronary artery disease;	chr11:107318365	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs10789617	ENSG00000255353.1	RP11-382M14.1	-3.75	0.000197	0.014	-0.21	-0.17	Coronary artery disease;	chr11:107318968	chr11:107176286~107177530:+
THCA	cis	rs7951911	0.915	rs10466475	ENSG00000254427.1	RP11-430H10.1	3.75	0.000197	0.014	0.31	0.17	IgG glycosylation;	chr11:45076549	chr11:45355371~45366121:+
THCA	cis	rs2163813	0.959	rs247773	ENSG00000271283.1	CTC-412M14.6	-3.75	0.000197	0.014	-0.23	-0.17	Toenail selenium levels;	chr19:19735277	chr19:19699203~19699409:-
THCA	cis	rs7246760	1	rs67844335	ENSG00000267106.4	ZNF561-AS1	3.75	0.000197	0.014	0.32	0.17	Pursuit maintenance gain;	chr19:9787363	chr19:9621291~9645896:+
THCA	cis	rs4538475	0.556	rs4403048	ENSG00000273133.1	RP11-799M12.2	-3.75	0.000197	0.014	-0.23	-0.17	Parkinson's disease;	chr4:15735497	chr4:15563698~15564253:-
THCA	cis	rs10129255	0.913	rs28861466	ENSG00000280411.1	IGHV1-69-2	-3.75	0.000197	0.014	-0.11	-0.17	Kawasaki disease;	chr14:106718572	chr14:106762092~106762588:-
THCA	cis	rs875971	0.638	rs7793569	ENSG00000275400.1	RP4-756H11.5	3.75	0.000197	0.014	0.16	0.17	Aortic root size;	chr7:66651646	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs6975195	ENSG00000275400.1	RP4-756H11.5	3.75	0.000197	0.014	0.16	0.17	Aortic root size;	chr7:66659787	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs3857688	ENSG00000275400.1	RP4-756H11.5	3.75	0.000197	0.014	0.16	0.17	Aortic root size;	chr7:66662819	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs2286684	ENSG00000275400.1	RP4-756H11.5	3.75	0.000197	0.014	0.16	0.17	Aortic root size;	chr7:66664843	chr7:66553805~66554199:-
THCA	cis	rs801193	0.935	rs2286683	ENSG00000275400.1	RP4-756H11.5	3.75	0.000197	0.014	0.16	0.17	Aortic root size;	chr7:66664856	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs10274773	ENSG00000275400.1	RP4-756H11.5	3.75	0.000197	0.014	0.16	0.17	Aortic root size;	chr7:66668591	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs11773829	ENSG00000275400.1	RP4-756H11.5	3.75	0.000197	0.014	0.16	0.17	Aortic root size;	chr7:66676087	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs7788576	ENSG00000275400.1	RP4-756H11.5	3.75	0.000197	0.014	0.16	0.17	Aortic root size;	chr7:66683315	chr7:66553805~66554199:-
THCA	cis	rs801193	0.935	rs2659916	ENSG00000275400.1	RP4-756H11.5	-3.75	0.000197	0.014	-0.16	-0.17	Aortic root size;	chr7:66686365	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs6958520	ENSG00000275400.1	RP4-756H11.5	-3.75	0.000197	0.014	-0.16	-0.17	Aortic root size;	chr7:66686466	chr7:66553805~66554199:-
THCA	cis	rs801193	0.967	rs2707849	ENSG00000275400.1	RP4-756H11.5	-3.75	0.000197	0.014	-0.16	-0.17	Aortic root size;	chr7:66687725	chr7:66553805~66554199:-
THCA	cis	rs2640806	0.505	rs6999279	ENSG00000253105.4	KB-1448A5.1	3.75	0.000197	0.014	0.2	0.17	Obesity-related traits;	chr8:96349525	chr8:96371865~96387438:-
THCA	cis	rs2640806	0.505	rs7012725	ENSG00000253105.4	KB-1448A5.1	3.75	0.000197	0.014	0.2	0.17	Obesity-related traits;	chr8:96349606	chr8:96371865~96387438:-
THCA	cis	rs7546094	0.875	rs11584092	ENSG00000273483.1	RP4-671G15.2	-3.75	0.000197	0.014	-0.16	-0.17	Platelet distribution width;	chr1:112633640	chr1:112517799~112518441:-
THCA	cis	rs7264396	0.887	rs224363	ENSG00000088340.14	FER1L4	3.75	0.000197	0.014	0.16	0.17	Total cholesterol levels;	chr20:35474885	chr20:35558737~35607562:-
THCA	cis	rs9843304	0.528	rs9880421	ENSG00000243885.1	RP11-278L15.2	-3.75	0.000197	0.014	-0.19	-0.17	Gallstone disease;	chr3:149465572	chr3:149384179~149385800:-
THCA	cis	rs7267979	0.816	rs1044573	ENSG00000274973.1	RP13-401N8.7	-3.75	0.000197	0.014	-0.19	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25845497~25845862:+
THCA	cis	rs7158359	0.955	rs4904512	ENSG00000222990.1	RNU4-22P	3.75	0.000197	0.014	0.24	0.17	Weight loss (gastric bypass surgery);	chr14:89129601	chr14:88513498~88513663:+
THCA	cis	rs9911578	0.933	rs2632508	ENSG00000224738.1	AC099850.1	3.75	0.000197	0.014	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58455874	chr17:59106598~59118267:+
THCA	cis	rs4761702	0.527	rs11106988	ENSG00000257322.4	RP11-511B23.2	-3.75	0.000197	0.014	-0.22	-0.17	Immature fraction of reticulocytes;	chr12:93340674	chr12:93003415~93215679:-
THCA	cis	rs970548	0.955	rs11239551	ENSG00000230869.1	CTGLF10P	3.75	0.000197	0.014	0.21	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45530659	chr10:45678692~45700532:+
THCA	cis	rs10256972	0.669	rs10229964	ENSG00000225146.1	AC073957.15	3.75	0.000197	0.014	0.18	0.17	Endometriosis;Longevity;	chr7:1012140	chr7:1029025~1043891:+
THCA	cis	rs11638352	1	rs1365456	ENSG00000166763.7	STRCP1	-3.75	0.000197	0.014	-0.38	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44086645	chr15:43699488~43718184:-
THCA	cis	rs7578199	0.576	rs13388333	ENSG00000223374.1	AC005104.3	-3.75	0.000197	0.014	-0.12	-0.17	Chronic lymphocytic leukemia;	chr2:241461182	chr2:241351340~241353104:-
THCA	cis	rs4792901	0.802	rs56357945	ENSG00000267151.3	RP11-100E5.2	3.75	0.000197	0.014	0.19	0.17	Dupuytren's disease;	chr17:43536323	chr17:43444707~43451200:+
THCA	cis	rs801193	0.613	rs2016325	ENSG00000229180.5	GS1-124K5.11	-3.75	0.000197	0.014	-0.12	-0.17	Aortic root size;	chr7:66858513	chr7:66526088~66542624:-
THCA	cis	rs8114671	0.527	rs2295352	ENSG00000126005.14	MMP24-AS1	3.75	0.000197	0.014	0.16	0.17	Height;	chr20:34732251	chr20:35216462~35278131:-
THCA	cis	rs11168187	0.506	rs12812960	ENSG00000257433.4	RP1-197B17.3	3.75	0.000197	0.014	0.17	0.17	Vertical cup-disc ratio;	chr12:47729395	chr12:47706085~47742294:+
THCA	cis	rs34792	0.688	rs153782	ENSG00000275910.1	RP11-680G24.6	3.75	0.000197	0.014	0.19	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:15015828~15016390:-
THCA	cis	rs9693857	0.501	rs67985496	ENSG00000254153.1	CTA-398F10.2	3.75	0.000197	0.014	0.21	0.17	Systolic blood pressure;	chr8:9405618	chr8:8456909~8461337:-
THCA	cis	rs6427356	0.876	rs1176552	ENSG00000237189.1	RP11-85G21.2	3.75	0.000197	0.014	0.19	0.17	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157166162	chr1:157287703~157288053:-
THCA	cis	rs453301	0.506	rs686189	ENSG00000253981.4	ALG1L13P	-3.75	0.000197	0.014	-0.16	-0.17	Joint mobility (Beighton score);	chr8:8766127	chr8:8236003~8244667:-
THCA	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	3.75	0.000197	0.014	0.22	0.17	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
THCA	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	3.75	0.000197	0.014	0.22	0.17	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
THCA	cis	rs12478296	1	rs11899408	ENSG00000220804.7	AC093642.5	3.75	0.000197	0.014	0.19	0.17	Obesity-related traits;	chr2:242072479	chr2:242088633~242160153:+
THCA	cis	rs786425	0.711	rs1515815	ENSG00000278112.1	RP11-972P1.11	3.75	0.000197	0.014	0.17	0.17	Pubertal anthropometrics;	chr12:123627452	chr12:123519390~123519856:-
THCA	cis	rs372883	0.613	rs1153274	ENSG00000176054.6	RPL23P2	-3.75	0.000197	0.014	-0.15	-0.17	Pancreatic cancer;	chr21:29287705	chr21:28997613~28998033:-
THCA	cis	rs10452033	1	rs10452033	ENSG00000242142.1	SERBP1P3	-3.75	0.000197	0.014	-0.23	-0.17	Electrocardiographic traits;	chr3:53407349	chr3:53064283~53065091:-
THCA	cis	rs61142792	1	rs335473	ENSG00000272459.1	RP11-1277A3.3	3.75	0.000197	0.014	0.38	0.17	Alzheimer disease and age of onset;	chr5:177559423	chr5:177554824~177555364:+
THCA	cis	rs2625529	0.824	rs4238449	ENSG00000260037.4	CTD-2524L6.3	-3.75	0.000197	0.014	-0.24	-0.17	Red blood cell count;	chr15:72129262	chr15:71818396~71823384:+
THCA	cis	rs7829975	0.714	rs7823757	ENSG00000253981.4	ALG1L13P	3.75	0.000197	0.014	0.16	0.17	Mood instability;	chr8:8812667	chr8:8236003~8244667:-
THCA	cis	rs12681366	0.881	rs3019145	ENSG00000261437.1	RP11-22C11.2	3.75	0.000197	0.014	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94401324	chr8:94637285~94639467:-
THCA	cis	rs10940346	0.506	rs4605740	ENSG00000271752.1	RP11-269M20.3	3.75	0.000197	0.014	0.17	0.17	Schizophrenia;	chr5:50574869	chr5:50662859~50663266:-
THCA	cis	rs12682352	0.652	rs1567398	ENSG00000253981.4	ALG1L13P	-3.75	0.000197	0.014	-0.17	-0.17	Neuroticism;	chr8:8869294	chr8:8236003~8244667:-
THCA	cis	rs10191559	0.613	rs2176549	ENSG00000236153.1	AC104076.3	-3.75	0.000197	0.014	-0.18	-0.17	Red blood cell count;	chr2:181103423	chr2:180979427~180980090:-
THCA	cis	rs9608946	1	rs9606739	ENSG00000279699.1	RP1-102K2.9	3.75	0.000197	0.014	0.2	0.17	Red cell distribution width;	chr22:30495307	chr22:30275215~30276951:-
THCA	cis	rs2281636	0.691	rs11190218	ENSG00000260475.1	RP11-85A1.3	3.75	0.000197	0.014	0.17	0.17	Obesity-related traits;	chr10:99650305	chr10:99621055~99621918:+
THCA	cis	rs3796352	1	rs35163227	ENSG00000280417.1	RP11-5O17.1	-3.75	0.000198	0.014	-0.26	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:53093860	chr3:53046166~53048122:+
THCA	cis	rs1832871	0.711	rs9459954	ENSG00000213078.3	RP5-933K21.2	-3.75	0.000198	0.014	-0.25	-0.17	Height;	chr6:158288313	chr6:157365990~157366923:-
THCA	cis	rs10844706	0.699	rs10844615	ENSG00000214776.8	RP11-726G1.1	3.75	0.000198	0.014	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725646	chr12:9467552~9576275:+
THCA	cis	rs10844706	0.699	rs11052717	ENSG00000214776.8	RP11-726G1.1	3.75	0.000198	0.014	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9726217	chr12:9467552~9576275:+
THCA	cis	rs2625529	0.938	rs9120	ENSG00000260037.4	CTD-2524L6.3	-3.75	0.000198	0.014	-0.24	-0.17	Red blood cell count;	chr15:71823422	chr15:71818396~71823384:+
THCA	cis	rs12893668	0.645	rs35229468	ENSG00000244691.1	RPL10AP1	-3.75	0.000198	0.014	-0.24	-0.17	Reticulocyte count;	chr14:103585720	chr14:103412119~103412761:-
THCA	cis	rs1005277	0.577	rs4934906	ENSG00000275858.1	RP11-291L22.8	3.75	0.000198	0.014	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38450738~38451069:-
THCA	cis	rs4389656	0.857	rs274679	ENSG00000248677.1	CTD-2044J15.1	3.75	0.000198	0.014	0.17	0.17	Coronary artery disease;	chr5:6751313	chr5:6686325~6707711:-
THCA	cis	rs1961102	0.521	rs657000	ENSG00000253320.4	KB-1507C5.2	-3.75	0.000198	0.014	-0.14	-0.17	QT interval;	chr8:102917514	chr8:102864300~102977876:+
THCA	cis	rs2574985	0.586	rs1569962	ENSG00000279863.1	RP11-521C22.2	-3.75	0.000198	0.014	-0.19	-0.17	Subjective well-being;	chr10:50496407	chr10:50334538~50336123:+
THCA	cis	rs4604234	1	rs112881252	ENSG00000260645.1	RP11-250B2.5	-3.75	0.000198	0.014	-0.32	-0.17	Cancer;	chr6:80397655	chr6:80466958~80469080:+
THCA	cis	rs1005277	0.505	rs10827835	ENSG00000120555.12	SEPT7P9	-3.75	0.000198	0.014	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38383069~38402916:-
THCA	cis	rs5758659	0.652	rs133347	ENSG00000182057.4	OGFRP1	3.75	0.000198	0.014	0.2	0.17	Cognitive function;	chr22:42027641	chr22:42269753~42275196:+
THCA	cis	rs9987353	0.589	rs1053036	ENSG00000254153.1	CTA-398F10.2	3.75	0.000198	0.014	0.19	0.17	Recombination measurement;	chr8:9202567	chr8:8456909~8461337:-
THCA	cis	rs1876206	0.507	rs7183203	ENSG00000259705.1	RP11-227D13.1	-3.75	0.000198	0.014	-0.22	-0.17	Breast cancer;	chr15:48578259	chr15:48645951~48652016:+
THCA	cis	rs4389656	0.857	rs274719	ENSG00000248677.1	CTD-2044J15.1	3.75	0.000198	0.014	0.17	0.17	Coronary artery disease;	chr5:6720803	chr5:6686325~6707711:-
THCA	cis	rs16975963	0.644	rs73031309	ENSG00000276846.1	CTD-3220F14.3	-3.75	0.000198	0.014	-0.16	-0.17	Longevity;	chr19:37541082	chr19:37314868~37315620:-
THCA	cis	rs765787	0.53	rs7167389	ENSG00000259539.1	CTD-2651B20.1	3.75	0.000198	0.014	0.21	0.17	Uric acid levels;	chr15:45243485	chr15:45152664~45167526:-
THCA	cis	rs944990	0.557	rs10821164	ENSG00000227603.1	RP11-165J3.6	3.75	0.000198	0.014	0.18	0.17	Body mass index;	chr9:93584947	chr9:93435332~93437121:-
THCA	cis	rs2562456	0.52	rs660063	ENSG00000268081.1	RP11-678G14.2	-3.75	0.000198	0.014	-0.28	-0.17	Pain;	chr19:21271103	chr19:21554640~21569237:-
THCA	cis	rs2562456	0.52	rs279793	ENSG00000268081.1	RP11-678G14.2	3.75	0.000198	0.014	0.28	0.17	Pain;	chr19:21272972	chr19:21554640~21569237:-
THCA	cis	rs9608946	1	rs8137718	ENSG00000279699.1	RP1-102K2.9	3.75	0.000198	0.014	0.2	0.17	Red cell distribution width;	chr22:30492972	chr22:30275215~30276951:-
THCA	cis	rs6430585	0.527	rs62168830	ENSG00000231890.6	DARS-AS1	-3.75	0.000198	0.014	-0.2	-0.17	Corneal structure;	chr2:135686330	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.527	rs57530667	ENSG00000231890.6	DARS-AS1	-3.75	0.000198	0.014	-0.2	-0.17	Corneal structure;	chr2:135686768	chr2:135985176~136022593:+
THCA	cis	rs17286411	0.671	rs9940990	ENSG00000260185.1	RP11-432I5.6	-3.75	0.000198	0.014	-0.24	-0.17	Blood protein levels;	chr16:71797440	chr16:71655027~71664212:+
THCA	cis	rs3176789	0.647	rs11052970	ENSG00000256673.1	RP11-599J14.2	3.75	0.000198	0.014	0.21	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766671	chr12:9398355~9414851:-
THCA	cis	rs7940646	0.812	rs2052691	ENSG00000254554.1	RP11-351I24.1	-3.75	0.000198	0.014	-0.21	-0.17	Platelet aggregation;	chr11:10642874	chr11:10302657~10303704:-
THCA	cis	rs459571	0.839	rs10993895	ENSG00000235106.7	LINC00094	-3.75	0.000198	0.014	-0.15	-0.17	Platelet distribution width;	chr9:134022604	chr9:134025439~134034666:+
THCA	cis	rs8130944	0.964	rs7283732	ENSG00000235772.1	AP001625.6	3.75	0.000198	0.014	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42717027	chr21:42560374~42561934:-
THCA	cis	rs7520050	0.778	rs3014218	ENSG00000281133.1	AL355480.3	3.75	0.000198	0.014	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45580892~45580996:-
THCA	cis	rs9926296	0.605	rs8047486	ENSG00000274627.1	RP11-104N10.2	-3.75	0.000198	0.014	-0.17	-0.17	Vitiligo;	chr16:89787617	chr16:89516797~89522217:+
THCA	cis	rs4533267	0.81	rs4246312	ENSG00000189419.6	SPATA41	3.75	0.000198	0.014	0.23	0.17	Height;	chr15:100247600	chr15:100344457~100349655:-
THCA	cis	rs8003054	0.616	rs58333467	ENSG00000258515.1	RP11-203M5.7	3.75	0.000198	0.014	0.11	0.17	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20441405	chr14:20451305~20451918:+
THCA	cis	rs56046484	0.871	rs34493704	ENSG00000218052.5	ADAMTS7P4	-3.75	0.000198	0.014	-0.28	-0.17	Testicular germ cell tumor;	chr15:85015539	chr15:85255369~85330334:-
THCA	cis	rs11884770	0.505	rs6756834	ENSG00000236432.6	AC097662.2	3.75	0.000198	0.014	0.17	0.17	Advanced age-related macular degeneration;	chr2:227218520	chr2:227221052~227325201:-
THCA	cis	rs11884770	0.522	rs34820446	ENSG00000236432.6	AC097662.2	3.75	0.000198	0.014	0.17	0.17	Advanced age-related macular degeneration;	chr2:227218749	chr2:227221052~227325201:-
THCA	cis	rs11884770	0.522	rs34169465	ENSG00000236432.6	AC097662.2	3.75	0.000198	0.014	0.17	0.17	Advanced age-related macular degeneration;	chr2:227218899	chr2:227221052~227325201:-
THCA	cis	rs11884770	0.522	rs6757320	ENSG00000236432.6	AC097662.2	3.75	0.000198	0.014	0.17	0.17	Advanced age-related macular degeneration;	chr2:227218936	chr2:227221052~227325201:-
THCA	cis	rs11884770	0.522	rs6742265	ENSG00000236432.6	AC097662.2	3.75	0.000198	0.014	0.17	0.17	Advanced age-related macular degeneration;	chr2:227218939	chr2:227221052~227325201:-
THCA	cis	rs7259376	0.525	rs1692599	ENSG00000269138.1	ZNF209P	3.75	0.000198	0.014	0.16	0.17	Menopause (age at onset);	chr19:22452746	chr19:22463922~22473036:+
THCA	cis	rs4908760	0.965	rs10864354	ENSG00000270282.1	RP5-1115A15.2	3.75	0.000198	0.014	0.2	0.17	Vitiligo;	chr1:8489681	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs7530745	ENSG00000270282.1	RP5-1115A15.2	3.75	0.000198	0.014	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497631	chr1:8512653~8513021:+
THCA	cis	rs2015599	0.623	rs3782510	ENSG00000273680.1	RP11-996F15.6	-3.75	0.000198	0.014	-0.24	-0.17	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29332733~29333383:-
THCA	cis	rs1113500	0.814	rs12039712	ENSG00000230489.1	VAV3-AS1	-3.75	0.000198	0.014	-0.15	-0.17	Growth-regulated protein alpha levels;	chr1:108098577	chr1:107964443~107994607:+
THCA	cis	rs12234571	0.546	rs12056061	ENSG00000214293.7	APTR	3.75	0.000198	0.014	0.22	0.17	Obesity-related traits;	chr7:77688668	chr7:77657660~77696265:-
THCA	cis	rs2729354	0.729	rs2581923	ENSG00000254602.1	AP000662.4	-3.75	0.000198	0.014	-0.22	-0.17	Blood protein levels;	chr11:57482518	chr11:57638024~57652790:+
THCA	cis	rs10129255	0.646	rs55995061	ENSG00000280411.1	IGHV1-69-2	-3.75	0.000198	0.014	-0.14	-0.17	Kawasaki disease;	chr14:106799309	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs76871148	ENSG00000280411.1	IGHV1-69-2	-3.75	0.000198	0.014	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106799722	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs61521632	ENSG00000280411.1	IGHV1-69-2	-3.75	0.000198	0.014	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106801091	chr14:106762092~106762588:-
THCA	cis	rs4460629	0.712	rs11264313	ENSG00000225855.5	RUSC1-AS1	3.75	0.000198	0.014	0.11	0.17	Serum magnesium levels;	chr1:155104029	chr1:155316863~155324176:-
THCA	cis	rs9970896	0.579	rs10803139	ENSG00000237845.1	RP5-940F7.2	-3.75	0.000198	0.014	-0.29	-0.17	Monocyte percentage of white cells;	chr1:235902256	chr1:235942553~235943805:-
THCA	cis	rs7578199	0.576	rs3771590	ENSG00000223374.1	AC005104.3	-3.75	0.000198	0.014	-0.13	-0.17	Chronic lymphocytic leukemia;	chr2:241496823	chr2:241351340~241353104:-
THCA	cis	rs9863	0.861	rs7132655	ENSG00000270028.1	RP11-380L11.4	3.75	0.000198	0.0141	0.18	0.17	White blood cell count;	chr12:123954426	chr12:123925461~123926083:-
THCA	cis	rs4767841	0.565	rs4462403	ENSG00000248636.5	RP11-768F21.1	-3.75	0.000198	0.0141	-0.17	-0.17	Urgency urinary incontinence;	chr12:119773788	chr12:119387987~119668079:-
THCA	cis	rs1200921	0.898	rs1148262	ENSG00000272983.1	RP11-508N22.12	3.75	0.000198	0.0141	0.15	0.17	Breast cancer;	chr10:37223332	chr10:38137337~38144399:+
THCA	cis	rs875971	0.838	rs2173570	ENSG00000272831.1	RP11-792A8.4	-3.75	0.000198	0.0141	-0.11	-0.17	Aortic root size;	chr7:66297976	chr7:66739829~66740385:-
THCA	cis	rs10089	0.953	rs3805615	ENSG00000245937.6	LINC01184	3.75	0.000198	0.0141	0.19	0.17	Ileal carcinoids;	chr5:128183357	chr5:127940426~128083172:-
THCA	cis	rs2153535	0.561	rs9328474	ENSG00000230939.1	RP11-314C16.1	-3.75	0.000198	0.0141	-0.18	-0.17	Motion sickness;	chr6:8506770	chr6:8784178~8785445:+
THCA	cis	rs683250	0.629	rs509815	ENSG00000254551.1	RP11-727A23.7	3.75	0.000198	0.0141	0.21	0.17	Subcortical brain region volumes;	chr11:83280450	chr11:83209431~83213379:-
THCA	cis	rs683250	0.629	rs682579	ENSG00000254551.1	RP11-727A23.7	3.75	0.000198	0.0141	0.21	0.17	Subcortical brain region volumes;	chr11:83284862	chr11:83209431~83213379:-
THCA	cis	rs13178541	0.578	rs10463942	ENSG00000250378.1	RP11-119J18.1	-3.75	0.000198	0.0141	-0.19	-0.17	IgG glycosylation;	chr5:135803482	chr5:135812667~135826582:+
THCA	cis	rs9635324	1	rs9635324	ENSG00000259536.4	RP11-111A22.1	3.75	0.000198	0.0141	0.22	0.17	Blood metabolite ratios;Blood metabolite levels;	chr15:40411012	chr15:40488041~40558019:+
THCA	cis	rs34929064	0.75	rs2961299	ENSG00000179428.2	AC073072.5	-3.75	0.000198	0.0141	-0.2	-0.17	Major depression and alcohol dependence;	chr7:22668551	chr7:22725395~22727620:-
THCA	cis	rs7615952	0.599	rs2333408	ENSG00000248787.1	RP11-666A20.4	-3.75	0.000198	0.0141	-0.26	-0.17	Blood pressure (smoking interaction);	chr3:126013255	chr3:125908005~125910272:-
THCA	cis	rs1371614	0.632	rs10196501	ENSG00000272148.1	RP11-195B17.1	3.75	0.000198	0.0141	0.16	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26924404	chr2:27062428~27062907:-
THCA	cis	rs754133	0.891	rs12426399	ENSG00000257534.1	RP11-834C11.10	3.75	0.000198	0.0141	0.21	0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026126	chr12:54162065~54164452:-
THCA	cis	rs17685	0.753	rs13240404	ENSG00000227038.2	AC005077.12	-3.75	0.000198	0.0141	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76046401	chr7:76090431~76108779:-
THCA	cis	rs17685	0.697	rs2302437	ENSG00000227038.2	AC005077.12	-3.75	0.000198	0.0141	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76047698	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs3757593	ENSG00000227038.2	AC005077.12	-3.75	0.000198	0.0141	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76049417	chr7:76090431~76108779:-
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000219891.2	ZSCAN12P1	3.75	0.000198	0.0141	0.23	0.17	Parkinson's disease;	chr6:28065745	chr6:28091154~28093664:+
THCA	cis	rs748404	0.534	rs489509	ENSG00000224677.1	PDIA3P2	3.75	0.000198	0.0141	0.2	0.17	Lung cancer;	chr15:43294709	chr15:43649123~43649280:+
THCA	cis	rs12476592	0.602	rs262484	ENSG00000242412.1	DBIL5P2	3.75	0.000198	0.0141	0.22	0.17	Childhood ear infection;	chr2:63650881	chr2:63117851~63119542:-
THCA	cis	rs4879656	0.564	rs2183870	ENSG00000225693.1	LAGE3P1	3.75	0.000198	0.0141	0.18	0.17	Menopause (age at onset);	chr9:32994502	chr9:33019682~33020165:-
THCA	cis	rs4792901	0.802	rs72833123	ENSG00000267151.3	RP11-100E5.2	3.75	0.000198	0.0141	0.19	0.17	Dupuytren's disease;	chr17:43475035	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.765	rs9905358	ENSG00000267151.3	RP11-100E5.2	3.75	0.000198	0.0141	0.19	0.17	Dupuytren's disease;	chr17:43478106	chr17:43444707~43451200:+
THCA	cis	rs9796	0.621	rs2578655	ENSG00000247556.5	OIP5-AS1	3.75	0.000198	0.0141	0.14	0.17	Menopause (age at onset);	chr15:41170611	chr15:41283990~41309737:+
THCA	cis	rs9902453	0.845	rs7501472	ENSG00000264290.1	RP11-68I3.4	3.75	0.000198	0.0141	0.13	0.17	Coffee consumption (cups per day);	chr17:29683610	chr17:29569580~29570519:+
THCA	cis	rs346923	0.764	rs73248638	ENSG00000226950.5	DANCR	3.75	0.000199	0.0141	0.2	0.17	Biochemical measures;	chr4:52480021	chr4:52712404~52720351:+
THCA	cis	rs7772697	0.635	rs9498207	ENSG00000223701.3	RAET1E-AS1	-3.75	0.000199	0.0141	-0.24	-0.17	Diabetic retinopathy;	chr6:149086322	chr6:149884431~149919508:+
THCA	cis	rs10802047	0.566	rs2360628	ENSG00000231365.4	RP11-418J17.1	-3.75	0.000199	0.0141	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118789825	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.566	rs4659122	ENSG00000231365.4	RP11-418J17.1	-3.75	0.000199	0.0141	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118790278	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.566	rs10802061	ENSG00000231365.4	RP11-418J17.1	-3.75	0.000199	0.0141	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118792430	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.541	rs6428783	ENSG00000231365.4	RP11-418J17.1	-3.75	0.000199	0.0141	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118794131	chr1:119140396~119275973:+
THCA	cis	rs4792901	0.802	rs12602059	ENSG00000279602.1	CTD-3014M21.1	-3.75	0.000199	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43496362	chr17:43360041~43361361:-
THCA	cis	rs1799922	0.965	rs62479585	ENSG00000271553.1	RP11-274B21.10	-3.75	0.000199	0.0141	-0.15	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128763741	chr7:128667043~128668156:+
THCA	cis	rs3764021	0.506	rs11052372	ENSG00000214776.8	RP11-726G1.1	3.75	0.000199	0.0141	0.23	0.17	Type 1 diabetes;	chr12:9679363	chr12:9467552~9576275:+
THCA	cis	rs7166081	1	rs8042007	ENSG00000270964.1	RP11-502I4.3	3.75	0.000199	0.0141	0.16	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67360638	chr15:67541072~67542604:-
THCA	cis	rs17123764	0.71	rs60121503	ENSG00000257464.1	RP11-161H23.8	-3.75	0.000199	0.0141	-0.3	-0.17	Intelligence (multi-trait analysis);	chr12:49694964	chr12:49442424~49442652:-
THCA	cis	rs875971	0.642	rs35526611	ENSG00000230295.1	RP11-458F8.2	3.75	0.000199	0.0141	0.13	0.17	Aortic root size;	chr7:66629021	chr7:66880708~66882981:+
THCA	cis	rs524281	0.692	rs2254388	ENSG00000255120.4	OVOL1-AS1	3.75	0.000199	0.0141	0.24	0.17	Electroencephalogram traits;	chr11:66070128	chr11:65789051~65790868:-
THCA	cis	rs6920965	0.509	rs654213	ENSG00000237742.5	RP11-624M8.1	3.75	0.000199	0.0141	0.15	0.17	High light scatter reticulocyte count;	chr6:125827981	chr6:125578558~125749190:-
THCA	cis	rs854765	0.583	rs5002487	ENSG00000281749.1	Y_RNA	3.75	0.000199	0.0141	0.22	0.17	Total body bone mineral density;	chr17:17929146	chr17:18001101~18001195:-
THCA	cis	rs875971	0.502	rs1796227	ENSG00000273024.4	INTS4P2	3.75	0.000199	0.0141	0.21	0.17	Aortic root size;	chr7:66622032	chr7:65647864~65715661:+
THCA	cis	rs4834770	1	rs4336213	ENSG00000260091.1	RP11-33B1.4	-3.75	0.000199	0.0141	-0.12	-0.17	Blood protein levels;	chr4:119315314	chr4:119409333~119410233:+
THCA	cis	rs950893	0.729	rs7004327	ENSG00000253837.1	RP11-177H13.2	3.75	0.000199	0.0141	0.17	0.17	Mean corpuscular hemoglobin;	chr8:23613070	chr8:23336171~23366125:+
THCA	cis	rs472402	0.58	rs7720479	ENSG00000250056.4	LINC01018	-3.75	0.000199	0.0141	-0.21	-0.17	Response to amphetamines;	chr5:6639936	chr5:6582136~6588499:+
THCA	cis	rs7824557	0.713	rs9286062	ENSG00000255495.1	AC145124.2	-3.75	0.000199	0.0141	-0.18	-0.17	Retinal vascular caliber;	chr8:11261018	chr8:12194467~12196280:+
THCA	cis	rs2442825	0.693	rs2648536	ENSG00000254485.4	RP11-380O24.1	-3.75	0.000199	0.0141	-0.16	-0.17	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9292588~9363303:-
THCA	cis	rs643506	0.715	rs11214031	ENSG00000230911.1	PPIHP1	-3.75	0.000199	0.0141	-0.23	-0.17	Breast cancer;	chr11:111895315	chr11:112029858~112030367:-
THCA	cis	rs7572644	0.712	rs10204832	ENSG00000223522.1	AC093690.1	3.75	0.000199	0.0141	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28005541	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.766	rs56046821	ENSG00000223522.1	AC093690.1	3.75	0.000199	0.0141	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28011834	chr2:28307691~28310459:-
THCA	cis	rs13256369	0.802	rs12681326	ENSG00000254153.1	CTA-398F10.2	-3.75	0.000199	0.0141	-0.2	-0.17	Obesity-related traits;	chr8:8708879	chr8:8456909~8461337:-
THCA	cis	rs9611565	0.649	rs5758442	ENSG00000237037.8	NDUFA6-AS1	-3.75	0.000199	0.0141	-0.15	-0.17	Vitiligo;	chr22:41737056	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.58	rs5758449	ENSG00000237037.8	NDUFA6-AS1	-3.75	0.000199	0.0141	-0.15	-0.17	Vitiligo;	chr22:41744156	chr22:42090931~42137742:+
THCA	cis	rs13113518	0.841	rs7699867	ENSG00000223305.1	RN7SKP30	3.75	0.000199	0.0141	0.22	0.17	Height;	chr4:55483718	chr4:55540502~55540835:-
THCA	cis	rs8192917	0.573	rs10135223	ENSG00000258744.1	RP11-80A15.1	-3.75	0.000199	0.0141	-0.27	-0.17	Vitiligo;	chr14:24639749	chr14:24501594~24508688:+
THCA	cis	rs9595908	0.669	rs7983309	ENSG00000212293.1	SNORA16	3.75	0.000199	0.0141	0.2	0.17	Body mass index;	chr13:32740254	chr13:32420390~32420516:-
THCA	cis	rs62458065	0.64	rs79619897	ENSG00000231952.3	DPY19L1P2	3.75	0.000199	0.0141	0.3	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32475207	chr7:32812757~32838570:+
THCA	cis	rs1125355	0.653	rs72937273	ENSG00000243792.1	OR7E89P	-3.75	0.000199	0.0141	-0.26	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158762204	chr2:158853755~158854576:+
THCA	cis	rs11633886	0.585	rs2460629	ENSG00000259200.1	RP11-718O11.1	3.75	0.000199	0.0141	0.21	0.17	Diisocyanate-induced asthma;	chr15:45798785	chr15:45705078~45931069:+
THCA	cis	rs7572644	0.766	rs6727432	ENSG00000223522.1	AC093690.1	3.75	0.000199	0.0141	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28028123	chr2:28307691~28310459:-
THCA	cis	rs4761470	0.943	rs68122601	ENSG00000258172.1	RP11-1105G2.4	-3.75	0.000199	0.0141	-0.26	-0.17	Estradiol plasma levels (breast cancer);	chr12:94428513	chr12:94272150~94277195:-
THCA	cis	rs9291683	0.53	rs73227883	ENSG00000250413.1	RP11-448G15.1	-3.75	0.000199	0.0141	-0.17	-0.17	Bone mineral density;	chr4:9977655	chr4:10006482~10009725:+
THCA	cis	rs16957091	0.528	rs35326878	ENSG00000249839.1	AC011330.5	3.75	0.000199	0.0141	0.27	0.17	MGMT methylation in smokers;	chr15:42983379	chr15:43663654~43684339:-
THCA	cis	rs6430585	0.527	rs76622824	ENSG00000231890.6	DARS-AS1	-3.75	0.000199	0.0141	-0.2	-0.17	Corneal structure;	chr2:135654309	chr2:135985176~136022593:+
THCA	cis	rs6430585	0.527	rs62168792	ENSG00000231890.6	DARS-AS1	-3.75	0.000199	0.0141	-0.2	-0.17	Corneal structure;	chr2:135657647	chr2:135985176~136022593:+
THCA	cis	rs9468199	0.505	rs72847381	ENSG00000226314.6	ZNF192P1	-3.75	0.000199	0.0141	-0.4	-0.17	Parkinson's disease;	chr6:27906153	chr6:28161781~28169594:+
THCA	cis	rs17767294	0.708	rs72848752	ENSG00000226314.6	ZNF192P1	-3.75	0.000199	0.0141	-0.4	-0.17	Parkinson's disease;	chr6:27910490	chr6:28161781~28169594:+
THCA	cis	rs1580019	0.961	rs4320456	ENSG00000231952.3	DPY19L1P2	-3.75	0.000199	0.0141	-0.22	-0.17	Cognitive ability;	chr7:32456391	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs4357201	ENSG00000231952.3	DPY19L1P2	-3.75	0.000199	0.0141	-0.22	-0.17	Cognitive ability;	chr7:32456721	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs4255041	ENSG00000231952.3	DPY19L1P2	-3.75	0.000199	0.0141	-0.22	-0.17	Cognitive ability;	chr7:32456771	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs4460271	ENSG00000231952.3	DPY19L1P2	-3.75	0.000199	0.0141	-0.22	-0.17	Cognitive ability;	chr7:32456891	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs3801328	ENSG00000231952.3	DPY19L1P2	-3.75	0.000199	0.0141	-0.22	-0.17	Cognitive ability;	chr7:32457318	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs1580022	ENSG00000231952.3	DPY19L1P2	-3.75	0.000199	0.0141	-0.22	-0.17	Cognitive ability;	chr7:32458100	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs1610143	ENSG00000231952.3	DPY19L1P2	-3.75	0.000199	0.0141	-0.22	-0.17	Cognitive ability;	chr7:32458719	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs1868776	ENSG00000231952.3	DPY19L1P2	3.75	0.000199	0.0141	0.22	0.17	Cognitive ability;	chr7:32454823	chr7:32812757~32838570:+
THCA	cis	rs1075265	0.584	rs1862122	ENSG00000272156.1	RP11-477N3.1	-3.75	0.000199	0.0141	-0.17	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54082554~54085066:+
THCA	cis	rs1383484	0.798	rs2086441	ENSG00000225151.9	GOLGA2P7	3.75	0.000199	0.0141	0.23	0.17	Height;	chr15:83881728	chr15:84199311~84230136:-
THCA	cis	rs7954584	0.616	rs10743185	ENSG00000272849.1	RP11-347I19.8	-3.75	0.000199	0.0141	-0.1	-0.17	Mean corpuscular volume;	chr12:121918529	chr12:121797511~121801972:+
THCA	cis	rs7954584	0.616	rs10743186	ENSG00000272849.1	RP11-347I19.8	-3.75	0.000199	0.0141	-0.1	-0.17	Mean corpuscular volume;	chr12:121918530	chr12:121797511~121801972:+
THCA	cis	rs586688	0.625	rs567337	ENSG00000224536.1	RP11-134G8.7	-3.75	0.000199	0.0141	-0.26	-0.17	Obesity-related traits;	chr1:201683851	chr1:201507241~201533608:+
THCA	cis	rs11073619	0.616	rs116665699	ENSG00000259728.4	LINC00933	-3.75	0.000199	0.0141	-0.33	-0.17	Positive affect;	chr15:84554498	chr15:84570649~84580175:+
THCA	cis	rs854765	0.547	rs28537385	ENSG00000281749.1	Y_RNA	3.75	0.000199	0.0141	0.21	0.17	Total body bone mineral density;	chr17:17998821	chr17:18001101~18001195:-
THCA	cis	rs10200159	0.793	rs2867964	ENSG00000206964.1	Y_RNA	-3.75	0.000199	0.0141	-0.38	-0.17	Vitiligo;	chr2:55698289	chr2:55286018~55286128:+
THCA	cis	rs7819412	0.715	rs2409727	ENSG00000280294.1	RP11-177H2.1	3.75	0.000199	0.0141	0.14	0.17	Triglycerides;	chr8:11185727	chr8:10856085~10859436:-
THCA	cis	rs7121800	0.603	rs4922835	ENSG00000242353.1	RP4-710M3.1	3.75	0.000199	0.0141	0.15	0.17	Pit-and-Fissure caries;	chr11:30517771	chr11:30368148~30368646:+
THCA	cis	rs4950322	0.744	rs2353987	ENSG00000180867.10	PDIA3P1	3.75	0.000199	0.0141	0.17	0.17	Protein quantitative trait loci;	chr1:147355845	chr1:147178113~147179622:+
THCA	cis	rs7674212	0.581	rs13150953	ENSG00000248971.2	KRT8P46	-3.75	0.000199	0.0141	-0.21	-0.17	Type 2 diabetes;	chr4:103021341	chr4:102728746~102730171:-
THCA	cis	rs7674212	0.556	rs13151569	ENSG00000248971.2	KRT8P46	-3.75	0.000199	0.0141	-0.21	-0.17	Type 2 diabetes;	chr4:103021633	chr4:102728746~102730171:-
THCA	cis	rs7178375	1	rs12907055	ENSG00000269930.1	RP11-932O9.9	-3.75	0.000199	0.0141	-0.23	-0.17	Hypertriglyceridemia;	chr15:30912091	chr15:30616958~30617749:+
THCA	cis	rs17122278	1	rs11216896	ENSG00000243431.1	RPL5P30	3.75	0.000199	0.0141	0.17	0.17	Total cholesterol levels;	chr11:118559333	chr11:118560690~118561580:+
THCA	cis	rs6439699	1	rs60246781	ENSG00000273486.1	RP11-731C17.2	3.75	0.000199	0.0141	0.18	0.17	Intelligence (multi-trait analysis);	chr3:137291161	chr3:136837338~136839021:-
THCA	cis	rs4578769	0.733	rs7226388	ENSG00000265939.1	UBE2CP2	3.75	0.000199	0.0141	0.21	0.17	Eosinophil percentage of white cells;	chr18:22865371	chr18:22900486~22900995:-
THCA	cis	rs10863936	0.557	rs4951435	ENSG00000198468.6	FLVCR1-AS1	-3.75	0.000199	0.0141	-0.19	-0.17	Height;	chr1:211985374	chr1:212852108~212858088:-
THCA	cis	rs10863936	0.523	rs2884428	ENSG00000198468.6	FLVCR1-AS1	-3.75	0.000199	0.0141	-0.19	-0.17	Height;	chr1:211993848	chr1:212852108~212858088:-
THCA	cis	rs11756659	0.505	rs62394320	ENSG00000272810.1	U91328.22	3.75	0.000199	0.0141	0.14	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25891952	chr6:26013241~26013757:+
THCA	cis	rs7819412	0.642	rs11250117	ENSG00000255310.2	AF131215.2	-3.75	0.000199	0.0141	-0.15	-0.17	Triglycerides;	chr8:11115230	chr8:11107788~11109726:-
THCA	cis	rs4822044	0.617	rs13054514	ENSG00000237037.8	NDUFA6-AS1	-3.75	2e-04	0.0141	-0.15	-0.17	Cannabis dependence symptom count;	chr22:41734379	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.568	rs5758441	ENSG00000237037.8	NDUFA6-AS1	-3.75	2e-04	0.0141	-0.15	-0.17	Vitiligo;	chr22:41736884	chr22:42090931~42137742:+
THCA	cis	rs910316	0.763	rs175016	ENSG00000259138.1	RP11-950C14.7	-3.75	2e-04	0.0141	-0.15	-0.17	Height;	chr14:74992930	chr14:75127153~75136930:+
THCA	cis	rs2436845	0.627	rs1055376	ENSG00000253320.4	KB-1507C5.2	-3.75	2e-04	0.0141	-0.15	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102865206	chr8:102864300~102977876:+
THCA	cis	rs7129556	0.737	rs623173	ENSG00000254459.1	RP11-91P24.7	-3.75	2e-04	0.0141	-0.22	-0.17	Weight loss (gastric bypass surgery);	chr11:77818482	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.737	rs484363	ENSG00000254459.1	RP11-91P24.7	3.75	2e-04	0.0141	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77781548	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.728	rs34130561	ENSG00000254459.1	RP11-91P24.7	3.75	2e-04	0.0141	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77785645	chr11:77829654~77872262:-
THCA	cis	rs4792901	0.765	rs9894264	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43500629	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs9908678	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43504177	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs55956367	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43504916	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs9907507	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43509677	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.765	rs9908030	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43510523	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs9915326	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43511234	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs9893137	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43513560	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.729	rs9891052	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43515151	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs9895324	ENSG00000279602.1	CTD-3014M21.1	-3.75	2e-04	0.0141	-0.22	-0.17	Dupuytren's disease;	chr17:43516800	chr17:43360041~43361361:-
THCA	cis	rs7045881	0.8	rs62544437	ENSG00000254396.1	RP11-56F10.3	3.75	2e-04	0.0141	0.3	0.17	Schizophrenia;	chr9:26906224	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.8	rs7044910	ENSG00000254396.1	RP11-56F10.3	3.75	2e-04	0.0141	0.3	0.17	Schizophrenia;	chr9:26907598	chr9:27102630~27104728:+
THCA	cis	rs76878669	0.617	rs10896114	ENSG00000255320.1	RP11-755F10.1	3.75	2e-04	0.0141	0.25	0.17	Educational attainment (years of education);	chr11:66376326	chr11:66244840~66246239:-
THCA	cis	rs9467773	1	rs9986382	ENSG00000228223.2	HCG11	-3.75	2e-04	0.0141	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26523450~26526579:+
THCA	cis	rs61237505	1	rs61237505	ENSG00000260711.2	RP11-747H7.3	3.75	2e-04	0.0141	0.21	0.17	Mean platelet volume;	chr14:91779639	chr14:91752856~91759798:-
THCA	cis	rs875971	1	rs7781698	ENSG00000230189.5	GS1-124K5.2	3.75	2e-04	0.0141	0.11	0.17	Aortic root size;	chr7:66431325	chr7:66409143~66490059:-
THCA	cis	rs4578769	0.531	rs4616385	ENSG00000273232.1	RP11-370A5.2	3.75	2e-04	0.0141	0.23	0.17	Eosinophil percentage of white cells;	chr18:22895327	chr18:22882825~22883357:-
THCA	cis	rs7829975	0.511	rs2976906	ENSG00000254153.1	CTA-398F10.2	-3.75	2e-04	0.0141	-0.19	-0.17	Mood instability;	chr8:8484905	chr8:8456909~8461337:-
THCA	cis	rs6012953	0.874	rs2426159	ENSG00000231715.1	COX6CP2	-3.75	2e-04	0.0141	-0.18	-0.17	Vitiligo;	chr20:50556642	chr20:50479767~50479991:+
THCA	cis	rs4660214	0.666	rs2275186	ENSG00000228060.1	RP11-69E11.8	3.75	2e-04	0.0141	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39565160~39573203:+
THCA	cis	rs3733585	0.753	rs1122141	ENSG00000250413.1	RP11-448G15.1	3.75	2e-04	0.0141	0.17	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9945654	chr4:10006482~10009725:+
THCA	cis	rs7833790	0.929	rs10958048	ENSG00000254689.1	RP11-354A14.1	-3.75	2e-04	0.0141	-0.22	-0.17	Diastolic blood pressure;	chr8:81880679	chr8:81885377~81923193:+
THCA	cis	rs9650657	0.737	rs2409669	ENSG00000255310.2	AF131215.2	-3.75	2e-04	0.0141	-0.14	-0.17	Neuroticism;	chr8:10766459	chr8:11107788~11109726:-
THCA	cis	rs804280	0.56	rs10503426	ENSG00000206014.6	OR7E161P	-3.75	2e-04	0.0141	-0.2	-0.17	Myopia (pathological);	chr8:11731874	chr8:11928597~11929563:-
THCA	cis	rs10811771	0.541	rs4338198	ENSG00000234840.1	LINC01239	-3.75	2e-04	0.0141	-0.19	-0.17	Response to antipsychotic therapy (extrapyramidal side effects);	chr9:22847737	chr9:22646200~22824213:+
THCA	cis	rs735539	0.556	rs9552277	ENSG00000278291.1	RP11-172H24.4	3.75	2e-04	0.0141	0.23	0.17	Dental caries;	chr13:20778148	chr13:20699307~20703718:-
THCA	cis	rs4908768	0.539	rs11121205	ENSG00000270282.1	RP5-1115A15.2	3.75	2e-04	0.0142	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8512653~8513021:+
THCA	cis	rs9926296	0.605	rs8046243	ENSG00000274627.1	RP11-104N10.2	-3.75	2e-04	0.0142	-0.17	-0.17	Vitiligo;	chr16:89785725	chr16:89516797~89522217:+
THCA	cis	rs801193	1	rs7785213	ENSG00000232546.1	RP11-458F8.1	3.75	2e-04	0.0142	0.14	0.17	Aortic root size;	chr7:66673991	chr7:66848496~66858136:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000232546.1	RP11-458F8.1	-3.75	2e-04	0.0142	-0.14	-0.17	Aortic root size;	chr7:66692033	chr7:66848496~66858136:+
THCA	cis	rs7618915	1	rs3844291	ENSG00000243224.1	RP5-1157M23.2	-3.75	2e-04	0.0142	-0.19	-0.17	Bipolar disorder;	chr3:52307199	chr3:52239258~52241097:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000219891.2	ZSCAN12P1	3.75	2e-04	0.0142	0.24	0.17	Parkinson's disease;	chr6:28066959	chr6:28091154~28093664:+
THCA	cis	rs10760158	0.832	rs10760159	ENSG00000226752.6	PSMD5-AS1	-3.75	2e-04	0.0142	-0.21	-0.17	Pulse pressure;	chr9:121236064	chr9:120824828~120854385:+
THCA	cis	rs7707921	1	rs7707921	ENSG00000251374.1	RPS23P5	-3.75	2e-04	0.0142	-0.25	-0.17	Breast cancer;	chr5:82242227	chr5:82265157~82265259:-
THCA	cis	rs2033711	0.783	rs8113810	ENSG00000232098.3	CTD-2619J13.14	3.75	2e-04	0.0142	0.15	0.17	Uric acid clearance;	chr19:58420739	chr19:58404238~58408484:-
THCA	cis	rs2033711	0.87	rs4801270	ENSG00000232098.3	CTD-2619J13.14	3.75	2e-04	0.0142	0.15	0.17	Uric acid clearance;	chr19:58421395	chr19:58404238~58408484:-
THCA	cis	rs472402	0.58	rs7706809	ENSG00000250056.4	LINC01018	-3.75	2e-04	0.0142	-0.2	-0.17	Response to amphetamines;	chr5:6635858	chr5:6582136~6588499:+
THCA	cis	rs9650657	0.775	rs10100265	ENSG00000269918.1	AF131215.9	-3.75	2e-04	0.0142	-0.18	-0.17	Neuroticism;	chr8:10775649	chr8:11104691~11106704:-
THCA	cis	rs7819412	0.745	rs4841498	ENSG00000206014.6	OR7E161P	3.75	2e-04	0.0142	0.2	0.17	Triglycerides;	chr8:11127922	chr8:11928597~11929563:-
THCA	cis	rs6929812	0.577	rs2294309	ENSG00000271755.1	RP1-153G14.4	3.75	2e-04	0.0142	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27516037	chr6:27404010~27406964:-
THCA	cis	rs801193	1	rs2659912	ENSG00000275400.1	RP4-756H11.5	-3.75	2e-04	0.0142	-0.16	-0.17	Aortic root size;	chr7:66693012	chr7:66553805~66554199:-
THCA	cis	rs73173548	0.502	rs12659818	ENSG00000247828.6	TMEM161B-AS1	3.75	2e-04	0.0142	0.16	0.17	Macular telangiectasia type 2;	chr5:88451964	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs12653074	ENSG00000247828.6	TMEM161B-AS1	3.75	2e-04	0.0142	0.16	0.17	Macular telangiectasia type 2;	chr5:88452920	chr5:88268895~88436685:+
THCA	cis	rs964611	0.882	rs6493315	ENSG00000259488.2	RP11-154J22.1	-3.75	2e-04	0.0142	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48274817	chr15:48312353~48331856:-
THCA	cis	rs1908814	0.516	rs4841641	ENSG00000255495.1	AC145124.2	3.75	2e-04	0.0142	0.2	0.17	Neuroticism;	chr8:11940718	chr8:12194467~12196280:+
THCA	cis	rs6921919	1	rs6922111	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0142	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28115628~28116551:+
THCA	cis	rs7259376	0.525	rs1692602	ENSG00000269138.1	ZNF209P	3.75	2e-04	0.0142	0.16	0.17	Menopause (age at onset);	chr19:22453485	chr19:22463922~22473036:+
THCA	cis	rs2252521	0.583	rs317707	ENSG00000272568.4	CTB-113D17.1	3.75	2e-04	0.0142	0.19	0.17	Cognitive performance;	chr7:29058720	chr7:28979967~29013367:+
THCA	cis	rs7737355	1	rs59808242	ENSG00000237714.1	P4HA2-AS1	-3.75	2e-04	0.0142	-0.24	-0.17	Life satisfaction;	chr5:131419201	chr5:132184876~132192808:+
THCA	cis	rs7737355	1	rs12521320	ENSG00000237714.1	P4HA2-AS1	-3.75	2e-04	0.0142	-0.24	-0.17	Life satisfaction;	chr5:131420227	chr5:132184876~132192808:+
THCA	cis	rs7737355	1	rs12654593	ENSG00000237714.1	P4HA2-AS1	-3.75	2e-04	0.0142	-0.24	-0.17	Life satisfaction;	chr5:131421174	chr5:132184876~132192808:+
THCA	cis	rs2055375	0.643	rs173946	ENSG00000251279.1	CTC-436P18.1	-3.75	2e-04	0.0142	-0.21	-0.17	Intelligence (multi-trait analysis);	chr5:61192470	chr5:61162070~61232040:+
THCA	cis	rs9487094	0.666	rs9480958	ENSG00000223537.2	RP5-919F19.5	3.75	2e-04	0.0142	0.17	0.17	Height;	chr6:109432968	chr6:109487906~109506800:+
THCA	cis	rs7259376	0.503	rs1692603	ENSG00000269138.1	ZNF209P	3.75	2e-04	0.0142	0.16	0.17	Menopause (age at onset);	chr19:22455504	chr19:22463922~22473036:+
THCA	cis	rs11583043	1	rs6660290	ENSG00000233184.5	RP11-421L21.3	-3.75	2e-04	0.0142	-0.18	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101017956	chr1:101025878~101087268:+
THCA	cis	rs860295	0.665	rs12079134	ENSG00000236675.1	MTX1P1	-3.75	2e-04	0.0142	-0.17	-0.17	Body mass index;	chr1:155496993	chr1:155230975~155234325:+
THCA	cis	rs683250	0.629	rs657324	ENSG00000254551.1	RP11-727A23.7	3.75	2e-04	0.0142	0.21	0.17	Subcortical brain region volumes;	chr11:83264088	chr11:83209431~83213379:-
THCA	cis	rs683250	0.66	rs645169	ENSG00000254551.1	RP11-727A23.7	3.75	2e-04	0.0142	0.21	0.17	Subcortical brain region volumes;	chr11:83264440	chr11:83209431~83213379:-
THCA	cis	rs67981189	0.896	rs7146932	ENSG00000269927.1	RP6-91H8.3	3.75	2e-04	0.0142	0.19	0.17	Schizophrenia;	chr14:71010328	chr14:71141125~71143253:-
THCA	cis	rs9590614	0.966	rs1887744	ENSG00000278390.3	RP11-74J13.8	3.75	2e-04	0.0142	0.16	0.17	Local histogram emphysema pattern;	chr13:41594840	chr13:41132939~41236686:+
THCA	cis	rs1019173	0.789	rs6971875	ENSG00000261455.1	LINC01003	-3.75	2e-04	0.0142	-0.15	-0.17	Kidney function decline traits;	chr7:152018890	chr7:152463786~152465549:+
THCA	cis	rs11098699	0.784	rs13114897	ENSG00000273007.1	RP11-170N16.3	3.75	2e-04	0.0142	0.14	0.17	Mosquito bite size;	chr4:123326251	chr4:122881878~122884712:-
THCA	cis	rs16944613	0.588	rs10852136	ENSG00000259212.1	CTD-3065B20.2	3.75	2e-04	0.0142	0.27	0.17	Colorectal cancer;	chr15:90596566	chr15:90595840~90596447:-
THCA	cis	rs16975963	0.644	rs111694872	ENSG00000276846.1	CTD-3220F14.3	-3.75	2e-04	0.0142	-0.16	-0.17	Longevity;	chr19:37555429	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.644	rs12162238	ENSG00000276846.1	CTD-3220F14.3	-3.75	2e-04	0.0142	-0.16	-0.17	Longevity;	chr19:37591484	chr19:37314868~37315620:-
THCA	cis	rs12493885	0.725	rs4680113	ENSG00000243069.6	ARHGEF26-AS1	-3.75	2e-04	0.0142	-0.28	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154009548	chr3:154024401~154121332:-
THCA	cis	rs7660883	0.897	rs236996	ENSG00000251411.1	RP11-397E7.4	-3.75	2e-04	0.0142	-0.16	-0.17	HDL cholesterol levels;	chr4:87084051	chr4:86913266~86914817:-
THCA	cis	rs321358	0.895	rs17457430	ENSG00000271390.1	RP11-89C3.3	3.75	2e-04	0.0142	0.27	0.17	Body mass index;	chr11:111085279	chr11:111089870~111090368:-
THCA	cis	rs6847067	1	rs1385263	ENSG00000180769.7	WDFY3-AS2	3.75	2e-04	0.0142	0.12	0.17	Oropharynx cancer;	chr4:84783821	chr4:84965682~85011277:+
THCA	cis	rs559555	0.74	rs413836	ENSG00000276517.1	AL133243.2	-3.75	2e-04	0.0142	-0.16	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31532977	chr2:32526504~32529507:+
THCA	cis	rs9921338	0.781	rs7205925	ENSG00000262636.1	CTD-3088G3.4	-3.75	2e-04	0.0142	-0.25	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11368621	chr16:11380859~11381118:-
THCA	cis	rs7824557	0.564	rs35009431	ENSG00000154316.13	TDH	3.75	2e-04	0.0142	0.13	0.17	Retinal vascular caliber;	chr8:11375279	chr8:11339637~11368452:+
THCA	cis	rs2337406	0.866	rs4774019	ENSG00000280411.1	IGHV1-69-2	-3.75	2e-04	0.0142	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106805386	chr14:106762092~106762588:-
THCA	cis	rs2033711	0.728	rs4801586	ENSG00000232098.3	CTD-2619J13.14	3.75	2e-04	0.0142	0.15	0.17	Uric acid clearance;	chr19:58423161	chr19:58404238~58408484:-
THCA	cis	rs7824557	0.527	rs2572369	ENSG00000227888.4	FAM66A	-3.75	2e-04	0.0142	-0.21	-0.17	Retinal vascular caliber;	chr8:11381088	chr8:12362019~12388296:+
THCA	cis	rs2120243	0.533	rs1392798	ENSG00000243176.4	RP11-550I24.2	-3.75	2e-04	0.0142	-0.16	-0.17	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338498	chr3:157175223~157381265:+
THCA	cis	rs860295	0.702	rs11264397	ENSG00000236675.1	MTX1P1	-3.75	2e-04	0.0142	-0.18	-0.17	Body mass index;	chr1:155641694	chr1:155230975~155234325:+
THCA	cis	rs1552244	0.554	rs6443275	ENSG00000269982.1	RP11-1020A11.2	3.75	2e-04	0.0142	0.12	0.17	Alzheimer's disease;	chr3:9967135	chr3:9958717~9962539:+
THCA	cis	rs12530	0.715	rs2294314	ENSG00000232218.1	RP1-149A16.16	-3.75	2e-04	0.0142	-0.26	-0.17	IgG glycosylation;	chr22:32398616	chr22:32386668~32386868:+
THCA	cis	rs12544026	0.548	rs517868	ENSG00000253669.3	KB-1732A1.1	-3.75	2e-04	0.0142	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101900802	chr8:102805517~102809971:+
THCA	cis	rs494526	0.736	rs11198762	ENSG00000229272.1	RP11-498J9.2	3.75	2e-04	0.0142	0.2	0.17	Alcoholic chronic pancreatitis;	chr10:119082698	chr10:119003536~119003884:-
THCA	cis	rs7614311	0.681	rs57766205	ENSG00000271843.1	RP11-245J9.5	-3.75	2e-04	0.0142	-0.28	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:63909627	chr3:64008082~64008692:-
THCA	cis	rs1113500	0.614	rs12565953	ENSG00000226822.1	RP11-356N1.2	3.75	2e-04	0.0142	0.19	0.17	Growth-regulated protein alpha levels;	chr1:108064465	chr1:108071482~108074519:+
THCA	cis	rs669446	0.533	rs11210913	ENSG00000237950.1	RP11-7O11.3	3.75	2e-04	0.0142	0.15	0.17	Amyotrophic lateral sclerosis (age of onset);	chr1:43756926	chr1:43944370~43946551:-
THCA	cis	rs4356203	0.905	rs10832733	ENSG00000272034.1	SNORD14A	-3.75	0.000201	0.0142	-0.17	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17089725	chr11:17074654~17074744:-
THCA	cis	rs13381277	0.717	rs60769917	ENSG00000263982.1	RP11-504I13.3	3.75	0.000201	0.0142	0.28	0.17	Dental caries;	chr18:76612649	chr18:76372717~76378275:+
THCA	cis	rs12681963	0.688	rs6997926	ENSG00000272375.1	RP11-51J9.6	3.75	0.000201	0.0142	0.28	0.17	Migraine;	chr8:30197384	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs73234779	ENSG00000272375.1	RP11-51J9.6	3.75	0.000201	0.0142	0.28	0.17	Migraine;	chr8:30200997	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs16876663	ENSG00000272375.1	RP11-51J9.6	3.75	0.000201	0.0142	0.28	0.17	Migraine;	chr8:30202182	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs73234780	ENSG00000272375.1	RP11-51J9.6	3.75	0.000201	0.0142	0.28	0.17	Migraine;	chr8:30202239	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs73234781	ENSG00000272375.1	RP11-51J9.6	3.75	0.000201	0.0142	0.28	0.17	Migraine;	chr8:30202242	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs7001629	ENSG00000272375.1	RP11-51J9.6	3.75	0.000201	0.0142	0.28	0.17	Migraine;	chr8:30203273	chr8:30197404~30198048:+
THCA	cis	rs7216064	0.953	rs1599859	ENSG00000278740.1	RP11-147L13.14	3.75	0.000201	0.0142	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841077	chr17:68188547~68189165:+
THCA	cis	rs875971	0.502	rs6460311	ENSG00000273024.4	INTS4P2	3.75	0.000201	0.0142	0.21	0.17	Aortic root size;	chr7:66646886	chr7:65647864~65715661:+
THCA	cis	rs7824557	0.547	rs2409749	ENSG00000254527.1	ENPP7P12	-3.75	0.000201	0.0142	-0.22	-0.17	Retinal vascular caliber;	chr8:11221440	chr8:12205759~12206389:-
THCA	cis	rs765787	0.53	rs2554456	ENSG00000259539.1	CTD-2651B20.1	3.75	0.000201	0.0142	0.21	0.17	Uric acid levels;	chr15:45228940	chr15:45152664~45167526:-
THCA	cis	rs2880765	0.546	rs36098649	ENSG00000259630.2	CTD-2262B20.1	-3.75	0.000201	0.0142	-0.22	-0.17	Coronary artery disease;	chr15:85513576	chr15:85415228~85415633:+
THCA	cis	rs4664304	0.789	rs2063439	ENSG00000226266.5	AC009961.3	3.75	0.000201	0.0142	0.21	0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159943590	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.764	rs2063440	ENSG00000226266.5	AC009961.3	3.75	0.000201	0.0142	0.21	0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159943591	chr2:159670708~159712435:-
THCA	cis	rs2562456	0.754	rs55771551	ENSG00000268658.4	LINC00664	3.75	0.000201	0.0142	0.25	0.17	Pain;	chr19:21563578	chr19:21483374~21503238:+
THCA	cis	rs6137726	0.524	rs1203952	ENSG00000237396.1	LINC01384	3.75	0.000201	0.0142	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22633494	chr20:22587522~22607517:-
THCA	cis	rs365302	1	rs444245	ENSG00000235086.1	FNDC1-IT1	3.75	0.000201	0.0142	0.24	0.17	Coronary heart disease;	chr6:159221931	chr6:159240786~159243329:+
THCA	cis	rs308403	0.533	rs309377	ENSG00000224786.1	CETN4P	3.75	0.000201	0.0142	0.17	0.17	Blood protein levels;	chr4:122755198	chr4:122730548~122732193:-
THCA	cis	rs875971	0.66	rs10229345	ENSG00000230295.1	RP11-458F8.2	-3.75	0.000201	0.0142	-0.13	-0.17	Aortic root size;	chr7:66517181	chr7:66880708~66882981:+
THCA	cis	rs748404	0.588	rs2255410	ENSG00000275601.1	AC011330.13	-3.75	0.000201	0.0142	-0.2	-0.17	Lung cancer;	chr15:43538899	chr15:43642389~43643023:-
THCA	cis	rs11634944	0.508	rs10451029	ENSG00000257647.1	RP11-701H24.3	3.75	0.000201	0.0142	0.09	0.17	Interleukin-8 levels;	chr15:24992196	chr15:25027736~25032047:-
THCA	cis	rs9437689	0.591	rs1146460	ENSG00000235501.4	RP4-639F20.1	-3.75	0.000201	0.0142	-0.19	-0.17	Phospholipid levels (plasma);	chr1:94943364	chr1:94927566~94963270:+
THCA	cis	rs972578	0.806	rs8140272	ENSG00000230319.1	AL022476.2	3.75	0.000201	0.0142	0.18	0.17	Mean platelet volume;	chr22:42826236	chr22:43038585~43052366:+
THCA	cis	rs9425766	0.924	rs9286895	ENSG00000270084.1	GAS5-AS1	-3.75	0.000201	0.0142	-0.17	-0.17	Life satisfaction;	chr1:173873329	chr1:173863248~173863941:+
THCA	cis	rs613391	0.522	rs7043015	ENSG00000234840.1	LINC01239	-3.75	0.000201	0.0142	-0.2	-0.17	Quantitative traits;	chr9:22729025	chr9:22646200~22824213:+
THCA	cis	rs987724	0.515	rs1574980	ENSG00000243926.1	TIPARP-AS1	3.75	0.000201	0.0142	0.21	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156917639	chr3:156671862~156674378:-
THCA	cis	rs4073582	1	rs801732	ENSG00000255320.1	RP11-755F10.1	-3.75	0.000201	0.0142	-0.23	-0.17	Gout;	chr11:66168031	chr11:66244840~66246239:-
THCA	cis	rs4743820	0.503	rs10820834	ENSG00000229694.5	RP11-305L7.6	3.75	0.000201	0.0142	0.2	0.17	Ulcerative colitis;Inflammatory bowel disease;	chr9:91155158	chr9:91119062~91182762:+
THCA	cis	rs12681963	0.764	rs7838088	ENSG00000248159.1	HSPA8P11	-3.75	0.000201	0.0142	-0.32	-0.17	Migraine;	chr8:30139308	chr8:30237382~30240997:+
THCA	cis	rs7713065	1	rs7713065	ENSG00000237714.1	P4HA2-AS1	3.75	0.000201	0.0142	0.25	0.17	Lung function (FEV1/FVC);	chr5:132452642	chr5:132184876~132192808:+
THCA	cis	rs10792320	1	rs10792320	ENSG00000279491.1	RP11-810P12.7	-3.75	0.000201	0.0142	-0.18	-0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61978819	chr11:61967794~61969490:+
THCA	cis	rs9532669	0.926	rs2039119	ENSG00000229473.2	RGS17P1	-3.75	0.000201	0.0142	-0.21	-0.17	Cervical cancer;	chr13:40872432	chr13:40992779~40993331:-
THCA	cis	rs6142618	0.84	rs6087896	ENSG00000224452.1	RSL24D1P6	-3.75	0.000201	0.0142	-0.21	-0.17	Inflammatory bowel disease;	chr20:32394916	chr20:32170390~32170790:-
THCA	cis	rs4853525	0.561	rs12693589	ENSG00000235852.1	AC005540.3	3.75	0.000201	0.0142	0.19	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190967936	chr2:190880797~190882059:-
THCA	cis	rs231361	0.608	rs231840	ENSG00000254757.1	RP13-726E6.1	3.75	0.000201	0.0142	0.22	0.17	Type 2 diabetes;	chr11:2702900	chr11:3469319~3531328:+
THCA	cis	rs1577917	0.958	rs1337843	ENSG00000220563.1	PKMP3	-3.75	0.000201	0.0142	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85965827	chr6:85659892~85660606:-
THCA	cis	rs7804306	0.522	rs34395699	ENSG00000233264.2	AC006042.8	3.75	0.000201	0.0142	0.23	0.17	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037257	chr7:7980312~7982228:+
THCA	cis	rs7804306	0.522	rs34466770	ENSG00000233264.2	AC006042.8	3.75	0.000201	0.0142	0.23	0.17	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037345	chr7:7980312~7982228:+
THCA	cis	rs6545883	0.868	rs7574631	ENSG00000212978.6	AC016747.3	3.75	0.000201	0.0142	0.18	0.17	Tuberculosis;	chr2:61598007	chr2:61141592~61144969:-
THCA	cis	rs9911578	1	rs4793952	ENSG00000224738.1	AC099850.1	-3.75	0.000201	0.0142	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58531104	chr17:59106598~59118267:+
THCA	cis	rs3924048	0.574	rs12096486	ENSG00000272482.1	RP11-474O21.5	-3.75	0.000201	0.0142	-0.15	-0.17	Optic cup area;	chr1:12556881	chr1:12618900~12619244:-
THCA	cis	rs3924048	0.574	rs11121930	ENSG00000272482.1	RP11-474O21.5	-3.75	0.000201	0.0142	-0.15	-0.17	Optic cup area;	chr1:12556926	chr1:12618900~12619244:-
THCA	cis	rs3924048	0.574	rs11121931	ENSG00000272482.1	RP11-474O21.5	-3.75	0.000201	0.0142	-0.15	-0.17	Optic cup area;	chr1:12556979	chr1:12618900~12619244:-
THCA	cis	rs6491750	0.557	rs76880831	ENSG00000276957.1	RP11-29B2.6	-3.75	0.000201	0.0142	-0.29	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103510263	chr13:102593338~102593873:-
THCA	cis	rs2613964	0.504	rs9288972	ENSG00000243795.1	RP11-572M11.3	3.75	0.000201	0.0142	0.19	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131422	chr3:113142350~113167819:-
THCA	cis	rs2613964	0.504	rs9838215	ENSG00000243795.1	RP11-572M11.3	3.75	0.000201	0.0142	0.19	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131616	chr3:113142350~113167819:-
THCA	cis	rs2613964	0.504	rs9838253	ENSG00000243795.1	RP11-572M11.3	3.75	0.000201	0.0142	0.19	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131678	chr3:113142350~113167819:-
THCA	cis	rs2613964	0.504	rs17317945	ENSG00000243795.1	RP11-572M11.3	3.75	0.000201	0.0142	0.19	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131934	chr3:113142350~113167819:-
THCA	cis	rs2613964	0.504	rs12695288	ENSG00000243795.1	RP11-572M11.3	3.75	0.000201	0.0142	0.19	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113132668	chr3:113142350~113167819:-
THCA	cis	rs7660883	1	rs3775221	ENSG00000251411.1	RP11-397E7.4	3.75	0.000201	0.0142	0.16	0.17	HDL cholesterol levels;	chr4:87090641	chr4:86913266~86914817:-
THCA	cis	rs1065852	0.526	rs4822079	ENSG00000232710.1	RP4-669P10.16	-3.75	0.000201	0.0142	-0.21	-0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41998608	chr22:42136433~42139927:-
THCA	cis	rs34421088	0.576	rs2572437	ENSG00000261451.1	RP11-981G7.1	-3.75	0.000201	0.0142	-0.24	-0.17	Neuroticism;	chr8:11240932	chr8:10433672~10438312:+
THCA	cis	rs2625529	0.641	rs2035379	ENSG00000260037.4	CTD-2524L6.3	-3.75	0.000201	0.0142	-0.24	-0.17	Red blood cell count;	chr15:72000861	chr15:71818396~71823384:+
THCA	cis	rs2380205	0.517	rs11255780	ENSG00000232807.2	RP11-536K7.3	-3.75	0.000201	0.0142	-0.17	-0.17	Breast cancer;	chr10:5897865	chr10:5934270~5945900:-
THCA	cis	rs7759001	0.779	rs12215117	ENSG00000271755.1	RP1-153G14.4	3.75	0.000201	0.0142	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27479517	chr6:27404010~27406964:-
THCA	cis	rs875971	0.638	rs6960778	ENSG00000230295.1	RP11-458F8.2	3.75	0.000201	0.0142	0.13	0.17	Aortic root size;	chr7:66606610	chr7:66880708~66882981:+
THCA	cis	rs11671005	0.779	rs731259	ENSG00000268912.1	CTD-2619J13.17	-3.75	0.000201	0.0142	-0.17	-0.17	Mean platelet volume;	chr19:58478057	chr19:58428632~58431148:-
THCA	cis	rs28510890	0.547	rs12441705	ENSG00000258647.4	LINC00930	3.75	0.000201	0.0142	0.24	0.17	Lung cancer in ever smokers;	chr15:92609319	chr15:92567818~92572042:-
THCA	cis	rs5758659	0.652	rs133313	ENSG00000234009.1	RPL5P34	-3.75	0.000201	0.0142	-0.16	-0.17	Cognitive function;	chr22:42005745	chr22:42776406~42777296:-
THCA	cis	rs5758659	0.652	rs133314	ENSG00000234009.1	RPL5P34	-3.75	0.000201	0.0142	-0.16	-0.17	Cognitive function;	chr22:42005837	chr22:42776406~42777296:-
THCA	cis	rs7819412	0.668	rs2409721	ENSG00000254839.1	AF131215.6	3.75	0.000201	0.0142	0.18	0.17	Triglycerides;	chr8:11180735	chr8:11062647~11067089:-
THCA	cis	rs2243480	0.901	rs3813708	ENSG00000213640.3	EEF1DP4	3.75	0.000201	0.0142	0.32	0.17	Diabetic kidney disease;	chr7:65840645	chr7:64862999~64864370:+
THCA	cis	rs11175834	1	rs11175834	ENSG00000277945.1	RP11-677M24.1	3.75	0.000201	0.0142	0.24	0.17	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65598856	chr12:65830750~65831050:+
THCA	cis	rs9437689	0.591	rs1271952	ENSG00000235501.4	RP4-639F20.1	3.75	0.000201	0.0142	0.19	0.17	Phospholipid levels (plasma);	chr1:94951792	chr1:94927566~94963270:+
THCA	cis	rs875971	0.66	rs7807930	ENSG00000230295.1	RP11-458F8.2	3.75	0.000201	0.0142	0.13	0.17	Aortic root size;	chr7:66622178	chr7:66880708~66882981:+
THCA	cis	rs11723261	0.582	rs6599293	ENSG00000250892.1	RP11-1365D11.1	3.75	0.000201	0.0142	0.25	0.17	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:201409~205009:-
THCA	cis	rs938554	0.513	rs10939650	ENSG00000261490.1	RP11-448G15.3	3.75	0.000201	0.0142	0.12	0.17	Blood metabolite levels;	chr4:9996816	chr4:10068089~10073019:-
THCA	cis	rs875971	0.545	rs6979636	ENSG00000232559.3	GS1-124K5.12	3.75	0.000201	0.0142	0.19	0.17	Aortic root size;	chr7:66276638	chr7:66554588~66576923:-
THCA	cis	rs7546	0.504	rs2015319	ENSG00000267077.1	RP11-127I20.5	-3.75	0.000201	0.0142	-0.2	-0.17	Cancer;	chr16:4886279	chr16:4795265~4796532:-
THCA	cis	rs17253792	0.822	rs74053651	ENSG00000186615.9	KTN1-AS1	-3.75	0.000201	0.0142	-0.27	-0.17	Putamen volume;	chr14:55658648	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs17685053	ENSG00000186615.9	KTN1-AS1	-3.75	0.000201	0.0142	-0.27	-0.17	Putamen volume;	chr14:55659053	chr14:55499278~55580110:-
THCA	cis	rs13108904	0.87	rs2291199	ENSG00000254094.1	AC078852.1	-3.75	0.000201	0.0142	-0.21	-0.17	Obesity-related traits;	chr4:1250479	chr4:1356581~1358075:+
THCA	cis	rs7308116	0.53	rs11113578	ENSG00000257951.1	RP11-554D14.4	3.75	0.000201	0.0142	0.2	0.17	Pelvic organ prolapse (moderate/severe);	chr12:107906609	chr12:107881242~107883382:+
THCA	cis	rs2522056	1	rs10900807	ENSG00000237714.1	P4HA2-AS1	-3.75	0.000201	0.0142	-0.25	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132421788	chr5:132184876~132192808:+
THCA	cis	rs28829049	0.57	rs12060125	ENSG00000270728.1	RP4-657E11.10	3.75	0.000201	0.0142	0.12	0.17	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19064614	chr1:19297080~19297903:+
THCA	cis	rs8177876	0.915	rs12444974	ENSG00000261061.1	RP11-303E16.2	-3.75	0.000201	0.0142	-0.27	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094625	chr16:81030770~81031485:+
THCA	cis	rs13256369	0.851	rs13267036	ENSG00000254153.1	CTA-398F10.2	-3.75	0.000201	0.0142	-0.2	-0.17	Obesity-related traits;	chr8:8709175	chr8:8456909~8461337:-
THCA	cis	rs9307551	0.602	rs7697040	ENSG00000250334.4	LINC00989	3.75	0.000201	0.0142	0.22	0.17	Refractive error;	chr4:79644498	chr4:79492416~79576460:+
THCA	cis	rs7737355	0.947	rs244733	ENSG00000237714.1	P4HA2-AS1	3.75	0.000201	0.0142	0.24	0.17	Life satisfaction;	chr5:131487085	chr5:132184876~132192808:+
THCA	cis	rs6724465	1	rs6752757	ENSG00000272644.1	RP11-33O4.1	3.75	0.000201	0.0142	0.26	0.17	Height;	chr2:219079079	chr2:219069354~219069809:-
THCA	cis	rs6724465	0.925	rs13408333	ENSG00000272644.1	RP11-33O4.1	3.75	0.000201	0.0142	0.26	0.17	Height;	chr2:219106795	chr2:219069354~219069809:-
THCA	cis	rs6724465	0.925	rs13408334	ENSG00000272644.1	RP11-33O4.1	3.75	0.000201	0.0142	0.26	0.17	Height;	chr2:219106796	chr2:219069354~219069809:-
THCA	cis	rs6724465	1	rs13408337	ENSG00000272644.1	RP11-33O4.1	3.75	0.000201	0.0142	0.26	0.17	Height;	chr2:219106804	chr2:219069354~219069809:-
THCA	cis	rs6724465	1	rs13396442	ENSG00000272644.1	RP11-33O4.1	3.75	0.000201	0.0142	0.26	0.17	Height;	chr2:219106808	chr2:219069354~219069809:-
THCA	cis	rs11175834	0.655	rs4631931	ENSG00000213344.2	PCNPP3	3.75	0.000201	0.0143	0.29	0.17	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65572195	chr12:65645992~65646462:-
THCA	cis	rs786425	0.627	rs35804181	ENSG00000278112.1	RP11-972P1.11	3.75	0.000201	0.0143	0.17	0.17	Pubertal anthropometrics;	chr12:123677797	chr12:123519390~123519856:-
THCA	cis	rs3748682	0.861	rs28411034	ENSG00000252448.1	SNORA63	-3.75	0.000201	0.0143	-0.22	-0.17	Hypothyroidism;	chr1:37811325	chr1:37884237~37884317:+
THCA	cis	rs7267979	0.873	rs6037062	ENSG00000125804.12	FAM182A	-3.75	0.000202	0.0143	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:26054655~26086917:+
THCA	cis	rs180358	0.738	rs180323	ENSG00000254851.1	RP11-109L13.1	-3.75	0.000202	0.0143	-0.25	-0.17	Multiple sclerosis (severity);	chr11:116755854	chr11:117135528~117138582:+
THCA	cis	rs9650657	0.836	rs3905581	ENSG00000255310.2	AF131215.2	-3.75	0.000202	0.0143	-0.14	-0.17	Neuroticism;	chr8:10746195	chr8:11107788~11109726:-
THCA	cis	rs2832191	0.692	rs2254872	ENSG00000176054.6	RPL23P2	3.75	0.000202	0.0143	0.15	0.17	Dental caries;	chr21:29042403	chr21:28997613~28998033:-
THCA	cis	rs12022452	0.506	rs11208363	ENSG00000237899.1	RP4-739H11.3	-3.75	0.000202	0.0143	-0.26	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40669089~40687588:-
THCA	cis	rs2307022	0.629	rs2863975	ENSG00000279649.1	RP11-96D1.8	-3.75	0.000202	0.0143	-0.11	-0.17	Body mass index;	chr16:68348544	chr16:68290087~68292790:-
THCA	cis	rs875971	0.545	rs13311962	ENSG00000273024.4	INTS4P2	3.75	0.000202	0.0143	0.21	0.17	Aortic root size;	chr7:66603142	chr7:65647864~65715661:+
THCA	cis	rs7246967	0.608	rs2569725	ENSG00000198153.8	ZNF849P	-3.75	0.000202	0.0143	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22833208	chr19:22685167~22686732:+
THCA	cis	rs1908814	0.516	rs10113042	ENSG00000255495.1	AC145124.2	3.75	0.000202	0.0143	0.2	0.17	Neuroticism;	chr8:11935669	chr8:12194467~12196280:+
THCA	cis	rs7737355	0.773	rs31252	ENSG00000224431.1	AC063976.7	3.75	0.000202	0.0143	0.16	0.17	Life satisfaction;	chr5:131497740	chr5:132199456~132203487:+
THCA	cis	rs6142618	0.783	rs1737896	ENSG00000224452.1	RSL24D1P6	3.75	0.000202	0.0143	0.21	0.17	Inflammatory bowel disease;	chr20:32439711	chr20:32170390~32170790:-
THCA	cis	rs1862618	0.754	rs252899	ENSG00000234553.1	AC022431.3	-3.75	0.000202	0.0143	-0.2	-0.17	Initial pursuit acceleration;	chr5:56892742	chr5:56536583~56537826:-
THCA	cis	rs7209700	0.745	rs8074348	ENSG00000262879.4	RP11-156P1.3	3.75	0.000202	0.0143	0.16	0.17	IgG glycosylation;	chr17:47276047	chr17:46984045~47100323:-
THCA	cis	rs7709377	0.628	rs73271270	ENSG00000250015.1	CTC-339F2.2	3.75	0.000202	0.0143	0.17	0.17	Metabolite levels  (X-11787);	chr5:116120518	chr5:116302354~116304134:-
THCA	cis	rs737008	0.586	rs7195820	ENSG00000262703.1	RP11-485G7.6	3.75	0.000202	0.0143	0.27	0.17	Obesity-related traits;	chr16:11309998	chr16:11348143~11349321:-
THCA	cis	rs1127311	1	rs10908419	ENSG00000236675.1	MTX1P1	-3.75	0.000202	0.0143	-0.16	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154595223	chr1:155230975~155234325:+
THCA	cis	rs7954584	0.583	rs6486782	ENSG00000272849.1	RP11-347I19.8	-3.75	0.000202	0.0143	-0.1	-0.17	Mean corpuscular volume;	chr12:121921266	chr12:121797511~121801972:+
THCA	cis	rs453301	0.686	rs13252797	ENSG00000233609.3	RP11-62H7.2	3.75	0.000202	0.0143	0.17	0.17	Joint mobility (Beighton score);	chr8:9003920	chr8:8961200~8979025:+
THCA	cis	rs7572644	0.766	rs13016573	ENSG00000223522.1	AC093690.1	3.75	0.000202	0.0143	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27871403	chr2:28307691~28310459:-
THCA	cis	rs56046484	0.871	rs7177110	ENSG00000218052.5	ADAMTS7P4	-3.75	0.000202	0.0143	-0.25	-0.17	Testicular germ cell tumor;	chr15:85128524	chr15:85255369~85330334:-
THCA	cis	rs2221894	0.922	rs4732894	ENSG00000251191.6	LINC00589	-3.75	0.000202	0.0143	-0.2	-0.17	Obesity-related traits;	chr8:28965534	chr8:29673922~29748109:-
THCA	cis	rs7208859	0.673	rs216424	ENSG00000264242.2	RP11-271K11.1	3.75	0.000202	0.0143	0.25	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30553697~30558962:+
THCA	cis	rs2921036	0.505	rs35190619	ENSG00000254153.1	CTA-398F10.2	3.75	0.000202	0.0143	0.21	0.17	Neuroticism;	chr8:8504313	chr8:8456909~8461337:-
THCA	cis	rs15676	0.947	rs2293968	ENSG00000234771.3	SLC25A25-AS1	3.75	0.000202	0.0143	0.14	0.17	Blood metabolite levels;	chr9:128824961	chr9:128108581~128118693:-
THCA	cis	rs3105593	0.933	rs3131601	ENSG00000242737.1	RP11-562A8.1	3.75	0.000202	0.0143	0.21	0.17	QT interval;	chr15:50584745	chr15:50466738~50467096:+
THCA	cis	rs6442522	0.809	rs749845	ENSG00000249786.6	EAF1-AS1	3.75	0.000202	0.0143	0.17	0.17	Uric acid levels;	chr3:15422811	chr3:15436171~15455940:-
THCA	cis	rs6772849	0.901	rs9289330	ENSG00000242551.2	POU5F1P6	-3.75	0.000202	0.0143	-0.22	-0.17	Monocyte percentage of white cells;Monocyte count;	chr3:128592224	chr3:128674735~128677005:-
THCA	cis	rs13178541	0.606	rs11242295	ENSG00000250378.1	RP11-119J18.1	-3.75	0.000202	0.0143	-0.19	-0.17	IgG glycosylation;	chr5:135797217	chr5:135812667~135826582:+
THCA	cis	rs7818688	0.614	rs12056517	ENSG00000253528.2	RP11-347C18.4	-3.75	0.000202	0.0143	-0.25	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94865057	chr8:94974573~94974853:-
THCA	cis	rs8005745	0.505	rs710047	ENSG00000232774.6	FLJ22447	-3.75	0.000202	0.0143	-0.22	-0.17	Select biomarker traits;	chr14:61652101	chr14:61570540~61658696:+
THCA	cis	rs6012564	0.893	rs4810896	ENSG00000230758.1	SNAP23P	-3.75	0.000202	0.0143	-0.21	-0.17	Anger;	chr20:48918761	chr20:49038357~49038602:-
THCA	cis	rs3862188	0.6	rs6679472	ENSG00000230576.1	OR6R1P	-3.75	0.000202	0.0143	-0.15	-0.17	Pre-treatment pain in head and neck squamous cell carcinoma;	chr1:247698214	chr1:247833349~247834288:-
THCA	cis	rs5753037	0.543	rs131267	ENSG00000273350.1	RP4-539M6.20	-3.75	0.000202	0.0143	-0.2	-0.17	Type 1 diabetes;	chr22:29751872	chr22:30420512~30420912:+
THCA	cis	rs5753037	0.543	rs131268	ENSG00000273350.1	RP4-539M6.20	-3.75	0.000202	0.0143	-0.2	-0.17	Type 1 diabetes;	chr22:29751949	chr22:30420512~30420912:+
THCA	cis	rs879500	0.921	rs17750187	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28548589	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs58924619	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28548895	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs10451398	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28549275	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs10451374	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28549378	chr18:27954519~27963687:+
THCA	cis	rs879500	0.96	rs10451375	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28549725	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs12608328	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28549989	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs59209371	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28550061	chr18:27954519~27963687:+
THCA	cis	rs879500	1	rs73946286	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28550282	chr18:27954519~27963687:+
THCA	cis	rs879500	0.92	rs72892364	ENSG00000227279.1	AC015933.2	3.75	0.000202	0.0143	0.19	0.17	Lung function (FVC);	chr18:28550364	chr18:27954519~27963687:+
THCA	cis	rs7829975	0.56	rs56094035	ENSG00000254153.1	CTA-398F10.2	3.75	0.000202	0.0143	0.2	0.17	Mood instability;	chr8:8694112	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.539	rs4841012	ENSG00000254153.1	CTA-398F10.2	3.75	0.000202	0.0143	0.2	0.17	Mood instability;	chr8:8694200	chr8:8456909~8461337:-
THCA	cis	rs7829975	0.56	rs4841013	ENSG00000254153.1	CTA-398F10.2	3.75	0.000202	0.0143	0.2	0.17	Mood instability;	chr8:8694503	chr8:8456909~8461337:-
THCA	cis	rs11124272	0.868	rs477517	ENSG00000276517.1	AL133243.2	-3.75	0.000202	0.0143	-0.16	-0.17	Interleukin-18 levels;	chr2:31623568	chr2:32526504~32529507:+
THCA	cis	rs2676071	0.64	rs2676073	ENSG00000259721.1	RP11-758N13.1	3.75	0.000202	0.0143	0.2	0.17	Periodontitis (Mean PAL);	chr15:33306784	chr15:32717270~32719007:-
THCA	cis	rs5769765	0.671	rs138833	ENSG00000260613.1	RP3-522J7.6	-3.75	0.000202	0.0143	-0.2	-0.17	Schizophrenia;	chr22:49785269	chr22:49832616~49837786:-
THCA	cis	rs643506	0.874	rs618421	ENSG00000230911.1	PPIHP1	-3.75	0.000202	0.0143	-0.23	-0.17	Breast cancer;	chr11:111778085	chr11:112029858~112030367:-
THCA	cis	rs56104184	0.779	rs17206686	ENSG00000243829.1	CTB-33G10.1	-3.75	0.000202	0.0143	-0.21	-0.17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48853060	chr19:49719498~49720081:-
THCA	cis	rs6832769	0.643	rs10003211	ENSG00000272969.1	RP11-528I4.2	-3.75	0.000202	0.0143	-0.21	-0.17	Personality dimensions;	chr4:55651165	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.643	rs11735910	ENSG00000272969.1	RP11-528I4.2	-3.75	0.000202	0.0143	-0.21	-0.17	Personality dimensions;	chr4:55652579	chr4:55547112~55547889:+
THCA	cis	rs7166081	1	rs17526859	ENSG00000270964.1	RP11-502I4.3	3.75	0.000202	0.0143	0.16	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67318728	chr15:67541072~67542604:-
THCA	cis	rs6723226	0.772	rs2366894	ENSG00000276517.1	AL133243.2	-3.75	0.000202	0.0143	-0.16	-0.17	Intelligence (multi-trait analysis);	chr2:32488639	chr2:32526504~32529507:+
THCA	cis	rs2625529	0.824	rs4776586	ENSG00000260037.4	CTD-2524L6.3	-3.75	0.000202	0.0143	-0.24	-0.17	Red blood cell count;	chr15:72138162	chr15:71818396~71823384:+
THCA	cis	rs15676	0.783	rs2417126	ENSG00000234771.3	SLC25A25-AS1	-3.75	0.000202	0.0143	-0.15	-0.17	Blood metabolite levels;	chr9:128800178	chr9:128108581~128118693:-
THCA	cis	rs1577917	0.771	rs4383777	ENSG00000220563.1	PKMP3	3.75	0.000202	0.0143	0.13	0.17	Response to antipsychotic treatment;	chr6:85726242	chr6:85659892~85660606:-
THCA	cis	rs2227564	0.761	rs2227552	ENSG00000271816.1	BMS1P4	3.75	0.000202	0.0143	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73909561	chr10:73699151~73730487:-
THCA	cis	rs4727027	0.704	rs13229244	ENSG00000244560.5	RP4-800G7.2	3.75	0.000202	0.0143	0.1	0.17	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149201127	chr7:149285281~149297312:+
THCA	cis	rs6806253	0.73	rs9877627	ENSG00000239405.1	TMED10P2	3.75	0.000202	0.0143	0.25	0.17	Pit-and-Fissure caries;	chr3:128530406	chr3:128538020~128538631:+
THCA	cis	rs7919656	0.516	rs2620888	ENSG00000228403.1	RP11-563N6.6	3.75	0.000202	0.0143	0.18	0.17	Clinically amyopathic dermatomyositis;	chr10:48770068	chr10:48878022~48878649:+
THCA	cis	rs30380	0.734	rs27044	ENSG00000272109.1	CTD-2260A17.3	-3.75	0.000202	0.0143	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96804353~96806105:+
THCA	cis	rs30380	0.69	rs27432	ENSG00000272109.1	CTD-2260A17.3	-3.75	0.000202	0.0143	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96804353~96806105:+
THCA	cis	rs11671005	0.735	rs3826684	ENSG00000269600.1	AC016629.3	-3.75	0.000202	0.0143	-0.25	-0.17	Mean platelet volume;	chr19:58407338	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs3826683	ENSG00000269600.1	AC016629.3	-3.75	0.000202	0.0143	-0.25	-0.17	Mean platelet volume;	chr19:58407366	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs3826681	ENSG00000269600.1	AC016629.3	-3.75	0.000202	0.0143	-0.25	-0.17	Mean platelet volume;	chr19:58407397	chr19:58593896~58599355:-
THCA	cis	rs9425766	0.679	rs2860846	ENSG00000270084.1	GAS5-AS1	-3.75	0.000202	0.0143	-0.17	-0.17	Life satisfaction;	chr1:174106786	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs2860847	ENSG00000270084.1	GAS5-AS1	-3.75	0.000202	0.0143	-0.17	-0.17	Life satisfaction;	chr1:174106787	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs6672986	ENSG00000270084.1	GAS5-AS1	-3.75	0.000202	0.0143	-0.17	-0.17	Life satisfaction;	chr1:174107726	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs7533430	ENSG00000270084.1	GAS5-AS1	-3.75	0.000202	0.0143	-0.17	-0.17	Life satisfaction;	chr1:174109279	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs7526024	ENSG00000270084.1	GAS5-AS1	-3.75	0.000202	0.0143	-0.17	-0.17	Life satisfaction;	chr1:174109722	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs12079062	ENSG00000270084.1	GAS5-AS1	-3.75	0.000202	0.0143	-0.17	-0.17	Life satisfaction;	chr1:174110446	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs12079063	ENSG00000270084.1	GAS5-AS1	-3.75	0.000202	0.0143	-0.17	-0.17	Life satisfaction;	chr1:174110447	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs12094341	ENSG00000270084.1	GAS5-AS1	-3.75	0.000202	0.0143	-0.17	-0.17	Life satisfaction;	chr1:174110562	chr1:173863248~173863941:+
THCA	cis	rs3087591	0.639	rs1048317	ENSG00000263535.1	AK4P1	3.75	0.000202	0.0143	0.2	0.17	Hip circumference;	chr17:31376984	chr17:31345521~31346187:+
THCA	cis	rs73787773	0.644	rs78455089	ENSG00000246859.2	STARD4-AS1	3.75	0.000202	0.0143	0.24	0.17	Itch intensity from mosquito bite adjusted by bite size;	chr5:112143173	chr5:111512226~111739726:+
THCA	cis	rs3783637	0.643	rs17832281	ENSG00000258413.1	RP11-665C16.6	3.75	0.000202	0.0143	0.36	0.17	Rheumatoid arthritis;Obesity-related traits;	chr14:54988297	chr14:55262767~55272075:-
THCA	cis	rs9425766	0.679	rs4650945	ENSG00000270084.1	GAS5-AS1	3.75	0.000202	0.0143	0.17	0.17	Life satisfaction;	chr1:174114966	chr1:173863248~173863941:+
THCA	cis	rs2221894	0.881	rs1948132	ENSG00000251191.6	LINC00589	3.75	0.000202	0.0143	0.2	0.17	Obesity-related traits;	chr8:29042570	chr8:29673922~29748109:-
THCA	cis	rs427943	0.766	rs372766	ENSG00000215447.6	BX322557.10	-3.75	0.000202	0.0143	-0.14	-0.17	Body mass index;	chr21:45165565	chr21:45288052~45291738:+
THCA	cis	rs36093844	0.527	rs4944555	ENSG00000279742.1	RP11-700A24.1	-3.75	0.000202	0.0143	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86049574	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.527	rs17817956	ENSG00000279742.1	RP11-700A24.1	-3.75	0.000202	0.0143	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86050328	chr11:85852557~85854943:-
THCA	cis	rs2221894	0.922	rs11136052	ENSG00000251191.6	LINC00589	-3.75	0.000202	0.0143	-0.2	-0.17	Obesity-related traits;	chr8:28945558	chr8:29673922~29748109:-
THCA	cis	rs944289	0.74	rs7150440	ENSG00000212071.1	AL162511.1	3.75	0.000203	0.0143	0.2	0.17	Thyroid cancer;	chr14:36114691	chr14:36196480~36196568:-
THCA	cis	rs944289	0.74	rs7150768	ENSG00000212071.1	AL162511.1	3.75	0.000203	0.0143	0.2	0.17	Thyroid cancer;	chr14:36114699	chr14:36196480~36196568:-
THCA	cis	rs860295	0.812	rs4278368	ENSG00000236675.1	MTX1P1	-3.75	0.000203	0.0143	-0.18	-0.17	Body mass index;	chr1:155752766	chr1:155230975~155234325:+
THCA	cis	rs881827	0.692	rs13048683	ENSG00000230982.1	DSTNP1	3.75	0.000203	0.0143	0.19	0.17	Lymphocyte counts;	chr21:46615251	chr21:46653558~46654022:-
THCA	cis	rs11992162	0.569	rs11786149	ENSG00000227888.4	FAM66A	-3.75	0.000203	0.0143	-0.22	-0.17	Monocyte count;	chr8:11943309	chr8:12362019~12388296:+
THCA	cis	rs17507216	0.671	rs4779035	ENSG00000255769.6	GOLGA2P10	-3.75	0.000203	0.0143	-0.26	-0.17	Excessive daytime sleepiness;	chr15:82591686	chr15:82472993~82513950:-
THCA	cis	rs6101567	0.517	rs4470396	ENSG00000224635.1	RP4-564F22.5	-3.75	0.000203	0.0143	-0.21	-0.17	Nose size;	chr20:39271780	chr20:38406011~38416797:-
THCA	cis	rs6545883	0.718	rs6715259	ENSG00000271889.1	RP11-493E12.1	3.75	0.000203	0.0143	0.16	0.17	Tuberculosis;	chr2:61624710	chr2:61151433~61162105:-
THCA	cis	rs9925964	0.933	rs2303223	ENSG00000279196.1	RP11-1072A3.3	-3.75	0.000203	0.0143	-0.16	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31063854	chr16:30984630~30988270:-
THCA	cis	rs17772222	0.606	rs1955598	ENSG00000222990.1	RNU4-22P	3.75	0.000203	0.0143	0.19	0.17	Coronary artery calcification;	chr14:88357311	chr14:88513498~88513663:+
THCA	cis	rs1799922	1	rs62479588	ENSG00000271553.1	RP11-274B21.10	-3.75	0.000203	0.0143	-0.15	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128765467	chr7:128667043~128668156:+
THCA	cis	rs73193808	0.614	rs11088112	ENSG00000176054.6	RPL23P2	3.75	0.000203	0.0143	0.15	0.17	Coronary artery disease;	chr21:29193915	chr21:28997613~28998033:-
THCA	cis	rs7074356	0.915	rs17617970	ENSG00000225484.5	NUTM2B-AS1	3.75	0.000203	0.0143	0.3	0.17	Borderline personality disorder;	chr10:80447136	chr10:79663088~79826594:-
THCA	cis	rs8105895	1	rs117638181	ENSG00000269345.1	VN1R85P	3.75	0.000203	0.0143	0.23	0.17	Body mass index (change over time);	chr19:21980212	chr19:22174766~22175191:-
THCA	cis	rs4660214	0.724	rs10788933	ENSG00000228060.1	RP11-69E11.8	3.75	0.000203	0.0143	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39229483	chr1:39565160~39573203:+
THCA	cis	rs6560517	0.747	rs7858497	ENSG00000234618.1	RPSAP9	-3.75	0.000203	0.0143	-0.2	-0.17	Dialysis-related mortality;	chr9:76474207	chr9:76398699~76399586:+
THCA	cis	rs8054556	0.733	rs35467921	ENSG00000183604.13	SMG1P5	-3.75	0.000203	0.0143	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30037232	chr16:30267553~30335374:-
THCA	cis	rs7572733	0.905	rs6735214	ENSG00000231621.1	AC013264.2	-3.75	0.000203	0.0143	-0.16	-0.17	Dermatomyositis;	chr2:197895783	chr2:197197991~197199273:+
THCA	cis	rs7074356	0.915	rs17618275	ENSG00000278616.1	BEND3P3	3.75	0.000203	0.0143	0.18	0.17	Borderline personality disorder;	chr10:80458629	chr10:79682997~79685436:+
THCA	cis	rs10875746	0.81	rs10875732	ENSG00000258234.1	RP11-370I10.2	3.75	0.000203	0.0143	0.2	0.17	Longevity (90 years and older);	chr12:48048322	chr12:48231098~48284210:-
THCA	cis	rs2235642	0.621	rs2667665	ENSG00000280231.1	LA16c-380F5.3	-3.75	0.000203	0.0143	-0.21	-0.17	Coronary artery disease;	chr16:1519523	chr16:1553655~1554130:-
THCA	cis	rs7824557	0.564	rs2572379	ENSG00000227888.4	FAM66A	-3.75	0.000203	0.0143	-0.21	-0.17	Retinal vascular caliber;	chr8:11379971	chr8:12362019~12388296:+
THCA	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	3.74	0.000203	0.0143	0.18	0.17	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
THCA	cis	rs1232027	0.616	rs6151615	ENSG00000249655.1	CTC-325J23.2	3.74	0.000203	0.0143	0.19	0.17	Huntington's disease progression;	chr5:80665613	chr5:80630313~80631590:-
THCA	cis	rs7088591	0.867	rs117636793	ENSG00000276818.1	AC026393.1	3.74	0.000203	0.0143	0.35	0.17	Blood pressure;	chr10:57995432	chr10:57095699~57095781:+
THCA	cis	rs4747241	0.626	rs4300326	ENSG00000272627.1	RP11-354E23.5	-3.74	0.000203	0.0143	-0.24	-0.17	Heschl's gyrus morphology;	chr10:72308938	chr10:72766560~72767052:+
THCA	cis	rs17248895	0.572	rs8015950	ENSG00000258561.1	RP11-72M17.1	-3.74	0.000203	0.0143	-0.21	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr14:67418453	chr14:66212810~66509394:-
THCA	cis	rs397969	0.646	rs203467	ENSG00000261033.1	RP11-209D14.2	-3.74	0.000203	0.0143	-0.26	-0.17	Platelet count;	chr17:19906436	chr17:20008051~20009234:-
THCA	cis	rs972540	1	rs74809591	ENSG00000229647.1	AC007879.7	-3.74	0.000203	0.0143	-0.2	-0.17	Body mass index;	chr2:206383953	chr2:207239650~207245887:+
THCA	cis	rs972540	0.961	rs79166192	ENSG00000229647.1	AC007879.7	-3.74	0.000203	0.0143	-0.2	-0.17	Body mass index;	chr2:206383963	chr2:207239650~207245887:+
THCA	cis	rs972540	0.961	rs79767740	ENSG00000229647.1	AC007879.7	-3.74	0.000203	0.0143	-0.2	-0.17	Body mass index;	chr2:206383989	chr2:207239650~207245887:+
THCA	cis	rs10802047	0.632	rs506189	ENSG00000231365.4	RP11-418J17.1	-3.74	0.000203	0.0143	-0.18	-0.17	Relative hand skill in reading disability;	chr1:118686578	chr1:119140396~119275973:+
THCA	cis	rs2904297	0.958	rs4613558	ENSG00000261490.1	RP11-448G15.3	-3.74	0.000203	0.0143	-0.11	-0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11026145	chr4:10068089~10073019:-
THCA	cis	rs944289	0.617	rs12431579	ENSG00000258844.1	RP11-259K15.2	3.74	0.000203	0.0143	0.16	0.17	Thyroid cancer;	chr14:36125191	chr14:36214607~36235608:+
THCA	cis	rs4869313	0.687	rs11135485	ENSG00000247121.5	CTD-2260A17.2	-3.74	0.000203	0.0143	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96951265	chr5:96814028~96935809:-
THCA	cis	rs11671005	0.572	rs11669127	ENSG00000265272.2	RN7SL693P	-3.74	0.000203	0.0143	-0.24	-0.17	Mean platelet volume;	chr19:58492463	chr19:58490797~58491075:+
THCA	cis	rs6756513	0.5	rs60515724	ENSG00000231024.1	AC092431.3	-3.74	0.000203	0.0143	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69889316	chr2:69700192~69713847:-
THCA	cis	rs8099594	0.565	rs1893526	ENSG00000266696.1	RP11-30L3.2	3.74	0.000203	0.0143	0.21	0.17	Height;	chr18:49185406	chr18:49205912~49208781:+
THCA	cis	rs7520050	0.751	rs2230657	ENSG00000227857.2	RP4-533D7.5	3.74	0.000203	0.0143	0.15	0.17	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:46134531~46139081:+
THCA	cis	rs79478560	0.518	rs11057388	ENSG00000270061.1	RP11-214K3.19	3.74	0.000203	0.0143	0.22	0.17	Lymphocyte counts;	chr12:123896746	chr12:123969990~123970344:-
THCA	cis	rs4906332	0.966	rs17679729	ENSG00000259775.1	RP11-45P15.4	-3.74	0.000203	0.0143	-0.15	-0.17	Coronary artery disease;	chr14:103457975	chr14:103331674~103332367:-
THCA	cis	rs4906332	0.933	rs35999760	ENSG00000259775.1	RP11-45P15.4	-3.74	0.000203	0.0143	-0.15	-0.17	Coronary artery disease;	chr14:103458144	chr14:103331674~103332367:-
THCA	cis	rs4906332	0.966	rs12185021	ENSG00000259775.1	RP11-45P15.4	-3.74	0.000203	0.0143	-0.15	-0.17	Coronary artery disease;	chr14:103461468	chr14:103331674~103332367:-
THCA	cis	rs250585	0.736	rs250559	ENSG00000260136.4	CTD-2270L9.4	3.74	0.000203	0.0144	0.13	0.17	Egg allergy;	chr16:23441503	chr16:23452758~23457606:+
THCA	cis	rs10181042	0.565	rs1177234	ENSG00000270820.4	RP11-355B11.2	3.74	0.000203	0.0144	0.14	0.17	Crohn's disease;	chr2:61032928	chr2:61471188~61484130:+
THCA	cis	rs7674212	1	rs7674212	ENSG00000248971.2	KRT8P46	-3.74	0.000203	0.0144	-0.21	-0.17	Type 2 diabetes;	chr4:103067742	chr4:102728746~102730171:-
THCA	cis	rs4434872	0.525	rs34752019	ENSG00000228013.1	RP11-350G8.5	-3.74	0.000203	0.0144	-0.31	-0.17	Conduct disorder (symptom count);	chr1:154054166	chr1:154402328~154406564:-
THCA	cis	rs9876781	0.559	rs1841178	ENSG00000244380.1	RP11-24C3.2	3.74	0.000203	0.0144	0.21	0.17	Longevity;	chr3:48355556	chr3:48440352~48446656:-
THCA	cis	rs8030605	0.704	rs1715919	ENSG00000277245.1	RP11-48G14.3	3.74	0.000203	0.0144	0.29	0.17	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56464087	chr15:56447120~56447697:+
THCA	cis	rs2221894	0.922	rs7018244	ENSG00000251191.6	LINC00589	3.74	0.000203	0.0144	0.2	0.17	Obesity-related traits;	chr8:29037474	chr8:29673922~29748109:-
THCA	cis	rs13256369	0.755	rs12680167	ENSG00000254153.1	CTA-398F10.2	-3.74	0.000203	0.0144	-0.19	-0.17	Obesity-related traits;	chr8:8704957	chr8:8456909~8461337:-
THCA	cis	rs6940638	0.688	rs9393790	ENSG00000220721.1	OR1F12	-3.74	0.000203	0.0144	-0.2	-0.17	Intelligence (multi-trait analysis);	chr6:27146273	chr6:28073316~28074233:+
THCA	cis	rs2455799	0.613	rs12637353	ENSG00000270409.1	RP11-44D5.1	-3.74	0.000203	0.0144	-0.18	-0.17	Mean platelet volume;	chr3:15790018	chr3:15732252~15733470:+
THCA	cis	rs9926296	0.585	rs8045232	ENSG00000274627.1	RP11-104N10.2	-3.74	0.000203	0.0144	-0.17	-0.17	Vitiligo;	chr16:89791140	chr16:89516797~89522217:+
THCA	cis	rs13401620	0.752	rs10190948	ENSG00000231013.1	AC013275.2	-3.74	0.000203	0.0144	-0.19	-0.17	Breast size;	chr2:119736515	chr2:119476448~119487346:+
THCA	cis	rs12962334	0.57	rs4800434	ENSG00000273232.1	RP11-370A5.2	3.74	0.000203	0.0144	0.23	0.17	Breast cancer;	chr18:22848311	chr18:22882825~22883357:-
THCA	cis	rs56046484	0.956	rs35885781	ENSG00000259630.2	CTD-2262B20.1	-3.74	0.000203	0.0144	-0.25	-0.17	Testicular germ cell tumor;	chr15:85047852	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.956	rs34105012	ENSG00000259630.2	CTD-2262B20.1	-3.74	0.000203	0.0144	-0.25	-0.17	Testicular germ cell tumor;	chr15:85048455	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.956	rs34054841	ENSG00000259630.2	CTD-2262B20.1	-3.74	0.000203	0.0144	-0.25	-0.17	Testicular germ cell tumor;	chr15:85058115	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.956	rs12908535	ENSG00000259630.2	CTD-2262B20.1	-3.74	0.000203	0.0144	-0.25	-0.17	Testicular germ cell tumor;	chr15:85058294	chr15:85415228~85415633:+
THCA	cis	rs11671005	0.693	rs11669665	ENSG00000269600.1	AC016629.3	-3.74	0.000203	0.0144	-0.25	-0.17	Mean platelet volume;	chr19:58420518	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.693	rs11084542	ENSG00000269600.1	AC016629.3	-3.74	0.000203	0.0144	-0.25	-0.17	Mean platelet volume;	chr19:58420732	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs11084543	ENSG00000269600.1	AC016629.3	-3.74	0.000203	0.0144	-0.25	-0.17	Mean platelet volume;	chr19:58421334	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs11881000	ENSG00000269600.1	AC016629.3	-3.74	0.000203	0.0144	-0.25	-0.17	Mean platelet volume;	chr19:58421421	chr19:58593896~58599355:-
THCA	cis	rs7737355	0.947	rs4996522	ENSG00000237714.1	P4HA2-AS1	-3.74	0.000203	0.0144	-0.25	-0.17	Life satisfaction;	chr5:131425777	chr5:132184876~132192808:+
THCA	cis	rs950893	0.729	rs7009775	ENSG00000253837.1	RP11-177H13.2	3.74	0.000203	0.0144	0.17	0.17	Mean corpuscular hemoglobin;	chr8:23613434	chr8:23336171~23366125:+
THCA	cis	rs10129255	0.917	rs7142373	ENSG00000280411.1	IGHV1-69-2	-3.74	0.000203	0.0144	-0.11	-0.17	Kawasaki disease;	chr14:106708947	chr14:106762092~106762588:-
THCA	cis	rs25645	0.76	rs11870683	ENSG00000264968.1	RP11-387H17.4	-3.74	0.000203	0.0144	-0.16	-0.17	Myeloid white cell count;	chr17:39973588	chr17:39927742~39939601:+
THCA	cis	rs17095355	0.539	rs3890722	ENSG00000203876.8	ADD3-AS1	-3.74	0.000203	0.0144	-0.18	-0.17	Biliary atresia;	chr10:110165475	chr10:109940104~110008381:-
THCA	cis	rs11583043	1	rs6675353	ENSG00000233184.5	RP11-421L21.3	3.74	0.000203	0.0144	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:100994069	chr1:101025878~101087268:+
THCA	cis	rs189798	0.807	rs330909	ENSG00000233609.3	RP11-62H7.2	3.74	0.000203	0.0144	0.17	0.17	Myopia (pathological);	chr8:9137877	chr8:8961200~8979025:+
THCA	cis	rs7259376	0.902	rs4932763	ENSG00000269345.1	VN1R85P	-3.74	0.000203	0.0144	-0.18	-0.17	Menopause (age at onset);	chr19:22421120	chr19:22174766~22175191:-
THCA	cis	rs9902453	0.808	rs1986555	ENSG00000264290.1	RP11-68I3.4	3.74	0.000203	0.0144	0.13	0.17	Coffee consumption (cups per day);	chr17:29687430	chr17:29569580~29570519:+
THCA	cis	rs12478296	1	rs73007138	ENSG00000220804.7	AC093642.5	3.74	0.000204	0.0144	0.21	0.17	Obesity-related traits;	chr2:242064890	chr2:242088633~242160153:+
THCA	cis	rs7176527	0.848	rs17600128	ENSG00000230373.7	GOLGA6L5P	3.74	0.000204	0.0144	0.24	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:84507885~84516814:-
THCA	cis	rs4443100	0.755	rs6003465	ENSG00000230701.2	FBXW4P1	3.74	0.000204	0.0144	0.2	0.17	Serum parathyroid hormone levels;	chr22:23023333	chr22:23262767~23265005:+
THCA	cis	rs4699052	0.927	rs1870888	ENSG00000246560.2	RP11-10L12.4	3.74	0.000204	0.0144	0.21	0.17	Testicular germ cell tumor;	chr4:103248169	chr4:102828055~102844075:+
THCA	cis	rs67478160	0.619	rs11160759	ENSG00000258534.1	CTD-2134A5.4	-3.74	0.000204	0.0144	-0.17	-0.17	Schizophrenia;	chr14:103765205	chr14:103854366~103880111:-
THCA	cis	rs924712	0.574	rs9370328	ENSG00000224984.1	RP11-524H19.2	-3.74	0.000204	0.0144	-0.2	-0.17	Breast cancer;	chr6:54815888	chr6:54840118~54840855:-
THCA	cis	rs4767841	0.874	rs6490269	ENSG00000252886.1	RN7SKP197	-3.74	0.000204	0.0144	-0.17	-0.17	Urgency urinary incontinence;	chr12:119769371	chr12:119631090~119631386:-
THCA	cis	rs34421088	0.548	rs2618443	ENSG00000270154.1	RP11-419I17.1	-3.74	0.000204	0.0144	-0.21	-0.17	Neuroticism;	chr8:11527047	chr8:12476462~12477122:+
THCA	cis	rs2442825	0.693	rs2648523	ENSG00000254485.4	RP11-380O24.1	-3.74	0.000204	0.0144	-0.16	-0.17	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9292588~9363303:-
THCA	cis	rs34975555	0.773	rs62498177	ENSG00000253671.1	RP11-806O11.1	-3.74	0.000204	0.0144	-0.27	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17955004	chr8:17808941~17820868:+
THCA	cis	rs34975555	0.892	rs62498178	ENSG00000253671.1	RP11-806O11.1	-3.74	0.000204	0.0144	-0.27	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17955005	chr8:17808941~17820868:+
THCA	cis	rs4578769	0.569	rs1597239	ENSG00000273232.1	RP11-370A5.2	3.74	0.000204	0.0144	0.23	0.17	Eosinophil percentage of white cells;	chr18:22805673	chr18:22882825~22883357:-
THCA	cis	rs73787773	0.866	rs79092804	ENSG00000246859.2	STARD4-AS1	3.74	0.000204	0.0144	0.24	0.17	Itch intensity from mosquito bite adjusted by bite size;	chr5:112143123	chr5:111512226~111739726:+
THCA	cis	rs4803480	1	rs4803480	ENSG00000270164.1	LINC01480	-3.74	0.000204	0.0144	-0.18	-0.17	Schizophrenia;	chr19:41559909	chr19:41535183~41536904:+
THCA	cis	rs5753037	0.809	rs997913	ENSG00000279699.1	RP1-102K2.9	3.74	0.000204	0.0144	0.16	0.17	Type 1 diabetes;	chr22:29978632	chr22:30275215~30276951:-
THCA	cis	rs9307551	0.779	rs12501981	ENSG00000249646.2	OR7E94P	-3.74	0.000204	0.0144	-0.21	-0.17	Refractive error;	chr4:79591850	chr4:79587302~79588130:-
THCA	cis	rs11168618	0.776	rs7955785	ENSG00000240399.1	RP1-228P16.1	3.74	0.000204	0.0144	0.17	0.17	Adiponectin levels;	chr12:48468755	chr12:48054813~48055591:-
THCA	cis	rs11168618	0.846	rs11168592	ENSG00000240399.1	RP1-228P16.1	3.74	0.000204	0.0144	0.17	0.17	Adiponectin levels;	chr12:48471296	chr12:48054813~48055591:-
THCA	cis	rs6456156	0.792	rs10946213	ENSG00000235272.1	FAM103A2P	-3.74	0.000204	0.0144	-0.23	-0.17	Primary biliary cholangitis;	chr6:167102607	chr6:166586124~166586477:-
THCA	cis	rs7828089	0.561	rs13266541	ENSG00000248738.5	RP11-87E22.2	-3.74	0.000204	0.0144	-0.18	-0.17	Verbal declarative memory;	chr8:22408622	chr8:22877972~22888022:+
THCA	cis	rs1964356	0.524	rs7839585	ENSG00000254153.1	CTA-398F10.2	3.74	0.000204	0.0144	0.18	0.17	Mean corpuscular volume;	chr8:8996725	chr8:8456909~8461337:-
THCA	cis	rs12149695	0.872	rs12934078	ENSG00000259940.2	CTD-3203P2.1	-3.74	0.000204	0.0144	-0.19	-0.17	Gut microbiota (bacterial taxa);	chr16:27236340	chr16:27213308~27214993:-
THCA	cis	rs11039571	0.588	rs10734564	ENSG00000200090.1	Y_RNA	-3.74	0.000204	0.0144	-0.15	-0.17	D-dimer levels;	chr11:48138877	chr11:47726894~47726992:-
THCA	cis	rs642858	0.747	rs627705	ENSG00000234147.1	RP3-460G2.2	3.74	0.000204	0.0144	0.19	0.17	Type 2 diabetes;	chr6:139920135	chr6:140845958~140852924:-
THCA	cis	rs11583043	1	rs6700743	ENSG00000233184.5	RP11-421L21.3	3.74	0.000204	0.0144	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:100981828	chr1:101025878~101087268:+
THCA	cis	rs950169	0.922	rs11633534	ENSG00000275120.1	RP11-182J1.17	3.74	0.000204	0.0144	0.21	0.17	Schizophrenia;	chr15:84581411	chr15:84599434~84606463:-
THCA	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	3.74	0.000204	0.0144	0.2	0.17	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
THCA	cis	rs17181170	1	rs62257768	ENSG00000239572.1	RP11-451B8.1	-3.74	0.000204	0.0144	-0.2	-0.17	Prostate cancer;	chr3:87133109	chr3:87731402~87793629:-
THCA	cis	rs17181170	0.967	rs60086365	ENSG00000239572.1	RP11-451B8.1	-3.74	0.000204	0.0144	-0.2	-0.17	Prostate cancer;	chr3:87142941	chr3:87731402~87793629:-
THCA	cis	rs17181170	0.934	rs2088396	ENSG00000239572.1	RP11-451B8.1	-3.74	0.000204	0.0144	-0.2	-0.17	Prostate cancer;	chr3:87143628	chr3:87731402~87793629:-
THCA	cis	rs10089	1	rs10060181	ENSG00000245937.6	LINC01184	3.74	0.000204	0.0144	0.19	0.17	Ileal carcinoids;	chr5:128139881	chr5:127940426~128083172:-
THCA	cis	rs7117932	0.935	rs7126621	ENSG00000270160.1	RP11-264E20.2	3.74	0.000204	0.0144	0.2	0.17	Obesity-related traits;	chr11:128576292	chr11:128614340~128615236:-
THCA	cis	rs12428035	0.536	rs12428062	ENSG00000247400.3	DNAJC3-AS1	-3.74	0.000204	0.0144	-0.17	-0.17	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96044955	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs16951448	ENSG00000247400.3	DNAJC3-AS1	-3.74	0.000204	0.0144	-0.17	-0.17	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96062024	chr13:95648733~95676925:-
THCA	cis	rs13217239	0.646	rs12527111	ENSG00000124549.13	BTN2A3P	3.74	0.000204	0.0144	0.16	0.17	Schizophrenia;	chr6:27038696	chr6:26421391~26432383:+
THCA	cis	rs11175194	0.655	rs11175195	ENSG00000255850.1	TMEM5-AS1	-3.74	0.000204	0.0144	-0.31	-0.17	Epithelial ovarian cancer;	chr12:63871944	chr12:63808845~63822156:-
THCA	cis	rs793571	0.822	rs17302038	ENSG00000245975.2	RP11-30K9.6	3.74	0.000204	0.0144	0.19	0.17	Schizophrenia;	chr15:58876603	chr15:58768072~58770974:-
THCA	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	3.74	0.000204	0.0144	0.35	0.17	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
THCA	cis	rs41313321	0.512	rs2416981	ENSG00000272696.1	RP11-339B21.13	3.74	0.000204	0.0144	0.12	0.17	Coenzyme Q10 levels;	chr9:128279473	chr9:128316337~128316909:+
THCA	cis	rs7178424	0.811	rs12899801	ENSG00000259251.2	RP11-643M14.1	3.74	0.000204	0.0144	0.17	0.17	Height;	chr15:61954665	chr15:62060503~62062434:+
THCA	cis	rs7959452	0.53	rs12811632	ENSG00000274979.1	RP11-1143G9.5	-3.74	0.000204	0.0144	-0.19	-0.17	Blood protein levels;	chr12:69361223	chr12:69326574~69331882:-
THCA	cis	rs55702914	0.805	rs11888760	ENSG00000231621.1	AC013264.2	3.74	0.000204	0.0144	0.16	0.17	Major depression and alcohol dependence;	chr2:197379025	chr2:197197991~197199273:+
THCA	cis	rs520525	0.963	rs600093	ENSG00000271811.1	RP1-79C4.4	3.74	0.000204	0.0144	0.21	0.17	Atrial fibrillation;	chr1:170660697	chr1:170667381~170669425:+
THCA	cis	rs3747767	1	rs4706789	ENSG00000233967.5	RP11-250B2.3	3.74	0.000204	0.0144	0.28	0.17	Hoarding;	chr6:79468648	chr6:80443344~80465927:+
THCA	cis	rs4389656	0.857	rs274713	ENSG00000248677.1	CTD-2044J15.1	3.74	0.000204	0.0144	0.17	0.17	Coronary artery disease;	chr5:6723447	chr5:6686325~6707711:-
THCA	cis	rs947583	0.588	rs2208574	ENSG00000272189.1	RP3-325F22.5	3.74	0.000204	0.0144	0.17	0.17	Phosphorus levels;	chr6:135754479	chr6:136550661~136552554:+
THCA	cis	rs708224	0.513	rs901598	ENSG00000277342.1	RP11-843B15.4	3.74	0.000204	0.0144	0.22	0.17	Pancreatic cancer;	chr12:32284263	chr12:32109076~32109602:+
THCA	cis	rs11089937	0.929	rs2236727	ENSG00000211638.2	IGLV8-61	-3.74	0.000204	0.0144	-0.13	-0.17	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22098700~22099212:+
THCA	cis	rs4660214	0.756	rs11205823	ENSG00000228060.1	RP11-69E11.8	3.74	0.000204	0.0144	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39565160~39573203:+
THCA	cis	rs7615952	0.546	rs11711150	ENSG00000241278.1	ENPP7P4	3.74	0.000204	0.0144	0.25	0.17	Blood pressure (smoking interaction);	chr3:125596819	chr3:125848223~125909372:+
THCA	cis	rs7178909	0.902	rs10459674	ENSG00000259677.1	RP11-493E3.1	3.74	0.000204	0.0144	0.21	0.17	Common traits (Other);	chr15:89895063	chr15:89876540~89877285:+
THCA	cis	rs7178909	0.902	rs2043881	ENSG00000259677.1	RP11-493E3.1	3.74	0.000204	0.0144	0.21	0.17	Common traits (Other);	chr15:89896728	chr15:89876540~89877285:+
THCA	cis	rs7819412	0.774	rs34208825	ENSG00000261451.1	RP11-981G7.1	-3.74	0.000204	0.0144	-0.21	-0.17	Triglycerides;	chr8:11157106	chr8:10433672~10438312:+
THCA	cis	rs372883	0.6	rs1153276	ENSG00000176054.6	RPL23P2	-3.74	0.000204	0.0144	-0.15	-0.17	Pancreatic cancer;	chr21:29289373	chr21:28997613~28998033:-
THCA	cis	rs5006884	0.585	rs12279751	ENSG00000167355.6	AC104389.28	-3.74	0.000204	0.0144	-0.29	-0.17	Fetal hemoglobin levels;	chr11:5442881	chr11:5304976~5505652:-
THCA	cis	rs5006884	0.531	rs12281453	ENSG00000167355.6	AC104389.28	-3.74	0.000204	0.0144	-0.29	-0.17	Fetal hemoglobin levels;	chr11:5443521	chr11:5304976~5505652:-
THCA	cis	rs2821260	0.644	rs2821246	ENSG00000227207.2	RPL31P12	3.74	0.000204	0.0144	0.19	0.17	Intelligence (multi-trait analysis);	chr1:72111496	chr1:72301472~72301829:+
THCA	cis	rs2625529	0.824	rs7172309	ENSG00000260037.4	CTD-2524L6.3	-3.74	0.000204	0.0144	-0.24	-0.17	Red blood cell count;	chr15:72092142	chr15:71818396~71823384:+
THCA	cis	rs3811273	0.614	rs6572348	ENSG00000211816.2	TRAV38-1	-3.74	0.000204	0.0144	-0.21	-0.17	Periodontal disease-related phenotypes;	chr14:22268353	chr14:22271968~22272563:+
THCA	cis	rs2933343	0.7	rs2624910	ENSG00000231305.3	RP11-723O4.2	3.74	0.000204	0.0144	0.18	0.17	IgG glycosylation;	chr3:128931432	chr3:128861313~128871540:-
THCA	cis	rs6840360	0.571	rs17275536	ENSG00000251611.1	RP11-610P16.1	-3.74	0.000204	0.0144	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151577473	chr4:151407551~151408835:-
THCA	cis	rs4787951	0.754	rs3024560	ENSG00000259940.2	CTD-3203P2.1	3.74	0.000204	0.0144	0.19	0.17	Eosinophil percentage of white cells;	chr16:27345346	chr16:27213308~27214993:-
THCA	cis	rs7166081	1	rs3743347	ENSG00000270964.1	RP11-502I4.3	-3.74	0.000204	0.0144	-0.16	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67254963	chr15:67541072~67542604:-
THCA	cis	rs6952407	1	rs6952407	ENSG00000229180.5	GS1-124K5.11	-3.74	0.000204	0.0144	-0.12	-0.17	Cotinine glucuronidation;	chr7:66580525	chr7:66526088~66542624:-
THCA	cis	rs1836229	0.874	rs10120501	ENSG00000225706.1	PTPRD-AS1	-3.74	0.000204	0.0144	-0.21	-0.17	Restless legs syndrome;	chr9:8826767	chr9:8858130~8862255:+
THCA	cis	rs17695224	0.545	rs66634805	ENSG00000275055.1	CTC-471J1.11	-3.74	0.000204	0.0144	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51816080	chr19:52049007~52049754:+
THCA	cis	rs7824557	0.527	rs2572449	ENSG00000227888.4	FAM66A	3.74	0.000204	0.0144	0.21	0.17	Retinal vascular caliber;	chr8:11381628	chr8:12362019~12388296:+
THCA	cis	rs669446	0.562	rs304303	ENSG00000237950.1	RP11-7O11.3	3.74	0.000204	0.0144	0.15	0.17	Amyotrophic lateral sclerosis (age of onset);	chr1:43712399	chr1:43944370~43946551:-
THCA	cis	rs2832077	0.943	rs2832099	ENSG00000232855.5	AF131217.1	3.74	0.000204	0.0144	0.21	0.17	Cognitive test performance;	chr21:28801137	chr21:28439346~28674848:-
THCA	cis	rs4073416	0.542	rs1953415	ENSG00000276116.2	FUT8-AS1	3.74	0.000204	0.0144	0.19	0.17	N-glycan levels;	chr14:65521316	chr14:65411170~65412690:-
THCA	cis	rs448720	1	rs440341	ENSG00000260657.2	RP11-315D16.4	-3.74	0.000204	0.0144	-0.21	-0.17	Cognitive performance;	chr15:67918621	chr15:68267792~68277994:-
THCA	cis	rs7615952	0.611	rs7632305	ENSG00000272840.1	RP11-379B18.6	3.74	0.000204	0.0144	0.32	0.17	Blood pressure (smoking interaction);	chr3:125915924	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.673	rs9841194	ENSG00000272840.1	RP11-379B18.6	3.74	0.000204	0.0144	0.32	0.17	Blood pressure (smoking interaction);	chr3:125916896	chr3:125774714~125797953:+
THCA	cis	rs16944613	0.588	rs12438183	ENSG00000259212.1	CTD-3065B20.2	3.74	0.000204	0.0144	0.26	0.17	Colorectal cancer;	chr15:90596012	chr15:90595840~90596447:-
THCA	cis	rs4950322	0.518	rs11811023	ENSG00000180867.10	PDIA3P1	-3.74	0.000204	0.0144	-0.16	-0.17	Protein quantitative trait loci;	chr1:147109536	chr1:147178113~147179622:+
THCA	cis	rs295490	0.748	rs75256094	ENSG00000272656.1	RP11-219D15.3	3.74	0.000204	0.0144	0.34	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139349504	chr3:139349024~139349371:-
THCA	cis	rs858239	0.636	rs28706766	ENSG00000230042.1	AK3P3	-3.74	0.000204	0.0144	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23129178~23129841:+
THCA	cis	rs2276314	1	rs4799832	ENSG00000267627.4	RP11-905K4.1	-3.74	0.000204	0.0144	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35951803~35966118:-
THCA	cis	rs7550636	0.76	rs1890974	ENSG00000276735.1	Metazoa_SRP	3.74	0.000204	0.0144	0.21	0.17	Coronary artery calcification;	chr1:192891014	chr1:193236794~193237107:-
THCA	cis	rs1552244	0.572	rs6797536	ENSG00000180385.7	EMC3-AS1	-3.74	0.000204	0.0144	-0.22	-0.17	Alzheimer's disease;	chr3:10127118	chr3:9986893~10006990:+
THCA	cis	rs889512	0.642	rs13337017	ENSG00000261783.1	RP11-252K23.2	3.74	0.000204	0.0144	0.34	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75238469	chr16:75379818~75381260:-
THCA	cis	rs9660180	0.967	rs12044597	ENSG00000215914.4	MMP23A	-3.74	0.000204	0.0144	-0.22	-0.17	Body mass index;	chr1:1777362	chr1:1699942~1701782:+
THCA	cis	rs2652822	0.525	rs35594365	ENSG00000259459.4	RP11-321G12.1	-3.74	0.000204	0.0144	-0.14	-0.17	Metabolic traits;	chr15:63227955	chr15:63390136~63438320:+
THCA	cis	rs754466	0.606	rs11002306	ENSG00000213514.2	RP11-428P16.2	3.74	0.000204	0.0144	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77831761	chr10:77730766~77734769:+
THCA	cis	rs6831352	0.851	rs1230164	ENSG00000263923.1	RP11-571L19.7	-3.74	0.000205	0.0144	-0.22	-0.17	Alcohol dependence;	chr4:99064872	chr4:98928897~98994994:+
THCA	cis	rs854765	0.583	rs66531105	ENSG00000281749.1	Y_RNA	3.74	0.000205	0.0144	0.21	0.17	Total body bone mineral density;	chr17:17905687	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs8070722	ENSG00000281749.1	Y_RNA	3.74	0.000205	0.0144	0.21	0.17	Total body bone mineral density;	chr17:17910248	chr17:18001101~18001195:-
THCA	cis	rs7259376	0.905	rs7258446	ENSG00000269345.1	VN1R85P	3.74	0.000205	0.0144	0.18	0.17	Menopause (age at onset);	chr19:22367539	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs17391718	ENSG00000269345.1	VN1R85P	3.74	0.000205	0.0144	0.18	0.17	Menopause (age at onset);	chr19:22371352	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.905	rs56027264	ENSG00000269345.1	VN1R85P	3.74	0.000205	0.0144	0.18	0.17	Menopause (age at onset);	chr19:22371552	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs1865075	ENSG00000269345.1	VN1R85P	3.74	0.000205	0.0144	0.18	0.17	Menopause (age at onset);	chr19:22372052	chr19:22174766~22175191:-
THCA	cis	rs2408955	0.521	rs10875749	ENSG00000257735.1	RP11-370I10.6	-3.74	0.000205	0.0144	-0.2	-0.17	Glycated hemoglobin levels;	chr12:48138134	chr12:48350945~48442411:+
THCA	cis	rs2408955	0.521	rs7301003	ENSG00000257735.1	RP11-370I10.6	3.74	0.000205	0.0144	0.2	0.17	Glycated hemoglobin levels;	chr12:48156444	chr12:48350945~48442411:+
THCA	cis	rs2034088	0.802	rs12937004	ENSG00000231784.7	DBIL5P	3.74	0.000205	0.0144	0.19	0.17	Hip circumference adjusted for BMI;	chr17:510488	chr17:752660~755336:+
THCA	cis	rs3105593	0.933	rs7174839	ENSG00000242737.1	RP11-562A8.1	3.74	0.000205	0.0144	0.21	0.17	QT interval;	chr15:50597427	chr15:50466738~50467096:+
THCA	cis	rs4664293	1	rs12692554	ENSG00000230783.1	AC009961.2	-3.74	0.000205	0.0144	-0.21	-0.17	Monocyte percentage of white cells;	chr2:159594777	chr2:159689217~159690291:-
THCA	cis	rs17122278	1	rs17122269	ENSG00000243431.1	RPL5P30	3.74	0.000205	0.0144	0.18	0.17	Total cholesterol levels;	chr11:118574560	chr11:118560690~118561580:+
THCA	cis	rs10875746	0.855	rs11168369	ENSG00000258234.1	RP11-370I10.2	3.74	0.000205	0.0144	0.2	0.17	Longevity (90 years and older);	chr12:48037385	chr12:48231098~48284210:-
THCA	cis	rs7819412	0.875	rs6981523	ENSG00000254839.1	AF131215.6	3.74	0.000205	0.0144	0.18	0.17	Triglycerides;	chr8:11204283	chr8:11062647~11067089:-
THCA	cis	rs754133	0.964	rs894737	ENSG00000257534.1	RP11-834C11.10	3.74	0.000205	0.0144	0.21	0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54024359	chr12:54162065~54164452:-
THCA	cis	rs12476592	0.602	rs6736411	ENSG00000242412.1	DBIL5P2	3.74	0.000205	0.0144	0.22	0.17	Childhood ear infection;	chr2:63446926	chr2:63117851~63119542:-
THCA	cis	rs1051424	0.591	rs78638044	ENSG00000266992.1	DHX40P1	-3.74	0.000205	0.0144	-0.34	-0.17	Obesity-related traits;	chr17:59897115	chr17:59976009~60002384:-
THCA	cis	rs9905704	0.723	rs71372848	ENSG00000224738.1	AC099850.1	3.74	0.000205	0.0144	0.23	0.17	Testicular germ cell tumor;	chr17:58659237	chr17:59106598~59118267:+
THCA	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	3.74	0.000205	0.0144	0.22	0.17	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
THCA	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	3.74	0.000205	0.0144	0.22	0.17	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
THCA	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	3.74	0.000205	0.0144	0.22	0.17	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
THCA	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	3.74	0.000205	0.0144	0.22	0.17	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
THCA	cis	rs7707921	1	rs2407064	ENSG00000251374.1	RPS23P5	-3.74	0.000205	0.0144	-0.25	-0.17	Breast cancer;	chr5:82161539	chr5:82265157~82265259:-
THCA	cis	rs35123781	0.696	rs356429	ENSG00000253404.1	AC034243.1	-3.74	0.000205	0.0144	-0.22	-0.17	Schizophrenia;	chr5:139693558	chr5:138744434~138753309:-
THCA	cis	rs4947019	1	rs74975304	ENSG00000260273.1	RP11-425D10.10	3.74	0.000205	0.0144	0.3	0.17	Hematological parameters;	chr6:109772836	chr6:109382795~109383666:+
THCA	cis	rs11992162	0.507	rs60902764	ENSG00000227888.4	FAM66A	-3.74	0.000205	0.0144	-0.22	-0.17	Monocyte count;	chr8:11927482	chr8:12362019~12388296:+
THCA	cis	rs964611	0.882	rs1872304	ENSG00000259488.2	RP11-154J22.1	3.74	0.000205	0.0145	0.16	0.17	Metabolite levels (Pyroglutamine);	chr15:48366591	chr15:48312353~48331856:-
THCA	cis	rs80130819	0.591	rs17122651	ENSG00000273765.1	RP11-370I10.11	-3.74	0.000205	0.0145	-0.18	-0.17	Prostate cancer;	chr12:48102877	chr12:48360920~48361377:+
THCA	cis	rs9435732	0.778	rs3738815	ENSG00000268869.4	ESPNP	3.74	0.000205	0.0145	0.2	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16988207	chr1:16687339~16720157:-
THCA	cis	rs10993625	1	rs10993625	ENSG00000231107.1	LINC01508	-3.74	0.000205	0.0145	-0.2	-0.17	Classic bladder exstrophy;	chr9:90679923	chr9:90300902~90433505:-
THCA	cis	rs9987353	0.519	rs2929465	ENSG00000253981.4	ALG1L13P	-3.74	0.000205	0.0145	-0.17	-0.17	Recombination measurement;	chr8:9206492	chr8:8236003~8244667:-
THCA	cis	rs6724465	1	rs72951747	ENSG00000272644.1	RP11-33O4.1	3.74	0.000205	0.0145	0.28	0.17	Height;	chr2:219107321	chr2:219069354~219069809:-
THCA	cis	rs3806843	0.548	rs246056	ENSG00000202515.1	VTRNA1-3	-3.74	0.000205	0.0145	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140946015	chr5:140726158~140726246:+
THCA	cis	rs3806843	0.607	rs246044	ENSG00000202515.1	VTRNA1-3	-3.74	0.000205	0.0145	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140951071	chr5:140726158~140726246:+
THCA	cis	rs6893300	0.826	rs7709723	ENSG00000225051.5	HMGB3P22	3.74	0.000205	0.0145	0.18	0.17	Resting heart rate;	chr5:179717262	chr5:179679032~179694768:+
THCA	cis	rs7178375	1	rs28881289	ENSG00000215302.7	CTD-3092A11.1	-3.74	0.000205	0.0145	-0.24	-0.17	Hypertriglyceridemia;	chr15:30931752	chr15:30470779~30507623:+
THCA	cis	rs520525	0.927	rs1234282	ENSG00000271811.1	RP1-79C4.4	3.74	0.000205	0.0145	0.21	0.17	Atrial fibrillation;	chr1:170650183	chr1:170667381~170669425:+
THCA	cis	rs36093844	0.527	rs55791429	ENSG00000279742.1	RP11-700A24.1	-3.74	0.000205	0.0145	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86050864	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.527	rs72965166	ENSG00000279742.1	RP11-700A24.1	-3.74	0.000205	0.0145	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86056758	chr11:85852557~85854943:-
THCA	cis	rs7587476	0.599	rs61073893	ENSG00000229267.2	AC072062.1	-3.74	0.000205	0.0145	-0.22	-0.17	Neuroblastoma;	chr2:214880090	chr2:214810229~214963274:+
THCA	cis	rs9400467	0.528	rs56827	ENSG00000272356.1	RP5-1112D6.8	-3.74	0.000205	0.0145	-0.13	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111309203~111313517:+
THCA	cis	rs7851693	0.928	rs10901186	ENSG00000232172.1	RP11-57C19.2	-3.74	0.000205	0.0145	-0.19	-0.17	Bone mineral density;	chr9:130566367	chr9:130651799~130652383:+
THCA	cis	rs5752326	0.558	rs1023496	ENSG00000261188.1	CTA-445C9.14	3.74	0.000205	0.0145	0.17	0.17	Ischemic stroke;	chr22:26469272	chr22:26512537~26514568:+
THCA	cis	rs7403037	1	rs12904329	ENSG00000260760.1	PWRN3	3.74	0.000205	0.0145	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24594723	chr15:24441127~24447967:+
THCA	cis	rs7403037	1	rs12372990	ENSG00000260760.1	PWRN3	3.74	0.000205	0.0145	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24594990	chr15:24441127~24447967:+
THCA	cis	rs950169	0.922	rs4338765	ENSG00000188388.10	GOLGA6L3	3.74	0.000205	0.0145	0.23	0.17	Schizophrenia;	chr15:84248084	chr15:85240472~85247170:+
THCA	cis	rs10483853	0.731	rs10162414	ENSG00000258695.2	RP3-414A15.2	3.74	0.000205	0.0145	0.23	0.17	Coronary artery calcification;	chr14:73296524	chr14:73522878~73530610:+
THCA	cis	rs757978	0.81	rs34123564	ENSG00000235351.1	AC114730.11	-3.74	0.000205	0.0145	-0.16	-0.17	Chronic lymphocytic leukemia;	chr2:241465022	chr2:241724615~241725693:-
THCA	cis	rs4908768	0.501	rs35865480	ENSG00000270282.1	RP5-1115A15.2	3.74	0.000205	0.0145	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs6702060	ENSG00000270282.1	RP5-1115A15.2	3.74	0.000205	0.0145	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8512653~8513021:+
THCA	cis	rs3617	0.539	rs9985365	ENSG00000243224.1	RP5-1157M23.2	3.74	0.000205	0.0145	0.18	0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52919828	chr3:52239258~52241097:+
THCA	cis	rs2777491	1	rs316613	ENSG00000247556.5	OIP5-AS1	3.74	0.000205	0.0145	0.14	0.17	Ulcerative colitis;	chr15:41455400	chr15:41283990~41309737:+
THCA	cis	rs1005277	0.579	rs2474595	ENSG00000120555.12	SEPT7P9	-3.74	0.000205	0.0145	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38383069~38402916:-
THCA	cis	rs854765	0.583	rs12452219	ENSG00000281749.1	Y_RNA	3.74	0.000205	0.0145	0.22	0.17	Total body bone mineral density;	chr17:17926109	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs12452254	ENSG00000281749.1	Y_RNA	3.74	0.000205	0.0145	0.22	0.17	Total body bone mineral density;	chr17:17926120	chr17:18001101~18001195:-
THCA	cis	rs2281603	1	rs2281603	ENSG00000258824.2	CTD-2555O16.2	-3.74	0.000205	0.0145	-0.17	-0.17	Lymphocyte counts;	chr14:64459379	chr14:64422935~64448557:-
THCA	cis	rs14027	0.921	rs12707880	ENSG00000279347.1	RP11-85I17.2	-3.74	0.000205	0.0145	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119838736~119840385:-
THCA	cis	rs11671005	0.736	rs11668201	ENSG00000268912.1	CTD-2619J13.17	-3.74	0.000205	0.0145	-0.16	-0.17	Mean platelet volume;	chr19:58492265	chr19:58428632~58431148:-
THCA	cis	rs4713118	0.55	rs9368527	ENSG00000220721.1	OR1F12	3.74	0.000205	0.0145	0.19	0.17	Parkinson's disease;	chr6:27711666	chr6:28073316~28074233:+
THCA	cis	rs13098911	0.54	rs13072267	ENSG00000226074.4	PRSS44	-3.74	0.000205	0.0145	-0.33	-0.17	Celiac disease;	chr3:46074518	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.598	rs36057789	ENSG00000226074.4	PRSS44	-3.74	0.000205	0.0145	-0.33	-0.17	Celiac disease;	chr3:46075604	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.92	rs76647202	ENSG00000226074.4	PRSS44	-3.74	0.000205	0.0145	-0.33	-0.17	Eosinophil percentage of granulocytes;	chr3:46076468	chr3:46809359~46812558:-
THCA	cis	rs7819412	0.818	rs11989439	ENSG00000206014.6	OR7E161P	3.74	0.000205	0.0145	0.2	0.17	Triglycerides;	chr8:11198088	chr8:11928597~11929563:-
THCA	cis	rs12188164	0.965	rs56182240	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000205	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:423054	chr5:473236~480884:+
THCA	cis	rs12188164	0.965	rs55948934	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000205	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:423556	chr5:473236~480884:+
THCA	cis	rs12188164	0.897	rs55932239	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000205	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:423791	chr5:473236~480884:+
THCA	cis	rs12188164	0.931	rs72717407	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000205	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:424538	chr5:473236~480884:+
THCA	cis	rs12188164	1	rs12188678	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000205	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:428116	chr5:473236~480884:+
THCA	cis	rs12188164	1	rs12188164	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000205	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:428121	chr5:473236~480884:+
THCA	cis	rs12188164	1	rs72717411	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000205	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:429009	chr5:473236~480884:+
THCA	cis	rs7824557	0.545	rs2572380	ENSG00000227888.4	FAM66A	-3.74	0.000205	0.0145	-0.21	-0.17	Retinal vascular caliber;	chr8:11379968	chr8:12362019~12388296:+
THCA	cis	rs16978956	0.592	rs16990336	ENSG00000236474.1	GCNT1P1	3.74	0.000205	0.0145	0.24	0.17	Body mass index;	chr20:18348968	chr20:18420160~18421454:-
THCA	cis	rs7616559	0.962	rs9875244	ENSG00000244515.1	KRT18P34	-3.74	0.000205	0.0145	-0.23	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157003808	chr3:157162663~157163932:-
THCA	cis	rs7924176	0.521	rs1904062	ENSG00000232342.6	RP11-46O21.2	3.74	0.000205	0.0145	0.22	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:74506081~74530553:-
THCA	cis	rs6137726	0.524	rs1203944	ENSG00000237396.1	LINC01384	-3.74	0.000205	0.0145	-0.16	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22616241	chr20:22587522~22607517:-
THCA	cis	rs17074492	1	rs55801218	ENSG00000214182.5	PTMAP5	3.74	0.000205	0.0145	0.2	0.17	Sjögren's syndrome;	chr13:81608333	chr13:81689911~81691072:+
THCA	cis	rs11250098	0.583	rs7001456	ENSG00000261451.1	RP11-981G7.1	-3.74	0.000205	0.0145	-0.21	-0.17	Morning vs. evening chronotype;	chr8:10947355	chr8:10433672~10438312:+
THCA	cis	rs41313321	0.526	rs2240960	ENSG00000272696.1	RP11-339B21.13	3.74	0.000205	0.0145	0.14	0.17	Coenzyme Q10 levels;	chr9:128276971	chr9:128316337~128316909:+
THCA	cis	rs5771242	0.776	rs6010198	ENSG00000273137.1	RP3-402G11.28	3.74	0.000205	0.0145	0.13	0.17	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50172199	chr22:50208461~50209542:-
THCA	cis	rs2243480	0.522	rs73150635	ENSG00000230295.1	RP11-458F8.2	-3.74	0.000205	0.0145	-0.27	-0.17	Diabetic kidney disease;	chr7:66507503	chr7:66880708~66882981:+
THCA	cis	rs724818	0.661	rs343189	ENSG00000251609.2	SETP12	3.74	0.000205	0.0145	0.44	0.17	Monobrow thickness;	chr4:120819013	chr4:120895494~120897083:-
THCA	cis	rs4722166	0.598	rs4722180	ENSG00000225541.1	AC002480.5	-3.74	0.000205	0.0145	-0.2	-0.17	Lung cancer;	chr7:22765453	chr7:22571607~22661792:-
THCA	cis	rs858239	0.73	rs858279	ENSG00000230042.1	AK3P3	-3.74	0.000205	0.0145	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23129178~23129841:+
THCA	cis	rs14027	0.921	rs1433951	ENSG00000279347.1	RP11-85I17.2	-3.74	0.000205	0.0145	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119838736~119840385:-
THCA	cis	rs10419113	0.645	rs12162230	ENSG00000268545.1	VN1R107P	3.74	0.000206	0.0145	0.2	0.17	Pediatric bone mineral density (spine);	chr19:57683020	chr19:57459912~57460120:+
THCA	cis	rs7819412	0.765	rs17783634	ENSG00000206014.6	OR7E161P	3.74	0.000206	0.0145	0.2	0.17	Triglycerides;	chr8:11196588	chr8:11928597~11929563:-
THCA	cis	rs6499640	0.664	rs8059991	ENSG00000275191.1	RP11-36I17.2	3.74	0.000206	0.0145	0.22	0.17	Body mass index;Weight;	chr16:53738434	chr16:53628256~53628816:-
THCA	cis	rs36093844	0.527	rs17745105	ENSG00000279742.1	RP11-700A24.1	-3.74	0.000206	0.0145	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86001394	chr11:85852557~85854943:-
THCA	cis	rs7954584	0.583	rs10770186	ENSG00000272849.1	RP11-347I19.8	-3.74	0.000206	0.0145	-0.1	-0.17	Mean corpuscular volume;	chr12:121923506	chr12:121797511~121801972:+
THCA	cis	rs6756513	0.5	rs58206747	ENSG00000231024.1	AC092431.3	-3.74	0.000206	0.0145	-0.26	-0.17	Breast cancer;Platelet count;	chr2:69899534	chr2:69700192~69713847:-
THCA	cis	rs7572644	0.551	rs12468596	ENSG00000223522.1	AC093690.1	-3.74	0.000206	0.0145	-0.22	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28281074	chr2:28307691~28310459:-
THCA	cis	rs6137726	0.524	rs1203933	ENSG00000237396.1	LINC01384	3.74	0.000206	0.0145	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22610551	chr20:22587522~22607517:-
THCA	cis	rs7572733	0.84	rs770666	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197747173	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.84	rs770667	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197748584	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.84	rs1065953	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197749888	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.84	rs700648	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197757912	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.84	rs700649	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197758028	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.84	rs700650	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197759561	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.811	rs771013	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197760513	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.84	rs1065949	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197762331	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.84	rs700653	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197772709	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.84	rs700654	ENSG00000231621.1	AC013264.2	-3.74	0.000206	0.0145	-0.16	-0.17	Dermatomyositis;	chr2:197778697	chr2:197197991~197199273:+
THCA	cis	rs2276314	1	rs62101367	ENSG00000267627.4	RP11-905K4.1	-3.74	0.000206	0.0145	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35951803~35966118:-
THCA	cis	rs607541	1	rs675413	ENSG00000259520.4	CTD-2651B20.3	-3.74	0.000206	0.0145	-0.24	-0.17	Obesity-related traits;	chr15:45644547	chr15:45251580~45279251:-
THCA	cis	rs7665090	1	rs11727546	ENSG00000248971.2	KRT8P46	-3.74	0.000206	0.0145	-0.2	-0.17	Primary biliary cholangitis;	chr4:102636507	chr4:102728746~102730171:-
THCA	cis	rs4722166	0.567	rs62449490	ENSG00000225541.1	AC002480.5	-3.74	0.000206	0.0145	-0.18	-0.17	Lung cancer;	chr7:22708872	chr7:22571607~22661792:-
THCA	cis	rs12188164	1	rs72717414	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000206	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:429703	chr5:473236~480884:+
THCA	cis	rs12188164	0.965	rs72717415	ENSG00000225138.6	CTD-2228K2.7	3.74	0.000206	0.0145	0.18	0.17	Cystic fibrosis severity;	chr5:429944	chr5:473236~480884:+
THCA	cis	rs6600671	1	rs10794671	ENSG00000226067.5	CH17-118O6.2	3.74	0.000206	0.0145	0.17	0.17	Hip geometry;	chr1:121426382	chr1:120913275~121009291:+
THCA	cis	rs7246967	0.608	rs437859	ENSG00000198153.8	ZNF849P	3.74	0.000206	0.0145	0.25	0.17	Bronchopulmonary dysplasia;	chr19:22824547	chr19:22685167~22686732:+
THCA	cis	rs10090774	0.965	rs12548549	ENSG00000280303.2	ERICD	3.74	0.000206	0.0145	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140957173	chr8:140636281~140638283:+
THCA	cis	rs11105298	0.891	rs10858909	ENSG00000266347.2	AC068641.1	3.74	0.000206	0.0145	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89592833~89592927:+
THCA	cis	rs1552244	0.572	rs58862481	ENSG00000180385.7	EMC3-AS1	3.74	0.000206	0.0145	0.22	0.17	Alzheimer's disease;	chr3:10122624	chr3:9986893~10006990:+
THCA	cis	rs9558942	0.545	rs943799	ENSG00000277863.1	RP11-282A11.4	-3.74	0.000206	0.0145	-0.21	-0.17	Obesity-related traits;	chr13:107071934	chr13:106903150~106904099:-
THCA	cis	rs12681366	0.537	rs2919659	ENSG00000253175.1	RP11-267M23.6	3.74	0.000206	0.0145	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94459544	chr8:94565036~94565715:+
THCA	cis	rs1559040	1	rs67951010	ENSG00000272156.1	RP11-477N3.1	-3.74	0.000206	0.0145	-0.26	-0.17	Sudden cardiac arrest;	chr2:54102818	chr2:54082554~54085066:+
THCA	cis	rs1559040	1	rs10166363	ENSG00000272156.1	RP11-477N3.1	-3.74	0.000206	0.0145	-0.26	-0.17	Sudden cardiac arrest;	chr2:54103105	chr2:54082554~54085066:+
THCA	cis	rs1559040	1	rs10169648	ENSG00000272156.1	RP11-477N3.1	-3.74	0.000206	0.0145	-0.26	-0.17	Sudden cardiac arrest;	chr2:54103980	chr2:54082554~54085066:+
THCA	cis	rs1850744	0.51	rs1401442	ENSG00000250942.1	ENPP7P11	3.74	0.000206	0.0145	0.22	0.17	Economic and political preferences;	chr4:9837823	chr4:9677308~9677934:+
THCA	cis	rs7829975	0.714	rs7823757	ENSG00000254340.1	RP11-10A14.3	3.74	0.000206	0.0145	0.18	0.17	Mood instability;	chr8:8812667	chr8:9141424~9145435:+
THCA	cis	rs3096299	0.738	rs9929606	ENSG00000261118.1	RP11-104N10.1	3.74	0.000206	0.0145	0.14	0.17	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89492017~89504460:-
THCA	cis	rs860295	0.812	rs2297775	ENSG00000236675.1	MTX1P1	3.74	0.000206	0.0145	0.17	0.17	Body mass index;	chr1:155765221	chr1:155230975~155234325:+
THCA	cis	rs4746818	1	rs6480385	ENSG00000229001.1	ACTBP14	-3.74	0.000206	0.0145	-0.27	-0.17	Left atrial antero-posterior diameter;	chr10:69145029	chr10:69022778~69023866:+
THCA	cis	rs293748	0.771	rs159141	ENSG00000250155.1	CTD-2353F22.1	-3.74	0.000206	0.0145	-0.23	-0.17	Obesity-related traits;	chr5:36925544	chr5:36666214~36725195:-
THCA	cis	rs10089	1	rs13356473	ENSG00000245937.6	LINC01184	3.74	0.000206	0.0145	0.19	0.17	Ileal carcinoids;	chr5:128142558	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs6887847	ENSG00000245937.6	LINC01184	3.74	0.000206	0.0145	0.19	0.17	Ileal carcinoids;	chr5:128138115	chr5:127940426~128083172:-
THCA	cis	rs9672608	0.687	rs5019044	ENSG00000261143.1	ADAMTS7P3	-3.74	0.000206	0.0145	-0.25	-0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78503940	chr15:77976042~77993057:+
THCA	cis	rs12476592	0.602	rs7563623	ENSG00000242412.1	DBIL5P2	3.74	0.000206	0.0145	0.22	0.17	Childhood ear infection;	chr2:63493076	chr2:63117851~63119542:-
THCA	cis	rs3758911	1	rs11212153	ENSG00000255353.1	RP11-382M14.1	-3.74	0.000206	0.0145	-0.21	-0.17	Coronary artery disease;	chr11:107319234	chr11:107176286~107177530:+
THCA	cis	rs3105593	0.933	rs2414059	ENSG00000242737.1	RP11-562A8.1	3.74	0.000206	0.0145	0.21	0.17	QT interval;	chr15:50581147	chr15:50466738~50467096:+
THCA	cis	rs12544026	0.547	rs478896	ENSG00000253669.3	KB-1732A1.1	-3.74	0.000206	0.0145	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101871327	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.547	rs477236	ENSG00000253669.3	KB-1732A1.1	-3.74	0.000206	0.0145	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101871467	chr8:102805517~102809971:+
THCA	cis	rs10857712	0.95	rs10857711	ENSG00000214279.11	SCART1	-3.74	0.000206	0.0145	-0.14	-0.17	Systemic lupus erythematosus;	chr10:133410555	chr10:133453928~133523558:+
THCA	cis	rs3126085	1	rs3126097	ENSG00000237975.5	FLG-AS1	3.74	0.000206	0.0145	0.27	0.17	Atopic dermatitis;	chr1:152338550	chr1:152168125~152445456:+
THCA	cis	rs4713118	0.869	rs9366700	ENSG00000261839.1	RP1-265C24.8	3.74	0.000206	0.0145	0.19	0.17	Parkinson's disease;	chr6:27729172	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs6456802	ENSG00000261839.1	RP1-265C24.8	3.74	0.000206	0.0145	0.19	0.17	Parkinson's disease;	chr6:27730576	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs9393851	ENSG00000261839.1	RP1-265C24.8	3.74	0.000206	0.0145	0.19	0.17	Parkinson's disease;	chr6:27731802	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs9461400	ENSG00000261839.1	RP1-265C24.8	3.74	0.000206	0.0145	0.19	0.17	Parkinson's disease;	chr6:27732780	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs9295742	ENSG00000261839.1	RP1-265C24.8	3.74	0.000206	0.0145	0.19	0.17	Parkinson's disease;	chr6:27735053	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs9461401	ENSG00000261839.1	RP1-265C24.8	3.74	0.000206	0.0145	0.19	0.17	Parkinson's disease;	chr6:27735512	chr6:28136849~28139678:+
THCA	cis	rs12935418	0.672	rs9925780	ENSG00000261061.1	RP11-303E16.2	-3.74	0.000206	0.0145	-0.17	-0.17	Mean corpuscular volume;	chr16:81011571	chr16:81030770~81031485:+
THCA	cis	rs875971	0.798	rs12698522	ENSG00000223473.2	GS1-124K5.3	3.74	0.000206	0.0145	0.12	0.17	Aortic root size;	chr7:66502354	chr7:66491049~66493566:-
THCA	cis	rs875971	0.83	rs28714531	ENSG00000223473.2	GS1-124K5.3	3.74	0.000206	0.0145	0.12	0.17	Aortic root size;	chr7:66503250	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs12698526	ENSG00000223473.2	GS1-124K5.3	3.74	0.000206	0.0145	0.12	0.17	Aortic root size;	chr7:66504118	chr7:66491049~66493566:-
THCA	cis	rs763121	0.853	rs5750677	ENSG00000228274.3	RP3-508I15.9	-3.74	0.000206	0.0145	-0.2	-0.17	Menopause (age at onset);	chr22:38751710	chr22:38667585~38681820:-
THCA	cis	rs763121	0.853	rs2072798	ENSG00000228274.3	RP3-508I15.9	-3.74	0.000206	0.0145	-0.2	-0.17	Menopause (age at onset);	chr22:38752478	chr22:38667585~38681820:-
THCA	cis	rs7873102	1	rs7850311	ENSG00000213839.4	TMX2P1	3.74	0.000206	0.0145	0.13	0.17	Brain structure;	chr9:38060971	chr9:37885683~37886390:+
THCA	cis	rs9650657	0.769	rs2116094	ENSG00000255310.2	AF131215.2	-3.74	0.000206	0.0145	-0.14	-0.17	Neuroticism;	chr8:10741312	chr8:11107788~11109726:-
THCA	cis	rs11710088	0.931	rs11920457	ENSG00000240541.2	TM4SF1-AS1	3.74	0.000206	0.0145	0.16	0.17	QRS duration;	chr3:149482082	chr3:149377778~149386583:+
THCA	cis	rs11710088	0.931	rs66482463	ENSG00000240541.2	TM4SF1-AS1	3.74	0.000206	0.0145	0.16	0.17	QRS duration;	chr3:149482293	chr3:149377778~149386583:+
THCA	cis	rs9475752	0.857	rs11962430	ENSG00000231441.1	RP11-472M19.2	3.74	0.000206	0.0145	0.18	0.17	Menarche (age at onset);	chr6:56909958	chr6:56844002~56864078:+
THCA	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	3.74	0.000206	0.0145	0.22	0.17	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
THCA	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	3.74	0.000206	0.0145	0.22	0.17	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
THCA	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	3.74	0.000206	0.0145	0.22	0.17	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
THCA	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	3.74	0.000206	0.0145	0.22	0.17	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
THCA	cis	rs791590	0.752	rs41295105	ENSG00000225948.2	RP11-554I8.1	3.74	0.000206	0.0145	0.26	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6080711	chr10:6618716~6625346:+
THCA	cis	rs7264396	0.836	rs961020	ENSG00000088340.14	FER1L4	3.74	0.000206	0.0145	0.17	0.17	Total cholesterol levels;	chr20:35594147	chr20:35558737~35607562:-
THCA	cis	rs1502337	0.532	rs6606689	ENSG00000278993.1	RP3-424M6.4	-3.74	0.000206	0.0145	-0.26	-0.17	Body mass index;	chr12:110537870	chr12:110501614~110503441:+
THCA	cis	rs1865760	0.532	rs2794719	ENSG00000272810.1	U91328.22	-3.74	0.000206	0.0145	-0.13	-0.17	Height;	chr6:26088662	chr6:26013241~26013757:+
THCA	cis	rs6929812	0.702	rs979352	ENSG00000271755.1	RP1-153G14.4	3.74	0.000206	0.0145	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27433417	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs6908086	ENSG00000271755.1	RP1-153G14.4	3.74	0.000206	0.0145	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27434244	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs6914585	ENSG00000271755.1	RP1-153G14.4	3.74	0.000206	0.0145	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27435566	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs12197858	ENSG00000271755.1	RP1-153G14.4	3.74	0.000206	0.0145	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27436992	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs10484397	ENSG00000271755.1	RP1-153G14.4	3.74	0.000206	0.0145	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27437904	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.665	rs12200018	ENSG00000271755.1	RP1-153G14.4	3.74	0.000206	0.0145	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27438377	chr6:27404010~27406964:-
THCA	cis	rs6662572	0.703	rs4420029	ENSG00000234329.1	RP11-767N6.2	3.74	0.000206	0.0145	0.18	0.17	Blood protein levels;	chr1:45959828	chr1:45651039~45651826:-
THCA	cis	rs9902453	0.868	rs11080118	ENSG00000263370.1	RP11-68I3.5	-3.74	0.000206	0.0145	-0.21	-0.17	Coffee consumption (cups per day);	chr17:30148361	chr17:29639627~29640825:+
THCA	cis	rs2880765	0.546	rs11639291	ENSG00000259630.2	CTD-2262B20.1	-3.74	0.000206	0.0145	-0.22	-0.17	Coronary artery disease;	chr15:85520899	chr15:85415228~85415633:+
THCA	cis	rs2880765	0.546	rs35316253	ENSG00000259630.2	CTD-2262B20.1	-3.74	0.000206	0.0145	-0.22	-0.17	Coronary artery disease;	chr15:85522329	chr15:85415228~85415633:+
THCA	cis	rs8083427	0.867	rs2298592	ENSG00000275805.1	RP11-349H17.2	3.74	0.000206	0.0145	0.39	0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr18:26542808	chr18:26565723~26575626:-
THCA	cis	rs453301	0.598	rs10104303	ENSG00000254340.1	RP11-10A14.3	3.74	0.000206	0.0145	0.18	0.17	Joint mobility (Beighton score);	chr8:8977018	chr8:9141424~9145435:+
THCA	cis	rs1577917	0.958	rs12191340	ENSG00000220563.1	PKMP3	-3.74	0.000206	0.0145	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85811682	chr6:85659892~85660606:-
THCA	cis	rs8076336	1	rs8076336	ENSG00000266677.1	RP11-258F1.1	-3.74	0.000206	0.0145	-0.18	-0.17	Parental longevity (combined parental age at death);	chr17:18309300	chr17:18172625~18184753:-
THCA	cis	rs2640806	0.505	rs17781856	ENSG00000253105.4	KB-1448A5.1	-3.74	0.000206	0.0145	-0.2	-0.17	Obesity-related traits;	chr8:96355322	chr8:96371865~96387438:-
THCA	cis	rs2191566	0.648	rs62115511	ENSG00000266921.1	RP11-15A1.7	-3.74	0.000206	0.0145	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:44079136	chr19:43996896~44002836:-
THCA	cis	rs657075	0.595	rs6878253	ENSG00000237714.1	P4HA2-AS1	-3.74	0.000206	0.0145	-0.35	-0.17	Rheumatoid arthritis;	chr5:132277600	chr5:132184876~132192808:+
THCA	cis	rs657075	0.595	rs6878192	ENSG00000237714.1	P4HA2-AS1	-3.74	0.000206	0.0145	-0.35	-0.17	Rheumatoid arthritis;	chr5:132277850	chr5:132184876~132192808:+
THCA	cis	rs657075	0.595	rs11954518	ENSG00000237714.1	P4HA2-AS1	-3.74	0.000206	0.0145	-0.35	-0.17	Rheumatoid arthritis;	chr5:132278406	chr5:132184876~132192808:+
THCA	cis	rs7577696	0.545	rs481126	ENSG00000276517.1	AL133243.2	-3.74	0.000206	0.0145	-0.15	-0.17	Inflammatory biomarkers;	chr2:31653174	chr2:32526504~32529507:+
THCA	cis	rs7973719	0.769	rs61917956	ENSG00000205885.6	C1RL-AS1	3.74	0.000206	0.0145	0.13	0.17	IgG glycosylation;	chr12:7196063	chr12:7108052~7122501:+
THCA	cis	rs6878727	0.815	rs9885338	ENSG00000253807.4	LINC01170	-3.74	0.000206	0.0145	-0.16	-0.17	Breast cancer;	chr5:124389627	chr5:124059794~124405079:-
THCA	cis	rs9481169	0.557	rs33980500	ENSG00000230177.1	RP5-1112D6.4	3.74	0.000206	0.0145	0.24	0.17	Inflammatory skin disease;	chr6:111592059	chr6:111277932~111278742:+
THCA	cis	rs4243849	0.572	rs11776098	ENSG00000279518.1	AC083843.4	-3.74	0.000206	0.0145	-0.12	-0.17	Non-alcoholic fatty liver disease histology (other);	chr8:135748949	chr8:134783694~134785879:-
THCA	cis	rs6580649	0.941	rs11612578	ENSG00000273765.1	RP11-370I10.11	-3.74	0.000206	0.0145	-0.18	-0.17	Lung cancer;	chr12:48021015	chr12:48360920~48361377:+
THCA	cis	rs7824557	0.564	rs34389419	ENSG00000227888.4	FAM66A	-3.74	0.000206	0.0145	-0.22	-0.17	Retinal vascular caliber;	chr8:11371810	chr8:12362019~12388296:+
THCA	cis	rs394563	0.601	rs391875	ENSG00000231760.4	RP11-350J20.5	3.74	0.000206	0.0145	0.23	0.17	Dupuytren's disease;	chr6:149474000	chr6:149796151~149826294:-
THCA	cis	rs1154275	0.537	rs6763014	ENSG00000272844.1	RP11-484K9.4	3.74	0.000206	0.0146	0.14	0.17	Takotsubo syndrome;	chr3:112793800	chr3:112990447~112991153:-
THCA	cis	rs9595908	0.655	rs2213377	ENSG00000212293.1	SNORA16	3.74	0.000207	0.0146	0.21	0.17	Body mass index;	chr13:32743076	chr13:32420390~32420516:-
THCA	cis	rs4908768	0.501	rs4908760	ENSG00000270282.1	RP5-1115A15.2	3.74	0.000207	0.0146	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8466082	chr1:8512653~8513021:+
THCA	cis	rs7615952	1	rs7616044	ENSG00000272840.1	RP11-379B18.6	3.74	0.000207	0.0146	0.28	0.17	Blood pressure (smoking interaction);	chr3:125930511	chr3:125774714~125797953:+
THCA	cis	rs17689437	0.813	rs112802086	ENSG00000260084.1	RP11-615I2.1	-3.74	0.000207	0.0146	-0.27	-0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68597851	chr16:68573782~68589512:-
THCA	cis	rs17689437	0.813	rs55952442	ENSG00000260084.1	RP11-615I2.1	-3.74	0.000207	0.0146	-0.27	-0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68598861	chr16:68573782~68589512:-
THCA	cis	rs6500602	0.964	rs62039173	ENSG00000280063.1	RP11-295D4.3	3.74	0.000207	0.0146	0.09	0.17	Schizophrenia;	chr16:4413845	chr16:4346694~4348648:-
THCA	cis	rs6494488	0.5	rs113645218	ENSG00000259635.1	AC100830.3	-3.74	0.000207	0.0146	-0.42	-0.17	Coronary artery disease;	chr15:64551383	chr15:64701248~64719602:+
THCA	cis	rs7296418	0.883	rs1727312	ENSG00000256092.2	RP13-942N8.1	3.74	0.000207	0.0146	0.12	0.17	Platelet count;	chr12:123157673	chr12:123363868~123366113:+
THCA	cis	rs17594362	0.563	rs61963027	ENSG00000264190.1	MIR5006	3.74	0.000207	0.0146	0.29	0.17	Multiple sclerosis;	chr13:41608600	chr13:41568286~41568395:-
THCA	cis	rs17594362	0.563	rs58729334	ENSG00000264190.1	MIR5006	3.74	0.000207	0.0146	0.29	0.17	Multiple sclerosis;	chr13:41609232	chr13:41568286~41568395:-
THCA	cis	rs17594362	0.563	rs12431090	ENSG00000264190.1	MIR5006	3.74	0.000207	0.0146	0.29	0.17	Multiple sclerosis;	chr13:41609530	chr13:41568286~41568395:-
THCA	cis	rs6456156	0.565	rs6921588	ENSG00000235272.1	FAM103A2P	3.74	0.000207	0.0146	0.24	0.17	Primary biliary cholangitis;	chr6:167080909	chr6:166586124~166586477:-
THCA	cis	rs7200543	1	rs6498540	ENSG00000260735.1	RP11-72I8.1	-3.74	0.000207	0.0146	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:15094411~15109197:+
THCA	cis	rs897984	0.683	rs12447534	ENSG00000260911.2	RP11-196G11.2	-3.74	0.000207	0.0146	-0.14	-0.17	Dementia with Lewy bodies;	chr16:30792936	chr16:31043150~31049868:+
THCA	cis	rs804280	0.509	rs13276433	ENSG00000255495.1	AC145124.2	3.74	0.000207	0.0146	0.2	0.17	Myopia (pathological);	chr8:11925527	chr8:12194467~12196280:+
THCA	cis	rs9296092	0.538	rs62407566	ENSG00000272217.1	XXbac-BPG157A10.21	3.74	0.000207	0.0146	0.19	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33568009	chr6:33246075~33246856:-
THCA	cis	rs2832077	0.943	rs11701445	ENSG00000232855.5	AF131217.1	3.74	0.000207	0.0146	0.21	0.17	Cognitive test performance;	chr21:28788485	chr21:28439346~28674848:-
THCA	cis	rs765787	0.53	rs28524974	ENSG00000259932.1	CTD-2651B20.7	3.74	0.000207	0.0146	0.21	0.17	Uric acid levels;	chr15:45251330	chr15:45198517~45199139:-
THCA	cis	rs36093844	0.527	rs72950456	ENSG00000279742.1	RP11-700A24.1	-3.74	0.000207	0.0146	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86063820	chr11:85852557~85854943:-
THCA	cis	rs1467979	0.527	rs12601285	ENSG00000279259.1	RP11-334C17.3	3.74	0.000207	0.0146	0.25	0.17	IgG glycosylation;	chr17:80087475	chr17:80147250~80148596:+
THCA	cis	rs6479891	0.63	rs78335399	ENSG00000232075.1	MRPL35P2	3.74	0.000207	0.0146	0.27	0.17	Arthritis (juvenile idiopathic);	chr10:63091534	chr10:63634317~63634827:-
THCA	cis	rs9905704	0.914	rs2643117	ENSG00000224738.1	AC099850.1	3.74	0.000207	0.0146	0.23	0.17	Testicular germ cell tumor;	chr17:58752155	chr17:59106598~59118267:+
THCA	cis	rs3758911	0.796	rs11212206	ENSG00000255353.1	RP11-382M14.1	-3.74	0.000207	0.0146	-0.22	-0.17	Coronary artery disease;	chr11:107404525	chr11:107176286~107177530:+
THCA	cis	rs10438797	0.677	rs8067915	ENSG00000276995.1	RP11-321A17.6	-3.74	0.000207	0.0146	-0.16	-0.17	Night sleep phenotypes;	chr17:29137543	chr17:29071124~29071594:-
THCA	cis	rs1433188	0.65	rs4114169	ENSG00000253582.1	RP11-649G15.2	-3.74	0.000207	0.0146	-0.19	-0.17	Subjective well-being;	chr8:107444577	chr8:106520474~106657548:-
THCA	cis	rs75828804	1	rs79835795	ENSG00000260922.1	RP11-538I12.3	-3.74	0.000207	0.0146	-0.37	-0.17	Intraocular pressure;	chr16:77574190	chr16:77234877~77290934:+
THCA	cis	rs944289	0.708	rs11622885	ENSG00000257520.1	RP11-896J10.3	3.74	0.000207	0.0146	0.17	0.17	Thyroid cancer;	chr14:36095036	chr14:36473207~36519521:-
THCA	cis	rs1930961	0.558	rs5996951	ENSG00000100058.11	CRYBB2P1	3.74	0.000207	0.0146	0.28	0.17	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25448105~25520854:+
THCA	cis	rs7179228	1	rs2271722	ENSG00000260657.2	RP11-315D16.4	3.74	0.000207	0.0146	0.24	0.17	Systolic blood pressure;	chr15:68326623	chr15:68267792~68277994:-
THCA	cis	rs7179228	1	rs11630928	ENSG00000260657.2	RP11-315D16.4	3.74	0.000207	0.0146	0.24	0.17	Systolic blood pressure;	chr15:68327709	chr15:68267792~68277994:-
THCA	cis	rs7179228	1	rs3736492	ENSG00000260657.2	RP11-315D16.4	3.74	0.000207	0.0146	0.24	0.17	Systolic blood pressure;	chr15:68327738	chr15:68267792~68277994:-
THCA	cis	rs7554547	0.69	rs7364817	ENSG00000199347.1	RNU5E-1	3.74	0.000207	0.0146	0.24	0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11877060	chr1:11908152~11908271:+
THCA	cis	rs4218	0.532	rs17236369	ENSG00000277144.1	RP11-59H7.4	-3.74	0.000207	0.0146	-0.23	-0.17	Social communication problems;	chr15:59021656	chr15:59115547~59116089:-
THCA	cis	rs964611	0.882	rs10152424	ENSG00000259488.2	RP11-154J22.1	-3.74	0.000207	0.0146	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48299790	chr15:48312353~48331856:-
THCA	cis	rs7259376	0.936	rs8111537	ENSG00000269345.1	VN1R85P	3.74	0.000207	0.0146	0.18	0.17	Menopause (age at onset);	chr19:22352743	chr19:22174766~22175191:-
THCA	cis	rs6142618	0.84	rs2424874	ENSG00000224452.1	RSL24D1P6	-3.74	0.000207	0.0146	-0.21	-0.17	Inflammatory bowel disease;	chr20:32353569	chr20:32170390~32170790:-
THCA	cis	rs1125355	0.655	rs11683568	ENSG00000243792.1	OR7E89P	-3.74	0.000207	0.0146	-0.25	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158762690	chr2:158853755~158854576:+
THCA	cis	rs858239	1	rs156421	ENSG00000230042.1	AK3P3	-3.74	0.000207	0.0146	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23129178~23129841:+
THCA	cis	rs9393777	0.841	rs13191474	ENSG00000220721.1	OR1F12	3.74	0.000207	0.0146	0.35	0.17	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28073316~28074233:+
THCA	cis	rs9393777	0.92	rs41269265	ENSG00000220721.1	OR1F12	3.74	0.000207	0.0146	0.35	0.17	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28073316~28074233:+
THCA	cis	rs944289	0.561	rs1755769	ENSG00000258844.1	RP11-259K15.2	3.74	0.000207	0.0146	0.17	0.17	Thyroid cancer;	chr14:36193617	chr14:36214607~36235608:+
THCA	cis	rs7845219	0.539	rs713113	ENSG00000253528.2	RP11-347C18.4	-3.74	0.000207	0.0146	-0.19	-0.17	Type 2 diabetes;	chr8:94865559	chr8:94974573~94974853:-
THCA	cis	rs2032366	0.63	rs1894094	ENSG00000267316.4	RP11-879F14.3	-3.74	0.000207	0.0146	-0.19	-0.17	Obesity-related traits;	chr18:61606390	chr18:61571342~61579456:-
THCA	cis	rs9863	0.513	rs34102591	ENSG00000269997.1	RP11-214K3.21	-3.74	0.000207	0.0146	-0.24	-0.17	White blood cell count;	chr12:123996254	chr12:123966077~123966629:-
THCA	cis	rs2980439	0.517	rs17594065	ENSG00000253981.4	ALG1L13P	-3.74	0.000207	0.0146	-0.17	-0.17	Neuroticism;	chr8:8247883	chr8:8236003~8244667:-
THCA	cis	rs7119038	0.818	rs10892279	ENSG00000255422.1	AP002954.4	3.74	0.000207	0.0146	0.2	0.17	Sjögren's syndrome;	chr11:118741072	chr11:118704607~118750263:+
THCA	cis	rs931608	0.565	rs13344143	ENSG00000269138.1	ZNF209P	3.74	0.000207	0.0146	0.23	0.17	Response to statins (LDL cholesterol change);Dental caries;	chr19:22348243	chr19:22463922~22473036:+
THCA	cis	rs2640806	0.505	rs28830572	ENSG00000253105.4	KB-1448A5.1	3.74	0.000207	0.0146	0.2	0.17	Obesity-related traits;	chr8:96351869	chr8:96371865~96387438:-
THCA	cis	rs447735	0.587	rs7188458	ENSG00000274627.1	RP11-104N10.2	3.74	0.000207	0.0146	0.17	0.17	Hemoglobin concentration;	chr16:89660076	chr16:89516797~89522217:+
THCA	cis	rs2665103	0.589	rs3858953	ENSG00000276710.3	CSPG4P8	-3.74	0.000207	0.0146	-0.16	-0.17	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82459472~82477258:+
THCA	cis	rs2337406	0.866	rs58850145	ENSG00000280411.1	IGHV1-69-2	-3.74	0.000207	0.0146	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106806185	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs2027901	ENSG00000280411.1	IGHV1-69-2	-3.74	0.000207	0.0146	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106807164	chr14:106762092~106762588:-
THCA	cis	rs6782029	0.517	rs11128563	ENSG00000225026.1	AC091492.2	-3.74	0.000207	0.0146	-0.28	-0.17	Anorexia nervosa;	chr3:11636627	chr3:12328003~12328274:+
THCA	cis	rs6545883	0.54	rs11687956	ENSG00000271889.1	RP11-493E12.1	-3.74	0.000207	0.0146	-0.16	-0.17	Tuberculosis;	chr2:61624207	chr2:61151433~61162105:-
THCA	cis	rs17685	0.753	rs6976532	ENSG00000227038.2	AC005077.12	3.74	0.000208	0.0146	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76051776	chr7:76090431~76108779:-
THCA	cis	rs2562456	0.876	rs11085467	ENSG00000268658.4	LINC00664	3.74	0.000208	0.0146	0.25	0.17	Pain;	chr19:21569041	chr19:21483374~21503238:+
THCA	cis	rs346923	1	rs10011820	ENSG00000226950.5	DANCR	3.74	0.000208	0.0146	0.19	0.17	Biochemical measures;	chr4:52495246	chr4:52712404~52720351:+
THCA	cis	rs346923	1	rs28599539	ENSG00000226950.5	DANCR	3.74	0.000208	0.0146	0.19	0.17	Biochemical measures;	chr4:52496033	chr4:52712404~52720351:+
THCA	cis	rs4906332	1	rs1951389	ENSG00000259775.1	RP11-45P15.4	-3.74	0.000208	0.0146	-0.15	-0.17	Coronary artery disease;	chr14:103432188	chr14:103331674~103332367:-
THCA	cis	rs4906332	0.901	rs4900575	ENSG00000259775.1	RP11-45P15.4	-3.74	0.000208	0.0146	-0.15	-0.17	Coronary artery disease;	chr14:103432832	chr14:103331674~103332367:-
THCA	cis	rs9291683	0.655	rs55941493	ENSG00000261490.1	RP11-448G15.3	-3.74	0.000208	0.0146	-0.11	-0.17	Bone mineral density;	chr4:10098717	chr4:10068089~10073019:-
THCA	cis	rs427691	0.625	rs370575	ENSG00000249476.1	CTD-2587M2.1	3.74	0.000208	0.0146	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr5:109675587	chr5:109237120~109326369:-
THCA	cis	rs858239	0.899	rs10262243	ENSG00000226816.2	AC005082.12	3.74	0.000208	0.0146	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23206013~23208045:+
THCA	cis	rs6137726	0.524	rs1203930	ENSG00000237396.1	LINC01384	3.74	0.000208	0.0146	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22610197	chr20:22587522~22607517:-
THCA	cis	rs9980	0.647	rs12149228	ENSG00000226232.7	RP11-419C5.2	-3.74	0.000208	0.0146	-0.26	-0.17	Blood osmolality (transformed sodium);	chr16:69731621	chr16:69976388~69996188:-
THCA	cis	rs4568518	0.619	rs4470902	ENSG00000279048.1	RP11-511H23.2	-3.74	0.000208	0.0146	-0.11	-0.17	Measles;	chr7:17968687	chr7:17940503~17942922:+
THCA	cis	rs4073416	0.542	rs1889731	ENSG00000276116.2	FUT8-AS1	3.74	0.000208	0.0146	0.19	0.17	N-glycan levels;	chr14:65475993	chr14:65411170~65412690:-
THCA	cis	rs7711186	0.656	rs4521498	ENSG00000252464.1	RN7SKP70	3.74	0.000208	0.0146	0.18	0.17	Urate levels in obese individuals;	chr5:178635776	chr5:178619728~178619998:-
THCA	cis	rs875971	0.965	rs697968	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000208	0.0146	-0.18	-0.17	Aortic root size;	chr7:66070046	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs1183245	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000208	0.0146	-0.18	-0.17	Aortic root size;	chr7:66076198	chr7:66025126~66031544:-
THCA	cis	rs875971	1	rs1144894	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000208	0.0146	-0.18	-0.17	Aortic root size;	chr7:66077907	chr7:66025126~66031544:-
THCA	cis	rs10090774	0.965	rs1349081	ENSG00000280303.2	ERICD	-3.74	0.000208	0.0146	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140933983	chr8:140636281~140638283:+
THCA	cis	rs10419113	0.628	rs12608585	ENSG00000268545.1	VN1R107P	3.74	0.000208	0.0146	0.2	0.17	Pediatric bone mineral density (spine);	chr19:57689260	chr19:57459912~57460120:+
THCA	cis	rs10844706	0.604	rs7964018	ENSG00000256594.6	RP11-705C15.2	-3.74	0.000208	0.0146	-0.14	-0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9713803	chr12:9633419~9658412:+
THCA	cis	rs7824557	0.525	rs12682349	ENSG00000154316.13	TDH	-3.74	0.000208	0.0146	-0.13	-0.17	Retinal vascular caliber;	chr8:11387794	chr8:11339637~11368452:+
THCA	cis	rs293748	0.882	rs16903459	ENSG00000250155.1	CTD-2353F22.1	-3.74	0.000208	0.0146	-0.23	-0.17	Obesity-related traits;	chr5:37031314	chr5:36666214~36725195:-
THCA	cis	rs9796	0.558	rs7166205	ENSG00000247556.5	OIP5-AS1	3.74	0.000208	0.0146	0.13	0.17	Menopause (age at onset);	chr15:41222535	chr15:41283990~41309737:+
THCA	cis	rs9796	0.558	rs7166905	ENSG00000247556.5	OIP5-AS1	3.74	0.000208	0.0146	0.13	0.17	Menopause (age at onset);	chr15:41222678	chr15:41283990~41309737:+
THCA	cis	rs7243790	0.805	rs3809947	ENSG00000277324.1	RP11-850A17.1	-3.74	0.000208	0.0146	-0.17	-0.17	Diastolic blood pressure;	chr18:54380396	chr18:54268346~54270028:-
THCA	cis	rs4950322	1	rs72694720	ENSG00000180867.10	PDIA3P1	3.74	0.000208	0.0146	0.18	0.17	Protein quantitative trait loci;	chr1:147371939	chr1:147178113~147179622:+
THCA	cis	rs10089	1	rs17764954	ENSG00000245937.6	LINC01184	3.74	0.000208	0.0146	0.19	0.17	Ileal carcinoids;	chr5:128178744	chr5:127940426~128083172:-
THCA	cis	rs7089973	0.61	rs17795212	ENSG00000236799.1	RP11-383C6.2	-3.74	0.000208	0.0146	-0.21	-0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114993538	chr10:114994657~114996593:+
THCA	cis	rs10540	1	rs61876340	ENSG00000279672.1	CMB9-55F22.1	3.74	0.000208	0.0146	0.33	0.17	Body mass index;	chr11:495699	chr11:779617~780755:+
THCA	cis	rs10540	1	rs61876341	ENSG00000279672.1	CMB9-55F22.1	3.74	0.000208	0.0146	0.33	0.17	Body mass index;	chr11:495892	chr11:779617~780755:+
THCA	cis	rs1580019	0.961	rs6949851	ENSG00000231952.3	DPY19L1P2	-3.74	0.000208	0.0146	-0.22	-0.17	Cognitive ability;	chr7:32454195	chr7:32812757~32838570:+
THCA	cis	rs2274273	0.84	rs11547116	ENSG00000258469.1	CHMP4BP1	3.74	0.000208	0.0146	0.15	0.17	Protein biomarker;	chr14:55271447	chr14:55298644~55299231:+
THCA	cis	rs896655	0.775	rs10114559	ENSG00000229835.2	KHSRPP1	-3.74	0.000208	0.0146	-0.21	-0.17	Coronary artery disease;	chr9:21816638	chr9:21695176~21696943:+
THCA	cis	rs4295623	0.556	rs10903343	ENSG00000254866.2	DEFB109P3	-3.74	0.000208	0.0146	-0.23	-0.17	Morning vs. evening chronotype;	chr8:11838363	chr8:12150895~12151134:-
THCA	cis	rs6012564	0.893	rs6019516	ENSG00000230758.1	SNAP23P	-3.74	0.000208	0.0146	-0.21	-0.17	Anger;	chr20:48913613	chr20:49038357~49038602:-
THCA	cis	rs10090774	0.901	rs10112148	ENSG00000280303.2	ERICD	-3.74	0.000208	0.0146	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140699769	chr8:140636281~140638283:+
THCA	cis	rs614226	1	rs1614223	ENSG00000278344.1	RP11-18C24.8	3.74	0.000208	0.0146	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120526240	chr12:120500735~120501090:-
THCA	cis	rs614226	1	rs1167727	ENSG00000278344.1	RP11-18C24.8	3.74	0.000208	0.0146	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120527705	chr12:120500735~120501090:-
THCA	cis	rs6138458	0.743	rs3746330	ENSG00000274173.1	RP4-568C11.4	3.74	0.000208	0.0146	0.15	0.17	Blood protein levels;	chr20:25019159	chr20:24931840~24932983:+
THCA	cis	rs1075265	0.584	rs2357954	ENSG00000272156.1	RP11-477N3.1	3.74	0.000208	0.0146	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54082554~54085066:+
THCA	cis	rs2299682	0.826	rs6086905	ENSG00000230506.1	RP11-416N4.4	3.74	0.000208	0.0146	0.28	0.17	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9486877	chr20:10173520~10196990:+
THCA	cis	rs875971	0.502	rs2465121	ENSG00000232559.3	GS1-124K5.12	-3.74	0.000208	0.0146	-0.19	-0.17	Aortic root size;	chr7:66156017	chr7:66554588~66576923:-
THCA	cis	rs7940646	0.817	rs10840457	ENSG00000254554.1	RP11-351I24.1	-3.74	0.000208	0.0146	-0.2	-0.17	Platelet aggregation;	chr11:10654191	chr11:10302657~10303704:-
THCA	cis	rs9863	0.794	rs12310367	ENSG00000270028.1	RP11-380L11.4	3.74	0.000208	0.0146	0.18	0.17	White blood cell count;	chr12:124002131	chr12:123925461~123926083:-
THCA	cis	rs6142618	0.935	rs4911552	ENSG00000224452.1	RSL24D1P6	3.74	0.000208	0.0146	0.21	0.17	Inflammatory bowel disease;	chr20:32159270	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.934	rs14316	ENSG00000224452.1	RSL24D1P6	3.74	0.000208	0.0146	0.21	0.17	Inflammatory bowel disease;	chr20:32165467	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.905	rs1546922	ENSG00000224452.1	RSL24D1P6	3.74	0.000208	0.0146	0.21	0.17	Inflammatory bowel disease;	chr20:32167895	chr20:32170390~32170790:-
THCA	cis	rs7927592	0.956	rs10896348	ENSG00000160172.9	FAM86C2P	3.74	0.000208	0.0147	0.16	0.17	Total body bone mineral density;	chr11:68589900	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.956	rs7113287	ENSG00000160172.9	FAM86C2P	3.74	0.000208	0.0147	0.16	0.17	Total body bone mineral density;	chr11:68604718	chr11:67791648~67805336:-
THCA	cis	rs321358	0.895	rs17457375	ENSG00000271390.1	RP11-89C3.3	3.74	0.000208	0.0147	0.27	0.17	Body mass index;	chr11:111085100	chr11:111089870~111090368:-
THCA	cis	rs321358	0.895	rs17535942	ENSG00000271390.1	RP11-89C3.3	3.74	0.000208	0.0147	0.27	0.17	Body mass index;	chr11:111085233	chr11:111089870~111090368:-
THCA	cis	rs321358	0.895	rs7101466	ENSG00000271390.1	RP11-89C3.3	3.74	0.000208	0.0147	0.27	0.17	Body mass index;	chr11:111085729	chr11:111089870~111090368:-
THCA	cis	rs321358	0.895	rs7101576	ENSG00000271390.1	RP11-89C3.3	3.74	0.000208	0.0147	0.27	0.17	Body mass index;	chr11:111085795	chr11:111089870~111090368:-
THCA	cis	rs7246967	0.544	rs403717	ENSG00000198153.8	ZNF849P	-3.74	0.000208	0.0147	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22826001	chr19:22685167~22686732:+
THCA	cis	rs6788895	0.661	rs57869178	ENSG00000244265.1	SIAH2-AS1	3.74	0.000208	0.0147	0.39	0.17	Breast cancer;	chr3:150775039	chr3:150761937~150762538:+
THCA	cis	rs875971	0.545	rs2279757	ENSG00000273024.4	INTS4P2	-3.74	0.000208	0.0147	-0.22	-0.17	Aortic root size;	chr7:66363676	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000273024.4	INTS4P2	-3.74	0.000208	0.0147	-0.22	-0.17	Aortic root size;	chr7:66374173	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000273024.4	INTS4P2	-3.74	0.000208	0.0147	-0.22	-0.17	Aortic root size;	chr7:66387213	chr7:65647864~65715661:+
THCA	cis	rs10995505	0.589	rs1553789	ENSG00000272767.1	JMJD1C-AS1	3.74	0.000208	0.0147	0.2	0.17	Intelligence (multi-trait analysis);	chr10:63119469	chr10:63465229~63466563:+
THCA	cis	rs9840812	0.559	rs6439640	ENSG00000273486.1	RP11-731C17.2	3.74	0.000208	0.0147	0.18	0.17	Fibrinogen levels;	chr3:136466838	chr3:136837338~136839021:-
THCA	cis	rs6921919	0.697	rs758398	ENSG00000176933.5	TOB2P1	-3.74	0.000208	0.0147	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28217643~28218634:-
THCA	cis	rs853679	0.882	rs9380069	ENSG00000273712.1	RP5-874C20.7	3.74	0.000208	0.0147	0.28	0.17	Depression;	chr6:28235522	chr6:28315613~28315883:-
THCA	cis	rs17772222	0.71	rs1028455	ENSG00000222990.1	RNU4-22P	3.74	0.000208	0.0147	0.21	0.17	Coronary artery calcification;	chr14:88363631	chr14:88513498~88513663:+
THCA	cis	rs7209700	0.894	rs7212751	ENSG00000262879.4	RP11-156P1.3	3.74	0.000208	0.0147	0.15	0.17	IgG glycosylation;	chr17:47278133	chr17:46984045~47100323:-
THCA	cis	rs357618	0.581	rs165335	ENSG00000260581.1	CTB-113P19.4	3.74	0.000208	0.0147	0.26	0.17	Basophil percentage of white cells;	chr5:151498616	chr5:151652275~151655449:+
THCA	cis	rs28830936	0.934	rs28401754	ENSG00000250379.1	RP11-23P13.4	3.74	0.000208	0.0147	0.2	0.17	Diastolic blood pressure;	chr15:41824705	chr15:41825099~41827936:-
THCA	cis	rs11671005	0.656	rs11671092	ENSG00000265272.2	RN7SL693P	3.74	0.000208	0.0147	0.25	0.17	Mean platelet volume;	chr19:58497742	chr19:58490797~58491075:+
THCA	cis	rs11671005	0.656	rs55928441	ENSG00000265272.2	RN7SL693P	3.74	0.000208	0.0147	0.25	0.17	Mean platelet volume;	chr19:58498307	chr19:58490797~58491075:+
THCA	cis	rs8113308	0.515	rs113082012	ENSG00000260160.1	CTC-471J1.2	3.74	0.000208	0.0147	0.26	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960980	chr19:52058490~52063703:-
THCA	cis	rs8113308	0.515	rs73066986	ENSG00000260160.1	CTC-471J1.2	3.74	0.000208	0.0147	0.26	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51962805	chr19:52058490~52063703:-
THCA	cis	rs8113308	0.515	rs4986770	ENSG00000260160.1	CTC-471J1.2	3.74	0.000208	0.0147	0.26	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51964781	chr19:52058490~52063703:-
THCA	cis	rs7826238	0.502	rs10503377	ENSG00000253981.4	ALG1L13P	3.74	0.000208	0.0147	0.18	0.17	Systolic blood pressure;	chr8:8520912	chr8:8236003~8244667:-
THCA	cis	rs10457678	0.579	rs10872495	ENSG00000225415.2	RP3-509I19.1	-3.74	0.000208	0.0147	-0.24	-0.17	Colorectal or endometrial cancer;	chr6:138834540	chr6:138822747~138823799:+
THCA	cis	rs3760982	0.585	rs11673534	ENSG00000268601.1	AC115522.3	-3.74	0.000208	0.0147	-0.21	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794732	chr19:43794309~43795658:-
THCA	cis	rs3760982	0.585	rs11673490	ENSG00000268601.1	AC115522.3	-3.74	0.000208	0.0147	-0.21	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794733	chr19:43794309~43795658:-
THCA	cis	rs3760982	0.585	rs11083724	ENSG00000268601.1	AC115522.3	-3.74	0.000208	0.0147	-0.21	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794836	chr19:43794309~43795658:-
THCA	cis	rs1555322	0.53	rs6060341	ENSG00000269202.1	RP4-614O4.12	3.74	0.000208	0.0147	0.18	0.17	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35201747~35203288:-
THCA	cis	rs2777491	0.874	rs28716108	ENSG00000247556.5	OIP5-AS1	3.74	0.000208	0.0147	0.15	0.17	Ulcerative colitis;	chr15:41363325	chr15:41283990~41309737:+
THCA	cis	rs877819	0.583	rs2663021	ENSG00000228403.1	RP11-563N6.6	-3.74	0.000208	0.0147	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48870072	chr10:48878022~48878649:+
THCA	cis	rs9309473	0.519	rs13009035	ENSG00000273245.1	RP11-434P11.2	-3.74	0.000208	0.0147	-0.21	-0.17	Metabolite levels;	chr2:73618582	chr2:73750256~73750786:-
THCA	cis	rs10129255	0.957	rs10141052	ENSG00000280411.1	IGHV1-69-2	-3.74	0.000209	0.0147	-0.11	-0.17	Kawasaki disease;	chr14:106776528	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs10141009	ENSG00000280411.1	IGHV1-69-2	-3.74	0.000209	0.0147	-0.11	-0.17	Kawasaki disease;	chr14:106776695	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.912	rs6576227	ENSG00000280411.1	IGHV1-69-2	-3.74	0.000209	0.0147	-0.11	-0.17	Kawasaki disease;	chr14:106778202	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs6576228	ENSG00000280411.1	IGHV1-69-2	-3.74	0.000209	0.0147	-0.11	-0.17	Kawasaki disease;	chr14:106778401	chr14:106762092~106762588:-
THCA	cis	rs763512	0.504	rs6607279	ENSG00000277501.1	RP11-697E22.2	3.74	0.000209	0.0147	0.25	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37564796	chr17:37642947~37684252:+
THCA	cis	rs1577917	1	rs2812972	ENSG00000220563.1	PKMP3	-3.74	0.000209	0.0147	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85960162	chr6:85659892~85660606:-
THCA	cis	rs4788570	0.578	rs4788553	ENSG00000260185.1	RP11-432I5.6	-3.74	0.000209	0.0147	-0.31	-0.17	Intelligence (multi-trait analysis);	chr16:71746374	chr16:71655027~71664212:+
THCA	cis	rs6499755	0.862	rs2588994	ENSG00000260135.5	RP11-212I21.2	-3.74	0.000209	0.0147	-0.19	-0.17	Hypospadias;	chr16:55323769	chr16:55426797~55462297:-
THCA	cis	rs6738627	0.931	rs13432797	ENSG00000223318.1	RNA5SP111	-3.74	0.000209	0.0147	-0.22	-0.17	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164670077	chr2:164895677~164895777:-
THCA	cis	rs7296418	0.675	rs1879379	ENSG00000256092.2	RP13-942N8.1	3.74	0.000209	0.0147	0.12	0.17	Platelet count;	chr12:123242896	chr12:123363868~123366113:+
THCA	cis	rs4819052	0.679	rs2236450	ENSG00000273796.1	LL21NC02-21A1.1	-3.74	0.000209	0.0147	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45403809~45404369:-
THCA	cis	rs6687821	0.774	rs11161891	ENSG00000261737.1	RP4-612B15.3	-3.74	0.000209	0.0147	-0.29	-0.17	Yeast infection;	chr1:86791615	chr1:86703502~86704462:-
THCA	cis	rs12549025	0.838	rs12549737	ENSG00000253390.1	CTC-756D1.2	-3.74	0.000209	0.0147	-0.32	-0.17	Reticulocyte fraction of red cells;	chr8:23536948	chr8:23458601~23484971:+
THCA	cis	rs1908814	0.516	rs13275143	ENSG00000255495.1	AC145124.2	3.74	0.000209	0.0147	0.2	0.17	Neuroticism;	chr8:11939481	chr8:12194467~12196280:+
THCA	cis	rs718433	0.616	rs7142911	ENSG00000211778.2	TRAV4	-3.74	0.000209	0.0147	-0.13	-0.17	Intraocular pressure;	chr14:21745252	chr14:21736152~21736982:+
THCA	cis	rs7656342	0.964	rs13148356	ENSG00000242034.1	RP11-1396O13.1	3.74	0.000209	0.0147	0.2	0.17	Gut microbiota (bacterial taxa);	chr4:9815446	chr4:9553614~9553985:-
THCA	cis	rs293748	0.882	rs13177875	ENSG00000250155.1	CTD-2353F22.1	-3.74	0.000209	0.0147	-0.23	-0.17	Obesity-related traits;	chr5:37078226	chr5:36666214~36725195:-
THCA	cis	rs7520050	0.966	rs7539932	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs61783200	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6680380	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs10890354	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs6697557	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6701614	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45581219~45581321:-
THCA	cis	rs9876781	1	rs9838618	ENSG00000199476.1	Y_RNA	-3.74	0.000209	0.0147	-0.21	-0.17	Longevity;	chr3:48445949	chr3:48288587~48288694:+
THCA	cis	rs1357692	0.899	rs1524288	ENSG00000238250.1	ST6GAL2-IT1	3.74	0.000209	0.0147	0.17	0.17	Alzheimer's disease;	chr2:107069407	chr2:106822923~106825031:-
THCA	cis	rs889312	0.5	rs33328	ENSG00000271828.1	CTD-2310F14.1	-3.74	0.000209	0.0147	-0.23	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56847592	chr5:56927874~56929573:+
THCA	cis	rs758324	0.628	rs2073506	ENSG00000224431.1	AC063976.7	-3.74	0.000209	0.0147	-0.24	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132059045	chr5:132199456~132203487:+
THCA	cis	rs2129782	0.558	rs75449632	ENSG00000253553.4	RP11-586K2.1	3.74	0.000209	0.0147	0.25	0.17	Electrodermal activity;	chr8:88475817	chr8:88326836~88737134:+
THCA	cis	rs7131987	0.683	rs3782511	ENSG00000273680.1	RP11-996F15.6	3.74	0.000209	0.0147	0.24	0.17	QT interval;	chr12:29343291	chr12:29332733~29333383:-
THCA	cis	rs10435719	0.902	rs12681142	ENSG00000254948.1	OR7E158P	-3.74	0.000209	0.0147	-0.22	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:11919900~11920809:-
THCA	cis	rs701145	0.537	rs1727952	ENSG00000243069.6	ARHGEF26-AS1	3.74	0.000209	0.0147	0.32	0.17	Coronary artery disease;	chr3:154153776	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713813	ENSG00000243069.6	ARHGEF26-AS1	3.74	0.000209	0.0147	0.32	0.17	Coronary artery disease;	chr3:154155854	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1632688	ENSG00000243069.6	ARHGEF26-AS1	3.74	0.000209	0.0147	0.32	0.17	Coronary artery disease;	chr3:154156350	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713811	ENSG00000243069.6	ARHGEF26-AS1	3.74	0.000209	0.0147	0.32	0.17	Coronary artery disease;	chr3:154156777	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1527800	ENSG00000243069.6	ARHGEF26-AS1	3.74	0.000209	0.0147	0.32	0.17	Coronary artery disease;	chr3:154157286	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727948	ENSG00000243069.6	ARHGEF26-AS1	3.74	0.000209	0.0147	0.32	0.17	Coronary artery disease;	chr3:154159140	chr3:154024401~154121332:-
THCA	cis	rs453301	0.686	rs10217044	ENSG00000254340.1	RP11-10A14.3	-3.74	0.000209	0.0147	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9037242	chr8:9141424~9145435:+
THCA	cis	rs720475	0.695	rs62483108	ENSG00000170356.8	OR2A20P	3.74	0.000209	0.0147	0.24	0.17	Breast cancer;	chr7:144442326	chr7:144250045~144252957:-
THCA	cis	rs16975963	0.793	rs56672492	ENSG00000276846.1	CTD-3220F14.3	-3.74	0.000209	0.0147	-0.16	-0.17	Longevity;	chr19:37957591	chr19:37314868~37315620:-
THCA	cis	rs4803480	1	rs7255679	ENSG00000270164.1	LINC01480	-3.74	0.000209	0.0147	-0.18	-0.17	Schizophrenia;	chr19:41557611	chr19:41535183~41536904:+
THCA	cis	rs4073416	0.542	rs6573616	ENSG00000276116.2	FUT8-AS1	3.74	0.000209	0.0147	0.19	0.17	N-glycan levels;	chr14:65580098	chr14:65411170~65412690:-
THCA	cis	rs2933343	0.672	rs1872545	ENSG00000231305.3	RP11-723O4.2	3.74	0.000209	0.0147	0.18	0.17	IgG glycosylation;	chr3:128926196	chr3:128861313~128871540:-
THCA	cis	rs13063635	0.831	rs36040135	ENSG00000226074.4	PRSS44	-3.74	0.000209	0.0147	-0.3	-0.17	Eosinophil percentage of granulocytes;	chr3:46019812	chr3:46809359~46812558:-
THCA	cis	rs62246343	0.504	rs7652415	ENSG00000254485.4	RP11-380O24.1	3.74	0.000209	0.0147	0.21	0.17	Fibrinogen levels;	chr3:9463554	chr3:9292588~9363303:-
THCA	cis	rs4950322	0.512	rs10736839	ENSG00000180867.10	PDIA3P1	-3.74	0.000209	0.0147	-0.15	-0.17	Protein quantitative trait loci;	chr1:147370431	chr1:147178113~147179622:+
THCA	cis	rs2904524	1	rs76044745	ENSG00000257815.4	RP11-611E13.2	-3.74	0.000209	0.0147	-0.16	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70345310	chr12:69904033~70243360:-
THCA	cis	rs2442825	0.693	rs1054975	ENSG00000254485.4	RP11-380O24.1	-3.74	0.000209	0.0147	-0.16	-0.17	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9292588~9363303:-
THCA	cis	rs2442825	0.693	rs2648535	ENSG00000254485.4	RP11-380O24.1	-3.74	0.000209	0.0147	-0.16	-0.17	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9292588~9363303:-
THCA	cis	rs2732480	0.5	rs2450989	ENSG00000257735.1	RP11-370I10.6	-3.74	0.000209	0.0147	-0.19	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48350945~48442411:+
THCA	cis	rs9532669	0.89	rs7333274	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40862531	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs2324737	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40862808	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4942003	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40863270	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs4942004	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40863598	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs9315791	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40863931	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.824	rs9315792	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40863951	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.684	rs7139788	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40864264	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7338617	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40870787	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.857	rs6560961	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40870878	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs6560962	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40870948	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs1055588	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40871306	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs3610	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40871334	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4942005	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40871636	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4942006	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40871862	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4942008	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40871989	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs2039118	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40872260	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4356347	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40872516	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7982346	ENSG00000229473.2	RGS17P1	3.74	0.000209	0.0147	0.22	0.17	Cervical cancer;	chr13:40873273	chr13:40992779~40993331:-
THCA	cis	rs10089	1	rs4836367	ENSG00000245937.6	LINC01184	3.74	0.000209	0.0147	0.19	0.17	Ileal carcinoids;	chr5:128146900	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs73337363	ENSG00000245937.6	LINC01184	3.74	0.000209	0.0147	0.19	0.17	Ileal carcinoids;	chr5:128147905	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs4836369	ENSG00000245937.6	LINC01184	3.74	0.000209	0.0147	0.19	0.17	Ileal carcinoids;	chr5:128150770	chr5:127940426~128083172:-
THCA	cis	rs10186029	0.509	rs10203749	ENSG00000270659.1	RP11-105N14.1	3.74	0.000209	0.0147	0.15	0.17	Systemic sclerosis;	chr2:213071131	chr2:213152970~213153659:+
THCA	cis	rs10186029	0.509	rs10203838	ENSG00000270659.1	RP11-105N14.1	3.74	0.000209	0.0147	0.15	0.17	Systemic sclerosis;	chr2:213071176	chr2:213152970~213153659:+
THCA	cis	rs757110	0.77	rs11024268	ENSG00000260196.1	RP1-239B22.5	3.74	0.000209	0.0147	0.19	0.17	Type 2 diabetes;	chr11:17366435	chr11:17380649~17383531:+
THCA	cis	rs757110	0.77	rs2051772	ENSG00000260196.1	RP1-239B22.5	3.74	0.000209	0.0147	0.19	0.17	Type 2 diabetes;	chr11:17368303	chr11:17380649~17383531:+
THCA	cis	rs2562456	0.833	rs62107539	ENSG00000268278.1	RP11-420K14.1	3.74	0.000209	0.0147	0.24	0.17	Pain;	chr19:21334910	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs76646508	ENSG00000268278.1	RP11-420K14.1	3.74	0.000209	0.0147	0.24	0.17	Pain;	chr19:21335247	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs77576302	ENSG00000268278.1	RP11-420K14.1	3.74	0.000209	0.0147	0.24	0.17	Pain;	chr19:21335385	chr19:21637974~21656300:+
THCA	cis	rs3758911	0.964	rs10789603	ENSG00000255353.1	RP11-382M14.1	-3.74	0.000209	0.0147	-0.22	-0.17	Coronary artery disease;	chr11:107311050	chr11:107176286~107177530:+
THCA	cis	rs2832077	1	rs9983229	ENSG00000232855.5	AF131217.1	-3.74	0.000209	0.0147	-0.21	-0.17	Cognitive test performance;	chr21:28765352	chr21:28439346~28674848:-
THCA	cis	rs4237845	0.537	rs11172367	ENSG00000270039.1	RP11-571M6.17	-3.74	0.000209	0.0147	-0.19	-0.17	Intelligence (multi-trait analysis);	chr12:57878703	chr12:57803838~57804415:+
THCA	cis	rs9788682	0.792	rs2869032	ENSG00000261143.1	ADAMTS7P3	3.74	0.000209	0.0147	0.26	0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78422219	chr15:77976042~77993057:+
THCA	cis	rs12295638	0.73	rs1353142	ENSG00000254862.4	RP11-159H22.2	3.74	0.000209	0.0147	0.22	0.17	Obesity (extreme);	chr11:26626524	chr11:27471729~27482433:+
THCA	cis	rs5758659	0.652	rs133336	ENSG00000281538.1	RP4-669P10.20	3.74	0.000209	0.0147	0.16	0.17	Cognitive function;	chr22:42020299	chr22:42138060~42139726:+
THCA	cis	rs4780401	0.967	rs11075012	ENSG00000274038.1	RP11-66H6.4	-3.74	0.000209	0.0147	-0.2	-0.17	Rheumatoid arthritis;	chr16:11737174	chr16:11056556~11057034:+
THCA	cis	rs4853036	0.904	rs2278934	ENSG00000179818.12	PCBP1-AS1	-3.74	0.000209	0.0147	-0.15	-0.17	Colorectal or endometrial cancer;	chr2:69894065	chr2:69962263~70103220:-
THCA	cis	rs61142792	1	rs61505517	ENSG00000272459.1	RP11-1277A3.3	3.74	0.000209	0.0147	0.38	0.17	Alzheimer disease and age of onset;	chr5:177555390	chr5:177554824~177555364:+
THCA	cis	rs61142792	1	rs61142792	ENSG00000272459.1	RP11-1277A3.3	3.74	0.000209	0.0147	0.38	0.17	Alzheimer disease and age of onset;	chr5:177556462	chr5:177554824~177555364:+
THCA	cis	rs11601239	0.668	rs1938956	ENSG00000254750.1	CASP1P2	3.74	0.000209	0.0147	0.13	0.17	Refractive error;	chr11:105769378	chr11:105063345~105071541:-
THCA	cis	rs7824557	0.564	rs2736304	ENSG00000255495.1	AC145124.2	-3.74	0.000209	0.0147	-0.19	-0.17	Retinal vascular caliber;	chr8:11379455	chr8:12194467~12196280:+
THCA	cis	rs145729347	1	rs145729347	ENSG00000254731.1	CTD-2005H7.1	-3.74	0.000209	0.0147	-0.31	-0.17	Lung function (FEV1);	chr11:86731691	chr11:86703099~86714092:+
THCA	cis	rs1411478	1	rs1411478	ENSG00000243155.1	RP11-46A10.5	3.74	0.000209	0.0147	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180993146	chr1:180944042~180976482:-
THCA	cis	rs6472235	0.681	rs4129057	ENSG00000272192.1	CTD-2532N20.1	3.74	0.000209	0.0147	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65943911	chr8:65842752~65843331:+
THCA	cis	rs911555	0.723	rs56227024	ENSG00000269940.1	RP11-73M18.7	-3.74	0.000209	0.0147	-0.17	-0.17	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103694560~103695170:+
THCA	cis	rs7246760	0.867	rs57943754	ENSG00000267106.4	ZNF561-AS1	3.74	0.000209	0.0147	0.31	0.17	Pursuit maintenance gain;	chr19:9730607	chr19:9621291~9645896:+
THCA	cis	rs875971	0.619	rs2302918	ENSG00000275400.1	RP4-756H11.5	-3.74	0.000209	0.0147	-0.16	-0.17	Aortic root size;	chr7:66535945	chr7:66553805~66554199:-
THCA	cis	rs7621025	0.691	rs9845762	ENSG00000239213.4	NCK1-AS1	3.74	0.000209	0.0147	0.15	0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136637622	chr3:136841726~136862054:-
THCA	cis	rs858239	1	rs199351	ENSG00000226816.2	AC005082.12	3.74	0.000209	0.0147	0.24	0.17	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23206013~23208045:+
THCA	cis	rs7520050	0.931	rs11211189	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs12411269	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs11211198	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs10890352	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6700597	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6695809	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs11211199	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs4376778	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6672898	ENSG00000280836.1	AL355480.1	3.74	0.000209	0.0147	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45581219~45581321:-
THCA	cis	rs459571	0.959	rs2810491	ENSG00000235106.7	LINC00094	-3.74	0.000209	0.0147	-0.15	-0.17	Platelet distribution width;	chr9:134058209	chr9:134025439~134034666:+
THCA	cis	rs559555	0.553	rs2754530	ENSG00000276517.1	AL133243.2	-3.74	0.000209	0.0147	-0.16	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31578333	chr2:32526504~32529507:+
THCA	cis	rs559555	0.553	rs2268799	ENSG00000276517.1	AL133243.2	-3.74	0.000209	0.0147	-0.16	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31578425	chr2:32526504~32529507:+
THCA	cis	rs708224	0.513	rs2728704	ENSG00000277342.1	RP11-843B15.4	3.74	0.000209	0.0147	0.22	0.17	Pancreatic cancer;	chr12:32289871	chr12:32109076~32109602:+
THCA	cis	rs703842	0.575	rs701006	ENSG00000270039.1	RP11-571M6.17	-3.74	0.000209	0.0147	-0.17	-0.17	Multiple sclerosis;	chr12:57713053	chr12:57803838~57804415:+
THCA	cis	rs10090774	0.965	rs11786709	ENSG00000280303.2	ERICD	-3.74	0.000209	0.0147	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140991849	chr8:140636281~140638283:+
THCA	cis	rs11158609	0.536	rs35433607	ENSG00000278784.1	RP11-468E2.11	3.74	0.000209	0.0147	0.17	0.17	Systolic blood pressure (cigarette smoking interaction);	chr14:24204331	chr14:24201612~24202811:-
THCA	cis	rs75828804	0.655	rs77167149	ENSG00000260922.1	RP11-538I12.3	-3.74	0.00021	0.0147	-0.36	-0.17	Intraocular pressure;	chr16:77515369	chr16:77234877~77290934:+
THCA	cis	rs853679	0.713	rs200991	ENSG00000261839.1	RP1-265C24.8	-3.74	0.00021	0.0147	-0.22	-0.17	Depression;	chr6:27847716	chr6:28136849~28139678:+
THCA	cis	rs1005277	0.579	rs1780137	ENSG00000120555.12	SEPT7P9	3.74	0.00021	0.0147	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38383069~38402916:-
THCA	cis	rs9905704	0.836	rs302875	ENSG00000224738.1	AC099850.1	-3.74	0.00021	0.0147	-0.23	-0.17	Testicular germ cell tumor;	chr17:58690513	chr17:59106598~59118267:+
THCA	cis	rs7665090	1	rs3733202	ENSG00000248971.2	KRT8P46	-3.74	0.00021	0.0147	-0.2	-0.17	Primary biliary cholangitis;	chr4:102635704	chr4:102728746~102730171:-
THCA	cis	rs9427116	0.502	rs12125166	ENSG00000236675.1	MTX1P1	3.74	0.00021	0.0147	0.15	0.17	Blood protein levels;	chr1:154609653	chr1:155230975~155234325:+
THCA	cis	rs1790761	0.967	rs7131041	ENSG00000255318.1	RP11-655M14.13	-3.74	0.00021	0.0147	-0.18	-0.17	Mean corpuscular volume;	chr11:67462713	chr11:67618279~67627304:-
THCA	cis	rs643506	0.874	rs634983	ENSG00000230911.1	PPIHP1	-3.74	0.00021	0.0147	-0.23	-0.17	Breast cancer;	chr11:111876703	chr11:112029858~112030367:-
THCA	cis	rs9291683	0.595	rs10939665	ENSG00000261490.1	RP11-448G15.3	3.74	0.00021	0.0147	0.1	0.17	Bone mineral density;	chr4:10036004	chr4:10068089~10073019:-
THCA	cis	rs1580019	0.921	rs1580023	ENSG00000231952.3	DPY19L1P2	-3.74	0.00021	0.0147	-0.22	-0.17	Cognitive ability;	chr7:32458269	chr7:32812757~32838570:+
THCA	cis	rs7927592	0.513	rs3853616	ENSG00000160172.9	FAM86C2P	3.74	0.00021	0.0147	0.16	0.17	Total body bone mineral density;	chr11:68430784	chr11:67791648~67805336:-
THCA	cis	rs2625529	0.73	rs4777485	ENSG00000260037.4	CTD-2524L6.3	-3.74	0.00021	0.0147	-0.22	-0.17	Red blood cell count;	chr15:72097043	chr15:71818396~71823384:+
THCA	cis	rs9911578	0.967	rs2333410	ENSG00000224738.1	AC099850.1	-3.74	0.00021	0.0147	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:59059768	chr17:59106598~59118267:+
THCA	cis	rs2980439	0.517	rs17594065	ENSG00000248538.5	RP11-10A14.5	3.74	0.00021	0.0147	0.21	0.17	Neuroticism;	chr8:8247883	chr8:9189011~9202854:+
THCA	cis	rs7577696	0.575	rs177083	ENSG00000276334.1	AL133243.1	3.74	0.00021	0.0147	0.18	0.17	Inflammatory biomarkers;	chr2:32222649	chr2:32521927~32523547:+
THCA	cis	rs7665090	1	rs10027437	ENSG00000248971.2	KRT8P46	-3.74	0.00021	0.0147	-0.2	-0.17	Primary biliary cholangitis;	chr4:102636094	chr4:102728746~102730171:-
THCA	cis	rs7737355	1	rs11242077	ENSG00000237714.1	P4HA2-AS1	-3.74	0.00021	0.0147	-0.24	-0.17	Life satisfaction;	chr5:131435344	chr5:132184876~132192808:+
THCA	cis	rs7959452	0.535	rs11615712	ENSG00000274979.1	RP11-1143G9.5	3.74	0.00021	0.0147	0.18	0.17	Blood protein levels;	chr12:69225956	chr12:69326574~69331882:-
THCA	cis	rs2228479	0.85	rs12598316	ENSG00000274627.1	RP11-104N10.2	-3.74	0.00021	0.0147	-0.31	-0.17	Skin colour saturation;	chr16:89850192	chr16:89516797~89522217:+
THCA	cis	rs4604234	0.901	rs73471414	ENSG00000260645.1	RP11-250B2.5	-3.74	0.00021	0.0147	-0.31	-0.17	Cancer;	chr6:80394685	chr6:80466958~80469080:+
THCA	cis	rs4950322	0.58	rs17355419	ENSG00000226015.2	CCT8P1	3.74	0.00021	0.0147	0.19	0.17	Protein quantitative trait loci;	chr1:147110094	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.58	rs72706428	ENSG00000226015.2	CCT8P1	3.74	0.00021	0.0147	0.19	0.17	Protein quantitative trait loci;	chr1:147110219	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.563	rs61838944	ENSG00000226015.2	CCT8P1	3.74	0.00021	0.0147	0.19	0.17	Protein quantitative trait loci;	chr1:147110275	chr1:147203276~147204932:-
THCA	cis	rs1577917	0.876	rs4618490	ENSG00000220563.1	PKMP3	-3.74	0.00021	0.0148	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85808685	chr6:85659892~85660606:-
THCA	cis	rs4908768	0.539	rs1809332	ENSG00000270282.1	RP5-1115A15.2	3.74	0.00021	0.0148	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8512653~8513021:+
THCA	cis	rs2268667	0.565	rs6657732	ENSG00000223653.4	RP11-131L23.1	-3.74	0.00021	0.0148	-0.19	-0.17	Asymmetrical dimethylarginine levels;	chr1:85408812	chr1:85276715~85448124:+
THCA	cis	rs72945132	0.562	rs7951959	ENSG00000254604.1	AP000487.6	-3.74	0.00021	0.0148	-0.32	-0.17	Coronary artery disease;	chr11:70388166	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.598	rs61887432	ENSG00000254604.1	AP000487.6	-3.74	0.00021	0.0148	-0.32	-0.17	Coronary artery disease;	chr11:70392959	chr11:70282367~70363368:-
THCA	cis	rs7577696	0.509	rs681482	ENSG00000276517.1	AL133243.2	-3.74	0.00021	0.0148	-0.16	-0.17	Inflammatory biomarkers;	chr2:31646187	chr2:32526504~32529507:+
THCA	cis	rs4906332	1	rs2065015	ENSG00000252469.1	RNU7-160P	-3.74	0.00021	0.0148	-0.18	-0.17	Coronary artery disease;	chr14:103437724	chr14:103550345~103550406:+
THCA	cis	rs1150668	0.796	rs1005125	ENSG00000220721.1	OR1F12	3.74	0.00021	0.0148	0.19	0.17	Pubertal anthropometrics;	chr6:28399578	chr6:28073316~28074233:+
THCA	cis	rs1003719	0.591	rs2040125	ENSG00000270116.1	AP001429.1	-3.74	0.00021	0.0148	-0.19	-0.17	Eye color traits;	chr21:37176934	chr21:37100814~37101343:+
THCA	cis	rs9840812	0.598	rs33999043	ENSG00000273486.1	RP11-731C17.2	3.74	0.00021	0.0148	0.18	0.17	Fibrinogen levels;	chr3:136381198	chr3:136837338~136839021:-
THCA	cis	rs9307551	0.857	rs7662551	ENSG00000249646.2	OR7E94P	-3.74	0.00021	0.0148	-0.22	-0.17	Refractive error;	chr4:79616484	chr4:79587302~79588130:-
THCA	cis	rs7665090	1	rs12498722	ENSG00000251288.2	RP11-10L12.2	-3.74	0.00021	0.0148	-0.22	-0.17	Primary biliary cholangitis;	chr4:102633365	chr4:102751401~102752641:+
THCA	cis	rs6963495	0.818	rs55922564	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105515443	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190161	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105516424	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190163	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105516847	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.872	rs1569134	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105517781	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs114865717	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105518079	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs55740553	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105519104	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs75116202	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105519612	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190167	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105519971	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.745	rs73190169	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105520053	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs117028299	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105521863	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.745	rs73190179	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105522365	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.745	rs75805443	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105522381	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190181	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105522460	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190183	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105522575	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs9769403	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105522644	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs56055535	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105523127	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.538	rs55967123	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105523231	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs115609508	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105523269	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190184	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105523289	chr7:105571083~105573660:+
THCA	cis	rs17711722	1	rs17711722	ENSG00000182722.5	SEPHS1P1	3.74	0.00021	0.0148	0.2	0.17	Calcium levels;	chr7:65806210	chr7:64852397~64853354:-
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000182722.5	SEPHS1P1	3.74	0.00021	0.0148	0.2	0.17	Calcium levels;	chr7:65808508	chr7:64852397~64853354:-
THCA	cis	rs6963495	0.818	rs73192126	ENSG00000272604.1	RP11-251G23.5	3.74	0.00021	0.0148	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105534968	chr7:105571083~105573660:+
THCA	cis	rs10109025	0.67	rs7825690	ENSG00000206014.6	OR7E161P	3.74	0.00021	0.0148	0.19	0.17	Joint mobility (Beighton score);	chr8:11000747	chr8:11928597~11929563:-
THCA	cis	rs12893668	0.638	rs11851616	ENSG00000244691.1	RPL10AP1	-3.74	0.00021	0.0148	-0.24	-0.17	Reticulocyte count;	chr14:103599263	chr14:103412119~103412761:-
THCA	cis	rs12893668	0.667	rs11844466	ENSG00000244691.1	RPL10AP1	-3.74	0.00021	0.0148	-0.24	-0.17	Reticulocyte count;	chr14:103600085	chr14:103412119~103412761:-
THCA	cis	rs12893668	0.637	rs12892038	ENSG00000244691.1	RPL10AP1	-3.74	0.00021	0.0148	-0.24	-0.17	Reticulocyte count;	chr14:103602292	chr14:103412119~103412761:-
THCA	cis	rs12893668	0.637	rs4525427	ENSG00000244691.1	RPL10AP1	-3.74	0.00021	0.0148	-0.24	-0.17	Reticulocyte count;	chr14:103606456	chr14:103412119~103412761:-
THCA	cis	rs10090774	0.965	rs13250787	ENSG00000280303.2	ERICD	3.74	0.00021	0.0148	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140906833	chr8:140636281~140638283:+
THCA	cis	rs372883	0.638	rs371432	ENSG00000176054.6	RPL23P2	-3.74	0.00021	0.0148	-0.15	-0.17	Pancreatic cancer;	chr21:29338555	chr21:28997613~28998033:-
THCA	cis	rs2562456	0.833	rs62109223	ENSG00000268278.1	RP11-420K14.1	3.74	0.00021	0.0148	0.24	0.17	Pain;	chr19:21349591	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62109225	ENSG00000268278.1	RP11-420K14.1	3.74	0.00021	0.0148	0.24	0.17	Pain;	chr19:21353861	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.754	rs62109226	ENSG00000268278.1	RP11-420K14.1	3.74	0.00021	0.0148	0.24	0.17	Pain;	chr19:21354111	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.754	rs62109227	ENSG00000268278.1	RP11-420K14.1	3.74	0.00021	0.0148	0.24	0.17	Pain;	chr19:21354128	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.754	rs62109228	ENSG00000268278.1	RP11-420K14.1	3.74	0.00021	0.0148	0.24	0.17	Pain;	chr19:21354129	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs8102783	ENSG00000268278.1	RP11-420K14.1	3.74	0.00021	0.0148	0.24	0.17	Pain;	chr19:21355751	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs2061916	ENSG00000268278.1	RP11-420K14.1	3.74	0.00021	0.0148	0.24	0.17	Pain;	chr19:21358906	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs4359573	ENSG00000268278.1	RP11-420K14.1	3.74	0.00021	0.0148	0.24	0.17	Pain;	chr19:21359494	chr19:21637974~21656300:+
THCA	cis	rs6416877	0.731	rs8069059	ENSG00000277491.1	RP11-676J12.9	-3.74	0.00021	0.0148	-0.21	-0.17	Myeloid white cell count;	chr17:1467794	chr17:795306~795794:+
THCA	cis	rs9908102	1	rs9908102	ENSG00000277621.1	RP11-597M12.2	-3.74	0.00021	0.0148	-0.18	-0.17	Schizophrenia;	chr17:12993236	chr17:12982613~12983002:-
THCA	cis	rs4389656	0.857	rs274676	ENSG00000248677.1	CTD-2044J15.1	3.74	0.00021	0.0148	0.17	0.17	Coronary artery disease;	chr5:6754649	chr5:6686325~6707711:-
THCA	cis	rs4389656	0.857	rs5001282	ENSG00000248677.1	CTD-2044J15.1	3.74	0.00021	0.0148	0.17	0.17	Coronary artery disease;	chr5:6757555	chr5:6686325~6707711:-
THCA	cis	rs4869313	0.721	rs7713127	ENSG00000247121.5	CTD-2260A17.2	-3.74	0.00021	0.0148	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96952434	chr5:96814028~96935809:-
THCA	cis	rs12755164	0.526	rs12138089	ENSG00000223479.3	RP4-788P17.1	3.74	0.00021	0.0148	0.19	0.17	Schizophrenia;	chr1:72826610	chr1:73635216~73715214:+
THCA	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	3.74	0.00021	0.0148	0.2	0.17	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
THCA	cis	rs11048434	0.518	rs7311509	ENSG00000256720.1	RP11-436I9.6	-3.74	0.00021	0.0148	-0.18	-0.17	Sjögren's syndrome;	chr12:9026438	chr12:9135084~9135591:+
THCA	cis	rs7560272	0.723	rs7562047	ENSG00000273245.1	RP11-434P11.2	3.74	0.00021	0.0148	0.2	0.17	Schizophrenia;	chr2:73498041	chr2:73750256~73750786:-
THCA	cis	rs1577917	0.958	rs10455448	ENSG00000220563.1	PKMP3	-3.74	0.00021	0.0148	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85823893	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.917	rs13196576	ENSG00000220563.1	PKMP3	-3.74	0.00021	0.0148	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85824348	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs3857480	ENSG00000220563.1	PKMP3	-3.74	0.00021	0.0148	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85825431	chr6:85659892~85660606:-
THCA	cis	rs12681366	0.801	rs2919668	ENSG00000253175.1	RP11-267M23.6	3.74	0.00021	0.0148	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94449193	chr8:94565036~94565715:+
THCA	cis	rs853679	0.882	rs3757188	ENSG00000261839.1	RP1-265C24.8	3.74	0.00021	0.0148	0.26	0.17	Depression;	chr6:28139579	chr6:28136849~28139678:+
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000280107.1	AL022393.9	-3.74	0.00021	0.0148	-0.17	-0.17	Pubertal anthropometrics;	chr6:28128502	chr6:28170845~28172521:+
THCA	cis	rs4578769	0.55	rs7237400	ENSG00000273232.1	RP11-370A5.2	3.74	0.00021	0.0148	0.23	0.17	Eosinophil percentage of white cells;	chr18:22986533	chr18:22882825~22883357:-
THCA	cis	rs12887734	0.546	rs12886637	ENSG00000258735.1	LINC00637	3.74	0.00021	0.0148	0.22	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103847721~103858049:+
THCA	cis	rs6030712	0.723	rs6130114	ENSG00000213979.3	RPL7AP14	-3.74	0.00021	0.0148	-0.27	-0.17	Height;	chr20:36922799	chr20:37444733~37445534:-
THCA	cis	rs4073416	0.508	rs7140341	ENSG00000276116.2	FUT8-AS1	3.74	0.00021	0.0148	0.19	0.17	N-glycan levels;	chr14:65603699	chr14:65411170~65412690:-
THCA	cis	rs1958560	0.932	rs61987992	ENSG00000276116.2	FUT8-AS1	3.74	0.00021	0.0148	0.19	0.17	Menarche (age at onset);	chr14:65604013	chr14:65411170~65412690:-
THCA	cis	rs1958560	0.932	rs61987993	ENSG00000276116.2	FUT8-AS1	3.74	0.00021	0.0148	0.19	0.17	Menarche (age at onset);	chr14:65604014	chr14:65411170~65412690:-
THCA	cis	rs1958560	0.932	rs61987994	ENSG00000276116.2	FUT8-AS1	3.74	0.00021	0.0148	0.19	0.17	Menarche (age at onset);	chr14:65604015	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.542	rs10145146	ENSG00000276116.2	FUT8-AS1	3.74	0.00021	0.0148	0.19	0.17	N-glycan levels;	chr14:65608286	chr14:65411170~65412690:-
THCA	cis	rs8042680	0.554	rs2301826	ENSG00000258725.1	PRC1-AS1	3.74	0.00021	0.0148	0.23	0.17	Type 2 diabetes;	chr15:90981967	chr15:90966345~90988624:+
THCA	cis	rs7927592	0.913	rs7118897	ENSG00000160172.9	FAM86C2P	3.74	0.00021	0.0148	0.17	0.17	Total body bone mineral density;	chr11:68593212	chr11:67791648~67805336:-
THCA	cis	rs7572733	0.555	rs11889006	ENSG00000231621.1	AC013264.2	-3.74	0.00021	0.0148	-0.18	-0.17	Dermatomyositis;	chr2:198063923	chr2:197197991~197199273:+
THCA	cis	rs4908768	0.539	rs2100888	ENSG00000270282.1	RP5-1115A15.2	3.74	0.00021	0.0148	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8512653~8513021:+
THCA	cis	rs17286411	0.675	rs11539980	ENSG00000260185.1	RP11-432I5.6	-3.74	0.00021	0.0148	-0.23	-0.17	Blood protein levels;	chr16:71731513	chr16:71655027~71664212:+
THCA	cis	rs13063635	0.915	rs71325091	ENSG00000226074.4	PRSS44	-3.74	0.00021	0.0148	-0.33	-0.17	Eosinophil percentage of granulocytes;	chr3:45890915	chr3:46809359~46812558:-
THCA	cis	rs708224	0.513	rs2650137	ENSG00000277342.1	RP11-843B15.4	3.74	0.00021	0.0148	0.22	0.17	Pancreatic cancer;	chr12:32289300	chr12:32109076~32109602:+
THCA	cis	rs6138458	0.626	rs6050261	ENSG00000274173.1	RP4-568C11.4	3.74	0.00021	0.0148	0.14	0.17	Blood protein levels;	chr20:25033570	chr20:24931840~24932983:+
THCA	cis	rs748404	0.589	rs62020612	ENSG00000166763.7	STRCP1	3.74	0.00021	0.0148	0.22	0.17	Lung cancer;	chr15:43525881	chr15:43699488~43718184:-
THCA	cis	rs72928364	1	rs73137276	ENSG00000256628.3	ZBTB11-AS1	3.74	0.00021	0.0148	0.3	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100895054	chr3:101676475~101679217:+
THCA	cis	rs801193	0.935	rs11772264	ENSG00000275400.1	RP4-756H11.5	-3.74	0.00021	0.0148	-0.16	-0.17	Aortic root size;	chr7:66711400	chr7:66553805~66554199:-
THCA	cis	rs7216064	1	rs58551145	ENSG00000265055.1	AC145343.2	3.74	0.00021	0.0148	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841119	chr17:68096046~68101474:-
THCA	cis	rs513088	0.681	rs495489	ENSG00000225171.2	DUTP6	-3.74	0.00021	0.0148	-0.25	-0.17	Schizophrenia;	chr1:166731394	chr1:166868748~166869209:+
THCA	cis	rs3806843	0.576	rs405192	ENSG00000202515.1	VTRNA1-3	-3.74	0.00021	0.0148	-0.2	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140945125	chr5:140726158~140726246:+
THCA	cis	rs12681366	0.663	rs2919666	ENSG00000261437.1	RP11-22C11.2	3.74	0.00021	0.0148	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94453059	chr8:94637285~94639467:-
THCA	cis	rs791590	0.752	rs41295055	ENSG00000225948.2	RP11-554I8.1	3.74	0.00021	0.0148	0.26	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6069659	chr10:6618716~6625346:+
THCA	cis	rs4853525	0.651	rs1921908	ENSG00000235852.1	AC005540.3	3.74	0.00021	0.0148	0.18	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190870481	chr2:190880797~190882059:-
THCA	cis	rs875971	0.66	rs801193	ENSG00000229180.5	GS1-124K5.11	-3.74	0.00021	0.0148	-0.12	-0.17	Aortic root size;	chr7:66565625	chr7:66526088~66542624:-
THCA	cis	rs6142618	0.811	rs6058597	ENSG00000224452.1	RSL24D1P6	3.74	0.000211	0.0148	0.21	0.17	Inflammatory bowel disease;	chr20:32254836	chr20:32170390~32170790:-
THCA	cis	rs4759375	0.79	rs28820735	ENSG00000256092.2	RP13-942N8.1	3.74	0.000211	0.0148	0.19	0.17	HDL cholesterol;	chr12:123393960	chr12:123363868~123366113:+
THCA	cis	rs7903847	0.62	rs17112676	ENSG00000225850.3	RP11-452K12.4	3.74	0.000211	0.0148	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97362531	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.62	rs954149	ENSG00000225850.3	RP11-452K12.4	3.74	0.000211	0.0148	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97363179	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.62	rs11189165	ENSG00000225850.3	RP11-452K12.4	3.74	0.000211	0.0148	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97363700	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.62	rs61863815	ENSG00000225850.3	RP11-452K12.4	3.74	0.000211	0.0148	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97364632	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.62	rs11189168	ENSG00000225850.3	RP11-452K12.4	3.74	0.000211	0.0148	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97366012	chr10:97334564~97343203:+
THCA	cis	rs62344088	1	rs10037843	ENSG00000277812.1	AC021087.1	3.74	0.000211	0.0148	0.44	0.17	Asthma (childhood onset);	chr5:119963	chr5:262769~262881:+
THCA	cis	rs62344088	1	rs13436694	ENSG00000277812.1	AC021087.1	3.74	0.000211	0.0148	0.44	0.17	Asthma (childhood onset);	chr5:122767	chr5:262769~262881:+
THCA	cis	rs62344088	1	rs7715867	ENSG00000277812.1	AC021087.1	3.74	0.000211	0.0148	0.44	0.17	Asthma (childhood onset);	chr5:128944	chr5:262769~262881:+
THCA	cis	rs1580019	0.563	rs2392071	ENSG00000273014.1	RP11-225B17.2	3.74	0.000211	0.0148	0.17	0.17	Cognitive ability;	chr7:32532924	chr7:32758882~32759353:+
THCA	cis	rs1555322	0.872	rs2425048	ENSG00000126005.14	MMP24-AS1	-3.74	0.000211	0.0148	-0.27	-0.17	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35216462~35278131:-
THCA	cis	rs3176789	0.671	rs10772128	ENSG00000256673.1	RP11-599J14.2	3.74	0.000211	0.0148	0.21	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9769272	chr12:9398355~9414851:-
THCA	cis	rs910316	0.763	rs1548807	ENSG00000259138.1	RP11-950C14.7	3.74	0.000211	0.0148	0.15	0.17	Height;	chr14:75012879	chr14:75127153~75136930:+
THCA	cis	rs1150668	0.835	rs203869	ENSG00000261839.1	RP1-265C24.8	3.74	0.000211	0.0148	0.16	0.17	Pubertal anthropometrics;	chr6:28073041	chr6:28136849~28139678:+
THCA	cis	rs6894216	0.651	rs6868888	ENSG00000248610.1	HSPA8P4	3.74	0.000211	0.0148	0.21	0.17	Response to amphetamines;	chr5:130348857	chr5:130140031~130141950:+
THCA	cis	rs613391	0.702	rs678038	ENSG00000234840.1	LINC01239	-3.74	0.000211	0.0148	-0.2	-0.17	Quantitative traits;	chr9:22707595	chr9:22646200~22824213:+
THCA	cis	rs8030379	1	rs11259928	ENSG00000176700.18	SCAND2P	-3.74	0.000211	0.0148	-0.11	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899343	chr15:84631451~84647478:+
THCA	cis	rs41294858	1	rs41294856	ENSG00000232876.1	CTA-212D2.2	-3.74	0.000211	0.0148	-0.35	-0.17	Red blood cell count;	chr6:135091244	chr6:135055033~135060550:+
THCA	cis	rs1062753	0.961	rs9620007	ENSG00000227370.1	RP4-669P10.19	3.74	0.000211	0.0148	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42009653	chr22:42132543~42132998:+
THCA	cis	rs2228479	0.85	rs117285117	ENSG00000274627.1	RP11-104N10.2	-3.74	0.000211	0.0148	-0.29	-0.17	Skin colour saturation;	chr16:89843842	chr16:89516797~89522217:+
THCA	cis	rs881375	0.967	rs1930781	ENSG00000270917.1	RP11-27I1.6	-3.74	0.000211	0.0148	-0.24	-0.17	Rheumatoid arthritis;	chr9:120925556	chr9:120812475~120812845:-
THCA	cis	rs15676	0.947	rs2280842	ENSG00000234771.3	SLC25A25-AS1	3.74	0.000211	0.0148	0.14	0.17	Blood metabolite levels;	chr9:128823529	chr9:128108581~128118693:-
THCA	cis	rs7010267	0.746	rs13250753	ENSG00000254278.1	RP11-278I4.2	3.74	0.000211	0.0148	0.21	0.17	Total body bone mineral density (age 45-60);	chr8:118894453	chr8:119062942~119068782:-
THCA	cis	rs9303542	0.729	rs34466582	ENSG00000278765.1	RP5-890E16.5	-3.74	0.000211	0.0148	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48356052	chr17:48066704~48067293:-
THCA	cis	rs9596863	0.898	rs9568911	ENSG00000136149.6	RPL13AP25	-3.74	0.000211	0.0148	-0.19	-0.17	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53763947	chr13:54440704~54441315:-
THCA	cis	rs6413860	0.911	rs7537432	ENSG00000260855.1	RP11-439E19.10	-3.74	0.000211	0.0148	-0.23	-0.17	Gut microbiome composition (summer);	chr1:246688863	chr1:246772301~246775772:+
THCA	cis	rs7586085	0.903	rs1968294	ENSG00000232411.1	AC009495.3	-3.74	0.000211	0.0148	-0.18	-0.17	Total body bone mineral density;	chr2:165761752	chr2:165833048~165839098:-
THCA	cis	rs2360027	0.93	rs7542883	ENSG00000231365.4	RP11-418J17.1	3.74	0.000211	0.0148	0.16	0.17	Tonsillectomy;	chr1:118573255	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.93	rs1911175	ENSG00000231365.4	RP11-418J17.1	3.74	0.000211	0.0148	0.16	0.17	Tonsillectomy;	chr1:118574997	chr1:119140396~119275973:+
THCA	cis	rs4819052	0.765	rs2838868	ENSG00000184274.3	LINC00315	3.74	0.000211	0.0148	0.22	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45300245~45305257:-
THCA	cis	rs10911363	0.573	rs2761580	ENSG00000232860.6	SMG7-AS1	-3.74	0.000211	0.0148	-0.13	-0.17	Systemic lupus erythematosus;	chr1:183547854	chr1:183460874~183472265:-
THCA	cis	rs4727027	0.704	rs12704073	ENSG00000244560.5	RP4-800G7.2	-3.74	0.000211	0.0148	-0.1	-0.17	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149207975	chr7:149285281~149297312:+
THCA	cis	rs1538970	0.924	rs1494812	ENSG00000234329.1	RP11-767N6.2	3.73	0.000211	0.0148	0.17	0.17	Platelet count;	chr1:45411327	chr1:45651039~45651826:-
THCA	cis	rs1538970	0.924	rs2088100	ENSG00000234329.1	RP11-767N6.2	3.73	0.000211	0.0148	0.17	0.17	Platelet count;	chr1:45411903	chr1:45651039~45651826:-
THCA	cis	rs7989332	0.698	rs9509242	ENSG00000277020.3	RP11-476H16.1	-3.73	0.000211	0.0148	-0.16	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486803	chr13:20564708~20567045:-
THCA	cis	rs2214442	0.712	rs3807941	ENSG00000271133.4	CTA-293F17.1	-3.73	0.000211	0.0148	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20362515	chr7:20328299~20331747:-
THCA	cis	rs337161	0.719	rs421736	ENSG00000221571.3	RNU6ATAC35P	-3.73	0.000211	0.0148	-0.19	-0.17	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220765330	chr1:220825620~220826063:+
THCA	cis	rs11105298	0.891	rs10858894	ENSG00000266347.2	AC068641.1	3.73	0.000211	0.0148	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs11105310	ENSG00000266347.2	AC068641.1	3.73	0.000211	0.0148	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89592833~89592927:+
THCA	cis	rs7474896	0.616	rs1985260	ENSG00000275858.1	RP11-291L22.8	3.73	0.000211	0.0148	0.26	0.17	Obesity (extreme);	chr10:38145162	chr10:38450738~38451069:-
THCA	cis	rs111756027	0.572	rs1549667	ENSG00000260922.1	RP11-538I12.3	3.73	0.000211	0.0148	0.24	0.17	Bone mineral density (Ward's triangle area);	chr16:77270872	chr16:77234877~77290934:+
THCA	cis	rs3808502	0.563	rs12541800	ENSG00000255046.1	RP11-297N6.4	-3.73	0.000211	0.0148	-0.18	-0.17	Neuroticism;	chr8:11565563	chr8:11797928~11802568:-
THCA	cis	rs332034	0.591	rs9650614	ENSG00000254153.1	CTA-398F10.2	3.73	0.000211	0.0148	0.27	0.17	Conduct disorder (maternal expressed emotions interaction);	chr8:8835876	chr8:8456909~8461337:-
THCA	cis	rs10089	1	rs4836366	ENSG00000245937.6	LINC01184	3.73	0.000211	0.0148	0.19	0.17	Ileal carcinoids;	chr5:128146802	chr5:127940426~128083172:-
THCA	cis	rs2640806	0.505	rs34269813	ENSG00000253105.4	KB-1448A5.1	3.73	0.000211	0.0148	0.2	0.17	Obesity-related traits;	chr8:96355296	chr8:96371865~96387438:-
THCA	cis	rs4389656	0.767	rs369769	ENSG00000248677.1	CTD-2044J15.1	3.73	0.000211	0.0148	0.17	0.17	Coronary artery disease;	chr5:6720599	chr5:6686325~6707711:-
THCA	cis	rs4389656	0.74	rs412643	ENSG00000248677.1	CTD-2044J15.1	3.73	0.000211	0.0148	0.17	0.17	Coronary artery disease;	chr5:6720602	chr5:6686325~6707711:-
THCA	cis	rs4389656	0.857	rs274715	ENSG00000248677.1	CTD-2044J15.1	-3.73	0.000211	0.0148	-0.17	-0.17	Coronary artery disease;	chr5:6723316	chr5:6686325~6707711:-
THCA	cis	rs6894216	0.651	rs6869287	ENSG00000248610.1	HSPA8P4	-3.73	0.000211	0.0148	-0.21	-0.17	Response to amphetamines;	chr5:130348863	chr5:130140031~130141950:+
THCA	cis	rs6894216	0.62	rs6869219	ENSG00000248610.1	HSPA8P4	-3.73	0.000211	0.0148	-0.21	-0.17	Response to amphetamines;	chr5:130349084	chr5:130140031~130141950:+
THCA	cis	rs7267979	0.816	rs8115257	ENSG00000276952.1	RP5-965G21.6	3.73	0.000211	0.0148	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25284915~25285588:-
THCA	cis	rs2880765	0.835	rs6496027	ENSG00000259407.1	RP11-158M2.3	-3.73	0.000211	0.0148	-0.17	-0.17	Coronary artery disease;	chr15:85506757	chr15:85744109~85750281:-
THCA	cis	rs277939	0.935	rs451229	ENSG00000251634.2	RP11-1280N14.3	3.73	0.000211	0.0148	0.18	0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71598448	chr5:71102898~71128753:-
THCA	cis	rs11638352	1	rs4924737	ENSG00000166763.7	STRCP1	-3.73	0.000211	0.0148	-0.38	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44072703	chr15:43699488~43718184:-
THCA	cis	rs7914558	0.966	rs10748835	ENSG00000213061.2	PFN1P11	3.73	0.000211	0.0148	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900499	chr10:102838011~102845473:-
THCA	cis	rs240993	0.595	rs1040383	ENSG00000220392.1	FCF1P5	3.73	0.000211	0.0148	0.18	0.17	Inflammatory skin disease;Psoriasis;	chr6:111580985	chr6:111353702~111354183:+
THCA	cis	rs9326248	0.53	rs1351452	ENSG00000280143.1	AP000892.6	-3.73	0.000211	0.0148	-0.27	-0.17	Blood protein levels;	chr11:117072638	chr11:117204967~117210292:+
THCA	cis	rs17253792	0.822	rs58569951	ENSG00000186615.9	KTN1-AS1	-3.73	0.000211	0.0148	-0.27	-0.17	Putamen volume;	chr14:55685527	chr14:55499278~55580110:-
THCA	cis	rs912593	0.872	rs73473580	ENSG00000225179.1	LINC00457	3.73	0.000211	0.0148	0.26	0.17	Cancer;	chr13:34477521	chr13:34435450~34640685:-
THCA	cis	rs13325613	0.915	rs34414382	ENSG00000223552.1	RP11-24F11.2	-3.73	0.000211	0.0148	-0.31	-0.17	Monocyte count;	chr3:46223699	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs35613615	ENSG00000223552.1	RP11-24F11.2	-3.73	0.000211	0.0148	-0.31	-0.17	Monocyte count;	chr3:46223752	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs34745455	ENSG00000223552.1	RP11-24F11.2	-3.73	0.000211	0.0148	-0.31	-0.17	Monocyte count;	chr3:46225842	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs71327041	ENSG00000223552.1	RP11-24F11.2	-3.73	0.000211	0.0148	-0.31	-0.17	Monocyte count;	chr3:46226091	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.748	rs114115904	ENSG00000223552.1	RP11-24F11.2	-3.73	0.000211	0.0148	-0.31	-0.17	Monocyte count;	chr3:46227173	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs34677490	ENSG00000223552.1	RP11-24F11.2	-3.73	0.000211	0.0148	-0.31	-0.17	Monocyte count;	chr3:46229257	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs1542755	ENSG00000223552.1	RP11-24F11.2	3.73	0.000211	0.0148	0.31	0.17	Monocyte count;	chr3:46230949	chr3:46364955~46407059:-
THCA	cis	rs72482608	0.865	rs10800541	ENSG00000271811.1	RP1-79C4.4	3.73	0.000211	0.0148	0.21	0.17	Emphysema imaging phenotypes;	chr1:170795766	chr1:170667381~170669425:+
THCA	cis	rs6724465	1	rs3731878	ENSG00000272644.1	RP11-33O4.1	3.73	0.000211	0.0148	0.25	0.17	Height;	chr2:219055843	chr2:219069354~219069809:-
THCA	cis	rs2692947	0.696	rs2969490	ENSG00000232931.4	LINC00342	3.73	0.000211	0.0148	0.13	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96138165	chr2:95807118~95816215:-
THCA	cis	rs4591358	0.705	rs6717199	ENSG00000223466.1	AC064834.2	3.73	0.000211	0.0148	0.2	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195467140	chr2:195533035~195538681:+
THCA	cis	rs2688608	0.617	rs6480709	ENSG00000272140.2	RP11-574K11.29	3.73	0.000211	0.0148	0.15	0.17	Inflammatory bowel disease;	chr10:73719367	chr10:73703735~73713581:-
THCA	cis	rs8007846	0.685	rs4902393	ENSG00000276116.2	FUT8-AS1	3.73	0.000211	0.0148	0.18	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr14:65372796	chr14:65411170~65412690:-
THCA	cis	rs453301	0.598	rs1025395	ENSG00000254340.1	RP11-10A14.3	3.73	0.000211	0.0148	0.18	0.17	Joint mobility (Beighton score);	chr8:8979093	chr8:9141424~9145435:+
THCA	cis	rs2625529	0.823	rs11072332	ENSG00000260037.4	CTD-2524L6.3	-3.73	0.000211	0.0148	-0.23	-0.17	Red blood cell count;	chr15:71815966	chr15:71818396~71823384:+
THCA	cis	rs6456156	0.586	rs2345753	ENSG00000235272.1	FAM103A2P	3.73	0.000211	0.0148	0.23	0.17	Primary biliary cholangitis;	chr6:167070856	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.603	rs2345754	ENSG00000235272.1	FAM103A2P	3.73	0.000211	0.0148	0.23	0.17	Primary biliary cholangitis;	chr6:167070873	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs7761977	ENSG00000235272.1	FAM103A2P	3.73	0.000211	0.0148	0.23	0.17	Primary biliary cholangitis;	chr6:167072190	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs7742305	ENSG00000235272.1	FAM103A2P	3.73	0.000211	0.0148	0.23	0.17	Primary biliary cholangitis;	chr6:167072235	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs7762156	ENSG00000235272.1	FAM103A2P	3.73	0.000211	0.0148	0.23	0.17	Primary biliary cholangitis;	chr6:167072343	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs2001115	ENSG00000235272.1	FAM103A2P	3.73	0.000211	0.0148	0.23	0.17	Primary biliary cholangitis;	chr6:167072730	chr6:166586124~166586477:-
THCA	cis	rs4218	0.543	rs11852461	ENSG00000259732.1	RP11-59H7.3	-3.73	0.000211	0.0148	-0.23	-0.17	Social communication problems;	chr15:59021728	chr15:59121034~59133250:+
THCA	cis	rs1510272	0.961	rs13319258	ENSG00000243926.1	TIPARP-AS1	-3.73	0.000211	0.0148	-0.17	-0.17	Testicular germ cell tumor;	chr3:156586782	chr3:156671862~156674378:-
THCA	cis	rs2191566	0.664	rs6509138	ENSG00000266921.1	RP11-15A1.7	-3.73	0.000211	0.0148	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:44066240	chr19:43996896~44002836:-
THCA	cis	rs7819412	0.669	rs28630509	ENSG00000255046.1	RP11-297N6.4	3.73	0.000211	0.0149	0.19	0.17	Triglycerides;	chr8:11139529	chr8:11797928~11802568:-
THCA	cis	rs4671400	0.571	rs6738482	ENSG00000271889.1	RP11-493E12.1	-3.73	0.000211	0.0149	-0.18	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267766	chr2:61151433~61162105:-
THCA	cis	rs7572733	0.935	rs771015	ENSG00000231621.1	AC013264.2	-3.73	0.000211	0.0149	-0.16	-0.17	Dermatomyositis;	chr2:197803570	chr2:197197991~197199273:+
THCA	cis	rs10266483	0.774	rs7796802	ENSG00000271550.1	BNIP3P11	-3.73	0.000212	0.0149	-0.23	-0.17	Response to statin therapy;	chr7:64323744	chr7:64678954~64687393:-
THCA	cis	rs2562456	0.917	rs11085463	ENSG00000268278.1	RP11-420K14.1	3.73	0.000212	0.0149	0.2	0.17	Pain;	chr19:21568500	chr19:21637974~21656300:+
THCA	cis	rs1577917	0.958	rs4707229	ENSG00000220563.1	PKMP3	-3.73	0.000212	0.0149	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85836519	chr6:85659892~85660606:-
THCA	cis	rs6832769	0.556	rs10003113	ENSG00000272969.1	RP11-528I4.2	-3.73	0.000212	0.0149	-0.2	-0.17	Personality dimensions;	chr4:55651074	chr4:55547112~55547889:+
THCA	cis	rs10938353	0.68	rs2173108	ENSG00000273369.1	RP11-700J17.1	3.73	0.000212	0.0149	0.2	0.17	Body mass index;	chr4:44838785	chr4:44693946~44694386:-
THCA	cis	rs11175834	0.655	rs12311233	ENSG00000277945.1	RP11-677M24.1	-3.73	0.000212	0.0149	-0.23	-0.17	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65607333	chr12:65830750~65831050:+
THCA	cis	rs9487094	0.621	rs9398202	ENSG00000223537.2	RP5-919F19.5	-3.73	0.000212	0.0149	-0.17	-0.17	Height;	chr6:109458989	chr6:109487906~109506800:+
THCA	cis	rs7129556	0.737	rs643388	ENSG00000254459.1	RP11-91P24.7	3.73	0.000212	0.0149	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77759997	chr11:77829654~77872262:-
THCA	cis	rs11992162	0.967	rs10112888	ENSG00000255046.1	RP11-297N6.4	-3.73	0.000212	0.0149	-0.18	-0.17	Monocyte count;	chr8:11972699	chr8:11797928~11802568:-
THCA	cis	rs8130944	1	rs4920137	ENSG00000225731.1	AP001627.1	3.73	0.000212	0.0149	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42720007	chr21:42733594~42741758:-
THCA	cis	rs8130944	0.964	rs4920138	ENSG00000225731.1	AP001627.1	3.73	0.000212	0.0149	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42720167	chr21:42733594~42741758:-
THCA	cis	rs8130944	1	rs4920139	ENSG00000225731.1	AP001627.1	3.73	0.000212	0.0149	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42720204	chr21:42733594~42741758:-
THCA	cis	rs2638953	0.853	rs11049622	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457637	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.888	rs10843177	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457737	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs10771428	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458070	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs10506035	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458159	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.815	rs11049627	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459389	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049628	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459781	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049629	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459856	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049632	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461130	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs3911810	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461669	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs3926041	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461776	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs2141203	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461928	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs1355474	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463599	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049636	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28465728	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11614463	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467278	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs10843183	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467775	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11494781	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469166	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049638	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469687	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049639	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469868	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049642	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471325	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049643	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471581	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.777	rs11049644	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471724	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049645	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28472615	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs10843184	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473339	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.815	rs61920658	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475519	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049646	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28476139	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.79	rs11049653	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28479882	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.815	rs11049654	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28480502	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049657	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481746	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049659	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482147	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs1918418	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483789	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs1511550	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28484182	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs12370338	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28486787	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049668	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497680	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.821	rs76265865	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504107	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs10843191	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507594	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.815	rs11049680	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508436	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.777	rs11049681	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508722	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.815	rs11049683	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509597	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.815	rs10843193	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509763	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs7485676	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000212	0.0149	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510734	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.815	rs11049634	ENSG00000247934.4	RP11-967K21.1	3.73	0.000212	0.0149	0.18	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461296	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs10506036	ENSG00000247934.4	RP11-967K21.1	3.73	0.000212	0.0149	0.18	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497632	chr12:28163298~28190738:-
THCA	cis	rs17685	0.712	rs28506984	ENSG00000227038.2	AC005077.12	3.73	0.000212	0.0149	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76134166	chr7:76090431~76108779:-
THCA	cis	rs4489787	0.568	rs2705160	ENSG00000240399.1	RP1-228P16.1	3.73	0.000212	0.0149	0.19	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48507373	chr12:48054813~48055591:-
THCA	cis	rs686320	0.748	rs481335	ENSG00000254614.2	AP003068.23	3.73	0.000212	0.0149	0.31	0.17	Hip circumference adjusted for BMI;	chr11:65439998	chr11:65177606~65181834:-
THCA	cis	rs12291225	0.679	rs1043237	ENSG00000251991.1	RNU7-49P	3.73	0.000212	0.0149	0.2	0.17	Sense of smell;	chr11:14267507	chr11:14478892~14478953:+
THCA	cis	rs757978	0.733	rs11684403	ENSG00000235351.1	AC114730.11	-3.73	0.000212	0.0149	-0.16	-0.17	Chronic lymphocytic leukemia;	chr2:241475459	chr2:241724615~241725693:-
THCA	cis	rs4925386	0.84	rs6143034	ENSG00000275437.1	RP5-908M14.10	3.73	0.000212	0.0149	0.17	0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62402236~62405935:-
THCA	cis	rs56077333	1	rs56077333	ENSG00000261762.1	RP11-650L12.2	-3.73	0.000212	0.0149	-0.22	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78606661	chr15:78589123~78591276:-
THCA	cis	rs138544659	1	rs138544659	ENSG00000261762.1	RP11-650L12.2	-3.73	0.000212	0.0149	-0.22	-0.17	Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78608359	chr15:78589123~78591276:-
THCA	cis	rs6589219	0.788	rs1987128	ENSG00000196167.8	COLCA1	-3.73	0.000212	0.0149	-0.18	-0.17	Colorectal cancer;	chr11:111281771	chr11:111290787~111305045:-
THCA	cis	rs293748	0.771	rs158798	ENSG00000250155.1	CTD-2353F22.1	-3.73	0.000212	0.0149	-0.22	-0.17	Obesity-related traits;	chr5:36869157	chr5:36666214~36725195:-
THCA	cis	rs4822983	0.516	rs695797	ENSG00000272858.1	CTA-292E10.8	-3.73	0.000212	0.0149	-0.19	-0.17	Esophageal cancer (squamous cell);	chr22:28453761	chr22:28814914~28815662:+
THCA	cis	rs853679	0.567	rs6905380	ENSG00000220721.1	OR1F12	3.73	0.000212	0.0149	0.21	0.17	Depression;	chr6:28407125	chr6:28073316~28074233:+
THCA	cis	rs7399018	0.643	rs6580810	ENSG00000278126.1	RP11-454E5.4	3.73	0.000212	0.0149	0.2	0.17	Cisplatin-induced ototoxicity;	chr12:51216694	chr12:51201684~51202581:-
THCA	cis	rs6088590	1	rs910870	ENSG00000250917.1	RP4-785G19.5	3.73	0.000212	0.0149	0.19	0.17	Coronary artery disease;	chr20:34705089	chr20:34234840~34281173:-
THCA	cis	rs1232027	0.7	rs13185915	ENSG00000249655.1	CTC-325J23.2	3.73	0.000212	0.0149	0.2	0.17	Huntington's disease progression;	chr5:80609592	chr5:80630313~80631590:-
THCA	cis	rs6580649	0.941	rs1968071	ENSG00000273765.1	RP11-370I10.11	-3.73	0.000212	0.0149	-0.18	-0.17	Lung cancer;	chr12:48095574	chr12:48360920~48361377:+
THCA	cis	rs7394190	0.748	rs60632610	ENSG00000272140.2	RP11-574K11.29	-3.73	0.000212	0.0149	-0.17	-0.17	Incident atrial fibrillation;	chr10:73655919	chr10:73703735~73713581:-
THCA	cis	rs4906332	0.899	rs12888042	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000212	0.0149	-0.15	-0.17	Coronary artery disease;	chr14:103425372	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs17617094	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000212	0.0149	-0.15	-0.17	Coronary artery disease;	chr14:103427091	chr14:103331674~103332367:-
THCA	cis	rs6589219	0.753	rs4548657	ENSG00000196167.8	COLCA1	-3.73	0.000212	0.0149	-0.18	-0.17	Colorectal cancer;	chr11:111269318	chr11:111290787~111305045:-
THCA	cis	rs2058059	0.551	rs2960924	ENSG00000205578.5	POM121B	-3.73	0.000212	0.0149	-0.27	-0.17	Subcutaneous adipose tissue;	chr7:72622795	chr7:73293497~73301161:+
THCA	cis	rs7919656	0.666	rs2663055	ENSG00000228403.1	RP11-563N6.6	3.73	0.000212	0.0149	0.19	0.17	Clinically amyopathic dermatomyositis;	chr10:48913277	chr10:48878022~48878649:+
THCA	cis	rs6724465	1	rs79986235	ENSG00000272644.1	RP11-33O4.1	3.73	0.000212	0.0149	0.26	0.17	Height;	chr2:219079413	chr2:219069354~219069809:-
THCA	cis	rs6724465	1	rs10197172	ENSG00000272644.1	RP11-33O4.1	3.73	0.000212	0.0149	0.26	0.17	Height;	chr2:219091214	chr2:219069354~219069809:-
THCA	cis	rs6724465	1	rs56388436	ENSG00000272644.1	RP11-33O4.1	3.73	0.000212	0.0149	0.26	0.17	Height;	chr2:219094181	chr2:219069354~219069809:-
THCA	cis	rs6724465	1	rs72951738	ENSG00000272644.1	RP11-33O4.1	3.73	0.000212	0.0149	0.26	0.17	Height;	chr2:219102079	chr2:219069354~219069809:-
THCA	cis	rs6724465	1	rs13394499	ENSG00000272644.1	RP11-33O4.1	3.73	0.000212	0.0149	0.26	0.17	Height;	chr2:219104363	chr2:219069354~219069809:-
THCA	cis	rs6496044	0.568	rs11636764	ENSG00000259407.1	RP11-158M2.3	-3.73	0.000212	0.0149	-0.17	-0.17	Interstitial lung disease;	chr15:85536520	chr15:85744109~85750281:-
THCA	cis	rs6496044	0.591	rs979825	ENSG00000259407.1	RP11-158M2.3	-3.73	0.000212	0.0149	-0.17	-0.17	Interstitial lung disease;	chr15:85537394	chr15:85744109~85750281:-
THCA	cis	rs6496044	0.547	rs8039929	ENSG00000259407.1	RP11-158M2.3	-3.73	0.000212	0.0149	-0.17	-0.17	Interstitial lung disease;	chr15:85537731	chr15:85744109~85750281:-
THCA	cis	rs17689437	0.813	rs72785118	ENSG00000260084.1	RP11-615I2.1	-3.73	0.000212	0.0149	-0.25	-0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68604306	chr16:68573782~68589512:-
THCA	cis	rs1065852	0.526	rs59993856	ENSG00000227370.1	RP4-669P10.19	3.73	0.000212	0.0149	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42007976	chr22:42132543~42132998:+
THCA	cis	rs7267979	0.549	rs11698185	ENSG00000274973.1	RP13-401N8.7	-3.73	0.000212	0.0149	-0.19	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:25845497~25845862:+
THCA	cis	rs6561151	0.957	rs3764147	ENSG00000274001.1	RP11-5G9.5	-3.73	0.000212	0.0149	-0.21	-0.17	Crohn's disease;	chr13:43883789	chr13:43877715~43878163:-
THCA	cis	rs6472235	0.656	rs11995784	ENSG00000272192.1	CTD-2532N20.1	3.73	0.000212	0.0149	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65967906	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.656	rs11993927	ENSG00000272192.1	CTD-2532N20.1	3.73	0.000212	0.0149	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65969407	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.609	rs11985589	ENSG00000272192.1	CTD-2532N20.1	3.73	0.000212	0.0149	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65972076	chr8:65842752~65843331:+
THCA	cis	rs113577745	0.697	rs3791758	ENSG00000188525.3	AC010969.1	-3.73	0.000212	0.0149	-0.24	-0.17	Breast cancer;	chr2:9979782	chr2:10003158~10006030:-
THCA	cis	rs113577745	0.697	rs2011516	ENSG00000188525.3	AC010969.1	-3.73	0.000212	0.0149	-0.24	-0.17	Breast cancer;	chr2:9980477	chr2:10003158~10006030:-
THCA	cis	rs113577745	0.767	rs1820964	ENSG00000188525.3	AC010969.1	-3.73	0.000212	0.0149	-0.24	-0.17	Breast cancer;	chr2:9980658	chr2:10003158~10006030:-
THCA	cis	rs4489787	0.527	rs7961289	ENSG00000273765.1	RP11-370I10.11	-3.73	0.000212	0.0149	-0.19	-0.17	Prostate cancer (SNP x SNP interaction);	chr12:48551366	chr12:48360920~48361377:+
THCA	cis	rs4489787	0.527	rs7961295	ENSG00000273765.1	RP11-370I10.11	-3.73	0.000212	0.0149	-0.19	-0.17	Prostate cancer (SNP x SNP interaction);	chr12:48551374	chr12:48360920~48361377:+
THCA	cis	rs3755605	0.52	rs1705602	ENSG00000242578.1	RP11-469J4.3	3.73	0.000212	0.0149	0.19	0.17	Testicular germ cell tumor;	chr3:170215127	chr3:170410512~170418615:+
THCA	cis	rs295490	0.748	rs58234450	ENSG00000272656.1	RP11-219D15.3	3.73	0.000212	0.0149	0.31	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139481465	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs114423015	ENSG00000272656.1	RP11-219D15.3	3.73	0.000212	0.0149	0.31	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139488980	chr3:139349024~139349371:-
THCA	cis	rs721917	0.506	rs2475756	ENSG00000244733.5	RP11-506M13.3	-3.73	0.000212	0.0149	-0.19	-0.17	Chronic obstructive pulmonary disease;	chr10:79897010	chr10:79660891~79677996:+
THCA	cis	rs10875746	0.669	rs61940962	ENSG00000258273.1	RP11-370I10.4	3.73	0.000212	0.0149	0.25	0.17	Longevity (90 years and older);	chr12:48201694	chr12:48333755~48333901:-
THCA	cis	rs7520050	0.808	rs11211195	ENSG00000280836.1	AL355480.1	3.73	0.000212	0.0149	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.808	rs11211196	ENSG00000280836.1	AL355480.1	3.73	0.000212	0.0149	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45581219~45581321:-
THCA	cis	rs10129255	0.957	rs10136560	ENSG00000211972.2	IGHV3-66	3.73	0.000212	0.0149	0.1	0.17	Kawasaki disease;	chr14:106787630	chr14:106675017~106675544:-
THCA	cis	rs7615952	0.688	rs4422259	ENSG00000241278.1	ENPP7P4	3.73	0.000212	0.0149	0.23	0.17	Blood pressure (smoking interaction);	chr3:125826988	chr3:125848223~125909372:+
THCA	cis	rs13064773	0.528	rs340273	ENSG00000279311.1	RP11-170K4.2	3.73	0.000212	0.0149	0.21	0.17	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158873253	chr3:158869898~158871821:+
THCA	cis	rs763121	0.813	rs2179143	ENSG00000228274.3	RP3-508I15.9	-3.73	0.000212	0.0149	-0.18	-0.17	Menopause (age at onset);	chr22:38641979	chr22:38667585~38681820:-
THCA	cis	rs4767841	0.565	rs11064906	ENSG00000252886.1	RN7SKP197	-3.73	0.000212	0.0149	-0.17	-0.17	Urgency urinary incontinence;	chr12:119786180	chr12:119631090~119631386:-
THCA	cis	rs7267979	0.739	rs6138555	ENSG00000276952.1	RP5-965G21.6	3.73	0.000212	0.0149	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25284915~25285588:-
THCA	cis	rs948562	0.642	rs60483579	ENSG00000280010.1	AP001350.4	3.73	0.000212	0.0149	0.3	0.17	Lymphoma;	chr11:58660991	chr11:58627435~58628528:+
THCA	cis	rs1371614	0.635	rs4665923	ENSG00000229122.1	AGBL5-IT1	3.73	0.000212	0.0149	0.12	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916043	chr2:27061038~27061815:+
THCA	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	3.73	0.000212	0.0149	0.15	0.17	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	3.73	0.000212	0.0149	0.15	0.17	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
THCA	cis	rs2281603	0.57	rs1470851	ENSG00000272909.1	CTD-2555O16.4	-3.73	0.000212	0.0149	-0.2	-0.17	Lymphocyte counts;	chr14:64509402	chr14:64440369~64442238:-
THCA	cis	rs10504130	0.696	rs17212256	ENSG00000272024.1	RP11-546K22.3	-3.73	0.000212	0.0149	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51919058	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs12676780	ENSG00000272024.1	RP11-546K22.3	-3.73	0.000212	0.0149	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51919420	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs12676835	ENSG00000272024.1	RP11-546K22.3	-3.73	0.000212	0.0149	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51919770	chr8:51950284~51950690:+
THCA	cis	rs208520	0.69	rs4710564	ENSG00000218890.1	NUFIP1P	3.73	0.000212	0.0149	0.26	0.17	Exhaled nitric oxide output;	chr6:66113585	chr6:66093431~66094909:-
THCA	cis	rs9291683	0.517	rs11736479	ENSG00000261490.1	RP11-448G15.3	3.73	0.000212	0.0149	0.1	0.17	Bone mineral density;	chr4:10015763	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.588	rs13113730	ENSG00000261490.1	RP11-448G15.3	3.73	0.000212	0.0149	0.1	0.17	Bone mineral density;	chr4:10016004	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.588	rs6857693	ENSG00000261490.1	RP11-448G15.3	3.73	0.000212	0.0149	0.1	0.17	Bone mineral density;	chr4:10016811	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.588	rs3796829	ENSG00000261490.1	RP11-448G15.3	3.73	0.000212	0.0149	0.1	0.17	Bone mineral density;	chr4:10017514	chr4:10068089~10073019:-
THCA	cis	rs3733585	0.773	rs13107466	ENSG00000261490.1	RP11-448G15.3	3.73	0.000212	0.0149	0.1	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.588	rs13133766	ENSG00000261490.1	RP11-448G15.3	3.73	0.000212	0.0149	0.1	0.17	Bone mineral density;	chr4:10018108	chr4:10068089~10073019:-
THCA	cis	rs1125355	0.69	rs62183016	ENSG00000243792.1	OR7E89P	-3.73	0.000212	0.0149	-0.25	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158764018	chr2:158853755~158854576:+
THCA	cis	rs1125355	0.661	rs62183017	ENSG00000243792.1	OR7E89P	-3.73	0.000212	0.0149	-0.25	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158766340	chr2:158853755~158854576:+
THCA	cis	rs10844706	0.735	rs11052754	ENSG00000214776.8	RP11-726G1.1	3.73	0.000212	0.0149	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9736046	chr12:9467552~9576275:+
THCA	cis	rs17594362	0.563	rs73181188	ENSG00000264190.1	MIR5006	3.73	0.000212	0.0149	0.29	0.17	Multiple sclerosis;	chr13:41603073	chr13:41568286~41568395:-
THCA	cis	rs17594362	0.563	rs60733304	ENSG00000264190.1	MIR5006	3.73	0.000212	0.0149	0.29	0.17	Multiple sclerosis;	chr13:41603074	chr13:41568286~41568395:-
THCA	cis	rs745109	0.504	rs77013753	ENSG00000273080.1	RP11-301O19.1	3.73	0.000212	0.0149	0.3	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86371654	chr2:86195590~86196049:+
THCA	cis	rs111226991	0.505	rs77207476	ENSG00000273080.1	RP11-301O19.1	3.73	0.000212	0.0149	0.3	0.17	Glomerular filtration rate in chronic kidney disease;	chr2:86371847	chr2:86195590~86196049:+
THCA	cis	rs7131987	0.585	rs6487795	ENSG00000275476.1	RP11-996F15.4	3.73	0.000212	0.0149	0.16	0.17	QT interval;	chr12:29266228	chr12:29277397~29277882:-
THCA	cis	rs7707921	0.914	rs4081859	ENSG00000251374.1	RPS23P5	-3.73	0.000212	0.0149	-0.24	-0.17	Breast cancer;	chr5:82170850	chr5:82265157~82265259:-
THCA	cis	rs832540	1	rs832540	ENSG00000271828.1	CTD-2310F14.1	-3.73	0.000213	0.0149	-0.23	-0.17	Coronary artery disease;	chr5:56903375	chr5:56927874~56929573:+
THCA	cis	rs9908102	0.9	rs11658321	ENSG00000277621.1	RP11-597M12.2	-3.73	0.000213	0.0149	-0.18	-0.17	Schizophrenia;	chr17:13011167	chr17:12982613~12983002:-
THCA	cis	rs72634258	0.554	rs10462018	ENSG00000224315.2	RPL7P7	-3.73	0.000213	0.0149	-0.3	-0.17	Inflammatory bowel disease;	chr1:7819567	chr1:8786211~8786913:-
THCA	cis	rs9863	0.861	rs7961449	ENSG00000269938.1	RP11-214K3.20	3.73	0.000213	0.0149	0.19	0.17	White blood cell count;	chr12:123952668	chr12:123968023~123968579:-
THCA	cis	rs754466	0.58	rs12354903	ENSG00000213514.2	RP11-428P16.2	3.73	0.000213	0.0149	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77776707	chr10:77730766~77734769:+
THCA	cis	rs11088226	0.681	rs74779447	ENSG00000186842.4	LINC00846	-3.73	0.000213	0.0149	-0.25	-0.17	Gastritis;	chr21:32556703	chr21:32572238~32575881:-
THCA	cis	rs267567	0.626	rs267568	ENSG00000235257.7	ITGA9-AS1	3.73	0.000213	0.0149	0.14	0.17	PR interval;	chr3:37532201	chr3:37745432~37861780:-
THCA	cis	rs5758511	0.633	rs5758689	ENSG00000270083.1	RP1-257I20.14	-3.73	0.000213	0.0149	-0.22	-0.17	Birth weight;	chr22:42268966	chr22:42089630~42090028:-
THCA	cis	rs6472827	0.953	rs7827128	ENSG00000253983.2	RP1-16A9.1	3.73	0.000213	0.0149	0.27	0.17	Uterine fibroids;	chr8:74209641	chr8:74199396~74208441:+
THCA	cis	rs6137726	0.652	rs2424459	ENSG00000237396.1	LINC01384	3.73	0.000213	0.0149	0.15	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22667434	chr20:22587522~22607517:-
THCA	cis	rs867186	0.614	rs34526995	ENSG00000126005.14	MMP24-AS1	-3.73	0.000213	0.0149	-0.35	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34931031	chr20:35216462~35278131:-
THCA	cis	rs14027	0.921	rs13270831	ENSG00000245330.4	KB-1471A8.1	3.73	0.000213	0.0149	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119867419~119874488:-
THCA	cis	rs7170668	0.965	rs9920453	ENSG00000259134.4	LINC00924	3.73	0.000213	0.0149	0.21	0.17	Motion sickness;	chr15:95488515	chr15:95433095~95507847:+
THCA	cis	rs9860428	0.844	rs9829184	ENSG00000243795.1	RP11-572M11.3	3.73	0.000213	0.0149	0.2	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112853837	chr3:113142350~113167819:-
THCA	cis	rs1577917	0.958	rs12190603	ENSG00000220563.1	PKMP3	-3.73	0.000213	0.0149	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85766000	chr6:85659892~85660606:-
THCA	cis	rs875971	0.545	rs6460281	ENSG00000273024.4	INTS4P2	-3.73	0.000213	0.0149	-0.21	-0.17	Aortic root size;	chr7:66216128	chr7:65647864~65715661:+
THCA	cis	rs1056107	0.513	rs10817338	ENSG00000230185.4	C9orf147	3.73	0.000213	0.0149	0.16	0.17	Colorectal cancer;	chr9:112419933	chr9:112433816~112487204:-
THCA	cis	rs2455799	0.634	rs62243671	ENSG00000270409.1	RP11-44D5.1	-3.73	0.000213	0.0149	-0.18	-0.17	Mean platelet volume;	chr3:15879591	chr3:15732252~15733470:+
THCA	cis	rs9333290	0.93	rs2084448	ENSG00000259915.2	RP11-410E4.1	3.73	0.000213	0.0149	0.2	0.17	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186665793	chr2:186354570~186356773:-
THCA	cis	rs9333290	0.93	rs11685758	ENSG00000259915.2	RP11-410E4.1	3.73	0.000213	0.0149	0.2	0.17	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186668641	chr2:186354570~186356773:-
THCA	cis	rs7824557	0.527	rs2736296	ENSG00000255495.1	AC145124.2	-3.73	0.000213	0.0149	-0.19	-0.17	Retinal vascular caliber;	chr8:11377335	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.51	rs2736297	ENSG00000255495.1	AC145124.2	-3.73	0.000213	0.0149	-0.19	-0.17	Retinal vascular caliber;	chr8:11377376	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.527	rs2736298	ENSG00000255495.1	AC145124.2	-3.73	0.000213	0.0149	-0.19	-0.17	Retinal vascular caliber;	chr8:11377627	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.527	rs57629785	ENSG00000255495.1	AC145124.2	-3.73	0.000213	0.0149	-0.19	-0.17	Retinal vascular caliber;	chr8:11377641	chr8:12194467~12196280:+
THCA	cis	rs8044868	0.861	rs7201225	ENSG00000260886.1	TAT-AS1	3.73	0.000213	0.0149	0.2	0.17	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72176151	chr16:71565789~71578187:+
THCA	cis	rs801193	1	rs2055682	ENSG00000232546.1	RP11-458F8.1	-3.73	0.000213	0.0149	-0.14	-0.17	Aortic root size;	chr7:66795302	chr7:66848496~66858136:+
THCA	cis	rs7246657	1	rs1529957	ENSG00000267422.1	CTD-2554C21.1	-3.73	0.000213	0.0149	-0.19	-0.17	Coronary artery calcification;	chr19:37248899	chr19:37779686~37792865:+
THCA	cis	rs7178909	0.866	rs3784388	ENSG00000259677.1	RP11-493E3.1	3.73	0.000213	0.0149	0.2	0.17	Common traits (Other);	chr15:89894069	chr15:89876540~89877285:+
THCA	cis	rs7178909	0.872	rs3784387	ENSG00000259677.1	RP11-493E3.1	3.73	0.000213	0.0149	0.2	0.17	Common traits (Other);	chr15:89894138	chr15:89876540~89877285:+
THCA	cis	rs7178909	0.8	rs3825866	ENSG00000259677.1	RP11-493E3.1	3.73	0.000213	0.0149	0.2	0.17	Common traits (Other);	chr15:89894406	chr15:89876540~89877285:+
THCA	cis	rs7178909	0.902	rs28372736	ENSG00000259677.1	RP11-493E3.1	3.73	0.000213	0.0149	0.2	0.17	Common traits (Other);	chr15:89894626	chr15:89876540~89877285:+
THCA	cis	rs2836974	0.653	rs8130556	ENSG00000255568.3	BRWD1-AS2	3.73	0.000213	0.0149	0.15	0.17	Cognitive function;	chr21:39144946	chr21:39313935~39314962:+
THCA	cis	rs2047076	0.785	rs62365098	ENSG00000225407.3	CTD-2384B11.2	-3.73	0.000213	0.0149	-0.26	-0.17	Monocyte count;	chr5:76796792	chr5:76691439~76716215:-
THCA	cis	rs1923243	0.714	rs4604650	ENSG00000223479.3	RP4-788P17.1	3.73	0.000213	0.0149	0.18	0.17	Migraine;	chr1:73053221	chr1:73635216~73715214:+
THCA	cis	rs7554547	0.667	rs59952418	ENSG00000199347.1	RNU5E-1	3.73	0.000213	0.0149	0.24	0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11878153	chr1:11908152~11908271:+
THCA	cis	rs7709377	0.672	rs10052301	ENSG00000250015.1	CTC-339F2.2	3.73	0.000213	0.0149	0.17	0.17	Metabolite levels  (X-11787);	chr5:116195860	chr5:116302354~116304134:-
THCA	cis	rs17122278	1	rs7108845	ENSG00000243431.1	RPL5P30	3.73	0.000213	0.0149	0.17	0.17	Total cholesterol levels;	chr11:118536808	chr11:118560690~118561580:+
THCA	cis	rs17359493	0.887	rs11786389	ENSG00000253528.2	RP11-347C18.4	-3.73	0.000213	0.0149	-0.24	-0.17	Type 2 diabetes;	chr8:94842592	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.614	rs17359493	ENSG00000253528.2	RP11-347C18.4	-3.73	0.000213	0.0149	-0.24	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94844683	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.614	rs16917079	ENSG00000253528.2	RP11-347C18.4	-3.73	0.000213	0.0149	-0.24	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94847943	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.614	rs59521030	ENSG00000253528.2	RP11-347C18.4	-3.73	0.000213	0.0149	-0.24	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94848075	chr8:94974573~94974853:-
THCA	cis	rs34421088	0.56	rs1478898	ENSG00000227888.4	FAM66A	-3.73	0.000213	0.0149	-0.21	-0.17	Neuroticism;	chr8:11537570	chr8:12362019~12388296:+
THCA	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	3.73	0.000213	0.0149	0.15	0.17	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	3.73	0.000213	0.0149	0.15	0.17	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-3.73	0.000213	0.0149	-0.15	-0.17	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
THCA	cis	rs7264396	0.79	rs2295355	ENSG00000088340.14	FER1L4	3.73	0.000213	0.0149	0.17	0.17	Total cholesterol levels;	chr20:35664732	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs6058294	ENSG00000088340.14	FER1L4	3.73	0.000213	0.0149	0.17	0.17	Total cholesterol levels;	chr20:35671474	chr20:35558737~35607562:-
THCA	cis	rs13178541	0.577	rs35771209	ENSG00000250378.1	RP11-119J18.1	-3.73	0.000213	0.0149	-0.2	-0.17	IgG glycosylation;	chr5:135789476	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.577	rs35269426	ENSG00000250378.1	RP11-119J18.1	-3.73	0.000213	0.0149	-0.2	-0.17	IgG glycosylation;	chr5:135789489	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.542	rs35636441	ENSG00000250378.1	RP11-119J18.1	-3.73	0.000213	0.0149	-0.2	-0.17	IgG glycosylation;	chr5:135789500	chr5:135812667~135826582:+
THCA	cis	rs372883	0.648	rs4817279	ENSG00000176054.6	RPL23P2	-3.73	0.000213	0.015	-0.15	-0.17	Pancreatic cancer;	chr21:29265964	chr21:28997613~28998033:-
THCA	cis	rs5821446	1	rs5821446	ENSG00000265055.1	AC145343.2	-3.73	0.000213	0.015	-0.24	-0.17	Eosinophil percentage of granulocytes;	chr17:67966422	chr17:68096046~68101474:-
THCA	cis	rs7267979	0.932	rs6115200	ENSG00000276952.1	RP5-965G21.6	3.73	0.000213	0.015	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.932	rs6138588	ENSG00000276952.1	RP5-965G21.6	3.73	0.000213	0.015	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25284915~25285588:-
THCA	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	3.73	0.000213	0.015	0.2	0.17	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	3.73	0.000213	0.015	0.2	0.17	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
THCA	cis	rs35123781	0.533	rs7728485	ENSG00000249526.1	CTB-35F21.1	3.73	0.000213	0.015	0.24	0.17	Schizophrenia;	chr5:139697559	chr5:139684645~139745010:+
THCA	cis	rs875971	0.502	rs11769702	ENSG00000232559.3	GS1-124K5.12	3.73	0.000213	0.015	0.19	0.17	Aortic root size;	chr7:66255529	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs6970498	ENSG00000232559.3	GS1-124K5.12	3.73	0.000213	0.015	0.19	0.17	Aortic root size;	chr7:66275908	chr7:66554588~66576923:-
THCA	cis	rs801193	0.935	rs3800820	ENSG00000232546.1	RP11-458F8.1	3.73	0.000213	0.015	0.14	0.17	Aortic root size;	chr7:66682191	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs2003301	ENSG00000232546.1	RP11-458F8.1	3.73	0.000213	0.015	0.14	0.17	Aortic root size;	chr7:66682669	chr7:66848496~66858136:+
THCA	cis	rs6479891	1	rs12412012	ENSG00000272767.1	JMJD1C-AS1	3.73	0.000213	0.015	0.25	0.17	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs61579729	ENSG00000272767.1	JMJD1C-AS1	3.73	0.000213	0.015	0.25	0.17	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63465229~63466563:+
THCA	cis	rs6479891	1	rs16918599	ENSG00000272767.1	JMJD1C-AS1	3.73	0.000213	0.015	0.25	0.17	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63465229~63466563:+
THCA	cis	rs6995541	0.647	rs7846449	ENSG00000248896.2	CTD-2135J3.3	-3.73	0.000213	0.015	-0.21	-0.17	Triglyceride levels;	chr8:10827160	chr8:10729314~10771392:+
THCA	cis	rs6995541	0.606	rs13274017	ENSG00000248896.2	CTD-2135J3.3	-3.73	0.000213	0.015	-0.21	-0.17	Triglyceride levels;	chr8:10827675	chr8:10729314~10771392:+
THCA	cis	rs10256972	0.553	rs4236381	ENSG00000225146.1	AC073957.15	3.73	0.000213	0.015	0.19	0.17	Endometriosis;Longevity;	chr7:1126087	chr7:1029025~1043891:+
THCA	cis	rs9487051	1	rs1008084	ENSG00000260273.1	RP11-425D10.10	3.73	0.000213	0.015	0.22	0.17	Reticulocyte fraction of red cells;	chr6:109305762	chr6:109382795~109383666:+
THCA	cis	rs2455799	0.593	rs2047852	ENSG00000270409.1	RP11-44D5.1	-3.73	0.000213	0.015	-0.18	-0.17	Mean platelet volume;	chr3:15691032	chr3:15732252~15733470:+
THCA	cis	rs4919694	0.536	rs12414777	ENSG00000272912.1	RP11-724N1.1	-3.73	0.000213	0.015	-0.24	-0.17	Arsenic metabolism;	chr10:102938024	chr10:102914585~102915404:+
THCA	cis	rs3845817	0.843	rs6705904	ENSG00000237979.1	AC007389.1	-3.73	0.000213	0.015	-0.19	-0.17	Bipolar disorder;	chr2:65542897	chr2:65500993~65502138:-
THCA	cis	rs987724	0.515	rs9876148	ENSG00000243926.1	TIPARP-AS1	3.73	0.000214	0.015	0.21	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156894349	chr3:156671862~156674378:-
THCA	cis	rs8035452	0.857	rs3098189	ENSG00000273674.3	CTD-2378E12.1	3.73	0.000214	0.015	0.22	0.17	Alzheimer's disease (late onset);	chr15:50520600	chr15:50839875~50908599:-
THCA	cis	rs73191547	0.706	rs17748267	ENSG00000248538.5	RP11-10A14.5	3.73	0.000214	0.015	0.2	0.17	Schizophrenia;	chr8:10183467	chr8:9189011~9202854:+
THCA	cis	rs9500256	0.715	rs7769674	ENSG00000215190.7	LINC00680	3.73	0.000214	0.015	0.19	0.17	Eosinophilic esophagitis (pediatric);	chr6:58020586	chr6:57946074~57961501:-
THCA	cis	rs2236231	0.55	rs61990080	ENSG00000259648.1	RP11-643G16.4	-3.73	0.000214	0.015	-0.21	-0.17	Plasma kynurenine levels in major depressive disorder;	chr14:67595207	chr14:67614929~67616626:+
THCA	cis	rs2236231	0.55	rs61990081	ENSG00000259648.1	RP11-643G16.4	-3.73	0.000214	0.015	-0.21	-0.17	Plasma kynurenine levels in major depressive disorder;	chr14:67595222	chr14:67614929~67616626:+
THCA	cis	rs1048886	0.872	rs112809632	ENSG00000271967.1	RP11-134K13.4	-3.73	0.000214	0.015	-0.21	-0.17	Type 2 diabetes;	chr6:70413963	chr6:70596438~70596980:+
THCA	cis	rs41308713	0.606	rs77984335	ENSG00000196756.10	SNHG17	-3.73	0.000214	0.015	-0.37	-0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38444643	chr20:38420588~38435353:-
THCA	cis	rs9400467	0.568	rs6568685	ENSG00000255389.1	C6orf3	-3.73	0.000214	0.015	-0.19	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111499910	chr6:111599875~111602295:+
THCA	cis	rs9608946	1	rs17738527	ENSG00000279699.1	RP1-102K2.9	3.73	0.000214	0.015	0.2	0.17	Red cell distribution width;	chr22:30492507	chr22:30275215~30276951:-
THCA	cis	rs5762430	0.512	rs134170	ENSG00000235954.5	TTC28-AS1	3.73	0.000214	0.015	0.17	0.17	Obesity;	chr22:28216657	chr22:27919376~28008581:+
THCA	cis	rs586688	0.625	rs481966	ENSG00000224536.1	RP11-134G8.7	-3.73	0.000214	0.015	-0.26	-0.17	Obesity-related traits;	chr1:201686618	chr1:201507241~201533608:+
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000230373.7	GOLGA6L5P	3.73	0.000214	0.015	0.16	0.17	P wave terminal force;	chr15:84655131	chr15:84507885~84516814:-
THCA	cis	rs2337406	0.866	rs7140974	ENSG00000280411.1	IGHV1-69-2	-3.73	0.000214	0.015	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106795976	chr14:106762092~106762588:-
THCA	cis	rs11751172	0.651	rs68057028	ENSG00000271857.1	RP1-244F24.1	3.73	0.000214	0.015	0.11	0.17	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45571409	chr6:45421079~45422005:-
THCA	cis	rs1502337	0.532	rs10160981	ENSG00000278993.1	RP3-424M6.4	-3.73	0.000214	0.015	-0.26	-0.17	Body mass index;	chr12:110466270	chr12:110501614~110503441:+
THCA	cis	rs1502337	0.561	rs7958683	ENSG00000278993.1	RP3-424M6.4	-3.73	0.000214	0.015	-0.26	-0.17	Body mass index;	chr12:110468064	chr12:110501614~110503441:+
THCA	cis	rs748404	0.588	rs506120	ENSG00000275601.1	AC011330.13	-3.73	0.000214	0.015	-0.21	-0.17	Lung cancer;	chr15:43509826	chr15:43642389~43643023:-
THCA	cis	rs7176527	0.848	rs3748374	ENSG00000229212.6	RP11-561C5.4	3.73	0.000214	0.015	0.3	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85205440~85234795:-
THCA	cis	rs55702914	0.775	rs17405686	ENSG00000231621.1	AC013264.2	-3.73	0.000214	0.015	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197377137	chr2:197197991~197199273:+
THCA	cis	rs2455799	0.613	rs11713820	ENSG00000270409.1	RP11-44D5.1	3.73	0.000214	0.015	0.18	0.17	Mean platelet volume;	chr3:15825083	chr3:15732252~15733470:+
THCA	cis	rs2692947	0.537	rs11164049	ENSG00000235959.1	AC009237.17	-3.73	0.000214	0.015	-0.19	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95679770	chr2:95640181~95640604:-
THCA	cis	rs7520050	0.966	rs7540325	ENSG00000281133.1	AL355480.3	3.73	0.000214	0.015	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45580892~45580996:-
THCA	cis	rs7520050	1	rs7540699	ENSG00000281133.1	AL355480.3	3.73	0.000214	0.015	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs4660319	ENSG00000281133.1	AL355480.3	3.73	0.000214	0.015	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs11211213	ENSG00000281133.1	AL355480.3	3.73	0.000214	0.015	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45580892~45580996:-
THCA	cis	rs5758659	0.652	rs5751195	ENSG00000270083.1	RP1-257I20.14	3.73	0.000214	0.015	0.18	0.17	Cognitive function;	chr22:41983997	chr22:42089630~42090028:-
THCA	cis	rs11673344	0.583	rs10425719	ENSG00000267422.1	CTD-2554C21.1	-3.73	0.000214	0.015	-0.15	-0.17	Obesity-related traits;	chr19:37459896	chr19:37779686~37792865:+
THCA	cis	rs7176527	0.519	rs12148368	ENSG00000229212.6	RP11-561C5.4	3.73	0.000214	0.015	0.24	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85205440~85234795:-
THCA	cis	rs877819	0.583	rs2663019	ENSG00000228403.1	RP11-563N6.6	-3.73	0.000214	0.015	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48867416	chr10:48878022~48878649:+
THCA	cis	rs877819	0.583	rs2663020	ENSG00000228403.1	RP11-563N6.6	-3.73	0.000214	0.015	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48868229	chr10:48878022~48878649:+
THCA	cis	rs1387259	0.57	rs12368659	ENSG00000257735.1	RP11-370I10.6	3.73	0.000214	0.015	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48350945~48442411:+
THCA	cis	rs4714902	0.564	rs2223776	ENSG00000231769.2	RP1-8B1.4	-3.73	0.000214	0.015	-0.16	-0.17	Colonoscopy-negative controls vs population controls;	chr6:46177724	chr6:46097093~46129706:-
THCA	cis	rs925946	0.518	rs10767647	ENSG00000245573.6	BDNF-AS	-3.73	0.000214	0.015	-0.16	-0.17	Weight;Body mass index;	chr11:27545845	chr11:27506838~27698174:+
THCA	cis	rs11073619	0.773	rs28612692	ENSG00000259728.4	LINC00933	-3.73	0.000214	0.015	-0.32	-0.17	Positive affect;	chr15:84601836	chr15:84570649~84580175:+
THCA	cis	rs643506	0.845	rs7114594	ENSG00000230911.1	PPIHP1	-3.73	0.000214	0.015	-0.23	-0.17	Breast cancer;	chr11:111897389	chr11:112029858~112030367:-
THCA	cis	rs9291683	0.527	rs3822241	ENSG00000261490.1	RP11-448G15.3	-3.73	0.000214	0.015	-0.11	-0.17	Bone mineral density;	chr4:10093307	chr4:10068089~10073019:-
THCA	cis	rs17286411	0.671	rs12920243	ENSG00000260185.1	RP11-432I5.6	-3.73	0.000214	0.015	-0.23	-0.17	Blood protein levels;	chr16:71767691	chr16:71655027~71664212:+
THCA	cis	rs775227	1	rs41271355	ENSG00000243849.1	CFAP44-AS1	3.73	0.000214	0.015	0.28	0.17	Dental caries;	chr3:113285308	chr3:113403991~113433992:+
THCA	cis	rs1943345	0.556	rs588956	ENSG00000254551.1	RP11-727A23.7	3.73	0.000214	0.015	0.21	0.17	Obesity-related traits;	chr11:83215005	chr11:83209431~83213379:-
THCA	cis	rs737008	0.922	rs11074957	ENSG00000263080.1	RP11-485G7.5	-3.73	0.000214	0.015	-0.21	-0.17	Obesity-related traits;	chr16:11284294	chr16:11341809~11345211:-
THCA	cis	rs17607347	0.542	rs806743	ENSG00000247324.2	RP11-510M2.2	3.73	0.000214	0.015	0.34	0.17	Intelligence (multi-trait analysis);	chr16:72398090	chr16:71462278~71465941:+
THCA	cis	rs4950322	0.518	rs11811023	ENSG00000271721.1	RP11-337C18.9	-3.73	0.000214	0.015	-0.19	-0.17	Protein quantitative trait loci;	chr1:147109536	chr1:147175602~147177740:+
THCA	cis	rs1153858	0.621	rs12913645	ENSG00000275672.1	GATM-AS1	3.73	0.000214	0.015	0.18	0.17	Homoarginine levels;	chr15:45262868	chr15:45378700~45380123:+
THCA	cis	rs12476592	0.602	rs959195	ENSG00000242412.1	DBIL5P2	3.73	0.000214	0.015	0.22	0.17	Childhood ear infection;	chr2:63576991	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.571	rs2028883	ENSG00000242412.1	DBIL5P2	3.73	0.000214	0.015	0.22	0.17	Childhood ear infection;	chr2:63577397	chr2:63117851~63119542:-
THCA	cis	rs9435732	0.778	rs3738815	ENSG00000186301.8	MST1P2	-3.73	0.000214	0.015	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16988207	chr1:16645622~16650289:+
THCA	cis	rs733592	0.929	rs4760678	ENSG00000258273.1	RP11-370I10.4	3.73	0.000214	0.015	0.2	0.17	Plateletcrit;	chr12:48067798	chr12:48333755~48333901:-
THCA	cis	rs939960	0.757	rs4339549	ENSG00000276538.1	RP11-545G3.2	-3.73	0.000214	0.015	-0.24	-0.17	Neutrophil percentage of white cells;	chr7:150590089	chr7:150047609~150047854:-
THCA	cis	rs7829975	0.56	rs56094035	ENSG00000253981.4	ALG1L13P	-3.73	0.000214	0.015	-0.17	-0.17	Mood instability;	chr8:8694112	chr8:8236003~8244667:-
THCA	cis	rs7829975	0.539	rs4841012	ENSG00000253981.4	ALG1L13P	-3.73	0.000214	0.015	-0.17	-0.17	Mood instability;	chr8:8694200	chr8:8236003~8244667:-
THCA	cis	rs7829975	0.56	rs4841013	ENSG00000253981.4	ALG1L13P	-3.73	0.000214	0.015	-0.17	-0.17	Mood instability;	chr8:8694503	chr8:8236003~8244667:-
THCA	cis	rs61160187	0.582	rs55814394	ENSG00000272308.1	RP11-231G3.1	-3.73	0.000214	0.015	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs10939879	ENSG00000272308.1	RP11-231G3.1	-3.73	0.000214	0.015	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs1479645	ENSG00000272308.1	RP11-231G3.1	-3.73	0.000214	0.015	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60866457~60866935:-
THCA	cis	rs6442522	0.615	rs13060973	ENSG00000249786.6	EAF1-AS1	-3.73	0.000214	0.015	-0.17	-0.17	Uric acid levels;	chr3:15459426	chr3:15436171~15455940:-
THCA	cis	rs17594362	0.563	rs73181185	ENSG00000264190.1	MIR5006	3.73	0.000214	0.015	0.29	0.17	Multiple sclerosis;	chr13:41600205	chr13:41568286~41568395:-
THCA	cis	rs17594362	0.563	rs61963024	ENSG00000264190.1	MIR5006	3.73	0.000214	0.015	0.29	0.17	Multiple sclerosis;	chr13:41601158	chr13:41568286~41568395:-
THCA	cis	rs76793172	1	rs10420834	ENSG00000207003.1	RNU6-611P	3.73	0.000214	0.015	0.31	0.17	Eosinophil counts;	chr19:45844284	chr19:45047458~45047561:+
THCA	cis	rs6600671	0.967	rs11249349	ENSG00000275585.1	CH17-118O6.3	-3.73	0.000214	0.015	-0.2	-0.17	Hip geometry;	chr1:121437310	chr1:120985692~121052167:-
THCA	cis	rs6472827	0.909	rs4382470	ENSG00000253983.2	RP1-16A9.1	-3.73	0.000214	0.015	-0.28	-0.17	Uterine fibroids;	chr8:74211840	chr8:74199396~74208441:+
THCA	cis	rs875971	0.545	rs73146609	ENSG00000232559.3	GS1-124K5.12	3.73	0.000214	0.015	0.19	0.17	Aortic root size;	chr7:66302477	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs2173571	ENSG00000232559.3	GS1-124K5.12	3.73	0.000214	0.015	0.19	0.17	Aortic root size;	chr7:66305392	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs11770063	ENSG00000232559.3	GS1-124K5.12	3.73	0.000214	0.015	0.19	0.17	Aortic root size;	chr7:66318029	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs3936065	ENSG00000232559.3	GS1-124K5.12	3.73	0.000214	0.015	0.19	0.17	Aortic root size;	chr7:66325577	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs4718335	ENSG00000232559.3	GS1-124K5.12	3.73	0.000214	0.015	0.19	0.17	Aortic root size;	chr7:66339619	chr7:66554588~66576923:-
THCA	cis	rs7819412	0.582	rs2409685	ENSG00000206014.6	OR7E161P	3.73	0.000214	0.015	0.2	0.17	Triglycerides;	chr8:11051683	chr8:11928597~11929563:-
THCA	cis	rs3126085	0.935	rs11204941	ENSG00000237975.5	FLG-AS1	-3.73	0.000214	0.015	-0.26	-0.17	Atopic dermatitis;	chr1:152230867	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.825	rs10788830	ENSG00000237975.5	FLG-AS1	-3.73	0.000214	0.015	-0.26	-0.17	Atopic dermatitis;	chr1:152234422	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs1466757	ENSG00000237975.5	FLG-AS1	-3.73	0.000214	0.015	-0.26	-0.17	Atopic dermatitis;	chr1:152239993	chr1:152168125~152445456:+
THCA	cis	rs13201929	0.81	rs11966946	ENSG00000230202.1	RP11-632C17__A.1	3.73	0.000214	0.015	0.28	0.17	Myopia (pathological);	chr6:117283658	chr6:117998975~117999448:+
THCA	cis	rs875971	0.862	rs709609	ENSG00000223473.2	GS1-124K5.3	-3.73	0.000214	0.015	-0.12	-0.17	Aortic root size;	chr7:66095574	chr7:66491049~66493566:-
THCA	cis	rs3892630	0.878	rs114224536	ENSG00000267475.1	CTD-2538C1.2	-3.73	0.000214	0.015	-0.25	-0.17	Red blood cell traits;	chr19:32720326	chr19:32687089~32691750:-
THCA	cis	rs7082209	0.938	rs11238983	ENSG00000224265.1	RP11-168L22.2	-3.73	0.000214	0.015	-0.26	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr10:44314757	chr10:43323665~43327932:+
THCA	cis	rs75828804	1	rs58282136	ENSG00000260922.1	RP11-538I12.3	-3.73	0.000214	0.015	-0.36	-0.17	Intraocular pressure;	chr16:77563830	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs78556536	ENSG00000260922.1	RP11-538I12.3	-3.73	0.000214	0.015	-0.36	-0.17	Intraocular pressure;	chr16:77568211	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs77087729	ENSG00000260922.1	RP11-538I12.3	-3.73	0.000214	0.015	-0.36	-0.17	Intraocular pressure;	chr16:77568999	chr16:77234877~77290934:+
THCA	cis	rs7586085	0.966	rs6726821	ENSG00000232411.1	AC009495.3	-3.73	0.000214	0.015	-0.18	-0.17	Total body bone mineral density;	chr2:165721604	chr2:165833048~165839098:-
THCA	cis	rs1881744	0.588	rs78808618	ENSG00000276691.1	RP5-1057I20.5	3.73	0.000214	0.015	0.29	0.17	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47788426~47788971:+
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000182586.6	LINC00334	-3.73	0.000214	0.015	-0.18	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45234340~45258730:+
THCA	cis	rs4746818	1	rs7918066	ENSG00000229001.1	ACTBP14	-3.73	0.000214	0.015	-0.27	-0.17	Left atrial antero-posterior diameter;	chr10:69153360	chr10:69022778~69023866:+
THCA	cis	rs9608946	1	rs9606738	ENSG00000279699.1	RP1-102K2.9	3.73	0.000214	0.015	0.2	0.17	Red cell distribution width;	chr22:30495263	chr22:30275215~30276951:-
THCA	cis	rs12410462	0.591	rs903692	ENSG00000227711.2	RP11-275O4.5	-3.73	0.000214	0.015	-0.21	-0.17	Major depressive disorder;	chr1:227545020	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.591	rs903693	ENSG00000227711.2	RP11-275O4.5	-3.73	0.000214	0.015	-0.21	-0.17	Major depressive disorder;	chr1:227545086	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.551	rs903694	ENSG00000227711.2	RP11-275O4.5	-3.73	0.000214	0.015	-0.21	-0.17	Major depressive disorder;	chr1:227545304	chr1:227509028~227520477:-
THCA	cis	rs2640806	0.505	rs7835247	ENSG00000253105.4	KB-1448A5.1	3.73	0.000214	0.015	0.2	0.17	Obesity-related traits;	chr8:96351640	chr8:96371865~96387438:-
THCA	cis	rs6560517	1	rs7861089	ENSG00000234618.1	RPSAP9	-3.73	0.000214	0.015	-0.19	-0.17	Dialysis-related mortality;	chr9:76426986	chr9:76398699~76399586:+
THCA	cis	rs7267979	1	rs7020	ENSG00000230772.1	VN1R108P	3.73	0.000214	0.015	0.15	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25734264~25735093:+
THCA	cis	rs964611	0.872	rs6493314	ENSG00000259488.2	RP11-154J22.1	-3.73	0.000214	0.015	-0.17	-0.17	Metabolite levels (Pyroglutamine);	chr15:48273292	chr15:48312353~48331856:-
THCA	cis	rs10043228	1	rs4286716	ENSG00000250015.1	CTC-339F2.2	-3.73	0.000214	0.015	-0.25	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116184000	chr5:116302354~116304134:-
THCA	cis	rs2034650	0.544	rs2289330	ENSG00000259211.1	RP11-64K12.8	-3.73	0.000214	0.015	-0.16	-0.17	Interstitial lung disease;	chr15:40412906	chr15:40464193~40466726:-
THCA	cis	rs755249	0.567	rs41270821	ENSG00000182109.6	RP11-69E11.4	3.73	0.000214	0.015	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs2296175	ENSG00000182109.6	RP11-69E11.4	3.73	0.000214	0.015	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39522280~39546187:-
THCA	cis	rs2554380	0.943	rs2562776	ENSG00000230373.7	GOLGA6L5P	-3.73	0.000214	0.015	-0.21	-0.17	Height;	chr15:83699411	chr15:84507885~84516814:-
THCA	cis	rs9928842	0.722	rs1035540	ENSG00000261783.1	RP11-252K23.2	3.73	0.000214	0.015	0.32	0.17	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75379818~75381260:-
THCA	cis	rs4792901	0.959	rs8077086	ENSG00000267151.3	RP11-100E5.2	-3.73	0.000215	0.015	-0.18	-0.17	Dupuytren's disease;	chr17:43594482	chr17:43444707~43451200:+
THCA	cis	rs9843304	0.546	rs13071608	ENSG00000243885.1	RP11-278L15.2	-3.73	0.000215	0.015	-0.19	-0.17	Gallstone disease;	chr3:149501803	chr3:149384179~149385800:-
THCA	cis	rs3096299	0.781	rs2965819	ENSG00000261118.1	RP11-104N10.1	-3.73	0.000215	0.015	-0.14	-0.17	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89492017~89504460:-
THCA	cis	rs9393813	0.529	rs73395360	ENSG00000204789.4	ZNF204P	-3.73	0.000215	0.015	-0.13	-0.17	Bipolar disorder;	chr6:27489538	chr6:27357825~27360221:-
THCA	cis	rs1979679	0.918	rs7312574	ENSG00000247934.4	RP11-967K21.1	3.73	0.000215	0.015	0.17	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28514977	chr12:28163298~28190738:-
THCA	cis	rs7307902	0.933	rs4141149	ENSG00000280054.1	RP1-197B17.7	3.73	0.000215	0.015	0.19	0.17	Obesity-related traits;	chr12:47543349	chr12:47728151~47730598:-
THCA	cis	rs7973683	0.541	rs6488910	ENSG00000269938.1	RP11-214K3.20	-3.73	0.000215	0.015	-0.18	-0.17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123909150	chr12:123968023~123968579:-
THCA	cis	rs929354	0.772	rs3802120	ENSG00000224629.1	RP5-1142J19.2	-3.73	0.000215	0.015	-0.17	-0.17	Body mass index;	chr7:157185100	chr7:157263022~157263229:-
THCA	cis	rs758324	0.687	rs152053	ENSG00000224431.1	AC063976.7	-3.73	0.000215	0.015	-0.17	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132191043	chr5:132199456~132203487:+
THCA	cis	rs12149074	0.901	rs8049829	ENSG00000260876.4	LINC01229	-3.73	0.000215	0.015	-0.17	-0.17	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80076563	chr16:79676108~79807922:+
THCA	cis	rs13098911	0.54	rs34000569	ENSG00000226074.4	PRSS44	-3.73	0.000215	0.015	-0.32	-0.17	Celiac disease;	chr3:45957717	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34324101	ENSG00000226074.4	PRSS44	-3.73	0.000215	0.015	-0.32	-0.17	Celiac disease;	chr3:45959236	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13069079	ENSG00000226074.4	PRSS44	-3.73	0.000215	0.015	-0.32	-0.17	Celiac disease;	chr3:45959378	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34849862	ENSG00000226074.4	PRSS44	-3.73	0.000215	0.015	-0.32	-0.17	Celiac disease;	chr3:45959875	chr3:46809359~46812558:-
THCA	cis	rs683250	0.629	rs584242	ENSG00000254551.1	RP11-727A23.7	3.73	0.000215	0.015	0.21	0.17	Subcortical brain region volumes;	chr11:83230878	chr11:83209431~83213379:-
THCA	cis	rs67478160	0.643	rs12878868	ENSG00000258534.1	CTD-2134A5.4	-3.73	0.000215	0.015	-0.17	-0.17	Schizophrenia;	chr14:103767388	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs11626377	ENSG00000258534.1	CTD-2134A5.4	-3.73	0.000215	0.015	-0.17	-0.17	Schizophrenia;	chr14:103768020	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.643	rs876002	ENSG00000258534.1	CTD-2134A5.4	-3.73	0.000215	0.015	-0.17	-0.17	Schizophrenia;	chr14:103773360	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.619	rs11628481	ENSG00000258534.1	CTD-2134A5.4	-3.73	0.000215	0.015	-0.17	-0.17	Schizophrenia;	chr14:103775162	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.595	rs8022783	ENSG00000258534.1	CTD-2134A5.4	-3.73	0.000215	0.015	-0.17	-0.17	Schizophrenia;	chr14:103779236	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.608	rs11160760	ENSG00000258534.1	CTD-2134A5.4	-3.73	0.000215	0.015	-0.17	-0.17	Schizophrenia;	chr14:103782601	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.619	rs11160761	ENSG00000258534.1	CTD-2134A5.4	-3.73	0.000215	0.015	-0.17	-0.17	Schizophrenia;	chr14:103788519	chr14:103854366~103880111:-
THCA	cis	rs10090774	0.71	rs10283368	ENSG00000279766.1	RP11-642A1.2	3.73	0.000215	0.015	0.21	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140669718	chr8:140572142~140572812:-
THCA	cis	rs8030605	0.778	rs2249183	ENSG00000277245.1	RP11-48G14.3	-3.73	0.000215	0.015	-0.28	-0.17	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56264953	chr15:56447120~56447697:+
THCA	cis	rs4650994	0.544	rs4652301	ENSG00000213057.5	C1orf220	-3.73	0.000215	0.015	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178530664	chr1:178542752~178548889:+
THCA	cis	rs4650994	0.544	rs10798613	ENSG00000213057.5	C1orf220	-3.73	0.000215	0.015	-0.13	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178530887	chr1:178542752~178548889:+
THCA	cis	rs288326	0.704	rs79576701	ENSG00000272800.1	RP11-438L19.1	3.73	0.000215	0.015	0.31	0.17	Blood protein levels;	chr2:182839931	chr2:183214319~183215400:+
THCA	cis	rs8113308	1	rs7246064	ENSG00000275055.1	CTC-471J1.11	-3.73	0.000215	0.015	-0.18	-0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939009	chr19:52049007~52049754:+
THCA	cis	rs875971	0.545	rs73142265	ENSG00000232559.3	GS1-124K5.12	3.73	0.000215	0.0151	0.19	0.17	Aortic root size;	chr7:66234510	chr7:66554588~66576923:-
THCA	cis	rs17685	0.753	rs1637037	ENSG00000227038.2	AC005077.12	3.73	0.000215	0.0151	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76063609	chr7:76090431~76108779:-
THCA	cis	rs7763441	0.545	rs9501844	ENSG00000250903.7	GMDS-AS1	3.73	0.000215	0.0151	0.15	0.17	Monobrow;	chr6:2452706	chr6:2245748~2482022:+
THCA	cis	rs7914558	1	rs7077291	ENSG00000272912.1	RP11-724N1.1	-3.73	0.000215	0.0151	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185994	chr10:102914585~102915404:+
THCA	cis	rs172166	0.538	rs1150686	ENSG00000261839.1	RP1-265C24.8	3.73	0.000215	0.0151	0.16	0.17	Cardiac Troponin-T levels;	chr6:28193493	chr6:28136849~28139678:+
THCA	cis	rs1150688	1	rs1150688	ENSG00000261839.1	RP1-265C24.8	3.73	0.000215	0.0151	0.16	0.17	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28136849~28139678:+
THCA	cis	rs6479891	0.908	rs11817901	ENSG00000272767.1	JMJD1C-AS1	3.73	0.000215	0.0151	0.25	0.17	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63465229~63466563:+
THCA	cis	rs2898290	0.622	rs978804	ENSG00000206014.6	OR7E161P	3.73	0.000215	0.0151	0.2	0.17	Systolic blood pressure;	chr8:11486164	chr8:11928597~11929563:-
THCA	cis	rs860295	0.812	rs12407800	ENSG00000203761.5	MSTO2P	-3.73	0.000215	0.0151	-0.13	-0.17	Body mass index;	chr1:155790951	chr1:155745829~155750137:+
THCA	cis	rs73230612	0.79	rs73230620	ENSG00000242767.1	ZBTB20-AS4	3.73	0.000215	0.0151	0.22	0.17	Type 2 diabetes;	chr3:115196146	chr3:115100423~115103061:+
THCA	cis	rs854765	0.663	rs16960744	ENSG00000281749.1	Y_RNA	-3.73	0.000215	0.0151	-0.21	-0.17	Total body bone mineral density;	chr17:17851945	chr17:18001101~18001195:-
THCA	cis	rs11671005	0.651	rs11878203	ENSG00000269600.1	AC016629.3	-3.73	0.000215	0.0151	-0.25	-0.17	Mean platelet volume;	chr19:58408683	chr19:58593896~58599355:-
THCA	cis	rs7665090	1	rs909349	ENSG00000251288.2	RP11-10L12.2	3.73	0.000215	0.0151	0.22	0.17	Primary biliary cholangitis;	chr4:102635159	chr4:102751401~102752641:+
THCA	cis	rs1113500	0.787	rs473704	ENSG00000230489.1	VAV3-AS1	3.73	0.000215	0.0151	0.15	0.17	Growth-regulated protein alpha levels;	chr1:108094688	chr1:107964443~107994607:+
THCA	cis	rs12439619	0.921	rs56042848	ENSG00000259429.4	UBE2Q2P2	-3.73	0.000215	0.0151	-0.16	-0.17	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82355142~82420075:+
THCA	cis	rs448720	1	rs414233	ENSG00000260657.2	RP11-315D16.4	-3.73	0.000215	0.0151	-0.22	-0.17	Cognitive performance;	chr15:67919049	chr15:68267792~68277994:-
THCA	cis	rs10129255	0.957	rs12590667	ENSG00000280411.1	IGHV1-69-2	3.73	0.000215	0.0151	0.11	0.17	Kawasaki disease;	chr14:106779223	chr14:106762092~106762588:-
THCA	cis	rs12493885	0.818	rs61791541	ENSG00000243069.6	ARHGEF26-AS1	-3.73	0.000215	0.0151	-0.29	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154040366	chr3:154024401~154121332:-
THCA	cis	rs348196	0.767	rs12744132	ENSG00000236675.1	MTX1P1	-3.73	0.000215	0.0151	-0.18	-0.17	Breast cancer;	chr1:155693535	chr1:155230975~155234325:+
THCA	cis	rs35740288	0.857	rs3803506	ENSG00000259407.1	RP11-158M2.3	-3.73	0.000215	0.0151	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85747709	chr15:85744109~85750281:-
THCA	cis	rs10089	1	rs4835945	ENSG00000245937.6	LINC01184	3.73	0.000215	0.0151	0.19	0.17	Ileal carcinoids;	chr5:128190789	chr5:127940426~128083172:-
THCA	cis	rs6121246	0.954	rs7266148	ENSG00000230613.1	HM13-AS1	3.73	0.000215	0.0151	0.19	0.17	Mean corpuscular hemoglobin;	chr20:31843267	chr20:31567707~31573263:-
THCA	cis	rs6573604	0.681	rs9635250	ENSG00000276116.2	FUT8-AS1	-3.73	0.000215	0.0151	-0.25	-0.17	N-glycan levels;	chr14:65332630	chr14:65411170~65412690:-
THCA	cis	rs6696239	1	rs6669236	ENSG00000227711.2	RP11-275O4.5	-3.73	0.000215	0.0151	-0.23	-0.17	Height;	chr1:227626208	chr1:227509028~227520477:-
THCA	cis	rs6696239	1	rs12120182	ENSG00000227711.2	RP11-275O4.5	-3.73	0.000215	0.0151	-0.23	-0.17	Height;	chr1:227626631	chr1:227509028~227520477:-
THCA	cis	rs2904524	1	rs2053102	ENSG00000257815.4	RP11-611E13.2	-3.73	0.000215	0.0151	-0.16	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70375628	chr12:69904033~70243360:-
THCA	cis	rs12681366	1	rs12681366	ENSG00000261437.1	RP11-22C11.2	3.73	0.000215	0.0151	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94389037	chr8:94637285~94639467:-
THCA	cis	rs3738814	0.529	rs761422	ENSG00000186715.9	MST1L	-3.73	0.000215	0.0151	-0.14	-0.17	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Height;	chr1:16975285	chr1:16754910~16770237:-
THCA	cis	rs7326068	0.61	rs2477165	ENSG00000278291.1	RP11-172H24.4	3.73	0.000215	0.0151	0.23	0.17	Schizophrenia, bipolar disorder and depression (combined);	chr13:20871296	chr13:20699307~20703718:-
THCA	cis	rs12476592	0.571	rs1031221	ENSG00000242412.1	DBIL5P2	-3.73	0.000215	0.0151	-0.22	-0.17	Childhood ear infection;	chr2:63515676	chr2:63117851~63119542:-
THCA	cis	rs7665090	1	rs5026476	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102633753	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.967	rs6812747	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102634260	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs6839064	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102634519	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs2272695	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102634646	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs2272696	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102634664	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs2272697	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102634835	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs2866413	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102635920	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs4547797	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102636035	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs2866414	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102636062	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs9996834	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102636372	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs2903283	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102636596	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs4579121	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102637012	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs6810869	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102637357	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.934	rs6533020	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102637648	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.934	rs6533021	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000215	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102637696	chr4:102751401~102752641:+
THCA	cis	rs9309711	0.643	rs4535074	ENSG00000271868.1	RP11-1293J14.1	-3.73	0.000215	0.0151	-0.22	-0.17	Neurofibrillary tangles;	chr2:3477866	chr2:3496956~3497428:+
THCA	cis	rs4948275	0.597	rs2650713	ENSG00000237233.2	TMEM26-AS1	-3.73	0.000215	0.0151	-0.22	-0.17	Night sleep phenotypes;	chr10:61603544	chr10:61452639~61481956:+
THCA	cis	rs17221829	0.521	rs12366176	ENSG00000280385.1	AP000648.5	3.73	0.000215	0.0151	0.17	0.17	Anxiety in major depressive disorder;	chr11:89583830	chr11:90193614~90198120:+
THCA	cis	rs12681366	0.881	rs2960121	ENSG00000261437.1	RP11-22C11.2	3.73	0.000215	0.0151	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94417678	chr8:94637285~94639467:-
THCA	cis	rs6500602	1	rs11647946	ENSG00000280063.1	RP11-295D4.3	3.73	0.000215	0.0151	0.1	0.17	Schizophrenia;	chr16:4412835	chr16:4346694~4348648:-
THCA	cis	rs765787	0.53	rs28815867	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45234607	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4775822	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45234929	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11854294	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45235798	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs2413784	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45238318	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs7165889	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45239442	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11070451	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45241343	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs28897155	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45241776	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4775831	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45242524	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4775832	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45242630	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4442750	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45243130	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4444275	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45243149	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4270107	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45243152	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs4544188	ENSG00000259539.1	CTD-2651B20.1	3.73	0.000215	0.0151	0.21	0.17	Uric acid levels;	chr15:45243195	chr15:45152664~45167526:-
THCA	cis	rs420259	0.516	rs7190131	ENSG00000260136.4	CTD-2270L9.4	-3.73	0.000215	0.0151	-0.13	-0.17	Bipolar disorder;	chr16:23490828	chr16:23452758~23457606:+
THCA	cis	rs4906332	0.966	rs35443927	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000215	0.0151	-0.15	-0.17	Coronary artery disease;	chr14:103383378	chr14:103331674~103332367:-
THCA	cis	rs7264396	0.79	rs6060582	ENSG00000088340.14	FER1L4	-3.73	0.000215	0.0151	-0.17	-0.17	Total cholesterol levels;	chr20:35725375	chr20:35558737~35607562:-
THCA	cis	rs28595532	0.668	rs58467651	ENSG00000260404.2	RP11-384K6.6	-3.73	0.000215	0.0151	-0.28	-0.17	Cannabis dependence symptom count;	chr4:118427856	chr4:118591773~118633729:+
THCA	cis	rs2664588	0.741	rs12479809	ENSG00000276923.1	RP11-321P16.1	-3.73	0.000216	0.0151	-0.22	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47992953	chr20:48073869~48074188:+
THCA	cis	rs427691	0.625	rs372062	ENSG00000249476.1	CTD-2587M2.1	3.73	0.000216	0.0151	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:109674826	chr5:109237120~109326369:-
THCA	cis	rs4388249	0.516	rs435494	ENSG00000249476.1	CTD-2587M2.1	3.73	0.000216	0.0151	0.2	0.17	Schizophrenia;	chr5:109674877	chr5:109237120~109326369:-
THCA	cis	rs4947019	0.609	rs9480934	ENSG00000223537.2	RP5-919F19.5	-3.73	0.000216	0.0151	-0.33	-0.17	Hematological parameters;	chr6:109350845	chr6:109487906~109506800:+
THCA	cis	rs9437689	0.714	rs4259714	ENSG00000235501.4	RP4-639F20.1	3.73	0.000216	0.0151	0.19	0.17	Phospholipid levels (plasma);	chr1:95058600	chr1:94927566~94963270:+
THCA	cis	rs10186029	0.667	rs6734174	ENSG00000270659.1	RP11-105N14.1	3.73	0.000216	0.0151	0.13	0.17	Systemic sclerosis;	chr2:213116704	chr2:213152970~213153659:+
THCA	cis	rs2797160	0.875	rs12527010	ENSG00000226409.1	RP11-735G4.1	3.73	0.000216	0.0151	0.2	0.17	Endometrial cancer;	chr6:125670361	chr6:125370211~125374324:-
THCA	cis	rs4853525	0.62	rs6718902	ENSG00000235852.1	AC005540.3	-3.73	0.000216	0.0151	-0.19	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190973478	chr2:190880797~190882059:-
THCA	cis	rs7843479	0.932	rs68023663	ENSG00000208037.1	MIR320A	-3.73	0.000216	0.0151	-0.21	-0.17	Mean corpuscular volume;	chr8:21936868	chr8:22244962~22245043:-
THCA	cis	rs1923243	0.714	rs11210119	ENSG00000223479.3	RP4-788P17.1	-3.73	0.000216	0.0151	-0.18	-0.17	Migraine;	chr1:73067011	chr1:73635216~73715214:+
THCA	cis	rs12450239	0.514	rs35884841	ENSG00000265096.1	C1QTNF1-AS1	3.73	0.000216	0.0151	0.23	0.17	Body mass index;	chr17:79463825	chr17:79019209~79027655:-
THCA	cis	rs2880765	0.805	rs34598679	ENSG00000218052.5	ADAMTS7P4	-3.73	0.000216	0.0151	-0.19	-0.17	Coronary artery disease;	chr15:85498974	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs4344688	ENSG00000218052.5	ADAMTS7P4	-3.73	0.000216	0.0151	-0.19	-0.17	Coronary artery disease;	chr15:85499776	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs4280192	ENSG00000218052.5	ADAMTS7P4	-3.73	0.000216	0.0151	-0.19	-0.17	Coronary artery disease;	chr15:85499789	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs7169632	ENSG00000218052.5	ADAMTS7P4	-3.73	0.000216	0.0151	-0.19	-0.17	Coronary artery disease;	chr15:85501436	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs12910373	ENSG00000218052.5	ADAMTS7P4	-3.73	0.000216	0.0151	-0.19	-0.17	Coronary artery disease;	chr15:85503571	chr15:85255369~85330334:-
THCA	cis	rs11233413	0.794	rs66653310	ENSG00000246067.6	RAB30-AS1	3.73	0.000216	0.0151	0.17	0.17	Economic and political preferences (feminism/equality);	chr11:83005958	chr11:83072066~83106719:+
THCA	cis	rs579113	0.629	rs237476	ENSG00000277449.1	CEBPB-AS1	3.73	0.000216	0.0151	0.15	0.17	Colonoscopy-negative controls vs population controls;	chr20:49434845	chr20:50184598~50191498:-
THCA	cis	rs7412746	0.503	rs72704639	ENSG00000224800.1	RP11-235D19.2	-3.73	0.000216	0.0151	-0.23	-0.17	Melanoma;	chr1:150825859	chr1:150881236~150881683:-
THCA	cis	rs9291683	0.632	rs12508991	ENSG00000261490.1	RP11-448G15.3	3.73	0.000216	0.0151	0.1	0.17	Bone mineral density;	chr4:10039480	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.632	rs7679916	ENSG00000261490.1	RP11-448G15.3	3.73	0.000216	0.0151	0.1	0.17	Bone mineral density;	chr4:10040536	chr4:10068089~10073019:-
THCA	cis	rs2898290	0.622	rs7829381	ENSG00000270154.1	RP11-419I17.1	-3.73	0.000216	0.0151	-0.21	-0.17	Systolic blood pressure;	chr8:11487064	chr8:12476462~12477122:+
THCA	cis	rs2898290	0.622	rs11250140	ENSG00000270154.1	RP11-419I17.1	-3.73	0.000216	0.0151	-0.21	-0.17	Systolic blood pressure;	chr8:11489083	chr8:12476462~12477122:+
THCA	cis	rs17428076	0.834	rs6749895	ENSG00000228389.1	AC068039.4	-3.73	0.000216	0.0151	-0.21	-0.17	Myopia;	chr2:172010535	chr2:171773482~171775844:+
THCA	cis	rs518600	1	rs518600	ENSG00000276334.1	AL133243.1	3.73	0.000216	0.0151	0.18	0.17	Interleukin-18 levels;	chr2:31629385	chr2:32521927~32523547:+
THCA	cis	rs7824557	0.564	rs13260727	ENSG00000255495.1	AC145124.2	3.73	0.000216	0.0151	0.19	0.17	Retinal vascular caliber;	chr8:11375351	chr8:12194467~12196280:+
THCA	cis	rs321358	1	rs321356	ENSG00000271390.1	RP11-89C3.3	-3.73	0.000216	0.0151	-0.29	-0.17	Body mass index;	chr11:111124957	chr11:111089870~111090368:-
THCA	cis	rs41313321	0.512	rs12335613	ENSG00000272696.1	RP11-339B21.13	3.73	0.000216	0.0151	0.12	0.17	Coenzyme Q10 levels;	chr9:128277982	chr9:128316337~128316909:+
THCA	cis	rs7824557	0.51	rs1435274	ENSG00000255495.1	AC145124.2	-3.73	0.000216	0.0151	-0.19	-0.17	Retinal vascular caliber;	chr8:11378401	chr8:12194467~12196280:+
THCA	cis	rs2051773	0.567	rs4255517	ENSG00000272034.1	SNORD14A	-3.73	0.000216	0.0151	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17021662	chr11:17074654~17074744:-
THCA	cis	rs2051773	0.567	rs7929927	ENSG00000272034.1	SNORD14A	-3.73	0.000216	0.0151	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17022811	chr11:17074654~17074744:-
THCA	cis	rs2051773	0.567	rs11024116	ENSG00000272034.1	SNORD14A	-3.73	0.000216	0.0151	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17024339	chr11:17074654~17074744:-
THCA	cis	rs2360027	0.965	rs4659107	ENSG00000231365.4	RP11-418J17.1	-3.73	0.000216	0.0151	-0.16	-0.17	Tonsillectomy;	chr1:118599173	chr1:119140396~119275973:+
THCA	cis	rs782212	0.527	rs34874247	ENSG00000227207.2	RPL31P12	3.73	0.000216	0.0151	0.28	0.17	Depression;	chr1:72279267	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.838	rs34579341	ENSG00000227207.2	RPL31P12	3.73	0.000216	0.0151	0.28	0.17	Childhood body mass index;	chr1:72280279	chr1:72301472~72301829:+
THCA	cis	rs131777	0.547	rs131753	ENSG00000205559.3	CHKB-AS1	-3.73	0.000216	0.0151	-0.21	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50583026~50583877:+
THCA	cis	rs7819412	0.668	rs920047	ENSG00000254866.2	DEFB109P3	3.73	0.000216	0.0151	0.23	0.17	Triglycerides;	chr8:11229966	chr8:12150895~12151134:-
THCA	cis	rs4578769	0.55	rs12966925	ENSG00000273232.1	RP11-370A5.2	3.73	0.000216	0.0151	0.23	0.17	Eosinophil percentage of white cells;	chr18:22953734	chr18:22882825~22883357:-
THCA	cis	rs1580019	0.961	rs1580021	ENSG00000231952.3	DPY19L1P2	-3.73	0.000216	0.0151	-0.21	-0.17	Cognitive ability;	chr7:32458090	chr7:32812757~32838570:+
THCA	cis	rs1005277	0.54	rs1814077	ENSG00000275858.1	RP11-291L22.8	3.73	0.000216	0.0151	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38450738~38451069:-
THCA	cis	rs1560104	0.576	rs11645674	ENSG00000262801.4	U91319.1	3.73	0.000216	0.0151	0.19	0.17	Obesity-related traits;	chr16:12615117	chr16:13246316~13562918:+
THCA	cis	rs62458065	0.64	rs4141788	ENSG00000231952.3	DPY19L1P2	3.73	0.000216	0.0151	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32479652	chr7:32812757~32838570:+
THCA	cis	rs35486314	1	rs35486314	ENSG00000231073.1	RP11-316M1.3	-3.73	0.000216	0.0151	-0.21	-0.17	Monocyte chemoattractant protein-1 levels;	chr1:150929385	chr1:150973123~150975534:+
THCA	cis	rs4568518	0.74	rs12699924	ENSG00000279048.1	RP11-511H23.2	3.73	0.000216	0.0151	0.11	0.17	Measles;	chr7:17970768	chr7:17940503~17942922:+
THCA	cis	rs858239	0.72	rs10227559	ENSG00000226816.2	AC005082.12	3.73	0.000216	0.0151	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23206013~23208045:+
THCA	cis	rs4073416	0.504	rs1953418	ENSG00000276116.2	FUT8-AS1	3.73	0.000216	0.0151	0.19	0.17	N-glycan levels;	chr14:65448508	chr14:65411170~65412690:-
THCA	cis	rs2562456	0.833	rs62110071	ENSG00000268278.1	RP11-420K14.1	3.73	0.000216	0.0151	0.24	0.17	Pain;	chr19:21288101	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs11667392	ENSG00000268278.1	RP11-420K14.1	3.73	0.000216	0.0151	0.24	0.17	Pain;	chr19:21289806	chr19:21637974~21656300:+
THCA	cis	rs7424096	0.56	rs7560263	ENSG00000279519.1	RP11-288C18.1	3.73	0.000216	0.0151	0.14	0.17	High light scatter reticulocyte percentage of red cells;	chr2:36956160	chr2:36839922~36842539:-
THCA	cis	rs9309473	0.95	rs7567585	ENSG00000273245.1	RP11-434P11.2	3.73	0.000216	0.0151	0.23	0.17	Metabolite levels;	chr2:73524839	chr2:73750256~73750786:-
THCA	cis	rs10089	1	rs3805612	ENSG00000245937.6	LINC01184	3.73	0.000216	0.0151	0.19	0.17	Ileal carcinoids;	chr5:128169624	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs1842006	ENSG00000245937.6	LINC01184	3.73	0.000216	0.0151	0.19	0.17	Ileal carcinoids;	chr5:128172995	chr5:127940426~128083172:-
THCA	cis	rs7551222	0.752	rs4252718	ENSG00000240219.1	RP11-430C7.5	-3.73	0.000216	0.0151	-0.16	-0.17	Schizophrenia;	chr1:204543067	chr1:204626775~204629712:+
THCA	cis	rs2933343	0.7	rs789239	ENSG00000231305.3	RP11-723O4.2	3.73	0.000216	0.0151	0.18	0.17	IgG glycosylation;	chr3:128914965	chr3:128861313~128871540:-
THCA	cis	rs2055729	0.71	rs6981023	ENSG00000261451.1	RP11-981G7.1	-3.73	0.000216	0.0151	-0.24	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9889075	chr8:10433672~10438312:+
THCA	cis	rs733592	1	rs1859440	ENSG00000258273.1	RP11-370I10.4	3.73	0.000216	0.0151	0.2	0.17	Plateletcrit;	chr12:48033546	chr12:48333755~48333901:-
THCA	cis	rs754466	0.58	rs10824575	ENSG00000213514.2	RP11-428P16.2	3.73	0.000216	0.0151	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77789289	chr10:77730766~77734769:+
THCA	cis	rs78487399	0.808	rs10203174	ENSG00000234936.1	AC010883.5	3.73	0.000216	0.0151	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43462891	chr2:43229573~43233394:+
THCA	cis	rs72928364	0.591	rs35379420	ENSG00000256628.3	ZBTB11-AS1	3.73	0.000216	0.0151	0.36	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100914722	chr3:101676475~101679217:+
THCA	cis	rs7264396	0.79	rs12480622	ENSG00000088340.14	FER1L4	3.73	0.000216	0.0151	0.17	0.17	Total cholesterol levels;	chr20:35646698	chr20:35558737~35607562:-
THCA	cis	rs4144027	0.904	rs10438243	ENSG00000269958.1	RP11-73M18.8	-3.73	0.000216	0.0151	-0.15	-0.17	Blood metabolite levels;	chr14:103879485	chr14:103696353~103697163:+
THCA	cis	rs12134133	0.752	rs6540874	ENSG00000237074.1	RP11-6J21.2	3.73	0.000216	0.0151	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207249067~207309121:+
THCA	cis	rs12134133	0.752	rs6683677	ENSG00000237074.1	RP11-6J21.2	3.73	0.000216	0.0151	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207249067~207309121:+
THCA	cis	rs427394	0.582	rs274661	ENSG00000248677.1	CTD-2044J15.1	3.73	0.000216	0.0151	0.16	0.17	Menopause (age at onset);	chr5:6704735	chr5:6686325~6707711:-
THCA	cis	rs57709857	0.957	rs4647903	ENSG00000272092.1	RP11-350N15.5	-3.73	0.000216	0.0151	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38415064	chr8:38382364~38383461:+
THCA	cis	rs7707921	1	rs1543911	ENSG00000251374.1	RPS23P5	-3.73	0.000216	0.0151	-0.24	-0.17	Breast cancer;	chr5:82209022	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.957	rs2059891	ENSG00000251374.1	RPS23P5	-3.73	0.000216	0.0151	-0.24	-0.17	Breast cancer;	chr5:82212973	chr5:82265157~82265259:-
THCA	cis	rs9287719	0.935	rs61424402	ENSG00000243819.4	RN7SL832P	3.73	0.000216	0.0151	0.13	0.17	Prostate cancer;	chr2:10618245	chr2:10690344~10692099:+
THCA	cis	rs62344088	1	rs7710931	ENSG00000277812.1	AC021087.1	3.73	0.000216	0.0151	0.44	0.17	Asthma (childhood onset);	chr5:152171	chr5:262769~262881:+
THCA	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-3.73	0.000216	0.0151	-0.2	-0.17	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
THCA	cis	rs867371	1	rs9944197	ENSG00000278603.1	RP13-608F4.5	3.73	0.000216	0.0151	0.22	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472203~82472426:+
THCA	cis	rs6756513	0.5	rs60168146	ENSG00000231024.1	AC092431.3	-3.73	0.000216	0.0151	-0.25	-0.17	Breast cancer;Platelet count;	chr2:69815200	chr2:69700192~69713847:-
THCA	cis	rs5752326	0.51	rs13056607	ENSG00000261188.1	CTA-445C9.14	-3.73	0.000216	0.0151	-0.18	-0.17	Ischemic stroke;	chr22:26515027	chr22:26512537~26514568:+
THCA	cis	rs6560517	0.789	rs3739516	ENSG00000234618.1	RPSAP9	-3.73	0.000216	0.0151	-0.2	-0.17	Dialysis-related mortality;	chr9:76474849	chr9:76398699~76399586:+
THCA	cis	rs7711186	0.748	rs10479501	ENSG00000252464.1	RN7SKP70	3.73	0.000216	0.0151	0.19	0.17	Urate levels in obese individuals;	chr5:178645145	chr5:178619728~178619998:-
THCA	cis	rs4325129	0.705	rs4233351	ENSG00000272668.1	RP11-190A12.8	3.73	0.000216	0.0151	0.2	0.17	Obesity-related traits;	chr1:159476580	chr1:159866954~159867685:+
THCA	cis	rs4789693	1	rs4789693	ENSG00000279744.1	RP13-20L14.10	-3.73	0.000216	0.0151	-0.15	-0.17	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82462601~82464255:+
THCA	cis	rs6142618	0.562	rs6142608	ENSG00000224452.1	RSL24D1P6	3.73	0.000216	0.0151	0.2	0.17	Inflammatory bowel disease;	chr20:32103140	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs6061159	ENSG00000224452.1	RSL24D1P6	3.73	0.000216	0.0151	0.2	0.17	Inflammatory bowel disease;	chr20:32104119	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs6142609	ENSG00000224452.1	RSL24D1P6	3.73	0.000216	0.0151	0.2	0.17	Inflammatory bowel disease;	chr20:32104232	chr20:32170390~32170790:-
THCA	cis	rs9926296	0.632	rs2011925	ENSG00000274627.1	RP11-104N10.2	-3.73	0.000216	0.0151	-0.18	-0.17	Vitiligo;	chr16:89747656	chr16:89516797~89522217:+
THCA	cis	rs7665090	0.875	rs6813322	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000216	0.0151	-0.22	-0.17	Primary biliary cholangitis;	chr4:102634462	chr4:102751401~102752641:+
THCA	cis	rs4805272	0.626	rs12610050	ENSG00000267799.1	MAN1A2P1	3.73	0.000216	0.0151	0.21	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840417	chr19:28790812~28792871:-
THCA	cis	rs4805272	0.626	rs12608533	ENSG00000267799.1	MAN1A2P1	3.73	0.000216	0.0151	0.21	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840498	chr19:28790812~28792871:-
THCA	cis	rs17604090	0.701	rs60930239	ENSG00000223813.2	AC007255.8	3.73	0.000217	0.0151	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29648928	chr7:29514225~29563670:-
THCA	cis	rs17604090	0.793	rs66956566	ENSG00000223813.2	AC007255.8	3.73	0.000217	0.0151	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649086	chr7:29514225~29563670:-
THCA	cis	rs17604090	0.793	rs73687726	ENSG00000223813.2	AC007255.8	3.73	0.000217	0.0151	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649157	chr7:29514225~29563670:-
THCA	cis	rs17604090	0.793	rs17150665	ENSG00000223813.2	AC007255.8	3.73	0.000217	0.0151	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649244	chr7:29514225~29563670:-
THCA	cis	rs17604090	0.793	rs17136535	ENSG00000223813.2	AC007255.8	3.73	0.000217	0.0151	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649542	chr7:29514225~29563670:-
THCA	cis	rs17604090	0.793	rs17150667	ENSG00000223813.2	AC007255.8	3.73	0.000217	0.0151	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649722	chr7:29514225~29563670:-
THCA	cis	rs17604090	0.775	rs10225523	ENSG00000223813.2	AC007255.8	3.73	0.000217	0.0151	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29650119	chr7:29514225~29563670:-
THCA	cis	rs9925964	0.9	rs9934438	ENSG00000279196.1	RP11-1072A3.3	-3.73	0.000217	0.0152	-0.16	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093557	chr16:30984630~30988270:-
THCA	cis	rs1048886	0.938	rs10455706	ENSG00000271967.1	RP11-134K13.4	-3.73	0.000217	0.0152	-0.19	-0.17	Type 2 diabetes;	chr6:70579292	chr6:70596438~70596980:+
THCA	cis	rs7824557	0.767	rs3808513	ENSG00000255495.1	AC145124.2	-3.73	0.000217	0.0152	-0.19	-0.17	Retinal vascular caliber;	chr8:11299951	chr8:12194467~12196280:+
THCA	cis	rs714027	0.546	rs5763614	ENSG00000279699.1	RP1-102K2.9	3.73	0.000217	0.0152	0.17	0.17	Lymphocyte counts;	chr22:29935301	chr22:30275215~30276951:-
THCA	cis	rs1334893	1	rs1334893	ENSG00000215409.4	RP11-748L13.2	-3.73	0.000217	0.0152	-0.37	-0.17	Fasting blood insulin (BMI interaction);	chr10:27404376	chr10:27331357~27341252:-
THCA	cis	rs1334893	1	rs2484192	ENSG00000215409.4	RP11-748L13.2	-3.73	0.000217	0.0152	-0.37	-0.17	Fasting blood insulin (BMI interaction);	chr10:27407165	chr10:27331357~27341252:-
THCA	cis	rs1334893	0.681	rs2429500	ENSG00000215409.4	RP11-748L13.2	-3.73	0.000217	0.0152	-0.37	-0.17	Fasting blood insulin (BMI interaction);	chr10:27412253	chr10:27331357~27341252:-
THCA	cis	rs2033711	0.87	rs7259841	ENSG00000232098.3	CTD-2619J13.14	3.73	0.000217	0.0152	0.15	0.17	Uric acid clearance;	chr19:58439756	chr19:58404238~58408484:-
THCA	cis	rs4664293	0.967	rs10202187	ENSG00000230783.1	AC009961.2	-3.73	0.000217	0.0152	-0.21	-0.17	Monocyte percentage of white cells;	chr2:159571135	chr2:159689217~159690291:-
THCA	cis	rs11039798	0.544	rs113253936	ENSG00000200090.1	Y_RNA	3.73	0.000217	0.0152	0.21	0.17	Axial length;	chr11:48139057	chr11:47726894~47726992:-
THCA	cis	rs295490	0.748	rs75866638	ENSG00000272656.1	RP11-219D15.3	3.73	0.000217	0.0152	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139338830	chr3:139349024~139349371:-
THCA	cis	rs6443245	0.611	rs7640402	ENSG00000227110.5	LMCD1-AS1	-3.73	0.000217	0.0152	-0.2	-0.17	Daytime sleep phenotypes;	chr3:9585399	chr3:7952805~8611924:-
THCA	cis	rs5753037	0.754	rs4820824	ENSG00000279699.1	RP1-102K2.9	3.73	0.000217	0.0152	0.16	0.17	Type 1 diabetes;	chr22:29964926	chr22:30275215~30276951:-
THCA	cis	rs7216064	1	rs6504542	ENSG00000278740.1	RP11-147L13.14	3.73	0.000217	0.0152	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840526	chr17:68188547~68189165:+
THCA	cis	rs656319	0.58	rs13272793	ENSG00000261451.1	RP11-981G7.1	-3.73	0.000217	0.0152	-0.22	-0.17	Myopia (pathological);	chr8:10144517	chr8:10433672~10438312:+
THCA	cis	rs17428076	0.872	rs62183808	ENSG00000228389.1	AC068039.4	-3.73	0.000217	0.0152	-0.21	-0.17	Myopia;	chr2:172015170	chr2:171773482~171775844:+
THCA	cis	rs17253792	0.822	rs10145687	ENSG00000186615.9	KTN1-AS1	-3.73	0.000217	0.0152	-0.28	-0.17	Putamen volume;	chr14:55657666	chr14:55499278~55580110:-
THCA	cis	rs7615952	0.546	rs2979340	ENSG00000241278.1	ENPP7P4	3.73	0.000217	0.0152	0.24	0.17	Blood pressure (smoking interaction);	chr3:125622540	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.546	rs2979338	ENSG00000241278.1	ENPP7P4	3.73	0.000217	0.0152	0.24	0.17	Blood pressure (smoking interaction);	chr3:125624282	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.546	rs2922171	ENSG00000241278.1	ENPP7P4	3.73	0.000217	0.0152	0.24	0.17	Blood pressure (smoking interaction);	chr3:125624349	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.546	rs112919177	ENSG00000241278.1	ENPP7P4	3.73	0.000217	0.0152	0.24	0.17	Blood pressure (smoking interaction);	chr3:125627226	chr3:125848223~125909372:+
THCA	cis	rs79349575	0.716	rs46522	ENSG00000270781.1	RP11-501C14.9	-3.73	0.000217	0.0152	-0.21	-0.17	Type 2 diabetes;	chr17:48911235	chr17:48899131~48899748:+
THCA	cis	rs7200543	1	rs16966952	ENSG00000260735.1	RP11-72I8.1	-3.73	0.000217	0.0152	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:15094411~15109197:+
THCA	cis	rs6969780	0.524	rs12530948	ENSG00000233429.8	HOTAIRM1	-3.73	0.000217	0.0152	-0.22	-0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27161639	chr7:27095647~27100265:+
THCA	cis	rs17604090	0.761	rs115923387	ENSG00000227855.3	DPY19L2P3	3.73	0.000217	0.0152	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29681086	chr7:29650227~29742594:+
THCA	cis	rs9393777	0.841	rs13191474	ENSG00000272009.1	RP1-313I6.12	-3.73	0.000217	0.0152	-0.29	-0.17	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28078792~28081130:-
THCA	cis	rs9393777	0.92	rs41269265	ENSG00000272009.1	RP1-313I6.12	-3.73	0.000217	0.0152	-0.29	-0.17	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28078792~28081130:-
THCA	cis	rs12780845	0.54	rs12770238	ENSG00000234961.1	RP11-124N14.3	-3.73	0.000217	0.0152	-0.17	-0.17	Homocysteine levels;	chr10:17167571	chr10:17233325~17234833:-
THCA	cis	rs10844154	0.638	rs811078	ENSG00000277342.1	RP11-843B15.4	3.73	0.000217	0.0152	0.21	0.17	Emphysema-related traits;Weight;	chr12:32246598	chr12:32109076~32109602:+
THCA	cis	rs6957923	0.818	rs10950949	ENSG00000234286.1	AC006026.13	-3.73	0.000217	0.0152	-0.22	-0.17	Height;	chr7:23479641	chr7:23680195~23680786:-
THCA	cis	rs59901009	0.577	rs7130610	ENSG00000246273.5	SBF2-AS1	-3.73	0.000217	0.0152	-0.22	-0.17	Hematocrit;Hemoglobin concentration;	chr11:10022557	chr11:9758292~9811319:+
THCA	cis	rs6847067	1	rs13145705	ENSG00000180769.7	WDFY3-AS2	3.73	0.000217	0.0152	0.12	0.17	Oropharynx cancer;	chr4:84799214	chr4:84965682~85011277:+
THCA	cis	rs858239	0.669	rs1618339	ENSG00000230042.1	AK3P3	-3.73	0.000217	0.0152	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23129178~23129841:+
THCA	cis	rs7824557	0.527	rs2736296	ENSG00000227888.4	FAM66A	-3.73	0.000217	0.0152	-0.21	-0.17	Retinal vascular caliber;	chr8:11377335	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.51	rs2736297	ENSG00000227888.4	FAM66A	-3.73	0.000217	0.0152	-0.21	-0.17	Retinal vascular caliber;	chr8:11377376	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.527	rs2736298	ENSG00000227888.4	FAM66A	-3.73	0.000217	0.0152	-0.21	-0.17	Retinal vascular caliber;	chr8:11377627	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.527	rs57629785	ENSG00000227888.4	FAM66A	-3.73	0.000217	0.0152	-0.21	-0.17	Retinal vascular caliber;	chr8:11377641	chr8:12362019~12388296:+
THCA	cis	rs10875746	0.729	rs1990028	ENSG00000258234.1	RP11-370I10.2	3.73	0.000217	0.0152	0.2	0.17	Longevity (90 years and older);	chr12:48014230	chr12:48231098~48284210:-
THCA	cis	rs2033711	0.87	rs3764534	ENSG00000232098.3	CTD-2619J13.14	3.73	0.000217	0.0152	0.15	0.17	Uric acid clearance;	chr19:58417769	chr19:58404238~58408484:-
THCA	cis	rs10129255	0.784	rs7147210	ENSG00000280411.1	IGHV1-69-2	-3.73	0.000217	0.0152	-0.11	-0.17	Kawasaki disease;	chr14:106705271	chr14:106762092~106762588:-
THCA	cis	rs2408955	0.522	rs973398	ENSG00000257735.1	RP11-370I10.6	-3.73	0.000217	0.0152	-0.2	-0.17	Glycated hemoglobin levels;	chr12:48097265	chr12:48350945~48442411:+
THCA	cis	rs793571	0.774	rs10851640	ENSG00000245975.2	RP11-30K9.6	-3.73	0.000217	0.0152	-0.17	-0.17	Schizophrenia;	chr15:58845671	chr15:58768072~58770974:-
THCA	cis	rs13217239	0.646	rs10946898	ENSG00000261353.1	CTA-14H9.5	-3.73	0.000217	0.0152	-0.18	-0.17	Schizophrenia;	chr6:27036105	chr6:26527063~26527404:+
THCA	cis	rs73193808	0.639	rs2832237	ENSG00000231125.2	AF129075.5	-3.73	0.000217	0.0152	-0.16	-0.17	Coronary artery disease;	chr21:29175362	chr21:29058073~29060095:-
THCA	cis	rs3177980	1	rs4987280	ENSG00000239494.2	RN7SL333P	-3.73	0.000217	0.0152	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr1:169710412	chr1:169859756~169860052:+
THCA	cis	rs4908760	0.965	rs301814	ENSG00000270282.1	RP5-1115A15.2	3.73	0.000217	0.0152	0.2	0.17	Vitiligo;	chr1:8450517	chr1:8512653~8513021:+
THCA	cis	rs6137726	0.613	rs747912	ENSG00000237396.1	LINC01384	3.73	0.000217	0.0152	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22652422	chr20:22587522~22607517:-
THCA	cis	rs7312933	0.533	rs17551006	ENSG00000257225.1	RP11-328C8.4	-3.73	0.000217	0.0152	-0.18	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42454936	chr12:42459366~42466128:+
THCA	cis	rs4906332	1	rs2065017	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000217	0.0152	-0.15	-0.17	Coronary artery disease;	chr14:103413242	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs12885762	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000217	0.0152	-0.15	-0.17	Coronary artery disease;	chr14:103415863	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs12892062	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000217	0.0152	-0.15	-0.17	Coronary artery disease;	chr14:103417175	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs7155980	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000217	0.0152	-0.15	-0.17	Coronary artery disease;	chr14:103456082	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs8012623	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000217	0.0152	-0.15	-0.17	Coronary artery disease;	chr14:103470749	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs34347076	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000217	0.0152	-0.15	-0.17	Coronary artery disease;	chr14:103488732	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs35344594	ENSG00000259775.1	RP11-45P15.4	-3.73	0.000217	0.0152	-0.15	-0.17	Coronary artery disease;	chr14:103489455	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs2065018	ENSG00000259775.1	RP11-45P15.4	3.73	0.000217	0.0152	0.15	0.17	Coronary artery disease;	chr14:103412850	chr14:103331674~103332367:-
THCA	cis	rs6449502	0.748	rs1445292	ENSG00000251279.1	CTC-436P18.1	-3.73	0.000217	0.0152	-0.26	-0.17	Mean platelet volume;	chr5:60824295	chr5:61162070~61232040:+
THCA	cis	rs7403037	1	rs7402804	ENSG00000260760.1	PWRN3	3.73	0.000217	0.0152	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24591453	chr15:24441127~24447967:+
THCA	cis	rs7403037	1	rs7402908	ENSG00000260760.1	PWRN3	3.73	0.000217	0.0152	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24591833	chr15:24441127~24447967:+
THCA	cis	rs494526	0.64	rs7907274	ENSG00000229272.1	RP11-498J9.2	-3.73	0.000217	0.0152	-0.2	-0.17	Alcoholic chronic pancreatitis;	chr10:119095515	chr10:119003536~119003884:-
THCA	cis	rs3845817	0.801	rs2438102	ENSG00000281920.1	RP11-418H16.1	-3.73	0.000217	0.0152	-0.21	-0.17	Bipolar disorder;	chr2:65530223	chr2:65623272~65628424:+
THCA	cis	rs2337406	0.866	rs7153964	ENSG00000280411.1	IGHV1-69-2	-3.73	0.000217	0.0152	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106790480	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs2301536	ENSG00000280411.1	IGHV1-69-2	-3.73	0.000217	0.0152	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106790636	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs7144369	ENSG00000280411.1	IGHV1-69-2	-3.73	0.000217	0.0152	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106793065	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs78525520	ENSG00000280411.1	IGHV1-69-2	-3.73	0.000217	0.0152	-0.14	-0.17	Alzheimer's disease (late onset);	chr14:106795643	chr14:106762092~106762588:-
THCA	cis	rs1923243	0.722	rs12044276	ENSG00000223479.3	RP4-788P17.1	-3.73	0.000217	0.0152	-0.18	-0.17	Migraine;	chr1:72993163	chr1:73635216~73715214:+
THCA	cis	rs34217772	0.824	rs61992433	ENSG00000258636.1	CTD-2298J14.2	3.73	0.000217	0.0152	0.32	0.17	Myopia;	chr14:41757997	chr14:41587861~41604856:-
THCA	cis	rs7615952	0.932	rs13314869	ENSG00000248787.1	RP11-666A20.4	-3.73	0.000217	0.0152	-0.29	-0.17	Blood pressure (smoking interaction);	chr3:125925826	chr3:125908005~125910272:-
THCA	cis	rs2227564	0.672	rs2459449	ENSG00000271816.1	BMS1P4	3.73	0.000217	0.0152	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73909255	chr10:73699151~73730487:-
THCA	cis	rs13098911	0.54	rs17330872	ENSG00000226074.4	PRSS44	-3.73	0.000217	0.0152	-0.33	-0.17	Celiac disease;	chr3:45993605	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.598	rs71327003	ENSG00000226074.4	PRSS44	-3.73	0.000217	0.0152	-0.33	-0.17	Celiac disease;	chr3:45995029	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs36023124	ENSG00000226074.4	PRSS44	-3.73	0.000217	0.0152	-0.33	-0.17	Celiac disease;	chr3:45997568	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs71615438	ENSG00000226074.4	PRSS44	-3.73	0.000217	0.0152	-0.33	-0.17	Celiac disease;	chr3:45998376	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34754340	ENSG00000226074.4	PRSS44	-3.73	0.000217	0.0152	-0.33	-0.17	Celiac disease;	chr3:46000345	chr3:46809359~46812558:-
THCA	cis	rs4389656	0.625	rs7712516	ENSG00000248677.1	CTD-2044J15.1	3.73	0.000217	0.0152	0.17	0.17	Coronary artery disease;	chr5:6745458	chr5:6686325~6707711:-
THCA	cis	rs2625529	0.824	rs10518979	ENSG00000260037.4	CTD-2524L6.3	-3.73	0.000217	0.0152	-0.24	-0.17	Red blood cell count;	chr15:71976645	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs16956452	ENSG00000260037.4	CTD-2524L6.3	-3.73	0.000217	0.0152	-0.24	-0.17	Red blood cell count;	chr15:71991751	chr15:71818396~71823384:+
THCA	cis	rs10875746	0.855	rs10875731	ENSG00000258234.1	RP11-370I10.2	3.73	0.000217	0.0152	0.2	0.17	Longevity (90 years and older);	chr12:48038960	chr12:48231098~48284210:-
THCA	cis	rs7216064	0.906	rs78452260	ENSG00000265055.1	AC145343.2	3.73	0.000217	0.0152	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852406	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs62084240	ENSG00000265055.1	AC145343.2	3.73	0.000217	0.0152	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67863117	chr17:68096046~68101474:-
THCA	cis	rs2797160	1	rs1739374	ENSG00000226409.1	RP11-735G4.1	3.73	0.000217	0.0152	0.2	0.17	Endometrial cancer;	chr6:125690679	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1739380	ENSG00000226409.1	RP11-735G4.1	3.73	0.000217	0.0152	0.2	0.17	Endometrial cancer;	chr6:125691712	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1630556	ENSG00000226409.1	RP11-735G4.1	3.73	0.000217	0.0152	0.2	0.17	Endometrial cancer;	chr6:125692009	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.967	rs1777182	ENSG00000226409.1	RP11-735G4.1	3.73	0.000217	0.0152	0.2	0.17	Endometrial cancer;	chr6:125692468	chr6:125370211~125374324:-
THCA	cis	rs9287719	0.967	rs12467642	ENSG00000243819.4	RN7SL832P	3.73	0.000217	0.0152	0.13	0.17	Prostate cancer;	chr2:10621358	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs12464908	ENSG00000243819.4	RN7SL832P	3.73	0.000217	0.0152	0.13	0.17	Prostate cancer;	chr2:10621370	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7563816	ENSG00000243819.4	RN7SL832P	3.73	0.000217	0.0152	0.13	0.17	Prostate cancer;	chr2:10623274	chr2:10690344~10692099:+
THCA	cis	rs4664304	1	rs3806603	ENSG00000226266.5	AC009961.3	3.73	0.000217	0.0152	0.21	0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159905297	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.934	rs72957586	ENSG00000226266.5	AC009961.3	3.73	0.000217	0.0152	0.21	0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159906176	chr2:159670708~159712435:-
THCA	cis	rs73173548	0.502	rs13185071	ENSG00000247828.6	TMEM161B-AS1	3.73	0.000217	0.0152	0.16	0.17	Macular telangiectasia type 2;	chr5:88429895	chr5:88268895~88436685:+
THCA	cis	rs2880765	0.835	rs7169429	ENSG00000218052.5	ADAMTS7P4	-3.73	0.000217	0.0152	-0.19	-0.17	Coronary artery disease;	chr15:85493417	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs7168860	ENSG00000218052.5	ADAMTS7P4	-3.73	0.000217	0.0152	-0.19	-0.17	Coronary artery disease;	chr15:85493799	chr15:85255369~85330334:-
THCA	cis	rs12681366	0.553	rs2930967	ENSG00000261437.1	RP11-22C11.2	-3.73	0.000217	0.0152	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94450371	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.663	rs2919665	ENSG00000261437.1	RP11-22C11.2	3.73	0.000217	0.0152	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94453147	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.571	rs2930959	ENSG00000261437.1	RP11-22C11.2	3.73	0.000217	0.0152	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94461930	chr8:94637285~94639467:-
THCA	cis	rs2434529	0.531	rs76530294	ENSG00000245275.6	SAP30L-AS1	3.73	0.000217	0.0152	0.24	0.17	Autism spectrum disorder or schizophrenia;	chr5:154175575	chr5:154329437~154445850:-
THCA	cis	rs4713118	0.662	rs4713120	ENSG00000220721.1	OR1F12	3.73	0.000218	0.0152	0.19	0.17	Parkinson's disease;	chr6:27754056	chr6:28073316~28074233:+
THCA	cis	rs9788721	0.9	rs72740964	ENSG00000261762.1	RP11-650L12.2	-3.73	0.000218	0.0152	-0.22	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78576294	chr15:78589123~78591276:-
THCA	cis	rs4886920	0.894	rs7182697	ENSG00000260776.4	RP11-114H24.2	-3.73	0.000218	0.0152	-0.2	-0.17	Neuroticism;	chr15:77826282	chr15:77914217~77926846:-
THCA	cis	rs7554547	0.716	rs34954501	ENSG00000199347.1	RNU5E-1	3.73	0.000218	0.0152	0.23	0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11878146	chr1:11908152~11908271:+
THCA	cis	rs301901	0.698	rs4869505	ENSG00000250155.1	CTD-2353F22.1	3.73	0.000218	0.0152	0.17	0.17	Height;	chr5:37425888	chr5:36666214~36725195:-
THCA	cis	rs9527	0.637	rs7085104	ENSG00000213277.3	MARCKSL1P1	3.73	0.000218	0.0152	0.18	0.17	Arsenic metabolism;	chr10:102869116	chr10:103175554~103176094:+
THCA	cis	rs6479891	0.591	rs72824934	ENSG00000232075.1	MRPL35P2	3.73	0.000218	0.0152	0.27	0.17	Arthritis (juvenile idiopathic);	chr10:63106041	chr10:63634317~63634827:-
THCA	cis	rs988712	0.921	rs12224883	ENSG00000245573.6	BDNF-AS	-3.73	0.000218	0.0152	-0.15	-0.17	Obesity;	chr11:27567069	chr11:27506838~27698174:+
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000184274.3	LINC00315	-3.73	0.000218	0.0152	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45300245~45305257:-
THCA	cis	rs3820928	0.605	rs6748311	ENSG00000212391.1	SNORA48	-3.73	0.000218	0.0152	-0.19	-0.17	Pulmonary function;	chr2:226927814	chr2:226968989~226969122:-
THCA	cis	rs1560104	0.597	rs735820	ENSG00000260601.1	RP11-552C15.1	-3.73	0.000218	0.0152	-0.2	-0.17	Obesity-related traits;	chr16:12618269	chr16:12545482~12546684:+
THCA	cis	rs9834970	0.815	rs1553656	ENSG00000281100.1	RP11-640L9.2	3.73	0.000218	0.0152	0.17	0.17	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36818214	chr3:36823151~36825158:-
THCA	cis	rs7637701	0.773	rs4098	ENSG00000243926.1	TIPARP-AS1	3.73	0.000218	0.0152	0.17	0.17	Breast cancer;	chr3:156783274	chr3:156671862~156674378:-
THCA	cis	rs7819412	0.537	rs2127127	ENSG00000206014.6	OR7E161P	3.73	0.000218	0.0152	0.19	0.17	Triglycerides;	chr8:11577283	chr8:11928597~11929563:-
THCA	cis	rs910316	0.763	rs735452	ENSG00000259138.1	RP11-950C14.7	-3.73	0.000218	0.0152	-0.15	-0.17	Height;	chr14:75031281	chr14:75127153~75136930:+
THCA	cis	rs41294858	1	rs76732255	ENSG00000232876.1	CTA-212D2.2	-3.73	0.000218	0.0152	-0.35	-0.17	Red blood cell count;	chr6:135087334	chr6:135055033~135060550:+
THCA	cis	rs9527	0.614	rs4919691	ENSG00000213277.3	MARCKSL1P1	3.73	0.000218	0.0152	0.18	0.17	Arsenic metabolism;	chr10:102864718	chr10:103175554~103176094:+
THCA	cis	rs7119038	0.865	rs11217044	ENSG00000255422.1	AP002954.4	3.73	0.000218	0.0152	0.21	0.17	Sjögren's syndrome;	chr11:118825313	chr11:118704607~118750263:+
THCA	cis	rs9532669	0.926	rs7328139	ENSG00000229473.2	RGS17P1	3.73	0.000218	0.0152	0.22	0.17	Cervical cancer;	chr13:40862295	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7328145	ENSG00000229473.2	RGS17P1	3.73	0.000218	0.0152	0.22	0.17	Cervical cancer;	chr13:40862307	chr13:40992779~40993331:-
THCA	cis	rs11638352	1	rs12900880	ENSG00000166763.7	STRCP1	-3.73	0.000218	0.0152	-0.33	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44047400	chr15:43699488~43718184:-
THCA	cis	rs2882667	0.931	rs10044736	ENSG00000249593.5	CTB-46B19.2	-3.73	0.000218	0.0152	-0.2	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:139012647~139051203:+
THCA	cis	rs7560272	0.589	rs34874205	ENSG00000273245.1	RP11-434P11.2	-3.73	0.000218	0.0152	-0.2	-0.17	Schizophrenia;	chr2:73648331	chr2:73750256~73750786:-
THCA	cis	rs2301436	0.512	rs6925969	ENSG00000235272.1	FAM103A2P	3.73	0.000218	0.0152	0.23	0.17	Crohn's disease;	chr6:167088250	chr6:166586124~166586477:-
THCA	cis	rs4761470	0.577	rs7302972	ENSG00000258172.1	RP11-1105G2.4	-3.73	0.000218	0.0152	-0.23	-0.17	Estradiol plasma levels (breast cancer);	chr12:94288831	chr12:94272150~94277195:-
THCA	cis	rs6456156	0.792	rs10946215	ENSG00000235272.1	FAM103A2P	-3.73	0.000218	0.0152	-0.23	-0.17	Primary biliary cholangitis;	chr6:167102693	chr6:166586124~166586477:-
THCA	cis	rs14027	0.921	rs13262434	ENSG00000245330.4	KB-1471A8.1	3.73	0.000218	0.0152	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733423	chr8:119867419~119874488:-
THCA	cis	rs10186029	0.623	rs10497996	ENSG00000270659.1	RP11-105N14.1	-3.73	0.000218	0.0152	-0.14	-0.17	Systemic sclerosis;	chr2:213133141	chr2:213152970~213153659:+
THCA	cis	rs2239557	0.508	rs10483857	ENSG00000259065.1	RP5-1021I20.1	3.73	0.000218	0.0152	0.25	0.17	Common traits (Other);	chr14:73899508	chr14:73787360~73803270:+
THCA	cis	rs7914558	1	rs10748838	ENSG00000272912.1	RP11-724N1.1	-3.73	0.000218	0.0152	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184229	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs3758543	ENSG00000272912.1	RP11-724N1.1	-3.73	0.000218	0.0152	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184987	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs4917997	ENSG00000272912.1	RP11-724N1.1	-3.73	0.000218	0.0152	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185456	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs7077097	ENSG00000272912.1	RP11-724N1.1	-3.73	0.000218	0.0152	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185706	chr10:102914585~102915404:+
THCA	cis	rs11239930	0.538	rs604716	ENSG00000180867.10	PDIA3P1	3.73	0.000218	0.0152	0.16	0.17	AIDS progression;	chr1:147073173	chr1:147178113~147179622:+
THCA	cis	rs9796	0.87	rs2412574	ENSG00000247556.5	OIP5-AS1	3.73	0.000218	0.0152	0.13	0.17	Menopause (age at onset);	chr15:40967509	chr15:41283990~41309737:+
THCA	cis	rs3096299	0.503	rs9940093	ENSG00000223959.7	AFG3L1P	3.73	0.000218	0.0152	0.09	0.17	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89972586~90002161:+
THCA	cis	rs9393813	0.506	rs13201985	ENSG00000271755.1	RP1-153G14.4	3.73	0.000218	0.0152	0.2	0.17	Bipolar disorder;	chr6:27465854	chr6:27404010~27406964:-
THCA	cis	rs12681963	0.702	rs2136958	ENSG00000272375.1	RP11-51J9.6	3.73	0.000218	0.0152	0.19	0.17	Migraine;	chr8:30054156	chr8:30197404~30198048:+
THCA	cis	rs7267979	0.816	rs1044573	ENSG00000277938.1	RP5-965G21.3	3.73	0.000218	0.0152	0.14	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25229150~25231933:+
THCA	cis	rs2071852	0.627	rs12165498	ENSG00000280383.1	CTA-941F9.10	-3.73	0.000218	0.0152	-0.18	-0.17	Lobe attachment (rater-scored or self-reported);	chr22:45810820	chr22:45657019~45680130:+
THCA	cis	rs4869313	0.694	rs7700332	ENSG00000247121.5	CTD-2260A17.2	-3.73	0.000218	0.0152	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96971908	chr5:96814028~96935809:-
THCA	cis	rs11673344	0.526	rs35153242	ENSG00000267470.4	ZNF571-AS1	3.73	0.000218	0.0152	0.21	0.17	Obesity-related traits;	chr19:37660841	chr19:37548914~37587348:+
THCA	cis	rs234720	0.593	rs1788479	ENSG00000233754.1	AP001628.7	3.73	0.000218	0.0152	0.19	0.17	Cognitive performance;	chr21:43014726	chr21:42781074~42782233:-
THCA	cis	rs2179367	0.959	rs514839	ENSG00000223701.3	RAET1E-AS1	3.73	0.000218	0.0152	0.22	0.17	Dupuytren's disease;	chr6:149327304	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.959	rs536203	ENSG00000223701.3	RAET1E-AS1	3.73	0.000218	0.0152	0.22	0.17	Dupuytren's disease;	chr6:149330128	chr6:149884431~149919508:+
THCA	cis	rs67478160	0.619	rs10083370	ENSG00000258534.1	CTD-2134A5.4	3.73	0.000218	0.0152	0.17	0.17	Schizophrenia;	chr14:103847845	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.619	rs10083367	ENSG00000258534.1	CTD-2134A5.4	3.73	0.000218	0.0152	0.17	0.17	Schizophrenia;	chr14:103847846	chr14:103854366~103880111:-
THCA	cis	rs12621844	0.67	rs58178746	ENSG00000234690.5	AC073283.4	-3.73	0.000218	0.0152	-0.17	-0.17	Glycated hemoglobin levels;	chr2:48166780	chr2:47192405~47345074:-
THCA	cis	rs4713118	0.539	rs510987	ENSG00000220721.1	OR1F12	3.73	0.000218	0.0152	0.21	0.17	Parkinson's disease;	chr6:27879739	chr6:28073316~28074233:+
THCA	cis	rs6963495	0.818	rs56251768	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105525144	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs56177071	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105525201	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs55794529	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105525300	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190200	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105525409	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.799	rs73190201	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105525444	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190202	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105526063	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs56268110	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105526265	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs55825845	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105526266	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.769	rs117986187	ENSG00000272604.1	RP11-251G23.5	3.73	0.000218	0.0152	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105526864	chr7:105571083~105573660:+
THCA	cis	rs11048434	0.518	rs7136274	ENSG00000256720.1	RP11-436I9.6	3.73	0.000218	0.0152	0.18	0.17	Sjögren's syndrome;	chr12:9022360	chr12:9135084~9135591:+
THCA	cis	rs2820315	1	rs2820309	ENSG00000223774.4	RP11-307B6.3	3.73	0.000218	0.0153	0.19	0.17	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201865816	chr1:201893842~201899978:+
THCA	cis	rs7701440	0.512	rs2055375	ENSG00000251279.1	CTC-436P18.1	3.73	0.000218	0.0153	0.2	0.17	Educational attainment;	chr5:61235393	chr5:61162070~61232040:+
THCA	cis	rs13053817	1	rs71329487	ENSG00000279159.1	RP3-394A18.1	3.73	0.000218	0.0153	0.17	0.17	Carotid atherosclerosis in HIV infection;	chr22:29437480	chr22:29978950~30028236:-
THCA	cis	rs17772222	0.511	rs3850392	ENSG00000222990.1	RNU4-22P	3.73	0.000218	0.0153	0.19	0.17	Coronary artery calcification;	chr14:88833286	chr14:88513498~88513663:+
THCA	cis	rs17772222	0.511	rs7155535	ENSG00000222990.1	RNU4-22P	3.73	0.000218	0.0153	0.19	0.17	Coronary artery calcification;	chr14:88844002	chr14:88513498~88513663:+
THCA	cis	rs11671005	0.611	rs56026876	ENSG00000252334.1	RNU6-1337P	3.73	0.000218	0.0153	0.25	0.17	Mean platelet volume;	chr19:58494790	chr19:58483749~58483843:-
THCA	cis	rs520525	0.963	rs663887	ENSG00000271811.1	RP1-79C4.4	3.73	0.000218	0.0153	0.21	0.17	Atrial fibrillation;	chr1:170657812	chr1:170667381~170669425:+
THCA	cis	rs10090774	0.93	rs4961293	ENSG00000280303.2	ERICD	3.73	0.000218	0.0153	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140802275	chr8:140636281~140638283:+
THCA	cis	rs11583043	0.958	rs12730160	ENSG00000233184.5	RP11-421L21.3	3.73	0.000218	0.0153	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:100973235	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.874	rs41312668	ENSG00000233184.5	RP11-421L21.3	3.73	0.000218	0.0153	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:100978026	chr1:101025878~101087268:+
THCA	cis	rs2880765	0.835	rs4842886	ENSG00000218052.5	ADAMTS7P4	-3.73	0.000218	0.0153	-0.19	-0.17	Coronary artery disease;	chr15:85492542	chr15:85255369~85330334:-
THCA	cis	rs7074356	0.831	rs12764048	ENSG00000225484.5	NUTM2B-AS1	-3.73	0.000218	0.0153	-0.3	-0.17	Borderline personality disorder;	chr10:80389207	chr10:79663088~79826594:-
THCA	cis	rs728616	0.558	rs61859215	ENSG00000225484.5	NUTM2B-AS1	-3.73	0.000218	0.0153	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391392	chr10:79663088~79826594:-
THCA	cis	rs728616	0.558	rs72817596	ENSG00000225484.5	NUTM2B-AS1	-3.73	0.000218	0.0153	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391838	chr10:79663088~79826594:-
THCA	cis	rs3087591	0.708	rs1129506	ENSG00000263535.1	AK4P1	3.73	0.000218	0.0153	0.2	0.17	Hip circumference;	chr17:31319014	chr17:31345521~31346187:+
THCA	cis	rs9926296	0.706	rs2159115	ENSG00000274627.1	RP11-104N10.2	-3.73	0.000218	0.0153	-0.18	-0.17	Vitiligo;	chr16:89765411	chr16:89516797~89522217:+
THCA	cis	rs13217239	0.511	rs3800314	ENSG00000216901.1	AL022393.7	3.73	0.000218	0.0153	0.21	0.17	Schizophrenia;	chr6:27268269	chr6:28176188~28176674:+
THCA	cis	rs1580019	0.539	rs11769109	ENSG00000273014.1	RP11-225B17.2	3.73	0.000218	0.0153	0.17	0.17	Cognitive ability;	chr7:32531740	chr7:32758882~32759353:+
THCA	cis	rs7572644	0.766	rs11886375	ENSG00000223522.1	AC093690.1	-3.73	0.000218	0.0153	-0.22	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27932881	chr2:28307691~28310459:-
THCA	cis	rs78153629	1	rs78153629	ENSG00000259330.1	INAFM2	-3.73	0.000218	0.0153	-0.19	-0.17	Heschl's gyrus morphology;	chr15:40381264	chr15:40325216~40326715:+
THCA	cis	rs78153629	1	rs77531164	ENSG00000259330.1	INAFM2	-3.73	0.000218	0.0153	-0.19	-0.17	Heschl's gyrus morphology;	chr15:40381265	chr15:40325216~40326715:+
THCA	cis	rs2228479	0.702	rs2074963	ENSG00000274627.1	RP11-104N10.2	-3.73	0.000219	0.0153	-0.29	-0.17	Skin colour saturation;	chr16:89810861	chr16:89516797~89522217:+
THCA	cis	rs765787	0.53	rs7167389	ENSG00000259932.1	CTD-2651B20.7	3.73	0.000219	0.0153	0.21	0.17	Uric acid levels;	chr15:45243485	chr15:45198517~45199139:-
THCA	cis	rs7824557	0.525	rs12682349	ENSG00000255046.1	RP11-297N6.4	-3.73	0.000219	0.0153	-0.18	-0.17	Retinal vascular caliber;	chr8:11387794	chr8:11797928~11802568:-
THCA	cis	rs17685	0.753	rs2868203	ENSG00000227038.2	AC005077.12	-3.73	0.000219	0.0153	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76050708	chr7:76090431~76108779:-
THCA	cis	rs2590942	0.73	rs61765646	ENSG00000227207.2	RPL31P12	3.73	0.000219	0.0153	0.28	0.17	Childhood body mass index;	chr1:72257528	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.783	rs34723450	ENSG00000227207.2	RPL31P12	3.73	0.000219	0.0153	0.28	0.17	Childhood body mass index;	chr1:72258726	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.783	rs34376163	ENSG00000227207.2	RPL31P12	3.73	0.000219	0.0153	0.28	0.17	Childhood body mass index;	chr1:72273016	chr1:72301472~72301829:+
THCA	cis	rs2590942	0.838	rs34020954	ENSG00000227207.2	RPL31P12	3.73	0.000219	0.0153	0.28	0.17	Childhood body mass index;	chr1:72276704	chr1:72301472~72301829:+
THCA	cis	rs12051443	1	rs12051443	ENSG00000260185.1	RP11-432I5.6	-3.73	0.000219	0.0153	-0.23	-0.17	Prostate cancer;	chr16:71657426	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs2303224	ENSG00000260185.1	RP11-432I5.6	-3.73	0.000219	0.0153	-0.23	-0.17	Blood protein levels;	chr16:71658540	chr16:71655027~71664212:+
THCA	cis	rs17286411	0.671	rs62053107	ENSG00000260185.1	RP11-432I5.6	-3.73	0.000219	0.0153	-0.23	-0.17	Blood protein levels;	chr16:71660308	chr16:71655027~71664212:+
THCA	cis	rs7737355	1	rs76753180	ENSG00000237714.1	P4HA2-AS1	-3.73	0.000219	0.0153	-0.24	-0.17	Life satisfaction;	chr5:131428008	chr5:132184876~132192808:+
THCA	cis	rs10090774	0.965	rs45613837	ENSG00000279766.1	RP11-642A1.2	3.73	0.000219	0.0153	0.21	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140734818	chr8:140572142~140572812:-
THCA	cis	rs9987353	0.522	rs2929466	ENSG00000248538.5	RP11-10A14.5	3.73	0.000219	0.0153	0.21	0.17	Recombination measurement;	chr8:9206389	chr8:9189011~9202854:+
THCA	cis	rs12190007	0.547	rs1018559	ENSG00000226194.4	RP1-137D17.1	3.73	0.000219	0.0153	0.21	0.17	Obesity-related traits;	chr6:169454081	chr6:169369998~169388385:-
THCA	cis	rs786425	0.682	rs11612479	ENSG00000278112.1	RP11-972P1.11	3.73	0.000219	0.0153	0.17	0.17	Pubertal anthropometrics;	chr12:123670979	chr12:123519390~123519856:-
THCA	cis	rs4906332	0.966	rs12894275	ENSG00000259775.1	RP11-45P15.4	3.73	0.000219	0.0153	0.14	0.17	Coronary artery disease;	chr14:103435087	chr14:103331674~103332367:-
THCA	cis	rs73193808	0.666	rs7276548	ENSG00000231125.2	AF129075.5	-3.73	0.000219	0.0153	-0.16	-0.17	Coronary artery disease;	chr21:29180518	chr21:29058073~29060095:-
THCA	cis	rs3770081	1	rs3770089	ENSG00000273080.1	RP11-301O19.1	-3.73	0.000219	0.0153	-0.39	-0.17	Facial emotion recognition (sad faces);	chr2:86036692	chr2:86195590~86196049:+
THCA	cis	rs4803480	1	rs3745937	ENSG00000270164.1	LINC01480	-3.73	0.000219	0.0153	-0.18	-0.17	Schizophrenia;	chr19:41564935	chr19:41535183~41536904:+
THCA	cis	rs11098499	0.826	rs4472123	ENSG00000249244.1	RP11-548H18.2	3.73	0.000219	0.0153	0.19	0.17	Corneal astigmatism;	chr4:119315475	chr4:119391831~119395335:-
THCA	cis	rs6137726	0.508	rs2424451	ENSG00000237396.1	LINC01384	3.73	0.000219	0.0153	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22662187	chr20:22587522~22607517:-
THCA	cis	rs9475752	0.53	rs9396250	ENSG00000231441.1	RP11-472M19.2	-3.73	0.000219	0.0153	-0.18	-0.17	Menarche (age at onset);	chr6:57006499	chr6:56844002~56864078:+
THCA	cis	rs7619427	0.591	rs7639728	ENSG00000271192.1	RP4-555D20.3	3.73	0.000219	0.0153	0.22	0.17	Schizophrenia;	chr3:44029914	chr3:43996896~43997443:+
THCA	cis	rs7619427	0.556	rs1524886	ENSG00000271192.1	RP4-555D20.3	3.73	0.000219	0.0153	0.22	0.17	Schizophrenia;	chr3:44030230	chr3:43996896~43997443:+
THCA	cis	rs7619427	0.556	rs9311348	ENSG00000271192.1	RP4-555D20.3	3.73	0.000219	0.0153	0.22	0.17	Schizophrenia;	chr3:44031058	chr3:43996896~43997443:+
THCA	cis	rs7619427	0.507	rs9863975	ENSG00000271192.1	RP4-555D20.3	3.73	0.000219	0.0153	0.22	0.17	Schizophrenia;	chr3:44032963	chr3:43996896~43997443:+
THCA	cis	rs7619427	0.591	rs7611726	ENSG00000271192.1	RP4-555D20.3	3.73	0.000219	0.0153	0.22	0.17	Schizophrenia;	chr3:44035463	chr3:43996896~43997443:+
THCA	cis	rs494526	0.641	rs10886381	ENSG00000229272.1	RP11-498J9.2	3.73	0.000219	0.0153	0.2	0.17	Alcoholic chronic pancreatitis;	chr10:119093142	chr10:119003536~119003884:-
THCA	cis	rs853679	0.542	rs9393892	ENSG00000219891.2	ZSCAN12P1	3.73	0.000219	0.0153	0.24	0.17	Depression;	chr6:28113616	chr6:28091154~28093664:+
THCA	cis	rs875971	0.522	rs709604	ENSG00000230295.1	RP11-458F8.2	3.73	0.000219	0.0153	0.13	0.17	Aortic root size;	chr7:66032447	chr7:66880708~66882981:+
THCA	cis	rs6724465	1	rs6436106	ENSG00000272644.1	RP11-33O4.1	3.73	0.000219	0.0153	0.26	0.17	Height;	chr2:219062191	chr2:219069354~219069809:-
THCA	cis	rs6724465	1	rs7595949	ENSG00000272644.1	RP11-33O4.1	3.73	0.000219	0.0153	0.26	0.17	Height;	chr2:219062496	chr2:219069354~219069809:-
THCA	cis	rs2562456	0.761	rs35008138	ENSG00000268658.4	LINC00664	3.73	0.000219	0.0153	0.24	0.17	Pain;	chr19:21548822	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.833	rs2681388	ENSG00000268658.4	LINC00664	3.73	0.000219	0.0153	0.24	0.17	Pain;	chr19:21549451	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.876	rs2681370	ENSG00000268658.4	LINC00664	3.73	0.000219	0.0153	0.24	0.17	Pain;	chr19:21554036	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.876	rs11668606	ENSG00000268658.4	LINC00664	3.73	0.000219	0.0153	0.24	0.17	Pain;	chr19:21554618	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.876	rs2681395	ENSG00000268658.4	LINC00664	3.73	0.000219	0.0153	0.24	0.17	Pain;	chr19:21555338	chr19:21483374~21503238:+
THCA	cis	rs765787	0.53	rs11636404	ENSG00000259932.1	CTD-2651B20.7	3.73	0.000219	0.0153	0.21	0.17	Uric acid levels;	chr15:45243663	chr15:45198517~45199139:-
THCA	cis	rs7219021	0.739	rs4793993	ENSG00000248278.1	SUMO2P17	-3.73	0.000219	0.0153	-0.22	-0.17	Schizophrenia or bipolar disorder;	chr17:48931184	chr17:48874860~48908983:-
THCA	cis	rs10929956	0.593	rs61010155	ENSG00000226266.5	AC009961.3	3.73	0.000219	0.0153	0.2	0.17	Crohn's disease-related phenotypes;	chr2:159842655	chr2:159670708~159712435:-
THCA	cis	rs1127311	0.846	rs61811388	ENSG00000236675.1	MTX1P1	-3.73	0.000219	0.0153	-0.15	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154608755	chr1:155230975~155234325:+
THCA	cis	rs9863	0.828	rs4765127	ENSG00000270028.1	RP11-380L11.4	3.73	0.000219	0.0153	0.18	0.17	White blood cell count;	chr12:123975620	chr12:123925461~123926083:-
THCA	cis	rs6504622	0.818	rs758391	ENSG00000238419.1	RNU7-186P	3.73	0.000219	0.0153	0.19	0.17	Orofacial clefts;	chr17:46939875	chr17:47259358~47259420:-
THCA	cis	rs2692947	0.683	rs62153700	ENSG00000235584.2	AC008268.1	-3.73	0.000219	0.0153	-0.19	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95915590	chr2:95666084~95668715:+
THCA	cis	rs1376303	0.643	rs4723222	ENSG00000205763.12	RP9P	-3.73	0.000219	0.0153	-0.22	-0.17	Intelligence (multi-trait analysis);	chr7:32918049	chr7:32916815~32943176:-
THCA	cis	rs721917	0.531	rs2256167	ENSG00000225484.5	NUTM2B-AS1	3.73	0.000219	0.0153	0.21	0.17	Chronic obstructive pulmonary disease;	chr10:79928592	chr10:79663088~79826594:-
THCA	cis	rs11992162	0.597	rs7016320	ENSG00000254948.1	OR7E158P	3.73	0.000219	0.0153	0.21	0.17	Monocyte count;	chr8:11923543	chr8:11919900~11920809:-
THCA	cis	rs1023500	0.573	rs13057094	ENSG00000270083.1	RP1-257I20.14	3.73	0.000219	0.0153	0.2	0.17	Schizophrenia;	chr22:42074313	chr22:42089630~42090028:-
THCA	cis	rs7176527	0.796	rs72630464	ENSG00000230373.7	GOLGA6L5P	3.73	0.000219	0.0153	0.24	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84754895	chr15:84507885~84516814:-
THCA	cis	rs11048434	0.518	rs4883206	ENSG00000256720.1	RP11-436I9.6	-3.73	0.000219	0.0153	-0.18	-0.17	Sjögren's syndrome;	chr12:9021169	chr12:9135084~9135591:+
THCA	cis	rs2179367	0.959	rs579789	ENSG00000223701.3	RAET1E-AS1	3.73	0.000219	0.0153	0.22	0.17	Dupuytren's disease;	chr6:149358235	chr6:149884431~149919508:+
THCA	cis	rs10540	1	rs12788729	ENSG00000279672.1	CMB9-55F22.1	3.73	0.000219	0.0153	0.33	0.17	Body mass index;	chr11:502371	chr11:779617~780755:+
THCA	cis	rs10844706	0.699	rs2058560	ENSG00000214776.8	RP11-726G1.1	3.72	0.000219	0.0153	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721093	chr12:9467552~9576275:+
THCA	cis	rs7246657	0.722	rs3095726	ENSG00000226686.6	LINC01535	3.72	0.000219	0.0153	0.25	0.17	Coronary artery calcification;	chr19:37738923	chr19:37251912~37265535:+
THCA	cis	rs4761702	0.527	rs12824664	ENSG00000257322.4	RP11-511B23.2	-3.72	0.000219	0.0153	-0.22	-0.17	Immature fraction of reticulocytes;	chr12:93343125	chr12:93003415~93215679:-
THCA	cis	rs910316	0.591	rs7157158	ENSG00000259138.1	RP11-950C14.7	3.72	0.000219	0.0153	0.15	0.17	Height;	chr14:74990535	chr14:75127153~75136930:+
THCA	cis	rs7542375	0.576	rs56347111	ENSG00000238078.1	LINC01352	-3.72	0.000219	0.0153	-0.26	-0.17	Obesity-related traits;	chr1:220887774	chr1:220829255~220832429:+
THCA	cis	rs11756659	0.653	rs199729	ENSG00000272462.2	U91328.19	3.72	0.000219	0.0153	0.16	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25949687	chr6:25992662~26001775:+
THCA	cis	rs2408955	0.522	rs11168408	ENSG00000257735.1	RP11-370I10.6	-3.72	0.000219	0.0153	-0.2	-0.17	Glycated hemoglobin levels;	chr12:48104544	chr12:48350945~48442411:+
THCA	cis	rs321358	0.895	rs7950087	ENSG00000271390.1	RP11-89C3.3	-3.72	0.000219	0.0153	-0.27	-0.17	Body mass index;	chr11:111082536	chr11:111089870~111090368:-
THCA	cis	rs2836974	0.897	rs1541102	ENSG00000255568.3	BRWD1-AS2	3.72	0.000219	0.0153	0.15	0.17	Cognitive function;	chr21:39256839	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.831	rs2836964	ENSG00000255568.3	BRWD1-AS2	3.72	0.000219	0.0153	0.15	0.17	Cognitive function;	chr21:39259080	chr21:39313935~39314962:+
THCA	cis	rs6600671	1	rs1832558	ENSG00000275585.1	CH17-118O6.3	-3.72	0.000219	0.0153	-0.2	-0.17	Hip geometry;	chr1:121435521	chr1:120985692~121052167:-
THCA	cis	rs7829975	0.714	rs4840362	ENSG00000253981.4	ALG1L13P	-3.72	0.000219	0.0153	-0.16	-0.17	Mood instability;	chr8:8812572	chr8:8236003~8244667:-
THCA	cis	rs7209700	1	rs7209700	ENSG00000228782.6	CTD-2026D20.3	-3.72	0.000219	0.0153	-0.17	-0.17	IgG glycosylation;	chr17:47273752	chr17:47450568~47492492:-
THCA	cis	rs13256369	0.802	rs13280101	ENSG00000254153.1	CTA-398F10.2	-3.72	0.000219	0.0153	-0.19	-0.17	Obesity-related traits;	chr8:8705263	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.802	rs13255789	ENSG00000254153.1	CTA-398F10.2	-3.72	0.000219	0.0153	-0.19	-0.17	Obesity-related traits;	chr8:8705281	chr8:8456909~8461337:-
THCA	cis	rs1510552	0.751	rs11900486	ENSG00000270659.1	RP11-105N14.1	3.72	0.000219	0.0153	0.16	0.17	Contrast sensitivity;	chr2:214137524	chr2:213152970~213153659:+
THCA	cis	rs394563	0.601	rs376269	ENSG00000231760.4	RP11-350J20.5	3.72	0.000219	0.0153	0.23	0.17	Dupuytren's disease;	chr6:149474018	chr6:149796151~149826294:-
THCA	cis	rs14027	0.883	rs28486074	ENSG00000245330.4	KB-1471A8.1	3.72	0.000219	0.0153	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720762	chr8:119867419~119874488:-
THCA	cis	rs14027	0.842	rs28634937	ENSG00000245330.4	KB-1471A8.1	3.72	0.000219	0.0153	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720877	chr8:119867419~119874488:-
THCA	cis	rs11710088	0.895	rs34897827	ENSG00000240541.2	TM4SF1-AS1	3.72	0.000219	0.0153	0.16	0.17	QRS duration;	chr3:149480543	chr3:149377778~149386583:+
THCA	cis	rs11710088	0.931	rs6440617	ENSG00000240541.2	TM4SF1-AS1	3.72	0.000219	0.0153	0.16	0.17	QRS duration;	chr3:149481139	chr3:149377778~149386583:+
THCA	cis	rs9527	0.518	rs10883802	ENSG00000236937.2	PTGES3P4	-3.72	0.000219	0.0153	-0.3	-0.17	Arsenic metabolism;	chr10:102920605	chr10:102845595~102845950:+
THCA	cis	rs2904524	0.588	rs12317962	ENSG00000257815.4	RP11-611E13.2	-3.72	0.000219	0.0153	-0.13	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70398802	chr12:69904033~70243360:-
THCA	cis	rs9863	0.896	rs34854841	ENSG00000270028.1	RP11-380L11.4	3.72	0.000219	0.0153	0.18	0.17	White blood cell count;	chr12:123966957	chr12:123925461~123926083:-
THCA	cis	rs7259376	0.869	rs4932984	ENSG00000269345.1	VN1R85P	3.72	0.000219	0.0153	0.18	0.17	Menopause (age at onset);	chr19:22350453	chr19:22174766~22175191:-
THCA	cis	rs1950832	0.723	rs6572104	ENSG00000258636.1	CTD-2298J14.2	-3.72	0.000219	0.0153	-0.23	-0.17	Urate levels in obese individuals;	chr14:41671064	chr14:41587861~41604856:-
THCA	cis	rs745109	0.504	rs74432925	ENSG00000273080.1	RP11-301O19.1	3.72	0.000219	0.0153	0.3	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86386592	chr2:86195590~86196049:+
THCA	cis	rs7010267	0.773	rs13277230	ENSG00000254278.1	RP11-278I4.2	3.72	0.000219	0.0153	0.21	0.17	Total body bone mineral density (age 45-60);	chr8:118910754	chr8:119062942~119068782:-
THCA	cis	rs7829975	0.501	rs2980769	ENSG00000253981.4	ALG1L13P	3.72	0.000219	0.0153	0.16	0.17	Mood instability;	chr8:8462781	chr8:8236003~8244667:-
THCA	cis	rs9926296	0.605	rs1800287	ENSG00000274627.1	RP11-104N10.2	-3.72	0.000219	0.0153	-0.17	-0.17	Vitiligo;	chr16:89792117	chr16:89516797~89522217:+
THCA	cis	rs9926296	0.605	rs6500453	ENSG00000274627.1	RP11-104N10.2	-3.72	0.000219	0.0153	-0.17	-0.17	Vitiligo;	chr16:89792249	chr16:89516797~89522217:+
THCA	cis	rs10090774	0.965	rs11990900	ENSG00000280303.2	ERICD	-3.72	0.000219	0.0153	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140967821	chr8:140636281~140638283:+
THCA	cis	rs1039766	0.706	rs72822420	ENSG00000204929.10	AC074391.1	-3.72	0.000219	0.0153	-0.36	-0.17	Lung adenocarcinoma;Lung cancer;	chr2:65286633	chr2:65436711~66084639:+
THCA	cis	rs7836436	0.686	rs72673639	ENSG00000245330.4	KB-1471A8.1	-3.72	0.00022	0.0153	-0.26	-0.17	HIV-1 viral setpoint;	chr8:119936037	chr8:119867419~119874488:-
THCA	cis	rs4908760	0.827	rs1463053	ENSG00000270282.1	RP5-1115A15.2	3.72	0.00022	0.0153	0.2	0.17	Vitiligo;	chr1:8644978	chr1:8512653~8513021:+
THCA	cis	rs17689437	0.813	rs11075691	ENSG00000260084.1	RP11-615I2.1	-3.72	0.00022	0.0153	-0.24	-0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68631352	chr16:68573782~68589512:-
THCA	cis	rs11971779	0.715	rs10954646	ENSG00000252332.1	RNU6-911P	3.72	0.00022	0.0153	0.2	0.17	Diisocyanate-induced asthma;	chr7:139376323	chr7:139448740~139448843:+
THCA	cis	rs73173548	0.502	rs4423262	ENSG00000247828.6	TMEM161B-AS1	3.72	0.00022	0.0153	0.16	0.17	Macular telangiectasia type 2;	chr5:88438609	chr5:88268895~88436685:+
THCA	cis	rs854765	0.624	rs12946746	ENSG00000281749.1	Y_RNA	-3.72	0.00022	0.0153	-0.22	-0.17	Total body bone mineral density;	chr17:17838355	chr17:18001101~18001195:-
THCA	cis	rs854765	0.624	rs7359509	ENSG00000281749.1	Y_RNA	-3.72	0.00022	0.0153	-0.22	-0.17	Total body bone mineral density;	chr17:17838561	chr17:18001101~18001195:-
THCA	cis	rs7665090	1	rs735403	ENSG00000248971.2	KRT8P46	3.72	0.00022	0.0153	0.2	0.17	Primary biliary cholangitis;	chr4:102632386	chr4:102728746~102730171:-
THCA	cis	rs10043228	1	rs62384493	ENSG00000248445.4	SEMA6A-AS1	-3.72	0.00022	0.0153	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116337751	chr5:116447547~116508276:+
THCA	cis	rs9309473	1	rs6546835	ENSG00000273245.1	RP11-434P11.2	3.72	0.00022	0.0153	0.23	0.17	Metabolite levels;	chr2:73437587	chr2:73750256~73750786:-
THCA	cis	rs17181170	0.967	rs55669402	ENSG00000239572.1	RP11-451B8.1	-3.72	0.00022	0.0153	-0.19	-0.17	Prostate cancer;	chr3:87125935	chr3:87731402~87793629:-
THCA	cis	rs6137726	0.529	rs2224316	ENSG00000237396.1	LINC01384	3.72	0.00022	0.0153	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22651202	chr20:22587522~22607517:-
THCA	cis	rs6142618	0.806	rs2424886	ENSG00000224452.1	RSL24D1P6	-3.72	0.00022	0.0153	-0.21	-0.17	Inflammatory bowel disease;	chr20:32396970	chr20:32170390~32170790:-
THCA	cis	rs301807	0.533	rs1466655	ENSG00000232912.4	RP5-1115A15.1	3.72	0.00022	0.0153	0.16	0.17	Vitiligo;Sum eosinophil basophil counts;	chr1:8315782	chr1:8424645~8434838:+
THCA	cis	rs2115630	0.905	rs1975277	ENSG00000259295.5	CSPG4P12	-3.72	0.00022	0.0153	-0.22	-0.17	P wave terminal force;	chr15:84786327	chr15:85191438~85213905:+
THCA	cis	rs2562456	0.833	rs2650776	ENSG00000268278.1	RP11-420K14.1	3.72	0.00022	0.0153	0.24	0.17	Pain;	chr19:21430595	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs2562416	ENSG00000268278.1	RP11-420K14.1	3.72	0.00022	0.0153	0.24	0.17	Pain;	chr19:21430609	chr19:21637974~21656300:+
THCA	cis	rs7911264	0.739	rs7914814	ENSG00000236493.2	EIF2S2P3	3.72	0.00022	0.0153	0.18	0.17	Inflammatory bowel disease;	chr10:92623193	chr10:92668745~92669743:-
THCA	cis	rs18122	0.846	rs6743811	ENSG00000236780.4	AC078941.1	3.72	0.00022	0.0153	0.23	0.17	Waist-to-hip ratio adjusted for body mass index;	chr2:67393025	chr2:67123357~67215319:-
THCA	cis	rs9309473	1	rs11674602	ENSG00000273245.1	RP11-434P11.2	3.72	0.00022	0.0153	0.23	0.17	Metabolite levels;	chr2:73496058	chr2:73750256~73750786:-
THCA	cis	rs748404	0.666	rs7177146	ENSG00000166763.7	STRCP1	3.72	0.00022	0.0153	0.22	0.17	Lung cancer;	chr15:43506110	chr15:43699488~43718184:-
THCA	cis	rs62380364	0.727	rs216057	ENSG00000247828.6	TMEM161B-AS1	3.72	0.00022	0.0153	0.13	0.17	Intelligence (multi-trait analysis);	chr5:88874514	chr5:88268895~88436685:+
THCA	cis	rs972578	0.776	rs3827363	ENSG00000274717.1	RP1-47A17.1	-3.72	0.00022	0.0153	-0.17	-0.17	Mean platelet volume;	chr22:42931581	chr22:42791814~42794313:-
THCA	cis	rs9467773	0.583	rs2498380	ENSG00000228223.2	HCG11	3.72	0.00022	0.0153	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26523450~26526579:+
THCA	cis	rs115575488	0.85	rs116448534	ENSG00000231365.4	RP11-418J17.1	3.72	0.00022	0.0154	0.27	0.17	Lobe attachment (rater-scored or self-reported);	chr1:119144589	chr1:119140396~119275973:+
THCA	cis	rs4746818	1	rs7901617	ENSG00000229001.1	ACTBP14	-3.72	0.00022	0.0154	-0.27	-0.17	Left atrial antero-posterior diameter;	chr10:69144307	chr10:69022778~69023866:+
THCA	cis	rs7267979	0.966	rs4815425	ENSG00000276952.1	RP5-965G21.6	-3.72	0.00022	0.0154	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25284915~25285588:-
THCA	cis	rs4448343	0.736	rs2236407	ENSG00000271155.1	RP11-435O5.5	-3.72	0.00022	0.0154	-0.17	-0.17	Height;	chr9:95475514	chr9:95506235~95507636:+
THCA	cis	rs2427308	0.643	rs477859	ENSG00000275437.1	RP5-908M14.10	-3.72	0.00022	0.0154	-0.17	-0.17	Colorectal cancer;	chr20:62362541	chr20:62402236~62405935:-
THCA	cis	rs9925964	0.933	rs881929	ENSG00000279196.1	RP11-1072A3.3	-3.72	0.00022	0.0154	-0.16	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31068050	chr16:30984630~30988270:-
THCA	cis	rs9308731	0.563	rs6760053	ENSG00000227992.1	AC108463.2	-3.72	0.00022	0.0154	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111175420	chr2:111203964~111206215:-
THCA	cis	rs875971	0.545	rs2460427	ENSG00000273024.4	INTS4P2	3.72	0.00022	0.0154	0.21	0.17	Aortic root size;	chr7:66154218	chr7:65647864~65715661:+
THCA	cis	rs838886	0.956	rs838882	ENSG00000275389.1	RP11-214K3.24	-3.72	0.00022	0.0154	-0.23	-0.17	HDL cholesterol;	chr12:124777267	chr12:124085761~124088598:+
THCA	cis	rs4538475	0.556	rs4266290	ENSG00000273133.1	RP11-799M12.2	-3.72	0.00022	0.0154	-0.23	-0.17	Parkinson's disease;	chr4:15735495	chr4:15563698~15564253:-
THCA	cis	rs901683	1	rs9422652	ENSG00000230869.1	CTGLF10P	-3.72	0.00022	0.0154	-0.39	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45552486	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs9422441	ENSG00000230869.1	CTGLF10P	-3.72	0.00022	0.0154	-0.39	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45552605	chr10:45678692~45700532:+
THCA	cis	rs757978	1	rs73116394	ENSG00000235351.1	AC114730.11	-3.72	0.00022	0.0154	-0.17	-0.17	Chronic lymphocytic leukemia;	chr2:241428500	chr2:241724615~241725693:-
THCA	cis	rs757978	1	rs73116396	ENSG00000235351.1	AC114730.11	-3.72	0.00022	0.0154	-0.17	-0.17	Chronic lymphocytic leukemia;	chr2:241429278	chr2:241724615~241725693:-
THCA	cis	rs4869313	0.668	rs2548529	ENSG00000247121.5	CTD-2260A17.2	3.72	0.00022	0.0154	0.13	0.17	Pediatric autoimmune diseases;	chr5:96904516	chr5:96814028~96935809:-
THCA	cis	rs7819412	0.74	rs11250119	ENSG00000254866.2	DEFB109P3	3.72	0.00022	0.0154	0.23	0.17	Triglycerides;	chr8:11179525	chr8:12150895~12151134:-
THCA	cis	rs2638953	0.741	rs10843194	ENSG00000247934.4	RP11-967K21.1	-3.72	0.00022	0.0154	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510237	chr12:28163298~28190738:-
THCA	cis	rs728616	0.681	rs117420340	ENSG00000278616.1	BEND3P3	3.72	0.00022	0.0154	0.17	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406739	chr10:79682997~79685436:+
THCA	cis	rs6545883	0.868	rs2518933	ENSG00000212978.6	AC016747.3	3.72	0.00022	0.0154	0.18	0.17	Tuberculosis;	chr2:61569895	chr2:61141592~61144969:-
THCA	cis	rs7737355	0.579	rs17171380	ENSG00000224431.1	AC063976.7	-3.72	0.00022	0.0154	-0.24	-0.17	Life satisfaction;	chr5:131684402	chr5:132199456~132203487:+
THCA	cis	rs7520050	0.933	rs11211203	ENSG00000280836.1	AL355480.1	3.72	0.00022	0.0154	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs4660317	ENSG00000280836.1	AL355480.1	3.72	0.00022	0.0154	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs10749860	ENSG00000280836.1	AL355480.1	3.72	0.00022	0.0154	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs6688365	ENSG00000280836.1	AL355480.1	3.72	0.00022	0.0154	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6656992	ENSG00000280836.1	AL355480.1	3.72	0.00022	0.0154	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs61783220	ENSG00000280836.1	AL355480.1	3.72	0.00022	0.0154	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45581219~45581321:-
THCA	cis	rs2455799	0.613	rs3856830	ENSG00000270409.1	RP11-44D5.1	-3.72	0.00022	0.0154	-0.18	-0.17	Mean platelet volume;	chr3:15765013	chr3:15732252~15733470:+
THCA	cis	rs600231	0.706	rs4244811	ENSG00000260233.3	SSSCA1-AS1	-3.72	0.00022	0.0154	-0.13	-0.17	Bone mineral density;	chr11:65553309	chr11:65568482~65570423:-
THCA	cis	rs6995541	0.565	rs6601533	ENSG00000248896.2	CTD-2135J3.3	-3.72	0.00022	0.0154	-0.2	-0.17	Triglyceride levels;	chr8:10830338	chr8:10729314~10771392:+
THCA	cis	rs12476592	0.714	rs262494	ENSG00000242412.1	DBIL5P2	3.72	0.00022	0.0154	0.22	0.17	Childhood ear infection;	chr2:63618350	chr2:63117851~63119542:-
THCA	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	3.72	0.00022	0.0154	0.22	0.17	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
THCA	cis	rs8177876	0.822	rs7203546	ENSG00000261838.4	RP11-303E16.6	-3.72	0.00022	0.0154	-0.27	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81069854~81076598:+
THCA	cis	rs7911264	0.703	rs7894183	ENSG00000232709.1	MARK2P9	-3.72	0.00022	0.0154	-0.21	-0.17	Inflammatory bowel disease;	chr10:92622283	chr10:92418667~92420875:+
THCA	cis	rs62458065	0.64	rs10274556	ENSG00000231952.3	DPY19L1P2	3.72	0.00022	0.0154	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32474335	chr7:32812757~32838570:+
THCA	cis	rs10938353	0.68	rs66829609	ENSG00000273369.1	RP11-700J17.1	3.72	0.00022	0.0154	0.2	0.17	Body mass index;	chr4:44769814	chr4:44693946~44694386:-
THCA	cis	rs34421088	0.624	rs13278982	ENSG00000255046.1	RP11-297N6.4	-3.72	0.00022	0.0154	-0.18	-0.17	Neuroticism;	chr8:11731524	chr8:11797928~11802568:-
THCA	cis	rs10483853	0.579	rs10134243	ENSG00000258443.1	RP3-414A15.11	-3.72	0.00022	0.0154	-0.25	-0.17	Coronary artery calcification;	chr14:73478444	chr14:73517233~73520648:-
THCA	cis	rs1065852	0.526	rs739296	ENSG00000232710.1	RP4-669P10.16	3.72	0.00022	0.0154	0.21	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993944	chr22:42136433~42139927:-
THCA	cis	rs7520050	0.966	rs12564541	ENSG00000280836.1	AL355480.1	3.72	0.00022	0.0154	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45581219~45581321:-
THCA	cis	rs13256369	0.774	rs13260303	ENSG00000248538.5	RP11-10A14.5	-3.72	0.00022	0.0154	-0.22	-0.17	Obesity-related traits;	chr8:8729832	chr8:9189011~9202854:+
THCA	cis	rs2179367	0.632	rs9285520	ENSG00000216906.2	RP11-350J20.9	-3.72	0.00022	0.0154	-0.21	-0.17	Dupuytren's disease;	chr6:149372001	chr6:149904243~149906418:+
THCA	cis	rs950893	0.729	rs11135759	ENSG00000253837.1	RP11-177H13.2	-3.72	0.00022	0.0154	-0.17	-0.17	Mean corpuscular hemoglobin;	chr8:23611575	chr8:23336171~23366125:+
THCA	cis	rs8062405	1	rs62036616	ENSG00000270424.1	RP11-1348G14.6	3.72	0.00022	0.0154	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28749959~28750595:-
THCA	cis	rs768090	0.747	rs6706279	ENSG00000237892.1	KLF7-IT1	-3.72	0.00022	0.0154	-0.19	-0.17	Hemoglobin concentration;Hematocrit;	chr2:207119491	chr2:207120884~207122044:-
THCA	cis	rs13256369	0.755	rs11776987	ENSG00000254153.1	CTA-398F10.2	-3.72	0.00022	0.0154	-0.19	-0.17	Obesity-related traits;	chr8:8701891	chr8:8456909~8461337:-
THCA	cis	rs293748	0.771	rs151947	ENSG00000250155.1	CTD-2353F22.1	-3.72	0.000221	0.0154	-0.22	-0.17	Obesity-related traits;	chr5:36865491	chr5:36666214~36725195:-
THCA	cis	rs10043228	0.793	rs62384477	ENSG00000248445.4	SEMA6A-AS1	-3.72	0.000221	0.0154	-0.22	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116313868	chr5:116447547~116508276:+
THCA	cis	rs41294858	1	rs41294858	ENSG00000232876.1	CTA-212D2.2	-3.72	0.000221	0.0154	-0.35	-0.17	Red blood cell count;	chr6:135091498	chr6:135055033~135060550:+
THCA	cis	rs10129255	0.912	rs61996059	ENSG00000211972.2	IGHV3-66	3.72	0.000221	0.0154	0.1	0.17	Kawasaki disease;	chr14:106716897	chr14:106675017~106675544:-
THCA	cis	rs6860806	0.661	rs28472559	ENSG00000263597.1	MIR3936	3.72	0.000221	0.0154	0.16	0.17	Breast cancer;	chr5:132245918	chr5:132365490~132365599:-
THCA	cis	rs791590	0.715	rs41295079	ENSG00000225948.2	RP11-554I8.1	3.72	0.000221	0.0154	0.26	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6077191	chr10:6618716~6625346:+
THCA	cis	rs4150642	1	rs7103375	ENSG00000256464.1	YWHABP2	-3.72	0.000221	0.0154	-0.27	-0.17	Amyloid A serum levels;	chr11:18353986	chr11:18490243~18490955:-
THCA	cis	rs3218092	0.872	rs10947997	ENSG00000213435.3	ATP6V0CP3	3.72	0.000221	0.0154	0.29	0.17	Red cell distribution width;	chr6:41953503	chr6:42727234~42727700:+
THCA	cis	rs2135507	0.53	rs13128592	ENSG00000270480.1	RP11-57B24.1	3.72	0.000221	0.0154	0.27	0.17	Juvenile osteochondritis dissecans;	chr4:82605756	chr4:82691737~82692468:+
THCA	cis	rs2692947	0.74	rs4907280	ENSG00000235584.2	AC008268.1	-3.72	0.000221	0.0154	-0.17	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95736378	chr2:95666084~95668715:+
THCA	cis	rs9818758	0.607	rs71324929	ENSG00000229759.1	MRPS18AP1	-3.72	0.000221	0.0154	-0.36	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49007280	chr3:48256350~48256938:-
THCA	cis	rs875971	0.545	rs73142245	ENSG00000232559.3	GS1-124K5.12	3.72	0.000221	0.0154	0.19	0.17	Aortic root size;	chr7:66226662	chr7:66554588~66576923:-
THCA	cis	rs1411478	1	rs12754041	ENSG00000243155.1	RP11-46A10.5	3.72	0.000221	0.0154	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180988826	chr1:180944042~180976482:-
THCA	cis	rs4144027	0.967	rs12879686	ENSG00000258534.1	CTD-2134A5.4	-3.72	0.000221	0.0154	-0.18	-0.17	Blood metabolite levels;	chr14:103894404	chr14:103854366~103880111:-
THCA	cis	rs7829975	0.684	rs488904	ENSG00000253981.4	ALG1L13P	-3.72	0.000221	0.0154	-0.16	-0.17	Mood instability;	chr8:8730061	chr8:8236003~8244667:-
THCA	cis	rs3748656	0.945	rs12117479	ENSG00000273483.1	RP4-671G15.2	3.72	0.000221	0.0154	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112534197	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.945	rs12029985	ENSG00000273483.1	RP4-671G15.2	3.72	0.000221	0.0154	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112539161	chr1:112517799~112518441:-
THCA	cis	rs3748656	0.945	rs35023236	ENSG00000273483.1	RP4-671G15.2	3.72	0.000221	0.0154	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112542830	chr1:112517799~112518441:-
THCA	cis	rs1862618	0.853	rs832554	ENSG00000234553.1	AC022431.3	-3.72	0.000221	0.0154	-0.2	-0.17	Initial pursuit acceleration;	chr5:56819209	chr5:56536583~56537826:-
THCA	cis	rs7142002	0.667	rs730573	ENSG00000272444.1	RP11-1017G21.6	-3.72	0.000221	0.0154	-0.2	-0.17	Autism;	chr14:101921262	chr14:101952416~101953063:+
THCA	cis	rs7142002	0.568	rs57534774	ENSG00000272444.1	RP11-1017G21.6	-3.72	0.000221	0.0154	-0.2	-0.17	Autism;	chr14:101921803	chr14:101952416~101953063:+
THCA	cis	rs7142002	0.568	rs736449	ENSG00000272444.1	RP11-1017G21.6	-3.72	0.000221	0.0154	-0.2	-0.17	Autism;	chr14:101921845	chr14:101952416~101953063:+
THCA	cis	rs1580019	0.587	rs7805311	ENSG00000273014.1	RP11-225B17.2	-3.72	0.000221	0.0154	-0.17	-0.17	Cognitive ability;	chr7:32518690	chr7:32758882~32759353:+
THCA	cis	rs9911578	0.839	rs1871751	ENSG00000224738.1	AC099850.1	3.72	0.000221	0.0154	0.19	0.17	Intelligence (multi-trait analysis);	chr17:59113007	chr17:59106598~59118267:+
THCA	cis	rs4950322	0.58	rs7541393	ENSG00000271721.1	RP11-337C18.9	3.72	0.000221	0.0154	0.19	0.17	Protein quantitative trait loci;	chr1:147117186	chr1:147175602~147177740:+
THCA	cis	rs520525	0.963	rs552277	ENSG00000271811.1	RP1-79C4.4	3.72	0.000221	0.0154	0.21	0.17	Atrial fibrillation;	chr1:170658653	chr1:170667381~170669425:+
THCA	cis	rs11992162	0.967	rs10108320	ENSG00000255046.1	RP11-297N6.4	3.72	0.000221	0.0154	0.18	0.17	Monocyte count;	chr8:11974754	chr8:11797928~11802568:-
THCA	cis	rs875971	0.502	rs6460311	ENSG00000232559.3	GS1-124K5.12	-3.72	0.000221	0.0154	-0.19	-0.17	Aortic root size;	chr7:66646886	chr7:66554588~66576923:-
THCA	cis	rs17074492	0.906	rs11840578	ENSG00000214182.5	PTMAP5	3.72	0.000221	0.0154	0.19	0.17	Sjögren's syndrome;	chr13:81588672	chr13:81689911~81691072:+
THCA	cis	rs34792	0.688	rs13339072	ENSG00000275910.1	RP11-680G24.6	-3.72	0.000221	0.0154	-0.19	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15504090	chr16:15015828~15016390:-
THCA	cis	rs34779708	0.741	rs34397613	ENSG00000233200.1	RP11-324I22.2	3.72	0.000221	0.0154	0.21	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35219894~35230598:-
THCA	cis	rs12681366	0.537	rs10956913	ENSG00000253175.1	RP11-267M23.6	3.72	0.000221	0.0154	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94471459	chr8:94565036~94565715:+
THCA	cis	rs6860806	0.661	rs2171247	ENSG00000263597.1	MIR3936	3.72	0.000221	0.0154	0.16	0.17	Breast cancer;	chr5:132244541	chr5:132365490~132365599:-
THCA	cis	rs7833790	1	rs7833790	ENSG00000254689.1	RP11-354A14.1	3.72	0.000221	0.0154	0.21	0.17	Diastolic blood pressure;	chr8:81818922	chr8:81885377~81923193:+
THCA	cis	rs2691273	0.53	rs2569430	ENSG00000269235.1	ZNF350-AS1	-3.72	0.000221	0.0154	-0.17	-0.17	Blood protein levels;	chr19:51106329	chr19:51949134~51981367:+
THCA	cis	rs10483853	0.525	rs7158272	ENSG00000258443.1	RP3-414A15.11	3.72	0.000221	0.0154	0.25	0.17	Coronary artery calcification;	chr14:73476486	chr14:73517233~73520648:-
THCA	cis	rs9303542	0.694	rs17694192	ENSG00000278765.1	RP5-890E16.5	-3.72	0.000221	0.0154	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48263679	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs62067799	ENSG00000278765.1	RP5-890E16.5	-3.72	0.000221	0.0154	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48270633	chr17:48066704~48067293:-
THCA	cis	rs7914558	1	rs10509757	ENSG00000272912.1	RP11-724N1.1	-3.72	0.000221	0.0154	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102914585~102915404:+
THCA	cis	rs41411047	0.826	rs73155069	ENSG00000252172.1	RNU6-720P	3.72	0.000221	0.0154	0.36	0.17	Myocardial infarction;	chr3:149821378	chr3:149917342~149917449:-
THCA	cis	rs41411047	0.826	rs7614059	ENSG00000252172.1	RNU6-720P	3.72	0.000221	0.0154	0.36	0.17	Myocardial infarction;	chr3:149822678	chr3:149917342~149917449:-
THCA	cis	rs494526	0.674	rs10749288	ENSG00000229272.1	RP11-498J9.2	-3.72	0.000221	0.0154	-0.19	-0.17	Alcoholic chronic pancreatitis;	chr10:119094287	chr10:119003536~119003884:-
THCA	cis	rs735539	0.521	rs2585902	ENSG00000278291.1	RP11-172H24.4	3.72	0.000221	0.0154	0.23	0.17	Dental caries;	chr13:20843497	chr13:20699307~20703718:-
THCA	cis	rs735539	0.521	rs2818994	ENSG00000278291.1	RP11-172H24.4	3.72	0.000221	0.0154	0.23	0.17	Dental caries;	chr13:20844271	chr13:20699307~20703718:-
THCA	cis	rs6963495	0.818	rs73192107	ENSG00000272604.1	RP11-251G23.5	3.72	0.000221	0.0154	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105527648	chr7:105571083~105573660:+
THCA	cis	rs7267979	0.966	rs8123949	ENSG00000276952.1	RP5-965G21.6	-3.72	0.000221	0.0154	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2184000	ENSG00000276952.1	RP5-965G21.6	-3.72	0.000221	0.0154	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25284915~25285588:-
THCA	cis	rs12134133	0.752	rs6673080	ENSG00000237074.1	RP11-6J21.2	3.72	0.000221	0.0154	0.18	0.17	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207249067~207309121:+
THCA	cis	rs1023500	0.505	rs134874	ENSG00000182057.4	OGFRP1	3.72	0.000221	0.0154	0.2	0.17	Schizophrenia;	chr22:42265138	chr22:42269753~42275196:+
THCA	cis	rs10043228	1	rs17139457	ENSG00000250015.1	CTC-339F2.2	-3.72	0.000221	0.0154	-0.25	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116304906	chr5:116302354~116304134:-
THCA	cis	rs12900463	0.752	rs12904777	ENSG00000259728.4	LINC00933	3.72	0.000221	0.0154	0.21	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:84570649~84580175:+
THCA	cis	rs804280	0.509	rs12719915	ENSG00000254948.1	OR7E158P	3.72	0.000221	0.0154	0.21	0.17	Myopia (pathological);	chr8:11928746	chr8:11919900~11920809:-
THCA	cis	rs13113518	0.812	rs56055342	ENSG00000223305.1	RN7SKP30	3.72	0.000221	0.0154	0.22	0.17	Height;	chr4:55540928	chr4:55540502~55540835:-
THCA	cis	rs11088226	0.681	rs2833891	ENSG00000186842.4	LINC00846	-3.72	0.000221	0.0154	-0.24	-0.17	Gastritis;	chr21:32556511	chr21:32572238~32575881:-
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000184274.3	LINC00315	-3.72	0.000221	0.0154	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000184274.3	LINC00315	-3.72	0.000221	0.0154	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000184274.3	LINC00315	-3.72	0.000221	0.0154	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000184274.3	LINC00315	-3.72	0.000221	0.0154	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45300245~45305257:-
THCA	cis	rs987724	0.501	rs2321293	ENSG00000243926.1	TIPARP-AS1	3.72	0.000221	0.0154	0.21	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156931311	chr3:156671862~156674378:-
THCA	cis	rs931608	0.64	rs2082478	ENSG00000269138.1	ZNF209P	3.72	0.000221	0.0154	0.26	0.17	Response to statins (LDL cholesterol change);Dental caries;	chr19:22357046	chr19:22463922~22473036:+
THCA	cis	rs931608	0.64	rs4932758	ENSG00000269138.1	ZNF209P	3.72	0.000221	0.0154	0.26	0.17	Response to statins (LDL cholesterol change);Dental caries;	chr19:22357292	chr19:22463922~22473036:+
THCA	cis	rs7824557	0.564	rs13274106	ENSG00000255495.1	AC145124.2	-3.72	0.000221	0.0154	-0.19	-0.17	Retinal vascular caliber;	chr8:11376449	chr8:12194467~12196280:+
THCA	cis	rs1979679	0.553	rs75547058	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000221	0.0154	-0.16	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28109716	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.553	rs17575785	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000221	0.0154	-0.16	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28109789	chr12:28163298~28190738:-
THCA	cis	rs1979679	0.553	rs59084530	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000221	0.0154	-0.16	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28112117	chr12:28163298~28190738:-
THCA	cis	rs7474896	1	rs3824585	ENSG00000276805.1	RP11-291L22.6	3.72	0.000221	0.0154	0.26	0.17	Obesity (extreme);	chr10:37820493	chr10:38451030~38451785:+
THCA	cis	rs889312	0.5	rs832552	ENSG00000271828.1	CTD-2310F14.1	3.72	0.000221	0.0154	0.23	0.17	Breast cancer (early onset);Breast cancer;	chr5:56818023	chr5:56927874~56929573:+
THCA	cis	rs2380205	0.935	rs2380201	ENSG00000232807.2	RP11-536K7.3	3.72	0.000221	0.0154	0.16	0.17	Breast cancer;	chr10:5852687	chr10:5934270~5945900:-
THCA	cis	rs755249	0.567	rs2018212	ENSG00000182109.6	RP11-69E11.4	3.72	0.000221	0.0154	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs4660751	ENSG00000182109.6	RP11-69E11.4	3.72	0.000221	0.0154	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39522280~39546187:-
THCA	cis	rs1864585	0.52	rs12375394	ENSG00000280294.1	RP11-177H2.1	3.72	0.000221	0.0154	0.17	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10831702	chr8:10856085~10859436:-
THCA	cis	rs4722166	0.532	rs1404008	ENSG00000225541.1	AC002480.5	-3.72	0.000221	0.0154	-0.19	-0.17	Lung cancer;	chr7:22716381	chr7:22571607~22661792:-
THCA	cis	rs8006682	0.548	rs12436964	ENSG00000259038.1	CTD-2325P2.4	3.72	0.000221	0.0154	0.18	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68641369	chr14:68627166~68628445:-
THCA	cis	rs4713118	0.506	rs9366697	ENSG00000280107.1	AL022393.9	-3.72	0.000221	0.0154	-0.17	-0.17	Parkinson's disease;	chr6:27665239	chr6:28170845~28172521:+
THCA	cis	rs948562	0.947	rs75708979	ENSG00000280010.1	AP001350.4	3.72	0.000221	0.0154	0.28	0.17	Lymphoma;	chr11:58662312	chr11:58627435~58628528:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000182722.5	SEPHS1P1	3.72	0.000221	0.0154	0.2	0.17	Aortic root size;	chr7:65800193	chr7:64852397~64853354:-
THCA	cis	rs7914558	0.966	rs3902934	ENSG00000272912.1	RP11-724N1.1	-3.72	0.000222	0.0154	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102986892	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs1890184	ENSG00000272912.1	RP11-724N1.1	-3.72	0.000222	0.0154	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988702	chr10:102914585~102915404:+
THCA	cis	rs11233413	0.957	rs1943341	ENSG00000246067.6	RAB30-AS1	3.72	0.000222	0.0154	0.17	0.17	Economic and political preferences (feminism/equality);	chr11:83055784	chr11:83072066~83106719:+
THCA	cis	rs2191566	0.691	rs56320525	ENSG00000266921.1	RP11-15A1.7	-3.72	0.000222	0.0154	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:44083726	chr19:43996896~44002836:-
THCA	cis	rs2191566	0.691	rs55812285	ENSG00000266921.1	RP11-15A1.7	-3.72	0.000222	0.0154	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:44083777	chr19:43996896~44002836:-
THCA	cis	rs7824557	0.564	rs12550129	ENSG00000255495.1	AC145124.2	-3.72	0.000222	0.0154	-0.19	-0.17	Retinal vascular caliber;	chr8:11376408	chr8:12194467~12196280:+
THCA	cis	rs73173548	0.502	rs4129236	ENSG00000247828.6	TMEM161B-AS1	3.72	0.000222	0.0154	0.16	0.17	Macular telangiectasia type 2;	chr5:88441542	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs36077166	ENSG00000247828.6	TMEM161B-AS1	3.72	0.000222	0.0154	0.16	0.17	Macular telangiectasia type 2;	chr5:88441770	chr5:88268895~88436685:+
THCA	cis	rs9329221	0.537	rs6986911	ENSG00000261451.1	RP11-981G7.1	3.72	0.000222	0.0154	0.2	0.17	Neuroticism;	chr8:10121013	chr8:10433672~10438312:+
THCA	cis	rs2033711	0.811	rs9304814	ENSG00000269054.1	CTD-2619J13.3	-3.72	0.000222	0.0154	-0.14	-0.17	Uric acid clearance;	chr19:58440444	chr19:58362585~58366591:+
THCA	cis	rs763121	0.889	rs6001209	ENSG00000273076.1	RP3-508I15.22	-3.72	0.000222	0.0154	-0.17	-0.17	Menopause (age at onset);	chr22:38725247	chr22:38743495~38743910:+
THCA	cis	rs801193	1	rs2659912	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000222	0.0155	-0.14	-0.17	Aortic root size;	chr7:66693012	chr7:66848496~66858136:+
THCA	cis	rs11583043	0.708	rs874905	ENSG00000233184.5	RP11-421L21.3	3.72	0.000222	0.0155	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101074146	chr1:101025878~101087268:+
THCA	cis	rs68170813	0.522	rs12154818	ENSG00000241764.3	AC002467.7	3.72	0.000222	0.0155	0.18	0.17	Coronary artery disease;	chr7:107434070	chr7:107742817~107744581:-
THCA	cis	rs2361718	0.568	rs1042397	ENSG00000279259.1	RP11-334C17.3	3.72	0.000222	0.0155	0.16	0.17	Yeast infection;	chr17:80118264	chr17:80147250~80148596:+
THCA	cis	rs372883	0.6	rs1236460	ENSG00000176054.6	RPL23P2	-3.72	0.000222	0.0155	-0.15	-0.17	Pancreatic cancer;	chr21:29243192	chr21:28997613~28998033:-
THCA	cis	rs1560104	0.597	rs4781299	ENSG00000260601.1	RP11-552C15.1	-3.72	0.000222	0.0155	-0.21	-0.17	Obesity-related traits;	chr16:12613756	chr16:12545482~12546684:+
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000237310.1	GS1-124K5.4	3.72	0.000222	0.0155	0.2	0.17	Diabetic kidney disease;	chr7:66521515	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs13237037	ENSG00000237310.1	GS1-124K5.4	3.72	0.000222	0.0155	0.2	0.17	Diabetic kidney disease;	chr7:66532895	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1796228	ENSG00000237310.1	GS1-124K5.4	3.72	0.000222	0.0155	0.2	0.17	Diabetic kidney disease;	chr7:66568097	chr7:66493706~66495474:+
THCA	cis	rs61160187	0.582	rs726824	ENSG00000272308.1	RP11-231G3.1	-3.72	0.000222	0.0155	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60866457~60866935:-
THCA	cis	rs10090774	0.813	rs11166996	ENSG00000280303.2	ERICD	-3.72	0.000222	0.0155	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140712561	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13280245	ENSG00000280303.2	ERICD	-3.72	0.000222	0.0155	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140717211	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13276301	ENSG00000280303.2	ERICD	-3.72	0.000222	0.0155	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140720628	chr8:140636281~140638283:+
THCA	cis	rs28595532	0.92	rs17325192	ENSG00000281731.1	RP11-384K6.8	3.72	0.000222	0.0155	0.35	0.17	Cannabis dependence symptom count;	chr4:118859190	chr4:118664087~118685341:-
THCA	cis	rs7665090	0.967	rs6533022	ENSG00000251288.2	RP11-10L12.2	-3.72	0.000222	0.0155	-0.22	-0.17	Primary biliary cholangitis;	chr4:102637794	chr4:102751401~102752641:+
THCA	cis	rs948562	1	rs79475579	ENSG00000280010.1	AP001350.4	3.72	0.000222	0.0155	0.26	0.17	Lymphoma;	chr11:58528427	chr11:58627435~58628528:+
THCA	cis	rs948562	1	rs111901203	ENSG00000280010.1	AP001350.4	3.72	0.000222	0.0155	0.26	0.17	Lymphoma;	chr11:58530069	chr11:58627435~58628528:+
THCA	cis	rs948562	1	rs3829218	ENSG00000280010.1	AP001350.4	3.72	0.000222	0.0155	0.26	0.17	Lymphoma;	chr11:58563836	chr11:58627435~58628528:+
THCA	cis	rs948562	0.895	rs11229537	ENSG00000280010.1	AP001350.4	3.72	0.000222	0.0155	0.26	0.17	Lymphoma;	chr11:58585392	chr11:58627435~58628528:+
THCA	cis	rs948562	1	rs12365551	ENSG00000280010.1	AP001350.4	3.72	0.000222	0.0155	0.26	0.17	Lymphoma;	chr11:58590895	chr11:58627435~58628528:+
THCA	cis	rs2821260	0.595	rs11209920	ENSG00000227207.2	RPL31P12	-3.72	0.000222	0.0155	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72145119	chr1:72301472~72301829:+
THCA	cis	rs2821260	0.694	rs12133604	ENSG00000227207.2	RPL31P12	-3.72	0.000222	0.0155	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72145196	chr1:72301472~72301829:+
THCA	cis	rs6687821	0.637	rs493341	ENSG00000261737.1	RP4-612B15.3	-3.72	0.000222	0.0155	-0.27	-0.17	Yeast infection;	chr1:86845499	chr1:86703502~86704462:-
THCA	cis	rs10129255	0.912	rs61996059	ENSG00000280411.1	IGHV1-69-2	-3.72	0.000222	0.0155	-0.11	-0.17	Kawasaki disease;	chr14:106716897	chr14:106762092~106762588:-
THCA	cis	rs6445975	1	rs4076852	ENSG00000272360.1	RP11-359I18.5	3.72	0.000222	0.0155	0.18	0.17	Systemic lupus erythematosus;	chr3:58389559	chr3:58490830~58491291:-
THCA	cis	rs854765	0.583	rs8078138	ENSG00000281749.1	Y_RNA	3.72	0.000222	0.0155	0.22	0.17	Total body bone mineral density;	chr17:17907937	chr17:18001101~18001195:-
THCA	cis	rs10129255	0.912	rs730099	ENSG00000280411.1	IGHV1-69-2	-3.72	0.000222	0.0155	-0.11	-0.17	Kawasaki disease;	chr14:106711838	chr14:106762092~106762588:-
THCA	cis	rs9650657	0.535	rs7011756	ENSG00000254948.1	OR7E158P	3.72	0.000222	0.0155	0.21	0.17	Neuroticism;	chr8:11162068	chr8:11919900~11920809:-
THCA	cis	rs773506	0.72	rs7036028	ENSG00000235641.4	LINC00484	3.72	0.000222	0.0155	0.22	0.17	Type 2 diabetes nephropathy;	chr9:91195254	chr9:91159573~91165658:+
THCA	cis	rs8014204	0.816	rs4903262	ENSG00000279594.1	RP11-950C14.10	3.72	0.000222	0.0155	0.16	0.17	Caffeine consumption;	chr14:74874115	chr14:75011269~75012851:-
THCA	cis	rs9410380	1	rs9410380	ENSG00000225385.3	RP11-350E12.4	3.72	0.000222	0.0155	0.17	0.17	Monocyte count;	chr9:88838716	chr9:88066915~88068037:+
THCA	cis	rs14027	0.843	rs1828238	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000222	0.0155	-0.17	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs1960438	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000222	0.0155	-0.17	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119867419~119874488:-
THCA	cis	rs7474896	0.616	rs2505239	ENSG00000275858.1	RP11-291L22.8	3.72	0.000222	0.0155	0.25	0.17	Obesity (extreme);	chr10:38151837	chr10:38450738~38451069:-
THCA	cis	rs7474896	0.561	rs2474603	ENSG00000275858.1	RP11-291L22.8	3.72	0.000222	0.0155	0.25	0.17	Obesity (extreme);	chr10:38156754	chr10:38450738~38451069:-
THCA	cis	rs1865760	0.566	rs9295686	ENSG00000272810.1	U91328.22	-3.72	0.000222	0.0155	-0.13	-0.17	Height;	chr6:26081755	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.532	rs9295687	ENSG00000272810.1	U91328.22	-3.72	0.000222	0.0155	-0.13	-0.17	Height;	chr6:26082482	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.566	rs4529296	ENSG00000272810.1	U91328.22	-3.72	0.000222	0.0155	-0.13	-0.17	Height;	chr6:26082907	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.566	rs1971509	ENSG00000272810.1	U91328.22	-3.72	0.000222	0.0155	-0.13	-0.17	Height;	chr6:26085549	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.532	rs2006736	ENSG00000272810.1	U91328.22	-3.72	0.000222	0.0155	-0.13	-0.17	Height;	chr6:26085789	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.566	rs1800702	ENSG00000272810.1	U91328.22	-3.72	0.000222	0.0155	-0.13	-0.17	Height;	chr6:26086235	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.566	rs2794720	ENSG00000272810.1	U91328.22	-3.72	0.000222	0.0155	-0.13	-0.17	Height;	chr6:26086974	chr6:26013241~26013757:+
THCA	cis	rs57709857	0.915	rs72630609	ENSG00000272092.1	RP11-350N15.5	-3.72	0.000222	0.0155	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38343714	chr8:38382364~38383461:+
THCA	cis	rs1693575	0.532	rs74358896	ENSG00000271882.1	KB-1410C5.5	3.72	0.000222	0.0155	0.26	0.17	Cerebrospinal fluid clusterin levels;	chr8:100667455	chr8:101208148~101208558:+
THCA	cis	rs9596863	0.898	rs9568908	ENSG00000136149.6	RPL13AP25	-3.72	0.000222	0.0155	-0.19	-0.17	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53762386	chr13:54440704~54441315:-
THCA	cis	rs1414896	1	rs1414896	ENSG00000226026.4	RP11-57H12.3	3.72	0.000222	0.0155	0.17	0.17	Non-alcoholic fatty liver disease histology (AST);	chr1:95226754	chr1:95163219~95233982:-
THCA	cis	rs2562456	0.793	rs2562428	ENSG00000268658.4	LINC00664	-3.72	0.000222	0.0155	-0.25	-0.17	Pain;	chr19:21442652	chr19:21483374~21503238:+
THCA	cis	rs2933343	0.7	rs2249514	ENSG00000231305.3	RP11-723O4.2	3.72	0.000222	0.0155	0.18	0.17	IgG glycosylation;	chr3:128924969	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.7	rs2630257	ENSG00000231305.3	RP11-723O4.2	3.72	0.000222	0.0155	0.18	0.17	IgG glycosylation;	chr3:128925172	chr3:128861313~128871540:-
THCA	cis	rs2408955	0.5	rs12816820	ENSG00000257735.1	RP11-370I10.6	3.72	0.000222	0.0155	0.19	0.17	Glycated hemoglobin levels;	chr12:48164542	chr12:48350945~48442411:+
THCA	cis	rs7819412	0.749	rs11991118	ENSG00000254948.1	OR7E158P	-3.72	0.000222	0.0155	-0.2	-0.17	Triglycerides;	chr8:11081763	chr8:11919900~11920809:-
THCA	cis	rs709400	0.965	rs861534	ENSG00000258735.1	LINC00637	3.72	0.000222	0.0155	0.22	0.17	Body mass index;	chr14:103702364	chr14:103847721~103858049:+
THCA	cis	rs2239908	0.718	rs241776	ENSG00000237575.4	PYY2	-3.72	0.000222	0.0155	-0.21	-0.17	Blood protein levels;	chr17:28317282	chr17:28226563~28228065:+
THCA	cis	rs78487399	0.731	rs13395302	ENSG00000234936.1	AC010883.5	3.72	0.000222	0.0155	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43479211	chr2:43229573~43233394:+
THCA	cis	rs2135507	0.565	rs906149	ENSG00000270480.1	RP11-57B24.1	3.72	0.000222	0.0155	0.27	0.17	Juvenile osteochondritis dissecans;	chr4:82616624	chr4:82691737~82692468:+
THCA	cis	rs889312	0.521	rs12651942	ENSG00000271828.1	CTD-2310F14.1	-3.72	0.000222	0.0155	-0.23	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56792657	chr5:56927874~56929573:+
THCA	cis	rs7572733	0.555	rs7590828	ENSG00000231621.1	AC013264.2	3.72	0.000222	0.0155	0.18	0.17	Dermatomyositis;	chr2:198075527	chr2:197197991~197199273:+
THCA	cis	rs8192917	0.524	rs7141222	ENSG00000258744.1	RP11-80A15.1	-3.72	0.000222	0.0155	-0.27	-0.17	Vitiligo;	chr14:24645954	chr14:24501594~24508688:+
THCA	cis	rs3785888	0.548	rs3885731	ENSG00000238419.1	RNU7-186P	3.72	0.000222	0.0155	0.2	0.17	Cleft lip with or without cleft palate;	chr17:46955944	chr17:47259358~47259420:-
THCA	cis	rs6491750	0.557	rs9284203	ENSG00000276957.1	RP11-29B2.6	3.72	0.000222	0.0155	0.22	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103473509	chr13:102593338~102593873:-
THCA	cis	rs3087591	0.708	rs2854319	ENSG00000263535.1	AK4P1	3.72	0.000222	0.0155	0.21	0.17	Hip circumference;	chr17:31367036	chr17:31345521~31346187:+
THCA	cis	rs8062405	0.688	rs3924376	ENSG00000270424.1	RP11-1348G14.6	-3.72	0.000222	0.0155	-0.21	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28749959~28750595:-
THCA	cis	rs2933343	0.729	rs1680785	ENSG00000231305.3	RP11-723O4.2	3.72	0.000222	0.0155	0.18	0.17	IgG glycosylation;	chr3:128925973	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.729	rs1680786	ENSG00000231305.3	RP11-723O4.2	3.72	0.000222	0.0155	0.18	0.17	IgG glycosylation;	chr3:128925997	chr3:128861313~128871540:-
THCA	cis	rs7520050	0.743	rs61789988	ENSG00000281133.1	AL355480.3	3.72	0.000222	0.0155	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45580892~45580996:-
THCA	cis	rs9316337	0.548	rs3847995	ENSG00000236953.1	ZDHHC20-IT1	-3.72	0.000222	0.0155	-0.19	-0.17	Schizophrenia;	chr13:21433751	chr13:21376977~21377874:-
THCA	cis	rs2839186	0.934	rs4819221	ENSG00000215424.8	MCM3AP-AS1	-3.72	0.000222	0.0155	-0.1	-0.17	Testicular germ cell tumor;	chr21:46275503	chr21:46229217~46259390:+
THCA	cis	rs11673344	0.566	rs11666708	ENSG00000268499.1	CTB-102L5.8	3.72	0.000222	0.0155	0.18	0.17	Obesity-related traits;	chr19:37396208	chr19:38199836~38200934:+
THCA	cis	rs875971	0.545	rs12671152	ENSG00000273024.4	INTS4P2	-3.72	0.000222	0.0155	-0.22	-0.17	Aortic root size;	chr7:66311140	chr7:65647864~65715661:+
THCA	cis	rs6546886	0.957	rs28450901	ENSG00000235499.1	AC073046.25	3.72	0.000222	0.0155	0.16	0.17	Dialysis-related mortality;	chr2:74025255	chr2:73985132~73986343:+
THCA	cis	rs73076966	1	rs73076965	ENSG00000274269.1	RP4-545L17.12	3.72	0.000222	0.0155	0.28	0.17	Plateletcrit;	chr20:1535534	chr20:1186092~1207036:+
THCA	cis	rs73076966	1	rs73076966	ENSG00000274269.1	RP4-545L17.12	3.72	0.000222	0.0155	0.28	0.17	Plateletcrit;	chr20:1535733	chr20:1186092~1207036:+
THCA	cis	rs7246760	1	rs67359088	ENSG00000267106.4	ZNF561-AS1	3.72	0.000222	0.0155	0.33	0.17	Pursuit maintenance gain;	chr19:9752992	chr19:9621291~9645896:+
THCA	cis	rs7246760	1	rs68176351	ENSG00000267106.4	ZNF561-AS1	3.72	0.000222	0.0155	0.33	0.17	Pursuit maintenance gain;	chr19:9753546	chr19:9621291~9645896:+
THCA	cis	rs7246760	1	rs67509260	ENSG00000267106.4	ZNF561-AS1	3.72	0.000222	0.0155	0.33	0.17	Pursuit maintenance gain;	chr19:9753645	chr19:9621291~9645896:+
THCA	cis	rs12188164	1	rs72717412	ENSG00000225138.6	CTD-2228K2.7	3.72	0.000223	0.0155	0.18	0.17	Cystic fibrosis severity;	chr5:429266	chr5:473236~480884:+
THCA	cis	rs17122278	1	rs112430997	ENSG00000243431.1	RPL5P30	3.72	0.000223	0.0155	0.17	0.17	Total cholesterol levels;	chr11:118558975	chr11:118560690~118561580:+
THCA	cis	rs9467773	0.62	rs2451732	ENSG00000228223.2	HCG11	3.72	0.000223	0.0155	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26523450~26526579:+
THCA	cis	rs4746818	0.818	rs7076011	ENSG00000229001.1	ACTBP14	-3.72	0.000223	0.0155	-0.27	-0.17	Left atrial antero-posterior diameter;	chr10:69140674	chr10:69022778~69023866:+
THCA	cis	rs4746818	1	rs7071904	ENSG00000229001.1	ACTBP14	-3.72	0.000223	0.0155	-0.27	-0.17	Left atrial antero-posterior diameter;	chr10:69143249	chr10:69022778~69023866:+
THCA	cis	rs4746818	0.901	rs7914719	ENSG00000229001.1	ACTBP14	-3.72	0.000223	0.0155	-0.27	-0.17	Left atrial antero-posterior diameter;	chr10:69144076	chr10:69022778~69023866:+
THCA	cis	rs17597773	0.638	rs12145674	ENSG00000238078.1	LINC01352	3.72	0.000223	0.0155	0.23	0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826931	chr1:220829255~220832429:+
THCA	cis	rs17689437	0.813	rs11075686	ENSG00000260084.1	RP11-615I2.1	-3.72	0.000223	0.0155	-0.27	-0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68603577	chr16:68573782~68589512:-
THCA	cis	rs9911578	0.817	rs304264	ENSG00000224738.1	AC099850.1	3.72	0.000223	0.0155	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58672267	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.874	rs302865	ENSG00000224738.1	AC099850.1	3.72	0.000223	0.0155	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58679616	chr17:59106598~59118267:+
THCA	cis	rs6902257	0.744	rs2444805	ENSG00000233967.5	RP11-250B2.3	3.72	0.000223	0.0155	0.34	0.17	Obesity-related traits;	chr6:80620633	chr6:80443344~80465927:+
THCA	cis	rs9607412	0.56	rs877908	ENSG00000233360.4	Z83844.1	3.72	0.000223	0.0155	0.19	0.17	Mean corpuscular volume;	chr22:37068584	chr22:37641832~37658377:-
THCA	cis	rs5762752	0.528	rs695796	ENSG00000272858.1	CTA-292E10.8	-3.72	0.000223	0.0155	-0.17	-0.17	Optic disc area;	chr22:28473444	chr22:28814914~28815662:+
THCA	cis	rs6598955	0.515	rs61776655	ENSG00000236782.4	RP11-96L14.7	-3.72	0.000223	0.0155	-0.21	-0.17	Obesity-related traits;	chr1:26214939	chr1:26169947~26171821:-
THCA	cis	rs56046484	0.797	rs907260	ENSG00000218052.5	ADAMTS7P4	3.72	0.000223	0.0155	0.25	0.17	Testicular germ cell tumor;	chr15:85133526	chr15:85255369~85330334:-
THCA	cis	rs6598541	0.862	rs2018860	ENSG00000278090.1	RP11-6O2.2	-3.72	0.000223	0.0155	-0.15	-0.17	Urate levels;	chr15:98715481	chr15:99028538~99031053:+
THCA	cis	rs6942407	0.546	rs2286268	ENSG00000224046.1	AC005076.5	-3.72	0.000223	0.0155	-0.17	-0.17	Food allergy;	chr7:87219069	chr7:87151423~87152420:-
THCA	cis	rs7188861	0.626	rs7193871	ENSG00000263080.1	RP11-485G7.5	3.72	0.000223	0.0155	0.2	0.17	HDL cholesterol;	chr16:11361749	chr16:11341809~11345211:-
THCA	cis	rs7520050	0.966	rs12139630	ENSG00000280836.1	AL355480.1	3.72	0.000223	0.0155	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs12144263	ENSG00000280836.1	AL355480.1	3.72	0.000223	0.0155	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6668284	ENSG00000280836.1	AL355480.1	3.72	0.000223	0.0155	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs4660321	ENSG00000280836.1	AL355480.1	3.72	0.000223	0.0155	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45581219~45581321:-
THCA	cis	rs5758659	0.714	rs133376	ENSG00000205702.9	CYP2D7	3.72	0.000223	0.0155	0.13	0.17	Cognitive function;	chr22:42070901	chr22:42140203~42144577:-
THCA	cis	rs6580649	0.941	rs4760614	ENSG00000273765.1	RP11-370I10.11	-3.72	0.000223	0.0155	-0.18	-0.17	Lung cancer;	chr12:48034101	chr12:48360920~48361377:+
THCA	cis	rs12681366	0.801	rs6981551	ENSG00000253175.1	RP11-267M23.6	3.72	0.000223	0.0155	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:94565036~94565715:+
THCA	cis	rs7809950	0.678	rs62483640	ENSG00000272072.1	CTA-363E19.2	3.72	0.000223	0.0155	0.18	0.17	Coronary artery disease;	chr7:107259769	chr7:107192559~107193300:-
THCA	cis	rs7824557	0.564	rs2572400	ENSG00000255495.1	AC145124.2	-3.72	0.000223	0.0155	-0.19	-0.17	Retinal vascular caliber;	chr8:11376858	chr8:12194467~12196280:+
THCA	cis	rs12544026	0.581	rs513472	ENSG00000253669.3	KB-1732A1.1	3.72	0.000223	0.0155	0.19	0.17	Major depression and alcohol dependence;	chr8:101881398	chr8:102805517~102809971:+
THCA	cis	rs17345786	0.906	rs72946021	ENSG00000244119.1	PDCL3P4	3.72	0.000223	0.0155	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr3:101531164	chr3:101712472~101713191:+
THCA	cis	rs11710088	0.895	rs13067320	ENSG00000240541.2	TM4SF1-AS1	3.72	0.000223	0.0155	0.16	0.17	QRS duration;	chr3:149481805	chr3:149377778~149386583:+
THCA	cis	rs10540	0.908	rs12792111	ENSG00000279672.1	CMB9-55F22.1	3.72	0.000223	0.0155	0.34	0.17	Body mass index;	chr11:520921	chr11:779617~780755:+
THCA	cis	rs728616	0.558	rs12772945	ENSG00000225484.5	NUTM2B-AS1	-3.72	0.000223	0.0155	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80394740	chr10:79663088~79826594:-
THCA	cis	rs728616	0.558	rs12414691	ENSG00000225484.5	NUTM2B-AS1	-3.72	0.000223	0.0155	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80397226	chr10:79663088~79826594:-
THCA	cis	rs728616	0.558	rs12767261	ENSG00000225484.5	NUTM2B-AS1	-3.72	0.000223	0.0155	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80402567	chr10:79663088~79826594:-
THCA	cis	rs9532669	0.926	rs9532640	ENSG00000229473.2	RGS17P1	3.72	0.000223	0.0155	0.22	0.17	Cervical cancer;	chr13:40880628	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.89	rs9532641	ENSG00000229473.2	RGS17P1	3.72	0.000223	0.0155	0.22	0.17	Cervical cancer;	chr13:40880648	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532643	ENSG00000229473.2	RGS17P1	3.72	0.000223	0.0155	0.22	0.17	Cervical cancer;	chr13:40880800	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.963	rs9532644	ENSG00000229473.2	RGS17P1	3.72	0.000223	0.0155	0.22	0.17	Cervical cancer;	chr13:40880860	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532645	ENSG00000229473.2	RGS17P1	3.72	0.000223	0.0155	0.22	0.17	Cervical cancer;	chr13:40880898	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9525419	ENSG00000229473.2	RGS17P1	3.72	0.000223	0.0155	0.22	0.17	Cervical cancer;	chr13:40881047	chr13:40992779~40993331:-
THCA	cis	rs875971	0.502	rs1796227	ENSG00000232559.3	GS1-124K5.12	-3.72	0.000223	0.0155	-0.19	-0.17	Aortic root size;	chr7:66622032	chr7:66554588~66576923:-
THCA	cis	rs2836326	0.954	rs2836316	ENSG00000231231.4	LINC01423	3.72	0.000223	0.0155	0.2	0.17	Metabolite levels (HVA);	chr21:38343867	chr21:38323635~38333421:-
THCA	cis	rs11105298	0.891	rs10858854	ENSG00000266347.2	AC068641.1	3.72	0.000223	0.0155	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89592833~89592927:+
THCA	cis	rs13256369	0.708	rs10903310	ENSG00000248538.5	RP11-10A14.5	3.72	0.000223	0.0155	0.22	0.17	Obesity-related traits;	chr8:8732177	chr8:9189011~9202854:+
THCA	cis	rs758324	0.797	rs253949	ENSG00000237714.1	P4HA2-AS1	3.72	0.000223	0.0155	0.25	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131987283	chr5:132184876~132192808:+
THCA	cis	rs748404	0.578	rs576557	ENSG00000224677.1	PDIA3P2	3.72	0.000223	0.0155	0.2	0.17	Lung cancer;	chr15:43305539	chr15:43649123~43649280:+
THCA	cis	rs7572733	0.935	rs10048735	ENSG00000231621.1	AC013264.2	-3.72	0.000223	0.0155	-0.16	-0.17	Dermatomyositis;	chr2:197877801	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs9288281	ENSG00000231621.1	AC013264.2	-3.72	0.000223	0.0155	-0.16	-0.17	Dermatomyositis;	chr2:197879642	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs1369511	ENSG00000231621.1	AC013264.2	-3.72	0.000223	0.0155	-0.16	-0.17	Dermatomyositis;	chr2:197881391	chr2:197197991~197199273:+
THCA	cis	rs6847067	0.8	rs6847811	ENSG00000180769.7	WDFY3-AS2	-3.72	0.000223	0.0155	-0.13	-0.17	Oropharynx cancer;	chr4:84946160	chr4:84965682~85011277:+
THCA	cis	rs17027258	0.697	rs1468789	ENSG00000234389.1	AC007278.3	-3.72	0.000223	0.0155	-0.23	-0.17	White blood cell types;	chr2:102476044	chr2:102438713~102440475:+
THCA	cis	rs559555	0.553	rs633233	ENSG00000276517.1	AL133243.2	-3.72	0.000223	0.0155	-0.16	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31616881	chr2:32526504~32529507:+
THCA	cis	rs11098499	0.722	rs7673476	ENSG00000249244.1	RP11-548H18.2	3.72	0.000223	0.0155	0.19	0.17	Corneal astigmatism;	chr4:119327528	chr4:119391831~119395335:-
THCA	cis	rs7520050	0.966	rs7550746	ENSG00000281133.1	AL355480.3	3.72	0.000223	0.0155	0.19	0.17	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45580892~45580996:-
THCA	cis	rs10844706	0.699	rs10844610	ENSG00000214776.8	RP11-726G1.1	3.72	0.000223	0.0155	0.22	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9724016	chr12:9467552~9576275:+
THCA	cis	rs7520050	0.966	rs12564541	ENSG00000281133.1	AL355480.3	3.72	0.000223	0.0155	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45580892~45580996:-
THCA	cis	rs2408955	0.521	rs1476607	ENSG00000257735.1	RP11-370I10.6	-3.72	0.000223	0.0155	-0.2	-0.17	Glycated hemoglobin levels;	chr12:48131021	chr12:48350945~48442411:+
THCA	cis	rs4713118	0.669	rs200997	ENSG00000261839.1	RP1-265C24.8	3.72	0.000223	0.0155	0.18	0.17	Parkinson's disease;	chr6:27844037	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.539	rs200967	ENSG00000220721.1	OR1F12	3.72	0.000223	0.0155	0.21	0.17	Parkinson's disease;	chr6:27894349	chr6:28073316~28074233:+
THCA	cis	rs71520386	0.846	rs13243243	ENSG00000228649.7	AC005682.5	3.72	0.000223	0.0155	0.26	0.17	Fibrinogen levels;	chr7:22781400	chr7:22854178~22861579:+
THCA	cis	rs1005277	0.557	rs2983338	ENSG00000120555.12	SEPT7P9	3.72	0.000223	0.0155	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38383069~38402916:-
THCA	cis	rs683250	0.629	rs1151243	ENSG00000254551.1	RP11-727A23.7	3.72	0.000223	0.0155	0.21	0.17	Subcortical brain region volumes;	chr11:83265369	chr11:83209431~83213379:-
THCA	cis	rs6142618	0.84	rs2424883	ENSG00000224452.1	RSL24D1P6	-3.72	0.000223	0.0155	-0.21	-0.17	Inflammatory bowel disease;	chr20:32393869	chr20:32170390~32170790:-
THCA	cis	rs2540949	0.538	rs2540970	ENSG00000281920.1	RP11-418H16.1	3.72	0.000223	0.0155	0.22	0.17	Atrial fibrillation;	chr2:65027965	chr2:65623272~65628424:+
THCA	cis	rs10089	1	rs6595806	ENSG00000245937.6	LINC01184	3.72	0.000223	0.0155	0.19	0.17	Ileal carcinoids;	chr5:128164072	chr5:127940426~128083172:-
THCA	cis	rs61270009	0.731	rs13189022	ENSG00000247828.6	TMEM161B-AS1	3.72	0.000223	0.0155	0.16	0.17	Depressive symptoms;	chr5:88445017	chr5:88268895~88436685:+
THCA	cis	rs3808502	0.563	rs12541800	ENSG00000255495.1	AC145124.2	3.72	0.000223	0.0155	0.19	0.17	Neuroticism;	chr8:11565563	chr8:12194467~12196280:+
THCA	cis	rs62292953	0.591	rs78117783	ENSG00000248724.5	NPHP3-AS1	-3.72	0.000223	0.0155	-0.37	-0.17	Red cell distribution width;	chr3:132495545	chr3:132721750~132874223:+
THCA	cis	rs17412738	0.51	rs77436593	ENSG00000248724.5	NPHP3-AS1	-3.72	0.000223	0.0155	-0.37	-0.17	Blood protein levels;	chr3:132496927	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.591	rs76569928	ENSG00000248724.5	NPHP3-AS1	-3.72	0.000223	0.0155	-0.37	-0.17	Red cell distribution width;	chr3:132497763	chr3:132721750~132874223:+
THCA	cis	rs62292953	0.591	rs78526588	ENSG00000248724.5	NPHP3-AS1	-3.72	0.000223	0.0155	-0.37	-0.17	Red cell distribution width;	chr3:132499113	chr3:132721750~132874223:+
THCA	cis	rs253959	0.705	rs153590	ENSG00000250015.1	CTC-339F2.2	-3.72	0.000223	0.0155	-0.15	-0.17	Bipolar disorder and schizophrenia;	chr5:116304341	chr5:116302354~116304134:-
THCA	cis	rs7111546	1	rs73484234	ENSG00000246225.5	RP11-17A1.3	3.72	0.000223	0.0155	0.3	0.17	Dialysis-related mortality;	chr11:22800665	chr11:22829380~22945393:+
THCA	cis	rs12476592	0.543	rs10170988	ENSG00000242412.1	DBIL5P2	3.72	0.000223	0.0155	0.22	0.17	Childhood ear infection;	chr2:63423447	chr2:63117851~63119542:-
THCA	cis	rs1667255	1	rs1375446	ENSG00000266521.1	RP11-650P15.1	3.72	0.000223	0.0155	0.21	0.17	Retinol levels;	chr18:31577372	chr18:31496645~31497195:-
THCA	cis	rs266717	0.788	rs266750	ENSG00000234197.1	ETV5-AS1	-3.72	0.000223	0.0155	-0.13	-0.17	Adiponectin levels;	chr3:186795046	chr3:186079170~186080947:+
THCA	cis	rs6120849	0.754	rs6088667	ENSG00000269202.1	RP4-614O4.12	-3.72	0.000223	0.0155	-0.18	-0.17	Protein C levels;	chr20:34978919	chr20:35201747~35203288:-
THCA	cis	rs10975370	0.527	rs7872052	ENSG00000206147.5	RP11-106A1.2	3.72	0.000223	0.0155	0.2	0.17	Breast cancer;	chr9:6026757	chr9:6639139~6639604:+
THCA	cis	rs9905704	0.846	rs35082135	ENSG00000224738.1	AC099850.1	3.72	0.000223	0.0156	0.22	0.17	Testicular germ cell tumor;	chr17:58862333	chr17:59106598~59118267:+
THCA	cis	rs11220082	0.644	rs34435097	ENSG00000254671.2	STT3A-AS1	-3.72	0.000223	0.0156	-0.2	-0.17	Schizophrenia;	chr11:125469075	chr11:125570284~125592568:-
THCA	cis	rs7176527	0.519	rs12148368	ENSG00000259728.4	LINC00933	3.72	0.000223	0.0156	0.22	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84570649~84580175:+
THCA	cis	rs2562456	0.833	rs56179986	ENSG00000268278.1	RP11-420K14.1	3.72	0.000223	0.0156	0.24	0.17	Pain;	chr19:21337882	chr19:21637974~21656300:+
THCA	cis	rs4886920	0.541	rs11853098	ENSG00000260776.4	RP11-114H24.2	3.72	0.000223	0.0156	0.21	0.17	Neuroticism;	chr15:77836691	chr15:77914217~77926846:-
THCA	cis	rs690037	0.966	rs574083	ENSG00000272529.1	RP11-415F23.4	3.72	0.000223	0.0156	0.15	0.17	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16354006	chr3:16345126~16346440:+
THCA	cis	rs801193	1	rs62466794	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000224	0.0156	-0.14	-0.17	Aortic root size;	chr7:66726592	chr7:66848496~66858136:+
THCA	cis	rs67478160	0.506	rs6575998	ENSG00000258534.1	CTD-2134A5.4	-3.72	0.000224	0.0156	-0.17	-0.17	Schizophrenia;	chr14:103784080	chr14:103854366~103880111:-
THCA	cis	rs877819	0.583	rs1904600	ENSG00000228403.1	RP11-563N6.6	-3.72	0.000224	0.0156	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48859171	chr10:48878022~48878649:+
THCA	cis	rs6687821	0.515	rs2390221	ENSG00000261737.1	RP4-612B15.3	3.72	0.000224	0.0156	0.25	0.17	Yeast infection;	chr1:86990333	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs2390224	ENSG00000261737.1	RP4-612B15.3	3.72	0.000224	0.0156	0.25	0.17	Yeast infection;	chr1:86991201	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs4656133	ENSG00000261737.1	RP4-612B15.3	3.72	0.000224	0.0156	0.25	0.17	Yeast infection;	chr1:87000140	chr1:86703502~86704462:-
THCA	cis	rs4908768	0.501	rs11121212	ENSG00000270282.1	RP5-1115A15.2	3.72	0.000224	0.0156	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665934	chr1:8512653~8513021:+
THCA	cis	rs10824518	0.744	rs3900539	ENSG00000199664.1	RNU6-1266P	-3.72	0.000224	0.0156	-0.22	-0.17	Myopia;	chr10:77399400	chr10:77776951~77777055:-
THCA	cis	rs9329221	0.505	rs7840347	ENSG00000261451.1	RP11-981G7.1	-3.72	0.000224	0.0156	-0.23	-0.17	Neuroticism;	chr8:10214840	chr8:10433672~10438312:+
THCA	cis	rs4578769	0.55	rs4517887	ENSG00000273232.1	RP11-370A5.2	-3.72	0.000224	0.0156	-0.23	-0.17	Eosinophil percentage of white cells;	chr18:22994715	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.55	rs4635434	ENSG00000273232.1	RP11-370A5.2	-3.72	0.000224	0.0156	-0.23	-0.17	Eosinophil percentage of white cells;	chr18:22996032	chr18:22882825~22883357:-
THCA	cis	rs5997397	0.934	rs6005863	ENSG00000226471.5	CTA-292E10.6	-3.72	0.000224	0.0156	-0.14	-0.17	Red cell distribution width;	chr22:28760460	chr22:28800683~28848559:+
THCA	cis	rs1065852	0.526	rs2097561	ENSG00000232710.1	RP4-669P10.16	-3.72	0.000224	0.0156	-0.21	-0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993427	chr22:42136433~42139927:-
THCA	cis	rs1065852	0.526	rs2097562	ENSG00000232710.1	RP4-669P10.16	-3.72	0.000224	0.0156	-0.21	-0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993496	chr22:42136433~42139927:-
THCA	cis	rs877529	0.967	rs139407	ENSG00000279833.1	RP4-742C19.13	-3.72	0.000224	0.0156	-0.11	-0.17	Multiple myeloma;	chr22:39156070	chr22:39133090~39136760:+
THCA	cis	rs7520050	0.807	rs12025621	ENSG00000281133.1	AL355480.3	3.72	0.000224	0.0156	0.19	0.17	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45580892~45580996:-
THCA	cis	rs7809950	0.723	rs2237662	ENSG00000272072.1	CTA-363E19.2	3.72	0.000224	0.0156	0.18	0.17	Coronary artery disease;	chr7:107233620	chr7:107192559~107193300:-
THCA	cis	rs2562784	0.638	rs2730097	ENSG00000225151.9	GOLGA2P7	-3.72	0.000224	0.0156	-0.3	-0.17	Height;	chr15:83599198	chr15:84199311~84230136:-
THCA	cis	rs17095355	0.642	rs4130278	ENSG00000203876.8	ADD3-AS1	-3.72	0.000224	0.0156	-0.18	-0.17	Biliary atresia;	chr10:110153764	chr10:109940104~110008381:-
THCA	cis	rs7829975	0.711	rs4841051	ENSG00000254340.1	RP11-10A14.3	-3.72	0.000224	0.0156	-0.19	-0.17	Mood instability;	chr8:8828136	chr8:9141424~9145435:+
THCA	cis	rs559928	0.597	rs947939	ENSG00000236935.1	AP003774.1	3.72	0.000224	0.0156	0.25	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64117815	chr11:64325050~64329504:-
THCA	cis	rs877819	0.583	rs2663030	ENSG00000228403.1	RP11-563N6.6	-3.72	0.000224	0.0156	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48879413	chr10:48878022~48878649:+
THCA	cis	rs3758911	0.964	rs10890702	ENSG00000255353.1	RP11-382M14.1	3.72	0.000224	0.0156	0.22	0.17	Coronary artery disease;	chr11:107310159	chr11:107176286~107177530:+
THCA	cis	rs12539814	1	rs12539814	ENSG00000204959.4	ARHGEF34P	3.72	0.000224	0.0156	0.23	0.17	Diastolic blood pressure;	chr7:144433417	chr7:144272445~144286966:-
THCA	cis	rs10129255	0.957	rs10150241	ENSG00000211972.2	IGHV3-66	-3.72	0.000224	0.0156	-0.1	-0.17	Kawasaki disease;	chr14:106775945	chr14:106675017~106675544:-
THCA	cis	rs740160	0.51	rs11771702	ENSG00000244219.5	GS1-259H13.2	-3.72	0.000224	0.0156	-0.26	-0.17	Dehydroepiandrosterone sulphate levels;	chr7:99306677	chr7:99598066~99610813:+
THCA	cis	rs28830936	0.966	rs1531140	ENSG00000250379.1	RP11-23P13.4	3.72	0.000224	0.0156	0.2	0.17	Diastolic blood pressure;	chr15:41833036	chr15:41825099~41827936:-
THCA	cis	rs5769765	0.74	rs2103932	ENSG00000260613.1	RP3-522J7.6	3.72	0.000224	0.0156	0.22	0.17	Schizophrenia;	chr22:49878867	chr22:49832616~49837786:-
THCA	cis	rs295490	0.748	rs77342235	ENSG00000272656.1	RP11-219D15.3	3.72	0.000224	0.0156	0.31	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139419212	chr3:139349024~139349371:-
THCA	cis	rs7246657	0.714	rs12972195	ENSG00000268499.1	CTB-102L5.8	3.72	0.000224	0.0156	0.22	0.17	Coronary artery calcification;	chr19:37261603	chr19:38199836~38200934:+
THCA	cis	rs7259376	0.871	rs34187872	ENSG00000270947.1	AC025811.3	-3.72	0.000224	0.0156	-0.18	-0.17	Menopause (age at onset);	chr19:22425081	chr19:22455988~22456459:+
THCA	cis	rs11671005	0.735	rs12981875	ENSG00000269600.1	AC016629.3	-3.72	0.000224	0.0156	-0.25	-0.17	Mean platelet volume;	chr19:58423763	chr19:58593896~58599355:-
THCA	cis	rs62158800	0.683	rs67372209	ENSG00000225588.2	AC096669.1	3.72	0.000224	0.0156	0.17	0.17	Facial morphology (factor 22);	chr2:107682933	chr2:107362282~107407329:+
THCA	cis	rs1048886	0.938	rs9294871	ENSG00000271967.1	RP11-134K13.4	-3.72	0.000224	0.0156	-0.18	-0.17	Type 2 diabetes;	chr6:70463524	chr6:70596438~70596980:+
THCA	cis	rs1125355	0.622	rs11678112	ENSG00000243792.1	OR7E89P	-3.72	0.000224	0.0156	-0.26	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158756825	chr2:158853755~158854576:+
THCA	cis	rs1125355	0.622	rs10497201	ENSG00000243792.1	OR7E89P	-3.72	0.000224	0.0156	-0.26	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158757632	chr2:158853755~158854576:+
THCA	cis	rs1125355	0.622	rs1515921	ENSG00000243792.1	OR7E89P	-3.72	0.000224	0.0156	-0.26	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158759156	chr2:158853755~158854576:+
THCA	cis	rs1125355	0.622	rs1515920	ENSG00000243792.1	OR7E89P	-3.72	0.000224	0.0156	-0.26	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158759252	chr2:158853755~158854576:+
THCA	cis	rs9300255	0.543	rs520088	ENSG00000235423.7	RP11-282O18.3	3.72	0.000224	0.0156	0.17	0.17	Neutrophil percentage of white cells;	chr12:123037603	chr12:123252030~123261483:-
THCA	cis	rs683250	0.598	rs647200	ENSG00000254551.1	RP11-727A23.7	3.72	0.000224	0.0156	0.21	0.17	Subcortical brain region volumes;	chr11:83267482	chr11:83209431~83213379:-
THCA	cis	rs7900823	0.5	rs11006956	ENSG00000230500.1	MKX-AS1	3.72	0.000224	0.0156	0.23	0.17	Lung cancer;	chr10:28254787	chr10:27744786~27767794:+
THCA	cis	rs7900823	0.599	rs11006965	ENSG00000230500.1	MKX-AS1	3.72	0.000224	0.0156	0.23	0.17	Lung cancer;	chr10:28261101	chr10:27744786~27767794:+
THCA	cis	rs12142240	0.667	rs12062	ENSG00000232022.5	FAAHP1	3.72	0.000224	0.0156	0.19	0.17	Menopause (age at onset);	chr1:46364775	chr1:46432129~46445521:+
THCA	cis	rs11123170	0.569	rs1049137	ENSG00000274877.1	RP11-65I12.1	3.72	0.000224	0.0156	0.1	0.17	Renal function-related traits (BUN);	chr2:113217533	chr2:113237595~113240825:+
THCA	cis	rs12439619	0.883	rs62012045	ENSG00000259429.4	UBE2Q2P2	-3.72	0.000224	0.0156	-0.16	-0.17	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82355142~82420075:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000232559.3	GS1-124K5.12	-3.72	0.000224	0.0156	-0.18	-0.17	Aortic root size;	chr7:66112359	chr7:66554588~66576923:-
THCA	cis	rs910316	1	rs4899546	ENSG00000259138.1	RP11-950C14.7	3.72	0.000224	0.0156	0.15	0.17	Height;	chr14:75128243	chr14:75127153~75136930:+
THCA	cis	rs10760158	0.832	rs4836845	ENSG00000226752.6	PSMD5-AS1	-3.72	0.000224	0.0156	-0.21	-0.17	Pulse pressure;	chr9:121287678	chr9:120824828~120854385:+
THCA	cis	rs6840360	0.934	rs6817058	ENSG00000270265.1	RP11-731D1.4	-3.72	0.000224	0.0156	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151682713	chr4:151333775~151353224:-
THCA	cis	rs10496034	0.541	rs13401431	ENSG00000237887.1	AC092839.1	-3.72	0.000224	0.0156	-0.33	-0.17	Refractive astigmatism;	chr2:54650228	chr2:54529343~54529801:+
THCA	cis	rs836788	0.571	rs6151766	ENSG00000251221.1	LINC01337	-3.72	0.000224	0.0156	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr5:80756429	chr5:80608623~80622524:-
THCA	cis	rs7656342	0.964	rs56139970	ENSG00000242034.1	RP11-1396O13.1	3.72	0.000224	0.0156	0.2	0.17	Gut microbiota (bacterial taxa);	chr4:9800648	chr4:9553614~9553985:-
THCA	cis	rs654950	0.783	rs639298	ENSG00000230638.4	RP11-486B10.4	3.72	0.000224	0.0156	0.18	0.17	Airway imaging phenotypes;	chr1:41535859	chr1:41542069~41544310:+
THCA	cis	rs7713065	0.802	rs111280764	ENSG00000263597.1	MIR3936	-3.72	0.000224	0.0156	-0.21	-0.17	Lung function (FEV1/FVC);	chr5:132450097	chr5:132365490~132365599:-
THCA	cis	rs113835537	0.935	rs3867133	ENSG00000199325.1	RNU4-39P	-3.72	0.000224	0.0156	-0.27	-0.17	Airway imaging phenotypes;	chr11:66684491	chr11:66614964~66615090:-
THCA	cis	rs17221829	0.733	rs11018668	ENSG00000280385.1	AP000648.5	-3.72	0.000224	0.0156	-0.17	-0.17	Anxiety in major depressive disorder;	chr11:89623010	chr11:90193614~90198120:+
THCA	cis	rs838886	0.912	rs1672877	ENSG00000275389.1	RP11-214K3.24	-3.72	0.000224	0.0156	-0.23	-0.17	HDL cholesterol;	chr12:124776662	chr12:124085761~124088598:+
THCA	cis	rs838886	0.833	rs1726339	ENSG00000275389.1	RP11-214K3.24	-3.72	0.000224	0.0156	-0.23	-0.17	HDL cholesterol;	chr12:124776663	chr12:124085761~124088598:+
THCA	cis	rs7259376	0.936	rs12151261	ENSG00000269345.1	VN1R85P	-3.72	0.000224	0.0156	-0.18	-0.17	Menopause (age at onset);	chr19:22405127	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs8111665	ENSG00000269345.1	VN1R85P	-3.72	0.000224	0.0156	-0.18	-0.17	Menopause (age at onset);	chr19:22405757	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs7247220	ENSG00000269345.1	VN1R85P	-3.72	0.000224	0.0156	-0.18	-0.17	Menopause (age at onset);	chr19:22406687	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs12983542	ENSG00000269345.1	VN1R85P	-3.72	0.000224	0.0156	-0.18	-0.17	Menopause (age at onset);	chr19:22407783	chr19:22174766~22175191:-
THCA	cis	rs9650657	0.836	rs2898252	ENSG00000255310.2	AF131215.2	-3.72	0.000224	0.0156	-0.14	-0.17	Neuroticism;	chr8:10746654	chr8:11107788~11109726:-
THCA	cis	rs4886920	0.563	rs8040813	ENSG00000260776.4	RP11-114H24.2	3.72	0.000224	0.0156	0.2	0.17	Neuroticism;	chr15:77780947	chr15:77914217~77926846:-
THCA	cis	rs420259	0.516	rs11074561	ENSG00000260136.4	CTD-2270L9.4	-3.72	0.000224	0.0156	-0.13	-0.17	Bipolar disorder;	chr16:23484374	chr16:23452758~23457606:+
THCA	cis	rs2797160	1	rs1739377	ENSG00000226409.1	RP11-735G4.1	3.72	0.000224	0.0156	0.2	0.17	Endometrial cancer;	chr6:125691090	chr6:125370211~125374324:-
THCA	cis	rs7829975	0.502	rs11785183	ENSG00000253981.4	ALG1L13P	-3.72	0.000224	0.0156	-0.17	-0.17	Mood instability;	chr8:8708447	chr8:8236003~8244667:-
THCA	cis	rs564148	1	rs564148	ENSG00000239670.1	RP4-803A2.2	3.72	0.000225	0.0156	0.28	0.17	Response to amphetamines;	chr1:33708220	chr1:32986952~32988233:+
THCA	cis	rs10090774	0.965	rs13258028	ENSG00000280303.2	ERICD	-3.72	0.000225	0.0156	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140880414	chr8:140636281~140638283:+
THCA	cis	rs1501138	0.54	rs1468667	ENSG00000263327.5	TAPT1-AS1	-3.72	0.000225	0.0156	-0.27	-0.17	Systemic juvenile idiopathic arthritis;	chr4:16315446	chr4:16226685~16320140:+
THCA	cis	rs17767392	0.626	rs11158898	ENSG00000259146.3	RP1-261D10.2	3.72	0.000225	0.0156	0.21	0.17	Mitral valve prolapse;	chr14:71218488	chr14:71292729~71321814:-
THCA	cis	rs853679	1	rs853694	ENSG00000261839.1	RP1-265C24.8	3.72	0.000225	0.0156	0.23	0.17	Depression;	chr6:28311323	chr6:28136849~28139678:+
THCA	cis	rs67478160	0.619	rs3742365	ENSG00000269940.1	RP11-73M18.7	3.72	0.000225	0.0156	0.16	0.17	Schizophrenia;	chr14:103731914	chr14:103694560~103695170:+
THCA	cis	rs12908161	0.65	rs182517	ENSG00000188388.10	GOLGA6L3	3.72	0.000225	0.0156	0.23	0.17	Schizophrenia;	chr15:84846400	chr15:85240472~85247170:+
THCA	cis	rs72996113	0.702	rs77786711	ENSG00000248027.1	CTD-2383M3.1	-3.72	0.000225	0.0156	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100687950	chr11:100684162~100687955:-
THCA	cis	rs2108225	0.934	rs2283045	ENSG00000233705.5	SLC26A4-AS1	-3.72	0.000225	0.0156	-0.14	-0.17	Ulcerative colitis;	chr7:107800269	chr7:107653968~107662151:-
THCA	cis	rs59901009	0.768	rs67404901	ENSG00000246273.5	SBF2-AS1	-3.72	0.000225	0.0156	-0.22	-0.17	Hematocrit;Hemoglobin concentration;	chr11:10037682	chr11:9758292~9811319:+
THCA	cis	rs36093844	0.527	rs56187740	ENSG00000279742.1	RP11-700A24.1	-3.72	0.000225	0.0156	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86053608	chr11:85852557~85854943:-
THCA	cis	rs6940638	0.744	rs858964	ENSG00000280107.1	AL022393.9	3.72	0.000225	0.0156	0.18	0.17	Intelligence (multi-trait analysis);	chr6:27174835	chr6:28170845~28172521:+
THCA	cis	rs4460629	0.742	rs11264314	ENSG00000236675.1	MTX1P1	-3.72	0.000225	0.0156	-0.16	-0.17	Serum magnesium levels;	chr1:155105947	chr1:155230975~155234325:+
THCA	cis	rs7616559	0.962	rs9880927	ENSG00000244515.1	KRT18P34	-3.72	0.000225	0.0156	-0.23	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157022122	chr3:157162663~157163932:-
THCA	cis	rs916888	0.821	rs70600	ENSG00000260075.1	NSFP1	-3.72	0.000225	0.0156	-0.27	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46372855~46487141:+
THCA	cis	rs2299587	0.56	rs7814692	ENSG00000253671.1	RP11-806O11.1	-3.72	0.000225	0.0156	-0.21	-0.17	Economic and political preferences;	chr8:17922648	chr8:17808941~17820868:+
THCA	cis	rs12476592	0.571	rs4671512	ENSG00000242412.1	DBIL5P2	3.72	0.000225	0.0156	0.22	0.17	Childhood ear infection;	chr2:63525961	chr2:63117851~63119542:-
THCA	cis	rs910316	1	rs11159117	ENSG00000259138.1	RP11-950C14.7	3.72	0.000225	0.0156	0.15	0.17	Height;	chr14:75118164	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs28626045	ENSG00000259138.1	RP11-950C14.7	3.72	0.000225	0.0156	0.15	0.17	Height;	chr14:75122492	chr14:75127153~75136930:+
THCA	cis	rs910316	0.967	rs12890371	ENSG00000259138.1	RP11-950C14.7	3.72	0.000225	0.0156	0.15	0.17	Height;	chr14:75127136	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs12889309	ENSG00000259138.1	RP11-950C14.7	3.72	0.000225	0.0156	0.15	0.17	Height;	chr14:75127199	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs4322591	ENSG00000259138.1	RP11-950C14.7	3.72	0.000225	0.0156	0.15	0.17	Height;	chr14:75133994	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs876403	ENSG00000259138.1	RP11-950C14.7	3.72	0.000225	0.0156	0.15	0.17	Height;	chr14:75136131	chr14:75127153~75136930:+
THCA	cis	rs910316	0.967	rs4903285	ENSG00000259138.1	RP11-950C14.7	3.72	0.000225	0.0156	0.15	0.17	Height;	chr14:75142565	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs7147118	ENSG00000259138.1	RP11-950C14.7	3.72	0.000225	0.0156	0.15	0.17	Height;	chr14:75143467	chr14:75127153~75136930:+
THCA	cis	rs73193808	0.639	rs9984810	ENSG00000231125.2	AF129075.5	-3.72	0.000225	0.0156	-0.16	-0.17	Coronary artery disease;	chr21:29181059	chr21:29058073~29060095:-
THCA	cis	rs73193808	0.614	rs4817274	ENSG00000231125.2	AF129075.5	-3.72	0.000225	0.0156	-0.16	-0.17	Coronary artery disease;	chr21:29181296	chr21:29058073~29060095:-
THCA	cis	rs73193808	0.59	rs2832244	ENSG00000231125.2	AF129075.5	-3.72	0.000225	0.0156	-0.16	-0.17	Coronary artery disease;	chr21:29181713	chr21:29058073~29060095:-
THCA	cis	rs1046491	0.614	rs76621624	ENSG00000264964.1	RP11-888D10.3	3.72	0.000225	0.0156	0.35	0.17	Scarlet fever;	chr18:9310401	chr18:9315194~9334441:-
THCA	cis	rs1923243	0.714	rs4128552	ENSG00000223479.3	RP4-788P17.1	-3.72	0.000225	0.0156	-0.18	-0.17	Migraine;	chr1:73095128	chr1:73635216~73715214:+
THCA	cis	rs4792901	0.802	rs9898286	ENSG00000279602.1	CTD-3014M21.1	-3.72	0.000225	0.0156	-0.22	-0.17	Dupuytren's disease;	chr17:43485174	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs79934399	ENSG00000279602.1	CTD-3014M21.1	-3.72	0.000225	0.0156	-0.22	-0.17	Dupuytren's disease;	chr17:43494593	chr17:43360041~43361361:-
THCA	cis	rs877819	0.583	rs2663050	ENSG00000228403.1	RP11-563N6.6	-3.72	0.000225	0.0156	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48862280	chr10:48878022~48878649:+
THCA	cis	rs964611	0.882	rs9635331	ENSG00000259488.2	RP11-154J22.1	-3.72	0.000225	0.0156	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48277940	chr15:48312353~48331856:-
THCA	cis	rs150992	0.79	rs325220	ENSG00000246763.5	RGMB-AS1	3.72	0.000225	0.0156	0.18	0.17	Body mass index;	chr5:98968860	chr5:98769618~98773469:-
THCA	cis	rs748404	0.601	rs489964	ENSG00000205771.5	CATSPER2P1	3.72	0.000225	0.0156	0.17	0.17	Lung cancer;	chr15:43225356	chr15:43726918~43747094:-
THCA	cis	rs7680126	0.536	rs4525975	ENSG00000261490.1	RP11-448G15.3	3.72	0.000225	0.0156	0.17	0.17	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10035766	chr4:10068089~10073019:-
THCA	cis	rs1371614	0.611	rs4665922	ENSG00000229122.1	AGBL5-IT1	-3.72	0.000225	0.0156	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26911066	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.635	rs12714002	ENSG00000229122.1	AGBL5-IT1	-3.72	0.000225	0.0156	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26912057	chr2:27061038~27061815:+
THCA	cis	rs2885805	0.507	rs12131279	ENSG00000203878.10	CHIAP2	3.72	0.000225	0.0156	0.18	0.17	Cytomegalovirus antibody response;	chr1:110922420	chr1:111280059~111286116:+
THCA	cis	rs7586085	0.967	rs13009603	ENSG00000232411.1	AC009495.3	-3.72	0.000225	0.0157	-0.18	-0.17	Total body bone mineral density;	chr2:165705435	chr2:165833048~165839098:-
THCA	cis	rs12476592	0.602	rs262482	ENSG00000242412.1	DBIL5P2	3.72	0.000225	0.0157	0.22	0.17	Childhood ear infection;	chr2:63649908	chr2:63117851~63119542:-
THCA	cis	rs10975370	0.503	rs411087	ENSG00000206147.5	RP11-106A1.2	3.72	0.000225	0.0157	0.2	0.17	Breast cancer;	chr9:6036496	chr9:6639139~6639604:+
THCA	cis	rs10129255	1	rs10141557	ENSG00000280411.1	IGHV1-69-2	-3.72	0.000225	0.0157	-0.11	-0.17	Kawasaki disease;	chr14:106767990	chr14:106762092~106762588:-
THCA	cis	rs6797464	0.536	rs7638569	ENSG00000241479.1	RP11-641D5.2	-3.72	0.000225	0.0157	-0.3	-0.17	Overall survival in osteosarcoma;	chr3:169494579	chr3:169447867~169477052:+
THCA	cis	rs4915077	1	rs11588186	ENSG00000226822.1	RP11-356N1.2	3.72	0.000225	0.0157	0.33	0.17	Hypothyroidism;	chr1:107763935	chr1:108071482~108074519:+
THCA	cis	rs1050631	0.96	rs4799848	ENSG00000260552.1	RP11-49I11.1	3.72	0.000225	0.0157	0.21	0.17	Esophageal squamous cell cancer (length of survival);	chr18:36106329	chr18:36179996~36187448:-
THCA	cis	rs4972539	0.5	rs4972536	ENSG00000238133.5	MLK7-AS1	3.72	0.000225	0.0157	0.22	0.17	Parental longevity (mother's age at death);	chr2:173211545	chr2:173166446~173282036:-
THCA	cis	rs4906332	1	rs7155822	ENSG00000244691.1	RPL10AP1	-3.72	0.000225	0.0157	-0.22	-0.17	Coronary artery disease;	chr14:103456053	chr14:103412119~103412761:-
THCA	cis	rs6500602	0.893	rs4785962	ENSG00000280063.1	RP11-295D4.3	3.72	0.000225	0.0157	0.1	0.17	Schizophrenia;	chr16:4434327	chr16:4346694~4348648:-
THCA	cis	rs860295	0.702	rs56675301	ENSG00000236675.1	MTX1P1	-3.72	0.000225	0.0157	-0.17	-0.17	Body mass index;	chr1:155394536	chr1:155230975~155234325:+
THCA	cis	rs3806843	0.576	rs251373	ENSG00000278901.1	AC005609.17	-3.72	0.000225	0.0157	-0.19	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140873030	chr5:140878073~140882642:-
THCA	cis	rs3806843	0.545	rs251375	ENSG00000278901.1	AC005609.17	-3.72	0.000225	0.0157	-0.19	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140873375	chr5:140878073~140882642:-
THCA	cis	rs7711186	0.786	rs11953546	ENSG00000252464.1	RN7SKP70	3.72	0.000225	0.0157	0.2	0.17	Urate levels in obese individuals;	chr5:178652396	chr5:178619728~178619998:-
THCA	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-3.72	0.000225	0.0157	-0.17	-0.17	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
THCA	cis	rs9911578	1	rs302840	ENSG00000224738.1	AC099850.1	3.72	0.000225	0.0157	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58595718	chr17:59106598~59118267:+
THCA	cis	rs5753037	0.543	rs140122	ENSG00000273350.1	RP4-539M6.20	-3.72	0.000225	0.0157	-0.19	-0.17	Type 1 diabetes;	chr22:29742919	chr22:30420512~30420912:+
THCA	cis	rs9796	0.561	rs7173086	ENSG00000247556.5	OIP5-AS1	3.72	0.000225	0.0157	0.13	0.17	Menopause (age at onset);	chr15:41217090	chr15:41283990~41309737:+
THCA	cis	rs10438797	0.838	rs7211011	ENSG00000276995.1	RP11-321A17.6	-3.72	0.000225	0.0157	-0.16	-0.17	Night sleep phenotypes;	chr17:29162485	chr17:29071124~29071594:-
THCA	cis	rs495337	0.735	rs2281217	ENSG00000229222.1	KRT18P4	-3.72	0.000225	0.0157	-0.21	-0.17	Psoriasis;	chr20:49951518	chr20:49956745~49958032:+
THCA	cis	rs4948102	0.69	rs35844144	ENSG00000226278.1	PSPHP1	-3.72	0.000225	0.0157	-0.2	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:55982832	chr7:55764797~55773288:+
THCA	cis	rs1039766	1	rs268864	ENSG00000204929.10	AC074391.1	-3.72	0.000225	0.0157	-0.28	-0.17	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr2:65436711~66084639:+
THCA	cis	rs9878978	0.964	rs17786885	ENSG00000227588.2	CNTN4-AS2	3.72	0.000225	0.0157	0.2	0.17	Blood pressure (smoking interaction);	chr3:2446983	chr3:2110409~2144241:-
THCA	cis	rs3026101	0.624	rs1065483	ENSG00000234327.6	AC012146.7	-3.72	0.000225	0.0157	-0.14	-0.17	Body mass index;	chr17:5381475	chr17:5111468~5115004:+
THCA	cis	rs4713118	0.591	rs2056924	ENSG00000220721.1	OR1F12	3.72	0.000225	0.0157	0.2	0.17	Parkinson's disease;	chr6:27722395	chr6:28073316~28074233:+
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000219891.2	ZSCAN12P1	-3.72	0.000225	0.0157	-0.23	-0.17	Parkinson's disease;	chr6:28065396	chr6:28091154~28093664:+
THCA	cis	rs7772697	0.635	rs6901626	ENSG00000223701.3	RAET1E-AS1	-3.72	0.000225	0.0157	-0.23	-0.17	Diabetic retinopathy;	chr6:149086990	chr6:149884431~149919508:+
THCA	cis	rs9650657	0.617	rs28680211	ENSG00000261451.1	RP11-981G7.1	-3.72	0.000225	0.0157	-0.2	-0.17	Neuroticism;	chr8:10661935	chr8:10433672~10438312:+
THCA	cis	rs4073416	0.542	rs4902404	ENSG00000276116.2	FUT8-AS1	3.72	0.000225	0.0157	0.19	0.17	N-glycan levels;	chr14:65580304	chr14:65411170~65412690:-
THCA	cis	rs4869313	0.642	rs2549796	ENSG00000247121.5	CTD-2260A17.2	3.72	0.000225	0.0157	0.13	0.17	Pediatric autoimmune diseases;	chr5:96909639	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2042385	ENSG00000247121.5	CTD-2260A17.2	3.72	0.000225	0.0157	0.13	0.17	Pediatric autoimmune diseases;	chr5:96912289	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2548522	ENSG00000247121.5	CTD-2260A17.2	3.72	0.000225	0.0157	0.13	0.17	Pediatric autoimmune diseases;	chr5:96914753	chr5:96814028~96935809:-
THCA	cis	rs35851103	0.506	rs4841659	ENSG00000254948.1	OR7E158P	-3.72	0.000225	0.0157	-0.21	-0.17	Neuroticism;	chr8:11970691	chr8:11919900~11920809:-
THCA	cis	rs61160187	0.582	rs34619	ENSG00000251279.1	CTC-436P18.1	-3.72	0.000225	0.0157	-0.21	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:61162070~61232040:+
THCA	cis	rs1433188	0.847	rs1433187	ENSG00000253582.1	RP11-649G15.2	3.72	0.000225	0.0157	0.19	0.17	Subjective well-being;	chr8:107434721	chr8:106520474~106657548:-
THCA	cis	rs7112925	0.932	rs2282502	ENSG00000255517.5	CTD-3074O7.5	3.72	0.000225	0.0157	0.13	0.17	Height;	chr11:67066781	chr11:66473490~66480233:-
THCA	cis	rs7267979	0.932	rs1541061	ENSG00000276952.1	RP5-965G21.6	3.72	0.000225	0.0157	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.932	rs6138600	ENSG00000276952.1	RP5-965G21.6	3.72	0.000225	0.0157	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.899	rs2104734	ENSG00000276952.1	RP5-965G21.6	3.72	0.000225	0.0157	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25284915~25285588:-
THCA	cis	rs9309711	0.689	rs4535075	ENSG00000271868.1	RP11-1293J14.1	-3.72	0.000225	0.0157	-0.22	-0.17	Neurofibrillary tangles;	chr2:3477945	chr2:3496956~3497428:+
THCA	cis	rs7176527	0.784	rs62021162	ENSG00000230373.7	GOLGA6L5P	3.72	0.000225	0.0157	0.2	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84507885~84516814:-
THCA	cis	rs13113518	0.812	rs13140173	ENSG00000272969.1	RP11-528I4.2	3.72	0.000226	0.0157	0.2	0.17	Height;	chr4:55527164	chr4:55547112~55547889:+
THCA	cis	rs6545883	0.894	rs778143	ENSG00000212978.6	AC016747.3	3.72	0.000226	0.0157	0.18	0.17	Tuberculosis;	chr2:61354755	chr2:61141592~61144969:-
THCA	cis	rs34779708	0.766	rs35308730	ENSG00000233200.1	RP11-324I22.2	3.72	0.000226	0.0157	0.21	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.736	rs34195979	ENSG00000233200.1	RP11-324I22.2	3.72	0.000226	0.0157	0.21	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.649	rs34421369	ENSG00000233200.1	RP11-324I22.2	3.72	0.000226	0.0157	0.21	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.677	rs112355105	ENSG00000233200.1	RP11-324I22.2	3.72	0.000226	0.0157	0.21	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35219894~35230598:-
THCA	cis	rs9368481	0.7	rs6911401	ENSG00000228223.2	HCG11	-3.72	0.000226	0.0157	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26523450~26526579:+
THCA	cis	rs9889262	0.641	rs663576	ENSG00000248714.5	RP11-1079K10.3	3.72	0.000226	0.0157	0.19	0.17	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49254625	chr17:49361165~49369998:+
THCA	cis	rs763121	0.813	rs4821807	ENSG00000225450.1	RP3-508I15.14	-3.72	0.000226	0.0157	-0.13	-0.17	Menopause (age at onset);	chr22:38669577	chr22:38739003~38749041:+
THCA	cis	rs17286411	0.671	rs9936903	ENSG00000260185.1	RP11-432I5.6	-3.72	0.000226	0.0157	-0.23	-0.17	Blood protein levels;	chr16:71693668	chr16:71655027~71664212:+
THCA	cis	rs6921919	0.638	rs7772827	ENSG00000176933.5	TOB2P1	-3.72	0.000226	0.0157	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28217643~28218634:-
THCA	cis	rs11601239	0.668	rs7115736	ENSG00000254750.1	CASP1P2	3.72	0.000226	0.0157	0.13	0.17	Refractive error;	chr11:105751181	chr11:105063345~105071541:-
THCA	cis	rs853679	0.517	rs1947863	ENSG00000219891.2	ZSCAN12P1	3.72	0.000226	0.0157	0.24	0.17	Depression;	chr6:28131566	chr6:28091154~28093664:+
THCA	cis	rs2919009	0.581	rs61872768	ENSG00000271670.1	RP11-95I16.4	3.72	0.000226	0.0157	0.19	0.17	Obesity-related traits;	chr10:120934409	chr10:120879256~120880667:-
THCA	cis	rs11671005	0.779	rs3794971	ENSG00000269600.1	AC016629.3	-3.72	0.000226	0.0157	-0.25	-0.17	Mean platelet volume;	chr19:58474499	chr19:58593896~58599355:-
THCA	cis	rs7772697	0.508	rs12153925	ENSG00000223701.3	RAET1E-AS1	-3.72	0.000226	0.0157	-0.24	-0.17	Diabetic retinopathy;	chr6:149047174	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.508	rs34118116	ENSG00000223701.3	RAET1E-AS1	-3.72	0.000226	0.0157	-0.24	-0.17	Diabetic retinopathy;	chr6:149048126	chr6:149884431~149919508:+
THCA	cis	rs7259376	0.525	rs1692594	ENSG00000269138.1	ZNF209P	3.72	0.000226	0.0157	0.16	0.17	Menopause (age at onset);	chr19:22451796	chr19:22463922~22473036:+
THCA	cis	rs7824557	0.547	rs4512344	ENSG00000254527.1	ENPP7P12	-3.72	0.000226	0.0157	-0.22	-0.17	Retinal vascular caliber;	chr8:11221272	chr8:12205759~12206389:-
THCA	cis	rs6568686	0.627	rs4245546	ENSG00000255389.1	C6orf3	-3.72	0.000226	0.0157	-0.22	-0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111582747	chr6:111599875~111602295:+
THCA	cis	rs701145	0.585	rs1727957	ENSG00000243069.6	ARHGEF26-AS1	3.72	0.000226	0.0157	0.32	0.17	Coronary artery disease;	chr3:154152618	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1470663	ENSG00000243069.6	ARHGEF26-AS1	3.72	0.000226	0.0157	0.32	0.17	Coronary artery disease;	chr3:154153094	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1470662	ENSG00000243069.6	ARHGEF26-AS1	3.72	0.000226	0.0157	0.32	0.17	Coronary artery disease;	chr3:154153208	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727954	ENSG00000243069.6	ARHGEF26-AS1	3.72	0.000226	0.0157	0.32	0.17	Coronary artery disease;	chr3:154153483	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1727953	ENSG00000243069.6	ARHGEF26-AS1	3.72	0.000226	0.0157	0.32	0.17	Coronary artery disease;	chr3:154153603	chr3:154024401~154121332:-
THCA	cis	rs2562456	0.876	rs62110163	ENSG00000268658.4	LINC00664	3.72	0.000226	0.0157	0.24	0.17	Pain;	chr19:21546020	chr19:21483374~21503238:+
THCA	cis	rs9303542	0.729	rs7206951	ENSG00000278765.1	RP5-890E16.5	3.72	0.000226	0.0157	0.22	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48319469	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs35974423	ENSG00000278765.1	RP5-890E16.5	-3.72	0.000226	0.0157	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48329258	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs17623154	ENSG00000278765.1	RP5-890E16.5	-3.72	0.000226	0.0157	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48338660	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs35509644	ENSG00000278765.1	RP5-890E16.5	-3.72	0.000226	0.0157	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48340785	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs12939680	ENSG00000278765.1	RP5-890E16.5	-3.72	0.000226	0.0157	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48381289	chr17:48066704~48067293:-
THCA	cis	rs11771526	0.551	rs6462344	ENSG00000272905.1	RP11-265E18.1	-3.72	0.000226	0.0157	-0.21	-0.17	Body mass index;	chr7:32215277	chr7:32845394~32846061:+
THCA	cis	rs16975963	0.644	rs2290999	ENSG00000276846.1	CTD-3220F14.3	-3.72	0.000226	0.0157	-0.15	-0.17	Longevity;	chr19:37647986	chr19:37314868~37315620:-
THCA	cis	rs4938303	0.756	rs4938301	ENSG00000254851.1	RP11-109L13.1	3.72	0.000226	0.0157	0.26	0.17	Triglycerides;	chr11:116704757	chr11:117135528~117138582:+
THCA	cis	rs4660456	0.913	rs657149	ENSG00000238287.1	RP11-656D10.3	3.72	0.000226	0.0157	0.21	0.17	Platelet count;	chr1:40692486	chr1:40493157~40508661:-
THCA	cis	rs73193808	0.851	rs12482584	ENSG00000273017.1	AP000240.9	3.72	0.000226	0.0157	0.21	0.17	Coronary artery disease;	chr21:29233532	chr21:29359002~29359453:+
THCA	cis	rs1577917	0.958	rs7453105	ENSG00000220563.1	PKMP3	-3.72	0.000226	0.0157	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85791043	chr6:85659892~85660606:-
THCA	cis	rs17194490	0.665	rs6800347	ENSG00000237990.3	CNTN4-AS1	3.72	0.000226	0.0157	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2529156	chr3:3039033~3069242:-
THCA	cis	rs17194490	0.609	rs6788062	ENSG00000237990.3	CNTN4-AS1	3.72	0.000226	0.0157	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2529428	chr3:3039033~3069242:-
THCA	cis	rs17194490	0.509	rs13081495	ENSG00000237990.3	CNTN4-AS1	3.72	0.000226	0.0157	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2529777	chr3:3039033~3069242:-
THCA	cis	rs17194490	0.665	rs17621371	ENSG00000237990.3	CNTN4-AS1	3.72	0.000226	0.0157	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2530794	chr3:3039033~3069242:-
THCA	cis	rs17194490	0.665	rs17621399	ENSG00000237990.3	CNTN4-AS1	3.72	0.000226	0.0157	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2531117	chr3:3039033~3069242:-
THCA	cis	rs17194490	0.665	rs13073522	ENSG00000237990.3	CNTN4-AS1	3.72	0.000226	0.0157	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2531237	chr3:3039033~3069242:-
THCA	cis	rs17194490	0.665	rs13093102	ENSG00000237990.3	CNTN4-AS1	3.72	0.000226	0.0157	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2531464	chr3:3039033~3069242:-
THCA	cis	rs7819412	0.875	rs11250121	ENSG00000255046.1	RP11-297N6.4	3.72	0.000226	0.0157	0.18	0.17	Triglycerides;	chr8:11202802	chr8:11797928~11802568:-
THCA	cis	rs5758511	0.68	rs5751243	ENSG00000230107.1	CTA-126B4.7	-3.72	0.000226	0.0157	-0.2	-0.17	Birth weight;	chr22:42221171	chr22:42438023~42446195:+
THCA	cis	rs6499755	0.932	rs31076	ENSG00000260135.5	RP11-212I21.2	-3.72	0.000226	0.0157	-0.19	-0.17	Hypospadias;	chr16:55323549	chr16:55426797~55462297:-
THCA	cis	rs7818688	0.578	rs73269188	ENSG00000253528.2	RP11-347C18.4	-3.72	0.000226	0.0157	-0.25	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94826118	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.614	rs73269199	ENSG00000253528.2	RP11-347C18.4	-3.72	0.000226	0.0157	-0.25	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94829485	chr8:94974573~94974853:-
THCA	cis	rs763121	0.962	rs6001159	ENSG00000225450.1	RP3-508I15.14	-3.72	0.000226	0.0157	-0.13	-0.17	Menopause (age at onset);	chr22:38570482	chr22:38739003~38749041:+
THCA	cis	rs964611	0.872	rs8039702	ENSG00000259488.2	RP11-154J22.1	-3.72	0.000226	0.0157	-0.16	-0.17	Metabolite levels (Pyroglutamine);	chr15:48271963	chr15:48312353~48331856:-
THCA	cis	rs9970896	1	rs9970896	ENSG00000237845.1	RP5-940F7.2	-3.72	0.000226	0.0157	-0.28	-0.17	Monocyte percentage of white cells;	chr1:235941681	chr1:235942553~235943805:-
THCA	cis	rs7851693	0.964	rs8181197	ENSG00000232172.1	RP11-57C19.2	-3.72	0.000226	0.0157	-0.18	-0.17	Bone mineral density;	chr9:130594603	chr9:130651799~130652383:+
THCA	cis	rs1065656	0.571	rs12149777	ENSG00000261123.1	RP11-304L19.3	-3.72	0.000226	0.0157	-0.19	-0.17	Insulin-like growth factors;	chr16:1784723	chr16:2094830~2097026:-
THCA	cis	rs7259376	0.902	rs10414591	ENSG00000269345.1	VN1R85P	-3.72	0.000226	0.0157	-0.18	-0.17	Menopause (age at onset);	chr19:22417320	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.902	rs10420380	ENSG00000269345.1	VN1R85P	-3.72	0.000226	0.0157	-0.18	-0.17	Menopause (age at onset);	chr19:22417822	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.869	rs10402396	ENSG00000269345.1	VN1R85P	-3.72	0.000226	0.0157	-0.18	-0.17	Menopause (age at onset);	chr19:22419007	chr19:22174766~22175191:-
THCA	cis	rs67478160	0.643	rs12880167	ENSG00000258534.1	CTD-2134A5.4	-3.72	0.000226	0.0157	-0.17	-0.17	Schizophrenia;	chr14:103834492	chr14:103854366~103880111:-
THCA	cis	rs3018712	0.532	rs948863	ENSG00000212093.1	AP000807.1	-3.72	0.000226	0.0157	-0.22	-0.17	Total body bone mineral density;	chr11:68653506	chr11:68506083~68506166:-
THCA	cis	rs7665090	0.875	rs6813322	ENSG00000248971.2	KRT8P46	-3.72	0.000226	0.0157	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634462	chr4:102728746~102730171:-
THCA	cis	rs11673344	0.563	rs55825113	ENSG00000267260.1	CTD-2162K18.4	-3.72	0.000226	0.0157	-0.2	-0.17	Obesity-related traits;	chr19:37191523	chr19:36773153~36777078:+
THCA	cis	rs80130819	0.688	rs2732476	ENSG00000226413.2	OR8T1P	3.72	0.000226	0.0157	0.24	0.17	Prostate cancer;	chr12:48306908	chr12:48442030~48442947:-
THCA	cis	rs55661361	0.553	rs11219765	ENSG00000255045.1	RP11-677M14.2	-3.72	0.000226	0.0157	-0.14	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124732351	chr11:124744634~124746337:-
THCA	cis	rs793571	0.822	rs11858989	ENSG00000245975.2	RP11-30K9.6	3.72	0.000226	0.0157	0.18	0.17	Schizophrenia;	chr15:58883029	chr15:58768072~58770974:-
THCA	cis	rs7923609	0.54	rs10995455	ENSG00000232075.1	MRPL35P2	-3.72	0.000226	0.0157	-0.26	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63176601	chr10:63634317~63634827:-
THCA	cis	rs2732480	0.557	rs2732454	ENSG00000257735.1	RP11-370I10.6	3.72	0.000226	0.0157	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48350945~48442411:+
THCA	cis	rs1790761	0.505	rs4320958	ENSG00000255318.1	RP11-655M14.13	-3.72	0.000226	0.0157	-0.19	-0.17	Mean corpuscular volume;	chr11:67542863	chr11:67618279~67627304:-
THCA	cis	rs709400	0.859	rs942863	ENSG00000258735.1	LINC00637	3.72	0.000226	0.0157	0.23	0.17	Body mass index;	chr14:103554931	chr14:103847721~103858049:+
THCA	cis	rs6957923	0.818	rs12538407	ENSG00000234286.1	AC006026.13	-3.72	0.000226	0.0157	-0.22	-0.17	Height;	chr7:23481697	chr7:23680195~23680786:-
THCA	cis	rs17689437	0.958	rs17622185	ENSG00000260084.1	RP11-615I2.1	-3.72	0.000226	0.0157	-0.28	-0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68574186	chr16:68573782~68589512:-
THCA	cis	rs2980439	0.517	rs793753	ENSG00000233609.3	RP11-62H7.2	-3.72	0.000226	0.0157	-0.17	-0.17	Neuroticism;	chr8:8247837	chr8:8961200~8979025:+
THCA	cis	rs10043228	1	rs7727882	ENSG00000248445.4	SEMA6A-AS1	-3.72	0.000226	0.0157	-0.22	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116278810	chr5:116447547~116508276:+
THCA	cis	rs4268898	0.722	rs11680491	ENSG00000242628.4	AC009228.1	-3.72	0.000226	0.0157	-0.2	-0.17	Asthma;	chr2:24193423	chr2:24214381~24221516:+
THCA	cis	rs42648	0.79	rs42637	ENSG00000225498.1	AC002064.5	3.72	0.000226	0.0157	0.18	0.17	Homocysteine levels;	chr7:90340517	chr7:90312496~90322592:+
THCA	cis	rs4908760	0.827	rs10864360	ENSG00000270282.1	RP5-1115A15.2	3.72	0.000226	0.0157	0.2	0.17	Vitiligo;	chr1:8664463	chr1:8512653~8513021:+
THCA	cis	rs1411478	1	rs6425657	ENSG00000243155.1	RP11-46A10.5	3.72	0.000226	0.0157	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180987769	chr1:180944042~180976482:-
THCA	cis	rs6546550	0.935	rs2305523	ENSG00000179818.12	PCBP1-AS1	3.72	0.000226	0.0157	0.14	0.17	Prevalent atrial fibrillation;	chr2:69812545	chr2:69962263~70103220:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000182722.5	SEPHS1P1	-3.72	0.000226	0.0157	-0.2	-0.17	Calcium levels;	chr7:65853042	chr7:64852397~64853354:-
THCA	cis	rs7119	0.635	rs867916	ENSG00000259362.2	RP11-307C19.1	3.72	0.000226	0.0157	0.22	0.17	Type 2 diabetes;	chr15:77590518	chr15:77525540~77534110:+
THCA	cis	rs76382185	0.808	rs17450565	ENSG00000233184.5	RP11-421L21.3	3.72	0.000226	0.0157	0.27	0.17	Lymphocyte counts;	chr1:101136374	chr1:101025878~101087268:+
THCA	cis	rs700641	1	rs700641	ENSG00000231621.1	AC013264.2	-3.72	0.000226	0.0157	-0.16	-0.17	Morning vs. evening chronotype;	chr2:197734509	chr2:197197991~197199273:+
THCA	cis	rs988712	0.55	rs988748	ENSG00000245573.6	BDNF-AS	3.72	0.000226	0.0157	0.16	0.17	Obesity;	chr11:27703198	chr11:27506838~27698174:+
THCA	cis	rs7927592	0.913	rs6591346	ENSG00000160172.9	FAM86C2P	3.72	0.000226	0.0157	0.16	0.17	Total body bone mineral density;	chr11:68617150	chr11:67791648~67805336:-
THCA	cis	rs911555	0.755	rs4143998	ENSG00000269958.1	RP11-73M18.8	3.72	0.000227	0.0157	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs1138400	ENSG00000269958.1	RP11-73M18.8	3.72	0.000227	0.0157	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103696353~103697163:+
THCA	cis	rs911555	0.755	rs7147664	ENSG00000269958.1	RP11-73M18.8	3.72	0.000227	0.0157	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103696353~103697163:+
THCA	cis	rs1113500	0.814	rs893983	ENSG00000230489.1	VAV3-AS1	3.72	0.000227	0.0157	0.15	0.17	Growth-regulated protein alpha levels;	chr1:108087716	chr1:107964443~107994607:+
THCA	cis	rs4908760	0.795	rs6693009	ENSG00000270282.1	RP5-1115A15.2	3.72	0.000227	0.0157	0.2	0.17	Vitiligo;	chr1:8683651	chr1:8512653~8513021:+
THCA	cis	rs3105593	0.932	rs2414073	ENSG00000242737.1	RP11-562A8.1	3.72	0.000227	0.0157	0.21	0.17	QT interval;	chr15:50558361	chr15:50466738~50467096:+
THCA	cis	rs3105593	0.932	rs2414072	ENSG00000242737.1	RP11-562A8.1	3.72	0.000227	0.0157	0.21	0.17	QT interval;	chr15:50558365	chr15:50466738~50467096:+
THCA	cis	rs7911264	0.739	rs7071905	ENSG00000236493.2	EIF2S2P3	3.72	0.000227	0.0157	0.18	0.17	Inflammatory bowel disease;	chr10:92626365	chr10:92668745~92669743:-
THCA	cis	rs7911264	0.739	rs10882094	ENSG00000236493.2	EIF2S2P3	3.72	0.000227	0.0157	0.18	0.17	Inflammatory bowel disease;	chr10:92627919	chr10:92668745~92669743:-
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000237310.1	GS1-124K5.4	3.72	0.000227	0.0157	0.2	0.17	Diabetic kidney disease;	chr7:66474549	chr7:66493706~66495474:+
THCA	cis	rs250585	0.736	rs30012	ENSG00000260136.4	CTD-2270L9.4	3.72	0.000227	0.0157	0.13	0.17	Egg allergy;	chr16:23409622	chr16:23452758~23457606:+
THCA	cis	rs250585	0.736	rs30010	ENSG00000260136.4	CTD-2270L9.4	3.72	0.000227	0.0157	0.13	0.17	Egg allergy;	chr16:23411337	chr16:23452758~23457606:+
THCA	cis	rs250585	0.736	rs40817	ENSG00000260136.4	CTD-2270L9.4	3.72	0.000227	0.0157	0.13	0.17	Egg allergy;	chr16:23411351	chr16:23452758~23457606:+
THCA	cis	rs250585	0.736	rs250579	ENSG00000260136.4	CTD-2270L9.4	3.72	0.000227	0.0157	0.13	0.17	Egg allergy;	chr16:23414264	chr16:23452758~23457606:+
THCA	cis	rs250585	0.704	rs11861636	ENSG00000260136.4	CTD-2270L9.4	3.72	0.000227	0.0157	0.13	0.17	Egg allergy;	chr16:23428676	chr16:23452758~23457606:+
THCA	cis	rs250585	0.736	rs250551	ENSG00000260136.4	CTD-2270L9.4	3.72	0.000227	0.0157	0.13	0.17	Egg allergy;	chr16:23429290	chr16:23452758~23457606:+
THCA	cis	rs962856	0.575	rs661435	ENSG00000236780.4	AC078941.1	-3.72	0.000227	0.0157	-0.22	-0.17	Pancreatic cancer;	chr2:67426981	chr2:67123357~67215319:-
THCA	cis	rs10479542	0.63	rs6879664	ENSG00000250999.1	RP11-1379J22.5	3.72	0.000227	0.0157	0.21	0.17	Lung cancer;	chr5:179547575	chr5:179657762~179664432:+
THCA	cis	rs10479542	0.642	rs6879665	ENSG00000250999.1	RP11-1379J22.5	3.72	0.000227	0.0157	0.21	0.17	Lung cancer;	chr5:179547580	chr5:179657762~179664432:+
THCA	cis	rs877529	1	rs139401	ENSG00000279833.1	RP4-742C19.13	-3.72	0.000227	0.0157	-0.11	-0.17	Multiple myeloma;	chr22:39150069	chr22:39133090~39136760:+
THCA	cis	rs4578769	0.691	rs28594790	ENSG00000265939.1	UBE2CP2	-3.72	0.000227	0.0157	-0.19	-0.17	Eosinophil percentage of white cells;	chr18:22985463	chr18:22900486~22900995:-
THCA	cis	rs7809950	0.678	rs62482499	ENSG00000272072.1	CTA-363E19.2	3.72	0.000227	0.0157	0.18	0.17	Coronary artery disease;	chr7:107334614	chr7:107192559~107193300:-
THCA	cis	rs9341808	0.718	rs2322636	ENSG00000260645.1	RP11-250B2.5	3.72	0.000227	0.0158	0.14	0.17	Sitting height ratio;	chr6:80187719	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.718	rs9448908	ENSG00000260645.1	RP11-250B2.5	3.72	0.000227	0.0158	0.14	0.17	Sitting height ratio;	chr6:80188352	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.718	rs3828754	ENSG00000260645.1	RP11-250B2.5	3.72	0.000227	0.0158	0.14	0.17	Sitting height ratio;	chr6:80190923	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.718	rs10943696	ENSG00000260645.1	RP11-250B2.5	3.72	0.000227	0.0158	0.14	0.17	Sitting height ratio;	chr6:80191555	chr6:80466958~80469080:+
THCA	cis	rs17270561	0.583	rs12662869	ENSG00000272462.2	U91328.19	3.72	0.000227	0.0158	0.14	0.17	Iron status biomarkers;	chr6:25784253	chr6:25992662~26001775:+
THCA	cis	rs4730276	0.674	rs10953554	ENSG00000241764.3	AC002467.7	-3.72	0.000227	0.0158	-0.14	-0.17	Ulcerative colitis;	chr7:107935112	chr7:107742817~107744581:-
THCA	cis	rs35343117	1	rs35343117	ENSG00000259630.2	CTD-2262B20.1	-3.72	0.000227	0.0158	-0.22	-0.17	Psoriasis;	chr15:85535884	chr15:85415228~85415633:+
THCA	cis	rs9646944	0.519	rs1041973	ENSG00000234389.1	AC007278.3	-3.72	0.000227	0.0158	-0.19	-0.17	Blood protein levels;	chr2:102339008	chr2:102438713~102440475:+
THCA	cis	rs3806843	0.606	rs251377	ENSG00000278901.1	AC005609.17	-3.72	0.000227	0.0158	-0.19	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140876207	chr5:140878073~140882642:-
THCA	cis	rs3824488	0.92	rs75614054	ENSG00000271155.1	RP11-435O5.5	-3.72	0.000227	0.0158	-0.31	-0.17	Neuroticism;	chr9:95513507	chr9:95506235~95507636:+
THCA	cis	rs804280	0.564	rs4639	ENSG00000254948.1	OR7E158P	-3.72	0.000227	0.0158	-0.19	-0.17	Myopia (pathological);	chr8:11787242	chr8:11919900~11920809:-
THCA	cis	rs427394	0.659	rs274717	ENSG00000248677.1	CTD-2044J15.1	-3.72	0.000227	0.0158	-0.16	-0.17	Menopause (age at onset);	chr5:6720954	chr5:6686325~6707711:-
THCA	cis	rs8053891	0.507	rs12919469	ENSG00000279206.1	RP5-991G20.6	3.72	0.000227	0.0158	0.18	0.17	Coronary artery disease;	chr16:71994713	chr16:72772673~72773272:+
THCA	cis	rs12476592	0.602	rs6732791	ENSG00000242412.1	DBIL5P2	3.72	0.000227	0.0158	0.22	0.17	Childhood ear infection;	chr2:63561767	chr2:63117851~63119542:-
THCA	cis	rs172166	0.61	rs276369	ENSG00000261839.1	RP1-265C24.8	3.72	0.000227	0.0158	0.16	0.17	Cardiac Troponin-T levels;	chr6:27951465	chr6:28136849~28139678:+
THCA	cis	rs3748656	1	rs61818802	ENSG00000273483.1	RP4-671G15.2	3.72	0.000227	0.0158	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112639117	chr1:112517799~112518441:-
THCA	cis	rs8141529	0.509	rs12628211	ENSG00000226471.5	CTA-292E10.6	-3.72	0.000227	0.0158	-0.15	-0.17	Lymphocyte counts;	chr22:28843262	chr22:28800683~28848559:+
THCA	cis	rs62158800	0.598	rs1606985	ENSG00000225588.2	AC096669.1	3.72	0.000227	0.0158	0.17	0.17	Facial morphology (factor 22);	chr2:107675347	chr2:107362282~107407329:+
THCA	cis	rs228614	0.502	rs78573682	ENSG00000248161.4	RP11-499E18.1	-3.72	0.000227	0.0158	-0.19	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102502510	chr4:102418602~102450010:-
THCA	cis	rs75504410	0.85	rs7700054	ENSG00000231160.8	KLF3-AS1	-3.72	0.000227	0.0158	-0.15	-0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38716744	chr4:38612701~38664883:-
THCA	cis	rs72945132	0.678	rs12786421	ENSG00000254604.1	AP000487.6	-3.72	0.000227	0.0158	-0.31	-0.17	Coronary artery disease;	chr11:70389208	chr11:70282367~70363368:-
THCA	cis	rs72945132	0.678	rs7113595	ENSG00000254604.1	AP000487.6	-3.72	0.000227	0.0158	-0.31	-0.17	Coronary artery disease;	chr11:70390713	chr11:70282367~70363368:-
THCA	cis	rs2562456	0.834	rs2173727	ENSG00000268278.1	RP11-420K14.1	-3.72	0.000227	0.0158	-0.2	-0.17	Pain;	chr19:21491155	chr19:21637974~21656300:+
THCA	cis	rs12476592	0.571	rs262475	ENSG00000242412.1	DBIL5P2	3.72	0.000227	0.0158	0.21	0.17	Childhood ear infection;	chr2:63641911	chr2:63117851~63119542:-
THCA	cis	rs13323323	0.691	rs9814256	ENSG00000214820.3	MPRIPP1	3.72	0.000227	0.0158	0.2	0.17	IgG glycosylation;	chr3:44626545	chr3:44579938~44581026:-
THCA	cis	rs683257	1	rs9495860	ENSG00000234147.1	RP3-460G2.2	-3.72	0.000227	0.0158	-0.32	-0.17	Facial emotion recognition (angry faces);	chr6:140895031	chr6:140845958~140852924:-
THCA	cis	rs6860806	0.507	rs169256	ENSG00000224431.1	AC063976.7	3.72	0.000227	0.0158	0.17	0.17	Breast cancer;	chr5:132352840	chr5:132199456~132203487:+
THCA	cis	rs208520	0.909	rs9453672	ENSG00000233859.2	ADH5P4	3.72	0.000227	0.0158	0.26	0.17	Exhaled nitric oxide output;	chr6:66281538	chr6:65836930~65838039:-
THCA	cis	rs2898290	0.622	rs1478890	ENSG00000270154.1	RP11-419I17.1	-3.72	0.000227	0.0158	-0.21	-0.17	Systolic blood pressure;	chr8:11498093	chr8:12476462~12477122:+
THCA	cis	rs2736345	0.742	rs4840568	ENSG00000269899.1	RP11-589N15.2	-3.72	0.000227	0.0158	-0.2	-0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11493510	chr8:11846154~11846391:-
THCA	cis	rs17345786	0.861	rs17402964	ENSG00000244119.1	PDCL3P4	3.72	0.000227	0.0158	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr3:101349101	chr3:101712472~101713191:+
THCA	cis	rs11176749	0.614	rs73126362	ENSG00000256172.1	RP11-473M14.3	3.72	0.000227	0.0158	0.3	0.17	Expressive vocabulary in infants;	chr12:67465562	chr12:67440998~67442559:-
THCA	cis	rs7528684	1	rs945635	ENSG00000236731.1	RP4-801G22.2	3.72	0.000227	0.0158	0.18	0.17	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157700500	chr1:157629939~157630728:-
THCA	cis	rs6589219	0.908	rs7130173	ENSG00000196167.8	COLCA1	-3.72	0.000227	0.0158	-0.19	-0.17	Colorectal cancer;	chr11:111283347	chr11:111290787~111305045:-
THCA	cis	rs5752326	0.558	rs134146	ENSG00000261188.1	CTA-445C9.14	-3.72	0.000227	0.0158	-0.18	-0.17	Ischemic stroke;	chr22:26514329	chr22:26512537~26514568:+
THCA	cis	rs854765	0.693	rs8079321	ENSG00000281749.1	Y_RNA	3.72	0.000227	0.0158	0.21	0.17	Total body bone mineral density;	chr17:17857475	chr17:18001101~18001195:-
THCA	cis	rs12368653	0.607	rs7966795	ENSG00000270039.1	RP11-571M6.17	3.72	0.000227	0.0158	0.18	0.17	Multiple sclerosis;	chr12:57637630	chr12:57803838~57804415:+
THCA	cis	rs28830936	0.966	rs2303516	ENSG00000250379.1	RP11-23P13.4	3.72	0.000227	0.0158	0.19	0.17	Diastolic blood pressure;	chr15:41836370	chr15:41825099~41827936:-
THCA	cis	rs17286411	0.613	rs10459804	ENSG00000260185.1	RP11-432I5.6	-3.72	0.000227	0.0158	-0.24	-0.17	Blood protein levels;	chr16:71799928	chr16:71655027~71664212:+
THCA	cis	rs16975963	0.793	rs12460735	ENSG00000226686.6	LINC01535	-3.72	0.000227	0.0158	-0.23	-0.17	Longevity;	chr19:37822910	chr19:37251912~37265535:+
THCA	cis	rs34421088	0.559	rs12386974	ENSG00000227888.4	FAM66A	3.72	0.000227	0.0158	0.22	0.17	Neuroticism;	chr8:11543119	chr8:12362019~12388296:+
THCA	cis	rs8035452	1	rs12438326	ENSG00000273674.3	CTD-2378E12.1	3.72	0.000227	0.0158	0.21	0.17	Alzheimer's disease (late onset);	chr15:50745777	chr15:50839875~50908599:-
THCA	cis	rs1124769	0.719	rs56036336	ENSG00000259378.1	DCAF13P3	3.72	0.000227	0.0158	0.26	0.17	Cognitive performance;	chr15:51097090	chr15:50944663~50945996:+
THCA	cis	rs6500602	1	rs6500602	ENSG00000280063.1	RP11-295D4.3	3.72	0.000227	0.0158	0.09	0.17	Schizophrenia;	chr16:4447450	chr16:4346694~4348648:-
THCA	cis	rs4764124	0.652	rs6488712	ENSG00000261324.2	RP11-174G6.5	-3.72	0.000227	0.0158	-0.12	-0.17	Pubertal anthropometrics;	chr12:14786398	chr12:14762504~14767931:-
THCA	cis	rs9309711	0.666	rs6767	ENSG00000271868.1	RP11-1293J14.1	-3.72	0.000227	0.0158	-0.22	-0.17	Neurofibrillary tangles;	chr2:3479434	chr2:3496956~3497428:+
THCA	cis	rs9309711	0.623	rs7569694	ENSG00000271868.1	RP11-1293J14.1	-3.72	0.000227	0.0158	-0.22	-0.17	Neurofibrillary tangles;	chr2:3479619	chr2:3496956~3497428:+
THCA	cis	rs14027	0.921	rs1567359	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs2043430	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs12543087	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs10101278	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs1976575	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs7837589	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs67905698	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs28756749	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs4871634	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs10109901	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs10109951	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119838736~119840385:-
THCA	cis	rs14027	0.883	rs4871642	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs2634	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs4870955	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs34718068	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000227	0.0158	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119838736~119840385:-
THCA	cis	rs4722166	0.598	rs35658589	ENSG00000225541.1	AC002480.5	-3.72	0.000227	0.0158	-0.19	-0.17	Lung cancer;	chr7:22760816	chr7:22571607~22661792:-
THCA	cis	rs1113500	0.787	rs10881501	ENSG00000230489.1	VAV3-AS1	-3.72	0.000227	0.0158	-0.15	-0.17	Growth-regulated protein alpha levels;	chr1:108099123	chr1:107964443~107994607:+
THCA	cis	rs8058578	0.887	rs28421305	ENSG00000260911.2	RP11-196G11.2	3.72	0.000227	0.0158	0.15	0.17	Multiple myeloma;	chr16:30826807	chr16:31043150~31049868:+
THCA	cis	rs7737355	0.853	rs6873582	ENSG00000237714.1	P4HA2-AS1	3.72	0.000228	0.0158	0.24	0.17	Life satisfaction;	chr5:131557048	chr5:132184876~132192808:+
THCA	cis	rs2625529	0.775	rs62023342	ENSG00000260037.4	CTD-2524L6.3	-3.72	0.000228	0.0158	-0.24	-0.17	Red blood cell count;	chr15:71868964	chr15:71818396~71823384:+
THCA	cis	rs6840360	0.571	rs12647566	ENSG00000251611.1	RP11-610P16.1	-3.72	0.000228	0.0158	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151561373	chr4:151407551~151408835:-
THCA	cis	rs948562	1	rs76435840	ENSG00000280010.1	AP001350.4	3.72	0.000228	0.0158	0.26	0.17	Lymphoma;	chr11:58518508	chr11:58627435~58628528:+
THCA	cis	rs4237845	0.735	rs11172375	ENSG00000270039.1	RP11-571M6.17	-3.72	0.000228	0.0158	-0.18	-0.17	Intelligence (multi-trait analysis);	chr12:57897791	chr12:57803838~57804415:+
THCA	cis	rs1612141	1	rs1782178	ENSG00000251363.2	RP11-129M6.1	-3.72	0.000228	0.0158	-0.25	-0.17	QT interval (drug interaction);	chr14:41222658	chr14:40954898~40975877:+
THCA	cis	rs1612141	1	rs1619488	ENSG00000251363.2	RP11-129M6.1	-3.72	0.000228	0.0158	-0.25	-0.17	QT interval (drug interaction);	chr14:41222985	chr14:40954898~40975877:+
THCA	cis	rs5769765	0.955	rs5770750	ENSG00000260613.1	RP3-522J7.6	3.72	0.000228	0.0158	0.22	0.17	Schizophrenia;	chr22:49883180	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs2092982	ENSG00000260613.1	RP3-522J7.6	3.72	0.000228	0.0158	0.22	0.17	Schizophrenia;	chr22:49888556	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs738711	ENSG00000260613.1	RP3-522J7.6	3.72	0.000228	0.0158	0.22	0.17	Schizophrenia;	chr22:49888955	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.913	rs28670284	ENSG00000280567.1	Metazoa_SRP	-3.72	0.000228	0.0158	-0.25	-0.17	Schizophrenia;	chr22:49828325	chr22:49878999~49879242:+
THCA	cis	rs911555	0.547	rs8006994	ENSG00000269958.1	RP11-73M18.8	3.72	0.000228	0.0158	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103374959	chr14:103696353~103697163:+
THCA	cis	rs972578	1	rs972577	ENSG00000230319.1	AL022476.2	3.72	0.000228	0.0158	0.18	0.17	Mean platelet volume;	chr22:42991639	chr22:43038585~43052366:+
THCA	cis	rs7656342	0.866	rs2280206	ENSG00000249866.1	OR7E83P	3.72	0.000228	0.0158	0.19	0.17	Gut microbiota (bacterial taxa);	chr4:9797613	chr4:9512905~9513874:+
THCA	cis	rs7107174	0.901	rs11237459	ENSG00000254459.1	RP11-91P24.7	-3.71	0.000228	0.0158	-0.22	-0.17	Testicular germ cell tumor;	chr11:78345227	chr11:77829654~77872262:-
THCA	cis	rs7107174	1	rs11237460	ENSG00000254459.1	RP11-91P24.7	-3.71	0.000228	0.0158	-0.22	-0.17	Testicular germ cell tumor;	chr11:78345228	chr11:77829654~77872262:-
THCA	cis	rs71327718	1	rs71327718	ENSG00000272840.1	RP11-379B18.6	3.71	0.000228	0.0158	0.32	0.17	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125774714~125797953:+
THCA	cis	rs6443245	0.611	rs2648378	ENSG00000227110.5	LMCD1-AS1	-3.71	0.000228	0.0158	-0.2	-0.17	Daytime sleep phenotypes;	chr3:9583889	chr3:7952805~8611924:-
THCA	cis	rs6443245	0.611	rs2648377	ENSG00000227110.5	LMCD1-AS1	-3.71	0.000228	0.0158	-0.2	-0.17	Daytime sleep phenotypes;	chr3:9583985	chr3:7952805~8611924:-
THCA	cis	rs925946	0.518	rs73430668	ENSG00000245573.6	BDNF-AS	-3.71	0.000228	0.0158	-0.16	-0.17	Weight;Body mass index;	chr11:27591872	chr11:27506838~27698174:+
THCA	cis	rs10911902	0.561	rs1919199	ENSG00000233196.2	GS1-304P7.1	-3.71	0.000228	0.0158	-0.28	-0.17	Schizophrenia;	chr1:186300752	chr1:186580515~186581191:-
THCA	cis	rs4906332	0.933	rs34606394	ENSG00000259775.1	RP11-45P15.4	-3.71	0.000228	0.0158	-0.14	-0.17	Coronary artery disease;	chr14:103449299	chr14:103331674~103332367:-
THCA	cis	rs11841001	0.556	rs17065026	ENSG00000261105.4	LMO7-AS1	3.71	0.000228	0.0158	0.24	0.17	Corneal astigmatism;	chr13:75779020	chr13:75604700~75635994:-
THCA	cis	rs17074492	1	rs17074500	ENSG00000214182.5	PTMAP5	3.71	0.000228	0.0158	0.19	0.17	Sjögren's syndrome;	chr13:81589066	chr13:81689911~81691072:+
THCA	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	3.71	0.000228	0.0158	0.15	0.17	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
THCA	cis	rs2243480	1	rs7804223	ENSG00000237310.1	GS1-124K5.4	-3.71	0.000228	0.0158	-0.2	-0.17	Diabetic kidney disease;	chr7:66199572	chr7:66493706~66495474:+
THCA	cis	rs2348418	0.733	rs7294486	ENSG00000278733.1	RP11-425D17.1	3.71	0.000228	0.0158	0.15	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28181989	chr12:28185625~28186190:-
THCA	cis	rs7845219	0.539	rs13271644	ENSG00000253528.2	RP11-347C18.4	3.71	0.000228	0.0158	0.19	0.17	Type 2 diabetes;	chr8:94841720	chr8:94974573~94974853:-
THCA	cis	rs4683346	0.702	rs4682863	ENSG00000273328.4	RP11-141M3.6	-3.71	0.000228	0.0158	-0.21	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42836219	chr3:42809414~42908105:+
THCA	cis	rs7824557	0.527	rs2572376	ENSG00000261451.1	RP11-981G7.1	-3.71	0.000228	0.0158	-0.21	-0.17	Retinal vascular caliber;	chr8:11380247	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.527	rs2736305	ENSG00000261451.1	RP11-981G7.1	-3.71	0.000228	0.0158	-0.21	-0.17	Retinal vascular caliber;	chr8:11380264	chr8:10433672~10438312:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000164669.11	INTS4P1	3.71	0.000228	0.0158	0.21	0.17	Aortic root size;	chr7:66113790	chr7:65141225~65234216:+
THCA	cis	rs9818758	0.607	rs34326553	ENSG00000229759.1	MRPS18AP1	-3.71	0.000228	0.0158	-0.35	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49096996	chr3:48256350~48256938:-
THCA	cis	rs1713985	0.508	rs4865171	ENSG00000269949.1	RP11-738E22.3	3.71	0.000228	0.0158	0.33	0.17	Age-related macular degeneration;	chr4:57026477	chr4:56960927~56961373:-
THCA	cis	rs17836934	1	rs7485419	ENSG00000271614.1	LINC00936	-3.71	0.000228	0.0158	-0.14	-0.17	Total body bone mineral density;	chr12:90080698	chr12:89708959~89712590:+
THCA	cis	rs56046484	0.956	rs2174218	ENSG00000259630.2	CTD-2262B20.1	3.71	0.000228	0.0158	0.24	0.17	Testicular germ cell tumor;	chr15:85081425	chr15:85415228~85415633:+
THCA	cis	rs9314614	0.872	rs2951864	ENSG00000245857.2	GS1-24F4.2	3.71	0.000228	0.0158	0.22	0.17	White blood cell count (basophil);IgA nephropathy;	chr8:6852400	chr8:6835554~6885276:+
THCA	cis	rs925946	0.666	rs17309874	ENSG00000245573.6	BDNF-AS	-3.71	0.000228	0.0158	-0.18	-0.17	Weight;Body mass index;	chr11:27645689	chr11:27506838~27698174:+
THCA	cis	rs2692947	0.794	rs2692949	ENSG00000235584.2	AC008268.1	-3.71	0.000228	0.0158	-0.17	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007777	chr2:95666084~95668715:+
THCA	cis	rs12681288	0.64	rs6985741	ENSG00000260721.1	AF067845.1	3.71	0.000228	0.0158	0.21	0.17	Schizophrenia;	chr8:1012858	chr8:1368642~1369833:-
THCA	cis	rs2276314	1	rs1789513	ENSG00000267627.4	RP11-905K4.1	3.71	0.000228	0.0158	0.21	0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35951803~35966118:-
THCA	cis	rs9890032	0.618	rs55872374	ENSG00000276250.1	CTD-2349P21.12	-3.71	0.000228	0.0158	-0.14	-0.17	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30803654~30804077:+
THCA	cis	rs7903847	0.673	rs3818908	ENSG00000225850.3	RP11-452K12.4	3.71	0.000228	0.0158	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97372944	chr10:97334564~97343203:+
THCA	cis	rs8177876	0.749	rs11537	ENSG00000261838.4	RP11-303E16.6	3.71	0.000228	0.0158	0.29	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81069854~81076598:+
THCA	cis	rs7572644	0.656	rs10196483	ENSG00000223522.1	AC093690.1	3.71	0.000228	0.0158	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27998315	chr2:28307691~28310459:-
THCA	cis	rs2933343	0.729	rs1680794	ENSG00000231305.3	RP11-723O4.2	3.71	0.000228	0.0158	0.18	0.17	IgG glycosylation;	chr3:128901547	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.7	rs1683777	ENSG00000231305.3	RP11-723O4.2	3.71	0.000228	0.0158	0.18	0.17	IgG glycosylation;	chr3:128906037	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.7	rs1680788	ENSG00000231305.3	RP11-723O4.2	3.71	0.000228	0.0158	0.18	0.17	IgG glycosylation;	chr3:128906475	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.7	rs789240	ENSG00000231305.3	RP11-723O4.2	3.71	0.000228	0.0158	0.18	0.17	IgG glycosylation;	chr3:128911792	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.7	rs789238	ENSG00000231305.3	RP11-723O4.2	3.71	0.000228	0.0158	0.18	0.17	IgG glycosylation;	chr3:128917872	chr3:128861313~128871540:-
THCA	cis	rs2562456	0.876	rs2650844	ENSG00000268278.1	RP11-420K14.1	3.71	0.000228	0.0158	0.23	0.17	Pain;	chr19:21419288	chr19:21637974~21656300:+
THCA	cis	rs10090774	0.841	rs13438888	ENSG00000280303.2	ERICD	3.71	0.000228	0.0158	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140831843	chr8:140636281~140638283:+
THCA	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-3.71	0.000228	0.0158	-0.18	-0.17	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
THCA	cis	rs4699052	0.963	rs6816055	ENSG00000230069.3	LRRC37A15P	-3.71	0.000228	0.0158	-0.17	-0.17	Testicular germ cell tumor;	chr4:103222003	chr4:102727274~102730721:-
THCA	cis	rs4699052	0.963	rs11097801	ENSG00000230069.3	LRRC37A15P	-3.71	0.000228	0.0158	-0.17	-0.17	Testicular germ cell tumor;	chr4:103229166	chr4:102727274~102730721:-
THCA	cis	rs4699052	0.963	rs56144793	ENSG00000230069.3	LRRC37A15P	-3.71	0.000228	0.0158	-0.17	-0.17	Testicular germ cell tumor;	chr4:103229496	chr4:102727274~102730721:-
THCA	cis	rs910316	1	rs12889472	ENSG00000259138.1	RP11-950C14.7	3.71	0.000228	0.0158	0.15	0.17	Height;	chr14:75077276	chr14:75127153~75136930:+
THCA	cis	rs340849	0.805	rs1019969	ENSG00000274895.1	RP11-478J18.2	3.71	0.000228	0.0158	0.14	0.17	Alzheimer's disease;	chr1:213928283	chr1:213983793~213986419:-
THCA	cis	rs6696239	0.956	rs10916189	ENSG00000227711.2	RP11-275O4.5	-3.71	0.000228	0.0158	-0.23	-0.17	Height;	chr1:227639425	chr1:227509028~227520477:-
THCA	cis	rs7403037	0.798	rs12148562	ENSG00000260760.1	PWRN3	3.71	0.000228	0.0158	0.2	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24588902	chr15:24441127~24447967:+
THCA	cis	rs7824557	0.564	rs7828263	ENSG00000154316.13	TDH	3.71	0.000228	0.0158	0.13	0.17	Retinal vascular caliber;	chr8:11374377	chr8:11339637~11368452:+
THCA	cis	rs11170631	0.504	rs12817180	ENSG00000270175.1	RP11-793H13.11	-3.71	0.000228	0.0158	-0.11	-0.17	Height;	chr12:53641664	chr12:53500162~53500936:-
THCA	cis	rs6991838	0.593	rs953593	ENSG00000272010.1	CTD-3025N20.3	-3.71	0.000228	0.0158	-0.16	-0.17	Intelligence (multi-trait analysis);	chr8:65719737	chr8:65591850~65592472:-
THCA	cis	rs12476592	0.571	rs10171223	ENSG00000242412.1	DBIL5P2	3.71	0.000228	0.0158	0.22	0.17	Childhood ear infection;	chr2:63460566	chr2:63117851~63119542:-
THCA	cis	rs901683	1	rs77649955	ENSG00000230869.1	CTGLF10P	-3.71	0.000228	0.0158	-0.39	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45555241	chr10:45678692~45700532:+
THCA	cis	rs901683	0.85	rs74874679	ENSG00000230869.1	CTGLF10P	-3.71	0.000228	0.0158	-0.39	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45555285	chr10:45678692~45700532:+
THCA	cis	rs4879656	0.564	rs1888869	ENSG00000225693.1	LAGE3P1	3.71	0.000228	0.0158	0.18	0.17	Menopause (age at onset);	chr9:32998239	chr9:33019682~33020165:-
THCA	cis	rs7819412	0.837	rs17724467	ENSG00000255046.1	RP11-297N6.4	3.71	0.000228	0.0158	0.18	0.17	Triglycerides;	chr8:11118172	chr8:11797928~11802568:-
THCA	cis	rs208520	1	rs9453671	ENSG00000233859.2	ADH5P4	3.71	0.000228	0.0158	0.26	0.17	Exhaled nitric oxide output;	chr6:66281315	chr6:65836930~65838039:-
THCA	cis	rs7359276	1	rs7359276	ENSG00000261143.1	ADAMTS7P3	3.71	0.000228	0.0158	0.23	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78600319	chr15:77976042~77993057:+
THCA	cis	rs7188445	0.736	rs11642757	ENSG00000277954.1	RP11-679B19.1	-3.71	0.000228	0.0158	-0.2	-0.17	Urate levels;	chr16:79719570	chr16:79202624~79206739:-
THCA	cis	rs7158359	1	rs7158359	ENSG00000222990.1	RNU4-22P	-3.71	0.000228	0.0158	-0.23	-0.17	Weight loss (gastric bypass surgery);	chr14:89127951	chr14:88513498~88513663:+
THCA	cis	rs55692468	0.883	rs6434068	ENSG00000213197.3	AC012066.1	3.71	0.000228	0.0158	0.22	0.17	Intraocular pressure;	chr2:152501027	chr2:152389937~152390630:+
THCA	cis	rs6449502	0.702	rs4700398	ENSG00000251279.1	CTC-436P18.1	-3.71	0.000228	0.0159	-0.25	-0.17	Mean platelet volume;	chr5:60840158	chr5:61162070~61232040:+
THCA	cis	rs758324	0.704	rs587759	ENSG00000237714.1	P4HA2-AS1	-3.71	0.000228	0.0159	-0.25	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132056787	chr5:132184876~132192808:+
THCA	cis	rs3020736	0.5	rs5996111	ENSG00000237037.8	NDUFA6-AS1	3.71	0.000228	0.0159	0.14	0.17	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42090931~42137742:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000182722.5	SEPHS1P1	-3.71	0.000228	0.0159	-0.2	-0.17	Aortic root size;	chr7:65827018	chr7:64852397~64853354:-
THCA	cis	rs6494488	0.5	rs72742941	ENSG00000259635.1	AC100830.3	-3.71	0.000228	0.0159	-0.42	-0.17	Coronary artery disease;	chr15:64596732	chr15:64701248~64719602:+
THCA	cis	rs7560272	0.723	rs780395	ENSG00000273245.1	RP11-434P11.2	-3.71	0.000228	0.0159	-0.2	-0.17	Schizophrenia;	chr2:73473726	chr2:73750256~73750786:-
THCA	cis	rs7560272	0.695	rs780394	ENSG00000273245.1	RP11-434P11.2	-3.71	0.000228	0.0159	-0.2	-0.17	Schizophrenia;	chr2:73473803	chr2:73750256~73750786:-
THCA	cis	rs7560272	0.723	rs1083923	ENSG00000273245.1	RP11-434P11.2	-3.71	0.000228	0.0159	-0.2	-0.17	Schizophrenia;	chr2:73476247	chr2:73750256~73750786:-
THCA	cis	rs2832191	0.74	rs2012645	ENSG00000176054.6	RPL23P2	3.71	0.000228	0.0159	0.15	0.17	Dental caries;	chr21:29073640	chr21:28997613~28998033:-
THCA	cis	rs2832191	0.716	rs2692625	ENSG00000176054.6	RPL23P2	3.71	0.000228	0.0159	0.15	0.17	Dental caries;	chr21:29074039	chr21:28997613~28998033:-
THCA	cis	rs2832191	0.716	rs7509628	ENSG00000176054.6	RPL23P2	3.71	0.000228	0.0159	0.15	0.17	Dental caries;	chr21:29081931	chr21:28997613~28998033:-
THCA	cis	rs2832191	0.716	rs1888440	ENSG00000176054.6	RPL23P2	3.71	0.000228	0.0159	0.15	0.17	Dental caries;	chr21:29082163	chr21:28997613~28998033:-
THCA	cis	rs3740713	0.748	rs35292478	ENSG00000256464.1	YWHABP2	3.71	0.000228	0.0159	0.27	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr11:18490243~18490955:-
THCA	cis	rs875971	0.545	rs73150604	ENSG00000232559.3	GS1-124K5.12	3.71	0.000228	0.0159	0.19	0.17	Aortic root size;	chr7:66480545	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs7810213	ENSG00000232559.3	GS1-124K5.12	3.71	0.000228	0.0159	0.19	0.17	Aortic root size;	chr7:66481592	chr7:66554588~66576923:-
THCA	cis	rs2179367	0.959	rs489551	ENSG00000223701.3	RAET1E-AS1	3.71	0.000228	0.0159	0.22	0.17	Dupuytren's disease;	chr6:149368321	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.959	rs9322178	ENSG00000223701.3	RAET1E-AS1	3.71	0.000228	0.0159	0.22	0.17	Dupuytren's disease;	chr6:149372131	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.959	rs9390677	ENSG00000223701.3	RAET1E-AS1	3.71	0.000228	0.0159	0.22	0.17	Dupuytren's disease;	chr6:149389361	chr6:149884431~149919508:+
THCA	cis	rs2590942	0.783	rs12737564	ENSG00000227207.2	RPL31P12	3.71	0.000229	0.0159	0.28	0.17	Childhood body mass index;	chr1:72273844	chr1:72301472~72301829:+
THCA	cis	rs972540	1	rs7355776	ENSG00000229647.1	AC007879.7	-3.71	0.000229	0.0159	-0.19	-0.17	Body mass index;	chr2:206367385	chr2:207239650~207245887:+
THCA	cis	rs972540	0.846	rs7355777	ENSG00000229647.1	AC007879.7	-3.71	0.000229	0.0159	-0.19	-0.17	Body mass index;	chr2:206367469	chr2:207239650~207245887:+
THCA	cis	rs2253762	0.54	rs79586669	ENSG00000226864.1	ATE1-AS1	3.71	0.000229	0.0159	0.27	0.17	Breast cancer;	chr10:122015153	chr10:121928312~121951965:+
THCA	cis	rs3892630	0.824	rs12327732	ENSG00000267475.1	CTD-2538C1.2	-3.71	0.000229	0.0159	-0.25	-0.17	Red blood cell traits;	chr19:32730861	chr19:32687089~32691750:-
THCA	cis	rs3892630	0.824	rs35654350	ENSG00000267475.1	CTD-2538C1.2	-3.71	0.000229	0.0159	-0.25	-0.17	Red blood cell traits;	chr19:32732860	chr19:32687089~32691750:-
THCA	cis	rs900400	0.931	rs56406311	ENSG00000244515.1	KRT18P34	-3.71	0.000229	0.0159	-0.2	-0.17	circulating leptin levels adjusted for BMI;Birth weight;Menarche (age at onset);Adiponectin levels in pregnancy;circulating leptin levels;	chr3:157077619	chr3:157162663~157163932:-
THCA	cis	rs17853159	0.558	rs3121771	ENSG00000281912.1	LINC01144	-3.71	0.000229	0.0159	-0.18	-0.17	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45279773	chr1:45303910~45305619:+
THCA	cis	rs6938	0.575	rs12909335	ENSG00000260269.4	CTD-2323K18.1	-3.71	0.000229	0.0159	-0.24	-0.17	Breast cancer;	chr15:74922448	chr15:75527150~75601205:-
THCA	cis	rs12681366	0.96	rs2930961	ENSG00000261437.1	RP11-22C11.2	3.71	0.000229	0.0159	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94431578	chr8:94637285~94639467:-
THCA	cis	rs10875746	0.669	rs10875792	ENSG00000258273.1	RP11-370I10.4	3.71	0.000229	0.0159	0.24	0.17	Longevity (90 years and older);	chr12:48303640	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.623	rs10875793	ENSG00000258273.1	RP11-370I10.4	3.71	0.000229	0.0159	0.24	0.17	Longevity (90 years and older);	chr12:48303647	chr12:48333755~48333901:-
THCA	cis	rs13325613	0.834	rs7631551	ENSG00000223552.1	RP11-24F11.2	-3.71	0.000229	0.0159	-0.27	-0.17	Monocyte count;	chr3:46144818	chr3:46364955~46407059:-
THCA	cis	rs791590	0.54	rs10795738	ENSG00000229664.1	RP11-536K7.5	-3.71	0.000229	0.0159	-0.21	-0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6007454	chr10:6025978~6036427:+
THCA	cis	rs9309473	0.66	rs10496192	ENSG00000273245.1	RP11-434P11.2	3.71	0.000229	0.0159	0.27	0.17	Metabolite levels;	chr2:73452739	chr2:73750256~73750786:-
THCA	cis	rs12476592	0.571	rs964903	ENSG00000242412.1	DBIL5P2	3.71	0.000229	0.0159	0.22	0.17	Childhood ear infection;	chr2:63514414	chr2:63117851~63119542:-
THCA	cis	rs4792901	0.918	rs11869927	ENSG00000267151.3	RP11-100E5.2	-3.71	0.000229	0.0159	-0.18	-0.17	Dupuytren's disease;	chr17:43597143	chr17:43444707~43451200:+
THCA	cis	rs72482608	0.835	rs7528424	ENSG00000271811.1	RP1-79C4.4	3.71	0.000229	0.0159	0.2	0.17	Emphysema imaging phenotypes;	chr1:170747319	chr1:170667381~170669425:+
THCA	cis	rs459571	0.839	rs2519831	ENSG00000235106.7	LINC00094	3.71	0.000229	0.0159	0.15	0.17	Platelet distribution width;	chr9:134021135	chr9:134025439~134034666:+
THCA	cis	rs7131987	0.621	rs57803026	ENSG00000273680.1	RP11-996F15.6	3.71	0.000229	0.0159	0.24	0.17	QT interval;	chr12:29344573	chr12:29332733~29333383:-
THCA	cis	rs7560272	0.501	rs11894953	ENSG00000273245.1	RP11-434P11.2	3.71	0.000229	0.0159	0.2	0.17	Schizophrenia;	chr2:73737504	chr2:73750256~73750786:-
THCA	cis	rs3758911	0.861	rs10890721	ENSG00000255353.1	RP11-382M14.1	-3.71	0.000229	0.0159	-0.21	-0.17	Coronary artery disease;	chr11:107336876	chr11:107176286~107177530:+
THCA	cis	rs7711186	0.786	rs6881073	ENSG00000252464.1	RN7SKP70	3.71	0.000229	0.0159	0.2	0.17	Urate levels in obese individuals;	chr5:178654188	chr5:178619728~178619998:-
THCA	cis	rs7267979	0.549	rs6138536	ENSG00000274973.1	RP13-401N8.7	-3.71	0.000229	0.0159	-0.19	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:25845497~25845862:+
THCA	cis	rs7709377	0.723	rs2161321	ENSG00000250015.1	CTC-339F2.2	3.71	0.000229	0.0159	0.17	0.17	Metabolite levels  (X-11787);	chr5:116216973	chr5:116302354~116304134:-
THCA	cis	rs7914558	1	rs4917996	ENSG00000272912.1	RP11-724N1.1	-3.71	0.000229	0.0159	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103166072	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs6584540	ENSG00000272912.1	RP11-724N1.1	-3.71	0.000229	0.0159	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103167877	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs7081075	ENSG00000272912.1	RP11-724N1.1	-3.71	0.000229	0.0159	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103169434	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs10786740	ENSG00000272912.1	RP11-724N1.1	-3.71	0.000229	0.0159	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103175836	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.901	rs35525740	ENSG00000272912.1	RP11-724N1.1	-3.71	0.000229	0.0159	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181355	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.869	rs10883842	ENSG00000272912.1	RP11-724N1.1	-3.71	0.000229	0.0159	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181832	chr10:102914585~102915404:+
THCA	cis	rs7709377	0.723	rs11955906	ENSG00000250015.1	CTC-339F2.2	3.71	0.000229	0.0159	0.17	0.17	Metabolite levels  (X-11787);	chr5:116201707	chr5:116302354~116304134:-
THCA	cis	rs11098499	0.954	rs11098524	ENSG00000249244.1	RP11-548H18.2	3.71	0.000229	0.0159	0.19	0.17	Corneal astigmatism;	chr4:119468877	chr4:119391831~119395335:-
THCA	cis	rs7572733	0.935	rs2880389	ENSG00000231621.1	AC013264.2	-3.71	0.000229	0.0159	-0.16	-0.17	Dermatomyositis;	chr2:197936983	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs11679040	ENSG00000231621.1	AC013264.2	-3.71	0.000229	0.0159	-0.16	-0.17	Dermatomyositis;	chr2:197942105	chr2:197197991~197199273:+
THCA	cis	rs2979481	1	rs2979481	ENSG00000254152.1	CTD-3107M8.2	3.71	0.000229	0.0159	0.2	0.17	Heart rate variability traits;	chr8:30405270	chr8:30349866~30350347:-
THCA	cis	rs11785400	0.963	rs6990126	ENSG00000177335.9	C8orf31	3.71	0.000229	0.0159	0.19	0.17	Schizophrenia;	chr8:142647003	chr8:143039209~143059942:+
THCA	cis	rs2117029	0.5	rs3741619	ENSG00000258017.1	RP11-386G11.10	3.71	0.000229	0.0159	0.22	0.17	Intelligence (multi-trait analysis);	chr12:48995693	chr12:49127782~49147869:+
THCA	cis	rs2179367	0.959	rs540538	ENSG00000223701.3	RAET1E-AS1	3.71	0.000229	0.0159	0.22	0.17	Dupuytren's disease;	chr6:149326808	chr6:149884431~149919508:+
THCA	cis	rs4713118	0.715	rs200480	ENSG00000220721.1	OR1F12	3.71	0.000229	0.0159	0.2	0.17	Parkinson's disease;	chr6:27805886	chr6:28073316~28074233:+
THCA	cis	rs7166081	0.95	rs12917612	ENSG00000270964.1	RP11-502I4.3	-3.71	0.000229	0.0159	-0.15	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67198936	chr15:67541072~67542604:-
THCA	cis	rs16957091	0.607	rs12913618	ENSG00000205771.5	CATSPER2P1	3.71	0.000229	0.0159	0.22	0.17	MGMT methylation in smokers;	chr15:42779131	chr15:43726918~43747094:-
THCA	cis	rs9915021	1	rs9915021	ENSG00000267364.1	RP11-47L3.1	3.71	0.000229	0.0159	0.32	0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35649600	chr17:35313502~35324900:+
THCA	cis	rs10875746	0.669	rs11168499	ENSG00000226413.2	OR8T1P	3.71	0.000229	0.0159	0.24	0.17	Longevity (90 years and older);	chr12:48268887	chr12:48442030~48442947:-
THCA	cis	rs10129255	0.957	rs10141052	ENSG00000211972.2	IGHV3-66	3.71	0.000229	0.0159	0.1	0.17	Kawasaki disease;	chr14:106776528	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs10141009	ENSG00000211972.2	IGHV3-66	3.71	0.000229	0.0159	0.1	0.17	Kawasaki disease;	chr14:106776695	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.912	rs6576227	ENSG00000211972.2	IGHV3-66	3.71	0.000229	0.0159	0.1	0.17	Kawasaki disease;	chr14:106778202	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs6576228	ENSG00000211972.2	IGHV3-66	3.71	0.000229	0.0159	0.1	0.17	Kawasaki disease;	chr14:106778401	chr14:106675017~106675544:-
THCA	cis	rs4389656	0.784	rs274723	ENSG00000248677.1	CTD-2044J15.1	3.71	0.000229	0.0159	0.17	0.17	Coronary artery disease;	chr5:6718450	chr5:6686325~6707711:-
THCA	cis	rs9595908	0.709	rs7318510	ENSG00000212293.1	SNORA16	3.71	0.000229	0.0159	0.2	0.17	Body mass index;	chr13:32752122	chr13:32420390~32420516:-
THCA	cis	rs12368653	0.582	rs2307095	ENSG00000270039.1	RP11-571M6.17	3.71	0.000229	0.0159	0.18	0.17	Multiple sclerosis;	chr12:57632218	chr12:57803838~57804415:+
THCA	cis	rs6504108	0.624	rs2123341	ENSG00000264920.1	RP11-6N17.4	-3.71	0.000229	0.0159	-0.14	-0.17	Body mass index;	chr17:48187264	chr17:47891255~47895812:-
THCA	cis	rs950776	0.518	rs62008174	ENSG00000261762.1	RP11-650L12.2	3.71	0.000229	0.0159	0.21	0.17	Sudden cardiac arrest;	chr15:78516605	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12910978	ENSG00000261762.1	RP11-650L12.2	3.71	0.000229	0.0159	0.21	0.17	Sudden cardiac arrest;	chr15:78517675	chr15:78589123~78591276:-
THCA	cis	rs950776	0.507	rs12912673	ENSG00000261762.1	RP11-650L12.2	3.71	0.000229	0.0159	0.21	0.17	Sudden cardiac arrest;	chr15:78517874	chr15:78589123~78591276:-
THCA	cis	rs950776	0.518	rs12591557	ENSG00000261762.1	RP11-650L12.2	3.71	0.000229	0.0159	0.21	0.17	Sudden cardiac arrest;	chr15:78519390	chr15:78589123~78591276:-
THCA	cis	rs7924176	0.502	rs10824134	ENSG00000232342.6	RP11-46O21.2	3.71	0.000229	0.0159	0.22	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74261866	chr10:74506081~74530553:-
THCA	cis	rs9660180	0.935	rs2180311	ENSG00000215914.4	MMP23A	-3.71	0.000229	0.0159	-0.22	-0.17	Body mass index;	chr1:1817295	chr1:1699942~1701782:+
THCA	cis	rs9660180	0.967	rs6664664	ENSG00000215914.4	MMP23A	-3.71	0.000229	0.0159	-0.22	-0.17	Body mass index;	chr1:1819825	chr1:1699942~1701782:+
THCA	cis	rs6894216	0.65	rs1473132	ENSG00000248610.1	HSPA8P4	-3.71	0.000229	0.0159	-0.21	-0.17	Response to amphetamines;	chr5:130333894	chr5:130140031~130141950:+
THCA	cis	rs7246657	0.882	rs8112610	ENSG00000268499.1	CTB-102L5.8	3.71	0.000229	0.0159	0.21	0.17	Coronary artery calcification;	chr19:37437828	chr19:38199836~38200934:+
THCA	cis	rs2408955	0.715	rs1793957	ENSG00000273765.1	RP11-370I10.11	3.71	0.000229	0.0159	0.17	0.17	Glycated hemoglobin levels;	chr12:47999041	chr12:48360920~48361377:+
THCA	cis	rs7748513	0.702	rs12194214	ENSG00000161912.16	ADCY10P1	3.71	0.000229	0.0159	0.25	0.17	C-reactive protein;	chr6:41060835	chr6:41101022~41140835:+
THCA	cis	rs9314614	0.872	rs2977792	ENSG00000245857.2	GS1-24F4.2	3.71	0.000229	0.0159	0.21	0.17	White blood cell count (basophil);IgA nephropathy;	chr8:6853986	chr8:6835554~6885276:+
THCA	cis	rs755249	0.567	rs4660543	ENSG00000182109.6	RP11-69E11.4	3.71	0.000229	0.0159	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39522280~39546187:-
THCA	cis	rs321358	1	rs321357	ENSG00000271390.1	RP11-89C3.3	3.71	0.000229	0.0159	0.28	0.17	Body mass index;	chr11:111125002	chr11:111089870~111090368:-
THCA	cis	rs2034650	0.544	rs8034416	ENSG00000259211.1	RP11-64K12.8	-3.71	0.000229	0.0159	-0.15	-0.17	Interstitial lung disease;	chr15:40411140	chr15:40464193~40466726:-
THCA	cis	rs1790761	0.505	rs7103713	ENSG00000255318.1	RP11-655M14.13	-3.71	0.000229	0.0159	-0.19	-0.17	Mean corpuscular volume;	chr11:67570771	chr11:67618279~67627304:-
THCA	cis	rs478304	0.627	rs11604568	ENSG00000255320.1	RP11-755F10.1	3.71	0.000229	0.0159	0.22	0.17	Acne (severe);	chr11:65743865	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs7110576	ENSG00000255320.1	RP11-755F10.1	3.71	0.000229	0.0159	0.22	0.17	Acne (severe);	chr11:65744586	chr11:66244840~66246239:-
THCA	cis	rs801193	1	rs4717310	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000229	0.0159	-0.14	-0.17	Aortic root size;	chr7:66696020	chr7:66848496~66858136:+
THCA	cis	rs875971	0.545	rs1638724	ENSG00000230295.1	RP11-458F8.2	-3.71	0.000229	0.0159	-0.15	-0.17	Aortic root size;	chr7:66575494	chr7:66880708~66882981:+
THCA	cis	rs13034020	1	rs35245715	ENSG00000271889.1	RP11-493E12.1	-3.71	0.000229	0.0159	-0.23	-0.17	Hodgkin's lymphoma;	chr2:60813516	chr2:61151433~61162105:-
THCA	cis	rs875971	0.545	rs17138149	ENSG00000273024.4	INTS4P2	-3.71	0.000229	0.0159	-0.21	-0.17	Aortic root size;	chr7:66228193	chr7:65647864~65715661:+
THCA	cis	rs9840812	0.645	rs9883916	ENSG00000273486.1	RP11-731C17.2	3.71	0.000229	0.0159	0.17	0.17	Fibrinogen levels;	chr3:136489946	chr3:136837338~136839021:-
THCA	cis	rs7968440	0.966	rs7977742	ENSG00000272368.2	RP4-605O3.4	3.71	0.000229	0.0159	0.11	0.17	Fibrinogen;	chr12:50736424	chr12:50112197~50165618:+
THCA	cis	rs4389656	0.826	rs192443	ENSG00000248677.1	CTD-2044J15.1	3.71	0.000229	0.0159	0.17	0.17	Coronary artery disease;	chr5:6733551	chr5:6686325~6707711:-
THCA	cis	rs6487679	1	rs6487679	ENSG00000245105.2	A2M-AS1	3.71	0.000229	0.0159	0.16	0.17	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9065177~9068060:+
THCA	cis	rs78487399	0.808	rs7561287	ENSG00000234936.1	AC010883.5	3.71	0.00023	0.0159	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43461932	chr2:43229573~43233394:+
THCA	cis	rs2120243	0.533	rs34263112	ENSG00000243176.4	RP11-550I24.2	3.71	0.00023	0.0159	0.16	0.17	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338259	chr3:157175223~157381265:+
THCA	cis	rs2638953	0.777	rs10843181	ENSG00000278733.1	RP11-425D17.1	-3.71	0.00023	0.0159	-0.18	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462824	chr12:28185625~28186190:-
THCA	cis	rs10129255	0.957	rs1024349	ENSG00000280411.1	IGHV1-69-2	-3.71	0.00023	0.0159	-0.11	-0.17	Kawasaki disease;	chr14:106689997	chr14:106762092~106762588:-
THCA	cis	rs478304	0.58	rs11606947	ENSG00000255320.1	RP11-755F10.1	3.71	0.00023	0.0159	0.22	0.17	Acne (severe);	chr11:65740766	chr11:66244840~66246239:-
THCA	cis	rs10045504	0.593	rs10941405	ENSG00000250492.1	INTS6P1	3.71	0.00023	0.0159	0.19	0.17	Night sleep phenotypes;	chr5:38756086	chr5:39718984~39721513:-
THCA	cis	rs2625529	0.668	rs12914070	ENSG00000260037.4	CTD-2524L6.3	-3.71	0.00023	0.0159	-0.23	-0.17	Red blood cell count;	chr15:72041938	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs35167572	ENSG00000260037.4	CTD-2524L6.3	-3.71	0.00023	0.0159	-0.23	-0.17	Red blood cell count;	chr15:72086619	chr15:71818396~71823384:+
THCA	cis	rs9291683	0.632	rs11734786	ENSG00000261490.1	RP11-448G15.3	3.71	0.00023	0.0159	0.1	0.17	Bone mineral density;	chr4:10039875	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.632	rs13137074	ENSG00000261490.1	RP11-448G15.3	3.71	0.00023	0.0159	0.1	0.17	Bone mineral density;	chr4:10041218	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.632	rs13101785	ENSG00000261490.1	RP11-448G15.3	3.71	0.00023	0.0159	0.1	0.17	Bone mineral density;	chr4:10041291	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.618	rs13137343	ENSG00000261490.1	RP11-448G15.3	3.71	0.00023	0.0159	0.1	0.17	Bone mineral density;	chr4:10041404	chr4:10068089~10073019:-
THCA	cis	rs1930961	1	rs6004669	ENSG00000272942.1	CTA-246H3.12	-3.71	0.00023	0.0159	-0.29	-0.17	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25434324~25435070:-
THCA	cis	rs4713118	0.539	rs510987	ENSG00000226314.6	ZNF192P1	-3.71	0.00023	0.0159	-0.21	-0.17	Parkinson's disease;	chr6:27879739	chr6:28161781~28169594:+
THCA	cis	rs875971	0.862	rs6460282	ENSG00000223473.2	GS1-124K5.3	-3.71	0.00023	0.0159	-0.12	-0.17	Aortic root size;	chr7:66226259	chr7:66491049~66493566:-
THCA	cis	rs9425766	1	rs9425766	ENSG00000270084.1	GAS5-AS1	-3.71	0.00023	0.0159	-0.17	-0.17	Life satisfaction;	chr1:173883989	chr1:173863248~173863941:+
THCA	cis	rs3770081	1	rs2278086	ENSG00000272564.1	RP11-548P2.2	-3.71	0.00023	0.0159	-0.32	-0.17	Facial emotion recognition (sad faces);	chr2:86054782	chr2:85904279~85904727:+
THCA	cis	rs12681366	0.801	rs2919657	ENSG00000253175.1	RP11-267M23.6	3.71	0.00023	0.0159	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94460724	chr8:94565036~94565715:+
THCA	cis	rs7819412	0.807	rs10105315	ENSG00000254948.1	OR7E158P	3.71	0.00023	0.0159	0.21	0.17	Triglycerides;	chr8:11074693	chr8:11919900~11920809:-
THCA	cis	rs79162905	1	rs79162905	ENSG00000222990.1	RNU4-22P	-3.71	0.00023	0.0159	-0.32	-0.17	Attention deficit hyperactivity disorder symptom score;	chr14:89329728	chr14:88513498~88513663:+
THCA	cis	rs78545713	0.536	rs11755618	ENSG00000216331.1	HIST1H1PS1	-3.71	0.00023	0.0159	-0.31	-0.17	Iron status biomarkers (total iron binding capacity);	chr6:26215574	chr6:26195566~26195771:+
THCA	cis	rs9368481	0.678	rs62402024	ENSG00000228223.2	HCG11	-3.71	0.00023	0.0159	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26523450~26526579:+
THCA	cis	rs7613875	0.58	rs2624819	ENSG00000281691.1	RBM5-AS1	3.71	0.00023	0.0159	0.14	0.17	Body mass index;	chr3:49973138	chr3:50099603~50100988:-
THCA	cis	rs4460629	0.742	rs11264312	ENSG00000236675.1	MTX1P1	-3.71	0.00023	0.0159	-0.16	-0.17	Serum magnesium levels;	chr1:155103412	chr1:155230975~155234325:+
THCA	cis	rs4460629	0.742	rs4625273	ENSG00000236675.1	MTX1P1	-3.71	0.00023	0.0159	-0.16	-0.17	Serum magnesium levels;	chr1:155103567	chr1:155230975~155234325:+
THCA	cis	rs4460629	0.742	rs7366355	ENSG00000236675.1	MTX1P1	-3.71	0.00023	0.0159	-0.16	-0.17	Serum magnesium levels;	chr1:155104258	chr1:155230975~155234325:+
THCA	cis	rs8099594	0.565	rs1943010	ENSG00000266696.1	RP11-30L3.2	3.71	0.00023	0.0159	0.21	0.17	Height;	chr18:49209901	chr18:49205912~49208781:+
THCA	cis	rs8099594	0.565	rs1943009	ENSG00000266696.1	RP11-30L3.2	3.71	0.00023	0.0159	0.21	0.17	Height;	chr18:49209955	chr18:49205912~49208781:+
THCA	cis	rs337161	0.719	rs337150	ENSG00000221571.3	RNU6ATAC35P	-3.71	0.00023	0.0159	-0.19	-0.17	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220767939	chr1:220825620~220826063:+
THCA	cis	rs2880765	0.835	rs4360874	ENSG00000218052.5	ADAMTS7P4	-3.71	0.00023	0.0159	-0.19	-0.17	Coronary artery disease;	chr15:85497589	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs4514633	ENSG00000218052.5	ADAMTS7P4	-3.71	0.00023	0.0159	-0.19	-0.17	Coronary artery disease;	chr15:85497786	chr15:85255369~85330334:-
THCA	cis	rs1005277	0.505	rs200931	ENSG00000275858.1	RP11-291L22.8	3.71	0.00023	0.0159	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:38450738~38451069:-
THCA	cis	rs2562456	0.793	rs2562474	ENSG00000268658.4	LINC00664	-3.71	0.00023	0.0159	-0.25	-0.17	Pain;	chr19:21463480	chr19:21483374~21503238:+
THCA	cis	rs9309711	0.666	rs6723126	ENSG00000271868.1	RP11-1293J14.1	-3.71	0.00023	0.0159	-0.22	-0.17	Neurofibrillary tangles;	chr2:3480729	chr2:3496956~3497428:+
THCA	cis	rs727563	0.638	rs5996058	ENSG00000237037.8	NDUFA6-AS1	-3.71	0.00023	0.0159	-0.16	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.512	rs5758450	ENSG00000237037.8	NDUFA6-AS1	-3.71	0.00023	0.0159	-0.16	-0.17	Vitiligo;	chr22:41745636	chr22:42090931~42137742:+
THCA	cis	rs9291683	0.53	rs11723591	ENSG00000250413.1	RP11-448G15.1	-3.71	0.00023	0.0159	-0.16	-0.17	Bone mineral density;	chr4:9983774	chr4:10006482~10009725:+
THCA	cis	rs755249	0.567	rs3754346	ENSG00000182109.6	RP11-69E11.4	3.71	0.00023	0.0159	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs16826093	ENSG00000182109.6	RP11-69E11.4	3.71	0.00023	0.0159	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs41270811	ENSG00000182109.6	RP11-69E11.4	3.71	0.00023	0.0159	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs61779274	ENSG00000182109.6	RP11-69E11.4	3.71	0.00023	0.0159	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs17264671	ENSG00000182109.6	RP11-69E11.4	3.71	0.00023	0.0159	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs4660690	ENSG00000182109.6	RP11-69E11.4	3.71	0.00023	0.0159	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs61779275	ENSG00000182109.6	RP11-69E11.4	3.71	0.00023	0.0159	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39522280~39546187:-
THCA	cis	rs911186	0.74	rs6938200	ENSG00000220721.1	OR1F12	3.71	0.00023	0.0159	0.24	0.17	Autism spectrum disorder or schizophrenia;	chr6:27263371	chr6:28073316~28074233:+
THCA	cis	rs2235642	0.75	rs2859310	ENSG00000260989.1	LA16c-395F10.2	3.71	0.00023	0.0159	0.17	0.17	Coronary artery disease;	chr16:1606764	chr16:1580527~1610328:+
THCA	cis	rs4408325	0.754	rs7107421	ENSG00000254509.1	RP11-677M14.6	-3.71	0.00023	0.0159	-0.13	-0.17	Parasitemia in Tripanosoma cruzi seropositivity;	chr11:124950601	chr11:124791228~124791660:+
THCA	cis	rs10043228	1	rs10066259	ENSG00000248445.4	SEMA6A-AS1	-3.71	0.00023	0.0159	-0.23	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116116195	chr5:116447547~116508276:+
THCA	cis	rs9487094	0.666	rs2277113	ENSG00000223537.2	RP5-919F19.5	-3.71	0.00023	0.0159	-0.17	-0.17	Height;	chr6:109454233	chr6:109487906~109506800:+
THCA	cis	rs875971	0.558	rs4433015	ENSG00000232546.1	RP11-458F8.1	3.71	0.00023	0.0159	0.14	0.17	Aortic root size;	chr7:66174736	chr7:66848496~66858136:+
THCA	cis	rs1577917	0.917	rs4098044	ENSG00000220563.1	PKMP3	-3.71	0.00023	0.016	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85752348	chr6:85659892~85660606:-
THCA	cis	rs4713118	0.505	rs276371	ENSG00000280107.1	AL022393.9	-3.71	0.00023	0.016	-0.17	-0.17	Parkinson's disease;	chr6:27942930	chr6:28170845~28172521:+
THCA	cis	rs12760731	0.544	rs34163217	ENSG00000213057.5	C1orf220	3.71	0.00023	0.016	0.17	0.17	Obesity-related traits;	chr1:178617849	chr1:178542752~178548889:+
THCA	cis	rs765787	0.53	rs2413786	ENSG00000259932.1	CTD-2651B20.7	3.71	0.00023	0.016	0.2	0.17	Uric acid levels;	chr15:45233196	chr15:45198517~45199139:-
THCA	cis	rs9481169	0.85	rs35815577	ENSG00000272356.1	RP5-1112D6.8	3.71	0.00023	0.016	0.28	0.17	Inflammatory skin disease;	chr6:111603527	chr6:111309203~111313517:+
THCA	cis	rs12681366	0.663	rs6980687	ENSG00000261437.1	RP11-22C11.2	3.71	0.00023	0.016	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94469685	chr8:94637285~94639467:-
THCA	cis	rs7824557	0.547	rs6601570	ENSG00000255495.1	AC145124.2	-3.71	0.00023	0.016	-0.2	-0.17	Retinal vascular caliber;	chr8:11221858	chr8:12194467~12196280:+
THCA	cis	rs6840360	0.615	rs62329085	ENSG00000251611.1	RP11-610P16.1	-3.71	0.00023	0.016	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151549085	chr4:151407551~151408835:-
THCA	cis	rs7615952	0.546	rs11717632	ENSG00000241278.1	ENPP7P4	3.71	0.00023	0.016	0.24	0.17	Blood pressure (smoking interaction);	chr3:125602286	chr3:125848223~125909372:+
THCA	cis	rs7615952	0.546	rs2922197	ENSG00000241278.1	ENPP7P4	3.71	0.00023	0.016	0.24	0.17	Blood pressure (smoking interaction);	chr3:125603188	chr3:125848223~125909372:+
THCA	cis	rs4713118	0.869	rs6930992	ENSG00000261839.1	RP1-265C24.8	3.71	0.00023	0.016	0.19	0.17	Parkinson's disease;	chr6:27744341	chr6:28136849~28139678:+
THCA	cis	rs17772222	0.63	rs7141608	ENSG00000222990.1	RNU4-22P	-3.71	0.00023	0.016	-0.21	-0.17	Coronary artery calcification;	chr14:88514045	chr14:88513498~88513663:+
THCA	cis	rs9309473	0.606	rs62149777	ENSG00000273245.1	RP11-434P11.2	3.71	0.00023	0.016	0.27	0.17	Metabolite levels;	chr2:73568237	chr2:73750256~73750786:-
THCA	cis	rs73076966	0.891	rs10485824	ENSG00000274269.1	RP4-545L17.12	3.71	0.00023	0.016	0.26	0.17	Plateletcrit;	chr20:1537454	chr20:1186092~1207036:+
THCA	cis	rs2762353	0.603	rs12201071	ENSG00000272462.2	U91328.19	3.71	0.00023	0.016	0.13	0.17	Blood metabolite levels;	chr6:25777827	chr6:25992662~26001775:+
THCA	cis	rs2762353	0.603	rs10946798	ENSG00000272462.2	U91328.19	3.71	0.00023	0.016	0.13	0.17	Blood metabolite levels;	chr6:25781625	chr6:25992662~26001775:+
THCA	cis	rs838886	0.956	rs838884	ENSG00000275389.1	RP11-214K3.24	-3.71	0.00023	0.016	-0.23	-0.17	HDL cholesterol;	chr12:124777558	chr12:124085761~124088598:+
THCA	cis	rs9660180	0.967	rs61422524	ENSG00000215914.4	MMP23A	-3.71	0.00023	0.016	-0.22	-0.17	Body mass index;	chr1:1836126	chr1:1699942~1701782:+
THCA	cis	rs5758659	0.714	rs7245	ENSG00000205702.9	CYP2D7	-3.71	0.00023	0.016	-0.13	-0.17	Cognitive function;	chr22:42085845	chr22:42140203~42144577:-
THCA	cis	rs7259376	0.936	rs2195965	ENSG00000269345.1	VN1R85P	3.71	0.000231	0.016	0.18	0.17	Menopause (age at onset);	chr19:22355309	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs2195964	ENSG00000269345.1	VN1R85P	3.71	0.000231	0.016	0.18	0.17	Menopause (age at onset);	chr19:22355536	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.905	rs2082480	ENSG00000269345.1	VN1R85P	3.71	0.000231	0.016	0.18	0.17	Menopause (age at onset);	chr19:22355848	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs58170323	ENSG00000269345.1	VN1R85P	3.71	0.000231	0.016	0.18	0.17	Menopause (age at onset);	chr19:22356313	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs2099354	ENSG00000269345.1	VN1R85P	3.71	0.000231	0.016	0.18	0.17	Menopause (age at onset);	chr19:22356730	chr19:22174766~22175191:-
THCA	cis	rs3743266	0.613	rs4775273	ENSG00000240163.1	RP11-745A24.1	-3.71	0.000231	0.016	-0.19	-0.17	Menarche (age at onset);	chr15:60446367	chr15:60390371~60390682:+
THCA	cis	rs4713118	0.786	rs200503	ENSG00000272009.1	RP1-313I6.12	-3.71	0.000231	0.016	-0.19	-0.17	Parkinson's disease;	chr6:27818104	chr6:28078792~28081130:-
THCA	cis	rs3764400	0.507	rs56161855	ENSG00000278765.1	RP5-890E16.5	3.71	0.000231	0.016	0.29	0.17	Body mass index;	chr17:48211287	chr17:48066704~48067293:-
THCA	cis	rs2055375	0.62	rs159543	ENSG00000251279.1	CTC-436P18.1	-3.71	0.000231	0.016	-0.21	-0.17	Intelligence (multi-trait analysis);	chr5:61190688	chr5:61162070~61232040:+
THCA	cis	rs7586085	0.966	rs777360	ENSG00000232411.1	AC009495.3	-3.71	0.000231	0.016	-0.18	-0.17	Total body bone mineral density;	chr2:165699434	chr2:165833048~165839098:-
THCA	cis	rs2299587	0.585	rs2285304	ENSG00000253671.1	RP11-806O11.1	-3.71	0.000231	0.016	-0.2	-0.17	Economic and political preferences;	chr8:17940422	chr8:17808941~17820868:+
THCA	cis	rs763121	0.889	rs6001209	ENSG00000235209.1	CTA-150C2.13	-3.71	0.000231	0.016	-0.22	-0.17	Menopause (age at onset);	chr22:38725247	chr22:38921227~38924708:+
THCA	cis	rs9410380	1	rs2799692	ENSG00000225385.3	RP11-350E12.4	3.71	0.000231	0.016	0.17	0.17	Monocyte count;	chr9:88842580	chr9:88066915~88068037:+
THCA	cis	rs5753037	0.585	rs7954	ENSG00000279699.1	RP1-102K2.9	3.71	0.000231	0.016	0.16	0.17	Type 1 diabetes;	chr22:29788961	chr22:30275215~30276951:-
THCA	cis	rs301901	0.54	rs12657783	ENSG00000250155.1	CTD-2353F22.1	3.71	0.000231	0.016	0.17	0.17	Height;	chr5:37397119	chr5:36666214~36725195:-
THCA	cis	rs7829975	0.714	rs59046059	ENSG00000254340.1	RP11-10A14.3	3.71	0.000231	0.016	0.19	0.17	Mood instability;	chr8:8813226	chr8:9141424~9145435:+
THCA	cis	rs1005277	0.522	rs1208684	ENSG00000275858.1	RP11-291L22.8	3.71	0.000231	0.016	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38450738~38451069:-
THCA	cis	rs9291683	0.609	rs3796836	ENSG00000261490.1	RP11-448G15.3	3.71	0.000231	0.016	0.1	0.17	Bone mineral density;	chr4:10009721	chr4:10068089~10073019:-
THCA	cis	rs2299587	0.65	rs12548412	ENSG00000253671.1	RP11-806O11.1	-3.71	0.000231	0.016	-0.2	-0.17	Economic and political preferences;	chr8:17939461	chr8:17808941~17820868:+
THCA	cis	rs372883	0.58	rs2254038	ENSG00000176054.6	RPL23P2	3.71	0.000231	0.016	0.15	0.17	Pancreatic cancer;	chr21:29373402	chr21:28997613~28998033:-
THCA	cis	rs3758911	0.964	rs10789602	ENSG00000255353.1	RP11-382M14.1	-3.71	0.000231	0.016	-0.22	-0.17	Coronary artery disease;	chr11:107310729	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.929	rs10749895	ENSG00000255353.1	RP11-382M14.1	-3.71	0.000231	0.016	-0.22	-0.17	Coronary artery disease;	chr11:107310855	chr11:107176286~107177530:+
THCA	cis	rs9863	1	rs9863	ENSG00000270061.1	RP11-214K3.19	-3.71	0.000231	0.016	-0.23	-0.17	White blood cell count;	chr12:123936906	chr12:123969990~123970344:-
THCA	cis	rs479105	0.645	rs3782777	ENSG00000278356.1	RP11-372B4.3	3.71	0.000231	0.016	0.17	0.17	Gut microbiota (bacterial taxa);	chr12:3261721	chr12:2885819~2886329:+
THCA	cis	rs72829446	0.505	rs4542712	ENSG00000266824.1	RP11-599B13.7	3.71	0.000231	0.016	0.26	0.17	Androgen levels;	chr17:7566010	chr17:8176812~8182812:+
THCA	cis	rs7176527	1	rs3762169	ENSG00000259683.1	RP11-182J1.14	3.71	0.000231	0.016	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84389729~84395903:+
THCA	cis	rs4460629	0.68	rs10796938	ENSG00000236675.1	MTX1P1	-3.71	0.000231	0.016	-0.16	-0.17	Serum magnesium levels;	chr1:155099579	chr1:155230975~155234325:+
THCA	cis	rs3743266	0.613	rs8027901	ENSG00000240163.1	RP11-745A24.1	-3.71	0.000231	0.016	-0.19	-0.17	Menarche (age at onset);	chr15:60441265	chr15:60390371~60390682:+
THCA	cis	rs61160187	0.555	rs34608	ENSG00000251279.1	CTC-436P18.1	-3.71	0.000231	0.016	-0.21	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61161807	chr5:61162070~61232040:+
THCA	cis	rs4950322	0.58	rs1813002	ENSG00000271721.1	RP11-337C18.9	3.71	0.000231	0.016	0.19	0.17	Protein quantitative trait loci;	chr1:147112579	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.518	rs4950304	ENSG00000271721.1	RP11-337C18.9	3.71	0.000231	0.016	0.19	0.17	Protein quantitative trait loci;	chr1:147116685	chr1:147175602~147177740:+
THCA	cis	rs4950322	0.518	rs4950305	ENSG00000271721.1	RP11-337C18.9	3.71	0.000231	0.016	0.19	0.17	Protein quantitative trait loci;	chr1:147117711	chr1:147175602~147177740:+
THCA	cis	rs2221894	0.922	rs2203209	ENSG00000251191.6	LINC00589	-3.71	0.000231	0.016	-0.2	-0.17	Obesity-related traits;	chr8:28930516	chr8:29673922~29748109:-
THCA	cis	rs6754311	0.517	rs60453613	ENSG00000231890.6	DARS-AS1	-3.71	0.000231	0.016	-0.2	-0.17	Mosquito bite size;	chr2:135769550	chr2:135985176~136022593:+
THCA	cis	rs17095355	0.748	rs2501577	ENSG00000234118.1	RPL13AP6	3.71	0.000231	0.016	0.19	0.17	Biliary atresia;	chr10:110086929	chr10:110936622~110937233:-
THCA	cis	rs2797160	0.837	rs1739364	ENSG00000226409.1	RP11-735G4.1	-3.71	0.000231	0.016	-0.2	-0.17	Endometrial cancer;	chr6:125701237	chr6:125370211~125374324:-
THCA	cis	rs11971779	0.638	rs77668044	ENSG00000252332.1	RNU6-911P	-3.71	0.000231	0.016	-0.24	-0.17	Diisocyanate-induced asthma;	chr7:139426339	chr7:139448740~139448843:+
THCA	cis	rs9840812	0.769	rs489398	ENSG00000239213.4	NCK1-AS1	3.71	0.000231	0.016	0.18	0.17	Fibrinogen levels;	chr3:136276656	chr3:136841726~136862054:-
THCA	cis	rs62292953	0.657	rs17404153	ENSG00000248724.5	NPHP3-AS1	3.71	0.000231	0.016	0.3	0.17	Red cell distribution width;	chr3:132444356	chr3:132721750~132874223:+
THCA	cis	rs6545883	0.868	rs6752938	ENSG00000212978.6	AC016747.3	3.71	0.000231	0.016	0.18	0.17	Tuberculosis;	chr2:61614453	chr2:61141592~61144969:-
THCA	cis	rs875971	0.545	rs73152714	ENSG00000232559.3	GS1-124K5.12	3.71	0.000231	0.016	0.18	0.17	Aortic root size;	chr7:66534641	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs4718364	ENSG00000232559.3	GS1-124K5.12	3.71	0.000231	0.016	0.18	0.17	Aortic root size;	chr7:66536353	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs801199	ENSG00000232559.3	GS1-124K5.12	-3.71	0.000231	0.016	-0.18	-0.17	Aortic root size;	chr7:66560286	chr7:66554588~66576923:-
THCA	cis	rs17248895	0.666	rs10148070	ENSG00000258561.1	RP11-72M17.1	-3.71	0.000231	0.016	-0.21	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr14:67419135	chr14:66212810~66509394:-
THCA	cis	rs17248895	0.764	rs8020262	ENSG00000258561.1	RP11-72M17.1	-3.71	0.000231	0.016	-0.21	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr14:67419400	chr14:66212810~66509394:-
THCA	cis	rs3892630	0.878	rs7246451	ENSG00000267475.1	CTD-2538C1.2	-3.71	0.000231	0.016	-0.25	-0.17	Red blood cell traits;	chr19:32718708	chr19:32687089~32691750:-
THCA	cis	rs3892630	0.878	rs1559177	ENSG00000267475.1	CTD-2538C1.2	-3.71	0.000231	0.016	-0.25	-0.17	Red blood cell traits;	chr19:32719740	chr19:32687089~32691750:-
THCA	cis	rs2051773	0.567	rs11024113	ENSG00000272034.1	SNORD14A	-3.71	0.000231	0.016	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17020897	chr11:17074654~17074744:-
THCA	cis	rs2486012	1	rs1636877	ENSG00000237950.1	RP11-7O11.3	-3.71	0.000231	0.016	-0.2	-0.17	Intelligence (multi-trait analysis);	chr1:43921953	chr1:43944370~43946551:-
THCA	cis	rs6545883	0.895	rs2177961	ENSG00000212978.6	AC016747.3	-3.71	0.000231	0.016	-0.18	-0.17	Tuberculosis;	chr2:61333129	chr2:61141592~61144969:-
THCA	cis	rs75828804	1	rs75828804	ENSG00000260922.1	RP11-538I12.3	-3.71	0.000231	0.016	-0.36	-0.17	Intraocular pressure;	chr16:77558038	chr16:77234877~77290934:+
THCA	cis	rs7176527	0.848	rs72630463	ENSG00000230373.7	GOLGA6L5P	3.71	0.000231	0.016	0.24	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84750699	chr15:84507885~84516814:-
THCA	cis	rs11971779	0.715	rs11772771	ENSG00000252332.1	RNU6-911P	-3.71	0.000231	0.016	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139374057	chr7:139448740~139448843:+
THCA	cis	rs10090774	0.76	rs13257090	ENSG00000280303.2	ERICD	-3.71	0.000231	0.016	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140719364	chr8:140636281~140638283:+
THCA	cis	rs189798	0.738	rs330911	ENSG00000233609.3	RP11-62H7.2	3.71	0.000231	0.016	0.17	0.17	Myopia (pathological);	chr8:9138763	chr8:8961200~8979025:+
THCA	cis	rs13325613	0.915	rs34005848	ENSG00000223552.1	RP11-24F11.2	-3.71	0.000231	0.016	-0.31	-0.17	Monocyte count;	chr3:46222254	chr3:46364955~46407059:-
THCA	cis	rs944289	0.708	rs34613409	ENSG00000257520.1	RP11-896J10.3	3.71	0.000231	0.016	0.17	0.17	Thyroid cancer;	chr14:36096489	chr14:36473207~36519521:-
THCA	cis	rs944289	0.774	rs2415312	ENSG00000257520.1	RP11-896J10.3	3.71	0.000231	0.016	0.17	0.17	Thyroid cancer;	chr14:36097145	chr14:36473207~36519521:-
THCA	cis	rs1065852	0.526	rs9611700	ENSG00000227370.1	RP4-669P10.19	3.71	0.000231	0.016	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42005510	chr22:42132543~42132998:+
THCA	cis	rs1065852	0.526	rs2413663	ENSG00000227370.1	RP4-669P10.19	3.71	0.000231	0.016	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42006395	chr22:42132543~42132998:+
THCA	cis	rs7178375	0.941	rs4779796	ENSG00000215302.7	CTD-3092A11.1	-3.71	0.000231	0.016	-0.23	-0.17	Hypertriglyceridemia;	chr15:30915847	chr15:30470779~30507623:+
THCA	cis	rs9341808	0.69	rs9343970	ENSG00000260645.1	RP11-250B2.5	3.71	0.000231	0.016	0.14	0.17	Sitting height ratio;	chr6:80171572	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.718	rs9343971	ENSG00000260645.1	RP11-250B2.5	3.71	0.000231	0.016	0.14	0.17	Sitting height ratio;	chr6:80172339	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.754	rs3805925	ENSG00000260645.1	RP11-250B2.5	3.71	0.000231	0.016	0.14	0.17	Sitting height ratio;	chr6:80174116	chr6:80466958~80469080:+
THCA	cis	rs3176789	0.647	rs10772127	ENSG00000256673.1	RP11-599J14.2	3.71	0.000231	0.016	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9769194	chr12:9398355~9414851:-
THCA	cis	rs72634501	0.517	rs7522362	ENSG00000182109.6	RP11-69E11.4	-3.71	0.000231	0.016	-0.16	-0.17	HDL cholesterol;	chr1:39139419	chr1:39522280~39546187:-
THCA	cis	rs1009077	1	rs2583610	ENSG00000245958.5	RP11-33B1.1	-3.71	0.000231	0.016	-0.2	-0.17	Endometriosis;	chr4:119703030	chr4:119454791~119552025:+
THCA	cis	rs4713118	0.869	rs4713121	ENSG00000261839.1	RP1-265C24.8	3.71	0.000231	0.016	0.2	0.17	Parkinson's disease;	chr6:27754285	chr6:28136849~28139678:+
THCA	cis	rs2191566	0.614	rs396497	ENSG00000277806.1	RP11-15A1.8	-3.71	0.000231	0.016	-0.17	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:43990278	chr19:43976815~43977448:+
THCA	cis	rs12451471	0.559	rs1042396	ENSG00000279259.1	RP11-334C17.3	-3.71	0.000231	0.016	-0.17	-0.17	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80110970	chr17:80147250~80148596:+
THCA	cis	rs7554547	0.622	rs72864769	ENSG00000199347.1	RNU5E-1	-3.71	0.000231	0.016	-0.24	-0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11881264	chr1:11908152~11908271:+
THCA	cis	rs2898290	0.622	rs978802	ENSG00000206014.6	OR7E161P	3.71	0.000231	0.016	0.2	0.17	Systolic blood pressure;	chr8:11485769	chr8:11928597~11929563:-
THCA	cis	rs1941184	0.5	rs1460598	ENSG00000266521.1	RP11-650P15.1	-3.71	0.000231	0.016	-0.27	-0.17	Parkinson's disease (age of onset);	chr18:31448528	chr18:31496645~31497195:-
THCA	cis	rs12544026	0.549	rs544928	ENSG00000253669.3	KB-1732A1.1	-3.71	0.000232	0.016	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101872917	chr8:102805517~102809971:+
THCA	cis	rs9475752	0.53	rs2397227	ENSG00000231441.1	RP11-472M19.2	-3.71	0.000232	0.016	-0.18	-0.17	Menarche (age at onset);	chr6:56974709	chr6:56844002~56864078:+
THCA	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-3.71	0.000232	0.016	-0.2	-0.17	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
THCA	cis	rs34102591	0.503	rs10846576	ENSG00000270061.1	RP11-214K3.19	-3.71	0.000232	0.016	-0.21	-0.17	Schizophrenia;	chr12:123902126	chr12:123969990~123970344:-
THCA	cis	rs34102591	0.503	rs28435362	ENSG00000270061.1	RP11-214K3.19	-3.71	0.000232	0.016	-0.21	-0.17	Schizophrenia;	chr12:123902629	chr12:123969990~123970344:-
THCA	cis	rs4879656	0.933	rs10813934	ENSG00000225693.1	LAGE3P1	-3.71	0.000232	0.016	-0.19	-0.17	Menopause (age at onset);	chr9:33078146	chr9:33019682~33020165:-
THCA	cis	rs4879656	0.966	rs3758274	ENSG00000225693.1	LAGE3P1	-3.71	0.000232	0.016	-0.19	-0.17	Menopause (age at onset);	chr9:33078321	chr9:33019682~33020165:-
THCA	cis	rs73222236	0.737	rs9854328	ENSG00000273455.1	RP11-305O4.3	-3.71	0.000232	0.016	-0.22	-0.17	Coronary artery disease;	chr3:136350878	chr3:136087475~136087913:-
THCA	cis	rs4699052	1	rs6533060	ENSG00000246560.2	RP11-10L12.4	3.71	0.000232	0.016	0.2	0.17	Testicular germ cell tumor;	chr4:103218839	chr4:102828055~102844075:+
THCA	cis	rs600231	0.719	rs7114809	ENSG00000254614.2	AP003068.23	3.71	0.000232	0.016	0.22	0.17	Bone mineral density;	chr11:65483973	chr11:65177606~65181834:-
THCA	cis	rs4434872	0.525	rs6671009	ENSG00000228013.1	RP11-350G8.5	-3.71	0.000232	0.016	-0.31	-0.17	Conduct disorder (symptom count);	chr1:154047902	chr1:154402328~154406564:-
THCA	cis	rs2179367	0.919	rs577001	ENSG00000223701.3	RAET1E-AS1	3.71	0.000232	0.016	0.22	0.17	Dupuytren's disease;	chr6:149325172	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.959	rs562428	ENSG00000223701.3	RAET1E-AS1	3.71	0.000232	0.016	0.22	0.17	Dupuytren's disease;	chr6:149326389	chr6:149884431~149919508:+
THCA	cis	rs11048434	0.518	rs2377678	ENSG00000256720.1	RP11-436I9.6	-3.71	0.000232	0.016	-0.18	-0.17	Sjögren's syndrome;	chr12:9021562	chr12:9135084~9135591:+
THCA	cis	rs7560272	0.501	rs12615807	ENSG00000163016.8	ALMS1P	-3.71	0.000232	0.016	-0.21	-0.17	Schizophrenia;	chr2:73720456	chr2:73644919~73685576:+
THCA	cis	rs2129782	0.558	rs59254696	ENSG00000253553.4	RP11-586K2.1	3.71	0.000232	0.0161	0.25	0.17	Electrodermal activity;	chr8:88469118	chr8:88326836~88737134:+
THCA	cis	rs7312933	0.558	rs11181466	ENSG00000257225.1	RP11-328C8.4	-3.71	0.000232	0.0161	-0.18	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42371379	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.558	rs11181467	ENSG00000257225.1	RP11-328C8.4	-3.71	0.000232	0.0161	-0.18	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42371448	chr12:42459366~42466128:+
THCA	cis	rs643506	0.874	rs648544	ENSG00000230911.1	PPIHP1	-3.71	0.000232	0.0161	-0.23	-0.17	Breast cancer;	chr11:111795404	chr11:112029858~112030367:-
THCA	cis	rs2638953	0.853	rs11049679	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000232	0.0161	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508161	chr12:28163298~28190738:-
THCA	cis	rs3087591	0.683	rs2525567	ENSG00000263535.1	AK4P1	3.71	0.000232	0.0161	0.2	0.17	Hip circumference;	chr17:31348655	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs2525569	ENSG00000263535.1	AK4P1	3.71	0.000232	0.0161	0.2	0.17	Hip circumference;	chr17:31348953	chr17:31345521~31346187:+
THCA	cis	rs4578769	0.569	rs12605806	ENSG00000273232.1	RP11-370A5.2	3.71	0.000232	0.0161	0.23	0.17	Eosinophil percentage of white cells;	chr18:22882093	chr18:22882825~22883357:-
THCA	cis	rs6860806	0.661	rs6871350	ENSG00000263597.1	MIR3936	3.71	0.000232	0.0161	0.16	0.17	Breast cancer;	chr5:132244527	chr5:132365490~132365599:-
THCA	cis	rs1580019	0.885	rs3801331	ENSG00000231952.3	DPY19L1P2	3.71	0.000232	0.0161	0.22	0.17	Cognitive ability;	chr7:32457427	chr7:32812757~32838570:+
THCA	cis	rs9863	0.827	rs7305864	ENSG00000270028.1	RP11-380L11.4	3.71	0.000232	0.0161	0.18	0.17	White blood cell count;	chr12:123957333	chr12:123925461~123926083:-
THCA	cis	rs150992	0.673	rs161953	ENSG00000246763.5	RGMB-AS1	3.71	0.000232	0.0161	0.18	0.17	Body mass index;	chr5:98921201	chr5:98769618~98773469:-
THCA	cis	rs150992	0.673	rs161952	ENSG00000246763.5	RGMB-AS1	3.71	0.000232	0.0161	0.18	0.17	Body mass index;	chr5:98921665	chr5:98769618~98773469:-
THCA	cis	rs73193808	0.639	rs2832241	ENSG00000231125.2	AF129075.5	-3.71	0.000232	0.0161	-0.16	-0.17	Coronary artery disease;	chr21:29179715	chr21:29058073~29060095:-
THCA	cis	rs7045881	0.576	rs7045747	ENSG00000254396.1	RP11-56F10.3	3.71	0.000232	0.0161	0.2	0.17	Schizophrenia;	chr9:27041317	chr9:27102630~27104728:+
THCA	cis	rs875971	0.545	rs73146609	ENSG00000273024.4	INTS4P2	-3.71	0.000232	0.0161	-0.21	-0.17	Aortic root size;	chr7:66302477	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000273024.4	INTS4P2	-3.71	0.000232	0.0161	-0.21	-0.17	Aortic root size;	chr7:66305392	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000273024.4	INTS4P2	-3.71	0.000232	0.0161	-0.21	-0.17	Aortic root size;	chr7:66318029	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000273024.4	INTS4P2	-3.71	0.000232	0.0161	-0.21	-0.17	Aortic root size;	chr7:66325577	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000273024.4	INTS4P2	-3.71	0.000232	0.0161	-0.21	-0.17	Aortic root size;	chr7:66339619	chr7:65647864~65715661:+
THCA	cis	rs62490346	1	rs10503407	ENSG00000255020.1	AF131216.5	-3.71	0.000232	0.0161	-0.16	-0.17	Chickenpox;	chr8:10371123	chr8:11345748~11347502:-
THCA	cis	rs17037831	0.667	rs11716701	ENSG00000274514.1	Metazoa_SRP	-3.71	0.000232	0.0161	-0.35	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr3:13225734	chr3:12576961~12577237:-
THCA	cis	rs9650657	0.504	rs10093053	ENSG00000261451.1	RP11-981G7.1	-3.71	0.000232	0.0161	-0.21	-0.17	Neuroticism;	chr8:11179678	chr8:10433672~10438312:+
THCA	cis	rs801193	0.935	rs2659899	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000232	0.0161	-0.14	-0.17	Aortic root size;	chr7:66721734	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs1553609	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000232	0.0161	-0.14	-0.17	Aortic root size;	chr7:66732152	chr7:66848496~66858136:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000232	0.0161	-0.14	-0.17	Aortic root size;	chr7:66749023	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs2659889	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000232	0.0161	-0.14	-0.17	Aortic root size;	chr7:66752125	chr7:66848496~66858136:+
THCA	cis	rs7680126	0.633	rs28378345	ENSG00000261490.1	RP11-448G15.3	-3.71	0.000232	0.0161	-0.13	-0.17	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10208273	chr4:10068089~10073019:-
THCA	cis	rs10435719	0.753	rs9694940	ENSG00000255495.1	AC145124.2	3.71	0.000232	0.0161	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:12194467~12196280:+
THCA	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-3.71	0.000232	0.0161	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
THCA	cis	rs972540	0.883	rs62195882	ENSG00000229647.1	AC007879.7	-3.71	0.000232	0.0161	-0.19	-0.17	Body mass index;	chr2:206366803	chr2:207239650~207245887:+
THCA	cis	rs587080	0.624	rs512715	ENSG00000197847.11	SLC22A20	3.71	0.000232	0.0161	0.18	0.17	Plateletcrit;	chr11:65423737	chr11:65213840~65242757:+
THCA	cis	rs2629751	0.962	rs2723867	ENSG00000214198.6	RP11-642P15.1	-3.71	0.000232	0.0161	-0.13	-0.17	Hepatitis C induced liver fibrosis;	chr12:104027212	chr12:103843749~103930211:-
THCA	cis	rs4915077	0.773	rs17019810	ENSG00000226822.1	RP11-356N1.2	3.71	0.000232	0.0161	0.3	0.17	Hypothyroidism;	chr1:107726179	chr1:108071482~108074519:+
THCA	cis	rs875971	0.545	rs6460298	ENSG00000273024.4	INTS4P2	-3.71	0.000232	0.0161	-0.21	-0.17	Aortic root size;	chr7:66442783	chr7:65647864~65715661:+
THCA	cis	rs55966801	0.898	rs72878047	ENSG00000277290.1	RP11-326C3.16	-3.71	0.000232	0.0161	-0.23	-0.17	Plateletcrit;	chr11:229811	chr11:243099~243483:-
THCA	cis	rs55966801	0.898	rs113919457	ENSG00000277290.1	RP11-326C3.16	-3.71	0.000232	0.0161	-0.23	-0.17	Plateletcrit;	chr11:230951	chr11:243099~243483:-
THCA	cis	rs55966801	0.898	rs11602248	ENSG00000277290.1	RP11-326C3.16	-3.71	0.000232	0.0161	-0.23	-0.17	Plateletcrit;	chr11:231305	chr11:243099~243483:-
THCA	cis	rs9788682	0.747	rs4887053	ENSG00000261143.1	ADAMTS7P3	3.71	0.000232	0.0161	0.26	0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78420357	chr15:77976042~77993057:+
THCA	cis	rs7267979	0.966	rs6050567	ENSG00000276952.1	RP5-965G21.6	-3.71	0.000232	0.0161	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25284915~25285588:-
THCA	cis	rs4660214	0.666	rs1180376	ENSG00000228060.1	RP11-69E11.8	-3.71	0.000232	0.0161	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39565160~39573203:+
THCA	cis	rs910316	1	rs10873275	ENSG00000259138.1	RP11-950C14.7	3.71	0.000232	0.0161	0.15	0.17	Height;	chr14:75064757	chr14:75127153~75136930:+
THCA	cis	rs2032366	0.606	rs7226896	ENSG00000267316.4	RP11-879F14.3	-3.71	0.000232	0.0161	-0.19	-0.17	Obesity-related traits;	chr18:61608946	chr18:61571342~61579456:-
THCA	cis	rs6942407	0.592	rs4728689	ENSG00000224046.1	AC005076.5	-3.71	0.000232	0.0161	-0.17	-0.17	Food allergy;	chr7:87221781	chr7:87151423~87152420:-
THCA	cis	rs6942407	0.592	rs10085726	ENSG00000224046.1	AC005076.5	-3.71	0.000232	0.0161	-0.17	-0.17	Food allergy;	chr7:87222081	chr7:87151423~87152420:-
THCA	cis	rs45544231	0.966	rs12929797	ENSG00000279344.1	RP11-44F14.7	3.71	0.000232	0.0161	0.16	0.17	Restless legs syndrome;	chr16:52599032	chr16:53478957~53481550:-
THCA	cis	rs4948275	0.597	rs2650712	ENSG00000233643.2	RP11-491H19.1	3.71	0.000232	0.0161	0.19	0.17	Night sleep phenotypes;	chr10:61605901	chr10:61781745~61821246:-
THCA	cis	rs1065852	0.503	rs9620006	ENSG00000227370.1	RP4-669P10.19	3.71	0.000232	0.0161	0.18	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42003543	chr22:42132543~42132998:+
THCA	cis	rs6894216	0.593	rs6595948	ENSG00000248610.1	HSPA8P4	-3.71	0.000232	0.0161	-0.21	-0.17	Response to amphetamines;	chr5:130333844	chr5:130140031~130141950:+
THCA	cis	rs738409	1	rs3747207	ENSG00000223843.4	EFCAB6-AS1	3.71	0.000232	0.0161	0.23	0.17	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43928975	chr22:43516107~43537117:+
THCA	cis	rs111756027	0.645	rs17712826	ENSG00000260922.1	RP11-538I12.3	3.71	0.000232	0.0161	0.25	0.17	Bone mineral density (Ward's triangle area);	chr16:77279984	chr16:77234877~77290934:+
THCA	cis	rs7656342	0.93	rs13106539	ENSG00000249866.1	OR7E83P	3.71	0.000232	0.0161	0.19	0.17	Gut microbiota (bacterial taxa);	chr4:9796079	chr4:9512905~9513874:+
THCA	cis	rs67478160	0.619	rs12878682	ENSG00000258534.1	CTD-2134A5.4	-3.71	0.000232	0.0161	-0.17	-0.17	Schizophrenia;	chr14:103767290	chr14:103854366~103880111:-
THCA	cis	rs10089	1	rs10463838	ENSG00000245937.6	LINC01184	3.71	0.000232	0.0161	0.19	0.17	Ileal carcinoids;	chr5:128182613	chr5:127940426~128083172:-
THCA	cis	rs11105298	0.891	rs10858879	ENSG00000266347.2	AC068641.1	-3.71	0.000232	0.0161	-0.21	-0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89592833~89592927:+
THCA	cis	rs733592	0.599	rs12819124	ENSG00000275228.1	RP11-370I10.10	-3.71	0.000233	0.0161	-0.18	-0.17	Plateletcrit;	chr12:48015271	chr12:48327942~48328472:-
THCA	cis	rs950893	0.729	rs1858401	ENSG00000253837.1	RP11-177H13.2	3.71	0.000233	0.0161	0.17	0.17	Mean corpuscular hemoglobin;	chr8:23608953	chr8:23336171~23366125:+
THCA	cis	rs16962242	1	rs76893557	ENSG00000276957.1	RP11-29B2.6	3.71	0.000233	0.0161	0.33	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr13:103413184	chr13:102593338~102593873:-
THCA	cis	rs2919009	0.581	rs2118962	ENSG00000271670.1	RP11-95I16.4	3.71	0.000233	0.0161	0.19	0.17	Obesity-related traits;	chr10:120937721	chr10:120879256~120880667:-
THCA	cis	rs2919009	0.581	rs56118695	ENSG00000271670.1	RP11-95I16.4	3.71	0.000233	0.0161	0.19	0.17	Obesity-related traits;	chr10:120938383	chr10:120879256~120880667:-
THCA	cis	rs73173548	0.502	rs34394411	ENSG00000247828.6	TMEM161B-AS1	3.71	0.000233	0.0161	0.16	0.17	Macular telangiectasia type 2;	chr5:88436903	chr5:88268895~88436685:+
THCA	cis	rs73193808	0.639	rs7277858	ENSG00000231125.2	AF129075.5	-3.71	0.000233	0.0161	-0.16	-0.17	Coronary artery disease;	chr21:29180556	chr21:29058073~29060095:-
THCA	cis	rs812925	0.512	rs7558954	ENSG00000270820.4	RP11-355B11.2	3.71	0.000233	0.0161	0.14	0.17	Immature fraction of reticulocytes;	chr2:61157771	chr2:61471188~61484130:+
THCA	cis	rs812925	0.553	rs1177307	ENSG00000270820.4	RP11-355B11.2	3.71	0.000233	0.0161	0.14	0.17	Immature fraction of reticulocytes;	chr2:61160253	chr2:61471188~61484130:+
THCA	cis	rs812925	0.512	rs1729674	ENSG00000270820.4	RP11-355B11.2	3.71	0.000233	0.0161	0.14	0.17	Immature fraction of reticulocytes;	chr2:61162602	chr2:61471188~61484130:+
THCA	cis	rs17181170	1	rs7628934	ENSG00000239572.1	RP11-451B8.1	-3.71	0.000233	0.0161	-0.19	-0.17	Prostate cancer;	chr3:87126834	chr3:87731402~87793629:-
THCA	cis	rs2276314	0.947	rs4799831	ENSG00000267627.4	RP11-905K4.1	-3.71	0.000233	0.0161	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35951803~35966118:-
THCA	cis	rs4460629	0.712	rs11264313	ENSG00000236675.1	MTX1P1	-3.71	0.000233	0.0161	-0.16	-0.17	Serum magnesium levels;	chr1:155104029	chr1:155230975~155234325:+
THCA	cis	rs13118159	0.767	rs2141656	ENSG00000254094.1	AC078852.1	-3.71	0.000233	0.0161	-0.19	-0.17	Longevity;	chr4:1323404	chr4:1356581~1358075:+
THCA	cis	rs11671005	0.735	rs35652377	ENSG00000269600.1	AC016629.3	-3.71	0.000233	0.0161	-0.25	-0.17	Mean platelet volume;	chr19:58417833	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs3764532	ENSG00000269600.1	AC016629.3	-3.71	0.000233	0.0161	-0.25	-0.17	Mean platelet volume;	chr19:58417855	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs3088284	ENSG00000269600.1	AC016629.3	-3.71	0.000233	0.0161	-0.25	-0.17	Mean platelet volume;	chr19:58418060	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs12981649	ENSG00000269600.1	AC016629.3	-3.71	0.000233	0.0161	-0.25	-0.17	Mean platelet volume;	chr19:58418676	chr19:58593896~58599355:-
THCA	cis	rs10090774	0.71	rs11166992	ENSG00000279766.1	RP11-642A1.2	-3.71	0.000233	0.0161	-0.2	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140667371	chr8:140572142~140572812:-
THCA	cis	rs2290416	0.786	rs60401352	ENSG00000254973.1	RP11-429J17.7	3.71	0.000233	0.0161	0.32	0.17	Attention deficit hyperactivity disorder;	chr8:143590927	chr8:143758153~143771822:-
THCA	cis	rs10089	0.904	rs2228112	ENSG00000245937.6	LINC01184	3.71	0.000233	0.0161	0.19	0.17	Ileal carcinoids;	chr5:128134167	chr5:127940426~128083172:-
THCA	cis	rs821367	0.871	rs17308266	ENSG00000229048.5	DUTP1	-3.71	0.000233	0.0161	-0.27	-0.17	Platelet distribution width;	chr3:124687251	chr3:125310881~125311350:+
THCA	cis	rs7572644	0.766	rs12614744	ENSG00000223522.1	AC093690.1	-3.71	0.000233	0.0161	-0.22	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28046835	chr2:28307691~28310459:-
THCA	cis	rs2839186	0.77	rs2330353	ENSG00000228137.1	AP001469.7	3.71	0.000233	0.0161	0.17	0.17	Testicular germ cell tumor;	chr21:46249734	chr21:46246890~46247682:+
THCA	cis	rs9309473	0.66	rs11679594	ENSG00000273245.1	RP11-434P11.2	3.71	0.000233	0.0161	0.27	0.17	Metabolite levels;	chr2:73552380	chr2:73750256~73750786:-
THCA	cis	rs6878727	0.552	rs1904461	ENSG00000253807.4	LINC01170	3.71	0.000233	0.0161	0.17	0.17	Breast cancer;	chr5:124354967	chr5:124059794~124405079:-
THCA	cis	rs7577696	0.575	rs212704	ENSG00000276334.1	AL133243.1	3.71	0.000233	0.0161	0.18	0.17	Inflammatory biomarkers;	chr2:32225279	chr2:32521927~32523547:+
THCA	cis	rs2880765	0.835	rs11074276	ENSG00000218052.5	ADAMTS7P4	-3.71	0.000233	0.0161	-0.19	-0.17	Coronary artery disease;	chr15:85487132	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.805	rs11858817	ENSG00000218052.5	ADAMTS7P4	-3.71	0.000233	0.0161	-0.19	-0.17	Coronary artery disease;	chr15:85488029	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs11633604	ENSG00000218052.5	ADAMTS7P4	-3.71	0.000233	0.0161	-0.19	-0.17	Coronary artery disease;	chr15:85488348	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs7164106	ENSG00000218052.5	ADAMTS7P4	-3.71	0.000233	0.0161	-0.19	-0.17	Coronary artery disease;	chr15:85489359	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs1872074	ENSG00000218052.5	ADAMTS7P4	-3.71	0.000233	0.0161	-0.19	-0.17	Coronary artery disease;	chr15:85489953	chr15:85255369~85330334:-
THCA	cis	rs7246967	0.673	rs4933017	ENSG00000198153.8	ZNF849P	-3.71	0.000233	0.0161	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22630178	chr19:22685167~22686732:+
THCA	cis	rs9880211	0.718	rs56398805	ENSG00000239213.4	NCK1-AS1	3.71	0.000233	0.0161	0.17	0.17	Height;Body mass index;	chr3:136213558	chr3:136841726~136862054:-
THCA	cis	rs9608946	1	rs17738540	ENSG00000279699.1	RP1-102K2.9	3.71	0.000233	0.0161	0.2	0.17	Red cell distribution width;	chr22:30492540	chr22:30275215~30276951:-
THCA	cis	rs2562152	0.53	rs216604	ENSG00000226942.2	IL9RP3	-3.71	0.000233	0.0161	-0.24	-0.17	Glioblastoma;	chr16:62515	chr16:29336~38321:-
THCA	cis	rs4713118	0.539	rs510987	ENSG00000216915.2	RP1-97D16.1	-3.71	0.000233	0.0161	-0.24	-0.17	Parkinson's disease;	chr6:27879739	chr6:27737000~27738494:-
THCA	cis	rs7772697	0.539	rs9498205	ENSG00000223701.3	RAET1E-AS1	-3.71	0.000233	0.0161	-0.24	-0.17	Diabetic retinopathy;	chr6:149085127	chr6:149884431~149919508:+
THCA	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	3.71	0.000233	0.0161	0.1	0.17	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
THCA	cis	rs7727544	0.584	rs7714191	ENSG00000263597.1	MIR3936	3.71	0.000233	0.0161	0.17	0.17	Blood metabolite levels;	chr5:132005848	chr5:132365490~132365599:-
THCA	cis	rs11723261	0.582	rs3747693	ENSG00000250892.1	RP11-1365D11.1	3.71	0.000233	0.0161	0.25	0.17	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:201409~205009:-
THCA	cis	rs13217239	0.646	rs7768407	ENSG00000261353.1	CTA-14H9.5	-3.71	0.000233	0.0161	-0.18	-0.17	Schizophrenia;	chr6:27049016	chr6:26527063~26527404:+
THCA	cis	rs3734729	1	rs3734730	ENSG00000218358.2	RAET1K	3.71	0.000233	0.0161	0.49	0.17	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150249804	chr6:149998019~150005157:-
THCA	cis	rs7259376	0.503	rs1704014	ENSG00000269138.1	ZNF209P	3.71	0.000233	0.0161	0.16	0.17	Menopause (age at onset);	chr19:22454101	chr19:22463922~22473036:+
THCA	cis	rs2360027	0.662	rs10754383	ENSG00000231365.4	RP11-418J17.1	3.71	0.000233	0.0161	0.17	0.17	Tonsillectomy;	chr1:118574851	chr1:119140396~119275973:+
THCA	cis	rs6903823	0.508	rs1150724	ENSG00000220721.1	OR1F12	3.71	0.000233	0.0161	0.19	0.17	Pulmonary function;	chr6:28282459	chr6:28073316~28074233:+
THCA	cis	rs67478160	0.619	rs1040813	ENSG00000258534.1	CTD-2134A5.4	-3.71	0.000233	0.0161	-0.17	-0.17	Schizophrenia;	chr14:103840359	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.619	rs1187416	ENSG00000258534.1	CTD-2134A5.4	-3.71	0.000233	0.0161	-0.17	-0.17	Schizophrenia;	chr14:103845128	chr14:103854366~103880111:-
THCA	cis	rs9400467	1	rs241768	ENSG00000271789.1	RP5-1112D6.7	-3.71	0.000233	0.0161	-0.17	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111170916	chr6:111297126~111298510:+
THCA	cis	rs3743772	0.655	rs62048545	ENSG00000279344.1	RP11-44F14.7	3.71	0.000233	0.0161	0.28	0.17	Depressive symptoms (SSRI exposure interaction);	chr16:53507209	chr16:53478957~53481550:-
THCA	cis	rs889312	0.5	rs252903	ENSG00000271828.1	CTD-2310F14.1	-3.71	0.000233	0.0161	-0.23	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56822125	chr5:56927874~56929573:+
THCA	cis	rs6142618	0.783	rs4911090	ENSG00000224452.1	RSL24D1P6	3.71	0.000233	0.0161	0.21	0.17	Inflammatory bowel disease;	chr20:32299103	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.74	rs4911214	ENSG00000224452.1	RSL24D1P6	3.71	0.000233	0.0161	0.21	0.17	Inflammatory bowel disease;	chr20:32299661	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.807	rs6057559	ENSG00000224452.1	RSL24D1P6	3.71	0.000233	0.0161	0.21	0.17	Inflammatory bowel disease;	chr20:32304151	chr20:32170390~32170790:-
THCA	cis	rs6724465	0.929	rs13410377	ENSG00000272644.1	RP11-33O4.1	3.71	0.000233	0.0161	0.25	0.17	Height;	chr2:219110326	chr2:219069354~219069809:-
THCA	cis	rs910316	0.935	rs3742771	ENSG00000259138.1	RP11-950C14.7	3.71	0.000233	0.0161	0.15	0.17	Height;	chr14:75132944	chr14:75127153~75136930:+
THCA	cis	rs2823962	0.697	rs12627380	ENSG00000270093.1	AP000473.8	-3.71	0.000233	0.0161	-0.16	-0.17	Amyotrophic lateral sclerosis;	chr21:16648240	chr21:16643529~16645065:+
THCA	cis	rs494453	0.736	rs548129	ENSG00000227811.2	FAM212B-AS1	-3.71	0.000233	0.0161	-0.2	-0.17	Osteoporosis-related phenotypes;	chr1:111658548	chr1:111739841~111747798:+
THCA	cis	rs6496667	1	rs58436485	ENSG00000259262.1	NDUFA3P4	3.71	0.000233	0.0161	0.23	0.17	Rheumatoid arthritis;	chr15:90357401	chr15:90385814~90386063:+
THCA	cis	rs853679	0.769	rs7752448	ENSG00000226314.6	ZNF192P1	-3.71	0.000233	0.0161	-0.3	-0.17	Depression;	chr6:28333322	chr6:28161781~28169594:+
THCA	cis	rs6894216	0.621	rs1157409	ENSG00000248610.1	HSPA8P4	-3.71	0.000233	0.0161	-0.21	-0.17	Response to amphetamines;	chr5:130333296	chr5:130140031~130141950:+
THCA	cis	rs13113518	0.812	rs2412648	ENSG00000272969.1	RP11-528I4.2	3.71	0.000233	0.0161	0.2	0.17	Height;	chr4:55454900	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs12512737	ENSG00000272969.1	RP11-528I4.2	3.71	0.000233	0.0161	0.2	0.17	Height;	chr4:55454938	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.812	rs13125984	ENSG00000272969.1	RP11-528I4.2	3.71	0.000233	0.0161	0.2	0.17	Height;	chr4:55455102	chr4:55547112~55547889:+
THCA	cis	rs72829446	0.53	rs11654859	ENSG00000266824.1	RP11-599B13.7	3.71	0.000233	0.0161	0.26	0.17	Androgen levels;	chr17:7562022	chr17:8176812~8182812:+
THCA	cis	rs13182402	0.901	rs17165056	ENSG00000230929.5	RP11-395C3.1	-3.71	0.000233	0.0161	-0.33	-0.17	Osteoporosis;	chr5:126592225	chr5:126628019~126628319:-
THCA	cis	rs10875746	0.669	rs11168510	ENSG00000258273.1	RP11-370I10.4	3.71	0.000233	0.0161	0.24	0.17	Longevity (90 years and older);	chr12:48291772	chr12:48333755~48333901:-
THCA	cis	rs754466	0.606	rs10824581	ENSG00000213514.2	RP11-428P16.2	3.71	0.000233	0.0161	0.19	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77839743	chr10:77730766~77734769:+
THCA	cis	rs12144309	0.543	rs2185827	ENSG00000232450.1	RP4-730K3.3	3.71	0.000233	0.0161	0.22	0.17	Coronary artery disease;	chr1:113843461	chr1:113698884~113699631:-
THCA	cis	rs10181042	0.565	rs62150982	ENSG00000232713.2	AC010733.5	-3.71	0.000233	0.0161	-0.15	-0.17	Crohn's disease;	chr2:61053540	chr2:60938204~60938604:-
THCA	cis	rs2832077	0.943	rs11701777	ENSG00000232855.5	AF131217.1	3.71	0.000233	0.0161	0.21	0.17	Cognitive test performance;	chr21:28783506	chr21:28439346~28674848:-
THCA	cis	rs9291683	0.704	rs11726271	ENSG00000261490.1	RP11-448G15.3	-3.71	0.000233	0.0161	-0.11	-0.17	Bone mineral density;	chr4:10096568	chr4:10068089~10073019:-
THCA	cis	rs10454142	0.7	rs72820427	ENSG00000202227.1	RNU6-282P	3.71	0.000233	0.0161	0.2	0.17	Sex hormone-binding globulin levels;	chr2:48358367	chr2:48501922~48502024:-
THCA	cis	rs2522056	1	rs2522050	ENSG00000237714.1	P4HA2-AS1	-3.71	0.000233	0.0161	-0.24	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132460917	chr5:132184876~132192808:+
THCA	cis	rs11601239	0.646	rs12790131	ENSG00000254750.1	CASP1P2	-3.71	0.000233	0.0161	-0.13	-0.17	Refractive error;	chr11:105697032	chr11:105063345~105071541:-
THCA	cis	rs9860428	0.787	rs12489734	ENSG00000243795.1	RP11-572M11.3	3.71	0.000233	0.0161	0.2	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112847644	chr3:113142350~113167819:-
THCA	cis	rs2276314	1	rs8086395	ENSG00000267627.4	RP11-905K4.1	-3.71	0.000233	0.0161	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35951803~35966118:-
THCA	cis	rs7665090	1	rs5026476	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102633753	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.967	rs6812747	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634260	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs6839064	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634519	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs2272695	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634646	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs2272696	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634664	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs2272697	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102634835	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs2866413	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102635920	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs4547797	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102636035	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs2866414	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102636062	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs9996834	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102636372	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs2903283	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102636596	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs4579121	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102637012	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs6810869	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102637357	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.934	rs6533020	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102637648	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.934	rs6533021	ENSG00000248971.2	KRT8P46	-3.71	0.000233	0.0161	-0.2	-0.17	Primary biliary cholangitis;	chr4:102637696	chr4:102728746~102730171:-
THCA	cis	rs7546094	0.905	rs10776755	ENSG00000273483.1	RP4-671G15.2	-3.71	0.000233	0.0161	-0.15	-0.17	Platelet distribution width;	chr1:112540352	chr1:112517799~112518441:-
THCA	cis	rs453301	0.653	rs7016139	ENSG00000253981.4	ALG1L13P	-3.71	0.000233	0.0161	-0.15	-0.17	Joint mobility (Beighton score);	chr8:9037960	chr8:8236003~8244667:-
THCA	cis	rs4699052	1	rs4699055	ENSG00000230069.3	LRRC37A15P	-3.71	0.000233	0.0161	-0.17	-0.17	Testicular germ cell tumor;	chr4:103233343	chr4:102727274~102730721:-
THCA	cis	rs3024505	1	rs3024505	ENSG00000234219.1	CDCA4P4	3.71	0.000233	0.0161	0.26	0.17	Type 1 diabetes;Systemic lupus erythematosus;Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:206766559	chr1:207762584~207763263:+
THCA	cis	rs1577917	0.958	rs16876530	ENSG00000220563.1	PKMP3	-3.71	0.000234	0.0162	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85885923	chr6:85659892~85660606:-
THCA	cis	rs972578	0.533	rs6002998	ENSG00000274717.1	RP1-47A17.1	-3.71	0.000234	0.0162	-0.19	-0.17	Mean platelet volume;	chr22:43024660	chr22:42791814~42794313:-
THCA	cis	rs3808502	0.509	rs2729940	ENSG00000255495.1	AC145124.2	3.71	0.000234	0.0162	0.19	0.17	Neuroticism;	chr8:11524858	chr8:12194467~12196280:+
THCA	cis	rs1600249	0.562	rs17153419	ENSG00000254948.1	OR7E158P	3.71	0.000234	0.0162	0.22	0.17	Rheumatoid arthritis;	chr8:11536724	chr8:11919900~11920809:-
THCA	cis	rs3738443	0.951	rs4582838	ENSG00000259865.1	RP11-488L18.10	3.71	0.000234	0.0162	0.18	0.17	Alcohol dependence;	chr1:247210269	chr1:247187281~247188526:-
THCA	cis	rs6477918	0.598	rs34409309	ENSG00000230185.4	C9orf147	-3.71	0.000234	0.0162	-0.18	-0.17	Obstetric antiphospholipid syndrome;	chr9:112398426	chr9:112433816~112487204:-
THCA	cis	rs3733585	0.781	rs6449183	ENSG00000250413.1	RP11-448G15.1	3.71	0.000234	0.0162	0.17	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9969067	chr4:10006482~10009725:+
THCA	cis	rs4869313	0.668	rs2549797	ENSG00000247121.5	CTD-2260A17.2	3.71	0.000234	0.0162	0.13	0.17	Pediatric autoimmune diseases;	chr5:96909814	chr5:96814028~96935809:-
THCA	cis	rs7903847	0.62	rs17112674	ENSG00000225850.3	RP11-452K12.4	-3.71	0.000234	0.0162	-0.17	-0.17	Granulocyte percentage of myeloid white cells;	chr10:97362421	chr10:97334564~97343203:+
THCA	cis	rs2486012	1	rs2245439	ENSG00000237950.1	RP11-7O11.3	-3.71	0.000234	0.0162	-0.2	-0.17	Intelligence (multi-trait analysis);	chr1:43924287	chr1:43944370~43946551:-
THCA	cis	rs7246657	0.943	rs3745765	ENSG00000268499.1	CTB-102L5.8	3.71	0.000234	0.0162	0.21	0.17	Coronary artery calcification;	chr19:37363333	chr19:38199836~38200934:+
THCA	cis	rs13325613	0.915	rs10510748	ENSG00000223552.1	RP11-24F11.2	-3.71	0.000234	0.0162	-0.26	-0.17	Monocyte count;	chr3:46137046	chr3:46364955~46407059:-
THCA	cis	rs754466	0.606	rs11002310	ENSG00000213514.2	RP11-428P16.2	3.71	0.000234	0.0162	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77836272	chr10:77730766~77734769:+
THCA	cis	rs875971	0.545	rs6950988	ENSG00000273024.4	INTS4P2	-3.71	0.000234	0.0162	-0.21	-0.17	Aortic root size;	chr7:66511428	chr7:65647864~65715661:+
THCA	cis	rs7727544	0.582	rs2278398	ENSG00000263597.1	MIR3936	-3.71	0.000234	0.0162	-0.16	-0.17	Blood metabolite levels;	chr5:132194748	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.57	rs7701237	ENSG00000263597.1	MIR3936	3.71	0.000234	0.0162	0.16	0.17	Blood metabolite levels;	chr5:132198688	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.582	rs3749756	ENSG00000263597.1	MIR3936	3.71	0.000234	0.0162	0.16	0.17	Blood metabolite levels;	chr5:132198806	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.582	rs3805683	ENSG00000263597.1	MIR3936	3.71	0.000234	0.0162	0.16	0.17	Blood metabolite levels;	chr5:132199432	chr5:132365490~132365599:-
THCA	cis	rs4906332	0.966	rs7401563	ENSG00000259775.1	RP11-45P15.4	-3.71	0.000234	0.0162	-0.14	-0.17	Coronary artery disease;	chr14:103498088	chr14:103331674~103332367:-
THCA	cis	rs9863	0.861	rs4765219	ENSG00000270028.1	RP11-380L11.4	3.71	0.000234	0.0162	0.18	0.17	White blood cell count;	chr12:123955563	chr12:123925461~123926083:-
THCA	cis	rs6019512	0.846	rs2024595	ENSG00000227431.4	CSE1L-AS1	-3.71	0.000234	0.0162	-0.21	-0.17	Intelligence (multi-trait analysis);	chr20:48901359	chr20:49040463~49046044:-
THCA	cis	rs11105298	0.891	rs10858881	ENSG00000266347.2	AC068641.1	3.71	0.000234	0.0162	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89592833~89592927:+
THCA	cis	rs9532669	0.926	rs9532657	ENSG00000229473.2	RGS17P1	-3.71	0.000234	0.0162	-0.21	-0.17	Cervical cancer;	chr13:40918208	chr13:40992779~40993331:-
THCA	cis	rs2360027	0.965	rs4353076	ENSG00000231365.4	RP11-418J17.1	-3.71	0.000234	0.0162	-0.16	-0.17	Tonsillectomy;	chr1:118601856	chr1:119140396~119275973:+
THCA	cis	rs2360027	1	rs2360027	ENSG00000231365.4	RP11-418J17.1	-3.71	0.000234	0.0162	-0.16	-0.17	Tonsillectomy;	chr1:118602013	chr1:119140396~119275973:+
THCA	cis	rs3768792	0.665	rs72944309	ENSG00000196096.3	AC079610.2	3.71	0.000234	0.0162	0.24	0.17	Systemic lupus erythematosus;	chr2:212977357	chr2:213276552~213284205:-
THCA	cis	rs197770	0.542	rs197731	ENSG00000279727.1	RP11-640L9.1	-3.71	0.000234	0.0162	-0.32	-0.17	Phospholipid levels (plasma);	chr3:37455850	chr3:36819276~36822498:-
THCA	cis	rs9291683	0.632	rs10939669	ENSG00000261490.1	RP11-448G15.3	3.71	0.000234	0.0162	0.1	0.17	Bone mineral density;	chr4:10044203	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.632	rs11734375	ENSG00000261490.1	RP11-448G15.3	3.71	0.000234	0.0162	0.1	0.17	Bone mineral density;	chr4:10044674	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.595	rs35250962	ENSG00000261490.1	RP11-448G15.3	3.71	0.000234	0.0162	0.1	0.17	Bone mineral density;	chr4:10046647	chr4:10068089~10073019:-
THCA	cis	rs11088226	0.645	rs11702343	ENSG00000186842.4	LINC00846	-3.71	0.000234	0.0162	-0.25	-0.17	Gastritis;	chr21:32565578	chr21:32572238~32575881:-
THCA	cis	rs9811920	0.965	rs9289981	ENSG00000273374.1	RP11-383I23.2	3.71	0.000234	0.0162	0.14	0.17	Axial length;	chr3:100149260	chr3:99802699~99806058:-
THCA	cis	rs7586085	0.967	rs10170839	ENSG00000232411.1	AC009495.3	-3.71	0.000234	0.0162	-0.18	-0.17	Total body bone mineral density;	chr2:165716396	chr2:165833048~165839098:-
THCA	cis	rs6806253	0.715	rs4857906	ENSG00000239405.1	TMED10P2	3.71	0.000234	0.0162	0.23	0.17	Pit-and-Fissure caries;	chr3:128556616	chr3:128538020~128538631:+
THCA	cis	rs10875746	0.624	rs11168498	ENSG00000226413.2	OR8T1P	3.71	0.000234	0.0162	0.24	0.17	Longevity (90 years and older);	chr12:48261305	chr12:48442030~48442947:-
THCA	cis	rs10760158	0.832	rs4837832	ENSG00000226752.6	PSMD5-AS1	3.71	0.000234	0.0162	0.21	0.17	Pulse pressure;	chr9:121294150	chr9:120824828~120854385:+
THCA	cis	rs867371	1	rs13380317	ENSG00000278603.1	RP13-608F4.5	-3.71	0.000234	0.0162	-0.22	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472203~82472426:+
THCA	cis	rs6921919	0.789	rs17301128	ENSG00000176933.5	TOB2P1	-3.71	0.000234	0.0162	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28217643~28218634:-
THCA	cis	rs13178541	0.641	rs4976534	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr5:135798716	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs10900839	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr5:135798845	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs10900841	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr5:135799020	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.574	rs11738505	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr5:135800107	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs10076272	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr5:135800540	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs2159660	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr5:135801356	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs2109670	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr5:135801529	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs2109669	ENSG00000250378.1	RP11-119J18.1	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr5:135801688	chr5:135812667~135826582:+
THCA	cis	rs6671200	1	rs10747468	ENSG00000235501.4	RP4-639F20.1	-3.71	0.000234	0.0162	-0.32	-0.17	Stearic acid (18:0) levels;	chr1:95220735	chr1:94927566~94963270:+
THCA	cis	rs11708578	0.554	rs67235276	ENSG00000237990.3	CNTN4-AS1	3.71	0.000234	0.0162	0.21	0.17	Schizophrenia;	chr3:2389914	chr3:3039033~3069242:-
THCA	cis	rs1864585	0.52	rs1549792	ENSG00000280294.1	RP11-177H2.1	3.71	0.000234	0.0162	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10798110	chr8:10856085~10859436:-
THCA	cis	rs6443245	0.591	rs2648382	ENSG00000227110.5	LMCD1-AS1	-3.71	0.000234	0.0162	-0.2	-0.17	Daytime sleep phenotypes;	chr3:9579992	chr3:7952805~8611924:-
THCA	cis	rs2839186	0.596	rs4819217	ENSG00000228137.1	AP001469.7	3.71	0.000234	0.0162	0.17	0.17	Testicular germ cell tumor;	chr21:46224178	chr21:46246890~46247682:+
THCA	cis	rs793571	0.774	rs4775096	ENSG00000245975.2	RP11-30K9.6	3.71	0.000234	0.0162	0.17	0.17	Schizophrenia;	chr15:58848130	chr15:58768072~58770974:-
THCA	cis	rs907612	0.638	rs11041476	ENSG00000226416.1	MRPL23-AS1	3.71	0.000234	0.0162	0.2	0.17	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Monocyte count;	chr11:1853837	chr11:1983237~1989920:-
THCA	cis	rs804280	0.527	rs2686187	ENSG00000254948.1	OR7E158P	-3.71	0.000234	0.0162	-0.18	-0.17	Myopia (pathological);	chr8:11797287	chr8:11919900~11920809:-
THCA	cis	rs2933343	0.621	rs6764682	ENSG00000231305.3	RP11-723O4.2	-3.71	0.000234	0.0162	-0.19	-0.17	IgG glycosylation;	chr3:128849540	chr3:128861313~128871540:-
THCA	cis	rs2562456	0.833	rs11666828	ENSG00000268278.1	RP11-420K14.1	3.71	0.000234	0.0162	0.24	0.17	Pain;	chr19:21342218	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs11671609	ENSG00000268278.1	RP11-420K14.1	3.71	0.000234	0.0162	0.24	0.17	Pain;	chr19:21342769	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs62109212	ENSG00000268278.1	RP11-420K14.1	3.71	0.000234	0.0162	0.24	0.17	Pain;	chr19:21343716	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs57250002	ENSG00000268278.1	RP11-420K14.1	3.71	0.000234	0.0162	0.24	0.17	Pain;	chr19:21344048	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62109218	ENSG00000268278.1	RP11-420K14.1	3.71	0.000234	0.0162	0.24	0.17	Pain;	chr19:21346059	chr19:21637974~21656300:+
THCA	cis	rs1823874	0.542	rs1962946	ENSG00000254744.3	CTD-3076O17.1	-3.71	0.000234	0.0162	-0.18	-0.17	IgG glycosylation;	chr15:99834410	chr15:99970215~99974010:+
THCA	cis	rs7546094	0.841	rs663533	ENSG00000273483.1	RP4-671G15.2	3.71	0.000234	0.0162	0.15	0.17	Platelet distribution width;	chr1:112586182	chr1:112517799~112518441:-
THCA	cis	rs3743162	1	rs3743162	ENSG00000275120.1	RP11-182J1.17	3.71	0.000234	0.0162	0.21	0.17	Alzheimer's disease (age of onset);	chr15:84887738	chr15:84599434~84606463:-
THCA	cis	rs17689437	0.789	rs745337	ENSG00000275383.1	RP11-615I2.6	3.71	0.000234	0.0162	0.3	0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68583103	chr16:68591382~68594424:+
THCA	cis	rs12544026	0.547	rs566264	ENSG00000253669.3	KB-1732A1.1	-3.71	0.000234	0.0162	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101862122	chr8:102805517~102809971:+
THCA	cis	rs3758911	0.894	rs10749902	ENSG00000255353.1	RP11-382M14.1	-3.71	0.000234	0.0162	-0.22	-0.17	Coronary artery disease;	chr11:107324855	chr11:107176286~107177530:+
THCA	cis	rs789852	0.867	rs1773176	ENSG00000231770.4	TMEM44-AS1	-3.71	0.000234	0.0162	-0.22	-0.17	QT interval;	chr3:194595509	chr3:194584011~194590260:+
THCA	cis	rs748404	0.578	rs510108	ENSG00000224677.1	PDIA3P2	3.71	0.000234	0.0162	0.2	0.17	Lung cancer;	chr15:43313241	chr15:43649123~43649280:+
THCA	cis	rs17604090	0.938	rs10253264	ENSG00000227855.3	DPY19L2P3	3.71	0.000234	0.0162	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29652927	chr7:29650227~29742594:+
THCA	cis	rs17604090	1	rs17661896	ENSG00000227855.3	DPY19L2P3	3.71	0.000234	0.0162	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29653092	chr7:29650227~29742594:+
THCA	cis	rs12428035	0.764	rs56077337	ENSG00000247400.3	DNAJC3-AS1	-3.71	0.000234	0.0162	-0.17	-0.17	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96006765	chr13:95648733~95676925:-
THCA	cis	rs6494488	0.5	rs7172505	ENSG00000259635.1	AC100830.3	-3.71	0.000234	0.0162	-0.39	-0.17	Coronary artery disease;	chr15:64524718	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs79866634	ENSG00000259635.1	AC100830.3	-3.71	0.000234	0.0162	-0.39	-0.17	Coronary artery disease;	chr15:64526422	chr15:64701248~64719602:+
THCA	cis	rs427394	0.582	rs274662	ENSG00000248677.1	CTD-2044J15.1	3.71	0.000234	0.0162	0.16	0.17	Menopause (age at onset);	chr5:6704747	chr5:6686325~6707711:-
THCA	cis	rs8040855	0.627	rs72757059	ENSG00000225151.9	GOLGA2P7	-3.71	0.000235	0.0162	-0.24	-0.17	Bulimia nervosa;	chr15:85059918	chr15:84199311~84230136:-
THCA	cis	rs669446	0.533	rs3791041	ENSG00000237950.1	RP11-7O11.3	3.71	0.000235	0.0162	0.15	0.17	Amyotrophic lateral sclerosis (age of onset);	chr1:43737320	chr1:43944370~43946551:-
THCA	cis	rs1876206	0.554	rs1354738	ENSG00000259705.1	RP11-227D13.1	3.71	0.000235	0.0162	0.21	0.17	Breast cancer;	chr15:48591499	chr15:48645951~48652016:+
THCA	cis	rs4950322	0.58	rs1813002	ENSG00000180867.10	PDIA3P1	3.71	0.000235	0.0162	0.16	0.17	Protein quantitative trait loci;	chr1:147112579	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.518	rs4950304	ENSG00000180867.10	PDIA3P1	3.71	0.000235	0.0162	0.16	0.17	Protein quantitative trait loci;	chr1:147116685	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.518	rs4950305	ENSG00000180867.10	PDIA3P1	3.71	0.000235	0.0162	0.16	0.17	Protein quantitative trait loci;	chr1:147117711	chr1:147178113~147179622:+
THCA	cis	rs346923	0.649	rs10084879	ENSG00000226950.5	DANCR	3.71	0.000235	0.0162	0.19	0.17	Biochemical measures;	chr4:52505855	chr4:52712404~52720351:+
THCA	cis	rs346923	1	rs55942533	ENSG00000226950.5	DANCR	3.71	0.000235	0.0162	0.19	0.17	Biochemical measures;	chr4:52506715	chr4:52712404~52720351:+
THCA	cis	rs346923	1	rs12186295	ENSG00000226950.5	DANCR	3.71	0.000235	0.0162	0.19	0.17	Biochemical measures;	chr4:52510159	chr4:52712404~52720351:+
THCA	cis	rs346923	1	rs73248643	ENSG00000226950.5	DANCR	3.71	0.000235	0.0162	0.19	0.17	Biochemical measures;	chr4:52512467	chr4:52712404~52720351:+
THCA	cis	rs6479874	0.68	rs2660213	ENSG00000223502.1	RP11-96B5.3	-3.71	0.000235	0.0162	-0.2	-0.17	Migraine;	chr10:50982469	chr10:51062579~51068553:-
THCA	cis	rs13178541	0.641	rs2345448	ENSG00000250378.1	RP11-119J18.1	3.71	0.000235	0.0162	0.19	0.17	IgG glycosylation;	chr5:135804128	chr5:135812667~135826582:+
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000254527.1	ENPP7P12	3.71	0.000235	0.0162	0.21	0.17	Neuroticism;	chr8:11991324	chr8:12205759~12206389:-
THCA	cis	rs16975963	0.644	rs1478462	ENSG00000276846.1	CTD-3220F14.3	-3.71	0.000235	0.0162	-0.16	-0.17	Longevity;	chr19:37656124	chr19:37314868~37315620:-
THCA	cis	rs7481311	0.956	rs2352802	ENSG00000245573.6	BDNF-AS	3.71	0.000235	0.0162	0.16	0.17	Weight;Body mass index;	chr11:27526279	chr11:27506838~27698174:+
THCA	cis	rs6500602	0.789	rs2404546	ENSG00000280063.1	RP11-295D4.3	3.71	0.000235	0.0162	0.09	0.17	Schizophrenia;	chr16:4429733	chr16:4346694~4348648:-
THCA	cis	rs2239557	0.539	rs7161037	ENSG00000259065.1	RP5-1021I20.1	-3.71	0.000235	0.0162	-0.25	-0.17	Common traits (Other);	chr14:73966426	chr14:73787360~73803270:+
THCA	cis	rs17122278	1	rs3825055	ENSG00000243431.1	RPL5P30	3.71	0.000235	0.0162	0.17	0.17	Total cholesterol levels;	chr11:118545358	chr11:118560690~118561580:+
THCA	cis	rs67478160	0.643	rs8003653	ENSG00000258534.1	CTD-2134A5.4	-3.71	0.000235	0.0162	-0.17	-0.17	Schizophrenia;	chr14:103832499	chr14:103854366~103880111:-
THCA	cis	rs3748656	1	rs17030613	ENSG00000273483.1	RP4-671G15.2	3.71	0.000235	0.0162	0.19	0.17	Hip circumference adjusted for BMI;	chr1:112648185	chr1:112517799~112518441:-
THCA	cis	rs9907295	0.818	rs4796112	ENSG00000270871.1	AC015849.19	-3.71	0.000235	0.0162	-0.14	-0.17	Fibroblast growth factor basic levels;	chr17:35831722	chr17:35816717~35830293:-
THCA	cis	rs8058578	1	rs6565197	ENSG00000260911.2	RP11-196G11.2	3.71	0.000235	0.0162	0.14	0.17	Multiple myeloma;	chr16:30695156	chr16:31043150~31049868:+
THCA	cis	rs7246967	0.544	rs391308	ENSG00000198153.8	ZNF849P	-3.71	0.000235	0.0162	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22826758	chr19:22685167~22686732:+
THCA	cis	rs9990333	0.544	rs11915082	ENSG00000207650.1	MIR570	3.71	0.000235	0.0162	0.19	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195699401~195699497:+
THCA	cis	rs875971	0.545	rs17138156	ENSG00000273024.4	INTS4P2	-3.71	0.000235	0.0162	-0.21	-0.17	Aortic root size;	chr7:66249708	chr7:65647864~65715661:+
THCA	cis	rs62246343	0.504	rs3915844	ENSG00000254485.4	RP11-380O24.1	3.71	0.000235	0.0162	0.21	0.17	Fibrinogen levels;	chr3:9473172	chr3:9292588~9363303:-
THCA	cis	rs3845817	0.67	rs840787	ENSG00000281920.1	RP11-418H16.1	-3.71	0.000235	0.0162	-0.21	-0.17	Bipolar disorder;	chr2:65548756	chr2:65623272~65628424:+
THCA	cis	rs7829975	0.658	rs907181	ENSG00000254340.1	RP11-10A14.3	3.71	0.000235	0.0162	0.18	0.17	Mood instability;	chr8:8845365	chr8:9141424~9145435:+
THCA	cis	rs2665103	0.61	rs1972460	ENSG00000276710.3	CSPG4P8	-3.71	0.000235	0.0162	-0.16	-0.17	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82459472~82477258:+
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000229212.6	RP11-561C5.4	3.71	0.000235	0.0162	0.22	0.17	P wave terminal force;	chr15:84632519	chr15:85205440~85234795:-
THCA	cis	rs6580649	0.941	rs6580651	ENSG00000273765.1	RP11-370I10.11	-3.71	0.000235	0.0162	-0.18	-0.17	Lung cancer;	chr12:48036150	chr12:48360920~48361377:+
THCA	cis	rs1580019	0.961	rs766660	ENSG00000231952.3	DPY19L1P2	-3.71	0.000235	0.0162	-0.21	-0.17	Cognitive ability;	chr7:32459465	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.922	rs766658	ENSG00000231952.3	DPY19L1P2	-3.71	0.000235	0.0162	-0.21	-0.17	Cognitive ability;	chr7:32459779	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.961	rs766657	ENSG00000231952.3	DPY19L1P2	-3.71	0.000235	0.0162	-0.21	-0.17	Cognitive ability;	chr7:32459898	chr7:32812757~32838570:+
THCA	cis	rs739310	0.855	rs74276996	ENSG00000235271.4	RP1-90L6.3	-3.71	0.000235	0.0162	-0.27	-0.17	Obesity-related traits;	chr22:26659554	chr22:26903292~26920611:+
THCA	cis	rs2228479	0.85	rs117675822	ENSG00000274627.1	RP11-104N10.2	-3.71	0.000235	0.0162	-0.3	-0.17	Skin colour saturation;	chr16:89852673	chr16:89516797~89522217:+
THCA	cis	rs10486391	0.837	rs1042277	ENSG00000271133.4	CTA-293F17.1	3.71	0.000235	0.0162	0.17	0.17	Allergic disease (asthma, hay fever or eczema);	chr7:20379303	chr7:20328299~20331747:-
THCA	cis	rs10486391	0.837	rs35527387	ENSG00000271133.4	CTA-293F17.1	3.71	0.000235	0.0162	0.17	0.17	Allergic disease (asthma, hay fever or eczema);	chr7:20379580	chr7:20328299~20331747:-
THCA	cis	rs9341808	0.718	rs3805922	ENSG00000260645.1	RP11-250B2.5	3.71	0.000235	0.0162	0.14	0.17	Sitting height ratio;	chr6:80182272	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.718	rs3805920	ENSG00000260645.1	RP11-250B2.5	3.71	0.000235	0.0162	0.14	0.17	Sitting height ratio;	chr6:80183028	chr6:80466958~80469080:+
THCA	cis	rs5015933	0.569	rs1463837	ENSG00000232630.1	PRPS1P2	-3.71	0.000235	0.0162	-0.14	-0.17	Body mass index;	chr9:125372936	chr9:125150653~125151589:+
THCA	cis	rs6918586	1	rs198806	ENSG00000272462.2	U91328.19	-3.71	0.000235	0.0162	-0.14	-0.17	Schizophrenia;	chr6:26133388	chr6:25992662~26001775:+
THCA	cis	rs72634501	0.517	rs6600289	ENSG00000228060.1	RP11-69E11.8	3.71	0.000235	0.0162	0.16	0.17	HDL cholesterol;	chr1:39148140	chr1:39565160~39573203:+
THCA	cis	rs7216064	1	rs1976054	ENSG00000278740.1	RP11-147L13.14	3.71	0.000235	0.0162	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67837108	chr17:68188547~68189165:+
THCA	cis	rs17680741	1	rs12260962	ENSG00000226659.1	RP11-137H2.4	3.71	0.000235	0.0162	0.25	0.17	Coronary artery disease;	chr10:80503070	chr10:80529597~80535942:-
THCA	cis	rs17122278	1	rs73022058	ENSG00000255239.1	AP002954.6	-3.71	0.000235	0.0162	-0.3	-0.17	Total cholesterol levels;	chr11:118552957	chr11:118688039~118690600:-
THCA	cis	rs7308116	0.53	rs12582286	ENSG00000257951.1	RP11-554D14.4	-3.71	0.000235	0.0162	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107907011	chr12:107881242~107883382:+
THCA	cis	rs6494488	0.5	rs72742918	ENSG00000259635.1	AC100830.3	-3.71	0.000235	0.0162	-0.42	-0.17	Coronary artery disease;	chr15:64560377	chr15:64701248~64719602:+
THCA	cis	rs720064	0.586	rs9961089	ENSG00000264745.1	TTC39C-AS1	3.71	0.000235	0.0162	0.18	0.17	Strep throat;	chr18:23967999	chr18:23994213~24015339:-
THCA	cis	rs935334	0.5	rs73304578	ENSG00000258454.1	RP11-361H10.3	-3.71	0.000235	0.0162	-0.25	-0.17	Blood pressure;	chr14:76127772	chr14:76235817~76263474:+
THCA	cis	rs10090774	0.965	rs13270490	ENSG00000280303.2	ERICD	-3.71	0.000235	0.0162	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140951080	chr8:140636281~140638283:+
THCA	cis	rs61677309	1	rs4938501	ENSG00000278376.1	RP11-158I9.8	3.71	0.000235	0.0162	0.13	0.17	Lung cancer in ever smokers;	chr11:118295782	chr11:118791254~118793137:+
THCA	cis	rs12549025	0.891	rs13266950	ENSG00000253390.1	CTC-756D1.2	3.71	0.000235	0.0162	0.31	0.17	Reticulocyte fraction of red cells;	chr8:23537427	chr8:23458601~23484971:+
THCA	cis	rs6902257	0.744	rs2496679	ENSG00000233967.5	RP11-250B2.3	3.71	0.000235	0.0162	0.34	0.17	Obesity-related traits;	chr6:80609375	chr6:80443344~80465927:+
THCA	cis	rs7726354	0.793	rs79488097	ENSG00000271828.1	CTD-2310F14.1	3.71	0.000235	0.0162	0.43	0.17	Breast cancer (early onset);	chr5:56726424	chr5:56927874~56929573:+
THCA	cis	rs710913	0.618	rs12030495	ENSG00000182109.6	RP11-69E11.4	3.71	0.000235	0.0163	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39623923	chr1:39522280~39546187:-
THCA	cis	rs801193	0.548	rs2659904	ENSG00000272831.1	RP11-792A8.4	3.71	0.000235	0.0163	0.11	0.17	Aortic root size;	chr7:66713615	chr7:66739829~66740385:-
THCA	cis	rs6751744	0.513	rs6738215	ENSG00000230783.1	AC009961.2	-3.71	0.000235	0.0163	-0.2	-0.17	Dysphagia;	chr2:159596794	chr2:159689217~159690291:-
THCA	cis	rs61160187	0.582	rs13359074	ENSG00000272308.1	RP11-231G3.1	-3.71	0.000235	0.0163	-0.17	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906758	chr5:60866457~60866935:-
THCA	cis	rs7819412	0.74	rs28633434	ENSG00000206014.6	OR7E161P	3.71	0.000235	0.0163	0.2	0.17	Triglycerides;	chr8:11196413	chr8:11928597~11929563:-
THCA	cis	rs57709857	0.957	rs28681082	ENSG00000272092.1	RP11-350N15.5	-3.71	0.000235	0.0163	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38402922	chr8:38382364~38383461:+
THCA	cis	rs6142618	0.587	rs2377474	ENSG00000224452.1	RSL24D1P6	3.71	0.000235	0.0163	0.21	0.17	Inflammatory bowel disease;	chr20:32376870	chr20:32170390~32170790:-
THCA	cis	rs1577917	0.916	rs4142546	ENSG00000220563.1	PKMP3	-3.71	0.000235	0.0163	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85795593	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs6900436	ENSG00000220563.1	PKMP3	-3.71	0.000235	0.0163	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85796570	chr6:85659892~85660606:-
THCA	cis	rs6439153	0.743	rs71331685	ENSG00000231305.3	RP11-723O4.2	3.71	0.000235	0.0163	0.18	0.17	Pneumococcal bacteremia;	chr3:128992582	chr3:128861313~128871540:-
THCA	cis	rs3750817	0.516	rs10736303	ENSG00000271670.1	RP11-95I16.4	-3.71	0.000235	0.0163	-0.15	-0.17	Breast cancer;	chr10:121574943	chr10:120879256~120880667:-
THCA	cis	rs9650657	0.737	rs4841436	ENSG00000255310.2	AF131215.2	3.71	0.000235	0.0163	0.14	0.17	Neuroticism;	chr8:10736964	chr8:11107788~11109726:-
THCA	cis	rs710913	0.618	rs6587	ENSG00000182109.6	RP11-69E11.4	3.71	0.000235	0.0163	0.15	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39522280~39546187:-
THCA	cis	rs2019137	0.936	rs4849169	ENSG00000234997.1	AC016745.3	-3.71	0.000235	0.0163	-0.17	-0.17	Lymphocyte counts;	chr2:113196080	chr2:113424495~113425324:+
THCA	cis	rs2019137	0.836	rs4848318	ENSG00000234997.1	AC016745.3	-3.71	0.000235	0.0163	-0.17	-0.17	Lymphocyte counts;	chr2:113196375	chr2:113424495~113425324:+
THCA	cis	rs2019137	0.936	rs2241978	ENSG00000234997.1	AC016745.3	-3.71	0.000235	0.0163	-0.17	-0.17	Lymphocyte counts;	chr2:113196429	chr2:113424495~113425324:+
THCA	cis	rs2019137	0.936	rs3828188	ENSG00000234997.1	AC016745.3	-3.71	0.000235	0.0163	-0.17	-0.17	Lymphocyte counts;	chr2:113196670	chr2:113424495~113425324:+
THCA	cis	rs9532669	0.89	rs35396630	ENSG00000229473.2	RGS17P1	3.71	0.000235	0.0163	0.22	0.17	Cervical cancer;	chr13:40863135	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs4942001	ENSG00000229473.2	RGS17P1	3.71	0.000235	0.0163	0.22	0.17	Cervical cancer;	chr13:40863176	chr13:40992779~40993331:-
THCA	cis	rs7836436	0.606	rs72673643	ENSG00000245330.4	KB-1471A8.1	-3.71	0.000235	0.0163	-0.26	-0.17	HIV-1 viral setpoint;	chr8:119940067	chr8:119867419~119874488:-
THCA	cis	rs6012953	0.845	rs2904270	ENSG00000231715.1	COX6CP2	-3.71	0.000235	0.0163	-0.17	-0.17	Vitiligo;	chr20:50568735	chr20:50479767~50479991:+
THCA	cis	rs2638953	0.853	rs10843196	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000235	0.0163	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513660	chr12:28163298~28190738:-
THCA	cis	rs1876206	0.554	rs612617	ENSG00000259705.1	RP11-227D13.1	-3.71	0.000236	0.0163	-0.21	-0.17	Breast cancer;	chr15:48614380	chr15:48645951~48652016:+
THCA	cis	rs4879656	0.966	rs10758178	ENSG00000225693.1	LAGE3P1	-3.71	0.000236	0.0163	-0.19	-0.17	Menopause (age at onset);	chr9:32999421	chr9:33019682~33020165:-
THCA	cis	rs12887734	0.524	rs12888002	ENSG00000269958.1	RP11-73M18.8	3.71	0.000236	0.0163	0.16	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103696353~103697163:+
THCA	cis	rs7819412	0.74	rs11250119	ENSG00000261451.1	RP11-981G7.1	-3.71	0.000236	0.0163	-0.21	-0.17	Triglycerides;	chr8:11179525	chr8:10433672~10438312:+
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000189316.3	RP11-797H7.5	-3.71	0.000236	0.0163	-0.18	-0.17	Calcium levels;	chr7:65829754	chr7:64888527~64890100:-
THCA	cis	rs7824557	0.688	rs2572397	ENSG00000254866.2	DEFB109P3	-3.71	0.000236	0.0163	-0.23	-0.17	Retinal vascular caliber;	chr8:11318894	chr8:12150895~12151134:-
THCA	cis	rs17211409	0.655	rs585749	ENSG00000254731.1	CTD-2005H7.1	3.71	0.000236	0.0163	0.34	0.17	JT interval (sulfonylurea treatment interaction);	chr11:86555144	chr11:86703099~86714092:+
THCA	cis	rs987724	0.515	rs344073	ENSG00000243926.1	TIPARP-AS1	-3.71	0.000236	0.0163	-0.21	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156829224	chr3:156671862~156674378:-
THCA	cis	rs12234571	0.793	rs59285626	ENSG00000214293.7	APTR	3.71	0.000236	0.0163	0.21	0.17	Obesity-related traits;	chr7:77784843	chr7:77657660~77696265:-
THCA	cis	rs7914558	1	rs12780843	ENSG00000213061.2	PFN1P11	3.71	0.000236	0.0163	0.2	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:102838011~102845473:-
THCA	cis	rs11098499	0.82	rs2389885	ENSG00000249244.1	RP11-548H18.2	3.71	0.000236	0.0163	0.2	0.17	Corneal astigmatism;	chr4:119612776	chr4:119391831~119395335:-
THCA	cis	rs785830	0.749	rs543379	ENSG00000231808.2	LINC01388	-3.71	0.000236	0.0163	-0.19	-0.17	Platelet distribution width;	chr9:265469	chr9:112713~113754:-
THCA	cis	rs11671005	0.572	rs11669127	ENSG00000269600.1	AC016629.3	3.71	0.000236	0.0163	0.25	0.17	Mean platelet volume;	chr19:58492463	chr19:58593896~58599355:-
THCA	cis	rs7296418	0.961	rs10848428	ENSG00000256092.2	RP13-942N8.1	3.71	0.000236	0.0163	0.12	0.17	Platelet count;	chr12:123087948	chr12:123363868~123366113:+
THCA	cis	rs600231	0.706	rs1111934	ENSG00000260233.3	SSSCA1-AS1	3.71	0.000236	0.0163	0.14	0.17	Bone mineral density;	chr11:65561921	chr11:65568482~65570423:-
THCA	cis	rs7312933	0.584	rs6582395	ENSG00000257225.1	RP11-328C8.4	-3.71	0.000236	0.0163	-0.18	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42306339	chr12:42459366~42466128:+
THCA	cis	rs2179367	0.959	rs564961	ENSG00000223701.3	RAET1E-AS1	3.71	0.000236	0.0163	0.22	0.17	Dupuytren's disease;	chr6:149336091	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.959	rs504985	ENSG00000223701.3	RAET1E-AS1	3.71	0.000236	0.0163	0.22	0.17	Dupuytren's disease;	chr6:149337842	chr6:149884431~149919508:+
THCA	cis	rs7586085	1	rs10211006	ENSG00000232411.1	AC009495.3	-3.71	0.000236	0.0163	-0.18	-0.17	Total body bone mineral density;	chr2:165721364	chr2:165833048~165839098:-
THCA	cis	rs11175194	0.744	rs12230811	ENSG00000255850.1	TMEM5-AS1	-3.71	0.000236	0.0163	-0.44	-0.17	Epithelial ovarian cancer;	chr12:63862606	chr12:63808845~63822156:-
THCA	cis	rs9393813	0.528	rs13207497	ENSG00000271755.1	RP1-153G14.4	3.71	0.000236	0.0163	0.19	0.17	Bipolar disorder;	chr6:27489601	chr6:27404010~27406964:-
THCA	cis	rs9467773	0.933	rs2024970	ENSG00000228223.2	HCG11	-3.71	0.000236	0.0163	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26497292	chr6:26523450~26526579:+
THCA	cis	rs6921919	1	rs6921919	ENSG00000280107.1	AL022393.9	-3.71	0.000236	0.0163	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28170845~28172521:+
THCA	cis	rs10411161	0.702	rs7250193	ENSG00000275055.1	CTC-471J1.11	3.71	0.000236	0.0163	0.16	0.17	Breast cancer;	chr19:51882267	chr19:52049007~52049754:+
THCA	cis	rs14027	0.921	rs16893113	ENSG00000245330.4	KB-1471A8.1	3.71	0.000236	0.0163	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs2326377	ENSG00000245330.4	KB-1471A8.1	3.71	0.000236	0.0163	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs13257002	ENSG00000245330.4	KB-1471A8.1	3.71	0.000236	0.0163	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs62526565	ENSG00000245330.4	KB-1471A8.1	3.71	0.000236	0.0163	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119867419~119874488:-
THCA	cis	rs7919656	0.693	rs2940710	ENSG00000228403.1	RP11-563N6.6	3.71	0.000236	0.0163	0.19	0.17	Clinically amyopathic dermatomyositis;	chr10:48896570	chr10:48878022~48878649:+
THCA	cis	rs9595908	0.785	rs7331393	ENSG00000212293.1	SNORA16	-3.71	0.000236	0.0163	-0.2	-0.17	Body mass index;	chr13:32647065	chr13:32420390~32420516:-
THCA	cis	rs11105298	0.891	rs4842664	ENSG00000266347.2	AC068641.1	3.71	0.000236	0.0163	0.22	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89592833~89592927:+
THCA	cis	rs2153535	0.585	rs7765238	ENSG00000230939.1	RP11-314C16.1	3.71	0.000236	0.0163	0.17	0.17	Motion sickness;	chr6:8632560	chr6:8784178~8785445:+
THCA	cis	rs7656342	0.93	rs1829413	ENSG00000249866.1	OR7E83P	3.71	0.000236	0.0163	0.19	0.17	Gut microbiota (bacterial taxa);	chr4:9790715	chr4:9512905~9513874:+
THCA	cis	rs775227	1	rs66518523	ENSG00000243849.1	CFAP44-AS1	3.71	0.000236	0.0163	0.28	0.17	Dental caries;	chr3:113285912	chr3:113403991~113433992:+
THCA	cis	rs6101567	0.517	rs9636515	ENSG00000224635.1	RP4-564F22.5	-3.71	0.000236	0.0163	-0.21	-0.17	Nose size;	chr20:39294269	chr20:38406011~38416797:-
THCA	cis	rs4906332	1	rs35366629	ENSG00000259775.1	RP11-45P15.4	-3.71	0.000236	0.0163	-0.14	-0.17	Coronary artery disease;	chr14:103436717	chr14:103331674~103332367:-
THCA	cis	rs12478296	1	rs55767645	ENSG00000261186.2	RP11-341N2.1	-3.71	0.000236	0.0163	-0.29	-0.17	Obesity-related traits;	chr2:242057199	chr2:242087351~242088457:-
THCA	cis	rs897984	0.683	rs8046001	ENSG00000260911.2	RP11-196G11.2	3.71	0.000236	0.0163	0.14	0.17	Dementia with Lewy bodies;	chr16:30822000	chr16:31043150~31049868:+
THCA	cis	rs2832077	1	rs12329875	ENSG00000232855.5	AF131217.1	3.71	0.000236	0.0163	0.2	0.17	Cognitive test performance;	chr21:28765474	chr21:28439346~28674848:-
THCA	cis	rs2832077	1	rs2832077	ENSG00000232855.5	AF131217.1	3.71	0.000236	0.0163	0.2	0.17	Cognitive test performance;	chr21:28768699	chr21:28439346~28674848:-
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000184274.3	LINC00315	-3.71	0.000236	0.0163	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000184274.3	LINC00315	-3.71	0.000236	0.0163	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000184274.3	LINC00315	-3.71	0.000236	0.0163	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000184274.3	LINC00315	-3.71	0.000236	0.0163	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000184274.3	LINC00315	-3.71	0.000236	0.0163	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000184274.3	LINC00315	-3.71	0.000236	0.0163	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000184274.3	LINC00315	3.71	0.000236	0.0163	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45300245~45305257:-
THCA	cis	rs4915077	0.803	rs12566129	ENSG00000226822.1	RP11-356N1.2	3.71	0.000236	0.0163	0.29	0.17	Hypothyroidism;	chr1:107754587	chr1:108071482~108074519:+
THCA	cis	rs3782123	0.539	rs10902111	ENSG00000277290.1	RP11-326C3.16	3.71	0.000236	0.0163	0.21	0.17	Red cell distribution width;Glycated hemoglobin levels;	chr11:241489	chr11:243099~243483:-
THCA	cis	rs7259376	0.936	rs4932760	ENSG00000269345.1	VN1R85P	3.71	0.000236	0.0163	0.18	0.17	Menopause (age at onset);	chr19:22357653	chr19:22174766~22175191:-
THCA	cis	rs11175194	0.744	rs57082798	ENSG00000280181.1	RP11-629N8.4	3.71	0.000236	0.0163	0.42	0.17	Epithelial ovarian cancer;	chr12:63837625	chr12:64709458~64710513:+
THCA	cis	rs7824557	0.592	rs2736280	ENSG00000154316.13	TDH	-3.71	0.000236	0.0163	-0.13	-0.17	Retinal vascular caliber;	chr8:11365513	chr8:11339637~11368452:+
THCA	cis	rs896655	0.738	rs4615669	ENSG00000229835.2	KHSRPP1	-3.71	0.000236	0.0163	-0.21	-0.17	Coronary artery disease;	chr9:21818675	chr9:21695176~21696943:+
THCA	cis	rs4073416	0.542	rs8017880	ENSG00000276116.2	FUT8-AS1	3.71	0.000236	0.0163	0.19	0.17	N-glycan levels;	chr14:65476206	chr14:65411170~65412690:-
THCA	cis	rs11105306	1	rs11105306	ENSG00000266347.2	AC068641.1	3.71	0.000236	0.0163	0.21	0.17	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89592833~89592927:+
THCA	cis	rs2562456	0.833	rs2650801	ENSG00000268658.4	LINC00664	3.71	0.000236	0.0163	0.26	0.17	Pain;	chr19:21452553	chr19:21483374~21503238:+
THCA	cis	rs1799922	1	rs11766175	ENSG00000271553.1	RP11-274B21.10	-3.71	0.000236	0.0163	-0.15	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128764959	chr7:128667043~128668156:+
THCA	cis	rs7819412	0.668	rs2409715	ENSG00000261451.1	RP11-981G7.1	-3.71	0.000236	0.0163	-0.22	-0.17	Triglycerides;	chr8:11152626	chr8:10433672~10438312:+
THCA	cis	rs6940638	0.513	rs4424065	ENSG00000261353.1	CTA-14H9.5	3.71	0.000236	0.0163	0.18	0.17	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26527063~26527404:+
THCA	cis	rs748404	1	rs12909095	ENSG00000166763.7	STRCP1	3.71	0.000236	0.0163	0.2	0.17	Lung cancer;	chr15:43265944	chr15:43699488~43718184:-
THCA	cis	rs62158800	0.598	rs57147583	ENSG00000225588.2	AC096669.1	3.71	0.000236	0.0163	0.17	0.17	Facial morphology (factor 22);	chr2:107668603	chr2:107362282~107407329:+
THCA	cis	rs7968440	0.808	rs829112	ENSG00000272368.2	RP4-605O3.4	-3.71	0.000236	0.0163	-0.11	-0.17	Fibrinogen;	chr12:50813921	chr12:50112197~50165618:+
THCA	cis	rs11822910	0.815	rs11229028	ENSG00000265566.2	RN7SL605P	3.71	0.000236	0.0163	0.27	0.17	Platelet distribution width;	chr11:57426445	chr11:57528085~57528365:-
THCA	cis	rs7074356	0.688	rs34894697	ENSG00000242600.5	MBL1P	3.71	0.000236	0.0163	0.18	0.17	Borderline personality disorder;	chr10:80410132	chr10:79904898~79950336:+
THCA	cis	rs5753037	0.653	rs140107	ENSG00000273350.1	RP4-539M6.20	-3.71	0.000237	0.0163	-0.19	-0.17	Type 1 diabetes;	chr22:29734527	chr22:30420512~30420912:+
THCA	cis	rs1577917	0.837	rs806529	ENSG00000220563.1	PKMP3	-3.71	0.000237	0.0163	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85757403	chr6:85659892~85660606:-
THCA	cis	rs4950322	0.518	rs61838938	ENSG00000226015.2	CCT8P1	3.7	0.000237	0.0163	0.19	0.17	Protein quantitative trait loci;	chr1:147105943	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.529	rs11809327	ENSG00000226015.2	CCT8P1	3.7	0.000237	0.0163	0.19	0.17	Protein quantitative trait loci;	chr1:147106679	chr1:147203276~147204932:-
THCA	cis	rs4950322	0.563	rs11809328	ENSG00000226015.2	CCT8P1	3.7	0.000237	0.0163	0.19	0.17	Protein quantitative trait loci;	chr1:147106681	chr1:147203276~147204932:-
THCA	cis	rs10457838	0.637	rs1934225	ENSG00000231760.4	RP11-350J20.5	3.7	0.000237	0.0163	0.25	0.17	Post-traumatic stress disorder;	chr6:149094918	chr6:149796151~149826294:-
THCA	cis	rs58722170	0.61	rs61776206	ENSG00000252448.1	SNORA63	-3.7	0.000237	0.0163	-0.24	-0.17	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37607447	chr1:37884237~37884317:+
THCA	cis	rs75828804	1	rs76369310	ENSG00000260922.1	RP11-538I12.3	-3.7	0.000237	0.0163	-0.36	-0.17	Intraocular pressure;	chr16:77561071	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs61391728	ENSG00000260922.1	RP11-538I12.3	-3.7	0.000237	0.0163	-0.36	-0.17	Intraocular pressure;	chr16:77563881	chr16:77234877~77290934:+
THCA	cis	rs6860806	0.661	rs4705929	ENSG00000263597.1	MIR3936	3.7	0.000237	0.0163	0.16	0.17	Breast cancer;	chr5:132248485	chr5:132365490~132365599:-
THCA	cis	rs1113500	0.614	rs1343192	ENSG00000226822.1	RP11-356N1.2	3.7	0.000237	0.0163	0.19	0.17	Growth-regulated protein alpha levels;	chr1:108071266	chr1:108071482~108074519:+
THCA	cis	rs7851693	0.928	rs7870114	ENSG00000232172.1	RP11-57C19.2	-3.7	0.000237	0.0163	-0.18	-0.17	Bone mineral density;	chr9:130565589	chr9:130651799~130652383:+
THCA	cis	rs2228479	0.85	rs62052660	ENSG00000274627.1	RP11-104N10.2	-3.7	0.000237	0.0163	-0.3	-0.17	Skin colour saturation;	chr16:89781012	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs11649501	ENSG00000274627.1	RP11-104N10.2	-3.7	0.000237	0.0163	-0.3	-0.17	Skin colour saturation;	chr16:89784549	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs11649510	ENSG00000274627.1	RP11-104N10.2	-3.7	0.000237	0.0163	-0.3	-0.17	Skin colour saturation;	chr16:89784596	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17232630	ENSG00000274627.1	RP11-104N10.2	-3.7	0.000237	0.0163	-0.3	-0.17	Skin colour saturation;	chr16:89784771	chr16:89516797~89522217:+
THCA	cis	rs2434529	1	rs2443523	ENSG00000245275.6	SAP30L-AS1	3.7	0.000237	0.0163	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154262565	chr5:154329437~154445850:-
THCA	cis	rs8007846	0.616	rs747541	ENSG00000276116.2	FUT8-AS1	3.7	0.000237	0.0163	0.17	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr14:65338692	chr14:65411170~65412690:-
THCA	cis	rs13182402	1	rs13182402	ENSG00000230929.5	RP11-395C3.1	3.7	0.000237	0.0163	0.31	0.17	Osteoporosis;	chr5:126582456	chr5:126628019~126628319:-
THCA	cis	rs7829975	0.714	rs11777085	ENSG00000254340.1	RP11-10A14.3	3.7	0.000237	0.0163	0.18	0.17	Mood instability;	chr8:8814919	chr8:9141424~9145435:+
THCA	cis	rs4915077	0.773	rs17019795	ENSG00000226822.1	RP11-356N1.2	-3.7	0.000237	0.0163	-0.3	-0.17	Hypothyroidism;	chr1:107724348	chr1:108071482~108074519:+
THCA	cis	rs5015933	0.801	rs6478703	ENSG00000232630.1	PRPS1P2	3.7	0.000237	0.0163	0.11	0.17	Body mass index;	chr9:125379069	chr9:125150653~125151589:+
THCA	cis	rs72827839	0.779	rs72823592	ENSG00000266601.1	RP11-6N17.3	3.7	0.000237	0.0163	0.19	0.17	Ease of getting up in the morning;	chr17:48045642	chr17:47929682~47933106:-
THCA	cis	rs6997458	0.967	rs13273654	ENSG00000253549.4	RP11-317J10.2	3.7	0.000237	0.0163	0.17	0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85374328	chr8:85441851~85464915:-
THCA	cis	rs4908768	0.911	rs12121933	ENSG00000232912.4	RP5-1115A15.1	-3.7	0.000237	0.0163	-0.19	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8717022	chr1:8424645~8434838:+
THCA	cis	rs12959333	0.527	rs12964584	ENSG00000274849.1	RP11-49I11.4	-3.7	0.000237	0.0163	-0.2	-0.17	Post bronchodilator FEV1;	chr18:35633677	chr18:36189824~36190272:+
THCA	cis	rs116095464	1	rs3777237	ENSG00000277812.1	AC021087.1	3.7	0.000237	0.0163	0.44	0.17	Breast cancer;	chr5:307526	chr5:262769~262881:+
THCA	cis	rs9291683	0.588	rs35438220	ENSG00000261490.1	RP11-448G15.3	3.7	0.000237	0.0163	0.1	0.17	Bone mineral density;	chr4:9997774	chr4:10068089~10073019:-
THCA	cis	rs5753618	0.583	rs71324184	ENSG00000214076.3	CPSF1P1	-3.7	0.000237	0.0164	-0.23	-0.17	Colorectal cancer;	chr22:31356075	chr22:32269381~32273110:+
THCA	cis	rs13325613	0.915	rs71327040	ENSG00000223552.1	RP11-24F11.2	-3.7	0.000237	0.0164	-0.31	-0.17	Monocyte count;	chr3:46221717	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.915	rs34289272	ENSG00000223552.1	RP11-24F11.2	-3.7	0.000237	0.0164	-0.31	-0.17	Monocyte count;	chr3:46221753	chr3:46364955~46407059:-
THCA	cis	rs7246657	0.663	rs9304568	ENSG00000226686.6	LINC01535	-3.7	0.000237	0.0164	-0.24	-0.17	Coronary artery calcification;	chr19:37563606	chr19:37251912~37265535:+
THCA	cis	rs72634501	0.517	rs10788925	ENSG00000182109.6	RP11-69E11.4	-3.7	0.000237	0.0164	-0.16	-0.17	HDL cholesterol;	chr1:39128430	chr1:39522280~39546187:-
THCA	cis	rs8030379	1	rs117031571	ENSG00000176700.18	SCAND2P	-3.7	0.000237	0.0164	-0.11	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903902	chr15:84631451~84647478:+
THCA	cis	rs2625529	0.713	rs12903980	ENSG00000260037.4	CTD-2524L6.3	-3.7	0.000237	0.0164	-0.24	-0.17	Red blood cell count;	chr15:71873208	chr15:71818396~71823384:+
THCA	cis	rs11723261	0.621	rs7692530	ENSG00000250892.1	RP11-1365D11.1	3.7	0.000237	0.0164	0.24	0.17	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:201409~205009:-
THCA	cis	rs6517329	0.538	rs879894	ENSG00000230212.5	AP000688.14	-3.7	0.000237	0.0164	-0.21	-0.17	Schizophrenia;	chr21:36136345	chr21:36069642~36126640:-
THCA	cis	rs10090774	0.901	rs13280609	ENSG00000280303.2	ERICD	-3.7	0.000237	0.0164	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140961641	chr8:140636281~140638283:+
THCA	cis	rs6449502	0.536	rs10055076	ENSG00000251279.1	CTC-436P18.1	3.7	0.000237	0.0164	0.33	0.17	Mean platelet volume;	chr5:61188260	chr5:61162070~61232040:+
THCA	cis	rs72996113	0.702	rs11224348	ENSG00000248027.1	CTD-2383M3.1	-3.7	0.000237	0.0164	-0.3	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100642385	chr11:100684162~100687955:-
THCA	cis	rs1790761	0.505	rs7106423	ENSG00000255318.1	RP11-655M14.13	-3.7	0.000237	0.0164	-0.19	-0.17	Mean corpuscular volume;	chr11:67546673	chr11:67618279~67627304:-
THCA	cis	rs812925	0.515	rs1177308	ENSG00000270820.4	RP11-355B11.2	3.7	0.000237	0.0164	0.14	0.17	Immature fraction of reticulocytes;	chr2:61160119	chr2:61471188~61484130:+
THCA	cis	rs2880765	0.835	rs4843063	ENSG00000218052.5	ADAMTS7P4	-3.7	0.000237	0.0164	-0.19	-0.17	Coronary artery disease;	chr15:85505517	chr15:85255369~85330334:-
THCA	cis	rs1200921	0.66	rs1148263	ENSG00000272983.1	RP11-508N22.12	3.7	0.000237	0.0164	0.15	0.17	Breast cancer;	chr10:37236968	chr10:38137337~38144399:+
THCA	cis	rs6546550	0.901	rs6546553	ENSG00000179818.12	PCBP1-AS1	-3.7	0.000237	0.0164	-0.13	-0.17	Prevalent atrial fibrillation;	chr2:69884579	chr2:69962263~70103220:-
THCA	cis	rs755249	0.567	rs61779308	ENSG00000182109.6	RP11-69E11.4	3.7	0.000237	0.0164	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39522280~39546187:-
THCA	cis	rs4722585	0.533	rs3753097	ENSG00000273237.1	CTB-119C2.1	-3.7	0.000237	0.0164	-0.16	-0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26158587	chr7:26173533~26174945:-
THCA	cis	rs7521681	0.838	rs11185176	ENSG00000230489.1	VAV3-AS1	-3.7	0.000237	0.0164	-0.19	-0.17	Asthma and hay fever;	chr1:107782086	chr1:107964443~107994607:+
THCA	cis	rs36093844	0.576	rs12287170	ENSG00000279742.1	RP11-700A24.1	-3.7	0.000237	0.0164	-0.22	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86024179	chr11:85852557~85854943:-
THCA	cis	rs7267979	1	rs10966	ENSG00000276952.1	RP5-965G21.6	3.7	0.000237	0.0164	0.17	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25284915~25285588:-
THCA	cis	rs4389656	0.767	rs274704	ENSG00000248677.1	CTD-2044J15.1	3.7	0.000237	0.0164	0.17	0.17	Coronary artery disease;	chr5:6728227	chr5:6686325~6707711:-
THCA	cis	rs4389656	0.857	rs274703	ENSG00000248677.1	CTD-2044J15.1	3.7	0.000237	0.0164	0.17	0.17	Coronary artery disease;	chr5:6728259	chr5:6686325~6707711:-
THCA	cis	rs6671200	0.831	rs113525652	ENSG00000235501.4	RP4-639F20.1	-3.7	0.000237	0.0164	-0.33	-0.17	Stearic acid (18:0) levels;	chr1:95139118	chr1:94927566~94963270:+
THCA	cis	rs9291683	0.588	rs11732054	ENSG00000261490.1	RP11-448G15.3	3.7	0.000237	0.0164	0.1	0.17	Bone mineral density;	chr4:9998253	chr4:10068089~10073019:-
THCA	cis	rs9878978	0.964	rs79638226	ENSG00000227588.2	CNTN4-AS2	3.7	0.000237	0.0164	0.2	0.17	Blood pressure (smoking interaction);	chr3:2451462	chr3:2110409~2144241:-
THCA	cis	rs972540	1	rs13398243	ENSG00000229647.1	AC007879.7	-3.7	0.000237	0.0164	-0.19	-0.17	Body mass index;	chr2:206389507	chr2:207239650~207245887:+
THCA	cis	rs972540	0.96	rs13427533	ENSG00000229647.1	AC007879.7	-3.7	0.000237	0.0164	-0.19	-0.17	Body mass index;	chr2:206390808	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs13427551	ENSG00000229647.1	AC007879.7	-3.7	0.000237	0.0164	-0.19	-0.17	Body mass index;	chr2:206390854	chr2:207239650~207245887:+
THCA	cis	rs6902257	1	rs2496676	ENSG00000233967.5	RP11-250B2.3	3.7	0.000237	0.0164	0.34	0.17	Obesity-related traits;	chr6:80595953	chr6:80443344~80465927:+
THCA	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	3.7	0.000237	0.0164	0.16	0.17	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
THCA	cis	rs10435719	0.867	rs34465618	ENSG00000255495.1	AC145124.2	3.7	0.000237	0.0164	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.867	rs34583868	ENSG00000255495.1	AC145124.2	3.7	0.000237	0.0164	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:12194467~12196280:+
THCA	cis	rs10089	0.953	rs10223203	ENSG00000245937.6	LINC01184	-3.7	0.000237	0.0164	-0.19	-0.17	Ileal carcinoids;	chr5:128191954	chr5:127940426~128083172:-
THCA	cis	rs728616	0.558	rs2343302	ENSG00000225484.5	NUTM2B-AS1	-3.7	0.000238	0.0164	-0.3	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80403430	chr10:79663088~79826594:-
THCA	cis	rs12478296	0.792	rs6738361	ENSG00000220804.7	AC093642.5	3.7	0.000238	0.0164	0.19	0.17	Obesity-related traits;	chr2:242072106	chr2:242088633~242160153:+
THCA	cis	rs9450351	0.744	rs9344559	ENSG00000203875.9	SNHG5	-3.7	0.000238	0.0164	-0.33	-0.17	Interferon gamma-induced protein 10 levels;	chr6:86012192	chr6:85660950~85678736:-
THCA	cis	rs2287838	1	rs2303100	ENSG00000267370.1	CTD-2623N2.3	3.7	0.000238	0.0164	0.16	0.17	Sleep duration;	chr19:9857758	chr19:9756152~9756863:-
THCA	cis	rs911555	0.603	rs8020912	ENSG00000244691.1	RPL10AP1	-3.7	0.000238	0.0164	-0.23	-0.17	Intelligence (multi-trait analysis);	chr14:103380937	chr14:103412119~103412761:-
THCA	cis	rs838886	0.956	rs838881	ENSG00000275389.1	RP11-214K3.24	3.7	0.000238	0.0164	0.23	0.17	HDL cholesterol;	chr12:124777251	chr12:124085761~124088598:+
THCA	cis	rs12022452	1	rs12022452	ENSG00000237899.1	RP4-739H11.3	-3.7	0.000238	0.0164	-0.28	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40669089~40687588:-
THCA	cis	rs6573604	0.681	rs10150168	ENSG00000276116.2	FUT8-AS1	-3.7	0.000238	0.0164	-0.26	-0.17	N-glycan levels;	chr14:65324531	chr14:65411170~65412690:-
THCA	cis	rs6573604	0.681	rs28595734	ENSG00000276116.2	FUT8-AS1	-3.7	0.000238	0.0164	-0.26	-0.17	N-glycan levels;	chr14:65325551	chr14:65411170~65412690:-
THCA	cis	rs4743820	0.603	rs7045740	ENSG00000230147.2	RP11-305L7.5	-3.7	0.000238	0.0164	-0.21	-0.17	Ulcerative colitis;Inflammatory bowel disease;	chr9:91164368	chr9:91169585~91170045:-
THCA	cis	rs9876781	1	rs9876781	ENSG00000199476.1	Y_RNA	-3.7	0.000238	0.0164	-0.21	-0.17	Longevity;	chr3:48445934	chr3:48288587~48288694:+
THCA	cis	rs3743266	0.613	rs1869484	ENSG00000240163.1	RP11-745A24.1	-3.7	0.000238	0.0164	-0.19	-0.17	Menarche (age at onset);	chr15:60449864	chr15:60390371~60390682:+
THCA	cis	rs3788317	0.526	rs5992495	ENSG00000232926.1	AC000078.5	-3.7	0.000238	0.0164	-0.2	-0.17	Glaucoma (primary angle closure);	chr22:19895461	chr22:19887289~19887970:+
THCA	cis	rs972578	0.806	rs5758955	ENSG00000230319.1	AL022476.2	3.7	0.000238	0.0164	0.18	0.17	Mean platelet volume;	chr22:42821143	chr22:43038585~43052366:+
THCA	cis	rs4650994	0.544	rs4132058	ENSG00000213057.5	C1orf220	-3.7	0.000238	0.0164	-0.12	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178536422	chr1:178542752~178548889:+
THCA	cis	rs4650994	0.544	rs4075631	ENSG00000213057.5	C1orf220	-3.7	0.000238	0.0164	-0.12	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178537459	chr1:178542752~178548889:+
THCA	cis	rs4650994	0.525	rs4316329	ENSG00000213057.5	C1orf220	-3.7	0.000238	0.0164	-0.12	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178540198	chr1:178542752~178548889:+
THCA	cis	rs206966	0.872	rs11065091	ENSG00000277283.1	RP1-267D11.6	3.7	0.000238	0.0164	0.17	0.17	Breast cancer;	chr12:120353134	chr12:120116907~120119000:+
THCA	cis	rs8179	0.514	rs11773884	ENSG00000230927.2	TMBIM7P	3.7	0.000238	0.0164	0.22	0.17	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92655809	chr7:92412976~92439562:-
THCA	cis	rs7763441	0.545	rs9391949	ENSG00000250903.7	GMDS-AS1	-3.7	0.000238	0.0164	-0.15	-0.17	Monobrow;	chr6:2451790	chr6:2245748~2482022:+
THCA	cis	rs4267450	0.842	rs11666278	ENSG00000261770.1	CTC-459F4.1	3.7	0.000238	0.0164	0.3	0.17	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28363434	chr19:27757184~27760849:-
THCA	cis	rs7216064	0.954	rs12602556	ENSG00000265055.1	AC145343.2	3.7	0.000238	0.0164	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67830745	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs62084208	ENSG00000265055.1	AC145343.2	3.7	0.000238	0.0164	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67831327	chr17:68096046~68101474:-
THCA	cis	rs853679	0.607	rs67998226	ENSG00000220721.1	OR1F12	3.7	0.000238	0.0164	0.38	0.17	Depression;	chr6:28270281	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34878803	ENSG00000220721.1	OR1F12	3.7	0.000238	0.0164	0.38	0.17	Depression;	chr6:28282402	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34396849	ENSG00000220721.1	OR1F12	3.7	0.000238	0.0164	0.38	0.17	Depression;	chr6:28283178	chr6:28073316~28074233:+
THCA	cis	rs9291683	0.509	rs998676	ENSG00000261490.1	RP11-448G15.3	-3.7	0.000238	0.0164	-0.11	-0.17	Bone mineral density;	chr4:9946940	chr4:10068089~10073019:-
THCA	cis	rs56309584	0.599	rs117347460	ENSG00000271002.1	RP11-599B13.8	-3.7	0.000238	0.0164	-0.26	-0.17	Initial pursuit acceleration;	chr17:8193853	chr17:8199123~8199437:-
THCA	cis	rs4245128	0.93	rs4245125	ENSG00000247416.2	RP11-629G13.1	3.7	0.000238	0.0164	0.16	0.17	Life satisfaction;	chr11:112920924	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.897	rs2121680	ENSG00000247416.2	RP11-629G13.1	3.7	0.000238	0.0164	0.16	0.17	Life satisfaction;	chr11:112920928	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.965	rs4245126	ENSG00000247416.2	RP11-629G13.1	3.7	0.000238	0.0164	0.16	0.17	Life satisfaction;	chr11:112921041	chr11:112959279~112963460:-
THCA	cis	rs4245128	1	rs4245128	ENSG00000247416.2	RP11-629G13.1	3.7	0.000238	0.0164	0.16	0.17	Life satisfaction;	chr11:112921260	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.965	rs10789926	ENSG00000247416.2	RP11-629G13.1	3.7	0.000238	0.0164	0.16	0.17	Life satisfaction;	chr11:112921437	chr11:112959279~112963460:-
THCA	cis	rs4699052	1	rs6533059	ENSG00000230069.3	LRRC37A15P	-3.7	0.000238	0.0164	-0.17	-0.17	Testicular germ cell tumor;	chr4:103212219	chr4:102727274~102730721:-
THCA	cis	rs394563	0.967	rs369643	ENSG00000268592.3	RAET1E-AS1	3.7	0.000238	0.0164	0.22	0.17	Dupuytren's disease;	chr6:149478662	chr6:149863494~149919507:+
THCA	cis	rs57709857	0.957	rs58279725	ENSG00000272092.1	RP11-350N15.5	-3.7	0.000238	0.0164	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38355093	chr8:38382364~38383461:+
THCA	cis	rs4787491	0.704	rs35605010	ENSG00000275371.1	RP11-455F5.6	-3.7	0.000238	0.0164	-0.15	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30022107	chr16:30110895~30111955:+
THCA	cis	rs875971	0.862	rs1167408	ENSG00000223473.2	GS1-124K5.3	-3.7	0.000238	0.0164	-0.12	-0.17	Aortic root size;	chr7:66091121	chr7:66491049~66493566:-
THCA	cis	rs875971	0.83	rs1167406	ENSG00000223473.2	GS1-124K5.3	-3.7	0.000238	0.0164	-0.12	-0.17	Aortic root size;	chr7:66091949	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs1167399	ENSG00000223473.2	GS1-124K5.3	-3.7	0.000238	0.0164	-0.12	-0.17	Aortic root size;	chr7:66096890	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs57866200	ENSG00000223473.2	GS1-124K5.3	-3.7	0.000238	0.0164	-0.12	-0.17	Aortic root size;	chr7:66100405	chr7:66491049~66493566:-
THCA	cis	rs7131987	0.585	rs6487795	ENSG00000257176.2	RP11-996F15.2	3.7	0.000238	0.0164	0.17	0.17	QT interval;	chr12:29266228	chr12:29280418~29317848:-
THCA	cis	rs2141079	0.71	rs12561920	ENSG00000230728.1	RP11-240D10.4	-3.7	0.000238	0.0164	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr1:53656308	chr1:54621477~54628438:-
THCA	cis	rs73173548	0.502	rs34969608	ENSG00000247828.6	TMEM161B-AS1	3.7	0.000238	0.0164	0.16	0.17	Macular telangiectasia type 2;	chr5:88448606	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs6885165	ENSG00000247828.6	TMEM161B-AS1	3.7	0.000238	0.0164	0.16	0.17	Macular telangiectasia type 2;	chr5:88449705	chr5:88268895~88436685:+
THCA	cis	rs2290416	0.792	rs62522167	ENSG00000253931.1	RP11-909N17.2	3.7	0.000238	0.0164	0.34	0.17	Attention deficit hyperactivity disorder;	chr8:143595864	chr8:143412749~143417054:+
THCA	cis	rs2290416	0.892	rs62522168	ENSG00000253931.1	RP11-909N17.2	3.7	0.000238	0.0164	0.34	0.17	Attention deficit hyperactivity disorder;	chr8:143597606	chr8:143412749~143417054:+
THCA	cis	rs4883201	0.611	rs4639983	ENSG00000245105.2	A2M-AS1	3.7	0.000238	0.0164	0.16	0.17	Total cholesterol levels;Cholesterol, total;	chr12:8951611	chr12:9065177~9068060:+
THCA	cis	rs7637701	0.773	rs7623691	ENSG00000243926.1	TIPARP-AS1	-3.7	0.000238	0.0164	-0.17	-0.17	Breast cancer;	chr3:156790921	chr3:156671862~156674378:-
THCA	cis	rs9843304	0.529	rs4681510	ENSG00000243885.1	RP11-278L15.2	3.7	0.000238	0.0164	0.18	0.17	Gallstone disease;	chr3:149483786	chr3:149384179~149385800:-
THCA	cis	rs9843304	0.529	rs4681511	ENSG00000243885.1	RP11-278L15.2	3.7	0.000238	0.0164	0.18	0.17	Gallstone disease;	chr3:149483792	chr3:149384179~149385800:-
THCA	cis	rs925946	0.541	rs12269837	ENSG00000245573.6	BDNF-AS	-3.7	0.000238	0.0164	-0.16	-0.17	Weight;Body mass index;	chr11:27572023	chr11:27506838~27698174:+
THCA	cis	rs925946	0.541	rs4923454	ENSG00000245573.6	BDNF-AS	-3.7	0.000238	0.0164	-0.16	-0.17	Weight;Body mass index;	chr11:27572582	chr11:27506838~27698174:+
THCA	cis	rs925946	0.518	rs10835197	ENSG00000245573.6	BDNF-AS	-3.7	0.000238	0.0164	-0.16	-0.17	Weight;Body mass index;	chr11:27585996	chr11:27506838~27698174:+
THCA	cis	rs58873874	0.579	rs79615135	ENSG00000251405.2	CTB-109A12.1	3.7	0.000238	0.0164	0.36	0.17	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157362615~157460078:-
THCA	cis	rs1371614	0.632	rs3769134	ENSG00000272148.1	RP11-195B17.1	3.7	0.000238	0.0164	0.16	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928023	chr2:27062428~27062907:-
THCA	cis	rs2880765	0.835	rs28874135	ENSG00000218052.5	ADAMTS7P4	-3.7	0.000238	0.0164	-0.19	-0.17	Coronary artery disease;	chr15:85488272	chr15:85255369~85330334:-
THCA	cis	rs4699052	1	rs4699052	ENSG00000230069.3	LRRC37A15P	-3.7	0.000238	0.0164	-0.17	-0.17	Testicular germ cell tumor;	chr4:103216633	chr4:102727274~102730721:-
THCA	cis	rs2839186	0.5	rs13049893	ENSG00000228137.1	AP001469.7	3.7	0.000238	0.0164	0.18	0.17	Testicular germ cell tumor;	chr21:46287140	chr21:46246890~46247682:+
THCA	cis	rs7660883	0.836	rs342453	ENSG00000251411.1	RP11-397E7.4	-3.7	0.000238	0.0164	-0.16	-0.17	HDL cholesterol levels;	chr4:87097337	chr4:86913266~86914817:-
THCA	cis	rs2129782	0.558	rs1586492	ENSG00000253553.4	RP11-586K2.1	3.7	0.000238	0.0164	0.24	0.17	Electrodermal activity;	chr8:88456585	chr8:88326836~88737134:+
THCA	cis	rs4073416	0.542	rs2898814	ENSG00000276116.2	FUT8-AS1	3.7	0.000238	0.0164	0.19	0.17	N-glycan levels;	chr14:65557243	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.568	rs7158153	ENSG00000276116.2	FUT8-AS1	3.7	0.000238	0.0164	0.19	0.17	N-glycan levels;	chr14:65567868	chr14:65411170~65412690:-
THCA	cis	rs7615952	0.546	rs2979306	ENSG00000272840.1	RP11-379B18.6	3.7	0.000238	0.0164	0.26	0.17	Blood pressure (smoking interaction);	chr3:125593286	chr3:125774714~125797953:+
THCA	cis	rs972578	0.967	rs738392	ENSG00000230319.1	AL022476.2	3.7	0.000238	0.0164	0.18	0.17	Mean platelet volume;	chr22:42944273	chr22:43038585~43052366:+
THCA	cis	rs1864585	0.52	rs17776427	ENSG00000280294.1	RP11-177H2.1	3.7	0.000238	0.0164	0.17	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10815462	chr8:10856085~10859436:-
THCA	cis	rs6671200	0.831	rs35961290	ENSG00000235501.4	RP4-639F20.1	-3.7	0.000239	0.0164	-0.34	-0.17	Stearic acid (18:0) levels;	chr1:95132019	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.831	rs35575248	ENSG00000235501.4	RP4-639F20.1	-3.7	0.000239	0.0164	-0.34	-0.17	Stearic acid (18:0) levels;	chr1:95135266	chr1:94927566~94963270:+
THCA	cis	rs4389656	0.857	rs274709	ENSG00000248677.1	CTD-2044J15.1	3.7	0.000239	0.0164	0.17	0.17	Coronary artery disease;	chr5:6726351	chr5:6686325~6707711:-
THCA	cis	rs4389656	0.74	rs274706	ENSG00000248677.1	CTD-2044J15.1	3.7	0.000239	0.0164	0.17	0.17	Coronary artery disease;	chr5:6726516	chr5:6686325~6707711:-
THCA	cis	rs4389656	0.857	rs274699	ENSG00000248677.1	CTD-2044J15.1	3.7	0.000239	0.0164	0.17	0.17	Coronary artery disease;	chr5:6730219	chr5:6686325~6707711:-
THCA	cis	rs7711186	0.786	rs4073633	ENSG00000252464.1	RN7SKP70	3.7	0.000239	0.0165	0.19	0.17	Urate levels in obese individuals;	chr5:178646826	chr5:178619728~178619998:-
THCA	cis	rs41313321	0.915	rs73672489	ENSG00000272696.1	RP11-339B21.13	3.7	0.000239	0.0165	0.15	0.17	Coenzyme Q10 levels;	chr9:128293281	chr9:128316337~128316909:+
THCA	cis	rs12476592	0.714	rs262492	ENSG00000242412.1	DBIL5P2	3.7	0.000239	0.0165	0.22	0.17	Childhood ear infection;	chr2:63617551	chr2:63117851~63119542:-
THCA	cis	rs9393777	0.92	rs34071253	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.28	-0.17	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28078792~28081130:-
THCA	cis	rs6120849	0.754	rs7268266	ENSG00000269202.1	RP4-614O4.12	-3.7	0.000239	0.0165	-0.18	-0.17	Protein C levels;	chr20:34994086	chr20:35201747~35203288:-
THCA	cis	rs1035144	0.654	rs4903956	ENSG00000258915.1	BHLHB9P1	-3.7	0.000239	0.0165	-0.19	-0.17	Male sexual orientation;	chr14:80978136	chr14:80981988~80983638:+
THCA	cis	rs2179367	0.959	rs537354	ENSG00000223701.3	RAET1E-AS1	3.7	0.000239	0.0165	0.22	0.17	Dupuytren's disease;	chr6:149344801	chr6:149884431~149919508:+
THCA	cis	rs838886	0.956	rs838879	ENSG00000275389.1	RP11-214K3.24	3.7	0.000239	0.0165	0.23	0.17	HDL cholesterol;	chr12:124776895	chr12:124085761~124088598:+
THCA	cis	rs858239	0.899	rs5850	ENSG00000226816.2	AC005082.12	3.7	0.000239	0.0165	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23206013~23208045:+
THCA	cis	rs7520050	0.831	rs61783170	ENSG00000281133.1	AL355480.3	3.7	0.000239	0.0165	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45580892~45580996:-
THCA	cis	rs34792	0.525	rs12923446	ENSG00000262332.1	RP11-517A5.7	-3.7	0.000239	0.0165	-0.19	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15509723	chr16:16223027~16224261:+
THCA	cis	rs2688608	0.698	rs2633313	ENSG00000271816.1	BMS1P4	3.7	0.000239	0.0165	0.16	0.17	Inflammatory bowel disease;	chr10:73924107	chr10:73699151~73730487:-
THCA	cis	rs7824557	0.564	rs2572395	ENSG00000227888.4	FAM66A	-3.7	0.000239	0.0165	-0.21	-0.17	Retinal vascular caliber;	chr8:11377851	chr8:12362019~12388296:+
THCA	cis	rs2562456	0.833	rs7246339	ENSG00000268278.1	RP11-420K14.1	3.7	0.000239	0.0165	0.24	0.17	Pain;	chr19:21292495	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs55899865	ENSG00000268278.1	RP11-420K14.1	3.7	0.000239	0.0165	0.24	0.17	Pain;	chr19:21298933	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs11667103	ENSG00000268278.1	RP11-420K14.1	3.7	0.000239	0.0165	0.24	0.17	Pain;	chr19:21303839	chr19:21637974~21656300:+
THCA	cis	rs7176527	0.848	rs3748374	ENSG00000176700.18	SCAND2P	3.7	0.000239	0.0165	0.15	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:84631451~84647478:+
THCA	cis	rs2274273	0.805	rs28612464	ENSG00000258469.1	CHMP4BP1	3.7	0.000239	0.0165	0.15	0.17	Protein biomarker;	chr14:55349693	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.773	rs28430823	ENSG00000258469.1	CHMP4BP1	3.7	0.000239	0.0165	0.15	0.17	Protein biomarker;	chr14:55349842	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs17741831	ENSG00000258469.1	CHMP4BP1	3.7	0.000239	0.0165	0.15	0.17	Protein biomarker;	chr14:55349997	chr14:55298644~55299231:+
THCA	cis	rs6738627	1	rs10187501	ENSG00000223318.1	RNA5SP111	3.7	0.000239	0.0165	0.22	0.17	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164675944	chr2:164895677~164895777:-
THCA	cis	rs427943	0.52	rs2838787	ENSG00000223768.1	LINC00205	3.7	0.000239	0.0165	0.15	0.17	Body mass index;	chr21:45119810	chr21:45293285~45297354:+
THCA	cis	rs35146811	0.735	rs858505	ENSG00000078319.8	PMS2P1	-3.7	0.000239	0.0165	-0.21	-0.17	Coronary artery disease;	chr7:100221954	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.695	rs858509	ENSG00000078319.8	PMS2P1	-3.7	0.000239	0.0165	-0.21	-0.17	Coronary artery disease;	chr7:100223847	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.625	rs858514	ENSG00000078319.8	PMS2P1	-3.7	0.000239	0.0165	-0.21	-0.17	Coronary artery disease;	chr7:100228125	chr7:100320992~100341908:-
THCA	cis	rs7586085	0.932	rs1863196	ENSG00000232411.1	AC009495.3	-3.7	0.000239	0.0165	-0.18	-0.17	Total body bone mineral density;	chr2:165701000	chr2:165833048~165839098:-
THCA	cis	rs14027	0.921	rs1567359	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs2043430	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs12543087	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs10101278	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs1976575	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs7837589	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs67905698	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs28756749	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs4871634	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs10109901	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs10109951	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119867419~119874488:-
THCA	cis	rs14027	0.883	rs4871642	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs2634	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs4870955	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs34718068	ENSG00000245330.4	KB-1471A8.1	3.7	0.000239	0.0165	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119867419~119874488:-
THCA	cis	rs9634489	0.678	rs1410339	ENSG00000247400.3	DNAJC3-AS1	-3.7	0.000239	0.0165	-0.1	-0.17	Body mass index;	chr13:96399375	chr13:95648733~95676925:-
THCA	cis	rs3018712	0.532	rs2513289	ENSG00000212093.1	AP000807.1	-3.7	0.000239	0.0165	-0.22	-0.17	Total body bone mineral density;	chr11:68652187	chr11:68506083~68506166:-
THCA	cis	rs875971	0.571	rs78668714	ENSG00000273024.4	INTS4P2	-3.7	0.000239	0.0165	-0.21	-0.17	Aortic root size;	chr7:66474464	chr7:65647864~65715661:+
THCA	cis	rs7737355	1	rs27421	ENSG00000237714.1	P4HA2-AS1	-3.7	0.000239	0.0165	-0.24	-0.17	Life satisfaction;	chr5:131408078	chr5:132184876~132192808:+
THCA	cis	rs8058578	0.832	rs3812999	ENSG00000260911.2	RP11-196G11.2	3.7	0.000239	0.0165	0.15	0.17	Multiple myeloma;	chr16:30762284	chr16:31043150~31049868:+
THCA	cis	rs7665090	0.875	rs6813687	ENSG00000251288.2	RP11-10L12.2	-3.7	0.000239	0.0165	-0.22	-0.17	Primary biliary cholangitis;	chr4:102634455	chr4:102751401~102752641:+
THCA	cis	rs854765	0.583	rs7214002	ENSG00000281749.1	Y_RNA	3.7	0.000239	0.0165	0.21	0.17	Total body bone mineral density;	chr17:17948790	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs12603148	ENSG00000281749.1	Y_RNA	3.7	0.000239	0.0165	0.21	0.17	Total body bone mineral density;	chr17:17961943	chr17:18001101~18001195:-
THCA	cis	rs854765	0.583	rs9908832	ENSG00000281749.1	Y_RNA	3.7	0.000239	0.0165	0.21	0.17	Total body bone mineral density;	chr17:17967754	chr17:18001101~18001195:-
THCA	cis	rs7246657	0.663	rs10408619	ENSG00000226686.6	LINC01535	-3.7	0.000239	0.0165	-0.24	-0.17	Coronary artery calcification;	chr19:37579573	chr19:37251912~37265535:+
THCA	cis	rs17134212	0.565	rs13187018	ENSG00000251187.4	CTC-459M5.2	-3.7	0.000239	0.0165	-0.16	-0.17	Common carotid intima-media thickness in HIV negative individuals;	chr5:112200182	chr5:112192020~112210139:+
THCA	cis	rs4713118	0.715	rs200480	ENSG00000280107.1	AL022393.9	-3.7	0.000239	0.0165	-0.17	-0.17	Parkinson's disease;	chr6:27805886	chr6:28170845~28172521:+
THCA	cis	rs61160187	0.548	rs68104763	ENSG00000251279.1	CTC-436P18.1	-3.7	0.000239	0.0165	-0.21	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:61162070~61232040:+
THCA	cis	rs2880765	0.835	rs4842884	ENSG00000218052.5	ADAMTS7P4	-3.7	0.000239	0.0165	-0.19	-0.17	Coronary artery disease;	chr15:85491943	chr15:85255369~85330334:-
THCA	cis	rs9487023	1	rs9487023	ENSG00000260273.1	RP11-425D10.10	3.7	0.000239	0.0165	0.21	0.17	Mean corpuscular volume;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin concentration;Mean corpuscular hemoglobin;Red blood cell count;High light scatter reticulocyte percentage of red cells;Neutrophil percentage of white cells;	chr6:109268801	chr6:109382795~109383666:+
THCA	cis	rs1436955	0.583	rs4775470	ENSG00000259251.2	RP11-643M14.1	3.7	0.000239	0.0165	0.29	0.17	Type 2 diabetes;	chr15:62124386	chr15:62060503~62062434:+
THCA	cis	rs7924176	0.521	rs10824137	ENSG00000232342.6	RP11-46O21.2	-3.7	0.000239	0.0165	-0.22	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:74506081~74530553:-
THCA	cis	rs10256972	0.616	rs6463001	ENSG00000225146.1	AC073957.15	3.7	0.000239	0.0165	0.17	0.17	Endometriosis;Longevity;	chr7:1068636	chr7:1029025~1043891:+
THCA	cis	rs7635879	1	rs7635879	ENSG00000230102.6	RP11-407B7.1	3.7	0.000239	0.0165	0.14	0.17	Breastfeeding duration;	chr3:194018584	chr3:194005259~194070970:-
THCA	cis	rs7635879	0.967	rs7624221	ENSG00000230102.6	RP11-407B7.1	3.7	0.000239	0.0165	0.14	0.17	Breastfeeding duration;	chr3:194018696	chr3:194005259~194070970:-
THCA	cis	rs4568518	0.619	rs6946266	ENSG00000279048.1	RP11-511H23.2	3.7	0.000239	0.0165	0.11	0.17	Measles;	chr7:17967965	chr7:17940503~17942922:+
THCA	cis	rs7924176	0.521	rs10824142	ENSG00000232342.6	RP11-46O21.2	3.7	0.000239	0.0165	0.21	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.521	rs11000965	ENSG00000232342.6	RP11-46O21.2	3.7	0.000239	0.0165	0.21	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.521	rs12357370	ENSG00000232342.6	RP11-46O21.2	3.7	0.000239	0.0165	0.21	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:74506081~74530553:-
THCA	cis	rs7259376	0.905	rs62118584	ENSG00000270947.1	AC025811.3	3.7	0.000239	0.0165	0.18	0.17	Menopause (age at onset);	chr19:22358340	chr19:22455988~22456459:+
THCA	cis	rs7665590	1	rs7665590	ENSG00000263923.1	RP11-571L19.7	3.7	0.000239	0.0165	0.19	0.17	Primary biliary cholangitis;	chr4:98875633	chr4:98928897~98994994:+
THCA	cis	rs8007846	0.65	rs12886168	ENSG00000276116.2	FUT8-AS1	3.7	0.000239	0.0165	0.17	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr14:65342568	chr14:65411170~65412690:-
THCA	cis	rs910316	1	rs12435391	ENSG00000259138.1	RP11-950C14.7	3.7	0.000239	0.0165	0.15	0.17	Height;	chr14:75135034	chr14:75127153~75136930:+
THCA	cis	rs7577696	0.741	rs2300703	ENSG00000276334.1	AL133243.1	3.7	0.000239	0.0165	0.16	0.17	Inflammatory biomarkers;	chr2:31574439	chr2:32521927~32523547:+
THCA	cis	rs9905704	0.918	rs390524	ENSG00000224738.1	AC099850.1	3.7	0.000239	0.0165	0.23	0.17	Testicular germ cell tumor;	chr17:58596812	chr17:59106598~59118267:+
THCA	cis	rs789852	0.764	rs1705999	ENSG00000231770.4	TMEM44-AS1	3.7	0.000239	0.0165	0.23	0.17	QT interval;	chr3:194595604	chr3:194584011~194590260:+
THCA	cis	rs972578	1	rs5759080	ENSG00000274717.1	RP1-47A17.1	-3.7	0.000239	0.0165	-0.17	-0.17	Mean platelet volume;	chr22:42997934	chr22:42791814~42794313:-
THCA	cis	rs17095355	0.818	rs11194997	ENSG00000203876.8	ADD3-AS1	-3.7	0.000239	0.0165	-0.18	-0.17	Biliary atresia;	chr10:110130021	chr10:109940104~110008381:-
THCA	cis	rs16957091	0.528	rs12908349	ENSG00000205771.5	CATSPER2P1	3.7	0.000239	0.0165	0.24	0.17	MGMT methylation in smokers;	chr15:42794029	chr15:43726918~43747094:-
THCA	cis	rs7474896	0.583	rs12783272	ENSG00000120555.12	SEPT7P9	3.7	0.000239	0.0165	0.23	0.17	Obesity (extreme);	chr10:37735957	chr10:38383069~38402916:-
THCA	cis	rs6662572	0.737	rs6429579	ENSG00000234329.1	RP11-767N6.2	3.7	0.000239	0.0165	0.18	0.17	Blood protein levels;	chr1:45792521	chr1:45651039~45651826:-
THCA	cis	rs7927592	0.913	rs2236708	ENSG00000160172.9	FAM86C2P	3.7	0.000239	0.0165	0.17	0.17	Total body bone mineral density;	chr11:68610577	chr11:67791648~67805336:-
THCA	cis	rs7142002	0.614	rs59784377	ENSG00000272444.1	RP11-1017G21.6	-3.7	0.000239	0.0165	-0.2	-0.17	Autism;	chr14:101924844	chr14:101952416~101953063:+
THCA	cis	rs7572733	0.935	rs10189897	ENSG00000231621.1	AC013264.2	3.7	0.000239	0.0165	0.16	0.17	Dermatomyositis;	chr2:197948686	chr2:197197991~197199273:+
THCA	cis	rs7927592	0.513	rs556442	ENSG00000160172.9	FAM86C2P	-3.7	0.000239	0.0165	-0.16	-0.17	Total body bone mineral density;	chr11:68425222	chr11:67791648~67805336:-
THCA	cis	rs2455799	0.502	rs2470532	ENSG00000270409.1	RP11-44D5.1	3.7	0.000239	0.0165	0.18	0.17	Mean platelet volume;	chr3:15655402	chr3:15732252~15733470:+
THCA	cis	rs972578	0.561	rs2413740	ENSG00000230319.1	AL022476.2	3.7	0.000239	0.0165	0.2	0.17	Mean platelet volume;	chr22:43023319	chr22:43038585~43052366:+
THCA	cis	rs4578769	0.55	rs12964830	ENSG00000273232.1	RP11-370A5.2	3.7	0.000239	0.0165	0.23	0.17	Eosinophil percentage of white cells;	chr18:22938970	chr18:22882825~22883357:-
THCA	cis	rs7142002	0.568	rs6575884	ENSG00000272444.1	RP11-1017G21.6	-3.7	0.000239	0.0165	-0.19	-0.17	Autism;	chr14:101924400	chr14:101952416~101953063:+
THCA	cis	rs6902257	0.59	rs2168107	ENSG00000233967.5	RP11-250B2.3	3.7	0.000239	0.0165	0.34	0.17	Obesity-related traits;	chr6:80600723	chr6:80443344~80465927:+
THCA	cis	rs1667255	1	rs2704058	ENSG00000266521.1	RP11-650P15.1	-3.7	0.000239	0.0165	-0.21	-0.17	Retinol levels;	chr18:31577605	chr18:31496645~31497195:-
THCA	cis	rs2904524	0.588	rs968122	ENSG00000257815.4	RP11-611E13.2	3.7	0.000239	0.0165	0.13	0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70397835	chr12:69904033~70243360:-
THCA	cis	rs853679	0.607	rs35749575	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28147040	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs72846780	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28151277	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13205911	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28156336	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13197176	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28161454	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs13201308	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28162311	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34765154	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28162672	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34505829	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28165461	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs35098436	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28166443	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs72846794	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000239	0.0165	-0.33	-0.17	Depression;	chr6:28169721	chr6:28078792~28081130:-
THCA	cis	rs28857569	0.514	rs7833730	ENSG00000254023.1	PKMP4	3.7	0.000239	0.0165	0.26	0.17	Body mass index;	chr8:75666947	chr8:75376709~75377014:+
THCA	cis	rs28857569	0.514	rs28650225	ENSG00000254023.1	PKMP4	3.7	0.000239	0.0165	0.26	0.17	Body mass index;	chr8:75669196	chr8:75376709~75377014:+
THCA	cis	rs28857569	0.514	rs12334575	ENSG00000254023.1	PKMP4	3.7	0.000239	0.0165	0.26	0.17	Body mass index;	chr8:75670641	chr8:75376709~75377014:+
THCA	cis	rs28857569	0.514	rs9643696	ENSG00000254023.1	PKMP4	3.7	0.000239	0.0165	0.26	0.17	Body mass index;	chr8:75671827	chr8:75376709~75377014:+
THCA	cis	rs28857569	0.514	rs56115131	ENSG00000254023.1	PKMP4	3.7	0.000239	0.0165	0.26	0.17	Body mass index;	chr8:75672767	chr8:75376709~75377014:+
THCA	cis	rs28857569	0.514	rs7002991	ENSG00000254023.1	PKMP4	3.7	0.000239	0.0165	0.26	0.17	Body mass index;	chr8:75673786	chr8:75376709~75377014:+
THCA	cis	rs7572644	0.766	rs6745379	ENSG00000223522.1	AC093690.1	3.7	0.000239	0.0165	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27924674	chr2:28307691~28310459:-
THCA	cis	rs7824557	0.564	rs12547100	ENSG00000255495.1	AC145124.2	-3.7	0.000239	0.0165	-0.19	-0.17	Retinal vascular caliber;	chr8:11385123	chr8:12194467~12196280:+
THCA	cis	rs8058578	1	rs67128646	ENSG00000260911.2	RP11-196G11.2	3.7	0.00024	0.0165	0.15	0.17	Multiple myeloma;	chr16:30660776	chr16:31043150~31049868:+
THCA	cis	rs7264396	0.79	rs6060530	ENSG00000088340.14	FER1L4	3.7	0.00024	0.0165	0.17	0.17	Total cholesterol levels;	chr20:35639741	chr20:35558737~35607562:-
THCA	cis	rs6687821	0.515	rs1970607	ENSG00000261737.1	RP4-612B15.3	-3.7	0.00024	0.0165	-0.25	-0.17	Yeast infection;	chr1:86962619	chr1:86703502~86704462:-
THCA	cis	rs7520050	0.966	rs7556436	ENSG00000280836.1	AL355480.1	-3.7	0.00024	0.0165	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45581219~45581321:-
THCA	cis	rs62434120	0.571	rs4242273	ENSG00000273132.1	RP11-350J20.12	3.7	0.00024	0.0165	0.2	0.17	Blood pressure traits (multi-trait analysis);Diastolic blood pressure;Systolic blood pressure;	chr6:150730145	chr6:149852462~149853192:+
THCA	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	3.7	0.00024	0.0165	0.15	0.17	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	3.7	0.00024	0.0165	0.15	0.17	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	3.7	0.00024	0.0165	0.15	0.17	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	3.7	0.00024	0.0165	0.15	0.17	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	3.7	0.00024	0.0165	0.15	0.17	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	3.7	0.00024	0.0165	0.15	0.17	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	3.7	0.00024	0.0165	0.15	0.17	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
THCA	cis	rs2239557	0.508	rs61245231	ENSG00000259065.1	RP5-1021I20.1	-3.7	0.00024	0.0165	-0.26	-0.17	Common traits (Other);	chr14:73845492	chr14:73787360~73803270:+
THCA	cis	rs6449502	0.858	rs6894795	ENSG00000251279.1	CTC-436P18.1	-3.7	0.00024	0.0165	-0.27	-0.17	Mean platelet volume;	chr5:60825535	chr5:61162070~61232040:+
THCA	cis	rs7176527	0.747	rs28363946	ENSG00000230373.7	GOLGA6L5P	3.7	0.00024	0.0165	0.24	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:84507885~84516814:-
THCA	cis	rs62246343	0.605	rs17746498	ENSG00000254485.4	RP11-380O24.1	3.7	0.00024	0.0165	0.2	0.17	Fibrinogen levels;	chr3:9411976	chr3:9292588~9363303:-
THCA	cis	rs737008	0.542	rs11640467	ENSG00000262703.1	RP11-485G7.6	3.7	0.00024	0.0165	0.27	0.17	Obesity-related traits;	chr16:11314152	chr16:11348143~11349321:-
THCA	cis	rs737008	0.586	rs11640800	ENSG00000262703.1	RP11-485G7.6	3.7	0.00024	0.0165	0.27	0.17	Obesity-related traits;	chr16:11314189	chr16:11348143~11349321:-
THCA	cis	rs11212260	0.737	rs519800	ENSG00000261098.1	RP11-819C21.1	-3.7	0.00024	0.0165	-0.32	-0.17	IgG glycosylation;	chr11:107514117	chr11:107312132~107316271:-
THCA	cis	rs7259376	0.905	rs11879791	ENSG00000269138.1	ZNF209P	3.7	0.00024	0.0165	0.17	0.17	Menopause (age at onset);	chr19:22354137	chr19:22463922~22473036:+
THCA	cis	rs7259376	0.936	rs59598661	ENSG00000269138.1	ZNF209P	3.7	0.00024	0.0165	0.17	0.17	Menopause (age at onset);	chr19:22354227	chr19:22463922~22473036:+
THCA	cis	rs1035144	0.679	rs2284722	ENSG00000258915.1	BHLHB9P1	-3.7	0.00024	0.0165	-0.19	-0.17	Male sexual orientation;	chr14:80978023	chr14:80981988~80983638:+
THCA	cis	rs8062405	0.655	rs7184597	ENSG00000270424.1	RP11-1348G14.6	-3.7	0.00024	0.0165	-0.21	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28749959~28750595:-
THCA	cis	rs11673344	0.523	rs7245520	ENSG00000233527.7	ZNF529-AS1	3.7	0.00024	0.0165	0.14	0.17	Obesity-related traits;	chr19:37036416	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.523	rs7256380	ENSG00000233527.7	ZNF529-AS1	3.7	0.00024	0.0165	0.14	0.17	Obesity-related traits;	chr19:37041178	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.523	rs6510585	ENSG00000233527.7	ZNF529-AS1	3.7	0.00024	0.0165	0.14	0.17	Obesity-related traits;	chr19:37063081	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.523	rs17206540	ENSG00000233527.7	ZNF529-AS1	3.7	0.00024	0.0165	0.14	0.17	Obesity-related traits;	chr19:37069009	chr19:36573070~36594708:+
THCA	cis	rs2668423	0.922	rs266805	ENSG00000261526.2	CTB-31O20.2	3.7	0.00024	0.0165	0.12	0.17	Nonalcoholic fatty liver disease;	chr19:1376724	chr19:1874871~1876169:-
THCA	cis	rs6142618	0.935	rs4911554	ENSG00000224452.1	RSL24D1P6	3.7	0.00024	0.0165	0.21	0.17	Inflammatory bowel disease;	chr20:32164207	chr20:32170390~32170790:-
THCA	cis	rs773506	0.628	rs10991816	ENSG00000235641.4	LINC00484	-3.7	0.00024	0.0165	-0.23	-0.17	Type 2 diabetes nephropathy;	chr9:91188231	chr9:91159573~91165658:+
THCA	cis	rs950169	0.887	rs3860265	ENSG00000188388.10	GOLGA6L3	3.7	0.00024	0.0165	0.23	0.17	Schizophrenia;	chr15:84390487	chr15:85240472~85247170:+
THCA	cis	rs950169	0.724	rs11632668	ENSG00000188388.10	GOLGA6L3	3.7	0.00024	0.0165	0.23	0.17	Schizophrenia;	chr15:84393989	chr15:85240472~85247170:+
THCA	cis	rs950169	0.881	rs34591918	ENSG00000188388.10	GOLGA6L3	3.7	0.00024	0.0165	0.23	0.17	Schizophrenia;	chr15:84396135	chr15:85240472~85247170:+
THCA	cis	rs9652601	0.676	rs9926615	ENSG00000263033.2	RP11-396B14.2	-3.7	0.00024	0.0165	-0.13	-0.17	Systemic lupus erythematosus;	chr16:11009303	chr16:11196177~11224969:+
THCA	cis	rs910316	1	rs10138183	ENSG00000259138.1	RP11-950C14.7	3.7	0.00024	0.0165	0.15	0.17	Height;	chr14:75148524	chr14:75127153~75136930:+
THCA	cis	rs16975963	0.793	rs11666497	ENSG00000276846.1	CTD-3220F14.3	-3.7	0.00024	0.0165	-0.16	-0.17	Longevity;	chr19:37973622	chr19:37314868~37315620:-
THCA	cis	rs1876206	0.554	rs924816	ENSG00000259705.1	RP11-227D13.1	3.7	0.00024	0.0165	0.2	0.17	Breast cancer;	chr15:48605219	chr15:48645951~48652016:+
THCA	cis	rs9905704	0.918	rs12947196	ENSG00000224738.1	AC099850.1	3.7	0.00024	0.0165	0.23	0.17	Testicular germ cell tumor;	chr17:58825083	chr17:59106598~59118267:+
THCA	cis	rs6560517	0.581	rs2501925	ENSG00000234618.1	RPSAP9	3.7	0.00024	0.0165	0.17	0.17	Dialysis-related mortality;	chr9:76388497	chr9:76398699~76399586:+
THCA	cis	rs7989332	0.627	rs9552201	ENSG00000277020.3	RP11-476H16.1	3.7	0.00024	0.0165	0.16	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20487813	chr13:20564708~20567045:-
THCA	cis	rs6012953	0.583	rs6095985	ENSG00000231715.1	COX6CP2	3.7	0.00024	0.0165	0.19	0.17	Vitiligo;	chr20:50506896	chr20:50479767~50479991:+
THCA	cis	rs9549260	0.755	rs2721067	ENSG00000168852.11	TPTE2P5	3.7	0.00024	0.0165	0.12	0.17	Red blood cell count;	chr13:40582571	chr13:40822296~40921749:-
THCA	cis	rs9549260	0.755	rs2701869	ENSG00000168852.11	TPTE2P5	3.7	0.00024	0.0165	0.12	0.17	Red blood cell count;	chr13:40583235	chr13:40822296~40921749:-
THCA	cis	rs3733585	0.66	rs13122290	ENSG00000250413.1	RP11-448G15.1	3.7	0.00024	0.0165	0.16	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9932208	chr4:10006482~10009725:+
THCA	cis	rs6456156	0.586	rs1358882	ENSG00000235272.1	FAM103A2P	3.7	0.00024	0.0165	0.23	0.17	Primary biliary cholangitis;	chr6:167053613	chr6:166586124~166586477:-
THCA	cis	rs7259376	0.934	rs7253315	ENSG00000269345.1	VN1R85P	-3.7	0.00024	0.0165	-0.18	-0.17	Menopause (age at onset);	chr19:22411637	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs6511350	ENSG00000269345.1	VN1R85P	-3.7	0.00024	0.0165	-0.18	-0.17	Menopause (age at onset);	chr19:22411895	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs10423736	ENSG00000269345.1	VN1R85P	-3.7	0.00024	0.0165	-0.18	-0.17	Menopause (age at onset);	chr19:22413330	chr19:22174766~22175191:-
THCA	cis	rs11168187	0.527	rs11168220	ENSG00000257433.4	RP1-197B17.3	3.7	0.00024	0.0165	0.17	0.17	Vertical cup-disc ratio;	chr12:47741807	chr12:47706085~47742294:+
THCA	cis	rs804280	0.565	rs1466785	ENSG00000270154.1	RP11-419I17.1	3.7	0.00024	0.0165	0.2	0.17	Myopia (pathological);	chr8:11765947	chr8:12476462~12477122:+
THCA	cis	rs2736345	0.742	rs4840568	ENSG00000254527.1	ENPP7P12	3.7	0.00024	0.0165	0.22	0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11493510	chr8:12205759~12206389:-
THCA	cis	rs2274273	0.837	rs10141552	ENSG00000258469.1	CHMP4BP1	-3.7	0.00024	0.0165	-0.15	-0.17	Protein biomarker;	chr14:55279373	chr14:55298644~55299231:+
THCA	cis	rs7178375	0.941	rs35497908	ENSG00000215302.7	CTD-3092A11.1	-3.7	0.00024	0.0165	-0.23	-0.17	Hypertriglyceridemia;	chr15:30931868	chr15:30470779~30507623:+
THCA	cis	rs17194490	0.665	rs13089709	ENSG00000237990.3	CNTN4-AS1	3.7	0.00024	0.0165	0.25	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2531309	chr3:3039033~3069242:-
THCA	cis	rs6456156	0.586	rs6456154	ENSG00000235272.1	FAM103A2P	3.7	0.00024	0.0165	0.23	0.17	Primary biliary cholangitis;	chr6:167058768	chr6:166586124~166586477:-
THCA	cis	rs150992	0.861	rs428836	ENSG00000246763.5	RGMB-AS1	3.7	0.00024	0.0165	0.17	0.17	Body mass index;	chr5:98951673	chr5:98769618~98773469:-
THCA	cis	rs2736345	0.755	rs2736340	ENSG00000254527.1	ENPP7P12	3.7	0.00024	0.0166	0.24	0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:12205759~12206389:-
THCA	cis	rs9911578	1	rs1057068	ENSG00000224738.1	AC099850.1	-3.7	0.00024	0.0166	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58521078	chr17:59106598~59118267:+
THCA	cis	rs7772697	0.632	rs6570939	ENSG00000223701.3	RAET1E-AS1	-3.7	0.00024	0.0166	-0.23	-0.17	Diabetic retinopathy;	chr6:149107861	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.632	rs12216011	ENSG00000223701.3	RAET1E-AS1	-3.7	0.00024	0.0166	-0.23	-0.17	Diabetic retinopathy;	chr6:149108310	chr6:149884431~149919508:+
THCA	cis	rs13325613	0.834	rs34870159	ENSG00000223552.1	RP11-24F11.2	-3.7	0.00024	0.0166	-0.29	-0.17	Monocyte count;	chr3:46147998	chr3:46364955~46407059:-
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000237310.1	GS1-124K5.4	3.7	0.00024	0.0166	0.2	0.17	Diabetic kidney disease;	chr7:66528779	chr7:66493706~66495474:+
THCA	cis	rs642858	0.747	rs6904492	ENSG00000234147.1	RP3-460G2.2	3.7	0.00024	0.0166	0.19	0.17	Type 2 diabetes;	chr6:139881086	chr6:140845958~140852924:-
THCA	cis	rs867186	1	rs56363533	ENSG00000126005.14	MMP24-AS1	-3.7	0.00024	0.0166	-0.27	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35038202	chr20:35216462~35278131:-
THCA	cis	rs4141404	0.818	rs6518737	ENSG00000235573.2	RP3-412A9.12	3.7	0.00024	0.0166	0.18	0.17	Paclitaxel-induced neuropathy;	chr22:31186676	chr22:31113017~31113396:+
THCA	cis	rs4141404	0.787	rs11913992	ENSG00000235573.2	RP3-412A9.12	3.7	0.00024	0.0166	0.18	0.17	Paclitaxel-induced neuropathy;	chr22:31189234	chr22:31113017~31113396:+
THCA	cis	rs7914558	0.966	rs7908280	ENSG00000213061.2	PFN1P11	3.7	0.00024	0.0166	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102838011~102845473:-
THCA	cis	rs3764021	0.527	rs10844380	ENSG00000257027.1	RP11-705C15.3	3.7	0.00024	0.0166	0.15	0.17	Type 1 diabetes;	chr12:9670678	chr12:9658567~9662085:+
THCA	cis	rs854765	0.547	rs2955384	ENSG00000281749.1	Y_RNA	3.7	0.00024	0.0166	0.21	0.17	Total body bone mineral density;	chr17:18036259	chr17:18001101~18001195:-
THCA	cis	rs745109	0.504	rs76654460	ENSG00000273080.1	RP11-301O19.1	3.7	0.00024	0.0166	0.3	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86378757	chr2:86195590~86196049:+
THCA	cis	rs12476592	0.602	rs7571325	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63558780	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs6724160	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63559289	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.571	rs7577952	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63560078	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs6736029	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63562036	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs4671516	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63563421	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs4671065	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63563997	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.571	rs7584404	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63567208	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs2166497	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63573025	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.571	rs68183503	ENSG00000242412.1	DBIL5P2	3.7	0.00024	0.0166	0.22	0.17	Childhood ear infection;	chr2:63575754	chr2:63117851~63119542:-
THCA	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	3.7	0.00024	0.0166	0.24	0.17	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
THCA	cis	rs12188164	0.93	rs11743825	ENSG00000225138.6	CTD-2228K2.7	3.7	0.00024	0.0166	0.18	0.17	Cystic fibrosis severity;	chr5:475348	chr5:473236~480884:+
THCA	cis	rs7632954	0.567	rs6808372	ENSG00000227110.5	LMCD1-AS1	3.7	0.000241	0.0166	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8493007	chr3:7952805~8611924:-
THCA	cis	rs7632954	0.567	rs6768518	ENSG00000227110.5	LMCD1-AS1	3.7	0.000241	0.0166	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8493142	chr3:7952805~8611924:-
THCA	cis	rs786425	0.966	rs4040225	ENSG00000270095.1	RP11-214K3.18	-3.7	0.000241	0.0166	-0.2	-0.17	Pubertal anthropometrics;	chr12:123612126	chr12:123971457~123971714:-
THCA	cis	rs1035144	0.505	rs6574617	ENSG00000271656.1	RP11-114N19.5	3.7	0.000241	0.0166	0.19	0.17	Male sexual orientation;	chr14:80991271	chr14:81003325~81003645:-
THCA	cis	rs6963495	0.674	rs75880756	ENSG00000272604.1	RP11-251G23.5	3.7	0.000241	0.0166	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105523374	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190186	ENSG00000272604.1	RP11-251G23.5	3.7	0.000241	0.0166	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105523921	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190187	ENSG00000272604.1	RP11-251G23.5	3.7	0.000241	0.0166	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105523954	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs73190189	ENSG00000272604.1	RP11-251G23.5	3.7	0.000241	0.0166	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105524005	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.872	rs73190193	ENSG00000272604.1	RP11-251G23.5	3.7	0.000241	0.0166	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105524405	chr7:105571083~105573660:+
THCA	cis	rs116979167	0.63	rs56230603	ENSG00000272604.1	RP11-251G23.5	3.7	0.000241	0.0166	0.23	0.17	Bipolar disorder (body mass index interaction);	chr7:105524821	chr7:105571083~105573660:+
THCA	cis	rs10871290	0.65	rs2288054	ENSG00000207525.1	Y_RNA	-3.7	0.000241	0.0166	-0.21	-0.17	Breast cancer;	chr16:74457835	chr16:74463888~74463988:-
THCA	cis	rs877819	0.583	rs2620887	ENSG00000228403.1	RP11-563N6.6	-3.7	0.000241	0.0166	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48852457	chr10:48878022~48878649:+
THCA	cis	rs9611565	0.694	rs9607816	ENSG00000237037.8	NDUFA6-AS1	3.7	0.000241	0.0166	0.16	0.17	Vitiligo;	chr22:41554893	chr22:42090931~42137742:+
THCA	cis	rs950169	0.959	rs12911210	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000241	0.0166	-0.18	-0.17	Schizophrenia;	chr15:84123331	chr15:84507885~84516814:-
THCA	cis	rs10043228	0.826	rs11241356	ENSG00000248445.4	SEMA6A-AS1	-3.7	0.000241	0.0166	-0.22	-0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116110826	chr5:116447547~116508276:+
THCA	cis	rs8046148	0.906	rs11640627	ENSG00000279356.1	RP11-429P3.8	3.7	0.000241	0.0166	0.23	0.17	Testicular germ cell tumor;	chr16:50103990	chr16:50072862~50074986:+
THCA	cis	rs11098699	0.784	rs2291933	ENSG00000273007.1	RP11-170N16.3	3.7	0.000241	0.0166	0.14	0.17	Mosquito bite size;	chr4:123326028	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs7693178	ENSG00000273007.1	RP11-170N16.3	3.7	0.000241	0.0166	0.14	0.17	Mosquito bite size;	chr4:123326239	chr4:122881878~122884712:-
THCA	cis	rs13217239	0.646	rs10946888	ENSG00000124549.13	BTN2A3P	3.7	0.000241	0.0166	0.16	0.17	Schizophrenia;	chr6:26983899	chr6:26421391~26432383:+
THCA	cis	rs2299682	0.826	rs6086907	ENSG00000230506.1	RP11-416N4.4	3.7	0.000241	0.0166	0.28	0.17	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9487877	chr20:10173520~10196990:+
THCA	cis	rs14027	0.921	rs16893101	ENSG00000245330.4	KB-1471A8.1	3.7	0.000241	0.0166	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119867419~119874488:-
THCA	cis	rs2357982	0.556	rs56325411	ENSG00000232320.6	AC009299.5	-3.7	0.000241	0.0166	-0.23	-0.17	Presence of antiphospholipid antibodies;	chr2:161043444	chr2:161340816~161341326:-
THCA	cis	rs1862618	0.853	rs832578	ENSG00000234553.1	AC022431.3	-3.7	0.000241	0.0166	-0.19	-0.17	Initial pursuit acceleration;	chr5:56868396	chr5:56536583~56537826:-
THCA	cis	rs4908768	0.539	rs6666191	ENSG00000270282.1	RP5-1115A15.2	3.7	0.000241	0.0166	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8512653~8513021:+
THCA	cis	rs7616559	0.789	rs6797982	ENSG00000244515.1	KRT18P34	-3.7	0.000241	0.0166	-0.21	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157065306	chr3:157162663~157163932:-
THCA	cis	rs9611565	0.512	rs715498	ENSG00000237037.8	NDUFA6-AS1	-3.7	0.000241	0.0166	-0.16	-0.17	Vitiligo;	chr22:41752463	chr22:42090931~42137742:+
THCA	cis	rs42648	0.792	rs4236517	ENSG00000225498.1	AC002064.5	3.7	0.000241	0.0166	0.18	0.17	Homocysteine levels;	chr7:90334151	chr7:90312496~90322592:+
THCA	cis	rs6921919	0.848	rs6903823	ENSG00000219392.1	RP1-265C24.5	-3.7	0.000241	0.0166	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28115628~28116551:+
THCA	cis	rs853679	0.567	rs13196606	ENSG00000226314.6	ZNF192P1	-3.7	0.000241	0.0166	-0.2	-0.17	Depression;	chr6:28402301	chr6:28161781~28169594:+
THCA	cis	rs4662750	0.58	rs4662743	ENSG00000236682.1	AC068282.3	-3.7	0.000241	0.0166	-0.21	-0.17	Renal cell carcinoma;	chr2:127593233	chr2:127389130~127400580:+
THCA	cis	rs785830	0.871	rs494637	ENSG00000231808.2	LINC01388	-3.7	0.000241	0.0166	-0.19	-0.17	Platelet distribution width;	chr9:267606	chr9:112713~113754:-
THCA	cis	rs8130944	1	rs4920137	ENSG00000235772.1	AP001625.6	3.7	0.000241	0.0166	0.19	0.17	Perceived unattractiveness to mosquitoes;	chr21:42720007	chr21:42560374~42561934:-
THCA	cis	rs8130944	0.964	rs4920138	ENSG00000235772.1	AP001625.6	3.7	0.000241	0.0166	0.19	0.17	Perceived unattractiveness to mosquitoes;	chr21:42720167	chr21:42560374~42561934:-
THCA	cis	rs8130944	1	rs4920139	ENSG00000235772.1	AP001625.6	3.7	0.000241	0.0166	0.19	0.17	Perceived unattractiveness to mosquitoes;	chr21:42720204	chr21:42560374~42561934:-
THCA	cis	rs683250	0.629	rs656515	ENSG00000254551.1	RP11-727A23.7	3.7	0.000241	0.0166	0.21	0.17	Subcortical brain region volumes;	chr11:83257666	chr11:83209431~83213379:-
THCA	cis	rs1799922	1	rs17475665	ENSG00000271553.1	RP11-274B21.10	-3.7	0.000241	0.0166	-0.15	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128768259	chr7:128667043~128668156:+
THCA	cis	rs5758511	0.68	rs5758687	ENSG00000230107.1	CTA-126B4.7	-3.7	0.000241	0.0166	-0.2	-0.17	Birth weight;	chr22:42260582	chr22:42438023~42446195:+
THCA	cis	rs11671005	0.504	rs3794963	ENSG00000269600.1	AC016629.3	3.7	0.000241	0.0166	0.21	0.17	Mean platelet volume;	chr19:58559684	chr19:58593896~58599355:-
THCA	cis	rs8023401	0.529	rs7164585	ENSG00000259705.1	RP11-227D13.1	3.7	0.000241	0.0166	0.21	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48534947	chr15:48645951~48652016:+
THCA	cis	rs2640806	0.505	rs7818838	ENSG00000253105.4	KB-1448A5.1	3.7	0.000241	0.0166	0.2	0.17	Obesity-related traits;	chr8:96347051	chr8:96371865~96387438:-
THCA	cis	rs801193	1	rs17566701	ENSG00000232546.1	RP11-458F8.1	-3.7	0.000241	0.0166	-0.14	-0.17	Aortic root size;	chr7:66728196	chr7:66848496~66858136:+
THCA	cis	rs972578	0.601	rs4820498	ENSG00000230319.1	AL022476.2	3.7	0.000241	0.0166	0.18	0.17	Mean platelet volume;	chr22:42931575	chr22:43038585~43052366:+
THCA	cis	rs4468007	0.865	rs7041912	ENSG00000261534.1	RP11-244O19.1	3.7	0.000241	0.0166	0.19	0.17	Educational attainment;	chr9:121852242	chr9:121815674~121819452:-
THCA	cis	rs9427116	0.532	rs9426828	ENSG00000236675.1	MTX1P1	-3.7	0.000241	0.0166	-0.15	-0.17	Blood protein levels;	chr1:154619013	chr1:155230975~155234325:+
THCA	cis	rs2688608	0.592	rs10824031	ENSG00000272140.2	RP11-574K11.29	3.7	0.000241	0.0166	0.14	0.17	Inflammatory bowel disease;	chr10:73749515	chr10:73703735~73713581:-
THCA	cis	rs2554380	0.943	rs2562777	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000241	0.0166	-0.21	-0.17	Height;	chr15:83697314	chr15:84507885~84516814:-
THCA	cis	rs7267979	0.565	rs6107060	ENSG00000276952.1	RP5-965G21.6	3.7	0.000241	0.0166	0.19	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:25284915~25285588:-
THCA	cis	rs1023500	0.573	rs133377	ENSG00000270083.1	RP1-257I20.14	3.7	0.000241	0.0166	0.19	0.17	Schizophrenia;	chr22:42070946	chr22:42089630~42090028:-
THCA	cis	rs972578	0.533	rs6002998	ENSG00000230319.1	AL022476.2	3.7	0.000241	0.0166	0.2	0.17	Mean platelet volume;	chr22:43024660	chr22:43038585~43052366:+
THCA	cis	rs17594362	0.563	rs61963026	ENSG00000264190.1	MIR5006	3.7	0.000241	0.0166	0.28	0.17	Multiple sclerosis;	chr13:41607644	chr13:41568286~41568395:-
THCA	cis	rs208520	0.955	rs12204033	ENSG00000233859.2	ADH5P4	3.7	0.000241	0.0166	0.27	0.17	Exhaled nitric oxide output;	chr6:66291632	chr6:65836930~65838039:-
THCA	cis	rs208520	0.955	rs12202599	ENSG00000233859.2	ADH5P4	3.7	0.000241	0.0166	0.27	0.17	Exhaled nitric oxide output;	chr6:66291680	chr6:65836930~65838039:-
THCA	cis	rs2033711	0.87	rs11084545	ENSG00000232098.3	CTD-2619J13.14	3.7	0.000241	0.0166	0.15	0.17	Uric acid clearance;	chr19:58440326	chr19:58404238~58408484:-
THCA	cis	rs193541	0.509	rs6899195	ENSG00000260686.1	CTB-36H16.2	-3.7	0.000241	0.0166	-0.16	-0.17	Glucose homeostasis traits;	chr5:122805764	chr5:122832356~122834533:+
THCA	cis	rs10857712	0.754	rs2297033	ENSG00000214279.11	SCART1	-3.7	0.000241	0.0166	-0.14	-0.17	Systemic lupus erythematosus;	chr10:133421344	chr10:133453928~133523558:+
THCA	cis	rs11089937	0.963	rs5757078	ENSG00000263366.2	LL22NC03-33B6.4	-3.7	0.000241	0.0166	-0.21	-0.17	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22114844~22118005:-
THCA	cis	rs2337406	0.866	rs78462736	ENSG00000280411.1	IGHV1-69-2	-3.7	0.000241	0.0166	-0.13	-0.17	Alzheimer's disease (late onset);	chr14:106779942	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs8016203	ENSG00000280411.1	IGHV1-69-2	-3.7	0.000241	0.0166	-0.13	-0.17	Alzheimer's disease (late onset);	chr14:106780575	chr14:106762092~106762588:-
THCA	cis	rs7216064	0.906	rs7223643	ENSG00000278740.1	RP11-147L13.14	3.7	0.000241	0.0166	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834166	chr17:68188547~68189165:+
THCA	cis	rs12755164	0.75	rs12117582	ENSG00000223479.3	RP4-788P17.1	3.7	0.000241	0.0166	0.2	0.17	Schizophrenia;	chr1:72898763	chr1:73635216~73715214:+
THCA	cis	rs150992	0.673	rs331549	ENSG00000246763.5	RGMB-AS1	-3.7	0.000241	0.0166	-0.18	-0.17	Body mass index;	chr5:98805731	chr5:98769618~98773469:-
THCA	cis	rs150992	0.673	rs992775	ENSG00000246763.5	RGMB-AS1	-3.7	0.000241	0.0166	-0.18	-0.17	Body mass index;	chr5:98807754	chr5:98769618~98773469:-
THCA	cis	rs2135507	0.565	rs906150	ENSG00000270480.1	RP11-57B24.1	3.7	0.000241	0.0166	0.26	0.17	Juvenile osteochondritis dissecans;	chr4:82616533	chr4:82691737~82692468:+
THCA	cis	rs9309473	0.519	rs7598901	ENSG00000273245.1	RP11-434P11.2	-3.7	0.000241	0.0166	-0.2	-0.17	Metabolite levels;	chr2:73448717	chr2:73750256~73750786:-
THCA	cis	rs9353324	1	rs58334368	ENSG00000203875.9	SNHG5	-3.7	0.000241	0.0166	-0.32	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85971591	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.748	rs2421552	ENSG00000273245.1	RP11-434P11.2	3.7	0.000241	0.0166	0.24	0.17	Metabolite levels;	chr2:73531676	chr2:73750256~73750786:-
THCA	cis	rs2109514	0.765	rs768108	ENSG00000237813.3	AC002066.1	3.7	0.000241	0.0166	0.15	0.17	Prevalent atrial fibrillation;	chr7:116468604	chr7:116238260~116499465:-
THCA	cis	rs765787	0.53	rs28815867	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45234607	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4775822	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45234929	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11854294	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45235798	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs2413784	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45238318	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs7165889	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45239442	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11070451	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45241343	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs28897155	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45241776	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4775831	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45242524	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4775832	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45242630	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4442750	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45243130	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4444275	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45243149	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4270107	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45243152	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs4544188	ENSG00000259932.1	CTD-2651B20.7	3.7	0.000241	0.0166	0.2	0.17	Uric acid levels;	chr15:45243195	chr15:45198517~45199139:-
THCA	cis	rs3743772	1	rs62048488	ENSG00000279344.1	RP11-44F14.7	3.7	0.000241	0.0166	0.3	0.17	Depressive symptoms (SSRI exposure interaction);	chr16:53420027	chr16:53478957~53481550:-
THCA	cis	rs2832191	0.74	rs13048618	ENSG00000176054.6	RPL23P2	3.7	0.000241	0.0166	0.15	0.17	Dental caries;	chr21:29086363	chr21:28997613~28998033:-
THCA	cis	rs6696239	0.956	rs11581704	ENSG00000227711.2	RP11-275O4.5	-3.7	0.000241	0.0166	-0.23	-0.17	Height;	chr1:227621033	chr1:227509028~227520477:-
THCA	cis	rs6496667	0.865	rs8043146	ENSG00000259262.1	NDUFA3P4	3.7	0.000241	0.0166	0.22	0.17	Rheumatoid arthritis;	chr15:90307141	chr15:90385814~90386063:+
THCA	cis	rs9902453	0.845	rs3115099	ENSG00000264290.1	RP11-68I3.4	3.7	0.000241	0.0166	0.13	0.17	Coffee consumption (cups per day);	chr17:29692275	chr17:29569580~29570519:+
THCA	cis	rs9902453	0.845	rs58606097	ENSG00000264290.1	RP11-68I3.4	3.7	0.000241	0.0166	0.13	0.17	Coffee consumption (cups per day);	chr17:29693361	chr17:29569580~29570519:+
THCA	cis	rs9902453	0.845	rs3102559	ENSG00000264290.1	RP11-68I3.4	3.7	0.000241	0.0166	0.13	0.17	Coffee consumption (cups per day);	chr17:29702705	chr17:29569580~29570519:+
THCA	cis	rs7818345	0.64	rs3802329	ENSG00000279858.1	RP11-618M23.5	-3.7	0.000241	0.0166	-0.19	-0.17	Language performance in older adults (adjusted for episodic memory);	chr8:19409216	chr8:19375128~19375622:-
THCA	cis	rs12534093	0.883	rs11769806	ENSG00000234286.1	AC006026.13	-3.7	0.000241	0.0166	-0.26	-0.17	Infant length;Height;	chr7:23440513	chr7:23680195~23680786:-
THCA	cis	rs11685222	0.589	rs2272053	ENSG00000229326.3	AC069154.4	3.7	0.000241	0.0166	0.28	0.17	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119679197	chr2:119698623~119700151:+
THCA	cis	rs11123694	1	rs11123694	ENSG00000228763.1	AC010095.5	-3.7	0.000242	0.0166	-0.18	-0.17	Mean platelet volume;	chr2:108448107	chr2:108676795~108678601:-
THCA	cis	rs893363	0.522	rs11130381	ENSG00000271916.1	RP11-884K10.6	-3.7	0.000242	0.0166	-0.18	-0.17	Axial length;	chr3:53815978	chr3:53797764~53798019:-
THCA	cis	rs9341808	0.69	rs9448909	ENSG00000260645.1	RP11-250B2.5	3.7	0.000242	0.0166	0.14	0.17	Sitting height ratio;	chr6:80199314	chr6:80466958~80469080:+
THCA	cis	rs801193	1	rs13239306	ENSG00000223473.2	GS1-124K5.3	-3.7	0.000242	0.0166	-0.11	-0.17	Aortic root size;	chr7:66671030	chr7:66491049~66493566:-
THCA	cis	rs9584850	0.874	rs9168	ENSG00000231194.1	FARP1-AS1	3.7	0.000242	0.0166	0.21	0.17	Neuroticism;	chr13:98449329	chr13:98435405~98435840:-
THCA	cis	rs250585	1	rs1610	ENSG00000260136.4	CTD-2270L9.4	-3.7	0.000242	0.0166	-0.15	-0.17	Egg allergy;	chr16:23570832	chr16:23452758~23457606:+
THCA	cis	rs877819	0.583	rs2620894	ENSG00000228403.1	RP11-563N6.6	-3.7	0.000242	0.0166	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48858616	chr10:48878022~48878649:+
THCA	cis	rs1557488	0.553	rs7947480	ENSG00000260209.1	RP11-680F20.10	-3.7	0.000242	0.0166	-0.23	-0.17	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126865298	chr11:125873031~125874528:-
THCA	cis	rs1876905	0.764	rs4947106	ENSG00000271789.1	RP5-1112D6.7	3.7	0.000242	0.0166	0.2	0.17	Mean corpuscular hemoglobin;	chr6:111100163	chr6:111297126~111298510:+
THCA	cis	rs10129255	0.957	rs12589190	ENSG00000211972.2	IGHV3-66	3.7	0.000242	0.0166	0.1	0.17	Kawasaki disease;	chr14:106783079	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs7493713	ENSG00000211972.2	IGHV3-66	3.7	0.000242	0.0166	0.1	0.17	Kawasaki disease;	chr14:106783685	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.912	rs35468694	ENSG00000211972.2	IGHV3-66	3.7	0.000242	0.0166	0.1	0.17	Kawasaki disease;	chr14:106784199	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs8019272	ENSG00000211972.2	IGHV3-66	3.7	0.000242	0.0166	0.1	0.17	Kawasaki disease;	chr14:106784709	chr14:106675017~106675544:-
THCA	cis	rs7927592	0.513	rs901823	ENSG00000160172.9	FAM86C2P	3.7	0.000242	0.0166	0.16	0.17	Total body bone mineral density;	chr11:68438110	chr11:67791648~67805336:-
THCA	cis	rs7264396	0.836	rs2010565	ENSG00000088340.14	FER1L4	3.7	0.000242	0.0166	0.17	0.17	Total cholesterol levels;	chr20:35594595	chr20:35558737~35607562:-
THCA	cis	rs9435732	0.725	rs10437047	ENSG00000186301.8	MST1P2	-3.7	0.000242	0.0166	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16994933	chr1:16645622~16650289:+
THCA	cis	rs1039766	0.929	rs55843720	ENSG00000204929.10	AC074391.1	3.7	0.000242	0.0166	0.27	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr2:65436711~66084639:+
THCA	cis	rs2235642	0.507	rs2235645	ENSG00000260989.1	LA16c-395F10.2	-3.7	0.000242	0.0166	-0.2	-0.17	Coronary artery disease;	chr16:1547923	chr16:1580527~1610328:+
THCA	cis	rs2408955	0.568	rs12099462	ENSG00000257735.1	RP11-370I10.6	-3.7	0.000242	0.0166	-0.19	-0.17	Glycated hemoglobin levels;	chr12:48109321	chr12:48350945~48442411:+
THCA	cis	rs11168187	0.514	rs1476580	ENSG00000280054.1	RP1-197B17.7	3.7	0.000242	0.0166	0.21	0.17	Vertical cup-disc ratio;	chr12:47568068	chr12:47728151~47730598:-
THCA	cis	rs7923609	0.818	rs10761716	ENSG00000232075.1	MRPL35P2	-3.7	0.000242	0.0166	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63122540	chr10:63634317~63634827:-
THCA	cis	rs3733585	0.781	rs13103690	ENSG00000250413.1	RP11-448G15.1	3.7	0.000242	0.0166	0.17	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9971154	chr4:10006482~10009725:+
THCA	cis	rs6738028	0.524	rs7565445	ENSG00000227992.1	AC108463.2	-3.7	0.000242	0.0166	-0.21	-0.17	Dehydroepiandrosterone sulphate levels;	chr2:111177884	chr2:111203964~111206215:-
THCA	cis	rs13077017	0.509	rs3772987	ENSG00000272360.1	RP11-359I18.5	-3.7	0.000242	0.0166	-0.18	-0.17	Eating disorders (purging via substances);	chr3:58206068	chr3:58490830~58491291:-
THCA	cis	rs13077017	0.509	rs3772988	ENSG00000272360.1	RP11-359I18.5	-3.7	0.000242	0.0166	-0.18	-0.17	Eating disorders (purging via substances);	chr3:58206069	chr3:58490830~58491291:-
THCA	cis	rs7737355	0.679	rs76386054	ENSG00000224431.1	AC063976.7	-3.7	0.000242	0.0166	-0.24	-0.17	Life satisfaction;	chr5:131687465	chr5:132199456~132203487:+
THCA	cis	rs427394	0.582	rs4701751	ENSG00000248677.1	CTD-2044J15.1	3.7	0.000242	0.0166	0.16	0.17	Menopause (age at onset);	chr5:6704024	chr5:6686325~6707711:-
THCA	cis	rs4240897	0.935	rs3766744	ENSG00000201801.1	RNU5E-4P	3.7	0.000242	0.0166	0.19	0.17	Tuberculosis;	chr1:11983660	chr1:11909808~11909927:-
THCA	cis	rs7851693	0.928	rs10120359	ENSG00000232172.1	RP11-57C19.2	-3.7	0.000242	0.0166	-0.18	-0.17	Bone mineral density;	chr9:130567268	chr9:130651799~130652383:+
THCA	cis	rs7851693	0.928	rs7037020	ENSG00000232172.1	RP11-57C19.2	-3.7	0.000242	0.0166	-0.18	-0.17	Bone mineral density;	chr9:130569257	chr9:130651799~130652383:+
THCA	cis	rs791590	0.887	rs11591302	ENSG00000229664.1	RP11-536K7.5	-3.7	0.000242	0.0166	-0.28	-0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6009778	chr10:6025978~6036427:+
THCA	cis	rs7829975	0.606	rs7819827	ENSG00000254340.1	RP11-10A14.3	-3.7	0.000242	0.0166	-0.19	-0.17	Mood instability;	chr8:8939545	chr8:9141424~9145435:+
THCA	cis	rs6142618	0.84	rs2424884	ENSG00000224452.1	RSL24D1P6	-3.7	0.000242	0.0166	-0.2	-0.17	Inflammatory bowel disease;	chr20:32396527	chr20:32170390~32170790:-
THCA	cis	rs7551222	0.749	rs11240764	ENSG00000240219.1	RP11-430C7.5	3.7	0.000242	0.0166	0.15	0.17	Schizophrenia;	chr1:204600248	chr1:204626775~204629712:+
THCA	cis	rs7833790	1	rs7833384	ENSG00000254689.1	RP11-354A14.1	3.7	0.000242	0.0166	0.21	0.17	Diastolic blood pressure;	chr8:81818680	chr8:81885377~81923193:+
THCA	cis	rs5758511	0.68	rs5751243	ENSG00000237037.8	NDUFA6-AS1	-3.7	0.000242	0.0166	-0.16	-0.17	Birth weight;	chr22:42221171	chr22:42090931~42137742:+
THCA	cis	rs7927592	0.956	rs11228258	ENSG00000160172.9	FAM86C2P	-3.7	0.000242	0.0166	-0.16	-0.17	Total body bone mineral density;	chr11:68486860	chr11:67791648~67805336:-
THCA	cis	rs860295	0.54	rs11264426	ENSG00000236675.1	MTX1P1	3.7	0.000242	0.0166	0.17	0.17	Body mass index;	chr1:155971157	chr1:155230975~155234325:+
THCA	cis	rs34102591	0.826	rs71458829	ENSG00000269997.1	RP11-214K3.21	-3.7	0.000242	0.0166	-0.27	-0.17	Schizophrenia;	chr12:123986200	chr12:123966077~123966629:-
THCA	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	3.7	0.000242	0.0166	0.15	0.17	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
THCA	cis	rs950169	0.959	rs12911210	ENSG00000275120.1	RP11-182J1.17	3.7	0.000242	0.0166	0.2	0.17	Schizophrenia;	chr15:84123331	chr15:84599434~84606463:-
THCA	cis	rs7615952	0.599	rs2270986	ENSG00000241288.6	RP11-379B18.5	-3.7	0.000242	0.0166	-0.19	-0.17	Blood pressure (smoking interaction);	chr3:125982256	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.599	rs12496921	ENSG00000241288.6	RP11-379B18.5	-3.7	0.000242	0.0166	-0.19	-0.17	Blood pressure (smoking interaction);	chr3:125983105	chr3:125827238~125916384:-
THCA	cis	rs6929812	0.577	rs2294308	ENSG00000271755.1	RP1-153G14.4	3.7	0.000242	0.0167	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27515481	chr6:27404010~27406964:-
THCA	cis	rs17772222	0.682	rs7142053	ENSG00000222990.1	RNU4-22P	3.7	0.000242	0.0167	0.2	0.17	Coronary artery calcification;	chr14:88511594	chr14:88513498~88513663:+
THCA	cis	rs854765	0.624	rs11652144	ENSG00000281749.1	Y_RNA	-3.7	0.000242	0.0167	-0.22	-0.17	Total body bone mineral density;	chr17:17830620	chr17:18001101~18001195:-
THCA	cis	rs854765	0.624	rs1889018	ENSG00000281749.1	Y_RNA	-3.7	0.000242	0.0167	-0.22	-0.17	Total body bone mineral density;	chr17:17831426	chr17:18001101~18001195:-
THCA	cis	rs241257	0.922	rs241268	ENSG00000227372.9	TP73-AS1	3.7	0.000242	0.0167	0.21	0.17	Anxiety disorder;	chr1:4562580	chr1:3735601~3747336:-
THCA	cis	rs1926657	0.932	rs1678403	ENSG00000223298.1	RNY3P8	-3.7	0.000242	0.0167	-0.24	-0.17	Breast cancer;	chr13:95209727	chr13:95310830~95310955:-
THCA	cis	rs2839186	0.9	rs2839200	ENSG00000228137.1	AP001469.7	3.7	0.000242	0.0167	0.17	0.17	Testicular germ cell tumor;	chr21:46289181	chr21:46246890~46247682:+
THCA	cis	rs9341808	0.718	rs6910201	ENSG00000260645.1	RP11-250B2.5	3.7	0.000242	0.0167	0.14	0.17	Sitting height ratio;	chr6:80195221	chr6:80466958~80469080:+
THCA	cis	rs7959452	0.558	rs1478464	ENSG00000274979.1	RP11-1143G9.5	-3.7	0.000242	0.0167	-0.18	-0.17	Blood protein levels;	chr12:69386009	chr12:69326574~69331882:-
THCA	cis	rs804280	0.56	rs10503426	ENSG00000270154.1	RP11-419I17.1	3.7	0.000242	0.0167	0.21	0.17	Myopia (pathological);	chr8:11731874	chr8:12476462~12477122:+
THCA	cis	rs2688608	0.62	rs7076525	ENSG00000272140.2	RP11-574K11.29	3.7	0.000242	0.0167	0.14	0.17	Inflammatory bowel disease;	chr10:73753039	chr10:73703735~73713581:-
THCA	cis	rs2688608	0.592	rs7908825	ENSG00000272140.2	RP11-574K11.29	-3.7	0.000242	0.0167	-0.14	-0.17	Inflammatory bowel disease;	chr10:73794783	chr10:73703735~73713581:-
THCA	cis	rs944289	0.646	rs394246	ENSG00000258844.1	RP11-259K15.2	-3.7	0.000242	0.0167	-0.15	-0.17	Thyroid cancer;	chr14:36066074	chr14:36214607~36235608:+
THCA	cis	rs2455799	0.594	rs11928773	ENSG00000270409.1	RP11-44D5.1	-3.7	0.000242	0.0167	-0.18	-0.17	Mean platelet volume;	chr3:15883628	chr3:15732252~15733470:+
THCA	cis	rs2051773	0.538	rs4468326	ENSG00000184669.7	OR7E14P	-3.7	0.000242	0.0167	-0.23	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17019487	chr11:17013998~17053024:+
THCA	cis	rs6472235	0.837	rs6985149	ENSG00000272192.1	CTD-2532N20.1	3.7	0.000242	0.0167	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65989166	chr8:65842752~65843331:+
THCA	cis	rs9435732	0.594	rs2647166	ENSG00000235241.1	RP11-108M9.5	-3.7	0.000242	0.0167	-0.19	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17016240	chr1:16889095~16889602:+
THCA	cis	rs1065852	0.526	rs1062753	ENSG00000232710.1	RP4-669P10.16	-3.7	0.000242	0.0167	-0.21	-0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41996807	chr22:42136433~42139927:-
THCA	cis	rs131777	0.575	rs963980	ENSG00000205559.3	CHKB-AS1	-3.7	0.000242	0.0167	-0.21	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50583026~50583877:+
THCA	cis	rs1842579	1	rs6697619	ENSG00000272691.1	RP11-290M5.4	-3.7	0.000242	0.0167	-0.16	-0.17	Coronary artery aneurysm in Kawasaki disease;	chr1:85824030	chr1:85578500~85578742:-
THCA	cis	rs4356203	0.84	rs7942094	ENSG00000272034.1	SNORD14A	-3.7	0.000242	0.0167	-0.17	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17237862	chr11:17074654~17074744:-
THCA	cis	rs12681366	0.801	rs2011246	ENSG00000253175.1	RP11-267M23.6	3.7	0.000242	0.0167	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.801	rs2043988	ENSG00000253175.1	RP11-267M23.6	3.7	0.000242	0.0167	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.801	rs2930956	ENSG00000253175.1	RP11-267M23.6	3.7	0.000242	0.0167	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.801	rs55963151	ENSG00000253175.1	RP11-267M23.6	3.7	0.000242	0.0167	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:94565036~94565715:+
THCA	cis	rs9584850	0.522	rs9517299	ENSG00000231194.1	FARP1-AS1	3.7	0.000242	0.0167	0.2	0.17	Neuroticism;	chr13:98442777	chr13:98435405~98435840:-
THCA	cis	rs17095355	0.818	rs11195006	ENSG00000203876.8	ADD3-AS1	-3.7	0.000242	0.0167	-0.18	-0.17	Biliary atresia;	chr10:110143548	chr10:109940104~110008381:-
THCA	cis	rs9287719	0.967	rs10929682	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10592063	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.901	rs10210859	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10593803	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs715247	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10596165	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs715246	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10596229	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs2010073	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10596352	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs2010080	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10596426	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.901	rs6432109	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10596695	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7592691	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10597300	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs6432110	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10597892	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7605461	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10598008	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7593496	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10598050	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7608498	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10598302	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7582775	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10598323	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6750891	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10598437	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6733416	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10598558	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6751398	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10598846	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4519489	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10598961	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4453662	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599002	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.901	rs13034017	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599466	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs13034061	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599525	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.935	rs7600495	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599674	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7600587	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599725	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.839	rs7600695	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599819	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7587114	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599837	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7600728	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599873	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7600820	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599918	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7587231	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10599967	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4668691	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10600368	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs10181806	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10601015	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs11687023	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10601286	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs10454738	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10601923	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6706542	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10602365	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs2287061	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10603027	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs2287062	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10603065	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.935	rs1309	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10603420	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs3815521	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10603528	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4470306	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10603872	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4613248	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10603925	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs10191883	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10604010	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs4629131	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10604033	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.901	rs4555317	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10604121	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4555318	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10604169	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs4622695	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10604201	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs6432111	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10604494	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6432114	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10604804	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.87	rs728135	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10605006	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs963831	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10605058	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs728134	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10605061	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs2884233	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10605177	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.839	rs12692415	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10605348	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs12692416	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10605501	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs12692417	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10605592	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs12692418	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10605744	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6755548	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10606000	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6761678	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10606215	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6759100	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10606584	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6759714	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10607081	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6744854	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10607120	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6759740	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10607145	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6709466	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10608131	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6719701	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10608157	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs6432115	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10608217	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6432116	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10608489	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs2110776	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10608684	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs2110778	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10608844	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6432117	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10609233	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6432118	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10609315	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.935	rs728283	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10609964	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs728282	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10610177	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs728281	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10610229	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs6706763	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10611281	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs9679581	ENSG00000243819.4	RN7SL832P	3.7	0.000242	0.0167	0.13	0.17	Prostate cancer;	chr2:10611610	chr2:10690344~10692099:+
THCA	cis	rs13053505	0.84	rs1569409	ENSG00000235209.1	CTA-150C2.13	-3.7	0.000242	0.0167	-0.26	-0.17	Menarche (age at onset);	chr22:38824355	chr22:38921227~38924708:+
THCA	cis	rs2278034	0.502	rs3747672	ENSG00000229178.1	AC069513.4	-3.7	0.000242	0.0167	-0.17	-0.17	Bronchopulmonary dysplasia;	chr3:195885163	chr3:195655565~195657927:-
THCA	cis	rs860295	0.966	rs821551	ENSG00000160766.13	GBAP1	-3.7	0.000242	0.0167	-0.19	-0.17	Body mass index;	chr1:155718789	chr1:155213821~155227422:-
THCA	cis	rs1555322	0.745	rs2425017	ENSG00000126005.14	MMP24-AS1	-3.7	0.000242	0.0167	-0.22	-0.17	Attention deficit hyperactivity disorder;	chr20:35229835	chr20:35216462~35278131:-
THCA	cis	rs7216064	0.817	rs28609796	ENSG00000265055.1	AC145343.2	3.7	0.000242	0.0167	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67858988	chr17:68096046~68101474:-
THCA	cis	rs6163	0.588	rs11191392	ENSG00000213061.2	PFN1P11	3.7	0.000242	0.0167	0.19	0.17	Waist circumference;Hip circumference;	chr10:102767194	chr10:102838011~102845473:-
THCA	cis	rs62289301	0.637	rs1990524	ENSG00000273133.1	RP11-799M12.2	3.7	0.000242	0.0167	0.21	0.17	Joint mobility (Beighton score);	chr4:15419209	chr4:15563698~15564253:-
THCA	cis	rs17385675	1	rs17385675	ENSG00000252148.1	RNU6-1206P	-3.7	0.000242	0.0167	-0.34	-0.17	Response to antipsychotic treatment;	chr2:201942473	chr2:201079842~201079944:+
THCA	cis	rs409045	1	rs455919	ENSG00000271874.1	CTD-2024P10.2	-3.7	0.000242	0.0167	-0.22	-0.17	Left ventricular mass;	chr5:34637098	chr5:34651457~34651888:-
THCA	cis	rs7166081	1	rs34699563	ENSG00000270964.1	RP11-502I4.3	-3.7	0.000243	0.0167	-0.15	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67221879	chr15:67541072~67542604:-
THCA	cis	rs7166081	0.951	rs12594065	ENSG00000270964.1	RP11-502I4.3	-3.7	0.000243	0.0167	-0.15	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67225663	chr15:67541072~67542604:-
THCA	cis	rs9473147	0.798	rs4711895	ENSG00000270761.1	RP11-385F7.1	3.7	0.000243	0.0167	0.13	0.17	Platelet distribution width;Mean platelet volume;	chr6:47659291	chr6:47477243~47477572:-
THCA	cis	rs34975555	0.892	rs17126008	ENSG00000253671.1	RP11-806O11.1	-3.7	0.000243	0.0167	-0.26	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17950219	chr8:17808941~17820868:+
THCA	cis	rs17723470	0.643	rs12274428	ENSG00000254427.1	RP11-430H10.1	3.7	0.000243	0.0167	0.18	0.17	Thyroid hormone levels;	chr11:45237078	chr11:45355371~45366121:+
THCA	cis	rs7246657	0.882	rs59224125	ENSG00000268499.1	CTB-102L5.8	3.7	0.000243	0.0167	0.21	0.17	Coronary artery calcification;	chr19:37472303	chr19:38199836~38200934:+
THCA	cis	rs11088226	0.709	rs55860967	ENSG00000186842.4	LINC00846	-3.7	0.000243	0.0167	-0.23	-0.17	Gastritis;	chr21:32507708	chr21:32572238~32575881:-
THCA	cis	rs3808502	0.563	rs12549144	ENSG00000154316.13	TDH	-3.7	0.000243	0.0167	-0.13	-0.17	Neuroticism;	chr8:11565352	chr8:11339637~11368452:+
THCA	cis	rs3758911	0.929	rs10789600	ENSG00000255353.1	RP11-382M14.1	-3.7	0.000243	0.0167	-0.22	-0.17	Coronary artery disease;	chr11:107310335	chr11:107176286~107177530:+
THCA	cis	rs6969780	0.545	rs983184	ENSG00000233429.8	HOTAIRM1	-3.7	0.000243	0.0167	-0.2	-0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27148760	chr7:27095647~27100265:+
THCA	cis	rs9925964	0.9	rs56813533	ENSG00000279196.1	RP11-1072A3.3	-3.7	0.000243	0.0167	-0.16	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31059160	chr16:30984630~30988270:-
THCA	cis	rs1559040	0.858	rs10192403	ENSG00000272156.1	RP11-477N3.1	-3.7	0.000243	0.0167	-0.25	-0.17	Sudden cardiac arrest;	chr2:54086370	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.932	rs10205315	ENSG00000272156.1	RP11-477N3.1	-3.7	0.000243	0.0167	-0.25	-0.17	Sudden cardiac arrest;	chr2:54086864	chr2:54082554~54085066:+
THCA	cis	rs5006884	0.585	rs9665744	ENSG00000167355.6	AC104389.28	3.7	0.000243	0.0167	0.28	0.17	Fetal hemoglobin levels;	chr11:5429418	chr11:5304976~5505652:-
THCA	cis	rs12681366	0.881	rs2381793	ENSG00000253175.1	RP11-267M23.6	3.7	0.000243	0.0167	0.22	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94388167	chr8:94565036~94565715:+
THCA	cis	rs972578	0.967	rs4822236	ENSG00000230319.1	AL022476.2	3.7	0.000243	0.0167	0.18	0.17	Mean platelet volume;	chr22:42962082	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs5759059	ENSG00000230319.1	AL022476.2	3.7	0.000243	0.0167	0.18	0.17	Mean platelet volume;	chr22:42962486	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs5751404	ENSG00000230319.1	AL022476.2	3.7	0.000243	0.0167	0.18	0.17	Mean platelet volume;	chr22:42962731	chr22:43038585~43052366:+
THCA	cis	rs7259376	0.729	rs3867187	ENSG00000269138.1	ZNF209P	3.7	0.000243	0.0167	0.17	0.17	Menopause (age at onset);	chr19:22387418	chr19:22463922~22473036:+
THCA	cis	rs6560517	0.71	rs4745552	ENSG00000234618.1	RPSAP9	-3.7	0.000243	0.0167	-0.2	-0.17	Dialysis-related mortality;	chr9:76482228	chr9:76398699~76399586:+
THCA	cis	rs7246967	0.673	rs937078	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22628865	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12978794	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22629332	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs4932782	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22629999	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs66866654	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22630937	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs73028776	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22630938	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs56968124	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22631647	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs57775631	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22631659	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs2361021	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22633522	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs2361022	ENSG00000198153.8	ZNF849P	-3.7	0.000243	0.0167	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22633731	chr19:22685167~22686732:+
THCA	cis	rs4792901	0.802	rs2271958	ENSG00000267151.3	RP11-100E5.2	3.7	0.000243	0.0167	0.19	0.17	Dupuytren's disease;	chr17:43522015	chr17:43444707~43451200:+
THCA	cis	rs13256369	0.802	rs13281933	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8705155	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.756	rs13282580	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8705393	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs13258283	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8706120	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs13249700	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8706127	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs13254997	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8706243	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs13255061	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8706324	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs12541477	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8706385	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs13266562	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8706555	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs13256611	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8706831	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs11786125	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8707060	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.802	rs11249888	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8707424	chr8:8456909~8461337:-
THCA	cis	rs13256369	0.851	rs11249889	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.19	-0.17	Obesity-related traits;	chr8:8707482	chr8:8456909~8461337:-
THCA	cis	rs875971	0.638	rs7793569	ENSG00000232546.1	RP11-458F8.1	3.7	0.000243	0.0167	0.14	0.17	Aortic root size;	chr7:66651646	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs6975195	ENSG00000232546.1	RP11-458F8.1	3.7	0.000243	0.0167	0.14	0.17	Aortic root size;	chr7:66659787	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs3857688	ENSG00000232546.1	RP11-458F8.1	3.7	0.000243	0.0167	0.14	0.17	Aortic root size;	chr7:66662819	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs2286684	ENSG00000232546.1	RP11-458F8.1	3.7	0.000243	0.0167	0.14	0.17	Aortic root size;	chr7:66664843	chr7:66848496~66858136:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000232546.1	RP11-458F8.1	3.7	0.000243	0.0167	0.14	0.17	Aortic root size;	chr7:66664856	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs10274773	ENSG00000232546.1	RP11-458F8.1	3.7	0.000243	0.0167	0.14	0.17	Aortic root size;	chr7:66668591	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs11773829	ENSG00000232546.1	RP11-458F8.1	3.7	0.000243	0.0167	0.14	0.17	Aortic root size;	chr7:66676087	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs7788576	ENSG00000232546.1	RP11-458F8.1	3.7	0.000243	0.0167	0.14	0.17	Aortic root size;	chr7:66683315	chr7:66848496~66858136:+
THCA	cis	rs801193	0.935	rs2659916	ENSG00000232546.1	RP11-458F8.1	-3.7	0.000243	0.0167	-0.14	-0.17	Aortic root size;	chr7:66686365	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs6958520	ENSG00000232546.1	RP11-458F8.1	-3.7	0.000243	0.0167	-0.14	-0.17	Aortic root size;	chr7:66686466	chr7:66848496~66858136:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000232546.1	RP11-458F8.1	-3.7	0.000243	0.0167	-0.14	-0.17	Aortic root size;	chr7:66687725	chr7:66848496~66858136:+
THCA	cis	rs1023500	0.573	rs133381	ENSG00000237037.8	NDUFA6-AS1	-3.7	0.000243	0.0167	-0.14	-0.17	Schizophrenia;	chr22:42074604	chr22:42090931~42137742:+
THCA	cis	rs73230612	0.676	rs2178555	ENSG00000242767.1	ZBTB20-AS4	-3.7	0.000243	0.0167	-0.25	-0.17	Type 2 diabetes;	chr3:114715311	chr3:115100423~115103061:+
THCA	cis	rs10256972	0.524	rs6945202	ENSG00000199023.2	MIR339	-3.7	0.000243	0.0167	-0.18	-0.17	Endometriosis;Longevity;	chr7:1076922	chr7:1022935~1023045:-
THCA	cis	rs12962334	0.518	rs4800141	ENSG00000273232.1	RP11-370A5.2	3.7	0.000243	0.0167	0.22	0.17	Breast cancer;	chr18:22984312	chr18:22882825~22883357:-
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000280107.1	AL022393.9	3.7	0.000243	0.0167	0.16	0.17	Pubertal anthropometrics;	chr6:28255953	chr6:28170845~28172521:+
THCA	cis	rs73198271	0.813	rs17697237	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000243	0.0167	-0.21	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8456909~8461337:-
THCA	cis	rs7824557	0.564	rs2736293	ENSG00000255495.1	AC145124.2	-3.7	0.000243	0.0167	-0.19	-0.17	Retinal vascular caliber;	chr8:11377104	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.564	rs2736294	ENSG00000255495.1	AC145124.2	-3.7	0.000243	0.0167	-0.19	-0.17	Retinal vascular caliber;	chr8:11377117	chr8:12194467~12196280:+
THCA	cis	rs1411478	1	rs1044595	ENSG00000243155.1	RP11-46A10.5	3.7	0.000243	0.0167	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180974393	chr1:180944042~180976482:-
THCA	cis	rs586688	0.625	rs510576	ENSG00000224536.1	RP11-134G8.7	-3.7	0.000243	0.0167	-0.26	-0.17	Obesity-related traits;	chr1:201685834	chr1:201507241~201533608:+
THCA	cis	rs804280	0.509	rs12719915	ENSG00000255495.1	AC145124.2	-3.7	0.000243	0.0167	-0.2	-0.17	Myopia (pathological);	chr8:11928746	chr8:12194467~12196280:+
THCA	cis	rs4742903	0.935	rs7853727	ENSG00000270332.1	SMC2-AS1	3.7	0.000243	0.0167	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104227767	chr9:104080024~104093073:-
THCA	cis	rs2803122	0.502	rs7873489	ENSG00000272842.1	RP11-513M16.7	-3.7	0.000243	0.0167	-0.18	-0.17	Pulse pressure;	chr9:19384789	chr9:19371386~19371945:-
THCA	cis	rs10089	1	rs10478798	ENSG00000245937.6	LINC01184	3.7	0.000243	0.0167	0.19	0.17	Ileal carcinoids;	chr5:128106702	chr5:127940426~128083172:-
THCA	cis	rs4761470	0.649	rs8553	ENSG00000258172.1	RP11-1105G2.4	-3.7	0.000243	0.0167	-0.24	-0.17	Estradiol plasma levels (breast cancer);	chr12:94307542	chr12:94272150~94277195:-
THCA	cis	rs806215	0.547	rs322820	ENSG00000224138.1	AC000123.4	3.7	0.000243	0.0167	0.17	0.17	Type 2 diabetes;	chr7:128091566	chr7:127350128~127351523:+
THCA	cis	rs889312	0.924	rs1910020	ENSG00000271828.1	CTD-2310F14.1	-3.7	0.000243	0.0167	-0.24	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56730673	chr5:56927874~56929573:+
THCA	cis	rs7824557	0.614	rs10503421	ENSG00000206014.6	OR7E161P	-3.7	0.000243	0.0167	-0.2	-0.17	Retinal vascular caliber;	chr8:11363804	chr8:11928597~11929563:-
THCA	cis	rs240993	0.516	rs241004	ENSG00000271789.1	RP5-1112D6.7	-3.7	0.000243	0.0167	-0.22	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111275341	chr6:111297126~111298510:+
THCA	cis	rs4664304	0.649	rs12692570	ENSG00000226266.5	AC009961.3	-3.7	0.000243	0.0167	-0.19	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159870088	chr2:159670708~159712435:-
THCA	cis	rs10090774	0.813	rs10098028	ENSG00000280303.2	ERICD	-3.7	0.000243	0.0167	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141000954	chr8:140636281~140638283:+
THCA	cis	rs11233413	0.874	rs3793986	ENSG00000246067.6	RAB30-AS1	3.7	0.000243	0.0167	0.17	0.17	Economic and political preferences (feminism/equality);	chr11:82993925	chr11:83072066~83106719:+
THCA	cis	rs11233413	0.874	rs3793987	ENSG00000246067.6	RAB30-AS1	3.7	0.000243	0.0167	0.17	0.17	Economic and political preferences (feminism/equality);	chr11:82993926	chr11:83072066~83106719:+
THCA	cis	rs2360027	0.662	rs12120076	ENSG00000231365.4	RP11-418J17.1	-3.7	0.000243	0.0167	-0.17	-0.17	Tonsillectomy;	chr1:118606316	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.662	rs28718637	ENSG00000231365.4	RP11-418J17.1	-3.7	0.000243	0.0167	-0.17	-0.17	Tonsillectomy;	chr1:118606607	chr1:119140396~119275973:+
THCA	cis	rs2074409	0.53	rs7224979	ENSG00000277501.1	RP11-697E22.2	-3.7	0.000243	0.0167	-0.24	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37593525	chr17:37642947~37684252:+
THCA	cis	rs1667255	1	rs1080093	ENSG00000266521.1	RP11-650P15.1	3.7	0.000243	0.0167	0.21	0.17	Retinol levels;	chr18:31593717	chr18:31496645~31497195:-
THCA	cis	rs8033133	0.647	rs1124767	ENSG00000251896.1	SNORD116-27	-3.7	0.000243	0.0167	-0.19	-0.17	Blood osmolality (transformed sodium);	chr15:25081026	chr15:25101575~25101666:+
THCA	cis	rs11069062	0.866	rs11069057	ENSG00000270482.1	RP11-131L12.2	3.7	0.000243	0.0167	0.14	0.17	Obesity-related traits;	chr12:118706472	chr12:118375350~118376275:-
THCA	cis	rs858239	0.899	rs28635122	ENSG00000226816.2	AC005082.12	3.7	0.000243	0.0167	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23206013~23208045:+
THCA	cis	rs6560517	0.789	rs11144922	ENSG00000234618.1	RPSAP9	-3.7	0.000243	0.0167	-0.19	-0.17	Dialysis-related mortality;	chr9:76481743	chr9:76398699~76399586:+
THCA	cis	rs614226	1	rs1167725	ENSG00000278344.1	RP11-18C24.8	3.7	0.000243	0.0167	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120530756	chr12:120500735~120501090:-
THCA	cis	rs614226	0.744	rs787832	ENSG00000278344.1	RP11-18C24.8	3.7	0.000243	0.0167	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120548998	chr12:120500735~120501090:-
THCA	cis	rs11098499	0.754	rs10518300	ENSG00000249244.1	RP11-548H18.2	-3.7	0.000243	0.0167	-0.2	-0.17	Corneal astigmatism;	chr4:119328344	chr4:119391831~119395335:-
THCA	cis	rs2251188	0.837	rs1474419	ENSG00000198580.7	RP11-611L7.2	-3.7	0.000243	0.0167	-0.19	-0.17	Sum basophil neutrophil counts;Neutrophil count;	chr7:6652974	chr7:6673494~6676366:+
THCA	cis	rs972578	0.837	rs4822228	ENSG00000274717.1	RP1-47A17.1	-3.7	0.000243	0.0167	-0.17	-0.17	Mean platelet volume;	chr22:42924210	chr22:42791814~42794313:-
THCA	cis	rs12681366	0.881	rs12682038	ENSG00000253175.1	RP11-267M23.6	3.7	0.000243	0.0167	0.22	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94393252	chr8:94565036~94565715:+
THCA	cis	rs10129255	0.956	rs10137268	ENSG00000274576.2	IGHV2-70	3.7	0.000243	0.0167	0.12	0.17	Kawasaki disease;	chr14:106697402	chr14:106770577~106771020:-
THCA	cis	rs7246657	0.941	rs12982333	ENSG00000268499.1	CTB-102L5.8	3.7	0.000243	0.0167	0.22	0.17	Coronary artery calcification;	chr19:37303822	chr19:38199836~38200934:+
THCA	cis	rs7246657	1	rs10426297	ENSG00000268499.1	CTB-102L5.8	3.7	0.000243	0.0167	0.22	0.17	Coronary artery calcification;	chr19:37307471	chr19:38199836~38200934:+
THCA	cis	rs7246657	1	rs1823061	ENSG00000268499.1	CTB-102L5.8	3.7	0.000243	0.0167	0.22	0.17	Coronary artery calcification;	chr19:37309724	chr19:38199836~38200934:+
THCA	cis	rs875971	0.545	rs73142245	ENSG00000273024.4	INTS4P2	-3.7	0.000243	0.0167	-0.21	-0.17	Aortic root size;	chr7:66226662	chr7:65647864~65715661:+
THCA	cis	rs4272720	0.562	rs4364979	ENSG00000234736.4	FAM170B-AS1	-3.7	0.000243	0.0167	-0.18	-0.17	Platelet count;Plateletcrit;	chr10:49112466	chr10:49121839~49151547:+
THCA	cis	rs877819	0.583	rs2663049	ENSG00000228403.1	RP11-563N6.6	-3.7	0.000243	0.0167	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48858716	chr10:48878022~48878649:+
THCA	cis	rs12544026	0.581	rs497905	ENSG00000253669.3	KB-1732A1.1	-3.7	0.000243	0.0167	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101867269	chr8:102805517~102809971:+
THCA	cis	rs2236231	0.55	rs2038490	ENSG00000259648.1	RP11-643G16.4	-3.7	0.000243	0.0167	-0.21	-0.17	Plasma kynurenine levels in major depressive disorder;	chr14:67593658	chr14:67614929~67616626:+
THCA	cis	rs2033711	0.87	rs1465789	ENSG00000268049.1	CTD-2619J13.9	-3.7	0.000244	0.0167	-0.21	-0.17	Uric acid clearance;	chr19:58434689	chr19:58357999~58359603:+
THCA	cis	rs881375	0.715	rs10818482	ENSG00000238181.2	AHCYP2	3.7	0.000244	0.0167	0.2	0.17	Rheumatoid arthritis;	chr9:120885807	chr9:120720673~120721972:+
THCA	cis	rs7264396	0.666	rs1536147	ENSG00000088340.14	FER1L4	-3.7	0.000244	0.0167	-0.16	-0.17	Total cholesterol levels;	chr20:35585124	chr20:35558737~35607562:-
THCA	cis	rs7829975	0.567	rs6601273	ENSG00000254340.1	RP11-10A14.3	-3.7	0.000244	0.0167	-0.19	-0.17	Mood instability;	chr8:8939009	chr8:9141424~9145435:+
THCA	cis	rs755249	1	rs17513135	ENSG00000182109.6	RP11-69E11.4	3.7	0.000244	0.0167	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39522280~39546187:-
THCA	cis	rs478304	0.654	rs7947604	ENSG00000255557.1	RP11-770G2.2	3.7	0.000244	0.0167	0.2	0.17	Acne (severe);	chr11:65674588	chr11:65745729~65771585:+
THCA	cis	rs2274273	0.87	rs11851169	ENSG00000258469.1	CHMP4BP1	3.7	0.000244	0.0167	0.15	0.17	Protein biomarker;	chr14:55349214	chr14:55298644~55299231:+
THCA	cis	rs11212260	1	rs75947863	ENSG00000261098.1	RP11-819C21.1	3.7	0.000244	0.0167	0.35	0.17	IgG glycosylation;	chr11:107478449	chr11:107312132~107316271:-
THCA	cis	rs6938	0.618	rs11638130	ENSG00000260269.4	CTD-2323K18.1	-3.7	0.000244	0.0167	-0.24	-0.17	Breast cancer;	chr15:74891594	chr15:75527150~75601205:-
THCA	cis	rs1062753	0.731	rs11914200	ENSG00000273366.1	CTA-989H11.1	3.7	0.000244	0.0167	0.22	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41982066	chr22:42278188~42278846:+
THCA	cis	rs62244186	0.659	rs9873072	ENSG00000214820.3	MPRIPP1	3.7	0.000244	0.0167	0.18	0.17	Depressive symptoms;	chr3:44475004	chr3:44579938~44581026:-
THCA	cis	rs13053817	1	rs13055707	ENSG00000279159.1	RP3-394A18.1	3.7	0.000244	0.0167	0.17	0.17	Carotid atherosclerosis in HIV infection;	chr22:29455183	chr22:29978950~30028236:-
THCA	cis	rs13053817	1	rs7290855	ENSG00000279159.1	RP3-394A18.1	3.7	0.000244	0.0167	0.17	0.17	Carotid atherosclerosis in HIV infection;	chr22:29456485	chr22:29978950~30028236:-
THCA	cis	rs13118159	0.714	rs6843025	ENSG00000254094.1	AC078852.1	-3.7	0.000244	0.0167	-0.19	-0.17	Longevity;	chr4:1340630	chr4:1356581~1358075:+
THCA	cis	rs13118159	0.771	rs13117476	ENSG00000254094.1	AC078852.1	-3.7	0.000244	0.0167	-0.19	-0.17	Longevity;	chr4:1340933	chr4:1356581~1358075:+
THCA	cis	rs72996113	0.702	rs78901113	ENSG00000248027.1	CTD-2383M3.1	-3.7	0.000244	0.0167	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100697708	chr11:100684162~100687955:-
THCA	cis	rs72996113	0.702	rs11224393	ENSG00000248027.1	CTD-2383M3.1	-3.7	0.000244	0.0167	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100698290	chr11:100684162~100687955:-
THCA	cis	rs6449957	0.639	rs831227	ENSG00000249335.1	CTC-340D7.1	3.7	0.000244	0.0168	0.2	0.17	Cleft lip with or without cleft palate;	chr5:68221818	chr5:68832585~68962158:-
THCA	cis	rs5753037	0.702	rs140101	ENSG00000279699.1	RP1-102K2.9	3.7	0.000244	0.0168	0.17	0.17	Type 1 diabetes;	chr22:29732391	chr22:30275215~30276951:-
THCA	cis	rs1991651	0.578	rs11778453	ENSG00000261451.1	RP11-981G7.1	-3.7	0.000244	0.0168	-0.2	-0.17	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632326	chr8:10433672~10438312:+
THCA	cis	rs13034020	0.641	rs12996153	ENSG00000271889.1	RP11-493E12.1	3.7	0.000244	0.0168	0.23	0.17	Hodgkin's lymphoma;	chr2:60995601	chr2:61151433~61162105:-
THCA	cis	rs10911902	0.56	rs76317001	ENSG00000233196.2	GS1-304P7.1	-3.7	0.000244	0.0168	-0.27	-0.17	Schizophrenia;	chr1:186303357	chr1:186580515~186581191:-
THCA	cis	rs78153629	1	rs78153629	ENSG00000259405.1	ISCA1P4	3.7	0.000244	0.0168	0.31	0.17	Heschl's gyrus morphology;	chr15:40381264	chr15:40948736~40948869:-
THCA	cis	rs78153629	1	rs77531164	ENSG00000259405.1	ISCA1P4	3.7	0.000244	0.0168	0.31	0.17	Heschl's gyrus morphology;	chr15:40381265	chr15:40948736~40948869:-
THCA	cis	rs2638953	0.853	rs3898068	ENSG00000247934.4	RP11-967K21.1	-3.7	0.000244	0.0168	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457084	chr12:28163298~28190738:-
THCA	cis	rs2749592	0.918	rs11011388	ENSG00000120555.12	SEPT7P9	-3.7	0.000244	0.0168	-0.2	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37866282	chr10:38383069~38402916:-
THCA	cis	rs9400467	0.537	rs12196955	ENSG00000255389.1	C6orf3	3.7	0.000244	0.0168	0.23	0.17	Amino acid levels;Blood metabolite levels;	chr6:111121734	chr6:111599875~111602295:+
THCA	cis	rs1555322	0.53	rs6060347	ENSG00000269202.1	RP4-614O4.12	-3.7	0.000244	0.0168	-0.18	-0.17	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35201747~35203288:-
THCA	cis	rs6138458	0.626	rs6138473	ENSG00000274173.1	RP4-568C11.4	-3.7	0.000244	0.0168	-0.14	-0.17	Blood protein levels;	chr20:25031519	chr20:24931840~24932983:+
THCA	cis	rs9309473	0.95	rs17009149	ENSG00000273245.1	RP11-434P11.2	3.7	0.000244	0.0168	0.23	0.17	Metabolite levels;	chr2:73563241	chr2:73750256~73750786:-
THCA	cis	rs11089937	0.963	rs2226943	ENSG00000263366.2	LL22NC03-33B6.4	-3.7	0.000244	0.0168	-0.21	-0.17	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22114844~22118005:-
THCA	cis	rs11800820	0.567	rs3124118	ENSG00000231612.1	RP11-522M21.3	3.7	0.000244	0.0168	0.22	0.17	Obesity-related traits;	chr1:246544190	chr1:245673732~245676478:-
THCA	cis	rs7259376	0.936	rs34643838	ENSG00000269138.1	ZNF209P	-3.7	0.000244	0.0168	-0.17	-0.17	Menopause (age at onset);	chr19:22425631	chr19:22463922~22473036:+
THCA	cis	rs12476592	0.571	rs185499	ENSG00000242412.1	DBIL5P2	3.7	0.000244	0.0168	0.21	0.17	Childhood ear infection;	chr2:63640389	chr2:63117851~63119542:-
THCA	cis	rs5762752	0.677	rs5762730	ENSG00000272858.1	CTA-292E10.8	-3.7	0.000244	0.0168	-0.16	-0.17	Optic disc area;	chr22:28643627	chr22:28814914~28815662:+
THCA	cis	rs295490	0.748	rs75634125	ENSG00000272656.1	RP11-219D15.3	3.7	0.000244	0.0168	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139371639	chr3:139349024~139349371:-
THCA	cis	rs2554380	0.943	rs2585052	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000244	0.0168	-0.2	-0.17	Height;	chr15:83687238	chr15:84507885~84516814:-
THCA	cis	rs2554380	0.891	rs2554383	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000244	0.0168	-0.2	-0.17	Height;	chr15:83687564	chr15:84507885~84516814:-
THCA	cis	rs997295	0.57	rs72747464	ENSG00000245719.1	RP11-34F13.2	3.7	0.000244	0.0168	0.18	0.17	Motion sickness;	chr15:67526202	chr15:67834310~67838879:-
THCA	cis	rs9890032	0.618	rs1979507	ENSG00000276250.1	CTD-2349P21.12	-3.7	0.000244	0.0168	-0.14	-0.17	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30803654~30804077:+
THCA	cis	rs11633886	0.529	rs4307893	ENSG00000259200.1	RP11-718O11.1	-3.7	0.000244	0.0168	-0.22	-0.17	Diisocyanate-induced asthma;	chr15:45805267	chr15:45705078~45931069:+
THCA	cis	rs7166081	1	rs8031500	ENSG00000270964.1	RP11-502I4.3	-3.7	0.000244	0.0168	-0.15	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67226702	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs12915085	ENSG00000270964.1	RP11-502I4.3	-3.7	0.000244	0.0168	-0.15	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67229800	chr15:67541072~67542604:-
THCA	cis	rs12022452	0.506	rs6673386	ENSG00000237899.1	RP4-739H11.3	-3.7	0.000244	0.0168	-0.25	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40669089~40687588:-
THCA	cis	rs12022452	0.506	rs61779163	ENSG00000237899.1	RP4-739H11.3	-3.7	0.000244	0.0168	-0.25	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40669089~40687588:-
THCA	cis	rs2898290	0.622	rs1600250	ENSG00000206014.6	OR7E161P	3.7	0.000244	0.0168	0.2	0.17	Systolic blood pressure;	chr8:11487916	chr8:11928597~11929563:-
THCA	cis	rs2898290	0.593	rs1600252	ENSG00000206014.6	OR7E161P	3.7	0.000244	0.0168	0.2	0.17	Systolic blood pressure;	chr8:11488135	chr8:11928597~11929563:-
THCA	cis	rs7520050	0.966	rs785464	ENSG00000280836.1	AL355480.1	3.7	0.000244	0.0168	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45581219~45581321:-
THCA	cis	rs6969780	0.722	rs985652	ENSG00000233429.8	HOTAIRM1	-3.7	0.000244	0.0168	-0.2	-0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27158464	chr7:27095647~27100265:+
THCA	cis	rs7243790	0.837	rs1992129	ENSG00000277324.1	RP11-850A17.1	-3.7	0.000244	0.0168	-0.17	-0.17	Diastolic blood pressure;	chr18:54419723	chr18:54268346~54270028:-
THCA	cis	rs7829975	0.511	rs2980426	ENSG00000233609.3	RP11-62H7.2	3.7	0.000244	0.0168	0.17	0.17	Mood instability;	chr8:8288087	chr8:8961200~8979025:+
THCA	cis	rs11671005	0.779	rs55875034	ENSG00000269600.1	AC016629.3	-3.7	0.000244	0.0168	-0.25	-0.17	Mean platelet volume;	chr19:58472191	chr19:58593896~58599355:-
THCA	cis	rs13063635	0.915	rs34518147	ENSG00000226074.4	PRSS44	-3.7	0.000244	0.0168	-0.33	-0.17	Eosinophil percentage of granulocytes;	chr3:45878806	chr3:46809359~46812558:-
THCA	cis	rs587080	0.624	rs674485	ENSG00000197847.11	SLC22A20	3.7	0.000244	0.0168	0.18	0.17	Plateletcrit;	chr11:65429922	chr11:65213840~65242757:+
THCA	cis	rs6437740	1	rs13065073	ENSG00000241218.1	RP11-446H18.1	-3.7	0.000244	0.0168	-0.24	-0.17	Smoking behavior;	chr3:107729797	chr3:107327830~107329197:-
THCA	cis	rs13325613	0.834	rs35960950	ENSG00000223552.1	RP11-24F11.2	-3.7	0.000244	0.0168	-0.27	-0.17	Monocyte count;	chr3:46158188	chr3:46364955~46407059:-
THCA	cis	rs2436845	0.589	rs2570950	ENSG00000253669.3	KB-1732A1.1	-3.7	0.000244	0.0168	-0.18	-0.17	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102871637	chr8:102805517~102809971:+
THCA	cis	rs2179367	0.6	rs9498356	ENSG00000216906.2	RP11-350J20.9	3.7	0.000244	0.0168	0.23	0.17	Dupuytren's disease;	chr6:149443337	chr6:149904243~149906418:+
THCA	cis	rs11671005	0.735	rs56292587	ENSG00000269600.1	AC016629.3	-3.7	0.000244	0.0168	-0.25	-0.17	Mean platelet volume;	chr19:58407699	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs56290606	ENSG00000269600.1	AC016629.3	-3.7	0.000244	0.0168	-0.25	-0.17	Mean platelet volume;	chr19:58407953	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs11878198	ENSG00000269600.1	AC016629.3	-3.7	0.000244	0.0168	-0.25	-0.17	Mean platelet volume;	chr19:58408935	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs11666716	ENSG00000269600.1	AC016629.3	-3.7	0.000244	0.0168	-0.25	-0.17	Mean platelet volume;	chr19:58409585	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs34511020	ENSG00000269600.1	AC016629.3	-3.7	0.000244	0.0168	-0.25	-0.17	Mean platelet volume;	chr19:58409929	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs11666303	ENSG00000269600.1	AC016629.3	-3.7	0.000244	0.0168	-0.25	-0.17	Mean platelet volume;	chr19:58411135	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs34152946	ENSG00000269600.1	AC016629.3	-3.7	0.000244	0.0168	-0.25	-0.17	Mean platelet volume;	chr19:58411896	chr19:58593896~58599355:-
THCA	cis	rs1065852	0.51	rs5751247	ENSG00000270083.1	RP1-257I20.14	-3.7	0.000244	0.0168	-0.2	-0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42237048	chr22:42089630~42090028:-
THCA	cis	rs1552244	0.554	rs6786636	ENSG00000269982.1	RP11-1020A11.2	3.7	0.000244	0.0168	0.12	0.17	Alzheimer's disease;	chr3:10004019	chr3:9958717~9962539:+
THCA	cis	rs6929812	0.613	rs9468140	ENSG00000271755.1	RP1-153G14.4	3.7	0.000244	0.0168	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27503736	chr6:27404010~27406964:-
THCA	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	3.7	0.000245	0.0168	0.15	0.17	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	3.7	0.000245	0.0168	0.15	0.17	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
THCA	cis	rs12200782	0.577	rs12208220	ENSG00000124549.13	BTN2A3P	-3.7	0.000245	0.0168	-0.2	-0.17	Small cell lung carcinoma;	chr6:26382407	chr6:26421391~26432383:+
THCA	cis	rs4792901	0.729	rs72833142	ENSG00000267151.3	RP11-100E5.2	3.7	0.000245	0.0168	0.19	0.17	Dupuytren's disease;	chr17:43538188	chr17:43444707~43451200:+
THCA	cis	rs875971	0.862	rs6952182	ENSG00000223473.2	GS1-124K5.3	-3.7	0.000245	0.0168	-0.11	-0.17	Aortic root size;	chr7:66218330	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6964437	ENSG00000223473.2	GS1-124K5.3	-3.7	0.000245	0.0168	-0.11	-0.17	Aortic root size;	chr7:66221457	chr7:66491049~66493566:-
THCA	cis	rs643506	0.845	rs2850245	ENSG00000230911.1	PPIHP1	-3.7	0.000245	0.0168	-0.23	-0.17	Breast cancer;	chr11:111890014	chr11:112029858~112030367:-
THCA	cis	rs559555	0.612	rs564310	ENSG00000276334.1	AL133243.1	-3.7	0.000245	0.0168	-0.17	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31667273	chr2:32521927~32523547:+
THCA	cis	rs9863	0.861	rs4405410	ENSG00000270028.1	RP11-380L11.4	3.7	0.000245	0.0168	0.18	0.17	White blood cell count;	chr12:123951241	chr12:123925461~123926083:-
THCA	cis	rs9527	0.637	rs11191424	ENSG00000213277.3	MARCKSL1P1	3.7	0.000245	0.0168	0.18	0.17	Arsenic metabolism;	chr10:102866129	chr10:103175554~103176094:+
THCA	cis	rs7259376	0.936	rs4932759	ENSG00000269345.1	VN1R85P	3.7	0.000245	0.0168	0.18	0.17	Menopause (age at onset);	chr19:22357303	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.936	rs12608491	ENSG00000269345.1	VN1R85P	3.7	0.000245	0.0168	0.18	0.17	Menopause (age at onset);	chr19:22358825	chr19:22174766~22175191:-
THCA	cis	rs948562	1	rs948562	ENSG00000280010.1	AP001350.4	3.7	0.000245	0.0168	0.25	0.17	Lymphoma;	chr11:58580292	chr11:58627435~58628528:+
THCA	cis	rs7824557	0.583	rs2736306	ENSG00000154316.13	TDH	-3.7	0.000245	0.0168	-0.13	-0.17	Retinal vascular caliber;	chr8:11382253	chr8:11339637~11368452:+
THCA	cis	rs2882667	0.894	rs1433008	ENSG00000249593.5	CTB-46B19.2	3.7	0.000245	0.0168	0.2	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:139012647~139051203:+
THCA	cis	rs2341873	0.542	rs1947964	ENSG00000204588.5	LINC01123	-3.7	0.000245	0.0168	-0.19	-0.17	Neutrophil percentage of white cells;	chr2:110914094	chr2:109987063~109996140:+
THCA	cis	rs2243480	1	rs4548056	ENSG00000273024.4	INTS4P2	3.7	0.000245	0.0168	0.28	0.17	Diabetic kidney disease;	chr7:65833886	chr7:65647864~65715661:+
THCA	cis	rs7246657	1	rs6508710	ENSG00000268499.1	CTB-102L5.8	3.7	0.000245	0.0168	0.22	0.17	Coronary artery calcification;	chr19:37258984	chr19:38199836~38200934:+
THCA	cis	rs4789693	0.938	rs4789694	ENSG00000279744.1	RP13-20L14.10	3.7	0.000245	0.0168	0.15	0.17	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82462601~82464255:+
THCA	cis	rs929354	0.772	rs933344	ENSG00000224629.1	RP5-1142J19.2	-3.7	0.000245	0.0168	-0.16	-0.17	Body mass index;	chr7:157218571	chr7:157263022~157263229:-
THCA	cis	rs2013441	0.613	rs9901125	ENSG00000261033.1	RP11-209D14.2	-3.7	0.000245	0.0168	-0.21	-0.17	Obesity-related traits;	chr17:20105616	chr17:20008051~20009234:-
THCA	cis	rs10043228	1	rs17139457	ENSG00000248445.4	SEMA6A-AS1	3.7	0.000245	0.0168	0.22	0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116304906	chr5:116447547~116508276:+
THCA	cis	rs7989332	0.925	rs9506494	ENSG00000277020.3	RP11-476H16.1	3.7	0.000245	0.0168	0.15	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20473719	chr13:20564708~20567045:-
THCA	cis	rs7632954	0.669	rs7647092	ENSG00000227110.5	LMCD1-AS1	3.7	0.000245	0.0168	0.2	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8486745	chr3:7952805~8611924:-
THCA	cis	rs2154427	0.938	rs114440021	ENSG00000238197.4	PAXBP1-AS1	3.7	0.000245	0.0168	0.17	0.17	Bilirubin levels;	chr21:32830362	chr21:32728115~32743122:+
THCA	cis	rs2154427	0.938	rs113791275	ENSG00000238197.4	PAXBP1-AS1	3.7	0.000245	0.0168	0.17	0.17	Bilirubin levels;	chr21:32830496	chr21:32728115~32743122:+
THCA	cis	rs1501911	0.509	rs330421	ENSG00000246763.5	RGMB-AS1	3.7	0.000245	0.0168	0.18	0.17	Lung function (FEV1/FVC);	chr5:98859077	chr5:98769618~98773469:-
THCA	cis	rs1927790	0.643	rs12050064	ENSG00000247400.3	DNAJC3-AS1	-3.7	0.000245	0.0168	-0.11	-0.17	Body mass index;	chr13:96359216	chr13:95648733~95676925:-
THCA	cis	rs755249	0.509	rs710913	ENSG00000228060.1	RP11-69E11.8	3.7	0.000245	0.0168	0.15	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39565160~39573203:+
THCA	cis	rs9925964	0.933	rs9923231	ENSG00000279196.1	RP11-1072A3.3	-3.7	0.000245	0.0168	-0.16	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31096368	chr16:30984630~30988270:-
THCA	cis	rs372883	0.6	rs1153277	ENSG00000176054.6	RPL23P2	-3.7	0.000245	0.0168	-0.15	-0.17	Pancreatic cancer;	chr21:29294546	chr21:28997613~28998033:-
THCA	cis	rs41307935	0.643	rs6658653	ENSG00000238231.2	RP11-460I13.6	3.7	0.000245	0.0168	0.47	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26999041	chr1:27990158~27990524:-
THCA	cis	rs78487399	0.808	rs74821293	ENSG00000234936.1	AC010883.5	3.7	0.000245	0.0168	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43515784	chr2:43229573~43233394:+
THCA	cis	rs11800820	0.536	rs10924739	ENSG00000227953.5	LINC01341	-3.7	0.000245	0.0168	-0.15	-0.17	Obesity-related traits;	chr1:246469645	chr1:246776013~246792385:+
THCA	cis	rs7824557	0.583	rs2736292	ENSG00000261451.1	RP11-981G7.1	3.7	0.000245	0.0168	0.21	0.17	Retinal vascular caliber;	chr8:11376991	chr8:10433672~10438312:+
THCA	cis	rs2360027	0.662	rs4658991	ENSG00000231365.4	RP11-418J17.1	-3.7	0.000245	0.0168	-0.17	-0.17	Tonsillectomy;	chr1:118607851	chr1:119140396~119275973:+
THCA	cis	rs11678584	0.686	rs67600408	ENSG00000276517.1	AL133243.2	-3.7	0.000245	0.0168	-0.26	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32568582	chr2:32526504~32529507:+
THCA	cis	rs1299548	1	rs1299548	ENSG00000272745.1	RP5-1007H16.1	3.7	0.000245	0.0168	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr7:7262662	chr7:7619872~7620543:+
THCA	cis	rs11601239	0.607	rs11226861	ENSG00000254750.1	CASP1P2	-3.7	0.000245	0.0168	-0.13	-0.17	Refractive error;	chr11:105835117	chr11:105063345~105071541:-
THCA	cis	rs1079596	0.501	rs34863235	ENSG00000270179.1	RP11-159N11.4	3.7	0.000245	0.0168	0.21	0.17	Select biomarker traits;	chr11:113395957	chr11:113368478~113369117:+
THCA	cis	rs12121840	0.79	rs55674257	ENSG00000237463.4	RP11-280O1.2	-3.7	0.000245	0.0168	-0.15	-0.17	Interleukin-1-receptor antagonist levels;	chr1:165573126	chr1:165476841~165582155:-
THCA	cis	rs12121840	0.79	rs56201005	ENSG00000237463.4	RP11-280O1.2	-3.7	0.000245	0.0168	-0.15	-0.17	Interleukin-1-receptor antagonist levels;	chr1:165573618	chr1:165476841~165582155:-
THCA	cis	rs12121840	0.79	rs6696050	ENSG00000237463.4	RP11-280O1.2	-3.7	0.000245	0.0168	-0.15	-0.17	Interleukin-1-receptor antagonist levels;	chr1:165574240	chr1:165476841~165582155:-
THCA	cis	rs1979679	0.515	rs17603585	ENSG00000247934.4	RP11-967K21.1	-3.7	0.000245	0.0168	-0.16	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28110120	chr12:28163298~28190738:-
THCA	cis	rs7394190	0.748	rs60212594	ENSG00000272140.2	RP11-574K11.29	-3.7	0.000245	0.0168	-0.17	-0.17	Incident atrial fibrillation;	chr10:73654586	chr10:73703735~73713581:-
THCA	cis	rs2408955	0.521	rs11168437	ENSG00000257735.1	RP11-370I10.6	3.7	0.000245	0.0168	0.2	0.17	Glycated hemoglobin levels;	chr12:48172373	chr12:48350945~48442411:+
THCA	cis	rs56046484	0.913	rs12906544	ENSG00000259630.2	CTD-2262B20.1	-3.7	0.000245	0.0168	-0.24	-0.17	Testicular germ cell tumor;	chr15:85032832	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.871	rs34978449	ENSG00000259630.2	CTD-2262B20.1	-3.7	0.000245	0.0168	-0.24	-0.17	Testicular germ cell tumor;	chr15:85036917	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.871	rs62021230	ENSG00000259630.2	CTD-2262B20.1	-3.7	0.000245	0.0168	-0.24	-0.17	Testicular germ cell tumor;	chr15:85040721	chr15:85415228~85415633:+
THCA	cis	rs6598955	0.724	rs12068388	ENSG00000236782.4	RP11-96L14.7	-3.7	0.000245	0.0168	-0.2	-0.17	Obesity-related traits;	chr1:26295105	chr1:26169947~26171821:-
THCA	cis	rs6940638	0.688	rs9393790	ENSG00000224843.5	LINC00240	-3.7	0.000245	0.0168	-0.15	-0.17	Intelligence (multi-trait analysis);	chr6:27146273	chr6:26956992~27023924:+
THCA	cis	rs28830936	0.934	rs2412641	ENSG00000250379.1	RP11-23P13.4	3.7	0.000245	0.0168	0.19	0.17	Diastolic blood pressure;	chr15:41832201	chr15:41825099~41827936:-
THCA	cis	rs28830936	0.966	rs11635067	ENSG00000250379.1	RP11-23P13.4	3.7	0.000245	0.0168	0.19	0.17	Diastolic blood pressure;	chr15:41832475	chr15:41825099~41827936:-
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000273024.4	INTS4P2	3.7	0.000245	0.0168	0.27	0.17	Diabetic kidney disease;	chr7:65988305	chr7:65647864~65715661:+
THCA	cis	rs12760731	0.843	rs12033565	ENSG00000213057.5	C1orf220	-3.7	0.000245	0.0168	-0.2	-0.17	Obesity-related traits;	chr1:178522831	chr1:178542752~178548889:+
THCA	cis	rs10090774	0.965	rs7839697	ENSG00000280303.2	ERICD	3.7	0.000245	0.0168	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140804566	chr8:140636281~140638283:+
THCA	cis	rs2299587	0.56	rs11996792	ENSG00000253671.1	RP11-806O11.1	-3.7	0.000245	0.0168	-0.2	-0.17	Economic and political preferences;	chr8:17923503	chr8:17808941~17820868:+
THCA	cis	rs9549260	0.755	rs9549236	ENSG00000275149.1	RP11-427J23.1	3.7	0.000245	0.0168	0.22	0.17	Red blood cell count;	chr13:40573021	chr13:40079106~40273509:-
THCA	cis	rs72945132	0.678	rs35733235	ENSG00000254604.1	AP000487.6	-3.7	0.000245	0.0168	-0.31	-0.17	Coronary artery disease;	chr11:70389489	chr11:70282367~70363368:-
THCA	cis	rs7572733	0.84	rs12472359	ENSG00000231621.1	AC013264.2	3.7	0.000245	0.0168	0.16	0.17	Dermatomyositis;	chr2:197723141	chr2:197197991~197199273:+
THCA	cis	rs9844666	0.512	rs9864775	ENSG00000273486.1	RP11-731C17.2	3.7	0.000245	0.0168	0.16	0.17	Height;	chr3:135924726	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs4718	ENSG00000273486.1	RP11-731C17.2	3.7	0.000245	0.0168	0.16	0.17	Height;	chr3:135925965	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs35722356	ENSG00000273486.1	RP11-731C17.2	3.7	0.000245	0.0168	0.16	0.17	Height;	chr3:135932260	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9818786	ENSG00000273486.1	RP11-731C17.2	3.7	0.000245	0.0168	0.16	0.17	Height;	chr3:135937059	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9858063	ENSG00000273486.1	RP11-731C17.2	3.7	0.000245	0.0168	0.16	0.17	Height;	chr3:135937938	chr3:136837338~136839021:-
THCA	cis	rs853679	0.546	rs35017208	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28377505	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs13213152	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28381921	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs36092177	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28390030	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs13213986	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28390232	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs2232429	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28391855	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs2232426	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28392882	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs34546986	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28394532	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs34871267	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28396455	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs2232423	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28398374	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs35883476	ENSG00000220721.1	OR1F12	3.7	0.000245	0.0168	0.38	0.17	Depression;	chr6:28400731	chr6:28073316~28074233:+
THCA	cis	rs12681366	0.563	rs6999103	ENSG00000253175.1	RP11-267M23.6	3.7	0.000245	0.0168	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94470309	chr8:94565036~94565715:+
THCA	cis	rs8046148	0.826	rs1558813	ENSG00000279356.1	RP11-429P3.8	3.7	0.000246	0.0169	0.23	0.17	Testicular germ cell tumor;	chr16:50105888	chr16:50072862~50074986:+
THCA	cis	rs7819412	0.634	rs4841485	ENSG00000206014.6	OR7E161P	-3.7	0.000246	0.0169	-0.19	-0.17	Triglycerides;	chr8:11052426	chr8:11928597~11929563:-
THCA	cis	rs271738	0.639	rs271769	ENSG00000231768.1	LINC01354	-3.7	0.000246	0.0169	-0.19	-0.17	Bipolar disorder;	chr1:234539563	chr1:234527891~234531779:-
THCA	cis	rs12539814	0.929	rs12671701	ENSG00000244198.4	RP4-545C24.1	3.7	0.000246	0.0169	0.21	0.17	Diastolic blood pressure;	chr7:144459893	chr7:144194858~144280547:+
THCA	cis	rs12780845	0.54	rs10904884	ENSG00000234961.1	RP11-124N14.3	3.7	0.000246	0.0169	0.18	0.17	Homocysteine levels;	chr10:17138101	chr10:17233325~17234833:-
THCA	cis	rs2276314	0.947	rs3898595	ENSG00000267627.4	RP11-905K4.1	-3.7	0.000246	0.0169	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35951803~35966118:-
THCA	cis	rs2276314	1	rs4799834	ENSG00000267627.4	RP11-905K4.1	-3.7	0.000246	0.0169	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35951803~35966118:-
THCA	cis	rs5758511	0.773	rs62241023	ENSG00000273366.1	CTA-989H11.1	3.7	0.000246	0.0169	0.25	0.17	Birth weight;	chr22:41989425	chr22:42278188~42278846:+
THCA	cis	rs1035144	0.704	rs72693069	ENSG00000258915.1	BHLHB9P1	-3.7	0.000246	0.0169	-0.18	-0.17	Male sexual orientation;	chr14:80979518	chr14:80981988~80983638:+
THCA	cis	rs6137726	0.652	rs6082777	ENSG00000237396.1	LINC01384	-3.7	0.000246	0.0169	-0.15	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22672079	chr20:22587522~22607517:-
THCA	cis	rs7119	0.7	rs4886883	ENSG00000259362.2	RP11-307C19.1	-3.7	0.000246	0.0169	-0.22	-0.17	Type 2 diabetes;	chr15:77596582	chr15:77525540~77534110:+
THCA	cis	rs2033711	0.87	rs1465789	ENSG00000269867.1	CTD-2583A14.8	-3.7	0.000246	0.0169	-0.14	-0.17	Uric acid clearance;	chr19:58434689	chr19:57867038~57868172:-
THCA	cis	rs721917	0.525	rs2250652	ENSG00000244733.5	RP11-506M13.3	-3.7	0.000246	0.0169	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79902893	chr10:79660891~79677996:+
THCA	cis	rs2243480	0.522	rs73150635	ENSG00000237310.1	GS1-124K5.4	3.7	0.000246	0.0169	0.25	0.17	Diabetic kidney disease;	chr7:66507503	chr7:66493706~66495474:+
THCA	cis	rs2522056	1	rs1003533	ENSG00000237714.1	P4HA2-AS1	-3.7	0.000246	0.0169	-0.24	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132184876~132192808:+
THCA	cis	rs10129255	0.828	rs10140989	ENSG00000280411.1	IGHV1-69-2	-3.7	0.000246	0.0169	-0.11	-0.17	Kawasaki disease;	chr14:106668657	chr14:106762092~106762588:-
THCA	cis	rs9467773	0.62	rs9461275	ENSG00000228223.2	HCG11	-3.7	0.000246	0.0169	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26523450~26526579:+
THCA	cis	rs1204798	1	rs1204842	ENSG00000237021.2	RP3-486I3.7	3.7	0.000246	0.0169	0.18	0.17	Dental caries;	chr6:116199185	chr6:116254207~116256743:+
THCA	cis	rs6963495	0.818	rs55691539	ENSG00000272604.1	RP11-251G23.5	3.7	0.000246	0.0169	0.22	0.17	Bipolar disorder (body mass index interaction);	chr7:105525327	chr7:105571083~105573660:+
THCA	cis	rs6600671	0.899	rs11249432	ENSG00000233029.3	RP11-439A17.9	-3.7	0.000246	0.0169	-0.19	-0.17	Hip geometry;	chr1:121541678	chr1:121090289~121097655:-
THCA	cis	rs13118159	0.742	rs34947293	ENSG00000254094.1	AC078852.1	-3.7	0.000246	0.0169	-0.19	-0.17	Longevity;	chr4:1341246	chr4:1356581~1358075:+
THCA	cis	rs12295638	0.73	rs10835031	ENSG00000254862.4	RP11-159H22.2	3.7	0.000246	0.0169	0.22	0.17	Obesity (extreme);	chr11:26628702	chr11:27471729~27482433:+
THCA	cis	rs12295638	0.73	rs12270321	ENSG00000254862.4	RP11-159H22.2	3.7	0.000246	0.0169	0.22	0.17	Obesity (extreme);	chr11:26630197	chr11:27471729~27482433:+
THCA	cis	rs972578	0.535	rs3091364	ENSG00000230319.1	AL022476.2	-3.7	0.000246	0.0169	-0.19	-0.17	Mean platelet volume;	chr22:43018324	chr22:43038585~43052366:+
THCA	cis	rs3864261	0.637	rs34647	ENSG00000249085.1	CTD-2631K10.1	-3.7	0.000246	0.0169	-0.26	-0.17	Discordance in emotional problems in monozygotic twins;	chr5:72816603	chr5:72794405~72816565:-
THCA	cis	rs3864261	0.836	rs34645	ENSG00000249085.1	CTD-2631K10.1	-3.7	0.000246	0.0169	-0.26	-0.17	Discordance in emotional problems in monozygotic twins;	chr5:72817426	chr5:72794405~72816565:-
THCA	cis	rs4869313	0.668	rs10076136	ENSG00000247121.5	CTD-2260A17.2	-3.7	0.000246	0.0169	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96967444	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.748	rs2113050	ENSG00000247121.5	CTD-2260A17.2	-3.7	0.000246	0.0169	-0.13	-0.17	Pediatric autoimmune diseases;	chr5:96978798	chr5:96814028~96935809:-
THCA	cis	rs10857712	0.754	rs2297032	ENSG00000214279.11	SCART1	-3.7	0.000246	0.0169	-0.14	-0.17	Systemic lupus erythematosus;	chr10:133421076	chr10:133453928~133523558:+
THCA	cis	rs10484434	1	rs17596719	ENSG00000272810.1	U91328.22	-3.69	0.000246	0.0169	-0.19	-0.17	HIV-1 viral setpoint;	chr6:26096966	chr6:26013241~26013757:+
THCA	cis	rs972578	0.804	rs2179872	ENSG00000230319.1	AL022476.2	3.69	0.000246	0.0169	0.18	0.17	Mean platelet volume;	chr22:42799691	chr22:43038585~43052366:+
THCA	cis	rs4948275	0.74	rs2787699	ENSG00000233643.2	RP11-491H19.1	3.69	0.000246	0.0169	0.19	0.17	Night sleep phenotypes;	chr10:61539102	chr10:61781745~61821246:-
THCA	cis	rs9532669	0.89	rs9525420	ENSG00000229473.2	RGS17P1	3.69	0.000246	0.0169	0.22	0.17	Cervical cancer;	chr13:40882628	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs7324383	ENSG00000229473.2	RGS17P1	3.69	0.000246	0.0169	0.22	0.17	Cervical cancer;	chr13:40882754	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532648	ENSG00000229473.2	RGS17P1	3.69	0.000246	0.0169	0.22	0.17	Cervical cancer;	chr13:40882795	chr13:40992779~40993331:-
THCA	cis	rs838886	0.871	rs838877	ENSG00000275389.1	RP11-214K3.24	-3.69	0.000246	0.0169	-0.23	-0.17	HDL cholesterol;	chr12:124775721	chr12:124085761~124088598:+
THCA	cis	rs7131987	0.641	rs2015599	ENSG00000257599.1	OVCH1-AS1	-3.69	0.000246	0.0169	-0.2	-0.17	QT interval;	chr12:29282547	chr12:29389294~29487488:+
THCA	cis	rs7131987	0.63	rs1006409	ENSG00000257599.1	OVCH1-AS1	-3.69	0.000246	0.0169	-0.2	-0.17	QT interval;	chr12:29282742	chr12:29389294~29487488:+
THCA	cis	rs854765	0.575	rs7207821	ENSG00000281749.1	Y_RNA	3.69	0.000246	0.0169	0.21	0.17	Total body bone mineral density;	chr17:17988467	chr17:18001101~18001195:-
THCA	cis	rs10090774	1	rs4291312	ENSG00000280303.2	ERICD	3.69	0.000246	0.0169	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140816039	chr8:140636281~140638283:+
THCA	cis	rs6496044	0.547	rs7173125	ENSG00000259407.1	RP11-158M2.3	3.69	0.000246	0.0169	0.17	0.17	Interstitial lung disease;	chr15:85512214	chr15:85744109~85750281:-
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000184274.3	LINC00315	-3.69	0.000246	0.0169	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45300245~45305257:-
THCA	cis	rs4938303	0.788	rs17092642	ENSG00000254851.1	RP11-109L13.1	3.69	0.000246	0.0169	0.26	0.17	Triglycerides;	chr11:116686532	chr11:117135528~117138582:+
THCA	cis	rs7973719	0.531	rs10743271	ENSG00000205885.6	C1RL-AS1	-3.69	0.000246	0.0169	-0.14	-0.17	IgG glycosylation;	chr12:7201194	chr12:7108052~7122501:+
THCA	cis	rs3733585	0.683	rs13112015	ENSG00000250413.1	RP11-448G15.1	3.69	0.000246	0.0169	0.16	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9932172	chr4:10006482~10009725:+
THCA	cis	rs11678825	0.789	rs10195717	ENSG00000272663.1	RP11-191L17.1	-3.69	0.000246	0.0169	-0.23	-0.17	Reticulocyte fraction of red cells;	chr2:48396295	chr2:48440043~48440597:-
THCA	cis	rs11678825	0.789	rs10191938	ENSG00000272663.1	RP11-191L17.1	-3.69	0.000246	0.0169	-0.23	-0.17	Reticulocyte fraction of red cells;	chr2:48400817	chr2:48440043~48440597:-
THCA	cis	rs889014	1	rs7704555	ENSG00000253959.1	CTB-43E15.1	-3.69	0.000246	0.0169	-0.22	-0.17	Height;	chr5:173572999	chr5:173642519~173658194:+
THCA	cis	rs7259376	0.902	rs11669179	ENSG00000270947.1	AC025811.3	-3.69	0.000246	0.0169	-0.18	-0.17	Menopause (age at onset);	chr19:22421927	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.902	rs11669270	ENSG00000270947.1	AC025811.3	-3.69	0.000246	0.0169	-0.18	-0.17	Menopause (age at onset);	chr19:22422014	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.902	rs11669353	ENSG00000270947.1	AC025811.3	-3.69	0.000246	0.0169	-0.18	-0.17	Menopause (age at onset);	chr19:22422301	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.902	rs11879678	ENSG00000270947.1	AC025811.3	-3.69	0.000246	0.0169	-0.18	-0.17	Menopause (age at onset);	chr19:22424510	chr19:22455988~22456459:+
THCA	cis	rs4713118	0.824	rs9366702	ENSG00000261839.1	RP1-265C24.8	3.69	0.000246	0.0169	0.2	0.17	Parkinson's disease;	chr6:27766691	chr6:28136849~28139678:+
THCA	cis	rs912593	0.872	rs73181262	ENSG00000225179.1	LINC00457	3.69	0.000246	0.0169	0.22	0.17	Cancer;	chr13:34478362	chr13:34435450~34640685:-
THCA	cis	rs2749592	0.531	rs10764134	ENSG00000120555.12	SEPT7P9	-3.69	0.000246	0.0169	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38383069~38402916:-
THCA	cis	rs8113308	1	rs8113308	ENSG00000275055.1	CTC-471J1.11	-3.69	0.000246	0.0169	-0.17	-0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942133	chr19:52049007~52049754:+
THCA	cis	rs5769765	1	rs764813	ENSG00000260613.1	RP3-522J7.6	-3.69	0.000246	0.0169	-0.21	-0.17	Schizophrenia;	chr22:49892524	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs768618	ENSG00000260613.1	RP3-522J7.6	-3.69	0.000246	0.0169	-0.21	-0.17	Schizophrenia;	chr22:49893179	chr22:49832616~49837786:-
THCA	cis	rs5769765	1	rs768619	ENSG00000260613.1	RP3-522J7.6	-3.69	0.000246	0.0169	-0.21	-0.17	Schizophrenia;	chr22:49893618	chr22:49832616~49837786:-
THCA	cis	rs4742903	0.935	rs1507513	ENSG00000270332.1	SMC2-AS1	3.69	0.000246	0.0169	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104211576	chr9:104080024~104093073:-
THCA	cis	rs721048	0.915	rs13431765	ENSG00000242412.1	DBIL5P2	-3.69	0.000246	0.0169	-0.22	-0.17	Prostate cancer;	chr2:63190594	chr2:63117851~63119542:-
THCA	cis	rs17123764	0.579	rs55637397	ENSG00000257464.1	RP11-161H23.8	-3.69	0.000246	0.0169	-0.34	-0.17	Intelligence (multi-trait analysis);	chr12:49620398	chr12:49442424~49442652:-
THCA	cis	rs1577917	0.958	rs12216074	ENSG00000220563.1	PKMP3	-3.69	0.000246	0.0169	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85810284	chr6:85659892~85660606:-
THCA	cis	rs7914558	0.932	rs4307650	ENSG00000272912.1	RP11-724N1.1	-3.69	0.000246	0.0169	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:102914585~102915404:+
THCA	cis	rs11098699	0.784	rs4833900	ENSG00000273007.1	RP11-170N16.3	3.69	0.000246	0.0169	0.13	0.17	Mosquito bite size;	chr4:123322840	chr4:122881878~122884712:-
THCA	cis	rs6598541	0.887	rs7166890	ENSG00000278090.1	RP11-6O2.2	3.69	0.000246	0.0169	0.16	0.17	Urate levels;	chr15:98710965	chr15:99028538~99031053:+
THCA	cis	rs9911578	0.967	rs72628392	ENSG00000224738.1	AC099850.1	-3.69	0.000246	0.0169	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58428799	chr17:59106598~59118267:+
THCA	cis	rs9525562	0.562	rs9532973	ENSG00000214222.2	TUBBP2	3.69	0.000246	0.0169	0.2	0.17	Ejection fraction in Tripanosoma cruzi seropositivity;	chr13:42030508	chr13:41384773~41385183:-
THCA	cis	rs881375	0.669	rs73541868	ENSG00000238181.2	AHCYP2	-3.69	0.000246	0.0169	-0.2	-0.17	Rheumatoid arthritis;	chr9:120876986	chr9:120720673~120721972:+
THCA	cis	rs4950322	0.547	rs56864370	ENSG00000271721.1	RP11-337C18.9	3.69	0.000246	0.0169	0.18	0.17	Protein quantitative trait loci;	chr1:147111847	chr1:147175602~147177740:+
THCA	cis	rs10090774	0.965	rs10094003	ENSG00000280303.2	ERICD	-3.69	0.000246	0.0169	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140847055	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs4445273	ENSG00000280303.2	ERICD	3.69	0.000246	0.0169	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140740574	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs4246123	ENSG00000280303.2	ERICD	3.69	0.000246	0.0169	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140765069	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs7826800	ENSG00000280303.2	ERICD	3.69	0.000246	0.0169	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140828313	chr8:140636281~140638283:+
THCA	cis	rs10435719	0.902	rs11250179	ENSG00000254948.1	OR7E158P	-3.69	0.000246	0.0169	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:11919900~11920809:-
THCA	cis	rs72928364	0.86	rs16843229	ENSG00000256628.3	ZBTB11-AS1	3.69	0.000246	0.0169	0.27	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101083376	chr3:101676475~101679217:+
THCA	cis	rs11168187	0.527	rs7957537	ENSG00000257433.4	RP1-197B17.3	3.69	0.000246	0.0169	0.18	0.17	Vertical cup-disc ratio;	chr12:47742199	chr12:47706085~47742294:+
THCA	cis	rs6598955	0.724	rs4659420	ENSG00000236782.4	RP11-96L14.7	-3.69	0.000246	0.0169	-0.2	-0.17	Obesity-related traits;	chr1:26287842	chr1:26169947~26171821:-
THCA	cis	rs6894216	0.651	rs6889557	ENSG00000248610.1	HSPA8P4	-3.69	0.000246	0.0169	-0.21	-0.17	Response to amphetamines;	chr5:130359142	chr5:130140031~130141950:+
THCA	cis	rs9543976	1	rs9543976	ENSG00000261105.4	LMO7-AS1	3.69	0.000246	0.0169	0.24	0.17	Diabetic retinopathy;	chr13:75562512	chr13:75604700~75635994:-
THCA	cis	rs4906332	0.834	rs12882130	ENSG00000252469.1	RNU7-160P	3.69	0.000246	0.0169	0.18	0.17	Coronary artery disease;	chr14:103412437	chr14:103550345~103550406:+
THCA	cis	rs6580649	0.943	rs1990029	ENSG00000273765.1	RP11-370I10.11	3.69	0.000246	0.0169	0.19	0.17	Lung cancer;	chr12:48014204	chr12:48360920~48361377:+
THCA	cis	rs7680126	0.671	rs7663044	ENSG00000261490.1	RP11-448G15.3	3.69	0.000247	0.0169	0.16	0.17	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10022315	chr4:10068089~10073019:-
THCA	cis	rs7246760	0.867	rs8102257	ENSG00000278611.1	CTC-543D15.8	-3.69	0.000247	0.0169	-0.27	-0.17	Pursuit maintenance gain;	chr19:9720119	chr19:9538733~9539734:+
THCA	cis	rs911555	0.574	rs34251103	ENSG00000269910.1	RP11-73M18.10	-3.69	0.000247	0.0169	-0.15	-0.17	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103694516~103695050:-
THCA	cis	rs6088580	0.524	rs4911437	ENSG00000126005.14	MMP24-AS1	3.69	0.000247	0.0169	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34678345	chr20:35216462~35278131:-
THCA	cis	rs2911132	0.564	rs731827	ENSG00000248734.2	CTD-2260A17.1	3.69	0.000247	0.0169	0.18	0.17	Urate levels (BMI interaction);	chr5:96751311	chr5:96784777~96785999:+
THCA	cis	rs1577917	0.629	rs7761762	ENSG00000220563.1	PKMP3	3.69	0.000247	0.0169	0.13	0.17	Response to antipsychotic treatment;	chr6:85496250	chr6:85659892~85660606:-
THCA	cis	rs35146811	0.624	rs1727134	ENSG00000078319.8	PMS2P1	-3.69	0.000247	0.0169	-0.21	-0.17	Coronary artery disease;	chr7:100216049	chr7:100320992~100341908:-
THCA	cis	rs35146811	0.735	rs1636978	ENSG00000078319.8	PMS2P1	-3.69	0.000247	0.0169	-0.21	-0.17	Coronary artery disease;	chr7:100216289	chr7:100320992~100341908:-
THCA	cis	rs7572644	0.723	rs10201105	ENSG00000223522.1	AC093690.1	3.69	0.000247	0.0169	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27908366	chr2:28307691~28310459:-
THCA	cis	rs4792901	0.765	rs34778116	ENSG00000267151.3	RP11-100E5.2	3.69	0.000247	0.0169	0.18	0.17	Dupuytren's disease;	chr17:43462330	chr17:43444707~43451200:+
THCA	cis	rs6988985	0.678	rs28571827	ENSG00000253741.1	CTD-2292P10.4	-3.69	0.000247	0.0169	-0.21	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921791	chr8:142702252~142726973:-
THCA	cis	rs7824557	0.564	rs2572394	ENSG00000227888.4	FAM66A	-3.69	0.000247	0.0169	-0.21	-0.17	Retinal vascular caliber;	chr8:11377884	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs2437152	ENSG00000227888.4	FAM66A	-3.69	0.000247	0.0169	-0.21	-0.17	Retinal vascular caliber;	chr8:11377988	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs2736300	ENSG00000227888.4	FAM66A	-3.69	0.000247	0.0169	-0.21	-0.17	Retinal vascular caliber;	chr8:11378070	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs2572392	ENSG00000227888.4	FAM66A	-3.69	0.000247	0.0169	-0.21	-0.17	Retinal vascular caliber;	chr8:11378096	chr8:12362019~12388296:+
THCA	cis	rs2762353	0.603	rs4145221	ENSG00000272462.2	U91328.19	3.69	0.000247	0.0169	0.13	0.17	Blood metabolite levels;	chr6:25762964	chr6:25992662~26001775:+
THCA	cis	rs6472235	0.656	rs11987304	ENSG00000272192.1	CTD-2532N20.1	3.69	0.000247	0.0169	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65957778	chr8:65842752~65843331:+
THCA	cis	rs9400467	0.568	rs4947121	ENSG00000255389.1	C6orf3	3.69	0.000247	0.0169	0.18	0.17	Amino acid levels;Blood metabolite levels;	chr6:111513751	chr6:111599875~111602295:+
THCA	cis	rs427943	0.712	rs983749	ENSG00000223768.1	LINC00205	-3.69	0.000247	0.0169	-0.15	-0.17	Body mass index;	chr21:45181936	chr21:45293285~45297354:+
THCA	cis	rs12101261	0.813	rs58417382	ENSG00000259167.2	NMNAT1P1	3.69	0.000247	0.0169	0.2	0.17	Graves' disease;	chr14:81002102	chr14:81032529~81033404:+
THCA	cis	rs34421088	0.531	rs2245232	ENSG00000227888.4	FAM66A	-3.69	0.000247	0.0169	-0.22	-0.17	Neuroticism;	chr8:11543435	chr8:12362019~12388296:+
THCA	cis	rs701145	0.585	rs1960241	ENSG00000243069.6	ARHGEF26-AS1	3.69	0.000247	0.0169	0.32	0.17	Coronary artery disease;	chr3:154140609	chr3:154024401~154121332:-
THCA	cis	rs701145	0.537	rs1358403	ENSG00000243069.6	ARHGEF26-AS1	3.69	0.000247	0.0169	0.32	0.17	Coronary artery disease;	chr3:154144968	chr3:154024401~154121332:-
THCA	cis	rs701145	0.585	rs1713822	ENSG00000243069.6	ARHGEF26-AS1	3.69	0.000247	0.0169	0.32	0.17	Coronary artery disease;	chr3:154145716	chr3:154024401~154121332:-
THCA	cis	rs17685	0.784	rs1637043	ENSG00000227038.2	AC005077.12	3.69	0.000247	0.0169	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76069781	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs1639617	ENSG00000227038.2	AC005077.12	3.69	0.000247	0.0169	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76072410	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs11982200	ENSG00000227038.2	AC005077.12	3.69	0.000247	0.0169	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76085565	chr7:76090431~76108779:-
THCA	cis	rs17685	0.587	rs1623759	ENSG00000227038.2	AC005077.12	3.69	0.000247	0.0169	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76095361	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs1637049	ENSG00000227038.2	AC005077.12	3.69	0.000247	0.0169	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76100657	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs1637051	ENSG00000227038.2	AC005077.12	3.69	0.000247	0.0169	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76101341	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs4573217	ENSG00000227038.2	AC005077.12	3.69	0.000247	0.0169	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76104628	chr7:76090431~76108779:-
THCA	cis	rs9303542	1	rs12946636	ENSG00000264920.1	RP11-6N17.4	-3.69	0.000247	0.0169	-0.17	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48395070	chr17:47891255~47895812:-
THCA	cis	rs375092	0.611	rs75733834	ENSG00000226816.2	AC005082.12	3.69	0.000247	0.0169	0.35	0.17	Personality dimensions;	chr7:23375762	chr7:23206013~23208045:+
THCA	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	3.69	0.000247	0.0169	0.15	0.17	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
THCA	cis	rs7613875	0.62	rs17657688	ENSG00000281691.1	RBM5-AS1	-3.69	0.000247	0.0169	-0.14	-0.17	Body mass index;	chr3:49995795	chr3:50099603~50100988:-
THCA	cis	rs4906332	1	rs10459573	ENSG00000259775.1	RP11-45P15.4	-3.69	0.000247	0.0169	-0.14	-0.17	Coronary artery disease;	chr14:103459120	chr14:103331674~103332367:-
THCA	cis	rs4906332	1	rs4906327	ENSG00000259775.1	RP11-45P15.4	-3.69	0.000247	0.0169	-0.14	-0.17	Coronary artery disease;	chr14:103462702	chr14:103331674~103332367:-
THCA	cis	rs3748682	0.821	rs71642605	ENSG00000252448.1	SNORA63	-3.69	0.000247	0.0169	-0.22	-0.17	Hypothyroidism;	chr1:37790755	chr1:37884237~37884317:+
THCA	cis	rs3738443	0.523	rs56338561	ENSG00000259865.1	RP11-488L18.10	3.69	0.000247	0.0169	0.15	0.17	Alcohol dependence;	chr1:247210592	chr1:247187281~247188526:-
THCA	cis	rs603446	1	rs603446	ENSG00000254851.1	RP11-109L13.1	-3.69	0.000247	0.0169	-0.22	-0.17	Triglycerides;	chr11:116783719	chr11:117135528~117138582:+
THCA	cis	rs7129556	0.737	rs72949616	ENSG00000254459.1	RP11-91P24.7	3.69	0.000247	0.0169	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77753325	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.737	rs72949618	ENSG00000254459.1	RP11-91P24.7	3.69	0.000247	0.0169	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77753485	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.737	rs56218634	ENSG00000254459.1	RP11-91P24.7	3.69	0.000247	0.0169	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77753789	chr11:77829654~77872262:-
THCA	cis	rs9987353	0.566	rs13260067	ENSG00000253981.4	ALG1L13P	-3.69	0.000247	0.0169	-0.17	-0.17	Recombination measurement;	chr8:9213523	chr8:8236003~8244667:-
THCA	cis	rs6921919	0.848	rs56131013	ENSG00000219392.1	RP1-265C24.5	-3.69	0.000247	0.0169	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28115628~28116551:+
THCA	cis	rs4950322	0.576	rs2353979	ENSG00000180867.10	PDIA3P1	-3.69	0.000247	0.0169	-0.15	-0.17	Protein quantitative trait loci;	chr1:147368185	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.576	rs2353980	ENSG00000180867.10	PDIA3P1	-3.69	0.000247	0.0169	-0.15	-0.17	Protein quantitative trait loci;	chr1:147368274	chr1:147178113~147179622:+
THCA	cis	rs1862618	0.853	rs252898	ENSG00000234553.1	AC022431.3	-3.69	0.000247	0.0169	-0.19	-0.17	Initial pursuit acceleration;	chr5:56893104	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.802	rs194058	ENSG00000234553.1	AC022431.3	-3.69	0.000247	0.0169	-0.19	-0.17	Initial pursuit acceleration;	chr5:56893150	chr5:56536583~56537826:-
THCA	cis	rs12893668	0.703	rs729438	ENSG00000258735.1	LINC00637	3.69	0.000247	0.017	0.23	0.17	Reticulocyte count;	chr14:103626452	chr14:103847721~103858049:+
THCA	cis	rs4908768	0.501	rs910581	ENSG00000270282.1	RP5-1115A15.2	3.69	0.000247	0.017	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469464	chr1:8512653~8513021:+
THCA	cis	rs4908768	0.501	rs1024197	ENSG00000270282.1	RP5-1115A15.2	3.69	0.000247	0.017	0.2	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8476998	chr1:8512653~8513021:+
THCA	cis	rs4656958	0.754	rs10443910	ENSG00000233691.2	RP11-312J18.7	3.69	0.000247	0.017	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160924739	chr1:160935537~160936126:+
THCA	cis	rs11971779	0.715	rs7787398	ENSG00000252332.1	RNU6-911P	-3.69	0.000247	0.017	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139377100	chr7:139448740~139448843:+
THCA	cis	rs6580649	0.941	rs4141065	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000247	0.017	-0.18	-0.17	Lung cancer;	chr12:48129716	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.883	rs4075913	ENSG00000273765.1	RP11-370I10.11	3.69	0.000247	0.017	0.18	0.17	Lung cancer;	chr12:48143841	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.783	rs7969749	ENSG00000273765.1	RP11-370I10.11	3.69	0.000247	0.017	0.18	0.17	Lung cancer;	chr12:48156972	chr12:48360920~48361377:+
THCA	cis	rs4533267	0.879	rs7171129	ENSG00000189419.6	SPATA41	3.69	0.000247	0.017	0.22	0.17	Height;	chr15:100253142	chr15:100344457~100349655:-
THCA	cis	rs7914558	1	rs7920251	ENSG00000272912.1	RP11-724N1.1	-3.69	0.000247	0.017	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:102914585~102915404:+
THCA	cis	rs561341	1	rs2470267	ENSG00000265798.5	RP11-271K11.5	3.69	0.000247	0.017	0.25	0.17	Hip circumference adjusted for BMI;	chr17:31947113	chr17:31038575~31059121:-
THCA	cis	rs2278702	0.79	rs11858943	ENSG00000259495.2	RP11-210M15.2	-3.69	0.000247	0.017	-0.24	-0.17	Bipolar disorder;	chr15:80388289	chr15:80344853~80403575:-
THCA	cis	rs14027	0.921	rs10505374	ENSG00000245330.4	KB-1471A8.1	3.69	0.000247	0.017	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119867419~119874488:-
THCA	cis	rs11671005	0.572	rs11669127	ENSG00000268912.1	CTD-2619J13.17	3.69	0.000247	0.017	0.16	0.17	Mean platelet volume;	chr19:58492463	chr19:58428632~58431148:-
THCA	cis	rs4727027	0.704	rs7784122	ENSG00000244560.5	RP4-800G7.2	3.69	0.000247	0.017	0.1	0.17	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149207532	chr7:149285281~149297312:+
THCA	cis	rs765787	0.53	rs2554454	ENSG00000259539.1	CTD-2651B20.1	3.69	0.000247	0.017	0.21	0.17	Uric acid levels;	chr15:45229338	chr15:45152664~45167526:-
THCA	cis	rs9309473	1	rs2140195	ENSG00000273245.1	RP11-434P11.2	3.69	0.000247	0.017	0.23	0.17	Metabolite levels;	chr2:73475217	chr2:73750256~73750786:-
THCA	cis	rs2013441	0.866	rs12941200	ENSG00000261033.1	RP11-209D14.2	-3.69	0.000247	0.017	-0.24	-0.17	Obesity-related traits;	chr17:20108248	chr17:20008051~20009234:-
THCA	cis	rs7178909	0.872	rs10852124	ENSG00000259677.1	RP11-493E3.1	3.69	0.000247	0.017	0.2	0.17	Common traits (Other);	chr15:89887232	chr15:89876540~89877285:+
THCA	cis	rs6121246	0.865	rs77130187	ENSG00000230613.1	HM13-AS1	3.69	0.000247	0.017	0.2	0.17	Mean corpuscular hemoglobin;	chr20:31681257	chr20:31567707~31573263:-
THCA	cis	rs9309473	1	rs6715819	ENSG00000273245.1	RP11-434P11.2	3.69	0.000247	0.017	0.23	0.17	Metabolite levels;	chr2:73545182	chr2:73750256~73750786:-
THCA	cis	rs7829975	0.514	rs2920991	ENSG00000248538.5	RP11-10A14.5	-3.69	0.000247	0.017	-0.2	-0.17	Mood instability;	chr8:8401607	chr8:9189011~9202854:+
THCA	cis	rs1560104	0.576	rs7202727	ENSG00000262801.4	U91319.1	-3.69	0.000247	0.017	-0.19	-0.17	Obesity-related traits;	chr16:12614087	chr16:13246316~13562918:+
THCA	cis	rs860295	0.702	rs1556488	ENSG00000236675.1	MTX1P1	-3.69	0.000247	0.017	-0.17	-0.17	Body mass index;	chr1:155570869	chr1:155230975~155234325:+
THCA	cis	rs11671005	0.735	rs12986387	ENSG00000269600.1	AC016629.3	-3.69	0.000247	0.017	-0.25	-0.17	Mean platelet volume;	chr19:58415848	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs11667723	ENSG00000269600.1	AC016629.3	-3.69	0.000247	0.017	-0.25	-0.17	Mean platelet volume;	chr19:58416122	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs11668789	ENSG00000269600.1	AC016629.3	-3.69	0.000247	0.017	-0.25	-0.17	Mean platelet volume;	chr19:58416942	chr19:58593896~58599355:-
THCA	cis	rs9314614	0.872	rs2951861	ENSG00000245857.2	GS1-24F4.2	3.69	0.000247	0.017	0.21	0.17	White blood cell count (basophil);IgA nephropathy;	chr8:6854171	chr8:6835554~6885276:+
THCA	cis	rs4699052	1	rs7661702	ENSG00000230069.3	LRRC37A15P	-3.69	0.000247	0.017	-0.17	-0.17	Testicular germ cell tumor;	chr4:103218972	chr4:102727274~102730721:-
THCA	cis	rs4699052	0.928	rs2126473	ENSG00000230069.3	LRRC37A15P	-3.69	0.000247	0.017	-0.17	-0.17	Testicular germ cell tumor;	chr4:103220376	chr4:102727274~102730721:-
THCA	cis	rs7246657	0.722	rs1564208	ENSG00000226686.6	LINC01535	-3.69	0.000247	0.017	-0.24	-0.17	Coronary artery calcification;	chr19:37550319	chr19:37251912~37265535:+
THCA	cis	rs7819412	0.502	rs4841499	ENSG00000261451.1	RP11-981G7.1	-3.69	0.000248	0.017	-0.22	-0.17	Triglycerides;	chr8:11130628	chr8:10433672~10438312:+
THCA	cis	rs1577917	0.771	rs9362239	ENSG00000220563.1	PKMP3	3.69	0.000248	0.017	0.12	0.17	Response to antipsychotic treatment;	chr6:85719545	chr6:85659892~85660606:-
THCA	cis	rs2276314	1	rs9956938	ENSG00000267627.4	RP11-905K4.1	-3.69	0.000248	0.017	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35951803~35966118:-
THCA	cis	rs1385374	0.687	rs12824879	ENSG00000274695.1	RP11-21K12.3	3.69	0.000248	0.017	0.37	0.17	Systemic lupus erythematosus;	chr12:128843111	chr12:128826836~128827579:+
THCA	cis	rs8062405	0.757	rs2411453	ENSG00000270424.1	RP11-1348G14.6	-3.69	0.000248	0.017	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28749959~28750595:-
THCA	cis	rs7521681	0.838	rs4915072	ENSG00000230489.1	VAV3-AS1	-3.69	0.000248	0.017	-0.19	-0.17	Asthma and hay fever;	chr1:107771229	chr1:107964443~107994607:+
THCA	cis	rs17604090	0.775	rs76480599	ENSG00000223813.2	AC007255.8	3.69	0.000248	0.017	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649564	chr7:29514225~29563670:-
THCA	cis	rs10760158	0.832	rs10760159	ENSG00000235865.2	GSN-AS1	3.69	0.000248	0.017	0.15	0.17	Pulse pressure;	chr9:121236064	chr9:121280768~121285530:-
THCA	cis	rs10435719	0.805	rs13269417	ENSG00000255495.1	AC145124.2	3.69	0.000248	0.017	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:12194467~12196280:+
THCA	cis	rs7474896	0.507	rs2474555	ENSG00000275858.1	RP11-291L22.8	3.69	0.000248	0.017	0.25	0.17	Obesity (extreme);	chr10:38176292	chr10:38450738~38451069:-
THCA	cis	rs2180341	0.7	rs4598100	ENSG00000220522.2	RP1-177A13.1	3.69	0.000248	0.017	0.22	0.17	Breast cancer;	chr6:127244169	chr6:127416535~127416952:-
THCA	cis	rs875971	0.545	rs35459055	ENSG00000273024.4	INTS4P2	-3.69	0.000248	0.017	-0.21	-0.17	Aortic root size;	chr7:66479399	chr7:65647864~65715661:+
THCA	cis	rs9287719	0.934	rs6721510	ENSG00000243819.4	RN7SL832P	3.69	0.000248	0.017	0.13	0.17	Prostate cancer;	chr2:10610920	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6721514	ENSG00000243819.4	RN7SL832P	3.69	0.000248	0.017	0.13	0.17	Prostate cancer;	chr2:10610936	chr2:10690344~10692099:+
THCA	cis	rs295490	0.748	rs77423224	ENSG00000272656.1	RP11-219D15.3	3.69	0.000248	0.017	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139384020	chr3:139349024~139349371:-
THCA	cis	rs13217239	0.646	rs10946897	ENSG00000124549.13	BTN2A3P	3.69	0.000248	0.017	0.16	0.17	Schizophrenia;	chr6:27027472	chr6:26421391~26432383:+
THCA	cis	rs1501911	0.53	rs162473	ENSG00000246763.5	RGMB-AS1	-3.69	0.000248	0.017	-0.18	-0.17	Lung function (FEV1/FVC);	chr5:98805276	chr5:98769618~98773469:-
THCA	cis	rs9925964	0.869	rs749670	ENSG00000279196.1	RP11-1072A3.3	-3.69	0.000248	0.017	-0.16	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077304	chr16:30984630~30988270:-
THCA	cis	rs6822297	0.841	rs6847438	ENSG00000240005.4	RP11-293A21.1	3.69	0.000248	0.017	0.19	0.17	Obesity-related traits;	chr4:26913022	chr4:26859806~26860599:-
THCA	cis	rs34102591	0.503	rs61587964	ENSG00000270061.1	RP11-214K3.19	-3.69	0.000248	0.017	-0.21	-0.17	Schizophrenia;	chr12:123903039	chr12:123969990~123970344:-
THCA	cis	rs9990333	0.562	rs12632706	ENSG00000185485.13	SDHAP1	3.69	0.000248	0.017	0.15	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195959748~195990318:-
THCA	cis	rs7632954	0.547	rs9847309	ENSG00000227110.5	LMCD1-AS1	3.69	0.000248	0.017	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8494874	chr3:7952805~8611924:-
THCA	cis	rs1009077	1	rs13143126	ENSG00000245958.5	RP11-33B1.1	3.69	0.000248	0.017	0.21	0.17	Endometriosis;	chr4:119716649	chr4:119454791~119552025:+
THCA	cis	rs17092148	0.636	rs59030726	ENSG00000269202.1	RP4-614O4.12	-3.69	0.000248	0.017	-0.18	-0.17	Neuroticism;	chr20:34866314	chr20:35201747~35203288:-
THCA	cis	rs459571	0.804	rs448918	ENSG00000235106.7	LINC00094	3.69	0.000248	0.017	0.15	0.17	Platelet distribution width;	chr9:134020857	chr9:134025439~134034666:+
THCA	cis	rs7142002	0.536	rs10083330	ENSG00000271780.1	RP11-1017G21.5	-3.69	0.000248	0.017	-0.31	-0.17	Autism;	chr14:102208211	chr14:101948347~101949425:+
THCA	cis	rs7487075	0.521	rs11183576	ENSG00000274723.1	RP11-618L22.1	3.69	0.000248	0.017	0.15	0.17	Itch intensity from mosquito bite;	chr12:46714734	chr12:46970504~46972155:+
THCA	cis	rs9863	0.828	rs12311848	ENSG00000270028.1	RP11-380L11.4	3.69	0.000248	0.017	0.18	0.17	White blood cell count;	chr12:124002304	chr12:123925461~123926083:-
THCA	cis	rs988712	0.921	rs10835195	ENSG00000245573.6	BDNF-AS	-3.69	0.000248	0.017	-0.15	-0.17	Obesity;	chr11:27555684	chr11:27506838~27698174:+
THCA	cis	rs7973719	0.509	rs10161405	ENSG00000256967.1	RP11-273B20.1	-3.69	0.000248	0.017	-0.14	-0.17	IgG glycosylation;	chr12:7206050	chr12:7129079~7131198:-
THCA	cis	rs7973719	0.509	rs10161542	ENSG00000256967.1	RP11-273B20.1	-3.69	0.000248	0.017	-0.14	-0.17	IgG glycosylation;	chr12:7206088	chr12:7129079~7131198:-
THCA	cis	rs17027633	0.867	rs7543384	ENSG00000234020.1	CHIAP3	3.69	0.000248	0.017	0.35	0.17	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405392	chr1:111353275~111367409:-
THCA	cis	rs9341808	0.69	rs6930534	ENSG00000260645.1	RP11-250B2.5	3.69	0.000248	0.017	0.14	0.17	Sitting height ratio;	chr6:80186333	chr6:80466958~80469080:+
THCA	cis	rs6957923	0.714	rs11766660	ENSG00000234286.1	AC006026.13	-3.69	0.000248	0.017	-0.22	-0.17	Height;	chr7:23484606	chr7:23680195~23680786:-
THCA	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	3.69	0.000248	0.017	0.19	0.17	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
THCA	cis	rs17428076	0.872	rs6761111	ENSG00000228389.1	AC068039.4	-3.69	0.000248	0.017	-0.21	-0.17	Myopia;	chr2:172018664	chr2:171773482~171775844:+
THCA	cis	rs12049671	0.932	rs12413190	ENSG00000227076.1	RP11-4C20.4	3.69	0.000248	0.017	0.18	0.17	Response to amphetamines;	chr10:127948473	chr10:127934698~127936167:+
THCA	cis	rs2625529	0.667	rs16956381	ENSG00000260037.4	CTD-2524L6.3	-3.69	0.000248	0.017	-0.24	-0.17	Red blood cell count;	chr15:71900896	chr15:71818396~71823384:+
THCA	cis	rs755249	0.642	rs11206430	ENSG00000228060.1	RP11-69E11.8	-3.69	0.000248	0.017	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39609695	chr1:39565160~39573203:+
THCA	cis	rs875971	0.964	rs6945019	ENSG00000230189.5	GS1-124K5.2	3.69	0.000248	0.017	0.11	0.17	Aortic root size;	chr7:66457471	chr7:66409143~66490059:-
THCA	cis	rs7713065	0.765	rs2158101	ENSG00000263597.1	MIR3936	-3.69	0.000248	0.017	-0.21	-0.17	Lung function (FEV1/FVC);	chr5:132433581	chr5:132365490~132365599:-
THCA	cis	rs3767627	1	rs4926400	ENSG00000203819.6	HIST2H2BC	3.69	0.000248	0.017	0.24	0.17	Height;	chr1:149959622	chr1:149850193~149850772:-
THCA	cis	rs2320614	1	rs72631677	ENSG00000250027.1	RP11-563E2.2	-3.69	0.000248	0.017	-0.15	-0.17	Lung adenocarcinoma;	chr4:163106583	chr4:163108785~163119965:+
THCA	cis	rs6687821	0.5	rs2753270	ENSG00000261737.1	RP4-612B15.3	-3.69	0.000248	0.017	-0.25	-0.17	Yeast infection;	chr1:86947874	chr1:86703502~86704462:-
THCA	cis	rs559555	0.888	rs10207755	ENSG00000276517.1	AL133243.2	-3.69	0.000248	0.017	-0.16	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31571900	chr2:32526504~32529507:+
THCA	cis	rs7578199	0.576	rs2074775	ENSG00000223374.1	AC005104.3	-3.69	0.000248	0.017	-0.12	-0.17	Chronic lymphocytic leukemia;	chr2:241456618	chr2:241351340~241353104:-
THCA	cis	rs2033711	0.84	rs4801590	ENSG00000268049.1	CTD-2619J13.9	-3.69	0.000248	0.017	-0.21	-0.17	Uric acid clearance;	chr19:58450446	chr19:58357999~58359603:+
THCA	cis	rs4767841	0.537	rs203352	ENSG00000248636.5	RP11-768F21.1	-3.69	0.000248	0.017	-0.17	-0.17	Urgency urinary incontinence;	chr12:119794663	chr12:119387987~119668079:-
THCA	cis	rs7824557	0.724	rs2572398	ENSG00000254866.2	DEFB109P3	-3.69	0.000248	0.017	-0.23	-0.17	Retinal vascular caliber;	chr8:11320584	chr8:12150895~12151134:-
THCA	cis	rs7246967	0.611	rs62118780	ENSG00000236312.3	RPL34P34	-3.69	0.000248	0.017	-0.23	-0.17	Bronchopulmonary dysplasia;	chr19:22648312	chr19:22368599~22368952:-
THCA	cis	rs7246967	0.611	rs4933019	ENSG00000236312.3	RPL34P34	-3.69	0.000248	0.017	-0.23	-0.17	Bronchopulmonary dysplasia;	chr19:22649184	chr19:22368599~22368952:-
THCA	cis	rs6088590	0.687	rs6088580	ENSG00000276073.1	RP5-1125A11.7	-3.69	0.000248	0.017	-0.15	-0.17	Coronary artery disease;	chr20:34697249	chr20:33985617~33988989:-
THCA	cis	rs6088590	0.813	rs1884668	ENSG00000276073.1	RP5-1125A11.7	-3.69	0.000248	0.017	-0.15	-0.17	Coronary artery disease;	chr20:34697710	chr20:33985617~33988989:-
THCA	cis	rs28374715	0.662	rs513280	ENSG00000247556.5	OIP5-AS1	-3.69	0.000248	0.017	-0.16	-0.17	Ulcerative colitis;	chr15:41190602	chr15:41283990~41309737:+
THCA	cis	rs6580649	0.943	rs9651993	ENSG00000273765.1	RP11-370I10.11	3.69	0.000248	0.017	0.19	0.17	Lung cancer;	chr12:48010909	chr12:48360920~48361377:+
THCA	cis	rs6479901	0.639	rs10995448	ENSG00000272767.1	JMJD1C-AS1	-3.69	0.000248	0.017	-0.2	-0.17	Intelligence (multi-trait analysis);	chr10:63127299	chr10:63465229~63466563:+
THCA	cis	rs6479901	0.639	rs7082200	ENSG00000272767.1	JMJD1C-AS1	-3.69	0.000248	0.017	-0.2	-0.17	Intelligence (multi-trait analysis);	chr10:63128561	chr10:63465229~63466563:+
THCA	cis	rs73173548	0.502	rs12516483	ENSG00000247828.6	TMEM161B-AS1	3.69	0.000248	0.017	0.15	0.17	Macular telangiectasia type 2;	chr5:88454718	chr5:88268895~88436685:+
THCA	cis	rs9905704	0.881	rs695137	ENSG00000224738.1	AC099850.1	3.69	0.000248	0.017	0.23	0.17	Testicular germ cell tumor;	chr17:58699302	chr17:59106598~59118267:+
THCA	cis	rs9450351	0.744	rs7752222	ENSG00000203875.9	SNHG5	-3.69	0.000248	0.017	-0.32	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85913874	chr6:85660950~85678736:-
THCA	cis	rs10090774	0.87	rs10093977	ENSG00000280303.2	ERICD	-3.69	0.000249	0.017	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141000585	chr8:140636281~140638283:+
THCA	cis	rs1009077	0.625	rs3756157	ENSG00000248280.1	RP11-33B1.2	-3.69	0.000249	0.017	-0.19	-0.17	Endometriosis;	chr4:119604255	chr4:119440561~119450157:-
THCA	cis	rs1009077	0.627	rs28650385	ENSG00000248280.1	RP11-33B1.2	-3.69	0.000249	0.017	-0.19	-0.17	Endometriosis;	chr4:119605320	chr4:119440561~119450157:-
THCA	cis	rs17685	0.671	rs10274404	ENSG00000227038.2	AC005077.12	3.69	0.000249	0.017	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76077316	chr7:76090431~76108779:-
THCA	cis	rs720064	0.586	rs9950106	ENSG00000264745.1	TTC39C-AS1	3.69	0.000249	0.017	0.18	0.17	Strep throat;	chr18:23967901	chr18:23994213~24015339:-
THCA	cis	rs7647973	0.769	rs11130181	ENSG00000229759.1	MRPS18AP1	3.69	0.000249	0.017	0.25	0.17	Menarche (age at onset);	chr3:49072486	chr3:48256350~48256938:-
THCA	cis	rs11064837	0.504	rs10774508	ENSG00000248636.5	RP11-768F21.1	3.69	0.000249	0.017	0.19	0.17	Schizophrenia;	chr12:119632301	chr12:119387987~119668079:-
THCA	cis	rs2191566	0.54	rs391267	ENSG00000277806.1	RP11-15A1.8	3.69	0.000249	0.017	0.17	0.17	Acute lymphoblastic leukemia (childhood);	chr19:43988335	chr19:43976815~43977448:+
THCA	cis	rs7142002	0.527	rs58186728	ENSG00000272444.1	RP11-1017G21.6	-3.69	0.000249	0.017	-0.19	-0.17	Autism;	chr14:101922824	chr14:101952416~101953063:+
THCA	cis	rs7142002	0.568	rs58337996	ENSG00000272444.1	RP11-1017G21.6	-3.69	0.000249	0.017	-0.19	-0.17	Autism;	chr14:101922950	chr14:101952416~101953063:+
THCA	cis	rs7142002	0.568	rs58304956	ENSG00000272444.1	RP11-1017G21.6	-3.69	0.000249	0.017	-0.19	-0.17	Autism;	chr14:101923434	chr14:101952416~101953063:+
THCA	cis	rs7142002	0.568	rs7158886	ENSG00000272444.1	RP11-1017G21.6	-3.69	0.000249	0.017	-0.19	-0.17	Autism;	chr14:101923615	chr14:101952416~101953063:+
THCA	cis	rs1959947	0.876	rs7150908	ENSG00000251363.2	RP11-129M6.1	3.69	0.000249	0.017	0.22	0.17	Hemostatic factors and hematological phenotypes;	chr14:41071721	chr14:40954898~40975877:+
THCA	cis	rs10802047	0.609	rs513252	ENSG00000231365.4	RP11-418J17.1	-3.69	0.000249	0.017	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118692389	chr1:119140396~119275973:+
THCA	cis	rs7010267	0.711	rs10955908	ENSG00000254278.1	RP11-278I4.2	3.69	0.000249	0.017	0.21	0.17	Total body bone mineral density (age 45-60);	chr8:118892318	chr8:119062942~119068782:-
THCA	cis	rs4887067	1	rs4887067	ENSG00000261762.1	RP11-650L12.2	-3.69	0.000249	0.017	-0.22	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78594605	chr15:78589123~78591276:-
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000255046.1	RP11-297N6.4	-3.69	0.000249	0.017	-0.17	-0.17	Neuroticism;	chr8:11991324	chr8:11797928~11802568:-
THCA	cis	rs875971	0.895	rs6460278	ENSG00000223473.2	GS1-124K5.3	-3.69	0.000249	0.017	-0.11	-0.17	Aortic root size;	chr7:66197749	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6460279	ENSG00000223473.2	GS1-124K5.3	-3.69	0.000249	0.017	-0.11	-0.17	Aortic root size;	chr7:66197774	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs28491091	ENSG00000223473.2	GS1-124K5.3	-3.69	0.000249	0.017	-0.11	-0.17	Aortic root size;	chr7:66204077	chr7:66491049~66493566:-
THCA	cis	rs7520050	0.898	rs785502	ENSG00000280836.1	AL355480.1	3.69	0.000249	0.017	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45581219~45581321:-
THCA	cis	rs4578769	0.569	rs12958551	ENSG00000273232.1	RP11-370A5.2	3.69	0.000249	0.017	0.23	0.17	Eosinophil percentage of white cells;	chr18:22897885	chr18:22882825~22883357:-
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000265443.1	CTD-2349P21.6	-3.69	0.000249	0.017	-0.28	-0.17	Body mass index;	chr17:30778787	chr17:30726305~30727564:-
THCA	cis	rs5758511	0.637	rs5751244	ENSG00000237037.8	NDUFA6-AS1	-3.69	0.000249	0.017	-0.16	-0.17	Birth weight;	chr22:42221405	chr22:42090931~42137742:+
THCA	cis	rs7212590	0.881	rs7214032	ENSG00000267302.4	RP11-178C3.2	3.69	0.000249	0.017	0.31	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808467	chr17:59964832~59996972:+
THCA	cis	rs13315871	1	rs9864325	ENSG00000272182.1	RP11-802O23.3	3.69	0.000249	0.017	0.27	0.17	Cholesterol, total;	chr3:58351119	chr3:58428255~58428815:+
THCA	cis	rs75828804	1	rs75298397	ENSG00000260922.1	RP11-538I12.3	-3.69	0.000249	0.017	-0.36	-0.17	Intraocular pressure;	chr16:77568031	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs79308106	ENSG00000260922.1	RP11-538I12.3	-3.69	0.000249	0.017	-0.36	-0.17	Intraocular pressure;	chr16:77571363	chr16:77234877~77290934:+
THCA	cis	rs3736858	0.932	rs17065145	ENSG00000261105.4	LMO7-AS1	-3.69	0.000249	0.017	-0.23	-0.17	Interleukin-9 levels;	chr13:75854052	chr13:75604700~75635994:-
THCA	cis	rs10540	0.73	rs12789735	ENSG00000279672.1	CMB9-55F22.1	3.69	0.000249	0.017	0.33	0.17	Body mass index;	chr11:518509	chr11:779617~780755:+
THCA	cis	rs2839186	0.771	rs13049175	ENSG00000228137.1	AP001469.7	-3.69	0.000249	0.017	-0.17	-0.17	Testicular germ cell tumor;	chr21:46221412	chr21:46246890~46247682:+
THCA	cis	rs757282	0.534	rs11608804	ENSG00000268069.2	RP5-1057I20.4	3.69	0.000249	0.017	0.27	0.17	Optic nerve measurement (cup-to-disc ratio);	chr12:47782319	chr12:47784923~47786002:+
THCA	cis	rs478304	0.651	rs11227279	ENSG00000255320.1	RP11-755F10.1	3.69	0.000249	0.017	0.22	0.17	Acne (severe);	chr11:65727740	chr11:66244840~66246239:-
THCA	cis	rs4853525	0.651	rs12623559	ENSG00000235852.1	AC005540.3	3.69	0.000249	0.017	0.18	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190868617	chr2:190880797~190882059:-
THCA	cis	rs17092148	0.636	rs6058107	ENSG00000269202.1	RP4-614O4.12	3.69	0.000249	0.0171	0.18	0.17	Neuroticism;	chr20:34700742	chr20:35201747~35203288:-
THCA	cis	rs929354	0.713	rs6459733	ENSG00000224629.1	RP5-1142J19.2	-3.69	0.000249	0.0171	-0.17	-0.17	Body mass index;	chr7:157137856	chr7:157263022~157263229:-
THCA	cis	rs2281603	0.571	rs59577187	ENSG00000258824.2	CTD-2555O16.2	-3.69	0.000249	0.0171	-0.15	-0.17	Lymphocyte counts;	chr14:64488953	chr14:64422935~64448557:-
THCA	cis	rs77147124	1	rs2255400	ENSG00000225292.2	RP11-57H14.3	-3.69	0.000249	0.0171	-0.22	-0.17	HDL cholesterol;	chr10:112176486	chr10:112888735~112906111:+
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000184274.3	LINC00315	-3.69	0.000249	0.0171	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45300245~45305257:-
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000281021.1	RP1-12G14.9	-3.69	0.000249	0.0171	-0.17	-0.17	Lung cancer;	chr6:149616921	chr6:149576089~149590864:-
THCA	cis	rs4763879	0.634	rs2012643	ENSG00000214776.8	RP11-726G1.1	-3.69	0.000249	0.0171	-0.2	-0.17	Type 1 diabetes;	chr12:9707128	chr12:9467552~9576275:+
THCA	cis	rs11190604	1	rs3750719	ENSG00000273030.1	RP11-285F16.1	3.69	0.000249	0.0171	0.2	0.17	Palmitoleic acid (16:1n-7) levels;	chr10:100489193	chr10:100412934~100413421:+
THCA	cis	rs1023500	0.551	rs2859438	ENSG00000270083.1	RP1-257I20.14	3.69	0.000249	0.0171	0.19	0.17	Schizophrenia;	chr22:42070976	chr22:42089630~42090028:-
THCA	cis	rs1023500	0.505	rs134887	ENSG00000273366.1	CTA-989H11.1	-3.69	0.000249	0.0171	-0.21	-0.17	Schizophrenia;	chr22:42278233	chr22:42278188~42278846:+
THCA	cis	rs2882667	0.931	rs6596457	ENSG00000249593.5	CTB-46B19.2	3.69	0.000249	0.0171	0.2	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:139012647~139051203:+
THCA	cis	rs9652490	0.646	rs12901420	ENSG00000214646.7	RP11-114H24.4	3.69	0.000249	0.0171	0.29	0.17	Essential tremor;	chr15:77674648	chr15:77941442~77944582:-
THCA	cis	rs765787	0.53	rs4774550	ENSG00000259932.1	CTD-2651B20.7	3.69	0.000249	0.0171	0.2	0.17	Uric acid levels;	chr15:45250114	chr15:45198517~45199139:-
THCA	cis	rs9987353	0.566	rs34491841	ENSG00000253981.4	ALG1L13P	-3.69	0.000249	0.0171	-0.17	-0.17	Recombination measurement;	chr8:9208000	chr8:8236003~8244667:-
THCA	cis	rs13217239	0.646	rs4269366	ENSG00000124549.13	BTN2A3P	3.69	0.000249	0.0171	0.16	0.17	Schizophrenia;	chr6:27048634	chr6:26421391~26432383:+
THCA	cis	rs9926296	0.569	rs4785708	ENSG00000274627.1	RP11-104N10.2	3.69	0.000249	0.0171	0.17	0.17	Vitiligo;	chr16:89730161	chr16:89516797~89522217:+
THCA	cis	rs9425766	0.55	rs57366619	ENSG00000270084.1	GAS5-AS1	-3.69	0.000249	0.0171	-0.17	-0.17	Life satisfaction;	chr1:174334929	chr1:173863248~173863941:+
THCA	cis	rs10802047	0.508	rs7524122	ENSG00000231365.4	RP11-418J17.1	-3.69	0.000249	0.0171	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118782571	chr1:119140396~119275973:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000272831.1	RP11-792A8.4	-3.69	0.000249	0.0171	-0.12	-0.17	Aortic root size;	chr7:66087510	chr7:66739829~66740385:-
THCA	cis	rs14027	0.921	rs12707880	ENSG00000245330.4	KB-1471A8.1	3.69	0.000249	0.0171	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119867419~119874488:-
THCA	cis	rs797680	0.576	rs55838267	ENSG00000229635.1	RP4-713B5.2	3.69	0.000249	0.0171	0.24	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93384487~93384998:-
THCA	cis	rs853679	0.517	rs16893666	ENSG00000219891.2	ZSCAN12P1	-3.69	0.000249	0.0171	-0.24	-0.17	Depression;	chr6:28086929	chr6:28091154~28093664:+
THCA	cis	rs56114371	0.53	rs9348774	ENSG00000220721.1	OR1F12	3.69	0.000249	0.0171	0.23	0.17	Breast cancer;	chr6:27721151	chr6:28073316~28074233:+
THCA	cis	rs7246760	0.867	rs2336089	ENSG00000267106.4	ZNF561-AS1	3.69	0.000249	0.0171	0.33	0.17	Pursuit maintenance gain;	chr19:9739296	chr19:9621291~9645896:+
THCA	cis	rs7246760	0.867	rs34648216	ENSG00000267106.4	ZNF561-AS1	3.69	0.000249	0.0171	0.33	0.17	Pursuit maintenance gain;	chr19:9740014	chr19:9621291~9645896:+
THCA	cis	rs7246760	1	rs67507476	ENSG00000267106.4	ZNF561-AS1	3.69	0.000249	0.0171	0.33	0.17	Pursuit maintenance gain;	chr19:9742272	chr19:9621291~9645896:+
THCA	cis	rs7246760	1	rs59771283	ENSG00000267106.4	ZNF561-AS1	3.69	0.000249	0.0171	0.33	0.17	Pursuit maintenance gain;	chr19:9744282	chr19:9621291~9645896:+
THCA	cis	rs4664304	0.62	rs10929957	ENSG00000226266.5	AC009961.3	-3.69	0.000249	0.0171	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159859997	chr2:159670708~159712435:-
THCA	cis	rs6137726	0.524	rs1203938	ENSG00000237396.1	LINC01384	3.69	0.000249	0.0171	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22614320	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1203939	ENSG00000237396.1	LINC01384	3.69	0.000249	0.0171	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22614618	chr20:22587522~22607517:-
THCA	cis	rs7711186	0.708	rs6869889	ENSG00000252464.1	RN7SKP70	3.69	0.000249	0.0171	0.18	0.17	Urate levels in obese individuals;	chr5:178634715	chr5:178619728~178619998:-
THCA	cis	rs2274273	0.84	rs6573020	ENSG00000258469.1	CHMP4BP1	3.69	0.000249	0.0171	0.15	0.17	Protein biomarker;	chr14:55404734	chr14:55298644~55299231:+
THCA	cis	rs13108904	0.87	rs3755927	ENSG00000254094.1	AC078852.1	-3.69	0.000249	0.0171	-0.19	-0.17	Obesity-related traits;	chr4:1244458	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.87	rs3755924	ENSG00000254094.1	AC078852.1	-3.69	0.000249	0.0171	-0.19	-0.17	Obesity-related traits;	chr4:1244575	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.87	rs3775094	ENSG00000254094.1	AC078852.1	-3.69	0.000249	0.0171	-0.19	-0.17	Obesity-related traits;	chr4:1245071	chr4:1356581~1358075:+
THCA	cis	rs3755605	0.793	rs6804193	ENSG00000242578.1	RP11-469J4.3	-3.69	0.000249	0.0171	-0.18	-0.17	Testicular germ cell tumor;	chr3:170064416	chr3:170410512~170418615:+
THCA	cis	rs1790761	0.505	rs34721562	ENSG00000255318.1	RP11-655M14.13	-3.69	0.000249	0.0171	-0.18	-0.17	Mean corpuscular volume;	chr11:67545237	chr11:67618279~67627304:-
THCA	cis	rs12121840	0.79	rs16847148	ENSG00000237463.4	RP11-280O1.2	-3.69	0.000249	0.0171	-0.15	-0.17	Interleukin-1-receptor antagonist levels;	chr1:165570567	chr1:165476841~165582155:-
THCA	cis	rs12121840	0.736	rs12142937	ENSG00000237463.4	RP11-280O1.2	-3.69	0.000249	0.0171	-0.15	-0.17	Interleukin-1-receptor antagonist levels;	chr1:165571455	chr1:165476841~165582155:-
THCA	cis	rs12121840	0.79	rs10918212	ENSG00000237463.4	RP11-280O1.2	-3.69	0.000249	0.0171	-0.15	-0.17	Interleukin-1-receptor antagonist levels;	chr1:165572440	chr1:165476841~165582155:-
THCA	cis	rs752590	0.524	rs45449699	ENSG00000227359.1	AC017074.2	3.69	0.000249	0.0171	0.29	0.17	Mucinous ovarian carcinoma;	chr2:113197656	chr2:113677702~113704078:-
THCA	cis	rs2320614	0.967	rs11938737	ENSG00000250027.1	RP11-563E2.2	-3.69	0.000249	0.0171	-0.15	-0.17	Lung adenocarcinoma;	chr4:163124239	chr4:163108785~163119965:+
THCA	cis	rs12681366	0.663	rs3099398	ENSG00000261437.1	RP11-22C11.2	3.69	0.000249	0.0171	0.15	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94467651	chr8:94637285~94639467:-
THCA	cis	rs8020289	0.957	rs2103452	ENSG00000258301.3	RP11-488C13.5	-3.69	0.000249	0.0171	-0.17	-0.17	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr14:76814738	chr14:76781733~76786724:-
THCA	cis	rs860295	1	rs708611	ENSG00000160766.13	GBAP1	3.69	0.000249	0.0171	0.19	0.17	Body mass index;	chr1:155773519	chr1:155213821~155227422:-
THCA	cis	rs6921919	0.848	rs9468350	ENSG00000176933.5	TOB2P1	-3.69	0.000249	0.0171	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28217643~28218634:-
THCA	cis	rs140330585	1	rs140330585	ENSG00000261762.1	RP11-650L12.2	-3.69	0.000249	0.0171	-0.22	-0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78574103	chr15:78589123~78591276:-
THCA	cis	rs7129556	0.863	rs11237225	ENSG00000254459.1	RP11-91P24.7	3.69	0.000249	0.0171	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77572516	chr11:77829654~77872262:-
THCA	cis	rs7621025	0.691	rs4678438	ENSG00000239213.4	NCK1-AS1	3.69	0.000249	0.0171	0.15	0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136626078	chr3:136841726~136862054:-
THCA	cis	rs9291683	0.588	rs2240724	ENSG00000261490.1	RP11-448G15.3	3.69	0.000249	0.0171	0.1	0.17	Bone mineral density;	chr4:10019666	chr4:10068089~10073019:-
THCA	cis	rs324126	1	rs324126	ENSG00000243680.1	RPL37P23	3.69	0.000249	0.0171	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr19:52382884	chr19:52143043~52143336:+
THCA	cis	rs2455799	0.573	rs2455812	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000249	0.0171	-0.18	-0.17	Mean platelet volume;	chr3:15692589	chr3:15732252~15733470:+
THCA	cis	rs2255336	0.679	rs11053804	ENSG00000245648.1	RP11-277P12.20	-3.69	0.000249	0.0171	-0.18	-0.17	Blood protein levels;	chr12:10447683	chr12:10363769~10398506:+
THCA	cis	rs1577917	1	rs791856	ENSG00000220563.1	PKMP3	3.69	0.000249	0.0171	0.13	0.17	Response to antipsychotic treatment;	chr6:85972123	chr6:85659892~85660606:-
THCA	cis	rs791590	0.941	rs12722561	ENSG00000225948.2	RP11-554I8.1	3.69	0.000249	0.0171	0.27	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6027930	chr10:6618716~6625346:+
THCA	cis	rs9843304	0.546	rs9858201	ENSG00000243885.1	RP11-278L15.2	-3.69	0.000249	0.0171	-0.19	-0.17	Gallstone disease;	chr3:149501881	chr3:149384179~149385800:-
THCA	cis	rs2522056	1	rs2706339	ENSG00000237714.1	P4HA2-AS1	-3.69	0.000249	0.0171	-0.24	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132464413	chr5:132184876~132192808:+
THCA	cis	rs3104964	0.614	rs3102484	ENSG00000253773.2	C8orf37-AS1	3.69	0.000249	0.0171	0.21	0.17	Colorectal cancer;	chr8:95692962	chr8:95204456~95810136:+
THCA	cis	rs7520050	0.966	rs61102033	ENSG00000281133.1	AL355480.3	3.69	0.000249	0.0171	0.19	0.17	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45580892~45580996:-
THCA	cis	rs7267979	1	rs6132835	ENSG00000276952.1	RP5-965G21.6	3.69	0.00025	0.0171	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25284915~25285588:-
THCA	cis	rs2287641	0.826	rs59093347	ENSG00000272156.1	RP11-477N3.1	3.69	0.00025	0.0171	0.31	0.17	Cannabis dependence symptom count;	chr2:54043366	chr2:54082554~54085066:+
THCA	cis	rs875971	0.505	rs1167386	ENSG00000232546.1	RP11-458F8.1	3.69	0.00025	0.0171	0.14	0.17	Aortic root size;	chr7:66048109	chr7:66848496~66858136:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000232546.1	RP11-458F8.1	3.69	0.00025	0.0171	0.14	0.17	Aortic root size;	chr7:66048321	chr7:66848496~66858136:+
THCA	cis	rs3750082	0.889	rs6462432	ENSG00000205763.12	RP9P	3.69	0.00025	0.0171	0.15	0.17	Glomerular filtration rate (creatinine);	chr7:32895912	chr7:32916815~32943176:-
THCA	cis	rs2898290	0.5	rs11998678	ENSG00000254866.2	DEFB109P3	3.69	0.00025	0.0171	0.23	0.17	Systolic blood pressure;	chr8:11972641	chr8:12150895~12151134:-
THCA	cis	rs6030712	0.723	rs7261175	ENSG00000213979.3	RPL7AP14	-3.69	0.00025	0.0171	-0.27	-0.17	Height;	chr20:36918247	chr20:37444733~37445534:-
THCA	cis	rs6030712	0.723	rs2342113	ENSG00000213979.3	RPL7AP14	-3.69	0.00025	0.0171	-0.27	-0.17	Height;	chr20:36922795	chr20:37444733~37445534:-
THCA	cis	rs2340727	0.66	rs9970209	ENSG00000229808.1	RP11-456P18.2	-3.69	0.00025	0.0171	-0.23	-0.17	White blood cell count;Hematology traits;	chr1:161972852	chr1:161890833~161892196:+
THCA	cis	rs420259	0.516	rs4968014	ENSG00000260136.4	CTD-2270L9.4	-3.69	0.00025	0.0171	-0.13	-0.17	Bipolar disorder;	chr16:23512554	chr16:23452758~23457606:+
THCA	cis	rs9510787	0.618	rs9507126	ENSG00000205861.10	C1QTNF9B-AS1	-3.69	0.00025	0.0171	-0.21	-0.17	Nasopharyngeal carcinoma;	chr13:23641894	chr13:23888889~23897263:+
THCA	cis	rs791590	0.887	rs11591302	ENSG00000225948.2	RP11-554I8.1	3.69	0.00025	0.0171	0.27	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6009778	chr10:6618716~6625346:+
THCA	cis	rs12691307	1	rs12691307	ENSG00000273724.1	RP11-347C12.12	-3.69	0.00025	0.0171	-0.16	-0.17	Schizophrenia;	chr16:29928556	chr16:30336400~30343336:+
THCA	cis	rs2434529	0.628	rs80107723	ENSG00000245275.6	SAP30L-AS1	3.69	0.00025	0.0171	0.28	0.17	Autism spectrum disorder or schizophrenia;	chr5:154275319	chr5:154329437~154445850:-
THCA	cis	rs708224	0.587	rs326641	ENSG00000277342.1	RP11-843B15.4	3.69	0.00025	0.0171	0.21	0.17	Pancreatic cancer;	chr12:32246935	chr12:32109076~32109602:+
THCA	cis	rs7968440	0.75	rs67356137	ENSG00000272368.2	RP4-605O3.4	3.69	0.00025	0.0171	0.11	0.17	Fibrinogen;	chr12:50778044	chr12:50112197~50165618:+
THCA	cis	rs7968440	0.808	rs66947035	ENSG00000272368.2	RP4-605O3.4	3.69	0.00025	0.0171	0.11	0.17	Fibrinogen;	chr12:50781260	chr12:50112197~50165618:+
THCA	cis	rs10833905	1	rs11026889	ENSG00000246225.5	RP11-17A1.3	-3.69	0.00025	0.0171	-0.24	-0.17	Sudden cardiac arrest;	chr11:22999897	chr11:22829380~22945393:+
THCA	cis	rs9905704	0.918	rs2611779	ENSG00000224738.1	AC099850.1	3.69	0.00025	0.0171	0.23	0.17	Testicular germ cell tumor;	chr17:58714471	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs35934668	ENSG00000224738.1	AC099850.1	3.69	0.00025	0.0171	0.23	0.17	Testicular germ cell tumor;	chr17:58817277	chr17:59106598~59118267:+
THCA	cis	rs2120243	0.533	rs1500921	ENSG00000243176.4	RP11-550I24.2	3.69	0.00025	0.0171	0.16	0.17	Hepatocellular carcinoma in hepatitis B infection;	chr3:157337638	chr3:157175223~157381265:+
THCA	cis	rs2120243	0.533	rs62278578	ENSG00000243176.4	RP11-550I24.2	3.69	0.00025	0.0171	0.16	0.17	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338078	chr3:157175223~157381265:+
THCA	cis	rs10129255	1	rs9324091	ENSG00000280411.1	IGHV1-69-2	-3.69	0.00025	0.0171	-0.11	-0.17	Kawasaki disease;	chr14:106676625	chr14:106762092~106762588:-
THCA	cis	rs10129255	1	rs61997605	ENSG00000280411.1	IGHV1-69-2	-3.69	0.00025	0.0171	-0.11	-0.17	Kawasaki disease;	chr14:106678368	chr14:106762092~106762588:-
THCA	cis	rs10129255	1	rs8012033	ENSG00000280411.1	IGHV1-69-2	-3.69	0.00025	0.0171	-0.11	-0.17	Kawasaki disease;	chr14:106678854	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.912	rs8011090	ENSG00000280411.1	IGHV1-69-2	-3.69	0.00025	0.0171	-0.11	-0.17	Kawasaki disease;	chr14:106678896	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.912	rs67410411	ENSG00000280411.1	IGHV1-69-2	-3.69	0.00025	0.0171	-0.11	-0.17	Kawasaki disease;	chr14:106680324	chr14:106762092~106762588:-
THCA	cis	rs9948	1	rs11897786	ENSG00000230606.9	AC159540.1	3.69	0.00025	0.0171	0.24	0.17	Erectile dysfunction and prostate cancer treatment;	chr2:96841135	chr2:97416165~97433527:-
THCA	cis	rs8130944	1	rs8130333	ENSG00000225731.1	AP001627.1	3.69	0.00025	0.0171	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42716342	chr21:42733594~42741758:-
THCA	cis	rs6686643	0.762	rs9333432	ENSG00000236206.1	RP11-306I1.2	3.69	0.00025	0.0171	0.23	0.17	Total ventricular volume;	chr1:165641922	chr1:165598463~165623331:+
THCA	cis	rs6686643	0.762	rs9333433	ENSG00000236206.1	RP11-306I1.2	3.69	0.00025	0.0171	0.23	0.17	Total ventricular volume;	chr1:165642218	chr1:165598463~165623331:+
THCA	cis	rs6686643	0.762	rs61800372	ENSG00000236206.1	RP11-306I1.2	3.69	0.00025	0.0171	0.23	0.17	Total ventricular volume;	chr1:165642744	chr1:165598463~165623331:+
THCA	cis	rs6686643	0.762	rs6672982	ENSG00000236206.1	RP11-306I1.2	3.69	0.00025	0.0171	0.23	0.17	Total ventricular volume;	chr1:165643578	chr1:165598463~165623331:+
THCA	cis	rs7637701	0.773	rs9859058	ENSG00000243926.1	TIPARP-AS1	3.69	0.00025	0.0171	0.17	0.17	Breast cancer;	chr3:156795028	chr3:156671862~156674378:-
THCA	cis	rs357618	0.581	rs165359	ENSG00000260581.1	CTB-113P19.4	3.69	0.00025	0.0171	0.25	0.17	Basophil percentage of white cells;	chr5:151481475	chr5:151652275~151655449:+
THCA	cis	rs6121246	0.909	rs6060960	ENSG00000224628.2	RP5-854E16.2	3.69	0.00025	0.0171	0.22	0.17	Mean corpuscular hemoglobin;	chr20:31806714	chr20:31285317~31286835:-
THCA	cis	rs2733201	1	rs1426658	ENSG00000166763.7	STRCP1	-3.69	0.00025	0.0171	-0.33	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44046721	chr15:43699488~43718184:-
THCA	cis	rs9303542	0.694	rs12941877	ENSG00000278765.1	RP5-890E16.5	-3.69	0.00025	0.0171	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48348972	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs7224686	ENSG00000278765.1	RP5-890E16.5	-3.69	0.00025	0.0171	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48351206	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs17696503	ENSG00000278765.1	RP5-890E16.5	-3.69	0.00025	0.0171	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48354476	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs17623482	ENSG00000278765.1	RP5-890E16.5	-3.69	0.00025	0.0171	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48354811	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs12150117	ENSG00000278765.1	RP5-890E16.5	-3.69	0.00025	0.0171	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48365896	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs17696640	ENSG00000278765.1	RP5-890E16.5	-3.69	0.00025	0.0171	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48367058	chr17:48066704~48067293:-
THCA	cis	rs7569084	1	rs13385171	ENSG00000214533.3	KRT18P33	-3.69	0.00025	0.0171	-0.21	-0.17	Sum eosinophil basophil counts;	chr2:65434709	chr2:65666695~65667737:+
THCA	cis	rs858239	0.537	rs6942981	ENSG00000230042.1	AK3P3	-3.69	0.00025	0.0171	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23129178~23129841:+
THCA	cis	rs3768792	0.665	rs7580927	ENSG00000196096.3	AC079610.2	3.69	0.00025	0.0171	0.24	0.17	Systemic lupus erythematosus;	chr2:212983338	chr2:213276552~213284205:-
THCA	cis	rs494003	0.951	rs11227283	ENSG00000214659.4	KRT8P26	3.69	0.00025	0.0171	0.19	0.17	Systemic lupus erythematosus;	chr11:65731551	chr11:65726939~65728214:+
THCA	cis	rs9287719	0.967	rs10929686	ENSG00000243819.4	RN7SL832P	3.69	0.00025	0.0171	0.13	0.17	Prostate cancer;	chr2:10603579	chr2:10690344~10692099:+
THCA	cis	rs7937	1	rs7937	ENSG00000279108.1	CTC-490E21.11	-3.69	0.00025	0.0171	-0.18	-0.17	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40796801	chr19:40840159~40842039:+
THCA	cis	rs2019137	0.936	rs3828189	ENSG00000234997.1	AC016745.3	-3.69	0.00025	0.0171	-0.16	-0.17	Lymphocyte counts;	chr2:113196919	chr2:113424495~113425324:+
THCA	cis	rs7178375	0.941	rs4779796	ENSG00000269930.1	RP11-932O9.9	-3.69	0.00025	0.0171	-0.23	-0.17	Hypertriglyceridemia;	chr15:30915847	chr15:30616958~30617749:+
THCA	cis	rs150992	0.512	rs161954	ENSG00000241597.2	CTD-2007H13.1	-3.69	0.00025	0.0171	-0.22	-0.17	Body mass index;	chr5:98920833	chr5:98954394~98954972:+
THCA	cis	rs13113518	0.812	rs11945371	ENSG00000223305.1	RN7SKP30	3.69	0.00025	0.0171	0.21	0.17	Height;	chr4:55409063	chr4:55540502~55540835:-
THCA	cis	rs10090774	0.901	rs10106406	ENSG00000280303.2	ERICD	-3.69	0.00025	0.0171	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140996099	chr8:140636281~140638283:+
THCA	cis	rs57709857	0.749	rs7845911	ENSG00000272092.1	RP11-350N15.5	-3.69	0.00025	0.0171	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38277894	chr8:38382364~38383461:+
THCA	cis	rs5756506	0.767	rs2235321	ENSG00000233360.4	Z83844.1	3.69	0.00025	0.0171	0.18	0.17	Hematological parameters;	chr22:37066886	chr22:37641832~37658377:-
THCA	cis	rs7312933	0.702	rs10785333	ENSG00000257225.1	RP11-328C8.4	3.69	0.00025	0.0171	0.18	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42192668	chr12:42459366~42466128:+
THCA	cis	rs911186	0.947	rs9379962	ENSG00000219392.1	RP1-265C24.5	-3.69	0.00025	0.0171	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:27177532	chr6:28115628~28116551:+
THCA	cis	rs6456156	0.586	rs9457261	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167054191	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs1407315	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167055171	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs12527827	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167055783	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.565	rs12529959	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167055804	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs911632	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167057973	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs2017338	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167058226	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.51	rs6456151	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Crohn's disease;	chr6:167058363	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.565	rs6456153	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167058679	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.565	rs12525345	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167065387	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs13195158	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167067904	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs9457266	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167069067	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.565	rs7750209	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167069407	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs7746628	ENSG00000235272.1	FAM103A2P	3.69	0.00025	0.0171	0.23	0.17	Primary biliary cholangitis;	chr6:167069747	chr6:166586124~166586477:-
THCA	cis	rs6990255	0.681	rs1495236	ENSG00000243181.2	RP11-734J24.1	-3.69	0.00025	0.0171	-0.3	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr8:34262232	chr8:34874159~34874633:+
THCA	cis	rs3924048	0.574	rs11121925	ENSG00000272482.1	RP11-474O21.5	-3.69	0.00025	0.0171	-0.15	-0.17	Optic cup area;	chr1:12553100	chr1:12618900~12619244:-
THCA	cis	rs16957091	0.647	rs12915116	ENSG00000205771.5	CATSPER2P1	3.69	0.00025	0.0171	0.23	0.17	MGMT methylation in smokers;	chr15:42782482	chr15:43726918~43747094:-
THCA	cis	rs9303542	0.729	rs8072521	ENSG00000278765.1	RP5-890E16.5	-3.69	0.00025	0.0171	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48352260	chr17:48066704~48067293:-
THCA	cis	rs2281603	0.808	rs10132424	ENSG00000258824.2	CTD-2555O16.2	-3.69	0.00025	0.0171	-0.17	-0.17	Lymphocyte counts;	chr14:64527157	chr14:64422935~64448557:-
THCA	cis	rs1560104	0.597	rs4781300	ENSG00000262801.4	U91319.1	-3.69	0.000251	0.0171	-0.19	-0.17	Obesity-related traits;	chr16:12613866	chr16:13246316~13562918:+
THCA	cis	rs6840360	1	rs6823002	ENSG00000270265.1	RP11-731D1.4	-3.69	0.000251	0.0171	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151683315	chr4:151333775~151353224:-
THCA	cis	rs4869313	0.668	rs2549791	ENSG00000247121.5	CTD-2260A17.2	3.69	0.000251	0.0171	0.13	0.17	Pediatric autoimmune diseases;	chr5:96906738	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2549792	ENSG00000247121.5	CTD-2260A17.2	3.69	0.000251	0.0171	0.13	0.17	Pediatric autoimmune diseases;	chr5:96906758	chr5:96814028~96935809:-
THCA	cis	rs7824557	0.564	rs2736290	ENSG00000255495.1	AC145124.2	-3.69	0.000251	0.0171	-0.19	-0.17	Retinal vascular caliber;	chr8:11376789	chr8:12194467~12196280:+
THCA	cis	rs150992	0.678	rs161950	ENSG00000241597.2	CTD-2007H13.1	3.69	0.000251	0.0172	0.22	0.17	Body mass index;	chr5:98924533	chr5:98954394~98954972:+
THCA	cis	rs1979679	0.553	rs78804134	ENSG00000247934.4	RP11-967K21.1	-3.69	0.000251	0.0172	-0.16	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28113449	chr12:28163298~28190738:-
THCA	cis	rs9308731	0.966	rs3827536	ENSG00000204581.2	AC096670.3	-3.69	0.000251	0.0172	-0.17	-0.17	Chronic lymphocytic leukemia;	chr2:111163164	chr2:111098345~111115588:-
THCA	cis	rs67478160	0.595	rs1475007	ENSG00000258534.1	CTD-2134A5.4	-3.69	0.000251	0.0172	-0.17	-0.17	Schizophrenia;	chr14:103830810	chr14:103854366~103880111:-
THCA	cis	rs765787	0.53	rs4774542	ENSG00000259932.1	CTD-2651B20.7	-3.69	0.000251	0.0172	-0.21	-0.17	Uric acid levels;	chr15:45233828	chr15:45198517~45199139:-
THCA	cis	rs6921919	0.848	rs6903823	ENSG00000176933.5	TOB2P1	-3.69	0.000251	0.0172	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28217643~28218634:-
THCA	cis	rs1555322	1	rs2425027	ENSG00000279253.1	RP4-614O4.13	-3.69	0.000251	0.0172	-0.23	-0.17	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35262727~35264187:-
THCA	cis	rs4759375	1	rs12366872	ENSG00000256092.2	RP13-942N8.1	-3.69	0.000251	0.0172	-0.18	-0.17	HDL cholesterol;	chr12:123320174	chr12:123363868~123366113:+
THCA	cis	rs5753037	0.639	rs5997534	ENSG00000279699.1	RP1-102K2.9	3.69	0.000251	0.0172	0.16	0.17	Type 1 diabetes;	chr22:29824201	chr22:30275215~30276951:-
THCA	cis	rs613391	0.671	rs504121	ENSG00000234840.1	LINC01239	-3.69	0.000251	0.0172	-0.2	-0.17	Quantitative traits;	chr9:22705424	chr9:22646200~22824213:+
THCA	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-3.69	0.000251	0.0172	-0.2	-0.17	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
THCA	cis	rs9905704	0.918	rs304293	ENSG00000224738.1	AC099850.1	3.69	0.000251	0.0172	0.23	0.17	Testicular germ cell tumor;	chr17:58745937	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs11657676	ENSG00000224738.1	AC099850.1	3.69	0.000251	0.0172	0.23	0.17	Testicular germ cell tumor;	chr17:58764682	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.874	rs28483505	ENSG00000224738.1	AC099850.1	3.69	0.000251	0.0172	0.23	0.17	Testicular germ cell tumor;	chr17:58766748	chr17:59106598~59118267:+
THCA	cis	rs889312	0.5	rs252906	ENSG00000271828.1	CTD-2310F14.1	-3.69	0.000251	0.0172	-0.23	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56823363	chr5:56927874~56929573:+
THCA	cis	rs1009077	0.536	rs13124532	ENSG00000245958.5	RP11-33B1.1	3.69	0.000251	0.0172	0.26	0.17	Endometriosis;	chr4:119495290	chr4:119454791~119552025:+
THCA	cis	rs962856	0.521	rs668175	ENSG00000236780.4	AC078941.1	3.69	0.000251	0.0172	0.23	0.17	Pancreatic cancer;	chr2:67437055	chr2:67123357~67215319:-
THCA	cis	rs365302	0.723	rs391046	ENSG00000235086.1	FNDC1-IT1	3.69	0.000251	0.0172	0.24	0.17	Coronary heart disease;	chr6:159225200	chr6:159240786~159243329:+
THCA	cis	rs959260	1	rs2053158	ENSG00000263843.1	RP11-649A18.12	-3.69	0.000251	0.0172	-0.18	-0.17	Systemic lupus erythematosus;	chr17:75397378	chr17:75271369~75273895:+
THCA	cis	rs2115630	1	rs4633690	ENSG00000275120.1	RP11-182J1.17	-3.69	0.000251	0.0172	-0.17	-0.17	P wave terminal force;	chr15:84818729	chr15:84599434~84606463:-
THCA	cis	rs2880765	0.835	rs4843062	ENSG00000259407.1	RP11-158M2.3	-3.69	0.000251	0.0172	-0.17	-0.17	Coronary artery disease;	chr15:85496906	chr15:85744109~85750281:-
THCA	cis	rs6580649	0.941	rs4760677	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000251	0.0172	-0.18	-0.17	Lung cancer;	chr12:48055380	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs11612970	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000251	0.0172	-0.18	-0.17	Lung cancer;	chr12:48057226	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs57380031	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000251	0.0172	-0.18	-0.17	Lung cancer;	chr12:48058454	chr12:48360920~48361377:+
THCA	cis	rs9902453	0.73	rs2020939	ENSG00000266865.5	RP11-848P1.9	-3.69	0.000251	0.0172	-0.14	-0.17	Coffee consumption (cups per day);	chr17:30223714	chr17:31008497~31093127:+
THCA	cis	rs2562456	0.917	rs9304987	ENSG00000268278.1	RP11-420K14.1	-3.69	0.000251	0.0172	-0.2	-0.17	Pain;	chr19:21499472	chr19:21637974~21656300:+
THCA	cis	rs4722166	0.508	rs4506102	ENSG00000225541.1	AC002480.5	-3.69	0.000251	0.0172	-0.18	-0.17	Lung cancer;	chr7:22707533	chr7:22571607~22661792:-
THCA	cis	rs4879656	0.897	rs1537255	ENSG00000225693.1	LAGE3P1	-3.69	0.000251	0.0172	-0.19	-0.17	Menopause (age at onset);	chr9:33004377	chr9:33019682~33020165:-
THCA	cis	rs6430585	0.527	rs60966546	ENSG00000231890.6	DARS-AS1	-3.69	0.000251	0.0172	-0.19	-0.17	Corneal structure;	chr2:135644273	chr2:135985176~136022593:+
THCA	cis	rs12200782	0.577	rs3757144	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26380694	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs7775720	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26381129	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.51	rs9467738	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26381953	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.578	rs9467739	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26382345	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs12189870	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26382537	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs4490658	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26384885	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs9467742	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26386135	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs9467743	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26386278	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs9467744	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26386483	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs9467745	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26386534	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs9467746	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26387177	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.578	rs2237233	ENSG00000124549.13	BTN2A3P	-3.69	0.000251	0.0172	-0.2	-0.17	Small cell lung carcinoma;	chr6:26387307	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs3757146	ENSG00000124549.13	BTN2A3P	3.69	0.000251	0.0172	0.2	0.17	Small cell lung carcinoma;	chr6:26380897	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.649	rs3757148	ENSG00000124549.13	BTN2A3P	3.69	0.000251	0.0172	0.2	0.17	Small cell lung carcinoma;	chr6:26380978	chr6:26421391~26432383:+
THCA	cis	rs737008	0.96	rs949429	ENSG00000263080.1	RP11-485G7.5	-3.69	0.000251	0.0172	-0.2	-0.17	Obesity-related traits;	chr16:11282172	chr16:11341809~11345211:-
THCA	cis	rs12681366	0.537	rs2919664	ENSG00000253175.1	RP11-267M23.6	3.69	0.000251	0.0172	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94456485	chr8:94565036~94565715:+
THCA	cis	rs4841134	0.684	rs878336	ENSG00000254153.1	CTA-398F10.2	3.69	0.000251	0.0172	0.18	0.17	Age-related disease endophenotypes;	chr8:9368119	chr8:8456909~8461337:-
THCA	cis	rs6812193	0.899	rs28689064	ENSG00000234036.4	TXNP6	3.69	0.000251	0.0172	0.23	0.17	Parkinson's disease;	chr4:76276243	chr4:76958860~76959169:-
THCA	cis	rs6812193	0.867	rs28636815	ENSG00000234036.4	TXNP6	3.69	0.000251	0.0172	0.23	0.17	Parkinson's disease;	chr4:76276244	chr4:76958860~76959169:-
THCA	cis	rs11992162	0.933	rs10108075	ENSG00000255046.1	RP11-297N6.4	-3.69	0.000251	0.0172	-0.18	-0.17	Monocyte count;	chr8:11974570	chr8:11797928~11802568:-
THCA	cis	rs2455799	0.613	rs2654654	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000251	0.0172	-0.18	-0.17	Mean platelet volume;	chr3:15747735	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs4684259	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000251	0.0172	-0.18	-0.17	Mean platelet volume;	chr3:15749772	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs4467435	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000251	0.0172	-0.18	-0.17	Mean platelet volume;	chr3:15750164	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs4685258	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000251	0.0172	-0.18	-0.17	Mean platelet volume;	chr3:15750808	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs7614204	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000251	0.0172	-0.18	-0.17	Mean platelet volume;	chr3:15751241	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs6795100	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000251	0.0172	-0.18	-0.17	Mean platelet volume;	chr3:15752291	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs4684261	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000251	0.0172	-0.18	-0.17	Mean platelet volume;	chr3:15754998	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs3924773	ENSG00000270409.1	RP11-44D5.1	-3.69	0.000251	0.0172	-0.18	-0.17	Mean platelet volume;	chr3:15755346	chr3:15732252~15733470:+
THCA	cis	rs17818399	0.712	rs13008088	ENSG00000279254.1	RP11-536C12.1	-3.69	0.000251	0.0172	-0.17	-0.17	Height;	chr2:46554441	chr2:46668870~46670778:+
THCA	cis	rs7129556	0.775	rs72945598	ENSG00000254459.1	RP11-91P24.7	3.69	0.000251	0.0172	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77656693	chr11:77829654~77872262:-
THCA	cis	rs7312933	0.612	rs10785334	ENSG00000257225.1	RP11-328C8.4	3.69	0.000251	0.0172	0.18	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42226575	chr12:42459366~42466128:+
THCA	cis	rs2806561	0.734	rs11578046	ENSG00000249087.5	ZNF436-AS1	-3.69	0.000251	0.0172	-0.11	-0.17	Height;	chr1:23098646	chr1:23368997~23371839:+
THCA	cis	rs288326	0.561	rs57018234	ENSG00000272800.1	RP11-438L19.1	3.69	0.000251	0.0172	0.28	0.17	Blood protein levels;	chr2:182843528	chr2:183214319~183215400:+
THCA	cis	rs6921919	0.789	rs13210258	ENSG00000176933.5	TOB2P1	-3.69	0.000251	0.0172	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28217643~28218634:-
THCA	cis	rs6938	0.597	rs11856413	ENSG00000260269.4	CTD-2323K18.1	-3.69	0.000251	0.0172	-0.24	-0.17	Breast cancer;	chr15:74907551	chr15:75527150~75601205:-
THCA	cis	rs28595532	0.748	rs55949457	ENSG00000260404.2	RP11-384K6.6	-3.69	0.000251	0.0172	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118415019	chr4:118591773~118633729:+
THCA	cis	rs11048434	0.518	rs759469	ENSG00000256720.1	RP11-436I9.6	3.69	0.000251	0.0172	0.18	0.17	Sjögren's syndrome;	chr12:9023108	chr12:9135084~9135591:+
THCA	cis	rs987724	0.515	rs6762708	ENSG00000243926.1	TIPARP-AS1	-3.69	0.000251	0.0172	-0.21	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973815	chr3:156671862~156674378:-
THCA	cis	rs972540	0.96	rs7355410	ENSG00000229647.1	AC007879.7	-3.69	0.000251	0.0172	-0.19	-0.17	Body mass index;	chr2:206382705	chr2:207239650~207245887:+
THCA	cis	rs11976180	1	rs6464574	ENSG00000244198.4	RP4-545C24.1	-3.69	0.000251	0.0172	-0.17	-0.17	Obesity-related traits;	chr7:144051164	chr7:144194858~144280547:+
THCA	cis	rs10089	1	rs3805607	ENSG00000245937.6	LINC01184	3.69	0.000251	0.0172	0.19	0.17	Ileal carcinoids;	chr5:128141726	chr5:127940426~128083172:-
THCA	cis	rs7914558	0.966	rs3977751	ENSG00000213061.2	PFN1P11	3.69	0.000251	0.0172	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:102838011~102845473:-
THCA	cis	rs11673344	0.504	rs10402907	ENSG00000233527.7	ZNF529-AS1	3.69	0.000251	0.0172	0.14	0.17	Obesity-related traits;	chr19:37112874	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.563	rs4805199	ENSG00000233527.7	ZNF529-AS1	3.69	0.000251	0.0172	0.14	0.17	Obesity-related traits;	chr19:37115527	chr19:36573070~36594708:+
THCA	cis	rs17767294	1	rs17767294	ENSG00000220721.1	OR1F12	3.69	0.000251	0.0172	0.36	0.17	Parkinson's disease;	chr6:28086420	chr6:28073316~28074233:+
THCA	cis	rs6756513	0.5	rs6546552	ENSG00000231024.1	AC092431.3	-3.69	0.000251	0.0172	-0.25	-0.17	Breast cancer;Platelet count;	chr2:69849518	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs7577662	ENSG00000231024.1	AC092431.3	-3.69	0.000251	0.0172	-0.25	-0.17	Breast cancer;Platelet count;	chr2:69850290	chr2:69700192~69713847:-
THCA	cis	rs6756513	0.5	rs7565230	ENSG00000231024.1	AC092431.3	-3.69	0.000251	0.0172	-0.25	-0.17	Breast cancer;Platelet count;	chr2:69850301	chr2:69700192~69713847:-
THCA	cis	rs2839186	0.508	rs6518278	ENSG00000228137.1	AP001469.7	-3.69	0.000251	0.0172	-0.18	-0.17	Testicular germ cell tumor;	chr21:46220657	chr21:46246890~46247682:+
THCA	cis	rs12935229	0.756	rs6564434	ENSG00000260922.1	RP11-538I12.3	-3.69	0.000251	0.0172	-0.26	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77362938	chr16:77234877~77290934:+
THCA	cis	rs7665090	1	rs7665090	ENSG00000248971.2	KRT8P46	3.69	0.000251	0.0172	0.19	0.17	Primary biliary cholangitis;	chr4:102630446	chr4:102728746~102730171:-
THCA	cis	rs8058578	0.943	rs35629860	ENSG00000260911.2	RP11-196G11.2	3.69	0.000251	0.0172	0.15	0.17	Multiple myeloma;	chr16:30660211	chr16:31043150~31049868:+
THCA	cis	rs6546886	0.871	rs12713810	ENSG00000235499.1	AC073046.25	-3.69	0.000251	0.0172	-0.16	-0.17	Dialysis-related mortality;	chr2:74093135	chr2:73985132~73986343:+
THCA	cis	rs4763879	0.778	rs9332411	ENSG00000214776.8	RP11-726G1.1	-3.69	0.000251	0.0172	-0.2	-0.17	Type 1 diabetes;	chr12:9681749	chr12:9467552~9576275:+
THCA	cis	rs7474896	0.537	rs2472149	ENSG00000272983.1	RP11-508N22.12	3.69	0.000251	0.0172	0.17	0.17	Obesity (extreme);	chr10:37973268	chr10:38137337~38144399:+
THCA	cis	rs2281603	0.57	rs2123460	ENSG00000258824.2	CTD-2555O16.2	-3.69	0.000251	0.0172	-0.15	-0.17	Lymphocyte counts;	chr14:64485507	chr14:64422935~64448557:-
THCA	cis	rs73193808	0.639	rs2832248	ENSG00000231125.2	AF129075.5	-3.69	0.000251	0.0172	-0.16	-0.17	Coronary artery disease;	chr21:29184660	chr21:29058073~29060095:-
THCA	cis	rs7829975	0.514	rs2976926	ENSG00000248538.5	RP11-10A14.5	-3.69	0.000251	0.0172	-0.2	-0.17	Mood instability;	chr8:8404114	chr8:9189011~9202854:+
THCA	cis	rs16975963	0.843	rs73041045	ENSG00000226686.6	LINC01535	-3.69	0.000252	0.0172	-0.23	-0.17	Longevity;	chr19:37805386	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.843	rs1056405	ENSG00000226686.6	LINC01535	-3.69	0.000252	0.0172	-0.23	-0.17	Longevity;	chr19:37822381	chr19:37251912~37265535:+
THCA	cis	rs4915077	0.656	rs4440889	ENSG00000226822.1	RP11-356N1.2	3.69	0.000252	0.0172	0.31	0.17	Hypothyroidism;	chr1:107717760	chr1:108071482~108074519:+
THCA	cis	rs59901009	0.532	rs7936461	ENSG00000246273.5	SBF2-AS1	-3.69	0.000252	0.0172	-0.22	-0.17	Hematocrit;Hemoglobin concentration;	chr11:10019339	chr11:9758292~9811319:+
THCA	cis	rs61160187	0.577	rs34741733	ENSG00000251279.1	CTC-436P18.1	-3.69	0.000252	0.0172	-0.2	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:61162070~61232040:+
THCA	cis	rs4267450	0.842	rs11666652	ENSG00000261770.1	CTC-459F4.1	3.69	0.000252	0.0172	0.3	0.17	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28397433	chr19:27757184~27760849:-
THCA	cis	rs7178375	1	rs28693590	ENSG00000269930.1	RP11-932O9.9	-3.69	0.000252	0.0172	-0.23	-0.17	Hypertriglyceridemia;	chr15:30902818	chr15:30616958~30617749:+
THCA	cis	rs4713118	0.786	rs200502	ENSG00000272009.1	RP1-313I6.12	-3.69	0.000252	0.0172	-0.19	-0.17	Parkinson's disease;	chr6:27820284	chr6:28078792~28081130:-
THCA	cis	rs9487051	1	rs1546723	ENSG00000260273.1	RP11-425D10.10	3.69	0.000252	0.0172	0.21	0.17	Reticulocyte fraction of red cells;	chr6:109304676	chr6:109382795~109383666:+
THCA	cis	rs938554	0.612	rs4385059	ENSG00000261490.1	RP11-448G15.3	-3.69	0.000252	0.0172	-0.14	-0.17	Blood metabolite levels;	chr4:9987609	chr4:10068089~10073019:-
THCA	cis	rs7824557	0.564	rs2736293	ENSG00000227888.4	FAM66A	-3.69	0.000252	0.0172	-0.21	-0.17	Retinal vascular caliber;	chr8:11377104	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs2736294	ENSG00000227888.4	FAM66A	-3.69	0.000252	0.0172	-0.21	-0.17	Retinal vascular caliber;	chr8:11377117	chr8:12362019~12388296:+
THCA	cis	rs8044868	0.893	rs12929749	ENSG00000260886.1	TAT-AS1	3.69	0.000252	0.0172	0.2	0.17	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72134342	chr16:71565789~71578187:+
THCA	cis	rs4648739	0.613	rs13303201	ENSG00000268575.1	RP1-283E3.8	3.69	0.000252	0.0172	0.17	0.17	Severe influenza A (H1N1) infection;	chr1:1972273	chr1:1702736~1737688:-
THCA	cis	rs7819412	0.635	rs4841501	ENSG00000255046.1	RP11-297N6.4	3.69	0.000252	0.0172	0.18	0.17	Triglycerides;	chr8:11143466	chr8:11797928~11802568:-
THCA	cis	rs12612619	0.689	rs10181551	ENSG00000272148.1	RP11-195B17.1	-3.69	0.000252	0.0172	-0.17	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27054406	chr2:27062428~27062907:-
THCA	cis	rs6058526	0.561	rs6119786	ENSG00000235217.6	TSPY26P	-3.69	0.000252	0.0172	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr20:32239479	chr20:32186477~32190527:-
THCA	cis	rs10438797	0.838	rs6505111	ENSG00000276995.1	RP11-321A17.6	-3.69	0.000252	0.0172	-0.16	-0.17	Night sleep phenotypes;	chr17:29165609	chr17:29071124~29071594:-
THCA	cis	rs7918232	0.574	rs10458708	ENSG00000215409.4	RP11-748L13.2	-3.69	0.000252	0.0172	-0.19	-0.17	Breast cancer;	chr10:27166676	chr10:27331357~27341252:-
THCA	cis	rs17181170	1	rs6791387	ENSG00000239572.1	RP11-451B8.1	-3.69	0.000252	0.0172	-0.19	-0.17	Prostate cancer;	chr3:87131998	chr3:87731402~87793629:-
THCA	cis	rs7809950	0.53	rs111865019	ENSG00000272072.1	CTA-363E19.2	3.69	0.000252	0.0172	0.19	0.17	Coronary artery disease;	chr7:107171801	chr7:107192559~107193300:-
THCA	cis	rs150992	0.593	rs326491	ENSG00000246763.5	RGMB-AS1	3.69	0.000252	0.0172	0.17	0.17	Body mass index;	chr5:98972225	chr5:98769618~98773469:-
THCA	cis	rs1153858	1	rs7171577	ENSG00000275672.1	GATM-AS1	-3.69	0.000252	0.0172	-0.17	-0.17	Homoarginine levels;	chr15:45335781	chr15:45378700~45380123:+
THCA	cis	rs853679	0.567	rs13209596	ENSG00000220721.1	OR1F12	3.69	0.000252	0.0172	0.21	0.17	Depression;	chr6:28428413	chr6:28073316~28074233:+
THCA	cis	rs853679	0.567	rs9969098	ENSG00000220721.1	OR1F12	3.69	0.000252	0.0172	0.21	0.17	Depression;	chr6:28430971	chr6:28073316~28074233:+
THCA	cis	rs853679	0.567	rs7740429	ENSG00000220721.1	OR1F12	3.69	0.000252	0.0172	0.21	0.17	Depression;	chr6:28431469	chr6:28073316~28074233:+
THCA	cis	rs853679	0.567	rs16894106	ENSG00000220721.1	OR1F12	3.69	0.000252	0.0172	0.21	0.17	Depression;	chr6:28432562	chr6:28073316~28074233:+
THCA	cis	rs11771526	0.901	rs62457494	ENSG00000272905.1	RP11-265E18.1	3.69	0.000252	0.0172	0.23	0.17	Body mass index;	chr7:32272687	chr7:32845394~32846061:+
THCA	cis	rs875971	0.545	rs2460427	ENSG00000232559.3	GS1-124K5.12	-3.69	0.000252	0.0172	-0.18	-0.17	Aortic root size;	chr7:66154218	chr7:66554588~66576923:-
THCA	cis	rs559928	0.549	rs57831436	ENSG00000236935.1	AP003774.1	3.69	0.000252	0.0172	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64239825	chr11:64325050~64329504:-
THCA	cis	rs9796	0.87	rs4244584	ENSG00000247556.5	OIP5-AS1	-3.69	0.000252	0.0172	-0.13	-0.17	Menopause (age at onset);	chr15:40967325	chr15:41283990~41309737:+
THCA	cis	rs7918232	0.627	rs10829165	ENSG00000262412.1	RP11-85G18.6	3.69	0.000252	0.0172	0.21	0.17	Breast cancer;	chr10:27030536	chr10:27243130~27250804:+
THCA	cis	rs6500602	0.647	rs4786501	ENSG00000280063.1	RP11-295D4.3	-3.69	0.000252	0.0172	-0.09	-0.17	Schizophrenia;	chr16:4486164	chr16:4346694~4348648:-
THCA	cis	rs2665103	0.589	rs2134046	ENSG00000276710.3	CSPG4P8	-3.69	0.000252	0.0172	-0.16	-0.17	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82459472~82477258:+
THCA	cis	rs13113518	0.812	rs1522114	ENSG00000223305.1	RN7SKP30	3.69	0.000252	0.0172	0.22	0.17	Height;	chr4:55489895	chr4:55540502~55540835:-
THCA	cis	rs6490294	0.747	rs659964	ENSG00000226469.1	ADAM1B	3.69	0.000252	0.0172	0.21	0.17	Mean platelet volume;	chr12:111692395	chr12:111927018~111929017:+
THCA	cis	rs2191566	0.959	rs7256345	ENSG00000267114.1	CTB-129P6.11	3.69	0.000252	0.0172	0.13	0.17	Acute lymphoblastic leukemia (childhood);	chr19:44006753	chr19:44950044~44954007:-
THCA	cis	rs2191566	0.959	rs7255623	ENSG00000267114.1	CTB-129P6.11	3.69	0.000252	0.0172	0.13	0.17	Acute lymphoblastic leukemia (childhood);	chr19:44006754	chr19:44950044~44954007:-
THCA	cis	rs9980	0.895	rs7193778	ENSG00000226232.7	RP11-419C5.2	-3.69	0.000252	0.0172	-0.26	-0.17	Blood osmolality (transformed sodium);	chr16:69529987	chr16:69976388~69996188:-
THCA	cis	rs9980	0.548	rs9934764	ENSG00000226232.7	RP11-419C5.2	3.69	0.000252	0.0172	0.26	0.17	Blood osmolality (transformed sodium);	chr16:69530429	chr16:69976388~69996188:-
THCA	cis	rs9402743	0.632	rs9389330	ENSG00000272189.1	RP3-325F22.5	-3.69	0.000252	0.0172	-0.15	-0.17	Systemic lupus erythematosus;	chr6:135787865	chr6:136550661~136552554:+
THCA	cis	rs1559040	1	rs10176406	ENSG00000272156.1	RP11-477N3.1	-3.69	0.000252	0.0172	-0.25	-0.17	Sudden cardiac arrest;	chr2:54106211	chr2:54082554~54085066:+
THCA	cis	rs2360027	0.622	rs10802047	ENSG00000231365.4	RP11-418J17.1	-3.69	0.000252	0.0172	-0.17	-0.17	Tonsillectomy;	chr1:118601809	chr1:119140396~119275973:+
THCA	cis	rs860295	1	rs822478	ENSG00000160766.13	GBAP1	3.69	0.000252	0.0172	0.19	0.17	Body mass index;	chr1:155824178	chr1:155213821~155227422:-
THCA	cis	rs56114371	0.53	rs2056923	ENSG00000220721.1	OR1F12	3.69	0.000252	0.0172	0.26	0.17	Breast cancer;	chr6:27722160	chr6:28073316~28074233:+
THCA	cis	rs2839186	0.786	rs7409792	ENSG00000228137.1	AP001469.7	3.69	0.000252	0.0172	0.17	0.17	Testicular germ cell tumor;	chr21:46271815	chr21:46246890~46247682:+
THCA	cis	rs62158800	0.598	rs1516215	ENSG00000225588.2	AC096669.1	3.69	0.000252	0.0172	0.17	0.17	Facial morphology (factor 22);	chr2:107676325	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs6542730	ENSG00000225588.2	AC096669.1	3.69	0.000252	0.0172	0.17	0.17	Facial morphology (factor 22);	chr2:107676927	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs1588950	ENSG00000225588.2	AC096669.1	3.69	0.000252	0.0172	0.17	0.17	Facial morphology (factor 22);	chr2:107681369	chr2:107362282~107407329:+
THCA	cis	rs7819412	1	rs7819412	ENSG00000261451.1	RP11-981G7.1	3.69	0.000252	0.0172	0.21	0.17	Triglycerides;	chr8:11187652	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.603	rs2249804	ENSG00000206014.6	OR7E161P	-3.69	0.000252	0.0172	-0.2	-0.17	Retinal vascular caliber;	chr8:11358108	chr8:11928597~11929563:-
THCA	cis	rs10461617	0.617	rs6874733	ENSG00000234553.1	AC022431.3	-3.69	0.000252	0.0172	-0.18	-0.17	Type 2 diabetes;	chr5:56773773	chr5:56536583~56537826:-
THCA	cis	rs5758511	0.68	rs5758692	ENSG00000270083.1	RP1-257I20.14	-3.69	0.000252	0.0172	-0.21	-0.17	Birth weight;	chr22:42273023	chr22:42089630~42090028:-
THCA	cis	rs7968440	0.808	rs6580769	ENSG00000272368.2	RP4-605O3.4	3.69	0.000252	0.0172	0.11	0.17	Fibrinogen;	chr12:50801738	chr12:50112197~50165618:+
THCA	cis	rs3176789	0.651	rs12819552	ENSG00000256673.1	RP11-599J14.2	3.69	0.000252	0.0172	0.21	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767236	chr12:9398355~9414851:-
THCA	cis	rs8023401	0.507	rs11070644	ENSG00000259705.1	RP11-227D13.1	3.69	0.000252	0.0172	0.2	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48492300	chr15:48645951~48652016:+
THCA	cis	rs1799922	1	rs12533022	ENSG00000271553.1	RP11-274B21.10	-3.69	0.000252	0.0172	-0.15	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128742819	chr7:128667043~128668156:+
THCA	cis	rs765787	0.53	rs2413786	ENSG00000259539.1	CTD-2651B20.1	3.69	0.000252	0.0172	0.2	0.17	Uric acid levels;	chr15:45233196	chr15:45152664~45167526:-
THCA	cis	rs4767841	0.565	rs4766949	ENSG00000252886.1	RN7SKP197	-3.69	0.000252	0.0172	-0.17	-0.17	Urgency urinary incontinence;	chr12:119789194	chr12:119631090~119631386:-
THCA	cis	rs6546886	0.826	rs13030414	ENSG00000235499.1	AC073046.25	3.69	0.000252	0.0172	0.16	0.17	Dialysis-related mortality;	chr2:74028157	chr2:73985132~73986343:+
THCA	cis	rs9467773	0.62	rs6925087	ENSG00000228223.2	HCG11	-3.69	0.000252	0.0172	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs4368798	ENSG00000228223.2	HCG11	-3.69	0.000252	0.0172	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26523450~26526579:+
THCA	cis	rs2290405	0.593	rs12499663	ENSG00000272927.1	RP11-1191J2.5	3.69	0.000252	0.0172	0.15	0.17	Systemic sclerosis;	chr4:894382	chr4:661209~661945:-
THCA	cis	rs1371614	0.635	rs12612520	ENSG00000229122.1	AGBL5-IT1	-3.69	0.000252	0.0173	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914439	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.635	rs12612619	ENSG00000229122.1	AGBL5-IT1	-3.69	0.000252	0.0173	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914803	chr2:27061038~27061815:+
THCA	cis	rs7833787	0.501	rs73202126	ENSG00000278886.1	RP11-108A14.1	-3.69	0.000252	0.0173	-0.24	-0.17	Obesity-related traits;	chr8:18828298	chr8:18864681~18865247:-
THCA	cis	rs11694172	0.821	rs36126443	ENSG00000273456.1	RP11-686O6.2	3.69	0.000252	0.0173	0.15	0.17	Cholesterol, total;	chr2:202693808	chr2:202374932~202375604:-
THCA	cis	rs9303542	0.694	rs8081754	ENSG00000278765.1	RP5-890E16.5	-3.69	0.000252	0.0173	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48251305	chr17:48066704~48067293:-
THCA	cis	rs9608946	1	rs9608942	ENSG00000279699.1	RP1-102K2.9	3.69	0.000253	0.0173	0.2	0.17	Red cell distribution width;	chr22:30491459	chr22:30275215~30276951:-
THCA	cis	rs11719291	0.915	rs1048940	ENSG00000270441.1	RP11-694I15.7	3.69	0.000253	0.0173	0.26	0.17	Cognitive function;	chr3:48688274	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.505	rs73080312	ENSG00000270441.1	RP11-694I15.7	3.69	0.000253	0.0173	0.26	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48700414	chr3:49140086~49160851:-
THCA	cis	rs12476592	0.602	rs10865340	ENSG00000242412.1	DBIL5P2	3.69	0.000253	0.0173	0.22	0.17	Childhood ear infection;	chr2:63596915	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.571	rs10865341	ENSG00000242412.1	DBIL5P2	3.69	0.000253	0.0173	0.22	0.17	Childhood ear infection;	chr2:63596916	chr2:63117851~63119542:-
THCA	cis	rs10911902	0.643	rs2297226	ENSG00000233196.2	GS1-304P7.1	-3.69	0.000253	0.0173	-0.26	-0.17	Schizophrenia;	chr1:186374627	chr1:186580515~186581191:-
THCA	cis	rs2562456	0.834	rs2650848	ENSG00000268521.1	VN1R83P	3.69	0.000253	0.0173	0.16	0.17	Pain;	chr19:21403835	chr19:21289554~21289998:-
THCA	cis	rs3924048	0.574	rs12410270	ENSG00000276830.1	MIR6730	-3.69	0.000253	0.0173	-0.17	-0.17	Optic cup area;	chr1:12552813	chr1:12578957~12579023:-
THCA	cis	rs7845127	0.552	rs1389111	ENSG00000253671.1	RP11-806O11.1	3.69	0.000253	0.0173	0.19	0.17	Night sleep phenotypes;	chr8:18259849	chr8:17808941~17820868:+
THCA	cis	rs11212260	0.85	rs583790	ENSG00000261098.1	RP11-819C21.1	-3.69	0.000253	0.0173	-0.34	-0.17	IgG glycosylation;	chr11:107497015	chr11:107312132~107316271:-
THCA	cis	rs765787	0.53	rs4774550	ENSG00000259539.1	CTD-2651B20.1	3.69	0.000253	0.0173	0.2	0.17	Uric acid levels;	chr15:45250114	chr15:45152664~45167526:-
THCA	cis	rs67478160	0.643	rs8005594	ENSG00000258534.1	CTD-2134A5.4	-3.69	0.000253	0.0173	-0.17	-0.17	Schizophrenia;	chr14:103813552	chr14:103854366~103880111:-
THCA	cis	rs1075265	0.933	rs7560947	ENSG00000235937.1	AC008280.1	3.69	0.000253	0.0173	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54029552~54030682:-
THCA	cis	rs4218	0.597	rs12438111	ENSG00000277144.1	RP11-59H7.4	-3.69	0.000253	0.0173	-0.24	-0.17	Social communication problems;	chr15:59057540	chr15:59115547~59116089:-
THCA	cis	rs10089	1	rs10478796	ENSG00000245937.6	LINC01184	3.69	0.000253	0.0173	0.19	0.17	Ileal carcinoids;	chr5:128100495	chr5:127940426~128083172:-
THCA	cis	rs875971	0.862	rs880166	ENSG00000223473.2	GS1-124K5.3	-3.69	0.000253	0.0173	-0.11	-0.17	Aortic root size;	chr7:66205775	chr7:66491049~66493566:-
THCA	cis	rs1665050	0.546	rs7175490	ENSG00000277144.1	RP11-59H7.4	-3.69	0.000253	0.0173	-0.22	-0.17	Atopic dermatitis;	chr15:59041735	chr15:59115547~59116089:-
THCA	cis	rs1009077	0.671	rs13118388	ENSG00000245958.5	RP11-33B1.1	3.69	0.000253	0.0173	0.25	0.17	Endometriosis;	chr4:119607662	chr4:119454791~119552025:+
THCA	cis	rs7127129	0.842	rs10898825	ENSG00000246889.2	AP000487.5	-3.69	0.000253	0.0173	-0.17	-0.17	Aortic root size;	chr11:70168567	chr11:70372246~70398488:-
THCA	cis	rs4656958	0.897	rs12075167	ENSG00000233691.2	RP11-312J18.7	3.69	0.000253	0.0173	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160921849	chr1:160935537~160936126:+
THCA	cis	rs2243480	1	rs313813	ENSG00000237310.1	GS1-124K5.4	3.69	0.000253	0.0173	0.19	0.17	Diabetic kidney disease;	chr7:66038513	chr7:66493706~66495474:+
THCA	cis	rs5762752	0.509	rs5752746	ENSG00000272858.1	CTA-292E10.8	-3.69	0.000253	0.0173	-0.15	-0.17	Optic disc area;	chr22:28450592	chr22:28814914~28815662:+
THCA	cis	rs10421328	0.784	rs11667828	ENSG00000271283.1	CTC-412M14.6	-3.69	0.000253	0.0173	-0.22	-0.17	Parental longevity (combined parental age at death);	chr19:19657665	chr19:19699203~19699409:-
THCA	cis	rs7246657	0.941	rs10418729	ENSG00000266916.4	ZNF793-AS1	-3.69	0.000253	0.0173	-0.16	-0.17	Coronary artery calcification;	chr19:37246163	chr19:37497159~37507046:-
THCA	cis	rs208520	1	rs12190316	ENSG00000233859.2	ADH5P4	3.69	0.000253	0.0173	0.26	0.17	Exhaled nitric oxide output;	chr6:66263472	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs12194996	ENSG00000233859.2	ADH5P4	3.69	0.000253	0.0173	0.26	0.17	Exhaled nitric oxide output;	chr6:66263473	chr6:65836930~65838039:-
THCA	cis	rs1577917	0.682	rs6935918	ENSG00000220563.1	PKMP3	3.69	0.000253	0.0173	0.12	0.17	Response to antipsychotic treatment;	chr6:85573857	chr6:85659892~85660606:-
THCA	cis	rs2185341	0.788	rs12092590	ENSG00000218510.5	LINC00339	3.69	0.000253	0.0173	0.2	0.17	Amyotrophic lateral sclerosis;	chr1:22358434	chr1:22025188~22031223:+
THCA	cis	rs11673344	0.523	rs2891766	ENSG00000233527.7	ZNF529-AS1	3.69	0.000253	0.0173	0.14	0.17	Obesity-related traits;	chr19:37037057	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.523	rs7245453	ENSG00000233527.7	ZNF529-AS1	3.69	0.000253	0.0173	0.14	0.17	Obesity-related traits;	chr19:37043447	chr19:36573070~36594708:+
THCA	cis	rs1577917	0.837	rs10944157	ENSG00000220563.1	PKMP3	-3.69	0.000253	0.0173	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85867481	chr6:85659892~85660606:-
THCA	cis	rs4742903	0.875	rs10991141	ENSG00000270332.1	SMC2-AS1	3.69	0.000253	0.0173	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104175999	chr9:104080024~104093073:-
THCA	cis	rs7903847	0.642	rs11189178	ENSG00000225850.3	RP11-452K12.4	3.69	0.000253	0.0173	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97383515	chr10:97334564~97343203:+
THCA	cis	rs2820315	0.867	rs2819348	ENSG00000223774.4	RP11-307B6.3	3.69	0.000253	0.0173	0.18	0.17	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201915824	chr1:201893842~201899978:+
THCA	cis	rs854765	0.547	rs2955377	ENSG00000281749.1	Y_RNA	3.69	0.000253	0.0173	0.21	0.17	Total body bone mineral density;	chr17:18029504	chr17:18001101~18001195:-
THCA	cis	rs72928364	0.725	rs13099753	ENSG00000256628.3	ZBTB11-AS1	3.69	0.000253	0.0173	0.24	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101050480	chr3:101676475~101679217:+
THCA	cis	rs7804306	0.655	rs34746652	ENSG00000233264.2	AC006042.8	3.69	0.000253	0.0173	0.3	0.17	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8012957	chr7:7980312~7982228:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000272831.1	RP11-792A8.4	3.69	0.000253	0.0173	0.11	0.17	Calcium levels;	chr7:65977808	chr7:66739829~66740385:-
THCA	cis	rs4815191	0.755	rs2424522	ENSG00000230387.2	RP4-737E23.2	3.69	0.000253	0.0173	0.24	0.17	Obesity-related traits;	chr20:23255710	chr20:23187961~23190307:+
THCA	cis	rs6088590	0.687	rs8115656	ENSG00000276073.1	RP5-1125A11.7	-3.69	0.000253	0.0173	-0.15	-0.17	Coronary artery disease;	chr20:34694976	chr20:33985617~33988989:-
THCA	cis	rs2179367	0.632	rs9498321	ENSG00000216906.2	RP11-350J20.9	3.69	0.000253	0.0173	0.21	0.17	Dupuytren's disease;	chr6:149322573	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs62426068	ENSG00000216906.2	RP11-350J20.9	3.69	0.000253	0.0173	0.21	0.17	Dupuytren's disease;	chr6:149325795	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs62426069	ENSG00000216906.2	RP11-350J20.9	3.69	0.000253	0.0173	0.21	0.17	Dupuytren's disease;	chr6:149325804	chr6:149904243~149906418:+
THCA	cis	rs944289	0.74	rs950319	ENSG00000257520.1	RP11-896J10.3	3.69	0.000253	0.0173	0.16	0.17	Thyroid cancer;	chr14:36096786	chr14:36473207~36519521:-
THCA	cis	rs1009077	0.951	rs13138402	ENSG00000245958.5	RP11-33B1.1	3.69	0.000253	0.0173	0.21	0.17	Endometriosis;	chr4:119701634	chr4:119454791~119552025:+
THCA	cis	rs1009077	1	rs13144584	ENSG00000245958.5	RP11-33B1.1	3.69	0.000253	0.0173	0.21	0.17	Endometriosis;	chr4:119704158	chr4:119454791~119552025:+
THCA	cis	rs3924048	0.574	rs34494202	ENSG00000276830.1	MIR6730	-3.69	0.000253	0.0173	-0.17	-0.17	Optic cup area;	chr1:12552838	chr1:12578957~12579023:-
THCA	cis	rs3924048	0.547	rs72642661	ENSG00000276830.1	MIR6730	-3.69	0.000253	0.0173	-0.17	-0.17	Optic cup area;	chr1:12552843	chr1:12578957~12579023:-
THCA	cis	rs1436955	0.712	rs4775462	ENSG00000259251.2	RP11-643M14.1	-3.69	0.000253	0.0173	-0.22	-0.17	Type 2 diabetes;	chr15:62095859	chr15:62060503~62062434:+
THCA	cis	rs2841277	0.708	rs28600075	ENSG00000258701.1	LINC00638	3.69	0.000253	0.0173	0.18	0.17	Rheumatoid arthritis;	chr14:104941978	chr14:104821201~104823718:+
THCA	cis	rs28830936	0.966	rs890505	ENSG00000250379.1	RP11-23P13.4	3.69	0.000253	0.0173	0.19	0.17	Diastolic blood pressure;	chr15:41836960	chr15:41825099~41827936:-
THCA	cis	rs9676308	0.579	rs73936795	ENSG00000267549.4	AC006116.17	-3.69	0.000254	0.0173	-0.24	-0.17	Colorectal cancer;	chr19:57073140	chr19:56314703~56341287:+
THCA	cis	rs9676308	0.579	rs61519495	ENSG00000267549.4	AC006116.17	-3.69	0.000254	0.0173	-0.24	-0.17	Colorectal cancer;	chr19:57073265	chr19:56314703~56341287:+
THCA	cis	rs1005277	0.638	rs1005278	ENSG00000275858.1	RP11-291L22.8	-3.69	0.000254	0.0173	-0.2	-0.17	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:38450738~38451069:-
THCA	cis	rs2179367	0.632	rs9485384	ENSG00000216906.2	RP11-350J20.9	3.69	0.000254	0.0173	0.21	0.17	Dupuytren's disease;	chr6:149328808	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12211357	ENSG00000216906.2	RP11-350J20.9	3.69	0.000254	0.0173	0.21	0.17	Dupuytren's disease;	chr6:149331148	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs11155642	ENSG00000216906.2	RP11-350J20.9	3.69	0.000254	0.0173	0.21	0.17	Dupuytren's disease;	chr6:149332984	chr6:149904243~149906418:+
THCA	cis	rs17689437	0.958	rs17621931	ENSG00000260084.1	RP11-615I2.1	-3.69	0.000254	0.0173	-0.3	-0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68540193	chr16:68573782~68589512:-
THCA	cis	rs2239557	0.539	rs2302118	ENSG00000259065.1	RP5-1021I20.1	-3.69	0.000254	0.0173	-0.25	-0.17	Common traits (Other);	chr14:73955626	chr14:73787360~73803270:+
THCA	cis	rs987724	1	rs987724	ENSG00000240875.4	LINC00886	3.69	0.000254	0.0173	0.14	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156965347	chr3:156747346~156817062:-
THCA	cis	rs9291683	0.588	rs3733586	ENSG00000261490.1	RP11-448G15.3	3.69	0.000254	0.0173	0.1	0.17	Bone mineral density;	chr4:9995910	chr4:10068089~10073019:-
THCA	cis	rs1065852	0.526	rs1062753	ENSG00000227370.1	RP4-669P10.19	3.69	0.000254	0.0173	0.17	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41996807	chr22:42132543~42132998:+
THCA	cis	rs8023401	0.529	rs11070641	ENSG00000259705.1	RP11-227D13.1	-3.69	0.000254	0.0173	-0.21	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48408832	chr15:48645951~48652016:+
THCA	cis	rs3864261	0.848	rs6452699	ENSG00000249085.1	CTD-2631K10.1	-3.69	0.000254	0.0173	-0.26	-0.17	Discordance in emotional problems in monozygotic twins;	chr5:72805040	chr5:72794405~72816565:-
THCA	cis	rs3864261	0.848	rs6884410	ENSG00000249085.1	CTD-2631K10.1	-3.69	0.000254	0.0173	-0.26	-0.17	Discordance in emotional problems in monozygotic twins;	chr5:72805859	chr5:72794405~72816565:-
THCA	cis	rs11638352	1	rs7176955	ENSG00000166763.7	STRCP1	-3.69	0.000254	0.0173	-0.36	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44016707	chr15:43699488~43718184:-
THCA	cis	rs559555	0.568	rs569320	ENSG00000276517.1	AL133243.2	-3.69	0.000254	0.0173	-0.17	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31642978	chr2:32526504~32529507:+
THCA	cis	rs4792901	0.765	rs9913605	ENSG00000279602.1	CTD-3014M21.1	-3.69	0.000254	0.0173	-0.22	-0.17	Dupuytren's disease;	chr17:43515142	chr17:43360041~43361361:-
THCA	cis	rs9291683	0.53	rs35908990	ENSG00000261490.1	RP11-448G15.3	3.69	0.000254	0.0173	0.11	0.17	Bone mineral density;	chr4:9974481	chr4:10068089~10073019:-
THCA	cis	rs9291683	0.551	rs62295971	ENSG00000261490.1	RP11-448G15.3	3.69	0.000254	0.0173	0.11	0.17	Bone mineral density;	chr4:9976518	chr4:10068089~10073019:-
THCA	cis	rs6500602	0.767	rs8060219	ENSG00000280063.1	RP11-295D4.3	3.69	0.000254	0.0173	0.09	0.17	Schizophrenia;	chr16:4430157	chr16:4346694~4348648:-
THCA	cis	rs722599	0.715	rs12147629	ENSG00000279594.1	RP11-950C14.10	-3.69	0.000254	0.0173	-0.17	-0.17	IgG glycosylation;	chr14:74840885	chr14:75011269~75012851:-
THCA	cis	rs11771526	0.901	rs11771230	ENSG00000272905.1	RP11-265E18.1	-3.69	0.000254	0.0173	-0.23	-0.17	Body mass index;	chr7:32275934	chr7:32845394~32846061:+
THCA	cis	rs1125355	0.622	rs17203501	ENSG00000243792.1	OR7E89P	-3.69	0.000254	0.0173	-0.25	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158757125	chr2:158853755~158854576:+
THCA	cis	rs2360027	0.662	rs4659109	ENSG00000231365.4	RP11-418J17.1	-3.69	0.000254	0.0173	-0.17	-0.17	Tonsillectomy;	chr1:118600256	chr1:119140396~119275973:+
THCA	cis	rs11583043	1	rs17100939	ENSG00000233184.5	RP11-421L21.3	3.69	0.000254	0.0173	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:100978145	chr1:101025878~101087268:+
THCA	cis	rs2276314	1	rs2298715	ENSG00000267627.4	RP11-905K4.1	-3.69	0.000254	0.0173	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35951803~35966118:-
THCA	cis	rs2276314	1	rs4573997	ENSG00000267627.4	RP11-905K4.1	-3.69	0.000254	0.0173	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35951803~35966118:-
THCA	cis	rs36093844	0.527	rs2084077	ENSG00000279742.1	RP11-700A24.1	-3.69	0.000254	0.0173	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85941884	chr11:85852557~85854943:-
THCA	cis	rs2638953	0.886	rs11049572	ENSG00000247934.4	RP11-967K21.1	-3.69	0.000254	0.0173	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397268	chr12:28163298~28190738:-
THCA	cis	rs875971	0.666	rs13242072	ENSG00000230189.5	GS1-124K5.2	-3.69	0.000254	0.0174	-0.11	-0.17	Aortic root size;	chr7:66301001	chr7:66409143~66490059:-
THCA	cis	rs10760158	0.8	rs4836847	ENSG00000226752.6	PSMD5-AS1	-3.69	0.000254	0.0174	-0.21	-0.17	Pulse pressure;	chr9:121296665	chr9:120824828~120854385:+
THCA	cis	rs14027	0.921	rs12542706	ENSG00000279347.1	RP11-85I17.2	-3.69	0.000254	0.0174	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119838736~119840385:-
THCA	cis	rs1062177	1	rs2915887	ENSG00000272112.1	CTB-113P19.5	3.69	0.000254	0.0174	0.15	0.17	Preschool internalizing problems;	chr5:151825943	chr5:151724831~151725356:-
THCA	cis	rs7088591	0.867	rs79125842	ENSG00000276818.1	AC026393.1	3.69	0.000254	0.0174	0.34	0.17	Blood pressure;	chr10:57999281	chr10:57095699~57095781:+
THCA	cis	rs9906944	0.933	rs9906710	ENSG00000248278.1	SUMO2P17	-3.69	0.000254	0.0174	-0.21	-0.17	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49013921	chr17:48874860~48908983:-
THCA	cis	rs6580649	0.941	rs1018973	ENSG00000273765.1	RP11-370I10.11	3.69	0.000254	0.0174	0.18	0.17	Lung cancer;	chr12:48047909	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs7959755	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48052535	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs72644842	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48054491	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs12580764	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48060099	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.882	rs7133249	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48063040	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs3742074	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48063602	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs17122611	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48064366	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs17122612	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48065705	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs17122613	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48066233	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs60681522	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48070412	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs72644843	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48071278	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs72644844	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48071642	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs7971668	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48075913	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.882	rs59766465	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48076386	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.657	rs57863747	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48076642	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs7963934	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48083303	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs4589362	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48084881	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs7312326	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48086860	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs57054831	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48093109	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs58046797	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48093836	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs7296913	ENSG00000273765.1	RP11-370I10.11	-3.69	0.000254	0.0174	-0.18	-0.17	Lung cancer;	chr12:48095137	chr12:48360920~48361377:+
THCA	cis	rs6496932	0.77	rs4843040	ENSG00000259630.2	CTD-2262B20.1	3.69	0.000254	0.0174	0.2	0.17	Central corneal thickness;Corneal structure;	chr15:85295405	chr15:85415228~85415633:+
THCA	cis	rs881375	0.678	rs7031752	ENSG00000270917.1	RP11-27I1.6	-3.69	0.000254	0.0174	-0.23	-0.17	Rheumatoid arthritis;	chr9:120901204	chr9:120812475~120812845:-
THCA	cis	rs12188164	0.965	rs41282625	ENSG00000225138.6	CTD-2228K2.7	3.69	0.000254	0.0174	0.18	0.17	Cystic fibrosis severity;	chr5:475511	chr5:473236~480884:+
THCA	cis	rs267567	0.626	rs267565	ENSG00000235257.7	ITGA9-AS1	3.69	0.000254	0.0174	0.14	0.17	PR interval;	chr3:37532849	chr3:37745432~37861780:-
THCA	cis	rs10875746	0.669	rs11168510	ENSG00000226413.2	OR8T1P	3.69	0.000254	0.0174	0.24	0.17	Longevity (90 years and older);	chr12:48291772	chr12:48442030~48442947:-
THCA	cis	rs56046484	0.913	rs17611290	ENSG00000259630.2	CTD-2262B20.1	-3.69	0.000254	0.0174	-0.24	-0.17	Testicular germ cell tumor;	chr15:85031188	chr15:85415228~85415633:+
THCA	cis	rs5752773	0.513	rs134543	ENSG00000272858.1	CTA-292E10.8	3.69	0.000254	0.0174	0.19	0.17	Vertical cup-disc ratio;	chr22:28401330	chr22:28814914~28815662:+
THCA	cis	rs4853525	0.59	rs12619138	ENSG00000235852.1	AC005540.3	3.69	0.000254	0.0174	0.19	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865474	chr2:190880797~190882059:-
THCA	cis	rs2562152	0.613	rs216599	ENSG00000226942.2	IL9RP3	-3.69	0.000254	0.0174	-0.23	-0.17	Glioblastoma;	chr16:59673	chr16:29336~38321:-
THCA	cis	rs924712	0.522	rs6931473	ENSG00000224984.1	RP11-524H19.2	-3.69	0.000254	0.0174	-0.2	-0.17	Breast cancer;	chr6:54833971	chr6:54840118~54840855:-
THCA	cis	rs73198271	0.751	rs617813	ENSG00000253981.4	ALG1L13P	-3.69	0.000254	0.0174	-0.17	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8236003~8244667:-
THCA	cis	rs11168187	0.514	rs7964953	ENSG00000280054.1	RP1-197B17.7	3.69	0.000254	0.0174	0.21	0.17	Vertical cup-disc ratio;	chr12:47571627	chr12:47728151~47730598:-
THCA	cis	rs1005277	0.565	rs2474565	ENSG00000120555.12	SEPT7P9	3.69	0.000254	0.0174	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38383069~38402916:-
THCA	cis	rs61160187	0.582	rs12653132	ENSG00000272308.1	RP11-231G3.1	-3.69	0.000254	0.0174	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs56284222	ENSG00000272308.1	RP11-231G3.1	-3.69	0.000254	0.0174	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60866457~60866935:-
THCA	cis	rs4927850	0.521	rs4927679	ENSG00000229178.1	AC069513.4	3.69	0.000254	0.0174	0.16	0.17	Pancreatic cancer;	chr3:195931489	chr3:195655565~195657927:-
THCA	cis	rs801193	1	rs62466793	ENSG00000232546.1	RP11-458F8.1	-3.69	0.000254	0.0174	-0.14	-0.17	Aortic root size;	chr7:66726530	chr7:66848496~66858136:+
THCA	cis	rs2839186	0.558	rs2968	ENSG00000225043.1	RPL18AP2	-3.69	0.000254	0.0174	-0.2	-0.17	Testicular germ cell tumor;	chr21:46188666	chr21:46420553~46421034:-
THCA	cis	rs944289	0.646	rs375095	ENSG00000258844.1	RP11-259K15.2	-3.69	0.000254	0.0174	-0.15	-0.17	Thyroid cancer;	chr14:36066043	chr14:36214607~36235608:+
THCA	cis	rs3087591	0.708	rs8067440	ENSG00000263535.1	AK4P1	3.69	0.000254	0.0174	0.2	0.17	Hip circumference;	chr17:31381137	chr17:31345521~31346187:+
THCA	cis	rs786425	0.502	rs10734903	ENSG00000270095.1	RP11-214K3.18	3.69	0.000254	0.0174	0.2	0.17	Pubertal anthropometrics;	chr12:123717695	chr12:123971457~123971714:-
THCA	cis	rs13063635	0.915	rs35334665	ENSG00000226074.4	PRSS44	-3.69	0.000254	0.0174	-0.32	-0.17	Eosinophil percentage of granulocytes;	chr3:46019726	chr3:46809359~46812558:-
THCA	cis	rs7246967	0.611	rs12983761	ENSG00000236312.3	RPL34P34	-3.69	0.000254	0.0174	-0.23	-0.17	Bronchopulmonary dysplasia;	chr19:22657795	chr19:22368599~22368952:-
THCA	cis	rs7246967	0.611	rs8108452	ENSG00000236312.3	RPL34P34	-3.69	0.000254	0.0174	-0.23	-0.17	Bronchopulmonary dysplasia;	chr19:22670816	chr19:22368599~22368952:-
THCA	cis	rs7246967	0.611	rs62120304	ENSG00000236312.3	RPL34P34	-3.69	0.000254	0.0174	-0.23	-0.17	Bronchopulmonary dysplasia;	chr19:22689466	chr19:22368599~22368952:-
THCA	cis	rs748404	0.518	rs2899074	ENSG00000166763.7	STRCP1	3.69	0.000254	0.0174	0.19	0.17	Lung cancer;	chr15:43109232	chr15:43699488~43718184:-
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000270154.1	RP11-419I17.1	-3.69	0.000254	0.0174	-0.2	-0.17	Neuroticism;	chr8:11986249	chr8:12476462~12477122:+
THCA	cis	rs7188445	0.592	rs7196490	ENSG00000277954.1	RP11-679B19.1	-3.69	0.000254	0.0174	-0.19	-0.17	Urate levels;	chr16:79718572	chr16:79202624~79206739:-
THCA	cis	rs34526934	0.566	rs34028621	ENSG00000226363.3	HAGLROS	3.69	0.000254	0.0174	0.22	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176178051	chr2:176177717~176179008:+
THCA	cis	rs4938303	0.671	rs12806224	ENSG00000254851.1	RP11-109L13.1	3.69	0.000255	0.0174	0.26	0.17	Triglycerides;	chr11:116682098	chr11:117135528~117138582:+
THCA	cis	rs4938303	0.788	rs12805061	ENSG00000254851.1	RP11-109L13.1	3.69	0.000255	0.0174	0.26	0.17	Triglycerides;	chr11:116682308	chr11:117135528~117138582:+
THCA	cis	rs4938303	0.788	rs11826999	ENSG00000254851.1	RP11-109L13.1	3.69	0.000255	0.0174	0.26	0.17	Triglycerides;	chr11:116683062	chr11:117135528~117138582:+
THCA	cis	rs3733585	0.631	rs7699671	ENSG00000261490.1	RP11-448G15.3	-3.69	0.000255	0.0174	-0.11	-0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10124250	chr4:10068089~10073019:-
THCA	cis	rs17597773	0.674	rs12117818	ENSG00000272823.1	RP11-295M18.6	-3.69	0.000255	0.0174	-0.23	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828141	chr1:220828676~220829211:-
THCA	cis	rs11671005	0.735	rs11668420	ENSG00000269600.1	AC016629.3	-3.69	0.000255	0.0174	-0.25	-0.17	Mean platelet volume;	chr19:58426469	chr19:58593896~58599355:-
THCA	cis	rs875971	0.505	rs2462573	ENSG00000232546.1	RP11-458F8.1	3.69	0.000255	0.0174	0.14	0.17	Aortic root size;	chr7:66042405	chr7:66848496~66858136:+
THCA	cis	rs875971	1	rs1981798	ENSG00000272831.1	RP11-792A8.4	3.69	0.000255	0.0174	0.11	0.17	Aortic root size;	chr7:66489916	chr7:66739829~66740385:-
THCA	cis	rs10090774	0.965	rs13261338	ENSG00000280303.2	ERICD	-3.69	0.000255	0.0174	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140881722	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs7830394	ENSG00000280303.2	ERICD	-3.69	0.000255	0.0174	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140884642	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11167006	ENSG00000280303.2	ERICD	-3.69	0.000255	0.0174	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140885398	chr8:140636281~140638283:+
THCA	cis	rs13217239	0.646	rs4403259	ENSG00000261353.1	CTA-14H9.5	-3.69	0.000255	0.0174	-0.17	-0.17	Schizophrenia;	chr6:27029838	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs6937880	ENSG00000261353.1	CTA-14H9.5	-3.69	0.000255	0.0174	-0.17	-0.17	Schizophrenia;	chr6:27032457	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.621	rs12527231	ENSG00000261353.1	CTA-14H9.5	-3.69	0.000255	0.0174	-0.17	-0.17	Schizophrenia;	chr6:27033509	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs12523820	ENSG00000261353.1	CTA-14H9.5	-3.69	0.000255	0.0174	-0.17	-0.17	Schizophrenia;	chr6:27033723	chr6:26527063~26527404:+
THCA	cis	rs7973683	0.513	rs57316347	ENSG00000270061.1	RP11-214K3.19	-3.69	0.000255	0.0174	-0.21	-0.17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123904506	chr12:123969990~123970344:-
THCA	cis	rs4742903	0.875	rs4543600	ENSG00000270332.1	SMC2-AS1	3.69	0.000255	0.0174	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104177603	chr9:104080024~104093073:-
THCA	cis	rs7142002	0.614	rs58553858	ENSG00000272444.1	RP11-1017G21.6	-3.69	0.000255	0.0174	-0.19	-0.17	Autism;	chr14:101924875	chr14:101952416~101953063:+
THCA	cis	rs78487399	0.908	rs80075345	ENSG00000234936.1	AC010883.5	3.69	0.000255	0.0174	0.21	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583559	chr2:43229573~43233394:+
THCA	cis	rs10090774	0.965	rs13250888	ENSG00000280303.2	ERICD	-3.69	0.000255	0.0174	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140888931	chr8:140636281~140638283:+
THCA	cis	rs2047076	0.576	rs112210382	ENSG00000225407.3	CTD-2384B11.2	-3.69	0.000255	0.0174	-0.26	-0.17	Monocyte count;	chr5:76799537	chr5:76691439~76716215:-
THCA	cis	rs57024841	0.5	rs6560652	ENSG00000238268.2	RP11-229P13.19	-3.69	0.000255	0.0174	-0.19	-0.17	Beta-trace protein levels;	chr9:136936488	chr9:136975094~136976981:+
THCA	cis	rs916888	0.779	rs199498	ENSG00000261575.2	RP11-259G18.1	3.69	0.000255	0.0174	0.21	0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46267037~46268694:+
THCA	cis	rs875971	0.825	rs59466412	ENSG00000223473.2	GS1-124K5.3	-3.69	0.000255	0.0174	-0.12	-0.17	Aortic root size;	chr7:66100371	chr7:66491049~66493566:-
THCA	cis	rs10993625	0.948	rs7023001	ENSG00000231107.1	LINC01508	-3.69	0.000255	0.0174	-0.19	-0.17	Classic bladder exstrophy;	chr9:90667347	chr9:90300902~90433505:-
THCA	cis	rs6762	0.748	rs7929032	ENSG00000255142.1	AP006621.6	3.69	0.000255	0.0174	0.12	0.17	Mean platelet volume;	chr11:839078	chr11:781645~782105:+
THCA	cis	rs6762	0.748	rs7936838	ENSG00000255142.1	AP006621.6	3.69	0.000255	0.0174	0.12	0.17	Mean platelet volume;	chr11:839093	chr11:781645~782105:+
THCA	cis	rs4792901	0.765	rs34778116	ENSG00000279602.1	CTD-3014M21.1	-3.69	0.000255	0.0174	-0.21	-0.17	Dupuytren's disease;	chr17:43462330	chr17:43360041~43361361:-
THCA	cis	rs9902453	0.845	rs3102558	ENSG00000264290.1	RP11-68I3.4	3.69	0.000255	0.0174	0.13	0.17	Coffee consumption (cups per day);	chr17:29696124	chr17:29569580~29570519:+
THCA	cis	rs9902453	0.845	rs2321331	ENSG00000264290.1	RP11-68I3.4	3.69	0.000255	0.0174	0.13	0.17	Coffee consumption (cups per day);	chr17:29698510	chr17:29569580~29570519:+
THCA	cis	rs7829975	0.514	rs2945873	ENSG00000248538.5	RP11-10A14.5	-3.69	0.000255	0.0174	-0.2	-0.17	Mood instability;	chr8:8402935	chr8:9189011~9202854:+
THCA	cis	rs9925964	0.933	rs2359612	ENSG00000279196.1	RP11-1072A3.3	3.69	0.000255	0.0174	0.16	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31092475	chr16:30984630~30988270:-
THCA	cis	rs1560104	0.576	rs11640886	ENSG00000260601.1	RP11-552C15.1	-3.69	0.000255	0.0174	-0.21	-0.17	Obesity-related traits;	chr16:12615377	chr16:12545482~12546684:+
THCA	cis	rs7665090	0.967	rs13106325	ENSG00000251288.2	RP11-10L12.2	-3.69	0.000255	0.0174	-0.22	-0.17	Primary biliary cholangitis;	chr4:102633835	chr4:102751401~102752641:+
THCA	cis	rs2033711	0.87	rs11669741	ENSG00000268049.1	CTD-2619J13.9	3.69	0.000255	0.0174	0.21	0.17	Uric acid clearance;	chr19:58449114	chr19:58357999~58359603:+
THCA	cis	rs76878669	0.561	rs4930362	ENSG00000255320.1	RP11-755F10.1	-3.69	0.000255	0.0174	-0.21	-0.17	Educational attainment (years of education);	chr11:66386889	chr11:66244840~66246239:-
THCA	cis	rs76878669	0.561	rs4930179	ENSG00000255320.1	RP11-755F10.1	-3.69	0.000255	0.0174	-0.21	-0.17	Educational attainment (years of education);	chr11:66389961	chr11:66244840~66246239:-
THCA	cis	rs1552172	0.853	rs2018027	ENSG00000234222.5	RP11-315I20.1	3.69	0.000255	0.0174	0.21	0.17	Breast cancer;	chr1:145839290	chr1:145926590~145959179:+
THCA	cis	rs643506	0.874	rs582465	ENSG00000230911.1	PPIHP1	-3.69	0.000255	0.0174	-0.23	-0.17	Breast cancer;	chr11:111797861	chr11:112029858~112030367:-
THCA	cis	rs643506	0.874	rs613292	ENSG00000230911.1	PPIHP1	-3.69	0.000255	0.0174	-0.23	-0.17	Breast cancer;	chr11:111798081	chr11:112029858~112030367:-
THCA	cis	rs2625529	0.938	rs8747	ENSG00000260037.4	CTD-2524L6.3	-3.69	0.000255	0.0174	-0.24	-0.17	Red blood cell count;	chr15:71823200	chr15:71818396~71823384:+
THCA	cis	rs755249	0.761	rs3768321	ENSG00000237624.1	OXCT2P1	3.69	0.000255	0.0174	0.25	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39514956~39516490:+
THCA	cis	rs10129255	0.957	rs8009464	ENSG00000211972.2	IGHV3-66	3.69	0.000255	0.0174	0.1	0.17	Kawasaki disease;	chr14:106777611	chr14:106675017~106675544:-
THCA	cis	rs656319	0.591	rs17734690	ENSG00000261451.1	RP11-981G7.1	-3.69	0.000255	0.0174	-0.22	-0.17	Myopia (pathological);	chr8:9855686	chr8:10433672~10438312:+
THCA	cis	rs11242704	0.962	rs2816288	ENSG00000218027.2	RP11-157J24.1	-3.69	0.000255	0.0174	-0.21	-0.17	Response to hepatitis C treatment;	chr6:1537041	chr6:1513698~1515289:-
THCA	cis	rs58873874	0.522	rs111370613	ENSG00000251405.2	CTB-109A12.1	3.69	0.000255	0.0174	0.37	0.17	Bipolar disorder (body mass index interaction);	chr5:157271128	chr5:157362615~157460078:-
THCA	cis	rs58873874	0.522	rs77458926	ENSG00000251405.2	CTB-109A12.1	3.69	0.000255	0.0174	0.37	0.17	Bipolar disorder (body mass index interaction);	chr5:157271198	chr5:157362615~157460078:-
THCA	cis	rs11013210	0.508	rs6482246	ENSG00000261671.1	RP11-573G6.6	-3.69	0.000255	0.0174	-0.23	-0.17	Systemic lupus erythematosus;	chr10:23012092	chr10:22257786~22258548:+
THCA	cis	rs3892630	0.878	rs11878394	ENSG00000267475.1	CTD-2538C1.2	-3.69	0.000255	0.0174	-0.25	-0.17	Red blood cell traits;	chr19:32714938	chr19:32687089~32691750:-
THCA	cis	rs9427116	0.502	rs9426830	ENSG00000236675.1	MTX1P1	-3.69	0.000255	0.0174	-0.15	-0.17	Blood protein levels;	chr1:154622214	chr1:155230975~155234325:+
THCA	cis	rs12544026	0.647	rs67887846	ENSG00000253669.3	KB-1732A1.1	-3.69	0.000255	0.0174	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101833350	chr8:102805517~102809971:+
THCA	cis	rs1873147	0.569	rs11636033	ENSG00000259672.1	RP11-69G7.1	3.68	0.000255	0.0174	0.21	0.17	Orofacial clefts;	chr15:63018892	chr15:63098870~63110403:+
THCA	cis	rs2919009	0.598	rs2420896	ENSG00000271670.1	RP11-95I16.4	3.68	0.000255	0.0174	0.19	0.17	Obesity-related traits;	chr10:120936893	chr10:120879256~120880667:-
THCA	cis	rs2919009	0.581	rs2420897	ENSG00000271670.1	RP11-95I16.4	3.68	0.000255	0.0174	0.19	0.17	Obesity-related traits;	chr10:120936918	chr10:120879256~120880667:-
THCA	cis	rs2919009	0.62	rs4437952	ENSG00000271670.1	RP11-95I16.4	3.68	0.000255	0.0174	0.19	0.17	Obesity-related traits;	chr10:120937138	chr10:120879256~120880667:-
THCA	cis	rs3892630	0.824	rs7247264	ENSG00000267475.1	CTD-2538C1.2	-3.68	0.000255	0.0174	-0.25	-0.17	Red blood cell traits;	chr19:32748940	chr19:32687089~32691750:-
THCA	cis	rs3892630	0.824	rs34748593	ENSG00000267475.1	CTD-2538C1.2	-3.68	0.000255	0.0174	-0.25	-0.17	Red blood cell traits;	chr19:32749541	chr19:32687089~32691750:-
THCA	cis	rs6456156	0.586	rs6456150	ENSG00000235272.1	FAM103A2P	3.68	0.000255	0.0174	0.23	0.17	Primary biliary cholangitis;	chr6:167055434	chr6:166586124~166586477:-
THCA	cis	rs875971	0.545	rs221986	ENSG00000232559.3	GS1-124K5.12	-3.68	0.000255	0.0174	-0.18	-0.17	Aortic root size;	chr7:66105323	chr7:66554588~66576923:-
THCA	cis	rs6456156	0.586	rs1358883	ENSG00000235272.1	FAM103A2P	-3.68	0.000255	0.0174	-0.23	-0.17	Primary biliary cholangitis;	chr6:167053945	chr6:166586124~166586477:-
THCA	cis	rs3924048	0.574	rs34494202	ENSG00000272482.1	RP11-474O21.5	-3.68	0.000256	0.0174	-0.15	-0.17	Optic cup area;	chr1:12552838	chr1:12618900~12619244:-
THCA	cis	rs3924048	0.547	rs72642661	ENSG00000272482.1	RP11-474O21.5	-3.68	0.000256	0.0174	-0.15	-0.17	Optic cup area;	chr1:12552843	chr1:12618900~12619244:-
THCA	cis	rs2652822	0.522	rs17762576	ENSG00000259459.4	RP11-321G12.1	-3.68	0.000256	0.0174	-0.14	-0.17	Metabolic traits;	chr15:63297773	chr15:63390136~63438320:+
THCA	cis	rs793571	1	rs793571	ENSG00000245975.2	RP11-30K9.6	3.68	0.000256	0.0174	0.18	0.17	Schizophrenia;	chr15:58849507	chr15:58768072~58770974:-
THCA	cis	rs10875746	0.625	rs2898065	ENSG00000226413.2	OR8T1P	3.68	0.000256	0.0174	0.23	0.17	Longevity (90 years and older);	chr12:48250836	chr12:48442030~48442947:-
THCA	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	3.68	0.000256	0.0174	0.15	0.17	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
THCA	cis	rs1950832	0.723	rs1447580	ENSG00000258636.1	CTD-2298J14.2	-3.68	0.000256	0.0174	-0.23	-0.17	Urate levels in obese individuals;	chr14:41656388	chr14:41587861~41604856:-
THCA	cis	rs3736986	0.908	rs7847671	ENSG00000215283.3	HMGB3P24	-3.68	0.000256	0.0174	-0.31	-0.17	Bipolar disorder (inflammation and infection response interaction);	chr9:36176985	chr9:36303499~36304924:-
THCA	cis	rs3736986	0.831	rs114823780	ENSG00000215283.3	HMGB3P24	-3.68	0.000256	0.0174	-0.31	-0.17	Bipolar disorder (inflammation and infection response interaction);	chr9:36177789	chr9:36303499~36304924:-
THCA	cis	rs3087591	0.708	rs9894648	ENSG00000263535.1	AK4P1	3.68	0.000256	0.0174	0.2	0.17	Hip circumference;	chr17:31326275	chr17:31345521~31346187:+
THCA	cis	rs4908760	0.86	rs11121202	ENSG00000270282.1	RP5-1115A15.2	3.68	0.000256	0.0174	0.2	0.17	Vitiligo;	chr1:8579298	chr1:8512653~8513021:+
THCA	cis	rs564343	0.583	rs2430978	ENSG00000255120.4	OVOL1-AS1	3.68	0.000256	0.0174	0.21	0.17	Obesity (early onset extreme);	chr11:66049185	chr11:65789051~65790868:-
THCA	cis	rs7637701	0.818	rs4680305	ENSG00000241544.1	RP11-6F2.5	-3.68	0.000256	0.0174	-0.2	-0.17	Breast cancer;	chr3:156815614	chr3:157081841~157088547:+
THCA	cis	rs11148252	0.51	rs7337430	ENSG00000273784.3	RP11-78J21.7	-3.68	0.000256	0.0175	-0.18	-0.17	Lewy body disease;	chr13:52010108	chr13:52600042~52642542:+
THCA	cis	rs7615952	0.741	rs13314845	ENSG00000248787.1	RP11-666A20.4	-3.68	0.000256	0.0175	-0.29	-0.17	Blood pressure (smoking interaction);	chr3:125925939	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.733	rs13314847	ENSG00000248787.1	RP11-666A20.4	-3.68	0.000256	0.0175	-0.29	-0.17	Blood pressure (smoking interaction);	chr3:125925945	chr3:125908005~125910272:-
THCA	cis	rs9427116	0.502	rs9427104	ENSG00000236675.1	MTX1P1	-3.68	0.000256	0.0175	-0.15	-0.17	Blood protein levels;	chr1:154616756	chr1:155230975~155234325:+
THCA	cis	rs2019137	0.967	rs902695	ENSG00000234997.1	AC016745.3	-3.68	0.000256	0.0175	-0.16	-0.17	Lymphocyte counts;	chr2:113197497	chr2:113424495~113425324:+
THCA	cis	rs4713118	0.513	rs200971	ENSG00000226314.6	ZNF192P1	-3.68	0.000256	0.0175	-0.2	-0.17	Parkinson's disease;	chr6:27891126	chr6:28161781~28169594:+
THCA	cis	rs1348850	0.554	rs11679519	ENSG00000280374.1	RP11-337N6.3	-3.68	0.000256	0.0175	-0.27	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177567382	chr2:177317715~177318471:-
THCA	cis	rs7916852	0.571	rs12220659	ENSG00000230500.1	MKX-AS1	3.68	0.000256	0.0175	0.28	0.17	Glaucoma (primary open-angle);	chr10:28107735	chr10:27744786~27767794:+
THCA	cis	rs2797160	1	rs2797161	ENSG00000226409.1	RP11-735G4.1	3.68	0.000256	0.0175	0.2	0.17	Endometrial cancer;	chr6:125689643	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs2747723	ENSG00000226409.1	RP11-735G4.1	3.68	0.000256	0.0175	0.2	0.17	Endometrial cancer;	chr6:125689644	chr6:125370211~125374324:-
THCA	cis	rs7914558	1	rs7094843	ENSG00000213061.2	PFN1P11	3.68	0.000256	0.0175	0.2	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103046897	chr10:102838011~102845473:-
THCA	cis	rs964611	0.882	rs2291342	ENSG00000259488.2	RP11-154J22.1	-3.68	0.000256	0.0175	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48291886	chr15:48312353~48331856:-
THCA	cis	rs964611	0.938	rs7174051	ENSG00000259488.2	RP11-154J22.1	-3.68	0.000256	0.0175	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48292131	chr15:48312353~48331856:-
THCA	cis	rs1153858	1	rs3809472	ENSG00000275672.1	GATM-AS1	-3.68	0.000256	0.0175	-0.17	-0.17	Homoarginine levels;	chr15:45402120	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs1820518	ENSG00000275672.1	GATM-AS1	-3.68	0.000256	0.0175	-0.17	-0.17	Homoarginine levels;	chr15:45402381	chr15:45378700~45380123:+
THCA	cis	rs897984	0.609	rs55979739	ENSG00000275263.1	RP11-1072A3.4	-3.68	0.000256	0.0175	-0.2	-0.17	Dementia with Lewy bodies;	chr16:31037834	chr16:30956872~30957199:-
THCA	cis	rs897984	0.609	rs732172	ENSG00000275263.1	RP11-1072A3.4	-3.68	0.000256	0.0175	-0.2	-0.17	Dementia with Lewy bodies;	chr16:31038712	chr16:30956872~30957199:-
THCA	cis	rs10495907	0.591	rs13398675	ENSG00000234936.1	AC010883.5	3.68	0.000256	0.0175	0.16	0.17	Coronary artery disease;	chr2:43723162	chr2:43229573~43233394:+
THCA	cis	rs7259811	0.56	rs56049479	ENSG00000279405.1	AC098795.1	-3.68	0.000256	0.0175	-0.18	-0.17	Western dietary pattern;	chr19:56706204	chr19:56480397~56483977:-
THCA	cis	rs7259811	0.56	rs56185441	ENSG00000279405.1	AC098795.1	-3.68	0.000256	0.0175	-0.18	-0.17	Western dietary pattern;	chr19:56706268	chr19:56480397~56483977:-
THCA	cis	rs12476592	0.543	rs4671510	ENSG00000242412.1	DBIL5P2	3.68	0.000256	0.0175	0.21	0.17	Childhood ear infection;	chr2:63515746	chr2:63117851~63119542:-
THCA	cis	rs3790515	1	rs3790515	ENSG00000269489.1	RP11-98D18.17	3.68	0.000256	0.0175	0.21	0.17	Depressive symptoms (SSRI exposure interaction);	chr1:151813896	chr1:151798054~151798602:+
THCA	cis	rs113577745	0.697	rs1897165	ENSG00000188525.3	AC010969.1	-3.68	0.000256	0.0175	-0.24	-0.17	Breast cancer;	chr2:9980713	chr2:10003158~10006030:-
THCA	cis	rs113577745	0.697	rs2033326	ENSG00000188525.3	AC010969.1	-3.68	0.000256	0.0175	-0.24	-0.17	Breast cancer;	chr2:9980857	chr2:10003158~10006030:-
THCA	cis	rs9367716	0.741	rs9396266	ENSG00000276576.1	MRPL30P1	3.68	0.000256	0.0175	0.21	0.17	Coronary artery disease;	chr6:57242524	chr6:57029521~57029988:+
THCA	cis	rs801193	0.548	rs2659904	ENSG00000230189.5	GS1-124K5.2	3.68	0.000256	0.0175	0.11	0.17	Aortic root size;	chr7:66713615	chr7:66409143~66490059:-
THCA	cis	rs7259376	0.905	rs2082479	ENSG00000269345.1	VN1R85P	3.68	0.000256	0.0175	0.18	0.17	Menopause (age at onset);	chr19:22357045	chr19:22174766~22175191:-
THCA	cis	rs301901	0.793	rs11750212	ENSG00000250155.1	CTD-2353F22.1	3.68	0.000256	0.0175	0.16	0.17	Height;	chr5:37463644	chr5:36666214~36725195:-
THCA	cis	rs10496034	0.541	rs79747576	ENSG00000237887.1	AC092839.1	-3.68	0.000256	0.0175	-0.32	-0.17	Refractive astigmatism;	chr2:54707707	chr2:54529343~54529801:+
THCA	cis	rs10029851	0.738	rs1436507	ENSG00000234492.4	RPL34-AS1	3.68	0.000256	0.0175	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr4:108709841	chr4:108538190~108620460:-
THCA	cis	rs478304	0.514	rs75601653	ENSG00000214659.4	KRT8P26	3.68	0.000256	0.0175	0.16	0.17	Acne (severe);	chr11:65715899	chr11:65726939~65728214:+
THCA	cis	rs8030379	1	rs11259931	ENSG00000176700.18	SCAND2P	3.68	0.000256	0.0175	0.1	0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911270	chr15:84631451~84647478:+
THCA	cis	rs3824488	0.92	rs28673156	ENSG00000271155.1	RP11-435O5.5	-3.68	0.000256	0.0175	-0.28	-0.17	Neuroticism;	chr9:95485508	chr9:95506235~95507636:+
THCA	cis	rs3736858	0.825	rs3759445	ENSG00000261105.4	LMO7-AS1	-3.68	0.000256	0.0175	-0.23	-0.17	Interleukin-9 levels;	chr13:75816090	chr13:75604700~75635994:-
THCA	cis	rs4950322	1	rs4950322	ENSG00000180867.10	PDIA3P1	-3.68	0.000256	0.0175	-0.18	-0.17	Protein quantitative trait loci;	chr1:147383114	chr1:147178113~147179622:+
THCA	cis	rs1502337	0.532	rs10744765	ENSG00000278993.1	RP3-424M6.4	3.68	0.000256	0.0175	0.25	0.17	Body mass index;	chr12:110445991	chr12:110501614~110503441:+
THCA	cis	rs7178375	1	rs35162264	ENSG00000269930.1	RP11-932O9.9	-3.68	0.000256	0.0175	-0.23	-0.17	Hypertriglyceridemia;	chr15:30908480	chr15:30616958~30617749:+
THCA	cis	rs9532669	0.926	rs9532647	ENSG00000229473.2	RGS17P1	3.68	0.000256	0.0175	0.22	0.17	Cervical cancer;	chr13:40881799	chr13:40992779~40993331:-
THCA	cis	rs73198271	0.586	rs3789850	ENSG00000253893.2	FAM85B	3.68	0.000256	0.0175	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8829335	chr8:8167819~8226614:-
THCA	cis	rs7119	0.7	rs2867311	ENSG00000259362.2	RP11-307C19.1	3.68	0.000256	0.0175	0.21	0.17	Type 2 diabetes;	chr15:77609849	chr15:77525540~77534110:+
THCA	cis	rs758324	0.661	rs25881	ENSG00000224431.1	AC063976.7	-3.68	0.000256	0.0175	-0.17	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132075445	chr5:132199456~132203487:+
THCA	cis	rs7296418	0.885	rs1727305	ENSG00000256092.2	RP13-942N8.1	3.68	0.000256	0.0175	0.12	0.17	Platelet count;	chr12:123148835	chr12:123363868~123366113:+
THCA	cis	rs7296418	0.885	rs1716184	ENSG00000256092.2	RP13-942N8.1	3.68	0.000256	0.0175	0.12	0.17	Platelet count;	chr12:123152962	chr12:123363868~123366113:+
THCA	cis	rs5769765	1	rs5770755	ENSG00000260613.1	RP3-522J7.6	3.68	0.000256	0.0175	0.22	0.17	Schizophrenia;	chr22:49886488	chr22:49832616~49837786:-
THCA	cis	rs2243480	1	rs34703416	ENSG00000273024.4	INTS4P2	3.68	0.000256	0.0175	0.28	0.17	Diabetic kidney disease;	chr7:65835655	chr7:65647864~65715661:+
THCA	cis	rs2885805	0.56	rs343822	ENSG00000259834.1	RP11-284N8.3	-3.68	0.000256	0.0175	-0.18	-0.17	Cytomegalovirus antibody response;	chr1:110800660	chr1:110653560~110657040:-
THCA	cis	rs62158800	0.598	rs10865014	ENSG00000225588.2	AC096669.1	3.68	0.000256	0.0175	0.17	0.17	Facial morphology (factor 22);	chr2:107674316	chr2:107362282~107407329:+
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000280107.1	AL022393.9	-3.68	0.000256	0.0175	-0.17	-0.17	Pubertal anthropometrics;	chr6:28197520	chr6:28170845~28172521:+
THCA	cis	rs7956611	0.603	rs12812084	ENSG00000213343.5	RPL21P18	-3.68	0.000256	0.0175	-0.19	-0.17	Age of smoking initiation;	chr12:66506656	chr12:66037235~66037714:+
THCA	cis	rs7956611	0.603	rs78568097	ENSG00000213343.5	RPL21P18	-3.68	0.000256	0.0175	-0.19	-0.17	Age of smoking initiation;	chr12:66506887	chr12:66037235~66037714:+
THCA	cis	rs16915157	0.512	rs11817221	ENSG00000254271.1	RP11-131N11.4	3.68	0.000256	0.0175	0.36	0.17	Schizophrenia;	chr10:60541060	chr10:60734342~60741828:+
THCA	cis	rs7615952	0.641	rs6438951	ENSG00000241288.6	RP11-379B18.5	-3.68	0.000256	0.0175	-0.19	-0.17	Blood pressure (smoking interaction);	chr3:125978156	chr3:125827238~125916384:-
THCA	cis	rs5751614	1	rs1004040	ENSG00000222037.5	IGLC6	-3.68	0.000256	0.0175	-0.11	-0.17	Height;	chr22:23242945	chr22:22919535~22919851:+
THCA	cis	rs860295	0.812	rs2297775	ENSG00000203761.5	MSTO2P	3.68	0.000256	0.0175	0.13	0.17	Body mass index;	chr1:155765221	chr1:155745829~155750137:+
THCA	cis	rs4915077	1	rs17020010	ENSG00000226822.1	RP11-356N1.2	3.68	0.000257	0.0175	0.32	0.17	Hypothyroidism;	chr1:107778780	chr1:108071482~108074519:+
THCA	cis	rs4915077	1	rs17020011	ENSG00000226822.1	RP11-356N1.2	3.68	0.000257	0.0175	0.32	0.17	Hypothyroidism;	chr1:107778919	chr1:108071482~108074519:+
THCA	cis	rs12893668	0.703	rs8017993	ENSG00000244691.1	RPL10AP1	-3.68	0.000257	0.0175	-0.23	-0.17	Reticulocyte count;	chr14:103581397	chr14:103412119~103412761:-
THCA	cis	rs7432375	0.899	rs6439655	ENSG00000273455.1	RP11-305O4.3	-3.68	0.000257	0.0175	-0.23	-0.17	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136747757	chr3:136087475~136087913:-
THCA	cis	rs59901009	0.516	rs7925889	ENSG00000246273.5	SBF2-AS1	3.68	0.000257	0.0175	0.21	0.17	Hematocrit;Hemoglobin concentration;	chr11:10026772	chr11:9758292~9811319:+
THCA	cis	rs2214442	0.934	rs3807945	ENSG00000271133.4	CTA-293F17.1	-3.68	0.000257	0.0175	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20376203	chr7:20328299~20331747:-
THCA	cis	rs4853525	0.59	rs12619017	ENSG00000235852.1	AC005540.3	3.68	0.000257	0.0175	0.19	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865167	chr2:190880797~190882059:-
THCA	cis	rs7267979	0.866	rs2424699	ENSG00000276952.1	RP5-965G21.6	3.68	0.000257	0.0175	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25284915~25285588:-
THCA	cis	rs4601821	0.858	rs7945132	ENSG00000270179.1	RP11-159N11.4	-3.68	0.000257	0.0175	-0.17	-0.17	Alcoholic chronic pancreatitis;	chr11:113391751	chr11:113368478~113369117:+
THCA	cis	rs62158800	0.638	rs1400116	ENSG00000225588.2	AC096669.1	3.68	0.000257	0.0175	0.17	0.17	Facial morphology (factor 22);	chr2:107677765	chr2:107362282~107407329:+
THCA	cis	rs13323323	0.842	rs56377787	ENSG00000214820.3	MPRIPP1	3.68	0.000257	0.0175	0.2	0.17	IgG glycosylation;	chr3:44252021	chr3:44579938~44581026:-
THCA	cis	rs972578	0.837	rs6002966	ENSG00000230319.1	AL022476.2	3.68	0.000257	0.0175	0.18	0.17	Mean platelet volume;	chr22:42863849	chr22:43038585~43052366:+
THCA	cis	rs722599	0.683	rs7160852	ENSG00000279594.1	RP11-950C14.10	3.68	0.000257	0.0175	0.17	0.17	IgG glycosylation;	chr14:74772721	chr14:75011269~75012851:-
THCA	cis	rs11633886	0.622	rs4774814	ENSG00000259200.1	RP11-718O11.1	-3.68	0.000257	0.0175	-0.21	-0.17	Diisocyanate-induced asthma;	chr15:45837944	chr15:45705078~45931069:+
THCA	cis	rs3104964	0.591	rs722084	ENSG00000253773.2	C8orf37-AS1	3.68	0.000257	0.0175	0.21	0.17	Colorectal cancer;	chr8:95692961	chr8:95204456~95810136:+
THCA	cis	rs4660214	0.666	rs1537818	ENSG00000228060.1	RP11-69E11.8	3.68	0.000257	0.0175	0.15	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181366	chr1:39565160~39573203:+
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000184274.3	LINC00315	-3.68	0.000257	0.0175	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45300245~45305257:-
THCA	cis	rs12681366	0.734	rs2515153	ENSG00000261437.1	RP11-22C11.2	-3.68	0.000257	0.0175	-0.15	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94411696	chr8:94637285~94639467:-
THCA	cis	rs7193541	0.825	rs4411525	ENSG00000262904.1	TMPOP2	-3.68	0.000257	0.0175	-0.2	-0.17	Multiple myeloma;	chr16:74561604	chr16:74667506~74668706:+
THCA	cis	rs2494663	0.61	rs11264875	ENSG00000231416.1	RP11-422P24.9	3.68	0.000257	0.0175	0.21	0.17	Mean platelet volume;	chr1:154022171	chr1:153995632~153995960:+
THCA	cis	rs12190007	0.508	rs7452203	ENSG00000226194.4	RP1-137D17.1	3.68	0.000257	0.0175	0.2	0.17	Obesity-related traits;	chr6:169341763	chr6:169369998~169388385:-
THCA	cis	rs35146811	0.735	rs2272345	ENSG00000078319.8	PMS2P1	3.68	0.000257	0.0175	0.21	0.17	Coronary artery disease;	chr7:100199408	chr7:100320992~100341908:-
THCA	cis	rs4915077	0.892	rs76257606	ENSG00000226822.1	RP11-356N1.2	3.68	0.000257	0.0175	0.27	0.17	Hypothyroidism;	chr1:107808055	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs77819196	ENSG00000226822.1	RP11-356N1.2	3.68	0.000257	0.0175	0.27	0.17	Hypothyroidism;	chr1:107808514	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs77097831	ENSG00000226822.1	RP11-356N1.2	3.68	0.000257	0.0175	0.27	0.17	Hypothyroidism;	chr1:107808857	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs78788276	ENSG00000226822.1	RP11-356N1.2	3.68	0.000257	0.0175	0.27	0.17	Hypothyroidism;	chr1:107808863	chr1:108071482~108074519:+
THCA	cis	rs6546886	0.912	rs6745792	ENSG00000235499.1	AC073046.25	3.68	0.000257	0.0175	0.16	0.17	Dialysis-related mortality;	chr2:74056906	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.912	rs10200470	ENSG00000235499.1	AC073046.25	3.68	0.000257	0.0175	0.16	0.17	Dialysis-related mortality;	chr2:74057560	chr2:73985132~73986343:+
THCA	cis	rs73108077	0.831	rs73116281	ENSG00000277112.2	RP11-755J8.1	-3.68	0.000257	0.0175	-0.37	-0.17	Red blood cell density in sickle cell anemia;	chr20:31478547	chr20:30681825~30723932:-
THCA	cis	rs4218	0.734	rs12912071	ENSG00000277144.1	RP11-59H7.4	-3.68	0.000257	0.0175	-0.22	-0.17	Social communication problems;	chr15:59150951	chr15:59115547~59116089:-
THCA	cis	rs7259376	0.902	rs8112041	ENSG00000269138.1	ZNF209P	-3.68	0.000257	0.0175	-0.17	-0.17	Menopause (age at onset);	chr19:22421763	chr19:22463922~22473036:+
THCA	cis	rs6938	0.618	rs1133323	ENSG00000260269.4	CTD-2323K18.1	-3.68	0.000257	0.0175	-0.25	-0.17	Breast cancer;	chr15:74919884	chr15:75527150~75601205:-
THCA	cis	rs2179367	0.887	rs2143076	ENSG00000223701.3	RAET1E-AS1	3.68	0.000257	0.0175	0.21	0.17	Dupuytren's disease;	chr6:149425315	chr6:149884431~149919508:+
THCA	cis	rs13091206	1	rs13091206	ENSG00000229759.1	MRPS18AP1	3.68	0.000257	0.0175	0.27	0.17	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr3:49201285	chr3:48256350~48256938:-
THCA	cis	rs2240395	0.754	rs10242990	ENSG00000228360.1	RP11-365F18.1	-3.68	0.000257	0.0175	-0.17	-0.17	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr7:140030700	chr7:139227537~139227828:-
THCA	cis	rs559555	0.849	rs2300698	ENSG00000276517.1	AL133243.2	-3.68	0.000257	0.0175	-0.15	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31561723	chr2:32526504~32529507:+
THCA	cis	rs1728785	0.901	rs12929568	ENSG00000274698.1	RP11-71L14.4	3.68	0.000257	0.0175	0.23	0.17	Ulcerative colitis;	chr16:68562786	chr16:68450283~68452318:+
THCA	cis	rs17689437	0.918	rs78978018	ENSG00000275383.1	RP11-615I2.6	3.68	0.000257	0.0175	0.29	0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68594445	chr16:68591382~68594424:+
THCA	cis	rs10457838	0.517	rs900313	ENSG00000216906.2	RP11-350J20.9	-3.68	0.000257	0.0175	-0.2	-0.17	Post-traumatic stress disorder;	chr6:148968047	chr6:149904243~149906418:+
THCA	cis	rs7577696	0.505	rs539213	ENSG00000276517.1	AL133243.2	-3.68	0.000257	0.0175	-0.16	-0.17	Inflammatory biomarkers;	chr2:31651423	chr2:32526504~32529507:+
THCA	cis	rs3806843	0.576	rs246009	ENSG00000202515.1	VTRNA1-3	3.68	0.000257	0.0175	0.2	0.17	Depressive symptoms (multi-trait analysis);	chr5:140958484	chr5:140726158~140726246:+
THCA	cis	rs2032366	0.606	rs9965972	ENSG00000267316.4	RP11-879F14.3	-3.68	0.000257	0.0175	-0.19	-0.17	Obesity-related traits;	chr18:61609468	chr18:61571342~61579456:-
THCA	cis	rs10090774	0.71	rs11166990	ENSG00000279766.1	RP11-642A1.2	3.68	0.000257	0.0175	0.2	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140653873	chr8:140572142~140572812:-
THCA	cis	rs372883	0.564	rs766928	ENSG00000176054.6	RPL23P2	3.68	0.000257	0.0175	0.15	0.17	Pancreatic cancer;	chr21:29381286	chr21:28997613~28998033:-
THCA	cis	rs2305707	0.611	rs8029807	ENSG00000273674.3	CTD-2378E12.1	3.68	0.000257	0.0175	0.35	0.17	Height;	chr15:51279840	chr15:50839875~50908599:-
THCA	cis	rs11633886	0.748	rs10519035	ENSG00000259200.1	RP11-718O11.1	-3.68	0.000257	0.0175	-0.21	-0.17	Diisocyanate-induced asthma;	chr15:45781393	chr15:45705078~45931069:+
THCA	cis	rs459571	0.792	rs55923934	ENSG00000235106.7	LINC00094	3.68	0.000257	0.0175	0.15	0.17	Platelet distribution width;	chr9:134023111	chr9:134025439~134034666:+
THCA	cis	rs561341	0.941	rs8066558	ENSG00000265798.5	RP11-271K11.5	3.68	0.000257	0.0175	0.24	0.17	Hip circumference adjusted for BMI;	chr17:31945860	chr17:31038575~31059121:-
THCA	cis	rs854765	0.52	rs7219324	ENSG00000281749.1	Y_RNA	-3.68	0.000257	0.0175	-0.2	-0.17	Total body bone mineral density;	chr17:18006461	chr17:18001101~18001195:-
THCA	cis	rs6671200	1	rs259354	ENSG00000235501.4	RP4-639F20.1	3.68	0.000257	0.0175	0.33	0.17	Stearic acid (18:0) levels;	chr1:95252649	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.92	rs259350	ENSG00000235501.4	RP4-639F20.1	3.68	0.000257	0.0175	0.33	0.17	Stearic acid (18:0) levels;	chr1:95259275	chr1:94927566~94963270:+
THCA	cis	rs9650657	0.771	rs4840516	ENSG00000255310.2	AF131215.2	3.68	0.000257	0.0175	0.13	0.17	Neuroticism;	chr8:10809825	chr8:11107788~11109726:-
THCA	cis	rs10129255	0.957	rs2013423	ENSG00000280411.1	IGHV1-69-2	-3.68	0.000257	0.0175	-0.11	-0.17	Kawasaki disease;	chr14:106690675	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs56134540	ENSG00000280411.1	IGHV1-69-2	-3.68	0.000257	0.0175	-0.11	-0.17	Kawasaki disease;	chr14:106691290	chr14:106762092~106762588:-
THCA	cis	rs9916302	0.706	rs903507	ENSG00000266469.1	CTB-131K11.1	-3.68	0.000257	0.0175	-0.16	-0.17	Glomerular filtration rate (creatinine);	chr17:39570170	chr17:39401793~39406233:+
THCA	cis	rs9287719	0.967	rs6735074	ENSG00000243819.4	RN7SL832P	-3.68	0.000257	0.0175	-0.13	-0.17	Prostate cancer;	chr2:10594640	chr2:10690344~10692099:+
THCA	cis	rs875971	0.545	rs316328	ENSG00000273024.4	INTS4P2	3.68	0.000257	0.0175	0.2	0.17	Aortic root size;	chr7:66143851	chr7:65647864~65715661:+
THCA	cis	rs9323497	0.826	rs57154550	ENSG00000258561.1	RP11-72M17.1	-3.68	0.000257	0.0175	-0.26	-0.17	Depressive symptom measurement or major depressive disorder;	chr14:67339293	chr14:66212810~66509394:-
THCA	cis	rs2797160	0.714	rs1777220	ENSG00000226409.1	RP11-735G4.1	3.68	0.000257	0.0175	0.2	0.17	Endometrial cancer;	chr6:125701456	chr6:125370211~125374324:-
THCA	cis	rs860295	0.812	rs7556519	ENSG00000203761.5	MSTO2P	-3.68	0.000257	0.0175	-0.13	-0.17	Body mass index;	chr1:155857755	chr1:155745829~155750137:+
THCA	cis	rs755249	0.835	rs4660877	ENSG00000182109.6	RP11-69E11.4	3.68	0.000257	0.0176	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613574	chr1:39522280~39546187:-
THCA	cis	rs12544026	0.712	rs7827304	ENSG00000253669.3	KB-1732A1.1	3.68	0.000257	0.0176	0.19	0.17	Major depression and alcohol dependence;	chr8:101828650	chr8:102805517~102809971:+
THCA	cis	rs2522056	1	rs2706383	ENSG00000237714.1	P4HA2-AS1	-3.68	0.000257	0.0176	-0.24	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132456710	chr5:132184876~132192808:+
THCA	cis	rs786425	0.711	rs67516712	ENSG00000270095.1	RP11-214K3.18	-3.68	0.000258	0.0176	-0.2	-0.17	Pubertal anthropometrics;	chr12:123716977	chr12:123971457~123971714:-
THCA	cis	rs7737355	0.947	rs1422871	ENSG00000237714.1	P4HA2-AS1	3.68	0.000258	0.0176	0.24	0.17	Life satisfaction;	chr5:131606788	chr5:132184876~132192808:+
THCA	cis	rs7243790	0.905	rs1523871	ENSG00000277324.1	RP11-850A17.1	-3.68	0.000258	0.0176	-0.17	-0.17	Diastolic blood pressure;	chr18:54424507	chr18:54268346~54270028:-
THCA	cis	rs57709857	0.957	rs11998709	ENSG00000272092.1	RP11-350N15.5	-3.68	0.000258	0.0176	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38394552	chr8:38382364~38383461:+
THCA	cis	rs9860428	0.844	rs6763318	ENSG00000243795.1	RP11-572M11.3	-3.68	0.000258	0.0176	-0.2	-0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112848305	chr3:113142350~113167819:-
THCA	cis	rs894638	1	rs894638	ENSG00000263327.5	TAPT1-AS1	-3.68	0.000258	0.0176	-0.21	-0.17	Glomerular filtration rate in chronic kidney disease;	chr4:16118049	chr4:16226685~16320140:+
THCA	cis	rs7572733	0.935	rs1607373	ENSG00000231621.1	AC013264.2	-3.68	0.000258	0.0176	-0.16	-0.17	Dermatomyositis;	chr2:197935808	chr2:197197991~197199273:+
THCA	cis	rs7707921	0.752	rs2406909	ENSG00000251374.1	RPS23P5	-3.68	0.000258	0.0176	-0.23	-0.17	Breast cancer;	chr5:81980268	chr5:82265157~82265259:-
THCA	cis	rs9926296	0.605	rs3743859	ENSG00000274627.1	RP11-104N10.2	3.68	0.000258	0.0176	0.17	0.17	Vitiligo;	chr16:89779642	chr16:89516797~89522217:+
THCA	cis	rs6546886	0.625	rs13019449	ENSG00000217702.2	RP11-287D1.4	-3.68	0.000258	0.0176	-0.28	-0.17	Dialysis-related mortality;	chr2:74030758	chr2:74130583~74135395:+
THCA	cis	rs901683	1	rs9422442	ENSG00000230869.1	CTGLF10P	-3.68	0.000258	0.0176	-0.38	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45552630	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs17157928	ENSG00000230869.1	CTGLF10P	-3.68	0.000258	0.0176	-0.38	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45552781	chr10:45678692~45700532:+
THCA	cis	rs172166	0.61	rs156737	ENSG00000261839.1	RP1-265C24.8	3.68	0.000258	0.0176	0.16	0.17	Cardiac Troponin-T levels;	chr6:27927435	chr6:28136849~28139678:+
THCA	cis	rs7131987	0.565	rs6487797	ENSG00000275476.1	RP11-996F15.4	3.68	0.000258	0.0176	0.16	0.17	QT interval;	chr12:29270063	chr12:29277397~29277882:-
THCA	cis	rs7608910	0.668	rs10207958	ENSG00000270820.4	RP11-355B11.2	3.68	0.000258	0.0176	0.14	0.17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60998195	chr2:61471188~61484130:+
THCA	cis	rs14027	0.883	rs10087723	ENSG00000245330.4	KB-1471A8.1	3.68	0.000258	0.0176	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711014	chr8:119867419~119874488:-
THCA	cis	rs2434529	0.531	rs4958707	ENSG00000245275.6	SAP30L-AS1	3.68	0.000258	0.0176	0.24	0.17	Autism spectrum disorder or schizophrenia;	chr5:154200844	chr5:154329437~154445850:-
THCA	cis	rs4664293	0.769	rs2729726	ENSG00000230783.1	AC009961.2	-3.68	0.000258	0.0176	-0.22	-0.17	Monocyte percentage of white cells;	chr2:159811597	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.738	rs1549580	ENSG00000230783.1	AC009961.2	-3.68	0.000258	0.0176	-0.22	-0.17	Monocyte percentage of white cells;	chr2:159812177	chr2:159689217~159690291:-
THCA	cis	rs409045	1	rs437465	ENSG00000271874.1	CTD-2024P10.2	-3.68	0.000258	0.0176	-0.22	-0.17	Left ventricular mass;	chr5:34638763	chr5:34651457~34651888:-
THCA	cis	rs7142002	0.568	rs746781	ENSG00000272444.1	RP11-1017G21.6	-3.68	0.000258	0.0176	-0.19	-0.17	Autism;	chr14:101922138	chr14:101952416~101953063:+
THCA	cis	rs970548	1	rs10900224	ENSG00000230869.1	CTGLF10P	3.68	0.000258	0.0176	0.21	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45529086	chr10:45678692~45700532:+
THCA	cis	rs7927592	0.913	rs11228276	ENSG00000160172.9	FAM86C2P	3.68	0.000258	0.0176	0.16	0.17	Total body bone mineral density;	chr11:68540057	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs67005337	ENSG00000160172.9	FAM86C2P	3.68	0.000258	0.0176	0.16	0.17	Total body bone mineral density;	chr11:68540290	chr11:67791648~67805336:-
THCA	cis	rs5753037	0.653	rs140131	ENSG00000279699.1	RP1-102K2.9	3.68	0.000258	0.0176	0.16	0.17	Type 1 diabetes;	chr22:29755727	chr22:30275215~30276951:-
THCA	cis	rs12439619	0.53	rs28883606	ENSG00000255769.6	GOLGA2P10	-3.68	0.000258	0.0176	-0.19	-0.17	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472993~82513950:-
THCA	cis	rs6715284	1	rs72934944	ENSG00000238829.1	RNU7-45P	-3.68	0.000258	0.0176	-0.37	-0.17	Rheumatoid arthritis;	chr2:201325887	chr2:201141904~201141966:+
THCA	cis	rs73198271	0.737	rs535094	ENSG00000254153.1	CTA-398F10.2	3.68	0.000258	0.0176	0.19	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776418	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.765	rs534103	ENSG00000254153.1	CTA-398F10.2	3.68	0.000258	0.0176	0.19	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776559	chr8:8456909~8461337:-
THCA	cis	rs972578	0.811	rs2284091	ENSG00000230319.1	AL022476.2	3.68	0.000258	0.0176	0.18	0.17	Mean platelet volume;	chr22:42875498	chr22:43038585~43052366:+
THCA	cis	rs801193	1	rs2659915	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000258	0.0176	-0.14	-0.17	Aortic root size;	chr7:66688114	chr7:66848496~66858136:+
THCA	cis	rs2214442	0.516	rs10215885	ENSG00000271133.4	CTA-293F17.1	3.68	0.000258	0.0176	0.17	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20380547	chr7:20328299~20331747:-
THCA	cis	rs9650657	0.547	rs11250099	ENSG00000261451.1	RP11-981G7.1	3.68	0.000258	0.0176	0.2	0.17	Neuroticism;	chr8:10961147	chr8:10433672~10438312:+
THCA	cis	rs8035452	0.857	rs3131604	ENSG00000273674.3	CTD-2378E12.1	3.68	0.000258	0.0176	0.21	0.17	Alzheimer's disease (late onset);	chr15:50521842	chr15:50839875~50908599:-
THCA	cis	rs7096965	0.958	rs17368701	ENSG00000242147.1	RP13-463N16.6	-3.68	0.000258	0.0176	-0.19	-0.17	Major depressive disorder;	chr10:4605026	chr10:5594991~5596118:-
THCA	cis	rs2486012	0.737	rs556667	ENSG00000237950.1	RP11-7O11.3	3.68	0.000258	0.0176	0.19	0.17	Intelligence (multi-trait analysis);	chr1:43821742	chr1:43944370~43946551:-
THCA	cis	rs7208859	0.573	rs216443	ENSG00000214719.10	AC005562.1	-3.68	0.000258	0.0176	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30576464~30672789:+
THCA	cis	rs643506	0.874	rs4245045	ENSG00000230911.1	PPIHP1	-3.68	0.000258	0.0176	-0.23	-0.17	Breast cancer;	chr11:111789200	chr11:112029858~112030367:-
THCA	cis	rs643506	0.874	rs625477	ENSG00000230911.1	PPIHP1	-3.68	0.000258	0.0176	-0.23	-0.17	Breast cancer;	chr11:111790962	chr11:112029858~112030367:-
THCA	cis	rs1035144	0.546	rs2215981	ENSG00000271656.1	RP11-114N19.5	3.68	0.000258	0.0176	0.19	0.17	Male sexual orientation;	chr14:80978623	chr14:81003325~81003645:-
THCA	cis	rs7259376	0.525	rs1692596	ENSG00000269138.1	ZNF209P	3.68	0.000258	0.0176	0.16	0.17	Menopause (age at onset);	chr19:22451927	chr19:22463922~22473036:+
THCA	cis	rs17604090	0.938	rs850027	ENSG00000223813.2	AC007255.8	3.68	0.000258	0.0176	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29636176	chr7:29514225~29563670:-
THCA	cis	rs7117932	0.935	rs7935676	ENSG00000270160.1	RP11-264E20.2	3.68	0.000258	0.0176	0.2	0.17	Obesity-related traits;	chr11:128573188	chr11:128614340~128615236:-
THCA	cis	rs7117932	0.935	rs7935393	ENSG00000270160.1	RP11-264E20.2	3.68	0.000258	0.0176	0.2	0.17	Obesity-related traits;	chr11:128573204	chr11:128614340~128615236:-
THCA	cis	rs793571	0.822	rs35477914	ENSG00000245975.2	RP11-30K9.6	3.68	0.000258	0.0176	0.19	0.17	Schizophrenia;	chr15:58905470	chr15:58768072~58770974:-
THCA	cis	rs4664304	0.537	rs6711770	ENSG00000226266.5	AC009961.3	-3.68	0.000258	0.0176	-0.2	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159836250	chr2:159670708~159712435:-
THCA	cis	rs911555	0.603	rs11626562	ENSG00000269958.1	RP11-73M18.8	3.68	0.000258	0.0176	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103379025	chr14:103696353~103697163:+
THCA	cis	rs3753275	0.684	rs6577532	ENSG00000230679.1	ENO1-AS1	3.68	0.000258	0.0176	0.15	0.17	Educational attainment;	chr1:8839246	chr1:8878835~8879894:+
THCA	cis	rs11583043	0.546	rs10493944	ENSG00000233184.5	RP11-421L21.3	3.68	0.000258	0.0176	0.19	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101130492	chr1:101025878~101087268:+
THCA	cis	rs1923243	0.743	rs4477222	ENSG00000223479.3	RP4-788P17.1	3.68	0.000258	0.0176	0.18	0.17	Migraine;	chr1:73118849	chr1:73635216~73715214:+
THCA	cis	rs7200543	1	rs16966953	ENSG00000260735.1	RP11-72I8.1	-3.68	0.000258	0.0176	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15094411~15109197:+
THCA	cis	rs893363	0.623	rs877483	ENSG00000271916.1	RP11-884K10.6	3.68	0.000258	0.0176	0.18	0.17	Axial length;	chr3:53812714	chr3:53797764~53798019:-
THCA	cis	rs76878669	0.652	rs10896117	ENSG00000255320.1	RP11-755F10.1	3.68	0.000258	0.0176	0.25	0.17	Educational attainment (years of education);	chr11:66393992	chr11:66244840~66246239:-
THCA	cis	rs910316	0.737	rs175071	ENSG00000273565.1	CTD-3075F15.1	-3.68	0.000258	0.0176	-0.19	-0.17	Height;	chr14:75031474	chr14:75176929~75177418:+
THCA	cis	rs11673344	0.764	rs10424584	ENSG00000267260.1	CTD-2162K18.4	-3.68	0.000258	0.0176	-0.21	-0.17	Obesity-related traits;	chr19:36975986	chr19:36773153~36777078:+
THCA	cis	rs9863	0.827	rs4930724	ENSG00000270061.1	RP11-214K3.19	-3.68	0.000258	0.0176	-0.23	-0.17	White blood cell count;	chr12:123939270	chr12:123969990~123970344:-
THCA	cis	rs9308731	0.505	rs10169613	ENSG00000227992.1	AC108463.2	-3.68	0.000258	0.0176	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111177400	chr2:111203964~111206215:-
THCA	cis	rs735539	0.521	rs2585896	ENSG00000278291.1	RP11-172H24.4	3.68	0.000258	0.0176	0.23	0.17	Dental caries;	chr13:20824722	chr13:20699307~20703718:-
THCA	cis	rs9287719	0.967	rs6721739	ENSG00000243819.4	RN7SL832P	-3.68	0.000258	0.0176	-0.13	-0.17	Prostate cancer;	chr2:10611120	chr2:10690344~10692099:+
THCA	cis	rs987724	0.927	rs7616633	ENSG00000240875.4	LINC00886	-3.68	0.000258	0.0176	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156863245	chr3:156747346~156817062:-
THCA	cis	rs206966	0.81	rs73416934	ENSG00000277283.1	RP1-267D11.6	3.68	0.000258	0.0176	0.17	0.17	Breast cancer;	chr12:120348884	chr12:120116907~120119000:+
THCA	cis	rs9425766	0.679	rs6695636	ENSG00000270084.1	GAS5-AS1	-3.68	0.000259	0.0176	-0.17	-0.17	Life satisfaction;	chr1:174303087	chr1:173863248~173863941:+
THCA	cis	rs1502337	0.532	rs4766501	ENSG00000278993.1	RP3-424M6.4	-3.68	0.000259	0.0176	-0.25	-0.17	Body mass index;	chr12:110560408	chr12:110501614~110503441:+
THCA	cis	rs1923243	0.695	rs7552256	ENSG00000223479.3	RP4-788P17.1	-3.68	0.000259	0.0176	-0.18	-0.17	Migraine;	chr1:73065132	chr1:73635216~73715214:+
THCA	cis	rs6494488	0.5	rs72744723	ENSG00000259635.1	AC100830.3	-3.68	0.000259	0.0176	-0.41	-0.17	Coronary artery disease;	chr15:64728528	chr15:64701248~64719602:+
THCA	cis	rs7727544	0.547	rs10076758	ENSG00000263597.1	MIR3936	3.68	0.000259	0.0176	0.16	0.17	Blood metabolite levels;	chr5:132188606	chr5:132365490~132365599:-
THCA	cis	rs2540949	0.538	rs2540971	ENSG00000237979.1	AC007389.1	-3.68	0.000259	0.0176	-0.21	-0.17	Atrial fibrillation;	chr2:65025251	chr2:65500993~65502138:-
THCA	cis	rs9425766	0.679	rs7552830	ENSG00000270084.1	GAS5-AS1	-3.68	0.000259	0.0176	-0.17	-0.17	Life satisfaction;	chr1:174321643	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs7523938	ENSG00000270084.1	GAS5-AS1	-3.68	0.000259	0.0176	-0.17	-0.17	Life satisfaction;	chr1:174327373	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.64	rs6681780	ENSG00000270084.1	GAS5-AS1	-3.68	0.000259	0.0176	-0.17	-0.17	Life satisfaction;	chr1:174328980	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.64	rs17301013	ENSG00000270084.1	GAS5-AS1	-3.68	0.000259	0.0176	-0.17	-0.17	Life satisfaction;	chr1:174343675	chr1:173863248~173863941:+
THCA	cis	rs735539	0.521	rs1966190	ENSG00000278291.1	RP11-172H24.4	3.68	0.000259	0.0176	0.23	0.17	Dental caries;	chr13:20834998	chr13:20699307~20703718:-
THCA	cis	rs735539	0.521	rs1810717	ENSG00000278291.1	RP11-172H24.4	3.68	0.000259	0.0176	0.23	0.17	Dental caries;	chr13:20838096	chr13:20699307~20703718:-
THCA	cis	rs4073416	0.518	rs11158595	ENSG00000276116.2	FUT8-AS1	3.68	0.000259	0.0176	0.19	0.17	N-glycan levels;	chr14:65439651	chr14:65411170~65412690:-
THCA	cis	rs7554511	1	rs41299637	ENSG00000260088.1	RP11-92G12.3	-3.68	0.000259	0.0176	-0.26	-0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908722	chr1:200669507~200694250:+
THCA	cis	rs4218	0.543	rs11852461	ENSG00000277144.1	RP11-59H7.4	-3.68	0.000259	0.0176	-0.23	-0.17	Social communication problems;	chr15:59021728	chr15:59115547~59116089:-
THCA	cis	rs9970896	0.579	rs6665519	ENSG00000237845.1	RP5-940F7.2	3.68	0.000259	0.0176	0.29	0.17	Monocyte percentage of white cells;	chr1:235903172	chr1:235942553~235943805:-
THCA	cis	rs1552244	0.572	rs59132826	ENSG00000180385.7	EMC3-AS1	3.68	0.000259	0.0176	0.21	0.17	Alzheimer's disease;	chr3:10128041	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs58223482	ENSG00000180385.7	EMC3-AS1	3.68	0.000259	0.0176	0.21	0.17	Alzheimer's disease;	chr3:10128062	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs113406084	ENSG00000180385.7	EMC3-AS1	3.68	0.000259	0.0176	0.21	0.17	Alzheimer's disease;	chr3:10128506	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs17032440	ENSG00000180385.7	EMC3-AS1	-3.68	0.000259	0.0176	-0.21	-0.17	Alzheimer's disease;	chr3:10128135	chr3:9986893~10006990:+
THCA	cis	rs13178541	0.641	rs4976532	ENSG00000250378.1	RP11-119J18.1	-3.68	0.000259	0.0176	-0.19	-0.17	IgG glycosylation;	chr5:135798385	chr5:135812667~135826582:+
THCA	cis	rs9889262	0.62	rs850521	ENSG00000248714.5	RP11-1079K10.3	3.68	0.000259	0.0176	0.19	0.17	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49255445	chr17:49361165~49369998:+
THCA	cis	rs9863	0.861	rs9971695	ENSG00000269938.1	RP11-214K3.20	-3.68	0.000259	0.0176	-0.2	-0.17	White blood cell count;	chr12:123928944	chr12:123968023~123968579:-
THCA	cis	rs9863	0.827	rs4930706	ENSG00000269938.1	RP11-214K3.20	-3.68	0.000259	0.0176	-0.2	-0.17	White blood cell count;	chr12:123932791	chr12:123968023~123968579:-
THCA	cis	rs10911902	0.643	rs7525634	ENSG00000233196.2	GS1-304P7.1	-3.68	0.000259	0.0176	-0.26	-0.17	Schizophrenia;	chr1:186411333	chr1:186580515~186581191:-
THCA	cis	rs10129255	0.957	rs10150241	ENSG00000280411.1	IGHV1-69-2	3.68	0.000259	0.0176	0.1	0.17	Kawasaki disease;	chr14:106775945	chr14:106762092~106762588:-
THCA	cis	rs8099594	0.565	rs7238371	ENSG00000266696.1	RP11-30L3.2	3.68	0.000259	0.0176	0.21	0.17	Height;	chr18:49185269	chr18:49205912~49208781:+
THCA	cis	rs7819412	0.549	rs28887839	ENSG00000261451.1	RP11-981G7.1	-3.68	0.000259	0.0176	-0.22	-0.17	Triglycerides;	chr8:11142903	chr8:10433672~10438312:+
THCA	cis	rs9650657	0.812	rs6601522	ENSG00000269918.1	AF131215.9	-3.68	0.000259	0.0176	-0.18	-0.17	Neuroticism;	chr8:10771551	chr8:11104691~11106704:-
THCA	cis	rs858239	0.896	rs1637193	ENSG00000230042.1	AK3P3	-3.68	0.000259	0.0176	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23129178~23129841:+
THCA	cis	rs10802047	0.643	rs1213858	ENSG00000231365.4	RP11-418J17.1	-3.68	0.000259	0.0176	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118619487	chr1:119140396~119275973:+
THCA	cis	rs741677	0.927	rs2586117	ENSG00000231784.7	DBIL5P	3.68	0.000259	0.0176	0.18	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:580647	chr17:752660~755336:+
THCA	cis	rs7246657	1	rs7246657	ENSG00000268499.1	CTB-102L5.8	-3.68	0.000259	0.0176	-0.21	-0.17	Coronary artery calcification;	chr19:37256206	chr19:38199836~38200934:+
THCA	cis	rs5758511	0.68	rs5758667	ENSG00000230107.1	CTA-126B4.7	-3.68	0.000259	0.0176	-0.21	-0.17	Birth weight;	chr22:42237198	chr22:42438023~42446195:+
THCA	cis	rs916888	0.773	rs199448	ENSG00000260075.1	NSFP1	-3.68	0.000259	0.0176	-0.27	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46372855~46487141:+
THCA	cis	rs916888	0.773	rs199447	ENSG00000260075.1	NSFP1	-3.68	0.000259	0.0176	-0.27	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46372855~46487141:+
THCA	cis	rs4742903	0.935	rs10991166	ENSG00000270332.1	SMC2-AS1	3.68	0.000259	0.0176	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104211815	chr9:104080024~104093073:-
THCA	cis	rs3758911	0.929	rs10749894	ENSG00000255353.1	RP11-382M14.1	-3.68	0.000259	0.0176	-0.22	-0.17	Coronary artery disease;	chr11:107309586	chr11:107176286~107177530:+
THCA	cis	rs2070488	0.965	rs1870915	ENSG00000229589.1	ACVR2B-AS1	3.68	0.000259	0.0176	0.16	0.17	Electrocardiographic conduction measures;	chr3:38452737	chr3:38451027~38454820:-
THCA	cis	rs2360027	0.965	rs1009458	ENSG00000231365.4	RP11-418J17.1	-3.68	0.000259	0.0176	-0.16	-0.17	Tonsillectomy;	chr1:118615286	chr1:119140396~119275973:+
THCA	cis	rs4568518	0.742	rs13245422	ENSG00000279048.1	RP11-511H23.2	3.68	0.000259	0.0176	0.11	0.17	Measles;	chr7:17976352	chr7:17940503~17942922:+
THCA	cis	rs12476592	0.602	rs262478	ENSG00000242412.1	DBIL5P2	3.68	0.000259	0.0176	0.21	0.17	Childhood ear infection;	chr2:63645252	chr2:63117851~63119542:-
THCA	cis	rs12681366	0.881	rs10464877	ENSG00000253175.1	RP11-267M23.6	3.68	0.000259	0.0176	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94385615	chr8:94565036~94565715:+
THCA	cis	rs1009077	1	rs2389901	ENSG00000245958.5	RP11-33B1.1	3.68	0.000259	0.0176	0.21	0.17	Endometriosis;	chr4:119714753	chr4:119454791~119552025:+
THCA	cis	rs10844154	0.533	rs161980	ENSG00000277342.1	RP11-843B15.4	3.68	0.000259	0.0176	0.22	0.17	Emphysema-related traits;Weight;	chr12:32266300	chr12:32109076~32109602:+
THCA	cis	rs1046896	1	rs9909940	ENSG00000263063.1	RP11-388C12.1	-3.68	0.000259	0.0176	-0.2	-0.17	Glycated hemoglobin levels;	chr17:82731160	chr17:82713908~82716255:-
THCA	cis	rs2562456	0.52	rs582992	ENSG00000268117.1	VN1R84P	-3.68	0.000259	0.0176	-0.27	-0.17	Pain;	chr19:21266744	chr19:21719801~21720035:-
THCA	cis	rs478304	0.654	rs10896035	ENSG00000214659.4	KRT8P26	3.68	0.000259	0.0176	0.16	0.17	Acne (severe);	chr11:65693689	chr11:65726939~65728214:+
THCA	cis	rs10089	1	rs10060390	ENSG00000245937.6	LINC01184	3.68	0.000259	0.0176	0.19	0.17	Ileal carcinoids;	chr5:128117255	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs4836361	ENSG00000245937.6	LINC01184	3.68	0.000259	0.0176	0.19	0.17	Ileal carcinoids;	chr5:128124299	chr5:127940426~128083172:-
THCA	cis	rs10089	0.951	rs56066100	ENSG00000245937.6	LINC01184	3.68	0.000259	0.0176	0.19	0.17	Ileal carcinoids;	chr5:128124879	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs2409109	ENSG00000245937.6	LINC01184	3.68	0.000259	0.0176	0.19	0.17	Ileal carcinoids;	chr5:128125779	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs4836363	ENSG00000245937.6	LINC01184	3.68	0.000259	0.0176	0.19	0.17	Ileal carcinoids;	chr5:128127045	chr5:127940426~128083172:-
THCA	cis	rs10089	0.951	rs736969	ENSG00000245937.6	LINC01184	3.68	0.000259	0.0176	0.19	0.17	Ileal carcinoids;	chr5:128130655	chr5:127940426~128083172:-
THCA	cis	rs9425766	0.64	rs7512930	ENSG00000270084.1	GAS5-AS1	-3.68	0.000259	0.0176	-0.17	-0.17	Life satisfaction;	chr1:174319464	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs7523460	ENSG00000270084.1	GAS5-AS1	-3.68	0.000259	0.0176	-0.17	-0.17	Life satisfaction;	chr1:174319664	chr1:173863248~173863941:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000232546.1	RP11-458F8.1	3.68	0.000259	0.0176	0.14	0.17	Aortic root size;	chr7:66039646	chr7:66848496~66858136:+
THCA	cis	rs793571	0.543	rs11854073	ENSG00000245975.2	RP11-30K9.6	3.68	0.000259	0.0177	0.15	0.17	Schizophrenia;	chr15:58680796	chr15:58768072~58770974:-
THCA	cis	rs2221894	0.922	rs4732890	ENSG00000251191.6	LINC00589	-3.68	0.000259	0.0177	-0.2	-0.17	Obesity-related traits;	chr8:28893864	chr8:29673922~29748109:-
THCA	cis	rs1923243	0.681	rs79767231	ENSG00000223479.3	RP4-788P17.1	3.68	0.000259	0.0177	0.18	0.17	Migraine;	chr1:73083380	chr1:73635216~73715214:+
THCA	cis	rs1971762	0.527	rs6580952	ENSG00000270175.1	RP11-793H13.11	-3.68	0.000259	0.0177	-0.11	-0.17	Height;	chr12:53543668	chr12:53500162~53500936:-
THCA	cis	rs2613964	0.504	rs4682466	ENSG00000243795.1	RP11-572M11.3	-3.68	0.000259	0.0177	-0.19	-0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130841	chr3:113142350~113167819:-
THCA	cis	rs6546550	0.935	rs2872075	ENSG00000179818.12	PCBP1-AS1	-3.68	0.000259	0.0177	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69841503	chr2:69962263~70103220:-
THCA	cis	rs763121	0.853	rs9610986	ENSG00000225450.1	RP3-508I15.14	-3.68	0.000259	0.0177	-0.13	-0.17	Menopause (age at onset);	chr22:38629272	chr22:38739003~38749041:+
THCA	cis	rs62380364	0.774	rs7730255	ENSG00000247828.6	TMEM161B-AS1	-3.68	0.000259	0.0177	-0.12	-0.17	Intelligence (multi-trait analysis);	chr5:88862329	chr5:88268895~88436685:+
THCA	cis	rs10129255	1	rs11627342	ENSG00000280411.1	IGHV1-69-2	-3.68	0.000259	0.0177	-0.11	-0.17	Kawasaki disease;	chr14:106675823	chr14:106762092~106762588:-
THCA	cis	rs1560104	0.597	rs12708757	ENSG00000262801.4	U91319.1	-3.68	0.000259	0.0177	-0.19	-0.17	Obesity-related traits;	chr16:12616724	chr16:13246316~13562918:+
THCA	cis	rs2836974	0.931	rs2836968	ENSG00000255568.3	BRWD1-AS2	3.68	0.000259	0.0177	0.15	0.17	Cognitive function;	chr21:39270460	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.931	rs7283569	ENSG00000255568.3	BRWD1-AS2	3.68	0.000259	0.0177	0.15	0.17	Cognitive function;	chr21:39272136	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.931	rs2836972	ENSG00000255568.3	BRWD1-AS2	3.68	0.000259	0.0177	0.15	0.17	Cognitive function;	chr21:39280216	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.965	rs7354783	ENSG00000255568.3	BRWD1-AS2	3.68	0.000259	0.0177	0.15	0.17	Cognitive function;	chr21:39281066	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.931	rs8132285	ENSG00000255568.3	BRWD1-AS2	3.68	0.000259	0.0177	0.15	0.17	Cognitive function;	chr21:39283826	chr21:39313935~39314962:+
THCA	cis	rs34421088	0.56	rs2467520	ENSG00000227888.4	FAM66A	-3.68	0.000259	0.0177	-0.22	-0.17	Neuroticism;	chr8:11541444	chr8:12362019~12388296:+
THCA	cis	rs295490	0.748	rs78652857	ENSG00000272656.1	RP11-219D15.3	3.68	0.000259	0.0177	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139509107	chr3:139349024~139349371:-
THCA	cis	rs1488902	0.785	rs1948188	ENSG00000280367.1	RP11-121L10.2	3.68	0.000259	0.0177	0.15	0.17	Amyotrophic lateral sclerosis;	chr11:89600217	chr11:90223153~90226538:+
THCA	cis	rs6957923	0.839	rs58201821	ENSG00000234286.1	AC006026.13	-3.68	0.000259	0.0177	-0.22	-0.17	Height;	chr7:23471241	chr7:23680195~23680786:-
THCA	cis	rs910873	1	rs62212343	ENSG00000269202.1	RP4-614O4.12	-3.68	0.000259	0.0177	-0.31	-0.17	Melanoma;	chr20:34609133	chr20:35201747~35203288:-
THCA	cis	rs12368653	0.651	rs2277326	ENSG00000270039.1	RP11-571M6.17	-3.68	0.000259	0.0177	-0.18	-0.17	Multiple sclerosis;	chr12:57808636	chr12:57803838~57804415:+
THCA	cis	rs1923243	0.71	rs12135546	ENSG00000223479.3	RP4-788P17.1	3.68	0.000259	0.0177	0.18	0.17	Migraine;	chr1:73129010	chr1:73635216~73715214:+
THCA	cis	rs6812193	1	rs6854006	ENSG00000234036.4	TXNP6	3.68	0.000259	0.0177	0.23	0.17	Parkinson's disease;	chr4:76276901	chr4:76958860~76959169:-
THCA	cis	rs1865760	0.713	rs7766342	ENSG00000272810.1	U91328.22	-3.68	0.000259	0.0177	-0.13	-0.17	Height;	chr6:25990446	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.713	rs9461229	ENSG00000272810.1	U91328.22	-3.68	0.000259	0.0177	-0.13	-0.17	Height;	chr6:25992051	chr6:26013241~26013757:+
THCA	cis	rs1555322	0.929	rs2247828	ENSG00000269202.1	RP4-614O4.12	3.68	0.000259	0.0177	0.2	0.17	Attention deficit hyperactivity disorder;	chr20:35252136	chr20:35201747~35203288:-
THCA	cis	rs875971	0.522	rs6960048	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000259	0.0177	-0.14	-0.17	Aortic root size;	chr7:65943052	chr7:66848496~66858136:+
THCA	cis	rs10089	0.953	rs2190797	ENSG00000245937.6	LINC01184	3.68	0.000259	0.0177	0.19	0.17	Ileal carcinoids;	chr5:128017183	chr5:127940426~128083172:-
THCA	cis	rs7927592	0.956	rs11228278	ENSG00000160172.9	FAM86C2P	3.68	0.00026	0.0177	0.16	0.17	Total body bone mineral density;	chr11:68541062	chr11:67791648~67805336:-
THCA	cis	rs9329221	0.662	rs34155841	ENSG00000253641.4	RP11-981G7.2	3.68	0.00026	0.0177	0.17	0.17	Neuroticism;	chr8:10390019	chr8:10474565~10481974:+
THCA	cis	rs7614311	0.555	rs58676857	ENSG00000271843.1	RP11-245J9.5	-3.68	0.00026	0.0177	-0.28	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:63918207	chr3:64008082~64008692:-
THCA	cis	rs4578769	0.84	rs12232566	ENSG00000265939.1	UBE2CP2	-3.68	0.00026	0.0177	-0.21	-0.17	Eosinophil percentage of white cells;	chr18:22897295	chr18:22900486~22900995:-
THCA	cis	rs7873102	0.967	rs7025303	ENSG00000213839.4	TMX2P1	-3.68	0.00026	0.0177	-0.13	-0.17	Brain structure;	chr9:38040098	chr9:37885683~37886390:+
THCA	cis	rs7709377	0.723	rs1876675	ENSG00000250015.1	CTC-339F2.2	3.68	0.00026	0.0177	0.17	0.17	Metabolite levels  (X-11787);	chr5:116172360	chr5:116302354~116304134:-
THCA	cis	rs1154275	0.537	rs6772960	ENSG00000272844.1	RP11-484K9.4	3.68	0.00026	0.0177	0.14	0.17	Takotsubo syndrome;	chr3:112796693	chr3:112990447~112991153:-
THCA	cis	rs10090774	0.965	rs1375062	ENSG00000280303.2	ERICD	-3.68	0.00026	0.0177	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955682	chr8:140636281~140638283:+
THCA	cis	rs1580019	0.563	rs34201720	ENSG00000273014.1	RP11-225B17.2	3.68	0.00026	0.0177	0.17	0.17	Cognitive ability;	chr7:32529323	chr7:32758882~32759353:+
THCA	cis	rs12621844	0.7	rs922902	ENSG00000234690.5	AC073283.4	-3.68	0.00026	0.0177	-0.16	-0.17	Glycated hemoglobin levels;	chr2:48145115	chr2:47192405~47345074:-
THCA	cis	rs3758911	1	rs10749901	ENSG00000255353.1	RP11-382M14.1	-3.68	0.00026	0.0177	-0.21	-0.17	Coronary artery disease;	chr11:107324776	chr11:107176286~107177530:+
THCA	cis	rs7819412	0.875	rs6981523	ENSG00000255046.1	RP11-297N6.4	3.68	0.00026	0.0177	0.18	0.17	Triglycerides;	chr8:11204283	chr8:11797928~11802568:-
THCA	cis	rs10208649	0.572	rs2068017	ENSG00000233266.1	HMGB1P31	3.68	0.00026	0.0177	0.29	0.17	Body mass index;	chr2:53892434	chr2:54051334~54051760:+
THCA	cis	rs12480732	1	rs11699129	ENSG00000175730.8	BAK1P1	-3.68	0.00026	0.0177	-0.24	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:32605014	chr20:32690180~32690815:-
THCA	cis	rs4971059	0.654	rs12028043	ENSG00000225855.5	RUSC1-AS1	3.68	0.00026	0.0177	0.11	0.17	Breast cancer;	chr1:155160360	chr1:155316863~155324176:-
THCA	cis	rs2290416	0.579	rs58573550	ENSG00000253931.1	RP11-909N17.2	3.68	0.00026	0.0177	0.34	0.17	Attention deficit hyperactivity disorder;	chr8:143599544	chr8:143412749~143417054:+
THCA	cis	rs6494488	0.5	rs28644480	ENSG00000259635.1	AC100830.3	-3.68	0.00026	0.0177	-0.38	-0.17	Coronary artery disease;	chr15:64734733	chr15:64701248~64719602:+
THCA	cis	rs17604090	0.646	rs75322793	ENSG00000227855.3	DPY19L2P3	3.68	0.00026	0.0177	0.21	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29643560	chr7:29650227~29742594:+
THCA	cis	rs470119	1	rs470119	ENSG00000273253.2	RP3-402G11.26	3.68	0.00026	0.0177	0.17	0.17	Mean corpuscular hemoglobin;	chr22:50528485	chr22:50199090~50200837:-
THCA	cis	rs737008	0.586	rs2867945	ENSG00000262703.1	RP11-485G7.6	-3.68	0.00026	0.0177	-0.27	-0.17	Obesity-related traits;	chr16:11312161	chr16:11348143~11349321:-
THCA	cis	rs3770081	1	rs60479377	ENSG00000272564.1	RP11-548P2.2	-3.68	0.00026	0.0177	-0.32	-0.17	Facial emotion recognition (sad faces);	chr2:86056825	chr2:85904279~85904727:+
THCA	cis	rs3770081	0.793	rs60719866	ENSG00000272564.1	RP11-548P2.2	-3.68	0.00026	0.0177	-0.32	-0.17	Facial emotion recognition (sad faces);	chr2:86057255	chr2:85904279~85904727:+
THCA	cis	rs3770081	1	rs76081054	ENSG00000272564.1	RP11-548P2.2	-3.68	0.00026	0.0177	-0.32	-0.17	Facial emotion recognition (sad faces);	chr2:86057914	chr2:85904279~85904727:+
THCA	cis	rs3770081	1	rs59947468	ENSG00000272564.1	RP11-548P2.2	-3.68	0.00026	0.0177	-0.32	-0.17	Facial emotion recognition (sad faces);	chr2:86062313	chr2:85904279~85904727:+
THCA	cis	rs929354	0.806	rs28446734	ENSG00000224629.1	RP5-1142J19.2	-3.68	0.00026	0.0177	-0.16	-0.17	Body mass index;	chr7:157204081	chr7:157263022~157263229:-
THCA	cis	rs524281	0.814	rs2270448	ENSG00000255120.4	OVOL1-AS1	-3.68	0.00026	0.0177	-0.26	-0.17	Electroencephalogram traits;	chr11:66068460	chr11:65789051~65790868:-
THCA	cis	rs11048434	0.518	rs1805707	ENSG00000256720.1	RP11-436I9.6	-3.68	0.00026	0.0177	-0.18	-0.17	Sjögren's syndrome;	chr12:9029110	chr12:9135084~9135591:+
THCA	cis	rs4722585	0.533	rs2237335	ENSG00000273237.1	CTB-119C2.1	-3.68	0.00026	0.0177	-0.16	-0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26160593	chr7:26173533~26174945:-
THCA	cis	rs16957091	0.528	rs35900502	ENSG00000249839.1	AC011330.5	3.68	0.00026	0.0177	0.26	0.17	MGMT methylation in smokers;	chr15:43081731	chr15:43663654~43684339:-
THCA	cis	rs4805834	0.92	rs8104077	ENSG00000267567.1	CTD-2538C1.3	3.68	0.00026	0.0177	0.32	0.17	Creatinine levels;	chr19:32916205	chr19:32718298~32719595:-
THCA	cis	rs12701220	0.655	rs7799656	ENSG00000225146.1	AC073957.15	3.68	0.00026	0.0177	0.22	0.17	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1029025~1043891:+
THCA	cis	rs11633886	0.565	rs1356881	ENSG00000259200.1	RP11-718O11.1	3.68	0.00026	0.0177	0.2	0.17	Diisocyanate-induced asthma;	chr15:45781261	chr15:45705078~45931069:+
THCA	cis	rs1125355	0.656	rs72937298	ENSG00000243792.1	OR7E89P	-3.68	0.00026	0.0177	-0.25	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158779536	chr2:158853755~158854576:+
THCA	cis	rs10089	0.953	rs10463839	ENSG00000245937.6	LINC01184	3.68	0.00026	0.0177	0.19	0.17	Ileal carcinoids;	chr5:128183983	chr5:127940426~128083172:-
THCA	cis	rs970548	0.505	rs2305299	ENSG00000230869.1	CTGLF10P	3.68	0.00026	0.0177	0.27	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45641545	chr10:45678692~45700532:+
THCA	cis	rs970548	0.505	rs17854567	ENSG00000230869.1	CTGLF10P	3.68	0.00026	0.0177	0.27	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45648510	chr10:45678692~45700532:+
THCA	cis	rs4460629	0.742	rs6693477	ENSG00000236675.1	MTX1P1	-3.68	0.00026	0.0177	-0.16	-0.17	Serum magnesium levels;	chr1:155109464	chr1:155230975~155234325:+
THCA	cis	rs9435732	0.832	rs2076602	ENSG00000186301.8	MST1P2	-3.68	0.00026	0.0177	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16996703	chr1:16645622~16650289:+
THCA	cis	rs9596863	0.898	rs9568906	ENSG00000136149.6	RPL13AP25	-3.68	0.00026	0.0177	-0.19	-0.17	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53761062	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs9563174	ENSG00000136149.6	RPL13AP25	-3.68	0.00026	0.0177	-0.19	-0.17	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53761163	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.948	rs9568907	ENSG00000136149.6	RPL13AP25	-3.68	0.00026	0.0177	-0.19	-0.17	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53761430	chr13:54440704~54441315:-
THCA	cis	rs10266483	0.739	rs11765764	ENSG00000271550.1	BNIP3P11	-3.68	0.00026	0.0177	-0.23	-0.17	Response to statin therapy;	chr7:64368163	chr7:64678954~64687393:-
THCA	cis	rs6920965	0.507	rs7754833	ENSG00000226409.1	RP11-735G4.1	-3.68	0.00026	0.0177	-0.21	-0.17	High light scatter reticulocyte count;	chr6:125869748	chr6:125370211~125374324:-
THCA	cis	rs4073416	0.518	rs2898820	ENSG00000276116.2	FUT8-AS1	3.68	0.00026	0.0177	0.19	0.17	N-glycan levels;	chr14:65412636	chr14:65411170~65412690:-
THCA	cis	rs7829975	0.501	rs2980769	ENSG00000253130.1	CTD-3023L14.2	-3.68	0.00026	0.0177	-0.18	-0.17	Mood instability;	chr8:8462781	chr8:8561391~8569688:+
THCA	cis	rs17772222	0.511	rs1013794	ENSG00000258983.2	RP11-507K2.2	3.68	0.00026	0.0177	0.19	0.17	Coronary artery calcification;	chr14:88847401	chr14:88499334~88515502:+
THCA	cis	rs7819412	0.549	rs28887839	ENSG00000255046.1	RP11-297N6.4	3.68	0.00026	0.0177	0.18	0.17	Triglycerides;	chr8:11142903	chr8:11797928~11802568:-
THCA	cis	rs2434529	1	rs693446	ENSG00000245275.6	SAP30L-AS1	3.68	0.00026	0.0177	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154263006	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs640288	ENSG00000245275.6	SAP30L-AS1	3.68	0.00026	0.0177	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154263561	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs580013	ENSG00000245275.6	SAP30L-AS1	3.68	0.00026	0.0177	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154263581	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs637505	ENSG00000245275.6	SAP30L-AS1	3.68	0.00026	0.0177	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154264169	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs625212	ENSG00000245275.6	SAP30L-AS1	3.68	0.00026	0.0177	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154264652	chr5:154329437~154445850:-
THCA	cis	rs7826238	0.653	rs2979202	ENSG00000254340.1	RP11-10A14.3	3.68	0.00026	0.0177	0.19	0.17	Systolic blood pressure;	chr8:8486617	chr8:9141424~9145435:+
THCA	cis	rs2191566	0.576	rs396786	ENSG00000277806.1	RP11-15A1.8	3.68	0.00026	0.0177	0.17	0.17	Acute lymphoblastic leukemia (childhood);	chr19:43990199	chr19:43976815~43977448:+
THCA	cis	rs1923243	0.649	rs4614208	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73071771	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12134194	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73072668	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12759558	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73077014	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs4650177	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73077217	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4650178	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73077345	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4650180	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73078387	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4650181	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73078873	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs61773609	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73080230	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs11589392	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73080679	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.649	rs12409265	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73084090	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.649	rs12402991	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73084096	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4623647	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73084681	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.686	rs12142184	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73085511	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12142377	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73086080	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12142414	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73086162	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12139217	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73086322	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4650182	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73086417	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs7512691	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73087244	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs7543826	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73087307	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12752404	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73088172	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12141451	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73088496	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12126658	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73088837	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs6424511	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73089039	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs6424513	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73089248	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs7550849	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73089340	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs6424514	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73089357	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs4649977	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73089750	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.686	rs4649978	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73089812	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12120198	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73089873	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.648	rs12127823	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73090183	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12120282	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73090191	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4649979	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73090610	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.649	rs4233097	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73091015	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.649	rs4233098	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73091020	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4498756	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73091573	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs79042555	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73091973	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs11210122	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73092293	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs10890005	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73092307	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs10890006	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73092417	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4358996	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73092829	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4310400	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73093410	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs11210123	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73094104	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.681	rs11210124	ENSG00000223479.3	RP4-788P17.1	3.68	0.00026	0.0177	0.18	0.17	Migraine;	chr1:73094173	chr1:73635216~73715214:+
THCA	cis	rs62158800	0.598	rs13416107	ENSG00000225588.2	AC096669.1	3.68	0.00026	0.0177	0.17	0.17	Facial morphology (factor 22);	chr2:107670987	chr2:107362282~107407329:+
THCA	cis	rs10129255	0.957	rs10132367	ENSG00000280411.1	IGHV1-69-2	-3.68	0.00026	0.0177	-0.11	-0.17	Kawasaki disease;	chr14:106690981	chr14:106762092~106762588:-
THCA	cis	rs267567	0.626	rs267564	ENSG00000235257.7	ITGA9-AS1	-3.68	0.000261	0.0177	-0.14	-0.17	PR interval;	chr3:37532946	chr3:37745432~37861780:-
THCA	cis	rs9843304	1	rs9843304	ENSG00000240541.2	TM4SF1-AS1	-3.68	0.000261	0.0177	-0.15	-0.17	Gallstone disease;	chr3:149493600	chr3:149377778~149386583:+
THCA	cis	rs10975370	0.527	rs7028961	ENSG00000206147.5	RP11-106A1.2	3.68	0.000261	0.0177	0.2	0.17	Breast cancer;	chr9:6027474	chr9:6639139~6639604:+
THCA	cis	rs7246657	0.678	rs2927740	ENSG00000226686.6	LINC01535	3.68	0.000261	0.0177	0.24	0.17	Coronary artery calcification;	chr19:37650065	chr19:37251912~37265535:+
THCA	cis	rs2251301	0.76	rs1865519	ENSG00000154316.13	TDH	3.68	0.000261	0.0177	0.14	0.17	Response to antipsychotic therapy (extrapyramidal side effects);	chr8:11254537	chr8:11339637~11368452:+
THCA	cis	rs9487094	0.689	rs1476387	ENSG00000223537.2	RP5-919F19.5	-3.68	0.000261	0.0177	-0.17	-0.17	Height;	chr6:109443332	chr6:109487906~109506800:+
THCA	cis	rs754466	0.58	rs2289311	ENSG00000213514.2	RP11-428P16.2	3.68	0.000261	0.0177	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77805897	chr10:77730766~77734769:+
THCA	cis	rs875971	0.545	rs316306	ENSG00000232559.3	GS1-124K5.12	-3.68	0.000261	0.0177	-0.18	-0.17	Aortic root size;	chr7:66153687	chr7:66554588~66576923:-
THCA	cis	rs875971	0.545	rs6969224	ENSG00000232559.3	GS1-124K5.12	3.68	0.000261	0.0177	0.19	0.17	Aortic root size;	chr7:66370011	chr7:66554588~66576923:-
THCA	cis	rs944990	0.538	rs10821166	ENSG00000227603.1	RP11-165J3.6	3.68	0.000261	0.0177	0.18	0.17	Body mass index;	chr9:93589641	chr9:93435332~93437121:-
THCA	cis	rs7212590	0.748	rs8074843	ENSG00000267302.4	RP11-178C3.2	3.68	0.000261	0.0177	0.31	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59858574	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.748	rs7223057	ENSG00000267302.4	RP11-178C3.2	3.68	0.000261	0.0177	0.31	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59859077	chr17:59964832~59996972:+
THCA	cis	rs1577917	0.958	rs6921315	ENSG00000220563.1	PKMP3	-3.68	0.000261	0.0177	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85761950	chr6:85659892~85660606:-
THCA	cis	rs10802047	0.566	rs12129194	ENSG00000231365.4	RP11-418J17.1	-3.68	0.000261	0.0177	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118786688	chr1:119140396~119275973:+
THCA	cis	rs6496667	1	rs4261510	ENSG00000259262.1	NDUFA3P4	3.68	0.000261	0.0177	0.22	0.17	Rheumatoid arthritis;	chr15:90347374	chr15:90385814~90386063:+
THCA	cis	rs2032366	0.606	rs713485	ENSG00000267316.4	RP11-879F14.3	-3.68	0.000261	0.0177	-0.19	-0.17	Obesity-related traits;	chr18:61603692	chr18:61571342~61579456:-
THCA	cis	rs790006	0.697	rs10878122	ENSG00000243024.5	RPS11P6	3.68	0.000261	0.0177	0.19	0.17	Response to cytidine analogues (gemcitabine);	chr12:64220394	chr12:64222337~64397065:+
THCA	cis	rs7914558	0.901	rs1926034	ENSG00000272912.1	RP11-724N1.1	-3.68	0.000261	0.0177	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103069345	chr10:102914585~102915404:+
THCA	cis	rs9368222	1	rs7451008	ENSG00000280989.1	LINC00581	3.68	0.000261	0.0177	0.21	0.17	Body mass index;Peak insulin response;Acute insulin response;	chr6:20673649	chr6:21486061~21511895:-
THCA	cis	rs2640806	0.524	rs34690929	ENSG00000253105.4	KB-1448A5.1	3.68	0.000261	0.0177	0.2	0.17	Obesity-related traits;	chr8:96351200	chr8:96371865~96387438:-
THCA	cis	rs1153858	0.621	rs2413769	ENSG00000275672.1	GATM-AS1	-3.68	0.000261	0.0177	-0.18	-0.17	Homoarginine levels;	chr15:45269670	chr15:45378700~45380123:+
THCA	cis	rs10090774	0.93	rs4246127	ENSG00000280303.2	ERICD	3.68	0.000261	0.0177	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830546	chr8:140636281~140638283:+
THCA	cis	rs9652601	0.691	rs9926078	ENSG00000263033.2	RP11-396B14.2	-3.68	0.000261	0.0178	-0.13	-0.17	Systemic lupus erythematosus;	chr16:11109708	chr16:11196177~11224969:+
THCA	cis	rs427394	0.582	rs274667	ENSG00000248677.1	CTD-2044J15.1	-3.68	0.000261	0.0178	-0.16	-0.17	Menopause (age at onset);	chr5:6710658	chr5:6686325~6707711:-
THCA	cis	rs1267303	1	rs1267303	ENSG00000232022.5	FAAHP1	3.68	0.000261	0.0178	0.18	0.17	Monobrow;	chr1:46524785	chr1:46432129~46445521:+
THCA	cis	rs4081724	0.638	rs73026246	ENSG00000267296.2	CEBPA-AS1	3.68	0.000261	0.0178	0.21	0.17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33345520	chr19:33302857~33305054:+
THCA	cis	rs3924048	0.574	rs11121925	ENSG00000276830.1	MIR6730	-3.68	0.000261	0.0178	-0.17	-0.17	Optic cup area;	chr1:12553100	chr1:12578957~12579023:-
THCA	cis	rs7142002	0.568	rs56701068	ENSG00000272444.1	RP11-1017G21.6	-3.68	0.000261	0.0178	-0.19	-0.17	Autism;	chr14:101922903	chr14:101952416~101953063:+
THCA	cis	rs10844706	0.699	rs2401390	ENSG00000257027.1	RP11-705C15.3	3.68	0.000261	0.0178	0.14	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9719218	chr12:9658567~9662085:+
THCA	cis	rs6894216	0.592	rs2108427	ENSG00000248610.1	HSPA8P4	-3.68	0.000261	0.0178	-0.21	-0.17	Response to amphetamines;	chr5:130343431	chr5:130140031~130141950:+
THCA	cis	rs1865760	0.663	rs9467656	ENSG00000272810.1	U91328.22	-3.68	0.000261	0.0178	-0.13	-0.17	Height;	chr6:25993331	chr6:26013241~26013757:+
THCA	cis	rs10802047	0.566	rs2361025	ENSG00000231365.4	RP11-418J17.1	-3.68	0.000261	0.0178	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118799729	chr1:119140396~119275973:+
THCA	cis	rs141413113	1	rs141413113	ENSG00000173811.9	CCDC13-AS1	3.68	0.000261	0.0178	0.17	0.17	Lymphocyte percentage of white cells;	chr3:42865919	chr3:42732575~42746768:+
THCA	cis	rs7267979	0.565	rs6107059	ENSG00000276952.1	RP5-965G21.6	-3.68	0.000261	0.0178	-0.19	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:25284915~25285588:-
THCA	cis	rs6546886	0.912	rs10164943	ENSG00000235499.1	AC073046.25	3.68	0.000261	0.0178	0.15	0.17	Dialysis-related mortality;	chr2:74078929	chr2:73985132~73986343:+
THCA	cis	rs5758511	0.637	rs5751244	ENSG00000230107.1	CTA-126B4.7	-3.68	0.000261	0.0178	-0.2	-0.17	Birth weight;	chr22:42221405	chr22:42438023~42446195:+
THCA	cis	rs77147124	0.959	rs1807800	ENSG00000225292.2	RP11-57H14.3	-3.68	0.000261	0.0178	-0.23	-0.17	HDL cholesterol;	chr10:112153794	chr10:112888735~112906111:+
THCA	cis	rs972578	0.773	rs2013730	ENSG00000230319.1	AL022476.2	3.68	0.000261	0.0178	0.18	0.17	Mean platelet volume;	chr22:42794811	chr22:43038585~43052366:+
THCA	cis	rs801193	1	rs2707836	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000261	0.0178	-0.14	-0.17	Aortic root size;	chr7:66695448	chr7:66848496~66858136:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000261	0.0178	-0.14	-0.17	Aortic root size;	chr7:66696803	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs2659906	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000261	0.0178	-0.14	-0.17	Aortic root size;	chr7:66700323	chr7:66848496~66858136:+
THCA	cis	rs6012953	0.654	rs6020566	ENSG00000237595.3	RP11-112L6.3	3.68	0.000261	0.0178	0.15	0.17	Vitiligo;	chr20:50506495	chr20:50162765~50166102:-
THCA	cis	rs7616559	0.849	rs922865	ENSG00000244515.1	KRT18P34	-3.68	0.000261	0.0178	-0.22	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157060165	chr3:157162663~157163932:-
THCA	cis	rs1005277	0.522	rs289650	ENSG00000120555.12	SEPT7P9	3.68	0.000261	0.0178	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38383069~38402916:-
THCA	cis	rs858239	0.669	rs1990365	ENSG00000230042.1	AK3P3	-3.68	0.000261	0.0178	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23129178~23129841:+
THCA	cis	rs7914558	0.966	rs10786745	ENSG00000272912.1	RP11-724N1.1	-3.68	0.000261	0.0178	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:102914585~102915404:+
THCA	cis	rs4699052	0.826	rs17033498	ENSG00000246560.2	RP11-10L12.4	3.68	0.000261	0.0178	0.21	0.17	Testicular germ cell tumor;	chr4:103258804	chr4:102828055~102844075:+
THCA	cis	rs7615952	0.673	rs9289270	ENSG00000272840.1	RP11-379B18.6	3.68	0.000261	0.0178	0.31	0.17	Blood pressure (smoking interaction);	chr3:125918136	chr3:125774714~125797953:+
THCA	cis	rs11771526	0.901	rs34376799	ENSG00000272905.1	RP11-265E18.1	3.68	0.000261	0.0178	0.22	0.17	Body mass index;	chr7:32277320	chr7:32845394~32846061:+
THCA	cis	rs8054556	0.787	rs3814877	ENSG00000183604.13	SMG1P5	-3.68	0.000261	0.0178	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30031356	chr16:30267553~30335374:-
THCA	cis	rs4879656	0.966	rs10971309	ENSG00000225693.1	LAGE3P1	-3.68	0.000261	0.0178	-0.19	-0.17	Menopause (age at onset);	chr9:33009857	chr9:33019682~33020165:-
THCA	cis	rs1056107	0.572	rs10981383	ENSG00000230185.4	C9orf147	3.68	0.000261	0.0178	0.15	0.17	Colorectal cancer;	chr9:112394505	chr9:112433816~112487204:-
THCA	cis	rs643506	0.845	rs762550	ENSG00000230911.1	PPIHP1	-3.68	0.000261	0.0178	-0.23	-0.17	Breast cancer;	chr11:111912376	chr11:112029858~112030367:-
THCA	cis	rs11723261	0.582	rs11248005	ENSG00000250892.1	RP11-1365D11.1	3.68	0.000261	0.0178	0.24	0.17	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:201409~205009:-
THCA	cis	rs11723261	0.582	rs11733927	ENSG00000250892.1	RP11-1365D11.1	3.68	0.000261	0.0178	0.24	0.17	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:201409~205009:-
THCA	cis	rs4073416	0.51	rs10873190	ENSG00000276116.2	FUT8-AS1	3.68	0.000261	0.0178	0.19	0.17	N-glycan levels;	chr14:65514721	chr14:65411170~65412690:-
THCA	cis	rs1923243	0.714	rs4512593	ENSG00000223479.3	RP4-788P17.1	3.68	0.000261	0.0178	0.18	0.17	Migraine;	chr1:73094614	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4128551	ENSG00000223479.3	RP4-788P17.1	3.68	0.000261	0.0178	0.18	0.17	Migraine;	chr1:73095212	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4307522	ENSG00000223479.3	RP4-788P17.1	3.68	0.000261	0.0178	0.18	0.17	Migraine;	chr1:73095357	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.659	rs11210126	ENSG00000223479.3	RP4-788P17.1	3.68	0.000261	0.0178	0.18	0.17	Migraine;	chr1:73096007	chr1:73635216~73715214:+
THCA	cis	rs860295	0.812	rs12081192	ENSG00000203761.5	MSTO2P	-3.68	0.000261	0.0178	-0.13	-0.17	Body mass index;	chr1:155768253	chr1:155745829~155750137:+
THCA	cis	rs13113518	0.812	rs4864996	ENSG00000272969.1	RP11-528I4.2	3.68	0.000261	0.0178	0.2	0.17	Height;	chr4:55452921	chr4:55547112~55547889:+
THCA	cis	rs17689437	0.914	rs55652840	ENSG00000275383.1	RP11-615I2.6	3.68	0.000261	0.0178	0.26	0.17	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68528195	chr16:68591382~68594424:+
THCA	cis	rs4907240	0.961	rs11682934	ENSG00000230606.9	AC159540.1	3.68	0.000261	0.0178	0.19	0.17	Event-related brain oscillations;	chr2:96571416	chr2:97416165~97433527:-
THCA	cis	rs4761702	0.551	rs11106987	ENSG00000257322.4	RP11-511B23.2	-3.68	0.000262	0.0178	-0.22	-0.17	Immature fraction of reticulocytes;	chr12:93339760	chr12:93003415~93215679:-
THCA	cis	rs4578769	0.55	rs11082225	ENSG00000273232.1	RP11-370A5.2	3.68	0.000262	0.0178	0.23	0.17	Eosinophil percentage of white cells;	chr18:22963794	chr18:22882825~22883357:-
THCA	cis	rs7916852	0.717	rs56349465	ENSG00000230500.1	MKX-AS1	3.68	0.000262	0.0178	0.28	0.17	Glaucoma (primary open-angle);	chr10:28107507	chr10:27744786~27767794:+
THCA	cis	rs4742903	0.904	rs10820628	ENSG00000270332.1	SMC2-AS1	3.68	0.000262	0.0178	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104244907	chr9:104080024~104093073:-
THCA	cis	rs7919656	0.626	rs2663041	ENSG00000228403.1	RP11-563N6.6	3.68	0.000262	0.0178	0.18	0.17	Clinically amyopathic dermatomyositis;	chr10:48899492	chr10:48878022~48878649:+
THCA	cis	rs9611565	0.512	rs4512	ENSG00000237037.8	NDUFA6-AS1	3.68	0.000262	0.0178	0.16	0.17	Vitiligo;	chr22:41810080	chr22:42090931~42137742:+
THCA	cis	rs7259376	0.936	rs7255829	ENSG00000269138.1	ZNF209P	3.68	0.000262	0.0178	0.17	0.17	Menopause (age at onset);	chr19:22354509	chr19:22463922~22473036:+
THCA	cis	rs9467773	0.869	rs9295689	ENSG00000228223.2	HCG11	-3.68	0.000262	0.0178	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26455583	chr6:26523450~26526579:+
THCA	cis	rs944990	0.538	rs10821165	ENSG00000227603.1	RP11-165J3.6	3.68	0.000262	0.0178	0.18	0.17	Body mass index;	chr9:93589352	chr9:93435332~93437121:-
THCA	cis	rs7267979	0.932	rs6132848	ENSG00000276952.1	RP5-965G21.6	3.68	0.000262	0.0178	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25284915~25285588:-
THCA	cis	rs6921919	0.697	rs6942030	ENSG00000176933.5	TOB2P1	-3.68	0.000262	0.0178	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28217643~28218634:-
THCA	cis	rs875971	0.861	rs801215	ENSG00000223473.2	GS1-124K5.3	-3.68	0.000262	0.0178	-0.11	-0.17	Aortic root size;	chr7:66546951	chr7:66491049~66493566:-
THCA	cis	rs3924048	0.574	rs61776783	ENSG00000276830.1	MIR6730	-3.68	0.000262	0.0178	-0.17	-0.17	Optic cup area;	chr1:12552627	chr1:12578957~12579023:-
THCA	cis	rs11105298	0.891	rs1054807	ENSG00000266347.2	AC068641.1	3.68	0.000262	0.0178	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89592833~89592927:+
THCA	cis	rs5758511	0.508	rs2854827	ENSG00000230107.1	CTA-126B4.7	-3.68	0.000262	0.0178	-0.22	-0.17	Birth weight;	chr22:42065914	chr22:42438023~42446195:+
THCA	cis	rs987724	0.515	rs6441101	ENSG00000243926.1	TIPARP-AS1	3.68	0.000262	0.0178	0.21	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156875409	chr3:156671862~156674378:-
THCA	cis	rs17407555	0.683	rs6852641	ENSG00000250413.1	RP11-448G15.1	-3.68	0.000262	0.0178	-0.19	-0.17	Schizophrenia (age at onset);	chr4:10274122	chr4:10006482~10009725:+
THCA	cis	rs11673344	0.615	rs2921561	ENSG00000268499.1	CTB-102L5.8	-3.68	0.000262	0.0178	-0.17	-0.17	Obesity-related traits;	chr19:37348969	chr19:38199836~38200934:+
THCA	cis	rs9303542	0.694	rs12948128	ENSG00000278765.1	RP5-890E16.5	-3.68	0.000262	0.0178	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48277311	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs17694895	ENSG00000278765.1	RP5-890E16.5	-3.68	0.000262	0.0178	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48284393	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs8076655	ENSG00000278765.1	RP5-890E16.5	-3.68	0.000262	0.0178	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48286425	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs8069900	ENSG00000278765.1	RP5-890E16.5	-3.68	0.000262	0.0178	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48289363	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs4128439	ENSG00000278765.1	RP5-890E16.5	-3.68	0.000262	0.0178	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48297849	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.659	rs7215143	ENSG00000278765.1	RP5-890E16.5	-3.68	0.000262	0.0178	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48302682	chr17:48066704~48067293:-
THCA	cis	rs2832191	0.632	rs2246777	ENSG00000176054.6	RPL23P2	-3.68	0.000262	0.0178	-0.15	-0.17	Dental caries;	chr21:28937264	chr21:28997613~28998033:-
THCA	cis	rs1993293	0.543	rs11636039	ENSG00000254744.3	CTD-3076O17.1	3.68	0.000262	0.0178	0.2	0.17	Coronary artery calcification;	chr15:99751886	chr15:99970215~99974010:+
THCA	cis	rs7824557	0.628	rs7820301	ENSG00000206014.6	OR7E161P	-3.68	0.000262	0.0178	-0.19	-0.17	Retinal vascular caliber;	chr8:11371163	chr8:11928597~11929563:-
THCA	cis	rs4295623	0.585	rs13259242	ENSG00000206014.6	OR7E161P	3.68	0.000262	0.0178	0.19	0.17	Morning vs. evening chronotype;	chr8:11735524	chr8:11928597~11929563:-
THCA	cis	rs14027	0.921	rs12542794	ENSG00000279347.1	RP11-85I17.2	-3.68	0.000262	0.0178	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119838736~119840385:-
THCA	cis	rs8054556	0.692	rs4424923	ENSG00000273724.1	RP11-347C12.12	-3.68	0.000262	0.0178	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29927972	chr16:30336400~30343336:+
THCA	cis	rs7737355	1	rs257390	ENSG00000237714.1	P4HA2-AS1	-3.68	0.000262	0.0178	-0.24	-0.17	Life satisfaction;	chr5:131404924	chr5:132184876~132192808:+
THCA	cis	rs394563	0.625	rs384306	ENSG00000268592.3	RAET1E-AS1	3.68	0.000262	0.0178	0.23	0.17	Dupuytren's disease;	chr6:149475004	chr6:149863494~149919507:+
THCA	cis	rs916888	0.773	rs199457	ENSG00000260075.1	NSFP1	-3.68	0.000262	0.0178	-0.27	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46372855~46487141:+
THCA	cis	rs1865760	0.566	rs9366634	ENSG00000272810.1	U91328.22	-3.68	0.000262	0.0178	-0.13	-0.17	Height;	chr6:26072168	chr6:26013241~26013757:+
THCA	cis	rs9308731	0.614	rs6755484	ENSG00000227992.1	AC108463.2	-3.68	0.000262	0.0178	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111191519	chr2:111203964~111206215:-
THCA	cis	rs7522061	0.546	rs10796981	ENSG00000236731.1	RP4-801G22.2	3.68	0.000262	0.0178	0.17	0.17	Blood protein levels;	chr1:157672292	chr1:157629939~157630728:-
THCA	cis	rs7522061	0.546	rs10908585	ENSG00000236731.1	RP4-801G22.2	3.68	0.000262	0.0178	0.17	0.17	Blood protein levels;	chr1:157672691	chr1:157629939~157630728:-
THCA	cis	rs7522061	0.546	rs10796982	ENSG00000236731.1	RP4-801G22.2	3.68	0.000262	0.0178	0.17	0.17	Blood protein levels;	chr1:157673406	chr1:157629939~157630728:-
THCA	cis	rs7522061	0.546	rs10908586	ENSG00000236731.1	RP4-801G22.2	3.68	0.000262	0.0178	0.17	0.17	Blood protein levels;	chr1:157673667	chr1:157629939~157630728:-
THCA	cis	rs7819412	0.669	rs2409743	ENSG00000254866.2	DEFB109P3	3.68	0.000262	0.0178	0.23	0.17	Triglycerides;	chr8:11212851	chr8:12150895~12151134:-
THCA	cis	rs5006884	0.627	rs17359438	ENSG00000167355.6	AC104389.28	3.68	0.000262	0.0178	0.28	0.17	Fetal hemoglobin levels;	chr11:5420996	chr11:5304976~5505652:-
THCA	cis	rs4869313	0.618	rs248215	ENSG00000247121.5	CTD-2260A17.2	3.68	0.000262	0.0178	0.12	0.17	Pediatric autoimmune diseases;	chr5:97035175	chr5:96814028~96935809:-
THCA	cis	rs478304	0.651	rs11532071	ENSG00000255320.1	RP11-755F10.1	3.68	0.000262	0.0178	0.22	0.17	Acne (severe);	chr11:65732727	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs12225620	ENSG00000255320.1	RP11-755F10.1	3.68	0.000262	0.0178	0.22	0.17	Acne (severe);	chr11:65737977	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs10896038	ENSG00000255320.1	RP11-755F10.1	3.68	0.000262	0.0178	0.22	0.17	Acne (severe);	chr11:65738057	chr11:66244840~66246239:-
THCA	cis	rs683250	0.629	rs680562	ENSG00000254551.1	RP11-727A23.7	3.68	0.000262	0.0178	0.21	0.17	Subcortical brain region volumes;	chr11:83237847	chr11:83209431~83213379:-
THCA	cis	rs683250	0.629	rs573053	ENSG00000254551.1	RP11-727A23.7	3.68	0.000262	0.0178	0.21	0.17	Subcortical brain region volumes;	chr11:83239931	chr11:83209431~83213379:-
THCA	cis	rs2051773	0.539	rs34902253	ENSG00000272034.1	SNORD14A	-3.68	0.000262	0.0178	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17027833	chr11:17074654~17074744:-
THCA	cis	rs2051773	0.567	rs6486346	ENSG00000272034.1	SNORD14A	-3.68	0.000262	0.0178	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17028343	chr11:17074654~17074744:-
THCA	cis	rs2051773	0.567	rs6486347	ENSG00000272034.1	SNORD14A	-3.68	0.000262	0.0178	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17028461	chr11:17074654~17074744:-
THCA	cis	rs35847492	1	rs17730481	ENSG00000233609.3	RP11-62H7.2	-3.68	0.000262	0.0178	-0.18	-0.17	Neuroticism;	chr8:9418653	chr8:8961200~8979025:+
THCA	cis	rs9611565	0.512	rs139571	ENSG00000237037.8	NDUFA6-AS1	3.68	0.000262	0.0178	0.17	0.17	Vitiligo;	chr22:41818234	chr22:42090931~42137742:+
THCA	cis	rs3790515	1	rs3790515	ENSG00000249602.1	RP11-98D18.3	3.68	0.000262	0.0178	0.26	0.17	Depressive symptoms (SSRI exposure interaction);	chr1:151813896	chr1:151763384~151769501:-
THCA	cis	rs3796352	1	rs71301808	ENSG00000280417.1	RP11-5O17.1	-3.68	0.000262	0.0178	-0.25	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:53051561	chr3:53046166~53048122:+
THCA	cis	rs2013441	0.83	rs2526469	ENSG00000261033.1	RP11-209D14.2	3.68	0.000262	0.0178	0.24	0.17	Obesity-related traits;	chr17:20259435	chr17:20008051~20009234:-
THCA	cis	rs3758911	0.861	rs11212175	ENSG00000255353.1	RP11-382M14.1	-3.68	0.000262	0.0178	-0.21	-0.17	Coronary artery disease;	chr11:107348581	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.894	rs72990443	ENSG00000255353.1	RP11-382M14.1	-3.68	0.000262	0.0178	-0.21	-0.17	Coronary artery disease;	chr11:107352050	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.894	rs4343000	ENSG00000255353.1	RP11-382M14.1	-3.68	0.000262	0.0178	-0.21	-0.17	Coronary artery disease;	chr11:107353992	chr11:107176286~107177530:+
THCA	cis	rs9450351	0.744	rs6937582	ENSG00000203875.9	SNHG5	-3.68	0.000262	0.0178	-0.33	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85855880	chr6:85660950~85678736:-
THCA	cis	rs9878978	0.722	rs17014540	ENSG00000227588.2	CNTN4-AS2	3.68	0.000262	0.0178	0.2	0.17	Blood pressure (smoking interaction);	chr3:2452358	chr3:2110409~2144241:-
THCA	cis	rs2290416	0.892	rs62523607	ENSG00000254973.1	RP11-429J17.7	3.68	0.000262	0.0178	0.33	0.17	Attention deficit hyperactivity disorder;	chr8:143585262	chr8:143758153~143771822:-
THCA	cis	rs7873102	0.967	rs7044992	ENSG00000213839.4	TMX2P1	3.68	0.000262	0.0178	0.13	0.17	Brain structure;	chr9:38039928	chr9:37885683~37886390:+
THCA	cis	rs9905704	0.918	rs11656666	ENSG00000224738.1	AC099850.1	3.68	0.000262	0.0178	0.23	0.17	Testicular germ cell tumor;	chr17:58852479	chr17:59106598~59118267:+
THCA	cis	rs972578	0.837	rs1811846	ENSG00000230319.1	AL022476.2	3.68	0.000262	0.0178	0.18	0.17	Mean platelet volume;	chr22:42797909	chr22:43038585~43052366:+
THCA	cis	rs7772697	0.539	rs2153251	ENSG00000223701.3	RAET1E-AS1	-3.68	0.000262	0.0178	-0.24	-0.17	Diabetic retinopathy;	chr6:149084082	chr6:149884431~149919508:+
THCA	cis	rs9813712	0.585	rs9855392	ENSG00000253540.4	FAM86HP	-3.68	0.000262	0.0178	-0.22	-0.17	Response to amphetamines;	chr3:130214403	chr3:130099092~130111472:-
THCA	cis	rs2749592	0.55	rs10764135	ENSG00000120555.12	SEPT7P9	-3.68	0.000262	0.0178	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38383069~38402916:-
THCA	cis	rs10838634	1	rs10838634	ENSG00000252874.2	Y_RNA	-3.68	0.000262	0.0178	-0.32	-0.17	Schizophrenia;	chr11:46908403	chr11:47820200~47820289:-
THCA	cis	rs10483853	0.54	rs2108552	ENSG00000259065.1	RP5-1021I20.1	-3.68	0.000262	0.0178	-0.22	-0.17	Coronary artery calcification;	chr14:73410218	chr14:73787360~73803270:+
THCA	cis	rs1713985	0.508	rs2687239	ENSG00000269949.1	RP11-738E22.3	-3.68	0.000262	0.0178	-0.35	-0.17	Age-related macular degeneration;	chr4:57012468	chr4:56960927~56961373:-
THCA	cis	rs1713985	0.508	rs1718866	ENSG00000269949.1	RP11-738E22.3	-3.68	0.000262	0.0178	-0.35	-0.17	Age-related macular degeneration;	chr4:57017009	chr4:56960927~56961373:-
THCA	cis	rs722414	0.813	rs10777178	ENSG00000258302.2	RP11-981P6.1	3.68	0.000262	0.0178	0.15	0.17	Blood protein levels;	chr12:89512452	chr12:89561129~89594878:+
THCA	cis	rs72765298	0.733	rs17253010	ENSG00000235332.2	RP11-366O20.5	3.68	0.000262	0.0178	0.31	0.17	Pulse pressure;	chr9:125218644	chr9:125194649~125195821:-
THCA	cis	rs4764124	0.615	rs1012683	ENSG00000261324.2	RP11-174G6.5	-3.68	0.000262	0.0178	-0.12	-0.17	Pubertal anthropometrics;	chr12:14798116	chr12:14762504~14767931:-
THCA	cis	rs494526	0.674	rs10886380	ENSG00000229272.1	RP11-498J9.2	3.68	0.000262	0.0178	0.2	0.17	Alcoholic chronic pancreatitis;	chr10:119091119	chr10:119003536~119003884:-
THCA	cis	rs4460629	0.742	rs11264314	ENSG00000225855.5	RUSC1-AS1	3.68	0.000262	0.0178	0.11	0.17	Serum magnesium levels;	chr1:155105947	chr1:155316863~155324176:-
THCA	cis	rs6472235	0.837	rs6989850	ENSG00000272192.1	CTD-2532N20.1	3.68	0.000262	0.0178	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65989541	chr8:65842752~65843331:+
THCA	cis	rs2640806	0.505	rs35834070	ENSG00000253105.4	KB-1448A5.1	3.68	0.000263	0.0178	0.2	0.17	Obesity-related traits;	chr8:96349873	chr8:96371865~96387438:-
THCA	cis	rs6088619	1	rs6088619	ENSG00000276073.1	RP5-1125A11.7	-3.68	0.000263	0.0178	-0.27	-0.17	Hip circumference adjusted for BMI;	chr20:34824068	chr20:33985617~33988989:-
THCA	cis	rs62158211	0.955	rs1823125	ENSG00000231292.6	IGKV1OR2-108	3.68	0.000263	0.0178	0.13	0.17	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113406396~113406872:+
THCA	cis	rs6049003	0.517	rs2897202	ENSG00000270001.1	RP11-218C14.8	-3.68	0.000263	0.0178	-0.19	-0.17	Cerebrospinal fluid biomarker levels;	chr20:23705014	chr20:23631826~23632316:-
THCA	cis	rs6049003	0.579	rs6114230	ENSG00000270001.1	RP11-218C14.8	-3.68	0.000263	0.0178	-0.19	-0.17	Cerebrospinal fluid biomarker levels;	chr20:23705167	chr20:23631826~23632316:-
THCA	cis	rs7178909	0.732	rs57163265	ENSG00000259677.1	RP11-493E3.1	3.68	0.000263	0.0178	0.2	0.17	Common traits (Other);	chr15:89857418	chr15:89876540~89877285:+
THCA	cis	rs9329221	0.682	rs6982308	ENSG00000269918.1	AF131215.9	-3.68	0.000263	0.0178	-0.18	-0.17	Neuroticism;	chr8:10336262	chr8:11104691~11106704:-
THCA	cis	rs9296092	0.538	rs62407567	ENSG00000272217.1	XXbac-BPG157A10.21	3.68	0.000263	0.0178	0.19	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33569436	chr6:33246075~33246856:-
THCA	cis	rs7819412	0.654	rs4840550	ENSG00000254948.1	OR7E158P	3.68	0.000263	0.0178	0.21	0.17	Triglycerides;	chr8:11171520	chr8:11919900~11920809:-
THCA	cis	rs4787491	0.729	rs11150584	ENSG00000275371.1	RP11-455F5.6	-3.68	0.000263	0.0179	-0.15	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028357	chr16:30110895~30111955:+
THCA	cis	rs2013441	0.866	rs2703811	ENSG00000261033.1	RP11-209D14.2	3.68	0.000263	0.0179	0.24	0.17	Obesity-related traits;	chr17:20210662	chr17:20008051~20009234:-
THCA	cis	rs11633886	0.585	rs2460630	ENSG00000259200.1	RP11-718O11.1	3.68	0.000263	0.0179	0.2	0.17	Diisocyanate-induced asthma;	chr15:45799596	chr15:45705078~45931069:+
THCA	cis	rs7824557	0.872	rs2572431	ENSG00000255495.1	AC145124.2	-3.68	0.000263	0.0179	-0.18	-0.17	Retinal vascular caliber;	chr8:11247568	chr8:12194467~12196280:+
THCA	cis	rs12681366	0.959	rs58826082	ENSG00000261437.1	RP11-22C11.2	3.68	0.000263	0.0179	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94351487	chr8:94637285~94639467:-
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000184274.3	LINC00315	-3.68	0.000263	0.0179	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000184274.3	LINC00315	3.68	0.000263	0.0179	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45300245~45305257:-
THCA	cis	rs11678584	0.697	rs114194282	ENSG00000276517.1	AL133243.2	-3.68	0.000263	0.0179	-0.23	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32417139	chr2:32526504~32529507:+
THCA	cis	rs11678584	0.697	rs72798777	ENSG00000276517.1	AL133243.2	-3.68	0.000263	0.0179	-0.23	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32417140	chr2:32526504~32529507:+
THCA	cis	rs1862618	0.671	rs832531	ENSG00000271828.1	CTD-2310F14.1	3.68	0.000263	0.0179	0.23	0.17	Initial pursuit acceleration;	chr5:56932574	chr5:56927874~56929573:+
THCA	cis	rs4262150	0.726	rs11956651	ENSG00000253921.1	CTB-113P19.3	3.68	0.000263	0.0179	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152632254	chr5:151753992~151767247:+
THCA	cis	rs7829975	0.659	rs4382480	ENSG00000248538.5	RP11-10A14.5	-3.68	0.000263	0.0179	-0.21	-0.17	Mood instability;	chr8:8863963	chr8:9189011~9202854:+
THCA	cis	rs10932886	0.76	rs10932885	ENSG00000224819.1	AC093843.1	3.68	0.000263	0.0179	0.16	0.17	Brain imaging;	chr2:220848053	chr2:220791078~220797893:+
THCA	cis	rs9475677	0.906	rs17225519	ENSG00000231441.1	RP11-472M19.2	3.68	0.000263	0.0179	0.21	0.17	Gut microbiota (functional units);	chr6:56352331	chr6:56844002~56864078:+
THCA	cis	rs9890032	0.57	rs8068504	ENSG00000276250.1	CTD-2349P21.12	-3.68	0.000263	0.0179	-0.14	-0.17	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30803654~30804077:+
THCA	cis	rs8058578	0.775	rs8046391	ENSG00000260911.2	RP11-196G11.2	3.68	0.000263	0.0179	0.15	0.17	Multiple myeloma;	chr16:30825327	chr16:31043150~31049868:+
THCA	cis	rs9650657	0.801	rs7018334	ENSG00000269918.1	AF131215.9	-3.68	0.000263	0.0179	-0.18	-0.17	Neuroticism;	chr8:10754565	chr8:11104691~11106704:-
THCA	cis	rs13217239	0.646	rs4403259	ENSG00000124549.13	BTN2A3P	3.68	0.000263	0.0179	0.16	0.17	Schizophrenia;	chr6:27029838	chr6:26421391~26432383:+
THCA	cis	rs2919009	0.62	rs17501806	ENSG00000271670.1	RP11-95I16.4	3.68	0.000263	0.0179	0.18	0.17	Obesity-related traits;	chr10:120868905	chr10:120879256~120880667:-
THCA	cis	rs10943724	0.959	rs11964999	ENSG00000272129.1	RP11-250B2.6	3.68	0.000263	0.0179	0.22	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80548700	chr6:80355424~80356859:+
THCA	cis	rs11583043	0.667	rs873760	ENSG00000233184.5	RP11-421L21.3	3.68	0.000263	0.0179	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101075005	chr1:101025878~101087268:+
THCA	cis	rs9928842	1	rs9928842	ENSG00000261783.1	RP11-252K23.2	3.68	0.000263	0.0179	0.32	0.17	Alcoholic chronic pancreatitis;	chr16:75208969	chr16:75379818~75381260:-
THCA	cis	rs5758659	0.652	rs133340	ENSG00000205702.9	CYP2D7	-3.68	0.000263	0.0179	-0.13	-0.17	Cognitive function;	chr22:42021683	chr22:42140203~42144577:-
THCA	cis	rs875971	0.522	rs4718286	ENSG00000182722.5	SEPHS1P1	-3.68	0.000263	0.0179	-0.2	-0.17	Aortic root size;	chr7:65827777	chr7:64852397~64853354:-
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000182722.5	SEPHS1P1	-3.68	0.000263	0.0179	-0.2	-0.17	Calcium levels;	chr7:65837419	chr7:64852397~64853354:-
THCA	cis	rs972578	0.806	rs4822212	ENSG00000230319.1	AL022476.2	3.68	0.000263	0.0179	0.18	0.17	Mean platelet volume;	chr22:42871867	chr22:43038585~43052366:+
THCA	cis	rs6738627	0.766	rs1128249	ENSG00000223318.1	RNA5SP111	3.68	0.000263	0.0179	0.2	0.17	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164672114	chr2:164895677~164895777:-
THCA	cis	rs62158800	0.598	rs10175087	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107671547	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs6746783	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107672162	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs6747019	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107672377	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs1606987	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107673961	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs10177715	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107675826	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs6542728	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107676853	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs6542729	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107676878	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs1400118	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107677403	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs1568055	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107678382	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.638	rs1157314	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107679182	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs1543138	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107679537	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs1516204	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107680431	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs4676149	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107682249	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.598	rs10171365	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107683345	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.714	rs1533430	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107684470	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.673	rs1533429	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107684561	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.638	rs1155113	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107684805	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.638	rs1155111	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107685150	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.638	rs1155110	ENSG00000225588.2	AC096669.1	3.68	0.000263	0.0179	0.17	0.17	Facial morphology (factor 22);	chr2:107685214	chr2:107362282~107407329:+
THCA	cis	rs4664293	0.967	rs13000070	ENSG00000230783.1	AC009961.2	-3.68	0.000263	0.0179	-0.21	-0.17	Monocyte percentage of white cells;	chr2:159669263	chr2:159689217~159690291:-
THCA	cis	rs4073582	1	rs524859	ENSG00000255320.1	RP11-755F10.1	-3.68	0.000263	0.0179	-0.23	-0.17	Gout;	chr11:66273608	chr11:66244840~66246239:-
THCA	cis	rs614226	1	rs541126	ENSG00000278344.1	RP11-18C24.8	-3.68	0.000263	0.0179	-0.22	-0.17	Type 1 diabetes nephropathy;	chr12:120534593	chr12:120500735~120501090:-
THCA	cis	rs62045849	0.557	rs9938463	ENSG00000259877.2	RP11-46C24.7	3.68	0.000263	0.0179	0.19	0.17	Red blood cell count;	chr16:89117364	chr16:89215211~89217653:-
THCA	cis	rs875971	0.545	rs12671152	ENSG00000273142.1	RP11-458F8.4	3.68	0.000263	0.0179	0.16	0.17	Aortic root size;	chr7:66311140	chr7:66902857~66906297:+
THCA	cis	rs72843506	1	rs7223910	ENSG00000260907.1	AC008088.4	3.68	0.000263	0.0179	0.22	0.17	Schizophrenia;	chr17:20079455	chr17:20530042~20530881:-
THCA	cis	rs154659	0.887	rs154660	ENSG00000274627.1	RP11-104N10.2	-3.68	0.000263	0.0179	-0.18	-0.17	Tanning;	chr16:89601229	chr16:89516797~89522217:+
THCA	cis	rs150992	0.587	rs11949103	ENSG00000246763.5	RGMB-AS1	-3.68	0.000263	0.0179	-0.17	-0.17	Body mass index;	chr5:99011939	chr5:98769618~98773469:-
THCA	cis	rs7727544	0.642	rs7705189	ENSG00000263597.1	MIR3936	-3.68	0.000263	0.0179	-0.16	-0.17	Blood metabolite levels;	chr5:132287665	chr5:132365490~132365599:-
THCA	cis	rs2749592	0.505	rs7915670	ENSG00000120555.12	SEPT7P9	-3.68	0.000263	0.0179	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38383069~38402916:-
THCA	cis	rs7216064	0.648	rs61676547	ENSG00000265055.1	AC145343.2	3.68	0.000263	0.0179	0.23	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896391	chr17:68096046~68101474:-
THCA	cis	rs12472274	0.617	rs7568705	ENSG00000279484.1	KLHL30-AS1	3.68	0.000263	0.0179	0.17	0.17	Phospholipid levels (plasma);	chr2:238173167	chr2:238152889~238155994:-
THCA	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	3.68	0.000263	0.0179	0.19	0.17	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
THCA	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	3.68	0.000263	0.0179	0.19	0.17	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
THCA	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	3.68	0.000263	0.0179	0.19	0.17	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
THCA	cis	rs4938303	0.788	rs12799766	ENSG00000254851.1	RP11-109L13.1	-3.68	0.000263	0.0179	-0.26	-0.17	Triglycerides;	chr11:116687711	chr11:117135528~117138582:+
THCA	cis	rs11633886	0.585	rs2244179	ENSG00000259200.1	RP11-718O11.1	3.68	0.000263	0.0179	0.2	0.17	Diisocyanate-induced asthma;	chr15:45797924	chr15:45705078~45931069:+
THCA	cis	rs7267979	0.932	rs6115215	ENSG00000276952.1	RP5-965G21.6	3.68	0.000263	0.0179	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25284915~25285588:-
THCA	cis	rs4742903	0.935	rs10820618	ENSG00000270332.1	SMC2-AS1	3.68	0.000263	0.0179	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104198222	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs10119876	ENSG00000270332.1	SMC2-AS1	3.68	0.000263	0.0179	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104198799	chr9:104080024~104093073:-
THCA	cis	rs2303282	0.664	rs2587867	ENSG00000274031.1	RP11-413H22.3	-3.68	0.000263	0.0179	-0.2	-0.17	Breast cancer;	chr16:56370099	chr16:56465642~56466162:-
THCA	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	-3.68	0.000263	0.0179	-0.08	-0.17	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
THCA	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	-3.68	0.000263	0.0179	-0.08	-0.17	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
THCA	cis	rs267567	0.626	rs182070	ENSG00000235257.7	ITGA9-AS1	3.68	0.000263	0.0179	0.14	0.17	PR interval;	chr3:37534479	chr3:37745432~37861780:-
THCA	cis	rs17772222	0.561	rs8020376	ENSG00000258789.1	RP11-507K2.3	-3.68	0.000263	0.0179	-0.16	-0.17	Coronary artery calcification;	chr14:88349823	chr14:88551597~88552493:+
THCA	cis	rs559555	0.778	rs765138	ENSG00000276517.1	AL133243.2	-3.68	0.000264	0.0179	-0.16	-0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31578869	chr2:32526504~32529507:+
THCA	cis	rs1005277	0.579	rs2505241	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.0179	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38383069~38402916:-
THCA	cis	rs494003	0.951	rs11227302	ENSG00000214659.4	KRT8P26	3.68	0.000264	0.0179	0.19	0.17	Systemic lupus erythematosus;	chr11:65787031	chr11:65726939~65728214:+
THCA	cis	rs7833790	0.963	rs6473312	ENSG00000254689.1	RP11-354A14.1	3.68	0.000264	0.0179	0.21	0.17	Diastolic blood pressure;	chr8:81820280	chr8:81885377~81923193:+
THCA	cis	rs6498068	0.633	rs7194566	ENSG00000260468.1	LINC01290	-3.68	0.000264	0.0179	-0.22	-0.17	Metabolite levels (MHPG);	chr16:10532140	chr16:10514842~10528202:-
THCA	cis	rs7551222	0.752	rs4245737	ENSG00000240219.1	RP11-430C7.5	3.68	0.000264	0.0179	0.16	0.17	Schizophrenia;	chr1:204517114	chr1:204626775~204629712:+
THCA	cis	rs5770917	1	rs1557503	ENSG00000279182.1	XX-C00717C00720L.1	3.68	0.000264	0.0179	0.26	0.17	Narcolepsy;	chr22:50574643	chr22:50316035~50317025:+
THCA	cis	rs835154	1	rs2934814	ENSG00000272057.1	CTB-40H15.4	3.68	0.000264	0.0179	0.16	0.17	Blood metabolite levels;	chr5:14872580	chr5:14872332~14872713:+
THCA	cis	rs73222236	0.794	rs60614489	ENSG00000273486.1	RP11-731C17.2	3.68	0.000264	0.0179	0.15	0.17	Coronary artery disease;	chr3:136268136	chr3:136837338~136839021:-
THCA	cis	rs72627123	1	rs17094021	ENSG00000259065.1	RP5-1021I20.1	-3.68	0.000264	0.0179	-0.26	-0.17	Morning vs. evening chronotype;	chr14:73927592	chr14:73787360~73803270:+
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000237310.1	GS1-124K5.4	3.68	0.000264	0.0179	0.2	0.17	Diabetic kidney disease;	chr7:66433290	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs58669269	ENSG00000237310.1	GS1-124K5.4	3.68	0.000264	0.0179	0.2	0.17	Diabetic kidney disease;	chr7:66486966	chr7:66493706~66495474:+
THCA	cis	rs9863	0.896	rs4930722	ENSG00000269938.1	RP11-214K3.20	-3.68	0.000264	0.0179	-0.2	-0.17	White blood cell count;	chr12:123938728	chr12:123968023~123968579:-
THCA	cis	rs2115630	1	rs11854313	ENSG00000259295.5	CSPG4P12	-3.68	0.000264	0.0179	-0.22	-0.17	P wave terminal force;	chr15:84760817	chr15:85191438~85213905:+
THCA	cis	rs7259376	1	rs7259376	ENSG00000269345.1	VN1R85P	-3.68	0.000264	0.0179	-0.18	-0.17	Menopause (age at onset);	chr19:22324903	chr19:22174766~22175191:-
THCA	cis	rs9427116	0.702	rs884618	ENSG00000236675.1	MTX1P1	-3.68	0.000264	0.0179	-0.15	-0.17	Blood protein levels;	chr1:154628681	chr1:155230975~155234325:+
THCA	cis	rs11048434	0.518	rs2377679	ENSG00000256720.1	RP11-436I9.6	-3.68	0.000264	0.0179	-0.18	-0.17	Sjögren's syndrome;	chr12:9023874	chr12:9135084~9135591:+
THCA	cis	rs394563	0.967	rs438852	ENSG00000268592.3	RAET1E-AS1	-3.68	0.000264	0.0179	-0.22	-0.17	Dupuytren's disease;	chr6:149473397	chr6:149863494~149919507:+
THCA	cis	rs2360027	0.965	rs7513680	ENSG00000231365.4	RP11-418J17.1	-3.68	0.000264	0.0179	-0.16	-0.17	Tonsillectomy;	chr1:118608345	chr1:119140396~119275973:+
THCA	cis	rs962856	0.575	rs10185288	ENSG00000236780.4	AC078941.1	3.68	0.000264	0.0179	0.22	0.17	Pancreatic cancer;	chr2:67405940	chr2:67123357~67215319:-
THCA	cis	rs13113518	0.783	rs1586555	ENSG00000272969.1	RP11-528I4.2	3.68	0.000264	0.0179	0.2	0.17	Height;	chr4:55587104	chr4:55547112~55547889:+
THCA	cis	rs9309711	0.666	rs6723101	ENSG00000271868.1	RP11-1293J14.1	-3.68	0.000264	0.0179	-0.22	-0.17	Neurofibrillary tangles;	chr2:3480672	chr2:3496956~3497428:+
THCA	cis	rs4908768	0.52	rs6695867	ENSG00000270282.1	RP5-1115A15.2	3.68	0.000264	0.0179	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8670720	chr1:8512653~8513021:+
THCA	cis	rs804280	0.662	rs804283	ENSG00000254948.1	OR7E158P	-3.68	0.000264	0.0179	-0.23	-0.17	Myopia (pathological);	chr8:11753534	chr8:11919900~11920809:-
THCA	cis	rs17685	0.753	rs869804	ENSG00000227038.2	AC005077.12	3.68	0.000264	0.0179	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76059636	chr7:76090431~76108779:-
THCA	cis	rs944990	0.576	rs10992791	ENSG00000227603.1	RP11-165J3.6	3.68	0.000264	0.0179	0.18	0.17	Body mass index;	chr9:93587851	chr9:93435332~93437121:-
THCA	cis	rs1005277	0.579	rs2505248	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.0179	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38383069~38402916:-
THCA	cis	rs4908760	0.827	rs7556169	ENSG00000270282.1	RP5-1115A15.2	-3.68	0.000264	0.0179	-0.19	-0.17	Vitiligo;	chr1:8681342	chr1:8512653~8513021:+
THCA	cis	rs3020736	0.5	rs7292241	ENSG00000237037.8	NDUFA6-AS1	3.68	0.000264	0.0179	0.14	0.17	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42090931~42137742:+
THCA	cis	rs7246967	0.673	rs7252925	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22683006	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs7253063	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22683095	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs7254097	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22683098	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs3902164	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22683479	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs6511374	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22683568	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs8103875	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22684060	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs4933024	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22684261	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs8104327	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22684357	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs8104564	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22684405	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs8107724	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22684612	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs12973264	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22684947	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs597906	ENSG00000198153.8	ZNF849P	-3.68	0.000264	0.0179	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22685403	chr19:22685167~22686732:+
THCA	cis	rs9475752	0.744	rs1903331	ENSG00000231441.1	RP11-472M19.2	3.68	0.000264	0.0179	0.18	0.17	Menarche (age at onset);	chr6:56908697	chr6:56844002~56864078:+
THCA	cis	rs1832871	0.643	rs112195967	ENSG00000213078.3	RP5-933K21.2	-3.68	0.000264	0.0179	-0.25	-0.17	Height;	chr6:158354663	chr6:157365990~157366923:-
THCA	cis	rs714027	0.585	rs9306468	ENSG00000279699.1	RP1-102K2.9	3.68	0.000264	0.0179	0.18	0.17	Lymphocyte counts;	chr22:29978292	chr22:30275215~30276951:-
THCA	cis	rs642803	0.569	rs44205	ENSG00000255557.1	RP11-770G2.2	-3.68	0.000264	0.0179	-0.2	-0.17	Urate levels;	chr11:65797315	chr11:65745729~65771585:+
THCA	cis	rs9400467	0.528	rs445349	ENSG00000272356.1	RP5-1112D6.8	3.68	0.000264	0.0179	0.13	0.17	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111309203~111313517:+
THCA	cis	rs1008126	0.6	rs2528869	ENSG00000234715.1	CTB-107G13.1	-3.68	0.000264	0.0179	-0.19	-0.17	Metabolite levels (Pyroglutamine);	chr7:103494517	chr7:103445207~103514007:+
THCA	cis	rs12681366	0.511	rs2919670	ENSG00000253175.1	RP11-267M23.6	3.68	0.000264	0.0179	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94444390	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.537	rs2197004	ENSG00000253175.1	RP11-267M23.6	3.68	0.000264	0.0179	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94444748	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.537	rs2919667	ENSG00000253175.1	RP11-267M23.6	3.68	0.000264	0.0179	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94452974	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.537	rs2919656	ENSG00000253175.1	RP11-267M23.6	3.68	0.000264	0.0179	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94460806	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.537	rs3019284	ENSG00000253175.1	RP11-267M23.6	3.68	0.000264	0.0179	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94460848	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.537	rs2381886	ENSG00000253175.1	RP11-267M23.6	3.68	0.000264	0.0179	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94464825	chr8:94565036~94565715:+
THCA	cis	rs801193	1	rs1553610	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66732246	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs2707845	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66733811	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs2707850	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66738883	chr7:66848496~66858136:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66740595	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs7783924	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66744070	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs7789184	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66745208	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs2707854	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66747610	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs3800812	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66758474	chr7:66848496~66858136:+
THCA	cis	rs801193	1	rs4279493	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66761633	chr7:66848496~66858136:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000264	0.0179	-0.14	-0.17	Aortic root size;	chr7:66765184	chr7:66848496~66858136:+
THCA	cis	rs7259376	0.936	rs55983151	ENSG00000269345.1	VN1R85P	3.68	0.000264	0.0179	0.18	0.17	Menopause (age at onset);	chr19:22370134	chr19:22174766~22175191:-
THCA	cis	rs4713118	0.738	rs200465	ENSG00000261839.1	RP1-265C24.8	3.68	0.000264	0.0179	0.19	0.17	Parkinson's disease;	chr6:27789875	chr6:28136849~28139678:+
THCA	cis	rs17836934	0.838	rs11105501	ENSG00000271614.1	LINC00936	-3.68	0.000264	0.0179	-0.14	-0.17	Total body bone mineral density;	chr12:90088859	chr12:89708959~89712590:+
THCA	cis	rs790006	0.697	rs73132149	ENSG00000243024.5	RPS11P6	-3.68	0.000264	0.0179	-0.19	-0.17	Response to cytidine analogues (gemcitabine);	chr12:64223590	chr12:64222337~64397065:+
THCA	cis	rs790006	0.697	rs11175285	ENSG00000243024.5	RPS11P6	-3.68	0.000264	0.0179	-0.19	-0.17	Response to cytidine analogues (gemcitabine);	chr12:64223598	chr12:64222337~64397065:+
THCA	cis	rs2904967	0.759	rs625427	ENSG00000254614.2	AP003068.23	-3.68	0.000264	0.0179	-0.31	-0.17	Mean corpuscular volume;	chr11:65236341	chr11:65177606~65181834:-
THCA	cis	rs5753037	0.676	rs6006267	ENSG00000279699.1	RP1-102K2.9	3.68	0.000264	0.0179	0.16	0.17	Type 1 diabetes;	chr22:29820993	chr22:30275215~30276951:-
THCA	cis	rs7572733	0.555	rs6434953	ENSG00000231621.1	AC013264.2	-3.68	0.000264	0.0179	-0.18	-0.17	Dermatomyositis;	chr2:198064969	chr2:197197991~197199273:+
THCA	cis	rs9309473	1	rs7558944	ENSG00000273245.1	RP11-434P11.2	3.68	0.000264	0.0179	0.23	0.17	Metabolite levels;	chr2:73583782	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs13432605	ENSG00000273245.1	RP11-434P11.2	3.68	0.000264	0.0179	0.23	0.17	Metabolite levels;	chr2:73583854	chr2:73750256~73750786:-
THCA	cis	rs1009077	0.716	rs2389868	ENSG00000245958.5	RP11-33B1.1	3.68	0.000264	0.018	0.26	0.17	Endometriosis;	chr4:119594344	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs35850447	ENSG00000245958.5	RP11-33B1.1	3.68	0.000264	0.018	0.26	0.17	Endometriosis;	chr4:119597610	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs62319647	ENSG00000245958.5	RP11-33B1.1	3.68	0.000264	0.018	0.26	0.17	Endometriosis;	chr4:119597862	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs35999787	ENSG00000245958.5	RP11-33B1.1	3.68	0.000264	0.018	0.26	0.17	Endometriosis;	chr4:119597949	chr4:119454791~119552025:+
THCA	cis	rs1005277	0.579	rs2474567	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2472175	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2472176	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474568	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2983343	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474569	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.602	rs2504142	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2472181	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474574	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2504140	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474575	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2472182	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.541	rs2263163	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2021649	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2472183	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2505197	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2505196	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.557	rs1854563	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2505237	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474599	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2505240	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.54	rs2224248	ENSG00000120555.12	SEPT7P9	3.68	0.000264	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38383069~38402916:-
THCA	cis	rs1555322	1	rs1555322	ENSG00000126005.14	MMP24-AS1	-3.68	0.000264	0.018	-0.23	-0.17	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35216462~35278131:-
THCA	cis	rs6600671	1	rs4844380	ENSG00000226067.5	CH17-118O6.2	3.68	0.000264	0.018	0.17	0.17	Hip geometry;	chr1:121451764	chr1:120913275~121009291:+
THCA	cis	rs9860428	0.815	rs9825873	ENSG00000240057.4	RP11-572M11.4	-3.68	0.000264	0.018	-0.17	-0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905547	chr3:113019532~113183301:+
THCA	cis	rs2688608	0.672	rs2688622	ENSG00000271816.1	BMS1P4	3.68	0.000264	0.018	0.16	0.17	Inflammatory bowel disease;	chr10:73929223	chr10:73699151~73730487:-
THCA	cis	rs12879264	0.697	rs7158526	ENSG00000273888.1	FRMD6-AS1	3.68	0.000264	0.018	0.2	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr14:51606640	chr14:51649516~51651744:-
THCA	cis	rs12682352	0.605	rs60707155	ENSG00000254340.1	RP11-10A14.3	3.68	0.000264	0.018	0.19	0.17	Neuroticism;	chr8:8866905	chr8:9141424~9145435:+
THCA	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-3.68	0.000265	0.018	-0.2	-0.17	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
THCA	cis	rs703842	0.532	rs238516	ENSG00000270039.1	RP11-571M6.17	3.68	0.000265	0.018	0.17	0.17	Multiple sclerosis;	chr12:57723572	chr12:57803838~57804415:+
THCA	cis	rs1046896	0.521	rs3859206	ENSG00000263063.1	RP11-388C12.1	-3.68	0.000265	0.018	-0.2	-0.17	Glycated hemoglobin levels;	chr17:82735252	chr17:82713908~82716255:-
THCA	cis	rs7572733	0.935	rs10497809	ENSG00000231621.1	AC013264.2	-3.68	0.000265	0.018	-0.16	-0.17	Dermatomyositis;	chr2:197960944	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.806	rs10169453	ENSG00000231621.1	AC013264.2	-3.68	0.000265	0.018	-0.16	-0.17	Dermatomyositis;	chr2:197970488	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs10204166	ENSG00000231621.1	AC013264.2	-3.68	0.000265	0.018	-0.16	-0.17	Dermatomyositis;	chr2:197970540	chr2:197197991~197199273:+
THCA	cis	rs613391	0.735	rs688066	ENSG00000234840.1	LINC01239	-3.68	0.000265	0.018	-0.2	-0.17	Quantitative traits;	chr9:22713036	chr9:22646200~22824213:+
THCA	cis	rs1580019	0.51	rs4723162	ENSG00000273014.1	RP11-225B17.2	3.68	0.000265	0.018	0.17	0.17	Cognitive ability;	chr7:32504192	chr7:32758882~32759353:+
THCA	cis	rs2749592	0.55	rs12255038	ENSG00000120555.12	SEPT7P9	-3.68	0.000265	0.018	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38383069~38402916:-
THCA	cis	rs9425766	0.679	rs6682017	ENSG00000270084.1	GAS5-AS1	-3.68	0.000265	0.018	-0.17	-0.17	Life satisfaction;	chr1:174097809	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.655	rs2145376	ENSG00000270084.1	GAS5-AS1	-3.68	0.000265	0.018	-0.17	-0.17	Life satisfaction;	chr1:174098911	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs6663794	ENSG00000270084.1	GAS5-AS1	-3.68	0.000265	0.018	-0.17	-0.17	Life satisfaction;	chr1:174099791	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.64	rs6658769	ENSG00000270084.1	GAS5-AS1	-3.68	0.000265	0.018	-0.17	-0.17	Life satisfaction;	chr1:174100843	chr1:173863248~173863941:+
THCA	cis	rs270601	0.661	rs10036208	ENSG00000263597.1	MIR3936	3.68	0.000265	0.018	0.16	0.17	Acylcarnitine levels;	chr5:132235630	chr5:132365490~132365599:-
THCA	cis	rs4601821	0.895	rs1055075	ENSG00000270179.1	RP11-159N11.4	-3.68	0.000265	0.018	-0.17	-0.17	Alcoholic chronic pancreatitis;	chr11:113368790	chr11:113368478~113369117:+
THCA	cis	rs2287641	0.737	rs78531993	ENSG00000272156.1	RP11-477N3.1	3.68	0.000265	0.018	0.3	0.17	Cannabis dependence symptom count;	chr2:54135508	chr2:54082554~54085066:+
THCA	cis	rs9291683	0.53	rs13115193	ENSG00000261490.1	RP11-448G15.3	3.68	0.000265	0.018	0.1	0.17	Bone mineral density;	chr4:9980567	chr4:10068089~10073019:-
THCA	cis	rs11157436	0.56	rs2242543	ENSG00000211812.1	TRAV26-2	-3.68	0.000265	0.018	-0.14	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22226436	chr14:22202583~22203368:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000230295.1	RP11-458F8.2	3.68	0.000265	0.018	0.15	0.17	Aortic root size;	chr7:66622723	chr7:66880708~66882981:+
THCA	cis	rs2281603	0.951	rs12385918	ENSG00000258824.2	CTD-2555O16.2	-3.68	0.000265	0.018	-0.17	-0.17	Lymphocyte counts;	chr14:64533227	chr14:64422935~64448557:-
THCA	cis	rs6840360	0.571	rs7678080	ENSG00000251611.1	RP11-610P16.1	-3.68	0.000265	0.018	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151636198	chr4:151407551~151408835:-
THCA	cis	rs7212590	0.581	rs8064505	ENSG00000267302.4	RP11-178C3.2	3.68	0.000265	0.018	0.31	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59761470	chr17:59964832~59996972:+
THCA	cis	rs3105593	0.933	rs3131576	ENSG00000242737.1	RP11-562A8.1	3.68	0.000265	0.018	0.21	0.17	QT interval;	chr15:50571461	chr15:50466738~50467096:+
THCA	cis	rs12780845	0.931	rs57751544	ENSG00000229124.5	VIM-AS1	3.68	0.000265	0.018	0.17	0.17	Homocysteine levels;	chr10:17203121	chr10:17214239~17229985:-
THCA	cis	rs9634489	0.903	rs9634490	ENSG00000247400.3	DNAJC3-AS1	-3.68	0.000265	0.018	-0.1	-0.17	Body mass index;	chr13:96396846	chr13:95648733~95676925:-
THCA	cis	rs14027	0.921	rs7833112	ENSG00000279347.1	RP11-85I17.2	-3.68	0.000265	0.018	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119838736~119840385:-
THCA	cis	rs1009077	0.67	rs28566610	ENSG00000248280.1	RP11-33B1.2	-3.68	0.000265	0.018	-0.19	-0.17	Endometriosis;	chr4:119613767	chr4:119440561~119450157:-
THCA	cis	rs791590	0.941	rs11597237	ENSG00000229664.1	RP11-536K7.5	-3.68	0.000265	0.018	-0.28	-0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6037054	chr10:6025978~6036427:+
THCA	cis	rs8141529	0.504	rs6005915	ENSG00000272858.1	CTA-292E10.8	-3.68	0.000265	0.018	-0.18	-0.17	Lymphocyte counts;	chr22:28837274	chr22:28814914~28815662:+
THCA	cis	rs4792901	0.538	rs34038525	ENSG00000279602.1	CTD-3014M21.1	-3.68	0.000265	0.018	-0.22	-0.17	Dupuytren's disease;	chr17:43457937	chr17:43360041~43361361:-
THCA	cis	rs7707921	0.505	rs12516434	ENSG00000251374.1	RPS23P5	-3.68	0.000265	0.018	-0.22	-0.17	Breast cancer;	chr5:82132253	chr5:82265157~82265259:-
THCA	cis	rs12681366	0.659	rs2450558	ENSG00000261437.1	RP11-22C11.2	-3.68	0.000265	0.018	-0.15	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94398279	chr8:94637285~94639467:-
THCA	cis	rs11239930	0.538	rs4950362	ENSG00000180867.10	PDIA3P1	3.68	0.000265	0.018	0.16	0.17	AIDS progression;	chr1:147088336	chr1:147178113~147179622:+
THCA	cis	rs61160187	0.556	rs10939881	ENSG00000272308.1	RP11-231G3.1	-3.68	0.000265	0.018	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60866457~60866935:-
THCA	cis	rs12188164	0.543	rs2434695	ENSG00000188242.4	PP7080	-3.68	0.000265	0.018	-0.15	-0.17	Cystic fibrosis severity;	chr5:464062	chr5:466124~473098:-
THCA	cis	rs4819052	0.679	rs4819053	ENSG00000273796.1	LL21NC02-21A1.1	3.68	0.000265	0.018	0.17	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45403809~45404369:-
THCA	cis	rs2692947	0.759	rs11687113	ENSG00000235584.2	AC008268.1	-3.68	0.000265	0.018	-0.16	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95992840	chr2:95666084~95668715:+
THCA	cis	rs10927875	0.632	rs2862162	ENSG00000179743.3	FLJ37453	3.68	0.000265	0.018	0.12	0.17	Dilated cardiomyopathy;	chr1:15816465	chr1:15834479~15848147:-
THCA	cis	rs889312	0.5	rs185219	ENSG00000271828.1	CTD-2310F14.1	-3.68	0.000265	0.018	-0.23	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56840665	chr5:56927874~56929573:+
THCA	cis	rs11175834	0.557	rs4444128	ENSG00000256915.1	RP11-221N13.4	3.68	0.000265	0.018	0.29	0.17	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65571793	chr12:65644334~65663299:+
THCA	cis	rs3096299	0.728	rs1011749	ENSG00000223959.7	AFG3L1P	3.67	0.000265	0.018	0.09	0.17	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89972586~90002161:+
THCA	cis	rs1005277	0.579	rs1985707	ENSG00000120555.12	SEPT7P9	3.67	0.000265	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38383069~38402916:-
THCA	cis	rs6901152	0.93	rs4896644	ENSG00000217648.1	RP1-95L4.4	-3.67	0.000265	0.018	-0.18	-0.17	Acute lymphoblastic leukemia (childhood);	chr6:143348901	chr6:143342246~143343383:+
THCA	cis	rs8066044	1	rs8066044	ENSG00000277491.1	RP11-676J12.9	-3.67	0.000265	0.018	-0.21	-0.17	Sum neutrophil eosinophil counts;	chr17:1464058	chr17:795306~795794:+
THCA	cis	rs4568518	0.561	rs4579426	ENSG00000279048.1	RP11-511H23.2	3.67	0.000265	0.018	0.1	0.17	Measles;	chr7:17968636	chr7:17940503~17942922:+
THCA	cis	rs4568518	0.619	rs34058374	ENSG00000279048.1	RP11-511H23.2	3.67	0.000265	0.018	0.1	0.17	Measles;	chr7:17968959	chr7:17940503~17942922:+
THCA	cis	rs11673344	0.526	rs8101610	ENSG00000267470.4	ZNF571-AS1	3.67	0.000265	0.018	0.21	0.17	Obesity-related traits;	chr19:37566604	chr19:37548914~37587348:+
THCA	cis	rs2228479	0.717	rs9282682	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000265	0.018	-0.27	-0.17	Skin colour saturation;	chr16:89739386	chr16:89516797~89522217:+
THCA	cis	rs8023401	0.507	rs35026266	ENSG00000259705.1	RP11-227D13.1	3.67	0.000265	0.018	0.2	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48476847	chr15:48645951~48652016:+
THCA	cis	rs9863	0.931	rs11057407	ENSG00000270028.1	RP11-380L11.4	3.67	0.000265	0.018	0.18	0.17	White blood cell count;	chr12:123965282	chr12:123925461~123926083:-
THCA	cis	rs16857609	1	rs57481445	ENSG00000233143.1	DIRC3-AS1	-3.67	0.000265	0.018	-0.18	-0.17	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217431651	chr2:217282739~217336120:+
THCA	cis	rs1031391	0.716	rs10772416	ENSG00000256682.2	TAS2R12	-3.67	0.000265	0.018	-0.24	-0.17	Bitter taste perception;	chr12:11017488	chr12:10894943~10896952:-
THCA	cis	rs875971	0.502	rs11769702	ENSG00000273024.4	INTS4P2	-3.67	0.000265	0.018	-0.21	-0.17	Aortic root size;	chr7:66255529	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs6970498	ENSG00000273024.4	INTS4P2	-3.67	0.000265	0.018	-0.21	-0.17	Aortic root size;	chr7:66275908	chr7:65647864~65715661:+
THCA	cis	rs1927790	0.616	rs1925119	ENSG00000247400.3	DNAJC3-AS1	-3.67	0.000265	0.018	-0.11	-0.17	Body mass index;	chr13:96287332	chr13:95648733~95676925:-
THCA	cis	rs1560104	0.597	rs12162027	ENSG00000262801.4	U91319.1	-3.67	0.000265	0.018	-0.19	-0.17	Obesity-related traits;	chr16:12616235	chr16:13246316~13562918:+
THCA	cis	rs972578	0.837	rs2073199	ENSG00000230319.1	AL022476.2	3.67	0.000265	0.018	0.18	0.17	Mean platelet volume;	chr22:42879244	chr22:43038585~43052366:+
THCA	cis	rs4262150	0.81	rs4958323	ENSG00000253921.1	CTB-113P19.3	3.67	0.000265	0.018	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152642207	chr5:151753992~151767247:+
THCA	cis	rs12476592	0.602	rs262503	ENSG00000242412.1	DBIL5P2	3.67	0.000265	0.018	0.21	0.17	Childhood ear infection;	chr2:63633303	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.571	rs166384	ENSG00000242412.1	DBIL5P2	3.67	0.000265	0.018	0.21	0.17	Childhood ear infection;	chr2:63636496	chr2:63117851~63119542:-
THCA	cis	rs2842346	0.568	rs916962	ENSG00000258623.1	CTD-2325P2.3	-3.67	0.000265	0.018	-0.22	-0.17	Breast cancer;	chr14:68526861	chr14:68683411~68685565:-
THCA	cis	rs7578199	0.576	rs2271030	ENSG00000223374.1	AC005104.3	-3.67	0.000266	0.018	-0.12	-0.17	Chronic lymphocytic leukemia;	chr2:241493289	chr2:241351340~241353104:-
THCA	cis	rs7188697	0.922	rs1549607	ENSG00000276259.1	RP11-481J2.4	3.67	0.000266	0.018	0.12	0.17	QT interval;	chr16:58550071	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.921	rs12445577	ENSG00000276259.1	RP11-481J2.4	3.67	0.000266	0.018	0.12	0.17	QT interval;	chr16:58553260	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.882	rs37054	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58525085	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs37056	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58526973	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs37057	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58528050	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs37061	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58532767	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.848	rs37062	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58533334	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs40188	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58533857	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs2243463	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58537285	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.885	rs246194	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58539997	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs246196	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58540349	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs37039	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58544187	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs37040	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58544358	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.848	rs42947	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58545254	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs37041	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58545982	chr16:58522970~58523842:+
THCA	cis	rs11089937	0.895	rs5756985	ENSG00000211638.2	IGLV8-61	-3.67	0.000266	0.018	-0.13	-0.17	Periodontitis (PAL4Q3);	chr22:22131847	chr22:22098700~22099212:+
THCA	cis	rs1005277	0.579	rs2474608	ENSG00000120555.12	SEPT7P9	3.67	0.000266	0.018	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38383069~38402916:-
THCA	cis	rs7824557	0.527	rs2572369	ENSG00000261451.1	RP11-981G7.1	-3.67	0.000266	0.018	-0.21	-0.17	Retinal vascular caliber;	chr8:11381088	chr8:10433672~10438312:+
THCA	cis	rs3740713	0.669	rs2896526	ENSG00000256464.1	YWHABP2	3.67	0.000266	0.018	0.27	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr11:18490243~18490955:-
THCA	cis	rs7824557	0.564	rs6601584	ENSG00000255495.1	AC145124.2	-3.67	0.000266	0.018	-0.19	-0.17	Retinal vascular caliber;	chr8:11374834	chr8:12194467~12196280:+
THCA	cis	rs314370	1	rs10278546	ENSG00000242294.5	STAG3L5P	3.67	0.000266	0.018	0.11	0.17	Resting heart rate;	chr7:100918383	chr7:100336079~100351900:+
THCA	cis	rs3736986	0.908	rs10814351	ENSG00000215283.3	HMGB3P24	-3.67	0.000266	0.018	-0.31	-0.17	Bipolar disorder (inflammation and infection response interaction);	chr9:36182675	chr9:36303499~36304924:-
THCA	cis	rs2797160	1	rs2747725	ENSG00000226409.1	RP11-735G4.1	3.67	0.000266	0.018	0.2	0.17	Endometrial cancer;	chr6:125691251	chr6:125370211~125374324:-
THCA	cis	rs3218092	0.81	rs34992963	ENSG00000213435.3	ATP6V0CP3	3.67	0.000266	0.018	0.28	0.17	Red cell distribution width;	chr6:41890130	chr6:42727234~42727700:+
THCA	cis	rs2239547	0.657	rs2071040	ENSG00000243224.1	RP5-1157M23.2	-3.67	0.000266	0.018	-0.2	-0.17	Schizophrenia;	chr3:52830844	chr3:52239258~52241097:+
THCA	cis	rs6142618	0.846	rs6061216	ENSG00000224452.1	RSL24D1P6	3.67	0.000266	0.018	0.21	0.17	Inflammatory bowel disease;	chr20:32194310	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.846	rs911129	ENSG00000224452.1	RSL24D1P6	3.67	0.000266	0.018	0.21	0.17	Inflammatory bowel disease;	chr20:32201385	chr20:32170390~32170790:-
THCA	cis	rs28595532	0.748	rs72670258	ENSG00000260404.2	RP11-384K6.6	-3.67	0.000266	0.018	-0.28	-0.17	Cannabis dependence symptom count;	chr4:118470505	chr4:118591773~118633729:+
THCA	cis	rs2066819	1	rs1274493	ENSG00000257303.1	RP11-977G19.11	3.67	0.000266	0.018	0.24	0.17	Psoriasis vulgaris;	chr12:56288587	chr12:56300142~56314808:+
THCA	cis	rs1560104	0.597	rs4781297	ENSG00000262801.4	U91319.1	-3.67	0.000266	0.018	-0.19	-0.17	Obesity-related traits;	chr16:12613347	chr16:13246316~13562918:+
THCA	cis	rs4705962	0.918	rs6879672	ENSG00000230612.2	AC004237.1	3.67	0.000266	0.018	0.22	0.17	Atopic dermatitis;	chr5:132690255	chr5:132688681~132723725:+
THCA	cis	rs34792	0.688	rs153785	ENSG00000275910.1	RP11-680G24.6	3.67	0.000266	0.018	0.18	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499435	chr16:15015828~15016390:-
THCA	cis	rs8141529	0.515	rs16986861	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000266	0.018	-0.21	-0.17	Lymphocyte counts;	chr22:28947200	chr22:28814914~28815662:+
THCA	cis	rs11098499	0.566	rs7664440	ENSG00000249244.1	RP11-548H18.2	3.67	0.000266	0.018	0.19	0.17	Corneal astigmatism;	chr4:119657385	chr4:119391831~119395335:-
THCA	cis	rs5769765	0.837	rs8142737	ENSG00000260613.1	RP3-522J7.6	-3.67	0.000266	0.018	-0.21	-0.17	Schizophrenia;	chr22:49898241	chr22:49832616~49837786:-
THCA	cis	rs11673344	0.523	rs1402468	ENSG00000267260.1	CTD-2162K18.4	-3.67	0.000266	0.018	-0.2	-0.17	Obesity-related traits;	chr19:37129346	chr19:36773153~36777078:+
THCA	cis	rs7216064	1	rs55896768	ENSG00000265055.1	AC145343.2	3.67	0.000266	0.018	0.23	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67917242	chr17:68096046~68101474:-
THCA	cis	rs7824557	0.583	rs4448232	ENSG00000261451.1	RP11-981G7.1	3.67	0.000266	0.018	0.21	0.17	Retinal vascular caliber;	chr8:11373845	chr8:10433672~10438312:+
THCA	cis	rs73173548	0.502	rs12189343	ENSG00000247828.6	TMEM161B-AS1	3.67	0.000266	0.018	0.16	0.17	Macular telangiectasia type 2;	chr5:88447510	chr5:88268895~88436685:+
THCA	cis	rs6878727	0.85	rs2408163	ENSG00000253807.4	LINC01170	-3.67	0.000266	0.018	-0.15	-0.17	Breast cancer;	chr5:124371323	chr5:124059794~124405079:-
THCA	cis	rs875971	0.66	rs3764903	ENSG00000232546.1	RP11-458F8.1	3.67	0.000266	0.018	0.14	0.17	Aortic root size;	chr7:66633495	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000232546.1	RP11-458F8.1	3.67	0.000266	0.018	0.14	0.17	Aortic root size;	chr7:66638707	chr7:66848496~66858136:+
THCA	cis	rs7178909	0.902	rs8033554	ENSG00000259677.1	RP11-493E3.1	3.67	0.000266	0.018	0.2	0.17	Common traits (Other);	chr15:89898337	chr15:89876540~89877285:+
THCA	cis	rs9611565	0.659	rs1810460	ENSG00000237037.8	NDUFA6-AS1	3.67	0.000266	0.018	0.15	0.17	Vitiligo;	chr22:41531696	chr22:42090931~42137742:+
THCA	cis	rs9329221	0.935	rs6601450	ENSG00000261451.1	RP11-981G7.1	3.67	0.000266	0.018	0.2	0.17	Neuroticism;	chr8:10385591	chr8:10433672~10438312:+
THCA	cis	rs7191700	0.836	rs28502009	ENSG00000262636.1	CTD-3088G3.4	3.67	0.000266	0.018	0.24	0.17	Multiple sclerosis;	chr16:11332684	chr16:11380859~11381118:-
THCA	cis	rs18122	0.846	rs12470785	ENSG00000236780.4	AC078941.1	3.67	0.000266	0.018	0.22	0.17	Waist-to-hip ratio adjusted for body mass index;	chr2:67406871	chr2:67123357~67215319:-
THCA	cis	rs8054556	0.74	rs11649612	ENSG00000273724.1	RP11-347C12.12	-3.67	0.000266	0.018	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30336400~30343336:+
THCA	cis	rs8054556	0.716	rs11642933	ENSG00000273724.1	RP11-347C12.12	-3.67	0.000266	0.018	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30336400~30343336:+
THCA	cis	rs7188697	0.922	rs28307	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58543234	chr16:58522970~58523842:+
THCA	cis	rs28374715	0.662	rs522063	ENSG00000247556.5	OIP5-AS1	-3.67	0.000266	0.018	-0.16	-0.17	Ulcerative colitis;	chr15:41184011	chr15:41283990~41309737:+
THCA	cis	rs11105298	0.891	rs11105302	ENSG00000266347.2	AC068641.1	-3.67	0.000266	0.018	-0.21	-0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89592833~89592927:+
THCA	cis	rs7267979	0.899	rs6115213	ENSG00000276952.1	RP5-965G21.6	3.67	0.000266	0.018	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25284915~25285588:-
THCA	cis	rs7188697	0.922	rs37051	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000266	0.018	-0.12	-0.17	QT interval;	chr16:58524198	chr16:58522970~58523842:+
THCA	cis	rs4819052	0.684	rs914216	ENSG00000184274.3	LINC00315	-3.67	0.000266	0.018	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45300245~45305257:-
THCA	cis	rs13113518	0.812	rs56055342	ENSG00000272969.1	RP11-528I4.2	3.67	0.000266	0.018	0.2	0.17	Height;	chr4:55540928	chr4:55547112~55547889:+
THCA	cis	rs3087591	0.664	rs2854308	ENSG00000263535.1	AK4P1	3.67	0.000266	0.018	0.2	0.17	Hip circumference;	chr17:31339521	chr17:31345521~31346187:+
THCA	cis	rs17092148	0.666	rs62212084	ENSG00000269202.1	RP4-614O4.12	-3.67	0.000266	0.018	-0.18	-0.17	Neuroticism;	chr20:34871048	chr20:35201747~35203288:-
THCA	cis	rs2625529	0.775	rs4777484	ENSG00000260037.4	CTD-2524L6.3	-3.67	0.000266	0.018	-0.23	-0.17	Red blood cell count;	chr15:72084202	chr15:71818396~71823384:+
THCA	cis	rs4759375	1	rs12317103	ENSG00000256092.2	RP13-942N8.1	-3.67	0.000266	0.0181	-0.18	-0.17	HDL cholesterol;	chr12:123318267	chr12:123363868~123366113:+
THCA	cis	rs2281603	0.57	rs11158542	ENSG00000258824.2	CTD-2555O16.2	3.67	0.000266	0.0181	0.15	0.17	Lymphocyte counts;	chr14:64462940	chr14:64422935~64448557:-
THCA	cis	rs7824557	0.836	rs1435278	ENSG00000255495.1	AC145124.2	-3.67	0.000266	0.0181	-0.18	-0.17	Retinal vascular caliber;	chr8:11265520	chr8:12194467~12196280:+
THCA	cis	rs9923856	0.611	rs2286975	ENSG00000263033.2	RP11-396B14.2	3.67	0.000266	0.0181	0.14	0.17	Atopic dermatitis;Adult asthma;	chr16:11020149	chr16:11196177~11224969:+
THCA	cis	rs875971	0.862	rs13536	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000266	0.0181	-0.11	-0.17	Aortic root size;	chr7:66554203	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs801209	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000266	0.0181	-0.11	-0.17	Aortic root size;	chr7:66554403	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs801206	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000266	0.0181	-0.11	-0.17	Aortic root size;	chr7:66556979	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs801204	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000266	0.0181	-0.11	-0.17	Aortic root size;	chr7:66557934	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs801203	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000266	0.0181	-0.11	-0.17	Aortic root size;	chr7:66558025	chr7:66491049~66493566:-
THCA	cis	rs875971	0.825	rs801202	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000266	0.0181	-0.11	-0.17	Aortic root size;	chr7:66558942	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs801195	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000266	0.0181	-0.11	-0.17	Aortic root size;	chr7:66561128	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs801194	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000266	0.0181	-0.11	-0.17	Aortic root size;	chr7:66563508	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs13232191	ENSG00000223473.2	GS1-124K5.3	3.67	0.000266	0.0181	0.11	0.17	Aortic root size;	chr7:66521661	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs10950043	ENSG00000223473.2	GS1-124K5.3	3.67	0.000266	0.0181	0.11	0.17	Aortic root size;	chr7:66523623	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs17747530	ENSG00000223473.2	GS1-124K5.3	3.67	0.000266	0.0181	0.11	0.17	Aortic root size;	chr7:66529742	chr7:66491049~66493566:-
THCA	cis	rs875971	0.767	rs61348003	ENSG00000223473.2	GS1-124K5.3	3.67	0.000266	0.0181	0.11	0.17	Aortic root size;	chr7:66540947	chr7:66491049~66493566:-
THCA	cis	rs964611	0.882	rs4325499	ENSG00000259488.2	RP11-154J22.1	-3.67	0.000266	0.0181	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48289551	chr15:48312353~48331856:-
THCA	cis	rs964611	0.872	rs6493320	ENSG00000259488.2	RP11-154J22.1	-3.67	0.000266	0.0181	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48290070	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs6493321	ENSG00000259488.2	RP11-154J22.1	-3.67	0.000266	0.0181	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48290117	chr15:48312353~48331856:-
THCA	cis	rs2625529	0.878	rs4777478	ENSG00000260037.4	CTD-2524L6.3	-3.67	0.000266	0.0181	-0.23	-0.17	Red blood cell count;	chr15:71986744	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs12593134	ENSG00000260037.4	CTD-2524L6.3	-3.67	0.000266	0.0181	-0.23	-0.17	Red blood cell count;	chr15:72010666	chr15:71818396~71823384:+
THCA	cis	rs9487094	0.601	rs4945831	ENSG00000223537.2	RP5-919F19.5	-3.67	0.000266	0.0181	-0.17	-0.17	Height;	chr6:109440234	chr6:109487906~109506800:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000230295.1	RP11-458F8.2	-3.67	0.000266	0.0181	-0.13	-0.17	Aortic root size;	chr7:66631041	chr7:66880708~66882981:+
THCA	cis	rs17291845	0.744	rs873203	ENSG00000260135.5	RP11-212I21.2	3.67	0.000266	0.0181	0.24	0.17	Information processing speed;	chr16:55239979	chr16:55426797~55462297:-
THCA	cis	rs748404	0.666	rs72709879	ENSG00000166763.7	STRCP1	3.67	0.000266	0.0181	0.22	0.17	Lung cancer;	chr15:43507777	chr15:43699488~43718184:-
THCA	cis	rs12959333	0.527	rs12326728	ENSG00000274849.1	RP11-49I11.4	-3.67	0.000266	0.0181	-0.2	-0.17	Post bronchodilator FEV1;	chr18:35694681	chr18:36189824~36190272:+
THCA	cis	rs4578769	0.513	rs34623893	ENSG00000273232.1	RP11-370A5.2	3.67	0.000266	0.0181	0.23	0.17	Eosinophil percentage of white cells;	chr18:22967224	chr18:22882825~22883357:-
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000185485.13	SDHAP1	3.67	0.000266	0.0181	0.14	0.17	Pancreatic cancer;	chr3:196026869	chr3:195959748~195990318:-
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000249889.1	ALG1L11P	3.67	0.000266	0.0181	0.2	0.17	Neuroticism;	chr8:11989569	chr8:12178697~12182719:+
THCA	cis	rs2732480	0.538	rs2732462	ENSG00000257735.1	RP11-370I10.6	3.67	0.000266	0.0181	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48350945~48442411:+
THCA	cis	rs6787172	0.54	rs28522438	ENSG00000272087.1	RP11-379F4.7	3.67	0.000266	0.0181	0.15	0.17	Subjective well-being;	chr3:158453207	chr3:158693120~158693768:-
THCA	cis	rs17604090	1	rs17661938	ENSG00000227855.3	DPY19L2P3	3.67	0.000266	0.0181	0.22	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29653762	chr7:29650227~29742594:+
THCA	cis	rs7711186	0.786	rs10479502	ENSG00000252464.1	RN7SKP70	3.67	0.000266	0.0181	0.19	0.17	Urate levels in obese individuals;	chr5:178648757	chr5:178619728~178619998:-
THCA	cis	rs17826219	0.706	rs609472	ENSG00000280069.1	CTD-2349P21.3	-3.67	0.000266	0.0181	-0.23	-0.17	Body mass index;	chr17:30624409	chr17:30738182~30740275:+
THCA	cis	rs7919656	0.687	rs2671695	ENSG00000228403.1	RP11-563N6.6	3.67	0.000266	0.0181	0.19	0.17	Clinically amyopathic dermatomyositis;	chr10:48908042	chr10:48878022~48878649:+
THCA	cis	rs7193541	0.929	rs12933037	ENSG00000262904.1	TMPOP2	-3.67	0.000266	0.0181	-0.2	-0.17	Multiple myeloma;	chr16:74626276	chr16:74667506~74668706:+
THCA	cis	rs7296418	0.961	rs10773921	ENSG00000256092.2	RP13-942N8.1	3.67	0.000266	0.0181	0.12	0.17	Platelet count;	chr12:123057059	chr12:123363868~123366113:+
THCA	cis	rs7296418	0.961	rs4148863	ENSG00000256092.2	RP13-942N8.1	3.67	0.000266	0.0181	0.12	0.17	Platelet count;	chr12:123084828	chr12:123363868~123366113:+
THCA	cis	rs11678825	0.789	rs72889641	ENSG00000272663.1	RP11-191L17.1	-3.67	0.000266	0.0181	-0.23	-0.17	Reticulocyte fraction of red cells;	chr2:48392694	chr2:48440043~48440597:-
THCA	cis	rs34792	0.554	rs12933773	ENSG00000275910.1	RP11-680G24.6	-3.67	0.000266	0.0181	-0.19	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:15015828~15016390:-
THCA	cis	rs17604090	0.793	rs10241305	ENSG00000223813.2	AC007255.8	3.67	0.000266	0.0181	0.16	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29650313	chr7:29514225~29563670:-
THCA	cis	rs295490	0.748	rs78069957	ENSG00000272656.1	RP11-219D15.3	3.67	0.000267	0.0181	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139375970	chr3:139349024~139349371:-
THCA	cis	rs9876781	0.559	rs11130167	ENSG00000244380.1	RP11-24C3.2	3.67	0.000267	0.0181	0.2	0.17	Longevity;	chr3:48358570	chr3:48440352~48446656:-
THCA	cis	rs9876781	0.559	rs13073692	ENSG00000244380.1	RP11-24C3.2	3.67	0.000267	0.0181	0.2	0.17	Longevity;	chr3:48361812	chr3:48440352~48446656:-
THCA	cis	rs9876781	0.559	rs7611415	ENSG00000244380.1	RP11-24C3.2	3.67	0.000267	0.0181	0.2	0.17	Longevity;	chr3:48363659	chr3:48440352~48446656:-
THCA	cis	rs1713985	0.508	rs1718862	ENSG00000269949.1	RP11-738E22.3	-3.67	0.000267	0.0181	-0.35	-0.17	Age-related macular degeneration;	chr4:57023166	chr4:56960927~56961373:-
THCA	cis	rs2235642	0.859	rs9927529	ENSG00000260989.1	LA16c-395F10.2	-3.67	0.000267	0.0181	-0.18	-0.17	Coronary artery disease;	chr16:1569487	chr16:1580527~1610328:+
THCA	cis	rs6901152	0.965	rs4896645	ENSG00000217648.1	RP1-95L4.4	-3.67	0.000267	0.0181	-0.18	-0.17	Acute lymphoblastic leukemia (childhood);	chr6:143349242	chr6:143342246~143343383:+
THCA	cis	rs6696239	1	rs6696239	ENSG00000227711.2	RP11-275O4.5	-3.67	0.000267	0.0181	-0.23	-0.17	Height;	chr1:227562367	chr1:227509028~227520477:-
THCA	cis	rs2562456	0.833	rs2359145	ENSG00000268521.1	VN1R83P	3.67	0.000267	0.0181	0.16	0.17	Pain;	chr19:21409791	chr19:21289554~21289998:-
THCA	cis	rs7660883	0.964	rs17012368	ENSG00000251411.1	RP11-397E7.4	3.67	0.000267	0.0181	0.16	0.17	HDL cholesterol levels;	chr4:87074967	chr4:86913266~86914817:-
THCA	cis	rs12497850	0.931	rs6442130	ENSG00000228638.1	FCF1P2	-3.67	0.000267	0.0181	-0.18	-0.17	Parkinson's disease;	chr3:48740594	chr3:48290793~48291375:-
THCA	cis	rs13108904	0.87	rs13110563	ENSG00000254094.1	AC078852.1	-3.67	0.000267	0.0181	-0.2	-0.17	Obesity-related traits;	chr4:1261984	chr4:1356581~1358075:+
THCA	cis	rs5758659	0.652	rs133349	ENSG00000205702.9	CYP2D7	3.67	0.000267	0.0181	0.13	0.17	Cognitive function;	chr22:42032723	chr22:42140203~42144577:-
THCA	cis	rs5758659	0.652	rs5758553	ENSG00000205702.9	CYP2D7	3.67	0.000267	0.0181	0.13	0.17	Cognitive function;	chr22:42035425	chr22:42140203~42144577:-
THCA	cis	rs7188697	0.922	rs37055	ENSG00000276259.1	RP11-481J2.4	-3.67	0.000267	0.0181	-0.12	-0.17	QT interval;	chr16:58526871	chr16:58522970~58523842:+
THCA	cis	rs73173548	0.502	rs13165211	ENSG00000247828.6	TMEM161B-AS1	3.67	0.000267	0.0181	0.15	0.17	Macular telangiectasia type 2;	chr5:88443772	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.528	rs68019847	ENSG00000247828.6	TMEM161B-AS1	3.67	0.000267	0.0181	0.15	0.17	Macular telangiectasia type 2;	chr5:88446795	chr5:88268895~88436685:+
THCA	cis	rs4073416	0.508	rs10152007	ENSG00000276116.2	FUT8-AS1	3.67	0.000267	0.0181	0.19	0.17	N-glycan levels;	chr14:65580716	chr14:65411170~65412690:-
THCA	cis	rs58785573	0.504	rs11947292	ENSG00000231160.8	KLF3-AS1	-3.67	0.000267	0.0181	-0.09	-0.17	Lymphocyte percentage of white cells;	chr4:38633128	chr4:38612701~38664883:-
THCA	cis	rs4915077	0.892	rs17020055	ENSG00000226822.1	RP11-356N1.2	3.67	0.000267	0.0181	0.3	0.17	Hypothyroidism;	chr1:107793911	chr1:108071482~108074519:+
THCA	cis	rs9818758	0.556	rs9814987	ENSG00000229759.1	MRPS18AP1	-3.67	0.000267	0.0181	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49170416	chr3:48256350~48256938:-
THCA	cis	rs11105298	0.786	rs10858867	ENSG00000266347.2	AC068641.1	3.67	0.000267	0.0181	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.786	rs3803128	ENSG00000266347.2	AC068641.1	3.67	0.000267	0.0181	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs10506972	ENSG00000266347.2	AC068641.1	3.67	0.000267	0.0181	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs12228177	ENSG00000266347.2	AC068641.1	3.67	0.000267	0.0181	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs10858872	ENSG00000266347.2	AC068641.1	3.67	0.000267	0.0181	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89592833~89592927:+
THCA	cis	rs7623291	0.504	rs9814812	ENSG00000272699.1	RP11-145M9.5	-3.67	0.000267	0.0181	-0.26	-0.17	Left ventricular obstructive tract defect (inherited effect);	chr3:178640194	chr3:179405448~179405944:+
THCA	cis	rs3812831	0.63	rs9562129	ENSG00000264539.1	MIR548AR	3.67	0.000267	0.0181	0.18	0.17	Schizophrenia;	chr13:114151677	chr13:114244505~114244561:+
THCA	cis	rs7403037	0.517	rs71461546	ENSG00000260760.1	PWRN3	3.67	0.000267	0.0181	0.24	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24552148	chr15:24441127~24447967:+
THCA	cis	rs7777677	0.963	rs4726550	ENSG00000226660.2	TRBV2	3.67	0.000267	0.0181	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142300924~142301432:+
THCA	cis	rs10479542	0.701	rs10479541	ENSG00000250999.1	RP11-1379J22.5	3.67	0.000267	0.0181	0.2	0.17	Lung cancer;	chr5:179554002	chr5:179657762~179664432:+
THCA	cis	rs62380364	0.727	rs304137	ENSG00000247828.6	TMEM161B-AS1	3.67	0.000267	0.0181	0.12	0.17	Intelligence (multi-trait analysis);	chr5:88873835	chr5:88268895~88436685:+
THCA	cis	rs9329221	0.617	rs615632	ENSG00000261451.1	RP11-981G7.1	-3.67	0.000267	0.0181	-0.21	-0.17	Neuroticism;	chr8:9938811	chr8:10433672~10438312:+
THCA	cis	rs910316	0.934	rs8006587	ENSG00000273565.1	CTD-3075F15.1	3.67	0.000267	0.0181	0.2	0.17	Height;	chr14:75198236	chr14:75176929~75177418:+
THCA	cis	rs3733585	0.654	rs4447863	ENSG00000250413.1	RP11-448G15.1	3.67	0.000267	0.0181	0.16	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9937345	chr4:10006482~10009725:+
THCA	cis	rs9906944	0.933	rs12945020	ENSG00000248278.1	SUMO2P17	-3.67	0.000267	0.0181	-0.2	-0.17	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49005413	chr17:48874860~48908983:-
THCA	cis	rs9906944	0.933	rs35051752	ENSG00000248278.1	SUMO2P17	-3.67	0.000267	0.0181	-0.2	-0.17	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49012546	chr17:48874860~48908983:-
THCA	cis	rs642858	0.521	rs856649	ENSG00000234147.1	RP3-460G2.2	3.67	0.000267	0.0181	0.19	0.17	Type 2 diabetes;	chr6:139924610	chr6:140845958~140852924:-
THCA	cis	rs722599	0.748	rs929579	ENSG00000279594.1	RP11-950C14.10	-3.67	0.000267	0.0181	-0.17	-0.17	IgG glycosylation;	chr14:74863994	chr14:75011269~75012851:-
THCA	cis	rs17221829	0.71	rs1844198	ENSG00000280385.1	AP000648.5	-3.67	0.000267	0.0181	-0.17	-0.17	Anxiety in major depressive disorder;	chr11:89655019	chr11:90193614~90198120:+
THCA	cis	rs10811771	0.527	rs4446815	ENSG00000234840.1	LINC01239	-3.67	0.000267	0.0181	-0.19	-0.17	Response to antipsychotic therapy (extrapyramidal side effects);	chr9:22847962	chr9:22646200~22824213:+
THCA	cis	rs4460629	0.742	rs6427158	ENSG00000236675.1	MTX1P1	-3.67	0.000267	0.0181	-0.16	-0.17	Serum magnesium levels;	chr1:155102427	chr1:155230975~155234325:+
THCA	cis	rs7819412	0.715	rs35223712	ENSG00000261451.1	RP11-981G7.1	-3.67	0.000267	0.0181	-0.21	-0.17	Triglycerides;	chr8:11186417	chr8:10433672~10438312:+
THCA	cis	rs17270561	0.609	rs1165208	ENSG00000272462.2	U91328.19	-3.67	0.000267	0.0181	-0.14	-0.17	Iron status biomarkers;	chr6:25803676	chr6:25992662~26001775:+
THCA	cis	rs642858	0.747	rs633026	ENSG00000234147.1	RP3-460G2.2	3.67	0.000267	0.0181	0.19	0.17	Type 2 diabetes;	chr6:139907782	chr6:140845958~140852924:-
THCA	cis	rs642858	0.747	rs606159	ENSG00000234147.1	RP3-460G2.2	3.67	0.000267	0.0181	0.19	0.17	Type 2 diabetes;	chr6:139907809	chr6:140845958~140852924:-
THCA	cis	rs642858	0.747	rs618471	ENSG00000234147.1	RP3-460G2.2	3.67	0.000267	0.0181	0.19	0.17	Type 2 diabetes;	chr6:139908699	chr6:140845958~140852924:-
THCA	cis	rs7474896	0.537	rs1208591	ENSG00000272983.1	RP11-508N22.12	-3.67	0.000267	0.0181	-0.17	-0.17	Obesity (extreme);	chr10:37923574	chr10:38137337~38144399:+
THCA	cis	rs11123170	0.529	rs1015755	ENSG00000274877.1	RP11-65I12.1	3.67	0.000267	0.0181	0.1	0.17	Renal function-related traits (BUN);	chr2:113210730	chr2:113237595~113240825:+
THCA	cis	rs77147124	0.921	rs2254532	ENSG00000225292.2	RP11-57H14.3	-3.67	0.000267	0.0181	-0.22	-0.17	HDL cholesterol;	chr10:112157077	chr10:112888735~112906111:+
THCA	cis	rs2676071	0.64	rs2676075	ENSG00000259721.1	RP11-758N13.1	-3.67	0.000267	0.0181	-0.2	-0.17	Periodontitis (Mean PAL);	chr15:33308229	chr15:32717270~32719007:-
THCA	cis	rs2820315	1	rs2820313	ENSG00000223774.4	RP11-307B6.3	3.67	0.000267	0.0181	0.18	0.17	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201901093	chr1:201893842~201899978:+
THCA	cis	rs791590	0.715	rs12722587	ENSG00000225948.2	RP11-554I8.1	3.67	0.000267	0.0181	0.23	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6018667	chr10:6618716~6625346:+
THCA	cis	rs6121246	0.542	rs2376990	ENSG00000224628.2	RP5-854E16.2	-3.67	0.000267	0.0181	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31650941	chr20:31285317~31286835:-
THCA	cis	rs2749592	0.55	rs4934881	ENSG00000120555.12	SEPT7P9	-3.67	0.000267	0.0181	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:38383069~38402916:-
THCA	cis	rs72945132	0.598	rs61887433	ENSG00000254604.1	AP000487.6	-3.67	0.000267	0.0181	-0.32	-0.17	Coronary artery disease;	chr11:70394891	chr11:70282367~70363368:-
THCA	cis	rs6589219	0.954	rs7122375	ENSG00000196167.8	COLCA1	-3.67	0.000267	0.0181	-0.18	-0.17	Colorectal cancer;	chr11:111300346	chr11:111290787~111305045:-
THCA	cis	rs5758659	0.652	rs133347	ENSG00000205702.9	CYP2D7	3.67	0.000267	0.0181	0.13	0.17	Cognitive function;	chr22:42027641	chr22:42140203~42144577:-
THCA	cis	rs7838490	0.504	rs7013550	ENSG00000253553.4	RP11-586K2.1	-3.67	0.000267	0.0181	-0.17	-0.17	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88498459	chr8:88326836~88737134:+
THCA	cis	rs4664293	1	rs6745766	ENSG00000230783.1	AC009961.2	-3.67	0.000268	0.0181	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159598284	chr2:159689217~159690291:-
THCA	cis	rs7178909	0.835	rs17241302	ENSG00000259677.1	RP11-493E3.1	3.67	0.000268	0.0181	0.2	0.17	Common traits (Other);	chr15:89863305	chr15:89876540~89877285:+
THCA	cis	rs12476592	0.636	rs196123	ENSG00000242412.1	DBIL5P2	3.67	0.000268	0.0181	0.22	0.17	Childhood ear infection;	chr2:63614578	chr2:63117851~63119542:-
THCA	cis	rs1552244	0.554	rs2272119	ENSG00000269982.1	RP11-1020A11.2	3.67	0.000268	0.0181	0.12	0.17	Alzheimer's disease;	chr3:10007668	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.608	rs9837460	ENSG00000269982.1	RP11-1020A11.2	3.67	0.000268	0.0181	0.12	0.17	Alzheimer's disease;	chr3:10008238	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs28667821	ENSG00000269982.1	RP11-1020A11.2	3.67	0.000268	0.0181	0.12	0.17	Alzheimer's disease;	chr3:10009083	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.543	rs28719585	ENSG00000269982.1	RP11-1020A11.2	3.67	0.000268	0.0181	0.12	0.17	Alzheimer's disease;	chr3:10009129	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.554	rs7349576	ENSG00000269982.1	RP11-1020A11.2	3.67	0.000268	0.0181	0.12	0.17	Alzheimer's disease;	chr3:10009209	chr3:9958717~9962539:+
THCA	cis	rs7246657	0.663	rs4803287	ENSG00000226686.6	LINC01535	-3.67	0.000268	0.0181	-0.24	-0.17	Coronary artery calcification;	chr19:37588534	chr19:37251912~37265535:+
THCA	cis	rs10129255	0.957	rs17113284	ENSG00000280411.1	IGHV1-69-2	3.67	0.000268	0.0181	0.11	0.17	Kawasaki disease;	chr14:106684476	chr14:106762092~106762588:-
THCA	cis	rs1383484	0.958	rs5016012	ENSG00000225151.9	GOLGA2P7	3.67	0.000268	0.0181	0.22	0.17	Height;	chr15:83843253	chr15:84199311~84230136:-
THCA	cis	rs9287719	0.967	rs6432119	ENSG00000243819.4	RN7SL832P	3.67	0.000268	0.0181	0.13	0.17	Prostate cancer;	chr2:10613561	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6727768	ENSG00000243819.4	RN7SL832P	3.67	0.000268	0.0181	0.13	0.17	Prostate cancer;	chr2:10617353	chr2:10690344~10692099:+
THCA	cis	rs720475	0.732	rs62483107	ENSG00000170356.8	OR2A20P	3.67	0.000268	0.0181	0.24	0.17	Breast cancer;	chr7:144442144	chr7:144250045~144252957:-
THCA	cis	rs11665867	0.877	rs66743282	ENSG00000279108.1	CTC-490E21.11	-3.67	0.000268	0.0181	-0.27	-0.17	Hematocrit;	chr19:40752047	chr19:40840159~40842039:+
THCA	cis	rs4915077	0.803	rs79748332	ENSG00000226822.1	RP11-356N1.2	3.67	0.000268	0.0181	0.29	0.17	Hypothyroidism;	chr1:107754654	chr1:108071482~108074519:+
THCA	cis	rs72928364	0.858	rs16843198	ENSG00000256628.3	ZBTB11-AS1	-3.67	0.000268	0.0181	-0.27	-0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101064231	chr3:101676475~101679217:+
THCA	cis	rs17741873	0.836	rs17631059	ENSG00000271848.1	RP11-464F9.21	-3.67	0.000268	0.0181	-0.21	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73865800	chr10:73654039~73674719:+
THCA	cis	rs12935229	0.756	rs9924611	ENSG00000260922.1	RP11-538I12.3	-3.67	0.000268	0.0181	-0.25	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77270346	chr16:77234877~77290934:+
THCA	cis	rs7660883	0.86	rs236984	ENSG00000251411.1	RP11-397E7.4	3.67	0.000268	0.0181	0.15	0.17	HDL cholesterol levels;	chr4:87087462	chr4:86913266~86914817:-
THCA	cis	rs4763879	0.865	rs4763840	ENSG00000214776.8	RP11-726G1.1	-3.67	0.000268	0.0181	-0.21	-0.17	Type 1 diabetes;	chr12:9731814	chr12:9467552~9576275:+
THCA	cis	rs11105298	0.838	rs4842488	ENSG00000266347.2	AC068641.1	3.67	0.000268	0.0181	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs6538189	ENSG00000266347.2	AC068641.1	3.67	0.000268	0.0181	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs6538190	ENSG00000266347.2	AC068641.1	3.67	0.000268	0.0181	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89592833~89592927:+
THCA	cis	rs14027	0.921	rs10505374	ENSG00000279347.1	RP11-85I17.2	-3.67	0.000268	0.0181	-0.2	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119838736~119840385:-
THCA	cis	rs4792901	0.765	rs2127224	ENSG00000279602.1	CTD-3014M21.1	-3.67	0.000268	0.0182	-0.22	-0.17	Dupuytren's disease;	chr17:43491657	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs28636996	ENSG00000279602.1	CTD-3014M21.1	-3.67	0.000268	0.0182	-0.22	-0.17	Dupuytren's disease;	chr17:43495418	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs9894910	ENSG00000279602.1	CTD-3014M21.1	-3.67	0.000268	0.0182	-0.22	-0.17	Dupuytren's disease;	chr17:43496938	chr17:43360041~43361361:-
THCA	cis	rs4763879	0.729	rs10844472	ENSG00000214776.8	RP11-726G1.1	-3.67	0.000268	0.0182	-0.2	-0.17	Type 1 diabetes;	chr12:9691137	chr12:9467552~9576275:+
THCA	cis	rs17622252	0.651	rs74650130	ENSG00000280989.1	LINC00581	3.67	0.000268	0.0182	0.29	0.17	Bipolar disorder;	chr6:21357820	chr6:21486061~21511895:-
THCA	cis	rs13098911	0.54	rs35501575	ENSG00000226074.4	PRSS44	-3.67	0.000268	0.0182	-0.31	-0.17	Celiac disease;	chr3:45952153	chr3:46809359~46812558:-
THCA	cis	rs7572733	0.935	rs1518364	ENSG00000231621.1	AC013264.2	-3.67	0.000268	0.0182	-0.16	-0.17	Dermatomyositis;	chr2:197945251	chr2:197197991~197199273:+
THCA	cis	rs7824557	0.51	rs4841524	ENSG00000255046.1	RP11-297N6.4	3.67	0.000268	0.0182	0.18	0.17	Retinal vascular caliber;	chr8:11385617	chr8:11797928~11802568:-
THCA	cis	rs2434529	1	rs153431	ENSG00000245275.6	SAP30L-AS1	3.67	0.000268	0.0182	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154269366	chr5:154329437~154445850:-
THCA	cis	rs972540	1	rs61570189	ENSG00000229647.1	AC007879.7	-3.67	0.000268	0.0182	-0.19	-0.17	Body mass index;	chr2:206399831	chr2:207239650~207245887:+
THCA	cis	rs6981523	0.553	rs11783890	ENSG00000255495.1	AC145124.2	-3.67	0.000268	0.0182	-0.2	-0.17	Neuroticism;	chr8:11198879	chr8:12194467~12196280:+
THCA	cis	rs10090774	0.76	rs10111852	ENSG00000280303.2	ERICD	3.67	0.000268	0.0182	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140927442	chr8:140636281~140638283:+
THCA	cis	rs12887734	0.524	rs4906364	ENSG00000258534.1	CTD-2134A5.4	-3.67	0.000268	0.0182	-0.18	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103854366~103880111:-
THCA	cis	rs17604090	0.756	rs113829432	ENSG00000227855.3	DPY19L2P3	3.67	0.000268	0.0182	0.21	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29685453	chr7:29650227~29742594:+
THCA	cis	rs2797160	1	rs1739347	ENSG00000226409.1	RP11-735G4.1	3.67	0.000268	0.0182	0.2	0.17	Endometrial cancer;	chr6:125693011	chr6:125370211~125374324:-
THCA	cis	rs7216064	0.817	rs12603589	ENSG00000265055.1	AC145343.2	3.67	0.000268	0.0182	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829132	chr17:68096046~68101474:-
THCA	cis	rs7216064	0.817	rs12601921	ENSG00000265055.1	AC145343.2	3.67	0.000268	0.0182	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829238	chr17:68096046~68101474:-
THCA	cis	rs7216064	0.813	rs12601919	ENSG00000265055.1	AC145343.2	3.67	0.000268	0.0182	0.25	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829258	chr17:68096046~68101474:-
THCA	cis	rs6580649	0.941	rs11613485	ENSG00000273765.1	RP11-370I10.11	-3.67	0.000268	0.0182	-0.18	-0.17	Lung cancer;	chr12:48068672	chr12:48360920~48361377:+
THCA	cis	rs61008539	0.893	rs7783487	ENSG00000229043.2	AC091729.9	-3.67	0.000268	0.0182	-0.19	-0.17	Perceived unattractiveness to mosquitoes;	chr7:820523	chr7:1160374~1165267:+
THCA	cis	rs10089	1	rs4836360	ENSG00000245937.6	LINC01184	3.67	0.000268	0.0182	0.19	0.17	Ileal carcinoids;	chr5:128122469	chr5:127940426~128083172:-
THCA	cis	rs2243480	1	rs7456042	ENSG00000273024.4	INTS4P2	3.67	0.000268	0.0182	0.28	0.17	Diabetic kidney disease;	chr7:65834791	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs73142121	ENSG00000273024.4	INTS4P2	3.67	0.000268	0.0182	0.28	0.17	Diabetic kidney disease;	chr7:65846219	chr7:65647864~65715661:+
THCA	cis	rs9650657	0.836	rs1073913	ENSG00000255310.2	AF131215.2	-3.67	0.000268	0.0182	-0.14	-0.17	Neuroticism;	chr8:10754198	chr8:11107788~11109726:-
THCA	cis	rs950169	0.922	rs62028133	ENSG00000188388.10	GOLGA6L3	3.67	0.000268	0.0182	0.22	0.17	Schizophrenia;	chr15:84250623	chr15:85240472~85247170:+
THCA	cis	rs950169	0.723	rs17589320	ENSG00000188388.10	GOLGA6L3	3.67	0.000268	0.0182	0.22	0.17	Schizophrenia;	chr15:84251244	chr15:85240472~85247170:+
THCA	cis	rs7208859	0.615	rs216462	ENSG00000265443.1	CTD-2349P21.6	3.67	0.000268	0.0182	0.29	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30726305~30727564:-
THCA	cis	rs12478296	0.591	rs6746311	ENSG00000220804.7	AC093642.5	3.67	0.000268	0.0182	0.16	0.17	Obesity-related traits;	chr2:242059128	chr2:242088633~242160153:+
THCA	cis	rs6929812	0.664	rs12529840	ENSG00000271755.1	RP1-153G14.4	3.67	0.000268	0.0182	0.19	0.17	Neuroticism (multi-trait analysis);	chr6:27426105	chr6:27404010~27406964:-
THCA	cis	rs875971	0.522	rs9530	ENSG00000275400.1	RP4-756H11.5	-3.67	0.000268	0.0182	-0.16	-0.17	Aortic root size;	chr7:65960907	chr7:66553805~66554199:-
THCA	cis	rs950169	0.881	rs4842852	ENSG00000188388.10	GOLGA6L3	3.67	0.000268	0.0182	0.23	0.17	Schizophrenia;	chr15:84387263	chr15:85240472~85247170:+
THCA	cis	rs950169	0.84	rs4842853	ENSG00000188388.10	GOLGA6L3	3.67	0.000268	0.0182	0.23	0.17	Schizophrenia;	chr15:84387606	chr15:85240472~85247170:+
THCA	cis	rs950169	0.922	rs4842946	ENSG00000188388.10	GOLGA6L3	3.67	0.000268	0.0182	0.23	0.17	Schizophrenia;	chr15:84387633	chr15:85240472~85247170:+
THCA	cis	rs950169	0.84	rs4842854	ENSG00000188388.10	GOLGA6L3	3.67	0.000268	0.0182	0.23	0.17	Schizophrenia;	chr15:84387641	chr15:85240472~85247170:+
THCA	cis	rs9527	0.83	rs10883790	ENSG00000236937.2	PTGES3P4	3.67	0.000268	0.0182	0.24	0.17	Arsenic metabolism;	chr10:102881198	chr10:102845595~102845950:+
THCA	cis	rs9527	0.83	rs11191440	ENSG00000236937.2	PTGES3P4	3.67	0.000268	0.0182	0.24	0.17	Arsenic metabolism;	chr10:102881754	chr10:102845595~102845950:+
THCA	cis	rs7522061	0.565	rs6695840	ENSG00000236731.1	RP4-801G22.2	3.67	0.000268	0.0182	0.17	0.17	Blood protein levels;	chr1:157675906	chr1:157629939~157630728:-
THCA	cis	rs10457678	0.579	rs11155008	ENSG00000225415.2	RP3-509I19.1	-3.67	0.000268	0.0182	-0.23	-0.17	Colorectal or endometrial cancer;	chr6:138816363	chr6:138822747~138823799:+
THCA	cis	rs9876781	1	rs9881491	ENSG00000199476.1	Y_RNA	-3.67	0.000268	0.0182	-0.21	-0.17	Longevity;	chr3:48446507	chr3:48288587~48288694:+
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000219891.2	ZSCAN12P1	3.67	0.000268	0.0182	0.23	0.17	Parkinson's disease;	chr6:28055973	chr6:28091154~28093664:+
THCA	cis	rs4950322	1	rs72694715	ENSG00000180867.10	PDIA3P1	3.67	0.000268	0.0182	0.18	0.17	Protein quantitative trait loci;	chr1:147368468	chr1:147178113~147179622:+
THCA	cis	rs2562456	0.833	rs55875743	ENSG00000268521.1	VN1R83P	3.67	0.000268	0.0182	0.16	0.17	Pain;	chr19:21383393	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs62110416	ENSG00000268521.1	VN1R83P	3.67	0.000268	0.0182	0.16	0.17	Pain;	chr19:21401924	chr19:21289554~21289998:-
THCA	cis	rs4767841	0.565	rs440299	ENSG00000252886.1	RN7SKP197	-3.67	0.000268	0.0182	-0.16	-0.17	Urgency urinary incontinence;	chr12:119782478	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.565	rs385959	ENSG00000252886.1	RN7SKP197	-3.67	0.000268	0.0182	-0.16	-0.17	Urgency urinary incontinence;	chr12:119782785	chr12:119631090~119631386:-
THCA	cis	rs4708832	0.529	rs240863	ENSG00000216480.2	RP3-393E18.1	3.67	0.000268	0.0182	0.27	0.17	QRS duration;	chr6:159494793	chr6:159526062~159526527:-
THCA	cis	rs2667011	0.512	rs61094689	ENSG00000226266.5	AC009961.3	-3.67	0.000268	0.0182	-0.24	-0.17	Bilirubin levels;	chr2:159941086	chr2:159670708~159712435:-
THCA	cis	rs1923243	0.714	rs12143820	ENSG00000223479.3	RP4-788P17.1	3.67	0.000268	0.0182	0.18	0.17	Migraine;	chr1:73050778	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.749	rs12410787	ENSG00000223479.3	RP4-788P17.1	3.67	0.000268	0.0182	0.18	0.17	Migraine;	chr1:73056906	chr1:73635216~73715214:+
THCA	cis	rs2455799	0.574	rs2455800	ENSG00000270409.1	RP11-44D5.1	-3.67	0.000268	0.0182	-0.17	-0.17	Mean platelet volume;	chr3:15660082	chr3:15732252~15733470:+
THCA	cis	rs7246967	0.551	rs12974117	ENSG00000236312.3	RPL34P34	-3.67	0.000269	0.0182	-0.24	-0.17	Bronchopulmonary dysplasia;	chr19:22685074	chr19:22368599~22368952:-
THCA	cis	rs2694917	0.68	rs1043011	ENSG00000257576.1	RP11-153M3.1	3.67	0.000269	0.0182	0.26	0.17	Blood metabolite ratios;	chr12:56471256	chr12:56511002~56512703:+
THCA	cis	rs2179367	0.632	rs9498325	ENSG00000216906.2	RP11-350J20.9	3.67	0.000269	0.0182	0.21	0.17	Dupuytren's disease;	chr6:149345993	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498326	ENSG00000216906.2	RP11-350J20.9	3.67	0.000269	0.0182	0.21	0.17	Dupuytren's disease;	chr6:149346112	chr6:149904243~149906418:+
THCA	cis	rs9487094	0.666	rs736830	ENSG00000223537.2	RP5-919F19.5	-3.67	0.000269	0.0182	-0.17	-0.17	Height;	chr6:109392096	chr6:109487906~109506800:+
THCA	cis	rs2013441	0.866	rs17686622	ENSG00000261033.1	RP11-209D14.2	3.67	0.000269	0.0182	0.24	0.17	Obesity-related traits;	chr17:20117051	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs2703797	ENSG00000261033.1	RP11-209D14.2	3.67	0.000269	0.0182	0.24	0.17	Obesity-related traits;	chr17:20176988	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.795	rs6587064	ENSG00000261033.1	RP11-209D14.2	3.67	0.000269	0.0182	0.24	0.17	Obesity-related traits;	chr17:20304571	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs12949485	ENSG00000261033.1	RP11-209D14.2	-3.67	0.000269	0.0182	-0.24	-0.17	Obesity-related traits;	chr17:20118348	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs62067558	ENSG00000261033.1	RP11-209D14.2	-3.67	0.000269	0.0182	-0.24	-0.17	Obesity-related traits;	chr17:20122393	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs12947950	ENSG00000261033.1	RP11-209D14.2	-3.67	0.000269	0.0182	-0.24	-0.17	Obesity-related traits;	chr17:20141863	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs10438824	ENSG00000261033.1	RP11-209D14.2	-3.67	0.000269	0.0182	-0.24	-0.17	Obesity-related traits;	chr17:20155197	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs1009082	ENSG00000261033.1	RP11-209D14.2	-3.67	0.000269	0.0182	-0.24	-0.17	Obesity-related traits;	chr17:20159646	chr17:20008051~20009234:-
THCA	cis	rs972578	0.837	rs1983647	ENSG00000230319.1	AL022476.2	3.67	0.000269	0.0182	0.18	0.17	Mean platelet volume;	chr22:42859176	chr22:43038585~43052366:+
THCA	cis	rs972578	0.837	rs5751390	ENSG00000230319.1	AL022476.2	3.67	0.000269	0.0182	0.18	0.17	Mean platelet volume;	chr22:42863535	chr22:43038585~43052366:+
THCA	cis	rs7829975	0.711	rs4481596	ENSG00000253981.4	ALG1L13P	3.67	0.000269	0.0182	0.16	0.17	Mood instability;	chr8:8846820	chr8:8236003~8244667:-
THCA	cis	rs4814894	1	rs4814894	ENSG00000236992.2	RPL12L3	-3.67	0.000269	0.0182	-0.17	-0.17	Breast cancer;	chr20:19772894	chr20:19823443~19823943:-
THCA	cis	rs586716	0.506	rs72697747	ENSG00000224549.1	RP11-370B11.3	3.67	0.000269	0.0182	0.2	0.17	Tuberculosis;	chr9:22510397	chr9:22767175~22768316:+
THCA	cis	rs4262150	0.726	rs67979431	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152632877	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.726	rs9324734	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152633235	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.726	rs6884556	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152633756	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.726	rs10515675	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152634229	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.726	rs10515676	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152634327	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.689	rs4958566	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152634501	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.69	rs6871699	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152635106	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.726	rs6895969	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152635648	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.726	rs4958567	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152636037	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.726	rs4958569	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152636545	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.726	rs4406125	ENSG00000253921.1	CTB-113P19.3	3.67	0.000269	0.0182	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:152637034	chr5:151753992~151767247:+
THCA	cis	rs9291683	0.509	rs6849717	ENSG00000261490.1	RP11-448G15.3	-3.67	0.000269	0.0182	-0.1	-0.17	Bone mineral density;	chr4:9957095	chr4:10068089~10073019:-
THCA	cis	rs2905347	0.755	rs2961288	ENSG00000232949.1	AC002480.4	-3.67	0.000269	0.0182	-0.21	-0.17	Major depression and alcohol dependence;	chr7:22625510	chr7:22589705~22591622:+
THCA	cis	rs2228479	0.702	rs62052710	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89788485	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs11076624	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89789341	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs2238531	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89789809	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62052714	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89790772	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs11646374	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89791527	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs1800331	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89792009	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs62053701	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89794176	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs62053702	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89794280	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.618	rs34689166	ENSG00000274627.1	RP11-104N10.2	-3.67	0.000269	0.0182	-0.3	-0.17	Skin colour saturation;	chr16:89794289	chr16:89516797~89522217:+
THCA	cis	rs897984	0.609	rs732173	ENSG00000275263.1	RP11-1072A3.4	-3.67	0.000269	0.0182	-0.2	-0.17	Dementia with Lewy bodies;	chr16:31038702	chr16:30956872~30957199:-
THCA	cis	rs7520050	0.897	rs4440807	ENSG00000280836.1	AL355480.1	3.67	0.000269	0.0182	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:45581219~45581321:-
THCA	cis	rs11992162	0.967	rs7461062	ENSG00000255046.1	RP11-297N6.4	-3.67	0.000269	0.0182	-0.18	-0.17	Monocyte count;	chr8:11974439	chr8:11797928~11802568:-
THCA	cis	rs295490	0.748	rs76778175	ENSG00000272656.1	RP11-219D15.3	3.67	0.000269	0.0182	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139440213	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs78230813	ENSG00000272656.1	RP11-219D15.3	3.67	0.000269	0.0182	0.32	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441345	chr3:139349024~139349371:-
THCA	cis	rs3820928	0.605	rs2228555	ENSG00000212391.1	SNORA48	3.67	0.000269	0.0182	0.18	0.17	Pulmonary function;	chr2:227008279	chr2:226968989~226969122:-
THCA	cis	rs57709857	0.957	rs4647905	ENSG00000272092.1	RP11-350N15.5	-3.67	0.000269	0.0182	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38415024	chr8:38382364~38383461:+
THCA	cis	rs7572644	0.941	rs2337700	ENSG00000223522.1	AC093690.1	-3.67	0.000269	0.0182	-0.2	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28084076	chr2:28307691~28310459:-
THCA	cis	rs2832191	0.716	rs7284006	ENSG00000176054.6	RPL23P2	3.67	0.000269	0.0182	0.15	0.17	Dental caries;	chr21:29102865	chr21:28997613~28998033:-
THCA	cis	rs57709857	0.957	rs55634742	ENSG00000272092.1	RP11-350N15.5	-3.67	0.000269	0.0182	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38333416	chr8:38382364~38383461:+
THCA	cis	rs5753037	0.543	rs140119	ENSG00000273350.1	RP4-539M6.20	-3.67	0.000269	0.0182	-0.19	-0.17	Type 1 diabetes;	chr22:29742160	chr22:30420512~30420912:+
THCA	cis	rs9427116	0.531	rs35504625	ENSG00000236675.1	MTX1P1	-3.67	0.000269	0.0182	-0.15	-0.17	Blood protein levels;	chr1:154627302	chr1:155230975~155234325:+
THCA	cis	rs7777677	0.925	rs4726546	ENSG00000226660.2	TRBV2	3.67	0.000269	0.0182	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142300924~142301432:+
THCA	cis	rs7777677	0.925	rs6960743	ENSG00000226660.2	TRBV2	3.67	0.000269	0.0182	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142300924~142301432:+
THCA	cis	rs7777677	0.925	rs6956756	ENSG00000226660.2	TRBV2	3.67	0.000269	0.0182	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142300924~142301432:+
THCA	cis	rs7777677	0.889	rs6975391	ENSG00000226660.2	TRBV2	3.67	0.000269	0.0182	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142300924~142301432:+
THCA	cis	rs7777677	0.925	rs9655661	ENSG00000226660.2	TRBV2	3.67	0.000269	0.0182	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142300924~142301432:+
THCA	cis	rs7777677	0.888	rs9655574	ENSG00000226660.2	TRBV2	3.67	0.000269	0.0182	0.14	0.17	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142300924~142301432:+
THCA	cis	rs7632954	0.567	rs9813104	ENSG00000227110.5	LMCD1-AS1	3.67	0.000269	0.0182	0.2	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8492807	chr3:7952805~8611924:-
THCA	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-3.67	0.000269	0.0182	-0.2	-0.17	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
THCA	cis	rs1862618	0.671	rs173763	ENSG00000271828.1	CTD-2310F14.1	3.67	0.000269	0.0182	0.23	0.17	Initial pursuit acceleration;	chr5:56929591	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.62	rs189695	ENSG00000271828.1	CTD-2310F14.1	3.67	0.000269	0.0182	0.23	0.17	Initial pursuit acceleration;	chr5:56929942	chr5:56927874~56929573:+
THCA	cis	rs2898290	0.622	rs4840567	ENSG00000270154.1	RP11-419I17.1	-3.67	0.000269	0.0182	-0.21	-0.17	Systolic blood pressure;	chr8:11490116	chr8:12476462~12477122:+
THCA	cis	rs12049671	0.932	rs10765179	ENSG00000227076.1	RP11-4C20.4	3.67	0.000269	0.0182	0.18	0.17	Response to amphetamines;	chr10:127949479	chr10:127934698~127936167:+
THCA	cis	rs11105298	0.891	rs10858889	ENSG00000266347.2	AC068641.1	3.67	0.000269	0.0182	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs11105309	ENSG00000266347.2	AC068641.1	3.67	0.000269	0.0182	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89592833~89592927:+
THCA	cis	rs420259	0.516	rs6497664	ENSG00000260136.4	CTD-2270L9.4	-3.67	0.000269	0.0182	-0.13	-0.17	Bipolar disorder;	chr16:23474032	chr16:23452758~23457606:+
THCA	cis	rs2562456	1	rs2562456	ENSG00000268658.4	LINC00664	3.67	0.000269	0.0182	0.23	0.17	Pain;	chr19:21483408	chr19:21483374~21503238:+
THCA	cis	rs7572733	0.935	rs6434946	ENSG00000231621.1	AC013264.2	-3.67	0.000269	0.0182	-0.16	-0.17	Dermatomyositis;	chr2:197933773	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs1105078	ENSG00000231621.1	AC013264.2	-3.67	0.000269	0.0182	-0.16	-0.17	Dermatomyositis;	chr2:197943161	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs1518366	ENSG00000231621.1	AC013264.2	-3.67	0.000269	0.0182	-0.16	-0.17	Dermatomyositis;	chr2:197944472	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs1914690	ENSG00000231621.1	AC013264.2	-3.67	0.000269	0.0182	-0.16	-0.17	Dermatomyositis;	chr2:197944644	chr2:197197991~197199273:+
THCA	cis	rs9314614	0.789	rs2951863	ENSG00000245857.2	GS1-24F4.2	3.67	0.000269	0.0182	0.21	0.17	White blood cell count (basophil);IgA nephropathy;	chr8:6852980	chr8:6835554~6885276:+
THCA	cis	rs2522056	1	rs2057655	ENSG00000237714.1	P4HA2-AS1	3.67	0.000269	0.0182	0.24	0.17	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132184876~132192808:+
THCA	cis	rs332034	0.546	rs28823269	ENSG00000254153.1	CTA-398F10.2	3.67	0.000269	0.0182	0.27	0.17	Conduct disorder (maternal expressed emotions interaction);	chr8:8833007	chr8:8456909~8461337:-
THCA	cis	rs35740288	0.787	rs2291047	ENSG00000259407.1	RP11-158M2.3	-3.67	0.000269	0.0182	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682574	chr15:85744109~85750281:-
THCA	cis	rs6142618	0.777	rs6058635	ENSG00000224452.1	RSL24D1P6	3.67	0.000269	0.0182	0.21	0.17	Inflammatory bowel disease;	chr20:32304122	chr20:32170390~32170790:-
THCA	cis	rs4845570	0.749	rs11576810	ENSG00000249602.1	RP11-98D18.3	-3.67	0.000269	0.0182	-0.27	-0.17	Coronary artery disease;	chr1:151739725	chr1:151763384~151769501:-
THCA	cis	rs721917	0.531	rs2758553	ENSG00000225484.5	NUTM2B-AS1	3.67	0.000269	0.0182	0.2	0.17	Chronic obstructive pulmonary disease;	chr10:79931624	chr10:79663088~79826594:-
THCA	cis	rs721917	0.531	rs2758551	ENSG00000225484.5	NUTM2B-AS1	3.67	0.000269	0.0182	0.2	0.17	Chronic obstructive pulmonary disease;	chr10:79932184	chr10:79663088~79826594:-
THCA	cis	rs7829975	0.902	rs777707	ENSG00000254340.1	RP11-10A14.3	3.67	0.000269	0.0182	0.18	0.17	Mood instability;	chr8:8726834	chr8:9141424~9145435:+
THCA	cis	rs9549367	0.577	rs7335409	ENSG00000269125.1	RP11-98F14.11	3.67	0.000269	0.0182	0.22	0.17	Platelet distribution width;	chr13:113155872	chr13:113165002~113165183:-
THCA	cis	rs7267979	1	rs6050573	ENSG00000276952.1	RP5-965G21.6	3.67	0.000269	0.0182	0.17	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25284915~25285588:-
THCA	cis	rs754466	0.606	rs55854323	ENSG00000213514.2	RP11-428P16.2	3.67	0.000269	0.0182	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77830146	chr10:77730766~77734769:+
THCA	cis	rs12216125	0.554	rs6942196	ENSG00000272810.1	U91328.22	-3.67	0.000269	0.0182	-0.13	-0.17	Iron status biomarkers;	chr6:26072576	chr6:26013241~26013757:+
THCA	cis	rs7312933	0.558	rs11181507	ENSG00000257225.1	RP11-328C8.4	-3.67	0.000269	0.0182	-0.17	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42450961	chr12:42459366~42466128:+
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000230373.7	GOLGA6L5P	-3.67	0.000269	0.0182	-0.16	-0.17	P wave terminal force;	chr15:84654022	chr15:84507885~84516814:-
THCA	cis	rs2933343	0.601	rs1680759	ENSG00000261159.1	RP11-723O4.9	3.67	0.000269	0.0182	0.17	0.17	IgG glycosylation;	chr3:128876053	chr3:128859716~128860526:-
THCA	cis	rs62045849	0.557	rs3743982	ENSG00000259877.2	RP11-46C24.7	3.67	0.000269	0.0182	0.19	0.17	Red blood cell count;	chr16:89114731	chr16:89215211~89217653:-
THCA	cis	rs720475	0.732	rs17195725	ENSG00000170356.8	OR2A20P	-3.67	0.000269	0.0182	-0.24	-0.17	Breast cancer;	chr7:144440044	chr7:144250045~144252957:-
THCA	cis	rs9488822	0.676	rs10456902	ENSG00000233558.1	RP3-486I3.4	-3.67	0.000269	0.0182	-0.19	-0.17	LDL cholesterol;Cholesterol, total;	chr6:116012579	chr6:116258493~116259115:-
THCA	cis	rs5753037	0.504	rs140114	ENSG00000273350.1	RP4-539M6.20	-3.67	0.00027	0.0182	-0.19	-0.17	Type 1 diabetes;	chr22:29737892	chr22:30420512~30420912:+
THCA	cis	rs150992	0.638	rs466340	ENSG00000246763.5	RGMB-AS1	3.67	0.00027	0.0182	0.17	0.17	Body mass index;	chr5:98904318	chr5:98769618~98773469:-
THCA	cis	rs150992	0.673	rs326463	ENSG00000246763.5	RGMB-AS1	3.67	0.00027	0.0182	0.17	0.17	Body mass index;	chr5:98905785	chr5:98769618~98773469:-
THCA	cis	rs150992	0.673	rs327792	ENSG00000246763.5	RGMB-AS1	3.67	0.00027	0.0182	0.17	0.17	Body mass index;	chr5:98909802	chr5:98769618~98773469:-
THCA	cis	rs1005277	0.579	rs1780116	ENSG00000120555.12	SEPT7P9	3.67	0.00027	0.0182	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780121	ENSG00000120555.12	SEPT7P9	3.67	0.00027	0.0182	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780122	ENSG00000120555.12	SEPT7P9	3.67	0.00027	0.0182	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780145	ENSG00000120555.12	SEPT7P9	3.67	0.00027	0.0182	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38383069~38402916:-
THCA	cis	rs4834770	1	rs878375	ENSG00000260091.1	RP11-33B1.4	-3.67	0.00027	0.0182	-0.12	-0.17	Blood protein levels;	chr4:119316419	chr4:119409333~119410233:+
THCA	cis	rs7911117	0.611	rs17754882	ENSG00000215409.4	RP11-748L13.2	3.67	0.00027	0.0182	0.31	0.17	Ulcerative colitis;	chr10:26909358	chr10:27331357~27341252:-
THCA	cis	rs7259376	1	rs11668269	ENSG00000269345.1	VN1R85P	3.67	0.00027	0.0182	0.18	0.17	Menopause (age at onset);	chr19:22331158	chr19:22174766~22175191:-
THCA	cis	rs4073416	0.542	rs9323460	ENSG00000276116.2	FUT8-AS1	3.67	0.00027	0.0182	0.19	0.17	N-glycan levels;	chr14:65466481	chr14:65411170~65412690:-
THCA	cis	rs56390833	1	rs56390833	ENSG00000261762.1	RP11-650L12.2	-3.67	0.00027	0.0182	-0.22	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78585039	chr15:78589123~78591276:-
THCA	cis	rs3743162	1	rs12909280	ENSG00000275120.1	RP11-182J1.17	3.67	0.00027	0.0183	0.2	0.17	Alzheimer's disease (age of onset);	chr15:84886125	chr15:84599434~84606463:-
THCA	cis	rs10483853	0.54	rs2108552	ENSG00000258695.2	RP3-414A15.2	-3.67	0.00027	0.0183	-0.25	-0.17	Coronary artery calcification;	chr14:73410218	chr14:73522878~73530610:+
THCA	cis	rs3755605	0.664	rs1798239	ENSG00000242578.1	RP11-469J4.3	3.67	0.00027	0.0183	0.18	0.17	Testicular germ cell tumor;	chr3:170197165	chr3:170410512~170418615:+
THCA	cis	rs2880765	0.835	rs7161880	ENSG00000218052.5	ADAMTS7P4	-3.67	0.00027	0.0183	-0.19	-0.17	Coronary artery disease;	chr15:85475515	chr15:85255369~85330334:-
THCA	cis	rs1023500	0.573	rs2269524	ENSG00000270083.1	RP1-257I20.14	-3.67	0.00027	0.0183	-0.19	-0.17	Schizophrenia;	chr22:42079699	chr22:42089630~42090028:-
THCA	cis	rs701145	0.585	rs1713810	ENSG00000238755.3	RP11-23D24.2	-3.67	0.00027	0.0183	-0.34	-0.17	Coronary artery disease;	chr3:154159037	chr3:153384934~153980186:-
THCA	cis	rs7560272	0.512	rs13026192	ENSG00000273245.1	RP11-434P11.2	-3.67	0.00027	0.0183	-0.19	-0.17	Schizophrenia;	chr2:73699945	chr2:73750256~73750786:-
THCA	cis	rs2191566	0.576	rs421505	ENSG00000277806.1	RP11-15A1.8	3.67	0.00027	0.0183	0.17	0.17	Acute lymphoblastic leukemia (childhood);	chr19:43991993	chr19:43976815~43977448:+
THCA	cis	rs3892630	0.824	rs12976069	ENSG00000267475.1	CTD-2538C1.2	-3.67	0.00027	0.0183	-0.24	-0.17	Red blood cell traits;	chr19:32789178	chr19:32687089~32691750:-
THCA	cis	rs7551222	0.752	rs12125533	ENSG00000240219.1	RP11-430C7.5	3.67	0.00027	0.0183	0.15	0.17	Schizophrenia;	chr1:204560174	chr1:204626775~204629712:+
THCA	cis	rs2640806	0.506	rs13254991	ENSG00000253105.4	KB-1448A5.1	3.67	0.00027	0.0183	0.2	0.17	Obesity-related traits;	chr8:96359458	chr8:96371865~96387438:-
THCA	cis	rs7737355	0.947	rs2021774	ENSG00000237714.1	P4HA2-AS1	3.67	0.00027	0.0183	0.24	0.17	Life satisfaction;	chr5:131585138	chr5:132184876~132192808:+
THCA	cis	rs12101261	0.744	rs724169	ENSG00000258915.1	BHLHB9P1	-3.67	0.00027	0.0183	-0.21	-0.17	Graves' disease;	chr14:80991512	chr14:80981988~80983638:+
THCA	cis	rs4073416	0.527	rs1959144	ENSG00000276116.2	FUT8-AS1	3.67	0.00027	0.0183	0.19	0.17	N-glycan levels;	chr14:65479333	chr14:65411170~65412690:-
THCA	cis	rs7188445	0.592	rs7199794	ENSG00000277954.1	RP11-679B19.1	3.67	0.00027	0.0183	0.18	0.17	Urate levels;	chr16:79708296	chr16:79202624~79206739:-
THCA	cis	rs1153858	1	rs7181167	ENSG00000275672.1	GATM-AS1	-3.67	0.00027	0.0183	-0.17	-0.17	Homoarginine levels;	chr15:45394038	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs11070456	ENSG00000275672.1	GATM-AS1	-3.67	0.00027	0.0183	-0.17	-0.17	Homoarginine levels;	chr15:45394637	chr15:45378700~45380123:+
THCA	cis	rs6058526	0.631	rs6119230	ENSG00000235217.6	TSPY26P	-3.67	0.00027	0.0183	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr20:32262171	chr20:32186477~32190527:-
THCA	cis	rs1864585	0.52	rs1549793	ENSG00000280294.1	RP11-177H2.1	3.67	0.00027	0.0183	0.17	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10798254	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs55637012	ENSG00000280294.1	RP11-177H2.1	3.67	0.00027	0.0183	0.17	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10799229	chr8:10856085~10859436:-
THCA	cis	rs1577917	0.958	rs4707236	ENSG00000220563.1	PKMP3	-3.67	0.00027	0.0183	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85874249	chr6:85659892~85660606:-
THCA	cis	rs7074356	0.704	rs1417220	ENSG00000242600.5	MBL1P	3.67	0.00027	0.0183	0.18	0.17	Borderline personality disorder;	chr10:80408398	chr10:79904898~79950336:+
THCA	cis	rs7916697	0.626	rs3858144	ENSG00000233590.1	RP11-153K11.3	-3.67	0.00027	0.0183	-0.21	-0.17	Optic disc area;	chr10:68251597	chr10:68233251~68242379:-
THCA	cis	rs14027	0.921	rs12542706	ENSG00000245330.4	KB-1471A8.1	3.67	0.00027	0.0183	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119867419~119874488:-
THCA	cis	rs2179367	0.92	rs638407	ENSG00000223701.3	RAET1E-AS1	3.67	0.00027	0.0183	0.22	0.17	Dupuytren's disease;	chr6:149417214	chr6:149884431~149919508:+
THCA	cis	rs12823128	0.904	rs10842784	ENSG00000256185.1	RP11-612B6.2	3.67	0.00027	0.0183	0.16	0.17	Birth weight;	chr12:26704648	chr12:26335864~26336950:-
THCA	cis	rs2074409	0.509	rs853231	ENSG00000275839.1	CTC-421K24.1	-3.67	0.00027	0.0183	-0.2	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37454281	chr17:37454171~37454931:+
THCA	cis	rs11671005	0.735	rs11084544	ENSG00000269600.1	AC016629.3	-3.67	0.00027	0.0183	-0.25	-0.17	Mean platelet volume;	chr19:58428760	chr19:58593896~58599355:-
THCA	cis	rs7937890	0.559	rs1116739	ENSG00000251991.1	RNU7-49P	3.67	0.00027	0.0183	0.19	0.17	Mitochondrial DNA levels;	chr11:14467636	chr11:14478892~14478953:+
THCA	cis	rs9863	0.861	rs10846580	ENSG00000270028.1	RP11-380L11.4	3.67	0.00027	0.0183	0.18	0.17	White blood cell count;	chr12:123930906	chr12:123925461~123926083:-
THCA	cis	rs427943	0.75	rs6518214	ENSG00000223768.1	LINC00205	-3.67	0.00027	0.0183	-0.15	-0.17	Body mass index;	chr21:45181784	chr21:45293285~45297354:+
THCA	cis	rs7119038	0.818	rs73003215	ENSG00000255422.1	AP002954.4	3.67	0.00027	0.0183	0.2	0.17	Sjögren's syndrome;	chr11:118778803	chr11:118704607~118750263:+
THCA	cis	rs6546550	0.867	rs4401231	ENSG00000179818.12	PCBP1-AS1	-3.67	0.00027	0.0183	-0.13	-0.17	Prevalent atrial fibrillation;	chr2:69836431	chr2:69962263~70103220:-
THCA	cis	rs10425465	0.513	rs12150970	ENSG00000267296.2	CEBPA-AS1	3.67	0.00027	0.0183	0.21	0.17	Schizophrenia;	chr19:33436565	chr19:33302857~33305054:+
THCA	cis	rs4073416	0.51	rs2268956	ENSG00000276116.2	FUT8-AS1	3.67	0.00027	0.0183	0.19	0.17	N-glycan levels;	chr14:65623427	chr14:65411170~65412690:-
THCA	cis	rs6902257	0.59	rs2503727	ENSG00000233967.5	RP11-250B2.3	3.67	0.00027	0.0183	0.34	0.17	Obesity-related traits;	chr6:80601100	chr6:80443344~80465927:+
THCA	cis	rs8002861	0.691	rs9525851	ENSG00000274001.1	RP11-5G9.5	-3.67	0.00027	0.0183	-0.2	-0.17	Leprosy;	chr13:43827996	chr13:43877715~43878163:-
THCA	cis	rs8002861	0.754	rs7330760	ENSG00000274001.1	RP11-5G9.5	-3.67	0.00027	0.0183	-0.2	-0.17	Leprosy;	chr13:43828952	chr13:43877715~43878163:-
THCA	cis	rs733175	0.855	rs6853437	ENSG00000261490.1	RP11-448G15.3	-3.67	0.00027	0.0183	-0.13	-0.17	Psychosis and Alzheimer's disease;	chr4:10003811	chr4:10068089~10073019:-
THCA	cis	rs17023223	0.537	rs12092807	ENSG00000227056.2	RPL6P2	3.67	0.00027	0.0183	0.23	0.17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119219314~119220096:-
THCA	cis	rs7572733	0.935	rs1518360	ENSG00000231621.1	AC013264.2	3.67	0.00027	0.0183	0.16	0.17	Dermatomyositis;	chr2:197950579	chr2:197197991~197199273:+
THCA	cis	rs7267979	0.873	rs6115093	ENSG00000276952.1	RP5-965G21.6	3.67	0.00027	0.0183	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25284915~25285588:-
THCA	cis	rs9863	0.861	rs12317176	ENSG00000269938.1	RP11-214K3.20	-3.67	0.00027	0.0183	-0.19	-0.17	White blood cell count;	chr12:123920171	chr12:123968023~123968579:-
THCA	cis	rs9393777	0.777	rs56114371	ENSG00000272009.1	RP1-313I6.12	-3.67	0.00027	0.0183	-0.32	-0.17	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28078792~28081130:-
THCA	cis	rs4578769	0.569	rs4800431	ENSG00000273232.1	RP11-370A5.2	3.67	0.00027	0.0183	0.23	0.17	Eosinophil percentage of white cells;	chr18:22803499	chr18:22882825~22883357:-
THCA	cis	rs6600671	1	rs4844607	ENSG00000226067.5	CH17-118O6.2	-3.67	0.00027	0.0183	-0.16	-0.17	Hip geometry;	chr1:121442201	chr1:120913275~121009291:+
THCA	cis	rs478304	0.654	rs11227260	ENSG00000214659.4	KRT8P26	3.67	0.00027	0.0183	0.16	0.17	Acne (severe);	chr11:65693687	chr11:65726939~65728214:+
THCA	cis	rs972578	0.715	rs4820483	ENSG00000230319.1	AL022476.2	3.67	0.00027	0.0183	0.18	0.17	Mean platelet volume;	chr22:42792174	chr22:43038585~43052366:+
THCA	cis	rs972578	0.806	rs4822225	ENSG00000274717.1	RP1-47A17.1	-3.67	0.00027	0.0183	-0.17	-0.17	Mean platelet volume;	chr22:42914646	chr22:42791814~42794313:-
THCA	cis	rs9980	0.947	rs72783110	ENSG00000226232.7	RP11-419C5.2	-3.67	0.00027	0.0183	-0.25	-0.17	Blood osmolality (transformed sodium);	chr16:69661740	chr16:69976388~69996188:-
THCA	cis	rs11157436	0.56	rs988997	ENSG00000211812.1	TRAV26-2	-3.67	0.000271	0.0183	-0.14	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22225937	chr14:22202583~22203368:+
THCA	cis	rs2360027	0.965	rs10802048	ENSG00000231365.4	RP11-418J17.1	-3.67	0.000271	0.0183	-0.16	-0.17	Tonsillectomy;	chr1:118604656	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.965	rs2135564	ENSG00000231365.4	RP11-418J17.1	-3.67	0.000271	0.0183	-0.16	-0.17	Tonsillectomy;	chr1:118605616	chr1:119140396~119275973:+
THCA	cis	rs7829975	0.5	rs7841082	ENSG00000233609.3	RP11-62H7.2	-3.67	0.000271	0.0183	-0.17	-0.17	Mood instability;	chr8:8311465	chr8:8961200~8979025:+
THCA	cis	rs875971	0.545	rs1638724	ENSG00000232559.3	GS1-124K5.12	-3.67	0.000271	0.0183	-0.18	-0.17	Aortic root size;	chr7:66575494	chr7:66554588~66576923:-
THCA	cis	rs9287719	0.935	rs10803723	ENSG00000243819.4	RN7SL832P	3.67	0.000271	0.0183	0.13	0.17	Prostate cancer;	chr2:10582751	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.935	rs6751075	ENSG00000243819.4	RN7SL832P	3.67	0.000271	0.0183	0.13	0.17	Prostate cancer;	chr2:10583420	chr2:10690344~10692099:+
THCA	cis	rs12823128	0.87	rs895964	ENSG00000256185.1	RP11-612B6.2	3.67	0.000271	0.0183	0.16	0.17	Birth weight;	chr12:26705133	chr12:26335864~26336950:-
THCA	cis	rs4908768	0.539	rs6663123	ENSG00000270282.1	RP5-1115A15.2	3.67	0.000271	0.0183	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8512653~8513021:+
THCA	cis	rs12681366	0.537	rs9297939	ENSG00000253175.1	RP11-267M23.6	3.67	0.000271	0.0183	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94467961	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.564	rs10808669	ENSG00000253175.1	RP11-267M23.6	3.67	0.000271	0.0183	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94468833	chr8:94565036~94565715:+
THCA	cis	rs11710088	1	rs11710088	ENSG00000240541.2	TM4SF1-AS1	3.67	0.000271	0.0183	0.16	0.17	QRS duration;	chr3:149475320	chr3:149377778~149386583:+
THCA	cis	rs67981189	0.896	rs12100737	ENSG00000269927.1	RP6-91H8.3	-3.67	0.000271	0.0183	-0.19	-0.17	Schizophrenia;	chr14:71004383	chr14:71141125~71143253:-
THCA	cis	rs2638953	0.853	rs11049678	ENSG00000247934.4	RP11-967K21.1	-3.67	0.000271	0.0183	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505546	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.888	rs10843189	ENSG00000247934.4	RP11-967K21.1	-3.67	0.000271	0.0183	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506985	chr12:28163298~28190738:-
THCA	cis	rs1371614	0.635	rs34803465	ENSG00000229122.1	AGBL5-IT1	-3.67	0.000271	0.0183	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26915417	chr2:27061038~27061815:+
THCA	cis	rs9894429	0.69	rs12949956	ENSG00000262049.1	RP13-1032I1.7	-3.67	0.000271	0.0183	-0.1	-0.17	Eye color traits;	chr17:81575787	chr17:81701324~81703300:-
THCA	cis	rs4664304	0.62	rs12692568	ENSG00000226266.5	AC009961.3	-3.67	0.000271	0.0183	-0.19	-0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159861929	chr2:159670708~159712435:-
THCA	cis	rs9287719	0.967	rs12622765	ENSG00000243819.4	RN7SL832P	3.67	0.000271	0.0183	0.13	0.17	Prostate cancer;	chr2:10588205	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs759402	ENSG00000243819.4	RN7SL832P	3.67	0.000271	0.0183	0.13	0.17	Prostate cancer;	chr2:10589428	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs759403	ENSG00000243819.4	RN7SL832P	3.67	0.000271	0.0183	0.13	0.17	Prostate cancer;	chr2:10589771	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs11674433	ENSG00000243819.4	RN7SL832P	3.67	0.000271	0.0183	0.13	0.17	Prostate cancer;	chr2:10590713	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs2024431	ENSG00000243819.4	RN7SL832P	3.67	0.000271	0.0183	0.13	0.17	Prostate cancer;	chr2:10591201	chr2:10690344~10692099:+
THCA	cis	rs11512640	0.677	rs7935039	ENSG00000254671.2	STT3A-AS1	3.67	0.000271	0.0183	0.45	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125445171	chr11:125570284~125592568:-
THCA	cis	rs9611565	0.532	rs4401299	ENSG00000237037.8	NDUFA6-AS1	-3.67	0.000271	0.0183	-0.15	-0.17	Vitiligo;	chr22:41760513	chr22:42090931~42137742:+
THCA	cis	rs4648045	0.598	rs6833745	ENSG00000246560.2	RP11-10L12.4	3.67	0.000271	0.0183	0.2	0.17	Lymphocyte percentage of white cells;	chr4:102494665	chr4:102828055~102844075:+
THCA	cis	rs2721195	0.967	rs1985022	ENSG00000265393.1	CTD-2517M22.17	-3.67	0.000271	0.0183	-0.21	-0.17	Age at first birth;	chr8:144458648	chr8:144512567~144513672:+
THCA	cis	rs877819	0.583	rs2170133	ENSG00000228403.1	RP11-563N6.6	-3.67	0.000271	0.0183	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48848166	chr10:48878022~48878649:+
THCA	cis	rs8054556	0.647	rs8048433	ENSG00000275371.1	RP11-455F5.6	-3.67	0.000271	0.0183	-0.14	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30110895~30111955:+
THCA	cis	rs7577696	0.671	rs216538	ENSG00000276334.1	AL133243.1	-3.67	0.000271	0.0183	-0.18	-0.17	Inflammatory biomarkers;	chr2:32065262	chr2:32521927~32523547:+
THCA	cis	rs60678552	1	rs60678552	ENSG00000237021.2	RP3-486I3.7	3.67	0.000271	0.0183	0.25	0.17	Heschl's gyrus morphology;	chr6:116289038	chr6:116254207~116256743:+
THCA	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	3.67	0.000271	0.0183	0.19	0.17	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
THCA	cis	rs9929215	0.522	rs13336975	ENSG00000270020.1	RP11-463O9.9	3.67	0.000271	0.0183	0.3	0.17	Colorectal cancer;	chr16:86477836	chr16:86520383~86523897:-
THCA	cis	rs6878727	0.562	rs2633527	ENSG00000253807.4	LINC01170	3.67	0.000271	0.0183	0.15	0.17	Breast cancer;	chr5:124303013	chr5:124059794~124405079:-
THCA	cis	rs2179367	0.632	rs9498324	ENSG00000216906.2	RP11-350J20.9	3.67	0.000271	0.0183	0.21	0.17	Dupuytren's disease;	chr6:149338973	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.586	rs62426088	ENSG00000216906.2	RP11-350J20.9	3.67	0.000271	0.0183	0.21	0.17	Dupuytren's disease;	chr6:149339301	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12204793	ENSG00000216906.2	RP11-350J20.9	3.67	0.000271	0.0183	0.21	0.17	Dupuytren's disease;	chr6:149340102	chr6:149904243~149906418:+
THCA	cis	rs6439699	1	rs6439699	ENSG00000273486.1	RP11-731C17.2	3.67	0.000271	0.0183	0.17	0.17	Intelligence (multi-trait analysis);	chr3:137296645	chr3:136837338~136839021:-
THCA	cis	rs3758911	0.964	rs10890703	ENSG00000255353.1	RP11-382M14.1	-3.67	0.000271	0.0183	-0.22	-0.17	Coronary artery disease;	chr11:107310403	chr11:107176286~107177530:+
THCA	cis	rs2638953	0.815	rs11049669	ENSG00000247934.4	RP11-967K21.1	3.67	0.000271	0.0183	0.17	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498982	chr12:28163298~28190738:-
THCA	cis	rs8077577	0.708	rs59366579	ENSG00000273018.4	CTD-2303H24.2	-3.67	0.000271	0.0183	-0.24	-0.17	Obesity-related traits;	chr17:18258430	chr17:18511221~18551705:-
THCA	cis	rs938554	0.578	rs7663032	ENSG00000261490.1	RP11-448G15.3	3.67	0.000271	0.0183	0.12	0.17	Blood metabolite levels;	chr4:9992214	chr4:10068089~10073019:-
THCA	cis	rs2235642	0.893	rs2143285	ENSG00000260989.1	LA16c-395F10.2	-3.67	0.000271	0.0183	-0.17	-0.17	Coronary artery disease;	chr16:1543170	chr16:1580527~1610328:+
THCA	cis	rs12410462	0.585	rs2644143	ENSG00000227711.2	RP11-275O4.5	-3.67	0.000271	0.0183	-0.2	-0.17	Major depressive disorder;	chr1:227543456	chr1:227509028~227520477:-
THCA	cis	rs78487399	0.908	rs17031092	ENSG00000234936.1	AC010883.5	3.67	0.000271	0.0183	0.2	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43582109	chr2:43229573~43233394:+
THCA	cis	rs6981523	0.5	rs4412337	ENSG00000255495.1	AC145124.2	3.67	0.000271	0.0183	0.2	0.17	Neuroticism;	chr8:11214511	chr8:12194467~12196280:+
THCA	cis	rs57709857	0.915	rs12681196	ENSG00000272092.1	RP11-350N15.5	-3.67	0.000271	0.0183	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38379076	chr8:38382364~38383461:+
THCA	cis	rs12188164	0.965	rs11742144	ENSG00000225138.6	CTD-2228K2.7	3.67	0.000271	0.0184	0.18	0.17	Cystic fibrosis severity;	chr5:422063	chr5:473236~480884:+
THCA	cis	rs7572733	0.555	rs10202569	ENSG00000231621.1	AC013264.2	-3.67	0.000271	0.0184	-0.18	-0.17	Dermatomyositis;	chr2:198070002	chr2:197197991~197199273:+
THCA	cis	rs10886471	0.606	rs4752304	ENSG00000228485.1	GRK5-IT1	3.67	0.000271	0.0184	0.17	0.17	Type 2 diabetes;	chr10:119417031	chr10:119208531~119211760:+
THCA	cis	rs4713118	0.591	rs2056924	ENSG00000216901.1	AL022393.7	3.67	0.000271	0.0184	0.21	0.17	Parkinson's disease;	chr6:27722395	chr6:28176188~28176674:+
THCA	cis	rs13064411	0.696	rs7619913	ENSG00000243849.1	CFAP44-AS1	3.67	0.000271	0.0184	0.26	0.17	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113298656	chr3:113403991~113433992:+
THCA	cis	rs6942407	0.546	rs2108272	ENSG00000224046.1	AC005076.5	-3.67	0.000271	0.0184	-0.16	-0.17	Food allergy;	chr7:87176083	chr7:87151423~87152420:-
THCA	cis	rs75828804	1	rs77918349	ENSG00000260922.1	RP11-538I12.3	-3.67	0.000271	0.0184	-0.36	-0.17	Intraocular pressure;	chr16:77571367	chr16:77234877~77290934:+
THCA	cis	rs9911578	1	rs3744109	ENSG00000224738.1	AC099850.1	-3.67	0.000272	0.0184	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58516836	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs11079354	ENSG00000224738.1	AC099850.1	-3.67	0.000272	0.0184	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58517099	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs2079703	ENSG00000224738.1	AC099850.1	-3.67	0.000272	0.0184	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58526617	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs11870671	ENSG00000224738.1	AC099850.1	-3.67	0.000272	0.0184	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58527999	chr17:59106598~59118267:+
THCA	cis	rs4664293	1	rs6432540	ENSG00000230783.1	AC009961.2	-3.67	0.000272	0.0184	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159594192	chr2:159689217~159690291:-
THCA	cis	rs2299587	0.56	rs3913555	ENSG00000253671.1	RP11-806O11.1	-3.67	0.000272	0.0184	-0.2	-0.17	Economic and political preferences;	chr8:17924301	chr8:17808941~17820868:+
THCA	cis	rs5753037	0.653	rs140107	ENSG00000279699.1	RP1-102K2.9	3.67	0.000272	0.0184	0.16	0.17	Type 1 diabetes;	chr22:29734527	chr22:30275215~30276951:-
THCA	cis	rs7551222	0.752	rs4951393	ENSG00000240219.1	RP11-430C7.5	-3.67	0.000272	0.0184	-0.16	-0.17	Schizophrenia;	chr1:204520429	chr1:204626775~204629712:+
THCA	cis	rs62292953	0.719	rs11920646	ENSG00000248724.5	NPHP3-AS1	-3.67	0.000272	0.0184	-0.31	-0.17	Red cell distribution width;	chr3:132475157	chr3:132721750~132874223:+
THCA	cis	rs12940923	1	rs2526379	ENSG00000264672.4	SEPT4-AS1	-3.67	0.000272	0.0184	-0.24	-0.17	Circulating myeloperoxidase levels (plasma);	chr17:58321739	chr17:58519837~58556977:+
THCA	cis	rs1555322	1	rs2425036	ENSG00000126005.14	MMP24-AS1	-3.67	0.000272	0.0184	-0.23	-0.17	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35216462~35278131:-
THCA	cis	rs1790761	0.501	rs4930210	ENSG00000184224.3	C11orf72	-3.67	0.000272	0.0184	-0.23	-0.17	Mean corpuscular volume;	chr11:67637255	chr11:67602880~67606706:-
THCA	cis	rs7707921	0.881	rs2407153	ENSG00000251374.1	RPS23P5	-3.67	0.000272	0.0184	-0.24	-0.17	Breast cancer;	chr5:82259509	chr5:82265157~82265259:-
THCA	cis	rs2882667	0.898	rs3828600	ENSG00000249593.5	CTB-46B19.2	3.67	0.000272	0.0184	0.2	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:139012647~139051203:+
THCA	cis	rs1048886	0.872	rs9455121	ENSG00000271967.1	RP11-134K13.4	-3.67	0.000272	0.0184	-0.18	-0.17	Type 2 diabetes;	chr6:70460144	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs9294872	ENSG00000271967.1	RP11-134K13.4	-3.67	0.000272	0.0184	-0.18	-0.17	Type 2 diabetes;	chr6:70463567	chr6:70596438~70596980:+
THCA	cis	rs9876781	0.53	rs35516531	ENSG00000244380.1	RP11-24C3.2	3.67	0.000272	0.0184	0.2	0.17	Longevity;	chr3:48364275	chr3:48440352~48446656:-
THCA	cis	rs9876781	1	rs898225	ENSG00000199476.1	Y_RNA	3.67	0.000272	0.0184	0.21	0.17	Longevity;	chr3:48371689	chr3:48288587~48288694:+
THCA	cis	rs9911578	0.967	rs1267542	ENSG00000224738.1	AC099850.1	-3.67	0.000272	0.0184	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58577329	chr17:59106598~59118267:+
THCA	cis	rs1478897	0.575	rs12679960	ENSG00000206014.6	OR7E161P	-3.67	0.000272	0.0184	-0.21	-0.17	Systemic lupus erythematosus;	chr8:11573481	chr8:11928597~11929563:-
THCA	cis	rs972578	0.715	rs9611904	ENSG00000230319.1	AL022476.2	3.67	0.000272	0.0184	0.18	0.17	Mean platelet volume;	chr22:42795362	chr22:43038585~43052366:+
THCA	cis	rs1959947	0.876	rs1954460	ENSG00000251363.2	RP11-129M6.1	3.67	0.000272	0.0184	0.22	0.17	Hemostatic factors and hematological phenotypes;	chr14:41072544	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs8014994	ENSG00000251363.2	RP11-129M6.1	3.67	0.000272	0.0184	0.22	0.17	Hemostatic factors and hematological phenotypes;	chr14:41075068	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.623	rs10136983	ENSG00000251363.2	RP11-129M6.1	3.67	0.000272	0.0184	0.22	0.17	Hemostatic factors and hematological phenotypes;	chr14:41075464	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.623	rs28542606	ENSG00000251363.2	RP11-129M6.1	3.67	0.000272	0.0184	0.22	0.17	Hemostatic factors and hematological phenotypes;	chr14:41075900	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs7158615	ENSG00000251363.2	RP11-129M6.1	3.67	0.000272	0.0184	0.22	0.17	Hemostatic factors and hematological phenotypes;	chr14:41076050	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.833	rs6572054	ENSG00000251363.2	RP11-129M6.1	3.67	0.000272	0.0184	0.22	0.17	Hemostatic factors and hematological phenotypes;	chr14:41076551	chr14:40954898~40975877:+
THCA	cis	rs13098911	0.51	rs75549687	ENSG00000223552.1	RP11-24F11.2	-3.67	0.000272	0.0184	-0.27	-0.17	Celiac disease;	chr3:46159434	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13059906	ENSG00000223552.1	RP11-24F11.2	-3.67	0.000272	0.0184	-0.27	-0.17	Monocyte count;	chr3:46167366	chr3:46364955~46407059:-
THCA	cis	rs755249	0.567	rs1537817	ENSG00000182109.6	RP11-69E11.4	-3.67	0.000272	0.0184	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39522280~39546187:-
THCA	cis	rs7296418	0.885	rs1051434	ENSG00000256092.2	RP13-942N8.1	3.67	0.000272	0.0184	0.12	0.17	Platelet count;	chr12:123156653	chr12:123363868~123366113:+
THCA	cis	rs614226	0.688	rs75111771	ENSG00000278344.1	RP11-18C24.8	-3.67	0.000272	0.0184	-0.22	-0.17	Type 1 diabetes nephropathy;	chr12:120572140	chr12:120500735~120501090:-
THCA	cis	rs614226	0.748	rs78714658	ENSG00000278344.1	RP11-18C24.8	-3.67	0.000272	0.0184	-0.22	-0.17	Type 1 diabetes nephropathy;	chr12:120572141	chr12:120500735~120501090:-
THCA	cis	rs614226	0.935	rs77955762	ENSG00000278344.1	RP11-18C24.8	-3.67	0.000272	0.0184	-0.22	-0.17	Type 1 diabetes nephropathy;	chr12:120572145	chr12:120500735~120501090:-
THCA	cis	rs7809950	0.817	rs2807	ENSG00000272072.1	CTA-363E19.2	-3.67	0.000272	0.0184	-0.18	-0.17	Coronary artery disease;	chr7:107620333	chr7:107192559~107193300:-
THCA	cis	rs4713118	0.869	rs9468214	ENSG00000261839.1	RP1-265C24.8	3.67	0.000272	0.0184	0.19	0.17	Parkinson's disease;	chr6:27745520	chr6:28136849~28139678:+
THCA	cis	rs861020	0.677	rs12723578	ENSG00000203706.7	SERTAD4-AS1	3.67	0.000272	0.0184	0.19	0.17	Orofacial clefts;	chr1:209859047	chr1:210231456~210234047:-
THCA	cis	rs929354	1	rs929354	ENSG00000224629.1	RP5-1142J19.2	3.67	0.000272	0.0184	0.17	0.17	Body mass index;	chr7:157252863	chr7:157263022~157263229:-
THCA	cis	rs4578769	0.55	rs9945620	ENSG00000273232.1	RP11-370A5.2	3.67	0.000272	0.0184	0.22	0.17	Eosinophil percentage of white cells;	chr18:22997367	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.55	rs2305886	ENSG00000273232.1	RP11-370A5.2	3.67	0.000272	0.0184	0.22	0.17	Eosinophil percentage of white cells;	chr18:22997493	chr18:22882825~22883357:-
THCA	cis	rs4073416	0.542	rs8019762	ENSG00000276116.2	FUT8-AS1	3.67	0.000272	0.0184	0.19	0.17	N-glycan levels;	chr14:65620460	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.542	rs11158604	ENSG00000276116.2	FUT8-AS1	3.67	0.000272	0.0184	0.19	0.17	N-glycan levels;	chr14:65627732	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.518	rs10148529	ENSG00000276116.2	FUT8-AS1	3.67	0.000272	0.0184	0.19	0.17	N-glycan levels;	chr14:65637985	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.542	rs7144345	ENSG00000276116.2	FUT8-AS1	3.67	0.000272	0.0184	0.19	0.17	N-glycan levels;	chr14:65645123	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.542	rs2300864	ENSG00000276116.2	FUT8-AS1	3.67	0.000272	0.0184	0.19	0.17	N-glycan levels;	chr14:65653082	chr14:65411170~65412690:-
THCA	cis	rs1501138	0.573	rs10805348	ENSG00000263327.5	TAPT1-AS1	-3.67	0.000272	0.0184	-0.27	-0.17	Systemic juvenile idiopathic arthritis;	chr4:16314316	chr4:16226685~16320140:+
THCA	cis	rs748404	0.533	rs7165861	ENSG00000249839.1	AC011330.5	3.67	0.000272	0.0184	0.2	0.17	Lung cancer;	chr15:43131129	chr15:43663654~43684339:-
THCA	cis	rs708224	0.608	rs11051875	ENSG00000277342.1	RP11-843B15.4	3.67	0.000272	0.0184	0.21	0.17	Pancreatic cancer;	chr12:32252882	chr12:32109076~32109602:+
THCA	cis	rs10090774	0.965	rs13265942	ENSG00000280303.2	ERICD	-3.67	0.000272	0.0184	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140865063	chr8:140636281~140638283:+
THCA	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	3.67	0.000272	0.0184	0.15	0.17	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
THCA	cis	rs7737355	0.812	rs6896132	ENSG00000224431.1	AC063976.7	3.67	0.000272	0.0184	0.14	0.17	Life satisfaction;	chr5:131437868	chr5:132199456~132203487:+
THCA	cis	rs7824557	0.564	rs2572389	ENSG00000227888.4	FAM66A	-3.67	0.000272	0.0184	-0.21	-0.17	Retinal vascular caliber;	chr8:11378883	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs2736301	ENSG00000227888.4	FAM66A	-3.67	0.000272	0.0184	-0.21	-0.17	Retinal vascular caliber;	chr8:11378904	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs2736302	ENSG00000227888.4	FAM66A	-3.67	0.000272	0.0184	-0.21	-0.17	Retinal vascular caliber;	chr8:11378910	chr8:12362019~12388296:+
THCA	cis	rs3808502	0.647	rs7821302	ENSG00000227888.4	FAM66A	-3.67	0.000272	0.0184	-0.21	-0.17	Neuroticism;	chr8:11379063	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs7821459	ENSG00000227888.4	FAM66A	-3.67	0.000272	0.0184	-0.21	-0.17	Retinal vascular caliber;	chr8:11379172	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs7834572	ENSG00000227888.4	FAM66A	-3.67	0.000272	0.0184	-0.21	-0.17	Retinal vascular caliber;	chr8:11379176	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.564	rs4631424	ENSG00000227888.4	FAM66A	-3.67	0.000272	0.0184	-0.21	-0.17	Retinal vascular caliber;	chr8:11379300	chr8:12362019~12388296:+
THCA	cis	rs7246657	0.943	rs7255785	ENSG00000268499.1	CTB-102L5.8	3.67	0.000272	0.0184	0.21	0.17	Coronary artery calcification;	chr19:37480781	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs7255996	ENSG00000268499.1	CTB-102L5.8	3.67	0.000272	0.0184	0.21	0.17	Coronary artery calcification;	chr19:37480797	chr19:38199836~38200934:+
THCA	cis	rs7572644	0.766	rs12997202	ENSG00000223522.1	AC093690.1	-3.67	0.000272	0.0184	-0.22	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28027522	chr2:28307691~28310459:-
THCA	cis	rs1232027	0.622	rs1650648	ENSG00000249655.1	CTC-325J23.2	-3.67	0.000272	0.0184	-0.19	-0.17	Huntington's disease progression;	chr5:80672439	chr5:80630313~80631590:-
THCA	cis	rs11710088	0.931	rs34659397	ENSG00000240541.2	TM4SF1-AS1	3.67	0.000272	0.0184	0.16	0.17	QRS duration;	chr3:149482575	chr3:149377778~149386583:+
THCA	cis	rs3788317	0.526	rs5992493	ENSG00000232926.1	AC000078.5	3.67	0.000272	0.0184	0.19	0.17	Glaucoma (primary angle closure);	chr22:19894033	chr22:19887289~19887970:+
THCA	cis	rs4713118	0.662	rs4713120	ENSG00000216915.2	RP1-97D16.1	-3.67	0.000272	0.0184	-0.22	-0.17	Parkinson's disease;	chr6:27754056	chr6:27737000~27738494:-
THCA	cis	rs7487075	0.521	rs4768130	ENSG00000274723.1	RP11-618L22.1	3.67	0.000273	0.0184	0.15	0.17	Itch intensity from mosquito bite;	chr12:46713610	chr12:46970504~46972155:+
THCA	cis	rs2120243	0.845	rs2305619	ENSG00000241770.1	RP11-555M1.3	-3.67	0.000273	0.0184	-0.22	-0.17	Hepatocellular carcinoma in hepatitis B infection;	chr3:157437072	chr3:157163452~157169133:+
THCA	cis	rs4906332	1	rs12879663	ENSG00000259775.1	RP11-45P15.4	-3.67	0.000273	0.0184	-0.14	-0.17	Coronary artery disease;	chr14:103407878	chr14:103331674~103332367:-
THCA	cis	rs2115630	0.846	rs8024538	ENSG00000230373.7	GOLGA6L5P	-3.67	0.000273	0.0184	-0.16	-0.17	P wave terminal force;	chr15:84825188	chr15:84507885~84516814:-
THCA	cis	rs9549260	0.755	rs3892360	ENSG00000168852.11	TPTE2P5	3.67	0.000273	0.0184	0.12	0.17	Red blood cell count;	chr13:40609941	chr13:40822296~40921749:-
THCA	cis	rs11822910	0.815	rs12422015	ENSG00000265566.2	RN7SL605P	3.67	0.000273	0.0184	0.26	0.17	Platelet distribution width;	chr11:57426180	chr11:57528085~57528365:-
THCA	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	3.67	0.000273	0.0184	0.15	0.17	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
THCA	cis	rs865483	0.63	rs7215774	ENSG00000273965.1	RP11-378E13.4	3.67	0.000273	0.0184	0.21	0.17	Monocyte count;	chr17:37383917	chr17:37407936~37408594:-
THCA	cis	rs4389656	0.857	rs2279657	ENSG00000248677.1	CTD-2044J15.1	3.67	0.000273	0.0184	0.17	0.17	Coronary artery disease;	chr5:6737458	chr5:6686325~6707711:-
THCA	cis	rs4908768	0.539	rs4480384	ENSG00000270282.1	RP5-1115A15.2	3.67	0.000273	0.0184	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8512653~8513021:+
THCA	cis	rs9880211	0.531	rs1356664	ENSG00000273486.1	RP11-731C17.2	3.67	0.000273	0.0184	0.16	0.17	Height;Body mass index;	chr3:135900743	chr3:136837338~136839021:-
THCA	cis	rs427943	0.695	rs8128889	ENSG00000223768.1	LINC00205	-3.67	0.000273	0.0184	-0.15	-0.17	Body mass index;	chr21:45195416	chr21:45293285~45297354:+
THCA	cis	rs427943	0.75	rs8130224	ENSG00000223768.1	LINC00205	-3.67	0.000273	0.0184	-0.15	-0.17	Body mass index;	chr21:45196526	chr21:45293285~45297354:+
THCA	cis	rs10802047	0.632	rs538971	ENSG00000231365.4	RP11-418J17.1	-3.67	0.000273	0.0184	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118691880	chr1:119140396~119275973:+
THCA	cis	rs7968440	0.808	rs66838741	ENSG00000272368.2	RP4-605O3.4	3.67	0.000273	0.0184	0.11	0.17	Fibrinogen;	chr12:50805231	chr12:50112197~50165618:+
THCA	cis	rs7968440	0.808	rs2554862	ENSG00000272368.2	RP4-605O3.4	3.67	0.000273	0.0184	0.11	0.17	Fibrinogen;	chr12:50808263	chr12:50112197~50165618:+
THCA	cis	rs793571	0.822	rs11630160	ENSG00000245975.2	RP11-30K9.6	-3.67	0.000273	0.0184	-0.18	-0.17	Schizophrenia;	chr15:58921479	chr15:58768072~58770974:-
THCA	cis	rs293748	0.771	rs158410	ENSG00000250155.1	CTD-2353F22.1	-3.67	0.000273	0.0184	-0.22	-0.17	Obesity-related traits;	chr5:36858559	chr5:36666214~36725195:-
THCA	cis	rs7474896	0.537	rs2749589	ENSG00000272983.1	RP11-508N22.12	3.67	0.000273	0.0184	0.17	0.17	Obesity (extreme);	chr10:37977942	chr10:38137337~38144399:+
THCA	cis	rs2357982	0.556	rs10490561	ENSG00000232320.6	AC009299.5	-3.67	0.000273	0.0184	-0.23	-0.17	Presence of antiphospholipid antibodies;	chr2:161043027	chr2:161340816~161341326:-
THCA	cis	rs11688816	0.569	rs7591708	ENSG00000242412.1	DBIL5P2	3.67	0.000273	0.0184	0.19	0.17	Body mass index;	chr2:62794915	chr2:63117851~63119542:-
THCA	cis	rs17270561	0.609	rs1165211	ENSG00000272462.2	U91328.19	-3.67	0.000273	0.0184	-0.14	-0.17	Iron status biomarkers;	chr6:25800694	chr6:25992662~26001775:+
THCA	cis	rs2554380	0.943	rs11636516	ENSG00000230373.7	GOLGA6L5P	-3.67	0.000273	0.0184	-0.21	-0.17	Height;	chr15:83693021	chr15:84507885~84516814:-
THCA	cis	rs16975963	0.793	rs73034946	ENSG00000276846.1	CTD-3220F14.3	-3.67	0.000273	0.0184	-0.16	-0.17	Longevity;	chr19:37969853	chr19:37314868~37315620:-
THCA	cis	rs7246967	0.542	rs56355379	ENSG00000198153.8	ZNF849P	-3.67	0.000273	0.0184	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22717653	chr19:22685167~22686732:+
THCA	cis	rs2235642	0.525	rs8048290	ENSG00000280231.1	LA16c-380F5.3	-3.67	0.000273	0.0184	-0.21	-0.17	Coronary artery disease;	chr16:1512025	chr16:1553655~1554130:-
THCA	cis	rs6137726	0.613	rs747911	ENSG00000237396.1	LINC01384	3.67	0.000273	0.0184	0.15	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22652293	chr20:22587522~22607517:-
THCA	cis	rs13325613	0.834	rs6765904	ENSG00000223552.1	RP11-24F11.2	-3.67	0.000273	0.0184	-0.28	-0.17	Monocyte count;	chr3:46154389	chr3:46364955~46407059:-
THCA	cis	rs972578	1	rs5759080	ENSG00000230319.1	AL022476.2	3.67	0.000273	0.0184	0.18	0.17	Mean platelet volume;	chr22:42997934	chr22:43038585~43052366:+
THCA	cis	rs739310	0.951	rs76790835	ENSG00000235271.4	RP1-90L6.3	-3.67	0.000273	0.0184	-0.26	-0.17	Obesity-related traits;	chr22:26659864	chr22:26903292~26920611:+
THCA	cis	rs654950	0.806	rs1535505	ENSG00000230638.4	RP11-486B10.4	-3.67	0.000273	0.0184	-0.2	-0.17	Airway imaging phenotypes;	chr1:41560481	chr1:41542069~41544310:+
THCA	cis	rs7045881	0.8	rs62544437	ENSG00000234676.1	IFT74-AS1	-3.67	0.000273	0.0184	-0.32	-0.17	Schizophrenia;	chr9:26906224	chr9:26955780~26956295:-
THCA	cis	rs7045881	0.8	rs7044910	ENSG00000234676.1	IFT74-AS1	-3.67	0.000273	0.0184	-0.32	-0.17	Schizophrenia;	chr9:26907598	chr9:26955780~26956295:-
THCA	cis	rs6920965	0.507	rs9401853	ENSG00000226409.1	RP11-735G4.1	-3.67	0.000273	0.0184	-0.21	-0.17	High light scatter reticulocyte count;	chr6:125894051	chr6:125370211~125374324:-
THCA	cis	rs9341808	0.754	rs9294173	ENSG00000260645.1	RP11-250B2.5	3.67	0.000273	0.0185	0.14	0.17	Sitting height ratio;	chr6:80281913	chr6:80466958~80469080:+
THCA	cis	rs8002861	0.727	rs9525852	ENSG00000274001.1	RP11-5G9.5	-3.67	0.000273	0.0185	-0.2	-0.17	Leprosy;	chr13:43831061	chr13:43877715~43878163:-
THCA	cis	rs6788895	1	rs2014279	ENSG00000244265.1	SIAH2-AS1	3.67	0.000273	0.0185	0.39	0.17	Breast cancer;	chr3:150770158	chr3:150761937~150762538:+
THCA	cis	rs3781264	0.6	rs12263737	ENSG00000273450.1	RP11-76P2.4	3.67	0.000273	0.0185	0.21	0.17	Esophageal cancer and gastric cancer;	chr10:94285156	chr10:94314907~94315327:-
THCA	cis	rs4908768	0.911	rs6693127	ENSG00000232912.4	RP5-1115A15.1	-3.67	0.000273	0.0185	-0.19	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8714914	chr1:8424645~8434838:+
THCA	cis	rs7111546	0.514	rs116947073	ENSG00000246225.5	RP11-17A1.3	3.67	0.000273	0.0185	0.29	0.17	Dialysis-related mortality;	chr11:22979229	chr11:22829380~22945393:+
THCA	cis	rs12451471	0.529	rs2278620	ENSG00000279259.1	RP11-334C17.3	-3.67	0.000273	0.0185	-0.17	-0.17	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80109766	chr17:80147250~80148596:+
THCA	cis	rs1005277	0.579	rs1614236	ENSG00000120555.12	SEPT7P9	3.67	0.000273	0.0185	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2749616	ENSG00000120555.12	SEPT7P9	3.67	0.000273	0.0185	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780146	ENSG00000120555.12	SEPT7P9	3.67	0.000273	0.0185	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38383069~38402916:-
THCA	cis	rs853679	0.599	rs156743	ENSG00000272009.1	RP1-313I6.12	-3.67	0.000273	0.0185	-0.23	-0.17	Depression;	chr6:27999311	chr6:28078792~28081130:-
THCA	cis	rs1799922	0.895	rs12530616	ENSG00000271553.1	RP11-274B21.10	-3.67	0.000273	0.0185	-0.14	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128743168	chr7:128667043~128668156:+
THCA	cis	rs758324	0.947	rs7708140	ENSG00000237714.1	P4HA2-AS1	3.67	0.000273	0.0185	0.24	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131916703	chr5:132184876~132192808:+
THCA	cis	rs9291683	0.53	rs4697698	ENSG00000261490.1	RP11-448G15.3	3.67	0.000273	0.0185	0.1	0.17	Bone mineral density;	chr4:9940953	chr4:10068089~10073019:-
THCA	cis	rs7312933	0.558	rs61926593	ENSG00000257225.1	RP11-328C8.4	-3.67	0.000273	0.0185	-0.17	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42425110	chr12:42459366~42466128:+
THCA	cis	rs7312933	0.558	rs11181502	ENSG00000257225.1	RP11-328C8.4	-3.67	0.000273	0.0185	-0.17	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42430031	chr12:42459366~42466128:+
THCA	cis	rs7647973	0.848	rs4955426	ENSG00000229759.1	MRPS18AP1	3.67	0.000273	0.0185	0.27	0.17	Menarche (age at onset);	chr3:49106005	chr3:48256350~48256938:-
THCA	cis	rs948562	0.947	rs78629620	ENSG00000280010.1	AP001350.4	3.67	0.000273	0.0185	0.27	0.17	Lymphoma;	chr11:58662329	chr11:58627435~58628528:+
THCA	cis	rs9905704	0.918	rs12952362	ENSG00000224738.1	AC099850.1	3.67	0.000273	0.0185	0.23	0.17	Testicular germ cell tumor;	chr17:58823509	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.918	rs4132924	ENSG00000224738.1	AC099850.1	3.67	0.000273	0.0185	0.23	0.17	Testicular germ cell tumor;	chr17:58860292	chr17:59106598~59118267:+
THCA	cis	rs4723738	1	rs7795499	ENSG00000227191.5	TRGC2	-3.67	0.000273	0.0185	-0.13	-0.17	Treatment response for severe sepsis;	chr7:38228794	chr7:38239580~38368091:-
THCA	cis	rs10857712	0.904	rs7918164	ENSG00000214279.11	SCART1	-3.67	0.000273	0.0185	-0.14	-0.17	Systemic lupus erythematosus;	chr10:133409819	chr10:133453928~133523558:+
THCA	cis	rs3018712	0.532	rs2510398	ENSG00000212093.1	AP000807.1	-3.67	0.000273	0.0185	-0.22	-0.17	Total body bone mineral density;	chr11:68653948	chr11:68506083~68506166:-
THCA	cis	rs12476592	0.543	rs262480	ENSG00000242412.1	DBIL5P2	3.67	0.000273	0.0185	0.21	0.17	Childhood ear infection;	chr2:63645898	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.571	rs112194	ENSG00000242412.1	DBIL5P2	3.67	0.000273	0.0185	0.21	0.17	Childhood ear infection;	chr2:63649738	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs262485	ENSG00000242412.1	DBIL5P2	3.67	0.000273	0.0185	0.21	0.17	Childhood ear infection;	chr2:63651279	chr2:63117851~63119542:-
THCA	cis	rs9902453	0.765	rs1531553	ENSG00000263603.1	CTD-2349P21.5	-3.67	0.000273	0.0185	-0.2	-0.17	Coffee consumption (cups per day);	chr17:29739734	chr17:30729469~30731202:+
THCA	cis	rs6840360	0.87	rs7680604	ENSG00000270265.1	RP11-731D1.4	-3.67	0.000273	0.0185	-0.16	-0.17	Intelligence (multi-trait analysis);	chr4:151548765	chr4:151333775~151353224:-
THCA	cis	rs11971779	0.752	rs4732371	ENSG00000252332.1	RNU6-911P	-3.67	0.000273	0.0185	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139392571	chr7:139448740~139448843:+
THCA	cis	rs9467773	0.62	rs2451711	ENSG00000228223.2	HCG11	-3.67	0.000273	0.0185	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26523450~26526579:+
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000254414.1	RP11-182J1.1	-3.67	0.000273	0.0185	-0.2	-0.17	P wave terminal force;	chr15:84654022	chr15:84631898~84633987:-
THCA	cis	rs12541437	0.617	rs4876685	ENSG00000253327.2	RAD21-AS1	3.67	0.000273	0.0185	0.2	0.17	Gut microbiome composition (winter);	chr8:116909012	chr8:116874424~116876868:+
THCA	cis	rs12541437	0.617	rs4876687	ENSG00000253327.2	RAD21-AS1	3.67	0.000273	0.0185	0.2	0.17	Gut microbiome composition (winter);	chr8:116909388	chr8:116874424~116876868:+
THCA	cis	rs7259376	0.902	rs12978477	ENSG00000270947.1	AC025811.3	-3.67	0.000273	0.0185	-0.18	-0.17	Menopause (age at onset);	chr19:22394907	chr19:22455988~22456459:+
THCA	cis	rs4578769	0.55	rs4471804	ENSG00000273232.1	RP11-370A5.2	-3.67	0.000273	0.0185	-0.22	-0.17	Eosinophil percentage of white cells;	chr18:22996218	chr18:22882825~22883357:-
THCA	cis	rs7522061	0.506	rs12097236	ENSG00000236731.1	RP4-801G22.2	3.67	0.000273	0.0185	0.17	0.17	Blood protein levels;	chr1:157646512	chr1:157629939~157630728:-
THCA	cis	rs6901152	1	rs2216917	ENSG00000217648.1	RP1-95L4.4	-3.67	0.000273	0.0185	-0.17	-0.17	Acute lymphoblastic leukemia (childhood);	chr6:143356169	chr6:143342246~143343383:+
THCA	cis	rs6963495	0.818	rs117907809	ENSG00000272604.1	RP11-251G23.5	3.67	0.000273	0.0185	0.22	0.17	Bipolar disorder (body mass index interaction);	chr7:105528025	chr7:105571083~105573660:+
THCA	cis	rs11971779	0.68	rs17691238	ENSG00000252332.1	RNU6-911P	3.67	0.000273	0.0185	0.19	0.17	Diisocyanate-induced asthma;	chr7:139367538	chr7:139448740~139448843:+
THCA	cis	rs9309473	0.861	rs6546856	ENSG00000273245.1	RP11-434P11.2	3.67	0.000273	0.0185	0.22	0.17	Metabolite levels;	chr2:73610624	chr2:73750256~73750786:-
THCA	cis	rs950893	0.729	rs7004793	ENSG00000253837.1	RP11-177H13.2	-3.67	0.000274	0.0185	-0.17	-0.17	Mean corpuscular hemoglobin;	chr8:23612602	chr8:23336171~23366125:+
THCA	cis	rs5769765	0.773	rs9616751	ENSG00000280567.1	Metazoa_SRP	-3.67	0.000274	0.0185	-0.24	-0.17	Schizophrenia;	chr22:49828588	chr22:49878999~49879242:+
THCA	cis	rs8054556	0.74	rs12716975	ENSG00000273724.1	RP11-347C12.12	-3.67	0.000274	0.0185	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29939508	chr16:30336400~30343336:+
THCA	cis	rs5753037	0.585	rs249401	ENSG00000279699.1	RP1-102K2.9	3.67	0.000274	0.0185	0.16	0.17	Type 1 diabetes;	chr22:29820179	chr22:30275215~30276951:-
THCA	cis	rs9308731	0.563	rs11899831	ENSG00000227992.1	AC108463.2	-3.67	0.000274	0.0185	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111175117	chr2:111203964~111206215:-
THCA	cis	rs41298997	1	rs41298997	ENSG00000261000.1	RP11-534L20.5	-3.67	0.000274	0.0185	-0.22	-0.17	Psoriasis;	chr1:206481989	chr1:206503948~206504456:+
THCA	cis	rs10540	1	rs12801148	ENSG00000279672.1	CMB9-55F22.1	3.67	0.000274	0.0185	0.33	0.17	Body mass index;	chr11:511707	chr11:779617~780755:+
THCA	cis	rs10540	0.73	rs61877766	ENSG00000279672.1	CMB9-55F22.1	3.67	0.000274	0.0185	0.33	0.17	Body mass index;	chr11:512973	chr11:779617~780755:+
THCA	cis	rs10540	1	rs35231079	ENSG00000279672.1	CMB9-55F22.1	3.67	0.000274	0.0185	0.33	0.17	Body mass index;	chr11:515224	chr11:779617~780755:+
THCA	cis	rs791590	0.54	rs10795737	ENSG00000229664.1	RP11-536K7.5	-3.67	0.000274	0.0185	-0.2	-0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6007381	chr10:6025978~6036427:+
THCA	cis	rs75828804	1	rs76367475	ENSG00000260922.1	RP11-538I12.3	-3.67	0.000274	0.0185	-0.36	-0.17	Intraocular pressure;	chr16:77552877	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs77279882	ENSG00000260922.1	RP11-538I12.3	-3.67	0.000274	0.0185	-0.36	-0.17	Intraocular pressure;	chr16:77553658	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs74379719	ENSG00000260922.1	RP11-538I12.3	-3.67	0.000274	0.0185	-0.36	-0.17	Intraocular pressure;	chr16:77553944	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs80253152	ENSG00000260922.1	RP11-538I12.3	-3.67	0.000274	0.0185	-0.36	-0.17	Intraocular pressure;	chr16:77555083	chr16:77234877~77290934:+
THCA	cis	rs75828804	1	rs76015361	ENSG00000260922.1	RP11-538I12.3	-3.67	0.000274	0.0185	-0.36	-0.17	Intraocular pressure;	chr16:77556214	chr16:77234877~77290934:+
THCA	cis	rs7824557	0.527	rs2572448	ENSG00000227888.4	FAM66A	-3.67	0.000274	0.0185	-0.21	-0.17	Retinal vascular caliber;	chr8:11381843	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.527	rs2572447	ENSG00000227888.4	FAM66A	-3.67	0.000274	0.0185	-0.21	-0.17	Retinal vascular caliber;	chr8:11382001	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.527	rs2572446	ENSG00000227888.4	FAM66A	-3.67	0.000274	0.0185	-0.21	-0.17	Retinal vascular caliber;	chr8:11382056	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.527	rs10109537	ENSG00000227888.4	FAM66A	-3.67	0.000274	0.0185	-0.21	-0.17	Retinal vascular caliber;	chr8:11382131	chr8:12362019~12388296:+
THCA	cis	rs6812193	0.761	rs4859442	ENSG00000234036.4	TXNP6	-3.67	0.000274	0.0185	-0.22	-0.17	Parkinson's disease;	chr4:76286954	chr4:76958860~76959169:-
THCA	cis	rs7829975	0.755	rs3789849	ENSG00000253981.4	ALG1L13P	3.67	0.000274	0.0185	0.16	0.17	Mood instability;	chr8:8829544	chr8:8236003~8244667:-
THCA	cis	rs295490	0.748	rs74846775	ENSG00000272656.1	RP11-219D15.3	3.67	0.000274	0.0185	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139354736	chr3:139349024~139349371:-
THCA	cis	rs2051773	0.567	rs77545208	ENSG00000272034.1	SNORD14A	-3.67	0.000274	0.0185	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17026200	chr11:17074654~17074744:-
THCA	cis	rs10857712	0.703	rs12253520	ENSG00000214279.11	SCART1	-3.67	0.000274	0.0185	-0.14	-0.17	Systemic lupus erythematosus;	chr10:133421817	chr10:133453928~133523558:+
THCA	cis	rs10857712	0.703	rs1056521	ENSG00000214279.11	SCART1	-3.67	0.000274	0.0185	-0.14	-0.17	Systemic lupus erythematosus;	chr10:133422386	chr10:133453928~133523558:+
THCA	cis	rs73173548	0.502	rs13165428	ENSG00000247828.6	TMEM161B-AS1	-3.67	0.000274	0.0185	-0.15	-0.17	Macular telangiectasia type 2;	chr5:88443945	chr5:88268895~88436685:+
THCA	cis	rs6947471	1	rs6947471	ENSG00000214106.6	PAXIP1-AS2	3.67	0.000274	0.0185	0.21	0.17	Pelvic organ prolapse;	chr7:154589765	chr7:154928498~154949908:+
THCA	cis	rs74233809	0.892	rs11191447	ENSG00000272912.1	RP11-724N1.1	-3.67	0.000274	0.0185	-0.3	-0.17	Birth weight;	chr10:102892566	chr10:102914585~102915404:+
THCA	cis	rs394563	0.534	rs388335	ENSG00000268592.3	RAET1E-AS1	3.67	0.000274	0.0185	0.23	0.17	Dupuytren's disease;	chr6:149470850	chr6:149863494~149919507:+
THCA	cis	rs5758511	0.68	rs5758687	ENSG00000237037.8	NDUFA6-AS1	-3.67	0.000274	0.0185	-0.16	-0.17	Birth weight;	chr22:42260582	chr22:42090931~42137742:+
THCA	cis	rs2455799	0.553	rs12495958	ENSG00000270409.1	RP11-44D5.1	-3.67	0.000274	0.0185	-0.18	-0.17	Mean platelet volume;	chr3:15899932	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs4685269	ENSG00000270409.1	RP11-44D5.1	-3.67	0.000274	0.0185	-0.18	-0.17	Mean platelet volume;	chr3:15900847	chr3:15732252~15733470:+
THCA	cis	rs479105	0.603	rs59778971	ENSG00000278356.1	RP11-372B4.3	3.67	0.000274	0.0185	0.16	0.17	Gut microbiota (bacterial taxa);	chr12:3261113	chr12:2885819~2886329:+
THCA	cis	rs875971	0.545	rs73378304	ENSG00000232559.3	GS1-124K5.12	3.67	0.000274	0.0185	0.18	0.17	Aortic root size;	chr7:66175760	chr7:66554588~66576923:-
THCA	cis	rs3892630	0.824	rs2287882	ENSG00000267475.1	CTD-2538C1.2	-3.67	0.000274	0.0185	-0.25	-0.17	Red blood cell traits;	chr19:32842046	chr19:32687089~32691750:-
THCA	cis	rs875971	1	rs3981131	ENSG00000229886.1	RP5-1132H15.3	3.67	0.000274	0.0185	0.17	0.17	Aortic root size;	chr7:66486690	chr7:66025126~66031544:-
THCA	cis	rs6142618	0.84	rs1022685	ENSG00000224452.1	RSL24D1P6	3.67	0.000274	0.0185	0.2	0.17	Inflammatory bowel disease;	chr20:32330959	chr20:32170390~32170790:-
THCA	cis	rs9487094	0.689	rs6939548	ENSG00000223537.2	RP5-919F19.5	-3.67	0.000274	0.0185	-0.17	-0.17	Height;	chr6:109464011	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.666	rs3734652	ENSG00000223537.2	RP5-919F19.5	-3.67	0.000274	0.0185	-0.17	-0.17	Height;	chr6:109465777	chr6:109487906~109506800:+
THCA	cis	rs61160187	0.788	rs12519587	ENSG00000215032.2	GNL3LP1	3.67	0.000274	0.0185	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60791073	chr5:60891935~60893577:-
THCA	cis	rs16857609	0.564	rs1478580	ENSG00000233143.1	DIRC3-AS1	-3.67	0.000274	0.0185	-0.2	-0.17	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217426926	chr2:217282739~217336120:+
THCA	cis	rs295490	0.748	rs74340696	ENSG00000272656.1	RP11-219D15.3	3.67	0.000274	0.0185	0.33	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341859	chr3:139349024~139349371:-
THCA	cis	rs12480732	1	rs61114499	ENSG00000175730.8	BAK1P1	-3.67	0.000274	0.0185	-0.24	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:32604555	chr20:32690180~32690815:-
THCA	cis	rs765787	0.505	rs11630884	ENSG00000259932.1	CTD-2651B20.7	3.67	0.000274	0.0185	0.2	0.17	Uric acid levels;	chr15:45240048	chr15:45198517~45199139:-
THCA	cis	rs765787	0.53	rs11634794	ENSG00000259932.1	CTD-2651B20.7	3.67	0.000274	0.0185	0.2	0.17	Uric acid levels;	chr15:45242294	chr15:45198517~45199139:-
THCA	cis	rs36093844	0.527	rs4944550	ENSG00000279742.1	RP11-700A24.1	-3.67	0.000274	0.0185	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85974531	chr11:85852557~85854943:-
THCA	cis	rs9878978	0.964	rs17194406	ENSG00000227588.2	CNTN4-AS2	3.67	0.000274	0.0185	0.2	0.17	Blood pressure (smoking interaction);	chr3:2446947	chr3:2110409~2144241:-
THCA	cis	rs7904321	1	rs10761689	ENSG00000232075.1	MRPL35P2	3.67	0.000274	0.0185	0.22	0.17	Intelligence (multi-trait analysis);	chr10:63073239	chr10:63634317~63634827:-
THCA	cis	rs7916852	0.717	rs56163384	ENSG00000230500.1	MKX-AS1	3.67	0.000274	0.0185	0.27	0.17	Glaucoma (primary open-angle);	chr10:28102479	chr10:27744786~27767794:+
THCA	cis	rs372883	0.6	rs2832298	ENSG00000176054.6	RPL23P2	3.67	0.000274	0.0185	0.15	0.17	Pancreatic cancer;	chr21:29371542	chr21:28997613~28998033:-
THCA	cis	rs6517329	0.933	rs12151967	ENSG00000230212.5	AP000688.14	-3.67	0.000274	0.0185	-0.2	-0.17	Schizophrenia;	chr21:36111456	chr21:36069642~36126640:-
THCA	cis	rs10129255	1	rs10141557	ENSG00000211972.2	IGHV3-66	3.67	0.000274	0.0185	0.1	0.17	Kawasaki disease;	chr14:106767990	chr14:106675017~106675544:-
THCA	cis	rs7572644	0.509	rs13001060	ENSG00000223522.1	AC093690.1	-3.67	0.000274	0.0185	-0.2	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27802194	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.564	rs12995865	ENSG00000223522.1	AC093690.1	-3.67	0.000274	0.0185	-0.2	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27802199	chr2:28307691~28310459:-
THCA	cis	rs7647973	0.56	rs7638154	ENSG00000228638.1	FCF1P2	-3.67	0.000274	0.0185	-0.17	-0.17	Menarche (age at onset);	chr3:49261942	chr3:48290793~48291375:-
THCA	cis	rs7656342	0.808	rs6815039	ENSG00000242034.1	RP11-1396O13.1	3.67	0.000275	0.0185	0.19	0.17	Gut microbiota (bacterial taxa);	chr4:9776185	chr4:9553614~9553985:-
THCA	cis	rs9843304	0.967	rs12633863	ENSG00000240541.2	TM4SF1-AS1	-3.67	0.000275	0.0185	-0.15	-0.17	Gallstone disease;	chr3:149493725	chr3:149377778~149386583:+
THCA	cis	rs42648	0.738	rs13247172	ENSG00000225498.1	AC002064.5	3.67	0.000275	0.0185	0.19	0.17	Homocysteine levels;	chr7:90259890	chr7:90312496~90322592:+
THCA	cis	rs1023500	0.551	rs133379	ENSG00000270083.1	RP1-257I20.14	3.67	0.000275	0.0185	0.19	0.17	Schizophrenia;	chr22:42072531	chr22:42089630~42090028:-
THCA	cis	rs4073416	0.508	rs12587057	ENSG00000276116.2	FUT8-AS1	3.67	0.000275	0.0185	0.18	0.17	N-glycan levels;	chr14:65599657	chr14:65411170~65412690:-
THCA	cis	rs6142618	0.84	rs2027030	ENSG00000224452.1	RSL24D1P6	3.67	0.000275	0.0185	0.2	0.17	Inflammatory bowel disease;	chr20:32335466	chr20:32170390~32170790:-
THCA	cis	rs478304	0.514	rs75601653	ENSG00000255557.1	RP11-770G2.2	3.67	0.000275	0.0185	0.2	0.17	Acne (severe);	chr11:65715899	chr11:65745729~65771585:+
THCA	cis	rs8035452	0.964	rs12899657	ENSG00000273674.3	CTD-2378E12.1	3.67	0.000275	0.0185	0.21	0.17	Alzheimer's disease (late onset);	chr15:50709758	chr15:50839875~50908599:-
THCA	cis	rs7520050	1	rs12143096	ENSG00000280836.1	AL355480.1	3.67	0.000275	0.0185	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:45581219~45581321:-
THCA	cis	rs6495122	0.651	rs11636952	ENSG00000260269.4	CTD-2323K18.1	-3.67	0.000275	0.0185	-0.23	-0.17	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:74821981	chr15:75527150~75601205:-
THCA	cis	rs758324	0.717	rs246999	ENSG00000224431.1	AC063976.7	3.67	0.000275	0.0185	0.17	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132012478	chr5:132199456~132203487:+
THCA	cis	rs9329221	0.537	rs12678800	ENSG00000261451.1	RP11-981G7.1	3.67	0.000275	0.0185	0.2	0.17	Neuroticism;	chr8:10121430	chr8:10433672~10438312:+
THCA	cis	rs763121	0.849	rs12004	ENSG00000225450.1	RP3-508I15.14	-3.67	0.000275	0.0185	-0.13	-0.17	Menopause (age at onset);	chr22:38481456	chr22:38739003~38749041:+
THCA	cis	rs35740288	0.77	rs4843086	ENSG00000259295.5	CSPG4P12	3.67	0.000275	0.0185	0.27	0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85619643	chr15:85191438~85213905:+
THCA	cis	rs7903847	0.619	rs10786336	ENSG00000225850.3	RP11-452K12.4	3.67	0.000275	0.0185	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97375196	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10882908	ENSG00000225850.3	RP11-452K12.4	3.67	0.000275	0.0185	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97375213	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs7084654	ENSG00000225850.3	RP11-452K12.4	3.67	0.000275	0.0185	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97375505	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs7088410	ENSG00000225850.3	RP11-452K12.4	3.67	0.000275	0.0185	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97375782	chr10:97334564~97343203:+
THCA	cis	rs3820928	0.605	rs7560867	ENSG00000212391.1	SNORA48	-3.67	0.000275	0.0185	-0.18	-0.17	Pulmonary function;	chr2:226916229	chr2:226968989~226969122:-
THCA	cis	rs17345786	0.861	rs74768235	ENSG00000244119.1	PDCL3P4	3.67	0.000275	0.0185	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr3:101423977	chr3:101712472~101713191:+
THCA	cis	rs60180747	1	rs80326387	ENSG00000261318.1	RP11-653J6.1	3.67	0.000275	0.0185	0.22	0.17	Testicular germ cell tumor;	chr15:66412705	chr15:66278498~66293357:-
THCA	cis	rs3858145	0.588	rs10998059	ENSG00000233590.1	RP11-153K11.3	3.67	0.000275	0.0185	0.23	0.17	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68302750	chr10:68233251~68242379:-
THCA	cis	rs972578	1	rs2010366	ENSG00000274717.1	RP1-47A17.1	-3.67	0.000275	0.0186	-0.18	-0.17	Mean platelet volume;	chr22:42985282	chr22:42791814~42794313:-
THCA	cis	rs875971	1	rs6945843	ENSG00000272831.1	RP11-792A8.4	-3.67	0.000275	0.0186	-0.1	-0.17	Aortic root size;	chr7:66269796	chr7:66739829~66740385:-
THCA	cis	rs11148252	0.967	rs11618716	ENSG00000273784.3	RP11-78J21.7	3.67	0.000275	0.0186	0.18	0.17	Lewy body disease;	chr13:52472701	chr13:52600042~52642542:+
THCA	cis	rs3924048	0.574	rs11589283	ENSG00000276830.1	MIR6730	-3.67	0.000275	0.0186	-0.17	-0.17	Optic cup area;	chr1:12552250	chr1:12578957~12579023:-
THCA	cis	rs3924048	0.574	rs11588028	ENSG00000276830.1	MIR6730	-3.67	0.000275	0.0186	-0.17	-0.17	Optic cup area;	chr1:12552355	chr1:12578957~12579023:-
THCA	cis	rs1144333	0.655	rs1361487	ENSG00000272855.1	RP5-1102E8.3	-3.67	0.000275	0.0186	-0.35	-0.17	Attention function in attention deficit hyperactive disorder;	chr1:75964786	chr1:76636877~76637339:+
THCA	cis	rs2762353	0.526	rs12215823	ENSG00000272462.2	U91328.19	-3.67	0.000275	0.0186	-0.13	-0.17	Blood metabolite levels;	chr6:25725846	chr6:25992662~26001775:+
THCA	cis	rs9333290	0.857	rs35251833	ENSG00000259915.2	RP11-410E4.1	3.67	0.000275	0.0186	0.2	0.17	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186676650	chr2:186354570~186356773:-
THCA	cis	rs7665090	0.936	rs5026474	ENSG00000248971.2	KRT8P46	-3.67	0.000275	0.0186	-0.2	-0.17	Primary biliary cholangitis;	chr4:102633653	chr4:102728746~102730171:-
THCA	cis	rs420259	0.516	rs1135045	ENSG00000260136.4	CTD-2270L9.4	-3.67	0.000275	0.0186	-0.13	-0.17	Bipolar disorder;	chr16:23478390	chr16:23452758~23457606:+
THCA	cis	rs17286411	0.671	rs8060867	ENSG00000260185.1	RP11-432I5.6	-3.67	0.000275	0.0186	-0.23	-0.17	Blood protein levels;	chr16:71766133	chr16:71655027~71664212:+
THCA	cis	rs3176789	0.647	rs12422685	ENSG00000256673.1	RP11-599J14.2	3.67	0.000275	0.0186	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767376	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.697	rs12422688	ENSG00000256673.1	RP11-599J14.2	3.67	0.000275	0.0186	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767426	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.647	rs12422955	ENSG00000256673.1	RP11-599J14.2	3.67	0.000275	0.0186	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767494	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.601	rs12427278	ENSG00000256673.1	RP11-599J14.2	3.67	0.000275	0.0186	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767525	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.624	rs12427301	ENSG00000256673.1	RP11-599J14.2	3.67	0.000275	0.0186	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767695	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.624	rs12427030	ENSG00000256673.1	RP11-599J14.2	3.67	0.000275	0.0186	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767776	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.624	rs11052978	ENSG00000256673.1	RP11-599J14.2	3.67	0.000275	0.0186	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767882	chr12:9398355~9414851:-
THCA	cis	rs925946	0.518	rs7107410	ENSG00000245573.6	BDNF-AS	3.67	0.000275	0.0186	0.16	0.17	Weight;Body mass index;	chr11:27529841	chr11:27506838~27698174:+
THCA	cis	rs4908768	0.52	rs7520025	ENSG00000270282.1	RP5-1115A15.2	3.67	0.000275	0.0186	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8512653~8513021:+
THCA	cis	rs4662750	0.65	rs1083297	ENSG00000236682.1	AC068282.3	3.67	0.000275	0.0186	0.2	0.17	Renal cell carcinoma;	chr2:127599422	chr2:127389130~127400580:+
THCA	cis	rs409045	1	rs372550	ENSG00000271874.1	CTD-2024P10.2	-3.67	0.000275	0.0186	-0.22	-0.17	Left ventricular mass;	chr5:34638318	chr5:34651457~34651888:-
THCA	cis	rs8040855	0.931	rs11855471	ENSG00000225151.9	GOLGA2P7	3.67	0.000275	0.0186	0.22	0.17	Bulimia nervosa;	chr15:85175976	chr15:84199311~84230136:-
THCA	cis	rs3087591	0.708	rs7502834	ENSG00000263535.1	AK4P1	3.67	0.000275	0.0186	0.2	0.17	Hip circumference;	chr17:31362412	chr17:31345521~31346187:+
THCA	cis	rs7259376	0.934	rs7253315	ENSG00000270947.1	AC025811.3	-3.67	0.000275	0.0186	-0.18	-0.17	Menopause (age at onset);	chr19:22411637	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs6511350	ENSG00000270947.1	AC025811.3	-3.67	0.000275	0.0186	-0.18	-0.17	Menopause (age at onset);	chr19:22411895	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs10423736	ENSG00000270947.1	AC025811.3	-3.67	0.000275	0.0186	-0.18	-0.17	Menopause (age at onset);	chr19:22413330	chr19:22455988~22456459:+
THCA	cis	rs420259	0.516	rs10459765	ENSG00000260136.4	CTD-2270L9.4	3.67	0.000275	0.0186	0.13	0.17	Bipolar disorder;	chr16:23455860	chr16:23452758~23457606:+
THCA	cis	rs867371	1	rs13380319	ENSG00000278603.1	RP13-608F4.5	3.67	0.000275	0.0186	0.21	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472203~82472426:+
THCA	cis	rs7873102	0.654	rs7048063	ENSG00000213839.4	TMX2P1	3.67	0.000275	0.0186	0.13	0.17	Brain structure;	chr9:37957232	chr9:37885683~37886390:+
THCA	cis	rs1153858	1	rs60476496	ENSG00000275672.1	GATM-AS1	-3.67	0.000275	0.0186	-0.17	-0.17	Homoarginine levels;	chr15:45421603	chr15:45378700~45380123:+
THCA	cis	rs2288884	1	rs76768215	ENSG00000260160.1	CTC-471J1.2	-3.67	0.000275	0.0186	-0.18	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069370	chr19:52058490~52063703:-
THCA	cis	rs929354	0.772	rs1182365	ENSG00000224629.1	RP5-1142J19.2	3.67	0.000275	0.0186	0.16	0.17	Body mass index;	chr7:157224561	chr7:157263022~157263229:-
THCA	cis	rs929354	0.709	rs1182363	ENSG00000224629.1	RP5-1142J19.2	3.67	0.000275	0.0186	0.16	0.17	Body mass index;	chr7:157226457	chr7:157263022~157263229:-
THCA	cis	rs1050631	1	rs11873168	ENSG00000260552.1	RP11-49I11.1	3.67	0.000275	0.0186	0.21	0.17	Esophageal squamous cell cancer (length of survival);	chr18:36127618	chr18:36179996~36187448:-
THCA	cis	rs12049351	0.665	rs10916491	ENSG00000229367.1	HMGN2P19	3.67	0.000275	0.0186	0.26	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229492923	chr1:229570532~229570796:+
THCA	cis	rs929354	0.739	rs12533082	ENSG00000224629.1	RP5-1142J19.2	-3.67	0.000275	0.0186	-0.16	-0.17	Body mass index;	chr7:157221478	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs6459741	ENSG00000224629.1	RP5-1142J19.2	-3.67	0.000275	0.0186	-0.16	-0.17	Body mass index;	chr7:157221859	chr7:157263022~157263229:-
THCA	cis	rs9425766	0.679	rs6670617	ENSG00000270084.1	GAS5-AS1	-3.67	0.000275	0.0186	-0.17	-0.17	Life satisfaction;	chr1:174277574	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs4650990	ENSG00000270084.1	GAS5-AS1	-3.67	0.000275	0.0186	-0.17	-0.17	Life satisfaction;	chr1:174289943	chr1:173863248~173863941:+
THCA	cis	rs875971	0.756	rs2901210	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000275	0.0186	-0.11	-0.17	Aortic root size;	chr7:66552518	chr7:66491049~66493566:-
THCA	cis	rs72843506	0.586	rs59890010	ENSG00000231258.2	ZSWIM5P2	3.67	0.000275	0.0186	0.26	0.17	Schizophrenia;	chr17:19960360	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.586	rs73980762	ENSG00000231258.2	ZSWIM5P2	3.67	0.000275	0.0186	0.26	0.17	Schizophrenia;	chr17:19966113	chr17:20583758~20591180:-
THCA	cis	rs745109	0.504	rs80252327	ENSG00000273080.1	RP11-301O19.1	3.67	0.000276	0.0186	0.3	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86385089	chr2:86195590~86196049:+
THCA	cis	rs881375	0.715	rs11794516	ENSG00000238181.2	AHCYP2	-3.66	0.000276	0.0186	-0.21	-0.17	Rheumatoid arthritis;	chr9:120877952	chr9:120720673~120721972:+
THCA	cis	rs5771242	0.518	rs67881086	ENSG00000273137.1	RP3-402G11.28	-3.66	0.000276	0.0186	-0.13	-0.17	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50235010	chr22:50208461~50209542:-
THCA	cis	rs7212590	0.581	rs8081710	ENSG00000267302.4	RP11-178C3.2	3.66	0.000276	0.0186	0.31	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59760679	chr17:59964832~59996972:+
THCA	cis	rs7246657	0.722	rs1531549	ENSG00000226686.6	LINC01535	-3.66	0.000276	0.0186	-0.24	-0.17	Coronary artery calcification;	chr19:37597108	chr19:37251912~37265535:+
THCA	cis	rs62434120	0.677	rs4446576	ENSG00000273132.1	RP11-350J20.12	3.66	0.000276	0.0186	0.2	0.17	Blood pressure traits (multi-trait analysis);Diastolic blood pressure;Systolic blood pressure;	chr6:150730022	chr6:149852462~149853192:+
THCA	cis	rs6137726	0.508	rs2424456	ENSG00000237396.1	LINC01384	3.66	0.000276	0.0186	0.15	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22663024	chr20:22587522~22607517:-
THCA	cis	rs3015497	0.616	rs1389650	ENSG00000270062.1	RP11-248J18.3	3.66	0.000276	0.0186	0.19	0.17	Mean platelet volume;	chr14:50614731	chr14:50723777~50724272:-
THCA	cis	rs6982240	0.514	rs28588820	ENSG00000253307.1	RP11-10J21.4	3.66	0.000276	0.0186	0.25	0.17	Tonsillectomy;	chr8:141275243	chr8:141252286~141253292:-
THCA	cis	rs34975555	0.892	rs7813503	ENSG00000253671.1	RP11-806O11.1	-3.66	0.000276	0.0186	-0.26	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17949480	chr8:17808941~17820868:+
THCA	cis	rs3796352	1	rs58660500	ENSG00000280417.1	RP11-5O17.1	-3.66	0.000276	0.0186	-0.25	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:53052557	chr3:53046166~53048122:+
THCA	cis	rs3796352	1	rs71301809	ENSG00000280417.1	RP11-5O17.1	-3.66	0.000276	0.0186	-0.25	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:53056296	chr3:53046166~53048122:+
THCA	cis	rs3796352	1	rs35576914	ENSG00000280417.1	RP11-5O17.1	-3.66	0.000276	0.0186	-0.25	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:53058254	chr3:53046166~53048122:+
THCA	cis	rs12682352	0.652	rs3789843	ENSG00000253981.4	ALG1L13P	3.66	0.000276	0.0186	0.17	0.17	Neuroticism;	chr8:8866747	chr8:8236003~8244667:-
THCA	cis	rs12682352	0.652	rs3827806	ENSG00000253981.4	ALG1L13P	3.66	0.000276	0.0186	0.17	0.17	Neuroticism;	chr8:8866766	chr8:8236003~8244667:-
THCA	cis	rs9487094	0.689	rs1046943	ENSG00000223537.2	RP5-919F19.5	-3.66	0.000276	0.0186	-0.17	-0.17	Height;	chr6:109462738	chr6:109487906~109506800:+
THCA	cis	rs9435732	0.62	rs12045097	ENSG00000280114.1	RP5-875O13.7	3.66	0.000276	0.0186	0.2	0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17019382	chr1:16681097~16688749:-
THCA	cis	rs36093844	0.527	rs72961110	ENSG00000279742.1	RP11-700A24.1	-3.66	0.000276	0.0186	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86007976	chr11:85852557~85854943:-
THCA	cis	rs12681366	0.843	rs3019147	ENSG00000253175.1	RP11-267M23.6	3.66	0.000276	0.0186	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94412804	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.881	rs3019149	ENSG00000253175.1	RP11-267M23.6	3.66	0.000276	0.0186	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94418351	chr8:94565036~94565715:+
THCA	cis	rs4869313	0.668	rs2548533	ENSG00000247121.5	CTD-2260A17.2	-3.66	0.000276	0.0186	-0.12	-0.17	Pediatric autoimmune diseases;	chr5:96902697	chr5:96814028~96935809:-
THCA	cis	rs7937890	0.559	rs4369365	ENSG00000251991.1	RNU7-49P	3.66	0.000276	0.0186	0.19	0.17	Mitochondrial DNA levels;	chr11:14422969	chr11:14478892~14478953:+
THCA	cis	rs12472274	0.618	rs12477307	ENSG00000186235.9	AC016757.3	3.66	0.000276	0.0186	0.21	0.17	Phospholipid levels (plasma);	chr2:238201873	chr2:238224552~238231677:-
THCA	cis	rs875971	0.54	rs736270	ENSG00000275400.1	RP4-756H11.5	-3.66	0.000276	0.0186	-0.16	-0.17	Aortic root size;	chr7:65963835	chr7:66553805~66554199:-
THCA	cis	rs9693857	0.52	rs11249927	ENSG00000261451.1	RP11-981G7.1	3.66	0.000276	0.0186	0.22	0.17	Systolic blood pressure;	chr8:9504096	chr8:10433672~10438312:+
THCA	cis	rs6546886	0.912	rs4853006	ENSG00000235499.1	AC073046.25	3.66	0.000276	0.0186	0.15	0.17	Dialysis-related mortality;	chr2:74036292	chr2:73985132~73986343:+
THCA	cis	rs1433188	0.847	rs13439018	ENSG00000253582.1	RP11-649G15.2	3.66	0.000276	0.0186	0.19	0.17	Subjective well-being;	chr8:107428282	chr8:106520474~106657548:-
THCA	cis	rs651907	1	rs662792	ENSG00000256628.3	ZBTB11-AS1	3.66	0.000276	0.0186	0.17	0.17	Colorectal cancer;	chr3:101880764	chr3:101676475~101679217:+
THCA	cis	rs17301013	0.965	rs2179214	ENSG00000270084.1	GAS5-AS1	-3.66	0.000276	0.0186	-0.17	-0.17	Systemic lupus erythematosus;	chr1:174413954	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.93	rs7523263	ENSG00000270084.1	GAS5-AS1	-3.66	0.000276	0.0186	-0.17	-0.17	Systemic lupus erythematosus;	chr1:174414542	chr1:173863248~173863941:+
THCA	cis	rs14027	0.921	rs12542794	ENSG00000245330.4	KB-1471A8.1	3.66	0.000276	0.0186	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119867419~119874488:-
THCA	cis	rs7819412	0.775	rs11773990	ENSG00000254839.1	AF131215.6	3.66	0.000276	0.0186	0.17	0.17	Triglycerides;	chr8:11077572	chr8:11062647~11067089:-
THCA	cis	rs7819412	0.775	rs4545055	ENSG00000254839.1	AF131215.6	3.66	0.000276	0.0186	0.17	0.17	Triglycerides;	chr8:11077856	chr8:11062647~11067089:-
THCA	cis	rs7819412	0.775	rs2898257	ENSG00000254839.1	AF131215.6	3.66	0.000276	0.0186	0.17	0.17	Triglycerides;	chr8:11077858	chr8:11062647~11067089:-
THCA	cis	rs9894429	0.624	rs9910935	ENSG00000262049.1	RP13-1032I1.7	3.66	0.000276	0.0186	0.1	0.17	Eye color traits;	chr17:81646923	chr17:81701324~81703300:-
THCA	cis	rs7824557	0.583	rs2263512	ENSG00000261451.1	RP11-981G7.1	-3.66	0.000276	0.0186	-0.21	-0.17	Retinal vascular caliber;	chr8:11375910	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.583	rs6601585	ENSG00000261451.1	RP11-981G7.1	-3.66	0.000276	0.0186	-0.21	-0.17	Retinal vascular caliber;	chr8:11376150	chr8:10433672~10438312:+
THCA	cis	rs7296418	0.961	rs12425850	ENSG00000256092.2	RP13-942N8.1	3.66	0.000276	0.0186	0.12	0.17	Platelet count;	chr12:123017425	chr12:123363868~123366113:+
THCA	cis	rs7296418	0.922	rs12425009	ENSG00000256092.2	RP13-942N8.1	3.66	0.000276	0.0186	0.12	0.17	Platelet count;	chr12:123017497	chr12:123363868~123366113:+
THCA	cis	rs10043228	1	rs62384468	ENSG00000250015.1	CTC-339F2.2	3.66	0.000276	0.0186	0.26	0.17	Asthma or chronic obstructive pulmonary disease;	chr5:116288153	chr5:116302354~116304134:-
THCA	cis	rs9925964	0.967	rs12716981	ENSG00000262766.1	RP11-196G11.4	-3.66	0.000276	0.0186	-0.11	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106703	chr16:31118078~31118747:+
THCA	cis	rs4566357	0.615	rs12621808	ENSG00000212391.1	SNORA48	-3.66	0.000276	0.0186	-0.18	-0.17	Coronary artery disease;	chr2:227044806	chr2:226968989~226969122:-
THCA	cis	rs4906332	0.868	rs4900578	ENSG00000259775.1	RP11-45P15.4	-3.66	0.000276	0.0186	-0.14	-0.17	Coronary artery disease;	chr14:103459673	chr14:103331674~103332367:-
THCA	cis	rs4742903	0.87	rs1354894	ENSG00000270332.1	SMC2-AS1	3.66	0.000276	0.0186	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104212956	chr9:104080024~104093073:-
THCA	cis	rs6546550	0.935	rs2168115	ENSG00000179818.12	PCBP1-AS1	-3.66	0.000276	0.0186	-0.14	-0.17	Prevalent atrial fibrillation;	chr2:69807661	chr2:69962263~70103220:-
THCA	cis	rs11118346	0.59	rs11118366	ENSG00000228536.1	RP11-392O17.1	-3.66	0.000276	0.0186	-0.2	-0.17	Height;	chr1:219616827	chr1:219409681~219411941:-
THCA	cis	rs7176527	0.848	rs1374463	ENSG00000176700.18	SCAND2P	3.66	0.000276	0.0186	0.16	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:84631451~84647478:+
THCA	cis	rs8133932	0.505	rs387320	ENSG00000182586.6	LINC00334	3.66	0.000276	0.0186	0.18	0.17	Schizophrenia;	chr21:45927836	chr21:45234340~45258730:+
THCA	cis	rs9425766	0.64	rs6693423	ENSG00000270084.1	GAS5-AS1	-3.66	0.000276	0.0186	-0.17	-0.17	Life satisfaction;	chr1:174364680	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs60363188	ENSG00000270084.1	GAS5-AS1	-3.66	0.000276	0.0186	-0.17	-0.17	Life satisfaction;	chr1:174375959	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs12084119	ENSG00000270084.1	GAS5-AS1	-3.66	0.000276	0.0186	-0.17	-0.17	Life satisfaction;	chr1:174377138	chr1:173863248~173863941:+
THCA	cis	rs7246657	0.943	rs4803229	ENSG00000268499.1	CTB-102L5.8	3.66	0.000276	0.0186	0.21	0.17	Coronary artery calcification;	chr19:37373780	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs1559229	ENSG00000268499.1	CTB-102L5.8	3.66	0.000276	0.0186	0.21	0.17	Coronary artery calcification;	chr19:37385295	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.882	rs6508719	ENSG00000268499.1	CTB-102L5.8	3.66	0.000276	0.0186	0.21	0.17	Coronary artery calcification;	chr19:37386517	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs4452075	ENSG00000268499.1	CTB-102L5.8	3.66	0.000276	0.0186	0.21	0.17	Coronary artery calcification;	chr19:37388687	chr19:38199836~38200934:+
THCA	cis	rs4845570	1	rs4845356	ENSG00000268288.1	RP11-98D18.16	3.66	0.000276	0.0186	0.24	0.17	Coronary artery disease;	chr1:151786747	chr1:151766486~151767000:-
THCA	cis	rs2287838	0.901	rs5004102	ENSG00000267370.1	CTD-2623N2.3	3.66	0.000276	0.0186	0.15	0.17	Sleep duration;	chr19:9871658	chr19:9756152~9756863:-
THCA	cis	rs17301013	0.965	rs7548540	ENSG00000270084.1	GAS5-AS1	-3.66	0.000276	0.0186	-0.17	-0.17	Systemic lupus erythematosus;	chr1:174411672	chr1:173863248~173863941:+
THCA	cis	rs7520050	0.966	rs11810993	ENSG00000280836.1	AL355480.1	3.66	0.000276	0.0186	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.898	rs34175029	ENSG00000280836.1	AL355480.1	3.66	0.000276	0.0186	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs2275426	ENSG00000280836.1	AL355480.1	3.66	0.000276	0.0186	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45581219~45581321:-
THCA	cis	rs854765	0.534	rs7207461	ENSG00000281749.1	Y_RNA	-3.66	0.000276	0.0186	-0.21	-0.17	Total body bone mineral density;	chr17:18046475	chr17:18001101~18001195:-
THCA	cis	rs7216064	0.532	rs8065296	ENSG00000267023.4	LRRC37A16P	3.66	0.000276	0.0186	0.12	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68022446	chr17:68125777~68152468:-
THCA	cis	rs9425766	0.679	rs4650989	ENSG00000270084.1	GAS5-AS1	-3.66	0.000276	0.0186	-0.17	-0.17	Life satisfaction;	chr1:174289739	chr1:173863248~173863941:+
THCA	cis	rs1421334	0.74	rs2344121	ENSG00000254109.4	RBPMS-AS1	3.66	0.000276	0.0186	0.17	0.17	Intelligence (multi-trait analysis);	chr8:30984006	chr8:30382119~30385401:-
THCA	cis	rs7267979	0.706	rs6138542	ENSG00000276952.1	RP5-965G21.6	3.66	0.000277	0.0187	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25284915~25285588:-
THCA	cis	rs7737355	0.679	rs76386054	ENSG00000237714.1	P4HA2-AS1	-3.66	0.000277	0.0187	-0.36	-0.17	Life satisfaction;	chr5:131687465	chr5:132184876~132192808:+
THCA	cis	rs2554380	0.943	rs4843152	ENSG00000230373.7	GOLGA6L5P	-3.66	0.000277	0.0187	-0.21	-0.17	Height;	chr15:83694790	chr15:84507885~84516814:-
THCA	cis	rs6671200	1	rs6671200	ENSG00000235501.4	RP4-639F20.1	3.66	0.000277	0.0187	0.33	0.17	Stearic acid (18:0) levels;	chr1:95231973	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.79	rs640527	ENSG00000235501.4	RP4-639F20.1	3.66	0.000277	0.0187	0.33	0.17	Stearic acid (18:0) levels;	chr1:95240059	chr1:94927566~94963270:+
THCA	cis	rs6671200	1	rs259359	ENSG00000235501.4	RP4-639F20.1	3.66	0.000277	0.0187	0.33	0.17	Stearic acid (18:0) levels;	chr1:95243483	chr1:94927566~94963270:+
THCA	cis	rs6671200	0.79	rs259357	ENSG00000235501.4	RP4-639F20.1	3.66	0.000277	0.0187	0.33	0.17	Stearic acid (18:0) levels;	chr1:95245922	chr1:94927566~94963270:+
THCA	cis	rs6671200	1	rs6678964	ENSG00000235501.4	RP4-639F20.1	-3.66	0.000277	0.0187	-0.33	-0.17	Stearic acid (18:0) levels;	chr1:95228712	chr1:94927566~94963270:+
THCA	cis	rs8179	0.553	rs42038	ENSG00000230927.2	TMBIM7P	-3.66	0.000277	0.0187	-0.22	-0.17	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92614405	chr7:92412976~92439562:-
THCA	cis	rs7246657	1	rs1529957	ENSG00000268499.1	CTB-102L5.8	3.66	0.000277	0.0187	0.22	0.17	Coronary artery calcification;	chr19:37248899	chr19:38199836~38200934:+
THCA	cis	rs6005807	0.563	rs112609566	ENSG00000272858.1	CTA-292E10.8	-3.66	0.000277	0.0187	-0.28	-0.17	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28682710	chr22:28814914~28815662:+
THCA	cis	rs1005277	0.54	rs7903942	ENSG00000120555.12	SEPT7P9	-3.66	0.000277	0.0187	-0.18	-0.17	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38383069~38402916:-
THCA	cis	rs972578	1	rs5751410	ENSG00000274717.1	RP1-47A17.1	-3.66	0.000277	0.0187	-0.17	-0.17	Mean platelet volume;	chr22:42997979	chr22:42791814~42794313:-
THCA	cis	rs2179367	0.959	rs9373589	ENSG00000223701.3	RAET1E-AS1	3.66	0.000277	0.0187	0.22	0.17	Dupuytren's disease;	chr6:149386152	chr6:149884431~149919508:+
THCA	cis	rs6674970	1	rs6674970	ENSG00000261168.1	RP11-68I18.10	-3.66	0.000277	0.0187	-0.21	-0.17	Childhood ear infection;	chr1:151143803	chr1:151130075~151131610:-
THCA	cis	rs8177876	0.642	rs12445303	ENSG00000261838.4	RP11-303E16.6	-3.66	0.000277	0.0187	-0.28	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81069854~81076598:+
THCA	cis	rs7394190	0.748	rs11000728	ENSG00000272140.2	RP11-574K11.29	-3.66	0.000277	0.0187	-0.16	-0.17	Incident atrial fibrillation;	chr10:73644542	chr10:73703735~73713581:-
THCA	cis	rs8130944	0.964	rs7283732	ENSG00000225731.1	AP001627.1	3.66	0.000277	0.0187	0.2	0.17	Perceived unattractiveness to mosquitoes;	chr21:42717027	chr21:42733594~42741758:-
THCA	cis	rs11603020	0.95	rs11229067	ENSG00000254602.1	AP000662.4	3.66	0.000277	0.0187	0.19	0.17	Blood protein levels;	chr11:57607473	chr11:57638024~57652790:+
THCA	cis	rs11233413	1	rs7928570	ENSG00000246067.6	RAB30-AS1	3.66	0.000277	0.0187	0.16	0.17	Economic and political preferences (feminism/equality);	chr11:83010484	chr11:83072066~83106719:+
THCA	cis	rs11233413	1	rs11233413	ENSG00000246067.6	RAB30-AS1	3.66	0.000277	0.0187	0.16	0.17	Economic and political preferences (feminism/equality);	chr11:83012030	chr11:83072066~83106719:+
THCA	cis	rs9876781	1	rs3774808	ENSG00000199476.1	Y_RNA	-3.66	0.000277	0.0187	-0.21	-0.17	Longevity;	chr3:48440237	chr3:48288587~48288694:+
THCA	cis	rs10844706	0.699	rs7296241	ENSG00000214776.8	RP11-726G1.1	3.66	0.000277	0.0187	0.21	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725044	chr12:9467552~9576275:+
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000219891.2	ZSCAN12P1	3.66	0.000277	0.0187	0.23	0.17	Parkinson's disease;	chr6:28110633	chr6:28091154~28093664:+
THCA	cis	rs12681366	0.614	rs3099401	ENSG00000261437.1	RP11-22C11.2	3.66	0.000277	0.0187	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94473303	chr8:94637285~94639467:-
THCA	cis	rs8054556	0.751	rs11642430	ENSG00000183604.13	SMG1P5	-3.66	0.000277	0.0187	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30034468	chr16:30267553~30335374:-
THCA	cis	rs8054556	0.787	rs35105141	ENSG00000183604.13	SMG1P5	-3.66	0.000277	0.0187	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30045827	chr16:30267553~30335374:-
THCA	cis	rs4916588	0.708	rs6785916	ENSG00000270170.1	NCBP2-AS2	3.66	0.000277	0.0187	0.16	0.17	Night sleep phenotypes;	chr3:196952248	chr3:196942623~196943540:+
THCA	cis	rs11758351	1	rs77957229	ENSG00000216331.1	HIST1H1PS1	3.66	0.000277	0.0187	0.28	0.17	Renal underexcretion gout;Gout;	chr6:26184998	chr6:26195566~26195771:+
THCA	cis	rs929354	0.742	rs1182396	ENSG00000224629.1	RP5-1142J19.2	3.66	0.000277	0.0187	0.16	0.17	Body mass index;	chr7:157239137	chr7:157263022~157263229:-
THCA	cis	rs7577696	0.524	rs545303	ENSG00000276334.1	AL133243.1	3.66	0.000277	0.0187	0.18	0.17	Inflammatory biomarkers;	chr2:31588929	chr2:32521927~32523547:+
THCA	cis	rs2276314	0.947	rs16967319	ENSG00000267627.4	RP11-905K4.1	-3.66	0.000277	0.0187	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35951803~35966118:-
THCA	cis	rs12681366	0.708	rs2515157	ENSG00000261437.1	RP11-22C11.2	-3.66	0.000277	0.0187	-0.15	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94366302	chr8:94637285~94639467:-
THCA	cis	rs17122278	1	rs3741320	ENSG00000243431.1	RPL5P30	3.66	0.000277	0.0187	0.16	0.17	Total cholesterol levels;	chr11:118545132	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs3741319	ENSG00000243431.1	RPL5P30	3.66	0.000277	0.0187	0.16	0.17	Total cholesterol levels;	chr11:118545133	chr11:118560690~118561580:+
THCA	cis	rs12780845	0.931	rs17381591	ENSG00000273153.1	RP11-406H21.2	-3.66	0.000277	0.0187	-0.16	-0.17	Homocysteine levels;	chr10:17202049	chr10:17137336~17137585:-
THCA	cis	rs478304	0.654	rs7947604	ENSG00000214659.4	KRT8P26	3.66	0.000277	0.0187	0.16	0.17	Acne (severe);	chr11:65674588	chr11:65726939~65728214:+
THCA	cis	rs2214442	0.764	rs10231365	ENSG00000271133.4	CTA-293F17.1	-3.66	0.000277	0.0187	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20391962	chr7:20328299~20331747:-
THCA	cis	rs10181042	0.514	rs1177288	ENSG00000270820.4	RP11-355B11.2	3.66	0.000277	0.0187	0.14	0.17	Crohn's disease;	chr2:61125850	chr2:61471188~61484130:+
THCA	cis	rs10181042	0.514	rs1177289	ENSG00000270820.4	RP11-355B11.2	3.66	0.000277	0.0187	0.14	0.17	Crohn's disease;	chr2:61126121	chr2:61471188~61484130:+
THCA	cis	rs7959452	0.59	rs6581889	ENSG00000274979.1	RP11-1143G9.5	-3.66	0.000277	0.0187	-0.18	-0.17	Blood protein levels;	chr12:69363649	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.59	rs11177619	ENSG00000274979.1	RP11-1143G9.5	-3.66	0.000277	0.0187	-0.18	-0.17	Blood protein levels;	chr12:69365091	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.532	rs2291005	ENSG00000274979.1	RP11-1143G9.5	-3.66	0.000277	0.0187	-0.18	-0.17	Blood protein levels;	chr12:69370608	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.59	rs11177628	ENSG00000274979.1	RP11-1143G9.5	-3.66	0.000277	0.0187	-0.18	-0.17	Blood protein levels;	chr12:69371641	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.562	rs11177630	ENSG00000274979.1	RP11-1143G9.5	-3.66	0.000277	0.0187	-0.18	-0.17	Blood protein levels;	chr12:69374183	chr12:69326574~69331882:-
THCA	cis	rs17270561	0.609	rs1179086	ENSG00000272462.2	U91328.19	-3.66	0.000277	0.0187	-0.14	-0.17	Iron status biomarkers;	chr6:25791517	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs1165157	ENSG00000272462.2	U91328.19	-3.66	0.000277	0.0187	-0.14	-0.17	Iron status biomarkers;	chr6:25792022	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs1165156	ENSG00000272462.2	U91328.19	-3.66	0.000277	0.0187	-0.14	-0.17	Iron status biomarkers;	chr6:25792750	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.609	rs1165155	ENSG00000272462.2	U91328.19	-3.66	0.000277	0.0187	-0.14	-0.17	Iron status biomarkers;	chr6:25795349	chr6:25992662~26001775:+
THCA	cis	rs17270561	0.636	rs9393671	ENSG00000272462.2	U91328.19	3.66	0.000277	0.0187	0.14	0.17	Iron status biomarkers;	chr6:25788961	chr6:25992662~26001775:+
THCA	cis	rs733175	0.83	rs6820756	ENSG00000261490.1	RP11-448G15.3	-3.66	0.000277	0.0187	-0.12	-0.17	Psychosis and Alzheimer's disease;	chr4:10061225	chr4:10068089~10073019:-
THCA	cis	rs9863	0.861	rs7958691	ENSG00000269938.1	RP11-214K3.20	-3.66	0.000277	0.0187	-0.19	-0.17	White blood cell count;	chr12:123956196	chr12:123968023~123968579:-
THCA	cis	rs11030122	0.635	rs10835540	ENSG00000230593.3	AC090804.1	3.66	0.000277	0.0187	0.23	0.17	Mean platelet volume;Platelet distribution width;	chr11:4050199	chr11:3892398~3892887:-
THCA	cis	rs10256972	0.732	rs12701856	ENSG00000199023.2	MIR339	-3.66	0.000277	0.0187	-0.17	-0.17	Endometriosis;Longevity;	chr7:1068071	chr7:1022935~1023045:-
THCA	cis	rs6083	0.536	rs4528512	ENSG00000245975.2	RP11-30K9.6	3.66	0.000277	0.0187	0.14	0.17	Schizophrenia;	chr15:58560027	chr15:58768072~58770974:-
THCA	cis	rs7647973	0.6	rs35174559	ENSG00000228638.1	FCF1P2	-3.66	0.000277	0.0187	-0.17	-0.17	Menarche (age at onset);	chr3:49250326	chr3:48290793~48291375:-
THCA	cis	rs2486012	1	rs61770289	ENSG00000237950.1	RP11-7O11.3	-3.66	0.000277	0.0187	-0.2	-0.17	Intelligence (multi-trait analysis);	chr1:43898038	chr1:43944370~43946551:-
THCA	cis	rs7819412	0.806	rs2409689	ENSG00000254948.1	OR7E158P	3.66	0.000277	0.0187	0.2	0.17	Triglycerides;	chr8:11075358	chr8:11919900~11920809:-
THCA	cis	rs9467773	0.62	rs2504592	ENSG00000228223.2	HCG11	-3.66	0.000278	0.0187	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2504599	ENSG00000228223.2	HCG11	-3.66	0.000278	0.0187	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26523450~26526579:+
THCA	cis	rs9329221	0.537	rs2062331	ENSG00000261451.1	RP11-981G7.1	-3.66	0.000278	0.0187	-0.2	-0.17	Neuroticism;	chr8:10122482	chr8:10433672~10438312:+
THCA	cis	rs2579500	0.66	rs6711452	ENSG00000235584.2	AC008268.1	-3.66	0.000278	0.0187	-0.19	-0.17	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96473570	chr2:95666084~95668715:+
THCA	cis	rs7615952	0.546	rs4428131	ENSG00000241278.1	ENPP7P4	3.66	0.000278	0.0187	0.24	0.17	Blood pressure (smoking interaction);	chr3:125627635	chr3:125848223~125909372:+
THCA	cis	rs9980	0.843	rs7200764	ENSG00000226232.7	RP11-419C5.2	3.66	0.000278	0.0187	0.25	0.17	Blood osmolality (transformed sodium);	chr16:69514885	chr16:69976388~69996188:-
THCA	cis	rs18122	0.781	rs2156717	ENSG00000236780.4	AC078941.1	3.66	0.000278	0.0187	0.22	0.17	Waist-to-hip ratio adjusted for body mass index;	chr2:67389845	chr2:67123357~67215319:-
THCA	cis	rs72827839	0.649	rs80347400	ENSG00000266601.1	RP11-6N17.3	3.66	0.000278	0.0187	0.23	0.17	Ease of getting up in the morning;	chr17:47935136	chr17:47929682~47933106:-
THCA	cis	rs8002861	0.692	rs9533646	ENSG00000274001.1	RP11-5G9.5	-3.66	0.000278	0.0187	-0.2	-0.17	Leprosy;	chr13:43836533	chr13:43877715~43878163:-
THCA	cis	rs7613875	0.641	rs6446194	ENSG00000281691.1	RBM5-AS1	-3.66	0.000278	0.0187	-0.14	-0.17	Body mass index;	chr3:50029865	chr3:50099603~50100988:-
THCA	cis	rs7613875	0.578	rs4688753	ENSG00000281691.1	RBM5-AS1	-3.66	0.000278	0.0187	-0.14	-0.17	Body mass index;	chr3:50037340	chr3:50099603~50100988:-
THCA	cis	rs7613875	0.578	rs2526749	ENSG00000281691.1	RBM5-AS1	-3.66	0.000278	0.0187	-0.14	-0.17	Body mass index;	chr3:50039301	chr3:50099603~50100988:-
THCA	cis	rs7613875	0.62	rs7430334	ENSG00000281691.1	RBM5-AS1	-3.66	0.000278	0.0187	-0.14	-0.17	Body mass index;	chr3:50040788	chr3:50099603~50100988:-
THCA	cis	rs7613875	0.641	rs6793528	ENSG00000281691.1	RBM5-AS1	-3.66	0.000278	0.0187	-0.14	-0.17	Body mass index;	chr3:50062755	chr3:50099603~50100988:-
THCA	cis	rs7613875	0.578	rs2624822	ENSG00000281691.1	RBM5-AS1	-3.66	0.000278	0.0187	-0.14	-0.17	Body mass index;	chr3:50069786	chr3:50099603~50100988:-
THCA	cis	rs28510890	0.828	rs77955994	ENSG00000258676.4	RP11-386M24.3	3.66	0.000278	0.0187	0.17	0.17	Lung cancer in ever smokers;	chr15:92582299	chr15:92580829~92600545:+
THCA	cis	rs1865760	0.566	rs1539183	ENSG00000272810.1	U91328.22	-3.66	0.000278	0.0187	-0.13	-0.17	Height;	chr6:26074823	chr6:26013241~26013757:+
THCA	cis	rs586688	0.625	rs624041	ENSG00000224536.1	RP11-134G8.7	-3.66	0.000278	0.0187	-0.26	-0.17	Obesity-related traits;	chr1:201683641	chr1:201507241~201533608:+
THCA	cis	rs586688	0.625	rs688122	ENSG00000224536.1	RP11-134G8.7	-3.66	0.000278	0.0187	-0.26	-0.17	Obesity-related traits;	chr1:201684216	chr1:201507241~201533608:+
THCA	cis	rs11168618	0.81	rs11168595	ENSG00000240399.1	RP1-228P16.1	3.66	0.000278	0.0187	0.17	0.17	Adiponectin levels;	chr12:48474428	chr12:48054813~48055591:-
THCA	cis	rs11168618	0.743	rs12815151	ENSG00000240399.1	RP1-228P16.1	3.66	0.000278	0.0187	0.17	0.17	Adiponectin levels;	chr12:48481053	chr12:48054813~48055591:-
THCA	cis	rs9863	0.931	rs35825716	ENSG00000270028.1	RP11-380L11.4	3.66	0.000278	0.0187	0.18	0.17	White blood cell count;	chr12:123942977	chr12:123925461~123926083:-
THCA	cis	rs2278702	0.622	rs3848200	ENSG00000259495.2	RP11-210M15.2	-3.66	0.000278	0.0187	-0.25	-0.17	Bipolar disorder;	chr15:80350581	chr15:80344853~80403575:-
THCA	cis	rs7119038	0.686	rs55894437	ENSG00000255422.1	AP002954.4	3.66	0.000278	0.0187	0.2	0.17	Sjögren's syndrome;	chr11:118736708	chr11:118704607~118750263:+
THCA	cis	rs7267979	0.866	rs6138609	ENSG00000276952.1	RP5-965G21.6	3.66	0.000278	0.0187	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.816	rs3746337	ENSG00000274973.1	RP13-401N8.7	-3.66	0.000278	0.0187	-0.19	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25845497~25845862:+
THCA	cis	rs1433188	0.847	rs13439823	ENSG00000253582.1	RP11-649G15.2	3.66	0.000278	0.0187	0.19	0.17	Subjective well-being;	chr8:107428149	chr8:106520474~106657548:-
THCA	cis	rs1433188	0.81	rs4734967	ENSG00000253582.1	RP11-649G15.2	3.66	0.000278	0.0187	0.19	0.17	Subjective well-being;	chr8:107428698	chr8:106520474~106657548:-
THCA	cis	rs8064029	0.655	rs77468976	ENSG00000267077.1	RP11-127I20.5	3.66	0.000278	0.0187	0.26	0.17	Cancer;	chr16:4819249	chr16:4795265~4796532:-
THCA	cis	rs7614311	0.636	rs56165216	ENSG00000271843.1	RP11-245J9.5	-3.66	0.000278	0.0187	-0.28	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:63930944	chr3:64008082~64008692:-
THCA	cis	rs7129556	0.69	rs687037	ENSG00000254459.1	RP11-91P24.7	3.66	0.000278	0.0187	0.22	0.17	Weight loss (gastric bypass surgery);	chr11:77885058	chr11:77829654~77872262:-
THCA	cis	rs1823874	0.605	rs1840300	ENSG00000254744.3	CTD-3076O17.1	-3.66	0.000278	0.0187	-0.18	-0.17	IgG glycosylation;	chr15:99826739	chr15:99970215~99974010:+
THCA	cis	rs7614311	0.636	rs67944903	ENSG00000271843.1	RP11-245J9.5	-3.66	0.000278	0.0187	-0.27	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:63885519	chr3:64008082~64008692:-
THCA	cis	rs12539814	0.929	rs12671701	ENSG00000204959.4	ARHGEF34P	3.66	0.000278	0.0187	0.23	0.17	Diastolic blood pressure;	chr7:144459893	chr7:144272445~144286966:-
THCA	cis	rs11233413	1	rs11233405	ENSG00000246067.6	RAB30-AS1	-3.66	0.000278	0.0187	-0.17	-0.17	Economic and political preferences (feminism/equality);	chr11:82998588	chr11:83072066~83106719:+
THCA	cis	rs4601821	0.823	rs4938013	ENSG00000270179.1	RP11-159N11.4	-3.66	0.000278	0.0187	-0.17	-0.17	Alcoholic chronic pancreatitis;	chr11:113393748	chr11:113368478~113369117:+
THCA	cis	rs11190604	0.943	rs11190568	ENSG00000273030.1	RP11-285F16.1	3.66	0.000278	0.0187	0.2	0.17	Palmitoleic acid (16:1n-7) levels;	chr10:100464520	chr10:100412934~100413421:+
THCA	cis	rs7572644	0.766	rs13008539	ENSG00000223522.1	AC093690.1	-3.66	0.000278	0.0187	-0.22	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27951540	chr2:28307691~28310459:-
THCA	cis	rs1200921	0.898	rs1200885	ENSG00000272983.1	RP11-508N22.12	-3.66	0.000278	0.0187	-0.15	-0.17	Breast cancer;	chr10:37155357	chr10:38137337~38144399:+
THCA	cis	rs10896135	0.526	rs624561	ENSG00000255320.1	RP11-755F10.1	-3.66	0.000278	0.0187	-0.22	-0.17	Bipolar disorder;	chr11:66647444	chr11:66244840~66246239:-
THCA	cis	rs972578	0.806	rs5759008	ENSG00000230319.1	AL022476.2	3.66	0.000278	0.0187	0.18	0.17	Mean platelet volume;	chr22:42878361	chr22:43038585~43052366:+
THCA	cis	rs5758659	0.652	rs133305	ENSG00000281538.1	RP4-669P10.20	3.66	0.000278	0.0187	0.15	0.17	Cognitive function;	chr22:41999956	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.682	rs133306	ENSG00000281538.1	RP4-669P10.20	3.66	0.000278	0.0187	0.15	0.17	Cognitive function;	chr22:42000146	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.519	rs133307	ENSG00000281538.1	RP4-669P10.20	3.66	0.000278	0.0187	0.15	0.17	Cognitive function;	chr22:42000564	chr22:42138060~42139726:+
THCA	cis	rs832187	0.704	rs3774720	ENSG00000224479.4	AC136289.1	3.66	0.000278	0.0187	0.21	0.17	Schizophrenia;	chr3:63966089	chr3:63742293~63827445:-
THCA	cis	rs4742903	0.935	rs1507507	ENSG00000270332.1	SMC2-AS1	3.66	0.000278	0.0187	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104187148	chr9:104080024~104093073:-
THCA	cis	rs6599077	0.573	rs12486621	ENSG00000223797.4	ENTPD3-AS1	3.66	0.000278	0.0187	0.15	0.17	Sleep-related phenotypes;	chr3:40153864	chr3:40313802~40453329:-
THCA	cis	rs9650657	0.812	rs6993841	ENSG00000269918.1	AF131215.9	-3.66	0.000278	0.0187	-0.17	-0.17	Neuroticism;	chr8:10775174	chr8:11104691~11106704:-
THCA	cis	rs10266483	0.774	rs1404679	ENSG00000271550.1	BNIP3P11	-3.66	0.000278	0.0187	-0.22	-0.17	Response to statin therapy;	chr7:64358254	chr7:64678954~64687393:-
THCA	cis	rs7819412	0.502	rs4840548	ENSG00000261451.1	RP11-981G7.1	-3.66	0.000278	0.0187	-0.23	-0.17	Triglycerides;	chr8:11135373	chr8:10433672~10438312:+
THCA	cis	rs7176527	1	rs7176527	ENSG00000259683.1	RP11-182J1.14	3.66	0.000278	0.0187	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84389729~84395903:+
THCA	cis	rs478304	0.654	rs7115734	ENSG00000214659.4	KRT8P26	3.66	0.000278	0.0187	0.16	0.17	Acne (severe);	chr11:65691493	chr11:65726939~65728214:+
THCA	cis	rs478304	0.654	rs10896032	ENSG00000214659.4	KRT8P26	3.66	0.000278	0.0187	0.16	0.17	Acne (severe);	chr11:65691948	chr11:65726939~65728214:+
THCA	cis	rs478304	0.654	rs6591187	ENSG00000214659.4	KRT8P26	3.66	0.000278	0.0187	0.16	0.17	Acne (severe);	chr11:65692615	chr11:65726939~65728214:+
THCA	cis	rs478304	0.654	rs10896034	ENSG00000214659.4	KRT8P26	3.66	0.000278	0.0187	0.16	0.17	Acne (severe);	chr11:65693312	chr11:65726939~65728214:+
THCA	cis	rs9788721	0.902	rs7180002	ENSG00000261762.1	RP11-650L12.2	-3.66	0.000278	0.0187	-0.22	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78581651	chr15:78589123~78591276:-
THCA	cis	rs755249	0.565	rs3768320	ENSG00000182109.6	RP11-69E11.4	-3.66	0.000278	0.0187	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39522280~39546187:-
THCA	cis	rs9876781	1	rs1109227	ENSG00000199476.1	Y_RNA	-3.66	0.000278	0.0187	-0.21	-0.17	Longevity;	chr3:48437797	chr3:48288587~48288694:+
THCA	cis	rs2797160	1	rs1777183	ENSG00000226409.1	RP11-735G4.1	3.66	0.000278	0.0187	0.2	0.17	Endometrial cancer;	chr6:125690849	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1739375	ENSG00000226409.1	RP11-735G4.1	3.66	0.000278	0.0187	0.2	0.17	Endometrial cancer;	chr6:125690867	chr6:125370211~125374324:-
THCA	cis	rs4789693	0.938	rs12952655	ENSG00000279744.1	RP13-20L14.10	3.66	0.000278	0.0188	0.15	0.17	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82462601~82464255:+
THCA	cis	rs8131065	0.901	rs58358090	ENSG00000273199.1	AP000692.10	-3.66	0.000278	0.0188	-0.27	-0.17	Iris color (L* coordinate);	chr21:36634510	chr21:36319792~36320670:-
THCA	cis	rs8131065	1	rs58974617	ENSG00000273199.1	AP000692.10	-3.66	0.000278	0.0188	-0.27	-0.17	Iris color (L* coordinate);	chr21:36634567	chr21:36319792~36320670:-
THCA	cis	rs8131065	1	rs66608412	ENSG00000273199.1	AP000692.10	-3.66	0.000278	0.0188	-0.27	-0.17	Iris color (L* coordinate);	chr21:36635064	chr21:36319792~36320670:-
THCA	cis	rs8131065	1	rs7277492	ENSG00000273199.1	AP000692.10	-3.66	0.000278	0.0188	-0.27	-0.17	Iris color (L* coordinate);	chr21:36635334	chr21:36319792~36320670:-
THCA	cis	rs8131065	1	rs7278590	ENSG00000273199.1	AP000692.10	-3.66	0.000278	0.0188	-0.27	-0.17	Iris color (L* coordinate);	chr21:36635379	chr21:36319792~36320670:-
THCA	cis	rs765787	0.53	rs1706837	ENSG00000259539.1	CTD-2651B20.1	3.66	0.000278	0.0188	0.2	0.17	Uric acid levels;	chr15:45226838	chr15:45152664~45167526:-
THCA	cis	rs836788	0.608	rs26784	ENSG00000251221.1	LINC01337	-3.66	0.000278	0.0188	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr5:80754073	chr5:80608623~80622524:-
THCA	cis	rs836788	0.57	rs26783	ENSG00000251221.1	LINC01337	-3.66	0.000278	0.0188	-0.18	-0.17	Glomerular filtration rate (creatinine);	chr5:80754284	chr5:80608623~80622524:-
THCA	cis	rs6030712	0.58	rs1291126	ENSG00000213979.3	RPL7AP14	3.66	0.000278	0.0188	0.27	0.17	Height;	chr20:36881006	chr20:37444733~37445534:-
THCA	cis	rs5758659	0.622	rs129856	ENSG00000281538.1	RP4-669P10.20	3.66	0.000278	0.0188	0.15	0.17	Cognitive function;	chr22:42003392	chr22:42138060~42139726:+
THCA	cis	rs7264396	0.836	rs6120995	ENSG00000088340.14	FER1L4	3.66	0.000278	0.0188	0.17	0.17	Total cholesterol levels;	chr20:35597804	chr20:35558737~35607562:-
THCA	cis	rs2688608	0.592	rs10824032	ENSG00000272140.2	RP11-574K11.29	3.66	0.000278	0.0188	0.14	0.17	Inflammatory bowel disease;	chr10:73768372	chr10:73703735~73713581:-
THCA	cis	rs1979679	0.553	rs10459089	ENSG00000247934.4	RP11-967K21.1	-3.66	0.000278	0.0188	-0.16	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28115957	chr12:28163298~28190738:-
THCA	cis	rs9534288	0.74	rs7989892	ENSG00000235903.6	CPB2-AS1	3.66	0.000278	0.0188	0.24	0.17	Blood protein levels;	chr13:46056506	chr13:46052806~46113332:+
THCA	cis	rs2243480	1	rs709607	ENSG00000232559.3	GS1-124K5.12	-3.66	0.000278	0.0188	-0.25	-0.17	Diabetic kidney disease;	chr7:65984554	chr7:66554588~66576923:-
THCA	cis	rs6430585	0.591	rs12475553	ENSG00000231890.6	DARS-AS1	-3.66	0.000279	0.0188	-0.2	-0.17	Corneal structure;	chr2:135725785	chr2:135985176~136022593:+
THCA	cis	rs9549260	0.755	rs7985364	ENSG00000168852.11	TPTE2P5	3.66	0.000279	0.0188	0.12	0.17	Red blood cell count;	chr13:40605443	chr13:40822296~40921749:-
THCA	cis	rs10875746	0.624	rs10875777	ENSG00000226413.2	OR8T1P	3.66	0.000279	0.0188	0.23	0.17	Longevity (90 years and older);	chr12:48228288	chr12:48442030~48442947:-
THCA	cis	rs10875746	0.669	rs61941006	ENSG00000226413.2	OR8T1P	3.66	0.000279	0.0188	0.23	0.17	Longevity (90 years and older);	chr12:48237350	chr12:48442030~48442947:-
THCA	cis	rs10875746	0.669	rs1021313	ENSG00000226413.2	OR8T1P	3.66	0.000279	0.0188	0.23	0.17	Longevity (90 years and older);	chr12:48244258	chr12:48442030~48442947:-
THCA	cis	rs1577330	0.528	rs10967680	ENSG00000254396.1	RP11-56F10.3	3.66	0.000279	0.0188	0.2	0.17	IgG glycosylation;	chr9:27046343	chr9:27102630~27104728:+
THCA	cis	rs6740660	0.935	rs16865548	ENSG00000228446.2	AC073052.1	-3.66	0.000279	0.0188	-0.23	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil);	chr2:224082536	chr2:224499387~224500100:-
THCA	cis	rs9863	0.861	rs11835839	ENSG00000269938.1	RP11-214K3.20	-3.66	0.000279	0.0188	-0.19	-0.17	White blood cell count;	chr12:123946502	chr12:123968023~123968579:-
THCA	cis	rs944289	0.509	rs934075	ENSG00000188831.4	DPPA3P2	3.66	0.000279	0.0188	0.22	0.17	Thyroid cancer;	chr14:36169016	chr14:36371165~36372383:+
THCA	cis	rs720064	0.555	rs11873358	ENSG00000264745.1	TTC39C-AS1	3.66	0.000279	0.0188	0.18	0.17	Strep throat;	chr18:23951942	chr18:23994213~24015339:-
THCA	cis	rs1971762	0.583	rs2365345	ENSG00000270175.1	RP11-793H13.11	-3.66	0.000279	0.0188	-0.11	-0.17	Height;	chr12:53693036	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.583	rs1864448	ENSG00000270175.1	RP11-793H13.11	-3.66	0.000279	0.0188	-0.11	-0.17	Height;	chr12:53694072	chr12:53500162~53500936:-
THCA	cis	rs10863936	0.667	rs12070369	ENSG00000198468.6	FLVCR1-AS1	-3.66	0.000279	0.0188	-0.2	-0.17	Height;	chr1:211956808	chr1:212852108~212858088:-
THCA	cis	rs12034383	0.818	rs61822977	ENSG00000274245.1	RP11-357P18.2	-3.66	0.000279	0.0188	-0.15	-0.17	Erythrocyte sedimentation rate;	chr1:207622720	chr1:207372559~207373252:+
THCA	cis	rs12034383	0.875	rs11579070	ENSG00000274245.1	RP11-357P18.2	-3.66	0.000279	0.0188	-0.15	-0.17	Erythrocyte sedimentation rate;	chr1:207625796	chr1:207372559~207373252:+
THCA	cis	rs910316	1	rs2098297	ENSG00000259138.1	RP11-950C14.7	-3.66	0.000279	0.0188	-0.15	-0.17	Height;	chr14:75152415	chr14:75127153~75136930:+
THCA	cis	rs12476592	0.602	rs262505	ENSG00000242412.1	DBIL5P2	3.66	0.000279	0.0188	0.21	0.17	Childhood ear infection;	chr2:63634652	chr2:63117851~63119542:-
THCA	cis	rs7824557	0.547	rs2409745	ENSG00000254527.1	ENPP7P12	3.66	0.000279	0.0188	0.21	0.17	Retinal vascular caliber;	chr8:11219126	chr8:12205759~12206389:-
THCA	cis	rs9926296	0.572	rs2376878	ENSG00000260259.1	RP11-368I7.4	-3.66	0.000279	0.0188	-0.17	-0.17	Vitiligo;	chr16:89818753	chr16:89682620~89686569:-
THCA	cis	rs10954779	0.514	rs2262639	ENSG00000127589.4	TUBBP1	3.66	0.000279	0.0188	0.2	0.17	Intelligence (multi-trait analysis);	chr8:31103550	chr8:30351873~30353518:+
THCA	cis	rs7665090	0.967	rs5026469	ENSG00000251288.2	RP11-10L12.2	-3.66	0.000279	0.0188	-0.21	-0.17	Primary biliary cholangitis;	chr4:102633556	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.967	rs5026470	ENSG00000251288.2	RP11-10L12.2	-3.66	0.000279	0.0188	-0.21	-0.17	Primary biliary cholangitis;	chr4:102633565	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.967	rs5026471	ENSG00000251288.2	RP11-10L12.2	-3.66	0.000279	0.0188	-0.21	-0.17	Primary biliary cholangitis;	chr4:102633576	chr4:102751401~102752641:+
THCA	cis	rs7829975	0.522	rs6601689	ENSG00000233609.3	RP11-62H7.2	3.66	0.000279	0.0188	0.17	0.17	Mood instability;	chr8:8314761	chr8:8961200~8979025:+
THCA	cis	rs9878978	0.722	rs35000138	ENSG00000227588.2	CNTN4-AS2	3.66	0.000279	0.0188	0.22	0.17	Blood pressure (smoking interaction);	chr3:2395549	chr3:2110409~2144241:-
THCA	cis	rs12681288	0.55	rs4410933	ENSG00000260721.1	AF067845.1	3.66	0.000279	0.0188	0.2	0.17	Schizophrenia;	chr8:1009581	chr8:1368642~1369833:-
THCA	cis	rs7924176	0.521	rs11000959	ENSG00000232342.6	RP11-46O21.2	3.66	0.000279	0.0188	0.21	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74287053	chr10:74506081~74530553:-
THCA	cis	rs73222236	0.825	rs9833162	ENSG00000273486.1	RP11-731C17.2	3.66	0.000279	0.0188	0.15	0.17	Coronary artery disease;	chr3:136316895	chr3:136837338~136839021:-
THCA	cis	rs6504108	0.624	rs3792692	ENSG00000264920.1	RP11-6N17.4	-3.66	0.000279	0.0188	-0.14	-0.17	Body mass index;	chr17:48177730	chr17:47891255~47895812:-
THCA	cis	rs16975963	0.793	rs59616348	ENSG00000276846.1	CTD-3220F14.3	-3.66	0.000279	0.0188	-0.15	-0.17	Longevity;	chr19:37957113	chr19:37314868~37315620:-
THCA	cis	rs4845570	0.834	rs13376155	ENSG00000249602.1	RP11-98D18.3	-3.66	0.000279	0.0188	-0.27	-0.17	Coronary artery disease;	chr1:151748794	chr1:151763384~151769501:-
THCA	cis	rs4237845	0.788	rs1962047	ENSG00000270039.1	RP11-571M6.17	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr12:57898924	chr12:57803838~57804415:+
THCA	cis	rs2074409	0.531	rs4795208	ENSG00000277501.1	RP11-697E22.2	-3.66	0.000279	0.0188	-0.25	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37610704	chr17:37642947~37684252:+
THCA	cis	rs4950322	0.518	rs61838936	ENSG00000180867.10	PDIA3P1	3.66	0.000279	0.0188	0.17	0.17	Protein quantitative trait loci;	chr1:147098422	chr1:147178113~147179622:+
THCA	cis	rs758324	0.531	rs74698078	ENSG00000237714.1	P4HA2-AS1	-3.66	0.000279	0.0188	-0.35	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132078028	chr5:132184876~132192808:+
THCA	cis	rs9611565	0.659	rs28623192	ENSG00000237037.8	NDUFA6-AS1	3.66	0.000279	0.0188	0.16	0.17	Vitiligo;	chr22:41544520	chr22:42090931~42137742:+
THCA	cis	rs9425766	0.679	rs6681618	ENSG00000270084.1	GAS5-AS1	3.66	0.000279	0.0188	0.17	0.17	Life satisfaction;	chr1:174201203	chr1:173863248~173863941:+
THCA	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	3.66	0.000279	0.0188	0.17	0.17	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
THCA	cis	rs7772697	0.508	rs10457839	ENSG00000223701.3	RAET1E-AS1	-3.66	0.000279	0.0188	-0.24	-0.17	Diabetic retinopathy;	chr6:149053184	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.508	rs1934221	ENSG00000223701.3	RAET1E-AS1	-3.66	0.000279	0.0188	-0.24	-0.17	Diabetic retinopathy;	chr6:149053469	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.508	rs1934222	ENSG00000223701.3	RAET1E-AS1	-3.66	0.000279	0.0188	-0.24	-0.17	Diabetic retinopathy;	chr6:149053757	chr6:149884431~149919508:+
THCA	cis	rs4656958	0.93	rs11488696	ENSG00000233691.2	RP11-312J18.7	3.66	0.000279	0.0188	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160924320	chr1:160935537~160936126:+
THCA	cis	rs8054556	0.76	rs12598856	ENSG00000183604.13	SMG1P5	-3.66	0.000279	0.0188	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30018227	chr16:30267553~30335374:-
THCA	cis	rs6472235	1	rs28407694	ENSG00000272192.1	CTD-2532N20.1	3.66	0.000279	0.0188	0.16	0.17	Plateletcrit;Myopia (pathological);	chr8:65949503	chr8:65842752~65843331:+
THCA	cis	rs757081	0.671	rs214091	ENSG00000184669.7	OR7E14P	-3.66	0.000279	0.0188	-0.24	-0.17	Systolic blood pressure;	chr11:17274916	chr11:17013998~17053024:+
THCA	cis	rs2320614	0.967	rs12500406	ENSG00000250027.1	RP11-563E2.2	-3.66	0.000279	0.0188	-0.15	-0.17	Lung adenocarcinoma;	chr4:163113846	chr4:163108785~163119965:+
THCA	cis	rs7647973	0.769	rs6772452	ENSG00000229759.1	MRPS18AP1	3.66	0.000279	0.0188	0.25	0.17	Menarche (age at onset);	chr3:49003029	chr3:48256350~48256938:-
THCA	cis	rs758324	0.947	rs253943	ENSG00000237714.1	P4HA2-AS1	3.66	0.000279	0.0188	0.24	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131985037	chr5:132184876~132192808:+
THCA	cis	rs1005277	0.541	rs2505193	ENSG00000120555.12	SEPT7P9	3.66	0.000279	0.0188	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474580	ENSG00000120555.12	SEPT7P9	3.66	0.000279	0.0188	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38383069~38402916:-
THCA	cis	rs9467773	0.62	rs2504540	ENSG00000228223.2	HCG11	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.596	rs2451750	ENSG00000228223.2	HCG11	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.596	rs2451751	ENSG00000228223.2	HCG11	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2504600	ENSG00000228223.2	HCG11	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2130657	ENSG00000228223.2	HCG11	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2498351	ENSG00000228223.2	HCG11	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2504566	ENSG00000228223.2	HCG11	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2494716	ENSG00000228223.2	HCG11	-3.66	0.000279	0.0188	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26523450~26526579:+
THCA	cis	rs6546550	0.901	rs12232914	ENSG00000179818.12	PCBP1-AS1	-3.66	0.000279	0.0188	-0.13	-0.17	Prevalent atrial fibrillation;	chr2:69890044	chr2:69962263~70103220:-
THCA	cis	rs4561483	0.603	rs17235629	ENSG00000263307.1	RP11-166B2.8	3.66	0.000279	0.0188	0.17	0.17	Testicular germ cell tumor;	chr16:11838564	chr16:11851649~11895611:+
THCA	cis	rs1560104	0.833	rs4381588	ENSG00000259876.1	CTD-3037G24.4	3.66	0.000279	0.0188	0.18	0.17	Obesity-related traits;	chr16:12623414	chr16:12556353~12557694:-
THCA	cis	rs1560104	0.879	rs2865578	ENSG00000259876.1	CTD-3037G24.4	3.66	0.000279	0.0188	0.18	0.17	Obesity-related traits;	chr16:12623457	chr16:12556353~12557694:-
THCA	cis	rs75828804	1	rs12448886	ENSG00000260922.1	RP11-538I12.3	-3.66	0.000279	0.0188	-0.36	-0.17	Intraocular pressure;	chr16:77556817	chr16:77234877~77290934:+
THCA	cis	rs1876905	0.68	rs193281	ENSG00000271789.1	RP5-1112D6.7	3.66	0.000279	0.0188	0.21	0.17	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111297126~111298510:+
THCA	cis	rs4722585	0.533	rs757371	ENSG00000273237.1	CTB-119C2.1	-3.66	0.000279	0.0188	-0.16	-0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26159587	chr7:26173533~26174945:-
THCA	cis	rs12368653	0.641	rs11172300	ENSG00000270039.1	RP11-571M6.17	3.66	0.000279	0.0188	0.18	0.17	Multiple sclerosis;	chr12:57682732	chr12:57803838~57804415:+
THCA	cis	rs1923243	0.617	rs12724536	ENSG00000223479.3	RP4-788P17.1	3.66	0.000279	0.0188	0.18	0.17	Migraine;	chr1:72981021	chr1:73635216~73715214:+
THCA	cis	rs17496827	0.78	rs36099214	ENSG00000261428.2	RP11-16P6.1	3.66	0.000279	0.0188	0.16	0.17	Anorexia nervosa;	chr2:222490169	chr2:222566899~222569719:-
THCA	cis	rs2288884	1	rs76368799	ENSG00000260160.1	CTC-471J1.2	-3.66	0.000279	0.0188	-0.18	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058254	chr19:52058490~52063703:-
THCA	cis	rs2288884	1	rs72483951	ENSG00000260160.1	CTC-471J1.2	-3.66	0.000279	0.0188	-0.18	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52070429	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.943	rs12611112	ENSG00000260160.1	CTC-471J1.2	-3.66	0.000279	0.0188	-0.18	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52071686	chr19:52058490~52063703:-
THCA	cis	rs2288884	1	rs56808319	ENSG00000260160.1	CTC-471J1.2	-3.66	0.000279	0.0188	-0.18	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074621	chr19:52058490~52063703:-
THCA	cis	rs972578	1	rs1071961	ENSG00000230319.1	AL022476.2	3.66	0.000279	0.0188	0.17	0.17	Mean platelet volume;	chr22:42953693	chr22:43038585~43052366:+
THCA	cis	rs3845817	0.868	rs702942	ENSG00000281920.1	RP11-418H16.1	-3.66	0.000279	0.0188	-0.2	-0.17	Bipolar disorder;	chr2:65529831	chr2:65623272~65628424:+
THCA	cis	rs10129255	0.913	rs28861466	ENSG00000211972.2	IGHV3-66	3.66	0.000279	0.0188	0.1	0.17	Kawasaki disease;	chr14:106718572	chr14:106675017~106675544:-
THCA	cis	rs765787	0.53	rs2413785	ENSG00000259932.1	CTD-2651B20.7	3.66	0.000279	0.0188	0.2	0.17	Uric acid levels;	chr15:45238183	chr15:45198517~45199139:-
THCA	cis	rs9329221	0.537	rs6983332	ENSG00000261451.1	RP11-981G7.1	-3.66	0.000279	0.0188	-0.2	-0.17	Neuroticism;	chr8:10120408	chr8:10433672~10438312:+
THCA	cis	rs2129782	0.558	rs73277624	ENSG00000253553.4	RP11-586K2.1	3.66	0.00028	0.0188	0.24	0.17	Electrodermal activity;	chr8:88475765	chr8:88326836~88737134:+
THCA	cis	rs853679	0.517	rs4713141	ENSG00000219891.2	ZSCAN12P1	3.66	0.00028	0.0188	0.24	0.17	Depression;	chr6:28133900	chr6:28091154~28093664:+
THCA	cis	rs4604234	0.614	rs73479918	ENSG00000260645.1	RP11-250B2.5	-3.66	0.00028	0.0188	-0.28	-0.17	Cancer;	chr6:80130255	chr6:80466958~80469080:+
THCA	cis	rs7615952	0.599	rs66532274	ENSG00000248787.1	RP11-666A20.4	-3.66	0.00028	0.0188	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126013002	chr3:125908005~125910272:-
THCA	cis	rs6942407	0.592	rs6966613	ENSG00000224046.1	AC005076.5	-3.66	0.00028	0.0188	-0.15	-0.17	Food allergy;	chr7:87164178	chr7:87151423~87152420:-
THCA	cis	rs4792901	0.802	rs2242598	ENSG00000267151.3	RP11-100E5.2	3.66	0.00028	0.0188	0.18	0.17	Dupuytren's disease;	chr17:43533030	chr17:43444707~43451200:+
THCA	cis	rs11064837	0.504	rs11064850	ENSG00000248636.5	RP11-768F21.1	3.66	0.00028	0.0188	0.19	0.17	Schizophrenia;	chr12:119617981	chr12:119387987~119668079:-
THCA	cis	rs4908768	0.539	rs6670508	ENSG00000270282.1	RP5-1115A15.2	3.66	0.00028	0.0188	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8512653~8513021:+
THCA	cis	rs28595532	0.748	rs67928655	ENSG00000260404.2	RP11-384K6.6	-3.66	0.00028	0.0188	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118415370	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.748	rs66615663	ENSG00000260404.2	RP11-384K6.6	-3.66	0.00028	0.0188	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118415546	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.8	rs67686161	ENSG00000260404.2	RP11-384K6.6	-3.66	0.00028	0.0188	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118415565	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.748	rs113336496	ENSG00000260404.2	RP11-384K6.6	-3.66	0.00028	0.0188	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118415802	chr4:118591773~118633729:+
THCA	cis	rs7665090	0.806	rs434644	ENSG00000230069.3	LRRC37A15P	3.66	0.00028	0.0188	0.17	0.17	Primary biliary cholangitis;	chr4:102662032	chr4:102727274~102730721:-
THCA	cis	rs3790515	0.826	rs2280471	ENSG00000203288.3	RP11-98D18.9	3.66	0.00028	0.0188	0.2	0.17	Depressive symptoms (SSRI exposure interaction);	chr1:151811260	chr1:151790804~151794402:+
THCA	cis	rs453301	0.631	rs17700611	ENSG00000253981.4	ALG1L13P	-3.66	0.00028	0.0188	-0.17	-0.17	Joint mobility (Beighton score);	chr8:8936144	chr8:8236003~8244667:-
THCA	cis	rs8105895	1	rs6511313	ENSG00000269345.1	VN1R85P	3.66	0.00028	0.0188	0.22	0.17	Body mass index (change over time);	chr19:22033103	chr19:22174766~22175191:-
THCA	cis	rs1552244	0.554	rs6762702	ENSG00000269982.1	RP11-1020A11.2	3.66	0.00028	0.0188	0.12	0.17	Alzheimer's disease;	chr3:10014105	chr3:9958717~9962539:+
THCA	cis	rs11710088	1	rs11710088	ENSG00000244503.1	RP11-278L15.6	3.66	0.00028	0.0188	0.21	0.17	QRS duration;	chr3:149475320	chr3:149494660~149495995:+
THCA	cis	rs6546886	0.912	rs12713809	ENSG00000235499.1	AC073046.25	3.66	0.00028	0.0188	0.15	0.17	Dialysis-related mortality;	chr2:74080070	chr2:73985132~73986343:+
THCA	cis	rs13217239	0.646	rs7451149	ENSG00000261353.1	CTA-14H9.5	3.66	0.00028	0.0188	0.17	0.17	Schizophrenia;	chr6:27089739	chr6:26527063~26527404:+
THCA	cis	rs4930561	0.765	rs34493482	ENSG00000184795.9	UNC93B5	-3.66	0.00028	0.0188	-0.19	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68202041	chr11:67711702~67716005:-
THCA	cis	rs420259	0.516	rs428438	ENSG00000260136.4	CTD-2270L9.4	3.66	0.00028	0.0188	0.13	0.17	Bipolar disorder;	chr16:23450433	chr16:23452758~23457606:+
THCA	cis	rs250585	0.79	rs437647	ENSG00000260136.4	CTD-2270L9.4	3.66	0.00028	0.0188	0.13	0.17	Egg allergy;	chr16:23450734	chr16:23452758~23457606:+
THCA	cis	rs73222236	0.825	rs6439638	ENSG00000273486.1	RP11-731C17.2	3.66	0.00028	0.0188	0.15	0.17	Coronary artery disease;	chr3:136338990	chr3:136837338~136839021:-
THCA	cis	rs2274273	0.87	rs3783652	ENSG00000258469.1	CHMP4BP1	3.66	0.00028	0.0188	0.15	0.17	Protein biomarker;	chr14:55387490	chr14:55298644~55299231:+
THCA	cis	rs13108904	0.87	rs4974543	ENSG00000254094.1	AC078852.1	-3.66	0.00028	0.0188	-0.2	-0.17	Obesity-related traits;	chr4:1257434	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.87	rs13132584	ENSG00000254094.1	AC078852.1	-3.66	0.00028	0.0188	-0.2	-0.17	Obesity-related traits;	chr4:1257716	chr4:1356581~1358075:+
THCA	cis	rs11105298	0.891	rs11105325	ENSG00000266347.2	AC068641.1	3.66	0.00028	0.0189	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89592833~89592927:+
THCA	cis	rs3845817	0.703	rs702909	ENSG00000281920.1	RP11-418H16.1	3.66	0.00028	0.0189	0.2	0.17	Bipolar disorder;	chr2:65540113	chr2:65623272~65628424:+
THCA	cis	rs1411478	1	rs4652545	ENSG00000243155.1	RP11-46A10.5	3.66	0.00028	0.0189	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180978472	chr1:180944042~180976482:-
THCA	cis	rs1411478	1	rs7516739	ENSG00000243155.1	RP11-46A10.5	3.66	0.00028	0.0189	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180979370	chr1:180944042~180976482:-
THCA	cis	rs1411478	1	rs7528526	ENSG00000243155.1	RP11-46A10.5	3.66	0.00028	0.0189	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180979438	chr1:180944042~180976482:-
THCA	cis	rs1411478	1	rs2331903	ENSG00000243155.1	RP11-46A10.5	3.66	0.00028	0.0189	0.18	0.17	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180981733	chr1:180944042~180976482:-
THCA	cis	rs34975555	0.892	rs17635381	ENSG00000253671.1	RP11-806O11.1	3.66	0.00028	0.0189	0.26	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17960044	chr8:17808941~17820868:+
THCA	cis	rs2839186	0.632	rs17176110	ENSG00000228137.1	AP001469.7	3.66	0.00028	0.0189	0.17	0.17	Testicular germ cell tumor;	chr21:46286621	chr21:46246890~46247682:+
THCA	cis	rs73198271	0.722	rs488566	ENSG00000253981.4	ALG1L13P	-3.66	0.00028	0.0189	-0.17	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8782065	chr8:8236003~8244667:-
THCA	cis	rs740750	1	rs3816018	ENSG00000254333.1	CTC-367J11.1	-3.66	0.00028	0.0189	-0.2	-0.17	Cerebrospinal fluid biomarker levels;	chr5:150128912	chr5:150475531~150485968:-
THCA	cis	rs7824557	0.527	rs4634600	ENSG00000227888.4	FAM66A	-3.66	0.00028	0.0189	-0.21	-0.17	Retinal vascular caliber;	chr8:11381508	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.527	rs4631425	ENSG00000227888.4	FAM66A	-3.66	0.00028	0.0189	-0.21	-0.17	Retinal vascular caliber;	chr8:11381545	chr8:12362019~12388296:+
THCA	cis	rs3808502	0.585	rs4549730	ENSG00000227888.4	FAM66A	-3.66	0.00028	0.0189	-0.21	-0.17	Neuroticism;	chr8:11381569	chr8:12362019~12388296:+
THCA	cis	rs16986825	0.57	rs5752822	ENSG00000272858.1	CTA-292E10.8	-3.66	0.00028	0.0189	-0.19	-0.17	Pancreatic cancer;	chr22:28870037	chr22:28814914~28815662:+
THCA	cis	rs7246657	0.943	rs4803460	ENSG00000268499.1	CTB-102L5.8	3.66	0.00028	0.0189	0.21	0.17	Coronary artery calcification;	chr19:37394326	chr19:38199836~38200934:+
THCA	cis	rs9426935	0.527	rs2790690	ENSG00000231416.1	RP11-422P24.9	3.66	0.00028	0.0189	0.2	0.17	Lentiform nucleus volume;	chr1:154086900	chr1:153995632~153995960:+
THCA	cis	rs2638953	0.853	rs1355475	ENSG00000247934.4	RP11-967K21.1	-3.66	0.00028	0.0189	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482398	chr12:28163298~28190738:-
THCA	cis	rs293748	0.771	rs158799	ENSG00000250155.1	CTD-2353F22.1	-3.66	0.00028	0.0189	-0.22	-0.17	Obesity-related traits;	chr5:36869149	chr5:36666214~36725195:-
THCA	cis	rs806215	1	rs712703	ENSG00000279265.1	AC000123.3	3.66	0.00028	0.0189	0.2	0.17	Type 2 diabetes;	chr7:127617444	chr7:127349833~127350293:-
THCA	cis	rs9475677	0.953	rs17225591	ENSG00000231441.1	RP11-472M19.2	3.66	0.00028	0.0189	0.21	0.17	Gut microbiota (functional units);	chr6:56352496	chr6:56844002~56864078:+
THCA	cis	rs16959442	0.786	rs921512	ENSG00000254912.2	RP11-632K20.2	-3.66	0.00028	0.0189	-0.25	-0.17	Lobe attachment (rater-scored or self-reported);	chr15:32825047	chr15:32494003~32500346:-
THCA	cis	rs7711186	0.786	rs6600942	ENSG00000252464.1	RN7SKP70	3.66	0.00028	0.0189	0.18	0.17	Urate levels in obese individuals;	chr5:178642105	chr5:178619728~178619998:-
THCA	cis	rs988712	0.921	rs7124596	ENSG00000245573.6	BDNF-AS	3.66	0.00028	0.0189	0.15	0.17	Obesity;	chr11:27573011	chr11:27506838~27698174:+
THCA	cis	rs7613875	0.62	rs7634441	ENSG00000281691.1	RBM5-AS1	-3.66	0.00028	0.0189	-0.14	-0.17	Body mass index;	chr3:50034244	chr3:50099603~50100988:-
THCA	cis	rs4722166	0.598	rs4722178	ENSG00000225541.1	AC002480.5	-3.66	0.00028	0.0189	-0.19	-0.17	Lung cancer;	chr7:22759031	chr7:22571607~22661792:-
THCA	cis	rs1552172	0.734	rs9729027	ENSG00000234222.5	RP11-315I20.1	3.66	0.00028	0.0189	0.21	0.17	Breast cancer;	chr1:145842998	chr1:145926590~145959179:+
THCA	cis	rs1959947	0.833	rs4904239	ENSG00000251363.2	RP11-129M6.1	3.66	0.00028	0.0189	0.22	0.17	Hemostatic factors and hematological phenotypes;	chr14:41083175	chr14:40954898~40975877:+
THCA	cis	rs10090774	0.965	rs10105905	ENSG00000280303.2	ERICD	-3.66	0.00028	0.0189	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140850796	chr8:140636281~140638283:+
THCA	cis	rs10844154	0.638	rs326643	ENSG00000277342.1	RP11-843B15.4	3.66	0.00028	0.0189	0.2	0.17	Emphysema-related traits;Weight;	chr12:32248228	chr12:32109076~32109602:+
THCA	cis	rs911555	0.603	rs11621300	ENSG00000269958.1	RP11-73M18.8	3.66	0.00028	0.0189	0.16	0.17	Intelligence (multi-trait analysis);	chr14:103378561	chr14:103696353~103697163:+
THCA	cis	rs7660883	0.897	rs2125787	ENSG00000251411.1	RP11-397E7.4	3.66	0.00028	0.0189	0.15	0.17	HDL cholesterol levels;	chr4:87075471	chr4:86913266~86914817:-
THCA	cis	rs7259376	0.936	rs1975173	ENSG00000269138.1	ZNF209P	3.66	0.00028	0.0189	0.17	0.17	Menopause (age at onset);	chr19:22351736	chr19:22463922~22473036:+
THCA	cis	rs9393813	0.528	rs9468141	ENSG00000271755.1	RP1-153G14.4	3.66	0.00028	0.0189	0.19	0.17	Bipolar disorder;	chr6:27506748	chr6:27404010~27406964:-
THCA	cis	rs7010267	0.773	rs72680380	ENSG00000254278.1	RP11-278I4.2	3.66	0.00028	0.0189	0.21	0.17	Total body bone mineral density (age 45-60);	chr8:118920502	chr8:119062942~119068782:-
THCA	cis	rs2836974	0.966	rs2836977	ENSG00000255568.3	BRWD1-AS2	3.66	0.00028	0.0189	0.15	0.17	Cognitive function;	chr21:39294140	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.865	rs34778912	ENSG00000255568.3	BRWD1-AS2	3.66	0.00028	0.0189	0.15	0.17	Cognitive function;	chr21:39295111	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.865	rs7282624	ENSG00000255568.3	BRWD1-AS2	3.66	0.00028	0.0189	0.15	0.17	Cognitive function;	chr21:39295114	chr21:39313935~39314962:+
THCA	cis	rs2836974	0.931	rs13625	ENSG00000255568.3	BRWD1-AS2	3.66	0.00028	0.0189	0.15	0.17	Cognitive function;	chr21:39297157	chr21:39313935~39314962:+
THCA	cis	rs9303542	0.694	rs12940931	ENSG00000278765.1	RP5-890E16.5	-3.66	0.00028	0.0189	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48259402	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs12943082	ENSG00000278765.1	RP5-890E16.5	-3.66	0.00028	0.0189	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48268623	chr17:48066704~48067293:-
THCA	cis	rs11756659	0.653	rs412968	ENSG00000272462.2	U91328.19	3.66	0.000281	0.0189	0.16	0.17	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25953965	chr6:25992662~26001775:+
THCA	cis	rs2904967	0.703	rs239257	ENSG00000254614.2	AP003068.23	-3.66	0.000281	0.0189	-0.41	-0.17	Mean corpuscular volume;	chr11:65221600	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.703	rs239261	ENSG00000254614.2	AP003068.23	-3.66	0.000281	0.0189	-0.41	-0.17	Mean corpuscular volume;	chr11:65225886	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.703	rs541829	ENSG00000254614.2	AP003068.23	-3.66	0.000281	0.0189	-0.41	-0.17	Mean corpuscular volume;	chr11:65230266	chr11:65177606~65181834:-
THCA	cis	rs10760158	0.8	rs10760167	ENSG00000235865.2	GSN-AS1	3.66	0.000281	0.0189	0.14	0.17	Pulse pressure;	chr9:121273267	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs7862876	ENSG00000235865.2	GSN-AS1	3.66	0.000281	0.0189	0.14	0.17	Pulse pressure;	chr9:121273818	chr9:121280768~121285530:-
THCA	cis	rs4664293	1	rs10204535	ENSG00000230783.1	AC009961.2	-3.66	0.000281	0.0189	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159607181	chr2:159689217~159690291:-
THCA	cis	rs17286411	0.642	rs3848389	ENSG00000260185.1	RP11-432I5.6	-3.66	0.000281	0.0189	-0.24	-0.17	Blood protein levels;	chr16:71806012	chr16:71655027~71664212:+
THCA	cis	rs7843479	0.965	rs17581910	ENSG00000208037.1	MIR320A	-3.66	0.000281	0.0189	-0.21	-0.17	Mean corpuscular volume;	chr8:21942115	chr8:22244962~22245043:-
THCA	cis	rs7843479	0.965	rs13278159	ENSG00000208037.1	MIR320A	-3.66	0.000281	0.0189	-0.21	-0.17	Mean corpuscular volume;	chr8:21942226	chr8:22244962~22245043:-
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000237310.1	GS1-124K5.4	3.66	0.000281	0.0189	0.19	0.17	Diabetic kidney disease;	chr7:65970805	chr7:66493706~66495474:+
THCA	cis	rs2303282	0.506	rs600390	ENSG00000274031.1	RP11-413H22.3	3.66	0.000281	0.0189	0.2	0.17	Breast cancer;	chr16:56535016	chr16:56465642~56466162:-
THCA	cis	rs9788682	0.747	rs3743078	ENSG00000261143.1	ADAMTS7P3	3.66	0.000281	0.0189	0.23	0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78602417	chr15:77976042~77993057:+
THCA	cis	rs74233809	0.636	rs284861	ENSG00000213277.3	MARCKSL1P1	-3.66	0.000281	0.0189	-0.23	-0.17	Birth weight;	chr10:102812519	chr10:103175554~103176094:+
THCA	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	3.66	0.000281	0.0189	0.15	0.17	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
THCA	cis	rs7665090	0.714	rs5026475	ENSG00000248971.2	KRT8P46	-3.66	0.000281	0.0189	-0.19	-0.17	Primary biliary cholangitis;	chr4:102633664	chr4:102728746~102730171:-
THCA	cis	rs7259376	0.936	rs6511344	ENSG00000269138.1	ZNF209P	3.66	0.000281	0.0189	0.17	0.17	Menopause (age at onset);	chr19:22352871	chr19:22463922~22473036:+
THCA	cis	rs765787	0.53	rs4775819	ENSG00000259539.1	CTD-2651B20.1	3.66	0.000281	0.0189	0.2	0.17	Uric acid levels;	chr15:45233768	chr15:45152664~45167526:-
THCA	cis	rs5758659	0.652	rs5758537	ENSG00000281538.1	RP4-669P10.20	3.66	0.000281	0.0189	0.15	0.17	Cognitive function;	chr22:42001038	chr22:42138060~42139726:+
THCA	cis	rs28530618	0.87	rs6058790	ENSG00000198547.7	C20orf203	-3.66	0.000281	0.0189	-0.12	-0.17	Birth weight;	chr20:32659515	chr20:32631652~32673941:-
THCA	cis	rs944289	0.561	rs1755769	ENSG00000212071.1	AL162511.1	3.66	0.000281	0.0189	0.21	0.17	Thyroid cancer;	chr14:36193617	chr14:36196480~36196568:-
THCA	cis	rs28595532	0.748	rs115651241	ENSG00000260404.2	RP11-384K6.6	-3.66	0.000281	0.0189	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118442354	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.702	rs72670256	ENSG00000260404.2	RP11-384K6.6	-3.66	0.000281	0.0189	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118469888	chr4:118591773~118633729:+
THCA	cis	rs7614311	0.563	rs10510907	ENSG00000271843.1	RP11-245J9.5	-3.66	0.000281	0.0189	-0.24	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:63779376	chr3:64008082~64008692:-
THCA	cis	rs7520050	0.966	rs12049588	ENSG00000280836.1	AL355480.1	3.66	0.000281	0.0189	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs12021587	ENSG00000280836.1	AL355480.1	3.66	0.000281	0.0189	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45581219~45581321:-
THCA	cis	rs10940346	0.506	rs7704183	ENSG00000271752.1	RP11-269M20.3	3.66	0.000281	0.0189	0.17	0.17	Schizophrenia;	chr5:50576738	chr5:50662859~50663266:-
THCA	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	3.66	0.000281	0.0189	0.2	0.17	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
THCA	cis	rs2033711	0.84	rs10423138	ENSG00000232098.3	CTD-2619J13.14	3.66	0.000281	0.0189	0.15	0.17	Uric acid clearance;	chr19:58416935	chr19:58404238~58408484:-
THCA	cis	rs2836326	1	rs2836326	ENSG00000231231.4	LINC01423	3.66	0.000281	0.0189	0.2	0.17	Metabolite levels (HVA);	chr21:38349842	chr21:38323635~38333421:-
THCA	cis	rs11710088	0.931	rs1802837	ENSG00000244503.1	RP11-278L15.6	3.66	0.000281	0.0189	0.21	0.17	QRS duration;	chr3:149475897	chr3:149494660~149495995:+
THCA	cis	rs11710088	0.931	rs3890113	ENSG00000244503.1	RP11-278L15.6	3.66	0.000281	0.0189	0.21	0.17	QRS duration;	chr3:149476254	chr3:149494660~149495995:+
THCA	cis	rs11710088	0.895	rs4321472	ENSG00000244503.1	RP11-278L15.6	3.66	0.000281	0.0189	0.21	0.17	QRS duration;	chr3:149477951	chr3:149494660~149495995:+
THCA	cis	rs11710088	0.931	rs4577407	ENSG00000244503.1	RP11-278L15.6	-3.66	0.000281	0.0189	-0.21	-0.17	QRS duration;	chr3:149477962	chr3:149494660~149495995:+
THCA	cis	rs11175194	0.744	rs57082798	ENSG00000255642.1	PABPC1P4	3.66	0.000281	0.0189	0.42	0.17	Epithelial ovarian cancer;	chr12:63837625	chr12:63822021~63823895:+
THCA	cis	rs2839186	0.934	rs17182538	ENSG00000228137.1	AP001469.7	3.66	0.000281	0.0189	0.16	0.17	Testicular germ cell tumor;	chr21:46285759	chr21:46246890~46247682:+
THCA	cis	rs9796	0.558	rs11855102	ENSG00000247556.5	OIP5-AS1	3.66	0.000281	0.0189	0.13	0.17	Menopause (age at onset);	chr15:41221059	chr15:41283990~41309737:+
THCA	cis	rs2638953	0.853	rs12367657	ENSG00000247934.4	RP11-967K21.1	-3.66	0.000281	0.0189	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475816	chr12:28163298~28190738:-
THCA	cis	rs2625529	0.824	rs12901886	ENSG00000260037.4	CTD-2524L6.3	-3.66	0.000281	0.0189	-0.23	-0.17	Red blood cell count;	chr15:72115728	chr15:71818396~71823384:+
THCA	cis	rs11175834	0.655	rs10047609	ENSG00000277945.1	RP11-677M24.1	-3.66	0.000281	0.0189	-0.24	-0.17	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65582534	chr12:65830750~65831050:+
THCA	cis	rs1476679	0.927	rs2405442	ENSG00000240211.1	RP11-758P17.3	-3.66	0.000281	0.0189	-0.17	-0.17	Alzheimer's disease (late onset);	chr7:100373690	chr7:100436204~100438504:+
THCA	cis	rs1559040	0.527	rs114498542	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000281	0.0189	-0.3	-0.17	Sudden cardiac arrest;	chr2:54006169	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.722	rs72799301	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000281	0.0189	-0.3	-0.17	Sudden cardiac arrest;	chr2:54009336	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.79	rs11676433	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000281	0.0189	-0.3	-0.17	Sudden cardiac arrest;	chr2:54009788	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.79	rs998381	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000281	0.0189	-0.3	-0.17	Sudden cardiac arrest;	chr2:54011519	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.656	rs11688581	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000281	0.0189	-0.3	-0.17	Sudden cardiac arrest;	chr2:54022591	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.79	rs55666400	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000281	0.0189	-0.3	-0.17	Sudden cardiac arrest;	chr2:54029350	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.79	rs115324582	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000281	0.0189	-0.3	-0.17	Sudden cardiac arrest;	chr2:54037461	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.79	rs28416116	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000281	0.0189	-0.3	-0.17	Sudden cardiac arrest;	chr2:54039080	chr2:54082554~54085066:+
THCA	cis	rs7432375	0.61	rs7621932	ENSG00000273486.1	RP11-731C17.2	3.66	0.000281	0.0189	0.14	0.17	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136798174	chr3:136837338~136839021:-
THCA	cis	rs7432375	0.61	rs7633629	ENSG00000273486.1	RP11-731C17.2	3.66	0.000281	0.0189	0.14	0.17	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136798186	chr3:136837338~136839021:-
THCA	cis	rs8023401	0.507	rs56686382	ENSG00000259705.1	RP11-227D13.1	3.66	0.000281	0.0189	0.2	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48474053	chr15:48645951~48652016:+
THCA	cis	rs4906332	0.782	rs2236281	ENSG00000269940.1	RP11-73M18.7	3.66	0.000281	0.0189	0.18	0.17	Coronary artery disease;	chr14:103534181	chr14:103694560~103695170:+
THCA	cis	rs12544026	0.581	rs549281	ENSG00000253669.3	KB-1732A1.1	3.66	0.000281	0.0189	0.19	0.17	Major depression and alcohol dependence;	chr8:101882788	chr8:102805517~102809971:+
THCA	cis	rs9420	0.528	rs7117896	ENSG00000254602.1	AP000662.4	-3.66	0.000281	0.0189	-0.19	-0.17	Schizophrenia;	chr11:57621078	chr11:57638024~57652790:+
THCA	cis	rs9863	0.861	rs10846579	ENSG00000269938.1	RP11-214K3.20	-3.66	0.000281	0.0189	-0.19	-0.17	White blood cell count;	chr12:123922856	chr12:123968023~123968579:-
THCA	cis	rs9863	0.861	rs11057394	ENSG00000269938.1	RP11-214K3.20	-3.66	0.000281	0.0189	-0.19	-0.17	White blood cell count;	chr12:123923129	chr12:123968023~123968579:-
THCA	cis	rs9863	0.861	rs12809125	ENSG00000269938.1	RP11-214K3.20	-3.66	0.000281	0.0189	-0.19	-0.17	White blood cell count;	chr12:123923444	chr12:123968023~123968579:-
THCA	cis	rs184234	0.764	rs304115	ENSG00000279970.1	RP11-299G20.5	3.66	0.000281	0.0189	0.23	0.17	Response to taxane treatment (placlitaxel);	chr15:100713352	chr15:101299656~101301648:-
THCA	cis	rs9426935	0.527	rs7537213	ENSG00000231416.1	RP11-422P24.9	-3.66	0.000281	0.0189	-0.2	-0.17	Lentiform nucleus volume;	chr1:154099811	chr1:153995632~153995960:+
THCA	cis	rs9611565	0.659	rs9607812	ENSG00000281538.1	RP4-669P10.20	3.66	0.000281	0.0189	0.19	0.17	Vitiligo;	chr22:41545239	chr22:42138060~42139726:+
THCA	cis	rs9611565	0.659	rs9607813	ENSG00000281538.1	RP4-669P10.20	3.66	0.000281	0.0189	0.19	0.17	Vitiligo;	chr22:41545475	chr22:42138060~42139726:+
THCA	cis	rs9611565	0.659	rs9611609	ENSG00000281538.1	RP4-669P10.20	3.66	0.000281	0.0189	0.19	0.17	Vitiligo;	chr22:41549353	chr22:42138060~42139726:+
THCA	cis	rs6445967	0.933	rs6796069	ENSG00000272360.1	RP11-359I18.5	3.66	0.000281	0.0189	0.18	0.17	Platelet count;	chr3:58346781	chr3:58490830~58491291:-
THCA	cis	rs12887734	0.524	rs12588797	ENSG00000258735.1	LINC00637	3.66	0.000281	0.0189	0.22	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103847721~103858049:+
THCA	cis	rs9287719	0.967	rs10195802	ENSG00000243819.4	RN7SL832P	3.66	0.000281	0.0189	0.13	0.17	Prostate cancer;	chr2:10614406	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7563894	ENSG00000243819.4	RN7SL832P	3.66	0.000281	0.0189	0.13	0.17	Prostate cancer;	chr2:10614523	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7566767	ENSG00000243819.4	RN7SL832P	3.66	0.000281	0.0189	0.13	0.17	Prostate cancer;	chr2:10614537	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs7566875	ENSG00000243819.4	RN7SL832P	3.66	0.000281	0.0189	0.13	0.17	Prostate cancer;	chr2:10614666	chr2:10690344~10692099:+
THCA	cis	rs10911902	0.643	rs16825150	ENSG00000228238.1	GS1-304P7.2	-3.66	0.000281	0.0189	-0.26	-0.17	Schizophrenia;	chr1:186306628	chr1:186578279~186579299:+
THCA	cis	rs2755237	0.519	rs80070740	ENSG00000239827.7	SUGT1P3	-3.66	0.000281	0.0189	-0.28	-0.17	Central corneal thickness;	chr13:40563647	chr13:40908159~40921774:-
THCA	cis	rs42648	0.642	rs11771963	ENSG00000225498.1	AC002064.5	3.66	0.000281	0.0189	0.17	0.17	Homocysteine levels;	chr7:90258273	chr7:90312496~90322592:+
THCA	cis	rs860295	0.557	rs348196	ENSG00000160766.13	GBAP1	-3.66	0.000281	0.0189	-0.2	-0.17	Body mass index;	chr1:155697170	chr1:155213821~155227422:-
THCA	cis	rs9611565	0.512	rs2050031	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Vitiligo;	chr22:41756262	chr22:42090931~42137742:+
THCA	cis	rs5751150	1	rs5751150	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Cannabis dependence symptom count;	chr22:41757288	chr22:42090931~42137742:+
THCA	cis	rs727563	0.562	rs5758458	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr22:42090931~42137742:+
THCA	cis	rs727563	0.635	rs713988	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.512	rs2050033	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Vitiligo;	chr22:41763225	chr22:42090931~42137742:+
THCA	cis	rs727563	0.593	rs5758461	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr22:42090931~42137742:+
THCA	cis	rs727563	0.635	rs2899348	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.512	rs2899349	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Vitiligo;	chr22:41768656	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.512	rs1983576	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Vitiligo;	chr22:41770482	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.503	rs5996062	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Vitiligo;	chr22:41771460	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.512	rs6002474	ENSG00000237037.8	NDUFA6-AS1	-3.66	0.000281	0.0189	-0.16	-0.17	Vitiligo;	chr22:41772177	chr22:42090931~42137742:+
THCA	cis	rs7873102	0.654	rs10115992	ENSG00000213839.4	TMX2P1	-3.66	0.000281	0.0189	-0.13	-0.17	Brain structure;	chr9:37962586	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.654	rs7047276	ENSG00000213839.4	TMX2P1	-3.66	0.000281	0.0189	-0.13	-0.17	Brain structure;	chr9:37962595	chr9:37885683~37886390:+
THCA	cis	rs9309473	1	rs6755217	ENSG00000273245.1	RP11-434P11.2	3.66	0.000281	0.0189	0.23	0.17	Metabolite levels;	chr2:73414157	chr2:73750256~73750786:-
THCA	cis	rs4713118	0.869	rs10214440	ENSG00000261839.1	RP1-265C24.8	3.66	0.000281	0.0189	0.19	0.17	Parkinson's disease;	chr6:27734661	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs6902689	ENSG00000261839.1	RP1-265C24.8	3.66	0.000281	0.0189	0.19	0.17	Parkinson's disease;	chr6:27741662	chr6:28136849~28139678:+
THCA	cis	rs3092566	1	rs3092566	ENSG00000227431.4	CSE1L-AS1	-3.66	0.000281	0.0189	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48882633	chr20:49040463~49046044:-
THCA	cis	rs6940638	1	rs6940638	ENSG00000220721.1	OR1F12	3.66	0.000281	0.0189	0.25	0.17	Intelligence (multi-trait analysis);	chr6:27078471	chr6:28073316~28074233:+
THCA	cis	rs1865760	0.82	rs9348697	ENSG00000218281.1	HIST1H2APS3	3.66	0.000281	0.0189	0.22	0.17	Height;	chr6:25890606	chr6:26233122~26233255:+
THCA	cis	rs600231	0.708	rs1784860	ENSG00000254614.2	AP003068.23	3.66	0.000282	0.0189	0.22	0.17	Bone mineral density;	chr11:65473241	chr11:65177606~65181834:-
THCA	cis	rs600231	0.708	rs2957269	ENSG00000254614.2	AP003068.23	3.66	0.000282	0.0189	0.22	0.17	Bone mineral density;	chr11:65475536	chr11:65177606~65181834:-
THCA	cis	rs600231	0.708	rs2957268	ENSG00000254614.2	AP003068.23	3.66	0.000282	0.0189	0.22	0.17	Bone mineral density;	chr11:65478345	chr11:65177606~65181834:-
THCA	cis	rs11633886	0.565	rs17554726	ENSG00000259200.1	RP11-718O11.1	3.66	0.000282	0.0189	0.2	0.17	Diisocyanate-induced asthma;	chr15:45759272	chr15:45705078~45931069:+
THCA	cis	rs4808779	0.884	rs7247222	ENSG00000268650.3	AC068499.10	-3.66	0.000282	0.0189	-0.17	-0.17	Granulocyte percentage of myeloid white cells;	chr19:18282063	chr19:18204730~18220480:+
THCA	cis	rs8062405	0.754	rs28410083	ENSG00000261766.1	RP11-22P6.2	3.66	0.000282	0.0189	0.16	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28862166~28863340:-
THCA	cis	rs8062405	0.789	rs1968751	ENSG00000261766.1	RP11-22P6.2	3.66	0.000282	0.0189	0.16	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28862166~28863340:-
THCA	cis	rs7824557	0.564	rs2736304	ENSG00000227888.4	FAM66A	-3.66	0.000282	0.0189	-0.21	-0.17	Retinal vascular caliber;	chr8:11379455	chr8:12362019~12388296:+
THCA	cis	rs6430585	0.527	rs59413285	ENSG00000231890.6	DARS-AS1	-3.66	0.000282	0.0189	-0.19	-0.17	Corneal structure;	chr2:135686615	chr2:135985176~136022593:+
THCA	cis	rs4489787	0.568	rs2731066	ENSG00000240399.1	RP1-228P16.1	3.66	0.000282	0.0189	0.19	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48504780	chr12:48054813~48055591:-
THCA	cis	rs7246657	0.639	rs12459015	ENSG00000226686.6	LINC01535	-3.66	0.000282	0.0189	-0.24	-0.17	Coronary artery calcification;	chr19:37592288	chr19:37251912~37265535:+
THCA	cis	rs17597773	0.638	rs7544735	ENSG00000238078.1	LINC01352	3.66	0.000282	0.0189	0.23	0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220825571	chr1:220829255~220832429:+
THCA	cis	rs3104964	1	rs904921	ENSG00000253773.2	C8orf37-AS1	3.66	0.000282	0.0189	0.22	0.17	Colorectal cancer;	chr8:95584126	chr8:95204456~95810136:+
THCA	cis	rs6430585	0.527	rs12467569	ENSG00000231890.6	DARS-AS1	-3.66	0.000282	0.0189	-0.19	-0.17	Corneal structure;	chr2:135656277	chr2:135985176~136022593:+
THCA	cis	rs4819052	0.851	rs875621	ENSG00000184274.3	LINC00315	-3.66	0.000282	0.0189	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45300245~45305257:-
THCA	cis	rs36093844	0.527	rs111955441	ENSG00000279742.1	RP11-700A24.1	-3.66	0.000282	0.0189	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86048610	chr11:85852557~85854943:-
THCA	cis	rs9402682	0.629	rs6924609	ENSG00000232876.1	CTA-212D2.2	3.66	0.000282	0.0189	0.22	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135119519	chr6:135055033~135060550:+
THCA	cis	rs2191566	1	rs10418363	ENSG00000267114.1	CTB-129P6.11	3.66	0.000282	0.0189	0.13	0.17	Acute lymphoblastic leukemia (childhood);	chr19:44021311	chr19:44950044~44954007:-
THCA	cis	rs8023401	0.507	rs2413906	ENSG00000259705.1	RP11-227D13.1	-3.66	0.000282	0.0189	-0.2	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48478383	chr15:48645951~48652016:+
THCA	cis	rs6545883	0.894	rs2121661	ENSG00000212978.6	AC016747.3	-3.66	0.000282	0.0189	-0.18	-0.17	Tuberculosis;	chr2:61334523	chr2:61141592~61144969:-
THCA	cis	rs10090774	0.687	rs13267705	ENSG00000279766.1	RP11-642A1.2	-3.66	0.000282	0.0189	-0.2	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655273	chr8:140572142~140572812:-
THCA	cis	rs9959145	0.85	rs76780647	ENSG00000267199.1	RP11-861E21.2	3.66	0.000282	0.0189	0.21	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12710821	chr18:12438890~12448205:+
THCA	cis	rs591584	0.59	rs7111719	ENSG00000255893.1	RP11-685N10.1	-3.66	0.000282	0.019	-0.18	-0.17	Macrophage Migration Inhibitory Factor levels;	chr11:94591299	chr11:94472908~94473570:-
THCA	cis	rs1008126	0.6	rs7808296	ENSG00000234715.1	CTB-107G13.1	-3.66	0.000282	0.019	-0.19	-0.17	Metabolite levels (Pyroglutamine);	chr7:103487173	chr7:103445207~103514007:+
THCA	cis	rs10090774	0.786	rs11780023	ENSG00000280303.2	ERICD	-3.66	0.000282	0.019	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140982679	chr8:140636281~140638283:+
THCA	cis	rs11069062	1	rs10851023	ENSG00000270482.1	RP11-131L12.2	3.66	0.000282	0.019	0.14	0.17	Obesity-related traits;	chr12:118731412	chr12:118375350~118376275:-
THCA	cis	rs17181170	1	rs17023964	ENSG00000239572.1	RP11-451B8.1	-3.66	0.000282	0.019	-0.19	-0.17	Prostate cancer;	chr3:87136609	chr3:87731402~87793629:-
THCA	cis	rs1552244	0.572	rs3843008	ENSG00000180385.7	EMC3-AS1	3.66	0.000282	0.019	0.22	0.17	Alzheimer's disease;	chr3:10132058	chr3:9986893~10006990:+
THCA	cis	rs6479901	0.639	rs10995450	ENSG00000272767.1	JMJD1C-AS1	3.66	0.000282	0.019	0.2	0.17	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63465229~63466563:+
THCA	cis	rs62380364	0.774	rs55740951	ENSG00000247828.6	TMEM161B-AS1	-3.66	0.000282	0.019	-0.12	-0.17	Intelligence (multi-trait analysis);	chr5:88858057	chr5:88268895~88436685:+
THCA	cis	rs758324	0.783	rs253941	ENSG00000237714.1	P4HA2-AS1	-3.66	0.000282	0.019	-0.24	-0.17	Alzheimer's disease in APOE e4- carriers;	chr5:131984600	chr5:132184876~132192808:+
THCA	cis	rs7824557	0.544	rs1865521	ENSG00000261451.1	RP11-981G7.1	3.66	0.000282	0.019	0.21	0.17	Retinal vascular caliber;	chr8:11373740	chr8:10433672~10438312:+
THCA	cis	rs13098911	0.54	rs17215008	ENSG00000226074.4	PRSS44	-3.66	0.000282	0.019	-0.31	-0.17	Celiac disease;	chr3:45970787	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs71325098	ENSG00000226074.4	PRSS44	-3.66	0.000282	0.019	-0.31	-0.17	Celiac disease;	chr3:45970899	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs71325100	ENSG00000226074.4	PRSS44	-3.66	0.000282	0.019	-0.31	-0.17	Celiac disease;	chr3:45972340	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs41289622	ENSG00000226074.4	PRSS44	-3.66	0.000282	0.019	-0.31	-0.17	Celiac disease;	chr3:45973053	chr3:46809359~46812558:-
THCA	cis	rs2228479	0.85	rs62052711	ENSG00000274627.1	RP11-104N10.2	-3.66	0.000282	0.019	-0.3	-0.17	Skin colour saturation;	chr16:89788692	chr16:89516797~89522217:+
THCA	cis	rs7680126	0.626	rs11721501	ENSG00000261490.1	RP11-448G15.3	-3.66	0.000282	0.019	-0.15	-0.17	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10187511	chr4:10068089~10073019:-
THCA	cis	rs2274273	0.774	rs17128440	ENSG00000258469.1	CHMP4BP1	3.66	0.000282	0.019	0.14	0.17	Protein biomarker;	chr14:55395194	chr14:55298644~55299231:+
THCA	cis	rs708224	0.513	rs814243	ENSG00000277342.1	RP11-843B15.4	3.66	0.000282	0.019	0.22	0.17	Pancreatic cancer;	chr12:32284697	chr12:32109076~32109602:+
THCA	cis	rs755249	0.567	rs61779309	ENSG00000182109.6	RP11-69E11.4	3.66	0.000282	0.019	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39522280~39546187:-
THCA	cis	rs701145	0.537	rs1713819	ENSG00000243069.6	ARHGEF26-AS1	3.66	0.000282	0.019	0.3	0.17	Coronary artery disease;	chr3:154146685	chr3:154024401~154121332:-
THCA	cis	rs12544026	0.548	rs575218	ENSG00000253669.3	KB-1732A1.1	-3.66	0.000282	0.019	-0.18	-0.17	Major depression and alcohol dependence;	chr8:101883351	chr8:102805517~102809971:+
THCA	cis	rs6494488	0.5	rs72742954	ENSG00000259635.1	AC100830.3	-3.66	0.000282	0.019	-0.38	-0.17	Coronary artery disease;	chr15:64610840	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs7161793	ENSG00000259635.1	AC100830.3	-3.66	0.000282	0.019	-0.38	-0.17	Coronary artery disease;	chr15:64616483	chr15:64701248~64719602:+
THCA	cis	rs10266483	0.639	rs6952592	ENSG00000234338.1	RP11-797H7.1	3.66	0.000282	0.019	0.12	0.17	Response to statin therapy;	chr7:64293667	chr7:64835280~64836882:-
THCA	cis	rs10266483	0.705	rs660228	ENSG00000234338.1	RP11-797H7.1	3.66	0.000282	0.019	0.12	0.17	Response to statin therapy;	chr7:64295867	chr7:64835280~64836882:-
THCA	cis	rs7264396	0.79	rs6060526	ENSG00000088340.14	FER1L4	-3.66	0.000282	0.019	-0.17	-0.17	Total cholesterol levels;	chr20:35637380	chr20:35558737~35607562:-
THCA	cis	rs1635	0.655	rs16893975	ENSG00000216901.1	AL022393.7	-3.66	0.000282	0.019	-0.36	-0.17	Schizophrenia;	chr6:28334501	chr6:28176188~28176674:+
THCA	cis	rs5758659	0.652	rs133300	ENSG00000281538.1	RP4-669P10.20	3.66	0.000282	0.019	0.15	0.17	Cognitive function;	chr22:41993835	chr22:42138060~42139726:+
THCA	cis	rs2549003	1	rs2549003	ENSG00000233006.5	AC034220.3	-3.66	0.000282	0.019	-0.12	-0.17	Asthma (sex interaction);	chr5:132493605	chr5:132311285~132369916:-
THCA	cis	rs3924048	0.574	rs12096486	ENSG00000276830.1	MIR6730	-3.66	0.000282	0.019	-0.17	-0.17	Optic cup area;	chr1:12556881	chr1:12578957~12579023:-
THCA	cis	rs3924048	0.574	rs11121930	ENSG00000276830.1	MIR6730	-3.66	0.000282	0.019	-0.17	-0.17	Optic cup area;	chr1:12556926	chr1:12578957~12579023:-
THCA	cis	rs3924048	0.574	rs11121931	ENSG00000276830.1	MIR6730	-3.66	0.000282	0.019	-0.17	-0.17	Optic cup area;	chr1:12556979	chr1:12578957~12579023:-
THCA	cis	rs1153858	1	rs9788780	ENSG00000275672.1	GATM-AS1	-3.66	0.000282	0.019	-0.17	-0.17	Homoarginine levels;	chr15:45393289	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs11070457	ENSG00000275672.1	GATM-AS1	-3.66	0.000282	0.019	-0.17	-0.17	Homoarginine levels;	chr15:45394745	chr15:45378700~45380123:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000282	0.019	-0.14	-0.17	Calcium levels;	chr7:65872915	chr7:66848496~66858136:+
THCA	cis	rs1005277	0.579	rs1740737	ENSG00000120555.12	SEPT7P9	3.66	0.000282	0.019	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38383069~38402916:-
THCA	cis	rs7824557	0.836	rs765731	ENSG00000255495.1	AC145124.2	-3.66	0.000282	0.019	-0.18	-0.17	Retinal vascular caliber;	chr8:11263989	chr8:12194467~12196280:+
THCA	cis	rs1436955	0.712	rs8033623	ENSG00000259251.2	RP11-643M14.1	-3.66	0.000282	0.019	-0.22	-0.17	Type 2 diabetes;	chr15:62095888	chr15:62060503~62062434:+
THCA	cis	rs944289	0.675	rs398745	ENSG00000258844.1	RP11-259K15.2	-3.66	0.000282	0.019	-0.15	-0.17	Thyroid cancer;	chr14:36066975	chr14:36214607~36235608:+
THCA	cis	rs10435719	0.867	rs35778860	ENSG00000255495.1	AC145124.2	3.66	0.000282	0.019	0.2	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:12194467~12196280:+
THCA	cis	rs4808199	0.649	rs12983940	ENSG00000267481.1	CTC-559E9.5	-3.66	0.000282	0.019	-0.17	-0.17	Nonalcoholic fatty liver disease;	chr19:19405622	chr19:19788755~19790531:-
THCA	cis	rs7520050	0.966	rs785471	ENSG00000281133.1	AL355480.3	3.66	0.000282	0.019	0.19	0.17	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45580892~45580996:-
THCA	cis	rs6479901	0.512	rs11817169	ENSG00000272767.1	JMJD1C-AS1	3.66	0.000282	0.019	0.26	0.17	Intelligence (multi-trait analysis);	chr10:63596549	chr10:63465229~63466563:+
THCA	cis	rs9878978	1	rs35941126	ENSG00000227588.2	CNTN4-AS2	3.66	0.000282	0.019	0.2	0.17	Blood pressure (smoking interaction);	chr3:2435698	chr3:2110409~2144241:-
THCA	cis	rs10165862	0.537	rs17009372	ENSG00000230002.2	ALMS1-IT1	-3.66	0.000282	0.019	-0.24	-0.17	Intelligence (multi-trait analysis);	chr2:73728444	chr2:73456764~73459484:+
THCA	cis	rs9287719	1	rs9679122	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10611584	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs10203664	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10612251	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs10201077	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10612300	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs10203785	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10612382	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs9287720	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10612538	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.87	rs10167676	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10613014	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs12995159	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10613197	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs12995602	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10613416	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6432120	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10613645	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6432122	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10613718	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6712406	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10614294	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs4371336	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10615597	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4405729	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10615653	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.839	rs11683335	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10616539	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs6432126	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10616975	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.904	rs55738250	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10617006	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.934	rs6710033	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10617551	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4669598	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10617712	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4669599	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10617903	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs10167129	ENSG00000243819.4	RN7SL832P	3.66	0.000283	0.019	0.13	0.17	Prostate cancer;	chr2:10618449	chr2:10690344~10692099:+
THCA	cis	rs1005277	0.579	rs1548255	ENSG00000120555.12	SEPT7P9	3.66	0.000283	0.019	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38383069~38402916:-
THCA	cis	rs6456156	0.792	rs2039321	ENSG00000235272.1	FAM103A2P	3.66	0.000283	0.019	0.23	0.17	Primary biliary cholangitis;	chr6:167102811	chr6:166586124~166586477:-
THCA	cis	rs13098911	0.54	rs6785091	ENSG00000226074.4	PRSS44	-3.66	0.000283	0.019	-0.28	-0.17	Celiac disease;	chr3:45943855	chr3:46809359~46812558:-
THCA	cis	rs6968419	0.925	rs11764793	ENSG00000237870.5	AC073130.1	3.66	0.000283	0.019	0.17	0.17	Intraocular pressure;	chr7:116191206	chr7:116275606~116286734:-
THCA	cis	rs2179367	0.959	rs4895788	ENSG00000223701.3	RAET1E-AS1	3.66	0.000283	0.019	0.22	0.17	Dupuytren's disease;	chr6:149426955	chr6:149884431~149919508:+
THCA	cis	rs7572733	0.901	rs13011918	ENSG00000231621.1	AC013264.2	3.66	0.000283	0.019	0.16	0.17	Dermatomyositis;	chr2:197914359	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs1401093	ENSG00000231621.1	AC013264.2	3.66	0.000283	0.019	0.16	0.17	Dermatomyositis;	chr2:197915115	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs1401094	ENSG00000231621.1	AC013264.2	3.66	0.000283	0.019	0.16	0.17	Dermatomyositis;	chr2:197915125	chr2:197197991~197199273:+
THCA	cis	rs801193	1	rs4717319	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000283	0.019	-0.14	-0.17	Aortic root size;	chr7:66777606	chr7:66848496~66858136:+
THCA	cis	rs801193	0.904	rs4718403	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000283	0.019	-0.14	-0.17	Aortic root size;	chr7:66777742	chr7:66848496~66858136:+
THCA	cis	rs878939	0.625	rs61871279	ENSG00000233690.1	EBAG9P1	3.66	0.000283	0.019	0.22	0.17	Warfarin maintenance dose;	chr10:99583948	chr10:99697407~99697949:-
THCA	cis	rs4930561	0.714	rs7950451	ENSG00000184795.9	UNC93B5	-3.66	0.000283	0.019	-0.19	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194939	chr11:67711702~67716005:-
THCA	cis	rs4930561	0.714	rs7950452	ENSG00000184795.9	UNC93B5	-3.66	0.000283	0.019	-0.19	-0.17	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194940	chr11:67711702~67716005:-
THCA	cis	rs3781264	0.595	rs10786161	ENSG00000273450.1	RP11-76P2.4	3.66	0.000283	0.019	0.21	0.17	Esophageal cancer and gastric cancer;	chr10:94347914	chr10:94314907~94315327:-
THCA	cis	rs1555322	1	rs2425034	ENSG00000126005.14	MMP24-AS1	-3.66	0.000283	0.019	-0.23	-0.17	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35216462~35278131:-
THCA	cis	rs1555322	0.858	rs2425035	ENSG00000126005.14	MMP24-AS1	-3.66	0.000283	0.019	-0.23	-0.17	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35216462~35278131:-
THCA	cis	rs1005277	0.602	rs1831315	ENSG00000120555.12	SEPT7P9	3.66	0.000283	0.019	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs1780130	ENSG00000120555.12	SEPT7P9	3.66	0.000283	0.019	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38383069~38402916:-
THCA	cis	rs1865760	0.622	rs9295685	ENSG00000272810.1	U91328.22	-3.66	0.000283	0.019	-0.13	-0.17	Height;	chr6:26071497	chr6:26013241~26013757:+
THCA	cis	rs4699052	1	rs6533059	ENSG00000251288.2	RP11-10L12.2	-3.66	0.000283	0.019	-0.21	-0.17	Testicular germ cell tumor;	chr4:103212219	chr4:102751401~102752641:+
THCA	cis	rs17074492	0.585	rs1387747	ENSG00000214182.5	PTMAP5	3.66	0.000283	0.019	0.23	0.17	Sjögren's syndrome;	chr13:81669345	chr13:81689911~81691072:+
THCA	cis	rs7216064	0.953	rs1966410	ENSG00000278740.1	RP11-147L13.14	3.66	0.000283	0.019	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841099	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs8067892	ENSG00000278740.1	RP11-147L13.14	3.66	0.000283	0.019	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841867	chr17:68188547~68189165:+
THCA	cis	rs7660883	0.866	rs342456	ENSG00000251411.1	RP11-397E7.4	-3.66	0.000283	0.019	-0.15	-0.17	HDL cholesterol levels;	chr4:87102718	chr4:86913266~86914817:-
THCA	cis	rs6921919	1	rs6922111	ENSG00000176933.5	TOB2P1	-3.66	0.000283	0.019	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28217643~28218634:-
THCA	cis	rs11723261	0.582	rs11732336	ENSG00000250892.1	RP11-1365D11.1	3.66	0.000283	0.019	0.24	0.17	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:201409~205009:-
THCA	cis	rs7216064	1	rs7221651	ENSG00000278740.1	RP11-147L13.14	-3.66	0.000283	0.019	-0.19	-0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836274	chr17:68188547~68189165:+
THCA	cis	rs2880765	0.835	rs7174323	ENSG00000218052.5	ADAMTS7P4	-3.66	0.000283	0.019	-0.19	-0.17	Coronary artery disease;	chr15:85506488	chr15:85255369~85330334:-
THCA	cis	rs7546094	0.846	rs55675817	ENSG00000273483.1	RP4-671G15.2	-3.66	0.000283	0.019	-0.15	-0.17	Platelet distribution width;	chr1:112624254	chr1:112517799~112518441:-
THCA	cis	rs754466	0.58	rs1344966	ENSG00000213514.2	RP11-428P16.2	3.66	0.000283	0.019	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77774769	chr10:77730766~77734769:+
THCA	cis	rs10129255	1	rs8010605	ENSG00000280411.1	IGHV1-69-2	-3.66	0.000283	0.019	-0.11	-0.17	Kawasaki disease;	chr14:106678742	chr14:106762092~106762588:-
THCA	cis	rs4664293	0.934	rs1365800	ENSG00000230783.1	AC009961.2	-3.66	0.000283	0.019	-0.21	-0.17	Monocyte percentage of white cells;	chr2:159699112	chr2:159689217~159690291:-
THCA	cis	rs875971	1	rs937495	ENSG00000272831.1	RP11-792A8.4	-3.66	0.000283	0.019	-0.1	-0.17	Aortic root size;	chr7:66314811	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs2036264	ENSG00000272831.1	RP11-792A8.4	-3.66	0.000283	0.019	-0.1	-0.17	Aortic root size;	chr7:66334917	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs7783613	ENSG00000272831.1	RP11-792A8.4	-3.66	0.000283	0.019	-0.1	-0.17	Aortic root size;	chr7:66340274	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs778735	ENSG00000272831.1	RP11-792A8.4	3.66	0.000283	0.019	0.1	0.17	Aortic root size;	chr7:66349822	chr7:66739829~66740385:-
THCA	cis	rs9928842	0.823	rs4888365	ENSG00000261783.1	RP11-252K23.2	3.66	0.000283	0.019	0.32	0.17	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75379818~75381260:-
THCA	cis	rs28595532	0.702	rs72670250	ENSG00000260404.2	RP11-384K6.6	-3.66	0.000283	0.019	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118415979	chr4:118591773~118633729:+
THCA	cis	rs7178375	1	rs11070678	ENSG00000215302.7	CTD-3092A11.1	-3.66	0.000283	0.019	-0.23	-0.17	Hypertriglyceridemia;	chr15:30927561	chr15:30470779~30507623:+
THCA	cis	rs7615952	0.605	rs11708269	ENSG00000171084.14	FAM86JP	3.66	0.000283	0.019	0.27	0.17	Blood pressure (smoking interaction);	chr3:125613306	chr3:125916620~125930024:+
THCA	cis	rs877529	1	rs139402	ENSG00000279833.1	RP4-742C19.13	-3.66	0.000283	0.019	-0.11	-0.17	Multiple myeloma;	chr22:39150140	chr22:39133090~39136760:+
THCA	cis	rs6687821	0.515	rs2390219	ENSG00000261737.1	RP4-612B15.3	3.66	0.000283	0.019	0.25	0.17	Yeast infection;	chr1:86988738	chr1:86703502~86704462:-
THCA	cis	rs2243480	1	rs313814	ENSG00000237310.1	GS1-124K5.4	3.66	0.000283	0.019	0.19	0.17	Diabetic kidney disease;	chr7:66038306	chr7:66493706~66495474:+
THCA	cis	rs7927592	0.763	rs10791982	ENSG00000160172.9	FAM86C2P	-3.66	0.000283	0.019	-0.15	-0.17	Total body bone mineral density;	chr11:68570196	chr11:67791648~67805336:-
THCA	cis	rs13325613	0.834	rs13084175	ENSG00000223552.1	RP11-24F11.2	-3.66	0.000283	0.019	-0.28	-0.17	Monocyte count;	chr3:46143147	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs13083914	ENSG00000223552.1	RP11-24F11.2	-3.66	0.000283	0.019	-0.28	-0.17	Monocyte count;	chr3:46143188	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs35754688	ENSG00000223552.1	RP11-24F11.2	-3.66	0.000283	0.019	-0.28	-0.17	Monocyte count;	chr3:46146214	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34191675	ENSG00000223552.1	RP11-24F11.2	-3.66	0.000283	0.019	-0.28	-0.17	Monocyte count;	chr3:46147956	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34401473	ENSG00000223552.1	RP11-24F11.2	-3.66	0.000283	0.019	-0.28	-0.17	Monocyte count;	chr3:46148280	chr3:46364955~46407059:-
THCA	cis	rs4853525	0.62	rs2066804	ENSG00000235852.1	AC005540.3	3.66	0.000283	0.019	0.19	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977033	chr2:190880797~190882059:-
THCA	cis	rs7216064	0.953	rs11868959	ENSG00000265055.1	AC145343.2	3.66	0.000283	0.019	0.24	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844694	chr17:68096046~68101474:-
THCA	cis	rs4568518	0.616	rs4721675	ENSG00000279048.1	RP11-511H23.2	3.66	0.000283	0.019	0.11	0.17	Measles;	chr7:17965079	chr7:17940503~17942922:+
THCA	cis	rs7824557	0.583	rs2263511	ENSG00000261451.1	RP11-981G7.1	-3.66	0.000283	0.019	-0.21	-0.17	Retinal vascular caliber;	chr8:11375809	chr8:10433672~10438312:+
THCA	cis	rs950169	1	rs950169	ENSG00000275120.1	RP11-182J1.17	3.66	0.000283	0.019	0.2	0.17	Schizophrenia;	chr15:84037709	chr15:84599434~84606463:-
THCA	cis	rs10435719	0.902	rs7006538	ENSG00000254948.1	OR7E158P	-3.66	0.000283	0.019	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:11919900~11920809:-
THCA	cis	rs9291683	0.53	rs4235346	ENSG00000261490.1	RP11-448G15.3	-3.66	0.000283	0.019	-0.1	-0.17	Bone mineral density;	chr4:9943672	chr4:10068089~10073019:-
THCA	cis	rs11800820	0.536	rs10802409	ENSG00000227953.5	LINC01341	3.66	0.000283	0.019	0.15	0.17	Obesity-related traits;	chr1:246468729	chr1:246776013~246792385:+
THCA	cis	rs2179367	0.632	rs11155640	ENSG00000216906.2	RP11-350J20.9	3.66	0.000283	0.019	0.21	0.17	Dupuytren's disease;	chr6:149323648	chr6:149904243~149906418:+
THCA	cis	rs6893300	0.826	rs7734102	ENSG00000225051.5	HMGB3P22	-3.66	0.000283	0.019	-0.17	-0.17	Resting heart rate;	chr5:179726796	chr5:179679032~179694768:+
THCA	cis	rs1383484	1	rs1383484	ENSG00000225151.9	GOLGA2P7	3.66	0.000283	0.019	0.22	0.17	Height;	chr15:83854003	chr15:84199311~84230136:-
THCA	cis	rs2635047	0.967	rs2571016	ENSG00000280212.1	RP11-49K24.3	3.66	0.000283	0.019	0.16	0.17	Educational attainment;	chr18:47112804	chr18:47076117~47076594:+
THCA	cis	rs704	0.523	rs11080054	ENSG00000237575.4	PYY2	3.66	0.000283	0.019	0.2	0.17	Osteoprotegerin levels;	chr17:28318965	chr17:28226563~28228065:+
THCA	cis	rs4144027	0.967	rs10133399	ENSG00000258534.1	CTD-2134A5.4	-3.66	0.000283	0.019	-0.17	-0.17	Blood metabolite levels;	chr14:103895506	chr14:103854366~103880111:-
THCA	cis	rs2832191	0.74	rs2853830	ENSG00000176054.6	RPL23P2	3.66	0.000283	0.019	0.15	0.17	Dental caries;	chr21:29044503	chr21:28997613~28998033:-
THCA	cis	rs10861661	1	rs10861661	ENSG00000260329.1	RP11-412D9.4	-3.66	0.000283	0.019	-0.18	-0.17	Triglyceride levels;	chr12:106780868	chr12:106954029~106955497:-
THCA	cis	rs11992162	0.613	rs56094399	ENSG00000255046.1	RP11-297N6.4	3.66	0.000283	0.019	0.18	0.17	Monocyte count;	chr8:11939961	chr8:11797928~11802568:-
THCA	cis	rs62229266	0.626	rs7280896	ENSG00000233393.1	AP000688.29	-3.66	0.000284	0.019	-0.21	-0.17	Mitral valve prolapse;	chr21:36088608	chr21:36104881~36109690:+
THCA	cis	rs11658311	0.85	rs11658846	ENSG00000232344.2	AC087163.2	3.66	0.000284	0.019	0.22	0.17	Obsessive-compulsive symptoms;	chr17:17768172	chr17:18010643~18011822:+
THCA	cis	rs6472235	0.681	rs58881093	ENSG00000272192.1	CTD-2532N20.1	3.66	0.000284	0.019	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65952396	chr8:65842752~65843331:+
THCA	cis	rs6088580	0.524	rs2889855	ENSG00000126005.14	MMP24-AS1	3.66	0.000284	0.019	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34689049	chr20:35216462~35278131:-
THCA	cis	rs10276381	0.579	rs9648026	ENSG00000234336.5	JAZF1-AS1	3.66	0.000284	0.019	0.3	0.17	Crohn's disease;	chr7:28122364	chr7:28180322~28243917:+
THCA	cis	rs1510552	0.507	rs11896697	ENSG00000270659.1	RP11-105N14.1	3.66	0.000284	0.0191	0.14	0.17	Contrast sensitivity;	chr2:214125932	chr2:213152970~213153659:+
THCA	cis	rs2904297	0.916	rs6827852	ENSG00000261490.1	RP11-448G15.3	-3.66	0.000284	0.0191	-0.11	-0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11023398	chr4:10068089~10073019:-
THCA	cis	rs10129255	0.872	rs10133674	ENSG00000211972.2	IGHV3-66	3.66	0.000284	0.0191	0.1	0.17	Kawasaki disease;	chr14:106692788	chr14:106675017~106675544:-
THCA	cis	rs9926296	0.656	rs7191144	ENSG00000274627.1	RP11-104N10.2	-3.66	0.000284	0.0191	-0.17	-0.17	Vitiligo;	chr16:89756985	chr16:89516797~89522217:+
THCA	cis	rs7763441	0.836	rs9503194	ENSG00000250903.7	GMDS-AS1	3.66	0.000284	0.0191	0.14	0.17	Monobrow;	chr6:2445046	chr6:2245748~2482022:+
THCA	cis	rs2019137	0.901	rs4849176	ENSG00000234997.1	AC016745.3	-3.66	0.000284	0.0191	-0.16	-0.17	Lymphocyte counts;	chr2:113220359	chr2:113424495~113425324:+
THCA	cis	rs901683	1	rs9422654	ENSG00000230869.1	CTGLF10P	-3.66	0.000284	0.0191	-0.39	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45555953	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs9422655	ENSG00000230869.1	CTGLF10P	-3.66	0.000284	0.0191	-0.39	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45555960	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs17451208	ENSG00000230869.1	CTGLF10P	-3.66	0.000284	0.0191	-0.39	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45556457	chr10:45678692~45700532:+
THCA	cis	rs7586085	1	rs12185748	ENSG00000232411.1	AC009495.3	3.66	0.000284	0.0191	0.18	0.17	Total body bone mineral density;	chr2:165720446	chr2:165833048~165839098:-
THCA	cis	rs701145	0.585	rs17766586	ENSG00000243069.6	ARHGEF26-AS1	-3.66	0.000284	0.0191	-0.28	-0.17	Coronary artery disease;	chr3:154061129	chr3:154024401~154121332:-
THCA	cis	rs7904321	0.966	rs2403211	ENSG00000232075.1	MRPL35P2	-3.66	0.000284	0.0191	-0.22	-0.17	Intelligence (multi-trait analysis);	chr10:63080065	chr10:63634317~63634827:-
THCA	cis	rs7819412	0.522	rs11776603	ENSG00000261451.1	RP11-981G7.1	-3.66	0.000284	0.0191	-0.23	-0.17	Triglycerides;	chr8:11162803	chr8:10433672~10438312:+
THCA	cis	rs9788721	0.504	rs6495314	ENSG00000261143.1	ADAMTS7P3	3.66	0.000284	0.0191	0.22	0.17	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78668187	chr15:77976042~77993057:+
THCA	cis	rs277939	1	rs157044	ENSG00000230847.4	RP11-195E2.1	-3.66	0.000284	0.0191	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71601624	chr5:71074225~71093193:-
THCA	cis	rs6687821	0.637	rs548440	ENSG00000261737.1	RP4-612B15.3	-3.66	0.000284	0.0191	-0.26	-0.17	Yeast infection;	chr1:86846948	chr1:86703502~86704462:-
THCA	cis	rs28595532	0.748	rs72670248	ENSG00000260404.2	RP11-384K6.6	-3.66	0.000284	0.0191	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118414381	chr4:118591773~118633729:+
THCA	cis	rs9400467	0.6	rs9487653	ENSG00000255389.1	C6orf3	3.66	0.000284	0.0191	0.19	0.17	Amino acid levels;Blood metabolite levels;	chr6:111501486	chr6:111599875~111602295:+
THCA	cis	rs34091558	1	rs34091558	ENSG00000223774.4	RP11-307B6.3	3.66	0.000284	0.0191	0.19	0.17	Breast size;	chr1:201917642	chr1:201893842~201899978:+
THCA	cis	rs467650	0.714	rs39785	ENSG00000246763.5	RGMB-AS1	-3.66	0.000284	0.0191	-0.16	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98579523	chr5:98769618~98773469:-
THCA	cis	rs7572733	0.555	rs2342558	ENSG00000231621.1	AC013264.2	-3.66	0.000284	0.0191	-0.18	-0.17	Dermatomyositis;	chr2:198055418	chr2:197197991~197199273:+
THCA	cis	rs10129255	0.879	rs7160512	ENSG00000280411.1	IGHV1-69-2	-3.66	0.000284	0.0191	-0.1	-0.17	Kawasaki disease;	chr14:106694574	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.879	rs7159157	ENSG00000280411.1	IGHV1-69-2	-3.66	0.000284	0.0191	-0.1	-0.17	Kawasaki disease;	chr14:106694578	chr14:106762092~106762588:-
THCA	cis	rs753778	0.57	rs10875465	ENSG00000253210.1	RP11-809O17.1	-3.66	0.000284	0.0191	-0.2	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141200401	chr8:141126044~141129961:-
THCA	cis	rs12962334	0.508	rs9966036	ENSG00000273232.1	RP11-370A5.2	3.66	0.000284	0.0191	0.23	0.17	Breast cancer;	chr18:22936105	chr18:22882825~22883357:-
THCA	cis	rs6696239	0.911	rs12137233	ENSG00000227711.2	RP11-275O4.5	-3.66	0.000284	0.0191	-0.23	-0.17	Height;	chr1:227635445	chr1:227509028~227520477:-
THCA	cis	rs4578769	0.729	rs72882140	ENSG00000265939.1	UBE2CP2	-3.66	0.000284	0.0191	-0.22	-0.17	Eosinophil percentage of white cells;	chr18:22805952	chr18:22900486~22900995:-
THCA	cis	rs4767841	0.565	rs393773	ENSG00000248636.5	RP11-768F21.1	-3.66	0.000284	0.0191	-0.17	-0.17	Urgency urinary incontinence;	chr12:119782242	chr12:119387987~119668079:-
THCA	cis	rs3758911	0.828	rs11212141	ENSG00000255353.1	RP11-382M14.1	-3.66	0.000284	0.0191	-0.22	-0.17	Coronary artery disease;	chr11:107298200	chr11:107176286~107177530:+
THCA	cis	rs17221829	0.521	rs76384137	ENSG00000280385.1	AP000648.5	-3.66	0.000284	0.0191	-0.17	-0.17	Anxiety in major depressive disorder;	chr11:89594098	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.555	rs72969140	ENSG00000280385.1	AP000648.5	-3.66	0.000284	0.0191	-0.17	-0.17	Anxiety in major depressive disorder;	chr11:89595135	chr11:90193614~90198120:+
THCA	cis	rs4915077	0.892	rs80353498	ENSG00000226822.1	RP11-356N1.2	3.66	0.000284	0.0191	0.27	0.17	Hypothyroidism;	chr1:107804122	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs76804309	ENSG00000226822.1	RP11-356N1.2	3.66	0.000284	0.0191	0.27	0.17	Hypothyroidism;	chr1:107804132	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs79729985	ENSG00000226822.1	RP11-356N1.2	3.66	0.000284	0.0191	0.27	0.17	Hypothyroidism;	chr1:107804156	chr1:108071482~108074519:+
THCA	cis	rs7219021	0.705	rs1962412	ENSG00000248278.1	SUMO2P17	3.66	0.000284	0.0191	0.22	0.17	Schizophrenia or bipolar disorder;	chr17:48892897	chr17:48874860~48908983:-
THCA	cis	rs357618	0.581	rs165365	ENSG00000260581.1	CTB-113P19.4	-3.66	0.000284	0.0191	-0.26	-0.17	Basophil percentage of white cells;	chr5:151486884	chr5:151652275~151655449:+
THCA	cis	rs9926296	0.605	rs7205053	ENSG00000274627.1	RP11-104N10.2	-3.66	0.000284	0.0191	-0.17	-0.17	Vitiligo;	chr16:89790355	chr16:89516797~89522217:+
THCA	cis	rs6787172	0.651	rs4680437	ENSG00000272087.1	RP11-379F4.7	3.66	0.000284	0.0191	0.15	0.17	Subjective well-being;	chr3:158452333	chr3:158693120~158693768:-
THCA	cis	rs9650657	0.737	rs4551304	ENSG00000255310.2	AF131215.2	-3.66	0.000284	0.0191	-0.14	-0.17	Neuroticism;	chr8:10807559	chr8:11107788~11109726:-
THCA	cis	rs9650657	0.771	rs4240670	ENSG00000255310.2	AF131215.2	-3.66	0.000284	0.0191	-0.14	-0.17	Neuroticism;	chr8:10808338	chr8:11107788~11109726:-
THCA	cis	rs1993293	0.636	rs1993294	ENSG00000259219.1	CTD-3076O17.2	-3.66	0.000284	0.0191	-0.2	-0.17	Coronary artery calcification;	chr15:99757486	chr15:99976481~99980774:+
THCA	cis	rs7572733	0.935	rs6734561	ENSG00000231621.1	AC013264.2	-3.66	0.000284	0.0191	-0.16	-0.17	Dermatomyositis;	chr2:197860352	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.901	rs700689	ENSG00000231621.1	AC013264.2	-3.66	0.000284	0.0191	-0.16	-0.17	Dermatomyositis;	chr2:197861925	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs700691	ENSG00000231621.1	AC013264.2	-3.66	0.000284	0.0191	-0.16	-0.17	Dermatomyositis;	chr2:197863128	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.905	rs700693	ENSG00000231621.1	AC013264.2	-3.66	0.000284	0.0191	-0.16	-0.17	Dermatomyositis;	chr2:197865291	chr2:197197991~197199273:+
THCA	cis	rs3824488	0.92	rs28474857	ENSG00000271155.1	RP11-435O5.5	-3.66	0.000284	0.0191	-0.28	-0.17	Neuroticism;	chr9:95484922	chr9:95506235~95507636:+
THCA	cis	rs4460629	0.742	rs7368345	ENSG00000236675.1	MTX1P1	3.66	0.000284	0.0191	0.16	0.17	Serum magnesium levels;	chr1:155107614	chr1:155230975~155234325:+
THCA	cis	rs6479901	0.501	rs7084396	ENSG00000272767.1	JMJD1C-AS1	-3.66	0.000284	0.0191	-0.2	-0.17	Intelligence (multi-trait analysis);	chr10:63116965	chr10:63465229~63466563:+
THCA	cis	rs11648785	0.59	rs10431948	ENSG00000222019.6	URAHP	-3.66	0.000284	0.0191	-0.13	-0.17	Tanning;	chr16:90033163	chr16:90039761~90047773:-
THCA	cis	rs862034	0.509	rs7149930	ENSG00000270000.1	RP3-449M8.9	3.66	0.000284	0.0191	0.16	0.17	Height;	chr14:74487356	chr14:74471930~74472360:-
THCA	cis	rs61160187	0.582	rs976630	ENSG00000272308.1	RP11-231G3.1	-3.66	0.000284	0.0191	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:60866457~60866935:-
THCA	cis	rs2839186	0.967	rs4819222	ENSG00000228137.1	AP001469.7	3.66	0.000284	0.0191	0.16	0.17	Testicular germ cell tumor;	chr21:46287864	chr21:46246890~46247682:+
THCA	cis	rs7520050	0.966	rs7540325	ENSG00000280836.1	AL355480.1	3.66	0.000284	0.0191	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45581219~45581321:-
THCA	cis	rs7520050	1	rs7540699	ENSG00000280836.1	AL355480.1	3.66	0.000284	0.0191	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs4660319	ENSG00000280836.1	AL355480.1	3.66	0.000284	0.0191	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs11211213	ENSG00000280836.1	AL355480.1	3.66	0.000284	0.0191	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45581219~45581321:-
THCA	cis	rs11992162	0.967	rs10088415	ENSG00000255046.1	RP11-297N6.4	3.66	0.000284	0.0191	0.17	0.17	Monocyte count;	chr8:11973316	chr8:11797928~11802568:-
THCA	cis	rs1707322	0.638	rs1707302	ENSG00000281133.1	AL355480.3	3.66	0.000284	0.0191	0.21	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr1:45580892~45580996:-
THCA	cis	rs9652601	0.691	rs9921287	ENSG00000263033.2	RP11-396B14.2	-3.66	0.000285	0.0191	-0.13	-0.17	Systemic lupus erythematosus;	chr16:11115882	chr16:11196177~11224969:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000232546.1	RP11-458F8.1	3.66	0.000285	0.0191	0.14	0.17	Aortic root size;	chr7:66589419	chr7:66848496~66858136:+
THCA	cis	rs7010267	0.773	rs4355801	ENSG00000254278.1	RP11-278I4.2	3.66	0.000285	0.0191	0.21	0.17	Total body bone mineral density (age 45-60);	chr8:118911634	chr8:119062942~119068782:-
THCA	cis	rs10129255	0.957	rs8009464	ENSG00000280411.1	IGHV1-69-2	-3.66	0.000285	0.0191	-0.1	-0.17	Kawasaki disease;	chr14:106777611	chr14:106762092~106762588:-
THCA	cis	rs3924048	0.574	rs10864561	ENSG00000272482.1	RP11-474O21.5	-3.66	0.000285	0.0191	-0.15	-0.17	Optic cup area;	chr1:12551439	chr1:12618900~12619244:-
THCA	cis	rs11239930	0.538	rs59064267	ENSG00000180867.10	PDIA3P1	3.66	0.000285	0.0191	0.16	0.17	AIDS progression;	chr1:147089146	chr1:147178113~147179622:+
THCA	cis	rs2980439	0.517	rs712253	ENSG00000253981.4	ALG1L13P	-3.66	0.000285	0.0191	-0.16	-0.17	Neuroticism;	chr8:8246260	chr8:8236003~8244667:-
THCA	cis	rs2841277	0.676	rs4264326	ENSG00000258701.1	LINC00638	3.66	0.000285	0.0191	0.18	0.17	Rheumatoid arthritis;	chr14:104945363	chr14:104821201~104823718:+
THCA	cis	rs7737355	0.504	rs31256	ENSG00000237714.1	P4HA2-AS1	3.66	0.000285	0.0191	0.24	0.17	Life satisfaction;	chr5:131493056	chr5:132184876~132192808:+
THCA	cis	rs950893	0.754	rs9650404	ENSG00000253837.1	RP11-177H13.2	3.66	0.000285	0.0191	0.16	0.17	Mean corpuscular hemoglobin;	chr8:23610889	chr8:23336171~23366125:+
THCA	cis	rs1577917	0.771	rs9450319	ENSG00000220563.1	PKMP3	3.66	0.000285	0.0191	0.12	0.17	Response to antipsychotic treatment;	chr6:85717607	chr6:85659892~85660606:-
THCA	cis	rs7632954	0.605	rs9824908	ENSG00000227110.5	LMCD1-AS1	3.66	0.000285	0.0191	0.2	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8482961	chr3:7952805~8611924:-
THCA	cis	rs7940646	0.651	rs2098839	ENSG00000254554.1	RP11-351I24.1	-3.66	0.000285	0.0191	-0.2	-0.17	Platelet aggregation;	chr11:10655440	chr11:10302657~10303704:-
THCA	cis	rs6982240	0.514	rs10093988	ENSG00000253307.1	RP11-10J21.4	3.66	0.000285	0.0191	0.25	0.17	Tonsillectomy;	chr8:141250896	chr8:141252286~141253292:-
THCA	cis	rs11638352	1	rs2733221	ENSG00000166763.7	STRCP1	-3.66	0.000285	0.0191	-0.36	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44097672	chr15:43699488~43718184:-
THCA	cis	rs10863936	0.523	rs6657728	ENSG00000198468.6	FLVCR1-AS1	-3.66	0.000285	0.0191	-0.19	-0.17	Height;	chr1:212082353	chr1:212852108~212858088:-
THCA	cis	rs638893	1	rs638893	ENSG00000255422.1	AP002954.4	-3.66	0.000285	0.0191	-0.26	-0.17	Vitiligo;	chr11:118827828	chr11:118704607~118750263:+
THCA	cis	rs638893	1	rs28827279	ENSG00000255422.1	AP002954.4	-3.66	0.000285	0.0191	-0.26	-0.17	Vitiligo;	chr11:118830054	chr11:118704607~118750263:+
THCA	cis	rs11098499	0.604	rs17051352	ENSG00000249244.1	RP11-548H18.2	3.66	0.000285	0.0191	0.2	0.17	Corneal astigmatism;	chr4:119660272	chr4:119391831~119395335:-
THCA	cis	rs11717455	1	rs3922578	ENSG00000232439.1	RPL18AP7	-3.66	0.000285	0.0191	-0.26	-0.17	Systemic lupus erythematosus;	chr3:38819631	chr3:38526802~38527325:-
THCA	cis	rs6600671	1	rs1591882	ENSG00000226067.5	CH17-118O6.2	3.66	0.000285	0.0191	0.16	0.17	Hip geometry;	chr1:121441455	chr1:120913275~121009291:+
THCA	cis	rs1580019	0.563	rs10486509	ENSG00000273014.1	RP11-225B17.2	-3.66	0.000285	0.0191	-0.17	-0.17	Cognitive ability;	chr7:32545831	chr7:32758882~32759353:+
THCA	cis	rs972540	1	rs972540	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206380059	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs972539	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206380103	chr2:207239650~207245887:+
THCA	cis	rs972540	0.96	rs62195891	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206381845	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs2122121	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206383108	chr2:207239650~207245887:+
THCA	cis	rs972540	0.96	rs7423990	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206383510	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs7424013	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206383643	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs7424014	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206383659	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs62195892	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206384061	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs62195893	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206384176	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs62195894	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206384191	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs2084499	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206385451	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs12052703	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206385879	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs12053062	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206385896	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs12052727	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206386305	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs12052372	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206386517	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs62195895	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206387073	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs62195896	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206387216	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs12052545	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206387911	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs62195930	ENSG00000229647.1	AC007879.7	-3.66	0.000285	0.0191	-0.19	-0.17	Body mass index;	chr2:206388588	chr2:207239650~207245887:+
THCA	cis	rs9788682	0.747	rs2568485	ENSG00000261143.1	ADAMTS7P3	3.66	0.000285	0.0191	0.24	0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78459772	chr15:77976042~77993057:+
THCA	cis	rs10504130	0.696	rs11785805	ENSG00000272024.1	RP11-546K22.3	-3.66	0.000285	0.0191	-0.18	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51950284~51950690:+
THCA	cis	rs11867129	0.915	rs12598641	ENSG00000260778.3	RP11-304L19.13	3.66	0.000285	0.0191	0.17	0.17	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2309767	chr16:2268155~2273418:+
THCA	cis	rs7296418	0.738	rs1568428	ENSG00000256092.2	RP13-942N8.1	-3.66	0.000285	0.0191	-0.12	-0.17	Platelet count;	chr12:123254329	chr12:123363868~123366113:+
THCA	cis	rs7069191	1	rs7069191	ENSG00000254271.1	RP11-131N11.4	3.66	0.000285	0.0191	0.24	0.17	Pediatric bone mineral density (spine);	chr10:60636615	chr10:60734342~60741828:+
THCA	cis	rs12148329	0.545	rs12592860	ENSG00000259594.4	CTD-2034I4.2	3.66	0.000285	0.0191	0.29	0.17	Immune response to smallpox vaccine (IL-6);	chr15:80741249	chr15:81554003~81696780:+
THCA	cis	rs6847067	0.965	rs11097024	ENSG00000180769.7	WDFY3-AS2	3.66	0.000285	0.0191	0.12	0.17	Oropharynx cancer;	chr4:84728404	chr4:84965682~85011277:+
THCA	cis	rs72634501	0.517	rs10788925	ENSG00000228060.1	RP11-69E11.8	3.66	0.000285	0.0191	0.15	0.17	HDL cholesterol;	chr1:39128430	chr1:39565160~39573203:+
THCA	cis	rs6088580	0.524	rs6088565	ENSG00000126005.14	MMP24-AS1	3.66	0.000285	0.0191	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34667182	chr20:35216462~35278131:-
THCA	cis	rs78487399	0.908	rs73925552	ENSG00000234936.1	AC010883.5	3.66	0.000285	0.0191	0.21	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583425	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs75597324	ENSG00000234936.1	AC010883.5	3.66	0.000285	0.0191	0.21	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43584100	chr2:43229573~43233394:+
THCA	cis	rs7707921	1	rs749401	ENSG00000251374.1	RPS23P5	3.66	0.000285	0.0191	0.24	0.17	Breast cancer;	chr5:82265550	chr5:82265157~82265259:-
THCA	cis	rs1127311	0.875	rs9427102	ENSG00000236675.1	MTX1P1	-3.66	0.000285	0.0191	-0.15	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr1:154614481	chr1:155230975~155234325:+
THCA	cis	rs7772697	0.508	rs12202158	ENSG00000223701.3	RAET1E-AS1	-3.66	0.000285	0.0191	-0.24	-0.17	Diabetic retinopathy;	chr6:149050002	chr6:149884431~149919508:+
THCA	cis	rs9880211	0.718	rs35320690	ENSG00000239213.4	NCK1-AS1	-3.66	0.000285	0.0191	-0.17	-0.17	Height;Body mass index;	chr3:136213652	chr3:136841726~136862054:-
THCA	cis	rs6929812	0.702	rs2064220	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27420248	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs6456782	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27420960	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs7771598	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27421479	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs7754086	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27421711	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs62401131	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27422113	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs6928314	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27423214	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs12212288	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27423464	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs12205189	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27423541	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs12525544	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27424262	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs13207099	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27424369	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs7747444	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27425930	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.702	rs2206253	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27428287	chr6:27404010~27406964:-
THCA	cis	rs6929812	0.664	rs10484396	ENSG00000271755.1	RP1-153G14.4	3.66	0.000285	0.0191	0.18	0.17	Neuroticism (multi-trait analysis);	chr6:27429419	chr6:27404010~27406964:-
THCA	cis	rs11048434	0.518	rs34651717	ENSG00000256720.1	RP11-436I9.6	-3.66	0.000285	0.0191	-0.18	-0.17	Sjögren's syndrome;	chr12:9025154	chr12:9135084~9135591:+
THCA	cis	rs11048434	0.518	rs35176717	ENSG00000256720.1	RP11-436I9.6	-3.66	0.000285	0.0191	-0.18	-0.17	Sjögren's syndrome;	chr12:9025170	chr12:9135084~9135591:+
THCA	cis	rs11048434	0.518	rs34533518	ENSG00000256720.1	RP11-436I9.6	-3.66	0.000285	0.0191	-0.18	-0.17	Sjögren's syndrome;	chr12:9025302	chr12:9135084~9135591:+
THCA	cis	rs4262150	0.883	rs72799142	ENSG00000253921.1	CTB-113P19.3	3.66	0.000285	0.0191	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152721172	chr5:151753992~151767247:+
THCA	cis	rs4656958	0.93	rs10908813	ENSG00000233691.2	RP11-312J18.7	3.66	0.000285	0.0191	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160926057	chr1:160935537~160936126:+
THCA	cis	rs11105298	0.891	rs11105314	ENSG00000266347.2	AC068641.1	3.66	0.000285	0.0191	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89592833~89592927:+
THCA	cis	rs896655	0.503	rs58377678	ENSG00000229835.2	KHSRPP1	3.66	0.000285	0.0191	0.21	0.17	Coronary artery disease;	chr9:21813719	chr9:21695176~21696943:+
THCA	cis	rs7259376	0.869	rs11671804	ENSG00000269138.1	ZNF209P	-3.66	0.000285	0.0191	-0.17	-0.17	Menopause (age at onset);	chr19:22408414	chr19:22463922~22473036:+
THCA	cis	rs9467773	0.572	rs13213953	ENSG00000228223.2	HCG11	-3.66	0.000285	0.0191	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26523450~26526579:+
THCA	cis	rs10760158	0.769	rs7870797	ENSG00000235865.2	GSN-AS1	3.66	0.000285	0.0191	0.15	0.17	Pulse pressure;	chr9:121298144	chr9:121280768~121285530:-
THCA	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	3.66	0.000285	0.0191	0.24	0.17	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
THCA	cis	rs7394190	0.63	rs4746150	ENSG00000271848.1	RP11-464F9.21	-3.66	0.000285	0.0191	-0.25	-0.17	Incident atrial fibrillation;	chr10:73806177	chr10:73654039~73674719:+
THCA	cis	rs9393813	0.529	rs7761966	ENSG00000216915.2	RP1-97D16.1	3.66	0.000285	0.0191	0.22	0.17	Bipolar disorder;	chr6:27477924	chr6:27737000~27738494:-
THCA	cis	rs478304	0.593	rs75162774	ENSG00000214659.4	KRT8P26	3.66	0.000285	0.0191	0.16	0.17	Acne (severe);	chr11:65725012	chr11:65726939~65728214:+
THCA	cis	rs11239930	0.517	rs2477569	ENSG00000278811.3	LINC00624	-3.66	0.000285	0.0192	-0.19	-0.17	AIDS progression;	chr1:147076261	chr1:147258885~147517875:-
THCA	cis	rs6137726	0.652	rs6113762	ENSG00000237396.1	LINC01384	-3.66	0.000285	0.0192	-0.14	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22672946	chr20:22587522~22607517:-
THCA	cis	rs6981523	0.553	rs11989369	ENSG00000261451.1	RP11-981G7.1	3.66	0.000285	0.0192	0.22	0.17	Neuroticism;	chr8:11197876	chr8:10433672~10438312:+
THCA	cis	rs7554547	0.69	rs4846066	ENSG00000199347.1	RNU5E-1	3.66	0.000285	0.0192	0.23	0.17	Nonsyndromic cleft lip with cleft palate;	chr1:11877993	chr1:11908152~11908271:+
THCA	cis	rs6684709	0.638	rs2038026	ENSG00000235052.1	RP1-150O5.3	3.66	0.000285	0.0192	0.18	0.17	White blood cell count;	chr1:23521479	chr1:23549139~23550915:-
THCA	cis	rs9457247	0.508	rs7760495	ENSG00000235272.1	FAM103A2P	3.66	0.000285	0.0192	0.23	0.17	Crohn's disease;	chr6:167093307	chr6:166586124~166586477:-
THCA	cis	rs6690583	0.562	rs6688354	ENSG00000226970.2	RP11-82H13.2	3.66	0.000286	0.0192	0.29	0.17	Serum sulfate level;	chr1:85055171	chr1:84244334~84244577:+
THCA	cis	rs6589219	0.826	rs36029541	ENSG00000196167.8	COLCA1	-3.66	0.000286	0.0192	-0.18	-0.17	Colorectal cancer;	chr11:111269217	chr11:111290787~111305045:-
THCA	cis	rs853679	0.599	rs13193295	ENSG00000220721.1	OR1F12	3.66	0.000286	0.0192	0.37	0.17	Depression;	chr6:28035450	chr6:28073316~28074233:+
THCA	cis	rs12439619	0.693	rs28665836	ENSG00000255769.6	GOLGA2P10	-3.66	0.000286	0.0192	-0.19	-0.17	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472993~82513950:-
THCA	cis	rs9380516	0.627	rs2143404	ENSG00000228559.1	RP3-340B19.3	-3.66	0.000286	0.0192	-0.26	-0.17	Hepatitis C induced liver fibrosis;	chr6:35642904	chr6:35544632~35545669:+
THCA	cis	rs4879656	0.897	rs1537256	ENSG00000225693.1	LAGE3P1	-3.66	0.000286	0.0192	-0.19	-0.17	Menopause (age at onset);	chr9:33004419	chr9:33019682~33020165:-
THCA	cis	rs62045849	0.557	rs4782444	ENSG00000259877.2	RP11-46C24.7	3.66	0.000286	0.0192	0.19	0.17	Red blood cell count;	chr16:89117565	chr16:89215211~89217653:-
THCA	cis	rs1150668	0.796	rs2531825	ENSG00000220721.1	OR1F12	3.66	0.000286	0.0192	0.18	0.17	Pubertal anthropometrics;	chr6:28381487	chr6:28073316~28074233:+
THCA	cis	rs57709857	0.957	rs11785041	ENSG00000272092.1	RP11-350N15.5	-3.66	0.000286	0.0192	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38348724	chr8:38382364~38383461:+
THCA	cis	rs150992	0.861	rs467728	ENSG00000246763.5	RGMB-AS1	3.66	0.000286	0.0192	0.17	0.17	Body mass index;	chr5:98953863	chr5:98769618~98773469:-
THCA	cis	rs17345786	0.906	rs56171035	ENSG00000244119.1	PDCL3P4	3.66	0.000286	0.0192	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr3:101392264	chr3:101712472~101713191:+
THCA	cis	rs57709857	0.957	rs10958682	ENSG00000272092.1	RP11-350N15.5	-3.66	0.000286	0.0192	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38415434	chr8:38382364~38383461:+
THCA	cis	rs924712	0.521	rs4712073	ENSG00000224984.1	RP11-524H19.2	-3.66	0.000286	0.0192	-0.2	-0.17	Breast cancer;	chr6:54808429	chr6:54840118~54840855:-
THCA	cis	rs733592	0.931	rs765260	ENSG00000258273.1	RP11-370I10.4	3.66	0.000286	0.0192	0.2	0.17	Plateletcrit;	chr12:48038153	chr12:48333755~48333901:-
THCA	cis	rs720064	0.586	rs12957815	ENSG00000264745.1	TTC39C-AS1	3.66	0.000286	0.0192	0.18	0.17	Strep throat;	chr18:23976626	chr18:23994213~24015339:-
THCA	cis	rs10496034	0.541	rs111404605	ENSG00000237887.1	AC092839.1	-3.66	0.000286	0.0192	-0.32	-0.17	Refractive astigmatism;	chr2:54700748	chr2:54529343~54529801:+
THCA	cis	rs12476592	0.602	rs2305157	ENSG00000242412.1	DBIL5P2	3.66	0.000286	0.0192	0.21	0.17	Childhood ear infection;	chr2:63595651	chr2:63117851~63119542:-
THCA	cis	rs972540	1	rs41388648	ENSG00000229647.1	AC007879.7	-3.66	0.000286	0.0192	-0.19	-0.17	Body mass index;	chr2:206366636	chr2:207239650~207245887:+
THCA	cis	rs34929064	0.536	rs2961278	ENSG00000232949.1	AC002480.4	-3.66	0.000286	0.0192	-0.22	-0.17	Major depression and alcohol dependence;	chr7:22595160	chr7:22589705~22591622:+
THCA	cis	rs78487399	0.908	rs6712944	ENSG00000234936.1	AC010883.5	3.66	0.000286	0.0192	0.21	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43606979	chr2:43229573~43233394:+
THCA	cis	rs7824557	0.564	rs34389419	ENSG00000154316.13	TDH	3.66	0.000286	0.0192	0.13	0.17	Retinal vascular caliber;	chr8:11371810	chr8:11339637~11368452:+
THCA	cis	rs972578	0.804	rs5758948	ENSG00000230319.1	AL022476.2	3.66	0.000286	0.0192	0.18	0.17	Mean platelet volume;	chr22:42799290	chr22:43038585~43052366:+
THCA	cis	rs754466	0.58	rs1058198	ENSG00000213514.2	RP11-428P16.2	3.66	0.000286	0.0192	0.18	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806874	chr10:77730766~77734769:+
THCA	cis	rs6942407	0.744	rs6968640	ENSG00000224046.1	AC005076.5	-3.66	0.000286	0.0192	-0.16	-0.17	Food allergy;	chr7:87233467	chr7:87151423~87152420:-
THCA	cis	rs6920965	0.602	rs10872302	ENSG00000226409.1	RP11-735G4.1	-3.66	0.000286	0.0192	-0.2	-0.17	High light scatter reticulocyte count;	chr6:125859485	chr6:125370211~125374324:-
THCA	cis	rs7394190	0.81	rs7394152	ENSG00000272140.2	RP11-574K11.29	-3.66	0.000286	0.0192	-0.16	-0.17	Incident atrial fibrillation;	chr10:73661688	chr10:73703735~73713581:-
THCA	cis	rs791590	0.752	rs62626325	ENSG00000225948.2	RP11-554I8.1	3.66	0.000286	0.0192	0.25	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6079322	chr10:6618716~6625346:+
THCA	cis	rs4240897	0.835	rs4845891	ENSG00000201801.1	RNU5E-4P	3.66	0.000286	0.0192	0.19	0.17	Tuberculosis;	chr1:11982449	chr1:11909808~11909927:-
THCA	cis	rs2179367	0.632	rs66672129	ENSG00000216906.2	RP11-350J20.9	3.66	0.000286	0.0192	0.21	0.17	Dupuytren's disease;	chr6:149334387	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498322	ENSG00000216906.2	RP11-350J20.9	3.66	0.000286	0.0192	0.21	0.17	Dupuytren's disease;	chr6:149335950	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498323	ENSG00000216906.2	RP11-350J20.9	3.66	0.000286	0.0192	0.21	0.17	Dupuytren's disease;	chr6:149336077	chr6:149904243~149906418:+
THCA	cis	rs150992	0.742	rs34495	ENSG00000246763.5	RGMB-AS1	3.66	0.000286	0.0192	0.17	0.17	Body mass index;	chr5:98930103	chr5:98769618~98773469:-
THCA	cis	rs1153858	0.723	rs1719238	ENSG00000275672.1	GATM-AS1	3.66	0.000286	0.0192	0.17	0.17	Homoarginine levels;	chr15:45302568	chr15:45378700~45380123:+
THCA	cis	rs763121	0.651	rs738249	ENSG00000225450.1	RP3-508I15.14	-3.66	0.000286	0.0192	-0.13	-0.17	Menopause (age at onset);	chr22:38641974	chr22:38739003~38749041:+
THCA	cis	rs875971	1	rs1363055	ENSG00000272831.1	RP11-792A8.4	3.66	0.000286	0.0192	0.1	0.17	Aortic root size;	chr7:66478288	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs9691480	ENSG00000272831.1	RP11-792A8.4	3.66	0.000286	0.0192	0.1	0.17	Aortic root size;	chr7:66479319	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs7789554	ENSG00000272831.1	RP11-792A8.4	3.66	0.000286	0.0192	0.1	0.17	Aortic root size;	chr7:66481051	chr7:66739829~66740385:-
THCA	cis	rs875971	0.895	rs1974769	ENSG00000272831.1	RP11-792A8.4	3.66	0.000286	0.0192	0.1	0.17	Aortic root size;	chr7:66485627	chr7:66739829~66740385:-
THCA	cis	rs875971	0.895	rs6460300	ENSG00000272831.1	RP11-792A8.4	3.66	0.000286	0.0192	0.1	0.17	Aortic root size;	chr7:66487937	chr7:66739829~66740385:-
THCA	cis	rs875971	0.862	rs7803416	ENSG00000272831.1	RP11-792A8.4	3.66	0.000286	0.0192	0.1	0.17	Aortic root size;	chr7:66489212	chr7:66739829~66740385:-
THCA	cis	rs875971	0.862	rs1981799	ENSG00000272831.1	RP11-792A8.4	3.66	0.000286	0.0192	0.1	0.17	Aortic root size;	chr7:66490572	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs2277911	ENSG00000272831.1	RP11-792A8.4	3.66	0.000286	0.0192	0.1	0.17	Aortic root size;	chr7:66493638	chr7:66739829~66740385:-
THCA	cis	rs7117932	0.935	rs11221356	ENSG00000270160.1	RP11-264E20.2	3.66	0.000286	0.0192	0.2	0.17	Obesity-related traits;	chr11:128573938	chr11:128614340~128615236:-
THCA	cis	rs875971	0.545	rs2420612	ENSG00000273024.4	INTS4P2	-3.66	0.000286	0.0192	-0.21	-0.17	Aortic root size;	chr7:66536825	chr7:65647864~65715661:+
THCA	cis	rs897984	0.609	rs1108431	ENSG00000275263.1	RP11-1072A3.4	-3.65	0.000286	0.0192	-0.2	-0.17	Dementia with Lewy bodies;	chr16:31043286	chr16:30956872~30957199:-
THCA	cis	rs12544026	0.515	rs486196	ENSG00000253669.3	KB-1732A1.1	-3.65	0.000286	0.0192	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101861105	chr8:102805517~102809971:+
THCA	cis	rs12544026	0.55	rs480955	ENSG00000253669.3	KB-1732A1.1	-3.65	0.000286	0.0192	-0.19	-0.17	Major depression and alcohol dependence;	chr8:101861153	chr8:102805517~102809971:+
THCA	cis	rs4906332	1	rs35224956	ENSG00000259775.1	RP11-45P15.4	-3.65	0.000286	0.0192	-0.14	-0.17	Coronary artery disease;	chr14:103434144	chr14:103331674~103332367:-
THCA	cis	rs7809615	0.515	rs10254729	ENSG00000274272.1	RP11-44M6.7	3.65	0.000286	0.0192	0.18	0.17	Blood metabolite ratios;	chr7:99598805	chr7:100572232~100578700:-
THCA	cis	rs293748	0.771	rs181755	ENSG00000250155.1	CTD-2353F22.1	-3.65	0.000286	0.0192	-0.22	-0.17	Obesity-related traits;	chr5:36839162	chr5:36666214~36725195:-
THCA	cis	rs12681366	0.839	rs3019282	ENSG00000253175.1	RP11-267M23.6	3.65	0.000286	0.0192	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94439898	chr8:94565036~94565715:+
THCA	cis	rs35146811	0.735	rs7811662	ENSG00000078319.8	PMS2P1	3.65	0.000286	0.0192	0.21	0.17	Coronary artery disease;	chr7:100194985	chr7:100320992~100341908:-
THCA	cis	rs6432852	0.932	rs4667851	ENSG00000232411.1	AC009495.3	3.65	0.000286	0.0192	0.18	0.17	Diabetic kidney disease;	chr2:165881155	chr2:165833048~165839098:-
THCA	cis	rs9291683	0.609	rs7678012	ENSG00000250413.1	RP11-448G15.1	-3.65	0.000286	0.0192	-0.16	-0.17	Bone mineral density;	chr4:9992148	chr4:10006482~10009725:+
THCA	cis	rs6496667	0.557	rs2601201	ENSG00000213471.7	TTLL13P	3.65	0.000286	0.0192	0.2	0.17	Rheumatoid arthritis;	chr15:90414768	chr15:90249530~90265482:+
THCA	cis	rs924712	0.522	rs9464146	ENSG00000224984.1	RP11-524H19.2	-3.65	0.000286	0.0192	-0.2	-0.17	Breast cancer;	chr6:54834441	chr6:54840118~54840855:-
THCA	cis	rs11673344	0.698	rs56161518	ENSG00000267309.1	CTD-2630F21.1	-3.65	0.000286	0.0192	-0.17	-0.17	Obesity-related traits;	chr19:36978555	chr19:36489649~36491040:+
THCA	cis	rs10090774	1	rs9650572	ENSG00000280303.2	ERICD	3.65	0.000286	0.0192	0.15	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140821890	chr8:140636281~140638283:+
THCA	cis	rs9828933	0.938	rs3816157	ENSG00000271843.1	RP11-245J9.5	3.65	0.000286	0.0192	0.26	0.17	Type 2 diabetes;	chr3:64013646	chr3:64008082~64008692:-
THCA	cis	rs267567	0.626	rs267560	ENSG00000235257.7	ITGA9-AS1	3.65	0.000286	0.0192	0.14	0.17	PR interval;	chr3:37533548	chr3:37745432~37861780:-
THCA	cis	rs61160187	0.582	rs17332824	ENSG00000251279.1	CTC-436P18.1	3.65	0.000286	0.0192	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60870360	chr5:61162070~61232040:+
THCA	cis	rs7819412	0.806	rs6980856	ENSG00000254948.1	OR7E158P	-3.65	0.000286	0.0192	-0.2	-0.17	Triglycerides;	chr8:11080750	chr8:11919900~11920809:-
THCA	cis	rs17027633	1	rs1539581	ENSG00000234020.1	CHIAP3	3.65	0.000286	0.0192	0.35	0.17	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111404336	chr1:111353275~111367409:-
THCA	cis	rs3743772	0.5	rs9924562	ENSG00000279344.1	RP11-44F14.7	3.65	0.000287	0.0192	0.23	0.17	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53478957~53481550:-
THCA	cis	rs267567	0.626	rs267563	ENSG00000235257.7	ITGA9-AS1	3.65	0.000287	0.0192	0.14	0.17	PR interval;	chr3:37532986	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs267562	ENSG00000235257.7	ITGA9-AS1	3.65	0.000287	0.0192	0.14	0.17	PR interval;	chr3:37532997	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs267561	ENSG00000235257.7	ITGA9-AS1	3.65	0.000287	0.0192	0.14	0.17	PR interval;	chr3:37533460	chr3:37745432~37861780:-
THCA	cis	rs7394190	1	rs7394190	ENSG00000272140.2	RP11-574K11.29	-3.65	0.000287	0.0192	-0.15	-0.17	Incident atrial fibrillation;	chr10:73661890	chr10:73703735~73713581:-
THCA	cis	rs7598759	1	rs7598759	ENSG00000281035.1	AC017104.3	-3.65	0.000287	0.0192	-0.17	-0.17	Noise-induced hearing loss;	chr2:231457245	chr2:231456417~231456557:-
THCA	cis	rs9308731	0.548	rs7581735	ENSG00000227992.1	AC108463.2	-3.65	0.000287	0.0192	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111180137	chr2:111203964~111206215:-
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000214719.10	AC005562.1	-3.65	0.000287	0.0192	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000214719.10	AC005562.1	-3.65	0.000287	0.0192	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000214719.10	AC005562.1	-3.65	0.000287	0.0192	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30576464~30672789:+
THCA	cis	rs8035452	0.857	rs3131603	ENSG00000273674.3	CTD-2378E12.1	3.65	0.000287	0.0192	0.21	0.17	Alzheimer's disease (late onset);	chr15:50522037	chr15:50839875~50908599:-
THCA	cis	rs17345786	0.861	rs11707689	ENSG00000244119.1	PDCL3P4	3.65	0.000287	0.0192	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr3:101367631	chr3:101712472~101713191:+
THCA	cis	rs10844154	0.508	rs1239398	ENSG00000277342.1	RP11-843B15.4	3.65	0.000287	0.0192	0.22	0.17	Emphysema-related traits;Weight;	chr12:32258465	chr12:32109076~32109602:+
THCA	cis	rs17556028	0.669	rs17484960	ENSG00000226822.1	RP11-356N1.2	3.65	0.000287	0.0192	0.17	0.17	Night sleep phenotypes;	chr1:107794486	chr1:108071482~108074519:+
THCA	cis	rs1065852	0.526	rs9623490	ENSG00000227370.1	RP4-669P10.19	3.65	0.000287	0.0192	0.17	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002262	chr22:42132543~42132998:+
THCA	cis	rs6586163	1	rs7072828	ENSG00000261438.1	RP11-399O19.9	3.65	0.000287	0.0192	0.13	0.17	Chronic lymphocytic leukemia;	chr10:88995196	chr10:89015836~89017059:+
THCA	cis	rs4819052	0.851	rs11558445	ENSG00000182586.6	LINC00334	-3.65	0.000287	0.0192	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45234340~45258730:+
THCA	cis	rs4671400	0.516	rs62152277	ENSG00000271889.1	RP11-493E12.1	-3.65	0.000287	0.0192	-0.18	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61276269	chr2:61151433~61162105:-
THCA	cis	rs4646450	0.945	rs12333760	ENSG00000274272.1	RP11-44M6.7	3.65	0.000287	0.0192	0.18	0.17	Blood metabolite levels;	chr7:99587783	chr7:100572232~100578700:-
THCA	cis	rs9308731	0.556	rs10166773	ENSG00000227992.1	AC108463.2	-3.65	0.000287	0.0192	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111179358	chr2:111203964~111206215:-
THCA	cis	rs9308731	0.591	rs13398360	ENSG00000227992.1	AC108463.2	-3.65	0.000287	0.0192	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111180363	chr2:111203964~111206215:-
THCA	cis	rs9308731	0.591	rs55878194	ENSG00000227992.1	AC108463.2	-3.65	0.000287	0.0192	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111182897	chr2:111203964~111206215:-
THCA	cis	rs9923283	1	rs1364182	ENSG00000278922.1	AC002310.14	-3.65	0.000287	0.0192	-0.25	-0.17	Plateletcrit;	chr16:29644772	chr16:30526918~30528294:+
THCA	cis	rs2281603	0.57	rs10136732	ENSG00000258824.2	CTD-2555O16.2	-3.65	0.000287	0.0192	-0.15	-0.17	Lymphocyte counts;	chr14:64484255	chr14:64422935~64448557:-
THCA	cis	rs14027	0.921	rs13261032	ENSG00000245330.4	KB-1471A8.1	3.65	0.000287	0.0192	0.17	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119867419~119874488:-
THCA	cis	rs713587	0.563	rs2033655	ENSG00000224165.4	DNAJC27-AS1	-3.65	0.000287	0.0192	-0.09	-0.17	Body mass index in non-asthmatics;	chr2:24878223	chr2:24971390~25039694:+
THCA	cis	rs1204798	0.685	rs1204794	ENSG00000237021.2	RP3-486I3.7	-3.65	0.000287	0.0192	-0.19	-0.17	Dental caries;	chr6:116220049	chr6:116254207~116256743:+
THCA	cis	rs453301	0.522	rs2929309	ENSG00000254340.1	RP11-10A14.3	-3.65	0.000287	0.0192	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9226261	chr8:9141424~9145435:+
THCA	cis	rs3018712	0.59	rs4930236	ENSG00000212093.1	AP000807.1	-3.65	0.000287	0.0192	-0.21	-0.17	Total body bone mineral density;	chr11:68646532	chr11:68506083~68506166:-
THCA	cis	rs6586163	1	rs6586165	ENSG00000261438.1	RP11-399O19.9	3.65	0.000287	0.0192	0.13	0.17	Chronic lymphocytic leukemia;	chr10:88995299	chr10:89015836~89017059:+
THCA	cis	rs875971	0.862	rs28470208	ENSG00000223473.2	GS1-124K5.3	-3.65	0.000287	0.0192	-0.11	-0.17	Aortic root size;	chr7:66119713	chr7:66491049~66493566:-
THCA	cis	rs13113518	0.557	rs13142096	ENSG00000272969.1	RP11-528I4.2	3.65	0.000287	0.0192	0.21	0.17	Height;	chr4:55566291	chr4:55547112~55547889:+
THCA	cis	rs1433188	0.847	rs10086241	ENSG00000253582.1	RP11-649G15.2	3.65	0.000287	0.0192	0.19	0.17	Subjective well-being;	chr8:107429344	chr8:106520474~106657548:-
THCA	cis	rs1433188	0.847	rs10086336	ENSG00000253582.1	RP11-649G15.2	3.65	0.000287	0.0192	0.19	0.17	Subjective well-being;	chr8:107429414	chr8:106520474~106657548:-
THCA	cis	rs2749592	0.513	rs9417249	ENSG00000226578.1	RP11-258F22.1	3.65	0.000287	0.0192	0.19	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37548227	chr10:37775371~37784131:-
THCA	cis	rs6586163	0.934	rs7897395	ENSG00000261438.1	RP11-399O19.9	3.65	0.000287	0.0192	0.13	0.17	Chronic lymphocytic leukemia;	chr10:88994850	chr10:89015836~89017059:+
THCA	cis	rs6586163	0.843	rs7069061	ENSG00000261438.1	RP11-399O19.9	3.65	0.000287	0.0192	0.13	0.17	Chronic lymphocytic leukemia;	chr10:88995152	chr10:89015836~89017059:+
THCA	cis	rs642858	0.747	rs581559	ENSG00000234147.1	RP3-460G2.2	3.65	0.000287	0.0192	0.19	0.17	Type 2 diabetes;	chr6:139911384	chr6:140845958~140852924:-
THCA	cis	rs7246657	0.943	rs7259968	ENSG00000268499.1	CTB-102L5.8	3.65	0.000287	0.0192	0.21	0.17	Coronary artery calcification;	chr19:37320952	chr19:38199836~38200934:+
THCA	cis	rs453301	0.658	rs6983877	ENSG00000254340.1	RP11-10A14.3	-3.65	0.000287	0.0192	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9047129	chr8:9141424~9145435:+
THCA	cis	rs4218	0.543	rs8025246	ENSG00000277144.1	RP11-59H7.4	-3.65	0.000287	0.0192	-0.22	-0.17	Social communication problems;	chr15:59025814	chr15:59115547~59116089:-
THCA	cis	rs459571	0.834	rs379417	ENSG00000235106.7	LINC00094	3.65	0.000287	0.0193	0.15	0.17	Platelet distribution width;	chr9:134025582	chr9:134025439~134034666:+
THCA	cis	rs3758911	0.861	rs2355840	ENSG00000255353.1	RP11-382M14.1	-3.65	0.000287	0.0193	-0.22	-0.17	Coronary artery disease;	chr11:107287251	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs11212132	ENSG00000255353.1	RP11-382M14.1	-3.65	0.000287	0.0193	-0.22	-0.17	Coronary artery disease;	chr11:107288576	chr11:107176286~107177530:+
THCA	cis	rs4561483	0.667	rs3743590	ENSG00000263307.1	RP11-166B2.8	3.65	0.000287	0.0193	0.17	0.17	Testicular germ cell tumor;	chr16:11836480	chr16:11851649~11895611:+
THCA	cis	rs9450351	0.744	rs6913958	ENSG00000203875.9	SNHG5	-3.65	0.000287	0.0193	-0.32	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85825481	chr6:85660950~85678736:-
THCA	cis	rs472402	0.507	rs8192139	ENSG00000250056.4	LINC01018	-3.65	0.000287	0.0193	-0.19	-0.17	Response to amphetamines;	chr5:6636860	chr5:6582136~6588499:+
THCA	cis	rs7551222	0.683	rs898386	ENSG00000240219.1	RP11-430C7.5	3.65	0.000287	0.0193	0.17	0.17	Schizophrenia;	chr1:204610569	chr1:204626775~204629712:+
THCA	cis	rs11126435	0.858	rs363620	ENSG00000234521.1	AC005041.11	-3.65	0.000287	0.0193	-0.23	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr2:74701223	chr2:74413020~74413481:-
THCA	cis	rs1005277	0.579	rs2472173	ENSG00000120555.12	SEPT7P9	3.65	0.000287	0.0193	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2472174	ENSG00000120555.12	SEPT7P9	3.65	0.000287	0.0193	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474563	ENSG00000120555.12	SEPT7P9	3.65	0.000287	0.0193	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs9418322	ENSG00000120555.12	SEPT7P9	3.65	0.000287	0.0193	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs9299760	ENSG00000120555.12	SEPT7P9	3.65	0.000287	0.0193	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2023351	ENSG00000120555.12	SEPT7P9	3.65	0.000287	0.0193	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38383069~38402916:-
THCA	cis	rs10802047	0.566	rs1408854	ENSG00000231365.4	RP11-418J17.1	3.65	0.000287	0.0193	0.17	0.17	Relative hand skill in reading disability;	chr1:118767385	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.536	rs2712286	ENSG00000231365.4	RP11-418J17.1	3.65	0.000287	0.0193	0.17	0.17	Relative hand skill in reading disability;	chr1:118767638	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.566	rs726637	ENSG00000231365.4	RP11-418J17.1	3.65	0.000287	0.0193	0.17	0.17	Relative hand skill in reading disability;	chr1:118768569	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.566	rs1853775	ENSG00000231365.4	RP11-418J17.1	3.65	0.000287	0.0193	0.17	0.17	Relative hand skill in reading disability;	chr1:118773313	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.516	rs2712251	ENSG00000231365.4	RP11-418J17.1	3.65	0.000287	0.0193	0.17	0.17	Relative hand skill in reading disability;	chr1:118774900	chr1:119140396~119275973:+
THCA	cis	rs10802047	0.566	rs1853774	ENSG00000231365.4	RP11-418J17.1	3.65	0.000287	0.0193	0.17	0.17	Relative hand skill in reading disability;	chr1:118776060	chr1:119140396~119275973:+
THCA	cis	rs42648	0.617	rs11563435	ENSG00000225498.1	AC002064.5	3.65	0.000287	0.0193	0.17	0.17	Homocysteine levels;	chr7:90270893	chr7:90312496~90322592:+
THCA	cis	rs929354	0.772	rs3802118	ENSG00000224629.1	RP5-1142J19.2	-3.65	0.000287	0.0193	-0.16	-0.17	Body mass index;	chr7:157194120	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs3802117	ENSG00000224629.1	RP5-1142J19.2	-3.65	0.000287	0.0193	-0.16	-0.17	Body mass index;	chr7:157194306	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs11980541	ENSG00000224629.1	RP5-1142J19.2	-3.65	0.000287	0.0193	-0.16	-0.17	Body mass index;	chr7:157196082	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs2366214	ENSG00000224629.1	RP5-1142J19.2	-3.65	0.000287	0.0193	-0.16	-0.17	Body mass index;	chr7:157199767	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs6967764	ENSG00000224629.1	RP5-1142J19.2	-3.65	0.000287	0.0193	-0.16	-0.17	Body mass index;	chr7:157202270	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs2023977	ENSG00000224629.1	RP5-1142J19.2	-3.65	0.000287	0.0193	-0.16	-0.17	Body mass index;	chr7:157203328	chr7:157263022~157263229:-
THCA	cis	rs17270561	0.583	rs6926425	ENSG00000272462.2	U91328.19	-3.65	0.000287	0.0193	-0.14	-0.17	Iron status biomarkers;	chr6:25785076	chr6:25992662~26001775:+
THCA	cis	rs972578	0.561	rs2413740	ENSG00000274717.1	RP1-47A17.1	-3.65	0.000287	0.0193	-0.19	-0.17	Mean platelet volume;	chr22:43023319	chr22:42791814~42794313:-
THCA	cis	rs7246967	0.611	rs12973627	ENSG00000236312.3	RPL34P34	-3.65	0.000287	0.0193	-0.23	-0.17	Bronchopulmonary dysplasia;	chr19:22684903	chr19:22368599~22368952:-
THCA	cis	rs7914558	1	rs7094843	ENSG00000272912.1	RP11-724N1.1	-3.65	0.000287	0.0193	-0.2	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103046897	chr10:102914585~102915404:+
THCA	cis	rs17407555	0.657	rs12505222	ENSG00000250413.1	RP11-448G15.1	-3.65	0.000287	0.0193	-0.18	-0.17	Schizophrenia (age at onset);	chr4:10269512	chr4:10006482~10009725:+
THCA	cis	rs7412746	0.611	rs1889740	ENSG00000224800.1	RP11-235D19.2	-3.65	0.000287	0.0193	-0.22	-0.17	Melanoma;	chr1:150827279	chr1:150881236~150881683:-
THCA	cis	rs9733	0.519	rs11800855	ENSG00000224800.1	RP11-235D19.2	-3.65	0.000287	0.0193	-0.22	-0.17	Tonsillectomy;	chr1:150828519	chr1:150881236~150881683:-
THCA	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-3.65	0.000287	0.0193	-0.19	-0.17	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
THCA	cis	rs7267979	0.744	rs6050464	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25284915~25285588:-
THCA	cis	rs80130819	0.642	rs4760607	ENSG00000257735.1	RP11-370I10.6	-3.65	0.000288	0.0193	-0.36	-0.17	Prostate cancer;	chr12:47971482	chr12:48350945~48442411:+
THCA	cis	rs17685	0.712	rs11770149	ENSG00000227038.2	AC005077.12	3.65	0.000288	0.0193	0.16	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76162326	chr7:76090431~76108779:-
THCA	cis	rs9549260	0.755	rs17061450	ENSG00000168852.11	TPTE2P5	3.65	0.000288	0.0193	0.12	0.17	Red blood cell count;	chr13:40609579	chr13:40822296~40921749:-
THCA	cis	rs2821260	0.694	rs12750634	ENSG00000227207.2	RPL31P12	-3.65	0.000288	0.0193	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72131971	chr1:72301472~72301829:+
THCA	cis	rs301901	0.796	rs1829292	ENSG00000250155.1	CTD-2353F22.1	3.65	0.000288	0.0193	0.16	0.17	Height;	chr5:37505544	chr5:36666214~36725195:-
THCA	cis	rs875971	0.66	rs10263935	ENSG00000275400.1	RP4-756H11.5	-3.65	0.000288	0.0193	-0.16	-0.17	Aortic root size;	chr7:66631041	chr7:66553805~66554199:-
THCA	cis	rs4915077	1	rs17020047	ENSG00000226822.1	RP11-356N1.2	3.65	0.000288	0.0193	0.32	0.17	Hypothyroidism;	chr1:107789448	chr1:108071482~108074519:+
THCA	cis	rs7833790	1	rs1463259	ENSG00000254689.1	RP11-354A14.1	3.65	0.000288	0.0193	0.21	0.17	Diastolic blood pressure;	chr8:81825510	chr8:81885377~81923193:+
THCA	cis	rs7660883	1	rs3775220	ENSG00000251411.1	RP11-397E7.4	-3.65	0.000288	0.0193	-0.16	-0.17	HDL cholesterol levels;	chr4:87093601	chr4:86913266~86914817:-
THCA	cis	rs12476592	0.602	rs262483	ENSG00000242412.1	DBIL5P2	3.65	0.000288	0.0193	0.21	0.17	Childhood ear infection;	chr2:63650112	chr2:63117851~63119542:-
THCA	cis	rs10483853	0.767	rs12590879	ENSG00000258891.1	RP5-1021I20.5	-3.65	0.000288	0.0193	-0.22	-0.17	Coronary artery calcification;	chr14:73338201	chr14:73896164~73938114:-
THCA	cis	rs7903847	0.642	rs2297667	ENSG00000225850.3	RP11-452K12.4	3.65	0.000288	0.0193	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97385735	chr10:97334564~97343203:+
THCA	cis	rs56046484	0.956	rs12904410	ENSG00000259630.2	CTD-2262B20.1	-3.65	0.000288	0.0193	-0.24	-0.17	Testicular germ cell tumor;	chr15:85066557	chr15:85415228~85415633:+
THCA	cis	rs2980436	1	rs2980436	ENSG00000233609.3	RP11-62H7.2	-3.65	0.000288	0.0193	-0.15	-0.17	Schizophrenia;	chr8:8234503	chr8:8961200~8979025:+
THCA	cis	rs57709857	0.957	rs10958670	ENSG00000272092.1	RP11-350N15.5	-3.65	0.000288	0.0193	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38400636	chr8:38382364~38383461:+
THCA	cis	rs7267979	0.933	rs11699203	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.933	rs6138571	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs416745	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs448396	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs447722	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs422424	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs422844	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs401166	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs404394	ENSG00000276952.1	RP5-965G21.6	3.65	0.000288	0.0193	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25284915~25285588:-
THCA	cis	rs4073416	0.568	rs1121885	ENSG00000276116.2	FUT8-AS1	3.65	0.000288	0.0193	0.19	0.17	N-glycan levels;	chr14:65690196	chr14:65411170~65412690:-
THCA	cis	rs206966	0.81	rs7314115	ENSG00000277283.1	RP1-267D11.6	3.65	0.000288	0.0193	0.16	0.17	Breast cancer;	chr12:120337167	chr12:120116907~120119000:+
THCA	cis	rs7208859	0.615	rs216462	ENSG00000280069.1	CTD-2349P21.3	3.65	0.000288	0.0193	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30738182~30740275:+
THCA	cis	rs1050631	0.924	rs1785918	ENSG00000260552.1	RP11-49I11.1	3.65	0.000288	0.0193	0.2	0.17	Esophageal squamous cell cancer (length of survival);	chr18:36113235	chr18:36179996~36187448:-
THCA	cis	rs1971762	0.583	rs1527068	ENSG00000270175.1	RP11-793H13.11	-3.65	0.000288	0.0193	-0.11	-0.17	Height;	chr12:53694904	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.583	rs11170648	ENSG00000270175.1	RP11-793H13.11	-3.65	0.000288	0.0193	-0.11	-0.17	Height;	chr12:53695876	chr12:53500162~53500936:-
THCA	cis	rs12142240	0.959	rs12137934	ENSG00000232022.5	FAAHP1	-3.65	0.000288	0.0193	-0.19	-0.17	Menopause (age at onset);	chr1:46263241	chr1:46432129~46445521:+
THCA	cis	rs7560272	0.501	rs10191988	ENSG00000163016.8	ALMS1P	-3.65	0.000288	0.0193	-0.21	-0.17	Schizophrenia;	chr2:73720660	chr2:73644919~73685576:+
THCA	cis	rs7508	0.552	rs429633	ENSG00000253671.1	RP11-806O11.1	-3.65	0.000288	0.0193	-0.2	-0.17	Atrial fibrillation;	chr8:17993739	chr8:17808941~17820868:+
THCA	cis	rs6957923	0.967	rs35133514	ENSG00000234286.1	AC006026.13	-3.65	0.000288	0.0193	-0.22	-0.17	Height;	chr7:23462189	chr7:23680195~23680786:-
THCA	cis	rs293748	0.882	rs293774	ENSG00000250155.1	CTD-2353F22.1	-3.65	0.000288	0.0193	-0.23	-0.17	Obesity-related traits;	chr5:36943166	chr5:36666214~36725195:-
THCA	cis	rs12681366	1	rs7825731	ENSG00000261437.1	RP11-22C11.2	3.65	0.000288	0.0193	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94362147	chr8:94637285~94639467:-
THCA	cis	rs4295623	0.585	rs34421088	ENSG00000206014.6	OR7E161P	3.65	0.000288	0.0193	0.19	0.17	Morning vs. evening chronotype;	chr8:11731533	chr8:11928597~11929563:-
THCA	cis	rs748404	0.601	rs530118	ENSG00000205771.5	CATSPER2P1	3.65	0.000288	0.0193	0.17	0.17	Lung cancer;	chr15:43186313	chr15:43726918~43747094:-
THCA	cis	rs11686241	0.872	rs284525	ENSG00000232485.2	AC098820.3	-3.65	0.000288	0.0193	-0.18	-0.17	Cancer;	chr2:216473196	chr2:216479030~216498761:-
THCA	cis	rs4742903	0.904	rs7038714	ENSG00000270332.1	SMC2-AS1	3.65	0.000288	0.0193	0.16	0.17	Breast cancer;High-grade serous ovarian cancer;	chr9:104230649	chr9:104080024~104093073:-
THCA	cis	rs881375	0.933	rs7031096	ENSG00000270917.1	RP11-27I1.6	-3.65	0.000288	0.0193	-0.23	-0.17	Rheumatoid arthritis;	chr9:120932664	chr9:120812475~120812845:-
THCA	cis	rs881375	0.967	rs10739580	ENSG00000270917.1	RP11-27I1.6	-3.65	0.000288	0.0193	-0.23	-0.17	Rheumatoid arthritis;	chr9:120933004	chr9:120812475~120812845:-
THCA	cis	rs7112925	0.966	rs11602157	ENSG00000255517.5	CTD-3074O7.5	3.65	0.000288	0.0193	0.13	0.17	Height;	chr11:67059848	chr11:66473490~66480233:-
THCA	cis	rs6095360	0.565	rs6019518	ENSG00000227431.4	CSE1L-AS1	-3.65	0.000288	0.0193	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48914708	chr20:49040463~49046044:-
THCA	cis	rs11018874	0.597	rs4268468	ENSG00000280367.1	RP11-121L10.2	3.65	0.000288	0.0193	0.19	0.17	White blood cell types;	chr11:90153116	chr11:90223153~90226538:+
THCA	cis	rs2235649	0.833	rs9925460	ENSG00000260541.1	LA16c-429E7.1	3.65	0.000288	0.0193	0.22	0.17	Blood metabolite levels;	chr16:1799942	chr16:1841020~1843547:-
THCA	cis	rs7560272	0.501	rs2006997	ENSG00000163016.8	ALMS1P	-3.65	0.000288	0.0193	-0.21	-0.17	Schizophrenia;	chr2:73720719	chr2:73644919~73685576:+
THCA	cis	rs2080501	0.628	rs1344530	ENSG00000275155.1	CTD-2595P9.4	-3.65	0.000288	0.0193	-0.16	-0.17	IgG glycosylation;	chr16:49631211	chr16:49847018~49847632:-
THCA	cis	rs8028182	0.725	rs8024276	ENSG00000260274.1	RP11-817O13.8	3.65	0.000288	0.0193	0.15	0.17	Sudden cardiac arrest;	chr15:75407182	chr15:75368155~75369584:+
THCA	cis	rs972578	0.967	rs738391	ENSG00000230319.1	AL022476.2	3.65	0.000288	0.0193	0.17	0.17	Mean platelet volume;	chr22:42943872	chr22:43038585~43052366:+
THCA	cis	rs6963495	0.719	rs73190172	ENSG00000272604.1	RP11-251G23.5	3.65	0.000288	0.0193	0.22	0.17	Bipolar disorder (body mass index interaction);	chr7:105520763	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.719	rs73190174	ENSG00000272604.1	RP11-251G23.5	3.65	0.000288	0.0193	0.22	0.17	Bipolar disorder (body mass index interaction);	chr7:105520769	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.818	rs118134111	ENSG00000272604.1	RP11-251G23.5	3.65	0.000288	0.0193	0.22	0.17	Bipolar disorder (body mass index interaction);	chr7:105520782	chr7:105571083~105573660:+
THCA	cis	rs7020830	0.861	rs2291589	ENSG00000260100.1	RP11-220I1.5	-3.65	0.000288	0.0193	-0.2	-0.17	Schizophrenia;	chr9:37079664	chr9:37078813~37079776:-
THCA	cis	rs17123764	1	rs75278574	ENSG00000257464.1	RP11-161H23.8	-3.65	0.000288	0.0193	-0.34	-0.17	Intelligence (multi-trait analysis);	chr12:49607162	chr12:49442424~49442652:-
THCA	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	3.65	0.000288	0.0193	0.15	0.17	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
THCA	cis	rs7085104	0.514	rs284855	ENSG00000236937.2	PTGES3P4	-3.65	0.000288	0.0193	-0.21	-0.17	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102845595~102845950:+
THCA	cis	rs910316	1	rs4899544	ENSG00000259138.1	RP11-950C14.7	3.65	0.000288	0.0193	0.15	0.17	Height;	chr14:75079853	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs4903279	ENSG00000259138.1	RP11-950C14.7	3.65	0.000288	0.0193	0.15	0.17	Height;	chr14:75079880	chr14:75127153~75136930:+
THCA	cis	rs910316	0.967	rs1071989	ENSG00000259138.1	RP11-950C14.7	3.65	0.000288	0.0193	0.15	0.17	Height;	chr14:75097956	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs9805979	ENSG00000259138.1	RP11-950C14.7	3.65	0.000288	0.0193	0.15	0.17	Height;	chr14:75099506	chr14:75127153~75136930:+
THCA	cis	rs9291683	0.567	rs12499857	ENSG00000250413.1	RP11-448G15.1	-3.65	0.000288	0.0193	-0.16	-0.17	Bone mineral density;	chr4:9993752	chr4:10006482~10009725:+
THCA	cis	rs2447820	0.5	rs30025	ENSG00000263432.2	RN7SL689P	3.65	0.000288	0.0193	0.21	0.17	Migraine;	chr5:122949047	chr5:123022487~123022783:-
THCA	cis	rs1577917	0.739	rs9450318	ENSG00000220563.1	PKMP3	3.65	0.000288	0.0193	0.12	0.17	Response to antipsychotic treatment;	chr6:85717459	chr6:85659892~85660606:-
THCA	cis	rs3087591	0.683	rs17826544	ENSG00000263535.1	AK4P1	3.65	0.000288	0.0193	0.2	0.17	Hip circumference;	chr17:31313207	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs3785956	ENSG00000263535.1	AK4P1	3.65	0.000288	0.0193	0.2	0.17	Hip circumference;	chr17:31320689	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.683	rs2525564	ENSG00000263535.1	AK4P1	3.65	0.000288	0.0193	0.2	0.17	Hip circumference;	chr17:31325513	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs10445402	ENSG00000263535.1	AK4P1	3.65	0.000288	0.0193	0.2	0.17	Hip circumference;	chr17:31334322	chr17:31345521~31346187:+
THCA	cis	rs1005277	0.522	rs1208681	ENSG00000120555.12	SEPT7P9	3.65	0.000288	0.0193	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38383069~38402916:-
THCA	cis	rs12368653	0.545	rs2277324	ENSG00000270039.1	RP11-571M6.17	3.65	0.000288	0.0193	0.18	0.17	Multiple sclerosis;	chr12:57619392	chr12:57803838~57804415:+
THCA	cis	rs8054556	0.787	rs12325539	ENSG00000183604.13	SMG1P5	-3.65	0.000288	0.0193	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30267553~30335374:-
THCA	cis	rs2658782	0.526	rs7131487	ENSG00000234106.3	RP11-288E14.2	3.65	0.000288	0.0193	0.18	0.17	Pulmonary function decline;	chr11:93452786	chr11:93535468~93535816:+
THCA	cis	rs910316	1	rs12589815	ENSG00000259138.1	RP11-950C14.7	3.65	0.000288	0.0193	0.15	0.17	Height;	chr14:75077398	chr14:75127153~75136930:+
THCA	cis	rs10496034	0.541	rs72913519	ENSG00000237887.1	AC092839.1	-3.65	0.000288	0.0193	-0.32	-0.17	Refractive astigmatism;	chr2:54721469	chr2:54529343~54529801:+
THCA	cis	rs11124272	0.504	rs4952220	ENSG00000276334.1	AL133243.1	3.65	0.000288	0.0193	0.17	0.17	Interleukin-18 levels;	chr2:31540486	chr2:32521927~32523547:+
THCA	cis	rs4713118	0.539	rs510987	ENSG00000273712.1	RP5-874C20.7	3.65	0.000288	0.0193	0.21	0.17	Parkinson's disease;	chr6:27879739	chr6:28315613~28315883:-
THCA	cis	rs7824557	0.547	rs6601570	ENSG00000261451.1	RP11-981G7.1	-3.65	0.000288	0.0193	-0.21	-0.17	Retinal vascular caliber;	chr8:11221858	chr8:10433672~10438312:+
THCA	cis	rs9435732	0.778	rs9435665	ENSG00000186301.8	MST1P2	-3.65	0.000288	0.0193	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16998042	chr1:16645622~16650289:+
THCA	cis	rs2033711	0.87	rs1465789	ENSG00000269054.1	CTD-2619J13.3	-3.65	0.000289	0.0193	-0.13	-0.17	Uric acid clearance;	chr19:58434689	chr19:58362585~58366591:+
THCA	cis	rs910316	1	rs12589376	ENSG00000259138.1	RP11-950C14.7	3.65	0.000289	0.0193	0.15	0.17	Height;	chr14:75094449	chr14:75127153~75136930:+
THCA	cis	rs2115630	0.967	rs10438428	ENSG00000259295.5	CSPG4P12	-3.65	0.000289	0.0193	-0.22	-0.17	P wave terminal force;	chr15:84787514	chr15:85191438~85213905:+
THCA	cis	rs2179367	0.632	rs55826712	ENSG00000216906.2	RP11-350J20.9	3.65	0.000289	0.0193	0.21	0.17	Dupuytren's disease;	chr6:149344716	chr6:149904243~149906418:+
THCA	cis	rs2579500	0.695	rs61008119	ENSG00000235584.2	AC008268.1	-3.65	0.000289	0.0193	-0.19	-0.17	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96466777	chr2:95666084~95668715:+
THCA	cis	rs7572733	0.935	rs1878732	ENSG00000231621.1	AC013264.2	-3.65	0.000289	0.0193	-0.16	-0.17	Dermatomyositis;	chr2:197944821	chr2:197197991~197199273:+
THCA	cis	rs34421088	0.548	rs2618443	ENSG00000206014.6	OR7E161P	3.65	0.000289	0.0193	0.19	0.17	Neuroticism;	chr8:11527047	chr8:11928597~11929563:-
THCA	cis	rs2797160	0.967	rs2226158	ENSG00000226409.1	RP11-735G4.1	-3.65	0.000289	0.0193	-0.2	-0.17	Endometrial cancer;	chr6:125674321	chr6:125370211~125374324:-
THCA	cis	rs12101261	0.744	rs2284720	ENSG00000258915.1	BHLHB9P1	-3.65	0.000289	0.0193	-0.21	-0.17	Graves' disease;	chr14:80976823	chr14:80981988~80983638:+
THCA	cis	rs9844666	0.532	rs7625040	ENSG00000273486.1	RP11-731C17.2	3.65	0.000289	0.0193	0.15	0.17	Height;	chr3:135943623	chr3:136837338~136839021:-
THCA	cis	rs10863936	0.667	rs4951561	ENSG00000198468.6	FLVCR1-AS1	-3.65	0.000289	0.0193	-0.2	-0.17	Height;	chr1:212008643	chr1:212852108~212858088:-
THCA	cis	rs7819412	0.594	rs17724226	ENSG00000255310.2	AF131215.2	-3.65	0.000289	0.0193	-0.15	-0.17	Triglycerides;	chr8:11111416	chr8:11107788~11109726:-
THCA	cis	rs786425	0.502	rs10846553	ENSG00000270095.1	RP11-214K3.18	3.65	0.000289	0.0193	0.2	0.17	Pubertal anthropometrics;	chr12:123759725	chr12:123971457~123971714:-
THCA	cis	rs34132583	0.614	rs74847445	ENSG00000279845.1	RP11-6L6.4	3.65	0.000289	0.0193	0.38	0.17	Hippocampal sclerosis;	chr4:145446809	chr4:146180851~146181316:+
THCA	cis	rs2821260	0.694	rs12132602	ENSG00000227207.2	RPL31P12	-3.65	0.000289	0.0193	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72131368	chr1:72301472~72301829:+
THCA	cis	rs4262150	0.739	rs4958328	ENSG00000253921.1	CTB-113P19.3	3.65	0.000289	0.0193	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152747445	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.774	rs72799164	ENSG00000253921.1	CTB-113P19.3	3.65	0.000289	0.0193	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152752588	chr5:151753992~151767247:+
THCA	cis	rs3924048	0.574	rs11121924	ENSG00000272482.1	RP11-474O21.5	-3.65	0.000289	0.0193	-0.15	-0.17	Optic cup area;	chr1:12551599	chr1:12618900~12619244:-
THCA	cis	rs9527	0.571	rs12765337	ENSG00000213277.3	MARCKSL1P1	3.65	0.000289	0.0193	0.18	0.17	Arsenic metabolism;	chr10:102875587	chr10:103175554~103176094:+
THCA	cis	rs8030379	0.967	rs62027761	ENSG00000176700.18	SCAND2P	-3.65	0.000289	0.0193	-0.1	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903845	chr15:84631451~84647478:+
THCA	cis	rs7246967	0.673	rs7249003	ENSG00000198153.8	ZNF849P	-3.65	0.000289	0.0193	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22705132	chr19:22685167~22686732:+
THCA	cis	rs3743162	1	rs3743162	ENSG00000225151.9	GOLGA2P7	-3.65	0.000289	0.0193	-0.25	-0.17	Alzheimer's disease (age of onset);	chr15:84887738	chr15:84199311~84230136:-
THCA	cis	rs10129255	0.642	rs11624918	ENSG00000224373.3	IGHV4-59	3.65	0.000289	0.0193	0.11	0.17	Kawasaki disease;	chr14:106664672	chr14:106627249~106627825:-
THCA	cis	rs6751744	0.513	rs7563368	ENSG00000230783.1	AC009961.2	3.65	0.000289	0.0193	0.2	0.17	Dysphagia;	chr2:159600564	chr2:159689217~159690291:-
THCA	cis	rs1873147	1	rs7179658	ENSG00000259672.1	RP11-69G7.1	3.65	0.000289	0.0193	0.18	0.17	Orofacial clefts;	chr15:63020496	chr15:63098870~63110403:+
THCA	cis	rs12101261	0.813	rs55960644	ENSG00000259167.2	NMNAT1P1	3.65	0.000289	0.0193	0.2	0.17	Graves' disease;	chr14:81003680	chr14:81032529~81033404:+
THCA	cis	rs12101261	0.813	rs55957493	ENSG00000259167.2	NMNAT1P1	3.65	0.000289	0.0193	0.2	0.17	Graves' disease;	chr14:81003710	chr14:81032529~81033404:+
THCA	cis	rs5753037	0.838	rs1076135	ENSG00000279699.1	RP1-102K2.9	3.65	0.000289	0.0194	0.16	0.17	Type 1 diabetes;	chr22:29842328	chr22:30275215~30276951:-
THCA	cis	rs7760535	0.794	rs12529158	ENSG00000272356.1	RP5-1112D6.8	3.65	0.000289	0.0194	0.13	0.17	Metabolic traits;	chr6:111501244	chr6:111309203~111313517:+
THCA	cis	rs9923856	0.532	rs17802927	ENSG00000263033.2	RP11-396B14.2	-3.65	0.000289	0.0194	-0.17	-0.17	Atopic dermatitis;Adult asthma;	chr16:10943881	chr16:11196177~11224969:+
THCA	cis	rs17807624	0.702	rs7815172	ENSG00000255495.1	AC145124.2	3.65	0.000289	0.0194	0.18	0.17	Systemic lupus erythematosus;	chr8:11596162	chr8:12194467~12196280:+
THCA	cis	rs301901	0.796	rs11742177	ENSG00000250155.1	CTD-2353F22.1	3.65	0.000289	0.0194	0.16	0.17	Height;	chr5:37504063	chr5:36666214~36725195:-
THCA	cis	rs8099594	0.565	rs1942998	ENSG00000266696.1	RP11-30L3.2	3.65	0.000289	0.0194	0.2	0.17	Height;	chr18:49186420	chr18:49205912~49208781:+
THCA	cis	rs6828577	0.774	rs7697022	ENSG00000248280.1	RP11-33B1.2	3.65	0.000289	0.0194	0.15	0.17	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118734522	chr4:119440561~119450157:-
THCA	cis	rs78487399	0.908	rs4339008	ENSG00000234936.1	AC010883.5	3.65	0.000289	0.0194	0.2	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43607213	chr2:43229573~43233394:+
THCA	cis	rs755249	0.583	rs61779328	ENSG00000182109.6	RP11-69E11.4	3.65	0.000289	0.0194	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39522280~39546187:-
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000184274.3	LINC00315	-3.65	0.000289	0.0194	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45300245~45305257:-
THCA	cis	rs17153755	0.931	rs12677897	ENSG00000255046.1	RP11-297N6.4	-3.65	0.000289	0.0194	-0.18	-0.17	Testicular germ cell tumor;	chr8:11755454	chr8:11797928~11802568:-
THCA	cis	rs10491083	0.661	rs4796538	ENSG00000261996.1	CTC-281F24.1	3.65	0.000289	0.0194	0.32	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6666073	chr17:6653464~6655009:-
THCA	cis	rs9287719	0.967	rs6712304	ENSG00000243819.4	RN7SL832P	3.65	0.000289	0.0194	0.13	0.17	Prostate cancer;	chr2:10614249	chr2:10690344~10692099:+
THCA	cis	rs9450351	0.744	rs75096179	ENSG00000203875.9	SNHG5	-3.65	0.000289	0.0194	-0.37	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85580606	chr6:85660950~85678736:-
THCA	cis	rs1862618	0.853	rs252915	ENSG00000234553.1	AC022431.3	3.65	0.000289	0.0194	0.19	0.17	Initial pursuit acceleration;	chr5:56825927	chr5:56536583~56537826:-
THCA	cis	rs6878727	0.85	rs12658088	ENSG00000253807.4	LINC01170	-3.65	0.000289	0.0194	-0.16	-0.17	Breast cancer;	chr5:124383755	chr5:124059794~124405079:-
THCA	cis	rs2252790	0.56	rs2187813	ENSG00000237021.2	RP3-486I3.7	-3.65	0.000289	0.0194	-0.18	-0.17	Fast beta electroencephalogram;	chr6:116361344	chr6:116254207~116256743:+
THCA	cis	rs7707921	0.522	rs4703537	ENSG00000251374.1	RPS23P5	-3.65	0.000289	0.0194	-0.19	-0.17	Breast cancer;	chr5:82184552	chr5:82265157~82265259:-
THCA	cis	rs8031584	0.736	rs11635775	ENSG00000270015.1	RP11-540B6.6	-3.65	0.000289	0.0194	-0.13	-0.17	Huntington's disease progression;	chr15:30868437	chr15:30926514~30928407:+
THCA	cis	rs34975555	0.803	rs3850748	ENSG00000253671.1	RP11-806O11.1	-3.65	0.000289	0.0194	-0.24	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17983118	chr8:17808941~17820868:+
THCA	cis	rs2115630	1	rs55646601	ENSG00000275120.1	RP11-182J1.17	-3.65	0.000289	0.0194	-0.17	-0.17	P wave terminal force;	chr15:84780337	chr15:84599434~84606463:-
THCA	cis	rs867371	1	rs8041868	ENSG00000278603.1	RP13-608F4.5	3.65	0.000289	0.0194	0.21	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472203~82472426:+
THCA	cis	rs720064	0.586	rs2241643	ENSG00000264745.1	TTC39C-AS1	3.65	0.000289	0.0194	0.18	0.17	Strep throat;	chr18:23949758	chr18:23994213~24015339:-
THCA	cis	rs1005277	0.522	rs9418276	ENSG00000120555.12	SEPT7P9	3.65	0.000289	0.0194	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.522	rs7072977	ENSG00000120555.12	SEPT7P9	3.65	0.000289	0.0194	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38383069~38402916:-
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000184274.3	LINC00315	-3.65	0.00029	0.0194	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45300245~45305257:-
THCA	cis	rs7819412	0.74	rs7844536	ENSG00000280294.1	RP11-177H2.1	3.65	0.00029	0.0194	0.14	0.17	Triglycerides;	chr8:11176519	chr8:10856085~10859436:-
THCA	cis	rs34421088	0.576	rs2736369	ENSG00000261451.1	RP11-981G7.1	-3.65	0.00029	0.0194	-0.23	-0.17	Neuroticism;	chr8:11243889	chr8:10433672~10438312:+
THCA	cis	rs9450351	0.744	rs9342047	ENSG00000203875.9	SNHG5	-3.65	0.00029	0.0194	-0.32	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85869115	chr6:85660950~85678736:-
THCA	cis	rs7829975	0.846	rs1879957	ENSG00000253981.4	ALG1L13P	-3.65	0.00029	0.0194	-0.16	-0.17	Mood instability;	chr8:8687298	chr8:8236003~8244667:-
THCA	cis	rs7577696	0.744	rs2268797	ENSG00000276334.1	AL133243.1	3.65	0.00029	0.0194	0.17	0.17	Inflammatory biomarkers;	chr2:31558682	chr2:32521927~32523547:+
THCA	cis	rs12478296	0.581	rs4973645	ENSG00000261186.2	RP11-341N2.1	-3.65	0.00029	0.0194	-0.28	-0.17	Obesity-related traits;	chr2:242051426	chr2:242087351~242088457:-
THCA	cis	rs7919656	0.626	rs2943245	ENSG00000228403.1	RP11-563N6.6	3.65	0.00029	0.0194	0.18	0.17	Clinically amyopathic dermatomyositis;	chr10:48894711	chr10:48878022~48878649:+
THCA	cis	rs75059851	1	rs73036062	ENSG00000280237.1	MIR4697HG	3.65	0.00029	0.0194	0.19	0.17	Schizophrenia;	chr11:133958292	chr11:133896438~133901601:-
THCA	cis	rs513088	0.515	rs579100	ENSG00000225171.2	DUTP6	-3.65	0.00029	0.0194	-0.21	-0.17	Schizophrenia;	chr1:166705052	chr1:166868748~166869209:+
THCA	cis	rs3808502	0.605	rs11784572	ENSG00000154316.13	TDH	3.65	0.00029	0.0194	0.13	0.17	Neuroticism;	chr8:11316975	chr8:11339637~11368452:+
THCA	cis	rs3749237	0.595	rs35701831	ENSG00000224424.7	PRKAR2A-AS1	3.65	0.00029	0.0194	0.14	0.17	Resting heart rate;	chr3:49477567	chr3:48847572~48851981:+
THCA	cis	rs2664588	0.561	rs4638853	ENSG00000276923.1	RP11-321P16.1	-3.65	0.00029	0.0194	-0.22	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47962927	chr20:48073869~48074188:+
THCA	cis	rs2664588	0.561	rs2869318	ENSG00000276923.1	RP11-321P16.1	-3.65	0.00029	0.0194	-0.22	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47962987	chr20:48073869~48074188:+
THCA	cis	rs913655	0.893	rs1159000	ENSG00000240291.1	RP11-499P20.2	-3.65	0.00029	0.0194	-0.12	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18812099	chr10:18513115~18545651:-
THCA	cis	rs7267979	0.903	rs6115101	ENSG00000276952.1	RP5-965G21.6	3.65	0.00029	0.0194	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.868	rs6107019	ENSG00000276952.1	RP5-965G21.6	3.65	0.00029	0.0194	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25284915~25285588:-
THCA	cis	rs9549260	0.561	rs2297014	ENSG00000239827.7	SUGT1P3	-3.65	0.00029	0.0194	-0.22	-0.17	Red blood cell count;	chr13:40798824	chr13:40908159~40921774:-
THCA	cis	rs847649	0.699	rs10241865	ENSG00000234715.1	CTB-107G13.1	-3.65	0.00029	0.0194	-0.19	-0.17	Morning vs. evening chronotype;	chr7:102887070	chr7:103445207~103514007:+
THCA	cis	rs6517329	0.513	rs62229302	ENSG00000230212.5	AP000688.14	-3.65	0.00029	0.0194	-0.21	-0.17	Schizophrenia;	chr21:36156202	chr21:36069642~36126640:-
THCA	cis	rs6517329	0.513	rs61232790	ENSG00000230212.5	AP000688.14	-3.65	0.00029	0.0194	-0.21	-0.17	Schizophrenia;	chr21:36156559	chr21:36069642~36126640:-
THCA	cis	rs858239	0.863	rs274058	ENSG00000230042.1	AK3P3	-3.65	0.00029	0.0194	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23129178~23129841:+
THCA	cis	rs875971	0.545	rs6961853	ENSG00000232559.3	GS1-124K5.12	3.65	0.00029	0.0194	0.18	0.17	Aortic root size;	chr7:66537035	chr7:66554588~66576923:-
THCA	cis	rs7940646	0.53	rs12363520	ENSG00000254554.1	RP11-351I24.1	-3.65	0.00029	0.0194	-0.23	-0.17	Platelet aggregation;	chr11:10670625	chr11:10302657~10303704:-
THCA	cis	rs17122278	1	rs3741325	ENSG00000255239.1	AP002954.6	-3.65	0.00029	0.0194	-0.29	-0.17	Total cholesterol levels;	chr11:118535274	chr11:118688039~118690600:-
THCA	cis	rs10129255	0.913	rs10140943	ENSG00000280411.1	IGHV1-69-2	-3.65	0.00029	0.0194	-0.11	-0.17	Kawasaki disease;	chr14:106767441	chr14:106762092~106762588:-
THCA	cis	rs7267979	0.528	rs2387976	ENSG00000276952.1	RP5-965G21.6	-3.65	0.00029	0.0194	-0.18	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:25284915~25285588:-
THCA	cis	rs7176527	0.848	rs72630462	ENSG00000176700.18	SCAND2P	3.65	0.00029	0.0194	0.16	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:84631451~84647478:+
THCA	cis	rs78153629	1	rs17671250	ENSG00000259330.1	INAFM2	3.65	0.00029	0.0194	0.18	0.17	Heschl's gyrus morphology;	chr15:40380923	chr15:40325216~40326715:+
THCA	cis	rs56046484	0.871	rs34493704	ENSG00000259630.2	CTD-2262B20.1	-3.65	0.00029	0.0194	-0.25	-0.17	Testicular germ cell tumor;	chr15:85015539	chr15:85415228~85415633:+
THCA	cis	rs8077577	0.895	rs62072500	ENSG00000273018.4	CTD-2303H24.2	-3.65	0.00029	0.0194	-0.28	-0.17	Obesity-related traits;	chr17:18223604	chr17:18511221~18551705:-
THCA	cis	rs4906332	1	rs3783398	ENSG00000259775.1	RP11-45P15.4	3.65	0.00029	0.0194	0.14	0.17	Coronary artery disease;	chr14:103483041	chr14:103331674~103332367:-
THCA	cis	rs440932	0.887	rs398801	ENSG00000254153.1	CTA-398F10.2	3.65	0.00029	0.0194	0.18	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8456909~8461337:-
THCA	cis	rs1580019	0.587	rs6951955	ENSG00000273014.1	RP11-225B17.2	3.65	0.00029	0.0194	0.17	0.17	Cognitive ability;	chr7:32509149	chr7:32758882~32759353:+
THCA	cis	rs1580019	0.587	rs6972365	ENSG00000273014.1	RP11-225B17.2	3.65	0.00029	0.0194	0.17	0.17	Cognitive ability;	chr7:32509319	chr7:32758882~32759353:+
THCA	cis	rs944289	0.646	rs1742868	ENSG00000258844.1	RP11-259K15.2	3.65	0.00029	0.0194	0.15	0.17	Thyroid cancer;	chr14:36067743	chr14:36214607~36235608:+
THCA	cis	rs2359239	0.519	rs8007145	ENSG00000279594.1	RP11-950C14.10	3.65	0.00029	0.0194	0.17	0.17	Neuroticism (multi-trait analysis);	chr14:74719045	chr14:75011269~75012851:-
THCA	cis	rs4578769	0.55	rs9951410	ENSG00000273232.1	RP11-370A5.2	3.65	0.00029	0.0194	0.23	0.17	Eosinophil percentage of white cells;	chr18:22964944	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.505	rs9951982	ENSG00000273232.1	RP11-370A5.2	3.65	0.00029	0.0194	0.23	0.17	Eosinophil percentage of white cells;	chr18:22965607	chr18:22882825~22883357:-
THCA	cis	rs1924981	0.509	rs628930	ENSG00000261485.1	PAN3-AS1	-3.65	0.00029	0.0194	-0.12	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr13:28484118	chr13:28136843~28138193:-
THCA	cis	rs1577917	1	rs2166663	ENSG00000220563.1	PKMP3	-3.65	0.00029	0.0194	-0.13	-0.17	Response to antipsychotic treatment;	chr6:85884178	chr6:85659892~85660606:-
THCA	cis	rs60695258	1	rs17605615	ENSG00000251411.1	RP11-397E7.4	-3.65	0.00029	0.0194	-0.15	-0.17	Hematocrit;	chr4:87075593	chr4:86913266~86914817:-
THCA	cis	rs12478296	1	rs55767645	ENSG00000220804.7	AC093642.5	3.65	0.00029	0.0194	0.2	0.17	Obesity-related traits;	chr2:242057199	chr2:242088633~242160153:+
THCA	cis	rs7259376	0.967	rs7252056	ENSG00000269345.1	VN1R85P	3.65	0.00029	0.0194	0.18	0.17	Menopause (age at onset);	chr19:22311250	chr19:22174766~22175191:-
THCA	cis	rs7727544	0.582	rs10478998	ENSG00000263597.1	MIR3936	3.65	0.00029	0.0194	0.15	0.17	Blood metabolite levels;	chr5:132180838	chr5:132365490~132365599:-
THCA	cis	rs3015497	0.789	rs7147956	ENSG00000270062.1	RP11-248J18.3	3.65	0.00029	0.0194	0.19	0.17	Mean platelet volume;	chr14:50675887	chr14:50723777~50724272:-
THCA	cis	rs409045	1	rs379727	ENSG00000271874.1	CTD-2024P10.2	3.65	0.00029	0.0194	0.22	0.17	Left ventricular mass;	chr5:34639005	chr5:34651457~34651888:-
THCA	cis	rs58722170	0.517	rs17559337	ENSG00000252448.1	SNORA63	-3.65	0.00029	0.0194	-0.24	-0.17	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37573433	chr1:37884237~37884317:+
THCA	cis	rs41313321	0.512	rs2240958	ENSG00000272696.1	RP11-339B21.13	3.65	0.00029	0.0194	0.12	0.17	Coenzyme Q10 levels;	chr9:128282905	chr9:128316337~128316909:+
THCA	cis	rs9487094	0.666	rs6920372	ENSG00000223537.2	RP5-919F19.5	-3.65	0.00029	0.0194	-0.17	-0.17	Height;	chr6:109402736	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.644	rs9320286	ENSG00000223537.2	RP5-919F19.5	-3.65	0.00029	0.0194	-0.17	-0.17	Height;	chr6:109403734	chr6:109487906~109506800:+
THCA	cis	rs7520050	0.966	rs946529	ENSG00000280836.1	AL355480.1	3.65	0.00029	0.0194	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45581219~45581321:-
THCA	cis	rs6921919	0.806	rs213230	ENSG00000280107.1	AL022393.9	-3.65	0.00029	0.0194	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28170845~28172521:+
THCA	cis	rs56046484	0.871	rs62021203	ENSG00000259630.2	CTD-2262B20.1	-3.65	0.00029	0.0194	-0.25	-0.17	Testicular germ cell tumor;	chr15:85020846	chr15:85415228~85415633:+
THCA	cis	rs3736986	0.808	rs10972775	ENSG00000215283.3	HMGB3P24	-3.65	0.00029	0.0194	-0.3	-0.17	Bipolar disorder (inflammation and infection response interaction);	chr9:36174859	chr9:36303499~36304924:-
THCA	cis	rs2836974	0.897	rs2836973	ENSG00000255568.3	BRWD1-AS2	3.65	0.00029	0.0194	0.14	0.17	Cognitive function;	chr21:39283002	chr21:39313935~39314962:+
THCA	cis	rs12034383	0.783	rs12036785	ENSG00000274245.1	RP11-357P18.2	-3.65	0.00029	0.0194	-0.15	-0.17	Erythrocyte sedimentation rate;	chr1:207619564	chr1:207372559~207373252:+
THCA	cis	rs11671005	0.735	rs11667591	ENSG00000269600.1	AC016629.3	-3.65	0.00029	0.0194	-0.24	-0.17	Mean platelet volume;	chr19:58426270	chr19:58593896~58599355:-
THCA	cis	rs7851693	0.928	rs7030440	ENSG00000232172.1	RP11-57C19.2	3.65	0.00029	0.0194	0.18	0.17	Bone mineral density;	chr9:130565233	chr9:130651799~130652383:+
THCA	cis	rs2115630	1	rs7183401	ENSG00000259295.5	CSPG4P12	-3.65	0.00029	0.0194	-0.22	-0.17	P wave terminal force;	chr15:84828713	chr15:85191438~85213905:+
THCA	cis	rs273909	0.514	rs77450473	ENSG00000263597.1	MIR3936	-3.65	0.00029	0.0194	-0.28	-0.17	Coronary artery disease;	chr5:132449844	chr5:132365490~132365599:-
THCA	cis	rs7809950	0.817	rs10224503	ENSG00000272072.1	CTA-363E19.2	3.65	0.00029	0.0194	0.17	0.17	Coronary artery disease;	chr7:107435124	chr7:107192559~107193300:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000232546.1	RP11-458F8.1	-3.65	0.00029	0.0194	-0.14	-0.17	Calcium levels;	chr7:65975383	chr7:66848496~66858136:+
THCA	cis	rs3176789	0.647	rs7295897	ENSG00000256673.1	RP11-599J14.2	3.65	0.00029	0.0194	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9768280	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.647	rs7309767	ENSG00000256673.1	RP11-599J14.2	3.65	0.00029	0.0194	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9768303	chr12:9398355~9414851:-
THCA	cis	rs2645424	0.639	rs35581201	ENSG00000255046.1	RP11-297N6.4	3.65	0.00029	0.0194	0.17	0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11849325	chr8:11797928~11802568:-
THCA	cis	rs913655	0.927	rs2480331	ENSG00000240291.1	RP11-499P20.2	-3.65	0.00029	0.0194	-0.12	-0.17	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18814543	chr10:18513115~18545651:-
THCA	cis	rs10911363	0.55	rs10911353	ENSG00000232860.6	SMG7-AS1	-3.65	0.00029	0.0194	-0.13	-0.17	Systemic lupus erythematosus;	chr1:183520068	chr1:183460874~183472265:-
THCA	cis	rs9650657	0.803	rs13276026	ENSG00000255310.2	AF131215.2	-3.65	0.00029	0.0194	-0.14	-0.17	Neuroticism;	chr8:10752445	chr8:11107788~11109726:-
THCA	cis	rs6546550	0.901	rs897120	ENSG00000179818.12	PCBP1-AS1	3.65	0.00029	0.0194	0.13	0.17	Prevalent atrial fibrillation;	chr2:69933850	chr2:69962263~70103220:-
THCA	cis	rs13217239	0.646	rs35691005	ENSG00000124549.13	BTN2A3P	3.65	0.00029	0.0194	0.16	0.17	Schizophrenia;	chr6:27004291	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs10946891	ENSG00000124549.13	BTN2A3P	3.65	0.00029	0.0194	0.16	0.17	Schizophrenia;	chr6:27005436	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs12201393	ENSG00000124549.13	BTN2A3P	3.65	0.00029	0.0194	0.16	0.17	Schizophrenia;	chr6:27007911	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs12209886	ENSG00000124549.13	BTN2A3P	3.65	0.00029	0.0194	0.16	0.17	Schizophrenia;	chr6:27016978	chr6:26421391~26432383:+
THCA	cis	rs6940638	0.531	rs12211984	ENSG00000124549.13	BTN2A3P	3.65	0.00029	0.0194	0.16	0.17	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs10456351	ENSG00000124549.13	BTN2A3P	3.65	0.00029	0.0194	0.16	0.17	Schizophrenia;	chr6:27019013	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs10456352	ENSG00000124549.13	BTN2A3P	3.65	0.00029	0.0194	0.16	0.17	Schizophrenia;	chr6:27022579	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs4583981	ENSG00000124549.13	BTN2A3P	3.65	0.00029	0.0194	0.16	0.17	Schizophrenia;	chr6:27024244	chr6:26421391~26432383:+
THCA	cis	rs2933343	0.729	rs789228	ENSG00000231305.3	RP11-723O4.2	3.65	0.00029	0.0194	0.18	0.17	IgG glycosylation;	chr3:128882207	chr3:128861313~128871540:-
THCA	cis	rs7660883	0.897	rs342454	ENSG00000251411.1	RP11-397E7.4	-3.65	0.000291	0.0194	-0.15	-0.17	HDL cholesterol levels;	chr4:87100348	chr4:86913266~86914817:-
THCA	cis	rs613391	0.742	rs499501	ENSG00000234840.1	LINC01239	-3.65	0.000291	0.0194	-0.19	-0.17	Quantitative traits;	chr9:22688555	chr9:22646200~22824213:+
THCA	cis	rs1200821	0.559	rs9418267	ENSG00000226578.1	RP11-258F22.1	3.65	0.000291	0.0194	0.2	0.17	Hemostatic factors and hematological phenotypes;	chr10:37531023	chr10:37775371~37784131:-
THCA	cis	rs62158800	0.598	rs12329017	ENSG00000225588.2	AC096669.1	3.65	0.000291	0.0194	0.17	0.17	Facial morphology (factor 22);	chr2:107668402	chr2:107362282~107407329:+
THCA	cis	rs62158800	0.526	rs13408969	ENSG00000225588.2	AC096669.1	3.65	0.000291	0.0194	0.17	0.17	Facial morphology (factor 22);	chr2:107669138	chr2:107362282~107407329:+
THCA	cis	rs7903847	0.642	rs11189179	ENSG00000225850.3	RP11-452K12.4	3.65	0.000291	0.0194	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97383563	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs11189180	ENSG00000225850.3	RP11-452K12.4	3.65	0.000291	0.0194	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97383772	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs11189182	ENSG00000225850.3	RP11-452K12.4	3.65	0.000291	0.0194	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97384429	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs11189183	ENSG00000225850.3	RP11-452K12.4	3.65	0.000291	0.0194	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97384564	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.544	rs61861865	ENSG00000225850.3	RP11-452K12.4	3.65	0.000291	0.0194	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97385110	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.596	rs869967	ENSG00000225850.3	RP11-452K12.4	3.65	0.000291	0.0194	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97388218	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs2275090	ENSG00000225850.3	RP11-452K12.4	3.65	0.000291	0.0194	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97388394	chr10:97334564~97343203:+
THCA	cis	rs8022179	0.58	rs58153827	ENSG00000269958.1	RP11-73M18.8	-3.65	0.000291	0.0194	-0.17	-0.17	Monocyte count;	chr14:103378293	chr14:103696353~103697163:+
THCA	cis	rs35740288	0.822	rs11638720	ENSG00000259407.1	RP11-158M2.3	-3.65	0.000291	0.0194	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686042	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.822	rs1961601	ENSG00000259407.1	RP11-158M2.3	-3.65	0.000291	0.0194	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686375	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.822	rs2016517	ENSG00000259407.1	RP11-158M2.3	-3.65	0.000291	0.0194	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686387	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.787	rs727379	ENSG00000259407.1	RP11-158M2.3	-3.65	0.000291	0.0194	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686659	chr15:85744109~85750281:-
THCA	cis	rs4656958	0.964	rs10908809	ENSG00000233691.2	RP11-312J18.7	3.65	0.000291	0.0194	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160888791	chr1:160935537~160936126:+
THCA	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	3.65	0.000291	0.0194	0.25	0.17	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
THCA	cis	rs4869313	0.694	rs10071975	ENSG00000247121.5	CTD-2260A17.2	-3.65	0.000291	0.0194	-0.12	-0.17	Pediatric autoimmune diseases;	chr5:96965438	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.694	rs1559267	ENSG00000247121.5	CTD-2260A17.2	-3.65	0.000291	0.0194	-0.12	-0.17	Pediatric autoimmune diseases;	chr5:96967994	chr5:96814028~96935809:-
THCA	cis	rs8115854	0.961	rs28622208	ENSG00000269846.1	RP4-621N11.2	-3.65	0.000291	0.0194	-0.21	-0.17	Hippocampal atrophy;	chr20:37118416	chr20:37095785~37097178:+
THCA	cis	rs5753037	0.869	rs5752992	ENSG00000279699.1	RP1-102K2.9	3.65	0.000291	0.0194	0.16	0.17	Type 1 diabetes;	chr22:29988055	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.869	rs5763671	ENSG00000279699.1	RP1-102K2.9	3.65	0.000291	0.0194	0.16	0.17	Type 1 diabetes;	chr22:29988583	chr22:30275215~30276951:-
THCA	cis	rs5753037	0.835	rs2007458	ENSG00000279699.1	RP1-102K2.9	3.65	0.000291	0.0194	0.16	0.17	Type 1 diabetes;	chr22:29992717	chr22:30275215~30276951:-
THCA	cis	rs9376098	0.651	rs9483798	ENSG00000232876.1	CTA-212D2.2	-3.65	0.000291	0.0195	-0.23	-0.17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135169760	chr6:135055033~135060550:+
THCA	cis	rs6598955	0.64	rs1577507	ENSG00000236782.4	RP11-96L14.7	-3.65	0.000291	0.0195	-0.2	-0.17	Obesity-related traits;	chr1:26220688	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.612	rs12738188	ENSG00000236782.4	RP11-96L14.7	-3.65	0.000291	0.0195	-0.2	-0.17	Obesity-related traits;	chr1:26221538	chr1:26169947~26171821:-
THCA	cis	rs860295	0.702	rs5005770	ENSG00000236675.1	MTX1P1	3.65	0.000291	0.0195	0.17	0.17	Body mass index;	chr1:155375252	chr1:155230975~155234325:+
THCA	cis	rs61160187	0.556	rs4647052	ENSG00000272308.1	RP11-231G3.1	-3.65	0.000291	0.0195	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60866457~60866935:-
THCA	cis	rs11881751	0.501	rs11878982	ENSG00000267011.4	CTB-50L17.16	3.65	0.000291	0.0195	0.25	0.17	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr19:5041038	chr19:4457962~4471493:-
THCA	cis	rs240993	0.595	rs3777912	ENSG00000272356.1	RP5-1112D6.8	3.65	0.000291	0.0195	0.14	0.17	Inflammatory skin disease;Psoriasis;	chr6:111581473	chr6:111309203~111313517:+
THCA	cis	rs603446	0.935	rs180376	ENSG00000254851.1	RP11-109L13.1	-3.65	0.000291	0.0195	-0.22	-0.17	Triglycerides;	chr11:116719323	chr11:117135528~117138582:+
THCA	cis	rs7829975	0.684	rs474892	ENSG00000253981.4	ALG1L13P	-3.65	0.000291	0.0195	-0.15	-0.17	Mood instability;	chr8:8739221	chr8:8236003~8244667:-
THCA	cis	rs2403221	0.656	rs3763862	ENSG00000246273.5	SBF2-AS1	3.65	0.000291	0.0195	0.19	0.17	Smoking initiation;	chr11:9781405	chr11:9758292~9811319:+
THCA	cis	rs944289	0.774	rs1958625	ENSG00000212071.1	AL162511.1	3.65	0.000291	0.0195	0.2	0.17	Thyroid cancer;	chr14:36133470	chr14:36196480~36196568:-
THCA	cis	rs853679	0.517	rs9283884	ENSG00000219891.2	ZSCAN12P1	-3.65	0.000291	0.0195	-0.23	-0.17	Depression;	chr6:28167882	chr6:28091154~28093664:+
THCA	cis	rs9911578	1	rs302848	ENSG00000224738.1	AC099850.1	3.65	0.000291	0.0195	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58609093	chr17:59106598~59118267:+
THCA	cis	rs3935740	0.649	rs10162610	ENSG00000260619.1	RP11-775C24.3	3.65	0.000291	0.0195	0.29	0.17	Parkinson's disease;	chr15:81352691	chr15:80990804~80993258:-
THCA	cis	rs6938	0.618	rs11633472	ENSG00000260269.4	CTD-2323K18.1	-3.65	0.000291	0.0195	-0.24	-0.17	Breast cancer;	chr15:74891743	chr15:75527150~75601205:-
THCA	cis	rs11168618	0.875	rs7972785	ENSG00000240399.1	RP1-228P16.1	3.65	0.000291	0.0195	0.16	0.17	Adiponectin levels;	chr12:48483273	chr12:48054813~48055591:-
THCA	cis	rs721917	0.531	rs2819105	ENSG00000225484.5	NUTM2B-AS1	3.65	0.000291	0.0195	0.2	0.17	Chronic obstructive pulmonary disease;	chr10:79927101	chr10:79663088~79826594:-
THCA	cis	rs9959145	0.925	rs78425322	ENSG00000267199.1	RP11-861E21.2	3.65	0.000291	0.0195	0.22	0.17	Immune response to smallpox vaccine (IL-6);	chr18:12725105	chr18:12438890~12448205:+
THCA	cis	rs561341	1	rs521919	ENSG00000265798.5	RP11-271K11.5	3.65	0.000291	0.0195	0.25	0.17	Hip circumference adjusted for BMI;	chr17:31971020	chr17:31038575~31059121:-
THCA	cis	rs56046484	0.871	rs35000527	ENSG00000259630.2	CTD-2262B20.1	-3.65	0.000291	0.0195	-0.25	-0.17	Testicular germ cell tumor;	chr15:85010550	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.826	rs35816571	ENSG00000259630.2	CTD-2262B20.1	-3.65	0.000291	0.0195	-0.25	-0.17	Testicular germ cell tumor;	chr15:85010891	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.871	rs12900736	ENSG00000259630.2	CTD-2262B20.1	-3.65	0.000291	0.0195	-0.25	-0.17	Testicular germ cell tumor;	chr15:85014909	chr15:85415228~85415633:+
THCA	cis	rs56046484	0.871	rs12904958	ENSG00000259630.2	CTD-2262B20.1	-3.65	0.000291	0.0195	-0.25	-0.17	Testicular germ cell tumor;	chr15:85014956	chr15:85415228~85415633:+
THCA	cis	rs42648	0.693	rs3747800	ENSG00000225498.1	AC002064.5	3.65	0.000291	0.0195	0.17	0.17	Homocysteine levels;	chr7:90270174	chr7:90312496~90322592:+
THCA	cis	rs2281603	0.57	rs11627387	ENSG00000272909.1	CTD-2555O16.4	-3.65	0.000291	0.0195	-0.19	-0.17	Lymphocyte counts;	chr14:64457259	chr14:64440369~64442238:-
THCA	cis	rs4723738	1	rs2159499	ENSG00000227191.5	TRGC2	-3.65	0.000291	0.0195	-0.13	-0.17	Treatment response for severe sepsis;	chr7:38189300	chr7:38239580~38368091:-
THCA	cis	rs7520050	1	rs785511	ENSG00000280836.1	AL355480.1	3.65	0.000291	0.0195	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs809775	ENSG00000280836.1	AL355480.1	3.65	0.000291	0.0195	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45581219~45581321:-
THCA	cis	rs3760982	0.585	rs61013802	ENSG00000268601.1	AC115522.3	-3.65	0.000291	0.0195	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787990	chr19:43794309~43795658:-
THCA	cis	rs3760982	0.565	rs8104300	ENSG00000268601.1	AC115522.3	-3.65	0.000291	0.0195	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788992	chr19:43794309~43795658:-
THCA	cis	rs45544231	1	rs4238750	ENSG00000279344.1	RP11-44F14.7	3.65	0.000291	0.0195	0.15	0.17	Restless legs syndrome;	chr16:52605324	chr16:53478957~53481550:-
THCA	cis	rs45544231	0.966	rs1112135	ENSG00000279344.1	RP11-44F14.7	3.65	0.000291	0.0195	0.15	0.17	Restless legs syndrome;	chr16:52605843	chr16:53478957~53481550:-
THCA	cis	rs2013441	0.866	rs9898295	ENSG00000261033.1	RP11-209D14.2	3.65	0.000291	0.0195	0.24	0.17	Obesity-related traits;	chr17:20217281	chr17:20008051~20009234:-
THCA	cis	rs1961102	0.521	rs644299	ENSG00000253320.4	KB-1507C5.2	-3.65	0.000291	0.0195	-0.14	-0.17	QT interval;	chr8:102918016	chr8:102864300~102977876:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000229180.5	GS1-124K5.11	-3.65	0.000291	0.0195	-0.11	-0.17	Aortic root size;	chr7:66589419	chr7:66526088~66542624:-
THCA	cis	rs2333021	0.78	rs2243596	ENSG00000258376.2	RP4-647C14.2	3.65	0.000291	0.0195	0.19	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72961952	chr14:73242651~73245979:-
THCA	cis	rs6840360	0.571	rs718800	ENSG00000251611.1	RP11-610P16.1	3.65	0.000291	0.0195	0.13	0.17	Intelligence (multi-trait analysis);	chr4:151628155	chr4:151407551~151408835:-
THCA	cis	rs2288884	1	rs58817690	ENSG00000260160.1	CTC-471J1.2	-3.65	0.000291	0.0195	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52033439	chr19:52058490~52063703:-
THCA	cis	rs929354	0.772	rs2301916	ENSG00000224629.1	RP5-1142J19.2	-3.65	0.000291	0.0195	-0.16	-0.17	Body mass index;	chr7:157181433	chr7:157263022~157263229:-
THCA	cis	rs2821260	0.694	rs57316908	ENSG00000227207.2	RPL31P12	-3.65	0.000292	0.0195	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72144272	chr1:72301472~72301829:+
THCA	cis	rs8031584	0.706	rs798084	ENSG00000270015.1	RP11-540B6.6	-3.65	0.000292	0.0195	-0.13	-0.17	Huntington's disease progression;	chr15:30834732	chr15:30926514~30928407:+
THCA	cis	rs34779708	0.931	rs10437420	ENSG00000233200.1	RP11-324I22.2	-3.65	0.000292	0.0195	-0.2	-0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35219894~35230598:-
THCA	cis	rs17685	0.753	rs1637045	ENSG00000227038.2	AC005077.12	3.65	0.000292	0.0195	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76074577	chr7:76090431~76108779:-
THCA	cis	rs7045881	0.576	rs10967679	ENSG00000254396.1	RP11-56F10.3	3.65	0.000292	0.0195	0.2	0.17	Schizophrenia;	chr9:27045769	chr9:27102630~27104728:+
THCA	cis	rs8064029	0.892	rs62036114	ENSG00000267077.1	RP11-127I20.5	3.65	0.000292	0.0195	0.26	0.17	Cancer;	chr16:4830826	chr16:4795265~4796532:-
THCA	cis	rs1580019	0.563	rs4723169	ENSG00000273014.1	RP11-225B17.2	3.65	0.000292	0.0195	0.17	0.17	Cognitive ability;	chr7:32527965	chr7:32758882~32759353:+
THCA	cis	rs17366136	0.895	rs1122913	ENSG00000232949.1	AC002480.4	3.65	0.000292	0.0195	0.2	0.17	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr7:22563313	chr7:22589705~22591622:+
THCA	cis	rs36093844	0.527	rs72949443	ENSG00000279742.1	RP11-700A24.1	-3.65	0.000292	0.0195	-0.23	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85944402	chr11:85852557~85854943:-
THCA	cis	rs13108904	0.87	rs11721789	ENSG00000254094.1	AC078852.1	-3.65	0.000292	0.0195	-0.2	-0.17	Obesity-related traits;	chr4:1260626	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.87	rs12499546	ENSG00000254094.1	AC078852.1	-3.65	0.000292	0.0195	-0.2	-0.17	Obesity-related traits;	chr4:1261406	chr4:1356581~1358075:+
THCA	cis	rs875971	0.825	rs28480509	ENSG00000223473.2	GS1-124K5.3	-3.65	0.000292	0.0195	-0.11	-0.17	Aortic root size;	chr7:66634237	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs9791712	ENSG00000223473.2	GS1-124K5.3	-3.65	0.000292	0.0195	-0.11	-0.17	Aortic root size;	chr7:66640176	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs9791713	ENSG00000223473.2	GS1-124K5.3	-3.65	0.000292	0.0195	-0.11	-0.17	Aortic root size;	chr7:66640211	chr7:66491049~66493566:-
THCA	cis	rs4073416	0.542	rs10873191	ENSG00000276116.2	FUT8-AS1	3.65	0.000292	0.0195	0.18	0.17	N-glycan levels;	chr14:65643910	chr14:65411170~65412690:-
THCA	cis	rs17286411	0.515	rs12598902	ENSG00000260185.1	RP11-432I5.6	-3.65	0.000292	0.0195	-0.24	-0.17	Blood protein levels;	chr16:71811283	chr16:71655027~71664212:+
THCA	cis	rs944289	0.774	rs1958624	ENSG00000212071.1	AL162511.1	-3.65	0.000292	0.0195	-0.19	-0.17	Thyroid cancer;	chr14:36128692	chr14:36196480~36196568:-
THCA	cis	rs10875746	0.669	rs17122812	ENSG00000258273.1	RP11-370I10.4	3.65	0.000292	0.0195	0.24	0.17	Longevity (90 years and older);	chr12:48203270	chr12:48333755~48333901:-
THCA	cis	rs7707921	0.522	rs10070637	ENSG00000251374.1	RPS23P5	-3.65	0.000292	0.0195	-0.19	-0.17	Breast cancer;	chr5:82194789	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.522	rs12374541	ENSG00000251374.1	RPS23P5	-3.65	0.000292	0.0195	-0.19	-0.17	Breast cancer;	chr5:82195589	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.541	rs10066167	ENSG00000251374.1	RPS23P5	-3.65	0.000292	0.0195	-0.19	-0.17	Breast cancer;	chr5:82199626	chr5:82265157~82265259:-
THCA	cis	rs478304	0.654	rs11601509	ENSG00000214659.4	KRT8P26	3.65	0.000292	0.0195	0.16	0.17	Acne (severe);	chr11:65689393	chr11:65726939~65728214:+
THCA	cis	rs2274273	0.84	rs1045002	ENSG00000258469.1	CHMP4BP1	3.65	0.000292	0.0195	0.15	0.17	Protein biomarker;	chr14:55351799	chr14:55298644~55299231:+
THCA	cis	rs10186029	0.509	rs6435755	ENSG00000270659.1	RP11-105N14.1	3.65	0.000292	0.0195	0.14	0.17	Systemic sclerosis;	chr2:213076407	chr2:213152970~213153659:+
THCA	cis	rs6691738	0.959	rs7553711	ENSG00000227373.4	RP11-160H22.5	3.65	0.000292	0.0195	0.22	0.17	Asthma;	chr1:173162769	chr1:174115300~174160004:-
THCA	cis	rs9326248	0.581	rs10892072	ENSG00000280143.1	AP000892.6	3.65	0.000292	0.0195	0.2	0.17	Blood protein levels;	chr11:117089597	chr11:117204967~117210292:+
THCA	cis	rs1862618	0.671	rs2591968	ENSG00000271828.1	CTD-2310F14.1	3.65	0.000292	0.0195	0.23	0.17	Initial pursuit acceleration;	chr5:56937714	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.671	rs2591970	ENSG00000271828.1	CTD-2310F14.1	-3.65	0.000292	0.0195	-0.23	-0.17	Initial pursuit acceleration;	chr5:56936768	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.62	rs2591967	ENSG00000271828.1	CTD-2310F14.1	-3.65	0.000292	0.0195	-0.23	-0.17	Initial pursuit acceleration;	chr5:56937724	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.671	rs2591964	ENSG00000271828.1	CTD-2310F14.1	-3.65	0.000292	0.0195	-0.23	-0.17	Initial pursuit acceleration;	chr5:56941073	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.671	rs2591958	ENSG00000271828.1	CTD-2310F14.1	-3.65	0.000292	0.0195	-0.23	-0.17	Initial pursuit acceleration;	chr5:56943542	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.671	rs72644088	ENSG00000271828.1	CTD-2310F14.1	-3.65	0.000292	0.0195	-0.23	-0.17	Initial pursuit acceleration;	chr5:56945192	chr5:56927874~56929573:+
THCA	cis	rs2120243	0.504	rs114107407	ENSG00000243176.4	RP11-550I24.2	3.65	0.000292	0.0195	0.16	0.17	Hepatocellular carcinoma in hepatitis B infection;	chr3:157344846	chr3:157175223~157381265:+
THCA	cis	rs11971779	0.68	rs10273527	ENSG00000252332.1	RNU6-911P	3.65	0.000292	0.0195	0.18	0.17	Diisocyanate-induced asthma;	chr7:139351852	chr7:139448740~139448843:+
THCA	cis	rs3736858	0.825	rs9544047	ENSG00000261105.4	LMO7-AS1	-3.65	0.000292	0.0195	-0.23	-0.17	Interleukin-9 levels;	chr13:75812019	chr13:75604700~75635994:-
THCA	cis	rs206966	0.872	rs67706074	ENSG00000277283.1	RP1-267D11.6	3.65	0.000292	0.0195	0.17	0.17	Breast cancer;	chr12:120353681	chr12:120116907~120119000:+
THCA	cis	rs4578769	0.55	rs4800442	ENSG00000273232.1	RP11-370A5.2	3.65	0.000292	0.0195	0.23	0.17	Eosinophil percentage of white cells;	chr18:22958337	chr18:22882825~22883357:-
THCA	cis	rs9309473	0.904	rs79145598	ENSG00000273245.1	RP11-434P11.2	3.65	0.000292	0.0195	0.24	0.17	Metabolite levels;	chr2:73594255	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.904	rs62149783	ENSG00000273245.1	RP11-434P11.2	3.65	0.000292	0.0195	0.24	0.17	Metabolite levels;	chr2:73594257	chr2:73750256~73750786:-
THCA	cis	rs8062405	1	rs62036622	ENSG00000270424.1	RP11-1348G14.6	3.65	0.000292	0.0195	0.2	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28749959~28750595:-
THCA	cis	rs9437689	0.714	rs10782996	ENSG00000235501.4	RP4-639F20.1	-3.65	0.000292	0.0195	-0.19	-0.17	Phospholipid levels (plasma);	chr1:95034162	chr1:94927566~94963270:+
THCA	cis	rs877819	0.583	rs2940729	ENSG00000228403.1	RP11-563N6.6	-3.65	0.000292	0.0195	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48866159	chr10:48878022~48878649:+
THCA	cis	rs2494663	0.585	rs12049128	ENSG00000231416.1	RP11-422P24.9	3.65	0.000292	0.0195	0.21	0.17	Mean platelet volume;	chr1:154021734	chr1:153995632~153995960:+
THCA	cis	rs6856693	1	rs6856693	ENSG00000251139.2	RP11-701P16.2	-3.65	0.000292	0.0195	-0.2	-0.17	Menopause (age at onset);	chr4:184827652	chr4:184813619~184821300:+
THCA	cis	rs1440410	0.798	rs11727441	ENSG00000250326.1	RP11-284M14.1	-3.65	0.000292	0.0195	-0.15	-0.17	Ischemic stroke;	chr4:143242602	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs10010367	ENSG00000250326.1	RP11-284M14.1	-3.65	0.000292	0.0195	-0.15	-0.17	Ischemic stroke;	chr4:143243669	chr4:142933195~143184861:-
THCA	cis	rs1389724	0.648	rs1999511	ENSG00000259834.1	RP11-284N8.3	3.65	0.000292	0.0195	0.14	0.17	Schizophrenia;	chr1:110779797	chr1:110653560~110657040:-
THCA	cis	rs2562456	0.834	rs2650848	ENSG00000268278.1	RP11-420K14.1	3.65	0.000292	0.0195	0.23	0.17	Pain;	chr19:21403835	chr19:21637974~21656300:+
THCA	cis	rs9863	0.861	rs4930726	ENSG00000269938.1	RP11-214K3.20	-3.65	0.000292	0.0195	-0.19	-0.17	White blood cell count;	chr12:123943784	chr12:123968023~123968579:-
THCA	cis	rs17685	0.712	rs1859792	ENSG00000227038.2	AC005077.12	3.65	0.000292	0.0195	0.16	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76159946	chr7:76090431~76108779:-
THCA	cis	rs6137726	0.652	rs6132537	ENSG00000237396.1	LINC01384	-3.65	0.000292	0.0195	-0.15	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22675285	chr20:22587522~22607517:-
THCA	cis	rs2919009	0.664	rs55968513	ENSG00000271670.1	RP11-95I16.4	3.65	0.000292	0.0195	0.18	0.17	Obesity-related traits;	chr10:120859067	chr10:120879256~120880667:-
THCA	cis	rs13098911	0.54	rs9838450	ENSG00000223552.1	RP11-24F11.2	-3.65	0.000292	0.0195	-0.19	-0.17	Celiac disease;	chr3:46081841	chr3:46364955~46407059:-
THCA	cis	rs1153858	0.668	rs63603561	ENSG00000275672.1	GATM-AS1	3.65	0.000292	0.0195	0.17	0.17	Homoarginine levels;	chr15:45301125	chr15:45378700~45380123:+
THCA	cis	rs409045	0.965	rs367892	ENSG00000271874.1	CTD-2024P10.2	-3.65	0.000292	0.0195	-0.22	-0.17	Left ventricular mass;	chr5:34638969	chr5:34651457~34651888:-
THCA	cis	rs1654345	0.561	rs1725462	ENSG00000275132.1	Metazoa_SRP	-3.65	0.000293	0.0195	-0.27	-0.17	Life satisfaction;Subjective well-being;	chr19:38050567	chr19:38200234~38200532:+
THCA	cis	rs10760158	0.769	rs10985200	ENSG00000235865.2	GSN-AS1	3.65	0.000293	0.0196	0.14	0.17	Pulse pressure;	chr9:121281589	chr9:121280768~121285530:-
THCA	cis	rs12476592	0.602	rs262495	ENSG00000242412.1	DBIL5P2	3.65	0.000293	0.0196	0.21	0.17	Childhood ear infection;	chr2:63621473	chr2:63117851~63119542:-
THCA	cis	rs1510272	0.924	rs4680284	ENSG00000243926.1	TIPARP-AS1	-3.65	0.000293	0.0196	-0.17	-0.17	Testicular germ cell tumor;	chr3:156587852	chr3:156671862~156674378:-
THCA	cis	rs1510272	0.883	rs9819534	ENSG00000243926.1	TIPARP-AS1	-3.65	0.000293	0.0196	-0.17	-0.17	Testicular germ cell tumor;	chr3:156593254	chr3:156671862~156674378:-
THCA	cis	rs2921073	0.509	rs2976931	ENSG00000248538.5	RP11-10A14.5	-3.65	0.000293	0.0196	-0.2	-0.17	Parkinson's disease;	chr8:8399807	chr8:9189011~9202854:+
THCA	cis	rs3749237	0.636	rs1568662	ENSG00000224424.7	PRKAR2A-AS1	3.65	0.000293	0.0196	0.14	0.17	Resting heart rate;	chr3:49483830	chr3:48847572~48851981:+
THCA	cis	rs2562456	0.876	rs7252585	ENSG00000268278.1	RP11-420K14.1	-3.65	0.000293	0.0196	-0.2	-0.17	Pain;	chr19:21475141	chr19:21637974~21656300:+
THCA	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	3.65	0.000293	0.0196	0.15	0.17	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	3.65	0.000293	0.0196	0.15	0.17	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
THCA	cis	rs3809566	0.71	rs4075583	ENSG00000259459.4	RP11-321G12.1	-3.65	0.000293	0.0196	-0.14	-0.17	Platelet count;	chr15:63048028	chr15:63390136~63438320:+
THCA	cis	rs1560104	0.879	rs2865581	ENSG00000259876.1	CTD-3037G24.4	3.65	0.000293	0.0196	0.18	0.17	Obesity-related traits;	chr16:12623770	chr16:12556353~12557694:-
THCA	cis	rs495337	0.76	rs492702	ENSG00000229222.1	KRT18P4	-3.65	0.000293	0.0196	-0.21	-0.17	Psoriasis;	chr20:49906048	chr20:49956745~49958032:+
THCA	cis	rs17407555	0.657	rs12505144	ENSG00000250413.1	RP11-448G15.1	-3.65	0.000293	0.0196	-0.18	-0.17	Schizophrenia (age at onset);	chr4:10269295	chr4:10006482~10009725:+
THCA	cis	rs9863	0.861	rs12301673	ENSG00000269938.1	RP11-214K3.20	-3.65	0.000293	0.0196	-0.19	-0.17	White blood cell count;	chr12:123971271	chr12:123968023~123968579:-
THCA	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	3.65	0.000293	0.0196	0.23	0.17	Depression;	chr6:28402301	chr6:28943877~28944537:+
THCA	cis	rs4268898	1	rs10195436	ENSG00000242628.4	AC009228.1	-3.65	0.000293	0.0196	-0.2	-0.17	Asthma;	chr2:24213243	chr2:24214381~24221516:+
THCA	cis	rs7711186	0.786	rs4437394	ENSG00000252464.1	RN7SKP70	3.65	0.000293	0.0196	0.18	0.17	Urate levels in obese individuals;	chr5:178647368	chr5:178619728~178619998:-
THCA	cis	rs964611	0.882	rs68004907	ENSG00000259488.2	RP11-154J22.1	-3.65	0.000293	0.0196	-0.15	-0.17	Metabolite levels (Pyroglutamine);	chr15:48293162	chr15:48312353~48331856:-
THCA	cis	rs10540	1	rs12801271	ENSG00000279672.1	CMB9-55F22.1	3.65	0.000293	0.0196	0.33	0.17	Body mass index;	chr11:508720	chr11:779617~780755:+
THCA	cis	rs10802047	0.566	rs12130535	ENSG00000231365.4	RP11-418J17.1	-3.65	0.000293	0.0196	-0.17	-0.17	Relative hand skill in reading disability;	chr1:118785026	chr1:119140396~119275973:+
THCA	cis	rs735539	0.521	rs1348370	ENSG00000278291.1	RP11-172H24.4	3.65	0.000293	0.0196	0.22	0.17	Dental caries;	chr13:20830519	chr13:20699307~20703718:-
THCA	cis	rs735539	0.521	rs2585906	ENSG00000278291.1	RP11-172H24.4	3.65	0.000293	0.0196	0.22	0.17	Dental caries;	chr13:20833353	chr13:20699307~20703718:-
THCA	cis	rs735539	0.521	rs1570672	ENSG00000278291.1	RP11-172H24.4	3.65	0.000293	0.0196	0.22	0.17	Dental caries;	chr13:20834679	chr13:20699307~20703718:-
THCA	cis	rs301901	0.698	rs2886593	ENSG00000250155.1	CTD-2353F22.1	3.65	0.000293	0.0196	0.17	0.17	Height;	chr5:37427041	chr5:36666214~36725195:-
THCA	cis	rs7166081	0.95	rs12476	ENSG00000270964.1	RP11-502I4.3	-3.65	0.000293	0.0196	-0.15	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67201388	chr15:67541072~67542604:-
THCA	cis	rs17604090	0.646	rs10258473	ENSG00000227855.3	DPY19L2P3	3.65	0.000293	0.0196	0.21	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29650823	chr7:29650227~29742594:+
THCA	cis	rs7332672	0.532	rs9284183	ENSG00000234005.3	GAPDHP22	-3.65	0.000293	0.0196	-0.21	-0.17	Eosinophil counts;	chr13:99294117	chr13:99190579~99190991:-
THCA	cis	rs7824557	0.815	rs958648	ENSG00000255495.1	AC145124.2	-3.65	0.000293	0.0196	-0.17	-0.17	Retinal vascular caliber;	chr8:11246386	chr8:12194467~12196280:+
THCA	cis	rs1412115	0.871	rs10763953	ENSG00000233387.1	RP11-342D11.3	-3.65	0.000293	0.0196	-0.16	-0.17	Schizophrenia;	chr10:33783775	chr10:33096257~33116672:-
THCA	cis	rs9650657	0.501	rs3021500	ENSG00000255046.1	RP11-297N6.4	3.65	0.000293	0.0196	0.17	0.17	Neuroticism;	chr8:11166488	chr8:11797928~11802568:-
THCA	cis	rs10802047	0.566	rs2764472	ENSG00000231365.4	RP11-418J17.1	3.65	0.000293	0.0196	0.17	0.17	Relative hand skill in reading disability;	chr1:118760136	chr1:119140396~119275973:+
THCA	cis	rs8054556	0.692	rs7201384	ENSG00000273724.1	RP11-347C12.12	-3.65	0.000293	0.0196	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29913584	chr16:30336400~30343336:+
THCA	cis	rs7200543	1	rs35574015	ENSG00000260735.1	RP11-72I8.1	-3.65	0.000293	0.0196	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:15094411~15109197:+
THCA	cis	rs867371	0.929	rs7176075	ENSG00000278603.1	RP13-608F4.5	3.65	0.000293	0.0196	0.21	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472203~82472426:+
THCA	cis	rs1555322	0.818	rs2425021	ENSG00000269202.1	RP4-614O4.12	-3.65	0.000293	0.0196	-0.19	-0.17	Attention deficit hyperactivity disorder;	chr20:35241975	chr20:35201747~35203288:-
THCA	cis	rs9309473	0.66	rs79370894	ENSG00000273245.1	RP11-434P11.2	3.65	0.000293	0.0196	0.27	0.17	Metabolite levels;	chr2:73456388	chr2:73750256~73750786:-
THCA	cis	rs875971	0.66	rs10229345	ENSG00000275400.1	RP4-756H11.5	-3.65	0.000293	0.0196	-0.16	-0.17	Aortic root size;	chr7:66517181	chr7:66553805~66554199:-
THCA	cis	rs755107	0.653	rs2273349	ENSG00000201512.1	SNORA71C	-3.65	0.000293	0.0196	-0.21	-0.17	Skin pigmentation;	chr20:37996354	chr20:38429670~38429803:-
THCA	cis	rs7809950	0.724	rs1858888	ENSG00000272072.1	CTA-363E19.2	3.65	0.000293	0.0196	0.18	0.17	Coronary artery disease;	chr7:107405617	chr7:107192559~107193300:-
THCA	cis	rs2185341	0.788	rs11578020	ENSG00000218510.5	LINC00339	-3.65	0.000293	0.0196	-0.2	-0.17	Amyotrophic lateral sclerosis;	chr1:22355640	chr1:22025188~22031223:+
THCA	cis	rs5762813	0.566	rs28360615	ENSG00000272858.1	CTA-292E10.8	-3.65	0.000293	0.0196	-0.21	-0.17	Hematocrit;Hemoglobin concentration;	chr22:28942668	chr22:28814914~28815662:+
THCA	cis	rs7127129	0.713	rs2155458	ENSG00000246889.2	AP000487.5	-3.65	0.000293	0.0196	-0.17	-0.17	Aortic root size;	chr11:70183515	chr11:70372246~70398488:-
THCA	cis	rs7127129	0.842	rs55799623	ENSG00000246889.2	AP000487.5	-3.65	0.000293	0.0196	-0.17	-0.17	Aortic root size;	chr11:70184359	chr11:70372246~70398488:-
THCA	cis	rs7127129	0.842	rs72942971	ENSG00000246889.2	AP000487.5	-3.65	0.000293	0.0196	-0.17	-0.17	Aortic root size;	chr11:70184539	chr11:70372246~70398488:-
THCA	cis	rs7772697	0.508	rs9498202	ENSG00000223701.3	RAET1E-AS1	3.65	0.000293	0.0196	0.24	0.17	Diabetic retinopathy;	chr6:149062121	chr6:149884431~149919508:+
THCA	cis	rs568617	0.716	rs17854357	ENSG00000245156.1	RP11-867G23.3	-3.65	0.000293	0.0196	-0.21	-0.17	Crohn's disease;	chr11:65834089	chr11:66269832~66278525:-
THCA	cis	rs9534288	0.83	rs1409435	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46057525	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.83	rs3783202	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46057734	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.83	rs2296641	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46058091	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.83	rs2404963	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46058701	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.783	rs1126366	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46059013	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.83	rs1126365	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46059061	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.83	rs1126364	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46059259	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.83	rs1126363	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46059324	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.783	rs7987385	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46059996	chr13:46052806~46113332:+
THCA	cis	rs9534288	0.83	rs7987953	ENSG00000235903.6	CPB2-AS1	3.65	0.000293	0.0196	0.24	0.17	Blood protein levels;	chr13:46060260	chr13:46052806~46113332:+
THCA	cis	rs875971	1	rs2420591	ENSG00000272831.1	RP11-792A8.4	3.65	0.000293	0.0196	0.1	0.17	Aortic root size;	chr7:66447394	chr7:66739829~66740385:-
THCA	cis	rs80130819	0.515	rs1476608	ENSG00000273765.1	RP11-370I10.11	3.65	0.000293	0.0196	0.18	0.17	Prostate cancer;	chr12:48099948	chr12:48360920~48361377:+
THCA	cis	rs860295	0.665	rs11264367	ENSG00000236675.1	MTX1P1	-3.65	0.000293	0.0196	-0.17	-0.17	Body mass index;	chr1:155367547	chr1:155230975~155234325:+
THCA	cis	rs11931598	0.509	rs10937771	ENSG00000245468.3	RP11-367J11.3	3.65	0.000293	0.0196	0.12	0.17	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:6938307	chr4:7094571~7103385:-
THCA	cis	rs9368481	0.761	rs6918835	ENSG00000228223.2	HCG11	3.65	0.000293	0.0196	0.19	0.17	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26523450~26526579:+
THCA	cis	rs950169	0.845	rs4502182	ENSG00000188388.10	GOLGA6L3	3.65	0.000293	0.0196	0.22	0.17	Schizophrenia;	chr15:84254768	chr15:85240472~85247170:+
THCA	cis	rs853679	0.766	rs9368561	ENSG00000261839.1	RP1-265C24.8	3.65	0.000293	0.0196	0.25	0.17	Depression;	chr6:28200565	chr6:28136849~28139678:+
THCA	cis	rs6137726	0.524	rs1203921	ENSG00000237396.1	LINC01384	3.65	0.000293	0.0196	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22604846	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1007458	ENSG00000237396.1	LINC01384	3.65	0.000293	0.0196	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22607038	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs995734	ENSG00000237396.1	LINC01384	3.65	0.000293	0.0196	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22607370	chr20:22587522~22607517:-
THCA	cis	rs3760982	0.585	rs4803659	ENSG00000268601.1	AC115522.3	-3.65	0.000294	0.0196	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43786083	chr19:43794309~43795658:-
THCA	cis	rs7680126	0.536	rs4484299	ENSG00000261490.1	RP11-448G15.3	3.65	0.000294	0.0196	0.16	0.17	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10048827	chr4:10068089~10073019:-
THCA	cis	rs2821260	0.72	rs1564970	ENSG00000227207.2	RPL31P12	-3.65	0.000294	0.0196	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72108115	chr1:72301472~72301829:+
THCA	cis	rs7829975	0.514	rs2976929	ENSG00000248538.5	RP11-10A14.5	-3.65	0.000294	0.0196	-0.2	-0.17	Mood instability;	chr8:8401202	chr8:9189011~9202854:+
THCA	cis	rs2228479	0.85	rs11076619	ENSG00000274627.1	RP11-104N10.2	-3.65	0.000294	0.0196	-0.29	-0.17	Skin colour saturation;	chr16:89764835	chr16:89516797~89522217:+
THCA	cis	rs875971	0.862	rs35378740	ENSG00000223473.2	GS1-124K5.3	3.65	0.000294	0.0196	0.11	0.17	Aortic root size;	chr7:66522725	chr7:66491049~66493566:-
THCA	cis	rs16975963	0.843	rs73041022	ENSG00000276846.1	CTD-3220F14.3	-3.65	0.000294	0.0196	-0.16	-0.17	Longevity;	chr19:37781754	chr19:37314868~37315620:-
THCA	cis	rs3105593	0.637	rs3098168	ENSG00000242737.1	RP11-562A8.1	3.65	0.000294	0.0196	0.21	0.17	QT interval;	chr15:50458853	chr15:50466738~50467096:+
THCA	cis	rs11239930	0.517	rs2477569	ENSG00000180867.10	PDIA3P1	-3.65	0.000294	0.0196	-0.16	-0.17	AIDS progression;	chr1:147076261	chr1:147178113~147179622:+
THCA	cis	rs6471393	0.964	rs10504930	ENSG00000253197.4	CTD-3239E11.2	3.65	0.000294	0.0196	0.19	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732585	chr8:92882984~92965645:+
THCA	cis	rs1005277	0.579	rs2504143	ENSG00000151963.4	RP11-775A3.1	-3.65	0.000294	0.0196	-0.17	-0.17	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:37883594~37884109:+
THCA	cis	rs28595532	0.668	rs56410164	ENSG00000260404.2	RP11-384K6.6	-3.65	0.000294	0.0196	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118410470	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.748	rs17594978	ENSG00000260404.2	RP11-384K6.6	-3.65	0.000294	0.0196	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118415243	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.748	rs72670249	ENSG00000260404.2	RP11-384K6.6	-3.65	0.000294	0.0196	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118415668	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.702	rs72670252	ENSG00000260404.2	RP11-384K6.6	-3.65	0.000294	0.0196	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118416391	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.702	rs56217716	ENSG00000260404.2	RP11-384K6.6	-3.65	0.000294	0.0196	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118417335	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.8	rs114321375	ENSG00000260404.2	RP11-384K6.6	-3.65	0.000294	0.0196	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118420508	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.8	rs111626798	ENSG00000260404.2	RP11-384K6.6	-3.65	0.000294	0.0196	-0.27	-0.17	Cannabis dependence symptom count;	chr4:118431362	chr4:118591773~118633729:+
THCA	cis	rs7819412	0.805	rs4333549	ENSG00000261451.1	RP11-981G7.1	-3.65	0.000294	0.0196	-0.21	-0.17	Triglycerides;	chr8:11122051	chr8:10433672~10438312:+
THCA	cis	rs7246967	0.673	rs8106180	ENSG00000198153.8	ZNF849P	-3.65	0.000294	0.0196	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22696558	chr19:22685167~22686732:+
THCA	cis	rs2338	1	rs2338	ENSG00000272279.1	RP11-157J24.2	3.65	0.000294	0.0196	0.22	0.17	Response to platinum-based agents;	chr6:1573378	chr6:1528364~1528911:-
THCA	cis	rs3176789	0.647	rs9971740	ENSG00000256673.1	RP11-599J14.2	3.65	0.000294	0.0196	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9768931	chr12:9398355~9414851:-
THCA	cis	rs73230612	1	rs60015778	ENSG00000242767.1	ZBTB20-AS4	3.65	0.000294	0.0196	0.22	0.17	Type 2 diabetes;	chr3:115214657	chr3:115100423~115103061:+
THCA	cis	rs10911902	0.643	rs1406294	ENSG00000228238.1	GS1-304P7.2	-3.65	0.000294	0.0196	-0.26	-0.17	Schizophrenia;	chr1:186314293	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs76559138	ENSG00000228238.1	GS1-304P7.2	-3.65	0.000294	0.0196	-0.26	-0.17	Schizophrenia;	chr1:186314891	chr1:186578279~186579299:+
THCA	cis	rs7980687	0.678	rs7132277	ENSG00000235423.7	RP11-282O18.3	-3.65	0.000294	0.0196	-0.19	-0.17	Head circumference (infant);Educational attainment;Height;	chr12:123108835	chr12:123252030~123261483:-
THCA	cis	rs7759001	0.681	rs13212050	ENSG00000271755.1	RP1-153G14.4	3.65	0.000294	0.0196	0.2	0.17	Glomerular filtration rate (creatinine);	chr6:27511830	chr6:27404010~27406964:-
THCA	cis	rs1383484	0.761	rs11259923	ENSG00000259728.4	LINC00933	-3.65	0.000294	0.0196	-0.21	-0.17	Height;	chr15:83866952	chr15:84570649~84580175:+
THCA	cis	rs17685	0.753	rs2286830	ENSG00000227038.2	AC005077.12	-3.65	0.000294	0.0196	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76064645	chr7:76090431~76108779:-
THCA	cis	rs1923539	0.662	rs2758557	ENSG00000244733.5	RP11-506M13.3	-3.65	0.000294	0.0196	-0.17	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928848	chr10:79660891~79677996:+
THCA	cis	rs10815468	0.553	rs72699673	ENSG00000229611.1	RP11-390F4.10	3.65	0.000294	0.0196	0.18	0.17	Bipolar disorder and schizophrenia;	chr9:6791082	chr9:6704471~6707780:+
THCA	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-3.65	0.000294	0.0196	-0.19	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	3.65	0.000294	0.0196	0.19	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
THCA	cis	rs7824557	0.591	rs2736282	ENSG00000206014.6	OR7E161P	-3.65	0.000294	0.0196	-0.19	-0.17	Retinal vascular caliber;	chr8:11367971	chr8:11928597~11929563:-
THCA	cis	rs586688	0.556	rs1256473	ENSG00000224536.1	RP11-134G8.7	-3.65	0.000294	0.0196	-0.25	-0.17	Obesity-related traits;	chr1:201683214	chr1:201507241~201533608:+
THCA	cis	rs721048	0.92	rs17408841	ENSG00000242412.1	DBIL5P2	-3.65	0.000294	0.0196	-0.22	-0.17	Prostate cancer;	chr2:63170839	chr2:63117851~63119542:-
THCA	cis	rs10975370	0.527	rs10758739	ENSG00000206147.5	RP11-106A1.2	3.65	0.000294	0.0197	0.2	0.17	Breast cancer;	chr9:6023927	chr9:6639139~6639604:+
THCA	cis	rs4604234	0.614	rs73479932	ENSG00000260645.1	RP11-250B2.5	-3.65	0.000294	0.0197	-0.27	-0.17	Cancer;	chr6:80132154	chr6:80466958~80469080:+
THCA	cis	rs8033133	0.602	rs12439159	ENSG00000251896.1	SNORD116-27	-3.65	0.000294	0.0197	-0.19	-0.17	Blood osmolality (transformed sodium);	chr15:25078727	chr15:25101575~25101666:+
THCA	cis	rs6430585	0.583	rs76097170	ENSG00000231890.6	DARS-AS1	-3.65	0.000294	0.0197	-0.19	-0.17	Corneal structure;	chr2:135835928	chr2:135985176~136022593:+
THCA	cis	rs13178541	0.641	rs4532359	ENSG00000250378.1	RP11-119J18.1	-3.65	0.000294	0.0197	-0.19	-0.17	IgG glycosylation;	chr5:135790641	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs4976457	ENSG00000250378.1	RP11-119J18.1	-3.65	0.000294	0.0197	-0.19	-0.17	IgG glycosylation;	chr5:135790948	chr5:135812667~135826582:+
THCA	cis	rs13178541	0.641	rs9637921	ENSG00000250378.1	RP11-119J18.1	-3.65	0.000294	0.0197	-0.19	-0.17	IgG glycosylation;	chr5:135791175	chr5:135812667~135826582:+
THCA	cis	rs7911264	0.739	rs7071905	ENSG00000232709.1	MARK2P9	-3.65	0.000294	0.0197	-0.2	-0.17	Inflammatory bowel disease;	chr10:92626365	chr10:92418667~92420875:+
THCA	cis	rs7911264	0.739	rs10882094	ENSG00000232709.1	MARK2P9	-3.65	0.000294	0.0197	-0.2	-0.17	Inflammatory bowel disease;	chr10:92627919	chr10:92418667~92420875:+
THCA	cis	rs12887734	0.569	rs66953418	ENSG00000258735.1	LINC00637	-3.65	0.000294	0.0197	-0.21	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103847721~103858049:+
THCA	cis	rs12887734	0.546	rs4900597	ENSG00000258735.1	LINC00637	3.65	0.000294	0.0197	0.21	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103800327	chr14:103847721~103858049:+
THCA	cis	rs7259376	0.875	rs6511345	ENSG00000269345.1	VN1R85P	3.65	0.000294	0.0197	0.18	0.17	Menopause (age at onset);	chr19:22354634	chr19:22174766~22175191:-
THCA	cis	rs7727544	0.606	rs200838	ENSG00000263597.1	MIR3936	-3.65	0.000295	0.0197	-0.16	-0.17	Blood metabolite levels;	chr5:132374707	chr5:132365490~132365599:-
THCA	cis	rs12893668	0.663	rs12889731	ENSG00000252469.1	RNU7-160P	3.65	0.000295	0.0197	0.2	0.17	Reticulocyte count;	chr14:103621145	chr14:103550345~103550406:+
THCA	cis	rs911555	0.662	rs4906322	ENSG00000269940.1	RP11-73M18.7	-3.65	0.000295	0.0197	-0.17	-0.17	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103694560~103695170:+
THCA	cis	rs9309473	0.615	rs62153183	ENSG00000273245.1	RP11-434P11.2	3.65	0.000295	0.0197	0.27	0.17	Metabolite levels;	chr2:73536239	chr2:73750256~73750786:-
THCA	cis	rs786425	0.683	rs11572920	ENSG00000278112.1	RP11-972P1.11	3.65	0.000295	0.0197	0.17	0.17	Pubertal anthropometrics;	chr12:123635436	chr12:123519390~123519856:-
THCA	cis	rs7487075	0.521	rs11183576	ENSG00000257261.4	RP11-96H19.1	3.65	0.000295	0.0197	0.12	0.17	Itch intensity from mosquito bite;	chr12:46714734	chr12:46383679~46876159:+
THCA	cis	rs6599077	0.573	rs12486603	ENSG00000223797.4	ENTPD3-AS1	3.65	0.000295	0.0197	0.15	0.17	Sleep-related phenotypes;	chr3:40153811	chr3:40313802~40453329:-
THCA	cis	rs4604234	0.803	rs73465590	ENSG00000260645.1	RP11-250B2.5	-3.65	0.000295	0.0197	-0.28	-0.17	Cancer;	chr6:80337459	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.708	rs3805862	ENSG00000260645.1	RP11-250B2.5	-3.65	0.000295	0.0197	-0.28	-0.17	Cancer;	chr6:80338534	chr6:80466958~80469080:+
THCA	cis	rs7572733	0.901	rs6734096	ENSG00000231621.1	AC013264.2	-3.65	0.000295	0.0197	-0.16	-0.17	Dermatomyositis;	chr2:197891735	chr2:197197991~197199273:+
THCA	cis	rs801193	1	rs3778909	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000295	0.0197	-0.14	-0.17	Aortic root size;	chr7:66790659	chr7:66848496~66858136:+
THCA	cis	rs713587	0.563	rs7605335	ENSG00000224165.4	DNAJC27-AS1	-3.65	0.000295	0.0197	-0.09	-0.17	Body mass index in non-asthmatics;	chr2:24886448	chr2:24971390~25039694:+
THCA	cis	rs3015497	0.586	rs7144714	ENSG00000270062.1	RP11-248J18.3	3.65	0.000295	0.0197	0.19	0.17	Mean platelet volume;	chr14:50611867	chr14:50723777~50724272:-
THCA	cis	rs11723261	0.582	rs6814287	ENSG00000250892.1	RP11-1365D11.1	3.65	0.000295	0.0197	0.24	0.17	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:201409~205009:-
THCA	cis	rs6499924	0.635	rs16959567	ENSG00000187185.4	CTD-2600O9.1	-3.65	0.000295	0.0197	-0.19	-0.17	Prudent dietary pattern;	chr16:57938017	chr16:57798186~57816946:+
THCA	cis	rs16975963	0.644	rs11666738	ENSG00000276846.1	CTD-3220F14.3	-3.65	0.000295	0.0197	-0.15	-0.17	Longevity;	chr19:37639418	chr19:37314868~37315620:-
THCA	cis	rs13323323	0.652	rs9825080	ENSG00000214820.3	MPRIPP1	3.65	0.000295	0.0197	0.2	0.17	IgG glycosylation;	chr3:44209778	chr3:44579938~44581026:-
THCA	cis	rs10454142	0.7	rs17037289	ENSG00000202227.1	RNU6-282P	3.65	0.000295	0.0197	0.2	0.17	Sex hormone-binding globulin levels;	chr2:48360059	chr2:48501922~48502024:-
THCA	cis	rs4950322	0.58	rs7541393	ENSG00000180867.10	PDIA3P1	3.65	0.000295	0.0197	0.16	0.17	Protein quantitative trait loci;	chr1:147117186	chr1:147178113~147179622:+
THCA	cis	rs931608	0.64	rs4932975	ENSG00000269138.1	ZNF209P	-3.65	0.000295	0.0197	-0.23	-0.17	Response to statins (LDL cholesterol change);Dental caries;	chr19:22308270	chr19:22463922~22473036:+
THCA	cis	rs7119038	0.774	rs7945144	ENSG00000255422.1	AP002954.4	3.65	0.000295	0.0197	0.2	0.17	Sjögren's syndrome;	chr11:118738007	chr11:118704607~118750263:+
THCA	cis	rs73222236	0.787	rs6806795	ENSG00000273486.1	RP11-731C17.2	3.65	0.000295	0.0197	0.15	0.17	Coronary artery disease;	chr3:136587297	chr3:136837338~136839021:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000295	0.0197	-0.14	-0.17	Calcium levels;	chr7:65892789	chr7:66848496~66858136:+
THCA	cis	rs10129255	0.957	rs8009073	ENSG00000211972.2	IGHV3-66	3.65	0.000295	0.0197	0.1	0.17	Kawasaki disease;	chr14:106777278	chr14:106675017~106675544:-
THCA	cis	rs785830	0.811	rs661356	ENSG00000231808.2	LINC01388	-3.65	0.000295	0.0197	-0.19	-0.17	Platelet distribution width;	chr9:244457	chr9:112713~113754:-
THCA	cis	rs804280	1	rs804280	ENSG00000254839.1	AF131215.6	-3.65	0.000295	0.0197	-0.17	-0.17	Myopia (pathological);	chr8:11755189	chr8:11062647~11067089:-
THCA	cis	rs7259376	0.936	rs8110854	ENSG00000269345.1	VN1R85P	3.65	0.000295	0.0197	0.18	0.17	Menopause (age at onset);	chr19:22366651	chr19:22174766~22175191:-
THCA	cis	rs11025523	1	rs11025523	ENSG00000254622.1	NAV2-AS4	-3.65	0.000295	0.0197	-0.19	-0.17	Obesity-related traits;	chr11:20356578	chr11:19510890~19519896:-
THCA	cis	rs7819412	0.668	rs2409721	ENSG00000280294.1	RP11-177H2.1	3.65	0.000295	0.0197	0.14	0.17	Triglycerides;	chr8:11180735	chr8:10856085~10859436:-
THCA	cis	rs9911578	0.933	rs2531726	ENSG00000224738.1	AC099850.1	-3.65	0.000295	0.0197	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58445172	chr17:59106598~59118267:+
THCA	cis	rs11864453	0.616	rs9938025	ENSG00000279206.1	RP5-991G20.6	-3.65	0.000295	0.0197	-0.17	-0.17	Fibrinogen levels;	chr16:71988142	chr16:72772673~72773272:+
THCA	cis	rs4578769	0.879	rs3863524	ENSG00000265939.1	UBE2CP2	3.65	0.000295	0.0197	0.2	0.17	Eosinophil percentage of white cells;	chr18:22881319	chr18:22900486~22900995:-
THCA	cis	rs4819052	0.851	rs914214	ENSG00000184274.3	LINC00315	-3.65	0.000295	0.0197	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45300245~45305257:-
THCA	cis	rs12142240	0.731	rs12385693	ENSG00000232022.5	FAAHP1	-3.65	0.000295	0.0197	-0.19	-0.17	Menopause (age at onset);	chr1:46353249	chr1:46432129~46445521:+
THCA	cis	rs3808502	0.503	rs34190028	ENSG00000154316.13	TDH	3.65	0.000295	0.0197	0.12	0.17	Neuroticism;	chr8:11559641	chr8:11339637~11368452:+
THCA	cis	rs11678825	0.639	rs77134676	ENSG00000272663.1	RP11-191L17.1	-3.65	0.000295	0.0197	-0.19	-0.17	Reticulocyte fraction of red cells;	chr2:48440510	chr2:48440043~48440597:-
THCA	cis	rs8177876	1	rs8177876	ENSG00000261838.4	RP11-303E16.6	3.65	0.000295	0.0197	0.36	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81069854~81076598:+
THCA	cis	rs9450351	0.744	rs7775016	ENSG00000280232.1	RP11-321N4.4	3.65	0.000295	0.0197	0.35	0.17	Interferon gamma-induced protein 10 levels;	chr6:85780196	chr6:85498441~85499058:-
THCA	cis	rs961764	0.708	rs514239	ENSG00000217241.1	CBX3P9	-3.65	0.000295	0.0197	-0.23	-0.17	Height;	chr6:117137574	chr6:116453014~116453565:-
THCA	cis	rs4845570	0.764	rs12141652	ENSG00000249602.1	RP11-98D18.3	-3.65	0.000295	0.0197	-0.27	-0.17	Coronary artery disease;	chr1:151744235	chr1:151763384~151769501:-
THCA	cis	rs4845570	0.764	rs12122917	ENSG00000249602.1	RP11-98D18.3	-3.65	0.000295	0.0197	-0.27	-0.17	Coronary artery disease;	chr1:151744236	chr1:151763384~151769501:-
THCA	cis	rs3020811	0.85	rs73060042	ENSG00000256274.1	TAS2R64P	3.65	0.000295	0.0197	0.43	0.17	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr12:12014786	chr12:11076769~11079171:-
THCA	cis	rs4819052	0.634	rs8128636	ENSG00000273796.1	LL21NC02-21A1.1	-3.65	0.000295	0.0197	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45403809~45404369:-
THCA	cis	rs875971	0.83	rs4718358	ENSG00000272831.1	RP11-792A8.4	3.65	0.000295	0.0197	0.1	0.17	Aortic root size;	chr7:66508681	chr7:66739829~66740385:-
THCA	cis	rs36207871	1	rs36207871	ENSG00000257303.1	RP11-977G19.11	3.65	0.000295	0.0197	0.24	0.17	Inflammatory skin disease;	chr12:56290717	chr12:56300142~56314808:+
THCA	cis	rs2066819	1	rs2643623	ENSG00000257303.1	RP11-977G19.11	3.65	0.000295	0.0197	0.24	0.17	Psoriasis vulgaris;	chr12:56295941	chr12:56300142~56314808:+
THCA	cis	rs5006884	1	rs7131367	ENSG00000167355.6	AC104389.28	-3.65	0.000295	0.0197	-0.23	-0.17	Fetal hemoglobin levels;	chr11:5370876	chr11:5304976~5505652:-
THCA	cis	rs950169	0.959	rs12902070	ENSG00000275120.1	RP11-182J1.17	3.65	0.000295	0.0197	0.2	0.17	Schizophrenia;	chr15:84124806	chr15:84599434~84606463:-
THCA	cis	rs6878727	0.85	rs1363308	ENSG00000253807.4	LINC01170	-3.65	0.000295	0.0197	-0.15	-0.17	Breast cancer;	chr5:124371529	chr5:124059794~124405079:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000235821.1	IFITM4P	-3.65	0.000295	0.0197	-0.25	-0.17	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29750729~29751148:-
THCA	cis	rs4722166	0.598	rs7804146	ENSG00000225541.1	AC002480.5	-3.65	0.000295	0.0197	-0.19	-0.17	Lung cancer;	chr7:22761310	chr7:22571607~22661792:-
THCA	cis	rs9876781	1	rs9883759	ENSG00000199476.1	Y_RNA	-3.65	0.000295	0.0197	-0.21	-0.17	Longevity;	chr3:48422209	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs6442120	ENSG00000199476.1	Y_RNA	-3.65	0.000295	0.0197	-0.21	-0.17	Longevity;	chr3:48423094	chr3:48288587~48288694:+
THCA	cis	rs9840812	0.645	rs13068119	ENSG00000273486.1	RP11-731C17.2	-3.65	0.000295	0.0197	-0.17	-0.17	Fibrinogen levels;	chr3:136487527	chr3:136837338~136839021:-
THCA	cis	rs1153858	1	rs1613559	ENSG00000275672.1	GATM-AS1	-3.65	0.000295	0.0197	-0.17	-0.17	Homoarginine levels;	chr15:45329918	chr15:45378700~45380123:+
THCA	cis	rs7312933	0.524	rs11181465	ENSG00000257225.1	RP11-328C8.4	-3.65	0.000295	0.0197	-0.17	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42371296	chr12:42459366~42466128:+
THCA	cis	rs4295623	0.553	rs11250163	ENSG00000270154.1	RP11-419I17.1	3.65	0.000295	0.0197	0.21	0.17	Morning vs. evening chronotype;	chr8:11738928	chr8:12476462~12477122:+
THCA	cis	rs3770081	1	rs17026854	ENSG00000273080.1	RP11-301O19.1	-3.65	0.000295	0.0197	-0.39	-0.17	Facial emotion recognition (sad faces);	chr2:86053373	chr2:86195590~86196049:+
THCA	cis	rs12216125	0.549	rs9358905	ENSG00000272810.1	U91328.22	-3.65	0.000295	0.0197	-0.13	-0.17	Iron status biomarkers;	chr6:26077611	chr6:26013241~26013757:+
THCA	cis	rs3087591	0.708	rs7503922	ENSG00000263535.1	AK4P1	3.65	0.000295	0.0197	0.2	0.17	Hip circumference;	chr17:31314917	chr17:31345521~31346187:+
THCA	cis	rs2635047	1	rs2684825	ENSG00000280212.1	RP11-49K24.3	-3.65	0.000295	0.0197	-0.16	-0.17	Educational attainment;	chr18:47140044	chr18:47076117~47076594:+
THCA	cis	rs600231	0.708	rs661403	ENSG00000254614.2	AP003068.23	3.65	0.000295	0.0197	0.22	0.17	Bone mineral density;	chr11:65475007	chr11:65177606~65181834:-
THCA	cis	rs6687821	0.681	rs481583	ENSG00000261737.1	RP4-612B15.3	-3.65	0.000295	0.0197	-0.26	-0.17	Yeast infection;	chr1:86849596	chr1:86703502~86704462:-
THCA	cis	rs61160187	0.51	rs6893642	ENSG00000215032.2	GNL3LP1	3.65	0.000296	0.0197	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60821896	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.51	rs3936423	ENSG00000215032.2	GNL3LP1	3.65	0.000296	0.0197	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823134	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.51	rs1445293	ENSG00000215032.2	GNL3LP1	3.65	0.000296	0.0197	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823910	chr5:60891935~60893577:-
THCA	cis	rs7216064	0.636	rs62084696	ENSG00000267023.4	LRRC37A16P	3.65	0.000296	0.0197	0.12	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68125777~68152468:-
THCA	cis	rs7216064	0.636	rs4638	ENSG00000267023.4	LRRC37A16P	3.65	0.000296	0.0197	0.12	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68125777~68152468:-
THCA	cis	rs7216064	0.601	rs35453056	ENSG00000267023.4	LRRC37A16P	3.65	0.000296	0.0197	0.12	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68125777~68152468:-
THCA	cis	rs7216064	0.628	rs62084702	ENSG00000267023.4	LRRC37A16P	3.65	0.000296	0.0197	0.12	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68125777~68152468:-
THCA	cis	rs910316	1	rs12589876	ENSG00000259138.1	RP11-950C14.7	3.65	0.000296	0.0197	0.14	0.17	Height;	chr14:75077486	chr14:75127153~75136930:+
THCA	cis	rs910316	0.967	rs10246	ENSG00000259138.1	RP11-950C14.7	3.65	0.000296	0.0197	0.14	0.17	Height;	chr14:75077767	chr14:75127153~75136930:+
THCA	cis	rs12101261	0.744	rs17544968	ENSG00000258915.1	BHLHB9P1	-3.65	0.000296	0.0197	-0.21	-0.17	Graves' disease;	chr14:80990959	chr14:80981988~80983638:+
THCA	cis	rs1371614	0.611	rs4665920	ENSG00000229122.1	AGBL5-IT1	-3.65	0.000296	0.0197	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26905966	chr2:27061038~27061815:+
THCA	cis	rs7707921	0.522	rs9293290	ENSG00000251374.1	RPS23P5	3.65	0.000296	0.0197	0.19	0.17	Breast cancer;	chr5:82178406	chr5:82265157~82265259:-
THCA	cis	rs7623687	0.786	rs73082337	ENSG00000229759.1	MRPS18AP1	3.65	0.000296	0.0197	0.3	0.17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr3:48972137	chr3:48256350~48256938:-
THCA	cis	rs7246657	0.943	rs4803347	ENSG00000268499.1	CTB-102L5.8	3.65	0.000296	0.0197	0.21	0.17	Coronary artery calcification;	chr19:37357115	chr19:38199836~38200934:+
THCA	cis	rs2797160	0.967	rs6910786	ENSG00000226409.1	RP11-735G4.1	3.65	0.000296	0.0197	0.2	0.17	Endometrial cancer;	chr6:125695995	chr6:125370211~125374324:-
THCA	cis	rs7818688	1	rs10110635	ENSG00000253528.2	RP11-347C18.4	-3.65	0.000296	0.0197	-0.27	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95012841	chr8:94974573~94974853:-
THCA	cis	rs8024893	0.764	rs7178760	ENSG00000215302.7	CTD-3092A11.1	3.65	0.000296	0.0197	0.25	0.17	Red cell distribution width;	chr15:31239170	chr15:30470779~30507623:+
THCA	cis	rs9308731	0.583	rs7596789	ENSG00000227992.1	AC108463.2	-3.65	0.000296	0.0197	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111175039	chr2:111203964~111206215:-
THCA	cis	rs2274273	0.804	rs28428911	ENSG00000258469.1	CHMP4BP1	3.65	0.000296	0.0197	0.15	0.17	Protein biomarker;	chr14:55376878	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.805	rs28660594	ENSG00000258469.1	CHMP4BP1	3.65	0.000296	0.0197	0.15	0.17	Protein biomarker;	chr14:55379456	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs10139000	ENSG00000258469.1	CHMP4BP1	3.65	0.000296	0.0197	0.15	0.17	Protein biomarker;	chr14:55383158	chr14:55298644~55299231:+
THCA	cis	rs2292873	0.908	rs2292870	ENSG00000234949.2	AC104667.3	-3.65	0.000296	0.0197	-0.26	-0.17	Obesity-related traits;	chr2:237591231	chr2:237591020~237595981:+
THCA	cis	rs2455799	0.574	rs2470534	ENSG00000270409.1	RP11-44D5.1	3.65	0.000296	0.0197	0.17	0.17	Mean platelet volume;	chr3:15659547	chr3:15732252~15733470:+
THCA	cis	rs6981523	0.553	rs2409730	ENSG00000255495.1	AC145124.2	-3.65	0.000296	0.0197	-0.2	-0.17	Neuroticism;	chr8:11203129	chr8:12194467~12196280:+
THCA	cis	rs2880765	0.835	rs7163958	ENSG00000218052.5	ADAMTS7P4	-3.65	0.000296	0.0197	-0.19	-0.17	Coronary artery disease;	chr15:85501984	chr15:85255369~85330334:-
THCA	cis	rs5753037	0.653	rs131270	ENSG00000279699.1	RP1-102K2.9	3.65	0.000296	0.0197	0.16	0.17	Type 1 diabetes;	chr22:29753907	chr22:30275215~30276951:-
THCA	cis	rs7560272	0.501	rs6750494	ENSG00000163016.8	ALMS1P	-3.65	0.000296	0.0197	-0.21	-0.17	Schizophrenia;	chr2:73719369	chr2:73644919~73685576:+
THCA	cis	rs4073416	0.542	rs2411820	ENSG00000276116.2	FUT8-AS1	3.65	0.000296	0.0197	0.19	0.17	N-glycan levels;	chr14:65480026	chr14:65411170~65412690:-
THCA	cis	rs7246967	0.608	rs2569725	ENSG00000269364.1	LINC01233	-3.65	0.000296	0.0197	-0.24	-0.17	Bronchopulmonary dysplasia;	chr19:22833208	chr19:22532626~22533494:+
THCA	cis	rs2904297	1	rs10015233	ENSG00000261490.1	RP11-448G15.3	3.65	0.000296	0.0197	0.11	0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11038782	chr4:10068089~10073019:-
THCA	cis	rs910316	1	rs4903281	ENSG00000259138.1	RP11-950C14.7	3.65	0.000296	0.0197	0.14	0.17	Height;	chr14:75087658	chr14:75127153~75136930:+
THCA	cis	rs1560104	0.709	rs9806858	ENSG00000259876.1	CTD-3037G24.4	3.65	0.000296	0.0197	0.19	0.17	Obesity-related traits;	chr16:12610564	chr16:12556353~12557694:-
THCA	cis	rs7296418	0.699	rs11057219	ENSG00000256092.2	RP13-942N8.1	3.65	0.000296	0.0197	0.12	0.17	Platelet count;	chr12:123265526	chr12:123363868~123366113:+
THCA	cis	rs13064773	0.51	rs340304	ENSG00000279311.1	RP11-170K4.2	3.65	0.000296	0.0197	0.22	0.17	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158854456	chr3:158869898~158871821:+
THCA	cis	rs7010267	0.773	rs13439134	ENSG00000254278.1	RP11-278I4.2	3.65	0.000296	0.0197	0.21	0.17	Total body bone mineral density (age 45-60);	chr8:118906629	chr8:119062942~119068782:-
THCA	cis	rs7481311	0.956	rs1038660	ENSG00000245573.6	BDNF-AS	3.65	0.000296	0.0197	0.16	0.17	Weight;Body mass index;	chr11:27527845	chr11:27506838~27698174:+
THCA	cis	rs7481311	0.956	rs6484314	ENSG00000245573.6	BDNF-AS	3.65	0.000296	0.0197	0.16	0.17	Weight;Body mass index;	chr11:27528652	chr11:27506838~27698174:+
THCA	cis	rs9584850	0.834	rs12463	ENSG00000231194.1	FARP1-AS1	3.65	0.000296	0.0197	0.2	0.17	Neuroticism;	chr13:98453048	chr13:98435405~98435840:-
THCA	cis	rs9584850	0.834	rs8481	ENSG00000231194.1	FARP1-AS1	3.65	0.000296	0.0197	0.2	0.17	Neuroticism;	chr13:98453141	chr13:98435405~98435840:-
THCA	cis	rs61160187	0.582	rs28436304	ENSG00000272308.1	RP11-231G3.1	-3.65	0.000296	0.0197	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60866457~60866935:-
THCA	cis	rs17345786	0.906	rs11708616	ENSG00000244119.1	PDCL3P4	3.65	0.000296	0.0197	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr3:101512887	chr3:101712472~101713191:+
THCA	cis	rs875971	1	rs3981131	ENSG00000272831.1	RP11-792A8.4	3.65	0.000296	0.0197	0.1	0.17	Aortic root size;	chr7:66486690	chr7:66739829~66740385:-
THCA	cis	rs916888	0.687	rs199456	ENSG00000260075.1	NSFP1	-3.65	0.000296	0.0197	-0.27	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46372855~46487141:+
THCA	cis	rs916888	0.773	rs199451	ENSG00000260075.1	NSFP1	-3.65	0.000296	0.0197	-0.27	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46372855~46487141:+
THCA	cis	rs10089	1	rs2054444	ENSG00000245937.6	LINC01184	-3.65	0.000296	0.0197	-0.19	-0.17	Ileal carcinoids;	chr5:128157514	chr5:127940426~128083172:-
THCA	cis	rs16959442	0.786	rs921510	ENSG00000254912.2	RP11-632K20.2	-3.65	0.000296	0.0197	-0.25	-0.17	Lobe attachment (rater-scored or self-reported);	chr15:32825101	chr15:32494003~32500346:-
THCA	cis	rs6573604	0.681	rs12436299	ENSG00000276116.2	FUT8-AS1	3.65	0.000296	0.0198	0.25	0.17	N-glycan levels;	chr14:65318476	chr14:65411170~65412690:-
THCA	cis	rs11098699	0.732	rs4833898	ENSG00000273007.1	RP11-170N16.3	3.65	0.000296	0.0198	0.13	0.17	Mosquito bite size;	chr4:123322708	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs4833899	ENSG00000273007.1	RP11-170N16.3	3.65	0.000296	0.0198	0.13	0.17	Mosquito bite size;	chr4:123322816	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs13150998	ENSG00000273007.1	RP11-170N16.3	3.65	0.000296	0.0198	0.13	0.17	Mosquito bite size;	chr4:123323918	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs13123959	ENSG00000273007.1	RP11-170N16.3	3.65	0.000296	0.0198	0.13	0.17	Mosquito bite size;	chr4:123323931	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.718	rs4833902	ENSG00000273007.1	RP11-170N16.3	3.65	0.000296	0.0198	0.13	0.17	Mosquito bite size;	chr4:123324233	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.687	rs4833903	ENSG00000273007.1	RP11-170N16.3	3.65	0.000296	0.0198	0.13	0.17	Mosquito bite size;	chr4:123324476	chr4:122881878~122884712:-
THCA	cis	rs972578	0.836	rs738539	ENSG00000230319.1	AL022476.2	3.65	0.000296	0.0198	0.18	0.17	Mean platelet volume;	chr22:42886795	chr22:43038585~43052366:+
THCA	cis	rs10256972	0.758	rs2280724	ENSG00000199023.2	MIR339	-3.65	0.000296	0.0198	-0.17	-0.17	Endometriosis;Longevity;	chr7:1025084	chr7:1022935~1023045:-
THCA	cis	rs8058578	0.943	rs7197770	ENSG00000260911.2	RP11-196G11.2	3.65	0.000296	0.0198	0.14	0.17	Multiple myeloma;	chr16:30704587	chr16:31043150~31049868:+
THCA	cis	rs9868809	0.656	rs73078362	ENSG00000229759.1	MRPS18AP1	-3.65	0.000296	0.0198	-0.37	-0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48666484	chr3:48256350~48256938:-
THCA	cis	rs17772222	0.655	rs7160717	ENSG00000222990.1	RNU4-22P	3.65	0.000296	0.0198	0.2	0.17	Coronary artery calcification;	chr14:88498232	chr14:88513498~88513663:+
THCA	cis	rs5752773	0.513	rs695591	ENSG00000272858.1	CTA-292E10.8	-3.65	0.000296	0.0198	-0.18	-0.17	Vertical cup-disc ratio;	chr22:28415341	chr22:28814914~28815662:+
THCA	cis	rs2288884	0.943	rs1433089	ENSG00000260160.1	CTC-471J1.2	-3.65	0.000296	0.0198	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52003732	chr19:52058490~52063703:-
THCA	cis	rs7311936	1	rs7311936	ENSG00000270130.1	RP11-214K3.23	-3.65	0.000296	0.0198	-0.18	-0.17	Vertical cup-disc ratio;	chr12:124147051	chr12:123960717~123961244:-
THCA	cis	rs2522056	0.935	rs1981524	ENSG00000237714.1	P4HA2-AS1	-3.65	0.000296	0.0198	-0.24	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132184876~132192808:+
THCA	cis	rs867186	0.925	rs11906160	ENSG00000126005.14	MMP24-AS1	-3.65	0.000296	0.0198	-0.25	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34977952	chr20:35216462~35278131:-
THCA	cis	rs12121840	0.79	rs16847083	ENSG00000237463.4	RP11-280O1.2	3.65	0.000296	0.0198	0.15	0.17	Interleukin-1-receptor antagonist levels;	chr1:165564893	chr1:165476841~165582155:-
THCA	cis	rs11867129	0.642	rs45461202	ENSG00000260778.3	RP11-304L19.13	3.65	0.000296	0.0198	0.17	0.17	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2309886	chr16:2268155~2273418:+
THCA	cis	rs654950	0.505	rs2475839	ENSG00000230638.4	RP11-486B10.4	3.65	0.000296	0.0198	0.19	0.17	Airway imaging phenotypes;	chr1:41540334	chr1:41542069~41544310:+
THCA	cis	rs763121	0.853	rs5757196	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38643850	chr22:38739003~38749041:+
THCA	cis	rs763121	0.785	rs5757199	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38644612	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs9610993	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38646813	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs5757200	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38647486	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs5757203	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38648147	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs2205802	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38650322	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs5757204	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38650695	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs8138996	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38651430	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs6001182	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38651438	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs5757208	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38653225	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs5757211	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38655700	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs6001184	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38656111	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs6001185	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38656150	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs2294296	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38657044	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs2064088	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38657377	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs5757213	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000296	0.0198	-0.13	-0.17	Menopause (age at onset);	chr22:38657883	chr22:38739003~38749041:+
THCA	cis	rs9367716	0.868	rs9396267	ENSG00000276576.1	MRPL30P1	3.65	0.000296	0.0198	0.21	0.17	Coronary artery disease;	chr6:57245613	chr6:57029521~57029988:+
THCA	cis	rs7572644	0.581	rs10205313	ENSG00000223522.1	AC093690.1	3.65	0.000297	0.0198	0.22	0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27953660	chr2:28307691~28310459:-
THCA	cis	rs62045844	0.536	rs9940965	ENSG00000259877.2	RP11-46C24.7	3.65	0.000297	0.0198	0.19	0.17	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:89114256	chr16:89215211~89217653:-
THCA	cis	rs2625529	0.878	rs16956302	ENSG00000260037.4	CTD-2524L6.3	-3.65	0.000297	0.0198	-0.23	-0.17	Red blood cell count;	chr15:71843902	chr15:71818396~71823384:+
THCA	cis	rs409045	1	rs450676	ENSG00000271874.1	CTD-2024P10.2	-3.65	0.000297	0.0198	-0.22	-0.17	Left ventricular mass;	chr5:34635405	chr5:34651457~34651888:-
THCA	cis	rs116095464	1	rs10069360	ENSG00000277812.1	AC021087.1	3.65	0.000297	0.0198	0.41	0.17	Breast cancer;	chr5:351500	chr5:262769~262881:+
THCA	cis	rs875971	0.597	rs11763224	ENSG00000273024.4	INTS4P2	-3.65	0.000297	0.0198	-0.21	-0.17	Aortic root size;	chr7:66518628	chr7:65647864~65715661:+
THCA	cis	rs9923856	0.571	rs13339285	ENSG00000263033.2	RP11-396B14.2	-3.65	0.000297	0.0198	-0.15	-0.17	Atopic dermatitis;Adult asthma;	chr16:10994837	chr16:11196177~11224969:+
THCA	cis	rs2239557	0.508	rs56120998	ENSG00000259065.1	RP5-1021I20.1	-3.65	0.000297	0.0198	-0.26	-0.17	Common traits (Other);	chr14:73844011	chr14:73787360~73803270:+
THCA	cis	rs10769945	0.679	rs217213	ENSG00000226416.1	MRPL23-AS1	3.65	0.000297	0.0198	0.17	0.17	DNA methylation (variation);	chr11:1957888	chr11:1983237~1989920:-
THCA	cis	rs9920506	0.536	rs11072768	ENSG00000261143.1	ADAMTS7P3	3.65	0.000297	0.0198	0.23	0.17	Post bronchodilator FEV1;	chr15:78637136	chr15:77976042~77993057:+
THCA	cis	rs10457678	0.579	rs12193938	ENSG00000225415.2	RP3-509I19.1	-3.65	0.000297	0.0198	-0.23	-0.17	Colorectal or endometrial cancer;	chr6:138821718	chr6:138822747~138823799:+
THCA	cis	rs10457678	0.579	rs7773177	ENSG00000225415.2	RP3-509I19.1	-3.65	0.000297	0.0198	-0.23	-0.17	Colorectal or endometrial cancer;	chr6:138821951	chr6:138822747~138823799:+
THCA	cis	rs10457678	0.579	rs6570291	ENSG00000225415.2	RP3-509I19.1	-3.65	0.000297	0.0198	-0.23	-0.17	Colorectal or endometrial cancer;	chr6:138822137	chr6:138822747~138823799:+
THCA	cis	rs765787	0.53	rs11636367	ENSG00000259932.1	CTD-2651B20.7	3.65	0.000297	0.0198	0.2	0.17	Uric acid levels;	chr15:45243664	chr15:45198517~45199139:-
THCA	cis	rs13098911	0.54	rs13079869	ENSG00000226074.4	PRSS44	-3.65	0.000297	0.0198	-0.31	-0.17	Celiac disease;	chr3:45966595	chr3:46809359~46812558:-
THCA	cis	rs1125355	0.69	rs1356173	ENSG00000243792.1	OR7E89P	-3.65	0.000297	0.0198	-0.24	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158795461	chr2:158853755~158854576:+
THCA	cis	rs7824557	0.583	rs2736292	ENSG00000255495.1	AC145124.2	3.65	0.000297	0.0198	0.19	0.17	Retinal vascular caliber;	chr8:11376991	chr8:12194467~12196280:+
THCA	cis	rs7894407	0.522	rs2274341	ENSG00000272912.1	RP11-724N1.1	3.65	0.000297	0.0198	0.26	0.17	White matter hyperintensity burden;	chr10:103093746	chr10:102914585~102915404:+
THCA	cis	rs2179367	0.959	rs9285519	ENSG00000223701.3	RAET1E-AS1	3.65	0.000297	0.0198	0.21	0.17	Dupuytren's disease;	chr6:149371799	chr6:149884431~149919508:+
THCA	cis	rs9634489	0.843	rs7982370	ENSG00000247400.3	DNAJC3-AS1	3.65	0.000297	0.0198	0.1	0.17	Body mass index;	chr13:96408503	chr13:95648733~95676925:-
THCA	cis	rs7980687	0.55	rs1727324	ENSG00000235423.7	RP11-282O18.3	3.65	0.000297	0.0198	0.19	0.17	Head circumference (infant);Educational attainment;Height;	chr12:123214056	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.51	rs1727322	ENSG00000235423.7	RP11-282O18.3	3.65	0.000297	0.0198	0.19	0.17	Neutrophil percentage of white cells;	chr12:123214973	chr12:123252030~123261483:-
THCA	cis	rs12476592	0.602	rs11125978	ENSG00000242412.1	DBIL5P2	3.65	0.000297	0.0198	0.21	0.17	Childhood ear infection;	chr2:63582468	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs10865339	ENSG00000242412.1	DBIL5P2	3.65	0.000297	0.0198	0.21	0.17	Childhood ear infection;	chr2:63584750	chr2:63117851~63119542:-
THCA	cis	rs3733585	0.806	rs7375599	ENSG00000261490.1	RP11-448G15.3	3.65	0.000297	0.0198	0.1	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9953294	chr4:10068089~10073019:-
THCA	cis	rs10496034	0.541	rs72911576	ENSG00000237887.1	AC092839.1	-3.65	0.000297	0.0198	-0.32	-0.17	Refractive astigmatism;	chr2:54695555	chr2:54529343~54529801:+
THCA	cis	rs3824488	0.92	rs28418339	ENSG00000271155.1	RP11-435O5.5	-3.65	0.000297	0.0198	-0.28	-0.17	Neuroticism;	chr9:95491194	chr9:95506235~95507636:+
THCA	cis	rs4908760	0.792	rs4908505	ENSG00000270282.1	RP5-1115A15.2	3.65	0.000297	0.0198	0.19	0.17	Vitiligo;	chr1:8668805	chr1:8512653~8513021:+
THCA	cis	rs9425766	0.679	rs7555067	ENSG00000270084.1	GAS5-AS1	-3.65	0.000297	0.0198	-0.17	-0.17	Life satisfaction;	chr1:174297504	chr1:173863248~173863941:+
THCA	cis	rs1376303	0.558	rs12533180	ENSG00000205763.12	RP9P	3.65	0.000297	0.0198	0.22	0.17	Intelligence (multi-trait analysis);	chr7:32904520	chr7:32916815~32943176:-
THCA	cis	rs1376303	0.558	rs41479949	ENSG00000205763.12	RP9P	-3.65	0.000297	0.0198	-0.22	-0.17	Intelligence (multi-trait analysis);	chr7:32906751	chr7:32916815~32943176:-
THCA	cis	rs34975555	0.803	rs3898982	ENSG00000253671.1	RP11-806O11.1	-3.65	0.000297	0.0198	-0.26	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:18003457	chr8:17808941~17820868:+
THCA	cis	rs755249	0.753	rs72663529	ENSG00000237624.1	OXCT2P1	3.65	0.000297	0.0198	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39514956~39516490:+
THCA	cis	rs8014204	0.816	rs11159107	ENSG00000279594.1	RP11-950C14.10	-3.65	0.000297	0.0198	-0.16	-0.17	Caffeine consumption;	chr14:74874563	chr14:75011269~75012851:-
THCA	cis	rs7179228	1	rs4777038	ENSG00000260657.2	RP11-315D16.4	-3.65	0.000297	0.0198	-0.23	-0.17	Systolic blood pressure;	chr15:68328835	chr15:68267792~68277994:-
THCA	cis	rs875971	0.522	rs7784623	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000297	0.0198	-0.14	-0.17	Aortic root size;	chr7:65930047	chr7:66848496~66858136:+
THCA	cis	rs2013441	0.866	rs8070401	ENSG00000261033.1	RP11-209D14.2	3.65	0.000297	0.0198	0.23	0.17	Obesity-related traits;	chr17:20311179	chr17:20008051~20009234:-
THCA	cis	rs72672639	0.749	rs930868	ENSG00000253878.4	RP11-347C18.3	-3.65	0.000297	0.0198	-0.26	-0.17	Carotid plaque burden;	chr8:94247788	chr8:94950037~94951396:+
THCA	cis	rs72672639	0.749	rs2623166	ENSG00000253878.4	RP11-347C18.3	-3.65	0.000297	0.0198	-0.26	-0.17	Carotid plaque burden;	chr8:94251045	chr8:94950037~94951396:+
THCA	cis	rs62289301	0.541	rs13132604	ENSG00000273133.1	RP11-799M12.2	3.65	0.000297	0.0198	0.21	0.17	Joint mobility (Beighton score);	chr4:15420921	chr4:15563698~15564253:-
THCA	cis	rs2039553	0.639	rs2248563	ENSG00000227354.5	RBM26-AS1	-3.65	0.000297	0.0198	-0.16	-0.17	Pancreatic cancer;	chr13:79744535	chr13:79406309~79424328:+
THCA	cis	rs17685	0.753	rs1574107	ENSG00000227038.2	AC005077.12	3.65	0.000297	0.0198	0.17	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76055729	chr7:76090431~76108779:-
THCA	cis	rs6573604	0.681	rs10131385	ENSG00000276116.2	FUT8-AS1	-3.65	0.000297	0.0198	-0.25	-0.17	N-glycan levels;	chr14:65306837	chr14:65411170~65412690:-
THCA	cis	rs712039	0.652	rs2946340	ENSG00000277501.1	RP11-697E22.2	3.64	0.000297	0.0198	0.24	0.17	Tuberculosis;	chr17:37392762	chr17:37642947~37684252:+
THCA	cis	rs9840812	0.725	rs3821445	ENSG00000239213.4	NCK1-AS1	-3.64	0.000297	0.0198	-0.18	-0.17	Fibrinogen levels;	chr3:136283967	chr3:136841726~136862054:-
THCA	cis	rs6137726	0.524	rs1007202	ENSG00000237396.1	LINC01384	3.64	0.000297	0.0198	0.16	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22608882	chr20:22587522~22607517:-
THCA	cis	rs6724465	1	rs7586856	ENSG00000272644.1	RP11-33O4.1	3.64	0.000297	0.0198	0.24	0.17	Height;	chr2:219103854	chr2:219069354~219069809:-
THCA	cis	rs786425	0.771	rs7135624	ENSG00000278112.1	RP11-972P1.11	3.64	0.000297	0.0198	0.16	0.17	Pubertal anthropometrics;	chr12:123663284	chr12:123519390~123519856:-
THCA	cis	rs1371614	0.632	rs10196501	ENSG00000229122.1	AGBL5-IT1	3.64	0.000297	0.0198	0.12	0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26924404	chr2:27061038~27061815:+
THCA	cis	rs758324	0.797	rs246998	ENSG00000237714.1	P4HA2-AS1	3.64	0.000297	0.0198	0.25	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132013185	chr5:132184876~132192808:+
THCA	cis	rs1864585	0.754	rs56043061	ENSG00000280294.1	RP11-177H2.1	3.64	0.000297	0.0198	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10921717	chr8:10856085~10859436:-
THCA	cis	rs875971	1	rs4717300	ENSG00000272831.1	RP11-792A8.4	3.64	0.000297	0.0198	0.1	0.17	Aortic root size;	chr7:66482393	chr7:66739829~66740385:-
THCA	cis	rs1971762	0.509	rs10783592	ENSG00000270175.1	RP11-793H13.11	-3.64	0.000297	0.0198	-0.11	-0.17	Height;	chr12:53643646	chr12:53500162~53500936:-
THCA	cis	rs61776719	0.738	rs7555461	ENSG00000252448.1	SNORA63	3.64	0.000297	0.0198	0.2	0.17	Coronary artery disease;	chr1:37979077	chr1:37884237~37884317:+
THCA	cis	rs7246657	0.722	rs2972458	ENSG00000226686.6	LINC01535	3.64	0.000297	0.0198	0.24	0.17	Coronary artery calcification;	chr19:37644502	chr19:37251912~37265535:+
THCA	cis	rs8030379	1	rs8041056	ENSG00000176700.18	SCAND2P	-3.64	0.000297	0.0198	-0.1	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896065	chr15:84631451~84647478:+
THCA	cis	rs7818688	0.614	rs11782617	ENSG00000253528.2	RP11-347C18.4	3.64	0.000297	0.0198	0.24	0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94862994	chr8:94974573~94974853:-
THCA	cis	rs4295623	0.789	rs12541318	ENSG00000270154.1	RP11-419I17.1	-3.64	0.000297	0.0198	-0.21	-0.17	Morning vs. evening chronotype;	chr8:11737461	chr8:12476462~12477122:+
THCA	cis	rs2721195	0.967	rs4925809	ENSG00000265393.1	CTD-2517M22.17	-3.64	0.000297	0.0198	-0.21	-0.17	Age at first birth;	chr8:144460930	chr8:144512567~144513672:+
THCA	cis	rs1125355	0.656	rs17809948	ENSG00000243792.1	OR7E89P	3.64	0.000297	0.0198	0.24	0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158776903	chr2:158853755~158854576:+
THCA	cis	rs78487399	0.908	rs7559723	ENSG00000234936.1	AC010883.5	3.64	0.000297	0.0198	0.21	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43604910	chr2:43229573~43233394:+
THCA	cis	rs409045	1	rs460836	ENSG00000271874.1	CTD-2024P10.2	-3.64	0.000297	0.0198	-0.22	-0.17	Left ventricular mass;	chr5:34634888	chr5:34651457~34651888:-
THCA	cis	rs10129255	0.957	rs12590799	ENSG00000280411.1	IGHV1-69-2	-3.64	0.000298	0.0198	-0.1	-0.17	Kawasaki disease;	chr14:106779713	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs10136781	ENSG00000280411.1	IGHV1-69-2	-3.64	0.000298	0.0198	-0.1	-0.17	Kawasaki disease;	chr14:106780451	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs8022165	ENSG00000280411.1	IGHV1-69-2	-3.64	0.000298	0.0198	-0.1	-0.17	Kawasaki disease;	chr14:106781682	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.917	rs8022493	ENSG00000280411.1	IGHV1-69-2	-3.64	0.000298	0.0198	-0.1	-0.17	Kawasaki disease;	chr14:106781820	chr14:106762092~106762588:-
THCA	cis	rs42648	0.935	rs42651	ENSG00000225498.1	AC002064.5	3.64	0.000298	0.0198	0.17	0.17	Homocysteine levels;	chr7:90349276	chr7:90312496~90322592:+
THCA	cis	rs3018712	0.532	rs2513294	ENSG00000212093.1	AP000807.1	-3.64	0.000298	0.0198	-0.22	-0.17	Total body bone mineral density;	chr11:68653726	chr11:68506083~68506166:-
THCA	cis	rs12701220	0.504	rs12702092	ENSG00000225146.1	AC073957.15	3.64	0.000298	0.0198	0.23	0.17	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1029025~1043891:+
THCA	cis	rs17685	0.753	rs1639609	ENSG00000227038.2	AC005077.12	3.64	0.000298	0.0198	0.16	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76054263	chr7:76090431~76108779:-
THCA	cis	rs1417770	0.931	rs778391	ENSG00000260971.3	RP11-504A18.1	3.64	0.000298	0.0198	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr1:56231381	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs778392	ENSG00000260971.3	RP11-504A18.1	3.64	0.000298	0.0198	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr1:56231573	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs801273	ENSG00000260971.3	RP11-504A18.1	3.64	0.000298	0.0198	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr1:56231648	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs778393	ENSG00000260971.3	RP11-504A18.1	3.64	0.000298	0.0198	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr1:56231744	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs778394	ENSG00000260971.3	RP11-504A18.1	3.64	0.000298	0.0198	0.16	0.17	Lobe attachment (rater-scored or self-reported);	chr1:56232623	chr1:56248294~56258571:-
THCA	cis	rs67478160	0.619	rs12897150	ENSG00000258534.1	CTD-2134A5.4	-3.64	0.000298	0.0198	-0.17	-0.17	Schizophrenia;	chr14:103853193	chr14:103854366~103880111:-
THCA	cis	rs1440410	0.798	rs1605581	ENSG00000250326.1	RP11-284M14.1	-3.64	0.000298	0.0198	-0.15	-0.17	Ischemic stroke;	chr4:143245634	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs1039763	ENSG00000250326.1	RP11-284M14.1	-3.64	0.000298	0.0198	-0.15	-0.17	Ischemic stroke;	chr4:143246860	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.763	rs1039762	ENSG00000250326.1	RP11-284M14.1	-3.64	0.000298	0.0198	-0.15	-0.17	Ischemic stroke;	chr4:143246893	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs10002867	ENSG00000250326.1	RP11-284M14.1	-3.64	0.000298	0.0198	-0.15	-0.17	Ischemic stroke;	chr4:143248497	chr4:142933195~143184861:-
THCA	cis	rs2243480	1	rs3885839	ENSG00000213640.3	EEF1DP4	3.64	0.000298	0.0198	0.3	0.17	Diabetic kidney disease;	chr7:65825416	chr7:64862999~64864370:+
THCA	cis	rs2243480	1	rs73142122	ENSG00000213640.3	EEF1DP4	3.64	0.000298	0.0198	0.3	0.17	Diabetic kidney disease;	chr7:65846311	chr7:64862999~64864370:+
THCA	cis	rs12915845	0.545	rs12907930	ENSG00000271997.1	RP11-97O12.6	3.64	0.000298	0.0198	0.11	0.17	Menarche (age at onset);	chr15:88540083	chr15:88501944~88505787:-
THCA	cis	rs7615952	0.736	rs11921945	ENSG00000272840.1	RP11-379B18.6	3.64	0.000298	0.0198	0.27	0.17	Blood pressure (smoking interaction);	chr3:125924876	chr3:125774714~125797953:+
THCA	cis	rs4578769	0.531	rs9957103	ENSG00000273232.1	RP11-370A5.2	3.64	0.000298	0.0198	0.23	0.17	Eosinophil percentage of white cells;	chr18:22870172	chr18:22882825~22883357:-
THCA	cis	rs7665090	1	rs5026472	ENSG00000248971.2	KRT8P46	-3.64	0.000298	0.0198	-0.19	-0.17	Primary biliary cholangitis;	chr4:102633616	chr4:102728746~102730171:-
THCA	cis	rs2832077	0.943	rs2832084	ENSG00000232855.5	AF131217.1	3.64	0.000298	0.0198	0.2	0.17	Cognitive test performance;	chr21:28782476	chr21:28439346~28674848:-
THCA	cis	rs12887734	0.546	rs66676135	ENSG00000269958.1	RP11-73M18.8	3.64	0.000298	0.0198	0.16	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103696353~103697163:+
THCA	cis	rs3087591	0.664	rs2525565	ENSG00000263535.1	AK4P1	3.64	0.000298	0.0198	0.2	0.17	Hip circumference;	chr17:31339570	chr17:31345521~31346187:+
THCA	cis	rs12148329	0.545	rs12591734	ENSG00000259594.4	CTD-2034I4.2	3.64	0.000298	0.0198	0.29	0.17	Immune response to smallpox vaccine (IL-6);	chr15:80734297	chr15:81554003~81696780:+
THCA	cis	rs2236521	0.659	rs73144993	ENSG00000226332.2	RP11-157P1.4	3.64	0.000298	0.0199	0.15	0.17	Pelvic organ prolapse;	chr20:62318402	chr20:62305432~62306325:-
THCA	cis	rs208520	1	rs12212063	ENSG00000233859.2	ADH5P4	3.64	0.000298	0.0199	0.25	0.17	Exhaled nitric oxide output;	chr6:66275255	chr6:65836930~65838039:-
THCA	cis	rs267567	0.626	rs267557	ENSG00000235257.7	ITGA9-AS1	3.64	0.000298	0.0199	0.14	0.17	PR interval;	chr3:37534420	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs267556	ENSG00000235257.7	ITGA9-AS1	3.64	0.000298	0.0199	0.14	0.17	PR interval;	chr3:37534648	chr3:37745432~37861780:-
THCA	cis	rs267567	0.587	rs267553	ENSG00000235257.7	ITGA9-AS1	3.64	0.000298	0.0199	0.14	0.17	PR interval;	chr3:37535558	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs267550	ENSG00000235257.7	ITGA9-AS1	3.64	0.000298	0.0199	0.14	0.17	PR interval;	chr3:37536082	chr3:37745432~37861780:-
THCA	cis	rs267567	0.587	rs267549	ENSG00000235257.7	ITGA9-AS1	3.64	0.000298	0.0199	0.14	0.17	PR interval;	chr3:37536144	chr3:37745432~37861780:-
THCA	cis	rs267567	0.647	rs267548	ENSG00000235257.7	ITGA9-AS1	3.64	0.000298	0.0199	0.14	0.17	PR interval;	chr3:37536185	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs267547	ENSG00000235257.7	ITGA9-AS1	3.64	0.000298	0.0199	0.14	0.17	PR interval;	chr3:37536196	chr3:37745432~37861780:-
THCA	cis	rs1923243	0.714	rs12731600	ENSG00000223479.3	RP4-788P17.1	3.64	0.000298	0.0199	0.18	0.17	Migraine;	chr1:73088005	chr1:73635216~73715214:+
THCA	cis	rs17685	0.753	rs2302435	ENSG00000227038.2	AC005077.12	-3.64	0.000298	0.0199	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76047669	chr7:76090431~76108779:-
THCA	cis	rs17685	0.725	rs2302436	ENSG00000227038.2	AC005077.12	-3.64	0.000298	0.0199	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76047670	chr7:76090431~76108779:-
THCA	cis	rs16975963	0.793	rs56672492	ENSG00000226686.6	LINC01535	-3.64	0.000298	0.0199	-0.22	-0.17	Longevity;	chr19:37957591	chr19:37251912~37265535:+
THCA	cis	rs73193808	0.614	rs2245023	ENSG00000231125.2	AF129075.5	-3.64	0.000298	0.0199	-0.16	-0.17	Coronary artery disease;	chr21:29174539	chr21:29058073~29060095:-
THCA	cis	rs9308731	0.591	rs7572367	ENSG00000227992.1	AC108463.2	-3.64	0.000298	0.0199	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111185394	chr2:111203964~111206215:-
THCA	cis	rs1153858	0.723	rs4580098	ENSG00000275672.1	GATM-AS1	-3.64	0.000298	0.0199	-0.17	-0.17	Homoarginine levels;	chr15:45304711	chr15:45378700~45380123:+
THCA	cis	rs17428076	0.793	rs3770449	ENSG00000228389.1	AC068039.4	-3.64	0.000298	0.0199	-0.19	-0.17	Myopia;	chr2:171835538	chr2:171773482~171775844:+
THCA	cis	rs4886920	0.775	rs8032021	ENSG00000260776.4	RP11-114H24.2	-3.64	0.000298	0.0199	-0.19	-0.17	Neuroticism;	chr15:77855194	chr15:77914217~77926846:-
THCA	cis	rs11233413	1	rs4944422	ENSG00000246067.6	RAB30-AS1	3.64	0.000298	0.0199	0.16	0.17	Economic and political preferences (feminism/equality);	chr11:83004440	chr11:83072066~83106719:+
THCA	cis	rs17122278	1	rs3741323	ENSG00000243431.1	RPL5P30	3.64	0.000298	0.0199	0.16	0.17	Total cholesterol levels;	chr11:118534926	chr11:118560690~118561580:+
THCA	cis	rs2562456	0.917	rs2650793	ENSG00000268278.1	RP11-420K14.1	-3.64	0.000298	0.0199	-0.2	-0.17	Pain;	chr19:21493313	chr19:21637974~21656300:+
THCA	cis	rs12476592	0.571	rs196125	ENSG00000242412.1	DBIL5P2	3.64	0.000298	0.0199	0.21	0.17	Childhood ear infection;	chr2:63632134	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs262504	ENSG00000242412.1	DBIL5P2	3.64	0.000298	0.0199	0.21	0.17	Childhood ear infection;	chr2:63634101	chr2:63117851~63119542:-
THCA	cis	rs929354	0.772	rs1182448	ENSG00000224629.1	RP5-1142J19.2	3.64	0.000298	0.0199	0.16	0.17	Body mass index;	chr7:157228721	chr7:157263022~157263229:-
THCA	cis	rs929354	0.707	rs1182445	ENSG00000224629.1	RP5-1142J19.2	3.64	0.000298	0.0199	0.16	0.17	Body mass index;	chr7:157231734	chr7:157263022~157263229:-
THCA	cis	rs11678825	0.789	rs10182093	ENSG00000272663.1	RP11-191L17.1	-3.64	0.000298	0.0199	-0.23	-0.17	Reticulocyte fraction of red cells;	chr2:48401171	chr2:48440043~48440597:-
THCA	cis	rs875971	0.545	rs6969224	ENSG00000273024.4	INTS4P2	-3.64	0.000298	0.0199	-0.21	-0.17	Aortic root size;	chr7:66370011	chr7:65647864~65715661:+
THCA	cis	rs16857609	1	rs16857611	ENSG00000233143.1	DIRC3-AS1	-3.64	0.000298	0.0199	-0.18	-0.17	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217432009	chr2:217282739~217336120:+
THCA	cis	rs12121840	0.68	rs79661923	ENSG00000237463.4	RP11-280O1.2	-3.64	0.000298	0.0199	-0.15	-0.17	Interleukin-1-receptor antagonist levels;	chr1:165565585	chr1:165476841~165582155:-
THCA	cis	rs12121840	0.79	rs56277222	ENSG00000237463.4	RP11-280O1.2	-3.64	0.000298	0.0199	-0.15	-0.17	Interleukin-1-receptor antagonist levels;	chr1:165567367	chr1:165476841~165582155:-
THCA	cis	rs11671005	0.779	rs55875034	ENSG00000252334.1	RNU6-1337P	3.64	0.000298	0.0199	0.25	0.17	Mean platelet volume;	chr19:58472191	chr19:58483749~58483843:-
THCA	cis	rs2880765	0.835	rs56406982	ENSG00000218052.5	ADAMTS7P4	-3.64	0.000298	0.0199	-0.19	-0.17	Coronary artery disease;	chr15:85493148	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.835	rs900573	ENSG00000218052.5	ADAMTS7P4	3.64	0.000298	0.0199	0.19	0.17	Coronary artery disease;	chr15:85494762	chr15:85255369~85330334:-
THCA	cis	rs4656958	0.93	rs7516660	ENSG00000233691.2	RP11-312J18.7	3.64	0.000298	0.0199	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160927867	chr1:160935537~160936126:+
THCA	cis	rs1150668	0.796	rs213237	ENSG00000220721.1	OR1F12	3.64	0.000298	0.0199	0.18	0.17	Pubertal anthropometrics;	chr6:28356161	chr6:28073316~28074233:+
THCA	cis	rs7117932	0.935	rs7943782	ENSG00000270160.1	RP11-264E20.2	3.64	0.000298	0.0199	0.2	0.17	Obesity-related traits;	chr11:128575375	chr11:128614340~128615236:-
THCA	cis	rs10186029	0.708	rs900368	ENSG00000270659.1	RP11-105N14.1	3.64	0.000298	0.0199	0.13	0.17	Systemic sclerosis;	chr2:213066548	chr2:213152970~213153659:+
THCA	cis	rs3218092	0.505	rs11753039	ENSG00000213435.3	ATP6V0CP3	3.64	0.000298	0.0199	0.28	0.17	Red cell distribution width;	chr6:41899212	chr6:42727234~42727700:+
THCA	cis	rs7264396	0.832	rs224381	ENSG00000261582.1	RP4-614O4.11	-3.64	0.000298	0.0199	-0.17	-0.17	Total cholesterol levels;	chr20:35509307	chr20:35267885~35280043:-
THCA	cis	rs7520050	0.966	rs1085243	ENSG00000280836.1	AL355480.1	3.64	0.000298	0.0199	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs1768803	ENSG00000280836.1	AL355480.1	3.64	0.000298	0.0199	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs1707333	ENSG00000280836.1	AL355480.1	3.64	0.000298	0.0199	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs4660910	ENSG00000280836.1	AL355480.1	3.64	0.000298	0.0199	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs785481	ENSG00000280836.1	AL355480.1	3.64	0.000298	0.0199	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6675726	ENSG00000280836.1	AL355480.1	3.64	0.000298	0.0199	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs785520	ENSG00000280836.1	AL355480.1	3.64	0.000298	0.0199	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45581219~45581321:-
THCA	cis	rs12188164	0.965	rs11739543	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000298	0.0199	0.17	0.17	Cystic fibrosis severity;	chr5:443561	chr5:473236~480884:+
THCA	cis	rs12188164	0.965	rs72717430	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000298	0.0199	0.17	0.17	Cystic fibrosis severity;	chr5:444387	chr5:473236~480884:+
THCA	cis	rs12188164	0.93	rs72717436	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000298	0.0199	0.17	0.17	Cystic fibrosis severity;	chr5:448176	chr5:473236~480884:+
THCA	cis	rs12188164	0.965	rs72717438	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000298	0.0199	0.17	0.17	Cystic fibrosis severity;	chr5:448548	chr5:473236~480884:+
THCA	cis	rs12188164	0.93	rs72717440	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000298	0.0199	0.17	0.17	Cystic fibrosis severity;	chr5:449586	chr5:473236~480884:+
THCA	cis	rs12188164	0.965	rs11743639	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000298	0.0199	0.17	0.17	Cystic fibrosis severity;	chr5:450595	chr5:473236~480884:+
THCA	cis	rs12188164	0.965	rs11745789	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000298	0.0199	0.17	0.17	Cystic fibrosis severity;	chr5:450662	chr5:473236~480884:+
THCA	cis	rs12188164	0.965	rs11744539	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000298	0.0199	0.17	0.17	Cystic fibrosis severity;	chr5:451310	chr5:473236~480884:+
THCA	cis	rs6747488	0.55	rs1272585	ENSG00000276334.1	AL133243.1	3.64	0.000298	0.0199	0.18	0.17	Interleukin-18 levels;	chr2:31875990	chr2:32521927~32523547:+
THCA	cis	rs6870983	0.584	rs10053933	ENSG00000247828.6	TMEM161B-AS1	3.64	0.000298	0.0199	0.14	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88145364	chr5:88268895~88436685:+
THCA	cis	rs8033133	0.958	rs6420956	ENSG00000257151.1	PWAR6	3.64	0.000299	0.0199	0.13	0.17	Blood osmolality (transformed sodium);	chr15:25064412	chr15:25031873~25036490:+
THCA	cis	rs7829975	0.509	rs7838674	ENSG00000254340.1	RP11-10A14.3	-3.64	0.000299	0.0199	-0.19	-0.17	Mood instability;	chr8:8939563	chr8:9141424~9145435:+
THCA	cis	rs6491750	1	rs76198387	ENSG00000276957.1	RP11-29B2.6	-3.64	0.000299	0.0199	-0.29	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103484275	chr13:102593338~102593873:-
THCA	cis	rs9309473	0.948	rs7603647	ENSG00000273245.1	RP11-434P11.2	3.64	0.000299	0.0199	0.23	0.17	Metabolite levels;	chr2:73590111	chr2:73750256~73750786:-
THCA	cis	rs7178909	0.872	rs2165070	ENSG00000259677.1	RP11-493E3.1	3.64	0.000299	0.0199	0.2	0.17	Common traits (Other);	chr15:89865744	chr15:89876540~89877285:+
THCA	cis	rs12368653	0.789	rs2270777	ENSG00000270039.1	RP11-571M6.17	3.64	0.000299	0.0199	0.18	0.17	Multiple sclerosis;	chr12:57751373	chr12:57803838~57804415:+
THCA	cis	rs1005277	0.522	rs289645	ENSG00000275858.1	RP11-291L22.8	3.64	0.000299	0.0199	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:38450738~38451069:-
THCA	cis	rs2274273	0.87	rs11625001	ENSG00000258469.1	CHMP4BP1	3.64	0.000299	0.0199	0.15	0.17	Protein biomarker;	chr14:55291442	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs67514154	ENSG00000258469.1	CHMP4BP1	3.64	0.000299	0.0199	0.15	0.17	Protein biomarker;	chr14:55300664	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.805	rs11628437	ENSG00000258469.1	CHMP4BP1	3.64	0.000299	0.0199	0.15	0.17	Protein biomarker;	chr14:55308750	chr14:55298644~55299231:+
THCA	cis	rs6430585	0.527	rs2278731	ENSG00000231890.6	DARS-AS1	-3.64	0.000299	0.0199	-0.19	-0.17	Corneal structure;	chr2:135638730	chr2:135985176~136022593:+
THCA	cis	rs7919656	0.662	rs1904604	ENSG00000228403.1	RP11-563N6.6	-3.64	0.000299	0.0199	-0.17	-0.17	Clinically amyopathic dermatomyositis;	chr10:48847171	chr10:48878022~48878649:+
THCA	cis	rs17181170	0.967	rs6770433	ENSG00000239572.1	RP11-451B8.1	-3.64	0.000299	0.0199	-0.19	-0.17	Prostate cancer;	chr3:87135161	chr3:87731402~87793629:-
THCA	cis	rs40363	0.645	rs1635392	ENSG00000261140.1	RP11-20I23.6	-3.64	0.000299	0.0199	-0.24	-0.17	Tuberculosis;	chr16:3467581	chr16:2569043~2571936:-
THCA	cis	rs668210	0.793	rs619701	ENSG00000214659.4	KRT8P26	-3.64	0.000299	0.0199	-0.19	-0.17	Cerebrospinal fluid biomarker levels;	chr11:66004609	chr11:65726939~65728214:+
THCA	cis	rs668210	0.793	rs1192184	ENSG00000214659.4	KRT8P26	-3.64	0.000299	0.0199	-0.19	-0.17	Cerebrospinal fluid biomarker levels;	chr11:66005911	chr11:65726939~65728214:+
THCA	cis	rs668210	0.793	rs590531	ENSG00000214659.4	KRT8P26	-3.64	0.000299	0.0199	-0.19	-0.17	Cerebrospinal fluid biomarker levels;	chr11:66006468	chr11:65726939~65728214:+
THCA	cis	rs6940638	0.956	rs3922717	ENSG00000224843.5	LINC00240	3.64	0.000299	0.0199	0.19	0.17	Intelligence (multi-trait analysis);	chr6:27063145	chr6:26956992~27023924:+
THCA	cis	rs6940638	0.956	rs13207365	ENSG00000224843.5	LINC00240	3.64	0.000299	0.0199	0.19	0.17	Intelligence (multi-trait analysis);	chr6:27063201	chr6:26956992~27023924:+
THCA	cis	rs6940638	0.956	rs12203454	ENSG00000224843.5	LINC00240	3.64	0.000299	0.0199	0.19	0.17	Intelligence (multi-trait analysis);	chr6:27063321	chr6:26956992~27023924:+
THCA	cis	rs10090774	0.965	rs11778798	ENSG00000280303.2	ERICD	3.64	0.000299	0.0199	0.16	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140908781	chr8:140636281~140638283:+
THCA	cis	rs763121	0.886	rs1013339	ENSG00000225450.1	RP3-508I15.14	-3.64	0.000299	0.0199	-0.12	-0.17	Menopause (age at onset);	chr22:38578675	chr22:38739003~38749041:+
THCA	cis	rs7819412	0.594	rs7460507	ENSG00000255310.2	AF131215.2	-3.64	0.000299	0.0199	-0.15	-0.17	Triglycerides;	chr8:11111565	chr8:11107788~11109726:-
THCA	cis	rs1005277	0.522	rs289643	ENSG00000275858.1	RP11-291L22.8	3.64	0.000299	0.0199	0.19	0.17	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38450738~38451069:-
THCA	cis	rs10029851	0.645	rs893036	ENSG00000234492.4	RPL34-AS1	-3.64	0.000299	0.0199	-0.16	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr4:108702194	chr4:108538190~108620460:-
THCA	cis	rs7809950	0.678	rs3801966	ENSG00000272072.1	CTA-363E19.2	3.64	0.000299	0.0199	0.18	0.17	Coronary artery disease;	chr7:107184135	chr7:107192559~107193300:-
THCA	cis	rs10457678	0.519	rs12207788	ENSG00000225415.2	RP3-509I19.1	-3.64	0.000299	0.0199	-0.23	-0.17	Colorectal or endometrial cancer;	chr6:138836177	chr6:138822747~138823799:+
THCA	cis	rs7873102	0.654	rs7043495	ENSG00000213839.4	TMX2P1	-3.64	0.000299	0.0199	-0.13	-0.17	Brain structure;	chr9:37961925	chr9:37885683~37886390:+
THCA	cis	rs7216064	0.861	rs62084252	ENSG00000278740.1	RP11-147L13.14	3.64	0.000299	0.0199	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883462	chr17:68188547~68189165:+
THCA	cis	rs78487399	0.808	rs998768	ENSG00000234936.1	AC010883.5	3.64	0.000299	0.0199	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43484384	chr2:43229573~43233394:+
THCA	cis	rs7620503	0.571	rs6443468	ENSG00000228561.2	RP11-114M1.1	3.64	0.000299	0.0199	0.2	0.17	Corneal structure;	chr3:177565231	chr3:177683627~177691250:+
THCA	cis	rs2880765	0.835	rs4842887	ENSG00000218052.5	ADAMTS7P4	-3.64	0.000299	0.0199	-0.19	-0.17	Coronary artery disease;	chr15:85492579	chr15:85255369~85330334:-
THCA	cis	rs11634944	0.508	rs10451029	ENSG00000251896.1	SNORD116-27	-3.64	0.000299	0.0199	-0.18	-0.17	Interleukin-8 levels;	chr15:24992196	chr15:25101575~25101666:+
THCA	cis	rs61008539	0.815	rs6960062	ENSG00000273151.1	RP11-449P15.2	-3.64	0.000299	0.0199	-0.11	-0.17	Perceived unattractiveness to mosquitoes;	chr7:845028	chr7:879790~886547:-
THCA	cis	rs7572733	0.555	rs6745726	ENSG00000231621.1	AC013264.2	-3.64	0.000299	0.0199	-0.18	-0.17	Dermatomyositis;	chr2:198069356	chr2:197197991~197199273:+
THCA	cis	rs700651	0.624	rs12105927	ENSG00000231621.1	AC013264.2	-3.64	0.000299	0.0199	-0.18	-0.17	Intracranial aneurysm;	chr2:198072534	chr2:197197991~197199273:+
THCA	cis	rs2652822	0.525	rs12148434	ENSG00000259459.4	RP11-321G12.1	-3.64	0.000299	0.0199	-0.13	-0.17	Metabolic traits;	chr15:63217915	chr15:63390136~63438320:+
THCA	cis	rs4747241	0.556	rs4433500	ENSG00000272627.1	RP11-354E23.5	3.64	0.000299	0.0199	0.23	0.17	Heschl's gyrus morphology;	chr10:72309240	chr10:72766560~72767052:+
THCA	cis	rs3800688	0.623	rs1684172	ENSG00000236753.4	MKLN1-AS	3.64	0.000299	0.0199	0.16	0.17	Hypertension;	chr7:131471005	chr7:131309744~131328222:-
THCA	cis	rs972578	0.837	rs4820497	ENSG00000274717.1	RP1-47A17.1	-3.64	0.000299	0.0199	-0.17	-0.17	Mean platelet volume;	chr22:42929768	chr22:42791814~42794313:-
THCA	cis	rs683250	0.629	rs612008	ENSG00000254551.1	RP11-727A23.7	3.64	0.000299	0.0199	0.2	0.17	Subcortical brain region volumes;	chr11:83232441	chr11:83209431~83213379:-
THCA	cis	rs683250	0.629	rs613790	ENSG00000254551.1	RP11-727A23.7	3.64	0.000299	0.0199	0.2	0.17	Subcortical brain region volumes;	chr11:83232853	chr11:83209431~83213379:-
THCA	cis	rs683250	0.629	rs588016	ENSG00000254551.1	RP11-727A23.7	3.64	0.000299	0.0199	0.2	0.17	Subcortical brain region volumes;	chr11:83236701	chr11:83209431~83213379:-
THCA	cis	rs683250	0.629	rs628223	ENSG00000254551.1	RP11-727A23.7	-3.64	0.000299	0.0199	-0.2	-0.17	Subcortical brain region volumes;	chr11:83257122	chr11:83209431~83213379:-
THCA	cis	rs12476592	0.602	rs2292793	ENSG00000242412.1	DBIL5P2	3.64	0.000299	0.0199	0.22	0.17	Childhood ear infection;	chr2:63434146	chr2:63117851~63119542:-
THCA	cis	rs9796	0.87	rs3900905	ENSG00000247556.5	OIP5-AS1	-3.64	0.000299	0.0199	-0.13	-0.17	Menopause (age at onset);	chr15:40968603	chr15:41283990~41309737:+
THCA	cis	rs17092148	0.636	rs7273470	ENSG00000269202.1	RP4-614O4.12	-3.64	0.000299	0.0199	-0.17	-0.17	Neuroticism;	chr20:34869118	chr20:35201747~35203288:-
THCA	cis	rs17092148	0.579	rs7265109	ENSG00000269202.1	RP4-614O4.12	-3.64	0.000299	0.0199	-0.17	-0.17	Neuroticism;	chr20:34871551	chr20:35201747~35203288:-
THCA	cis	rs17092148	0.636	rs11697978	ENSG00000269202.1	RP4-614O4.12	-3.64	0.000299	0.0199	-0.17	-0.17	Neuroticism;	chr20:34872563	chr20:35201747~35203288:-
THCA	cis	rs11992162	0.636	rs11250182	ENSG00000227888.4	FAM66A	-3.64	0.000299	0.0199	-0.21	-0.17	Monocyte count;	chr8:11950067	chr8:12362019~12388296:+
THCA	cis	rs4262150	0.672	rs72797254	ENSG00000253921.1	CTB-113P19.3	3.64	0.000299	0.0199	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152632947	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.774	rs56014830	ENSG00000253921.1	CTB-113P19.3	3.64	0.000299	0.0199	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152648644	chr5:151753992~151767247:+
THCA	cis	rs11971779	0.793	rs4732366	ENSG00000252332.1	RNU6-911P	-3.64	0.000299	0.0199	-0.19	-0.17	Diisocyanate-induced asthma;	chr7:139343099	chr7:139448740~139448843:+
THCA	cis	rs4879656	0.897	rs1537042	ENSG00000225693.1	LAGE3P1	-3.64	0.000299	0.0199	-0.18	-0.17	Menopause (age at onset);	chr9:33045278	chr9:33019682~33020165:-
THCA	cis	rs962856	0.619	rs4671181	ENSG00000236780.4	AC078941.1	3.64	0.000299	0.0199	0.22	0.17	Pancreatic cancer;	chr2:67377715	chr2:67123357~67215319:-
THCA	cis	rs8031584	0.541	rs2959037	ENSG00000178081.11	ULK4P3	-3.64	0.000299	0.0199	-0.21	-0.17	Huntington's disease progression;	chr15:30925961	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.505	rs2959036	ENSG00000178081.11	ULK4P3	-3.64	0.000299	0.0199	-0.21	-0.17	Huntington's disease progression;	chr15:30927539	chr15:30103720~30131757:+
THCA	cis	rs8031584	0.541	rs2955777	ENSG00000178081.11	ULK4P3	-3.64	0.000299	0.0199	-0.21	-0.17	Huntington's disease progression;	chr15:30927585	chr15:30103720~30131757:+
THCA	cis	rs7520050	0.966	rs61102033	ENSG00000280836.1	AL355480.1	3.64	3e-04	0.0199	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45581219~45581321:-
THCA	cis	rs62289301	0.614	rs13123785	ENSG00000273133.1	RP11-799M12.2	3.64	3e-04	0.0199	0.21	0.17	Joint mobility (Beighton score);	chr4:15429405	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.592	rs13129124	ENSG00000273133.1	RP11-799M12.2	3.64	3e-04	0.0199	0.21	0.17	Joint mobility (Beighton score);	chr4:15430193	chr4:15563698~15564253:-
THCA	cis	rs1062177	1	rs62377945	ENSG00000272112.1	CTB-113P19.5	3.64	3e-04	0.0199	0.14	0.17	Preschool internalizing problems;	chr5:151828443	chr5:151724831~151725356:-
THCA	cis	rs7903847	0.642	rs7074511	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97380420	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs7092350	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97380461	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs7078004	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97380754	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.667	rs7096801	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97381212	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs2275089	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97381448	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs11189177	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97381906	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10882913	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97382088	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10882914	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97382300	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10882915	ENSG00000225850.3	RP11-452K12.4	3.64	3e-04	0.0199	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97382427	chr10:97334564~97343203:+
THCA	cis	rs17685	0.753	rs8200	ENSG00000227038.2	AC005077.12	-3.64	3e-04	0.0199	-0.16	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76067288	chr7:76090431~76108779:-
THCA	cis	rs3758911	0.861	rs10890688	ENSG00000255353.1	RP11-382M14.1	-3.64	3e-04	0.0199	-0.21	-0.17	Coronary artery disease;	chr11:107272020	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs1388170	ENSG00000255353.1	RP11-382M14.1	-3.64	3e-04	0.0199	-0.21	-0.17	Coronary artery disease;	chr11:107272130	chr11:107176286~107177530:+
THCA	cis	rs9894429	0.604	rs9912071	ENSG00000262049.1	RP13-1032I1.7	3.64	3e-04	0.0199	0.1	0.17	Eye color traits;	chr17:81642628	chr17:81701324~81703300:-
THCA	cis	rs4705962	0.876	rs6897429	ENSG00000230612.2	AC004237.1	3.64	3e-04	0.0199	0.21	0.17	Atopic dermatitis;	chr5:132687571	chr5:132688681~132723725:+
THCA	cis	rs4705962	0.918	rs2406539	ENSG00000230612.2	AC004237.1	3.64	3e-04	0.0199	0.21	0.17	Atopic dermatitis;	chr5:132687584	chr5:132688681~132723725:+
THCA	cis	rs9402682	0.629	rs9483789	ENSG00000232876.1	CTA-212D2.2	-3.64	3e-04	0.0199	-0.22	-0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135120027	chr6:135055033~135060550:+
THCA	cis	rs9693857	0.52	rs10107887	ENSG00000248538.5	RP11-10A14.5	-3.64	3e-04	0.0199	-0.22	-0.17	Systolic blood pressure;	chr8:9507154	chr8:9189011~9202854:+
THCA	cis	rs3733589	0.59	rs35201034	ENSG00000250413.1	RP11-448G15.1	3.64	3e-04	0.0199	0.28	0.17	Renal overload gout;	chr4:10005827	chr4:10006482~10009725:+
THCA	cis	rs2434529	0.876	rs721868	ENSG00000245275.6	SAP30L-AS1	3.64	3e-04	0.02	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr5:154228166	chr5:154329437~154445850:-
THCA	cis	rs964611	0.882	rs10163162	ENSG00000259488.2	RP11-154J22.1	-3.64	3e-04	0.02	-0.14	-0.17	Metabolite levels (Pyroglutamine);	chr15:48266334	chr15:48312353~48331856:-
THCA	cis	rs6500395	0.588	rs2354580	ENSG00000260052.1	CTC-527H23.3	3.64	3e-04	0.02	0.2	0.17	Response to tocilizumab in rheumatoid arthritis;	chr16:48603267	chr16:48637143~48638719:+
THCA	cis	rs2243480	1	rs2243480	ENSG00000164669.11	INTS4P1	3.64	3e-04	0.02	0.32	0.17	Diabetic kidney disease;	chr7:66134209	chr7:65141225~65234216:+
THCA	cis	rs793571	0.822	rs11637077	ENSG00000245975.2	RP11-30K9.6	3.64	3e-04	0.02	0.19	0.17	Schizophrenia;	chr15:58906197	chr15:58768072~58770974:-
THCA	cis	rs5758511	0.68	rs5751243	ENSG00000270083.1	RP1-257I20.14	-3.64	3e-04	0.02	-0.21	-0.17	Birth weight;	chr22:42221171	chr22:42089630~42090028:-
THCA	cis	rs489332	0.553	rs530785	ENSG00000234618.1	RPSAP9	-3.64	3e-04	0.02	-0.18	-0.17	Schizophrenia;	chr9:75413087	chr9:76398699~76399586:+
THCA	cis	rs7520050	0.898	rs4660885	ENSG00000227857.2	RP4-533D7.5	3.64	3e-04	0.02	0.15	0.17	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:46134531~46139081:+
THCA	cis	rs7259376	0.807	rs6511348	ENSG00000270947.1	AC025811.3	3.64	3e-04	0.02	0.18	0.17	Menopause (age at onset);	chr19:22374572	chr19:22455988~22456459:+
THCA	cis	rs11098499	0.863	rs17050695	ENSG00000249244.1	RP11-548H18.2	3.64	3e-04	0.02	0.19	0.17	Corneal astigmatism;	chr4:119568372	chr4:119391831~119395335:-
THCA	cis	rs944289	0.74	rs1467794	ENSG00000257520.1	RP11-896J10.3	-3.64	3e-04	0.02	-0.16	-0.17	Thyroid cancer;	chr14:36097617	chr14:36473207~36519521:-
THCA	cis	rs4604234	0.901	rs59779073	ENSG00000260645.1	RP11-250B2.5	-3.64	3e-04	0.02	-0.31	-0.17	Cancer;	chr6:80394880	chr6:80466958~80469080:+
THCA	cis	rs40363	0.645	rs1690450	ENSG00000261140.1	RP11-20I23.6	-3.64	3e-04	0.02	-0.23	-0.17	Tuberculosis;	chr16:3471051	chr16:2569043~2571936:-
THCA	cis	rs7647973	0.848	rs4955411	ENSG00000229759.1	MRPS18AP1	3.64	3e-04	0.02	0.25	0.17	Menarche (age at onset);	chr3:49107871	chr3:48256350~48256938:-
THCA	cis	rs7647973	0.848	rs4292260	ENSG00000229759.1	MRPS18AP1	3.64	3e-04	0.02	0.25	0.17	Menarche (age at onset);	chr3:49111457	chr3:48256350~48256938:-
THCA	cis	rs76878669	0.561	rs11823140	ENSG00000255320.1	RP11-755F10.1	3.64	3e-04	0.02	0.21	0.17	Educational attainment (years of education);	chr11:66330851	chr11:66244840~66246239:-
THCA	cis	rs9457247	0.602	rs2157388	ENSG00000235272.1	FAM103A2P	3.64	3e-04	0.02	0.23	0.17	Crohn's disease;	chr6:167068424	chr6:166586124~166586477:-
THCA	cis	rs7296418	0.754	rs1619283	ENSG00000256092.2	RP13-942N8.1	3.64	3e-04	0.02	0.12	0.17	Platelet count;	chr12:123232815	chr12:123363868~123366113:+
THCA	cis	rs9860428	0.844	rs13063847	ENSG00000243795.1	RP11-572M11.3	3.64	3e-04	0.02	0.2	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112850701	chr3:113142350~113167819:-
THCA	cis	rs6498068	0.594	rs1875928	ENSG00000260468.1	LINC01290	-3.64	3e-04	0.02	-0.21	-0.17	Metabolite levels (MHPG);	chr16:10528028	chr16:10514842~10528202:-
THCA	cis	rs11638352	1	rs4923976	ENSG00000166763.7	STRCP1	-3.64	3e-04	0.02	-0.33	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44148560	chr15:43699488~43718184:-
THCA	cis	rs11638352	0.661	rs2706495	ENSG00000166763.7	STRCP1	-3.64	3e-04	0.02	-0.33	-0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44153410	chr15:43699488~43718184:-
THCA	cis	rs7307902	1	rs10875660	ENSG00000280054.1	RP1-197B17.7	-3.64	3e-04	0.02	-0.19	-0.17	Obesity-related traits;	chr12:47540248	chr12:47728151~47730598:-
THCA	cis	rs459571	0.635	rs379471	ENSG00000235106.7	LINC00094	3.64	3e-04	0.02	0.15	0.17	Platelet distribution width;	chr9:134025527	chr9:134025439~134034666:+
THCA	cis	rs17253792	0.822	rs58589065	ENSG00000186615.9	KTN1-AS1	-3.64	3e-04	0.02	-0.27	-0.17	Putamen volume;	chr14:55685760	chr14:55499278~55580110:-
THCA	cis	rs12544026	0.581	rs1148499	ENSG00000253669.3	KB-1732A1.1	3.64	3e-04	0.02	0.19	0.17	Major depression and alcohol dependence;	chr8:101846549	chr8:102805517~102809971:+
THCA	cis	rs7656342	0.866	rs6841397	ENSG00000242034.1	RP11-1396O13.1	3.64	3e-04	0.02	0.19	0.17	Gut microbiota (bacterial taxa);	chr4:9813778	chr4:9553614~9553985:-
THCA	cis	rs13113518	0.812	rs12649507	ENSG00000223305.1	RN7SKP30	-3.64	3e-04	0.02	-0.21	-0.17	Height;	chr4:55514317	chr4:55540502~55540835:-
THCA	cis	rs7246967	0.611	rs62118770	ENSG00000236312.3	RPL34P34	-3.64	3e-04	0.02	-0.23	-0.17	Bronchopulmonary dysplasia;	chr19:22641227	chr19:22368599~22368952:-
THCA	cis	rs7246967	0.611	rs62118771	ENSG00000236312.3	RPL34P34	-3.64	3e-04	0.02	-0.23	-0.17	Bronchopulmonary dysplasia;	chr19:22641496	chr19:22368599~22368952:-
THCA	cis	rs4648045	0.621	rs10013613	ENSG00000246560.2	RP11-10L12.4	3.64	3e-04	0.02	0.2	0.17	Lymphocyte percentage of white cells;	chr4:102502336	chr4:102828055~102844075:+
THCA	cis	rs2749592	0.531	rs994804	ENSG00000120555.12	SEPT7P9	-3.64	3e-04	0.02	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38383069~38402916:-
THCA	cis	rs7616559	0.606	rs9859727	ENSG00000244515.1	KRT18P34	-3.64	3e-04	0.02	-0.19	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157016189	chr3:157162663~157163932:-
THCA	cis	rs12999542	0.5	rs1362347	ENSG00000234389.1	AC007278.3	3.64	3e-04	0.02	0.26	0.17	Serum protein levels (sST2);	chr2:102303125	chr2:102438713~102440475:+
THCA	cis	rs5758511	0.68	rs5758699	ENSG00000230107.1	CTA-126B4.7	-3.64	3e-04	0.02	-0.19	-0.17	Birth weight;	chr22:42292028	chr22:42438023~42446195:+
THCA	cis	rs7656342	0.651	rs11942665	ENSG00000242034.1	RP11-1396O13.1	3.64	3e-04	0.02	0.19	0.17	Gut microbiota (bacterial taxa);	chr4:9741228	chr4:9553614~9553985:-
THCA	cis	rs1580019	0.587	rs2392069	ENSG00000273014.1	RP11-225B17.2	3.64	3e-04	0.02	0.17	0.17	Cognitive ability;	chr7:32507542	chr7:32758882~32759353:+
THCA	cis	rs1580019	0.587	rs34488151	ENSG00000273014.1	RP11-225B17.2	3.64	3e-04	0.02	0.17	0.17	Cognitive ability;	chr7:32508534	chr7:32758882~32759353:+
THCA	cis	rs7542375	0.52	rs12141189	ENSG00000272823.1	RP11-295M18.6	-3.64	3e-04	0.02	-0.23	-0.17	Obesity-related traits;	chr1:220880203	chr1:220828676~220829211:-
THCA	cis	rs459571	0.959	rs378740	ENSG00000235106.7	LINC00094	3.64	3e-04	0.02	0.15	0.17	Platelet distribution width;	chr9:134025754	chr9:134025439~134034666:+
THCA	cis	rs6940638	0.662	rs6915678	ENSG00000219392.1	RP1-265C24.5	-3.64	0.000301	0.02	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:27268087	chr6:28115628~28116551:+
THCA	cis	rs7178909	0.902	rs3784386	ENSG00000259677.1	RP11-493E3.1	3.64	0.000301	0.02	0.2	0.17	Common traits (Other);	chr15:89894194	chr15:89876540~89877285:+
THCA	cis	rs6449502	0.92	rs162232	ENSG00000251279.1	CTC-436P18.1	3.64	0.000301	0.02	0.26	0.17	Mean platelet volume;	chr5:61012220	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.92	rs162231	ENSG00000251279.1	CTC-436P18.1	-3.64	0.000301	0.02	-0.26	-0.17	Mean platelet volume;	chr5:61012137	chr5:61162070~61232040:+
THCA	cis	rs9487094	0.666	rs1074765	ENSG00000223537.2	RP5-919F19.5	3.64	0.000301	0.02	0.17	0.17	Height;	chr6:109360458	chr6:109487906~109506800:+
THCA	cis	rs7824557	0.872	rs2572417	ENSG00000269918.1	AF131215.9	-3.64	0.000301	0.02	-0.17	-0.17	Retinal vascular caliber;	chr8:11253953	chr8:11104691~11106704:-
THCA	cis	rs28510890	0.547	rs35070516	ENSG00000258647.4	LINC00930	-3.64	0.000301	0.02	-0.23	-0.17	Lung cancer in ever smokers;	chr15:92607968	chr15:92567818~92572042:-
THCA	cis	rs5753037	0.869	rs5763645	ENSG00000279699.1	RP1-102K2.9	3.64	0.000301	0.02	0.16	0.17	Type 1 diabetes;	chr22:29961812	chr22:30275215~30276951:-
THCA	cis	rs7246967	0.611	rs7246424	ENSG00000198153.8	ZNF849P	-3.64	0.000301	0.02	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22699383	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs7249685	ENSG00000198153.8	ZNF849P	-3.64	0.000301	0.02	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22699577	chr19:22685167~22686732:+
THCA	cis	rs17772222	0.511	rs12880017	ENSG00000222990.1	RNU4-22P	3.64	0.000301	0.02	0.2	0.17	Coronary artery calcification;	chr14:88840228	chr14:88513498~88513663:+
THCA	cis	rs6957923	0.934	rs9969137	ENSG00000234286.1	AC006026.13	-3.64	0.000301	0.02	-0.22	-0.17	Height;	chr7:23438669	chr7:23680195~23680786:-
THCA	cis	rs3740713	0.669	rs2896526	ENSG00000256588.1	RP11-613F22.8	3.64	0.000301	0.02	0.25	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr11:18507608~18508820:-
THCA	cis	rs12549025	0.891	rs12543956	ENSG00000253390.1	CTC-756D1.2	-3.64	0.000301	0.02	-0.28	-0.17	Reticulocyte fraction of red cells;	chr8:23550523	chr8:23458601~23484971:+
THCA	cis	rs8099594	0.565	rs1942999	ENSG00000266696.1	RP11-30L3.2	3.64	0.000301	0.02	0.2	0.17	Height;	chr18:49186458	chr18:49205912~49208781:+
THCA	cis	rs7927592	0.956	rs12281742	ENSG00000160172.9	FAM86C2P	-3.64	0.000301	0.02	-0.16	-0.17	Total body bone mineral density;	chr11:68536161	chr11:67791648~67805336:-
THCA	cis	rs7945705	0.905	rs7947631	ENSG00000254860.4	TMEM9B-AS1	3.64	0.000301	0.02	0.18	0.17	Hemoglobin concentration;	chr11:8823362	chr11:8964675~8977527:+
THCA	cis	rs1864585	0.806	rs73196838	ENSG00000280294.1	RP11-177H2.1	3.64	0.000301	0.02	0.18	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10923810	chr8:10856085~10859436:-
THCA	cis	rs9868809	0.772	rs34096717	ENSG00000270441.1	RP11-694I15.7	3.64	0.000301	0.02	0.22	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48682020	chr3:49140086~49160851:-
THCA	cis	rs12681366	0.708	rs2450554	ENSG00000261437.1	RP11-22C11.2	3.64	0.000301	0.02	0.15	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94331552	chr8:94637285~94639467:-
THCA	cis	rs11671005	0.735	rs34873624	ENSG00000269600.1	AC016629.3	-3.64	0.000301	0.02	-0.24	-0.17	Mean platelet volume;	chr19:58432035	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.693	rs34230465	ENSG00000269600.1	AC016629.3	-3.64	0.000301	0.02	-0.24	-0.17	Mean platelet volume;	chr19:58432209	chr19:58593896~58599355:-
THCA	cis	rs7665090	1	rs2866409	ENSG00000251288.2	RP11-10L12.2	-3.64	0.000301	0.02	-0.21	-0.17	Primary biliary cholangitis;	chr4:102633104	chr4:102751401~102752641:+
THCA	cis	rs13034020	0.895	rs35083477	ENSG00000271889.1	RP11-493E12.1	-3.64	0.000301	0.02	-0.22	-0.17	Hodgkin's lymphoma;	chr2:60813747	chr2:61151433~61162105:-
THCA	cis	rs10090774	0.687	rs11774679	ENSG00000280303.2	ERICD	-3.64	0.000301	0.02	-0.15	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140907557	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11167007	ENSG00000280303.2	ERICD	-3.64	0.000301	0.02	-0.15	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140908082	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13264974	ENSG00000280303.2	ERICD	-3.64	0.000301	0.02	-0.15	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140908621	chr8:140636281~140638283:+
THCA	cis	rs838886	0.956	rs838878	ENSG00000275389.1	RP11-214K3.24	-3.64	0.000301	0.02	-0.23	-0.17	HDL cholesterol;	chr12:124776099	chr12:124085761~124088598:+
THCA	cis	rs7243790	1	rs17558111	ENSG00000277324.1	RP11-850A17.1	-3.64	0.000301	0.02	-0.17	-0.17	Diastolic blood pressure;	chr18:54437583	chr18:54268346~54270028:-
THCA	cis	rs2179367	0.543	rs9498328	ENSG00000216906.2	RP11-350J20.9	3.64	0.000301	0.02	0.21	0.17	Dupuytren's disease;	chr6:149348715	chr6:149904243~149906418:+
THCA	cis	rs6840360	0.615	rs7695412	ENSG00000251611.1	RP11-610P16.1	-3.64	0.000301	0.02	-0.13	-0.17	Intelligence (multi-trait analysis);	chr4:151566923	chr4:151407551~151408835:-
THCA	cis	rs9923856	0.571	rs13330041	ENSG00000263033.2	RP11-396B14.2	-3.64	0.000301	0.02	-0.16	-0.17	Atopic dermatitis;Adult asthma;	chr16:10994951	chr16:11196177~11224969:+
THCA	cis	rs740160	0.681	rs11980995	ENSG00000244219.5	GS1-259H13.2	-3.64	0.000301	0.02	-0.31	-0.17	Dehydroepiandrosterone sulphate levels;	chr7:99375656	chr7:99598066~99610813:+
THCA	cis	rs6847067	0.672	rs1838038	ENSG00000180769.7	WDFY3-AS2	3.64	0.000301	0.02	0.13	0.17	Oropharynx cancer;	chr4:84649211	chr4:84965682~85011277:+
THCA	cis	rs16975963	0.644	rs11083427	ENSG00000276846.1	CTD-3220F14.3	-3.64	0.000301	0.02	-0.15	-0.17	Longevity;	chr19:37583251	chr19:37314868~37315620:-
THCA	cis	rs12893668	0.581	rs34843146	ENSG00000244691.1	RPL10AP1	-3.64	0.000301	0.02	-0.23	-0.17	Reticulocyte count;	chr14:103613527	chr14:103412119~103412761:-
THCA	cis	rs4792901	0.765	rs9892162	ENSG00000267151.3	RP11-100E5.2	3.64	0.000301	0.02	0.18	0.17	Dupuytren's disease;	chr17:43523432	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.694	rs9907819	ENSG00000267151.3	RP11-100E5.2	3.64	0.000301	0.02	0.18	0.17	Dupuytren's disease;	chr17:43525497	chr17:43444707~43451200:+
THCA	cis	rs4792901	0.802	rs9908559	ENSG00000267151.3	RP11-100E5.2	3.64	0.000301	0.02	0.18	0.17	Dupuytren's disease;	chr17:43525793	chr17:43444707~43451200:+
THCA	cis	rs8023401	0.507	rs9652450	ENSG00000259705.1	RP11-227D13.1	-3.64	0.000301	0.02	-0.2	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48500247	chr15:48645951~48652016:+
THCA	cis	rs11881751	0.868	rs117864137	ENSG00000267011.4	CTB-50L17.16	3.64	0.000301	0.02	0.25	0.17	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr19:4983293	chr19:4457962~4471493:-
THCA	cis	rs6030712	0.723	rs6130139	ENSG00000213979.3	RPL7AP14	-3.64	0.000301	0.02	-0.27	-0.17	Height;	chr20:36933066	chr20:37444733~37445534:-
THCA	cis	rs267567	0.774	rs60354613	ENSG00000235257.7	ITGA9-AS1	3.64	0.000301	0.02	0.14	0.17	PR interval;	chr3:37532635	chr3:37745432~37861780:-
THCA	cis	rs7707921	1	rs6884232	ENSG00000251374.1	RPS23P5	-3.64	0.000301	0.02	-0.24	-0.17	Breast cancer;	chr5:82254224	chr5:82265157~82265259:-
THCA	cis	rs7903847	0.642	rs11189191	ENSG00000225850.3	RP11-452K12.4	3.64	0.000301	0.02	0.17	0.17	Granulocyte percentage of myeloid white cells;	chr10:97389039	chr10:97334564~97343203:+
THCA	cis	rs12478296	0.591	rs4973646	ENSG00000220804.7	AC093642.5	-3.64	0.000301	0.02	-0.16	-0.17	Obesity-related traits;	chr2:242059222	chr2:242088633~242160153:+
THCA	cis	rs6840360	1	rs10019048	ENSG00000270265.1	RP11-731D1.4	-3.64	0.000301	0.02	-0.15	-0.17	Intelligence (multi-trait analysis);	chr4:151682463	chr4:151333775~151353224:-
THCA	cis	rs8040855	0.597	rs12902942	ENSG00000225151.9	GOLGA2P7	-3.64	0.000301	0.02	-0.24	-0.17	Bulimia nervosa;	chr15:85041573	chr15:84199311~84230136:-
THCA	cis	rs12148329	0.545	rs12916634	ENSG00000259594.4	CTD-2034I4.2	3.64	0.000301	0.02	0.29	0.17	Immune response to smallpox vaccine (IL-6);	chr15:80732790	chr15:81554003~81696780:+
THCA	cis	rs11671005	0.735	rs11670871	ENSG00000269600.1	AC016629.3	3.64	0.000301	0.02	0.24	0.17	Mean platelet volume;	chr19:58429147	chr19:58593896~58599355:-
THCA	cis	rs73198271	0.74	rs11781430	ENSG00000254153.1	CTA-398F10.2	3.64	0.000302	0.0201	0.2	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8456909~8461337:-
THCA	cis	rs2638953	0.853	rs10843185	ENSG00000247934.4	RP11-967K21.1	-3.64	0.000302	0.0201	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473778	chr12:28163298~28190738:-
THCA	cis	rs720064	0.586	rs2288592	ENSG00000264745.1	TTC39C-AS1	3.64	0.000302	0.0201	0.18	0.17	Strep throat;	chr18:23946123	chr18:23994213~24015339:-
THCA	cis	rs4578769	0.765	rs72882147	ENSG00000265939.1	UBE2CP2	-3.64	0.000302	0.0201	-0.21	-0.17	Eosinophil percentage of white cells;	chr18:22816590	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs35151054	ENSG00000265939.1	UBE2CP2	-3.64	0.000302	0.0201	-0.21	-0.17	Eosinophil percentage of white cells;	chr18:22818375	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs72882153	ENSG00000265939.1	UBE2CP2	-3.64	0.000302	0.0201	-0.21	-0.17	Eosinophil percentage of white cells;	chr18:22823275	chr18:22900486~22900995:-
THCA	cis	rs9987353	0.62	rs34455383	ENSG00000253981.4	ALG1L13P	-3.64	0.000302	0.0201	-0.17	-0.17	Recombination measurement;	chr8:9208948	chr8:8236003~8244667:-
THCA	cis	rs1842579	1	rs6698139	ENSG00000272691.1	RP11-290M5.4	3.64	0.000302	0.0201	0.16	0.17	Coronary artery aneurysm in Kawasaki disease;	chr1:85824757	chr1:85578500~85578742:-
THCA	cis	rs858239	0.67	rs3807452	ENSG00000230042.1	AK3P3	3.64	0.000302	0.0201	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23129178~23129841:+
THCA	cis	rs7259376	0.871	rs34187872	ENSG00000269345.1	VN1R85P	-3.64	0.000302	0.0201	-0.18	-0.17	Menopause (age at onset);	chr19:22425081	chr19:22174766~22175191:-
THCA	cis	rs11123170	0.543	rs2166421	ENSG00000274877.1	RP11-65I12.1	3.64	0.000302	0.0201	0.1	0.17	Renal function-related traits (BUN);	chr2:113232665	chr2:113237595~113240825:+
THCA	cis	rs6893300	0.857	rs62406181	ENSG00000225051.5	HMGB3P22	3.64	0.000302	0.0201	0.17	0.17	Resting heart rate;	chr5:179744802	chr5:179679032~179694768:+
THCA	cis	rs913672	0.637	rs12625213	ENSG00000231742.4	LINC01273	3.64	0.000302	0.0201	0.2	0.17	Monocyte count;	chr20:50278382	chr20:50172550~50176671:+
THCA	cis	rs11168187	0.514	rs1476581	ENSG00000280054.1	RP1-197B17.7	3.64	0.000302	0.0201	0.21	0.17	Vertical cup-disc ratio;	chr12:47568216	chr12:47728151~47730598:-
THCA	cis	rs6583331	1	rs6583331	ENSG00000232065.1	LINC01063	-3.64	0.000302	0.0201	-0.18	-0.17	Vitiligo;	chr3:196620382	chr3:196631498~196632587:-
THCA	cis	rs804280	0.662	rs11784693	ENSG00000270154.1	RP11-419I17.1	-3.64	0.000302	0.0201	-0.22	-0.17	Myopia (pathological);	chr8:11753165	chr8:12476462~12477122:+
THCA	cis	rs9796	0.689	rs576336	ENSG00000247556.5	OIP5-AS1	3.64	0.000302	0.0201	0.13	0.17	Menopause (age at onset);	chr15:41160573	chr15:41283990~41309737:+
THCA	cis	rs7520050	0.966	rs4545281	ENSG00000280836.1	AL355480.1	3.64	0.000302	0.0201	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45894382	chr1:45581219~45581321:-
THCA	cis	rs2842346	0.568	rs2525523	ENSG00000258623.1	CTD-2325P2.3	-3.64	0.000302	0.0201	-0.22	-0.17	Breast cancer;	chr14:68540196	chr14:68683411~68685565:-
THCA	cis	rs2842346	0.568	rs2525524	ENSG00000258623.1	CTD-2325P2.3	-3.64	0.000302	0.0201	-0.22	-0.17	Breast cancer;	chr14:68540205	chr14:68683411~68685565:-
THCA	cis	rs875971	1	rs11974264	ENSG00000272831.1	RP11-792A8.4	-3.64	0.000302	0.0201	-0.1	-0.17	Aortic root size;	chr7:66182595	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs1540651	ENSG00000272831.1	RP11-792A8.4	-3.64	0.000302	0.0201	-0.1	-0.17	Aortic root size;	chr7:66185134	chr7:66739829~66740385:-
THCA	cis	rs4713118	0.696	rs2394002	ENSG00000261839.1	RP1-265C24.8	3.64	0.000302	0.0201	0.19	0.17	Parkinson's disease;	chr6:27780236	chr6:28136849~28139678:+
THCA	cis	rs9532669	0.926	rs2324742	ENSG00000229473.2	RGS17P1	3.64	0.000302	0.0201	0.21	0.17	Cervical cancer;	chr13:40919059	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.857	rs9594455	ENSG00000229473.2	RGS17P1	3.64	0.000302	0.0201	0.21	0.17	Cervical cancer;	chr13:40919452	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9532659	ENSG00000229473.2	RGS17P1	3.64	0.000302	0.0201	0.21	0.17	Cervical cancer;	chr13:40920380	chr13:40992779~40993331:-
THCA	cis	rs2404602	0.598	rs11634019	ENSG00000196274.5	Metazoa_SRP	-3.64	0.000302	0.0201	-0.19	-0.17	Blood metabolite levels;	chr15:76342339	chr15:76230048~76230390:-
THCA	cis	rs11800820	0.555	rs6661155	ENSG00000227953.5	LINC01341	-3.64	0.000302	0.0201	-0.15	-0.17	Obesity-related traits;	chr1:246465641	chr1:246776013~246792385:+
THCA	cis	rs743757	0.652	rs399484	ENSG00000232352.1	SEMA3B-AS1	-3.64	0.000302	0.0201	-0.23	-0.17	Diastolic blood pressure;	chr3:50552024	chr3:50266641~50267371:-
THCA	cis	rs9876781	1	rs1459242	ENSG00000199476.1	Y_RNA	3.64	0.000302	0.0201	0.21	0.17	Longevity;	chr3:48372047	chr3:48288587~48288694:+
THCA	cis	rs6137726	0.524	rs2424439	ENSG00000237396.1	LINC01384	3.64	0.000302	0.0201	0.15	0.17	Amyotrophic lateral sclerosis (sporadic);	chr20:22639402	chr20:22587522~22607517:-
THCA	cis	rs10911902	0.643	rs78468398	ENSG00000228238.1	GS1-304P7.2	-3.64	0.000302	0.0201	-0.26	-0.17	Schizophrenia;	chr1:186315149	chr1:186578279~186579299:+
THCA	cis	rs11098699	0.687	rs4833906	ENSG00000273007.1	RP11-170N16.3	3.64	0.000302	0.0201	0.13	0.17	Mosquito bite size;	chr4:123325096	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs7661575	ENSG00000273007.1	RP11-170N16.3	3.64	0.000302	0.0201	0.13	0.17	Mosquito bite size;	chr4:123325184	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs7687083	ENSG00000273007.1	RP11-170N16.3	3.64	0.000302	0.0201	0.13	0.17	Mosquito bite size;	chr4:123325447	chr4:122881878~122884712:-
THCA	cis	rs4865762	0.557	rs12515400	ENSG00000247796.2	CTD-2366F13.1	-3.64	0.000302	0.0201	-0.14	-0.17	Intraocular pressure;	chr5:53285349	chr5:53109842~53115126:+
THCA	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-3.64	0.000302	0.0201	-0.16	-0.17	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
THCA	cis	rs4792901	0.918	rs1728181	ENSG00000267151.3	RP11-100E5.2	-3.64	0.000302	0.0201	-0.18	-0.17	Dupuytren's disease;	chr17:43597608	chr17:43444707~43451200:+
THCA	cis	rs7188697	0.922	rs7199856	ENSG00000276259.1	RP11-481J2.4	-3.64	0.000302	0.0201	-0.11	-0.17	QT interval;	chr16:58550868	chr16:58522970~58523842:+
THCA	cis	rs6560517	1	rs35837300	ENSG00000234618.1	RPSAP9	-3.64	0.000302	0.0201	-0.18	-0.17	Dialysis-related mortality;	chr9:76429078	chr9:76398699~76399586:+
THCA	cis	rs3176789	0.671	rs11052969	ENSG00000256673.1	RP11-599J14.2	3.64	0.000302	0.0201	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766655	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.671	rs11052971	ENSG00000256673.1	RP11-599J14.2	3.64	0.000302	0.0201	0.2	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766683	chr12:9398355~9414851:-
THCA	cis	rs2933343	0.679	rs789229	ENSG00000231305.3	RP11-723O4.2	3.64	0.000302	0.0201	0.18	0.17	IgG glycosylation;	chr3:128883683	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.729	rs789230	ENSG00000231305.3	RP11-723O4.2	3.64	0.000302	0.0201	0.18	0.17	IgG glycosylation;	chr3:128883715	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.729	rs789231	ENSG00000231305.3	RP11-723O4.2	3.64	0.000302	0.0201	0.18	0.17	IgG glycosylation;	chr3:128884004	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.661	rs2630259	ENSG00000231305.3	RP11-723O4.2	3.64	0.000302	0.0201	0.18	0.17	IgG glycosylation;	chr3:128887479	chr3:128861313~128871540:-
THCA	cis	rs2933343	0.729	rs6790091	ENSG00000231305.3	RP11-723O4.2	3.64	0.000302	0.0201	0.18	0.17	IgG glycosylation;	chr3:128889908	chr3:128861313~128871540:-
THCA	cis	rs13108904	0.87	rs12642797	ENSG00000254094.1	AC078852.1	-3.64	0.000302	0.0201	-0.2	-0.17	Obesity-related traits;	chr4:1252202	chr4:1356581~1358075:+
THCA	cis	rs7216064	1	rs62084238	ENSG00000265055.1	AC145343.2	3.64	0.000302	0.0201	0.24	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67860457	chr17:68096046~68101474:-
THCA	cis	rs10844154	0.638	rs326645	ENSG00000277342.1	RP11-843B15.4	3.64	0.000302	0.0201	0.2	0.17	Emphysema-related traits;Weight;	chr12:32249187	chr12:32109076~32109602:+
THCA	cis	rs62158800	0.598	rs11123670	ENSG00000237880.1	AC096669.2	3.64	0.000302	0.0201	0.17	0.17	Facial morphology (factor 22);	chr2:107674278	chr2:107385632~107542649:-
THCA	cis	rs495337	0.76	rs4810994	ENSG00000229222.1	KRT18P4	-3.64	0.000302	0.0201	-0.2	-0.17	Psoriasis;	chr20:49955136	chr20:49956745~49958032:+
THCA	cis	rs8040855	0.627	rs12900012	ENSG00000225151.9	GOLGA2P7	-3.64	0.000302	0.0201	-0.24	-0.17	Bulimia nervosa;	chr15:85046955	chr15:84199311~84230136:-
THCA	cis	rs1065852	0.526	rs4822079	ENSG00000227370.1	RP4-669P10.19	3.64	0.000302	0.0201	0.17	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41998608	chr22:42132543~42132998:+
THCA	cis	rs804280	0.542	rs35647515	ENSG00000255495.1	AC145124.2	3.64	0.000302	0.0201	0.2	0.17	Myopia (pathological);	chr8:11934120	chr8:12194467~12196280:+
THCA	cis	rs6049003	0.579	rs947010	ENSG00000270001.1	RP11-218C14.8	-3.64	0.000302	0.0201	-0.18	-0.17	Cerebrospinal fluid biomarker levels;	chr20:23698253	chr20:23631826~23632316:-
THCA	cis	rs3015497	0.637	rs12587877	ENSG00000270062.1	RP11-248J18.3	-3.64	0.000302	0.0201	-0.19	-0.17	Mean platelet volume;	chr14:50710284	chr14:50723777~50724272:-
THCA	cis	rs6088590	0.687	rs6088582	ENSG00000276073.1	RP5-1125A11.7	-3.64	0.000302	0.0201	-0.15	-0.17	Coronary artery disease;	chr20:34698994	chr20:33985617~33988989:-
THCA	cis	rs1371614	0.611	rs3845685	ENSG00000229122.1	AGBL5-IT1	-3.64	0.000302	0.0201	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26907464	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.611	rs7557229	ENSG00000229122.1	AGBL5-IT1	-3.64	0.000302	0.0201	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908023	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.611	rs3910615	ENSG00000229122.1	AGBL5-IT1	-3.64	0.000302	0.0201	-0.12	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908154	chr2:27061038~27061815:+
THCA	cis	rs11239930	0.538	rs4950359	ENSG00000180867.10	PDIA3P1	3.64	0.000302	0.0201	0.16	0.17	AIDS progression;	chr1:147087196	chr1:147178113~147179622:+
THCA	cis	rs7212590	0.748	rs55794618	ENSG00000267302.4	RP11-178C3.2	3.64	0.000302	0.0201	0.31	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59856976	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.748	rs58681483	ENSG00000267302.4	RP11-178C3.2	3.64	0.000302	0.0201	0.31	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59857293	chr17:59964832~59996972:+
THCA	cis	rs603446	0.967	rs180361	ENSG00000254851.1	RP11-109L13.1	-3.64	0.000302	0.0201	-0.22	-0.17	Triglycerides;	chr11:116727933	chr11:117135528~117138582:+
THCA	cis	rs4660214	0.666	rs663892	ENSG00000228060.1	RP11-69E11.8	-3.64	0.000302	0.0201	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39424005	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs1180384	ENSG00000228060.1	RP11-69E11.8	-3.64	0.000302	0.0201	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427102	chr1:39565160~39573203:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000223473.2	GS1-124K5.3	-3.64	0.000302	0.0201	-0.11	-0.17	Aortic root size;	chr7:66682114	chr7:66491049~66493566:-
THCA	cis	rs2447820	0.5	rs26371	ENSG00000263432.2	RN7SL689P	3.64	0.000302	0.0201	0.2	0.17	Migraine;	chr5:122870830	chr5:123022487~123022783:-
THCA	cis	rs7737355	0.812	rs10076930	ENSG00000224431.1	AC063976.7	-3.64	0.000302	0.0201	-0.15	-0.17	Life satisfaction;	chr5:131428344	chr5:132199456~132203487:+
THCA	cis	rs10181042	0.514	rs1177283	ENSG00000270820.4	RP11-355B11.2	3.64	0.000303	0.0201	0.14	0.17	Crohn's disease;	chr2:61121669	chr2:61471188~61484130:+
THCA	cis	rs2187895	0.796	rs489090	ENSG00000271811.1	RP1-79C4.4	3.64	0.000303	0.0201	0.25	0.17	Tonsillectomy;	chr1:170692623	chr1:170667381~170669425:+
THCA	cis	rs854765	0.547	rs2955385	ENSG00000281749.1	Y_RNA	3.64	0.000303	0.0201	0.21	0.17	Total body bone mineral density;	chr17:18035933	chr17:18001101~18001195:-
THCA	cis	rs214785	0.932	rs214801	ENSG00000226644.4	RP11-128M1.1	3.64	0.000303	0.0201	0.17	0.17	Basal cell carcinoma;	chr20:2307944	chr20:2207217~2213151:+
THCA	cis	rs240993	0.548	rs1040382	ENSG00000220392.1	FCF1P5	3.64	0.000303	0.0201	0.18	0.17	Inflammatory skin disease;Psoriasis;	chr6:111580876	chr6:111353702~111354183:+
THCA	cis	rs1821002	1	rs1821002	ENSG00000255310.2	AF131215.2	-3.64	0.000303	0.0201	-0.14	-0.17	Systolic blood pressure;	chr8:10782555	chr8:11107788~11109726:-
THCA	cis	rs11069062	1	rs11069062	ENSG00000270482.1	RP11-131L12.2	3.64	0.000303	0.0201	0.13	0.17	Obesity-related traits;	chr12:118725274	chr12:118375350~118376275:-
THCA	cis	rs4648045	0.624	rs1609798	ENSG00000230069.3	LRRC37A15P	-3.64	0.000303	0.0201	-0.18	-0.17	Lymphocyte percentage of white cells;	chr4:102616285	chr4:102727274~102730721:-
THCA	cis	rs1908814	0.516	rs11996277	ENSG00000255495.1	AC145124.2	3.64	0.000303	0.0201	0.2	0.17	Neuroticism;	chr8:11942522	chr8:12194467~12196280:+
THCA	cis	rs4879656	0.966	rs7869475	ENSG00000225693.1	LAGE3P1	-3.64	0.000303	0.0201	-0.18	-0.17	Menopause (age at onset);	chr9:32986250	chr9:33019682~33020165:-
THCA	cis	rs735539	0.521	rs2818992	ENSG00000278291.1	RP11-172H24.4	3.64	0.000303	0.0201	0.22	0.17	Dental caries;	chr13:20823948	chr13:20699307~20703718:-
THCA	cis	rs17221829	0.555	rs11605844	ENSG00000280385.1	AP000648.5	-3.64	0.000303	0.0201	-0.16	-0.17	Anxiety in major depressive disorder;	chr11:89615807	chr11:90193614~90198120:+
THCA	cis	rs17023223	0.537	rs12081198	ENSG00000227056.2	RPL6P2	-3.64	0.000303	0.0201	-0.22	-0.17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs12081327	ENSG00000227056.2	RPL6P2	-3.64	0.000303	0.0201	-0.22	-0.17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs12086686	ENSG00000227056.2	RPL6P2	-3.64	0.000303	0.0201	-0.22	-0.17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs12085616	ENSG00000227056.2	RPL6P2	-3.64	0.000303	0.0201	-0.22	-0.17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119219314~119220096:-
THCA	cis	rs9693857	0.52	rs6601320	ENSG00000248538.5	RP11-10A14.5	-3.64	0.000303	0.0201	-0.22	-0.17	Systolic blood pressure;	chr8:9498378	chr8:9189011~9202854:+
THCA	cis	rs6940638	0.956	rs12190473	ENSG00000224843.5	LINC00240	3.64	0.000303	0.0201	0.19	0.17	Intelligence (multi-trait analysis);	chr6:27056908	chr6:26956992~27023924:+
THCA	cis	rs4908768	0.911	rs953535	ENSG00000232912.4	RP5-1115A15.1	-3.64	0.000303	0.0201	-0.19	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8716660	chr1:8424645~8434838:+
THCA	cis	rs208520	1	rs28773210	ENSG00000233859.2	ADH5P4	3.64	0.000303	0.0201	0.26	0.17	Exhaled nitric oxide output;	chr6:66283673	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs72884025	ENSG00000233859.2	ADH5P4	3.64	0.000303	0.0201	0.26	0.17	Exhaled nitric oxide output;	chr6:66284292	chr6:65836930~65838039:-
THCA	cis	rs7713065	0.765	rs28655019	ENSG00000263597.1	MIR3936	-3.64	0.000303	0.0201	-0.21	-0.17	Lung function (FEV1/FVC);	chr5:132435189	chr5:132365490~132365599:-
THCA	cis	rs7713065	0.765	rs11741543	ENSG00000263597.1	MIR3936	-3.64	0.000303	0.0201	-0.21	-0.17	Lung function (FEV1/FVC);	chr5:132435623	chr5:132365490~132365599:-
THCA	cis	rs11168187	0.514	rs1476582	ENSG00000280054.1	RP1-197B17.7	3.64	0.000303	0.0201	0.21	0.17	Vertical cup-disc ratio;	chr12:47568278	chr12:47728151~47730598:-
THCA	cis	rs11168187	0.514	rs12815103	ENSG00000280054.1	RP1-197B17.7	3.64	0.000303	0.0201	0.21	0.17	Vertical cup-disc ratio;	chr12:47568976	chr12:47728151~47730598:-
THCA	cis	rs237743	1	rs381262	ENSG00000222365.1	SNORD12B	-3.64	0.000303	0.0201	-0.2	-0.17	Height;	chr20:49316942	chr20:49280319~49280409:+
THCA	cis	rs7307902	1	rs11168144	ENSG00000280054.1	RP1-197B17.7	-3.64	0.000303	0.0201	-0.19	-0.17	Obesity-related traits;	chr12:47535223	chr12:47728151~47730598:-
THCA	cis	rs35740288	0.787	rs11635418	ENSG00000259407.1	RP11-158M2.3	-3.64	0.000303	0.0201	-0.21	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700947	chr15:85744109~85750281:-
THCA	cis	rs17345786	0.861	rs11711808	ENSG00000244119.1	PDCL3P4	3.64	0.000303	0.0201	0.16	0.17	Colonoscopy-negative controls vs population controls;	chr3:101516257	chr3:101712472~101713191:+
THCA	cis	rs2033711	0.87	rs7259841	ENSG00000268049.1	CTD-2619J13.9	-3.64	0.000303	0.0201	-0.21	-0.17	Uric acid clearance;	chr19:58439756	chr19:58357999~58359603:+
THCA	cis	rs11673344	0.526	rs17305823	ENSG00000267470.4	ZNF571-AS1	3.64	0.000303	0.0201	0.2	0.17	Obesity-related traits;	chr19:37644145	chr19:37548914~37587348:+
THCA	cis	rs7616559	0.925	rs4680326	ENSG00000244515.1	KRT18P34	-3.64	0.000303	0.0201	-0.22	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:156997661	chr3:157162663~157163932:-
THCA	cis	rs62380364	0.727	rs188582	ENSG00000247828.6	TMEM161B-AS1	3.64	0.000303	0.0201	0.12	0.17	Intelligence (multi-trait analysis);	chr5:88871923	chr5:88268895~88436685:+
THCA	cis	rs931127	0.505	rs746429	ENSG00000245532.5	NEAT1	-3.64	0.000303	0.0201	-0.12	-0.17	Systemic lupus erythematosus;	chr11:65649963	chr11:65422774~65445540:+
THCA	cis	rs2051773	0.567	rs7935677	ENSG00000184669.7	OR7E14P	-3.64	0.000303	0.0201	-0.23	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17018285	chr11:17013998~17053024:+
THCA	cis	rs2051773	0.567	rs12288579	ENSG00000184669.7	OR7E14P	-3.64	0.000303	0.0201	-0.23	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17018363	chr11:17013998~17053024:+
THCA	cis	rs73222236	0.787	rs35681043	ENSG00000273486.1	RP11-731C17.2	3.64	0.000303	0.0201	0.15	0.17	Coronary artery disease;	chr3:136261583	chr3:136837338~136839021:-
THCA	cis	rs929354	0.772	rs10230895	ENSG00000224629.1	RP5-1142J19.2	-3.64	0.000303	0.0201	-0.16	-0.17	Body mass index;	chr7:157214344	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs2051877	ENSG00000224629.1	RP5-1142J19.2	-3.64	0.000303	0.0201	-0.16	-0.17	Body mass index;	chr7:157216119	chr7:157263022~157263229:-
THCA	cis	rs7737355	0.812	rs10062078	ENSG00000224431.1	AC063976.7	-3.64	0.000303	0.0201	-0.15	-0.17	Life satisfaction;	chr5:131428409	chr5:132199456~132203487:+
THCA	cis	rs1862618	0.613	rs252889	ENSG00000271828.1	CTD-2310F14.1	3.64	0.000303	0.0201	0.23	0.17	Initial pursuit acceleration;	chr5:56931242	chr5:56927874~56929573:+
THCA	cis	rs1005277	0.54	rs289638	ENSG00000120555.12	SEPT7P9	3.64	0.000303	0.0201	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38383069~38402916:-
THCA	cis	rs1062177	1	rs1062177	ENSG00000272112.1	CTB-113P19.5	3.64	0.000303	0.0201	0.15	0.17	Preschool internalizing problems;	chr5:151805140	chr5:151724831~151725356:-
THCA	cis	rs7726839	0.526	rs11960159	ENSG00000225138.6	CTD-2228K2.7	3.64	0.000303	0.0201	0.19	0.17	Obesity-related traits;	chr5:568570	chr5:473236~480884:+
THCA	cis	rs172166	0.561	rs149976	ENSG00000261839.1	RP1-265C24.8	-3.64	0.000303	0.0201	-0.16	-0.17	Cardiac Troponin-T levels;	chr6:28019998	chr6:28136849~28139678:+
THCA	cis	rs701145	0.537	rs2695845	ENSG00000243069.6	ARHGEF26-AS1	3.64	0.000303	0.0201	0.31	0.17	Coronary artery disease;	chr3:154164047	chr3:154024401~154121332:-
THCA	cis	rs459571	0.959	rs467379	ENSG00000235106.7	LINC00094	3.64	0.000303	0.0201	0.15	0.17	Platelet distribution width;	chr9:134040352	chr9:134025439~134034666:+
THCA	cis	rs7615952	1	rs7615952	ENSG00000272840.1	RP11-379B18.6	-3.64	0.000303	0.0201	-0.27	-0.17	Blood pressure (smoking interaction);	chr3:125930560	chr3:125774714~125797953:+
THCA	cis	rs1153858	1	rs1618874	ENSG00000275672.1	GATM-AS1	-3.64	0.000303	0.0201	-0.17	-0.17	Homoarginine levels;	chr15:45330588	chr15:45378700~45380123:+
THCA	cis	rs12817549	0.817	rs3741675	ENSG00000186076.5	RP11-887P2.3	-3.64	0.000303	0.0201	-0.19	-0.17	Hip circumference adjusted for BMI;	chr12:93714753	chr12:93640822~93641586:-
THCA	cis	rs7178909	0.872	rs28468074	ENSG00000259677.1	RP11-493E3.1	3.64	0.000303	0.0201	0.2	0.17	Common traits (Other);	chr15:89892368	chr15:89876540~89877285:+
THCA	cis	rs7178909	0.872	rs61345389	ENSG00000259677.1	RP11-493E3.1	3.64	0.000303	0.0201	0.2	0.17	Common traits (Other);	chr15:89892653	chr15:89876540~89877285:+
THCA	cis	rs7919656	0.662	rs2620893	ENSG00000228403.1	RP11-563N6.6	-3.64	0.000303	0.0201	-0.17	-0.17	Clinically amyopathic dermatomyositis;	chr10:48859062	chr10:48878022~48878649:+
THCA	cis	rs4761470	0.637	rs11107531	ENSG00000258172.1	RP11-1105G2.4	-3.64	0.000303	0.0201	-0.22	-0.17	Estradiol plasma levels (breast cancer);	chr12:94407545	chr12:94272150~94277195:-
THCA	cis	rs1035144	0.704	rs77647068	ENSG00000258915.1	BHLHB9P1	-3.64	0.000303	0.0201	-0.18	-0.17	Male sexual orientation;	chr14:80979232	chr14:80981988~80983638:+
THCA	cis	rs72634501	0.568	rs6679564	ENSG00000228060.1	RP11-69E11.8	3.64	0.000303	0.0202	0.15	0.17	HDL cholesterol;	chr1:39151408	chr1:39565160~39573203:+
THCA	cis	rs9868809	0.881	rs7620853	ENSG00000270441.1	RP11-694I15.7	3.64	0.000303	0.0202	0.22	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629070	chr3:49140086~49160851:-
THCA	cis	rs7899106	1	rs12411664	ENSG00000270002.1	RP11-93H12.4	3.64	0.000303	0.0202	0.3	0.17	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85582140	chr10:85644073~85648066:+
THCA	cis	rs11583043	0.918	rs11582211	ENSG00000233184.5	RP11-421L21.3	3.64	0.000303	0.0202	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:100951315	chr1:101025878~101087268:+
THCA	cis	rs2549003	1	rs2070722	ENSG00000233006.5	AC034220.3	-3.64	0.000303	0.0202	-0.13	-0.17	Asthma (sex interaction);	chr5:132488794	chr5:132311285~132369916:-
THCA	cis	rs2483374	1	rs2483374	ENSG00000253771.4	TPTE2P1	-3.64	0.000304	0.0202	-0.15	-0.17	Obesity-related traits;	chr13:24959693	chr13:24924677~24968487:-
THCA	cis	rs78487399	0.908	rs35478206	ENSG00000234936.1	AC010883.5	3.64	0.000304	0.0202	0.21	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43603893	chr2:43229573~43233394:+
THCA	cis	rs1153858	1	rs1719247	ENSG00000275672.1	GATM-AS1	-3.64	0.000304	0.0202	-0.17	-0.17	Homoarginine levels;	chr15:45328787	chr15:45378700~45380123:+
THCA	cis	rs11719291	0.584	rs13080725	ENSG00000229759.1	MRPS18AP1	-3.64	0.000304	0.0202	-0.34	-0.17	Cognitive function;	chr3:49038659	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs35108630	ENSG00000229759.1	MRPS18AP1	-3.64	0.000304	0.0202	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49050923	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs35283189	ENSG00000229759.1	MRPS18AP1	-3.64	0.000304	0.0202	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076235	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs34580506	ENSG00000229759.1	MRPS18AP1	-3.64	0.000304	0.0202	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076280	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs35673421	ENSG00000229759.1	MRPS18AP1	-3.64	0.000304	0.0202	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49101973	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs11552724	ENSG00000229759.1	MRPS18AP1	-3.64	0.000304	0.0202	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49119040	chr3:48256350~48256938:-
THCA	cis	rs7264396	0.79	rs10211771	ENSG00000088340.14	FER1L4	3.64	0.000304	0.0202	0.17	0.17	Total cholesterol levels;	chr20:35632072	chr20:35558737~35607562:-
THCA	cis	rs10861661	0.963	rs10861669	ENSG00000260329.1	RP11-412D9.4	-3.64	0.000304	0.0202	-0.19	-0.17	Triglyceride levels;	chr12:106806290	chr12:106954029~106955497:-
THCA	cis	rs6885307	0.824	rs4460145	ENSG00000272335.1	RP11-53O19.3	-3.64	0.000304	0.0202	-0.16	-0.17	Age at first birth;	chr5:44968224	chr5:44826076~44828592:+
THCA	cis	rs708224	0.513	rs751720	ENSG00000277342.1	RP11-843B15.4	3.64	0.000304	0.0202	0.22	0.17	Pancreatic cancer;	chr12:32284340	chr12:32109076~32109602:+
THCA	cis	rs708224	0.513	rs1151045	ENSG00000277342.1	RP11-843B15.4	3.64	0.000304	0.0202	0.22	0.17	Pancreatic cancer;	chr12:32284399	chr12:32109076~32109602:+
THCA	cis	rs267567	0.626	rs267545	ENSG00000235257.7	ITGA9-AS1	3.64	0.000304	0.0202	0.14	0.17	PR interval;	chr3:37537386	chr3:37745432~37861780:-
THCA	cis	rs2227564	0.597	rs2633305	ENSG00000271816.1	BMS1P4	3.64	0.000304	0.0202	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73892365	chr10:73699151~73730487:-
THCA	cis	rs2227564	0.729	rs2675674	ENSG00000271816.1	BMS1P4	3.64	0.000304	0.0202	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73892924	chr10:73699151~73730487:-
THCA	cis	rs5758659	0.652	rs133301	ENSG00000234009.1	RPL5P34	-3.64	0.000304	0.0202	-0.16	-0.17	Cognitive function;	chr22:41994089	chr22:42776406~42777296:-
THCA	cis	rs41313321	0.92	rs77704737	ENSG00000272696.1	RP11-339B21.13	3.64	0.000304	0.0202	0.15	0.17	Coenzyme Q10 levels;	chr9:128280836	chr9:128316337~128316909:+
THCA	cis	rs6121246	0.954	rs73241710	ENSG00000224628.2	RP5-854E16.2	-3.64	0.000304	0.0202	-0.23	-0.17	Mean corpuscular hemoglobin;	chr20:31837153	chr20:31285317~31286835:-
THCA	cis	rs6060987	1	rs6060987	ENSG00000224628.2	RP5-854E16.2	-3.64	0.000304	0.0202	-0.23	-0.17	Mean corpuscular volume;	chr20:31839274	chr20:31285317~31286835:-
THCA	cis	rs7119	0.667	rs2867312	ENSG00000259362.2	RP11-307C19.1	-3.64	0.000304	0.0202	-0.21	-0.17	Type 2 diabetes;	chr15:77609951	chr15:77525540~77534110:+
THCA	cis	rs1729951	0.575	rs10935213	ENSG00000239213.4	NCK1-AS1	3.64	0.000304	0.0202	0.14	0.17	Neuroticism;	chr3:136974617	chr3:136841726~136862054:-
THCA	cis	rs3760982	0.813	rs10426528	ENSG00000176761.7	ZNF285B	-3.64	0.000304	0.0202	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43795146	chr19:44467641~44473227:+
THCA	cis	rs131777	0.576	rs131758	ENSG00000272836.1	RP3-402G11.27	-3.64	0.000304	0.0202	-0.13	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50578653	chr22:50205585~50206062:-
THCA	cis	rs4074961	0.692	rs11264075	ENSG00000233621.1	LINC01137	-3.64	0.000304	0.0202	-0.17	-0.17	Axial length;	chr1:37618269	chr1:37454879~37474411:-
THCA	cis	rs1556032	0.582	rs1323339	ENSG00000225472.1	RP11-120J1.1	-3.64	0.000304	0.0202	-0.16	-0.17	AIDS;	chr9:14444318	chr9:14317085~14357908:+
THCA	cis	rs2836974	0.899	rs68004583	ENSG00000255568.3	BRWD1-AS2	3.64	0.000304	0.0202	0.14	0.17	Cognitive function;	chr21:39287661	chr21:39313935~39314962:+
THCA	cis	rs658349	1	rs633059	ENSG00000251332.1	RP11-177C12.4	3.64	0.000304	0.0202	0.2	0.17	Lymphocyte counts;	chr4:38131378	chr4:37995494~37996203:-
THCA	cis	rs7665090	1	rs7665090	ENSG00000251288.2	RP11-10L12.2	3.64	0.000304	0.0202	0.21	0.17	Primary biliary cholangitis;	chr4:102630446	chr4:102751401~102752641:+
THCA	cis	rs16975963	0.793	rs1807157	ENSG00000276846.1	CTD-3220F14.3	-3.64	0.000304	0.0202	-0.15	-0.17	Longevity;	chr19:37974883	chr19:37314868~37315620:-
THCA	cis	rs1005277	0.579	rs176880	ENSG00000151963.4	RP11-775A3.1	3.64	0.000304	0.0202	0.17	0.17	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:37883594~37884109:+
THCA	cis	rs713587	0.563	rs2384057	ENSG00000224165.4	DNAJC27-AS1	-3.64	0.000304	0.0202	-0.09	-0.17	Body mass index in non-asthmatics;	chr2:24877298	chr2:24971390~25039694:+
THCA	cis	rs12681366	0.761	rs2930963	ENSG00000253175.1	RP11-267M23.6	3.64	0.000304	0.0202	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94565036~94565715:+
THCA	cis	rs6693017	1	rs11590678	ENSG00000238078.1	LINC01352	-3.64	0.000304	0.0202	-0.28	-0.17	Monocyte early outgrowth colony forming units;	chr1:220808107	chr1:220829255~220832429:+
THCA	cis	rs453301	0.522	rs2929455	ENSG00000254340.1	RP11-10A14.3	-3.64	0.000304	0.0202	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9225923	chr8:9141424~9145435:+
THCA	cis	rs972578	0.677	rs1807591	ENSG00000230319.1	AL022476.2	3.64	0.000304	0.0202	0.18	0.17	Mean platelet volume;	chr22:42798267	chr22:43038585~43052366:+
THCA	cis	rs4268898	0.735	rs34125395	ENSG00000242628.4	AC009228.1	-3.64	0.000304	0.0202	-0.2	-0.17	Asthma;	chr2:24335373	chr2:24214381~24221516:+
THCA	cis	rs17120471	0.818	rs28588727	ENSG00000255052.4	FAM66D	3.64	0.000304	0.0202	0.3	0.17	IgG glycosylation;	chr8:12835713	chr8:12115782~12177550:+
THCA	cis	rs10754283	0.935	rs1934046	ENSG00000237505.5	PKN2-AS1	3.64	0.000304	0.0202	0.2	0.17	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:88537513~88685204:-
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000184274.3	LINC00315	-3.64	0.000304	0.0202	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000184274.3	LINC00315	-3.64	0.000304	0.0202	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000184274.3	LINC00315	-3.64	0.000304	0.0202	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45300245~45305257:-
THCA	cis	rs9693857	0.52	rs4841163	ENSG00000261451.1	RP11-981G7.1	3.64	0.000304	0.0202	0.22	0.17	Systolic blood pressure;	chr8:9508668	chr8:10433672~10438312:+
THCA	cis	rs1958560	0.897	rs7160780	ENSG00000276116.2	FUT8-AS1	3.64	0.000304	0.0202	0.18	0.17	Menarche (age at onset);	chr14:65585995	chr14:65411170~65412690:-
THCA	cis	rs9287719	0.967	rs6432121	ENSG00000243819.4	RN7SL832P	3.64	0.000304	0.0202	0.13	0.17	Prostate cancer;	chr2:10613678	chr2:10690344~10692099:+
THCA	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	3.64	0.000304	0.0202	0.15	0.17	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
THCA	cis	rs911555	0.755	rs2273702	ENSG00000269940.1	RP11-73M18.7	-3.64	0.000304	0.0202	-0.17	-0.17	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103694560~103695170:+
THCA	cis	rs5758659	0.652	rs133313	ENSG00000182057.4	OGFRP1	3.64	0.000304	0.0202	0.19	0.17	Cognitive function;	chr22:42005745	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.652	rs133314	ENSG00000182057.4	OGFRP1	3.64	0.000304	0.0202	0.19	0.17	Cognitive function;	chr22:42005837	chr22:42269753~42275196:+
THCA	cis	rs11658311	1	rs9903503	ENSG00000266803.1	RP1-77H15.1	3.64	0.000304	0.0202	0.34	0.17	Obsessive-compulsive symptoms;	chr17:17553913	chr17:16557985~16559269:-
THCA	cis	rs4713118	0.869	rs9295743	ENSG00000261839.1	RP1-265C24.8	3.64	0.000304	0.0202	0.19	0.17	Parkinson's disease;	chr6:27747323	chr6:28136849~28139678:+
THCA	cis	rs4905558	0.927	rs4900350	ENSG00000227051.5	C14orf132	-3.64	0.000304	0.0202	-0.19	-0.17	Neutrophil count;	chr14:96827946	chr14:96039324~96094080:+
THCA	cis	rs5758511	0.68	rs58654759	ENSG00000270083.1	RP1-257I20.14	-3.64	0.000304	0.0202	-0.22	-0.17	Birth weight;	chr22:42246570	chr22:42089630~42090028:-
THCA	cis	rs4272720	0.562	rs55947405	ENSG00000234736.4	FAM170B-AS1	-3.64	0.000304	0.0202	-0.18	-0.17	Platelet count;Plateletcrit;	chr10:49134584	chr10:49121839~49151547:+
THCA	cis	rs12476592	0.602	rs7608470	ENSG00000242412.1	DBIL5P2	3.64	0.000304	0.0202	0.21	0.17	Childhood ear infection;	chr2:63464344	chr2:63117851~63119542:-
THCA	cis	rs2797160	1	rs1612249	ENSG00000226409.1	RP11-735G4.1	3.64	0.000304	0.0202	0.2	0.17	Endometrial cancer;	chr6:125693770	chr6:125370211~125374324:-
THCA	cis	rs208520	0.954	rs72884027	ENSG00000233859.2	ADH5P4	3.64	0.000304	0.0202	0.26	0.17	Exhaled nitric oxide output;	chr6:66285151	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs72884033	ENSG00000233859.2	ADH5P4	3.64	0.000304	0.0202	0.26	0.17	Exhaled nitric oxide output;	chr6:66285854	chr6:65836930~65838039:-
THCA	cis	rs656319	0.607	rs35437983	ENSG00000248538.5	RP11-10A14.5	3.64	0.000304	0.0202	0.22	0.17	Myopia (pathological);	chr8:10147543	chr8:9189011~9202854:+
THCA	cis	rs4841097	0.876	rs6601288	ENSG00000233609.3	RP11-62H7.2	3.64	0.000304	0.0202	0.17	0.17	Platelet distribution width;	chr8:9085920	chr8:8961200~8979025:+
THCA	cis	rs6832769	0.579	rs1118271	ENSG00000272969.1	RP11-528I4.2	-3.64	0.000304	0.0202	-0.2	-0.17	Personality dimensions;	chr4:55646973	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.579	rs1948189	ENSG00000272969.1	RP11-528I4.2	-3.64	0.000304	0.0202	-0.2	-0.17	Personality dimensions;	chr4:55646975	chr4:55547112~55547889:+
THCA	cis	rs6832769	0.598	rs1118272	ENSG00000272969.1	RP11-528I4.2	-3.64	0.000304	0.0202	-0.2	-0.17	Personality dimensions;	chr4:55647055	chr4:55547112~55547889:+
THCA	cis	rs1510552	0.935	rs17207375	ENSG00000270659.1	RP11-105N14.1	3.64	0.000304	0.0202	0.18	0.17	Contrast sensitivity;	chr2:214049997	chr2:213152970~213153659:+
THCA	cis	rs73230612	1	rs2177039	ENSG00000242767.1	ZBTB20-AS4	3.64	0.000304	0.0202	0.22	0.17	Type 2 diabetes;	chr3:115114436	chr3:115100423~115103061:+
THCA	cis	rs7819412	0.774	rs34208825	ENSG00000254948.1	OR7E158P	3.64	0.000304	0.0202	0.2	0.17	Triglycerides;	chr8:11157106	chr8:11919900~11920809:-
THCA	cis	rs25645	0.83	rs4072639	ENSG00000264968.1	RP11-387H17.4	-3.64	0.000304	0.0202	-0.15	-0.17	Myeloid white cell count;	chr17:40032796	chr17:39927742~39939601:+
THCA	cis	rs2629751	0.962	rs2722170	ENSG00000214198.6	RP11-642P15.1	-3.64	0.000305	0.0202	-0.13	-0.17	Hepatitis C induced liver fibrosis;	chr12:104023899	chr12:103843749~103930211:-
THCA	cis	rs9296092	0.517	rs76361685	ENSG00000272217.1	XXbac-BPG157A10.21	3.64	0.000305	0.0202	0.18	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33568681	chr6:33246075~33246856:-
THCA	cis	rs4930838	1	rs11049927	ENSG00000274315.1	RP11-996F15.5	3.64	0.000305	0.0202	0.31	0.17	Facial emotion recognition (angry faces);	chr12:28937755	chr12:29331434~29331936:-
THCA	cis	rs860295	0.871	rs11582072	ENSG00000160766.13	GBAP1	3.64	0.000305	0.0202	0.18	0.17	Body mass index;	chr1:155507779	chr1:155213821~155227422:-
THCA	cis	rs3783637	0.908	rs8003903	ENSG00000258413.1	RP11-665C16.6	-3.64	0.000305	0.0202	-0.35	-0.17	Rheumatoid arthritis;Obesity-related traits;	chr14:54891053	chr14:55262767~55272075:-
THCA	cis	rs10200159	0.793	rs11691977	ENSG00000206964.1	Y_RNA	-3.64	0.000305	0.0202	-0.38	-0.17	Vitiligo;	chr2:55698753	chr2:55286018~55286128:+
THCA	cis	rs10200159	0.793	rs12623625	ENSG00000206964.1	Y_RNA	-3.64	0.000305	0.0202	-0.38	-0.17	Vitiligo;	chr2:55699981	chr2:55286018~55286128:+
THCA	cis	rs17428076	0.793	rs3770448	ENSG00000228389.1	AC068039.4	-3.64	0.000305	0.0202	-0.19	-0.17	Myopia;	chr2:171835755	chr2:171773482~171775844:+
THCA	cis	rs9487051	1	rs1341271	ENSG00000260273.1	RP11-425D10.10	3.64	0.000305	0.0202	0.21	0.17	Reticulocyte fraction of red cells;	chr6:109296339	chr6:109382795~109383666:+
THCA	cis	rs1153858	1	rs4625670	ENSG00000275672.1	GATM-AS1	-3.64	0.000305	0.0202	-0.17	-0.17	Homoarginine levels;	chr15:45360728	chr15:45378700~45380123:+
THCA	cis	rs2074409	0.509	rs2680720	ENSG00000275839.1	CTC-421K24.1	-3.64	0.000305	0.0202	-0.2	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37458360	chr17:37454171~37454931:+
THCA	cis	rs6988985	0.818	rs3802230	ENSG00000247317.3	RP11-273G15.2	-3.64	0.000305	0.0202	-0.18	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142911448	chr8:142981738~143018437:-
THCA	cis	rs8030379	1	rs6603003	ENSG00000176700.18	SCAND2P	-3.64	0.000305	0.0202	-0.1	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896850	chr15:84631451~84647478:+
THCA	cis	rs6840360	1	rs10007015	ENSG00000270265.1	RP11-731D1.4	-3.64	0.000305	0.0202	-0.15	-0.17	Intelligence (multi-trait analysis);	chr4:151682376	chr4:151333775~151353224:-
THCA	cis	rs6565180	0.507	rs4471699	ENSG00000274653.1	RP11-347C12.11	3.64	0.000305	0.0202	0.16	0.17	Tonsillectomy;	chr16:30308986	chr16:30359825~30360336:+
THCA	cis	rs17248895	1	rs17248895	ENSG00000258561.1	RP11-72M17.1	3.64	0.000305	0.0202	0.22	0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr14:67416907	chr14:66212810~66509394:-
THCA	cis	rs9457247	0.602	rs4710175	ENSG00000235272.1	FAM103A2P	3.64	0.000305	0.0202	0.23	0.17	Crohn's disease;	chr6:167054312	chr6:166586124~166586477:-
THCA	cis	rs7160336	0.738	rs7161721	ENSG00000259065.1	RP5-1021I20.1	-3.64	0.000305	0.0202	-0.2	-0.17	Blood protein levels;	chr14:74031630	chr14:73787360~73803270:+
THCA	cis	rs7833790	1	rs7460277	ENSG00000254689.1	RP11-354A14.1	3.64	0.000305	0.0202	0.2	0.17	Diastolic blood pressure;	chr8:81797542	chr8:81885377~81923193:+
THCA	cis	rs2446066	0.872	rs10876452	ENSG00000257379.1	RP11-793H13.8	3.64	0.000305	0.0202	0.25	0.17	Red blood cell count;	chr12:53420474	chr12:53441741~53467528:+
THCA	cis	rs875971	0.862	rs4718330	ENSG00000223473.2	GS1-124K5.3	-3.64	0.000305	0.0202	-0.11	-0.17	Aortic root size;	chr7:66250256	chr7:66491049~66493566:-
THCA	cis	rs13256369	0.851	rs11249890	ENSG00000254153.1	CTA-398F10.2	-3.64	0.000305	0.0202	-0.19	-0.17	Obesity-related traits;	chr8:8707735	chr8:8456909~8461337:-
THCA	cis	rs738409	1	rs738409	ENSG00000223843.4	EFCAB6-AS1	3.64	0.000305	0.0202	0.22	0.17	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43928847	chr22:43516107~43537117:+
THCA	cis	rs738409	0.955	rs738408	ENSG00000223843.4	EFCAB6-AS1	3.64	0.000305	0.0202	0.22	0.17	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43928850	chr22:43516107~43537117:+
THCA	cis	rs11822910	1	rs2439448	ENSG00000265566.2	RN7SL605P	3.64	0.000305	0.0202	0.26	0.17	Platelet distribution width;	chr11:57431738	chr11:57528085~57528365:-
THCA	cis	rs11633886	0.707	rs11070471	ENSG00000259200.1	RP11-718O11.1	3.64	0.000305	0.0202	0.2	0.17	Diisocyanate-induced asthma;	chr15:45743923	chr15:45705078~45931069:+
THCA	cis	rs10863936	0.765	rs3010006	ENSG00000198468.6	FLVCR1-AS1	-3.64	0.000305	0.0203	-0.19	-0.17	Height;	chr1:211969298	chr1:212852108~212858088:-
THCA	cis	rs478304	0.593	rs9666878	ENSG00000214659.4	KRT8P26	-3.64	0.000305	0.0203	-0.15	-0.17	Acne (severe);	chr11:65708345	chr11:65726939~65728214:+
THCA	cis	rs6738627	1	rs12692737	ENSG00000223318.1	RNA5SP111	3.64	0.000305	0.0203	0.21	0.17	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164697799	chr2:164895677~164895777:-
THCA	cis	rs6738627	1	rs9653282	ENSG00000223318.1	RNA5SP111	3.64	0.000305	0.0203	0.21	0.17	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164698148	chr2:164895677~164895777:-
THCA	cis	rs6738627	1	rs7609045	ENSG00000223318.1	RNA5SP111	3.64	0.000305	0.0203	0.21	0.17	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164698697	chr2:164895677~164895777:-
THCA	cis	rs7711186	0.786	rs11740396	ENSG00000252464.1	RN7SKP70	3.64	0.000305	0.0203	0.19	0.17	Urate levels in obese individuals;	chr5:178655840	chr5:178619728~178619998:-
THCA	cis	rs9309473	1	rs1881245	ENSG00000273245.1	RP11-434P11.2	3.64	0.000305	0.0203	0.22	0.17	Metabolite levels;	chr2:73422800	chr2:73750256~73750786:-
THCA	cis	rs12681366	0.663	rs10216902	ENSG00000261437.1	RP11-22C11.2	3.64	0.000305	0.0203	0.15	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94467750	chr8:94637285~94639467:-
THCA	cis	rs2980439	0.525	rs1850511	ENSG00000248538.5	RP11-10A14.5	-3.64	0.000305	0.0203	-0.2	-0.17	Neuroticism;	chr8:8312807	chr8:9189011~9202854:+
THCA	cis	rs7873102	0.542	rs4878743	ENSG00000213839.4	TMX2P1	-3.64	0.000305	0.0203	-0.13	-0.17	Brain structure;	chr9:38058427	chr9:37885683~37886390:+
THCA	cis	rs6030712	0.723	rs4812586	ENSG00000213979.3	RPL7AP14	3.64	0.000305	0.0203	0.26	0.17	Height;	chr20:36916270	chr20:37444733~37445534:-
THCA	cis	rs4604234	0.614	rs59155686	ENSG00000260645.1	RP11-250B2.5	-3.64	0.000305	0.0203	-0.27	-0.17	Cancer;	chr6:80141499	chr6:80466958~80469080:+
THCA	cis	rs17428076	0.831	rs55957712	ENSG00000228389.1	AC068039.4	-3.64	0.000305	0.0203	-0.2	-0.17	Myopia;	chr2:171731446	chr2:171773482~171775844:+
THCA	cis	rs1124769	0.778	rs2614787	ENSG00000259378.1	DCAF13P3	-3.64	0.000305	0.0203	-0.27	-0.17	Cognitive performance;	chr15:50908021	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.871	rs2614793	ENSG00000259378.1	DCAF13P3	-3.64	0.000305	0.0203	-0.27	-0.17	Cognitive performance;	chr15:50917477	chr15:50944663~50945996:+
THCA	cis	rs904092	0.554	rs4699733	ENSG00000272777.1	RP11-571L19.8	-3.64	0.000305	0.0203	-0.15	-0.17	Alcohol dependence;	chr4:99216377	chr4:99067256~99068125:-
THCA	cis	rs13325613	0.834	rs35111399	ENSG00000223552.1	RP11-24F11.2	-3.64	0.000305	0.0203	-0.26	-0.17	Monocyte count;	chr3:46200037	chr3:46364955~46407059:-
THCA	cis	rs5758659	0.652	rs133322	ENSG00000281538.1	RP4-669P10.20	3.64	0.000305	0.0203	0.15	0.17	Cognitive function;	chr22:42009655	chr22:42138060~42139726:+
THCA	cis	rs5758659	0.623	rs133328	ENSG00000281538.1	RP4-669P10.20	3.64	0.000305	0.0203	0.15	0.17	Cognitive function;	chr22:42012075	chr22:42138060~42139726:+
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000189316.3	RP11-797H7.5	3.64	0.000305	0.0203	0.18	0.17	Calcium levels;	chr7:65733651	chr7:64888527~64890100:-
THCA	cis	rs7178909	0.902	rs3853638	ENSG00000259677.1	RP11-493E3.1	-3.64	0.000305	0.0203	-0.2	-0.17	Common traits (Other);	chr15:89899908	chr15:89876540~89877285:+
THCA	cis	rs3796352	1	rs13078971	ENSG00000280417.1	RP11-5O17.1	-3.64	0.000305	0.0203	-0.25	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:53069629	chr3:53046166~53048122:+
THCA	cis	rs7259811	0.56	rs7248974	ENSG00000279405.1	AC098795.1	-3.64	0.000305	0.0203	-0.18	-0.17	Western dietary pattern;	chr19:56705841	chr19:56480397~56483977:-
THCA	cis	rs9341808	0.727	rs9352809	ENSG00000260645.1	RP11-250B2.5	3.64	0.000305	0.0203	0.14	0.17	Sitting height ratio;	chr6:80289599	chr6:80466958~80469080:+
THCA	cis	rs2562456	0.792	rs2562398	ENSG00000268658.4	LINC00664	-3.64	0.000305	0.0203	-0.24	-0.17	Pain;	chr19:21540147	chr19:21483374~21503238:+
THCA	cis	rs9634489	0.678	rs4771942	ENSG00000247400.3	DNAJC3-AS1	-3.64	0.000305	0.0203	-0.1	-0.17	Body mass index;	chr13:96398069	chr13:95648733~95676925:-
THCA	cis	rs867186	0.544	rs56280929	ENSG00000279253.1	RP4-614O4.13	-3.64	0.000305	0.0203	-0.28	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35237354	chr20:35262727~35264187:-
THCA	cis	rs7826238	0.601	rs2979206	ENSG00000254340.1	RP11-10A14.3	3.64	0.000305	0.0203	0.19	0.17	Systolic blood pressure;	chr8:8488071	chr8:9141424~9145435:+
THCA	cis	rs2281636	0.858	rs7068079	ENSG00000233690.1	EBAG9P1	-3.64	0.000306	0.0203	-0.16	-0.17	Obesity-related traits;	chr10:99607558	chr10:99697407~99697949:-
THCA	cis	rs860295	0.702	rs10796943	ENSG00000236675.1	MTX1P1	-3.64	0.000306	0.0203	-0.17	-0.17	Body mass index;	chr1:155444938	chr1:155230975~155234325:+
THCA	cis	rs944289	0.576	rs1820604	ENSG00000258844.1	RP11-259K15.2	-3.64	0.000306	0.0203	-0.16	-0.17	Thyroid cancer;	chr14:36170000	chr14:36214607~36235608:+
THCA	cis	rs3758911	1	rs10890716	ENSG00000255353.1	RP11-382M14.1	-3.64	0.000306	0.0203	-0.2	-0.17	Coronary artery disease;	chr11:107324310	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs10789619	ENSG00000255353.1	RP11-382M14.1	-3.64	0.000306	0.0203	-0.2	-0.17	Coronary artery disease;	chr11:107324570	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.964	rs11212157	ENSG00000255353.1	RP11-382M14.1	-3.64	0.000306	0.0203	-0.2	-0.17	Coronary artery disease;	chr11:107324572	chr11:107176286~107177530:+
THCA	cis	rs2652822	0.525	rs11632192	ENSG00000259459.4	RP11-321G12.1	-3.64	0.000306	0.0203	-0.13	-0.17	Metabolic traits;	chr15:63223747	chr15:63390136~63438320:+
THCA	cis	rs2652822	0.525	rs8037296	ENSG00000259459.4	RP11-321G12.1	-3.64	0.000306	0.0203	-0.13	-0.17	Metabolic traits;	chr15:63224560	chr15:63390136~63438320:+
THCA	cis	rs34779708	0.733	rs4102764	ENSG00000233200.1	RP11-324I22.2	3.64	0.000306	0.0203	0.2	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35219894~35230598:-
THCA	cis	rs4389656	0.845	rs13163920	ENSG00000248677.1	CTD-2044J15.1	-3.64	0.000306	0.0203	-0.17	-0.17	Coronary artery disease;	chr5:6759601	chr5:6686325~6707711:-
THCA	cis	rs10954779	0.764	rs2553256	ENSG00000127589.4	TUBBP1	3.64	0.000306	0.0203	0.2	0.17	Intelligence (multi-trait analysis);	chr8:31169798	chr8:30351873~30353518:+
THCA	cis	rs721917	0.531	rs2256703	ENSG00000225484.5	NUTM2B-AS1	-3.64	0.000306	0.0203	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79924588	chr10:79663088~79826594:-
THCA	cis	rs9923856	0.779	rs2110605	ENSG00000263033.2	RP11-396B14.2	-3.64	0.000306	0.0203	-0.14	-0.17	Atopic dermatitis;Adult asthma;	chr16:11112606	chr16:11196177~11224969:+
THCA	cis	rs732716	0.853	rs12459922	ENSG00000280239.1	CTB-50L17.8	-3.64	0.000306	0.0203	-0.14	-0.17	Mean corpuscular volume;	chr19:4455865	chr19:4448810~4450836:+
THCA	cis	rs7648466	0.551	rs12631342	ENSG00000223552.1	RP11-24F11.2	-3.64	0.000306	0.0203	-0.16	-0.17	Eotaxin levels;	chr3:46296944	chr3:46364955~46407059:-
THCA	cis	rs7246657	0.943	rs1035479	ENSG00000268499.1	CTB-102L5.8	-3.64	0.000306	0.0203	-0.21	-0.17	Coronary artery calcification;	chr19:37402398	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.882	rs4803539	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37406620	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs10406177	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37417045	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.882	rs28623164	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37422551	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs7252346	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37423780	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs2891699	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37429335	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs9676967	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37437187	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs8109632	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37440223	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs7255407	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37443034	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.941	rs7256130	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37443079	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs2112923	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37449425	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs3760825	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37454699	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs10420754	ENSG00000268499.1	CTB-102L5.8	3.64	0.000306	0.0203	0.21	0.17	Coronary artery calcification;	chr19:37468470	chr19:38199836~38200934:+
THCA	cis	rs7824557	0.564	rs2572399	ENSG00000255495.1	AC145124.2	-3.64	0.000306	0.0203	-0.19	-0.17	Retinal vascular caliber;	chr8:11377011	chr8:12194467~12196280:+
THCA	cis	rs9905704	0.918	rs36071323	ENSG00000224738.1	AC099850.1	3.64	0.000306	0.0203	0.23	0.17	Testicular germ cell tumor;	chr17:58839443	chr17:59106598~59118267:+
THCA	cis	rs4822752	0.63	rs5761635	ENSG00000244625.4	MIATNB	-3.64	0.000306	0.0203	-0.19	-0.17	Bipolar disorder and schizophrenia;	chr22:26618503	chr22:26672767~26780207:+
THCA	cis	rs7819412	0.74	rs7844536	ENSG00000154316.13	TDH	3.64	0.000306	0.0203	0.13	0.17	Triglycerides;	chr8:11176519	chr8:11339637~11368452:+
THCA	cis	rs2191566	0.839	rs35292176	ENSG00000266921.1	RP11-15A1.7	-3.64	0.000306	0.0203	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:43997475	chr19:43996896~44002836:-
THCA	cis	rs76382185	0.61	rs6658449	ENSG00000233184.5	RP11-421L21.3	3.64	0.000306	0.0203	0.25	0.17	Lymphocyte counts;	chr1:101108353	chr1:101025878~101087268:+
THCA	cis	rs2442825	0.691	rs2596912	ENSG00000254485.4	RP11-380O24.1	-3.64	0.000306	0.0203	-0.16	-0.17	Cerebrospinal fluid clusterin levels;	chr3:9397062	chr3:9292588~9363303:-
THCA	cis	rs9527	1	rs12416687	ENSG00000236937.2	PTGES3P4	3.64	0.000306	0.0203	0.24	0.17	Arsenic metabolism;	chr10:102869254	chr10:102845595~102845950:+
THCA	cis	rs10995505	0.589	rs4601646	ENSG00000272767.1	JMJD1C-AS1	-3.64	0.000306	0.0203	-0.2	-0.17	Intelligence (multi-trait analysis);	chr10:63120520	chr10:63465229~63466563:+
THCA	cis	rs72482608	0.865	rs10753819	ENSG00000271811.1	RP1-79C4.4	3.64	0.000306	0.0203	0.2	0.17	Emphysema imaging phenotypes;	chr1:170793495	chr1:170667381~170669425:+
THCA	cis	rs1865760	0.516	rs9295684	ENSG00000272810.1	U91328.22	-3.64	0.000306	0.0203	-0.13	-0.17	Height;	chr6:26069441	chr6:26013241~26013757:+
THCA	cis	rs2455799	0.573	rs2455831	ENSG00000270409.1	RP11-44D5.1	-3.64	0.000306	0.0203	-0.17	-0.17	Mean platelet volume;	chr3:15710076	chr3:15732252~15733470:+
THCA	cis	rs9308731	0.591	rs9808225	ENSG00000227992.1	AC108463.2	-3.64	0.000306	0.0203	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111185937	chr2:111203964~111206215:-
THCA	cis	rs9308731	0.591	rs9308742	ENSG00000227992.1	AC108463.2	-3.64	0.000306	0.0203	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111186044	chr2:111203964~111206215:-
THCA	cis	rs9308731	0.591	rs7565473	ENSG00000227992.1	AC108463.2	-3.64	0.000306	0.0203	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111186213	chr2:111203964~111206215:-
THCA	cis	rs7737355	0.947	rs31258	ENSG00000237714.1	P4HA2-AS1	3.64	0.000306	0.0203	0.23	0.17	Life satisfaction;	chr5:131488843	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs31253	ENSG00000237714.1	P4HA2-AS1	3.64	0.000306	0.0203	0.23	0.17	Life satisfaction;	chr5:131497318	chr5:132184876~132192808:+
THCA	cis	rs6546886	0.957	rs4853003	ENSG00000235499.1	AC073046.25	3.64	0.000306	0.0203	0.15	0.17	Dialysis-related mortality;	chr2:74021744	chr2:73985132~73986343:+
THCA	cis	rs8002861	0.665	rs2065926	ENSG00000274001.1	RP11-5G9.5	-3.64	0.000306	0.0203	-0.2	-0.17	Leprosy;	chr13:43848235	chr13:43877715~43878163:-
THCA	cis	rs11105298	0.891	rs10858902	ENSG00000266347.2	AC068641.1	3.64	0.000306	0.0203	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs10858903	ENSG00000266347.2	AC068641.1	3.64	0.000306	0.0203	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89592833~89592927:+
THCA	cis	rs11030122	0.959	rs10835262	ENSG00000230593.3	AC090804.1	3.64	0.000306	0.0203	0.21	0.17	Mean platelet volume;Platelet distribution width;	chr11:3895276	chr11:3892398~3892887:-
THCA	cis	rs34102591	0.826	rs12322694	ENSG00000269938.1	RP11-214K3.20	-3.64	0.000306	0.0203	-0.23	-0.17	Schizophrenia;	chr12:123922745	chr12:123968023~123968579:-
THCA	cis	rs9634489	0.678	rs4771945	ENSG00000247400.3	DNAJC3-AS1	-3.64	0.000306	0.0203	-0.1	-0.17	Body mass index;	chr13:96399116	chr13:95648733~95676925:-
THCA	cis	rs642858	0.91	rs6570390	ENSG00000234147.1	RP3-460G2.2	-3.64	0.000306	0.0203	-0.2	-0.17	Type 2 diabetes;	chr6:140244336	chr6:140845958~140852924:-
THCA	cis	rs875971	1	rs12533997	ENSG00000272831.1	RP11-792A8.4	3.64	0.000306	0.0203	0.1	0.17	Aortic root size;	chr7:66500390	chr7:66739829~66740385:-
THCA	cis	rs12817211	0.658	rs6580742	ENSG00000272368.2	RP4-605O3.4	-3.64	0.000306	0.0203	-0.14	-0.17	Colorectal or endometrial cancer;	chr12:50334028	chr12:50112197~50165618:+
THCA	cis	rs4965006	0.508	rs75594148	ENSG00000273568.1	RP11-417L19.6	-3.64	0.000306	0.0203	-0.25	-0.17	Posterior cortical atrophy and Alzheimer's disease;	chr12:131929142	chr12:131934642~131934928:+
THCA	cis	rs1065852	0.526	rs9623489	ENSG00000227370.1	RP4-669P10.19	3.64	0.000306	0.0203	0.17	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42001022	chr22:42132543~42132998:+
THCA	cis	rs12612619	0.689	rs6721395	ENSG00000229122.1	AGBL5-IT1	3.64	0.000306	0.0203	0.13	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057259	chr2:27061038~27061815:+
THCA	cis	rs7178909	0.902	rs2043882	ENSG00000259677.1	RP11-493E3.1	3.64	0.000306	0.0203	0.2	0.17	Common traits (Other);	chr15:89896521	chr15:89876540~89877285:+
THCA	cis	rs372883	0.53	rs2832305	ENSG00000176054.6	RPL23P2	3.64	0.000306	0.0203	0.15	0.17	Pancreatic cancer;	chr21:29380644	chr21:28997613~28998033:-
THCA	cis	rs293748	0.771	rs35011787	ENSG00000250155.1	CTD-2353F22.1	-3.64	0.000306	0.0203	-0.21	-0.17	Obesity-related traits;	chr5:37010302	chr5:36666214~36725195:-
THCA	cis	rs57709857	1	rs2411257	ENSG00000272092.1	RP11-350N15.5	-3.64	0.000306	0.0203	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38435959	chr8:38382364~38383461:+
THCA	cis	rs7873102	0.654	rs7038759	ENSG00000213839.4	TMX2P1	-3.64	0.000306	0.0203	-0.13	-0.17	Brain structure;	chr9:37958732	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.654	rs3922775	ENSG00000213839.4	TMX2P1	-3.64	0.000306	0.0203	-0.13	-0.17	Brain structure;	chr9:37959400	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.654	rs10114319	ENSG00000213839.4	TMX2P1	-3.64	0.000306	0.0203	-0.13	-0.17	Brain structure;	chr9:37960396	chr9:37885683~37886390:+
THCA	cis	rs2836950	0.565	rs4816617	ENSG00000235701.1	PCBP2P1	-3.64	0.000306	0.0203	-0.18	-0.17	Menarche (age at onset);	chr21:39168764	chr21:39171130~39172106:-
THCA	cis	rs7481311	0.956	rs7125904	ENSG00000245573.6	BDNF-AS	3.64	0.000306	0.0203	0.16	0.17	Weight;Body mass index;	chr11:27521456	chr11:27506838~27698174:+
THCA	cis	rs7236492	0.572	rs76694706	ENSG00000267655.1	CTD-2286N8.2	3.64	0.000306	0.0203	0.38	0.17	Inflammatory bowel disease;Crohn's disease;	chr18:79476006	chr18:79117207~79117920:+
THCA	cis	rs7236492	0.872	rs112187368	ENSG00000267655.1	CTD-2286N8.2	3.64	0.000306	0.0203	0.38	0.17	Inflammatory bowel disease;Crohn's disease;	chr18:79476259	chr18:79117207~79117920:+
THCA	cis	rs9980	0.947	rs168637	ENSG00000226232.7	RP11-419C5.2	3.64	0.000306	0.0203	0.25	0.17	Blood osmolality (transformed sodium);	chr16:69585485	chr16:69976388~69996188:-
THCA	cis	rs9980	0.948	rs33063	ENSG00000226232.7	RP11-419C5.2	3.64	0.000306	0.0203	0.25	0.17	Blood osmolality (transformed sodium);	chr16:69606314	chr16:69976388~69996188:-
THCA	cis	rs791590	0.941	rs41294713	ENSG00000225948.2	RP11-554I8.1	3.64	0.000306	0.0203	0.26	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:6038391	chr10:6618716~6625346:+
THCA	cis	rs9906944	0.898	rs9909861	ENSG00000248278.1	SUMO2P17	-3.64	0.000306	0.0203	-0.2	-0.17	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49002054	chr17:48874860~48908983:-
THCA	cis	rs875971	0.545	rs6961853	ENSG00000230295.1	RP11-458F8.2	3.64	0.000307	0.0203	0.15	0.17	Aortic root size;	chr7:66537035	chr7:66880708~66882981:+
THCA	cis	rs9393777	0.92	rs34953377	ENSG00000226314.6	ZNF192P1	-3.64	0.000307	0.0203	-0.32	-0.17	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28161781~28169594:+
THCA	cis	rs8130944	0.866	rs2839576	ENSG00000235772.1	AP001625.6	3.64	0.000307	0.0203	0.19	0.17	Perceived unattractiveness to mosquitoes;	chr21:42719847	chr21:42560374~42561934:-
THCA	cis	rs8130944	1	rs7278264	ENSG00000235772.1	AP001625.6	3.64	0.000307	0.0203	0.19	0.17	Perceived unattractiveness to mosquitoes;	chr21:42719931	chr21:42560374~42561934:-
THCA	cis	rs2799081	1	rs2799081	ENSG00000176933.5	TOB2P1	-3.64	0.000307	0.0203	-0.19	-0.17	Myopia;	chr6:28302807	chr6:28217643~28218634:-
THCA	cis	rs765787	0.53	rs2413785	ENSG00000259539.1	CTD-2651B20.1	3.64	0.000307	0.0203	0.2	0.17	Uric acid levels;	chr15:45238183	chr15:45152664~45167526:-
THCA	cis	rs867371	0.614	rs1814739	ENSG00000255769.6	GOLGA2P10	-3.64	0.000307	0.0203	-0.2	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82472993~82513950:-
THCA	cis	rs9291683	0.655	rs35750364	ENSG00000261490.1	RP11-448G15.3	3.64	0.000307	0.0203	0.1	0.17	Bone mineral density;	chr4:10047425	chr4:10068089~10073019:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000273024.4	INTS4P2	3.64	0.000307	0.0203	0.28	0.17	Diabetic kidney disease;	chr7:65924743	chr7:65647864~65715661:+
THCA	cis	rs6589219	0.954	rs4520624	ENSG00000196167.8	COLCA1	-3.64	0.000307	0.0203	-0.18	-0.17	Colorectal cancer;	chr11:111301485	chr11:111290787~111305045:-
THCA	cis	rs6589219	0.954	rs10789823	ENSG00000196167.8	COLCA1	-3.64	0.000307	0.0203	-0.18	-0.17	Colorectal cancer;	chr11:111301678	chr11:111290787~111305045:-
THCA	cis	rs2985684	0.894	rs6572585	ENSG00000259155.2	RP11-831F12.3	-3.64	0.000307	0.0203	-0.21	-0.17	Carotid intima media thickness;	chr14:49554357	chr14:49677369~49677893:+
THCA	cis	rs4788570	0.615	rs9888756	ENSG00000260593.1	RP11-432I5.2	-3.64	0.000307	0.0203	-0.26	-0.17	Intelligence (multi-trait analysis);	chr16:71706574	chr16:71623708~71626816:-
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000237310.1	GS1-124K5.4	3.64	0.000307	0.0203	0.2	0.17	Diabetic kidney disease;	chr7:66557269	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1267820	ENSG00000237310.1	GS1-124K5.4	3.64	0.000307	0.0203	0.2	0.17	Diabetic kidney disease;	chr7:66585308	chr7:66493706~66495474:+
THCA	cis	rs17767392	0.645	rs17767296	ENSG00000259146.3	RP1-261D10.2	3.64	0.000307	0.0203	0.22	0.17	Mitral valve prolapse;	chr14:71220067	chr14:71292729~71321814:-
THCA	cis	rs34783982	0.529	rs8039998	ENSG00000259699.2	HMGB1P8	-3.64	0.000307	0.0203	-0.22	-0.17	Squamous cell lung carcinoma;	chr15:88931428	chr15:89135547~89136495:-
THCA	cis	rs721917	0.506	rs2758543	ENSG00000244733.5	RP11-506M13.3	-3.64	0.000307	0.0203	-0.19	-0.17	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79660891~79677996:+
THCA	cis	rs721917	0.525	rs2250473	ENSG00000244733.5	RP11-506M13.3	-3.64	0.000307	0.0203	-0.19	-0.17	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79660891~79677996:+
THCA	cis	rs721917	0.506	rs2758561	ENSG00000244733.5	RP11-506M13.3	-3.64	0.000307	0.0203	-0.19	-0.17	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79660891~79677996:+
THCA	cis	rs250585	0.646	rs66569010	ENSG00000260136.4	CTD-2270L9.4	-3.64	0.000307	0.0203	-0.13	-0.17	Egg allergy;	chr16:23475631	chr16:23452758~23457606:+
THCA	cis	rs12681366	1	rs10956911	ENSG00000261437.1	RP11-22C11.2	3.64	0.000307	0.0204	0.16	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94371647	chr8:94637285~94639467:-
THCA	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-3.64	0.000307	0.0204	-0.21	-0.17	Height;	chr20:49235382	chr20:49280319~49280409:+
THCA	cis	rs929354	0.742	rs7785227	ENSG00000224629.1	RP5-1142J19.2	-3.64	0.000307	0.0204	-0.16	-0.17	Body mass index;	chr7:157206603	chr7:157263022~157263229:-
THCA	cis	rs56309584	0.678	rs8076031	ENSG00000271002.1	RP11-599B13.8	-3.64	0.000307	0.0204	-0.21	-0.17	Initial pursuit acceleration;	chr17:8247086	chr17:8199123~8199437:-
THCA	cis	rs2625529	0.824	rs4777471	ENSG00000260037.4	CTD-2524L6.3	-3.64	0.000307	0.0204	-0.23	-0.17	Red blood cell count;	chr15:71915463	chr15:71818396~71823384:+
THCA	cis	rs669446	0.562	rs3791036	ENSG00000237950.1	RP11-7O11.3	3.64	0.000307	0.0204	0.14	0.17	Amyotrophic lateral sclerosis (age of onset);	chr1:43689712	chr1:43944370~43946551:-
THCA	cis	rs877819	0.697	rs10776651	ENSG00000228403.1	RP11-563N6.6	-3.64	0.000307	0.0204	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48876481	chr10:48878022~48878649:+
THCA	cis	rs11583043	1	rs12567858	ENSG00000233184.5	RP11-421L21.3	3.64	0.000307	0.0204	0.18	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr1:101052132	chr1:101025878~101087268:+
THCA	cis	rs7824557	0.713	rs6601575	ENSG00000255046.1	RP11-297N6.4	-3.64	0.000307	0.0204	-0.17	-0.17	Retinal vascular caliber;	chr8:11240295	chr8:11797928~11802568:-
THCA	cis	rs2243480	1	rs316315	ENSG00000237310.1	GS1-124K5.4	-3.64	0.000307	0.0204	-0.16	-0.17	Diabetic kidney disease;	chr7:66126218	chr7:66493706~66495474:+
THCA	cis	rs1799922	0.708	rs339099	ENSG00000273270.1	RP11-212P7.2	-3.64	0.000307	0.0204	-0.18	-0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128756291	chr7:128524016~128531069:-
THCA	cis	rs4648045	0.621	rs980455	ENSG00000246560.2	RP11-10L12.4	3.64	0.000307	0.0204	0.2	0.17	Lymphocyte percentage of white cells;	chr4:102497800	chr4:102828055~102844075:+
THCA	cis	rs2288884	1	rs80278704	ENSG00000260160.1	CTC-471J1.2	-3.64	0.000307	0.0204	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52045930	chr19:52058490~52063703:-
THCA	cis	rs2288884	1	rs11669540	ENSG00000260160.1	CTC-471J1.2	-3.64	0.000307	0.0204	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52046486	chr19:52058490~52063703:-
THCA	cis	rs2288884	1	rs78543982	ENSG00000260160.1	CTC-471J1.2	-3.64	0.000307	0.0204	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047614	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.943	rs3752120	ENSG00000260160.1	CTC-471J1.2	-3.64	0.000307	0.0204	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048768	chr19:52058490~52063703:-
THCA	cis	rs2288884	1	rs79817140	ENSG00000260160.1	CTC-471J1.2	-3.64	0.000307	0.0204	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068404	chr19:52058490~52063703:-
THCA	cis	rs2288884	1	rs11669385	ENSG00000260160.1	CTC-471J1.2	-3.64	0.000307	0.0204	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068699	chr19:52058490~52063703:-
THCA	cis	rs2288884	1	rs17835749	ENSG00000260160.1	CTC-471J1.2	-3.64	0.000307	0.0204	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075442	chr19:52058490~52063703:-
THCA	cis	rs2288884	1	rs12609219	ENSG00000260160.1	CTC-471J1.2	-3.64	0.000307	0.0204	-0.17	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077743	chr19:52058490~52063703:-
THCA	cis	rs889312	0.5	rs865570	ENSG00000271828.1	CTD-2310F14.1	-3.64	0.000307	0.0204	-0.22	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56866148	chr5:56927874~56929573:+
THCA	cis	rs889312	0.5	rs832577	ENSG00000271828.1	CTD-2310F14.1	-3.64	0.000307	0.0204	-0.22	-0.17	Breast cancer (early onset);Breast cancer;	chr5:56867960	chr5:56927874~56929573:+
THCA	cis	rs642858	0.521	rs856648	ENSG00000234147.1	RP3-460G2.2	3.64	0.000307	0.0204	0.19	0.17	Type 2 diabetes;	chr6:139924882	chr6:140845958~140852924:-
THCA	cis	rs7208859	0.573	rs216442	ENSG00000214719.10	AC005562.1	-3.64	0.000307	0.0204	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs216445	ENSG00000214719.10	AC005562.1	-3.64	0.000307	0.0204	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs216446	ENSG00000214719.10	AC005562.1	-3.64	0.000307	0.0204	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30576464~30672789:+
THCA	cis	rs11190604	1	rs2298074	ENSG00000273030.1	RP11-285F16.1	3.64	0.000307	0.0204	0.2	0.17	Palmitoleic acid (16:1n-7) levels;	chr10:100487769	chr10:100412934~100413421:+
THCA	cis	rs55946907	1	rs55946907	ENSG00000227141.2	RP11-545A16.3	-3.64	0.000307	0.0204	-0.36	-0.17	Anorexia nervosa;	chr1:180161588	chr1:179586705~179589175:+
THCA	cis	rs10411161	0.702	rs7250138	ENSG00000275055.1	CTC-471J1.11	-3.64	0.000307	0.0204	-0.16	-0.17	Breast cancer;	chr19:51881979	chr19:52049007~52049754:+
THCA	cis	rs614226	0.935	rs588132	ENSG00000278344.1	RP11-18C24.8	3.64	0.000307	0.0204	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120586263	chr12:120500735~120501090:-
THCA	cis	rs3015497	0.616	rs11157759	ENSG00000270062.1	RP11-248J18.3	3.64	0.000307	0.0204	0.19	0.17	Mean platelet volume;	chr14:50620545	chr14:50723777~50724272:-
THCA	cis	rs1050631	1	rs1050631	ENSG00000260552.1	RP11-49I11.1	-3.64	0.000307	0.0204	-0.2	-0.17	Esophageal squamous cell cancer (length of survival);	chr18:36114157	chr18:36179996~36187448:-
THCA	cis	rs78388617	0.579	rs58161991	ENSG00000214908.3	RP11-229M1.2	-3.64	0.000307	0.0204	-0.27	-0.17	Subjective well-being;	chr9:86989358	chr9:86374966~86375706:-
THCA	cis	rs1538970	0.847	rs1771550	ENSG00000234329.1	RP11-767N6.2	-3.64	0.000307	0.0204	-0.17	-0.17	Platelet count;	chr1:45417893	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000184274.3	LINC00315	-3.64	0.000307	0.0204	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45300245~45305257:-
THCA	cis	rs17045328	1	rs17045328	ENSG00000274245.1	RP11-357P18.2	3.64	0.000307	0.0204	0.32	0.17	Type 2 diabetes;	chr1:207478831	chr1:207372559~207373252:+
THCA	cis	rs57709857	0.957	rs6984464	ENSG00000272092.1	RP11-350N15.5	-3.64	0.000307	0.0204	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38283861	chr8:38382364~38383461:+
THCA	cis	rs11673344	0.801	rs17707446	ENSG00000229481.2	CTD-2554C21.3	3.64	0.000307	0.0204	0.15	0.17	Obesity-related traits;	chr19:37092140	chr19:37829551~37832160:+
THCA	cis	rs17092148	1	rs6060047	ENSG00000269202.1	RP4-614O4.12	-3.64	0.000308	0.0204	-0.19	-0.17	Neuroticism;	chr20:34779597	chr20:35201747~35203288:-
THCA	cis	rs7614311	0.594	rs3774709	ENSG00000271843.1	RP11-245J9.5	-3.64	0.000308	0.0204	-0.27	-0.17	Lung function (FVC);Lung function (FEV1);	chr3:63896800	chr3:64008082~64008692:-
THCA	cis	rs7520050	0.966	rs10789481	ENSG00000281133.1	AL355480.3	3.64	0.000308	0.0204	0.19	0.17	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:45580892~45580996:-
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000184274.3	LINC00315	-3.64	0.000308	0.0204	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45300245~45305257:-
THCA	cis	rs4973397	0.921	rs12622248	ENSG00000224376.1	AC017104.6	3.64	0.000308	0.0204	0.19	0.17	Anti-saccade response;	chr2:231424416	chr2:231388976~231394991:+
THCA	cis	rs4908768	0.822	rs12122737	ENSG00000232912.4	RP5-1115A15.1	-3.64	0.000308	0.0204	-0.2	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556345	chr1:8424645~8434838:+
THCA	cis	rs13108904	0.84	rs13106092	ENSG00000254094.1	AC078852.1	-3.64	0.000308	0.0204	-0.2	-0.17	Obesity-related traits;	chr4:1263502	chr4:1356581~1358075:+
THCA	cis	rs2019137	0.936	rs3811059	ENSG00000234997.1	AC016745.3	-3.64	0.000308	0.0204	-0.16	-0.17	Lymphocyte counts;	chr2:113204494	chr2:113424495~113425324:+
THCA	cis	rs2019137	0.936	rs12620738	ENSG00000234997.1	AC016745.3	-3.64	0.000308	0.0204	-0.16	-0.17	Lymphocyte counts;	chr2:113206162	chr2:113424495~113425324:+
THCA	cis	rs17741873	0.779	rs17631000	ENSG00000271848.1	RP11-464F9.21	3.64	0.000308	0.0204	0.2	0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73842742	chr10:73654039~73674719:+
THCA	cis	rs17741873	0.836	rs10824039	ENSG00000271848.1	RP11-464F9.21	-3.64	0.000308	0.0204	-0.2	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73843091	chr10:73654039~73674719:+
THCA	cis	rs875971	1	rs4718357	ENSG00000272831.1	RP11-792A8.4	3.64	0.000308	0.0204	0.1	0.17	Aortic root size;	chr7:66495891	chr7:66739829~66740385:-
THCA	cis	rs4906332	0.782	rs2236281	ENSG00000269958.1	RP11-73M18.8	3.64	0.000308	0.0204	0.17	0.17	Coronary artery disease;	chr14:103534181	chr14:103696353~103697163:+
THCA	cis	rs2880765	0.743	rs8032488	ENSG00000218052.5	ADAMTS7P4	-3.64	0.000308	0.0204	-0.19	-0.17	Coronary artery disease;	chr15:85469537	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.743	rs8028240	ENSG00000218052.5	ADAMTS7P4	-3.64	0.000308	0.0204	-0.19	-0.17	Coronary artery disease;	chr15:85470017	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.743	rs6497194	ENSG00000218052.5	ADAMTS7P4	-3.64	0.000308	0.0204	-0.19	-0.17	Coronary artery disease;	chr15:85470885	chr15:85255369~85330334:-
THCA	cis	rs603446	0.967	rs108533	ENSG00000254851.1	RP11-109L13.1	3.64	0.000308	0.0204	0.21	0.17	Triglycerides;	chr11:116730995	chr11:117135528~117138582:+
THCA	cis	rs7216064	1	rs56148300	ENSG00000265055.1	AC145343.2	3.64	0.000308	0.0204	0.23	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896636	chr17:68096046~68101474:-
THCA	cis	rs9652490	0.646	rs12914049	ENSG00000214646.7	RP11-114H24.4	3.64	0.000308	0.0204	0.29	0.17	Essential tremor;	chr15:77676783	chr15:77941442~77944582:-
THCA	cis	rs9652490	0.646	rs35971971	ENSG00000214646.7	RP11-114H24.4	3.64	0.000308	0.0204	0.29	0.17	Essential tremor;	chr15:77680108	chr15:77941442~77944582:-
THCA	cis	rs12291225	0.679	rs11238	ENSG00000251991.1	RNU7-49P	-3.64	0.000308	0.0204	-0.19	-0.17	Sense of smell;	chr11:14266582	chr11:14478892~14478953:+
THCA	cis	rs1075265	0.744	rs10203576	ENSG00000235937.1	AC008280.1	3.64	0.000308	0.0204	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54029552~54030682:-
THCA	cis	rs7615952	0.599	rs1875683	ENSG00000241288.6	RP11-379B18.5	-3.64	0.000308	0.0204	-0.19	-0.17	Blood pressure (smoking interaction);	chr3:126013638	chr3:125827238~125916384:-
THCA	cis	rs2255336	0.684	rs6416265	ENSG00000245648.1	RP11-277P12.20	3.64	0.000308	0.0204	0.23	0.17	Blood protein levels;	chr12:10344268	chr12:10363769~10398506:+
THCA	cis	rs860295	0.702	rs34620961	ENSG00000236675.1	MTX1P1	-3.64	0.000308	0.0204	-0.17	-0.17	Body mass index;	chr1:155680036	chr1:155230975~155234325:+
THCA	cis	rs858239	0.508	rs10242104	ENSG00000230042.1	AK3P3	-3.64	0.000308	0.0204	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23129178~23129841:+
THCA	cis	rs3736986	0.908	rs10814347	ENSG00000215283.3	HMGB3P24	-3.64	0.000308	0.0204	-0.3	-0.17	Bipolar disorder (inflammation and infection response interaction);	chr9:36174240	chr9:36303499~36304924:-
THCA	cis	rs3736986	0.831	rs10972774	ENSG00000215283.3	HMGB3P24	-3.64	0.000308	0.0204	-0.3	-0.17	Bipolar disorder (inflammation and infection response interaction);	chr9:36174688	chr9:36303499~36304924:-
THCA	cis	rs5743289	0.614	rs749910	ENSG00000260929.1	RP11-327F22.1	3.64	0.000308	0.0204	0.2	0.17	Crohn's disease;Inflammatory bowel disease;	chr16:50724938	chr16:50740910~50742815:-
THCA	cis	rs1371614	0.523	rs12468721	ENSG00000272148.1	RP11-195B17.1	-3.64	0.000308	0.0204	-0.15	-0.17	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26960883	chr2:27062428~27062907:-
THCA	cis	rs7688540	0.723	rs9684973	ENSG00000250892.1	RP11-1365D11.1	3.64	0.000308	0.0204	0.24	0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:201409~205009:-
THCA	cis	rs67839313	0.541	rs10163076	ENSG00000273855.1	RP11-133K1.12	3.64	0.000308	0.0204	0.31	0.17	Type 2 diabetes;	chr15:40314283	chr15:40285468~40285909:-
THCA	cis	rs2227564	0.729	rs2633303	ENSG00000271816.1	BMS1P4	3.64	0.000308	0.0204	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73886124	chr10:73699151~73730487:-
THCA	cis	rs2227564	0.729	rs2688617	ENSG00000271816.1	BMS1P4	3.64	0.000308	0.0204	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73886389	chr10:73699151~73730487:-
THCA	cis	rs2227564	0.729	rs2675675	ENSG00000271816.1	BMS1P4	3.64	0.000308	0.0204	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73889290	chr10:73699151~73730487:-
THCA	cis	rs2227564	0.729	rs2688615	ENSG00000271816.1	BMS1P4	3.64	0.000308	0.0204	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73891741	chr10:73699151~73730487:-
THCA	cis	rs9309473	1	rs1534471	ENSG00000273245.1	RP11-434P11.2	3.64	0.000308	0.0204	0.22	0.17	Metabolite levels;	chr2:73420380	chr2:73750256~73750786:-
THCA	cis	rs12200782	0.649	rs9467747	ENSG00000124549.13	BTN2A3P	-3.64	0.000308	0.0204	-0.2	-0.17	Small cell lung carcinoma;	chr6:26388844	chr6:26421391~26432383:+
THCA	cis	rs16975963	0.843	rs73041047	ENSG00000226686.6	LINC01535	-3.64	0.000308	0.0204	-0.23	-0.17	Longevity;	chr19:37808649	chr19:37251912~37265535:+
THCA	cis	rs7707921	1	rs891159	ENSG00000251374.1	RPS23P5	3.64	0.000308	0.0204	0.23	0.17	Breast cancer;	chr5:82195268	chr5:82265157~82265259:-
THCA	cis	rs7259376	0.902	rs11669356	ENSG00000269345.1	VN1R85P	-3.64	0.000308	0.0204	-0.18	-0.17	Menopause (age at onset);	chr19:22422318	chr19:22174766~22175191:-
THCA	cis	rs2494663	0.61	rs11264886	ENSG00000231416.1	RP11-422P24.9	-3.64	0.000308	0.0204	-0.21	-0.17	Mean platelet volume;	chr1:154024870	chr1:153995632~153995960:+
THCA	cis	rs9902453	0.845	rs2617865	ENSG00000264290.1	RP11-68I3.4	-3.64	0.000308	0.0204	-0.13	-0.17	Coffee consumption (cups per day);	chr17:29722786	chr17:29569580~29570519:+
THCA	cis	rs11633958	1	rs11633958	ENSG00000261762.1	RP11-650L12.2	-3.64	0.000308	0.0204	-0.22	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78569722	chr15:78589123~78591276:-
THCA	cis	rs4845570	1	rs17568246	ENSG00000249602.1	RP11-98D18.3	-3.64	0.000308	0.0204	-0.26	-0.17	Coronary artery disease;	chr1:151763980	chr1:151763384~151769501:-
THCA	cis	rs57709857	0.801	rs2898674	ENSG00000272092.1	RP11-350N15.5	3.64	0.000308	0.0204	0.17	0.17	Autism spectrum disorder or schizophrenia;	chr8:38252697	chr8:38382364~38383461:+
THCA	cis	rs854765	0.547	rs2955353	ENSG00000281749.1	Y_RNA	-3.64	0.000308	0.0204	-0.21	-0.17	Total body bone mineral density;	chr17:18045665	chr17:18001101~18001195:-
THCA	cis	rs9425766	0.962	rs941989	ENSG00000200674.1	RN7SKP160	-3.64	0.000308	0.0204	-0.22	-0.17	Life satisfaction;	chr1:173912733	chr1:173791548~173791887:+
THCA	cis	rs2886497	1	rs4427476	ENSG00000224215.1	RP11-371A19.2	-3.64	0.000308	0.0204	-0.2	-0.17	Major depression and alcohol dependence;	chr10:23381873	chr10:23343957~23345181:+
THCA	cis	rs61160187	0.582	rs976631	ENSG00000272308.1	RP11-231G3.1	-3.64	0.000308	0.0204	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60866457~60866935:-
THCA	cis	rs2911280	0.656	rs9931108	ENSG00000278985.1	RP11-303E16.9	-3.64	0.000308	0.0204	-0.31	-0.17	Dehydroepiandrosterone sulphate levels;	chr16:81528423	chr16:80982319~80984094:-
THCA	cis	rs6724465	1	rs13398898	ENSG00000272644.1	RP11-33O4.1	3.64	0.000308	0.0204	0.25	0.17	Height;	chr2:219063025	chr2:219069354~219069809:-
THCA	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	3.64	0.000308	0.0204	0.22	0.17	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
THCA	cis	rs9488822	0.596	rs6568921	ENSG00000233558.1	RP3-486I3.4	3.64	0.000308	0.0204	0.19	0.17	LDL cholesterol;Cholesterol, total;	chr6:116052453	chr6:116258493~116259115:-
THCA	cis	rs4869313	0.694	rs2112974	ENSG00000247121.5	CTD-2260A17.2	-3.64	0.000308	0.0204	-0.12	-0.17	Pediatric autoimmune diseases;	chr5:96977404	chr5:96814028~96935809:-
THCA	cis	rs9611565	0.659	rs28623192	ENSG00000281538.1	RP4-669P10.20	3.64	0.000308	0.0204	0.19	0.17	Vitiligo;	chr22:41544520	chr22:42138060~42139726:+
THCA	cis	rs2235642	0.533	rs17135391	ENSG00000260989.1	LA16c-395F10.2	-3.64	0.000308	0.0204	-0.19	-0.17	Coronary artery disease;	chr16:1555605	chr16:1580527~1610328:+
THCA	cis	rs4073416	0.542	rs1113962	ENSG00000276116.2	FUT8-AS1	3.64	0.000308	0.0204	0.19	0.17	N-glycan levels;	chr14:65539080	chr14:65411170~65412690:-
THCA	cis	rs11710088	0.931	rs1802837	ENSG00000240541.2	TM4SF1-AS1	3.64	0.000308	0.0204	0.16	0.17	QRS duration;	chr3:149475897	chr3:149377778~149386583:+
THCA	cis	rs11710088	0.931	rs3890113	ENSG00000240541.2	TM4SF1-AS1	3.64	0.000308	0.0204	0.16	0.17	QRS duration;	chr3:149476254	chr3:149377778~149386583:+
THCA	cis	rs11710088	0.895	rs4321472	ENSG00000240541.2	TM4SF1-AS1	3.64	0.000308	0.0204	0.16	0.17	QRS duration;	chr3:149477951	chr3:149377778~149386583:+
THCA	cis	rs11710088	0.931	rs4577407	ENSG00000240541.2	TM4SF1-AS1	-3.64	0.000308	0.0204	-0.16	-0.17	QRS duration;	chr3:149477962	chr3:149377778~149386583:+
THCA	cis	rs6988985	0.818	rs7463212	ENSG00000247317.3	RP11-273G15.2	3.64	0.000308	0.0204	0.18	0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142910442	chr8:142981738~143018437:-
THCA	cis	rs638893	0.842	rs480791	ENSG00000255422.1	AP002954.4	-3.64	0.000308	0.0204	-0.26	-0.17	Vitiligo;	chr11:118833546	chr11:118704607~118750263:+
THCA	cis	rs13063635	0.915	rs34068335	ENSG00000226074.4	PRSS44	-3.64	0.000308	0.0204	-0.31	-0.17	Eosinophil percentage of granulocytes;	chr3:45912847	chr3:46809359~46812558:-
THCA	cis	rs9650657	0.711	rs10100209	ENSG00000255310.2	AF131215.2	-3.64	0.000308	0.0204	-0.14	-0.17	Neuroticism;	chr8:10726702	chr8:11107788~11109726:-
THCA	cis	rs78487399	0.908	rs17031079	ENSG00000234936.1	AC010883.5	3.64	0.000308	0.0204	0.21	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43577794	chr2:43229573~43233394:+
THCA	cis	rs4879656	0.966	rs10971361	ENSG00000225693.1	LAGE3P1	-3.64	0.000309	0.0204	-0.18	-0.17	Menopause (age at onset);	chr9:33042564	chr9:33019682~33020165:-
THCA	cis	rs2554380	0.943	rs1477593	ENSG00000230373.7	GOLGA6L5P	-3.64	0.000309	0.0204	-0.21	-0.17	Height;	chr15:83694293	chr15:84507885~84516814:-
THCA	cis	rs7520050	0.966	rs7556615	ENSG00000280836.1	AL355480.1	3.64	0.000309	0.0204	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45581219~45581321:-
THCA	cis	rs801193	0.742	rs9969300	ENSG00000275400.1	RP4-756H11.5	3.64	0.000309	0.0204	0.16	0.17	Aortic root size;	chr7:66316659	chr7:66553805~66554199:-
THCA	cis	rs12479254	0.6	rs4675800	ENSG00000228989.1	AC133528.2	-3.64	0.000309	0.0204	-0.13	-0.17	Brain structure;	chr2:241563227	chr2:241690414~241694289:+
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000264242.2	RP11-271K11.1	3.64	0.000309	0.0204	0.24	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs216433	ENSG00000264242.2	RP11-271K11.1	3.64	0.000309	0.0204	0.24	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30553697~30558962:+
THCA	cis	rs17597773	0.638	rs12129004	ENSG00000238078.1	LINC01352	-3.64	0.000309	0.0204	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812173	chr1:220829255~220832429:+
THCA	cis	rs3849570	0.695	rs62265411	ENSG00000241593.4	RP11-520D19.2	-3.64	0.000309	0.0204	-0.21	-0.17	Waist circumference;Body mass index;	chr3:81524509	chr3:81246579~81297345:-
THCA	cis	rs7989336	0.663	rs1925101	ENSG00000247400.3	DNAJC3-AS1	-3.63	0.000309	0.0205	-0.11	-0.17	Obesity;	chr13:96368514	chr13:95648733~95676925:-
THCA	cis	rs7833790	1	rs7834808	ENSG00000254689.1	RP11-354A14.1	3.63	0.000309	0.0205	0.21	0.17	Diastolic blood pressure;	chr8:81792761	chr8:81885377~81923193:+
THCA	cis	rs656900	0.765	rs599842	ENSG00000261229.4	MTHFS	-3.63	0.000309	0.0205	-0.17	-0.17	Cerebrospinal P-tau181p levels;	chr15:79819549	chr15:79843547~79897285:-
THCA	cis	rs755249	1	rs755249	ENSG00000182109.6	RP11-69E11.4	3.63	0.000309	0.0205	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39522280~39546187:-
THCA	cis	rs240993	0.595	rs4947127	ENSG00000272356.1	RP5-1112D6.8	3.63	0.000309	0.0205	0.14	0.17	Inflammatory skin disease;Psoriasis;	chr6:111581595	chr6:111309203~111313517:+
THCA	cis	rs6030712	0.761	rs1291149	ENSG00000213979.3	RPL7AP14	3.63	0.000309	0.0205	0.26	0.17	Height;	chr20:36905059	chr20:37444733~37445534:-
THCA	cis	rs2274273	0.87	rs8021583	ENSG00000258469.1	CHMP4BP1	3.63	0.000309	0.0205	0.15	0.17	Protein biomarker;	chr14:55282889	chr14:55298644~55299231:+
THCA	cis	rs4915077	0.773	rs55711603	ENSG00000226822.1	RP11-356N1.2	3.63	0.000309	0.0205	0.31	0.17	Hypothyroidism;	chr1:107731595	chr1:108071482~108074519:+
THCA	cis	rs9309473	0.948	rs2421550	ENSG00000273245.1	RP11-434P11.2	3.63	0.000309	0.0205	0.22	0.17	Metabolite levels;	chr2:73431558	chr2:73750256~73750786:-
THCA	cis	rs7781557	0.64	rs66712128	ENSG00000170629.13	DPY19L2P2	-3.63	0.000309	0.0205	-0.2	-0.17	Colorectal adenoma (advanced);	chr7:102976540	chr7:103175133~103280410:-
THCA	cis	rs720064	0.586	rs12956330	ENSG00000264745.1	TTC39C-AS1	3.63	0.000309	0.0205	0.18	0.17	Strep throat;	chr18:23981536	chr18:23994213~24015339:-
THCA	cis	rs7919656	0.662	rs2620883	ENSG00000228403.1	RP11-563N6.6	-3.63	0.000309	0.0205	-0.17	-0.17	Clinically amyopathic dermatomyositis;	chr10:48869158	chr10:48878022~48878649:+
THCA	cis	rs28857569	0.514	rs28505086	ENSG00000254023.1	PKMP4	3.63	0.000309	0.0205	0.25	0.17	Body mass index;	chr8:75679786	chr8:75376709~75377014:+
THCA	cis	rs28857569	0.514	rs13438936	ENSG00000254023.1	PKMP4	3.63	0.000309	0.0205	0.25	0.17	Body mass index;	chr8:75680805	chr8:75376709~75377014:+
THCA	cis	rs7572733	0.555	rs35563720	ENSG00000231621.1	AC013264.2	-3.63	0.000309	0.0205	-0.18	-0.17	Dermatomyositis;	chr2:198058351	chr2:197197991~197199273:+
THCA	cis	rs4792901	0.722	rs7220615	ENSG00000279602.1	CTD-3014M21.1	-3.63	0.000309	0.0205	-0.21	-0.17	Dupuytren's disease;	chr17:43463276	chr17:43360041~43361361:-
THCA	cis	rs2904297	0.958	rs4622992	ENSG00000261490.1	RP11-448G15.3	-3.63	0.000309	0.0205	-0.11	-0.17	Hashimoto thyroiditis versus Graves' disease;	chr4:11026190	chr4:10068089~10073019:-
THCA	cis	rs9420	0.528	rs7102271	ENSG00000254602.1	AP000662.4	-3.63	0.000309	0.0205	-0.19	-0.17	Schizophrenia;	chr11:57629352	chr11:57638024~57652790:+
THCA	cis	rs7712401	0.599	rs35128692	ENSG00000249996.1	RP11-359P5.1	3.63	0.000309	0.0205	0.17	0.17	Mean platelet volume;	chr5:123033319	chr5:123036271~123054667:+
THCA	cis	rs7777677	0.925	rs6969951	ENSG00000226660.2	TRBV2	-3.63	0.000309	0.0205	-0.14	-0.17	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142300924~142301432:+
THCA	cis	rs479105	0.603	rs3782775	ENSG00000278356.1	RP11-372B4.3	3.63	0.000309	0.0205	0.16	0.17	Gut microbiota (bacterial taxa);	chr12:3262064	chr12:2885819~2886329:+
THCA	cis	rs853679	0.607	rs13211507	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28289600	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34691223	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28290431	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13207345	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28297795	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs72854513	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28298177	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs56189111	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28304196	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34950484	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28310911	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs35072899	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28313764	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34661125	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28314117	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13190888	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28318208	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs56075693	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28322551	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34218844	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.37	0.17	Depression;	chr6:28322870	chr6:28073316~28074233:+
THCA	cis	rs7264396	0.676	rs6060730	ENSG00000088340.14	FER1L4	3.63	0.000309	0.0205	0.16	0.17	Total cholesterol levels;	chr20:35970581	chr20:35558737~35607562:-
THCA	cis	rs8131065	1	rs6517373	ENSG00000273199.1	AP000692.10	-3.63	0.000309	0.0205	-0.26	-0.17	Iris color (L* coordinate);	chr21:36641082	chr21:36319792~36320670:-
THCA	cis	rs17407555	0.741	rs12509713	ENSG00000250413.1	RP11-448G15.1	3.63	0.000309	0.0205	0.18	0.17	Schizophrenia (age at onset);	chr4:10105445	chr4:10006482~10009725:+
THCA	cis	rs1005277	0.522	rs11011343	ENSG00000120555.12	SEPT7P9	3.63	0.000309	0.0205	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38383069~38402916:-
THCA	cis	rs929354	0.685	rs1808217	ENSG00000224629.1	RP5-1142J19.2	-3.63	0.000309	0.0205	-0.16	-0.17	Body mass index;	chr7:157210047	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs2006844	ENSG00000224629.1	RP5-1142J19.2	-3.63	0.000309	0.0205	-0.16	-0.17	Body mass index;	chr7:157210157	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs886677	ENSG00000224629.1	RP5-1142J19.2	-3.63	0.000309	0.0205	-0.16	-0.17	Body mass index;	chr7:157211088	chr7:157263022~157263229:-
THCA	cis	rs6878727	0.6	rs2619946	ENSG00000253807.4	LINC01170	3.63	0.000309	0.0205	0.15	0.17	Breast cancer;	chr5:124305546	chr5:124059794~124405079:-
THCA	cis	rs6903823	0.508	rs1150726	ENSG00000220721.1	OR1F12	3.63	0.000309	0.0205	0.19	0.17	Pulmonary function;	chr6:28275265	chr6:28073316~28074233:+
THCA	cis	rs875971	0.756	rs4718328	ENSG00000223473.2	GS1-124K5.3	-3.63	0.000309	0.0205	-0.11	-0.17	Aortic root size;	chr7:66228350	chr7:66491049~66493566:-
THCA	cis	rs9863	0.861	rs7312404	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000309	0.0205	-0.19	-0.17	White blood cell count;	chr12:123962181	chr12:123968023~123968579:-
THCA	cis	rs9863	0.827	rs7134121	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000309	0.0205	-0.19	-0.17	White blood cell count;	chr12:123962799	chr12:123968023~123968579:-
THCA	cis	rs9393777	0.844	rs28360634	ENSG00000272009.1	RP1-313I6.12	-3.63	0.000309	0.0205	-0.3	-0.17	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28078792~28081130:-
THCA	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-3.63	0.000309	0.0205	-0.13	-0.17	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
THCA	cis	rs5758511	0.68	rs1107554	ENSG00000182057.4	OGFRP1	-3.63	0.000309	0.0205	-0.22	-0.17	Birth weight;	chr22:42271588	chr22:42269753~42275196:+
THCA	cis	rs4656958	0.93	rs2184064	ENSG00000233691.2	RP11-312J18.7	3.63	0.000309	0.0205	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160917685	chr1:160935537~160936126:+
THCA	cis	rs4656958	0.897	rs12740520	ENSG00000233691.2	RP11-312J18.7	3.63	0.000309	0.0205	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160917819	chr1:160935537~160936126:+
THCA	cis	rs4656958	0.93	rs3953093	ENSG00000233691.2	RP11-312J18.7	3.63	0.000309	0.0205	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160917961	chr1:160935537~160936126:+
THCA	cis	rs12149695	0.735	rs11641348	ENSG00000259940.2	CTD-3203P2.1	-3.63	0.000309	0.0205	-0.18	-0.17	Gut microbiota (bacterial taxa);	chr16:27233765	chr16:27213308~27214993:-
THCA	cis	rs7188697	0.922	rs9926577	ENSG00000276259.1	RP11-481J2.4	3.63	0.000309	0.0205	0.12	0.17	QT interval;	chr16:58579527	chr16:58522970~58523842:+
THCA	cis	rs1577330	0.848	rs7872477	ENSG00000254396.1	RP11-56F10.3	3.63	0.000309	0.0205	0.2	0.17	IgG glycosylation;	chr9:27069287	chr9:27102630~27104728:+
THCA	cis	rs1577330	0.898	rs7872478	ENSG00000254396.1	RP11-56F10.3	3.63	0.000309	0.0205	0.2	0.17	IgG glycosylation;	chr9:27069288	chr9:27102630~27104728:+
THCA	cis	rs3753275	0.508	rs2781068	ENSG00000230679.1	ENO1-AS1	3.63	0.000309	0.0205	0.16	0.17	Educational attainment;	chr1:8864862	chr1:8878835~8879894:+
THCA	cis	rs853679	1	rs1936365	ENSG00000261839.1	RP1-265C24.8	-3.63	0.000309	0.0205	-0.22	-0.17	Depression;	chr6:28300675	chr6:28136849~28139678:+
THCA	cis	rs758324	0.755	rs555662	ENSG00000224431.1	AC063976.7	3.63	0.000309	0.0205	0.16	0.17	Alzheimer's disease in APOE e4- carriers;	chr5:132015210	chr5:132199456~132203487:+
THCA	cis	rs7824557	0.583	rs2736292	ENSG00000227888.4	FAM66A	3.63	0.000309	0.0205	0.21	0.17	Retinal vascular caliber;	chr8:11376991	chr8:12362019~12388296:+
THCA	cis	rs875971	0.929	rs34406470	ENSG00000272831.1	RP11-792A8.4	3.63	0.00031	0.0205	0.1	0.17	Aortic root size;	chr7:66464969	chr7:66739829~66740385:-
THCA	cis	rs1874124	0.577	rs2807872	ENSG00000238078.1	LINC01352	-3.63	0.00031	0.0205	-0.29	-0.17	Cholesterol, total;	chr1:220866908	chr1:220829255~220832429:+
THCA	cis	rs4073416	0.518	rs2149839	ENSG00000276116.2	FUT8-AS1	3.63	0.00031	0.0205	0.19	0.17	N-glycan levels;	chr14:65516730	chr14:65411170~65412690:-
THCA	cis	rs875971	0.964	rs6978429	ENSG00000272831.1	RP11-792A8.4	3.63	0.00031	0.0205	0.1	0.17	Aortic root size;	chr7:66494889	chr7:66739829~66740385:-
THCA	cis	rs875971	0.929	rs12535036	ENSG00000272831.1	RP11-792A8.4	3.63	0.00031	0.0205	0.1	0.17	Aortic root size;	chr7:66499076	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs12698523	ENSG00000272831.1	RP11-792A8.4	3.63	0.00031	0.0205	0.1	0.17	Aortic root size;	chr7:66503126	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6970030	ENSG00000272831.1	RP11-792A8.4	3.63	0.00031	0.0205	0.1	0.17	Aortic root size;	chr7:66503692	chr7:66739829~66740385:-
THCA	cis	rs875971	0.928	rs6970357	ENSG00000272831.1	RP11-792A8.4	3.63	0.00031	0.0205	0.1	0.17	Aortic root size;	chr7:66503891	chr7:66739829~66740385:-
THCA	cis	rs3750082	0.754	rs35110377	ENSG00000205763.12	RP9P	-3.63	0.00031	0.0205	-0.14	-0.17	Glomerular filtration rate (creatinine);	chr7:32932158	chr7:32916815~32943176:-
THCA	cis	rs8058578	0.945	rs885107	ENSG00000260911.2	RP11-196G11.2	3.63	0.00031	0.0205	0.14	0.17	Multiple myeloma;	chr16:30661398	chr16:31043150~31049868:+
THCA	cis	rs7897654	0.578	rs11191506	ENSG00000236937.2	PTGES3P4	-3.63	0.00031	0.0205	-0.24	-0.17	Schizophrenia;	chr10:103008877	chr10:102845595~102845950:+
THCA	cis	rs1350171	0.764	rs4631906	ENSG00000255471.1	RP11-736K20.5	-3.63	0.00031	0.0205	-0.21	-0.17	Hepatocellular carcinoma in hepatitis B infection;	chr11:86939240	chr11:86892214~86925037:-
THCA	cis	rs2227564	0.729	rs2675676	ENSG00000271816.1	BMS1P4	3.63	0.00031	0.0205	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73888529	chr10:73699151~73730487:-
THCA	cis	rs77622099	0.609	rs17815124	ENSG00000233426.3	EIF3FP3	-3.63	0.00031	0.0205	-0.41	-0.17	Neuroticism;	chr2:57764400	chr2:58251440~58252525:+
THCA	cis	rs4908768	0.539	rs11121204	ENSG00000270282.1	RP5-1115A15.2	-3.63	0.00031	0.0205	-0.2	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8512653~8513021:+
THCA	cis	rs7395662	0.853	rs10838885	ENSG00000200090.1	Y_RNA	-3.63	0.00031	0.0205	-0.11	-0.17	HDL cholesterol;	chr11:48377254	chr11:47726894~47726992:-
THCA	cis	rs11673344	0.764	rs10403679	ENSG00000267260.1	CTD-2162K18.4	-3.63	0.00031	0.0205	-0.21	-0.17	Obesity-related traits;	chr19:36980810	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.764	rs13345491	ENSG00000267260.1	CTD-2162K18.4	-3.63	0.00031	0.0205	-0.21	-0.17	Obesity-related traits;	chr19:36982197	chr19:36773153~36777078:+
THCA	cis	rs453301	0.631	rs17700611	ENSG00000254340.1	RP11-10A14.3	-3.63	0.00031	0.0205	-0.2	-0.17	Joint mobility (Beighton score);	chr8:8936144	chr8:9141424~9145435:+
THCA	cis	rs3750965	0.575	rs3892895	ENSG00000260895.1	RP11-554A11.7	-3.63	0.00031	0.0205	-0.2	-0.17	Hair color;	chr11:69117287	chr11:69103493~69109094:+
THCA	cis	rs453301	0.631	rs13250781	ENSG00000253981.4	ALG1L13P	-3.63	0.00031	0.0205	-0.17	-0.17	Joint mobility (Beighton score);	chr8:8935833	chr8:8236003~8244667:-
THCA	cis	rs853679	0.607	rs67340775	ENSG00000220721.1	OR1F12	3.63	0.00031	0.0205	0.37	0.17	Depression;	chr6:28336607	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs35030260	ENSG00000220721.1	OR1F12	3.63	0.00031	0.0205	0.37	0.17	Depression;	chr6:28337731	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13217619	ENSG00000220721.1	OR1F12	3.63	0.00031	0.0205	0.37	0.17	Depression;	chr6:28338894	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs35016036	ENSG00000220721.1	OR1F12	3.63	0.00031	0.0205	0.37	0.17	Depression;	chr6:28347103	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs35744819	ENSG00000220721.1	OR1F12	3.63	0.00031	0.0205	0.37	0.17	Depression;	chr6:28350554	chr6:28073316~28074233:+
THCA	cis	rs34779708	0.801	rs12242110	ENSG00000233200.1	RP11-324I22.2	3.63	0.00031	0.0205	0.2	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35219894~35230598:-
THCA	cis	rs7246967	0.673	rs2361023	ENSG00000198153.8	ZNF849P	-3.63	0.00031	0.0205	-0.25	-0.17	Bronchopulmonary dysplasia;	chr19:22634065	chr19:22685167~22686732:+
THCA	cis	rs12101261	0.744	rs17545038	ENSG00000258915.1	BHLHB9P1	-3.63	0.00031	0.0205	-0.2	-0.17	Graves' disease;	chr14:80991228	chr14:80981988~80983638:+
THCA	cis	rs7267979	0.966	rs2261795	ENSG00000276952.1	RP5-965G21.6	3.63	0.00031	0.0205	0.17	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25284915~25285588:-
THCA	cis	rs4703129	0.967	rs4702979	ENSG00000246763.5	RGMB-AS1	-3.63	0.00031	0.0205	-0.17	-0.17	Asperger disorder;	chr5:98508688	chr5:98769618~98773469:-
THCA	cis	rs4703129	0.967	rs4702980	ENSG00000246763.5	RGMB-AS1	-3.63	0.00031	0.0205	-0.17	-0.17	Asperger disorder;	chr5:98508704	chr5:98769618~98773469:-
THCA	cis	rs7737355	1	rs27663	ENSG00000237714.1	P4HA2-AS1	-3.63	0.00031	0.0205	-0.23	-0.17	Life satisfaction;	chr5:131405745	chr5:132184876~132192808:+
THCA	cis	rs7546094	0.875	rs7522288	ENSG00000273483.1	RP4-671G15.2	3.63	0.00031	0.0205	0.15	0.17	Platelet distribution width;	chr1:112608583	chr1:112517799~112518441:-
THCA	cis	rs875971	1	rs1167411	ENSG00000230189.5	GS1-124K5.2	-3.63	0.00031	0.0205	-0.11	-0.17	Aortic root size;	chr7:66074277	chr7:66409143~66490059:-
THCA	cis	rs13279522	0.831	rs7006611	ENSG00000272192.1	CTD-2532N20.1	3.63	0.00031	0.0205	0.2	0.17	Coronary heart disease event reduction (statin therapy interaction);	chr8:66050791	chr8:65842752~65843331:+
THCA	cis	rs6494488	0.5	rs56093925	ENSG00000259635.1	AC100830.3	-3.63	0.00031	0.0205	-0.38	-0.17	Coronary artery disease;	chr15:64497600	chr15:64701248~64719602:+
THCA	cis	rs4666002	0.789	rs13023094	ENSG00000234072.1	AC074117.10	-3.63	0.00031	0.0205	-0.15	-0.17	Phospholipid levels (plasma);	chr2:27687839	chr2:27356246~27367622:+
THCA	cis	rs2836326	1	rs2836326	ENSG00000231123.1	SPATA20P1	3.63	0.00031	0.0205	0.23	0.17	Metabolite levels (HVA);	chr21:38349842	chr21:38238227~38238664:-
THCA	cis	rs4869313	0.668	rs6874656	ENSG00000247121.5	CTD-2260A17.2	3.63	0.00031	0.0205	0.12	0.17	Pediatric autoimmune diseases;	chr5:96898671	chr5:96814028~96935809:-
THCA	cis	rs4925386	0.84	rs6143024	ENSG00000275437.1	RP5-908M14.10	3.63	0.00031	0.0205	0.16	0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62402236~62405935:-
THCA	cis	rs4325129	0.705	rs12127080	ENSG00000272668.1	RP11-190A12.8	3.63	0.00031	0.0205	0.19	0.17	Obesity-related traits;	chr1:159481765	chr1:159866954~159867685:+
THCA	cis	rs2980439	0.517	rs712253	ENSG00000248538.5	RP11-10A14.5	3.63	0.00031	0.0205	0.21	0.17	Neuroticism;	chr8:8246260	chr8:9189011~9202854:+
THCA	cis	rs1348850	0.645	rs7571386	ENSG00000280374.1	RP11-337N6.3	-3.63	0.00031	0.0205	-0.25	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177577959	chr2:177317715~177318471:-
THCA	cis	rs4664304	0.781	rs3828323	ENSG00000226266.5	AC009961.3	3.63	0.00031	0.0205	0.2	0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159951564	chr2:159670708~159712435:-
THCA	cis	rs11601239	0.561	rs7930116	ENSG00000254750.1	CASP1P2	3.63	0.00031	0.0205	0.13	0.17	Refractive error;	chr11:105792311	chr11:105063345~105071541:-
THCA	cis	rs9876781	1	rs9864371	ENSG00000199476.1	Y_RNA	-3.63	0.00031	0.0205	-0.21	-0.17	Longevity;	chr3:48385276	chr3:48288587~48288694:+
THCA	cis	rs1560104	0.549	rs7201160	ENSG00000260601.1	RP11-552C15.1	-3.63	0.00031	0.0205	-0.2	-0.17	Obesity-related traits;	chr16:12614022	chr16:12545482~12546684:+
THCA	cis	rs1153858	1	rs2467863	ENSG00000275672.1	GATM-AS1	-3.63	0.00031	0.0205	-0.17	-0.17	Homoarginine levels;	chr15:45349682	chr15:45378700~45380123:+
THCA	cis	rs7819412	0.745	rs6601569	ENSG00000254866.2	DEFB109P3	3.63	0.00031	0.0205	0.23	0.17	Triglycerides;	chr8:11216069	chr8:12150895~12151134:-
THCA	cis	rs72996113	0.702	rs11224390	ENSG00000248027.1	CTD-2383M3.1	-3.63	0.00031	0.0205	-0.34	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100693816	chr11:100684162~100687955:-
THCA	cis	rs6142618	0.846	rs1407013	ENSG00000224452.1	RSL24D1P6	3.63	0.00031	0.0205	0.2	0.17	Inflammatory bowel disease;	chr20:32206982	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.74	rs1923095	ENSG00000224452.1	RSL24D1P6	3.63	0.00031	0.0205	0.2	0.17	Inflammatory bowel disease;	chr20:32208016	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.819	rs6141637	ENSG00000224452.1	RSL24D1P6	3.63	0.00031	0.0205	0.2	0.17	Inflammatory bowel disease;	chr20:32213213	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.819	rs6057540	ENSG00000224452.1	RSL24D1P6	3.63	0.00031	0.0205	0.2	0.17	Inflammatory bowel disease;	chr20:32225342	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.819	rs6141641	ENSG00000224452.1	RSL24D1P6	3.63	0.00031	0.0205	0.2	0.17	Inflammatory bowel disease;	chr20:32227947	chr20:32170390~32170790:-
THCA	cis	rs4218	0.731	rs11539756	ENSG00000277144.1	RP11-59H7.4	-3.63	0.00031	0.0205	-0.24	-0.17	Social communication problems;	chr15:59136912	chr15:59115547~59116089:-
THCA	cis	rs2562456	0.833	rs516519	ENSG00000268117.1	VN1R84P	-3.63	0.00031	0.0205	-0.23	-0.17	Pain;	chr19:21298730	chr19:21719801~21720035:-
THCA	cis	rs2562456	0.833	rs552800	ENSG00000268117.1	VN1R84P	-3.63	0.00031	0.0205	-0.23	-0.17	Pain;	chr19:21301840	chr19:21719801~21720035:-
THCA	cis	rs34102591	0.504	rs12307524	ENSG00000270061.1	RP11-214K3.19	-3.63	0.00031	0.0205	-0.21	-0.17	Schizophrenia;	chr12:123897041	chr12:123969990~123970344:-
THCA	cis	rs293748	0.54	rs10461978	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.00031	0.0205	-0.2	-0.17	Obesity-related traits;	chr5:37274810	chr5:36666214~36725195:-
THCA	cis	rs1005277	0.603	rs1998062	ENSG00000120555.12	SEPT7P9	3.63	0.00031	0.0205	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38383069~38402916:-
THCA	cis	rs2625529	0.73	rs12908882	ENSG00000260037.4	CTD-2524L6.3	-3.63	0.00031	0.0205	-0.23	-0.17	Red blood cell count;	chr15:72145231	chr15:71818396~71823384:+
THCA	cis	rs9928842	0.823	rs8061356	ENSG00000261783.1	RP11-252K23.2	3.63	0.00031	0.0205	0.3	0.17	Alcoholic chronic pancreatitis;	chr16:75260334	chr16:75379818~75381260:-
THCA	cis	rs17496827	0.78	rs6757951	ENSG00000261428.2	RP11-16P6.1	3.63	0.00031	0.0206	0.16	0.17	Anorexia nervosa;	chr2:222490332	chr2:222566899~222569719:-
THCA	cis	rs911555	0.692	rs7140647	ENSG00000269940.1	RP11-73M18.7	-3.63	0.00031	0.0206	-0.17	-0.17	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103694560~103695170:+
THCA	cis	rs2191566	0.691	rs8104802	ENSG00000266921.1	RP11-15A1.7	-3.63	0.00031	0.0206	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:44084816	chr19:43996896~44002836:-
THCA	cis	rs2191566	0.664	rs8105574	ENSG00000266921.1	RP11-15A1.7	-3.63	0.00031	0.0206	-0.16	-0.17	Acute lymphoblastic leukemia (childhood);	chr19:44084889	chr19:43996896~44002836:-
THCA	cis	rs7619427	0.556	rs7619828	ENSG00000271192.1	RP4-555D20.3	3.63	0.00031	0.0206	0.22	0.17	Schizophrenia;	chr3:44028027	chr3:43996896~43997443:+
THCA	cis	rs7259376	0.902	rs4932763	ENSG00000270947.1	AC025811.3	-3.63	0.00031	0.0206	-0.17	-0.17	Menopause (age at onset);	chr19:22421120	chr19:22455988~22456459:+
THCA	cis	rs867371	0.82	rs7164362	ENSG00000278603.1	RP13-608F4.5	3.63	0.00031	0.0206	0.21	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472203~82472426:+
THCA	cis	rs1552172	0.821	rs9286836	ENSG00000234222.5	RP11-315I20.1	3.63	0.000311	0.0206	0.2	0.17	Breast cancer;	chr1:145846532	chr1:145926590~145959179:+
THCA	cis	rs6723226	0.708	rs2754513	ENSG00000276517.1	AL133243.2	-3.63	0.000311	0.0206	-0.16	-0.17	Intelligence (multi-trait analysis);	chr2:32557696	chr2:32526504~32529507:+
THCA	cis	rs5769765	0.862	rs7410537	ENSG00000260613.1	RP3-522J7.6	-3.63	0.000311	0.0206	-0.22	-0.17	Schizophrenia;	chr22:49923682	chr22:49832616~49837786:-
THCA	cis	rs7968440	0.722	rs11609941	ENSG00000272368.2	RP4-605O3.4	3.63	0.000311	0.0206	0.11	0.17	Fibrinogen;	chr12:50773835	chr12:50112197~50165618:+
THCA	cis	rs12439619	0.921	rs4778672	ENSG00000259429.4	UBE2Q2P2	3.63	0.000311	0.0206	0.16	0.17	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82355142~82420075:+
THCA	cis	rs7045881	0.8	rs57890470	ENSG00000234676.1	IFT74-AS1	-3.63	0.000311	0.0206	-0.33	-0.17	Schizophrenia;	chr9:26909450	chr9:26955780~26956295:-
THCA	cis	rs911555	0.557	rs8022179	ENSG00000244691.1	RPL10AP1	-3.63	0.000311	0.0206	-0.23	-0.17	Intelligence (multi-trait analysis);	chr14:103380950	chr14:103412119~103412761:-
THCA	cis	rs858239	1	rs858240	ENSG00000230042.1	AK3P3	-3.63	0.000311	0.0206	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23129178~23129841:+
THCA	cis	rs9309473	0.898	rs10185080	ENSG00000273245.1	RP11-434P11.2	3.63	0.000311	0.0206	0.23	0.17	Metabolite levels;	chr2:73570380	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.898	rs10197755	ENSG00000273245.1	RP11-434P11.2	3.63	0.000311	0.0206	0.23	0.17	Metabolite levels;	chr2:73570496	chr2:73750256~73750786:-
THCA	cis	rs2251301	0.689	rs6986275	ENSG00000154316.13	TDH	3.63	0.000311	0.0206	0.14	0.17	Response to antipsychotic therapy (extrapyramidal side effects);	chr8:11263401	chr8:11339637~11368452:+
THCA	cis	rs10760158	0.832	rs4837832	ENSG00000235865.2	GSN-AS1	-3.63	0.000311	0.0206	-0.15	-0.17	Pulse pressure;	chr9:121294150	chr9:121280768~121285530:-
THCA	cis	rs9309473	0.95	rs73947808	ENSG00000273245.1	RP11-434P11.2	3.63	0.000311	0.0206	0.23	0.17	Metabolite levels;	chr2:73494123	chr2:73750256~73750786:-
THCA	cis	rs28830936	0.966	rs890498	ENSG00000250379.1	RP11-23P13.4	3.63	0.000311	0.0206	0.19	0.17	Diastolic blood pressure;	chr15:41819100	chr15:41825099~41827936:-
THCA	cis	rs62380364	0.87	rs4373304	ENSG00000247828.6	TMEM161B-AS1	-3.63	0.000311	0.0206	-0.12	-0.17	Intelligence (multi-trait analysis);	chr5:88856385	chr5:88268895~88436685:+
THCA	cis	rs4434872	0.525	rs34752019	ENSG00000223599.1	RP11-216N14.7	-3.63	0.000311	0.0206	-0.32	-0.17	Conduct disorder (symptom count);	chr1:154054166	chr1:153852106~153853414:-
THCA	cis	rs7631605	0.967	rs4678949	ENSG00000224080.1	UBE2FP1	3.63	0.000311	0.0206	0.19	0.17	Cerebrospinal P-tau181p levels;	chr3:37211786	chr3:37143512~37143958:-
THCA	cis	rs7631605	0.967	rs4678950	ENSG00000224080.1	UBE2FP1	3.63	0.000311	0.0206	0.19	0.17	Cerebrospinal P-tau181p levels;	chr3:37212191	chr3:37143512~37143958:-
THCA	cis	rs7647973	0.58	rs12629759	ENSG00000228638.1	FCF1P2	-3.63	0.000311	0.0206	-0.17	-0.17	Menarche (age at onset);	chr3:49199961	chr3:48290793~48291375:-
THCA	cis	rs6545883	0.894	rs2177962	ENSG00000212978.6	AC016747.3	-3.63	0.000311	0.0206	-0.18	-0.17	Tuberculosis;	chr2:61360935	chr2:61141592~61144969:-
THCA	cis	rs7188697	0.769	rs9932944	ENSG00000276259.1	RP11-481J2.4	3.63	0.000311	0.0206	0.12	0.17	QT interval;	chr16:58582261	chr16:58522970~58523842:+
THCA	cis	rs877529	0.756	rs79506	ENSG00000279833.1	RP4-742C19.13	-3.63	0.000311	0.0206	-0.12	-0.17	Multiple myeloma;	chr22:39155623	chr22:39133090~39136760:+
THCA	cis	rs72765298	0.733	rs10986636	ENSG00000235332.2	RP11-366O20.5	3.63	0.000311	0.0206	0.3	0.17	Pulse pressure;	chr9:125200693	chr9:125194649~125195821:-
THCA	cis	rs6788895	0.661	rs73010947	ENSG00000244265.1	SIAH2-AS1	3.63	0.000311	0.0206	0.43	0.17	Breast cancer;	chr3:150767955	chr3:150761937~150762538:+
THCA	cis	rs7919656	0.904	rs2620904	ENSG00000228403.1	RP11-563N6.6	-3.63	0.000311	0.0206	-0.17	-0.17	Clinically amyopathic dermatomyositis;	chr10:48836976	chr10:48878022~48878649:+
THCA	cis	rs6878727	0.665	rs2633530	ENSG00000253807.4	LINC01170	3.63	0.000311	0.0206	0.15	0.17	Breast cancer;	chr5:124316783	chr5:124059794~124405079:-
THCA	cis	rs3764021	0.527	rs10844427	ENSG00000256069.6	A2MP1	-3.63	0.000311	0.0206	-0.19	-0.17	Type 1 diabetes;	chr12:9681798	chr12:9228533~9275817:-
THCA	cis	rs9650657	0.836	rs6601523	ENSG00000255310.2	AF131215.2	-3.63	0.000311	0.0206	-0.14	-0.17	Neuroticism;	chr8:10777631	chr8:11107788~11109726:-
THCA	cis	rs459571	0.92	rs417142	ENSG00000235106.7	LINC00094	3.63	0.000311	0.0206	0.15	0.17	Platelet distribution width;	chr9:134026248	chr9:134025439~134034666:+
THCA	cis	rs6921919	0.697	rs12180820	ENSG00000176933.5	TOB2P1	3.63	0.000311	0.0206	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28217643~28218634:-
THCA	cis	rs16918636	0.541	rs74776324	ENSG00000249867.4	RP11-115J23.1	-3.63	0.000311	0.0206	-0.24	-0.17	Menarche (age at onset);	chr11:29159073	chr11:28702615~29063821:+
THCA	cis	rs6547705	0.858	rs6750263	ENSG00000231259.4	AC125232.1	-3.63	0.000311	0.0206	-0.23	-0.17	Progressive supranuclear palsy;	chr2:86766405	chr2:87031815~87053069:-
THCA	cis	rs6710503	0.748	rs6753096	ENSG00000271936.1	RP11-443B20.1	-3.63	0.000311	0.0206	-0.19	-0.17	Lung cancer in ever smokers;Breast cancer;	chr2:24832761	chr2:24825610~24826717:+
THCA	cis	rs4218	0.574	rs12907957	ENSG00000259732.1	RP11-59H7.3	-3.63	0.000311	0.0206	-0.23	-0.17	Social communication problems;	chr15:59109486	chr15:59121034~59133250:+
THCA	cis	rs4788570	0.584	rs6499534	ENSG00000260185.1	RP11-432I5.6	-3.63	0.000311	0.0206	-0.31	-0.17	Intelligence (multi-trait analysis);	chr16:71721375	chr16:71655027~71664212:+
THCA	cis	rs2098713	0.599	rs62359042	ENSG00000250155.1	CTD-2353F22.1	3.63	0.000311	0.0206	0.16	0.17	Telomere length;	chr5:37577604	chr5:36666214~36725195:-
THCA	cis	rs34792	0.678	rs153787	ENSG00000275910.1	RP11-680G24.6	3.63	0.000311	0.0206	0.18	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499916	chr16:15015828~15016390:-
THCA	cis	rs7267979	0.868	rs6138546	ENSG00000276952.1	RP5-965G21.6	3.63	0.000311	0.0206	0.18	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25284915~25285588:-
THCA	cis	rs9876781	1	rs13091785	ENSG00000199476.1	Y_RNA	-3.63	0.000311	0.0206	-0.21	-0.17	Longevity;	chr3:48452692	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs6776700	ENSG00000199476.1	Y_RNA	-3.63	0.000311	0.0206	-0.21	-0.17	Longevity;	chr3:48455358	chr3:48288587~48288694:+
THCA	cis	rs12546962	0.58	rs1461730	ENSG00000254153.1	CTA-398F10.2	-3.63	0.000311	0.0206	-0.19	-0.17	Body mass index;	chr8:9329632	chr8:8456909~8461337:-
THCA	cis	rs12476592	0.516	rs6734648	ENSG00000242412.1	DBIL5P2	3.63	0.000311	0.0206	0.21	0.17	Childhood ear infection;	chr2:63574391	chr2:63117851~63119542:-
THCA	cis	rs796395	0.967	rs2798631	ENSG00000232480.1	TGFB2-AS1	3.63	0.000311	0.0206	0.19	0.17	Post bronchodilator FEV1/FVC ratio;	chr1:218438536	chr1:218344196~218345678:-
THCA	cis	rs67478160	0.506	rs6575998	ENSG00000269910.1	RP11-73M18.10	3.63	0.000311	0.0206	0.14	0.17	Schizophrenia;	chr14:103784080	chr14:103694516~103695050:-
THCA	cis	rs2882667	0.931	rs10075039	ENSG00000249593.5	CTB-46B19.2	3.63	0.000311	0.0206	0.2	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:139012647~139051203:+
THCA	cis	rs704	0.752	rs6505079	ENSG00000279532.1	CTB-96E2.6	3.63	0.000311	0.0206	0.2	0.17	Osteoprotegerin levels;	chr17:28391158	chr17:28373673~28374301:-
THCA	cis	rs704	0.79	rs9913833	ENSG00000279532.1	CTB-96E2.6	3.63	0.000311	0.0206	0.2	0.17	Osteoprotegerin levels;	chr17:28391573	chr17:28373673~28374301:-
THCA	cis	rs12083887	0.583	rs17257841	ENSG00000236866.4	AL157902.3	-3.63	0.000311	0.0206	-0.19	-0.17	Male-pattern baldness;	chr1:118340673	chr1:117596832~117605770:-
THCA	cis	rs8005150	0.529	rs7150985	ENSG00000258867.4	LINC01146	3.63	0.000311	0.0206	0.24	0.17	Hepatitis B;	chr14:88068622	chr14:88024550~88097619:+
THCA	cis	rs8005150	0.529	rs73318432	ENSG00000258867.4	LINC01146	3.63	0.000311	0.0206	0.24	0.17	Hepatitis B;	chr14:88069661	chr14:88024550~88097619:+
THCA	cis	rs7819412	0.634	rs4841485	ENSG00000254839.1	AF131215.6	-3.63	0.000311	0.0206	-0.17	-0.17	Triglycerides;	chr8:11052426	chr8:11062647~11067089:-
THCA	cis	rs10435719	0.902	rs11250179	ENSG00000255495.1	AC145124.2	3.63	0.000311	0.0206	0.19	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:12194467~12196280:+
THCA	cis	rs786425	0.618	rs12817576	ENSG00000278112.1	RP11-972P1.11	3.63	0.000312	0.0206	0.17	0.17	Pubertal anthropometrics;	chr12:123641792	chr12:123519390~123519856:-
THCA	cis	rs786425	0.618	rs11572952	ENSG00000278112.1	RP11-972P1.11	3.63	0.000312	0.0206	0.17	0.17	Pubertal anthropometrics;	chr12:123645262	chr12:123519390~123519856:-
THCA	cis	rs929354	0.772	rs6459738	ENSG00000224629.1	RP5-1142J19.2	-3.63	0.000312	0.0206	-0.16	-0.17	Body mass index;	chr7:157205838	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs6459739	ENSG00000224629.1	RP5-1142J19.2	-3.63	0.000312	0.0206	-0.16	-0.17	Body mass index;	chr7:157206169	chr7:157263022~157263229:-
THCA	cis	rs266717	0.816	rs187868	ENSG00000234197.1	ETV5-AS1	-3.63	0.000312	0.0206	-0.13	-0.17	Adiponectin levels;	chr3:186791728	chr3:186079170~186080947:+
THCA	cis	rs2625529	0.712	rs2054601	ENSG00000260037.4	CTD-2524L6.3	-3.63	0.000312	0.0206	-0.23	-0.17	Red blood cell count;	chr15:71892627	chr15:71818396~71823384:+
THCA	cis	rs9863	0.513	rs34102591	ENSG00000270061.1	RP11-214K3.19	-3.63	0.000312	0.0206	-0.26	-0.17	White blood cell count;	chr12:123996254	chr12:123969990~123970344:-
THCA	cis	rs793571	0.822	rs173214	ENSG00000245975.2	RP11-30K9.6	3.63	0.000312	0.0206	0.18	0.17	Schizophrenia;	chr15:58867989	chr15:58768072~58770974:-
THCA	cis	rs10129255	0.785	rs10150044	ENSG00000211972.2	IGHV3-66	3.63	0.000312	0.0206	0.1	0.17	Kawasaki disease;	chr14:106775695	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs10137980	ENSG00000211972.2	IGHV3-66	3.63	0.000312	0.0206	0.1	0.17	Kawasaki disease;	chr14:106775735	chr14:106675017~106675544:-
THCA	cis	rs1065852	0.526	rs11090066	ENSG00000281538.1	RP4-669P10.20	-3.63	0.000312	0.0206	-0.17	-0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002191	chr22:42138060~42139726:+
THCA	cis	rs3808502	0.525	rs9650661	ENSG00000255046.1	RP11-297N6.4	3.63	0.000312	0.0206	0.17	0.17	Neuroticism;	chr8:11569624	chr8:11797928~11802568:-
THCA	cis	rs288326	0.561	rs80231765	ENSG00000272800.1	RP11-438L19.1	3.63	0.000312	0.0206	0.31	0.17	Blood protein levels;	chr2:182881049	chr2:183214319~183215400:+
THCA	cis	rs190217029	1	rs190217029	ENSG00000271584.1	RP11-89C3.4	3.63	0.000312	0.0206	0.31	0.17	Carotid plaque burden;	chr11:111222261	chr11:111091932~111097357:-
THCA	cis	rs11638815	0.626	rs11635624	ENSG00000259429.4	UBE2Q2P2	-3.63	0.000312	0.0206	-0.14	-0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:82355142~82420075:+
THCA	cis	rs7658584	0.562	rs35677388	ENSG00000246375.2	RP11-10L7.1	3.63	0.000312	0.0206	0.26	0.17	Squamous cell lung carcinoma;	chr4:88185225	chr4:88284942~88331421:+
THCA	cis	rs2235642	0.893	rs2076440	ENSG00000260989.1	LA16c-395F10.2	-3.63	0.000312	0.0206	-0.17	-0.17	Coronary artery disease;	chr16:1537321	chr16:1580527~1610328:+
THCA	cis	rs2880765	0.835	rs11856869	ENSG00000259407.1	RP11-158M2.3	-3.63	0.000312	0.0206	-0.17	-0.17	Coronary artery disease;	chr15:85485866	chr15:85744109~85750281:-
THCA	cis	rs600231	0.706	rs4244811	ENSG00000254614.2	AP003068.23	-3.63	0.000312	0.0206	-0.22	-0.17	Bone mineral density;	chr11:65553309	chr11:65177606~65181834:-
THCA	cis	rs6546550	0.835	rs3752781	ENSG00000179818.12	PCBP1-AS1	-3.63	0.000312	0.0206	-0.13	-0.17	Prevalent atrial fibrillation;	chr2:69897184	chr2:69962263~70103220:-
THCA	cis	rs28510890	0.828	rs56874300	ENSG00000258676.4	RP11-386M24.3	3.63	0.000312	0.0206	0.17	0.17	Lung cancer in ever smokers;	chr15:92583525	chr15:92580829~92600545:+
THCA	cis	rs8072100	0.576	rs7216112	ENSG00000263293.2	RP11-290H9.4	-3.63	0.000312	0.0206	-0.2	-0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47303460~47323613:-
THCA	cis	rs2821260	0.72	rs1352082	ENSG00000227207.2	RPL31P12	-3.63	0.000312	0.0206	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72105973	chr1:72301472~72301829:+
THCA	cis	rs9921338	0.509	rs28448519	ENSG00000262636.1	CTD-3088G3.4	-3.63	0.000312	0.0206	-0.22	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346126	chr16:11380859~11381118:-
THCA	cis	rs2540949	0.538	rs2540971	ENSG00000281920.1	RP11-418H16.1	-3.63	0.000312	0.0206	-0.22	-0.17	Atrial fibrillation;	chr2:65025251	chr2:65623272~65628424:+
THCA	cis	rs9611565	0.504	rs5758452	ENSG00000237037.8	NDUFA6-AS1	-3.63	0.000312	0.0206	-0.15	-0.17	Vitiligo;	chr22:41748923	chr22:42090931~42137742:+
THCA	cis	rs6142618	0.562	rs2281360	ENSG00000224452.1	RSL24D1P6	3.63	0.000312	0.0206	0.19	0.17	Inflammatory bowel disease;	chr20:32139026	chr20:32170390~32170790:-
THCA	cis	rs929354	0.772	rs1182444	ENSG00000224629.1	RP5-1142J19.2	3.63	0.000312	0.0206	0.16	0.17	Body mass index;	chr7:157231816	chr7:157263022~157263229:-
THCA	cis	rs6894216	0.532	rs6876137	ENSG00000248610.1	HSPA8P4	-3.63	0.000312	0.0206	-0.2	-0.17	Response to amphetamines;	chr5:130337513	chr5:130140031~130141950:+
THCA	cis	rs2274273	0.84	rs72715769	ENSG00000258469.1	CHMP4BP1	3.63	0.000312	0.0206	0.15	0.17	Protein biomarker;	chr14:55295711	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs66696758	ENSG00000258469.1	CHMP4BP1	3.63	0.000312	0.0206	0.15	0.17	Protein biomarker;	chr14:55299791	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs7153645	ENSG00000258469.1	CHMP4BP1	3.63	0.000312	0.0206	0.15	0.17	Protein biomarker;	chr14:55304800	chr14:55298644~55299231:+
THCA	cis	rs4814894	0.682	rs6081724	ENSG00000236992.2	RPL12L3	3.63	0.000312	0.0206	0.17	0.17	Breast cancer;	chr20:19733810	chr20:19823443~19823943:-
THCA	cis	rs9399599	0.805	rs1039083	ENSG00000233452.5	STXBP5-AS1	-3.63	0.000312	0.0207	-0.17	-0.17	Plasma plasminogen activator levels;	chr6:147314249	chr6:146841901~147204614:-
THCA	cis	rs16982689	1	rs16982689	ENSG00000211670.2	IGLV3-9	3.63	0.000312	0.0207	0.19	0.17	Attention function in attention deficit hyperactive disorder;	chr22:22081907	chr22:22819010~22819756:+
THCA	cis	rs3924048	0.574	rs12062307	ENSG00000272482.1	RP11-474O21.5	-3.63	0.000312	0.0207	-0.15	-0.17	Optic cup area;	chr1:12551822	chr1:12618900~12619244:-
THCA	cis	rs2013441	0.579	rs34370440	ENSG00000261033.1	RP11-209D14.2	-3.63	0.000312	0.0207	-0.2	-0.17	Obesity-related traits;	chr17:20100117	chr17:20008051~20009234:-
THCA	cis	rs3859192	0.561	rs12451547	ENSG00000264968.1	RP11-387H17.4	-3.63	0.000312	0.0207	-0.16	-0.17	White blood cell count;	chr17:40024915	chr17:39927742~39939601:+
THCA	cis	rs3859192	0.561	rs12453343	ENSG00000264968.1	RP11-387H17.4	-3.63	0.000312	0.0207	-0.16	-0.17	White blood cell count;	chr17:40024923	chr17:39927742~39939601:+
THCA	cis	rs4803480	0.572	rs17710743	ENSG00000267107.5	PCAT19	-3.63	0.000312	0.0207	-0.32	-0.17	Schizophrenia;	chr19:41569079	chr19:41454169~41500649:-
THCA	cis	rs9287719	0.967	rs4669596	ENSG00000243819.4	RN7SL832P	3.63	0.000312	0.0207	0.13	0.17	Prostate cancer;	chr2:10580446	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs4284804	ENSG00000243819.4	RN7SL832P	3.63	0.000312	0.0207	0.13	0.17	Prostate cancer;	chr2:10581998	chr2:10690344~10692099:+
THCA	cis	rs15676	0.783	rs10988134	ENSG00000234771.3	SLC25A25-AS1	-3.63	0.000312	0.0207	-0.14	-0.17	Blood metabolite levels;	chr9:128833128	chr9:128108581~128118693:-
THCA	cis	rs2820315	0.54	rs10920259	ENSG00000223774.4	RP11-307B6.3	3.63	0.000312	0.0207	0.16	0.17	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201828568	chr1:201893842~201899978:+
THCA	cis	rs6560517	0.519	rs707739	ENSG00000234618.1	RPSAP9	-3.63	0.000312	0.0207	-0.19	-0.17	Dialysis-related mortality;	chr9:76503987	chr9:76398699~76399586:+
THCA	cis	rs17685	0.743	rs10277259	ENSG00000227038.2	AC005077.12	3.63	0.000312	0.0207	0.16	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76173356	chr7:76090431~76108779:-
THCA	cis	rs2235642	0.533	rs9922661	ENSG00000260989.1	LA16c-395F10.2	-3.63	0.000312	0.0207	-0.2	-0.17	Coronary artery disease;	chr16:1555162	chr16:1580527~1610328:+
THCA	cis	rs6439699	0.825	rs35173106	ENSG00000273486.1	RP11-731C17.2	3.63	0.000312	0.0207	0.18	0.17	Intelligence (multi-trait analysis);	chr3:137354862	chr3:136837338~136839021:-
THCA	cis	rs3796352	1	rs34244302	ENSG00000280417.1	RP11-5O17.1	-3.63	0.000312	0.0207	-0.25	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:53068220	chr3:53046166~53048122:+
THCA	cis	rs3796352	1	rs13072457	ENSG00000280417.1	RP11-5O17.1	-3.63	0.000312	0.0207	-0.25	-0.17	Immune reponse to smallpox (secreted IL-2);	chr3:53068373	chr3:53046166~53048122:+
THCA	cis	rs7521681	0.838	rs6685881	ENSG00000230489.1	VAV3-AS1	-3.63	0.000312	0.0207	-0.19	-0.17	Asthma and hay fever;	chr1:107773406	chr1:107964443~107994607:+
THCA	cis	rs7521681	0.838	rs6686061	ENSG00000230489.1	VAV3-AS1	-3.63	0.000312	0.0207	-0.19	-0.17	Asthma and hay fever;	chr1:107773567	chr1:107964443~107994607:+
THCA	cis	rs4705962	0.879	rs11747814	ENSG00000230612.2	AC004237.1	3.63	0.000312	0.0207	0.21	0.17	Atopic dermatitis;	chr5:132688474	chr5:132688681~132723725:+
THCA	cis	rs8054556	0.74	rs10083738	ENSG00000273724.1	RP11-347C12.12	-3.63	0.000312	0.0207	-0.16	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29916381	chr16:30336400~30343336:+
THCA	cis	rs1046896	0.52	rs9895409	ENSG00000263063.1	RP11-388C12.1	-3.63	0.000312	0.0207	-0.21	-0.17	Glycated hemoglobin levels;	chr17:82944843	chr17:82713908~82716255:-
THCA	cis	rs471756	0.523	rs2479319	ENSG00000231808.2	LINC01388	-3.63	0.000312	0.0207	-0.19	-0.17	Mean platelet volume;	chr9:219528	chr9:112713~113754:-
THCA	cis	rs7919656	0.662	rs10745284	ENSG00000228403.1	RP11-563N6.6	-3.63	0.000313	0.0207	-0.17	-0.17	Clinically amyopathic dermatomyositis;	chr10:48857545	chr10:48878022~48878649:+
THCA	cis	rs12148329	0.545	rs12903231	ENSG00000259594.4	CTD-2034I4.2	3.63	0.000313	0.0207	0.29	0.17	Immune response to smallpox vaccine (IL-6);	chr15:80725003	chr15:81554003~81696780:+
THCA	cis	rs806215	0.547	rs322821	ENSG00000224138.1	AC000123.4	-3.63	0.000313	0.0207	-0.17	-0.17	Type 2 diabetes;	chr7:128089835	chr7:127350128~127351523:+
THCA	cis	rs7826238	0.535	rs2979179	ENSG00000253130.1	CTD-3023L14.2	-3.63	0.000313	0.0207	-0.17	-0.17	Systolic blood pressure;	chr8:8462519	chr8:8561391~8569688:+
THCA	cis	rs7020830	0.898	rs2047010	ENSG00000260100.1	RP11-220I1.5	-3.63	0.000313	0.0207	-0.2	-0.17	Schizophrenia;	chr9:37077950	chr9:37078813~37079776:-
THCA	cis	rs7520050	0.966	rs11211208	ENSG00000280836.1	AL355480.1	3.63	0.000313	0.0207	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45581219~45581321:-
THCA	cis	rs875971	0.895	rs7788984	ENSG00000272831.1	RP11-792A8.4	3.63	0.000313	0.0207	0.1	0.17	Aortic root size;	chr7:66450629	chr7:66739829~66740385:-
THCA	cis	rs1005277	0.579	rs2474587	ENSG00000120555.12	SEPT7P9	3.63	0.000313	0.0207	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474588	ENSG00000120555.12	SEPT7P9	3.63	0.000313	0.0207	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38383069~38402916:-
THCA	cis	rs853679	1	rs9986596	ENSG00000261839.1	RP1-265C24.8	3.63	0.000313	0.0207	0.23	0.17	Depression;	chr6:28251883	chr6:28136849~28139678:+
THCA	cis	rs1560104	0.549	rs7201160	ENSG00000262801.4	U91319.1	-3.63	0.000313	0.0207	-0.19	-0.17	Obesity-related traits;	chr16:12614022	chr16:13246316~13562918:+
THCA	cis	rs2821260	0.694	rs12141628	ENSG00000227207.2	RPL31P12	-3.63	0.000313	0.0207	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72128084	chr1:72301472~72301829:+
THCA	cis	rs1009077	1	rs28450611	ENSG00000245958.5	RP11-33B1.1	3.63	0.000313	0.0207	0.21	0.17	Endometriosis;	chr4:119721618	chr4:119454791~119552025:+
THCA	cis	rs3750965	0.65	rs61882972	ENSG00000260895.1	RP11-554A11.7	3.63	0.000313	0.0207	0.22	0.17	Hair color;	chr11:69119685	chr11:69103493~69109094:+
THCA	cis	rs867186	1	rs73905019	ENSG00000126005.14	MMP24-AS1	-3.63	0.000313	0.0207	-0.27	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34972511	chr20:35216462~35278131:-
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000270154.1	RP11-419I17.1	3.63	0.000313	0.0207	0.2	0.17	Neuroticism;	chr8:11991324	chr8:12476462~12477122:+
THCA	cis	rs11671005	0.504	rs7257669	ENSG00000252334.1	RNU6-1337P	3.63	0.000313	0.0207	0.22	0.17	Mean platelet volume;	chr19:58553572	chr19:58483749~58483843:-
THCA	cis	rs1908814	0.516	rs11250178	ENSG00000254948.1	OR7E158P	-3.63	0.000313	0.0207	-0.21	-0.17	Neuroticism;	chr8:11942725	chr8:11919900~11920809:-
THCA	cis	rs301901	0.772	rs301867	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.000313	0.0207	-0.17	-0.17	Height;	chr5:37130754	chr5:36666214~36725195:-
THCA	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	3.63	0.000313	0.0207	0.15	0.17	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
THCA	cis	rs9878978	0.754	rs6787085	ENSG00000227588.2	CNTN4-AS2	-3.63	0.000313	0.0207	-0.21	-0.17	Blood pressure (smoking interaction);	chr3:2394550	chr3:2110409~2144241:-
THCA	cis	rs944289	0.536	rs1951375	ENSG00000258844.1	RP11-259K15.2	3.63	0.000313	0.0207	0.15	0.17	Thyroid cancer;	chr14:36051569	chr14:36214607~36235608:+
THCA	cis	rs1958560	0.897	rs8016322	ENSG00000276116.2	FUT8-AS1	3.63	0.000313	0.0207	0.18	0.17	Menarche (age at onset);	chr14:65584818	chr14:65411170~65412690:-
THCA	cis	rs8070740	0.838	rs57745425	ENSG00000234327.6	AC012146.7	-3.63	0.000313	0.0207	-0.16	-0.17	Menopause (age at onset);	chr17:5424208	chr17:5111468~5115004:+
THCA	cis	rs7824557	0.51	rs1435274	ENSG00000255046.1	RP11-297N6.4	3.63	0.000313	0.0207	0.17	0.17	Retinal vascular caliber;	chr8:11378401	chr8:11797928~11802568:-
THCA	cis	rs4272720	0.562	rs4073138	ENSG00000234736.4	FAM170B-AS1	-3.63	0.000313	0.0207	-0.18	-0.17	Platelet count;Plateletcrit;	chr10:49139030	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.562	rs4073139	ENSG00000234736.4	FAM170B-AS1	-3.63	0.000313	0.0207	-0.18	-0.17	Platelet count;Plateletcrit;	chr10:49139095	chr10:49121839~49151547:+
THCA	cis	rs7267979	0.714	rs6132825	ENSG00000125804.12	FAM182A	-3.63	0.000313	0.0207	-0.2	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:26054655~26086917:+
THCA	cis	rs1842579	0.597	rs12753056	ENSG00000272691.1	RP11-290M5.4	-3.63	0.000313	0.0207	-0.16	-0.17	Coronary artery aneurysm in Kawasaki disease;	chr1:85787761	chr1:85578500~85578742:-
THCA	cis	rs240993	0.595	rs3777912	ENSG00000220392.1	FCF1P5	3.63	0.000313	0.0207	0.18	0.17	Inflammatory skin disease;Psoriasis;	chr6:111581473	chr6:111353702~111354183:+
THCA	cis	rs4533267	0.843	rs4471661	ENSG00000189419.6	SPATA41	3.63	0.000313	0.0207	0.21	0.17	Height;	chr15:100254415	chr15:100344457~100349655:-
THCA	cis	rs1862618	0.853	rs252904	ENSG00000234553.1	AC022431.3	-3.63	0.000313	0.0207	-0.19	-0.17	Initial pursuit acceleration;	chr5:56822906	chr5:56536583~56537826:-
THCA	cis	rs2839186	0.814	rs13052376	ENSG00000228137.1	AP001469.7	3.63	0.000313	0.0207	0.16	0.17	Testicular germ cell tumor;	chr21:46287489	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.934	rs13046494	ENSG00000228137.1	AP001469.7	3.63	0.000313	0.0207	0.16	0.17	Testicular germ cell tumor;	chr21:46287516	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.872	rs13052495	ENSG00000228137.1	AP001469.7	3.63	0.000313	0.0207	0.16	0.17	Testicular germ cell tumor;	chr21:46287560	chr21:46246890~46247682:+
THCA	cis	rs8070128	0.583	rs7406982	ENSG00000281749.1	Y_RNA	3.63	0.000313	0.0207	0.21	0.17	Total body bone mineral density;	chr17:18039299	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs2955380	ENSG00000281749.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Total body bone mineral density;	chr17:18041035	chr17:18001101~18001195:-
THCA	cis	rs854765	0.562	rs2955381	ENSG00000281749.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Total body bone mineral density;	chr17:18042186	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs2955359	ENSG00000281749.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Total body bone mineral density;	chr17:18043416	chr17:18001101~18001195:-
THCA	cis	rs854765	0.533	rs2955354	ENSG00000281749.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Total body bone mineral density;	chr17:18045402	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs4925135	ENSG00000281749.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Total body bone mineral density;	chr17:18049554	chr17:18001101~18001195:-
THCA	cis	rs8070128	0.534	rs2955350	ENSG00000281749.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Total body bone mineral density;	chr17:18050234	chr17:18001101~18001195:-
THCA	cis	rs8070128	0.601	rs8080602	ENSG00000281749.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Total body bone mineral density;	chr17:18051414	chr17:18001101~18001195:-
THCA	cis	rs854765	0.547	rs2955370	ENSG00000281749.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Total body bone mineral density;	chr17:18063631	chr17:18001101~18001195:-
THCA	cis	rs67478160	0.619	rs28698555	ENSG00000258534.1	CTD-2134A5.4	3.63	0.000313	0.0207	0.16	0.17	Schizophrenia;	chr14:103850149	chr14:103854366~103880111:-
THCA	cis	rs2832191	0.74	rs2832177	ENSG00000176054.6	RPL23P2	-3.63	0.000313	0.0207	-0.14	-0.17	Dental caries;	chr21:29106032	chr21:28997613~28998033:-
THCA	cis	rs2115630	0.936	rs11073663	ENSG00000229212.6	RP11-561C5.4	3.63	0.000313	0.0207	0.21	0.17	P wave terminal force;	chr15:84717037	chr15:85205440~85234795:-
THCA	cis	rs9876781	0.9	rs1037773	ENSG00000199476.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Longevity;	chr3:48426493	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs2279077	ENSG00000199476.1	Y_RNA	-3.63	0.000313	0.0207	-0.21	-0.17	Longevity;	chr3:48432839	chr3:48288587~48288694:+
THCA	cis	rs4356203	0.905	rs7478986	ENSG00000272034.1	SNORD14A	-3.63	0.000313	0.0207	-0.16	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17109702	chr11:17074654~17074744:-
THCA	cis	rs1927790	0.643	rs9556574	ENSG00000247400.3	DNAJC3-AS1	-3.63	0.000313	0.0207	-0.11	-0.17	Body mass index;	chr13:96359395	chr13:95648733~95676925:-
THCA	cis	rs1005277	0.579	rs2505257	ENSG00000151963.4	RP11-775A3.1	-3.63	0.000313	0.0207	-0.17	-0.17	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:37883594~37884109:+
THCA	cis	rs8002861	0.727	rs9533652	ENSG00000274001.1	RP11-5G9.5	-3.63	0.000313	0.0207	-0.19	-0.17	Leprosy;	chr13:43845396	chr13:43877715~43878163:-
THCA	cis	rs4656958	0.93	rs6691672	ENSG00000233691.2	RP11-312J18.7	3.63	0.000313	0.0207	0.19	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160915740	chr1:160935537~160936126:+
THCA	cis	rs7551222	0.752	rs4951075	ENSG00000240219.1	RP11-430C7.5	3.63	0.000313	0.0207	0.15	0.17	Schizophrenia;	chr1:204495318	chr1:204626775~204629712:+
THCA	cis	rs720475	0.732	rs17172978	ENSG00000170356.8	OR2A20P	3.63	0.000313	0.0207	0.24	0.17	Breast cancer;	chr7:144429551	chr7:144250045~144252957:-
THCA	cis	rs73198271	0.74	rs10100066	ENSG00000254153.1	CTA-398F10.2	3.63	0.000313	0.0207	0.2	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.74	rs10110711	ENSG00000254153.1	CTA-398F10.2	3.63	0.000313	0.0207	0.2	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.74	rs10103163	ENSG00000254153.1	CTA-398F10.2	3.63	0.000313	0.0207	0.2	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8456909~8461337:-
THCA	cis	rs1876206	0.554	rs1506524	ENSG00000259705.1	RP11-227D13.1	3.63	0.000313	0.0207	0.19	0.17	Breast cancer;	chr15:48596791	chr15:48645951~48652016:+
THCA	cis	rs7111546	1	rs12271805	ENSG00000246225.5	RP11-17A1.3	3.63	0.000313	0.0207	0.29	0.17	Dialysis-related mortality;	chr11:22805919	chr11:22829380~22945393:+
THCA	cis	rs16857609	1	rs13388294	ENSG00000233143.1	DIRC3-AS1	3.63	0.000313	0.0207	0.18	0.17	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217430683	chr2:217282739~217336120:+
THCA	cis	rs67478160	0.643	rs4906369	ENSG00000258534.1	CTD-2134A5.4	-3.63	0.000313	0.0207	-0.16	-0.17	Schizophrenia;	chr14:103776121	chr14:103854366~103880111:-
THCA	cis	rs9868809	0.764	rs2633958	ENSG00000270441.1	RP11-694I15.7	-3.63	0.000313	0.0207	-0.24	-0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48597999	chr3:49140086~49160851:-
THCA	cis	rs293748	0.771	rs245587	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.000313	0.0207	-0.22	-0.17	Obesity-related traits;	chr5:36839445	chr5:36666214~36725195:-
THCA	cis	rs6120849	0.754	rs36003887	ENSG00000269202.1	RP4-614O4.12	-3.63	0.000313	0.0207	-0.18	-0.17	Protein C levels;	chr20:35001304	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs8501	ENSG00000269202.1	RP4-614O4.12	-3.63	0.000313	0.0207	-0.18	-0.17	Protein C levels;	chr20:35002781	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.707	rs752075	ENSG00000269202.1	RP4-614O4.12	-3.63	0.000313	0.0207	-0.18	-0.17	Protein C levels;	chr20:35003788	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs752448	ENSG00000269202.1	RP4-614O4.12	-3.63	0.000313	0.0207	-0.18	-0.17	Protein C levels;	chr20:35004445	chr20:35201747~35203288:-
THCA	cis	rs3924048	0.574	rs11589283	ENSG00000272482.1	RP11-474O21.5	-3.63	0.000313	0.0207	-0.15	-0.17	Optic cup area;	chr1:12552250	chr1:12618900~12619244:-
THCA	cis	rs3924048	0.574	rs11588028	ENSG00000272482.1	RP11-474O21.5	-3.63	0.000313	0.0207	-0.15	-0.17	Optic cup area;	chr1:12552355	chr1:12618900~12619244:-
THCA	cis	rs2692947	0.666	rs10183151	ENSG00000235584.2	AC008268.1	3.63	0.000313	0.0207	0.17	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96109038	chr2:95666084~95668715:+
THCA	cis	rs8112211	0.731	rs3745951	ENSG00000267291.1	CTB-186G2.1	3.63	0.000313	0.0207	0.18	0.17	Blood protein levels;	chr19:38326846	chr19:38596346~38601694:+
THCA	cis	rs9898058	0.66	rs9915811	ENSG00000279036.1	RP11-81K2.2	-3.63	0.000313	0.0207	-0.25	-0.17	Milk allergy;	chr17:49708970	chr17:49494223~49497800:-
THCA	cis	rs11048434	0.518	rs1805669	ENSG00000256720.1	RP11-436I9.6	-3.63	0.000313	0.0207	-0.18	-0.17	Sjögren's syndrome;	chr12:9027655	chr12:9135084~9135591:+
THCA	cis	rs9902453	0.845	rs3115101	ENSG00000264290.1	RP11-68I3.4	3.63	0.000314	0.0207	0.13	0.17	Coffee consumption (cups per day);	chr17:29714609	chr17:29569580~29570519:+
THCA	cis	rs9902453	0.845	rs3102556	ENSG00000264290.1	RP11-68I3.4	3.63	0.000314	0.0207	0.13	0.17	Coffee consumption (cups per day);	chr17:29715524	chr17:29569580~29570519:+
THCA	cis	rs2839186	0.609	rs2839189	ENSG00000228137.1	AP001469.7	-3.63	0.000314	0.0207	-0.17	-0.17	Testicular germ cell tumor;	chr21:46274443	chr21:46246890~46247682:+
THCA	cis	rs4713118	0.869	rs7773070	ENSG00000261839.1	RP1-265C24.8	3.63	0.000314	0.0207	0.19	0.17	Parkinson's disease;	chr6:27761048	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs7776351	ENSG00000261839.1	RP1-265C24.8	-3.63	0.000314	0.0207	-0.19	-0.17	Parkinson's disease;	chr6:27758952	chr6:28136849~28139678:+
THCA	cis	rs11686934	0.78	rs6731423	ENSG00000179818.12	PCBP1-AS1	-3.63	0.000314	0.0207	-0.13	-0.17	High light scatter reticulocyte count;	chr2:69946195	chr2:69962263~70103220:-
THCA	cis	rs2821260	0.755	rs1486093	ENSG00000227207.2	RPL31P12	-3.63	0.000314	0.0207	-0.19	-0.17	Intelligence (multi-trait analysis);	chr1:72107680	chr1:72301472~72301829:+
THCA	cis	rs3892630	0.824	rs2287884	ENSG00000267475.1	CTD-2538C1.2	-3.63	0.000314	0.0207	-0.25	-0.17	Red blood cell traits;	chr19:32830541	chr19:32687089~32691750:-
THCA	cis	rs3781264	0.56	rs3765524	ENSG00000273450.1	RP11-76P2.4	3.63	0.000314	0.0207	0.21	0.17	Esophageal cancer and gastric cancer;	chr10:94298541	chr10:94314907~94315327:-
THCA	cis	rs6439699	0.825	rs66527272	ENSG00000273486.1	RP11-731C17.2	3.63	0.000314	0.0207	0.18	0.17	Intelligence (multi-trait analysis);	chr3:137352185	chr3:136837338~136839021:-
THCA	cis	rs911555	0.755	rs9671414	ENSG00000269940.1	RP11-73M18.7	-3.63	0.000314	0.0207	-0.17	-0.17	Intelligence (multi-trait analysis);	chr14:103500962	chr14:103694560~103695170:+
THCA	cis	rs10875746	0.669	rs10875770	ENSG00000275228.1	RP11-370I10.10	3.63	0.000314	0.0207	0.19	0.17	Longevity (90 years and older);	chr12:48206737	chr12:48327942~48328472:-
THCA	cis	rs7772697	0.632	rs1316536	ENSG00000223701.3	RAET1E-AS1	-3.63	0.000314	0.0207	-0.22	-0.17	Diabetic retinopathy;	chr6:149096774	chr6:149884431~149919508:+
THCA	cis	rs17741873	0.779	rs58125091	ENSG00000271848.1	RP11-464F9.21	-3.63	0.000314	0.0207	-0.2	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73845662	chr10:73654039~73674719:+
THCA	cis	rs293748	0.771	rs151945	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.000314	0.0207	-0.22	-0.17	Obesity-related traits;	chr5:36838494	chr5:36666214~36725195:-
THCA	cis	rs7403037	0.617	rs35149769	ENSG00000260760.1	PWRN3	3.63	0.000314	0.0207	0.23	0.17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24591731	chr15:24441127~24447967:+
THCA	cis	rs7246967	0.736	rs411131	ENSG00000269364.1	LINC01233	-3.63	0.000314	0.0207	-0.24	-0.17	Bronchopulmonary dysplasia;	chr19:22810637	chr19:22532626~22533494:+
THCA	cis	rs420259	0.516	rs369856	ENSG00000260136.4	CTD-2270L9.4	3.63	0.000314	0.0207	0.13	0.17	Bipolar disorder;	chr16:23463343	chr16:23452758~23457606:+
THCA	cis	rs763121	0.853	rs6001175	ENSG00000225450.1	RP3-508I15.14	-3.63	0.000314	0.0207	-0.13	-0.17	Menopause (age at onset);	chr22:38622329	chr22:38739003~38749041:+
THCA	cis	rs931127	0.505	rs2306362	ENSG00000245532.5	NEAT1	-3.63	0.000314	0.0207	-0.13	-0.17	Systemic lupus erythematosus;	chr11:65638039	chr11:65422774~65445540:+
THCA	cis	rs1125355	0.69	rs62183019	ENSG00000243792.1	OR7E89P	-3.63	0.000314	0.0207	-0.25	-0.17	Alzheimer's disease in APOE e4+ carriers;	chr2:158771854	chr2:158853755~158854576:+
THCA	cis	rs10129255	0.957	rs12590667	ENSG00000211972.2	IGHV3-66	-3.63	0.000314	0.0207	-0.1	-0.17	Kawasaki disease;	chr14:106779223	chr14:106675017~106675544:-
THCA	cis	rs9860428	0.526	rs9871985	ENSG00000240057.4	RP11-572M11.4	-3.63	0.000314	0.0207	-0.16	-0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942507	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.526	rs9854885	ENSG00000240057.4	RP11-572M11.4	-3.63	0.000314	0.0207	-0.16	-0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942871	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.526	rs4682125	ENSG00000240057.4	RP11-572M11.4	-3.63	0.000314	0.0207	-0.16	-0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112943772	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.526	rs6769091	ENSG00000240057.4	RP11-572M11.4	-3.63	0.000314	0.0207	-0.16	-0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112943929	chr3:113019532~113183301:+
THCA	cis	rs2276314	1	rs4799835	ENSG00000267627.4	RP11-905K4.1	-3.63	0.000314	0.0207	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35951803~35966118:-
THCA	cis	rs2227564	0.729	rs2633304	ENSG00000271816.1	BMS1P4	3.63	0.000314	0.0207	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73890892	chr10:73699151~73730487:-
THCA	cis	rs2227564	0.729	rs2688616	ENSG00000271816.1	BMS1P4	3.63	0.000314	0.0207	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73890894	chr10:73699151~73730487:-
THCA	cis	rs10090774	0.965	rs11786116	ENSG00000280303.2	ERICD	-3.63	0.000314	0.0207	-0.16	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140853997	chr8:140636281~140638283:+
THCA	cis	rs11841001	0.556	rs12859043	ENSG00000261105.4	LMO7-AS1	-3.63	0.000314	0.0207	-0.24	-0.17	Corneal astigmatism;	chr13:75769362	chr13:75604700~75635994:-
THCA	cis	rs4073416	0.542	rs10144979	ENSG00000276116.2	FUT8-AS1	3.63	0.000314	0.0207	0.19	0.17	N-glycan levels;	chr14:65530920	chr14:65411170~65412690:-
THCA	cis	rs11685222	0.777	rs4849798	ENSG00000229326.3	AC069154.4	-3.63	0.000314	0.0207	-0.27	-0.17	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119707918	chr2:119698623~119700151:+
THCA	cis	rs11685222	0.668	rs4849799	ENSG00000229326.3	AC069154.4	-3.63	0.000314	0.0207	-0.27	-0.17	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119708201	chr2:119698623~119700151:+
THCA	cis	rs11685222	0.668	rs61642940	ENSG00000229326.3	AC069154.4	-3.63	0.000314	0.0207	-0.27	-0.17	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119708850	chr2:119698623~119700151:+
THCA	cis	rs11685222	0.668	rs6542543	ENSG00000229326.3	AC069154.4	-3.63	0.000314	0.0207	-0.27	-0.17	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119709364	chr2:119698623~119700151:+
THCA	cis	rs568617	0.716	rs77779142	ENSG00000245156.1	RP11-867G23.3	-3.63	0.000314	0.0207	-0.2	-0.17	Crohn's disease;	chr11:65832185	chr11:66269832~66278525:-
THCA	cis	rs14027	0.921	rs13261032	ENSG00000279347.1	RP11-85I17.2	-3.63	0.000314	0.0207	-0.19	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119838736~119840385:-
THCA	cis	rs9911578	1	rs11869828	ENSG00000224738.1	AC099850.1	-3.63	0.000314	0.0207	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58532164	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs12453049	ENSG00000224738.1	AC099850.1	-3.63	0.000314	0.0207	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58534011	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs2009948	ENSG00000224738.1	AC099850.1	-3.63	0.000314	0.0207	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58534559	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs6503866	ENSG00000224738.1	AC099850.1	-3.63	0.000314	0.0207	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58542220	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs12453459	ENSG00000224738.1	AC099850.1	-3.63	0.000314	0.0207	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58546930	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs2333332	ENSG00000224738.1	AC099850.1	-3.63	0.000314	0.0207	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58553693	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs1267545	ENSG00000224738.1	AC099850.1	3.63	0.000314	0.0207	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58569548	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs6503870	ENSG00000224738.1	AC099850.1	3.63	0.000314	0.0207	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58581657	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs2567892	ENSG00000224738.1	AC099850.1	3.63	0.000314	0.0207	0.19	0.17	Intelligence (multi-trait analysis);	chr17:58591568	chr17:59106598~59118267:+
THCA	cis	rs559555	0.812	rs2300701	ENSG00000276517.1	AL133243.2	3.63	0.000314	0.0207	0.15	0.17	Blood metabolite ratios;Blood metabolite levels;	chr2:31561938	chr2:32526504~32529507:+
THCA	cis	rs3747767	1	rs9352737	ENSG00000233967.5	RP11-250B2.3	3.63	0.000314	0.0207	0.26	0.17	Hoarding;	chr6:79471226	chr6:80443344~80465927:+
THCA	cis	rs13064411	0.696	rs6787026	ENSG00000243849.1	CFAP44-AS1	3.63	0.000314	0.0208	0.27	0.17	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113443270	chr3:113403991~113433992:+
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000237310.1	GS1-124K5.4	3.63	0.000314	0.0208	0.19	0.17	Diabetic kidney disease;	chr7:66500146	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000237310.1	GS1-124K5.4	3.63	0.000314	0.0208	0.19	0.17	Diabetic kidney disease;	chr7:66500834	chr7:66493706~66495474:+
THCA	cis	rs10791097	0.609	rs3751039	ENSG00000255455.2	RP11-890B15.3	3.63	0.000314	0.0208	0.15	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130903181	chr11:130866254~130870247:-
THCA	cis	rs1062177	1	rs12515762	ENSG00000272112.1	CTB-113P19.5	3.63	0.000314	0.0208	0.14	0.17	Preschool internalizing problems;	chr5:151830361	chr5:151724831~151725356:-
THCA	cis	rs7246657	0.943	rs10414904	ENSG00000268499.1	CTB-102L5.8	3.63	0.000314	0.0208	0.21	0.17	Coronary artery calcification;	chr19:37339186	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs10417844	ENSG00000268499.1	CTB-102L5.8	3.63	0.000314	0.0208	0.21	0.17	Coronary artery calcification;	chr19:37346685	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs1373991	ENSG00000268499.1	CTB-102L5.8	3.63	0.000314	0.0208	0.21	0.17	Coronary artery calcification;	chr19:37348009	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs10405407	ENSG00000268499.1	CTB-102L5.8	3.63	0.000314	0.0208	0.21	0.17	Coronary artery calcification;	chr19:37348262	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs12709813	ENSG00000268499.1	CTB-102L5.8	3.63	0.000314	0.0208	0.21	0.17	Coronary artery calcification;	chr19:37354081	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs13345116	ENSG00000268499.1	CTB-102L5.8	3.63	0.000314	0.0208	0.21	0.17	Coronary artery calcification;	chr19:37356196	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.765	rs7247259	ENSG00000268499.1	CTB-102L5.8	3.63	0.000314	0.0208	0.21	0.17	Coronary artery calcification;	chr19:37360188	chr19:38199836~38200934:+
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000264242.2	RP11-271K11.1	3.63	0.000314	0.0208	0.25	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30553697~30558962:+
THCA	cis	rs9880211	0.613	rs13081671	ENSG00000273486.1	RP11-731C17.2	3.63	0.000314	0.0208	0.16	0.17	Height;Body mass index;	chr3:136157707	chr3:136837338~136839021:-
THCA	cis	rs7395662	0.927	rs4882141	ENSG00000200090.1	Y_RNA	-3.63	0.000314	0.0208	-0.11	-0.17	HDL cholesterol;	chr11:48605973	chr11:47726894~47726992:-
THCA	cis	rs11250098	0.547	rs2409764	ENSG00000254866.2	DEFB109P3	-3.63	0.000314	0.0208	-0.22	-0.17	Morning vs. evening chronotype;	chr8:11423764	chr8:12150895~12151134:-
THCA	cis	rs1923243	0.714	rs7543704	ENSG00000223479.3	RP4-788P17.1	-3.63	0.000314	0.0208	-0.18	-0.17	Migraine;	chr1:73087152	chr1:73635216~73715214:+
THCA	cis	rs2652822	0.525	rs17828874	ENSG00000259459.4	RP11-321G12.1	3.63	0.000314	0.0208	0.13	0.17	Metabolic traits;	chr15:63224067	chr15:63390136~63438320:+
THCA	cis	rs2447820	0.5	rs28891	ENSG00000263432.2	RN7SL689P	-3.63	0.000314	0.0208	-0.2	-0.17	Migraine;	chr5:122947929	chr5:123022487~123022783:-
THCA	cis	rs271738	0.674	rs271766	ENSG00000231768.1	LINC01354	-3.63	0.000314	0.0208	-0.18	-0.17	Bipolar disorder;	chr1:234539056	chr1:234527891~234531779:-
THCA	cis	rs9990333	0.562	rs58079878	ENSG00000207650.1	MIR570	3.63	0.000314	0.0208	0.18	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195699401~195699497:+
THCA	cis	rs6121246	0.865	rs6089055	ENSG00000224628.2	RP5-854E16.2	-3.63	0.000314	0.0208	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31736242	chr20:31285317~31286835:-
THCA	cis	rs2071852	0.778	rs6006800	ENSG00000280383.1	CTA-941F9.10	3.63	0.000314	0.0208	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr22:45737973	chr22:45657019~45680130:+
THCA	cis	rs2562456	0.793	rs61445561	ENSG00000268278.1	RP11-420K14.1	3.63	0.000314	0.0208	0.24	0.17	Pain;	chr19:21321230	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs57299552	ENSG00000268278.1	RP11-420K14.1	3.63	0.000314	0.0208	0.24	0.17	Pain;	chr19:21321326	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.754	rs76688173	ENSG00000268278.1	RP11-420K14.1	3.63	0.000314	0.0208	0.24	0.17	Pain;	chr19:21321856	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs74711277	ENSG00000268278.1	RP11-420K14.1	3.63	0.000314	0.0208	0.24	0.17	Pain;	chr19:21322641	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62107479	ENSG00000268278.1	RP11-420K14.1	3.63	0.000314	0.0208	0.24	0.17	Pain;	chr19:21323962	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62107531	ENSG00000268278.1	RP11-420K14.1	3.63	0.000314	0.0208	0.24	0.17	Pain;	chr19:21326263	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs55756795	ENSG00000268278.1	RP11-420K14.1	3.63	0.000314	0.0208	0.24	0.17	Pain;	chr19:21327257	chr19:21637974~21656300:+
THCA	cis	rs7819412	0.669	rs35499486	ENSG00000254866.2	DEFB109P3	3.63	0.000314	0.0208	0.23	0.17	Triglycerides;	chr8:11216527	chr8:12150895~12151134:-
THCA	cis	rs5758511	0.689	rs56906457	ENSG00000237037.8	NDUFA6-AS1	-3.63	0.000314	0.0208	-0.18	-0.17	Birth weight;	chr22:42232329	chr22:42090931~42137742:+
THCA	cis	rs935334	0.5	rs73304587	ENSG00000258454.1	RP11-361H10.3	-3.63	0.000314	0.0208	-0.24	-0.17	Blood pressure;	chr14:76130691	chr14:76235817~76263474:+
THCA	cis	rs7142002	0.73	rs3742424	ENSG00000272444.1	RP11-1017G21.6	-3.63	0.000314	0.0208	-0.21	-0.17	Autism;	chr14:101925240	chr14:101952416~101953063:+
THCA	cis	rs7259376	0.936	rs11085524	ENSG00000269138.1	ZNF209P	3.63	0.000314	0.0208	0.17	0.17	Menopause (age at onset);	chr19:22353620	chr19:22463922~22473036:+
THCA	cis	rs5015933	0.801	rs4837016	ENSG00000232630.1	PRPS1P2	3.63	0.000314	0.0208	0.11	0.17	Body mass index;	chr9:125379530	chr9:125150653~125151589:+
THCA	cis	rs12935418	0.634	rs9934940	ENSG00000261061.1	RP11-303E16.2	-3.63	0.000314	0.0208	-0.16	-0.17	Mean corpuscular volume;	chr16:81016021	chr16:81030770~81031485:+
THCA	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-3.63	0.000314	0.0208	-0.15	-0.17	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
THCA	cis	rs2179367	0.632	rs6920383	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149356361	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs11155645	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149360056	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs10155766	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149364577	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498332	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149367490	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498333	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149368196	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498334	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149370902	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498335	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149372648	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498336	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149374208	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs1980774	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149375030	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498337	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149375970	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498338	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149376428	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.586	rs9498341	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149379737	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs9498342	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149379806	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12191079	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149380333	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12204461	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149380399	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12196656	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149383104	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12211570	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149383616	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.568	rs11155647	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149384499	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs12197598	ENSG00000216906.2	RP11-350J20.9	3.63	0.000315	0.0208	0.21	0.17	Dupuytren's disease;	chr6:149385418	chr6:149904243~149906418:+
THCA	cis	rs9788682	0.747	rs2869045	ENSG00000261143.1	ADAMTS7P3	3.63	0.000315	0.0208	0.25	0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78426557	chr15:77976042~77993057:+
THCA	cis	rs7819412	0.765	rs17783634	ENSG00000254839.1	AF131215.6	3.63	0.000315	0.0208	0.17	0.17	Triglycerides;	chr8:11196588	chr8:11062647~11067089:-
THCA	cis	rs614226	0.938	rs7972244	ENSG00000278344.1	RP11-18C24.8	3.63	0.000315	0.0208	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120557069	chr12:120500735~120501090:-
THCA	cis	rs614226	0.935	rs7956998	ENSG00000278344.1	RP11-18C24.8	3.63	0.000315	0.0208	0.22	0.17	Type 1 diabetes nephropathy;	chr12:120557129	chr12:120500735~120501090:-
THCA	cis	rs6940638	0.956	rs12199218	ENSG00000224843.5	LINC00240	3.63	0.000315	0.0208	0.19	0.17	Intelligence (multi-trait analysis);	chr6:27057502	chr6:26956992~27023924:+
THCA	cis	rs4660214	0.666	rs683135	ENSG00000228060.1	RP11-69E11.8	-3.63	0.000315	0.0208	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39429788	chr1:39565160~39573203:+
THCA	cis	rs12476592	0.516	rs196124	ENSG00000242412.1	DBIL5P2	3.63	0.000315	0.0208	0.21	0.17	Childhood ear infection;	chr2:63627004	chr2:63117851~63119542:-
THCA	cis	rs7919656	0.662	rs2620885	ENSG00000228403.1	RP11-563N6.6	-3.63	0.000315	0.0208	-0.17	-0.17	Clinically amyopathic dermatomyositis;	chr10:48868118	chr10:48878022~48878649:+
THCA	cis	rs7919656	0.662	rs2620884	ENSG00000228403.1	RP11-563N6.6	-3.63	0.000315	0.0208	-0.17	-0.17	Clinically amyopathic dermatomyositis;	chr10:48868430	chr10:48878022~48878649:+
THCA	cis	rs9948	0.881	rs7594727	ENSG00000230606.9	AC159540.1	-3.63	0.000315	0.0208	-0.23	-0.17	Erectile dysfunction and prostate cancer treatment;	chr2:96824133	chr2:97416165~97433527:-
THCA	cis	rs4767841	0.594	rs390366	ENSG00000252886.1	RN7SKP197	-3.63	0.000315	0.0208	-0.16	-0.17	Urgency urinary incontinence;	chr12:119785518	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.537	rs385844	ENSG00000252886.1	RN7SKP197	-3.63	0.000315	0.0208	-0.16	-0.17	Urgency urinary incontinence;	chr12:119785964	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.565	rs369180	ENSG00000252886.1	RN7SKP197	-3.63	0.000315	0.0208	-0.16	-0.17	Urgency urinary incontinence;	chr12:119786421	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.565	rs400551	ENSG00000252886.1	RN7SKP197	-3.63	0.000315	0.0208	-0.16	-0.17	Urgency urinary incontinence;	chr12:119786547	chr12:119631090~119631386:-
THCA	cis	rs293748	0.771	rs292179	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.000315	0.0208	-0.21	-0.17	Obesity-related traits;	chr5:36947511	chr5:36666214~36725195:-
THCA	cis	rs8028182	0.549	rs4886696	ENSG00000275645.1	RP11-817O13.9	-3.63	0.000315	0.0208	-0.16	-0.17	Sudden cardiac arrest;	chr15:75372229	chr15:75346744~75347161:-
THCA	cis	rs8030379	1	rs7162129	ENSG00000176700.18	SCAND2P	-3.63	0.000315	0.0208	-0.1	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897692	chr15:84631451~84647478:+
THCA	cis	rs3737883	1	rs3737883	ENSG00000229652.1	RP11-435P24.2	-3.63	0.000315	0.0208	-0.18	-0.17	Early onset atrial fibrillation;	chr1:203065778	chr1:203353365~203353651:-
THCA	cis	rs12506899	0.932	rs12649712	ENSG00000221639.1	SNORA3	3.63	0.000315	0.0208	0.19	0.17	Tumor biomarkers;	chr4:73427128	chr4:73263960~73264084:+
THCA	cis	rs7911264	0.703	rs7894183	ENSG00000236493.2	EIF2S2P3	3.63	0.000315	0.0208	0.18	0.17	Inflammatory bowel disease;	chr10:92622283	chr10:92668745~92669743:-
THCA	cis	rs2235642	0.821	rs2281236	ENSG00000260989.1	LA16c-395F10.2	-3.63	0.000315	0.0208	-0.17	-0.17	Coronary artery disease;	chr16:1553575	chr16:1580527~1610328:+
THCA	cis	rs875971	0.545	rs2420612	ENSG00000232559.3	GS1-124K5.12	3.63	0.000315	0.0208	0.18	0.17	Aortic root size;	chr7:66536825	chr7:66554588~66576923:-
THCA	cis	rs5758511	0.634	rs1001587	ENSG00000270083.1	RP1-257I20.14	-3.63	0.000315	0.0208	-0.21	-0.17	Birth weight;	chr22:42274105	chr22:42089630~42090028:-
THCA	cis	rs3758911	0.894	rs10890718	ENSG00000255353.1	RP11-382M14.1	-3.63	0.000315	0.0208	-0.21	-0.17	Coronary artery disease;	chr11:107326257	chr11:107176286~107177530:+
THCA	cis	rs17406451	0.759	rs12989996	ENSG00000234936.1	AC010883.5	3.63	0.000315	0.0208	0.14	0.17	Mitochondrial DNA levels;	chr2:43425030	chr2:43229573~43233394:+
THCA	cis	rs9400467	0.537	rs10457232	ENSG00000255389.1	C6orf3	3.63	0.000315	0.0208	0.23	0.17	Amino acid levels;Blood metabolite levels;	chr6:111113204	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.537	rs77212954	ENSG00000255389.1	C6orf3	3.63	0.000315	0.0208	0.23	0.17	Amino acid levels;Blood metabolite levels;	chr6:111124178	chr6:111599875~111602295:+
THCA	cis	rs7296418	0.738	rs10846489	ENSG00000256092.2	RP13-942N8.1	-3.63	0.000315	0.0208	-0.12	-0.17	Platelet count;	chr12:123259380	chr12:123363868~123366113:+
THCA	cis	rs7959452	0.684	rs11177615	ENSG00000274979.1	RP11-1143G9.5	-3.63	0.000315	0.0208	-0.18	-0.17	Blood protein levels;	chr12:69360409	chr12:69326574~69331882:-
THCA	cis	rs4262150	0.81	rs72797233	ENSG00000253921.1	CTB-113P19.3	3.63	0.000315	0.0208	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152613205	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs72797237	ENSG00000253921.1	CTB-113P19.3	3.63	0.000315	0.0208	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152618903	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs72797243	ENSG00000253921.1	CTB-113P19.3	3.63	0.000315	0.0208	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:152620346	chr5:151753992~151767247:+
THCA	cis	rs138529210	1	rs138529210	ENSG00000258819.1	RP11-7F17.3	3.63	0.000315	0.0208	0.35	0.17	Chronic sinus infection;	chr14:77767002	chr14:77069180~77076344:-
THCA	cis	rs60180747	0.863	rs11635184	ENSG00000261318.1	RP11-653J6.1	3.63	0.000315	0.0208	0.22	0.17	Testicular germ cell tumor;	chr15:66422405	chr15:66278498~66293357:-
THCA	cis	rs910316	0.737	rs175043	ENSG00000259138.1	RP11-950C14.7	-3.63	0.000315	0.0208	-0.14	-0.17	Height;	chr14:75005100	chr14:75127153~75136930:+
THCA	cis	rs6432852	0.966	rs6710878	ENSG00000232411.1	AC009495.3	3.63	0.000315	0.0208	0.18	0.17	Diabetic kidney disease;	chr2:165882121	chr2:165833048~165839098:-
THCA	cis	rs7665090	0.967	rs5026469	ENSG00000248971.2	KRT8P46	-3.63	0.000315	0.0208	-0.19	-0.17	Primary biliary cholangitis;	chr4:102633556	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.967	rs5026470	ENSG00000248971.2	KRT8P46	-3.63	0.000315	0.0208	-0.19	-0.17	Primary biliary cholangitis;	chr4:102633565	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.967	rs5026471	ENSG00000248971.2	KRT8P46	-3.63	0.000315	0.0208	-0.19	-0.17	Primary biliary cholangitis;	chr4:102633576	chr4:102728746~102730171:-
THCA	cis	rs2625529	0.652	rs2034879	ENSG00000260037.4	CTD-2524L6.3	-3.63	0.000315	0.0208	-0.21	-0.17	Red blood cell count;	chr15:72137648	chr15:71818396~71823384:+
THCA	cis	rs970548	0.955	rs10900232	ENSG00000230869.1	CTGLF10P	3.63	0.000315	0.0208	0.21	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45662444	chr10:45678692~45700532:+
THCA	cis	rs17685	0.753	rs4728586	ENSG00000227038.2	AC005077.12	3.63	0.000315	0.0208	0.16	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76173551	chr7:76090431~76108779:-
THCA	cis	rs7158359	0.955	rs4904511	ENSG00000222990.1	RNU4-22P	3.63	0.000315	0.0208	0.23	0.17	Weight loss (gastric bypass surgery);	chr14:89129072	chr14:88513498~88513663:+
THCA	cis	rs7259376	0.525	rs8108229	ENSG00000269138.1	ZNF209P	3.63	0.000315	0.0208	0.16	0.17	Menopause (age at onset);	chr19:22454354	chr19:22463922~22473036:+
THCA	cis	rs875971	0.545	rs75840613	ENSG00000273024.4	INTS4P2	-3.63	0.000315	0.0208	-0.21	-0.17	Aortic root size;	chr7:66376399	chr7:65647864~65715661:+
THCA	cis	rs75828804	1	rs74928612	ENSG00000260922.1	RP11-538I12.3	-3.63	0.000315	0.0208	-0.36	-0.17	Intraocular pressure;	chr16:77572583	chr16:77234877~77290934:+
THCA	cis	rs75828804	0.826	rs114786189	ENSG00000260922.1	RP11-538I12.3	-3.63	0.000315	0.0208	-0.36	-0.17	Intraocular pressure;	chr16:77572889	chr16:77234877~77290934:+
THCA	cis	rs7873102	0.654	rs7043870	ENSG00000213839.4	TMX2P1	-3.63	0.000315	0.0208	-0.13	-0.17	Brain structure;	chr9:37956376	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.654	rs10733491	ENSG00000213839.4	TMX2P1	-3.63	0.000315	0.0208	-0.13	-0.17	Brain structure;	chr9:37956727	chr9:37885683~37886390:+
THCA	cis	rs66887589	0.774	rs9307477	ENSG00000249244.1	RP11-548H18.2	3.63	0.000316	0.0208	0.17	0.17	Diastolic blood pressure;	chr4:119500654	chr4:119391831~119395335:-
THCA	cis	rs1577917	0.518	rs6454482	ENSG00000220563.1	PKMP3	3.63	0.000316	0.0208	0.12	0.17	Response to antipsychotic treatment;	chr6:85708470	chr6:85659892~85660606:-
THCA	cis	rs7178375	1	rs1474381	ENSG00000215302.7	CTD-3092A11.1	-3.63	0.000316	0.0208	-0.23	-0.17	Hypertriglyceridemia;	chr15:30922788	chr15:30470779~30507623:+
THCA	cis	rs2058059	0.551	rs68044527	ENSG00000205578.5	POM121B	-3.63	0.000316	0.0208	-0.27	-0.17	Subcutaneous adipose tissue;	chr7:72599814	chr7:73293497~73301161:+
THCA	cis	rs8040855	0.627	rs1532776	ENSG00000225151.9	GOLGA2P7	-3.63	0.000316	0.0208	-0.24	-0.17	Bulimia nervosa;	chr15:85081383	chr15:84199311~84230136:-
THCA	cis	rs7944735	0.575	rs34972471	ENSG00000200090.1	Y_RNA	3.63	0.000316	0.0208	0.13	0.17	Intraocular pressure;	chr11:48028839	chr11:47726894~47726992:-
THCA	cis	rs7924176	0.521	rs7477710	ENSG00000232342.6	RP11-46O21.2	3.63	0.000316	0.0208	0.21	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.521	rs11000960	ENSG00000232342.6	RP11-46O21.2	3.63	0.000316	0.0208	0.21	0.17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:74506081~74530553:-
THCA	cis	rs8005150	0.529	rs10140316	ENSG00000258867.4	LINC01146	3.63	0.000316	0.0208	0.24	0.17	Hepatitis B;	chr14:88067208	chr14:88024550~88097619:+
THCA	cis	rs4656958	0.93	rs7530965	ENSG00000233691.2	RP11-312J18.7	3.63	0.000316	0.0208	0.2	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160927350	chr1:160935537~160936126:+
THCA	cis	rs4879656	0.966	rs3780475	ENSG00000225693.1	LAGE3P1	3.63	0.000316	0.0208	0.18	0.17	Menopause (age at onset);	chr9:32984393	chr9:33019682~33020165:-
THCA	cis	rs10844154	0.638	rs326642	ENSG00000277342.1	RP11-843B15.4	3.63	0.000316	0.0208	0.2	0.17	Emphysema-related traits;Weight;	chr12:32247094	chr12:32109076~32109602:+
THCA	cis	rs2243123	0.602	rs2115176	ENSG00000244040.4	IL12A-AS1	3.63	0.000316	0.0208	0.22	0.17	Multiple sclerosis;	chr3:159998320	chr3:159913400~160225299:-
THCA	cis	rs2657294	0.796	rs6480770	ENSG00000226051.5	ZNF503-AS1	-3.63	0.000316	0.0208	-0.24	-0.17	Pneumonia;	chr10:75098799	chr10:75269819~75373500:+
THCA	cis	rs3935996	0.901	rs11206669	ENSG00000233147.1	RP11-90C4.1	-3.63	0.000316	0.0208	-0.14	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55856524	chr1:55823807~55868248:+
THCA	cis	rs3935996	0.965	rs11206671	ENSG00000233147.1	RP11-90C4.1	-3.63	0.000316	0.0208	-0.14	-0.17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55856648	chr1:55823807~55868248:+
THCA	cis	rs7216064	1	rs9915108	ENSG00000278740.1	RP11-147L13.14	3.63	0.000316	0.0208	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878347	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs9913471	ENSG00000278740.1	RP11-147L13.14	3.63	0.000316	0.0208	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878379	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.861	rs73352810	ENSG00000278740.1	RP11-147L13.14	3.63	0.000316	0.0208	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67879068	chr17:68188547~68189165:+
THCA	cis	rs7216064	0.906	rs8074644	ENSG00000278740.1	RP11-147L13.14	3.63	0.000316	0.0208	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882101	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs3935969	ENSG00000278740.1	RP11-147L13.14	3.63	0.000316	0.0208	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67885843	chr17:68188547~68189165:+
THCA	cis	rs2839186	0.867	rs13050387	ENSG00000228137.1	AP001469.7	3.63	0.000316	0.0208	0.16	0.17	Testicular germ cell tumor;	chr21:46281509	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.872	rs13046834	ENSG00000228137.1	AP001469.7	3.63	0.000316	0.0208	0.16	0.17	Testicular germ cell tumor;	chr21:46281571	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.721	rs13051200	ENSG00000228137.1	AP001469.7	3.63	0.000316	0.0208	0.16	0.17	Testicular germ cell tumor;	chr21:46281779	chr21:46246890~46247682:+
THCA	cis	rs2055375	0.62	rs159543	ENSG00000215032.2	GNL3LP1	3.63	0.000316	0.0208	0.21	0.17	Intelligence (multi-trait analysis);	chr5:61190688	chr5:60891935~60893577:-
THCA	cis	rs875971	0.545	rs2420456	ENSG00000273024.4	INTS4P2	-3.63	0.000316	0.0208	-0.2	-0.17	Aortic root size;	chr7:66280619	chr7:65647864~65715661:+
THCA	cis	rs12935229	0.756	rs66515609	ENSG00000260922.1	RP11-538I12.3	-3.63	0.000316	0.0208	-0.27	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77270385	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.756	rs12149784	ENSG00000260922.1	RP11-538I12.3	-3.63	0.000316	0.0208	-0.27	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77270911	chr16:77234877~77290934:+
THCA	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	3.63	0.000316	0.0208	0.15	0.17	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
THCA	cis	rs6687821	0.515	rs61800752	ENSG00000261737.1	RP4-612B15.3	-3.63	0.000316	0.0209	-0.25	-0.17	Yeast infection;	chr1:86932001	chr1:86703502~86704462:-
THCA	cis	rs668210	0.793	rs645571	ENSG00000214659.4	KRT8P26	-3.63	0.000316	0.0209	-0.19	-0.17	Cerebrospinal fluid biomarker levels;	chr11:65985381	chr11:65726939~65728214:+
THCA	cis	rs12681366	0.659	rs2046666	ENSG00000261437.1	RP11-22C11.2	-3.63	0.000316	0.0209	-0.15	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94375920	chr8:94637285~94639467:-
THCA	cis	rs12544026	0.647	rs7840760	ENSG00000253669.3	KB-1732A1.1	3.63	0.000316	0.0209	0.18	0.17	Major depression and alcohol dependence;	chr8:101829653	chr8:102805517~102809971:+
THCA	cis	rs683257	0.866	rs11758847	ENSG00000234147.1	RP3-460G2.2	-3.63	0.000316	0.0209	-0.27	-0.17	Facial emotion recognition (angry faces);	chr6:140693962	chr6:140845958~140852924:-
THCA	cis	rs2625529	0.668	rs8192431	ENSG00000260037.4	CTD-2524L6.3	-3.63	0.000316	0.0209	-0.23	-0.17	Red blood cell count;	chr15:72200011	chr15:71818396~71823384:+
THCA	cis	rs5758659	0.652	rs133326	ENSG00000234009.1	RPL5P34	-3.63	0.000316	0.0209	-0.16	-0.17	Cognitive function;	chr22:42010881	chr22:42776406~42777296:-
THCA	cis	rs13217239	0.574	rs9366680	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000316	0.0209	-0.17	-0.17	Schizophrenia;	chr6:27038344	chr6:26527063~26527404:+
THCA	cis	rs10792665	0.546	rs10792673	ENSG00000255503.1	RP11-113K21.4	-3.63	0.000316	0.0209	-0.17	-0.17	Obesity-related traits;	chr11:83050382	chr11:83072402~83097196:-
THCA	cis	rs9309473	0.66	rs11686541	ENSG00000273245.1	RP11-434P11.2	3.63	0.000316	0.0209	0.26	0.17	Metabolite levels;	chr2:73477348	chr2:73750256~73750786:-
THCA	cis	rs2592394	0.675	rs711819	ENSG00000279205.1	RP11-632P5.1	-3.63	0.000316	0.0209	-0.23	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);Magnesium levels;	chr2:176120968	chr2:176822030~176823653:+
THCA	cis	rs12049671	0.627	rs11018406	ENSG00000227076.1	RP11-4C20.4	3.63	0.000316	0.0209	0.17	0.17	Response to amphetamines;	chr10:127931269	chr10:127934698~127936167:+
THCA	cis	rs9549260	0.709	rs4943795	ENSG00000275149.1	RP11-427J23.1	3.63	0.000316	0.0209	0.22	0.17	Red blood cell count;	chr13:40599296	chr13:40079106~40273509:-
THCA	cis	rs7216064	1	rs8074078	ENSG00000278740.1	RP11-147L13.14	3.63	0.000316	0.0209	0.19	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67842627	chr17:68188547~68189165:+
THCA	cis	rs1062177	0.906	rs2964573	ENSG00000272112.1	CTB-113P19.5	3.63	0.000316	0.0209	0.15	0.17	Preschool internalizing problems;	chr5:151780561	chr5:151724831~151725356:-
THCA	cis	rs4664304	0.966	rs3792198	ENSG00000226266.5	AC009961.3	3.63	0.000316	0.0209	0.21	0.17	Crohn's disease;Inflammatory bowel disease;	chr2:159903827	chr2:159670708~159712435:-
THCA	cis	rs5758659	0.729	rs134866	ENSG00000237037.8	NDUFA6-AS1	3.63	0.000316	0.0209	0.12	0.17	Cognitive function;	chr22:42254657	chr22:42090931~42137742:+
THCA	cis	rs3760982	0.585	rs4803659	ENSG00000267058.1	RP11-15A1.3	-3.63	0.000316	0.0209	-0.14	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43786083	chr19:43891804~43901805:-
THCA	cis	rs7572733	0.905	rs1866664	ENSG00000231621.1	AC013264.2	-3.63	0.000316	0.0209	-0.16	-0.17	Dermatomyositis;	chr2:197995704	chr2:197197991~197199273:+
THCA	cis	rs2242663	0.705	rs551708	ENSG00000275484.1	CTC-1337H24.4	3.63	0.000316	0.0209	0.12	0.17	Bipolar disorder;	chr11:66718672	chr11:67374416~67374932:+
THCA	cis	rs3924048	0.574	rs12062307	ENSG00000276830.1	MIR6730	-3.63	0.000316	0.0209	-0.17	-0.17	Optic cup area;	chr1:12551822	chr1:12578957~12579023:-
THCA	cis	rs365302	1	rs371023	ENSG00000235086.1	FNDC1-IT1	3.63	0.000316	0.0209	0.23	0.17	Coronary heart disease;	chr6:159197365	chr6:159240786~159243329:+
THCA	cis	rs365302	1	rs411523	ENSG00000235086.1	FNDC1-IT1	3.63	0.000316	0.0209	0.23	0.17	Coronary heart disease;	chr6:159197758	chr6:159240786~159243329:+
THCA	cis	rs17407555	0.657	rs12508233	ENSG00000250413.1	RP11-448G15.1	-3.63	0.000316	0.0209	-0.18	-0.17	Schizophrenia (age at onset);	chr4:10269413	chr4:10006482~10009725:+
THCA	cis	rs17407555	0.632	rs12510726	ENSG00000250413.1	RP11-448G15.1	-3.63	0.000316	0.0209	-0.18	-0.17	Schizophrenia (age at onset);	chr4:10269443	chr4:10006482~10009725:+
THCA	cis	rs13381277	0.764	rs28563919	ENSG00000263982.1	RP11-504I13.3	3.63	0.000316	0.0209	0.27	0.17	Dental caries;	chr18:76612512	chr18:76372717~76378275:+
THCA	cis	rs13381277	0.764	rs28459221	ENSG00000263982.1	RP11-504I13.3	3.63	0.000316	0.0209	0.27	0.17	Dental caries;	chr18:76612722	chr18:76372717~76378275:+
THCA	cis	rs9450351	0.744	rs9351072	ENSG00000203875.9	SNHG5	-3.63	0.000316	0.0209	-0.32	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85917611	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs6912150	ENSG00000203875.9	SNHG5	-3.63	0.000316	0.0209	-0.32	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85925291	chr6:85660950~85678736:-
THCA	cis	rs10760158	0.8	rs10739595	ENSG00000235865.2	GSN-AS1	3.63	0.000316	0.0209	0.14	0.17	Pulse pressure;	chr9:121293743	chr9:121280768~121285530:-
THCA	cis	rs1030877	0.96	rs3792050	ENSG00000235319.1	AC012360.4	3.63	0.000316	0.0209	0.19	0.17	Obesity-related traits;	chr2:105285798	chr2:105324210~105330529:+
THCA	cis	rs9611565	0.559	rs132761	ENSG00000237037.8	NDUFA6-AS1	-3.63	0.000316	0.0209	-0.16	-0.17	Vitiligo;	chr22:41608367	chr22:42090931~42137742:+
THCA	cis	rs6472235	0.681	rs66644630	ENSG00000272192.1	CTD-2532N20.1	3.63	0.000316	0.0209	0.17	0.17	Plateletcrit;Myopia (pathological);	chr8:65956483	chr8:65842752~65843331:+
THCA	cis	rs17741873	0.836	rs17630952	ENSG00000271848.1	RP11-464F9.21	-3.63	0.000316	0.0209	-0.2	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73841656	chr10:73654039~73674719:+
THCA	cis	rs17741873	0.836	rs2254266	ENSG00000271848.1	RP11-464F9.21	-3.63	0.000316	0.0209	-0.2	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73841930	chr10:73654039~73674719:+
THCA	cis	rs17741873	0.836	rs4745723	ENSG00000271848.1	RP11-464F9.21	-3.63	0.000316	0.0209	-0.2	-0.17	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73843580	chr10:73654039~73674719:+
THCA	cis	rs2047076	0.785	rs72761085	ENSG00000225407.3	CTD-2384B11.2	-3.63	0.000316	0.0209	-0.25	-0.17	Monocyte count;	chr5:76798684	chr5:76691439~76716215:-
THCA	cis	rs4671400	0.602	rs2694623	ENSG00000271889.1	RP11-493E12.1	-3.63	0.000316	0.0209	-0.18	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61326331	chr2:61151433~61162105:-
THCA	cis	rs614226	1	rs614226	ENSG00000278344.1	RP11-18C24.8	-3.63	0.000316	0.0209	-0.22	-0.17	Type 1 diabetes nephropathy;	chr12:120536707	chr12:120500735~120501090:-
THCA	cis	rs1876905	0.62	rs354525	ENSG00000271789.1	RP5-1112D6.7	-3.63	0.000316	0.0209	-0.2	-0.17	Mean corpuscular hemoglobin;	chr6:111186193	chr6:111297126~111298510:+
THCA	cis	rs875971	0.965	rs9969301	ENSG00000272831.1	RP11-792A8.4	-3.63	0.000316	0.0209	-0.1	-0.17	Aortic root size;	chr7:66316668	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs709595	ENSG00000272831.1	RP11-792A8.4	3.63	0.000316	0.0209	0.1	0.17	Aortic root size;	chr7:66352346	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs811880	ENSG00000272831.1	RP11-792A8.4	3.63	0.000316	0.0209	0.1	0.17	Aortic root size;	chr7:66353659	chr7:66739829~66740385:-
THCA	cis	rs1876206	0.554	rs1678979	ENSG00000259705.1	RP11-227D13.1	-3.63	0.000316	0.0209	-0.21	-0.17	Breast cancer;	chr15:48604633	chr15:48645951~48652016:+
THCA	cis	rs9911578	1	rs4793950	ENSG00000224738.1	AC099850.1	-3.63	0.000316	0.0209	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58515750	chr17:59106598~59118267:+
THCA	cis	rs12681288	0.55	rs4637864	ENSG00000260721.1	AF067845.1	3.63	0.000317	0.0209	0.2	0.17	Schizophrenia;	chr8:1009761	chr8:1368642~1369833:-
THCA	cis	rs1552172	0.853	rs10752826	ENSG00000234222.5	RP11-315I20.1	3.63	0.000317	0.0209	0.2	0.17	Breast cancer;	chr1:145832321	chr1:145926590~145959179:+
THCA	cis	rs62289301	0.592	rs1024758	ENSG00000273133.1	RP11-799M12.2	3.63	0.000317	0.0209	0.21	0.17	Joint mobility (Beighton score);	chr4:15425874	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.614	rs16891939	ENSG00000273133.1	RP11-799M12.2	3.63	0.000317	0.0209	0.21	0.17	Joint mobility (Beighton score);	chr4:15426092	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.592	rs1024759	ENSG00000273133.1	RP11-799M12.2	3.63	0.000317	0.0209	0.21	0.17	Joint mobility (Beighton score);	chr4:15426491	chr4:15563698~15564253:-
THCA	cis	rs6940638	0.956	rs36048693	ENSG00000224843.5	LINC00240	3.63	0.000317	0.0209	0.18	0.17	Intelligence (multi-trait analysis);	chr6:27064932	chr6:26956992~27023924:+
THCA	cis	rs7521681	0.838	rs7530428	ENSG00000230489.1	VAV3-AS1	-3.63	0.000317	0.0209	-0.19	-0.17	Asthma and hay fever;	chr1:107771058	chr1:107964443~107994607:+
THCA	cis	rs7528684	0.737	rs6427397	ENSG00000236731.1	RP4-801G22.2	3.63	0.000317	0.0209	0.18	0.17	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157735935	chr1:157629939~157630728:-
THCA	cis	rs13108904	0.87	rs1960426	ENSG00000254094.1	AC078852.1	-3.63	0.000317	0.0209	-0.2	-0.17	Obesity-related traits;	chr4:1280577	chr4:1356581~1358075:+
THCA	cis	rs7500321	1	rs7500321	ENSG00000278665.1	RP11-666O2.4	-3.63	0.000317	0.0209	-0.19	-0.17	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28599241~28601881:-
THCA	cis	rs642858	0.822	rs2050717	ENSG00000234147.1	RP3-460G2.2	-3.63	0.000317	0.0209	-0.2	-0.17	Type 2 diabetes;	chr6:140048644	chr6:140845958~140852924:-
THCA	cis	rs2549003	0.966	rs10213701	ENSG00000233006.5	AC034220.3	-3.63	0.000317	0.0209	-0.13	-0.17	Asthma (sex interaction);	chr5:132488372	chr5:132311285~132369916:-
THCA	cis	rs7481311	0.828	rs12790913	ENSG00000245573.6	BDNF-AS	3.63	0.000317	0.0209	0.16	0.17	Weight;Body mass index;	chr11:27490451	chr11:27506838~27698174:+
THCA	cis	rs7216064	1	rs4791212	ENSG00000265055.1	AC145343.2	3.63	0.000317	0.0209	0.24	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67979269	chr17:68096046~68101474:-
THCA	cis	rs1560104	0.597	rs17227296	ENSG00000260601.1	RP11-552C15.1	-3.63	0.000317	0.0209	-0.2	-0.17	Obesity-related traits;	chr16:12618342	chr16:12545482~12546684:+
THCA	cis	rs801193	0.613	rs2016325	ENSG00000223473.2	GS1-124K5.3	-3.63	0.000317	0.0209	-0.11	-0.17	Aortic root size;	chr7:66858513	chr7:66491049~66493566:-
THCA	cis	rs10129255	1	rs11621409	ENSG00000211972.2	IGHV3-66	3.63	0.000317	0.0209	0.1	0.17	Kawasaki disease;	chr14:106695603	chr14:106675017~106675544:-
THCA	cis	rs804280	0.509	rs35626932	ENSG00000255495.1	AC145124.2	3.63	0.000317	0.0209	0.19	0.17	Myopia (pathological);	chr8:11929423	chr8:12194467~12196280:+
THCA	cis	rs1923539	1	rs1923539	ENSG00000225484.5	NUTM2B-AS1	3.63	0.000317	0.0209	0.23	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935194	chr10:79663088~79826594:-
THCA	cis	rs7914558	1	rs7911789	ENSG00000272912.1	RP11-724N1.1	-3.63	0.000317	0.0209	-0.19	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs67908413	ENSG00000272912.1	RP11-724N1.1	-3.63	0.000317	0.0209	-0.19	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102914585~102915404:+
THCA	cis	rs3760982	0.585	rs8109478	ENSG00000267058.1	RP11-15A1.3	-3.63	0.000317	0.0209	-0.14	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794104	chr19:43891804~43901805:-
THCA	cis	rs3760982	0.585	rs8109812	ENSG00000267058.1	RP11-15A1.3	-3.63	0.000317	0.0209	-0.14	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794342	chr19:43891804~43901805:-
THCA	cis	rs1862618	0.853	rs2548665	ENSG00000234553.1	AC022431.3	-3.63	0.000317	0.0209	-0.19	-0.17	Initial pursuit acceleration;	chr5:56835978	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.802	rs2591949	ENSG00000234553.1	AC022431.3	-3.63	0.000317	0.0209	-0.19	-0.17	Initial pursuit acceleration;	chr5:56836800	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs2548664	ENSG00000234553.1	AC022431.3	-3.63	0.000317	0.0209	-0.19	-0.17	Initial pursuit acceleration;	chr5:56837728	chr5:56536583~56537826:-
THCA	cis	rs7586085	0.934	rs1346004	ENSG00000232411.1	AC009495.3	-3.63	0.000317	0.0209	-0.18	-0.17	Total body bone mineral density;	chr2:165744536	chr2:165833048~165839098:-
THCA	cis	rs4780355	0.918	rs1646019	ENSG00000263080.1	RP11-485G7.5	3.63	0.000317	0.0209	0.2	0.17	Crohn's disease and psoriasis;	chr16:11265823	chr16:11341809~11345211:-
THCA	cis	rs478304	0.651	rs78412025	ENSG00000255320.1	RP11-755F10.1	3.63	0.000317	0.0209	0.21	0.17	Acne (severe);	chr11:65728225	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs11227281	ENSG00000255320.1	RP11-755F10.1	3.63	0.000317	0.0209	0.21	0.17	Acne (severe);	chr11:65729087	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs4014192	ENSG00000255320.1	RP11-755F10.1	3.63	0.000317	0.0209	0.21	0.17	Acne (severe);	chr11:65731444	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs4930312	ENSG00000255320.1	RP11-755F10.1	3.63	0.000317	0.0209	0.21	0.17	Acne (severe);	chr11:65732248	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs11537193	ENSG00000255320.1	RP11-755F10.1	3.63	0.000317	0.0209	0.21	0.17	Acne (severe);	chr11:65732532	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs4930313	ENSG00000255320.1	RP11-755F10.1	3.63	0.000317	0.0209	0.21	0.17	Acne (severe);	chr11:65732957	chr11:66244840~66246239:-
THCA	cis	rs7829975	0.782	rs6990746	ENSG00000233609.3	RP11-62H7.2	-3.63	0.000317	0.0209	-0.16	-0.17	Mood instability;	chr8:8690301	chr8:8961200~8979025:+
THCA	cis	rs11671005	0.693	rs11668757	ENSG00000269600.1	AC016629.3	-3.63	0.000317	0.0209	-0.25	-0.17	Mean platelet volume;	chr19:58416932	chr19:58593896~58599355:-
THCA	cis	rs5753037	0.838	rs1894474	ENSG00000279699.1	RP1-102K2.9	3.63	0.000317	0.0209	0.16	0.17	Type 1 diabetes;	chr22:29842085	chr22:30275215~30276951:-
THCA	cis	rs7412746	0.524	rs58304714	ENSG00000224800.1	RP11-235D19.2	-3.63	0.000317	0.0209	-0.23	-0.17	Melanoma;	chr1:150859085	chr1:150881236~150881683:-
THCA	cis	rs8141529	0.664	rs5762862	ENSG00000272858.1	CTA-292E10.8	-3.63	0.000317	0.0209	-0.18	-0.17	Lymphocyte counts;	chr22:28856744	chr22:28814914~28815662:+
THCA	cis	rs4144027	0.967	rs10133399	ENSG00000269910.1	RP11-73M18.10	3.63	0.000317	0.0209	0.14	0.17	Blood metabolite levels;	chr14:103895506	chr14:103694516~103695050:-
THCA	cis	rs5758659	0.504	rs133367	ENSG00000182057.4	OGFRP1	-3.63	0.000317	0.0209	-0.19	-0.17	Cognitive function;	chr22:42067362	chr22:42269753~42275196:+
THCA	cis	rs875971	0.8	rs427557	ENSG00000230189.5	GS1-124K5.2	3.63	0.000317	0.0209	0.11	0.17	Aortic root size;	chr7:66054263	chr7:66409143~66490059:-
THCA	cis	rs4785204	1	rs9936966	ENSG00000279356.1	RP11-429P3.8	3.63	0.000317	0.0209	0.3	0.17	Esophageal cancer (squamous cell);	chr16:50056455	chr16:50072862~50074986:+
THCA	cis	rs2243480	1	rs4718333	ENSG00000237310.1	GS1-124K5.4	-3.63	0.000317	0.0209	-0.19	-0.17	Diabetic kidney disease;	chr7:66307771	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs7792391	ENSG00000237310.1	GS1-124K5.4	-3.63	0.000317	0.0209	-0.19	-0.17	Diabetic kidney disease;	chr7:66308442	chr7:66493706~66495474:+
THCA	cis	rs9400467	0.537	rs55831749	ENSG00000255389.1	C6orf3	3.63	0.000317	0.0209	0.23	0.17	Amino acid levels;Blood metabolite levels;	chr6:111109079	chr6:111599875~111602295:+
THCA	cis	rs9487051	1	rs6568571	ENSG00000260273.1	RP11-425D10.10	3.63	0.000317	0.0209	0.21	0.17	Reticulocyte fraction of red cells;	chr6:109292049	chr6:109382795~109383666:+
THCA	cis	rs42648	0.667	rs2157793	ENSG00000225498.1	AC002064.5	3.63	0.000317	0.0209	0.17	0.17	Homocysteine levels;	chr7:90251040	chr7:90312496~90322592:+
THCA	cis	rs42648	0.693	rs2106274	ENSG00000225498.1	AC002064.5	3.63	0.000317	0.0209	0.17	0.17	Homocysteine levels;	chr7:90251234	chr7:90312496~90322592:+
THCA	cis	rs28530618	0.87	rs6057612	ENSG00000198547.7	C20orf203	-3.63	0.000317	0.0209	-0.12	-0.17	Birth weight;	chr20:32660723	chr20:32631652~32673941:-
THCA	cis	rs2013441	0.613	rs12451841	ENSG00000261033.1	RP11-209D14.2	-3.63	0.000317	0.0209	-0.2	-0.17	Obesity-related traits;	chr17:20101562	chr17:20008051~20009234:-
THCA	cis	rs9788721	0.934	rs16969968	ENSG00000261762.1	RP11-650L12.2	-3.63	0.000317	0.0209	-0.22	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78590583	chr15:78589123~78591276:-
THCA	cis	rs8192482	1	rs8192482	ENSG00000261762.1	RP11-650L12.2	-3.63	0.000317	0.0209	-0.22	-0.17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78593856	chr15:78589123~78591276:-
THCA	cis	rs10844154	0.638	rs812645	ENSG00000277342.1	RP11-843B15.4	3.63	0.000317	0.0209	0.2	0.17	Emphysema-related traits;Weight;	chr12:32246664	chr12:32109076~32109602:+
THCA	cis	rs6580649	0.883	rs879242	ENSG00000273765.1	RP11-370I10.11	-3.63	0.000317	0.0209	-0.18	-0.17	Lung cancer;	chr12:48109518	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs72644845	ENSG00000273765.1	RP11-370I10.11	-3.63	0.000317	0.0209	-0.18	-0.17	Lung cancer;	chr12:48110098	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs78649179	ENSG00000273765.1	RP11-370I10.11	-3.63	0.000317	0.0209	-0.18	-0.17	Lung cancer;	chr12:48114413	chr12:48360920~48361377:+
THCA	cis	rs80130819	0.515	rs72644846	ENSG00000273765.1	RP11-370I10.11	-3.63	0.000317	0.0209	-0.18	-0.17	Prostate cancer;	chr12:48114500	chr12:48360920~48361377:+
THCA	cis	rs61160187	0.582	rs3797559	ENSG00000272308.1	RP11-231G3.1	-3.63	0.000317	0.0209	-0.16	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:60866457~60866935:-
THCA	cis	rs4664293	0.967	rs12611922	ENSG00000230783.1	AC009961.2	-3.63	0.000317	0.0209	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159606238	chr2:159689217~159690291:-
THCA	cis	rs7111546	0.565	rs76537179	ENSG00000246225.5	RP11-17A1.3	3.63	0.000317	0.0209	0.28	0.17	Dialysis-related mortality;	chr11:22944446	chr11:22829380~22945393:+
THCA	cis	rs875971	0.522	rs1617484	ENSG00000229180.5	GS1-124K5.11	3.63	0.000317	0.0209	0.12	0.17	Aortic root size;	chr7:65998108	chr7:66526088~66542624:-
THCA	cis	rs3758911	1	rs1046094	ENSG00000255353.1	RP11-382M14.1	-3.63	0.000317	0.0209	-0.21	-0.17	Coronary artery disease;	chr11:107326530	chr11:107176286~107177530:+
THCA	cis	rs6030712	0.688	rs1291147	ENSG00000213979.3	RPL7AP14	3.63	0.000317	0.0209	0.26	0.17	Height;	chr20:36901350	chr20:37444733~37445534:-
THCA	cis	rs7656342	0.614	rs13132835	ENSG00000242034.1	RP11-1396O13.1	3.63	0.000317	0.0209	0.19	0.17	Gut microbiota (bacterial taxa);	chr4:9727557	chr4:9553614~9553985:-
THCA	cis	rs3758911	0.861	rs10789594	ENSG00000255353.1	RP11-382M14.1	-3.63	0.000317	0.0209	-0.21	-0.17	Coronary artery disease;	chr11:107290391	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.828	rs11212138	ENSG00000255353.1	RP11-382M14.1	-3.63	0.000317	0.0209	-0.21	-0.17	Coronary artery disease;	chr11:107294553	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.828	rs10789598	ENSG00000255353.1	RP11-382M14.1	-3.63	0.000317	0.0209	-0.21	-0.17	Coronary artery disease;	chr11:107307878	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs11212143	ENSG00000255353.1	RP11-382M14.1	-3.63	0.000317	0.0209	-0.21	-0.17	Coronary artery disease;	chr11:107308554	chr11:107176286~107177530:+
THCA	cis	rs2754412	1	rs2754412	ENSG00000272983.1	RP11-508N22.12	3.63	0.000317	0.0209	0.15	0.17	Breast cancer;	chr10:38338906	chr10:38137337~38144399:+
THCA	cis	rs6142618	0.846	rs6058569	ENSG00000224452.1	RSL24D1P6	3.63	0.000318	0.0209	0.2	0.17	Inflammatory bowel disease;	chr20:32230016	chr20:32170390~32170790:-
THCA	cis	rs9400467	0.528	rs465796	ENSG00000272356.1	RP5-1112D6.8	-3.63	0.000318	0.0209	-0.13	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111309203~111313517:+
THCA	cis	rs1005277	0.683	rs7923868	ENSG00000120555.12	SEPT7P9	3.63	0.000318	0.0209	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38383069~38402916:-
THCA	cis	rs713587	0.563	rs11686663	ENSG00000224165.4	DNAJC27-AS1	-3.63	0.000318	0.0209	-0.09	-0.17	Body mass index in non-asthmatics;	chr2:24884890	chr2:24971390~25039694:+
THCA	cis	rs13437751	0.881	rs55737822	ENSG00000223558.1	TRIM60P17	3.63	0.000318	0.0209	0.35	0.17	QT interval (drug interaction);	chr7:63938950	chr7:64085560~64086576:+
THCA	cis	rs10200159	0.793	rs11691977	ENSG00000272606.1	RP11-554J4.1	3.63	0.000318	0.0209	0.31	0.17	Vitiligo;	chr2:55698753	chr2:55617909~55618373:+
THCA	cis	rs10200159	0.793	rs12623625	ENSG00000272606.1	RP11-554J4.1	3.63	0.000318	0.0209	0.31	0.17	Vitiligo;	chr2:55699981	chr2:55617909~55618373:+
THCA	cis	rs3770081	1	rs12614260	ENSG00000273080.1	RP11-301O19.1	-3.63	0.000318	0.0209	-0.4	-0.17	Facial emotion recognition (sad faces);	chr2:86075956	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs74733602	ENSG00000273080.1	RP11-301O19.1	-3.63	0.000318	0.0209	-0.4	-0.17	Facial emotion recognition (sad faces);	chr2:86076319	chr2:86195590~86196049:+
THCA	cis	rs7259376	0.525	rs1692601	ENSG00000269138.1	ZNF209P	3.63	0.000318	0.0209	0.16	0.17	Menopause (age at onset);	chr19:22453333	chr19:22463922~22473036:+
THCA	cis	rs2613964	1	rs2613964	ENSG00000243795.1	RP11-572M11.3	3.63	0.000318	0.0209	0.19	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113141933	chr3:113142350~113167819:-
THCA	cis	rs2832191	0.679	rs2705659	ENSG00000176054.6	RPL23P2	3.63	0.000318	0.021	0.15	0.17	Dental caries;	chr21:28991587	chr21:28997613~28998033:-
THCA	cis	rs9911578	0.704	rs72628393	ENSG00000224738.1	AC099850.1	-3.63	0.000318	0.021	-0.19	-0.17	Intelligence (multi-trait analysis);	chr17:58507953	chr17:59106598~59118267:+
THCA	cis	rs2638953	0.853	rs10843195	ENSG00000247934.4	RP11-967K21.1	-3.63	0.000318	0.021	-0.17	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513633	chr12:28163298~28190738:-
THCA	cis	rs10984970	0.826	rs62578020	ENSG00000226752.6	PSMD5-AS1	3.63	0.000318	0.021	0.41	0.17	Lung cancer;	chr9:120703241	chr9:120824828~120854385:+
THCA	cis	rs7220401	0.521	rs2292973	ENSG00000263370.1	RP11-68I3.5	3.63	0.000318	0.021	0.22	0.17	Coronary artery disease;	chr17:29565997	chr17:29639627~29640825:+
THCA	cis	rs12722605	0.503	rs12722606	ENSG00000229664.1	RP11-536K7.5	3.63	0.000318	0.021	0.22	0.17	Inflammatory biomarkers;	chr10:6011170	chr10:6025978~6036427:+
THCA	cis	rs7916697	0.52	rs10762201	ENSG00000233590.1	RP11-153K11.3	3.63	0.000318	0.021	0.21	0.17	Optic disc area;	chr10:68280354	chr10:68233251~68242379:-
THCA	cis	rs1153858	0.621	rs1719237	ENSG00000275672.1	GATM-AS1	-3.63	0.000318	0.021	-0.18	-0.17	Homoarginine levels;	chr15:45287624	chr15:45378700~45380123:+
THCA	cis	rs73198271	0.74	rs10105920	ENSG00000254153.1	CTA-398F10.2	-3.63	0.000318	0.021	-0.2	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8456909~8461337:-
THCA	cis	rs11779988	0.5	rs208023	ENSG00000253671.1	RP11-806O11.1	-3.63	0.000318	0.021	-0.2	-0.17	Breast cancer;	chr8:18021373	chr8:17808941~17820868:+
THCA	cis	rs72827839	0.846	rs16953461	ENSG00000278765.1	RP5-890E16.5	3.63	0.000318	0.021	0.24	0.17	Ease of getting up in the morning;	chr17:48184374	chr17:48066704~48067293:-
THCA	cis	rs7560272	0.501	rs12713789	ENSG00000163016.8	ALMS1P	-3.63	0.000318	0.021	-0.2	-0.17	Schizophrenia;	chr2:73718473	chr2:73644919~73685576:+
THCA	cis	rs7560272	0.501	rs12713790	ENSG00000163016.8	ALMS1P	-3.63	0.000318	0.021	-0.2	-0.17	Schizophrenia;	chr2:73718484	chr2:73644919~73685576:+
THCA	cis	rs2658782	0.526	rs7127240	ENSG00000234106.3	RP11-288E14.2	3.63	0.000318	0.021	0.18	0.17	Pulmonary function decline;	chr11:93451726	chr11:93535468~93535816:+
THCA	cis	rs2115630	0.936	rs8033459	ENSG00000229212.6	RP11-561C5.4	3.63	0.000318	0.021	0.21	0.17	P wave terminal force;	chr15:84710027	chr15:85205440~85234795:-
THCA	cis	rs78487399	0.908	rs7568901	ENSG00000234936.1	AC010883.5	3.63	0.000318	0.021	0.21	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43587845	chr2:43229573~43233394:+
THCA	cis	rs8141529	0.6	rs916332	ENSG00000272858.1	CTA-292E10.8	-3.63	0.000318	0.021	-0.21	-0.17	Lymphocyte counts;	chr22:28912426	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.6	rs739196	ENSG00000272858.1	CTA-292E10.8	-3.63	0.000318	0.021	-0.21	-0.17	Lymphocyte counts;	chr22:28915283	chr22:28814914~28815662:+
THCA	cis	rs8141529	0.6	rs16986838	ENSG00000272858.1	CTA-292E10.8	-3.63	0.000318	0.021	-0.21	-0.17	Lymphocyte counts;	chr22:28916590	chr22:28814914~28815662:+
THCA	cis	rs2179367	0.632	rs10872636	ENSG00000216906.2	RP11-350J20.9	3.63	0.000318	0.021	0.21	0.17	Dupuytren's disease;	chr6:149353678	chr6:149904243~149906418:+
THCA	cis	rs860295	0.702	rs2025669	ENSG00000236675.1	MTX1P1	-3.63	0.000318	0.021	-0.17	-0.17	Body mass index;	chr1:155387818	chr1:155230975~155234325:+
THCA	cis	rs860295	0.702	rs12081067	ENSG00000236675.1	MTX1P1	-3.63	0.000318	0.021	-0.17	-0.17	Body mass index;	chr1:155389191	chr1:155230975~155234325:+
THCA	cis	rs860295	0.702	rs10908465	ENSG00000236675.1	MTX1P1	-3.63	0.000318	0.021	-0.17	-0.17	Body mass index;	chr1:155419897	chr1:155230975~155234325:+
THCA	cis	rs7208859	0.623	rs609063	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs383436	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30576464~30672789:+
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Body mass index;	chr17:30641132	chr17:30576464~30672789:+
THCA	cis	rs11190604	0.767	rs11190519	ENSG00000273030.1	RP11-285F16.1	3.63	0.000318	0.021	0.19	0.17	Palmitoleic acid (16:1n-7) levels;	chr10:100415376	chr10:100412934~100413421:+
THCA	cis	rs997295	0.57	rs72747462	ENSG00000245719.1	RP11-34F13.2	3.63	0.000318	0.021	0.18	0.17	Motion sickness;	chr15:67526200	chr15:67834310~67838879:-
THCA	cis	rs72765298	0.848	rs55736103	ENSG00000235332.2	RP11-366O20.5	3.63	0.000318	0.021	0.3	0.17	Pulse pressure;	chr9:125207551	chr9:125194649~125195821:-
THCA	cis	rs72765298	0.848	rs113658620	ENSG00000235332.2	RP11-366O20.5	3.63	0.000318	0.021	0.3	0.17	Pulse pressure;	chr9:125210129	chr9:125194649~125195821:-
THCA	cis	rs12817549	0.81	rs10745658	ENSG00000186076.5	RP11-887P2.3	3.63	0.000318	0.021	0.2	0.17	Hip circumference adjusted for BMI;	chr12:93697091	chr12:93640822~93641586:-
THCA	cis	rs75828804	1	rs76558985	ENSG00000260922.1	RP11-538I12.3	-3.63	0.000318	0.021	-0.36	-0.17	Intraocular pressure;	chr16:77543616	chr16:77234877~77290934:+
THCA	cis	rs1153858	1	rs4534782	ENSG00000275672.1	GATM-AS1	-3.63	0.000318	0.021	-0.17	-0.17	Homoarginine levels;	chr15:45360735	chr15:45378700~45380123:+
THCA	cis	rs7208859	0.623	rs170051	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.51	rs216402	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs216434	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs216436	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs216439	ENSG00000214719.10	AC005562.1	-3.63	0.000318	0.021	-0.22	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30576464~30672789:+
THCA	cis	rs613391	0.702	rs570955	ENSG00000234840.1	LINC01239	-3.63	0.000318	0.021	-0.19	-0.17	Quantitative traits;	chr9:22708312	chr9:22646200~22824213:+
THCA	cis	rs13256369	0.802	rs12541520	ENSG00000254153.1	CTA-398F10.2	-3.63	0.000318	0.021	-0.19	-0.17	Obesity-related traits;	chr8:8706636	chr8:8456909~8461337:-
THCA	cis	rs9467773	0.62	rs2494696	ENSG00000228223.2	HCG11	-3.63	0.000318	0.021	-0.17	-0.17	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26523450~26526579:+
THCA	cis	rs9844666	0.512	rs9824558	ENSG00000273486.1	RP11-731C17.2	3.63	0.000318	0.021	0.14	0.17	Height;	chr3:135915187	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs7609938	ENSG00000273486.1	RP11-731C17.2	3.63	0.000318	0.021	0.14	0.17	Height;	chr3:135916075	chr3:136837338~136839021:-
THCA	cis	rs66887589	0.807	rs7694483	ENSG00000249244.1	RP11-548H18.2	3.63	0.000318	0.021	0.17	0.17	Diastolic blood pressure;	chr4:119484774	chr4:119391831~119395335:-
THCA	cis	rs17604090	0.648	rs823384	ENSG00000223813.2	AC007255.8	3.63	0.000318	0.021	0.15	0.17	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29617999	chr7:29514225~29563670:-
THCA	cis	rs66887589	0.807	rs13134517	ENSG00000249244.1	RP11-548H18.2	3.63	0.000318	0.021	0.17	0.17	Diastolic blood pressure;	chr4:119484107	chr4:119391831~119395335:-
THCA	cis	rs66887589	0.837	rs6534135	ENSG00000249244.1	RP11-548H18.2	3.63	0.000318	0.021	0.17	0.17	Diastolic blood pressure;	chr4:119485147	chr4:119391831~119395335:-
THCA	cis	rs7216064	1	rs7210027	ENSG00000265055.1	AC145343.2	-3.63	0.000318	0.021	-0.23	-0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67980937	chr17:68096046~68101474:-
THCA	cis	rs3806843	0.521	rs192231	ENSG00000278901.1	AC005609.17	-3.63	0.000318	0.021	-0.19	-0.17	Depressive symptoms (multi-trait analysis);	chr5:140868954	chr5:140878073~140882642:-
THCA	cis	rs25645	0.83	rs3935281	ENSG00000264968.1	RP11-387H17.4	-3.63	0.000318	0.021	-0.15	-0.17	Myeloid white cell count;	chr17:40032166	chr17:39927742~39939601:+
THCA	cis	rs7560272	0.501	rs11891140	ENSG00000163016.8	ALMS1P	-3.63	0.000318	0.021	-0.2	-0.16	Schizophrenia;	chr2:73716957	chr2:73644919~73685576:+
THCA	cis	rs7520050	0.933	rs12565042	ENSG00000280836.1	AL355480.1	3.63	0.000318	0.021	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs10789475	ENSG00000280836.1	AL355480.1	3.63	0.000318	0.021	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.933	rs6666743	ENSG00000280836.1	AL355480.1	3.63	0.000318	0.021	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.933	rs9787208	ENSG00000280836.1	AL355480.1	3.63	0.000318	0.021	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45581219~45581321:-
THCA	cis	rs4907240	0.883	rs11678174	ENSG00000230606.9	AC159540.1	3.63	0.000318	0.021	0.18	0.16	Event-related brain oscillations;	chr2:96583366	chr2:97416165~97433527:-
THCA	cis	rs6824218	1	rs6824218	ENSG00000270720.1	RP11-84C13.2	3.63	0.000318	0.021	0.18	0.16	Post bronchodilator FEV1;	chr4:88919919	chr4:89119284~89119871:+
THCA	cis	rs7618915	1	rs7618915	ENSG00000239557.1	RP11-168J18.6	3.63	0.000318	0.021	0.21	0.16	Bipolar disorder;	chr3:52245578	chr3:52373652~52374882:+
THCA	cis	rs9990333	0.687	rs62285383	ENSG00000226155.1	AC124944.3	-3.63	0.000318	0.021	-0.19	-0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196087052	chr3:195912049~195913986:+
THCA	cis	rs7119	0.635	rs907374	ENSG00000259362.2	RP11-307C19.1	3.63	0.000318	0.021	0.21	0.16	Type 2 diabetes;	chr15:77591684	chr15:77525540~77534110:+
THCA	cis	rs2832191	1	rs2832191	ENSG00000232855.5	AF131217.1	3.63	0.000318	0.021	0.17	0.16	Dental caries;	chr21:29116979	chr21:28439346~28674848:-
THCA	cis	rs2337406	0.852	rs12050239	ENSG00000280411.1	IGHV1-69-2	-3.63	0.000318	0.021	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106781132	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74092535	ENSG00000280411.1	IGHV1-69-2	-3.63	0.000318	0.021	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106781722	chr14:106762092~106762588:-
THCA	cis	rs877529	1	rs877529	ENSG00000279833.1	RP4-742C19.13	-3.63	0.000319	0.021	-0.11	-0.16	Multiple myeloma;	chr22:39146287	chr22:39133090~39136760:+
THCA	cis	rs7759001	0.711	rs13217248	ENSG00000271755.1	RP1-153G14.4	3.63	0.000319	0.021	0.19	0.16	Glomerular filtration rate (creatinine);	chr6:27509170	chr6:27404010~27406964:-
THCA	cis	rs6687821	0.515	rs10782587	ENSG00000261737.1	RP4-612B15.3	3.63	0.000319	0.021	0.25	0.16	Yeast infection;	chr1:86962204	chr1:86703502~86704462:-
THCA	cis	rs4908768	0.539	rs1381928	ENSG00000270282.1	RP5-1115A15.2	3.63	0.000319	0.021	0.19	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8630874	chr1:8512653~8513021:+
THCA	cis	rs9863	0.931	rs2178663	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000319	0.021	-0.19	-0.16	White blood cell count;	chr12:123949358	chr12:123968023~123968579:-
THCA	cis	rs7208859	0.673	rs450585	ENSG00000264242.2	RP11-271K11.1	3.63	0.000319	0.021	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30553697~30558962:+
THCA	cis	rs2842346	0.568	rs2247048	ENSG00000258623.1	CTD-2325P2.3	-3.63	0.000319	0.021	-0.21	-0.16	Breast cancer;	chr14:68531603	chr14:68683411~68685565:-
THCA	cis	rs804280	0.509	rs7461273	ENSG00000206014.6	OR7E161P	-3.63	0.000319	0.021	-0.2	-0.16	Myopia (pathological);	chr8:11920468	chr8:11928597~11929563:-
THCA	cis	rs9863	0.828	rs7307277	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000319	0.021	-0.19	-0.16	White blood cell count;	chr12:123990609	chr12:123968023~123968579:-
THCA	cis	rs9863	0.828	rs71458830	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000319	0.021	-0.19	-0.16	White blood cell count;	chr12:123992014	chr12:123968023~123968579:-
THCA	cis	rs9863	0.828	rs12809473	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000319	0.021	-0.19	-0.16	White blood cell count;	chr12:123992052	chr12:123968023~123968579:-
THCA	cis	rs9863	0.828	rs12827409	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000319	0.021	-0.19	-0.16	White blood cell count;	chr12:123992159	chr12:123968023~123968579:-
THCA	cis	rs9863	0.828	rs7135314	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000319	0.021	-0.19	-0.16	White blood cell count;	chr12:123994019	chr12:123968023~123968579:-
THCA	cis	rs9863	0.828	rs56041971	ENSG00000269938.1	RP11-214K3.20	-3.63	0.000319	0.021	-0.19	-0.16	White blood cell count;	chr12:123996319	chr12:123968023~123968579:-
THCA	cis	rs3924048	0.574	rs11121928	ENSG00000276830.1	MIR6730	-3.63	0.000319	0.021	-0.16	-0.16	Optic cup area;	chr1:12555858	chr1:12578957~12579023:-
THCA	cis	rs17023223	0.508	rs12096448	ENSG00000227056.2	RPL6P2	-3.63	0.000319	0.021	-0.22	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs4508058	ENSG00000227056.2	RPL6P2	-3.63	0.000319	0.021	-0.22	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119219314~119220096:-
THCA	cis	rs412658	0.504	rs385774	ENSG00000268117.1	VN1R84P	-3.63	0.000319	0.021	-0.21	-0.16	Telomere length;	chr19:21913273	chr19:21719801~21720035:-
THCA	cis	rs5758659	0.652	rs133349	ENSG00000182057.4	OGFRP1	3.63	0.000319	0.021	0.19	0.16	Cognitive function;	chr22:42032723	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.652	rs5758553	ENSG00000182057.4	OGFRP1	3.63	0.000319	0.021	0.19	0.16	Cognitive function;	chr22:42035425	chr22:42269753~42275196:+
THCA	cis	rs11018904	0.906	rs17227345	ENSG00000280367.1	RP11-121L10.2	-3.63	0.000319	0.021	-0.22	-0.16	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90223153~90226538:+
THCA	cis	rs7223966	0.729	rs7921	ENSG00000228979.4	CTD-2501B8.5	-3.63	0.000319	0.021	-0.23	-0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63928899	chr17:63471604~63472093:+
THCA	cis	rs2180341	0.96	rs9401953	ENSG00000220522.2	RP1-177A13.1	3.63	0.000319	0.021	0.21	0.16	Breast cancer;	chr6:127366429	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.883	rs7760748	ENSG00000220522.2	RP1-177A13.1	3.63	0.000319	0.021	0.21	0.16	Breast cancer;	chr6:127368917	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.883	rs9388568	ENSG00000220522.2	RP1-177A13.1	3.63	0.000319	0.021	0.21	0.16	Breast cancer;	chr6:127369549	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.96	rs7766942	ENSG00000220522.2	RP1-177A13.1	3.63	0.000319	0.021	0.21	0.16	Breast cancer;	chr6:127370178	chr6:127416535~127416952:-
THCA	cis	rs7777677	1	rs7777677	ENSG00000226660.2	TRBV2	3.63	0.000319	0.021	0.14	0.16	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142300924~142301432:+
THCA	cis	rs4578769	0.84	rs67940971	ENSG00000265939.1	UBE2CP2	-3.63	0.000319	0.021	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22902777	chr18:22900486~22900995:-
THCA	cis	rs293748	0.713	rs2937116	ENSG00000250155.1	CTD-2353F22.1	-3.63	0.000319	0.021	-0.22	-0.16	Obesity-related traits;	chr5:36824900	chr5:36666214~36725195:-
THCA	cis	rs7246967	0.551	rs7248993	ENSG00000198153.8	ZNF849P	-3.63	0.000319	0.021	-0.26	-0.16	Bronchopulmonary dysplasia;	chr19:22666350	chr19:22685167~22686732:+
THCA	cis	rs78487399	0.908	rs55855805	ENSG00000234936.1	AC010883.5	3.63	0.000319	0.021	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43581351	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs6715003	ENSG00000234936.1	AC010883.5	3.63	0.000319	0.021	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43581520	chr2:43229573~43233394:+
THCA	cis	rs57709857	0.957	rs72644720	ENSG00000272092.1	RP11-350N15.5	-3.63	0.000319	0.021	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38277262	chr8:38382364~38383461:+
THCA	cis	rs76878669	0.561	rs56321771	ENSG00000255320.1	RP11-755F10.1	-3.63	0.000319	0.021	-0.21	-0.16	Educational attainment (years of education);	chr11:66393601	chr11:66244840~66246239:-
THCA	cis	rs1560104	0.518	rs11645483	ENSG00000260601.1	RP11-552C15.1	-3.63	0.000319	0.021	-0.21	-0.16	Obesity-related traits;	chr16:12615400	chr16:12545482~12546684:+
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000254866.2	DEFB109P3	-3.63	0.000319	0.021	-0.22	-0.16	Neuroticism;	chr8:11991324	chr8:12150895~12151134:-
THCA	cis	rs6472235	0.807	rs4262311	ENSG00000272192.1	CTD-2532N20.1	3.63	0.000319	0.021	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66031432	chr8:65842752~65843331:+
THCA	cis	rs1612141	0.744	rs2415659	ENSG00000251363.2	RP11-129M6.1	-3.63	0.000319	0.021	-0.24	-0.16	QT interval (drug interaction);	chr14:41102834	chr14:40954898~40975877:+
THCA	cis	rs4262150	0.726	rs4398624	ENSG00000253921.1	CTB-113P19.3	-3.63	0.000319	0.021	-0.21	-0.16	Bipolar disorder and schizophrenia;	chr5:152638783	chr5:151753992~151767247:+
THCA	cis	rs2179367	0.887	rs2789492	ENSG00000223701.3	RAET1E-AS1	-3.63	0.000319	0.021	-0.21	-0.16	Dupuytren's disease;	chr6:149426243	chr6:149884431~149919508:+
THCA	cis	rs7089973	0.526	rs7100026	ENSG00000236799.1	RP11-383C6.2	-3.63	0.000319	0.021	-0.21	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114990280	chr10:114994657~114996593:+
THCA	cis	rs116095464	1	rs62331562	ENSG00000277812.1	AC021087.1	3.63	0.000319	0.021	0.43	0.16	Breast cancer;	chr5:349183	chr5:262769~262881:+
THCA	cis	rs9980	0.553	rs4783719	ENSG00000226232.7	RP11-419C5.2	3.63	0.000319	0.021	0.17	0.16	Blood osmolality (transformed sodium);	chr16:69525412	chr16:69976388~69996188:-
THCA	cis	rs911555	0.723	rs12436956	ENSG00000269910.1	RP11-73M18.10	-3.63	0.000319	0.021	-0.15	-0.16	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103694516~103695050:-
THCA	cis	rs7520050	0.933	rs6694340	ENSG00000280836.1	AL355480.1	3.63	0.000319	0.021	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45581219~45581321:-
THCA	cis	rs4578769	0.694	rs72882142	ENSG00000265939.1	UBE2CP2	-3.63	0.000319	0.021	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22806755	chr18:22900486~22900995:-
THCA	cis	rs9876781	1	rs6442123	ENSG00000199476.1	Y_RNA	-3.63	0.000319	0.021	-0.21	-0.16	Longevity;	chr3:48458887	chr3:48288587~48288694:+
THCA	cis	rs1858037	0.867	rs1039765	ENSG00000252414.1	RNU6-100P	3.63	0.000319	0.021	0.18	0.16	Rheumatoid arthritis;	chr2:65387228	chr2:64578892~64578997:+
THCA	cis	rs150992	0.673	rs692832	ENSG00000246763.5	RGMB-AS1	3.63	0.000319	0.021	0.17	0.16	Body mass index;	chr5:98856761	chr5:98769618~98773469:-
THCA	cis	rs7829975	0.582	rs11783950	ENSG00000253981.4	ALG1L13P	-3.63	0.000319	0.021	-0.16	-0.16	Mood instability;	chr8:8740321	chr8:8236003~8244667:-
THCA	cis	rs8179	0.553	rs42235	ENSG00000230927.2	TMBIM7P	3.63	0.000319	0.021	0.22	0.16	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92618762	chr7:92412976~92439562:-
THCA	cis	rs733175	0.857	rs10018663	ENSG00000163612.10	FAM86KP	-3.63	0.000319	0.021	-0.27	-0.16	Psychosis and Alzheimer's disease;	chr4:10003173	chr4:9153296~9165451:+
THCA	cis	rs340849	0.933	rs10746444	ENSG00000274895.1	RP11-478J18.2	3.63	0.000319	0.021	0.14	0.16	Alzheimer's disease;	chr1:213930938	chr1:213983793~213986419:-
THCA	cis	rs11662586	1	rs8093291	ENSG00000267251.2	AC139100.3	3.63	0.000319	0.021	0.19	0.16	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79941294	chr18:80183680~80202992:+
THCA	cis	rs5771225	0.544	rs13055135	ENSG00000273137.1	RP3-402G11.28	-3.63	0.000319	0.021	-0.13	-0.16	Late-onset Alzheimer's disease;	chr22:50234050	chr22:50208461~50209542:-
THCA	cis	rs5758659	0.652	rs133326	ENSG00000182057.4	OGFRP1	3.63	0.000319	0.021	0.19	0.16	Cognitive function;	chr22:42010881	chr22:42269753~42275196:+
THCA	cis	rs66887589	0.807	rs9799664	ENSG00000249244.1	RP11-548H18.2	3.63	0.000319	0.021	0.17	0.16	Diastolic blood pressure;	chr4:119405523	chr4:119391831~119395335:-
THCA	cis	rs722599	0.683	rs11848876	ENSG00000279594.1	RP11-950C14.10	3.63	0.000319	0.021	0.17	0.16	IgG glycosylation;	chr14:74757923	chr14:75011269~75012851:-
THCA	cis	rs7660883	0.836	rs442177	ENSG00000251411.1	RP11-397E7.4	-3.63	0.000319	0.021	-0.16	-0.16	HDL cholesterol levels;	chr4:87109109	chr4:86913266~86914817:-
THCA	cis	rs3782123	0.514	rs11246007	ENSG00000277290.1	RP11-326C3.16	-3.63	0.000319	0.021	-0.2	-0.16	Red cell distribution width;Glycated hemoglobin levels;	chr11:221584	chr11:243099~243483:-
THCA	cis	rs7833790	0.963	rs2400473	ENSG00000254689.1	RP11-354A14.1	3.63	0.000319	0.0211	0.21	0.16	Diastolic blood pressure;	chr8:81791168	chr8:81885377~81923193:+
THCA	cis	rs763121	0.815	rs9306328	ENSG00000228274.3	RP3-508I15.9	-3.63	0.000319	0.0211	-0.17	-0.16	Menopause (age at onset);	chr22:38632908	chr22:38667585~38681820:-
THCA	cis	rs17689437	0.541	rs2862779	ENSG00000260084.1	RP11-615I2.1	3.63	0.000319	0.0211	0.19	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68605630	chr16:68573782~68589512:-
THCA	cis	rs3806843	0.547	rs183679	ENSG00000278901.1	AC005609.17	-3.63	0.000319	0.0211	-0.19	-0.16	Depressive symptoms (multi-trait analysis);	chr5:140891432	chr5:140878073~140882642:-
THCA	cis	rs3806843	0.576	rs550475	ENSG00000278901.1	AC005609.17	3.63	0.000319	0.0211	0.19	0.16	Depressive symptoms (multi-trait analysis);	chr5:140893943	chr5:140878073~140882642:-
THCA	cis	rs13098911	0.54	rs2373087	ENSG00000226074.4	PRSS44	-3.63	0.000319	0.0211	-0.31	-0.16	Celiac disease;	chr3:45926551	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13099120	ENSG00000226074.4	PRSS44	-3.63	0.000319	0.0211	-0.31	-0.16	Celiac disease;	chr3:45929452	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs35477280	ENSG00000226074.4	PRSS44	-3.63	0.000319	0.0211	-0.31	-0.16	Celiac disease;	chr3:45932600	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13066516	ENSG00000226074.4	PRSS44	-3.63	0.000319	0.0211	-0.31	-0.16	Celiac disease;	chr3:45933951	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs77902290	ENSG00000226074.4	PRSS44	-3.63	0.000319	0.0211	-0.31	-0.16	Eosinophil percentage of granulocytes;	chr3:45935170	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs2171531	ENSG00000226074.4	PRSS44	-3.63	0.000319	0.0211	-0.31	-0.16	Celiac disease;	chr3:45939679	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs55920693	ENSG00000226074.4	PRSS44	-3.63	0.000319	0.0211	-0.31	-0.16	Celiac disease;	chr3:45941984	chr3:46809359~46812558:-
THCA	cis	rs854765	0.624	rs11657130	ENSG00000281749.1	Y_RNA	-3.63	0.000319	0.0211	-0.22	-0.16	Total body bone mineral density;	chr17:17830512	chr17:18001101~18001195:-
THCA	cis	rs7777677	0.925	rs4726540	ENSG00000226660.2	TRBV2	3.63	0.00032	0.0211	0.14	0.16	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142300924~142301432:+
THCA	cis	rs4727027	0.704	rs12704070	ENSG00000244560.5	RP4-800G7.2	-3.63	0.00032	0.0211	-0.1	-0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149205697	chr7:149285281~149297312:+
THCA	cis	rs11976180	1	rs6464574	ENSG00000204959.4	ARHGEF34P	3.63	0.00032	0.0211	0.19	0.16	Obesity-related traits;	chr7:144051164	chr7:144272445~144286966:-
THCA	cis	rs6747488	0.505	rs553464	ENSG00000276517.1	AL133243.2	-3.63	0.00032	0.0211	-0.16	-0.16	Interleukin-18 levels;	chr2:31648407	chr2:32526504~32529507:+
THCA	cis	rs2034088	0.93	rs9907540	ENSG00000231784.7	DBIL5P	3.63	0.00032	0.0211	0.19	0.16	Hip circumference adjusted for BMI;	chr17:544802	chr17:752660~755336:+
THCA	cis	rs7665090	1	rs7677509	ENSG00000248971.2	KRT8P46	-3.63	0.00032	0.0211	-0.19	-0.16	Primary biliary cholangitis;	chr4:102628849	chr4:102728746~102730171:-
THCA	cis	rs7665090	0.967	rs7699231	ENSG00000248971.2	KRT8P46	-3.63	0.00032	0.0211	-0.19	-0.16	Primary biliary cholangitis;	chr4:102628918	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs7699678	ENSG00000248971.2	KRT8P46	-3.63	0.00032	0.0211	-0.19	-0.16	Primary biliary cholangitis;	chr4:102628939	chr4:102728746~102730171:-
THCA	cis	rs7665090	1	rs11724614	ENSG00000248971.2	KRT8P46	-3.63	0.00032	0.0211	-0.19	-0.16	Primary biliary cholangitis;	chr4:102629091	chr4:102728746~102730171:-
THCA	cis	rs7610761	0.967	rs13085568	ENSG00000228804.4	RP11-211G3.3	3.63	0.00032	0.0211	0.19	0.16	Schizophrenia;	chr3:188478994	chr3:187702313~187733849:+
THCA	cis	rs11168618	0.904	rs7135125	ENSG00000240399.1	RP1-228P16.1	3.63	0.00032	0.0211	0.16	0.16	Adiponectin levels;	chr12:48532485	chr12:48054813~48055591:-
THCA	cis	rs11168618	0.904	rs10875829	ENSG00000240399.1	RP1-228P16.1	3.63	0.00032	0.0211	0.16	0.16	Adiponectin levels;	chr12:48533414	chr12:48054813~48055591:-
THCA	cis	rs12681366	0.763	rs3019277	ENSG00000253175.1	RP11-267M23.6	3.63	0.00032	0.0211	0.21	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94428195	chr8:94565036~94565715:+
THCA	cis	rs9450351	0.546	rs9344550	ENSG00000203875.9	SNHG5	-3.63	0.00032	0.0211	-0.32	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85829000	chr6:85660950~85678736:-
THCA	cis	rs9549260	0.755	rs2701863	ENSG00000168852.11	TPTE2P5	3.63	0.00032	0.0211	0.12	0.16	Red blood cell count;	chr13:40596003	chr13:40822296~40921749:-
THCA	cis	rs17134212	0.545	rs7705102	ENSG00000251187.4	CTC-459M5.2	-3.63	0.00032	0.0211	-0.15	-0.16	Common carotid intima-media thickness in HIV negative individuals;	chr5:112200382	chr5:112192020~112210139:+
THCA	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	3.63	0.00032	0.0211	0.19	0.16	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
THCA	cis	rs17345786	0.906	rs72940399	ENSG00000244119.1	PDCL3P4	3.63	0.00032	0.0211	0.16	0.16	Colonoscopy-negative controls vs population controls;	chr3:101403731	chr3:101712472~101713191:+
THCA	cis	rs11671005	0.735	rs3764529	ENSG00000269600.1	AC016629.3	-3.63	0.00032	0.0211	-0.24	-0.16	Mean platelet volume;	chr19:58433722	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs1122955	ENSG00000269600.1	AC016629.3	-3.63	0.00032	0.0211	-0.24	-0.16	Mean platelet volume;	chr19:58434836	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.735	rs11668814	ENSG00000269600.1	AC016629.3	-3.63	0.00032	0.0211	-0.24	-0.16	Mean platelet volume;	chr19:58435466	chr19:58593896~58599355:-
THCA	cis	rs10129255	0.957	rs10138532	ENSG00000280411.1	IGHV1-69-2	-3.63	0.00032	0.0211	-0.11	-0.16	Kawasaki disease;	chr14:106803901	chr14:106762092~106762588:-
THCA	cis	rs11710088	0.707	rs35551531	ENSG00000243885.1	RP11-278L15.2	3.63	0.00032	0.0211	0.18	0.16	QRS duration;	chr3:149489199	chr3:149384179~149385800:-
THCA	cis	rs8054556	0.73	rs4788190	ENSG00000273724.1	RP11-347C12.12	-3.63	0.00032	0.0211	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30336400~30343336:+
THCA	cis	rs7188697	0.922	rs8047769	ENSG00000276259.1	RP11-481J2.4	3.63	0.00032	0.0211	0.12	0.16	QT interval;	chr16:58558083	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.883	rs4485352	ENSG00000276259.1	RP11-481J2.4	3.63	0.00032	0.0211	0.12	0.16	QT interval;	chr16:58567506	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs6499962	ENSG00000276259.1	RP11-481J2.4	3.63	0.00032	0.0211	0.12	0.16	QT interval;	chr16:58576846	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs9924805	ENSG00000276259.1	RP11-481J2.4	3.63	0.00032	0.0211	0.12	0.16	QT interval;	chr16:58581755	chr16:58522970~58523842:+
THCA	cis	rs2736345	0.89	rs4840565	ENSG00000254527.1	ENPP7P12	3.63	0.00032	0.0211	0.21	0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11488036	chr8:12205759~12206389:-
THCA	cis	rs651907	0.817	rs675779	ENSG00000256628.3	ZBTB11-AS1	3.63	0.00032	0.0211	0.18	0.16	Colorectal cancer;	chr3:101880175	chr3:101676475~101679217:+
THCA	cis	rs7772697	0.632	rs7775412	ENSG00000223701.3	RAET1E-AS1	-3.63	0.00032	0.0211	-0.22	-0.16	Diabetic retinopathy;	chr6:149102418	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.632	rs7741346	ENSG00000223701.3	RAET1E-AS1	-3.63	0.00032	0.0211	-0.22	-0.16	Diabetic retinopathy;	chr6:149104670	chr6:149884431~149919508:+
THCA	cis	rs115769866	0.609	rs2859356	ENSG00000216901.1	AL022393.7	3.63	0.00032	0.0211	0.24	0.16	Bipolar disorder;	chr6:28497578	chr6:28176188~28176674:+
THCA	cis	rs860295	0.702	rs11264380	ENSG00000236675.1	MTX1P1	-3.63	0.00032	0.0211	-0.17	-0.16	Body mass index;	chr1:155550353	chr1:155230975~155234325:+
THCA	cis	rs7216064	1	rs56404791	ENSG00000265055.1	AC145343.2	3.63	0.00032	0.0211	0.23	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896903	chr17:68096046~68101474:-
THCA	cis	rs7246967	0.673	rs8102006	ENSG00000198153.8	ZNF849P	-3.63	0.00032	0.0211	-0.26	-0.16	Bronchopulmonary dysplasia;	chr19:22687301	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs55932152	ENSG00000198153.8	ZNF849P	-3.63	0.00032	0.0211	-0.26	-0.16	Bronchopulmonary dysplasia;	chr19:22690626	chr19:22685167~22686732:+
THCA	cis	rs2235642	0.525	rs2667688	ENSG00000280231.1	LA16c-380F5.3	-3.63	0.00032	0.0211	-0.21	-0.16	Coronary artery disease;	chr16:1511445	chr16:1553655~1554130:-
THCA	cis	rs2562456	0.833	rs11666447	ENSG00000268521.1	VN1R83P	3.63	0.00032	0.0211	0.16	0.16	Pain;	chr19:21416270	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs11666525	ENSG00000268521.1	VN1R83P	3.63	0.00032	0.0211	0.16	0.16	Pain;	chr19:21416503	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.793	rs62110424	ENSG00000268521.1	VN1R83P	3.63	0.00032	0.0211	0.16	0.16	Pain;	chr19:21416835	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.793	rs3853837	ENSG00000268521.1	VN1R83P	3.63	0.00032	0.0211	0.16	0.16	Pain;	chr19:21419172	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.793	rs3853838	ENSG00000268521.1	VN1R83P	3.63	0.00032	0.0211	0.16	0.16	Pain;	chr19:21419192	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs62110426	ENSG00000268521.1	VN1R83P	3.63	0.00032	0.0211	0.16	0.16	Pain;	chr19:21420124	chr19:21289554~21289998:-
THCA	cis	rs12476592	0.602	rs262506	ENSG00000242412.1	DBIL5P2	3.63	0.00032	0.0211	0.21	0.16	Childhood ear infection;	chr2:63635888	chr2:63117851~63119542:-
THCA	cis	rs11822910	1	rs4477456	ENSG00000265566.2	RN7SL605P	3.63	0.00032	0.0211	0.28	0.16	Platelet distribution width;	chr11:57430308	chr11:57528085~57528365:-
THCA	cis	rs1371614	0.592	rs12613534	ENSG00000229122.1	AGBL5-IT1	-3.63	0.00032	0.0211	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26915726	chr2:27061038~27061815:+
THCA	cis	rs58365266	1	rs58365266	ENSG00000273009.1	RP11-352G9.1	-3.63	0.00032	0.0211	-0.25	-0.16	Red cell distribution width;	chr3:196086886	chr3:195913078~195913683:-
THCA	cis	rs927833	0.655	rs2424422	ENSG00000214535.3	RPS15AP1	-3.63	0.00032	0.0211	-0.24	-0.16	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr20:21987581	chr20:21166206~21166596:-
THCA	cis	rs7246657	0.722	rs4802051	ENSG00000226686.6	LINC01535	-3.63	0.00032	0.0211	-0.24	-0.16	Coronary artery calcification;	chr19:37581427	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.663	rs4803276	ENSG00000226686.6	LINC01535	-3.63	0.00032	0.0211	-0.24	-0.16	Coronary artery calcification;	chr19:37581429	chr19:37251912~37265535:+
THCA	cis	rs12887734	0.524	rs4906363	ENSG00000258735.1	LINC00637	-3.63	0.00032	0.0211	-0.22	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103847721~103858049:+
THCA	cis	rs4930561	0.714	rs7126326	ENSG00000184795.9	UNC93B5	-3.63	0.00032	0.0211	-0.21	-0.16	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68179808	chr11:67711702~67716005:-
THCA	cis	rs113577745	0.697	rs3791760	ENSG00000188525.3	AC010969.1	-3.63	0.00032	0.0211	-0.23	-0.16	Breast cancer;	chr2:9978296	chr2:10003158~10006030:-
THCA	cis	rs11039798	0.588	rs11039781	ENSG00000200090.1	Y_RNA	3.63	0.00032	0.0211	0.13	0.16	Axial length;	chr11:48501533	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.588	rs11039782	ENSG00000200090.1	Y_RNA	3.63	0.00032	0.0211	0.13	0.16	Axial length;	chr11:48503233	chr11:47726894~47726992:-
THCA	cis	rs7572733	0.935	rs700659	ENSG00000231621.1	AC013264.2	-3.63	0.00032	0.0211	-0.15	-0.16	Dermatomyositis;	chr2:197795199	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs771016	ENSG00000231621.1	AC013264.2	-3.63	0.00032	0.0211	-0.15	-0.16	Dermatomyositis;	chr2:197800796	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs700665	ENSG00000231621.1	AC013264.2	-3.63	0.00032	0.0211	-0.15	-0.16	Dermatomyositis;	chr2:197808655	chr2:197197991~197199273:+
THCA	cis	rs2839186	0.967	rs17176131	ENSG00000228137.1	AP001469.7	3.63	0.00032	0.0211	0.16	0.16	Testicular germ cell tumor;	chr21:46285323	chr21:46246890~46247682:+
THCA	cis	rs12898370	0.641	rs11632999	ENSG00000259362.2	RP11-307C19.1	-3.63	0.00032	0.0211	-0.27	-0.16	Risky sexual behaviors (alcohol dependence interaction);	chr15:77144653	chr15:77525540~77534110:+
THCA	cis	rs17027633	0.881	rs41301285	ENSG00000260948.1	RP11-552M11.8	-3.63	0.00032	0.0211	-0.4	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111477130	chr1:111431046~111433068:-
THCA	cis	rs4262150	0.81	rs12188715	ENSG00000253921.1	CTB-113P19.3	3.63	0.00032	0.0211	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152594323	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.774	rs17453740	ENSG00000253921.1	CTB-113P19.3	3.63	0.00032	0.0211	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152596582	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs17453775	ENSG00000253921.1	CTB-113P19.3	3.63	0.00032	0.0211	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152596683	chr5:151753992~151767247:+
THCA	cis	rs7819412	0.522	rs11776603	ENSG00000206014.6	OR7E161P	3.63	0.00032	0.0211	0.21	0.16	Triglycerides;	chr8:11162803	chr8:11928597~11929563:-
THCA	cis	rs420259	0.516	rs531805	ENSG00000260136.4	CTD-2270L9.4	3.63	0.00032	0.0211	0.13	0.16	Bipolar disorder;	chr16:23454714	chr16:23452758~23457606:+
THCA	cis	rs7246967	0.673	rs34376806	ENSG00000198153.8	ZNF849P	-3.63	0.00032	0.0211	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22718059	chr19:22685167~22686732:+
THCA	cis	rs3781264	0.557	rs10882437	ENSG00000273450.1	RP11-76P2.4	3.63	0.000321	0.0211	0.21	0.16	Esophageal cancer and gastric cancer;	chr10:94362073	chr10:94314907~94315327:-
THCA	cis	rs5758511	0.689	rs17002947	ENSG00000230107.1	CTA-126B4.7	3.62	0.000321	0.0211	0.2	0.16	Birth weight;	chr22:42292526	chr22:42438023~42446195:+
THCA	cis	rs7819412	0.669	rs2409743	ENSG00000254839.1	AF131215.6	3.62	0.000321	0.0211	0.17	0.16	Triglycerides;	chr8:11212851	chr8:11062647~11067089:-
THCA	cis	rs7674212	0.57	rs2069274	ENSG00000230069.3	LRRC37A15P	-3.62	0.000321	0.0211	-0.17	-0.16	Type 2 diabetes;	chr4:103099624	chr4:102727274~102730721:-
THCA	cis	rs5769765	0.955	rs4075330	ENSG00000278869.1	CITF22-49E9.3	3.62	0.000321	0.0211	0.21	0.16	Schizophrenia;	chr22:49909601	chr22:49933198~49934074:-
THCA	cis	rs12549025	0.891	rs35469695	ENSG00000253390.1	CTC-756D1.2	-3.62	0.000321	0.0211	-0.27	-0.16	Reticulocyte fraction of red cells;	chr8:23548656	chr8:23458601~23484971:+
THCA	cis	rs2131877	0.573	rs9848862	ENSG00000238097.1	RP11-513G11.3	3.62	0.000321	0.0211	0.19	0.16	Non-small cell lung cancer;	chr3:195121473	chr3:194247648~194257772:+
THCA	cis	rs10090774	0.965	rs4246126	ENSG00000280303.2	ERICD	3.62	0.000321	0.0211	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140780793	chr8:140636281~140638283:+
THCA	cis	rs494526	0.641	rs7080040	ENSG00000229272.1	RP11-498J9.2	-3.62	0.000321	0.0211	-0.18	-0.16	Alcoholic chronic pancreatitis;	chr10:119098761	chr10:119003536~119003884:-
THCA	cis	rs17772222	0.516	rs1006259	ENSG00000258789.1	RP11-507K2.3	-3.62	0.000321	0.0211	-0.16	-0.16	Coronary artery calcification;	chr14:88339759	chr14:88551597~88552493:+
THCA	cis	rs1009077	0.951	rs17296659	ENSG00000245958.5	RP11-33B1.1	3.62	0.000321	0.0211	0.21	0.16	Endometriosis;	chr4:119739471	chr4:119454791~119552025:+
THCA	cis	rs7587476	0.626	rs7593780	ENSG00000229267.2	AC072062.1	-3.62	0.000321	0.0211	-0.18	-0.16	Neuroblastoma;	chr2:214775672	chr2:214810229~214963274:+
THCA	cis	rs9309473	0.519	rs2421583	ENSG00000273245.1	RP11-434P11.2	-3.62	0.000321	0.0211	-0.2	-0.16	Metabolite levels;	chr2:73671658	chr2:73750256~73750786:-
THCA	cis	rs4915077	0.892	rs6698523	ENSG00000226822.1	RP11-356N1.2	3.62	0.000321	0.0211	0.27	0.16	Hypothyroidism;	chr1:107812544	chr1:108071482~108074519:+
THCA	cis	rs1005277	0.579	rs2472173	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000321	0.0211	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2472174	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000321	0.0211	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474563	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000321	0.0211	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs9418322	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000321	0.0211	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs9299760	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000321	0.0211	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2023351	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000321	0.0211	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:37883594~37884109:+
THCA	cis	rs4268898	0.76	rs55863105	ENSG00000242628.4	AC009228.1	-3.62	0.000321	0.0211	-0.2	-0.16	Asthma;	chr2:24347826	chr2:24214381~24221516:+
THCA	cis	rs9400467	0.537	rs12199840	ENSG00000255389.1	C6orf3	3.62	0.000321	0.0211	0.23	0.16	Amino acid levels;Blood metabolite levels;	chr6:111107662	chr6:111599875~111602295:+
THCA	cis	rs17270561	0.636	rs1165216	ENSG00000272462.2	U91328.19	-3.62	0.000321	0.0211	-0.13	-0.16	Iron status biomarkers;	chr6:25797743	chr6:25992662~26001775:+
THCA	cis	rs6546537	0.911	rs13027712	ENSG00000231024.1	AC092431.3	3.62	0.000321	0.0211	0.22	0.16	Serum thyroid-stimulating hormone levels;	chr2:69664235	chr2:69700192~69713847:-
THCA	cis	rs14027	0.883	rs1469755	ENSG00000245330.4	KB-1471A8.1	3.62	0.000321	0.0211	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119728107	chr8:119867419~119874488:-
THCA	cis	rs8083427	0.867	rs8083482	ENSG00000275805.1	RP11-349H17.2	-3.62	0.000321	0.0211	-0.38	-0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr18:26547349	chr18:26565723~26575626:-
THCA	cis	rs763121	0.657	rs5995603	ENSG00000273076.1	RP3-508I15.22	3.62	0.000321	0.0211	0.17	0.16	Menopause (age at onset);	chr22:38644728	chr22:38743495~38743910:+
THCA	cis	rs7772697	0.632	rs9498214	ENSG00000223701.3	RAET1E-AS1	-3.62	0.000321	0.0211	-0.22	-0.16	Diabetic retinopathy;	chr6:149097174	chr6:149884431~149919508:+
THCA	cis	rs2243480	1	rs316327	ENSG00000237310.1	GS1-124K5.4	-3.62	0.000321	0.0211	-0.19	-0.16	Diabetic kidney disease;	chr7:66144214	chr7:66493706~66495474:+
THCA	cis	rs7824557	0.564	rs2736288	ENSG00000227888.4	FAM66A	-3.62	0.000321	0.0211	-0.21	-0.16	Retinal vascular caliber;	chr8:11370591	chr8:12362019~12388296:+
THCA	cis	rs720475	0.732	rs62483106	ENSG00000170356.8	OR2A20P	3.62	0.000321	0.0211	0.23	0.16	Breast cancer;	chr7:144439533	chr7:144250045~144252957:-
THCA	cis	rs7631605	0.846	rs11926768	ENSG00000224080.1	UBE2FP1	-3.62	0.000321	0.0211	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36926856	chr3:37143512~37143958:-
THCA	cis	rs853679	0.607	rs66886492	ENSG00000220721.1	OR1F12	3.62	0.000321	0.0211	0.38	0.16	Depression;	chr6:28121953	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs35345226	ENSG00000220721.1	OR1F12	3.62	0.000321	0.0211	0.38	0.16	Depression;	chr6:28123802	chr6:28073316~28074233:+
THCA	cis	rs1880529	0.778	rs7667286	ENSG00000206820.1	RNU1-138P	3.62	0.000321	0.0211	0.18	0.16	White matter integrity (bipolar disorder risk interaction);	chr4:113433086	chr4:113420323~113420486:+
THCA	cis	rs847649	0.692	rs7800548	ENSG00000234715.1	CTB-107G13.1	3.62	0.000321	0.0212	0.18	0.16	Morning vs. evening chronotype;	chr7:102841395	chr7:103445207~103514007:+
THCA	cis	rs11685222	0.513	rs116092847	ENSG00000229326.3	AC069154.4	3.62	0.000321	0.0212	0.28	0.16	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119661848	chr2:119698623~119700151:+
THCA	cis	rs5770917	1	rs5770911	ENSG00000279182.1	XX-C00717C00720L.1	3.62	0.000321	0.0212	0.28	0.16	Narcolepsy;	chr22:50572812	chr22:50316035~50317025:+
THCA	cis	rs1923243	0.617	rs11210100	ENSG00000223479.3	RP4-788P17.1	-3.62	0.000321	0.0212	-0.18	-0.16	Migraine;	chr1:72969946	chr1:73635216~73715214:+
THCA	cis	rs9333290	0.893	rs13001028	ENSG00000259915.2	RP11-410E4.1	3.62	0.000321	0.0212	0.2	0.16	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186682168	chr2:186354570~186356773:-
THCA	cis	rs13053817	0.898	rs35847236	ENSG00000279699.1	RP1-102K2.9	3.62	0.000321	0.0212	0.25	0.16	Carotid atherosclerosis in HIV infection;	chr22:29470605	chr22:30275215~30276951:-
THCA	cis	rs854765	0.547	rs4368210	ENSG00000281749.1	Y_RNA	-3.62	0.000321	0.0212	-0.21	-0.16	Total body bone mineral density;	chr17:17992776	chr17:18001101~18001195:-
THCA	cis	rs889312	0.961	rs6450401	ENSG00000271828.1	CTD-2310F14.1	-3.62	0.000321	0.0212	-0.23	-0.16	Breast cancer (early onset);Breast cancer;	chr5:56737407	chr5:56927874~56929573:+
THCA	cis	rs6724465	0.673	rs72951800	ENSG00000272644.1	RP11-33O4.1	3.62	0.000321	0.0212	0.24	0.16	Height;	chr2:219140689	chr2:219069354~219069809:-
THCA	cis	rs66887589	0.837	rs7661498	ENSG00000249244.1	RP11-548H18.2	3.62	0.000321	0.0212	0.17	0.16	Diastolic blood pressure;	chr4:119486953	chr4:119391831~119395335:-
THCA	cis	rs17345786	0.906	rs59359251	ENSG00000244119.1	PDCL3P4	3.62	0.000321	0.0212	0.16	0.16	Colonoscopy-negative controls vs population controls;	chr3:101427518	chr3:101712472~101713191:+
THCA	cis	rs17345786	0.906	rs55710435	ENSG00000244119.1	PDCL3P4	3.62	0.000321	0.0212	0.16	0.16	Colonoscopy-negative controls vs population controls;	chr3:101461486	chr3:101712472~101713191:+
THCA	cis	rs17345786	0.906	rs72944107	ENSG00000244119.1	PDCL3P4	3.62	0.000321	0.0212	0.16	0.16	Colonoscopy-negative controls vs population controls;	chr3:101478346	chr3:101712472~101713191:+
THCA	cis	rs9693857	0.52	rs4841163	ENSG00000248538.5	RP11-10A14.5	-3.62	0.000321	0.0212	-0.22	-0.16	Systolic blood pressure;	chr8:9508668	chr8:9189011~9202854:+
THCA	cis	rs1153858	1	rs10519021	ENSG00000275672.1	GATM-AS1	-3.62	0.000321	0.0212	-0.17	-0.16	Homoarginine levels;	chr15:45339597	chr15:45378700~45380123:+
THCA	cis	rs2562456	0.558	rs62108173	ENSG00000268117.1	VN1R84P	3.62	0.000321	0.0212	0.26	0.16	Pain;	chr19:21244386	chr19:21719801~21720035:-
THCA	cis	rs2292873	1	rs34052613	ENSG00000234949.2	AC104667.3	-3.62	0.000321	0.0212	-0.28	-0.16	Obesity-related traits;	chr2:237586038	chr2:237591020~237595981:+
THCA	cis	rs9467773	0.62	rs2451737	ENSG00000228223.2	HCG11	-3.62	0.000322	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.596	rs2494693	ENSG00000228223.2	HCG11	-3.62	0.000322	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2494694	ENSG00000228223.2	HCG11	-3.62	0.000322	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.595	rs2451736	ENSG00000228223.2	HCG11	-3.62	0.000322	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26523450~26526579:+
THCA	cis	rs9611565	0.659	rs9607812	ENSG00000237037.8	NDUFA6-AS1	3.62	0.000322	0.0212	0.16	0.16	Vitiligo;	chr22:41545239	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.659	rs9607813	ENSG00000237037.8	NDUFA6-AS1	3.62	0.000322	0.0212	0.16	0.16	Vitiligo;	chr22:41545475	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.659	rs9611609	ENSG00000237037.8	NDUFA6-AS1	3.62	0.000322	0.0212	0.16	0.16	Vitiligo;	chr22:41549353	chr22:42090931~42137742:+
THCA	cis	rs9467773	0.62	rs2101581	ENSG00000228223.2	HCG11	-3.62	0.000322	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26523450~26526579:+
THCA	cis	rs1850744	0.702	rs10939427	ENSG00000163612.10	FAM86KP	-3.62	0.000322	0.0212	-0.39	-0.16	Economic and political preferences;	chr4:9626914	chr4:9153296~9165451:+
THCA	cis	rs6499755	0.73	rs31080	ENSG00000260135.5	RP11-212I21.2	-3.62	0.000322	0.0212	-0.18	-0.16	Hypospadias;	chr16:55325696	chr16:55426797~55462297:-
THCA	cis	rs708547	0.705	rs4355453	ENSG00000269949.1	RP11-738E22.3	-3.62	0.000322	0.0212	-0.22	-0.16	Response to bleomycin (chromatid breaks);	chr4:56861710	chr4:56960927~56961373:-
THCA	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-3.62	0.000322	0.0212	-0.16	-0.16	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
THCA	cis	rs3739034	1	rs16830945	ENSG00000224043.6	CCNT2-AS1	3.62	0.000322	0.0212	0.2	0.16	Gut microbiome composition (winter);	chr2:134714178	chr2:134735464~134918710:-
THCA	cis	rs10954779	0.764	rs2725365	ENSG00000127589.4	TUBBP1	3.62	0.000322	0.0212	0.19	0.16	Intelligence (multi-trait analysis);	chr8:31142727	chr8:30351873~30353518:+
THCA	cis	rs12681366	1	rs66787185	ENSG00000261437.1	RP11-22C11.2	3.62	0.000322	0.0212	0.16	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94365254	chr8:94637285~94639467:-
THCA	cis	rs12681366	1	rs67808321	ENSG00000261437.1	RP11-22C11.2	3.62	0.000322	0.0212	0.16	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94373317	chr8:94637285~94639467:-
THCA	cis	rs6747488	0.515	rs599300	ENSG00000276517.1	AL133243.2	-3.62	0.000322	0.0212	-0.15	-0.16	Interleukin-18 levels;	chr2:31586237	chr2:32526504~32529507:+
THCA	cis	rs929354	0.772	rs6459737	ENSG00000224629.1	RP5-1142J19.2	-3.62	0.000322	0.0212	-0.16	-0.16	Body mass index;	chr7:157182442	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs6971896	ENSG00000224629.1	RP5-1142J19.2	-3.62	0.000322	0.0212	-0.16	-0.16	Body mass index;	chr7:157185718	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs6957939	ENSG00000224629.1	RP5-1142J19.2	-3.62	0.000322	0.0212	-0.16	-0.16	Body mass index;	chr7:157185791	chr7:157263022~157263229:-
THCA	cis	rs2933343	0.621	rs883843	ENSG00000231305.3	RP11-723O4.2	-3.62	0.000322	0.0212	-0.18	-0.16	IgG glycosylation;	chr3:128848540	chr3:128861313~128871540:-
THCA	cis	rs9868809	0.772	rs73078349	ENSG00000229759.1	MRPS18AP1	-3.62	0.000322	0.0212	-0.36	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48650681	chr3:48256350~48256938:-
THCA	cis	rs11771526	0.579	rs117934886	ENSG00000272905.1	RP11-265E18.1	3.62	0.000322	0.0212	0.26	0.16	Body mass index;	chr7:32340935	chr7:32845394~32846061:+
THCA	cis	rs8054556	0.787	rs11642612	ENSG00000183604.13	SMG1P5	-3.62	0.000322	0.0212	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30018874	chr16:30267553~30335374:-
THCA	cis	rs8054556	0.787	rs11150581	ENSG00000183604.13	SMG1P5	-3.62	0.000322	0.0212	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30019378	chr16:30267553~30335374:-
THCA	cis	rs3924048	0.574	rs11121928	ENSG00000272482.1	RP11-474O21.5	-3.62	0.000322	0.0212	-0.14	-0.16	Optic cup area;	chr1:12555858	chr1:12618900~12619244:-
THCA	cis	rs2736345	0.788	rs9693589	ENSG00000269899.1	RP11-589N15.2	-3.62	0.000322	0.0212	-0.21	-0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491452	chr8:11846154~11846391:-
THCA	cis	rs2736345	0.788	rs13277113	ENSG00000269899.1	RP11-589N15.2	-3.62	0.000322	0.0212	-0.21	-0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491677	chr8:11846154~11846391:-
THCA	cis	rs13201929	1	rs13201929	ENSG00000230202.1	RP11-632C17__A.1	-3.62	0.000322	0.0212	-0.25	-0.16	Myopia (pathological);	chr6:117284828	chr6:117998975~117999448:+
THCA	cis	rs253959	0.881	rs1669135	ENSG00000272265.1	CTD-2287O16.4	3.62	0.000322	0.0212	0.17	0.16	Bipolar disorder and schizophrenia;	chr5:116276178	chr5:116078110~116078570:-
THCA	cis	rs5771242	0.518	rs6010216	ENSG00000273137.1	RP3-402G11.28	-3.62	0.000322	0.0212	-0.13	-0.16	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50241042	chr22:50208461~50209542:-
THCA	cis	rs867371	0.502	rs28610286	ENSG00000276710.3	CSPG4P8	-3.62	0.000322	0.0212	-0.16	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82459472~82477258:+
THCA	cis	rs875971	1	rs3735148	ENSG00000272831.1	RP11-792A8.4	3.62	0.000322	0.0212	0.1	0.16	Aortic root size;	chr7:66506022	chr7:66739829~66740385:-
THCA	cis	rs470119	1	rs131801	ENSG00000273253.2	RP3-402G11.26	-3.62	0.000322	0.0212	-0.16	-0.16	Mean corpuscular hemoglobin;	chr22:50528205	chr22:50199090~50200837:-
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000229212.6	RP11-561C5.4	3.62	0.000322	0.0212	0.22	0.16	P wave terminal force;	chr15:84631400	chr15:85205440~85234795:-
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000229212.6	RP11-561C5.4	3.62	0.000322	0.0212	0.22	0.16	P wave terminal force;	chr15:84631524	chr15:85205440~85234795:-
THCA	cis	rs875971	0.545	rs1796219	ENSG00000230295.1	RP11-458F8.2	-3.62	0.000322	0.0212	-0.15	-0.16	Aortic root size;	chr7:66645977	chr7:66880708~66882981:+
THCA	cis	rs10760158	0.8	rs10760167	ENSG00000226752.6	PSMD5-AS1	-3.62	0.000322	0.0212	-0.19	-0.16	Pulse pressure;	chr9:121273267	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs7862876	ENSG00000226752.6	PSMD5-AS1	-3.62	0.000322	0.0212	-0.19	-0.16	Pulse pressure;	chr9:121273818	chr9:120824828~120854385:+
THCA	cis	rs7259376	0.775	rs7257134	ENSG00000269138.1	ZNF209P	3.62	0.000322	0.0212	0.17	0.16	Menopause (age at onset);	chr19:22358055	chr19:22463922~22473036:+
THCA	cis	rs1654345	0.813	rs1654351	ENSG00000275132.1	Metazoa_SRP	-3.62	0.000322	0.0212	-0.19	-0.16	Life satisfaction;Subjective well-being;	chr19:38064085	chr19:38200234~38200532:+
THCA	cis	rs4879656	0.931	rs3758275	ENSG00000225693.1	LAGE3P1	-3.62	0.000322	0.0212	-0.18	-0.16	Menopause (age at onset);	chr9:33024960	chr9:33019682~33020165:-
THCA	cis	rs9788682	0.747	rs2938671	ENSG00000261143.1	ADAMTS7P3	3.62	0.000322	0.0212	0.24	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78440412	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs2568488	ENSG00000261143.1	ADAMTS7P3	3.62	0.000322	0.0212	0.24	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78444251	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs2915695	ENSG00000261143.1	ADAMTS7P3	3.62	0.000322	0.0212	0.24	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78447129	chr15:77976042~77993057:+
THCA	cis	rs6030712	0.58	rs1024191	ENSG00000213979.3	RPL7AP14	3.62	0.000322	0.0212	0.27	0.16	Height;	chr20:36879632	chr20:37444733~37445534:-
THCA	cis	rs1075265	0.901	rs7591194	ENSG00000235937.1	AC008280.1	-3.62	0.000322	0.0212	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54029552~54030682:-
THCA	cis	rs13098911	0.54	rs33910087	ENSG00000226074.4	PRSS44	-3.62	0.000322	0.0212	-0.31	-0.16	Celiac disease;	chr3:45967995	chr3:46809359~46812558:-
THCA	cis	rs2287838	0.967	rs11085425	ENSG00000267370.1	CTD-2623N2.3	3.62	0.000322	0.0212	0.15	0.16	Sleep duration;	chr19:9867979	chr19:9756152~9756863:-
THCA	cis	rs1075265	0.901	rs1058320	ENSG00000235937.1	AC008280.1	3.62	0.000322	0.0212	0.19	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54029552~54030682:-
THCA	cis	rs2839186	0.708	rs6518285	ENSG00000228137.1	AP001469.7	3.62	0.000322	0.0212	0.16	0.16	Testicular germ cell tumor;	chr21:46224753	chr21:46246890~46247682:+
THCA	cis	rs149866169	1	rs149866169	ENSG00000272009.1	RP1-313I6.12	-3.62	0.000322	0.0212	-0.27	-0.16	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28078792~28081130:-
THCA	cis	rs8058578	1	rs7187359	ENSG00000260911.2	RP11-196G11.2	3.62	0.000322	0.0212	0.14	0.16	Multiple myeloma;	chr16:30691834	chr16:31043150~31049868:+
THCA	cis	rs2839186	0.564	rs4819215	ENSG00000225043.1	RPL18AP2	3.62	0.000322	0.0212	0.19	0.16	Testicular germ cell tumor;	chr21:46203659	chr21:46420553~46421034:-
THCA	cis	rs9878978	0.927	rs62245752	ENSG00000227588.2	CNTN4-AS2	3.62	0.000322	0.0212	0.2	0.16	Blood pressure (smoking interaction);	chr3:2420801	chr3:2110409~2144241:-
THCA	cis	rs9788721	0.902	rs17486195	ENSG00000261762.1	RP11-650L12.2	-3.62	0.000322	0.0212	-0.22	-0.16	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78572855	chr15:78589123~78591276:-
THCA	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	3.62	0.000322	0.0212	0.23	0.16	Depression;	chr6:28364057	chr6:28943877~28944537:+
THCA	cis	rs17660992	1	rs17660992	ENSG00000273837.1	LLNLR-470E3.1	-3.62	0.000322	0.0212	-0.19	-0.16	Blood protein levels;	chr19:51660695	chr19:51639478~51639931:-
THCA	cis	rs4948275	0.624	rs2606119	ENSG00000233643.2	RP11-491H19.1	3.62	0.000322	0.0212	0.19	0.16	Night sleep phenotypes;	chr10:61597149	chr10:61781745~61821246:-
THCA	cis	rs12121840	0.92	rs2252342	ENSG00000237463.4	RP11-280O1.2	-3.62	0.000322	0.0212	-0.16	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165563993	chr1:165476841~165582155:-
THCA	cis	rs285757	1	rs285754	ENSG00000259064.2	RP11-386M24.5	3.62	0.000322	0.0212	0.25	0.16	HIV-1 susceptibility;	chr15:92633263	chr15:92627073~92627414:+
THCA	cis	rs2625529	0.617	rs2415120	ENSG00000260037.4	CTD-2524L6.3	-3.62	0.000322	0.0212	-0.21	-0.16	Red blood cell count;	chr15:71813204	chr15:71818396~71823384:+
THCA	cis	rs397969	0.596	rs9901294	ENSG00000261033.1	RP11-209D14.2	-3.62	0.000322	0.0212	-0.22	-0.16	Platelet count;	chr17:19985188	chr17:20008051~20009234:-
THCA	cis	rs7129556	0.911	rs11237244	ENSG00000254459.1	RP11-91P24.7	3.62	0.000323	0.0212	0.21	0.16	Weight loss (gastric bypass surgery);	chr11:77624291	chr11:77829654~77872262:-
THCA	cis	rs7520050	0.966	rs785491	ENSG00000280836.1	AL355480.1	3.62	0.000323	0.0212	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs785503	ENSG00000280836.1	AL355480.1	3.62	0.000323	0.0212	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45581219~45581321:-
THCA	cis	rs2447820	0.5	rs35801915	ENSG00000263432.2	RN7SL689P	3.62	0.000323	0.0212	0.2	0.16	Migraine;	chr5:122796358	chr5:123022487~123022783:-
THCA	cis	rs7088591	0.867	rs76335225	ENSG00000276818.1	AC026393.1	3.62	0.000323	0.0212	0.33	0.16	Blood pressure;	chr10:57990598	chr10:57095699~57095781:+
THCA	cis	rs7873102	0.967	rs4878742	ENSG00000213839.4	TMX2P1	3.62	0.000323	0.0212	0.13	0.16	Brain structure;	chr9:38034184	chr9:37885683~37886390:+
THCA	cis	rs12410462	0.688	rs2031132	ENSG00000227711.2	RP11-275O4.5	-3.62	0.000323	0.0212	-0.22	-0.16	Major depressive disorder;	chr1:227743859	chr1:227509028~227520477:-
THCA	cis	rs6921919	0.789	rs1119211	ENSG00000176933.5	TOB2P1	3.62	0.000323	0.0212	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28217643~28218634:-
THCA	cis	rs78487399	0.908	rs73925554	ENSG00000234936.1	AC010883.5	3.62	0.000323	0.0212	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583600	chr2:43229573~43233394:+
THCA	cis	rs4792901	0.918	rs12373134	ENSG00000267151.3	RP11-100E5.2	-3.62	0.000323	0.0212	-0.18	-0.16	Dupuytren's disease;	chr17:43595008	chr17:43444707~43451200:+
THCA	cis	rs6768930	1	rs7651518	ENSG00000272202.1	RP11-157F20.3	3.62	0.000323	0.0212	0.18	0.16	Obesity-related traits;	chr3:57815987	chr3:57078943~57080101:+
THCA	cis	rs115344852	0.575	rs1015811	ENSG00000216901.1	AL022393.7	3.62	0.000323	0.0212	0.21	0.16	Epithelial ovarian cancer;	chr6:28480309	chr6:28176188~28176674:+
THCA	cis	rs9467773	0.62	rs2451731	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs9295701	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2451741	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2494700	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.584	rs1021372	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.583	rs1021373	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2451744	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2494701	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs1027204	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2504567	ENSG00000228223.2	HCG11	-3.62	0.000323	0.0212	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26523450~26526579:+
THCA	cis	rs9650657	0.537	rs4841457	ENSG00000261451.1	RP11-981G7.1	-3.62	0.000323	0.0212	-0.2	-0.16	Neuroticism;	chr8:10916001	chr8:10433672~10438312:+
THCA	cis	rs6546550	0.901	rs12613947	ENSG00000179818.12	PCBP1-AS1	-3.62	0.000323	0.0212	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69934210	chr2:69962263~70103220:-
THCA	cis	rs875971	0.862	rs2420174	ENSG00000223473.2	GS1-124K5.3	-3.62	0.000323	0.0212	-0.11	-0.16	Aortic root size;	chr7:66180374	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs2420173	ENSG00000223473.2	GS1-124K5.3	-3.62	0.000323	0.0212	-0.11	-0.16	Aortic root size;	chr7:66180412	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs4718319	ENSG00000223473.2	GS1-124K5.3	-3.62	0.000323	0.0212	-0.11	-0.16	Aortic root size;	chr7:66187797	chr7:66491049~66493566:-
THCA	cis	rs2191566	0.691	rs56182773	ENSG00000266921.1	RP11-15A1.7	-3.62	0.000323	0.0212	-0.16	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44084172	chr19:43996896~44002836:-
THCA	cis	rs559555	0.626	rs499362	ENSG00000276517.1	AL133243.2	-3.62	0.000323	0.0212	-0.15	-0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31586503	chr2:32526504~32529507:+
THCA	cis	rs3758911	0.894	rs6588964	ENSG00000255353.1	RP11-382M14.1	-3.62	0.000323	0.0212	-0.21	-0.16	Coronary artery disease;	chr11:107330725	chr11:107176286~107177530:+
THCA	cis	rs961764	0.733	rs783374	ENSG00000217241.1	CBX3P9	-3.62	0.000323	0.0212	-0.22	-0.16	Height;	chr6:117119740	chr6:116453014~116453565:-
THCA	cis	rs7829975	0.714	rs11784052	ENSG00000254340.1	RP11-10A14.3	3.62	0.000323	0.0212	0.18	0.16	Mood instability;	chr8:8814452	chr8:9141424~9145435:+
THCA	cis	rs7264396	0.623	rs6119609	ENSG00000261582.1	RP4-614O4.11	-3.62	0.000323	0.0212	-0.17	-0.16	Total cholesterol levels;	chr20:35451572	chr20:35267885~35280043:-
THCA	cis	rs11671005	0.737	rs11673101	ENSG00000268912.1	CTD-2619J13.17	-3.62	0.000323	0.0212	-0.16	-0.16	Mean platelet volume;	chr19:58483686	chr19:58428632~58431148:-
THCA	cis	rs10956805	0.544	rs709817	ENSG00000246792.2	RP11-68L18.1	3.62	0.000323	0.0212	0.14	0.16	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);	chr8:91516795	chr8:90646441~90656598:+
THCA	cis	rs2898290	0.512	rs899366	ENSG00000227888.4	FAM66A	3.62	0.000323	0.0212	0.22	0.16	Systolic blood pressure;	chr8:11572976	chr8:12362019~12388296:+
THCA	cis	rs4869313	0.668	rs2548536	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000323	0.0212	0.12	0.16	Pediatric autoimmune diseases;	chr5:96896698	chr5:96814028~96935809:-
THCA	cis	rs2434529	1	rs149329	ENSG00000245275.6	SAP30L-AS1	3.62	0.000323	0.0212	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154272166	chr5:154329437~154445850:-
THCA	cis	rs12476592	0.602	rs262477	ENSG00000242412.1	DBIL5P2	3.62	0.000323	0.0213	0.21	0.16	Childhood ear infection;	chr2:63643825	chr2:63117851~63119542:-
THCA	cis	rs2067615	0.931	rs1216006	ENSG00000260329.1	RP11-412D9.4	-3.62	0.000323	0.0213	-0.14	-0.16	Heart rate;	chr12:106794002	chr12:106954029~106955497:-
THCA	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	3.62	0.000323	0.0213	0.15	0.16	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	3.62	0.000323	0.0213	0.15	0.16	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
THCA	cis	rs11648785	0.59	rs4324129	ENSG00000222019.6	URAHP	3.62	0.000323	0.0213	0.13	0.16	Tanning;	chr16:90032653	chr16:90039761~90047773:-
THCA	cis	rs13063635	0.915	rs1994492	ENSG00000226074.4	PRSS44	-3.62	0.000323	0.0213	-0.31	-0.16	Eosinophil percentage of granulocytes;	chr3:45919154	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs1994493	ENSG00000226074.4	PRSS44	-3.62	0.000323	0.0213	-0.31	-0.16	Eosinophil percentage of granulocytes;	chr3:45919208	chr3:46809359~46812558:-
THCA	cis	rs13063635	0.915	rs75928798	ENSG00000226074.4	PRSS44	-3.62	0.000323	0.0213	-0.31	-0.16	Eosinophil percentage of granulocytes;	chr3:45921111	chr3:46809359~46812558:-
THCA	cis	rs4588572	0.644	rs10805920	ENSG00000245556.2	SCAMP1-AS1	-3.62	0.000323	0.0213	-0.13	-0.16	Triglycerides;	chr5:78402398	chr5:78342365~78360507:-
THCA	cis	rs2911280	0.764	rs7198024	ENSG00000278985.1	RP11-303E16.9	-3.62	0.000323	0.0213	-0.31	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81528155	chr16:80982319~80984094:-
THCA	cis	rs7259376	0.875	rs1091182	ENSG00000269138.1	ZNF209P	-3.62	0.000323	0.0213	-0.17	-0.16	Menopause (age at onset);	chr19:22292820	chr19:22463922~22473036:+
THCA	cis	rs13053817	1	rs13057382	ENSG00000279159.1	RP3-394A18.1	3.62	0.000323	0.0213	0.17	0.16	Carotid atherosclerosis in HIV infection;	chr22:29454345	chr22:29978950~30028236:-
THCA	cis	rs9652601	0.691	rs9939397	ENSG00000263033.2	RP11-396B14.2	-3.62	0.000323	0.0213	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11115907	chr16:11196177~11224969:+
THCA	cis	rs1555322	0.932	rs1205411	ENSG00000126005.14	MMP24-AS1	-3.62	0.000323	0.0213	-0.23	-0.16	Attention deficit hyperactivity disorder;	chr20:35269439	chr20:35216462~35278131:-
THCA	cis	rs6871536	1	rs2706338	ENSG00000233006.5	AC034220.3	3.62	0.000323	0.0213	0.15	0.16	Asthma (childhood onset);	chr5:132560157	chr5:132311285~132369916:-
THCA	cis	rs929354	0.772	rs6954050	ENSG00000224629.1	RP5-1142J19.2	-3.62	0.000323	0.0213	-0.16	-0.16	Body mass index;	chr7:157185860	chr7:157263022~157263229:-
THCA	cis	rs7520050	0.966	rs785479	ENSG00000280836.1	AL355480.1	3.62	0.000323	0.0213	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45581219~45581321:-
THCA	cis	rs2051773	0.567	rs4456241	ENSG00000272034.1	SNORD14A	-3.62	0.000323	0.0213	-0.18	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17021494	chr11:17074654~17074744:-
THCA	cis	rs2051773	0.567	rs4517490	ENSG00000272034.1	SNORD14A	-3.62	0.000323	0.0213	-0.18	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17021507	chr11:17074654~17074744:-
THCA	cis	rs10954779	0.702	rs2737334	ENSG00000127589.4	TUBBP1	3.62	0.000323	0.0213	0.19	0.16	Intelligence (multi-trait analysis);	chr8:31135951	chr8:30351873~30353518:+
THCA	cis	rs9303542	0.729	rs7218217	ENSG00000278765.1	RP5-890E16.5	-3.62	0.000323	0.0213	-0.22	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48425526	chr17:48066704~48067293:-
THCA	cis	rs9607412	0.59	rs5756506	ENSG00000233360.4	Z83844.1	3.62	0.000323	0.0213	0.18	0.16	Mean corpuscular volume;	chr22:37071352	chr22:37641832~37658377:-
THCA	cis	rs7804306	1	rs12702689	ENSG00000233264.2	AC006042.8	3.62	0.000323	0.0213	0.31	0.16	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046767	chr7:7980312~7982228:+
THCA	cis	rs643506	0.774	rs11214033	ENSG00000230911.1	PPIHP1	3.62	0.000323	0.0213	0.23	0.16	Breast cancer;	chr11:111898978	chr11:112029858~112030367:-
THCA	cis	rs785830	0.717	rs542669	ENSG00000231808.2	LINC01388	-3.62	0.000323	0.0213	-0.19	-0.16	Platelet distribution width;	chr9:224367	chr9:112713~113754:-
THCA	cis	rs2797160	1	rs2211420	ENSG00000226409.1	RP11-735G4.1	-3.62	0.000323	0.0213	-0.2	-0.16	Endometrial cancer;	chr6:125674403	chr6:125370211~125374324:-
THCA	cis	rs7727544	0.545	rs10074490	ENSG00000263597.1	MIR3936	3.62	0.000323	0.0213	0.16	0.16	Blood metabolite levels;	chr5:132004339	chr5:132365490~132365599:-
THCA	cis	rs763121	0.889	rs6001209	ENSG00000225450.1	RP3-508I15.14	3.62	0.000324	0.0213	0.13	0.16	Menopause (age at onset);	chr22:38725247	chr22:38739003~38749041:+
THCA	cis	rs11633886	0.585	rs17636535	ENSG00000273972.1	CTD-2306A12.1	3.62	0.000324	0.0213	0.19	0.16	Diisocyanate-induced asthma;	chr15:45786680	chr15:45702640~45703183:+
THCA	cis	rs12121840	0.79	rs16847085	ENSG00000237463.4	RP11-280O1.2	-3.62	0.000324	0.0213	-0.15	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165565004	chr1:165476841~165582155:-
THCA	cis	rs2013441	0.613	rs7215803	ENSG00000261033.1	RP11-209D14.2	-3.62	0.000324	0.0213	-0.2	-0.16	Obesity-related traits;	chr17:20095064	chr17:20008051~20009234:-
THCA	cis	rs6472235	0.586	rs34464051	ENSG00000272192.1	CTD-2532N20.1	3.62	0.000324	0.0213	0.18	0.16	Plateletcrit;Myopia (pathological);	chr8:65989769	chr8:65842752~65843331:+
THCA	cis	rs267567	0.626	rs267554	ENSG00000235257.7	ITGA9-AS1	-3.62	0.000324	0.0213	-0.14	-0.16	PR interval;	chr3:37535494	chr3:37745432~37861780:-
THCA	cis	rs1577917	0.538	rs7755996	ENSG00000220563.1	PKMP3	3.62	0.000324	0.0213	0.12	0.16	Response to antipsychotic treatment;	chr6:85714002	chr6:85659892~85660606:-
THCA	cis	rs7727544	0.582	rs10075459	ENSG00000263597.1	MIR3936	3.62	0.000324	0.0213	0.15	0.16	Blood metabolite levels;	chr5:132205670	chr5:132365490~132365599:-
THCA	cis	rs9889262	0.641	rs686112	ENSG00000248714.5	RP11-1079K10.3	3.62	0.000324	0.0213	0.19	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49248355	chr17:49361165~49369998:+
THCA	cis	rs1923243	0.749	rs7526372	ENSG00000223479.3	RP4-788P17.1	-3.62	0.000324	0.0213	-0.18	-0.16	Migraine;	chr1:73064563	chr1:73635216~73715214:+
THCA	cis	rs4869313	0.642	rs2548539	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96895800	chr5:96814028~96935809:-
THCA	cis	rs4788570	0.538	rs72797728	ENSG00000260185.1	RP11-432I5.6	3.62	0.000324	0.0213	0.32	0.16	Intelligence (multi-trait analysis);	chr16:71518886	chr16:71655027~71664212:+
THCA	cis	rs7959452	0.59	rs11177643	ENSG00000274979.1	RP11-1143G9.5	-3.62	0.000324	0.0213	-0.18	-0.16	Blood protein levels;	chr12:69391932	chr12:69326574~69331882:-
THCA	cis	rs7267979	1	rs12428	ENSG00000276952.1	RP5-965G21.6	-3.62	0.000324	0.0213	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25284915~25285588:-
THCA	cis	rs2839186	0.843	rs17182671	ENSG00000228137.1	AP001469.7	3.62	0.000324	0.0213	0.16	0.16	Testicular germ cell tumor;	chr21:46276324	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.739	rs7282763	ENSG00000228137.1	AP001469.7	3.62	0.000324	0.0213	0.16	0.16	Testicular germ cell tumor;	chr21:46276886	chr21:46246890~46247682:+
THCA	cis	rs5758659	0.652	rs133358	ENSG00000205702.9	CYP2D7	3.62	0.000324	0.0213	0.12	0.16	Cognitive function;	chr22:42046535	chr22:42140203~42144577:-
THCA	cis	rs4588572	0.57	rs2115433	ENSG00000245556.2	SCAMP1-AS1	-3.62	0.000324	0.0213	-0.13	-0.16	Triglycerides;	chr5:78404539	chr5:78342365~78360507:-
THCA	cis	rs7560272	0.501	rs4852978	ENSG00000163016.8	ALMS1P	-3.62	0.000324	0.0213	-0.2	-0.16	Schizophrenia;	chr2:73715983	chr2:73644919~73685576:+
THCA	cis	rs6479891	1	rs4746195	ENSG00000272767.1	JMJD1C-AS1	3.62	0.000324	0.0213	0.23	0.16	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63465229~63466563:+
THCA	cis	rs5758659	0.652	rs133336	ENSG00000205702.9	CYP2D7	3.62	0.000324	0.0213	0.13	0.16	Cognitive function;	chr22:42020299	chr22:42140203~42144577:-
THCA	cis	rs7919656	0.904	rs2620891	ENSG00000228403.1	RP11-563N6.6	-3.62	0.000324	0.0213	-0.17	-0.16	Clinically amyopathic dermatomyositis;	chr10:48821660	chr10:48878022~48878649:+
THCA	cis	rs337161	0.935	rs17008613	ENSG00000221571.3	RNU6ATAC35P	-3.62	0.000324	0.0213	-0.19	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220770239	chr1:220825620~220826063:+
THCA	cis	rs9393777	0.557	rs36034627	ENSG00000220721.1	OR1F12	3.62	0.000324	0.0213	0.24	0.16	Intelligence (multi-trait analysis);	chr6:27269584	chr6:28073316~28074233:+
THCA	cis	rs4869313	0.583	rs2548540	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96894474	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.643	rs6556943	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96894699	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.594	rs2549782	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96895296	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.593	rs2549784	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96895816	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.642	rs2548538	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96896438	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.617	rs2548537	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96896518	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.617	rs2549785	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96896582	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.703	rs2548535	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96896995	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.618	rs2548534	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96897904	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.595	rs3096167	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96898510	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2042383	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96898917	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs193993	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96899168	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs2248374	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96900192	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.642	rs2113190	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96900614	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.642	rs2287988	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96901622	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs171647	ENSG00000247121.5	CTD-2260A17.2	3.62	0.000324	0.0213	0.12	0.16	Pediatric autoimmune diseases;	chr5:96901709	chr5:96814028~96935809:-
THCA	cis	rs7829975	0.782	rs6990746	ENSG00000253981.4	ALG1L13P	-3.62	0.000324	0.0213	-0.16	-0.16	Mood instability;	chr8:8690301	chr8:8236003~8244667:-
THCA	cis	rs9527	1	rs9527	ENSG00000236937.2	PTGES3P4	3.62	0.000324	0.0213	0.25	0.16	Arsenic metabolism;	chr10:102863821	chr10:102845595~102845950:+
THCA	cis	rs656319	0.513	rs34990153	ENSG00000248538.5	RP11-10A14.5	3.62	0.000324	0.0213	0.21	0.16	Myopia (pathological);	chr8:10138879	chr8:9189011~9202854:+
THCA	cis	rs5762752	0.618	rs134545	ENSG00000272858.1	CTA-292E10.8	3.62	0.000324	0.0213	0.16	0.16	Optic disc area;	chr22:28403092	chr22:28814914~28815662:+
THCA	cis	rs1560104	0.833	rs2903044	ENSG00000259876.1	CTD-3037G24.4	3.62	0.000324	0.0213	0.18	0.16	Obesity-related traits;	chr16:12623535	chr16:12556353~12557694:-
THCA	cis	rs6456156	0.792	rs10946214	ENSG00000235272.1	FAM103A2P	3.62	0.000324	0.0213	0.23	0.16	Primary biliary cholangitis;	chr6:167102634	chr6:166586124~166586477:-
THCA	cis	rs62344088	1	rs6872393	ENSG00000277812.1	AC021087.1	-3.62	0.000324	0.0213	-0.4	-0.16	Asthma (childhood onset);	chr5:155739	chr5:262769~262881:+
THCA	cis	rs4853525	0.561	rs7597768	ENSG00000235852.1	AC005540.3	3.62	0.000324	0.0213	0.18	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977153	chr2:190880797~190882059:-
THCA	cis	rs7246657	0.943	rs3803895	ENSG00000268499.1	CTB-102L5.8	3.62	0.000324	0.0213	0.21	0.16	Coronary artery calcification;	chr19:37407767	chr19:38199836~38200934:+
THCA	cis	rs3760982	0.585	rs67773424	ENSG00000268601.1	AC115522.3	-3.62	0.000324	0.0213	-0.2	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789842	chr19:43794309~43795658:-
THCA	cis	rs4846580	0.87	rs4846574	ENSG00000230024.1	RP11-95P13.1	-3.62	0.000324	0.0213	-0.19	-0.16	Total body bone mineral density;	chr1:219673596	chr1:219435152~219442642:-
THCA	cis	rs10833905	0.938	rs10833928	ENSG00000246225.5	RP11-17A1.3	-3.62	0.000324	0.0213	-0.24	-0.16	Sudden cardiac arrest;	chr11:23071258	chr11:22829380~22945393:+
THCA	cis	rs6546886	0.957	rs35609589	ENSG00000235499.1	AC073046.25	3.62	0.000324	0.0213	0.15	0.16	Dialysis-related mortality;	chr2:74028888	chr2:73985132~73986343:+
THCA	cis	rs2562456	0.754	rs112195516	ENSG00000268521.1	VN1R83P	3.62	0.000324	0.0213	0.16	0.16	Pain;	chr19:21410849	chr19:21289554~21289998:-
THCA	cis	rs12570188	1	rs12570188	ENSG00000224934.2	RP11-441O15.3	3.62	0.000324	0.0213	0.2	0.16	Asthma (childhood onset);	chr10:99095945	chr10:99431191~99438117:+
THCA	cis	rs801193	1	rs2707856	ENSG00000232546.1	RP11-458F8.1	-3.62	0.000324	0.0213	-0.13	-0.16	Aortic root size;	chr7:66746023	chr7:66848496~66858136:+
THCA	cis	rs2688608	0.752	rs1916341	ENSG00000271816.1	BMS1P4	3.62	0.000324	0.0213	0.16	0.16	Inflammatory bowel disease;	chr10:73911404	chr10:73699151~73730487:-
THCA	cis	rs970548	1	rs7086046	ENSG00000230869.1	CTGLF10P	-3.62	0.000324	0.0213	-0.19	-0.16	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45580787	chr10:45678692~45700532:+
THCA	cis	rs12497850	1	rs10865952	ENSG00000228638.1	FCF1P2	-3.62	0.000324	0.0213	-0.17	-0.16	Parkinson's disease;	chr3:48707051	chr3:48290793~48291375:-
THCA	cis	rs12681366	0.839	rs2931632	ENSG00000253175.1	RP11-267M23.6	3.62	0.000324	0.0213	0.21	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:94565036~94565715:+
THCA	cis	rs7903847	0.642	rs12258560	ENSG00000225850.3	RP11-452K12.4	3.62	0.000325	0.0213	0.17	0.16	Granulocyte percentage of myeloid white cells;	chr10:97377291	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10882909	ENSG00000225850.3	RP11-452K12.4	3.62	0.000325	0.0213	0.17	0.16	Granulocyte percentage of myeloid white cells;	chr10:97378241	chr10:97334564~97343203:+
THCA	cis	rs73173548	0.502	rs10452479	ENSG00000247828.6	TMEM161B-AS1	3.62	0.000325	0.0213	0.15	0.16	Macular telangiectasia type 2;	chr5:88445131	chr5:88268895~88436685:+
THCA	cis	rs61270009	0.738	rs73171756	ENSG00000247828.6	TMEM161B-AS1	3.62	0.000325	0.0213	0.15	0.16	Depressive symptoms;	chr5:88446454	chr5:88268895~88436685:+
THCA	cis	rs7615952	0.8	rs12489350	ENSG00000272840.1	RP11-379B18.6	3.62	0.000325	0.0213	0.27	0.16	Blood pressure (smoking interaction);	chr3:125925273	chr3:125774714~125797953:+
THCA	cis	rs16944613	0.588	rs8042497	ENSG00000259212.1	CTD-3065B20.2	3.62	0.000325	0.0213	0.27	0.16	Colorectal cancer;	chr15:90567099	chr15:90595840~90596447:-
THCA	cis	rs1153858	1	rs8032904	ENSG00000275672.1	GATM-AS1	-3.62	0.000325	0.0213	-0.17	-0.16	Homoarginine levels;	chr15:45359111	chr15:45378700~45380123:+
THCA	cis	rs1153858	0.943	rs8038342	ENSG00000275672.1	GATM-AS1	-3.62	0.000325	0.0213	-0.17	-0.16	Homoarginine levels;	chr15:45359339	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs4774579	ENSG00000275672.1	GATM-AS1	-3.62	0.000325	0.0213	-0.17	-0.16	Homoarginine levels;	chr15:45359605	chr15:45378700~45380123:+
THCA	cis	rs9929215	0.649	rs12935023	ENSG00000270020.1	RP11-463O9.9	3.62	0.000325	0.0213	0.34	0.16	Colorectal cancer;	chr16:86470427	chr16:86520383~86523897:-
THCA	cis	rs7178909	0.872	rs7174330	ENSG00000259677.1	RP11-493E3.1	-3.62	0.000325	0.0213	-0.2	-0.16	Common traits (Other);	chr15:89891347	chr15:89876540~89877285:+
THCA	cis	rs4648045	0.565	rs17033014	ENSG00000251288.2	RP11-10L12.2	-3.62	0.000325	0.0213	-0.22	-0.16	Lymphocyte percentage of white cells;	chr4:102625029	chr4:102751401~102752641:+
THCA	cis	rs60180747	1	rs11630608	ENSG00000261318.1	RP11-653J6.1	3.62	0.000325	0.0213	0.22	0.16	Testicular germ cell tumor;	chr15:66452799	chr15:66278498~66293357:-
THCA	cis	rs897984	0.806	rs10782002	ENSG00000232748.3	RP11-196G11.6	3.62	0.000325	0.0213	0.2	0.16	Dementia with Lewy bodies;	chr16:30935185	chr16:31056460~31062803:+
THCA	cis	rs786425	0.637	rs7308234	ENSG00000278112.1	RP11-972P1.11	3.62	0.000325	0.0213	0.16	0.16	Pubertal anthropometrics;	chr12:123699257	chr12:123519390~123519856:-
THCA	cis	rs7142002	0.568	rs3783370	ENSG00000271780.1	RP11-1017G21.5	-3.62	0.000325	0.0213	-0.21	-0.16	Autism;	chr14:101919120	chr14:101948347~101949425:+
THCA	cis	rs4700393	0.967	rs4700394	ENSG00000215032.2	GNL3LP1	-3.62	0.000325	0.0213	-0.21	-0.16	Intelligence (multi-trait analysis);	chr5:60821375	chr5:60891935~60893577:-
THCA	cis	rs721048	0.764	rs62177782	ENSG00000242412.1	DBIL5P2	-3.62	0.000325	0.0213	-0.22	-0.16	Prostate cancer;	chr2:63223725	chr2:63117851~63119542:-
THCA	cis	rs10833905	0.938	rs11026959	ENSG00000246225.5	RP11-17A1.3	3.62	0.000325	0.0213	0.24	0.16	Sudden cardiac arrest;	chr11:23067229	chr11:22829380~22945393:+
THCA	cis	rs2486012	0.737	rs37457	ENSG00000237950.1	RP11-7O11.3	3.62	0.000325	0.0214	0.19	0.16	Intelligence (multi-trait analysis);	chr1:43825519	chr1:43944370~43946551:-
THCA	cis	rs1707322	0.638	rs1416706	ENSG00000281133.1	AL355480.3	3.62	0.000325	0.0214	0.21	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45580892~45580996:-
THCA	cis	rs7737355	0.628	rs4705893	ENSG00000224431.1	AC063976.7	3.62	0.000325	0.0214	0.24	0.16	Life satisfaction;	chr5:131740228	chr5:132199456~132203487:+
THCA	cis	rs7647973	0.58	rs7652746	ENSG00000228638.1	FCF1P2	3.62	0.000325	0.0214	0.17	0.16	Menarche (age at onset);	chr3:49224874	chr3:48290793~48291375:-
THCA	cis	rs7959452	0.557	rs7980883	ENSG00000274979.1	RP11-1143G9.5	-3.62	0.000325	0.0214	-0.18	-0.16	Blood protein levels;	chr12:69385134	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.527	rs4761157	ENSG00000274979.1	RP11-1143G9.5	-3.62	0.000325	0.0214	-0.18	-0.16	Blood protein levels;	chr12:69387127	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.59	rs10878974	ENSG00000274979.1	RP11-1143G9.5	-3.62	0.000325	0.0214	-0.18	-0.16	Blood protein levels;	chr12:69387748	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.562	rs10878975	ENSG00000274979.1	RP11-1143G9.5	-3.62	0.000325	0.0214	-0.18	-0.16	Blood protein levels;	chr12:69388264	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.557	rs899224	ENSG00000274979.1	RP11-1143G9.5	-3.62	0.000325	0.0214	-0.18	-0.16	Blood protein levels;	chr12:69390994	chr12:69326574~69331882:-
THCA	cis	rs724950	0.581	rs9307594	ENSG00000248491.4	RP11-125O18.1	3.62	0.000325	0.0214	0.21	0.16	Obesity-related traits;	chr4:127173154	chr4:127096891~127470569:-
THCA	cis	rs2635047	0.934	rs11663321	ENSG00000280212.1	RP11-49K24.3	-3.62	0.000325	0.0214	-0.16	-0.16	Educational attainment;	chr18:47096333	chr18:47076117~47076594:+
THCA	cis	rs12935229	0.756	rs9937032	ENSG00000260922.1	RP11-538I12.3	-3.62	0.000325	0.0214	-0.26	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77262196	chr16:77234877~77290934:+
THCA	cis	rs150992	0.678	rs327793	ENSG00000246763.5	RGMB-AS1	3.62	0.000325	0.0214	0.17	0.16	Body mass index;	chr5:98913717	chr5:98769618~98773469:-
THCA	cis	rs1371614	0.523	rs12468761	ENSG00000272148.1	RP11-195B17.1	-3.62	0.000325	0.0214	-0.15	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26960925	chr2:27062428~27062907:-
THCA	cis	rs1122401	0.921	rs10069245	ENSG00000280159.1	CTD-2591A1.1	-3.62	0.000325	0.0214	-0.2	-0.16	Smoking initiation;	chr5:54578455	chr5:54643557~54645987:+
THCA	cis	rs2153535	0.585	rs980083	ENSG00000230939.1	RP11-314C16.1	3.62	0.000325	0.0214	0.17	0.16	Motion sickness;	chr6:8589683	chr6:8784178~8785445:+
THCA	cis	rs4713118	0.786	rs200502	ENSG00000261839.1	RP1-265C24.8	3.62	0.000325	0.0214	0.19	0.16	Parkinson's disease;	chr6:27820284	chr6:28136849~28139678:+
THCA	cis	rs7546094	0.846	rs4838959	ENSG00000273483.1	RP4-671G15.2	-3.62	0.000325	0.0214	-0.15	-0.16	Platelet distribution width;	chr1:112543099	chr1:112517799~112518441:-
THCA	cis	rs7587476	0.626	rs4672729	ENSG00000229267.2	AC072062.1	3.62	0.000325	0.0214	0.18	0.16	Neuroblastoma;	chr2:214778759	chr2:214810229~214963274:+
THCA	cis	rs7246967	0.673	rs34342502	ENSG00000198153.8	ZNF849P	-3.62	0.000325	0.0214	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22698626	chr19:22685167~22686732:+
THCA	cis	rs6847067	0.8	rs7699226	ENSG00000180769.7	WDFY3-AS2	3.62	0.000325	0.0214	0.12	0.16	Oropharynx cancer;	chr4:84956408	chr4:84965682~85011277:+
THCA	cis	rs9650657	0.513	rs4314618	ENSG00000206014.6	OR7E161P	3.62	0.000325	0.0214	0.19	0.16	Neuroticism;	chr8:10959262	chr8:11928597~11929563:-
THCA	cis	rs73222236	0.825	rs9858457	ENSG00000273486.1	RP11-731C17.2	3.62	0.000325	0.0214	0.15	0.16	Coronary artery disease;	chr3:136530735	chr3:136837338~136839021:-
THCA	cis	rs7520050	0.966	rs7524495	ENSG00000280836.1	AL355480.1	3.62	0.000325	0.0214	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45581219~45581321:-
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000184274.3	LINC00315	-3.62	0.000325	0.0214	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45300245~45305257:-
THCA	cis	rs28830936	0.934	rs3959569	ENSG00000250379.1	RP11-23P13.4	3.62	0.000325	0.0214	0.19	0.16	Diastolic blood pressure;	chr15:41823549	chr15:41825099~41827936:-
THCA	cis	rs961764	0.733	rs783376	ENSG00000217241.1	CBX3P9	3.62	0.000325	0.0214	0.22	0.16	Height;	chr6:117120211	chr6:116453014~116453565:-
THCA	cis	rs10780792	0.554	rs7033669	ENSG00000165121.10	RP11-213G2.3	3.62	0.000325	0.0214	0.14	0.16	Lobe attachment (rater-scored or self-reported);	chr9:86806661	chr9:85815966~85849511:+
THCA	cis	rs12780845	0.931	rs34709865	ENSG00000229124.5	VIM-AS1	3.62	0.000325	0.0214	0.17	0.16	Homocysteine levels;	chr10:17203330	chr10:17214239~17229985:-
THCA	cis	rs11673344	0.523	rs7248948	ENSG00000233527.7	ZNF529-AS1	3.62	0.000325	0.0214	0.14	0.16	Obesity-related traits;	chr19:37056317	chr19:36573070~36594708:+
THCA	cis	rs9928842	0.941	rs1808427	ENSG00000261783.1	RP11-252K23.2	3.62	0.000325	0.0214	0.31	0.16	Alcoholic chronic pancreatitis;	chr16:75207496	chr16:75379818~75381260:-
THCA	cis	rs7296418	0.961	rs1790121	ENSG00000256092.2	RP13-942N8.1	3.62	0.000325	0.0214	0.12	0.16	Platelet count;	chr12:123119945	chr12:123363868~123366113:+
THCA	cis	rs875971	0.825	rs1129531	ENSG00000223473.2	GS1-124K5.3	-3.62	0.000325	0.0214	-0.11	-0.16	Aortic root size;	chr7:66154117	chr7:66491049~66493566:-
THCA	cis	rs9843304	0.508	rs11926459	ENSG00000243885.1	RP11-278L15.2	-3.62	0.000325	0.0214	-0.18	-0.16	Gallstone disease;	chr3:149494295	chr3:149384179~149385800:-
THCA	cis	rs3087591	0.708	rs2525563	ENSG00000263535.1	AK4P1	3.62	0.000326	0.0214	0.2	0.16	Hip circumference;	chr17:31320890	chr17:31345521~31346187:+
THCA	cis	rs9875589	0.957	rs1433358	ENSG00000228242.5	AC093495.4	-3.62	0.000326	0.0214	-0.09	-0.16	Ovarian reserve;	chr3:13902365	chr3:14144637~14165978:+
THCA	cis	rs4664304	0.62	rs4665125	ENSG00000226266.5	AC009961.3	-3.62	0.000326	0.0214	-0.19	-0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159857803	chr2:159670708~159712435:-
THCA	cis	rs7444	0.66	rs11089637	ENSG00000253120.1	IGLV2-34	-3.62	0.000326	0.0214	-0.11	-0.16	Systemic lupus erythematosus;	chr22:21624807	chr22:22580014~22580296:+
THCA	cis	rs4218	0.597	rs4775114	ENSG00000277144.1	RP11-59H7.4	-3.62	0.000326	0.0214	-0.23	-0.16	Social communication problems;	chr15:59059635	chr15:59115547~59116089:-
THCA	cis	rs55702914	0.628	rs61327788	ENSG00000231621.1	AC013264.2	-3.62	0.000326	0.0214	-0.16	-0.16	Major depression and alcohol dependence;	chr2:197473498	chr2:197197991~197199273:+
THCA	cis	rs2832191	1	rs2832189	ENSG00000232855.5	AF131217.1	3.62	0.000326	0.0214	0.17	0.16	Dental caries;	chr21:29115093	chr21:28439346~28674848:-
THCA	cis	rs3808502	0.516	rs6983727	ENSG00000255046.1	RP11-297N6.4	-3.62	0.000326	0.0214	-0.17	-0.16	Neuroticism;	chr8:11558303	chr8:11797928~11802568:-
THCA	cis	rs3750082	0.889	rs6962267	ENSG00000205763.12	RP9P	3.62	0.000326	0.0214	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32900162	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.889	rs11766608	ENSG00000205763.12	RP9P	3.62	0.000326	0.0214	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32900474	chr7:32916815~32943176:-
THCA	cis	rs7520050	0.966	rs785494	ENSG00000280836.1	AL355480.1	3.62	0.000326	0.0214	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45581219~45581321:-
THCA	cis	rs5753037	0.665	rs1961926	ENSG00000279699.1	RP1-102K2.9	3.62	0.000326	0.0214	0.16	0.16	Type 1 diabetes;	chr22:29827824	chr22:30275215~30276951:-
THCA	cis	rs2180341	0.96	rs9398842	ENSG00000220522.2	RP1-177A13.1	3.62	0.000326	0.0214	0.21	0.16	Breast cancer;	chr6:127353517	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.96	rs9401952	ENSG00000220522.2	RP1-177A13.1	3.62	0.000326	0.0214	0.21	0.16	Breast cancer;	chr6:127355882	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.92	rs1073931	ENSG00000220522.2	RP1-177A13.1	3.62	0.000326	0.0214	0.21	0.16	Breast cancer;	chr6:127360617	chr6:127416535~127416952:-
THCA	cis	rs2749592	1	rs2749592	ENSG00000120555.12	SEPT7P9	3.62	0.000326	0.0214	0.2	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37969914	chr10:38383069~38402916:-
THCA	cis	rs4705962	0.959	rs4426908	ENSG00000230612.2	AC004237.1	3.62	0.000326	0.0214	0.22	0.16	Atopic dermatitis;	chr5:132687026	chr5:132688681~132723725:+
THCA	cis	rs9532669	0.926	rs9532646	ENSG00000229473.2	RGS17P1	3.62	0.000326	0.0214	0.21	0.16	Cervical cancer;	chr13:40880989	chr13:40992779~40993331:-
THCA	cis	rs11098499	0.954	rs13145352	ENSG00000249244.1	RP11-548H18.2	-3.62	0.000326	0.0214	-0.2	-0.16	Corneal astigmatism;	chr4:119488808	chr4:119391831~119395335:-
THCA	cis	rs7824557	0.545	rs2572450	ENSG00000261451.1	RP11-981G7.1	-3.62	0.000326	0.0214	-0.21	-0.16	Retinal vascular caliber;	chr8:11372129	chr8:10433672~10438312:+
THCA	cis	rs2281603	0.57	rs2123459	ENSG00000258824.2	CTD-2555O16.2	-3.62	0.000326	0.0214	-0.15	-0.16	Lymphocyte counts;	chr14:64485585	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs11626222	ENSG00000258824.2	CTD-2555O16.2	-3.62	0.000326	0.0214	-0.15	-0.16	Lymphocyte counts;	chr14:64486541	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs10132969	ENSG00000258824.2	CTD-2555O16.2	-3.62	0.000326	0.0214	-0.15	-0.16	Lymphocyte counts;	chr14:64486862	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs10143839	ENSG00000258824.2	CTD-2555O16.2	-3.62	0.000326	0.0214	-0.15	-0.16	Lymphocyte counts;	chr14:64486873	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs57525201	ENSG00000258824.2	CTD-2555O16.2	-3.62	0.000326	0.0214	-0.15	-0.16	Lymphocyte counts;	chr14:64488974	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs10150781	ENSG00000258824.2	CTD-2555O16.2	-3.62	0.000326	0.0214	-0.15	-0.16	Lymphocyte counts;	chr14:64489141	chr14:64422935~64448557:-
THCA	cis	rs9291683	0.53	rs882223	ENSG00000261490.1	RP11-448G15.3	3.62	0.000326	0.0214	0.1	0.16	Bone mineral density;	chr4:9980001	chr4:10068089~10073019:-
THCA	cis	rs1923539	0.662	rs7893691	ENSG00000244733.5	RP11-506M13.3	-3.62	0.000326	0.0214	-0.17	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79931504	chr10:79660891~79677996:+
THCA	cis	rs9425766	0.628	rs6425274	ENSG00000270084.1	GAS5-AS1	-3.62	0.000326	0.0214	-0.17	-0.16	Life satisfaction;	chr1:174144270	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.566	rs6696076	ENSG00000270084.1	GAS5-AS1	-3.62	0.000326	0.0214	-0.17	-0.16	Life satisfaction;	chr1:174149900	chr1:173863248~173863941:+
THCA	cis	rs11233413	1	rs11233418	ENSG00000246067.6	RAB30-AS1	3.62	0.000326	0.0214	0.16	0.16	Economic and political preferences (feminism/equality);	chr11:83017420	chr11:83072066~83106719:+
THCA	cis	rs9425766	0.665	rs7553788	ENSG00000270084.1	GAS5-AS1	-3.62	0.000326	0.0214	-0.17	-0.16	Life satisfaction;	chr1:174093773	chr1:173863248~173863941:+
THCA	cis	rs340849	0.678	rs6696711	ENSG00000274895.1	RP11-478J18.2	-3.62	0.000326	0.0214	-0.14	-0.16	Alzheimer's disease;	chr1:213931328	chr1:213983793~213986419:-
THCA	cis	rs6963495	0.818	rs73190166	ENSG00000272604.1	RP11-251G23.5	3.62	0.000326	0.0214	0.22	0.16	Bipolar disorder (body mass index interaction);	chr7:105519508	chr7:105571083~105573660:+
THCA	cis	rs7296418	0.663	rs4553407	ENSG00000256092.2	RP13-942N8.1	3.62	0.000326	0.0214	0.12	0.16	Platelet count;	chr12:123266201	chr12:123363868~123366113:+
THCA	cis	rs9425766	0.523	rs6668959	ENSG00000270084.1	GAS5-AS1	-3.62	0.000326	0.0214	-0.17	-0.16	Life satisfaction;	chr1:174088488	chr1:173863248~173863941:+
THCA	cis	rs1009077	0.627	rs4834788	ENSG00000245958.5	RP11-33B1.1	3.62	0.000326	0.0214	0.24	0.16	Endometriosis;	chr4:119615235	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs4834789	ENSG00000245958.5	RP11-33B1.1	3.62	0.000326	0.0214	0.24	0.16	Endometriosis;	chr4:119616839	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.669	rs4834790	ENSG00000245958.5	RP11-33B1.1	3.62	0.000326	0.0214	0.24	0.16	Endometriosis;	chr4:119616866	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs9992502	ENSG00000245958.5	RP11-33B1.1	3.62	0.000326	0.0214	0.24	0.16	Endometriosis;	chr4:119621659	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs10025536	ENSG00000245958.5	RP11-33B1.1	3.62	0.000326	0.0214	0.24	0.16	Endometriosis;	chr4:119621715	chr4:119454791~119552025:+
THCA	cis	rs6427356	0.956	rs1176554	ENSG00000237189.1	RP11-85G21.2	3.62	0.000326	0.0214	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157166278	chr1:157287703~157288053:-
THCA	cis	rs10911902	0.643	rs34585917	ENSG00000228238.1	GS1-304P7.2	-3.62	0.000326	0.0214	-0.26	-0.16	Schizophrenia;	chr1:186317650	chr1:186578279~186579299:+
THCA	cis	rs3126085	0.935	rs3126091	ENSG00000237975.5	FLG-AS1	3.62	0.000326	0.0214	0.26	0.16	Atopic dermatitis;	chr1:152334862	chr1:152168125~152445456:+
THCA	cis	rs11658311	0.85	rs112244104	ENSG00000226478.3	UPF3AP1	-3.62	0.000326	0.0214	-0.39	-0.16	Obsessive-compulsive symptoms;	chr17:17534804	chr17:16745636~16746761:-
THCA	cis	rs4713118	0.786	rs200503	ENSG00000261839.1	RP1-265C24.8	3.62	0.000326	0.0214	0.19	0.16	Parkinson's disease;	chr6:27818104	chr6:28136849~28139678:+
THCA	cis	rs2882667	0.931	rs10077796	ENSG00000249593.5	CTB-46B19.2	-3.62	0.000326	0.0214	-0.2	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:139012647~139051203:+
THCA	cis	rs7430456	0.901	rs9824206	ENSG00000225790.1	RP11-2L8.1	-3.62	0.000326	0.0214	-0.2	-0.16	Breast cancer;	chr3:177742093	chr3:177934823~177937662:+
THCA	cis	rs875971	1	rs7781698	ENSG00000272831.1	RP11-792A8.4	3.62	0.000326	0.0214	0.1	0.16	Aortic root size;	chr7:66431325	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs10257427	ENSG00000272831.1	RP11-792A8.4	-3.62	0.000326	0.0214	-0.1	-0.16	Aortic root size;	chr7:66278221	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs10215948	ENSG00000272831.1	RP11-792A8.4	-3.62	0.000326	0.0214	-0.1	-0.16	Aortic root size;	chr7:66282799	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs55748098	ENSG00000272831.1	RP11-792A8.4	-3.62	0.000326	0.0214	-0.1	-0.16	Aortic root size;	chr7:66298631	chr7:66739829~66740385:-
THCA	cis	rs8070128	0.637	rs4925133	ENSG00000281749.1	Y_RNA	3.62	0.000326	0.0214	0.21	0.16	Total body bone mineral density;	chr17:17981487	chr17:18001101~18001195:-
THCA	cis	rs4908768	0.501	rs2045820	ENSG00000270282.1	RP5-1115A15.2	3.62	0.000326	0.0214	0.19	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8512653~8513021:+
THCA	cis	rs61160187	0.582	rs62372103	ENSG00000251279.1	CTC-436P18.1	-3.62	0.000326	0.0214	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:61162070~61232040:+
THCA	cis	rs4742903	0.904	rs7047747	ENSG00000270332.1	SMC2-AS1	3.62	0.000326	0.0214	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104177641	chr9:104080024~104093073:-
THCA	cis	rs10875746	0.669	rs4760701	ENSG00000258273.1	RP11-370I10.4	3.62	0.000326	0.0214	0.23	0.16	Longevity (90 years and older);	chr12:48304735	chr12:48333755~48333901:-
THCA	cis	rs875971	0.502	rs1796227	ENSG00000230295.1	RP11-458F8.2	-3.62	0.000326	0.0214	-0.15	-0.16	Aortic root size;	chr7:66622032	chr7:66880708~66882981:+
THCA	cis	rs6728642	0.901	rs7584641	ENSG00000230606.9	AC159540.1	3.62	0.000326	0.0214	0.23	0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941918	chr2:97416165~97433527:-
THCA	cis	rs8033133	0.881	rs8031260	ENSG00000251815.1	SNORD116-26	-3.62	0.000326	0.0214	-0.2	-0.16	Blood osmolality (transformed sodium);	chr15:25071684	chr15:25099499~25099594:+
THCA	cis	rs4144027	0.869	rs55924227	ENSG00000258534.1	CTD-2134A5.4	-3.62	0.000327	0.0214	-0.17	-0.16	Blood metabolite levels;	chr14:103895013	chr14:103854366~103880111:-
THCA	cis	rs709400	0.526	rs11622473	ENSG00000258735.1	LINC00637	3.62	0.000327	0.0214	0.27	0.16	Body mass index;	chr14:103513425	chr14:103847721~103858049:+
THCA	cis	rs4742903	0.818	rs1857981	ENSG00000270332.1	SMC2-AS1	3.62	0.000327	0.0214	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104230303	chr9:104080024~104093073:-
THCA	cis	rs2340727	0.66	rs1962508	ENSG00000229808.1	RP11-456P18.2	-3.62	0.000327	0.0215	-0.23	-0.16	White blood cell count;Hematology traits;	chr1:161975629	chr1:161890833~161892196:+
THCA	cis	rs2340727	0.66	rs1962509	ENSG00000229808.1	RP11-456P18.2	-3.62	0.000327	0.0215	-0.23	-0.16	White blood cell count;Hematology traits;	chr1:161975677	chr1:161890833~161892196:+
THCA	cis	rs540425	0.626	rs217361	ENSG00000279853.1	RP5-844F9.1	-3.62	0.000327	0.0215	-0.21	-0.16	Schizophrenia;	chr7:44579703	chr7:44367140~44369292:-
THCA	cis	rs4578769	0.765	rs1609464	ENSG00000265939.1	UBE2CP2	-3.62	0.000327	0.0215	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22844191	chr18:22900486~22900995:-
THCA	cis	rs8141529	0.551	rs34578331	ENSG00000272858.1	CTA-292E10.8	-3.62	0.000327	0.0215	-0.21	-0.16	Lymphocyte counts;	chr22:28951227	chr22:28814914~28815662:+
THCA	cis	rs9527	0.518	rs4633383	ENSG00000236937.2	PTGES3P4	3.62	0.000327	0.0215	0.3	0.16	Arsenic metabolism;	chr10:103035966	chr10:102845595~102845950:+
THCA	cis	rs11710088	0.931	rs4630883	ENSG00000240541.2	TM4SF1-AS1	-3.62	0.000327	0.0215	-0.15	-0.16	QRS duration;	chr3:149481373	chr3:149377778~149386583:+
THCA	cis	rs6969780	0.722	rs3823764	ENSG00000233429.8	HOTAIRM1	-3.62	0.000327	0.0215	-0.2	-0.16	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27148134	chr7:27095647~27100265:+
THCA	cis	rs11157436	0.56	rs11623957	ENSG00000211812.1	TRAV26-2	-3.62	0.000327	0.0215	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22224735	chr14:22202583~22203368:+
THCA	cis	rs1200921	0.898	rs1209750	ENSG00000272983.1	RP11-508N22.12	-3.62	0.000327	0.0215	-0.15	-0.16	Breast cancer;	chr10:37199761	chr10:38137337~38144399:+
THCA	cis	rs1200921	0.862	rs1200895	ENSG00000272983.1	RP11-508N22.12	-3.62	0.000327	0.0215	-0.15	-0.16	Breast cancer;	chr10:37200003	chr10:38137337~38144399:+
THCA	cis	rs6120849	0.754	rs3746446	ENSG00000269202.1	RP4-614O4.12	-3.62	0.000327	0.0215	-0.18	-0.16	Protein C levels;	chr20:34986962	chr20:35201747~35203288:-
THCA	cis	rs34421088	0.532	rs2736258	ENSG00000154316.13	TDH	-3.62	0.000327	0.0215	-0.12	-0.16	Neuroticism;	chr8:11312940	chr8:11339637~11368452:+
THCA	cis	rs9902453	0.704	rs2628179	ENSG00000264290.1	RP11-68I3.4	-3.62	0.000327	0.0215	-0.13	-0.16	Coffee consumption (cups per day);	chr17:29744778	chr17:29569580~29570519:+
THCA	cis	rs9309473	0.615	rs11680965	ENSG00000273245.1	RP11-434P11.2	3.62	0.000327	0.0215	0.26	0.16	Metabolite levels;	chr2:73498789	chr2:73750256~73750786:-
THCA	cis	rs972578	1	rs2267482	ENSG00000230319.1	AL022476.2	3.62	0.000327	0.0215	0.17	0.16	Mean platelet volume;	chr22:42984542	chr22:43038585~43052366:+
THCA	cis	rs9400467	0.587	rs6568681	ENSG00000255389.1	C6orf3	3.62	0.000327	0.0215	0.17	0.16	Amino acid levels;Blood metabolite levels;	chr6:111491269	chr6:111599875~111602295:+
THCA	cis	rs929354	0.772	rs2301914	ENSG00000224629.1	RP5-1142J19.2	-3.62	0.000327	0.0215	-0.16	-0.16	Body mass index;	chr7:157207482	chr7:157263022~157263229:-
THCA	cis	rs4713118	0.588	rs200994	ENSG00000272009.1	RP1-313I6.12	3.62	0.000327	0.0215	0.19	0.16	Parkinson's disease;	chr6:27846035	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.614	rs9468209	ENSG00000280107.1	AL022393.9	-3.62	0.000327	0.0215	-0.16	-0.16	Parkinson's disease;	chr6:27726642	chr6:28170845~28172521:+
THCA	cis	rs9450351	1	rs7774219	ENSG00000203875.9	SNHG5	-3.62	0.000327	0.0215	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85908837	chr6:85660950~85678736:-
THCA	cis	rs1383484	1	rs12443111	ENSG00000259728.4	LINC00933	-3.62	0.000327	0.0215	-0.2	-0.16	Height;	chr15:83835727	chr15:84570649~84580175:+
THCA	cis	rs2076028	0.506	rs9611007	ENSG00000225450.1	RP3-508I15.14	-3.62	0.000327	0.0215	-0.18	-0.16	Resting heart rate;	chr22:38681053	chr22:38739003~38749041:+
THCA	cis	rs7777677	0.925	rs4726542	ENSG00000226660.2	TRBV2	3.62	0.000327	0.0215	0.14	0.16	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142300924~142301432:+
THCA	cis	rs2562456	0.876	rs11085465	ENSG00000268658.4	LINC00664	-3.62	0.000327	0.0215	-0.24	-0.16	Pain;	chr19:21568988	chr19:21483374~21503238:+
THCA	cis	rs1023500	0.573	rs4822088	ENSG00000270083.1	RP1-257I20.14	3.62	0.000327	0.0215	0.18	0.16	Schizophrenia;	chr22:42074585	chr22:42089630~42090028:-
THCA	cis	rs1150668	0.699	rs1736895	ENSG00000280107.1	AL022393.9	-3.62	0.000327	0.0215	-0.16	-0.16	Pubertal anthropometrics;	chr6:28252048	chr6:28170845~28172521:+
THCA	cis	rs972578	0.868	rs2413727	ENSG00000230319.1	AL022476.2	3.62	0.000327	0.0215	0.17	0.16	Mean platelet volume;	chr22:42896108	chr22:43038585~43052366:+
THCA	cis	rs10911902	0.602	rs74370445	ENSG00000228238.1	GS1-304P7.2	-3.62	0.000327	0.0215	-0.26	-0.16	Schizophrenia;	chr1:186380327	chr1:186578279~186579299:+
THCA	cis	rs1062177	1	rs17804178	ENSG00000272112.1	CTB-113P19.5	3.62	0.000327	0.0215	0.15	0.16	Preschool internalizing problems;	chr5:151818168	chr5:151724831~151725356:-
THCA	cis	rs1062177	1	rs2964612	ENSG00000272112.1	CTB-113P19.5	3.62	0.000327	0.0215	0.15	0.16	Preschool internalizing problems;	chr5:151819189	chr5:151724831~151725356:-
THCA	cis	rs1864585	0.52	rs73208781	ENSG00000280294.1	RP11-177H2.1	3.62	0.000327	0.0215	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10819988	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs73208785	ENSG00000280294.1	RP11-177H2.1	3.62	0.000327	0.0215	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10820610	chr8:10856085~10859436:-
THCA	cis	rs4268898	1	rs6746005	ENSG00000242628.4	AC009228.1	-3.62	0.000327	0.0215	-0.2	-0.16	Asthma;	chr2:24211476	chr2:24214381~24221516:+
THCA	cis	rs1008126	0.6	rs4727570	ENSG00000234715.1	CTB-107G13.1	3.62	0.000327	0.0215	0.19	0.16	Metabolite levels (Pyroglutamine);	chr7:103494228	chr7:103445207~103514007:+
THCA	cis	rs1923243	0.714	rs7528312	ENSG00000223479.3	RP4-788P17.1	3.62	0.000327	0.0215	0.18	0.16	Migraine;	chr1:73067800	chr1:73635216~73715214:+
THCA	cis	rs34779708	0.931	rs12261654	ENSG00000233200.1	RP11-324I22.2	3.62	0.000327	0.0215	0.2	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35219894~35230598:-
THCA	cis	rs9291683	0.588	rs12507330	ENSG00000250413.1	RP11-448G15.1	-3.62	0.000327	0.0215	-0.16	-0.16	Bone mineral density;	chr4:10000571	chr4:10006482~10009725:+
THCA	cis	rs10256972	0.732	rs1574108	ENSG00000199023.2	MIR339	-3.62	0.000327	0.0215	-0.17	-0.16	Endometriosis;Longevity;	chr7:1066169	chr7:1022935~1023045:-
THCA	cis	rs4764124	0.616	rs2052325	ENSG00000261324.2	RP11-174G6.5	-3.62	0.000327	0.0215	-0.12	-0.16	Pubertal anthropometrics;	chr12:14795500	chr12:14762504~14767931:-
THCA	cis	rs1559040	1	rs10176342	ENSG00000272156.1	RP11-477N3.1	-3.62	0.000327	0.0215	-0.25	-0.16	Sudden cardiac arrest;	chr2:54105941	chr2:54082554~54085066:+
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000230189.5	GS1-124K5.2	3.62	0.000327	0.0215	0.11	0.16	Calcium levels;	chr7:65800652	chr7:66409143~66490059:-
THCA	cis	rs17027633	1	rs2275794	ENSG00000260948.1	RP11-552M11.8	-3.62	0.000327	0.0215	-0.39	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111421640	chr1:111431046~111433068:-
THCA	cis	rs17027633	1	rs17027642	ENSG00000260948.1	RP11-552M11.8	-3.62	0.000327	0.0215	-0.39	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111422023	chr1:111431046~111433068:-
THCA	cis	rs17027633	1	rs79891093	ENSG00000260948.1	RP11-552M11.8	-3.62	0.000327	0.0215	-0.39	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111423955	chr1:111431046~111433068:-
THCA	cis	rs12428035	0.505	rs6492817	ENSG00000247400.3	DNAJC3-AS1	3.62	0.000327	0.0215	0.13	0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95718039	chr13:95648733~95676925:-
THCA	cis	rs12200782	0.649	rs9467733	ENSG00000124549.13	BTN2A3P	-3.62	0.000327	0.0215	-0.2	-0.16	Small cell lung carcinoma;	chr6:26379447	chr6:26421391~26432383:+
THCA	cis	rs12200782	0.685	rs9467734	ENSG00000124549.13	BTN2A3P	-3.62	0.000327	0.0215	-0.2	-0.16	Small cell lung carcinoma;	chr6:26379466	chr6:26421391~26432383:+
THCA	cis	rs4604234	0.803	rs73463518	ENSG00000260645.1	RP11-250B2.5	-3.62	0.000327	0.0215	-0.27	-0.16	Cancer;	chr6:80266300	chr6:80466958~80469080:+
THCA	cis	rs7772697	0.632	rs9498215	ENSG00000223701.3	RAET1E-AS1	-3.62	0.000327	0.0215	-0.22	-0.16	Diabetic retinopathy;	chr6:149099947	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.632	rs9498217	ENSG00000223701.3	RAET1E-AS1	-3.62	0.000327	0.0215	-0.22	-0.16	Diabetic retinopathy;	chr6:149100962	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.632	rs2340800	ENSG00000223701.3	RAET1E-AS1	-3.62	0.000327	0.0215	-0.22	-0.16	Diabetic retinopathy;	chr6:149101908	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.632	rs12191381	ENSG00000223701.3	RAET1E-AS1	-3.62	0.000327	0.0215	-0.22	-0.16	Diabetic retinopathy;	chr6:149103900	chr6:149884431~149919508:+
THCA	cis	rs6580649	0.941	rs757556	ENSG00000273765.1	RP11-370I10.11	-3.62	0.000327	0.0215	-0.18	-0.16	Lung cancer;	chr12:48108710	chr12:48360920~48361377:+
THCA	cis	rs8031584	0.541	rs1983459	ENSG00000178081.11	ULK4P3	3.62	0.000327	0.0215	0.21	0.16	Huntington's disease progression;	chr15:30916546	chr15:30103720~30131757:+
THCA	cis	rs3121446	0.629	rs1033606	ENSG00000229654.1	RP1-60O19.2	-3.62	0.000327	0.0215	-0.17	-0.16	Daytime sleep phenotypes;	chr6:106717327	chr6:106695535~106699994:+
THCA	cis	rs7819412	0.838	rs3021494	ENSG00000261451.1	RP11-981G7.1	-3.62	0.000327	0.0215	-0.21	-0.16	Triglycerides;	chr8:11126024	chr8:10433672~10438312:+
THCA	cis	rs12780845	0.54	rs6602180	ENSG00000234961.1	RP11-124N14.3	-3.62	0.000327	0.0215	-0.17	-0.16	Homocysteine levels;	chr10:17150363	chr10:17233325~17234833:-
THCA	cis	rs9400467	0.537	rs12214886	ENSG00000255389.1	C6orf3	3.62	0.000327	0.0215	0.23	0.16	Amino acid levels;Blood metabolite levels;	chr6:111178878	chr6:111599875~111602295:+
THCA	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	3.62	0.000327	0.0215	0.15	0.16	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
THCA	cis	rs1560104	0.518	rs11645483	ENSG00000262801.4	U91319.1	-3.62	0.000328	0.0215	-0.19	-0.16	Obesity-related traits;	chr16:12615400	chr16:13246316~13562918:+
THCA	cis	rs7897654	0.571	rs12771681	ENSG00000213061.2	PFN1P11	3.62	0.000328	0.0215	0.22	0.16	Schizophrenia;	chr10:102875863	chr10:102838011~102845473:-
THCA	cis	rs7520050	0.966	rs785488	ENSG00000280836.1	AL355480.1	3.62	0.000328	0.0215	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs785489	ENSG00000280836.1	AL355480.1	3.62	0.000328	0.0215	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45581219~45581321:-
THCA	cis	rs478304	0.654	rs1074156	ENSG00000255557.1	RP11-770G2.2	3.62	0.000328	0.0215	0.2	0.16	Acne (severe);	chr11:65690698	chr11:65745729~65771585:+
THCA	cis	rs5770917	1	rs17848459	ENSG00000279182.1	XX-C00717C00720L.1	3.62	0.000328	0.0215	0.26	0.16	Narcolepsy;	chr22:50573882	chr22:50316035~50317025:+
THCA	cis	rs3924048	0.574	rs3923904	ENSG00000272482.1	RP11-474O21.5	-3.62	0.000328	0.0215	-0.15	-0.16	Optic cup area;	chr1:12556505	chr1:12618900~12619244:-
THCA	cis	rs9296092	0.517	rs56069946	ENSG00000272217.1	XXbac-BPG157A10.21	3.62	0.000328	0.0215	0.18	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33543359	chr6:33246075~33246856:-
THCA	cis	rs7914558	0.966	rs12571568	ENSG00000272912.1	RP11-724N1.1	-3.62	0.000328	0.0215	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs12766205	ENSG00000272912.1	RP11-724N1.1	-3.62	0.000328	0.0215	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs10883837	ENSG00000272912.1	RP11-724N1.1	-3.62	0.000328	0.0215	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs746293	ENSG00000272912.1	RP11-724N1.1	-3.62	0.000328	0.0215	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs11191577	ENSG00000272912.1	RP11-724N1.1	-3.62	0.000328	0.0215	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:102914585~102915404:+
THCA	cis	rs56804039	0.524	rs4840988	ENSG00000253893.2	FAM85B	-3.62	0.000328	0.0215	-0.3	-0.16	Cervical cancer;	chr8:8545879	chr8:8167819~8226614:-
THCA	cis	rs1417770	0.931	rs778404	ENSG00000260971.3	RP11-504A18.1	3.62	0.000328	0.0215	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56237113	chr1:56248294~56258571:-
THCA	cis	rs173896	0.681	rs255890	ENSG00000246859.2	STARD4-AS1	3.62	0.000328	0.0215	0.26	0.16	Bipolar disorder and schizophrenia;	chr5:111773142	chr5:111512226~111739726:+
THCA	cis	rs11751172	0.651	rs1928531	ENSG00000271857.1	RP1-244F24.1	3.62	0.000328	0.0215	0.11	0.16	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45564819	chr6:45421079~45422005:-
THCA	cis	rs9330264	0.508	rs7364869	ENSG00000236675.1	MTX1P1	-3.62	0.000328	0.0215	-0.16	-0.16	1,5-anhydroglucitol levels;	chr1:155114712	chr1:155230975~155234325:+
THCA	cis	rs7927592	0.913	rs948316	ENSG00000160172.9	FAM86C2P	3.62	0.000328	0.0215	0.16	0.16	Total body bone mineral density;	chr11:68542202	chr11:67791648~67805336:-
THCA	cis	rs2380205	0.967	rs11255581	ENSG00000232807.2	RP11-536K7.3	3.62	0.000328	0.0215	0.15	0.16	Breast cancer;	chr10:5856919	chr10:5934270~5945900:-
THCA	cis	rs7914558	1	rs1926030	ENSG00000272912.1	RP11-724N1.1	-3.62	0.000328	0.0215	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:102914585~102915404:+
THCA	cis	rs7200543	1	rs4985124	ENSG00000188599.16	NPIPP1	-3.62	0.000328	0.0215	-0.13	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:15104312~15123498:-
THCA	cis	rs4727027	0.704	rs7787753	ENSG00000244560.5	RP4-800G7.2	-3.62	0.000328	0.0215	-0.1	-0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149204687	chr7:149285281~149297312:+
THCA	cis	rs11800820	0.596	rs3124112	ENSG00000231612.1	RP11-522M21.3	3.62	0.000328	0.0215	0.23	0.16	Obesity-related traits;	chr1:246542633	chr1:245673732~245676478:-
THCA	cis	rs6545883	0.965	rs6545872	ENSG00000212978.6	AC016747.3	3.62	0.000328	0.0215	0.18	0.16	Tuberculosis;	chr2:61497433	chr2:61141592~61144969:-
THCA	cis	rs3924048	0.574	rs3923904	ENSG00000276830.1	MIR6730	-3.62	0.000328	0.0215	-0.16	-0.16	Optic cup area;	chr1:12556505	chr1:12578957~12579023:-
THCA	cis	rs478304	0.651	rs78412025	ENSG00000214659.4	KRT8P26	3.62	0.000328	0.0215	0.15	0.16	Acne (severe);	chr11:65728225	chr11:65726939~65728214:+
THCA	cis	rs478304	0.651	rs11227281	ENSG00000214659.4	KRT8P26	3.62	0.000328	0.0215	0.15	0.16	Acne (severe);	chr11:65729087	chr11:65726939~65728214:+
THCA	cis	rs478304	0.651	rs4014192	ENSG00000214659.4	KRT8P26	3.62	0.000328	0.0215	0.15	0.16	Acne (severe);	chr11:65731444	chr11:65726939~65728214:+
THCA	cis	rs478304	0.651	rs4930312	ENSG00000214659.4	KRT8P26	3.62	0.000328	0.0215	0.15	0.16	Acne (severe);	chr11:65732248	chr11:65726939~65728214:+
THCA	cis	rs478304	0.651	rs11537193	ENSG00000214659.4	KRT8P26	3.62	0.000328	0.0215	0.15	0.16	Acne (severe);	chr11:65732532	chr11:65726939~65728214:+
THCA	cis	rs478304	0.651	rs4930313	ENSG00000214659.4	KRT8P26	3.62	0.000328	0.0215	0.15	0.16	Acne (severe);	chr11:65732957	chr11:65726939~65728214:+
THCA	cis	rs2235642	0.685	rs2667681	ENSG00000260989.1	LA16c-395F10.2	-3.62	0.000328	0.0215	-0.17	-0.16	Coronary artery disease;	chr16:1603205	chr16:1580527~1610328:+
THCA	cis	rs2290416	0.892	rs62523607	ENSG00000254338.1	MAFA-AS1	3.62	0.000328	0.0215	0.33	0.16	Attention deficit hyperactivity disorder;	chr8:143585262	chr8:143417679~143419150:+
THCA	cis	rs10200159	0.793	rs6545512	ENSG00000206964.1	Y_RNA	-3.62	0.000328	0.0215	-0.38	-0.16	Vitiligo;	chr2:55656896	chr2:55286018~55286128:+
THCA	cis	rs9987353	0.519	rs11779181	ENSG00000253981.4	ALG1L13P	3.62	0.000328	0.0215	0.16	0.16	Recombination measurement;	chr8:9205517	chr8:8236003~8244667:-
THCA	cis	rs7707921	1	rs1019806	ENSG00000251374.1	RPS23P5	-3.62	0.000328	0.0215	-0.24	-0.16	Breast cancer;	chr5:82255840	chr5:82265157~82265259:-
THCA	cis	rs10129255	0.957	rs12589190	ENSG00000280411.1	IGHV1-69-2	-3.62	0.000328	0.0215	-0.1	-0.16	Kawasaki disease;	chr14:106783079	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs7493713	ENSG00000280411.1	IGHV1-69-2	-3.62	0.000328	0.0215	-0.1	-0.16	Kawasaki disease;	chr14:106783685	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.912	rs35468694	ENSG00000280411.1	IGHV1-69-2	-3.62	0.000328	0.0215	-0.1	-0.16	Kawasaki disease;	chr14:106784199	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs8019272	ENSG00000280411.1	IGHV1-69-2	-3.62	0.000328	0.0215	-0.1	-0.16	Kawasaki disease;	chr14:106784709	chr14:106762092~106762588:-
THCA	cis	rs11671005	0.737	rs11671033	ENSG00000269600.1	AC016629.3	-3.62	0.000328	0.0215	-0.25	-0.16	Mean platelet volume;	chr19:58452302	chr19:58593896~58599355:-
THCA	cis	rs3733585	0.683	rs6449140	ENSG00000250413.1	RP11-448G15.1	3.62	0.000328	0.0215	0.16	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9934813	chr4:10006482~10009725:+
THCA	cis	rs5753037	0.653	rs131277	ENSG00000273350.1	RP4-539M6.20	-3.62	0.000328	0.0215	-0.19	-0.16	Type 1 diabetes;	chr22:29758112	chr22:30420512~30420912:+
THCA	cis	rs150992	0.673	rs330419	ENSG00000246763.5	RGMB-AS1	-3.62	0.000328	0.0215	-0.17	-0.16	Body mass index;	chr5:98857460	chr5:98769618~98773469:-
THCA	cis	rs10186029	0.582	rs10497995	ENSG00000270659.1	RP11-105N14.1	-3.62	0.000328	0.0215	-0.13	-0.16	Systemic sclerosis;	chr2:213130622	chr2:213152970~213153659:+
THCA	cis	rs875971	0.723	rs28391294	ENSG00000223473.2	GS1-124K5.3	-3.62	0.000328	0.0215	-0.11	-0.16	Aortic root size;	chr7:66189328	chr7:66491049~66493566:-
THCA	cis	rs6788895	1	rs58418105	ENSG00000244265.1	SIAH2-AS1	3.62	0.000328	0.0215	0.49	0.16	Breast cancer;	chr3:150759259	chr3:150761937~150762538:+
THCA	cis	rs11671005	0.695	rs11673069	ENSG00000269600.1	AC016629.3	-3.62	0.000328	0.0215	-0.25	-0.16	Mean platelet volume;	chr19:58423551	chr19:58593896~58599355:-
THCA	cis	rs559555	0.888	rs2300697	ENSG00000276517.1	AL133243.2	-3.62	0.000328	0.0215	-0.15	-0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31561567	chr2:32526504~32529507:+
THCA	cis	rs16857609	0.564	rs12624106	ENSG00000233143.1	DIRC3-AS1	-3.62	0.000328	0.0215	-0.2	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217425722	chr2:217282739~217336120:+
THCA	cis	rs35740288	0.822	rs17637142	ENSG00000259407.1	RP11-158M2.3	-3.62	0.000328	0.0215	-0.2	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85697272	chr15:85744109~85750281:-
THCA	cis	rs3768792	0.665	rs9288461	ENSG00000196096.3	AC079610.2	-3.62	0.000328	0.0215	-0.23	-0.16	Systemic lupus erythematosus;	chr2:212991703	chr2:213276552~213284205:-
THCA	cis	rs6787172	0.622	rs12107104	ENSG00000272087.1	RP11-379F4.7	-3.62	0.000328	0.0215	-0.15	-0.16	Subjective well-being;	chr3:158408538	chr3:158693120~158693768:-
THCA	cis	rs790006	0.697	rs11175286	ENSG00000243024.5	RPS11P6	-3.62	0.000328	0.0215	-0.19	-0.16	Response to cytidine analogues (gemcitabine);	chr12:64224828	chr12:64222337~64397065:+
THCA	cis	rs12887734	0.524	rs17791722	ENSG00000258735.1	LINC00637	-3.62	0.000328	0.0215	-0.21	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103819873	chr14:103847721~103858049:+
THCA	cis	rs765787	0.53	rs4775819	ENSG00000259932.1	CTD-2651B20.7	3.62	0.000328	0.0215	0.2	0.16	Uric acid levels;	chr15:45233768	chr15:45198517~45199139:-
THCA	cis	rs2562456	0.833	rs11669790	ENSG00000268278.1	RP11-420K14.1	3.62	0.000328	0.0215	0.24	0.16	Pain;	chr19:21328980	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62107534	ENSG00000268278.1	RP11-420K14.1	3.62	0.000328	0.0215	0.24	0.16	Pain;	chr19:21329389	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs7258473	ENSG00000268278.1	RP11-420K14.1	3.62	0.000328	0.0215	0.24	0.16	Pain;	chr19:21331795	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs2219839	ENSG00000268278.1	RP11-420K14.1	3.62	0.000328	0.0215	0.24	0.16	Pain;	chr19:21333520	chr19:21637974~21656300:+
THCA	cis	rs1005277	0.683	rs7923868	ENSG00000273019.1	RP11-508N22.13	-3.62	0.000328	0.0215	-0.18	-0.16	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38149968~38150293:+
THCA	cis	rs860295	0.665	rs12028416	ENSG00000236675.1	MTX1P1	-3.62	0.000328	0.0215	-0.17	-0.16	Body mass index;	chr1:155431370	chr1:155230975~155234325:+
THCA	cis	rs860295	0.629	rs12026638	ENSG00000236675.1	MTX1P1	-3.62	0.000328	0.0215	-0.17	-0.16	Body mass index;	chr1:155431469	chr1:155230975~155234325:+
THCA	cis	rs270601	0.633	rs733300	ENSG00000263597.1	MIR3936	3.62	0.000328	0.0215	0.16	0.16	Acylcarnitine levels;	chr5:132236550	chr5:132365490~132365599:-
THCA	cis	rs270601	0.633	rs4535443	ENSG00000263597.1	MIR3936	3.62	0.000328	0.0215	0.16	0.16	Acylcarnitine levels;	chr5:132236868	chr5:132365490~132365599:-
THCA	cis	rs1005277	0.579	rs2505257	ENSG00000099251.13	HSD17B7P2	3.62	0.000328	0.0215	0.14	0.16	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38356380~38378505:+
THCA	cis	rs2832191	0.935	rs67287920	ENSG00000232855.5	AF131217.1	3.62	0.000328	0.0215	0.17	0.16	Dental caries;	chr21:29151198	chr21:28439346~28674848:-
THCA	cis	rs1371614	0.635	rs4316900	ENSG00000229122.1	AGBL5-IT1	-3.62	0.000328	0.0216	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917474	chr2:27061038~27061815:+
THCA	cis	rs847649	0.699	rs7794668	ENSG00000234715.1	CTB-107G13.1	3.62	0.000328	0.0216	0.18	0.16	Morning vs. evening chronotype;	chr7:102869969	chr7:103445207~103514007:+
THCA	cis	rs5752128	1	rs5752128	ENSG00000230637.2	CTA-246H3.8	3.62	0.000328	0.0216	0.19	0.16	Monokine induced by gamma interferon levels;	chr22:25322656	chr22:25327252~25339975:+
THCA	cis	rs9341808	0.754	rs9341811	ENSG00000260645.1	RP11-250B2.5	3.62	0.000328	0.0216	0.14	0.16	Sitting height ratio;	chr6:80272984	chr6:80466958~80469080:+
THCA	cis	rs7665090	1	rs909349	ENSG00000248971.2	KRT8P46	3.62	0.000328	0.0216	0.19	0.16	Primary biliary cholangitis;	chr4:102635159	chr4:102728746~102730171:-
THCA	cis	rs6546886	1	rs6743073	ENSG00000235499.1	AC073046.25	3.62	0.000328	0.0216	0.15	0.16	Dialysis-related mortality;	chr2:74013910	chr2:73985132~73986343:+
THCA	cis	rs1065852	0.526	rs7290907	ENSG00000232710.1	RP4-669P10.16	-3.62	0.000329	0.0216	-0.21	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994205	chr22:42136433~42139927:-
THCA	cis	rs1065852	0.526	rs7290655	ENSG00000232710.1	RP4-669P10.16	-3.62	0.000329	0.0216	-0.21	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994221	chr22:42136433~42139927:-
THCA	cis	rs3026445	0.519	rs3026444	ENSG00000278993.1	RP3-424M6.4	3.62	0.000329	0.0216	0.25	0.16	QT interval;	chr12:110284827	chr12:110501614~110503441:+
THCA	cis	rs1862618	0.715	rs6866779	ENSG00000234553.1	AC022431.3	-3.62	0.000329	0.0216	-0.19	-0.16	Initial pursuit acceleration;	chr5:56794173	chr5:56536583~56537826:-
THCA	cis	rs7818688	0.614	rs11783589	ENSG00000253528.2	RP11-347C18.4	-3.62	0.000329	0.0216	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94833736	chr8:94974573~94974853:-
THCA	cis	rs10266483	0.661	rs608769	ENSG00000234338.1	RP11-797H7.1	3.62	0.000329	0.0216	0.12	0.16	Response to statin therapy;	chr7:64292783	chr7:64835280~64836882:-
THCA	cis	rs6738627	0.965	rs2198550	ENSG00000223318.1	RNA5SP111	3.62	0.000329	0.0216	0.21	0.16	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164700250	chr2:164895677~164895777:-
THCA	cis	rs1005277	0.579	rs2474587	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000329	0.0216	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474588	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000329	0.0216	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:37883594~37884109:+
THCA	cis	rs4460629	0.742	rs7365544	ENSG00000236675.1	MTX1P1	-3.62	0.000329	0.0216	-0.16	-0.16	Serum magnesium levels;	chr1:155096272	chr1:155230975~155234325:+
THCA	cis	rs4460629	0.804	rs56112907	ENSG00000236675.1	MTX1P1	-3.62	0.000329	0.0216	-0.16	-0.16	Serum magnesium levels;	chr1:155098386	chr1:155230975~155234325:+
THCA	cis	rs8103033	0.748	rs17795711	ENSG00000226025.8	LGALS17A	-3.62	0.000329	0.0216	-0.15	-0.16	Obesity-related traits;	chr19:39626354	chr19:39679374~39686373:+
THCA	cis	rs8103033	0.748	rs58981361	ENSG00000226025.8	LGALS17A	-3.62	0.000329	0.0216	-0.15	-0.16	Obesity-related traits;	chr19:39626477	chr19:39679374~39686373:+
THCA	cis	rs7873102	0.58	rs4637937	ENSG00000213839.4	TMX2P1	-3.62	0.000329	0.0216	-0.13	-0.16	Brain structure;	chr9:37965819	chr9:37885683~37886390:+
THCA	cis	rs7546094	0.508	rs12042407	ENSG00000273483.1	RP4-671G15.2	-3.62	0.000329	0.0216	-0.15	-0.16	Platelet distribution width;	chr1:112641257	chr1:112517799~112518441:-
THCA	cis	rs789852	0.867	rs9288751	ENSG00000231770.4	TMEM44-AS1	-3.62	0.000329	0.0216	-0.22	-0.16	QT interval;	chr3:194595565	chr3:194584011~194590260:+
THCA	cis	rs6496044	0.568	rs11632326	ENSG00000259407.1	RP11-158M2.3	-3.62	0.000329	0.0216	-0.17	-0.16	Interstitial lung disease;	chr15:85536603	chr15:85744109~85750281:-
THCA	cis	rs786425	0.646	rs11612927	ENSG00000278112.1	RP11-972P1.11	3.62	0.000329	0.0216	0.17	0.16	Pubertal anthropometrics;	chr12:123647180	chr12:123519390~123519856:-
THCA	cis	rs2033711	0.783	rs11671113	ENSG00000268049.1	CTD-2619J13.9	-3.62	0.000329	0.0216	-0.21	-0.16	Uric acid clearance;	chr19:58446720	chr19:58357999~58359603:+
THCA	cis	rs2179367	0.959	rs480034	ENSG00000223701.3	RAET1E-AS1	-3.62	0.000329	0.0216	-0.21	-0.16	Dupuytren's disease;	chr6:149414294	chr6:149884431~149919508:+
THCA	cis	rs10089	1	rs1560636	ENSG00000245937.6	LINC01184	3.62	0.000329	0.0216	0.18	0.16	Ileal carcinoids;	chr5:128112295	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs9968597	ENSG00000245937.6	LINC01184	3.62	0.000329	0.0216	0.18	0.16	Ileal carcinoids;	chr5:128119691	chr5:127940426~128083172:-
THCA	cis	rs964611	0.882	rs11854679	ENSG00000259488.2	RP11-154J22.1	-3.62	0.000329	0.0216	-0.15	-0.16	Metabolite levels (Pyroglutamine);	chr15:48265376	chr15:48312353~48331856:-
THCA	cis	rs10984970	0.826	rs10984984	ENSG00000226752.6	PSMD5-AS1	3.62	0.000329	0.0216	0.41	0.16	Lung cancer;	chr9:120701198	chr9:120824828~120854385:+
THCA	cis	rs9818758	0.556	rs13086240	ENSG00000229759.1	MRPS18AP1	-3.62	0.000329	0.0216	-0.34	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48963976	chr3:48256350~48256938:-
THCA	cis	rs9990333	0.622	rs57783901	ENSG00000278820.1	AC024937.1	3.62	0.000329	0.0216	0.17	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195960500~195960612:-
THCA	cis	rs2341873	0.524	rs2056014	ENSG00000204588.5	LINC01123	-3.62	0.000329	0.0216	-0.19	-0.16	Neutrophil percentage of white cells;	chr2:110923893	chr2:109987063~109996140:+
THCA	cis	rs17023223	0.537	rs4590715	ENSG00000227056.2	RPL6P2	-3.62	0.000329	0.0216	-0.22	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119219314~119220096:-
THCA	cis	rs3758911	0.964	rs10890715	ENSG00000255353.1	RP11-382M14.1	-3.62	0.000329	0.0216	-0.2	-0.16	Coronary artery disease;	chr11:107322457	chr11:107176286~107177530:+
THCA	cis	rs9863	0.827	rs6488913	ENSG00000269938.1	RP11-214K3.20	3.62	0.000329	0.0216	0.19	0.16	White blood cell count;	chr12:123961022	chr12:123968023~123968579:-
THCA	cis	rs804280	0.662	rs11250164	ENSG00000254527.1	ENPP7P12	-3.62	0.000329	0.0216	-0.22	-0.16	Myopia (pathological);	chr8:11753177	chr8:12205759~12206389:-
THCA	cis	rs6715284	0.892	rs8105	ENSG00000238829.1	RNU7-45P	-3.62	0.000329	0.0216	-0.42	-0.16	Rheumatoid arthritis;	chr2:201377412	chr2:201141904~201141966:+
THCA	cis	rs478304	0.651	rs4014195	ENSG00000214659.4	KRT8P26	-3.62	0.000329	0.0216	-0.15	-0.16	Acne (severe);	chr11:65739351	chr11:65726939~65728214:+
THCA	cis	rs7632954	0.567	rs6793940	ENSG00000227110.5	LMCD1-AS1	3.62	0.000329	0.0216	0.2	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8493320	chr3:7952805~8611924:-
THCA	cis	rs427691	0.625	rs845738	ENSG00000249476.1	CTD-2587M2.1	3.62	0.000329	0.0216	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:109682414	chr5:109237120~109326369:-
THCA	cis	rs4908768	0.871	rs7553298	ENSG00000232912.4	RP5-1115A15.1	-3.62	0.000329	0.0216	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8710824	chr1:8424645~8434838:+
THCA	cis	rs11640436	0.524	rs2343043	ENSG00000226348.1	VN2R10P	3.62	0.000329	0.0216	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr16:77252577	chr16:77220406~77221258:+
THCA	cis	rs11671005	0.504	rs3794964	ENSG00000269600.1	AC016629.3	-3.62	0.000329	0.0216	-0.21	-0.16	Mean platelet volume;	chr19:58559549	chr19:58593896~58599355:-
THCA	cis	rs453301	0.686	rs6601280	ENSG00000254340.1	RP11-10A14.3	3.62	0.000329	0.0216	0.18	0.16	Joint mobility (Beighton score);	chr8:9051726	chr8:9141424~9145435:+
THCA	cis	rs853679	1	rs853685	ENSG00000261839.1	RP1-265C24.8	3.62	0.000329	0.0216	0.22	0.16	Depression;	chr6:28321008	chr6:28136849~28139678:+
THCA	cis	rs7474896	0.515	rs662928	ENSG00000272983.1	RP11-508N22.12	3.62	0.000329	0.0216	0.17	0.16	Obesity (extreme);	chr10:38027288	chr10:38137337~38144399:+
THCA	cis	rs3743266	0.613	rs1869485	ENSG00000240163.1	RP11-745A24.1	-3.62	0.000329	0.0216	-0.19	-0.16	Menarche (age at onset);	chr15:60454406	chr15:60390371~60390682:+
THCA	cis	rs3753275	0.624	rs12125668	ENSG00000230679.1	ENO1-AS1	3.62	0.000329	0.0216	0.17	0.16	Educational attainment;	chr1:8843799	chr1:8878835~8879894:+
THCA	cis	rs9287719	0.649	rs58633964	ENSG00000243819.4	RN7SL832P	3.62	0.00033	0.0216	0.13	0.16	Prostate cancer;	chr2:10596256	chr2:10690344~10692099:+
THCA	cis	rs9393813	0.529	rs4711155	ENSG00000216915.2	RP1-97D16.1	3.62	0.00033	0.0216	0.22	0.16	Bipolar disorder;	chr6:27478667	chr6:27737000~27738494:-
THCA	cis	rs875971	0.964	rs60193905	ENSG00000272831.1	RP11-792A8.4	3.62	0.00033	0.0216	0.1	0.16	Aortic root size;	chr7:66506273	chr7:66739829~66740385:-
THCA	cis	rs875971	0.929	rs10950041	ENSG00000272831.1	RP11-792A8.4	3.62	0.00033	0.0216	0.1	0.16	Aortic root size;	chr7:66508888	chr7:66739829~66740385:-
THCA	cis	rs6546550	0.867	rs4852349	ENSG00000179818.12	PCBP1-AS1	-3.62	0.00033	0.0216	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69849822	chr2:69962263~70103220:-
THCA	cis	rs7572733	0.935	rs10192466	ENSG00000231621.1	AC013264.2	-3.62	0.00033	0.0216	-0.16	-0.16	Dermatomyositis;	chr2:197873295	chr2:197197991~197199273:+
THCA	cis	rs7267979	0.586	rs6050445	ENSG00000274973.1	RP13-401N8.7	-3.62	0.00033	0.0216	-0.19	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25845497~25845862:+
THCA	cis	rs6738028	0.522	rs6753977	ENSG00000227992.1	AC108463.2	-3.62	0.00033	0.0216	-0.2	-0.16	Dehydroepiandrosterone sulphate levels;	chr2:111193226	chr2:111203964~111206215:-
THCA	cis	rs7283707	0.688	rs460497	ENSG00000229425.1	AJ006998.2	-3.62	0.00033	0.0216	-0.23	-0.16	QRS complex (12-leadsum);	chr21:15721340	chr21:15370522~15402305:-
THCA	cis	rs875971	0.862	rs13226170	ENSG00000223473.2	GS1-124K5.3	3.62	0.00033	0.0216	0.11	0.16	Aortic root size;	chr7:66534311	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs2420611	ENSG00000223473.2	GS1-124K5.3	3.62	0.00033	0.0216	0.11	0.16	Aortic root size;	chr7:66534333	chr7:66491049~66493566:-
THCA	cis	rs28830936	0.966	rs4924576	ENSG00000250379.1	RP11-23P13.4	3.62	0.00033	0.0216	0.19	0.16	Diastolic blood pressure;	chr15:41827395	chr15:41825099~41827936:-
THCA	cis	rs28830936	0.934	rs4923915	ENSG00000250379.1	RP11-23P13.4	3.62	0.00033	0.0216	0.19	0.16	Diastolic blood pressure;	chr15:41827408	chr15:41825099~41827936:-
THCA	cis	rs1124769	0.654	rs12441919	ENSG00000259378.1	DCAF13P3	3.62	0.00033	0.0216	0.25	0.16	Cognitive performance;	chr15:51179503	chr15:50944663~50945996:+
THCA	cis	rs9980	1	rs1465451	ENSG00000226232.7	RP11-419C5.2	3.62	0.00033	0.0216	0.25	0.16	Blood osmolality (transformed sodium);	chr16:69557677	chr16:69976388~69996188:-
THCA	cis	rs4908768	0.539	rs1061039	ENSG00000270282.1	RP5-1115A15.2	3.62	0.00033	0.0216	0.19	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8512653~8513021:+
THCA	cis	rs12188164	0.965	rs72717435	ENSG00000225138.6	CTD-2228K2.7	3.62	0.00033	0.0216	0.17	0.16	Cystic fibrosis severity;	chr5:448087	chr5:473236~480884:+
THCA	cis	rs11250098	0.642	rs4841460	ENSG00000206014.6	OR7E161P	3.62	0.00033	0.0216	0.18	0.16	Morning vs. evening chronotype;	chr8:10931983	chr8:11928597~11929563:-
THCA	cis	rs765787	0.505	rs1648302	ENSG00000259932.1	CTD-2651B20.7	3.62	0.00033	0.0216	0.2	0.16	Uric acid levels;	chr15:45202040	chr15:45198517~45199139:-
THCA	cis	rs2625529	0.824	rs55854204	ENSG00000260037.4	CTD-2524L6.3	-3.62	0.00033	0.0216	-0.23	-0.16	Red blood cell count;	chr15:72140841	chr15:71818396~71823384:+
THCA	cis	rs9487094	0.62	rs6939953	ENSG00000223537.2	RP5-919F19.5	-3.62	0.00033	0.0216	-0.16	-0.16	Height;	chr6:109390116	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.666	rs3757235	ENSG00000223537.2	RP5-919F19.5	-3.62	0.00033	0.0216	-0.16	-0.16	Height;	chr6:109390638	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.666	rs746794	ENSG00000223537.2	RP5-919F19.5	-3.62	0.00033	0.0216	-0.16	-0.16	Height;	chr6:109391534	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.643	rs730089	ENSG00000223537.2	RP5-919F19.5	-3.62	0.00033	0.0216	-0.16	-0.16	Height;	chr6:109393881	chr6:109487906~109506800:+
THCA	cis	rs9303542	0.729	rs7220387	ENSG00000278765.1	RP5-890E16.5	-3.62	0.00033	0.0216	-0.22	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48422738	chr17:48066704~48067293:-
THCA	cis	rs34761973	1	rs34761973	ENSG00000277200.1	RP11-74E22.8	-3.62	0.00033	0.0216	-0.27	-0.16	Depressive symptoms (multi-trait analysis);Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis);	chr17:2614804	chr17:2720801~2723947:-
THCA	cis	rs5762752	0.555	rs695388	ENSG00000272858.1	CTA-292E10.8	-3.62	0.00033	0.0216	-0.15	-0.16	Optic disc area;	chr22:28437514	chr22:28814914~28815662:+
THCA	cis	rs4879628	0.656	rs10971211	ENSG00000225693.1	LAGE3P1	-3.62	0.00033	0.0216	-0.3	-0.16	Amyotrophic lateral sclerosis;	chr9:32910294	chr9:33019682~33020165:-
THCA	cis	rs76076331	0.838	rs77966298	ENSG00000271952.1	RP11-245G13.2	-3.62	0.00033	0.0216	-0.32	-0.16	Educational attainment (college completion);Educational attainment (years of education);	chr2:10844388	chr2:10878269~10885118:+
THCA	cis	rs62289301	0.614	rs12233742	ENSG00000273133.1	RP11-799M12.2	3.62	0.00033	0.0216	0.21	0.16	Joint mobility (Beighton score);	chr4:15412721	chr4:15563698~15564253:-
THCA	cis	rs2522056	1	rs886286	ENSG00000237714.1	P4HA2-AS1	-3.62	0.00033	0.0216	-0.24	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132459905	chr5:132184876~132192808:+
THCA	cis	rs2522056	1	rs757105	ENSG00000237714.1	P4HA2-AS1	-3.62	0.00033	0.0216	-0.24	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132459971	chr5:132184876~132192808:+
THCA	cis	rs2522056	1	rs2522047	ENSG00000237714.1	P4HA2-AS1	-3.62	0.00033	0.0216	-0.24	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132460190	chr5:132184876~132192808:+
THCA	cis	rs2522056	1	rs2706393	ENSG00000237714.1	P4HA2-AS1	-3.62	0.00033	0.0216	-0.24	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132460375	chr5:132184876~132192808:+
THCA	cis	rs13217239	0.646	rs10946888	ENSG00000261353.1	CTA-14H9.5	-3.62	0.00033	0.0216	-0.17	-0.16	Schizophrenia;	chr6:26983899	chr6:26527063~26527404:+
THCA	cis	rs4950322	0.547	rs56864370	ENSG00000180867.10	PDIA3P1	3.62	0.00033	0.0216	0.16	0.16	Protein quantitative trait loci;	chr1:147111847	chr1:147178113~147179622:+
THCA	cis	rs16975963	0.79	rs11083434	ENSG00000276846.1	CTD-3220F14.3	-3.62	0.00033	0.0216	-0.16	-0.16	Longevity;	chr19:37793313	chr19:37314868~37315620:-
THCA	cis	rs3015497	0.526	rs10136630	ENSG00000270062.1	RP11-248J18.3	3.62	0.00033	0.0216	0.18	0.16	Mean platelet volume;	chr14:50579756	chr14:50723777~50724272:-
THCA	cis	rs7572733	0.515	rs13382697	ENSG00000231621.1	AC013264.2	-3.62	0.00033	0.0216	-0.17	-0.16	Dermatomyositis;	chr2:198055836	chr2:197197991~197199273:+
THCA	cis	rs2237234	0.58	rs7763910	ENSG00000124549.13	BTN2A3P	-3.62	0.00033	0.0216	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr6:26472427	chr6:26421391~26432383:+
THCA	cis	rs745109	0.504	rs72926475	ENSG00000273080.1	RP11-301O19.1	3.62	0.00033	0.0216	0.28	0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86367364	chr2:86195590~86196049:+
THCA	cis	rs11671005	0.61	rs4756	ENSG00000269600.1	AC016629.3	-3.62	0.00033	0.0216	-0.21	-0.16	Mean platelet volume;	chr19:58563286	chr19:58593896~58599355:-
THCA	cis	rs1580019	0.587	rs1597555	ENSG00000273014.1	RP11-225B17.2	3.62	0.00033	0.0216	0.17	0.16	Cognitive ability;	chr7:32506506	chr7:32758882~32759353:+
THCA	cis	rs7259376	0.936	rs8111537	ENSG00000269138.1	ZNF209P	3.62	0.00033	0.0216	0.16	0.16	Menopause (age at onset);	chr19:22352743	chr19:22463922~22473036:+
THCA	cis	rs62209	0.752	rs11256935	ENSG00000181800.5	CELF2-AS1	3.62	0.00033	0.0217	0.17	0.16	Alzheimer's disease (late onset);	chr10:10962214	chr10:11316834~11319884:-
THCA	cis	rs6472235	0.803	rs7010113	ENSG00000272192.1	CTD-2532N20.1	3.62	0.00033	0.0217	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65989756	chr8:65842752~65843331:+
THCA	cis	rs6687821	0.515	rs10493794	ENSG00000261737.1	RP4-612B15.3	3.62	0.00033	0.0217	0.24	0.16	Yeast infection;	chr1:87004946	chr1:86703502~86704462:-
THCA	cis	rs1707322	0.638	rs9429095	ENSG00000281133.1	AL355480.3	3.62	0.00033	0.0217	0.2	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45580892~45580996:-
THCA	cis	rs2898290	0.622	rs1600250	ENSG00000270154.1	RP11-419I17.1	-3.62	0.00033	0.0217	-0.21	-0.16	Systolic blood pressure;	chr8:11487916	chr8:12476462~12477122:+
THCA	cis	rs2898290	0.593	rs1600252	ENSG00000270154.1	RP11-419I17.1	-3.62	0.00033	0.0217	-0.21	-0.16	Systolic blood pressure;	chr8:11488135	chr8:12476462~12477122:+
THCA	cis	rs9287719	0.967	rs10929688	ENSG00000243819.4	RN7SL832P	3.62	0.00033	0.0217	0.13	0.16	Prostate cancer;	chr2:10616524	chr2:10690344~10692099:+
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000230189.5	GS1-124K5.2	3.62	0.00033	0.0217	0.11	0.16	Calcium levels;	chr7:65829754	chr7:66409143~66490059:-
THCA	cis	rs7620503	0.625	rs7620805	ENSG00000228561.2	RP11-114M1.1	3.62	0.00033	0.0217	0.19	0.16	Corneal structure;	chr3:177586637	chr3:177683627~177691250:+
THCA	cis	rs950169	0.922	rs12906983	ENSG00000188388.10	GOLGA6L3	3.62	0.00033	0.0217	0.22	0.16	Schizophrenia;	chr15:84262270	chr15:85240472~85247170:+
THCA	cis	rs7142002	0.614	rs58553858	ENSG00000271780.1	RP11-1017G21.5	-3.62	0.00033	0.0217	-0.2	-0.16	Autism;	chr14:101924875	chr14:101948347~101949425:+
THCA	cis	rs3770081	1	rs1036554	ENSG00000272564.1	RP11-548P2.2	-3.62	0.00033	0.0217	-0.29	-0.16	Facial emotion recognition (sad faces);	chr2:86008976	chr2:85904279~85904727:+
THCA	cis	rs7307902	1	rs10875659	ENSG00000280054.1	RP1-197B17.7	-3.62	0.00033	0.0217	-0.19	-0.16	Obesity-related traits;	chr12:47534831	chr12:47728151~47730598:-
THCA	cis	rs6487679	1	rs1017302	ENSG00000245105.2	A2M-AS1	3.62	0.00033	0.0217	0.15	0.16	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9065177~9068060:+
THCA	cis	rs6487679	1	rs10734765	ENSG00000245105.2	A2M-AS1	3.62	0.00033	0.0217	0.15	0.16	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9065177~9068060:+
THCA	cis	rs889014	1	rs6885032	ENSG00000253959.1	CTB-43E15.1	-3.62	0.00033	0.0217	-0.21	-0.16	Height;	chr5:173556276	chr5:173642519~173658194:+
THCA	cis	rs1009077	0.627	rs6847164	ENSG00000248280.1	RP11-33B1.2	-3.62	0.00033	0.0217	-0.18	-0.16	Endometriosis;	chr4:119613579	chr4:119440561~119450157:-
THCA	cis	rs853679	0.517	rs9380058	ENSG00000219891.2	ZSCAN12P1	3.62	0.00033	0.0217	0.23	0.16	Depression;	chr6:28159666	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000219891.2	ZSCAN12P1	3.62	0.00033	0.0217	0.23	0.16	Depression;	chr6:28162598	chr6:28091154~28093664:+
THCA	cis	rs11672691	0.67	rs4802119	ENSG00000268355.1	AC006129.1	-3.62	0.00033	0.0217	-0.21	-0.16	Prostate cancer;	chr19:41484417	chr19:41531206~41532174:+
THCA	cis	rs4568518	0.873	rs4535616	ENSG00000279048.1	RP11-511H23.2	3.62	0.00033	0.0217	0.11	0.16	Measles;	chr7:17989040	chr7:17940503~17942922:+
THCA	cis	rs1050631	0.96	rs1789516	ENSG00000260552.1	RP11-49I11.1	3.62	0.00033	0.0217	0.2	0.16	Esophageal squamous cell cancer (length of survival);	chr18:36111725	chr18:36179996~36187448:-
THCA	cis	rs1050631	1	rs1785919	ENSG00000260552.1	RP11-49I11.1	3.62	0.00033	0.0217	0.2	0.16	Esophageal squamous cell cancer (length of survival);	chr18:36112001	chr18:36179996~36187448:-
THCA	cis	rs10911902	0.643	rs76469621	ENSG00000233196.2	GS1-304P7.1	-3.62	0.000331	0.0217	-0.25	-0.16	Schizophrenia;	chr1:186363848	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs79081972	ENSG00000233196.2	GS1-304P7.1	-3.62	0.000331	0.0217	-0.25	-0.16	Schizophrenia;	chr1:186364669	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs75490185	ENSG00000233196.2	GS1-304P7.1	-3.62	0.000331	0.0217	-0.25	-0.16	Schizophrenia;	chr1:186366319	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs112738913	ENSG00000233196.2	GS1-304P7.1	-3.62	0.000331	0.0217	-0.25	-0.16	Schizophrenia;	chr1:186367231	chr1:186580515~186581191:-
THCA	cis	rs113577745	0.616	rs13009358	ENSG00000188525.3	AC010969.1	-3.62	0.000331	0.0217	-0.26	-0.16	Breast cancer;	chr2:9949726	chr2:10003158~10006030:-
THCA	cis	rs7520050	0.966	rs12405451	ENSG00000280836.1	AL355480.1	3.62	0.000331	0.0217	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs11211224	ENSG00000280836.1	AL355480.1	3.62	0.000331	0.0217	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.933	rs6656022	ENSG00000280836.1	AL355480.1	3.62	0.000331	0.0217	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs4134386	ENSG00000280836.1	AL355480.1	3.62	0.000331	0.0217	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs12561806	ENSG00000280836.1	AL355480.1	3.62	0.000331	0.0217	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6669522	ENSG00000280836.1	AL355480.1	3.62	0.000331	0.0217	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45581219~45581321:-
THCA	cis	rs8058578	1	rs67456513	ENSG00000260911.2	RP11-196G11.2	3.62	0.000331	0.0217	0.14	0.16	Multiple myeloma;	chr16:30703507	chr16:31043150~31049868:+
THCA	cis	rs2235642	0.893	rs2076439	ENSG00000260989.1	LA16c-395F10.2	-3.62	0.000331	0.0217	-0.17	-0.16	Coronary artery disease;	chr16:1537276	chr16:1580527~1610328:+
THCA	cis	rs2179367	0.632	rs59820585	ENSG00000216906.2	RP11-350J20.9	3.62	0.000331	0.0217	0.21	0.16	Dupuytren's disease;	chr6:149350249	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.632	rs56924465	ENSG00000216906.2	RP11-350J20.9	3.62	0.000331	0.0217	0.21	0.16	Dupuytren's disease;	chr6:149350270	chr6:149904243~149906418:+
THCA	cis	rs2179367	0.568	rs62426092	ENSG00000216906.2	RP11-350J20.9	3.62	0.000331	0.0217	0.21	0.16	Dupuytren's disease;	chr6:149352720	chr6:149904243~149906418:+
THCA	cis	rs266717	0.816	rs266759	ENSG00000234197.1	ETV5-AS1	-3.62	0.000331	0.0217	-0.13	-0.16	Adiponectin levels;	chr3:186790523	chr3:186079170~186080947:+
THCA	cis	rs2629751	0.962	rs2629799	ENSG00000214198.6	RP11-642P15.1	-3.62	0.000331	0.0217	-0.13	-0.16	Hepatitis C induced liver fibrosis;	chr12:104020027	chr12:103843749~103930211:-
THCA	cis	rs11658311	1	rs8074742	ENSG00000266803.1	RP1-77H15.1	3.62	0.000331	0.0217	0.33	0.16	Obsessive-compulsive symptoms;	chr17:17551882	chr17:16557985~16559269:-
THCA	cis	rs11658311	1	rs9897362	ENSG00000266803.1	RP1-77H15.1	3.62	0.000331	0.0217	0.33	0.16	Obsessive-compulsive symptoms;	chr17:17553432	chr17:16557985~16559269:-
THCA	cis	rs7819412	0.745	rs7017567	ENSG00000261451.1	RP11-981G7.1	-3.62	0.000331	0.0217	-0.21	-0.16	Triglycerides;	chr8:11076189	chr8:10433672~10438312:+
THCA	cis	rs7020830	0.931	rs3802422	ENSG00000260100.1	RP11-220I1.5	-3.62	0.000331	0.0217	-0.2	-0.16	Schizophrenia;	chr9:37097175	chr9:37078813~37079776:-
THCA	cis	rs7660883	0.897	rs342452	ENSG00000251411.1	RP11-397E7.4	-3.62	0.000331	0.0217	-0.15	-0.16	HDL cholesterol levels;	chr4:87097256	chr4:86913266~86914817:-
THCA	cis	rs1322639	0.531	rs11751421	ENSG00000226445.1	XXyac-YX65C7_A.2	3.62	0.000331	0.0217	0.19	0.16	Pulse pressure;	chr6:169174898	chr6:169213254~169239565:+
THCA	cis	rs2380205	0.517	rs2387092	ENSG00000232807.2	RP11-536K7.3	3.62	0.000331	0.0217	0.17	0.16	Breast cancer;	chr10:5918246	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.517	rs11255971	ENSG00000232807.2	RP11-536K7.3	3.62	0.000331	0.0217	0.17	0.16	Breast cancer;	chr10:5925213	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.517	rs12767690	ENSG00000232807.2	RP11-536K7.3	3.62	0.000331	0.0217	0.17	0.16	Breast cancer;	chr10:5926008	chr10:5934270~5945900:-
THCA	cis	rs2380205	0.517	rs11255974	ENSG00000232807.2	RP11-536K7.3	3.62	0.000331	0.0217	0.17	0.16	Breast cancer;	chr10:5926931	chr10:5934270~5945900:-
THCA	cis	rs2131877	0.529	rs4677813	ENSG00000238097.1	RP11-513G11.3	-3.62	0.000331	0.0217	-0.19	-0.16	Non-small cell lung cancer;	chr3:195143131	chr3:194247648~194257772:+
THCA	cis	rs6494488	0.5	rs28731170	ENSG00000259635.1	AC100830.3	-3.62	0.000331	0.0217	-0.38	-0.16	Coronary artery disease;	chr15:64464900	chr15:64701248~64719602:+
THCA	cis	rs9303542	0.729	rs7211712	ENSG00000278765.1	RP5-890E16.5	-3.62	0.000331	0.0217	-0.22	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48428334	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs8073466	ENSG00000278765.1	RP5-890E16.5	-3.62	0.000331	0.0217	-0.22	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48429317	chr17:48066704~48067293:-
THCA	cis	rs10186029	0.582	rs12052695	ENSG00000270659.1	RP11-105N14.1	-3.62	0.000331	0.0217	-0.13	-0.16	Systemic sclerosis;	chr2:213138835	chr2:213152970~213153659:+
THCA	cis	rs7246657	0.722	rs2909105	ENSG00000226686.6	LINC01535	3.62	0.000331	0.0217	0.24	0.16	Coronary artery calcification;	chr19:37677005	chr19:37251912~37265535:+
THCA	cis	rs721048	0.764	rs10203263	ENSG00000242412.1	DBIL5P2	-3.62	0.000331	0.0217	-0.22	-0.16	Prostate cancer;	chr2:63227266	chr2:63117851~63119542:-
THCA	cis	rs9309473	0.848	rs9750915	ENSG00000273245.1	RP11-434P11.2	3.62	0.000331	0.0217	0.23	0.16	Metabolite levels;	chr2:73584753	chr2:73750256~73750786:-
THCA	cis	rs2228479	0.85	rs62056061	ENSG00000274627.1	RP11-104N10.2	-3.62	0.000331	0.0217	-0.29	-0.16	Skin colour saturation;	chr16:89835359	chr16:89516797~89522217:+
THCA	cis	rs4761470	1	rs4761470	ENSG00000258172.1	RP11-1105G2.4	-3.62	0.000331	0.0217	-0.26	-0.16	Estradiol plasma levels (breast cancer);	chr12:94289428	chr12:94272150~94277195:-
THCA	cis	rs4578769	0.765	rs9949825	ENSG00000265939.1	UBE2CP2	-3.62	0.000331	0.0217	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22806055	chr18:22900486~22900995:-
THCA	cis	rs73198271	0.599	rs10103169	ENSG00000254153.1	CTA-398F10.2	3.62	0.000331	0.0217	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.7	rs10103282	ENSG00000254153.1	CTA-398F10.2	3.62	0.000331	0.0217	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.74	rs964771	ENSG00000254153.1	CTA-398F10.2	-3.62	0.000331	0.0217	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8456909~8461337:-
THCA	cis	rs7819412	0.617	rs10087081	ENSG00000254948.1	OR7E158P	3.62	0.000331	0.0217	0.21	0.16	Triglycerides;	chr8:11117407	chr8:11919900~11920809:-
THCA	cis	rs9868809	0.881	rs13324142	ENSG00000270441.1	RP11-694I15.7	3.62	0.000331	0.0217	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48632014	chr3:49140086~49160851:-
THCA	cis	rs791590	0.887	rs764851	ENSG00000229664.1	RP11-536K7.5	-3.62	0.000331	0.0217	-0.28	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6005981	chr10:6025978~6036427:+
THCA	cis	rs791590	0.887	rs41294671	ENSG00000229664.1	RP11-536K7.5	-3.62	0.000331	0.0217	-0.28	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6007834	chr10:6025978~6036427:+
THCA	cis	rs11583043	0.708	rs915405	ENSG00000233184.5	RP11-421L21.3	3.62	0.000331	0.0217	0.18	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101108589	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.708	rs36023027	ENSG00000233184.5	RP11-421L21.3	3.62	0.000331	0.0217	0.18	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101109649	chr1:101025878~101087268:+
THCA	cis	rs321358	0.895	rs7131434	ENSG00000271390.1	RP11-89C3.3	3.62	0.000331	0.0217	0.27	0.16	Body mass index;	chr11:111085693	chr11:111089870~111090368:-
THCA	cis	rs909002	0.745	rs4949458	ENSG00000223382.3	RP1-65J11.1	-3.62	0.000331	0.0217	-0.16	-0.16	Intelligence (multi-trait analysis);	chr1:31676731	chr1:30824228~30834284:+
THCA	cis	rs2898279	0.801	rs2001463	ENSG00000242296.2	DEFB109P1	-3.62	0.000331	0.0217	-0.23	-0.16	Small cell lung carcinoma;	chr8:11438002	chr8:12393209~12400366:-
THCA	cis	rs2898290	0.617	rs13278965	ENSG00000254948.1	OR7E158P	-3.62	0.000331	0.0217	-0.2	-0.16	Systolic blood pressure;	chr8:11609236	chr8:11919900~11920809:-
THCA	cis	rs7819412	0.744	rs4841503	ENSG00000255046.1	RP11-297N6.4	3.62	0.000331	0.0217	0.17	0.16	Triglycerides;	chr8:11166817	chr8:11797928~11802568:-
THCA	cis	rs9527	0.518	rs12776863	ENSG00000236937.2	PTGES3P4	3.62	0.000331	0.0217	0.29	0.16	Arsenic metabolism;	chr10:102881922	chr10:102845595~102845950:+
THCA	cis	rs2814021	0.567	rs1456286	ENSG00000233643.2	RP11-491H19.1	3.62	0.000331	0.0217	0.18	0.16	Obesity-related traits;	chr10:61613229	chr10:61781745~61821246:-
THCA	cis	rs77147124	1	rs2803608	ENSG00000225292.2	RP11-57H14.3	-3.62	0.000331	0.0217	-0.22	-0.16	HDL cholesterol;	chr10:112156544	chr10:112888735~112906111:+
THCA	cis	rs7283707	0.591	rs2823454	ENSG00000229425.1	AJ006998.2	3.62	0.000331	0.0217	0.23	0.16	QRS complex (12-leadsum);	chr21:15694357	chr21:15370522~15402305:-
THCA	cis	rs427943	0.75	rs7281416	ENSG00000223768.1	LINC00205	-3.62	0.000331	0.0217	-0.15	-0.16	Body mass index;	chr21:45185924	chr21:45293285~45297354:+
THCA	cis	rs11098699	0.784	rs11930165	ENSG00000273007.1	RP11-170N16.3	3.62	0.000331	0.0217	0.13	0.16	Mosquito bite size;	chr4:123315824	chr4:122881878~122884712:-
THCA	cis	rs346923	1	rs10013113	ENSG00000226950.5	DANCR	3.62	0.000331	0.0217	0.19	0.16	Biochemical measures;	chr4:52482726	chr4:52712404~52720351:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000232546.1	RP11-458F8.1	-3.62	0.000331	0.0217	-0.13	-0.16	Aortic root size;	chr7:66521858	chr7:66848496~66858136:+
THCA	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	3.62	0.000331	0.0217	0.19	0.16	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
THCA	cis	rs6598955	0.756	rs10902723	ENSG00000236782.4	RP11-96L14.7	-3.62	0.000331	0.0217	-0.2	-0.16	Obesity-related traits;	chr1:26242051	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.724	rs7526545	ENSG00000236782.4	RP11-96L14.7	-3.62	0.000331	0.0217	-0.2	-0.16	Obesity-related traits;	chr1:26243499	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.724	rs869683	ENSG00000236782.4	RP11-96L14.7	-3.62	0.000331	0.0217	-0.2	-0.16	Obesity-related traits;	chr1:26244502	chr1:26169947~26171821:-
THCA	cis	rs2839627	0.561	rs1107830	ENSG00000225218.1	AP001628.6	3.62	0.000331	0.0217	0.24	0.16	Information processing speed;	chr21:42854987	chr21:42831040~42836477:-
THCA	cis	rs2299682	0.826	rs6077552	ENSG00000230506.1	RP11-416N4.4	3.62	0.000331	0.0217	0.28	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9490928	chr20:10173520~10196990:+
THCA	cis	rs7829975	0.577	rs7816329	ENSG00000253981.4	ALG1L13P	-3.62	0.000331	0.0217	-0.17	-0.16	Mood instability;	chr8:8686333	chr8:8236003~8244667:-
THCA	cis	rs7903847	0.642	rs6584127	ENSG00000225850.3	RP11-452K12.4	3.62	0.000331	0.0217	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97383191	chr10:97334564~97343203:+
THCA	cis	rs9860428	0.526	rs9834353	ENSG00000240057.4	RP11-572M11.4	-3.62	0.000331	0.0217	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942339	chr3:113019532~113183301:+
THCA	cis	rs4568518	0.616	rs17661083	ENSG00000279048.1	RP11-511H23.2	3.62	0.000331	0.0217	0.1	0.16	Measles;	chr7:17965230	chr7:17940503~17942922:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000230295.1	RP11-458F8.2	3.62	0.000331	0.0217	0.13	0.16	Aortic root size;	chr7:66597493	chr7:66880708~66882981:+
THCA	cis	rs7903847	0.642	rs61863819	ENSG00000225850.3	RP11-452K12.4	3.62	0.000331	0.0217	0.17	0.16	Granulocyte percentage of myeloid white cells;	chr10:97382643	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.667	rs11189181	ENSG00000225850.3	RP11-452K12.4	3.62	0.000331	0.0217	0.17	0.16	Granulocyte percentage of myeloid white cells;	chr10:97384397	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs11189172	ENSG00000225850.3	RP11-452K12.4	3.62	0.000331	0.0217	0.17	0.16	Granulocyte percentage of myeloid white cells;	chr10:97375458	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs12359257	ENSG00000225850.3	RP11-452K12.4	3.62	0.000331	0.0217	0.17	0.16	Granulocyte percentage of myeloid white cells;	chr10:97376602	chr10:97334564~97343203:+
THCA	cis	rs975752	0.717	rs4917887	ENSG00000227492.1	RP11-316M21.6	3.62	0.000331	0.0217	0.32	0.16	Schizophrenia;	chr10:100190351	chr10:100229667~100234000:+
THCA	cis	rs2299587	0.56	rs3913556	ENSG00000253671.1	RP11-806O11.1	-3.62	0.000331	0.0217	-0.2	-0.16	Economic and political preferences;	chr8:17923892	chr8:17808941~17820868:+
THCA	cis	rs479105	0.603	rs1860385	ENSG00000278356.1	RP11-372B4.3	3.62	0.000331	0.0217	0.16	0.16	Gut microbiota (bacterial taxa);	chr12:3255529	chr12:2885819~2886329:+
THCA	cis	rs7665090	1	rs735404	ENSG00000251288.2	RP11-10L12.2	-3.62	0.000332	0.0217	-0.21	-0.16	Primary biliary cholangitis;	chr4:102632508	chr4:102751401~102752641:+
THCA	cis	rs9425766	0.679	rs12563301	ENSG00000270084.1	GAS5-AS1	-3.62	0.000332	0.0217	-0.17	-0.16	Life satisfaction;	chr1:174090924	chr1:173863248~173863941:+
THCA	cis	rs987724	0.515	rs344079	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837783	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs344080	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837996	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs344082	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838290	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs344084	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838591	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs344087	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156842608	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs4680309	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156865807	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs2874488	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868027	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs6765353	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868755	chr3:156671862~156674378:-
THCA	cis	rs987724	0.515	rs7638330	ENSG00000243926.1	TIPARP-AS1	3.62	0.000332	0.0217	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156869976	chr3:156671862~156674378:-
THCA	cis	rs3750082	0.889	rs6972006	ENSG00000205763.12	RP9P	3.62	0.000332	0.0217	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32898680	chr7:32916815~32943176:-
THCA	cis	rs3758911	0.828	rs11212207	ENSG00000255353.1	RP11-382M14.1	3.62	0.000332	0.0217	0.21	0.16	Coronary artery disease;	chr11:107404796	chr11:107176286~107177530:+
THCA	cis	rs2836974	0.897	rs7280375	ENSG00000255568.3	BRWD1-AS2	-3.62	0.000332	0.0217	-0.14	-0.16	Cognitive function;	chr21:39180482	chr21:39313935~39314962:+
THCA	cis	rs9329221	0.507	rs12678938	ENSG00000261451.1	RP11-981G7.1	-3.62	0.000332	0.0217	-0.21	-0.16	Neuroticism;	chr8:10159459	chr8:10433672~10438312:+
THCA	cis	rs7264396	0.635	rs6060688	ENSG00000088340.14	FER1L4	-3.62	0.000332	0.0217	-0.16	-0.16	Total cholesterol levels;	chr20:35928809	chr20:35558737~35607562:-
THCA	cis	rs2880765	0.743	rs4551990	ENSG00000218052.5	ADAMTS7P4	-3.62	0.000332	0.0217	-0.19	-0.16	Coronary artery disease;	chr15:85472056	chr15:85255369~85330334:-
THCA	cis	rs28830936	1	rs2412622	ENSG00000250379.1	RP11-23P13.4	3.62	0.000332	0.0217	0.19	0.16	Diastolic blood pressure;	chr15:41668113	chr15:41825099~41827936:-
THCA	cis	rs910316	1	rs7145159	ENSG00000259138.1	RP11-950C14.7	3.62	0.000332	0.0217	0.14	0.16	Height;	chr14:75116565	chr14:75127153~75136930:+
THCA	cis	rs1923243	0.743	rs12724780	ENSG00000223479.3	RP4-788P17.1	3.62	0.000332	0.0217	0.18	0.16	Migraine;	chr1:73120242	chr1:73635216~73715214:+
THCA	cis	rs9291683	0.53	rs11723970	ENSG00000261490.1	RP11-448G15.3	3.62	0.000332	0.0217	0.1	0.16	Bone mineral density;	chr4:9978838	chr4:10068089~10073019:-
THCA	cis	rs3733585	0.805	rs882222	ENSG00000261490.1	RP11-448G15.3	3.62	0.000332	0.0217	0.1	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9979670	chr4:10068089~10073019:-
THCA	cis	rs2338	1	rs2206603	ENSG00000272279.1	RP11-157J24.2	-3.62	0.000332	0.0217	-0.22	-0.16	Response to platinum-based agents;	chr6:1573521	chr6:1528364~1528911:-
THCA	cis	rs4788570	0.584	rs4788548	ENSG00000260593.1	RP11-432I5.2	-3.62	0.000332	0.0218	-0.26	-0.16	Intelligence (multi-trait analysis);	chr16:71621458	chr16:71623708~71626816:-
THCA	cis	rs7208859	0.673	rs216435	ENSG00000264242.2	RP11-271K11.1	3.62	0.000332	0.0218	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30553697~30558962:+
THCA	cis	rs6589219	0.954	rs3802841	ENSG00000196167.8	COLCA1	-3.62	0.000332	0.0218	-0.18	-0.16	Colorectal cancer;	chr11:111300947	chr11:111290787~111305045:-
THCA	cis	rs6589219	0.954	rs3802842	ENSG00000196167.8	COLCA1	-3.62	0.000332	0.0218	-0.18	-0.16	Colorectal cancer;	chr11:111300984	chr11:111290787~111305045:-
THCA	cis	rs6589219	0.954	rs3802840	ENSG00000196167.8	COLCA1	3.62	0.000332	0.0218	0.18	0.16	Colorectal cancer;	chr11:111300921	chr11:111290787~111305045:-
THCA	cis	rs6920372	0.799	rs9480947	ENSG00000223537.2	RP5-919F19.5	-3.62	0.000332	0.0218	-0.16	-0.16	Height;	chr6:109397362	chr6:109487906~109506800:+
THCA	cis	rs5753037	0.869	rs5763649	ENSG00000279699.1	RP1-102K2.9	3.62	0.000332	0.0218	0.16	0.16	Type 1 diabetes;	chr22:29965396	chr22:30275215~30276951:-
THCA	cis	rs6030712	0.723	rs1291139	ENSG00000213979.3	RPL7AP14	3.62	0.000332	0.0218	0.26	0.16	Height;	chr20:36887791	chr20:37444733~37445534:-
THCA	cis	rs6030712	0.723	rs1291141	ENSG00000213979.3	RPL7AP14	3.62	0.000332	0.0218	0.26	0.16	Height;	chr20:36890036	chr20:37444733~37445534:-
THCA	cis	rs7176527	0.848	rs72630461	ENSG00000176700.18	SCAND2P	3.62	0.000332	0.0218	0.16	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84696913	chr15:84631451~84647478:+
THCA	cis	rs6920965	0.527	rs584032	ENSG00000237742.5	RP11-624M8.1	3.62	0.000332	0.0218	0.14	0.16	High light scatter reticulocyte count;	chr6:125843857	chr6:125578558~125749190:-
THCA	cis	rs3131513	1	rs3131513	ENSG00000225643.1	RP11-70P17.1	-3.62	0.000332	0.0218	-0.2	-0.16	Alcohol dependence;	chr1:24866664	chr1:25581478~25590356:+
THCA	cis	rs4568518	0.616	rs11766489	ENSG00000279048.1	RP11-511H23.2	3.62	0.000332	0.0218	0.1	0.16	Measles;	chr7:17964047	chr7:17940503~17942922:+
THCA	cis	rs4568518	0.616	rs11766586	ENSG00000279048.1	RP11-511H23.2	3.62	0.000332	0.0218	0.1	0.16	Measles;	chr7:17964342	chr7:17940503~17942922:+
THCA	cis	rs7312933	0.558	rs11181501	ENSG00000257225.1	RP11-328C8.4	-3.62	0.000332	0.0218	-0.17	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42428869	chr12:42459366~42466128:+
THCA	cis	rs600231	0.706	rs3782091	ENSG00000260233.3	SSSCA1-AS1	-3.62	0.000332	0.0218	-0.13	-0.16	Bone mineral density;	chr11:65569012	chr11:65568482~65570423:-
THCA	cis	rs847649	0.732	rs6465876	ENSG00000234715.1	CTB-107G13.1	-3.62	0.000332	0.0218	-0.18	-0.16	Morning vs. evening chronotype;	chr7:102857122	chr7:103445207~103514007:+
THCA	cis	rs7826238	0.502	rs10503377	ENSG00000254153.1	CTA-398F10.2	-3.62	0.000332	0.0218	-0.19	-0.16	Systolic blood pressure;	chr8:8520912	chr8:8456909~8461337:-
THCA	cis	rs8040855	0.627	rs11634975	ENSG00000225151.9	GOLGA2P7	-3.62	0.000332	0.0218	-0.23	-0.16	Bulimia nervosa;	chr15:85063247	chr15:84199311~84230136:-
THCA	cis	rs10984970	0.826	rs10984964	ENSG00000226752.6	PSMD5-AS1	3.62	0.000332	0.0218	0.42	0.16	Lung cancer;	chr9:120597522	chr9:120824828~120854385:+
THCA	cis	rs12893668	0.628	rs57072546	ENSG00000258735.1	LINC00637	-3.62	0.000332	0.0218	-0.22	-0.16	Reticulocyte count;	chr14:103597386	chr14:103847721~103858049:+
THCA	cis	rs1005277	0.579	rs2474571	ENSG00000151963.4	RP11-775A3.1	-3.62	0.000332	0.0218	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:37883594~37884109:+
THCA	cis	rs7819412	0.522	rs10088853	ENSG00000261451.1	RP11-981G7.1	-3.62	0.000332	0.0218	-0.22	-0.16	Triglycerides;	chr8:11130457	chr8:10433672~10438312:+
THCA	cis	rs61142792	1	rs7734910	ENSG00000272459.1	RP11-1277A3.3	3.62	0.000332	0.0218	0.37	0.16	Alzheimer disease and age of onset;	chr5:177559299	chr5:177554824~177555364:+
THCA	cis	rs8053891	0.507	rs10852510	ENSG00000279206.1	RP5-991G20.6	3.62	0.000332	0.0218	0.17	0.16	Coronary artery disease;	chr16:71992142	chr16:72772673~72773272:+
THCA	cis	rs9863	0.931	rs34180676	ENSG00000269938.1	RP11-214K3.20	-3.62	0.000332	0.0218	-0.19	-0.16	White blood cell count;	chr12:123946972	chr12:123968023~123968579:-
THCA	cis	rs9863	0.931	rs7955815	ENSG00000269938.1	RP11-214K3.20	-3.62	0.000332	0.0218	-0.19	-0.16	White blood cell count;	chr12:123948159	chr12:123968023~123968579:-
THCA	cis	rs897984	0.683	rs12926237	ENSG00000260911.2	RP11-196G11.2	-3.62	0.000332	0.0218	-0.14	-0.16	Dementia with Lewy bodies;	chr16:30826275	chr16:31043150~31049868:+
THCA	cis	rs237743	1	rs237743	ENSG00000222365.1	SNORD12B	3.62	0.000332	0.0218	0.21	0.16	Height;	chr20:49286482	chr20:49280319~49280409:+
THCA	cis	rs6546886	0.912	rs34201525	ENSG00000235499.1	AC073046.25	3.62	0.000333	0.0218	0.16	0.16	Dialysis-related mortality;	chr2:74071867	chr2:73985132~73986343:+
THCA	cis	rs3770081	0.793	rs73943946	ENSG00000272564.1	RP11-548P2.2	-3.62	0.000333	0.0218	-0.32	-0.16	Facial emotion recognition (sad faces);	chr2:85999500	chr2:85904279~85904727:+
THCA	cis	rs7147624	1	rs4902408	ENSG00000276116.2	FUT8-AS1	3.62	0.000333	0.0218	0.23	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65645183	chr14:65411170~65412690:-
THCA	cis	rs11671005	0.735	rs34188294	ENSG00000269600.1	AC016629.3	-3.62	0.000333	0.0218	-0.25	-0.16	Mean platelet volume;	chr19:58408190	chr19:58593896~58599355:-
THCA	cis	rs9400467	0.537	rs12111379	ENSG00000255389.1	C6orf3	3.62	0.000333	0.0218	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111113606	chr6:111599875~111602295:+
THCA	cis	rs4938303	0.788	rs12803249	ENSG00000254851.1	RP11-109L13.1	3.62	0.000333	0.0218	0.25	0.16	Triglycerides;	chr11:116665701	chr11:117135528~117138582:+
THCA	cis	rs7088591	0.867	rs16911541	ENSG00000276818.1	AC026393.1	3.62	0.000333	0.0218	0.33	0.16	Blood pressure;	chr10:57997932	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs16911544	ENSG00000276818.1	AC026393.1	3.62	0.000333	0.0218	0.33	0.16	Blood pressure;	chr10:57998232	chr10:57095699~57095781:+
THCA	cis	rs9467773	0.62	rs1490488	ENSG00000228223.2	HCG11	-3.62	0.000333	0.0218	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26523450~26526579:+
THCA	cis	rs9467773	0.62	rs2494692	ENSG00000228223.2	HCG11	-3.62	0.000333	0.0218	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26523450~26526579:+
THCA	cis	rs3806843	0.608	rs155364	ENSG00000202515.1	VTRNA1-3	-3.62	0.000333	0.0218	-0.2	-0.16	Depressive symptoms (multi-trait analysis);	chr5:140966883	chr5:140726158~140726246:+
THCA	cis	rs1729951	0.575	rs168635	ENSG00000239213.4	NCK1-AS1	3.62	0.000333	0.0218	0.14	0.16	Neuroticism;	chr3:136980236	chr3:136841726~136862054:-
THCA	cis	rs73173548	0.502	rs4601863	ENSG00000247828.6	TMEM161B-AS1	3.62	0.000333	0.0218	0.15	0.16	Macular telangiectasia type 2;	chr5:88433804	chr5:88268895~88436685:+
THCA	cis	rs73173548	0.502	rs34634636	ENSG00000247828.6	TMEM161B-AS1	3.62	0.000333	0.0218	0.15	0.16	Macular telangiectasia type 2;	chr5:88435989	chr5:88268895~88436685:+
THCA	cis	rs448720	1	rs430610	ENSG00000260657.2	RP11-315D16.4	3.62	0.000333	0.0218	0.2	0.16	Cognitive performance;	chr15:67906284	chr15:68267792~68277994:-
THCA	cis	rs1198872	0.892	rs10427170	ENSG00000243819.4	RN7SL832P	-3.61	0.000333	0.0218	-0.13	-0.16	Cardiac Troponin-T levels;	chr2:10762044	chr2:10690344~10692099:+
THCA	cis	rs2527866	0.509	rs2706177	ENSG00000234450.1	AC005534.6	3.61	0.000333	0.0218	0.18	0.16	Quantitative traits;	chr7:157295036	chr7:156633355~156633787:+
THCA	cis	rs6427356	1	rs1176551	ENSG00000237189.1	RP11-85G21.2	3.61	0.000333	0.0218	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157165865	chr1:157287703~157288053:-
THCA	cis	rs412658	0.535	rs1651558	ENSG00000268117.1	VN1R84P	3.61	0.000333	0.0218	0.21	0.16	Telomere length;	chr19:21906773	chr19:21719801~21720035:-
THCA	cis	rs3176789	0.647	rs12824297	ENSG00000256673.1	RP11-599J14.2	3.61	0.000333	0.0218	0.2	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767068	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.647	rs12824308	ENSG00000256673.1	RP11-599J14.2	3.61	0.000333	0.0218	0.2	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767088	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.647	rs12817268	ENSG00000256673.1	RP11-599J14.2	3.61	0.000333	0.0218	0.2	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767157	chr12:9398355~9414851:-
THCA	cis	rs1555322	1	rs2425040	ENSG00000126005.14	MMP24-AS1	-3.61	0.000333	0.0218	-0.23	-0.16	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35216462~35278131:-
THCA	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-3.61	0.000333	0.0218	-0.19	-0.16	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
THCA	cis	rs301901	0.772	rs7711452	ENSG00000250155.1	CTD-2353F22.1	-3.61	0.000333	0.0218	-0.17	-0.16	Height;	chr5:37216735	chr5:36666214~36725195:-
THCA	cis	rs7246760	0.737	rs57296518	ENSG00000278611.1	CTC-543D15.8	-3.61	0.000333	0.0218	-0.25	-0.16	Pursuit maintenance gain;	chr19:9709274	chr19:9538733~9539734:+
THCA	cis	rs929354	0.772	rs1182442	ENSG00000224629.1	RP5-1142J19.2	3.61	0.000333	0.0218	0.16	0.16	Body mass index;	chr7:157233939	chr7:157263022~157263229:-
THCA	cis	rs7264396	0.887	rs224362	ENSG00000261582.1	RP4-614O4.11	-3.61	0.000333	0.0218	-0.17	-0.16	Total cholesterol levels;	chr20:35474817	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs224364	ENSG00000261582.1	RP4-614O4.11	-3.61	0.000333	0.0218	-0.17	-0.16	Total cholesterol levels;	chr20:35476040	chr20:35267885~35280043:-
THCA	cis	rs73193808	0.851	rs2223036	ENSG00000273017.1	AP000240.9	-3.61	0.000333	0.0218	-0.21	-0.16	Coronary artery disease;	chr21:29232461	chr21:29359002~29359453:+
THCA	cis	rs28830936	0.966	rs11635415	ENSG00000250379.1	RP11-23P13.4	3.61	0.000333	0.0218	0.19	0.16	Diastolic blood pressure;	chr15:41841304	chr15:41825099~41827936:-
THCA	cis	rs1005277	0.563	rs2505215	ENSG00000120555.12	SEPT7P9	3.61	0.000333	0.0218	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.563	rs2505216	ENSG00000120555.12	SEPT7P9	3.61	0.000333	0.0218	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2749612	ENSG00000120555.12	SEPT7P9	3.61	0.000333	0.0218	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38383069~38402916:-
THCA	cis	rs958025	1	rs958025	ENSG00000261143.1	ADAMTS7P3	-3.61	0.000333	0.0218	-0.24	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78467006	chr15:77976042~77993057:+
THCA	cis	rs28602670	1	rs28602670	ENSG00000261143.1	ADAMTS7P3	-3.61	0.000333	0.0218	-0.24	-0.16	Post bronchodilator FEV1;	chr15:78475825	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.694	rs10851906	ENSG00000261143.1	ADAMTS7P3	-3.61	0.000333	0.0218	-0.24	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78482334	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs2036533	ENSG00000261143.1	ADAMTS7P3	-3.61	0.000333	0.0218	-0.24	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78489345	chr15:77976042~77993057:+
THCA	cis	rs7174348	1	rs7174348	ENSG00000261143.1	ADAMTS7P3	-3.61	0.000333	0.0218	-0.24	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78500097	chr15:77976042~77993057:+
THCA	cis	rs6430585	0.527	rs961360	ENSG00000231890.6	DARS-AS1	-3.61	0.000333	0.0218	-0.19	-0.16	Corneal structure;	chr2:135636088	chr2:135985176~136022593:+
THCA	cis	rs9860428	0.526	rs7615572	ENSG00000240057.4	RP11-572M11.4	-3.61	0.000333	0.0218	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112934486	chr3:113019532~113183301:+
THCA	cis	rs62158211	0.955	rs1823125	ENSG00000240356.5	RP11-395L14.11	3.61	0.000333	0.0218	0.22	0.16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113610502~113627090:-
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000184274.3	LINC00315	-3.61	0.000333	0.0218	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45300245~45305257:-
THCA	cis	rs17270561	0.609	rs7746609	ENSG00000272462.2	U91328.19	3.61	0.000333	0.0218	0.14	0.16	Iron status biomarkers;	chr6:25727768	chr6:25992662~26001775:+
THCA	cis	rs17772222	0.682	rs2274736	ENSG00000222990.1	RNU4-22P	3.61	0.000333	0.0218	0.2	0.16	Coronary artery calcification;	chr14:88472308	chr14:88513498~88513663:+
THCA	cis	rs875971	0.545	rs6950988	ENSG00000230295.1	RP11-458F8.2	3.61	0.000333	0.0218	0.15	0.16	Aortic root size;	chr7:66511428	chr7:66880708~66882981:+
THCA	cis	rs875971	0.505	rs6955582	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000333	0.0218	-0.14	-0.16	Aortic root size;	chr7:65966699	chr7:66848496~66858136:+
THCA	cis	rs1978968	0.707	rs13058527	ENSG00000280007.1	AC008079.10	3.61	0.000333	0.0218	0.17	0.16	Presence of antiphospholipid antibodies;	chr22:17930163	chr22:18110759~18131154:-
THCA	cis	rs4268898	1	rs2303294	ENSG00000242628.4	AC009228.1	-3.61	0.000333	0.0218	-0.2	-0.16	Asthma;	chr2:24209751	chr2:24214381~24221516:+
THCA	cis	rs2179367	0.92	rs560051	ENSG00000223701.3	RAET1E-AS1	3.61	0.000333	0.0218	0.21	0.16	Dupuytren's disease;	chr6:149345841	chr6:149884431~149919508:+
THCA	cis	rs7631605	0.783	rs11129744	ENSG00000224080.1	UBE2FP1	3.61	0.000333	0.0218	0.19	0.16	Cerebrospinal P-tau181p levels;	chr3:36924958	chr3:37143512~37143958:-
THCA	cis	rs11083475	0.599	rs7250443	ENSG00000269050.1	CTC-360G5.6	-3.61	0.000333	0.0218	-0.19	-0.16	Heart rate;	chr19:38776705	chr19:38870159~38873763:+
THCA	cis	rs2185341	0.788	rs12089677	ENSG00000218510.5	LINC00339	3.61	0.000333	0.0218	0.2	0.16	Amyotrophic lateral sclerosis;	chr1:22356537	chr1:22025188~22031223:+
THCA	cis	rs6570726	0.935	rs449377	ENSG00000270638.1	RP3-466P17.1	3.61	0.000333	0.0218	0.13	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145735570~145737218:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000232546.1	RP11-458F8.1	3.61	0.000333	0.0218	0.13	0.16	Aortic root size;	chr7:66545590	chr7:66848496~66858136:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000232546.1	RP11-458F8.1	3.61	0.000333	0.0218	0.13	0.16	Aortic root size;	chr7:66546680	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000232546.1	RP11-458F8.1	3.61	0.000333	0.0218	0.13	0.16	Aortic root size;	chr7:66550702	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs62465434	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000333	0.0218	-0.13	-0.16	Aortic root size;	chr7:66540165	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000232546.1	RP11-458F8.1	-3.61	0.000333	0.0218	-0.13	-0.16	Aortic root size;	chr7:66542376	chr7:66848496~66858136:+
THCA	cis	rs7838490	0.943	rs1094197	ENSG00000253553.4	RP11-586K2.1	3.61	0.000333	0.0218	0.23	0.16	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88458269	chr8:88326836~88737134:+
THCA	cis	rs7572733	0.555	rs7600269	ENSG00000231621.1	AC013264.2	-3.61	0.000333	0.0218	-0.18	-0.16	Dermatomyositis;	chr2:198058744	chr2:197197991~197199273:+
THCA	cis	rs17095355	0.584	rs12243027	ENSG00000203876.8	ADD3-AS1	-3.61	0.000333	0.0218	-0.17	-0.16	Biliary atresia;	chr10:110165059	chr10:109940104~110008381:-
THCA	cis	rs12681366	0.881	rs3019150	ENSG00000253175.1	RP11-267M23.6	3.61	0.000333	0.0218	0.21	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94420055	chr8:94565036~94565715:+
THCA	cis	rs12506899	0.967	rs16849384	ENSG00000221639.1	SNORA3	3.61	0.000334	0.0218	0.19	0.16	Tumor biomarkers;	chr4:73437153	chr4:73263960~73264084:+
THCA	cis	rs7131987	0.903	rs7302129	ENSG00000257599.1	OVCH1-AS1	-3.61	0.000334	0.0218	-0.2	-0.16	QT interval;	chr12:29262347	chr12:29389294~29487488:+
THCA	cis	rs12379034	0.611	rs7853439	ENSG00000226752.6	PSMD5-AS1	3.61	0.000334	0.0218	0.21	0.16	Rheumatoid arthritis;	chr9:120410587	chr9:120824828~120854385:+
THCA	cis	rs116095464	1	rs56700778	ENSG00000277812.1	AC021087.1	3.61	0.000334	0.0218	0.41	0.16	Breast cancer;	chr5:313071	chr5:262769~262881:+
THCA	cis	rs7824557	0.564	rs2572399	ENSG00000261451.1	RP11-981G7.1	-3.61	0.000334	0.0218	-0.21	-0.16	Retinal vascular caliber;	chr8:11377011	chr8:10433672~10438312:+
THCA	cis	rs1923243	0.649	rs66820357	ENSG00000223479.3	RP4-788P17.1	-3.61	0.000334	0.0218	-0.18	-0.16	Migraine;	chr1:72984504	chr1:73635216~73715214:+
THCA	cis	rs11102159	0.607	rs975230	ENSG00000259834.1	RP11-284N8.3	3.61	0.000334	0.0218	0.18	0.16	Schizophrenia;	chr1:110798535	chr1:110653560~110657040:-
THCA	cis	rs3018712	0.532	rs61889616	ENSG00000212093.1	AP000807.1	-3.61	0.000334	0.0218	-0.22	-0.16	Total body bone mineral density;	chr11:68644538	chr11:68506083~68506166:-
THCA	cis	rs875971	0.929	rs6970860	ENSG00000272831.1	RP11-792A8.4	3.61	0.000334	0.0218	0.1	0.16	Aortic root size;	chr7:66511647	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6957199	ENSG00000272831.1	RP11-792A8.4	3.61	0.000334	0.0218	0.1	0.16	Aortic root size;	chr7:66513532	chr7:66739829~66740385:-
THCA	cis	rs11992162	0.508	rs7003792	ENSG00000227888.4	FAM66A	-3.61	0.000334	0.0218	-0.21	-0.16	Monocyte count;	chr8:11923955	chr8:12362019~12388296:+
THCA	cis	rs763121	0.853	rs6001214	ENSG00000228274.3	RP3-508I15.9	-3.61	0.000334	0.0218	-0.19	-0.16	Menopause (age at onset);	chr22:38753150	chr22:38667585~38681820:-
THCA	cis	rs2625529	0.824	rs4777475	ENSG00000260037.4	CTD-2524L6.3	-3.61	0.000334	0.0218	-0.23	-0.16	Red blood cell count;	chr15:71925865	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.761	rs11853268	ENSG00000260037.4	CTD-2524L6.3	-3.61	0.000334	0.0218	-0.23	-0.16	Red blood cell count;	chr15:71946632	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.824	rs11072338	ENSG00000260037.4	CTD-2524L6.3	-3.61	0.000334	0.0218	-0.23	-0.16	Red blood cell count;	chr15:71953106	chr15:71818396~71823384:+
THCA	cis	rs17689437	0.918	rs11075685	ENSG00000260084.1	RP11-615I2.1	-3.61	0.000334	0.0218	-0.27	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68591532	chr16:68573782~68589512:-
THCA	cis	rs11583043	0.708	rs1060481	ENSG00000233184.5	RP11-421L21.3	3.61	0.000334	0.0218	0.18	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101081143	chr1:101025878~101087268:+
THCA	cis	rs72996113	0.938	rs11224340	ENSG00000248027.1	CTD-2383M3.1	-3.61	0.000334	0.0218	-0.3	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100637868	chr11:100684162~100687955:-
THCA	cis	rs6472235	0.681	rs34174890	ENSG00000272192.1	CTD-2532N20.1	3.61	0.000334	0.0218	0.17	0.16	Plateletcrit;Myopia (pathological);	chr8:65954892	chr8:65842752~65843331:+
THCA	cis	rs1799949	0.965	rs8067269	ENSG00000236383.6	LINC00854	-3.61	0.000334	0.0218	-0.16	-0.16	Menopause (age at onset);	chr17:43083782	chr17:43216941~43305976:-
THCA	cis	rs10089	1	rs4836370	ENSG00000245937.6	LINC01184	3.61	0.000334	0.0219	0.18	0.16	Ileal carcinoids;	chr5:128163532	chr5:127940426~128083172:-
THCA	cis	rs6496667	0.865	rs7171422	ENSG00000259262.1	NDUFA3P4	3.61	0.000334	0.0219	0.23	0.16	Rheumatoid arthritis;	chr15:90361509	chr15:90385814~90386063:+
THCA	cis	rs4908760	0.827	rs10864362	ENSG00000270282.1	RP5-1115A15.2	3.61	0.000334	0.0219	0.19	0.16	Vitiligo;	chr1:8672395	chr1:8512653~8513021:+
THCA	cis	rs733175	0.599	rs6856396	ENSG00000261490.1	RP11-448G15.3	3.61	0.000334	0.0219	0.16	0.16	Psychosis and Alzheimer's disease;	chr4:10029539	chr4:10068089~10073019:-
THCA	cis	rs7586085	1	rs6719426	ENSG00000232411.1	AC009495.3	-3.61	0.000334	0.0219	-0.18	-0.16	Total body bone mineral density;	chr2:165729056	chr2:165833048~165839098:-
THCA	cis	rs7259376	0.905	rs1975172	ENSG00000269345.1	VN1R85P	3.61	0.000334	0.0219	0.18	0.16	Menopause (age at onset);	chr19:22351801	chr19:22174766~22175191:-
THCA	cis	rs14027	0.883	rs16893027	ENSG00000245330.4	KB-1471A8.1	3.61	0.000334	0.0219	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701534	chr8:119867419~119874488:-
THCA	cis	rs2839186	0.609	rs2839189	ENSG00000215424.8	MCM3AP-AS1	-3.61	0.000334	0.0219	-0.1	-0.16	Testicular germ cell tumor;	chr21:46274443	chr21:46229217~46259390:+
THCA	cis	rs5758511	0.689	rs5758691	ENSG00000205702.9	CYP2D7	3.61	0.000334	0.0219	0.15	0.16	Birth weight;	chr22:42272498	chr22:42140203~42144577:-
THCA	cis	rs5758511	0.68	rs1001586	ENSG00000205702.9	CYP2D7	3.61	0.000334	0.0219	0.15	0.16	Birth weight;	chr22:42274287	chr22:42140203~42144577:-
THCA	cis	rs12935418	1	rs2602431	ENSG00000278985.1	RP11-303E16.9	-3.61	0.000334	0.0219	-0.22	-0.16	Mean corpuscular volume;	chr16:81037092	chr16:80982319~80984094:-
THCA	cis	rs61160187	0.582	rs11740632	ENSG00000251279.1	CTC-436P18.1	-3.61	0.000334	0.0219	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.582	rs67555188	ENSG00000251279.1	CTC-436P18.1	-3.61	0.000334	0.0219	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.582	rs67858932	ENSG00000251279.1	CTC-436P18.1	-3.61	0.000334	0.0219	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:61162070~61232040:+
THCA	cis	rs765787	0.53	rs2899381	ENSG00000259932.1	CTD-2651B20.7	3.61	0.000334	0.0219	0.2	0.16	Uric acid levels;	chr15:45237432	chr15:45198517~45199139:-
THCA	cis	rs206966	0.81	rs11614028	ENSG00000277283.1	RP1-267D11.6	3.61	0.000334	0.0219	0.2	0.16	Breast cancer;	chr12:120337791	chr12:120116907~120119000:+
THCA	cis	rs7572733	0.935	rs6434942	ENSG00000231621.1	AC013264.2	-3.61	0.000334	0.0219	-0.16	-0.16	Dermatomyositis;	chr2:197891964	chr2:197197991~197199273:+
THCA	cis	rs988712	0.921	rs1906654	ENSG00000245573.6	BDNF-AS	-3.61	0.000334	0.0219	-0.15	-0.16	Obesity;	chr11:27552861	chr11:27506838~27698174:+
THCA	cis	rs301901	0.743	rs10073054	ENSG00000250155.1	CTD-2353F22.1	-3.61	0.000334	0.0219	-0.17	-0.16	Height;	chr5:37172281	chr5:36666214~36725195:-
THCA	cis	rs10895987	0.531	rs2282498	ENSG00000197847.11	SLC22A20	-3.61	0.000334	0.0219	-0.17	-0.16	Blood protein levels;	chr11:65088514	chr11:65213840~65242757:+
THCA	cis	rs7307902	1	rs7136055	ENSG00000280054.1	RP1-197B17.7	-3.61	0.000334	0.0219	-0.19	-0.16	Obesity-related traits;	chr12:47541899	chr12:47728151~47730598:-
THCA	cis	rs10457678	0.579	rs10872496	ENSG00000225415.2	RP3-509I19.1	-3.61	0.000334	0.0219	-0.24	-0.16	Colorectal or endometrial cancer;	chr6:138837539	chr6:138822747~138823799:+
THCA	cis	rs6687821	0.515	rs7552285	ENSG00000261737.1	RP4-612B15.3	3.61	0.000334	0.0219	0.24	0.16	Yeast infection;	chr1:87017482	chr1:86703502~86704462:-
THCA	cis	rs9527	0.525	rs12770034	ENSG00000213277.3	MARCKSL1P1	3.61	0.000334	0.0219	0.18	0.16	Arsenic metabolism;	chr10:102875838	chr10:103175554~103176094:+
THCA	cis	rs12893668	0.628	rs57072546	ENSG00000252469.1	RNU7-160P	3.61	0.000334	0.0219	0.19	0.16	Reticulocyte count;	chr14:103597386	chr14:103550345~103550406:+
THCA	cis	rs683250	0.515	rs481321	ENSG00000254551.1	RP11-727A23.7	3.61	0.000334	0.0219	0.21	0.16	Subcortical brain region volumes;	chr11:83246291	chr11:83209431~83213379:-
THCA	cis	rs9634489	0.843	rs1925129	ENSG00000247400.3	DNAJC3-AS1	-3.61	0.000334	0.0219	-0.1	-0.16	Body mass index;	chr13:96397659	chr13:95648733~95676925:-
THCA	cis	rs2019137	1	rs2019137	ENSG00000234997.1	AC016745.3	-3.61	0.000334	0.0219	-0.16	-0.16	Lymphocyte counts;	chr2:113216055	chr2:113424495~113425324:+
THCA	cis	rs2019137	0.967	rs895412	ENSG00000234997.1	AC016745.3	-3.61	0.000334	0.0219	-0.16	-0.16	Lymphocyte counts;	chr2:113216387	chr2:113424495~113425324:+
THCA	cis	rs6878727	0.599	rs256610	ENSG00000253807.4	LINC01170	3.61	0.000334	0.0219	0.15	0.16	Breast cancer;	chr5:124334367	chr5:124059794~124405079:-
THCA	cis	rs9863	0.861	rs7132655	ENSG00000269938.1	RP11-214K3.20	-3.61	0.000334	0.0219	-0.19	-0.16	White blood cell count;	chr12:123954426	chr12:123968023~123968579:-
THCA	cis	rs17074492	1	rs67218188	ENSG00000214182.5	PTMAP5	3.61	0.000334	0.0219	0.19	0.16	Sjögren's syndrome;	chr13:81602732	chr13:81689911~81691072:+
THCA	cis	rs17074492	1	rs17074505	ENSG00000214182.5	PTMAP5	3.61	0.000334	0.0219	0.19	0.16	Sjögren's syndrome;	chr13:81603629	chr13:81689911~81691072:+
THCA	cis	rs11633886	0.51	rs12594473	ENSG00000259200.1	RP11-718O11.1	3.61	0.000334	0.0219	0.2	0.16	Diisocyanate-induced asthma;	chr15:45750399	chr15:45705078~45931069:+
THCA	cis	rs9400467	0.537	rs73528982	ENSG00000255389.1	C6orf3	3.61	0.000334	0.0219	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111110435	chr6:111599875~111602295:+
THCA	cis	rs2360027	0.662	rs10754384	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000335	0.0219	-0.16	-0.16	Tonsillectomy;	chr1:118608327	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.64	rs6428762	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000335	0.0219	-0.16	-0.16	Tonsillectomy;	chr1:118608494	chr1:119140396~119275973:+
THCA	cis	rs2288884	0.505	rs11666461	ENSG00000260160.1	CTC-471J1.2	-3.61	0.000335	0.0219	-0.19	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51934234	chr19:52058490~52063703:-
THCA	cis	rs6598541	0.887	rs3743264	ENSG00000278090.1	RP11-6O2.2	-3.61	0.000335	0.0219	-0.15	-0.16	Urate levels;	chr15:98739358	chr15:99028538~99031053:+
THCA	cis	rs7737355	0.947	rs39600	ENSG00000237714.1	P4HA2-AS1	3.61	0.000335	0.0219	0.23	0.16	Life satisfaction;	chr5:131492956	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs31257	ENSG00000237714.1	P4HA2-AS1	3.61	0.000335	0.0219	0.23	0.16	Life satisfaction;	chr5:131493022	chr5:132184876~132192808:+
THCA	cis	rs5753037	0.869	rs5763559	ENSG00000279699.1	RP1-102K2.9	3.61	0.000335	0.0219	0.16	0.16	Type 1 diabetes;	chr22:29862368	chr22:30275215~30276951:-
THCA	cis	rs6510186	0.887	rs2047336	ENSG00000267662.1	AC007796.1	-3.61	0.000335	0.0219	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr19:31169743	chr19:31348881~31417794:+
THCA	cis	rs889312	1	rs889312	ENSG00000271828.1	CTD-2310F14.1	-3.61	0.000335	0.0219	-0.23	-0.16	Breast cancer (early onset);Breast cancer;	chr5:56736057	chr5:56927874~56929573:+
THCA	cis	rs478304	0.654	rs12289836	ENSG00000255557.1	RP11-770G2.2	-3.61	0.000335	0.0219	-0.2	-0.16	Acne (severe);	chr11:65669417	chr11:65745729~65771585:+
THCA	cis	rs41294858	1	rs41294860	ENSG00000232876.1	CTA-212D2.2	-3.61	0.000335	0.0219	-0.34	-0.16	Red blood cell count;	chr6:135092931	chr6:135055033~135060550:+
THCA	cis	rs41294858	1	rs56076748	ENSG00000232876.1	CTA-212D2.2	-3.61	0.000335	0.0219	-0.34	-0.16	Red blood cell count;	chr6:135093071	chr6:135055033~135060550:+
THCA	cis	rs721048	0.85	rs17348134	ENSG00000242412.1	DBIL5P2	-3.61	0.000335	0.0219	-0.22	-0.16	Prostate cancer;	chr2:63208061	chr2:63117851~63119542:-
THCA	cis	rs72482608	0.835	rs7527200	ENSG00000271811.1	RP1-79C4.4	3.61	0.000335	0.0219	0.2	0.16	Emphysema imaging phenotypes;	chr1:170771949	chr1:170667381~170669425:+
THCA	cis	rs1577917	0.917	rs12665464	ENSG00000220563.1	PKMP3	-3.61	0.000335	0.0219	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85864415	chr6:85659892~85660606:-
THCA	cis	rs16982689	1	rs16982689	ENSG00000211644.2	IGLV1-51	3.61	0.000335	0.0219	0.2	0.16	Attention function in attention deficit hyperactive disorder;	chr22:22081907	chr22:22322472~22322980:+
THCA	cis	rs10090774	0.786	rs11776239	ENSG00000280303.2	ERICD	-3.61	0.000335	0.0219	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708602	chr8:140636281~140638283:+
THCA	cis	rs3760982	0.585	rs68073292	ENSG00000267058.1	RP11-15A1.3	-3.61	0.000335	0.0219	-0.14	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787249	chr19:43891804~43901805:-
THCA	cis	rs3760982	0.585	rs62116964	ENSG00000267058.1	RP11-15A1.3	-3.61	0.000335	0.0219	-0.14	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787834	chr19:43891804~43901805:-
THCA	cis	rs9902453	0.967	rs12450956	ENSG00000250462.7	LRRC37BP1	3.61	0.000335	0.0219	0.13	0.16	Coffee consumption (cups per day);	chr17:30202007	chr17:30629680~30637466:+
THCA	cis	rs854765	0.522	rs63721860	ENSG00000281749.1	Y_RNA	3.61	0.000335	0.0219	0.2	0.16	Total body bone mineral density;	chr17:17926262	chr17:18001101~18001195:-
THCA	cis	rs2014572	0.933	rs8109882	ENSG00000276449.1	AC004076.5	3.61	0.000335	0.0219	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57244250	chr19:57449689~57453011:+
THCA	cis	rs2014572	0.901	rs35658377	ENSG00000276449.1	AC004076.5	3.61	0.000335	0.0219	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57244259	chr19:57449689~57453011:+
THCA	cis	rs71007656	1	rs71007656	ENSG00000120555.12	SEPT7P9	3.61	0.000335	0.0219	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.522	rs289648	ENSG00000120555.12	SEPT7P9	3.61	0.000335	0.0219	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38383069~38402916:-
THCA	cis	rs4588572	0.688	rs1594055	ENSG00000245556.2	SCAMP1-AS1	-3.61	0.000335	0.0219	-0.13	-0.16	Triglycerides;	chr5:78399264	chr5:78342365~78360507:-
THCA	cis	rs6921919	0.887	rs7766356	ENSG00000280107.1	AL022393.9	-3.61	0.000335	0.0219	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28170845~28172521:+
THCA	cis	rs1560104	0.597	rs4781299	ENSG00000262801.4	U91319.1	-3.61	0.000335	0.0219	-0.19	-0.16	Obesity-related traits;	chr16:12613756	chr16:13246316~13562918:+
THCA	cis	rs875971	0.862	rs2024192	ENSG00000223473.2	GS1-124K5.3	-3.61	0.000335	0.0219	-0.11	-0.16	Aortic root size;	chr7:66576460	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6955837	ENSG00000223473.2	GS1-124K5.3	-3.61	0.000335	0.0219	-0.11	-0.16	Aortic root size;	chr7:66578155	chr7:66491049~66493566:-
THCA	cis	rs875971	0.825	rs10281499	ENSG00000223473.2	GS1-124K5.3	-3.61	0.000335	0.0219	-0.11	-0.16	Aortic root size;	chr7:66583979	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs4718377	ENSG00000223473.2	GS1-124K5.3	-3.61	0.000335	0.0219	-0.11	-0.16	Aortic root size;	chr7:66584691	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs10278014	ENSG00000223473.2	GS1-124K5.3	-3.61	0.000335	0.0219	-0.11	-0.16	Aortic root size;	chr7:66586277	chr7:66491049~66493566:-
THCA	cis	rs6921919	0.887	rs7766356	ENSG00000273712.1	RP5-874C20.7	3.61	0.000335	0.0219	0.24	0.16	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28315613~28315883:-
THCA	cis	rs17767294	0.612	rs9461424	ENSG00000217539.2	IQCB2P	3.61	0.000335	0.0219	0.34	0.16	Parkinson's disease;	chr6:27951623	chr6:28010723~28012355:+
THCA	cis	rs301901	0.772	rs301874	ENSG00000250155.1	CTD-2353F22.1	-3.61	0.000335	0.0219	-0.17	-0.16	Height;	chr5:37094189	chr5:36666214~36725195:-
THCA	cis	rs972578	0.837	rs3788601	ENSG00000274717.1	RP1-47A17.1	-3.61	0.000335	0.0219	-0.17	-0.16	Mean platelet volume;	chr22:42931520	chr22:42791814~42794313:-
THCA	cis	rs73173548	0.502	rs6452789	ENSG00000247828.6	TMEM161B-AS1	3.61	0.000335	0.0219	0.15	0.16	Macular telangiectasia type 2;	chr5:88429498	chr5:88268895~88436685:+
THCA	cis	rs34779708	0.931	rs7923217	ENSG00000233200.1	RP11-324I22.2	3.61	0.000335	0.0219	0.2	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35219894~35230598:-
THCA	cis	rs72634258	0.554	rs17374292	ENSG00000224315.2	RPL7P7	-3.61	0.000335	0.0219	-0.3	-0.16	Inflammatory bowel disease;	chr1:7821174	chr1:8786211~8786913:-
THCA	cis	rs13325613	0.834	rs13084057	ENSG00000223552.1	RP11-24F11.2	3.61	0.000335	0.0219	0.28	0.16	Monocyte count;	chr3:46143233	chr3:46364955~46407059:-
THCA	cis	rs6600671	0.934	rs11249429	ENSG00000226067.5	CH17-118O6.2	-3.61	0.000335	0.0219	-0.16	-0.16	Hip geometry;	chr1:121549282	chr1:120913275~121009291:+
THCA	cis	rs10858047	0.7	rs178445	ENSG00000231128.4	RP5-1073O3.2	3.61	0.000335	0.0219	0.23	0.16	Autism;	chr1:114627245	chr1:113812379~113829171:+
THCA	cis	rs2898290	0.617	rs13278965	ENSG00000269918.1	AF131215.9	3.61	0.000335	0.0219	0.18	0.16	Systolic blood pressure;	chr8:11609236	chr8:11104691~11106704:-
THCA	cis	rs7267979	1	rs3761117	ENSG00000276952.1	RP5-965G21.6	-3.61	0.000335	0.0219	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25284915~25285588:-
THCA	cis	rs6933660	0.8	rs963193	ENSG00000219395.2	HSPA8P15	3.61	0.000335	0.0219	0.14	0.16	Menarche (age at onset);	chr6:151468220	chr6:151411259~151413945:-
THCA	cis	rs13437751	0.764	rs55680273	ENSG00000223558.1	TRIM60P17	3.61	0.000335	0.0219	0.35	0.16	QT interval (drug interaction);	chr7:63938166	chr7:64085560~64086576:+
THCA	cis	rs9329221	0.537	rs13254175	ENSG00000261451.1	RP11-981G7.1	3.61	0.000335	0.0219	0.19	0.16	Neuroticism;	chr8:10121262	chr8:10433672~10438312:+
THCA	cis	rs972540	1	rs62195931	ENSG00000229647.1	AC007879.7	-3.61	0.000335	0.0219	-0.19	-0.16	Body mass index;	chr2:206389551	chr2:207239650~207245887:+
THCA	cis	rs253959	0.739	rs37181	ENSG00000250015.1	CTC-339F2.2	-3.61	0.000336	0.0219	-0.15	-0.16	Bipolar disorder and schizophrenia;	chr5:116294307	chr5:116302354~116304134:-
THCA	cis	rs62289301	0.637	rs13124984	ENSG00000273133.1	RP11-799M12.2	3.61	0.000336	0.0219	0.21	0.16	Joint mobility (Beighton score);	chr4:15419835	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs10488970	ENSG00000273133.1	RP11-799M12.2	3.61	0.000336	0.0219	0.21	0.16	Joint mobility (Beighton score);	chr4:15420023	chr4:15563698~15564253:-
THCA	cis	rs2360027	0.662	rs10923630	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000336	0.022	-0.16	-0.16	Tonsillectomy;	chr1:118609994	chr1:119140396~119275973:+
THCA	cis	rs1862618	0.853	rs252921	ENSG00000234553.1	AC022431.3	-3.61	0.000336	0.022	-0.19	-0.16	Initial pursuit acceleration;	chr5:56841960	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs33325	ENSG00000234553.1	AC022431.3	-3.61	0.000336	0.022	-0.19	-0.16	Initial pursuit acceleration;	chr5:56846720	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.802	rs42769	ENSG00000234553.1	AC022431.3	-3.61	0.000336	0.022	-0.19	-0.16	Initial pursuit acceleration;	chr5:56848325	chr5:56536583~56537826:-
THCA	cis	rs11779988	0.545	rs436506	ENSG00000253671.1	RP11-806O11.1	3.61	0.000336	0.022	0.22	0.16	Breast cancer;	chr8:17940734	chr8:17808941~17820868:+
THCA	cis	rs9810089	0.706	rs521746	ENSG00000273455.1	RP11-305O4.3	-3.61	0.000336	0.022	-0.21	-0.16	Gestational age at birth (child effect);	chr3:136385078	chr3:136087475~136087913:-
THCA	cis	rs2732480	0.577	rs2732457	ENSG00000257735.1	RP11-370I10.6	-3.61	0.000336	0.022	-0.19	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48350945~48442411:+
THCA	cis	rs911555	0.755	rs975892	ENSG00000269940.1	RP11-73M18.7	3.61	0.000336	0.022	0.17	0.16	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103694560~103695170:+
THCA	cis	rs35740288	0.822	rs4843092	ENSG00000259407.1	RP11-158M2.3	-3.61	0.000336	0.022	-0.21	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85689949	chr15:85744109~85750281:-
THCA	cis	rs12022452	0.591	rs11208356	ENSG00000237899.1	RP4-739H11.3	-3.61	0.000336	0.022	-0.25	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40669089~40687588:-
THCA	cis	rs453301	0.686	rs17702602	ENSG00000253981.4	ALG1L13P	-3.61	0.000336	0.022	-0.16	-0.16	Joint mobility (Beighton score);	chr8:9051086	chr8:8236003~8244667:-
THCA	cis	rs2235642	0.821	rs2281234	ENSG00000260989.1	LA16c-395F10.2	-3.61	0.000336	0.022	-0.17	-0.16	Coronary artery disease;	chr16:1552937	chr16:1580527~1610328:+
THCA	cis	rs5758659	0.652	rs133322	ENSG00000182057.4	OGFRP1	3.61	0.000336	0.022	0.19	0.16	Cognitive function;	chr22:42009655	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.623	rs133328	ENSG00000182057.4	OGFRP1	3.61	0.000336	0.022	0.19	0.16	Cognitive function;	chr22:42012075	chr22:42269753~42275196:+
THCA	cis	rs9287719	0.674	rs1387566	ENSG00000243819.4	RN7SL832P	-3.61	0.000336	0.022	-0.13	-0.16	Prostate cancer;	chr2:10688524	chr2:10690344~10692099:+
THCA	cis	rs12681366	0.881	rs3019145	ENSG00000253175.1	RP11-267M23.6	3.61	0.000336	0.022	0.21	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94401324	chr8:94565036~94565715:+
THCA	cis	rs17122278	1	rs55857590	ENSG00000243431.1	RPL5P30	3.61	0.000336	0.022	0.16	0.16	Total cholesterol levels;	chr11:118554348	chr11:118560690~118561580:+
THCA	cis	rs11030122	0.959	rs10835261	ENSG00000230593.3	AC090804.1	3.61	0.000336	0.022	0.21	0.16	Mean platelet volume;Platelet distribution width;	chr11:3895271	chr11:3892398~3892887:-
THCA	cis	rs10954779	0.514	rs2344456	ENSG00000127589.4	TUBBP1	-3.61	0.000336	0.022	-0.2	-0.16	Intelligence (multi-trait analysis);	chr8:31103569	chr8:30351873~30353518:+
THCA	cis	rs9307551	0.618	rs10021556	ENSG00000250334.4	LINC00989	-3.61	0.000336	0.022	-0.21	-0.16	Refractive error;	chr4:79475741	chr4:79492416~79576460:+
THCA	cis	rs6889746	1	rs12519037	ENSG00000248898.1	CTD-2288O8.1	-3.61	0.000336	0.022	-0.19	-0.16	Presence of antiphospholipid antibodies;	chr5:52409700	chr5:52675193~52788026:-
THCA	cis	rs2882667	0.931	rs10068237	ENSG00000249593.5	CTB-46B19.2	3.61	0.000336	0.022	0.2	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:139012647~139051203:+
THCA	cis	rs1383484	1	rs4357909	ENSG00000259728.4	LINC00933	3.61	0.000336	0.022	0.2	0.16	Height;	chr15:83846823	chr15:84570649~84580175:+
THCA	cis	rs7954584	0.635	rs7309024	ENSG00000274292.1	RP11-347I19.7	-3.61	0.000336	0.022	-0.12	-0.16	Mean corpuscular volume;	chr12:121900428	chr12:121800797~121803403:+
THCA	cis	rs8114671	0.562	rs959829	ENSG00000126005.14	MMP24-AS1	3.61	0.000336	0.022	0.16	0.16	Height;	chr20:34758244	chr20:35216462~35278131:-
THCA	cis	rs6921919	0.673	rs13201681	ENSG00000220721.1	OR1F12	3.61	0.000336	0.022	0.37	0.16	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28073316~28074233:+
THCA	cis	rs6921919	0.778	rs67381177	ENSG00000220721.1	OR1F12	3.61	0.000336	0.022	0.37	0.16	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28073316~28074233:+
THCA	cis	rs9309711	0.666	rs11127429	ENSG00000271868.1	RP11-1293J14.1	-3.61	0.000336	0.022	-0.22	-0.16	Neurofibrillary tangles;	chr2:3481453	chr2:3496956~3497428:+
THCA	cis	rs9309711	0.666	rs11127430	ENSG00000271868.1	RP11-1293J14.1	-3.61	0.000336	0.022	-0.22	-0.16	Neurofibrillary tangles;	chr2:3481471	chr2:3496956~3497428:+
THCA	cis	rs11239930	0.934	rs10900313	ENSG00000278811.3	LINC00624	3.61	0.000336	0.022	0.16	0.16	AIDS progression;	chr1:147089200	chr1:147258885~147517875:-
THCA	cis	rs5753037	0.653	rs131273	ENSG00000273350.1	RP4-539M6.20	-3.61	0.000336	0.022	-0.19	-0.16	Type 1 diabetes;	chr22:29757732	chr22:30420512~30420912:+
THCA	cis	rs7412746	0.621	rs72704656	ENSG00000224800.1	RP11-235D19.2	-3.61	0.000336	0.022	-0.22	-0.16	Melanoma;	chr1:150855831	chr1:150881236~150881683:-
THCA	cis	rs881375	0.9	rs1930786	ENSG00000270917.1	RP11-27I1.6	-3.61	0.000336	0.022	-0.23	-0.16	Rheumatoid arthritis;	chr9:120929191	chr9:120812475~120812845:-
THCA	cis	rs881375	0.967	rs7864019	ENSG00000270917.1	RP11-27I1.6	-3.61	0.000336	0.022	-0.23	-0.16	Rheumatoid arthritis;	chr9:120930590	chr9:120812475~120812845:-
THCA	cis	rs881375	0.967	rs10739579	ENSG00000270917.1	RP11-27I1.6	-3.61	0.000336	0.022	-0.23	-0.16	Rheumatoid arthritis;	chr9:120932510	chr9:120812475~120812845:-
THCA	cis	rs6674176	0.542	rs803675	ENSG00000237950.1	RP11-7O11.3	3.61	0.000336	0.022	0.15	0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43887565	chr1:43944370~43946551:-
THCA	cis	rs2014572	0.967	rs7248000	ENSG00000276449.1	AC004076.5	3.61	0.000336	0.022	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57250771	chr19:57449689~57453011:+
THCA	cis	rs2494663	0.61	rs7526558	ENSG00000231416.1	RP11-422P24.9	3.61	0.000336	0.022	0.21	0.16	Mean platelet volume;	chr1:154042952	chr1:153995632~153995960:+
THCA	cis	rs5753037	0.702	rs131301	ENSG00000273350.1	RP4-539M6.20	-3.61	0.000336	0.022	-0.18	-0.16	Type 1 diabetes;	chr22:29789900	chr22:30420512~30420912:+
THCA	cis	rs8030605	0.925	rs72738651	ENSG00000277245.1	RP11-48G14.3	3.61	0.000336	0.022	0.3	0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56202691	chr15:56447120~56447697:+
THCA	cis	rs11039798	0.588	rs6485891	ENSG00000200090.1	Y_RNA	3.61	0.000336	0.022	0.14	0.16	Axial length;	chr11:48590472	chr11:47726894~47726992:-
THCA	cis	rs2243480	1	rs1404147	ENSG00000213640.3	EEF1DP4	3.61	0.000336	0.022	0.28	0.16	Diabetic kidney disease;	chr7:65799537	chr7:64862999~64864370:+
THCA	cis	rs11975235	1	rs11975235	ENSG00000272905.1	RP11-265E18.1	-3.61	0.000336	0.022	-0.14	-0.16	Presence of antiphospholipid antibodies;	chr7:32149928	chr7:32845394~32846061:+
THCA	cis	rs10043228	1	rs12152964	ENSG00000250015.1	CTC-339F2.2	3.61	0.000337	0.022	0.26	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116274268	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12522027	ENSG00000250015.1	CTC-339F2.2	3.61	0.000337	0.022	0.26	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116280834	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs112428033	ENSG00000250015.1	CTC-339F2.2	3.61	0.000337	0.022	0.26	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116282563	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs76112204	ENSG00000250015.1	CTC-339F2.2	3.61	0.000337	0.022	0.26	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116283192	chr5:116302354~116304134:-
THCA	cis	rs10043228	0.826	rs12520613	ENSG00000250015.1	CTC-339F2.2	3.61	0.000337	0.022	0.26	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116286023	chr5:116302354~116304134:-
THCA	cis	rs950169	0.922	rs2033284	ENSG00000188388.10	GOLGA6L3	3.61	0.000337	0.022	0.22	0.16	Schizophrenia;	chr15:84391575	chr15:85240472~85247170:+
THCA	cis	rs3808502	0.525	rs13280813	ENSG00000206014.6	OR7E161P	3.61	0.000337	0.022	0.19	0.16	Neuroticism;	chr8:11567596	chr8:11928597~11929563:-
THCA	cis	rs7919656	0.541	rs6537576	ENSG00000228403.1	RP11-563N6.6	-3.61	0.000337	0.022	-0.18	-0.16	Clinically amyopathic dermatomyositis;	chr10:48771788	chr10:48878022~48878649:+
THCA	cis	rs7172118	1	rs7172118	ENSG00000261762.1	RP11-650L12.2	-3.61	0.000337	0.022	-0.22	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78570111	chr15:78589123~78591276:-
THCA	cis	rs6840360	0.571	rs17275598	ENSG00000251611.1	RP11-610P16.1	-3.61	0.000337	0.022	-0.13	-0.16	Intelligence (multi-trait analysis);	chr4:151647326	chr4:151407551~151408835:-
THCA	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-3.61	0.000337	0.022	-0.19	-0.16	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-3.61	0.000337	0.022	-0.19	-0.16	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-3.61	0.000337	0.022	-0.19	-0.16	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-3.61	0.000337	0.022	-0.19	-0.16	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-3.61	0.000337	0.022	-0.19	-0.16	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
THCA	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-3.61	0.000337	0.022	-0.19	-0.16	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-3.61	0.000337	0.022	-0.19	-0.16	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-3.61	0.000337	0.022	-0.19	-0.16	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
THCA	cis	rs7088591	0.614	rs16911550	ENSG00000276818.1	AC026393.1	3.61	0.000337	0.022	0.28	0.16	Blood pressure;	chr10:57998746	chr10:57095699~57095781:+
THCA	cis	rs17122278	0.929	rs113739713	ENSG00000243431.1	RPL5P30	3.61	0.000337	0.022	0.16	0.16	Total cholesterol levels;	chr11:118549386	chr11:118560690~118561580:+
THCA	cis	rs875971	0.638	rs801205	ENSG00000232546.1	RP11-458F8.1	3.61	0.000337	0.022	0.13	0.16	Aortic root size;	chr7:66557157	chr7:66848496~66858136:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000232546.1	RP11-458F8.1	3.61	0.000337	0.022	0.13	0.16	Aortic root size;	chr7:66557902	chr7:66848496~66858136:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000232546.1	RP11-458F8.1	3.61	0.000337	0.022	0.13	0.16	Aortic root size;	chr7:66571411	chr7:66848496~66858136:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000232546.1	RP11-458F8.1	3.61	0.000337	0.022	0.13	0.16	Aortic root size;	chr7:66572000	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000232546.1	RP11-458F8.1	3.61	0.000337	0.022	0.13	0.16	Aortic root size;	chr7:66577454	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000232546.1	RP11-458F8.1	3.61	0.000337	0.022	0.13	0.16	Aortic root size;	chr7:66577989	chr7:66848496~66858136:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000232546.1	RP11-458F8.1	3.61	0.000337	0.022	0.13	0.16	Aortic root size;	chr7:66591816	chr7:66848496~66858136:+
THCA	cis	rs7613875	0.6	rs2247510	ENSG00000281691.1	RBM5-AS1	3.61	0.000337	0.022	0.14	0.16	Body mass index;	chr3:50088782	chr3:50099603~50100988:-
THCA	cis	rs7520050	0.933	rs6680211	ENSG00000280836.1	AL355480.1	3.61	0.000337	0.022	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45581219~45581321:-
THCA	cis	rs7829975	0.573	rs7842359	ENSG00000254340.1	RP11-10A14.3	-3.61	0.000337	0.022	-0.18	-0.16	Mood instability;	chr8:8939568	chr8:9141424~9145435:+
THCA	cis	rs4705962	0.917	rs2243293	ENSG00000230612.2	AC004237.1	3.61	0.000337	0.022	0.21	0.16	Atopic dermatitis;	chr5:132684107	chr5:132688681~132723725:+
THCA	cis	rs4705962	0.918	rs35081016	ENSG00000230612.2	AC004237.1	3.61	0.000337	0.022	0.21	0.16	Atopic dermatitis;	chr5:132684610	chr5:132688681~132723725:+
THCA	cis	rs4705962	0.959	rs10066662	ENSG00000230612.2	AC004237.1	3.61	0.000337	0.022	0.21	0.16	Atopic dermatitis;	chr5:132685304	chr5:132688681~132723725:+
THCA	cis	rs9878978	0.964	rs34966409	ENSG00000227588.2	CNTN4-AS2	3.61	0.000337	0.022	0.19	0.16	Blood pressure (smoking interaction);	chr3:2447205	chr3:2110409~2144241:-
THCA	cis	rs7819412	0.608	rs28417109	ENSG00000254948.1	OR7E158P	3.61	0.000337	0.022	0.21	0.16	Triglycerides;	chr8:11117571	chr8:11919900~11920809:-
THCA	cis	rs11073619	0.616	rs116163737	ENSG00000259728.4	LINC00933	-3.61	0.000337	0.022	-0.31	-0.16	Positive affect;	chr15:84531745	chr15:84570649~84580175:+
THCA	cis	rs7259376	0.902	rs10414591	ENSG00000270947.1	AC025811.3	-3.61	0.000337	0.022	-0.17	-0.16	Menopause (age at onset);	chr19:22417320	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.902	rs10420380	ENSG00000270947.1	AC025811.3	-3.61	0.000337	0.022	-0.17	-0.16	Menopause (age at onset);	chr19:22417822	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.869	rs10402396	ENSG00000270947.1	AC025811.3	-3.61	0.000337	0.022	-0.17	-0.16	Menopause (age at onset);	chr19:22419007	chr19:22455988~22456459:+
THCA	cis	rs17095355	0.818	rs12572438	ENSG00000203876.8	ADD3-AS1	-3.61	0.000337	0.022	-0.19	-0.16	Biliary atresia;	chr10:110009478	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.818	rs57239324	ENSG00000203876.8	ADD3-AS1	-3.61	0.000337	0.022	-0.19	-0.16	Biliary atresia;	chr10:110011113	chr10:109940104~110008381:-
THCA	cis	rs6690583	0.623	rs7540706	ENSG00000226970.2	RP11-82H13.2	-3.61	0.000337	0.022	-0.28	-0.16	Serum sulfate level;	chr1:85068962	chr1:84244334~84244577:+
THCA	cis	rs3924048	0.574	rs10864561	ENSG00000276830.1	MIR6730	-3.61	0.000337	0.022	-0.17	-0.16	Optic cup area;	chr1:12551439	chr1:12578957~12579023:-
THCA	cis	rs2522056	1	rs2522054	ENSG00000237714.1	P4HA2-AS1	-3.61	0.000337	0.022	-0.24	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132463834	chr5:132184876~132192808:+
THCA	cis	rs6918586	0.565	rs13196986	ENSG00000272810.1	U91328.22	3.61	0.000337	0.022	0.14	0.16	Schizophrenia;	chr6:26090224	chr6:26013241~26013757:+
THCA	cis	rs2658782	0.547	rs6483244	ENSG00000234106.3	RP11-288E14.2	3.61	0.000337	0.022	0.18	0.16	Pulmonary function decline;	chr11:93464769	chr11:93535468~93535816:+
THCA	cis	rs12410462	0.636	rs1495849	ENSG00000227711.2	RP11-275O4.5	-3.61	0.000337	0.022	-0.2	-0.16	Major depressive disorder;	chr1:227548662	chr1:227509028~227520477:-
THCA	cis	rs78944489	0.867	rs75299406	ENSG00000217702.2	RP11-287D1.4	-3.61	0.000337	0.022	-0.44	-0.16	Schizophrenia;	chr2:73225232	chr2:74130583~74135395:+
THCA	cis	rs11673344	0.542	rs826324	ENSG00000267260.1	CTD-2162K18.4	-3.61	0.000337	0.022	-0.2	-0.16	Obesity-related traits;	chr19:37014343	chr19:36773153~36777078:+
THCA	cis	rs9788682	0.747	rs16969894	ENSG00000261143.1	ADAMTS7P3	-3.61	0.000337	0.022	-0.24	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78484114	chr15:77976042~77993057:+
THCA	cis	rs34783982	0.96	rs4347601	ENSG00000259699.2	HMGB1P8	-3.61	0.000337	0.022	-0.22	-0.16	Squamous cell lung carcinoma;	chr15:88967604	chr15:89135547~89136495:-
THCA	cis	rs34783982	0.96	rs4932456	ENSG00000259699.2	HMGB1P8	-3.61	0.000337	0.022	-0.22	-0.16	Squamous cell lung carcinoma;	chr15:88970920	chr15:89135547~89136495:-
THCA	cis	rs34783982	0.96	rs4932457	ENSG00000259699.2	HMGB1P8	-3.61	0.000337	0.022	-0.22	-0.16	Squamous cell lung carcinoma;	chr15:88971013	chr15:89135547~89136495:-
THCA	cis	rs17194490	0.608	rs35792972	ENSG00000237990.3	CNTN4-AS1	3.61	0.000337	0.022	0.24	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2526719	chr3:3039033~3069242:-
THCA	cis	rs2360027	0.662	rs10802049	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000337	0.022	-0.16	-0.16	Tonsillectomy;	chr1:118606805	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.662	rs4659111	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000337	0.022	-0.16	-0.16	Tonsillectomy;	chr1:118607561	chr1:119140396~119275973:+
THCA	cis	rs2115630	1	rs10220733	ENSG00000275120.1	RP11-182J1.17	-3.61	0.000337	0.022	-0.17	-0.16	P wave terminal force;	chr15:84737633	chr15:84599434~84606463:-
THCA	cis	rs2115630	1	rs1030863	ENSG00000275120.1	RP11-182J1.17	-3.61	0.000337	0.022	-0.17	-0.16	P wave terminal force;	chr15:84739404	chr15:84599434~84606463:-
THCA	cis	rs6137726	0.652	rs6075934	ENSG00000237396.1	LINC01384	-3.61	0.000337	0.022	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22673477	chr20:22587522~22607517:-
THCA	cis	rs6449502	0.614	rs13159372	ENSG00000251279.1	CTC-436P18.1	3.61	0.000337	0.022	0.3	0.16	Mean platelet volume;	chr5:60820706	chr5:61162070~61232040:+
THCA	cis	rs17095355	0.818	rs12571549	ENSG00000203876.8	ADD3-AS1	-3.61	0.000337	0.022	-0.19	-0.16	Biliary atresia;	chr10:110010255	chr10:109940104~110008381:-
THCA	cis	rs150992	0.673	rs161747	ENSG00000241597.2	CTD-2007H13.1	3.61	0.000337	0.022	0.21	0.16	Body mass index;	chr5:98920433	chr5:98954394~98954972:+
THCA	cis	rs614226	1	rs7174	ENSG00000278344.1	RP11-18C24.8	3.61	0.000337	0.022	0.21	0.16	Type 1 diabetes nephropathy;	chr12:120579368	chr12:120500735~120501090:-
THCA	cis	rs2337406	0.789	rs60000589	ENSG00000280411.1	IGHV1-69-2	-3.61	0.000337	0.022	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106782459	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs111881598	ENSG00000280411.1	IGHV1-69-2	-3.61	0.000337	0.022	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106783113	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs61164979	ENSG00000280411.1	IGHV1-69-2	-3.61	0.000337	0.022	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106783133	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs61419485	ENSG00000280411.1	IGHV1-69-2	-3.61	0.000337	0.022	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106783374	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs8015361	ENSG00000280411.1	IGHV1-69-2	-3.61	0.000337	0.022	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106783991	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74090151	ENSG00000280411.1	IGHV1-69-2	-3.61	0.000337	0.022	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106785377	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs8012619	ENSG00000280411.1	IGHV1-69-2	-3.61	0.000337	0.022	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106793907	chr14:106762092~106762588:-
THCA	cis	rs9488822	0.676	rs6918059	ENSG00000233558.1	RP3-486I3.4	3.61	0.000337	0.022	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116027878	chr6:116258493~116259115:-
THCA	cis	rs1383484	1	rs11259921	ENSG00000259728.4	LINC00933	-3.61	0.000337	0.022	-0.2	-0.16	Height;	chr15:83836734	chr15:84570649~84580175:+
THCA	cis	rs11662586	1	rs7243921	ENSG00000267251.2	AC139100.3	3.61	0.000337	0.022	0.18	0.16	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79935237	chr18:80183680~80202992:+
THCA	cis	rs753778	0.57	rs4961335	ENSG00000253210.1	RP11-809O17.1	-3.61	0.000337	0.022	-0.19	-0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141199043	chr8:141126044~141129961:-
THCA	cis	rs6012953	0.654	rs6020561	ENSG00000231715.1	COX6CP2	3.61	0.000337	0.022	0.18	0.16	Vitiligo;	chr20:50503019	chr20:50479767~50479991:+
THCA	cis	rs2071852	0.66	rs11090654	ENSG00000280383.1	CTA-941F9.10	3.61	0.000337	0.022	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr22:45765111	chr22:45657019~45680130:+
THCA	cis	rs4879656	0.966	rs2274769	ENSG00000225693.1	LAGE3P1	-3.61	0.000337	0.022	-0.18	-0.16	Menopause (age at onset);	chr9:33026640	chr9:33019682~33020165:-
THCA	cis	rs11069062	0.683	rs11069063	ENSG00000270482.1	RP11-131L12.2	3.61	0.000337	0.022	0.13	0.16	Obesity-related traits;	chr12:118736616	chr12:118375350~118376275:-
THCA	cis	rs2692947	0.696	rs1724121	ENSG00000232931.4	LINC00342	3.61	0.000337	0.022	0.13	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96142810	chr2:95807118~95816215:-
THCA	cis	rs988712	0.883	rs1304100	ENSG00000245573.6	BDNF-AS	-3.61	0.000337	0.022	-0.15	-0.16	Obesity;	chr11:27550056	chr11:27506838~27698174:+
THCA	cis	rs6546886	0.625	rs13019449	ENSG00000235499.1	AC073046.25	3.61	0.000337	0.022	0.18	0.16	Dialysis-related mortality;	chr2:74030758	chr2:73985132~73986343:+
THCA	cis	rs7763441	1	rs2007680	ENSG00000250903.7	GMDS-AS1	3.61	0.000337	0.022	0.14	0.16	Monobrow;	chr6:2450818	chr6:2245748~2482022:+
THCA	cis	rs1560104	0.619	rs3829519	ENSG00000260601.1	RP11-552C15.1	-3.61	0.000337	0.022	-0.2	-0.16	Obesity-related traits;	chr16:12614854	chr16:12545482~12546684:+
THCA	cis	rs1560104	0.576	rs7186185	ENSG00000260601.1	RP11-552C15.1	-3.61	0.000337	0.022	-0.2	-0.16	Obesity-related traits;	chr16:12614985	chr16:12545482~12546684:+
THCA	cis	rs3924048	0.574	rs11121924	ENSG00000276830.1	MIR6730	-3.61	0.000337	0.022	-0.17	-0.16	Optic cup area;	chr1:12551599	chr1:12578957~12579023:-
THCA	cis	rs1580019	0.885	rs4460269	ENSG00000231952.3	DPY19L1P2	-3.61	0.000337	0.022	-0.21	-0.16	Cognitive ability;	chr7:32456833	chr7:32812757~32838570:+
THCA	cis	rs1580019	0.885	rs4460270	ENSG00000231952.3	DPY19L1P2	-3.61	0.000337	0.022	-0.21	-0.16	Cognitive ability;	chr7:32456838	chr7:32812757~32838570:+
THCA	cis	rs911555	0.603	rs8020912	ENSG00000269940.1	RP11-73M18.7	3.61	0.000337	0.022	0.17	0.16	Intelligence (multi-trait analysis);	chr14:103380937	chr14:103694560~103695170:+
THCA	cis	rs7403037	0.55	rs34469274	ENSG00000260760.1	PWRN3	3.61	0.000337	0.022	0.24	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24362112	chr15:24441127~24447967:+
THCA	cis	rs7919656	0.662	rs2663052	ENSG00000228403.1	RP11-563N6.6	-3.61	0.000337	0.022	-0.17	-0.16	Clinically amyopathic dermatomyositis;	chr10:48861350	chr10:48878022~48878649:+
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000254948.1	OR7E158P	-3.61	0.000337	0.022	-0.2	-0.16	Neuroticism;	chr8:11989569	chr8:11919900~11920809:-
THCA	cis	rs12682352	0.602	rs635594	ENSG00000254340.1	RP11-10A14.3	-3.61	0.000337	0.022	-0.18	-0.16	Neuroticism;	chr8:8755877	chr8:9141424~9145435:+
THCA	cis	rs6589219	0.788	rs11213823	ENSG00000196167.8	COLCA1	-3.61	0.000337	0.022	-0.18	-0.16	Colorectal cancer;	chr11:111299265	chr11:111290787~111305045:-
THCA	cis	rs700651	0.789	rs882954	ENSG00000231621.1	AC013264.2	-3.61	0.000337	0.022	-0.17	-0.16	Intracranial aneurysm;	chr2:198042720	chr2:197197991~197199273:+
THCA	cis	rs6456156	0.792	rs10946212	ENSG00000235272.1	FAM103A2P	3.61	0.000338	0.0221	0.23	0.16	Primary biliary cholangitis;	chr6:167102459	chr6:166586124~166586477:-
THCA	cis	rs922692	0.935	rs4886580	ENSG00000261143.1	ADAMTS7P3	3.61	0.000338	0.0221	0.21	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78677043	chr15:77976042~77993057:+
THCA	cis	rs7246760	0.867	rs67539464	ENSG00000278611.1	CTC-543D15.8	-3.61	0.000338	0.0221	-0.26	-0.16	Pursuit maintenance gain;	chr19:9721748	chr19:9538733~9539734:+
THCA	cis	rs7246760	0.867	rs73011937	ENSG00000278611.1	CTC-543D15.8	-3.61	0.000338	0.0221	-0.26	-0.16	Pursuit maintenance gain;	chr19:9721854	chr19:9538733~9539734:+
THCA	cis	rs7772697	0.508	rs4313020	ENSG00000223701.3	RAET1E-AS1	-3.61	0.000338	0.0221	-0.23	-0.16	Diabetic retinopathy;	chr6:149060091	chr6:149884431~149919508:+
THCA	cis	rs7481311	0.956	rs7127239	ENSG00000245573.6	BDNF-AS	3.61	0.000338	0.0221	0.16	0.16	Weight;Body mass index;	chr11:27525832	chr11:27506838~27698174:+
THCA	cis	rs786425	0.532	rs10773026	ENSG00000270095.1	RP11-214K3.18	3.61	0.000338	0.0221	0.2	0.16	Pubertal anthropometrics;	chr12:123728325	chr12:123971457~123971714:-
THCA	cis	rs9650657	0.535	rs7011756	ENSG00000261451.1	RP11-981G7.1	-3.61	0.000338	0.0221	-0.21	-0.16	Neuroticism;	chr8:11162068	chr8:10433672~10438312:+
THCA	cis	rs35847492	1	rs35847492	ENSG00000233609.3	RP11-62H7.2	3.61	0.000338	0.0221	0.18	0.16	Neuroticism;	chr8:9418515	chr8:8961200~8979025:+
THCA	cis	rs10496034	0.541	rs76988803	ENSG00000237887.1	AC092839.1	-3.61	0.000338	0.0221	-0.31	-0.16	Refractive astigmatism;	chr2:54693554	chr2:54529343~54529801:+
THCA	cis	rs7772697	0.508	rs3949414	ENSG00000223701.3	RAET1E-AS1	-3.61	0.000338	0.0221	-0.23	-0.16	Diabetic retinopathy;	chr6:149045203	chr6:149884431~149919508:+
THCA	cis	rs17301013	0.932	rs1793297	ENSG00000270084.1	GAS5-AS1	3.61	0.000338	0.0221	0.17	0.16	Systemic lupus erythematosus;	chr1:174784411	chr1:173863248~173863941:+
THCA	cis	rs7131987	0.845	rs7299861	ENSG00000275476.1	RP11-996F15.4	-3.61	0.000338	0.0221	-0.16	-0.16	QT interval;	chr12:29256734	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.934	rs7316004	ENSG00000275476.1	RP11-996F15.4	-3.61	0.000338	0.0221	-0.16	-0.16	QT interval;	chr12:29258765	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.903	rs2216853	ENSG00000275476.1	RP11-996F15.4	-3.61	0.000338	0.0221	-0.16	-0.16	QT interval;	chr12:29260315	chr12:29277397~29277882:-
THCA	cis	rs7131987	0.868	rs10771508	ENSG00000275476.1	RP11-996F15.4	-3.61	0.000338	0.0221	-0.16	-0.16	QT interval;	chr12:29261278	chr12:29277397~29277882:-
THCA	cis	rs76878669	0.793	rs7924580	ENSG00000255320.1	RP11-755F10.1	3.61	0.000338	0.0221	0.23	0.16	Educational attainment (years of education);	chr11:66313299	chr11:66244840~66246239:-
THCA	cis	rs4787491	0.729	rs4238960	ENSG00000275371.1	RP11-455F5.6	-3.61	0.000338	0.0221	-0.14	-0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30027327	chr16:30110895~30111955:+
THCA	cis	rs9863	0.861	rs75321546	ENSG00000269938.1	RP11-214K3.20	-3.61	0.000338	0.0221	-0.19	-0.16	White blood cell count;	chr12:123962918	chr12:123968023~123968579:-
THCA	cis	rs9863	0.861	rs55990776	ENSG00000269938.1	RP11-214K3.20	-3.61	0.000338	0.0221	-0.19	-0.16	White blood cell count;	chr12:123962919	chr12:123968023~123968579:-
THCA	cis	rs2888875	0.888	rs12466030	ENSG00000200924.1	RNU6-1048P	-3.61	0.000338	0.0221	-0.19	-0.16	Glomerular filtration rate (creatinine);	chr2:43585692	chr2:43892690~43892796:+
THCA	cis	rs4792901	0.759	rs9907813	ENSG00000267151.3	RP11-100E5.2	3.61	0.000338	0.0221	0.18	0.16	Dupuytren's disease;	chr17:43525490	chr17:43444707~43451200:+
THCA	cis	rs9650657	0.812	rs11250074	ENSG00000269918.1	AF131215.9	-3.61	0.000338	0.0221	-0.17	-0.16	Neuroticism;	chr8:10774749	chr8:11104691~11106704:-
THCA	cis	rs9911578	0.967	rs9907940	ENSG00000224738.1	AC099850.1	3.61	0.000338	0.0221	0.19	0.16	Intelligence (multi-trait analysis);	chr17:58586481	chr17:59106598~59118267:+
THCA	cis	rs889312	0.924	rs4700485	ENSG00000271828.1	CTD-2310F14.1	-3.61	0.000338	0.0221	-0.24	-0.16	Breast cancer (early onset);Breast cancer;	chr5:56738380	chr5:56927874~56929573:+
THCA	cis	rs758324	0.58	rs35566767	ENSG00000237714.1	P4HA2-AS1	-3.61	0.000338	0.0221	-0.38	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:132270356	chr5:132184876~132192808:+
THCA	cis	rs3924048	0.547	rs12410652	ENSG00000272482.1	RP11-474O21.5	-3.61	0.000338	0.0221	-0.15	-0.16	Optic cup area;	chr1:12551203	chr1:12618900~12619244:-
THCA	cis	rs7572644	0.709	rs7607546	ENSG00000223522.1	AC093690.1	3.61	0.000338	0.0221	0.22	0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27895795	chr2:28307691~28310459:-
THCA	cis	rs7520050	0.966	rs9429183	ENSG00000280836.1	AL355480.1	3.61	0.000338	0.0221	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45581219~45581321:-
THCA	cis	rs972578	0.967	rs2413736	ENSG00000230319.1	AL022476.2	3.61	0.000338	0.0221	0.17	0.16	Mean platelet volume;	chr22:42942833	chr22:43038585~43052366:+
THCA	cis	rs7690839	1	rs4505789	ENSG00000270720.1	RP11-84C13.2	3.61	0.000338	0.0221	0.18	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88904464	chr4:89119284~89119871:+
THCA	cis	rs301901	0.828	rs4308503	ENSG00000250155.1	CTD-2353F22.1	3.61	0.000338	0.0221	0.16	0.16	Height;	chr5:37454091	chr5:36666214~36725195:-
THCA	cis	rs875971	1	rs11971949	ENSG00000272831.1	RP11-792A8.4	-3.61	0.000338	0.0221	-0.1	-0.16	Aortic root size;	chr7:66161027	chr7:66739829~66740385:-
THCA	cis	rs34102591	0.535	rs28654550	ENSG00000270061.1	RP11-214K3.19	-3.61	0.000338	0.0221	-0.21	-0.16	Schizophrenia;	chr12:123902507	chr12:123969990~123970344:-
THCA	cis	rs11190604	1	rs2495758	ENSG00000273030.1	RP11-285F16.1	3.61	0.000338	0.0221	0.2	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100562143	chr10:100412934~100413421:+
THCA	cis	rs5758511	0.637	rs5751244	ENSG00000270083.1	RP1-257I20.14	-3.61	0.000338	0.0221	-0.21	-0.16	Birth weight;	chr22:42221405	chr22:42089630~42090028:-
THCA	cis	rs1577917	0.74	rs9353320	ENSG00000220563.1	PKMP3	3.61	0.000338	0.0221	0.12	0.16	Response to antipsychotic treatment;	chr6:85535130	chr6:85659892~85660606:-
THCA	cis	rs56046484	0.871	rs71397837	ENSG00000259630.2	CTD-2262B20.1	-3.61	0.000338	0.0221	-0.25	-0.16	Testicular germ cell tumor;	chr15:85020330	chr15:85415228~85415633:+
THCA	cis	rs913655	0.893	rs2480322	ENSG00000240291.1	RP11-499P20.2	-3.61	0.000338	0.0221	-0.12	-0.16	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18811752	chr10:18513115~18545651:-
THCA	cis	rs7520050	0.966	rs1707336	ENSG00000280836.1	AL355480.1	3.61	0.000338	0.0221	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45581219~45581321:-
THCA	cis	rs944289	0.517	rs1766125	ENSG00000258844.1	RP11-259K15.2	3.61	0.000339	0.0221	0.15	0.16	Thyroid cancer;	chr14:36197511	chr14:36214607~36235608:+
THCA	cis	rs11758351	1	rs80095925	ENSG00000216331.1	HIST1H1PS1	3.61	0.000339	0.0221	0.28	0.16	Renal underexcretion gout;Gout;	chr6:26184714	chr6:26195566~26195771:+
THCA	cis	rs11758351	1	rs77961951	ENSG00000216331.1	HIST1H1PS1	3.61	0.000339	0.0221	0.28	0.16	Renal underexcretion gout;Gout;	chr6:26185847	chr6:26195566~26195771:+
THCA	cis	rs7216064	1	rs7223930	ENSG00000278740.1	RP11-147L13.14	3.61	0.000339	0.0221	0.19	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846070	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs8081517	ENSG00000278740.1	RP11-147L13.14	3.61	0.000339	0.0221	0.19	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67849581	chr17:68188547~68189165:+
THCA	cis	rs7216064	1	rs4790908	ENSG00000278740.1	RP11-147L13.14	3.61	0.000339	0.0221	0.19	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67856791	chr17:68188547~68189165:+
THCA	cis	rs8102150	1	rs8102150	ENSG00000269194.1	AC006942.4	3.61	0.000339	0.0221	0.34	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr19:49727070	chr19:49808933~49809738:+
THCA	cis	rs2180341	0.96	rs6900074	ENSG00000220522.2	RP1-177A13.1	3.61	0.000339	0.0221	0.21	0.16	Breast cancer;	chr6:127364748	chr6:127416535~127416952:-
THCA	cis	rs9450351	0.744	rs6906618	ENSG00000280232.1	RP11-321N4.4	3.61	0.000339	0.0221	0.35	0.16	Interferon gamma-induced protein 10 levels;	chr6:85741719	chr6:85498441~85499058:-
THCA	cis	rs75059851	0.932	rs73034295	ENSG00000280237.1	MIR4697HG	3.61	0.000339	0.0221	0.2	0.16	Schizophrenia;	chr11:133952238	chr11:133896438~133901601:-
THCA	cis	rs6546537	0.868	rs62133967	ENSG00000231024.1	AC092431.3	3.61	0.000339	0.0221	0.22	0.16	Serum thyroid-stimulating hormone levels;	chr2:69664576	chr2:69700192~69713847:-
THCA	cis	rs6546537	0.911	rs62133968	ENSG00000231024.1	AC092431.3	3.61	0.000339	0.0221	0.22	0.16	Serum thyroid-stimulating hormone levels;	chr2:69664778	chr2:69700192~69713847:-
THCA	cis	rs75504410	0.85	rs58940025	ENSG00000231160.8	KLF3-AS1	-3.61	0.000339	0.0221	-0.14	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38707968	chr4:38612701~38664883:-
THCA	cis	rs860295	0.702	rs11264387	ENSG00000236675.1	MTX1P1	-3.61	0.000339	0.0221	-0.17	-0.16	Body mass index;	chr1:155593361	chr1:155230975~155234325:+
THCA	cis	rs7523875	0.516	rs6682599	ENSG00000153363.11	LINC00467	3.61	0.000339	0.0221	0.13	0.16	Mean corpuscular volume;	chr1:211349085	chr1:211382803~211435333:+
THCA	cis	rs478304	0.651	rs10896037	ENSG00000255320.1	RP11-755F10.1	3.61	0.000339	0.0221	0.21	0.16	Acne (severe);	chr11:65735953	chr11:66244840~66246239:-
THCA	cis	rs4788570	0.511	rs4788830	ENSG00000260185.1	RP11-432I5.6	-3.61	0.000339	0.0221	-0.32	-0.16	Intelligence (multi-trait analysis);	chr16:71698364	chr16:71655027~71664212:+
THCA	cis	rs7474896	1	rs9417261	ENSG00000276805.1	RP11-291L22.6	3.61	0.000339	0.0221	0.25	0.16	Obesity (extreme);	chr10:37822841	chr10:38451030~38451785:+
THCA	cis	rs2919009	0.62	rs11199664	ENSG00000271670.1	RP11-95I16.4	3.61	0.000339	0.0221	0.18	0.16	Obesity-related traits;	chr10:120936790	chr10:120879256~120880667:-
THCA	cis	rs57590327	0.503	rs13066091	ENSG00000241593.4	RP11-520D19.2	-3.61	0.000339	0.0221	-0.21	-0.16	Extraversion;	chr3:81540761	chr3:81246579~81297345:-
THCA	cis	rs1538970	0.847	rs781230	ENSG00000234329.1	RP11-767N6.2	-3.61	0.000339	0.0221	-0.16	-0.16	Platelet count;	chr1:45415079	chr1:45651039~45651826:-
THCA	cis	rs7412746	0.611	rs2256355	ENSG00000224800.1	RP11-235D19.2	-3.61	0.000339	0.0221	-0.22	-0.16	Melanoma;	chr1:150839318	chr1:150881236~150881683:-
THCA	cis	rs9634489	0.678	rs1925127	ENSG00000247400.3	DNAJC3-AS1	-3.61	0.000339	0.0221	-0.1	-0.16	Body mass index;	chr13:96398142	chr13:95648733~95676925:-
THCA	cis	rs12935418	0.887	rs2873310	ENSG00000278985.1	RP11-303E16.9	-3.61	0.000339	0.0221	-0.22	-0.16	Mean corpuscular volume;	chr16:81038540	chr16:80982319~80984094:-
THCA	cis	rs4819052	0.679	rs2838859	ENSG00000273796.1	LL21NC02-21A1.1	-3.61	0.000339	0.0221	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45403809~45404369:-
THCA	cis	rs4915077	0.892	rs17020108	ENSG00000226822.1	RP11-356N1.2	3.61	0.000339	0.0221	0.27	0.16	Hypothyroidism;	chr1:107811339	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs17020112	ENSG00000226822.1	RP11-356N1.2	3.61	0.000339	0.0221	0.27	0.16	Hypothyroidism;	chr1:107811677	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs6695696	ENSG00000226822.1	RP11-356N1.2	3.61	0.000339	0.0221	0.27	0.16	Hypothyroidism;	chr1:107812067	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs6683295	ENSG00000226822.1	RP11-356N1.2	3.61	0.000339	0.0221	0.27	0.16	Hypothyroidism;	chr1:107812317	chr1:108071482~108074519:+
THCA	cis	rs6137726	0.524	rs1203928	ENSG00000237396.1	LINC01384	3.61	0.000339	0.0221	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22609245	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1203931	ENSG00000237396.1	LINC01384	3.61	0.000339	0.0221	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22610325	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1203934	ENSG00000237396.1	LINC01384	3.61	0.000339	0.0221	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22611326	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1203936	ENSG00000237396.1	LINC01384	3.61	0.000339	0.0221	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22611792	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1203937	ENSG00000237396.1	LINC01384	3.61	0.000339	0.0221	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22612728	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1203940	ENSG00000237396.1	LINC01384	3.61	0.000339	0.0221	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22615005	chr20:22587522~22607517:-
THCA	cis	rs2116941	0.523	rs17000211	ENSG00000238364.1	RNU7-140P	-3.61	0.000339	0.0221	-0.24	-0.16	Pulse pressure;	chr19:10258410	chr19:10551033~10551092:-
THCA	cis	rs73222236	0.825	rs35644083	ENSG00000273486.1	RP11-731C17.2	3.61	0.000339	0.0221	0.15	0.16	Coronary artery disease;	chr3:136503626	chr3:136837338~136839021:-
THCA	cis	rs7660883	0.897	rs236992	ENSG00000251411.1	RP11-397E7.4	-3.61	0.000339	0.0221	-0.15	-0.16	HDL cholesterol levels;	chr4:87095587	chr4:86913266~86914817:-
THCA	cis	rs7660883	0.897	rs236993	ENSG00000251411.1	RP11-397E7.4	-3.61	0.000339	0.0221	-0.15	-0.16	HDL cholesterol levels;	chr4:87095722	chr4:86913266~86914817:-
THCA	cis	rs11751172	0.651	rs16873510	ENSG00000271857.1	RP1-244F24.1	3.61	0.000339	0.0221	0.1	0.16	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45565416	chr6:45421079~45422005:-
THCA	cis	rs801193	1	rs2420824	ENSG00000230295.1	RP11-458F8.2	3.61	0.000339	0.0221	0.12	0.16	Aortic root size;	chr7:66666129	chr7:66880708~66882981:+
THCA	cis	rs8058578	1	rs8048448	ENSG00000260911.2	RP11-196G11.2	3.61	0.000339	0.0221	0.14	0.16	Multiple myeloma;	chr16:30680887	chr16:31043150~31049868:+
THCA	cis	rs9650657	0.645	rs56057779	ENSG00000261451.1	RP11-981G7.1	-3.61	0.000339	0.0221	-0.19	-0.16	Neuroticism;	chr8:10659370	chr8:10433672~10438312:+
THCA	cis	rs7246657	0.722	rs10410588	ENSG00000226686.6	LINC01535	-3.61	0.000339	0.0221	-0.24	-0.16	Coronary artery calcification;	chr19:37551508	chr19:37251912~37265535:+
THCA	cis	rs7267979	0.844	rs8184820	ENSG00000276952.1	RP5-965G21.6	-3.61	0.000339	0.0221	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25284915~25285588:-
THCA	cis	rs7090512	0.593	rs10752194	ENSG00000223784.1	RP11-554I8.2	3.61	0.000339	0.0221	0.18	0.16	Multiple sclerosis;	chr10:6072330	chr10:6737382~6739026:+
THCA	cis	rs7216064	0.953	rs4790981	ENSG00000278740.1	RP11-147L13.14	3.61	0.000339	0.0221	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67925718	chr17:68188547~68189165:+
THCA	cis	rs7615952	0.512	rs4679430	ENSG00000248787.1	RP11-666A20.4	-3.61	0.000339	0.0221	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125639049	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.512	rs34651730	ENSG00000248787.1	RP11-666A20.4	-3.61	0.000339	0.0221	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125639796	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.512	rs2979334	ENSG00000248787.1	RP11-666A20.4	-3.61	0.000339	0.0221	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125639980	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.512	rs11929125	ENSG00000248787.1	RP11-666A20.4	-3.61	0.000339	0.0221	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125640599	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.512	rs11921452	ENSG00000248787.1	RP11-666A20.4	-3.61	0.000339	0.0221	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125640906	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.512	rs2922175	ENSG00000248787.1	RP11-666A20.4	-3.61	0.000339	0.0221	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125642516	chr3:125908005~125910272:-
THCA	cis	rs4913250	0.889	rs11176774	ENSG00000256077.4	RP11-335O4.1	-3.61	0.000339	0.0222	-0.2	-0.16	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr12:67535469	chr12:67571197~67589987:-
THCA	cis	rs875971	0.545	rs73152714	ENSG00000230295.1	RP11-458F8.2	3.61	0.000339	0.0222	0.15	0.16	Aortic root size;	chr7:66534641	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000230295.1	RP11-458F8.2	3.61	0.000339	0.0222	0.15	0.16	Aortic root size;	chr7:66536353	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000230295.1	RP11-458F8.2	-3.61	0.000339	0.0222	-0.15	-0.16	Aortic root size;	chr7:66560286	chr7:66880708~66882981:+
THCA	cis	rs1577917	0.74	rs9450302	ENSG00000220563.1	PKMP3	3.61	0.000339	0.0222	0.12	0.16	Response to antipsychotic treatment;	chr6:85579955	chr6:85659892~85660606:-
THCA	cis	rs2115630	0.905	rs6496401	ENSG00000275120.1	RP11-182J1.17	-3.61	0.000339	0.0222	-0.17	-0.16	P wave terminal force;	chr15:84754562	chr15:84599434~84606463:-
THCA	cis	rs4434138	0.533	rs11130324	ENSG00000243224.1	RP5-1157M23.2	-3.61	0.000339	0.0222	-0.17	-0.16	Intelligence (multi-trait analysis);	chr3:52736294	chr3:52239258~52241097:+
THCA	cis	rs2274273	0.87	rs10139083	ENSG00000258469.1	CHMP4BP1	3.61	0.00034	0.0222	0.15	0.16	Protein biomarker;	chr14:55316017	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs10145203	ENSG00000258469.1	CHMP4BP1	3.61	0.00034	0.0222	0.15	0.16	Protein biomarker;	chr14:55317740	chr14:55298644~55299231:+
THCA	cis	rs720475	0.732	rs73159066	ENSG00000170356.8	OR2A20P	3.61	0.00034	0.0222	0.23	0.16	Breast cancer;	chr7:144426495	chr7:144250045~144252957:-
THCA	cis	rs7520050	0.966	rs6677007	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs4660898	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs11211230	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs35743647	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs7522601	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs10789487	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs34102169	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs4076006	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs11211234	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs11211241	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.902	rs4638056	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs11576305	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45581219~45581321:-
THCA	cis	rs9400467	0.506	rs73530915	ENSG00000255389.1	C6orf3	3.61	0.00034	0.0222	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111136245	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.537	rs1891387	ENSG00000255389.1	C6orf3	3.61	0.00034	0.0222	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111141087	chr6:111599875~111602295:+
THCA	cis	rs10089	1	rs10064357	ENSG00000245937.6	LINC01184	3.61	0.00034	0.0222	0.18	0.16	Ileal carcinoids;	chr5:128081580	chr5:127940426~128083172:-
THCA	cis	rs9462027	1	rs6457796	ENSG00000272288.4	RP11-140K17.3	-3.61	0.00034	0.0222	-0.13	-0.16	Systemic lupus erythematosus;	chr6:34860776	chr6:34696317~34697470:+
THCA	cis	rs4073416	0.508	rs2898818	ENSG00000276116.2	FUT8-AS1	3.61	0.00034	0.0222	0.18	0.16	N-glycan levels;	chr14:65505866	chr14:65411170~65412690:-
THCA	cis	rs7542375	0.655	rs1889795	ENSG00000238078.1	LINC01352	-3.61	0.00034	0.0222	-0.25	-0.16	Obesity-related traits;	chr1:220889759	chr1:220829255~220832429:+
THCA	cis	rs9400467	0.508	rs11153293	ENSG00000272356.1	RP5-1112D6.8	-3.61	0.00034	0.0222	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.508	rs11756643	ENSG00000272356.1	RP5-1112D6.8	-3.61	0.00034	0.0222	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111309203~111313517:+
THCA	cis	rs1790761	0.505	rs7927657	ENSG00000255318.1	RP11-655M14.13	-3.61	0.00034	0.0222	-0.18	-0.16	Mean corpuscular volume;	chr11:67579517	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.505	rs7941395	ENSG00000255318.1	RP11-655M14.13	-3.61	0.00034	0.0222	-0.18	-0.16	Mean corpuscular volume;	chr11:67579946	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.505	rs7941648	ENSG00000255318.1	RP11-655M14.13	-3.61	0.00034	0.0222	-0.18	-0.16	Mean corpuscular volume;	chr11:67580124	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.505	rs7945035	ENSG00000255318.1	RP11-655M14.13	-3.61	0.00034	0.0222	-0.18	-0.16	Mean corpuscular volume;	chr11:67580691	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.505	rs2370141	ENSG00000255318.1	RP11-655M14.13	-3.61	0.00034	0.0222	-0.18	-0.16	Mean corpuscular volume;	chr11:67581058	chr11:67618279~67627304:-
THCA	cis	rs2179367	0.632	rs9498329	ENSG00000216906.2	RP11-350J20.9	3.61	0.00034	0.0222	0.21	0.16	Dupuytren's disease;	chr6:149349941	chr6:149904243~149906418:+
THCA	cis	rs12681366	0.881	rs12674614	ENSG00000253175.1	RP11-267M23.6	3.61	0.00034	0.0222	0.21	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94396605	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.881	rs3019155	ENSG00000253175.1	RP11-267M23.6	3.61	0.00034	0.0222	0.21	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94405359	chr8:94565036~94565715:+
THCA	cis	rs785830	0.63	rs526509	ENSG00000231808.2	LINC01388	-3.61	0.00034	0.0222	-0.19	-0.16	Platelet distribution width;	chr9:268740	chr9:112713~113754:-
THCA	cis	rs7824557	0.527	rs2572369	ENSG00000255495.1	AC145124.2	-3.61	0.00034	0.0222	-0.18	-0.16	Retinal vascular caliber;	chr8:11381088	chr8:12194467~12196280:+
THCA	cis	rs4723738	1	rs10240479	ENSG00000227191.5	TRGC2	-3.61	0.00034	0.0222	-0.13	-0.16	Treatment response for severe sepsis;	chr7:38181654	chr7:38239580~38368091:-
THCA	cis	rs354225	0.544	rs28581481	ENSG00000212175.1	SNORA12	-3.61	0.00034	0.0222	-0.21	-0.16	Schizophrenia;	chr2:54585235	chr2:55565703~55565850:+
THCA	cis	rs2288884	0.943	rs11084131	ENSG00000260160.1	CTC-471J1.2	-3.61	0.00034	0.0222	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011193	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.943	rs11084132	ENSG00000260160.1	CTC-471J1.2	-3.61	0.00034	0.0222	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011327	chr19:52058490~52063703:-
THCA	cis	rs4073416	0.542	rs6573614	ENSG00000276116.2	FUT8-AS1	3.61	0.00034	0.0222	0.18	0.16	N-glycan levels;	chr14:65491985	chr14:65411170~65412690:-
THCA	cis	rs301901	0.796	rs62359002	ENSG00000250155.1	CTD-2353F22.1	3.61	0.00034	0.0222	0.16	0.16	Height;	chr5:37499677	chr5:36666214~36725195:-
THCA	cis	rs4646404	0.509	rs4646356	ENSG00000225442.2	MPRIP-AS1	-3.61	0.00034	0.0222	-0.2	-0.16	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr17:17567861	chr17:17076038~17077752:-
THCA	cis	rs2337406	0.866	rs4773949	ENSG00000280411.1	IGHV1-69-2	3.61	0.00034	0.0222	0.12	0.16	Alzheimer's disease (late onset);	chr14:106808070	chr14:106762092~106762588:-
THCA	cis	rs7394190	0.748	rs4746139	ENSG00000272599.2	RP11-152N13.16	3.61	0.00034	0.0222	0.21	0.16	Incident atrial fibrillation;	chr10:73647891	chr10:73124573~73125532:-
THCA	cis	rs7520050	0.966	rs7515491	ENSG00000280836.1	AL355480.1	3.61	0.00034	0.0222	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45889407	chr1:45581219~45581321:-
THCA	cis	rs10863936	0.667	rs4951560	ENSG00000198468.6	FLVCR1-AS1	-3.61	0.00034	0.0222	-0.2	-0.16	Height;	chr1:211956129	chr1:212852108~212858088:-
THCA	cis	rs6580649	0.941	rs72644841	ENSG00000273765.1	RP11-370I10.11	-3.61	0.00034	0.0222	-0.18	-0.16	Lung cancer;	chr12:48018204	chr12:48360920~48361377:+
THCA	cis	rs10181042	0.565	rs1177233	ENSG00000270820.4	RP11-355B11.2	-3.61	0.00034	0.0222	-0.13	-0.16	Crohn's disease;	chr2:61034999	chr2:61471188~61484130:+
THCA	cis	rs7182621	0.793	rs12904168	ENSG00000182397.13	DNM1P46	3.61	0.00034	0.0222	0.19	0.16	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99790156~99806927:-
THCA	cis	rs9329221	0.537	rs2062332	ENSG00000261451.1	RP11-981G7.1	3.61	0.00034	0.0222	0.19	0.16	Neuroticism;	chr8:10122514	chr8:10433672~10438312:+
THCA	cis	rs7674212	1	rs7691873	ENSG00000248971.2	KRT8P46	3.61	0.00034	0.0222	0.2	0.16	Type 2 diabetes;	chr4:103066742	chr4:102728746~102730171:-
THCA	cis	rs2549003	0.674	rs960757	ENSG00000237714.1	P4HA2-AS1	-3.61	0.00034	0.0222	-0.22	-0.16	Asthma (sex interaction);	chr5:132490618	chr5:132184876~132192808:+
THCA	cis	rs7044106	1	rs7044106	ENSG00000238181.2	AHCYP2	-3.61	0.00034	0.0222	-0.24	-0.16	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120720673~120721972:+
THCA	cis	rs12681366	0.683	rs2450572	ENSG00000261437.1	RP11-22C11.2	-3.61	0.00034	0.0222	-0.15	-0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94412107	chr8:94637285~94639467:-
THCA	cis	rs1923243	0.649	rs12145685	ENSG00000223479.3	RP4-788P17.1	3.61	0.00034	0.0222	0.18	0.16	Migraine;	chr1:73085702	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs12138301	ENSG00000223479.3	RP4-788P17.1	3.61	0.00034	0.0222	0.18	0.16	Migraine;	chr1:73085743	chr1:73635216~73715214:+
THCA	cis	rs13113518	0.812	rs12648271	ENSG00000272969.1	RP11-528I4.2	3.61	0.00034	0.0222	0.2	0.16	Height;	chr4:55501955	chr4:55547112~55547889:+
THCA	cis	rs7246967	0.673	rs4932784	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22691449	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs73022711	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22692602	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs73022713	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22693420	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs57027767	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22693733	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs62120313	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22694381	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs7248107	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22695727	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs8102812	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22696441	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs8106215	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22696644	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs16994997	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22696808	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs34806882	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22697302	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs57736314	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22697470	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.604	rs58536761	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22697529	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs3853649	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22697658	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs3853650	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22697688	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs3844578	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22697808	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs3925175	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22698156	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs7257333	ENSG00000198153.8	ZNF849P	-3.61	0.00034	0.0222	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22698347	chr19:22685167~22686732:+
THCA	cis	rs4723738	0.967	rs12531618	ENSG00000227191.5	TRGC2	-3.61	0.00034	0.0222	-0.13	-0.16	Treatment response for severe sepsis;	chr7:38213263	chr7:38239580~38368091:-
THCA	cis	rs9611565	0.512	rs45500192	ENSG00000237037.8	NDUFA6-AS1	3.61	0.00034	0.0222	0.16	0.16	Vitiligo;	chr22:41781895	chr22:42090931~42137742:+
THCA	cis	rs910316	1	rs12897094	ENSG00000259138.1	RP11-950C14.7	3.61	0.00034	0.0222	0.14	0.16	Height;	chr14:75112713	chr14:75127153~75136930:+
THCA	cis	rs912593	1	rs73471574	ENSG00000225179.1	LINC00457	3.61	0.00034	0.0222	0.21	0.16	Cancer;	chr13:34457667	chr13:34435450~34640685:-
THCA	cis	rs9611565	0.659	rs9607815	ENSG00000281538.1	RP4-669P10.20	3.61	0.00034	0.0222	0.18	0.16	Vitiligo;	chr22:41554667	chr22:42138060~42139726:+
THCA	cis	rs9611565	0.659	rs12484175	ENSG00000281538.1	RP4-669P10.20	3.61	0.00034	0.0222	0.18	0.16	Vitiligo;	chr22:41557735	chr22:42138060~42139726:+
THCA	cis	rs36093844	0.527	rs17745273	ENSG00000279742.1	RP11-700A24.1	-3.61	0.00034	0.0222	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86044496	chr11:85852557~85854943:-
THCA	cis	rs879324	0.74	rs59288483	ENSG00000280092.1	AC002044.3	3.61	0.00034	0.0222	0.24	0.16	Stroke (ischemic);	chr16:73004957	chr16:73005601~73006141:-
THCA	cis	rs879324	0.639	rs55649472	ENSG00000280092.1	AC002044.3	3.61	0.00034	0.0222	0.24	0.16	Stroke (ischemic);	chr16:73005489	chr16:73005601~73006141:-
THCA	cis	rs2243480	1	rs10807701	ENSG00000237310.1	GS1-124K5.4	-3.61	0.00034	0.0222	-0.19	-0.16	Diabetic kidney disease;	chr7:66259699	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1499613	ENSG00000237310.1	GS1-124K5.4	-3.61	0.00034	0.0222	-0.19	-0.16	Diabetic kidney disease;	chr7:66265873	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1553174	ENSG00000237310.1	GS1-124K5.4	-3.61	0.00034	0.0222	-0.19	-0.16	Diabetic kidney disease;	chr7:66266207	chr7:66493706~66495474:+
THCA	cis	rs12681366	0.881	rs2931631	ENSG00000253175.1	RP11-267M23.6	3.61	0.00034	0.0222	0.21	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94401415	chr8:94565036~94565715:+
THCA	cis	rs3758911	1	rs12146472	ENSG00000255353.1	RP11-382M14.1	-3.61	0.00034	0.0222	-0.2	-0.16	Coronary artery disease;	chr11:107323450	chr11:107176286~107177530:+
THCA	cis	rs3758911	1	rs12146473	ENSG00000255353.1	RP11-382M14.1	-3.61	0.00034	0.0222	-0.2	-0.16	Coronary artery disease;	chr11:107323540	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.929	rs55837508	ENSG00000255353.1	RP11-382M14.1	-3.61	0.00034	0.0222	-0.2	-0.16	Coronary artery disease;	chr11:107323756	chr11:107176286~107177530:+
THCA	cis	rs3733585	0.806	rs11723382	ENSG00000261490.1	RP11-448G15.3	-3.61	0.00034	0.0222	-0.1	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953036	chr4:10068089~10073019:-
THCA	cis	rs3733585	0.674	rs7375643	ENSG00000261490.1	RP11-448G15.3	-3.61	0.00034	0.0222	-0.1	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953615	chr4:10068089~10073019:-
THCA	cis	rs4262150	0.81	rs72797241	ENSG00000253921.1	CTB-113P19.3	3.61	0.00034	0.0222	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152619850	chr5:151753992~151767247:+
THCA	cis	rs80130819	0.748	rs1074174	ENSG00000226413.2	OR8T1P	3.61	0.00034	0.0222	0.24	0.16	Prostate cancer;	chr12:48302937	chr12:48442030~48442947:-
THCA	cis	rs7744813	0.602	rs4706515	ENSG00000229852.2	RP11-398K22.12	3.61	0.00034	0.0222	0.13	0.16	Myopia;Refractive error;Spherical equivalent (joint analysis main effects and education interaction);	chr6:72868692	chr6:73263215~73301401:+
THCA	cis	rs7744813	0.579	rs2211390	ENSG00000229852.2	RP11-398K22.12	3.61	0.00034	0.0222	0.13	0.16	Myopia;Refractive error;Spherical equivalent (joint analysis main effects and education interaction);	chr6:72868931	chr6:73263215~73301401:+
THCA	cis	rs28830936	0.966	rs2277535	ENSG00000250379.1	RP11-23P13.4	3.61	0.00034	0.0222	0.19	0.16	Diastolic blood pressure;	chr15:41827513	chr15:41825099~41827936:-
THCA	cis	rs28830936	0.966	rs8025714	ENSG00000250379.1	RP11-23P13.4	3.61	0.00034	0.0222	0.19	0.16	Diastolic blood pressure;	chr15:41827959	chr15:41825099~41827936:-
THCA	cis	rs701145	0.585	rs1620712	ENSG00000238755.3	RP11-23D24.2	3.61	0.00034	0.0222	0.33	0.16	Coronary artery disease;	chr3:154072261	chr3:153384934~153980186:-
THCA	cis	rs701145	0.585	rs62276842	ENSG00000238755.3	RP11-23D24.2	-3.61	0.00034	0.0222	-0.33	-0.16	Coronary artery disease;	chr3:154066259	chr3:153384934~153980186:-
THCA	cis	rs701145	0.585	rs1612933	ENSG00000238755.3	RP11-23D24.2	-3.61	0.00034	0.0222	-0.33	-0.16	Coronary artery disease;	chr3:154068330	chr3:153384934~153980186:-
THCA	cis	rs701145	0.585	rs1713843	ENSG00000238755.3	RP11-23D24.2	-3.61	0.00034	0.0222	-0.33	-0.16	Coronary artery disease;	chr3:154068605	chr3:153384934~153980186:-
THCA	cis	rs7259376	0.902	rs11669179	ENSG00000269345.1	VN1R85P	-3.61	0.00034	0.0222	-0.18	-0.16	Menopause (age at onset);	chr19:22421927	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.902	rs11669270	ENSG00000269345.1	VN1R85P	-3.61	0.00034	0.0222	-0.18	-0.16	Menopause (age at onset);	chr19:22422014	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.902	rs11669353	ENSG00000269345.1	VN1R85P	-3.61	0.00034	0.0222	-0.18	-0.16	Menopause (age at onset);	chr19:22422301	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.902	rs11879678	ENSG00000269345.1	VN1R85P	-3.61	0.00034	0.0222	-0.18	-0.16	Menopause (age at onset);	chr19:22424510	chr19:22174766~22175191:-
THCA	cis	rs7763441	1	rs7763441	ENSG00000250903.7	GMDS-AS1	-3.61	0.000341	0.0222	-0.14	-0.16	Monobrow;	chr6:2452463	chr6:2245748~2482022:+
THCA	cis	rs6812193	1	rs6812193	ENSG00000234036.4	TXNP6	3.61	0.000341	0.0222	0.23	0.16	Parkinson's disease;	chr4:76277833	chr4:76958860~76959169:-
THCA	cis	rs10186029	0.539	rs4672676	ENSG00000270659.1	RP11-105N14.1	-3.61	0.000341	0.0222	-0.13	-0.16	Systemic sclerosis;	chr2:213137224	chr2:213152970~213153659:+
THCA	cis	rs10186029	0.548	rs4673728	ENSG00000270659.1	RP11-105N14.1	-3.61	0.000341	0.0222	-0.13	-0.16	Systemic sclerosis;	chr2:213137273	chr2:213152970~213153659:+
THCA	cis	rs910316	0.935	rs175076	ENSG00000259138.1	RP11-950C14.7	-3.61	0.000341	0.0222	-0.14	-0.16	Height;	chr14:75038783	chr14:75127153~75136930:+
THCA	cis	rs2839186	0.9	rs56840278	ENSG00000228137.1	AP001469.7	3.61	0.000341	0.0222	0.16	0.16	Testicular germ cell tumor;	chr21:46289019	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.933	rs56955294	ENSG00000228137.1	AP001469.7	3.61	0.000341	0.0222	0.16	0.16	Testicular germ cell tumor;	chr21:46289039	chr21:46246890~46247682:+
THCA	cis	rs4568518	0.616	rs13223642	ENSG00000279048.1	RP11-511H23.2	3.61	0.000341	0.0222	0.1	0.16	Measles;	chr7:17965352	chr7:17940503~17942922:+
THCA	cis	rs910316	1	rs4903284	ENSG00000259138.1	RP11-950C14.7	3.61	0.000341	0.0222	0.14	0.16	Height;	chr14:75125780	chr14:75127153~75136930:+
THCA	cis	rs910316	0.967	rs2024653	ENSG00000259138.1	RP11-950C14.7	3.61	0.000341	0.0222	0.14	0.16	Height;	chr14:75128451	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs1047418	ENSG00000259138.1	RP11-950C14.7	3.61	0.000341	0.0222	0.14	0.16	Height;	chr14:75139089	chr14:75127153~75136930:+
THCA	cis	rs862034	0.531	rs8008540	ENSG00000270000.1	RP3-449M8.9	3.61	0.000341	0.0222	0.16	0.16	Height;	chr14:74481477	chr14:74471930~74472360:-
THCA	cis	rs7914558	0.901	rs1926034	ENSG00000213061.2	PFN1P11	3.61	0.000341	0.0222	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103069345	chr10:102838011~102845473:-
THCA	cis	rs875971	0.895	rs12698520	ENSG00000272831.1	RP11-792A8.4	3.61	0.000341	0.0222	0.1	0.16	Aortic root size;	chr7:66453720	chr7:66739829~66740385:-
THCA	cis	rs2814021	0.54	rs1456285	ENSG00000233643.2	RP11-491H19.1	3.61	0.000341	0.0222	0.19	0.16	Obesity-related traits;	chr10:61609874	chr10:61781745~61821246:-
THCA	cis	rs34421088	0.576	rs2572432	ENSG00000261451.1	RP11-981G7.1	-3.61	0.000341	0.0222	-0.23	-0.16	Neuroticism;	chr8:11244214	chr8:10433672~10438312:+
THCA	cis	rs2880765	0.835	rs12708553	ENSG00000259407.1	RP11-158M2.3	3.61	0.000341	0.0222	0.16	0.16	Coronary artery disease;	chr15:85503602	chr15:85744109~85750281:-
THCA	cis	rs6545883	0.894	rs2694632	ENSG00000212978.6	AC016747.3	-3.61	0.000341	0.0222	-0.18	-0.16	Tuberculosis;	chr2:61331547	chr2:61141592~61144969:-
THCA	cis	rs6545883	0.825	rs7578139	ENSG00000212978.6	AC016747.3	-3.61	0.000341	0.0222	-0.18	-0.16	Tuberculosis;	chr2:61336986	chr2:61141592~61144969:-
THCA	cis	rs2483519	0.511	rs11196874	ENSG00000228169.3	PPIAP19	-3.61	0.000341	0.0222	-0.19	-0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114685009	chr10:114690143~114690634:-
THCA	cis	rs9650657	0.836	rs891556	ENSG00000269918.1	AF131215.9	-3.61	0.000341	0.0222	-0.17	-0.16	Neuroticism;	chr8:10766123	chr8:11104691~11106704:-
THCA	cis	rs11633886	0.707	rs11070472	ENSG00000259200.1	RP11-718O11.1	-3.61	0.000341	0.0222	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45744031	chr15:45705078~45931069:+
THCA	cis	rs6479874	0.749	rs2666540	ENSG00000223502.1	RP11-96B5.3	3.61	0.000341	0.0222	0.19	0.16	Migraine;	chr10:50963380	chr10:51062579~51068553:-
THCA	cis	rs7520050	0.807	rs28378621	ENSG00000281133.1	AL355480.3	-3.61	0.000341	0.0222	-0.19	-0.16	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45580892~45580996:-
THCA	cis	rs1707322	0.613	rs1473840	ENSG00000281133.1	AL355480.3	3.61	0.000341	0.0222	0.21	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr1:45580892~45580996:-
THCA	cis	rs6890684	0.569	rs34627	ENSG00000251279.1	CTC-436P18.1	-3.61	0.000341	0.0222	-0.2	-0.16	Intelligence (multi-trait analysis);	chr5:61232979	chr5:61162070~61232040:+
THCA	cis	rs17123764	0.818	rs57916875	ENSG00000257464.1	RP11-161H23.8	-3.61	0.000341	0.0222	-0.29	-0.16	Intelligence (multi-trait analysis);	chr12:49595553	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs52824916	ENSG00000257464.1	RP11-161H23.8	-3.61	0.000341	0.0222	-0.29	-0.16	Intelligence (multi-trait analysis);	chr12:49599895	chr12:49442424~49442652:-
THCA	cis	rs11673344	0.526	rs2291001	ENSG00000267470.4	ZNF571-AS1	-3.61	0.000341	0.0222	-0.2	-0.16	Obesity-related traits;	chr19:37594431	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.518	rs73033134	ENSG00000267470.4	ZNF571-AS1	-3.61	0.000341	0.0222	-0.2	-0.16	Obesity-related traits;	chr19:37596046	chr19:37548914~37587348:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000219891.2	ZSCAN12P1	3.61	0.000341	0.0222	0.23	0.16	Depression;	chr6:28071808	chr6:28091154~28093664:+
THCA	cis	rs1113500	0.547	rs12076264	ENSG00000226822.1	RP11-356N1.2	-3.61	0.000341	0.0222	-0.17	-0.16	Growth-regulated protein alpha levels;	chr1:108014486	chr1:108071482~108074519:+
THCA	cis	rs875971	0.619	rs10278371	ENSG00000232546.1	RP11-458F8.1	3.61	0.000341	0.0222	0.13	0.16	Aortic root size;	chr7:66586553	chr7:66848496~66858136:+
THCA	cis	rs3808502	0.549	rs4841564	ENSG00000255046.1	RP11-297N6.4	3.61	0.000341	0.0222	0.17	0.16	Neuroticism;	chr8:11568300	chr8:11797928~11802568:-
THCA	cis	rs17122278	0.79	rs45548238	ENSG00000243431.1	RPL5P30	3.61	0.000341	0.0223	0.16	0.16	Total cholesterol levels;	chr11:118534722	chr11:118560690~118561580:+
THCA	cis	rs7578199	0.576	rs7607425	ENSG00000223374.1	AC005104.3	-3.61	0.000341	0.0223	-0.11	-0.16	Chronic lymphocytic leukemia;	chr2:241489495	chr2:241351340~241353104:-
THCA	cis	rs11148252	0.51	rs35895576	ENSG00000273784.3	RP11-78J21.7	-3.61	0.000341	0.0223	-0.17	-0.16	Lewy body disease;	chr13:52010764	chr13:52600042~52642542:+
THCA	cis	rs1552244	0.507	rs6443274	ENSG00000269982.1	RP11-1020A11.2	3.61	0.000341	0.0223	0.12	0.16	Alzheimer's disease;	chr3:9953604	chr3:9958717~9962539:+
THCA	cis	rs1961102	0.521	rs599777	ENSG00000253320.4	KB-1507C5.2	-3.61	0.000341	0.0223	-0.14	-0.16	QT interval;	chr8:102919710	chr8:102864300~102977876:+
THCA	cis	rs1009077	0.582	rs4626181	ENSG00000248280.1	RP11-33B1.2	-3.61	0.000341	0.0223	-0.18	-0.16	Endometriosis;	chr4:119609956	chr4:119440561~119450157:-
THCA	cis	rs9863	0.828	rs11057409	ENSG00000269938.1	RP11-214K3.20	3.61	0.000341	0.0223	0.19	0.16	White blood cell count;	chr12:123994784	chr12:123968023~123968579:-
THCA	cis	rs7824557	0.564	rs1435275	ENSG00000261451.1	RP11-981G7.1	-3.61	0.000341	0.0223	-0.21	-0.16	Retinal vascular caliber;	chr8:11378226	chr8:10433672~10438312:+
THCA	cis	rs2281636	0.63	rs12355655	ENSG00000260475.1	RP11-85A1.3	3.61	0.000341	0.0223	0.17	0.16	Obesity-related traits;	chr10:99616982	chr10:99621055~99621918:+
THCA	cis	rs9584850	0.874	rs4584	ENSG00000231194.1	FARP1-AS1	3.61	0.000342	0.0223	0.2	0.16	Neuroticism;	chr13:98449615	chr13:98435405~98435840:-
THCA	cis	rs2180341	1	rs6569479	ENSG00000220522.2	RP1-177A13.1	3.61	0.000342	0.0223	0.21	0.16	Breast cancer;	chr6:127285443	chr6:127416535~127416952:-
THCA	cis	rs10492096	0.898	rs12426815	ENSG00000276718.1	RP1-102E24.10	-3.61	0.000342	0.0223	-0.18	-0.16	Hip geometry;	chr12:6471148	chr12:6466537~6467135:+
THCA	cis	rs7737355	0.947	rs4996522	ENSG00000224431.1	AC063976.7	-3.61	0.000342	0.0223	-0.16	-0.16	Life satisfaction;	chr5:131425777	chr5:132199456~132203487:+
THCA	cis	rs7088591	0.614	rs16911518	ENSG00000276818.1	AC026393.1	3.61	0.000342	0.0223	0.28	0.16	Blood pressure;	chr10:57993227	chr10:57095699~57095781:+
THCA	cis	rs4664304	0.511	rs7606160	ENSG00000226266.5	AC009961.3	3.61	0.000342	0.0223	0.2	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159837395	chr2:159670708~159712435:-
THCA	cis	rs11992162	0.591	rs34123222	ENSG00000227888.4	FAM66A	-3.61	0.000342	0.0223	-0.22	-0.16	Monocyte count;	chr8:11937840	chr8:12362019~12388296:+
THCA	cis	rs2179367	0.959	rs544947	ENSG00000223701.3	RAET1E-AS1	3.61	0.000342	0.0223	0.21	0.16	Dupuytren's disease;	chr6:149402412	chr6:149884431~149919508:+
THCA	cis	rs17253792	0.73	rs77079997	ENSG00000186615.9	KTN1-AS1	-3.61	0.000342	0.0223	-0.27	-0.16	Putamen volume;	chr14:55688532	chr14:55499278~55580110:-
THCA	cis	rs11180559	0.534	rs1542570	ENSG00000257497.2	RP11-585P4.5	3.61	0.000342	0.0223	0.3	0.16	Daytime sleep phenotypes;	chr12:75604823	chr12:75483454~75489820:-
THCA	cis	rs6840360	0.869	rs55668815	ENSG00000270265.1	RP11-731D1.4	-3.61	0.000342	0.0223	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151552676	chr4:151333775~151353224:-
THCA	cis	rs9353324	1	rs9444356	ENSG00000203875.9	SNHG5	-3.61	0.000342	0.0223	-0.32	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85651200	chr6:85660950~85678736:-
THCA	cis	rs7216064	1	rs6504555	ENSG00000265055.1	AC145343.2	-3.61	0.000342	0.0223	-0.23	-0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67944611	chr17:68096046~68101474:-
THCA	cis	rs1957429	0.901	rs2884308	ENSG00000272158.1	RP11-840I19.5	3.61	0.000342	0.0223	0.29	0.16	Pediatric areal bone mineral density (radius);	chr14:64883688	chr14:65003325~65003767:-
THCA	cis	rs252152	0.652	rs2906077	ENSG00000280047.1	CTC-463A16.1	3.61	0.000342	0.0223	0.17	0.16	Squamous cell lung carcinoma;	chr5:142191759	chr5:142165767~142168387:+
THCA	cis	rs7176527	0.706	rs35641144	ENSG00000230373.7	GOLGA6L5P	3.61	0.000342	0.0223	0.23	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84723543	chr15:84507885~84516814:-
THCA	cis	rs6893300	0.785	rs12522263	ENSG00000225051.5	HMGB3P22	3.61	0.000342	0.0223	0.17	0.16	Resting heart rate;	chr5:179749691	chr5:179679032~179694768:+
THCA	cis	rs12544026	0.581	rs488034	ENSG00000253669.3	KB-1732A1.1	-3.61	0.000342	0.0223	-0.19	-0.16	Major depression and alcohol dependence;	chr8:101847352	chr8:102805517~102809971:+
THCA	cis	rs9987353	0.566	rs6998368	ENSG00000253981.4	ALG1L13P	-3.61	0.000342	0.0223	-0.17	-0.16	Recombination measurement;	chr8:9212778	chr8:8236003~8244667:-
THCA	cis	rs9309473	1	rs13398956	ENSG00000273245.1	RP11-434P11.2	3.61	0.000342	0.0223	0.23	0.16	Metabolite levels;	chr2:73493131	chr2:73750256~73750786:-
THCA	cis	rs6012953	0.817	rs1060402	ENSG00000231715.1	COX6CP2	-3.61	0.000342	0.0223	-0.18	-0.16	Vitiligo;	chr20:50588558	chr20:50479767~50479991:+
THCA	cis	rs73222236	0.825	rs34962604	ENSG00000273486.1	RP11-731C17.2	3.61	0.000342	0.0223	0.15	0.16	Coronary artery disease;	chr3:136511148	chr3:136837338~136839021:-
THCA	cis	rs6901004	0.803	rs1322214	ENSG00000271789.1	RP5-1112D6.7	-3.61	0.000342	0.0223	-0.16	-0.16	Blood metabolite levels;	chr6:111158842	chr6:111297126~111298510:+
THCA	cis	rs995834	0.869	rs1476763	ENSG00000261770.1	CTC-459F4.1	-3.61	0.000342	0.0223	-0.22	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394591	chr19:27757184~27760849:-
THCA	cis	rs995834	0.828	rs10460161	ENSG00000261770.1	CTC-459F4.1	-3.61	0.000342	0.0223	-0.22	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394686	chr19:27757184~27760849:-
THCA	cis	rs7737355	0.773	rs32103	ENSG00000237714.1	P4HA2-AS1	3.61	0.000342	0.0223	0.24	0.16	Life satisfaction;	chr5:131695268	chr5:132184876~132192808:+
THCA	cis	rs2360027	0.662	rs34315290	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000342	0.0223	-0.16	-0.16	Tonsillectomy;	chr1:118610791	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.662	rs10159148	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000342	0.0223	-0.16	-0.16	Tonsillectomy;	chr1:118611182	chr1:119140396~119275973:+
THCA	cis	rs9660180	0.967	rs6603803	ENSG00000215914.4	MMP23A	-3.61	0.000342	0.0223	-0.21	-0.16	Body mass index;	chr1:1881249	chr1:1699942~1701782:+
THCA	cis	rs7474896	0.515	rs2505233	ENSG00000272983.1	RP11-508N22.12	-3.61	0.000342	0.0223	-0.17	-0.16	Obesity (extreme);	chr10:38051337	chr10:38137337~38144399:+
THCA	cis	rs1009077	0.627	rs4597811	ENSG00000248280.1	RP11-33B1.2	-3.61	0.000342	0.0223	-0.18	-0.16	Endometriosis;	chr4:119610044	chr4:119440561~119450157:-
THCA	cis	rs3770081	1	rs13390702	ENSG00000272564.1	RP11-548P2.2	-3.61	0.000342	0.0223	-0.28	-0.16	Facial emotion recognition (sad faces);	chr2:86010812	chr2:85904279~85904727:+
THCA	cis	rs17685	0.753	rs10262501	ENSG00000227038.2	AC005077.12	-3.61	0.000342	0.0223	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76038854	chr7:76090431~76108779:-
THCA	cis	rs9303542	0.729	rs1396870	ENSG00000278765.1	RP5-890E16.5	-3.61	0.000342	0.0223	-0.22	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48418050	chr17:48066704~48067293:-
THCA	cis	rs34779708	0.966	rs11010095	ENSG00000233200.1	RP11-324I22.2	3.61	0.000342	0.0223	0.2	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35219894~35230598:-
THCA	cis	rs9898058	0.556	rs1135034	ENSG00000279036.1	RP11-81K2.2	-3.61	0.000342	0.0223	-0.24	-0.16	Milk allergy;	chr17:49706301	chr17:49494223~49497800:-
THCA	cis	rs944990	0.538	rs10821167	ENSG00000227603.1	RP11-165J3.6	3.61	0.000342	0.0223	0.18	0.16	Body mass index;	chr9:93593722	chr9:93435332~93437121:-
THCA	cis	rs7819412	0.537	rs2127127	ENSG00000251402.3	FAM90A25P	-3.61	0.000342	0.0223	-0.21	-0.16	Triglycerides;	chr8:11577283	chr8:12415080~12418090:-
THCA	cis	rs7100689	0.542	rs7096715	ENSG00000242600.5	MBL1P	-3.61	0.000342	0.0223	-0.15	-0.16	Post bronchodilator FEV1;	chr10:80436193	chr10:79904898~79950336:+
THCA	cis	rs17270561	0.609	rs7746502	ENSG00000272462.2	U91328.19	3.61	0.000342	0.0223	0.14	0.16	Iron status biomarkers;	chr6:25718534	chr6:25992662~26001775:+
THCA	cis	rs5758659	0.652	rs129857	ENSG00000234009.1	RPL5P34	3.61	0.000342	0.0223	0.15	0.16	Cognitive function;	chr22:42003682	chr22:42776406~42777296:-
THCA	cis	rs2919009	0.664	rs11815788	ENSG00000271670.1	RP11-95I16.4	3.61	0.000342	0.0223	0.18	0.16	Obesity-related traits;	chr10:120924582	chr10:120879256~120880667:-
THCA	cis	rs2919009	0.664	rs55848502	ENSG00000271670.1	RP11-95I16.4	3.61	0.000342	0.0223	0.18	0.16	Obesity-related traits;	chr10:120925258	chr10:120879256~120880667:-
THCA	cis	rs17194490	0.607	rs5004845	ENSG00000237990.3	CNTN4-AS1	3.61	0.000342	0.0223	0.24	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2526902	chr3:3039033~3069242:-
THCA	cis	rs17194490	0.623	rs5004844	ENSG00000237990.3	CNTN4-AS1	3.61	0.000342	0.0223	0.24	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2526904	chr3:3039033~3069242:-
THCA	cis	rs6456156	0.586	rs6909180	ENSG00000235272.1	FAM103A2P	3.61	0.000342	0.0223	0.22	0.16	Primary biliary cholangitis;	chr6:167047049	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs12213683	ENSG00000235272.1	FAM103A2P	3.61	0.000342	0.0223	0.22	0.16	Primary biliary cholangitis;	chr6:167047230	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs12529876	ENSG00000235272.1	FAM103A2P	3.61	0.000342	0.0223	0.22	0.16	Primary biliary cholangitis;	chr6:167048013	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs12528323	ENSG00000235272.1	FAM103A2P	3.61	0.000342	0.0223	0.22	0.16	Primary biliary cholangitis;	chr6:167048157	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs12528689	ENSG00000235272.1	FAM103A2P	3.61	0.000342	0.0223	0.22	0.16	Primary biliary cholangitis;	chr6:167048258	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs13208636	ENSG00000235272.1	FAM103A2P	3.61	0.000342	0.0223	0.22	0.16	Primary biliary cholangitis;	chr6:167048477	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.586	rs6456149	ENSG00000235272.1	FAM103A2P	3.61	0.000342	0.0223	0.22	0.16	Primary biliary cholangitis;	chr6:167050414	chr6:166586124~166586477:-
THCA	cis	rs1322639	0.542	rs9689153	ENSG00000261039.2	RP11-417E7.2	3.61	0.000342	0.0223	0.23	0.16	Pulse pressure;	chr6:169186730	chr6:169175304~169182740:-
THCA	cis	rs17428076	0.872	rs56218609	ENSG00000228389.1	AC068039.4	-3.61	0.000342	0.0223	-0.2	-0.16	Myopia;	chr2:171997407	chr2:171773482~171775844:+
THCA	cis	rs6997458	1	rs1532423	ENSG00000253549.4	RP11-317J10.2	3.61	0.000342	0.0223	0.16	0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85356084	chr8:85441851~85464915:-
THCA	cis	rs4073416	0.508	rs6573619	ENSG00000276116.2	FUT8-AS1	3.61	0.000342	0.0223	0.18	0.16	N-glycan levels;	chr14:65594842	chr14:65411170~65412690:-
THCA	cis	rs7193541	0.826	rs56143602	ENSG00000262904.1	TMPOP2	-3.61	0.000342	0.0223	-0.2	-0.16	Multiple myeloma;	chr16:74660794	chr16:74667506~74668706:+
THCA	cis	rs7680126	0.626	rs11723388	ENSG00000261490.1	RP11-448G15.3	-3.61	0.000342	0.0223	-0.15	-0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10194178	chr4:10068089~10073019:-
THCA	cis	rs7264396	0.676	rs6058380	ENSG00000088340.14	FER1L4	3.61	0.000342	0.0223	0.16	0.16	Total cholesterol levels;	chr20:35964978	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs6058382	ENSG00000088340.14	FER1L4	3.61	0.000342	0.0223	0.16	0.16	Total cholesterol levels;	chr20:35966026	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.676	rs58372200	ENSG00000088340.14	FER1L4	3.61	0.000342	0.0223	0.16	0.16	Total cholesterol levels;	chr20:35967523	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.676	rs6060727	ENSG00000088340.14	FER1L4	3.61	0.000342	0.0223	0.16	0.16	Total cholesterol levels;	chr20:35968078	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.676	rs6058383	ENSG00000088340.14	FER1L4	3.61	0.000342	0.0223	0.16	0.16	Total cholesterol levels;	chr20:35968083	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.676	rs1341603	ENSG00000088340.14	FER1L4	3.61	0.000342	0.0223	0.16	0.16	Total cholesterol levels;	chr20:35968294	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.676	rs6060729	ENSG00000088340.14	FER1L4	3.61	0.000342	0.0223	0.16	0.16	Total cholesterol levels;	chr20:35969082	chr20:35558737~35607562:-
THCA	cis	rs763121	0.888	rs2235229	ENSG00000225450.1	RP3-508I15.14	-3.61	0.000342	0.0223	-0.13	-0.16	Menopause (age at onset);	chr22:38728907	chr22:38739003~38749041:+
THCA	cis	rs67839313	0.541	rs10163093	ENSG00000273855.1	RP11-133K1.12	3.61	0.000343	0.0223	0.32	0.16	Type 2 diabetes;	chr15:40314717	chr15:40285468~40285909:-
THCA	cis	rs1005277	0.579	rs2505241	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000343	0.0223	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:37883594~37884109:+
THCA	cis	rs7726414	1	rs115808154	ENSG00000250994.1	AC005355.1	-3.61	0.000343	0.0223	-0.34	-0.16	Systemic lupus erythematosus;	chr5:134128584	chr5:134436711~134492519:+
THCA	cis	rs8023401	0.507	rs11634866	ENSG00000259705.1	RP11-227D13.1	3.61	0.000343	0.0223	0.19	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48482091	chr15:48645951~48652016:+
THCA	cis	rs4906332	0.811	rs2021965	ENSG00000269940.1	RP11-73M18.7	-3.61	0.000343	0.0223	-0.17	-0.16	Coronary artery disease;	chr14:103530911	chr14:103694560~103695170:+
THCA	cis	rs2380205	0.517	rs7090411	ENSG00000232807.2	RP11-536K7.3	3.61	0.000343	0.0223	0.17	0.16	Breast cancer;	chr10:5920764	chr10:5934270~5945900:-
THCA	cis	rs683250	0.629	rs504105	ENSG00000254551.1	RP11-727A23.7	-3.61	0.000343	0.0223	-0.22	-0.16	Subcortical brain region volumes;	chr11:83252917	chr11:83209431~83213379:-
THCA	cis	rs1941184	0.5	rs8096400	ENSG00000266521.1	RP11-650P15.1	3.61	0.000343	0.0223	0.26	0.16	Parkinson's disease (age of onset);	chr18:31437363	chr18:31496645~31497195:-
THCA	cis	rs2736345	1	rs922483	ENSG00000254527.1	ENPP7P12	3.61	0.000343	0.0223	0.21	0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11494403	chr8:12205759~12206389:-
THCA	cis	rs9890032	0.581	rs62070592	ENSG00000276250.1	CTD-2349P21.12	-3.61	0.000343	0.0223	-0.14	-0.16	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30803654~30804077:+
THCA	cis	rs10457678	0.579	rs11155012	ENSG00000225415.2	RP3-509I19.1	-3.61	0.000343	0.0223	-0.23	-0.16	Colorectal or endometrial cancer;	chr6:138830647	chr6:138822747~138823799:+
THCA	cis	rs7191700	1	rs7191700	ENSG00000262636.1	CTD-3088G3.4	3.61	0.000343	0.0223	0.24	0.16	Multiple sclerosis;	chr16:11312946	chr16:11380859~11381118:-
THCA	cis	rs34421088	0.56	rs2245250	ENSG00000270154.1	RP11-419I17.1	-3.61	0.000343	0.0223	-0.21	-0.16	Neuroticism;	chr8:11543171	chr8:12476462~12477122:+
THCA	cis	rs10875746	0.669	rs11168516	ENSG00000258273.1	RP11-370I10.4	3.61	0.000343	0.0223	0.24	0.16	Longevity (90 years and older);	chr12:48308282	chr12:48333755~48333901:-
THCA	cis	rs7615952	0.599	rs6779141	ENSG00000241288.6	RP11-379B18.5	-3.61	0.000343	0.0223	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:125991152	chr3:125827238~125916384:-
THCA	cis	rs11992162	0.569	rs35283519	ENSG00000255046.1	RP11-297N6.4	3.61	0.000343	0.0223	0.2	0.16	Monocyte count;	chr8:11974152	chr8:11797928~11802568:-
THCA	cis	rs11694172	0.826	rs16839308	ENSG00000273456.1	RP11-686O6.2	-3.61	0.000343	0.0223	-0.15	-0.16	Cholesterol, total;	chr2:202757077	chr2:202374932~202375604:-
THCA	cis	rs7572733	0.555	rs2164071	ENSG00000231621.1	AC013264.2	-3.61	0.000343	0.0223	-0.17	-0.16	Dermatomyositis;	chr2:198050743	chr2:197197991~197199273:+
THCA	cis	rs8112211	0.731	rs8101488	ENSG00000267291.1	CTB-186G2.1	3.61	0.000343	0.0223	0.18	0.16	Blood protein levels;	chr19:38334454	chr19:38596346~38601694:+
THCA	cis	rs208520	1	rs9453663	ENSG00000233859.2	ADH5P4	3.61	0.000343	0.0223	0.25	0.16	Exhaled nitric oxide output;	chr6:66266184	chr6:65836930~65838039:-
THCA	cis	rs208520	0.955	rs9453664	ENSG00000233859.2	ADH5P4	3.61	0.000343	0.0223	0.25	0.16	Exhaled nitric oxide output;	chr6:66266186	chr6:65836930~65838039:-
THCA	cis	rs73173548	0.502	rs10505856	ENSG00000247828.6	TMEM161B-AS1	3.61	0.000343	0.0223	0.15	0.16	Macular telangiectasia type 2;	chr5:88440636	chr5:88268895~88436685:+
THCA	cis	rs7560272	0.501	rs12624267	ENSG00000163016.8	ALMS1P	-3.61	0.000343	0.0223	-0.2	-0.16	Schizophrenia;	chr2:73759804	chr2:73644919~73685576:+
THCA	cis	rs6545883	0.826	rs2694651	ENSG00000212978.6	AC016747.3	-3.61	0.000343	0.0224	-0.18	-0.16	Tuberculosis;	chr2:61361507	chr2:61141592~61144969:-
THCA	cis	rs7296418	0.961	rs1790106	ENSG00000256092.2	RP13-942N8.1	3.61	0.000343	0.0224	0.12	0.16	Platelet count;	chr12:123107049	chr12:123363868~123366113:+
THCA	cis	rs2933343	0.729	rs1683816	ENSG00000231305.3	RP11-723O4.2	-3.61	0.000343	0.0224	-0.17	-0.16	IgG glycosylation;	chr3:128932352	chr3:128861313~128871540:-
THCA	cis	rs2625529	0.775	rs12913042	ENSG00000260037.4	CTD-2524L6.3	-3.61	0.000343	0.0224	-0.23	-0.16	Red blood cell count;	chr15:71909968	chr15:71818396~71823384:+
THCA	cis	rs2214442	0.817	rs3807940	ENSG00000271133.4	CTA-293F17.1	-3.61	0.000343	0.0224	-0.17	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20361880	chr7:20328299~20331747:-
THCA	cis	rs6430585	1	rs6732236	ENSG00000231890.6	DARS-AS1	-3.61	0.000343	0.0224	-0.19	-0.16	Corneal structure;	chr2:135743939	chr2:135985176~136022593:+
THCA	cis	rs7608910	0.668	rs6754585	ENSG00000270820.4	RP11-355B11.2	3.61	0.000343	0.0224	0.14	0.16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60995008	chr2:61471188~61484130:+
THCA	cis	rs116979167	0.507	rs12705314	ENSG00000272604.1	RP11-251G23.5	-3.61	0.000343	0.0224	-0.17	-0.16	Bipolar disorder (body mass index interaction);	chr7:105575458	chr7:105571083~105573660:+
THCA	cis	rs875971	1	rs1144895	ENSG00000230189.5	GS1-124K5.2	-3.61	0.000343	0.0224	-0.11	-0.16	Aortic root size;	chr7:66076320	chr7:66409143~66490059:-
THCA	cis	rs5758511	0.689	rs17478227	ENSG00000270083.1	RP1-257I20.14	3.61	0.000343	0.0224	0.25	0.16	Birth weight;	chr22:42258321	chr22:42089630~42090028:-
THCA	cis	rs10863936	0.644	rs67417805	ENSG00000198468.6	FLVCR1-AS1	-3.61	0.000343	0.0224	-0.2	-0.16	Height;	chr1:212052742	chr1:212852108~212858088:-
THCA	cis	rs62292953	0.719	rs11926095	ENSG00000248724.5	NPHP3-AS1	-3.61	0.000343	0.0224	-0.29	-0.16	Red cell distribution width;	chr3:132452074	chr3:132721750~132874223:+
THCA	cis	rs7216064	1	rs7214758	ENSG00000265055.1	AC145343.2	3.61	0.000343	0.0224	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67884422	chr17:68096046~68101474:-
THCA	cis	rs6546550	1	rs6546550	ENSG00000179818.12	PCBP1-AS1	-3.61	0.000343	0.0224	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69811100	chr2:69962263~70103220:-
THCA	cis	rs1075265	0.933	rs2287642	ENSG00000235937.1	AC008280.1	3.61	0.000343	0.0224	0.19	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54029552~54030682:-
THCA	cis	rs4915077	0.773	rs17019768	ENSG00000226822.1	RP11-356N1.2	3.61	0.000343	0.0224	0.3	0.16	Hypothyroidism;	chr1:107720934	chr1:108071482~108074519:+
THCA	cis	rs3740713	0.669	rs78098319	ENSG00000256588.1	RP11-613F22.8	3.61	0.000343	0.0224	0.25	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr11:18507608~18508820:-
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000184274.3	LINC00315	-3.61	0.000343	0.0224	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000184274.3	LINC00315	-3.61	0.000343	0.0224	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000184274.3	LINC00315	-3.61	0.000343	0.0224	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000184274.3	LINC00315	-3.61	0.000343	0.0224	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45300245~45305257:-
THCA	cis	rs5758511	0.68	rs5758651	ENSG00000270083.1	RP1-257I20.14	-3.61	0.000344	0.0224	-0.22	-0.16	Birth weight;	chr22:42213142	chr22:42089630~42090028:-
THCA	cis	rs3808502	0.503	rs2061830	ENSG00000270154.1	RP11-419I17.1	3.61	0.000344	0.0224	0.2	0.16	Neuroticism;	chr8:11539948	chr8:12476462~12477122:+
THCA	cis	rs9863	0.931	rs4765335	ENSG00000269938.1	RP11-214K3.20	-3.61	0.000344	0.0224	-0.19	-0.16	White blood cell count;	chr12:123946265	chr12:123968023~123968579:-
THCA	cis	rs10882873	0.503	rs1253407	ENSG00000237169.1	RP11-452K12.3	-3.61	0.000344	0.0224	-0.21	-0.16	Lymphocyte percentage of white cells;	chr10:97209311	chr10:97309138~97309958:-
THCA	cis	rs240993	0.595	rs4947127	ENSG00000220392.1	FCF1P5	3.61	0.000344	0.0224	0.18	0.16	Inflammatory skin disease;Psoriasis;	chr6:111581595	chr6:111353702~111354183:+
THCA	cis	rs6743226	0.603	rs62186419	ENSG00000223374.1	AC005104.3	3.61	0.000344	0.0224	0.12	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241307450	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.557	rs62186420	ENSG00000223374.1	AC005104.3	3.61	0.000344	0.0224	0.12	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241307460	chr2:241351340~241353104:-
THCA	cis	rs4262150	0.846	rs4958574	ENSG00000253921.1	CTB-113P19.3	3.61	0.000344	0.0224	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152712341	chr5:151753992~151767247:+
THCA	cis	rs7259376	0.936	rs8108630	ENSG00000269138.1	ZNF209P	3.61	0.000344	0.0224	0.17	0.16	Menopause (age at onset);	chr19:22352375	chr19:22463922~22473036:+
THCA	cis	rs7829975	0.902	rs777707	ENSG00000253981.4	ALG1L13P	3.61	0.000344	0.0224	0.16	0.16	Mood instability;	chr8:8726834	chr8:8236003~8244667:-
THCA	cis	rs2360027	0.64	rs1343298	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000344	0.0224	-0.16	-0.16	Tonsillectomy;	chr1:118581188	chr1:119140396~119275973:+
THCA	cis	rs9863	0.931	rs3186071	ENSG00000269938.1	RP11-214K3.20	-3.61	0.000344	0.0224	-0.19	-0.16	White blood cell count;	chr12:123944732	chr12:123968023~123968579:-
THCA	cis	rs8054556	0.787	rs1140239	ENSG00000183604.13	SMG1P5	-3.61	0.000344	0.0224	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30010081	chr16:30267553~30335374:-
THCA	cis	rs614226	1	rs591992	ENSG00000278344.1	RP11-18C24.8	3.61	0.000344	0.0224	0.21	0.16	Type 1 diabetes nephropathy;	chr12:120581520	chr12:120500735~120501090:-
THCA	cis	rs4792901	0.802	rs72833123	ENSG00000279602.1	CTD-3014M21.1	-3.61	0.000344	0.0224	-0.21	-0.16	Dupuytren's disease;	chr17:43475035	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.765	rs9905358	ENSG00000279602.1	CTD-3014M21.1	-3.61	0.000344	0.0224	-0.21	-0.16	Dupuytren's disease;	chr17:43478106	chr17:43360041~43361361:-
THCA	cis	rs9309473	1	rs56154726	ENSG00000273245.1	RP11-434P11.2	3.61	0.000344	0.0224	0.23	0.16	Metabolite levels;	chr2:73494640	chr2:73750256~73750786:-
THCA	cis	rs754466	0.58	rs10430530	ENSG00000213514.2	RP11-428P16.2	3.61	0.000344	0.0224	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77823054	chr10:77730766~77734769:+
THCA	cis	rs7829975	0.84	rs555617	ENSG00000233609.3	RP11-62H7.2	-3.61	0.000344	0.0224	-0.16	-0.16	Mood instability;	chr8:8735335	chr8:8961200~8979025:+
THCA	cis	rs3770081	1	rs17618001	ENSG00000273080.1	RP11-301O19.1	-3.61	0.000344	0.0224	-0.39	-0.16	Facial emotion recognition (sad faces);	chr2:86062180	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs75109362	ENSG00000273080.1	RP11-301O19.1	-3.61	0.000344	0.0224	-0.39	-0.16	Facial emotion recognition (sad faces);	chr2:86062766	chr2:86195590~86196049:+
THCA	cis	rs896655	0.541	rs7023329	ENSG00000229835.2	KHSRPP1	-3.61	0.000344	0.0224	-0.2	-0.16	Coronary artery disease;	chr9:21816529	chr9:21695176~21696943:+
THCA	cis	rs11800820	0.567	rs3124110	ENSG00000231612.1	RP11-522M21.3	3.61	0.000344	0.0224	0.23	0.16	Obesity-related traits;	chr1:246542452	chr1:245673732~245676478:-
THCA	cis	rs4908760	0.792	rs6577515	ENSG00000270282.1	RP5-1115A15.2	3.61	0.000344	0.0224	0.19	0.16	Vitiligo;	chr1:8654143	chr1:8512653~8513021:+
THCA	cis	rs1005277	0.579	rs2474567	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2472175	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2472176	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474568	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2983343	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474569	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.602	rs2504142	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2472181	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474574	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2504140	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474575	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2472182	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.541	rs2263163	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2021649	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2472183	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2505197	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2505196	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.557	rs1854563	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2505237	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474599	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2505240	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.54	rs2224248	ENSG00000151963.4	RP11-775A3.1	-3.61	0.000344	0.0224	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:37883594~37884109:+
THCA	cis	rs897984	0.683	rs729482	ENSG00000275263.1	RP11-1072A3.4	-3.61	0.000344	0.0224	-0.2	-0.16	Dementia with Lewy bodies;	chr16:31005649	chr16:30956872~30957199:-
THCA	cis	rs972540	1	rs13396393	ENSG00000229647.1	AC007879.7	-3.61	0.000344	0.0224	-0.19	-0.16	Body mass index;	chr2:206370968	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs13422132	ENSG00000229647.1	AC007879.7	-3.61	0.000344	0.0224	-0.19	-0.16	Body mass index;	chr2:206371013	chr2:207239650~207245887:+
THCA	cis	rs651907	1	rs665211	ENSG00000256628.3	ZBTB11-AS1	3.61	0.000344	0.0224	0.16	0.16	Colorectal cancer;	chr3:101881184	chr3:101676475~101679217:+
THCA	cis	rs7259376	0.782	rs113181884	ENSG00000270947.1	AC025811.3	-3.61	0.000344	0.0224	-0.18	-0.16	Menopause (age at onset);	chr19:22403282	chr19:22455988~22456459:+
THCA	cis	rs9341808	0.718	rs9352806	ENSG00000260645.1	RP11-250B2.5	3.61	0.000344	0.0224	0.14	0.16	Sitting height ratio;	chr6:80270340	chr6:80466958~80469080:+
THCA	cis	rs6968419	0.887	rs10235059	ENSG00000237870.5	AC073130.1	3.61	0.000344	0.0224	0.17	0.16	Intraocular pressure;	chr7:116198216	chr7:116275606~116286734:-
THCA	cis	rs7656342	0.628	rs2867383	ENSG00000242034.1	RP11-1396O13.1	-3.61	0.000344	0.0224	-0.19	-0.16	Gut microbiota (bacterial taxa);	chr4:9786311	chr4:9553614~9553985:-
THCA	cis	rs7656342	0.628	rs2903564	ENSG00000242034.1	RP11-1396O13.1	-3.61	0.000344	0.0224	-0.19	-0.16	Gut microbiota (bacterial taxa);	chr4:9786313	chr4:9553614~9553985:-
THCA	cis	rs927833	0.502	rs74802944	ENSG00000214535.3	RPS15AP1	-3.61	0.000344	0.0224	-0.24	-0.16	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr20:21955269	chr20:21166206~21166596:-
THCA	cis	rs2235642	0.533	rs2076436	ENSG00000260989.1	LA16c-395F10.2	-3.61	0.000344	0.0224	-0.19	-0.16	Coronary artery disease;	chr16:1558081	chr16:1580527~1610328:+
THCA	cis	rs1559040	1	rs1559040	ENSG00000272156.1	RP11-477N3.1	-3.61	0.000344	0.0224	-0.26	-0.16	Sudden cardiac arrest;	chr2:54120613	chr2:54082554~54085066:+
THCA	cis	rs867186	0.544	rs56280929	ENSG00000126005.14	MMP24-AS1	-3.61	0.000344	0.0224	-0.28	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35237354	chr20:35216462~35278131:-
THCA	cis	rs1881744	0.588	rs78808618	ENSG00000280054.1	RP1-197B17.7	3.61	0.000344	0.0224	0.33	0.16	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47728151~47730598:-
THCA	cis	rs8046011	0.535	rs1052259	ENSG00000262703.1	RP11-485G7.6	3.61	0.000344	0.0224	0.18	0.16	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr16:11224685	chr16:11348143~11349321:-
THCA	cis	rs3758911	0.894	rs10890698	ENSG00000255353.1	RP11-382M14.1	-3.61	0.000344	0.0224	-0.21	-0.16	Coronary artery disease;	chr11:107308080	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.929	rs10890700	ENSG00000255353.1	RP11-382M14.1	-3.61	0.000344	0.0224	-0.21	-0.16	Coronary artery disease;	chr11:107308243	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.964	rs10789599	ENSG00000255353.1	RP11-382M14.1	-3.61	0.000344	0.0224	-0.21	-0.16	Coronary artery disease;	chr11:107309145	chr11:107176286~107177530:+
THCA	cis	rs11673344	0.504	rs7245882	ENSG00000267260.1	CTD-2162K18.4	3.61	0.000344	0.0224	0.2	0.16	Obesity-related traits;	chr19:37089513	chr19:36773153~36777078:+
THCA	cis	rs10833905	0.878	rs875248	ENSG00000246225.5	RP11-17A1.3	-3.61	0.000344	0.0224	-0.24	-0.16	Sudden cardiac arrest;	chr11:23061279	chr11:22829380~22945393:+
THCA	cis	rs10857712	0.754	rs2297031	ENSG00000214279.11	SCART1	-3.61	0.000344	0.0224	-0.14	-0.16	Systemic lupus erythematosus;	chr10:133419150	chr10:133453928~133523558:+
THCA	cis	rs7613875	0.62	rs17657664	ENSG00000281691.1	RBM5-AS1	3.61	0.000344	0.0224	0.14	0.16	Body mass index;	chr3:49994575	chr3:50099603~50100988:-
THCA	cis	rs7613875	0.62	rs34312088	ENSG00000281691.1	RBM5-AS1	3.61	0.000344	0.0224	0.14	0.16	Body mass index;	chr3:49994700	chr3:50099603~50100988:-
THCA	cis	rs5758511	0.68	rs739147	ENSG00000205702.9	CYP2D7	3.61	0.000344	0.0224	0.15	0.16	Birth weight;	chr22:42275060	chr22:42140203~42144577:-
THCA	cis	rs2242663	0.558	rs11227485	ENSG00000255320.1	RP11-755F10.1	3.61	0.000344	0.0224	0.21	0.16	Bipolar disorder;	chr11:66447952	chr11:66244840~66246239:-
THCA	cis	rs9911578	1	rs3744108	ENSG00000224738.1	AC099850.1	-3.61	0.000344	0.0224	-0.19	-0.16	Intelligence (multi-trait analysis);	chr17:58508511	chr17:59106598~59118267:+
THCA	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	3.61	0.000345	0.0224	0.22	0.16	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
THCA	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	3.61	0.000345	0.0224	0.22	0.16	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
THCA	cis	rs73198271	0.74	rs10109886	ENSG00000254153.1	CTA-398F10.2	3.61	0.000345	0.0224	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8456909~8461337:-
THCA	cis	rs1510272	0.961	rs12696040	ENSG00000243926.1	TIPARP-AS1	-3.61	0.000345	0.0224	-0.17	-0.16	Testicular germ cell tumor;	chr3:156587022	chr3:156671862~156674378:-
THCA	cis	rs17122278	0.929	rs45485302	ENSG00000243431.1	RPL5P30	3.61	0.000345	0.0224	0.16	0.16	Total cholesterol levels;	chr11:118534662	chr11:118560690~118561580:+
THCA	cis	rs4218	0.619	rs10851643	ENSG00000259732.1	RP11-59H7.3	-3.61	0.000345	0.0224	-0.22	-0.16	Social communication problems;	chr15:59102985	chr15:59121034~59133250:+
THCA	cis	rs1065656	0.502	rs1178436	ENSG00000261123.1	RP11-304L19.3	3.61	0.000345	0.0224	0.22	0.16	Insulin-like growth factors;	chr16:1781652	chr16:2094830~2097026:-
THCA	cis	rs7117932	0.935	rs10893889	ENSG00000270160.1	RP11-264E20.2	3.61	0.000345	0.0224	0.2	0.16	Obesity-related traits;	chr11:128573749	chr11:128614340~128615236:-
THCA	cis	rs3924048	0.547	rs12410652	ENSG00000276830.1	MIR6730	-3.61	0.000345	0.0224	-0.16	-0.16	Optic cup area;	chr1:12551203	chr1:12578957~12579023:-
THCA	cis	rs2299682	0.826	rs59512206	ENSG00000230506.1	RP11-416N4.4	3.61	0.000345	0.0224	0.27	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9494778	chr20:10173520~10196990:+
THCA	cis	rs2299682	0.826	rs57453039	ENSG00000230506.1	RP11-416N4.4	3.61	0.000345	0.0224	0.27	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9495127	chr20:10173520~10196990:+
THCA	cis	rs1065852	0.526	rs56234624	ENSG00000281538.1	RP4-669P10.20	-3.61	0.000345	0.0224	-0.17	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41992822	chr22:42138060~42139726:+
THCA	cis	rs9650657	0.707	rs6984744	ENSG00000255310.2	AF131215.2	-3.61	0.000345	0.0224	-0.14	-0.16	Neuroticism;	chr8:10758755	chr8:11107788~11109726:-
THCA	cis	rs3796352	1	rs71301814	ENSG00000280417.1	RP11-5O17.1	-3.61	0.000345	0.0224	-0.25	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:53083647	chr3:53046166~53048122:+
THCA	cis	rs3796352	1	rs11710292	ENSG00000280417.1	RP11-5O17.1	-3.61	0.000345	0.0224	-0.25	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:53083782	chr3:53046166~53048122:+
THCA	cis	rs5758511	0.689	rs55906806	ENSG00000237037.8	NDUFA6-AS1	-3.61	0.000345	0.0224	-0.19	-0.16	Birth weight;	chr22:42248465	chr22:42090931~42137742:+
THCA	cis	rs1876905	0.597	rs1150076	ENSG00000271789.1	RP5-1112D6.7	-3.61	0.000345	0.0224	-0.21	-0.16	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111297126~111298510:+
THCA	cis	rs2360027	0.662	rs4463652	ENSG00000231365.4	RP11-418J17.1	-3.61	0.000345	0.0224	-0.16	-0.16	Tonsillectomy;	chr1:118601150	chr1:119140396~119275973:+
THCA	cis	rs8033133	0.602	rs4906699	ENSG00000251896.1	SNORD116-27	3.61	0.000345	0.0224	0.18	0.16	Blood osmolality (transformed sodium);	chr15:25075882	chr15:25101575~25101666:+
THCA	cis	rs586688	0.625	rs654631	ENSG00000224536.1	RP11-134G8.7	3.61	0.000345	0.0224	0.25	0.16	Obesity-related traits;	chr1:201689321	chr1:201507241~201533608:+
THCA	cis	rs6890684	0.569	rs159360	ENSG00000251279.1	CTC-436P18.1	-3.61	0.000345	0.0224	-0.2	-0.16	Intelligence (multi-trait analysis);	chr5:61233623	chr5:61162070~61232040:+
THCA	cis	rs7701440	0.512	rs10939886	ENSG00000251279.1	CTC-436P18.1	-3.61	0.000345	0.0224	-0.2	-0.16	Educational attainment;	chr5:61235738	chr5:61162070~61232040:+
THCA	cis	rs7701440	0.508	rs476099	ENSG00000251279.1	CTC-436P18.1	-3.61	0.000345	0.0224	-0.2	-0.16	Educational attainment;	chr5:61237147	chr5:61162070~61232040:+
THCA	cis	rs7188697	0.848	rs40187	ENSG00000276259.1	RP11-481J2.4	-3.61	0.000345	0.0224	-0.11	-0.16	QT interval;	chr16:58522662	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs37053	ENSG00000276259.1	RP11-481J2.4	-3.61	0.000345	0.0224	-0.11	-0.16	QT interval;	chr16:58524803	chr16:58522970~58523842:+
THCA	cis	rs7824557	0.564	rs2043508	ENSG00000227888.4	FAM66A	-3.61	0.000345	0.0224	-0.21	-0.16	Retinal vascular caliber;	chr8:11369897	chr8:12362019~12388296:+
THCA	cis	rs11088226	0.681	rs2833895	ENSG00000186842.4	LINC00846	-3.61	0.000345	0.0225	-0.24	-0.16	Gastritis;	chr21:32557492	chr21:32572238~32575881:-
THCA	cis	rs11088226	0.645	rs2409457	ENSG00000186842.4	LINC00846	-3.61	0.000345	0.0225	-0.24	-0.16	Gastritis;	chr21:32557585	chr21:32572238~32575881:-
THCA	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	3.61	0.000345	0.0225	0.15	0.16	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
THCA	cis	rs13196561	0.694	rs6930495	ENSG00000270987.1	RP3-467N11.2	3.61	0.000345	0.0225	0.23	0.16	Menarche (age at onset);	chr6:100251396	chr6:100889603~100890338:+
THCA	cis	rs1013209	0.554	rs12547212	ENSG00000253837.1	RP11-177H13.2	-3.61	0.000345	0.0225	-0.24	-0.16	Height;	chr8:24251118	chr8:23336171~23366125:+
THCA	cis	rs11992186	0.505	rs7845203	ENSG00000248538.5	RP11-10A14.5	-3.61	0.000345	0.0225	-0.2	-0.16	Neuroticism;	chr8:8287918	chr8:9189011~9202854:+
THCA	cis	rs7572733	0.935	rs2217837	ENSG00000231621.1	AC013264.2	-3.61	0.000345	0.0225	-0.16	-0.16	Dermatomyositis;	chr2:197881535	chr2:197197991~197199273:+
THCA	cis	rs7924176	0.502	rs10824134	ENSG00000271848.1	RP11-464F9.21	-3.61	0.000345	0.0225	-0.18	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74261866	chr10:73654039~73674719:+
THCA	cis	rs11064837	0.504	rs11064846	ENSG00000248636.5	RP11-768F21.1	3.61	0.000345	0.0225	0.19	0.16	Schizophrenia;	chr12:119616346	chr12:119387987~119668079:-
THCA	cis	rs9510787	0.649	rs9507127	ENSG00000205861.10	C1QTNF9B-AS1	-3.61	0.000345	0.0225	-0.21	-0.16	Nasopharyngeal carcinoma;	chr13:23642816	chr13:23888889~23897263:+
THCA	cis	rs2434529	1	rs2443524	ENSG00000245275.6	SAP30L-AS1	3.61	0.000345	0.0225	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154262636	chr5:154329437~154445850:-
THCA	cis	rs7737355	0.773	rs3756291	ENSG00000224431.1	AC063976.7	3.61	0.000345	0.0225	0.15	0.16	Life satisfaction;	chr5:131591129	chr5:132199456~132203487:+
THCA	cis	rs757081	0.671	rs214090	ENSG00000184669.7	OR7E14P	-3.61	0.000345	0.0225	-0.24	-0.16	Systolic blood pressure;	chr11:17275614	chr11:17013998~17053024:+
THCA	cis	rs72996113	0.702	rs11224350	ENSG00000248027.1	CTD-2383M3.1	3.61	0.000345	0.0225	0.29	0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100643149	chr11:100684162~100687955:-
THCA	cis	rs7246657	0.722	rs954504	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37554492	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs8110865	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37556485	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.678	rs4802024	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37561291	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs4802029	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37564710	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs28512414	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37565672	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs6508736	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37570855	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.765	rs4803262	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37575858	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.712	rs4803263	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37575880	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs10412510	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37585043	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs3829688	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37586199	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs13744	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37587011	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs10403173	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37587779	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.679	rs12461113	ENSG00000226686.6	LINC01535	-3.61	0.000345	0.0225	-0.24	-0.16	Coronary artery calcification;	chr19:37592287	chr19:37251912~37265535:+
THCA	cis	rs1412115	0.871	rs11009517	ENSG00000233387.1	RP11-342D11.3	-3.61	0.000345	0.0225	-0.16	-0.16	Schizophrenia;	chr10:33786509	chr10:33096257~33116672:-
THCA	cis	rs2979481	1	rs2979479	ENSG00000254152.1	CTD-3107M8.2	3.61	0.000345	0.0225	0.2	0.16	Heart rate variability traits;	chr8:30404538	chr8:30349866~30350347:-
THCA	cis	rs3781264	0.595	rs11187853	ENSG00000273450.1	RP11-76P2.4	3.61	0.000345	0.0225	0.21	0.16	Esophageal cancer and gastric cancer;	chr10:94312471	chr10:94314907~94315327:-
THCA	cis	rs3018712	0.532	rs2510399	ENSG00000212093.1	AP000807.1	-3.61	0.000345	0.0225	-0.21	-0.16	Total body bone mineral density;	chr11:68653990	chr11:68506083~68506166:-
THCA	cis	rs4886920	0.672	rs12437900	ENSG00000214646.7	RP11-114H24.4	3.61	0.000345	0.0225	0.2	0.16	Neuroticism;	chr15:77841796	chr15:77941442~77944582:-
THCA	cis	rs4704187	0.617	rs12656177	ENSG00000250889.2	LINC01336	-3.61	0.000345	0.0225	-0.17	-0.16	Response to amphetamines;	chr5:75058597	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.617	rs7356697	ENSG00000250889.2	LINC01336	-3.61	0.000345	0.0225	-0.17	-0.16	Response to amphetamines;	chr5:75058717	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.64	rs7707246	ENSG00000250889.2	LINC01336	-3.61	0.000345	0.0225	-0.17	-0.16	Response to amphetamines;	chr5:75059050	chr5:75047719~75052843:-
THCA	cis	rs7665090	1	rs5026472	ENSG00000251288.2	RP11-10L12.2	-3.61	0.000345	0.0225	-0.21	-0.16	Primary biliary cholangitis;	chr4:102633616	chr4:102751401~102752641:+
THCA	cis	rs2839186	0.619	rs55689527	ENSG00000225043.1	RPL18AP2	3.61	0.000345	0.0225	0.19	0.16	Testicular germ cell tumor;	chr21:46202813	chr21:46420553~46421034:-
THCA	cis	rs11800820	0.536	rs61839815	ENSG00000227953.5	LINC01341	-3.61	0.000345	0.0225	-0.15	-0.16	Obesity-related traits;	chr1:246470489	chr1:246776013~246792385:+
THCA	cis	rs9558942	0.52	rs9301188	ENSG00000277863.1	RP11-282A11.4	-3.61	0.000345	0.0225	-0.2	-0.16	Obesity-related traits;	chr13:107073332	chr13:106903150~106904099:-
THCA	cis	rs6121246	0.909	rs6088962	ENSG00000224628.2	RP5-854E16.2	-3.61	0.000345	0.0225	-0.24	-0.16	Mean corpuscular hemoglobin;	chr20:31680381	chr20:31285317~31286835:-
THCA	cis	rs10089	0.953	rs17164427	ENSG00000245937.6	LINC01184	-3.61	0.000345	0.0225	-0.18	-0.16	Ileal carcinoids;	chr5:128026044	chr5:127940426~128083172:-
THCA	cis	rs867371	0.502	rs1846908	ENSG00000276710.3	CSPG4P8	-3.61	0.000345	0.0225	-0.16	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82459472~82477258:+
THCA	cis	rs2665103	0.655	rs1501367	ENSG00000276710.3	CSPG4P8	-3.61	0.000345	0.0225	-0.16	-0.16	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82459472~82477258:+
THCA	cis	rs10181042	0.565	rs2564117	ENSG00000270820.4	RP11-355B11.2	3.61	0.000345	0.0225	0.13	0.16	Crohn's disease;	chr2:61005887	chr2:61471188~61484130:+
THCA	cis	rs912593	1	rs912593	ENSG00000225179.1	LINC00457	3.61	0.000345	0.0225	0.21	0.16	Cancer;	chr13:34458354	chr13:34435450~34640685:-
THCA	cis	rs791590	0.752	rs3118475	ENSG00000229664.1	RP11-536K7.5	-3.61	0.000345	0.0225	-0.26	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6065302	chr10:6025978~6036427:+
THCA	cis	rs13381277	0.764	rs28567594	ENSG00000263982.1	RP11-504I13.3	3.61	0.000345	0.0225	0.27	0.16	Dental caries;	chr18:76612203	chr18:76372717~76378275:+
THCA	cis	rs1009077	0.951	rs11723555	ENSG00000245958.5	RP11-33B1.1	3.61	0.000345	0.0225	0.2	0.16	Endometriosis;	chr4:119737335	chr4:119454791~119552025:+
THCA	cis	rs9878978	0.964	rs11718236	ENSG00000227588.2	CNTN4-AS2	3.61	0.000345	0.0225	0.2	0.16	Blood pressure (smoking interaction);	chr3:2436948	chr3:2110409~2144241:-
THCA	cis	rs9878978	0.964	rs11707598	ENSG00000227588.2	CNTN4-AS2	3.61	0.000345	0.0225	0.2	0.16	Blood pressure (smoking interaction);	chr3:2437273	chr3:2110409~2144241:-
THCA	cis	rs9860428	0.844	rs7641119	ENSG00000240057.4	RP11-572M11.4	-3.61	0.000345	0.0225	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112891978	chr3:113019532~113183301:+
THCA	cis	rs75504410	0.85	rs2045770	ENSG00000231160.8	KLF3-AS1	-3.61	0.000346	0.0225	-0.15	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38719382	chr4:38612701~38664883:-
THCA	cis	rs73198271	0.681	rs35457364	ENSG00000254153.1	CTA-398F10.2	3.6	0.000346	0.0225	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.641	rs34473848	ENSG00000254153.1	CTA-398F10.2	3.6	0.000346	0.0225	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.601	rs11997731	ENSG00000254153.1	CTA-398F10.2	3.6	0.000346	0.0225	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.681	rs11987924	ENSG00000254153.1	CTA-398F10.2	3.6	0.000346	0.0225	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8456909~8461337:-
THCA	cis	rs7188445	0.614	rs62043313	ENSG00000277954.1	RP11-679B19.1	-3.6	0.000346	0.0225	-0.18	-0.16	Urate levels;	chr16:79710237	chr16:79202624~79206739:-
THCA	cis	rs934734	0.532	rs12470883	ENSG00000214533.3	KRT18P33	-3.6	0.000346	0.0225	-0.2	-0.16	Rheumatoid arthritis;	chr2:65424717	chr2:65666695~65667737:+
THCA	cis	rs4879656	0.966	rs4879658	ENSG00000225693.1	LAGE3P1	-3.6	0.000346	0.0225	-0.18	-0.16	Menopause (age at onset);	chr9:33029017	chr9:33019682~33020165:-
THCA	cis	rs4950322	1	rs4448568	ENSG00000180867.10	PDIA3P1	3.6	0.000346	0.0225	0.17	0.16	Protein quantitative trait loci;	chr1:147377296	chr1:147178113~147179622:+
THCA	cis	rs7267979	0.745	rs6132845	ENSG00000276952.1	RP5-965G21.6	3.6	0.000346	0.0225	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25284915~25285588:-
THCA	cis	rs9326248	0.559	rs12808524	ENSG00000280143.1	AP000892.6	3.6	0.000346	0.0225	0.2	0.16	Blood protein levels;	chr11:117020277	chr11:117204967~117210292:+
THCA	cis	rs372883	0.648	rs11088117	ENSG00000176054.6	RPL23P2	3.6	0.000346	0.0225	0.14	0.16	Pancreatic cancer;	chr21:29365495	chr21:28997613~28998033:-
THCA	cis	rs5758659	0.652	rs133305	ENSG00000182057.4	OGFRP1	3.6	0.000346	0.0225	0.19	0.16	Cognitive function;	chr22:41999956	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.682	rs133306	ENSG00000182057.4	OGFRP1	3.6	0.000346	0.0225	0.19	0.16	Cognitive function;	chr22:42000146	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.519	rs133307	ENSG00000182057.4	OGFRP1	3.6	0.000346	0.0225	0.19	0.16	Cognitive function;	chr22:42000564	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.622	rs129856	ENSG00000182057.4	OGFRP1	3.6	0.000346	0.0225	0.19	0.16	Cognitive function;	chr22:42003392	chr22:42269753~42275196:+
THCA	cis	rs12032381	1	rs6688377	ENSG00000238042.4	RP11-815M8.1	3.6	0.000346	0.0225	0.16	0.16	Dupuytren's disease;	chr1:221444065	chr1:221880981~221978523:-
THCA	cis	rs12032381	0.947	rs6688476	ENSG00000238042.4	RP11-815M8.1	3.6	0.000346	0.0225	0.16	0.16	Dupuytren's disease;	chr1:221444119	chr1:221880981~221978523:-
THCA	cis	rs5758659	0.652	rs5758537	ENSG00000182057.4	OGFRP1	3.6	0.000346	0.0225	0.19	0.16	Cognitive function;	chr22:42001038	chr22:42269753~42275196:+
THCA	cis	rs11662721	0.63	rs78054198	ENSG00000265142.5	MIR133A1HG	-3.6	0.000346	0.0225	-0.3	-0.16	Phospholipid levels (plasma);	chr18:21489738	chr18:21825487~21831410:-
THCA	cis	rs6499755	0.901	rs4784522	ENSG00000260135.5	RP11-212I21.2	-3.6	0.000346	0.0225	-0.18	-0.16	Hypospadias;	chr16:55314837	chr16:55426797~55462297:-
THCA	cis	rs668210	0.793	rs622779	ENSG00000214659.4	KRT8P26	-3.6	0.000346	0.0225	-0.19	-0.16	Cerebrospinal fluid biomarker levels;	chr11:65976776	chr11:65726939~65728214:+
THCA	cis	rs61160187	0.582	rs17332824	ENSG00000272308.1	RP11-231G3.1	3.6	0.000346	0.0225	0.16	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60870360	chr5:60866457~60866935:-
THCA	cis	rs1964356	0.524	rs7839585	ENSG00000233609.3	RP11-62H7.2	-3.6	0.000346	0.0225	-0.16	-0.16	Mean corpuscular volume;	chr8:8996725	chr8:8961200~8979025:+
THCA	cis	rs12959333	0.527	rs7231862	ENSG00000274849.1	RP11-49I11.4	-3.6	0.000346	0.0225	-0.2	-0.16	Post bronchodilator FEV1;	chr18:35639361	chr18:36189824~36190272:+
THCA	cis	rs12959333	0.527	rs12966701	ENSG00000274849.1	RP11-49I11.4	-3.6	0.000346	0.0225	-0.2	-0.16	Post bronchodilator FEV1;	chr18:35651805	chr18:36189824~36190272:+
THCA	cis	rs11089937	0.929	rs5757155	ENSG00000211638.2	IGLV8-61	-3.6	0.000346	0.0225	-0.12	-0.16	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22098700~22099212:+
THCA	cis	rs7296418	0.961	rs4275659	ENSG00000256092.2	RP13-942N8.1	-3.6	0.000346	0.0225	-0.12	-0.16	Platelet count;	chr12:122963381	chr12:123363868~123366113:+
THCA	cis	rs9341808	0.754	rs9343973	ENSG00000260645.1	RP11-250B2.5	3.6	0.000346	0.0225	0.14	0.16	Sitting height ratio;	chr6:80203499	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.718	rs7740627	ENSG00000260645.1	RP11-250B2.5	3.6	0.000346	0.0225	0.14	0.16	Sitting height ratio;	chr6:80206630	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.718	rs2143887	ENSG00000260645.1	RP11-250B2.5	3.6	0.000346	0.0225	0.14	0.16	Sitting height ratio;	chr6:80207570	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.683	rs7771449	ENSG00000260645.1	RP11-250B2.5	3.6	0.000346	0.0225	0.14	0.16	Sitting height ratio;	chr6:80210260	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.718	rs910266	ENSG00000260645.1	RP11-250B2.5	3.6	0.000346	0.0225	0.14	0.16	Sitting height ratio;	chr6:80211453	chr6:80466958~80469080:+
THCA	cis	rs4272720	0.59	rs7897289	ENSG00000234736.4	FAM170B-AS1	-3.6	0.000346	0.0225	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49060718	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.526	rs7906722	ENSG00000234736.4	FAM170B-AS1	-3.6	0.000346	0.0225	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49063190	chr10:49121839~49151547:+
THCA	cis	rs5758659	0.652	rs133300	ENSG00000182057.4	OGFRP1	3.6	0.000346	0.0225	0.19	0.16	Cognitive function;	chr22:41993835	chr22:42269753~42275196:+
THCA	cis	rs7572733	0.555	rs7420608	ENSG00000231621.1	AC013264.2	-3.6	0.000346	0.0225	-0.17	-0.16	Dermatomyositis;	chr2:198051206	chr2:197197991~197199273:+
THCA	cis	rs7560272	0.501	rs6755500	ENSG00000163016.8	ALMS1P	-3.6	0.000346	0.0225	-0.2	-0.16	Schizophrenia;	chr2:73715106	chr2:73644919~73685576:+
THCA	cis	rs7737355	1	rs6876350	ENSG00000237714.1	P4HA2-AS1	3.6	0.000346	0.0225	0.24	0.16	Life satisfaction;	chr5:131268416	chr5:132184876~132192808:+
THCA	cis	rs7737355	1	rs7737355	ENSG00000237714.1	P4HA2-AS1	3.6	0.000346	0.0225	0.24	0.16	Life satisfaction;	chr5:131269118	chr5:132184876~132192808:+
THCA	cis	rs60180747	1	rs77515996	ENSG00000261318.1	RP11-653J6.1	3.6	0.000346	0.0225	0.21	0.16	Testicular germ cell tumor;	chr15:66416601	chr15:66278498~66293357:-
THCA	cis	rs6121246	0.909	rs7354225	ENSG00000224628.2	RP5-854E16.2	-3.6	0.000346	0.0225	-0.24	-0.16	Mean corpuscular hemoglobin;	chr20:31709078	chr20:31285317~31286835:-
THCA	cis	rs12935418	0.672	rs78895138	ENSG00000261838.4	RP11-303E16.6	3.6	0.000346	0.0225	0.2	0.16	Mean corpuscular volume;	chr16:81014820	chr16:81069854~81076598:+
THCA	cis	rs6674970	1	rs6656450	ENSG00000261168.1	RP11-68I18.10	-3.6	0.000346	0.0225	-0.22	-0.16	Childhood ear infection;	chr1:151117126	chr1:151130075~151131610:-
THCA	cis	rs301901	0.663	rs217847	ENSG00000250155.1	CTD-2353F22.1	3.6	0.000346	0.0225	0.17	0.16	Height;	chr5:37367135	chr5:36666214~36725195:-
THCA	cis	rs867371	1	rs6495643	ENSG00000278603.1	RP13-608F4.5	3.6	0.000346	0.0225	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472203~82472426:+
THCA	cis	rs3924048	0.574	rs61776783	ENSG00000272482.1	RP11-474O21.5	-3.6	0.000346	0.0225	-0.15	-0.16	Optic cup area;	chr1:12552627	chr1:12618900~12619244:-
THCA	cis	rs7824557	0.872	rs2572417	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000346	0.0225	-0.2	-0.16	Retinal vascular caliber;	chr8:11253953	chr8:10433672~10438312:+
THCA	cis	rs722599	0.683	rs10139016	ENSG00000279594.1	RP11-950C14.10	3.6	0.000346	0.0225	0.17	0.16	IgG glycosylation;	chr14:74807585	chr14:75011269~75012851:-
THCA	cis	rs722599	0.683	rs2302834	ENSG00000279594.1	RP11-950C14.10	3.6	0.000346	0.0225	0.17	0.16	IgG glycosylation;	chr14:74812692	chr14:75011269~75012851:-
THCA	cis	rs722599	0.683	rs10144860	ENSG00000279594.1	RP11-950C14.10	3.6	0.000346	0.0225	0.17	0.16	IgG glycosylation;	chr14:74819723	chr14:75011269~75012851:-
THCA	cis	rs722599	0.683	rs8014695	ENSG00000279594.1	RP11-950C14.10	3.6	0.000346	0.0225	0.17	0.16	IgG glycosylation;	chr14:74834914	chr14:75011269~75012851:-
THCA	cis	rs9393777	0.72	rs56401801	ENSG00000272009.1	RP1-313I6.12	-3.6	0.000346	0.0225	-0.29	-0.16	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28078792~28081130:-
THCA	cis	rs11887277	0.507	rs6547254	ENSG00000272148.1	RP11-195B17.1	-3.6	0.000346	0.0225	-0.15	-0.16	Obesity-related traits;	chr2:26832750	chr2:27062428~27062907:-
THCA	cis	rs765787	0.53	rs1706837	ENSG00000259932.1	CTD-2651B20.7	3.6	0.000346	0.0225	0.2	0.16	Uric acid levels;	chr15:45226838	chr15:45198517~45199139:-
THCA	cis	rs6598541	0.928	rs4966019	ENSG00000278090.1	RP11-6O2.2	-3.6	0.000346	0.0225	-0.15	-0.16	Urate levels;	chr15:98731097	chr15:99028538~99031053:+
THCA	cis	rs972578	1	rs1569508	ENSG00000230319.1	AL022476.2	3.6	0.000346	0.0225	0.17	0.16	Mean platelet volume;	chr22:42963124	chr22:43038585~43052366:+
THCA	cis	rs2074409	0.572	rs4074605	ENSG00000277501.1	RP11-697E22.2	-3.6	0.000346	0.0225	-0.24	-0.16	Response to angiotensin II receptor blocker therapy;	chr17:37562341	chr17:37642947~37684252:+
THCA	cis	rs7020830	0.928	rs11544336	ENSG00000260100.1	RP11-220I1.5	-3.6	0.000346	0.0225	-0.2	-0.16	Schizophrenia;	chr9:37089153	chr9:37078813~37079776:-
THCA	cis	rs4834770	1	rs878374	ENSG00000249244.1	RP11-548H18.2	3.6	0.000346	0.0225	0.18	0.16	Blood protein levels;	chr4:119316409	chr4:119391831~119395335:-
THCA	cis	rs1978968	0.717	rs35645198	ENSG00000280007.1	AC008079.10	3.6	0.000346	0.0225	0.17	0.16	Presence of antiphospholipid antibodies;	chr22:17925556	chr22:18110759~18131154:-
THCA	cis	rs867371	1	rs8041924	ENSG00000278603.1	RP13-608F4.5	3.6	0.000346	0.0225	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472203~82472426:+
THCA	cis	rs867371	1	rs2088858	ENSG00000278603.1	RP13-608F4.5	3.6	0.000346	0.0225	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472203~82472426:+
THCA	cis	rs867371	1	rs4778982	ENSG00000278603.1	RP13-608F4.5	3.6	0.000346	0.0225	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472203~82472426:+
THCA	cis	rs867371	1	rs2867579	ENSG00000278603.1	RP13-608F4.5	3.6	0.000346	0.0225	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472203~82472426:+
THCA	cis	rs867371	1	rs881308	ENSG00000278603.1	RP13-608F4.5	3.6	0.000346	0.0225	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472203~82472426:+
THCA	cis	rs7216064	1	rs6504548	ENSG00000278740.1	RP11-147L13.14	3.6	0.000346	0.0225	0.19	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889932	chr17:68188547~68189165:+
THCA	cis	rs16852403	0.619	rs10047059	ENSG00000224687.1	RASAL2-AS1	-3.6	0.000347	0.0225	-0.27	-0.16	Childhood ear infection;	chr1:178173061	chr1:178091508~178093984:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000230295.1	RP11-458F8.2	-3.6	0.000347	0.0225	-0.13	-0.16	Aortic root size;	chr7:65966699	chr7:66880708~66882981:+
THCA	cis	rs9980	1	rs17298067	ENSG00000226232.7	RP11-419C5.2	-3.6	0.000347	0.0225	-0.25	-0.16	Blood osmolality (transformed sodium);	chr16:69667584	chr16:69976388~69996188:-
THCA	cis	rs12681366	0.708	rs2470728	ENSG00000261437.1	RP11-22C11.2	-3.6	0.000347	0.0225	-0.15	-0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94354142	chr8:94637285~94639467:-
THCA	cis	rs3885907	0.546	rs9551963	ENSG00000224511.1	LINC00365	-3.6	0.000347	0.0225	-0.21	-0.16	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);	chr13:30758410	chr13:30103178~30108875:-
THCA	cis	rs9437689	0.69	rs9437810	ENSG00000235501.4	RP4-639F20.1	3.6	0.000347	0.0225	0.19	0.16	Phospholipid levels (plasma);	chr1:95071067	chr1:94927566~94963270:+
THCA	cis	rs2729354	0.953	rs2848625	ENSG00000254602.1	AP000662.4	-3.6	0.000347	0.0225	-0.21	-0.16	Blood protein levels;	chr11:57563177	chr11:57638024~57652790:+
THCA	cis	rs867371	0.964	rs7169961	ENSG00000278603.1	RP13-608F4.5	3.6	0.000347	0.0225	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472203~82472426:+
THCA	cis	rs7312933	0.533	rs11181499	ENSG00000257225.1	RP11-328C8.4	-3.6	0.000347	0.0225	-0.17	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42424959	chr12:42459366~42466128:+
THCA	cis	rs17660992	0.928	rs12460840	ENSG00000273837.1	LLNLR-470E3.1	-3.6	0.000347	0.0225	-0.19	-0.16	Blood protein levels;	chr19:51662141	chr19:51639478~51639931:-
THCA	cis	rs875971	0.545	rs1796222	ENSG00000230295.1	RP11-458F8.2	-3.6	0.000347	0.0225	-0.15	-0.16	Aortic root size;	chr7:66592167	chr7:66880708~66882981:+
THCA	cis	rs3733585	0.781	rs6449183	ENSG00000261490.1	RP11-448G15.3	-3.6	0.000347	0.0226	-0.1	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9969067	chr4:10068089~10073019:-
THCA	cis	rs77147124	0.959	rs2297991	ENSG00000225292.2	RP11-57H14.3	-3.6	0.000347	0.0226	-0.22	-0.16	HDL cholesterol;	chr10:112153464	chr10:112888735~112906111:+
THCA	cis	rs7296418	0.922	rs1790134	ENSG00000256092.2	RP13-942N8.1	3.6	0.000347	0.0226	0.12	0.16	Platelet count;	chr12:123213351	chr12:123363868~123366113:+
THCA	cis	rs757081	0.506	rs11529609	ENSG00000184669.7	OR7E14P	-3.6	0.000347	0.0226	-0.23	-0.16	Systolic blood pressure;	chr11:17042243	chr11:17013998~17053024:+
THCA	cis	rs758324	0.661	rs246844	ENSG00000224431.1	AC063976.7	-3.6	0.000347	0.0226	-0.17	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:132065641	chr5:132199456~132203487:+
THCA	cis	rs354225	0.673	rs354232	ENSG00000162997.14	PRORSD1P	-3.6	0.000347	0.0226	-0.18	-0.16	Schizophrenia;	chr2:54689773	chr2:55282319~55284522:+
THCA	cis	rs9309473	1	rs6745368	ENSG00000273245.1	RP11-434P11.2	3.6	0.000347	0.0226	0.23	0.16	Metabolite levels;	chr2:73582847	chr2:73750256~73750786:-
THCA	cis	rs7954584	0.611	rs3887885	ENSG00000274292.1	RP11-347I19.7	-3.6	0.000347	0.0226	-0.12	-0.16	Mean corpuscular volume;	chr12:121898580	chr12:121800797~121803403:+
THCA	cis	rs10129255	0.957	rs10142918	ENSG00000280411.1	IGHV1-69-2	-3.6	0.000347	0.0226	-0.1	-0.16	Kawasaki disease;	chr14:106782206	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.957	rs10142859	ENSG00000280411.1	IGHV1-69-2	-3.6	0.000347	0.0226	-0.1	-0.16	Kawasaki disease;	chr14:106782238	chr14:106762092~106762588:-
THCA	cis	rs8031584	0.56	rs1056118	ENSG00000178081.11	ULK4P3	-3.6	0.000347	0.0226	-0.21	-0.16	Huntington's disease progression;	chr15:30911583	chr15:30103720~30131757:+
THCA	cis	rs9450351	0.744	rs6902904	ENSG00000203875.9	SNHG5	-3.6	0.000347	0.0226	-0.32	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85492985	chr6:85660950~85678736:-
THCA	cis	rs9309473	1	rs7572722	ENSG00000273245.1	RP11-434P11.2	3.6	0.000347	0.0226	0.23	0.16	Metabolite levels;	chr2:73497548	chr2:73750256~73750786:-
THCA	cis	rs10911902	0.643	rs76748438	ENSG00000233196.2	GS1-304P7.1	-3.6	0.000347	0.0226	-0.26	-0.16	Schizophrenia;	chr1:186367379	chr1:186580515~186581191:-
THCA	cis	rs911555	0.603	rs11621300	ENSG00000244691.1	RPL10AP1	-3.6	0.000347	0.0226	-0.22	-0.16	Intelligence (multi-trait analysis);	chr14:103378561	chr14:103412119~103412761:-
THCA	cis	rs1864585	0.52	rs17718772	ENSG00000280294.1	RP11-177H2.1	3.6	0.000347	0.0226	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10790546	chr8:10856085~10859436:-
THCA	cis	rs17301013	0.932	rs1653627	ENSG00000270084.1	GAS5-AS1	3.6	0.000347	0.0226	0.17	0.16	Systemic lupus erythematosus;	chr1:174771879	chr1:173863248~173863941:+
THCA	cis	rs1005277	0.579	rs1985707	ENSG00000151963.4	RP11-775A3.1	-3.6	0.000347	0.0226	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:37883594~37884109:+
THCA	cis	rs752590	0.666	rs67081417	ENSG00000274877.1	RP11-65I12.1	3.6	0.000347	0.0226	0.11	0.16	Mucinous ovarian carcinoma;	chr2:113244868	chr2:113237595~113240825:+
THCA	cis	rs737008	0.922	rs2550475	ENSG00000263080.1	RP11-485G7.5	3.6	0.000347	0.0226	0.2	0.16	Obesity-related traits;	chr16:11278129	chr16:11341809~11345211:-
THCA	cis	rs1865760	0.566	rs9348706	ENSG00000272810.1	U91328.22	-3.6	0.000347	0.0226	-0.13	-0.16	Height;	chr6:26065253	chr6:26013241~26013757:+
THCA	cis	rs2977125	0.774	rs2948374	ENSG00000251468.2	RP11-369K16.1	-3.6	0.000347	0.0226	-0.24	-0.16	Schizophrenia;	chr8:12882937	chr8:12958387~12962200:+
THCA	cis	rs7647973	0.58	rs11716334	ENSG00000228638.1	FCF1P2	-3.6	0.000347	0.0226	-0.17	-0.16	Menarche (age at onset);	chr3:49192663	chr3:48290793~48291375:-
THCA	cis	rs5753037	0.869	rs5763651	ENSG00000279699.1	RP1-102K2.9	3.6	0.000347	0.0226	0.16	0.16	Type 1 diabetes;	chr22:29968272	chr22:30275215~30276951:-
THCA	cis	rs28830936	0.966	rs3743024	ENSG00000250379.1	RP11-23P13.4	3.6	0.000347	0.0226	0.19	0.16	Diastolic blood pressure;	chr15:41826773	chr15:41825099~41827936:-
THCA	cis	rs7680126	0.536	rs7661701	ENSG00000261490.1	RP11-448G15.3	3.6	0.000347	0.0226	0.16	0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10062474	chr4:10068089~10073019:-
THCA	cis	rs1204798	0.685	rs1211388	ENSG00000237021.2	RP3-486I3.7	-3.6	0.000347	0.0226	-0.18	-0.16	Dental caries;	chr6:116205412	chr6:116254207~116256743:+
THCA	cis	rs7572644	0.766	rs34483784	ENSG00000223522.1	AC093690.1	-3.6	0.000347	0.0226	-0.21	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27906524	chr2:28307691~28310459:-
THCA	cis	rs9487094	0.689	rs9487076	ENSG00000223537.2	RP5-919F19.5	-3.6	0.000347	0.0226	-0.16	-0.16	Height;	chr6:109371524	chr6:109487906~109506800:+
THCA	cis	rs1008126	0.6	rs2711881	ENSG00000234715.1	CTB-107G13.1	-3.6	0.000347	0.0226	-0.19	-0.16	Metabolite levels (Pyroglutamine);	chr7:103494984	chr7:103445207~103514007:+
THCA	cis	rs1008126	0.6	rs2528871	ENSG00000234715.1	CTB-107G13.1	-3.6	0.000347	0.0226	-0.19	-0.16	Metabolite levels (Pyroglutamine);	chr7:103495023	chr7:103445207~103514007:+
THCA	cis	rs875971	1	rs6460296	ENSG00000272831.1	RP11-792A8.4	3.6	0.000347	0.0226	0.1	0.16	Aortic root size;	chr7:66430152	chr7:66739829~66740385:-
THCA	cis	rs875971	0.895	rs4718349	ENSG00000272831.1	RP11-792A8.4	3.6	0.000347	0.0226	0.1	0.16	Aortic root size;	chr7:66444024	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs2042133	ENSG00000272831.1	RP11-792A8.4	3.6	0.000347	0.0226	0.1	0.16	Aortic root size;	chr7:66466935	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs2161065	ENSG00000272831.1	RP11-792A8.4	3.6	0.000347	0.0226	0.1	0.16	Aortic root size;	chr7:66467918	chr7:66739829~66740385:-
THCA	cis	rs875971	0.862	rs12698521	ENSG00000272831.1	RP11-792A8.4	3.6	0.000347	0.0226	0.1	0.16	Aortic root size;	chr7:66474502	chr7:66739829~66740385:-
THCA	cis	rs1560104	0.597	rs881667	ENSG00000260601.1	RP11-552C15.1	-3.6	0.000347	0.0226	-0.2	-0.16	Obesity-related traits;	chr16:12618569	chr16:12545482~12546684:+
THCA	cis	rs7829975	0.846	rs6601724	ENSG00000253981.4	ALG1L13P	-3.6	0.000347	0.0226	-0.15	-0.16	Mood instability;	chr8:8687362	chr8:8236003~8244667:-
THCA	cis	rs7616559	0.629	rs6774654	ENSG00000240875.4	LINC00886	-3.6	0.000347	0.0226	-0.13	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157053044	chr3:156747346~156817062:-
THCA	cis	rs17301013	0.896	rs332773	ENSG00000270084.1	GAS5-AS1	-3.6	0.000347	0.0226	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174695711	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs444678	ENSG00000270084.1	GAS5-AS1	-3.6	0.000347	0.0226	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174706080	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.896	rs332791	ENSG00000270084.1	GAS5-AS1	-3.6	0.000347	0.0226	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174709784	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs332795	ENSG00000270084.1	GAS5-AS1	-3.6	0.000347	0.0226	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174726785	chr1:173863248~173863941:+
THCA	cis	rs2692947	0.566	rs11676901	ENSG00000168992.4	OR7E102P	3.6	0.000347	0.0226	0.21	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95704823	chr2:95546531~95547545:+
THCA	cis	rs7176527	0.747	rs28363946	ENSG00000259683.1	RP11-182J1.14	3.6	0.000347	0.0226	0.27	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:84389729~84395903:+
THCA	cis	rs7246657	0.943	rs7253091	ENSG00000268499.1	CTB-102L5.8	3.6	0.000347	0.0226	0.21	0.16	Coronary artery calcification;	chr19:37476312	chr19:38199836~38200934:+
THCA	cis	rs9467773	0.935	rs4573	ENSG00000228223.2	HCG11	-3.6	0.000347	0.0226	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26523450~26526579:+
THCA	cis	rs7923609	0.875	rs10822143	ENSG00000232075.1	MRPL35P2	-3.6	0.000348	0.0226	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63128096	chr10:63634317~63634827:-
THCA	cis	rs4648045	0.621	rs747559	ENSG00000246560.2	RP11-10L12.4	-3.6	0.000348	0.0226	-0.2	-0.16	Lymphocyte percentage of white cells;	chr4:102493018	chr4:102828055~102844075:+
THCA	cis	rs17095355	0.901	rs28365866	ENSG00000203876.8	ADD3-AS1	-3.6	0.000348	0.0226	-0.2	-0.16	Biliary atresia;	chr10:110007456	chr10:109940104~110008381:-
THCA	cis	rs867371	1	rs8037224	ENSG00000278603.1	RP13-608F4.5	3.6	0.000348	0.0226	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472203~82472426:+
THCA	cis	rs7259376	0.936	rs1865074	ENSG00000270947.1	AC025811.3	3.6	0.000348	0.0226	0.18	0.16	Menopause (age at onset);	chr19:22372147	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs1865073	ENSG00000270947.1	AC025811.3	3.6	0.000348	0.0226	0.18	0.16	Menopause (age at onset);	chr19:22372178	chr19:22455988~22456459:+
THCA	cis	rs972578	0.905	rs9623736	ENSG00000230319.1	AL022476.2	3.6	0.000348	0.0226	0.18	0.16	Mean platelet volume;	chr22:43010667	chr22:43038585~43052366:+
THCA	cis	rs3760982	0.585	rs61013802	ENSG00000267058.1	RP11-15A1.3	-3.6	0.000348	0.0226	-0.14	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787990	chr19:43891804~43901805:-
THCA	cis	rs3760982	0.565	rs8104300	ENSG00000267058.1	RP11-15A1.3	-3.6	0.000348	0.0226	-0.14	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788992	chr19:43891804~43901805:-
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000184274.3	LINC00315	-3.6	0.000348	0.0226	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45300245~45305257:-
THCA	cis	rs875971	0.502	rs2465121	ENSG00000273024.4	INTS4P2	3.6	0.000348	0.0226	0.21	0.16	Aortic root size;	chr7:66156017	chr7:65647864~65715661:+
THCA	cis	rs732072	0.826	rs11605773	ENSG00000214659.4	KRT8P26	-3.6	0.000348	0.0226	-0.27	-0.16	Inflammatory bowel disease;	chr11:65706619	chr11:65726939~65728214:+
THCA	cis	rs9863	1	rs9863	ENSG00000270028.1	RP11-380L11.4	3.6	0.000348	0.0226	0.18	0.16	White blood cell count;	chr12:123936906	chr12:123925461~123926083:-
THCA	cis	rs7044106	0.791	rs747819	ENSG00000235865.2	GSN-AS1	-3.6	0.000348	0.0226	-0.15	-0.16	Hip circumference adjusted for BMI;	chr9:120726163	chr9:121280768~121285530:-
THCA	cis	rs7044106	0.791	rs735110	ENSG00000235865.2	GSN-AS1	-3.6	0.000348	0.0226	-0.15	-0.16	Hip circumference adjusted for BMI;	chr9:120726662	chr9:121280768~121285530:-
THCA	cis	rs17345786	0.906	rs11710016	ENSG00000244119.1	PDCL3P4	-3.6	0.000348	0.0226	-0.16	-0.16	Colonoscopy-negative controls vs population controls;	chr3:101401186	chr3:101712472~101713191:+
THCA	cis	rs6921919	0.789	rs11970439	ENSG00000176933.5	TOB2P1	-3.6	0.000348	0.0226	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28217643~28218634:-
THCA	cis	rs7619427	0.556	rs7639831	ENSG00000271192.1	RP4-555D20.3	-3.6	0.000348	0.0226	-0.22	-0.16	Schizophrenia;	chr3:44029985	chr3:43996896~43997443:+
THCA	cis	rs293748	0.54	rs13163937	ENSG00000250155.1	CTD-2353F22.1	-3.6	0.000348	0.0226	-0.2	-0.16	Obesity-related traits;	chr5:37253547	chr5:36666214~36725195:-
THCA	cis	rs7089973	0.668	rs61868024	ENSG00000228169.3	PPIAP19	3.6	0.000348	0.0226	0.19	0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114878180	chr10:114690143~114690634:-
THCA	cis	rs7089973	0.646	rs35453961	ENSG00000228169.3	PPIAP19	3.6	0.000348	0.0226	0.19	0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114878407	chr10:114690143~114690634:-
THCA	cis	rs785830	0.749	rs2479325	ENSG00000231808.2	LINC01388	3.6	0.000348	0.0226	0.19	0.16	Platelet distribution width;	chr9:253282	chr9:112713~113754:-
THCA	cis	rs801193	0.935	rs3800820	ENSG00000275400.1	RP4-756H11.5	3.6	0.000348	0.0226	0.15	0.16	Aortic root size;	chr7:66682191	chr7:66553805~66554199:-
THCA	cis	rs801193	1	rs2003301	ENSG00000275400.1	RP4-756H11.5	3.6	0.000348	0.0226	0.15	0.16	Aortic root size;	chr7:66682669	chr7:66553805~66554199:-
THCA	cis	rs12780845	0.931	rs3758418	ENSG00000229124.5	VIM-AS1	3.6	0.000348	0.0226	0.16	0.16	Homocysteine levels;	chr10:17203639	chr10:17214239~17229985:-
THCA	cis	rs2299682	0.826	rs61235873	ENSG00000230506.1	RP11-416N4.4	3.6	0.000348	0.0226	0.27	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9496691	chr20:10173520~10196990:+
THCA	cis	rs2299682	0.826	rs6077554	ENSG00000230506.1	RP11-416N4.4	3.6	0.000348	0.0226	0.27	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9497458	chr20:10173520~10196990:+
THCA	cis	rs9467773	0.572	rs62394558	ENSG00000228223.2	HCG11	-3.6	0.000348	0.0226	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26523450~26526579:+
THCA	cis	rs2562456	0.833	rs2650776	ENSG00000268521.1	VN1R83P	3.6	0.000348	0.0226	0.16	0.16	Pain;	chr19:21430595	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs2562416	ENSG00000268521.1	VN1R83P	3.6	0.000348	0.0226	0.16	0.16	Pain;	chr19:21430609	chr19:21289554~21289998:-
THCA	cis	rs735539	0.521	rs2585898	ENSG00000278291.1	RP11-172H24.4	3.6	0.000348	0.0226	0.22	0.16	Dental caries;	chr13:20826162	chr13:20699307~20703718:-
THCA	cis	rs910316	1	rs11845639	ENSG00000259138.1	RP11-950C14.7	3.6	0.000348	0.0226	0.14	0.16	Height;	chr14:75103590	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs8017642	ENSG00000259138.1	RP11-950C14.7	3.6	0.000348	0.0226	0.14	0.16	Height;	chr14:75124119	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs2268617	ENSG00000259138.1	RP11-950C14.7	3.6	0.000348	0.0226	0.14	0.16	Height;	chr14:75142025	chr14:75127153~75136930:+
THCA	cis	rs2820315	1	rs2678204	ENSG00000223774.4	RP11-307B6.3	3.6	0.000348	0.0226	0.18	0.16	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201831383	chr1:201893842~201899978:+
THCA	cis	rs853679	0.538	rs13199081	ENSG00000226314.6	ZNF192P1	-3.6	0.000348	0.0226	-0.2	-0.16	Depression;	chr6:28364057	chr6:28161781~28169594:+
THCA	cis	rs8035452	0.929	rs8032980	ENSG00000273674.3	CTD-2378E12.1	3.6	0.000348	0.0226	0.2	0.16	Alzheimer's disease (late onset);	chr15:50711649	chr15:50839875~50908599:-
THCA	cis	rs7246967	0.673	rs12971914	ENSG00000198153.8	ZNF849P	-3.6	0.000348	0.0226	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22706096	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs8105441	ENSG00000198153.8	ZNF849P	-3.6	0.000348	0.0226	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22708664	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs8112442	ENSG00000198153.8	ZNF849P	-3.6	0.000348	0.0226	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22710567	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs73022763	ENSG00000198153.8	ZNF849P	-3.6	0.000348	0.0226	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22711414	chr19:22685167~22686732:+
THCA	cis	rs4915077	0.656	rs116617506	ENSG00000226822.1	RP11-356N1.2	3.6	0.000348	0.0226	0.27	0.16	Hypothyroidism;	chr1:107811839	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.656	rs114087238	ENSG00000226822.1	RP11-356N1.2	3.6	0.000348	0.0226	0.27	0.16	Hypothyroidism;	chr1:107811840	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs78484451	ENSG00000226822.1	RP11-356N1.2	3.6	0.000348	0.0226	0.27	0.16	Hypothyroidism;	chr1:107811845	chr1:108071482~108074519:+
THCA	cis	rs962856	0.719	rs12713597	ENSG00000236780.4	AC078941.1	3.6	0.000348	0.0226	0.21	0.16	Pancreatic cancer;	chr2:67393935	chr2:67123357~67215319:-
THCA	cis	rs962856	0.756	rs4671799	ENSG00000236780.4	AC078941.1	3.6	0.000348	0.0226	0.21	0.16	Pancreatic cancer;	chr2:67395111	chr2:67123357~67215319:-
THCA	cis	rs962856	0.756	rs4671800	ENSG00000236780.4	AC078941.1	3.6	0.000348	0.0226	0.21	0.16	Pancreatic cancer;	chr2:67395216	chr2:67123357~67215319:-
THCA	cis	rs972540	0.921	rs6757701	ENSG00000229647.1	AC007879.7	-3.6	0.000348	0.0226	-0.19	-0.16	Body mass index;	chr2:206366818	chr2:207239650~207245887:+
THCA	cis	rs2290416	0.584	rs3816477	ENSG00000255050.1	RP11-661A12.9	-3.6	0.000348	0.0226	-0.25	-0.16	Attention deficit hyperactivity disorder;	chr8:143603101	chr8:143573490~143577397:+
THCA	cis	rs6840360	0.87	rs7680604	ENSG00000251611.1	RP11-610P16.1	-3.6	0.000348	0.0226	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151548765	chr4:151407551~151408835:-
THCA	cis	rs4950322	0.512	rs2883318	ENSG00000180867.10	PDIA3P1	3.6	0.000348	0.0226	0.14	0.16	Protein quantitative trait loci;	chr1:147377422	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.512	rs12409455	ENSG00000180867.10	PDIA3P1	3.6	0.000348	0.0226	0.14	0.16	Protein quantitative trait loci;	chr1:147378563	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.6	rs11240014	ENSG00000180867.10	PDIA3P1	3.6	0.000348	0.0226	0.14	0.16	Protein quantitative trait loci;	chr1:147380674	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.576	rs11240015	ENSG00000180867.10	PDIA3P1	3.6	0.000348	0.0226	0.14	0.16	Protein quantitative trait loci;	chr1:147380813	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.553	rs12093870	ENSG00000180867.10	PDIA3P1	3.6	0.000348	0.0226	0.14	0.16	Protein quantitative trait loci;	chr1:147380815	chr1:147178113~147179622:+
THCA	cis	rs12501370	0.959	rs1876493	ENSG00000250906.1	RP11-632F7.3	3.6	0.000348	0.0226	0.15	0.16	Iris color (L* coordinate);	chr4:41042921	chr4:40812779~40826151:+
THCA	cis	rs9813712	0.585	rs16824839	ENSG00000253540.4	FAM86HP	-3.6	0.000348	0.0226	-0.22	-0.16	Response to amphetamines;	chr3:130220886	chr3:130099092~130111472:-
THCA	cis	rs10435719	0.61	rs76311455	ENSG00000255495.1	AC145124.2	3.6	0.000348	0.0226	0.19	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933017	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.61	rs80269926	ENSG00000255495.1	AC145124.2	3.6	0.000348	0.0226	0.19	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933018	chr8:12194467~12196280:+
THCA	cis	rs4723738	0.935	rs10233340	ENSG00000227191.5	TRGC2	-3.6	0.000348	0.0226	-0.13	-0.16	Treatment response for severe sepsis;	chr7:38183679	chr7:38239580~38368091:-
THCA	cis	rs4723738	1	rs35997004	ENSG00000227191.5	TRGC2	-3.6	0.000348	0.0226	-0.13	-0.16	Treatment response for severe sepsis;	chr7:38186081	chr7:38239580~38368091:-
THCA	cis	rs4723738	1	rs7788819	ENSG00000227191.5	TRGC2	-3.6	0.000348	0.0226	-0.13	-0.16	Treatment response for severe sepsis;	chr7:38187056	chr7:38239580~38368091:-
THCA	cis	rs4723738	1	rs11766312	ENSG00000227191.5	TRGC2	-3.6	0.000348	0.0226	-0.13	-0.16	Treatment response for severe sepsis;	chr7:38187990	chr7:38239580~38368091:-
THCA	cis	rs4723738	1	rs17171307	ENSG00000227191.5	TRGC2	-3.6	0.000348	0.0226	-0.13	-0.16	Treatment response for severe sepsis;	chr7:38188976	chr7:38239580~38368091:-
THCA	cis	rs4723738	1	rs10951552	ENSG00000227191.5	TRGC2	-3.6	0.000348	0.0226	-0.13	-0.16	Treatment response for severe sepsis;	chr7:38190180	chr7:38239580~38368091:-
THCA	cis	rs80130819	0.748	rs2732440	ENSG00000226413.2	OR8T1P	3.6	0.000348	0.0226	0.24	0.16	Prostate cancer;	chr12:48266646	chr12:48442030~48442947:-
THCA	cis	rs10844706	0.699	rs2058560	ENSG00000257027.1	RP11-705C15.3	3.6	0.000348	0.0226	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721093	chr12:9658567~9662085:+
THCA	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	3.6	0.000348	0.0226	0.18	0.16	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
THCA	cis	rs3096299	0.559	rs9931073	ENSG00000261118.1	RP11-104N10.1	3.6	0.000348	0.0226	0.14	0.16	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89492017~89504460:-
THCA	cis	rs6977955	0.646	rs2158624	ENSG00000234336.5	JAZF1-AS1	-3.6	0.000348	0.0226	-0.2	-0.16	Allergic disease (asthma, hay fever or eczema);	chr7:28109321	chr7:28180322~28243917:+
THCA	cis	rs6427356	1	rs1176550	ENSG00000237189.1	RP11-85G21.2	3.6	0.000349	0.0227	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157165374	chr1:157287703~157288053:-
THCA	cis	rs4787491	0.729	rs3814878	ENSG00000275371.1	RP11-455F5.6	-3.6	0.000349	0.0227	-0.14	-0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30030645	chr16:30110895~30111955:+
THCA	cis	rs4915077	0.773	rs17019823	ENSG00000226822.1	RP11-356N1.2	3.6	0.000349	0.0227	0.31	0.16	Hypothyroidism;	chr1:107727331	chr1:108071482~108074519:+
THCA	cis	rs7528684	0.584	rs11264798	ENSG00000236731.1	RP4-801G22.2	-3.6	0.000349	0.0227	-0.17	-0.16	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157692058	chr1:157629939~157630728:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000230189.5	GS1-124K5.2	3.6	0.000349	0.0227	0.11	0.16	Calcium levels;	chr7:65806798	chr7:66409143~66490059:-
THCA	cis	rs4262150	0.81	rs72797284	ENSG00000253921.1	CTB-113P19.3	3.6	0.000349	0.0227	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152652090	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.846	rs72797296	ENSG00000253921.1	CTB-113P19.3	3.6	0.000349	0.0227	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152664885	chr5:151753992~151767247:+
THCA	cis	rs12188164	0.965	rs1056465	ENSG00000225138.6	CTD-2228K2.7	3.6	0.000349	0.0227	0.17	0.16	Cystic fibrosis severity;	chr5:442323	chr5:473236~480884:+
THCA	cis	rs12188164	0.965	rs56146525	ENSG00000225138.6	CTD-2228K2.7	3.6	0.000349	0.0227	0.17	0.16	Cystic fibrosis severity;	chr5:442456	chr5:473236~480884:+
THCA	cis	rs12188164	0.931	rs115554641	ENSG00000225138.6	CTD-2228K2.7	3.6	0.000349	0.0227	0.17	0.16	Cystic fibrosis severity;	chr5:443121	chr5:473236~480884:+
THCA	cis	rs17122278	1	rs3741325	ENSG00000243431.1	RPL5P30	3.6	0.000349	0.0227	0.17	0.16	Total cholesterol levels;	chr11:118535274	chr11:118560690~118561580:+
THCA	cis	rs910316	1	rs3742773	ENSG00000259138.1	RP11-950C14.7	3.6	0.000349	0.0227	0.14	0.16	Height;	chr14:75112940	chr14:75127153~75136930:+
THCA	cis	rs11633886	0.585	rs12915664	ENSG00000273972.1	CTD-2306A12.1	3.6	0.000349	0.0227	0.19	0.16	Diisocyanate-induced asthma;	chr15:45787855	chr15:45702640~45703183:+
THCA	cis	rs1007190	1	rs1007190	ENSG00000221044.2	U3	-3.6	0.000349	0.0227	-0.25	-0.16	DNA methylation (variation);	chr17:44960841	chr17:44025020~44025223:-
THCA	cis	rs12410462	0.591	rs2819496	ENSG00000227711.2	RP11-275O4.5	-3.6	0.000349	0.0227	-0.2	-0.16	Major depressive disorder;	chr1:227546201	chr1:227509028~227520477:-
THCA	cis	rs12410462	0.591	rs2814061	ENSG00000227711.2	RP11-275O4.5	-3.6	0.000349	0.0227	-0.2	-0.16	Major depressive disorder;	chr1:227547413	chr1:227509028~227520477:-
THCA	cis	rs4646450	0.891	rs34777615	ENSG00000274272.1	RP11-44M6.7	3.6	0.000349	0.0227	0.18	0.16	Blood metabolite levels;	chr7:99595834	chr7:100572232~100578700:-
THCA	cis	rs7833787	0.501	rs12548087	ENSG00000278886.1	RP11-108A14.1	-3.6	0.000349	0.0227	-0.23	-0.16	Obesity-related traits;	chr8:18826716	chr8:18864681~18865247:-
THCA	cis	rs73198271	0.7	rs10090152	ENSG00000254153.1	CTA-398F10.2	3.6	0.000349	0.0227	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8456909~8461337:-
THCA	cis	rs7119038	0.58	rs7123726	ENSG00000255422.1	AP002954.4	3.6	0.000349	0.0227	0.2	0.16	Sjögren's syndrome;	chr11:118823838	chr11:118704607~118750263:+
THCA	cis	rs7829975	0.774	rs11249893	ENSG00000253981.4	ALG1L13P	3.6	0.000349	0.0227	0.16	0.16	Mood instability;	chr8:8843341	chr8:8236003~8244667:-
THCA	cis	rs4947019	1	rs12192279	ENSG00000260273.1	RP11-425D10.10	-3.6	0.000349	0.0227	-0.29	-0.16	Hematological parameters;	chr6:109734110	chr6:109382795~109383666:+
THCA	cis	rs4604234	0.803	rs73465567	ENSG00000260645.1	RP11-250B2.5	-3.6	0.000349	0.0227	-0.27	-0.16	Cancer;	chr6:80330975	chr6:80466958~80469080:+
THCA	cis	rs7824557	0.564	rs11781637	ENSG00000255495.1	AC145124.2	-3.6	0.000349	0.0227	-0.18	-0.16	Retinal vascular caliber;	chr8:11357463	chr8:12194467~12196280:+
THCA	cis	rs6005807	0.563	rs12169262	ENSG00000272858.1	CTA-292E10.8	-3.6	0.000349	0.0227	-0.28	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28683365	chr22:28814914~28815662:+
THCA	cis	rs288326	0.561	rs80252162	ENSG00000272800.1	RP11-438L19.1	3.6	0.000349	0.0227	0.3	0.16	Blood protein levels;	chr2:182852377	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs17265859	ENSG00000272800.1	RP11-438L19.1	3.6	0.000349	0.0227	0.3	0.16	Blood protein levels;	chr2:182859884	chr2:183214319~183215400:+
THCA	cis	rs11118346	0.64	rs12046004	ENSG00000228536.1	RP11-392O17.1	3.6	0.000349	0.0227	0.2	0.16	Height;	chr1:219567991	chr1:219409681~219411941:-
THCA	cis	rs1993293	0.569	rs62042315	ENSG00000259219.1	CTD-3076O17.2	3.6	0.000349	0.0227	0.2	0.16	Coronary artery calcification;	chr15:99751724	chr15:99976481~99980774:+
THCA	cis	rs950169	0.922	rs8037078	ENSG00000230373.7	GOLGA6L5P	3.6	0.000349	0.0227	0.18	0.16	Schizophrenia;	chr15:84150119	chr15:84507885~84516814:-
THCA	cis	rs11971779	0.793	rs11543827	ENSG00000252332.1	RNU6-911P	-3.6	0.000349	0.0227	-0.19	-0.16	Diisocyanate-induced asthma;	chr7:139347947	chr7:139448740~139448843:+
THCA	cis	rs6494488	0.5	rs66586340	ENSG00000259635.1	AC100830.3	-3.6	0.000349	0.0227	-0.38	-0.16	Coronary artery disease;	chr15:64691050	chr15:64701248~64719602:+
THCA	cis	rs14027	0.883	rs13255850	ENSG00000279347.1	RP11-85I17.2	-3.6	0.000349	0.0227	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119705923	chr8:119838736~119840385:-
THCA	cis	rs2486012	1	rs2485991	ENSG00000237950.1	RP11-7O11.3	3.6	0.000349	0.0227	0.18	0.16	Intelligence (multi-trait analysis);	chr1:43926050	chr1:43944370~43946551:-
THCA	cis	rs1023500	0.573	rs6002592	ENSG00000270083.1	RP1-257I20.14	-3.6	0.000349	0.0227	-0.18	-0.16	Schizophrenia;	chr22:42080750	chr22:42089630~42090028:-
THCA	cis	rs875971	0.83	rs6967708	ENSG00000223473.2	GS1-124K5.3	-3.6	0.000349	0.0227	-0.11	-0.16	Aortic root size;	chr7:66192326	chr7:66491049~66493566:-
THCA	cis	rs6801044	0.954	rs862063	ENSG00000223711.1	AC091633.3	-3.6	0.000349	0.0227	-0.22	-0.16	Creatinine levels in ischemic stroke;	chr3:195557541	chr3:195544048~195550581:+
THCA	cis	rs6546886	0.536	rs828869	ENSG00000217702.2	RP11-287D1.4	-3.6	0.000349	0.0227	-0.21	-0.16	Dialysis-related mortality;	chr2:74096373	chr2:74130583~74135395:+
THCA	cis	rs10771431	0.817	rs17202253	ENSG00000256427.1	RP11-118B22.4	3.6	0.000349	0.0227	0.18	0.16	Breast size;	chr12:9209254	chr12:9246497~9257960:+
THCA	cis	rs9876781	1	rs11130170	ENSG00000199476.1	Y_RNA	-3.6	0.000349	0.0227	-0.21	-0.16	Longevity;	chr3:48408490	chr3:48288587~48288694:+
THCA	cis	rs1057510	1	rs1057510	ENSG00000276718.1	RP1-102E24.10	-3.6	0.000349	0.0227	-0.19	-0.16	Myopia (pathological);	chr12:6574121	chr12:6466537~6467135:+
THCA	cis	rs17301013	0.861	rs332770	ENSG00000270084.1	GAS5-AS1	-3.6	0.000349	0.0227	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174681511	chr1:173863248~173863941:+
THCA	cis	rs11671005	0.652	rs11670864	ENSG00000252334.1	RNU6-1337P	3.6	0.000349	0.0227	0.24	0.16	Mean platelet volume;	chr19:58519213	chr19:58483749~58483843:-
THCA	cis	rs2692947	0.727	rs1657502	ENSG00000232931.4	LINC00342	3.6	0.000349	0.0227	0.13	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129869	chr2:95807118~95816215:-
THCA	cis	rs59901009	0.577	rs61877043	ENSG00000246273.5	SBF2-AS1	-3.6	0.00035	0.0227	-0.21	-0.16	Hematocrit;Hemoglobin concentration;	chr11:10023082	chr11:9758292~9811319:+
THCA	cis	rs754466	0.58	rs10824576	ENSG00000213514.2	RP11-428P16.2	3.6	0.00035	0.0227	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806282	chr10:77730766~77734769:+
THCA	cis	rs60180747	1	rs74397736	ENSG00000261318.1	RP11-653J6.1	3.6	0.00035	0.0227	0.21	0.16	Testicular germ cell tumor;	chr15:66409162	chr15:66278498~66293357:-
THCA	cis	rs10090774	0.71	rs13273096	ENSG00000279766.1	RP11-642A1.2	-3.6	0.00035	0.0227	-0.2	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140665832	chr8:140572142~140572812:-
THCA	cis	rs4879656	1	rs4879656	ENSG00000225693.1	LAGE3P1	-3.6	0.00035	0.0227	-0.18	-0.16	Menopause (age at onset);	chr9:33012384	chr9:33019682~33020165:-
THCA	cis	rs7914558	0.966	rs10748837	ENSG00000272912.1	RP11-724N1.1	-3.6	0.00035	0.0227	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:102914585~102915404:+
THCA	cis	rs2074409	0.509	rs853219	ENSG00000275839.1	CTC-421K24.1	3.6	0.00035	0.0227	0.19	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37427296	chr17:37454171~37454931:+
THCA	cis	rs9896933	0.723	rs7224189	ENSG00000262410.1	RP11-388C12.8	-3.6	0.00035	0.0227	-0.21	-0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82824351	chr17:82745068~82745709:+
THCA	cis	rs801193	1	rs7785213	ENSG00000275400.1	RP4-756H11.5	3.6	0.00035	0.0227	0.15	0.16	Aortic root size;	chr7:66673991	chr7:66553805~66554199:-
THCA	cis	rs801193	0.967	rs2707841	ENSG00000275400.1	RP4-756H11.5	-3.6	0.00035	0.0227	-0.15	-0.16	Aortic root size;	chr7:66692033	chr7:66553805~66554199:-
THCA	cis	rs10129255	0.83	rs61997609	ENSG00000280411.1	IGHV1-69-2	-3.6	0.00035	0.0227	-0.11	-0.16	Kawasaki disease;	chr14:106692376	chr14:106762092~106762588:-
THCA	cis	rs6901152	1	rs9373390	ENSG00000217648.1	RP1-95L4.4	-3.6	0.00035	0.0227	-0.17	-0.16	Acute lymphoblastic leukemia (childhood);	chr6:143347140	chr6:143342246~143343383:+
THCA	cis	rs9970896	0.522	rs6658426	ENSG00000237845.1	RP5-940F7.2	-3.6	0.00035	0.0227	-0.27	-0.16	Monocyte percentage of white cells;	chr1:235901715	chr1:235942553~235943805:-
THCA	cis	rs10911363	0.57	rs2702204	ENSG00000232860.6	SMG7-AS1	-3.6	0.00035	0.0227	-0.13	-0.16	Systemic lupus erythematosus;	chr1:183488261	chr1:183460874~183472265:-
THCA	cis	rs10911363	0.549	rs2794619	ENSG00000232860.6	SMG7-AS1	-3.6	0.00035	0.0227	-0.13	-0.16	Systemic lupus erythematosus;	chr1:183490535	chr1:183460874~183472265:-
THCA	cis	rs9450351	0.744	rs56344601	ENSG00000203875.9	SNHG5	-3.6	0.00035	0.0227	-0.32	-0.16	Interferon gamma-induced protein 10 levels;	chr6:86057967	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs6913399	ENSG00000203875.9	SNHG5	-3.6	0.00035	0.0227	-0.32	-0.16	Interferon gamma-induced protein 10 levels;	chr6:86068202	chr6:85660950~85678736:-
THCA	cis	rs8179	0.645	rs10264916	ENSG00000230927.2	TMBIM7P	3.6	0.00035	0.0227	0.22	0.16	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92657062	chr7:92412976~92439562:-
THCA	cis	rs8179	0.593	rs17164683	ENSG00000230927.2	TMBIM7P	3.6	0.00035	0.0227	0.22	0.16	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92657666	chr7:92412976~92439562:-
THCA	cis	rs7176527	0.784	rs62021162	ENSG00000259570.1	RP11-671M22.4	-3.6	0.00035	0.0227	-0.24	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84394512~84395514:+
THCA	cis	rs753778	0.667	rs10103731	ENSG00000253210.1	RP11-809O17.1	-3.6	0.00035	0.0227	-0.19	-0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141195969	chr8:141126044~141129961:-
THCA	cis	rs2033711	0.755	rs4801587	ENSG00000232098.3	CTD-2619J13.14	3.6	0.00035	0.0227	0.15	0.16	Uric acid clearance;	chr19:58425312	chr19:58404238~58408484:-
THCA	cis	rs9467773	0.62	rs1027203	ENSG00000228223.2	HCG11	-3.6	0.00035	0.0227	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26523450~26526579:+
THCA	cis	rs9788682	0.948	rs59133824	ENSG00000261143.1	ADAMTS7P3	-3.6	0.00035	0.0227	-0.24	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78541108	chr15:77976042~77993057:+
THCA	cis	rs9341808	0.718	rs10943699	ENSG00000260645.1	RP11-250B2.5	3.6	0.00035	0.0227	0.14	0.16	Sitting height ratio;	chr6:80230824	chr6:80466958~80469080:+
THCA	cis	rs267567	0.626	rs267513	ENSG00000235257.7	ITGA9-AS1	3.6	0.00035	0.0227	0.14	0.16	PR interval;	chr3:37528889	chr3:37745432~37861780:-
THCA	cis	rs972578	0.967	rs9623737	ENSG00000230319.1	AL022476.2	3.6	0.00035	0.0227	0.18	0.16	Mean platelet volume;	chr22:43010674	chr22:43038585~43052366:+
THCA	cis	rs755249	0.501	rs2484133	ENSG00000182109.6	RP11-69E11.4	3.6	0.00035	0.0227	0.16	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39522280~39546187:-
THCA	cis	rs7759001	0.779	rs4711153	ENSG00000271755.1	RP1-153G14.4	3.6	0.00035	0.0227	0.19	0.16	Glomerular filtration rate (creatinine);	chr6:27467130	chr6:27404010~27406964:-
THCA	cis	rs6580649	0.941	rs4760683	ENSG00000273765.1	RP11-370I10.11	-3.6	0.00035	0.0227	-0.18	-0.16	Lung cancer;	chr12:48122513	chr12:48360920~48361377:+
THCA	cis	rs12679254	0.504	rs12334531	ENSG00000253983.2	RP1-16A9.1	-3.6	0.00035	0.0227	-0.2	-0.16	Inattentive symptoms;	chr8:73351395	chr8:74199396~74208441:+
THCA	cis	rs7849270	0.959	rs4836641	ENSG00000204055.4	RP11-247A12.2	3.6	0.00035	0.0227	0.21	0.16	Blood metabolite ratios;	chr9:129149953	chr9:129176771~129210548:+
THCA	cis	rs6921919	1	rs6922111	ENSG00000280107.1	AL022393.9	-3.6	0.00035	0.0227	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28170845~28172521:+
THCA	cis	rs9693857	0.518	rs7001721	ENSG00000254153.1	CTA-398F10.2	3.6	0.00035	0.0227	0.2	0.16	Systolic blood pressure;	chr8:9413900	chr8:8456909~8461337:-
THCA	cis	rs7554547	0.791	rs1321073	ENSG00000199347.1	RNU5E-1	-3.6	0.00035	0.0227	-0.22	-0.16	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr1:11908152~11908271:+
THCA	cis	rs13108904	0.87	rs3775092	ENSG00000254094.1	AC078852.1	-3.6	0.00035	0.0227	-0.2	-0.16	Obesity-related traits;	chr4:1247174	chr4:1356581~1358075:+
THCA	cis	rs7264396	0.836	rs1886695	ENSG00000088340.14	FER1L4	-3.6	0.00035	0.0227	-0.17	-0.16	Total cholesterol levels;	chr20:35592613	chr20:35558737~35607562:-
THCA	cis	rs7267979	0.565	rs3752273	ENSG00000276952.1	RP5-965G21.6	-3.6	0.00035	0.0227	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:25284915~25285588:-
THCA	cis	rs1015362	0.54	rs2050209	ENSG00000275784.1	RP5-1125A11.6	3.6	0.00035	0.0227	0.19	0.16	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33989480~33991818:-
THCA	cis	rs138024639	1	rs138024639	ENSG00000220721.1	OR1F12	3.6	0.00035	0.0227	0.37	0.16	Breast cancer;	chr6:28468244	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs55690788	ENSG00000220721.1	OR1F12	3.6	0.00035	0.0227	0.37	0.16	Depression;	chr6:28468368	chr6:28073316~28074233:+
THCA	cis	rs1062177	1	rs973529	ENSG00000272112.1	CTB-113P19.5	3.6	0.00035	0.0227	0.14	0.16	Preschool internalizing problems;	chr5:151808597	chr5:151724831~151725356:-
THCA	cis	rs9450351	0.744	rs7775016	ENSG00000203875.9	SNHG5	-3.6	0.00035	0.0227	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85780196	chr6:85660950~85678736:-
THCA	cis	rs853679	0.517	rs4713145	ENSG00000219891.2	ZSCAN12P1	3.6	0.00035	0.0227	0.23	0.16	Depression;	chr6:28139049	chr6:28091154~28093664:+
THCA	cis	rs6547705	0.858	rs2271666	ENSG00000231259.4	AC125232.1	-3.6	0.00035	0.0227	-0.23	-0.16	Progressive supranuclear palsy;	chr2:86770425	chr2:87031815~87053069:-
THCA	cis	rs7903847	0.642	rs11189174	ENSG00000225850.3	RP11-452K12.4	3.6	0.00035	0.0227	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97379843	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs11189175	ENSG00000225850.3	RP11-452K12.4	3.6	0.00035	0.0227	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97379852	chr10:97334564~97343203:+
THCA	cis	rs4742903	0.904	rs10761015	ENSG00000270332.1	SMC2-AS1	3.6	0.00035	0.0227	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104244919	chr9:104080024~104093073:-
THCA	cis	rs9314614	0.872	rs2977794	ENSG00000245857.2	GS1-24F4.2	3.6	0.00035	0.0227	0.21	0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6852835	chr8:6835554~6885276:+
THCA	cis	rs4648045	0.565	rs11733749	ENSG00000251288.2	RP11-10L12.2	-3.6	0.00035	0.0227	-0.22	-0.16	Lymphocyte percentage of white cells;	chr4:102625985	chr4:102751401~102752641:+
THCA	cis	rs6921919	0.562	rs13198809	ENSG00000220721.1	OR1F12	3.6	0.00035	0.0227	0.36	0.16	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs35353359	ENSG00000220721.1	OR1F12	3.6	0.00035	0.0227	0.36	0.16	Depression;	chr6:28356601	chr6:28073316~28074233:+
THCA	cis	rs301901	0.729	rs217781	ENSG00000250155.1	CTD-2353F22.1	-3.6	0.00035	0.0227	-0.17	-0.16	Height;	chr5:37344444	chr5:36666214~36725195:-
THCA	cis	rs4792901	0.722	rs12601849	ENSG00000279602.1	CTD-3014M21.1	-3.6	0.00035	0.0227	-0.21	-0.16	Dupuytren's disease;	chr17:43468920	chr17:43360041~43361361:-
THCA	cis	rs2274273	0.87	rs59629906	ENSG00000258469.1	CHMP4BP1	3.6	0.00035	0.0227	0.15	0.16	Protein biomarker;	chr14:55314471	chr14:55298644~55299231:+
THCA	cis	rs9314614	0.789	rs2980951	ENSG00000245857.2	GS1-24F4.2	3.6	0.00035	0.0227	0.21	0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6855162	chr8:6835554~6885276:+
THCA	cis	rs9487051	0.872	rs9487034	ENSG00000260273.1	RP11-425D10.10	3.6	0.00035	0.0227	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109284696	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs4601178	ENSG00000260273.1	RP11-425D10.10	3.6	0.00035	0.0227	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109290043	chr6:109382795~109383666:+
THCA	cis	rs559555	0.523	rs490457	ENSG00000276517.1	AL133243.2	-3.6	0.00035	0.0227	-0.16	-0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31614037	chr2:32526504~32529507:+
THCA	cis	rs7586085	0.902	rs777359	ENSG00000232411.1	AC009495.3	-3.6	0.00035	0.0227	-0.17	-0.16	Total body bone mineral density;	chr2:165699378	chr2:165833048~165839098:-
THCA	cis	rs301901	0.698	rs217837	ENSG00000250155.1	CTD-2353F22.1	3.6	0.00035	0.0227	0.17	0.16	Height;	chr5:37376570	chr5:36666214~36725195:-
THCA	cis	rs4879656	0.931	rs10971314	ENSG00000225693.1	LAGE3P1	-3.6	0.00035	0.0227	-0.18	-0.16	Menopause (age at onset);	chr9:33013945	chr9:33019682~33020165:-
THCA	cis	rs10844154	0.638	rs179104	ENSG00000277342.1	RP11-843B15.4	3.6	0.00035	0.0227	0.2	0.16	Emphysema-related traits;Weight;	chr12:32249463	chr12:32109076~32109602:+
THCA	cis	rs2274273	0.837	rs59871474	ENSG00000258469.1	CHMP4BP1	3.6	0.00035	0.0227	0.15	0.16	Protein biomarker;	chr14:55312645	chr14:55298644~55299231:+
THCA	cis	rs4785204	0.867	rs72794301	ENSG00000279356.1	RP11-429P3.8	-3.6	0.00035	0.0228	-0.32	-0.16	Esophageal cancer (squamous cell);	chr16:50022295	chr16:50072862~50074986:+
THCA	cis	rs17134212	0.632	rs62370374	ENSG00000251187.4	CTC-459M5.2	-3.6	0.00035	0.0228	-0.15	-0.16	Common carotid intima-media thickness in HIV negative individuals;	chr5:112207836	chr5:112192020~112210139:+
THCA	cis	rs847649	0.699	rs10271157	ENSG00000234715.1	CTB-107G13.1	-3.6	0.000351	0.0228	-0.18	-0.16	Morning vs. evening chronotype;	chr7:102887144	chr7:103445207~103514007:+
THCA	cis	rs7129556	0.954	rs2032395	ENSG00000254459.1	RP11-91P24.7	3.6	0.000351	0.0228	0.21	0.16	Weight loss (gastric bypass surgery);	chr11:77603458	chr11:77829654~77872262:-
THCA	cis	rs3785888	0.548	rs3890958	ENSG00000238419.1	RNU7-186P	3.6	0.000351	0.0228	0.19	0.16	Cleft lip with or without cleft palate;	chr17:46969499	chr17:47259358~47259420:-
THCA	cis	rs4815191	0.855	rs1541234	ENSG00000230387.2	RP4-737E23.2	-3.6	0.000351	0.0228	-0.24	-0.16	Obesity-related traits;	chr20:23287020	chr20:23187961~23190307:+
THCA	cis	rs7819412	0.654	rs6987059	ENSG00000255495.1	AC145124.2	-3.6	0.000351	0.0228	-0.19	-0.16	Triglycerides;	chr8:11213548	chr8:12194467~12196280:+
THCA	cis	rs917063	0.773	rs740069	ENSG00000269927.1	RP6-91H8.3	-3.6	0.000351	0.0228	-0.22	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:71166344	chr14:71141125~71143253:-
THCA	cis	rs917063	0.773	rs11628267	ENSG00000269927.1	RP6-91H8.3	-3.6	0.000351	0.0228	-0.22	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:71166577	chr14:71141125~71143253:-
THCA	cis	rs917063	0.773	rs12433971	ENSG00000269927.1	RP6-91H8.3	3.6	0.000351	0.0228	0.22	0.16	Gestational age at birth in labor-initiated deliveries (child effect);Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:71170579	chr14:71141125~71143253:-
THCA	cis	rs1005277	0.505	rs200931	ENSG00000120555.12	SEPT7P9	3.6	0.000351	0.0228	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:38383069~38402916:-
THCA	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	3.6	0.000351	0.0228	0.15	0.16	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
THCA	cis	rs12541437	0.617	rs4876688	ENSG00000253327.2	RAD21-AS1	3.6	0.000351	0.0228	0.21	0.16	Gut microbiome composition (winter);	chr8:116912262	chr8:116874424~116876868:+
THCA	cis	rs2310173	0.521	rs6722640	ENSG00000281162.1	LINC01127	-3.6	0.000351	0.0228	-0.13	-0.16	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102045151	chr2:101962056~101987167:+
THCA	cis	rs4742903	0.935	rs10122352	ENSG00000270332.1	SMC2-AS1	3.6	0.000351	0.0228	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104231230	chr9:104080024~104093073:-
THCA	cis	rs78487399	0.908	rs12469695	ENSG00000234936.1	AC010883.5	3.6	0.000351	0.0228	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43606119	chr2:43229573~43233394:+
THCA	cis	rs4742903	0.935	rs10991168	ENSG00000270332.1	SMC2-AS1	3.6	0.000351	0.0228	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104212621	chr9:104080024~104093073:-
THCA	cis	rs875971	1	rs2077593	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66427543	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs4717292	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66430611	chr7:66739829~66740385:-
THCA	cis	rs875971	0.895	rs10755833	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66448930	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs12668936	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66449417	chr7:66739829~66740385:-
THCA	cis	rs875971	0.895	rs1833495	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66456608	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs6945032	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66457499	chr7:66739829~66740385:-
THCA	cis	rs875971	0.929	rs12673810	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66458866	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6961155	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66468308	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs7789768	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66473993	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6979382	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66421388	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6961990	ENSG00000272831.1	RP11-792A8.4	3.6	0.000351	0.0228	0.1	0.16	Aortic root size;	chr7:66423583	chr7:66739829~66740385:-
THCA	cis	rs11603020	0.851	rs10896631	ENSG00000254602.1	AP000662.4	-3.6	0.000351	0.0228	-0.19	-0.16	Blood protein levels;	chr11:57613790	chr11:57638024~57652790:+
THCA	cis	rs11603020	0.904	rs4926	ENSG00000254602.1	AP000662.4	-3.6	0.000351	0.0228	-0.19	-0.16	Blood protein levels;	chr11:57614516	chr11:57638024~57652790:+
THCA	cis	rs11603020	0.904	rs11606677	ENSG00000254602.1	AP000662.4	-3.6	0.000351	0.0228	-0.19	-0.16	Blood protein levels;	chr11:57615904	chr11:57638024~57652790:+
THCA	cis	rs793571	0.5	rs2555356	ENSG00000245975.2	RP11-30K9.6	3.6	0.000351	0.0228	0.15	0.16	Schizophrenia;	chr15:58724232	chr15:58768072~58770974:-
THCA	cis	rs910316	1	rs12588240	ENSG00000259138.1	RP11-950C14.7	3.6	0.000351	0.0228	0.14	0.16	Height;	chr14:75145380	chr14:75127153~75136930:+
THCA	cis	rs9650657	0.771	rs6601513	ENSG00000269918.1	AF131215.9	-3.6	0.000351	0.0228	-0.17	-0.16	Neuroticism;	chr8:10737333	chr8:11104691~11106704:-
THCA	cis	rs2736340	0.539	rs11250138	ENSG00000154316.13	TDH	3.6	0.000351	0.0228	0.13	0.16	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465803	chr8:11339637~11368452:+
THCA	cis	rs10792665	0.541	rs2170009	ENSG00000255503.1	RP11-113K21.4	-3.6	0.000351	0.0228	-0.17	-0.16	Obesity-related traits;	chr11:82930115	chr11:83072402~83097196:-
THCA	cis	rs17095355	0.748	rs6584972	ENSG00000203876.8	ADD3-AS1	-3.6	0.000351	0.0228	-0.18	-0.16	Biliary atresia;	chr10:110141809	chr10:109940104~110008381:-
THCA	cis	rs911555	0.655	rs10149470	ENSG00000244691.1	RPL10AP1	-3.6	0.000351	0.0228	-0.22	-0.16	Intelligence (multi-trait analysis);	chr14:103551616	chr14:103412119~103412761:-
THCA	cis	rs9650657	0.707	rs1115867	ENSG00000255310.2	AF131215.2	-3.6	0.000351	0.0228	-0.14	-0.16	Neuroticism;	chr8:10781240	chr8:11107788~11109726:-
THCA	cis	rs2115630	1	rs11854313	ENSG00000275120.1	RP11-182J1.17	-3.6	0.000351	0.0228	-0.17	-0.16	P wave terminal force;	chr15:84760817	chr15:84599434~84606463:-
THCA	cis	rs4788570	0.545	rs8044144	ENSG00000260185.1	RP11-432I5.6	-3.6	0.000351	0.0228	-0.3	-0.16	Intelligence (multi-trait analysis);	chr16:71749218	chr16:71655027~71664212:+
THCA	cis	rs80130819	1	rs41291969	ENSG00000257735.1	RP11-370I10.6	-3.6	0.000351	0.0228	-0.36	-0.16	Prostate cancer;	chr12:48144832	chr12:48350945~48442411:+
THCA	cis	rs28595532	0.702	rs72670238	ENSG00000260404.2	RP11-384K6.6	-3.6	0.000351	0.0228	-0.24	-0.16	Cannabis dependence symptom count;	chr4:118401596	chr4:118591773~118633729:+
THCA	cis	rs11233413	1	rs7106216	ENSG00000246067.6	RAB30-AS1	3.6	0.000351	0.0228	0.16	0.16	Economic and political preferences (feminism/equality);	chr11:83001576	chr11:83072066~83106719:+
THCA	cis	rs55692468	0.804	rs10169514	ENSG00000213197.3	AC012066.1	-3.6	0.000351	0.0228	-0.21	-0.16	Intraocular pressure;	chr2:152470643	chr2:152389937~152390630:+
THCA	cis	rs55692468	0.804	rs6742066	ENSG00000213197.3	AC012066.1	-3.6	0.000351	0.0228	-0.21	-0.16	Intraocular pressure;	chr2:152472649	chr2:152389937~152390630:+
THCA	cis	rs9987353	0.566	rs34389718	ENSG00000253981.4	ALG1L13P	-3.6	0.000351	0.0228	-0.17	-0.16	Recombination measurement;	chr8:9208015	chr8:8236003~8244667:-
THCA	cis	rs2179367	0.959	rs237034	ENSG00000223701.3	RAET1E-AS1	3.6	0.000351	0.0228	0.21	0.16	Dupuytren's disease;	chr6:149390726	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.959	rs628488	ENSG00000223701.3	RAET1E-AS1	3.6	0.000351	0.0228	0.21	0.16	Dupuytren's disease;	chr6:149398264	chr6:149884431~149919508:+
THCA	cis	rs2179367	0.959	rs9373592	ENSG00000223701.3	RAET1E-AS1	3.6	0.000351	0.0228	0.21	0.16	Dupuytren's disease;	chr6:149412119	chr6:149884431~149919508:+
THCA	cis	rs12362063	1	rs11606780	ENSG00000249867.4	RP11-115J23.1	3.6	0.000351	0.0228	0.17	0.16	Hepatitis B;	chr11:29255751	chr11:28702615~29063821:+
THCA	cis	rs9467773	0.595	rs2172007	ENSG00000228223.2	HCG11	-3.6	0.000351	0.0228	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26523450~26526579:+
THCA	cis	rs11250098	0.583	rs7000276	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000351	0.0228	-0.21	-0.16	Morning vs. evening chronotype;	chr8:10947333	chr8:10433672~10438312:+
THCA	cis	rs889512	0.642	rs60879082	ENSG00000261783.1	RP11-252K23.2	3.6	0.000351	0.0228	0.33	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75249167	chr16:75379818~75381260:-
THCA	cis	rs7572733	0.84	rs4286272	ENSG00000231621.1	AC013264.2	3.6	0.000351	0.0228	0.15	0.16	Dermatomyositis;	chr2:197670954	chr2:197197991~197199273:+
THCA	cis	rs76382185	0.756	rs7547030	ENSG00000225169.1	BRI3P1	-3.6	0.000351	0.0228	-0.32	-0.16	Lymphocyte counts;	chr1:101129201	chr1:100213293~100213670:+
THCA	cis	rs7819412	0.521	rs11777887	ENSG00000154316.13	TDH	-3.6	0.000351	0.0228	-0.13	-0.16	Triglycerides;	chr8:11179290	chr8:11339637~11368452:+
THCA	cis	rs6545883	0.894	rs778144	ENSG00000212978.6	AC016747.3	-3.6	0.000351	0.0228	-0.18	-0.16	Tuberculosis;	chr2:61355993	chr2:61141592~61144969:-
THCA	cis	rs7085104	0.572	rs284856	ENSG00000236937.2	PTGES3P4	-3.6	0.000351	0.0228	-0.21	-0.16	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102845595~102845950:+
THCA	cis	rs73193808	0.59	rs9981735	ENSG00000231125.2	AF129075.5	-3.6	0.000351	0.0228	-0.16	-0.16	Coronary artery disease;	chr21:29195543	chr21:29058073~29060095:-
THCA	cis	rs73193808	0.59	rs9982010	ENSG00000231125.2	AF129075.5	-3.6	0.000351	0.0228	-0.16	-0.16	Coronary artery disease;	chr21:29195855	chr21:29058073~29060095:-
THCA	cis	rs1348850	0.567	rs3770011	ENSG00000271996.1	RP11-337N6.1	3.6	0.000352	0.0228	0.21	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177673162	chr2:177306373~177310572:+
THCA	cis	rs1577917	0.538	rs6454483	ENSG00000220563.1	PKMP3	3.6	0.000352	0.0228	0.12	0.16	Response to antipsychotic treatment;	chr6:85708565	chr6:85659892~85660606:-
THCA	cis	rs1005277	0.541	rs2505193	ENSG00000151963.4	RP11-775A3.1	-3.6	0.000352	0.0228	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474580	ENSG00000151963.4	RP11-775A3.1	-3.6	0.000352	0.0228	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:37883594~37884109:+
THCA	cis	rs1009077	0.671	rs13120581	ENSG00000245958.5	RP11-33B1.1	3.6	0.000352	0.0228	0.26	0.16	Endometriosis;	chr4:119602481	chr4:119454791~119552025:+
THCA	cis	rs972578	0.967	rs2038058	ENSG00000274717.1	RP1-47A17.1	-3.6	0.000352	0.0228	-0.17	-0.16	Mean platelet volume;	chr22:42938289	chr22:42791814~42794313:-
THCA	cis	rs773506	1	rs773509	ENSG00000229694.5	RP11-305L7.6	-3.6	0.000352	0.0228	-0.2	-0.16	Type 2 diabetes nephropathy;	chr9:91196140	chr9:91119062~91182762:+
THCA	cis	rs961764	0.733	rs1508303	ENSG00000217241.1	CBX3P9	-3.6	0.000352	0.0228	-0.22	-0.16	Height;	chr6:117125940	chr6:116453014~116453565:-
THCA	cis	rs961764	0.733	rs783371	ENSG00000217241.1	CBX3P9	-3.6	0.000352	0.0228	-0.22	-0.16	Height;	chr6:117127657	chr6:116453014~116453565:-
THCA	cis	rs721048	0.92	rs17432775	ENSG00000242412.1	DBIL5P2	-3.6	0.000352	0.0228	-0.22	-0.16	Prostate cancer;	chr2:63239328	chr2:63117851~63119542:-
THCA	cis	rs769267	1	rs2285627	ENSG00000269131.1	AC004447.2	3.6	0.000352	0.0228	0.11	0.16	Tonsillectomy;	chr19:19357128	chr19:18990893~18993610:+
THCA	cis	rs7520050	0.831	rs61783170	ENSG00000280836.1	AL355480.1	3.6	0.000352	0.0228	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45581219~45581321:-
THCA	cis	rs17122278	0.79	rs45522239	ENSG00000243431.1	RPL5P30	3.6	0.000352	0.0228	0.16	0.16	Total cholesterol levels;	chr11:118534723	chr11:118560690~118561580:+
THCA	cis	rs950027	0.62	rs1719245	ENSG00000259479.5	SORD2P	3.6	0.000352	0.0228	0.17	0.16	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:44826371~44884694:-
THCA	cis	rs854765	0.663	rs1108648	ENSG00000281749.1	Y_RNA	-3.6	0.000352	0.0228	-0.21	-0.16	Total body bone mineral density;	chr17:17847244	chr17:18001101~18001195:-
THCA	cis	rs10043228	1	rs76292674	ENSG00000250015.1	CTC-339F2.2	3.6	0.000352	0.0228	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116289563	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs76414143	ENSG00000250015.1	CTC-339F2.2	3.6	0.000352	0.0228	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116289699	chr5:116302354~116304134:-
THCA	cis	rs9844666	0.512	rs9839259	ENSG00000273486.1	RP11-731C17.2	-3.6	0.000352	0.0228	-0.14	-0.16	Height;	chr3:135923495	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs6779603	ENSG00000273486.1	RP11-731C17.2	3.6	0.000352	0.0228	0.14	0.16	Height;	chr3:135921113	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9829329	ENSG00000273486.1	RP11-731C17.2	3.6	0.000352	0.0228	0.14	0.16	Height;	chr3:135921818	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9829476	ENSG00000273486.1	RP11-731C17.2	3.6	0.000352	0.0228	0.14	0.16	Height;	chr3:135921914	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9833799	ENSG00000273486.1	RP11-731C17.2	3.6	0.000352	0.0228	0.14	0.16	Height;	chr3:135922325	chr3:136837338~136839021:-
THCA	cis	rs2287838	0.967	rs12610468	ENSG00000267370.1	CTD-2623N2.3	3.6	0.000352	0.0228	0.15	0.16	Sleep duration;	chr19:9878794	chr19:9756152~9756863:-
THCA	cis	rs886774	0.585	rs1017055	ENSG00000241764.3	AC002467.7	-3.6	0.000352	0.0228	-0.14	-0.16	Ulcerative colitis;	chr7:107853496	chr7:107742817~107744581:-
THCA	cis	rs5758659	0.714	rs6002607	ENSG00000205702.9	CYP2D7	-3.6	0.000352	0.0228	-0.12	-0.16	Cognitive function;	chr22:42100502	chr22:42140203~42144577:-
THCA	cis	rs6546550	0.935	rs13392884	ENSG00000179818.12	PCBP1-AS1	-3.6	0.000352	0.0228	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69809579	chr2:69962263~70103220:-
THCA	cis	rs2276314	1	rs9304154	ENSG00000267627.4	RP11-905K4.1	-3.6	0.000352	0.0228	-0.21	-0.16	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35951803~35966118:-
THCA	cis	rs9358749	0.661	rs1915462	ENSG00000220517.2	ASS1P1	-3.6	0.000352	0.0228	-0.45	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr6:24066798	chr6:25023247~25024483:-
THCA	cis	rs14027	0.705	rs13265683	ENSG00000279347.1	RP11-85I17.2	-3.6	0.000352	0.0228	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119838736~119840385:-
THCA	cis	rs7615952	0.599	rs2270986	ENSG00000248787.1	RP11-666A20.4	-3.6	0.000352	0.0228	-0.25	-0.16	Blood pressure (smoking interaction);	chr3:125982256	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.599	rs12496921	ENSG00000248787.1	RP11-666A20.4	-3.6	0.000352	0.0228	-0.25	-0.16	Blood pressure (smoking interaction);	chr3:125983105	chr3:125908005~125910272:-
THCA	cis	rs3924048	0.574	rs12410270	ENSG00000272482.1	RP11-474O21.5	-3.6	0.000352	0.0228	-0.15	-0.16	Optic cup area;	chr1:12552813	chr1:12618900~12619244:-
THCA	cis	rs6878727	0.85	rs11241738	ENSG00000253807.4	LINC01170	-3.6	0.000352	0.0228	-0.15	-0.16	Breast cancer;	chr5:124385732	chr5:124059794~124405079:-
THCA	cis	rs2131877	0.529	rs4677810	ENSG00000238097.1	RP11-513G11.3	-3.6	0.000352	0.0228	-0.19	-0.16	Non-small cell lung cancer;	chr3:195136018	chr3:194247648~194257772:+
THCA	cis	rs2191566	1	rs2356549	ENSG00000267114.1	CTB-129P6.11	3.6	0.000352	0.0228	0.12	0.16	Acute lymphoblastic leukemia (childhood);	chr19:44007050	chr19:44950044~44954007:-
THCA	cis	rs2933343	0.7	rs1683779	ENSG00000261159.1	RP11-723O4.9	3.6	0.000352	0.0228	0.17	0.16	IgG glycosylation;	chr3:128923205	chr3:128859716~128860526:-
THCA	cis	rs9910055	0.821	rs4473241	ENSG00000267080.4	ASB16-AS1	-3.6	0.000352	0.0229	-0.15	-0.16	Total body bone mineral density;	chr17:44203914	chr17:44175973~44186717:-
THCA	cis	rs4663476	0.673	rs940954	ENSG00000235529.1	AGAP1-IT1	3.6	0.000352	0.0229	0.25	0.16	Response to angiotensin II receptor blocker therapy;	chr2:234676935	chr2:235505751~235507566:+
THCA	cis	rs2455799	0.573	rs2062824	ENSG00000270409.1	RP11-44D5.1	-3.6	0.000352	0.0229	-0.17	-0.16	Mean platelet volume;	chr3:15716394	chr3:15732252~15733470:+
THCA	cis	rs1411478	0.967	rs4111520	ENSG00000243155.1	RP11-46A10.5	3.6	0.000352	0.0229	0.17	0.16	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180989810	chr1:180944042~180976482:-
THCA	cis	rs4660214	0.666	rs6600290	ENSG00000228060.1	RP11-69E11.8	3.6	0.000352	0.0229	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157151	chr1:39565160~39573203:+
THCA	cis	rs12817549	0.817	rs2196424	ENSG00000186076.5	RP11-887P2.3	-3.6	0.000352	0.0229	-0.19	-0.16	Hip circumference adjusted for BMI;	chr12:93710505	chr12:93640822~93641586:-
THCA	cis	rs4295623	0.531	rs2898295	ENSG00000270154.1	RP11-419I17.1	-3.6	0.000352	0.0229	-0.19	-0.16	Morning vs. evening chronotype;	chr8:11738460	chr8:12476462~12477122:+
THCA	cis	rs10540	1	rs116101630	ENSG00000279672.1	CMB9-55F22.1	3.6	0.000352	0.0229	0.32	0.16	Body mass index;	chr11:506826	chr11:779617~780755:+
THCA	cis	rs11250098	0.547	rs2409764	ENSG00000254527.1	ENPP7P12	3.6	0.000352	0.0229	0.2	0.16	Morning vs. evening chronotype;	chr8:11423764	chr8:12205759~12206389:-
THCA	cis	rs55692468	0.848	rs12471183	ENSG00000213197.3	AC012066.1	3.6	0.000352	0.0229	0.22	0.16	Intraocular pressure;	chr2:152510313	chr2:152389937~152390630:+
THCA	cis	rs465969	1	rs1407644	ENSG00000230177.1	RP5-1112D6.4	-3.6	0.000353	0.0229	-0.25	-0.16	Psoriasis;	chr6:111480895	chr6:111277932~111278742:+
THCA	cis	rs8033133	0.602	rs3803326	ENSG00000251896.1	SNORD116-27	-3.6	0.000353	0.0229	-0.19	-0.16	Blood osmolality (transformed sodium);	chr15:25083568	chr15:25101575~25101666:+
THCA	cis	rs867186	1	rs79438986	ENSG00000126005.14	MMP24-AS1	-3.6	0.000353	0.0229	-0.26	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35114477	chr20:35216462~35278131:-
THCA	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	3.6	0.000353	0.0229	0.15	0.16	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
THCA	cis	rs916888	0.821	rs415430	ENSG00000260075.1	NSFP1	3.6	0.000353	0.0229	0.26	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46372855~46487141:+
THCA	cis	rs916888	0.779	rs430685	ENSG00000260075.1	NSFP1	3.6	0.000353	0.0229	0.26	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46372855~46487141:+
THCA	cis	rs9368222	0.917	rs6931514	ENSG00000280989.1	LINC00581	3.6	0.000353	0.0229	0.21	0.16	Body mass index;Peak insulin response;Acute insulin response;	chr6:20703721	chr6:21486061~21511895:-
THCA	cis	rs11658311	0.85	rs11654482	ENSG00000232344.2	AC087163.2	-3.6	0.000353	0.0229	-0.21	-0.16	Obsessive-compulsive symptoms;	chr17:17713773	chr17:18010643~18011822:+
THCA	cis	rs6723108	0.515	rs16831001	ENSG00000224043.6	CCNT2-AS1	3.6	0.000353	0.0229	0.17	0.16	Type 2 diabetes;	chr2:134777224	chr2:134735464~134918710:-
THCA	cis	rs11717455	1	rs6804644	ENSG00000232439.1	RPL18AP7	-3.6	0.000353	0.0229	-0.26	-0.16	Systemic lupus erythematosus;	chr3:38816556	chr3:38526802~38527325:-
THCA	cis	rs35740288	0.787	rs35250181	ENSG00000259407.1	RP11-158M2.3	-3.6	0.000353	0.0229	-0.2	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85699431	chr15:85744109~85750281:-
THCA	cis	rs9863	0.861	rs4930723	ENSG00000270028.1	RP11-380L11.4	3.6	0.000353	0.0229	0.18	0.16	White blood cell count;	chr12:123939053	chr12:123925461~123926083:-
THCA	cis	rs13168506	0.56	rs2287746	ENSG00000271824.1	AC009014.3	-3.6	0.000353	0.0229	-0.17	-0.16	Stroke;	chr5:136212349	chr5:136191468~136193134:-
THCA	cis	rs10129255	0.826	rs7150693	ENSG00000280411.1	IGHV1-69-2	-3.6	0.000353	0.0229	-0.11	-0.16	Kawasaki disease;	chr14:106705382	chr14:106762092~106762588:-
THCA	cis	rs10129255	0.869	rs7150549	ENSG00000280411.1	IGHV1-69-2	-3.6	0.000353	0.0229	-0.11	-0.16	Kawasaki disease;	chr14:106705441	chr14:106762092~106762588:-
THCA	cis	rs7520050	0.966	rs2486447	ENSG00000280836.1	AL355480.1	3.6	0.000353	0.0229	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs1085244	ENSG00000280836.1	AL355480.1	3.6	0.000353	0.0229	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs6662641	ENSG00000280836.1	AL355480.1	3.6	0.000353	0.0229	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs1707335	ENSG00000280836.1	AL355480.1	3.6	0.000353	0.0229	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45581219~45581321:-
THCA	cis	rs448720	1	rs7172137	ENSG00000260657.2	RP11-315D16.4	-3.6	0.000353	0.0229	-0.21	-0.16	Cognitive performance;	chr15:67912019	chr15:68267792~68277994:-
THCA	cis	rs10411161	0.702	rs8110531	ENSG00000275055.1	CTC-471J1.11	-3.6	0.000353	0.0229	-0.16	-0.16	Breast cancer;	chr19:51880257	chr19:52049007~52049754:+
THCA	cis	rs13126694	0.65	rs13103614	ENSG00000248429.4	RP11-597D13.9	3.6	0.000353	0.0229	0.18	0.16	Blood osmolality (transformed sodium);	chr4:157938359	chr4:158170752~158202877:+
THCA	cis	rs2797160	1	rs13328298	ENSG00000226409.1	RP11-735G4.1	3.6	0.000353	0.0229	0.19	0.16	Endometrial cancer;	chr6:125695434	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs6933302	ENSG00000226409.1	RP11-735G4.1	3.6	0.000353	0.0229	0.19	0.16	Endometrial cancer;	chr6:125695805	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs6933471	ENSG00000226409.1	RP11-735G4.1	3.6	0.000353	0.0229	0.19	0.16	Endometrial cancer;	chr6:125695883	chr6:125370211~125374324:-
THCA	cis	rs250585	0.736	rs250578	ENSG00000260136.4	CTD-2270L9.4	3.6	0.000353	0.0229	0.12	0.16	Egg allergy;	chr16:23415789	chr16:23452758~23457606:+
THCA	cis	rs6982240	0.514	rs10089212	ENSG00000253307.1	RP11-10J21.4	3.6	0.000353	0.0229	0.24	0.16	Tonsillectomy;	chr8:141255281	chr8:141252286~141253292:-
THCA	cis	rs10487112	0.56	rs2888796	ENSG00000225498.1	AC002064.5	3.6	0.000353	0.0229	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr7:90359357	chr7:90312496~90322592:+
THCA	cis	rs7259811	0.56	rs2191435	ENSG00000279405.1	AC098795.1	-3.6	0.000353	0.0229	-0.17	-0.16	Western dietary pattern;	chr19:56706439	chr19:56480397~56483977:-
THCA	cis	rs1476587	0.92	rs55657695	ENSG00000224046.1	AC005076.5	3.6	0.000353	0.0229	0.16	0.16	Brachial circumference;	chr7:87105393	chr7:87151423~87152420:-
THCA	cis	rs4819052	0.565	rs35776291	ENSG00000273796.1	LL21NC02-21A1.1	-3.6	0.000353	0.0229	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45403809~45404369:-
THCA	cis	rs5752326	0.558	rs134134	ENSG00000261188.1	CTA-445C9.14	-3.6	0.000353	0.0229	-0.17	-0.16	Ischemic stroke;	chr22:26502925	chr22:26512537~26514568:+
THCA	cis	rs1510552	0.81	rs71428314	ENSG00000270659.1	RP11-105N14.1	3.6	0.000353	0.0229	0.19	0.16	Contrast sensitivity;	chr2:214040233	chr2:213152970~213153659:+
THCA	cis	rs765787	0.53	rs11636410	ENSG00000259539.1	CTD-2651B20.1	-3.6	0.000353	0.0229	-0.2	-0.16	Uric acid levels;	chr15:45243715	chr15:45152664~45167526:-
THCA	cis	rs7615952	0.512	rs2979336	ENSG00000248787.1	RP11-666A20.4	-3.6	0.000353	0.0229	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125638626	chr3:125908005~125910272:-
THCA	cis	rs7824557	0.806	rs10503418	ENSG00000255310.2	AF131215.2	-3.6	0.000353	0.0229	-0.13	-0.16	Retinal vascular caliber;	chr8:11261474	chr8:11107788~11109726:-
THCA	cis	rs642858	0.91	rs494794	ENSG00000234147.1	RP3-460G2.2	-3.6	0.000353	0.0229	-0.19	-0.16	Type 2 diabetes;	chr6:140186457	chr6:140845958~140852924:-
THCA	cis	rs9527	0.571	rs3740400	ENSG00000213277.3	MARCKSL1P1	3.6	0.000353	0.0229	0.18	0.16	Arsenic metabolism;	chr10:102869708	chr10:103175554~103176094:+
THCA	cis	rs9527	0.571	rs7904113	ENSG00000213277.3	MARCKSL1P1	3.6	0.000353	0.0229	0.18	0.16	Arsenic metabolism;	chr10:102873357	chr10:103175554~103176094:+
THCA	cis	rs7647973	0.6	rs11920267	ENSG00000228638.1	FCF1P2	-3.6	0.000353	0.0229	-0.17	-0.16	Menarche (age at onset);	chr3:49238531	chr3:48290793~48291375:-
THCA	cis	rs2929278	0.561	rs2927071	ENSG00000275601.1	AC011330.13	-3.6	0.000353	0.0229	-0.2	-0.16	Schizophrenia;	chr15:43626883	chr15:43642389~43643023:-
THCA	cis	rs6687821	0.515	rs1407132	ENSG00000261737.1	RP4-612B15.3	-3.6	0.000353	0.0229	-0.25	-0.16	Yeast infection;	chr1:86928231	chr1:86703502~86704462:-
THCA	cis	rs7246657	0.943	rs10415937	ENSG00000268499.1	CTB-102L5.8	3.6	0.000353	0.0229	0.21	0.16	Coronary artery calcification;	chr19:37339162	chr19:38199836~38200934:+
THCA	cis	rs7246967	0.673	rs7245540	ENSG00000198153.8	ZNF849P	-3.6	0.000353	0.0229	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22698702	chr19:22685167~22686732:+
THCA	cis	rs11673344	0.542	rs2562598	ENSG00000267260.1	CTD-2162K18.4	-3.6	0.000353	0.0229	-0.19	-0.16	Obesity-related traits;	chr19:37025318	chr19:36773153~36777078:+
THCA	cis	rs6449502	0.748	rs6449505	ENSG00000251279.1	CTC-436P18.1	3.6	0.000353	0.0229	0.25	0.16	Mean platelet volume;	chr5:60821053	chr5:61162070~61232040:+
THCA	cis	rs656319	0.58	rs13279701	ENSG00000248538.5	RP11-10A14.5	3.6	0.000353	0.0229	0.21	0.16	Myopia (pathological);	chr8:10111940	chr8:9189011~9202854:+
THCA	cis	rs72996113	0.702	rs11224383	ENSG00000248027.1	CTD-2383M3.1	-3.6	0.000353	0.0229	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100682934	chr11:100684162~100687955:-
THCA	cis	rs72996113	0.702	rs11224384	ENSG00000248027.1	CTD-2383M3.1	-3.6	0.000353	0.0229	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100683334	chr11:100684162~100687955:-
THCA	cis	rs875971	0.545	rs75577046	ENSG00000230295.1	RP11-458F8.2	3.6	0.000353	0.0229	0.15	0.16	Aortic root size;	chr7:66493729	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000230295.1	RP11-458F8.2	3.6	0.000353	0.0229	0.15	0.16	Aortic root size;	chr7:66505541	chr7:66880708~66882981:+
THCA	cis	rs4915077	1	rs12563783	ENSG00000226822.1	RP11-356N1.2	3.6	0.000353	0.0229	0.32	0.16	Hypothyroidism;	chr1:107769832	chr1:108071482~108074519:+
THCA	cis	rs5769765	1	rs910800	ENSG00000260613.1	RP3-522J7.6	3.6	0.000353	0.0229	0.21	0.16	Schizophrenia;	chr22:49884994	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.874	rs4624	ENSG00000260613.1	RP3-522J7.6	3.6	0.000353	0.0229	0.21	0.16	Schizophrenia;	chr22:49888269	chr22:49832616~49837786:-
THCA	cis	rs948562	0.793	rs79170562	ENSG00000280010.1	AP001350.4	3.6	0.000353	0.0229	0.27	0.16	Lymphoma;	chr11:58604081	chr11:58627435~58628528:+
THCA	cis	rs17689437	0.918	rs78978018	ENSG00000260084.1	RP11-615I2.1	-3.6	0.000353	0.0229	-0.29	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68594445	chr16:68573782~68589512:-
THCA	cis	rs10129255	0.957	rs4387509	ENSG00000280411.1	IGHV1-69-2	-3.6	0.000353	0.0229	-0.11	-0.16	Kawasaki disease;	chr14:106704386	chr14:106762092~106762588:-
THCA	cis	rs10760158	0.832	rs4240466	ENSG00000235865.2	GSN-AS1	3.6	0.000353	0.0229	0.14	0.16	Pulse pressure;	chr9:121277456	chr9:121280768~121285530:-
THCA	cis	rs7586879	0.616	rs6726199	ENSG00000224165.4	DNAJC27-AS1	-3.6	0.000353	0.0229	-0.09	-0.16	Body mass index;	chr2:24903459	chr2:24971390~25039694:+
THCA	cis	rs8062405	0.69	rs6498089	ENSG00000261766.1	RP11-22P6.2	3.6	0.000354	0.0229	0.16	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28862166~28863340:-
THCA	cis	rs3770081	1	rs3770066	ENSG00000273080.1	RP11-301O19.1	-3.6	0.000354	0.0229	-0.35	-0.16	Facial emotion recognition (sad faces);	chr2:86165227	chr2:86195590~86196049:+
THCA	cis	rs2274273	0.837	rs56949365	ENSG00000258469.1	CHMP4BP1	3.6	0.000354	0.0229	0.15	0.16	Protein biomarker;	chr14:55323360	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs4496026	ENSG00000258469.1	CHMP4BP1	3.6	0.000354	0.0229	0.15	0.16	Protein biomarker;	chr14:55323794	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs4366639	ENSG00000258469.1	CHMP4BP1	3.6	0.000354	0.0229	0.15	0.16	Protein biomarker;	chr14:55323798	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.87	rs11625423	ENSG00000258469.1	CHMP4BP1	3.6	0.000354	0.0229	0.15	0.16	Protein biomarker;	chr14:55329195	chr14:55298644~55299231:+
THCA	cis	rs9287719	0.781	rs12472807	ENSG00000243819.4	RN7SL832P	3.6	0.000354	0.0229	0.13	0.16	Prostate cancer;	chr2:10641479	chr2:10690344~10692099:+
THCA	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-3.6	0.000354	0.0229	-0.19	-0.16	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
THCA	cis	rs7954584	0.635	rs7313252	ENSG00000274292.1	RP11-347I19.7	-3.6	0.000354	0.0229	-0.12	-0.16	Mean corpuscular volume;	chr12:121909694	chr12:121800797~121803403:+
THCA	cis	rs13217239	0.646	rs6937880	ENSG00000124549.13	BTN2A3P	3.6	0.000354	0.0229	0.15	0.16	Schizophrenia;	chr6:27032457	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.621	rs12527231	ENSG00000124549.13	BTN2A3P	3.6	0.000354	0.0229	0.15	0.16	Schizophrenia;	chr6:27033509	chr6:26421391~26432383:+
THCA	cis	rs13217239	0.646	rs12523820	ENSG00000124549.13	BTN2A3P	3.6	0.000354	0.0229	0.15	0.16	Schizophrenia;	chr6:27033723	chr6:26421391~26432383:+
THCA	cis	rs1371614	0.679	rs4441421	ENSG00000229122.1	AGBL5-IT1	3.6	0.000354	0.0229	0.12	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26919223	chr2:27061038~27061815:+
THCA	cis	rs1541160	1	rs546894	ENSG00000239494.2	RN7SL333P	-3.6	0.000354	0.0229	-0.16	-0.16	Amyotrophic lateral sclerosis;	chr1:169987309	chr1:169859756~169860052:+
THCA	cis	rs2455799	0.573	rs2174172	ENSG00000270409.1	RP11-44D5.1	-3.6	0.000354	0.0229	-0.17	-0.16	Mean platelet volume;	chr3:15727072	chr3:15732252~15733470:+
THCA	cis	rs72765298	0.848	rs55707035	ENSG00000235332.2	RP11-366O20.5	3.6	0.000354	0.0229	0.25	0.16	Pulse pressure;	chr9:125177775	chr9:125194649~125195821:-
THCA	cis	rs72765298	0.848	rs72767014	ENSG00000235332.2	RP11-366O20.5	3.6	0.000354	0.0229	0.25	0.16	Pulse pressure;	chr9:125178287	chr9:125194649~125195821:-
THCA	cis	rs7216064	0.953	rs62086044	ENSG00000265055.1	AC145343.2	3.6	0.000354	0.0229	0.23	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67974721	chr17:68096046~68101474:-
THCA	cis	rs11671005	0.735	rs12977592	ENSG00000269600.1	AC016629.3	-3.6	0.000354	0.0229	-0.23	-0.16	Mean platelet volume;	chr19:58449689	chr19:58593896~58599355:-
THCA	cis	rs763121	0.925	rs5757165	ENSG00000225450.1	RP3-508I15.14	-3.6	0.000354	0.0229	-0.12	-0.16	Menopause (age at onset);	chr22:38598572	chr22:38739003~38749041:+
THCA	cis	rs2749097	0.825	rs2749100	ENSG00000244256.3	RN7SL130P	3.6	0.000354	0.0229	0.21	0.16	Alcohol consumption (transferrin glycosylation);	chr1:63659308	chr1:63655743~63656047:+
THCA	cis	rs17248895	0.764	rs8021730	ENSG00000258561.1	RP11-72M17.1	3.6	0.000354	0.0229	0.2	0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr14:67420064	chr14:66212810~66509394:-
THCA	cis	rs7809950	0.817	rs3779495	ENSG00000272072.1	CTA-363E19.2	-3.6	0.000354	0.0229	-0.17	-0.16	Coronary artery disease;	chr7:107609815	chr7:107192559~107193300:-
THCA	cis	rs6788895	0.661	rs77431731	ENSG00000244265.1	SIAH2-AS1	3.6	0.000354	0.0229	0.43	0.16	Breast cancer;	chr3:150772124	chr3:150761937~150762538:+
THCA	cis	rs10875746	0.669	rs10467101	ENSG00000226413.2	OR8T1P	3.6	0.000354	0.0229	0.23	0.16	Longevity (90 years and older);	chr12:48213954	chr12:48442030~48442947:-
THCA	cis	rs12908161	0.853	rs11633788	ENSG00000188388.10	GOLGA6L3	3.6	0.000354	0.0229	0.2	0.16	Schizophrenia;	chr15:84761911	chr15:85240472~85247170:+
THCA	cis	rs1729951	0.546	rs12054218	ENSG00000239213.4	NCK1-AS1	3.6	0.000354	0.023	0.14	0.16	Neuroticism;	chr3:136958654	chr3:136841726~136862054:-
THCA	cis	rs11637445	0.677	rs10152422	ENSG00000260657.2	RP11-315D16.4	3.6	0.000354	0.023	0.21	0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67810591	chr15:68267792~68277994:-
THCA	cis	rs9650657	0.769	rs2116093	ENSG00000269918.1	AF131215.9	-3.6	0.000354	0.023	-0.17	-0.16	Neuroticism;	chr8:10755789	chr8:11104691~11106704:-
THCA	cis	rs28510890	0.508	rs8041521	ENSG00000258647.4	LINC00930	3.6	0.000354	0.023	0.18	0.16	Lung cancer in ever smokers;	chr15:92616397	chr15:92567818~92572042:-
THCA	cis	rs5758659	0.652	rs133324	ENSG00000182057.4	OGFRP1	3.6	0.000354	0.023	0.19	0.16	Cognitive function;	chr22:42010367	chr22:42269753~42275196:+
THCA	cis	rs801193	0.844	rs2244022	ENSG00000230295.1	RP11-458F8.2	-3.6	0.000354	0.023	-0.12	-0.16	Aortic root size;	chr7:66737443	chr7:66880708~66882981:+
THCA	cis	rs7615952	0.932	rs13065725	ENSG00000272840.1	RP11-379B18.6	3.6	0.000354	0.023	0.28	0.16	Blood pressure (smoking interaction);	chr3:125913446	chr3:125774714~125797953:+
THCA	cis	rs478304	0.654	rs10896029	ENSG00000214659.4	KRT8P26	3.6	0.000354	0.023	0.15	0.16	Acne (severe);	chr11:65685481	chr11:65726939~65728214:+
THCA	cis	rs478304	0.627	rs11227254	ENSG00000214659.4	KRT8P26	3.6	0.000354	0.023	0.15	0.16	Acne (severe);	chr11:65686529	chr11:65726939~65728214:+
THCA	cis	rs478304	0.637	rs11227255	ENSG00000214659.4	KRT8P26	3.6	0.000354	0.023	0.15	0.16	Acne (severe);	chr11:65686573	chr11:65726939~65728214:+
THCA	cis	rs478304	0.627	rs1073602	ENSG00000214659.4	KRT8P26	3.6	0.000354	0.023	0.15	0.16	Acne (severe);	chr11:65687915	chr11:65726939~65728214:+
THCA	cis	rs478304	0.654	rs6591185	ENSG00000214659.4	KRT8P26	3.6	0.000354	0.023	0.15	0.16	Acne (severe);	chr11:65688271	chr11:65726939~65728214:+
THCA	cis	rs5758659	0.652	rs133321	ENSG00000182057.4	OGFRP1	3.6	0.000354	0.023	0.19	0.16	Cognitive function;	chr22:42009318	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.652	rs133323	ENSG00000182057.4	OGFRP1	3.6	0.000354	0.023	0.19	0.16	Cognitive function;	chr22:42009918	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.652	rs133327	ENSG00000182057.4	OGFRP1	3.6	0.000354	0.023	0.19	0.16	Cognitive function;	chr22:42011685	chr22:42269753~42275196:+
THCA	cis	rs5758659	0.652	rs133330	ENSG00000182057.4	OGFRP1	3.6	0.000354	0.023	0.19	0.16	Cognitive function;	chr22:42013452	chr22:42269753~42275196:+
THCA	cis	rs11634944	0.865	rs2554443	ENSG00000257151.1	PWAR6	3.6	0.000354	0.023	0.12	0.16	Interleukin-8 levels;	chr15:25016686	chr15:25031873~25036490:+
THCA	cis	rs950893	0.625	rs13254114	ENSG00000253837.1	RP11-177H13.2	3.6	0.000354	0.023	0.16	0.16	Mean corpuscular hemoglobin;	chr8:23612015	chr8:23336171~23366125:+
THCA	cis	rs7010267	0.773	rs10101385	ENSG00000254278.1	RP11-278I4.2	3.6	0.000354	0.023	0.21	0.16	Total body bone mineral density (age 45-60);	chr8:118911611	chr8:119062942~119068782:-
THCA	cis	rs36093844	0.565	rs17744938	ENSG00000279742.1	RP11-700A24.1	-3.6	0.000354	0.023	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85965523	chr11:85852557~85854943:-
THCA	cis	rs8040855	0.627	rs12909130	ENSG00000225151.9	GOLGA2P7	-3.6	0.000354	0.023	-0.24	-0.16	Bulimia nervosa;	chr15:85047270	chr15:84199311~84230136:-
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000237310.1	GS1-124K5.4	-3.6	0.000354	0.023	-0.19	-0.16	Diabetic kidney disease;	chr7:66219914	chr7:66493706~66495474:+
THCA	cis	rs10246939	0.544	rs12668089	ENSG00000270923.1	TAS2R6P	-3.6	0.000354	0.023	-0.16	-0.16	Bitter taste perception;	chr7:141875111	chr7:141787815~141788640:+
THCA	cis	rs11673344	0.566	rs1968251	ENSG00000268499.1	CTB-102L5.8	3.6	0.000354	0.023	0.17	0.16	Obesity-related traits;	chr19:37457005	chr19:38199836~38200934:+
THCA	cis	rs6691738	0.851	rs7518129	ENSG00000232751.1	RP11-296O14.1	3.6	0.000355	0.023	0.2	0.16	Asthma;	chr1:173194429	chr1:173351689~173352004:+
THCA	cis	rs6981523	0.553	rs11783045	ENSG00000255495.1	AC145124.2	-3.6	0.000355	0.023	-0.19	-0.16	Neuroticism;	chr8:11198666	chr8:12194467~12196280:+
THCA	cis	rs4262150	0.81	rs72797203	ENSG00000253921.1	CTB-113P19.3	3.6	0.000355	0.023	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152573316	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs113759615	ENSG00000253921.1	CTB-113P19.3	3.6	0.000355	0.023	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152573501	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs72797215	ENSG00000253921.1	CTB-113P19.3	3.6	0.000355	0.023	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152580999	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs17454420	ENSG00000253921.1	CTB-113P19.3	-3.6	0.000355	0.023	-0.21	-0.16	Bipolar disorder and schizophrenia;	chr5:152635381	chr5:151753992~151767247:+
THCA	cis	rs11971779	0.588	rs6969786	ENSG00000252332.1	RNU6-911P	-3.6	0.000355	0.023	-0.19	-0.16	Diisocyanate-induced asthma;	chr7:139443364	chr7:139448740~139448843:+
THCA	cis	rs10090774	0.965	rs7010459	ENSG00000280303.2	ERICD	3.6	0.000355	0.023	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140821142	chr8:140636281~140638283:+
THCA	cis	rs14027	0.921	rs2289011	ENSG00000245330.4	KB-1471A8.1	-3.6	0.000355	0.023	-0.17	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119744768	chr8:119867419~119874488:-
THCA	cis	rs9309473	0.5	rs11126402	ENSG00000273245.1	RP11-434P11.2	3.6	0.000355	0.023	0.19	0.16	Metabolite levels;	chr2:73549455	chr2:73750256~73750786:-
THCA	cis	rs2977125	0.815	rs2977160	ENSG00000251468.2	RP11-369K16.1	-3.6	0.000355	0.023	-0.24	-0.16	Schizophrenia;	chr8:12884460	chr8:12958387~12962200:+
THCA	cis	rs765787	0.53	rs2899381	ENSG00000259539.1	CTD-2651B20.1	3.6	0.000355	0.023	0.2	0.16	Uric acid levels;	chr15:45237432	chr15:45152664~45167526:-
THCA	cis	rs9596863	1	rs9568939	ENSG00000136149.6	RPL13AP25	-3.6	0.000355	0.023	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53837362	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9568940	ENSG00000136149.6	RPL13AP25	-3.6	0.000355	0.023	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53845116	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9568941	ENSG00000136149.6	RPL13AP25	-3.6	0.000355	0.023	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53845291	chr13:54440704~54441315:-
THCA	cis	rs6788895	0.661	rs1533711	ENSG00000244265.1	SIAH2-AS1	-3.6	0.000355	0.023	-0.35	-0.16	Breast cancer;	chr3:150752209	chr3:150761937~150762538:+
THCA	cis	rs8023401	0.507	rs8036173	ENSG00000259705.1	RP11-227D13.1	3.6	0.000355	0.023	0.2	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48527871	chr15:48645951~48652016:+
THCA	cis	rs1153858	0.887	rs7164139	ENSG00000275672.1	GATM-AS1	-3.6	0.000355	0.023	-0.17	-0.16	Homoarginine levels;	chr15:45378653	chr15:45378700~45380123:+
THCA	cis	rs1862618	0.641	rs252893	ENSG00000271828.1	CTD-2310F14.1	3.6	0.000355	0.023	0.23	0.16	Initial pursuit acceleration;	chr5:56928887	chr5:56927874~56929573:+
THCA	cis	rs8054556	0.74	rs4609871	ENSG00000273724.1	RP11-347C12.12	3.6	0.000355	0.023	0.15	0.16	Autism spectrum disorder or schizophrenia;	chr16:29920743	chr16:30336400~30343336:+
THCA	cis	rs3785309	0.519	rs111739409	ENSG00000268836.1	LA16c-OS12.2	-3.6	0.000355	0.023	-0.29	-0.16	Immature fraction of reticulocytes;	chr16:233956	chr16:185748~186294:-
THCA	cis	rs875971	1	rs35149210	ENSG00000272831.1	RP11-792A8.4	3.6	0.000355	0.023	0.1	0.16	Aortic root size;	chr7:66464938	chr7:66739829~66740385:-
THCA	cis	rs7020830	0.931	rs13288178	ENSG00000260100.1	RP11-220I1.5	-3.6	0.000355	0.023	-0.2	-0.16	Schizophrenia;	chr9:37107802	chr9:37078813~37079776:-
THCA	cis	rs4787951	0.58	rs1805010	ENSG00000261557.1	EEF1A1P38	-3.6	0.000355	0.023	-0.13	-0.16	Eosinophil percentage of white cells;	chr16:27344882	chr16:27133483~27135179:-
THCA	cis	rs7142002	0.881	rs73343484	ENSG00000271780.1	RP11-1017G21.5	-3.6	0.000355	0.023	-0.26	-0.16	Autism;	chr14:101941364	chr14:101948347~101949425:+
THCA	cis	rs1348850	0.519	rs1544002	ENSG00000271996.1	RP11-337N6.1	3.6	0.000355	0.023	0.21	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177664806	chr2:177306373~177310572:+
THCA	cis	rs9329221	0.662	rs12541491	ENSG00000253641.4	RP11-981G7.2	3.6	0.000355	0.023	0.16	0.16	Neuroticism;	chr8:10392538	chr8:10474565~10481974:+
THCA	cis	rs13108904	0.87	rs13124876	ENSG00000254094.1	AC078852.1	-3.6	0.000355	0.023	-0.19	-0.16	Obesity-related traits;	chr4:1254167	chr4:1356581~1358075:+
THCA	cis	rs7216064	1	rs7208663	ENSG00000278740.1	RP11-147L13.14	3.6	0.000355	0.023	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889055	chr17:68188547~68189165:+
THCA	cis	rs10435719	0.902	rs11250179	ENSG00000270154.1	RP11-419I17.1	3.6	0.000355	0.023	0.21	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:12476462~12477122:+
THCA	cis	rs7914558	1	rs7896547	ENSG00000272912.1	RP11-724N1.1	-3.6	0.000355	0.023	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.933	rs2066323	ENSG00000272912.1	RP11-724N1.1	-3.6	0.000355	0.023	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs7899084	ENSG00000272912.1	RP11-724N1.1	-3.6	0.000355	0.023	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:102914585~102915404:+
THCA	cis	rs2486288	0.656	rs12908581	ENSG00000259479.5	SORD2P	-3.6	0.000355	0.023	-0.18	-0.16	Glomerular filtration rate;	chr15:45256437	chr15:44826371~44884694:-
THCA	cis	rs11694172	0.69	rs11691958	ENSG00000273456.1	RP11-686O6.2	3.6	0.000355	0.023	0.15	0.16	Cholesterol, total;	chr2:202743630	chr2:202374932~202375604:-
THCA	cis	rs7259376	0.869	rs8110636	ENSG00000269345.1	VN1R85P	-3.6	0.000355	0.023	-0.18	-0.16	Menopause (age at onset);	chr19:22418025	chr19:22174766~22175191:-
THCA	cis	rs7259376	0.902	rs8100087	ENSG00000269345.1	VN1R85P	-3.6	0.000355	0.023	-0.18	-0.16	Menopause (age at onset);	chr19:22418557	chr19:22174766~22175191:-
THCA	cis	rs1799922	1	rs35105361	ENSG00000271553.1	RP11-274B21.10	-3.6	0.000355	0.023	-0.14	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128743714	chr7:128667043~128668156:+
THCA	cis	rs12544026	0.647	rs7827941	ENSG00000253669.3	KB-1732A1.1	3.6	0.000355	0.023	0.18	0.16	Major depression and alcohol dependence;	chr8:101828803	chr8:102805517~102809971:+
THCA	cis	rs14027	0.883	rs16893025	ENSG00000279347.1	RP11-85I17.2	-3.6	0.000355	0.023	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701440	chr8:119838736~119840385:-
THCA	cis	rs14027	0.883	rs10102038	ENSG00000279347.1	RP11-85I17.2	-3.6	0.000355	0.023	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119702544	chr8:119838736~119840385:-
THCA	cis	rs793571	0.822	rs28538484	ENSG00000245975.2	RP11-30K9.6	3.6	0.000355	0.023	0.19	0.16	Schizophrenia;	chr15:58909023	chr15:58768072~58770974:-
THCA	cis	rs793571	0.822	rs10518992	ENSG00000245975.2	RP11-30K9.6	3.6	0.000355	0.023	0.19	0.16	Schizophrenia;	chr15:58911416	chr15:58768072~58770974:-
THCA	cis	rs7220401	0.512	rs2289629	ENSG00000263370.1	RP11-68I3.5	3.6	0.000355	0.023	0.23	0.16	Coronary artery disease;	chr17:29632885	chr17:29639627~29640825:+
THCA	cis	rs1612141	1	rs1779510	ENSG00000251363.2	RP11-129M6.1	-3.6	0.000355	0.023	-0.24	-0.16	QT interval (drug interaction);	chr14:41276338	chr14:40954898~40975877:+
THCA	cis	rs13325613	0.834	rs35178150	ENSG00000223552.1	RP11-24F11.2	-3.6	0.000355	0.023	-0.28	-0.16	Monocyte count;	chr3:46153277	chr3:46364955~46407059:-
THCA	cis	rs2839186	0.732	rs8131458	ENSG00000228137.1	AP001469.7	3.6	0.000355	0.023	0.16	0.16	Testicular germ cell tumor;	chr21:46274798	chr21:46246890~46247682:+
THCA	cis	rs12362063	1	rs10742216	ENSG00000249867.4	RP11-115J23.1	3.6	0.000355	0.023	0.17	0.16	Hepatitis B;	chr11:29244128	chr11:28702615~29063821:+
THCA	cis	rs9923856	0.57	rs9888873	ENSG00000263033.2	RP11-396B14.2	3.6	0.000355	0.023	0.15	0.16	Atopic dermatitis;Adult asthma;	chr16:10989017	chr16:11196177~11224969:+
THCA	cis	rs875971	0.66	rs10229345	ENSG00000230189.5	GS1-124K5.2	3.6	0.000355	0.023	0.11	0.16	Aortic root size;	chr7:66517181	chr7:66409143~66490059:-
THCA	cis	rs10863936	0.558	rs56289586	ENSG00000198468.6	FLVCR1-AS1	-3.6	0.000355	0.023	-0.2	-0.16	Height;	chr1:211964632	chr1:212852108~212858088:-
THCA	cis	rs3015497	0.663	rs12434932	ENSG00000270062.1	RP11-248J18.3	3.6	0.000355	0.023	0.2	0.16	Mean platelet volume;	chr14:50690896	chr14:50723777~50724272:-
THCA	cis	rs7989332	0.662	rs9552202	ENSG00000277020.3	RP11-476H16.1	-3.6	0.000355	0.023	-0.16	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20487830	chr13:20564708~20567045:-
THCA	cis	rs67478160	0.643	rs11847468	ENSG00000258534.1	CTD-2134A5.4	-3.6	0.000355	0.023	-0.16	-0.16	Schizophrenia;	chr14:103753958	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.595	rs67768834	ENSG00000258534.1	CTD-2134A5.4	-3.6	0.000355	0.023	-0.16	-0.16	Schizophrenia;	chr14:103754748	chr14:103854366~103880111:-
THCA	cis	rs757978	1	rs3732276	ENSG00000235351.1	AC114730.11	-3.6	0.000355	0.023	-0.17	-0.16	Chronic lymphocytic leukemia;	chr2:241403989	chr2:241724615~241725693:-
THCA	cis	rs5770917	1	rs12627787	ENSG00000279182.1	XX-C00717C00720L.1	3.6	0.000355	0.023	0.26	0.16	Narcolepsy;	chr22:50573952	chr22:50316035~50317025:+
THCA	cis	rs2839186	0.967	rs9637172	ENSG00000228137.1	AP001469.7	3.6	0.000355	0.023	0.16	0.16	Testicular germ cell tumor;	chr21:46265873	chr21:46246890~46247682:+
THCA	cis	rs2839186	1	rs2839186	ENSG00000228137.1	AP001469.7	3.6	0.000355	0.023	0.16	0.16	Testicular germ cell tumor;	chr21:46270154	chr21:46246890~46247682:+
THCA	cis	rs10029851	0.541	rs75108036	ENSG00000234492.4	RPL34-AS1	3.6	0.000355	0.023	0.2	0.16	Amyotrophic lateral sclerosis (sporadic);	chr4:108666496	chr4:108538190~108620460:-
THCA	cis	rs9634489	0.678	rs1410266	ENSG00000247400.3	DNAJC3-AS1	3.6	0.000355	0.023	0.1	0.16	Body mass index;	chr13:96398652	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.678	rs1925128	ENSG00000247400.3	DNAJC3-AS1	-3.6	0.000355	0.023	-0.1	-0.16	Body mass index;	chr13:96398003	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.678	rs1410265	ENSG00000247400.3	DNAJC3-AS1	-3.6	0.000355	0.023	-0.1	-0.16	Body mass index;	chr13:96398777	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.678	rs4771943	ENSG00000247400.3	DNAJC3-AS1	-3.6	0.000355	0.023	-0.1	-0.16	Body mass index;	chr13:96398862	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.678	rs4771944	ENSG00000247400.3	DNAJC3-AS1	-3.6	0.000355	0.023	-0.1	-0.16	Body mass index;	chr13:96398963	chr13:95648733~95676925:-
THCA	cis	rs2933343	0.679	rs789254	ENSG00000261159.1	RP11-723O4.9	3.6	0.000355	0.023	0.17	0.16	IgG glycosylation;	chr3:128855750	chr3:128859716~128860526:-
THCA	cis	rs6163	0.588	rs11191392	ENSG00000236937.2	PTGES3P4	3.6	0.000355	0.023	0.2	0.16	Waist circumference;Hip circumference;	chr10:102767194	chr10:102845595~102845950:+
THCA	cis	rs3770081	0.793	rs73943946	ENSG00000273080.1	RP11-301O19.1	-3.6	0.000355	0.023	-0.38	-0.16	Facial emotion recognition (sad faces);	chr2:85999500	chr2:86195590~86196049:+
THCA	cis	rs11123170	0.542	rs11123169	ENSG00000234997.1	AC016745.3	-3.6	0.000355	0.023	-0.17	-0.16	Renal function-related traits (BUN);	chr2:113209498	chr2:113424495~113425324:+
THCA	cis	rs73222236	0.825	rs9866535	ENSG00000273486.1	RP11-731C17.2	3.6	0.000355	0.023	0.15	0.16	Coronary artery disease;	chr3:136465513	chr3:136837338~136839021:-
THCA	cis	rs875971	0.54	rs736270	ENSG00000232546.1	RP11-458F8.1	-3.6	0.000355	0.023	-0.14	-0.16	Aortic root size;	chr7:65963835	chr7:66848496~66858136:+
THCA	cis	rs614226	1	rs563920	ENSG00000278344.1	RP11-18C24.8	3.6	0.000355	0.023	0.21	0.16	Type 1 diabetes nephropathy;	chr12:120579636	chr12:120500735~120501090:-
THCA	cis	rs1455244	0.665	rs4797552	ENSG00000267199.1	RP11-861E21.2	3.6	0.000355	0.023	0.14	0.16	Schizophrenia;	chr18:11522533	chr18:12438890~12448205:+
THCA	cis	rs7212590	0.618	rs56142307	ENSG00000267302.4	RP11-178C3.2	3.6	0.000355	0.023	0.3	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59800788	chr17:59964832~59996972:+
THCA	cis	rs5758659	0.652	rs133324	ENSG00000234009.1	RPL5P34	-3.6	0.000356	0.023	-0.15	-0.16	Cognitive function;	chr22:42010367	chr22:42776406~42777296:-
THCA	cis	rs197770	0.505	rs171963	ENSG00000279727.1	RP11-640L9.1	-3.6	0.000356	0.023	-0.31	-0.16	Phospholipid levels (plasma);	chr3:37471720	chr3:36819276~36822498:-
THCA	cis	rs2229238	0.866	rs112231452	ENSG00000273026.1	RP11-422P24.10	-3.6	0.000356	0.023	-0.19	-0.16	Coronary heart disease;	chr1:154532424	chr1:153966516~153966930:+
THCA	cis	rs9796	0.621	rs7170049	ENSG00000247556.5	OIP5-AS1	3.6	0.000356	0.023	0.13	0.16	Menopause (age at onset);	chr15:41192089	chr15:41283990~41309737:+
THCA	cis	rs6030712	0.669	rs62208120	ENSG00000213979.3	RPL7AP14	-3.6	0.000356	0.023	-0.26	-0.16	Height;	chr20:36932224	chr20:37444733~37445534:-
THCA	cis	rs1396485	0.505	rs6863132	ENSG00000250015.1	CTC-339F2.2	3.6	0.000356	0.023	0.21	0.16	Inflammatory biomarkers;	chr5:116076710	chr5:116302354~116304134:-
THCA	cis	rs6046396	1	rs6112627	ENSG00000233895.1	RP1-122P22.2	-3.6	0.000356	0.023	-0.14	-0.16	Bipolar disorder and schizophrenia;	chr20:19877342	chr20:19757708~19809675:+
THCA	cis	rs2820315	1	rs2494114	ENSG00000223774.4	RP11-307B6.3	3.6	0.000356	0.023	0.18	0.16	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201831883	chr1:201893842~201899978:+
THCA	cis	rs2886497	1	rs4287251	ENSG00000224215.1	RP11-371A19.2	3.6	0.000356	0.023	0.21	0.16	Major depression and alcohol dependence;	chr10:23381668	chr10:23343957~23345181:+
THCA	cis	rs7246657	0.722	rs2927746	ENSG00000226686.6	LINC01535	3.6	0.000356	0.023	0.24	0.16	Coronary artery calcification;	chr19:37665669	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs2927747	ENSG00000226686.6	LINC01535	3.6	0.000356	0.023	0.24	0.16	Coronary artery calcification;	chr19:37668629	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs2909102	ENSG00000226686.6	LINC01535	3.6	0.000356	0.023	0.24	0.16	Coronary artery calcification;	chr19:37676463	chr19:37251912~37265535:+
THCA	cis	rs7264396	0.832	rs224378	ENSG00000261582.1	RP4-614O4.11	-3.6	0.000356	0.023	-0.17	-0.16	Total cholesterol levels;	chr20:35500935	chr20:35267885~35280043:-
THCA	cis	rs853679	0.769	rs7752448	ENSG00000204709.4	LINC01556	3.6	0.000356	0.023	0.34	0.16	Depression;	chr6:28333322	chr6:28943877~28944537:+
THCA	cis	rs12216545	0.961	rs111350935	ENSG00000241134.3	BET1P1	3.6	0.000356	0.023	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150512645	chr7:150749736~150750094:+
THCA	cis	rs11971779	0.65	rs6969699	ENSG00000252332.1	RNU6-911P	-3.6	0.000356	0.023	-0.19	-0.16	Diisocyanate-induced asthma;	chr7:139443532	chr7:139448740~139448843:+
THCA	cis	rs11971779	0.715	rs11772551	ENSG00000252332.1	RNU6-911P	-3.6	0.000356	0.023	-0.19	-0.16	Diisocyanate-induced asthma;	chr7:139444232	chr7:139448740~139448843:+
THCA	cis	rs686320	0.666	rs11605125	ENSG00000245532.5	NEAT1	3.6	0.000356	0.023	0.16	0.16	Hip circumference adjusted for BMI;	chr11:65443548	chr11:65422774~65445540:+
THCA	cis	rs12549025	0.838	rs4871880	ENSG00000253390.1	CTC-756D1.2	-3.6	0.000356	0.023	-0.28	-0.16	Reticulocyte fraction of red cells;	chr8:23536059	chr8:23458601~23484971:+
THCA	cis	rs7536700	0.915	rs3891075	ENSG00000272030.1	RP1-178F15.4	3.6	0.000356	0.0231	0.27	0.16	Multiple myeloma (IgH translocation);	chr1:153685711	chr1:153631438~153634397:-
THCA	cis	rs59972978	0.538	rs6025584	ENSG00000124097.7	HMGB1P1	3.6	0.000356	0.0231	0.22	0.16	Alcohol consumption;	chr20:57485646	chr20:57488392~57489027:-
THCA	cis	rs6416877	0.959	rs2302459	ENSG00000277491.1	RP11-676J12.9	-3.6	0.000356	0.0231	-0.2	-0.16	Myeloid white cell count;	chr17:1467165	chr17:795306~795794:+
THCA	cis	rs3126085	0.935	rs1390488	ENSG00000237975.5	FLG-AS1	-3.6	0.000356	0.0231	-0.25	-0.16	Atopic dermatitis;	chr1:152227024	chr1:152168125~152445456:+
THCA	cis	rs7621025	0.69	rs11715257	ENSG00000273486.1	RP11-731C17.2	3.6	0.000356	0.0231	0.14	0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136463211	chr3:136837338~136839021:-
THCA	cis	rs1577917	1	rs6454513	ENSG00000220563.1	PKMP3	3.6	0.000356	0.0231	0.12	0.16	Response to antipsychotic treatment;	chr6:86010331	chr6:85659892~85660606:-
THCA	cis	rs240993	0.595	rs3777911	ENSG00000272356.1	RP5-1112D6.8	3.6	0.000356	0.0231	0.14	0.16	Inflammatory skin disease;Psoriasis;	chr6:111581277	chr6:111309203~111313517:+
THCA	cis	rs7267979	0.966	rs910996	ENSG00000276952.1	RP5-965G21.6	3.6	0.000356	0.0231	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25284915~25285588:-
THCA	cis	rs3845817	0.838	rs697150	ENSG00000281920.1	RP11-418H16.1	-3.6	0.000356	0.0231	-0.2	-0.16	Bipolar disorder;	chr2:65522950	chr2:65623272~65628424:+
THCA	cis	rs12410462	0.901	rs16847844	ENSG00000227711.2	RP11-275O4.5	-3.6	0.000356	0.0231	-0.24	-0.16	Major depressive disorder;	chr1:227450409	chr1:227509028~227520477:-
THCA	cis	rs721917	0.531	rs2758554	ENSG00000225484.5	NUTM2B-AS1	-3.6	0.000356	0.0231	-0.2	-0.16	Chronic obstructive pulmonary disease;	chr10:79931324	chr10:79663088~79826594:-
THCA	cis	rs9329221	0.741	rs9650622	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000356	0.0231	-0.2	-0.16	Neuroticism;	chr8:9946782	chr8:10433672~10438312:+
THCA	cis	rs934734	0.673	rs7575614	ENSG00000214533.3	KRT18P33	3.6	0.000356	0.0231	0.2	0.16	Rheumatoid arthritis;	chr2:65462666	chr2:65666695~65667737:+
THCA	cis	rs934734	0.673	rs6742215	ENSG00000214533.3	KRT18P33	3.6	0.000356	0.0231	0.2	0.16	Rheumatoid arthritis;	chr2:65463362	chr2:65666695~65667737:+
THCA	cis	rs2839186	0.934	rs13049797	ENSG00000228137.1	AP001469.7	3.6	0.000356	0.0231	0.16	0.16	Testicular germ cell tumor;	chr21:46287668	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.732	rs55904887	ENSG00000228137.1	AP001469.7	3.6	0.000356	0.0231	0.16	0.16	Testicular germ cell tumor;	chr21:46287897	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.934	rs2839197	ENSG00000228137.1	AP001469.7	3.6	0.000356	0.0231	0.16	0.16	Testicular germ cell tumor;	chr21:46288219	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.868	rs2839199	ENSG00000228137.1	AP001469.7	3.6	0.000356	0.0231	0.16	0.16	Testicular germ cell tumor;	chr21:46288355	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.933	rs4818832	ENSG00000228137.1	AP001469.7	3.6	0.000356	0.0231	0.16	0.16	Testicular germ cell tumor;	chr21:46288720	chr21:46246890~46247682:+
THCA	cis	rs2839186	0.9	rs59828751	ENSG00000228137.1	AP001469.7	3.6	0.000356	0.0231	0.16	0.16	Testicular germ cell tumor;	chr21:46289004	chr21:46246890~46247682:+
THCA	cis	rs7824557	0.564	rs2572389	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000356	0.0231	-0.21	-0.16	Retinal vascular caliber;	chr8:11378883	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs2736301	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000356	0.0231	-0.21	-0.16	Retinal vascular caliber;	chr8:11378904	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs2736302	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000356	0.0231	-0.21	-0.16	Retinal vascular caliber;	chr8:11378910	chr8:10433672~10438312:+
THCA	cis	rs3808502	0.647	rs7821302	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000356	0.0231	-0.21	-0.16	Neuroticism;	chr8:11379063	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs7821459	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000356	0.0231	-0.21	-0.16	Retinal vascular caliber;	chr8:11379172	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs7834572	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000356	0.0231	-0.21	-0.16	Retinal vascular caliber;	chr8:11379176	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs4631424	ENSG00000261451.1	RP11-981G7.1	-3.6	0.000356	0.0231	-0.21	-0.16	Retinal vascular caliber;	chr8:11379300	chr8:10433672~10438312:+
THCA	cis	rs354225	0.584	rs6706263	ENSG00000212175.1	SNORA12	-3.6	0.000356	0.0231	-0.2	-0.16	Schizophrenia;	chr2:54588103	chr2:55565703~55565850:+
THCA	cis	rs354225	0.584	rs10206143	ENSG00000212175.1	SNORA12	-3.6	0.000356	0.0231	-0.2	-0.16	Schizophrenia;	chr2:54590316	chr2:55565703~55565850:+
THCA	cis	rs354225	0.554	rs4374410	ENSG00000212175.1	SNORA12	-3.6	0.000356	0.0231	-0.2	-0.16	Schizophrenia;	chr2:54591951	chr2:55565703~55565850:+
THCA	cis	rs354225	0.584	rs6739140	ENSG00000212175.1	SNORA12	-3.6	0.000356	0.0231	-0.2	-0.16	Schizophrenia;	chr2:54596365	chr2:55565703~55565850:+
THCA	cis	rs354225	0.584	rs6749802	ENSG00000212175.1	SNORA12	-3.6	0.000356	0.0231	-0.2	-0.16	Schizophrenia;	chr2:54597009	chr2:55565703~55565850:+
THCA	cis	rs9527	0.83	rs11191442	ENSG00000236937.2	PTGES3P4	3.6	0.000356	0.0231	0.23	0.16	Arsenic metabolism;	chr10:102883839	chr10:102845595~102845950:+
THCA	cis	rs7474896	0.609	rs1830612	ENSG00000120555.12	SEPT7P9	3.6	0.000356	0.0231	0.21	0.16	Obesity (extreme);	chr10:37710955	chr10:38383069~38402916:-
THCA	cis	rs7129556	0.701	rs72947668	ENSG00000254459.1	RP11-91P24.7	3.6	0.000357	0.0231	0.22	0.16	Weight loss (gastric bypass surgery);	chr11:77717888	chr11:77829654~77872262:-
THCA	cis	rs853679	0.607	rs33932084	ENSG00000220721.1	OR1F12	3.6	0.000357	0.0231	0.35	0.16	Depression;	chr6:28301047	chr6:28073316~28074233:+
THCA	cis	rs4742903	0.935	rs7026246	ENSG00000270332.1	SMC2-AS1	3.6	0.000357	0.0231	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104193405	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs7872170	ENSG00000270332.1	SMC2-AS1	3.6	0.000357	0.0231	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104194822	chr9:104080024~104093073:-
THCA	cis	rs5758659	0.652	rs133321	ENSG00000234009.1	RPL5P34	-3.6	0.000357	0.0231	-0.15	-0.16	Cognitive function;	chr22:42009318	chr22:42776406~42777296:-
THCA	cis	rs5758659	0.652	rs133323	ENSG00000234009.1	RPL5P34	-3.6	0.000357	0.0231	-0.15	-0.16	Cognitive function;	chr22:42009918	chr22:42776406~42777296:-
THCA	cis	rs5758659	0.652	rs133327	ENSG00000234009.1	RPL5P34	-3.6	0.000357	0.0231	-0.15	-0.16	Cognitive function;	chr22:42011685	chr22:42776406~42777296:-
THCA	cis	rs5758659	0.652	rs133330	ENSG00000234009.1	RPL5P34	-3.6	0.000357	0.0231	-0.15	-0.16	Cognitive function;	chr22:42013452	chr22:42776406~42777296:-
THCA	cis	rs5753618	0.583	rs738657	ENSG00000214076.3	CPSF1P1	-3.6	0.000357	0.0231	-0.22	-0.16	Colorectal cancer;	chr22:31445763	chr22:32269381~32273110:+
THCA	cis	rs11124272	0.682	rs623419	ENSG00000276517.1	AL133243.2	-3.6	0.000357	0.0231	-0.15	-0.16	Interleukin-18 levels;	chr2:31609009	chr2:32526504~32529507:+
THCA	cis	rs9296095	0.519	rs6918046	ENSG00000197251.3	LINC00336	-3.6	0.000357	0.0231	-0.18	-0.16	Platelet count;	chr6:33546790	chr6:33586106~33593338:-
THCA	cis	rs8179	0.553	rs42377	ENSG00000230927.2	TMBIM7P	3.6	0.000357	0.0231	0.21	0.16	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92614358	chr7:92412976~92439562:-
THCA	cis	rs6696239	0.956	rs7540754	ENSG00000227711.2	RP11-275O4.5	-3.6	0.000357	0.0231	-0.25	-0.16	Height;	chr1:227662887	chr1:227509028~227520477:-
THCA	cis	rs7759001	0.744	rs4478400	ENSG00000271755.1	RP1-153G14.4	3.6	0.000357	0.0231	0.19	0.16	Glomerular filtration rate (creatinine);	chr6:27518524	chr6:27404010~27406964:-
THCA	cis	rs12101261	0.778	rs58241131	ENSG00000259167.2	NMNAT1P1	3.6	0.000357	0.0231	0.2	0.16	Graves' disease;	chr14:81002235	chr14:81032529~81033404:+
THCA	cis	rs739496	0.615	rs77684561	ENSG00000226469.1	ADAM1B	3.6	0.000357	0.0231	0.2	0.16	Platelet count;	chr12:111623919	chr12:111927018~111929017:+
THCA	cis	rs2625529	0.73	rs2957725	ENSG00000260037.4	CTD-2524L6.3	3.6	0.000357	0.0231	0.21	0.16	Red blood cell count;	chr15:71955864	chr15:71818396~71823384:+
THCA	cis	rs12101261	1	rs17111346	ENSG00000259167.2	NMNAT1P1	3.6	0.000357	0.0231	0.19	0.16	Graves' disease;	chr14:80985828	chr14:81032529~81033404:+
THCA	cis	rs13201294	1	rs13201294	ENSG00000273712.1	RP5-874C20.7	3.6	0.000357	0.0231	0.29	0.16	Squamous cell lung carcinoma;	chr6:27588362	chr6:28315613~28315883:-
THCA	cis	rs11190604	0.767	rs11190520	ENSG00000273030.1	RP11-285F16.1	3.6	0.000357	0.0231	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100415552	chr10:100412934~100413421:+
THCA	cis	rs337161	0.935	rs4131748	ENSG00000221571.3	RNU6ATAC35P	-3.6	0.000357	0.0231	-0.19	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220792132	chr1:220825620~220826063:+
THCA	cis	rs12148329	1	rs12148329	ENSG00000259594.4	CTD-2034I4.2	3.6	0.000357	0.0231	0.26	0.16	Immune response to smallpox vaccine (IL-6);	chr15:80708937	chr15:81554003~81696780:+
THCA	cis	rs7131987	0.801	rs6487804	ENSG00000273680.1	RP11-996F15.6	3.6	0.000357	0.0231	0.22	0.16	QT interval;	chr12:29302001	chr12:29332733~29333383:-
THCA	cis	rs116095464	1	rs61079948	ENSG00000277812.1	AC021087.1	3.6	0.000357	0.0231	0.41	0.16	Breast cancer;	chr5:325388	chr5:262769~262881:+
THCA	cis	rs9911578	1	rs1494977	ENSG00000224738.1	AC099850.1	3.6	0.000357	0.0231	0.19	0.16	Intelligence (multi-trait analysis);	chr17:58785703	chr17:59106598~59118267:+
THCA	cis	rs80130819	0.636	rs2732451	ENSG00000226413.2	OR8T1P	3.6	0.000357	0.0231	0.24	0.16	Prostate cancer;	chr12:48326163	chr12:48442030~48442947:-
THCA	cis	rs10129255	0.957	rs12590799	ENSG00000211972.2	IGHV3-66	3.6	0.000357	0.0231	0.1	0.16	Kawasaki disease;	chr14:106779713	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs10136781	ENSG00000211972.2	IGHV3-66	3.6	0.000357	0.0231	0.1	0.16	Kawasaki disease;	chr14:106780451	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.957	rs8022165	ENSG00000211972.2	IGHV3-66	3.6	0.000357	0.0231	0.1	0.16	Kawasaki disease;	chr14:106781682	chr14:106675017~106675544:-
THCA	cis	rs10129255	0.917	rs8022493	ENSG00000211972.2	IGHV3-66	3.6	0.000357	0.0231	0.1	0.16	Kawasaki disease;	chr14:106781820	chr14:106675017~106675544:-
THCA	cis	rs668210	0.793	rs540584	ENSG00000214659.4	KRT8P26	-3.6	0.000357	0.0231	-0.19	-0.16	Cerebrospinal fluid biomarker levels;	chr11:65998395	chr11:65726939~65728214:+
THCA	cis	rs7737355	0.685	rs257388	ENSG00000237714.1	P4HA2-AS1	-3.6	0.000357	0.0231	-0.35	-0.16	Life satisfaction;	chr5:131410831	chr5:132184876~132192808:+
THCA	cis	rs10461617	0.592	rs6450403	ENSG00000234553.1	AC022431.3	-3.6	0.000357	0.0231	-0.17	-0.16	Type 2 diabetes;	chr5:56766910	chr5:56536583~56537826:-
THCA	cis	rs9911578	0.9	rs7214335	ENSG00000224738.1	AC099850.1	3.6	0.000357	0.0231	0.19	0.16	Intelligence (multi-trait analysis);	chr17:59081479	chr17:59106598~59118267:+
THCA	cis	rs17604090	1	rs67970052	ENSG00000223813.2	AC007255.8	3.6	0.000357	0.0231	0.17	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29615422	chr7:29514225~29563670:-
THCA	cis	rs1943345	0.556	rs613175	ENSG00000254551.1	RP11-727A23.7	3.6	0.000357	0.0231	0.2	0.16	Obesity-related traits;	chr11:83209858	chr11:83209431~83213379:-
THCA	cis	rs9329221	0.682	rs6982308	ENSG00000255310.2	AF131215.2	-3.6	0.000357	0.0231	-0.14	-0.16	Neuroticism;	chr8:10336262	chr8:11107788~11109726:-
THCA	cis	rs11671005	0.779	rs3794971	ENSG00000252334.1	RNU6-1337P	3.6	0.000357	0.0231	0.25	0.16	Mean platelet volume;	chr19:58474499	chr19:58483749~58483843:-
THCA	cis	rs1729951	0.575	rs16844325	ENSG00000239213.4	NCK1-AS1	3.6	0.000357	0.0231	0.14	0.16	Neuroticism;	chr3:136959319	chr3:136841726~136862054:-
THCA	cis	rs962856	0.729	rs7568231	ENSG00000236780.4	AC078941.1	3.6	0.000357	0.0231	0.2	0.16	Pancreatic cancer;	chr2:67293718	chr2:67123357~67215319:-
THCA	cis	rs172166	0.637	rs1233708	ENSG00000261839.1	RP1-265C24.8	3.6	0.000357	0.0231	0.17	0.16	Cardiac Troponin-T levels;	chr6:28205441	chr6:28136849~28139678:+
THCA	cis	rs2692947	0.537	rs11682182	ENSG00000236750.1	AC009237.16	-3.6	0.000357	0.0231	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712462	chr2:95641634~95641980:-
THCA	cis	rs11583043	0.708	rs1335745	ENSG00000233184.5	RP11-421L21.3	3.6	0.000357	0.0231	0.18	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101080883	chr1:101025878~101087268:+
THCA	cis	rs494526	0.671	rs12356334	ENSG00000229272.1	RP11-498J9.2	-3.6	0.000357	0.0231	-0.18	-0.16	Alcoholic chronic pancreatitis;	chr10:119116044	chr10:119003536~119003884:-
THCA	cis	rs13108904	0.935	rs6853002	ENSG00000254094.1	AC078852.1	-3.6	0.000357	0.0231	-0.18	-0.16	Obesity-related traits;	chr4:1302203	chr4:1356581~1358075:+
THCA	cis	rs9393777	0.841	rs67092078	ENSG00000272009.1	RP1-313I6.12	-3.6	0.000357	0.0231	-0.32	-0.16	Intelligence (multi-trait analysis);	chr6:27086993	chr6:28078792~28081130:-
THCA	cis	rs72843506	0.656	rs77540008	ENSG00000189423.10	USP32P3	3.6	0.000357	0.0231	0.26	0.16	Schizophrenia;	chr17:20069886	chr17:20415547~20431008:+
THCA	cis	rs7619427	0.556	rs7652264	ENSG00000271192.1	RP4-555D20.3	3.6	0.000357	0.0231	0.22	0.16	Schizophrenia;	chr3:44026582	chr3:43996896~43997443:+
THCA	cis	rs7619427	0.556	rs7652286	ENSG00000271192.1	RP4-555D20.3	3.6	0.000357	0.0231	0.22	0.16	Schizophrenia;	chr3:44026648	chr3:43996896~43997443:+
THCA	cis	rs7619427	0.556	rs1608729	ENSG00000271192.1	RP4-555D20.3	3.6	0.000357	0.0231	0.22	0.16	Schizophrenia;	chr3:44027140	chr3:43996896~43997443:+
THCA	cis	rs7737355	0.812	rs257391	ENSG00000224431.1	AC063976.7	3.6	0.000357	0.0231	0.15	0.16	Life satisfaction;	chr5:131404312	chr5:132199456~132203487:+
THCA	cis	rs7914558	0.899	rs7913682	ENSG00000213061.2	PFN1P11	3.6	0.000357	0.0231	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102924635	chr10:102838011~102845473:-
THCA	cis	rs7166081	1	rs12901312	ENSG00000270964.1	RP11-502I4.3	-3.6	0.000357	0.0231	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67299634	chr15:67541072~67542604:-
THCA	cis	rs4730276	0.674	rs7777259	ENSG00000250474.1	WBP1LP2	-3.6	0.000357	0.0231	-0.15	-0.16	Ulcerative colitis;	chr7:107920206	chr7:107628553~107629498:+
THCA	cis	rs7142002	0.614	rs59784377	ENSG00000271780.1	RP11-1017G21.5	-3.6	0.000357	0.0231	-0.2	-0.16	Autism;	chr14:101924844	chr14:101948347~101949425:+
THCA	cis	rs7656342	0.964	rs56139970	ENSG00000249866.1	OR7E83P	3.6	0.000358	0.0231	0.18	0.16	Gut microbiota (bacterial taxa);	chr4:9800648	chr4:9512905~9513874:+
THCA	cis	rs10992471	0.56	rs10992513	ENSG00000187984.11	ANKRD19P	-3.6	0.000358	0.0231	-0.1	-0.16	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92890818	chr9:92809388~92888693:+
THCA	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	3.6	0.000358	0.0231	0.15	0.16	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
THCA	cis	rs5753037	0.653	rs131272	ENSG00000273350.1	RP4-539M6.20	-3.6	0.000358	0.0231	-0.19	-0.16	Type 1 diabetes;	chr22:29757666	chr22:30420512~30420912:+
THCA	cis	rs11088226	0.681	rs2409456	ENSG00000186842.4	LINC00846	-3.6	0.000358	0.0231	-0.24	-0.16	Gastritis;	chr21:32557064	chr21:32572238~32575881:-
THCA	cis	rs2919009	0.766	rs56259440	ENSG00000271670.1	RP11-95I16.4	3.6	0.000358	0.0231	0.19	0.16	Obesity-related traits;	chr10:120809566	chr10:120879256~120880667:-
THCA	cis	rs478304	0.593	rs12576766	ENSG00000214659.4	KRT8P26	3.6	0.000358	0.0231	0.15	0.16	Acne (severe);	chr11:65721085	chr11:65726939~65728214:+
THCA	cis	rs57709857	0.801	rs16887277	ENSG00000272092.1	RP11-350N15.5	-3.6	0.000358	0.0231	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38243641	chr8:38382364~38383461:+
THCA	cis	rs2051773	0.567	rs7924495	ENSG00000184669.7	OR7E14P	3.6	0.000358	0.0231	0.23	0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17017181	chr11:17013998~17053024:+
THCA	cis	rs642858	0.747	rs590585	ENSG00000234147.1	RP3-460G2.2	3.6	0.000358	0.0231	0.19	0.16	Type 2 diabetes;	chr6:139910343	chr6:140845958~140852924:-
THCA	cis	rs8030379	0.967	rs6603001	ENSG00000176700.18	SCAND2P	-3.6	0.000358	0.0231	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896516	chr15:84631451~84647478:+
THCA	cis	rs561341	0.769	rs12941700	ENSG00000280033.1	CTD-2095E4.3	3.6	0.000358	0.0231	0.26	0.16	Hip circumference adjusted for BMI;	chr17:31858003	chr17:32159311~32160371:+
THCA	cis	rs10875746	0.551	rs10875799	ENSG00000258273.1	RP11-370I10.4	3.6	0.000358	0.0231	0.24	0.16	Longevity (90 years and older);	chr12:48347096	chr12:48333755~48333901:-
THCA	cis	rs61041384	0.661	rs4474478	ENSG00000235423.7	RP11-282O18.3	3.6	0.000358	0.0232	0.32	0.16	Schizophrenia;	chr12:123249821	chr12:123252030~123261483:-
THCA	cis	rs61041384	0.661	rs4759411	ENSG00000235423.7	RP11-282O18.3	3.6	0.000358	0.0232	0.32	0.16	Schizophrenia;	chr12:123256296	chr12:123252030~123261483:-
THCA	cis	rs7142002	0.568	rs6575884	ENSG00000271780.1	RP11-1017G21.5	-3.6	0.000358	0.0232	-0.2	-0.16	Autism;	chr14:101924400	chr14:101948347~101949425:+
THCA	cis	rs4713118	0.629	rs203887	ENSG00000219891.2	ZSCAN12P1	3.6	0.000358	0.0232	0.24	0.16	Parkinson's disease;	chr6:28053491	chr6:28091154~28093664:+
THCA	cis	rs10411161	0.702	rs11878580	ENSG00000275055.1	CTC-471J1.11	-3.6	0.000358	0.0232	-0.16	-0.16	Breast cancer;	chr19:51885232	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs11878586	ENSG00000275055.1	CTC-471J1.11	-3.6	0.000358	0.0232	-0.16	-0.16	Breast cancer;	chr19:51885323	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs7251755	ENSG00000275055.1	CTC-471J1.11	-3.6	0.000358	0.0232	-0.16	-0.16	Breast cancer;	chr19:51885695	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs7251689	ENSG00000275055.1	CTC-471J1.11	-3.6	0.000358	0.0232	-0.16	-0.16	Breast cancer;	chr19:51885864	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.69	rs7252336	ENSG00000275055.1	CTC-471J1.11	-3.6	0.000358	0.0232	-0.16	-0.16	Breast cancer;	chr19:51886261	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs11878583	ENSG00000275055.1	CTC-471J1.11	3.6	0.000358	0.0232	0.16	0.16	Breast cancer;	chr19:51885293	chr19:52049007~52049754:+
THCA	cis	rs2839186	0.872	rs13052233	ENSG00000228137.1	AP001469.7	3.6	0.000358	0.0232	0.16	0.16	Testicular germ cell tumor;	chr21:46287370	chr21:46246890~46247682:+
THCA	cis	rs6479901	0.588	rs10740105	ENSG00000272767.1	JMJD1C-AS1	-3.6	0.000358	0.0232	-0.2	-0.16	Intelligence (multi-trait analysis);	chr10:63129957	chr10:63465229~63466563:+
THCA	cis	rs7824557	0.679	rs7004362	ENSG00000255495.1	AC145124.2	-3.6	0.000358	0.0232	-0.19	-0.16	Retinal vascular caliber;	chr8:11278465	chr8:12194467~12196280:+
THCA	cis	rs642858	0.91	rs12523815	ENSG00000234147.1	RP3-460G2.2	3.6	0.000358	0.0232	0.21	0.16	Type 2 diabetes;	chr6:140067841	chr6:140845958~140852924:-
THCA	cis	rs7824557	0.527	rs2572449	ENSG00000255495.1	AC145124.2	3.6	0.000358	0.0232	0.18	0.16	Retinal vascular caliber;	chr8:11381628	chr8:12194467~12196280:+
THCA	cis	rs9287719	0.81	rs1990612	ENSG00000243819.4	RN7SL832P	3.6	0.000358	0.0232	0.13	0.16	Prostate cancer;	chr2:10641818	chr2:10690344~10692099:+
THCA	cis	rs559555	0.597	rs502139	ENSG00000276517.1	AL133243.2	-3.6	0.000358	0.0232	-0.16	-0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31586199	chr2:32526504~32529507:+
THCA	cis	rs11673344	0.523	rs2562594	ENSG00000267260.1	CTD-2162K18.4	-3.6	0.000358	0.0232	-0.19	-0.16	Obesity-related traits;	chr19:37023783	chr19:36773153~36777078:+
THCA	cis	rs7267979	1	rs2257420	ENSG00000276952.1	RP5-965G21.6	3.6	0.000358	0.0232	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25284915~25285588:-
THCA	cis	rs3902035	0.964	rs28710027	ENSG00000253194.1	RP11-351A11.1	3.6	0.000358	0.0232	0.25	0.16	QT interval;	chr6:118688132	chr6:118934785~119031541:+
THCA	cis	rs1577917	0.917	rs1838959	ENSG00000220563.1	PKMP3	-3.6	0.000358	0.0232	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85847086	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.917	rs1579886	ENSG00000220563.1	PKMP3	-3.6	0.000358	0.0232	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85847473	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs1816937	ENSG00000220563.1	PKMP3	-3.6	0.000358	0.0232	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85847533	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs7382798	ENSG00000220563.1	PKMP3	-3.6	0.000358	0.0232	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85850116	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs1838958	ENSG00000220563.1	PKMP3	-3.6	0.000358	0.0232	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85854250	chr6:85659892~85660606:-
THCA	cis	rs12362504	0.52	rs360169	ENSG00000246273.5	SBF2-AS1	3.6	0.000358	0.0232	0.19	0.16	Survival in pancreatic cancer;	chr11:9853972	chr11:9758292~9811319:+
THCA	cis	rs931608	0.778	rs59870410	ENSG00000269138.1	ZNF209P	3.6	0.000358	0.0232	0.23	0.16	Response to statins (LDL cholesterol change);Dental caries;	chr19:22301161	chr19:22463922~22473036:+
THCA	cis	rs758324	0.681	rs68167176	ENSG00000237714.1	P4HA2-AS1	-3.6	0.000358	0.0232	-0.25	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:132036592	chr5:132184876~132192808:+
THCA	cis	rs7665090	1	rs4586937	ENSG00000251288.2	RP11-10L12.2	3.6	0.000358	0.0232	0.21	0.16	Primary biliary cholangitis;	chr4:102635305	chr4:102751401~102752641:+
THCA	cis	rs6580649	0.574	rs7964359	ENSG00000269514.1	RP11-370I10.12	3.6	0.000358	0.0232	0.14	0.16	Lung cancer;	chr12:48016783	chr12:48198387~48202031:+
THCA	cis	rs7082209	1	rs12265086	ENSG00000224265.1	RP11-168L22.2	-3.6	0.000358	0.0232	-0.26	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr10:44315892	chr10:43323665~43327932:+
THCA	cis	rs6988985	0.818	rs3802228	ENSG00000247317.3	RP11-273G15.2	-3.6	0.000358	0.0232	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142910802	chr8:142981738~143018437:-
THCA	cis	rs12355688	0.764	rs4246943	ENSG00000224596.6	ZMIZ1-AS1	3.6	0.000358	0.0232	0.27	0.16	Breast cancer;	chr10:79300248	chr10:78943328~79067895:-
THCA	cis	rs7727544	0.582	rs3828675	ENSG00000263597.1	MIR3936	3.6	0.000358	0.0232	0.15	0.16	Blood metabolite levels;	chr5:132211175	chr5:132365490~132365599:-
THCA	cis	rs13437751	0.649	rs10247646	ENSG00000223558.1	TRIM60P17	3.6	0.000358	0.0232	0.31	0.16	QT interval (drug interaction);	chr7:63986524	chr7:64085560~64086576:+
THCA	cis	rs13437751	0.764	rs55764153	ENSG00000223558.1	TRIM60P17	3.6	0.000358	0.0232	0.31	0.16	QT interval (drug interaction);	chr7:63989571	chr7:64085560~64086576:+
THCA	cis	rs9287719	0.967	rs6432112	ENSG00000243819.4	RN7SL832P	-3.6	0.000358	0.0232	-0.13	-0.16	Prostate cancer;	chr2:10604748	chr2:10690344~10692099:+
THCA	cis	rs7246657	0.722	rs2291002	ENSG00000226686.6	LINC01535	-3.6	0.000358	0.0232	-0.24	-0.16	Coronary artery calcification;	chr19:37543024	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs10404031	ENSG00000226686.6	LINC01535	-3.6	0.000358	0.0232	-0.24	-0.16	Coronary artery calcification;	chr19:37545052	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs10406379	ENSG00000226686.6	LINC01535	-3.6	0.000358	0.0232	-0.24	-0.16	Coronary artery calcification;	chr19:37545823	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs1564206	ENSG00000226686.6	LINC01535	-3.6	0.000358	0.0232	-0.24	-0.16	Coronary artery calcification;	chr19:37549174	chr19:37251912~37265535:+
THCA	cis	rs3789045	0.685	rs12036042	ENSG00000235363.1	SNRPGP10	-3.6	0.000359	0.0232	-0.25	-0.16	Educational attainment (college completion);	chr1:204500186	chr1:205351247~205351471:+
THCA	cis	rs6583331	1	rs34088166	ENSG00000232065.1	LINC01063	-3.6	0.000359	0.0232	-0.18	-0.16	Vitiligo;	chr3:196620833	chr3:196631498~196632587:-
THCA	cis	rs7522061	0.546	rs10908582	ENSG00000236731.1	RP4-801G22.2	3.6	0.000359	0.0232	0.17	0.16	Blood protein levels;	chr1:157668768	chr1:157629939~157630728:-
THCA	cis	rs11773103	0.708	rs55825235	ENSG00000224046.1	AC005076.5	3.6	0.000359	0.0232	0.19	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87130385	chr7:87151423~87152420:-
THCA	cis	rs4218	0.56	rs8039514	ENSG00000277144.1	RP11-59H7.4	-3.59	0.000359	0.0232	-0.22	-0.16	Social communication problems;	chr15:59114382	chr15:59115547~59116089:-
THCA	cis	rs7631605	0.846	rs4678555	ENSG00000272334.1	RP11-129K12.1	-3.59	0.000359	0.0232	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36946082	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.846	rs60404305	ENSG00000272334.1	RP11-129K12.1	-3.59	0.000359	0.0232	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36946730	chr3:36973117~36973672:-
THCA	cis	rs643506	0.874	rs687152	ENSG00000230911.1	PPIHP1	-3.59	0.000359	0.0232	-0.22	-0.16	Breast cancer;	chr11:111850950	chr11:112029858~112030367:-
THCA	cis	rs643506	0.874	rs4936786	ENSG00000230911.1	PPIHP1	-3.59	0.000359	0.0232	-0.22	-0.16	Breast cancer;	chr11:111856504	chr11:112029858~112030367:-
THCA	cis	rs791590	0.887	rs764851	ENSG00000225948.2	RP11-554I8.1	3.59	0.000359	0.0232	0.26	0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6005981	chr10:6618716~6625346:+
THCA	cis	rs791590	0.887	rs41294671	ENSG00000225948.2	RP11-554I8.1	3.59	0.000359	0.0232	0.26	0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6007834	chr10:6618716~6625346:+
THCA	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	3.59	0.000359	0.0232	0.23	0.16	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
THCA	cis	rs31872	0.526	rs810277	ENSG00000202515.1	VTRNA1-3	3.59	0.000359	0.0232	0.19	0.16	Visceral adipose tissue adjusted for BMI;	chr5:141072909	chr5:140726158~140726246:+
THCA	cis	rs75422866	0.541	rs61918136	ENSG00000276691.1	RP5-1057I20.5	3.59	0.000359	0.0232	0.29	0.16	Pneumonia;	chr12:47566798	chr12:47788426~47788971:+
THCA	cis	rs13325613	0.834	rs17282391	ENSG00000223552.1	RP11-24F11.2	3.59	0.000359	0.0232	0.29	0.16	Monocyte count;	chr3:46137989	chr3:46364955~46407059:-
THCA	cis	rs5753037	0.838	rs140147	ENSG00000273350.1	RP4-539M6.20	-3.59	0.000359	0.0232	-0.19	-0.16	Type 1 diabetes;	chr22:29788610	chr22:30420512~30420912:+
THCA	cis	rs11212260	0.737	rs567102	ENSG00000261098.1	RP11-819C21.1	-3.59	0.000359	0.0232	-0.32	-0.16	IgG glycosylation;	chr11:107499337	chr11:107312132~107316271:-
THCA	cis	rs11065706	0.747	rs1860561	ENSG00000278993.1	RP3-424M6.4	3.59	0.000359	0.0232	0.25	0.16	Heart rate;	chr12:110345436	chr12:110501614~110503441:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000232546.1	RP11-458F8.1	-3.59	0.000359	0.0232	-0.14	-0.16	Calcium levels;	chr7:65996954	chr7:66848496~66858136:+
THCA	cis	rs2896526	0.736	rs78950598	ENSG00000256588.1	RP11-613F22.8	3.59	0.000359	0.0232	0.25	0.16	Amyloid A serum levels;	chr11:18375599	chr11:18507608~18508820:-
THCA	cis	rs2337406	0.929	rs12050233	ENSG00000280411.1	IGHV1-69-2	-3.59	0.000359	0.0232	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106781123	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.852	rs12050466	ENSG00000280411.1	IGHV1-69-2	-3.59	0.000359	0.0232	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106781131	chr14:106762092~106762588:-
THCA	cis	rs9905704	0.918	rs302867	ENSG00000224738.1	AC099850.1	-3.59	0.000359	0.0232	-0.22	-0.16	Testicular germ cell tumor;	chr17:58675458	chr17:59106598~59118267:+
THCA	cis	rs7520050	0.966	rs12405451	ENSG00000281133.1	AL355480.3	3.59	0.000359	0.0232	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs11211224	ENSG00000281133.1	AL355480.3	3.59	0.000359	0.0232	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.933	rs6656022	ENSG00000281133.1	AL355480.3	3.59	0.000359	0.0232	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs4134386	ENSG00000281133.1	AL355480.3	3.59	0.000359	0.0232	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs12561806	ENSG00000281133.1	AL355480.3	3.59	0.000359	0.0232	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6669522	ENSG00000281133.1	AL355480.3	3.59	0.000359	0.0232	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45580892~45580996:-
THCA	cis	rs2821260	0.694	rs12402629	ENSG00000227207.2	RPL31P12	-3.59	0.000359	0.0232	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:72113026	chr1:72301472~72301829:+
THCA	cis	rs8040855	0.965	rs4843027	ENSG00000225151.9	GOLGA2P7	3.59	0.000359	0.0232	0.21	0.16	Bulimia nervosa;	chr15:85171892	chr15:84199311~84230136:-
THCA	cis	rs12887734	0.546	rs66676135	ENSG00000258735.1	LINC00637	-3.59	0.000359	0.0232	-0.21	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103847721~103858049:+
THCA	cis	rs586716	0.548	rs505447	ENSG00000234840.1	LINC01239	3.59	0.000359	0.0232	0.19	0.16	Tuberculosis;	chr9:22455893	chr9:22646200~22824213:+
THCA	cis	rs4460629	0.65	rs11264319	ENSG00000236675.1	MTX1P1	-3.59	0.000359	0.0232	-0.15	-0.16	Serum magnesium levels;	chr1:155111466	chr1:155230975~155234325:+
THCA	cis	rs11673344	0.526	rs73035160	ENSG00000267470.4	ZNF571-AS1	-3.59	0.000359	0.0232	-0.2	-0.16	Obesity-related traits;	chr19:37655135	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.526	rs1871196	ENSG00000267470.4	ZNF571-AS1	-3.59	0.000359	0.0232	-0.2	-0.16	Obesity-related traits;	chr19:37656022	chr19:37548914~37587348:+
THCA	cis	rs12545912	0.569	rs499005	ENSG00000248538.5	RP11-10A14.5	3.59	0.000359	0.0232	0.26	0.16	Multiple myeloma (hyperdiploidy);	chr8:9939120	chr8:9189011~9202854:+
THCA	cis	rs12101261	0.66	rs11850464	ENSG00000258915.1	BHLHB9P1	-3.59	0.000359	0.0232	-0.19	-0.16	Graves' disease;	chr14:80973118	chr14:80981988~80983638:+
THCA	cis	rs4295623	0.504	rs11250160	ENSG00000255046.1	RP11-297N6.4	3.59	0.000359	0.0232	0.16	0.16	Morning vs. evening chronotype;	chr8:11735208	chr8:11797928~11802568:-
THCA	cis	rs836788	0.535	rs6151840	ENSG00000251050.1	RP11-168A11.4	-3.59	0.000359	0.0232	-0.13	-0.16	Glomerular filtration rate (creatinine);	chr5:80791435	chr5:80019609~80019920:+
THCA	cis	rs867371	0.519	rs1566560	ENSG00000276710.3	CSPG4P8	-3.59	0.000359	0.0232	-0.16	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82459472~82477258:+
THCA	cis	rs867371	0.519	rs1566559	ENSG00000276710.3	CSPG4P8	-3.59	0.000359	0.0232	-0.16	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82459472~82477258:+
THCA	cis	rs1953600	0.729	rs2819872	ENSG00000225484.5	NUTM2B-AS1	-3.59	0.000359	0.0232	-0.19	-0.16	Sarcoidosis;	chr10:80146513	chr10:79663088~79826594:-
THCA	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	3.59	0.000359	0.0232	0.15	0.16	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	3.59	0.000359	0.0232	0.15	0.16	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	3.59	0.000359	0.0232	0.15	0.16	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	3.59	0.000359	0.0232	0.15	0.16	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	3.59	0.000359	0.0232	0.15	0.16	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
THCA	cis	rs332034	0.546	rs28581487	ENSG00000254153.1	CTA-398F10.2	3.59	0.000359	0.0232	0.27	0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8838832	chr8:8456909~8461337:-
THCA	cis	rs332034	0.546	rs28481744	ENSG00000254153.1	CTA-398F10.2	3.59	0.000359	0.0232	0.27	0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8838836	chr8:8456909~8461337:-
THCA	cis	rs6684709	0.557	rs3218148	ENSG00000235052.1	RP1-150O5.3	3.59	0.000359	0.0232	0.18	0.16	White blood cell count;	chr1:23525295	chr1:23549139~23550915:-
THCA	cis	rs2014572	0.967	rs10413671	ENSG00000276449.1	AC004076.5	3.59	0.000359	0.0232	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57252121	chr19:57449689~57453011:+
THCA	cis	rs6878727	0.85	rs988410	ENSG00000253807.4	LINC01170	-3.59	0.000359	0.0232	-0.15	-0.16	Breast cancer;	chr5:124394837	chr5:124059794~124405079:-
THCA	cis	rs7131987	0.801	rs962866	ENSG00000257599.1	OVCH1-AS1	-3.59	0.000359	0.0232	-0.19	-0.16	QT interval;	chr12:29281214	chr12:29389294~29487488:+
THCA	cis	rs7131987	0.834	rs7139273	ENSG00000257599.1	OVCH1-AS1	-3.59	0.000359	0.0232	-0.19	-0.16	QT interval;	chr12:29281717	chr12:29389294~29487488:+
THCA	cis	rs9923856	0.611	rs7192393	ENSG00000263033.2	RP11-396B14.2	-3.59	0.000359	0.0232	-0.15	-0.16	Atopic dermatitis;Adult asthma;	chr16:10993239	chr16:11196177~11224969:+
THCA	cis	rs11643654	0.745	rs1465338	ENSG00000280344.1	AC009166.7	3.59	0.000359	0.0232	0.13	0.16	Educational attainment (years of education);	chr16:51137759	chr16:51176066~51178898:+
THCA	cis	rs3760982	0.585	rs11673534	ENSG00000267058.1	RP11-15A1.3	-3.59	0.000359	0.0232	-0.14	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794732	chr19:43891804~43901805:-
THCA	cis	rs3760982	0.585	rs11673490	ENSG00000267058.1	RP11-15A1.3	-3.59	0.000359	0.0232	-0.14	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794733	chr19:43891804~43901805:-
THCA	cis	rs3760982	0.585	rs11083724	ENSG00000267058.1	RP11-15A1.3	-3.59	0.000359	0.0232	-0.14	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794836	chr19:43891804~43901805:-
THCA	cis	rs11118346	0.64	rs2050594	ENSG00000228536.1	RP11-392O17.1	-3.59	0.00036	0.0232	-0.2	-0.16	Height;	chr1:219571506	chr1:219409681~219411941:-
THCA	cis	rs4656958	0.93	rs1930598	ENSG00000233691.2	RP11-312J18.7	3.59	0.00036	0.0232	0.2	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160924905	chr1:160935537~160936126:+
THCA	cis	rs11673344	0.503	rs703531	ENSG00000267260.1	CTD-2162K18.4	-3.59	0.00036	0.0232	-0.19	-0.16	Obesity-related traits;	chr19:37010050	chr19:36773153~36777078:+
THCA	cis	rs9652601	0.691	rs9888868	ENSG00000263033.2	RP11-396B14.2	-3.59	0.00036	0.0232	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11089706	chr16:11196177~11224969:+
THCA	cis	rs6963495	0.745	rs56239334	ENSG00000272604.1	RP11-251G23.5	3.59	0.00036	0.0232	0.22	0.16	Bipolar disorder (body mass index interaction);	chr7:105524904	chr7:105571083~105573660:+
THCA	cis	rs6963495	0.745	rs55906043	ENSG00000272604.1	RP11-251G23.5	3.59	0.00036	0.0232	0.22	0.16	Bipolar disorder (body mass index interaction);	chr7:105524920	chr7:105571083~105573660:+
THCA	cis	rs12887734	0.524	rs12888002	ENSG00000258735.1	LINC00637	-3.59	0.00036	0.0233	-0.22	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103847721~103858049:+
THCA	cis	rs73193808	0.901	rs8134232	ENSG00000176054.6	RPL23P2	-3.59	0.00036	0.0233	-0.18	-0.16	Coronary artery disease;	chr21:29199348	chr21:28997613~28998033:-
THCA	cis	rs738409	0.657	rs4823173	ENSG00000223843.4	EFCAB6-AS1	3.59	0.00036	0.0233	0.23	0.16	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43932850	chr22:43516107~43537117:+
THCA	cis	rs2676071	0.505	rs2251107	ENSG00000259721.1	RP11-758N13.1	-3.59	0.00036	0.0233	-0.19	-0.16	Periodontitis (Mean PAL);	chr15:33306201	chr15:32717270~32719007:-
THCA	cis	rs67539049	0.898	rs58319820	ENSG00000227888.4	FAM66A	-3.59	0.00036	0.0233	-0.25	-0.16	Itch intensity from mosquito bite;	chr8:11450987	chr8:12362019~12388296:+
THCA	cis	rs181553	0.664	rs4567802	ENSG00000266696.1	RP11-30L3.2	3.59	0.00036	0.0233	0.2	0.16	Hip circumference adjusted for BMI;	chr18:49170994	chr18:49205912~49208781:+
THCA	cis	rs7727544	0.557	rs2897096	ENSG00000263597.1	MIR3936	3.59	0.00036	0.0233	0.15	0.16	Blood metabolite levels;	chr5:132150591	chr5:132365490~132365599:-
THCA	cis	rs459571	1	rs2810489	ENSG00000235106.7	LINC00094	3.59	0.00036	0.0233	0.15	0.16	Platelet distribution width;	chr9:134057578	chr9:134025439~134034666:+
THCA	cis	rs867371	1	rs1501372	ENSG00000278603.1	RP13-608F4.5	3.59	0.00036	0.0233	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472203~82472426:+
THCA	cis	rs867371	1	rs1846911	ENSG00000278603.1	RP13-608F4.5	3.59	0.00036	0.0233	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472203~82472426:+
THCA	cis	rs8099594	0.565	rs8090015	ENSG00000266696.1	RP11-30L3.2	3.59	0.00036	0.0233	0.2	0.16	Height;	chr18:49187716	chr18:49205912~49208781:+
THCA	cis	rs61160187	0.582	rs17419290	ENSG00000251279.1	CTC-436P18.1	3.59	0.00036	0.0233	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:61162070~61232040:+
THCA	cis	rs10932679	0.595	rs11688933	ENSG00000237930.1	AC007563.4	-3.59	0.00036	0.0233	-0.23	-0.16	Pulse pressure;	chr2:216771382	chr2:216785774~216786144:-
THCA	cis	rs7916697	0.626	rs61854803	ENSG00000233590.1	RP11-153K11.3	-3.59	0.00036	0.0233	-0.2	-0.16	Optic disc area;	chr10:68254881	chr10:68233251~68242379:-
THCA	cis	rs748404	0.66	rs690367	ENSG00000275601.1	AC011330.13	3.59	0.00036	0.0233	0.19	0.16	Lung cancer;	chr15:43456106	chr15:43642389~43643023:-
THCA	cis	rs2013441	0.866	rs2703813	ENSG00000261033.1	RP11-209D14.2	3.59	0.00036	0.0233	0.23	0.16	Obesity-related traits;	chr17:20212002	chr17:20008051~20009234:-
THCA	cis	rs2013441	0.866	rs7207817	ENSG00000261033.1	RP11-209D14.2	3.59	0.00036	0.0233	0.23	0.16	Obesity-related traits;	chr17:20318015	chr17:20008051~20009234:-
THCA	cis	rs3020811	0.717	rs73060038	ENSG00000256274.1	TAS2R64P	3.59	0.00036	0.0233	0.43	0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr12:12014135	chr12:11076769~11079171:-
THCA	cis	rs394563	0.967	rs444784	ENSG00000268592.3	RAET1E-AS1	3.59	0.00036	0.0233	0.22	0.16	Dupuytren's disease;	chr6:149477230	chr6:149863494~149919507:+
THCA	cis	rs4660214	0.724	rs3931300	ENSG00000182109.6	RP11-69E11.4	-3.59	0.00036	0.0233	-0.16	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39195175	chr1:39522280~39546187:-
THCA	cis	rs453301	0.631	rs11780774	ENSG00000253981.4	ALG1L13P	-3.59	0.00036	0.0233	-0.17	-0.16	Joint mobility (Beighton score);	chr8:8941601	chr8:8236003~8244667:-
THCA	cis	rs6472235	0.586	rs2357567	ENSG00000272192.1	CTD-2532N20.1	-3.59	0.00036	0.0233	-0.18	-0.16	Plateletcrit;Myopia (pathological);	chr8:66003718	chr8:65842752~65843331:+
THCA	cis	rs9303280	0.936	rs12950209	ENSG00000263818.4	CTD-2206N4.4	3.59	0.00036	0.0233	0.21	0.16	Self-reported allergy;	chr17:39892849	chr17:39057019~39113190:+
THCA	cis	rs7688540	0.8	rs28429717	ENSG00000250892.1	RP11-1365D11.1	3.59	0.00036	0.0233	0.24	0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:201409~205009:-
THCA	cis	rs72843506	0.656	rs111249650	ENSG00000189423.10	USP32P3	3.59	0.00036	0.0233	0.27	0.16	Schizophrenia;	chr17:20008517	chr17:20415547~20431008:+
THCA	cis	rs17074492	1	rs56042026	ENSG00000214182.5	PTMAP5	3.59	0.00036	0.0233	0.19	0.16	Sjögren's syndrome;	chr13:81601492	chr13:81689911~81691072:+
THCA	cis	rs453301	0.624	rs330049	ENSG00000254340.1	RP11-10A14.3	3.59	0.00036	0.0233	0.18	0.16	Joint mobility (Beighton score);	chr8:9229789	chr8:9141424~9145435:+
THCA	cis	rs9876781	1	rs7651407	ENSG00000199476.1	Y_RNA	-3.59	0.00036	0.0233	-0.21	-0.16	Longevity;	chr3:48402409	chr3:48288587~48288694:+
THCA	cis	rs7818688	1	rs11786878	ENSG00000253528.2	RP11-347C18.4	-3.59	0.00036	0.0233	-0.27	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95021064	chr8:94974573~94974853:-
THCA	cis	rs3087591	0.639	rs2854333	ENSG00000263535.1	AK4P1	3.59	0.00036	0.0233	0.2	0.16	Hip circumference;	chr17:31386282	chr17:31345521~31346187:+
THCA	cis	rs6137726	0.652	rs73304706	ENSG00000237396.1	LINC01384	-3.59	0.00036	0.0233	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22673756	chr20:22587522~22607517:-
THCA	cis	rs8030379	0.967	rs11857009	ENSG00000176700.18	SCAND2P	-3.59	0.00036	0.0233	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83898661	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2046120	ENSG00000176700.18	SCAND2P	-3.59	0.00036	0.0233	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899010	chr15:84631451~84647478:+
THCA	cis	rs9796	0.866	rs692155	ENSG00000247556.5	OIP5-AS1	3.59	0.00036	0.0233	0.13	0.16	Menopause (age at onset);	chr15:41114863	chr15:41283990~41309737:+
THCA	cis	rs11089937	0.857	rs5750578	ENSG00000211638.2	IGLV8-61	-3.59	0.00036	0.0233	-0.13	-0.16	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22098700~22099212:+
THCA	cis	rs9650657	0.513	rs4314618	ENSG00000261451.1	RP11-981G7.1	-3.59	0.00036	0.0233	-0.2	-0.16	Neuroticism;	chr8:10959262	chr8:10433672~10438312:+
THCA	cis	rs3749237	0.595	rs17650792	ENSG00000224424.7	PRKAR2A-AS1	3.59	0.00036	0.0233	0.14	0.16	Resting heart rate;	chr3:49352817	chr3:48847572~48851981:+
THCA	cis	rs11751172	0.688	rs7752324	ENSG00000271857.1	RP1-244F24.1	3.59	0.00036	0.0233	0.1	0.16	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45567352	chr6:45421079~45422005:-
THCA	cis	rs6885099	0.509	rs832785	ENSG00000251400.1	ALDH7A1P1	3.59	0.00036	0.0233	0.19	0.16	Thyroid hormone levels;	chr5:77254504	chr5:77290268~77291800:+
THCA	cis	rs427943	0.778	rs13047803	ENSG00000223768.1	LINC00205	-3.59	0.00036	0.0233	-0.15	-0.16	Body mass index;	chr21:45202454	chr21:45293285~45297354:+
THCA	cis	rs7572733	0.504	rs72928581	ENSG00000231621.1	AC013264.2	-3.59	0.00036	0.0233	-0.17	-0.16	Dermatomyositis;	chr2:198001896	chr2:197197991~197199273:+
THCA	cis	rs1572511	0.628	rs1415342	ENSG00000213058.3	RP4-765C7.2	-3.59	0.00036	0.0233	-0.22	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:177611514	chr1:178411616~178411972:+
THCA	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	3.59	0.00036	0.0233	0.15	0.16	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
THCA	cis	rs972578	1	rs2010366	ENSG00000230319.1	AL022476.2	3.59	0.000361	0.0233	0.18	0.16	Mean platelet volume;	chr22:42985282	chr22:43038585~43052366:+
THCA	cis	rs1876206	0.554	rs585256	ENSG00000259705.1	RP11-227D13.1	3.59	0.000361	0.0233	0.2	0.16	Breast cancer;	chr15:48607548	chr15:48645951~48652016:+
THCA	cis	rs10927875	0.578	rs10927859	ENSG00000179743.3	FLJ37453	-3.59	0.000361	0.0233	-0.12	-0.16	Dilated cardiomyopathy;	chr1:15815367	chr1:15834479~15848147:-
THCA	cis	rs1979679	0.608	rs4931084	ENSG00000278733.1	RP11-425D17.1	-3.59	0.000361	0.0233	-0.17	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28569378	chr12:28185625~28186190:-
THCA	cis	rs7937682	0.587	rs611607	ENSG00000271584.1	RP11-89C3.4	-3.59	0.000361	0.0233	-0.22	-0.16	Primary sclerosing cholangitis;	chr11:111479040	chr11:111091932~111097357:-
THCA	cis	rs11694172	0.826	rs11676950	ENSG00000273456.1	RP11-686O6.2	3.59	0.000361	0.0233	0.15	0.16	Cholesterol, total;	chr2:202746217	chr2:202374932~202375604:-
THCA	cis	rs4713118	0.824	rs7759217	ENSG00000261839.1	RP1-265C24.8	3.59	0.000361	0.0233	0.19	0.16	Parkinson's disease;	chr6:27762684	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.784	rs9468219	ENSG00000261839.1	RP1-265C24.8	3.59	0.000361	0.0233	0.19	0.16	Parkinson's disease;	chr6:27763976	chr6:28136849~28139678:+
THCA	cis	rs73173548	0.502	rs7726289	ENSG00000247828.6	TMEM161B-AS1	3.59	0.000361	0.0233	0.15	0.16	Macular telangiectasia type 2;	chr5:88437392	chr5:88268895~88436685:+
THCA	cis	rs8054556	0.74	rs8059619	ENSG00000273724.1	RP11-347C12.12	-3.59	0.000361	0.0233	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29914124	chr16:30336400~30343336:+
THCA	cis	rs964611	0.882	rs6493316	ENSG00000259488.2	RP11-154J22.1	-3.59	0.000361	0.0233	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48275280	chr15:48312353~48331856:-
THCA	cis	rs1876206	0.554	rs645509	ENSG00000259705.1	RP11-227D13.1	3.59	0.000361	0.0233	0.2	0.16	Breast cancer;	chr15:48609192	chr15:48645951~48652016:+
THCA	cis	rs35146811	0.695	rs1623264	ENSG00000078319.8	PMS2P1	-3.59	0.000361	0.0233	-0.2	-0.16	Coronary artery disease;	chr7:100213581	chr7:100320992~100341908:-
THCA	cis	rs453301	0.652	rs2043129	ENSG00000254340.1	RP11-10A14.3	3.59	0.000361	0.0233	0.18	0.16	Joint mobility (Beighton score);	chr8:8967994	chr8:9141424~9145435:+
THCA	cis	rs479105	0.689	rs11610052	ENSG00000278356.1	RP11-372B4.3	3.59	0.000361	0.0233	0.16	0.16	Gut microbiota (bacterial taxa);	chr12:3266057	chr12:2885819~2886329:+
THCA	cis	rs2071852	0.66	rs6007155	ENSG00000280383.1	CTA-941F9.10	3.59	0.000361	0.0233	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr22:45758486	chr22:45657019~45680130:+
THCA	cis	rs7010267	0.602	rs1485307	ENSG00000254278.1	RP11-278I4.2	-3.59	0.000361	0.0233	-0.21	-0.16	Total body bone mineral density (age 45-60);	chr8:118995156	chr8:119062942~119068782:-
THCA	cis	rs5753037	0.869	rs3788420	ENSG00000279699.1	RP1-102K2.9	3.59	0.000361	0.0233	0.16	0.16	Type 1 diabetes;	chr22:29980930	chr22:30275215~30276951:-
THCA	cis	rs9650657	0.524	rs10088408	ENSG00000206014.6	OR7E161P	3.59	0.000361	0.0233	0.19	0.16	Neuroticism;	chr8:10959687	chr8:11928597~11929563:-
THCA	cis	rs12618769	0.594	rs3754876	ENSG00000228970.6	UBTFL6	-3.59	0.000361	0.0233	-0.24	-0.16	Bipolar disorder;	chr2:98569404	chr2:97636780~97637803:-
THCA	cis	rs875971	0.929	rs4122249	ENSG00000272831.1	RP11-792A8.4	3.59	0.000361	0.0233	0.1	0.16	Aortic root size;	chr7:66455949	chr7:66739829~66740385:-
THCA	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	3.59	0.000361	0.0233	0.22	0.16	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
THCA	cis	rs944289	0.774	rs8013429	ENSG00000212071.1	AL162511.1	3.59	0.000361	0.0233	0.19	0.16	Thyroid cancer;	chr14:36131855	chr14:36196480~36196568:-
THCA	cis	rs2898290	0.622	rs17799486	ENSG00000206014.6	OR7E161P	3.59	0.000361	0.0233	0.19	0.16	Systolic blood pressure;	chr8:11482985	chr8:11928597~11929563:-
THCA	cis	rs7919656	0.662	rs2940728	ENSG00000228403.1	RP11-563N6.6	-3.59	0.000361	0.0233	-0.17	-0.16	Clinically amyopathic dermatomyositis;	chr10:48865445	chr10:48878022~48878649:+
THCA	cis	rs10090774	0.965	rs13271554	ENSG00000280303.2	ERICD	-3.59	0.000361	0.0233	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140863589	chr8:140636281~140638283:+
THCA	cis	rs2380205	0.517	rs12360409	ENSG00000232807.2	RP11-536K7.3	3.59	0.000361	0.0233	0.17	0.16	Breast cancer;	chr10:5933835	chr10:5934270~5945900:-
THCA	cis	rs2236295	0.533	rs931977	ENSG00000238280.1	RP11-436D10.3	3.59	0.000361	0.0233	0.19	0.16	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62898218	chr10:62793562~62805887:-
THCA	cis	rs1923243	0.714	rs4495635	ENSG00000223479.3	RP4-788P17.1	3.59	0.000361	0.0233	0.18	0.16	Migraine;	chr1:73091163	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.714	rs4562575	ENSG00000223479.3	RP4-788P17.1	3.59	0.000361	0.0233	0.18	0.16	Migraine;	chr1:73091173	chr1:73635216~73715214:+
THCA	cis	rs7246967	0.673	rs1433085	ENSG00000198153.8	ZNF849P	-3.59	0.000361	0.0233	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22628297	chr19:22685167~22686732:+
THCA	cis	rs5758511	0.68	rs17002902	ENSG00000270083.1	RP1-257I20.14	-3.59	0.000361	0.0233	-0.21	-0.16	Birth weight;	chr22:42229503	chr22:42089630~42090028:-
THCA	cis	rs73198271	0.74	rs10092600	ENSG00000254153.1	CTA-398F10.2	3.59	0.000361	0.0233	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.74	rs10105690	ENSG00000254153.1	CTA-398F10.2	3.59	0.000361	0.0233	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8456909~8461337:-
THCA	cis	rs12023718	0.588	rs6659392	ENSG00000213057.5	C1orf220	3.59	0.000361	0.0233	0.17	0.16	Obesity-related traits;	chr1:178629738	chr1:178542752~178548889:+
THCA	cis	rs17027633	0.881	rs76940009	ENSG00000260948.1	RP11-552M11.8	-3.59	0.000361	0.0233	-0.4	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111466408	chr1:111431046~111433068:-
THCA	cis	rs17027633	0.881	rs77558823	ENSG00000260948.1	RP11-552M11.8	-3.59	0.000361	0.0233	-0.4	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111471173	chr1:111431046~111433068:-
THCA	cis	rs17027633	0.881	rs78403721	ENSG00000260948.1	RP11-552M11.8	-3.59	0.000361	0.0233	-0.4	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111472244	chr1:111431046~111433068:-
THCA	cis	rs7551222	0.784	rs2045624	ENSG00000240219.1	RP11-430C7.5	-3.59	0.000361	0.0233	-0.16	-0.16	Schizophrenia;	chr1:204615257	chr1:204626775~204629712:+
THCA	cis	rs7572733	0.935	rs12995110	ENSG00000231621.1	AC013264.2	3.59	0.000361	0.0233	0.16	0.16	Dermatomyositis;	chr2:197924289	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs4850816	ENSG00000231621.1	AC013264.2	3.59	0.000361	0.0233	0.16	0.16	Dermatomyositis;	chr2:197925041	chr2:197197991~197199273:+
THCA	cis	rs12942207	1	rs12942207	ENSG00000264920.1	RP11-6N17.4	-3.59	0.000361	0.0233	-0.15	-0.16	Birth weight;	chr17:47890928	chr17:47891255~47895812:-
THCA	cis	rs9450351	0.744	rs9353339	ENSG00000280232.1	RP11-321N4.4	-3.59	0.000361	0.0233	-0.35	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85794480	chr6:85498441~85499058:-
THCA	cis	rs2744375	0.6	rs2237102	ENSG00000261189.1	RP3-512B11.3	3.59	0.000361	0.0233	0.17	0.16	Resting heart rate;	chr6:7551912	chr6:7540451~7541338:-
THCA	cis	rs6724465	1	rs868945	ENSG00000272644.1	RP11-33O4.1	3.59	0.000361	0.0233	0.24	0.16	Height;	chr2:219059717	chr2:219069354~219069809:-
THCA	cis	rs3755605	0.833	rs7635670	ENSG00000242578.1	RP11-469J4.3	3.59	0.000361	0.0233	0.18	0.16	Testicular germ cell tumor;	chr3:170060837	chr3:170410512~170418615:+
THCA	cis	rs9863	0.931	rs34180676	ENSG00000270028.1	RP11-380L11.4	3.59	0.000362	0.0234	0.17	0.16	White blood cell count;	chr12:123946972	chr12:123925461~123926083:-
THCA	cis	rs9863	0.931	rs7955815	ENSG00000270028.1	RP11-380L11.4	3.59	0.000362	0.0234	0.17	0.16	White blood cell count;	chr12:123948159	chr12:123925461~123926083:-
THCA	cis	rs61869271	0.799	rs35501899	ENSG00000236799.1	RP11-383C6.2	-3.59	0.000362	0.0234	-0.2	-0.16	Tonsillectomy;	chr10:114979350	chr10:114994657~114996593:+
THCA	cis	rs7089973	0.549	rs34434610	ENSG00000236799.1	RP11-383C6.2	-3.59	0.000362	0.0234	-0.2	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114979986	chr10:114994657~114996593:+
THCA	cis	rs7089973	0.523	rs34170154	ENSG00000236799.1	RP11-383C6.2	-3.59	0.000362	0.0234	-0.2	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114981200	chr10:114994657~114996593:+
THCA	cis	rs7089973	0.523	rs7093330	ENSG00000236799.1	RP11-383C6.2	-3.59	0.000362	0.0234	-0.2	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114984815	chr10:114994657~114996593:+
THCA	cis	rs7089973	0.549	rs7094440	ENSG00000236799.1	RP11-383C6.2	-3.59	0.000362	0.0234	-0.2	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114985649	chr10:114994657~114996593:+
THCA	cis	rs61869271	0.797	rs6585313	ENSG00000236799.1	RP11-383C6.2	-3.59	0.000362	0.0234	-0.2	-0.16	Tonsillectomy;	chr10:114985799	chr10:114994657~114996593:+
THCA	cis	rs11679564	0.714	rs4016031	ENSG00000279519.1	RP11-288C18.1	3.59	0.000362	0.0234	0.13	0.16	Immature fraction of reticulocytes;	chr2:36957611	chr2:36839922~36842539:-
THCA	cis	rs2191566	0.691	rs8105315	ENSG00000266921.1	RP11-15A1.7	-3.59	0.000362	0.0234	-0.16	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44084633	chr19:43996896~44002836:-
THCA	cis	rs2191566	0.691	rs8104437	ENSG00000266921.1	RP11-15A1.7	-3.59	0.000362	0.0234	-0.16	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44084636	chr19:43996896~44002836:-
THCA	cis	rs11102159	0.607	rs11102161	ENSG00000259834.1	RP11-284N8.3	3.59	0.000362	0.0234	0.17	0.16	Schizophrenia;	chr1:110789487	chr1:110653560~110657040:-
THCA	cis	rs972578	0.804	rs5758944	ENSG00000230319.1	AL022476.2	3.59	0.000362	0.0234	0.17	0.16	Mean platelet volume;	chr22:42795313	chr22:43038585~43052366:+
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000230373.7	GOLGA6L5P	-3.59	0.000362	0.0234	-0.16	-0.16	P wave terminal force;	chr15:84635039	chr15:84507885~84516814:-
THCA	cis	rs791590	0.715	rs12722588	ENSG00000225948.2	RP11-554I8.1	-3.59	0.000362	0.0234	-0.22	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6018470	chr10:6618716~6625346:+
THCA	cis	rs911555	0.557	rs8022179	ENSG00000269940.1	RP11-73M18.7	3.59	0.000362	0.0234	0.17	0.16	Intelligence (multi-trait analysis);	chr14:103380950	chr14:103694560~103695170:+
THCA	cis	rs2882667	0.931	rs10075893	ENSG00000249593.5	CTB-46B19.2	-3.59	0.000362	0.0234	-0.2	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:139012647~139051203:+
THCA	cis	rs7088591	1	rs80032439	ENSG00000276818.1	AC026393.1	3.59	0.000362	0.0234	0.32	0.16	Blood pressure;	chr10:57970678	chr10:57095699~57095781:+
THCA	cis	rs683250	0.598	rs590847	ENSG00000254551.1	RP11-727A23.7	3.59	0.000362	0.0234	0.2	0.16	Subcortical brain region volumes;	chr11:83255127	chr11:83209431~83213379:-
THCA	cis	rs7122539	0.684	rs11227610	ENSG00000275484.1	CTC-1337H24.4	-3.59	0.000362	0.0234	-0.14	-0.16	HIV-1 susceptibility;	chr11:66861558	chr11:67374416~67374932:+
THCA	cis	rs115769866	0.618	rs7759252	ENSG00000216901.1	AL022393.7	3.59	0.000362	0.0234	0.25	0.16	Bipolar disorder;	chr6:28501645	chr6:28176188~28176674:+
THCA	cis	rs7613875	0.6	rs2856238	ENSG00000281691.1	RBM5-AS1	3.59	0.000362	0.0234	0.14	0.16	Body mass index;	chr3:50120758	chr3:50099603~50100988:-
THCA	cis	rs12148329	1	rs17225874	ENSG00000259594.4	CTD-2034I4.2	3.59	0.000362	0.0234	0.26	0.16	Immune response to smallpox vaccine (IL-6);	chr15:80705567	chr15:81554003~81696780:+
THCA	cis	rs11658311	1	rs9905032	ENSG00000266803.1	RP1-77H15.1	3.59	0.000362	0.0234	0.33	0.16	Obsessive-compulsive symptoms;	chr17:17554454	chr17:16557985~16559269:-
THCA	cis	rs12506899	0.934	rs6818116	ENSG00000221639.1	SNORA3	3.59	0.000362	0.0234	0.2	0.16	Tumor biomarkers;	chr4:73368538	chr4:73263960~73264084:+
THCA	cis	rs875971	1	rs1565531	ENSG00000272831.1	RP11-792A8.4	-3.59	0.000362	0.0234	-0.1	-0.16	Aortic root size;	chr7:66198126	chr7:66739829~66740385:-
THCA	cis	rs9650657	0.504	rs10108347	ENSG00000261451.1	RP11-981G7.1	-3.59	0.000362	0.0234	-0.21	-0.16	Neuroticism;	chr8:11176008	chr8:10433672~10438312:+
THCA	cis	rs6517329	0.538	rs1028997	ENSG00000230212.5	AP000688.14	-3.59	0.000362	0.0234	-0.2	-0.16	Schizophrenia;	chr21:36159924	chr21:36069642~36126640:-
THCA	cis	rs7028939	1	rs10988967	ENSG00000255145.2	STX17-AS1	-3.59	0.000362	0.0234	-0.24	-0.16	Preeclampsia;	chr9:100087257	chr9:99886322~99906601:-
THCA	cis	rs1124769	0.57	rs17702978	ENSG00000273674.3	CTD-2378E12.1	3.59	0.000362	0.0234	0.22	0.16	Cognitive performance;	chr15:50868358	chr15:50839875~50908599:-
THCA	cis	rs7665090	0.806	rs413967	ENSG00000230069.3	LRRC37A15P	3.59	0.000362	0.0234	0.17	0.16	Primary biliary cholangitis;	chr4:102662039	chr4:102727274~102730721:-
THCA	cis	rs7665090	0.806	rs404574	ENSG00000230069.3	LRRC37A15P	3.59	0.000362	0.0234	0.17	0.16	Primary biliary cholangitis;	chr4:102662051	chr4:102727274~102730721:-
THCA	cis	rs11148252	0.712	rs61957257	ENSG00000273784.3	RP11-78J21.7	-3.59	0.000362	0.0234	-0.18	-0.16	Lewy body disease;	chr13:52195567	chr13:52600042~52642542:+
THCA	cis	rs8033133	1	rs8033133	ENSG00000257151.1	PWAR6	3.59	0.000362	0.0234	0.12	0.16	Blood osmolality (transformed sodium);	chr15:25105327	chr15:25031873~25036490:+
THCA	cis	rs6546886	0.912	rs4574138	ENSG00000235499.1	AC073046.25	3.59	0.000362	0.0234	0.15	0.16	Dialysis-related mortality;	chr2:74067279	chr2:73985132~73986343:+
THCA	cis	rs875971	0.545	rs73142265	ENSG00000273024.4	INTS4P2	-3.59	0.000362	0.0234	-0.21	-0.16	Aortic root size;	chr7:66234510	chr7:65647864~65715661:+
THCA	cis	rs4073416	0.542	rs10142283	ENSG00000276116.2	FUT8-AS1	3.59	0.000362	0.0234	0.18	0.16	N-glycan levels;	chr14:65577411	chr14:65411170~65412690:-
THCA	cis	rs8033133	0.581	rs8042796	ENSG00000270523.1	RP11-145P16.3	3.59	0.000362	0.0234	0.16	0.16	Blood osmolality (transformed sodium);	chr15:25082249	chr15:25130978~25131337:+
THCA	cis	rs2638953	0.853	rs10843179	ENSG00000247934.4	RP11-967K21.1	3.59	0.000362	0.0234	0.17	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28163298~28190738:-
THCA	cis	rs7829975	0.557	rs7816427	ENSG00000253981.4	ALG1L13P	-3.59	0.000362	0.0234	-0.17	-0.16	Mood instability;	chr8:8688374	chr8:8236003~8244667:-
THCA	cis	rs7586085	0.899	rs1346003	ENSG00000232411.1	AC009495.3	-3.59	0.000362	0.0234	-0.18	-0.16	Total body bone mineral density;	chr2:165740847	chr2:165833048~165839098:-
THCA	cis	rs478304	0.934	rs537786	ENSG00000214659.4	KRT8P26	-3.59	0.000362	0.0234	-0.14	-0.16	Acne (severe);	chr11:65727516	chr11:65726939~65728214:+
THCA	cis	rs853679	0.567	rs16894091	ENSG00000226314.6	ZNF192P1	3.59	0.000362	0.0234	0.2	0.16	Depression;	chr6:28422360	chr6:28161781~28169594:+
THCA	cis	rs2692947	0.537	rs11685849	ENSG00000168992.4	OR7E102P	3.59	0.000362	0.0234	0.22	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578056	chr2:95546531~95547545:+
THCA	cis	rs2692947	0.537	rs11688045	ENSG00000168992.4	OR7E102P	3.59	0.000362	0.0234	0.22	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578057	chr2:95546531~95547545:+
THCA	cis	rs2337406	0.81	rs7161739	ENSG00000280411.1	IGHV1-69-2	-3.59	0.000363	0.0234	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106776118	chr14:106762092~106762588:-
THCA	cis	rs150992	0.72	rs469018	ENSG00000246763.5	RGMB-AS1	3.59	0.000363	0.0234	0.17	0.16	Body mass index;	chr5:98953530	chr5:98769618~98773469:-
THCA	cis	rs72634258	0.554	rs1012477	ENSG00000224315.2	RPL7P7	3.59	0.000363	0.0234	0.3	0.16	Inflammatory bowel disease;	chr1:7798075	chr1:8786211~8786913:-
THCA	cis	rs34102591	0.503	rs7977078	ENSG00000270061.1	RP11-214K3.19	-3.59	0.000363	0.0234	-0.2	-0.16	Schizophrenia;	chr12:123900930	chr12:123969990~123970344:-
THCA	cis	rs1062177	1	rs2347596	ENSG00000272112.1	CTB-113P19.5	3.59	0.000363	0.0234	0.14	0.16	Preschool internalizing problems;	chr5:151799638	chr5:151724831~151725356:-
THCA	cis	rs1062177	0.95	rs892005	ENSG00000272112.1	CTB-113P19.5	3.59	0.000363	0.0234	0.14	0.16	Preschool internalizing problems;	chr5:151801060	chr5:151724831~151725356:-
THCA	cis	rs1062177	1	rs72802204	ENSG00000272112.1	CTB-113P19.5	3.59	0.000363	0.0234	0.14	0.16	Preschool internalizing problems;	chr5:151803622	chr5:151724831~151725356:-
THCA	cis	rs4819052	0.635	rs2838808	ENSG00000215447.6	BX322557.10	-3.59	0.000363	0.0234	-0.14	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45201191	chr21:45288052~45291738:+
THCA	cis	rs4144027	0.967	rs72712857	ENSG00000258534.1	CTD-2134A5.4	-3.59	0.000363	0.0234	-0.17	-0.16	Blood metabolite levels;	chr14:103896336	chr14:103854366~103880111:-
THCA	cis	rs861020	0.677	rs2049998	ENSG00000203706.7	SERTAD4-AS1	3.59	0.000363	0.0234	0.19	0.16	Orofacial clefts;	chr1:209857809	chr1:210231456~210234047:-
THCA	cis	rs875971	0.54	rs781152	ENSG00000232546.1	RP11-458F8.1	-3.59	0.000363	0.0234	-0.14	-0.16	Aortic root size;	chr7:66014585	chr7:66848496~66858136:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000232546.1	RP11-458F8.1	-3.59	0.000363	0.0234	-0.14	-0.16	Calcium levels;	chr7:66014891	chr7:66848496~66858136:+
THCA	cis	rs875971	0.862	rs6944374	ENSG00000223473.2	GS1-124K5.3	-3.59	0.000363	0.0234	-0.11	-0.16	Aortic root size;	chr7:66221942	chr7:66491049~66493566:-
THCA	cis	rs7551222	0.752	rs2369244	ENSG00000240219.1	RP11-430C7.5	-3.59	0.000363	0.0234	-0.15	-0.16	Schizophrenia;	chr1:204546171	chr1:204626775~204629712:+
THCA	cis	rs1609391	0.567	rs835633	ENSG00000239213.4	NCK1-AS1	3.59	0.000363	0.0234	0.14	0.16	Neuroticism;	chr3:136957654	chr3:136841726~136862054:-
THCA	cis	rs9527	0.83	rs12249194	ENSG00000236937.2	PTGES3P4	3.59	0.000363	0.0234	0.23	0.16	Arsenic metabolism;	chr10:102883941	chr10:102845595~102845950:+
THCA	cis	rs733175	0.857	rs751092	ENSG00000163612.10	FAM86KP	-3.59	0.000363	0.0234	-0.26	-0.16	Psychosis and Alzheimer's disease;	chr4:10004273	chr4:9153296~9165451:+
THCA	cis	rs12931792	0.782	rs13331817	ENSG00000274678.1	RP11-2C24.7	3.59	0.000363	0.0234	0.16	0.16	Tonsillectomy;	chr16:30161306	chr16:30821338~30821884:+
THCA	cis	rs7487075	0.93	rs6582656	ENSG00000272369.1	RP11-446N19.1	3.59	0.000363	0.0234	0.12	0.16	Itch intensity from mosquito bite;	chr12:46449633	chr12:46537502~46652550:+
THCA	cis	rs7660883	0.897	rs1037814	ENSG00000251411.1	RP11-397E7.4	-3.59	0.000363	0.0234	-0.15	-0.16	HDL cholesterol levels;	chr4:87128698	chr4:86913266~86914817:-
THCA	cis	rs7660883	0.897	rs342469	ENSG00000251411.1	RP11-397E7.4	-3.59	0.000363	0.0234	-0.15	-0.16	HDL cholesterol levels;	chr4:87129402	chr4:86913266~86914817:-
THCA	cis	rs7209700	0.778	rs3851807	ENSG00000262879.4	RP11-156P1.3	3.59	0.000363	0.0234	0.15	0.16	IgG glycosylation;	chr17:47274153	chr17:46984045~47100323:-
THCA	cis	rs793571	0.669	rs28864995	ENSG00000245975.2	RP11-30K9.6	3.59	0.000363	0.0234	0.15	0.16	Schizophrenia;	chr15:58653472	chr15:58768072~58770974:-
THCA	cis	rs7707921	1	rs79616997	ENSG00000251374.1	RPS23P5	3.59	0.000363	0.0234	0.24	0.16	Breast cancer;	chr5:82208781	chr5:82265157~82265259:-
THCA	cis	rs146817970	1	rs146817970	ENSG00000251374.1	RPS23P5	3.59	0.000363	0.0234	0.24	0.16	Breast cancer;	chr5:82217129	chr5:82265157~82265259:-
THCA	cis	rs1850744	0.51	rs938557	ENSG00000250942.1	ENPP7P11	3.59	0.000363	0.0234	0.22	0.16	Economic and political preferences;	chr4:9825932	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.51	rs4697896	ENSG00000250942.1	ENPP7P11	3.59	0.000363	0.0234	0.22	0.16	Economic and political preferences;	chr4:9826945	chr4:9677308~9677934:+
THCA	cis	rs763121	0.962	rs6001193	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000363	0.0234	-0.12	-0.16	Menopause (age at onset);	chr22:38678732	chr22:38739003~38749041:+
THCA	cis	rs6121246	0.697	rs6087716	ENSG00000224628.2	RP5-854E16.2	-3.59	0.000363	0.0234	-0.23	-0.16	Mean corpuscular hemoglobin;	chr20:31641237	chr20:31285317~31286835:-
THCA	cis	rs12780845	0.931	rs2884039	ENSG00000229124.5	VIM-AS1	3.59	0.000363	0.0234	0.16	0.16	Homocysteine levels;	chr10:17210242	chr10:17214239~17229985:-
THCA	cis	rs7259376	0.936	rs7259586	ENSG00000270947.1	AC025811.3	3.59	0.000363	0.0234	0.17	0.16	Menopause (age at onset);	chr19:22355060	chr19:22455988~22456459:+
THCA	cis	rs1362756	0.958	rs7196852	ENSG00000260057.4	LINC01571	-3.59	0.000363	0.0234	-0.18	-0.16	Optic disc parameters;Optic disc area;	chr16:51428912	chr16:51762519~51773173:+
THCA	cis	rs76878669	0.516	rs7104570	ENSG00000255320.1	RP11-755F10.1	-3.59	0.000363	0.0234	-0.21	-0.16	Educational attainment (years of education);	chr11:66391627	chr11:66244840~66246239:-
THCA	cis	rs77147124	1	rs7899096	ENSG00000225292.2	RP11-57H14.3	-3.59	0.000363	0.0234	-0.22	-0.16	HDL cholesterol;	chr10:112159367	chr10:112888735~112906111:+
THCA	cis	rs77147124	1	rs2792736	ENSG00000225292.2	RP11-57H14.3	-3.59	0.000363	0.0234	-0.22	-0.16	HDL cholesterol;	chr10:112161401	chr10:112888735~112906111:+
THCA	cis	rs9611565	0.694	rs106860	ENSG00000237037.8	NDUFA6-AS1	3.59	0.000363	0.0234	0.16	0.16	Vitiligo;	chr22:41444403	chr22:42090931~42137742:+
THCA	cis	rs7203193	0.932	rs6498219	ENSG00000241641.1	RPS23P6	3.59	0.000363	0.0234	0.16	0.16	LDL cholesterol;	chr16:11542717	chr16:12081237~12081902:+
THCA	cis	rs7131987	0.868	rs737160	ENSG00000257599.1	OVCH1-AS1	-3.59	0.000363	0.0234	-0.19	-0.16	QT interval;	chr12:29276079	chr12:29389294~29487488:+
THCA	cis	rs56046484	0.956	rs35885781	ENSG00000218052.5	ADAMTS7P4	-3.59	0.000363	0.0234	-0.25	-0.16	Testicular germ cell tumor;	chr15:85047852	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.956	rs34105012	ENSG00000218052.5	ADAMTS7P4	-3.59	0.000363	0.0234	-0.25	-0.16	Testicular germ cell tumor;	chr15:85048455	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.956	rs34054841	ENSG00000218052.5	ADAMTS7P4	-3.59	0.000363	0.0234	-0.25	-0.16	Testicular germ cell tumor;	chr15:85058115	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.956	rs12908535	ENSG00000218052.5	ADAMTS7P4	-3.59	0.000363	0.0234	-0.25	-0.16	Testicular germ cell tumor;	chr15:85058294	chr15:85255369~85330334:-
THCA	cis	rs11649653	0.502	rs62057232	ENSG00000279196.1	RP11-1072A3.3	-3.59	0.000363	0.0234	-0.16	-0.16	Triglycerides;	chr16:30809545	chr16:30984630~30988270:-
THCA	cis	rs7897654	0.571	rs12765002	ENSG00000213061.2	PFN1P11	3.59	0.000363	0.0234	0.21	0.16	Schizophrenia;	chr10:102875591	chr10:102838011~102845473:-
THCA	cis	rs8058578	0.943	rs3747486	ENSG00000260911.2	RP11-196G11.2	3.59	0.000363	0.0234	0.14	0.16	Multiple myeloma;	chr16:30775606	chr16:31043150~31049868:+
THCA	cis	rs2522056	1	rs2405528	ENSG00000237714.1	P4HA2-AS1	-3.59	0.000363	0.0235	-0.23	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132458606	chr5:132184876~132192808:+
THCA	cis	rs5758659	0.652	rs133301	ENSG00000182057.4	OGFRP1	3.59	0.000363	0.0235	0.19	0.16	Cognitive function;	chr22:41994089	chr22:42269753~42275196:+
THCA	cis	rs9393777	0.92	rs34953377	ENSG00000220721.1	OR1F12	3.59	0.000363	0.0235	0.32	0.16	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28073316~28074233:+
THCA	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	-3.59	0.000363	0.0235	-0.08	-0.16	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
THCA	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	-3.59	0.000363	0.0235	-0.08	-0.16	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
THCA	cis	rs57709857	0.957	rs9643870	ENSG00000272092.1	RP11-350N15.5	-3.59	0.000363	0.0235	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38259274	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs6981405	ENSG00000272092.1	RP11-350N15.5	-3.59	0.000363	0.0235	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38262758	chr8:38382364~38383461:+
THCA	cis	rs57590327	0.504	rs4856348	ENSG00000241593.4	RP11-520D19.2	3.59	0.000363	0.0235	0.2	0.16	Extraversion;	chr3:81453772	chr3:81246579~81297345:-
THCA	cis	rs11640533	0.901	rs11862250	ENSG00000279344.1	RP11-44F14.7	3.59	0.000364	0.0235	0.17	0.16	Intelligence (multi-trait analysis);	chr16:53381126	chr16:53478957~53481550:-
THCA	cis	rs13108904	0.87	rs4974545	ENSG00000254094.1	AC078852.1	-3.59	0.000364	0.0235	-0.2	-0.16	Obesity-related traits;	chr4:1278135	chr4:1356581~1358075:+
THCA	cis	rs1501138	0.597	rs203442	ENSG00000263327.5	TAPT1-AS1	-3.59	0.000364	0.0235	-0.27	-0.16	Systemic juvenile idiopathic arthritis;	chr4:16245045	chr4:16226685~16320140:+
THCA	cis	rs1927790	0.697	rs7981931	ENSG00000247400.3	DNAJC3-AS1	-3.59	0.000364	0.0235	-0.11	-0.16	Body mass index;	chr13:96281922	chr13:95648733~95676925:-
THCA	cis	rs8192917	0.573	rs72681039	ENSG00000258744.1	RP11-80A15.1	-3.59	0.000364	0.0235	-0.26	-0.16	Vitiligo;	chr14:24646696	chr14:24501594~24508688:+
THCA	cis	rs4913250	0.927	rs36001410	ENSG00000256077.4	RP11-335O4.1	-3.59	0.000364	0.0235	-0.21	-0.16	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr12:67537301	chr12:67571197~67589987:-
THCA	cis	rs7089973	0.668	rs10885622	ENSG00000228169.3	PPIAP19	3.59	0.000364	0.0235	0.19	0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114884085	chr10:114690143~114690634:-
THCA	cis	rs10200159	0.793	rs13420929	ENSG00000272606.1	RP11-554J4.1	3.59	0.000364	0.0235	0.31	0.16	Vitiligo;	chr2:55692185	chr2:55617909~55618373:+
THCA	cis	rs10200159	0.793	rs7586115	ENSG00000272606.1	RP11-554J4.1	3.59	0.000364	0.0235	0.31	0.16	Vitiligo;	chr2:55692501	chr2:55617909~55618373:+
THCA	cis	rs939960	0.757	rs4339549	ENSG00000224016.2	RP11-728K20.1	-3.59	0.000364	0.0235	-0.23	-0.16	Neutrophil percentage of white cells;	chr7:150590089	chr7:149891191~149909704:-
THCA	cis	rs9287719	0.967	rs6748036	ENSG00000243819.4	RN7SL832P	3.59	0.000364	0.0235	0.13	0.16	Prostate cancer;	chr2:10577363	chr2:10690344~10692099:+
THCA	cis	rs875971	0.66	rs801193	ENSG00000232546.1	RP11-458F8.1	3.59	0.000364	0.0235	0.13	0.16	Aortic root size;	chr7:66565625	chr7:66848496~66858136:+
THCA	cis	rs7620503	0.659	rs11707350	ENSG00000228561.2	RP11-114M1.1	3.59	0.000364	0.0235	0.2	0.16	Corneal structure;	chr3:177570055	chr3:177683627~177691250:+
THCA	cis	rs2625529	0.938	rs4238447	ENSG00000260037.4	CTD-2524L6.3	-3.59	0.000364	0.0235	-0.23	-0.16	Red blood cell count;	chr15:71839539	chr15:71818396~71823384:+
THCA	cis	rs1862618	0.853	rs252909	ENSG00000234553.1	AC022431.3	-3.59	0.000364	0.0235	-0.19	-0.16	Initial pursuit acceleration;	chr5:56825304	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs252919	ENSG00000234553.1	AC022431.3	-3.59	0.000364	0.0235	-0.19	-0.16	Initial pursuit acceleration;	chr5:56828284	chr5:56536583~56537826:-
THCA	cis	rs786425	0.966	rs786444	ENSG00000278112.1	RP11-972P1.11	3.59	0.000364	0.0235	0.15	0.16	Pubertal anthropometrics;	chr12:123580869	chr12:123519390~123519856:-
THCA	cis	rs10792665	0.512	rs2127363	ENSG00000255503.1	RP11-113K21.4	-3.59	0.000364	0.0235	-0.17	-0.16	Obesity-related traits;	chr11:82929959	chr11:83072402~83097196:-
THCA	cis	rs6545883	0.524	rs2463101	ENSG00000273302.1	RP11-493E12.2	-3.59	0.000364	0.0235	-0.15	-0.16	Tuberculosis;	chr2:61347287	chr2:61199979~61200769:+
THCA	cis	rs2190422	0.551	rs10262559	ENSG00000234715.1	CTB-107G13.1	-3.59	0.000364	0.0235	-0.22	-0.16	Morning vs. evening chronotype;	chr7:103517580	chr7:103445207~103514007:+
THCA	cis	rs10771431	0.817	rs10843149	ENSG00000256427.1	RP11-118B22.4	3.59	0.000364	0.0235	0.18	0.16	Breast size;	chr12:9209471	chr12:9246497~9257960:+
THCA	cis	rs7487075	0.754	rs10880962	ENSG00000272369.1	RP11-446N19.1	3.59	0.000364	0.0235	0.12	0.16	Itch intensity from mosquito bite;	chr12:46379661	chr12:46537502~46652550:+
THCA	cis	rs7131987	0.617	rs3764953	ENSG00000273680.1	RP11-996F15.6	3.59	0.000364	0.0235	0.23	0.16	QT interval;	chr12:29349303	chr12:29332733~29333383:-
THCA	cis	rs704	0.726	rs11080055	ENSG00000279532.1	CTB-96E2.6	3.59	0.000364	0.0235	0.19	0.16	Osteoprotegerin levels;	chr17:28322698	chr17:28373673~28374301:-
THCA	cis	rs1048886	0.938	rs79421004	ENSG00000271967.1	RP11-134K13.4	-3.59	0.000364	0.0235	-0.2	-0.16	Type 2 diabetes;	chr6:70478869	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs17713105	ENSG00000271967.1	RP11-134K13.4	-3.59	0.000364	0.0235	-0.2	-0.16	Type 2 diabetes;	chr6:70484097	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs17713212	ENSG00000271967.1	RP11-134K13.4	-3.59	0.000364	0.0235	-0.2	-0.16	Type 2 diabetes;	chr6:70489129	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs55761717	ENSG00000271967.1	RP11-134K13.4	-3.59	0.000364	0.0235	-0.2	-0.16	Type 2 diabetes;	chr6:70489778	chr6:70596438~70596980:+
THCA	cis	rs11583043	0.918	rs6693456	ENSG00000233184.5	RP11-421L21.3	3.59	0.000364	0.0235	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100959005	chr1:101025878~101087268:+
THCA	cis	rs9987353	0.522	rs2929466	ENSG00000253981.4	ALG1L13P	-3.59	0.000364	0.0235	-0.16	-0.16	Recombination measurement;	chr8:9206389	chr8:8236003~8244667:-
THCA	cis	rs55966801	0.647	rs11602372	ENSG00000277290.1	RP11-326C3.16	-3.59	0.000364	0.0235	-0.2	-0.16	Plateletcrit;	chr11:266957	chr11:243099~243483:-
THCA	cis	rs7586879	0.616	rs6545809	ENSG00000224165.4	DNAJC27-AS1	-3.59	0.000364	0.0235	-0.09	-0.16	Body mass index;	chr2:24903846	chr2:24971390~25039694:+
THCA	cis	rs9287719	0.781	rs6714413	ENSG00000243819.4	RN7SL832P	3.59	0.000364	0.0235	0.13	0.16	Prostate cancer;	chr2:10618733	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.753	rs2018512	ENSG00000243819.4	RN7SL832P	3.59	0.000364	0.0235	0.13	0.16	Prostate cancer;	chr2:10619153	chr2:10690344~10692099:+
THCA	cis	rs1865760	0.516	rs10807007	ENSG00000272810.1	U91328.22	-3.59	0.000364	0.0235	-0.13	-0.16	Height;	chr6:26048703	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.516	rs9379819	ENSG00000272810.1	U91328.22	-3.59	0.000364	0.0235	-0.13	-0.16	Height;	chr6:26049591	chr6:26013241~26013757:+
THCA	cis	rs7737355	0.812	rs10041712	ENSG00000224431.1	AC063976.7	-3.59	0.000364	0.0235	-0.15	-0.16	Life satisfaction;	chr5:131429977	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs6891387	ENSG00000224431.1	AC063976.7	-3.59	0.000364	0.0235	-0.15	-0.16	Life satisfaction;	chr5:131430224	chr5:132199456~132203487:+
THCA	cis	rs3800688	0.527	rs1426470	ENSG00000236753.4	MKLN1-AS	-3.59	0.000364	0.0235	-0.15	-0.16	Hypertension;	chr7:131482811	chr7:131309744~131328222:-
THCA	cis	rs7819412	0.74	rs7844536	ENSG00000255046.1	RP11-297N6.4	3.59	0.000364	0.0235	0.17	0.16	Triglycerides;	chr8:11176519	chr8:11797928~11802568:-
THCA	cis	rs7572733	0.875	rs7587043	ENSG00000231621.1	AC013264.2	-3.59	0.000364	0.0235	-0.15	-0.16	Dermatomyositis;	chr2:197977005	chr2:197197991~197199273:+
THCA	cis	rs7572733	0.935	rs7587598	ENSG00000231621.1	AC013264.2	-3.59	0.000364	0.0235	-0.15	-0.16	Dermatomyositis;	chr2:197977520	chr2:197197991~197199273:+
THCA	cis	rs8030379	1	rs10906983	ENSG00000176700.18	SCAND2P	-3.59	0.000364	0.0235	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900431	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs922664	ENSG00000176700.18	SCAND2P	-3.59	0.000364	0.0235	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900803	chr15:84631451~84647478:+
THCA	cis	rs12532878	0.652	rs11768465	ENSG00000224729.5	PCOLCE-AS1	-3.59	0.000364	0.0235	-0.23	-0.16	Mean corpuscular hemoglobin;	chr7:100600763	chr7:100589402~100604206:-
THCA	cis	rs763121	0.853	rs5750649	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000364	0.0235	-0.13	-0.16	Menopause (age at onset);	chr22:38640764	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs6519124	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000364	0.0235	-0.13	-0.16	Menopause (age at onset);	chr22:38649094	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs5750652	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000364	0.0235	-0.13	-0.16	Menopause (age at onset);	chr22:38652311	chr22:38739003~38749041:+
THCA	cis	rs763121	0.814	rs5757212	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000364	0.0235	-0.13	-0.16	Menopause (age at onset);	chr22:38657752	chr22:38739003~38749041:+
THCA	cis	rs1200921	0.795	rs2486108	ENSG00000272983.1	RP11-508N22.12	-3.59	0.000364	0.0235	-0.14	-0.16	Breast cancer;	chr10:37144369	chr10:38137337~38144399:+
THCA	cis	rs2562456	0.754	rs62107469	ENSG00000268278.1	RP11-420K14.1	3.59	0.000364	0.0235	0.23	0.16	Pain;	chr19:21312699	chr19:21637974~21656300:+
THCA	cis	rs7851660	0.527	rs7870540	ENSG00000214417.4	KRT18P13	-3.59	0.000364	0.0235	-0.15	-0.16	Strep throat;	chr9:97811643	chr9:97698922~97700734:+
THCA	cis	rs1153858	1	rs4271549	ENSG00000275672.1	GATM-AS1	-3.59	0.000364	0.0235	-0.17	-0.16	Homoarginine levels;	chr15:45360532	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs4627277	ENSG00000275672.1	GATM-AS1	-3.59	0.000364	0.0235	-0.17	-0.16	Homoarginine levels;	chr15:45360570	chr15:45378700~45380123:+
THCA	cis	rs14027	0.883	rs13272852	ENSG00000245330.4	KB-1471A8.1	3.59	0.000364	0.0235	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712921	chr8:119867419~119874488:-
THCA	cis	rs2228479	0.85	rs11644526	ENSG00000274627.1	RP11-104N10.2	-3.59	0.000364	0.0235	-0.28	-0.16	Skin colour saturation;	chr16:89832252	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62054257	ENSG00000274627.1	RP11-104N10.2	-3.59	0.000364	0.0235	-0.28	-0.16	Skin colour saturation;	chr16:89833787	chr16:89516797~89522217:+
THCA	cis	rs17023223	0.537	rs10923759	ENSG00000227056.2	RPL6P2	3.59	0.000364	0.0235	0.22	0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119219314~119220096:-
THCA	cis	rs754466	0.58	rs11002301	ENSG00000213514.2	RP11-428P16.2	3.59	0.000364	0.0235	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77814320	chr10:77730766~77734769:+
THCA	cis	rs420259	0.516	rs2369013	ENSG00000260136.4	CTD-2270L9.4	-3.59	0.000364	0.0235	-0.13	-0.16	Bipolar disorder;	chr16:23485025	chr16:23452758~23457606:+
THCA	cis	rs703842	0.56	rs11533604	ENSG00000270039.1	RP11-571M6.17	-3.59	0.000365	0.0235	-0.2	-0.16	Multiple sclerosis;	chr12:57653930	chr12:57803838~57804415:+
THCA	cis	rs9500256	0.625	rs1936228	ENSG00000215190.7	LINC00680	-3.59	0.000365	0.0235	-0.19	-0.16	Eosinophilic esophagitis (pediatric);	chr6:58018478	chr6:57946074~57961501:-
THCA	cis	rs7487075	0.93	rs7308910	ENSG00000272369.1	RP11-446N19.1	3.59	0.000365	0.0235	0.12	0.16	Itch intensity from mosquito bite;	chr12:46444459	chr12:46537502~46652550:+
THCA	cis	rs6840360	0.967	rs1105534	ENSG00000270265.1	RP11-731D1.4	-3.59	0.000365	0.0235	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151684160	chr4:151333775~151353224:-
THCA	cis	rs9450351	0.744	rs7764843	ENSG00000203875.9	SNHG5	-3.59	0.000365	0.0235	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85903875	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	3.59	0.000365	0.0235	0.15	0.16	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
THCA	cis	rs6546886	0.912	rs6756474	ENSG00000235499.1	AC073046.25	-3.59	0.000365	0.0235	-0.16	-0.16	Dialysis-related mortality;	chr2:74055579	chr2:73985132~73986343:+
THCA	cis	rs4604234	0.708	rs6906392	ENSG00000260645.1	RP11-250B2.5	-3.59	0.000365	0.0235	-0.28	-0.16	Cancer;	chr6:80337730	chr6:80466958~80469080:+
THCA	cis	rs2408955	0.522	rs10875721	ENSG00000257735.1	RP11-370I10.6	-3.59	0.000365	0.0235	-0.19	-0.16	Glycated hemoglobin levels;	chr12:48019810	chr12:48350945~48442411:+
THCA	cis	rs7819412	0.74	rs7844536	ENSG00000261451.1	RP11-981G7.1	-3.59	0.000365	0.0235	-0.21	-0.16	Triglycerides;	chr8:11176519	chr8:10433672~10438312:+
THCA	cis	rs6723226	0.552	rs62136336	ENSG00000276517.1	AL133243.2	-3.59	0.000365	0.0235	-0.16	-0.16	Intelligence (multi-trait analysis);	chr2:32579039	chr2:32526504~32529507:+
THCA	cis	rs757978	0.777	rs11693232	ENSG00000235351.1	AC114730.11	-3.59	0.000365	0.0235	-0.17	-0.16	Chronic lymphocytic leukemia;	chr2:241422825	chr2:241724615~241725693:-
THCA	cis	rs340849	0.703	rs1367951	ENSG00000274895.1	RP11-478J18.2	3.59	0.000365	0.0235	0.14	0.16	Alzheimer's disease;	chr1:213952170	chr1:213983793~213986419:-
THCA	cis	rs7957197	0.628	rs692902	ENSG00000278344.1	RP11-18C24.8	3.59	0.000365	0.0235	0.24	0.16	Type 2 diabetes;	chr12:120759321	chr12:120500735~120501090:-
THCA	cis	rs7005380	0.733	rs2037346	ENSG00000279347.1	RP11-85I17.2	-3.59	0.000365	0.0235	-0.18	-0.16	Interstitial lung disease;	chr8:119923212	chr8:119838736~119840385:-
THCA	cis	rs72634501	0.568	rs6679564	ENSG00000182109.6	RP11-69E11.4	-3.59	0.000365	0.0235	-0.15	-0.16	HDL cholesterol;	chr1:39151408	chr1:39522280~39546187:-
THCA	cis	rs875971	0.651	rs313829	ENSG00000232559.3	GS1-124K5.12	-3.59	0.000365	0.0235	-0.17	-0.16	Aortic root size;	chr7:66087510	chr7:66554588~66576923:-
THCA	cis	rs7129556	0.815	rs72947625	ENSG00000254459.1	RP11-91P24.7	3.59	0.000365	0.0235	0.22	0.16	Weight loss (gastric bypass surgery);	chr11:77688557	chr11:77829654~77872262:-
THCA	cis	rs2574985	0.53	rs7071603	ENSG00000279863.1	RP11-521C22.2	3.59	0.000365	0.0235	0.18	0.16	Subjective well-being;	chr10:50512247	chr10:50334538~50336123:+
THCA	cis	rs14027	0.921	rs1433951	ENSG00000245330.4	KB-1471A8.1	3.59	0.000365	0.0235	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119867419~119874488:-
THCA	cis	rs701145	0.537	rs1713842	ENSG00000238755.3	RP11-23D24.2	-3.59	0.000365	0.0235	-0.35	-0.16	Coronary artery disease;	chr3:154068454	chr3:153384934~153980186:-
THCA	cis	rs786425	0.966	rs4456350	ENSG00000278112.1	RP11-972P1.11	3.59	0.000365	0.0235	0.15	0.16	Pubertal anthropometrics;	chr12:123573942	chr12:123519390~123519856:-
THCA	cis	rs6822297	0.905	rs724624	ENSG00000240005.4	RP11-293A21.1	-3.59	0.000365	0.0235	-0.18	-0.16	Obesity-related traits;	chr4:27014099	chr4:26859806~26860599:-
THCA	cis	rs7829975	0.54	rs2976909	ENSG00000254340.1	RP11-10A14.3	-3.59	0.000365	0.0236	-0.19	-0.16	Mood instability;	chr8:8489180	chr8:9141424~9145435:+
THCA	cis	rs4763879	0.778	rs1044771	ENSG00000214776.8	RP11-726G1.1	-3.59	0.000365	0.0236	-0.2	-0.16	Type 1 diabetes;	chr12:9699333	chr12:9467552~9576275:+
THCA	cis	rs2636697	0.5	rs7660502	ENSG00000251175.4	RP11-45L9.1	-3.59	0.000365	0.0236	-0.25	-0.16	Response to antipsychotic treatment;	chr4:105496264	chr4:105746245~105827172:-
THCA	cis	rs853679	0.567	rs3799499	ENSG00000226314.6	ZNF192P1	-3.59	0.000365	0.0236	-0.19	-0.16	Depression;	chr6:28386473	chr6:28161781~28169594:+
THCA	cis	rs853679	0.567	rs2232427	ENSG00000226314.6	ZNF192P1	-3.59	0.000365	0.0236	-0.19	-0.16	Depression;	chr6:28391932	chr6:28161781~28169594:+
THCA	cis	rs12817549	0.781	rs10859561	ENSG00000186076.5	RP11-887P2.3	-3.59	0.000365	0.0236	-0.19	-0.16	Hip circumference adjusted for BMI;	chr12:93713936	chr12:93640822~93641586:-
THCA	cis	rs7147624	1	rs61987807	ENSG00000276116.2	FUT8-AS1	3.59	0.000365	0.0236	0.24	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65740332	chr14:65411170~65412690:-
THCA	cis	rs7246657	0.943	rs28373708	ENSG00000268499.1	CTB-102L5.8	3.59	0.000365	0.0236	0.21	0.16	Coronary artery calcification;	chr19:37485757	chr19:38199836~38200934:+
THCA	cis	rs62380364	0.727	rs1671539	ENSG00000247828.6	TMEM161B-AS1	3.59	0.000365	0.0236	0.12	0.16	Intelligence (multi-trait analysis);	chr5:88872578	chr5:88268895~88436685:+
THCA	cis	rs62380364	0.727	rs797419	ENSG00000247828.6	TMEM161B-AS1	3.59	0.000365	0.0236	0.12	0.16	Intelligence (multi-trait analysis);	chr5:88873138	chr5:88268895~88436685:+
THCA	cis	rs62380364	0.701	rs304138	ENSG00000247828.6	TMEM161B-AS1	3.59	0.000365	0.0236	0.12	0.16	Intelligence (multi-trait analysis);	chr5:88873750	chr5:88268895~88436685:+
THCA	cis	rs9309473	1	rs6711033	ENSG00000273245.1	RP11-434P11.2	3.59	0.000365	0.0236	0.22	0.16	Metabolite levels;	chr2:73519516	chr2:73750256~73750786:-
THCA	cis	rs6137726	0.524	rs1203923	ENSG00000237396.1	LINC01384	-3.59	0.000365	0.0236	-0.15	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22605190	chr20:22587522~22607517:-
THCA	cis	rs11190604	0.767	rs77838250	ENSG00000273030.1	RP11-285F16.1	3.59	0.000366	0.0236	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100420333	chr10:100412934~100413421:+
THCA	cis	rs6479901	0.639	rs871690	ENSG00000272767.1	JMJD1C-AS1	-3.59	0.000366	0.0236	-0.2	-0.16	Intelligence (multi-trait analysis);	chr10:63134299	chr10:63465229~63466563:+
THCA	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	3.59	0.000366	0.0236	0.19	0.16	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
THCA	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	3.59	0.000366	0.0236	0.19	0.16	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	3.59	0.000366	0.0236	0.19	0.16	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
THCA	cis	rs2732480	0.577	rs2634684	ENSG00000257735.1	RP11-370I10.6	-3.59	0.000366	0.0236	-0.19	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48350945~48442411:+
THCA	cis	rs7520050	0.966	rs7556615	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45580892~45580996:-
THCA	cis	rs11673344	0.566	rs256733	ENSG00000268499.1	CTB-102L5.8	-3.59	0.000366	0.0236	-0.17	-0.16	Obesity-related traits;	chr19:37384729	chr19:38199836~38200934:+
THCA	cis	rs4808199	0.901	rs11669516	ENSG00000267481.1	CTC-559E9.5	-3.59	0.000366	0.0236	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19421873	chr19:19788755~19790531:-
THCA	cis	rs7264396	0.528	rs7273880	ENSG00000088340.14	FER1L4	3.59	0.000366	0.0236	0.16	0.16	Total cholesterol levels;	chr20:35963585	chr20:35558737~35607562:-
THCA	cis	rs10875746	0.551	rs11168536	ENSG00000258273.1	RP11-370I10.4	3.59	0.000366	0.0236	0.24	0.16	Longevity (90 years and older);	chr12:48351268	chr12:48333755~48333901:-
THCA	cis	rs13196561	0.586	rs2281425	ENSG00000270987.1	RP3-467N11.2	3.59	0.000366	0.0236	0.24	0.16	Menarche (age at onset);	chr6:100232384	chr6:100889603~100890338:+
THCA	cis	rs1204798	0.685	rs1204785	ENSG00000237021.2	RP3-486I3.7	-3.59	0.000366	0.0236	-0.18	-0.16	Dental caries;	chr6:116211102	chr6:116254207~116256743:+
THCA	cis	rs7927592	0.913	rs4316515	ENSG00000160172.9	FAM86C2P	-3.59	0.000366	0.0236	-0.16	-0.16	Total body bone mineral density;	chr11:68541372	chr11:67791648~67805336:-
THCA	cis	rs7200543	0.961	rs3803573	ENSG00000260735.1	RP11-72I8.1	-3.59	0.000366	0.0236	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:15094411~15109197:+
THCA	cis	rs875971	0.545	rs6460298	ENSG00000230295.1	RP11-458F8.2	3.59	0.000366	0.0236	0.14	0.16	Aortic root size;	chr7:66442783	chr7:66880708~66882981:+
THCA	cis	rs13098911	0.54	rs35831747	ENSG00000226074.4	PRSS44	-3.59	0.000366	0.0236	-0.31	-0.16	Celiac disease;	chr3:45928899	chr3:46809359~46812558:-
THCA	cis	rs853679	0.607	rs67998226	ENSG00000272009.1	RP1-313I6.12	-3.59	0.000366	0.0236	-0.31	-0.16	Depression;	chr6:28270281	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34878803	ENSG00000272009.1	RP1-313I6.12	-3.59	0.000366	0.0236	-0.31	-0.16	Depression;	chr6:28282402	chr6:28078792~28081130:-
THCA	cis	rs853679	0.607	rs34396849	ENSG00000272009.1	RP1-313I6.12	-3.59	0.000366	0.0236	-0.31	-0.16	Depression;	chr6:28283178	chr6:28078792~28081130:-
THCA	cis	rs7665090	0.875	rs6813687	ENSG00000248971.2	KRT8P46	-3.59	0.000366	0.0236	-0.19	-0.16	Primary biliary cholangitis;	chr4:102634455	chr4:102728746~102730171:-
THCA	cis	rs4656958	0.866	rs4656281	ENSG00000233691.2	RP11-312J18.7	3.59	0.000366	0.0236	0.2	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160928050	chr1:160935537~160936126:+
THCA	cis	rs4819052	0.851	rs914218	ENSG00000184274.3	LINC00315	-3.59	0.000366	0.0236	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45300245~45305257:-
THCA	cis	rs2635047	1	rs2684826	ENSG00000280212.1	RP11-49K24.3	-3.59	0.000366	0.0236	-0.16	-0.16	Educational attainment;	chr18:47152776	chr18:47076117~47076594:+
THCA	cis	rs7551222	0.646	rs1398148	ENSG00000240219.1	RP11-430C7.5	3.59	0.000366	0.0236	0.16	0.16	Schizophrenia;	chr1:204489200	chr1:204626775~204629712:+
THCA	cis	rs7520050	0.966	rs6677007	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs4660898	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs11211230	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs35743647	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs7522601	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs10789487	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs34102169	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs4076006	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs11211234	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs11211241	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.902	rs4638056	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.931	rs11576305	ENSG00000281133.1	AL355480.3	3.59	0.000366	0.0236	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45580892~45580996:-
THCA	cis	rs911555	0.755	rs1116095	ENSG00000269940.1	RP11-73M18.7	-3.59	0.000366	0.0236	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs8010247	ENSG00000269940.1	RP11-73M18.7	-3.59	0.000366	0.0236	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs55742283	ENSG00000269940.1	RP11-73M18.7	-3.59	0.000366	0.0236	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs8014800	ENSG00000269940.1	RP11-73M18.7	-3.59	0.000366	0.0236	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs12435516	ENSG00000269940.1	RP11-73M18.7	-3.59	0.000366	0.0236	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs2756135	ENSG00000269940.1	RP11-73M18.7	-3.59	0.000366	0.0236	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103694560~103695170:+
THCA	cis	rs11992162	0.597	rs7011924	ENSG00000227888.4	FAM66A	-3.59	0.000366	0.0236	-0.21	-0.16	Monocyte count;	chr8:11923084	chr8:12362019~12388296:+
THCA	cis	rs1865760	0.516	rs9358903	ENSG00000272810.1	U91328.22	-3.59	0.000366	0.0236	-0.13	-0.16	Height;	chr6:26061721	chr6:26013241~26013757:+
THCA	cis	rs7772697	0.539	rs10499251	ENSG00000223701.3	RAET1E-AS1	-3.59	0.000366	0.0236	-0.23	-0.16	Diabetic retinopathy;	chr6:149083700	chr6:149884431~149919508:+
THCA	cis	rs3853824	0.636	rs6503773	ENSG00000263089.1	RP11-166P13.4	3.59	0.000366	0.0236	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56840540	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.61	rs2271898	ENSG00000263089.1	RP11-166P13.4	3.59	0.000366	0.0236	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56848977	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs4793835	ENSG00000263089.1	RP11-166P13.4	3.59	0.000366	0.0236	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56851481	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs9908291	ENSG00000263089.1	RP11-166P13.4	3.59	0.000366	0.0236	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56853166	chr17:57092145~57096425:-
THCA	cis	rs1823874	1	rs1823874	ENSG00000254744.3	CTD-3076O17.1	-3.59	0.000366	0.0236	-0.17	-0.16	IgG glycosylation;	chr15:99817230	chr15:99970215~99974010:+
THCA	cis	rs17301013	0.9	rs1793300	ENSG00000270084.1	GAS5-AS1	3.59	0.000366	0.0236	0.17	0.16	Systemic lupus erythematosus;	chr1:174768559	chr1:173863248~173863941:+
THCA	cis	rs28643277	0.632	rs1376691	ENSG00000237470.3	DCLRE1CP1	3.59	0.000366	0.0236	0.21	0.16	Periodontitis (CDC/AAP);	chr10:15506545	chr10:15015370~15021863:-
THCA	cis	rs959260	0.557	rs12943902	ENSG00000263843.1	RP11-649A18.12	3.59	0.000366	0.0236	0.18	0.16	Systemic lupus erythematosus;	chr17:75404546	chr17:75271369~75273895:+
THCA	cis	rs7633075	0.614	rs1877648	ENSG00000228956.7	SATB1-AS1	-3.59	0.000366	0.0236	-0.23	-0.16	Symmetrical dimethylarginine levels;	chr3:18543873	chr3:18445024~18920401:+
THCA	cis	rs3126085	0.935	rs4845426	ENSG00000237975.5	FLG-AS1	-3.59	0.000366	0.0236	-0.25	-0.16	Atopic dermatitis;	chr1:152222883	chr1:152168125~152445456:+
THCA	cis	rs7660883	0.897	rs236995	ENSG00000251411.1	RP11-397E7.4	3.59	0.000366	0.0236	0.15	0.16	HDL cholesterol levels;	chr4:87079271	chr4:86913266~86914817:-
THCA	cis	rs739496	0.579	rs7975437	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0236	0.16	0.16	Platelet count;	chr12:111939145	chr12:111839764~111842902:-
THCA	cis	rs12887734	0.524	rs4900599	ENSG00000258735.1	LINC00637	-3.59	0.000366	0.0236	-0.21	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103847721~103858049:+
THCA	cis	rs7759001	0.744	rs7774613	ENSG00000271755.1	RP1-153G14.4	3.59	0.000366	0.0236	0.19	0.16	Glomerular filtration rate (creatinine);	chr6:27518854	chr6:27404010~27406964:-
THCA	cis	rs6787172	0.564	rs4289388	ENSG00000272087.1	RP11-379F4.7	3.59	0.000366	0.0236	0.15	0.16	Subjective well-being;	chr3:158446499	chr3:158693120~158693768:-
THCA	cis	rs1959947	0.793	rs7156811	ENSG00000251363.2	RP11-129M6.1	3.59	0.000366	0.0236	0.22	0.16	Hemostatic factors and hematological phenotypes;	chr14:41071812	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.833	rs7155395	ENSG00000251363.2	RP11-129M6.1	3.59	0.000366	0.0236	0.22	0.16	Hemostatic factors and hematological phenotypes;	chr14:41071826	chr14:40954898~40975877:+
THCA	cis	rs9923856	0.866	rs11648049	ENSG00000263033.2	RP11-396B14.2	-3.59	0.000366	0.0236	-0.14	-0.16	Atopic dermatitis;Adult asthma;	chr16:11106325	chr16:11196177~11224969:+
THCA	cis	rs12121840	0.79	rs79586623	ENSG00000237463.4	RP11-280O1.2	-3.59	0.000367	0.0236	-0.15	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165562775	chr1:165476841~165582155:-
THCA	cis	rs12121840	0.79	rs78906931	ENSG00000237463.4	RP11-280O1.2	-3.59	0.000367	0.0236	-0.15	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165562893	chr1:165476841~165582155:-
THCA	cis	rs2074409	0.509	rs853217	ENSG00000276054.1	RP11-378E13.3	-3.59	0.000367	0.0236	-0.21	-0.16	Response to angiotensin II receptor blocker therapy;	chr17:37495449	chr17:37386886~37387926:+
THCA	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-3.59	0.000367	0.0236	-0.24	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
THCA	cis	rs6732426	0.548	rs6544650	ENSG00000234936.1	AC010883.5	3.59	0.000367	0.0236	0.14	0.16	Hair morphology;	chr2:43389673	chr2:43229573~43233394:+
THCA	cis	rs3087591	0.636	rs736598	ENSG00000263535.1	AK4P1	3.59	0.000367	0.0236	0.19	0.16	Hip circumference;	chr17:31393452	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.639	rs2342052	ENSG00000263535.1	AK4P1	3.59	0.000367	0.0236	0.19	0.16	Hip circumference;	chr17:31393993	chr17:31345521~31346187:+
THCA	cis	rs2898290	0.622	rs17799486	ENSG00000270154.1	RP11-419I17.1	-3.59	0.000367	0.0236	-0.21	-0.16	Systolic blood pressure;	chr8:11482985	chr8:12476462~12477122:+
THCA	cis	rs9863	0.898	rs7301953	ENSG00000270028.1	RP11-380L11.4	3.59	0.000367	0.0236	0.18	0.16	White blood cell count;	chr12:123921324	chr12:123925461~123926083:-
THCA	cis	rs2991971	1	rs667626	ENSG00000234329.1	RP11-767N6.2	-3.59	0.000367	0.0236	-0.15	-0.16	High light scatter reticulocyte count;	chr1:45554879	chr1:45651039~45651826:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000232546.1	RP11-458F8.1	3.59	0.000367	0.0236	0.13	0.16	Aortic root size;	chr7:66603522	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000232546.1	RP11-458F8.1	3.59	0.000367	0.0236	0.13	0.16	Aortic root size;	chr7:66622208	chr7:66848496~66858136:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000232546.1	RP11-458F8.1	3.59	0.000367	0.0236	0.13	0.16	Aortic root size;	chr7:66624003	chr7:66848496~66858136:+
THCA	cis	rs6982240	0.514	rs10481391	ENSG00000253307.1	RP11-10J21.4	3.59	0.000367	0.0236	0.23	0.16	Tonsillectomy;	chr8:141267050	chr8:141252286~141253292:-
THCA	cis	rs9377188	0.619	rs747944	ENSG00000252244.1	RNU7-3P	3.59	0.000367	0.0236	0.19	0.16	Cancer;	chr6:148973337	chr6:149516956~149517017:+
THCA	cis	rs17301013	0.9	rs1754351	ENSG00000270084.1	GAS5-AS1	3.59	0.000367	0.0236	0.17	0.16	Systemic lupus erythematosus;	chr1:174762458	chr1:173863248~173863941:+
THCA	cis	rs17345786	0.667	rs7622940	ENSG00000244119.1	PDCL3P4	3.59	0.000367	0.0236	0.15	0.16	Colonoscopy-negative controls vs population controls;	chr3:101414311	chr3:101712472~101713191:+
THCA	cis	rs793571	0.866	rs11071401	ENSG00000245975.2	RP11-30K9.6	3.59	0.000367	0.0236	0.18	0.16	Schizophrenia;	chr15:58918736	chr15:58768072~58770974:-
THCA	cis	rs2880765	0.835	rs7180923	ENSG00000218052.5	ADAMTS7P4	-3.59	0.000367	0.0236	-0.19	-0.16	Coronary artery disease;	chr15:85507659	chr15:85255369~85330334:-
THCA	cis	rs10089	1	rs13355233	ENSG00000245937.6	LINC01184	-3.59	0.000367	0.0236	-0.18	-0.16	Ileal carcinoids;	chr5:128089658	chr5:127940426~128083172:-
THCA	cis	rs7824557	0.51	rs1435274	ENSG00000261451.1	RP11-981G7.1	-3.59	0.000367	0.0236	-0.21	-0.16	Retinal vascular caliber;	chr8:11378401	chr8:10433672~10438312:+
THCA	cis	rs11102159	0.607	rs724032	ENSG00000259834.1	RP11-284N8.3	3.59	0.000367	0.0236	0.18	0.16	Schizophrenia;	chr1:110791769	chr1:110653560~110657040:-
THCA	cis	rs11102159	0.607	rs12035150	ENSG00000259834.1	RP11-284N8.3	3.59	0.000367	0.0236	0.18	0.16	Schizophrenia;	chr1:110792348	chr1:110653560~110657040:-
THCA	cis	rs1065852	0.526	rs59993856	ENSG00000281538.1	RP4-669P10.20	-3.59	0.000367	0.0236	-0.17	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42007976	chr22:42138060~42139726:+
THCA	cis	rs78905543	0.772	rs11135694	ENSG00000253616.4	RP11-875O11.3	3.59	0.000367	0.0236	0.18	0.16	Mean corpuscular volume;	chr8:23068002	chr8:23071377~23074488:-
THCA	cis	rs8054556	0.76	rs11642740	ENSG00000183604.13	SMG1P5	3.59	0.000367	0.0236	0.17	0.16	Autism spectrum disorder or schizophrenia;	chr16:30049334	chr16:30267553~30335374:-
THCA	cis	rs7903847	0.642	rs4635018	ENSG00000225850.3	RP11-452K12.4	-3.59	0.000367	0.0236	-0.17	-0.16	Granulocyte percentage of myeloid white cells;	chr10:97378082	chr10:97334564~97343203:+
THCA	cis	rs7020830	0.789	rs17408112	ENSG00000260100.1	RP11-220I1.5	-3.59	0.000367	0.0236	-0.2	-0.16	Schizophrenia;	chr9:37114068	chr9:37078813~37079776:-
THCA	cis	rs73173548	0.502	rs34743961	ENSG00000247828.6	TMEM161B-AS1	3.59	0.000367	0.0236	0.15	0.16	Macular telangiectasia type 2;	chr5:88435952	chr5:88268895~88436685:+
THCA	cis	rs80130819	0.688	rs2634672	ENSG00000226413.2	OR8T1P	3.59	0.000367	0.0236	0.24	0.16	Prostate cancer;	chr12:48255857	chr12:48442030~48442947:-
THCA	cis	rs80130819	0.591	rs10875783	ENSG00000226413.2	OR8T1P	3.59	0.000367	0.0236	0.24	0.16	Prostate cancer;	chr12:48255953	chr12:48442030~48442947:-
THCA	cis	rs80130819	0.688	rs2468945	ENSG00000226413.2	OR8T1P	3.59	0.000367	0.0236	0.24	0.16	Prostate cancer;	chr12:48258631	chr12:48442030~48442947:-
THCA	cis	rs80130819	0.748	rs2932095	ENSG00000226413.2	OR8T1P	3.59	0.000367	0.0236	0.24	0.16	Prostate cancer;	chr12:48264429	chr12:48442030~48442947:-
THCA	cis	rs80130819	0.636	rs2732470	ENSG00000226413.2	OR8T1P	3.59	0.000367	0.0236	0.24	0.16	Prostate cancer;	chr12:48270974	chr12:48442030~48442947:-
THCA	cis	rs80130819	0.748	rs2732487	ENSG00000226413.2	OR8T1P	3.59	0.000367	0.0236	0.24	0.16	Prostate cancer;	chr12:48292958	chr12:48442030~48442947:-
THCA	cis	rs3758911	0.828	rs10890695	ENSG00000255353.1	RP11-382M14.1	-3.59	0.000367	0.0236	-0.21	-0.16	Coronary artery disease;	chr11:107294923	chr11:107176286~107177530:+
THCA	cis	rs2921073	0.604	rs2979140	ENSG00000233609.3	RP11-62H7.2	3.59	0.000367	0.0236	0.16	0.16	Parkinson's disease;	chr8:8409692	chr8:8961200~8979025:+
THCA	cis	rs2933343	0.533	rs13086121	ENSG00000231305.3	RP11-723O4.2	3.59	0.000367	0.0236	0.18	0.16	IgG glycosylation;	chr3:128985447	chr3:128861313~128871540:-
THCA	cis	rs4588572	0.644	rs10942856	ENSG00000245556.2	SCAMP1-AS1	3.59	0.000367	0.0236	0.13	0.16	Triglycerides;	chr5:78450376	chr5:78342365~78360507:-
THCA	cis	rs2066819	1	rs2629447	ENSG00000257303.1	RP11-977G19.11	3.59	0.000367	0.0236	0.24	0.16	Psoriasis vulgaris;	chr12:56307025	chr12:56300142~56314808:+
THCA	cis	rs2066819	0.818	rs703830	ENSG00000257303.1	RP11-977G19.11	3.59	0.000367	0.0236	0.24	0.16	Psoriasis vulgaris;	chr12:56308088	chr12:56300142~56314808:+
THCA	cis	rs2066819	0.901	rs773665	ENSG00000257303.1	RP11-977G19.11	3.59	0.000367	0.0236	0.24	0.16	Psoriasis vulgaris;	chr12:56323682	chr12:56300142~56314808:+
THCA	cis	rs9796	0.87	rs12905926	ENSG00000247556.5	OIP5-AS1	-3.59	0.000367	0.0236	-0.13	-0.16	Menopause (age at onset);	chr15:40991210	chr15:41283990~41309737:+
THCA	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	3.59	0.000367	0.0237	0.15	0.16	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	3.59	0.000367	0.0237	0.15	0.16	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	3.59	0.000367	0.0237	0.15	0.16	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	3.59	0.000367	0.0237	0.15	0.16	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	3.59	0.000367	0.0237	0.15	0.16	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
THCA	cis	rs74181299	0.75	rs2723067	ENSG00000237979.1	AC007389.1	-3.59	0.000367	0.0237	-0.2	-0.16	Pulse pressure;	chr2:65050817	chr2:65500993~65502138:-
THCA	cis	rs7395662	0.782	rs4882064	ENSG00000200090.1	Y_RNA	3.59	0.000367	0.0237	0.11	0.16	HDL cholesterol;	chr11:48434205	chr11:47726894~47726992:-
THCA	cis	rs2135507	0.515	rs12647788	ENSG00000270480.1	RP11-57B24.1	-3.59	0.000367	0.0237	-0.25	-0.16	Juvenile osteochondritis dissecans;	chr4:82611223	chr4:82691737~82692468:+
THCA	cis	rs6598541	0.963	rs1007212	ENSG00000278090.1	RP11-6O2.2	3.59	0.000367	0.0237	0.15	0.16	Urate levels;	chr15:98740689	chr15:99028538~99031053:+
THCA	cis	rs8060686	0.858	rs7198357	ENSG00000261396.1	CTD-2012K14.2	3.59	0.000367	0.0237	0.25	0.16	HDL cholesterol;Metabolic syndrome;	chr16:67850716	chr16:67538557~67540106:-
THCA	cis	rs61160187	0.582	rs4700407	ENSG00000251279.1	CTC-436P18.1	3.59	0.000367	0.0237	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:61162070~61232040:+
THCA	cis	rs11048434	0.698	rs10842537	ENSG00000245105.2	A2M-AS1	3.59	0.000367	0.0237	0.13	0.16	Sjögren's syndrome;	chr12:8913562	chr12:9065177~9068060:+
THCA	cis	rs1501911	0.509	rs330422	ENSG00000241597.2	CTD-2007H13.1	-3.59	0.000367	0.0237	-0.21	-0.16	Lung function (FEV1/FVC);	chr5:98859184	chr5:98954394~98954972:+
THCA	cis	rs2625529	0.668	rs12591313	ENSG00000260037.4	CTD-2524L6.3	-3.59	0.000367	0.0237	-0.23	-0.16	Red blood cell count;	chr15:72264405	chr15:71818396~71823384:+
THCA	cis	rs2625529	0.668	rs12591338	ENSG00000260037.4	CTD-2524L6.3	-3.59	0.000367	0.0237	-0.23	-0.16	Red blood cell count;	chr15:72264506	chr15:71818396~71823384:+
THCA	cis	rs9796	0.87	rs12910027	ENSG00000247556.5	OIP5-AS1	-3.59	0.000367	0.0237	-0.13	-0.16	Menopause (age at onset);	chr15:40991619	chr15:41283990~41309737:+
THCA	cis	rs9309473	1	rs11899740	ENSG00000273245.1	RP11-434P11.2	3.59	0.000367	0.0237	0.23	0.16	Metabolite levels;	chr2:73404084	chr2:73750256~73750786:-
THCA	cis	rs3806843	0.576	rs251376	ENSG00000278901.1	AC005609.17	-3.59	0.000367	0.0237	-0.19	-0.16	Depressive symptoms (multi-trait analysis);	chr5:140874104	chr5:140878073~140882642:-
THCA	cis	rs1850744	0.702	rs6836184	ENSG00000163612.10	FAM86KP	-3.59	0.000367	0.0237	-0.36	-0.16	Economic and political preferences;	chr4:9632087	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.536	rs6843869	ENSG00000163612.10	FAM86KP	-3.59	0.000367	0.0237	-0.36	-0.16	Economic and political preferences;	chr4:9632827	chr4:9153296~9165451:+
THCA	cis	rs4791641	0.756	rs1132554	ENSG00000178977.3	LINC00324	3.59	0.000367	0.0237	0.18	0.16	Red blood cell count;LDL cholesterol;Hematocrit;Hemoglobin concentration;LDL cholesterol levels;	chr17:8270449	chr17:8220642~8224043:-
THCA	cis	rs6929812	0.702	rs1569566	ENSG00000271755.1	RP1-153G14.4	3.59	0.000367	0.0237	0.18	0.16	Neuroticism (multi-trait analysis);	chr6:27432252	chr6:27404010~27406964:-
THCA	cis	rs669446	0.529	rs6697354	ENSG00000237950.1	RP11-7O11.3	3.59	0.000367	0.0237	0.14	0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:43685344	chr1:43944370~43946551:-
THCA	cis	rs479105	0.713	rs35201994	ENSG00000278356.1	RP11-372B4.3	3.59	0.000367	0.0237	0.16	0.16	Gut microbiota (bacterial taxa);	chr12:3269727	chr12:2885819~2886329:+
THCA	cis	rs9464760	0.527	rs9476757	ENSG00000271888.1	RP11-560J1.2	-3.59	0.000367	0.0237	-0.23	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr6:15157058	chr6:15243923~15245000:-
THCA	cis	rs858239	0.73	rs10255155	ENSG00000230042.1	AK3P3	3.59	0.000367	0.0237	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23129178~23129841:+
THCA	cis	rs9487094	0.643	rs35146243	ENSG00000223537.2	RP5-919F19.5	-3.59	0.000367	0.0237	-0.16	-0.16	Height;	chr6:109477209	chr6:109487906~109506800:+
THCA	cis	rs9860428	0.526	rs12497951	ENSG00000240057.4	RP11-572M11.4	-3.59	0.000367	0.0237	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112937216	chr3:113019532~113183301:+
THCA	cis	rs55966801	0.647	rs57522649	ENSG00000277290.1	RP11-326C3.16	-3.59	0.000368	0.0237	-0.2	-0.16	Plateletcrit;	chr11:265777	chr11:243099~243483:-
THCA	cis	rs55966801	0.647	rs7928791	ENSG00000277290.1	RP11-326C3.16	-3.59	0.000368	0.0237	-0.2	-0.16	Plateletcrit;	chr11:266248	chr11:243099~243483:-
THCA	cis	rs8177876	0.749	rs2911159	ENSG00000261838.4	RP11-303E16.6	-3.59	0.000368	0.0237	-0.26	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057653	chr16:81069854~81076598:+
THCA	cis	rs266717	0.816	rs710450	ENSG00000234197.1	ETV5-AS1	-3.59	0.000368	0.0237	-0.13	-0.16	Adiponectin levels;	chr3:186804844	chr3:186079170~186080947:+
THCA	cis	rs929354	0.772	rs1182441	ENSG00000224629.1	RP5-1142J19.2	3.59	0.000368	0.0237	0.16	0.16	Body mass index;	chr7:157233956	chr7:157263022~157263229:-
THCA	cis	rs917063	0.773	rs7144242	ENSG00000269927.1	RP6-91H8.3	-3.59	0.000368	0.0237	-0.22	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:71171626	chr14:71141125~71143253:-
THCA	cis	rs1536827	0.841	rs3813866	ENSG00000278518.1	RP11-108K14.12	-3.59	0.000368	0.0237	-0.38	-0.16	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr10:133525830	chr10:133526259~133527513:-
THCA	cis	rs684232	0.583	rs2543776	ENSG00000231784.7	DBIL5P	3.59	0.000368	0.0237	0.18	0.16	Prostate cancer;	chr17:653909	chr17:752660~755336:+
THCA	cis	rs600231	0.651	rs2846862	ENSG00000254614.2	AP003068.23	3.59	0.000368	0.0237	0.21	0.16	Bone mineral density;	chr11:65452319	chr11:65177606~65181834:-
THCA	cis	rs7707921	1	rs4703879	ENSG00000251374.1	RPS23P5	3.59	0.000368	0.0237	0.24	0.16	Breast cancer;	chr5:82257996	chr5:82265157~82265259:-
THCA	cis	rs6802315	0.575	rs1864508	ENSG00000271778.1	RP11-379F4.8	3.59	0.000368	0.0237	0.16	0.16	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158782547~158783124:+
THCA	cis	rs6598955	0.694	rs4659416	ENSG00000236782.4	RP11-96L14.7	-3.59	0.000368	0.0237	-0.2	-0.16	Obesity-related traits;	chr1:26254446	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.724	rs884533	ENSG00000236782.4	RP11-96L14.7	-3.59	0.000368	0.0237	-0.2	-0.16	Obesity-related traits;	chr1:26259166	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.724	rs7547520	ENSG00000236782.4	RP11-96L14.7	-3.59	0.000368	0.0237	-0.2	-0.16	Obesity-related traits;	chr1:26265819	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.67	rs11247892	ENSG00000236782.4	RP11-96L14.7	-3.59	0.000368	0.0237	-0.2	-0.16	Obesity-related traits;	chr1:26266236	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.724	rs12096059	ENSG00000236782.4	RP11-96L14.7	-3.59	0.000368	0.0237	-0.2	-0.16	Obesity-related traits;	chr1:26270218	chr1:26169947~26171821:-
THCA	cis	rs9970896	0.579	rs4660121	ENSG00000237845.1	RP5-940F7.2	-3.59	0.000368	0.0237	-0.27	-0.16	Monocyte percentage of white cells;	chr1:235881929	chr1:235942553~235943805:-
THCA	cis	rs603446	0.967	rs3741301	ENSG00000254851.1	RP11-109L13.1	-3.59	0.000368	0.0237	-0.22	-0.16	Triglycerides;	chr11:116760675	chr11:117135528~117138582:+
THCA	cis	rs1737890	0.778	rs6087882	ENSG00000235217.6	TSPY26P	-3.59	0.000368	0.0237	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr20:32336989	chr20:32186477~32190527:-
THCA	cis	rs2841277	0.771	rs2819469	ENSG00000258701.1	LINC00638	-3.59	0.000368	0.0237	-0.17	-0.16	Rheumatoid arthritis;	chr14:104928522	chr14:104821201~104823718:+
THCA	cis	rs72827839	1	rs72827876	ENSG00000228782.6	CTD-2026D20.3	3.59	0.000368	0.0237	0.2	0.16	Ease of getting up in the morning;	chr17:48446612	chr17:47450568~47492492:-
THCA	cis	rs72827839	1	rs72827877	ENSG00000228782.6	CTD-2026D20.3	3.59	0.000368	0.0237	0.2	0.16	Ease of getting up in the morning;	chr17:48447542	chr17:47450568~47492492:-
THCA	cis	rs11633886	0.656	rs10153037	ENSG00000259200.1	RP11-718O11.1	-3.59	0.000368	0.0237	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45832155	chr15:45705078~45931069:+
THCA	cis	rs6456156	0.583	rs7748224	ENSG00000235272.1	FAM103A2P	3.59	0.000368	0.0237	0.22	0.16	Primary biliary cholangitis;	chr6:167043372	chr6:166586124~166586477:-
THCA	cis	rs2310173	0.521	rs2110564	ENSG00000281162.1	LINC01127	-3.59	0.000368	0.0237	-0.13	-0.16	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102044088	chr2:101962056~101987167:+
THCA	cis	rs1433188	0.818	rs1433193	ENSG00000253582.1	RP11-649G15.2	3.59	0.000368	0.0237	0.19	0.16	Subjective well-being;	chr8:107404634	chr8:106520474~106657548:-
THCA	cis	rs4789693	0.938	rs8078595	ENSG00000279744.1	RP13-20L14.10	-3.59	0.000368	0.0237	-0.14	-0.16	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82462601~82464255:+
THCA	cis	rs7089973	0.604	rs55759483	ENSG00000228169.3	PPIAP19	3.59	0.000368	0.0237	0.19	0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114813664	chr10:114690143~114690634:-
THCA	cis	rs10496034	0.541	rs7561112	ENSG00000237887.1	AC092839.1	-3.59	0.000368	0.0237	-0.28	-0.16	Refractive astigmatism;	chr2:54689481	chr2:54529343~54529801:+
THCA	cis	rs4660214	0.666	rs11205698	ENSG00000228060.1	RP11-69E11.8	3.59	0.000368	0.0237	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39158708	chr1:39565160~39573203:+
THCA	cis	rs9902453	0.74	rs2254414	ENSG00000263603.1	CTD-2349P21.5	-3.59	0.000368	0.0237	-0.19	-0.16	Coffee consumption (cups per day);	chr17:29734112	chr17:30729469~30731202:+
THCA	cis	rs9788682	0.747	rs2656071	ENSG00000261143.1	ADAMTS7P3	3.59	0.000368	0.0237	0.24	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78453001	chr15:77976042~77993057:+
THCA	cis	rs792448	0.59	rs36010081	ENSG00000226251.4	RP11-15I11.3	-3.59	0.000368	0.0237	-0.28	-0.16	White blood cell count (basophil);	chr1:212250440	chr1:212225278~212238977:-
THCA	cis	rs1062177	1	rs17741826	ENSG00000272112.1	CTB-113P19.5	-3.59	0.000368	0.0237	-0.14	-0.16	Preschool internalizing problems;	chr5:151769701	chr5:151724831~151725356:-
THCA	cis	rs8031584	0.678	rs798086	ENSG00000270015.1	RP11-540B6.6	3.59	0.000368	0.0237	0.13	0.16	Huntington's disease progression;	chr15:30837008	chr15:30926514~30928407:+
THCA	cis	rs12544026	0.515	rs513159	ENSG00000253669.3	KB-1732A1.1	-3.59	0.000368	0.0237	-0.18	-0.16	Major depression and alcohol dependence;	chr8:101887248	chr8:102805517~102809971:+
THCA	cis	rs9341808	0.754	rs9361591	ENSG00000260645.1	RP11-250B2.5	3.59	0.000368	0.0237	0.14	0.16	Sitting height ratio;	chr6:80243538	chr6:80466958~80469080:+
THCA	cis	rs9333290	0.897	rs13028817	ENSG00000259915.2	RP11-410E4.1	3.59	0.000368	0.0237	0.19	0.16	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186682772	chr2:186354570~186356773:-
THCA	cis	rs9333290	0.897	rs13016261	ENSG00000259915.2	RP11-410E4.1	3.59	0.000368	0.0237	0.19	0.16	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186684566	chr2:186354570~186356773:-
THCA	cis	rs9333290	0.93	rs12615659	ENSG00000259915.2	RP11-410E4.1	3.59	0.000368	0.0237	0.19	0.16	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186686580	chr2:186354570~186356773:-
THCA	cis	rs9333290	0.893	rs12998294	ENSG00000259915.2	RP11-410E4.1	3.59	0.000368	0.0237	0.19	0.16	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186690852	chr2:186354570~186356773:-
THCA	cis	rs9902453	0.765	rs2628167	ENSG00000263603.1	CTD-2349P21.5	-3.59	0.000368	0.0237	-0.19	-0.16	Coffee consumption (cups per day);	chr17:29737480	chr17:30729469~30731202:+
THCA	cis	rs2562456	0.755	rs11670868	ENSG00000268521.1	VN1R83P	3.59	0.000368	0.0237	0.16	0.16	Pain;	chr19:21373613	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs55961038	ENSG00000268521.1	VN1R83P	3.59	0.000368	0.0237	0.16	0.16	Pain;	chr19:21375205	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs2358993	ENSG00000268521.1	VN1R83P	3.59	0.000368	0.0237	0.16	0.16	Pain;	chr19:21375367	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs11672583	ENSG00000268521.1	VN1R83P	3.59	0.000368	0.0237	0.16	0.16	Pain;	chr19:21379363	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs17680605	ENSG00000268521.1	VN1R83P	3.59	0.000368	0.0237	0.16	0.16	Pain;	chr19:21379646	chr19:21289554~21289998:-
THCA	cis	rs372883	0.648	rs2832297	ENSG00000176054.6	RPL23P2	3.59	0.000368	0.0237	0.15	0.16	Pancreatic cancer;	chr21:29370675	chr21:28997613~28998033:-
THCA	cis	rs8105895	0.932	rs8105913	ENSG00000269345.1	VN1R85P	3.59	0.000368	0.0237	0.23	0.16	Body mass index (change over time);	chr19:22018690	chr19:22174766~22175191:-
THCA	cis	rs7615952	0.932	rs11922218	ENSG00000248787.1	RP11-666A20.4	-3.59	0.000368	0.0237	-0.28	-0.16	Blood pressure (smoking interaction);	chr3:125912446	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.866	rs11922276	ENSG00000248787.1	RP11-666A20.4	-3.59	0.000368	0.0237	-0.28	-0.16	Blood pressure (smoking interaction);	chr3:125912483	chr3:125908005~125910272:-
THCA	cis	rs72827839	0.74	rs72823509	ENSG00000266601.1	RP11-6N17.3	3.59	0.000368	0.0237	0.2	0.16	Ease of getting up in the morning;	chr17:47967223	chr17:47929682~47933106:-
THCA	cis	rs9393813	0.528	rs4713109	ENSG00000271755.1	RP1-153G14.4	3.59	0.000368	0.0237	0.19	0.16	Bipolar disorder;	chr6:27508489	chr6:27404010~27406964:-
THCA	cis	rs1941184	0.526	rs9956575	ENSG00000263823.1	RP11-326K13.4	-3.59	0.000368	0.0237	-0.17	-0.16	Parkinson's disease (age of onset);	chr18:31450534	chr18:31942575~31944156:+
THCA	cis	rs9309473	0.5	rs10865398	ENSG00000273245.1	RP11-434P11.2	-3.59	0.000368	0.0237	-0.2	-0.16	Metabolite levels;	chr2:73514370	chr2:73750256~73750786:-
THCA	cis	rs7178375	1	rs4779797	ENSG00000215302.7	CTD-3092A11.1	3.59	0.000368	0.0237	0.22	0.16	Hypertriglyceridemia;	chr15:30916222	chr15:30470779~30507623:+
THCA	cis	rs7919656	0.662	rs2620907	ENSG00000228403.1	RP11-563N6.6	-3.59	0.000369	0.0237	-0.17	-0.16	Clinically amyopathic dermatomyositis;	chr10:48844596	chr10:48878022~48878649:+
THCA	cis	rs7919656	0.662	rs2127592	ENSG00000228403.1	RP11-563N6.6	-3.59	0.000369	0.0237	-0.17	-0.16	Clinically amyopathic dermatomyositis;	chr10:48845778	chr10:48878022~48878649:+
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000281021.1	RP1-12G14.9	-3.59	0.000369	0.0237	-0.17	-0.16	Lung cancer;	chr6:149616860	chr6:149576089~149590864:-
THCA	cis	rs73001065	0.591	rs57009615	ENSG00000267481.1	CTC-559E9.5	-3.59	0.000369	0.0237	-0.2	-0.16	LDL cholesterol;	chr19:19502813	chr19:19788755~19790531:-
THCA	cis	rs7474896	1	rs9418289	ENSG00000276805.1	RP11-291L22.6	3.59	0.000369	0.0237	0.25	0.16	Obesity (extreme);	chr10:37820877	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs10827831	ENSG00000276805.1	RP11-291L22.6	3.59	0.000369	0.0237	0.25	0.16	Obesity (extreme);	chr10:37821885	chr10:38451030~38451785:+
THCA	cis	rs867186	1	rs8118978	ENSG00000126005.14	MMP24-AS1	-3.59	0.000369	0.0237	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34986655	chr20:35216462~35278131:-
THCA	cis	rs854765	0.547	rs6502633	ENSG00000281749.1	Y_RNA	3.59	0.000369	0.0237	0.21	0.16	Total body bone mineral density;	chr17:18037723	chr17:18001101~18001195:-
THCA	cis	rs10200159	0.793	rs12615063	ENSG00000272606.1	RP11-554J4.1	3.59	0.000369	0.0237	0.3	0.16	Vitiligo;	chr2:55680347	chr2:55617909~55618373:+
THCA	cis	rs478304	0.619	rs10791822	ENSG00000255557.1	RP11-770G2.2	3.59	0.000369	0.0237	0.2	0.16	Acne (severe);	chr11:65661235	chr11:65745729~65771585:+
THCA	cis	rs8057939	0.593	rs27801	ENSG00000260614.1	RP11-491F9.1	3.59	0.000369	0.0237	0.23	0.16	Prostate cancer (SNP x SNP interaction);	chr16:49399893	chr16:49287430~49290227:+
THCA	cis	rs12493885	0.769	rs61791504	ENSG00000243069.6	ARHGEF26-AS1	-3.59	0.000369	0.0237	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154027748	chr3:154024401~154121332:-
THCA	cis	rs12539814	1	rs12666210	ENSG00000204959.4	ARHGEF34P	-3.59	0.000369	0.0237	-0.22	-0.16	Diastolic blood pressure;	chr7:144435635	chr7:144272445~144286966:-
THCA	cis	rs9634489	0.617	rs4771941	ENSG00000247400.3	DNAJC3-AS1	-3.59	0.000369	0.0237	-0.1	-0.16	Body mass index;	chr13:96397862	chr13:95648733~95676925:-
THCA	cis	rs11717455	1	rs3922579	ENSG00000232439.1	RPL18AP7	-3.59	0.000369	0.0237	-0.26	-0.16	Systemic lupus erythematosus;	chr3:38819782	chr3:38526802~38527325:-
THCA	cis	rs17122278	0.544	rs499189	ENSG00000243431.1	RPL5P30	-3.59	0.000369	0.0237	-0.17	-0.16	Total cholesterol levels;	chr11:118486899	chr11:118560690~118561580:+
THCA	cis	rs1865760	0.516	rs9393683	ENSG00000272810.1	U91328.22	-3.59	0.000369	0.0237	-0.13	-0.16	Height;	chr6:26065970	chr6:26013241~26013757:+
THCA	cis	rs10515778	0.95	rs72814002	ENSG00000280834.1	U6	3.59	0.000369	0.0237	0.28	0.16	Inflammatory skin disease;	chr5:159215633	chr5:160072268~160072364:+
THCA	cis	rs17685	0.753	rs10233282	ENSG00000227038.2	AC005077.12	3.59	0.000369	0.0237	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76160763	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs10251863	ENSG00000227038.2	AC005077.12	3.59	0.000369	0.0237	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76160874	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs9691174	ENSG00000227038.2	AC005077.12	3.59	0.000369	0.0237	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76161087	chr7:76090431~76108779:-
THCA	cis	rs17685	0.664	rs9801113	ENSG00000227038.2	AC005077.12	3.59	0.000369	0.0237	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76162713	chr7:76090431~76108779:-
THCA	cis	rs17685	0.558	rs60787921	ENSG00000227038.2	AC005077.12	3.59	0.000369	0.0237	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76163526	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs56965035	ENSG00000227038.2	AC005077.12	3.59	0.000369	0.0237	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76166352	chr7:76090431~76108779:-
THCA	cis	rs17685	0.672	rs56343450	ENSG00000227038.2	AC005077.12	3.59	0.000369	0.0237	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76166917	chr7:76090431~76108779:-
THCA	cis	rs9863	0.896	rs4765148	ENSG00000269938.1	RP11-214K3.20	-3.59	0.000369	0.0238	-0.19	-0.16	White blood cell count;	chr12:123994090	chr12:123968023~123968579:-
THCA	cis	rs1003719	0.591	rs1053966	ENSG00000270116.1	AP001429.1	3.59	0.000369	0.0238	0.19	0.16	Eye color traits;	chr21:37195708	chr21:37100814~37101343:+
THCA	cis	rs6738627	1	rs6752978	ENSG00000223318.1	RNA5SP111	3.59	0.000369	0.0238	0.21	0.16	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164696432	chr2:164895677~164895777:-
THCA	cis	rs5753037	0.615	rs131279	ENSG00000273350.1	RP4-539M6.20	-3.59	0.000369	0.0238	-0.19	-0.16	Type 1 diabetes;	chr22:29759262	chr22:30420512~30420912:+
THCA	cis	rs9650657	0.504	rs10109167	ENSG00000261451.1	RP11-981G7.1	-3.59	0.000369	0.0238	-0.21	-0.16	Neuroticism;	chr8:11176016	chr8:10433672~10438312:+
THCA	cis	rs1357692	0.899	rs2971894	ENSG00000238250.1	ST6GAL2-IT1	3.59	0.000369	0.0238	0.16	0.16	Alzheimer's disease;	chr2:107068501	chr2:106822923~106825031:-
THCA	cis	rs8054556	0.74	rs8052502	ENSG00000273724.1	RP11-347C12.12	-3.59	0.000369	0.0238	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29918407	chr16:30336400~30343336:+
THCA	cis	rs11992162	0.613	rs6601634	ENSG00000227888.4	FAM66A	-3.59	0.000369	0.0238	-0.21	-0.16	Monocyte count;	chr8:11948947	chr8:12362019~12388296:+
THCA	cis	rs3748682	1	rs3748682	ENSG00000252448.1	SNORA63	3.59	0.000369	0.0238	0.21	0.16	Hypothyroidism;	chr1:37814315	chr1:37884237~37884317:+
THCA	cis	rs56309584	0.71	rs7211247	ENSG00000271002.1	RP11-599B13.8	-3.59	0.000369	0.0238	-0.21	-0.16	Initial pursuit acceleration;	chr17:8240835	chr17:8199123~8199437:-
THCA	cis	rs7246657	0.882	rs10412043	ENSG00000268499.1	CTB-102L5.8	3.59	0.000369	0.0238	0.21	0.16	Coronary artery calcification;	chr19:37335724	chr19:38199836~38200934:+
THCA	cis	rs1790761	0.505	rs7938563	ENSG00000255318.1	RP11-655M14.13	-3.59	0.000369	0.0238	-0.18	-0.16	Mean corpuscular volume;	chr11:67536660	chr11:67618279~67627304:-
THCA	cis	rs5770917	1	rs5770922	ENSG00000279182.1	XX-C00717C00720L.1	3.59	0.000369	0.0238	0.28	0.16	Narcolepsy;	chr22:50584979	chr22:50316035~50317025:+
THCA	cis	rs911555	0.723	rs4906320	ENSG00000269940.1	RP11-73M18.7	-3.59	0.000369	0.0238	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103694560~103695170:+
THCA	cis	rs7781557	0.582	rs2411061	ENSG00000170629.13	DPY19L2P2	-3.59	0.000369	0.0238	-0.21	-0.16	Colorectal adenoma (advanced);	chr7:102973043	chr7:103175133~103280410:-
THCA	cis	rs8113308	0.515	rs60581730	ENSG00000275055.1	CTC-471J1.11	-3.59	0.000369	0.0238	-0.23	-0.16	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51937883	chr19:52049007~52049754:+
THCA	cis	rs11673344	0.504	rs8099987	ENSG00000233527.7	ZNF529-AS1	3.59	0.000369	0.0238	0.14	0.16	Obesity-related traits;	chr19:37132570	chr19:36573070~36594708:+
THCA	cis	rs7191700	0.836	rs12708722	ENSG00000262636.1	CTD-3088G3.4	3.59	0.000369	0.0238	0.23	0.16	Multiple sclerosis;	chr16:11335048	chr16:11380859~11381118:-
THCA	cis	rs7191700	0.836	rs10163410	ENSG00000262636.1	CTD-3088G3.4	3.59	0.000369	0.0238	0.23	0.16	Multiple sclerosis;	chr16:11336758	chr16:11380859~11381118:-
THCA	cis	rs9532669	0.89	rs9594457	ENSG00000229473.2	RGS17P1	3.59	0.000369	0.0238	0.2	0.16	Cervical cancer;	chr13:40920439	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9594458	ENSG00000229473.2	RGS17P1	3.59	0.000369	0.0238	0.2	0.16	Cervical cancer;	chr13:40920448	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.926	rs9590562	ENSG00000229473.2	RGS17P1	3.59	0.000369	0.0238	0.2	0.16	Cervical cancer;	chr13:40920503	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.963	rs12857052	ENSG00000229473.2	RGS17P1	3.59	0.000369	0.0238	0.2	0.16	Cervical cancer;	chr13:40920831	chr13:40992779~40993331:-
THCA	cis	rs4948275	0.597	rs2251482	ENSG00000233643.2	RP11-491H19.1	-3.59	0.000369	0.0238	-0.18	-0.16	Night sleep phenotypes;	chr10:61606156	chr10:61781745~61821246:-
THCA	cis	rs5758511	0.68	rs5758692	ENSG00000205702.9	CYP2D7	3.59	0.000369	0.0238	0.15	0.16	Birth weight;	chr22:42273023	chr22:42140203~42144577:-
THCA	cis	rs10844706	0.699	rs10844610	ENSG00000257027.1	RP11-705C15.3	3.59	0.000369	0.0238	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9724016	chr12:9658567~9662085:+
THCA	cis	rs854765	0.505	rs4506969	ENSG00000281749.1	Y_RNA	3.59	0.000369	0.0238	0.21	0.16	Total body bone mineral density;	chr17:17996525	chr17:18001101~18001195:-
THCA	cis	rs4705962	0.918	rs11242122	ENSG00000230612.2	AC004237.1	-3.59	0.000369	0.0238	-0.21	-0.16	Atopic dermatitis;	chr5:132689016	chr5:132688681~132723725:+
THCA	cis	rs4287000	0.508	rs17533702	ENSG00000227603.1	RP11-165J3.6	-3.59	0.000369	0.0238	-0.17	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93598946	chr9:93435332~93437121:-
THCA	cis	rs11168618	0.904	rs4359253	ENSG00000240399.1	RP1-228P16.1	3.59	0.000369	0.0238	0.17	0.16	Adiponectin levels;	chr12:48533925	chr12:48054813~48055591:-
THCA	cis	rs11168618	0.904	rs12366459	ENSG00000240399.1	RP1-228P16.1	3.59	0.000369	0.0238	0.17	0.16	Adiponectin levels;	chr12:48537117	chr12:48054813~48055591:-
THCA	cis	rs57709857	0.915	rs9198	ENSG00000272092.1	RP11-350N15.5	-3.59	0.000369	0.0238	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38263203	chr8:38382364~38383461:+
THCA	cis	rs4664293	1	rs10432413	ENSG00000230783.1	AC009961.2	-3.59	0.000369	0.0238	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159639243	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs13397722	ENSG00000230783.1	AC009961.2	-3.59	0.000369	0.0238	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159659140	chr2:159689217~159690291:-
THCA	cis	rs12681963	0.688	rs6994064	ENSG00000272375.1	RP11-51J9.6	-3.59	0.000369	0.0238	-0.24	-0.16	Migraine;	chr8:30199673	chr8:30197404~30198048:+
THCA	cis	rs12438945	0.703	rs55721632	ENSG00000277548.1	RP11-139H15.6	-3.59	0.00037	0.0238	-0.26	-0.16	Glucose homeostasis traits;	chr15:54897156	chr15:55346347~55346752:-
THCA	cis	rs2911280	0.764	rs9926999	ENSG00000278985.1	RP11-303E16.9	-3.59	0.00037	0.0238	-0.3	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81531332	chr16:80982319~80984094:-
THCA	cis	rs453301	0.624	rs7014430	ENSG00000253981.4	ALG1L13P	3.59	0.00037	0.0238	0.16	0.16	Joint mobility (Beighton score);	chr8:8970227	chr8:8236003~8244667:-
THCA	cis	rs1436955	0.959	rs7180689	ENSG00000259251.2	RP11-643M14.1	-3.59	0.00037	0.0238	-0.18	-0.16	Type 2 diabetes;	chr15:62105437	chr15:62060503~62062434:+
THCA	cis	rs9329221	0.537	rs1351876	ENSG00000261451.1	RP11-981G7.1	-3.59	0.00037	0.0238	-0.2	-0.16	Neuroticism;	chr8:10127267	chr8:10433672~10438312:+
THCA	cis	rs1048886	0.938	rs76784072	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70417191	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs56397968	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70419103	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs114047845	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70421021	chr6:70596438~70596980:+
THCA	cis	rs1048886	1	rs74552954	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70422914	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs41265349	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70428289	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.808	rs17706748	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70430664	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs17634272	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70436792	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs76730904	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70440983	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs76917369	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70443516	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs12528385	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70448582	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.808	rs76320501	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70449586	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs76830193	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70461113	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs76513668	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70465172	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs79485742	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70465305	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs74749095	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70467165	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs76309923	ENSG00000271967.1	RP11-134K13.4	-3.59	0.00037	0.0238	-0.2	-0.16	Type 2 diabetes;	chr6:70471257	chr6:70596438~70596980:+
THCA	cis	rs786425	0.707	rs1969272	ENSG00000278112.1	RP11-972P1.11	3.59	0.00037	0.0238	0.15	0.16	Pubertal anthropometrics;	chr12:123685746	chr12:123519390~123519856:-
THCA	cis	rs9287719	0.746	rs6742448	ENSG00000243819.4	RN7SL832P	3.59	0.00037	0.0238	0.13	0.16	Prostate cancer;	chr2:10619000	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.781	rs6714795	ENSG00000243819.4	RN7SL832P	3.59	0.00037	0.0238	0.13	0.16	Prostate cancer;	chr2:10619008	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.781	rs6732671	ENSG00000243819.4	RN7SL832P	3.59	0.00037	0.0238	0.13	0.16	Prostate cancer;	chr2:10619023	chr2:10690344~10692099:+
THCA	cis	rs9393777	0.92	rs34953377	ENSG00000272009.1	RP1-313I6.12	-3.59	0.00037	0.0238	-0.28	-0.16	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28078792~28081130:-
THCA	cis	rs854765	0.624	rs4925119	ENSG00000281749.1	Y_RNA	-3.59	0.00037	0.0238	-0.21	-0.16	Total body bone mineral density;	chr17:17839590	chr17:18001101~18001195:-
THCA	cis	rs7631605	0.536	rs7624304	ENSG00000224080.1	UBE2FP1	3.59	0.00037	0.0238	0.19	0.16	Cerebrospinal P-tau181p levels;	chr3:37408988	chr3:37143512~37143958:-
THCA	cis	rs6416877	0.878	rs7220504	ENSG00000277491.1	RP11-676J12.9	-3.59	0.00037	0.0238	-0.19	-0.16	Myeloid white cell count;	chr17:1424923	chr17:795306~795794:+
THCA	cis	rs17685	0.753	rs6951808	ENSG00000227038.2	AC005077.12	3.59	0.00037	0.0238	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76143095	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs10952840	ENSG00000227038.2	AC005077.12	3.59	0.00037	0.0238	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76143560	chr7:76090431~76108779:-
THCA	cis	rs17685	0.672	rs10952841	ENSG00000227038.2	AC005077.12	3.59	0.00037	0.0238	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76149308	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs1806885	ENSG00000227038.2	AC005077.12	3.59	0.00037	0.0238	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76156294	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs1859791	ENSG00000227038.2	AC005077.12	3.59	0.00037	0.0238	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76156725	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs6464999	ENSG00000227038.2	AC005077.12	3.59	0.00037	0.0238	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76157997	chr7:76090431~76108779:-
THCA	cis	rs17685	0.753	rs6465000	ENSG00000227038.2	AC005077.12	3.59	0.00037	0.0238	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76158099	chr7:76090431~76108779:-
THCA	cis	rs3736858	0.825	rs2120061	ENSG00000261105.4	LMO7-AS1	-3.59	0.00037	0.0238	-0.22	-0.16	Interleukin-9 levels;	chr13:75813370	chr13:75604700~75635994:-
THCA	cis	rs34779708	0.931	rs4934704	ENSG00000233200.1	RP11-324I22.2	3.59	0.00037	0.0238	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35219894~35230598:-
THCA	cis	rs9876781	1	rs7630741	ENSG00000199476.1	Y_RNA	-3.59	0.00037	0.0238	-0.21	-0.16	Longevity;	chr3:48378233	chr3:48288587~48288694:+
THCA	cis	rs12362063	1	rs11030646	ENSG00000249867.4	RP11-115J23.1	3.59	0.00037	0.0238	0.18	0.16	Hepatitis B;	chr11:29257824	chr11:28702615~29063821:+
THCA	cis	rs38055	0.668	rs2112876	ENSG00000247796.2	CTD-2366F13.1	3.59	0.00037	0.0238	0.16	0.16	Acne (severe);	chr5:53182885	chr5:53109842~53115126:+
THCA	cis	rs9392556	0.829	rs584585	ENSG00000230648.1	RP3-406P24.3	3.59	0.00037	0.0238	0.21	0.16	Blood metabolite levels;	chr6:4118555	chr6:4018843~4021215:-
THCA	cis	rs7873102	0.654	rs10758466	ENSG00000213839.4	TMX2P1	-3.59	0.00037	0.0238	-0.12	-0.16	Brain structure;	chr9:37969038	chr9:37885683~37886390:+
THCA	cis	rs293748	0.571	rs13171061	ENSG00000250155.1	CTD-2353F22.1	-3.59	0.00037	0.0238	-0.2	-0.16	Obesity-related traits;	chr5:37154591	chr5:36666214~36725195:-
THCA	cis	rs45544231	1	rs12597685	ENSG00000279344.1	RP11-44F14.7	3.59	0.00037	0.0238	0.15	0.16	Restless legs syndrome;	chr16:52603868	chr16:53478957~53481550:-
THCA	cis	rs642858	0.784	rs608122	ENSG00000234147.1	RP3-460G2.2	3.59	0.00037	0.0238	0.19	0.16	Type 2 diabetes;	chr6:139915306	chr6:140845958~140852924:-
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000206014.6	OR7E161P	3.59	0.00037	0.0238	0.19	0.16	Neuroticism;	chr8:11986249	chr8:11928597~11929563:-
THCA	cis	rs9650657	0.801	rs718741	ENSG00000269918.1	AF131215.9	-3.59	0.00037	0.0238	-0.17	-0.16	Neuroticism;	chr8:10756874	chr8:11104691~11106704:-
THCA	cis	rs1958560	0.897	rs2411356	ENSG00000276116.2	FUT8-AS1	3.59	0.00037	0.0238	0.17	0.16	Menarche (age at onset);	chr14:65586443	chr14:65411170~65412690:-
THCA	cis	rs7829975	0.624	rs7823056	ENSG00000254340.1	RP11-10A14.3	3.59	0.00037	0.0238	0.18	0.16	Mood instability;	chr8:8525195	chr8:9141424~9145435:+
THCA	cis	rs6442522	0.839	rs1107596	ENSG00000249786.6	EAF1-AS1	3.59	0.00037	0.0238	0.17	0.16	Uric acid levels;	chr3:15366832	chr3:15436171~15455940:-
THCA	cis	rs8062405	0.655	rs7184597	ENSG00000278665.1	RP11-666O2.4	-3.59	0.00037	0.0238	-0.19	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28599241~28601881:-
THCA	cis	rs7824557	0.525	rs12682349	ENSG00000255495.1	AC145124.2	3.59	0.00037	0.0238	0.19	0.16	Retinal vascular caliber;	chr8:11387794	chr8:12194467~12196280:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000230295.1	RP11-458F8.2	3.59	0.00037	0.0238	0.13	0.16	Aortic root size;	chr7:66836124	chr7:66880708~66882981:+
THCA	cis	rs7911264	0.739	rs10882091	ENSG00000236493.2	EIF2S2P3	3.59	0.00037	0.0238	0.18	0.16	Inflammatory bowel disease;	chr10:92614620	chr10:92668745~92669743:-
THCA	cis	rs8040855	0.547	rs17611171	ENSG00000225151.9	GOLGA2P7	-3.59	0.00037	0.0238	-0.24	-0.16	Bulimia nervosa;	chr15:85029468	chr15:84199311~84230136:-
THCA	cis	rs11088226	0.692	rs2833863	ENSG00000186842.4	LINC00846	-3.59	0.00037	0.0238	-0.2	-0.16	Gastritis;	chr21:32514676	chr21:32572238~32575881:-
THCA	cis	rs4938303	0.589	rs11216100	ENSG00000254851.1	RP11-109L13.1	3.59	0.00037	0.0238	0.23	0.16	Triglycerides;	chr11:116701814	chr11:117135528~117138582:+
THCA	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	3.59	0.00037	0.0238	0.18	0.16	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
THCA	cis	rs10760158	0.832	rs10760164	ENSG00000235865.2	GSN-AS1	3.59	0.00037	0.0238	0.14	0.16	Pulse pressure;	chr9:121248884	chr9:121280768~121285530:-
THCA	cis	rs7818688	0.745	rs11779282	ENSG00000253528.2	RP11-347C18.4	-3.59	0.00037	0.0238	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94933259	chr8:94974573~94974853:-
THCA	cis	rs4767841	0.625	rs574155	ENSG00000252886.1	RN7SKP197	-3.59	0.00037	0.0238	-0.16	-0.16	Urgency urinary incontinence;	chr12:119790006	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.537	rs574142	ENSG00000252886.1	RN7SKP197	-3.59	0.00037	0.0238	-0.16	-0.16	Urgency urinary incontinence;	chr12:119790010	chr12:119631090~119631386:-
THCA	cis	rs11190604	1	rs12355721	ENSG00000273030.1	RP11-285F16.1	3.59	0.00037	0.0238	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100485154	chr10:100412934~100413421:+
THCA	cis	rs2039553	0.553	rs9565528	ENSG00000227354.5	RBM26-AS1	3.59	0.00037	0.0238	0.16	0.16	Pancreatic cancer;	chr13:79810457	chr13:79406309~79424328:+
THCA	cis	rs11992162	0.548	rs4841631	ENSG00000227888.4	FAM66A	-3.59	0.00037	0.0238	-0.21	-0.16	Monocyte count;	chr8:11924159	chr8:12362019~12388296:+
THCA	cis	rs656319	0.674	rs1484639	ENSG00000261451.1	RP11-981G7.1	3.59	0.00037	0.0238	0.2	0.16	Myopia (pathological);	chr8:10125714	chr8:10433672~10438312:+
THCA	cis	rs9608946	1	rs17670808	ENSG00000279699.1	RP1-102K2.9	3.59	0.00037	0.0238	0.19	0.16	Red cell distribution width;	chr22:30489993	chr22:30275215~30276951:-
THCA	cis	rs7487075	0.619	rs4768724	ENSG00000274723.1	RP11-618L22.1	3.59	0.000371	0.0238	0.16	0.16	Itch intensity from mosquito bite;	chr12:46454633	chr12:46970504~46972155:+
THCA	cis	rs7297018	1	rs7297018	ENSG00000257604.1	RP11-359M6.2	-3.59	0.000371	0.0238	-0.26	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr12:79668450	chr12:79500119~79500687:-
THCA	cis	rs3853824	0.636	rs9905199	ENSG00000263089.1	RP11-166P13.4	3.59	0.000371	0.0238	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56840278	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs9903097	ENSG00000263089.1	RP11-166P13.4	3.59	0.000371	0.0238	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56855657	chr17:57092145~57096425:-
THCA	cis	rs6545883	0.859	rs2600661	ENSG00000212978.6	AC016747.3	-3.59	0.000371	0.0238	-0.17	-0.16	Tuberculosis;	chr2:61315946	chr2:61141592~61144969:-
THCA	cis	rs9911578	0.967	rs7214892	ENSG00000224738.1	AC099850.1	3.59	0.000371	0.0238	0.19	0.16	Intelligence (multi-trait analysis);	chr17:58988040	chr17:59106598~59118267:+
THCA	cis	rs4792901	0.729	rs72833142	ENSG00000279602.1	CTD-3014M21.1	-3.59	0.000371	0.0238	-0.21	-0.16	Dupuytren's disease;	chr17:43538188	chr17:43360041~43361361:-
THCA	cis	rs6479352	0.637	rs6479347	ENSG00000225511.5	LINC00475	-3.59	0.000371	0.0238	-0.16	-0.16	Bipolar disorder (inflammation and infection response interaction);	chr9:91506284	chr9:92141298~92160114:+
THCA	cis	rs150992	0.673	rs331934	ENSG00000246763.5	RGMB-AS1	-3.59	0.000371	0.0238	-0.17	-0.16	Body mass index;	chr5:98804016	chr5:98769618~98773469:-
THCA	cis	rs150992	0.673	rs331545	ENSG00000246763.5	RGMB-AS1	-3.59	0.000371	0.0238	-0.17	-0.16	Body mass index;	chr5:98810402	chr5:98769618~98773469:-
THCA	cis	rs735539	0.598	rs2149769	ENSG00000238286.1	SLC35E1P1	3.59	0.000371	0.0238	0.17	0.16	Dental caries;	chr13:20692088	chr13:20607268~20608131:+
THCA	cis	rs8081395	0.741	rs1292053	ENSG00000267302.4	RP11-178C3.2	-3.59	0.000371	0.0238	-0.19	-0.16	White blood cell count;	chr17:59886176	chr17:59964832~59996972:+
THCA	cis	rs944289	0.74	rs379426	ENSG00000212071.1	AL162511.1	-3.59	0.000371	0.0238	-0.19	-0.16	Thyroid cancer;	chr14:36075253	chr14:36196480~36196568:-
THCA	cis	rs1125355	0.589	rs62183012	ENSG00000243792.1	OR7E89P	-3.59	0.000371	0.0238	-0.26	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158751248	chr2:158853755~158854576:+
THCA	cis	rs1125355	0.589	rs62183013	ENSG00000243792.1	OR7E89P	-3.59	0.000371	0.0238	-0.26	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158751362	chr2:158853755~158854576:+
THCA	cis	rs34975555	0.73	rs2299594	ENSG00000253671.1	RP11-806O11.1	-3.59	0.000371	0.0238	-0.24	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17945358	chr8:17808941~17820868:+
THCA	cis	rs28830936	0.966	rs28432037	ENSG00000250379.1	RP11-23P13.4	3.59	0.000371	0.0238	0.19	0.16	Diastolic blood pressure;	chr15:41834581	chr15:41825099~41827936:-
THCA	cis	rs8031584	0.56	rs7171208	ENSG00000178081.11	ULK4P3	-3.59	0.000371	0.0238	-0.21	-0.16	Huntington's disease progression;	chr15:30906726	chr15:30103720~30131757:+
THCA	cis	rs2841277	0.738	rs1036713	ENSG00000258701.1	LINC00638	-3.59	0.000371	0.0238	-0.16	-0.16	Rheumatoid arthritis;	chr14:104930356	chr14:104821201~104823718:+
THCA	cis	rs10833905	0.938	rs11026958	ENSG00000246225.5	RP11-17A1.3	-3.59	0.000371	0.0239	-0.24	-0.16	Sudden cardiac arrest;	chr11:23066231	chr11:22829380~22945393:+
THCA	cis	rs9902453	0.691	rs140701	ENSG00000263370.1	RP11-68I3.5	3.59	0.000371	0.0239	0.21	0.16	Coffee consumption (cups per day);	chr17:30211514	chr17:29639627~29640825:+
THCA	cis	rs972578	0.967	rs1040427	ENSG00000230319.1	AL022476.2	-3.59	0.000371	0.0239	-0.18	-0.16	Mean platelet volume;	chr22:42977564	chr22:43038585~43052366:+
THCA	cis	rs55702914	0.625	rs59757315	ENSG00000231621.1	AC013264.2	-3.59	0.000371	0.0239	-0.16	-0.16	Major depression and alcohol dependence;	chr2:197385489	chr2:197197991~197199273:+
THCA	cis	rs80130819	0.748	rs2732478	ENSG00000226413.2	OR8T1P	3.59	0.000371	0.0239	0.24	0.16	Prostate cancer;	chr12:48305754	chr12:48442030~48442947:-
THCA	cis	rs73108077	1	rs115577082	ENSG00000277112.2	RP11-755J8.1	-3.59	0.000371	0.0239	-0.34	-0.16	Red blood cell density in sickle cell anemia;	chr20:31433893	chr20:30681825~30723932:-
THCA	cis	rs9457247	0.561	rs916331	ENSG00000235272.1	FAM103A2P	3.59	0.000371	0.0239	0.22	0.16	Crohn's disease;	chr6:167057071	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.602	rs13204839	ENSG00000235272.1	FAM103A2P	3.59	0.000371	0.0239	0.22	0.16	Crohn's disease;	chr6:167057631	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.602	rs6456152	ENSG00000235272.1	FAM103A2P	3.59	0.000371	0.0239	0.22	0.16	Crohn's disease;	chr6:167058574	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.602	rs9457262	ENSG00000235272.1	FAM103A2P	3.59	0.000371	0.0239	0.22	0.16	Crohn's disease;	chr6:167060197	chr6:166586124~166586477:-
THCA	cis	rs7267979	0.932	rs1985737	ENSG00000276952.1	RP5-965G21.6	3.59	0.000371	0.0239	0.18	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25284915~25285588:-
THCA	cis	rs1971762	0.523	rs3852562	ENSG00000270175.1	RP11-793H13.11	-3.59	0.000371	0.0239	-0.11	-0.16	Height;	chr12:53691966	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.583	rs3852561	ENSG00000270175.1	RP11-793H13.11	-3.59	0.000371	0.0239	-0.11	-0.16	Height;	chr12:53692058	chr12:53500162~53500936:-
THCA	cis	rs7737355	0.773	rs10793812	ENSG00000224431.1	AC063976.7	-3.59	0.000371	0.0239	-0.15	-0.16	Life satisfaction;	chr5:131257670	chr5:132199456~132203487:+
THCA	cis	rs6005807	0.719	rs6005809	ENSG00000226471.5	CTA-292E10.6	3.59	0.000371	0.0239	0.19	0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28546239	chr22:28800683~28848559:+
THCA	cis	rs9611565	0.659	rs28530678	ENSG00000237037.8	NDUFA6-AS1	3.59	0.000371	0.0239	0.16	0.16	Vitiligo;	chr22:41538957	chr22:42090931~42137742:+
THCA	cis	rs1005277	0.579	rs2504148	ENSG00000120555.12	SEPT7P9	3.59	0.000371	0.0239	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs176886	ENSG00000120555.12	SEPT7P9	3.59	0.000371	0.0239	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.557	rs176887	ENSG00000120555.12	SEPT7P9	3.59	0.000371	0.0239	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474594	ENSG00000120555.12	SEPT7P9	3.59	0.000371	0.0239	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs11011461	ENSG00000120555.12	SEPT7P9	3.59	0.000371	0.0239	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38383069~38402916:-
THCA	cis	rs67478160	0.643	rs11160762	ENSG00000258534.1	CTD-2134A5.4	3.59	0.000371	0.0239	0.16	0.16	Schizophrenia;	chr14:103788746	chr14:103854366~103880111:-
THCA	cis	rs7394190	0.688	rs3812629	ENSG00000272140.2	RP11-574K11.29	-3.59	0.000371	0.0239	-0.16	-0.16	Incident atrial fibrillation;	chr10:73647532	chr10:73703735~73713581:-
THCA	cis	rs66887589	0.967	rs59516282	ENSG00000249244.1	RP11-548H18.2	-3.59	0.000371	0.0239	-0.17	-0.16	Diastolic blood pressure;	chr4:119580861	chr4:119391831~119395335:-
THCA	cis	rs66887589	0.934	rs12648182	ENSG00000249244.1	RP11-548H18.2	-3.59	0.000371	0.0239	-0.17	-0.16	Diastolic blood pressure;	chr4:119582736	chr4:119391831~119395335:-
THCA	cis	rs6687821	0.515	rs2764427	ENSG00000261737.1	RP4-612B15.3	3.59	0.000371	0.0239	0.25	0.16	Yeast infection;	chr1:87076636	chr1:86703502~86704462:-
THCA	cis	rs7759001	0.744	rs10946932	ENSG00000271755.1	RP1-153G14.4	3.59	0.000371	0.0239	0.19	0.16	Glomerular filtration rate (creatinine);	chr6:27502334	chr6:27404010~27406964:-
THCA	cis	rs337161	0.639	rs12402066	ENSG00000221571.3	RNU6ATAC35P	-3.59	0.000371	0.0239	-0.18	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220776864	chr1:220825620~220826063:+
THCA	cis	rs2635047	0.935	rs2461247	ENSG00000280212.1	RP11-49K24.3	-3.59	0.000371	0.0239	-0.16	-0.16	Educational attainment;	chr18:47172166	chr18:47076117~47076594:+
THCA	cis	rs7833790	0.777	rs6473301	ENSG00000254689.1	RP11-354A14.1	3.59	0.000371	0.0239	0.21	0.16	Diastolic blood pressure;	chr8:81779105	chr8:81885377~81923193:+
THCA	cis	rs7819412	0.538	rs4523214	ENSG00000255046.1	RP11-297N6.4	3.59	0.000371	0.0239	0.17	0.16	Triglycerides;	chr8:11113263	chr8:11797928~11802568:-
THCA	cis	rs7665090	0.967	rs13106325	ENSG00000248971.2	KRT8P46	-3.59	0.000371	0.0239	-0.19	-0.16	Primary biliary cholangitis;	chr4:102633835	chr4:102728746~102730171:-
THCA	cis	rs28530618	0.564	rs4911248	ENSG00000198547.7	C20orf203	3.59	0.000371	0.0239	0.12	0.16	Birth weight;	chr20:32626432	chr20:32631652~32673941:-
THCA	cis	rs1005277	0.522	rs289647	ENSG00000275858.1	RP11-291L22.8	3.59	0.000371	0.0239	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38450738~38451069:-
THCA	cis	rs55966801	0.647	rs11603942	ENSG00000277290.1	RP11-326C3.16	-3.59	0.000371	0.0239	-0.2	-0.16	Plateletcrit;	chr11:266804	chr11:243099~243483:-
THCA	cis	rs55966801	0.647	rs11604857	ENSG00000277290.1	RP11-326C3.16	-3.59	0.000371	0.0239	-0.2	-0.16	Plateletcrit;	chr11:266921	chr11:243099~243483:-
THCA	cis	rs459482	0.587	rs469083	ENSG00000227698.1	AP001619.2	3.59	0.000371	0.0239	0.19	0.16	IgG glycosylation;	chr21:41436789	chr21:41874756~41877613:-
THCA	cis	rs6545883	0.783	rs12713442	ENSG00000270820.4	RP11-355B11.2	3.59	0.000371	0.0239	0.14	0.16	Tuberculosis;	chr2:61620943	chr2:61471188~61484130:+
THCA	cis	rs6545883	1	rs778758	ENSG00000212978.6	AC016747.3	3.59	0.000371	0.0239	0.18	0.16	Tuberculosis;	chr2:61555026	chr2:61141592~61144969:-
THCA	cis	rs7528684	1	rs2210913	ENSG00000236731.1	RP4-801G22.2	3.59	0.000371	0.0239	0.17	0.16	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;	chr1:157699203	chr1:157629939~157630728:-
THCA	cis	rs7927592	0.956	rs10896341	ENSG00000160172.9	FAM86C2P	3.59	0.000372	0.0239	0.16	0.16	Total body bone mineral density;	chr11:68545712	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs67947146	ENSG00000160172.9	FAM86C2P	3.59	0.000372	0.0239	0.16	0.16	Total body bone mineral density;	chr11:68547512	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.913	rs7104345	ENSG00000160172.9	FAM86C2P	3.59	0.000372	0.0239	0.16	0.16	Total body bone mineral density;	chr11:68549304	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.871	rs11228284	ENSG00000160172.9	FAM86C2P	3.59	0.000372	0.0239	0.16	0.16	Total body bone mineral density;	chr11:68555299	chr11:67791648~67805336:-
THCA	cis	rs875971	0.642	rs35526611	ENSG00000232546.1	RP11-458F8.1	3.59	0.000372	0.0239	0.13	0.16	Aortic root size;	chr7:66629021	chr7:66848496~66858136:+
THCA	cis	rs36093924	0.646	rs4822069	ENSG00000227370.1	RP4-669P10.19	3.59	0.000372	0.0239	0.16	0.16	Intelligence;	chr22:41955477	chr22:42132543~42132998:+
THCA	cis	rs1642645	0.597	rs1011281	ENSG00000228452.1	RP5-994D16.9	3.59	0.000372	0.0239	0.21	0.16	Left ventricular obstructive tract defect (maternal effect);	chr1:42105163	chr1:42775813~42776790:-
THCA	cis	rs950169	0.8	rs4842847	ENSG00000188388.10	GOLGA6L3	3.59	0.000372	0.0239	0.22	0.16	Schizophrenia;	chr15:84262447	chr15:85240472~85247170:+
THCA	cis	rs9650657	0.535	rs7011756	ENSG00000255046.1	RP11-297N6.4	3.59	0.000372	0.0239	0.17	0.16	Neuroticism;	chr8:11162068	chr8:11797928~11802568:-
THCA	cis	rs9527	0.637	rs7096169	ENSG00000213277.3	MARCKSL1P1	3.59	0.000372	0.0239	0.18	0.16	Arsenic metabolism;	chr10:102858938	chr10:103175554~103176094:+
THCA	cis	rs2694528	0.623	rs1563517	ENSG00000250148.1	KRT8P31	3.59	0.000372	0.0239	0.27	0.16	Parkinson's disease;	chr5:60767684	chr5:60743563~60744970:-
THCA	cis	rs34102591	0.826	rs71458829	ENSG00000270028.1	RP11-380L11.4	3.59	0.000372	0.0239	0.23	0.16	Schizophrenia;	chr12:123986200	chr12:123925461~123926083:-
THCA	cis	rs6456156	0.565	rs2181058	ENSG00000235272.1	FAM103A2P	3.59	0.000372	0.0239	0.22	0.16	Primary biliary cholangitis;	chr6:167051842	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.565	rs12529238	ENSG00000235272.1	FAM103A2P	3.59	0.000372	0.0239	0.22	0.16	Primary biliary cholangitis;	chr6:167052088	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.524	rs6932740	ENSG00000235272.1	FAM103A2P	3.59	0.000372	0.0239	0.22	0.16	Primary biliary cholangitis;	chr6:167052951	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.524	rs6934043	ENSG00000235272.1	FAM103A2P	3.59	0.000372	0.0239	0.22	0.16	Primary biliary cholangitis;	chr6:167052961	chr6:166586124~166586477:-
THCA	cis	rs2562456	0.839	rs2562411	ENSG00000268278.1	RP11-420K14.1	3.59	0.000372	0.0239	0.22	0.16	Pain;	chr19:21419181	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.876	rs2562413	ENSG00000268278.1	RP11-420K14.1	3.59	0.000372	0.0239	0.22	0.16	Pain;	chr19:21420084	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.916	rs1967182	ENSG00000268278.1	RP11-420K14.1	3.59	0.000372	0.0239	0.22	0.16	Pain;	chr19:21420337	chr19:21637974~21656300:+
THCA	cis	rs9450351	0.744	rs9362247	ENSG00000203875.9	SNHG5	-3.59	0.000372	0.0239	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85822546	chr6:85660950~85678736:-
THCA	cis	rs9329221	0.741	rs13264066	ENSG00000261451.1	RP11-981G7.1	-3.59	0.000372	0.0239	-0.2	-0.16	Neuroticism;	chr8:9946565	chr8:10433672~10438312:+
THCA	cis	rs6684709	0.617	rs2075996	ENSG00000235052.1	RP1-150O5.3	3.59	0.000372	0.0239	0.17	0.16	White blood cell count;	chr1:23521217	chr1:23549139~23550915:-
THCA	cis	rs7809950	0.637	rs3801964	ENSG00000272072.1	CTA-363E19.2	3.59	0.000372	0.0239	0.18	0.16	Coronary artery disease;	chr7:107195797	chr7:107192559~107193300:-
THCA	cis	rs13182402	1	rs56397023	ENSG00000230929.5	RP11-395C3.1	-3.59	0.000372	0.0239	-0.31	-0.16	Osteoporosis;	chr5:126580087	chr5:126628019~126628319:-
THCA	cis	rs7615952	0.932	rs7629977	ENSG00000272840.1	RP11-379B18.6	3.59	0.000372	0.0239	0.27	0.16	Blood pressure (smoking interaction);	chr3:125930730	chr3:125774714~125797953:+
THCA	cis	rs7246967	0.611	rs3931771	ENSG00000198153.8	ZNF849P	-3.59	0.000372	0.0239	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22714018	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.604	rs8107322	ENSG00000198153.8	ZNF849P	-3.59	0.000372	0.0239	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22714630	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs7247191	ENSG00000198153.8	ZNF849P	-3.59	0.000372	0.0239	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22716783	chr19:22685167~22686732:+
THCA	cis	rs11671005	0.652	rs11670864	ENSG00000265272.2	RN7SL693P	3.59	0.000372	0.0239	0.22	0.16	Mean platelet volume;	chr19:58519213	chr19:58490797~58491075:+
THCA	cis	rs61160187	0.75	rs1807017	ENSG00000251279.1	CTC-436P18.1	-3.59	0.000372	0.0239	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:61162070~61232040:+
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000182586.6	LINC00334	-3.59	0.000372	0.0239	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45234340~45258730:+
THCA	cis	rs2243480	1	rs2420171	ENSG00000237310.1	GS1-124K5.4	-3.59	0.000372	0.0239	-0.18	-0.16	Diabetic kidney disease;	chr7:66172773	chr7:66493706~66495474:+
THCA	cis	rs727563	0.608	rs2076200	ENSG00000237037.8	NDUFA6-AS1	3.59	0.000372	0.0239	0.16	0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr22:42090931~42137742:+
THCA	cis	rs727563	0.552	rs4822045	ENSG00000237037.8	NDUFA6-AS1	3.59	0.000372	0.0239	0.16	0.16	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.559	rs9611619	ENSG00000237037.8	NDUFA6-AS1	3.59	0.000372	0.0239	0.16	0.16	Vitiligo;	chr22:41590710	chr22:42090931~42137742:+
THCA	cis	rs4822752	0.646	rs2071860	ENSG00000244625.4	MIATNB	3.59	0.000372	0.0239	0.19	0.16	Bipolar disorder and schizophrenia;	chr22:26623164	chr22:26672767~26780207:+
THCA	cis	rs12195230	0.649	rs13192929	ENSG00000233797.1	UFL1-AS1	3.59	0.000372	0.0239	0.26	0.16	Blood pressure;	chr6:97014878	chr6:96358374~96521669:-
THCA	cis	rs11673344	0.542	rs2562585	ENSG00000267260.1	CTD-2162K18.4	-3.59	0.000372	0.0239	-0.19	-0.16	Obesity-related traits;	chr19:37018321	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs8101392	ENSG00000267260.1	CTD-2162K18.4	-3.59	0.000372	0.0239	-0.19	-0.16	Obesity-related traits;	chr19:37024416	chr19:36773153~36777078:+
THCA	cis	rs6968419	0.588	rs7785501	ENSG00000237870.5	AC073130.1	-3.59	0.000372	0.0239	-0.18	-0.16	Intraocular pressure;	chr7:116111920	chr7:116275606~116286734:-
THCA	cis	rs4950322	1	rs1806618	ENSG00000180867.10	PDIA3P1	3.59	0.000372	0.0239	0.17	0.16	Protein quantitative trait loci;	chr1:147377075	chr1:147178113~147179622:+
THCA	cis	rs4950322	0.895	rs17356735	ENSG00000180867.10	PDIA3P1	3.59	0.000372	0.0239	0.17	0.16	Protein quantitative trait loci;	chr1:147378328	chr1:147178113~147179622:+
THCA	cis	rs2832191	0.74	rs2832168	ENSG00000176054.6	RPL23P2	3.59	0.000372	0.0239	0.14	0.16	Dental caries;	chr21:29091374	chr21:28997613~28998033:-
THCA	cis	rs4767841	0.565	rs405300	ENSG00000252886.1	RN7SKP197	-3.59	0.000372	0.0239	-0.16	-0.16	Urgency urinary incontinence;	chr12:119788269	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.565	rs386928	ENSG00000252886.1	RN7SKP197	-3.59	0.000372	0.0239	-0.16	-0.16	Urgency urinary incontinence;	chr12:119788628	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.565	rs407464	ENSG00000252886.1	RN7SKP197	-3.59	0.000372	0.0239	-0.16	-0.16	Urgency urinary incontinence;	chr12:119789059	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.539	rs407692	ENSG00000252886.1	RN7SKP197	-3.59	0.000372	0.0239	-0.16	-0.16	Urgency urinary incontinence;	chr12:119789119	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.565	rs804716	ENSG00000252886.1	RN7SKP197	-3.59	0.000372	0.0239	-0.16	-0.16	Urgency urinary incontinence;	chr12:119789578	chr12:119631090~119631386:-
THCA	cis	rs4767841	0.568	rs804717	ENSG00000252886.1	RN7SKP197	-3.59	0.000372	0.0239	-0.16	-0.16	Urgency urinary incontinence;	chr12:119789616	chr12:119631090~119631386:-
THCA	cis	rs836788	0.633	rs245013	ENSG00000251050.1	RP11-168A11.4	-3.59	0.000372	0.0239	-0.13	-0.16	Glomerular filtration rate (creatinine);	chr5:80751257	chr5:80019609~80019920:+
THCA	cis	rs9880211	0.718	rs28631273	ENSG00000239213.4	NCK1-AS1	3.59	0.000372	0.0239	0.17	0.16	Height;Body mass index;	chr3:136215869	chr3:136841726~136862054:-
THCA	cis	rs591584	0.704	rs12574292	ENSG00000255893.1	RP11-685N10.1	-3.58	0.000372	0.0239	-0.19	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94586652	chr11:94472908~94473570:-
THCA	cis	rs6500602	0.702	rs9929475	ENSG00000280063.1	RP11-295D4.3	-3.58	0.000372	0.0239	-0.09	-0.16	Schizophrenia;	chr16:4490884	chr16:4346694~4348648:-
THCA	cis	rs9788682	0.747	rs2938674	ENSG00000261143.1	ADAMTS7P3	-3.58	0.000372	0.0239	-0.24	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78465571	chr15:77976042~77993057:+
THCA	cis	rs2337406	0.85	rs1858678	ENSG00000254174.1	IGHV1-12	3.58	0.000372	0.0239	0.12	0.16	Alzheimer's disease (late onset);	chr14:106706790	chr14:106122420~106122709:-
THCA	cis	rs9863	0.861	rs34878139	ENSG00000269938.1	RP11-214K3.20	-3.58	0.000372	0.0239	-0.18	-0.16	White blood cell count;	chr12:123961706	chr12:123968023~123968579:-
THCA	cis	rs9863	0.861	rs11833002	ENSG00000269938.1	RP11-214K3.20	-3.58	0.000372	0.0239	-0.18	-0.16	White blood cell count;	chr12:123962069	chr12:123968023~123968579:-
THCA	cis	rs10844706	0.699	rs10844615	ENSG00000257027.1	RP11-705C15.3	3.58	0.000372	0.0239	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725646	chr12:9658567~9662085:+
THCA	cis	rs10844706	0.699	rs11052717	ENSG00000257027.1	RP11-705C15.3	3.58	0.000372	0.0239	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9726217	chr12:9658567~9662085:+
THCA	cis	rs860295	1	rs10908482	ENSG00000160766.13	GBAP1	-3.58	0.000372	0.0239	-0.18	-0.16	Body mass index;	chr1:155744082	chr1:155213821~155227422:-
THCA	cis	rs9467773	0.62	rs2504565	ENSG00000228223.2	HCG11	-3.58	0.000372	0.0239	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26523450~26526579:+
THCA	cis	rs12497850	0.863	rs4858799	ENSG00000228638.1	FCF1P2	-3.58	0.000372	0.0239	-0.17	-0.16	Parkinson's disease;	chr3:48690771	chr3:48290793~48291375:-
THCA	cis	rs10457838	0.755	rs11755147	ENSG00000223701.3	RAET1E-AS1	-3.58	0.000372	0.0239	-0.24	-0.16	Post-traumatic stress disorder;	chr6:149090029	chr6:149884431~149919508:+
THCA	cis	rs9487051	1	rs9374080	ENSG00000260273.1	RP11-425D10.10	-3.58	0.000373	0.0239	-0.21	-0.16	Reticulocyte fraction of red cells;	chr6:109295217	chr6:109382795~109383666:+
THCA	cis	rs10954779	0.728	rs2737333	ENSG00000127589.4	TUBBP1	-3.58	0.000373	0.0239	-0.19	-0.16	Intelligence (multi-trait analysis);	chr8:31135619	chr8:30351873~30353518:+
THCA	cis	rs7660883	1	rs9998251	ENSG00000251411.1	RP11-397E7.4	3.58	0.000373	0.0239	0.16	0.16	HDL cholesterol levels;	chr4:87077903	chr4:86913266~86914817:-
THCA	cis	rs7660883	1	rs3775223	ENSG00000251411.1	RP11-397E7.4	3.58	0.000373	0.0239	0.16	0.16	HDL cholesterol levels;	chr4:87079294	chr4:86913266~86914817:-
THCA	cis	rs7162943	0.887	rs28556293	ENSG00000260123.1	RP11-326A19.4	-3.58	0.000373	0.0239	-0.21	-0.16	Mean platelet volume;	chr15:89062078	chr15:89041223~89082819:+
THCA	cis	rs28830936	1	rs2004162	ENSG00000250379.1	RP11-23P13.4	3.58	0.000373	0.0239	0.19	0.16	Diastolic blood pressure;	chr15:41673344	chr15:41825099~41827936:-
THCA	cis	rs12541437	0.617	rs12550179	ENSG00000253327.2	RAD21-AS1	3.58	0.000373	0.0239	0.2	0.16	Gut microbiome composition (winter);	chr8:116908834	chr8:116874424~116876868:+
THCA	cis	rs3760982	0.585	rs10422108	ENSG00000268601.1	AC115522.3	-3.58	0.000373	0.0239	-0.2	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790716	chr19:43794309~43795658:-
THCA	cis	rs17181170	0.754	rs7638889	ENSG00000239572.1	RP11-451B8.1	-3.58	0.000373	0.0239	-0.19	-0.16	Prostate cancer;	chr3:87130359	chr3:87731402~87793629:-
THCA	cis	rs2251188	0.609	rs2254249	ENSG00000187953.9	PMS2CL	3.58	0.000373	0.024	0.17	0.16	Sum basophil neutrophil counts;Neutrophil count;	chr7:6641043	chr7:6710128~6753862:+
THCA	cis	rs3758911	0.861	rs11212142	ENSG00000255353.1	RP11-382M14.1	-3.58	0.000373	0.024	-0.21	-0.16	Coronary artery disease;	chr11:107302994	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs10789597	ENSG00000255353.1	RP11-382M14.1	-3.58	0.000373	0.024	-0.21	-0.16	Coronary artery disease;	chr11:107304314	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs12285607	ENSG00000255353.1	RP11-382M14.1	-3.58	0.000373	0.024	-0.21	-0.16	Coronary artery disease;	chr11:107304608	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs10890696	ENSG00000255353.1	RP11-382M14.1	-3.58	0.000373	0.024	-0.21	-0.16	Coronary artery disease;	chr11:107306487	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.828	rs10890697	ENSG00000255353.1	RP11-382M14.1	-3.58	0.000373	0.024	-0.21	-0.16	Coronary artery disease;	chr11:107307915	chr11:107176286~107177530:+
THCA	cis	rs4913250	0.889	rs11176774	ENSG00000203585.3	RP11-542B15.1	-3.58	0.000373	0.024	-0.13	-0.16	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr12:67535469	chr12:67519829~67567126:+
THCA	cis	rs12681366	0.636	rs2921388	ENSG00000261437.1	RP11-22C11.2	3.58	0.000373	0.024	0.15	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94440531	chr8:94637285~94639467:-
THCA	cis	rs7129556	0.813	rs11237249	ENSG00000254459.1	RP11-91P24.7	3.58	0.000373	0.024	0.22	0.16	Weight loss (gastric bypass surgery);	chr11:77630090	chr11:77829654~77872262:-
THCA	cis	rs9876781	0.967	rs9876891	ENSG00000199476.1	Y_RNA	-3.58	0.000373	0.024	-0.21	-0.16	Longevity;	chr3:48440024	chr3:48288587~48288694:+
THCA	cis	rs2066819	1	rs2695788	ENSG00000257303.1	RP11-977G19.11	3.58	0.000373	0.024	0.24	0.16	Psoriasis vulgaris;	chr12:56303326	chr12:56300142~56314808:+
THCA	cis	rs7432375	0.61	rs60574021	ENSG00000273486.1	RP11-731C17.2	3.58	0.000373	0.024	0.14	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136801439	chr3:136837338~136839021:-
THCA	cis	rs4272720	0.526	rs6537493	ENSG00000234736.4	FAM170B-AS1	-3.58	0.000373	0.024	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49056002	chr10:49121839~49151547:+
THCA	cis	rs206966	0.935	rs11065094	ENSG00000277283.1	RP1-267D11.6	3.58	0.000373	0.024	0.17	0.16	Breast cancer;	chr12:120368903	chr12:120116907~120119000:+
THCA	cis	rs6580649	0.941	rs1793933	ENSG00000273765.1	RP11-370I10.11	3.58	0.000373	0.024	0.18	0.16	Lung cancer;	chr12:48002667	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs1793931	ENSG00000273765.1	RP11-370I10.11	3.58	0.000373	0.024	0.18	0.16	Lung cancer;	chr12:48002722	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.783	rs1635526	ENSG00000273765.1	RP11-370I10.11	3.58	0.000373	0.024	0.18	0.16	Lung cancer;	chr12:48003002	chr12:48360920~48361377:+
THCA	cis	rs1005277	0.579	rs2474571	ENSG00000120555.12	SEPT7P9	3.58	0.000373	0.024	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38383069~38402916:-
THCA	cis	rs17023223	0.537	rs61806983	ENSG00000227056.2	RPL6P2	-3.58	0.000373	0.024	-0.22	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119219314~119220096:-
THCA	cis	rs916888	0.773	rs1378358	ENSG00000260075.1	NSFP1	-3.58	0.000373	0.024	-0.27	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46372855~46487141:+
THCA	cis	rs862034	0.688	rs12882065	ENSG00000270000.1	RP3-449M8.9	3.58	0.000373	0.024	0.16	0.16	Height;	chr14:74535294	chr14:74471930~74472360:-
THCA	cis	rs13401620	0.827	rs11686821	ENSG00000231013.1	AC013275.2	3.58	0.000373	0.024	0.19	0.16	Breast size;	chr2:119730060	chr2:119476448~119487346:+
THCA	cis	rs8030379	1	rs4842838	ENSG00000176700.18	SCAND2P	3.58	0.000373	0.024	0.1	0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84631451~84647478:+
THCA	cis	rs1923626	1	rs1923626	ENSG00000224968.1	RP1-35C21.1	3.58	0.000373	0.024	0.19	0.16	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr1:177787369	chr1:177351586~177366272:+
THCA	cis	rs801193	1	rs7782320	ENSG00000275400.1	RP4-756H11.5	-3.58	0.000373	0.024	-0.15	-0.16	Aortic root size;	chr7:66712111	chr7:66553805~66554199:-
THCA	cis	rs11638815	0.581	rs783537	ENSG00000259429.4	UBE2Q2P2	-3.58	0.000373	0.024	-0.14	-0.16	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:82355142~82420075:+
THCA	cis	rs9420	0.528	rs11229077	ENSG00000254602.1	AP000662.4	3.58	0.000373	0.024	0.19	0.16	Schizophrenia;	chr11:57631599	chr11:57638024~57652790:+
THCA	cis	rs2839186	0.584	rs2032111	ENSG00000215424.8	MCM3AP-AS1	3.58	0.000373	0.024	0.1	0.16	Testicular germ cell tumor;	chr21:46484656	chr21:46229217~46259390:+
THCA	cis	rs3770081	1	rs111295372	ENSG00000272564.1	RP11-548P2.2	-3.58	0.000373	0.024	-0.31	-0.16	Facial emotion recognition (sad faces);	chr2:86056234	chr2:85904279~85904727:+
THCA	cis	rs6012953	0.63	rs6067473	ENSG00000231715.1	COX6CP2	3.58	0.000373	0.024	0.18	0.16	Vitiligo;	chr20:50517457	chr20:50479767~50479991:+
THCA	cis	rs9316337	0.582	rs3847996	ENSG00000236953.1	ZDHHC20-IT1	-3.58	0.000373	0.024	-0.19	-0.16	Schizophrenia;	chr13:21433927	chr13:21376977~21377874:-
THCA	cis	rs6598541	0.887	rs1567811	ENSG00000278090.1	RP11-6O2.2	-3.58	0.000373	0.024	-0.15	-0.16	Urate levels;	chr15:98738604	chr15:99028538~99031053:+
THCA	cis	rs7208487	0.684	rs12449852	ENSG00000266469.1	CTB-131K11.1	-3.58	0.000373	0.024	-0.16	-0.16	Glomerular filtration rate in non diabetics (creatinine);Primary biliary cholangitis;	chr17:39475835	chr17:39401793~39406233:+
THCA	cis	rs17407555	0.632	rs12510727	ENSG00000250413.1	RP11-448G15.1	-3.58	0.000373	0.024	-0.18	-0.16	Schizophrenia (age at onset);	chr4:10269446	chr4:10006482~10009725:+
THCA	cis	rs6598955	0.724	rs10902737	ENSG00000236782.4	RP11-96L14.7	-3.58	0.000373	0.024	-0.2	-0.16	Obesity-related traits;	chr1:26309225	chr1:26169947~26171821:-
THCA	cis	rs11048434	0.698	rs1805784	ENSG00000245105.2	A2M-AS1	3.58	0.000373	0.024	0.13	0.16	Sjögren's syndrome;	chr12:8912576	chr12:9065177~9068060:+
THCA	cis	rs11048434	0.698	rs1805745	ENSG00000245105.2	A2M-AS1	3.58	0.000373	0.024	0.13	0.16	Sjögren's syndrome;	chr12:8912630	chr12:9065177~9068060:+
THCA	cis	rs73222236	0.787	rs34379561	ENSG00000273486.1	RP11-731C17.2	3.58	0.000373	0.024	0.15	0.16	Coronary artery disease;	chr3:136464374	chr3:136837338~136839021:-
THCA	cis	rs73222236	0.75	rs6439642	ENSG00000273486.1	RP11-731C17.2	3.58	0.000373	0.024	0.15	0.16	Coronary artery disease;	chr3:136473965	chr3:136837338~136839021:-
THCA	cis	rs73222236	0.857	rs16843991	ENSG00000273486.1	RP11-731C17.2	3.58	0.000373	0.024	0.15	0.16	Coronary artery disease;	chr3:136477186	chr3:136837338~136839021:-
THCA	cis	rs2299682	0.826	rs6086914	ENSG00000230506.1	RP11-416N4.4	3.58	0.000374	0.024	0.26	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9492258	chr20:10173520~10196990:+
THCA	cis	rs2299682	0.826	rs6086915	ENSG00000230506.1	RP11-416N4.4	3.58	0.000374	0.024	0.26	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9492357	chr20:10173520~10196990:+
THCA	cis	rs2191566	0.691	rs55771992	ENSG00000266921.1	RP11-15A1.7	-3.58	0.000374	0.024	-0.15	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44084125	chr19:43996896~44002836:-
THCA	cis	rs1348850	0.645	rs10164417	ENSG00000280374.1	RP11-337N6.3	-3.58	0.000374	0.024	-0.25	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177579402	chr2:177317715~177318471:-
THCA	cis	rs11073619	0.616	rs79416421	ENSG00000259728.4	LINC00933	-3.58	0.000374	0.024	-0.32	-0.16	Positive affect;	chr15:84539090	chr15:84570649~84580175:+
THCA	cis	rs6870983	0.749	rs6884911	ENSG00000247828.6	TMEM161B-AS1	3.58	0.000374	0.024	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88148141	chr5:88268895~88436685:+
THCA	cis	rs76878669	0.561	rs7105015	ENSG00000255320.1	RP11-755F10.1	-3.58	0.000374	0.024	-0.21	-0.16	Educational attainment (years of education);	chr11:66391919	chr11:66244840~66246239:-
THCA	cis	rs7660883	0.86	rs10023050	ENSG00000251411.1	RP11-397E7.4	3.58	0.000374	0.024	0.16	0.16	HDL cholesterol levels;	chr4:87143279	chr4:86913266~86914817:-
THCA	cis	rs12682352	0.652	rs3789843	ENSG00000233609.3	RP11-62H7.2	3.58	0.000374	0.024	0.17	0.16	Neuroticism;	chr8:8866747	chr8:8961200~8979025:+
THCA	cis	rs12682352	0.652	rs3827806	ENSG00000233609.3	RP11-62H7.2	3.58	0.000374	0.024	0.17	0.16	Neuroticism;	chr8:8866766	chr8:8961200~8979025:+
THCA	cis	rs6598955	0.64	rs6667826	ENSG00000236782.4	RP11-96L14.7	-3.58	0.000374	0.024	-0.2	-0.16	Obesity-related traits;	chr1:26204917	chr1:26169947~26171821:-
THCA	cis	rs12780845	0.931	rs2884038	ENSG00000229124.5	VIM-AS1	3.58	0.000374	0.024	0.16	0.16	Homocysteine levels;	chr10:17210159	chr10:17214239~17229985:-
THCA	cis	rs9291683	0.588	rs3796842	ENSG00000250413.1	RP11-448G15.1	-3.58	0.000374	0.024	-0.16	-0.16	Bone mineral density;	chr4:9994227	chr4:10006482~10009725:+
THCA	cis	rs2236295	0.533	rs10995356	ENSG00000238280.1	RP11-436D10.3	-3.58	0.000374	0.024	-0.19	-0.16	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62896153	chr10:62793562~62805887:-
THCA	cis	rs7129556	0.775	rs12286317	ENSG00000254459.1	RP11-91P24.7	3.58	0.000374	0.024	0.21	0.16	Weight loss (gastric bypass surgery);	chr11:77677975	chr11:77829654~77872262:-
THCA	cis	rs2952156	0.684	rs1877031	ENSG00000214546.3	AC087491.2	-3.58	0.000374	0.024	-0.2	-0.16	Asthma;	chr17:39657827	chr17:39619613~39622513:+
THCA	cis	rs943466	0.955	rs2281819	ENSG00000274259.2	XXbac-BPG294E21.9	-3.58	0.000374	0.024	-0.23	-0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33803896	chr6:33437363~33454453:-
THCA	cis	rs9860428	0.844	rs9845041	ENSG00000240057.4	RP11-572M11.4	-3.58	0.000374	0.024	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905212	chr3:113019532~113183301:+
THCA	cis	rs4272720	0.562	rs2725179	ENSG00000234736.4	FAM170B-AS1	-3.58	0.000374	0.024	-0.18	-0.16	Platelet count;Plateletcrit;	chr10:49162594	chr10:49121839~49151547:+
THCA	cis	rs9660180	0.875	rs4648727	ENSG00000215914.4	MMP23A	3.58	0.000374	0.024	0.21	0.16	Body mass index;	chr1:1844830	chr1:1699942~1701782:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000232546.1	RP11-458F8.1	3.58	0.000374	0.024	0.14	0.16	Aortic root size;	chr7:66120784	chr7:66848496~66858136:+
THCA	cis	rs2064219	0.554	rs6914846	ENSG00000216915.2	RP1-97D16.1	3.58	0.000374	0.024	0.21	0.16	Depressive symptoms;Depressive symptoms (multi-trait analysis);	chr6:27442900	chr6:27737000~27738494:-
THCA	cis	rs7560272	0.529	rs2421672	ENSG00000163016.8	ALMS1P	-3.58	0.000374	0.024	-0.2	-0.16	Schizophrenia;	chr2:73728413	chr2:73644919~73685576:+
THCA	cis	rs72765298	0.748	rs55958414	ENSG00000235332.2	RP11-366O20.5	3.58	0.000374	0.024	0.29	0.16	Pulse pressure;	chr9:125194569	chr9:125194649~125195821:-
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000184274.3	LINC00315	-3.58	0.000374	0.024	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45300245~45305257:-
THCA	cis	rs755107	0.715	rs76728310	ENSG00000201512.1	SNORA71C	-3.58	0.000374	0.024	-0.21	-0.16	Skin pigmentation;	chr20:37981113	chr20:38429670~38429803:-
THCA	cis	rs9811920	0.928	rs9865713	ENSG00000273374.1	RP11-383I23.2	3.58	0.000374	0.024	0.14	0.16	Axial length;	chr3:100151455	chr3:99802699~99806058:-
THCA	cis	rs8077577	0.895	rs62072498	ENSG00000273018.4	CTD-2303H24.2	-3.58	0.000374	0.024	-0.27	-0.16	Obesity-related traits;	chr17:18222637	chr17:18511221~18551705:-
THCA	cis	rs7851660	0.548	rs1156850	ENSG00000214417.4	KRT18P13	-3.58	0.000374	0.024	-0.15	-0.16	Strep throat;	chr9:97810882	chr9:97698922~97700734:+
THCA	cis	rs7010267	0.935	rs6469788	ENSG00000254278.1	RP11-278I4.2	-3.58	0.000374	0.024	-0.21	-0.16	Total body bone mineral density (age 45-60);	chr8:118940511	chr8:119062942~119068782:-
THCA	cis	rs7686660	1	rs4323053	ENSG00000250326.1	RP11-284M14.1	-3.58	0.000374	0.024	-0.16	-0.16	Asthma;	chr4:143087991	chr4:142933195~143184861:-
THCA	cis	rs9850274	1	rs9850274	ENSG00000231443.2	AC024937.6	-3.58	0.000374	0.024	-0.14	-0.16	Mean corpuscular hemoglobin;	chr3:196195556	chr3:195937243~195938739:+
THCA	cis	rs17407555	0.657	rs10489076	ENSG00000250413.1	RP11-448G15.1	-3.58	0.000374	0.024	-0.18	-0.16	Schizophrenia (age at onset);	chr4:10269224	chr4:10006482~10009725:+
THCA	cis	rs2455799	0.573	rs2455829	ENSG00000270409.1	RP11-44D5.1	-3.58	0.000374	0.024	-0.17	-0.16	Mean platelet volume;	chr3:15705430	chr3:15732252~15733470:+
THCA	cis	rs860295	0.58	rs12032720	ENSG00000236675.1	MTX1P1	-3.58	0.000374	0.024	-0.17	-0.16	Body mass index;	chr1:155305169	chr1:155230975~155234325:+
THCA	cis	rs10256972	0.63	rs10282584	ENSG00000225146.1	AC073957.15	3.58	0.000374	0.024	0.18	0.16	Endometriosis;Longevity;	chr7:1041806	chr7:1029025~1043891:+
THCA	cis	rs867371	0.826	rs2047678	ENSG00000278603.1	RP13-608F4.5	3.58	0.000374	0.024	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472203~82472426:+
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000264242.2	RP11-271K11.1	3.58	0.000375	0.024	0.25	0.16	Body mass index;	chr17:30730179	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000264242.2	RP11-271K11.1	3.58	0.000375	0.024	0.25	0.16	Body mass index;	chr17:30730744	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000264242.2	RP11-271K11.1	3.58	0.000375	0.024	0.25	0.16	Body mass index;	chr17:30731712	chr17:30553697~30558962:+
THCA	cis	rs7117932	0.905	rs10790963	ENSG00000270160.1	RP11-264E20.2	3.58	0.000375	0.024	0.19	0.16	Obesity-related traits;	chr11:128570751	chr11:128614340~128615236:-
THCA	cis	rs7819412	0.645	rs4841508	ENSG00000255046.1	RP11-297N6.4	3.58	0.000375	0.0241	0.17	0.16	Triglycerides;	chr8:11207494	chr8:11797928~11802568:-
THCA	cis	rs4272720	0.526	rs2246463	ENSG00000234736.4	FAM170B-AS1	3.58	0.000375	0.0241	0.17	0.16	Platelet count;Plateletcrit;	chr10:49050690	chr10:49121839~49151547:+
THCA	cis	rs6878727	0.549	rs920997	ENSG00000253807.4	LINC01170	3.58	0.000375	0.0241	0.15	0.16	Breast cancer;	chr5:124312328	chr5:124059794~124405079:-
THCA	cis	rs11671005	0.651	rs55716128	ENSG00000252334.1	RNU6-1337P	3.58	0.000375	0.0241	0.24	0.16	Mean platelet volume;	chr19:58537387	chr19:58483749~58483843:-
THCA	cis	rs1371614	0.566	rs10203050	ENSG00000272148.1	RP11-195B17.1	-3.58	0.000375	0.0241	-0.15	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26963693	chr2:27062428~27062907:-
THCA	cis	rs9303542	0.694	rs17621707	ENSG00000278765.1	RP5-890E16.5	-3.58	0.000375	0.0241	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48281916	chr17:48066704~48067293:-
THCA	cis	rs7665090	0.936	rs5026474	ENSG00000251288.2	RP11-10L12.2	-3.58	0.000375	0.0241	-0.21	-0.16	Primary biliary cholangitis;	chr4:102633653	chr4:102751401~102752641:+
THCA	cis	rs910873	0.505	rs6058089	ENSG00000276073.1	RP5-1125A11.7	3.58	0.000375	0.0241	0.2	0.16	Melanoma;	chr20:34606453	chr20:33985617~33988989:-
THCA	cis	rs7259376	0.704	rs1897613	ENSG00000270947.1	AC025811.3	3.58	0.000375	0.0241	0.18	0.16	Menopause (age at onset);	chr19:22390773	chr19:22455988~22456459:+
THCA	cis	rs4262150	0.774	rs4958564	ENSG00000253921.1	CTB-113P19.3	3.58	0.000375	0.0241	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152626381	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs4246033	ENSG00000253921.1	CTB-113P19.3	3.58	0.000375	0.0241	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152629857	chr5:151753992~151767247:+
THCA	cis	rs332034	0.546	rs28870140	ENSG00000254153.1	CTA-398F10.2	3.58	0.000375	0.0241	0.26	0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8832260	chr8:8456909~8461337:-
THCA	cis	rs12497850	1	rs12497850	ENSG00000228638.1	FCF1P2	-3.58	0.000375	0.0241	-0.17	-0.16	Parkinson's disease;	chr3:48711556	chr3:48290793~48291375:-
THCA	cis	rs12497850	1	rs6788650	ENSG00000228638.1	FCF1P2	-3.58	0.000375	0.0241	-0.17	-0.16	Parkinson's disease;	chr3:48712110	chr3:48290793~48291375:-
THCA	cis	rs11190604	0.767	rs10883483	ENSG00000273030.1	RP11-285F16.1	3.58	0.000375	0.0241	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100414487	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs10883484	ENSG00000273030.1	RP11-285F16.1	3.58	0.000375	0.0241	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100415046	chr10:100412934~100413421:+
THCA	cis	rs2625529	1	rs2625529	ENSG00000260037.4	CTD-2524L6.3	3.58	0.000375	0.0241	0.21	0.16	Red blood cell count;	chr15:71826436	chr15:71818396~71823384:+
THCA	cis	rs36093844	0.527	rs80333693	ENSG00000279742.1	RP11-700A24.1	-3.58	0.000375	0.0241	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86056863	chr11:85852557~85854943:-
THCA	cis	rs1560104	0.879	rs2865582	ENSG00000259876.1	CTD-3037G24.4	3.58	0.000375	0.0241	0.18	0.16	Obesity-related traits;	chr16:12623978	chr16:12556353~12557694:-
THCA	cis	rs9990333	0.544	rs112577972	ENSG00000207650.1	MIR570	3.58	0.000375	0.0241	0.18	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195699401~195699497:+
THCA	cis	rs7833787	0.644	rs4921965	ENSG00000278886.1	RP11-108A14.1	-3.58	0.000375	0.0241	-0.21	-0.16	Obesity-related traits;	chr8:18822356	chr8:18864681~18865247:-
THCA	cis	rs755249	0.501	rs2490945	ENSG00000182109.6	RP11-69E11.4	3.58	0.000375	0.0241	0.16	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39522280~39546187:-
THCA	cis	rs2305707	0.544	rs71471600	ENSG00000273674.3	CTD-2378E12.1	3.58	0.000375	0.0241	0.34	0.16	Height;	chr15:51268682	chr15:50839875~50908599:-
THCA	cis	rs2305707	0.544	rs34080711	ENSG00000273674.3	CTD-2378E12.1	3.58	0.000375	0.0241	0.34	0.16	Height;	chr15:51269259	chr15:50839875~50908599:-
THCA	cis	rs9650657	0.783	rs28570522	ENSG00000255310.2	AF131215.2	-3.58	0.000375	0.0241	-0.14	-0.16	Neuroticism;	chr8:10773058	chr8:11107788~11109726:-
THCA	cis	rs6499755	0.901	rs2042447	ENSG00000260135.5	RP11-212I21.2	3.58	0.000375	0.0241	0.18	0.16	Hypospadias;	chr16:55318110	chr16:55426797~55462297:-
THCA	cis	rs7259376	0.837	rs10420149	ENSG00000269345.1	VN1R85P	-3.58	0.000375	0.0241	-0.18	-0.16	Menopause (age at onset);	chr19:22400123	chr19:22174766~22175191:-
THCA	cis	rs4601821	0.858	rs4938012	ENSG00000270179.1	RP11-159N11.4	-3.58	0.000375	0.0241	-0.17	-0.16	Alcoholic chronic pancreatitis;	chr11:113388932	chr11:113368478~113369117:+
THCA	cis	rs7819412	0.669	rs2409743	ENSG00000261451.1	RP11-981G7.1	-3.58	0.000375	0.0241	-0.21	-0.16	Triglycerides;	chr8:11212851	chr8:10433672~10438312:+
THCA	cis	rs34779708	0.931	rs4934709	ENSG00000233200.1	RP11-324I22.2	-3.58	0.000375	0.0241	-0.19	-0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35219894~35230598:-
THCA	cis	rs9309473	1	rs11689392	ENSG00000273245.1	RP11-434P11.2	3.58	0.000375	0.0241	0.22	0.16	Metabolite levels;	chr2:73394898	chr2:73750256~73750786:-
THCA	cis	rs7259376	0.936	rs34643838	ENSG00000269345.1	VN1R85P	-3.58	0.000375	0.0241	-0.18	-0.16	Menopause (age at onset);	chr19:22425631	chr19:22174766~22175191:-
THCA	cis	rs12497850	1	rs1352420	ENSG00000228638.1	FCF1P2	-3.58	0.000375	0.0241	-0.18	-0.16	Parkinson's disease;	chr3:48719858	chr3:48290793~48291375:-
THCA	cis	rs2549003	1	rs2549002	ENSG00000233006.5	AC034220.3	3.58	0.000375	0.0241	0.12	0.16	Asthma (sex interaction);	chr5:132493886	chr5:132311285~132369916:-
THCA	cis	rs1053338	0.529	rs17654237	ENSG00000271843.1	RP11-245J9.5	-3.58	0.000375	0.0241	-0.25	-0.16	Breast cancer;	chr3:63749909	chr3:64008082~64008692:-
THCA	cis	rs7572733	0.555	rs11903129	ENSG00000231621.1	AC013264.2	-3.58	0.000375	0.0241	-0.17	-0.16	Dermatomyositis;	chr2:198053867	chr2:197197991~197199273:+
THCA	cis	rs78487399	0.908	rs72868628	ENSG00000234936.1	AC010883.5	3.58	0.000375	0.0241	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43605900	chr2:43229573~43233394:+
THCA	cis	rs754466	0.58	rs10762765	ENSG00000213514.2	RP11-428P16.2	3.58	0.000375	0.0241	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806649	chr10:77730766~77734769:+
THCA	cis	rs2302190	0.882	rs7216856	ENSG00000224738.1	AC099850.1	3.58	0.000375	0.0241	0.22	0.16	Vitamin D levels;	chr17:58394934	chr17:59106598~59118267:+
THCA	cis	rs1062177	1	rs12654573	ENSG00000272112.1	CTB-113P19.5	3.58	0.000375	0.0241	0.14	0.16	Preschool internalizing problems;	chr5:151827912	chr5:151724831~151725356:-
THCA	cis	rs13113518	0.738	rs6849883	ENSG00000272969.1	RP11-528I4.2	3.58	0.000375	0.0241	0.19	0.16	Height;	chr4:55387515	chr4:55547112~55547889:+
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000264242.2	RP11-271K11.1	3.58	0.000375	0.0241	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000264242.2	RP11-271K11.1	3.58	0.000375	0.0241	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30553697~30558962:+
THCA	cis	rs4869313	0.668	rs38041	ENSG00000247121.5	CTD-2260A17.2	3.58	0.000375	0.0241	0.12	0.16	Pediatric autoimmune diseases;	chr5:96994598	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.694	rs27305	ENSG00000247121.5	CTD-2260A17.2	3.58	0.000375	0.0241	0.12	0.16	Pediatric autoimmune diseases;	chr5:96997630	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.694	rs38042	ENSG00000247121.5	CTD-2260A17.2	3.58	0.000375	0.0241	0.12	0.16	Pediatric autoimmune diseases;	chr5:96999646	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.694	rs38036	ENSG00000247121.5	CTD-2260A17.2	-3.58	0.000375	0.0241	-0.12	-0.16	Pediatric autoimmune diseases;	chr5:96987799	chr5:96814028~96935809:-
THCA	cis	rs4915077	0.892	rs17020078	ENSG00000226822.1	RP11-356N1.2	3.58	0.000375	0.0241	0.27	0.16	Hypothyroidism;	chr1:107806611	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs17020080	ENSG00000226822.1	RP11-356N1.2	3.58	0.000375	0.0241	0.27	0.16	Hypothyroidism;	chr1:107806657	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs76568279	ENSG00000226822.1	RP11-356N1.2	3.58	0.000375	0.0241	0.27	0.16	Hypothyroidism;	chr1:107807112	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs17020081	ENSG00000226822.1	RP11-356N1.2	3.58	0.000375	0.0241	0.27	0.16	Hypothyroidism;	chr1:107807230	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs78998525	ENSG00000226822.1	RP11-356N1.2	3.58	0.000375	0.0241	0.27	0.16	Hypothyroidism;	chr1:107807444	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs78088580	ENSG00000226822.1	RP11-356N1.2	3.58	0.000375	0.0241	0.27	0.16	Hypothyroidism;	chr1:107807764	chr1:108071482~108074519:+
THCA	cis	rs7178375	1	rs7178375	ENSG00000215302.7	CTD-3092A11.1	-3.58	0.000375	0.0241	-0.23	-0.16	Hypertriglyceridemia;	chr15:30923732	chr15:30470779~30507623:+
THCA	cis	rs2011503	0.739	rs10412176	ENSG00000271283.1	CTC-412M14.6	-3.58	0.000375	0.0241	-0.24	-0.16	Bipolar disorder;	chr19:19578355	chr19:19699203~19699409:-
THCA	cis	rs4972539	0.547	rs1439977	ENSG00000238133.5	MLK7-AS1	3.58	0.000375	0.0241	0.21	0.16	Parental longevity (mother's age at death);	chr2:173215005	chr2:173166446~173282036:-
THCA	cis	rs11216126	0.556	rs1893460	ENSG00000254851.1	RP11-109L13.1	3.58	0.000376	0.0241	0.25	0.16	HDL cholesterol;	chr11:116732961	chr11:117135528~117138582:+
THCA	cis	rs2243480	1	rs12698509	ENSG00000273024.4	INTS4P2	3.58	0.000376	0.0241	0.27	0.16	Diabetic kidney disease;	chr7:65953889	chr7:65647864~65715661:+
THCA	cis	rs250585	0.736	rs30014	ENSG00000260136.4	CTD-2270L9.4	3.58	0.000376	0.0241	0.12	0.16	Egg allergy;	chr16:23404577	chr16:23452758~23457606:+
THCA	cis	rs250585	0.736	rs193937	ENSG00000260136.4	CTD-2270L9.4	3.58	0.000376	0.0241	0.12	0.16	Egg allergy;	chr16:23425037	chr16:23452758~23457606:+
THCA	cis	rs14027	0.883	rs35660840	ENSG00000279347.1	RP11-85I17.2	-3.58	0.000376	0.0241	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704351	chr8:119838736~119840385:-
THCA	cis	rs6600671	0.899	rs6674392	ENSG00000233029.3	RP11-439A17.9	-3.58	0.000376	0.0241	-0.18	-0.16	Hip geometry;	chr1:121518864	chr1:121090289~121097655:-
THCA	cis	rs1232027	0.616	rs6151615	ENSG00000244076.1	CTC-512J14.1	3.58	0.000376	0.0241	0.2	0.16	Huntington's disease progression;	chr5:80665613	chr5:80315671~80315826:+
THCA	cis	rs73230612	1	rs7653569	ENSG00000242767.1	ZBTB20-AS4	3.58	0.000376	0.0241	0.22	0.16	Type 2 diabetes;	chr3:115213378	chr3:115100423~115103061:+
THCA	cis	rs9788682	1	rs35212593	ENSG00000261143.1	ADAMTS7P3	-3.58	0.000376	0.0241	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78539484	chr15:77976042~77993057:+
THCA	cis	rs2692947	0.644	rs1168970	ENSG00000235584.2	AC008268.1	-3.58	0.000376	0.0241	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96150867	chr2:95666084~95668715:+
THCA	cis	rs57709857	0.957	rs16887325	ENSG00000272092.1	RP11-350N15.5	-3.58	0.000376	0.0241	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38315857	chr8:38382364~38383461:+
THCA	cis	rs929354	0.713	rs3802129	ENSG00000224629.1	RP5-1142J19.2	-3.58	0.000376	0.0241	-0.16	-0.16	Body mass index;	chr7:157172603	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs1002389	ENSG00000224629.1	RP5-1142J19.2	-3.58	0.000376	0.0241	-0.16	-0.16	Body mass index;	chr7:157175629	chr7:157263022~157263229:-
THCA	cis	rs853679	0.517	rs4713152	ENSG00000219891.2	ZSCAN12P1	3.58	0.000376	0.0241	0.23	0.16	Depression;	chr6:28169676	chr6:28091154~28093664:+
THCA	cis	rs7089973	0.641	rs7079234	ENSG00000236799.1	RP11-383C6.2	-3.58	0.000376	0.0241	-0.2	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114982051	chr10:114994657~114996593:+
THCA	cis	rs10492201	0.529	rs7313068	ENSG00000255733.4	IFNG-AS1	-3.58	0.000376	0.0241	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68011805	chr12:67989445~68234686:+
THCA	cis	rs11711311	0.747	rs7638378	ENSG00000241529.3	RN7SL767P	-3.58	0.000376	0.0241	-0.24	-0.16	IgG glycosylation;	chr3:113624783	chr3:113632704~113632998:+
THCA	cis	rs6545883	0.507	rs4411680	ENSG00000273302.1	RP11-493E12.2	-3.58	0.000376	0.0241	-0.15	-0.16	Tuberculosis;	chr2:61356970	chr2:61199979~61200769:+
THCA	cis	rs270601	0.69	rs162907	ENSG00000263597.1	MIR3936	-3.58	0.000376	0.0241	-0.16	-0.16	Acylcarnitine levels;	chr5:132244459	chr5:132365490~132365599:-
THCA	cis	rs270601	0.71	rs371709	ENSG00000263597.1	MIR3936	3.58	0.000376	0.0241	0.16	0.16	Acylcarnitine levels;	chr5:132247547	chr5:132365490~132365599:-
THCA	cis	rs4805834	0.719	rs111484921	ENSG00000267567.1	CTD-2538C1.3	-3.58	0.000376	0.0241	-0.31	-0.16	Creatinine levels;	chr19:32786742	chr19:32718298~32719595:-
THCA	cis	rs12149074	0.933	rs8045670	ENSG00000260876.4	LINC01229	3.58	0.000376	0.0241	0.17	0.16	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80062701	chr16:79676108~79807922:+
THCA	cis	rs56804039	0.524	rs11783173	ENSG00000254153.1	CTA-398F10.2	3.58	0.000376	0.0241	0.23	0.16	Cervical cancer;	chr8:8505200	chr8:8456909~8461337:-
THCA	cis	rs6487679	0.526	rs7972426	ENSG00000256069.6	A2MP1	3.58	0.000376	0.0241	0.19	0.16	Non-alcoholic fatty liver disease histology (AST);	chr12:9228658	chr12:9228533~9275817:-
THCA	cis	rs6431644	0.588	rs4663979	ENSG00000263941.2	RN7SL32P	-3.58	0.000376	0.0241	-0.21	-0.16	Left atrial antero-posterior diameter;	chr2:233894786	chr2:233205199~233205479:+
THCA	cis	rs7737355	1	rs27873	ENSG00000224431.1	AC063976.7	-3.58	0.000376	0.0241	-0.16	-0.16	Life satisfaction;	chr5:131395458	chr5:132199456~132203487:+
THCA	cis	rs17685	0.712	rs9800948	ENSG00000227038.2	AC005077.12	3.58	0.000376	0.0241	0.17	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76181155	chr7:76090431~76108779:-
THCA	cis	rs6120849	0.615	rs11167248	ENSG00000269202.1	RP4-614O4.12	-3.58	0.000376	0.0241	-0.17	-0.16	Protein C levels;	chr20:34950918	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.586	rs2025096	ENSG00000269202.1	RP4-614O4.12	-3.58	0.000376	0.0241	-0.17	-0.16	Protein C levels;	chr20:34952197	chr20:35201747~35203288:-
THCA	cis	rs7631605	0.809	rs1055095	ENSG00000272334.1	RP11-129K12.1	-3.58	0.000376	0.0241	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36986442	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.845	rs1133661	ENSG00000272334.1	RP11-129K12.1	-3.58	0.000376	0.0241	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36986575	chr3:36973117~36973672:-
THCA	cis	rs5758659	0.692	rs5751251	ENSG00000227370.1	RP4-669P10.19	-3.58	0.000376	0.0241	-0.15	-0.16	Cognitive function;	chr22:42244600	chr22:42132543~42132998:+
THCA	cis	rs875971	0.619	rs12533585	ENSG00000232546.1	RP11-458F8.1	-3.58	0.000376	0.0241	-0.13	-0.16	Aortic root size;	chr7:66519618	chr7:66848496~66858136:+
THCA	cis	rs42648	0.693	rs194533	ENSG00000225498.1	AC002064.5	3.58	0.000376	0.0241	0.17	0.16	Homocysteine levels;	chr7:90241463	chr7:90312496~90322592:+
THCA	cis	rs76382185	0.756	rs35658092	ENSG00000233184.5	RP11-421L21.3	3.58	0.000376	0.0241	0.24	0.16	Lymphocyte counts;	chr1:101119302	chr1:101025878~101087268:+
THCA	cis	rs189798	1	rs189798	ENSG00000254153.1	CTA-398F10.2	3.58	0.000376	0.0241	0.18	0.16	Myopia (pathological);	chr8:9133067	chr8:8456909~8461337:-
THCA	cis	rs875971	0.898	rs6977501	ENSG00000272831.1	RP11-792A8.4	-3.58	0.000376	0.0241	-0.1	-0.16	Aortic root size;	chr7:66228355	chr7:66739829~66740385:-
THCA	cis	rs4743820	0.503	rs10820835	ENSG00000229694.5	RP11-305L7.6	-3.58	0.000376	0.0241	-0.19	-0.16	Ulcerative colitis;Inflammatory bowel disease;	chr9:91158945	chr9:91119062~91182762:+
THCA	cis	rs9948	1	rs1320149	ENSG00000230606.9	AC159540.1	3.58	0.000376	0.0241	0.23	0.16	Erectile dysfunction and prostate cancer treatment;	chr2:96828140	chr2:97416165~97433527:-
THCA	cis	rs2320614	1	rs66609411	ENSG00000250027.1	RP11-563E2.2	-3.58	0.000376	0.0241	-0.15	-0.16	Lung adenocarcinoma;	chr4:163130689	chr4:163108785~163119965:+
THCA	cis	rs763121	0.819	rs5757161	ENSG00000225450.1	RP3-508I15.14	-3.58	0.000376	0.0241	-0.12	-0.16	Menopause (age at onset);	chr22:38594657	chr22:38739003~38749041:+
THCA	cis	rs5758659	0.652	rs133335	ENSG00000234009.1	RPL5P34	3.58	0.000376	0.0241	0.15	0.16	Cognitive function;	chr22:42020052	chr22:42776406~42777296:-
THCA	cis	rs2179367	0.959	rs521845	ENSG00000223701.3	RAET1E-AS1	-3.58	0.000376	0.0241	-0.21	-0.16	Dupuytren's disease;	chr6:149350562	chr6:149884431~149919508:+
THCA	cis	rs10741243	1	rs1891801	ENSG00000230098.1	TCERG1L-AS1	3.58	0.000376	0.0241	0.22	0.16	Type 2 diabetes;	chr10:131142956	chr10:131095218~131095777:+
THCA	cis	rs4671400	0.571	rs4672428	ENSG00000271889.1	RP11-493E12.1	-3.58	0.000376	0.0242	-0.18	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61251362	chr2:61151433~61162105:-
THCA	cis	rs6494488	0.5	rs111858590	ENSG00000259635.1	AC100830.3	-3.58	0.000376	0.0242	-0.41	-0.16	Coronary artery disease;	chr15:64771423	chr15:64701248~64719602:+
THCA	cis	rs1959947	0.876	rs2211543	ENSG00000251363.2	RP11-129M6.1	3.58	0.000376	0.0242	0.22	0.16	Hemostatic factors and hematological phenotypes;	chr14:41089413	chr14:40954898~40975877:+
THCA	cis	rs5758511	0.689	rs17002947	ENSG00000227370.1	RP4-669P10.19	-3.58	0.000376	0.0242	-0.19	-0.16	Birth weight;	chr22:42292526	chr22:42132543~42132998:+
THCA	cis	rs6560517	0.519	rs11144926	ENSG00000234618.1	RPSAP9	-3.58	0.000377	0.0242	-0.19	-0.16	Dialysis-related mortality;	chr9:76495162	chr9:76398699~76399586:+
THCA	cis	rs6137726	0.652	rs6075933	ENSG00000237396.1	LINC01384	-3.58	0.000377	0.0242	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22673421	chr20:22587522~22607517:-
THCA	cis	rs10129255	0.826	rs7150693	ENSG00000274576.2	IGHV2-70	3.58	0.000377	0.0242	0.11	0.16	Kawasaki disease;	chr14:106705382	chr14:106770577~106771020:-
THCA	cis	rs10129255	0.869	rs7150549	ENSG00000274576.2	IGHV2-70	3.58	0.000377	0.0242	0.11	0.16	Kawasaki disease;	chr14:106705441	chr14:106770577~106771020:-
THCA	cis	rs2562456	0.793	rs279807	ENSG00000268278.1	RP11-420K14.1	3.58	0.000377	0.0242	0.23	0.16	Pain;	chr19:21283020	chr19:21637974~21656300:+
THCA	cis	rs7045881	0.696	rs7024415	ENSG00000254396.1	RP11-56F10.3	3.58	0.000377	0.0242	0.22	0.16	Schizophrenia;	chr9:26809430	chr9:27102630~27104728:+
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000264242.2	RP11-271K11.1	3.58	0.000377	0.0242	0.25	0.16	Body mass index;	chr17:30806554	chr17:30553697~30558962:+
THCA	cis	rs7296418	0.922	rs1727293	ENSG00000256092.2	RP13-942N8.1	3.58	0.000377	0.0242	0.12	0.16	Platelet count;	chr12:123163485	chr12:123363868~123366113:+
THCA	cis	rs4908768	0.501	rs6577513	ENSG00000270282.1	RP5-1115A15.2	3.58	0.000377	0.0242	0.19	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8642694	chr1:8512653~8513021:+
THCA	cis	rs929354	0.772	rs1182432	ENSG00000224629.1	RP5-1142J19.2	-3.58	0.000377	0.0242	-0.16	-0.16	Body mass index;	chr7:157236482	chr7:157263022~157263229:-
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000184274.3	LINC00315	-3.58	0.000377	0.0242	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45300245~45305257:-
THCA	cis	rs1023500	0.573	rs2413666	ENSG00000270083.1	RP1-257I20.14	3.58	0.000377	0.0242	0.18	0.16	Schizophrenia;	chr22:42063618	chr22:42089630~42090028:-
THCA	cis	rs7737355	1	rs12719444	ENSG00000237714.1	P4HA2-AS1	3.58	0.000377	0.0242	0.24	0.16	Life satisfaction;	chr5:131271685	chr5:132184876~132192808:+
THCA	cis	rs5753618	0.583	rs5749279	ENSG00000224050.1	RP1-90G24.6	-3.58	0.000377	0.0242	-0.21	-0.16	Colorectal cancer;	chr22:31458223	chr22:32273420~32277186:+
THCA	cis	rs854765	0.583	rs4925126	ENSG00000281749.1	Y_RNA	3.58	0.000377	0.0242	0.2	0.16	Total body bone mineral density;	chr17:17895319	chr17:18001101~18001195:-
THCA	cis	rs4730276	0.674	rs6943999	ENSG00000250474.1	WBP1LP2	-3.58	0.000377	0.0242	-0.15	-0.16	Ulcerative colitis;	chr7:107890834	chr7:107628553~107629498:+
THCA	cis	rs8040855	0.86	rs7172266	ENSG00000259630.2	CTD-2262B20.1	3.58	0.000377	0.0242	0.2	0.16	Bulimia nervosa;	chr15:85172982	chr15:85415228~85415633:+
THCA	cis	rs72928364	0.685	rs1823360	ENSG00000256628.3	ZBTB11-AS1	3.58	0.000377	0.0242	0.23	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101060377	chr3:101676475~101679217:+
THCA	cis	rs4218	0.587	rs1446237	ENSG00000259732.1	RP11-59H7.3	-3.58	0.000377	0.0242	-0.22	-0.16	Social communication problems;	chr15:59052603	chr15:59121034~59133250:+
THCA	cis	rs11638815	0.626	rs11633829	ENSG00000259429.4	UBE2Q2P2	3.58	0.000377	0.0242	0.14	0.16	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:82355142~82420075:+
THCA	cis	rs3858145	0.505	rs12765827	ENSG00000233590.1	RP11-153K11.3	3.58	0.000377	0.0242	0.24	0.16	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68286821	chr10:68233251~68242379:-
THCA	cis	rs6801044	0.954	rs28564334	ENSG00000223711.1	AC091633.3	-3.58	0.000377	0.0242	-0.22	-0.16	Creatinine levels in ischemic stroke;	chr3:195560481	chr3:195544048~195550581:+
THCA	cis	rs1560104	0.619	rs3829519	ENSG00000262801.4	U91319.1	-3.58	0.000377	0.0242	-0.19	-0.16	Obesity-related traits;	chr16:12614854	chr16:13246316~13562918:+
THCA	cis	rs1560104	0.576	rs7186185	ENSG00000262801.4	U91319.1	-3.58	0.000377	0.0242	-0.19	-0.16	Obesity-related traits;	chr16:12614985	chr16:13246316~13562918:+
THCA	cis	rs6499755	0.712	rs31111	ENSG00000260135.5	RP11-212I21.2	-3.58	0.000377	0.0242	-0.18	-0.16	Hypospadias;	chr16:55344774	chr16:55426797~55462297:-
THCA	cis	rs791590	0.715	rs12722588	ENSG00000229664.1	RP11-536K7.5	3.58	0.000377	0.0242	0.23	0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6018470	chr10:6025978~6036427:+
THCA	cis	rs7577696	0.706	rs2268796	ENSG00000276334.1	AL133243.1	3.58	0.000377	0.0242	0.17	0.16	Inflammatory biomarkers;	chr2:31557210	chr2:32521927~32523547:+
THCA	cis	rs2221894	0.922	rs983365	ENSG00000251191.6	LINC00589	-3.58	0.000377	0.0242	-0.2	-0.16	Obesity-related traits;	chr8:28892912	chr8:29673922~29748109:-
THCA	cis	rs2821260	0.686	rs12140090	ENSG00000227207.2	RPL31P12	-3.58	0.000377	0.0242	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:72092455	chr1:72301472~72301829:+
THCA	cis	rs11771526	0.901	rs10282699	ENSG00000272905.1	RP11-265E18.1	3.58	0.000377	0.0242	0.19	0.16	Body mass index;	chr7:32258355	chr7:32845394~32846061:+
THCA	cis	rs929354	0.713	rs10085650	ENSG00000224629.1	RP5-1142J19.2	-3.58	0.000377	0.0242	-0.16	-0.16	Body mass index;	chr7:157200719	chr7:157263022~157263229:-
THCA	cis	rs643506	0.874	rs609007	ENSG00000230911.1	PPIHP1	3.58	0.000377	0.0242	0.22	0.16	Breast cancer;	chr11:111848870	chr11:112029858~112030367:-
THCA	cis	rs11685222	0.64	rs114685812	ENSG00000229326.3	AC069154.4	3.58	0.000377	0.0242	0.27	0.16	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119668313	chr2:119698623~119700151:+
THCA	cis	rs131777	0.708	rs131749	ENSG00000272836.1	RP3-402G11.27	3.58	0.000377	0.0242	0.15	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50205585~50206062:-
THCA	cis	rs3808502	0.527	rs4410870	ENSG00000254948.1	OR7E158P	3.58	0.000377	0.0242	0.21	0.16	Neuroticism;	chr8:11298611	chr8:11919900~11920809:-
THCA	cis	rs931608	0.569	rs17461312	ENSG00000269138.1	ZNF209P	3.58	0.000377	0.0242	0.24	0.16	Response to statins (LDL cholesterol change);Dental caries;	chr19:22371305	chr19:22463922~22473036:+
THCA	cis	rs1881797	0.932	rs4551631	ENSG00000215795.2	RP11-488L18.3	-3.58	0.000377	0.0242	-0.19	-0.16	Acute lymphoblastic leukemia (childhood);	chr1:247504361	chr1:247183813~247185482:-
THCA	cis	rs11089937	0.626	rs9619800	ENSG00000215456.5	BCRP4	3.58	0.000377	0.0242	0.21	0.16	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22630061~22636153:+
THCA	cis	rs11139399	0.613	rs1471723	ENSG00000233926.1	RP11-154D17.1	-3.58	0.000377	0.0242	-0.2	-0.16	Hippocampal atrophy;	chr9:81722132	chr9:81689713~81776900:+
THCA	cis	rs7665090	0.665	rs227277	ENSG00000248971.2	KRT8P46	3.58	0.000377	0.0242	0.19	0.16	Primary biliary cholangitis;	chr4:102673781	chr4:102728746~102730171:-
THCA	cis	rs2274273	0.87	rs7153612	ENSG00000258469.1	CHMP4BP1	3.58	0.000377	0.0242	0.15	0.16	Protein biomarker;	chr14:55322044	chr14:55298644~55299231:+
THCA	cis	rs4869313	0.694	rs27292	ENSG00000247121.5	CTD-2260A17.2	3.58	0.000377	0.0242	0.12	0.16	Pediatric autoimmune diseases;	chr5:97021276	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.694	rs27747	ENSG00000247121.5	CTD-2260A17.2	3.58	0.000377	0.0242	0.12	0.16	Pediatric autoimmune diseases;	chr5:97024208	chr5:96814028~96935809:-
THCA	cis	rs939960	0.959	rs35188092	ENSG00000276538.1	RP11-545G3.2	3.58	0.000377	0.0242	0.23	0.16	Neutrophil percentage of white cells;	chr7:150596974	chr7:150047609~150047854:-
THCA	cis	rs6788895	1	rs56840421	ENSG00000244265.1	SIAH2-AS1	3.58	0.000377	0.0242	0.43	0.16	Breast cancer;	chr3:150778413	chr3:150761937~150762538:+
THCA	cis	rs7914558	0.966	rs10748839	ENSG00000272912.1	RP11-724N1.1	-3.58	0.000377	0.0242	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:102914585~102915404:+
THCA	cis	rs4218	0.689	rs12907187	ENSG00000277144.1	RP11-59H7.4	-3.58	0.000377	0.0242	-0.23	-0.16	Social communication problems;	chr15:59100607	chr15:59115547~59116089:-
THCA	cis	rs911555	0.603	rs11621300	ENSG00000269910.1	RP11-73M18.10	3.58	0.000377	0.0242	0.15	0.16	Intelligence (multi-trait analysis);	chr14:103378561	chr14:103694516~103695050:-
THCA	cis	rs495337	0.721	rs554263	ENSG00000229222.1	KRT18P4	-3.58	0.000377	0.0242	-0.21	-0.16	Psoriasis;	chr20:49897356	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs2769975	ENSG00000229222.1	KRT18P4	-3.58	0.000377	0.0242	-0.21	-0.16	Psoriasis;	chr20:49899974	chr20:49956745~49958032:+
THCA	cis	rs495337	0.76	rs615868	ENSG00000229222.1	KRT18P4	-3.58	0.000377	0.0242	-0.21	-0.16	Psoriasis;	chr20:49902687	chr20:49956745~49958032:+
THCA	cis	rs7219021	0.798	rs11652858	ENSG00000248278.1	SUMO2P17	-3.58	0.000377	0.0242	-0.2	-0.16	Schizophrenia or bipolar disorder;	chr17:48767634	chr17:48874860~48908983:-
THCA	cis	rs8058578	0.945	rs34480360	ENSG00000260911.2	RP11-196G11.2	3.58	0.000377	0.0242	0.14	0.16	Multiple myeloma;	chr16:30787368	chr16:31043150~31049868:+
THCA	cis	rs10419113	0.641	rs12983947	ENSG00000270804.1	CTD-2583A14.11	3.58	0.000377	0.0242	0.14	0.16	Pediatric bone mineral density (spine);	chr19:57763541	chr19:57867885~57868834:+
THCA	cis	rs7572644	0.64	rs4632296	ENSG00000223522.1	AC093690.1	-3.58	0.000377	0.0242	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27802117	chr2:28307691~28310459:-
THCA	cis	rs853679	0.567	rs1005126	ENSG00000226314.6	ZNF192P1	-3.58	0.000377	0.0242	-0.19	-0.16	Depression;	chr6:28399846	chr6:28161781~28169594:+
THCA	cis	rs10863936	0.667	rs11119836	ENSG00000198468.6	FLVCR1-AS1	-3.58	0.000377	0.0242	-0.19	-0.16	Height;	chr1:212037032	chr1:212852108~212858088:-
THCA	cis	rs10863936	0.667	rs61828539	ENSG00000198468.6	FLVCR1-AS1	-3.58	0.000377	0.0242	-0.19	-0.16	Height;	chr1:212038134	chr1:212852108~212858088:-
THCA	cis	rs972578	0.715	rs9607948	ENSG00000230319.1	AL022476.2	3.58	0.000377	0.0242	0.18	0.16	Mean platelet volume;	chr22:42793074	chr22:43038585~43052366:+
THCA	cis	rs9487094	0.6	rs9372213	ENSG00000223537.2	RP5-919F19.5	-3.58	0.000377	0.0242	-0.17	-0.16	Height;	chr6:109370985	chr6:109487906~109506800:+
THCA	cis	rs6565180	0.507	rs4471699	ENSG00000274678.1	RP11-2C24.7	-3.58	0.000377	0.0242	-0.15	-0.16	Tonsillectomy;	chr16:30308986	chr16:30821338~30821884:+
THCA	cis	rs10200159	0.793	rs2867964	ENSG00000272606.1	RP11-554J4.1	3.58	0.000378	0.0242	0.3	0.16	Vitiligo;	chr2:55698289	chr2:55617909~55618373:+
THCA	cis	rs2228479	0.85	rs76075456	ENSG00000274627.1	RP11-104N10.2	-3.58	0.000378	0.0242	-0.29	-0.16	Skin colour saturation;	chr16:89767862	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs11645916	ENSG00000274627.1	RP11-104N10.2	-3.58	0.000378	0.0242	-0.29	-0.16	Skin colour saturation;	chr16:89768826	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17226666	ENSG00000274627.1	RP11-104N10.2	-3.58	0.000378	0.0242	-0.29	-0.16	Skin colour saturation;	chr16:89768993	chr16:89516797~89522217:+
THCA	cis	rs11039798	0.588	rs666165	ENSG00000200090.1	Y_RNA	-3.58	0.000378	0.0242	-0.13	-0.16	Axial length;	chr11:48435887	chr11:47726894~47726992:-
THCA	cis	rs3114020	0.771	rs1481017	ENSG00000246375.2	RP11-10L7.1	3.58	0.000378	0.0242	0.22	0.16	Gout;	chr4:88176325	chr4:88284942~88331421:+
THCA	cis	rs9880211	0.635	rs6775778	ENSG00000239213.4	NCK1-AS1	-3.58	0.000378	0.0242	-0.18	-0.16	Height;Body mass index;	chr3:136007837	chr3:136841726~136862054:-
THCA	cis	rs9309473	1	rs10169714	ENSG00000273245.1	RP11-434P11.2	3.58	0.000378	0.0242	0.23	0.16	Metabolite levels;	chr2:73581646	chr2:73750256~73750786:-
THCA	cis	rs7216064	1	rs8071463	ENSG00000278740.1	RP11-147L13.14	-3.58	0.000378	0.0242	-0.18	-0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942539	chr17:68188547~68189165:+
THCA	cis	rs12681288	0.55	rs4272405	ENSG00000260721.1	AF067845.1	3.58	0.000378	0.0242	0.2	0.16	Schizophrenia;	chr8:1009014	chr8:1368642~1369833:-
THCA	cis	rs12681288	0.55	rs12549204	ENSG00000260721.1	AF067845.1	3.58	0.000378	0.0242	0.2	0.16	Schizophrenia;	chr8:1009085	chr8:1368642~1369833:-
THCA	cis	rs7572733	0.536	rs6732517	ENSG00000231621.1	AC013264.2	-3.58	0.000378	0.0242	-0.17	-0.16	Dermatomyositis;	chr2:198048178	chr2:197197991~197199273:+
THCA	cis	rs2652822	0.525	rs2053633	ENSG00000259459.4	RP11-321G12.1	-3.58	0.000378	0.0242	-0.13	-0.16	Metabolic traits;	chr15:63213450	chr15:63390136~63438320:+
THCA	cis	rs2652822	0.525	rs11634159	ENSG00000259459.4	RP11-321G12.1	-3.58	0.000378	0.0242	-0.13	-0.16	Metabolic traits;	chr15:63215223	chr15:63390136~63438320:+
THCA	cis	rs11992162	0.529	rs6995037	ENSG00000227888.4	FAM66A	-3.58	0.000378	0.0242	-0.21	-0.16	Monocyte count;	chr8:11923378	chr8:12362019~12388296:+
THCA	cis	rs7216064	0.953	rs11871285	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844693	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs62084213	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845900	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs7224923	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846149	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs62084214	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67847209	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs2046323	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853811	chr17:68096046~68101474:-
THCA	cis	rs7216064	0.773	rs74541577	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67857535	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs2128792	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861061	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs2365764	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861598	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs59950564	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864743	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs34872586	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867350	chr17:68096046~68101474:-
THCA	cis	rs7216064	0.953	rs58141639	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67868786	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs62084246	ENSG00000265055.1	AC145343.2	3.58	0.000378	0.0242	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871795	chr17:68096046~68101474:-
THCA	cis	rs7911264	1	rs10786052	ENSG00000232709.1	MARK2P9	-3.58	0.000378	0.0242	-0.19	-0.16	Inflammatory bowel disease;	chr10:92686878	chr10:92418667~92420875:+
THCA	cis	rs10760158	0.832	rs10760169	ENSG00000235865.2	GSN-AS1	3.58	0.000378	0.0242	0.14	0.16	Pulse pressure;	chr9:121295404	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs10760171	ENSG00000235865.2	GSN-AS1	3.58	0.000378	0.0242	0.14	0.16	Pulse pressure;	chr9:121296081	chr9:121280768~121285530:-
THCA	cis	rs7520050	0.966	rs785492	ENSG00000280836.1	AL355480.1	3.58	0.000378	0.0242	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45581219~45581321:-
THCA	cis	rs10940346	0.506	rs12657678	ENSG00000271752.1	RP11-269M20.3	-3.58	0.000378	0.0242	-0.16	-0.16	Schizophrenia;	chr5:50564284	chr5:50662859~50663266:-
THCA	cis	rs7520050	0.778	rs3014216	ENSG00000281912.1	LINC01144	-3.58	0.000378	0.0242	-0.11	-0.16	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45303910~45305619:+
THCA	cis	rs2281603	0.57	rs73265640	ENSG00000258824.2	CTD-2555O16.2	-3.58	0.000378	0.0242	-0.14	-0.16	Lymphocyte counts;	chr14:64483083	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.57	rs73265641	ENSG00000258824.2	CTD-2555O16.2	-3.58	0.000378	0.0242	-0.14	-0.16	Lymphocyte counts;	chr14:64483146	chr14:64422935~64448557:-
THCA	cis	rs2281603	0.521	rs35115595	ENSG00000258824.2	CTD-2555O16.2	-3.58	0.000378	0.0242	-0.14	-0.16	Lymphocyte counts;	chr14:64483206	chr14:64422935~64448557:-
THCA	cis	rs8130944	1	rs4920140	ENSG00000235772.1	AP001625.6	3.58	0.000378	0.0242	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42720525	chr21:42560374~42561934:-
THCA	cis	rs8130944	1	rs2269148	ENSG00000235772.1	AP001625.6	3.58	0.000378	0.0242	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42721144	chr21:42560374~42561934:-
THCA	cis	rs8130944	1	rs2269149	ENSG00000235772.1	AP001625.6	3.58	0.000378	0.0242	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42721247	chr21:42560374~42561934:-
THCA	cis	rs8130944	1	rs7281911	ENSG00000235772.1	AP001625.6	3.58	0.000378	0.0242	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42721800	chr21:42560374~42561934:-
THCA	cis	rs8130944	1	rs7281934	ENSG00000235772.1	AP001625.6	3.58	0.000378	0.0242	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42721837	chr21:42560374~42561934:-
THCA	cis	rs878131	0.727	rs1417449	ENSG00000231119.2	RP4-569M23.2	-3.58	0.000378	0.0242	-0.14	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr20:47044907	chr20:47352561~47354633:+
THCA	cis	rs10488360	0.69	rs7789446	ENSG00000270822.1	RP11-730B22.1	3.58	0.000378	0.0242	0.2	0.16	Factor VII;	chr7:4374261	chr7:5009164~5009328:-
THCA	cis	rs7216064	1	rs6504543	ENSG00000278740.1	RP11-147L13.14	3.58	0.000378	0.0242	0.19	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841543	chr17:68188547~68189165:+
THCA	cis	rs10908458	0.584	rs10908454	ENSG00000236675.1	MTX1P1	-3.58	0.000378	0.0242	-0.15	-0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155093940	chr1:155230975~155234325:+
THCA	cis	rs7554182	1	rs6661640	ENSG00000225982.1	RP11-538D16.3	3.58	0.000378	0.0242	0.45	0.16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr1:182042431	chr1:182086551~182090112:+
THCA	cis	rs7554182	1	rs12566732	ENSG00000225982.1	RP11-538D16.3	3.58	0.000378	0.0242	0.45	0.16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr1:182043776	chr1:182086551~182090112:+
THCA	cis	rs7188697	0.809	rs4784956	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58562387	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs11862156	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58562849	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.845	rs1981960	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58563385	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs1981961	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58563387	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs4471670	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58567461	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.743	rs11859781	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58568685	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs9923491	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58569272	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs7186997	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58569444	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs2090727	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58570257	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.882	rs9921370	ENSG00000276259.1	RP11-481J2.4	3.58	0.000378	0.0242	0.11	0.16	QT interval;	chr16:58578031	chr16:58522970~58523842:+
THCA	cis	rs4568518	0.71	rs12699929	ENSG00000279048.1	RP11-511H23.2	3.58	0.000378	0.0242	0.1	0.16	Measles;	chr7:17972634	chr7:17940503~17942922:+
THCA	cis	rs4568518	0.71	rs12699930	ENSG00000279048.1	RP11-511H23.2	3.58	0.000378	0.0242	0.1	0.16	Measles;	chr7:17972635	chr7:17940503~17942922:+
THCA	cis	rs2367725	1	rs2367725	ENSG00000237950.1	RP11-7O11.3	3.58	0.000378	0.0242	0.14	0.16	Aging (time to event);	chr1:43750157	chr1:43944370~43946551:-
THCA	cis	rs9307551	0.619	rs7670107	ENSG00000249646.2	OR7E94P	-3.58	0.000378	0.0242	-0.22	-0.16	Refractive error;	chr4:79502861	chr4:79587302~79588130:-
THCA	cis	rs330048	0.525	rs10112237	ENSG00000248538.5	RP11-10A14.5	3.58	0.000378	0.0242	0.2	0.16	Systemic lupus erythematosus;	chr8:9215219	chr8:9189011~9202854:+
THCA	cis	rs6449502	0.702	rs6877757	ENSG00000251279.1	CTC-436P18.1	-3.58	0.000378	0.0242	-0.25	-0.16	Mean platelet volume;	chr5:60813695	chr5:61162070~61232040:+
THCA	cis	rs11673344	0.523	rs2562599	ENSG00000267260.1	CTD-2162K18.4	3.58	0.000378	0.0242	0.19	0.16	Obesity-related traits;	chr19:37025472	chr19:36773153~36777078:+
THCA	cis	rs13064773	0.546	rs340252	ENSG00000240207.5	RP11-379F4.4	-3.58	0.000378	0.0242	-0.18	-0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158881342	chr3:158732263~158784070:+
THCA	cis	rs10090774	0.932	rs13259836	ENSG00000280303.2	ERICD	-3.58	0.000378	0.0242	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955789	chr8:140636281~140638283:+
THCA	cis	rs7615952	0.866	rs13063119	ENSG00000272840.1	RP11-379B18.6	3.58	0.000378	0.0242	0.27	0.16	Blood pressure (smoking interaction);	chr3:125925004	chr3:125774714~125797953:+
THCA	cis	rs10875746	0.855	rs12310999	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48053875	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs61918774	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48054351	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.807	rs12297004	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48060037	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs10875735	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48070023	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.855	rs17122620	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48070692	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.859	rs4760680	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48072914	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs11168386	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48074194	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.807	rs12313300	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48076934	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs12315625	ENSG00000258234.1	RP11-370I10.2	3.58	0.000378	0.0242	0.19	0.16	Longevity (90 years and older);	chr12:48078670	chr12:48231098~48284210:-
THCA	cis	rs7572733	0.846	rs1518359	ENSG00000231621.1	AC013264.2	-3.58	0.000378	0.0242	-0.15	-0.16	Dermatomyositis;	chr2:197982659	chr2:197197991~197199273:+
THCA	cis	rs7824557	0.564	rs2736290	ENSG00000227888.4	FAM66A	-3.58	0.000378	0.0242	-0.21	-0.16	Retinal vascular caliber;	chr8:11376789	chr8:12362019~12388296:+
THCA	cis	rs3812762	0.871	rs10734637	ENSG00000254860.4	TMEM9B-AS1	-3.58	0.000378	0.0242	-0.18	-0.16	Hypospadias;	chr11:8766678	chr11:8964675~8977527:+
THCA	cis	rs9991779	0.657	rs11736429	ENSG00000237125.7	HAND2-AS1	3.58	0.000378	0.0242	0.27	0.16	Pediatric bone mineral content (hip);	chr4:173978425	chr4:173527270~173591324:+
THCA	cis	rs4931000	1	rs10771895	ENSG00000255760.1	RP11-428G5.5	-3.58	0.000378	0.0242	-0.16	-0.16	Testicular germ cell tumor;	chr12:31986484	chr12:31877079~31887203:-
THCA	cis	rs7613875	0.58	rs11709503	ENSG00000281691.1	RBM5-AS1	3.58	0.000378	0.0243	0.14	0.16	Body mass index;	chr3:49953734	chr3:50099603~50100988:-
THCA	cis	rs2228479	0.85	rs1108063	ENSG00000274627.1	RP11-104N10.2	-3.58	0.000378	0.0243	-0.27	-0.16	Skin colour saturation;	chr16:89827575	chr16:89516797~89522217:+
THCA	cis	rs10975370	0.527	rs58963098	ENSG00000206147.5	RP11-106A1.2	3.58	0.000378	0.0243	0.2	0.16	Breast cancer;	chr9:6020955	chr9:6639139~6639604:+
THCA	cis	rs9341808	0.538	rs688867	ENSG00000272129.1	RP11-250B2.6	3.58	0.000378	0.0243	0.21	0.16	Sitting height ratio;	chr6:80229511	chr6:80355424~80356859:+
THCA	cis	rs7208859	0.673	rs216409	ENSG00000264242.2	RP11-271K11.1	-3.58	0.000378	0.0243	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30553697~30558962:+
THCA	cis	rs17270561	0.636	rs1185977	ENSG00000272462.2	U91328.19	-3.58	0.000378	0.0243	-0.13	-0.16	Iron status biomarkers;	chr6:25828826	chr6:25992662~26001775:+
THCA	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	3.58	0.000378	0.0243	0.19	0.16	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
THCA	cis	rs2310173	0.521	rs974950	ENSG00000281162.1	LINC01127	-3.58	0.000379	0.0243	-0.13	-0.16	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102042732	chr2:101962056~101987167:+
THCA	cis	rs4588572	0.606	rs2362828	ENSG00000245556.2	SCAMP1-AS1	-3.58	0.000379	0.0243	-0.13	-0.16	Triglycerides;	chr5:78423011	chr5:78342365~78360507:-
THCA	cis	rs972540	1	rs113426863	ENSG00000229647.1	AC007879.7	-3.58	0.000379	0.0243	-0.19	-0.16	Body mass index;	chr2:206372073	chr2:207239650~207245887:+
THCA	cis	rs9650657	0.538	rs11250093	ENSG00000269899.1	RP11-589N15.2	-3.58	0.000379	0.0243	-0.18	-0.16	Neuroticism;	chr8:10941318	chr8:11846154~11846391:-
THCA	cis	rs8114671	0.527	rs2253484	ENSG00000126005.14	MMP24-AS1	3.58	0.000379	0.0243	0.15	0.16	Height;	chr20:34817460	chr20:35216462~35278131:-
THCA	cis	rs875971	0.66	rs28698552	ENSG00000232546.1	RP11-458F8.1	-3.58	0.000379	0.0243	-0.13	-0.16	Aortic root size;	chr7:66540031	chr7:66848496~66858136:+
THCA	cis	rs10090774	0.965	rs4961290	ENSG00000280303.2	ERICD	-3.58	0.000379	0.0243	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140741613	chr8:140636281~140638283:+
THCA	cis	rs2821260	0.755	rs1486091	ENSG00000227207.2	RPL31P12	3.58	0.000379	0.0243	0.18	0.16	Intelligence (multi-trait analysis);	chr1:72105681	chr1:72301472~72301829:+
THCA	cis	rs681383	1	rs635416	ENSG00000264964.1	RP11-888D10.3	3.58	0.000379	0.0243	0.24	0.16	Sitting height ratio;	chr18:8350180	chr18:9315194~9334441:-
THCA	cis	rs755249	0.727	rs16826349	ENSG00000228060.1	RP11-69E11.8	-3.58	0.000379	0.0243	-0.15	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39565160~39573203:+
THCA	cis	rs4792901	0.759	rs9907813	ENSG00000279602.1	CTD-3014M21.1	-3.58	0.000379	0.0243	-0.21	-0.16	Dupuytren's disease;	chr17:43525490	chr17:43360041~43361361:-
THCA	cis	rs9584850	0.874	rs7988959	ENSG00000231194.1	FARP1-AS1	3.58	0.000379	0.0243	0.2	0.16	Neuroticism;	chr13:98451750	chr13:98435405~98435840:-
THCA	cis	rs6580649	1	rs7132668	ENSG00000273765.1	RP11-370I10.11	3.58	0.000379	0.0243	0.18	0.16	Lung cancer;	chr12:48012077	chr12:48360920~48361377:+
THCA	cis	rs1153858	1	rs1049503	ENSG00000275672.1	GATM-AS1	-3.58	0.000379	0.0243	-0.17	-0.16	Homoarginine levels;	chr15:45361509	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs3759899	ENSG00000275672.1	GATM-AS1	-3.58	0.000379	0.0243	-0.17	-0.16	Homoarginine levels;	chr15:45363705	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs7164602	ENSG00000275672.1	GATM-AS1	-3.58	0.000379	0.0243	-0.17	-0.16	Homoarginine levels;	chr15:45379127	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs12441971	ENSG00000275672.1	GATM-AS1	-3.58	0.000379	0.0243	-0.17	-0.16	Homoarginine levels;	chr15:45379759	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs1346268	ENSG00000275672.1	GATM-AS1	-3.58	0.000379	0.0243	-0.17	-0.16	Homoarginine levels;	chr15:45380831	chr15:45378700~45380123:+
THCA	cis	rs1153858	0.943	rs67045941	ENSG00000275672.1	GATM-AS1	-3.58	0.000379	0.0243	-0.17	-0.16	Homoarginine levels;	chr15:45384813	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs67744121	ENSG00000275672.1	GATM-AS1	-3.58	0.000379	0.0243	-0.17	-0.16	Homoarginine levels;	chr15:45385039	chr15:45378700~45380123:+
THCA	cis	rs9868809	0.772	rs9812977	ENSG00000270441.1	RP11-694I15.7	3.58	0.000379	0.0243	0.23	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48682870	chr3:49140086~49160851:-
THCA	cis	rs875971	0.66	rs6460308	ENSG00000232546.1	RP11-458F8.1	3.58	0.000379	0.0243	0.13	0.16	Aortic root size;	chr7:66619753	chr7:66848496~66858136:+
THCA	cis	rs875971	0.522	rs6960048	ENSG00000230295.1	RP11-458F8.2	-3.58	0.000379	0.0243	-0.13	-0.16	Aortic root size;	chr7:65943052	chr7:66880708~66882981:+
THCA	cis	rs9596863	1	rs9596858	ENSG00000136149.6	RPL13AP25	-3.58	0.000379	0.0243	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53847723	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9568943	ENSG00000136149.6	RPL13AP25	-3.58	0.000379	0.0243	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53848930	chr13:54440704~54441315:-
THCA	cis	rs1065852	0.526	rs8138080	ENSG00000227370.1	RP4-669P10.19	-3.58	0.000379	0.0243	-0.17	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42000367	chr22:42132543~42132998:+
THCA	cis	rs2549003	0.934	rs2549006	ENSG00000233006.5	AC034220.3	3.58	0.000379	0.0243	0.13	0.16	Asthma (sex interaction);	chr5:132491373	chr5:132311285~132369916:-
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000184274.3	LINC00315	-3.58	0.000379	0.0243	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45300245~45305257:-
THCA	cis	rs12887734	0.566	rs8548	ENSG00000269958.1	RP11-73M18.8	3.58	0.000379	0.0243	0.16	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103696353~103697163:+
THCA	cis	rs7267979	0.933	rs2258728	ENSG00000276952.1	RP5-965G21.6	3.58	0.000379	0.0243	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25284915~25285588:-
THCA	cis	rs4773860	0.601	rs4148446	ENSG00000223298.1	RNY3P8	-3.58	0.000379	0.0243	-0.19	-0.16	Plateletcrit;	chr13:95245048	chr13:95310830~95310955:-
THCA	cis	rs7474896	0.559	rs1024202	ENSG00000272983.1	RP11-508N22.12	3.58	0.000379	0.0243	0.17	0.16	Obesity (extreme);	chr10:37990049	chr10:38137337~38144399:+
THCA	cis	rs7474896	0.537	rs1022449	ENSG00000272983.1	RP11-508N22.12	3.58	0.000379	0.0243	0.17	0.16	Obesity (extreme);	chr10:37990539	chr10:38137337~38144399:+
THCA	cis	rs73198271	0.74	rs3827807	ENSG00000254153.1	CTA-398F10.2	3.58	0.000379	0.0243	0.21	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8456909~8461337:-
THCA	cis	rs7951911	0.915	rs12274670	ENSG00000254427.1	RP11-430H10.1	3.58	0.000379	0.0243	0.3	0.16	IgG glycosylation;	chr11:45060728	chr11:45355371~45366121:+
THCA	cis	rs11124272	0.716	rs527112	ENSG00000276517.1	AL133243.2	-3.58	0.000379	0.0243	-0.16	-0.16	Interleukin-18 levels;	chr2:31640549	chr2:32526504~32529507:+
THCA	cis	rs10780792	0.553	rs374503	ENSG00000165121.10	RP11-213G2.3	3.58	0.000379	0.0243	0.14	0.16	Lobe attachment (rater-scored or self-reported);	chr9:86807254	chr9:85815966~85849511:+
THCA	cis	rs9309473	1	rs10190219	ENSG00000273245.1	RP11-434P11.2	3.58	0.000379	0.0243	0.22	0.16	Metabolite levels;	chr2:73431203	chr2:73750256~73750786:-
THCA	cis	rs2299587	0.56	rs12718385	ENSG00000253671.1	RP11-806O11.1	-3.58	0.000379	0.0243	-0.2	-0.16	Economic and political preferences;	chr8:17923748	chr8:17808941~17820868:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000275400.1	RP4-756H11.5	3.58	0.000379	0.0243	0.16	0.16	Aortic root size;	chr7:66597493	chr7:66553805~66554199:-
THCA	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	3.58	0.000379	0.0243	0.15	0.16	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
THCA	cis	rs409045	0.965	rs462352	ENSG00000271874.1	CTD-2024P10.2	-3.58	0.000379	0.0243	-0.22	-0.16	Left ventricular mass;	chr5:34635891	chr5:34651457~34651888:-
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000264242.2	RP11-271K11.1	3.58	0.000379	0.0243	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30553697~30558962:+
THCA	cis	rs763121	0.853	rs8140617	ENSG00000272669.1	RP3-508I15.21	3.58	0.000379	0.0243	0.11	0.16	Menopause (age at onset);	chr22:38574434	chr22:38742625~38743115:+
THCA	cis	rs1923243	0.617	rs12122377	ENSG00000223479.3	RP4-788P17.1	3.58	0.000379	0.0243	0.17	0.16	Migraine;	chr1:72961301	chr1:73635216~73715214:+
THCA	cis	rs7131987	0.903	rs10843367	ENSG00000257599.1	OVCH1-AS1	-3.58	0.000379	0.0243	-0.2	-0.16	QT interval;	chr12:29255447	chr12:29389294~29487488:+
THCA	cis	rs9858542	0.537	rs2304442	ENSG00000270441.1	RP11-694I15.7	-3.58	0.000379	0.0243	-0.18	-0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49284594	chr3:49140086~49160851:-
THCA	cis	rs4295623	0.789	rs12541318	ENSG00000255046.1	RP11-297N6.4	3.58	0.000379	0.0243	0.17	0.16	Morning vs. evening chronotype;	chr8:11737461	chr8:11797928~11802568:-
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000184274.3	LINC00315	-3.58	0.000379	0.0243	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45300245~45305257:-
THCA	cis	rs72765298	0.848	rs869248	ENSG00000235332.2	RP11-366O20.5	3.58	0.000379	0.0243	0.29	0.16	Pulse pressure;	chr9:125198824	chr9:125194649~125195821:-
THCA	cis	rs72765298	0.848	rs59356323	ENSG00000235332.2	RP11-366O20.5	3.58	0.000379	0.0243	0.29	0.16	Pulse pressure;	chr9:125203121	chr9:125194649~125195821:-
THCA	cis	rs13217239	0.646	rs35691005	ENSG00000261353.1	CTA-14H9.5	-3.58	0.00038	0.0243	-0.17	-0.16	Schizophrenia;	chr6:27004291	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs10946891	ENSG00000261353.1	CTA-14H9.5	-3.58	0.00038	0.0243	-0.17	-0.16	Schizophrenia;	chr6:27005436	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs12201393	ENSG00000261353.1	CTA-14H9.5	-3.58	0.00038	0.0243	-0.17	-0.16	Schizophrenia;	chr6:27007911	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs12209886	ENSG00000261353.1	CTA-14H9.5	-3.58	0.00038	0.0243	-0.17	-0.16	Schizophrenia;	chr6:27016978	chr6:26527063~26527404:+
THCA	cis	rs6940638	0.531	rs12211984	ENSG00000261353.1	CTA-14H9.5	-3.58	0.00038	0.0243	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs10456351	ENSG00000261353.1	CTA-14H9.5	-3.58	0.00038	0.0243	-0.17	-0.16	Schizophrenia;	chr6:27019013	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs10456352	ENSG00000261353.1	CTA-14H9.5	-3.58	0.00038	0.0243	-0.17	-0.16	Schizophrenia;	chr6:27022579	chr6:26527063~26527404:+
THCA	cis	rs13217239	0.646	rs4583981	ENSG00000261353.1	CTA-14H9.5	-3.58	0.00038	0.0243	-0.17	-0.16	Schizophrenia;	chr6:27024244	chr6:26527063~26527404:+
THCA	cis	rs10411161	0.702	rs10424202	ENSG00000275055.1	CTC-471J1.11	-3.58	0.00038	0.0243	-0.16	-0.16	Breast cancer;	chr19:51884044	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs10423835	ENSG00000275055.1	CTC-471J1.11	-3.58	0.00038	0.0243	-0.16	-0.16	Breast cancer;	chr19:51884069	chr19:52049007~52049754:+
THCA	cis	rs7264396	0.887	rs224344	ENSG00000261582.1	RP4-614O4.11	-3.58	0.00038	0.0243	-0.17	-0.16	Total cholesterol levels;	chr20:35449053	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs224347	ENSG00000261582.1	RP4-614O4.11	-3.58	0.00038	0.0243	-0.17	-0.16	Total cholesterol levels;	chr20:35449712	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.832	rs224349	ENSG00000261582.1	RP4-614O4.11	-3.58	0.00038	0.0243	-0.17	-0.16	Total cholesterol levels;	chr20:35457571	chr20:35267885~35280043:-
THCA	cis	rs877819	0.583	rs2620890	ENSG00000228403.1	RP11-563N6.6	-3.58	0.00038	0.0243	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48851723	chr10:48878022~48878649:+
THCA	cis	rs877819	0.583	rs2889699	ENSG00000228403.1	RP11-563N6.6	-3.58	0.00038	0.0243	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48854659	chr10:48878022~48878649:+
THCA	cis	rs7267979	1	rs6076339	ENSG00000276952.1	RP5-965G21.6	-3.58	0.00038	0.0243	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25284915~25285588:-
THCA	cis	rs7744813	0.563	rs2096182	ENSG00000229852.2	RP11-398K22.12	3.58	0.00038	0.0243	0.13	0.16	Myopia;Refractive error;Spherical equivalent (joint analysis main effects and education interaction);	chr6:72868057	chr6:73263215~73301401:+
THCA	cis	rs7010267	0.902	rs10505348	ENSG00000254278.1	RP11-278I4.2	-3.58	0.00038	0.0243	-0.21	-0.16	Total body bone mineral density (age 45-60);	chr8:118960457	chr8:119062942~119068782:-
THCA	cis	rs11168618	0.846	rs7958521	ENSG00000240399.1	RP1-228P16.1	3.58	0.00038	0.0243	0.16	0.16	Adiponectin levels;	chr12:48483617	chr12:48054813~48055591:-
THCA	cis	rs7619427	0.556	rs9823715	ENSG00000271192.1	RP4-555D20.3	-3.58	0.00038	0.0243	-0.22	-0.16	Schizophrenia;	chr3:44036914	chr3:43996896~43997443:+
THCA	cis	rs12148329	0.542	rs7183484	ENSG00000259594.4	CTD-2034I4.2	3.58	0.00038	0.0243	0.27	0.16	Immune response to smallpox vaccine (IL-6);	chr15:80720567	chr15:81554003~81696780:+
THCA	cis	rs9876781	1	rs9815103	ENSG00000199476.1	Y_RNA	-3.58	0.00038	0.0243	-0.21	-0.16	Longevity;	chr3:48372725	chr3:48288587~48288694:+
THCA	cis	rs16975963	0.843	rs241935	ENSG00000276846.1	CTD-3220F14.3	3.58	0.00038	0.0243	0.15	0.16	Longevity;	chr19:37803323	chr19:37314868~37315620:-
THCA	cis	rs2180341	0.782	rs6912750	ENSG00000220522.2	RP1-177A13.1	3.58	0.00038	0.0243	0.19	0.16	Breast cancer;	chr6:127401936	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.782	rs4487601	ENSG00000220522.2	RP1-177A13.1	3.58	0.00038	0.0243	0.19	0.16	Breast cancer;	chr6:127402376	chr6:127416535~127416952:-
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000184274.3	LINC00315	3.58	0.00038	0.0243	0.2	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45300245~45305257:-
THCA	cis	rs9863	0.828	rs11057413	ENSG00000270028.1	RP11-380L11.4	3.58	0.00038	0.0243	0.17	0.16	White blood cell count;	chr12:124004615	chr12:123925461~123926083:-
THCA	cis	rs875971	0.867	rs1002053	ENSG00000272831.1	RP11-792A8.4	-3.58	0.00038	0.0243	-0.1	-0.16	Aortic root size;	chr7:66333558	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6460292	ENSG00000272831.1	RP11-792A8.4	-3.58	0.00038	0.0243	-0.1	-0.16	Aortic root size;	chr7:66345088	chr7:66739829~66740385:-
THCA	cis	rs11638352	1	rs2623017	ENSG00000166763.7	STRCP1	-3.58	0.00038	0.0243	-0.36	-0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44111087	chr15:43699488~43718184:-
THCA	cis	rs10833905	0.938	rs10833927	ENSG00000246225.5	RP11-17A1.3	-3.58	0.00038	0.0243	-0.24	-0.16	Sudden cardiac arrest;	chr11:23067190	chr11:22829380~22945393:+
THCA	cis	rs10833905	0.938	rs3909701	ENSG00000246225.5	RP11-17A1.3	-3.58	0.00038	0.0243	-0.24	-0.16	Sudden cardiac arrest;	chr11:23068738	chr11:22829380~22945393:+
THCA	cis	rs80130819	1	rs17122571	ENSG00000257735.1	RP11-370I10.6	3.58	0.00038	0.0243	0.33	0.16	Prostate cancer;	chr12:48027251	chr12:48350945~48442411:+
THCA	cis	rs4845570	0.834	rs7007	ENSG00000249602.1	RP11-98D18.3	-3.58	0.00038	0.0243	-0.26	-0.16	Coronary artery disease;	chr1:151763100	chr1:151763384~151769501:-
THCA	cis	rs17428076	0.872	rs55863868	ENSG00000228389.1	AC068039.4	-3.58	0.00038	0.0243	-0.2	-0.16	Myopia;	chr2:172023605	chr2:171773482~171775844:+
THCA	cis	rs5758511	0.573	rs1883205	ENSG00000230107.1	CTA-126B4.7	3.58	0.00038	0.0243	0.17	0.16	Birth weight;	chr22:41847016	chr22:42438023~42446195:+
THCA	cis	rs2006771	0.846	rs6518754	ENSG00000214076.3	CPSF1P1	-3.58	0.00038	0.0243	-0.19	-0.16	Nonsyndromic cleft lip with cleft palate;	chr22:31701789	chr22:32269381~32273110:+
THCA	cis	rs11673344	0.504	rs8110796	ENSG00000233527.7	ZNF529-AS1	3.58	0.00038	0.0243	0.14	0.16	Obesity-related traits;	chr19:37132682	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.504	rs8111285	ENSG00000233527.7	ZNF529-AS1	3.58	0.00038	0.0243	0.14	0.16	Obesity-related traits;	chr19:37132747	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.504	rs6510591	ENSG00000233527.7	ZNF529-AS1	3.58	0.00038	0.0243	0.14	0.16	Obesity-related traits;	chr19:37133186	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.504	rs6510592	ENSG00000233527.7	ZNF529-AS1	3.58	0.00038	0.0243	0.14	0.16	Obesity-related traits;	chr19:37133430	chr19:36573070~36594708:+
THCA	cis	rs3015497	0.616	rs7152874	ENSG00000270062.1	RP11-248J18.3	3.58	0.00038	0.0243	0.18	0.16	Mean platelet volume;	chr14:50579322	chr14:50723777~50724272:-
THCA	cis	rs1865760	0.541	rs1436309	ENSG00000272810.1	U91328.22	-3.58	0.00038	0.0243	-0.13	-0.16	Height;	chr6:25969881	chr6:26013241~26013757:+
THCA	cis	rs17213965	0.925	rs3898632	ENSG00000207425.1	Y_RNA	-3.58	0.00038	0.0243	-0.25	-0.16	Waist-hip ratio;	chr16:15789384	chr16:14915457~14915556:-
THCA	cis	rs5762752	0.521	rs695709	ENSG00000272858.1	CTA-292E10.8	-3.58	0.00038	0.0243	-0.15	-0.16	Optic disc area;	chr22:28516867	chr22:28814914~28815662:+
THCA	cis	rs8042680	0.784	rs6496742	ENSG00000258725.1	PRC1-AS1	-3.58	0.00038	0.0243	-0.21	-0.16	Type 2 diabetes;	chr15:90979806	chr15:90966345~90988624:+
THCA	cis	rs73193808	0.851	rs11911017	ENSG00000176054.6	RPL23P2	-3.58	0.00038	0.0243	-0.19	-0.16	Coronary artery disease;	chr21:29195620	chr21:28997613~28998033:-
THCA	cis	rs7178375	1	rs1474382	ENSG00000215302.7	CTD-3092A11.1	-3.58	0.00038	0.0243	-0.23	-0.16	Hypertriglyceridemia;	chr15:30922446	chr15:30470779~30507623:+
THCA	cis	rs950169	0.92	rs2135551	ENSG00000275120.1	RP11-182J1.17	3.58	0.00038	0.0244	0.2	0.16	Schizophrenia;	chr15:84039099	chr15:84599434~84606463:-
THCA	cis	rs950169	1	rs12902672	ENSG00000275120.1	RP11-182J1.17	3.58	0.00038	0.0244	0.2	0.16	Schizophrenia;	chr15:84048234	chr15:84599434~84606463:-
THCA	cis	rs950169	1	rs12903820	ENSG00000275120.1	RP11-182J1.17	3.58	0.00038	0.0244	0.2	0.16	Schizophrenia;	chr15:84055068	chr15:84599434~84606463:-
THCA	cis	rs950169	0.919	rs12915589	ENSG00000275120.1	RP11-182J1.17	3.58	0.00038	0.0244	0.2	0.16	Schizophrenia;	chr15:84065712	chr15:84599434~84606463:-
THCA	cis	rs950169	0.959	rs66801143	ENSG00000275120.1	RP11-182J1.17	3.58	0.00038	0.0244	0.2	0.16	Schizophrenia;	chr15:84067905	chr15:84599434~84606463:-
THCA	cis	rs950169	1	rs35648189	ENSG00000275120.1	RP11-182J1.17	3.58	0.00038	0.0244	0.2	0.16	Schizophrenia;	chr15:84071996	chr15:84599434~84606463:-
THCA	cis	rs950169	0.92	rs17300048	ENSG00000275120.1	RP11-182J1.17	3.58	0.00038	0.0244	0.2	0.16	Schizophrenia;	chr15:84080725	chr15:84599434~84606463:-
THCA	cis	rs950169	1	rs1848093	ENSG00000275120.1	RP11-182J1.17	3.58	0.00038	0.0244	0.2	0.16	Schizophrenia;	chr15:84086775	chr15:84599434~84606463:-
THCA	cis	rs35146811	0.735	rs1637001	ENSG00000078319.8	PMS2P1	-3.58	0.00038	0.0244	-0.2	-0.16	Coronary artery disease;	chr7:100210528	chr7:100320992~100341908:-
THCA	cis	rs1501911	0.53	rs162611	ENSG00000246763.5	RGMB-AS1	-3.58	0.00038	0.0244	-0.17	-0.16	Lung function (FEV1/FVC);	chr5:98809801	chr5:98769618~98773469:-
THCA	cis	rs11603020	0.95	rs78364821	ENSG00000265566.2	RN7SL605P	-3.58	0.00038	0.0244	-0.25	-0.16	Blood protein levels;	chr11:57603269	chr11:57528085~57528365:-
THCA	cis	rs13315871	0.929	rs11706920	ENSG00000272182.1	RP11-802O23.3	3.58	0.00038	0.0244	0.28	0.16	Cholesterol, total;	chr3:58293945	chr3:58428255~58428815:+
THCA	cis	rs8062405	0.54	rs151226	ENSG00000261766.1	RP11-22P6.2	-3.58	0.00038	0.0244	-0.15	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28862166~28863340:-
THCA	cis	rs16857609	0.529	rs74723351	ENSG00000233143.1	DIRC3-AS1	-3.58	0.00038	0.0244	-0.2	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217423494	chr2:217282739~217336120:+
THCA	cis	rs2290416	0.786	rs77951814	ENSG00000253931.1	RP11-909N17.2	3.58	0.00038	0.0244	0.34	0.16	Attention deficit hyperactivity disorder;	chr8:143574982	chr8:143412749~143417054:+
THCA	cis	rs860295	1	rs6427286	ENSG00000160766.13	GBAP1	-3.58	0.00038	0.0244	-0.18	-0.16	Body mass index;	chr1:155753506	chr1:155213821~155227422:-
THCA	cis	rs860295	1	rs6427287	ENSG00000160766.13	GBAP1	-3.58	0.00038	0.0244	-0.18	-0.16	Body mass index;	chr1:155753629	chr1:155213821~155227422:-
THCA	cis	rs8033133	0.602	rs12438531	ENSG00000251896.1	SNORD116-27	-3.58	0.00038	0.0244	-0.18	-0.16	Blood osmolality (transformed sodium);	chr15:25078729	chr15:25101575~25101666:+
THCA	cis	rs3218092	0.688	rs56311009	ENSG00000213435.3	ATP6V0CP3	3.58	0.00038	0.0244	0.28	0.16	Red cell distribution width;	chr6:41836507	chr6:42727234~42727700:+
THCA	cis	rs3218092	0.688	rs112001527	ENSG00000213435.3	ATP6V0CP3	3.58	0.00038	0.0244	0.28	0.16	Red cell distribution width;	chr6:41839401	chr6:42727234~42727700:+
THCA	cis	rs7520050	0.966	rs785495	ENSG00000280836.1	AL355480.1	3.58	0.000381	0.0244	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45581219~45581321:-
THCA	cis	rs6938	0.618	rs12901190	ENSG00000260269.4	CTD-2323K18.1	-3.58	0.000381	0.0244	-0.24	-0.16	Breast cancer;	chr15:74939111	chr15:75527150~75601205:-
THCA	cis	rs911555	0.755	rs6575988	ENSG00000269940.1	RP11-73M18.7	-3.58	0.000381	0.0244	-0.17	-0.16	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103694560~103695170:+
THCA	cis	rs4262150	0.81	rs17565470	ENSG00000253921.1	CTB-113P19.3	3.58	0.000381	0.0244	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152684284	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.739	rs3890802	ENSG00000253921.1	CTB-113P19.3	3.58	0.000381	0.0244	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152702367	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs56047721	ENSG00000253921.1	CTB-113P19.3	3.58	0.000381	0.0244	0.22	0.16	Bipolar disorder and schizophrenia;	chr5:152703305	chr5:151753992~151767247:+
THCA	cis	rs929354	0.739	rs1182439	ENSG00000224629.1	RP5-1142J19.2	3.58	0.000381	0.0244	0.16	0.16	Body mass index;	chr7:157234673	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs1182438	ENSG00000224629.1	RP5-1142J19.2	3.58	0.000381	0.0244	0.16	0.16	Body mass index;	chr7:157234744	chr7:157263022~157263229:-
THCA	cis	rs7914558	0.966	rs10450373	ENSG00000272912.1	RP11-724N1.1	-3.58	0.000381	0.0244	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102968859	chr10:102914585~102915404:+
THCA	cis	rs2839186	0.5	rs13049893	ENSG00000215424.8	MCM3AP-AS1	3.58	0.000381	0.0244	0.1	0.16	Testicular germ cell tumor;	chr21:46287140	chr21:46229217~46259390:+
THCA	cis	rs12681366	0.683	rs2470746	ENSG00000261437.1	RP11-22C11.2	-3.58	0.000381	0.0244	-0.15	-0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94383580	chr8:94637285~94639467:-
THCA	cis	rs2888875	0.963	rs11890152	ENSG00000200924.1	RNU6-1048P	-3.58	0.000381	0.0244	-0.18	-0.16	Glomerular filtration rate (creatinine);	chr2:43580229	chr2:43892690~43892796:+
THCA	cis	rs62289301	0.571	rs16891945	ENSG00000273133.1	RP11-799M12.2	3.58	0.000381	0.0244	0.2	0.16	Joint mobility (Beighton score);	chr4:15426989	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.592	rs3797006	ENSG00000273133.1	RP11-799M12.2	3.58	0.000381	0.0244	0.2	0.16	Joint mobility (Beighton score);	chr4:15427752	chr4:15563698~15564253:-
THCA	cis	rs10975370	0.552	rs10975406	ENSG00000206147.5	RP11-106A1.2	3.58	0.000381	0.0244	0.2	0.16	Breast cancer;	chr9:6041603	chr9:6639139~6639604:+
THCA	cis	rs10975370	0.552	rs11532876	ENSG00000206147.5	RP11-106A1.2	3.58	0.000381	0.0244	0.2	0.16	Breast cancer;	chr9:6042187	chr9:6639139~6639604:+
THCA	cis	rs12506899	0.967	rs2051512	ENSG00000221639.1	SNORA3	-3.58	0.000381	0.0244	-0.19	-0.16	Tumor biomarkers;	chr4:73413832	chr4:73263960~73264084:+
THCA	cis	rs2483519	0.511	rs7075935	ENSG00000228169.3	PPIAP19	3.58	0.000381	0.0244	0.19	0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114690977	chr10:114690143~114690634:-
THCA	cis	rs3018712	0.532	rs7932726	ENSG00000212093.1	AP000807.1	-3.58	0.000381	0.0244	-0.21	-0.16	Total body bone mineral density;	chr11:68647259	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.532	rs4930587	ENSG00000212093.1	AP000807.1	-3.58	0.000381	0.0244	-0.21	-0.16	Total body bone mineral density;	chr11:68647667	chr11:68506083~68506166:-
THCA	cis	rs77204473	0.744	rs17120293	ENSG00000276505.1	CMB9-94B1.2	-3.58	0.000381	0.0244	-0.33	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117297005~117297328:-
THCA	cis	rs875971	0.895	rs7782806	ENSG00000223473.2	GS1-124K5.3	-3.58	0.000381	0.0244	-0.11	-0.16	Aortic root size;	chr7:66192910	chr7:66491049~66493566:-
THCA	cis	rs7819412	0.775	rs4840551	ENSG00000254866.2	DEFB109P3	3.58	0.000381	0.0244	0.23	0.16	Triglycerides;	chr8:11171530	chr8:12150895~12151134:-
THCA	cis	rs293748	0.605	rs13188136	ENSG00000250155.1	CTD-2353F22.1	-3.58	0.000381	0.0244	-0.2	-0.16	Obesity-related traits;	chr5:37117132	chr5:36666214~36725195:-
THCA	cis	rs1433188	0.847	rs7816817	ENSG00000253582.1	RP11-649G15.2	3.58	0.000381	0.0244	0.19	0.16	Subjective well-being;	chr8:107431176	chr8:106520474~106657548:-
THCA	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	3.58	0.000381	0.0244	0.15	0.16	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
THCA	cis	rs4646450	0.891	rs1011024	ENSG00000274272.1	RP11-44M6.7	3.58	0.000381	0.0244	0.18	0.16	Blood metabolite levels;	chr7:99599778	chr7:100572232~100578700:-
THCA	cis	rs7829975	0.508	rs1594437	ENSG00000254340.1	RP11-10A14.3	3.58	0.000381	0.0244	0.18	0.16	Mood instability;	chr8:8968365	chr8:9141424~9145435:+
THCA	cis	rs7474896	0.515	rs2738208	ENSG00000272983.1	RP11-508N22.12	3.58	0.000381	0.0244	0.17	0.16	Obesity (extreme);	chr10:38017200	chr10:38137337~38144399:+
THCA	cis	rs7924176	0.564	rs12569971	ENSG00000232342.6	RP11-46O21.2	3.58	0.000381	0.0244	0.21	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74194617	chr10:74506081~74530553:-
THCA	cis	rs9611565	0.649	rs139553	ENSG00000237037.8	NDUFA6-AS1	-3.58	0.000381	0.0244	-0.14	-0.16	Vitiligo;	chr22:41791195	chr22:42090931~42137742:+
THCA	cis	rs1383484	1	rs4438273	ENSG00000225151.9	GOLGA2P7	3.58	0.000381	0.0244	0.22	0.16	Height;	chr15:83832524	chr15:84199311~84230136:-
THCA	cis	rs4713118	0.955	rs9468206	ENSG00000219891.2	ZSCAN12P1	3.58	0.000381	0.0244	0.22	0.16	Parkinson's disease;	chr6:27722674	chr6:28091154~28093664:+
THCA	cis	rs11771526	0.748	rs11765652	ENSG00000272905.1	RP11-265E18.1	3.58	0.000381	0.0244	0.2	0.16	Body mass index;	chr7:32296832	chr7:32845394~32846061:+
THCA	cis	rs17291845	0.744	rs2003305	ENSG00000260135.5	RP11-212I21.2	3.58	0.000381	0.0244	0.22	0.16	Information processing speed;	chr16:55213049	chr16:55426797~55462297:-
THCA	cis	rs7824557	0.564	rs2572379	ENSG00000261451.1	RP11-981G7.1	-3.58	0.000381	0.0244	-0.2	-0.16	Retinal vascular caliber;	chr8:11379971	chr8:10433672~10438312:+
THCA	cis	rs5752773	0.513	rs134541	ENSG00000272858.1	CTA-292E10.8	3.58	0.000381	0.0244	0.18	0.16	Vertical cup-disc ratio;	chr22:28399275	chr22:28814914~28815662:+
THCA	cis	rs9635324	1	rs2289329	ENSG00000259536.4	RP11-111A22.1	3.58	0.000381	0.0244	0.21	0.16	Blood metabolite ratios;Blood metabolite levels;	chr15:40412960	chr15:40488041~40558019:+
THCA	cis	rs6995541	0.614	rs7824384	ENSG00000248896.2	CTD-2135J3.3	-3.58	0.000381	0.0244	-0.23	-0.16	Triglyceride levels;	chr8:10825815	chr8:10729314~10771392:+
THCA	cis	rs2839186	0.588	rs2839140	ENSG00000225043.1	RPL18AP2	-3.58	0.000381	0.0244	-0.19	-0.16	Testicular germ cell tumor;	chr21:46196166	chr21:46420553~46421034:-
THCA	cis	rs2839186	0.647	rs9976233	ENSG00000225043.1	RPL18AP2	-3.58	0.000381	0.0244	-0.19	-0.16	Testicular germ cell tumor;	chr21:46196999	chr21:46420553~46421034:-
THCA	cis	rs2839186	0.588	rs7280110	ENSG00000225043.1	RPL18AP2	-3.58	0.000381	0.0244	-0.19	-0.16	Testicular germ cell tumor;	chr21:46199125	chr21:46420553~46421034:-
THCA	cis	rs2839186	0.616	rs4819213	ENSG00000225043.1	RPL18AP2	-3.58	0.000381	0.0244	-0.19	-0.16	Testicular germ cell tumor;	chr21:46199386	chr21:46420553~46421034:-
THCA	cis	rs2486012	1	rs2428960	ENSG00000237950.1	RP11-7O11.3	-3.58	0.000381	0.0244	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43927474	chr1:43944370~43946551:-
THCA	cis	rs10129255	0.912	rs730099	ENSG00000211972.2	IGHV3-66	3.58	0.000381	0.0244	0.1	0.16	Kawasaki disease;	chr14:106711838	chr14:106675017~106675544:-
THCA	cis	rs7709377	0.516	rs73257302	ENSG00000271918.1	CTD-2287O16.5	3.58	0.000381	0.0244	0.16	0.16	Metabolite levels  (X-11787);	chr5:116207391	chr5:116083807~116085416:-
THCA	cis	rs453301	0.597	rs7001187	ENSG00000253981.4	ALG1L13P	-3.58	0.000381	0.0244	-0.17	-0.16	Joint mobility (Beighton score);	chr8:8935272	chr8:8236003~8244667:-
THCA	cis	rs6494488	0.5	rs55960029	ENSG00000259635.1	AC100830.3	-3.58	0.000381	0.0244	-0.41	-0.16	Coronary artery disease;	chr15:64754881	chr15:64701248~64719602:+
THCA	cis	rs875971	0.862	rs7786892	ENSG00000223473.2	GS1-124K5.3	-3.58	0.000381	0.0244	-0.11	-0.16	Aortic root size;	chr7:66163889	chr7:66491049~66493566:-
THCA	cis	rs2744375	0.6	rs2744362	ENSG00000261189.1	RP3-512B11.3	3.58	0.000381	0.0244	0.17	0.16	Resting heart rate;	chr6:7550975	chr6:7540451~7541338:-
THCA	cis	rs683250	0.629	rs694566	ENSG00000254551.1	RP11-727A23.7	3.58	0.000381	0.0244	0.2	0.16	Subcortical brain region volumes;	chr11:83228490	chr11:83209431~83213379:-
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000264242.2	RP11-271K11.1	3.58	0.000381	0.0244	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30553697~30558962:+
THCA	cis	rs2455799	0.613	rs62241264	ENSG00000270409.1	RP11-44D5.1	-3.58	0.000381	0.0244	-0.18	-0.16	Mean platelet volume;	chr3:15901964	chr3:15732252~15733470:+
THCA	cis	rs6787172	0.622	rs7426603	ENSG00000272087.1	RP11-379F4.7	3.58	0.000382	0.0244	0.15	0.16	Subjective well-being;	chr3:158389308	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs67385174	ENSG00000272087.1	RP11-379F4.7	3.58	0.000382	0.0244	0.15	0.16	Subjective well-being;	chr3:158393536	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.537	rs9811217	ENSG00000272087.1	RP11-379F4.7	3.58	0.000382	0.0244	0.15	0.16	Subjective well-being;	chr3:158399911	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs9870731	ENSG00000272087.1	RP11-379F4.7	3.58	0.000382	0.0244	0.15	0.16	Subjective well-being;	chr3:158400055	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs10446336	ENSG00000272087.1	RP11-379F4.7	3.58	0.000382	0.0244	0.15	0.16	Subjective well-being;	chr3:158401866	chr3:158693120~158693768:-
THCA	cis	rs4971059	0.654	rs4276913	ENSG00000225855.5	RUSC1-AS1	3.58	0.000382	0.0244	0.11	0.16	Breast cancer;	chr1:155159197	chr1:155316863~155324176:-
THCA	cis	rs11118346	0.64	rs7526373	ENSG00000228536.1	RP11-392O17.1	-3.58	0.000382	0.0244	-0.19	-0.16	Height;	chr1:219575246	chr1:219409681~219411941:-
THCA	cis	rs9863	0.828	rs7975482	ENSG00000269938.1	RP11-214K3.20	-3.58	0.000382	0.0244	-0.19	-0.16	White blood cell count;	chr12:123997143	chr12:123968023~123968579:-
THCA	cis	rs12681366	0.659	rs2470742	ENSG00000261437.1	RP11-22C11.2	-3.58	0.000382	0.0244	-0.15	-0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94385929	chr8:94637285~94639467:-
THCA	cis	rs11190604	0.767	rs7090150	ENSG00000273030.1	RP11-285F16.1	3.58	0.000382	0.0244	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100413689	chr10:100412934~100413421:+
THCA	cis	rs12887734	0.546	rs12886637	ENSG00000269958.1	RP11-73M18.8	-3.58	0.000382	0.0244	-0.15	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103696353~103697163:+
THCA	cis	rs7111546	1	rs57862275	ENSG00000246225.5	RP11-17A1.3	3.58	0.000382	0.0244	0.28	0.16	Dialysis-related mortality;	chr11:22800509	chr11:22829380~22945393:+
THCA	cis	rs7111546	1	rs11026797	ENSG00000246225.5	RP11-17A1.3	3.58	0.000382	0.0244	0.28	0.16	Dialysis-related mortality;	chr11:22800724	chr11:22829380~22945393:+
THCA	cis	rs2006933	1	rs9892047	ENSG00000267644.1	CTD-2008P7.10	3.58	0.000382	0.0244	0.21	0.16	Amyotrophic lateral sclerosis;	chr17:28265331	chr17:28219285~28220005:+
THCA	cis	rs67981189	0.789	rs2810073	ENSG00000269927.1	RP6-91H8.3	-3.58	0.000382	0.0244	-0.19	-0.16	Schizophrenia;	chr14:70917131	chr14:71141125~71143253:-
THCA	cis	rs7819412	0.608	rs28417109	ENSG00000255310.2	AF131215.2	-3.58	0.000382	0.0244	-0.15	-0.16	Triglycerides;	chr8:11117571	chr8:11107788~11109726:-
THCA	cis	rs12121840	0.79	rs6657863	ENSG00000237463.4	RP11-280O1.2	-3.58	0.000382	0.0244	-0.14	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165577434	chr1:165476841~165582155:-
THCA	cis	rs73230612	1	rs56260350	ENSG00000242767.1	ZBTB20-AS4	3.58	0.000382	0.0244	0.22	0.16	Type 2 diabetes;	chr3:115201353	chr3:115100423~115103061:+
THCA	cis	rs73230612	1	rs9832181	ENSG00000242767.1	ZBTB20-AS4	3.58	0.000382	0.0244	0.22	0.16	Type 2 diabetes;	chr3:115201897	chr3:115100423~115103061:+
THCA	cis	rs62289301	0.637	rs34028526	ENSG00000273133.1	RP11-799M12.2	3.58	0.000382	0.0244	0.2	0.16	Joint mobility (Beighton score);	chr4:15409025	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs35866305	ENSG00000273133.1	RP11-799M12.2	3.58	0.000382	0.0244	0.2	0.16	Joint mobility (Beighton score);	chr4:15410265	chr4:15563698~15564253:-
THCA	cis	rs17122278	0.932	rs45505501	ENSG00000243431.1	RPL5P30	3.58	0.000382	0.0244	0.16	0.16	Total cholesterol levels;	chr11:118534590	chr11:118560690~118561580:+
THCA	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-3.58	0.000382	0.0244	-0.14	-0.16	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
THCA	cis	rs7554511	1	rs12132298	ENSG00000260088.1	RP11-92G12.3	-3.58	0.000382	0.0244	-0.25	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905967	chr1:200669507~200694250:+
THCA	cis	rs7554511	1	rs12132349	ENSG00000260088.1	RP11-92G12.3	-3.58	0.000382	0.0244	-0.25	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906114	chr1:200669507~200694250:+
THCA	cis	rs7142002	0.881	rs56872637	ENSG00000271780.1	RP11-1017G21.5	-3.58	0.000382	0.0244	-0.25	-0.16	Autism;	chr14:101941065	chr14:101948347~101949425:+
THCA	cis	rs6491750	0.655	rs78096846	ENSG00000276957.1	RP11-29B2.6	-3.58	0.000382	0.0244	-0.27	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103500869	chr13:102593338~102593873:-
THCA	cis	rs7873730	1	rs79139846	ENSG00000230185.4	C9orf147	3.58	0.000382	0.0244	0.26	0.16	Menarche (age at onset);	chr9:111546930	chr9:112433816~112487204:-
THCA	cis	rs11671005	0.693	rs11668821	ENSG00000269600.1	AC016629.3	-3.58	0.000382	0.0244	-0.24	-0.16	Mean platelet volume;	chr19:58444446	chr19:58593896~58599355:-
THCA	cis	rs11671005	0.616	rs12980907	ENSG00000269600.1	AC016629.3	-3.58	0.000382	0.0244	-0.24	-0.16	Mean platelet volume;	chr19:58444959	chr19:58593896~58599355:-
THCA	cis	rs9400467	0.537	rs449308	ENSG00000255389.1	C6orf3	-3.58	0.000382	0.0244	-0.22	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111159192	chr6:111599875~111602295:+
THCA	cis	rs9911578	0.967	rs57869245	ENSG00000224738.1	AC099850.1	-3.58	0.000382	0.0244	-0.19	-0.16	Intelligence (multi-trait analysis);	chr17:59029269	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.867	rs72628394	ENSG00000224738.1	AC099850.1	-3.58	0.000382	0.0244	-0.19	-0.16	Intelligence (multi-trait analysis);	chr17:59043952	chr17:59106598~59118267:+
THCA	cis	rs9650657	0.812	rs10107289	ENSG00000269918.1	AF131215.9	-3.58	0.000382	0.0244	-0.17	-0.16	Neuroticism;	chr8:10776738	chr8:11104691~11106704:-
THCA	cis	rs9788682	0.948	rs59683676	ENSG00000261143.1	ADAMTS7P3	-3.58	0.000382	0.0244	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78541111	chr15:77976042~77993057:+
THCA	cis	rs12935418	1	rs62054589	ENSG00000261838.4	RP11-303E16.6	3.58	0.000382	0.0244	0.25	0.16	Mean corpuscular volume;	chr16:81035143	chr16:81069854~81076598:+
THCA	cis	rs13113518	0.783	rs12504300	ENSG00000272969.1	RP11-528I4.2	3.58	0.000382	0.0244	0.2	0.16	Height;	chr4:55482360	chr4:55547112~55547889:+
THCA	cis	rs4761702	0.614	rs11106976	ENSG00000257252.4	RP11-486A14.2	-3.58	0.000382	0.0245	-0.27	-0.16	Immature fraction of reticulocytes;	chr12:93327763	chr12:93317135~93377736:-
THCA	cis	rs9634489	0.843	rs9516678	ENSG00000247400.3	DNAJC3-AS1	-3.58	0.000382	0.0245	-0.1	-0.16	Body mass index;	chr13:96397210	chr13:95648733~95676925:-
THCA	cis	rs3126085	0.935	rs4845431	ENSG00000237975.5	FLG-AS1	-3.58	0.000382	0.0245	-0.26	-0.16	Atopic dermatitis;	chr1:152255501	chr1:152168125~152445456:+
THCA	cis	rs2948294	0.566	rs13261997	ENSG00000233609.3	RP11-62H7.2	3.58	0.000382	0.0245	0.16	0.16	Red cell distribution width;	chr8:8254773	chr8:8961200~8979025:+
THCA	cis	rs7911264	0.739	rs10882091	ENSG00000232709.1	MARK2P9	-3.58	0.000382	0.0245	-0.2	-0.16	Inflammatory bowel disease;	chr10:92614620	chr10:92418667~92420875:+
THCA	cis	rs2288884	1	rs11673286	ENSG00000260160.1	CTC-471J1.2	-3.58	0.000382	0.0245	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037065	chr19:52058490~52063703:-
THCA	cis	rs11018904	0.906	rs61903722	ENSG00000280367.1	RP11-121L10.2	3.58	0.000382	0.0245	0.22	0.16	Intelligence (multi-trait analysis);	chr11:90233874	chr11:90223153~90226538:+
THCA	cis	rs7873102	0.654	rs7874305	ENSG00000213839.4	TMX2P1	-3.58	0.000382	0.0245	-0.12	-0.16	Brain structure;	chr9:37969885	chr9:37885683~37886390:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000232546.1	RP11-458F8.1	3.58	0.000382	0.0245	0.13	0.16	Aortic root size;	chr7:66566965	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000232546.1	RP11-458F8.1	3.58	0.000382	0.0245	0.13	0.16	Aortic root size;	chr7:66568046	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000232546.1	RP11-458F8.1	3.58	0.000382	0.0245	0.13	0.16	Aortic root size;	chr7:66571204	chr7:66848496~66858136:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000232546.1	RP11-458F8.1	3.58	0.000382	0.0245	0.13	0.16	Aortic root size;	chr7:66595421	chr7:66848496~66858136:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000232546.1	RP11-458F8.1	3.58	0.000382	0.0245	0.13	0.16	Aortic root size;	chr7:66598087	chr7:66848496~66858136:+
THCA	cis	rs10496034	0.618	rs72911575	ENSG00000237887.1	AC092839.1	-3.58	0.000382	0.0245	-0.31	-0.16	Refractive astigmatism;	chr2:54694212	chr2:54529343~54529801:+
THCA	cis	rs2692947	0.644	rs1030864	ENSG00000235584.2	AC008268.1	-3.58	0.000382	0.0245	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96156634	chr2:95666084~95668715:+
THCA	cis	rs6981523	0.553	rs11989369	ENSG00000205879.4	FAM90A2P	3.58	0.000383	0.0245	0.21	0.16	Neuroticism;	chr8:11197876	chr8:12172202~12178575:-
THCA	cis	rs11190604	1	rs2489035	ENSG00000273030.1	RP11-285F16.1	3.58	0.000383	0.0245	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100559638	chr10:100412934~100413421:+
THCA	cis	rs739525	0.518	rs178268	ENSG00000215493.3	XXbac-B562F10.11	3.58	0.000383	0.0245	0.12	0.16	Testicular germ cell tumor;	chr22:20975977	chr22:20450122~20451824:+
THCA	cis	rs73787773	0.644	rs76564228	ENSG00000246859.2	STARD4-AS1	3.58	0.000383	0.0245	0.21	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr5:112144274	chr5:111512226~111739726:+
THCA	cis	rs73787773	0.644	rs17134153	ENSG00000246859.2	STARD4-AS1	3.58	0.000383	0.0245	0.21	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr5:112144627	chr5:111512226~111739726:+
THCA	cis	rs17604090	0.756	rs10249388	ENSG00000227855.3	DPY19L2P3	3.58	0.000383	0.0245	0.2	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29689519	chr7:29650227~29742594:+
THCA	cis	rs36093844	0.527	rs111552865	ENSG00000279742.1	RP11-700A24.1	-3.58	0.000383	0.0245	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86049069	chr11:85852557~85854943:-
THCA	cis	rs9470794	0.528	rs115773136	ENSG00000225945.1	RP3-441A12.1	3.58	0.000383	0.0245	0.22	0.16	Type 2 diabetes;	chr6:37820272	chr6:37815777~37819218:-
THCA	cis	rs8057939	0.593	rs27800	ENSG00000260614.1	RP11-491F9.1	3.58	0.000383	0.0245	0.23	0.16	Prostate cancer (SNP x SNP interaction);	chr16:49399677	chr16:49287430~49290227:+
THCA	cis	rs897876	0.659	rs12053124	ENSG00000281920.1	RP11-418H16.1	3.58	0.000383	0.0245	0.21	0.16	Pulse pressure in young-onset hypertension;	chr2:65550240	chr2:65623272~65628424:+
THCA	cis	rs2115630	0.755	rs7169629	ENSG00000229212.6	RP11-561C5.4	-3.58	0.000383	0.0245	-0.21	-0.16	P wave terminal force;	chr15:84648043	chr15:85205440~85234795:-
THCA	cis	rs7089973	0.641	rs12772737	ENSG00000236799.1	RP11-383C6.2	-3.58	0.000383	0.0245	-0.2	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114981742	chr10:114994657~114996593:+
THCA	cis	rs6137726	0.652	rs6048249	ENSG00000237396.1	LINC01384	-3.58	0.000383	0.0245	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22679473	chr20:22587522~22607517:-
THCA	cis	rs10090774	0.965	rs4961233	ENSG00000280303.2	ERICD	3.58	0.000383	0.0245	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140798849	chr8:140636281~140638283:+
THCA	cis	rs7772697	0.508	rs13190879	ENSG00000223701.3	RAET1E-AS1	-3.58	0.000383	0.0245	-0.23	-0.16	Diabetic retinopathy;	chr6:149062743	chr6:149884431~149919508:+
THCA	cis	rs10744955	1	rs10744955	ENSG00000259618.1	RP11-562A8.5	3.58	0.000383	0.0245	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr15:50152627	chr15:50494018~50497080:-
THCA	cis	rs9481169	0.557	rs13190932	ENSG00000272356.1	RP5-1112D6.8	3.58	0.000383	0.0245	0.27	0.16	Inflammatory skin disease;	chr6:111591867	chr6:111309203~111313517:+
THCA	cis	rs17301013	0.612	rs56199565	ENSG00000270084.1	GAS5-AS1	-3.58	0.000383	0.0245	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174640992	chr1:173863248~173863941:+
THCA	cis	rs11992162	0.591	rs4240678	ENSG00000227888.4	FAM66A	-3.58	0.000383	0.0245	-0.21	-0.16	Monocyte count;	chr8:11944917	chr8:12362019~12388296:+
THCA	cis	rs2980439	0.525	rs2945238	ENSG00000248538.5	RP11-10A14.5	-3.58	0.000383	0.0245	-0.2	-0.16	Neuroticism;	chr8:8312614	chr8:9189011~9202854:+
THCA	cis	rs561341	0.609	rs7209493	ENSG00000214708.4	AC090616.2	-3.58	0.000383	0.0245	-0.2	-0.16	Hip circumference adjusted for BMI;	chr17:31870304	chr17:32141226~32143135:-
THCA	cis	rs6982240	0.514	rs11778579	ENSG00000253307.1	RP11-10J21.4	3.58	0.000383	0.0245	0.24	0.16	Tonsillectomy;	chr8:141251522	chr8:141252286~141253292:-
THCA	cis	rs7647973	0.58	rs4955432	ENSG00000228638.1	FCF1P2	-3.58	0.000383	0.0245	-0.17	-0.16	Menarche (age at onset);	chr3:49229339	chr3:48290793~48291375:-
THCA	cis	rs1908814	0.503	rs34657250	ENSG00000255495.1	AC145124.2	-3.58	0.000383	0.0245	-0.19	-0.16	Neuroticism;	chr8:11937864	chr8:12194467~12196280:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000232546.1	RP11-458F8.1	-3.58	0.000383	0.0245	-0.13	-0.16	Aortic root size;	chr7:66631041	chr7:66848496~66858136:+
THCA	cis	rs860295	0.627	rs11264410	ENSG00000203761.5	MSTO2P	-3.58	0.000383	0.0245	-0.13	-0.16	Body mass index;	chr1:155775558	chr1:155745829~155750137:+
THCA	cis	rs337161	0.719	rs11118597	ENSG00000221571.3	RNU6ATAC35P	-3.58	0.000383	0.0245	-0.18	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220763226	chr1:220825620~220826063:+
THCA	cis	rs2002675	0.507	rs6444089	ENSG00000171658.7	RP11-443P15.2	3.58	0.000383	0.0245	0.21	0.16	Menarche (age at onset);	chr3:185958561	chr3:185959943~185980872:+
THCA	cis	rs67478160	0.634	rs1955660	ENSG00000258534.1	CTD-2134A5.4	-3.58	0.000383	0.0245	-0.16	-0.16	Schizophrenia;	chr14:103763648	chr14:103854366~103880111:-
THCA	cis	rs847649	0.732	rs56269620	ENSG00000234715.1	CTB-107G13.1	-3.58	0.000383	0.0245	-0.18	-0.16	Morning vs. evening chronotype;	chr7:102849009	chr7:103445207~103514007:+
THCA	cis	rs4819052	0.572	rs4819027	ENSG00000215447.6	BX322557.10	3.58	0.000383	0.0245	0.15	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45075309	chr21:45288052~45291738:+
THCA	cis	rs7665090	1	rs2866406	ENSG00000251288.2	RP11-10L12.2	-3.58	0.000383	0.0245	-0.21	-0.16	Primary biliary cholangitis;	chr4:102632862	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs2866407	ENSG00000251288.2	RP11-10L12.2	-3.58	0.000383	0.0245	-0.21	-0.16	Primary biliary cholangitis;	chr4:102632951	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs2866408	ENSG00000251288.2	RP11-10L12.2	-3.58	0.000383	0.0245	-0.21	-0.16	Primary biliary cholangitis;	chr4:102632956	chr4:102751401~102752641:+
THCA	cis	rs9425766	0.692	rs4652294	ENSG00000270084.1	GAS5-AS1	-3.58	0.000383	0.0245	-0.17	-0.16	Life satisfaction;	chr1:174272027	chr1:173863248~173863941:+
THCA	cis	rs2911280	0.764	rs75584947	ENSG00000278985.1	RP11-303E16.9	-3.58	0.000383	0.0245	-0.3	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81529480	chr16:80982319~80984094:-
THCA	cis	rs11175834	0.655	rs11175829	ENSG00000277945.1	RP11-677M24.1	3.58	0.000383	0.0245	0.23	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65587275	chr12:65830750~65831050:+
THCA	cis	rs10515778	0.948	rs72813994	ENSG00000280834.1	U6	3.58	0.000383	0.0245	0.28	0.16	Inflammatory skin disease;	chr5:159189395	chr5:160072268~160072364:+
THCA	cis	rs9991779	0.657	rs11736786	ENSG00000237125.7	HAND2-AS1	-3.58	0.000383	0.0245	-0.28	-0.16	Pediatric bone mineral content (hip);	chr4:173953645	chr4:173527270~173591324:+
THCA	cis	rs9450351	0.744	rs9450313	ENSG00000280232.1	RP11-321N4.4	3.58	0.000383	0.0245	0.35	0.16	Interferon gamma-induced protein 10 levels;	chr6:85684419	chr6:85498441~85499058:-
THCA	cis	rs9353324	1	rs9351066	ENSG00000280232.1	RP11-321N4.4	3.58	0.000383	0.0245	0.35	0.16	Interferon gamma-induced protein 10 levels;	chr6:85689099	chr6:85498441~85499058:-
THCA	cis	rs2288884	0.943	rs75722407	ENSG00000260160.1	CTC-471J1.2	-3.58	0.000383	0.0245	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021989	chr19:52058490~52063703:-
THCA	cis	rs2573652	0.723	rs2573655	ENSG00000254744.3	CTD-3076O17.1	-3.58	0.000383	0.0245	-0.18	-0.16	Height;	chr15:99975504	chr15:99970215~99974010:+
THCA	cis	rs9926296	0.656	rs7191144	ENSG00000260259.1	RP11-368I7.4	-3.58	0.000383	0.0245	-0.18	-0.16	Vitiligo;	chr16:89756985	chr16:89682620~89686569:-
THCA	cis	rs4841097	0.806	rs6992247	ENSG00000253981.4	ALG1L13P	3.58	0.000383	0.0245	0.16	0.16	Platelet distribution width;	chr8:9090959	chr8:8236003~8244667:-
THCA	cis	rs7998202	0.667	rs410948	ENSG00000274922.1	RP11-88E10.5	-3.58	0.000383	0.0245	-0.23	-0.16	Glycated hemoglobin levels;	chr13:112715826	chr13:112686769~112689815:-
THCA	cis	rs7296418	0.961	rs949143	ENSG00000256092.2	RP13-942N8.1	3.58	0.000384	0.0245	0.12	0.16	Platelet count;	chr12:123110616	chr12:123363868~123366113:+
THCA	cis	rs962856	0.756	rs13016812	ENSG00000236780.4	AC078941.1	-3.58	0.000384	0.0245	-0.21	-0.16	Pancreatic cancer;	chr2:67397170	chr2:67123357~67215319:-
THCA	cis	rs2251301	0.8	rs2736379	ENSG00000154316.13	TDH	3.58	0.000384	0.0245	0.14	0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr8:11267753	chr8:11339637~11368452:+
THCA	cis	rs7615952	0.932	rs13086087	ENSG00000248787.1	RP11-666A20.4	-3.58	0.000384	0.0245	-0.28	-0.16	Blood pressure (smoking interaction);	chr3:125927438	chr3:125908005~125910272:-
THCA	cis	rs116095464	1	rs10475185	ENSG00000277812.1	AC021087.1	3.58	0.000384	0.0245	0.41	0.16	Breast cancer;	chr5:306866	chr5:262769~262881:+
THCA	cis	rs116095464	1	rs56095714	ENSG00000277812.1	AC021087.1	3.58	0.000384	0.0245	0.41	0.16	Breast cancer;	chr5:311141	chr5:262769~262881:+
THCA	cis	rs12428035	0.764	rs816142	ENSG00000247400.3	DNAJC3-AS1	3.58	0.000384	0.0245	0.15	0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95986382	chr13:95648733~95676925:-
THCA	cis	rs4474633	1	rs4474633	ENSG00000275580.1	RP11-295H24.4	3.58	0.000384	0.0245	0.13	0.16	Major depressive disorder;	chr15:48968404	chr15:49343608~49344254:+
THCA	cis	rs214785	1	rs214796	ENSG00000226644.4	RP11-128M1.1	-3.58	0.000384	0.0245	-0.16	-0.16	Basal cell carcinoma;	chr20:2305697	chr20:2207217~2213151:+
THCA	cis	rs7520050	0.872	rs1707308	ENSG00000234329.1	RP11-767N6.2	-3.58	0.000384	0.0245	-0.15	-0.16	Reticulocyte count;Red blood cell count;	chr1:46138643	chr1:45651039~45651826:-
THCA	cis	rs9987353	1	rs9987353	ENSG00000248538.5	RP11-10A14.5	3.58	0.000384	0.0246	0.23	0.16	Recombination measurement;	chr8:9258839	chr8:9189011~9202854:+
THCA	cis	rs9308731	0.966	rs36018702	ENSG00000204581.2	AC096670.3	3.58	0.000384	0.0246	0.16	0.16	Chronic lymphocytic leukemia;	chr2:111170796	chr2:111098345~111115588:-
THCA	cis	rs9875589	0.957	rs6768050	ENSG00000228242.5	AC093495.4	-3.58	0.000384	0.0246	-0.09	-0.16	Ovarian reserve;	chr3:13888993	chr3:14144637~14165978:+
THCA	cis	rs2625529	0.668	rs8192386	ENSG00000260037.4	CTD-2524L6.3	3.58	0.000384	0.0246	0.23	0.16	Red blood cell count;	chr15:72220807	chr15:71818396~71823384:+
THCA	cis	rs3176789	0.671	rs12425365	ENSG00000256673.1	RP11-599J14.2	3.58	0.000384	0.0246	0.2	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767422	chr12:9398355~9414851:-
THCA	cis	rs972578	0.677	rs5751371	ENSG00000230319.1	AL022476.2	3.58	0.000384	0.0246	0.18	0.16	Mean platelet volume;	chr22:42792605	chr22:43038585~43052366:+
THCA	cis	rs12893668	0.663	rs12889731	ENSG00000244691.1	RPL10AP1	-3.58	0.000384	0.0246	-0.23	-0.16	Reticulocyte count;	chr14:103621145	chr14:103412119~103412761:-
THCA	cis	rs61160187	0.51	rs10072745	ENSG00000251279.1	CTC-436P18.1	-3.58	0.000384	0.0246	-0.21	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60787448	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.527	rs6449500	ENSG00000251279.1	CTC-436P18.1	-3.58	0.000384	0.0246	-0.21	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60788076	chr5:61162070~61232040:+
THCA	cis	rs3176789	0.671	rs35559880	ENSG00000256673.1	RP11-599J14.2	3.58	0.000384	0.0246	0.2	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766965	chr12:9398355~9414851:-
THCA	cis	rs62158800	0.526	rs62161276	ENSG00000225588.2	AC096669.1	3.58	0.000384	0.0246	0.16	0.16	Facial morphology (factor 22);	chr2:107672556	chr2:107362282~107407329:+
THCA	cis	rs7727544	0.606	rs17622208	ENSG00000263597.1	MIR3936	3.58	0.000384	0.0246	0.16	0.16	Blood metabolite levels;	chr5:132381358	chr5:132365490~132365599:-
THCA	cis	rs1926657	1	rs9524835	ENSG00000223298.1	RNY3P8	-3.58	0.000384	0.0246	-0.21	-0.16	Breast cancer;	chr13:95215375	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs9524836	ENSG00000223298.1	RNY3P8	-3.58	0.000384	0.0246	-0.21	-0.16	Breast cancer;	chr13:95215378	chr13:95310830~95310955:-
THCA	cis	rs7809950	0.817	rs4727678	ENSG00000272072.1	CTA-363E19.2	3.58	0.000384	0.0246	0.17	0.16	Coronary artery disease;	chr7:107443190	chr7:107192559~107193300:-
THCA	cis	rs7809950	0.817	rs4727679	ENSG00000272072.1	CTA-363E19.2	3.58	0.000384	0.0246	0.17	0.16	Coronary artery disease;	chr7:107444573	chr7:107192559~107193300:-
THCA	cis	rs6479874	0.598	rs2660220	ENSG00000223502.1	RP11-96B5.3	-3.58	0.000384	0.0246	-0.19	-0.16	Migraine;	chr10:50976339	chr10:51062579~51068553:-
THCA	cis	rs6012953	0.845	rs718053	ENSG00000231715.1	COX6CP2	-3.58	0.000384	0.0246	-0.17	-0.16	Vitiligo;	chr20:50580065	chr20:50479767~50479991:+
THCA	cis	rs2360027	0.965	rs2360023	ENSG00000231365.4	RP11-418J17.1	3.58	0.000384	0.0246	0.16	0.16	Tonsillectomy;	chr1:118578708	chr1:119140396~119275973:+
THCA	cis	rs4915077	1	rs78287223	ENSG00000226822.1	RP11-356N1.2	3.58	0.000384	0.0246	0.31	0.16	Hypothyroidism;	chr1:107780024	chr1:108071482~108074519:+
THCA	cis	rs11671005	0.61	rs2305122	ENSG00000252334.1	RNU6-1337P	3.58	0.000384	0.0246	0.24	0.16	Mean platelet volume;	chr19:58545385	chr19:58483749~58483843:-
THCA	cis	rs17194490	0.665	rs5004846	ENSG00000237990.3	CNTN4-AS1	3.58	0.000384	0.0246	0.23	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2526795	chr3:3039033~3069242:-
THCA	cis	rs2251188	1	rs2251188	ENSG00000198580.7	RP11-611L7.2	-3.58	0.000384	0.0246	-0.19	-0.16	Sum basophil neutrophil counts;Neutrophil count;	chr7:6664701	chr7:6673494~6676366:+
THCA	cis	rs6878727	0.707	rs7717536	ENSG00000253807.4	LINC01170	-3.58	0.000384	0.0246	-0.15	-0.16	Breast cancer;	chr5:124383128	chr5:124059794~124405079:-
THCA	cis	rs6878727	0.707	rs7737676	ENSG00000253807.4	LINC01170	-3.58	0.000384	0.0246	-0.15	-0.16	Breast cancer;	chr5:124383129	chr5:124059794~124405079:-
THCA	cis	rs4792901	0.759	rs1382685	ENSG00000279602.1	CTD-3014M21.1	-3.58	0.000385	0.0246	-0.21	-0.16	Dupuytren's disease;	chr17:43485783	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.765	rs9894019	ENSG00000279602.1	CTD-3014M21.1	-3.58	0.000385	0.0246	-0.21	-0.16	Dupuytren's disease;	chr17:43488137	chr17:43360041~43361361:-
THCA	cis	rs5769765	0.817	rs11912619	ENSG00000260613.1	RP3-522J7.6	-3.58	0.000385	0.0246	-0.22	-0.16	Schizophrenia;	chr22:49923753	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.73	rs62233964	ENSG00000260613.1	RP3-522J7.6	-3.58	0.000385	0.0246	-0.22	-0.16	Schizophrenia;	chr22:49923762	chr22:49832616~49837786:-
THCA	cis	rs1891275	0.55	rs4933694	ENSG00000232709.1	MARK2P9	3.58	0.000385	0.0246	0.18	0.16	Intelligence (multi-trait analysis);	chr10:91739456	chr10:92418667~92420875:+
THCA	cis	rs10186029	0.582	rs2371795	ENSG00000270659.1	RP11-105N14.1	-3.58	0.000385	0.0246	-0.13	-0.16	Systemic sclerosis;	chr2:213130065	chr2:213152970~213153659:+
THCA	cis	rs2905347	0.895	rs2961283	ENSG00000179428.2	AC073072.5	-3.58	0.000385	0.0246	-0.19	-0.16	Major depression and alcohol dependence;	chr7:22600879	chr7:22725395~22727620:-
THCA	cis	rs7819412	0.807	rs9657519	ENSG00000254948.1	OR7E158P	3.58	0.000385	0.0246	0.2	0.16	Triglycerides;	chr8:11087929	chr8:11919900~11920809:-
THCA	cis	rs11160190	1	rs9671989	ENSG00000258572.1	RP11-1070N10.3	-3.58	0.000385	0.0246	-0.17	-0.16	Vaspin levels;	chr14:94547244	chr14:95516136~95517911:+
THCA	cis	rs9329221	0.736	rs11249999	ENSG00000253641.4	RP11-981G7.2	-3.58	0.000385	0.0246	-0.16	-0.16	Neuroticism;	chr8:10393755	chr8:10474565~10481974:+
THCA	cis	rs6545883	0.507	rs59981505	ENSG00000273302.1	RP11-493E12.2	-3.58	0.000385	0.0246	-0.15	-0.16	Tuberculosis;	chr2:61353394	chr2:61199979~61200769:+
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000265443.1	CTD-2349P21.6	-3.58	0.000385	0.0246	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30726305~30727564:-
THCA	cis	rs12264252	0.767	rs35998463	ENSG00000225484.5	NUTM2B-AS1	-3.58	0.000385	0.0246	-0.21	-0.16	Coronary artery disease;	chr10:80485754	chr10:79663088~79826594:-
THCA	cis	rs4660214	0.666	rs11205696	ENSG00000228060.1	RP11-69E11.8	3.58	0.000385	0.0246	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155880	chr1:39565160~39573203:+
THCA	cis	rs10863936	0.667	rs2358333	ENSG00000198468.6	FLVCR1-AS1	-3.58	0.000385	0.0246	-0.19	-0.16	Height;	chr1:212022869	chr1:212852108~212858088:-
THCA	cis	rs1009077	0.627	rs10022664	ENSG00000248280.1	RP11-33B1.2	-3.58	0.000385	0.0246	-0.18	-0.16	Endometriosis;	chr4:119607886	chr4:119440561~119450157:-
THCA	cis	rs3733585	0.631	rs4697925	ENSG00000261490.1	RP11-448G15.3	-3.58	0.000385	0.0246	-0.11	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10122706	chr4:10068089~10073019:-
THCA	cis	rs2522056	0.932	rs2522064	ENSG00000237714.1	P4HA2-AS1	-3.58	0.000385	0.0246	-0.24	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132470796	chr5:132184876~132192808:+
THCA	cis	rs1383484	0.545	rs7171383	ENSG00000259683.1	RP11-182J1.14	3.58	0.000385	0.0246	0.17	0.16	Height;	chr15:83976087	chr15:84389729~84395903:+
THCA	cis	rs72675573	0.515	rs1935050	ENSG00000260971.3	RP11-504A18.1	-3.58	0.000385	0.0246	-0.15	-0.16	Monocyte count;	chr1:56260154	chr1:56248294~56258571:-
THCA	cis	rs9928842	0.679	rs4888361	ENSG00000261783.1	RP11-252K23.2	3.58	0.000385	0.0246	0.31	0.16	Alcoholic chronic pancreatitis;	chr16:75233778	chr16:75379818~75381260:-
THCA	cis	rs793571	0.738	rs12595482	ENSG00000245975.2	RP11-30K9.6	3.58	0.000385	0.0246	0.19	0.16	Schizophrenia;	chr15:58903480	chr15:58768072~58770974:-
THCA	cis	rs12121840	0.736	rs76593835	ENSG00000237463.4	RP11-280O1.2	-3.58	0.000385	0.0246	-0.15	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165562205	chr1:165476841~165582155:-
THCA	cis	rs13034020	0.857	rs7590126	ENSG00000271889.1	RP11-493E12.1	3.58	0.000385	0.0246	0.2	0.16	Hodgkin's lymphoma;	chr2:60805697	chr2:61151433~61162105:-
THCA	cis	rs9300255	0.602	rs1106240	ENSG00000274427.1	RP11-972P1.10	3.58	0.000385	0.0246	0.17	0.16	Neutrophil percentage of white cells;	chr12:123142435	chr12:123515275~123515513:-
THCA	cis	rs9300255	0.602	rs1727313	ENSG00000274427.1	RP11-972P1.10	3.58	0.000385	0.0246	0.17	0.16	Neutrophil percentage of white cells;	chr12:123156306	chr12:123515275~123515513:-
THCA	cis	rs9863	0.862	rs6488912	ENSG00000269938.1	RP11-214K3.20	-3.58	0.000385	0.0246	-0.18	-0.16	White blood cell count;	chr12:123958205	chr12:123968023~123968579:-
THCA	cis	rs17604090	0.938	rs10241566	ENSG00000227855.3	DPY19L2P3	3.58	0.000385	0.0246	0.2	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29650563	chr7:29650227~29742594:+
THCA	cis	rs9948	1	rs62152795	ENSG00000230606.9	AC159540.1	3.58	0.000385	0.0246	0.23	0.16	Erectile dysfunction and prostate cancer treatment;	chr2:96821962	chr2:97416165~97433527:-
THCA	cis	rs9948	0.881	rs1317911	ENSG00000230606.9	AC159540.1	3.58	0.000385	0.0246	0.23	0.16	Erectile dysfunction and prostate cancer treatment;	chr2:96822961	chr2:97416165~97433527:-
THCA	cis	rs10411161	0.702	rs8110546	ENSG00000275055.1	CTC-471J1.11	-3.58	0.000385	0.0246	-0.16	-0.16	Breast cancer;	chr19:51880303	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs8110461	ENSG00000275055.1	CTC-471J1.11	-3.58	0.000385	0.0246	-0.16	-0.16	Breast cancer;	chr19:51880316	chr19:52049007~52049754:+
THCA	cis	rs4081724	0.565	rs7253994	ENSG00000267130.1	CTD-2540B15.9	3.58	0.000385	0.0246	0.25	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33314772	chr19:33305036~33309387:+
THCA	cis	rs7833787	0.501	rs6586767	ENSG00000278886.1	RP11-108A14.1	-3.58	0.000385	0.0246	-0.23	-0.16	Obesity-related traits;	chr8:18828819	chr8:18864681~18865247:-
THCA	cis	rs4787491	0.729	rs11642399	ENSG00000275371.1	RP11-455F5.6	-3.58	0.000385	0.0246	-0.14	-0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30048272	chr16:30110895~30111955:+
THCA	cis	rs6005807	0.719	rs73430168	ENSG00000272858.1	CTA-292E10.8	-3.58	0.000385	0.0246	-0.26	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28589440	chr22:28814914~28815662:+
THCA	cis	rs7267979	1	rs2257991	ENSG00000276952.1	RP5-965G21.6	-3.58	0.000385	0.0246	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25284915~25285588:-
THCA	cis	rs1880529	1	rs1524998	ENSG00000206820.1	RNU1-138P	-3.58	0.000385	0.0246	-0.19	-0.16	White matter integrity (bipolar disorder risk interaction);	chr4:113458392	chr4:113420323~113420486:+
THCA	cis	rs2948294	0.566	rs13274039	ENSG00000233609.3	RP11-62H7.2	3.58	0.000385	0.0246	0.16	0.16	Red cell distribution width;	chr8:8254137	chr8:8961200~8979025:+
THCA	cis	rs1853665	0.58	rs12524576	ENSG00000231760.4	RP11-350J20.5	3.58	0.000385	0.0246	0.26	0.16	Radiation response;	chr6:149950808	chr6:149796151~149826294:-
THCA	cis	rs34779708	0.931	rs3740083	ENSG00000233200.1	RP11-324I22.2	3.58	0.000385	0.0246	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35219894~35230598:-
THCA	cis	rs11212260	0.85	rs682919	ENSG00000261098.1	RP11-819C21.1	-3.58	0.000385	0.0246	-0.32	-0.16	IgG glycosylation;	chr11:107532895	chr11:107312132~107316271:-
THCA	cis	rs11212260	0.85	rs635386	ENSG00000261098.1	RP11-819C21.1	-3.58	0.000385	0.0246	-0.32	-0.16	IgG glycosylation;	chr11:107535599	chr11:107312132~107316271:-
THCA	cis	rs6671200	0.831	rs13375406	ENSG00000235501.4	RP4-639F20.1	-3.58	0.000385	0.0246	-0.32	-0.16	Stearic acid (18:0) levels;	chr1:95140749	chr1:94927566~94963270:+
THCA	cis	rs4434872	0.525	rs12042836	ENSG00000228013.1	RP11-350G8.5	-3.58	0.000385	0.0246	-0.3	-0.16	Conduct disorder (symptom count);	chr1:154004680	chr1:154402328~154406564:-
THCA	cis	rs4434872	0.525	rs9700537	ENSG00000228013.1	RP11-350G8.5	-3.58	0.000385	0.0246	-0.3	-0.16	Conduct disorder (symptom count);	chr1:154005373	chr1:154402328~154406564:-
THCA	cis	rs9309473	0.948	rs13391552	ENSG00000273245.1	RP11-434P11.2	3.58	0.000385	0.0246	0.23	0.16	Metabolite levels;	chr2:73591809	chr2:73750256~73750786:-
THCA	cis	rs7660883	1	rs3736669	ENSG00000251411.1	RP11-397E7.4	3.58	0.000385	0.0246	0.15	0.16	HDL cholesterol levels;	chr4:87071601	chr4:86913266~86914817:-
THCA	cis	rs10863936	0.667	rs4394721	ENSG00000198468.6	FLVCR1-AS1	-3.58	0.000385	0.0246	-0.19	-0.16	Height;	chr1:212056129	chr1:212852108~212858088:-
THCA	cis	rs2836950	0.545	rs2836922	ENSG00000235701.1	PCBP2P1	-3.58	0.000385	0.0246	-0.18	-0.16	Menarche (age at onset);	chr21:39144382	chr21:39171130~39172106:-
THCA	cis	rs181553	0.748	rs1052695	ENSG00000266696.1	RP11-30L3.2	-3.58	0.000386	0.0246	-0.2	-0.16	Hip circumference adjusted for BMI;	chr18:49036415	chr18:49205912~49208781:+
THCA	cis	rs4566357	0.595	rs6707159	ENSG00000212391.1	SNORA48	-3.58	0.000386	0.0246	-0.18	-0.16	Coronary artery disease;	chr2:227044623	chr2:226968989~226969122:-
THCA	cis	rs80130819	0.688	rs2732475	ENSG00000226413.2	OR8T1P	3.58	0.000386	0.0246	0.24	0.16	Prostate cancer;	chr12:48306971	chr12:48442030~48442947:-
THCA	cis	rs80130819	0.748	rs2732474	ENSG00000226413.2	OR8T1P	3.58	0.000386	0.0246	0.24	0.16	Prostate cancer;	chr12:48307034	chr12:48442030~48442947:-
THCA	cis	rs4662750	0.58	rs4662742	ENSG00000236682.1	AC068282.3	3.58	0.000386	0.0246	0.2	0.16	Renal cell carcinoma;	chr2:127593169	chr2:127389130~127400580:+
THCA	cis	rs4660214	0.568	rs967530	ENSG00000182109.6	RP11-69E11.4	-3.58	0.000386	0.0246	-0.16	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39130465	chr1:39522280~39546187:-
THCA	cis	rs76695126	0.686	rs1114532	ENSG00000271851.1	RP11-565F19.2	3.58	0.000386	0.0246	0.16	0.16	Borderline personality disorder;	chr17:9531247	chr17:9553323~9555696:-
THCA	cis	rs28643277	0.671	rs10752392	ENSG00000237470.3	DCLRE1CP1	3.58	0.000386	0.0246	0.21	0.16	Periodontitis (CDC/AAP);	chr10:15504005	chr10:15015370~15021863:-
THCA	cis	rs10911902	0.602	rs1919200	ENSG00000233196.2	GS1-304P7.1	-3.58	0.000386	0.0246	-0.27	-0.16	Schizophrenia;	chr1:186300848	chr1:186580515~186581191:-
THCA	cis	rs7680126	0.596	rs714436	ENSG00000261490.1	RP11-448G15.3	-3.58	0.000386	0.0246	-0.14	-0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10313043	chr4:10068089~10073019:-
THCA	cis	rs8033133	0.522	rs4906944	ENSG00000251896.1	SNORD116-27	-3.58	0.000386	0.0246	-0.19	-0.16	Blood osmolality (transformed sodium);	chr15:25071004	chr15:25101575~25101666:+
THCA	cis	rs7924176	0.601	rs10824073	ENSG00000232342.6	RP11-46O21.2	3.58	0.000386	0.0247	0.2	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74506081~74530553:-
THCA	cis	rs9902453	0.584	rs3809790	ENSG00000264290.1	RP11-68I3.4	-3.58	0.000386	0.0247	-0.12	-0.16	Coffee consumption (cups per day);	chr17:29628522	chr17:29569580~29570519:+
THCA	cis	rs10802047	0.632	rs1951362	ENSG00000231365.4	RP11-418J17.1	-3.58	0.000386	0.0247	-0.17	-0.16	Relative hand skill in reading disability;	chr1:118676975	chr1:119140396~119275973:+
THCA	cis	rs11681884	1	rs3811054	ENSG00000236397.3	DDX11L2	-3.58	0.000386	0.0247	-0.31	-0.16	Stroke;	chr2:113073363	chr2:113599036~113601261:-
THCA	cis	rs78487399	0.908	rs12474030	ENSG00000234936.1	AC010883.5	3.58	0.000386	0.0247	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43585178	chr2:43229573~43233394:+
THCA	cis	rs1560104	0.576	rs11640886	ENSG00000262801.4	U91319.1	-3.58	0.000386	0.0247	-0.19	-0.16	Obesity-related traits;	chr16:12615377	chr16:13246316~13562918:+
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000184274.3	LINC00315	3.58	0.000386	0.0247	0.2	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45300245~45305257:-
THCA	cis	rs28374715	0.662	rs521890	ENSG00000247556.5	OIP5-AS1	3.58	0.000386	0.0247	0.15	0.16	Ulcerative colitis;	chr15:41180945	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.662	rs691906	ENSG00000247556.5	OIP5-AS1	-3.58	0.000386	0.0247	-0.15	-0.16	Ulcerative colitis;	chr15:41182438	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.662	rs691907	ENSG00000247556.5	OIP5-AS1	-3.58	0.000386	0.0247	-0.15	-0.16	Ulcerative colitis;	chr15:41182459	chr15:41283990~41309737:+
THCA	cis	rs11662586	0.511	rs55757913	ENSG00000267251.2	AC139100.3	3.58	0.000386	0.0247	0.19	0.16	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79889684	chr18:80183680~80202992:+
THCA	cis	rs494526	0.641	rs10787918	ENSG00000229272.1	RP11-498J9.2	-3.58	0.000386	0.0247	-0.18	-0.16	Alcoholic chronic pancreatitis;	chr10:119114575	chr10:119003536~119003884:-
THCA	cis	rs1850744	0.826	rs115893429	ENSG00000163612.10	FAM86KP	3.58	0.000386	0.0247	0.38	0.16	Economic and political preferences;	chr4:9592194	chr4:9153296~9165451:+
THCA	cis	rs9393813	0.528	rs6903282	ENSG00000271755.1	RP1-153G14.4	3.58	0.000386	0.0247	0.19	0.16	Bipolar disorder;	chr6:27498933	chr6:27404010~27406964:-
THCA	cis	rs5993586	1	rs5746728	ENSG00000223461.1	AC004471.9	3.58	0.000386	0.0247	0.36	0.16	Coronary artery disease;	chr22:19374306	chr22:19121529~19124503:+
THCA	cis	rs12887734	0.524	rs722637	ENSG00000269958.1	RP11-73M18.8	-3.58	0.000386	0.0247	-0.15	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103696353~103697163:+
THCA	cis	rs453301	0.506	rs686189	ENSG00000248538.5	RP11-10A14.5	3.58	0.000386	0.0247	0.2	0.16	Joint mobility (Beighton score);	chr8:8766127	chr8:9189011~9202854:+
THCA	cis	rs2777491	0.574	rs316611	ENSG00000247556.5	OIP5-AS1	-3.58	0.000386	0.0247	-0.16	-0.16	Ulcerative colitis;	chr15:41459480	chr15:41283990~41309737:+
THCA	cis	rs2640806	0.505	rs13265799	ENSG00000253105.4	KB-1448A5.1	3.58	0.000386	0.0247	0.19	0.16	Obesity-related traits;	chr8:96348244	chr8:96371865~96387438:-
THCA	cis	rs4240897	0.935	rs4846082	ENSG00000201801.1	RNU5E-4P	3.58	0.000386	0.0247	0.19	0.16	Tuberculosis;	chr1:11982386	chr1:11909808~11909927:-
THCA	cis	rs5769765	0.908	rs9616216	ENSG00000260613.1	RP3-522J7.6	-3.58	0.000386	0.0247	-0.21	-0.16	Schizophrenia;	chr22:49925279	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.908	rs9627800	ENSG00000260613.1	RP3-522J7.6	-3.58	0.000386	0.0247	-0.21	-0.16	Schizophrenia;	chr22:49925703	chr22:49832616~49837786:-
THCA	cis	rs972540	1	rs62195884	ENSG00000229647.1	AC007879.7	-3.58	0.000386	0.0247	-0.19	-0.16	Body mass index;	chr2:206367996	chr2:207239650~207245887:+
THCA	cis	rs6058526	0.631	rs3813922	ENSG00000235217.6	TSPY26P	-3.58	0.000386	0.0247	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr20:32189533	chr20:32186477~32190527:-
THCA	cis	rs7709377	0.857	rs1031364	ENSG00000272265.1	CTD-2287O16.4	3.58	0.000386	0.0247	0.19	0.16	Metabolite levels  (X-11787);	chr5:116233663	chr5:116078110~116078570:-
THCA	cis	rs7308116	0.53	rs7980811	ENSG00000257951.1	RP11-554D14.4	-3.58	0.000386	0.0247	-0.2	-0.16	Pelvic organ prolapse (moderate/severe);	chr12:107903896	chr12:107881242~107883382:+
THCA	cis	rs7308116	0.53	rs7962490	ENSG00000257951.1	RP11-554D14.4	-3.58	0.000386	0.0247	-0.2	-0.16	Pelvic organ prolapse (moderate/severe);	chr12:107904194	chr12:107881242~107883382:+
THCA	cis	rs250518	1	rs250518	ENSG00000251467.1	CTC-250P20.2	-3.58	0.000386	0.0247	-0.23	-0.16	Mean corpuscular hemoglobin concentration;	chr5:72905231	chr5:72996920~72997642:+
THCA	cis	rs8192917	0.623	rs2273843	ENSG00000258657.4	RP11-104E19.1	-3.58	0.000386	0.0247	-0.28	-0.16	Vitiligo;	chr14:24634203	chr14:24595723~24657774:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000272831.1	RP11-792A8.4	3.58	0.000386	0.0247	0.1	0.16	Aortic root size;	chr7:66473171	chr7:66739829~66740385:-
THCA	cis	rs6101567	0.749	rs2067034	ENSG00000224635.1	RP4-564F22.5	-3.58	0.000386	0.0247	-0.2	-0.16	Nose size;	chr20:39285535	chr20:38406011~38416797:-
THCA	cis	rs11671005	0.504	rs3794964	ENSG00000252334.1	RNU6-1337P	3.58	0.000386	0.0247	0.21	0.16	Mean platelet volume;	chr19:58559549	chr19:58483749~58483843:-
THCA	cis	rs7737355	1	rs6876350	ENSG00000224431.1	AC063976.7	3.58	0.000386	0.0247	0.16	0.16	Life satisfaction;	chr5:131268416	chr5:132199456~132203487:+
THCA	cis	rs7737355	1	rs7737355	ENSG00000224431.1	AC063976.7	3.58	0.000386	0.0247	0.16	0.16	Life satisfaction;	chr5:131269118	chr5:132199456~132203487:+
THCA	cis	rs8030379	1	rs2401175	ENSG00000176700.18	SCAND2P	3.58	0.000386	0.0247	0.1	0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909465	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs1564474	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901281	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2401172	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908205	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2401173	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908218	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2401174	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908240	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs11259929	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908450	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs11259930	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908598	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs1480827	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909040	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2401176	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909612	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2401179	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910196	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2401180	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910434	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs11259932	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911305	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs11259934	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911419	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs11259935	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911675	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs12914857	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912414	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2055712	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912853	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2061999	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913988	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs3934135	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915047	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2030838	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915058	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2030839	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915207	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2030840	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915382	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs1880730	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915432	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs7496814	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916207	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs8024418	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917556	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs8042970	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917616	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs11259937	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919081	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs11637866	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919206	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs2135880	ENSG00000176700.18	SCAND2P	-3.58	0.000386	0.0247	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83920861	chr15:84631451~84647478:+
THCA	cis	rs972578	0.837	rs5759017	ENSG00000230319.1	AL022476.2	3.58	0.000386	0.0247	0.17	0.16	Mean platelet volume;	chr22:42900318	chr22:43038585~43052366:+
THCA	cis	rs2832077	0.527	rs2250141	ENSG00000232855.5	AF131217.1	-3.58	0.000386	0.0247	-0.18	-0.16	Cognitive test performance;	chr21:28869662	chr21:28439346~28674848:-
THCA	cis	rs13098911	0.54	rs13079478	ENSG00000226074.4	PRSS44	-3.58	0.000386	0.0247	-0.31	-0.16	Celiac disease;	chr3:45966331	chr3:46809359~46812558:-
THCA	cis	rs9863	0.931	rs4930721	ENSG00000270028.1	RP11-380L11.4	3.58	0.000386	0.0247	0.18	0.16	White blood cell count;	chr12:123933342	chr12:123925461~123926083:-
THCA	cis	rs6494488	0.5	rs72744726	ENSG00000259635.1	AC100830.3	-3.58	0.000386	0.0247	-0.42	-0.16	Coronary artery disease;	chr15:64738796	chr15:64701248~64719602:+
THCA	cis	rs9425766	0.655	rs6666767	ENSG00000270084.1	GAS5-AS1	-3.58	0.000386	0.0247	-0.17	-0.16	Life satisfaction;	chr1:174357564	chr1:173863248~173863941:+
THCA	cis	rs11992162	0.573	rs61468577	ENSG00000227888.4	FAM66A	-3.58	0.000386	0.0247	-0.21	-0.16	Monocyte count;	chr8:11927416	chr8:12362019~12388296:+
THCA	cis	rs10943724	0.959	rs13203786	ENSG00000272129.1	RP11-250B2.6	3.58	0.000386	0.0247	0.21	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80515832	chr6:80355424~80356859:+
THCA	cis	rs7259376	0.84	rs3862494	ENSG00000269138.1	ZNF209P	3.57	0.000386	0.0247	0.17	0.16	Menopause (age at onset);	chr19:22336720	chr19:22463922~22473036:+
THCA	cis	rs73198271	0.74	rs67766414	ENSG00000254153.1	CTA-398F10.2	3.57	0.000386	0.0247	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8456909~8461337:-
THCA	cis	rs1357692	0.867	rs2971892	ENSG00000238250.1	ST6GAL2-IT1	-3.57	0.000387	0.0247	-0.16	-0.16	Alzheimer's disease;	chr2:107067603	chr2:106822923~106825031:-
THCA	cis	rs1357692	0.899	rs2971650	ENSG00000238250.1	ST6GAL2-IT1	-3.57	0.000387	0.0247	-0.16	-0.16	Alzheimer's disease;	chr2:107067959	chr2:106822923~106825031:-
THCA	cis	rs972578	0.967	rs5759091	ENSG00000230319.1	AL022476.2	3.57	0.000387	0.0247	0.18	0.16	Mean platelet volume;	chr22:43011458	chr22:43038585~43052366:+
THCA	cis	rs7707921	1	rs749402	ENSG00000251374.1	RPS23P5	3.57	0.000387	0.0247	0.24	0.16	Breast cancer;	chr5:82265506	chr5:82265157~82265259:-
THCA	cis	rs972578	0.875	rs4822250	ENSG00000230319.1	AL022476.2	3.57	0.000387	0.0247	0.18	0.16	Mean platelet volume;	chr22:43013052	chr22:43038585~43052366:+
THCA	cis	rs2494663	0.61	rs6427457	ENSG00000231416.1	RP11-422P24.9	3.57	0.000387	0.0247	0.2	0.16	Mean platelet volume;	chr1:154106815	chr1:153995632~153995960:+
THCA	cis	rs858239	0.601	rs6461702	ENSG00000230042.1	AK3P3	-3.57	0.000387	0.0247	-0.22	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23129178~23129841:+
THCA	cis	rs6870983	0.749	rs10044744	ENSG00000247828.6	TMEM161B-AS1	3.57	0.000387	0.0247	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88154167	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs13357105	ENSG00000247828.6	TMEM161B-AS1	3.57	0.000387	0.0247	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88161381	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs6891381	ENSG00000247828.6	TMEM161B-AS1	3.57	0.000387	0.0247	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88172278	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs2165380	ENSG00000247828.6	TMEM161B-AS1	3.57	0.000387	0.0247	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88176481	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs2410761	ENSG00000247828.6	TMEM161B-AS1	3.57	0.000387	0.0247	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88177160	chr5:88268895~88436685:+
THCA	cis	rs7539542	0.538	rs12070525	ENSG00000234996.3	RP11-480I12.7	3.57	0.000387	0.0247	0.24	0.16	Mean platelet volume;	chr1:202935713	chr1:202861754~202875241:+
THCA	cis	rs7660883	0.866	rs1674999	ENSG00000251411.1	RP11-397E7.4	-3.57	0.000387	0.0247	-0.15	-0.16	HDL cholesterol levels;	chr4:87106498	chr4:86913266~86914817:-
THCA	cis	rs7618915	1	rs34569561	ENSG00000239557.1	RP11-168J18.6	3.57	0.000387	0.0247	0.2	0.16	Bipolar disorder;	chr3:52253277	chr3:52373652~52374882:+
THCA	cis	rs889312	0.923	rs12697152	ENSG00000271828.1	CTD-2310F14.1	3.57	0.000387	0.0247	0.23	0.16	Breast cancer (early onset);Breast cancer;	chr5:56729889	chr5:56927874~56929573:+
THCA	cis	rs9818758	0.607	rs9880088	ENSG00000229759.1	MRPS18AP1	-3.57	0.000387	0.0247	-0.33	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49141557	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs9862483	ENSG00000229759.1	MRPS18AP1	-3.57	0.000387	0.0247	-0.33	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49158008	chr3:48256350~48256938:-
THCA	cis	rs11634944	0.644	rs2554419	ENSG00000257647.1	RP11-701H24.3	3.57	0.000387	0.0247	0.09	0.16	Interleukin-8 levels;	chr15:24995018	chr15:25027736~25032047:-
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000264242.2	RP11-271K11.1	3.57	0.000387	0.0247	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30553697~30558962:+
THCA	cis	rs12285326	0.559	rs11032474	ENSG00000280798.1	LINC00294	3.57	0.000387	0.0247	0.15	0.16	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr11:33988996	chr11:33076149~33079454:+
THCA	cis	rs10858047	0.883	rs72698011	ENSG00000231128.4	RP5-1073O3.2	3.57	0.000387	0.0247	0.24	0.16	Autism;	chr1:114551033	chr1:113812379~113829171:+
THCA	cis	rs1979679	0.801	rs7979524	ENSG00000278733.1	RP11-425D17.1	-3.57	0.000387	0.0247	-0.16	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28550900	chr12:28185625~28186190:-
THCA	cis	rs2882667	0.931	rs13153618	ENSG00000249593.5	CTB-46B19.2	3.57	0.000387	0.0247	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:139012647~139051203:+
THCA	cis	rs4664304	0.511	rs2303547	ENSG00000226266.5	AC009961.3	3.57	0.000387	0.0247	0.19	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159835318	chr2:159670708~159712435:-
THCA	cis	rs372883	0.6	rs2832293	ENSG00000176054.6	RPL23P2	3.57	0.000387	0.0247	0.15	0.16	Pancreatic cancer;	chr21:29366551	chr21:28997613~28998033:-
THCA	cis	rs12101261	0.813	rs4903964	ENSG00000259167.2	NMNAT1P1	3.57	0.000387	0.0247	0.2	0.16	Graves' disease;	chr14:81002610	chr14:81032529~81033404:+
THCA	cis	rs2832191	0.903	rs11700687	ENSG00000232855.5	AF131217.1	3.57	0.000387	0.0247	0.17	0.16	Dental caries;	chr21:29114446	chr21:28439346~28674848:-
THCA	cis	rs10496034	0.541	rs6740018	ENSG00000237887.1	AC092839.1	-3.57	0.000387	0.0247	-0.31	-0.16	Refractive astigmatism;	chr2:54677683	chr2:54529343~54529801:+
THCA	cis	rs10266483	0.741	rs10254313	ENSG00000271550.1	BNIP3P11	3.57	0.000387	0.0247	0.2	0.16	Response to statin therapy;	chr7:64278935	chr7:64678954~64687393:-
THCA	cis	rs10266483	0.741	rs35244017	ENSG00000271550.1	BNIP3P11	3.57	0.000387	0.0247	0.2	0.16	Response to statin therapy;	chr7:64278939	chr7:64678954~64687393:-
THCA	cis	rs10266483	0.843	rs10272639	ENSG00000271550.1	BNIP3P11	3.57	0.000387	0.0247	0.2	0.16	Response to statin therapy;	chr7:64278944	chr7:64678954~64687393:-
THCA	cis	rs944289	0.6	rs2774166	ENSG00000258844.1	RP11-259K15.2	-3.57	0.000387	0.0247	-0.15	-0.16	Thyroid cancer;	chr14:36169449	chr14:36214607~36235608:+
THCA	cis	rs62380364	0.692	rs61104616	ENSG00000247828.6	TMEM161B-AS1	-3.57	0.000387	0.0247	-0.12	-0.16	Intelligence (multi-trait analysis);	chr5:88867954	chr5:88268895~88436685:+
THCA	cis	rs786425	0.689	rs2222060	ENSG00000278112.1	RP11-972P1.11	3.57	0.000387	0.0247	0.16	0.16	Pubertal anthropometrics;	chr12:123709891	chr12:123519390~123519856:-
THCA	cis	rs853679	0.769	rs7752608	ENSG00000220721.1	OR1F12	3.57	0.000387	0.0247	0.33	0.16	Depression;	chr6:28333418	chr6:28073316~28074233:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000273024.4	INTS4P2	-3.57	0.000387	0.0247	-0.2	-0.16	Aortic root size;	chr7:66622723	chr7:65647864~65715661:+
THCA	cis	rs476633	0.691	rs2164996	ENSG00000247556.5	OIP5-AS1	3.57	0.000387	0.0247	0.13	0.16	Glomerular filtration rate (creatinine);	chr15:41244426	chr15:41283990~41309737:+
THCA	cis	rs11018904	0.906	rs55685917	ENSG00000280367.1	RP11-121L10.2	3.57	0.000387	0.0247	0.22	0.16	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90223153~90226538:+
THCA	cis	rs11018904	0.906	rs35286339	ENSG00000280367.1	RP11-121L10.2	3.57	0.000387	0.0247	0.22	0.16	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90223153~90226538:+
THCA	cis	rs7701440	0.512	rs7443733	ENSG00000251279.1	CTC-436P18.1	-3.57	0.000387	0.0247	-0.2	-0.16	Educational attainment;	chr5:61238155	chr5:61162070~61232040:+
THCA	cis	rs13437751	0.536	rs10263768	ENSG00000223558.1	TRIM60P17	3.57	0.000387	0.0247	0.34	0.16	QT interval (drug interaction);	chr7:63936201	chr7:64085560~64086576:+
THCA	cis	rs6940116	1	rs6940116	ENSG00000220721.1	OR1F12	3.57	0.000387	0.0247	0.25	0.16	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28073316~28074233:+
THCA	cis	rs1504749	0.53	rs55988742	ENSG00000254142.2	RP11-53M11.3	-3.57	0.000387	0.0247	-0.29	-0.16	Intracranial aneurysm;	chr8:54376602	chr8:54554361~54561927:+
THCA	cis	rs1874124	0.577	rs2807853	ENSG00000238078.1	LINC01352	3.57	0.000387	0.0247	0.29	0.16	Cholesterol, total;	chr1:220851011	chr1:220829255~220832429:+
THCA	cis	rs1874124	0.504	rs2491257	ENSG00000238078.1	LINC01352	3.57	0.000387	0.0247	0.29	0.16	Cholesterol, total;	chr1:220855900	chr1:220829255~220832429:+
THCA	cis	rs997295	0.57	rs60066681	ENSG00000245719.1	RP11-34F13.2	3.57	0.000387	0.0247	0.17	0.16	Motion sickness;	chr15:67515738	chr15:67834310~67838879:-
THCA	cis	rs6580649	0.831	rs1635528	ENSG00000273765.1	RP11-370I10.11	3.57	0.000387	0.0247	0.18	0.16	Lung cancer;	chr12:48002117	chr12:48360920~48361377:+
THCA	cis	rs17622252	0.651	rs76218728	ENSG00000280989.1	LINC00581	3.57	0.000387	0.0247	0.31	0.16	Bipolar disorder;	chr6:21357418	chr6:21486061~21511895:-
THCA	cis	rs7208859	0.673	rs216420	ENSG00000265443.1	CTD-2349P21.6	-3.57	0.000387	0.0247	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30726305~30727564:-
THCA	cis	rs7487075	1	rs7487075	ENSG00000272369.1	RP11-446N19.1	3.57	0.000387	0.0247	0.12	0.16	Itch intensity from mosquito bite;	chr12:46435135	chr12:46537502~46652550:+
THCA	cis	rs116248771	0.549	rs9811858	ENSG00000240207.5	RP11-379F4.4	3.57	0.000387	0.0247	0.22	0.16	diarrhoeal disease at age 2;	chr3:158725304	chr3:158732263~158784070:+
THCA	cis	rs3808502	0.526	rs36048422	ENSG00000154316.13	TDH	3.57	0.000387	0.0247	0.12	0.16	Neuroticism;	chr8:11559635	chr8:11339637~11368452:+
THCA	cis	rs3808502	0.526	rs11783065	ENSG00000154316.13	TDH	3.57	0.000387	0.0247	0.12	0.16	Neuroticism;	chr8:11559748	chr8:11339637~11368452:+
THCA	cis	rs3758911	0.828	rs10890684	ENSG00000255353.1	RP11-382M14.1	-3.57	0.000387	0.0247	-0.21	-0.16	Coronary artery disease;	chr11:107266325	chr11:107176286~107177530:+
THCA	cis	rs12681366	0.839	rs3019280	ENSG00000253175.1	RP11-267M23.6	3.57	0.000388	0.0247	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.839	rs3019281	ENSG00000253175.1	RP11-267M23.6	3.57	0.000388	0.0247	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94565036~94565715:+
THCA	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	3.57	0.000388	0.0247	0.15	0.16	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
THCA	cis	rs35740288	0.822	rs2306225	ENSG00000259407.1	RP11-158M2.3	-3.57	0.000388	0.0247	-0.2	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85684721	chr15:85744109~85750281:-
THCA	cis	rs860295	0.702	rs3738590	ENSG00000236675.1	MTX1P1	-3.57	0.000388	0.0248	-0.17	-0.16	Body mass index;	chr1:155660961	chr1:155230975~155234325:+
THCA	cis	rs7259376	0.936	rs1975173	ENSG00000270947.1	AC025811.3	3.57	0.000388	0.0248	0.17	0.16	Menopause (age at onset);	chr19:22351736	chr19:22455988~22456459:+
THCA	cis	rs4703129	0.967	rs13173747	ENSG00000246763.5	RGMB-AS1	-3.57	0.000388	0.0248	-0.16	-0.16	Asperger disorder;	chr5:98559851	chr5:98769618~98773469:-
THCA	cis	rs346923	1	rs17675398	ENSG00000226950.5	DANCR	-3.57	0.000388	0.0248	-0.18	-0.16	Biochemical measures;	chr4:52438386	chr4:52712404~52720351:+
THCA	cis	rs9513593	0.901	rs7997943	ENSG00000234005.3	GAPDHP22	3.57	0.000388	0.0248	0.22	0.16	Psoriasis;	chr13:99158089	chr13:99190579~99190991:-
THCA	cis	rs806215	0.526	rs322837	ENSG00000224138.1	AC000123.4	-3.57	0.000388	0.0248	-0.17	-0.16	Type 2 diabetes;	chr7:128071649	chr7:127350128~127351523:+
THCA	cis	rs78487399	0.908	rs11904361	ENSG00000234936.1	AC010883.5	3.57	0.000388	0.0248	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43621525	chr2:43229573~43233394:+
THCA	cis	rs1560104	0.576	rs11645674	ENSG00000260601.1	RP11-552C15.1	3.57	0.000388	0.0248	0.2	0.16	Obesity-related traits;	chr16:12615117	chr16:12545482~12546684:+
THCA	cis	rs7660883	0.897	rs236985	ENSG00000251411.1	RP11-397E7.4	3.57	0.000388	0.0248	0.15	0.16	HDL cholesterol levels;	chr4:87087630	chr4:86913266~86914817:-
THCA	cis	rs944990	0.694	rs3922729	ENSG00000227603.1	RP11-165J3.6	3.57	0.000388	0.0248	0.17	0.16	Body mass index;	chr9:93587303	chr9:93435332~93437121:-
THCA	cis	rs73198271	0.773	rs66618176	ENSG00000254340.1	RP11-10A14.3	-3.57	0.000388	0.0248	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:9141424~9145435:+
THCA	cis	rs2839186	0.709	rs2156117	ENSG00000228137.1	AP001469.7	3.57	0.000388	0.0248	0.16	0.16	Testicular germ cell tumor;	chr21:46249386	chr21:46246890~46247682:+
THCA	cis	rs6430585	0.527	rs1438303	ENSG00000231890.6	DARS-AS1	-3.57	0.000388	0.0248	-0.19	-0.16	Corneal structure;	chr2:135672287	chr2:135985176~136022593:+
THCA	cis	rs295490	0.667	rs78684868	ENSG00000272656.1	RP11-219D15.3	3.57	0.000388	0.0248	0.3	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139485651	chr3:139349024~139349371:-
THCA	cis	rs295490	0.748	rs74636199	ENSG00000272656.1	RP11-219D15.3	3.57	0.000388	0.0248	0.3	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139493679	chr3:139349024~139349371:-
THCA	cis	rs603446	0.935	rs180372	ENSG00000254851.1	RP11-109L13.1	-3.57	0.000388	0.0248	-0.21	-0.16	Triglycerides;	chr11:116721218	chr11:117135528~117138582:+
THCA	cis	rs4604234	0.614	rs11961937	ENSG00000260645.1	RP11-250B2.5	-3.57	0.000388	0.0248	-0.27	-0.16	Cancer;	chr6:80119518	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.614	rs73479907	ENSG00000260645.1	RP11-250B2.5	-3.57	0.000388	0.0248	-0.27	-0.16	Cancer;	chr6:80124706	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.614	rs73479909	ENSG00000260645.1	RP11-250B2.5	-3.57	0.000388	0.0248	-0.27	-0.16	Cancer;	chr6:80125477	chr6:80466958~80469080:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66364510	chr7:66739829~66740385:-
THCA	cis	rs875971	0.929	rs778712	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66384991	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs778710	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66389847	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs778708	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66391332	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs778696	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66405826	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs778694	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66406571	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs4718344	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66409394	chr7:66739829~66740385:-
THCA	cis	rs875971	0.737	rs7803424	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66415618	chr7:66739829~66740385:-
THCA	cis	rs875971	0.83	rs7799834	ENSG00000272831.1	RP11-792A8.4	3.57	0.000388	0.0248	0.1	0.16	Aortic root size;	chr7:66415707	chr7:66739829~66740385:-
THCA	cis	rs11098699	0.784	rs13123501	ENSG00000273007.1	RP11-170N16.3	3.57	0.000388	0.0248	0.13	0.16	Mosquito bite size;	chr4:123323744	chr4:122881878~122884712:-
THCA	cis	rs4906172	0.838	rs1677995	ENSG00000259230.1	CTD-2555C10.3	-3.57	0.000388	0.0248	-0.24	-0.16	Menopause (age at onset);	chr14:101956776	chr14:102545254~102555826:+
THCA	cis	rs4906172	0.838	rs1677996	ENSG00000259230.1	CTD-2555C10.3	-3.57	0.000388	0.0248	-0.24	-0.16	Menopause (age at onset);	chr14:101956791	chr14:102545254~102555826:+
THCA	cis	rs14027	1	rs14027	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000388	0.0248	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119834349	chr8:119838736~119840385:-
THCA	cis	rs453301	0.658	rs12114954	ENSG00000254340.1	RP11-10A14.3	-3.57	0.000388	0.0248	-0.18	-0.16	Joint mobility (Beighton score);	chr8:9047352	chr8:9141424~9145435:+
THCA	cis	rs10760158	0.739	rs4837819	ENSG00000235865.2	GSN-AS1	3.57	0.000388	0.0248	0.14	0.16	Pulse pressure;	chr9:121246156	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.739	rs10760163	ENSG00000235865.2	GSN-AS1	3.57	0.000388	0.0248	0.14	0.16	Pulse pressure;	chr9:121246174	chr9:121280768~121285530:-
THCA	cis	rs1371614	0.632	rs3820823	ENSG00000229122.1	AGBL5-IT1	3.57	0.000388	0.0248	0.12	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26941938	chr2:27061038~27061815:+
THCA	cis	rs7296418	0.961	rs1790122	ENSG00000256092.2	RP13-942N8.1	3.57	0.000388	0.0248	0.12	0.16	Platelet count;	chr12:123122192	chr12:123363868~123366113:+
THCA	cis	rs524281	0.692	rs11227395	ENSG00000255120.4	OVOL1-AS1	-3.57	0.000388	0.0248	-0.24	-0.16	Electroencephalogram traits;	chr11:66062166	chr11:65789051~65790868:-
THCA	cis	rs708224	0.966	rs261873	ENSG00000274964.1	RP11-817I4.1	3.57	0.000388	0.0248	0.17	0.16	Pancreatic cancer;	chr12:32291358	chr12:32339368~32340724:+
THCA	cis	rs4780401	0.967	rs11075011	ENSG00000274038.1	RP11-66H6.4	-3.57	0.000388	0.0248	-0.19	-0.16	Rheumatoid arthritis;	chr16:11734426	chr16:11056556~11057034:+
THCA	cis	rs2276314	0.857	rs28530656	ENSG00000267627.4	RP11-905K4.1	3.57	0.000388	0.0248	0.2	0.16	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35951803~35966118:-
THCA	cis	rs9650657	0.504	rs10093053	ENSG00000254839.1	AF131215.6	3.57	0.000388	0.0248	0.17	0.16	Neuroticism;	chr8:11179678	chr8:11062647~11067089:-
THCA	cis	rs875971	0.862	rs1612452	ENSG00000223473.2	GS1-124K5.3	-3.57	0.000388	0.0248	-0.11	-0.16	Aortic root size;	chr7:66108909	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs1167390	ENSG00000223473.2	GS1-124K5.3	-3.57	0.000388	0.0248	-0.11	-0.16	Aortic root size;	chr7:66110906	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs35034167	ENSG00000223473.2	GS1-124K5.3	-3.57	0.000388	0.0248	-0.11	-0.16	Aortic root size;	chr7:66115179	chr7:66491049~66493566:-
THCA	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	3.57	0.000388	0.0248	0.23	0.16	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
THCA	cis	rs3770081	1	rs78646493	ENSG00000272564.1	RP11-548P2.2	-3.57	0.000388	0.0248	-0.31	-0.16	Facial emotion recognition (sad faces);	chr2:86056072	chr2:85904279~85904727:+
THCA	cis	rs57709857	0.957	rs12674515	ENSG00000272092.1	RP11-350N15.5	-3.57	0.000388	0.0248	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38280012	chr8:38382364~38383461:+
THCA	cis	rs11675251	0.68	rs3933629	ENSG00000273456.1	RP11-686O6.2	3.57	0.000388	0.0248	0.13	0.16	Butyrylcholinesterase levels;	chr2:202901644	chr2:202374932~202375604:-
THCA	cis	rs7474896	1	rs11597286	ENSG00000276805.1	RP11-291L22.6	3.57	0.000388	0.0248	0.25	0.16	Obesity (extreme);	chr10:37817527	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs9418288	ENSG00000276805.1	RP11-291L22.6	3.57	0.000388	0.0248	0.25	0.16	Obesity (extreme);	chr10:37818208	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs9418294	ENSG00000276805.1	RP11-291L22.6	3.57	0.000388	0.0248	0.25	0.16	Obesity (extreme);	chr10:37826658	chr10:38451030~38451785:+
THCA	cis	rs4907240	0.961	rs11691670	ENSG00000230606.9	AC159540.1	3.57	0.000389	0.0248	0.18	0.16	Event-related brain oscillations;	chr2:96573033	chr2:97416165~97433527:-
THCA	cis	rs1348850	0.608	rs10176632	ENSG00000280374.1	RP11-337N6.3	3.57	0.000389	0.0248	0.21	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177361206	chr2:177317715~177318471:-
THCA	cis	rs1348850	0.539	rs1453371	ENSG00000280374.1	RP11-337N6.3	3.57	0.000389	0.0248	0.21	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177363134	chr2:177317715~177318471:-
THCA	cis	rs56046484	0.956	rs12904410	ENSG00000218052.5	ADAMTS7P4	-3.57	0.000389	0.0248	-0.25	-0.16	Testicular germ cell tumor;	chr15:85066557	chr15:85255369~85330334:-
THCA	cis	rs8040855	0.627	rs11630697	ENSG00000225151.9	GOLGA2P7	-3.57	0.000389	0.0248	-0.23	-0.16	Bulimia nervosa;	chr15:85063214	chr15:84199311~84230136:-
THCA	cis	rs8040855	0.627	rs4980357	ENSG00000225151.9	GOLGA2P7	-3.57	0.000389	0.0248	-0.23	-0.16	Bulimia nervosa;	chr15:85064878	chr15:84199311~84230136:-
THCA	cis	rs8040855	0.627	rs4980356	ENSG00000225151.9	GOLGA2P7	-3.57	0.000389	0.0248	-0.23	-0.16	Bulimia nervosa;	chr15:85064901	chr15:84199311~84230136:-
THCA	cis	rs11756659	0.697	rs7746105	ENSG00000272810.1	U91328.22	-3.57	0.000389	0.0248	-0.15	-0.16	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25944050	chr6:26013241~26013757:+
THCA	cis	rs72996113	0.702	rs79152974	ENSG00000248027.1	CTD-2383M3.1	-3.57	0.000389	0.0248	-0.31	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100666544	chr11:100684162~100687955:-
THCA	cis	rs875971	0.545	rs6460281	ENSG00000230295.1	RP11-458F8.2	3.57	0.000389	0.0248	0.14	0.16	Aortic root size;	chr7:66216128	chr7:66880708~66882981:+
THCA	cis	rs7267979	0.78	rs6050679	ENSG00000276952.1	RP5-965G21.6	3.57	0.000389	0.0248	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25284915~25285588:-
THCA	cis	rs6568686	0.786	rs4458728	ENSG00000255389.1	C6orf3	3.57	0.000389	0.0248	0.24	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111519359	chr6:111599875~111602295:+
THCA	cis	rs9905704	0.801	rs2013182	ENSG00000224738.1	AC099850.1	-3.57	0.000389	0.0248	-0.21	-0.16	Testicular germ cell tumor;	chr17:58560409	chr17:59106598~59118267:+
THCA	cis	rs7660883	1	rs11946481	ENSG00000251411.1	RP11-397E7.4	3.57	0.000389	0.0248	0.16	0.16	HDL cholesterol levels;	chr4:87063458	chr4:86913266~86914817:-
THCA	cis	rs7129556	0.954	rs4509797	ENSG00000254459.1	RP11-91P24.7	-3.57	0.000389	0.0248	-0.2	-0.16	Weight loss (gastric bypass surgery);	chr11:77552158	chr11:77829654~77872262:-
THCA	cis	rs3808502	0.527	rs2736389	ENSG00000254948.1	OR7E158P	-3.57	0.000389	0.0248	-0.21	-0.16	Neuroticism;	chr8:11303801	chr8:11919900~11920809:-
THCA	cis	rs10411161	0.702	rs16983200	ENSG00000275055.1	CTC-471J1.11	-3.57	0.000389	0.0248	-0.16	-0.16	Breast cancer;	chr19:51883470	chr19:52049007~52049754:+
THCA	cis	rs7173964	1	rs6494307	ENSG00000259251.2	RP11-643M14.1	3.57	0.000389	0.0248	0.16	0.16	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62102491	chr15:62060503~62062434:+
THCA	cis	rs2299587	0.585	rs2299590	ENSG00000253671.1	RP11-806O11.1	-3.57	0.000389	0.0248	-0.2	-0.16	Economic and political preferences;	chr8:17944683	chr8:17808941~17820868:+
THCA	cis	rs9487051	1	rs6568569	ENSG00000260273.1	RP11-425D10.10	3.57	0.000389	0.0248	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109291993	chr6:109382795~109383666:+
THCA	cis	rs9487051	1	rs6568570	ENSG00000260273.1	RP11-425D10.10	3.57	0.000389	0.0248	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109292038	chr6:109382795~109383666:+
THCA	cis	rs9487051	1	rs11757567	ENSG00000260273.1	RP11-425D10.10	3.57	0.000389	0.0248	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109293510	chr6:109382795~109383666:+
THCA	cis	rs9487051	1	rs9386795	ENSG00000260273.1	RP11-425D10.10	3.57	0.000389	0.0248	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109295325	chr6:109382795~109383666:+
THCA	cis	rs9487051	1	rs9386796	ENSG00000260273.1	RP11-425D10.10	3.57	0.000389	0.0248	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109297501	chr6:109382795~109383666:+
THCA	cis	rs2766547	1	rs1075091	ENSG00000228559.1	RP3-340B19.3	-3.57	0.000389	0.0248	-0.18	-0.16	Eosinophil percentage of granulocytes;	chr6:35745710	chr6:35544632~35545669:+
THCA	cis	rs7763441	0.836	rs9378332	ENSG00000250903.7	GMDS-AS1	3.57	0.000389	0.0248	0.14	0.16	Monobrow;	chr6:2446186	chr6:2245748~2482022:+
THCA	cis	rs2455799	0.613	rs2470538	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000389	0.0248	-0.17	-0.16	Mean platelet volume;	chr3:15675617	chr3:15732252~15733470:+
THCA	cis	rs3015497	0.616	rs10131107	ENSG00000270062.1	RP11-248J18.3	3.57	0.000389	0.0248	0.18	0.16	Mean platelet volume;	chr14:50595737	chr14:50723777~50724272:-
THCA	cis	rs916888	0.697	rs199516	ENSG00000260075.1	NSFP1	3.57	0.000389	0.0248	0.26	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46372855~46487141:+
THCA	cis	rs1823874	0.924	rs4965542	ENSG00000254744.3	CTD-3076O17.1	-3.57	0.000389	0.0248	-0.17	-0.16	IgG glycosylation;	chr15:99816414	chr15:99970215~99974010:+
THCA	cis	rs301901	0.734	rs216386	ENSG00000250155.1	CTD-2353F22.1	-3.57	0.000389	0.0248	-0.16	-0.16	Height;	chr5:37276224	chr5:36666214~36725195:-
THCA	cis	rs7819412	0.74	rs28633434	ENSG00000254839.1	AF131215.6	3.57	0.000389	0.0248	0.17	0.16	Triglycerides;	chr8:11196413	chr8:11062647~11067089:-
THCA	cis	rs1005277	0.579	rs2474584	ENSG00000120555.12	SEPT7P9	3.57	0.000389	0.0248	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.579	rs2474586	ENSG00000120555.12	SEPT7P9	3.57	0.000389	0.0248	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38383069~38402916:-
THCA	cis	rs7845127	0.552	rs6586730	ENSG00000253671.1	RP11-806O11.1	-3.57	0.000389	0.0248	-0.19	-0.16	Night sleep phenotypes;	chr8:18263798	chr8:17808941~17820868:+
THCA	cis	rs6598541	1	rs7166287	ENSG00000278090.1	RP11-6O2.2	-3.57	0.000389	0.0248	-0.15	-0.16	Urate levels;	chr15:98729846	chr15:99028538~99031053:+
THCA	cis	rs1862618	0.853	rs863840	ENSG00000234553.1	AC022431.3	-3.57	0.000389	0.0248	-0.19	-0.16	Initial pursuit acceleration;	chr5:56833172	chr5:56536583~56537826:-
THCA	cis	rs1541160	1	rs1330377	ENSG00000239494.2	RN7SL333P	3.57	0.000389	0.0248	0.16	0.16	Amyotrophic lateral sclerosis;	chr1:170081461	chr1:169859756~169860052:+
THCA	cis	rs1979679	0.608	rs4931082	ENSG00000278733.1	RP11-425D17.1	-3.57	0.000389	0.0248	-0.17	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28567087	chr12:28185625~28186190:-
THCA	cis	rs34102591	0.503	rs58411567	ENSG00000270061.1	RP11-214K3.19	-3.57	0.000389	0.0248	-0.21	-0.16	Schizophrenia;	chr12:123903027	chr12:123969990~123970344:-
THCA	cis	rs10863936	0.667	rs17700264	ENSG00000198468.6	FLVCR1-AS1	-3.57	0.000389	0.0248	-0.19	-0.16	Height;	chr1:211948068	chr1:212852108~212858088:-
THCA	cis	rs7264396	0.887	rs224370	ENSG00000261582.1	RP4-614O4.11	-3.57	0.000389	0.0248	-0.17	-0.16	Total cholesterol levels;	chr20:35485555	chr20:35267885~35280043:-
THCA	cis	rs2436845	0.554	rs567395	ENSG00000253669.3	KB-1732A1.1	-3.57	0.000389	0.0248	-0.17	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102902262	chr8:102805517~102809971:+
THCA	cis	rs2274273	0.84	rs7144737	ENSG00000258469.1	CHMP4BP1	3.57	0.000389	0.0248	0.15	0.16	Protein biomarker;	chr14:55356228	chr14:55298644~55299231:+
THCA	cis	rs13098911	0.54	rs35516580	ENSG00000226074.4	PRSS44	-3.57	0.000389	0.0249	-0.31	-0.16	Celiac disease;	chr3:46066006	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34766614	ENSG00000226074.4	PRSS44	-3.57	0.000389	0.0249	-0.31	-0.16	Celiac disease;	chr3:46066109	chr3:46809359~46812558:-
THCA	cis	rs2933343	0.7	rs1683787	ENSG00000261159.1	RP11-723O4.9	-3.57	0.00039	0.0249	-0.17	-0.16	IgG glycosylation;	chr3:128908178	chr3:128859716~128860526:-
THCA	cis	rs12101261	1	rs8003061	ENSG00000259167.2	NMNAT1P1	3.57	0.00039	0.0249	0.19	0.16	Graves' disease;	chr14:80985612	chr14:81032529~81033404:+
THCA	cis	rs1204798	0.588	rs11153597	ENSG00000237021.2	RP3-486I3.7	-3.57	0.00039	0.0249	-0.25	-0.16	Dental caries;	chr6:116116124	chr6:116254207~116256743:+
THCA	cis	rs4703129	1	rs6869049	ENSG00000246763.5	RGMB-AS1	-3.57	0.00039	0.0249	-0.16	-0.16	Asperger disorder;	chr5:98521203	chr5:98769618~98773469:-
THCA	cis	rs17027633	1	rs3754035	ENSG00000260948.1	RP11-552M11.8	-3.57	0.00039	0.0249	-0.39	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111430607	chr1:111431046~111433068:-
THCA	cis	rs17027633	1	rs77952923	ENSG00000260948.1	RP11-552M11.8	-3.57	0.00039	0.0249	-0.39	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111432030	chr1:111431046~111433068:-
THCA	cis	rs17027633	0.881	rs11548427	ENSG00000260948.1	RP11-552M11.8	-3.57	0.00039	0.0249	-0.39	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111449146	chr1:111431046~111433068:-
THCA	cis	rs12893668	0.581	rs34843146	ENSG00000258735.1	LINC00637	-3.57	0.00039	0.0249	-0.22	-0.16	Reticulocyte count;	chr14:103613527	chr14:103847721~103858049:+
THCA	cis	rs495337	0.76	rs471054	ENSG00000229222.1	KRT18P4	-3.57	0.00039	0.0249	-0.2	-0.16	Psoriasis;	chr20:49896699	chr20:49956745~49958032:+
THCA	cis	rs14027	0.843	rs1828238	ENSG00000279347.1	RP11-85I17.2	3.57	0.00039	0.0249	0.19	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs1960438	ENSG00000279347.1	RP11-85I17.2	3.57	0.00039	0.0249	0.19	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119838736~119840385:-
THCA	cis	rs11673344	0.526	rs17305193	ENSG00000267470.4	ZNF571-AS1	-3.57	0.00039	0.0249	-0.2	-0.16	Obesity-related traits;	chr19:37598764	chr19:37548914~37587348:+
THCA	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	3.57	0.00039	0.0249	0.22	0.16	Depression;	chr6:28379133	chr6:28943877~28944537:+
THCA	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	3.57	0.00039	0.0249	0.22	0.16	Depression;	chr6:28379168	chr6:28943877~28944537:+
THCA	cis	rs7264396	0.887	rs224351	ENSG00000261582.1	RP4-614O4.11	-3.57	0.00039	0.0249	-0.17	-0.16	Total cholesterol levels;	chr20:35464448	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs224354	ENSG00000261582.1	RP4-614O4.11	-3.57	0.00039	0.0249	-0.17	-0.16	Total cholesterol levels;	chr20:35466784	chr20:35267885~35280043:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000232546.1	RP11-458F8.1	-3.57	0.00039	0.0249	-0.13	-0.16	Calcium levels;	chr7:65853042	chr7:66848496~66858136:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000232546.1	RP11-458F8.1	-3.57	0.00039	0.0249	-0.13	-0.16	Aortic root size;	chr7:65871069	chr7:66848496~66858136:+
THCA	cis	rs6479891	1	rs4469774	ENSG00000272767.1	JMJD1C-AS1	3.57	0.00039	0.0249	0.23	0.16	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63465229~63466563:+
THCA	cis	rs9990333	0.562	rs56038600	ENSG00000185485.13	SDHAP1	3.57	0.00039	0.0249	0.15	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195959748~195990318:-
THCA	cis	rs3783637	0.643	rs75790544	ENSG00000258413.1	RP11-665C16.6	-3.57	0.00039	0.0249	-0.34	-0.16	Rheumatoid arthritis;Obesity-related traits;	chr14:54978408	chr14:55262767~55272075:-
THCA	cis	rs2455799	0.613	rs2246960	ENSG00000270409.1	RP11-44D5.1	-3.57	0.00039	0.0249	-0.17	-0.16	Mean platelet volume;	chr3:15676186	chr3:15732252~15733470:+
THCA	cis	rs7615952	0.599	rs6779141	ENSG00000248787.1	RP11-666A20.4	-3.57	0.00039	0.0249	-0.25	-0.16	Blood pressure (smoking interaction);	chr3:125991152	chr3:125908005~125910272:-
THCA	cis	rs2274273	0.84	rs10136596	ENSG00000258469.1	CHMP4BP1	3.57	0.00039	0.0249	0.15	0.16	Protein biomarker;	chr14:55370055	chr14:55298644~55299231:+
THCA	cis	rs8030379	1	rs10152119	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901629	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs1471553	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83902286	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs1564475	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903477	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs7183263	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904289	chr15:84631451~84647478:+
THCA	cis	rs8030379	0.967	rs899926	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904739	chr15:84631451~84647478:+
THCA	cis	rs8030379	0.967	rs8029387	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906523	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs940934	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906776	chr15:84631451~84647478:+
THCA	cis	rs8030379	0.935	rs1815172	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907080	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs1810049	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907300	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs11853052	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907407	chr15:84631451~84647478:+
THCA	cis	rs912593	1	rs730737	ENSG00000225179.1	LINC00457	-3.57	0.00039	0.0249	-0.21	-0.16	Cancer;	chr13:34458243	chr13:34435450~34640685:-
THCA	cis	rs6427356	1	rs1176553	ENSG00000237189.1	RP11-85G21.2	3.57	0.00039	0.0249	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157166244	chr1:157287703~157288053:-
THCA	cis	rs9369640	0.674	rs13219256	ENSG00000212802.4	RPL15P3	-3.57	0.00039	0.0249	-0.16	-0.16	Coronary artery disease;	chr6:12898060	chr6:12514110~12514724:+
THCA	cis	rs995834	0.869	rs9304581	ENSG00000261770.1	CTC-459F4.1	-3.57	0.00039	0.0249	-0.22	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394084	chr19:27757184~27760849:-
THCA	cis	rs77147124	1	rs1129555	ENSG00000225292.2	RP11-57H14.3	3.57	0.00039	0.0249	0.22	0.16	HDL cholesterol;	chr10:112150963	chr10:112888735~112906111:+
THCA	cis	rs9309473	0.5	rs13022837	ENSG00000273245.1	RP11-434P11.2	-3.57	0.00039	0.0249	-0.19	-0.16	Metabolite levels;	chr2:73685440	chr2:73750256~73750786:-
THCA	cis	rs9875589	0.747	rs1488378	ENSG00000228242.5	AC093495.4	3.57	0.00039	0.0249	0.1	0.16	Ovarian reserve;	chr3:13973225	chr3:14144637~14165978:+
THCA	cis	rs34779708	0.966	rs12257770	ENSG00000233200.1	RP11-324I22.2	3.57	0.00039	0.0249	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35219894~35230598:-
THCA	cis	rs17689437	0.813	rs56281049	ENSG00000260084.1	RP11-615I2.1	-3.57	0.00039	0.0249	-0.26	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68640368	chr16:68573782~68589512:-
THCA	cis	rs4660214	0.666	rs10888682	ENSG00000228060.1	RP11-69E11.8	3.57	0.00039	0.0249	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157635	chr1:39565160~39573203:+
THCA	cis	rs6443245	0.963	rs2648573	ENSG00000227110.5	LMCD1-AS1	-3.57	0.00039	0.0249	-0.2	-0.16	Daytime sleep phenotypes;	chr3:9593787	chr3:7952805~8611924:-
THCA	cis	rs9860428	0.808	rs34147006	ENSG00000240057.4	RP11-572M11.4	-3.57	0.00039	0.0249	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112903063	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.844	rs9819621	ENSG00000240057.4	RP11-572M11.4	-3.57	0.00039	0.0249	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904219	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.844	rs12490586	ENSG00000240057.4	RP11-572M11.4	-3.57	0.00039	0.0249	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904386	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.844	rs12487198	ENSG00000240057.4	RP11-572M11.4	-3.57	0.00039	0.0249	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904423	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.844	rs9863580	ENSG00000240057.4	RP11-572M11.4	-3.57	0.00039	0.0249	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905883	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.844	rs9877803	ENSG00000240057.4	RP11-572M11.4	-3.57	0.00039	0.0249	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112906290	chr3:113019532~113183301:+
THCA	cis	rs8030379	1	rs10906982	ENSG00000176700.18	SCAND2P	-3.57	0.00039	0.0249	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899406	chr15:84631451~84647478:+
THCA	cis	rs7208859	0.673	rs423151	ENSG00000265443.1	CTD-2349P21.6	-3.57	0.00039	0.0249	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30726305~30727564:-
THCA	cis	rs786425	0.966	rs7302183	ENSG00000278112.1	RP11-972P1.11	3.57	0.000391	0.0249	0.15	0.16	Pubertal anthropometrics;	chr12:123619913	chr12:123519390~123519856:-
THCA	cis	rs9889262	0.582	rs11655466	ENSG00000248714.5	RP11-1079K10.3	3.57	0.000391	0.0249	0.18	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49267168	chr17:49361165~49369998:+
THCA	cis	rs738722	0.518	rs695272	ENSG00000272858.1	CTA-292E10.8	-3.57	0.000391	0.0249	-0.16	-0.16	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28460772	chr22:28814914~28815662:+
THCA	cis	rs875971	0.965	rs697968	ENSG00000230189.5	GS1-124K5.2	-3.57	0.000391	0.0249	-0.11	-0.16	Aortic root size;	chr7:66070046	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs1183245	ENSG00000230189.5	GS1-124K5.2	-3.57	0.000391	0.0249	-0.11	-0.16	Aortic root size;	chr7:66076198	chr7:66409143~66490059:-
THCA	cis	rs875971	1	rs1144894	ENSG00000230189.5	GS1-124K5.2	-3.57	0.000391	0.0249	-0.11	-0.16	Aortic root size;	chr7:66077907	chr7:66409143~66490059:-
THCA	cis	rs7474896	0.583	rs1208770	ENSG00000272983.1	RP11-508N22.12	-3.57	0.000391	0.0249	-0.17	-0.16	Obesity (extreme);	chr10:37755755	chr10:38137337~38144399:+
THCA	cis	rs7474896	0.526	rs1742235	ENSG00000272983.1	RP11-508N22.12	-3.57	0.000391	0.0249	-0.17	-0.16	Obesity (extreme);	chr10:37763328	chr10:38137337~38144399:+
THCA	cis	rs7474896	0.559	rs1208779	ENSG00000272983.1	RP11-508N22.12	-3.57	0.000391	0.0249	-0.17	-0.16	Obesity (extreme);	chr10:37788801	chr10:38137337~38144399:+
THCA	cis	rs4650994	0.525	rs4457535	ENSG00000213057.5	C1orf220	3.57	0.000391	0.0249	0.12	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178528051	chr1:178542752~178548889:+
THCA	cis	rs4650994	0.544	rs11579513	ENSG00000213057.5	C1orf220	-3.57	0.000391	0.0249	-0.12	-0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178526957	chr1:178542752~178548889:+
THCA	cis	rs4650994	0.544	rs6675811	ENSG00000213057.5	C1orf220	-3.57	0.000391	0.0249	-0.12	-0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178529933	chr1:178542752~178548889:+
THCA	cis	rs2729354	0.909	rs2729374	ENSG00000254602.1	AP000662.4	-3.57	0.000391	0.0249	-0.21	-0.16	Blood protein levels;	chr11:57559454	chr11:57638024~57652790:+
THCA	cis	rs997295	0.554	rs7180312	ENSG00000270964.1	RP11-502I4.3	3.57	0.000391	0.0249	0.13	0.16	Motion sickness;	chr15:67812918	chr15:67541072~67542604:-
THCA	cis	rs17739167	0.532	rs11638953	ENSG00000246740.2	PLA2G4E-AS1	-3.57	0.000391	0.0249	-0.19	-0.16	Monocyte count;	chr15:41953454	chr15:41972763~41999094:+
THCA	cis	rs748404	0.666	rs72709871	ENSG00000166763.7	STRCP1	3.57	0.000391	0.0249	0.21	0.16	Lung cancer;	chr15:43499025	chr15:43699488~43718184:-
THCA	cis	rs1552244	0.554	rs3846169	ENSG00000269982.1	RP11-1020A11.2	-3.57	0.000391	0.0249	-0.11	-0.16	Alzheimer's disease;	chr3:9955370	chr3:9958717~9962539:+
THCA	cis	rs6787172	0.593	rs9876322	ENSG00000272087.1	RP11-379F4.7	-3.57	0.000391	0.0249	-0.15	-0.16	Subjective well-being;	chr3:158401449	chr3:158693120~158693768:-
THCA	cis	rs8112211	0.731	rs118185142	ENSG00000267291.1	CTB-186G2.1	3.57	0.000391	0.0249	0.18	0.16	Blood protein levels;	chr19:38331069	chr19:38596346~38601694:+
THCA	cis	rs8112211	0.731	rs11673012	ENSG00000267291.1	CTB-186G2.1	3.57	0.000391	0.0249	0.18	0.16	Blood protein levels;	chr19:38333331	chr19:38596346~38601694:+
THCA	cis	rs8112211	0.731	rs11673222	ENSG00000267291.1	CTB-186G2.1	3.57	0.000391	0.0249	0.18	0.16	Blood protein levels;	chr19:38333704	chr19:38596346~38601694:+
THCA	cis	rs2289328	0.941	rs11636147	ENSG00000223313.1	RNU6-516P	-3.57	0.000391	0.0249	-0.25	-0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40428929	chr15:40529570~40529673:+
THCA	cis	rs494003	0.951	rs11227302	ENSG00000199325.1	RNU4-39P	-3.57	0.000391	0.0249	-0.23	-0.16	Systemic lupus erythematosus;	chr11:65787031	chr11:66614964~66615090:-
THCA	cis	rs72928364	0.725	rs2053861	ENSG00000256628.3	ZBTB11-AS1	3.57	0.000391	0.0249	0.23	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101062385	chr3:101676475~101679217:+
THCA	cis	rs3820928	0.56	rs12620324	ENSG00000212391.1	SNORA48	-3.57	0.000391	0.0249	-0.2	-0.16	Pulmonary function;	chr2:227085305	chr2:226968989~226969122:-
THCA	cis	rs76439304	1	rs77430005	ENSG00000247903.1	RP11-421F16.3	-3.57	0.000391	0.0249	-0.25	-0.16	Mean corpuscular volume;	chr12:26934076	chr12:26971586~26979582:+
THCA	cis	rs76439304	1	rs80127764	ENSG00000247903.1	RP11-421F16.3	-3.57	0.000391	0.0249	-0.25	-0.16	Mean corpuscular volume;	chr12:26934077	chr12:26971586~26979582:+
THCA	cis	rs12428035	0.881	rs1330557	ENSG00000247400.3	DNAJC3-AS1	3.57	0.000391	0.0249	0.16	0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95940875	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.656	rs7999737	ENSG00000247400.3	DNAJC3-AS1	3.57	0.000391	0.0249	0.16	0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95950480	chr13:95648733~95676925:-
THCA	cis	rs3018712	0.508	rs4930581	ENSG00000212093.1	AP000807.1	-3.57	0.000391	0.0249	-0.21	-0.16	Total body bone mineral density;	chr11:68643625	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.508	rs4930582	ENSG00000212093.1	AP000807.1	-3.57	0.000391	0.0249	-0.21	-0.16	Total body bone mineral density;	chr11:68643636	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.547	rs4930583	ENSG00000212093.1	AP000807.1	-3.57	0.000391	0.0249	-0.21	-0.16	Total body bone mineral density;	chr11:68643711	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.59	rs4930584	ENSG00000212093.1	AP000807.1	-3.57	0.000391	0.0249	-0.21	-0.16	Total body bone mineral density;	chr11:68643828	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.59	rs4930585	ENSG00000212093.1	AP000807.1	-3.57	0.000391	0.0249	-0.21	-0.16	Total body bone mineral density;	chr11:68643879	chr11:68506083~68506166:-
THCA	cis	rs875971	0.545	rs1796222	ENSG00000232559.3	GS1-124K5.12	-3.57	0.000391	0.0249	-0.18	-0.16	Aortic root size;	chr7:66592167	chr7:66554588~66576923:-
THCA	cis	rs1876905	0.68	rs354547	ENSG00000271789.1	RP5-1112D6.7	3.57	0.000391	0.0249	0.2	0.16	Mean corpuscular hemoglobin;	chr6:111213919	chr6:111297126~111298510:+
THCA	cis	rs7542375	0.507	rs2784270	ENSG00000238078.1	LINC01352	3.57	0.000391	0.0249	0.2	0.16	Obesity-related traits;	chr1:220921625	chr1:220829255~220832429:+
THCA	cis	rs6968419	0.963	rs10261818	ENSG00000237870.5	AC073130.1	3.57	0.000391	0.0249	0.17	0.16	Intraocular pressure;	chr7:116185232	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.781	rs10261823	ENSG00000237870.5	AC073130.1	3.57	0.000391	0.0249	0.17	0.16	Intraocular pressure;	chr7:116185237	chr7:116275606~116286734:-
THCA	cis	rs6968419	1	rs6947586	ENSG00000237870.5	AC073130.1	3.57	0.000391	0.0249	0.17	0.16	Intraocular pressure;	chr7:116186706	chr7:116275606~116286734:-
THCA	cis	rs7613875	0.62	rs7624030	ENSG00000281691.1	RBM5-AS1	-3.57	0.000391	0.0249	-0.14	-0.16	Body mass index;	chr3:50033846	chr3:50099603~50100988:-
THCA	cis	rs1560104	0.536	rs34480785	ENSG00000260601.1	RP11-552C15.1	-3.57	0.000391	0.0249	-0.19	-0.16	Obesity-related traits;	chr16:12624032	chr16:12545482~12546684:+
THCA	cis	rs12476592	0.636	rs262493	ENSG00000242412.1	DBIL5P2	3.57	0.000391	0.0249	0.21	0.16	Childhood ear infection;	chr2:63617932	chr2:63117851~63119542:-
THCA	cis	rs4566357	0.615	rs4675139	ENSG00000212391.1	SNORA48	-3.57	0.000391	0.0249	-0.18	-0.16	Coronary artery disease;	chr2:227043811	chr2:226968989~226969122:-
THCA	cis	rs9402682	0.629	rs6925841	ENSG00000232876.1	CTA-212D2.2	-3.57	0.000391	0.0249	-0.22	-0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135120107	chr6:135055033~135060550:+
THCA	cis	rs72996113	0.938	rs749433	ENSG00000248027.1	CTD-2383M3.1	-3.57	0.000391	0.0249	-0.29	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100627978	chr11:100684162~100687955:-
THCA	cis	rs7216064	0.684	rs62084675	ENSG00000267023.4	LRRC37A16P	3.57	0.000391	0.0249	0.12	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68030909	chr17:68125777~68152468:-
THCA	cis	rs7216064	0.953	rs9890629	ENSG00000278740.1	RP11-147L13.14	3.57	0.000391	0.0249	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875443	chr17:68188547~68189165:+
THCA	cis	rs4713118	0.869	rs9283883	ENSG00000272009.1	RP1-313I6.12	-3.57	0.000391	0.0249	-0.18	-0.16	Parkinson's disease;	chr6:27747691	chr6:28078792~28081130:-
THCA	cis	rs5770917	1	rs2269385	ENSG00000279182.1	XX-C00717C00720L.1	3.57	0.000391	0.025	0.25	0.16	Narcolepsy;	chr22:50572510	chr22:50316035~50317025:+
THCA	cis	rs5770917	1	rs2269384	ENSG00000279182.1	XX-C00717C00720L.1	3.57	0.000391	0.025	0.25	0.16	Narcolepsy;	chr22:50572686	chr22:50316035~50317025:+
THCA	cis	rs5770917	1	rs115743514	ENSG00000279182.1	XX-C00717C00720L.1	3.57	0.000391	0.025	0.25	0.16	Narcolepsy;	chr22:50573504	chr22:50316035~50317025:+
THCA	cis	rs7701440	0.512	rs7444594	ENSG00000251279.1	CTC-436P18.1	-3.57	0.000391	0.025	-0.2	-0.16	Educational attainment;	chr5:61238832	chr5:61162070~61232040:+
THCA	cis	rs7824557	0.527	rs2572376	ENSG00000255495.1	AC145124.2	-3.57	0.000391	0.025	-0.18	-0.16	Retinal vascular caliber;	chr8:11380247	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.527	rs2736305	ENSG00000255495.1	AC145124.2	-3.57	0.000391	0.025	-0.18	-0.16	Retinal vascular caliber;	chr8:11380264	chr8:12194467~12196280:+
THCA	cis	rs12544026	0.515	rs537941	ENSG00000253669.3	KB-1732A1.1	-3.57	0.000391	0.025	-0.18	-0.16	Major depression and alcohol dependence;	chr8:101852994	chr8:102805517~102809971:+
THCA	cis	rs6743226	0.603	rs11675957	ENSG00000223374.1	AC005104.3	-3.57	0.000391	0.025	-0.12	-0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241269377	chr2:241351340~241353104:-
THCA	cis	rs950169	1	rs62026530	ENSG00000230373.7	GOLGA6L5P	-3.57	0.000391	0.025	-0.18	-0.16	Schizophrenia;	chr15:84107088	chr15:84507885~84516814:-
THCA	cis	rs7833787	0.501	rs6586766	ENSG00000278886.1	RP11-108A14.1	-3.57	0.000391	0.025	-0.23	-0.16	Obesity-related traits;	chr8:18827792	chr8:18864681~18865247:-
THCA	cis	rs2635047	0.967	rs9960264	ENSG00000280212.1	RP11-49K24.3	-3.57	0.000392	0.025	-0.16	-0.16	Educational attainment;	chr18:47080625	chr18:47076117~47076594:+
THCA	cis	rs14027	0.921	rs2048239	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000392	0.025	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119838736~119840385:-
THCA	cis	rs10090774	0.965	rs6578135	ENSG00000280303.2	ERICD	3.57	0.000392	0.025	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140768550	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs4554515	ENSG00000280303.2	ERICD	3.57	0.000392	0.025	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140768594	chr8:140636281~140638283:+
THCA	cis	rs710913	0.587	rs6690413	ENSG00000182109.6	RP11-69E11.4	3.57	0.000392	0.025	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620620	chr1:39522280~39546187:-
THCA	cis	rs3853824	0.636	rs7218364	ENSG00000263089.1	RP11-166P13.4	3.57	0.000392	0.025	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56854939	chr17:57092145~57096425:-
THCA	cis	rs10844706	0.699	rs1008610	ENSG00000257027.1	RP11-705C15.3	3.57	0.000392	0.025	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9731264	chr12:9658567~9662085:+
THCA	cis	rs5758511	0.68	rs739146	ENSG00000230107.1	CTA-126B4.7	-3.57	0.000392	0.025	-0.2	-0.16	Birth weight;	chr22:42264408	chr22:42438023~42446195:+
THCA	cis	rs332034	0.546	rs28886957	ENSG00000254153.1	CTA-398F10.2	3.57	0.000392	0.025	0.26	0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8832983	chr8:8456909~8461337:-
THCA	cis	rs728616	0.51	rs7074356	ENSG00000225484.5	NUTM2B-AS1	-3.57	0.000392	0.025	-0.25	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80431578	chr10:79663088~79826594:-
THCA	cis	rs7824557	0.564	rs2572400	ENSG00000261451.1	RP11-981G7.1	-3.57	0.000392	0.025	-0.2	-0.16	Retinal vascular caliber;	chr8:11376858	chr8:10433672~10438312:+
THCA	cis	rs6546550	0.935	rs3771541	ENSG00000179818.12	PCBP1-AS1	-3.57	0.000392	0.025	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69804665	chr2:69962263~70103220:-
THCA	cis	rs7646881	0.504	rs7617304	ENSG00000279311.1	RP11-170K4.2	-3.57	0.000392	0.025	-0.23	-0.16	Tetralogy of Fallot;	chr3:158745312	chr3:158869898~158871821:+
THCA	cis	rs6901152	0.965	rs7738887	ENSG00000217648.1	RP1-95L4.4	-3.57	0.000392	0.025	-0.17	-0.16	Acute lymphoblastic leukemia (childhood);	chr6:143353754	chr6:143342246~143343383:+
THCA	cis	rs853679	0.882	rs9461432	ENSG00000261839.1	RP1-265C24.8	3.57	0.000392	0.025	0.24	0.16	Depression;	chr6:28119105	chr6:28136849~28139678:+
THCA	cis	rs1371614	0.611	rs877272	ENSG00000229122.1	AGBL5-IT1	3.57	0.000392	0.025	0.12	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917020	chr2:27061038~27061815:+
THCA	cis	rs853679	0.517	rs9468297	ENSG00000219891.2	ZSCAN12P1	3.57	0.000392	0.025	0.23	0.16	Depression;	chr6:28151096	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000219891.2	ZSCAN12P1	3.57	0.000392	0.025	0.23	0.16	Depression;	chr6:28152885	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000219891.2	ZSCAN12P1	3.57	0.000392	0.025	0.23	0.16	Depression;	chr6:28153120	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000219891.2	ZSCAN12P1	3.57	0.000392	0.025	0.23	0.16	Depression;	chr6:28161802	chr6:28091154~28093664:+
THCA	cis	rs9596863	0.851	rs9568913	ENSG00000136149.6	RPL13AP25	-3.57	0.000392	0.025	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53766365	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs9568914	ENSG00000136149.6	RPL13AP25	-3.57	0.000392	0.025	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53766972	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs9568915	ENSG00000136149.6	RPL13AP25	-3.57	0.000392	0.025	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53767079	chr13:54440704~54441315:-
THCA	cis	rs2882667	0.931	rs10070021	ENSG00000249593.5	CTB-46B19.2	3.57	0.000392	0.025	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:139012647~139051203:+
THCA	cis	rs9959145	0.866	rs113413902	ENSG00000267199.1	RP11-861E21.2	3.57	0.000392	0.025	0.21	0.16	Immune response to smallpox vaccine (IL-6);	chr18:12731558	chr18:12438890~12448205:+
THCA	cis	rs1003719	0.667	rs2835606	ENSG00000270116.1	AP001429.1	-3.57	0.000392	0.025	-0.18	-0.16	Eye color traits;	chr21:37118551	chr21:37100814~37101343:+
THCA	cis	rs875971	1	rs778726	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66363744	chr7:66739829~66740385:-
THCA	cis	rs875971	0.767	rs1695815	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66366357	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs778685	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66371189	chr7:66739829~66740385:-
THCA	cis	rs875971	0.929	rs778682	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66372947	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs11765965	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66377234	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs1643388	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66379575	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs778722	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66379841	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs778721	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66380410	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs778706	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66395437	chr7:66739829~66740385:-
THCA	cis	rs875971	0.895	rs778700	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66401463	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs778699	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66403303	chr7:66739829~66740385:-
THCA	cis	rs875971	0.929	rs778692	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66407462	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs4718343	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66409301	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs1968225	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66409786	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6460295	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66417741	chr7:66739829~66740385:-
THCA	cis	rs875971	0.964	rs6978721	ENSG00000272831.1	RP11-792A8.4	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66418217	chr7:66739829~66740385:-
THCA	cis	rs875971	0.706	rs1643374	ENSG00000230189.5	GS1-124K5.2	3.57	0.000392	0.025	0.1	0.16	Aortic root size;	chr7:66407695	chr7:66409143~66490059:-
THCA	cis	rs7819412	0.669	rs35499486	ENSG00000261451.1	RP11-981G7.1	-3.57	0.000392	0.025	-0.21	-0.16	Triglycerides;	chr8:11216527	chr8:10433672~10438312:+
THCA	cis	rs1153858	0.621	rs1706824	ENSG00000275672.1	GATM-AS1	-3.57	0.000392	0.025	-0.17	-0.16	Homoarginine levels;	chr15:45287750	chr15:45378700~45380123:+
THCA	cis	rs67340775	0.541	rs169287	ENSG00000272009.1	RP1-313I6.12	-3.57	0.000392	0.025	-0.21	-0.16	Lung cancer in ever smokers;	chr6:27886982	chr6:28078792~28081130:-
THCA	cis	rs9878978	0.928	rs17786873	ENSG00000227588.2	CNTN4-AS2	3.57	0.000392	0.025	0.19	0.16	Blood pressure (smoking interaction);	chr3:2444044	chr3:2110409~2144241:-
THCA	cis	rs4648045	0.598	rs6811263	ENSG00000246560.2	RP11-10L12.4	3.57	0.000392	0.025	0.2	0.16	Lymphocyte percentage of white cells;	chr4:102494656	chr4:102828055~102844075:+
THCA	cis	rs6662572	0.737	rs9429093	ENSG00000234329.1	RP11-767N6.2	-3.57	0.000392	0.025	-0.17	-0.16	Blood protein levels;	chr1:46089580	chr1:45651039~45651826:-
THCA	cis	rs16975963	0.843	rs17249047	ENSG00000276846.1	CTD-3220F14.3	-3.57	0.000392	0.025	-0.15	-0.16	Longevity;	chr19:37845923	chr19:37314868~37315620:-
THCA	cis	rs14027	0.883	rs16893027	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000392	0.025	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701534	chr8:119838736~119840385:-
THCA	cis	rs801193	1	rs10252765	ENSG00000275400.1	RP4-756H11.5	-3.57	0.000392	0.025	-0.15	-0.16	Aortic root size;	chr7:66763745	chr7:66553805~66554199:-
THCA	cis	rs16975963	0.843	rs73025630	ENSG00000226686.6	LINC01535	-3.57	0.000392	0.025	-0.22	-0.16	Longevity;	chr19:37860644	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.793	rs73027418	ENSG00000226686.6	LINC01535	-3.57	0.000392	0.025	-0.22	-0.16	Longevity;	chr19:37870380	chr19:37251912~37265535:+
THCA	cis	rs16975963	0.843	rs113690074	ENSG00000226686.6	LINC01535	-3.57	0.000392	0.025	-0.22	-0.16	Longevity;	chr19:37884753	chr19:37251912~37265535:+
THCA	cis	rs4713118	0.869	rs9461405	ENSG00000272009.1	RP1-313I6.12	-3.57	0.000392	0.025	-0.18	-0.16	Parkinson's disease;	chr6:27751596	chr6:28078792~28081130:-
THCA	cis	rs4389656	0.857	rs453536	ENSG00000248677.1	CTD-2044J15.1	3.57	0.000392	0.025	0.16	0.16	Coronary artery disease;	chr5:6736345	chr5:6686325~6707711:-
THCA	cis	rs821367	0.83	rs115146054	ENSG00000229048.5	DUTP1	-3.57	0.000392	0.025	-0.26	-0.16	Platelet distribution width;	chr3:124710561	chr3:125310881~125311350:+
THCA	cis	rs8081187	0.803	rs9903995	ENSG00000266490.1	CTD-2349P21.9	3.57	0.000392	0.025	0.31	0.16	Breast cancer;	chr17:30548548	chr17:30792372~30792833:+
THCA	cis	rs860295	1	rs7541060	ENSG00000160766.13	GBAP1	-3.57	0.000392	0.025	-0.18	-0.16	Body mass index;	chr1:155758297	chr1:155213821~155227422:-
THCA	cis	rs16975963	0.644	rs12151280	ENSG00000276846.1	CTD-3220F14.3	-3.57	0.000393	0.025	-0.15	-0.16	Longevity;	chr19:37576988	chr19:37314868~37315620:-
THCA	cis	rs9348440	0.73	rs9295472	ENSG00000280989.1	LINC00581	3.57	0.000393	0.025	0.24	0.16	Glycemic traits;	chr6:20622121	chr6:21486061~21511895:-
THCA	cis	rs41313321	0.541	rs2240956	ENSG00000272696.1	RP11-339B21.13	-3.57	0.000393	0.025	-0.11	-0.16	Coenzyme Q10 levels;	chr9:128286481	chr9:128316337~128316909:+
THCA	cis	rs755249	0.567	rs61779306	ENSG00000182109.6	RP11-69E11.4	3.57	0.000393	0.025	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39522280~39546187:-
THCA	cis	rs7474896	0.515	rs624359	ENSG00000272983.1	RP11-508N22.12	3.57	0.000393	0.025	0.17	0.16	Obesity (extreme);	chr10:38010204	chr10:38137337~38144399:+
THCA	cis	rs7474896	0.537	rs598857	ENSG00000272983.1	RP11-508N22.12	3.57	0.000393	0.025	0.17	0.16	Obesity (extreme);	chr10:38013998	chr10:38137337~38144399:+
THCA	cis	rs878361	0.96	rs10231751	ENSG00000280255.1	RP5-1007F24.1	-3.57	0.000393	0.025	-0.23	-0.16	Post bronchodilator FEV1/FVC ratio;	chr7:26508802	chr7:26538378~26541048:+
THCA	cis	rs3733585	0.604	rs73215003	ENSG00000261490.1	RP11-448G15.3	-3.57	0.000393	0.025	-0.11	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10124693	chr4:10068089~10073019:-
THCA	cis	rs2337406	0.866	rs7152038	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106778230	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs7152809	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106778385	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs7152832	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106778427	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.5	rs7152934	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106778702	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.789	rs12050392	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106779073	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74092505	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106779163	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.789	rs74092507	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106779174	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74092511	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106779234	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74092512	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106779306	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.789	rs74092514	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106779385	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74092520	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106779632	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs4583128	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106780669	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.929	rs12050200	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106780983	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.929	rs59263250	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106781183	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs58083017	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106781256	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.789	rs60390024	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106781327	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74092532	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106781363	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74092534	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106781364	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs74092537	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106781883	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.81	rs74092538	ENSG00000280411.1	IGHV1-69-2	-3.57	0.000393	0.025	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106781942	chr14:106762092~106762588:-
THCA	cis	rs2014572	0.967	rs10418480	ENSG00000268379.1	CTC-360J11.4	3.57	0.000393	0.025	0.19	0.16	Hyperactive-impulsive symptoms;	chr19:57243687	chr19:57175233~57177921:+
THCA	cis	rs1124769	0.619	rs7177664	ENSG00000259378.1	DCAF13P3	-3.57	0.000393	0.025	-0.21	-0.16	Cognitive performance;	chr15:51093137	chr15:50944663~50945996:+
THCA	cis	rs2704588	0.505	rs1513811	ENSG00000270720.1	RP11-84C13.2	-3.57	0.000393	0.025	-0.31	-0.16	Longevity;	chr4:89074647	chr4:89119284~89119871:+
THCA	cis	rs7572733	0.935	rs7571869	ENSG00000231621.1	AC013264.2	-3.57	0.000393	0.025	-0.15	-0.16	Dermatomyositis;	chr2:197976891	chr2:197197991~197199273:+
THCA	cis	rs12216545	0.765	rs3946494	ENSG00000241134.3	BET1P1	-3.57	0.000393	0.025	-0.19	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150556230	chr7:150749736~150750094:+
THCA	cis	rs944289	0.74	rs368187	ENSG00000212071.1	AL162511.1	-3.57	0.000393	0.025	-0.18	-0.16	Thyroid cancer;	chr14:36063370	chr14:36196480~36196568:-
THCA	cis	rs8040855	0.575	rs12912860	ENSG00000225151.9	GOLGA2P7	-3.57	0.000393	0.025	-0.24	-0.16	Bulimia nervosa;	chr15:85030267	chr15:84199311~84230136:-
THCA	cis	rs931608	0.64	rs2957824	ENSG00000269138.1	ZNF209P	-3.57	0.000393	0.025	-0.24	-0.16	Response to statins (LDL cholesterol change);Dental caries;	chr19:22396514	chr19:22463922~22473036:+
THCA	cis	rs10911902	0.561	rs1919199	ENSG00000228238.1	GS1-304P7.2	-3.57	0.000393	0.025	-0.27	-0.16	Schizophrenia;	chr1:186300752	chr1:186578279~186579299:+
THCA	cis	rs948562	0.744	rs60998298	ENSG00000280010.1	AP001350.4	3.57	0.000393	0.025	0.27	0.16	Lymphoma;	chr11:58534382	chr11:58627435~58628528:+
THCA	cis	rs948562	0.793	rs1944051	ENSG00000280010.1	AP001350.4	3.57	0.000393	0.025	0.27	0.16	Lymphoma;	chr11:58607820	chr11:58627435~58628528:+
THCA	cis	rs948562	0.793	rs1800169	ENSG00000280010.1	AP001350.4	3.57	0.000393	0.025	0.27	0.16	Lymphoma;	chr11:58624028	chr11:58627435~58628528:+
THCA	cis	rs948562	0.696	rs17568220	ENSG00000280010.1	AP001350.4	3.57	0.000393	0.025	0.27	0.16	Lymphoma;	chr11:58627550	chr11:58627435~58628528:+
THCA	cis	rs948562	0.793	rs11229552	ENSG00000280010.1	AP001350.4	3.57	0.000393	0.025	0.27	0.16	Lymphoma;	chr11:58633441	chr11:58627435~58628528:+
THCA	cis	rs7432375	0.61	rs56695781	ENSG00000273486.1	RP11-731C17.2	3.57	0.000393	0.025	0.14	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136791759	chr3:136837338~136839021:-
THCA	cis	rs17428076	0.633	rs705870	ENSG00000228389.1	AC068039.4	-3.57	0.000393	0.025	-0.17	-0.16	Myopia;	chr2:172067555	chr2:171773482~171775844:+
THCA	cis	rs9393777	0.841	rs34332556	ENSG00000226314.6	ZNF192P1	-3.57	0.000393	0.025	-0.31	-0.16	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28161781~28169594:+
THCA	cis	rs12760731	0.511	rs10429850	ENSG00000213057.5	C1orf220	3.57	0.000393	0.025	0.16	0.16	Obesity-related traits;	chr1:178642865	chr1:178542752~178548889:+
THCA	cis	rs10266483	0.705	rs599522	ENSG00000234338.1	RP11-797H7.1	3.57	0.000393	0.025	0.12	0.16	Response to statin therapy;	chr7:64298104	chr7:64835280~64836882:-
THCA	cis	rs8044868	1	rs8052338	ENSG00000260886.1	TAT-AS1	3.57	0.000393	0.025	0.19	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72151775	chr16:71565789~71578187:+
THCA	cis	rs321358	0.895	rs7110930	ENSG00000271390.1	RP11-89C3.3	-3.57	0.000393	0.025	-0.26	-0.16	Body mass index;	chr11:111088556	chr11:111089870~111090368:-
THCA	cis	rs4578769	0.55	rs9961760	ENSG00000273232.1	RP11-370A5.2	3.57	0.000393	0.025	0.22	0.16	Eosinophil percentage of white cells;	chr18:23021545	chr18:22882825~22883357:-
THCA	cis	rs4869313	0.846	rs11135482	ENSG00000247121.5	CTD-2260A17.2	-3.57	0.000393	0.025	-0.12	-0.16	Pediatric autoimmune diseases;	chr5:96885722	chr5:96814028~96935809:-
THCA	cis	rs4664293	0.867	rs2059698	ENSG00000230783.1	AC009961.2	3.57	0.000393	0.025	0.21	0.16	Monocyte percentage of white cells;	chr2:159785905	chr2:159689217~159690291:-
THCA	cis	rs2281603	0.57	rs10134530	ENSG00000258824.2	CTD-2555O16.2	3.57	0.000393	0.025	0.14	0.16	Lymphocyte counts;	chr14:64484240	chr14:64422935~64448557:-
THCA	cis	rs2033711	0.87	rs11084545	ENSG00000268049.1	CTD-2619J13.9	-3.57	0.000393	0.025	-0.21	-0.16	Uric acid clearance;	chr19:58440326	chr19:58357999~58359603:+
THCA	cis	rs9995093	0.881	rs12641788	ENSG00000246375.2	RP11-10L7.1	-3.57	0.000393	0.025	-0.32	-0.16	Bipolar disorder;	chr4:88301012	chr4:88284942~88331421:+
THCA	cis	rs67478160	0.643	rs2295145	ENSG00000269940.1	RP11-73M18.7	3.57	0.000393	0.025	0.16	0.16	Schizophrenia;	chr14:103735967	chr14:103694560~103695170:+
THCA	cis	rs7082209	1	rs4491167	ENSG00000224265.1	RP11-168L22.2	-3.57	0.000393	0.025	-0.25	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr10:44315372	chr10:43323665~43327932:+
THCA	cis	rs6494488	0.5	rs72744729	ENSG00000259635.1	AC100830.3	-3.57	0.000393	0.025	-0.41	-0.16	Coronary artery disease;	chr15:64746285	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744730	ENSG00000259635.1	AC100830.3	-3.57	0.000393	0.025	-0.41	-0.16	Coronary artery disease;	chr15:64747866	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744734	ENSG00000259635.1	AC100830.3	-3.57	0.000393	0.025	-0.41	-0.16	Coronary artery disease;	chr15:64750113	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs951721	ENSG00000259635.1	AC100830.3	-3.57	0.000393	0.025	-0.41	-0.16	Coronary artery disease;	chr15:64752236	chr15:64701248~64719602:+
THCA	cis	rs3764618	1	rs3810176	ENSG00000269420.4	CTD-2265M8.2	-3.57	0.000393	0.025	-0.35	-0.16	Follicule stimulating hormone;	chr19:48993529	chr19:48061371~48064945:+
THCA	cis	rs9810089	0.676	rs526574	ENSG00000273455.1	RP11-305O4.3	3.57	0.000393	0.025	0.21	0.16	Gestational age at birth (child effect);	chr3:136384507	chr3:136087475~136087913:-
THCA	cis	rs897984	0.683	rs9932572	ENSG00000260911.2	RP11-196G11.2	3.57	0.000393	0.0251	0.14	0.16	Dementia with Lewy bodies;	chr16:30830321	chr16:31043150~31049868:+
THCA	cis	rs9902453	1	rs60967688	ENSG00000250462.7	LRRC37BP1	3.57	0.000393	0.0251	0.12	0.16	Coffee consumption (cups per day);	chr17:30110034	chr17:30629680~30637466:+
THCA	cis	rs9309473	0.898	rs28879089	ENSG00000273245.1	RP11-434P11.2	3.57	0.000393	0.0251	0.22	0.16	Metabolite levels;	chr2:73585759	chr2:73750256~73750786:-
THCA	cis	rs2098713	0.549	rs62359033	ENSG00000250155.1	CTD-2353F22.1	3.57	0.000393	0.0251	0.16	0.16	Telomere length;	chr5:37549741	chr5:36666214~36725195:-
THCA	cis	rs2032366	0.63	rs7235404	ENSG00000267316.4	RP11-879F14.3	3.57	0.000393	0.0251	0.18	0.16	Obesity-related traits;	chr18:61628753	chr18:61571342~61579456:-
THCA	cis	rs1930961	1	rs6004667	ENSG00000272942.1	CTA-246H3.12	3.57	0.000393	0.0251	0.28	0.16	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25434324~25435070:-
THCA	cis	rs12893668	0.638	rs11851616	ENSG00000258735.1	LINC00637	-3.57	0.000394	0.0251	-0.22	-0.16	Reticulocyte count;	chr14:103599263	chr14:103847721~103858049:+
THCA	cis	rs12893668	0.667	rs11844466	ENSG00000258735.1	LINC00637	-3.57	0.000394	0.0251	-0.22	-0.16	Reticulocyte count;	chr14:103600085	chr14:103847721~103858049:+
THCA	cis	rs12893668	0.637	rs12892038	ENSG00000258735.1	LINC00637	-3.57	0.000394	0.0251	-0.22	-0.16	Reticulocyte count;	chr14:103602292	chr14:103847721~103858049:+
THCA	cis	rs12893668	0.637	rs4525427	ENSG00000258735.1	LINC00637	-3.57	0.000394	0.0251	-0.22	-0.16	Reticulocyte count;	chr14:103606456	chr14:103847721~103858049:+
THCA	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-3.57	0.000394	0.0251	-0.19	-0.16	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
THCA	cis	rs832540	0.966	rs252925	ENSG00000271828.1	CTD-2310F14.1	-3.57	0.000394	0.0251	-0.22	-0.16	Coronary artery disease;	chr5:56907946	chr5:56927874~56929573:+
THCA	cis	rs2522056	1	rs2706395	ENSG00000237714.1	P4HA2-AS1	-3.57	0.000394	0.0251	-0.23	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132461111	chr5:132184876~132192808:+
THCA	cis	rs61160187	0.582	rs12652878	ENSG00000251279.1	CTC-436P18.1	-3.57	0.000394	0.0251	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.548	rs17392014	ENSG00000251279.1	CTC-436P18.1	-3.57	0.000394	0.0251	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:61162070~61232040:+
THCA	cis	rs5758511	0.634	rs1001587	ENSG00000205702.9	CYP2D7	3.57	0.000394	0.0251	0.15	0.16	Birth weight;	chr22:42274105	chr22:42140203~42144577:-
THCA	cis	rs8027587	0.925	rs4078151	ENSG00000259699.2	HMGB1P8	3.57	0.000394	0.0251	0.22	0.16	Obesity-related traits;	chr15:88696400	chr15:89135547~89136495:-
THCA	cis	rs8027587	0.889	rs4078152	ENSG00000259699.2	HMGB1P8	3.57	0.000394	0.0251	0.22	0.16	Obesity-related traits;	chr15:88696494	chr15:89135547~89136495:-
THCA	cis	rs924712	0.572	rs9367594	ENSG00000224984.1	RP11-524H19.2	-3.57	0.000394	0.0251	-0.19	-0.16	Breast cancer;	chr6:54838072	chr6:54840118~54840855:-
THCA	cis	rs10090774	1	rs4961296	ENSG00000280303.2	ERICD	3.57	0.000394	0.0251	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140815482	chr8:140636281~140638283:+
THCA	cis	rs10090774	1	rs11166999	ENSG00000280303.2	ERICD	3.57	0.000394	0.0251	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140819711	chr8:140636281~140638283:+
THCA	cis	rs4699052	0.963	rs11733615	ENSG00000251288.2	RP11-10L12.2	-3.57	0.000394	0.0251	-0.21	-0.16	Testicular germ cell tumor;	chr4:103236007	chr4:102751401~102752641:+
THCA	cis	rs9634489	0.903	rs1164586	ENSG00000247400.3	DNAJC3-AS1	-3.57	0.000394	0.0251	-0.1	-0.16	Body mass index;	chr13:96396887	chr13:95648733~95676925:-
THCA	cis	rs3738443	0.523	rs56338561	ENSG00000227671.4	RP11-488L18.4	-3.57	0.000394	0.0251	-0.09	-0.16	Alcohol dependence;	chr1:247210592	chr1:247189851~247210856:-
THCA	cis	rs875971	0.789	rs28815324	ENSG00000232559.3	GS1-124K5.12	-3.57	0.000394	0.0251	-0.18	-0.16	Aortic root size;	chr7:66100789	chr7:66554588~66576923:-
THCA	cis	rs17122278	1	rs11216914	ENSG00000243431.1	RPL5P30	3.57	0.000394	0.0251	0.17	0.16	Total cholesterol levels;	chr11:118585699	chr11:118560690~118561580:+
THCA	cis	rs2880765	0.835	rs12324277	ENSG00000259407.1	RP11-158M2.3	-3.57	0.000394	0.0251	-0.16	-0.16	Coronary artery disease;	chr15:85498504	chr15:85744109~85750281:-
THCA	cis	rs7656342	0.599	rs10939561	ENSG00000250342.1	SNRPCP16	3.57	0.000394	0.0251	0.21	0.16	Gut microbiota (bacterial taxa);	chr4:9849918	chr4:9051842~9052051:-
THCA	cis	rs9341808	0.754	rs9352808	ENSG00000260645.1	RP11-250B2.5	3.57	0.000394	0.0251	0.14	0.16	Sitting height ratio;	chr6:80287625	chr6:80466958~80469080:+
THCA	cis	rs2455799	0.613	rs4685264	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000394	0.0251	-0.17	-0.16	Mean platelet volume;	chr3:15816840	chr3:15732252~15733470:+
THCA	cis	rs1729951	0.546	rs835632	ENSG00000239213.4	NCK1-AS1	3.57	0.000394	0.0251	0.14	0.16	Neuroticism;	chr3:136957683	chr3:136841726~136862054:-
THCA	cis	rs7826238	0.524	rs2921055	ENSG00000253130.1	CTD-3023L14.2	-3.57	0.000394	0.0251	-0.17	-0.16	Systolic blood pressure;	chr8:8461832	chr8:8561391~8569688:+
THCA	cis	rs4965006	0.591	rs4964913	ENSG00000273568.1	RP11-417L19.6	3.57	0.000394	0.0251	0.24	0.16	Posterior cortical atrophy and Alzheimer's disease;	chr12:131927943	chr12:131934642~131934928:+
THCA	cis	rs258324	0.79	rs166297	ENSG00000274627.1	RP11-104N10.2	3.57	0.000394	0.0251	0.22	0.16	Height;	chr16:89664777	chr16:89516797~89522217:+
THCA	cis	rs911555	0.755	rs2756132	ENSG00000269940.1	RP11-73M18.7	-3.57	0.000394	0.0251	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103694560~103695170:+
THCA	cis	rs1654345	0.561	rs1654341	ENSG00000275132.1	Metazoa_SRP	-3.57	0.000394	0.0251	-0.25	-0.16	Life satisfaction;Subjective well-being;	chr19:38050106	chr19:38200234~38200532:+
THCA	cis	rs1654345	0.561	rs1612361	ENSG00000275132.1	Metazoa_SRP	-3.57	0.000394	0.0251	-0.25	-0.16	Life satisfaction;Subjective well-being;	chr19:38050474	chr19:38200234~38200532:+
THCA	cis	rs3824488	0.79	rs1805155	ENSG00000271155.1	RP11-435O5.5	3.57	0.000394	0.0251	0.25	0.16	Neuroticism;	chr9:95476097	chr9:95506235~95507636:+
THCA	cis	rs55692468	0.883	rs6714213	ENSG00000213197.3	AC012066.1	-3.57	0.000394	0.0251	-0.22	-0.16	Intraocular pressure;	chr2:152500869	chr2:152389937~152390630:+
THCA	cis	rs11640734	0.609	rs11647746	ENSG00000274627.1	RP11-104N10.2	-3.57	0.000394	0.0251	-0.26	-0.16	Interleukin-17 levels;	chr16:89739935	chr16:89516797~89522217:+
THCA	cis	rs972578	0.806	rs738397	ENSG00000230319.1	AL022476.2	3.57	0.000394	0.0251	0.17	0.16	Mean platelet volume;	chr22:42899265	chr22:43038585~43052366:+
THCA	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-3.57	0.000394	0.0251	-0.15	-0.16	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
THCA	cis	rs10090774	0.965	rs13251663	ENSG00000280303.2	ERICD	-3.57	0.000394	0.0251	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140831478	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11167001	ENSG00000280303.2	ERICD	-3.57	0.000394	0.0251	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844303	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs11167002	ENSG00000280303.2	ERICD	-3.57	0.000394	0.0251	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844410	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13256101	ENSG00000280303.2	ERICD	-3.57	0.000394	0.0251	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844865	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.896	rs11787521	ENSG00000280303.2	ERICD	-3.57	0.000394	0.0251	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844994	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10875458	ENSG00000280303.2	ERICD	3.57	0.000394	0.0251	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140769727	chr8:140636281~140638283:+
THCA	cis	rs10090774	1	rs6578140	ENSG00000280303.2	ERICD	3.57	0.000394	0.0251	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140824011	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs10088621	ENSG00000280303.2	ERICD	3.57	0.000394	0.0251	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140828127	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs4961297	ENSG00000280303.2	ERICD	3.57	0.000394	0.0251	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140829135	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs4434666	ENSG00000280303.2	ERICD	3.57	0.000394	0.0251	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830069	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs4246128	ENSG00000280303.2	ERICD	3.57	0.000394	0.0251	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830640	chr8:140636281~140638283:+
THCA	cis	rs860295	0.702	rs10908479	ENSG00000236675.1	MTX1P1	-3.57	0.000394	0.0251	-0.17	-0.16	Body mass index;	chr1:155673612	chr1:155230975~155234325:+
THCA	cis	rs10975370	0.526	rs629318	ENSG00000206147.5	RP11-106A1.2	3.57	0.000394	0.0251	0.19	0.16	Breast cancer;	chr9:6041473	chr9:6639139~6639604:+
THCA	cis	rs9474614	1	rs3823111	ENSG00000227885.1	RP11-79N23.1	-3.57	0.000394	0.0251	-0.23	-0.16	Obesity-related traits;	chr6:53652237	chr6:53740749~53747022:-
THCA	cis	rs933688	0.532	rs4916851	ENSG00000260871.1	CTD-2373J6.1	-3.57	0.000394	0.0251	-0.24	-0.16	Smoking behavior;	chr5:91240483	chr5:90388468~90389363:-
THCA	cis	rs2688608	0.623	rs2633318	ENSG00000271816.1	BMS1P4	3.57	0.000394	0.0251	0.16	0.16	Inflammatory bowel disease;	chr10:73930676	chr10:73699151~73730487:-
THCA	cis	rs732716	0.889	rs11666856	ENSG00000280239.1	CTB-50L17.8	-3.57	0.000394	0.0251	-0.13	-0.16	Mean corpuscular volume;	chr19:4437453	chr19:4448810~4450836:+
THCA	cis	rs28521457	1	rs28521457	ENSG00000270681.1	RP11-372K14.2	-3.57	0.000394	0.0251	-0.33	-0.16	Drug-induced hepatocellular liver injury;	chr4:150759175	chr4:151139991~151141103:+
THCA	cis	rs912593	0.872	rs73471578	ENSG00000225179.1	LINC00457	3.57	0.000394	0.0251	0.25	0.16	Cancer;	chr13:34458145	chr13:34435450~34640685:-
THCA	cis	rs912593	0.872	rs1974036	ENSG00000225179.1	LINC00457	3.57	0.000394	0.0251	0.25	0.16	Cancer;	chr13:34460710	chr13:34435450~34640685:-
THCA	cis	rs34271465	1	rs34271465	ENSG00000223318.1	RNA5SP111	3.57	0.000394	0.0251	0.2	0.16	Systolic blood pressure;	chr2:164656556	chr2:164895677~164895777:-
THCA	cis	rs6738627	0.71	rs10195252	ENSG00000223318.1	RNA5SP111	3.57	0.000394	0.0251	0.2	0.16	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164656581	chr2:164895677~164895777:-
THCA	cis	rs4568518	0.74	rs12699925	ENSG00000279048.1	RP11-511H23.2	3.57	0.000394	0.0251	0.1	0.16	Measles;	chr7:17971039	chr7:17940503~17942922:+
THCA	cis	rs9611565	0.559	rs4822048	ENSG00000237037.8	NDUFA6-AS1	3.57	0.000394	0.0251	0.16	0.16	Vitiligo;	chr22:41592221	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.559	rs4822049	ENSG00000237037.8	NDUFA6-AS1	3.57	0.000394	0.0251	0.16	0.16	Vitiligo;	chr22:41597492	chr22:42090931~42137742:+
THCA	cis	rs2455799	0.634	rs11128764	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000394	0.0251	-0.17	-0.16	Mean platelet volume;	chr3:15861329	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.634	rs1584326	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000394	0.0251	-0.17	-0.16	Mean platelet volume;	chr3:15862444	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.634	rs6771390	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000394	0.0251	-0.17	-0.16	Mean platelet volume;	chr3:15865130	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.593	rs13085352	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000394	0.0251	-0.17	-0.16	Mean platelet volume;	chr3:15873338	chr3:15732252~15733470:+
THCA	cis	rs61160187	0.582	rs1021005	ENSG00000272308.1	RP11-231G3.1	-3.57	0.000394	0.0251	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.517	rs6884966	ENSG00000272308.1	RP11-231G3.1	-3.57	0.000394	0.0251	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60866457~60866935:-
THCA	cis	rs4243971	0.516	rs17270685	ENSG00000224452.1	RSL24D1P6	3.57	0.000395	0.0251	0.2	0.16	Inflammatory bowel disease;Crohn's disease;	chr20:32424134	chr20:32170390~32170790:-
THCA	cis	rs467650	0.714	rs171529	ENSG00000246763.5	RGMB-AS1	3.57	0.000395	0.0251	0.16	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98593098	chr5:98769618~98773469:-
THCA	cis	rs9307551	0.619	rs13118924	ENSG00000249646.2	OR7E94P	-3.57	0.000395	0.0251	-0.21	-0.16	Refractive error;	chr4:79502369	chr4:79587302~79588130:-
THCA	cis	rs2243480	1	rs427044	ENSG00000237310.1	GS1-124K5.4	3.57	0.000395	0.0251	0.18	0.16	Diabetic kidney disease;	chr7:66043558	chr7:66493706~66495474:+
THCA	cis	rs613391	0.522	rs1031289	ENSG00000234840.1	LINC01239	3.57	0.000395	0.0251	0.19	0.16	Quantitative traits;	chr9:22731107	chr9:22646200~22824213:+
THCA	cis	rs9393777	0.92	rs35120058	ENSG00000226314.6	ZNF192P1	-3.57	0.000395	0.0251	-0.31	-0.16	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28161781~28169594:+
THCA	cis	rs10929956	0.76	rs2729704	ENSG00000226266.5	AC009961.3	3.57	0.000395	0.0251	0.19	0.16	Crohn's disease-related phenotypes;	chr2:159851355	chr2:159670708~159712435:-
THCA	cis	rs7520050	0.807	rs5021934	ENSG00000281133.1	AL355480.3	3.57	0.000395	0.0251	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45580892~45580996:-
THCA	cis	rs7615952	0.599	rs6766327	ENSG00000241288.6	RP11-379B18.5	-3.57	0.000395	0.0251	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126004834	chr3:125827238~125916384:-
THCA	cis	rs4723738	1	rs4723734	ENSG00000227191.5	TRGC2	-3.57	0.000395	0.0251	-0.12	-0.16	Treatment response for severe sepsis;	chr7:38192459	chr7:38239580~38368091:-
THCA	cis	rs4723738	1	rs10282407	ENSG00000227191.5	TRGC2	-3.57	0.000395	0.0251	-0.12	-0.16	Treatment response for severe sepsis;	chr7:38193791	chr7:38239580~38368091:-
THCA	cis	rs7336933	0.733	rs7339425	ENSG00000278338.3	VWA8-AS1	-3.57	0.000395	0.0251	-0.27	-0.16	Calcium levels;	chr13:41787979	chr13:41955808~41981565:+
THCA	cis	rs7336933	0.799	rs968980	ENSG00000278338.3	VWA8-AS1	-3.57	0.000395	0.0251	-0.27	-0.16	Calcium levels;	chr13:41789703	chr13:41955808~41981565:+
THCA	cis	rs9488822	0.676	rs13194714	ENSG00000237021.2	RP3-486I3.7	3.57	0.000395	0.0251	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116073656	chr6:116254207~116256743:+
THCA	cis	rs2243480	1	rs781142	ENSG00000237310.1	GS1-124K5.4	3.57	0.000395	0.0251	0.18	0.16	Diabetic kidney disease;	chr7:65973791	chr7:66493706~66495474:+
THCA	cis	rs6921919	0.806	rs213230	ENSG00000273712.1	RP5-874C20.7	3.57	0.000395	0.0251	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28315613~28315883:-
THCA	cis	rs877529	0.683	rs79501	ENSG00000279833.1	RP4-742C19.13	3.57	0.000395	0.0251	0.11	0.16	Multiple myeloma;	chr22:39126935	chr22:39133090~39136760:+
THCA	cis	rs4081724	0.706	rs12151054	ENSG00000267296.2	CEBPA-AS1	3.57	0.000395	0.0251	0.22	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33333097	chr19:33302857~33305054:+
THCA	cis	rs7208859	0.673	rs216420	ENSG00000264242.2	RP11-271K11.1	3.57	0.000395	0.0251	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30553697~30558962:+
THCA	cis	rs11637445	0.627	rs72751453	ENSG00000260657.2	RP11-315D16.4	3.57	0.000395	0.0251	0.21	0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67832327	chr15:68267792~68277994:-
THCA	cis	rs8030379	1	rs1471552	ENSG00000176700.18	SCAND2P	-3.57	0.000395	0.0251	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901982	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs7178962	ENSG00000176700.18	SCAND2P	-3.57	0.000395	0.0251	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904496	chr15:84631451~84647478:+
THCA	cis	rs2832191	0.655	rs2247110	ENSG00000176054.6	RPL23P2	-3.57	0.000395	0.0251	-0.14	-0.16	Dental caries;	chr21:28951566	chr21:28997613~28998033:-
THCA	cis	rs6545883	0.894	rs9677047	ENSG00000212978.6	AC016747.3	-3.57	0.000395	0.0251	-0.18	-0.16	Tuberculosis;	chr2:61358160	chr2:61141592~61144969:-
THCA	cis	rs8040855	0.627	rs62019482	ENSG00000225151.9	GOLGA2P7	-3.57	0.000395	0.0251	-0.23	-0.16	Bulimia nervosa;	chr15:85071796	chr15:84199311~84230136:-
THCA	cis	rs8040855	0.627	rs11631548	ENSG00000225151.9	GOLGA2P7	-3.57	0.000395	0.0251	-0.23	-0.16	Bulimia nervosa;	chr15:85076017	chr15:84199311~84230136:-
THCA	cis	rs4906332	0.811	rs2296487	ENSG00000269958.1	RP11-73M18.8	3.57	0.000395	0.0251	0.16	0.16	Coronary artery disease;	chr14:103529868	chr14:103696353~103697163:+
THCA	cis	rs7550636	0.808	rs1856840	ENSG00000276735.1	Metazoa_SRP	3.57	0.000395	0.0252	0.19	0.16	Coronary artery calcification;	chr1:192842157	chr1:193236794~193237107:-
THCA	cis	rs3015497	0.616	rs34061700	ENSG00000270062.1	RP11-248J18.3	3.57	0.000395	0.0252	0.18	0.16	Mean platelet volume;	chr14:50618142	chr14:50723777~50724272:-
THCA	cis	rs10760158	0.832	rs4836845	ENSG00000235865.2	GSN-AS1	3.57	0.000395	0.0252	0.14	0.16	Pulse pressure;	chr9:121287678	chr9:121280768~121285530:-
THCA	cis	rs7554511	0.964	rs59655222	ENSG00000260088.1	RP11-92G12.3	-3.57	0.000395	0.0252	-0.25	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906769	chr1:200669507~200694250:+
THCA	cis	rs948562	0.793	rs79869893	ENSG00000280010.1	AP001350.4	3.57	0.000395	0.0252	0.27	0.16	Lymphoma;	chr11:58514409	chr11:58627435~58628528:+
THCA	cis	rs3126085	0.935	rs11204951	ENSG00000237975.5	FLG-AS1	-3.57	0.000395	0.0252	-0.25	-0.16	Atopic dermatitis;	chr1:152251928	chr1:152168125~152445456:+
THCA	cis	rs7829975	0.514	rs2979151	ENSG00000248538.5	RP11-10A14.5	3.57	0.000395	0.0252	0.2	0.16	Mood instability;	chr8:8400509	chr8:9189011~9202854:+
THCA	cis	rs6942407	0.744	rs10273853	ENSG00000224046.1	AC005076.5	3.57	0.000395	0.0252	0.15	0.16	Food allergy;	chr7:87233744	chr7:87151423~87152420:-
THCA	cis	rs1153858	1	rs12595087	ENSG00000275672.1	GATM-AS1	-3.57	0.000395	0.0252	-0.17	-0.16	Homoarginine levels;	chr15:45363034	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs1890565	ENSG00000275672.1	GATM-AS1	-3.57	0.000395	0.0252	-0.17	-0.16	Homoarginine levels;	chr15:45371101	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs12594857	ENSG00000275672.1	GATM-AS1	-3.57	0.000395	0.0252	-0.17	-0.16	Homoarginine levels;	chr15:45374980	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs16942568	ENSG00000275672.1	GATM-AS1	-3.57	0.000395	0.0252	-0.17	-0.16	Homoarginine levels;	chr15:45385192	chr15:45378700~45380123:+
THCA	cis	rs1153858	0.943	rs11070454	ENSG00000275672.1	GATM-AS1	-3.57	0.000395	0.0252	-0.17	-0.16	Homoarginine levels;	chr15:45388054	chr15:45378700~45380123:+
THCA	cis	rs853679	1	rs1679732	ENSG00000261839.1	RP1-265C24.8	-3.57	0.000396	0.0252	-0.23	-0.16	Depression;	chr6:28253486	chr6:28136849~28139678:+
THCA	cis	rs2446066	0.818	rs10876434	ENSG00000257379.1	RP11-793H13.8	3.57	0.000396	0.0252	0.24	0.16	Red blood cell count;	chr12:53340891	chr12:53441741~53467528:+
THCA	cis	rs7572644	0.582	rs7570730	ENSG00000223522.1	AC093690.1	-3.57	0.000396	0.0252	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27799808	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.64	rs11127125	ENSG00000223522.1	AC093690.1	-3.57	0.000396	0.0252	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27800253	chr2:28307691~28310459:-
THCA	cis	rs9876781	1	rs7653691	ENSG00000199476.1	Y_RNA	3.57	0.000396	0.0252	0.2	0.16	Longevity;	chr3:48378199	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs6442117	ENSG00000199476.1	Y_RNA	3.57	0.000396	0.0252	0.2	0.16	Longevity;	chr3:48378407	chr3:48288587~48288694:+
THCA	cis	rs7259376	0.807	rs11669254	ENSG00000269345.1	VN1R85P	3.57	0.000396	0.0252	0.18	0.16	Menopause (age at onset);	chr19:22362003	chr19:22174766~22175191:-
THCA	cis	rs9611565	0.659	rs9611610	ENSG00000237037.8	NDUFA6-AS1	3.57	0.000396	0.0252	0.15	0.16	Vitiligo;	chr22:41553255	chr22:42090931~42137742:+
THCA	cis	rs642858	0.784	rs590587	ENSG00000234147.1	RP3-460G2.2	3.57	0.000396	0.0252	0.2	0.16	Type 2 diabetes;	chr6:139916902	chr6:140845958~140852924:-
THCA	cis	rs2638953	0.886	rs10843168	ENSG00000247934.4	RP11-967K21.1	-3.57	0.000396	0.0252	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430038	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs10843170	ENSG00000247934.4	RP11-967K21.1	-3.57	0.000396	0.0252	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430118	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.925	rs11049604	ENSG00000247934.4	RP11-967K21.1	-3.57	0.000396	0.0252	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443092	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049608	ENSG00000247934.4	RP11-967K21.1	-3.57	0.000396	0.0252	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445528	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049609	ENSG00000247934.4	RP11-967K21.1	-3.57	0.000396	0.0252	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445732	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049612	ENSG00000247934.4	RP11-967K21.1	-3.57	0.000396	0.0252	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449160	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049613	ENSG00000247934.4	RP11-967K21.1	-3.57	0.000396	0.0252	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449859	chr12:28163298~28190738:-
THCA	cis	rs34975555	0.73	rs6991775	ENSG00000253671.1	RP11-806O11.1	-3.57	0.000396	0.0252	-0.24	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17963205	chr8:17808941~17820868:+
THCA	cis	rs1383484	0.545	rs9329363	ENSG00000259683.1	RP11-182J1.14	3.57	0.000396	0.0252	0.17	0.16	Height;	chr15:83974382	chr15:84389729~84395903:+
THCA	cis	rs786425	0.627	rs7133734	ENSG00000278112.1	RP11-972P1.11	3.57	0.000396	0.0252	0.16	0.16	Pubertal anthropometrics;	chr12:123712188	chr12:123519390~123519856:-
THCA	cis	rs10911363	0.592	rs2761581	ENSG00000232860.6	SMG7-AS1	-3.57	0.000396	0.0252	-0.12	-0.16	Systemic lupus erythematosus;	chr1:183505715	chr1:183460874~183472265:-
THCA	cis	rs1580019	0.563	rs34319173	ENSG00000273014.1	RP11-225B17.2	3.57	0.000396	0.0252	0.16	0.16	Cognitive ability;	chr7:32546292	chr7:32758882~32759353:+
THCA	cis	rs66887589	0.775	rs6843229	ENSG00000249244.1	RP11-548H18.2	3.57	0.000396	0.0252	0.17	0.16	Diastolic blood pressure;	chr4:119502932	chr4:119391831~119395335:-
THCA	cis	rs867371	1	rs7166570	ENSG00000278603.1	RP13-608F4.5	3.57	0.000396	0.0252	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472203~82472426:+
THCA	cis	rs2288884	1	rs17779301	ENSG00000260160.1	CTC-471J1.2	3.57	0.000396	0.0252	0.17	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035990	chr19:52058490~52063703:-
THCA	cis	rs7395662	0.853	rs10769356	ENSG00000200090.1	Y_RNA	-3.57	0.000396	0.0252	-0.11	-0.16	HDL cholesterol;	chr11:48423102	chr11:47726894~47726992:-
THCA	cis	rs1050631	1	rs719147	ENSG00000260552.1	RP11-49I11.1	3.57	0.000396	0.0252	0.2	0.16	Esophageal squamous cell cancer (length of survival);	chr18:36118229	chr18:36179996~36187448:-
THCA	cis	rs9796	0.87	rs2412572	ENSG00000247556.5	OIP5-AS1	-3.57	0.000396	0.0252	-0.13	-0.16	Menopause (age at onset);	chr15:40972228	chr15:41283990~41309737:+
THCA	cis	rs6121246	0.821	rs115585940	ENSG00000230613.1	HM13-AS1	3.57	0.000396	0.0252	0.18	0.16	Mean corpuscular hemoglobin;	chr20:31730099	chr20:31567707~31573263:-
THCA	cis	rs17685	0.712	rs60232511	ENSG00000227038.2	AC005077.12	3.57	0.000396	0.0252	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76170764	chr7:76090431~76108779:-
THCA	cis	rs754466	0.58	rs2289309	ENSG00000213514.2	RP11-428P16.2	3.57	0.000396	0.0252	0.17	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77811350	chr10:77730766~77734769:+
THCA	cis	rs754466	0.58	rs10824577	ENSG00000213514.2	RP11-428P16.2	3.57	0.000396	0.0252	0.17	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77817650	chr10:77730766~77734769:+
THCA	cis	rs656319	0.58	rs13272793	ENSG00000248538.5	RP11-10A14.5	3.57	0.000396	0.0252	0.21	0.16	Myopia (pathological);	chr8:10144517	chr8:9189011~9202854:+
THCA	cis	rs11710088	0.726	rs4314111	ENSG00000240541.2	TM4SF1-AS1	3.57	0.000396	0.0252	0.15	0.16	QRS duration;	chr3:149480889	chr3:149377778~149386583:+
THCA	cis	rs17428076	0.793	rs3765166	ENSG00000228389.1	AC068039.4	-3.57	0.000396	0.0252	-0.19	-0.16	Myopia;	chr2:171837270	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.793	rs3765167	ENSG00000228389.1	AC068039.4	-3.57	0.000396	0.0252	-0.19	-0.16	Myopia;	chr2:171837434	chr2:171773482~171775844:+
THCA	cis	rs911555	0.755	rs12436729	ENSG00000269940.1	RP11-73M18.7	-3.57	0.000396	0.0252	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103694560~103695170:+
THCA	cis	rs10090774	0.93	rs6578132	ENSG00000280303.2	ERICD	3.57	0.000396	0.0252	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140752459	chr8:140636281~140638283:+
THCA	cis	rs6600671	0.934	rs7528274	ENSG00000226067.5	CH17-118O6.2	3.57	0.000396	0.0252	0.16	0.16	Hip geometry;	chr1:121545103	chr1:120913275~121009291:+
THCA	cis	rs2455799	0.613	rs7620787	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000396	0.0252	-0.17	-0.16	Mean platelet volume;	chr3:15841319	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs7642876	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000396	0.0252	-0.17	-0.16	Mean platelet volume;	chr3:15841587	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs13078485	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000396	0.0252	-0.17	-0.16	Mean platelet volume;	chr3:15841729	chr3:15732252~15733470:+
THCA	cis	rs2836950	0.501	rs2070865	ENSG00000238141.2	BRWD1-AS1	-3.57	0.000396	0.0252	-0.19	-0.16	Menarche (age at onset);	chr21:39343593	chr21:39315707~39323218:+
THCA	cis	rs9925964	0.967	rs1978487	ENSG00000262766.1	RP11-196G11.4	3.57	0.000396	0.0252	0.11	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118621	chr16:31118078~31118747:+
THCA	cis	rs4930561	0.739	rs10896303	ENSG00000184795.9	UNC93B5	-3.57	0.000396	0.0252	-0.19	-0.16	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68206825	chr11:67711702~67716005:-
THCA	cis	rs4930561	0.739	rs12225316	ENSG00000184795.9	UNC93B5	-3.57	0.000396	0.0252	-0.19	-0.16	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68208536	chr11:67711702~67716005:-
THCA	cis	rs1023500	0.505	rs134878	ENSG00000233903.2	Z83851.4	3.57	0.000396	0.0252	0.21	0.16	Schizophrenia;	chr22:42267868	chr22:42276355~42277052:+
THCA	cis	rs7829975	0.577	rs79495969	ENSG00000253981.4	ALG1L13P	-3.57	0.000396	0.0252	-0.17	-0.16	Mood instability;	chr8:8687740	chr8:8236003~8244667:-
THCA	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000396	0.0252	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
THCA	cis	rs7824557	0.614	rs7816606	ENSG00000255052.4	FAM66D	-3.57	0.000396	0.0252	-0.21	-0.16	Retinal vascular caliber;	chr8:11348093	chr8:12115782~12177550:+
THCA	cis	rs9650657	0.738	rs11250078	ENSG00000255310.2	AF131215.2	-3.57	0.000397	0.0252	-0.14	-0.16	Neuroticism;	chr8:10809071	chr8:11107788~11109726:-
THCA	cis	rs7208859	0.673	rs450585	ENSG00000265443.1	CTD-2349P21.6	-3.57	0.000397	0.0252	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30726305~30727564:-
THCA	cis	rs7818688	0.516	rs73269198	ENSG00000253528.2	RP11-347C18.4	-3.57	0.000397	0.0252	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94826817	chr8:94974573~94974853:-
THCA	cis	rs14027	0.883	rs16893025	ENSG00000245330.4	KB-1471A8.1	3.57	0.000397	0.0252	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701440	chr8:119867419~119874488:-
THCA	cis	rs14027	0.883	rs10102038	ENSG00000245330.4	KB-1471A8.1	3.57	0.000397	0.0252	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119702544	chr8:119867419~119874488:-
THCA	cis	rs6500395	0.588	rs2047601	ENSG00000260052.1	CTC-527H23.3	-3.57	0.000397	0.0252	-0.2	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr16:48544190	chr16:48637143~48638719:+
THCA	cis	rs987724	0.511	rs386736	ENSG00000243926.1	TIPARP-AS1	3.57	0.000397	0.0252	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156795619	chr3:156671862~156674378:-
THCA	cis	rs2562456	0.876	rs2359144	ENSG00000268278.1	RP11-420K14.1	3.57	0.000397	0.0252	0.22	0.16	Pain;	chr19:21407834	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.876	rs4638726	ENSG00000268278.1	RP11-420K14.1	3.57	0.000397	0.0252	0.22	0.16	Pain;	chr19:21409710	chr19:21637974~21656300:+
THCA	cis	rs17685	0.633	rs3801471	ENSG00000227038.2	AC005077.12	3.57	0.000397	0.0252	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76066870	chr7:76090431~76108779:-
THCA	cis	rs910316	0.789	rs4899552	ENSG00000273565.1	CTD-3075F15.1	-3.57	0.000397	0.0252	-0.19	-0.16	Height;	chr14:75201218	chr14:75176929~75177418:+
THCA	cis	rs7615952	0.599	rs2279821	ENSG00000241288.6	RP11-379B18.5	-3.57	0.000397	0.0252	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126015465	chr3:125827238~125916384:-
THCA	cis	rs2268667	0.511	rs1874807	ENSG00000223653.4	RP11-131L23.1	-3.57	0.000397	0.0252	-0.18	-0.16	Asymmetrical dimethylarginine levels;	chr1:85313710	chr1:85276715~85448124:+
THCA	cis	rs6982240	0.569	rs6992286	ENSG00000253307.1	RP11-10J21.4	3.57	0.000397	0.0252	0.23	0.16	Tonsillectomy;	chr8:141269313	chr8:141252286~141253292:-
THCA	cis	rs11105298	0.838	rs10858862	ENSG00000266347.2	AC068641.1	3.57	0.000397	0.0252	0.21	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89592833~89592927:+
THCA	cis	rs7085104	0.572	rs284857	ENSG00000236937.2	PTGES3P4	-3.57	0.000397	0.0252	-0.2	-0.16	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814306	chr10:102845595~102845950:+
THCA	cis	rs7665090	1	rs1054029	ENSG00000251288.2	RP11-10L12.2	-3.57	0.000397	0.0252	-0.21	-0.16	Primary biliary cholangitis;	chr4:102631896	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs3194585	ENSG00000251288.2	RP11-10L12.2	-3.57	0.000397	0.0252	-0.21	-0.16	Primary biliary cholangitis;	chr4:102631933	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs735405	ENSG00000251288.2	RP11-10L12.2	-3.57	0.000397	0.0252	-0.21	-0.16	Primary biliary cholangitis;	chr4:102632759	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs1077358	ENSG00000251288.2	RP11-10L12.2	-3.57	0.000397	0.0252	-0.21	-0.16	Primary biliary cholangitis;	chr4:102632769	chr4:102751401~102752641:+
THCA	cis	rs6430585	1	rs73958618	ENSG00000231890.6	DARS-AS1	-3.57	0.000397	0.0252	-0.19	-0.16	Corneal structure;	chr2:135742905	chr2:135985176~136022593:+
THCA	cis	rs7973719	0.509	rs7969751	ENSG00000256967.1	RP11-273B20.1	-3.57	0.000397	0.0252	-0.14	-0.16	IgG glycosylation;	chr12:7218106	chr12:7129079~7131198:-
THCA	cis	rs9596863	1	rs35429587	ENSG00000136149.6	RPL13AP25	-3.57	0.000397	0.0252	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53832388	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9596855	ENSG00000136149.6	RPL13AP25	-3.57	0.000397	0.0252	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53832897	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9591538	ENSG00000136149.6	RPL13AP25	-3.57	0.000397	0.0252	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53833438	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9596856	ENSG00000136149.6	RPL13AP25	-3.57	0.000397	0.0252	-0.19	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53835266	chr13:54440704~54441315:-
THCA	cis	rs4907240	0.961	rs12469420	ENSG00000230606.9	AC159540.1	-3.57	0.000397	0.0252	-0.18	-0.16	Event-related brain oscillations;	chr2:96577568	chr2:97416165~97433527:-
THCA	cis	rs9308731	0.583	rs10211562	ENSG00000227992.1	AC108463.2	-3.57	0.000397	0.0252	-0.2	-0.16	Chronic lymphocytic leukemia;	chr2:111173219	chr2:111203964~111206215:-
THCA	cis	rs6687821	0.515	rs2798676	ENSG00000261737.1	RP4-612B15.3	-3.57	0.000397	0.0252	-0.24	-0.16	Yeast infection;	chr1:87086066	chr1:86703502~86704462:-
THCA	cis	rs4742903	0.935	rs10120101	ENSG00000270332.1	SMC2-AS1	3.57	0.000397	0.0252	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104238628	chr9:104080024~104093073:-
THCA	cis	rs7819412	0.642	rs11250117	ENSG00000255046.1	RP11-297N6.4	3.57	0.000397	0.0252	0.18	0.16	Triglycerides;	chr8:11115230	chr8:11797928~11802568:-
THCA	cis	rs1124769	0.523	rs1276855	ENSG00000259378.1	DCAF13P3	-3.57	0.000397	0.0252	-0.23	-0.16	Cognitive performance;	chr15:50862083	chr15:50944663~50945996:+
THCA	cis	rs5758511	0.68	rs5758652	ENSG00000270083.1	RP1-257I20.14	-3.57	0.000397	0.0252	-0.21	-0.16	Birth weight;	chr22:42216402	chr22:42089630~42090028:-
THCA	cis	rs5758511	0.68	rs1033460	ENSG00000270083.1	RP1-257I20.14	-3.57	0.000397	0.0252	-0.21	-0.16	Birth weight;	chr22:42223302	chr22:42089630~42090028:-
THCA	cis	rs5758511	0.679	rs55867855	ENSG00000270083.1	RP1-257I20.14	-3.57	0.000397	0.0252	-0.21	-0.16	Birth weight;	chr22:42227252	chr22:42089630~42090028:-
THCA	cis	rs916888	0.821	rs199514	ENSG00000260075.1	NSFP1	3.57	0.000397	0.0253	0.26	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46372855~46487141:+
THCA	cis	rs11064837	0.504	rs746297	ENSG00000248636.5	RP11-768F21.1	3.57	0.000397	0.0253	0.18	0.16	Schizophrenia;	chr12:119604996	chr12:119387987~119668079:-
THCA	cis	rs17428076	0.837	rs62182430	ENSG00000228389.1	AC068039.4	-3.57	0.000397	0.0253	-0.2	-0.16	Myopia;	chr2:171916327	chr2:171773482~171775844:+
THCA	cis	rs7824557	0.806	rs7007394	ENSG00000255046.1	RP11-297N6.4	3.57	0.000397	0.0253	0.16	0.16	Retinal vascular caliber;	chr8:11237057	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.806	rs6601573	ENSG00000255046.1	RP11-297N6.4	3.57	0.000397	0.0253	0.16	0.16	Retinal vascular caliber;	chr8:11237242	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.806	rs6601574	ENSG00000255046.1	RP11-297N6.4	3.57	0.000397	0.0253	0.16	0.16	Retinal vascular caliber;	chr8:11237376	chr8:11797928~11802568:-
THCA	cis	rs972578	0.677	rs9607949	ENSG00000230319.1	AL022476.2	3.57	0.000397	0.0253	0.18	0.16	Mean platelet volume;	chr22:42793826	chr22:43038585~43052366:+
THCA	cis	rs6472235	0.843	rs55861240	ENSG00000272192.1	CTD-2532N20.1	3.57	0.000397	0.0253	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65987055	chr8:65842752~65843331:+
THCA	cis	rs9925964	0.935	rs12597511	ENSG00000279196.1	RP11-1072A3.3	-3.57	0.000397	0.0253	-0.16	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31133898	chr16:30984630~30988270:-
THCA	cis	rs1538970	1	rs61791368	ENSG00000234329.1	RP11-767N6.2	3.57	0.000397	0.0253	0.16	0.16	Platelet count;	chr1:45402272	chr1:45651039~45651826:-
THCA	cis	rs4845570	1	rs6681093	ENSG00000249602.1	RP11-98D18.3	-3.57	0.000397	0.0253	-0.24	-0.16	Coronary artery disease;	chr1:151782808	chr1:151763384~151769501:-
THCA	cis	rs12546962	0.551	rs28457812	ENSG00000254153.1	CTA-398F10.2	-3.57	0.000397	0.0253	-0.2	-0.16	Body mass index;	chr8:9353656	chr8:8456909~8461337:-
THCA	cis	rs11088226	0.645	rs7281844	ENSG00000186842.4	LINC00846	-3.57	0.000397	0.0253	-0.24	-0.16	Gastritis;	chr21:32560125	chr21:32572238~32575881:-
THCA	cis	rs365302	1	rs294923	ENSG00000235086.1	FNDC1-IT1	3.57	0.000397	0.0253	0.23	0.16	Coronary heart disease;	chr6:159199893	chr6:159240786~159243329:+
THCA	cis	rs9393777	0.778	rs66841633	ENSG00000272009.1	RP1-313I6.12	-3.57	0.000397	0.0253	-0.28	-0.16	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28078792~28081130:-
THCA	cis	rs7111546	1	rs80216128	ENSG00000246225.5	RP11-17A1.3	3.57	0.000397	0.0253	0.3	0.16	Dialysis-related mortality;	chr11:22801324	chr11:22829380~22945393:+
THCA	cis	rs7264396	0.887	rs2236159	ENSG00000261582.1	RP4-614O4.11	-3.57	0.000397	0.0253	-0.17	-0.16	Total cholesterol levels;	chr20:35514360	chr20:35267885~35280043:-
THCA	cis	rs2729354	1	rs2511983	ENSG00000254602.1	AP000662.4	-3.57	0.000397	0.0253	-0.21	-0.16	Blood protein levels;	chr11:57579401	chr11:57638024~57652790:+
THCA	cis	rs10871290	0.65	rs3760055	ENSG00000207525.1	Y_RNA	-3.57	0.000397	0.0253	-0.21	-0.16	Breast cancer;	chr16:74456631	chr16:74463888~74463988:-
THCA	cis	rs4664293	0.903	rs10185155	ENSG00000230783.1	AC009961.2	-3.57	0.000398	0.0253	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159696717	chr2:159689217~159690291:-
THCA	cis	rs6801044	1	rs6801044	ENSG00000223711.1	AC091633.3	-3.57	0.000398	0.0253	-0.22	-0.16	Creatinine levels in ischemic stroke;	chr3:195562517	chr3:195544048~195550581:+
THCA	cis	rs17711722	0.701	rs781145	ENSG00000230295.1	RP11-458F8.2	-3.57	0.000398	0.0253	-0.13	-0.16	Calcium levels;	chr7:65975383	chr7:66880708~66882981:+
THCA	cis	rs9650657	0.572	rs11250098	ENSG00000261451.1	RP11-981G7.1	-3.57	0.000398	0.0253	-0.2	-0.16	Neuroticism;	chr8:10961097	chr8:10433672~10438312:+
THCA	cis	rs1971762	0.527	rs7952858	ENSG00000270175.1	RP11-793H13.11	-3.57	0.000398	0.0253	-0.11	-0.16	Height;	chr12:53645908	chr12:53500162~53500936:-
THCA	cis	rs2288884	1	rs2043298	ENSG00000260160.1	CTC-471J1.2	3.57	0.000398	0.0253	0.17	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069814	chr19:52058490~52063703:-
THCA	cis	rs3018712	0.505	rs7102308	ENSG00000212093.1	AP000807.1	-3.57	0.000398	0.0253	-0.21	-0.16	Total body bone mineral density;	chr11:68645762	chr11:68506083~68506166:-
THCA	cis	rs2243480	1	rs34815098	ENSG00000273024.4	INTS4P2	3.57	0.000398	0.0253	0.27	0.16	Diabetic kidney disease;	chr7:65827267	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs35735127	ENSG00000273024.4	INTS4P2	3.57	0.000398	0.0253	0.27	0.16	Diabetic kidney disease;	chr7:65835436	chr7:65647864~65715661:+
THCA	cis	rs2243480	0.901	rs35256305	ENSG00000273024.4	INTS4P2	3.57	0.000398	0.0253	0.27	0.16	Diabetic kidney disease;	chr7:65841418	chr7:65647864~65715661:+
THCA	cis	rs2243480	0.803	rs34004500	ENSG00000273024.4	INTS4P2	3.57	0.000398	0.0253	0.27	0.16	Diabetic kidney disease;	chr7:65847191	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs35825738	ENSG00000273024.4	INTS4P2	3.57	0.000398	0.0253	0.27	0.16	Diabetic kidney disease;	chr7:65853040	chr7:65647864~65715661:+
THCA	cis	rs2455799	0.634	rs62243670	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000398	0.0253	-0.17	-0.16	Mean platelet volume;	chr3:15877483	chr3:15732252~15733470:+
THCA	cis	rs9878978	0.963	rs62233814	ENSG00000227588.2	CNTN4-AS2	3.57	0.000398	0.0253	0.2	0.16	Blood pressure (smoking interaction);	chr3:2440094	chr3:2110409~2144241:-
THCA	cis	rs7829975	0.806	rs2428	ENSG00000248538.5	RP11-10A14.5	-3.57	0.000398	0.0253	-0.19	-0.16	Mood instability;	chr8:8783635	chr8:9189011~9202854:+
THCA	cis	rs2191566	0.691	rs56149185	ENSG00000266921.1	RP11-15A1.7	-3.57	0.000398	0.0253	-0.15	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44083914	chr19:43996896~44002836:-
THCA	cis	rs10489202	0.632	rs6659713	ENSG00000250762.1	RP1-313L4.4	3.57	0.000398	0.0253	0.22	0.16	Schizophrenia;	chr1:168103011	chr1:167819898~167820248:-
THCA	cis	rs9374842	0.956	rs1330113	ENSG00000253194.1	RP11-351A11.1	3.57	0.000398	0.0253	0.26	0.16	Body mass index;	chr6:119889340	chr6:118934785~119031541:+
THCA	cis	rs10043228	1	rs12520568	ENSG00000250015.1	CTC-339F2.2	3.57	0.000398	0.0253	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116285808	chr5:116302354~116304134:-
THCA	cis	rs35740288	1	rs11637212	ENSG00000259407.1	RP11-158M2.3	3.57	0.000398	0.0253	0.2	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85749866	chr15:85744109~85750281:-
THCA	cis	rs2455799	0.613	rs12485852	ENSG00000270409.1	RP11-44D5.1	-3.57	0.000398	0.0253	-0.17	-0.16	Mean platelet volume;	chr3:15873004	chr3:15732252~15733470:+
THCA	cis	rs61160187	0.518	rs62372133	ENSG00000272308.1	RP11-231G3.1	-3.57	0.000398	0.0253	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs12655603	ENSG00000272308.1	RP11-231G3.1	-3.57	0.000398	0.0253	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60866457~60866935:-
THCA	cis	rs250518	0.926	rs13157511	ENSG00000251467.1	CTC-250P20.2	-3.57	0.000398	0.0253	-0.23	-0.16	Mean corpuscular hemoglobin concentration;	chr5:72775976	chr5:72996920~72997642:+
THCA	cis	rs2952156	0.684	rs11658786	ENSG00000214546.3	AC087491.2	-3.57	0.000398	0.0253	-0.2	-0.16	Asthma;	chr17:39659646	chr17:39619613~39622513:+
THCA	cis	rs354225	0.584	rs11898032	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54594378	chr2:55565703~55565850:+
THCA	cis	rs354225	0.584	rs11898033	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54594381	chr2:55565703~55565850:+
THCA	cis	rs42648	1	rs42658	ENSG00000225498.1	AC002064.5	3.57	0.000398	0.0253	0.17	0.16	Homocysteine levels;	chr7:90352601	chr7:90312496~90322592:+
THCA	cis	rs1371614	0.523	rs4665924	ENSG00000229122.1	AGBL5-IT1	-3.57	0.000398	0.0253	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916437	chr2:27061038~27061815:+
THCA	cis	rs12612619	0.765	rs12615303	ENSG00000229122.1	AGBL5-IT1	-3.57	0.000398	0.0253	-0.12	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26917705	chr2:27061038~27061815:+
THCA	cis	rs6580649	0.941	rs726354	ENSG00000273765.1	RP11-370I10.11	-3.57	0.000398	0.0253	-0.17	-0.16	Lung cancer;	chr12:48106551	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs11609399	ENSG00000273765.1	RP11-370I10.11	-3.57	0.000398	0.0253	-0.17	-0.16	Lung cancer;	chr12:48107378	chr12:48360920~48361377:+
THCA	cis	rs6580649	0.941	rs10492080	ENSG00000273765.1	RP11-370I10.11	-3.57	0.000398	0.0253	-0.17	-0.16	Lung cancer;	chr12:48107628	chr12:48360920~48361377:+
THCA	cis	rs6121246	0.821	rs115585940	ENSG00000224628.2	RP5-854E16.2	-3.57	0.000398	0.0253	-0.23	-0.16	Mean corpuscular hemoglobin;	chr20:31730099	chr20:31285317~31286835:-
THCA	cis	rs10844706	0.699	rs7296241	ENSG00000257027.1	RP11-705C15.3	3.57	0.000398	0.0253	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725044	chr12:9658567~9662085:+
THCA	cis	rs6545883	0.894	rs2463102	ENSG00000212978.6	AC016747.3	-3.57	0.000398	0.0253	-0.17	-0.16	Tuberculosis;	chr2:61344160	chr2:61141592~61144969:-
THCA	cis	rs6545883	0.894	rs2593633	ENSG00000212978.6	AC016747.3	-3.57	0.000398	0.0253	-0.17	-0.16	Tuberculosis;	chr2:61344378	chr2:61141592~61144969:-
THCA	cis	rs9905704	0.918	rs11650343	ENSG00000224738.1	AC099850.1	3.57	0.000398	0.0253	0.22	0.16	Testicular germ cell tumor;	chr17:58842188	chr17:59106598~59118267:+
THCA	cis	rs354225	0.513	rs10187338	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54579474	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs10187447	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54579574	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs3796019	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54580142	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs3796018	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54580144	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs3796017	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54580315	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs1137645	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54580455	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs3287	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54580520	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs4616509	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54580845	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs10169954	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54580980	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs10169975	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54581022	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs10182538	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54581114	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs10170355	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54581185	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs10182836	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54581367	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs12713269	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54582017	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs7556752	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54582907	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs4641979	ENSG00000212175.1	SNORA12	-3.57	0.000398	0.0253	-0.2	-0.16	Schizophrenia;	chr2:54584780	chr2:55565703~55565850:+
THCA	cis	rs2276314	1	rs16967317	ENSG00000267627.4	RP11-905K4.1	-3.57	0.000398	0.0253	-0.2	-0.16	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35951803~35966118:-
THCA	cis	rs4578769	0.879	rs11659315	ENSG00000265939.1	UBE2CP2	-3.57	0.000398	0.0253	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22836405	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.879	rs11659384	ENSG00000265939.1	UBE2CP2	-3.57	0.000398	0.0253	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22836662	chr18:22900486~22900995:-
THCA	cis	rs11633886	0.967	rs7165191	ENSG00000259200.1	RP11-718O11.1	3.57	0.000398	0.0253	0.19	0.16	Diisocyanate-induced asthma;	chr15:45783735	chr15:45705078~45931069:+
THCA	cis	rs2180341	0.814	rs6914131	ENSG00000220522.2	RP1-177A13.1	3.57	0.000398	0.0253	0.19	0.16	Breast cancer;	chr6:127416344	chr6:127416535~127416952:-
THCA	cis	rs6901152	1	rs9376745	ENSG00000217648.1	RP1-95L4.4	-3.57	0.000398	0.0253	-0.17	-0.16	Acute lymphoblastic leukemia (childhood);	chr6:143336155	chr6:143342246~143343383:+
THCA	cis	rs6901152	1	rs1559598	ENSG00000217648.1	RP1-95L4.4	-3.57	0.000398	0.0253	-0.17	-0.16	Acute lymphoblastic leukemia (childhood);	chr6:143336714	chr6:143342246~143343383:+
THCA	cis	rs7613875	0.6	rs2856237	ENSG00000281691.1	RBM5-AS1	-3.57	0.000398	0.0253	-0.14	-0.16	Body mass index;	chr3:50121341	chr3:50099603~50100988:-
THCA	cis	rs11662586	1	rs12605316	ENSG00000267251.2	AC139100.3	3.57	0.000398	0.0253	0.18	0.16	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79933600	chr18:80183680~80202992:+
THCA	cis	rs1908814	0.503	rs34657250	ENSG00000255046.1	RP11-297N6.4	3.57	0.000398	0.0253	0.18	0.16	Neuroticism;	chr8:11937864	chr8:11797928~11802568:-
THCA	cis	rs261967	0.692	rs2578698	ENSG00000236882.6	LINC01554	-3.57	0.000399	0.0253	-0.19	-0.16	Body mass index;	chr5:96521561	chr5:95852232~95860133:+
THCA	cis	rs748404	0.66	rs518288	ENSG00000275601.1	AC011330.13	-3.57	0.000399	0.0253	-0.19	-0.16	Lung cancer;	chr15:43471801	chr15:43642389~43643023:-
THCA	cis	rs3733829	0.853	rs11547373	ENSG00000233622.1	CYP2T1P	-3.57	0.000399	0.0253	-0.18	-0.16	Smoking behavior;	chr19:40800457	chr19:40808525~40811390:-
THCA	cis	rs3749237	0.555	rs2117939	ENSG00000224424.7	PRKAR2A-AS1	3.57	0.000399	0.0253	0.14	0.16	Resting heart rate;	chr3:49377746	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs6797765	ENSG00000224424.7	PRKAR2A-AS1	3.57	0.000399	0.0253	0.14	0.16	Resting heart rate;	chr3:49386543	chr3:48847572~48851981:+
THCA	cis	rs933117	0.892	rs75975774	ENSG00000174680.8	GRIK1-AS1	-3.57	0.000399	0.0253	-0.38	-0.16	Body mass index;	chr21:29685600	chr21:29748175~29764002:+
THCA	cis	rs7707921	1	rs6888977	ENSG00000251374.1	RPS23P5	-3.57	0.000399	0.0253	-0.23	-0.16	Breast cancer;	chr5:82237916	chr5:82265157~82265259:-
THCA	cis	rs7829975	0.508	rs1594437	ENSG00000253981.4	ALG1L13P	3.57	0.000399	0.0253	0.15	0.16	Mood instability;	chr8:8968365	chr8:8236003~8244667:-
THCA	cis	rs9368481	0.761	rs3931464	ENSG00000228223.2	HCG11	-3.57	0.000399	0.0253	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26523450~26526579:+
THCA	cis	rs2898290	0.622	rs978802	ENSG00000270154.1	RP11-419I17.1	-3.57	0.000399	0.0253	-0.2	-0.16	Systolic blood pressure;	chr8:11485769	chr8:12476462~12477122:+
THCA	cis	rs786425	0.77	rs71458814	ENSG00000278112.1	RP11-972P1.11	3.57	0.000399	0.0253	0.16	0.16	Pubertal anthropometrics;	chr12:123712344	chr12:123519390~123519856:-
THCA	cis	rs1552244	0.572	rs67227131	ENSG00000180385.7	EMC3-AS1	3.57	0.000399	0.0253	0.21	0.16	Alzheimer's disease;	chr3:10131060	chr3:9986893~10006990:+
THCA	cis	rs4822752	0.646	rs2283843	ENSG00000244625.4	MIATNB	3.57	0.000399	0.0253	0.18	0.16	Bipolar disorder and schizophrenia;	chr22:26621336	chr22:26672767~26780207:+
THCA	cis	rs7940646	0.906	rs2052692	ENSG00000254554.1	RP11-351I24.1	3.57	0.000399	0.0253	0.19	0.16	Platelet aggregation;	chr11:10646094	chr11:10302657~10303704:-
THCA	cis	rs11673344	0.526	rs55754546	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37552860	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.526	rs17244713	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37559938	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.526	rs17244769	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37562031	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.526	rs8111790	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37565861	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.526	rs55909413	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37578663	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.526	rs55865869	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37578683	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.502	rs17304703	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37582646	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.526	rs73033122	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37586006	chr19:37548914~37587348:+
THCA	cis	rs11673344	0.526	rs2306201	ENSG00000267470.4	ZNF571-AS1	-3.57	0.000399	0.0253	-0.2	-0.16	Obesity-related traits;	chr19:37586573	chr19:37548914~37587348:+
THCA	cis	rs1560104	0.709	rs2217271	ENSG00000259876.1	CTD-3037G24.4	3.57	0.000399	0.0253	0.18	0.16	Obesity-related traits;	chr16:12610623	chr16:12556353~12557694:-
THCA	cis	rs7824557	0.524	rs7835318	ENSG00000254948.1	OR7E158P	3.57	0.000399	0.0253	0.2	0.16	Retinal vascular caliber;	chr8:11096364	chr8:11919900~11920809:-
THCA	cis	rs775227	0.574	rs66866534	ENSG00000243849.1	CFAP44-AS1	3.57	0.000399	0.0253	0.3	0.16	Dental caries;	chr3:113428468	chr3:113403991~113433992:+
THCA	cis	rs10090774	0.932	rs13256088	ENSG00000280303.2	ERICD	-3.57	0.000399	0.0254	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844857	chr8:140636281~140638283:+
THCA	cis	rs7394190	0.748	rs34163229	ENSG00000272140.2	RP11-574K11.29	-3.57	0.000399	0.0254	-0.16	-0.16	Incident atrial fibrillation;	chr10:73647154	chr10:73703735~73713581:-
THCA	cis	rs12681366	0.708	rs2515099	ENSG00000261437.1	RP11-22C11.2	-3.57	0.000399	0.0254	-0.15	-0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94367430	chr8:94637285~94639467:-
THCA	cis	rs754466	0.606	rs3740250	ENSG00000213514.2	RP11-428P16.2	3.57	0.000399	0.0254	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77820343	chr10:77730766~77734769:+
THCA	cis	rs975752	0.867	rs7358099	ENSG00000227492.1	RP11-316M21.6	-3.57	0.000399	0.0254	-0.31	-0.16	Schizophrenia;	chr10:100195245	chr10:100229667~100234000:+
THCA	cis	rs12472274	0.617	rs7568705	ENSG00000186235.9	AC016757.3	3.57	0.000399	0.0254	0.21	0.16	Phospholipid levels (plasma);	chr2:238173167	chr2:238224552~238231677:-
THCA	cis	rs14027	0.883	rs35660840	ENSG00000245330.4	KB-1471A8.1	3.57	0.000399	0.0254	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704351	chr8:119867419~119874488:-
THCA	cis	rs9911578	1	rs2270097	ENSG00000224738.1	AC099850.1	-3.57	0.000399	0.0254	-0.18	-0.16	Intelligence (multi-trait analysis);	chr17:58494709	chr17:59106598~59118267:+
THCA	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000399	0.0254	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000399	0.0254	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000399	0.0254	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
THCA	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000399	0.0254	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
THCA	cis	rs9652601	0.719	rs12103174	ENSG00000263033.2	RP11-396B14.2	-3.57	0.000399	0.0254	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11109873	chr16:11196177~11224969:+
THCA	cis	rs9652601	0.649	rs767448	ENSG00000263033.2	RP11-396B14.2	-3.57	0.000399	0.0254	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11110364	chr16:11196177~11224969:+
THCA	cis	rs9300255	0.602	rs2695478	ENSG00000235423.7	RP11-282O18.3	3.57	0.000399	0.0254	0.19	0.16	Neutrophil percentage of white cells;	chr12:123204974	chr12:123252030~123261483:-
THCA	cis	rs12621844	0.706	rs4953555	ENSG00000234690.5	AC073283.4	-3.57	0.000399	0.0254	-0.16	-0.16	Glycated hemoglobin levels;	chr2:48169636	chr2:47192405~47345074:-
THCA	cis	rs2243480	1	rs10950032	ENSG00000237310.1	GS1-124K5.4	-3.57	0.000399	0.0254	-0.19	-0.16	Diabetic kidney disease;	chr7:66273604	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6958420	ENSG00000237310.1	GS1-124K5.4	-3.57	0.000399	0.0254	-0.19	-0.16	Diabetic kidney disease;	chr7:66286184	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1392104	ENSG00000237310.1	GS1-124K5.4	-3.57	0.000399	0.0254	-0.19	-0.16	Diabetic kidney disease;	chr7:66294120	chr7:66493706~66495474:+
THCA	cis	rs1864585	0.52	rs73209918	ENSG00000280294.1	RP11-177H2.1	3.57	0.000399	0.0254	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10845754	chr8:10856085~10859436:-
THCA	cis	rs6005807	0.64	rs2013784	ENSG00000226471.5	CTA-292E10.6	3.57	0.000399	0.0254	0.19	0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28527945	chr22:28800683~28848559:+
THCA	cis	rs6443245	0.539	rs2542368	ENSG00000227110.5	LMCD1-AS1	-3.57	0.000399	0.0254	-0.19	-0.16	Daytime sleep phenotypes;	chr3:9578957	chr3:7952805~8611924:-
THCA	cis	rs4869313	0.668	rs2549781	ENSG00000247121.5	CTD-2260A17.2	3.57	0.000399	0.0254	0.12	0.16	Pediatric autoimmune diseases;	chr5:96894418	chr5:96814028~96935809:-
THCA	cis	rs1560104	0.597	rs12708758	ENSG00000262801.4	U91319.1	-3.57	0.000399	0.0254	-0.19	-0.16	Obesity-related traits;	chr16:12616844	chr16:13246316~13562918:+
THCA	cis	rs10515778	1	rs72815808	ENSG00000280834.1	U6	3.57	0.000399	0.0254	0.28	0.16	Inflammatory skin disease;	chr5:159228402	chr5:160072268~160072364:+
THCA	cis	rs730566	1	rs730566	ENSG00000229759.1	MRPS18AP1	-3.57	0.000399	0.0254	-0.2	-0.16	Prion diseases;	chr3:48445644	chr3:48256350~48256938:-
THCA	cis	rs16975963	0.793	rs73041034	ENSG00000276846.1	CTD-3220F14.3	-3.57	0.000399	0.0254	-0.15	-0.16	Longevity;	chr19:37795632	chr19:37314868~37315620:-
THCA	cis	rs40363	0.645	rs1690449	ENSG00000261140.1	RP11-20I23.6	-3.57	0.000399	0.0254	-0.23	-0.16	Tuberculosis;	chr16:3470893	chr16:2569043~2571936:-
THCA	cis	rs1005277	0.579	rs2504148	ENSG00000151963.4	RP11-775A3.1	-3.57	0.000399	0.0254	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs176886	ENSG00000151963.4	RP11-775A3.1	-3.57	0.000399	0.0254	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.557	rs176887	ENSG00000151963.4	RP11-775A3.1	-3.57	0.000399	0.0254	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474594	ENSG00000151963.4	RP11-775A3.1	-3.57	0.000399	0.0254	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs11011461	ENSG00000151963.4	RP11-775A3.1	-3.57	0.000399	0.0254	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:37883594~37884109:+
THCA	cis	rs1667255	1	rs1791201	ENSG00000266521.1	RP11-650P15.1	3.57	0.000399	0.0254	0.21	0.16	Retinol levels;	chr18:31605305	chr18:31496645~31497195:-
THCA	cis	rs957448	0.503	rs752460	ENSG00000261437.1	RP11-22C11.2	3.57	4e-04	0.0254	0.16	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94477994	chr8:94637285~94639467:-
THCA	cis	rs12681366	0.801	rs4735293	ENSG00000261437.1	RP11-22C11.2	3.57	4e-04	0.0254	0.16	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94478175	chr8:94637285~94639467:-
THCA	cis	rs11168618	0.967	rs10875831	ENSG00000240399.1	RP1-228P16.1	3.57	4e-04	0.0254	0.17	0.16	Adiponectin levels;	chr12:48544597	chr12:48054813~48055591:-
THCA	cis	rs206966	0.81	rs10849743	ENSG00000277283.1	RP1-267D11.6	3.57	4e-04	0.0254	0.16	0.16	Breast cancer;	chr12:120351211	chr12:120116907~120119000:+
THCA	cis	rs763121	0.785	rs5750646	ENSG00000225450.1	RP3-508I15.14	-3.57	4e-04	0.0254	-0.13	-0.16	Menopause (age at onset);	chr22:38617825	chr22:38739003~38749041:+
THCA	cis	rs2243480	1	rs67536397	ENSG00000237310.1	GS1-124K5.4	3.57	4e-04	0.0254	0.19	0.16	Diabetic kidney disease;	chr7:66482930	chr7:66493706~66495474:+
THCA	cis	rs2562456	0.52	rs660063	ENSG00000268119.4	CTD-2561J22.5	-3.57	4e-04	0.0254	-0.23	-0.16	Pain;	chr19:21271103	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.52	rs279793	ENSG00000268119.4	CTD-2561J22.5	3.57	4e-04	0.0254	0.23	0.16	Pain;	chr19:21272972	chr19:21444241~21463908:-
THCA	cis	rs9341808	0.69	rs3805926	ENSG00000260645.1	RP11-250B2.5	3.57	4e-04	0.0254	0.14	0.16	Sitting height ratio;	chr6:80169563	chr6:80466958~80469080:+
THCA	cis	rs208520	1	rs12199876	ENSG00000233859.2	ADH5P4	3.57	4e-04	0.0254	0.25	0.16	Exhaled nitric oxide output;	chr6:66279576	chr6:65836930~65838039:-
THCA	cis	rs2494663	0.61	rs11264974	ENSG00000231416.1	RP11-422P24.9	3.57	4e-04	0.0254	0.2	0.16	Mean platelet volume;	chr1:154063657	chr1:153995632~153995960:+
THCA	cis	rs763121	0.962	rs6001193	ENSG00000228274.3	RP3-508I15.9	-3.57	4e-04	0.0254	-0.17	-0.16	Menopause (age at onset);	chr22:38678732	chr22:38667585~38681820:-
THCA	cis	rs453301	0.606	rs7462373	ENSG00000254340.1	RP11-10A14.3	-3.57	4e-04	0.0254	-0.18	-0.16	Joint mobility (Beighton score);	chr8:9041808	chr8:9141424~9145435:+
THCA	cis	rs6449502	0.512	rs4700401	ENSG00000251279.1	CTC-436P18.1	-3.57	4e-04	0.0254	-0.23	-0.16	Mean platelet volume;	chr5:60872338	chr5:61162070~61232040:+
THCA	cis	rs12680842	0.576	rs35593078	ENSG00000253175.1	RP11-267M23.6	3.57	4e-04	0.0254	0.19	0.16	Body mass index;	chr8:94614917	chr8:94565036~94565715:+
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000232546.1	RP11-458F8.1	-3.57	4e-04	0.0254	-0.13	-0.16	Calcium levels;	chr7:65903721	chr7:66848496~66858136:+
THCA	cis	rs786425	0.683	rs12830927	ENSG00000278112.1	RP11-972P1.11	3.57	4e-04	0.0254	0.16	0.16	Pubertal anthropometrics;	chr12:123636444	chr12:123519390~123519856:-
THCA	cis	rs3015497	0.637	rs7156129	ENSG00000270062.1	RP11-248J18.3	3.57	4e-04	0.0254	0.19	0.16	Mean platelet volume;	chr14:50710705	chr14:50723777~50724272:-
THCA	cis	rs613391	0.826	rs2122074	ENSG00000234840.1	LINC01239	-3.57	4e-04	0.0254	-0.19	-0.16	Quantitative traits;	chr9:22682046	chr9:22646200~22824213:+
THCA	cis	rs10256972	0.64	rs10271082	ENSG00000225146.1	AC073957.15	3.57	4e-04	0.0254	0.18	0.16	Endometriosis;Longevity;	chr7:1041926	chr7:1029025~1043891:+
THCA	cis	rs6929812	0.613	rs13215560	ENSG00000271755.1	RP1-153G14.4	3.57	4e-04	0.0254	0.19	0.16	Neuroticism (multi-trait analysis);	chr6:27514160	chr6:27404010~27406964:-
THCA	cis	rs708224	0.513	rs753296	ENSG00000277342.1	RP11-843B15.4	3.57	4e-04	0.0254	0.22	0.16	Pancreatic cancer;	chr12:32282579	chr12:32109076~32109602:+
THCA	cis	rs10863936	0.667	rs17656163	ENSG00000198468.6	FLVCR1-AS1	-3.57	4e-04	0.0254	-0.19	-0.16	Height;	chr1:212067883	chr1:212852108~212858088:-
THCA	cis	rs2040609	0.961	rs11867566	ENSG00000200013.1	RNU6-623P	3.57	4e-04	0.0254	0.19	0.16	Multiple keratinocyte cancers;	chr17:61650489	chr17:60662333~60662437:-
THCA	cis	rs1933755	0.541	rs11154595	ENSG00000219776.2	RPL21P67	3.57	4e-04	0.0254	0.29	0.16	Colorectal cancer (calcium intake interaction);	chr6:130595520	chr6:131469059~131469536:+
THCA	cis	rs656319	0.513	rs3885723	ENSG00000248538.5	RP11-10A14.5	3.57	4e-04	0.0254	0.21	0.16	Myopia (pathological);	chr8:10134151	chr8:9189011~9202854:+
THCA	cis	rs73198271	0.737	rs565203	ENSG00000254153.1	CTA-398F10.2	3.57	4e-04	0.0254	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8775447	chr8:8456909~8461337:-
THCA	cis	rs9796	0.558	rs8043253	ENSG00000247556.5	OIP5-AS1	3.57	4e-04	0.0254	0.13	0.16	Menopause (age at onset);	chr15:41211532	chr15:41283990~41309737:+
THCA	cis	rs6929812	0.628	rs2206254	ENSG00000271755.1	RP1-153G14.4	3.57	4e-04	0.0254	0.18	0.16	Neuroticism (multi-trait analysis);	chr6:27431852	chr6:27404010~27406964:-
THCA	cis	rs13126694	0.574	rs10002472	ENSG00000248429.4	RP11-597D13.9	3.57	4e-04	0.0254	0.18	0.16	Blood osmolality (transformed sodium);	chr4:157946821	chr4:158170752~158202877:+
THCA	cis	rs9399599	0.902	rs9390462	ENSG00000233452.5	STXBP5-AS1	3.57	4e-04	0.0254	0.16	0.16	Plasma plasminogen activator levels;	chr6:147380085	chr6:146841901~147204614:-
THCA	cis	rs600231	0.706	rs10896016	ENSG00000260233.3	SSSCA1-AS1	-3.57	4e-04	0.0254	-0.13	-0.16	Bone mineral density;	chr11:65568234	chr11:65568482~65570423:-
THCA	cis	rs12497850	1	rs4858828	ENSG00000228638.1	FCF1P2	-3.57	0.000401	0.0254	-0.17	-0.16	Parkinson's disease;	chr3:48687378	chr3:48290793~48291375:-
THCA	cis	rs12497850	1	rs4858798	ENSG00000228638.1	FCF1P2	-3.57	0.000401	0.0254	-0.17	-0.16	Parkinson's disease;	chr3:48689679	chr3:48290793~48291375:-
THCA	cis	rs2483519	0.511	rs11196881	ENSG00000228169.3	PPIAP19	3.57	0.000401	0.0254	0.19	0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114691308	chr10:114690143~114690634:-
THCA	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	3.57	0.000401	0.0254	0.18	0.16	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
THCA	cis	rs944289	0.617	rs11156905	ENSG00000257520.1	RP11-896J10.3	3.57	0.000401	0.0254	0.17	0.16	Thyroid cancer;	chr14:36100314	chr14:36473207~36519521:-
THCA	cis	rs2412819	0.599	rs2470120	ENSG00000275601.1	AC011330.13	-3.57	0.000401	0.0254	-0.2	-0.16	Lung cancer;	chr15:43636872	chr15:43642389~43643023:-
THCA	cis	rs875971	0.638	rs6960778	ENSG00000232546.1	RP11-458F8.1	3.57	0.000401	0.0254	0.13	0.16	Aortic root size;	chr7:66606610	chr7:66848496~66858136:+
THCA	cis	rs208520	1	rs72884017	ENSG00000233859.2	ADH5P4	3.57	0.000401	0.0254	0.26	0.16	Exhaled nitric oxide output;	chr6:66282620	chr6:65836930~65838039:-
THCA	cis	rs4908768	0.906	rs11121223	ENSG00000232912.4	RP5-1115A15.1	-3.57	0.000401	0.0254	-0.2	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8712786	chr1:8424645~8434838:+
THCA	cis	rs7010267	0.935	rs4319131	ENSG00000254278.1	RP11-278I4.2	3.57	0.000401	0.0254	0.2	0.16	Total body bone mineral density (age 45-60);	chr8:118935412	chr8:119062942~119068782:-
THCA	cis	rs10858047	0.883	rs12039811	ENSG00000231128.4	RP5-1073O3.2	3.57	0.000401	0.0254	0.24	0.16	Autism;	chr1:114564929	chr1:113812379~113829171:+
THCA	cis	rs4788815	0.718	rs6499545	ENSG00000260886.1	TAT-AS1	3.57	0.000401	0.0254	0.24	0.16	Metabolite levels;	chr16:71855270	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.586	rs4788564	ENSG00000260886.1	TAT-AS1	3.57	0.000401	0.0254	0.24	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71857959	chr16:71565789~71578187:+
THCA	cis	rs6012953	0.654	rs2206656	ENSG00000237595.3	RP11-112L6.3	3.57	0.000401	0.0254	0.15	0.16	Vitiligo;	chr20:50513582	chr20:50162765~50166102:-
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000184274.3	LINC00315	-3.57	0.000401	0.0254	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45300245~45305257:-
THCA	cis	rs2638953	0.853	rs10843178	ENSG00000247934.4	RP11-967K21.1	-3.57	0.000401	0.0254	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460501	chr12:28163298~28190738:-
THCA	cis	rs8033133	0.957	rs3742952	ENSG00000257151.1	PWAR6	3.57	0.000401	0.0254	0.12	0.16	Blood osmolality (transformed sodium);	chr15:25105879	chr15:25031873~25036490:+
THCA	cis	rs1153858	1	rs66528868	ENSG00000275672.1	GATM-AS1	-3.57	0.000401	0.0255	-0.17	-0.16	Homoarginine levels;	chr15:45376349	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs7494956	ENSG00000275672.1	GATM-AS1	-3.57	0.000401	0.0255	-0.17	-0.16	Homoarginine levels;	chr15:45376367	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs2114501	ENSG00000275672.1	GATM-AS1	-3.57	0.000401	0.0255	-0.17	-0.16	Homoarginine levels;	chr15:45378118	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs67461176	ENSG00000275672.1	GATM-AS1	-3.57	0.000401	0.0255	-0.17	-0.16	Homoarginine levels;	chr15:45384621	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs66939267	ENSG00000275672.1	GATM-AS1	-3.57	0.000401	0.0255	-0.17	-0.16	Homoarginine levels;	chr15:45384704	chr15:45378700~45380123:+
THCA	cis	rs7188697	0.922	rs37060	ENSG00000276259.1	RP11-481J2.4	-3.57	0.000401	0.0255	-0.11	-0.16	QT interval;	chr16:58532400	chr16:58522970~58523842:+
THCA	cis	rs193541	0.565	rs6888751	ENSG00000260686.1	CTB-36H16.2	-3.57	0.000401	0.0255	-0.15	-0.16	Glucose homeostasis traits;	chr5:122856340	chr5:122832356~122834533:+
THCA	cis	rs11168351	0.927	rs7971880	ENSG00000257735.1	RP11-370I10.6	3.57	0.000401	0.0255	0.19	0.16	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48350945~48442411:+
THCA	cis	rs61776719	0.5	rs11210866	ENSG00000252448.1	SNORA63	-3.57	0.000401	0.0255	-0.19	-0.16	Coronary artery disease;	chr1:37983893	chr1:37884237~37884317:+
THCA	cis	rs4879656	0.966	rs12000958	ENSG00000225693.1	LAGE3P1	-3.57	0.000401	0.0255	-0.18	-0.16	Menopause (age at onset);	chr9:33031432	chr9:33019682~33020165:-
THCA	cis	rs929354	1	rs1182391	ENSG00000224629.1	RP5-1142J19.2	3.57	0.000401	0.0255	0.16	0.16	Body mass index;	chr7:157245674	chr7:157263022~157263229:-
THCA	cis	rs7395662	0.818	rs2200181	ENSG00000200090.1	Y_RNA	-3.57	0.000401	0.0255	-0.11	-0.16	HDL cholesterol;	chr11:48391623	chr11:47726894~47726992:-
THCA	cis	rs42648	1	rs42648	ENSG00000225498.1	AC002064.5	3.57	0.000401	0.0255	0.17	0.16	Homocysteine levels;	chr7:90348446	chr7:90312496~90322592:+
THCA	cis	rs10802047	0.54	rs952593	ENSG00000231365.4	RP11-418J17.1	3.57	0.000401	0.0255	0.17	0.16	Relative hand skill in reading disability;	chr1:118861587	chr1:119140396~119275973:+
THCA	cis	rs4771122	0.728	rs7992289	ENSG00000261485.1	PAN3-AS1	-3.57	0.000401	0.0255	-0.15	-0.16	Body mass index;	chr13:27462293	chr13:28136843~28138193:-
THCA	cis	rs6049003	0.668	rs6049064	ENSG00000270001.1	RP11-218C14.8	-3.57	0.000401	0.0255	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr20:23746508	chr20:23631826~23632316:-
THCA	cis	rs9487094	0.666	rs2236084	ENSG00000223537.2	RP5-919F19.5	-3.57	0.000401	0.0255	-0.16	-0.16	Height;	chr6:109476101	chr6:109487906~109506800:+
THCA	cis	rs4081724	0.565	rs59527310	ENSG00000267296.2	CEBPA-AS1	3.57	0.000401	0.0255	0.25	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33307487	chr19:33302857~33305054:+
THCA	cis	rs7216064	1	rs8082512	ENSG00000265055.1	AC145343.2	3.57	0.000401	0.0255	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840943	chr17:68096046~68101474:-
THCA	cis	rs7216064	0.953	rs8073510	ENSG00000265055.1	AC145343.2	3.57	0.000401	0.0255	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67843094	chr17:68096046~68101474:-
THCA	cis	rs7111546	0.943	rs16910194	ENSG00000246225.5	RP11-17A1.3	3.57	0.000401	0.0255	0.29	0.16	Dialysis-related mortality;	chr11:22807366	chr11:22829380~22945393:+
THCA	cis	rs2486012	0.737	rs641356	ENSG00000237950.1	RP11-7O11.3	3.57	0.000401	0.0255	0.19	0.16	Intelligence (multi-trait analysis);	chr1:43821514	chr1:43944370~43946551:-
THCA	cis	rs2841277	0.708	rs10083496	ENSG00000258701.1	LINC00638	3.57	0.000401	0.0255	0.17	0.16	Rheumatoid arthritis;	chr14:104936449	chr14:104821201~104823718:+
THCA	cis	rs10995505	0.578	rs1533068	ENSG00000272767.1	JMJD1C-AS1	-3.57	0.000401	0.0255	-0.2	-0.16	Intelligence (multi-trait analysis);	chr10:63132407	chr10:63465229~63466563:+
THCA	cis	rs7713065	0.959	rs2548992	ENSG00000224431.1	AC063976.7	3.56	0.000401	0.0255	0.16	0.16	Lung function (FEV1/FVC);	chr5:132472976	chr5:132199456~132203487:+
THCA	cis	rs875971	1	rs6958271	ENSG00000272831.1	RP11-792A8.4	3.56	0.000401	0.0255	0.1	0.16	Aortic root size;	chr7:66514344	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6958277	ENSG00000272831.1	RP11-792A8.4	3.56	0.000401	0.0255	0.1	0.16	Aortic root size;	chr7:66514362	chr7:66739829~66740385:-
THCA	cis	rs354225	0.819	rs241661	ENSG00000162997.14	PRORSD1P	-3.56	0.000401	0.0255	-0.18	-0.16	Schizophrenia;	chr2:54697330	chr2:55282319~55284522:+
THCA	cis	rs8058578	1	rs7204278	ENSG00000260911.2	RP11-196G11.2	3.56	0.000401	0.0255	0.14	0.16	Multiple myeloma;	chr16:30718953	chr16:31043150~31049868:+
THCA	cis	rs10089	0.953	rs7713860	ENSG00000245937.6	LINC01184	3.56	0.000401	0.0255	0.18	0.16	Ileal carcinoids;	chr5:128093097	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs4835941	ENSG00000245937.6	LINC01184	3.56	0.000401	0.0255	0.18	0.16	Ileal carcinoids;	chr5:128095213	chr5:127940426~128083172:-
THCA	cis	rs972540	0.961	rs59825268	ENSG00000229647.1	AC007879.7	-3.56	0.000401	0.0255	-0.19	-0.16	Body mass index;	chr2:206392509	chr2:207239650~207245887:+
THCA	cis	rs2522056	0.808	rs2706373	ENSG00000237714.1	P4HA2-AS1	-3.56	0.000401	0.0255	-0.23	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132468564	chr5:132184876~132192808:+
THCA	cis	rs2522056	1	rs2522062	ENSG00000237714.1	P4HA2-AS1	-3.56	0.000401	0.0255	-0.23	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132469724	chr5:132184876~132192808:+
THCA	cis	rs2522056	1	rs2522063	ENSG00000237714.1	P4HA2-AS1	-3.56	0.000401	0.0255	-0.23	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132469899	chr5:132184876~132192808:+
THCA	cis	rs2522056	1	rs2706379	ENSG00000237714.1	P4HA2-AS1	-3.56	0.000401	0.0255	-0.23	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132470043	chr5:132184876~132192808:+
THCA	cis	rs5758659	0.652	rs133305	ENSG00000234009.1	RPL5P34	-3.56	0.000401	0.0255	-0.15	-0.16	Cognitive function;	chr22:41999956	chr22:42776406~42777296:-
THCA	cis	rs5758659	0.682	rs133306	ENSG00000234009.1	RPL5P34	-3.56	0.000401	0.0255	-0.15	-0.16	Cognitive function;	chr22:42000146	chr22:42776406~42777296:-
THCA	cis	rs5758659	0.519	rs133307	ENSG00000234009.1	RPL5P34	-3.56	0.000401	0.0255	-0.15	-0.16	Cognitive function;	chr22:42000564	chr22:42776406~42777296:-
THCA	cis	rs4272720	0.562	rs2725181	ENSG00000234736.4	FAM170B-AS1	-3.56	0.000401	0.0255	-0.18	-0.16	Platelet count;Plateletcrit;	chr10:49161327	chr10:49121839~49151547:+
THCA	cis	rs853679	0.513	rs9468296	ENSG00000219891.2	ZSCAN12P1	3.56	0.000401	0.0255	0.23	0.16	Depression;	chr6:28145952	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000219891.2	ZSCAN12P1	3.56	0.000401	0.0255	0.23	0.16	Depression;	chr6:28147378	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000219891.2	ZSCAN12P1	3.56	0.000401	0.0255	0.23	0.16	Depression;	chr6:28147406	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000219891.2	ZSCAN12P1	3.56	0.000401	0.0255	0.23	0.16	Depression;	chr6:28148143	chr6:28091154~28093664:+
THCA	cis	rs7520050	0.833	rs1085242	ENSG00000280836.1	AL355480.1	3.56	0.000401	0.0255	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45581219~45581321:-
THCA	cis	rs7727544	0.582	rs3805681	ENSG00000263597.1	MIR3936	3.56	0.000401	0.0255	0.15	0.16	Blood metabolite levels;	chr5:132202167	chr5:132365490~132365599:-
THCA	cis	rs7660883	0.866	rs342468	ENSG00000251411.1	RP11-397E7.4	-3.56	0.000401	0.0255	-0.15	-0.16	HDL cholesterol levels;	chr4:87130756	chr4:86913266~86914817:-
THCA	cis	rs7824557	0.564	rs12550129	ENSG00000261451.1	RP11-981G7.1	-3.56	0.000402	0.0255	-0.2	-0.16	Retinal vascular caliber;	chr8:11376408	chr8:10433672~10438312:+
THCA	cis	rs7267979	0.816	rs443009	ENSG00000276952.1	RP5-965G21.6	-3.56	0.000402	0.0255	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25284915~25285588:-
THCA	cis	rs6982240	0.514	rs2060357	ENSG00000253307.1	RP11-10J21.4	3.56	0.000402	0.0255	0.24	0.16	Tonsillectomy;	chr8:141249730	chr8:141252286~141253292:-
THCA	cis	rs8177876	0.658	rs889516	ENSG00000261838.4	RP11-303E16.6	-3.56	0.000402	0.0255	-0.27	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034943	chr16:81069854~81076598:+
THCA	cis	rs877819	0.583	rs2940712	ENSG00000228403.1	RP11-563N6.6	-3.56	0.000402	0.0255	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48848403	chr10:48878022~48878649:+
THCA	cis	rs721917	0.607	rs4319455	ENSG00000225484.5	NUTM2B-AS1	-3.56	0.000402	0.0255	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr10:79979389	chr10:79663088~79826594:-
THCA	cis	rs17489649	1	rs2284988	ENSG00000249476.1	CTD-2587M2.1	-3.56	0.000402	0.0255	-0.15	-0.16	Intelligence (multi-trait analysis);	chr5:109705607	chr5:109237120~109326369:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000232546.1	RP11-458F8.1	-3.56	0.000402	0.0255	-0.13	-0.16	Calcium levels;	chr7:65974892	chr7:66848496~66858136:+
THCA	cis	rs7542375	0.683	rs11118625	ENSG00000238078.1	LINC01352	-3.56	0.000402	0.0255	-0.23	-0.16	Obesity-related traits;	chr1:220930046	chr1:220829255~220832429:+
THCA	cis	rs7572733	0.935	rs7558450	ENSG00000231621.1	AC013264.2	-3.56	0.000402	0.0255	-0.15	-0.16	Dermatomyositis;	chr2:197973042	chr2:197197991~197199273:+
THCA	cis	rs9880211	0.635	rs9827662	ENSG00000239213.4	NCK1-AS1	3.56	0.000402	0.0255	0.18	0.16	Height;Body mass index;	chr3:135991999	chr3:136841726~136862054:-
THCA	cis	rs261967	0.654	rs261985	ENSG00000236882.6	LINC01554	-3.56	0.000402	0.0255	-0.19	-0.16	Body mass index;	chr5:96507283	chr5:95852232~95860133:+
THCA	cis	rs2297441	0.55	rs73622887	ENSG00000229873.1	OGFR-AS1	-3.56	0.000402	0.0255	-0.22	-0.16	Ulcerative colitis;	chr20:63747986	chr20:62800627~62805587:-
THCA	cis	rs2549003	1	rs2549007	ENSG00000233006.5	AC034220.3	3.56	0.000402	0.0255	0.13	0.16	Asthma (sex interaction);	chr5:132491183	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs2706384	ENSG00000233006.5	AC034220.3	3.56	0.000402	0.0255	0.13	0.16	Asthma (sex interaction);	chr5:132491188	chr5:132311285~132369916:-
THCA	cis	rs7621025	0.586	rs34553037	ENSG00000239213.4	NCK1-AS1	-3.56	0.000402	0.0255	-0.17	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136660571	chr3:136841726~136862054:-
THCA	cis	rs5758659	0.622	rs129856	ENSG00000234009.1	RPL5P34	-3.56	0.000402	0.0255	-0.15	-0.16	Cognitive function;	chr22:42003392	chr22:42776406~42777296:-
THCA	cis	rs3740713	0.669	rs113003553	ENSG00000256588.1	RP11-613F22.8	3.56	0.000402	0.0255	0.24	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr11:18507608~18508820:-
THCA	cis	rs10208649	0.536	rs12162343	ENSG00000233266.1	HMGB1P31	3.56	0.000402	0.0255	0.27	0.16	Body mass index;	chr2:53900617	chr2:54051334~54051760:+
THCA	cis	rs250518	0.926	rs6875670	ENSG00000251467.1	CTC-250P20.2	3.56	0.000402	0.0255	0.23	0.16	Mean corpuscular hemoglobin concentration;	chr5:72785943	chr5:72996920~72997642:+
THCA	cis	rs4819052	0.655	rs2330102	ENSG00000273796.1	LL21NC02-21A1.1	-3.56	0.000402	0.0255	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45403809~45404369:-
THCA	cis	rs4819052	0.679	rs8132135	ENSG00000273796.1	LL21NC02-21A1.1	-3.56	0.000402	0.0255	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45403809~45404369:-
THCA	cis	rs9368481	0.672	rs3931463	ENSG00000228223.2	HCG11	-3.56	0.000402	0.0255	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26523450~26526579:+
THCA	cis	rs17023223	0.537	rs3934789	ENSG00000227056.2	RPL6P2	-3.56	0.000402	0.0255	-0.22	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119219314~119220096:-
THCA	cis	rs881375	0.967	rs10733648	ENSG00000270917.1	RP11-27I1.6	-3.56	0.000402	0.0255	-0.22	-0.16	Rheumatoid arthritis;	chr9:120938501	chr9:120812475~120812845:-
THCA	cis	rs11671005	0.736	rs11668201	ENSG00000252334.1	RNU6-1337P	3.56	0.000402	0.0255	0.24	0.16	Mean platelet volume;	chr19:58492265	chr19:58483749~58483843:-
THCA	cis	rs2074409	0.509	rs11655957	ENSG00000275839.1	CTC-421K24.1	-3.56	0.000402	0.0255	-0.19	-0.16	Response to angiotensin II receptor blocker therapy;	chr17:37459133	chr17:37454171~37454931:+
THCA	cis	rs1009077	0.716	rs17358524	ENSG00000245958.5	RP11-33B1.1	3.56	0.000402	0.0255	0.25	0.16	Endometriosis;	chr4:119570559	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs34676199	ENSG00000245958.5	RP11-33B1.1	3.56	0.000402	0.0255	0.25	0.16	Endometriosis;	chr4:119589154	chr4:119454791~119552025:+
THCA	cis	rs4938303	0.589	rs11601584	ENSG00000254851.1	RP11-109L13.1	3.56	0.000402	0.0255	0.23	0.16	Triglycerides;	chr11:116700568	chr11:117135528~117138582:+
THCA	cis	rs9287719	0.967	rs7570118	ENSG00000243819.4	RN7SL832P	3.56	0.000402	0.0255	0.13	0.16	Prostate cancer;	chr2:10577881	chr2:10690344~10692099:+
THCA	cis	rs2562456	0.526	rs950504	ENSG00000268357.1	VN1R81P	-3.56	0.000402	0.0255	-0.15	-0.16	Pain;	chr19:21601193	chr19:21123817~21124188:+
THCA	cis	rs7829975	0.511	rs2976902	ENSG00000254153.1	CTA-398F10.2	-3.56	0.000402	0.0255	-0.18	-0.16	Mood instability;	chr8:8483595	chr8:8456909~8461337:-
THCA	cis	rs4660214	0.666	rs7553009	ENSG00000228060.1	RP11-69E11.8	3.56	0.000402	0.0255	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39247441	chr1:39565160~39573203:+
THCA	cis	rs6456156	1	rs9457274	ENSG00000235272.1	FAM103A2P	3.56	0.000402	0.0255	0.22	0.16	Primary biliary cholangitis;	chr6:167107377	chr6:166586124~166586477:-
THCA	cis	rs34421088	0.56	rs2245250	ENSG00000251402.3	FAM90A25P	-3.56	0.000402	0.0255	-0.21	-0.16	Neuroticism;	chr8:11543171	chr8:12415080~12418090:-
THCA	cis	rs858239	0.932	rs858275	ENSG00000230042.1	AK3P3	-3.56	0.000402	0.0255	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23129178~23129841:+
THCA	cis	rs6121246	0.909	rs7354225	ENSG00000230613.1	HM13-AS1	3.56	0.000402	0.0255	0.19	0.16	Mean corpuscular hemoglobin;	chr20:31709078	chr20:31567707~31573263:-
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000184274.3	LINC00315	-3.56	0.000402	0.0255	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45300245~45305257:-
THCA	cis	rs3805389	1	rs3805389	ENSG00000273257.1	RP11-177J6.1	-3.56	0.000402	0.0255	-0.26	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55616583	chr4:55387949~55388271:+
THCA	cis	rs2749097	0.825	rs11208265	ENSG00000244256.3	RN7SL130P	-3.56	0.000402	0.0255	-0.21	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63659563	chr1:63655743~63656047:+
THCA	cis	rs11992162	0.569	rs35283519	ENSG00000255354.1	RP11-148O21.2	3.56	0.000403	0.0255	0.18	0.16	Monocyte count;	chr8:11974152	chr8:11558466~11560020:-
THCA	cis	rs9425766	0.679	rs6681390	ENSG00000270084.1	GAS5-AS1	-3.56	0.000403	0.0255	-0.17	-0.16	Life satisfaction;	chr1:174261331	chr1:173863248~173863941:+
THCA	cis	rs1842579	0.737	rs1564517	ENSG00000272691.1	RP11-290M5.4	-3.56	0.000403	0.0255	-0.16	-0.16	Coronary artery aneurysm in Kawasaki disease;	chr1:85874841	chr1:85578500~85578742:-
THCA	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	3.56	0.000403	0.0255	0.15	0.16	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	3.56	0.000403	0.0255	0.15	0.16	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	3.56	0.000403	0.0255	0.15	0.16	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
THCA	cis	rs11711311	0.747	rs11928590	ENSG00000241529.3	RN7SL767P	-3.56	0.000403	0.0255	-0.24	-0.16	IgG glycosylation;	chr3:113624631	chr3:113632704~113632998:+
THCA	cis	rs1124769	0.719	rs12911168	ENSG00000259378.1	DCAF13P3	3.56	0.000403	0.0255	0.25	0.16	Cognitive performance;	chr15:51088391	chr15:50944663~50945996:+
THCA	cis	rs5758659	0.652	rs5758537	ENSG00000234009.1	RPL5P34	-3.56	0.000403	0.0255	-0.15	-0.16	Cognitive function;	chr22:42001038	chr22:42776406~42777296:-
THCA	cis	rs559555	0.612	rs585890	ENSG00000276334.1	AL133243.1	3.56	0.000403	0.0255	0.17	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31594361	chr2:32521927~32523547:+
THCA	cis	rs4660456	0.913	rs7551747	ENSG00000238287.1	RP11-656D10.3	3.56	0.000403	0.0256	0.2	0.16	Platelet count;	chr1:40699407	chr1:40493157~40508661:-
THCA	cis	rs2832191	1	rs9984793	ENSG00000232855.5	AF131217.1	3.56	0.000403	0.0256	0.17	0.16	Dental caries;	chr21:29114150	chr21:28439346~28674848:-
THCA	cis	rs2832191	0.967	rs2898160	ENSG00000232855.5	AF131217.1	3.56	0.000403	0.0256	0.17	0.16	Dental caries;	chr21:29115175	chr21:28439346~28674848:-
THCA	cis	rs2832191	1	rs2832190	ENSG00000232855.5	AF131217.1	3.56	0.000403	0.0256	0.17	0.16	Dental caries;	chr21:29115905	chr21:28439346~28674848:-
THCA	cis	rs1556032	0.617	rs7031064	ENSG00000225472.1	RP11-120J1.1	3.56	0.000403	0.0256	0.15	0.16	AIDS;	chr9:14455078	chr9:14317085~14357908:+
THCA	cis	rs9307551	0.901	rs6850999	ENSG00000249646.2	OR7E94P	-3.56	0.000403	0.0256	-0.22	-0.16	Refractive error;	chr4:79580784	chr4:79587302~79588130:-
THCA	cis	rs7829975	0.564	rs2976855	ENSG00000248538.5	RP11-10A14.5	-3.56	0.000403	0.0256	-0.2	-0.16	Mood instability;	chr8:8444284	chr8:9189011~9202854:+
THCA	cis	rs12497850	1	rs12493578	ENSG00000228638.1	FCF1P2	3.56	0.000403	0.0256	0.17	0.16	Parkinson's disease;	chr3:48692683	chr3:48290793~48291375:-
THCA	cis	rs9549260	0.755	rs3900833	ENSG00000168852.11	TPTE2P5	3.56	0.000403	0.0256	0.12	0.16	Red blood cell count;	chr13:40614155	chr13:40822296~40921749:-
THCA	cis	rs12701220	0.522	rs1881116	ENSG00000199023.2	MIR339	-3.56	0.000403	0.0256	-0.19	-0.16	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1022935~1023045:-
THCA	cis	rs853679	0.517	rs12332979	ENSG00000219891.2	ZSCAN12P1	3.56	0.000403	0.0256	0.23	0.16	Depression;	chr6:28173770	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000219891.2	ZSCAN12P1	3.56	0.000403	0.0256	0.23	0.16	Depression;	chr6:28174809	chr6:28091154~28093664:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000219891.2	ZSCAN12P1	3.56	0.000403	0.0256	0.23	0.16	Depression;	chr6:28175233	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000219891.2	ZSCAN12P1	3.56	0.000403	0.0256	0.23	0.16	Depression;	chr6:28176973	chr6:28091154~28093664:+
THCA	cis	rs13063635	0.831	rs13089855	ENSG00000226074.4	PRSS44	-3.56	0.000403	0.0256	-0.29	-0.16	Eosinophil percentage of granulocytes;	chr3:46010771	chr3:46809359~46812558:-
THCA	cis	rs12101261	0.744	rs2284727	ENSG00000258915.1	BHLHB9P1	-3.56	0.000403	0.0256	-0.2	-0.16	Graves' disease;	chr14:80988340	chr14:80981988~80983638:+
THCA	cis	rs10875746	0.903	rs58952582	ENSG00000258234.1	RP11-370I10.2	3.56	0.000403	0.0256	0.19	0.16	Longevity (90 years and older);	chr12:48064665	chr12:48231098~48284210:-
THCA	cis	rs2904524	1	rs17107933	ENSG00000257815.4	RP11-611E13.2	3.56	0.000403	0.0256	0.15	0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70283707	chr12:69904033~70243360:-
THCA	cis	rs6500395	0.609	rs8057605	ENSG00000260052.1	CTC-527H23.3	3.56	0.000403	0.0256	0.2	0.16	Response to tocilizumab in rheumatoid arthritis;	chr16:48531658	chr16:48637143~48638719:+
THCA	cis	rs6500395	0.588	rs6500393	ENSG00000260052.1	CTC-527H23.3	3.56	0.000403	0.0256	0.2	0.16	Response to tocilizumab in rheumatoid arthritis;	chr16:48534197	chr16:48637143~48638719:+
THCA	cis	rs9488822	0.676	rs11153594	ENSG00000233558.1	RP3-486I3.4	-3.56	0.000403	0.0256	-0.18	-0.16	LDL cholesterol;Cholesterol, total;	chr6:116033428	chr6:116258493~116259115:-
THCA	cis	rs881827	0.589	rs13052824	ENSG00000230982.1	DSTNP1	3.56	0.000403	0.0256	0.18	0.16	Lymphocyte counts;	chr21:46667413	chr21:46653558~46654022:-
THCA	cis	rs939960	0.959	rs34035483	ENSG00000276538.1	RP11-545G3.2	3.56	0.000403	0.0256	0.23	0.16	Neutrophil percentage of white cells;	chr7:150597126	chr7:150047609~150047854:-
THCA	cis	rs478304	0.654	rs12289836	ENSG00000214659.4	KRT8P26	-3.56	0.000403	0.0256	-0.16	-0.16	Acne (severe);	chr11:65669417	chr11:65726939~65728214:+
THCA	cis	rs5753618	0.583	rs5749279	ENSG00000214076.3	CPSF1P1	-3.56	0.000403	0.0256	-0.21	-0.16	Colorectal cancer;	chr22:31458223	chr22:32269381~32273110:+
THCA	cis	rs7709377	0.638	rs13163088	ENSG00000250015.1	CTC-339F2.2	-3.56	0.000403	0.0256	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:116187682	chr5:116302354~116304134:-
THCA	cis	rs7709377	0.68	rs9326997	ENSG00000250015.1	CTC-339F2.2	-3.56	0.000403	0.0256	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:116197329	chr5:116302354~116304134:-
THCA	cis	rs7709377	0.671	rs7449449	ENSG00000250015.1	CTC-339F2.2	-3.56	0.000403	0.0256	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:116197849	chr5:116302354~116304134:-
THCA	cis	rs2455826	0.834	rs2470530	ENSG00000270409.1	RP11-44D5.1	-3.56	0.000403	0.0256	-0.19	-0.16	Inflammatory skin disease;	chr3:15647251	chr3:15732252~15733470:+
THCA	cis	rs330048	0.525	rs10112237	ENSG00000254153.1	CTA-398F10.2	3.56	0.000403	0.0256	0.17	0.16	Systemic lupus erythematosus;	chr8:9215219	chr8:8456909~8461337:-
THCA	cis	rs6472235	0.803	rs9918852	ENSG00000272192.1	CTD-2532N20.1	3.56	0.000403	0.0256	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65989607	chr8:65842752~65843331:+
THCA	cis	rs1580019	0.563	rs896137	ENSG00000273014.1	RP11-225B17.2	3.56	0.000403	0.0256	0.16	0.16	Cognitive ability;	chr7:32539733	chr7:32758882~32759353:+
THCA	cis	rs1580019	0.523	rs9791770	ENSG00000273014.1	RP11-225B17.2	3.56	0.000403	0.0256	0.16	0.16	Cognitive ability;	chr7:32542640	chr7:32758882~32759353:+
THCA	cis	rs62289301	0.637	rs2192355	ENSG00000273133.1	RP11-799M12.2	3.56	0.000403	0.0256	0.2	0.16	Joint mobility (Beighton score);	chr4:15419055	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs7442554	ENSG00000273133.1	RP11-799M12.2	3.56	0.000403	0.0256	0.2	0.16	Joint mobility (Beighton score);	chr4:15419702	chr4:15563698~15564253:-
THCA	cis	rs12544026	0.617	rs6991592	ENSG00000253669.3	KB-1732A1.1	3.56	0.000403	0.0256	0.18	0.16	Major depression and alcohol dependence;	chr8:101833424	chr8:102805517~102809971:+
THCA	cis	rs801193	1	rs7782320	ENSG00000232546.1	RP11-458F8.1	-3.56	0.000403	0.0256	-0.13	-0.16	Aortic root size;	chr7:66712111	chr7:66848496~66858136:+
THCA	cis	rs9584850	0.834	rs7339274	ENSG00000231194.1	FARP1-AS1	-3.56	0.000403	0.0256	-0.2	-0.16	Neuroticism;	chr13:98468018	chr13:98435405~98435840:-
THCA	cis	rs10863936	0.667	rs61828530	ENSG00000198468.6	FLVCR1-AS1	-3.56	0.000403	0.0256	-0.19	-0.16	Height;	chr1:212003423	chr1:212852108~212858088:-
THCA	cis	rs10863936	0.667	rs55960291	ENSG00000198468.6	FLVCR1-AS1	-3.56	0.000403	0.0256	-0.19	-0.16	Height;	chr1:212004670	chr1:212852108~212858088:-
THCA	cis	rs10863936	0.667	rs61828533	ENSG00000198468.6	FLVCR1-AS1	-3.56	0.000403	0.0256	-0.19	-0.16	Height;	chr1:212013782	chr1:212852108~212858088:-
THCA	cis	rs6870983	0.749	rs10474271	ENSG00000247828.6	TMEM161B-AS1	3.56	0.000403	0.0256	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88158453	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs3936337	ENSG00000247828.6	TMEM161B-AS1	3.56	0.000403	0.0256	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88158570	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs10474272	ENSG00000247828.6	TMEM161B-AS1	3.56	0.000403	0.0256	0.15	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88158647	chr5:88268895~88436685:+
THCA	cis	rs8054556	0.74	rs12444978	ENSG00000273724.1	RP11-347C12.12	-3.56	0.000403	0.0256	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29913101	chr16:30336400~30343336:+
THCA	cis	rs2882667	0.931	rs10075951	ENSG00000249593.5	CTB-46B19.2	3.56	0.000403	0.0256	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:139012647~139051203:+
THCA	cis	rs1125355	0.69	rs62183662	ENSG00000243792.1	OR7E89P	-3.56	0.000403	0.0256	-0.23	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158785067	chr2:158853755~158854576:+
THCA	cis	rs7759001	0.744	rs13217162	ENSG00000271755.1	RP1-153G14.4	3.56	0.000403	0.0256	0.19	0.16	Glomerular filtration rate (creatinine);	chr6:27509320	chr6:27404010~27406964:-
THCA	cis	rs12499086	0.642	rs12646618	ENSG00000251175.4	RP11-45L9.1	3.56	0.000403	0.0256	0.2	0.16	Economic and political preferences (time);	chr4:105487789	chr4:105746245~105827172:-
THCA	cis	rs7819412	0.522	rs3021495	ENSG00000261451.1	RP11-981G7.1	-3.56	0.000403	0.0256	-0.22	-0.16	Triglycerides;	chr8:11137233	chr8:10433672~10438312:+
THCA	cis	rs1433188	0.847	rs1433185	ENSG00000253582.1	RP11-649G15.2	3.56	0.000404	0.0256	0.19	0.16	Subjective well-being;	chr8:107435407	chr8:106520474~106657548:-
THCA	cis	rs6687821	0.515	rs2040064	ENSG00000261737.1	RP4-612B15.3	3.56	0.000404	0.0256	0.24	0.16	Yeast infection;	chr1:87088226	chr1:86703502~86704462:-
THCA	cis	rs10421328	0.784	rs8107058	ENSG00000271283.1	CTC-412M14.6	3.56	0.000404	0.0256	0.23	0.16	Parental longevity (combined parental age at death);	chr19:19648842	chr19:19699203~19699409:-
THCA	cis	rs13064411	0.696	rs2399479	ENSG00000243849.1	CFAP44-AS1	3.56	0.000404	0.0256	0.25	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113508203	chr3:113403991~113433992:+
THCA	cis	rs10956805	0.544	rs2657197	ENSG00000246792.2	RP11-68L18.1	3.56	0.000404	0.0256	0.13	0.16	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);	chr8:91518892	chr8:90646441~90656598:+
THCA	cis	rs7828089	0.582	rs13282084	ENSG00000248738.5	RP11-87E22.2	-3.56	0.000404	0.0256	-0.18	-0.16	Verbal declarative memory;	chr8:22408767	chr8:22877972~22888022:+
THCA	cis	rs7828089	0.582	rs13259873	ENSG00000248738.5	RP11-87E22.2	-3.56	0.000404	0.0256	-0.18	-0.16	Verbal declarative memory;	chr8:22408779	chr8:22877972~22888022:+
THCA	cis	rs453301	0.522	rs1964356	ENSG00000254340.1	RP11-10A14.3	3.56	0.000404	0.0256	0.18	0.16	Joint mobility (Beighton score);	chr8:8995760	chr8:9141424~9145435:+
THCA	cis	rs8058578	1	rs7198250	ENSG00000260911.2	RP11-196G11.2	3.56	0.000404	0.0256	0.14	0.16	Multiple myeloma;	chr16:30735501	chr16:31043150~31049868:+
THCA	cis	rs8058578	1	rs6565201	ENSG00000260911.2	RP11-196G11.2	3.56	0.000404	0.0256	0.14	0.16	Multiple myeloma;	chr16:30735870	chr16:31043150~31049868:+
THCA	cis	rs972540	0.883	rs2884693	ENSG00000229647.1	AC007879.7	-3.56	0.000404	0.0256	-0.19	-0.16	Body mass index;	chr2:206368923	chr2:207239650~207245887:+
THCA	cis	rs2658782	0.547	rs2085334	ENSG00000234106.3	RP11-288E14.2	3.56	0.000404	0.0256	0.18	0.16	Pulmonary function decline;	chr11:93447884	chr11:93535468~93535816:+
THCA	cis	rs9425766	0.511	rs10912676	ENSG00000270084.1	GAS5-AS1	-3.56	0.000404	0.0256	-0.16	-0.16	Life satisfaction;	chr1:173740477	chr1:173863248~173863941:+
THCA	cis	rs4846580	1	rs1338227	ENSG00000230024.1	RP11-95P13.1	-3.56	0.000404	0.0256	-0.18	-0.16	Total body bone mineral density;	chr1:219680400	chr1:219435152~219442642:-
THCA	cis	rs2337406	0.641	rs10133227	ENSG00000211974.3	IGHV2-70	3.56	0.000404	0.0256	0.16	0.16	Alzheimer's disease (late onset);	chr14:106814260	chr14:106723574~106724093:-
THCA	cis	rs709400	0.859	rs7693	ENSG00000258735.1	LINC00637	3.56	0.000404	0.0256	0.22	0.16	Body mass index;	chr14:103557367	chr14:103847721~103858049:+
THCA	cis	rs12681366	0.843	rs3019156	ENSG00000253175.1	RP11-267M23.6	3.56	0.000404	0.0256	0.21	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94409552	chr8:94565036~94565715:+
THCA	cis	rs7111546	1	rs7105185	ENSG00000246225.5	RP11-17A1.3	3.56	0.000404	0.0256	0.3	0.16	Dialysis-related mortality;	chr11:22796040	chr11:22829380~22945393:+
THCA	cis	rs9513627	0.573	rs12431100	ENSG00000280710.1	RP11-214F16.8	-3.56	0.000404	0.0256	-0.2	-0.16	Obesity-related traits;	chr13:99532664	chr13:99498524~99501315:+
THCA	cis	rs6687821	0.515	rs7534355	ENSG00000261737.1	RP4-612B15.3	3.56	0.000404	0.0256	0.24	0.16	Yeast infection;	chr1:87015237	chr1:86703502~86704462:-
THCA	cis	rs17270561	0.583	rs7765833	ENSG00000272462.2	U91328.19	-3.56	0.000404	0.0256	-0.14	-0.16	Iron status biomarkers;	chr6:25712205	chr6:25992662~26001775:+
THCA	cis	rs2483519	0.547	rs882870	ENSG00000228169.3	PPIAP19	3.56	0.000404	0.0256	0.19	0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114693974	chr10:114690143~114690634:-
THCA	cis	rs7665090	1	rs4013	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000404	0.0256	-0.21	-0.16	Primary biliary cholangitis;	chr4:102631656	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.967	rs4019	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000404	0.0256	-0.21	-0.16	Primary biliary cholangitis;	chr4:102631673	chr4:102751401~102752641:+
THCA	cis	rs7731390	0.541	rs112385424	ENSG00000233006.5	AC034220.3	3.56	0.000404	0.0256	0.21	0.16	IgG glycosylation;	chr5:132243152	chr5:132311285~132369916:-
THCA	cis	rs12893668	0.663	rs12889731	ENSG00000258914.1	CTD-2134A5.3	-3.56	0.000404	0.0256	-0.2	-0.16	Reticulocyte count;	chr14:103621145	chr14:103875055~103877478:+
THCA	cis	rs2736345	0.755	rs2736340	ENSG00000269899.1	RP11-589N15.2	-3.56	0.000404	0.0256	-0.21	-0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:11846154~11846391:-
THCA	cis	rs72827839	0.793	rs72825512	ENSG00000278765.1	RP5-890E16.5	-3.56	0.000404	0.0256	-0.24	-0.16	Ease of getting up in the morning;	chr17:48077707	chr17:48066704~48067293:-
THCA	cis	rs10984970	0.826	rs62578018	ENSG00000226752.6	PSMD5-AS1	3.56	0.000404	0.0256	0.42	0.16	Lung cancer;	chr9:120697596	chr9:120824828~120854385:+
THCA	cis	rs858239	0.601	rs28673077	ENSG00000230042.1	AK3P3	-3.56	0.000404	0.0256	-0.22	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23129178~23129841:+
THCA	cis	rs7088591	0.764	rs59337109	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57965851	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs10509081	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57971997	chr10:57095699~57095781:+
THCA	cis	rs7088591	1	rs58619315	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57973160	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs16911437	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57973224	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs76589396	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57974018	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs61122499	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57975170	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs2110021	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57975612	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs114164759	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57977818	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs57336732	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57978365	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs75128250	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57978776	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.571	rs77372046	ENSG00000276818.1	AC026393.1	3.56	0.000404	0.0256	0.32	0.16	Blood pressure;	chr10:57979333	chr10:57095699~57095781:+
THCA	cis	rs10792665	0.604	rs7933350	ENSG00000279900.1	RP11-113K21.6	-3.56	0.000404	0.0256	-0.13	-0.16	Obesity-related traits;	chr11:82940951	chr11:83083687~83084138:+
THCA	cis	rs2227564	0.729	rs2227551	ENSG00000271816.1	BMS1P4	3.56	0.000404	0.0256	0.18	0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73909432	chr10:73699151~73730487:-
THCA	cis	rs266717	0.904	rs843991	ENSG00000234197.1	ETV5-AS1	-3.56	0.000404	0.0256	-0.13	-0.16	Adiponectin levels;	chr3:186798639	chr3:186079170~186080947:+
THCA	cis	rs9843304	0.624	rs13061914	ENSG00000243885.1	RP11-278L15.2	3.56	0.000404	0.0256	0.17	0.16	Gallstone disease;	chr3:149484345	chr3:149384179~149385800:-
THCA	cis	rs9843304	0.529	rs61382471	ENSG00000243885.1	RP11-278L15.2	3.56	0.000404	0.0256	0.17	0.16	Gallstone disease;	chr3:149484373	chr3:149384179~149385800:-
THCA	cis	rs12493885	0.725	rs11717851	ENSG00000243069.6	ARHGEF26-AS1	-3.56	0.000404	0.0256	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154023946	chr3:154024401~154121332:-
THCA	cis	rs1669338	0.507	rs4685609	ENSG00000271870.1	RP11-97C16.1	3.56	0.000404	0.0256	0.15	0.16	White matter integrity;	chr3:3160595	chr3:3152942~3153435:+
THCA	cis	rs8177876	0.584	rs13185	ENSG00000261838.4	RP11-303E16.6	-3.56	0.000404	0.0256	-0.25	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046036	chr16:81069854~81076598:+
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000184274.3	LINC00315	3.56	0.000404	0.0256	0.2	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45300245~45305257:-
THCA	cis	rs17095355	0.818	rs10509907	ENSG00000203876.8	ADD3-AS1	-3.56	0.000404	0.0256	-0.19	-0.16	Biliary atresia;	chr10:110021957	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.818	rs56367935	ENSG00000203876.8	ADD3-AS1	-3.56	0.000404	0.0256	-0.19	-0.16	Biliary atresia;	chr10:110023508	chr10:109940104~110008381:-
THCA	cis	rs657075	0.54	rs27438	ENSG00000224431.1	AC063976.7	-3.56	0.000404	0.0256	-0.15	-0.16	Rheumatoid arthritis;	chr5:132077562	chr5:132199456~132203487:+
THCA	cis	rs854765	0.583	rs4925130	ENSG00000281749.1	Y_RNA	3.56	0.000404	0.0256	0.21	0.16	Total body bone mineral density;	chr17:17904544	chr17:18001101~18001195:-
THCA	cis	rs11673344	0.526	rs55754546	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37552860	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.526	rs17244713	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37559938	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.526	rs17244769	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37562031	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.526	rs8111790	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37565861	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.526	rs55909413	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37578663	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.526	rs55865869	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37578683	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.502	rs17304703	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37582646	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.526	rs73033122	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37586006	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.526	rs2306201	ENSG00000229481.2	CTD-2554C21.3	-3.56	0.000404	0.0256	-0.15	-0.16	Obesity-related traits;	chr19:37586573	chr19:37829551~37832160:+
THCA	cis	rs2455799	0.613	rs4685260	ENSG00000270409.1	RP11-44D5.1	-3.56	0.000404	0.0256	-0.17	-0.16	Mean platelet volume;	chr3:15790910	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs13096622	ENSG00000270409.1	RP11-44D5.1	-3.56	0.000404	0.0256	-0.17	-0.16	Mean platelet volume;	chr3:15796149	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs13080234	ENSG00000270409.1	RP11-44D5.1	-3.56	0.000404	0.0256	-0.17	-0.16	Mean platelet volume;	chr3:15810985	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs11920540	ENSG00000270409.1	RP11-44D5.1	-3.56	0.000404	0.0256	-0.17	-0.16	Mean platelet volume;	chr3:15813101	chr3:15732252~15733470:+
THCA	cis	rs7131987	0.903	rs1035604	ENSG00000257599.1	OVCH1-AS1	-3.56	0.000404	0.0256	-0.2	-0.16	QT interval;	chr12:29240169	chr12:29389294~29487488:+
THCA	cis	rs17741873	0.836	rs12221230	ENSG00000271848.1	RP11-464F9.21	-3.56	0.000404	0.0256	-0.2	-0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73845214	chr10:73654039~73674719:+
THCA	cis	rs17741873	0.836	rs57771499	ENSG00000271848.1	RP11-464F9.21	-3.56	0.000404	0.0256	-0.2	-0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73845734	chr10:73654039~73674719:+
THCA	cis	rs4879656	0.797	rs10971389	ENSG00000225693.1	LAGE3P1	-3.56	0.000404	0.0256	-0.18	-0.16	Menopause (age at onset);	chr9:33081125	chr9:33019682~33020165:-
THCA	cis	rs397969	0.596	rs12453720	ENSG00000261033.1	RP11-209D14.2	3.56	0.000404	0.0256	0.23	0.16	Platelet count;	chr17:19991889	chr17:20008051~20009234:-
THCA	cis	rs11751172	0.651	rs12192817	ENSG00000271857.1	RP1-244F24.1	3.56	0.000404	0.0256	0.1	0.16	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45566644	chr6:45421079~45422005:-
THCA	cis	rs950169	0.763	rs35372971	ENSG00000188388.10	GOLGA6L3	3.56	0.000404	0.0256	0.22	0.16	Schizophrenia;	chr15:84387097	chr15:85240472~85247170:+
THCA	cis	rs6696239	0.84	rs10799445	ENSG00000227711.2	RP11-275O4.5	-3.56	0.000405	0.0256	-0.2	-0.16	Height;	chr1:227724182	chr1:227509028~227520477:-
THCA	cis	rs2880765	0.835	rs4536419	ENSG00000259407.1	RP11-158M2.3	-3.56	0.000405	0.0256	-0.16	-0.16	Coronary artery disease;	chr15:85496240	chr15:85744109~85750281:-
THCA	cis	rs1832871	0.643	rs9456282	ENSG00000213078.3	RP5-933K21.2	-3.56	0.000405	0.0256	-0.25	-0.16	Height;	chr6:158303711	chr6:157365990~157366923:-
THCA	cis	rs9611565	0.659	rs56364401	ENSG00000281538.1	RP4-669P10.20	3.56	0.000405	0.0256	0.18	0.16	Vitiligo;	chr22:41555239	chr22:42138060~42139726:+
THCA	cis	rs3784262	1	rs3204689	ENSG00000259250.1	RP11-50C13.1	3.56	0.000405	0.0256	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57954604	chr15:58587507~58591676:+
THCA	cis	rs6546886	0.912	rs11898903	ENSG00000235499.1	AC073046.25	3.56	0.000405	0.0256	0.16	0.16	Dialysis-related mortality;	chr2:74041007	chr2:73985132~73986343:+
THCA	cis	rs7296418	0.961	rs7957096	ENSG00000256092.2	RP13-942N8.1	3.56	0.000405	0.0256	0.12	0.16	Platelet count;	chr12:123060331	chr12:123363868~123366113:+
THCA	cis	rs755249	0.567	rs76111861	ENSG00000182109.6	RP11-69E11.4	3.56	0.000405	0.0256	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs72661965	ENSG00000182109.6	RP11-69E11.4	3.56	0.000405	0.0256	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39522280~39546187:-
THCA	cis	rs9307551	0.619	rs1899232	ENSG00000249646.2	OR7E94P	-3.56	0.000405	0.0257	-0.21	-0.16	Refractive error;	chr4:79501789	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.619	rs7684683	ENSG00000249646.2	OR7E94P	-3.56	0.000405	0.0257	-0.21	-0.16	Refractive error;	chr4:79501867	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.584	rs7663844	ENSG00000249646.2	OR7E94P	-3.56	0.000405	0.0257	-0.21	-0.16	Refractive error;	chr4:79502053	chr4:79587302~79588130:-
THCA	cis	rs6598955	0.724	rs12726972	ENSG00000236782.4	RP11-96L14.7	3.56	0.000405	0.0257	0.19	0.16	Obesity-related traits;	chr1:26313143	chr1:26169947~26171821:-
THCA	cis	rs250585	0.736	rs30015	ENSG00000260136.4	CTD-2270L9.4	3.56	0.000405	0.0257	0.12	0.16	Egg allergy;	chr16:23402453	chr16:23452758~23457606:+
THCA	cis	rs13113518	0.513	rs13132085	ENSG00000223305.1	RN7SKP30	-3.56	0.000405	0.0257	-0.21	-0.16	Height;	chr4:55593918	chr4:55540502~55540835:-
THCA	cis	rs2790216	1	rs1199101	ENSG00000183055.5	FAM133CP	3.56	0.000405	0.0257	0.25	0.16	Inflammatory bowel disease;	chr10:58188140	chr10:58715554~58716257:+
THCA	cis	rs34975555	0.803	rs13253463	ENSG00000253671.1	RP11-806O11.1	-3.56	0.000405	0.0257	-0.24	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17956916	chr8:17808941~17820868:+
THCA	cis	rs7873102	0.654	rs10114348	ENSG00000213839.4	TMX2P1	-3.56	0.000405	0.0257	-0.12	-0.16	Brain structure;	chr9:37960696	chr9:37885683~37886390:+
THCA	cis	rs2209875	0.549	rs3211707	ENSG00000265112.1	MIR3153	-3.56	0.000405	0.0257	-0.2	-0.16	Pelvic organ prolapse (moderate/severe);	chr9:89318219	chr9:89312225~89312306:+
THCA	cis	rs2228479	0.717	rs11644967	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000405	0.0257	-0.26	-0.16	Skin colour saturation;	chr16:89740206	chr16:89516797~89522217:+
THCA	cis	rs55692468	0.761	rs62180804	ENSG00000213197.3	AC012066.1	3.56	0.000405	0.0257	0.21	0.16	Intraocular pressure;	chr2:152502998	chr2:152389937~152390630:+
THCA	cis	rs7937890	0.505	rs4403769	ENSG00000251991.1	RNU7-49P	3.56	0.000405	0.0257	0.19	0.16	Mitochondrial DNA levels;	chr11:14428630	chr11:14478892~14478953:+
THCA	cis	rs481331	0.799	rs210270	ENSG00000215146.4	RP11-313J2.1	-3.56	0.000405	0.0257	-0.29	-0.16	Systemic juvenile idiopathic arthritis;	chr10:42505362	chr10:42331866~42367974:-
THCA	cis	rs76382185	0.61	rs7533697	ENSG00000233184.5	RP11-421L21.3	3.56	0.000405	0.0257	0.24	0.16	Lymphocyte counts;	chr1:101099679	chr1:101025878~101087268:+
THCA	cis	rs76382185	0.61	rs7531958	ENSG00000233184.5	RP11-421L21.3	3.56	0.000405	0.0257	0.24	0.16	Lymphocyte counts;	chr1:101103876	chr1:101025878~101087268:+
THCA	cis	rs4578769	0.765	rs55762801	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22807096	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs11662489	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22816959	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs1609463	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22824144	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs10432158	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22826406	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs10432159	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22826596	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.729	rs12456875	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22830208	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs67551099	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22831167	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs16972382	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22831403	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs12455548	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22831514	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs16972427	ENSG00000265939.1	UBE2CP2	-3.56	0.000405	0.0257	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22833393	chr18:22900486~22900995:-
THCA	cis	rs564148	0.507	rs543988	ENSG00000239670.1	RP4-803A2.2	3.56	0.000405	0.0257	0.21	0.16	Response to amphetamines;	chr1:33717407	chr1:32986952~32988233:+
THCA	cis	rs2797501	1	rs2386620	ENSG00000272764.1	RP11-318E3.9	3.56	0.000405	0.0257	0.24	0.16	Osteosarcoma;	chr10:5726530	chr10:5813985~5814441:+
THCA	cis	rs9425766	0.679	rs6667267	ENSG00000270084.1	GAS5-AS1	-3.56	0.000405	0.0257	-0.17	-0.16	Life satisfaction;	chr1:174243623	chr1:173863248~173863941:+
THCA	cis	rs3015497	0.616	rs3825571	ENSG00000270062.1	RP11-248J18.3	3.56	0.000405	0.0257	0.18	0.16	Mean platelet volume;	chr14:50585400	chr14:50723777~50724272:-
THCA	cis	rs9860428	0.526	rs9833991	ENSG00000240057.4	RP11-572M11.4	-3.56	0.000405	0.0257	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112933151	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.526	rs7615462	ENSG00000240057.4	RP11-572M11.4	-3.56	0.000405	0.0257	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112934306	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.526	rs9877631	ENSG00000240057.4	RP11-572M11.4	-3.56	0.000405	0.0257	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112936287	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.526	rs9823363	ENSG00000240057.4	RP11-572M11.4	-3.56	0.000405	0.0257	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112940231	chr3:113019532~113183301:+
THCA	cis	rs2839186	0.771	rs2280957	ENSG00000228137.1	AP001469.7	-3.56	0.000405	0.0257	-0.16	-0.16	Testicular germ cell tumor;	chr21:46222358	chr21:46246890~46247682:+
THCA	cis	rs1556032	0.542	rs10124636	ENSG00000225472.1	RP11-120J1.1	-3.56	0.000405	0.0257	-0.15	-0.16	AIDS;	chr9:14442531	chr9:14317085~14357908:+
THCA	cis	rs7737355	0.812	rs152789	ENSG00000224431.1	AC063976.7	3.56	0.000405	0.0257	0.15	0.16	Life satisfaction;	chr5:131690897	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.773	rs28852	ENSG00000224431.1	AC063976.7	3.56	0.000405	0.0257	0.15	0.16	Life satisfaction;	chr5:131692149	chr5:132199456~132203487:+
THCA	cis	rs8067545	0.967	rs1034904	ENSG00000270091.1	RP11-78O7.2	3.56	0.000405	0.0257	0.12	0.16	Schizophrenia;	chr17:20024386	chr17:19896590~19897287:-
THCA	cis	rs6570726	0.935	rs380883	ENSG00000270638.1	RP3-466P17.1	3.56	0.000405	0.0257	0.13	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145735570~145737218:+
THCA	cis	rs10090774	0.965	rs10087782	ENSG00000280303.2	ERICD	-3.56	0.000405	0.0257	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140848521	chr8:140636281~140638283:+
THCA	cis	rs34779708	0.931	rs4934700	ENSG00000233200.1	RP11-324I22.2	3.56	0.000405	0.0257	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35219894~35230598:-
THCA	cis	rs7949566	0.647	rs4502008	ENSG00000255062.1	RP11-712L6.5	-3.56	0.000405	0.0257	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr11:126417859	chr11:126294298~126304318:-
THCA	cis	rs6546886	0.869	rs7593050	ENSG00000235499.1	AC073046.25	3.56	0.000405	0.0257	0.16	0.16	Dialysis-related mortality;	chr2:74089287	chr2:73985132~73986343:+
THCA	cis	rs6504108	0.624	rs12947089	ENSG00000264920.1	RP11-6N17.4	-3.56	0.000405	0.0257	-0.14	-0.16	Body mass index;	chr17:48160628	chr17:47891255~47895812:-
THCA	cis	rs9393813	0.516	rs4713098	ENSG00000216915.2	RP1-97D16.1	3.56	0.000405	0.0257	0.21	0.16	Bipolar disorder;	chr6:27435826	chr6:27737000~27738494:-
THCA	cis	rs7246657	0.943	rs6508711	ENSG00000268499.1	CTB-102L5.8	3.56	0.000405	0.0257	0.21	0.16	Coronary artery calcification;	chr19:37324232	chr19:38199836~38200934:+
THCA	cis	rs1612141	0.744	rs1954447	ENSG00000251363.2	RP11-129M6.1	3.56	0.000405	0.0257	0.24	0.16	QT interval (drug interaction);	chr14:41126008	chr14:40954898~40975877:+
THCA	cis	rs7111546	1	rs11026798	ENSG00000246225.5	RP11-17A1.3	3.56	0.000406	0.0257	0.28	0.16	Dialysis-related mortality;	chr11:22801033	chr11:22829380~22945393:+
THCA	cis	rs7897654	0.571	rs7920697	ENSG00000213061.2	PFN1P11	3.56	0.000406	0.0257	0.21	0.16	Schizophrenia;	chr10:102873580	chr10:102838011~102845473:-
THCA	cis	rs11583043	0.546	rs12733135	ENSG00000233184.5	RP11-421L21.3	3.56	0.000406	0.0257	0.18	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101130427	chr1:101025878~101087268:+
THCA	cis	rs721917	0.586	rs2758550	ENSG00000272489.1	RP11-182L21.5	-3.56	0.000406	0.0257	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79663192~79664786:+
THCA	cis	rs9990333	0.521	rs3862281	ENSG00000185485.13	SDHAP1	3.56	0.000406	0.0257	0.15	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195959748~195990318:-
THCA	cis	rs9296092	0.56	rs17627049	ENSG00000272217.1	XXbac-BPG157A10.21	3.56	0.000406	0.0257	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33570025	chr6:33246075~33246856:-
THCA	cis	rs7911264	0.739	rs10736069	ENSG00000232709.1	MARK2P9	-3.56	0.000406	0.0257	-0.2	-0.16	Inflammatory bowel disease;	chr10:92635636	chr10:92418667~92420875:+
THCA	cis	rs7911264	0.739	rs7900689	ENSG00000232709.1	MARK2P9	-3.56	0.000406	0.0257	-0.2	-0.16	Inflammatory bowel disease;	chr10:92635991	chr10:92418667~92420875:+
THCA	cis	rs7911264	0.739	rs6583830	ENSG00000232709.1	MARK2P9	-3.56	0.000406	0.0257	-0.2	-0.16	Inflammatory bowel disease;	chr10:92638361	chr10:92418667~92420875:+
THCA	cis	rs4578769	0.55	rs9957690	ENSG00000273232.1	RP11-370A5.2	3.56	0.000406	0.0257	0.22	0.16	Eosinophil percentage of white cells;	chr18:22942697	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.55	rs12956837	ENSG00000273232.1	RP11-370A5.2	3.56	0.000406	0.0257	0.22	0.16	Eosinophil percentage of white cells;	chr18:22946865	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.55	rs9953479	ENSG00000273232.1	RP11-370A5.2	3.56	0.000406	0.0257	0.22	0.16	Eosinophil percentage of white cells;	chr18:22962644	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.55	rs12971230	ENSG00000273232.1	RP11-370A5.2	3.56	0.000406	0.0257	0.22	0.16	Eosinophil percentage of white cells;	chr18:22962987	chr18:22882825~22883357:-
THCA	cis	rs6674970	1	rs61819219	ENSG00000261168.1	RP11-68I18.10	-3.56	0.000406	0.0257	-0.21	-0.16	Childhood ear infection;	chr1:151111899	chr1:151130075~151131610:-
THCA	cis	rs7927592	0.913	rs12284933	ENSG00000160172.9	FAM86C2P	3.56	0.000406	0.0257	0.16	0.16	Total body bone mineral density;	chr11:68552021	chr11:67791648~67805336:-
THCA	cis	rs9450351	0.744	rs9362250	ENSG00000203875.9	SNHG5	-3.56	0.000406	0.0257	-0.32	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85867970	chr6:85660950~85678736:-
THCA	cis	rs4792901	0.765	rs3809751	ENSG00000279602.1	CTD-3014M21.1	-3.56	0.000406	0.0257	-0.21	-0.16	Dupuytren's disease;	chr17:43482417	chr17:43360041~43361361:-
THCA	cis	rs5769765	0.908	rs9616211	ENSG00000260613.1	RP3-522J7.6	-3.56	0.000406	0.0257	-0.21	-0.16	Schizophrenia;	chr22:49924028	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.817	rs9616212	ENSG00000260613.1	RP3-522J7.6	-3.56	0.000406	0.0257	-0.21	-0.16	Schizophrenia;	chr22:49924039	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.908	rs9616213	ENSG00000260613.1	RP3-522J7.6	-3.56	0.000406	0.0257	-0.21	-0.16	Schizophrenia;	chr22:49924203	chr22:49832616~49837786:-
THCA	cis	rs11190604	0.767	rs7078070	ENSG00000273030.1	RP11-285F16.1	3.56	0.000406	0.0257	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100406658	chr10:100412934~100413421:+
THCA	cis	rs925255	0.901	rs906805	ENSG00000270210.1	RP11-373D23.3	3.56	0.000406	0.0257	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr2:28382012	chr2:28425945~28426719:+
THCA	cis	rs2434529	0.911	rs2443525	ENSG00000245275.6	SAP30L-AS1	3.56	0.000406	0.0257	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154262876	chr5:154329437~154445850:-
THCA	cis	rs2434529	0.911	rs2431685	ENSG00000245275.6	SAP30L-AS1	3.56	0.000406	0.0257	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154262879	chr5:154329437~154445850:-
THCA	cis	rs2562456	0.833	rs4321312	ENSG00000268278.1	RP11-420K14.1	3.56	0.000406	0.0257	0.22	0.16	Pain;	chr19:21336614	chr19:21637974~21656300:+
THCA	cis	rs6101567	0.749	rs9636528	ENSG00000224635.1	RP4-564F22.5	-3.56	0.000406	0.0257	-0.2	-0.16	Nose size;	chr20:39293163	chr20:38406011~38416797:-
THCA	cis	rs17027633	1	rs17027633	ENSG00000260948.1	RP11-552M11.8	-3.56	0.000406	0.0257	-0.38	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111419634	chr1:111431046~111433068:-
THCA	cis	rs944289	0.774	rs12589124	ENSG00000257520.1	RP11-896J10.3	3.56	0.000406	0.0257	0.16	0.16	Thyroid cancer;	chr14:36094718	chr14:36473207~36519521:-
THCA	cis	rs944289	0.74	rs2183451	ENSG00000257520.1	RP11-896J10.3	3.56	0.000406	0.0257	0.16	0.16	Thyroid cancer;	chr14:36095227	chr14:36473207~36519521:-
THCA	cis	rs944289	0.774	rs884090	ENSG00000257520.1	RP11-896J10.3	3.56	0.000406	0.0257	0.16	0.16	Thyroid cancer;	chr14:36095741	chr14:36473207~36519521:-
THCA	cis	rs2562784	0.638	rs2099126	ENSG00000225151.9	GOLGA2P7	-3.56	0.000406	0.0257	-0.3	-0.16	Height;	chr15:83623472	chr15:84199311~84230136:-
THCA	cis	rs853679	1	rs853676	ENSG00000261839.1	RP1-265C24.8	3.56	0.000406	0.0257	0.22	0.16	Depression;	chr6:28331910	chr6:28136849~28139678:+
THCA	cis	rs6938	0.618	rs2044157	ENSG00000260269.4	CTD-2323K18.1	-3.56	0.000406	0.0257	-0.24	-0.16	Breast cancer;	chr15:74933467	chr15:75527150~75601205:-
THCA	cis	rs714027	0.585	rs41173	ENSG00000279699.1	RP1-102K2.9	-3.56	0.000406	0.0257	-0.17	-0.16	Lymphocyte counts;	chr22:30028874	chr22:30275215~30276951:-
THCA	cis	rs7142002	0.881	rs8022268	ENSG00000271780.1	RP11-1017G21.5	-3.56	0.000406	0.0257	-0.25	-0.16	Autism;	chr14:101933650	chr14:101948347~101949425:+
THCA	cis	rs2274273	0.84	rs11626751	ENSG00000258469.1	CHMP4BP1	3.56	0.000406	0.0257	0.15	0.16	Protein biomarker;	chr14:55368509	chr14:55298644~55299231:+
THCA	cis	rs9929218	0.581	rs12185157	ENSG00000260459.2	FTLP14	3.56	0.000406	0.0257	0.18	0.16	Colorectal cancer;	chr16:68750684	chr16:68822587~68823070:+
THCA	cis	rs16975963	0.843	rs60731897	ENSG00000276846.1	CTD-3220F14.3	-3.56	0.000406	0.0257	-0.15	-0.16	Longevity;	chr19:37778619	chr19:37314868~37315620:-
THCA	cis	rs7178909	0.872	rs3931863	ENSG00000259677.1	RP11-493E3.1	3.56	0.000406	0.0257	0.2	0.16	Common traits (Other);	chr15:89890681	chr15:89876540~89877285:+
THCA	cis	rs7178909	0.872	rs57715404	ENSG00000259677.1	RP11-493E3.1	3.56	0.000406	0.0257	0.2	0.16	Common traits (Other);	chr15:89890726	chr15:89876540~89877285:+
THCA	cis	rs4915077	1	rs4147302	ENSG00000230489.1	VAV3-AS1	3.56	0.000406	0.0257	0.26	0.16	Hypothyroidism;	chr1:107776767	chr1:107964443~107994607:+
THCA	cis	rs4245128	0.965	rs6589342	ENSG00000247416.2	RP11-629G13.1	3.56	0.000406	0.0257	0.16	0.16	Life satisfaction;	chr11:112922373	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.965	rs1374704	ENSG00000247416.2	RP11-629G13.1	3.56	0.000406	0.0257	0.16	0.16	Life satisfaction;	chr11:112923495	chr11:112959279~112963460:-
THCA	cis	rs4245128	0.965	rs4937858	ENSG00000247416.2	RP11-629G13.1	3.56	0.000406	0.0257	0.16	0.16	Life satisfaction;	chr11:112924065	chr11:112959279~112963460:-
THCA	cis	rs427943	0.52	rs2838778	ENSG00000237664.1	LINC00316	3.56	0.000406	0.0257	0.16	0.16	Body mass index;	chr21:45094903	chr21:45338590~45341990:-
THCA	cis	rs613391	0.826	rs639548	ENSG00000234840.1	LINC01239	-3.56	0.000406	0.0257	-0.19	-0.16	Quantitative traits;	chr9:22680268	chr9:22646200~22824213:+
THCA	cis	rs2243480	0.522	rs778717	ENSG00000230295.1	RP11-458F8.2	-3.56	0.000406	0.0257	-0.25	-0.16	Diabetic kidney disease;	chr7:66383164	chr7:66880708~66882981:+
THCA	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	3.56	0.000406	0.0257	0.14	0.16	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	3.56	0.000406	0.0257	0.14	0.16	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
THCA	cis	rs6433895	0.601	rs56096261	ENSG00000236153.1	AC104076.3	-3.56	0.000406	0.0257	-0.2	-0.16	Lymphocyte counts;	chr2:181174837	chr2:180979427~180980090:-
THCA	cis	rs1560104	0.576	rs7202727	ENSG00000260601.1	RP11-552C15.1	-3.56	0.000406	0.0257	-0.2	-0.16	Obesity-related traits;	chr16:12614087	chr16:12545482~12546684:+
THCA	cis	rs962856	0.693	rs2902005	ENSG00000236780.4	AC078941.1	3.56	0.000406	0.0257	0.21	0.16	Pancreatic cancer;	chr2:67395949	chr2:67123357~67215319:-
THCA	cis	rs3740713	0.669	rs34740438	ENSG00000256588.1	RP11-613F22.8	3.56	0.000406	0.0257	0.24	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr11:18507608~18508820:-
THCA	cis	rs3026101	0.624	rs1058400	ENSG00000234327.6	AC012146.7	-3.56	0.000406	0.0257	-0.13	-0.16	Body mass index;	chr17:5385474	chr17:5111468~5115004:+
THCA	cis	rs704	0.605	rs2071379	ENSG00000237575.4	PYY2	3.56	0.000406	0.0257	0.19	0.16	Osteoprotegerin levels;	chr17:28368811	chr17:28226563~28228065:+
THCA	cis	rs6012953	0.63	rs6512651	ENSG00000231715.1	COX6CP2	3.56	0.000406	0.0257	0.18	0.16	Vitiligo;	chr20:50503451	chr20:50479767~50479991:+
THCA	cis	rs1113500	0.614	rs61797342	ENSG00000226822.1	RP11-356N1.2	3.56	0.000406	0.0257	0.18	0.16	Growth-regulated protein alpha levels;	chr1:108065763	chr1:108071482~108074519:+
THCA	cis	rs200972	1	rs200972	ENSG00000220721.1	OR1F12	3.56	0.000406	0.0257	0.19	0.16	Urinary tract infection frequency;	chr6:27891059	chr6:28073316~28074233:+
THCA	cis	rs73222236	0.825	rs7644471	ENSG00000273486.1	RP11-731C17.2	3.56	0.000406	0.0257	0.15	0.16	Coronary artery disease;	chr3:136565719	chr3:136837338~136839021:-
THCA	cis	rs73222236	0.825	rs9834631	ENSG00000273486.1	RP11-731C17.2	3.56	0.000406	0.0257	0.15	0.16	Coronary artery disease;	chr3:136577757	chr3:136837338~136839021:-
THCA	cis	rs73222236	0.787	rs7621970	ENSG00000273486.1	RP11-731C17.2	3.56	0.000406	0.0257	0.15	0.16	Coronary artery disease;	chr3:136645500	chr3:136837338~136839021:-
THCA	cis	rs78487399	0.808	rs6728106	ENSG00000234936.1	AC010883.5	3.56	0.000407	0.0258	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43456746	chr2:43229573~43233394:+
THCA	cis	rs12440869	1	rs8028934	ENSG00000270964.1	RP11-502I4.3	3.56	0.000407	0.0258	0.14	0.16	Peak velocity of the mitral A-wave;	chr15:67370946	chr15:67541072~67542604:-
THCA	cis	rs5758511	0.68	rs5758662	ENSG00000270083.1	RP1-257I20.14	-3.56	0.000407	0.0258	-0.21	-0.16	Birth weight;	chr22:42232082	chr22:42089630~42090028:-
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000184274.3	LINC00315	-3.56	0.000407	0.0258	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45300245~45305257:-
THCA	cis	rs427943	0.75	rs9974232	ENSG00000223768.1	LINC00205	-3.56	0.000407	0.0258	-0.15	-0.16	Body mass index;	chr21:45197672	chr21:45293285~45297354:+
THCA	cis	rs7085104	0.572	rs284858	ENSG00000236937.2	PTGES3P4	-3.56	0.000407	0.0258	-0.2	-0.16	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102845595~102845950:+
THCA	cis	rs9635324	0.964	rs11633883	ENSG00000259536.4	RP11-111A22.1	3.56	0.000407	0.0258	0.21	0.16	Blood metabolite ratios;Blood metabolite levels;	chr15:40422202	chr15:40488041~40558019:+
THCA	cis	rs9400467	0.528	rs459403	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000407	0.0258	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111309203~111313517:+
THCA	cis	rs7520050	0.966	rs1768816	ENSG00000280836.1	AL355480.1	3.56	0.000407	0.0258	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45581219~45581321:-
THCA	cis	rs4588572	0.615	rs4143070	ENSG00000245556.2	SCAMP1-AS1	-3.56	0.000407	0.0258	-0.12	-0.16	Triglycerides;	chr5:78473271	chr5:78342365~78360507:-
THCA	cis	rs722599	0.639	rs12882676	ENSG00000279594.1	RP11-950C14.10	3.56	0.000407	0.0258	0.16	0.16	IgG glycosylation;	chr14:74805730	chr14:75011269~75012851:-
THCA	cis	rs11673344	0.504	rs4806407	ENSG00000233527.7	ZNF529-AS1	-3.56	0.000407	0.0258	-0.14	-0.16	Obesity-related traits;	chr19:37097849	chr19:36573070~36594708:+
THCA	cis	rs1371614	0.635	rs10175737	ENSG00000229122.1	AGBL5-IT1	-3.56	0.000407	0.0258	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916879	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.635	rs877273	ENSG00000229122.1	AGBL5-IT1	-3.56	0.000407	0.0258	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917154	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.577	rs877274	ENSG00000229122.1	AGBL5-IT1	-3.56	0.000407	0.0258	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917231	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.635	rs6706127	ENSG00000229122.1	AGBL5-IT1	-3.56	0.000407	0.0258	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917873	chr2:27061038~27061815:+
THCA	cis	rs1371614	0.635	rs9309558	ENSG00000229122.1	AGBL5-IT1	-3.56	0.000407	0.0258	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918636	chr2:27061038~27061815:+
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000264242.2	RP11-271K11.1	3.56	0.000407	0.0258	0.25	0.16	Body mass index;	chr17:30776148	chr17:30553697~30558962:+
THCA	cis	rs4785204	0.867	rs8043695	ENSG00000279356.1	RP11-429P3.8	-3.56	0.000407	0.0258	-0.3	-0.16	Esophageal cancer (squamous cell);	chr16:50019658	chr16:50072862~50074986:+
THCA	cis	rs4767841	0.775	rs203330	ENSG00000252886.1	RN7SKP197	-3.56	0.000407	0.0258	-0.16	-0.16	Urgency urinary incontinence;	chr12:119771954	chr12:119631090~119631386:-
THCA	cis	rs3755605	0.76	rs2302864	ENSG00000242578.1	RP11-469J4.3	3.56	0.000407	0.0258	0.18	0.16	Testicular germ cell tumor;	chr3:170064099	chr3:170410512~170418615:+
THCA	cis	rs11123170	0.542	rs28522253	ENSG00000274877.1	RP11-65I12.1	3.56	0.000407	0.0258	0.09	0.16	Renal function-related traits (BUN);	chr2:113209810	chr2:113237595~113240825:+
THCA	cis	rs9788682	1	rs7181245	ENSG00000261143.1	ADAMTS7P3	-3.56	0.000407	0.0258	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78522047	chr15:77976042~77993057:+
THCA	cis	rs34779708	0.931	rs10508815	ENSG00000233200.1	RP11-324I22.2	3.56	0.000407	0.0258	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35219894~35230598:-
THCA	cis	rs853679	0.882	rs4713139	ENSG00000261839.1	RP1-265C24.8	3.56	0.000407	0.0258	0.24	0.16	Depression;	chr6:28124907	chr6:28136849~28139678:+
THCA	cis	rs7772697	0.635	rs6902195	ENSG00000223701.3	RAET1E-AS1	-3.56	0.000407	0.0258	-0.23	-0.16	Diabetic retinopathy;	chr6:149087319	chr6:149884431~149919508:+
THCA	cis	rs988712	0.622	rs4922793	ENSG00000245573.6	BDNF-AS	-3.56	0.000407	0.0258	-0.16	-0.16	Obesity;	chr11:27707958	chr11:27506838~27698174:+
THCA	cis	rs1005277	0.563	rs2800550	ENSG00000120555.12	SEPT7P9	3.56	0.000407	0.0258	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38383069~38402916:-
THCA	cis	rs950169	1	rs11638394	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000407	0.0258	-0.18	-0.16	Schizophrenia;	chr15:84110176	chr15:84507885~84516814:-
THCA	cis	rs950169	1	rs35658069	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000407	0.0258	-0.18	-0.16	Schizophrenia;	chr15:84111394	chr15:84507885~84516814:-
THCA	cis	rs9300255	0.77	rs7980687	ENSG00000235423.7	RP11-282O18.3	-3.56	0.000407	0.0258	-0.18	-0.16	Neutrophil percentage of white cells;	chr12:123338164	chr12:123252030~123261483:-
THCA	cis	rs17301013	0.932	rs1653632	ENSG00000270084.1	GAS5-AS1	3.56	0.000407	0.0258	0.17	0.16	Systemic lupus erythematosus;	chr1:174786459	chr1:173863248~173863941:+
THCA	cis	rs4907240	0.961	rs6759099	ENSG00000230606.9	AC159540.1	3.56	0.000407	0.0258	0.18	0.16	Event-related brain oscillations;	chr2:96601523	chr2:97416165~97433527:-
THCA	cis	rs4907240	0.961	rs6749159	ENSG00000230606.9	AC159540.1	3.56	0.000407	0.0258	0.18	0.16	Event-related brain oscillations;	chr2:96601556	chr2:97416165~97433527:-
THCA	cis	rs4907240	0.961	rs62154845	ENSG00000230606.9	AC159540.1	3.56	0.000407	0.0258	0.18	0.16	Event-related brain oscillations;	chr2:96601907	chr2:97416165~97433527:-
THCA	cis	rs11633886	0.604	rs2413795	ENSG00000259200.1	RP11-718O11.1	-3.56	0.000407	0.0258	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45816532	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.604	rs8029233	ENSG00000259200.1	RP11-718O11.1	-3.56	0.000407	0.0258	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45817791	chr15:45705078~45931069:+
THCA	cis	rs7665090	1	rs7664828	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0258	-0.21	-0.16	Primary biliary cholangitis;	chr4:102630219	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.967	rs7690123	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0258	-0.21	-0.16	Primary biliary cholangitis;	chr4:102630602	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs7665659	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0258	-0.21	-0.16	Primary biliary cholangitis;	chr4:102630661	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs7665854	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0258	-0.21	-0.16	Primary biliary cholangitis;	chr4:102630752	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.846	rs7690700	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0258	-0.21	-0.16	Primary biliary cholangitis;	chr4:102630911	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs13112557	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0258	-0.21	-0.16	Primary biliary cholangitis;	chr4:102631096	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs12644381	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0258	-0.21	-0.16	Primary biliary cholangitis;	chr4:102631273	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs1054037	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0258	-0.21	-0.16	Primary biliary cholangitis;	chr4:102631552	chr4:102751401~102752641:+
THCA	cis	rs2108225	0.9	rs2051956	ENSG00000233705.5	SLC26A4-AS1	-3.56	0.000408	0.0258	-0.13	-0.16	Ulcerative colitis;	chr7:107800913	chr7:107653968~107662151:-
THCA	cis	rs76076331	0.838	rs6704744	ENSG00000271952.1	RP11-245G13.2	-3.56	0.000408	0.0258	-0.25	-0.16	Educational attainment (college completion);Educational attainment (years of education);	chr2:10840089	chr2:10878269~10885118:+
THCA	cis	rs76076331	0.838	rs6737620	ENSG00000271952.1	RP11-245G13.2	-3.56	0.000408	0.0258	-0.25	-0.16	Educational attainment (college completion);Educational attainment (years of education);	chr2:10840413	chr2:10878269~10885118:+
THCA	cis	rs12893668	0.703	rs34026011	ENSG00000258735.1	LINC00637	-3.56	0.000408	0.0258	-0.22	-0.16	Reticulocyte count;	chr14:103584546	chr14:103847721~103858049:+
THCA	cis	rs1411478	1	rs10753232	ENSG00000243155.1	RP11-46A10.5	-3.56	0.000408	0.0258	-0.18	-0.16	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180980990	chr1:180944042~180976482:-
THCA	cis	rs1371614	0.655	rs509047	ENSG00000229122.1	AGBL5-IT1	-3.56	0.000408	0.0258	-0.12	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26905661	chr2:27061038~27061815:+
THCA	cis	rs16918636	0.541	rs78075845	ENSG00000249867.4	RP11-115J23.1	-3.56	0.000408	0.0258	-0.24	-0.16	Menarche (age at onset);	chr11:29192615	chr11:28702615~29063821:+
THCA	cis	rs423955	0.957	rs841990	ENSG00000272866.1	RP11-12D24.10	-3.56	0.000408	0.0258	-0.22	-0.16	Platelet count;	chr9:4793254	chr9:5351796~5352410:-
THCA	cis	rs4869313	0.668	rs27397	ENSG00000247121.5	CTD-2260A17.2	3.56	0.000408	0.0258	0.12	0.16	Pediatric autoimmune diseases;	chr5:97004912	chr5:96814028~96935809:-
THCA	cis	rs12935418	0.733	rs11150329	ENSG00000278985.1	RP11-303E16.9	3.56	0.000408	0.0258	0.25	0.16	Mean corpuscular volume;	chr16:80945189	chr16:80982319~80984094:-
THCA	cis	rs12539814	1	rs10487628	ENSG00000244198.4	RP4-545C24.1	3.56	0.000408	0.0258	0.2	0.16	Diastolic blood pressure;	chr7:144467232	chr7:144194858~144280547:+
THCA	cis	rs853679	0.599	rs188015	ENSG00000272009.1	RP1-313I6.12	-3.56	0.000408	0.0258	-0.23	-0.16	Depression;	chr6:27909668	chr6:28078792~28081130:-
THCA	cis	rs11089937	0.626	rs2213161	ENSG00000215456.5	BCRP4	3.56	0.000408	0.0258	0.22	0.16	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22630061~22636153:+
THCA	cis	rs4568518	0.71	rs6966083	ENSG00000279048.1	RP11-511H23.2	3.56	0.000408	0.0258	0.1	0.16	Measles;	chr7:17976921	chr7:17940503~17942922:+
THCA	cis	rs7259376	0.936	rs6511344	ENSG00000270947.1	AC025811.3	3.56	0.000408	0.0258	0.17	0.16	Menopause (age at onset);	chr19:22352871	chr19:22455988~22456459:+
THCA	cis	rs2562456	0.833	rs4334427	ENSG00000268278.1	RP11-420K14.1	3.56	0.000408	0.0258	0.23	0.16	Pain;	chr19:21338090	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs4644962	ENSG00000268278.1	RP11-420K14.1	3.56	0.000408	0.0258	0.23	0.16	Pain;	chr19:21338125	chr19:21637974~21656300:+
THCA	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	3.56	0.000408	0.0258	0.34	0.16	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	3.56	0.000408	0.0258	0.34	0.16	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	3.56	0.000408	0.0258	0.34	0.16	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	3.56	0.000408	0.0258	0.34	0.16	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
THCA	cis	rs12621844	0.671	rs6545019	ENSG00000272663.1	RP11-191L17.1	3.56	0.000408	0.0258	0.16	0.16	Glycated hemoglobin levels;	chr2:48087663	chr2:48440043~48440597:-
THCA	cis	rs12379034	0.611	rs10119716	ENSG00000226752.6	PSMD5-AS1	3.56	0.000408	0.0258	0.21	0.16	Rheumatoid arthritis;	chr9:120410004	chr9:120824828~120854385:+
THCA	cis	rs6929812	0.665	rs6456786	ENSG00000216915.2	RP1-97D16.1	3.56	0.000408	0.0258	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27448052	chr6:27737000~27738494:-
THCA	cis	rs8062405	0.54	rs480400	ENSG00000261766.1	RP11-22P6.2	-3.56	0.000408	0.0258	-0.15	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28862166~28863340:-
THCA	cis	rs853679	0.607	rs200489	ENSG00000220721.1	OR1F12	3.56	0.000408	0.0258	0.28	0.16	Depression;	chr6:27830479	chr6:28073316~28074233:+
THCA	cis	rs11168187	0.514	rs12810252	ENSG00000280054.1	RP1-197B17.7	3.56	0.000408	0.0258	0.2	0.16	Vertical cup-disc ratio;	chr12:47568828	chr12:47728151~47730598:-
THCA	cis	rs11658311	1	rs7219568	ENSG00000232344.2	AC087163.2	3.56	0.000408	0.0258	0.21	0.16	Obsessive-compulsive symptoms;	chr17:17626292	chr17:18010643~18011822:+
THCA	cis	rs7394190	0.81	rs7394178	ENSG00000272140.2	RP11-574K11.29	-3.56	0.000408	0.0258	-0.16	-0.16	Incident atrial fibrillation;	chr10:73661822	chr10:73703735~73713581:-
THCA	cis	rs5753037	0.653	rs140102	ENSG00000279699.1	RP1-102K2.9	3.56	0.000408	0.0258	0.16	0.16	Type 1 diabetes;	chr22:29732454	chr22:30275215~30276951:-
THCA	cis	rs6847067	0.965	rs2218323	ENSG00000180769.7	WDFY3-AS2	3.56	0.000408	0.0258	0.12	0.16	Oropharynx cancer;	chr4:84705665	chr4:84965682~85011277:+
THCA	cis	rs1412115	0.501	rs10827289	ENSG00000233387.1	RP11-342D11.3	-3.56	0.000408	0.0258	-0.16	-0.16	Schizophrenia;	chr10:33802564	chr10:33096257~33116672:-
THCA	cis	rs2948294	0.566	rs13274039	ENSG00000254340.1	RP11-10A14.3	3.56	0.000408	0.0258	0.18	0.16	Red cell distribution width;	chr8:8254137	chr8:9141424~9145435:+
THCA	cis	rs861020	0.563	rs61820640	ENSG00000203706.7	SERTAD4-AS1	3.56	0.000408	0.0258	0.18	0.16	Orofacial clefts;	chr1:209867952	chr1:210231456~210234047:-
THCA	cis	rs354225	0.539	rs7582640	ENSG00000162997.14	PRORSD1P	-3.56	0.000408	0.0258	-0.2	-0.16	Schizophrenia;	chr2:54730636	chr2:55282319~55284522:+
THCA	cis	rs1062177	0.855	rs62395861	ENSG00000272112.1	CTB-113P19.5	3.56	0.000408	0.0258	0.14	0.16	Preschool internalizing problems;	chr5:151889709	chr5:151724831~151725356:-
THCA	cis	rs1062177	0.95	rs59580263	ENSG00000272112.1	CTB-113P19.5	3.56	0.000408	0.0258	0.14	0.16	Preschool internalizing problems;	chr5:151890016	chr5:151724831~151725356:-
THCA	cis	rs755249	0.727	rs2242500	ENSG00000228060.1	RP11-69E11.8	-3.56	0.000408	0.0258	-0.15	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39565160~39573203:+
THCA	cis	rs2066819	1	rs2695789	ENSG00000257303.1	RP11-977G19.11	3.56	0.000408	0.0258	0.24	0.16	Psoriasis vulgaris;	chr12:56300477	chr12:56300142~56314808:+
THCA	cis	rs2066819	1	rs773664	ENSG00000257303.1	RP11-977G19.11	3.56	0.000408	0.0258	0.24	0.16	Psoriasis vulgaris;	chr12:56308392	chr12:56300142~56314808:+
THCA	cis	rs2980439	0.87	rs2945230	ENSG00000233609.3	RP11-62H7.2	3.56	0.000408	0.0258	0.16	0.16	Neuroticism;	chr8:8252414	chr8:8961200~8979025:+
THCA	cis	rs2857078	0.654	rs9896789	ENSG00000267080.4	ASB16-AS1	-3.56	0.000408	0.0258	-0.14	-0.16	Red cell distribution width;Reticulocyte count;	chr17:44237199	chr17:44175973~44186717:-
THCA	cis	rs7818688	1	rs28477467	ENSG00000253528.2	RP11-347C18.4	-3.56	0.000408	0.0258	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95020677	chr8:94974573~94974853:-
THCA	cis	rs10435719	0.509	rs13248956	ENSG00000255495.1	AC145124.2	3.56	0.000408	0.0258	0.19	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932259	chr8:12194467~12196280:+
THCA	cis	rs10435719	0.528	rs13250020	ENSG00000255495.1	AC145124.2	3.56	0.000408	0.0258	0.19	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932260	chr8:12194467~12196280:+
THCA	cis	rs7818688	1	rs10113545	ENSG00000253528.2	RP11-347C18.4	-3.56	0.000408	0.0259	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017479	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs10098453	ENSG00000253528.2	RP11-347C18.4	3.56	0.000408	0.0259	0.26	0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017528	chr8:94974573~94974853:-
THCA	cis	rs11190604	0.767	rs10883479	ENSG00000273030.1	RP11-285F16.1	3.56	0.000408	0.0259	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100403103	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs10786590	ENSG00000273030.1	RP11-285F16.1	3.56	0.000408	0.0259	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100404847	chr10:100412934~100413421:+
THCA	cis	rs9536318	0.673	rs7984541	ENSG00000273784.3	RP11-78J21.7	3.56	0.000408	0.0259	0.21	0.16	Airflow obstruction;	chr13:52936594	chr13:52600042~52642542:+
THCA	cis	rs2288278	0.693	rs1553754	ENSG00000230148.7	HOXB-AS1	3.56	0.000409	0.0259	0.16	0.16	Hand grip strength;	chr17:48486345	chr17:48543551~48551250:+
THCA	cis	rs11039798	0.565	rs7118675	ENSG00000200090.1	Y_RNA	3.56	0.000409	0.0259	0.13	0.16	Axial length;	chr11:48510511	chr11:47726894~47726992:-
THCA	cis	rs11190604	0.767	rs4919458	ENSG00000273030.1	RP11-285F16.1	-3.56	0.000409	0.0259	-0.18	-0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100417971	chr10:100412934~100413421:+
THCA	cis	rs1864585	0.52	rs9650659	ENSG00000280294.1	RP11-177H2.1	3.56	0.000409	0.0259	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10810255	chr8:10856085~10859436:-
THCA	cis	rs1880529	1	rs1880529	ENSG00000206820.1	RNU1-138P	-3.56	0.000409	0.0259	-0.18	-0.16	White matter integrity (bipolar disorder risk interaction);	chr4:113458223	chr4:113420323~113420486:+
THCA	cis	rs2625529	0.689	rs12898868	ENSG00000260037.4	CTD-2524L6.3	3.56	0.000409	0.0259	0.2	0.16	Red blood cell count;	chr15:71820577	chr15:71818396~71823384:+
THCA	cis	rs916888	0.821	rs199512	ENSG00000260075.1	NSFP1	3.56	0.000409	0.0259	0.25	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46372855~46487141:+
THCA	cis	rs916888	0.821	rs199509	ENSG00000260075.1	NSFP1	3.56	0.000409	0.0259	0.25	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46372855~46487141:+
THCA	cis	rs916888	0.821	rs199507	ENSG00000260075.1	NSFP1	3.56	0.000409	0.0259	0.25	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46372855~46487141:+
THCA	cis	rs7508	0.511	rs371922	ENSG00000253671.1	RP11-806O11.1	-3.56	0.000409	0.0259	-0.2	-0.16	Atrial fibrillation;	chr8:18042494	chr8:17808941~17820868:+
THCA	cis	rs9393777	0.841	rs34332556	ENSG00000220721.1	OR1F12	3.56	0.000409	0.0259	0.32	0.16	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28073316~28074233:+
THCA	cis	rs2475553	0.52	rs62437129	ENSG00000213078.3	RP5-933K21.2	-3.56	0.000409	0.0259	-0.25	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:158234725	chr6:157365990~157366923:-
THCA	cis	rs62289301	0.637	rs62289285	ENSG00000273133.1	RP11-799M12.2	3.56	0.000409	0.0259	0.2	0.16	Joint mobility (Beighton score);	chr4:15405680	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs13114788	ENSG00000273133.1	RP11-799M12.2	3.56	0.000409	0.0259	0.2	0.16	Joint mobility (Beighton score);	chr4:15405952	chr4:15563698~15564253:-
THCA	cis	rs7246657	0.722	rs2927739	ENSG00000226686.6	LINC01535	3.56	0.000409	0.0259	0.24	0.16	Coronary artery calcification;	chr19:37658429	chr19:37251912~37265535:+
THCA	cis	rs7122539	0.646	rs543191	ENSG00000275484.1	CTC-1337H24.4	-3.56	0.000409	0.0259	-0.12	-0.16	HIV-1 susceptibility;	chr11:66816308	chr11:67374416~67374932:+
THCA	cis	rs116248771	0.549	rs9849301	ENSG00000240207.5	RP11-379F4.4	3.56	0.000409	0.0259	0.22	0.16	diarrhoeal disease at age 2;	chr3:158727071	chr3:158732263~158784070:+
THCA	cis	rs42648	0.819	rs2285399	ENSG00000225498.1	AC002064.5	3.56	0.000409	0.0259	0.17	0.16	Homocysteine levels;	chr7:90340564	chr7:90312496~90322592:+
THCA	cis	rs42648	0.755	rs1557650	ENSG00000225498.1	AC002064.5	3.56	0.000409	0.0259	0.17	0.16	Homocysteine levels;	chr7:90342242	chr7:90312496~90322592:+
THCA	cis	rs3733585	0.781	rs13103690	ENSG00000261490.1	RP11-448G15.3	-3.56	0.000409	0.0259	-0.1	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9971154	chr4:10068089~10073019:-
THCA	cis	rs1858037	0.867	rs55945621	ENSG00000252414.1	RNU6-100P	-3.56	0.000409	0.0259	-0.18	-0.16	Rheumatoid arthritis;	chr2:65388220	chr2:64578892~64578997:+
THCA	cis	rs2288884	0.505	rs2278415	ENSG00000260160.1	CTC-471J1.2	-3.56	0.000409	0.0259	-0.19	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964950	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.505	rs3764538	ENSG00000260160.1	CTC-471J1.2	-3.56	0.000409	0.0259	-0.19	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965334	chr19:52058490~52063703:-
THCA	cis	rs10875746	0.669	rs10875767	ENSG00000226413.2	OR8T1P	3.56	0.000409	0.0259	0.22	0.16	Longevity (90 years and older);	chr12:48205474	chr12:48442030~48442947:-
THCA	cis	rs7809950	0.817	rs34325395	ENSG00000272072.1	CTA-363E19.2	3.56	0.000409	0.0259	0.17	0.16	Coronary artery disease;	chr7:107473363	chr7:107192559~107193300:-
THCA	cis	rs757978	1	rs2074771	ENSG00000235351.1	AC114730.11	-3.56	0.000409	0.0259	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:241411529	chr2:241724615~241725693:-
THCA	cis	rs7147624	0.573	rs10148699	ENSG00000276116.2	FUT8-AS1	3.56	0.000409	0.0259	0.24	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65732944	chr14:65411170~65412690:-
THCA	cis	rs7147624	1	rs10083363	ENSG00000276116.2	FUT8-AS1	3.56	0.000409	0.0259	0.24	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65734050	chr14:65411170~65412690:-
THCA	cis	rs2019137	0.868	rs3748916	ENSG00000234997.1	AC016745.3	-3.56	0.000409	0.0259	-0.16	-0.16	Lymphocyte counts;	chr2:113226456	chr2:113424495~113425324:+
THCA	cis	rs471144	1	rs471144	ENSG00000237975.5	FLG-AS1	-3.56	0.000409	0.0259	-0.39	-0.16	Inflammatory skin disease;	chr1:152481779	chr1:152168125~152445456:+
THCA	cis	rs2243480	1	rs34702770	ENSG00000273024.4	INTS4P2	3.56	0.000409	0.0259	0.27	0.16	Diabetic kidney disease;	chr7:65879836	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs34637256	ENSG00000273024.4	INTS4P2	3.56	0.000409	0.0259	0.27	0.16	Diabetic kidney disease;	chr7:65895144	chr7:65647864~65715661:+
THCA	cis	rs42235	0.683	rs60814640	ENSG00000230927.2	TMBIM7P	3.56	0.000409	0.0259	0.2	0.16	Height;Hip circumference adjusted for BMI;	chr7:92657604	chr7:92412976~92439562:-
THCA	cis	rs1005277	0.522	rs1208767	ENSG00000120555.12	SEPT7P9	3.56	0.000409	0.0259	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38383069~38402916:-
THCA	cis	rs8058578	1	rs3747481	ENSG00000260911.2	RP11-196G11.2	3.56	0.000409	0.0259	0.14	0.16	Multiple myeloma;	chr16:30655046	chr16:31043150~31049868:+
THCA	cis	rs853679	0.517	rs9380056	ENSG00000219891.2	ZSCAN12P1	3.56	0.000409	0.0259	0.23	0.16	Depression;	chr6:28136698	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000219891.2	ZSCAN12P1	3.56	0.000409	0.0259	0.23	0.16	Depression;	chr6:28136856	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000219891.2	ZSCAN12P1	3.56	0.000409	0.0259	0.23	0.16	Depression;	chr6:28137418	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000219891.2	ZSCAN12P1	3.56	0.000409	0.0259	0.23	0.16	Depression;	chr6:28138363	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000219891.2	ZSCAN12P1	3.56	0.000409	0.0259	0.23	0.16	Parkinson's disease;	chr6:28138569	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000219891.2	ZSCAN12P1	3.56	0.000409	0.0259	0.23	0.16	Depression;	chr6:28138981	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000219891.2	ZSCAN12P1	3.56	0.000409	0.0259	0.23	0.16	Depression;	chr6:28139012	chr6:28091154~28093664:+
THCA	cis	rs6598541	0.926	rs3743263	ENSG00000278090.1	RP11-6O2.2	-3.56	0.000409	0.0259	-0.15	-0.16	Urate levels;	chr15:98739329	chr15:99028538~99031053:+
THCA	cis	rs9309473	0.95	rs6546854	ENSG00000273245.1	RP11-434P11.2	3.56	0.000409	0.0259	0.22	0.16	Metabolite levels;	chr2:73606907	chr2:73750256~73750786:-
THCA	cis	rs2729354	0.817	rs2649667	ENSG00000254602.1	AP000662.4	-3.56	0.000409	0.0259	-0.2	-0.16	Blood protein levels;	chr11:57503036	chr11:57638024~57652790:+
THCA	cis	rs2978263	0.567	rs4733499	ENSG00000254152.1	CTD-3107M8.2	3.56	0.000409	0.0259	0.21	0.16	Cognitive performance;	chr8:30551720	chr8:30349866~30350347:-
THCA	cis	rs9400467	0.528	rs455247	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111309203~111313517:+
THCA	cis	rs7760535	0.811	rs464401	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Metabolic traits;	chr6:111347804	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.509	rs463854	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.509	rs463853	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs456569	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs455335	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs465795	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs110732	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.592	rs462493	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.508	rs456871	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111309203~111313517:+
THCA	cis	rs7760535	0.811	rs455732	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Metabolic traits;	chr6:111374065	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs458486	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs455726	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000409	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111309203~111313517:+
THCA	cis	rs6546550	0.869	rs6712827	ENSG00000179818.12	PCBP1-AS1	-3.56	0.000409	0.0259	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69929408	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs6741449	ENSG00000179818.12	PCBP1-AS1	-3.56	0.000409	0.0259	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69929457	chr2:69962263~70103220:-
THCA	cis	rs7520050	0.933	rs6661163	ENSG00000280836.1	AL355480.1	3.56	0.000409	0.0259	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45789332	chr1:45581219~45581321:-
THCA	cis	rs12701220	0.655	rs34696066	ENSG00000225146.1	AC073957.15	3.56	0.000409	0.0259	0.21	0.16	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1029025~1043891:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000232546.1	RP11-458F8.1	-3.56	0.000409	0.0259	-0.13	-0.16	Aortic root size;	chr7:65931217	chr7:66848496~66858136:+
THCA	cis	rs642858	0.702	rs661063	ENSG00000234147.1	RP3-460G2.2	3.56	0.000409	0.0259	0.19	0.16	Type 2 diabetes;	chr6:139925184	chr6:140845958~140852924:-
THCA	cis	rs600231	0.683	rs588298	ENSG00000254614.2	AP003068.23	3.56	0.000409	0.0259	0.21	0.16	Bone mineral density;	chr11:65486103	chr11:65177606~65181834:-
THCA	cis	rs7707921	0.752	rs12108681	ENSG00000251374.1	RPS23P5	3.56	0.000409	0.0259	0.24	0.16	Breast cancer;	chr5:81982556	chr5:82265157~82265259:-
THCA	cis	rs11098699	0.614	rs1874204	ENSG00000273007.1	RP11-170N16.3	3.56	0.000409	0.0259	0.13	0.16	Mosquito bite size;	chr4:123350611	chr4:122881878~122884712:-
THCA	cis	rs6687821	0.515	rs10747335	ENSG00000261737.1	RP4-612B15.3	3.56	0.000409	0.0259	0.24	0.16	Yeast infection;	chr1:87006739	chr1:86703502~86704462:-
THCA	cis	rs7551222	0.75	rs898387	ENSG00000240219.1	RP11-430C7.5	-3.56	0.000409	0.0259	-0.17	-0.16	Schizophrenia;	chr1:204610245	chr1:204626775~204629712:+
THCA	cis	rs11992162	0.597	rs7824564	ENSG00000227888.4	FAM66A	-3.56	0.000409	0.0259	-0.21	-0.16	Monocyte count;	chr8:11922671	chr8:12362019~12388296:+
THCA	cis	rs1577917	1	rs4707239	ENSG00000220563.1	PKMP3	-3.56	0.000409	0.0259	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85900999	chr6:85659892~85660606:-
THCA	cis	rs1577917	1	rs1911552	ENSG00000220563.1	PKMP3	-3.56	0.000409	0.0259	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85928306	chr6:85659892~85660606:-
THCA	cis	rs1577917	1	rs2816821	ENSG00000220563.1	PKMP3	-3.56	0.000409	0.0259	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85947366	chr6:85659892~85660606:-
THCA	cis	rs10911363	0.592	rs10911354	ENSG00000232860.6	SMG7-AS1	-3.56	0.000409	0.0259	-0.12	-0.16	Systemic lupus erythematosus;	chr1:183520143	chr1:183460874~183472265:-
THCA	cis	rs829883	1	rs249819	ENSG00000227825.4	SLC9A7P1	3.56	0.000409	0.0259	0.14	0.16	Colorectal adenoma (advanced);	chr12:98503487	chr12:98453835~98457145:-
THCA	cis	rs1555322	0.53	rs2297789	ENSG00000269202.1	RP4-614O4.12	-3.56	0.00041	0.0259	-0.17	-0.16	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35201747~35203288:-
THCA	cis	rs10975370	0.527	rs459525	ENSG00000206147.5	RP11-106A1.2	3.56	0.00041	0.0259	0.19	0.16	Breast cancer;	chr9:6032924	chr9:6639139~6639604:+
THCA	cis	rs7045881	0.576	rs6475954	ENSG00000254396.1	RP11-56F10.3	3.56	0.00041	0.0259	0.2	0.16	Schizophrenia;	chr9:27048533	chr9:27102630~27104728:+
THCA	cis	rs7829975	0.777	rs560544	ENSG00000248538.5	RP11-10A14.5	3.56	0.00041	0.0259	0.2	0.16	Mood instability;	chr8:8779919	chr8:9189011~9202854:+
THCA	cis	rs853679	0.607	rs33932084	ENSG00000272009.1	RP1-313I6.12	-3.56	0.00041	0.0259	-0.29	-0.16	Depression;	chr6:28301047	chr6:28078792~28081130:-
THCA	cis	rs704	0.79	rs4795433	ENSG00000279532.1	CTB-96E2.6	3.56	0.00041	0.0259	0.19	0.16	Osteoprotegerin levels;	chr17:28389802	chr17:28373673~28374301:-
THCA	cis	rs56804039	0.573	rs11777722	ENSG00000253893.2	FAM85B	3.56	0.00041	0.0259	0.32	0.16	Cervical cancer;	chr8:8557785	chr8:8167819~8226614:-
THCA	cis	rs7577696	0.545	rs2300700	ENSG00000276517.1	AL133243.2	3.56	0.00041	0.0259	0.15	0.16	Inflammatory biomarkers;	chr2:31561922	chr2:32526504~32529507:+
THCA	cis	rs9487094	0.666	rs3778478	ENSG00000223537.2	RP5-919F19.5	-3.56	0.00041	0.0259	-0.16	-0.16	Height;	chr6:109470427	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.644	rs9791241	ENSG00000223537.2	RP5-919F19.5	-3.56	0.00041	0.0259	-0.16	-0.16	Height;	chr6:109470900	chr6:109487906~109506800:+
THCA	cis	rs72634501	0.517	rs6600289	ENSG00000182109.6	RP11-69E11.4	-3.56	0.00041	0.0259	-0.15	-0.16	HDL cholesterol;	chr1:39148140	chr1:39522280~39546187:-
THCA	cis	rs6137726	0.524	rs1203945	ENSG00000237396.1	LINC01384	3.56	0.00041	0.0259	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22616255	chr20:22587522~22607517:-
THCA	cis	rs12149074	1	rs12149074	ENSG00000260876.4	LINC01229	-3.56	0.00041	0.0259	-0.16	-0.16	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80071969	chr16:79676108~79807922:+
THCA	cis	rs2841277	0.708	rs10083374	ENSG00000258701.1	LINC00638	3.56	0.00041	0.0259	0.17	0.16	Rheumatoid arthritis;	chr14:104936657	chr14:104821201~104823718:+
THCA	cis	rs2841277	0.77	rs10149193	ENSG00000258701.1	LINC00638	3.56	0.00041	0.0259	0.17	0.16	Rheumatoid arthritis;	chr14:104937137	chr14:104821201~104823718:+
THCA	cis	rs2841277	0.646	rs3742935	ENSG00000258701.1	LINC00638	3.56	0.00041	0.0259	0.17	0.16	Rheumatoid arthritis;	chr14:104939262	chr14:104821201~104823718:+
THCA	cis	rs2841277	0.708	rs28454709	ENSG00000258701.1	LINC00638	3.56	0.00041	0.0259	0.17	0.16	Rheumatoid arthritis;	chr14:104939605	chr14:104821201~104823718:+
THCA	cis	rs2841277	0.708	rs11623422	ENSG00000258701.1	LINC00638	3.56	0.00041	0.0259	0.17	0.16	Rheumatoid arthritis;	chr14:104940694	chr14:104821201~104823718:+
THCA	cis	rs2841277	0.708	rs11851053	ENSG00000258701.1	LINC00638	3.56	0.00041	0.0259	0.17	0.16	Rheumatoid arthritis;	chr14:104940871	chr14:104821201~104823718:+
THCA	cis	rs7395662	0.853	rs35255233	ENSG00000200090.1	Y_RNA	-3.56	0.00041	0.0259	-0.11	-0.16	HDL cholesterol;	chr11:48421318	chr11:47726894~47726992:-
THCA	cis	rs17213965	0.561	rs9929522	ENSG00000207425.1	Y_RNA	-3.56	0.00041	0.0259	-0.2	-0.16	Waist-hip ratio;	chr16:15785903	chr16:14915457~14915556:-
THCA	cis	rs9400467	0.528	rs462432	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.00041	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111309203~111313517:+
THCA	cis	rs7760535	0.931	rs466923	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.00041	0.0259	-0.13	-0.16	Metabolic traits;	chr6:111341774	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs1623806	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.00041	0.0259	-0.13	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111309203~111313517:+
THCA	cis	rs860295	0.557	rs348196	ENSG00000203761.5	MSTO2P	-3.56	0.00041	0.0259	-0.13	-0.16	Body mass index;	chr1:155697170	chr1:155745829~155750137:+
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000264242.2	RP11-271K11.1	3.56	0.00041	0.0259	0.25	0.16	Body mass index;	chr17:30737900	chr17:30553697~30558962:+
THCA	cis	rs495337	0.76	rs624115	ENSG00000229222.1	KRT18P4	-3.56	0.00041	0.0259	-0.2	-0.16	Psoriasis;	chr20:49907091	chr20:49956745~49958032:+
THCA	cis	rs2236521	0.714	rs6062210	ENSG00000226332.2	RP11-157P1.4	3.56	0.00041	0.0259	0.13	0.16	Pelvic organ prolapse;	chr20:62315319	chr20:62305432~62306325:-
THCA	cis	rs860295	0.702	rs12040100	ENSG00000236675.1	MTX1P1	-3.56	0.00041	0.0259	-0.17	-0.16	Body mass index;	chr1:155642056	chr1:155230975~155234325:+
THCA	cis	rs72482608	0.865	rs10753820	ENSG00000271811.1	RP1-79C4.4	3.56	0.00041	0.0259	0.2	0.16	Emphysema imaging phenotypes;	chr1:170794495	chr1:170667381~170669425:+
THCA	cis	rs9532669	0.926	rs7331435	ENSG00000229473.2	RGS17P1	-3.56	0.00041	0.0259	-0.21	-0.16	Cervical cancer;	chr13:40862396	chr13:40992779~40993331:-
THCA	cis	rs7786877	0.587	rs56328569	ENSG00000224729.5	PCOLCE-AS1	-3.56	0.00041	0.0259	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr7:100604596	chr7:100589402~100604206:-
THCA	cis	rs9611565	0.512	rs4820444	ENSG00000237037.8	NDUFA6-AS1	-3.56	0.00041	0.0259	-0.15	-0.16	Vitiligo;	chr22:41806602	chr22:42090931~42137742:+
THCA	cis	rs2274273	0.773	rs10147765	ENSG00000258469.1	CHMP4BP1	3.56	0.00041	0.0259	0.15	0.16	Protein biomarker;	chr14:55361108	chr14:55298644~55299231:+
THCA	cis	rs200972	1	rs200972	ENSG00000261839.1	RP1-265C24.8	3.56	0.00041	0.026	0.16	0.16	Urinary tract infection frequency;	chr6:27891059	chr6:28136849~28139678:+
THCA	cis	rs467650	0.509	rs2545678	ENSG00000248489.1	CTD-2007H13.3	-3.56	0.00041	0.026	-0.14	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98664664	chr5:98929171~98995013:+
THCA	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-3.56	0.00041	0.026	-0.19	-0.16	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
THCA	cis	rs775227	0.574	rs13068107	ENSG00000243849.1	CFAP44-AS1	3.56	0.00041	0.026	0.3	0.16	Dental caries;	chr3:113310683	chr3:113403991~113433992:+
THCA	cis	rs708224	0.605	rs161977	ENSG00000277342.1	RP11-843B15.4	3.56	0.00041	0.026	0.21	0.16	Pancreatic cancer;	chr12:32268523	chr12:32109076~32109602:+
THCA	cis	rs7914558	0.902	rs3736922	ENSG00000213061.2	PFN1P11	-3.56	0.00041	0.026	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102838011~102845473:-
THCA	cis	rs847649	0.699	rs10242028	ENSG00000234715.1	CTB-107G13.1	-3.56	0.00041	0.026	-0.18	-0.16	Morning vs. evening chronotype;	chr7:102887338	chr7:103445207~103514007:+
THCA	cis	rs7188697	0.922	rs37034	ENSG00000276259.1	RP11-481J2.4	-3.56	0.00041	0.026	-0.11	-0.16	QT interval;	chr16:58517456	chr16:58522970~58523842:+
THCA	cis	rs7188697	0.922	rs37036	ENSG00000276259.1	RP11-481J2.4	-3.56	0.00041	0.026	-0.11	-0.16	QT interval;	chr16:58519444	chr16:58522970~58523842:+
THCA	cis	rs478304	0.654	rs7934036	ENSG00000214659.4	KRT8P26	3.56	0.000411	0.026	0.15	0.16	Acne (severe);	chr11:65683549	chr11:65726939~65728214:+
THCA	cis	rs12681366	0.839	rs3019278	ENSG00000253175.1	RP11-267M23.6	3.56	0.000411	0.026	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.839	rs2930964	ENSG00000253175.1	RP11-267M23.6	3.56	0.000411	0.026	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94565036~94565715:+
THCA	cis	rs6687821	0.515	rs12734749	ENSG00000261737.1	RP4-612B15.3	3.56	0.000411	0.026	0.24	0.16	Yeast infection;	chr1:86971063	chr1:86703502~86704462:-
THCA	cis	rs12493885	0.769	rs11718319	ENSG00000238755.3	RP11-23D24.2	-3.56	0.000411	0.026	-0.35	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059155	chr3:153384934~153980186:-
THCA	cis	rs12493885	0.697	rs11710478	ENSG00000238755.3	RP11-23D24.2	-3.56	0.000411	0.026	-0.35	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059248	chr3:153384934~153980186:-
THCA	cis	rs12493885	0.769	rs11710560	ENSG00000238755.3	RP11-23D24.2	-3.56	0.000411	0.026	-0.35	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059487	chr3:153384934~153980186:-
THCA	cis	rs939960	0.879	rs73474862	ENSG00000276538.1	RP11-545G3.2	3.56	0.000411	0.026	0.26	0.16	Neutrophil percentage of white cells;	chr7:150644467	chr7:150047609~150047854:-
THCA	cis	rs4460629	0.742	rs11581730	ENSG00000236675.1	MTX1P1	-3.56	0.000411	0.026	-0.15	-0.16	Serum magnesium levels;	chr1:155109682	chr1:155230975~155234325:+
THCA	cis	rs4460629	0.742	rs7548955	ENSG00000236675.1	MTX1P1	-3.56	0.000411	0.026	-0.15	-0.16	Serum magnesium levels;	chr1:155109822	chr1:155230975~155234325:+
THCA	cis	rs8177876	0.731	rs4889235	ENSG00000261061.1	RP11-303E16.2	3.56	0.000411	0.026	0.23	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81110033	chr16:81030770~81031485:+
THCA	cis	rs72765298	0.848	rs3780599	ENSG00000235332.2	RP11-366O20.5	3.56	0.000411	0.026	0.25	0.16	Pulse pressure;	chr9:125152155	chr9:125194649~125195821:-
THCA	cis	rs72765298	0.806	rs72767010	ENSG00000235332.2	RP11-366O20.5	3.56	0.000411	0.026	0.25	0.16	Pulse pressure;	chr9:125167111	chr9:125194649~125195821:-
THCA	cis	rs72765298	0.848	rs11788062	ENSG00000235332.2	RP11-366O20.5	3.56	0.000411	0.026	0.25	0.16	Pulse pressure;	chr9:125168100	chr9:125194649~125195821:-
THCA	cis	rs10967505	0.53	rs10967486	ENSG00000254396.1	RP11-56F10.3	-3.56	0.000411	0.026	-0.2	-0.16	Schizophrenia;	chr9:26714024	chr9:27102630~27104728:+
THCA	cis	rs11098699	0.732	rs2132077	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123319483	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs12510460	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123319782	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs12506890	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123319827	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs12510530	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123319924	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs4833894	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123320770	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs4833895	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123321062	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.732	rs4833897	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123321674	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs4833271	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123321776	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.732	rs11733133	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123321841	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.784	rs2132076	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123322305	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.75	rs2132075	ENSG00000273007.1	RP11-170N16.3	3.56	0.000411	0.026	0.13	0.16	Mosquito bite size;	chr4:123322332	chr4:122881878~122884712:-
THCA	cis	rs7129556	0.954	rs11823651	ENSG00000254459.1	RP11-91P24.7	3.56	0.000411	0.026	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77542834	chr11:77829654~77872262:-
THCA	cis	rs875971	1	rs12532998	ENSG00000272831.1	RP11-792A8.4	3.56	0.000411	0.026	0.1	0.16	Aortic root size;	chr7:66502472	chr7:66739829~66740385:-
THCA	cis	rs11658311	0.85	rs60149982	ENSG00000232344.2	AC087163.2	3.56	0.000411	0.026	0.22	0.16	Obsessive-compulsive symptoms;	chr17:17763926	chr17:18010643~18011822:+
THCA	cis	rs2067615	1	rs2067615	ENSG00000260329.1	RP11-412D9.4	3.56	0.000411	0.026	0.14	0.16	Heart rate;	chr12:106755644	chr12:106954029~106955497:-
THCA	cis	rs10760158	0.832	rs10818519	ENSG00000235865.2	GSN-AS1	3.56	0.000411	0.026	0.14	0.16	Pulse pressure;	chr9:121250657	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs4837825	ENSG00000235865.2	GSN-AS1	3.56	0.000411	0.026	0.14	0.16	Pulse pressure;	chr9:121253136	chr9:121280768~121285530:-
THCA	cis	rs7267979	1	rs2424704	ENSG00000276952.1	RP5-965G21.6	3.56	0.000411	0.026	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25284915~25285588:-
THCA	cis	rs3864261	0.887	rs155430	ENSG00000249085.1	CTD-2631K10.1	-3.56	0.000411	0.026	-0.25	-0.16	Discordance in emotional problems in monozygotic twins;	chr5:72825297	chr5:72794405~72816565:-
THCA	cis	rs1908814	0.516	rs11996277	ENSG00000270154.1	RP11-419I17.1	3.56	0.000411	0.026	0.21	0.16	Neuroticism;	chr8:11942522	chr8:12476462~12477122:+
THCA	cis	rs643506	0.874	rs663511	ENSG00000230911.1	PPIHP1	-3.56	0.000411	0.026	-0.22	-0.16	Breast cancer;	chr11:111839311	chr11:112029858~112030367:-
THCA	cis	rs9296092	0.538	rs62407564	ENSG00000272217.1	XXbac-BPG157A10.21	3.56	0.000411	0.026	0.18	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33566233	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.538	rs56199698	ENSG00000272217.1	XXbac-BPG157A10.21	3.56	0.000411	0.026	0.18	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33566728	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.517	rs11752179	ENSG00000272217.1	XXbac-BPG157A10.21	3.56	0.000411	0.026	0.18	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33566936	chr6:33246075~33246856:-
THCA	cis	rs683250	0.629	rs513468	ENSG00000254551.1	RP11-727A23.7	-3.56	0.000411	0.026	-0.2	-0.16	Subcortical brain region volumes;	chr11:83222507	chr11:83209431~83213379:-
THCA	cis	rs6517329	0.565	rs73374920	ENSG00000236830.5	CBR3-AS1	3.56	0.000411	0.026	0.15	0.16	Schizophrenia;	chr21:36170687	chr21:36131767~36175815:-
THCA	cis	rs540425	0.626	rs217377	ENSG00000279853.1	RP5-844F9.1	-3.56	0.000411	0.026	-0.21	-0.16	Schizophrenia;	chr7:44570253	chr7:44367140~44369292:-
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000261839.1	RP1-265C24.8	3.56	0.000411	0.026	0.15	0.16	Pubertal anthropometrics;	chr6:28420988	chr6:28136849~28139678:+
THCA	cis	rs17666538	1	rs59631161	ENSG00000254207.1	RP11-43A14.1	-3.56	0.000411	0.026	-0.38	-0.16	IgG glycosylation;	chr8:637808	chr8:725188~725877:-
THCA	cis	rs17666538	1	rs61064968	ENSG00000254207.1	RP11-43A14.1	-3.56	0.000411	0.026	-0.38	-0.16	IgG glycosylation;	chr8:637933	chr8:725188~725877:-
THCA	cis	rs17092148	0.636	rs17122844	ENSG00000269202.1	RP4-614O4.12	-3.56	0.000411	0.026	-0.17	-0.16	Neuroticism;	chr20:34864797	chr20:35201747~35203288:-
THCA	cis	rs17092148	0.579	rs62212082	ENSG00000269202.1	RP4-614O4.12	-3.56	0.000411	0.026	-0.17	-0.16	Neuroticism;	chr20:34866438	chr20:35201747~35203288:-
THCA	cis	rs911555	0.755	rs11627446	ENSG00000269940.1	RP11-73M18.7	3.56	0.000411	0.026	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103694560~103695170:+
THCA	cis	rs17023223	0.537	rs12097967	ENSG00000227056.2	RPL6P2	-3.56	0.000411	0.026	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119219314~119220096:-
THCA	cis	rs6500602	0.727	rs11644481	ENSG00000280063.1	RP11-295D4.3	3.56	0.000411	0.026	0.09	0.16	Schizophrenia;	chr16:4531001	chr16:4346694~4348648:-
THCA	cis	rs3758911	0.861	rs12287772	ENSG00000255353.1	RP11-382M14.1	-3.56	0.000411	0.026	-0.21	-0.16	Coronary artery disease;	chr11:107271121	chr11:107176286~107177530:+
THCA	cis	rs11992162	0.56	rs7846248	ENSG00000227888.4	FAM66A	3.56	0.000411	0.026	0.21	0.16	Monocyte count;	chr8:11936540	chr8:12362019~12388296:+
THCA	cis	rs1927790	0.727	rs7320065	ENSG00000247400.3	DNAJC3-AS1	-3.56	0.000411	0.026	-0.11	-0.16	Body mass index;	chr13:96285484	chr13:95648733~95676925:-
THCA	cis	rs57709857	0.957	rs10107763	ENSG00000272092.1	RP11-350N15.5	-3.56	0.000411	0.026	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38375220	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs55796824	ENSG00000272092.1	RP11-350N15.5	-3.56	0.000411	0.026	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38385610	chr8:38382364~38383461:+
THCA	cis	rs7577696	0.524	rs805831	ENSG00000276334.1	AL133243.1	3.56	0.000411	0.026	0.19	0.16	Inflammatory biomarkers;	chr2:32259159	chr2:32521927~32523547:+
THCA	cis	rs57709857	0.957	rs16887343	ENSG00000272092.1	RP11-350N15.5	-3.56	0.000411	0.026	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38368759	chr8:38382364~38383461:+
THCA	cis	rs7824557	0.564	rs13274106	ENSG00000261451.1	RP11-981G7.1	-3.56	0.000411	0.026	-0.2	-0.16	Retinal vascular caliber;	chr8:11376449	chr8:10433672~10438312:+
THCA	cis	rs346923	0.881	rs28833244	ENSG00000226950.5	DANCR	3.56	0.000411	0.026	0.18	0.16	Biochemical measures;	chr4:52453631	chr4:52712404~52720351:+
THCA	cis	rs7819412	0.594	rs60921132	ENSG00000254948.1	OR7E158P	3.56	0.000411	0.026	0.21	0.16	Triglycerides;	chr8:11107459	chr8:11919900~11920809:-
THCA	cis	rs11671005	0.61	rs11669345	ENSG00000252334.1	RNU6-1337P	3.56	0.000412	0.026	0.24	0.16	Mean platelet volume;	chr19:58550892	chr19:58483749~58483843:-
THCA	cis	rs11771526	0.551	rs1123868	ENSG00000272905.1	RP11-265E18.1	3.56	0.000412	0.026	0.19	0.16	Body mass index;	chr7:32212360	chr7:32845394~32846061:+
THCA	cis	rs11719291	0.504	rs34571182	ENSG00000229759.1	MRPS18AP1	-3.56	0.000412	0.026	-0.33	-0.16	Cognitive function;	chr3:49171624	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs11706189	ENSG00000229759.1	MRPS18AP1	-3.56	0.000412	0.026	-0.33	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49173400	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.967	rs1053438	ENSG00000228172.4	RP1-317E23.3	-3.56	0.000412	0.026	-0.13	-0.16	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25816749~25820797:-
THCA	cis	rs6499755	0.897	rs8046197	ENSG00000260135.5	RP11-212I21.2	-3.56	0.000412	0.026	-0.18	-0.16	Hypospadias;	chr16:55312100	chr16:55426797~55462297:-
THCA	cis	rs988712	0.921	rs2883039	ENSG00000245573.6	BDNF-AS	-3.56	0.000412	0.026	-0.15	-0.16	Obesity;	chr11:27552150	chr11:27506838~27698174:+
THCA	cis	rs741677	0.963	rs9907102	ENSG00000231784.7	DBIL5P	3.56	0.000412	0.026	0.18	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:561592	chr17:752660~755336:+
THCA	cis	rs7246657	0.943	rs2045908	ENSG00000268499.1	CTB-102L5.8	3.56	0.000412	0.026	0.21	0.16	Coronary artery calcification;	chr19:37488866	chr19:38199836~38200934:+
THCA	cis	rs7680126	0.597	rs78917351	ENSG00000261490.1	RP11-448G15.3	-3.56	0.000412	0.026	-0.13	-0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10206439	chr4:10068089~10073019:-
THCA	cis	rs7954584	0.635	rs7137218	ENSG00000274292.1	RP11-347I19.7	-3.56	0.000412	0.026	-0.12	-0.16	Mean corpuscular volume;	chr12:121904971	chr12:121800797~121803403:+
THCA	cis	rs9796	0.689	rs28497404	ENSG00000247556.5	OIP5-AS1	3.56	0.000412	0.026	0.13	0.16	Menopause (age at onset);	chr15:41157312	chr15:41283990~41309737:+
THCA	cis	rs7551222	0.716	rs4951083	ENSG00000240219.1	RP11-430C7.5	3.56	0.000412	0.026	0.17	0.16	Schizophrenia;	chr1:204613602	chr1:204626775~204629712:+
THCA	cis	rs9876781	0.967	rs2885509	ENSG00000199476.1	Y_RNA	3.56	0.000412	0.026	0.2	0.16	Longevity;	chr3:48376729	chr3:48288587~48288694:+
THCA	cis	rs4908768	0.539	rs1934138	ENSG00000270282.1	RP5-1115A15.2	3.56	0.000412	0.026	0.19	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8512653~8513021:+
THCA	cis	rs5769765	0.908	rs7410318	ENSG00000260613.1	RP3-522J7.6	-3.56	0.000412	0.026	-0.21	-0.16	Schizophrenia;	chr22:49923401	chr22:49832616~49837786:-
THCA	cis	rs1383484	0.798	rs12438269	ENSG00000259728.4	LINC00933	-3.56	0.000412	0.026	-0.21	-0.16	Height;	chr15:83833797	chr15:84570649~84580175:+
THCA	cis	rs2904967	0.929	rs673147	ENSG00000254614.2	AP003068.23	3.56	0.000412	0.026	0.31	0.16	Mean corpuscular volume;	chr11:65292956	chr11:65177606~65181834:-
THCA	cis	rs9878978	1	rs11716221	ENSG00000227588.2	CNTN4-AS2	3.56	0.000412	0.026	0.19	0.16	Blood pressure (smoking interaction);	chr3:2423054	chr3:2110409~2144241:-
THCA	cis	rs45544231	1	rs4290467	ENSG00000279344.1	RP11-44F14.7	3.56	0.000412	0.026	0.15	0.16	Restless legs syndrome;	chr16:52604847	chr16:53478957~53481550:-
THCA	cis	rs867371	1	rs1392976	ENSG00000278603.1	RP13-608F4.5	-3.56	0.000412	0.026	-0.21	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472203~82472426:+
THCA	cis	rs7911264	0.739	rs7914814	ENSG00000232709.1	MARK2P9	-3.56	0.000412	0.026	-0.2	-0.16	Inflammatory bowel disease;	chr10:92623193	chr10:92418667~92420875:+
THCA	cis	rs78153629	1	rs76994419	ENSG00000259330.1	INAFM2	-3.56	0.000412	0.026	-0.2	-0.16	Heschl's gyrus morphology;	chr15:40421951	chr15:40325216~40326715:+
THCA	cis	rs7192750	0.586	rs2335712	ENSG00000260886.1	TAT-AS1	-3.56	0.000412	0.026	-0.24	-0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71872694	chr16:71565789~71578187:+
THCA	cis	rs13108904	0.84	rs3915420	ENSG00000254094.1	AC078852.1	-3.56	0.000412	0.026	-0.19	-0.16	Obesity-related traits;	chr4:1266549	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.87	rs11727987	ENSG00000254094.1	AC078852.1	-3.56	0.000412	0.026	-0.19	-0.16	Obesity-related traits;	chr4:1267647	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.87	rs13115355	ENSG00000254094.1	AC078852.1	-3.56	0.000412	0.026	-0.19	-0.16	Obesity-related traits;	chr4:1267788	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.87	rs12506095	ENSG00000254094.1	AC078852.1	-3.56	0.000412	0.026	-0.19	-0.16	Obesity-related traits;	chr4:1268445	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.84	rs13149790	ENSG00000254094.1	AC078852.1	-3.56	0.000412	0.026	-0.19	-0.16	Obesity-related traits;	chr4:1268451	chr4:1356581~1358075:+
THCA	cis	rs7216064	1	rs8072225	ENSG00000278740.1	RP11-147L13.14	3.56	0.000412	0.026	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67916844	chr17:68188547~68189165:+
THCA	cis	rs9450351	0.744	rs35510369	ENSG00000203875.9	SNHG5	-3.56	0.000412	0.026	-0.32	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85556411	chr6:85660950~85678736:-
THCA	cis	rs11673344	0.542	rs826327	ENSG00000267260.1	CTD-2162K18.4	-3.56	0.000412	0.026	-0.19	-0.16	Obesity-related traits;	chr19:37004397	chr19:36773153~36777078:+
THCA	cis	rs2736340	0.539	rs11250138	ENSG00000254527.1	ENPP7P12	-3.56	0.000412	0.026	-0.21	-0.16	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465803	chr8:12205759~12206389:-
THCA	cis	rs910316	0.967	rs175505	ENSG00000259138.1	RP11-950C14.7	-3.56	0.000412	0.026	-0.14	-0.16	Height;	chr14:75062916	chr14:75127153~75136930:+
THCA	cis	rs9400467	0.528	rs456865	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000412	0.026	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.508	rs1676863	ENSG00000272356.1	RP5-1112D6.8	-3.56	0.000412	0.026	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111309203~111313517:+
THCA	cis	rs28510890	0.688	rs12593253	ENSG00000258676.4	RP11-386M24.3	3.56	0.000412	0.026	0.15	0.16	Lung cancer in ever smokers;	chr15:92587690	chr15:92580829~92600545:+
THCA	cis	rs479105	0.627	rs4766081	ENSG00000278356.1	RP11-372B4.3	3.56	0.000412	0.026	0.16	0.16	Gut microbiota (bacterial taxa);	chr12:3263824	chr12:2885819~2886329:+
THCA	cis	rs8131065	1	rs1569307	ENSG00000273199.1	AP000692.10	-3.56	0.000412	0.026	-0.26	-0.16	Iris color (L* coordinate);	chr21:36638352	chr21:36319792~36320670:-
THCA	cis	rs8131065	1	rs66716978	ENSG00000273199.1	AP000692.10	-3.56	0.000412	0.026	-0.26	-0.16	Iris color (L* coordinate);	chr21:36638803	chr21:36319792~36320670:-
THCA	cis	rs8131065	1	rs2835419	ENSG00000273199.1	AP000692.10	-3.56	0.000412	0.026	-0.26	-0.16	Iris color (L* coordinate);	chr21:36639050	chr21:36319792~36320670:-
THCA	cis	rs8131065	1	rs8127516	ENSG00000273199.1	AP000692.10	-3.56	0.000412	0.026	-0.26	-0.16	Iris color (L* coordinate);	chr21:36639265	chr21:36319792~36320670:-
THCA	cis	rs561341	0.609	rs2051810	ENSG00000214708.4	AC090616.2	-3.56	0.000412	0.026	-0.19	-0.16	Hip circumference adjusted for BMI;	chr17:31868822	chr17:32141226~32143135:-
THCA	cis	rs7246657	0.678	rs2972446	ENSG00000226686.6	LINC01535	3.56	0.000412	0.026	0.24	0.16	Coronary artery calcification;	chr19:37638992	chr19:37251912~37265535:+
THCA	cis	rs7131987	0.903	rs11050152	ENSG00000257599.1	OVCH1-AS1	-3.56	0.000412	0.026	-0.2	-0.16	QT interval;	chr12:29251491	chr12:29389294~29487488:+
THCA	cis	rs7829975	0.684	rs546603	ENSG00000253981.4	ALG1L13P	-3.56	0.000412	0.026	-0.15	-0.16	Mood instability;	chr8:8738328	chr8:8236003~8244667:-
THCA	cis	rs7713065	0.797	rs3846730	ENSG00000263597.1	MIR3936	-3.56	0.000412	0.0261	-0.2	-0.16	Lung function (FEV1/FVC);	chr5:132471088	chr5:132365490~132365599:-
THCA	cis	rs9291683	0.552	rs17187075	ENSG00000261490.1	RP11-448G15.3	3.56	0.000412	0.0261	0.1	0.16	Bone mineral density;	chr4:9988704	chr4:10068089~10073019:-
THCA	cis	rs354225	0.544	rs10183867	ENSG00000212175.1	SNORA12	-3.56	0.000412	0.0261	-0.2	-0.16	Schizophrenia;	chr2:54585585	chr2:55565703~55565850:+
THCA	cis	rs7560272	0.501	rs17350188	ENSG00000230002.2	ALMS1-IT1	3.56	0.000412	0.0261	0.19	0.16	Schizophrenia;	chr2:73737715	chr2:73456764~73459484:+
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000264242.2	RP11-271K11.1	3.56	0.000412	0.0261	0.25	0.16	Body mass index;	chr17:30778787	chr17:30553697~30558962:+
THCA	cis	rs12101261	0.813	rs60462373	ENSG00000259167.2	NMNAT1P1	3.56	0.000413	0.0261	0.2	0.16	Graves' disease;	chr14:81002311	chr14:81032529~81033404:+
THCA	cis	rs2455799	0.573	rs2455833	ENSG00000270409.1	RP11-44D5.1	-3.56	0.000413	0.0261	-0.17	-0.16	Mean platelet volume;	chr3:15711323	chr3:15732252~15733470:+
THCA	cis	rs478304	0.651	rs10896037	ENSG00000214659.4	KRT8P26	3.56	0.000413	0.0261	0.15	0.16	Acne (severe);	chr11:65735953	chr11:65726939~65728214:+
THCA	cis	rs4606360	1	rs4606360	ENSG00000270084.1	GAS5-AS1	-3.56	0.000413	0.0261	-0.16	-0.16	Subjective well-being;	chr1:173729868	chr1:173863248~173863941:+
THCA	cis	rs6449502	0.748	rs7730827	ENSG00000251279.1	CTC-436P18.1	-3.56	0.000413	0.0261	-0.25	-0.16	Mean platelet volume;	chr5:60813097	chr5:61162070~61232040:+
THCA	cis	rs11048434	0.518	rs17730331	ENSG00000256720.1	RP11-436I9.6	-3.56	0.000413	0.0261	-0.17	-0.16	Sjögren's syndrome;	chr12:9025836	chr12:9135084~9135591:+
THCA	cis	rs365302	1	rs294917	ENSG00000235086.1	FNDC1-IT1	3.56	0.000413	0.0261	0.23	0.16	Coronary heart disease;	chr6:159206045	chr6:159240786~159243329:+
THCA	cis	rs9894429	0.789	rs7213849	ENSG00000262049.1	RP13-1032I1.7	-3.56	0.000413	0.0261	-0.1	-0.16	Eye color traits;	chr17:81600584	chr17:81701324~81703300:-
THCA	cis	rs9894429	0.69	rs11869779	ENSG00000262049.1	RP13-1032I1.7	-3.56	0.000413	0.0261	-0.1	-0.16	Eye color traits;	chr17:81603041	chr17:81701324~81703300:-
THCA	cis	rs11098699	0.784	rs56129659	ENSG00000273007.1	RP11-170N16.3	3.56	0.000413	0.0261	0.13	0.16	Mosquito bite size;	chr4:123321171	chr4:122881878~122884712:-
THCA	cis	rs656900	0.715	rs673018	ENSG00000261229.4	MTHFS	3.56	0.000413	0.0261	0.17	0.16	Cerebrospinal P-tau181p levels;	chr15:79823005	chr15:79843547~79897285:-
THCA	cis	rs656900	0.715	rs673079	ENSG00000261229.4	MTHFS	3.56	0.000413	0.0261	0.17	0.16	Cerebrospinal P-tau181p levels;	chr15:79823064	chr15:79843547~79897285:-
THCA	cis	rs3825942	0.612	rs72745367	ENSG00000261801.4	LOXL1-AS1	3.56	0.000413	0.0261	0.2	0.16	Glaucoma (exfoliation);	chr15:73939725	chr15:73908071~73928248:-
THCA	cis	rs7937890	0.531	rs2575828	ENSG00000251991.1	RNU7-49P	3.56	0.000413	0.0261	0.19	0.16	Mitochondrial DNA levels;	chr11:14462646	chr11:14478892~14478953:+
THCA	cis	rs17622252	0.651	rs9466040	ENSG00000280989.1	LINC00581	3.56	0.000413	0.0261	0.28	0.16	Bipolar disorder;	chr6:21357058	chr6:21486061~21511895:-
THCA	cis	rs11678825	0.852	rs77520628	ENSG00000272663.1	RP11-191L17.1	-3.56	0.000413	0.0261	-0.23	-0.16	Reticulocyte fraction of red cells;	chr2:48436809	chr2:48440043~48440597:-
THCA	cis	rs17540621	0.744	rs116777406	ENSG00000228925.1	AC016722.4	-3.56	0.000413	0.0261	-0.28	-0.16	Response to statin therapy;	chr2:46969113	chr2:46899275~46908678:+
THCA	cis	rs6472235	0.656	rs72650541	ENSG00000272192.1	CTD-2532N20.1	3.56	0.000413	0.0261	0.17	0.16	Plateletcrit;Myopia (pathological);	chr8:65966056	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.656	rs62506593	ENSG00000272192.1	CTD-2532N20.1	3.56	0.000413	0.0261	0.17	0.16	Plateletcrit;Myopia (pathological);	chr8:65966114	chr8:65842752~65843331:+
THCA	cis	rs13113518	1	rs13132420	ENSG00000223305.1	RN7SKP30	-3.56	0.000413	0.0261	-0.2	-0.16	Height;	chr4:55526646	chr4:55540502~55540835:-
THCA	cis	rs634537	0.559	rs567453	ENSG00000229298.1	TUBB8P1	-3.56	0.000413	0.0261	-0.17	-0.16	Glioma;Non-glioblastoma glioma;Glioblastoma;	chr9:22021738	chr9:21811621~21812347:-
THCA	cis	rs17689437	0.957	rs7194242	ENSG00000260084.1	RP11-615I2.1	-3.56	0.000413	0.0261	-0.26	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68573838	chr16:68573782~68589512:-
THCA	cis	rs7520050	0.966	rs4073846	ENSG00000281133.1	AL355480.3	-3.56	0.000413	0.0261	-0.19	-0.16	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45580892~45580996:-
THCA	cis	rs7824557	0.527	rs2572448	ENSG00000255495.1	AC145124.2	-3.56	0.000413	0.0261	-0.18	-0.16	Retinal vascular caliber;	chr8:11381843	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.527	rs2572447	ENSG00000255495.1	AC145124.2	-3.56	0.000413	0.0261	-0.18	-0.16	Retinal vascular caliber;	chr8:11382001	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.527	rs2572446	ENSG00000255495.1	AC145124.2	-3.56	0.000413	0.0261	-0.18	-0.16	Retinal vascular caliber;	chr8:11382056	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.527	rs10109537	ENSG00000255495.1	AC145124.2	-3.56	0.000413	0.0261	-0.18	-0.16	Retinal vascular caliber;	chr8:11382131	chr8:12194467~12196280:+
THCA	cis	rs72819454	0.522	rs56275413	ENSG00000280693.1	SH3PXD2A-AS1	-3.56	0.000413	0.0261	-0.32	-0.16	Interleukin-9 levels;	chr10:103760666	chr10:103745966~103755423:+
THCA	cis	rs4767841	0.537	rs203352	ENSG00000252886.1	RN7SKP197	-3.56	0.000413	0.0261	-0.16	-0.16	Urgency urinary incontinence;	chr12:119794663	chr12:119631090~119631386:-
THCA	cis	rs889122	0.513	rs6511235	ENSG00000267289.1	CTD-2623N2.11	-3.56	0.000413	0.0261	-0.18	-0.16	Menarche (age at onset);	chr19:9901990	chr19:9834079~9835013:-
THCA	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	3.56	0.000413	0.0261	0.22	0.16	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
THCA	cis	rs9296095	0.747	rs12206050	ENSG00000197251.3	LINC00336	-3.56	0.000413	0.0261	-0.21	-0.16	Platelet count;	chr6:33596519	chr6:33586106~33593338:-
THCA	cis	rs1913185	0.787	rs2864794	ENSG00000261051.1	RP11-274H2.5	-3.56	0.000413	0.0261	-0.22	-0.16	Obesity-related traits;	chr3:146148583	chr3:146059585~146061679:-
THCA	cis	rs7188697	0.885	rs1646010	ENSG00000276259.1	RP11-481J2.4	-3.56	0.000413	0.0261	-0.11	-0.16	QT interval;	chr16:58515300	chr16:58522970~58523842:+
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000264242.2	RP11-271K11.1	3.56	0.000413	0.0261	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30553697~30558962:+
THCA	cis	rs7973683	0.541	rs57078519	ENSG00000269938.1	RP11-214K3.20	-3.56	0.000413	0.0261	-0.18	-0.16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123904237	chr12:123968023~123968579:-
THCA	cis	rs28437878	1	rs28437878	ENSG00000261143.1	ADAMTS7P3	-3.56	0.000413	0.0261	-0.24	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78515530	chr15:77976042~77993057:+
THCA	cis	rs7937890	0.559	rs2034480	ENSG00000251991.1	RNU7-49P	3.56	0.000413	0.0261	0.19	0.16	Mitochondrial DNA levels;	chr11:14445377	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.532	rs2256884	ENSG00000251991.1	RNU7-49P	3.56	0.000413	0.0261	0.19	0.16	Mitochondrial DNA levels;	chr11:14454856	chr11:14478892~14478953:+
THCA	cis	rs7737355	0.812	rs251015	ENSG00000224431.1	AC063976.7	3.56	0.000413	0.0261	0.15	0.16	Life satisfaction;	chr5:131693990	chr5:132199456~132203487:+
THCA	cis	rs12780845	1	rs7072634	ENSG00000229124.5	VIM-AS1	3.56	0.000413	0.0261	0.16	0.16	Homocysteine levels;	chr10:17198919	chr10:17214239~17229985:-
THCA	cis	rs4742903	0.87	rs10991172	ENSG00000270332.1	SMC2-AS1	3.56	0.000413	0.0261	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104213870	chr9:104080024~104093073:-
THCA	cis	rs7615952	0.932	rs7630077	ENSG00000272840.1	RP11-379B18.6	3.56	0.000413	0.0261	0.27	0.16	Blood pressure (smoking interaction);	chr3:125930833	chr3:125774714~125797953:+
THCA	cis	rs10090774	0.897	rs306950	ENSG00000280303.2	ERICD	3.56	0.000414	0.0261	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141005751	chr8:140636281~140638283:+
THCA	cis	rs6840360	1	rs6845944	ENSG00000270265.1	RP11-731D1.4	-3.56	0.000414	0.0261	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151683368	chr4:151333775~151353224:-
THCA	cis	rs2236231	0.55	rs12897715	ENSG00000259648.1	RP11-643G16.4	-3.56	0.000414	0.0261	-0.2	-0.16	Plasma kynurenine levels in major depressive disorder;	chr14:67593117	chr14:67614929~67616626:+
THCA	cis	rs11583043	0.708	rs11590358	ENSG00000233184.5	RP11-421L21.3	3.56	0.000414	0.0261	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101094658	chr1:101025878~101087268:+
THCA	cis	rs79478560	0.518	rs28528904	ENSG00000270061.1	RP11-214K3.19	-3.56	0.000414	0.0261	-0.2	-0.16	Lymphocyte counts;	chr12:123902619	chr12:123969990~123970344:-
THCA	cis	rs758324	0.679	rs17132144	ENSG00000224431.1	AC063976.7	-3.56	0.000414	0.0261	-0.24	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131958045	chr5:132199456~132203487:+
THCA	cis	rs345013	0.92	rs9811263	ENSG00000240032.1	RP11-274H2.3	3.56	0.000414	0.0261	0.25	0.16	Prostate cancer;	chr3:145266345	chr3:146066344~146069185:-
THCA	cis	rs12506899	0.932	rs13114289	ENSG00000221639.1	SNORA3	3.56	0.000414	0.0261	0.19	0.16	Tumor biomarkers;	chr4:73411643	chr4:73263960~73264084:+
THCA	cis	rs12506899	0.967	rs4621399	ENSG00000221639.1	SNORA3	3.56	0.000414	0.0261	0.19	0.16	Tumor biomarkers;	chr4:73414162	chr4:73263960~73264084:+
THCA	cis	rs12506899	0.932	rs1475934	ENSG00000221639.1	SNORA3	3.56	0.000414	0.0261	0.19	0.16	Tumor biomarkers;	chr4:73418565	chr4:73263960~73264084:+
THCA	cis	rs12506899	0.967	rs4076	ENSG00000221639.1	SNORA3	3.56	0.000414	0.0261	0.19	0.16	Tumor biomarkers;	chr4:73419835	chr4:73263960~73264084:+
THCA	cis	rs12506899	0.967	rs962005	ENSG00000221639.1	SNORA3	3.56	0.000414	0.0261	0.19	0.16	Tumor biomarkers;	chr4:73419850	chr4:73263960~73264084:+
THCA	cis	rs12506899	0.967	rs2236767	ENSG00000221639.1	SNORA3	3.56	0.000414	0.0261	0.19	0.16	Tumor biomarkers;	chr4:73420106	chr4:73263960~73264084:+
THCA	cis	rs1062177	1	rs892006	ENSG00000272112.1	CTB-113P19.5	3.56	0.000414	0.0261	0.14	0.16	Preschool internalizing problems;	chr5:151801329	chr5:151724831~151725356:-
THCA	cis	rs1005277	0.579	rs2504143	ENSG00000120555.12	SEPT7P9	3.56	0.000414	0.0261	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38383069~38402916:-
THCA	cis	rs34779708	0.801	rs12255409	ENSG00000233200.1	RP11-324I22.2	3.56	0.000414	0.0261	0.2	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35219894~35230598:-
THCA	cis	rs7246967	0.673	rs2361245	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22651728	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs2082445	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22651785	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs7250285	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22654306	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs66620859	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22654428	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs73020703	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22661537	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12980342	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22666555	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs3951784	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22669124	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs3951785	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22669126	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs7250608	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22670254	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs7250620	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22670324	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs4244915	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22671336	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs8104052	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22675002	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs75360744	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22675154	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12975767	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22680007	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.604	rs12975793	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22680042	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12979264	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22682332	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs34795935	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22682386	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs35335083	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22686790	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs8102172	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22687217	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs3853652	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22689111	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs3853653	ENSG00000198153.8	ZNF849P	-3.56	0.000414	0.0261	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22689130	chr19:22685167~22686732:+
THCA	cis	rs2638953	0.853	rs11049635	ENSG00000247934.4	RP11-967K21.1	-3.56	0.000414	0.0261	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28464293	chr12:28163298~28190738:-
THCA	cis	rs6662572	0.906	rs11590549	ENSG00000234329.1	RP11-767N6.2	-3.56	0.000414	0.0261	-0.18	-0.16	Blood protein levels;	chr1:45620657	chr1:45651039~45651826:-
THCA	cis	rs301901	0.828	rs56007618	ENSG00000250155.1	CTD-2353F22.1	3.56	0.000414	0.0261	0.16	0.16	Height;	chr5:37475788	chr5:36666214~36725195:-
THCA	cis	rs301901	0.828	rs55731764	ENSG00000250155.1	CTD-2353F22.1	3.56	0.000414	0.0261	0.16	0.16	Height;	chr5:37475789	chr5:36666214~36725195:-
THCA	cis	rs17074492	1	rs7317571	ENSG00000214182.5	PTMAP5	3.56	0.000414	0.0261	0.19	0.16	Sjögren's syndrome;	chr13:81606305	chr13:81689911~81691072:+
THCA	cis	rs17074492	1	rs73524128	ENSG00000214182.5	PTMAP5	3.56	0.000414	0.0261	0.19	0.16	Sjögren's syndrome;	chr13:81606328	chr13:81689911~81691072:+
THCA	cis	rs853679	0.546	rs200490	ENSG00000220721.1	OR1F12	3.56	0.000414	0.0261	0.28	0.16	Depression;	chr6:27829157	chr6:28073316~28074233:+
THCA	cis	rs6019512	0.846	rs2024596	ENSG00000227431.4	CSE1L-AS1	3.56	0.000414	0.0261	0.2	0.16	Intelligence (multi-trait analysis);	chr20:48901515	chr20:49040463~49046044:-
THCA	cis	rs9788682	0.948	rs34664138	ENSG00000261143.1	ADAMTS7P3	-3.56	0.000414	0.0261	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78539282	chr15:77976042~77993057:+
THCA	cis	rs9788682	1	rs34138960	ENSG00000261143.1	ADAMTS7P3	-3.56	0.000414	0.0261	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78539326	chr15:77976042~77993057:+
THCA	cis	rs2980439	0.557	rs2921056	ENSG00000253130.1	CTD-3023L14.2	-3.56	0.000414	0.0261	-0.17	-0.16	Neuroticism;	chr8:8461672	chr8:8561391~8569688:+
THCA	cis	rs7474896	1	rs2753878	ENSG00000276805.1	RP11-291L22.6	-3.56	0.000414	0.0261	-0.25	-0.16	Obesity (extreme);	chr10:37882576	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs2738223	ENSG00000276805.1	RP11-291L22.6	-3.56	0.000414	0.0261	-0.25	-0.16	Obesity (extreme);	chr10:37896970	chr10:38451030~38451785:+
THCA	cis	rs10833905	0.938	rs10766999	ENSG00000246225.5	RP11-17A1.3	-3.56	0.000414	0.0261	-0.24	-0.16	Sudden cardiac arrest;	chr11:23056757	chr11:22829380~22945393:+
THCA	cis	rs2446066	0.872	rs10876450	ENSG00000257379.1	RP11-793H13.8	-3.56	0.000414	0.0261	-0.23	-0.16	Red blood cell count;	chr12:53417250	chr12:53441741~53467528:+
THCA	cis	rs7259376	0.775	rs7257134	ENSG00000270947.1	AC025811.3	3.56	0.000414	0.0261	0.17	0.16	Menopause (age at onset);	chr19:22358055	chr19:22455988~22456459:+
THCA	cis	rs16975963	0.644	rs73035164	ENSG00000276846.1	CTD-3220F14.3	-3.56	0.000414	0.0261	-0.15	-0.16	Longevity;	chr19:37655819	chr19:37314868~37315620:-
THCA	cis	rs7308116	1	rs4390387	ENSG00000257951.1	RP11-554D14.4	3.56	0.000414	0.0261	0.19	0.16	Pelvic organ prolapse (moderate/severe);	chr12:107812430	chr12:107881242~107883382:+
THCA	cis	rs4906172	0.838	rs2619092	ENSG00000259230.1	CTD-2555C10.3	3.56	0.000414	0.0261	0.24	0.16	Menopause (age at onset);	chr14:101959638	chr14:102545254~102555826:+
THCA	cis	rs7927592	0.956	rs7104877	ENSG00000160172.9	FAM86C2P	-3.56	0.000414	0.0261	-0.16	-0.16	Total body bone mineral density;	chr11:68610134	chr11:67791648~67805336:-
THCA	cis	rs758324	0.773	rs4705901	ENSG00000224431.1	AC063976.7	3.56	0.000414	0.0261	0.15	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131811300	chr5:132199456~132203487:+
THCA	cis	rs758324	0.773	rs2404776	ENSG00000224431.1	AC063976.7	3.56	0.000414	0.0261	0.15	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131833244	chr5:132199456~132203487:+
THCA	cis	rs758324	0.853	rs1604082	ENSG00000224431.1	AC063976.7	3.56	0.000414	0.0261	0.15	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131841224	chr5:132199456~132203487:+
THCA	cis	rs7085104	0.572	rs284860	ENSG00000236937.2	PTGES3P4	-3.56	0.000414	0.0261	-0.21	-0.16	Immature fraction of reticulocytes;Schizophrenia;	chr10:102813206	chr10:102845595~102845950:+
THCA	cis	rs8070740	0.503	rs10792	ENSG00000234327.6	AC012146.7	-3.56	0.000414	0.0261	-0.14	-0.16	Menopause (age at onset);	chr17:5384859	chr17:5111468~5115004:+
THCA	cis	rs6545883	0.931	rs12713437	ENSG00000212978.6	AC016747.3	3.56	0.000414	0.0261	0.18	0.16	Tuberculosis;	chr2:61495769	chr2:61141592~61144969:-
THCA	cis	rs2726040	0.902	rs33957528	ENSG00000261766.1	RP11-22P6.2	3.56	0.000414	0.0261	0.14	0.16	Hip circumference;	chr16:28296619	chr16:28862166~28863340:-
THCA	cis	rs9788721	0.934	rs1051730	ENSG00000261762.1	RP11-650L12.2	-3.56	0.000414	0.0262	-0.22	-0.16	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78601997	chr15:78589123~78591276:-
THCA	cis	rs9863	0.861	rs4405410	ENSG00000269938.1	RP11-214K3.20	-3.56	0.000414	0.0262	-0.19	-0.16	White blood cell count;	chr12:123951241	chr12:123968023~123968579:-
THCA	cis	rs7308116	0.53	rs11113571	ENSG00000257951.1	RP11-554D14.4	-3.56	0.000414	0.0262	-0.2	-0.16	Pelvic organ prolapse (moderate/severe);	chr12:107889079	chr12:107881242~107883382:+
THCA	cis	rs1005277	0.522	rs289645	ENSG00000120555.12	SEPT7P9	3.56	0.000414	0.0262	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:38383069~38402916:-
THCA	cis	rs9487094	0.6	rs3799842	ENSG00000223537.2	RP5-919F19.5	-3.56	0.000414	0.0262	-0.16	-0.16	Height;	chr6:109471826	chr6:109487906~109506800:+
THCA	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	3.56	0.000414	0.0262	0.19	0.16	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	3.56	0.000414	0.0262	0.19	0.16	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
THCA	cis	rs4919087	0.81	rs10786321	ENSG00000237169.1	RP11-452K12.3	-3.56	0.000414	0.0262	-0.2	-0.16	Monocyte count;	chr10:97266355	chr10:97309138~97309958:-
THCA	cis	rs354225	0.544	rs12713268	ENSG00000212175.1	SNORA12	3.56	0.000414	0.0262	0.2	0.16	Schizophrenia;	chr2:54581708	chr2:55565703~55565850:+
THCA	cis	rs6674970	0.777	rs11204782	ENSG00000261168.1	RP11-68I18.10	3.56	0.000414	0.0262	0.23	0.16	Childhood ear infection;	chr1:151145559	chr1:151130075~151131610:-
THCA	cis	rs6674970	0.777	rs12087892	ENSG00000261168.1	RP11-68I18.10	3.56	0.000414	0.0262	0.23	0.16	Childhood ear infection;	chr1:151146024	chr1:151130075~151131610:-
THCA	cis	rs34779708	0.931	rs7923172	ENSG00000233200.1	RP11-324I22.2	3.56	0.000414	0.0262	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35219894~35230598:-
THCA	cis	rs6812193	1	rs28628748	ENSG00000234036.4	TXNP6	3.56	0.000414	0.0262	0.23	0.16	Parkinson's disease;	chr4:76278760	chr4:76958860~76959169:-
THCA	cis	rs1864585	0.52	rs73208782	ENSG00000280294.1	RP11-177H2.1	3.56	0.000414	0.0262	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10820045	chr8:10856085~10859436:-
THCA	cis	rs11168618	0.846	rs11168599	ENSG00000240399.1	RP1-228P16.1	3.56	0.000414	0.0262	0.16	0.16	Adiponectin levels;	chr12:48486168	chr12:48054813~48055591:-
THCA	cis	rs1005277	0.579	rs2474584	ENSG00000151963.4	RP11-775A3.1	-3.56	0.000414	0.0262	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474586	ENSG00000151963.4	RP11-775A3.1	-3.56	0.000414	0.0262	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:37883594~37884109:+
THCA	cis	rs11686241	0.938	rs284550	ENSG00000232485.2	AC098820.3	3.56	0.000414	0.0262	0.18	0.16	Cancer;	chr2:216446907	chr2:216479030~216498761:-
THCA	cis	rs7089973	0.668	rs7077148	ENSG00000228169.3	PPIAP19	3.56	0.000414	0.0262	0.19	0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114885137	chr10:114690143~114690634:-
THCA	cis	rs7122539	0.646	rs627330	ENSG00000275484.1	CTC-1337H24.4	-3.56	0.000414	0.0262	-0.12	-0.16	HIV-1 susceptibility;	chr11:66834628	chr11:67374416~67374932:+
THCA	cis	rs6920965	0.507	rs9385389	ENSG00000226409.1	RP11-735G4.1	-3.56	0.000414	0.0262	-0.2	-0.16	High light scatter reticulocyte count;	chr6:125894340	chr6:125370211~125374324:-
THCA	cis	rs7727544	0.582	rs10052046	ENSG00000263597.1	MIR3936	3.56	0.000414	0.0262	0.15	0.16	Blood metabolite levels;	chr5:132208773	chr5:132365490~132365599:-
THCA	cis	rs7119	0.623	rs12905318	ENSG00000260776.4	RP11-114H24.2	-3.56	0.000414	0.0262	-0.22	-0.16	Type 2 diabetes;	chr15:77553531	chr15:77914217~77926846:-
THCA	cis	rs7119	0.651	rs12904200	ENSG00000260776.4	RP11-114H24.2	-3.56	0.000414	0.0262	-0.22	-0.16	Type 2 diabetes;	chr15:77553560	chr15:77914217~77926846:-
THCA	cis	rs7119	0.651	rs12904208	ENSG00000260776.4	RP11-114H24.2	-3.56	0.000414	0.0262	-0.22	-0.16	Type 2 diabetes;	chr15:77553569	chr15:77914217~77926846:-
THCA	cis	rs7119	0.651	rs12905044	ENSG00000260776.4	RP11-114H24.2	-3.56	0.000414	0.0262	-0.22	-0.16	Type 2 diabetes;	chr15:77553873	chr15:77914217~77926846:-
THCA	cis	rs7119	0.623	rs11637932	ENSG00000260776.4	RP11-114H24.2	-3.56	0.000414	0.0262	-0.22	-0.16	Type 2 diabetes;	chr15:77555011	chr15:77914217~77926846:-
THCA	cis	rs7119	0.651	rs12915057	ENSG00000260776.4	RP11-114H24.2	-3.56	0.000414	0.0262	-0.22	-0.16	Type 2 diabetes;	chr15:77555403	chr15:77914217~77926846:-
THCA	cis	rs7119	0.651	rs35657172	ENSG00000260776.4	RP11-114H24.2	-3.56	0.000414	0.0262	-0.22	-0.16	Type 2 diabetes;	chr15:77555471	chr15:77914217~77926846:-
THCA	cis	rs7119	0.651	rs34607443	ENSG00000260776.4	RP11-114H24.2	-3.56	0.000414	0.0262	-0.22	-0.16	Type 2 diabetes;	chr15:77555550	chr15:77914217~77926846:-
THCA	cis	rs73193808	0.614	rs11088112	ENSG00000231125.2	AF129075.5	-3.56	0.000414	0.0262	-0.16	-0.16	Coronary artery disease;	chr21:29193915	chr21:29058073~29060095:-
THCA	cis	rs988712	0.622	rs10767664	ENSG00000245573.6	BDNF-AS	3.56	0.000415	0.0262	0.16	0.16	Obesity;	chr11:27704439	chr11:27506838~27698174:+
THCA	cis	rs988712	0.622	rs2030323	ENSG00000245573.6	BDNF-AS	3.56	0.000415	0.0262	0.16	0.16	Obesity;	chr11:27706992	chr11:27506838~27698174:+
THCA	cis	rs1383484	0.575	rs10520571	ENSG00000259728.4	LINC00933	-3.56	0.000415	0.0262	-0.19	-0.16	Height;	chr15:83947580	chr15:84570649~84580175:+
THCA	cis	rs1153858	0.943	rs4774580	ENSG00000275672.1	GATM-AS1	-3.56	0.000415	0.0262	-0.17	-0.16	Homoarginine levels;	chr15:45359888	chr15:45378700~45380123:+
THCA	cis	rs7166081	1	rs12148121	ENSG00000270964.1	RP11-502I4.3	-3.56	0.000415	0.0262	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67202584	chr15:67541072~67542604:-
THCA	cis	rs10256972	0.528	rs7784607	ENSG00000225146.1	AC073957.15	3.56	0.000415	0.0262	0.18	0.16	Endometriosis;Longevity;	chr7:1139058	chr7:1029025~1043891:+
THCA	cis	rs9876781	1	rs11712561	ENSG00000199476.1	Y_RNA	-3.56	0.000415	0.0262	-0.21	-0.16	Longevity;	chr3:48393807	chr3:48288587~48288694:+
THCA	cis	rs9584850	0.834	rs2031239	ENSG00000231194.1	FARP1-AS1	3.56	0.000415	0.0262	0.2	0.16	Neuroticism;	chr13:98459306	chr13:98435405~98435840:-
THCA	cis	rs10911363	0.592	rs2782411	ENSG00000232860.6	SMG7-AS1	-3.56	0.000415	0.0262	-0.12	-0.16	Systemic lupus erythematosus;	chr1:183507794	chr1:183460874~183472265:-
THCA	cis	rs7819412	0.805	rs2409710	ENSG00000261451.1	RP11-981G7.1	-3.56	0.000415	0.0262	-0.21	-0.16	Triglycerides;	chr8:11122311	chr8:10433672~10438312:+
THCA	cis	rs9393777	0.546	rs35589403	ENSG00000220721.1	OR1F12	3.56	0.000415	0.0262	0.24	0.16	Intelligence (multi-trait analysis);	chr6:27251712	chr6:28073316~28074233:+
THCA	cis	rs8177876	0.658	rs11150337	ENSG00000261838.4	RP11-303E16.6	3.56	0.000415	0.0262	0.27	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81069854~81076598:+
THCA	cis	rs11673344	0.642	rs12462708	ENSG00000267470.4	ZNF571-AS1	3.56	0.000415	0.0262	0.18	0.16	Obesity-related traits;	chr19:37306676	chr19:37548914~37587348:+
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000184274.3	LINC00315	-3.56	0.000415	0.0262	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45300245~45305257:-
THCA	cis	rs301901	0.734	rs216387	ENSG00000250155.1	CTD-2353F22.1	-3.56	0.000415	0.0262	-0.17	-0.16	Height;	chr5:37276657	chr5:36666214~36725195:-
THCA	cis	rs9796	0.689	rs9888710	ENSG00000247556.5	OIP5-AS1	3.56	0.000415	0.0262	0.13	0.16	Menopause (age at onset);	chr15:41153955	chr15:41283990~41309737:+
THCA	cis	rs9796	0.653	rs28516683	ENSG00000247556.5	OIP5-AS1	3.56	0.000415	0.0262	0.13	0.16	Menopause (age at onset);	chr15:41154447	chr15:41283990~41309737:+
THCA	cis	rs9796	0.689	rs28409432	ENSG00000247556.5	OIP5-AS1	3.56	0.000415	0.0262	0.13	0.16	Menopause (age at onset);	chr15:41155256	chr15:41283990~41309737:+
THCA	cis	rs2882667	0.931	rs10069528	ENSG00000249593.5	CTB-46B19.2	3.56	0.000415	0.0262	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:139012647~139051203:+
THCA	cis	rs791590	0.752	rs41295055	ENSG00000229664.1	RP11-536K7.5	-3.56	0.000415	0.0262	-0.26	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6069659	chr10:6025978~6036427:+
THCA	cis	rs9973361	0.51	rs3815993	ENSG00000232411.1	AC009495.3	-3.56	0.000415	0.0262	-0.23	-0.16	Total body bone mineral density;	chr2:165875827	chr2:165833048~165839098:-
THCA	cis	rs10911902	0.643	rs16825185	ENSG00000228238.1	GS1-304P7.2	-3.56	0.000415	0.0262	-0.26	-0.16	Schizophrenia;	chr1:186337932	chr1:186578279~186579299:+
THCA	cis	rs948562	0.681	rs11229573	ENSG00000280010.1	AP001350.4	-3.56	0.000415	0.0262	-0.23	-0.16	Lymphoma;	chr11:58667095	chr11:58627435~58628528:+
THCA	cis	rs12893668	0.667	rs71417869	ENSG00000258735.1	LINC00637	-3.56	0.000415	0.0262	-0.21	-0.16	Reticulocyte count;	chr14:103611097	chr14:103847721~103858049:+
THCA	cis	rs2980439	0.557	rs2976876	ENSG00000253130.1	CTD-3023L14.2	-3.56	0.000415	0.0262	-0.17	-0.16	Neuroticism;	chr8:8461340	chr8:8561391~8569688:+
THCA	cis	rs9308731	0.966	rs1877331	ENSG00000204581.2	AC096670.3	-3.56	0.000415	0.0262	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:111148933	chr2:111098345~111115588:-
THCA	cis	rs9308731	1	rs6542334	ENSG00000204581.2	AC096670.3	-3.56	0.000415	0.0262	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:111149637	chr2:111098345~111115588:-
THCA	cis	rs9467773	0.62	rs2451738	ENSG00000228223.2	HCG11	3.56	0.000415	0.0262	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26523450~26526579:+
THCA	cis	rs7824557	0.751	rs2099456	ENSG00000255310.2	AF131215.2	3.56	0.000415	0.0262	0.14	0.16	Retinal vascular caliber;	chr8:11269492	chr8:11107788~11109726:-
THCA	cis	rs7819412	0.765	rs7000132	ENSG00000280294.1	RP11-177H2.1	3.56	0.000415	0.0262	0.14	0.16	Triglycerides;	chr8:11173426	chr8:10856085~10859436:-
THCA	cis	rs7520050	0.933	rs4504835	ENSG00000280836.1	AL355480.1	3.56	0.000415	0.0262	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45581219~45581321:-
THCA	cis	rs7615952	0.551	rs6438945	ENSG00000272840.1	RP11-379B18.6	3.56	0.000415	0.0262	0.27	0.16	Blood pressure (smoking interaction);	chr3:125915630	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.673	rs7632557	ENSG00000272840.1	RP11-379B18.6	3.56	0.000415	0.0262	0.27	0.16	Blood pressure (smoking interaction);	chr3:125916038	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.932	rs9841157	ENSG00000272840.1	RP11-379B18.6	3.56	0.000415	0.0262	0.27	0.16	Blood pressure (smoking interaction);	chr3:125916812	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.551	rs12695470	ENSG00000272840.1	RP11-379B18.6	3.56	0.000415	0.0262	0.27	0.16	Blood pressure (smoking interaction);	chr3:125916875	chr3:125774714~125797953:+
THCA	cis	rs4073416	0.568	rs7145759	ENSG00000276116.2	FUT8-AS1	3.56	0.000415	0.0262	0.18	0.16	N-glycan levels;	chr14:65417819	chr14:65411170~65412690:-
THCA	cis	rs4857855	0.735	rs7631955	ENSG00000239405.1	TMED10P2	3.56	0.000415	0.0262	0.23	0.16	Eosinophil counts;	chr3:128529662	chr3:128538020~128538631:+
THCA	cis	rs1923243	0.714	rs4649975	ENSG00000223479.3	RP4-788P17.1	3.56	0.000415	0.0262	0.17	0.16	Migraine;	chr1:73066468	chr1:73635216~73715214:+
THCA	cis	rs2281603	0.694	rs12385910	ENSG00000258824.2	CTD-2555O16.2	-3.56	0.000415	0.0262	-0.16	-0.16	Lymphocyte counts;	chr14:64533252	chr14:64422935~64448557:-
THCA	cis	rs13325613	0.834	rs34198655	ENSG00000223552.1	RP11-24F11.2	-3.56	0.000415	0.0262	-0.26	-0.16	Monocyte count;	chr3:46173615	chr3:46364955~46407059:-
THCA	cis	rs13325613	0.834	rs34013035	ENSG00000223552.1	RP11-24F11.2	-3.56	0.000415	0.0262	-0.26	-0.16	Monocyte count;	chr3:46179190	chr3:46364955~46407059:-
THCA	cis	rs6416877	0.885	rs8072859	ENSG00000277491.1	RP11-676J12.9	-3.56	0.000415	0.0262	-0.2	-0.16	Myeloid white cell count;	chr17:1467829	chr17:795306~795794:+
THCA	cis	rs7713065	0.765	rs10076733	ENSG00000263597.1	MIR3936	-3.56	0.000415	0.0262	-0.2	-0.16	Lung function (FEV1/FVC);	chr5:132425039	chr5:132365490~132365599:-
THCA	cis	rs6137726	0.524	rs1203950	ENSG00000237396.1	LINC01384	3.56	0.000415	0.0262	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22628463	chr20:22587522~22607517:-
THCA	cis	rs12544026	0.548	rs550281	ENSG00000253669.3	KB-1732A1.1	3.56	0.000415	0.0262	0.18	0.16	Major depression and alcohol dependence;	chr8:101902092	chr8:102805517~102809971:+
THCA	cis	rs10911902	0.643	rs16825248	ENSG00000228238.1	GS1-304P7.2	-3.56	0.000415	0.0262	-0.27	-0.16	Schizophrenia;	chr1:186358057	chr1:186578279~186579299:+
THCA	cis	rs11671005	0.61	rs8103813	ENSG00000267858.4	MZF1-AS1	-3.56	0.000415	0.0262	-0.12	-0.16	Mean platelet volume;	chr19:58561317	chr19:58559129~58574797:+
THCA	cis	rs1383484	0.761	rs10906981	ENSG00000259728.4	LINC00933	-3.56	0.000415	0.0262	-0.21	-0.16	Height;	chr15:83853807	chr15:84570649~84580175:+
THCA	cis	rs11887277	0.507	rs1821410	ENSG00000272148.1	RP11-195B17.1	-3.56	0.000416	0.0262	-0.15	-0.16	Obesity-related traits;	chr2:26835639	chr2:27062428~27062907:-
THCA	cis	rs7772486	0.875	rs7767660	ENSG00000270638.1	RP3-466P17.1	3.56	0.000416	0.0262	0.13	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145735570~145737218:+
THCA	cis	rs17095355	0.818	rs59339754	ENSG00000203876.8	ADD3-AS1	-3.56	0.000416	0.0262	-0.19	-0.16	Biliary atresia;	chr10:110040358	chr10:109940104~110008381:-
THCA	cis	rs9532669	0.926	rs9525418	ENSG00000229473.2	RGS17P1	-3.56	0.000416	0.0262	-0.21	-0.16	Cervical cancer;	chr13:40879081	chr13:40992779~40993331:-
THCA	cis	rs16975963	0.644	rs35205379	ENSG00000276846.1	CTD-3220F14.3	3.56	0.000416	0.0262	0.15	0.16	Longevity;	chr19:37685941	chr19:37314868~37315620:-
THCA	cis	rs9876781	1	rs4858793	ENSG00000199476.1	Y_RNA	3.56	0.000416	0.0262	0.2	0.16	Longevity;	chr3:48373517	chr3:48288587~48288694:+
THCA	cis	rs75504410	1	rs59048840	ENSG00000231160.8	KLF3-AS1	-3.56	0.000416	0.0262	-0.18	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38683244	chr4:38612701~38664883:-
THCA	cis	rs1383484	0.798	rs7179241	ENSG00000259728.4	LINC00933	-3.56	0.000416	0.0262	-0.21	-0.16	Height;	chr15:83882959	chr15:84570649~84580175:+
THCA	cis	rs2055375	0.643	rs173946	ENSG00000215032.2	GNL3LP1	3.56	0.000416	0.0262	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61192470	chr5:60891935~60893577:-
THCA	cis	rs2562456	0.834	rs2173727	ENSG00000268658.4	LINC00664	-3.56	0.000416	0.0262	-0.23	-0.16	Pain;	chr19:21491155	chr19:21483374~21503238:+
THCA	cis	rs9818758	0.607	rs3923475	ENSG00000229759.1	MRPS18AP1	-3.56	0.000416	0.0262	-0.34	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49018355	chr3:48256350~48256938:-
THCA	cis	rs7709377	0.808	rs12515329	ENSG00000272265.1	CTD-2287O16.4	3.56	0.000416	0.0262	0.19	0.16	Metabolite levels  (X-11787);	chr5:116233015	chr5:116078110~116078570:-
THCA	cis	rs10857712	0.784	rs2265639	ENSG00000214279.11	SCART1	3.56	0.000416	0.0262	0.13	0.16	Systemic lupus erythematosus;	chr10:133408072	chr10:133453928~133523558:+
THCA	cis	rs57709857	1	rs3925	ENSG00000272092.1	RP11-350N15.5	-3.56	0.000416	0.0262	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38424140	chr8:38382364~38383461:+
THCA	cis	rs3760982	0.585	rs1386502	ENSG00000267058.1	RP11-15A1.3	-3.56	0.000416	0.0262	-0.13	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789204	chr19:43891804~43901805:-
THCA	cis	rs853679	0.607	rs201002	ENSG00000220721.1	OR1F12	3.56	0.000416	0.0262	0.28	0.16	Depression;	chr6:27840414	chr6:28073316~28074233:+
THCA	cis	rs4588572	0.688	rs2362829	ENSG00000245556.2	SCAMP1-AS1	-3.56	0.000416	0.0262	-0.12	-0.16	Triglycerides;	chr5:78428212	chr5:78342365~78360507:-
THCA	cis	rs875971	0.965	rs10267430	ENSG00000272831.1	RP11-792A8.4	-3.56	0.000416	0.0262	-0.1	-0.16	Aortic root size;	chr7:66278036	chr7:66739829~66740385:-
THCA	cis	rs2228479	0.85	rs74251568	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89837008	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62056063	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89837272	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.557	rs62056064	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89837435	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62056065	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89838707	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62056066	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89840155	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs11639925	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89841842	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62056068	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89843329	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs74251570	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89843660	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs117880578	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89843822	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62056069	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89845592	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.718	rs11645376	ENSG00000274627.1	RP11-104N10.2	-3.56	0.000416	0.0262	-0.28	-0.16	Skin colour saturation;	chr16:89845873	chr16:89516797~89522217:+
THCA	cis	rs4489787	0.568	rs2705135	ENSG00000240399.1	RP1-228P16.1	3.56	0.000416	0.0262	0.19	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48496773	chr12:48054813~48055591:-
THCA	cis	rs13217239	0.646	rs11756275	ENSG00000261353.1	CTA-14H9.5	3.56	0.000416	0.0262	0.17	0.16	Schizophrenia;	chr6:27039334	chr6:26527063~26527404:+
THCA	cis	rs7737355	1	rs40396	ENSG00000237714.1	P4HA2-AS1	-3.56	0.000416	0.0262	-0.23	-0.16	Life satisfaction;	chr5:131372351	chr5:132184876~132192808:+
THCA	cis	rs7824557	0.679	rs10110008	ENSG00000255495.1	AC145124.2	-3.56	0.000416	0.0262	-0.18	-0.16	Retinal vascular caliber;	chr8:11276227	chr8:12194467~12196280:+
THCA	cis	rs478304	0.654	rs1074156	ENSG00000214659.4	KRT8P26	3.56	0.000416	0.0262	0.16	0.16	Acne (severe);	chr11:65690698	chr11:65726939~65728214:+
THCA	cis	rs1005277	0.522	rs289643	ENSG00000120555.12	SEPT7P9	3.56	0.000416	0.0262	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38383069~38402916:-
THCA	cis	rs4883201	0.561	rs1805725	ENSG00000245105.2	A2M-AS1	3.56	0.000416	0.0262	0.16	0.16	Total cholesterol levels;Cholesterol, total;	chr12:8945337	chr12:9065177~9068060:+
THCA	cis	rs8177876	0.915	rs4889233	ENSG00000261061.1	RP11-303E16.2	3.56	0.000416	0.0262	0.25	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093378	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.915	rs11866124	ENSG00000261061.1	RP11-303E16.2	3.56	0.000416	0.0262	0.25	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093866	chr16:81030770~81031485:+
THCA	cis	rs9487094	0.689	rs9480936	ENSG00000223537.2	RP5-919F19.5	-3.56	0.000416	0.0262	-0.17	-0.16	Height;	chr6:109358227	chr6:109487906~109506800:+
THCA	cis	rs73222236	0.825	rs6804194	ENSG00000273486.1	RP11-731C17.2	3.56	0.000416	0.0262	0.14	0.16	Coronary artery disease;	chr3:136441890	chr3:136837338~136839021:-
THCA	cis	rs56309584	0.597	rs78296773	ENSG00000271002.1	RP11-599B13.8	-3.56	0.000416	0.0262	-0.25	-0.16	Initial pursuit acceleration;	chr17:8264644	chr17:8199123~8199437:-
THCA	cis	rs2006933	1	rs9892047	ENSG00000237575.4	PYY2	3.56	0.000416	0.0262	0.21	0.16	Amyotrophic lateral sclerosis;	chr17:28265331	chr17:28226563~28228065:+
THCA	cis	rs944289	0.74	rs1742869	ENSG00000212071.1	AL162511.1	-3.56	0.000416	0.0262	-0.18	-0.16	Thyroid cancer;	chr14:36067601	chr14:36196480~36196568:-
THCA	cis	rs10760158	0.769	rs10985200	ENSG00000226752.6	PSMD5-AS1	-3.56	0.000416	0.0262	-0.19	-0.16	Pulse pressure;	chr9:121281589	chr9:120824828~120854385:+
THCA	cis	rs7809799	0.571	rs111251485	ENSG00000242798.1	RP11-506M12.1	-3.56	0.000416	0.0263	-0.33	-0.16	Ulcerative colitis;	chr7:99360607	chr7:100115214~100127139:-
THCA	cis	rs7403037	0.505	rs2002104	ENSG00000259905.4	PWRN1	3.55	0.000416	0.0263	0.17	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24173752	chr15:24493137~24652130:+
THCA	cis	rs7129556	0.815	rs11607715	ENSG00000254985.1	RSF1-IT2	-3.55	0.000416	0.0263	-0.25	-0.16	Weight loss (gastric bypass surgery);	chr11:77527814	chr11:77717712~77718411:-
THCA	cis	rs3781264	0.595	rs11187901	ENSG00000273450.1	RP11-76P2.4	3.55	0.000416	0.0263	0.2	0.16	Esophageal cancer and gastric cancer;	chr10:94355251	chr10:94314907~94315327:-
THCA	cis	rs950169	1	rs79318564	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000416	0.0263	-0.18	-0.16	Schizophrenia;	chr15:84117398	chr15:84507885~84516814:-
THCA	cis	rs950169	1	rs1911155	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000416	0.0263	-0.18	-0.16	Schizophrenia;	chr15:84118883	chr15:84507885~84516814:-
THCA	cis	rs875971	0.66	rs7807930	ENSG00000232546.1	RP11-458F8.1	3.55	0.000416	0.0263	0.13	0.16	Aortic root size;	chr7:66622178	chr7:66848496~66858136:+
THCA	cis	rs12493885	0.769	rs61791508	ENSG00000243069.6	ARHGEF26-AS1	-3.55	0.000416	0.0263	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154033027	chr3:154024401~154121332:-
THCA	cis	rs1488902	0.746	rs1986670	ENSG00000280367.1	RP11-121L10.2	-3.55	0.000416	0.0263	-0.15	-0.16	Amyotrophic lateral sclerosis;	chr11:89585680	chr11:90223153~90226538:+
THCA	cis	rs6437740	1	rs13066717	ENSG00000241218.1	RP11-446H18.1	-3.55	0.000416	0.0263	-0.23	-0.16	Smoking behavior;	chr3:107747564	chr3:107327830~107329197:-
THCA	cis	rs2522056	1	rs2522056	ENSG00000237714.1	P4HA2-AS1	-3.55	0.000416	0.0263	-0.23	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132466034	chr5:132184876~132192808:+
THCA	cis	rs1153858	1	rs4774577	ENSG00000275672.1	GATM-AS1	-3.55	0.000417	0.0263	-0.17	-0.16	Homoarginine levels;	chr15:45352487	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs4774578	ENSG00000275672.1	GATM-AS1	-3.55	0.000417	0.0263	-0.17	-0.16	Homoarginine levels;	chr15:45353853	chr15:45378700~45380123:+
THCA	cis	rs61524473	1	rs61524473	ENSG00000275672.1	GATM-AS1	-3.55	0.000417	0.0263	-0.17	-0.16	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs10444821	ENSG00000275672.1	GATM-AS1	-3.55	0.000417	0.0263	-0.17	-0.16	Homoarginine levels;	chr15:45355038	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs72623915	ENSG00000275672.1	GATM-AS1	-3.55	0.000417	0.0263	-0.17	-0.16	Homoarginine levels;	chr15:45355235	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs66714503	ENSG00000275672.1	GATM-AS1	-3.55	0.000417	0.0263	-0.17	-0.16	Homoarginine levels;	chr15:45355840	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs2066090	ENSG00000275672.1	GATM-AS1	-3.55	0.000417	0.0263	-0.17	-0.16	Homoarginine levels;	chr15:45357820	chr15:45378700~45380123:+
THCA	cis	rs9878978	0.964	rs6762278	ENSG00000227588.2	CNTN4-AS2	3.55	0.000417	0.0263	0.2	0.16	Blood pressure (smoking interaction);	chr3:2451667	chr3:2110409~2144241:-
THCA	cis	rs2625529	0.761	rs3743224	ENSG00000260037.4	CTD-2524L6.3	-3.55	0.000417	0.0263	-0.23	-0.16	Red blood cell count;	chr15:72174458	chr15:71818396~71823384:+
THCA	cis	rs1048886	0.745	rs12524814	ENSG00000271967.1	RP11-134K13.4	-3.55	0.000417	0.0263	-0.2	-0.16	Type 2 diabetes;	chr6:70519449	chr6:70596438~70596980:+
THCA	cis	rs11574514	0.744	rs7185536	ENSG00000280214.1	CTD-2012K14.5	-3.55	0.000417	0.0263	-0.28	-0.16	Crohn's disease;	chr16:67958261	chr16:67550815~67552935:-
THCA	cis	rs8049040	0.586	rs8060176	ENSG00000261513.1	RP11-432I5.8	3.55	0.000417	0.0263	0.22	0.16	Blood protein levels;	chr16:71422854	chr16:71723180~71724230:+
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000237310.1	GS1-124K5.4	-3.55	0.000417	0.0263	-0.19	-0.16	Diabetic kidney disease;	chr7:66226660	chr7:66493706~66495474:+
THCA	cis	rs9911578	0.967	rs2611781	ENSG00000224738.1	AC099850.1	3.55	0.000417	0.0263	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58625763	chr17:59106598~59118267:+
THCA	cis	rs7259376	0.777	rs2664067	ENSG00000269345.1	VN1R85P	3.55	0.000417	0.0263	0.18	0.16	Menopause (age at onset);	chr19:22455264	chr19:22174766~22175191:-
THCA	cis	rs6982240	0.514	rs28681435	ENSG00000253307.1	RP11-10J21.4	3.55	0.000417	0.0263	0.24	0.16	Tonsillectomy;	chr8:141276474	chr8:141252286~141253292:-
THCA	cis	rs5006884	0.95	rs2647608	ENSG00000167355.6	AC104389.28	-3.55	0.000417	0.0263	-0.23	-0.16	Fetal hemoglobin levels;	chr11:5364702	chr11:5304976~5505652:-
THCA	cis	rs7359257	0.576	rs56038097	ENSG00000260657.2	RP11-315D16.4	3.55	0.000417	0.0263	0.22	0.16	Menarche (age at onset);	chr15:67612231	chr15:68267792~68277994:-
THCA	cis	rs3784262	1	rs4646640	ENSG00000259250.1	RP11-50C13.1	-3.55	0.000417	0.0263	-0.14	-0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57955365	chr15:58587507~58591676:+
THCA	cis	rs6743226	0.603	rs10933546	ENSG00000223374.1	AC005104.3	3.55	0.000417	0.0263	0.12	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241286583	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.603	rs11896191	ENSG00000223374.1	AC005104.3	3.55	0.000417	0.0263	0.12	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241287336	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.603	rs67625947	ENSG00000223374.1	AC005104.3	3.55	0.000417	0.0263	0.12	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241287985	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.603	rs58226367	ENSG00000223374.1	AC005104.3	3.55	0.000417	0.0263	0.12	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241288132	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.603	rs62186405	ENSG00000223374.1	AC005104.3	3.55	0.000417	0.0263	0.12	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241292738	chr2:241351340~241353104:-
THCA	cis	rs9611565	0.512	rs139573	ENSG00000237037.8	NDUFA6-AS1	3.55	0.000417	0.0263	0.16	0.16	Vitiligo;	chr22:41818781	chr22:42090931~42137742:+
THCA	cis	rs1383484	0.754	rs10520572	ENSG00000225151.9	GOLGA2P7	3.55	0.000417	0.0263	0.22	0.16	Height;	chr15:83922923	chr15:84199311~84230136:-
THCA	cis	rs13064411	0.597	rs2291905	ENSG00000243849.1	CFAP44-AS1	3.55	0.000417	0.0263	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113291619	chr3:113403991~113433992:+
THCA	cis	rs4767841	0.565	rs11064911	ENSG00000252886.1	RN7SKP197	-3.55	0.000417	0.0263	-0.16	-0.16	Urgency urinary incontinence;	chr12:119793275	chr12:119631090~119631386:-
THCA	cis	rs1023500	0.505	rs2143139	ENSG00000233903.2	Z83851.4	3.55	0.000417	0.0263	0.21	0.16	Schizophrenia;	chr22:42218395	chr22:42276355~42277052:+
THCA	cis	rs11723261	0.582	rs6830247	ENSG00000250892.1	RP11-1365D11.1	3.55	0.000417	0.0263	0.23	0.16	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:201409~205009:-
THCA	cis	rs11864453	0.682	rs10852509	ENSG00000279206.1	RP5-991G20.6	3.55	0.000417	0.0263	0.17	0.16	Fibrinogen levels;	chr16:71992111	chr16:72772673~72773272:+
THCA	cis	rs1153858	1	rs8042786	ENSG00000275672.1	GATM-AS1	-3.55	0.000417	0.0263	-0.17	-0.16	Homoarginine levels;	chr15:45411341	chr15:45378700~45380123:+
THCA	cis	rs11158609	1	rs12879736	ENSG00000278784.1	RP11-468E2.11	3.55	0.000417	0.0263	0.15	0.16	Systolic blood pressure (cigarette smoking interaction);	chr14:24205587	chr14:24201612~24202811:-
THCA	cis	rs4073416	0.518	rs10150412	ENSG00000276116.2	FUT8-AS1	3.55	0.000417	0.0263	0.18	0.16	N-glycan levels;	chr14:65450073	chr14:65411170~65412690:-
THCA	cis	rs13065560	0.56	rs11716777	ENSG00000200579.1	Y_RNA	3.55	0.000417	0.0263	0.21	0.16	Interleukin-18 levels;	chr3:38916264	chr3:38014568~38014669:+
THCA	cis	rs1560104	0.536	rs11075131	ENSG00000260601.1	RP11-552C15.1	-3.55	0.000417	0.0263	-0.19	-0.16	Obesity-related traits;	chr16:12623130	chr16:12545482~12546684:+
THCA	cis	rs3018712	0.532	rs4930588	ENSG00000212093.1	AP000807.1	3.55	0.000417	0.0263	0.21	0.16	Total body bone mineral density;	chr11:68647767	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.532	rs4930589	ENSG00000212093.1	AP000807.1	-3.55	0.000417	0.0263	-0.21	-0.16	Total body bone mineral density;	chr11:68647789	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.532	rs11228312	ENSG00000212093.1	AP000807.1	-3.55	0.000417	0.0263	-0.21	-0.16	Total body bone mineral density;	chr11:68648049	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.532	rs10791988	ENSG00000212093.1	AP000807.1	-3.55	0.000417	0.0263	-0.21	-0.16	Total body bone mineral density;	chr11:68648583	chr11:68506083~68506166:-
THCA	cis	rs3018712	0.532	rs2513280	ENSG00000212093.1	AP000807.1	-3.55	0.000417	0.0263	-0.21	-0.16	Total body bone mineral density;	chr11:68649439	chr11:68506083~68506166:-
THCA	cis	rs4763879	0.54	rs741200	ENSG00000278635.1	CTD-2318O12.1	3.55	0.000417	0.0263	0.18	0.16	Type 1 diabetes;	chr12:9717819	chr12:9415641~9416718:+
THCA	cis	rs71537559	1	rs71537559	ENSG00000226314.6	ZNF192P1	-3.55	0.000417	0.0263	-0.32	-0.16	Squamous cell lung carcinoma;	chr6:27342000	chr6:28161781~28169594:+
THCA	cis	rs9527	0.571	rs7096249	ENSG00000272912.1	RP11-724N1.1	-3.55	0.000417	0.0263	-0.19	-0.16	Arsenic metabolism;	chr10:102858767	chr10:102914585~102915404:+
THCA	cis	rs9527	0.571	rs10786715	ENSG00000272912.1	RP11-724N1.1	-3.55	0.000417	0.0263	-0.19	-0.16	Arsenic metabolism;	chr10:102860978	chr10:102914585~102915404:+
THCA	cis	rs7819412	0.807	rs4840542	ENSG00000261451.1	RP11-981G7.1	-3.55	0.000417	0.0263	-0.21	-0.16	Triglycerides;	chr8:11087299	chr8:10433672~10438312:+
THCA	cis	rs9475752	0.53	rs1562908	ENSG00000231441.1	RP11-472M19.2	-3.55	0.000417	0.0263	-0.18	-0.16	Menarche (age at onset);	chr6:56992867	chr6:56844002~56864078:+
THCA	cis	rs524281	0.861	rs580891	ENSG00000255038.1	RP11-1167A19.2	-3.55	0.000417	0.0263	-0.18	-0.16	Electroencephalogram traits;	chr11:66187210	chr11:66067277~66069619:-
THCA	cis	rs758324	0.947	rs476428	ENSG00000237714.1	P4HA2-AS1	-3.55	0.000417	0.0263	-0.23	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131965922	chr5:132184876~132192808:+
THCA	cis	rs330071	0.5	rs17662123	ENSG00000254153.1	CTA-398F10.2	-3.55	0.000417	0.0263	-0.17	-0.16	Acne (severe);	chr8:9389327	chr8:8456909~8461337:-
THCA	cis	rs2797160	1	rs2211419	ENSG00000226409.1	RP11-735G4.1	3.55	0.000417	0.0263	0.19	0.16	Endometrial cancer;	chr6:125674387	chr6:125370211~125374324:-
THCA	cis	rs11867129	1	rs4787277	ENSG00000260778.3	RP11-304L19.13	3.55	0.000417	0.0263	0.16	0.16	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2318168	chr16:2268155~2273418:+
THCA	cis	rs7826238	0.543	rs2976908	ENSG00000233609.3	RP11-62H7.2	3.55	0.000417	0.0263	0.17	0.16	Systolic blood pressure;	chr8:8488264	chr8:8961200~8979025:+
THCA	cis	rs4713118	0.513	rs149975	ENSG00000176933.5	TOB2P1	-3.55	0.000417	0.0263	-0.19	-0.16	Parkinson's disease;	chr6:28018562	chr6:28217643~28218634:-
THCA	cis	rs2235573	0.868	rs4821737	ENSG00000222044.1	RP5-1039K5.16	3.55	0.000417	0.0263	0.18	0.16	Glioma;Glioblastoma;	chr22:38104375	chr22:38032165~38034228:-
THCA	cis	rs9650657	0.871	rs7814142	ENSG00000255310.2	AF131215.2	-3.55	0.000417	0.0263	-0.13	-0.16	Neuroticism;	chr8:10780042	chr8:11107788~11109726:-
THCA	cis	rs11048434	0.636	rs11047953	ENSG00000245105.2	A2M-AS1	3.55	0.000417	0.0263	0.12	0.16	Sjögren's syndrome;	chr12:8912327	chr12:9065177~9068060:+
THCA	cis	rs72634501	0.542	rs2134472	ENSG00000182109.6	RP11-69E11.4	-3.55	0.000417	0.0263	-0.15	-0.16	HDL cholesterol;	chr1:39137542	chr1:39522280~39546187:-
THCA	cis	rs13401620	0.708	rs112427597	ENSG00000231013.1	AC013275.2	-3.55	0.000417	0.0263	-0.19	-0.16	Breast size;	chr2:119717279	chr2:119476448~119487346:+
THCA	cis	rs13401620	0.641	rs58394585	ENSG00000231013.1	AC013275.2	-3.55	0.000417	0.0263	-0.19	-0.16	Breast size;	chr2:119717591	chr2:119476448~119487346:+
THCA	cis	rs6545883	0.899	rs12473030	ENSG00000212978.6	AC016747.3	3.55	0.000417	0.0263	0.18	0.16	Tuberculosis;	chr2:61493362	chr2:61141592~61144969:-
THCA	cis	rs853679	0.517	rs9468298	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28154567	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28156691	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28158424	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28159056	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28159925	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28159932	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28162053	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28163375	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28163759	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28164580	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28164825	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28164948	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28165025	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28165528	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Parkinson's disease;	chr6:28165750	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Parkinson's disease;	chr6:28168578	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28169019	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28169249	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28169755	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28169791	chr6:28091154~28093664:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000219891.2	ZSCAN12P1	3.55	0.000417	0.0263	0.23	0.16	Depression;	chr6:28170075	chr6:28091154~28093664:+
THCA	cis	rs7924176	0.521	rs7477710	ENSG00000271848.1	RP11-464F9.21	-3.55	0.000418	0.0263	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:73654039~73674719:+
THCA	cis	rs7924176	0.521	rs11000960	ENSG00000271848.1	RP11-464F9.21	-3.55	0.000418	0.0263	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:73654039~73674719:+
THCA	cis	rs116988415	0.748	rs12587471	ENSG00000272909.1	CTD-2555O16.4	3.55	0.000418	0.0263	0.22	0.16	Daytime sleep phenotypes;	chr14:64825597	chr14:64440369~64442238:-
THCA	cis	rs12682352	0.715	rs332039	ENSG00000233609.3	RP11-62H7.2	3.55	0.000418	0.0263	0.16	0.16	Neuroticism;	chr8:8866141	chr8:8961200~8979025:+
THCA	cis	rs8054556	0.647	rs8048433	ENSG00000183604.13	SMG1P5	-3.55	0.000418	0.0263	-0.15	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30267553~30335374:-
THCA	cis	rs12893668	0.663	rs12889731	ENSG00000258735.1	LINC00637	-3.55	0.000418	0.0263	-0.22	-0.16	Reticulocyte count;	chr14:103621145	chr14:103847721~103858049:+
THCA	cis	rs11098699	0.607	rs7689547	ENSG00000273007.1	RP11-170N16.3	3.55	0.000418	0.0263	0.13	0.16	Mosquito bite size;	chr4:123346716	chr4:122881878~122884712:-
THCA	cis	rs72482608	0.865	rs10800542	ENSG00000271811.1	RP1-79C4.4	3.55	0.000418	0.0263	0.2	0.16	Emphysema imaging phenotypes;	chr1:170795774	chr1:170667381~170669425:+
THCA	cis	rs72482608	0.865	rs10800543	ENSG00000271811.1	RP1-79C4.4	3.55	0.000418	0.0263	0.2	0.16	Emphysema imaging phenotypes;	chr1:170796627	chr1:170667381~170669425:+
THCA	cis	rs2625529	0.73	rs6494990	ENSG00000260037.4	CTD-2524L6.3	3.55	0.000418	0.0263	0.21	0.16	Red blood cell count;	chr15:72108733	chr15:71818396~71823384:+
THCA	cis	rs11574514	0.744	rs11860125	ENSG00000280214.1	CTD-2012K14.5	-3.55	0.000418	0.0263	-0.28	-0.16	Crohn's disease;	chr16:67947066	chr16:67550815~67552935:-
THCA	cis	rs11574514	0.744	rs7200210	ENSG00000280214.1	CTD-2012K14.5	-3.55	0.000418	0.0263	-0.28	-0.16	Crohn's disease;	chr16:67947993	chr16:67550815~67552935:-
THCA	cis	rs2898290	0.622	rs13272061	ENSG00000270154.1	RP11-419I17.1	-3.55	0.000418	0.0263	-0.2	-0.16	Systolic blood pressure;	chr8:11494752	chr8:12476462~12477122:+
THCA	cis	rs8030379	1	rs4842924	ENSG00000176700.18	SCAND2P	3.55	0.000418	0.0263	0.1	0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84631451~84647478:+
THCA	cis	rs317689	0.559	rs710794	ENSG00000274979.1	RP11-1143G9.5	-3.55	0.000418	0.0263	-0.26	-0.16	Response to diuretic therapy;	chr12:69353397	chr12:69326574~69331882:-
THCA	cis	rs7028939	0.892	rs10989001	ENSG00000255145.2	STX17-AS1	-3.55	0.000418	0.0263	-0.25	-0.16	Preeclampsia;	chr9:100181866	chr9:99886322~99906601:-
THCA	cis	rs7924176	0.521	rs11000959	ENSG00000271848.1	RP11-464F9.21	-3.55	0.000418	0.0263	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74287053	chr10:73654039~73674719:+
THCA	cis	rs13021401	0.656	rs342071	ENSG00000228950.1	AC023137.2	3.55	0.000418	0.0263	0.18	0.16	Systemic sclerosis;	chr2:20485421	chr2:20451042~20452947:+
THCA	cis	rs45509595	0.822	rs200484	ENSG00000220721.1	OR1F12	3.55	0.000418	0.0263	0.28	0.16	Breast cancer;	chr6:27807896	chr6:28073316~28074233:+
THCA	cis	rs9487094	0.62	rs7768973	ENSG00000223537.2	RP5-919F19.5	-3.55	0.000418	0.0263	-0.16	-0.16	Height;	chr6:109424122	chr6:109487906~109506800:+
THCA	cis	rs4272720	0.535	rs17700872	ENSG00000234736.4	FAM170B-AS1	-3.55	0.000418	0.0263	-0.18	-0.16	Platelet count;Plateletcrit;	chr10:49079822	chr10:49121839~49151547:+
THCA	cis	rs9596863	1	rs9596859	ENSG00000136149.6	RPL13AP25	-3.55	0.000418	0.0263	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53857065	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9596860	ENSG00000136149.6	RPL13AP25	-3.55	0.000418	0.0263	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53857080	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9596862	ENSG00000136149.6	RPL13AP25	-3.55	0.000418	0.0263	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53858773	chr13:54440704~54441315:-
THCA	cis	rs2841277	0.616	rs1048257	ENSG00000258701.1	LINC00638	3.55	0.000418	0.0263	0.17	0.16	Rheumatoid arthritis;	chr14:104938047	chr14:104821201~104823718:+
THCA	cis	rs1858037	0.867	rs67817304	ENSG00000252414.1	RNU6-100P	-3.55	0.000418	0.0263	-0.18	-0.16	Rheumatoid arthritis;	chr2:65346982	chr2:64578892~64578997:+
THCA	cis	rs720064	0.586	rs8099403	ENSG00000264745.1	TTC39C-AS1	-3.55	0.000418	0.0263	-0.17	-0.16	Strep throat;	chr18:23933031	chr18:23994213~24015339:-
THCA	cis	rs35740288	0.822	rs17636864	ENSG00000259407.1	RP11-158M2.3	-3.55	0.000418	0.0263	-0.2	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85691358	chr15:85744109~85750281:-
THCA	cis	rs17123764	0.681	rs74086911	ENSG00000257464.1	RP11-161H23.8	-3.55	0.000418	0.0263	-0.33	-0.16	Intelligence (multi-trait analysis);	chr12:49622159	chr12:49442424~49442652:-
THCA	cis	rs2253017	0.723	rs2818989	ENSG00000278291.1	RP11-172H24.4	3.55	0.000418	0.0263	0.22	0.16	PR segment;	chr13:20812712	chr13:20699307~20703718:-
THCA	cis	rs2797160	0.904	rs2326292	ENSG00000226409.1	RP11-735G4.1	-3.55	0.000418	0.0263	-0.19	-0.16	Endometrial cancer;	chr6:125678528	chr6:125370211~125374324:-
THCA	cis	rs9296095	0.554	rs12214883	ENSG00000197251.3	LINC00336	-3.55	0.000418	0.0263	-0.2	-0.16	Platelet count;	chr6:33546191	chr6:33586106~33593338:-
THCA	cis	rs7264396	0.887	rs224363	ENSG00000261582.1	RP4-614O4.11	-3.55	0.000418	0.0264	-0.17	-0.16	Total cholesterol levels;	chr20:35474885	chr20:35267885~35280043:-
THCA	cis	rs3935996	0.965	rs7539074	ENSG00000233147.1	RP11-90C4.1	-3.55	0.000418	0.0264	-0.14	-0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55854399	chr1:55823807~55868248:+
THCA	cis	rs11971779	0.793	rs11772447	ENSG00000252332.1	RNU6-911P	-3.55	0.000418	0.0264	-0.19	-0.16	Diisocyanate-induced asthma;	chr7:139348843	chr7:139448740~139448843:+
THCA	cis	rs3784262	0.967	rs4646612	ENSG00000259250.1	RP11-50C13.1	3.55	0.000418	0.0264	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57972879	chr15:58587507~58591676:+
THCA	cis	rs6598955	0.67	rs7522905	ENSG00000236782.4	RP11-96L14.7	-3.55	0.000418	0.0264	-0.2	-0.16	Obesity-related traits;	chr1:26282768	chr1:26169947~26171821:-
THCA	cis	rs1876905	0.68	rs3749867	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000418	0.0264	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111103615	chr6:111297126~111298510:+
THCA	cis	rs7028939	1	rs1529195	ENSG00000255145.2	STX17-AS1	-3.55	0.000418	0.0264	-0.25	-0.16	Preeclampsia;	chr9:100086405	chr9:99886322~99906601:-
THCA	cis	rs61008539	0.893	rs4719460	ENSG00000229043.2	AC091729.9	3.55	0.000418	0.0264	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr7:819973	chr7:1160374~1165267:+
THCA	cis	rs2562456	1	rs2562456	ENSG00000268278.1	RP11-420K14.1	3.55	0.000418	0.0264	0.19	0.16	Pain;	chr19:21483408	chr19:21637974~21656300:+
THCA	cis	rs2692947	0.702	rs7604842	ENSG00000235584.2	AC008268.1	3.55	0.000418	0.0264	0.16	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96111592	chr2:95666084~95668715:+
THCA	cis	rs16918636	0.541	rs78073919	ENSG00000249867.4	RP11-115J23.1	-3.55	0.000418	0.0264	-0.24	-0.16	Menarche (age at onset);	chr11:29158078	chr11:28702615~29063821:+
THCA	cis	rs16918636	0.541	rs11602851	ENSG00000249867.4	RP11-115J23.1	-3.55	0.000418	0.0264	-0.24	-0.16	Menarche (age at onset);	chr11:29159279	chr11:28702615~29063821:+
THCA	cis	rs16918636	0.541	rs78518239	ENSG00000249867.4	RP11-115J23.1	-3.55	0.000418	0.0264	-0.24	-0.16	Menarche (age at onset);	chr11:29161044	chr11:28702615~29063821:+
THCA	cis	rs16918636	0.541	rs16918737	ENSG00000249867.4	RP11-115J23.1	-3.55	0.000418	0.0264	-0.24	-0.16	Menarche (age at onset);	chr11:29162193	chr11:28702615~29063821:+
THCA	cis	rs950169	0.845	rs4106951	ENSG00000230373.7	GOLGA6L5P	-3.55	0.000418	0.0264	-0.18	-0.16	Schizophrenia;	chr15:84164642	chr15:84507885~84516814:-
THCA	cis	rs2688608	0.623	rs2633317	ENSG00000271816.1	BMS1P4	3.55	0.000418	0.0264	0.16	0.16	Inflammatory bowel disease;	chr10:73930510	chr10:73699151~73730487:-
THCA	cis	rs2562456	0.92	rs2650784	ENSG00000268278.1	RP11-420K14.1	-3.55	0.000418	0.0264	-0.19	-0.16	Pain;	chr19:21483795	chr19:21637974~21656300:+
THCA	cis	rs2235649	0.663	rs12596160	ENSG00000260541.1	LA16c-429E7.1	3.55	0.000418	0.0264	0.22	0.16	Blood metabolite levels;	chr16:1798783	chr16:1841020~1843547:-
THCA	cis	rs1153858	1	rs12437840	ENSG00000275672.1	GATM-AS1	-3.55	0.000418	0.0264	-0.17	-0.16	Homoarginine levels;	chr15:45376857	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs4775937	ENSG00000275672.1	GATM-AS1	-3.55	0.000418	0.0264	-0.17	-0.16	Homoarginine levels;	chr15:45386416	chr15:45378700~45380123:+
THCA	cis	rs4325129	0.651	rs10908727	ENSG00000272668.1	RP11-190A12.8	3.55	0.000418	0.0264	0.19	0.16	Obesity-related traits;	chr1:159499322	chr1:159866954~159867685:+
THCA	cis	rs2455799	0.573	rs2455830	ENSG00000270409.1	RP11-44D5.1	-3.55	0.000418	0.0264	-0.17	-0.16	Mean platelet volume;	chr3:15707706	chr3:15732252~15733470:+
THCA	cis	rs11168618	0.626	rs11609074	ENSG00000240399.1	RP1-228P16.1	3.55	0.000418	0.0264	0.16	0.16	Adiponectin levels;	chr12:48425552	chr12:48054813~48055591:-
THCA	cis	rs11168618	0.626	rs11514105	ENSG00000240399.1	RP1-228P16.1	3.55	0.000418	0.0264	0.16	0.16	Adiponectin levels;	chr12:48427151	chr12:48054813~48055591:-
THCA	cis	rs2562456	0.917	rs2650825	ENSG00000268658.4	LINC00664	3.55	0.000418	0.0264	0.24	0.16	Pain;	chr19:21516423	chr19:21483374~21503238:+
THCA	cis	rs55894533	0.597	rs2645408	ENSG00000255046.1	RP11-297N6.4	-3.55	0.000418	0.0264	-0.17	-0.16	Leprosy;	chr8:11888849	chr8:11797928~11802568:-
THCA	cis	rs4792901	0.802	rs56357945	ENSG00000279602.1	CTD-3014M21.1	-3.55	0.000418	0.0264	-0.21	-0.16	Dupuytren's disease;	chr17:43536323	chr17:43360041~43361361:-
THCA	cis	rs916888	0.773	rs169201	ENSG00000260075.1	NSFP1	-3.55	0.000419	0.0264	-0.27	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46372855~46487141:+
THCA	cis	rs9427116	0.502	rs9426829	ENSG00000236675.1	MTX1P1	-3.55	0.000419	0.0264	-0.15	-0.16	Blood protein levels;	chr1:154619725	chr1:155230975~155234325:+
THCA	cis	rs6546886	1	rs6713313	ENSG00000235499.1	AC073046.25	3.55	0.000419	0.0264	0.15	0.16	Dialysis-related mortality;	chr2:74018808	chr2:73985132~73986343:+
THCA	cis	rs1433188	0.847	rs28577060	ENSG00000253582.1	RP11-649G15.2	3.55	0.000419	0.0264	0.19	0.16	Subjective well-being;	chr8:107437848	chr8:106520474~106657548:-
THCA	cis	rs10741243	1	rs2996077	ENSG00000230098.1	TCERG1L-AS1	3.55	0.000419	0.0264	0.21	0.16	Type 2 diabetes;	chr10:131153775	chr10:131095218~131095777:+
THCA	cis	rs2348418	0.733	rs9651832	ENSG00000278733.1	RP11-425D17.1	3.55	0.000419	0.0264	0.14	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28185625~28186190:-
THCA	cis	rs8177876	0.915	rs1563072	ENSG00000261838.4	RP11-303E16.6	-3.55	0.000419	0.0264	-0.34	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095811	chr16:81069854~81076598:+
THCA	cis	rs8177876	0.841	rs874437	ENSG00000261838.4	RP11-303E16.6	-3.55	0.000419	0.0264	-0.34	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095890	chr16:81069854~81076598:+
THCA	cis	rs9863	0.896	rs12829951	ENSG00000270130.1	RP11-214K3.23	-3.55	0.000419	0.0264	-0.2	-0.16	White blood cell count;	chr12:123941294	chr12:123960717~123961244:-
THCA	cis	rs9863	0.861	rs7131882	ENSG00000270130.1	RP11-214K3.23	-3.55	0.000419	0.0264	-0.2	-0.16	White blood cell count;	chr12:123942189	chr12:123960717~123961244:-
THCA	cis	rs17331151	0.573	rs3755801	ENSG00000242142.1	SERBP1P3	-3.55	0.000419	0.0264	-0.26	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52831782	chr3:53064283~53065091:-
THCA	cis	rs6030712	0.723	rs1291143	ENSG00000213979.3	RPL7AP14	3.55	0.000419	0.0264	0.26	0.16	Height;	chr20:36897237	chr20:37444733~37445534:-
THCA	cis	rs2797501	0.932	rs2797484	ENSG00000272764.1	RP11-318E3.9	3.55	0.000419	0.0264	0.23	0.16	Osteosarcoma;	chr10:5736982	chr10:5813985~5814441:+
THCA	cis	rs17023223	0.553	rs72691108	ENSG00000227056.2	RPL6P2	-3.55	0.000419	0.0264	-0.23	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119219314~119220096:-
THCA	cis	rs735539	0.914	rs7997065	ENSG00000238286.1	SLC35E1P1	3.55	0.000419	0.0264	0.17	0.16	Dental caries;	chr13:20699657	chr13:20607268~20608131:+
THCA	cis	rs7487075	0.93	rs4076484	ENSG00000257261.4	RP11-96H19.1	3.55	0.000419	0.0264	0.13	0.16	Itch intensity from mosquito bite;	chr12:46440129	chr12:46383679~46876159:+
THCA	cis	rs7487075	0.823	rs34472481	ENSG00000257261.4	RP11-96H19.1	3.55	0.000419	0.0264	0.13	0.16	Itch intensity from mosquito bite;	chr12:46442565	chr12:46383679~46876159:+
THCA	cis	rs540425	0.626	rs217367	ENSG00000279853.1	RP5-844F9.1	3.55	0.000419	0.0264	0.21	0.16	Schizophrenia;	chr7:44576389	chr7:44367140~44369292:-
THCA	cis	rs11642862	1	rs11641321	ENSG00000275263.1	RP11-1072A3.4	-3.55	0.000419	0.0264	-0.35	-0.16	Tonsillectomy;	chr16:30868998	chr16:30956872~30957199:-
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000184274.3	LINC00315	-3.55	0.000419	0.0264	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45300245~45305257:-
THCA	cis	rs6674970	1	rs4970941	ENSG00000261168.1	RP11-68I18.10	-3.55	0.000419	0.0264	-0.21	-0.16	Childhood ear infection;	chr1:151096070	chr1:151130075~151131610:-
THCA	cis	rs6657613	0.503	rs9435739	ENSG00000235241.1	RP11-108M9.5	3.55	0.000419	0.0264	0.18	0.16	Hip circumference adjusted for BMI;	chr1:17016429	chr1:16889095~16889602:+
THCA	cis	rs10861661	0.963	rs10861662	ENSG00000260329.1	RP11-412D9.4	-3.55	0.000419	0.0264	-0.18	-0.16	Triglyceride levels;	chr12:106784875	chr12:106954029~106955497:-
THCA	cis	rs72945132	0.619	rs34552378	ENSG00000254604.1	AP000487.6	-3.55	0.000419	0.0264	-0.3	-0.16	Coronary artery disease;	chr11:70397102	chr11:70282367~70363368:-
THCA	cis	rs3767627	0.505	rs12022928	ENSG00000203819.6	HIST2H2BC	3.55	0.000419	0.0264	0.21	0.16	Height;	chr1:150022996	chr1:149850193~149850772:-
THCA	cis	rs7511006	1	rs7364173	ENSG00000273137.1	RP3-402G11.28	3.55	0.000419	0.0264	0.11	0.16	Obesity-related traits;	chr22:50242600	chr22:50208461~50209542:-
THCA	cis	rs1153858	1	rs12437887	ENSG00000275672.1	GATM-AS1	-3.55	0.000419	0.0264	-0.17	-0.16	Homoarginine levels;	chr15:45376896	chr15:45378700~45380123:+
THCA	cis	rs7674212	0.772	rs13113099	ENSG00000248971.2	KRT8P46	-3.55	0.000419	0.0264	-0.2	-0.16	Type 2 diabetes;	chr4:103052965	chr4:102728746~102730171:-
THCA	cis	rs7819412	0.594	rs7460507	ENSG00000255046.1	RP11-297N6.4	3.55	0.000419	0.0264	0.17	0.16	Triglycerides;	chr8:11111565	chr8:11797928~11802568:-
THCA	cis	rs9863	0.828	rs12311848	ENSG00000269938.1	RP11-214K3.20	-3.55	0.000419	0.0264	-0.19	-0.16	White blood cell count;	chr12:124002304	chr12:123968023~123968579:-
THCA	cis	rs467650	0.75	rs36766	ENSG00000246763.5	RGMB-AS1	3.55	0.000419	0.0264	0.16	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98612986	chr5:98769618~98773469:-
THCA	cis	rs3758911	0.796	rs112617433	ENSG00000255353.1	RP11-382M14.1	-3.55	0.000419	0.0264	-0.21	-0.16	Coronary artery disease;	chr11:107282855	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs7929343	ENSG00000255353.1	RP11-382M14.1	-3.55	0.000419	0.0264	-0.21	-0.16	Coronary artery disease;	chr11:107285183	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs7929345	ENSG00000255353.1	RP11-382M14.1	-3.55	0.000419	0.0264	-0.21	-0.16	Coronary artery disease;	chr11:107285185	chr11:107176286~107177530:+
THCA	cis	rs6657613	0.524	rs2746478	ENSG00000186301.8	MST1P2	3.55	0.000419	0.0264	0.13	0.16	Hip circumference adjusted for BMI;	chr1:17015765	chr1:16645622~16650289:+
THCA	cis	rs7474896	0.537	rs1779068	ENSG00000272983.1	RP11-508N22.12	3.55	0.000419	0.0264	0.17	0.16	Obesity (extreme);	chr10:37961857	chr10:38137337~38144399:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000281021.1	RP1-12G14.9	-3.55	0.000419	0.0264	-0.16	-0.16	Lung cancer;	chr6:149791033	chr6:149576089~149590864:-
THCA	cis	rs7311936	1	rs10773058	ENSG00000270130.1	RP11-214K3.23	-3.55	0.000419	0.0264	-0.17	-0.16	Vertical cup-disc ratio;	chr12:124146329	chr12:123960717~123961244:-
THCA	cis	rs7572644	0.723	rs12473400	ENSG00000223522.1	AC093690.1	-3.55	0.000419	0.0264	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27801157	chr2:28307691~28310459:-
THCA	cis	rs7020830	0.898	rs12554874	ENSG00000260100.1	RP11-220I1.5	-3.55	0.000419	0.0264	-0.2	-0.16	Schizophrenia;	chr9:37073905	chr9:37078813~37079776:-
THCA	cis	rs10488360	0.708	rs7459304	ENSG00000270822.1	RP11-730B22.1	3.55	0.000419	0.0264	0.2	0.16	Factor VII;	chr7:4372197	chr7:5009164~5009328:-
THCA	cis	rs970548	0.862	rs10900230	ENSG00000230869.1	CTGLF10P	3.55	0.000419	0.0264	0.2	0.16	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45634941	chr10:45678692~45700532:+
THCA	cis	rs970548	0.955	rs61854156	ENSG00000230869.1	CTGLF10P	3.55	0.000419	0.0264	0.2	0.16	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45643216	chr10:45678692~45700532:+
THCA	cis	rs453301	0.686	rs11787026	ENSG00000253981.4	ALG1L13P	3.55	0.000419	0.0264	0.15	0.16	Joint mobility (Beighton score);	chr8:9044861	chr8:8236003~8244667:-
THCA	cis	rs61160187	0.582	rs17444495	ENSG00000272308.1	RP11-231G3.1	-3.55	0.00042	0.0264	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:60866457~60866935:-
THCA	cis	rs7481311	0.956	rs1873078	ENSG00000245573.6	BDNF-AS	3.55	0.00042	0.0264	0.15	0.16	Weight;Body mass index;	chr11:27526456	chr11:27506838~27698174:+
THCA	cis	rs9291683	0.53	rs6449196	ENSG00000261490.1	RP11-448G15.3	-3.55	0.00042	0.0264	-0.1	-0.16	Bone mineral density;	chr4:9972036	chr4:10068089~10073019:-
THCA	cis	rs3808502	0.527	rs2736374	ENSG00000255046.1	RP11-297N6.4	3.55	0.00042	0.0264	0.17	0.16	Neuroticism;	chr8:11256319	chr8:11797928~11802568:-
THCA	cis	rs7267979	1	rs2297497	ENSG00000276952.1	RP5-965G21.6	-3.55	0.00042	0.0264	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25284915~25285588:-
THCA	cis	rs11098499	0.644	rs2389880	ENSG00000249244.1	RP11-548H18.2	3.55	0.00042	0.0264	0.18	0.16	Corneal astigmatism;	chr4:119638715	chr4:119391831~119395335:-
THCA	cis	rs9911578	0.874	rs302874	ENSG00000224738.1	AC099850.1	3.55	0.00042	0.0264	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58690635	chr17:59106598~59118267:+
THCA	cis	rs9923856	0.57	rs9652599	ENSG00000263033.2	RP11-396B14.2	3.55	0.00042	0.0264	0.15	0.16	Atopic dermatitis;Adult asthma;	chr16:10985304	chr16:11196177~11224969:+
THCA	cis	rs7824557	0.547	rs2736287	ENSG00000206014.6	OR7E161P	3.55	0.00042	0.0264	0.19	0.16	Retinal vascular caliber;	chr8:11370497	chr8:11928597~11929563:-
THCA	cis	rs4262150	0.81	rs4958320	ENSG00000253921.1	CTB-113P19.3	3.55	0.00042	0.0264	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152584654	chr5:151753992~151767247:+
THCA	cis	rs1862618	0.853	rs9283717	ENSG00000234553.1	AC022431.3	-3.55	0.00042	0.0264	-0.19	-0.16	Initial pursuit acceleration;	chr5:56782832	chr5:56536583~56537826:-
THCA	cis	rs16975963	0.639	rs112997435	ENSG00000276846.1	CTD-3220F14.3	-3.55	0.00042	0.0264	-0.15	-0.16	Longevity;	chr19:37713730	chr19:37314868~37315620:-
THCA	cis	rs10508774	1	rs10508777	ENSG00000217094.2	PPIAP31	3.55	0.00042	0.0264	0.27	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32685772	chr10:32188323~32188817:-
THCA	cis	rs7225537	0.738	rs12941341	ENSG00000260328.1	RP11-416I2.1	3.55	0.00042	0.0264	0.13	0.16	Mean platelet volume;	chr17:17003432	chr17:17011914~17014990:-
THCA	cis	rs801193	0.66	rs2659897	ENSG00000272831.1	RP11-792A8.4	-3.55	0.00042	0.0264	-0.1	-0.16	Aortic root size;	chr7:66722728	chr7:66739829~66740385:-
THCA	cis	rs67073037	0.565	rs13008915	ENSG00000273233.1	RP11-713D19.1	3.55	0.00042	0.0264	0.19	0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28921646	chr2:28810281~28810706:-
THCA	cis	rs9393777	0.92	rs35120058	ENSG00000220721.1	OR1F12	3.55	0.00042	0.0264	0.32	0.16	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28073316~28074233:+
THCA	cis	rs3002142	0.524	rs2378585	ENSG00000229399.1	RP11-378J18.6	3.55	0.00042	0.0264	0.26	0.16	LDL peak particle diameter (total fat intake interaction);	chr1:222608480	chr1:222641414~222641858:-
THCA	cis	rs6500637	0.86	rs11644917	ENSG00000267077.1	RP11-127I20.5	-3.55	0.00042	0.0264	-0.19	-0.16	Cancer;	chr16:4890386	chr16:4795265~4796532:-
THCA	cis	rs2919009	0.882	rs3011384	ENSG00000271670.1	RP11-95I16.4	3.55	0.00042	0.0264	0.18	0.16	Obesity-related traits;	chr10:120833599	chr10:120879256~120880667:-
THCA	cis	rs4972539	0.525	rs10198810	ENSG00000238133.5	MLK7-AS1	3.55	0.00042	0.0264	0.21	0.16	Parental longevity (mother's age at death);	chr2:173208331	chr2:173166446~173282036:-
THCA	cis	rs7777677	0.963	rs7796324	ENSG00000226660.2	TRBV2	3.55	0.00042	0.0264	0.14	0.16	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142300924~142301432:+
THCA	cis	rs17597773	1	rs17597773	ENSG00000272823.1	RP11-295M18.6	-3.55	0.00042	0.0265	-0.22	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220881419	chr1:220828676~220829211:-
THCA	cis	rs7937682	0.601	rs2187388	ENSG00000196167.8	COLCA1	3.55	0.00042	0.0265	0.17	0.16	Primary sclerosing cholangitis;	chr11:111516391	chr11:111290787~111305045:-
THCA	cis	rs2898290	0.593	rs2199690	ENSG00000206014.6	OR7E161P	3.55	0.00042	0.0265	0.19	0.16	Systolic blood pressure;	chr8:11482107	chr8:11928597~11929563:-
THCA	cis	rs972578	1	rs1546860	ENSG00000230319.1	AL022476.2	3.55	0.00042	0.0265	0.17	0.16	Mean platelet volume;	chr22:43004323	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs1569507	ENSG00000230319.1	AL022476.2	-3.55	0.00042	0.0265	-0.18	-0.16	Mean platelet volume;	chr22:42960693	chr22:43038585~43052366:+
THCA	cis	rs6568686	0.786	rs6929494	ENSG00000255389.1	C6orf3	-3.55	0.00042	0.0265	-0.22	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111536127	chr6:111599875~111602295:+
THCA	cis	rs7975161	0.572	rs4964228	ENSG00000214198.6	RP11-642P15.1	3.55	0.00042	0.0265	0.27	0.16	Toenail selenium levels;	chr12:104178981	chr12:103843749~103930211:-
THCA	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-3.55	0.00042	0.0265	-0.19	-0.16	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0265	0.19	0.16	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
THCA	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0265	0.19	0.16	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0265	0.19	0.16	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0265	0.19	0.16	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0265	0.19	0.16	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
THCA	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0265	0.19	0.16	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0265	0.19	0.16	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0265	0.19	0.16	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
THCA	cis	rs8113308	0.515	rs55866828	ENSG00000275055.1	CTC-471J1.11	-3.55	0.00042	0.0265	-0.23	-0.16	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938332	chr19:52049007~52049754:+
THCA	cis	rs6546886	0.956	rs35749047	ENSG00000235499.1	AC073046.25	3.55	0.00042	0.0265	0.15	0.16	Dialysis-related mortality;	chr2:74053242	chr2:73985132~73986343:+
THCA	cis	rs7824557	0.505	rs2736313	ENSG00000254866.2	DEFB109P3	-3.55	0.00042	0.0265	-0.22	-0.16	Retinal vascular caliber;	chr8:11229433	chr8:12150895~12151134:-
THCA	cis	rs9291683	0.588	rs34501273	ENSG00000250413.1	RP11-448G15.1	-3.55	0.00042	0.0265	-0.15	-0.16	Bone mineral density;	chr4:9995372	chr4:10006482~10009725:+
THCA	cis	rs6496667	1	rs3803539	ENSG00000259262.1	NDUFA3P4	3.55	0.00042	0.0265	0.22	0.16	Rheumatoid arthritis;	chr15:90348750	chr15:90385814~90386063:+
THCA	cis	rs4819052	0.851	rs2256000	ENSG00000182586.6	LINC00334	-3.55	0.000421	0.0265	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45234340~45258730:+
THCA	cis	rs28643277	0.671	rs7901351	ENSG00000237470.3	DCLRE1CP1	-3.55	0.000421	0.0265	-0.21	-0.16	Periodontitis (CDC/AAP);	chr10:15502078	chr10:15015370~15021863:-
THCA	cis	rs964611	0.872	rs60820695	ENSG00000259488.2	RP11-154J22.1	-3.55	0.000421	0.0265	-0.16	-0.16	Metabolite levels (Pyroglutamine);	chr15:48292686	chr15:48312353~48331856:-
THCA	cis	rs7829975	0.688	rs6995407	ENSG00000254340.1	RP11-10A14.3	3.55	0.000421	0.0265	0.18	0.16	Mood instability;	chr8:8527137	chr8:9141424~9145435:+
THCA	cis	rs4723738	1	rs6462817	ENSG00000227191.5	TRGC2	-3.55	0.000421	0.0265	-0.12	-0.16	Treatment response for severe sepsis;	chr7:38211264	chr7:38239580~38368091:-
THCA	cis	rs6012953	0.63	rs6067474	ENSG00000231715.1	COX6CP2	3.55	0.000421	0.0265	0.18	0.16	Vitiligo;	chr20:50519450	chr20:50479767~50479991:+
THCA	cis	rs4886920	0.601	rs12901558	ENSG00000260776.4	RP11-114H24.2	-3.55	0.000421	0.0265	-0.19	-0.16	Neuroticism;	chr15:77784037	chr15:77914217~77926846:-
THCA	cis	rs4792901	0.802	rs72833136	ENSG00000279602.1	CTD-3014M21.1	-3.55	0.000421	0.0265	-0.21	-0.16	Dupuytren's disease;	chr17:43522322	chr17:43360041~43361361:-
THCA	cis	rs2280018	0.538	rs7404526	ENSG00000255277.3	ABCC6P2	3.55	0.000421	0.0265	0.18	0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:14820792~14824702:-
THCA	cis	rs7088591	0.702	rs16911465	ENSG00000276818.1	AC026393.1	3.55	0.000421	0.0265	0.32	0.16	Blood pressure;	chr10:57981054	chr10:57095699~57095781:+
THCA	cis	rs17291845	0.744	rs12931525	ENSG00000260135.5	RP11-212I21.2	3.55	0.000421	0.0265	0.23	0.16	Information processing speed;	chr16:55227217	chr16:55426797~55462297:-
THCA	cis	rs763121	0.925	rs4821797	ENSG00000225450.1	RP3-508I15.14	-3.55	0.000421	0.0265	-0.12	-0.16	Menopause (age at onset);	chr22:38620177	chr22:38739003~38749041:+
THCA	cis	rs10129255	0.957	rs8014696	ENSG00000280411.1	IGHV1-69-2	3.55	0.000421	0.0265	0.1	0.16	Kawasaki disease;	chr14:106769752	chr14:106762092~106762588:-
THCA	cis	rs35359187	0.557	rs4374547	ENSG00000229912.1	AC128709.4	3.55	0.000421	0.0265	0.31	0.16	Facial morphology (factor 22);	chr3:197535089	chr3:197450327~197456654:-
THCA	cis	rs950169	1	rs12915234	ENSG00000275120.1	RP11-182J1.17	3.55	0.000421	0.0265	0.19	0.16	Schizophrenia;	chr15:84089549	chr15:84599434~84606463:-
THCA	cis	rs950169	1	rs34751999	ENSG00000275120.1	RP11-182J1.17	3.55	0.000421	0.0265	0.19	0.16	Schizophrenia;	chr15:84089667	chr15:84599434~84606463:-
THCA	cis	rs950169	0.919	rs17300292	ENSG00000275120.1	RP11-182J1.17	3.55	0.000421	0.0265	0.19	0.16	Schizophrenia;	chr15:84093816	chr15:84599434~84606463:-
THCA	cis	rs9860428	0.723	rs1354055	ENSG00000240057.4	RP11-572M11.4	-3.55	0.000421	0.0265	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896099	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.844	rs6795428	ENSG00000240057.4	RP11-572M11.4	-3.55	0.000421	0.0265	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896508	chr3:113019532~113183301:+
THCA	cis	rs12476592	0.602	rs262476	ENSG00000242412.1	DBIL5P2	-3.55	0.000421	0.0265	-0.21	-0.16	Childhood ear infection;	chr2:63643473	chr2:63117851~63119542:-
THCA	cis	rs17023223	0.537	rs6677107	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs12064033	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs12064137	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.509	rs61806978	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.509	rs56195272	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs12065809	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.553	rs11484962	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs55836852	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs66715579	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs11487668	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119219314~119220096:-
THCA	cis	rs17023223	0.537	rs10923766	ENSG00000227056.2	RPL6P2	-3.55	0.000421	0.0265	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119219314~119220096:-
THCA	cis	rs7010267	0.869	rs1982763	ENSG00000254278.1	RP11-278I4.2	3.55	0.000421	0.0265	0.2	0.16	Total body bone mineral density (age 45-60);	chr8:118935589	chr8:119062942~119068782:-
THCA	cis	rs9309711	0.922	rs13385119	ENSG00000271868.1	RP11-1293J14.1	-3.55	0.000421	0.0265	-0.23	-0.16	Neurofibrillary tangles;	chr2:3480750	chr2:3496956~3497428:+
THCA	cis	rs9308731	1	rs9308731	ENSG00000204581.2	AC096670.3	-3.55	0.000421	0.0265	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:111150685	chr2:111098345~111115588:-
THCA	cis	rs7615952	0.8	rs11914298	ENSG00000272840.1	RP11-379B18.6	3.55	0.000421	0.0265	0.27	0.16	Blood pressure (smoking interaction);	chr3:125924929	chr3:125774714~125797953:+
THCA	cis	rs11686241	0.872	rs8179823	ENSG00000232485.2	AC098820.3	3.55	0.000421	0.0265	0.18	0.16	Cancer;	chr2:216483403	chr2:216479030~216498761:-
THCA	cis	rs13177180	0.523	rs256980	ENSG00000271797.1	CTC-428G20.6	3.55	0.000421	0.0265	0.16	0.16	Conotruncal heart defects (inherited effects);	chr5:115567110	chr5:115262505~115263448:+
THCA	cis	rs4907240	0.922	rs4907246	ENSG00000230606.9	AC159540.1	3.55	0.000421	0.0265	0.18	0.16	Event-related brain oscillations;	chr2:96660549	chr2:97416165~97433527:-
THCA	cis	rs72765298	0.848	rs17337635	ENSG00000235332.2	RP11-366O20.5	3.55	0.000421	0.0265	0.29	0.16	Pulse pressure;	chr9:125196575	chr9:125194649~125195821:-
THCA	cis	rs7976269	0.583	rs2117997	ENSG00000275476.1	RP11-996F15.4	3.55	0.000421	0.0265	0.16	0.16	Male-pattern baldness;	chr12:29143428	chr12:29277397~29277882:-
THCA	cis	rs72482608	0.826	rs763770	ENSG00000271811.1	RP1-79C4.4	3.55	0.000421	0.0265	0.2	0.16	Emphysema imaging phenotypes;	chr1:170798378	chr1:170667381~170669425:+
THCA	cis	rs6545883	0.86	rs13023037	ENSG00000212978.6	AC016747.3	-3.55	0.000421	0.0265	-0.18	-0.16	Tuberculosis;	chr2:61393854	chr2:61141592~61144969:-
THCA	cis	rs2439831	0.541	rs12440854	ENSG00000166763.7	STRCP1	3.55	0.000421	0.0265	0.25	0.16	Lung cancer in ever smokers;	chr15:43318474	chr15:43699488~43718184:-
THCA	cis	rs427394	0.659	rs187295	ENSG00000248677.1	CTD-2044J15.1	3.55	0.000421	0.0265	0.16	0.16	Menopause (age at onset);	chr5:6734213	chr5:6686325~6707711:-
THCA	cis	rs6449502	0.92	rs11951504	ENSG00000251279.1	CTC-436P18.1	-3.55	0.000421	0.0265	-0.26	-0.16	Mean platelet volume;	chr5:61076611	chr5:61162070~61232040:+
THCA	cis	rs9291683	0.53	rs17246501	ENSG00000250413.1	RP11-448G15.1	-3.55	0.000421	0.0265	-0.15	-0.16	Bone mineral density;	chr4:9984086	chr4:10006482~10009725:+
THCA	cis	rs13098911	0.54	rs67937868	ENSG00000226074.4	PRSS44	-3.55	0.000421	0.0265	-0.29	-0.16	Celiac disease;	chr3:46008335	chr3:46809359~46812558:-
THCA	cis	rs7615952	0.546	rs2976733	ENSG00000248787.1	RP11-666A20.4	-3.55	0.000421	0.0265	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125695294	chr3:125908005~125910272:-
THCA	cis	rs4144027	0.967	rs10133399	ENSG00000269958.1	RP11-73M18.8	3.55	0.000421	0.0265	0.15	0.16	Blood metabolite levels;	chr14:103895506	chr14:103696353~103697163:+
THCA	cis	rs8037137	1	rs8037137	ENSG00000258725.1	PRC1-AS1	-3.55	0.000421	0.0265	-0.25	-0.16	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90963407	chr15:90966345~90988624:+
THCA	cis	rs9341808	0.718	rs9352803	ENSG00000260645.1	RP11-250B2.5	3.55	0.000421	0.0265	0.14	0.16	Sitting height ratio;	chr6:80154950	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.655	rs9350846	ENSG00000260645.1	RP11-250B2.5	3.55	0.000421	0.0265	0.14	0.16	Sitting height ratio;	chr6:80155764	chr6:80466958~80469080:+
THCA	cis	rs4240897	0.935	rs2236055	ENSG00000201801.1	RNU5E-4P	3.55	0.000421	0.0265	0.19	0.16	Tuberculosis;	chr1:11982204	chr1:11909808~11909927:-
THCA	cis	rs965469	0.895	rs6051840	ENSG00000226632.1	UBE2V1P1	3.55	0.000421	0.0265	0.25	0.16	IFN-related cytopenia;	chr20:3410836	chr20:3361880~3362324:-
THCA	cis	rs4578769	0.55	rs12954377	ENSG00000273232.1	RP11-370A5.2	3.55	0.000421	0.0265	0.22	0.16	Eosinophil percentage of white cells;	chr18:22940862	chr18:22882825~22883357:-
THCA	cis	rs76382185	0.756	rs11577369	ENSG00000233184.5	RP11-421L21.3	3.55	0.000421	0.0265	0.25	0.16	Lymphocyte counts;	chr1:101122255	chr1:101025878~101087268:+
THCA	cis	rs875971	0.577	rs35072105	ENSG00000232546.1	RP11-458F8.1	3.55	0.000421	0.0265	0.13	0.16	Aortic root size;	chr7:66144830	chr7:66848496~66858136:+
THCA	cis	rs12410462	0.681	rs114950580	ENSG00000227711.2	RP11-275O4.5	-3.55	0.000421	0.0265	-0.31	-0.16	Major depressive disorder;	chr1:227485633	chr1:227509028~227520477:-
THCA	cis	rs11190604	0.767	rs10883485	ENSG00000273030.1	RP11-285F16.1	3.55	0.000421	0.0265	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100415048	chr10:100412934~100413421:+
THCA	cis	rs1864585	0.52	rs55848210	ENSG00000280294.1	RP11-177H2.1	3.55	0.000421	0.0265	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10836217	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs56046029	ENSG00000280294.1	RP11-177H2.1	3.55	0.000421	0.0265	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10836293	chr8:10856085~10859436:-
THCA	cis	rs1478897	0.575	rs12679960	ENSG00000255495.1	AC145124.2	3.55	0.000421	0.0265	0.2	0.16	Systemic lupus erythematosus;	chr8:11573481	chr8:12194467~12196280:+
THCA	cis	rs6443245	0.511	rs2542366	ENSG00000227110.5	LMCD1-AS1	-3.55	0.000421	0.0265	-0.19	-0.16	Daytime sleep phenotypes;	chr3:9578671	chr3:7952805~8611924:-
THCA	cis	rs6787172	0.748	rs7630443	ENSG00000272087.1	RP11-379F4.7	-3.55	0.000421	0.0265	-0.15	-0.16	Subjective well-being;	chr3:158406115	chr3:158693120~158693768:-
THCA	cis	rs1923243	0.749	rs9919151	ENSG00000223479.3	RP4-788P17.1	-3.55	0.000421	0.0265	-0.18	-0.16	Migraine;	chr1:73065477	chr1:73635216~73715214:+
THCA	cis	rs2835345	0.962	rs2835344	ENSG00000230479.1	AP000695.6	3.55	0.000421	0.0265	0.2	0.16	Pulmonary function;	chr21:36429047	chr21:36430360~36481070:+
THCA	cis	rs181553	0.664	rs8094480	ENSG00000266696.1	RP11-30L3.2	3.55	0.000421	0.0265	0.2	0.16	Hip circumference adjusted for BMI;	chr18:49161306	chr18:49205912~49208781:+
THCA	cis	rs17156371	0.803	rs61844196	ENSG00000182531.7	OR7E115P	-3.55	0.000421	0.0265	-0.3	-0.16	Clozapine-induced agranulocytosis;	chr10:15162464	chr10:15007861~15008884:-
THCA	cis	rs7824557	0.507	rs7010590	ENSG00000254839.1	AF131215.6	-3.55	0.000422	0.0265	-0.17	-0.16	Retinal vascular caliber;	chr8:11205373	chr8:11062647~11067089:-
THCA	cis	rs4815191	0.788	rs1114221	ENSG00000230387.2	RP4-737E23.2	3.55	0.000422	0.0265	0.23	0.16	Obesity-related traits;	chr20:23269446	chr20:23187961~23190307:+
THCA	cis	rs2562456	0.754	rs58338799	ENSG00000268278.1	RP11-420K14.1	3.55	0.000422	0.0265	0.22	0.16	Pain;	chr19:21339009	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs7259396	ENSG00000268278.1	RP11-420K14.1	3.55	0.000422	0.0265	0.22	0.16	Pain;	chr19:21340661	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.678	rs7260140	ENSG00000268278.1	RP11-420K14.1	3.55	0.000422	0.0265	0.22	0.16	Pain;	chr19:21340723	chr19:21637974~21656300:+
THCA	cis	rs2163813	1	rs247776	ENSG00000271283.1	CTC-412M14.6	-3.55	0.000422	0.0265	-0.22	-0.16	Toenail selenium levels;	chr19:19731806	chr19:19699203~19699409:-
THCA	cis	rs3176789	0.624	rs12422989	ENSG00000256673.1	RP11-599J14.2	3.55	0.000422	0.0265	0.2	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767732	chr12:9398355~9414851:-
THCA	cis	rs1433188	0.847	rs6469113	ENSG00000253582.1	RP11-649G15.2	3.55	0.000422	0.0265	0.19	0.16	Subjective well-being;	chr8:107441274	chr8:106520474~106657548:-
THCA	cis	rs7096965	0.918	rs12259949	ENSG00000242147.1	RP13-463N16.6	-3.55	0.000422	0.0265	-0.18	-0.16	Major depressive disorder;	chr10:4596627	chr10:5594991~5596118:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000232546.1	RP11-458F8.1	3.55	0.000422	0.0265	0.13	0.16	Aortic root size;	chr7:66032447	chr7:66848496~66858136:+
THCA	cis	rs7973719	0.509	rs3816424	ENSG00000256967.1	RP11-273B20.1	3.55	0.000422	0.0265	0.14	0.16	IgG glycosylation;	chr12:7207633	chr12:7129079~7131198:-
THCA	cis	rs11887277	0.507	rs6547274	ENSG00000272148.1	RP11-195B17.1	-3.55	0.000422	0.0265	-0.15	-0.16	Obesity-related traits;	chr2:26841481	chr2:27062428~27062907:-
THCA	cis	rs45544231	1	rs4238749	ENSG00000279344.1	RP11-44F14.7	3.55	0.000422	0.0265	0.15	0.16	Restless legs syndrome;	chr16:52605322	chr16:53478957~53481550:-
THCA	cis	rs17689437	0.671	rs1645937	ENSG00000260084.1	RP11-615I2.1	3.55	0.000422	0.0265	0.19	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68559941	chr16:68573782~68589512:-
THCA	cis	rs17689437	0.625	rs1728791	ENSG00000260084.1	RP11-615I2.1	3.55	0.000422	0.0265	0.19	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68562606	chr16:68573782~68589512:-
THCA	cis	rs2243480	1	rs937108	ENSG00000237310.1	GS1-124K5.4	3.55	0.000422	0.0265	0.18	0.16	Diabetic kidney disease;	chr7:65963465	chr7:66493706~66495474:+
THCA	cis	rs4568518	0.903	rs6957876	ENSG00000279048.1	RP11-511H23.2	-3.55	0.000422	0.0266	-0.11	-0.16	Measles;	chr7:18000641	chr7:17940503~17942922:+
THCA	cis	rs6137726	0.652	rs6036172	ENSG00000237396.1	LINC01384	-3.55	0.000422	0.0266	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22670551	chr20:22587522~22607517:-
THCA	cis	rs11800820	0.557	rs12045741	ENSG00000227953.5	LINC01341	-3.55	0.000422	0.0266	-0.15	-0.16	Obesity-related traits;	chr1:246501332	chr1:246776013~246792385:+
THCA	cis	rs8030379	0.519	rs11259926	ENSG00000176700.18	SCAND2P	-3.55	0.000422	0.0266	-0.11	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897496	chr15:84631451~84647478:+
THCA	cis	rs516805	0.748	rs155461	ENSG00000279114.1	RP3-425C14.5	-3.55	0.000422	0.0266	-0.2	-0.16	Lymphocyte counts;	chr6:122499547	chr6:122471923~122484161:+
THCA	cis	rs13034020	0.739	rs34023434	ENSG00000271889.1	RP11-493E12.1	-3.55	0.000422	0.0266	-0.23	-0.16	Hodgkin's lymphoma;	chr2:60895182	chr2:61151433~61162105:-
THCA	cis	rs7236492	0.872	rs79617804	ENSG00000267655.1	CTD-2286N8.2	3.55	0.000422	0.0266	0.37	0.16	Inflammatory bowel disease;Crohn's disease;	chr18:79477142	chr18:79117207~79117920:+
THCA	cis	rs9420	0.528	rs11229075	ENSG00000254602.1	AP000662.4	-3.55	0.000422	0.0266	-0.19	-0.16	Schizophrenia;	chr11:57623550	chr11:57638024~57652790:+
THCA	cis	rs7713065	0.612	rs10060626	ENSG00000237714.1	P4HA2-AS1	-3.55	0.000422	0.0266	-0.27	-0.16	Lung function (FEV1/FVC);	chr5:132468275	chr5:132184876~132192808:+
THCA	cis	rs911555	0.547	rs8006994	ENSG00000244691.1	RPL10AP1	-3.55	0.000422	0.0266	-0.22	-0.16	Intelligence (multi-trait analysis);	chr14:103374959	chr14:103412119~103412761:-
THCA	cis	rs13064411	0.696	rs7622740	ENSG00000243849.1	CFAP44-AS1	3.55	0.000422	0.0266	0.25	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113487924	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs1486897	ENSG00000243849.1	CFAP44-AS1	3.55	0.000422	0.0266	0.25	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113496971	chr3:113403991~113433992:+
THCA	cis	rs478304	0.627	rs11604568	ENSG00000255120.4	OVOL1-AS1	-3.55	0.000422	0.0266	-0.21	-0.16	Acne (severe);	chr11:65743865	chr11:65789051~65790868:-
THCA	cis	rs478304	0.651	rs7110576	ENSG00000255120.4	OVOL1-AS1	-3.55	0.000422	0.0266	-0.21	-0.16	Acne (severe);	chr11:65744586	chr11:65789051~65790868:-
THCA	cis	rs4081724	0.638	rs17530479	ENSG00000267296.2	CEBPA-AS1	-3.55	0.000422	0.0266	-0.2	-0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33369130	chr19:33302857~33305054:+
THCA	cis	rs7824557	0.527	rs4634600	ENSG00000255495.1	AC145124.2	-3.55	0.000422	0.0266	-0.18	-0.16	Retinal vascular caliber;	chr8:11381508	chr8:12194467~12196280:+
THCA	cis	rs7824557	0.527	rs4631425	ENSG00000255495.1	AC145124.2	-3.55	0.000422	0.0266	-0.18	-0.16	Retinal vascular caliber;	chr8:11381545	chr8:12194467~12196280:+
THCA	cis	rs3808502	0.585	rs4549730	ENSG00000255495.1	AC145124.2	-3.55	0.000422	0.0266	-0.18	-0.16	Neuroticism;	chr8:11381569	chr8:12194467~12196280:+
THCA	cis	rs11764561	0.918	rs7783638	ENSG00000236018.2	RP4-814D15.1	3.55	0.000422	0.0266	0.23	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr7:156223205	chr7:157197600~157198511:-
THCA	cis	rs7824557	0.836	rs1435278	ENSG00000255310.2	AF131215.2	-3.55	0.000422	0.0266	-0.14	-0.16	Retinal vascular caliber;	chr8:11265520	chr8:11107788~11109726:-
THCA	cis	rs2348418	0.765	rs12368743	ENSG00000278733.1	RP11-425D17.1	3.55	0.000422	0.0266	0.14	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28192409	chr12:28185625~28186190:-
THCA	cis	rs728616	0.558	rs35698456	ENSG00000225484.5	NUTM2B-AS1	-3.55	0.000423	0.0266	-0.27	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80381806	chr10:79663088~79826594:-
THCA	cis	rs1555322	1	rs6058219	ENSG00000126005.14	MMP24-AS1	-3.55	0.000423	0.0266	-0.23	-0.16	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35216462~35278131:-
THCA	cis	rs4664304	0.966	rs1397707	ENSG00000226266.5	AC009961.3	3.55	0.000423	0.0266	0.2	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159904461	chr2:159670708~159712435:-
THCA	cis	rs1153858	1	rs56850226	ENSG00000275672.1	GATM-AS1	-3.55	0.000423	0.0266	-0.17	-0.16	Homoarginine levels;	chr15:45340920	chr15:45378700~45380123:+
THCA	cis	rs4713118	0.869	rs10214440	ENSG00000216915.2	RP1-97D16.1	-3.55	0.000423	0.0266	-0.24	-0.16	Parkinson's disease;	chr6:27734661	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.869	rs6902689	ENSG00000216915.2	RP1-97D16.1	-3.55	0.000423	0.0266	-0.24	-0.16	Parkinson's disease;	chr6:27741662	chr6:27737000~27738494:-
THCA	cis	rs722599	0.562	rs2193597	ENSG00000279594.1	RP11-950C14.10	3.55	0.000423	0.0266	0.16	0.16	IgG glycosylation;	chr14:74767626	chr14:75011269~75012851:-
THCA	cis	rs5744897	0.655	rs35131280	ENSG00000246394.6	RP11-386I8.6	3.55	0.000423	0.0266	0.28	0.16	Urate levels in overweight individuals;	chr12:132699388	chr12:133030389~133037222:-
THCA	cis	rs6456156	0.586	rs2285148	ENSG00000235272.1	FAM103A2P	3.55	0.000423	0.0266	0.22	0.16	Primary biliary cholangitis;	chr6:167077511	chr6:166586124~166586477:-
THCA	cis	rs2228479	0.85	rs17233567	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89747413	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs45567439	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89748196	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs45524643	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89749416	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17227064	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89749906	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17227057	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89749925	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs1800344	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89749959	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17233455	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89749999	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17233448	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89750016	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62054609	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89750161	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62054610	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89750512	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62054611	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89750609	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs17233441	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000423	0.0266	-0.29	-0.16	Skin colour saturation;	chr16:89751590	chr16:89516797~89522217:+
THCA	cis	rs11239930	0.538	rs4950361	ENSG00000278811.3	LINC00624	-3.55	0.000423	0.0266	-0.18	-0.16	AIDS progression;	chr1:147087618	chr1:147258885~147517875:-
THCA	cis	rs4788815	0.712	rs4788563	ENSG00000260886.1	TAT-AS1	3.55	0.000423	0.0266	0.23	0.16	Metabolite levels;	chr16:71845965	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.563	rs12921084	ENSG00000260886.1	TAT-AS1	3.55	0.000423	0.0266	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71847062	chr16:71565789~71578187:+
THCA	cis	rs6940638	0.688	rs6456766	ENSG00000224843.5	LINC00240	3.55	0.000423	0.0266	0.15	0.16	Intelligence (multi-trait analysis);	chr6:27051796	chr6:26956992~27023924:+
THCA	cis	rs5753037	0.869	rs41159	ENSG00000279699.1	RP1-102K2.9	3.55	0.000423	0.0266	0.16	0.16	Type 1 diabetes;	chr22:30011375	chr22:30275215~30276951:-
THCA	cis	rs6121246	0.697	rs6088864	ENSG00000224628.2	RP5-854E16.2	-3.55	0.000423	0.0266	-0.23	-0.16	Mean corpuscular hemoglobin;	chr20:31640354	chr20:31285317~31286835:-
THCA	cis	rs2447820	0.5	rs165976	ENSG00000263432.2	RN7SL689P	3.55	0.000423	0.0266	0.2	0.16	Migraine;	chr5:122878151	chr5:123022487~123022783:-
THCA	cis	rs2736337	0.53	rs2003422	ENSG00000227888.4	FAM66A	3.55	0.000423	0.0266	0.2	0.16	Rheumatoid arthritis;	chr8:11445628	chr8:12362019~12388296:+
THCA	cis	rs6439153	0.933	rs2630262	ENSG00000231305.3	RP11-723O4.2	-3.55	0.000423	0.0266	-0.17	-0.16	Pneumococcal bacteremia;	chr3:128958255	chr3:128861313~128871540:-
THCA	cis	rs786425	0.682	rs12828408	ENSG00000278112.1	RP11-972P1.11	3.55	0.000423	0.0266	0.16	0.16	Pubertal anthropometrics;	chr12:123714171	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs3817309	ENSG00000278112.1	RP11-972P1.11	3.55	0.000423	0.0266	0.16	0.16	Pubertal anthropometrics;	chr12:123714174	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs66471742	ENSG00000278112.1	RP11-972P1.11	3.55	0.000423	0.0266	0.16	0.16	Pubertal anthropometrics;	chr12:123714459	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs7135267	ENSG00000278112.1	RP11-972P1.11	3.55	0.000423	0.0266	0.16	0.16	Pubertal anthropometrics;	chr12:123714573	chr12:123519390~123519856:-
THCA	cis	rs889312	0.961	rs1862626	ENSG00000271828.1	CTD-2310F14.1	-3.55	0.000423	0.0266	-0.23	-0.16	Breast cancer (early onset);Breast cancer;	chr5:56737113	chr5:56927874~56929573:+
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000273024.4	INTS4P2	3.55	0.000423	0.0266	0.27	0.16	Diabetic kidney disease;	chr7:65970805	chr7:65647864~65715661:+
THCA	cis	rs494526	0.641	rs4752250	ENSG00000229272.1	RP11-498J9.2	3.55	0.000423	0.0266	0.18	0.16	Alcoholic chronic pancreatitis;	chr10:119116292	chr10:119003536~119003884:-
THCA	cis	rs12506899	0.967	rs3775486	ENSG00000221639.1	SNORA3	3.55	0.000423	0.0266	0.19	0.16	Tumor biomarkers;	chr4:73409798	chr4:73263960~73264084:+
THCA	cis	rs944289	0.74	rs56400346	ENSG00000212071.1	AL162511.1	3.55	0.000423	0.0266	0.19	0.16	Thyroid cancer;	chr14:36114681	chr14:36196480~36196568:-
THCA	cis	rs763121	0.853	rs5757187	ENSG00000272669.1	RP3-508I15.21	3.55	0.000423	0.0266	0.11	0.16	Menopause (age at onset);	chr22:38625517	chr22:38742625~38743115:+
THCA	cis	rs2692947	0.537	rs4907274	ENSG00000168992.4	OR7E102P	3.55	0.000423	0.0266	0.21	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95697934	chr2:95546531~95547545:+
THCA	cis	rs10223402	0.838	rs67836109	ENSG00000233558.1	RP3-486I3.4	3.55	0.000423	0.0266	0.29	0.16	Appendicular lean mass;	chr6:115624006	chr6:116258493~116259115:-
THCA	cis	rs10223402	0.838	rs72957739	ENSG00000233558.1	RP3-486I3.4	3.55	0.000423	0.0266	0.29	0.16	Appendicular lean mass;	chr6:115631402	chr6:116258493~116259115:-
THCA	cis	rs345013	0.92	rs1596719	ENSG00000240032.1	RP11-274H2.3	-3.55	0.000423	0.0266	-0.25	-0.16	Prostate cancer;	chr3:145270343	chr3:146066344~146069185:-
THCA	cis	rs10495907	0.591	rs72790990	ENSG00000234936.1	AC010883.5	3.55	0.000423	0.0266	0.16	0.16	Coronary artery disease;	chr2:43723495	chr2:43229573~43233394:+
THCA	cis	rs10495907	0.591	rs1594581	ENSG00000234936.1	AC010883.5	3.55	0.000423	0.0266	0.16	0.16	Coronary artery disease;	chr2:43723674	chr2:43229573~43233394:+
THCA	cis	rs875971	0.558	rs4433015	ENSG00000230295.1	RP11-458F8.2	3.55	0.000423	0.0266	0.12	0.16	Aortic root size;	chr7:66174736	chr7:66880708~66882981:+
THCA	cis	rs7737355	0.853	rs1468453	ENSG00000237714.1	P4HA2-AS1	3.55	0.000423	0.0266	0.23	0.16	Life satisfaction;	chr5:131251766	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.947	rs6895586	ENSG00000237714.1	P4HA2-AS1	3.55	0.000423	0.0266	0.23	0.16	Life satisfaction;	chr5:131252315	chr5:132184876~132192808:+
THCA	cis	rs2337406	0.866	rs112089985	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000423	0.0266	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106780074	chr14:106762092~106762588:-
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000264242.2	RP11-271K11.1	3.55	0.000423	0.0266	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000264242.2	RP11-271K11.1	3.55	0.000423	0.0266	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000264242.2	RP11-271K11.1	3.55	0.000423	0.0266	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000264242.2	RP11-271K11.1	3.55	0.000423	0.0266	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000264242.2	RP11-271K11.1	3.55	0.000423	0.0266	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000264242.2	RP11-271K11.1	3.55	0.000423	0.0266	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000264242.2	RP11-271K11.1	3.55	0.000423	0.0266	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30553697~30558962:+
THCA	cis	rs240993	0.595	rs1040383	ENSG00000272356.1	RP5-1112D6.8	3.55	0.000423	0.0266	0.14	0.16	Inflammatory skin disease;Psoriasis;	chr6:111580985	chr6:111309203~111313517:+
THCA	cis	rs2882667	0.931	rs3749665	ENSG00000249593.5	CTB-46B19.2	3.55	0.000423	0.0266	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:139012647~139051203:+
THCA	cis	rs41357746	0.525	rs57030473	ENSG00000270964.1	RP11-502I4.3	-3.55	0.000423	0.0266	-0.14	-0.16	Total body bone mineral density;	chr15:67484340	chr15:67541072~67542604:-
THCA	cis	rs5753037	0.835	rs737908	ENSG00000279699.1	RP1-102K2.9	3.55	0.000423	0.0266	0.16	0.16	Type 1 diabetes;	chr22:29992313	chr22:30275215~30276951:-
THCA	cis	rs732716	0.74	rs78869060	ENSG00000280239.1	CTB-50L17.8	-3.55	0.000423	0.0266	-0.13	-0.16	Mean corpuscular volume;	chr19:4444745	chr19:4448810~4450836:+
THCA	cis	rs17122278	0.929	rs45474901	ENSG00000243431.1	RPL5P30	3.55	0.000423	0.0266	0.16	0.16	Total cholesterol levels;	chr11:118534738	chr11:118560690~118561580:+
THCA	cis	rs6546550	0.901	rs897119	ENSG00000179818.12	PCBP1-AS1	-3.55	0.000423	0.0266	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69933526	chr2:69962263~70103220:-
THCA	cis	rs12906542	0.507	rs4395040	ENSG00000214646.7	RP11-114H24.4	3.55	0.000423	0.0266	0.24	0.16	Breast cancer;	chr15:77990191	chr15:77941442~77944582:-
THCA	cis	rs3087591	0.573	rs731758	ENSG00000263535.1	AK4P1	3.55	0.000423	0.0266	0.19	0.16	Hip circumference;	chr17:31395982	chr17:31345521~31346187:+
THCA	cis	rs972578	0.535	rs3091364	ENSG00000274717.1	RP1-47A17.1	3.55	0.000423	0.0266	0.17	0.16	Mean platelet volume;	chr22:43018324	chr22:42791814~42794313:-
THCA	cis	rs62289301	0.637	rs34351987	ENSG00000273133.1	RP11-799M12.2	3.55	0.000423	0.0266	0.2	0.16	Joint mobility (Beighton score);	chr4:15403326	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs13132007	ENSG00000273133.1	RP11-799M12.2	3.55	0.000423	0.0266	0.2	0.16	Joint mobility (Beighton score);	chr4:15403749	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs13132446	ENSG00000273133.1	RP11-799M12.2	3.55	0.000423	0.0266	0.2	0.16	Joint mobility (Beighton score);	chr4:15403919	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs34352292	ENSG00000273133.1	RP11-799M12.2	3.55	0.000423	0.0266	0.2	0.16	Joint mobility (Beighton score);	chr4:15404690	chr4:15563698~15564253:-
THCA	cis	rs10191559	0.919	rs7562830	ENSG00000238171.1	AC068196.1	-3.55	0.000424	0.0266	-0.21	-0.16	Red blood cell count;	chr2:180971611	chr2:181076051~181105968:-
THCA	cis	rs6674970	1	rs6676190	ENSG00000261168.1	RP11-68I18.10	-3.55	0.000424	0.0266	-0.21	-0.16	Childhood ear infection;	chr1:151106841	chr1:151130075~151131610:-
THCA	cis	rs478304	0.593	rs2236682	ENSG00000214659.4	KRT8P26	3.55	0.000424	0.0266	0.15	0.16	Acne (severe);	chr11:65712619	chr11:65726939~65728214:+
THCA	cis	rs478304	0.593	rs7120713	ENSG00000214659.4	KRT8P26	3.55	0.000424	0.0266	0.15	0.16	Acne (severe);	chr11:65715903	chr11:65726939~65728214:+
THCA	cis	rs7267979	0.873	rs7453	ENSG00000276952.1	RP5-965G21.6	3.55	0.000424	0.0266	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25284915~25285588:-
THCA	cis	rs6600671	0.966	rs6600664	ENSG00000233029.3	RP11-439A17.9	-3.55	0.000424	0.0266	-0.18	-0.16	Hip geometry;	chr1:121480638	chr1:121090289~121097655:-
THCA	cis	rs6600671	0.932	rs6600663	ENSG00000233029.3	RP11-439A17.9	-3.55	0.000424	0.0266	-0.18	-0.16	Hip geometry;	chr1:121480639	chr1:121090289~121097655:-
THCA	cis	rs763121	0.819	rs5757160	ENSG00000225450.1	RP3-508I15.14	-3.55	0.000424	0.0266	-0.13	-0.16	Menopause (age at onset);	chr22:38593641	chr22:38739003~38749041:+
THCA	cis	rs9488822	0.676	rs12154016	ENSG00000233558.1	RP3-486I3.4	3.55	0.000424	0.0266	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116034025	chr6:116258493~116259115:-
THCA	cis	rs2744375	0.6	rs2237104	ENSG00000261189.1	RP3-512B11.3	-3.55	0.000424	0.0266	-0.17	-0.16	Resting heart rate;	chr6:7551939	chr6:7540451~7541338:-
THCA	cis	rs7824557	0.564	rs2736290	ENSG00000261451.1	RP11-981G7.1	-3.55	0.000424	0.0266	-0.2	-0.16	Retinal vascular caliber;	chr8:11376789	chr8:10433672~10438312:+
THCA	cis	rs5758511	0.68	rs5758657	ENSG00000270083.1	RP1-257I20.14	-3.55	0.000424	0.0266	-0.21	-0.16	Birth weight;	chr22:42222663	chr22:42089630~42090028:-
THCA	cis	rs5758511	0.68	rs1033459	ENSG00000270083.1	RP1-257I20.14	-3.55	0.000424	0.0266	-0.21	-0.16	Birth weight;	chr22:42223061	chr22:42089630~42090028:-
THCA	cis	rs2841277	0.712	rs2841280	ENSG00000258701.1	LINC00638	-3.55	0.000424	0.0266	-0.17	-0.16	Rheumatoid arthritis;	chr14:104927219	chr14:104821201~104823718:+
THCA	cis	rs9889262	0.625	rs4794031	ENSG00000248714.5	RP11-1079K10.3	3.55	0.000424	0.0266	0.18	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49264791	chr17:49361165~49369998:+
THCA	cis	rs11168351	0.889	rs12817104	ENSG00000257735.1	RP11-370I10.6	3.55	0.000424	0.0266	0.19	0.16	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48350945~48442411:+
THCA	cis	rs4713118	0.955	rs9468204	ENSG00000219891.2	ZSCAN12P1	3.55	0.000424	0.0266	0.21	0.16	Parkinson's disease;	chr6:27721030	chr6:28091154~28093664:+
THCA	cis	rs7178909	0.872	rs7179633	ENSG00000259677.1	RP11-493E3.1	3.55	0.000424	0.0266	0.19	0.16	Common traits (Other);	chr15:89891645	chr15:89876540~89877285:+
THCA	cis	rs7178909	0.872	rs28865973	ENSG00000259677.1	RP11-493E3.1	3.55	0.000424	0.0266	0.19	0.16	Common traits (Other);	chr15:89891946	chr15:89876540~89877285:+
THCA	cis	rs964611	0.872	rs11855410	ENSG00000259488.2	RP11-154J22.1	-3.55	0.000424	0.0266	-0.15	-0.16	Metabolite levels (Pyroglutamine);	chr15:48301657	chr15:48312353~48331856:-
THCA	cis	rs9475752	0.53	rs1451709	ENSG00000231441.1	RP11-472M19.2	-3.55	0.000424	0.0266	-0.17	-0.16	Menarche (age at onset);	chr6:56980836	chr6:56844002~56864078:+
THCA	cis	rs4713118	0.869	rs6901520	ENSG00000272009.1	RP1-313I6.12	-3.55	0.000424	0.0266	-0.18	-0.16	Parkinson's disease;	chr6:27746796	chr6:28078792~28081130:-
THCA	cis	rs60695258	0.963	rs3775228	ENSG00000251411.1	RP11-397E7.4	-3.55	0.000424	0.0267	-0.15	-0.16	Hematocrit;	chr4:87064014	chr4:86913266~86914817:-
THCA	cis	rs763121	0.719	rs9610995	ENSG00000225450.1	RP3-508I15.14	-3.55	0.000424	0.0267	-0.13	-0.16	Menopause (age at onset);	chr22:38661758	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs8142098	ENSG00000225450.1	RP3-508I15.14	-3.55	0.000424	0.0267	-0.13	-0.16	Menopause (age at onset);	chr22:38662752	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs2413544	ENSG00000225450.1	RP3-508I15.14	-3.55	0.000424	0.0267	-0.13	-0.16	Menopause (age at onset);	chr22:38663399	chr22:38739003~38749041:+
THCA	cis	rs763121	0.752	rs5757222	ENSG00000225450.1	RP3-508I15.14	-3.55	0.000424	0.0267	-0.13	-0.16	Menopause (age at onset);	chr22:38664468	chr22:38739003~38749041:+
THCA	cis	rs763121	0.819	rs5750658	ENSG00000225450.1	RP3-508I15.14	-3.55	0.000424	0.0267	-0.13	-0.16	Menopause (age at onset);	chr22:38664912	chr22:38739003~38749041:+
THCA	cis	rs763121	0.819	rs8137829	ENSG00000225450.1	RP3-508I15.14	-3.55	0.000424	0.0267	-0.13	-0.16	Menopause (age at onset);	chr22:38665025	chr22:38739003~38749041:+
THCA	cis	rs1502337	0.532	rs4766430	ENSG00000278993.1	RP3-424M6.4	-3.55	0.000424	0.0267	-0.25	-0.16	Body mass index;	chr12:110569474	chr12:110501614~110503441:+
THCA	cis	rs2351088	0.572	rs2238824	ENSG00000280383.1	CTA-941F9.10	3.55	0.000424	0.0267	0.17	0.16	Tonsillectomy;	chr22:45684500	chr22:45657019~45680130:+
THCA	cis	rs1476679	1	rs34919929	ENSG00000240211.1	RP11-758P17.3	-3.55	0.000424	0.0267	-0.16	-0.16	Alzheimer's disease (late onset);	chr7:100414711	chr7:100436204~100438504:+
THCA	cis	rs73242632	0.737	rs4242005	ENSG00000269949.1	RP11-738E22.3	3.55	0.000424	0.0267	0.41	0.16	Congenital heart disease (maternal effect);	chr4:57096301	chr4:56960927~56961373:-
THCA	cis	rs478304	0.934	rs537786	ENSG00000255557.1	RP11-770G2.2	-3.55	0.000424	0.0267	-0.17	-0.16	Acne (severe);	chr11:65727516	chr11:65745729~65771585:+
THCA	cis	rs11658311	1	rs28636952	ENSG00000266803.1	RP1-77H15.1	3.55	0.000424	0.0267	0.32	0.16	Obsessive-compulsive symptoms;	chr17:17559192	chr17:16557985~16559269:-
THCA	cis	rs4262150	0.883	rs55737372	ENSG00000253921.1	CTB-113P19.3	3.55	0.000424	0.0267	0.2	0.16	Bipolar disorder and schizophrenia;	chr5:152718002	chr5:151753992~151767247:+
THCA	cis	rs1510552	0.529	rs13020812	ENSG00000270659.1	RP11-105N14.1	3.55	0.000424	0.0267	0.14	0.16	Contrast sensitivity;	chr2:214119225	chr2:213152970~213153659:+
THCA	cis	rs881375	0.967	rs1930780	ENSG00000270917.1	RP11-27I1.6	-3.55	0.000424	0.0267	-0.23	-0.16	Rheumatoid arthritis;	chr9:120923941	chr9:120812475~120812845:-
THCA	cis	rs4730276	0.64	rs8721	ENSG00000250474.1	WBP1LP2	-3.55	0.000424	0.0267	-0.15	-0.16	Ulcerative colitis;	chr7:107919277	chr7:107628553~107629498:+
THCA	cis	rs735539	1	rs3000676	ENSG00000238286.1	SLC35E1P1	-3.55	0.000424	0.0267	-0.18	-0.16	Dental caries;	chr13:20712303	chr13:20607268~20608131:+
THCA	cis	rs13063635	0.831	rs76281521	ENSG00000226074.4	PRSS44	-3.55	0.000424	0.0267	-0.31	-0.16	Eosinophil percentage of granulocytes;	chr3:46008272	chr3:46809359~46812558:-
THCA	cis	rs1030877	0.96	rs3792049	ENSG00000235319.1	AC012360.4	3.55	0.000424	0.0267	0.19	0.16	Obesity-related traits;	chr2:105285451	chr2:105324210~105330529:+
THCA	cis	rs721048	0.85	rs17432684	ENSG00000242412.1	DBIL5P2	-3.55	0.000424	0.0267	-0.22	-0.16	Prostate cancer;	chr2:63206708	chr2:63117851~63119542:-
THCA	cis	rs181553	0.664	rs1838963	ENSG00000266696.1	RP11-30L3.2	3.55	0.000424	0.0267	0.2	0.16	Hip circumference adjusted for BMI;	chr18:49153498	chr18:49205912~49208781:+
THCA	cis	rs3218092	0.63	rs11969866	ENSG00000213435.3	ATP6V0CP3	3.55	0.000425	0.0267	0.27	0.16	Red cell distribution width;	chr6:41914385	chr6:42727234~42727700:+
THCA	cis	rs806215	0.547	rs322830	ENSG00000224138.1	AC000123.4	-3.55	0.000425	0.0267	-0.17	-0.16	Type 2 diabetes;	chr7:128077925	chr7:127350128~127351523:+
THCA	cis	rs806215	0.547	rs322829	ENSG00000224138.1	AC000123.4	-3.55	0.000425	0.0267	-0.17	-0.16	Type 2 diabetes;	chr7:128079191	chr7:127350128~127351523:+
THCA	cis	rs806215	0.547	rs322824	ENSG00000224138.1	AC000123.4	-3.55	0.000425	0.0267	-0.17	-0.16	Type 2 diabetes;	chr7:128082667	chr7:127350128~127351523:+
THCA	cis	rs988712	0.921	rs1488829	ENSG00000245573.6	BDNF-AS	-3.55	0.000425	0.0267	-0.15	-0.16	Obesity;	chr11:27530432	chr11:27506838~27698174:+
THCA	cis	rs6500395	0.588	rs3826176	ENSG00000260052.1	CTC-527H23.3	3.55	0.000425	0.0267	0.2	0.16	Response to tocilizumab in rheumatoid arthritis;	chr16:48555151	chr16:48637143~48638719:+
THCA	cis	rs28643277	0.671	rs10752393	ENSG00000237470.3	DCLRE1CP1	3.55	0.000425	0.0267	0.21	0.16	Periodontitis (CDC/AAP);	chr10:15506038	chr10:15015370~15021863:-
THCA	cis	rs6499755	0.768	rs31098	ENSG00000260135.5	RP11-212I21.2	-3.55	0.000425	0.0267	-0.18	-0.16	Hypospadias;	chr16:55335186	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.739	rs31099	ENSG00000260135.5	RP11-212I21.2	-3.55	0.000425	0.0267	-0.18	-0.16	Hypospadias;	chr16:55336995	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.768	rs31103	ENSG00000260135.5	RP11-212I21.2	-3.55	0.000425	0.0267	-0.18	-0.16	Hypospadias;	chr16:55339938	chr16:55426797~55462297:-
THCA	cis	rs755249	0.501	rs621807	ENSG00000182109.6	RP11-69E11.4	3.55	0.000425	0.0267	0.16	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39522280~39546187:-
THCA	cis	rs9393777	0.841	rs13207082	ENSG00000272009.1	RP1-313I6.12	-3.55	0.000425	0.0267	-0.27	-0.16	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28078792~28081130:-
THCA	cis	rs7246967	0.673	rs60675447	ENSG00000198153.8	ZNF849P	-3.55	0.000425	0.0267	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22628090	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs56725192	ENSG00000198153.8	ZNF849P	-3.55	0.000425	0.0267	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22628136	chr19:22685167~22686732:+
THCA	cis	rs149291347	1	rs149291347	ENSG00000279114.1	RP3-425C14.5	-3.55	0.000425	0.0267	-0.15	-0.16	Plateletcrit;	chr6:122457804	chr6:122471923~122484161:+
THCA	cis	rs10975370	0.552	rs58030850	ENSG00000206147.5	RP11-106A1.2	3.55	0.000425	0.0267	0.19	0.16	Breast cancer;	chr9:6040876	chr9:6639139~6639604:+
THCA	cis	rs453301	0.652	rs2043129	ENSG00000253981.4	ALG1L13P	3.55	0.000425	0.0267	0.15	0.16	Joint mobility (Beighton score);	chr8:8967994	chr8:8236003~8244667:-
THCA	cis	rs6061231	0.544	rs2427314	ENSG00000228812.6	LAMA5-AS1	-3.55	0.000425	0.0267	-0.17	-0.16	Colorectal cancer;	chr20:62398610	chr20:62352995~62356480:+
THCA	cis	rs4915077	0.773	rs12565046	ENSG00000226822.1	RP11-356N1.2	3.55	0.000425	0.0267	0.3	0.16	Hypothyroidism;	chr1:107740654	chr1:108071482~108074519:+
THCA	cis	rs11884770	0.624	rs13022362	ENSG00000236432.6	AC097662.2	3.55	0.000425	0.0267	0.16	0.16	Advanced age-related macular degeneration;	chr2:227223169	chr2:227221052~227325201:-
THCA	cis	rs11884770	0.602	rs12999389	ENSG00000236432.6	AC097662.2	3.55	0.000425	0.0267	0.16	0.16	Advanced age-related macular degeneration;	chr2:227223242	chr2:227221052~227325201:-
THCA	cis	rs7777677	0.925	rs73543808	ENSG00000226660.2	TRBV2	3.55	0.000425	0.0267	0.14	0.16	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142300924~142301432:+
THCA	cis	rs2898290	0.622	rs13272061	ENSG00000206014.6	OR7E161P	3.55	0.000425	0.0267	0.19	0.16	Systolic blood pressure;	chr8:11494752	chr8:11928597~11929563:-
THCA	cis	rs1348850	0.526	rs7588049	ENSG00000280374.1	RP11-337N6.3	3.55	0.000425	0.0267	0.28	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177526050	chr2:177317715~177318471:-
THCA	cis	rs7615952	0.8	rs2062773	ENSG00000272840.1	RP11-379B18.6	3.55	0.000425	0.0267	0.26	0.16	Blood pressure (smoking interaction);	chr3:125920805	chr3:125774714~125797953:+
THCA	cis	rs17345786	0.798	rs4257518	ENSG00000244119.1	PDCL3P4	-3.55	0.000425	0.0267	-0.15	-0.16	Colonoscopy-negative controls vs population controls;	chr3:101562865	chr3:101712472~101713191:+
THCA	cis	rs7916852	0.717	rs11006867	ENSG00000230500.1	MKX-AS1	3.55	0.000425	0.0267	0.27	0.16	Glaucoma (primary open-angle);	chr10:28100360	chr10:27744786~27767794:+
THCA	cis	rs7819412	0.818	rs11989439	ENSG00000154316.13	TDH	3.55	0.000425	0.0267	0.12	0.16	Triglycerides;	chr8:11198088	chr8:11339637~11368452:+
THCA	cis	rs9650657	0.737	rs2116095	ENSG00000255310.2	AF131215.2	-3.55	0.000425	0.0267	-0.13	-0.16	Neuroticism;	chr8:10777787	chr8:11107788~11109726:-
THCA	cis	rs12780845	0.54	rs11254413	ENSG00000234961.1	RP11-124N14.3	-3.55	0.000425	0.0267	-0.17	-0.16	Homocysteine levels;	chr10:17162188	chr10:17233325~17234833:-
THCA	cis	rs9462027	0.959	rs205262	ENSG00000272288.4	RP11-140K17.3	-3.55	0.000425	0.0267	-0.13	-0.16	Systemic lupus erythematosus;	chr6:34595387	chr6:34696317~34697470:+
THCA	cis	rs76878669	0.561	rs4630308	ENSG00000255320.1	RP11-755F10.1	-3.55	0.000425	0.0267	-0.2	-0.16	Educational attainment (years of education);	chr11:66395116	chr11:66244840~66246239:-
THCA	cis	rs76878669	0.561	rs12420203	ENSG00000255320.1	RP11-755F10.1	-3.55	0.000425	0.0267	-0.2	-0.16	Educational attainment (years of education);	chr11:66396323	chr11:66244840~66246239:-
THCA	cis	rs10844706	0.699	rs10772087	ENSG00000257027.1	RP11-705C15.3	3.55	0.000425	0.0267	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9730515	chr12:9658567~9662085:+
THCA	cis	rs34421088	0.56	rs2245357	ENSG00000251402.3	FAM90A25P	-3.55	0.000425	0.0267	-0.21	-0.16	Neuroticism;	chr8:11541975	chr8:12415080~12418090:-
THCA	cis	rs9926296	0.585	rs6500450	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000425	0.0267	-0.16	-0.16	Vitiligo;	chr16:89791616	chr16:89516797~89522217:+
THCA	cis	rs3758911	0.861	rs1388171	ENSG00000255353.1	RP11-382M14.1	-3.55	0.000425	0.0267	-0.21	-0.16	Coronary artery disease;	chr11:107272411	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs11212112	ENSG00000255353.1	RP11-382M14.1	-3.55	0.000425	0.0267	-0.21	-0.16	Coronary artery disease;	chr11:107272667	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs11212113	ENSG00000255353.1	RP11-382M14.1	-3.55	0.000425	0.0267	-0.21	-0.16	Coronary artery disease;	chr11:107272776	chr11:107176286~107177530:+
THCA	cis	rs1871744	0.746	rs6532049	ENSG00000246375.2	RP11-10L7.1	3.55	0.000425	0.0267	0.25	0.16	Renal underexcretion gout;	chr4:88146374	chr4:88284942~88331421:+
THCA	cis	rs2721195	1	rs1871541	ENSG00000265393.1	CTD-2517M22.17	3.55	0.000425	0.0267	0.2	0.16	Age at first birth;	chr8:144456330	chr8:144512567~144513672:+
THCA	cis	rs7267979	0.816	rs1044573	ENSG00000276952.1	RP5-965G21.6	3.55	0.000425	0.0267	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25284915~25285588:-
THCA	cis	rs2635047	0.904	rs2635046	ENSG00000280212.1	RP11-49K24.3	-3.55	0.000425	0.0267	-0.16	-0.16	Educational attainment;	chr18:47202058	chr18:47076117~47076594:+
THCA	cis	rs2337406	0.866	rs2301535	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000425	0.0267	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106790663	chr14:106762092~106762588:-
THCA	cis	rs4742903	0.935	rs10820616	ENSG00000270332.1	SMC2-AS1	3.55	0.000426	0.0267	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104183710	chr9:104080024~104093073:-
THCA	cis	rs12188164	0.561	rs2251843	ENSG00000188242.4	PP7080	3.55	0.000426	0.0267	0.14	0.16	Cystic fibrosis severity;	chr5:457840	chr5:466124~473098:-
THCA	cis	rs1200921	0.501	rs1767345	ENSG00000272983.1	RP11-508N22.12	-3.55	0.000426	0.0267	-0.14	-0.16	Breast cancer;	chr10:37146957	chr10:38137337~38144399:+
THCA	cis	rs12499086	0.568	rs4508886	ENSG00000251175.4	RP11-45L9.1	3.55	0.000426	0.0267	0.2	0.16	Economic and political preferences (time);	chr4:105487539	chr4:105746245~105827172:-
THCA	cis	rs4792901	0.685	rs9898065	ENSG00000279602.1	CTD-3014M21.1	-3.55	0.000426	0.0267	-0.21	-0.16	Dupuytren's disease;	chr17:43485105	chr17:43360041~43361361:-
THCA	cis	rs56104184	0.83	rs17206679	ENSG00000243829.1	CTB-33G10.1	-3.55	0.000426	0.0267	-0.22	-0.16	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48838980	chr19:49719498~49720081:-
THCA	cis	rs56104184	0.83	rs55966626	ENSG00000243829.1	CTB-33G10.1	-3.55	0.000426	0.0267	-0.22	-0.16	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48839139	chr19:49719498~49720081:-
THCA	cis	rs875971	0.893	rs62465470	ENSG00000223473.2	GS1-124K5.3	-3.55	0.000426	0.0267	-0.11	-0.16	Aortic root size;	chr7:66136231	chr7:66491049~66493566:-
THCA	cis	rs10857712	0.904	rs36118799	ENSG00000214279.11	SCART1	-3.55	0.000426	0.0267	-0.13	-0.16	Systemic lupus erythematosus;	chr10:133408865	chr10:133453928~133523558:+
THCA	cis	rs4272720	0.535	rs12769361	ENSG00000234736.4	FAM170B-AS1	-3.55	0.000426	0.0267	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49078575	chr10:49121839~49151547:+
THCA	cis	rs17159640	0.655	rs10276727	ENSG00000226851.1	AC004112.4	-3.55	0.000426	0.0267	-0.33	-0.16	Mortality in heart failure;	chr7:112336738	chr7:112328189~112409623:-
THCA	cis	rs11671005	0.57	rs73062110	ENSG00000269600.1	AC016629.3	-3.55	0.000426	0.0268	-0.24	-0.16	Mean platelet volume;	chr19:58425275	chr19:58593896~58599355:-
THCA	cis	rs4973397	0.883	rs4973392	ENSG00000224376.1	AC017104.6	3.55	0.000426	0.0268	0.18	0.16	Anti-saccade response;	chr2:231421841	chr2:231388976~231394991:+
THCA	cis	rs6942407	0.744	rs6980450	ENSG00000224046.1	AC005076.5	-3.55	0.000426	0.0268	-0.15	-0.16	Food allergy;	chr7:87231885	chr7:87151423~87152420:-
THCA	cis	rs755249	1	rs2293476	ENSG00000182109.6	RP11-69E11.4	-3.55	0.000426	0.0268	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39522280~39546187:-
THCA	cis	rs6687821	0.515	rs2096286	ENSG00000261737.1	RP4-612B15.3	3.55	0.000426	0.0268	0.24	0.16	Yeast infection;	chr1:87075298	chr1:86703502~86704462:-
THCA	cis	rs9796	0.87	rs3101436	ENSG00000247556.5	OIP5-AS1	-3.55	0.000426	0.0268	-0.13	-0.16	Menopause (age at onset);	chr15:40995491	chr15:41283990~41309737:+
THCA	cis	rs9796	0.835	rs3100807	ENSG00000247556.5	OIP5-AS1	-3.55	0.000426	0.0268	-0.13	-0.16	Menopause (age at onset);	chr15:41000008	chr15:41283990~41309737:+
THCA	cis	rs3820928	0.618	rs2141828	ENSG00000212391.1	SNORA48	-3.55	0.000426	0.0268	-0.18	-0.16	Pulmonary function;	chr2:227057754	chr2:226968989~226969122:-
THCA	cis	rs1669338	0.588	rs73009149	ENSG00000271870.1	RP11-97C16.1	3.55	0.000426	0.0268	0.15	0.16	White matter integrity;	chr3:3178789	chr3:3152942~3153435:+
THCA	cis	rs972578	1	rs1569509	ENSG00000230319.1	AL022476.2	3.55	0.000426	0.0268	0.17	0.16	Mean platelet volume;	chr22:42963255	chr22:43038585~43052366:+
THCA	cis	rs9902453	0.612	rs2617868	ENSG00000214719.10	AC005562.1	-3.55	0.000426	0.0268	-0.15	-0.16	Coffee consumption (cups per day);	chr17:29746229	chr17:30576464~30672789:+
THCA	cis	rs11887277	0.507	rs6547275	ENSG00000272148.1	RP11-195B17.1	-3.55	0.000426	0.0268	-0.15	-0.16	Obesity-related traits;	chr2:26841709	chr2:27062428~27062907:-
THCA	cis	rs293748	0.771	rs16903490	ENSG00000250155.1	CTD-2353F22.1	-3.55	0.000426	0.0268	-0.21	-0.16	Obesity-related traits;	chr5:37067944	chr5:36666214~36725195:-
THCA	cis	rs944289	0.74	rs398501	ENSG00000212071.1	AL162511.1	3.55	0.000426	0.0268	0.18	0.16	Thyroid cancer;	chr14:36078452	chr14:36196480~36196568:-
THCA	cis	rs1153858	1	rs1365610	ENSG00000275672.1	GATM-AS1	-3.55	0.000426	0.0268	-0.17	-0.16	Homoarginine levels;	chr15:45402412	chr15:45378700~45380123:+
THCA	cis	rs9796	0.87	rs2925342	ENSG00000247556.5	OIP5-AS1	-3.55	0.000426	0.0268	-0.13	-0.16	Menopause (age at onset);	chr15:41013535	chr15:41283990~41309737:+
THCA	cis	rs17045328	1	rs72644189	ENSG00000274245.1	RP11-357P18.2	-3.55	0.000426	0.0268	-0.32	-0.16	Type 2 diabetes;	chr1:207451050	chr1:207372559~207373252:+
THCA	cis	rs2882667	0.898	rs11950819	ENSG00000249593.5	CTB-46B19.2	3.55	0.000426	0.0268	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:139012647~139051203:+
THCA	cis	rs2337406	0.866	rs8003852	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000426	0.0268	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106776648	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs988131	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000426	0.0268	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106776833	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs8005518	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000426	0.0268	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106777009	chr14:106762092~106762588:-
THCA	cis	rs2337406	0.866	rs57684263	ENSG00000280411.1	IGHV1-69-2	-3.55	0.000426	0.0268	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106777263	chr14:106762092~106762588:-
THCA	cis	rs847649	0.618	rs6465880	ENSG00000234715.1	CTB-107G13.1	-3.55	0.000426	0.0268	-0.18	-0.16	Morning vs. evening chronotype;	chr7:102874790	chr7:103445207~103514007:+
THCA	cis	rs6847067	0.86	rs11735449	ENSG00000180769.7	WDFY3-AS2	3.55	0.000426	0.0268	0.12	0.16	Oropharynx cancer;	chr4:84654230	chr4:84965682~85011277:+
THCA	cis	rs2360027	0.965	rs2360030	ENSG00000231365.4	RP11-418J17.1	-3.55	0.000426	0.0268	-0.16	-0.16	Tonsillectomy;	chr1:118612866	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.965	rs10158744	ENSG00000231365.4	RP11-418J17.1	-3.55	0.000426	0.0268	-0.16	-0.16	Tonsillectomy;	chr1:118613231	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.965	rs1157847	ENSG00000231365.4	RP11-418J17.1	-3.55	0.000426	0.0268	-0.16	-0.16	Tonsillectomy;	chr1:118614059	chr1:119140396~119275973:+
THCA	cis	rs9878978	0.893	rs13091098	ENSG00000227588.2	CNTN4-AS2	3.55	0.000426	0.0268	0.19	0.16	Blood pressure (smoking interaction);	chr3:2422166	chr3:2110409~2144241:-
THCA	cis	rs944289	0.503	rs4999746	ENSG00000212071.1	AL162511.1	3.55	0.000426	0.0268	0.2	0.16	Thyroid cancer;	chr14:36190730	chr14:36196480~36196568:-
THCA	cis	rs151450	1	rs151450	ENSG00000251411.1	RP11-397E7.4	-3.55	0.000426	0.0268	-0.15	-0.16	Basophil percentage of white cells;	chr4:87095362	chr4:86913266~86914817:-
THCA	cis	rs7082209	1	rs61856381	ENSG00000224265.1	RP11-168L22.2	-3.55	0.000426	0.0268	-0.25	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr10:44315724	chr10:43323665~43327932:+
THCA	cis	rs7082209	1	rs12265306	ENSG00000224265.1	RP11-168L22.2	-3.55	0.000426	0.0268	-0.25	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr10:44316169	chr10:43323665~43327932:+
THCA	cis	rs61160187	0.673	rs10062240	ENSG00000251279.1	CTC-436P18.1	3.55	0.000426	0.0268	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782585	chr5:61162070~61232040:+
THCA	cis	rs62458065	0.85	rs10239812	ENSG00000231952.3	DPY19L1P2	3.55	0.000426	0.0268	0.27	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32420736	chr7:32812757~32838570:+
THCA	cis	rs1267303	0.563	rs2486163	ENSG00000232022.5	FAAHP1	3.55	0.000426	0.0268	0.19	0.16	Monobrow;	chr1:46539008	chr1:46432129~46445521:+
THCA	cis	rs3087591	0.683	rs2854303	ENSG00000263535.1	AK4P1	3.55	0.000426	0.0268	0.19	0.16	Hip circumference;	chr17:31389324	chr17:31345521~31346187:+
THCA	cis	rs6870983	0.749	rs33706	ENSG00000247828.6	TMEM161B-AS1	3.55	0.000426	0.0268	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88209347	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs33707	ENSG00000247828.6	TMEM161B-AS1	3.55	0.000426	0.0268	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88209412	chr5:88268895~88436685:+
THCA	cis	rs4915077	0.892	rs6682419	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107802487	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs12563210	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107803328	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs12563228	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107803472	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs76359608	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107803932	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs80235198	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107804008	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs4396144	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107804038	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs79548971	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107804915	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs78175580	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107805016	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs74225262	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107805140	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs79458835	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107805180	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs78452835	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107805751	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.892	rs77477575	ENSG00000226822.1	RP11-356N1.2	3.55	0.000426	0.0268	0.27	0.16	Hypothyroidism;	chr1:107806170	chr1:108071482~108074519:+
THCA	cis	rs73198271	0.855	rs57301822	ENSG00000254153.1	CTA-398F10.2	3.55	0.000426	0.0268	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8456909~8461337:-
THCA	cis	rs701145	0.585	rs17817774	ENSG00000238755.3	RP11-23D24.2	-3.55	0.000426	0.0268	-0.32	-0.16	Coronary artery disease;	chr3:154062079	chr3:153384934~153980186:-
THCA	cis	rs910316	0.737	rs175045	ENSG00000259138.1	RP11-950C14.7	-3.55	0.000426	0.0268	-0.14	-0.16	Height;	chr14:75008572	chr14:75127153~75136930:+
THCA	cis	rs1009077	0.868	rs62321186	ENSG00000245958.5	RP11-33B1.1	3.55	0.000426	0.0268	0.21	0.16	Endometriosis;	chr4:119681707	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.909	rs13103531	ENSG00000245958.5	RP11-33B1.1	3.55	0.000426	0.0268	0.21	0.16	Endometriosis;	chr4:119684289	chr4:119454791~119552025:+
THCA	cis	rs1865760	0.613	rs2071300	ENSG00000272810.1	U91328.22	-3.55	0.000426	0.0268	-0.12	-0.16	Height;	chr6:25914344	chr6:26013241~26013757:+
THCA	cis	rs7208859	0.615	rs216462	ENSG00000264242.2	RP11-271K11.1	-3.55	0.000426	0.0268	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30553697~30558962:+
THCA	cis	rs6715284	0.748	rs7597639	ENSG00000238829.1	RNU7-45P	-3.55	0.000426	0.0268	-0.39	-0.16	Rheumatoid arthritis;	chr2:201338667	chr2:201141904~201141966:+
THCA	cis	rs6715284	0.748	rs7598059	ENSG00000238829.1	RNU7-45P	-3.55	0.000426	0.0268	-0.39	-0.16	Rheumatoid arthritis;	chr2:201338864	chr2:201141904~201141966:+
THCA	cis	rs6715284	0.748	rs72934957	ENSG00000238829.1	RNU7-45P	-3.55	0.000426	0.0268	-0.39	-0.16	Rheumatoid arthritis;	chr2:201339100	chr2:201141904~201141966:+
THCA	cis	rs10844154	0.638	rs2632366	ENSG00000277342.1	RP11-843B15.4	3.55	0.000426	0.0268	0.2	0.16	Emphysema-related traits;Weight;	chr12:32253655	chr12:32109076~32109602:+
THCA	cis	rs4578769	0.765	rs12458947	ENSG00000265939.1	UBE2CP2	-3.55	0.000426	0.0268	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22856655	chr18:22900486~22900995:-
THCA	cis	rs897984	0.609	rs72800847	ENSG00000275263.1	RP11-1072A3.4	-3.55	0.000427	0.0268	-0.2	-0.16	Dementia with Lewy bodies;	chr16:31011318	chr16:30956872~30957199:-
THCA	cis	rs897984	0.806	rs12924903	ENSG00000232748.3	RP11-196G11.6	-3.55	0.000427	0.0268	-0.2	-0.16	Dementia with Lewy bodies;	chr16:30917649	chr16:31056460~31062803:+
THCA	cis	rs6487679	0.614	rs6487668	ENSG00000245105.2	A2M-AS1	3.55	0.000427	0.0268	0.15	0.16	Non-alcoholic fatty liver disease histology (AST);	chr12:9200312	chr12:9065177~9068060:+
THCA	cis	rs12681366	0.708	rs2515100	ENSG00000261437.1	RP11-22C11.2	3.55	0.000427	0.0268	0.15	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94368728	chr8:94637285~94639467:-
THCA	cis	rs4566357	0.615	rs12618793	ENSG00000212391.1	SNORA48	-3.55	0.000427	0.0268	-0.17	-0.16	Coronary artery disease;	chr2:227044836	chr2:226968989~226969122:-
THCA	cis	rs7589561	0.543	rs17031736	ENSG00000272861.1	RP11-332H14.1	-3.55	0.000427	0.0268	-0.21	-0.16	Addiction;	chr2:105770783	chr2:105249404~105249794:-
THCA	cis	rs7615952	0.799	rs13315434	ENSG00000272840.1	RP11-379B18.6	3.55	0.000427	0.0268	0.26	0.16	Blood pressure (smoking interaction);	chr3:125922551	chr3:125774714~125797953:+
THCA	cis	rs4761638	0.954	rs6538520	ENSG00000241556.1	RP11-490G8.1	-3.55	0.000427	0.0268	-0.18	-0.16	Insulin disposition index;	chr12:94609582	chr12:95467397~95467861:-
THCA	cis	rs972578	1	rs972578	ENSG00000274717.1	RP1-47A17.1	-3.55	0.000427	0.0268	-0.16	-0.16	Mean platelet volume;	chr22:42991689	chr22:42791814~42794313:-
THCA	cis	rs1729951	0.575	rs1654925	ENSG00000239213.4	NCK1-AS1	-3.55	0.000427	0.0268	-0.14	-0.16	Neuroticism;	chr3:136971549	chr3:136841726~136862054:-
THCA	cis	rs17181170	1	rs17181170	ENSG00000239572.1	RP11-451B8.1	-3.55	0.000427	0.0268	-0.18	-0.16	Prostate cancer;	chr3:87124174	chr3:87731402~87793629:-
THCA	cis	rs875971	1	rs4718307	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000427	0.0268	-0.1	-0.16	Aortic root size;	chr7:66146001	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs7801282	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000427	0.0268	-0.1	-0.16	Aortic root size;	chr7:66148700	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs55962648	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000427	0.0268	-0.1	-0.16	Aortic root size;	chr7:66160764	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs2420168	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000427	0.0268	-0.1	-0.16	Aortic root size;	chr7:66165644	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs11974219	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000427	0.0268	-0.1	-0.16	Aortic root size;	chr7:66182423	chr7:66739829~66740385:-
THCA	cis	rs7267979	0.78	rs2500413	ENSG00000277938.1	RP5-965G21.3	3.55	0.000427	0.0268	0.13	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.714	rs2474763	ENSG00000277938.1	RP5-965G21.3	3.55	0.000427	0.0268	0.13	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25229150~25231933:+
THCA	cis	rs7554511	1	rs7554511	ENSG00000260088.1	RP11-92G12.3	3.55	0.000427	0.0268	0.25	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908434	chr1:200669507~200694250:+
THCA	cis	rs3024505	0.947	rs3024493	ENSG00000234219.1	CDCA4P4	3.55	0.000427	0.0268	0.25	0.16	Type 1 diabetes;Systemic lupus erythematosus;Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:206770623	chr1:207762584~207763263:+
THCA	cis	rs56159542	1	rs56159542	ENSG00000271283.1	CTC-412M14.6	-3.55	0.000427	0.0268	-0.24	-0.16	Attention deficit hyperactivity disorder symptom score;	chr19:19572162	chr19:19699203~19699409:-
THCA	cis	rs720064	0.586	rs9963697	ENSG00000264745.1	TTC39C-AS1	3.55	0.000427	0.0268	0.17	0.16	Strep throat;	chr18:23944796	chr18:23994213~24015339:-
THCA	cis	rs9634489	0.678	rs2389670	ENSG00000247400.3	DNAJC3-AS1	-3.55	0.000427	0.0268	-0.1	-0.16	Body mass index;	chr13:96402790	chr13:95648733~95676925:-
THCA	cis	rs2251188	0.565	rs2254504	ENSG00000187953.9	PMS2CL	-3.55	0.000427	0.0268	-0.17	-0.16	Sum basophil neutrophil counts;Neutrophil count;	chr7:6638930	chr7:6710128~6753862:+
THCA	cis	rs11673344	0.504	rs2385374	ENSG00000233527.7	ZNF529-AS1	3.55	0.000427	0.0268	0.14	0.16	Obesity-related traits;	chr19:37092115	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.504	rs4254428	ENSG00000233527.7	ZNF529-AS1	3.55	0.000427	0.0268	0.14	0.16	Obesity-related traits;	chr19:37093748	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.504	rs8109501	ENSG00000233527.7	ZNF529-AS1	3.55	0.000427	0.0268	0.14	0.16	Obesity-related traits;	chr19:37102194	chr19:36573070~36594708:+
THCA	cis	rs1927790	0.697	rs61966875	ENSG00000247400.3	DNAJC3-AS1	-3.55	0.000427	0.0268	-0.11	-0.16	Body mass index;	chr13:96284271	chr13:95648733~95676925:-
THCA	cis	rs1927790	0.637	rs7337506	ENSG00000247400.3	DNAJC3-AS1	-3.55	0.000427	0.0268	-0.11	-0.16	Body mass index;	chr13:96284724	chr13:95648733~95676925:-
THCA	cis	rs7216064	0.684	rs7406031	ENSG00000267023.4	LRRC37A16P	3.55	0.000427	0.0268	0.12	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68025637	chr17:68125777~68152468:-
THCA	cis	rs2304003	0.561	rs12151689	ENSG00000232411.1	AC009495.3	-3.55	0.000427	0.0268	-0.17	-0.16	Social communication problems;	chr2:165799645	chr2:165833048~165839098:-
THCA	cis	rs2298574	0.614	rs17468095	ENSG00000274578.1	RP11-430E17.1	3.55	0.000427	0.0268	0.39	0.16	vWF and FVIII levels;	chr18:27975482	chr18:28146233~28146703:-
THCA	cis	rs11673344	0.504	rs11084874	ENSG00000233527.7	ZNF529-AS1	3.55	0.000427	0.0268	0.14	0.16	Obesity-related traits;	chr19:37096667	chr19:36573070~36594708:+
THCA	cis	rs11405769	1	rs11405769	ENSG00000242412.1	DBIL5P2	3.55	0.000427	0.0268	0.21	0.16	Childhood ear infection;	chr2:63431159	chr2:63117851~63119542:-
THCA	cis	rs3733418	0.929	rs7656863	ENSG00000248632.1	RP11-366M4.11	3.55	0.000427	0.0268	0.23	0.16	Obesity-related traits;	chr4:164962092	chr4:164968587~164970002:-
THCA	cis	rs4656958	0.725	rs1092415	ENSG00000233691.2	RP11-312J18.7	-3.55	0.000427	0.0268	-0.23	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160925601	chr1:160935537~160936126:+
THCA	cis	rs240993	0.548	rs1040382	ENSG00000272356.1	RP5-1112D6.8	3.55	0.000427	0.0268	0.14	0.16	Inflammatory skin disease;Psoriasis;	chr6:111580876	chr6:111309203~111313517:+
THCA	cis	rs75504410	1	rs75504410	ENSG00000231160.8	KLF3-AS1	-3.55	0.000427	0.0268	-0.18	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38656198	chr4:38612701~38664883:-
THCA	cis	rs6806253	0.793	rs4857907	ENSG00000239405.1	TMED10P2	3.55	0.000427	0.0268	0.23	0.16	Pit-and-Fissure caries;	chr3:128557905	chr3:128538020~128538631:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000273024.4	INTS4P2	-3.55	0.000427	0.0268	-0.27	-0.16	Diabetic kidney disease;	chr7:65928187	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65916269	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65918212	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65922114	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65923503	chr7:65647864~65715661:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65925372	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65925938	chr7:65647864~65715661:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65940221	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65943626	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65944004	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000273024.4	INTS4P2	3.55	0.000427	0.0268	0.27	0.16	Diabetic kidney disease;	chr7:65944182	chr7:65647864~65715661:+
THCA	cis	rs12682352	0.715	rs332039	ENSG00000254340.1	RP11-10A14.3	3.55	0.000427	0.0268	0.18	0.16	Neuroticism;	chr8:8866141	chr8:9141424~9145435:+
THCA	cis	rs7520050	0.966	rs785485	ENSG00000280836.1	AL355480.1	3.55	0.000427	0.0268	0.2	0.16	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45581219~45581321:-
THCA	cis	rs45544231	1	rs4578643	ENSG00000279344.1	RP11-44F14.7	3.55	0.000427	0.0268	0.15	0.16	Restless legs syndrome;	chr16:52603523	chr16:53478957~53481550:-
THCA	cis	rs78487399	0.71	rs72881068	ENSG00000234936.1	AC010883.5	3.55	0.000427	0.0268	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43463721	chr2:43229573~43233394:+
THCA	cis	rs3808502	0.549	rs1382563	ENSG00000255046.1	RP11-297N6.4	-3.55	0.000428	0.0268	-0.17	-0.16	Neuroticism;	chr8:11569281	chr8:11797928~11802568:-
THCA	cis	rs7267979	0.714	rs1555329	ENSG00000277938.1	RP5-965G21.3	3.55	0.000428	0.0268	0.13	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.714	rs3787082	ENSG00000277938.1	RP5-965G21.3	3.55	0.000428	0.0268	0.13	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.714	rs6115107	ENSG00000277938.1	RP5-965G21.3	3.55	0.000428	0.0268	0.13	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25229150~25231933:+
THCA	cis	rs42648	0.819	rs10953006	ENSG00000225498.1	AC002064.5	3.55	0.000428	0.0268	0.17	0.16	Homocysteine levels;	chr7:90400839	chr7:90312496~90322592:+
THCA	cis	rs2228479	0.85	rs62054638	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89754723	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.557	rs62054639	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89755081	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs12597296	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89755923	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs12597299	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89755956	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62054640	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89756749	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs3785281	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89757855	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs3785279	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89758154	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17226980	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89758657	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17226973	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89758840	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17226966	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89758930	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs3819574	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89760222	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs2239358	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89760922	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs12599473	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89761027	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs2283565	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89761148	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.557	rs12933317	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89761812	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs17233253	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89762029	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs17226841	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89762076	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs11076620	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89765112	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs12600151	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89765150	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs17233176	ENSG00000274627.1	RP11-104N10.2	-3.55	0.000428	0.0268	-0.29	-0.16	Skin colour saturation;	chr16:89766343	chr16:89516797~89522217:+
THCA	cis	rs11048434	0.518	rs7311267	ENSG00000256720.1	RP11-436I9.6	3.55	0.000428	0.0268	0.17	0.16	Sjögren's syndrome;	chr12:9026082	chr12:9135084~9135591:+
THCA	cis	rs6137726	0.652	rs6082774	ENSG00000237396.1	LINC01384	3.55	0.000428	0.0268	0.14	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22669410	chr20:22587522~22607517:-
THCA	cis	rs4073416	0.542	rs2411815	ENSG00000276116.2	FUT8-AS1	-3.55	0.000428	0.0268	-0.18	-0.16	N-glycan levels;	chr14:65553353	chr14:65411170~65412690:-
THCA	cis	rs9393813	0.506	rs4713105	ENSG00000271755.1	RP1-153G14.4	3.55	0.000428	0.0268	0.19	0.16	Bipolar disorder;	chr6:27467141	chr6:27404010~27406964:-
THCA	cis	rs4568518	0.72	rs58338223	ENSG00000279048.1	RP11-511H23.2	3.55	0.000428	0.0268	0.11	0.16	Measles;	chr7:18000506	chr7:17940503~17942922:+
THCA	cis	rs4568518	0.803	rs12699947	ENSG00000279048.1	RP11-511H23.2	3.55	0.000428	0.0268	0.11	0.16	Measles;	chr7:18000616	chr7:17940503~17942922:+
THCA	cis	rs4656958	0.897	rs4656282	ENSG00000233691.2	RP11-312J18.7	3.55	0.000428	0.0268	0.19	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160930359	chr1:160935537~160936126:+
THCA	cis	rs11190604	0.767	rs3829162	ENSG00000273030.1	RP11-285F16.1	3.55	0.000428	0.0269	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100412995	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.747	rs11190516	ENSG00000273030.1	RP11-285F16.1	3.55	0.000428	0.0269	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100413768	chr10:100412934~100413421:+
THCA	cis	rs9876781	1	rs725309	ENSG00000199476.1	Y_RNA	3.55	0.000428	0.0269	0.2	0.16	Longevity;	chr3:48377218	chr3:48288587~48288694:+
THCA	cis	rs4930561	0.714	rs6591335	ENSG00000184795.9	UNC93B5	-3.55	0.000428	0.0269	-0.2	-0.16	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68209345	chr11:67711702~67716005:-
THCA	cis	rs9905704	0.831	rs12939500	ENSG00000224738.1	AC099850.1	3.55	0.000428	0.0269	0.22	0.16	Testicular germ cell tumor;	chr17:58771316	chr17:59106598~59118267:+
THCA	cis	rs972578	0.967	rs7291153	ENSG00000230319.1	AL022476.2	3.55	0.000428	0.0269	0.17	0.16	Mean platelet volume;	chr22:42960493	chr22:43038585~43052366:+
THCA	cis	rs9796	0.649	rs8035828	ENSG00000247556.5	OIP5-AS1	3.55	0.000428	0.0269	0.13	0.16	Menopause (age at onset);	chr15:41175089	chr15:41283990~41309737:+
THCA	cis	rs285757	0.857	rs184048	ENSG00000259064.2	RP11-386M24.5	-3.55	0.000428	0.0269	-0.24	-0.16	HIV-1 susceptibility;	chr15:92633795	chr15:92627073~92627414:+
THCA	cis	rs757081	0.507	rs10832727	ENSG00000272034.1	SNORD14A	-3.55	0.000428	0.0269	-0.18	-0.16	Systolic blood pressure;	chr11:17043742	chr11:17074654~17074744:-
THCA	cis	rs7412746	0.611	rs4319334	ENSG00000224800.1	RP11-235D19.2	-3.55	0.000428	0.0269	-0.21	-0.16	Melanoma;	chr1:150794346	chr1:150881236~150881683:-
THCA	cis	rs1654345	0.561	rs1654343	ENSG00000275132.1	Metazoa_SRP	-3.55	0.000428	0.0269	-0.25	-0.16	Life satisfaction;Subjective well-being;	chr19:38052438	chr19:38200234~38200532:+
THCA	cis	rs308403	0.509	rs309372	ENSG00000224786.1	CETN4P	3.55	0.000428	0.0269	0.17	0.16	Blood protein levels;	chr4:122761484	chr4:122730548~122732193:-
THCA	cis	rs4272720	0.535	rs72785015	ENSG00000234736.4	FAM170B-AS1	-3.55	0.000428	0.0269	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49077861	chr10:49121839~49151547:+
THCA	cis	rs883565	0.654	rs6779880	ENSG00000223668.1	EEF1A1P24	3.55	0.000428	0.0269	0.14	0.16	Handedness;	chr3:38981435	chr3:39358545~39359922:+
THCA	cis	rs7671266	0.528	rs11728025	ENSG00000261490.1	RP11-448G15.3	-3.55	0.000428	0.0269	-0.13	-0.16	Cardiovascular disease risk factors;	chr4:10406597	chr4:10068089~10073019:-
THCA	cis	rs4704187	0.687	rs10214239	ENSG00000250889.2	LINC01336	-3.55	0.000428	0.0269	-0.17	-0.16	Response to amphetamines;	chr5:75061650	chr5:75047719~75052843:-
THCA	cis	rs9902453	0.726	rs4795523	ENSG00000263603.1	CTD-2349P21.5	3.55	0.000428	0.0269	0.19	0.16	Coffee consumption (cups per day);	chr17:29849296	chr17:30729469~30731202:+
THCA	cis	rs3750082	0.889	rs6963831	ENSG00000205763.12	RP9P	3.55	0.000428	0.0269	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32895215	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.889	rs55647647	ENSG00000205763.12	RP9P	3.55	0.000428	0.0269	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32895408	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.815	rs6964458	ENSG00000205763.12	RP9P	3.55	0.000428	0.0269	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32895612	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.889	rs6462431	ENSG00000205763.12	RP9P	3.55	0.000428	0.0269	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32895827	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.889	rs12536400	ENSG00000205763.12	RP9P	3.55	0.000428	0.0269	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32896778	chr7:32916815~32943176:-
THCA	cis	rs9608946	1	rs737942	ENSG00000279699.1	RP1-102K2.9	3.55	0.000428	0.0269	0.18	0.16	Red cell distribution width;	chr22:30480848	chr22:30275215~30276951:-
THCA	cis	rs9894429	0.683	rs112612275	ENSG00000262049.1	RP13-1032I1.7	-3.55	0.000428	0.0269	-0.1	-0.16	Eye color traits;	chr17:81585578	chr17:81701324~81703300:-
THCA	cis	rs10760158	0.832	rs10760172	ENSG00000226752.6	PSMD5-AS1	-3.55	0.000428	0.0269	-0.2	-0.16	Pulse pressure;	chr9:121299624	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs4836848	ENSG00000226752.6	PSMD5-AS1	-3.55	0.000428	0.0269	-0.2	-0.16	Pulse pressure;	chr9:121301074	chr9:120824828~120854385:+
THCA	cis	rs9903692	0.866	rs11079807	ENSG00000263412.1	RP5-890E16.2	3.55	0.000428	0.0269	0.12	0.16	Pulse pressure;	chr17:48098685	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs10853094	ENSG00000263412.1	RP5-890E16.2	3.55	0.000428	0.0269	0.12	0.16	Pulse pressure;	chr17:48098700	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs4794441	ENSG00000263412.1	RP5-890E16.2	3.55	0.000428	0.0269	0.12	0.16	Pulse pressure;	chr17:48099094	chr17:48045141~48048073:-
THCA	cis	rs9309473	1	rs9653557	ENSG00000273245.1	RP11-434P11.2	3.55	0.000428	0.0269	0.22	0.16	Metabolite levels;	chr2:73568835	chr2:73750256~73750786:-
THCA	cis	rs12121840	0.688	rs285438	ENSG00000237463.4	RP11-280O1.2	3.55	0.000428	0.0269	0.14	0.16	Interleukin-1-receptor antagonist levels;	chr1:165548949	chr1:165476841~165582155:-
THCA	cis	rs3811273	0.614	rs6572349	ENSG00000211816.2	TRAV38-1	-3.55	0.000429	0.0269	-0.19	-0.16	Periodontal disease-related phenotypes;	chr14:22268365	chr14:22271968~22272563:+
THCA	cis	rs9487051	1	rs9487048	ENSG00000260273.1	RP11-425D10.10	3.55	0.000429	0.0269	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109294400	chr6:109382795~109383666:+
THCA	cis	rs9487051	1	rs9400272	ENSG00000260273.1	RP11-425D10.10	3.55	0.000429	0.0269	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109295559	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.933	rs5005289	ENSG00000260273.1	RP11-425D10.10	3.55	0.000429	0.0269	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109296470	chr6:109382795~109383666:+
THCA	cis	rs1999930	0.505	rs1416190	ENSG00000237021.2	RP3-486I3.7	3.55	0.000429	0.0269	0.19	0.16	Age-related macular degeneration;	chr6:115919351	chr6:116254207~116256743:+
THCA	cis	rs7216064	1	rs4791299	ENSG00000278740.1	RP11-147L13.14	3.55	0.000429	0.0269	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934821	chr17:68188547~68189165:+
THCA	cis	rs2281603	0.57	rs10145013	ENSG00000258824.2	CTD-2555O16.2	-3.55	0.000429	0.0269	-0.14	-0.16	Lymphocyte counts;	chr14:64474873	chr14:64422935~64448557:-
THCA	cis	rs5769765	0.908	rs138866	ENSG00000280567.1	Metazoa_SRP	3.55	0.000429	0.0269	0.22	0.16	Schizophrenia;	chr22:49812255	chr22:49878999~49879242:+
THCA	cis	rs1124769	0.827	rs77725238	ENSG00000244879.4	GABPB1-AS1	-3.55	0.000429	0.0269	-0.17	-0.16	Cognitive performance;	chr15:50807448	chr15:50354959~50372202:+
THCA	cis	rs16857609	0.564	rs1478581	ENSG00000233143.1	DIRC3-AS1	-3.55	0.000429	0.0269	-0.19	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217427929	chr2:217282739~217336120:+
THCA	cis	rs4907240	0.925	rs4907242	ENSG00000230606.9	AC159540.1	3.55	0.000429	0.0269	0.18	0.16	Event-related brain oscillations;	chr2:96607376	chr2:97416165~97433527:-
THCA	cis	rs4907240	0.925	rs7575254	ENSG00000230606.9	AC159540.1	3.55	0.000429	0.0269	0.18	0.16	Event-related brain oscillations;	chr2:96610023	chr2:97416165~97433527:-
THCA	cis	rs6600671	0.934	rs12131379	ENSG00000233029.3	RP11-439A17.9	-3.55	0.000429	0.0269	-0.18	-0.16	Hip geometry;	chr1:121551639	chr1:121090289~121097655:-
THCA	cis	rs72634501	0.517	rs7522362	ENSG00000228060.1	RP11-69E11.8	3.55	0.000429	0.0269	0.15	0.16	HDL cholesterol;	chr1:39139419	chr1:39565160~39573203:+
THCA	cis	rs11658311	1	rs13342397	ENSG00000266803.1	RP1-77H15.1	3.55	0.000429	0.0269	0.32	0.16	Obsessive-compulsive symptoms;	chr17:17557612	chr17:16557985~16559269:-
THCA	cis	rs4578769	0.765	rs11082147	ENSG00000265939.1	UBE2CP2	-3.55	0.000429	0.0269	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22806559	chr18:22900486~22900995:-
THCA	cis	rs9928842	0.941	rs8057145	ENSG00000261783.1	RP11-252K23.2	3.55	0.000429	0.0269	0.3	0.16	Alcoholic chronic pancreatitis;	chr16:75222353	chr16:75379818~75381260:-
THCA	cis	rs10090774	0.862	rs62524109	ENSG00000280303.2	ERICD	3.55	0.000429	0.0269	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140797368	chr8:140636281~140638283:+
THCA	cis	rs12476592	0.602	rs10469944	ENSG00000242412.1	DBIL5P2	3.55	0.000429	0.0269	0.21	0.16	Childhood ear infection;	chr2:63589538	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs10469945	ENSG00000242412.1	DBIL5P2	3.55	0.000429	0.0269	0.21	0.16	Childhood ear infection;	chr2:63589642	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs6546018	ENSG00000242412.1	DBIL5P2	3.55	0.000429	0.0269	0.21	0.16	Childhood ear infection;	chr2:63590288	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs6546019	ENSG00000242412.1	DBIL5P2	3.55	0.000429	0.0269	0.21	0.16	Childhood ear infection;	chr2:63590306	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.543	rs1446569	ENSG00000242412.1	DBIL5P2	3.55	0.000429	0.0269	0.21	0.16	Childhood ear infection;	chr2:63591180	chr2:63117851~63119542:-
THCA	cis	rs56309584	0.883	rs9896745	ENSG00000271002.1	RP11-599B13.8	-3.55	0.000429	0.0269	-0.21	-0.16	Initial pursuit acceleration;	chr17:8238811	chr17:8199123~8199437:-
THCA	cis	rs8002861	0.626	rs9533634	ENSG00000274001.1	RP11-5G9.5	-3.55	0.000429	0.0269	-0.19	-0.16	Leprosy;	chr13:43823679	chr13:43877715~43878163:-
THCA	cis	rs78487399	0.908	rs12467151	ENSG00000234936.1	AC010883.5	3.55	0.000429	0.0269	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43586625	chr2:43229573~43233394:+
THCA	cis	rs5758511	0.68	rs5758698	ENSG00000182057.4	OGFRP1	-3.55	0.000429	0.0269	-0.22	-0.16	Birth weight;	chr22:42288812	chr22:42269753~42275196:+
THCA	cis	rs7819412	0.582	rs2409685	ENSG00000254839.1	AF131215.6	3.55	0.000429	0.0269	0.17	0.16	Triglycerides;	chr8:11051683	chr8:11062647~11067089:-
THCA	cis	rs7259376	0.967	rs808369	ENSG00000269138.1	ZNF209P	-3.55	0.000429	0.0269	-0.16	-0.16	Menopause (age at onset);	chr19:22291480	chr19:22463922~22473036:+
THCA	cis	rs7129556	0.701	rs11237280	ENSG00000254459.1	RP11-91P24.7	3.55	0.000429	0.0269	0.21	0.16	Weight loss (gastric bypass surgery);	chr11:77745861	chr11:77829654~77872262:-
THCA	cis	rs9788682	0.633	rs2656070	ENSG00000261143.1	ADAMTS7P3	3.55	0.000429	0.0269	0.24	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78437910	chr15:77976042~77993057:+
THCA	cis	rs67478160	0.608	rs4906368	ENSG00000258534.1	CTD-2134A5.4	-3.55	0.000429	0.0269	-0.16	-0.16	Schizophrenia;	chr14:103776060	chr14:103854366~103880111:-
THCA	cis	rs3845817	0.703	rs702904	ENSG00000281920.1	RP11-418H16.1	-3.55	0.000429	0.0269	-0.19	-0.16	Bipolar disorder;	chr2:65538960	chr2:65623272~65628424:+
THCA	cis	rs11671005	0.568	rs73068329	ENSG00000267858.4	MZF1-AS1	-3.55	0.000429	0.0269	-0.12	-0.16	Mean platelet volume;	chr19:58568958	chr19:58559129~58574797:+
THCA	cis	rs7259376	0.936	rs8108630	ENSG00000270947.1	AC025811.3	3.55	0.000429	0.0269	0.17	0.16	Menopause (age at onset);	chr19:22352375	chr19:22455988~22456459:+
THCA	cis	rs7873102	0.654	rs10732358	ENSG00000213839.4	TMX2P1	-3.55	0.000429	0.0269	-0.12	-0.16	Brain structure;	chr9:37954916	chr9:37885683~37886390:+
THCA	cis	rs11247915	0.54	rs11582416	ENSG00000236782.4	RP11-96L14.7	3.55	0.000429	0.0269	0.2	0.16	Obesity-related traits;	chr1:26351230	chr1:26169947~26171821:-
THCA	cis	rs9341808	0.754	rs3793000	ENSG00000260645.1	RP11-250B2.5	3.55	0.000429	0.0269	0.14	0.16	Sitting height ratio;	chr6:80285420	chr6:80466958~80469080:+
THCA	cis	rs3018712	0.547	rs4930237	ENSG00000212093.1	AP000807.1	-3.55	0.000429	0.0269	-0.21	-0.16	Total body bone mineral density;	chr11:68646570	chr11:68506083~68506166:-
THCA	cis	rs3126085	0.935	rs2338430	ENSG00000237975.5	FLG-AS1	3.55	0.000429	0.0269	0.25	0.16	Atopic dermatitis;	chr1:152241944	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs7534716	ENSG00000237975.5	FLG-AS1	-3.55	0.000429	0.0269	-0.25	-0.16	Atopic dermatitis;	chr1:152226178	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs10888470	ENSG00000237975.5	FLG-AS1	-3.55	0.000429	0.0269	-0.25	-0.16	Atopic dermatitis;	chr1:152227996	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs11204943	ENSG00000237975.5	FLG-AS1	-3.55	0.000429	0.0269	-0.25	-0.16	Atopic dermatitis;	chr1:152231430	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs4845751	ENSG00000237975.5	FLG-AS1	-3.55	0.000429	0.0269	-0.25	-0.16	Atopic dermatitis;	chr1:152236521	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs6675889	ENSG00000237975.5	FLG-AS1	-3.55	0.000429	0.0269	-0.25	-0.16	Atopic dermatitis;	chr1:152240590	chr1:152168125~152445456:+
THCA	cis	rs453301	0.606	rs7462373	ENSG00000253981.4	ALG1L13P	-3.55	0.000429	0.0269	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9041808	chr8:8236003~8244667:-
THCA	cis	rs860295	0.702	rs12043132	ENSG00000236675.1	MTX1P1	-3.55	0.000429	0.0269	-0.16	-0.16	Body mass index;	chr1:155592576	chr1:155230975~155234325:+
THCA	cis	rs7246760	0.867	rs57943754	ENSG00000278611.1	CTC-543D15.8	-3.55	0.000429	0.0269	-0.26	-0.16	Pursuit maintenance gain;	chr19:9730607	chr19:9538733~9539734:+
THCA	cis	rs2434529	1	rs2434535	ENSG00000245275.6	SAP30L-AS1	-3.55	0.000429	0.0269	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr5:154262375	chr5:154329437~154445850:-
THCA	cis	rs10946940	0.632	rs9366698	ENSG00000216915.2	RP1-97D16.1	-3.55	0.000429	0.0269	-0.23	-0.16	Systemic lupus erythematosus;	chr6:27704256	chr6:27737000~27738494:-
THCA	cis	rs2718812	0.904	rs2718809	ENSG00000242337.4	TFP1	3.55	0.00043	0.0269	0.17	0.16	Iron status biomarkers;	chr3:133690574	chr3:133661998~133754576:+
THCA	cis	rs56046484	0.913	rs12906544	ENSG00000218052.5	ADAMTS7P4	-3.55	0.00043	0.0269	-0.25	-0.16	Testicular germ cell tumor;	chr15:85032832	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.871	rs34978449	ENSG00000218052.5	ADAMTS7P4	-3.55	0.00043	0.0269	-0.25	-0.16	Testicular germ cell tumor;	chr15:85036917	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.871	rs62021230	ENSG00000218052.5	ADAMTS7P4	-3.55	0.00043	0.0269	-0.25	-0.16	Testicular germ cell tumor;	chr15:85040721	chr15:85255369~85330334:-
THCA	cis	rs11887277	0.507	rs6743539	ENSG00000272148.1	RP11-195B17.1	-3.55	0.00043	0.0269	-0.15	-0.16	Obesity-related traits;	chr2:26833371	chr2:27062428~27062907:-
THCA	cis	rs970548	0.643	rs7068039	ENSG00000230869.1	CTGLF10P	3.55	0.00043	0.0269	0.23	0.16	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45436816	chr10:45678692~45700532:+
THCA	cis	rs2832077	0.527	rs2738953	ENSG00000232855.5	AF131217.1	-3.55	0.00043	0.0269	-0.18	-0.16	Cognitive test performance;	chr21:28866041	chr21:28439346~28674848:-
THCA	cis	rs2832077	0.527	rs2705690	ENSG00000232855.5	AF131217.1	-3.55	0.00043	0.0269	-0.18	-0.16	Cognitive test performance;	chr21:28866923	chr21:28439346~28674848:-
THCA	cis	rs13381277	0.764	rs28611217	ENSG00000263982.1	RP11-504I13.3	3.55	0.00043	0.0269	0.26	0.16	Dental caries;	chr18:76612602	chr18:76372717~76378275:+
THCA	cis	rs13381277	0.764	rs28385537	ENSG00000263982.1	RP11-504I13.3	3.55	0.00043	0.0269	0.26	0.16	Dental caries;	chr18:76612613	chr18:76372717~76378275:+
THCA	cis	rs294588	1	rs294588	ENSG00000250061.4	RP11-541P9.3	-3.55	0.00043	0.0269	-0.22	-0.16	Aging;	chr5:163571509	chr5:163012265~163437326:-
THCA	cis	rs1560104	0.597	rs11075126	ENSG00000260601.1	RP11-552C15.1	-3.55	0.00043	0.027	-0.2	-0.16	Obesity-related traits;	chr16:12613117	chr16:12545482~12546684:+
THCA	cis	rs5769765	0.955	rs6520066	ENSG00000278869.1	CITF22-49E9.3	3.55	0.00043	0.027	0.2	0.16	Schizophrenia;	chr22:49901340	chr22:49933198~49934074:-
THCA	cis	rs786425	0.618	rs7294984	ENSG00000278112.1	RP11-972P1.11	3.55	0.00043	0.027	0.16	0.16	Pubertal anthropometrics;	chr12:123657202	chr12:123519390~123519856:-
THCA	cis	rs786425	0.594	rs6488888	ENSG00000278112.1	RP11-972P1.11	3.55	0.00043	0.027	0.16	0.16	Pubertal anthropometrics;	chr12:123658044	chr12:123519390~123519856:-
THCA	cis	rs7833790	0.963	rs10958046	ENSG00000254689.1	RP11-354A14.1	3.55	0.00043	0.027	0.2	0.16	Diastolic blood pressure;	chr8:81816975	chr8:81885377~81923193:+
THCA	cis	rs972578	1	rs5751405	ENSG00000230319.1	AL022476.2	3.55	0.00043	0.027	0.17	0.16	Mean platelet volume;	chr22:42965073	chr22:43038585~43052366:+
THCA	cis	rs7176527	0.796	rs1057946	ENSG00000176700.18	SCAND2P	3.55	0.00043	0.027	0.14	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:84631451~84647478:+
THCA	cis	rs755249	0.567	rs72661961	ENSG00000182109.6	RP11-69E11.4	3.55	0.00043	0.027	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39522280~39546187:-
THCA	cis	rs755249	0.532	rs61779277	ENSG00000182109.6	RP11-69E11.4	3.55	0.00043	0.027	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39522280~39546187:-
THCA	cis	rs755249	0.532	rs61779278	ENSG00000182109.6	RP11-69E11.4	3.55	0.00043	0.027	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs2296172	ENSG00000182109.6	RP11-69E11.4	3.55	0.00043	0.027	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs61779279	ENSG00000182109.6	RP11-69E11.4	3.55	0.00043	0.027	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs6668369	ENSG00000182109.6	RP11-69E11.4	3.55	0.00043	0.027	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39522280~39546187:-
THCA	cis	rs755249	0.567	rs61779284	ENSG00000182109.6	RP11-69E11.4	3.55	0.00043	0.027	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39522280~39546187:-
THCA	cis	rs2911280	0.764	rs76294479	ENSG00000278985.1	RP11-303E16.9	-3.55	0.00043	0.027	-0.3	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81547979	chr16:80982319~80984094:-
THCA	cis	rs1978968	0.654	rs13056749	ENSG00000280007.1	AC008079.10	3.55	0.00043	0.027	0.17	0.16	Presence of antiphospholipid antibodies;	chr22:17920158	chr22:18110759~18131154:-
THCA	cis	rs1125355	0.557	rs4362514	ENSG00000243792.1	OR7E89P	-3.55	0.00043	0.027	-0.25	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158750464	chr2:158853755~158854576:+
THCA	cis	rs2574985	0.54	rs4935712	ENSG00000279863.1	RP11-521C22.2	-3.55	0.00043	0.027	-0.18	-0.16	Subjective well-being;	chr10:50499653	chr10:50334538~50336123:+
THCA	cis	rs7765004	1	rs7765004	ENSG00000230943.1	RP11-367G18.1	-3.55	0.00043	0.027	-0.16	-0.16	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113750518	chr6:113623535~113650074:-
THCA	cis	rs754466	0.58	rs11002293	ENSG00000213514.2	RP11-428P16.2	3.55	0.00043	0.027	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77778207	chr10:77730766~77734769:+
THCA	cis	rs6088813	0.635	rs2425054	ENSG00000279253.1	RP4-614O4.13	-3.55	0.00043	0.027	-0.18	-0.16	Height;	chr20:35306288	chr20:35262727~35264187:-
THCA	cis	rs7502499	0.581	rs9904835	ENSG00000253730.1	RP11-893F2.13	-3.55	0.00043	0.027	-0.2	-0.16	Cancer;Coronary artery disease;	chr17:49432418	chr17:50158333~50161276:-
THCA	cis	rs6598955	0.724	rs6656716	ENSG00000236782.4	RP11-96L14.7	-3.55	0.00043	0.027	-0.2	-0.16	Obesity-related traits;	chr1:26236614	chr1:26169947~26171821:-
THCA	cis	rs8099594	0.524	rs12961303	ENSG00000266696.1	RP11-30L3.2	3.55	0.00043	0.027	0.2	0.16	Height;	chr18:49212678	chr18:49205912~49208781:+
THCA	cis	rs2455799	0.552	rs2470516	ENSG00000270409.1	RP11-44D5.1	-3.55	0.00043	0.027	-0.17	-0.16	Mean platelet volume;	chr3:15717543	chr3:15732252~15733470:+
THCA	cis	rs804280	0.638	rs36038176	ENSG00000254948.1	OR7E158P	3.55	0.00043	0.027	0.23	0.16	Myopia (pathological);	chr8:11752486	chr8:11919900~11920809:-
THCA	cis	rs4073582	0.964	rs801742	ENSG00000255320.1	RP11-755F10.1	-3.55	0.00043	0.027	-0.23	-0.16	Gout;	chr11:66147295	chr11:66244840~66246239:-
THCA	cis	rs987724	0.515	rs4315647	ENSG00000243926.1	TIPARP-AS1	3.55	0.00043	0.027	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156941199	chr3:156671862~156674378:-
THCA	cis	rs2446066	0.872	rs10876451	ENSG00000257379.1	RP11-793H13.8	3.55	0.00043	0.027	0.24	0.16	Red blood cell count;	chr12:53419640	chr12:53441741~53467528:+
THCA	cis	rs2243480	1	rs10247526	ENSG00000237310.1	GS1-124K5.4	-3.55	0.00043	0.027	-0.19	-0.16	Diabetic kidney disease;	chr7:66315709	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000237310.1	GS1-124K5.4	-3.55	0.00043	0.027	-0.19	-0.16	Diabetic kidney disease;	chr7:66333815	chr7:66493706~66495474:+
THCA	cis	rs7615952	0.605	rs34865555	ENSG00000272840.1	RP11-379B18.6	3.55	0.00043	0.027	0.31	0.16	Blood pressure (smoking interaction);	chr3:125585290	chr3:125774714~125797953:+
THCA	cis	rs7264396	0.887	rs2236165	ENSG00000261582.1	RP4-614O4.11	-3.55	0.00043	0.027	-0.17	-0.16	Total cholesterol levels;	chr20:35508896	chr20:35267885~35280043:-
THCA	cis	rs911555	0.723	rs4906324	ENSG00000269940.1	RP11-73M18.7	-3.55	0.00043	0.027	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103694560~103695170:+
THCA	cis	rs911555	0.723	rs2273701	ENSG00000269940.1	RP11-73M18.7	-3.55	0.00043	0.027	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103694560~103695170:+
THCA	cis	rs9400467	0.537	rs584937	ENSG00000255389.1	C6orf3	3.55	0.00043	0.027	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111160374	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.537	rs354533	ENSG00000255389.1	C6orf3	3.55	0.00043	0.027	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111165901	chr6:111599875~111602295:+
THCA	cis	rs4713118	0.869	rs9283880	ENSG00000272009.1	RP1-313I6.12	-3.55	0.00043	0.027	-0.18	-0.16	Parkinson's disease;	chr6:27747464	chr6:28078792~28081130:-
THCA	cis	rs10483853	1	rs177385	ENSG00000258891.1	RP5-1021I20.5	3.55	0.000431	0.027	0.22	0.16	Coronary artery calcification;	chr14:73263582	chr14:73896164~73938114:-
THCA	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	3.55	0.000431	0.027	0.15	0.16	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
THCA	cis	rs763121	0.853	rs9610986	ENSG00000272669.1	RP3-508I15.21	-3.55	0.000431	0.027	-0.11	-0.16	Menopause (age at onset);	chr22:38629272	chr22:38742625~38743115:+
THCA	cis	rs2979481	1	rs61650361	ENSG00000254152.1	CTD-3107M8.2	3.55	0.000431	0.027	0.21	0.16	Heart rate variability traits;	chr8:30401065	chr8:30349866~30350347:-
THCA	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	3.55	0.000431	0.027	0.19	0.16	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	3.55	0.000431	0.027	0.19	0.16	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	3.55	0.000431	0.027	0.19	0.16	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
THCA	cis	rs12032381	1	rs6674252	ENSG00000200033.1	RNU6-403P	3.55	0.000431	0.027	0.16	0.16	Dupuytren's disease;	chr1:221444228	chr1:221837334~221837437:-
THCA	cis	rs17095355	0.818	rs61881638	ENSG00000203876.8	ADD3-AS1	-3.55	0.000431	0.027	-0.19	-0.16	Biliary atresia;	chr10:110103638	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.818	rs61881639	ENSG00000203876.8	ADD3-AS1	-3.55	0.000431	0.027	-0.19	-0.16	Biliary atresia;	chr10:110103743	chr10:109940104~110008381:-
THCA	cis	rs1436955	0.798	rs17205498	ENSG00000259251.2	RP11-643M14.1	-3.55	0.000431	0.027	-0.21	-0.16	Type 2 diabetes;	chr15:62113056	chr15:62060503~62062434:+
THCA	cis	rs793571	0.784	rs12915713	ENSG00000259250.1	RP11-50C13.1	-3.55	0.000431	0.027	-0.16	-0.16	Schizophrenia;	chr15:58815663	chr15:58587507~58591676:+
THCA	cis	rs8130944	0.893	rs2839577	ENSG00000225731.1	AP001627.1	3.55	0.000431	0.027	0.2	0.16	Perceived unattractiveness to mosquitoes;	chr21:42731323	chr21:42733594~42741758:-
THCA	cis	rs7903847	0.62	rs3737194	ENSG00000225850.3	RP11-452K12.4	3.55	0.000431	0.027	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97370370	chr10:97334564~97343203:+
THCA	cis	rs962856	0.619	rs6546301	ENSG00000236780.4	AC078941.1	3.55	0.000431	0.027	0.22	0.16	Pancreatic cancer;	chr2:67377107	chr2:67123357~67215319:-
THCA	cis	rs962856	0.619	rs6546302	ENSG00000236780.4	AC078941.1	3.55	0.000431	0.027	0.22	0.16	Pancreatic cancer;	chr2:67378601	chr2:67123357~67215319:-
THCA	cis	rs862034	0.653	rs7148461	ENSG00000270000.1	RP3-449M8.9	3.55	0.000431	0.027	0.16	0.16	Height;	chr14:74548396	chr14:74471930~74472360:-
THCA	cis	rs1153858	1	rs11852800	ENSG00000275672.1	GATM-AS1	3.55	0.000431	0.027	0.17	0.16	Homoarginine levels;	chr15:45346933	chr15:45378700~45380123:+
THCA	cis	rs9303280	0.806	rs8069176	ENSG00000263818.4	CTD-2206N4.4	3.55	0.000431	0.027	0.22	0.16	Self-reported allergy;	chr17:39900944	chr17:39057019~39113190:+
THCA	cis	rs6885099	0.545	rs251429	ENSG00000251400.1	ALDH7A1P1	3.55	0.000431	0.027	0.19	0.16	Thyroid hormone levels;	chr5:77257284	chr5:77290268~77291800:+
THCA	cis	rs2991971	1	rs518365	ENSG00000234329.1	RP11-767N6.2	-3.55	0.000431	0.027	-0.15	-0.16	High light scatter reticulocyte count;	chr1:45544980	chr1:45651039~45651826:-
THCA	cis	rs10895987	0.83	rs12292693	ENSG00000197847.11	SLC22A20	3.55	0.000431	0.027	0.2	0.16	Blood protein levels;	chr11:65169248	chr11:65213840~65242757:+
THCA	cis	rs9487051	1	rs9400273	ENSG00000260273.1	RP11-425D10.10	3.55	0.000431	0.027	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109311596	chr6:109382795~109383666:+
THCA	cis	rs9487051	1	rs13191948	ENSG00000260273.1	RP11-425D10.10	3.55	0.000431	0.027	0.21	0.16	Reticulocyte fraction of red cells;	chr6:109313396	chr6:109382795~109383666:+
THCA	cis	rs9905704	0.881	rs2611774	ENSG00000224738.1	AC099850.1	3.55	0.000431	0.027	0.22	0.16	Testicular germ cell tumor;	chr17:58654943	chr17:59106598~59118267:+
THCA	cis	rs67478160	0.608	rs11628787	ENSG00000258534.1	CTD-2134A5.4	3.55	0.000431	0.027	0.16	0.16	Schizophrenia;	chr14:103857647	chr14:103854366~103880111:-
THCA	cis	rs13217239	0.646	rs62401067	ENSG00000124549.13	BTN2A3P	3.55	0.000431	0.027	0.15	0.16	Schizophrenia;	chr6:27050322	chr6:26421391~26432383:+
THCA	cis	rs3126085	0.935	rs3120661	ENSG00000237975.5	FLG-AS1	3.55	0.000431	0.027	0.26	0.16	Atopic dermatitis;	chr1:152321926	chr1:152168125~152445456:+
THCA	cis	rs2732480	0.5	rs7966829	ENSG00000257735.1	RP11-370I10.6	3.55	0.000431	0.027	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48350945~48442411:+
THCA	cis	rs2455799	0.573	rs2654648	ENSG00000270409.1	RP11-44D5.1	-3.55	0.000431	0.027	-0.17	-0.16	Mean platelet volume;	chr3:15733918	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.573	rs2654650	ENSG00000270409.1	RP11-44D5.1	-3.55	0.000431	0.027	-0.17	-0.16	Mean platelet volume;	chr3:15737707	chr3:15732252~15733470:+
THCA	cis	rs791590	0.941	rs12722553	ENSG00000212743.2	RP11-563J2.3	3.55	0.000431	0.027	0.22	0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6029321	chr10:6350316~6352762:+
THCA	cis	rs4262150	0.774	rs17565839	ENSG00000253921.1	CTB-113P19.3	3.55	0.000431	0.027	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152703180	chr5:151753992~151767247:+
THCA	cis	rs2905347	0.895	rs2961281	ENSG00000179428.2	AC073072.5	3.55	0.000431	0.027	0.18	0.16	Major depression and alcohol dependence;	chr7:22600673	chr7:22725395~22727620:-
THCA	cis	rs7864204	0.508	rs10869048	ENSG00000234506.4	LINC01506	-3.55	0.000431	0.027	-0.22	-0.16	Body mass index (recreational physical activity interaction);	chr9:68563262	chr9:68543541~68546589:-
THCA	cis	rs683250	0.629	rs645954	ENSG00000254551.1	RP11-727A23.7	3.55	0.000431	0.027	0.2	0.16	Subcortical brain region volumes;	chr11:83262003	chr11:83209431~83213379:-
THCA	cis	rs2836950	0.565	rs7279497	ENSG00000235701.1	PCBP2P1	3.55	0.000431	0.027	0.18	0.16	Menarche (age at onset);	chr21:39159380	chr21:39171130~39172106:-
THCA	cis	rs9487051	0.872	rs6924815	ENSG00000260273.1	RP11-425D10.10	3.55	0.000431	0.027	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109291141	chr6:109382795~109383666:+
THCA	cis	rs2744375	0.6	rs874646	ENSG00000261189.1	RP3-512B11.3	3.55	0.000431	0.027	0.17	0.16	Resting heart rate;	chr6:7550458	chr6:7540451~7541338:-
THCA	cis	rs6496932	0.865	rs4842874	ENSG00000259630.2	CTD-2262B20.1	3.55	0.000431	0.027	0.22	0.16	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85415228~85415633:+
THCA	cis	rs8177876	0.915	rs6420421	ENSG00000261061.1	RP11-303E16.2	3.55	0.000431	0.027	0.25	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094601	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.749	rs5023849	ENSG00000261061.1	RP11-303E16.2	3.55	0.000431	0.027	0.25	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094694	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.841	rs5023850	ENSG00000261061.1	RP11-303E16.2	3.55	0.000431	0.027	0.25	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094755	chr16:81030770~81031485:+
THCA	cis	rs8177876	0.915	rs5023852	ENSG00000261061.1	RP11-303E16.2	3.55	0.000431	0.027	0.25	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094800	chr16:81030770~81031485:+
THCA	cis	rs10483853	0.689	rs11623977	ENSG00000259065.1	RP5-1021I20.1	-3.55	0.000432	0.027	-0.22	-0.16	Coronary artery calcification;	chr14:73370662	chr14:73787360~73803270:+
THCA	cis	rs11233413	1	rs4944425	ENSG00000246067.6	RAB30-AS1	3.55	0.000432	0.0271	0.16	0.16	Economic and political preferences (feminism/equality);	chr11:83065819	chr11:83072066~83106719:+
THCA	cis	rs3126085	0.935	rs10788824	ENSG00000237975.5	FLG-AS1	-3.55	0.000432	0.0271	-0.25	-0.16	Atopic dermatitis;	chr1:152189218	chr1:152168125~152445456:+
THCA	cis	rs910316	0.783	rs11850751	ENSG00000259138.1	RP11-950C14.7	3.55	0.000432	0.0271	0.14	0.16	Height;	chr14:75123410	chr14:75127153~75136930:+
THCA	cis	rs9876781	1	rs2885510	ENSG00000199476.1	Y_RNA	3.55	0.000432	0.0271	0.2	0.16	Longevity;	chr3:48376736	chr3:48288587~48288694:+
THCA	cis	rs6787172	0.651	rs4680436	ENSG00000272087.1	RP11-379F4.7	3.55	0.000432	0.0271	0.14	0.16	Subjective well-being;	chr3:158441528	chr3:158693120~158693768:-
THCA	cis	rs10975370	0.526	rs10815345	ENSG00000206147.5	RP11-106A1.2	3.55	0.000432	0.0271	0.19	0.16	Breast cancer;	chr9:6042708	chr9:6639139~6639604:+
THCA	cis	rs11123406	0.651	rs744530	ENSG00000227992.1	AC108463.2	-3.55	0.000432	0.0271	-0.2	-0.16	Type 2 diabetes;	chr2:111193636	chr2:111203964~111206215:-
THCA	cis	rs7615952	0.599	rs6438955	ENSG00000248787.1	RP11-666A20.4	-3.55	0.000432	0.0271	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126011490	chr3:125908005~125910272:-
THCA	cis	rs4267450	0.697	rs11667683	ENSG00000261770.1	CTC-459F4.1	3.55	0.000432	0.0271	0.29	0.16	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28381856	chr19:27757184~27760849:-
THCA	cis	rs7246967	0.673	rs118059742	ENSG00000198153.8	ZNF849P	-3.55	0.000432	0.0271	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22636644	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs56663398	ENSG00000198153.8	ZNF849P	-3.55	0.000432	0.0271	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22637398	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs35731237	ENSG00000198153.8	ZNF849P	-3.55	0.000432	0.0271	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22637708	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12979173	ENSG00000198153.8	ZNF849P	-3.55	0.000432	0.0271	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22637879	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12979848	ENSG00000198153.8	ZNF849P	-3.55	0.000432	0.0271	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22637996	chr19:22685167~22686732:+
THCA	cis	rs901683	1	rs9422651	ENSG00000230869.1	CTGLF10P	-3.55	0.000432	0.0271	-0.36	-0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45552008	chr10:45678692~45700532:+
THCA	cis	rs9811920	0.893	rs720688	ENSG00000273374.1	RP11-383I23.2	3.55	0.000432	0.0271	0.13	0.16	Axial length;	chr3:100161725	chr3:99802699~99806058:-
THCA	cis	rs9662633	1	rs6664760	ENSG00000227372.9	TP73-AS1	3.55	0.000432	0.0271	0.24	0.16	Visceral adipose tissue adjusted for BMI;	chr1:3731704	chr1:3735601~3747336:-
THCA	cis	rs2243480	1	rs4149468	ENSG00000237310.1	GS1-124K5.4	3.55	0.000432	0.0271	0.19	0.16	Diabetic kidney disease;	chr7:66360703	chr7:66493706~66495474:+
THCA	cis	rs34783982	0.529	rs12917490	ENSG00000259699.2	HMGB1P8	3.55	0.000432	0.0271	0.22	0.16	Squamous cell lung carcinoma;	chr15:88930574	chr15:89135547~89136495:-
THCA	cis	rs72482608	0.835	rs10733057	ENSG00000271811.1	RP1-79C4.4	3.55	0.000432	0.0271	0.19	0.16	Emphysema imaging phenotypes;	chr1:170779135	chr1:170667381~170669425:+
THCA	cis	rs643506	0.874	rs673679	ENSG00000230911.1	PPIHP1	-3.54	0.000432	0.0271	-0.22	-0.16	Breast cancer;	chr11:111816076	chr11:112029858~112030367:-
THCA	cis	rs16857609	1	rs3821098	ENSG00000233143.1	DIRC3-AS1	3.54	0.000432	0.0271	0.18	0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217427418	chr2:217282739~217336120:+
THCA	cis	rs7660883	0.897	rs342467	ENSG00000251411.1	RP11-397E7.4	-3.54	0.000432	0.0271	-0.15	-0.16	HDL cholesterol levels;	chr4:87131067	chr4:86913266~86914817:-
THCA	cis	rs724818	0.661	rs1397774	ENSG00000251609.2	SETP12	-3.54	0.000432	0.0271	-0.46	-0.16	Monobrow thickness;	chr4:120768753	chr4:120895494~120897083:-
THCA	cis	rs1865760	0.593	rs2097273	ENSG00000272810.1	U91328.22	-3.54	0.000432	0.0271	-0.12	-0.16	Height;	chr6:25941082	chr6:26013241~26013757:+
THCA	cis	rs3748656	1	rs2306937	ENSG00000273483.1	RP4-671G15.2	3.54	0.000432	0.0271	0.18	0.16	Hip circumference adjusted for BMI;	chr1:112703884	chr1:112517799~112518441:-
THCA	cis	rs1862618	0.853	rs10051747	ENSG00000234553.1	AC022431.3	-3.54	0.000432	0.0271	-0.19	-0.16	Initial pursuit acceleration;	chr5:56787462	chr5:56536583~56537826:-
THCA	cis	rs775227	0.574	rs60131925	ENSG00000243849.1	CFAP44-AS1	3.54	0.000432	0.0271	0.3	0.16	Dental caries;	chr3:113315921	chr3:113403991~113433992:+
THCA	cis	rs35740288	0.621	rs12916001	ENSG00000259295.5	CSPG4P12	3.54	0.000432	0.0271	0.22	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85702038	chr15:85191438~85213905:+
THCA	cis	rs748404	0.626	rs57938858	ENSG00000166763.7	STRCP1	3.54	0.000432	0.0271	0.22	0.16	Lung cancer;	chr15:43520259	chr15:43699488~43718184:-
THCA	cis	rs12681963	0.688	rs55725858	ENSG00000272375.1	RP11-51J9.6	3.54	0.000432	0.0271	0.24	0.16	Migraine;	chr8:30194695	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.541	rs56339843	ENSG00000272375.1	RP11-51J9.6	3.54	0.000432	0.0271	0.24	0.16	Migraine;	chr8:30194766	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs73242337	ENSG00000272375.1	RP11-51J9.6	3.54	0.000432	0.0271	0.24	0.16	Migraine;	chr8:30200526	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs73242338	ENSG00000272375.1	RP11-51J9.6	3.54	0.000432	0.0271	0.24	0.16	Migraine;	chr8:30200574	chr8:30197404~30198048:+
THCA	cis	rs1488902	0.709	rs4145712	ENSG00000280385.1	AP000648.5	3.54	0.000432	0.0271	0.15	0.16	Amyotrophic lateral sclerosis;	chr11:89621418	chr11:90193614~90198120:+
THCA	cis	rs2404602	0.622	rs2003344	ENSG00000196274.5	Metazoa_SRP	-3.54	0.000432	0.0271	-0.19	-0.16	Blood metabolite levels;	chr15:76339960	chr15:76230048~76230390:-
THCA	cis	rs17428076	0.71	rs62181740	ENSG00000228389.1	AC068039.4	-3.54	0.000432	0.0271	-0.23	-0.16	Myopia;	chr2:171683891	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.749	rs62181741	ENSG00000228389.1	AC068039.4	-3.54	0.000432	0.0271	-0.23	-0.16	Myopia;	chr2:171684565	chr2:171773482~171775844:+
THCA	cis	rs372883	0.638	rs117213	ENSG00000176054.6	RPL23P2	-3.54	0.000432	0.0271	-0.15	-0.16	Pancreatic cancer;	chr21:29348215	chr21:28997613~28998033:-
THCA	cis	rs17095355	0.818	rs72828263	ENSG00000203876.8	ADD3-AS1	-3.54	0.000432	0.0271	-0.19	-0.16	Biliary atresia;	chr10:110025945	chr10:109940104~110008381:-
THCA	cis	rs7439493	0.865	rs3181187	ENSG00000247950.5	SEC24B-AS1	-3.54	0.000432	0.0271	-0.1	-0.16	Blood protein levels;	chr4:109701754	chr4:109347475~109433817:-
THCA	cis	rs7944735	0.517	rs11039538	ENSG00000200090.1	Y_RNA	3.54	0.000432	0.0271	0.16	0.16	Intraocular pressure;	chr11:48133438	chr11:47726894~47726992:-
THCA	cis	rs2554380	0.891	rs1896816	ENSG00000230373.7	GOLGA6L5P	-3.54	0.000432	0.0271	-0.2	-0.16	Height;	chr15:83630619	chr15:84507885~84516814:-
THCA	cis	rs910316	0.934	rs8016330	ENSG00000273565.1	CTD-3075F15.1	-3.54	0.000432	0.0271	-0.19	-0.16	Height;	chr14:75190804	chr14:75176929~75177418:+
THCA	cis	rs4713118	0.513	rs200971	ENSG00000273712.1	RP5-874C20.7	3.54	0.000432	0.0271	0.2	0.16	Parkinson's disease;	chr6:27891126	chr6:28315613~28315883:-
THCA	cis	rs116095464	0.867	rs62330032	ENSG00000277812.1	AC021087.1	3.54	0.000432	0.0271	0.4	0.16	Breast cancer;	chr5:330442	chr5:262769~262881:+
THCA	cis	rs910316	1	rs10149880	ENSG00000259138.1	RP11-950C14.7	-3.54	0.000432	0.0271	-0.14	-0.16	Height;	chr14:75166305	chr14:75127153~75136930:+
THCA	cis	rs910316	0.935	rs175076	ENSG00000273565.1	CTD-3075F15.1	-3.54	0.000432	0.0271	-0.19	-0.16	Height;	chr14:75038783	chr14:75176929~75177418:+
THCA	cis	rs6545883	0.894	rs6760075	ENSG00000212978.6	AC016747.3	-3.54	0.000432	0.0271	-0.18	-0.16	Tuberculosis;	chr2:61385746	chr2:61141592~61144969:-
THCA	cis	rs10932886	0.76	rs17397524	ENSG00000224819.1	AC093843.1	3.54	0.000432	0.0271	0.15	0.16	Brain imaging;	chr2:220837852	chr2:220791078~220797893:+
THCA	cis	rs9875589	0.957	rs60060718	ENSG00000233121.1	VN1R20P	3.54	0.000432	0.0271	0.19	0.16	Ovarian reserve;	chr3:13908836	chr3:13926813~13927778:+
THCA	cis	rs9875589	0.957	rs4407395	ENSG00000233121.1	VN1R20P	3.54	0.000432	0.0271	0.19	0.16	Ovarian reserve;	chr3:13910176	chr3:13926813~13927778:+
THCA	cis	rs10832963	1	rs10832963	ENSG00000256361.1	RP11-613F22.6	3.54	0.000432	0.0271	0.21	0.16	Breast cancer;	chr11:18642694	chr11:18511043~18511475:-
THCA	cis	rs801193	1	rs2659909	ENSG00000230295.1	RP11-458F8.2	-3.54	0.000432	0.0271	-0.12	-0.16	Aortic root size;	chr7:66695292	chr7:66880708~66882981:+
THCA	cis	rs12022452	0.908	rs11811487	ENSG00000272145.1	NFYC-AS1	3.54	0.000432	0.0271	0.14	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40690380~40692066:-
THCA	cis	rs1154275	0.537	rs9875150	ENSG00000272844.1	RP11-484K9.4	3.54	0.000432	0.0271	0.13	0.16	Takotsubo syndrome;	chr3:112796937	chr3:112990447~112991153:-
THCA	cis	rs1729951	0.575	rs1682356	ENSG00000239213.4	NCK1-AS1	3.54	0.000432	0.0271	0.14	0.16	Neuroticism;	chr3:136973195	chr3:136841726~136862054:-
THCA	cis	rs6743226	0.603	rs12619677	ENSG00000223374.1	AC005104.3	3.54	0.000432	0.0271	0.12	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241273780	chr2:241351340~241353104:-
THCA	cis	rs17604090	0.648	rs823384	ENSG00000227855.3	DPY19L2P3	3.54	0.000432	0.0271	0.18	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29617999	chr7:29650227~29742594:+
THCA	cis	rs2048656	0.523	rs1976673	ENSG00000261451.1	RP11-981G7.1	3.54	0.000432	0.0271	0.22	0.16	Schizophrenia;	chr8:9822270	chr8:10433672~10438312:+
THCA	cis	rs9660180	0.783	rs1107910	ENSG00000215914.4	MMP23A	-3.54	0.000433	0.0271	-0.21	-0.16	Body mass index;	chr1:1760882	chr1:1699942~1701782:+
THCA	cis	rs11613189	0.546	rs1027569	ENSG00000235423.7	RP11-282O18.3	3.54	0.000433	0.0271	0.14	0.16	Optic cup area;	chr12:124158845	chr12:123252030~123261483:-
THCA	cis	rs889312	0.5	rs252920	ENSG00000271828.1	CTD-2310F14.1	-3.54	0.000433	0.0271	-0.22	-0.16	Breast cancer (early onset);Breast cancer;	chr5:56852914	chr5:56927874~56929573:+
THCA	cis	rs8064029	1	rs72633273	ENSG00000267077.1	RP11-127I20.5	3.54	0.000433	0.0271	0.25	0.16	Cancer;	chr16:4857615	chr16:4795265~4796532:-
THCA	cis	rs4730250	0.711	rs117026964	ENSG00000241764.3	AC002467.7	3.54	0.000433	0.0271	0.19	0.16	Osteoarthritis;	chr7:107423211	chr7:107742817~107744581:-
THCA	cis	rs8177876	0.841	rs8177851	ENSG00000261838.4	RP11-303E16.6	3.54	0.000433	0.0271	0.35	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81092747	chr16:81069854~81076598:+
THCA	cis	rs8130944	1	rs2269152	ENSG00000235772.1	AP001625.6	3.54	0.000433	0.0271	0.19	0.16	Perceived unattractiveness to mosquitoes;	chr21:42724534	chr21:42560374~42561934:-
THCA	cis	rs7188697	0.922	rs246258	ENSG00000276259.1	RP11-481J2.4	3.54	0.000433	0.0271	0.11	0.16	QT interval;	chr16:58545370	chr16:58522970~58523842:+
THCA	cis	rs9878978	1	rs13074392	ENSG00000227588.2	CNTN4-AS2	3.54	0.000433	0.0271	0.19	0.16	Blood pressure (smoking interaction);	chr3:2444111	chr3:2110409~2144241:-
THCA	cis	rs9858542	0.543	rs2230929	ENSG00000270441.1	RP11-694I15.7	3.54	0.000433	0.0271	0.19	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49305742	chr3:49140086~49160851:-
THCA	cis	rs7178909	0.902	rs8038480	ENSG00000259677.1	RP11-493E3.1	3.54	0.000433	0.0271	0.2	0.16	Common traits (Other);	chr15:89898365	chr15:89876540~89877285:+
THCA	cis	rs76382185	0.877	rs80053937	ENSG00000233184.5	RP11-421L21.3	3.54	0.000433	0.0271	0.26	0.16	Lymphocyte counts;	chr1:101142745	chr1:101025878~101087268:+
THCA	cis	rs7727544	0.557	rs715285	ENSG00000263597.1	MIR3936	3.54	0.000433	0.0271	0.15	0.16	Blood metabolite levels;	chr5:132149690	chr5:132365490~132365599:-
THCA	cis	rs12493885	0.818	rs73158489	ENSG00000243069.6	ARHGEF26-AS1	-3.54	0.000433	0.0271	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154040073	chr3:154024401~154121332:-
THCA	cis	rs12049351	0.774	rs35421764	ENSG00000229367.1	HMGN2P19	3.54	0.000433	0.0271	0.26	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229565742	chr1:229570532~229570796:+
THCA	cis	rs1557488	0.599	rs7111298	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000433	0.0271	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126849615	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs4937207	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000433	0.0271	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126851450	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs4937208	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000433	0.0271	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126851581	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs7113957	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000433	0.0271	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126853653	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs7128471	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000433	0.0271	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126853783	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs9943531	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000433	0.0271	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126854469	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs7102096	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000433	0.0271	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126854582	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs7122367	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000433	0.0271	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126855517	chr11:125873031~125874528:-
THCA	cis	rs11603020	0.95	rs11229063	ENSG00000265566.2	RN7SL605P	-3.54	0.000433	0.0271	-0.25	-0.16	Blood protein levels;	chr11:57602257	chr11:57528085~57528365:-
THCA	cis	rs7236492	0.748	rs7228738	ENSG00000267655.1	CTD-2286N8.2	3.54	0.000433	0.0271	0.36	0.16	Inflammatory bowel disease;Crohn's disease;	chr18:79471307	chr18:79117207~79117920:+
THCA	cis	rs2842346	0.568	rs2525526	ENSG00000258623.1	CTD-2325P2.3	-3.54	0.000433	0.0271	-0.21	-0.16	Breast cancer;	chr14:68542449	chr14:68683411~68685565:-
THCA	cis	rs9635324	0.964	rs12902310	ENSG00000259536.4	RP11-111A22.1	3.54	0.000433	0.0271	0.21	0.16	Blood metabolite ratios;Blood metabolite levels;	chr15:40423228	chr15:40488041~40558019:+
THCA	cis	rs72996113	0.702	rs61910470	ENSG00000248027.1	CTD-2383M3.1	-3.54	0.000433	0.0271	-0.31	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100710965	chr11:100684162~100687955:-
THCA	cis	rs9896933	0.887	rs78483419	ENSG00000262410.1	RP11-388C12.8	-3.54	0.000433	0.0271	-0.22	-0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82913008	chr17:82745068~82745709:+
THCA	cis	rs867186	0.614	rs116707649	ENSG00000279253.1	RP4-614O4.13	-3.54	0.000433	0.0271	-0.33	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34836868	chr20:35262727~35264187:-
THCA	cis	rs867186	0.614	rs75848331	ENSG00000279253.1	RP4-614O4.13	-3.54	0.000433	0.0271	-0.33	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34837186	chr20:35262727~35264187:-
THCA	cis	rs867186	0.614	rs78260746	ENSG00000279253.1	RP4-614O4.13	-3.54	0.000433	0.0271	-0.33	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34838312	chr20:35262727~35264187:-
THCA	cis	rs867186	0.614	rs117065834	ENSG00000279253.1	RP4-614O4.13	-3.54	0.000433	0.0271	-0.33	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34838765	chr20:35262727~35264187:-
THCA	cis	rs34102591	0.784	rs7964945	ENSG00000270028.1	RP11-380L11.4	3.54	0.000433	0.0271	0.22	0.16	Schizophrenia;	chr12:123953121	chr12:123925461~123926083:-
THCA	cis	rs9878978	1	rs13084976	ENSG00000227588.2	CNTN4-AS2	3.54	0.000433	0.0271	0.2	0.16	Blood pressure (smoking interaction);	chr3:2421168	chr3:2110409~2144241:-
THCA	cis	rs2695743	0.675	rs1438063	ENSG00000222043.2	AC079305.10	3.54	0.000433	0.0271	0.15	0.16	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177831117	chr2:177264359~177265515:+
THCA	cis	rs9650657	0.812	rs11250072	ENSG00000269918.1	AF131215.9	-3.54	0.000433	0.0271	-0.17	-0.16	Neuroticism;	chr8:10774611	chr8:11104691~11106704:-
THCA	cis	rs7246967	0.673	rs59567211	ENSG00000198153.8	ZNF849P	-3.54	0.000433	0.0271	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22647080	chr19:22685167~22686732:+
THCA	cis	rs4660214	0.666	rs625384	ENSG00000228060.1	RP11-69E11.8	-3.54	0.000433	0.0271	-0.15	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39565160~39573203:+
THCA	cis	rs6840360	1	rs6535814	ENSG00000270265.1	RP11-731D1.4	-3.54	0.000433	0.0271	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151688542	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.967	rs6535815	ENSG00000270265.1	RP11-731D1.4	-3.54	0.000433	0.0271	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151688548	chr4:151333775~151353224:-
THCA	cis	rs11992162	0.551	rs35010200	ENSG00000227888.4	FAM66A	-3.54	0.000433	0.0271	-0.21	-0.16	Monocyte count;	chr8:11928146	chr8:12362019~12388296:+
THCA	cis	rs4578769	0.729	rs12456891	ENSG00000265939.1	UBE2CP2	-3.54	0.000433	0.0271	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22830243	chr18:22900486~22900995:-
THCA	cis	rs7615952	0.512	rs4679430	ENSG00000243429.1	OR7E29P	3.54	0.000433	0.0271	0.21	0.16	Blood pressure (smoking interaction);	chr3:125639049	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.512	rs34651730	ENSG00000243429.1	OR7E29P	3.54	0.000433	0.0271	0.21	0.16	Blood pressure (smoking interaction);	chr3:125639796	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.512	rs2979334	ENSG00000243429.1	OR7E29P	3.54	0.000433	0.0271	0.21	0.16	Blood pressure (smoking interaction);	chr3:125639980	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.512	rs11929125	ENSG00000243429.1	OR7E29P	3.54	0.000433	0.0271	0.21	0.16	Blood pressure (smoking interaction);	chr3:125640599	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.512	rs11921452	ENSG00000243429.1	OR7E29P	3.54	0.000433	0.0271	0.21	0.16	Blood pressure (smoking interaction);	chr3:125640906	chr3:125712139~125713045:+
THCA	cis	rs7615952	0.512	rs2922175	ENSG00000243429.1	OR7E29P	3.54	0.000433	0.0271	0.21	0.16	Blood pressure (smoking interaction);	chr3:125642516	chr3:125712139~125713045:+
THCA	cis	rs2333021	0.727	rs1986616	ENSG00000258376.2	RP4-647C14.2	3.54	0.000433	0.0271	0.19	0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73074228	chr14:73242651~73245979:-
THCA	cis	rs10744955	0.964	rs11070755	ENSG00000259618.1	RP11-562A8.5	3.54	0.000433	0.0271	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr15:50150099	chr15:50494018~50497080:-
THCA	cis	rs7829975	0.564	rs2921057	ENSG00000253130.1	CTD-3023L14.2	-3.54	0.000433	0.0271	-0.18	-0.16	Mood instability;	chr8:8461157	chr8:8561391~8569688:+
THCA	cis	rs1009077	0.627	rs6534146	ENSG00000248280.1	RP11-33B1.2	-3.54	0.000433	0.0271	-0.18	-0.16	Endometriosis;	chr4:119617668	chr4:119440561~119450157:-
THCA	cis	rs9987353	0.83	rs2126267	ENSG00000248538.5	RP11-10A14.5	3.54	0.000433	0.0271	0.22	0.16	Recombination measurement;	chr8:9250441	chr8:9189011~9202854:+
THCA	cis	rs17301013	0.761	rs332805	ENSG00000270084.1	GAS5-AS1	-3.54	0.000433	0.0271	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174652487	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.861	rs34819375	ENSG00000270084.1	GAS5-AS1	-3.54	0.000433	0.0271	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174654958	chr1:173863248~173863941:+
THCA	cis	rs6871536	1	rs58760622	ENSG00000233006.5	AC034220.3	-3.54	0.000433	0.0271	-0.15	-0.16	Asthma (childhood onset);	chr5:132572420	chr5:132311285~132369916:-
THCA	cis	rs11673344	0.504	rs4806409	ENSG00000233527.7	ZNF529-AS1	3.54	0.000433	0.0271	0.14	0.16	Obesity-related traits;	chr19:37097923	chr19:36573070~36594708:+
THCA	cis	rs944289	0.74	rs1537425	ENSG00000257520.1	RP11-896J10.3	-3.54	0.000433	0.0271	-0.16	-0.16	Thyroid cancer;	chr14:36098954	chr14:36473207~36519521:-
THCA	cis	rs7216064	1	rs56148300	ENSG00000278740.1	RP11-147L13.14	3.54	0.000433	0.0271	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896636	chr17:68188547~68189165:+
THCA	cis	rs10129255	0.719	rs7156660	ENSG00000211972.2	IGHV3-66	3.54	0.000434	0.0271	0.09	0.16	Kawasaki disease;	chr14:106673171	chr14:106675017~106675544:-
THCA	cis	rs853679	0.517	rs9295761	ENSG00000219891.2	ZSCAN12P1	3.54	0.000434	0.0272	0.23	0.16	Depression;	chr6:28180209	chr6:28091154~28093664:+
THCA	cis	rs2341260	0.541	rs11210289	ENSG00000223479.3	RP4-788P17.1	3.54	0.000434	0.0272	0.21	0.16	Cardiac Troponin-T levels;	chr1:73577245	chr1:73635216~73715214:+
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000184274.3	LINC00315	-3.54	0.000434	0.0272	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000184274.3	LINC00315	-3.54	0.000434	0.0272	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000184274.3	LINC00315	-3.54	0.000434	0.0272	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000184274.3	LINC00315	-3.54	0.000434	0.0272	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000184274.3	LINC00315	-3.54	0.000434	0.0272	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45300245~45305257:-
THCA	cis	rs76695126	0.659	rs8067541	ENSG00000271851.1	RP11-565F19.2	3.54	0.000434	0.0272	0.16	0.16	Borderline personality disorder;	chr17:9533219	chr17:9553323~9555696:-
THCA	cis	rs2135507	0.515	rs6814526	ENSG00000270480.1	RP11-57B24.1	3.54	0.000434	0.0272	0.25	0.16	Juvenile osteochondritis dissecans;	chr4:82613494	chr4:82691737~82692468:+
THCA	cis	rs7660883	1	rs7660883	ENSG00000251411.1	RP11-397E7.4	-3.54	0.000434	0.0272	-0.15	-0.16	HDL cholesterol levels;	chr4:87061724	chr4:86913266~86914817:-
THCA	cis	rs751728	0.664	rs4711347	ENSG00000274259.2	XXbac-BPG294E21.9	3.54	0.000434	0.0272	0.18	0.16	Crohn's disease;	chr6:33767515	chr6:33437363~33454453:-
THCA	cis	rs3176789	0.914	rs724668	ENSG00000256673.1	RP11-599J14.2	3.54	0.000434	0.0272	0.21	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9770233	chr12:9398355~9414851:-
THCA	cis	rs7829975	0.777	rs486781	ENSG00000248538.5	RP11-10A14.5	3.54	0.000434	0.0272	0.2	0.16	Mood instability;	chr8:8782230	chr8:9189011~9202854:+
THCA	cis	rs9650657	0.547	rs11250099	ENSG00000206014.6	OR7E161P	-3.54	0.000434	0.0272	-0.18	-0.16	Neuroticism;	chr8:10961147	chr8:11928597~11929563:-
THCA	cis	rs343092	1	rs189339	ENSG00000241749.4	RPSAP52	-3.54	0.000434	0.0272	-0.17	-0.16	Type 2 diabetes;	chr12:65858514	chr12:65758020~65826997:-
THCA	cis	rs9788682	0.894	rs4461039	ENSG00000261143.1	ADAMTS7P3	3.54	0.000434	0.0272	0.23	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78525105	chr15:77976042~77993057:+
THCA	cis	rs6456156	0.792	rs7775443	ENSG00000235272.1	FAM103A2P	-3.54	0.000434	0.0272	-0.22	-0.16	Primary biliary cholangitis;	chr6:167099764	chr6:166586124~166586477:-
THCA	cis	rs2549003	1	rs2549004	ENSG00000233006.5	AC034220.3	3.54	0.000434	0.0272	0.12	0.16	Asthma (sex interaction);	chr5:132492133	chr5:132311285~132369916:-
THCA	cis	rs2625529	0.824	rs7182776	ENSG00000260037.4	CTD-2524L6.3	3.54	0.000434	0.0272	0.21	0.16	Red blood cell count;	chr15:72170490	chr15:71818396~71823384:+
THCA	cis	rs9420	0.528	rs34052104	ENSG00000254602.1	AP000662.4	-3.54	0.000434	0.0272	-0.19	-0.16	Schizophrenia;	chr11:57617046	chr11:57638024~57652790:+
THCA	cis	rs1124769	0.871	rs2619695	ENSG00000244879.4	GABPB1-AS1	3.54	0.000434	0.0272	0.17	0.16	Cognitive performance;	chr15:50867893	chr15:50354959~50372202:+
THCA	cis	rs931127	0.658	rs7926512	ENSG00000255557.1	RP11-770G2.2	3.54	0.000434	0.0272	0.18	0.16	Systemic lupus erythematosus;	chr11:65697016	chr11:65745729~65771585:+
THCA	cis	rs61160187	0.51	rs4700393	ENSG00000272308.1	RP11-231G3.1	-3.54	0.000434	0.0272	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60802440	chr5:60866457~60866935:-
THCA	cis	rs7824557	0.527	rs2572448	ENSG00000255046.1	RP11-297N6.4	3.54	0.000434	0.0272	0.17	0.16	Retinal vascular caliber;	chr8:11381843	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.527	rs2572447	ENSG00000255046.1	RP11-297N6.4	3.54	0.000434	0.0272	0.17	0.16	Retinal vascular caliber;	chr8:11382001	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.527	rs2572446	ENSG00000255046.1	RP11-297N6.4	3.54	0.000434	0.0272	0.17	0.16	Retinal vascular caliber;	chr8:11382056	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.527	rs10109537	ENSG00000255046.1	RP11-297N6.4	3.54	0.000434	0.0272	0.17	0.16	Retinal vascular caliber;	chr8:11382131	chr8:11797928~11802568:-
THCA	cis	rs17507216	0.667	rs72753916	ENSG00000255769.6	GOLGA2P10	-3.54	0.000434	0.0272	-0.23	-0.16	Excessive daytime sleepiness;	chr15:82684001	chr15:82472993~82513950:-
THCA	cis	rs9902453	0.765	rs3115087	ENSG00000264290.1	RP11-68I3.4	3.54	0.000434	0.0272	0.12	0.16	Coffee consumption (cups per day);	chr17:29703249	chr17:29569580~29570519:+
THCA	cis	rs9902453	0.817	rs3115089	ENSG00000264290.1	RP11-68I3.4	3.54	0.000434	0.0272	0.12	0.16	Coffee consumption (cups per day);	chr17:29704863	chr17:29569580~29570519:+
THCA	cis	rs911555	0.603	rs8016326	ENSG00000269958.1	RP11-73M18.8	3.54	0.000434	0.0272	0.15	0.16	Intelligence (multi-trait analysis);	chr14:103380379	chr14:103696353~103697163:+
THCA	cis	rs9837602	0.529	rs793495	ENSG00000273374.1	RP11-383I23.2	3.54	0.000434	0.0272	0.14	0.16	Breast cancer;	chr3:99789090	chr3:99802699~99806058:-
THCA	cis	rs2447820	0.5	rs39818	ENSG00000263432.2	RN7SL689P	3.54	0.000434	0.0272	0.2	0.16	Migraine;	chr5:122968743	chr5:123022487~123022783:-
THCA	cis	rs11673344	0.523	rs7258438	ENSG00000233527.7	ZNF529-AS1	3.54	0.000434	0.0272	0.14	0.16	Obesity-related traits;	chr19:37032534	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.503	rs10414520	ENSG00000233527.7	ZNF529-AS1	3.54	0.000434	0.0272	0.14	0.16	Obesity-related traits;	chr19:37057279	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.503	rs1829603	ENSG00000233527.7	ZNF529-AS1	3.54	0.000434	0.0272	0.14	0.16	Obesity-related traits;	chr19:37065396	chr19:36573070~36594708:+
THCA	cis	rs6138458	0.717	rs2179732	ENSG00000274173.1	RP4-568C11.4	3.54	0.000434	0.0272	0.14	0.16	Blood protein levels;	chr20:25019810	chr20:24931840~24932983:+
THCA	cis	rs9595908	0.785	rs7331393	ENSG00000281026.1	N4BP2L2-IT2	3.54	0.000434	0.0272	0.1	0.16	Body mass index;	chr13:32647065	chr13:32504506~32509395:-
THCA	cis	rs12780845	0.931	rs72775092	ENSG00000273153.1	RP11-406H21.2	3.54	0.000434	0.0272	0.15	0.16	Homocysteine levels;	chr10:17207649	chr10:17137336~17137585:-
THCA	cis	rs847649	0.692	rs10271184	ENSG00000234715.1	CTB-107G13.1	-3.54	0.000434	0.0272	-0.18	-0.16	Morning vs. evening chronotype;	chr7:102836729	chr7:103445207~103514007:+
THCA	cis	rs6787172	0.651	rs6441198	ENSG00000272087.1	RP11-379F4.7	3.54	0.000434	0.0272	0.14	0.16	Subjective well-being;	chr3:158443710	chr3:158693120~158693768:-
THCA	cis	rs6471393	0.929	rs58575315	ENSG00000261437.1	RP11-22C11.2	3.54	0.000434	0.0272	0.15	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749495	chr8:94637285~94639467:-
THCA	cis	rs10492096	0.945	rs2041386	ENSG00000276718.1	RP1-102E24.10	-3.54	0.000434	0.0272	-0.2	-0.16	Hip geometry;	chr12:6453372	chr12:6466537~6467135:+
THCA	cis	rs2562456	0.917	rs2562466	ENSG00000268658.4	LINC00664	-3.54	0.000434	0.0272	-0.23	-0.16	Pain;	chr19:21531402	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.917	rs2562468	ENSG00000268658.4	LINC00664	-3.54	0.000434	0.0272	-0.23	-0.16	Pain;	chr19:21532048	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.917	rs2562471	ENSG00000268658.4	LINC00664	-3.54	0.000434	0.0272	-0.23	-0.16	Pain;	chr19:21533017	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.917	rs2681377	ENSG00000268658.4	LINC00664	-3.54	0.000434	0.0272	-0.23	-0.16	Pain;	chr19:21533718	chr19:21483374~21503238:+
THCA	cis	rs72765298	0.848	rs72767015	ENSG00000235332.2	RP11-366O20.5	3.54	0.000434	0.0272	0.24	0.16	Pulse pressure;	chr9:125178402	chr9:125194649~125195821:-
THCA	cis	rs911186	0.812	rs6932590	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000434	0.0272	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr6:27281152	chr6:28115628~28116551:+
THCA	cis	rs11992162	0.569	rs35283519	ENSG00000227888.4	FAM66A	-3.54	0.000434	0.0272	-0.24	-0.16	Monocyte count;	chr8:11974152	chr8:12362019~12388296:+
THCA	cis	rs7916852	0.717	rs11006863	ENSG00000230500.1	MKX-AS1	3.54	0.000434	0.0272	0.27	0.16	Glaucoma (primary open-angle);	chr10:28098452	chr10:27744786~27767794:+
THCA	cis	rs7903847	0.596	rs11189203	ENSG00000225850.3	RP11-452K12.4	3.54	0.000434	0.0272	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97399339	chr10:97334564~97343203:+
THCA	cis	rs67478160	0.634	rs2144080	ENSG00000258534.1	CTD-2134A5.4	-3.54	0.000434	0.0272	-0.16	-0.16	Schizophrenia;	chr14:103792424	chr14:103854366~103880111:-
THCA	cis	rs10760158	0.8	rs4836847	ENSG00000235865.2	GSN-AS1	3.54	0.000434	0.0272	0.14	0.16	Pulse pressure;	chr9:121296665	chr9:121280768~121285530:-
THCA	cis	rs832187	0.666	rs2241823	ENSG00000224479.4	AC136289.1	3.54	0.000434	0.0272	0.2	0.16	Schizophrenia;	chr3:63979417	chr3:63742293~63827445:-
THCA	cis	rs11637445	0.677	rs4539549	ENSG00000260657.2	RP11-315D16.4	-3.54	0.000434	0.0272	-0.21	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67778281	chr15:68267792~68277994:-
THCA	cis	rs17604090	0.878	rs4000284	ENSG00000227855.3	DPY19L2P3	3.54	0.000435	0.0272	0.2	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29687301	chr7:29650227~29742594:+
THCA	cis	rs1153858	1	rs11070453	ENSG00000275672.1	GATM-AS1	-3.54	0.000435	0.0272	-0.17	-0.16	Homoarginine levels;	chr15:45352956	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs12593230	ENSG00000275672.1	GATM-AS1	-3.54	0.000435	0.0272	-0.17	-0.16	Homoarginine levels;	chr15:45354770	chr15:45378700~45380123:+
THCA	cis	rs1654345	0.813	rs1654353	ENSG00000275132.1	Metazoa_SRP	-3.54	0.000435	0.0272	-0.18	-0.16	Life satisfaction;Subjective well-being;	chr19:38065520	chr19:38200234~38200532:+
THCA	cis	rs721048	0.92	rs62177792	ENSG00000242412.1	DBIL5P2	-3.54	0.000435	0.0272	-0.22	-0.16	Prostate cancer;	chr2:63235385	chr2:63117851~63119542:-
THCA	cis	rs7759001	0.69	rs6933354	ENSG00000271755.1	RP1-153G14.4	3.54	0.000435	0.0272	0.19	0.16	Glomerular filtration rate (creatinine);	chr6:27496279	chr6:27404010~27406964:-
THCA	cis	rs7829975	0.626	rs332040	ENSG00000248538.5	RP11-10A14.5	-3.54	0.000435	0.0272	-0.21	-0.16	Mood instability;	chr8:8872978	chr8:9189011~9202854:+
THCA	cis	rs34779708	0.966	rs12761675	ENSG00000233200.1	RP11-324I22.2	-3.54	0.000435	0.0272	-0.19	-0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35219894~35230598:-
THCA	cis	rs6088580	0.505	rs6058106	ENSG00000126005.14	MMP24-AS1	3.54	0.000435	0.0272	0.16	0.16	Glomerular filtration rate (creatinine);	chr20:34690451	chr20:35216462~35278131:-
THCA	cis	rs3845817	0.733	rs702906	ENSG00000281920.1	RP11-418H16.1	-3.54	0.000435	0.0272	-0.19	-0.16	Bipolar disorder;	chr2:65539745	chr2:65623272~65628424:+
THCA	cis	rs6929812	0.605	rs12526495	ENSG00000216915.2	RP1-97D16.1	3.54	0.000435	0.0272	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27426092	chr6:27737000~27738494:-
THCA	cis	rs3026101	0.624	rs1058383	ENSG00000234327.6	AC012146.7	-3.54	0.000435	0.0272	-0.13	-0.16	Body mass index;	chr17:5384883	chr17:5111468~5115004:+
THCA	cis	rs2504916	0.651	rs73014164	ENSG00000213071.9	LPAL2	3.54	0.000435	0.0272	0.25	0.16	Response to hepatitis C treatment;	chr6:160555588	chr6:160453428~160511124:-
THCA	cis	rs9788721	0.9	rs4243084	ENSG00000261762.1	RP11-650L12.2	-3.54	0.000435	0.0272	-0.21	-0.16	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78619330	chr15:78589123~78591276:-
THCA	cis	rs10844706	0.666	rs10844609	ENSG00000257027.1	RP11-705C15.3	3.54	0.000435	0.0272	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9723909	chr12:9658567~9662085:+
THCA	cis	rs10760158	0.832	rs3827678	ENSG00000235865.2	GSN-AS1	3.54	0.000435	0.0272	0.14	0.16	Pulse pressure;	chr9:121284444	chr9:121280768~121285530:-
THCA	cis	rs7119038	0.818	rs6589685	ENSG00000255422.1	AP002954.4	3.54	0.000435	0.0272	0.19	0.16	Sjögren's syndrome;	chr11:118741488	chr11:118704607~118750263:+
THCA	cis	rs301901	0.662	rs7726960	ENSG00000250155.1	CTD-2353F22.1	3.54	0.000435	0.0272	0.16	0.16	Height;	chr5:37490184	chr5:36666214~36725195:-
THCA	cis	rs6499755	0.965	rs9932163	ENSG00000260135.5	RP11-212I21.2	-3.54	0.000435	0.0272	-0.18	-0.16	Hypospadias;	chr16:55316771	chr16:55426797~55462297:-
THCA	cis	rs7989336	0.515	rs9556575	ENSG00000247400.3	DNAJC3-AS1	-3.54	0.000435	0.0272	-0.11	-0.16	Obesity;	chr13:96360924	chr13:95648733~95676925:-
THCA	cis	rs1927790	0.511	rs9556576	ENSG00000247400.3	DNAJC3-AS1	-3.54	0.000435	0.0272	-0.11	-0.16	Body mass index;	chr13:96361434	chr13:95648733~95676925:-
THCA	cis	rs1580019	0.563	rs764483	ENSG00000273014.1	RP11-225B17.2	3.54	0.000435	0.0272	0.16	0.16	Cognitive ability;	chr7:32538538	chr7:32758882~32759353:+
THCA	cis	rs4763879	0.634	rs917913	ENSG00000256594.6	RP11-705C15.2	-3.54	0.000435	0.0272	-0.13	-0.16	Type 1 diabetes;	chr12:9707040	chr12:9633419~9658412:+
THCA	cis	rs11971779	0.554	rs11772686	ENSG00000252332.1	RNU6-911P	-3.54	0.000435	0.0272	-0.19	-0.16	Diisocyanate-induced asthma;	chr7:139444625	chr7:139448740~139448843:+
THCA	cis	rs748404	0.518	rs480108	ENSG00000275601.1	AC011330.13	-3.54	0.000435	0.0272	-0.19	-0.16	Lung cancer;	chr15:43525208	chr15:43642389~43643023:-
THCA	cis	rs748404	0.56	rs572837	ENSG00000275601.1	AC011330.13	-3.54	0.000435	0.0272	-0.19	-0.16	Lung cancer;	chr15:43531615	chr15:43642389~43643023:-
THCA	cis	rs7216064	1	rs12602655	ENSG00000265055.1	AC145343.2	3.54	0.000435	0.0272	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67913326	chr17:68096046~68101474:-
THCA	cis	rs7829975	0.501	rs74345345	ENSG00000253981.4	ALG1L13P	-3.54	0.000435	0.0272	-0.17	-0.16	Mood instability;	chr8:8720925	chr8:8236003~8244667:-
THCA	cis	rs4604234	0.614	rs73479950	ENSG00000260645.1	RP11-250B2.5	-3.54	0.000435	0.0272	-0.26	-0.16	Cancer;	chr6:80167590	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.614	rs73479953	ENSG00000260645.1	RP11-250B2.5	-3.54	0.000435	0.0272	-0.26	-0.16	Cancer;	chr6:80167654	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.614	rs78131248	ENSG00000260645.1	RP11-250B2.5	-3.54	0.000435	0.0272	-0.26	-0.16	Cancer;	chr6:80176949	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.614	rs3805923	ENSG00000260645.1	RP11-250B2.5	-3.54	0.000435	0.0272	-0.26	-0.16	Cancer;	chr6:80177802	chr6:80466958~80469080:+
THCA	cis	rs4824093	0.61	rs73443986	ENSG00000278869.1	CITF22-49E9.3	3.54	0.000435	0.0272	0.32	0.16	Amyotrophic lateral sclerosis (sporadic);	chr22:49927545	chr22:49933198~49934074:-
THCA	cis	rs6427356	1	rs1176549	ENSG00000237189.1	RP11-85G21.2	3.54	0.000435	0.0272	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157164973	chr1:157287703~157288053:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000244425.3	RN7SL268P	3.54	0.000435	0.0272	0.16	0.16	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23879493~23879790:-
THCA	cis	rs7439493	0.865	rs10004377	ENSG00000247950.5	SEC24B-AS1	-3.54	0.000435	0.0272	-0.11	-0.16	Blood protein levels;	chr4:109726968	chr4:109347475~109433817:-
THCA	cis	rs9818758	0.607	rs11706052	ENSG00000229759.1	MRPS18AP1	-3.54	0.000435	0.0272	-0.34	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49026677	chr3:48256350~48256938:-
THCA	cis	rs10975370	0.527	rs6477028	ENSG00000206147.5	RP11-106A1.2	3.54	0.000435	0.0272	0.2	0.16	Breast cancer;	chr9:6024844	chr9:6639139~6639604:+
THCA	cis	rs2288884	1	rs2288884	ENSG00000260160.1	CTC-471J1.2	-3.54	0.000435	0.0272	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52029018	chr19:52058490~52063703:-
THCA	cis	rs7192750	0.586	rs8044342	ENSG00000260886.1	TAT-AS1	3.54	0.000435	0.0272	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71835629	chr16:71565789~71578187:+
THCA	cis	rs12935418	0.583	rs80181133	ENSG00000261838.4	RP11-303E16.6	3.54	0.000435	0.0272	0.23	0.16	Mean corpuscular volume;	chr16:80934053	chr16:81069854~81076598:+
THCA	cis	rs7045881	0.8	rs17694324	ENSG00000234676.1	IFT74-AS1	-3.54	0.000435	0.0272	-0.33	-0.16	Schizophrenia;	chr9:26916072	chr9:26955780~26956295:-
THCA	cis	rs7045881	0.733	rs62544440	ENSG00000234676.1	IFT74-AS1	-3.54	0.000435	0.0272	-0.33	-0.16	Schizophrenia;	chr9:26916910	chr9:26955780~26956295:-
THCA	cis	rs2115536	0.704	rs2163005	ENSG00000278600.1	RP11-81A1.6	-3.54	0.000435	0.0272	-0.1	-0.16	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79902138	chr15:79920195~79922455:-
THCA	cis	rs17742757	0.521	rs2736324	ENSG00000254527.1	ENPP7P12	3.54	0.000435	0.0272	0.21	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11470673	chr8:12205759~12206389:-
THCA	cis	rs757110	0.526	rs757081	ENSG00000260196.1	RP1-239B22.5	-3.54	0.000435	0.0272	-0.19	-0.16	Type 2 diabetes;	chr11:17330136	chr11:17380649~17383531:+
THCA	cis	rs10488360	0.734	rs9639771	ENSG00000270822.1	RP11-730B22.1	3.54	0.000435	0.0272	0.2	0.16	Factor VII;	chr7:4375172	chr7:5009164~5009328:-
THCA	cis	rs1978968	0.717	rs13057517	ENSG00000280007.1	AC008079.10	3.54	0.000435	0.0272	0.17	0.16	Presence of antiphospholipid antibodies;	chr22:17919903	chr22:18110759~18131154:-
THCA	cis	rs9980	1	rs1549287	ENSG00000226232.7	RP11-419C5.2	3.54	0.000435	0.0272	0.24	0.16	Blood osmolality (transformed sodium);	chr16:69556463	chr16:69976388~69996188:-
THCA	cis	rs11884770	0.647	rs2141831	ENSG00000236432.6	AC097662.2	3.54	0.000435	0.0272	0.16	0.16	Advanced age-related macular degeneration;	chr2:227222973	chr2:227221052~227325201:-
THCA	cis	rs9457247	0.565	rs2239823	ENSG00000235272.1	FAM103A2P	3.54	0.000435	0.0272	0.22	0.16	Crohn's disease;	chr6:167098643	chr6:166586124~166586477:-
THCA	cis	rs9308731	0.591	rs7569300	ENSG00000227992.1	AC108463.2	-3.54	0.000435	0.0272	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111187296	chr2:111203964~111206215:-
THCA	cis	rs9308731	0.569	rs7585054	ENSG00000227992.1	AC108463.2	-3.54	0.000435	0.0272	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111187350	chr2:111203964~111206215:-
THCA	cis	rs9308731	0.591	rs7588534	ENSG00000227992.1	AC108463.2	-3.54	0.000435	0.0272	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111187510	chr2:111203964~111206215:-
THCA	cis	rs3824488	0.92	rs10512249	ENSG00000271155.1	RP11-435O5.5	-3.54	0.000435	0.0273	-0.26	-0.16	Neuroticism;	chr9:95494027	chr9:95506235~95507636:+
THCA	cis	rs7709377	0.723	rs7725500	ENSG00000250015.1	CTC-339F2.2	-3.54	0.000435	0.0273	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:116198747	chr5:116302354~116304134:-
THCA	cis	rs66887589	0.777	rs2017058	ENSG00000249244.1	RP11-548H18.2	3.54	0.000435	0.0273	0.17	0.16	Diastolic blood pressure;	chr4:119336584	chr4:119391831~119395335:-
THCA	cis	rs66887589	0.777	rs1814815	ENSG00000249244.1	RP11-548H18.2	3.54	0.000435	0.0273	0.17	0.16	Diastolic blood pressure;	chr4:119336936	chr4:119391831~119395335:-
THCA	cis	rs66887589	0.748	rs28439855	ENSG00000249244.1	RP11-548H18.2	3.54	0.000435	0.0273	0.17	0.16	Diastolic blood pressure;	chr4:119341101	chr4:119391831~119395335:-
THCA	cis	rs453301	0.686	rs3989373	ENSG00000248538.5	RP11-10A14.5	3.54	0.000436	0.0273	0.2	0.16	Joint mobility (Beighton score);	chr8:9053798	chr8:9189011~9202854:+
THCA	cis	rs897984	0.806	rs1046276	ENSG00000232748.3	RP11-196G11.6	3.54	0.000436	0.0273	0.2	0.16	Dementia with Lewy bodies;	chr16:30903305	chr16:31056460~31062803:+
THCA	cis	rs10760158	0.8	rs4837823	ENSG00000235865.2	GSN-AS1	3.54	0.000436	0.0273	0.14	0.16	Pulse pressure;	chr9:121249733	chr9:121280768~121285530:-
THCA	cis	rs2228479	1	rs4257207	ENSG00000223959.7	AFG3L1P	-3.54	0.000436	0.0273	-0.15	-0.16	Skin colour saturation;	chr16:89881453	chr16:89972586~90002161:+
THCA	cis	rs875971	0.862	rs4368860	ENSG00000223473.2	GS1-124K5.3	-3.54	0.000436	0.0273	-0.11	-0.16	Aortic root size;	chr7:66143495	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs7809814	ENSG00000223473.2	GS1-124K5.3	-3.54	0.000436	0.0273	-0.11	-0.16	Aortic root size;	chr7:66150410	chr7:66491049~66493566:-
THCA	cis	rs7308116	0.53	rs12820279	ENSG00000257951.1	RP11-554D14.4	-3.54	0.000436	0.0273	-0.2	-0.16	Pelvic organ prolapse (moderate/severe);	chr12:107889542	chr12:107881242~107883382:+
THCA	cis	rs34779708	0.966	rs1057108	ENSG00000233200.1	RP11-324I22.2	3.54	0.000436	0.0273	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35219894~35230598:-
THCA	cis	rs11971779	0.648	rs10230407	ENSG00000252332.1	RNU6-911P	-3.54	0.000436	0.0273	-0.18	-0.16	Diisocyanate-induced asthma;	chr7:139419147	chr7:139448740~139448843:+
THCA	cis	rs7259376	0.84	rs1808668	ENSG00000269138.1	ZNF209P	3.54	0.000436	0.0273	0.16	0.16	Menopause (age at onset);	chr19:22335855	chr19:22463922~22473036:+
THCA	cis	rs5006884	0.627	rs12291806	ENSG00000167355.6	AC104389.28	-3.54	0.000436	0.0273	-0.27	-0.16	Fetal hemoglobin levels;	chr11:5423831	chr11:5304976~5505652:-
THCA	cis	rs10129255	0.872	rs10133674	ENSG00000224373.3	IGHV4-59	3.54	0.000436	0.0273	0.1	0.16	Kawasaki disease;	chr14:106692788	chr14:106627249~106627825:-
THCA	cis	rs7829975	0.593	rs2921077	ENSG00000254340.1	RP11-10A14.3	3.54	0.000436	0.0273	0.18	0.16	Mood instability;	chr8:8446992	chr8:9141424~9145435:+
THCA	cis	rs17689437	0.789	rs745337	ENSG00000260084.1	RP11-615I2.1	-3.54	0.000436	0.0273	-0.29	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68583103	chr16:68573782~68589512:-
THCA	cis	rs4542783	1	rs4072910	ENSG00000267986.1	AC130469.2	3.54	0.000436	0.0273	0.17	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr19:8579147	chr19:8581160~8582715:+
THCA	cis	rs748404	0.578	rs507178	ENSG00000224677.1	PDIA3P2	3.54	0.000436	0.0273	0.19	0.16	Lung cancer;	chr15:43317937	chr15:43649123~43649280:+
THCA	cis	rs10932679	0.595	rs7599100	ENSG00000237930.1	AC007563.4	-3.54	0.000436	0.0273	-0.22	-0.16	Pulse pressure;	chr2:216773219	chr2:216785774~216786144:-
THCA	cis	rs10089	0.953	rs1012851	ENSG00000245937.6	LINC01184	3.54	0.000436	0.0273	0.18	0.16	Ileal carcinoids;	chr5:128024549	chr5:127940426~128083172:-
THCA	cis	rs5758511	0.573	rs2267439	ENSG00000230107.1	CTA-126B4.7	3.54	0.000436	0.0273	0.17	0.16	Birth weight;	chr22:41841765	chr22:42438023~42446195:+
THCA	cis	rs929354	0.742	rs10274687	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157140487	chr7:157263022~157263229:-
THCA	cis	rs929354	0.685	rs7807856	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157141804	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs6459734	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157142760	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs7801905	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157147417	chr7:157263022~157263229:-
THCA	cis	rs929354	0.713	rs7798816	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157147880	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs3808317	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157151766	chr7:157263022~157263229:-
THCA	cis	rs929354	0.605	rs7806314	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157154209	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs7806775	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157154505	chr7:157263022~157263229:-
THCA	cis	rs929354	0.713	rs6946660	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157155954	chr7:157263022~157263229:-
THCA	cis	rs929354	0.713	rs6946947	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157156093	chr7:157263022~157263229:-
THCA	cis	rs929354	0.651	rs6951298	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157156455	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs62491945	ENSG00000224629.1	RP5-1142J19.2	-3.54	0.000436	0.0273	-0.16	-0.16	Body mass index;	chr7:157162886	chr7:157263022~157263229:-
THCA	cis	rs56283067	0.847	rs1283948	ENSG00000237686.5	RP5-1120P11.1	-3.54	0.000436	0.0273	-0.14	-0.16	Total body bone mineral density;	chr6:44723965	chr6:43995723~44074652:-
THCA	cis	rs7259376	0.84	rs808372	ENSG00000269345.1	VN1R85P	-3.54	0.000436	0.0273	-0.18	-0.16	Menopause (age at onset);	chr19:22287566	chr19:22174766~22175191:-
THCA	cis	rs73787773	0.866	rs73227493	ENSG00000246859.2	STARD4-AS1	3.54	0.000436	0.0273	0.23	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr5:112141962	chr5:111512226~111739726:+
THCA	cis	rs3734729	0.702	rs9371831	ENSG00000231120.3	BTF3P10	3.54	0.000436	0.0273	0.36	0.16	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150222490	chr6:149977922~149978416:+
THCA	cis	rs2718812	0.935	rs1867502	ENSG00000242337.4	TFP1	3.54	0.000436	0.0273	0.17	0.16	Iron status biomarkers;	chr3:133691781	chr3:133661998~133754576:+
THCA	cis	rs1502337	0.504	rs3026433	ENSG00000278993.1	RP3-424M6.4	3.54	0.000436	0.0273	0.25	0.16	Body mass index;	chr12:110281387	chr12:110501614~110503441:+
THCA	cis	rs881375	0.9	rs1008383	ENSG00000270917.1	RP11-27I1.6	-3.54	0.000436	0.0273	-0.22	-0.16	Rheumatoid arthritis;	chr9:120921301	chr9:120812475~120812845:-
THCA	cis	rs701145	0.585	rs17766586	ENSG00000238755.3	RP11-23D24.2	-3.54	0.000436	0.0273	-0.31	-0.16	Coronary artery disease;	chr3:154061129	chr3:153384934~153980186:-
THCA	cis	rs540425	0.626	rs217388	ENSG00000279853.1	RP5-844F9.1	3.54	0.000436	0.0273	0.2	0.16	Schizophrenia;	chr7:44559869	chr7:44367140~44369292:-
THCA	cis	rs7520050	1	rs12143096	ENSG00000281133.1	AL355480.3	3.54	0.000436	0.0273	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:45580892~45580996:-
THCA	cis	rs7737355	0.773	rs6890410	ENSG00000224431.1	AC063976.7	3.54	0.000436	0.0273	0.15	0.16	Life satisfaction;	chr5:131259054	chr5:132199456~132203487:+
THCA	cis	rs1865760	0.573	rs7450342	ENSG00000272810.1	U91328.22	-3.54	0.000436	0.0273	-0.12	-0.16	Height;	chr6:25919252	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.613	rs7749342	ENSG00000272810.1	U91328.22	-3.54	0.000436	0.0273	-0.12	-0.16	Height;	chr6:25920037	chr6:26013241~26013757:+
THCA	cis	rs4948275	0.693	rs2814033	ENSG00000233643.2	RP11-491H19.1	-3.54	0.000436	0.0273	-0.18	-0.16	Night sleep phenotypes;	chr10:61571836	chr10:61781745~61821246:-
THCA	cis	rs9796	0.689	rs8032195	ENSG00000247556.5	OIP5-AS1	3.54	0.000436	0.0273	0.13	0.16	Menopause (age at onset);	chr15:41156592	chr15:41283990~41309737:+
THCA	cis	rs10760158	0.832	rs3810942	ENSG00000235865.2	GSN-AS1	3.54	0.000436	0.0273	0.14	0.16	Pulse pressure;	chr9:121282717	chr9:121280768~121285530:-
THCA	cis	rs17407555	0.657	rs1558488	ENSG00000250413.1	RP11-448G15.1	-3.54	0.000436	0.0273	-0.17	-0.16	Schizophrenia (age at onset);	chr4:10325790	chr4:10006482~10009725:+
THCA	cis	rs2281603	0.57	rs73265639	ENSG00000258824.2	CTD-2555O16.2	-3.54	0.000436	0.0273	-0.14	-0.16	Lymphocyte counts;	chr14:64482973	chr14:64422935~64448557:-
THCA	cis	rs7088591	0.867	rs16911508	ENSG00000276818.1	AC026393.1	3.54	0.000436	0.0273	0.32	0.16	Blood pressure;	chr10:57986315	chr10:57095699~57095781:+
THCA	cis	rs4972539	0.506	rs1866632	ENSG00000238133.5	MLK7-AS1	3.54	0.000436	0.0273	0.21	0.16	Parental longevity (mother's age at death);	chr2:173209137	chr2:173166446~173282036:-
THCA	cis	rs995834	0.869	rs10405674	ENSG00000261770.1	CTC-459F4.1	-3.54	0.000436	0.0273	-0.22	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393703	chr19:27757184~27760849:-
THCA	cis	rs7520050	0.807	rs3013595	ENSG00000281133.1	AL355480.3	-3.54	0.000436	0.0273	-0.19	-0.16	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45580892~45580996:-
THCA	cis	rs9475677	0.953	rs9475680	ENSG00000231441.1	RP11-472M19.2	3.54	0.000436	0.0273	0.2	0.16	Gut microbiota (functional units);	chr6:56353076	chr6:56844002~56864078:+
THCA	cis	rs5758511	0.68	rs5758699	ENSG00000237037.8	NDUFA6-AS1	-3.54	0.000437	0.0273	-0.14	-0.16	Birth weight;	chr22:42292028	chr22:42090931~42137742:+
THCA	cis	rs8053891	0.673	rs10492825	ENSG00000262140.1	RP11-417N10.3	3.54	0.000437	0.0273	0.22	0.16	Coronary artery disease;	chr16:71984518	chr16:71833787~71835932:+
THCA	cis	rs7192750	0.501	rs6499542	ENSG00000260886.1	TAT-AS1	3.54	0.000437	0.0273	0.24	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71825927	chr16:71565789~71578187:+
THCA	cis	rs2243480	1	rs383402	ENSG00000237310.1	GS1-124K5.4	-3.54	0.000437	0.0273	-0.18	-0.16	Diabetic kidney disease;	chr7:66121666	chr7:66493706~66495474:+
THCA	cis	rs4308124	1	rs57874285	ENSG00000230499.1	AC108463.1	-3.54	0.000437	0.0273	-0.21	-0.16	Vitiligo;	chr2:111255095	chr2:111195963~111206494:+
THCA	cis	rs4308124	1	rs57707030	ENSG00000230499.1	AC108463.1	-3.54	0.000437	0.0273	-0.21	-0.16	Vitiligo;	chr2:111255105	chr2:111195963~111206494:+
THCA	cis	rs12887734	0.546	rs4900597	ENSG00000269958.1	RP11-73M18.8	-3.54	0.000437	0.0273	-0.15	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103800327	chr14:103696353~103697163:+
THCA	cis	rs12887734	0.569	rs66953418	ENSG00000269958.1	RP11-73M18.8	3.54	0.000437	0.0273	0.15	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103696353~103697163:+
THCA	cis	rs6787172	0.651	rs6800887	ENSG00000272087.1	RP11-379F4.7	3.54	0.000437	0.0273	0.15	0.16	Subjective well-being;	chr3:158445839	chr3:158693120~158693768:-
THCA	cis	rs2070488	0.93	rs2370840	ENSG00000229589.1	ACVR2B-AS1	3.54	0.000437	0.0273	0.15	0.16	Electrocardiographic conduction measures;	chr3:38488334	chr3:38451027~38454820:-
THCA	cis	rs1003719	0.591	rs13046303	ENSG00000270116.1	AP001429.1	3.54	0.000437	0.0273	0.18	0.16	Eye color traits;	chr21:37179674	chr21:37100814~37101343:+
THCA	cis	rs2191566	1	rs367499	ENSG00000267114.1	CTB-129P6.11	-3.54	0.000437	0.0273	-0.13	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44000829	chr19:44950044~44954007:-
THCA	cis	rs9650657	0.572	rs4841465	ENSG00000206014.6	OR7E161P	3.54	0.000437	0.0273	0.18	0.16	Neuroticism;	chr8:10962344	chr8:11928597~11929563:-
THCA	cis	rs56046484	1	rs12911330	ENSG00000218052.5	ADAMTS7P4	-3.54	0.000437	0.0273	-0.25	-0.16	Testicular germ cell tumor;	chr15:85087103	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.956	rs34919315	ENSG00000218052.5	ADAMTS7P4	-3.54	0.000437	0.0273	-0.25	-0.16	Testicular germ cell tumor;	chr15:85088675	chr15:85255369~85330334:-
THCA	cis	rs12541437	0.617	rs7014118	ENSG00000253327.2	RAD21-AS1	3.54	0.000437	0.0273	0.2	0.16	Gut microbiome composition (winter);	chr8:116905073	chr8:116874424~116876868:+
THCA	cis	rs4742903	0.87	rs10991171	ENSG00000270332.1	SMC2-AS1	3.54	0.000437	0.0273	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104213869	chr9:104080024~104093073:-
THCA	cis	rs111756027	0.645	rs67913279	ENSG00000260922.1	RP11-538I12.3	3.54	0.000437	0.0273	0.23	0.16	Bone mineral density (Ward's triangle area);	chr16:77270003	chr16:77234877~77290934:+
THCA	cis	rs722599	0.847	rs2058919	ENSG00000258976.1	CTD-2207P18.2	3.54	0.000437	0.0273	0.19	0.16	IgG glycosylation;	chr14:74844109	chr14:74614693~74616647:-
THCA	cis	rs9573567	0.609	rs9565165	ENSG00000261105.4	LMO7-AS1	-3.54	0.000437	0.0273	-0.35	-0.16	Red blood cell count;Mean corpuscular volume;	chr13:75478654	chr13:75604700~75635994:-
THCA	cis	rs11800820	0.565	rs3129576	ENSG00000231612.1	RP11-522M21.3	3.54	0.000437	0.0273	0.22	0.16	Obesity-related traits;	chr1:246549107	chr1:245673732~245676478:-
THCA	cis	rs7005380	1	rs7005380	ENSG00000279347.1	RP11-85I17.2	3.54	0.000437	0.0273	0.19	0.16	Interstitial lung disease;	chr8:119941633	chr8:119838736~119840385:-
THCA	cis	rs9487051	0.872	rs9400271	ENSG00000260273.1	RP11-425D10.10	3.54	0.000437	0.0273	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109286353	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs9386791	ENSG00000260273.1	RP11-425D10.10	3.54	0.000437	0.0273	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109287294	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs9372211	ENSG00000260273.1	RP11-425D10.10	3.54	0.000437	0.0273	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109288445	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs9487038	ENSG00000260273.1	RP11-425D10.10	3.54	0.000437	0.0273	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109288949	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs1111864	ENSG00000260273.1	RP11-425D10.10	3.54	0.000437	0.0273	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109289935	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.837	rs4403290	ENSG00000260273.1	RP11-425D10.10	3.54	0.000437	0.0273	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109290380	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.735	rs882074	ENSG00000260273.1	RP11-425D10.10	3.54	0.000437	0.0273	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109290517	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs1320612	ENSG00000260273.1	RP11-425D10.10	3.54	0.000437	0.0273	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109290787	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs1111865	ENSG00000260273.1	RP11-425D10.10	-3.54	0.000437	0.0273	-0.19	-0.16	Reticulocyte fraction of red cells;	chr6:109289660	chr6:109382795~109383666:+
THCA	cis	rs10411161	0.702	rs8113584	ENSG00000275055.1	CTC-471J1.11	-3.54	0.000437	0.0273	-0.16	-0.16	Breast cancer;	chr19:51880621	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs8113685	ENSG00000275055.1	CTC-471J1.11	-3.54	0.000437	0.0273	-0.16	-0.16	Breast cancer;	chr19:51880637	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs8113768	ENSG00000275055.1	CTC-471J1.11	-3.54	0.000437	0.0273	-0.16	-0.16	Breast cancer;	chr19:51880685	chr19:52049007~52049754:+
THCA	cis	rs12780845	0.54	rs2273734	ENSG00000234961.1	RP11-124N14.3	-3.54	0.000437	0.0273	-0.17	-0.16	Homocysteine levels;	chr10:17174557	chr10:17233325~17234833:-
THCA	cis	rs12780845	0.558	rs7090965	ENSG00000234961.1	RP11-124N14.3	-3.54	0.000437	0.0273	-0.17	-0.16	Homocysteine levels;	chr10:17174804	chr10:17233325~17234833:-
THCA	cis	rs7520050	0.897	rs4440807	ENSG00000281133.1	AL355480.3	3.54	0.000437	0.0274	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:45580892~45580996:-
THCA	cis	rs2836950	0.565	rs8134214	ENSG00000235701.1	PCBP2P1	-3.54	0.000437	0.0274	-0.18	-0.16	Menarche (age at onset);	chr21:39170441	chr21:39171130~39172106:-
THCA	cis	rs11239930	0.934	rs10900313	ENSG00000237188.3	RP11-337C18.8	3.54	0.000437	0.0274	0.16	0.16	AIDS progression;	chr1:147089200	chr1:147172771~147211568:+
THCA	cis	rs4730276	0.674	rs8440	ENSG00000250474.1	WBP1LP2	-3.54	0.000437	0.0274	-0.15	-0.16	Ulcerative colitis;	chr7:107920947	chr7:107628553~107629498:+
THCA	cis	rs11190604	1	rs2298075	ENSG00000273030.1	RP11-285F16.1	3.54	0.000438	0.0274	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100487651	chr10:100412934~100413421:+
THCA	cis	rs34975555	0.803	rs7003879	ENSG00000253671.1	RP11-806O11.1	-3.54	0.000438	0.0274	-0.26	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17968784	chr8:17808941~17820868:+
THCA	cis	rs7142002	0.527	rs58186728	ENSG00000271780.1	RP11-1017G21.5	-3.54	0.000438	0.0274	-0.19	-0.16	Autism;	chr14:101922824	chr14:101948347~101949425:+
THCA	cis	rs7142002	0.568	rs58337996	ENSG00000271780.1	RP11-1017G21.5	-3.54	0.000438	0.0274	-0.19	-0.16	Autism;	chr14:101922950	chr14:101948347~101949425:+
THCA	cis	rs7142002	0.568	rs58304956	ENSG00000271780.1	RP11-1017G21.5	-3.54	0.000438	0.0274	-0.19	-0.16	Autism;	chr14:101923434	chr14:101948347~101949425:+
THCA	cis	rs7142002	0.568	rs7158886	ENSG00000271780.1	RP11-1017G21.5	-3.54	0.000438	0.0274	-0.19	-0.16	Autism;	chr14:101923615	chr14:101948347~101949425:+
THCA	cis	rs7246657	0.943	rs1382357	ENSG00000268499.1	CTB-102L5.8	3.54	0.000438	0.0274	0.21	0.16	Coronary artery calcification;	chr19:37486707	chr19:38199836~38200934:+
THCA	cis	rs786425	0.932	rs786448	ENSG00000278112.1	RP11-972P1.11	-3.54	0.000438	0.0274	-0.15	-0.16	Pubertal anthropometrics;	chr12:123585667	chr12:123519390~123519856:-
THCA	cis	rs786425	0.966	rs786449	ENSG00000278112.1	RP11-972P1.11	-3.54	0.000438	0.0274	-0.15	-0.16	Pubertal anthropometrics;	chr12:123587181	chr12:123519390~123519856:-
THCA	cis	rs786425	0.966	rs6551	ENSG00000278112.1	RP11-972P1.11	-3.54	0.000438	0.0274	-0.15	-0.16	Pubertal anthropometrics;	chr12:123597693	chr12:123519390~123519856:-
THCA	cis	rs786425	0.838	rs1543075	ENSG00000278112.1	RP11-972P1.11	-3.54	0.000438	0.0274	-0.15	-0.16	Pubertal anthropometrics;	chr12:123601901	chr12:123519390~123519856:-
THCA	cis	rs13098911	0.54	rs34340587	ENSG00000226074.4	PRSS44	-3.54	0.000438	0.0274	-0.31	-0.16	Celiac disease;	chr3:46054551	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs77399277	ENSG00000226074.4	PRSS44	-3.54	0.000438	0.0274	-0.31	-0.16	Celiac disease;	chr3:46055306	chr3:46809359~46812558:-
THCA	cis	rs4950322	0.58	rs7541393	ENSG00000226015.2	CCT8P1	3.54	0.000438	0.0274	0.18	0.16	Protein quantitative trait loci;	chr1:147117186	chr1:147203276~147204932:-
THCA	cis	rs740160	0.558	rs17161662	ENSG00000244219.5	GS1-259H13.2	-3.54	0.000438	0.0274	-0.26	-0.16	Dehydroepiandrosterone sulphate levels;	chr7:99309773	chr7:99598066~99610813:+
THCA	cis	rs66887589	0.777	rs10015883	ENSG00000249244.1	RP11-548H18.2	3.54	0.000438	0.0274	0.17	0.16	Diastolic blood pressure;	chr4:119346991	chr4:119391831~119395335:-
THCA	cis	rs17095355	0.642	rs7918758	ENSG00000203876.8	ADD3-AS1	-3.54	0.000438	0.0274	-0.17	-0.16	Biliary atresia;	chr10:110160108	chr10:109940104~110008381:-
THCA	cis	rs1557488	0.599	rs6590230	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000438	0.0274	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126833514	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.565	rs10790845	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000438	0.0274	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126835949	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs7947216	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000438	0.0274	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126840758	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs7129447	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000438	0.0274	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126841193	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.599	rs939515	ENSG00000260209.1	RP11-680F20.10	-3.54	0.000438	0.0274	-0.23	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126841678	chr11:125873031~125874528:-
THCA	cis	rs1411478	1	rs6665134	ENSG00000243155.1	RP11-46A10.5	3.54	0.000438	0.0274	0.17	0.16	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180980492	chr1:180944042~180976482:-
THCA	cis	rs3758911	0.894	rs999985	ENSG00000255353.1	RP11-382M14.1	-3.54	0.000438	0.0274	-0.21	-0.16	Coronary artery disease;	chr11:107321531	chr11:107176286~107177530:+
THCA	cis	rs9876781	0.53	rs35516531	ENSG00000228638.1	FCF1P2	-3.54	0.000438	0.0274	-0.16	-0.16	Longevity;	chr3:48364275	chr3:48290793~48291375:-
THCA	cis	rs73193808	0.639	rs9976274	ENSG00000231125.2	AF129075.5	-3.54	0.000438	0.0274	-0.16	-0.16	Coronary artery disease;	chr21:29181615	chr21:29058073~29060095:-
THCA	cis	rs7188445	0.932	rs17767742	ENSG00000277954.1	RP11-679B19.1	-3.54	0.000438	0.0274	-0.19	-0.16	Urate levels;	chr16:79715108	chr16:79202624~79206739:-
THCA	cis	rs9487051	0.872	rs9386793	ENSG00000260273.1	RP11-425D10.10	3.54	0.000438	0.0274	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109288799	chr6:109382795~109383666:+
THCA	cis	rs6840360	1	rs6823421	ENSG00000270265.1	RP11-731D1.4	-3.54	0.000438	0.0274	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151683567	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.967	rs6823423	ENSG00000270265.1	RP11-731D1.4	-3.54	0.000438	0.0274	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151683571	chr4:151333775~151353224:-
THCA	cis	rs3740713	0.592	rs73434674	ENSG00000256588.1	RP11-613F22.8	3.54	0.000438	0.0274	0.24	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr11:18507608~18508820:-
THCA	cis	rs1864585	0.505	rs10503410	ENSG00000280294.1	RP11-177H2.1	3.54	0.000438	0.0274	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10794842	chr8:10856085~10859436:-
THCA	cis	rs2842346	0.509	rs2525525	ENSG00000258623.1	CTD-2325P2.3	3.54	0.000438	0.0274	0.21	0.16	Breast cancer;	chr14:68541858	chr14:68683411~68685565:-
THCA	cis	rs2609255	1	rs2125409	ENSG00000270720.1	RP11-84C13.2	3.54	0.000438	0.0274	0.18	0.16	Interstitial lung disease;	chr4:88929391	chr4:89119284~89119871:+
THCA	cis	rs10090774	0.664	rs10282830	ENSG00000279766.1	RP11-642A1.2	-3.54	0.000438	0.0274	-0.19	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140661435	chr8:140572142~140572812:-
THCA	cis	rs10090774	0.71	rs10283164	ENSG00000279766.1	RP11-642A1.2	-3.54	0.000438	0.0274	-0.19	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140661530	chr8:140572142~140572812:-
THCA	cis	rs6500395	0.588	rs3785138	ENSG00000260052.1	CTC-527H23.3	3.54	0.000438	0.0274	0.2	0.16	Response to tocilizumab in rheumatoid arthritis;	chr16:48554703	chr16:48637143~48638719:+
THCA	cis	rs2290416	0.892	rs62522165	ENSG00000254338.1	MAFA-AS1	3.54	0.000438	0.0274	0.32	0.16	Attention deficit hyperactivity disorder;	chr8:143593209	chr8:143417679~143419150:+
THCA	cis	rs6142618	0.562	rs4911543	ENSG00000224452.1	RSL24D1P6	3.54	0.000438	0.0274	0.19	0.16	Inflammatory bowel disease;	chr20:32107342	chr20:32170390~32170790:-
THCA	cis	rs11212260	0.85	rs7125903	ENSG00000261098.1	RP11-819C21.1	3.54	0.000438	0.0274	0.35	0.16	IgG glycosylation;	chr11:107483131	chr11:107312132~107316271:-
THCA	cis	rs7737355	1	rs76753180	ENSG00000224431.1	AC063976.7	-3.54	0.000438	0.0274	-0.16	-0.16	Life satisfaction;	chr5:131428008	chr5:132199456~132203487:+
THCA	cis	rs9911578	1	rs12952832	ENSG00000224738.1	AC099850.1	3.54	0.000438	0.0274	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58828893	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs8079774	ENSG00000224738.1	AC099850.1	3.54	0.000438	0.0274	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58830827	chr17:59106598~59118267:+
THCA	cis	rs4588572	0.688	rs2115436	ENSG00000245556.2	SCAMP1-AS1	-3.54	0.000438	0.0274	-0.12	-0.16	Triglycerides;	chr5:78396793	chr5:78342365~78360507:-
THCA	cis	rs7671266	0.616	rs4320137	ENSG00000261490.1	RP11-448G15.3	3.54	0.000438	0.0274	0.15	0.16	Cardiovascular disease risk factors;	chr4:10071345	chr4:10068089~10073019:-
THCA	cis	rs7246657	0.722	rs2972437	ENSG00000267640.4	CTD-2554C21.2	-3.54	0.000438	0.0274	-0.15	-0.16	Coronary artery calcification;	chr19:37719610	chr19:37817359~37826638:+
THCA	cis	rs875971	1	rs6961717	ENSG00000272831.1	RP11-792A8.4	-3.54	0.000438	0.0274	-0.1	-0.16	Aortic root size;	chr7:66122550	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs2087647	ENSG00000272831.1	RP11-792A8.4	-3.54	0.000438	0.0274	-0.1	-0.16	Aortic root size;	chr7:66128201	chr7:66739829~66740385:-
THCA	cis	rs875971	1	rs6958484	ENSG00000272831.1	RP11-792A8.4	-3.54	0.000438	0.0274	-0.1	-0.16	Aortic root size;	chr7:66134459	chr7:66739829~66740385:-
THCA	cis	rs10875746	0.903	rs12301339	ENSG00000258234.1	RP11-370I10.2	3.54	0.000438	0.0274	0.19	0.16	Longevity (90 years and older);	chr12:48081450	chr12:48231098~48284210:-
THCA	cis	rs10875746	0.903	rs886588	ENSG00000258234.1	RP11-370I10.2	3.54	0.000438	0.0274	0.19	0.16	Longevity (90 years and older);	chr12:48083639	chr12:48231098~48284210:-
THCA	cis	rs7550636	0.78	rs1775692	ENSG00000276735.1	Metazoa_SRP	3.54	0.000438	0.0274	0.19	0.16	Coronary artery calcification;	chr1:192838049	chr1:193236794~193237107:-
THCA	cis	rs7586085	0.783	rs777362	ENSG00000232411.1	AC009495.3	-3.54	0.000438	0.0274	-0.17	-0.16	Total body bone mineral density;	chr2:165705937	chr2:165833048~165839098:-
THCA	cis	rs4767841	0.565	rs7953072	ENSG00000252886.1	RN7SKP197	-3.54	0.000438	0.0274	-0.16	-0.16	Urgency urinary incontinence;	chr12:119790899	chr12:119631090~119631386:-
THCA	cis	rs4930561	0.765	rs1894204	ENSG00000184795.9	UNC93B5	-3.54	0.000438	0.0274	-0.18	-0.16	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68162204	chr11:67711702~67716005:-
THCA	cis	rs5769765	0.865	rs10854860	ENSG00000260613.1	RP3-522J7.6	-3.54	0.000438	0.0274	-0.21	-0.16	Schizophrenia;	chr22:49926381	chr22:49832616~49837786:-
THCA	cis	rs924712	0.522	rs12194012	ENSG00000224984.1	RP11-524H19.2	3.54	0.000438	0.0274	0.19	0.16	Breast cancer;	chr6:54845053	chr6:54840118~54840855:-
THCA	cis	rs11153306	0.677	rs3777921	ENSG00000271789.1	RP5-1112D6.7	3.54	0.000438	0.0274	0.15	0.16	Tonsillectomy;	chr6:111603207	chr6:111297126~111298510:+
THCA	cis	rs1555322	1	rs2425041	ENSG00000279253.1	RP4-614O4.13	-3.54	0.000438	0.0274	-0.23	-0.16	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35262727~35264187:-
THCA	cis	rs9676308	0.737	rs7251769	ENSG00000267549.4	AC006116.17	-3.54	0.000438	0.0274	-0.26	-0.16	Colorectal cancer;	chr19:57078261	chr19:56314703~56341287:+
THCA	cis	rs9676308	0.571	rs10418921	ENSG00000267549.4	AC006116.17	-3.54	0.000438	0.0274	-0.26	-0.16	Colorectal cancer;	chr19:57078991	chr19:56314703~56341287:+
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000219891.2	ZSCAN12P1	3.54	0.000439	0.0274	0.22	0.16	Parkinson's disease;	chr6:28069254	chr6:28091154~28093664:+
THCA	cis	rs1153858	1	rs1554521	ENSG00000275672.1	GATM-AS1	3.54	0.000439	0.0274	0.17	0.16	Homoarginine levels;	chr15:45371991	chr15:45378700~45380123:+
THCA	cis	rs9796	0.689	rs7180494	ENSG00000247556.5	OIP5-AS1	3.54	0.000439	0.0274	0.13	0.16	Menopause (age at onset);	chr15:41159643	chr15:41283990~41309737:+
THCA	cis	rs12681963	0.748	rs6468070	ENSG00000272375.1	RP11-51J9.6	-3.54	0.000439	0.0274	-0.18	-0.16	Migraine;	chr8:30039082	chr8:30197404~30198048:+
THCA	cis	rs7586879	0.593	rs6733224	ENSG00000224165.4	DNAJC27-AS1	3.54	0.000439	0.0274	0.09	0.16	Body mass index;	chr2:24908038	chr2:24971390~25039694:+
THCA	cis	rs1560104	0.597	rs735819	ENSG00000260601.1	RP11-552C15.1	3.54	0.000439	0.0274	0.19	0.16	Obesity-related traits;	chr16:12618370	chr16:12545482~12546684:+
THCA	cis	rs9296092	0.517	rs11751684	ENSG00000272217.1	XXbac-BPG157A10.21	3.54	0.000439	0.0274	0.18	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33560962	chr6:33246075~33246856:-
THCA	cis	rs11098499	0.644	rs3806808	ENSG00000249244.1	RP11-548H18.2	3.54	0.000439	0.0274	0.18	0.16	Corneal astigmatism;	chr4:119629930	chr4:119391831~119395335:-
THCA	cis	rs9980	0.571	rs244414	ENSG00000226232.7	RP11-419C5.2	3.54	0.000439	0.0274	0.24	0.16	Blood osmolality (transformed sodium);	chr16:69612875	chr16:69976388~69996188:-
THCA	cis	rs7044106	0.887	rs1359328	ENSG00000235865.2	GSN-AS1	-3.54	0.000439	0.0274	-0.16	-0.16	Hip circumference adjusted for BMI;	chr9:120608544	chr9:121280768~121285530:-
THCA	cis	rs7252981	0.632	rs8101679	ENSG00000271283.1	CTC-412M14.6	-3.54	0.000439	0.0274	-0.22	-0.16	Perceived unattractiveness to mosquitoes;	chr19:19623068	chr19:19699203~19699409:-
THCA	cis	rs3096299	0.658	rs3934737	ENSG00000223959.7	AFG3L1P	3.54	0.000439	0.0274	0.09	0.16	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89972586~90002161:+
THCA	cis	rs3785574	0.962	rs2665840	ENSG00000279369.1	RP11-51F16.1	-3.54	0.000439	0.0274	-0.11	-0.16	Height;	chr17:63795947	chr17:63700847~63702670:+
THCA	cis	rs7586879	0.639	rs2384058	ENSG00000224165.4	DNAJC27-AS1	-3.54	0.000439	0.0274	-0.09	-0.16	Body mass index;	chr2:24877459	chr2:24971390~25039694:+
THCA	cis	rs17122278	0.613	rs477106	ENSG00000255239.1	AP002954.6	3.54	0.000439	0.0274	0.25	0.16	Total cholesterol levels;	chr11:118492709	chr11:118688039~118690600:-
THCA	cis	rs6012953	0.654	rs6067471	ENSG00000237595.3	RP11-112L6.3	3.54	0.000439	0.0274	0.15	0.16	Vitiligo;	chr20:50510745	chr20:50162765~50166102:-
THCA	cis	rs924712	0.522	rs7752214	ENSG00000224984.1	RP11-524H19.2	3.54	0.000439	0.0274	0.19	0.16	Breast cancer;	chr6:54834954	chr6:54840118~54840855:-
THCA	cis	rs9303542	0.729	rs12945780	ENSG00000278765.1	RP5-890E16.5	-3.54	0.000439	0.0274	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48419579	chr17:48066704~48067293:-
THCA	cis	rs7212590	0.581	rs8070961	ENSG00000267302.4	RP11-178C3.2	3.54	0.000439	0.0274	0.3	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59735807	chr17:59964832~59996972:+
THCA	cis	rs7989332	0.698	rs9315620	ENSG00000277020.3	RP11-476H16.1	-3.54	0.000439	0.0274	-0.16	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486906	chr13:20564708~20567045:-
THCA	cis	rs7989332	0.698	rs9315621	ENSG00000277020.3	RP11-476H16.1	-3.54	0.000439	0.0274	-0.16	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486914	chr13:20564708~20567045:-
THCA	cis	rs791590	0.715	rs41295079	ENSG00000229664.1	RP11-536K7.5	-3.54	0.000439	0.0274	-0.26	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6077191	chr10:6025978~6036427:+
THCA	cis	rs9863	0.828	rs75989601	ENSG00000269938.1	RP11-214K3.20	-3.54	0.000439	0.0274	-0.19	-0.16	White blood cell count;	chr12:123982176	chr12:123968023~123968579:-
THCA	cis	rs9863	0.828	rs35099862	ENSG00000269938.1	RP11-214K3.20	-3.54	0.000439	0.0274	-0.19	-0.16	White blood cell count;	chr12:123982657	chr12:123968023~123968579:-
THCA	cis	rs12368653	0.84	rs10877020	ENSG00000270039.1	RP11-571M6.17	3.54	0.000439	0.0274	0.17	0.16	Multiple sclerosis;	chr12:57794231	chr12:57803838~57804415:+
THCA	cis	rs944289	0.708	rs2755194	ENSG00000212071.1	AL162511.1	3.54	0.000439	0.0274	0.18	0.16	Thyroid cancer;	chr14:36079176	chr14:36196480~36196568:-
THCA	cis	rs944289	0.74	rs11156902	ENSG00000212071.1	AL162511.1	3.54	0.000439	0.0274	0.18	0.16	Thyroid cancer;	chr14:36080016	chr14:36196480~36196568:-
THCA	cis	rs944289	0.712	rs35736442	ENSG00000212071.1	AL162511.1	3.54	0.000439	0.0274	0.18	0.16	Thyroid cancer;	chr14:36081119	chr14:36196480~36196568:-
THCA	cis	rs1799949	0.965	rs799912	ENSG00000279602.1	CTD-3014M21.1	-3.54	0.000439	0.0274	-0.2	-0.16	Menopause (age at onset);	chr17:43105117	chr17:43360041~43361361:-
THCA	cis	rs7028939	1	rs10989015	ENSG00000255145.2	STX17-AS1	-3.54	0.000439	0.0274	-0.25	-0.16	Preeclampsia;	chr9:100206341	chr9:99886322~99906601:-
THCA	cis	rs12780845	0.931	rs11595208	ENSG00000229124.5	VIM-AS1	3.54	0.000439	0.0274	0.16	0.16	Homocysteine levels;	chr10:17209637	chr10:17214239~17229985:-
THCA	cis	rs1048886	0.872	rs74818996	ENSG00000271967.1	RP11-134K13.4	-3.54	0.000439	0.0274	-0.19	-0.16	Type 2 diabetes;	chr6:70419970	chr6:70596438~70596980:+
THCA	cis	rs1823874	0.584	rs1823872	ENSG00000254744.3	CTD-3076O17.1	-3.54	0.000439	0.0274	-0.17	-0.16	IgG glycosylation;	chr15:99839246	chr15:99970215~99974010:+
THCA	cis	rs9475677	0.906	rs60268580	ENSG00000231441.1	RP11-472M19.2	3.54	0.000439	0.0274	0.2	0.16	Gut microbiota (functional units);	chr6:56373069	chr6:56844002~56864078:+
THCA	cis	rs9596863	1	rs9316669	ENSG00000136149.6	RPL13AP25	-3.54	0.000439	0.0274	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53827701	chr13:54440704~54441315:-
THCA	cis	rs2797160	0.935	rs926855	ENSG00000226409.1	RP11-735G4.1	3.54	0.000439	0.0274	0.19	0.16	Endometrial cancer;	chr6:125700636	chr6:125370211~125374324:-
THCA	cis	rs4971059	0.617	rs12025371	ENSG00000225855.5	RUSC1-AS1	3.54	0.000439	0.0274	0.1	0.16	Breast cancer;	chr1:155146851	chr1:155316863~155324176:-
THCA	cis	rs2749592	0.55	rs7081464	ENSG00000275858.1	RP11-291L22.8	-3.54	0.000439	0.0275	-0.19	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38450738~38451069:-
THCA	cis	rs354225	0.544	rs13399656	ENSG00000212175.1	SNORA12	-3.54	0.000439	0.0275	-0.2	-0.16	Schizophrenia;	chr2:54575559	chr2:55565703~55565850:+
THCA	cis	rs7577696	0.741	rs2300702	ENSG00000276334.1	AL133243.1	3.54	0.000439	0.0275	0.17	0.16	Inflammatory biomarkers;	chr2:31562948	chr2:32521927~32523547:+
THCA	cis	rs7246967	0.673	rs8103012	ENSG00000198153.8	ZNF849P	-3.54	0.000439	0.0275	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22696483	chr19:22685167~22686732:+
THCA	cis	rs3800688	0.527	rs1733861	ENSG00000236753.4	MKLN1-AS	-3.54	0.000439	0.0275	-0.15	-0.16	Hypertension;	chr7:131470829	chr7:131309744~131328222:-
THCA	cis	rs1150668	0.796	rs1052215	ENSG00000220721.1	OR1F12	-3.54	0.000439	0.0275	-0.18	-0.16	Pubertal anthropometrics;	chr6:28380381	chr6:28073316~28074233:+
THCA	cis	rs620729	0.749	rs62394925	ENSG00000272097.1	RP11-421M1.8	3.54	0.00044	0.0275	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482170	chr6:10743324~10747663:-
THCA	cis	rs2629751	1	rs2629751	ENSG00000214198.6	RP11-642P15.1	-3.54	0.00044	0.0275	-0.13	-0.16	Hepatitis C induced liver fibrosis;	chr12:104028030	chr12:103843749~103930211:-
THCA	cis	rs16957091	0.528	rs4924699	ENSG00000249839.1	AC011330.5	3.54	0.00044	0.0275	0.25	0.16	MGMT methylation in smokers;	chr15:42908911	chr15:43663654~43684339:-
THCA	cis	rs7647973	0.58	rs35218722	ENSG00000228638.1	FCF1P2	-3.54	0.00044	0.0275	-0.17	-0.16	Menarche (age at onset);	chr3:49238372	chr3:48290793~48291375:-
THCA	cis	rs11671005	0.571	rs56243535	ENSG00000252334.1	RNU6-1337P	3.54	0.00044	0.0275	0.24	0.16	Mean platelet volume;	chr19:58494783	chr19:58483749~58483843:-
THCA	cis	rs2289328	1	rs11634187	ENSG00000223313.1	RNU6-516P	-3.54	0.00044	0.0275	-0.24	-0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40430582	chr15:40529570~40529673:+
THCA	cis	rs9450351	0.744	rs12528808	ENSG00000203875.9	SNHG5	-3.54	0.00044	0.0275	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85495926	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs9353319	ENSG00000203875.9	SNHG5	-3.54	0.00044	0.0275	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85522825	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs9450295	ENSG00000203875.9	SNHG5	-3.54	0.00044	0.0275	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85548156	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs7744309	ENSG00000203875.9	SNHG5	-3.54	0.00044	0.0275	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85556764	chr6:85660950~85678736:-
THCA	cis	rs6137726	0.524	rs1203927	ENSG00000237396.1	LINC01384	3.54	0.00044	0.0275	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22608927	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1203935	ENSG00000237396.1	LINC01384	3.54	0.00044	0.0275	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22611348	chr20:22587522~22607517:-
THCA	cis	rs1667255	1	rs6506932	ENSG00000266521.1	RP11-650P15.1	3.54	0.00044	0.0275	0.2	0.16	Retinol levels;	chr18:31579987	chr18:31496645~31497195:-
THCA	cis	rs1667255	1	rs4799581	ENSG00000266521.1	RP11-650P15.1	3.54	0.00044	0.0275	0.2	0.16	Retinol levels;	chr18:31581548	chr18:31496645~31497195:-
THCA	cis	rs2797160	0.684	rs1832937	ENSG00000226409.1	RP11-735G4.1	3.54	0.00044	0.0275	0.19	0.16	Endometrial cancer;	chr6:125664788	chr6:125370211~125374324:-
THCA	cis	rs7246657	0.943	rs4803460	ENSG00000266916.4	ZNF793-AS1	-3.54	0.00044	0.0275	-0.15	-0.16	Coronary artery calcification;	chr19:37394326	chr19:37497159~37507046:-
THCA	cis	rs10844706	0.699	rs741199	ENSG00000257027.1	RP11-705C15.3	3.54	0.00044	0.0275	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9720769	chr12:9658567~9662085:+
THCA	cis	rs2933343	0.729	rs1680780	ENSG00000231305.3	RP11-723O4.2	3.54	0.00044	0.0275	0.17	0.16	IgG glycosylation;	chr3:128893816	chr3:128861313~128871540:-
THCA	cis	rs6598541	0.832	rs11857366	ENSG00000278090.1	RP11-6O2.2	-3.54	0.00044	0.0275	-0.14	-0.16	Urate levels;	chr15:98720572	chr15:99028538~99031053:+
THCA	cis	rs9907295	1	rs9904675	ENSG00000270871.1	AC015849.19	3.54	0.00044	0.0275	0.15	0.16	Fibroblast growth factor basic levels;	chr17:35921435	chr17:35816717~35830293:-
THCA	cis	rs7176527	1	rs3762168	ENSG00000229212.6	RP11-561C5.4	3.54	0.00044	0.0275	0.26	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85205440~85234795:-
THCA	cis	rs6580649	0.883	rs1793955	ENSG00000273765.1	RP11-370I10.11	3.54	0.00044	0.0275	0.18	0.16	Lung cancer;	chr12:47999323	chr12:48360920~48361377:+
THCA	cis	rs722599	0.683	rs2058918	ENSG00000279594.1	RP11-950C14.10	3.54	0.00044	0.0275	0.16	0.16	IgG glycosylation;	chr14:74821815	chr14:75011269~75012851:-
THCA	cis	rs3733589	0.661	rs4697943	ENSG00000250413.1	RP11-448G15.1	3.54	0.00044	0.0275	0.29	0.16	Renal overload gout;	chr4:10163737	chr4:10006482~10009725:+
THCA	cis	rs2348418	0.733	rs7137557	ENSG00000278733.1	RP11-425D17.1	-3.54	0.00044	0.0275	-0.14	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28185625~28186190:-
THCA	cis	rs2348418	0.733	rs12425200	ENSG00000278733.1	RP11-425D17.1	-3.54	0.00044	0.0275	-0.14	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28185625~28186190:-
THCA	cis	rs16857609	0.564	rs3732009	ENSG00000233143.1	DIRC3-AS1	-3.54	0.00044	0.0275	-0.19	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217426670	chr2:217282739~217336120:+
THCA	cis	rs6901152	1	rs7760341	ENSG00000217648.1	RP1-95L4.4	-3.54	0.00044	0.0275	-0.17	-0.16	Acute lymphoblastic leukemia (childhood);	chr6:143356194	chr6:143342246~143343383:+
THCA	cis	rs7296418	0.63	rs11608305	ENSG00000256092.2	RP13-942N8.1	3.54	0.00044	0.0275	0.12	0.16	Platelet count;	chr12:123306618	chr12:123363868~123366113:+
THCA	cis	rs2298574	0.614	rs17445742	ENSG00000274578.1	RP11-430E17.1	3.54	0.00044	0.0275	0.39	0.16	vWF and FVIII levels;	chr18:27977341	chr18:28146233~28146703:-
THCA	cis	rs2638953	0.815	rs11049682	ENSG00000247934.4	RP11-967K21.1	-3.54	0.00044	0.0275	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509062	chr12:28163298~28190738:-
THCA	cis	rs2625529	0.824	rs16953769	ENSG00000260037.4	CTD-2524L6.3	-3.54	0.00044	0.0275	-0.23	-0.16	Red blood cell count;	chr15:72170984	chr15:71818396~71823384:+
THCA	cis	rs10419113	0.522	rs13037	ENSG00000269794.1	AC010642.2	-3.54	0.00044	0.0275	-0.17	-0.16	Pediatric bone mineral density (spine);	chr19:57757805	chr19:58319277~58320489:+
THCA	cis	rs4915077	0.773	rs72705627	ENSG00000226822.1	RP11-356N1.2	3.54	0.00044	0.0275	0.3	0.16	Hypothyroidism;	chr1:107724998	chr1:108071482~108074519:+
THCA	cis	rs1993293	0.636	rs2924778	ENSG00000259219.1	CTD-3076O17.2	3.54	0.00044	0.0275	0.19	0.16	Coronary artery calcification;	chr15:99758621	chr15:99976481~99980774:+
THCA	cis	rs9860428	0.844	rs9820561	ENSG00000240057.4	RP11-572M11.4	-3.54	0.00044	0.0275	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897693	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.808	rs6805341	ENSG00000240057.4	RP11-572M11.4	-3.54	0.00044	0.0275	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899471	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.808	rs9868922	ENSG00000240057.4	RP11-572M11.4	-3.54	0.00044	0.0275	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899503	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.844	rs2399437	ENSG00000240057.4	RP11-572M11.4	-3.54	0.00044	0.0275	-0.16	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112900369	chr3:113019532~113183301:+
THCA	cis	rs10844706	0.699	rs10844627	ENSG00000257027.1	RP11-705C15.3	3.54	0.00044	0.0275	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733781	chr12:9658567~9662085:+
THCA	cis	rs10844706	0.699	rs10844632	ENSG00000257027.1	RP11-705C15.3	3.54	0.00044	0.0275	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734309	chr12:9658567~9662085:+
THCA	cis	rs737008	0.922	rs2070923	ENSG00000263080.1	RP11-485G7.5	3.54	0.00044	0.0275	0.2	0.16	Obesity-related traits;	chr16:11275998	chr16:11341809~11345211:-
THCA	cis	rs2886497	1	rs2886497	ENSG00000224215.1	RP11-371A19.2	3.54	0.00044	0.0275	0.2	0.16	Major depression and alcohol dependence;	chr10:23381413	chr10:23343957~23345181:+
THCA	cis	rs6733301	0.529	rs2196792	ENSG00000224165.4	DNAJC27-AS1	3.54	0.00044	0.0275	0.11	0.16	Height;	chr2:25037084	chr2:24971390~25039694:+
THCA	cis	rs970548	1	rs12257549	ENSG00000230869.1	CTGLF10P	3.54	0.00044	0.0275	0.2	0.16	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45534183	chr10:45678692~45700532:+
THCA	cis	rs1908814	0.516	rs13275143	ENSG00000254527.1	ENPP7P12	3.54	0.00044	0.0275	0.21	0.16	Neuroticism;	chr8:11939481	chr8:12205759~12206389:-
THCA	cis	rs12023718	0.588	rs74471321	ENSG00000213057.5	C1orf220	3.54	0.00044	0.0275	0.16	0.16	Obesity-related traits;	chr1:178636157	chr1:178542752~178548889:+
THCA	cis	rs11190604	1	rs2295770	ENSG00000273030.1	RP11-285F16.1	3.54	0.00044	0.0275	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100480072	chr10:100412934~100413421:+
THCA	cis	rs9876781	1	rs6442119	ENSG00000199476.1	Y_RNA	-3.54	0.00044	0.0275	-0.2	-0.16	Longevity;	chr3:48398713	chr3:48288587~48288694:+
THCA	cis	rs13217239	0.646	rs12527111	ENSG00000261353.1	CTA-14H9.5	-3.54	0.00044	0.0275	-0.17	-0.16	Schizophrenia;	chr6:27038696	chr6:26527063~26527404:+
THCA	cis	rs17005891	0.586	rs55669422	ENSG00000270480.1	RP11-57B24.1	3.54	0.00044	0.0275	0.25	0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82604631	chr4:82691737~82692468:+
THCA	cis	rs2836950	0.565	rs2836926	ENSG00000235701.1	PCBP2P1	-3.54	0.00044	0.0275	-0.18	-0.16	Menarche (age at onset);	chr21:39164864	chr21:39171130~39172106:-
THCA	cis	rs2836950	0.565	rs8131132	ENSG00000235701.1	PCBP2P1	-3.54	0.00044	0.0275	-0.18	-0.16	Menarche (age at onset);	chr21:39166330	chr21:39171130~39172106:-
THCA	cis	rs12681288	0.723	rs12545453	ENSG00000260721.1	AF067845.1	3.54	0.000441	0.0275	0.19	0.16	Schizophrenia;	chr8:1020582	chr8:1368642~1369833:-
THCA	cis	rs10911363	0.659	rs7518244	ENSG00000232860.6	SMG7-AS1	3.54	0.000441	0.0275	0.12	0.16	Systemic lupus erythematosus;	chr1:183465672	chr1:183460874~183472265:-
THCA	cis	rs7267979	0.727	rs4815431	ENSG00000277938.1	RP5-965G21.3	-3.54	0.000441	0.0275	-0.13	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25229150~25231933:+
THCA	cis	rs67478160	0.625	rs7141473	ENSG00000258534.1	CTD-2134A5.4	3.54	0.000441	0.0275	0.16	0.16	Schizophrenia;	chr14:103849718	chr14:103854366~103880111:-
THCA	cis	rs11259403	1	rs11259403	ENSG00000223784.1	RP11-554I8.2	-3.54	0.000441	0.0275	-0.19	-0.16	Body mass index in asthmatics;	chr10:6530263	chr10:6737382~6739026:+
THCA	cis	rs17027633	1	rs1419092	ENSG00000260948.1	RP11-552M11.8	-3.54	0.000441	0.0275	-0.35	-0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111419587	chr1:111431046~111433068:-
THCA	cis	rs17270561	0.723	rs12192635	ENSG00000218281.1	HIST1H2APS3	3.54	0.000441	0.0275	0.23	0.16	Iron status biomarkers;	chr6:25880679	chr6:26233122~26233255:+
THCA	cis	rs9393777	0.778	rs13212921	ENSG00000226314.6	ZNF192P1	-3.54	0.000441	0.0275	-0.3	-0.16	Intelligence (multi-trait analysis);	chr6:27237643	chr6:28161781~28169594:+
THCA	cis	rs10090774	0.965	rs7008498	ENSG00000280303.2	ERICD	-3.54	0.000441	0.0275	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140866929	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs9324536	ENSG00000280303.2	ERICD	-3.54	0.000441	0.0275	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140868315	chr8:140636281~140638283:+
THCA	cis	rs7188445	0.932	rs17767491	ENSG00000277954.1	RP11-679B19.1	-3.54	0.000441	0.0275	-0.19	-0.16	Urate levels;	chr16:79711590	chr16:79202624~79206739:-
THCA	cis	rs4073416	0.518	rs7141536	ENSG00000276116.2	FUT8-AS1	3.54	0.000441	0.0275	0.18	0.16	N-glycan levels;	chr14:65520594	chr14:65411170~65412690:-
THCA	cis	rs9844985	0.669	rs4145156	ENSG00000243014.1	PTMAP8	3.54	0.000441	0.0275	0.2	0.16	Major depression and alcohol dependence;	chr3:117157018	chr3:117026698~117027039:+
THCA	cis	rs950169	0.959	rs12902070	ENSG00000230373.7	GOLGA6L5P	-3.54	0.000441	0.0275	-0.18	-0.16	Schizophrenia;	chr15:84124806	chr15:84507885~84516814:-
THCA	cis	rs9652601	0.622	rs8049882	ENSG00000263033.2	RP11-396B14.2	-3.54	0.000441	0.0275	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11025629	chr16:11196177~11224969:+
THCA	cis	rs6957923	1	rs6956228	ENSG00000234286.1	AC006026.13	-3.54	0.000441	0.0275	-0.21	-0.16	Height;	chr7:23448096	chr7:23680195~23680786:-
THCA	cis	rs346923	0.764	rs73248635	ENSG00000226950.5	DANCR	3.54	0.000441	0.0275	0.19	0.16	Biochemical measures;	chr4:52458211	chr4:52712404~52720351:+
THCA	cis	rs7989332	0.593	rs9315623	ENSG00000277020.3	RP11-476H16.1	-3.54	0.000441	0.0275	-0.16	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20488214	chr13:20564708~20567045:-
THCA	cis	rs9488822	0.676	rs12524249	ENSG00000233558.1	RP3-486I3.4	3.54	0.000441	0.0275	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116047650	chr6:116258493~116259115:-
THCA	cis	rs9488822	0.636	rs10872142	ENSG00000233558.1	RP3-486I3.4	3.54	0.000441	0.0275	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116047889	chr6:116258493~116259115:-
THCA	cis	rs2898290	0.622	rs978804	ENSG00000270154.1	RP11-419I17.1	-3.54	0.000441	0.0275	-0.2	-0.16	Systolic blood pressure;	chr8:11486164	chr8:12476462~12477122:+
THCA	cis	rs9393777	0.778	rs13219354	ENSG00000220721.1	OR1F12	3.54	0.000441	0.0275	0.31	0.16	Intelligence (multi-trait analysis);	chr6:27217885	chr6:28073316~28074233:+
THCA	cis	rs9393777	0.778	rs67457459	ENSG00000220721.1	OR1F12	3.54	0.000441	0.0275	0.31	0.16	Intelligence (multi-trait analysis);	chr6:27230564	chr6:28073316~28074233:+
THCA	cis	rs11758351	0.66	rs6918339	ENSG00000216331.1	HIST1H1PS1	3.54	0.000441	0.0275	0.22	0.16	Renal underexcretion gout;Gout;	chr6:26211552	chr6:26195566~26195771:+
THCA	cis	rs7166081	1	rs11071940	ENSG00000270964.1	RP11-502I4.3	-3.54	0.000441	0.0275	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67207139	chr15:67541072~67542604:-
THCA	cis	rs11089937	0.825	rs5757012	ENSG00000211638.2	IGLV8-61	-3.54	0.000441	0.0275	-0.13	-0.16	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22098700~22099212:+
THCA	cis	rs12362063	1	rs12362063	ENSG00000249867.4	RP11-115J23.1	3.54	0.000441	0.0275	0.17	0.16	Hepatitis B;	chr11:29246483	chr11:28702615~29063821:+
THCA	cis	rs10807026	1	rs10807026	ENSG00000216915.2	RP1-97D16.1	3.54	0.000441	0.0275	0.23	0.16	Lung adenocarcinoma;	chr6:27587740	chr6:27737000~27738494:-
THCA	cis	rs2806561	0.765	rs2776815	ENSG00000249087.5	ZNF436-AS1	3.54	0.000441	0.0275	0.1	0.16	Height;	chr1:23184091	chr1:23368997~23371839:+
THCA	cis	rs61160187	0.582	rs1460961	ENSG00000251279.1	CTC-436P18.1	-3.54	0.000441	0.0276	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:61162070~61232040:+
THCA	cis	rs12887734	0.566	rs3742366	ENSG00000269958.1	RP11-73M18.8	3.54	0.000441	0.0276	0.15	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103696353~103697163:+
THCA	cis	rs4692589	0.556	rs13133562	ENSG00000229204.3	PTGES3P3	-3.54	0.000441	0.0276	-0.21	-0.16	Anxiety disorder;	chr4:170044558	chr4:169791221~169791702:-
THCA	cis	rs9584850	0.874	rs3742136	ENSG00000231194.1	FARP1-AS1	3.54	0.000441	0.0276	0.2	0.16	Neuroticism;	chr13:98450353	chr13:98435405~98435840:-
THCA	cis	rs9287719	0.81	rs7601748	ENSG00000243819.4	RN7SL832P	3.54	0.000441	0.0276	0.13	0.16	Prostate cancer;	chr2:10645320	chr2:10690344~10692099:+
THCA	cis	rs9905704	0.914	rs2643120	ENSG00000224738.1	AC099850.1	3.54	0.000441	0.0276	0.22	0.16	Testicular germ cell tumor;	chr17:58749588	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.914	rs34556895	ENSG00000224738.1	AC099850.1	3.54	0.000441	0.0276	0.22	0.16	Testicular germ cell tumor;	chr17:58749592	chr17:59106598~59118267:+
THCA	cis	rs9905704	0.914	rs2611777	ENSG00000224738.1	AC099850.1	3.54	0.000441	0.0276	0.22	0.16	Testicular germ cell tumor;	chr17:58749597	chr17:59106598~59118267:+
THCA	cis	rs9287719	0.934	rs6727884	ENSG00000243819.4	RN7SL832P	-3.54	0.000441	0.0276	-0.13	-0.16	Prostate cancer;	chr2:10617431	chr2:10690344~10692099:+
THCA	cis	rs2351088	0.611	rs9614747	ENSG00000280383.1	CTA-941F9.10	3.54	0.000442	0.0276	0.19	0.16	Tonsillectomy;	chr22:45657330	chr22:45657019~45680130:+
THCA	cis	rs10488360	0.734	rs10252970	ENSG00000270822.1	RP11-730B22.1	3.54	0.000442	0.0276	0.2	0.16	Factor VII;	chr7:4372316	chr7:5009164~5009328:-
THCA	cis	rs4869313	0.694	rs27621	ENSG00000247121.5	CTD-2260A17.2	3.54	0.000442	0.0276	0.12	0.16	Pediatric autoimmune diseases;	chr5:97025629	chr5:96814028~96935809:-
THCA	cis	rs739496	0.579	rs12423041	ENSG00000234608.6	MAPKAPK5-AS1	3.54	0.000442	0.0276	0.15	0.16	Platelet count;	chr12:111887042	chr12:111839764~111842902:-
THCA	cis	rs261967	0.692	rs2570467	ENSG00000236882.6	LINC01554	3.54	0.000442	0.0276	0.19	0.16	Body mass index;	chr5:96520975	chr5:95852232~95860133:+
THCA	cis	rs17301013	0.932	rs11804941	ENSG00000270084.1	GAS5-AS1	3.54	0.000442	0.0276	0.17	0.16	Systemic lupus erythematosus;	chr1:174624074	chr1:173863248~173863941:+
THCA	cis	rs61160187	0.582	rs17444495	ENSG00000251279.1	CTC-436P18.1	-3.54	0.000442	0.0276	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:61162070~61232040:+
THCA	cis	rs881375	0.678	rs7037195	ENSG00000238181.2	AHCYP2	-3.54	0.000442	0.0276	-0.19	-0.16	Rheumatoid arthritis;	chr9:120921722	chr9:120720673~120721972:+
THCA	cis	rs8130944	1	rs8130944	ENSG00000225731.1	AP001627.1	3.54	0.000442	0.0276	0.2	0.16	Perceived unattractiveness to mosquitoes;	chr21:42725797	chr21:42733594~42741758:-
THCA	cis	rs1153858	1	rs4395020	ENSG00000275672.1	GATM-AS1	-3.54	0.000442	0.0276	-0.17	-0.16	Homoarginine levels;	chr15:45360691	chr15:45378700~45380123:+
THCA	cis	rs9450351	0.744	rs9359674	ENSG00000203875.9	SNHG5	3.54	0.000442	0.0276	0.3	0.16	Interferon gamma-induced protein 10 levels;	chr6:85996191	chr6:85660950~85678736:-
THCA	cis	rs4788570	0.578	rs8062188	ENSG00000260185.1	RP11-432I5.6	-3.54	0.000442	0.0276	-0.31	-0.16	Intelligence (multi-trait analysis);	chr16:71695922	chr16:71655027~71664212:+
THCA	cis	rs3808502	0.525	rs9650661	ENSG00000206014.6	OR7E161P	3.54	0.000442	0.0276	0.19	0.16	Neuroticism;	chr8:11569624	chr8:11928597~11929563:-
THCA	cis	rs10089	1	rs72794401	ENSG00000245937.6	LINC01184	3.54	0.000442	0.0276	0.19	0.16	Ileal carcinoids;	chr5:128181934	chr5:127940426~128083172:-
THCA	cis	rs513088	0.681	rs565418	ENSG00000225171.2	DUTP6	3.54	0.000442	0.0276	0.22	0.16	Schizophrenia;	chr1:166679839	chr1:166868748~166869209:+
THCA	cis	rs2228479	0.702	rs62056087	ENSG00000274627.1	RP11-104N10.2	-3.54	0.000442	0.0276	-0.28	-0.16	Skin colour saturation;	chr16:89853975	chr16:89516797~89522217:+
THCA	cis	rs2460905	0.717	rs62487523	ENSG00000251468.2	RP11-369K16.1	-3.54	0.000442	0.0276	-0.32	-0.16	Post-traumatic stress disorder;	chr8:12925625	chr8:12958387~12962200:+
THCA	cis	rs758324	0.73	rs76876329	ENSG00000237714.1	P4HA2-AS1	-3.54	0.000442	0.0276	-0.3	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131902066	chr5:132184876~132192808:+
THCA	cis	rs9309473	1	rs1114380	ENSG00000273245.1	RP11-434P11.2	3.54	0.000442	0.0276	0.22	0.16	Metabolite levels;	chr2:73577581	chr2:73750256~73750786:-
THCA	cis	rs1577917	0.958	rs10944136	ENSG00000220563.1	PKMP3	-3.54	0.000442	0.0276	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85738781	chr6:85659892~85660606:-
THCA	cis	rs111756027	0.54	rs17701924	ENSG00000260922.1	RP11-538I12.3	3.54	0.000442	0.0276	0.23	0.16	Bone mineral density (Ward's triangle area);	chr16:77277898	chr16:77234877~77290934:+
THCA	cis	rs4272720	0.535	rs56291725	ENSG00000234736.4	FAM170B-AS1	-3.54	0.000442	0.0276	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49081940	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.535	rs34364659	ENSG00000234736.4	FAM170B-AS1	-3.54	0.000442	0.0276	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49082631	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.535	rs12257242	ENSG00000234736.4	FAM170B-AS1	-3.54	0.000442	0.0276	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49083355	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.51	rs34878380	ENSG00000234736.4	FAM170B-AS1	-3.54	0.000442	0.0276	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49085014	chr10:49121839~49151547:+
THCA	cis	rs1046896	0.553	rs2292965	ENSG00000263063.1	RP11-388C12.1	-3.54	0.000442	0.0276	-0.21	-0.16	Glycated hemoglobin levels;	chr17:82942769	chr17:82713908~82716255:-
THCA	cis	rs7665090	1	rs5026473	ENSG00000251288.2	RP11-10L12.2	-3.54	0.000442	0.0276	-0.21	-0.16	Primary biliary cholangitis;	chr4:102633636	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.54	rs2711897	ENSG00000230069.3	LRRC37A15P	-3.54	0.000442	0.0276	-0.16	-0.16	Type 2 diabetes;	chr4:103102410	chr4:102727274~102730721:-
THCA	cis	rs9474614	1	rs9474616	ENSG00000227885.1	RP11-79N23.1	-3.54	0.000442	0.0276	-0.23	-0.16	Obesity-related traits;	chr6:53653056	chr6:53740749~53747022:-
THCA	cis	rs9308731	0.591	rs10439381	ENSG00000227992.1	AC108463.2	-3.54	0.000442	0.0276	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111178882	chr2:111203964~111206215:-
THCA	cis	rs7216064	1	rs62084210	ENSG00000265055.1	AC145343.2	3.54	0.000442	0.0276	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67832594	chr17:68096046~68101474:-
THCA	cis	rs7804306	1	rs13225545	ENSG00000233264.2	AC006042.8	3.54	0.000442	0.0276	0.29	0.16	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027509	chr7:7980312~7982228:+
THCA	cis	rs7737355	0.773	rs11242069	ENSG00000224431.1	AC063976.7	-3.54	0.000442	0.0276	-0.15	-0.16	Life satisfaction;	chr5:131262625	chr5:132199456~132203487:+
THCA	cis	rs1005277	0.54	rs4934907	ENSG00000120555.12	SEPT7P9	3.54	0.000442	0.0276	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38383069~38402916:-
THCA	cis	rs1005277	0.54	rs11011351	ENSG00000120555.12	SEPT7P9	3.54	0.000442	0.0276	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38383069~38402916:-
THCA	cis	rs12893668	0.542	rs12884809	ENSG00000258735.1	LINC00637	-3.54	0.000442	0.0276	-0.21	-0.16	Reticulocyte count;	chr14:103628983	chr14:103847721~103858049:+
THCA	cis	rs2287641	0.826	rs7558563	ENSG00000272156.1	RP11-477N3.1	3.54	0.000442	0.0276	0.28	0.16	Cannabis dependence symptom count;	chr2:54111803	chr2:54082554~54085066:+
THCA	cis	rs5753037	0.653	rs131282	ENSG00000273350.1	RP4-539M6.20	-3.54	0.000442	0.0276	-0.19	-0.16	Type 1 diabetes;	chr22:29760619	chr22:30420512~30420912:+
THCA	cis	rs9902453	0.73	rs4583306	ENSG00000263370.1	RP11-68I3.5	-3.54	0.000442	0.0276	-0.21	-0.16	Coffee consumption (cups per day);	chr17:30211697	chr17:29639627~29640825:+
THCA	cis	rs7819988	0.634	rs4871179	ENSG00000248690.5	HAS2-AS1	3.54	0.000442	0.0276	0.17	0.16	Periodontitis (CDC/AAP);	chr8:121235439	chr8:121639293~121644693:+
THCA	cis	rs916888	0.773	rs199534	ENSG00000260075.1	NSFP1	-3.54	0.000442	0.0276	-0.26	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46372855~46487141:+
THCA	cis	rs2797160	1	rs1739348	ENSG00000226409.1	RP11-735G4.1	3.54	0.000443	0.0276	0.19	0.16	Endometrial cancer;	chr6:125693427	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1739349	ENSG00000226409.1	RP11-735G4.1	3.54	0.000443	0.0276	0.19	0.16	Endometrial cancer;	chr6:125693838	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.967	rs1578793	ENSG00000226409.1	RP11-735G4.1	3.54	0.000443	0.0276	0.19	0.16	Endometrial cancer;	chr6:125693911	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1578794	ENSG00000226409.1	RP11-735G4.1	3.54	0.000443	0.0276	0.19	0.16	Endometrial cancer;	chr6:125694323	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs6927161	ENSG00000226409.1	RP11-735G4.1	3.54	0.000443	0.0276	0.19	0.16	Endometrial cancer;	chr6:125694808	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs6904992	ENSG00000226409.1	RP11-735G4.1	3.54	0.000443	0.0276	0.19	0.16	Endometrial cancer;	chr6:125694857	chr6:125370211~125374324:-
THCA	cis	rs4262150	0.81	rs10046082	ENSG00000253921.1	CTB-113P19.3	3.54	0.000443	0.0276	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152581885	chr5:151753992~151767247:+
THCA	cis	rs6942407	0.744	rs10244350	ENSG00000224046.1	AC005076.5	-3.54	0.000443	0.0276	-0.15	-0.16	Food allergy;	chr7:87233962	chr7:87151423~87152420:-
THCA	cis	rs738409	0.657	rs2294433	ENSG00000223843.4	EFCAB6-AS1	3.54	0.000443	0.0276	0.23	0.16	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43933395	chr22:43516107~43537117:+
THCA	cis	rs6938	0.618	rs11857695	ENSG00000260269.4	CTD-2323K18.1	-3.54	0.000443	0.0276	-0.23	-0.16	Breast cancer;	chr15:74873410	chr15:75527150~75601205:-
THCA	cis	rs365302	1	rs369160	ENSG00000235086.1	FNDC1-IT1	3.54	0.000443	0.0276	0.23	0.16	Coronary heart disease;	chr6:159217547	chr6:159240786~159243329:+
THCA	cis	rs3783637	0.643	rs67317740	ENSG00000258413.1	RP11-665C16.6	-3.54	0.000443	0.0276	-0.34	-0.16	Rheumatoid arthritis;Obesity-related traits;	chr14:54937511	chr14:55262767~55272075:-
THCA	cis	rs910316	0.737	rs175510	ENSG00000259138.1	RP11-950C14.7	-3.54	0.000443	0.0276	-0.14	-0.16	Height;	chr14:75058136	chr14:75127153~75136930:+
THCA	cis	rs7192750	0.539	rs7193731	ENSG00000260886.1	TAT-AS1	3.54	0.000443	0.0276	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71863496	chr16:71565789~71578187:+
THCA	cis	rs11782517	0.961	rs4276692	ENSG00000261451.1	RP11-981G7.1	3.54	0.000443	0.0276	0.22	0.16	Nose size;	chr8:10258185	chr8:10433672~10438312:+
THCA	cis	rs4915077	0.881	rs11578263	ENSG00000226822.1	RP11-356N1.2	-3.54	0.000443	0.0276	-0.3	-0.16	Hypothyroidism;	chr1:107782235	chr1:108071482~108074519:+
THCA	cis	rs250518	0.926	rs3846650	ENSG00000251467.1	CTC-250P20.2	3.54	0.000443	0.0276	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72768560	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs3916445	ENSG00000251467.1	CTC-250P20.2	3.54	0.000443	0.0276	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72773821	chr5:72996920~72997642:+
THCA	cis	rs4971059	0.654	rs4971078	ENSG00000225855.5	RUSC1-AS1	3.54	0.000443	0.0276	0.1	0.16	Breast cancer;	chr1:155156547	chr1:155316863~155324176:-
THCA	cis	rs7481311	0.956	rs11030075	ENSG00000245573.6	BDNF-AS	-3.54	0.000443	0.0276	-0.15	-0.16	Weight;Body mass index;	chr11:27605749	chr11:27506838~27698174:+
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000230295.1	RP11-458F8.2	-3.54	0.000443	0.0276	-0.12	-0.16	Calcium levels;	chr7:65892789	chr7:66880708~66882981:+
THCA	cis	rs911555	0.603	rs8016326	ENSG00000244691.1	RPL10AP1	-3.54	0.000443	0.0276	-0.22	-0.16	Intelligence (multi-trait analysis);	chr14:103380379	chr14:103412119~103412761:-
THCA	cis	rs11681884	0.892	rs60341065	ENSG00000236397.3	DDX11L2	-3.54	0.000443	0.0276	-0.34	-0.16	Stroke;	chr2:113101789	chr2:113599036~113601261:-
THCA	cis	rs11681884	0.786	rs58187820	ENSG00000236397.3	DDX11L2	-3.54	0.000443	0.0276	-0.34	-0.16	Stroke;	chr2:113102057	chr2:113599036~113601261:-
THCA	cis	rs11681884	0.892	rs58036696	ENSG00000236397.3	DDX11L2	-3.54	0.000443	0.0276	-0.34	-0.16	Stroke;	chr2:113102269	chr2:113599036~113601261:-
THCA	cis	rs6487679	0.543	rs7956661	ENSG00000245105.2	A2M-AS1	3.54	0.000443	0.0276	0.21	0.16	Non-alcoholic fatty liver disease histology (AST);	chr12:9201988	chr12:9065177~9068060:+
THCA	cis	rs6449957	0.639	rs40419	ENSG00000249335.1	CTC-340D7.1	3.54	0.000443	0.0276	0.2	0.16	Cleft lip with or without cleft palate;	chr5:68219774	chr5:68832585~68962158:-
THCA	cis	rs7819412	0.818	rs11989439	ENSG00000255495.1	AC145124.2	-3.54	0.000443	0.0276	-0.19	-0.16	Triglycerides;	chr8:11198088	chr8:12194467~12196280:+
THCA	cis	rs4853525	0.59	rs11893307	ENSG00000235852.1	AC005540.3	-3.54	0.000443	0.0276	-0.18	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190863318	chr2:190880797~190882059:-
THCA	cis	rs56283067	0.847	rs1418432	ENSG00000237686.5	RP5-1120P11.1	-3.54	0.000443	0.0276	-0.14	-0.16	Total body bone mineral density;	chr6:44723635	chr6:43995723~44074652:-
THCA	cis	rs721048	0.92	rs13422328	ENSG00000242412.1	DBIL5P2	-3.54	0.000443	0.0276	-0.21	-0.16	Prostate cancer;	chr2:63239042	chr2:63117851~63119542:-
THCA	cis	rs57709857	0.957	rs2171616	ENSG00000272092.1	RP11-350N15.5	-3.54	0.000443	0.0276	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38305785	chr8:38382364~38383461:+
THCA	cis	rs45544231	0.932	rs12920540	ENSG00000279344.1	RP11-44F14.7	3.54	0.000443	0.0276	0.15	0.16	Restless legs syndrome;	chr16:52591701	chr16:53478957~53481550:-
THCA	cis	rs453301	0.631	rs28572014	ENSG00000253981.4	ALG1L13P	-3.54	0.000443	0.0276	-0.16	-0.16	Joint mobility (Beighton score);	chr8:8936097	chr8:8236003~8244667:-
THCA	cis	rs6723226	0.699	rs805830	ENSG00000276517.1	AL133243.2	-3.54	0.000443	0.0276	-0.16	-0.16	Intelligence (multi-trait analysis);	chr2:32276406	chr2:32526504~32529507:+
THCA	cis	rs1577917	0.958	rs66807489	ENSG00000220563.1	PKMP3	-3.54	0.000443	0.0276	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85730984	chr6:85659892~85660606:-
THCA	cis	rs875971	1	rs6963646	ENSG00000272831.1	RP11-792A8.4	-3.54	0.000443	0.0276	-0.1	-0.16	Aortic root size;	chr7:66220780	chr7:66739829~66740385:-
THCA	cis	rs7474896	0.537	rs1208587	ENSG00000272983.1	RP11-508N22.12	3.54	0.000443	0.0276	0.16	0.16	Obesity (extreme);	chr10:37918831	chr10:38137337~38144399:+
THCA	cis	rs17362650	0.694	rs17589193	ENSG00000271855.1	RP11-214N9.1	3.54	0.000443	0.0277	0.13	0.16	Alcohol dependence (age at onset);	chr2:9440337	chr2:9555899~9556775:+
THCA	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-3.54	0.000443	0.0277	-0.14	-0.16	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
THCA	cis	rs7690839	1	rs4693978	ENSG00000270720.1	RP11-84C13.2	3.54	0.000443	0.0277	0.18	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88933016	chr4:89119284~89119871:+
THCA	cis	rs7690839	0.967	rs13149750	ENSG00000270720.1	RP11-84C13.2	3.54	0.000443	0.0277	0.18	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88933843	chr4:89119284~89119871:+
THCA	cis	rs9287719	0.967	rs12464817	ENSG00000243819.4	RN7SL832P	3.54	0.000443	0.0277	0.13	0.16	Prostate cancer;	chr2:10567086	chr2:10690344~10692099:+
THCA	cis	rs6427356	0.956	rs1176556	ENSG00000237189.1	RP11-85G21.2	3.54	0.000443	0.0277	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157167321	chr1:157287703~157288053:-
THCA	cis	rs9377188	0.619	rs2500514	ENSG00000252244.1	RNU7-3P	-3.54	0.000443	0.0277	-0.18	-0.16	Cancer;	chr6:148972099	chr6:149516956~149517017:+
THCA	cis	rs1865760	0.663	rs9379815	ENSG00000272810.1	U91328.22	-3.54	0.000443	0.0277	-0.12	-0.16	Height;	chr6:25979888	chr6:26013241~26013757:+
THCA	cis	rs72765298	0.79	rs2161753	ENSG00000235332.2	RP11-366O20.5	3.54	0.000444	0.0277	0.24	0.16	Pulse pressure;	chr9:125172893	chr9:125194649~125195821:-
THCA	cis	rs66887589	0.967	rs3775842	ENSG00000249244.1	RP11-548H18.2	3.54	0.000444	0.0277	0.16	0.16	Diastolic blood pressure;	chr4:119506577	chr4:119391831~119395335:-
THCA	cis	rs9287719	1	rs9287719	ENSG00000243819.4	RN7SL832P	3.54	0.000444	0.0277	0.13	0.16	Prostate cancer;	chr2:10570604	chr2:10690344~10692099:+
THCA	cis	rs9650657	0.513	rs7005884	ENSG00000206014.6	OR7E161P	3.54	0.000444	0.0277	0.18	0.16	Neuroticism;	chr8:10938962	chr8:11928597~11929563:-
THCA	cis	rs7615952	0.605	rs11708269	ENSG00000241278.1	ENPP7P4	3.54	0.000444	0.0277	0.28	0.16	Blood pressure (smoking interaction);	chr3:125613306	chr3:125848223~125909372:+
THCA	cis	rs17695224	0.545	rs4802875	ENSG00000275055.1	CTC-471J1.11	-3.54	0.000444	0.0277	-0.12	-0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51827056	chr19:52049007~52049754:+
THCA	cis	rs9467773	0.935	rs1884947	ENSG00000228223.2	HCG11	-3.54	0.000444	0.0277	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26523450~26526579:+
THCA	cis	rs250518	0.926	rs1509131	ENSG00000251467.1	CTC-250P20.2	3.54	0.000444	0.0277	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72797651	chr5:72996920~72997642:+
THCA	cis	rs61677309	1	rs3825051	ENSG00000278376.1	RP11-158I9.8	3.54	0.000444	0.0277	0.12	0.16	Lung cancer in ever smokers;	chr11:118303914	chr11:118791254~118793137:+
THCA	cis	rs9796	0.835	rs2927062	ENSG00000247556.5	OIP5-AS1	3.54	0.000444	0.0277	0.13	0.16	Menopause (age at onset);	chr15:41010489	chr15:41283990~41309737:+
THCA	cis	rs4824093	0.535	rs12171243	ENSG00000278869.1	CITF22-49E9.3	3.54	0.000444	0.0277	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr22:49922726	chr22:49933198~49934074:-
THCA	cis	rs208520	1	rs12193077	ENSG00000233859.2	ADH5P4	3.54	0.000444	0.0277	0.25	0.16	Exhaled nitric oxide output;	chr6:66279655	chr6:65836930~65838039:-
THCA	cis	rs3853824	0.636	rs9911560	ENSG00000263089.1	RP11-166P13.4	-3.54	0.000444	0.0277	-0.16	-0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56862354	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs3826295	ENSG00000263089.1	RP11-166P13.4	-3.54	0.000444	0.0277	-0.16	-0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56862376	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs8071009	ENSG00000263089.1	RP11-166P13.4	3.54	0.000444	0.0277	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56863030	chr17:57092145~57096425:-
THCA	cis	rs76878669	0.561	rs11227465	ENSG00000255320.1	RP11-755F10.1	3.54	0.000444	0.0277	0.2	0.16	Educational attainment (years of education);	chr11:66348408	chr11:66244840~66246239:-
THCA	cis	rs972578	0.837	rs6002964	ENSG00000274717.1	RP1-47A17.1	-3.54	0.000444	0.0277	-0.17	-0.16	Mean platelet volume;	chr22:42850242	chr22:42791814~42794313:-
THCA	cis	rs4841134	0.745	rs13278594	ENSG00000254153.1	CTA-398F10.2	3.54	0.000444	0.0277	0.17	0.16	Age-related disease endophenotypes;	chr8:9338956	chr8:8456909~8461337:-
THCA	cis	rs6561151	0.718	rs11842000	ENSG00000274001.1	RP11-5G9.5	3.54	0.000444	0.0277	0.25	0.16	Crohn's disease;	chr13:43839331	chr13:43877715~43878163:-
THCA	cis	rs1198872	0.892	rs1198865	ENSG00000243819.4	RN7SL832P	3.54	0.000444	0.0277	0.13	0.16	Cardiac Troponin-T levels;	chr2:10760936	chr2:10690344~10692099:+
THCA	cis	rs5751901	0.761	rs2006094	ENSG00000225098.1	BCRP1	3.54	0.000444	0.0277	0.2	0.16	Protein quantitative trait loci;	chr22:24601119	chr22:24259929~24263764:-
THCA	cis	rs8112211	0.682	rs11671779	ENSG00000267291.1	CTB-186G2.1	3.54	0.000444	0.0277	0.18	0.16	Blood protein levels;	chr19:38342710	chr19:38596346~38601694:+
THCA	cis	rs79478560	0.518	rs12306328	ENSG00000270061.1	RP11-214K3.19	-3.54	0.000444	0.0277	-0.2	-0.16	Lymphocyte counts;	chr12:123898497	chr12:123969990~123970344:-
THCA	cis	rs4705952	0.557	rs4588593	ENSG00000233006.5	AC034220.3	3.54	0.000444	0.0277	0.13	0.16	C-reactive protein levels;	chr5:132509641	chr5:132311285~132369916:-
THCA	cis	rs2235642	0.653	rs7197288	ENSG00000260989.1	LA16c-395F10.2	-3.54	0.000444	0.0277	-0.17	-0.16	Coronary artery disease;	chr16:1604752	chr16:1580527~1610328:+
THCA	cis	rs72843506	0.656	rs28567541	ENSG00000189423.10	USP32P3	3.54	0.000444	0.0277	0.25	0.16	Schizophrenia;	chr17:20051789	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs80250684	ENSG00000189423.10	USP32P3	3.54	0.000444	0.0277	0.25	0.16	Schizophrenia;	chr17:20054983	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs28622601	ENSG00000189423.10	USP32P3	3.54	0.000444	0.0277	0.25	0.16	Schizophrenia;	chr17:20055341	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.586	rs75048432	ENSG00000189423.10	USP32P3	3.54	0.000444	0.0277	0.25	0.16	Schizophrenia;	chr17:20057571	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs16960660	ENSG00000189423.10	USP32P3	3.54	0.000444	0.0277	0.25	0.16	Schizophrenia;	chr17:20062274	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs73984564	ENSG00000189423.10	USP32P3	3.54	0.000444	0.0277	0.25	0.16	Schizophrenia;	chr17:20068535	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs13339684	ENSG00000189423.10	USP32P3	3.54	0.000444	0.0277	0.25	0.16	Schizophrenia;	chr17:20073898	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs73984568	ENSG00000189423.10	USP32P3	3.54	0.000444	0.0277	0.25	0.16	Schizophrenia;	chr17:20074301	chr17:20415547~20431008:+
THCA	cis	rs1009077	0.716	rs62319606	ENSG00000245958.5	RP11-33B1.1	3.54	0.000444	0.0277	0.25	0.16	Endometriosis;	chr4:119544091	chr4:119454791~119552025:+
THCA	cis	rs941408	0.963	rs2537854	ENSG00000261342.1	AC006538.1	3.54	0.000444	0.0277	0.17	0.16	Total cholesterol levels;	chr19:2786728	chr19:2727743~2729327:-
THCA	cis	rs2034650	0.563	rs2412523	ENSG00000259211.1	RP11-64K12.8	-3.54	0.000444	0.0277	-0.14	-0.16	Interstitial lung disease;	chr15:40417487	chr15:40464193~40466726:-
THCA	cis	rs7028939	1	rs73505717	ENSG00000255145.2	STX17-AS1	-3.54	0.000444	0.0277	-0.24	-0.16	Preeclampsia;	chr9:100066709	chr9:99886322~99906601:-
THCA	cis	rs7028939	0.892	rs112652609	ENSG00000255145.2	STX17-AS1	-3.54	0.000444	0.0277	-0.24	-0.16	Preeclampsia;	chr9:100077362	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs74647103	ENSG00000255145.2	STX17-AS1	-3.54	0.000444	0.0277	-0.24	-0.16	Preeclampsia;	chr9:100117477	chr9:99886322~99906601:-
THCA	cis	rs5753037	0.869	rs5763650	ENSG00000279699.1	RP1-102K2.9	3.54	0.000444	0.0277	0.16	0.16	Type 1 diabetes;	chr22:29968235	chr22:30275215~30276951:-
THCA	cis	rs6768930	0.901	rs7609911	ENSG00000272202.1	RP11-157F20.3	3.54	0.000444	0.0277	0.18	0.16	Obesity-related traits;	chr3:57727633	chr3:57078943~57080101:+
THCA	cis	rs9314614	0.789	rs2951858	ENSG00000245857.2	GS1-24F4.2	-3.54	0.000444	0.0277	-0.21	-0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6856287	chr8:6835554~6885276:+
THCA	cis	rs11190604	0.767	rs10748794	ENSG00000273030.1	RP11-285F16.1	-3.54	0.000444	0.0277	-0.18	-0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100416161	chr10:100412934~100413421:+
THCA	cis	rs9450351	0.744	rs9450313	ENSG00000203875.9	SNHG5	-3.54	0.000444	0.0277	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85684419	chr6:85660950~85678736:-
THCA	cis	rs9353324	1	rs9351066	ENSG00000203875.9	SNHG5	-3.54	0.000444	0.0277	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85689099	chr6:85660950~85678736:-
THCA	cis	rs9394159	1	rs9394159	ENSG00000197251.3	LINC00336	3.54	0.000444	0.0277	0.17	0.16	Graves' disease;	chr6:33650385	chr6:33586106~33593338:-
THCA	cis	rs6500602	0.561	rs62039231	ENSG00000280063.1	RP11-295D4.3	3.54	0.000444	0.0277	0.09	0.16	Schizophrenia;	chr16:4469547	chr16:4346694~4348648:-
THCA	cis	rs10200159	1	rs6705295	ENSG00000272606.1	RP11-554J4.1	3.54	0.000444	0.0277	0.3	0.16	Vitiligo;	chr2:55686874	chr2:55617909~55618373:+
THCA	cis	rs4742903	0.935	rs1507515	ENSG00000270332.1	SMC2-AS1	-3.54	0.000444	0.0277	-0.15	-0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104227372	chr9:104080024~104093073:-
THCA	cis	rs6560517	0.519	rs1057406	ENSG00000234618.1	RPSAP9	-3.54	0.000445	0.0277	-0.19	-0.16	Dialysis-related mortality;	chr9:76503413	chr9:76398699~76399586:+
THCA	cis	rs3770081	1	rs3770089	ENSG00000272564.1	RP11-548P2.2	-3.54	0.000445	0.0277	-0.31	-0.16	Facial emotion recognition (sad faces);	chr2:86036692	chr2:85904279~85904727:+
THCA	cis	rs7520050	0.966	rs12049588	ENSG00000281133.1	AL355480.3	3.54	0.000445	0.0277	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs12021587	ENSG00000281133.1	AL355480.3	3.54	0.000445	0.0277	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45580892~45580996:-
THCA	cis	rs763121	0.815	rs4821799	ENSG00000225450.1	RP3-508I15.14	-3.54	0.000445	0.0277	-0.12	-0.16	Menopause (age at onset);	chr22:38625321	chr22:38739003~38749041:+
THCA	cis	rs4073582	0.595	rs9326370	ENSG00000245156.1	RP11-867G23.3	3.54	0.000445	0.0277	0.13	0.16	Gout;	chr11:66224537	chr11:66269832~66278525:-
THCA	cis	rs11098499	1	rs1011054	ENSG00000250950.1	RP11-33B1.3	3.54	0.000445	0.0277	0.2	0.16	Corneal astigmatism;	chr4:119281232	chr4:119456350~119457277:+
THCA	cis	rs2882667	0.931	rs10077896	ENSG00000249593.5	CTB-46B19.2	3.54	0.000445	0.0277	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:139012647~139051203:+
THCA	cis	rs943466	0.955	rs3763253	ENSG00000274259.2	XXbac-BPG294E21.9	3.54	0.000445	0.0277	0.22	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33804984	chr6:33437363~33454453:-
THCA	cis	rs9450351	0.744	rs6901489	ENSG00000203875.9	SNHG5	-3.54	0.000445	0.0277	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:86066343	chr6:85660950~85678736:-
THCA	cis	rs72827839	0.74	rs72823509	ENSG00000278765.1	RP5-890E16.5	-3.54	0.000445	0.0277	-0.24	-0.16	Ease of getting up in the morning;	chr17:47967223	chr17:48066704~48067293:-
THCA	cis	rs4925114	0.568	rs4925109	ENSG00000281749.1	Y_RNA	-3.54	0.000445	0.0277	-0.2	-0.16	Body mass index;	chr17:17758488	chr17:18001101~18001195:-
THCA	cis	rs7192750	0.586	rs4788447	ENSG00000260886.1	TAT-AS1	3.54	0.000445	0.0277	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71840957	chr16:71565789~71578187:+
THCA	cis	rs3758911	0.894	rs11212162	ENSG00000255353.1	RP11-382M14.1	-3.54	0.000445	0.0277	-0.2	-0.16	Coronary artery disease;	chr11:107327884	chr11:107176286~107177530:+
THCA	cis	rs860295	1	rs822490	ENSG00000236675.1	MTX1P1	-3.54	0.000445	0.0277	-0.16	-0.16	Body mass index;	chr1:155853180	chr1:155230975~155234325:+
THCA	cis	rs7020830	0.931	rs7034554	ENSG00000260100.1	RP11-220I1.5	-3.54	0.000445	0.0277	-0.2	-0.16	Schizophrenia;	chr9:37081304	chr9:37078813~37079776:-
THCA	cis	rs1799922	0.965	rs2402935	ENSG00000271553.1	RP11-274B21.10	-3.54	0.000445	0.0277	-0.14	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128761412	chr7:128667043~128668156:+
THCA	cis	rs1799922	0.965	rs55673058	ENSG00000271553.1	RP11-274B21.10	-3.54	0.000445	0.0277	-0.14	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128762657	chr7:128667043~128668156:+
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000265443.1	CTD-2349P21.6	-3.54	0.000445	0.0277	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30726305~30727564:-
THCA	cis	rs2115630	1	rs55646601	ENSG00000259295.5	CSPG4P12	-3.54	0.000445	0.0277	-0.22	-0.16	P wave terminal force;	chr15:84780337	chr15:85191438~85213905:+
THCA	cis	rs4713118	0.869	rs6922574	ENSG00000216915.2	RP1-97D16.1	-3.54	0.000445	0.0277	-0.24	-0.16	Parkinson's disease;	chr6:27725224	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.869	rs9348775	ENSG00000216915.2	RP1-97D16.1	-3.54	0.000445	0.0277	-0.24	-0.16	Parkinson's disease;	chr6:27727550	chr6:27737000~27738494:-
THCA	cis	rs972578	0.905	rs55682747	ENSG00000230319.1	AL022476.2	3.54	0.000445	0.0277	0.17	0.16	Mean platelet volume;	chr22:42965922	chr22:43038585~43052366:+
THCA	cis	rs7246967	0.611	rs57013651	ENSG00000198153.8	ZNF849P	-3.54	0.000445	0.0277	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22680225	chr19:22685167~22686732:+
THCA	cis	rs6870983	0.749	rs33710	ENSG00000247828.6	TMEM161B-AS1	3.54	0.000445	0.0277	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88213443	chr5:88268895~88436685:+
THCA	cis	rs7246967	0.673	rs4414616	ENSG00000198153.8	ZNF849P	-3.54	0.000445	0.0277	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22649609	chr19:22685167~22686732:+
THCA	cis	rs10911902	0.643	rs7525634	ENSG00000228238.1	GS1-304P7.2	-3.54	0.000445	0.0278	-0.26	-0.16	Schizophrenia;	chr1:186411333	chr1:186578279~186579299:+
THCA	cis	rs4081724	0.565	rs73026209	ENSG00000267130.1	CTD-2540B15.9	3.54	0.000445	0.0278	0.25	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33315704	chr19:33305036~33309387:+
THCA	cis	rs4081724	0.565	rs118046236	ENSG00000267130.1	CTD-2540B15.9	3.54	0.000445	0.0278	0.25	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33316199	chr19:33305036~33309387:+
THCA	cis	rs10191559	0.919	rs7589062	ENSG00000238171.1	AC068196.1	-3.54	0.000445	0.0278	-0.21	-0.16	Red blood cell count;	chr2:180971245	chr2:181076051~181105968:-
THCA	cis	rs1486437	1	rs1486437	ENSG00000261238.1	AC009166.5	-3.54	0.000445	0.0278	-0.27	-0.16	Recurrent major depressive disorder;	chr16:51865949	chr16:51149239~51149819:+
THCA	cis	rs10089	0.953	rs13358455	ENSG00000245937.6	LINC01184	3.54	0.000445	0.0278	0.18	0.16	Ileal carcinoids;	chr5:128030094	chr5:127940426~128083172:-
THCA	cis	rs10089	0.909	rs7732599	ENSG00000245937.6	LINC01184	3.54	0.000445	0.0278	0.18	0.16	Ileal carcinoids;	chr5:128034729	chr5:127940426~128083172:-
THCA	cis	rs7707921	0.671	rs2406911	ENSG00000251374.1	RPS23P5	-3.54	0.000445	0.0278	-0.21	-0.16	Breast cancer;	chr5:82016437	chr5:82265157~82265259:-
THCA	cis	rs4703129	1	rs1550809	ENSG00000246763.5	RGMB-AS1	-3.54	0.000445	0.0278	-0.16	-0.16	Asperger disorder;	chr5:98556811	chr5:98769618~98773469:-
THCA	cis	rs804280	0.662	rs11784764	ENSG00000254527.1	ENPP7P12	-3.54	0.000445	0.0278	-0.23	-0.16	Myopia (pathological);	chr8:11753365	chr8:12205759~12206389:-
THCA	cis	rs7216064	0.953	rs2086744	ENSG00000265055.1	AC145343.2	3.54	0.000445	0.0278	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853159	chr17:68096046~68101474:-
THCA	cis	rs7131987	0.565	rs6487797	ENSG00000257176.2	RP11-996F15.2	3.54	0.000445	0.0278	0.16	0.16	QT interval;	chr12:29270063	chr12:29280418~29317848:-
THCA	cis	rs10911902	0.643	rs10494584	ENSG00000233196.2	GS1-304P7.1	-3.54	0.000445	0.0278	-0.26	-0.16	Schizophrenia;	chr1:186321389	chr1:186580515~186581191:-
THCA	cis	rs2290416	0.681	rs3793371	ENSG00000254973.1	RP11-429J17.7	3.54	0.000445	0.0278	0.31	0.16	Attention deficit hyperactivity disorder;	chr8:143582129	chr8:143758153~143771822:-
THCA	cis	rs42648	0.837	rs3761804	ENSG00000225498.1	AC002064.5	3.54	0.000445	0.0278	0.16	0.16	Homocysteine levels;	chr7:90286024	chr7:90312496~90322592:+
THCA	cis	rs6715284	0.786	rs13418478	ENSG00000183308.6	AC005037.3	3.54	0.000445	0.0278	0.32	0.16	Rheumatoid arthritis;	chr2:201279041	chr2:200963263~201009102:+
THCA	cis	rs6715284	0.786	rs13393110	ENSG00000183308.6	AC005037.3	3.54	0.000445	0.0278	0.32	0.16	Rheumatoid arthritis;	chr2:201279332	chr2:200963263~201009102:+
THCA	cis	rs1065852	0.526	rs8138080	ENSG00000232710.1	RP4-669P10.16	3.54	0.000446	0.0278	0.2	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42000367	chr22:42136433~42139927:-
THCA	cis	rs6657613	0.658	rs3738814	ENSG00000186715.9	MST1L	3.54	0.000446	0.0278	0.14	0.16	Hip circumference adjusted for BMI;	chr1:17005181	chr1:16754910~16770237:-
THCA	cis	rs7246967	0.673	rs2915932	ENSG00000198153.8	ZNF849P	-3.54	0.000446	0.0278	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22660899	chr19:22685167~22686732:+
THCA	cis	rs7264396	0.635	rs6060681	ENSG00000088340.14	FER1L4	3.54	0.000446	0.0278	0.16	0.16	Total cholesterol levels;	chr20:35918225	chr20:35558737~35607562:-
THCA	cis	rs911555	0.617	rs7156036	ENSG00000269940.1	RP11-73M18.7	-3.54	0.000446	0.0278	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103694560~103695170:+
THCA	cis	rs911555	0.723	rs6575991	ENSG00000269940.1	RP11-73M18.7	-3.54	0.000446	0.0278	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103694560~103695170:+
THCA	cis	rs6546886	0.956	rs10168249	ENSG00000235499.1	AC073046.25	3.54	0.000446	0.0278	0.15	0.16	Dialysis-related mortality;	chr2:74016326	chr2:73985132~73986343:+
THCA	cis	rs4660456	0.913	rs2744808	ENSG00000238287.1	RP11-656D10.3	-3.54	0.000446	0.0278	-0.2	-0.16	Platelet count;	chr1:40712271	chr1:40493157~40508661:-
THCA	cis	rs721048	0.598	rs10169579	ENSG00000242412.1	DBIL5P2	-3.54	0.000446	0.0278	-0.22	-0.16	Prostate cancer;	chr2:63231246	chr2:63117851~63119542:-
THCA	cis	rs494526	0.767	rs2901172	ENSG00000229272.1	RP11-498J9.2	-3.54	0.000446	0.0278	-0.18	-0.16	Alcoholic chronic pancreatitis;	chr10:119092076	chr10:119003536~119003884:-
THCA	cis	rs524281	0.954	rs549187	ENSG00000255120.4	OVOL1-AS1	-3.54	0.000446	0.0278	-0.22	-0.16	Electroencephalogram traits;	chr11:66131160	chr11:65789051~65790868:-
THCA	cis	rs11673344	0.665	rs74435359	ENSG00000267260.1	CTD-2162K18.4	-3.54	0.000446	0.0278	-0.22	-0.16	Obesity-related traits;	chr19:36955252	chr19:36773153~36777078:+
THCA	cis	rs860295	0.651	rs6677385	ENSG00000236675.1	MTX1P1	-3.54	0.000446	0.0278	-0.16	-0.16	Body mass index;	chr1:155334790	chr1:155230975~155234325:+
THCA	cis	rs7824557	0.583	rs2263511	ENSG00000227888.4	FAM66A	-3.54	0.000446	0.0278	-0.2	-0.16	Retinal vascular caliber;	chr8:11375809	chr8:12362019~12388296:+
THCA	cis	rs7709377	0.723	rs12515182	ENSG00000250015.1	CTC-339F2.2	3.54	0.000446	0.0278	0.17	0.16	Metabolite levels  (X-11787);	chr5:116114296	chr5:116302354~116304134:-
THCA	cis	rs7709377	0.723	rs12515280	ENSG00000250015.1	CTC-339F2.2	3.54	0.000446	0.0278	0.17	0.16	Metabolite levels  (X-11787);	chr5:116114604	chr5:116302354~116304134:-
THCA	cis	rs7709377	0.723	rs1876672	ENSG00000250015.1	CTC-339F2.2	3.54	0.000446	0.0278	0.17	0.16	Metabolite levels  (X-11787);	chr5:116114960	chr5:116302354~116304134:-
THCA	cis	rs9863	0.861	rs7961449	ENSG00000270028.1	RP11-380L11.4	-3.54	0.000446	0.0278	-0.17	-0.16	White blood cell count;	chr12:123952668	chr12:123925461~123926083:-
THCA	cis	rs875971	0.545	rs75577046	ENSG00000273024.4	INTS4P2	-3.54	0.000446	0.0278	-0.2	-0.16	Aortic root size;	chr7:66493729	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000273024.4	INTS4P2	-3.54	0.000446	0.0278	-0.2	-0.16	Aortic root size;	chr7:66505541	chr7:65647864~65715661:+
THCA	cis	rs240993	0.595	rs3777910	ENSG00000272356.1	RP5-1112D6.8	3.54	0.000446	0.0278	0.14	0.16	Inflammatory skin disease;Psoriasis;	chr6:111581248	chr6:111309203~111313517:+
THCA	cis	rs862034	0.902	rs862052	ENSG00000270000.1	RP3-449M8.9	3.54	0.000446	0.0278	0.16	0.16	Height;	chr14:74514113	chr14:74471930~74472360:-
THCA	cis	rs8192917	0.573	rs60113952	ENSG00000258744.1	RP11-80A15.1	-3.54	0.000446	0.0278	-0.26	-0.16	Vitiligo;	chr14:24649530	chr14:24501594~24508688:+
THCA	cis	rs453301	0.657	rs36056437	ENSG00000253981.4	ALG1L13P	-3.54	0.000446	0.0278	-0.16	-0.16	Joint mobility (Beighton score);	chr8:8935355	chr8:8236003~8244667:-
THCA	cis	rs17685	0.672	rs55807301	ENSG00000227038.2	AC005077.12	3.54	0.000446	0.0278	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76178083	chr7:76090431~76108779:-
THCA	cis	rs6840360	1	rs4696283	ENSG00000270265.1	RP11-731D1.4	-3.54	0.000446	0.0278	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151659364	chr4:151333775~151353224:-
THCA	cis	rs1550115	0.57	rs6545730	ENSG00000224165.4	DNAJC27-AS1	3.54	0.000446	0.0278	0.12	0.16	Coronary artery disease;	chr2:24792205	chr2:24971390~25039694:+
THCA	cis	rs1113500	0.965	rs10881495	ENSG00000230489.1	VAV3-AS1	-3.54	0.000446	0.0278	-0.15	-0.16	Growth-regulated protein alpha levels;	chr1:108068364	chr1:107964443~107994607:+
THCA	cis	rs1113500	0.966	rs11185249	ENSG00000230489.1	VAV3-AS1	-3.54	0.000446	0.0278	-0.15	-0.16	Growth-regulated protein alpha levels;	chr1:108069024	chr1:107964443~107994607:+
THCA	cis	rs12476592	0.602	rs262487	ENSG00000242412.1	DBIL5P2	-3.54	0.000446	0.0278	-0.21	-0.16	Childhood ear infection;	chr2:63653383	chr2:63117851~63119542:-
THCA	cis	rs1560104	0.665	rs4381587	ENSG00000259876.1	CTD-3037G24.4	3.54	0.000446	0.0278	0.18	0.16	Obesity-related traits;	chr16:12609047	chr16:12556353~12557694:-
THCA	cis	rs11710088	0.74	rs13069729	ENSG00000244503.1	RP11-278L15.6	-3.54	0.000446	0.0278	-0.23	-0.16	QRS duration;	chr3:149473092	chr3:149494660~149495995:+
THCA	cis	rs12478296	0.901	rs73007142	ENSG00000220804.7	AC093642.5	3.54	0.000446	0.0278	0.19	0.16	Obesity-related traits;	chr2:242068701	chr2:242088633~242160153:+
THCA	cis	rs2841277	0.708	rs9671643	ENSG00000258701.1	LINC00638	3.54	0.000446	0.0278	0.17	0.16	Rheumatoid arthritis;	chr14:104941693	chr14:104821201~104823718:+
THCA	cis	rs708547	1	rs2412770	ENSG00000269949.1	RP11-738E22.3	3.54	0.000446	0.0278	0.22	0.16	Response to bleomycin (chromatid breaks);	chr4:56928494	chr4:56960927~56961373:-
THCA	cis	rs7809950	0.678	rs2237659	ENSG00000272072.1	CTA-363E19.2	-3.54	0.000446	0.0278	-0.18	-0.16	Coronary artery disease;	chr7:107207047	chr7:107192559~107193300:-
THCA	cis	rs944289	0.745	rs1537427	ENSG00000212071.1	AL162511.1	-3.54	0.000446	0.0278	-0.19	-0.16	Thyroid cancer;	chr14:36117640	chr14:36196480~36196568:-
THCA	cis	rs8014204	0.747	rs2070598	ENSG00000279594.1	RP11-950C14.10	-3.54	0.000446	0.0278	-0.15	-0.16	Caffeine consumption;	chr14:74894203	chr14:75011269~75012851:-
THCA	cis	rs1153858	1	rs7402650	ENSG00000275672.1	GATM-AS1	-3.54	0.000446	0.0278	-0.17	-0.16	Homoarginine levels;	chr15:45409697	chr15:45378700~45380123:+
THCA	cis	rs394563	1	rs394563	ENSG00000268592.3	RAET1E-AS1	3.54	0.000446	0.0278	0.21	0.16	Dupuytren's disease;	chr6:149475878	chr6:149863494~149919507:+
THCA	cis	rs78487399	0.731	rs13408697	ENSG00000234936.1	AC010883.5	3.54	0.000446	0.0278	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43479105	chr2:43229573~43233394:+
THCA	cis	rs145729347	1	rs145729347	ENSG00000255250.1	CTD-2005H7.2	3.54	0.000446	0.0278	0.27	0.16	Lung function (FEV1);	chr11:86731691	chr11:86727355~86765265:+
THCA	cis	rs5770917	1	rs5770917	ENSG00000279182.1	XX-C00717C00720L.1	3.54	0.000446	0.0278	0.26	0.16	Narcolepsy;	chr22:50578924	chr22:50316035~50317025:+
THCA	cis	rs28643277	0.671	rs10796306	ENSG00000237470.3	DCLRE1CP1	3.54	0.000446	0.0278	0.21	0.16	Periodontitis (CDC/AAP);	chr10:15506087	chr10:15015370~15021863:-
THCA	cis	rs67478160	0.643	rs12434686	ENSG00000258534.1	CTD-2134A5.4	3.54	0.000447	0.0278	0.16	0.16	Schizophrenia;	chr14:103849696	chr14:103854366~103880111:-
THCA	cis	rs11583043	0.668	rs6681915	ENSG00000233184.5	RP11-421L21.3	3.54	0.000447	0.0278	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101092965	chr1:101025878~101087268:+
THCA	cis	rs7737355	0.947	rs6596007	ENSG00000237714.1	P4HA2-AS1	-3.54	0.000447	0.0278	-0.23	-0.16	Life satisfaction;	chr5:131252857	chr5:132184876~132192808:+
THCA	cis	rs6957923	1	rs4304239	ENSG00000234286.1	AC006026.13	-3.54	0.000447	0.0278	-0.21	-0.16	Height;	chr7:23456342	chr7:23680195~23680786:-
THCA	cis	rs6957923	0.967	rs34677598	ENSG00000234286.1	AC006026.13	-3.54	0.000447	0.0278	-0.21	-0.16	Height;	chr7:23460008	chr7:23680195~23680786:-
THCA	cis	rs9911578	0.967	rs4598970	ENSG00000224738.1	AC099850.1	-3.54	0.000447	0.0278	-0.19	-0.16	Intelligence (multi-trait analysis);	chr17:58999532	chr17:59106598~59118267:+
THCA	cis	rs683257	0.866	rs118084505	ENSG00000234147.1	RP3-460G2.2	-3.54	0.000447	0.0278	-0.26	-0.16	Facial emotion recognition (angry faces);	chr6:140703974	chr6:140845958~140852924:-
THCA	cis	rs7474896	0.537	rs2749588	ENSG00000272983.1	RP11-508N22.12	-3.54	0.000447	0.0278	-0.16	-0.16	Obesity (extreme);	chr10:37980529	chr10:38137337~38144399:+
THCA	cis	rs7522061	0.546	rs6427392	ENSG00000236731.1	RP4-801G22.2	3.54	0.000447	0.0278	0.16	0.16	Blood protein levels;	chr1:157670373	chr1:157629939~157630728:-
THCA	cis	rs3176789	1	rs3176789	ENSG00000256673.1	RP11-599J14.2	3.54	0.000447	0.0278	0.22	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9760134	chr12:9398355~9414851:-
THCA	cis	rs4664293	0.867	rs34392518	ENSG00000230783.1	AC009961.2	-3.54	0.000447	0.0278	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159749367	chr2:159689217~159690291:-
THCA	cis	rs713587	0.935	rs11676272	ENSG00000224165.4	DNAJC27-AS1	-3.54	0.000447	0.0278	-0.09	-0.16	Body mass index in non-asthmatics;	chr2:24918669	chr2:24971390~25039694:+
THCA	cis	rs1958560	1	rs1958560	ENSG00000276116.2	FUT8-AS1	3.54	0.000447	0.0278	0.17	0.16	Menarche (age at onset);	chr14:65570077	chr14:65411170~65412690:-
THCA	cis	rs10863936	0.667	rs66858610	ENSG00000198468.6	FLVCR1-AS1	-3.54	0.000447	0.0278	-0.19	-0.16	Height;	chr1:212051419	chr1:212852108~212858088:-
THCA	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	3.54	0.000447	0.0278	0.18	0.16	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
THCA	cis	rs2625529	0.73	rs2957373	ENSG00000260037.4	CTD-2524L6.3	3.54	0.000447	0.0278	0.21	0.16	Red blood cell count;	chr15:72048588	chr15:71818396~71823384:+
THCA	cis	rs7404843	0.925	rs72774861	ENSG00000188599.16	NPIPP1	3.54	0.000447	0.0279	0.18	0.16	Testicular germ cell tumor;	chr16:15415777	chr16:15104312~15123498:-
THCA	cis	rs9488822	0.676	rs13210143	ENSG00000237021.2	RP3-486I3.7	3.54	0.000447	0.0279	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116068473	chr6:116254207~116256743:+
THCA	cis	rs7746199	0.668	rs7749305	ENSG00000272009.1	RP1-313I6.12	-3.54	0.000447	0.0279	-0.27	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28078792~28081130:-
THCA	cis	rs1472360	0.505	rs1496526	ENSG00000253549.4	RP11-317J10.2	3.54	0.000447	0.0279	0.18	0.16	Mean corpuscular hemoglobin concentration;	chr8:85361670	chr8:85441851~85464915:-
THCA	cis	rs758324	0.628	rs75624804	ENSG00000224431.1	AC063976.7	-3.54	0.000447	0.0279	-0.23	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:132157682	chr5:132199456~132203487:+
THCA	cis	rs724818	0.661	rs3804175	ENSG00000251609.2	SETP12	-3.54	0.000447	0.0279	-0.34	-0.16	Monobrow thickness;	chr4:120798863	chr4:120895494~120897083:-
THCA	cis	rs9410380	0.967	rs1779317	ENSG00000225385.3	RP11-350E12.4	3.54	0.000447	0.0279	0.16	0.16	Monocyte count;	chr9:88837506	chr9:88066915~88068037:+
THCA	cis	rs2446066	0.872	rs57676448	ENSG00000257379.1	RP11-793H13.8	3.54	0.000447	0.0279	0.24	0.16	Red blood cell count;	chr12:53401003	chr12:53441741~53467528:+
THCA	cis	rs1667255	1	rs1791197	ENSG00000266521.1	RP11-650P15.1	3.54	0.000447	0.0279	0.21	0.16	Retinol levels;	chr18:31609494	chr18:31496645~31497195:-
THCA	cis	rs1154275	0.537	rs6793183	ENSG00000272844.1	RP11-484K9.4	3.54	0.000447	0.0279	0.13	0.16	Takotsubo syndrome;	chr3:112798908	chr3:112990447~112991153:-
THCA	cis	rs9650657	0.524	rs10088408	ENSG00000261451.1	RP11-981G7.1	-3.54	0.000447	0.0279	-0.2	-0.16	Neuroticism;	chr8:10959687	chr8:10433672~10438312:+
THCA	cis	rs8058578	1	rs8058578	ENSG00000260911.2	RP11-196G11.2	3.54	0.000447	0.0279	0.14	0.16	Multiple myeloma;	chr16:30714927	chr16:31043150~31049868:+
THCA	cis	rs1124769	0.748	rs11070834	ENSG00000259378.1	DCAF13P3	3.54	0.000447	0.0279	0.24	0.16	Cognitive performance;	chr15:51087339	chr15:50944663~50945996:+
THCA	cis	rs7919656	0.87	rs2940727	ENSG00000228403.1	RP11-563N6.6	-3.54	0.000447	0.0279	-0.17	-0.16	Clinically amyopathic dermatomyositis;	chr10:48864057	chr10:48878022~48878649:+
THCA	cis	rs6445967	0.506	rs67644593	ENSG00000272360.1	RP11-359I18.5	3.54	0.000447	0.0279	0.2	0.16	Platelet count;	chr3:58483273	chr3:58490830~58491291:-
THCA	cis	rs3776081	0.734	rs3776079	ENSG00000254333.1	CTC-367J11.1	-3.54	0.000447	0.0279	-0.19	-0.16	Blood protein levels;	chr5:150148756	chr5:150475531~150485968:-
THCA	cis	rs9353324	1	rs9353324	ENSG00000203875.9	SNHG5	-3.54	0.000447	0.0279	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85653156	chr6:85660950~85678736:-
THCA	cis	rs8058578	1	rs13338946	ENSG00000260911.2	RP11-196G11.2	3.54	0.000448	0.0279	0.14	0.16	Multiple myeloma;	chr16:30689537	chr16:31043150~31049868:+
THCA	cis	rs10091877	0.505	rs709829	ENSG00000270154.1	RP11-419I17.1	-3.54	0.000448	0.0279	-0.27	-0.16	Lung adenocarcinoma;	chr8:13032868	chr8:12476462~12477122:+
THCA	cis	rs13113518	0.783	rs1586555	ENSG00000223305.1	RN7SKP30	3.54	0.000448	0.0279	0.21	0.16	Height;	chr4:55587104	chr4:55540502~55540835:-
THCA	cis	rs4081724	0.63	rs17529595	ENSG00000267130.1	CTD-2540B15.9	3.54	0.000448	0.0279	0.25	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33315233	chr19:33305036~33309387:+
THCA	cis	rs7819412	0.561	rs2001328	ENSG00000206014.6	OR7E161P	3.54	0.000448	0.0279	0.19	0.16	Triglycerides;	chr8:11129689	chr8:11928597~11929563:-
THCA	cis	rs7142002	0.881	rs8006108	ENSG00000272444.1	RP11-1017G21.6	-3.54	0.000448	0.0279	-0.24	-0.16	Autism;	chr14:101933189	chr14:101952416~101953063:+
THCA	cis	rs12893668	0.628	rs57072546	ENSG00000244691.1	RPL10AP1	-3.54	0.000448	0.0279	-0.22	-0.16	Reticulocyte count;	chr14:103597386	chr14:103412119~103412761:-
THCA	cis	rs2120243	0.874	rs1840680	ENSG00000241770.1	RP11-555M1.3	-3.54	0.000448	0.0279	-0.2	-0.16	Hepatocellular carcinoma in hepatitis B infection;	chr3:157438240	chr3:157163452~157169133:+
THCA	cis	rs854765	0.52	rs9899355	ENSG00000281749.1	Y_RNA	3.54	0.000448	0.0279	0.2	0.16	Total body bone mineral density;	chr17:17994929	chr17:18001101~18001195:-
THCA	cis	rs1729951	0.546	rs835634	ENSG00000239213.4	NCK1-AS1	3.54	0.000448	0.0279	0.14	0.16	Neuroticism;	chr3:136957461	chr3:136841726~136862054:-
THCA	cis	rs10256972	0.758	rs11979275	ENSG00000199023.2	MIR339	-3.54	0.000448	0.0279	-0.17	-0.16	Endometriosis;Longevity;	chr7:1029699	chr7:1022935~1023045:-
THCA	cis	rs10256972	0.758	rs11980081	ENSG00000199023.2	MIR339	-3.54	0.000448	0.0279	-0.17	-0.16	Endometriosis;Longevity;	chr7:1029736	chr7:1022935~1023045:-
THCA	cis	rs7028939	1	rs7858119	ENSG00000255145.2	STX17-AS1	-3.54	0.000448	0.0279	-0.24	-0.16	Preeclampsia;	chr9:100138996	chr9:99886322~99906601:-
THCA	cis	rs2880765	0.835	rs7162502	ENSG00000259407.1	RP11-158M2.3	-3.54	0.000448	0.0279	-0.16	-0.16	Coronary artery disease;	chr15:85501242	chr15:85744109~85750281:-
THCA	cis	rs4851016	0.506	rs2310303	ENSG00000281162.1	LINC01127	-3.54	0.000448	0.0279	-0.14	-0.16	Blood protein levels;	chr2:102487420	chr2:101962056~101987167:+
THCA	cis	rs7829975	0.564	rs2921057	ENSG00000233609.3	RP11-62H7.2	3.54	0.000448	0.0279	0.16	0.16	Mood instability;	chr8:8461157	chr8:8961200~8979025:+
THCA	cis	rs80130819	0.636	rs2634690	ENSG00000226413.2	OR8T1P	3.54	0.000448	0.0279	0.24	0.16	Prostate cancer;	chr12:48318855	chr12:48442030~48442947:-
THCA	cis	rs1669338	0.51	rs3804788	ENSG00000271870.1	RP11-97C16.1	3.54	0.000448	0.0279	0.15	0.16	White matter integrity;	chr3:3127782	chr3:3152942~3153435:+
THCA	cis	rs853679	0.657	rs1778483	ENSG00000220721.1	OR1F12	3.54	0.000448	0.0279	0.19	0.16	Depression;	chr6:28273214	chr6:28073316~28074233:+
THCA	cis	rs853679	0.657	rs1778482	ENSG00000220721.1	OR1F12	3.54	0.000448	0.0279	0.19	0.16	Depression;	chr6:28273215	chr6:28073316~28074233:+
THCA	cis	rs643506	0.845	rs607327	ENSG00000230911.1	PPIHP1	-3.54	0.000448	0.0279	-0.22	-0.16	Breast cancer;	chr11:111824985	chr11:112029858~112030367:-
THCA	cis	rs722599	0.683	rs7145246	ENSG00000279594.1	RP11-950C14.10	-3.54	0.000448	0.0279	-0.16	-0.16	IgG glycosylation;	chr14:74775691	chr14:75011269~75012851:-
THCA	cis	rs12520053	1	rs12520537	ENSG00000248734.2	CTD-2260A17.1	3.54	0.000448	0.0279	0.22	0.16	Blood protein levels;	chr5:96828202	chr5:96784777~96785999:+
THCA	cis	rs4150642	1	rs4150642	ENSG00000256464.1	YWHABP2	-3.54	0.000448	0.0279	-0.25	-0.16	Amyloid A serum levels;	chr11:18349351	chr11:18490243~18490955:-
THCA	cis	rs35791980	0.607	rs4729343	ENSG00000273341.1	RP5-899E9.1	-3.54	0.000448	0.0279	-0.17	-0.16	Pursuit maintenance gain;	chr7:77349590	chr7:77416673~77425443:+
THCA	cis	rs2880765	0.566	rs55899824	ENSG00000259407.1	RP11-158M2.3	-3.54	0.000448	0.0279	-0.18	-0.16	Coronary artery disease;	chr15:85460860	chr15:85744109~85750281:-
THCA	cis	rs732716	0.853	rs1127888	ENSG00000280239.1	CTB-50L17.8	-3.54	0.000448	0.0279	-0.13	-0.16	Mean corpuscular volume;	chr19:4454086	chr19:4448810~4450836:+
THCA	cis	rs6938	0.575	rs12902515	ENSG00000260269.4	CTD-2323K18.1	-3.54	0.000448	0.0279	-0.22	-0.16	Breast cancer;	chr15:74868657	chr15:75527150~75601205:-
THCA	cis	rs11158588	0.507	rs76922762	ENSG00000276116.2	FUT8-AS1	-3.54	0.000448	0.0279	-0.18	-0.16	Plateletcrit;	chr14:65270862	chr14:65411170~65412690:-
THCA	cis	rs875971	0.83	rs427575	ENSG00000230189.5	GS1-124K5.2	3.53	0.000448	0.0279	0.11	0.16	Aortic root size;	chr7:66054232	chr7:66409143~66490059:-
THCA	cis	rs9818758	0.607	rs113186424	ENSG00000229759.1	MRPS18AP1	-3.53	0.000448	0.0279	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49235293	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs34784192	ENSG00000229759.1	MRPS18AP1	-3.53	0.000448	0.0279	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49237390	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs9850917	ENSG00000229759.1	MRPS18AP1	-3.53	0.000448	0.0279	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49249550	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs9847839	ENSG00000229759.1	MRPS18AP1	-3.53	0.000448	0.0279	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49251570	chr3:48256350~48256938:-
THCA	cis	rs11992162	0.55	rs61426048	ENSG00000227888.4	FAM66A	-3.53	0.000448	0.0279	-0.21	-0.16	Monocyte count;	chr8:11927447	chr8:12362019~12388296:+
THCA	cis	rs9905704	0.918	rs304282	ENSG00000224738.1	AC099850.1	3.53	0.000448	0.0279	0.22	0.16	Testicular germ cell tumor;	chr17:58708210	chr17:59106598~59118267:+
THCA	cis	rs775227	0.574	rs13064411	ENSG00000243849.1	CFAP44-AS1	3.53	0.000448	0.0279	0.3	0.16	Dental caries;	chr3:113327793	chr3:113403991~113433992:+
THCA	cis	rs7432375	0.61	rs56163507	ENSG00000273486.1	RP11-731C17.2	3.53	0.000448	0.0279	0.13	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136797214	chr3:136837338~136839021:-
THCA	cis	rs4915077	0.773	rs17019823	ENSG00000230489.1	VAV3-AS1	3.53	0.000448	0.0279	0.27	0.16	Hypothyroidism;	chr1:107727331	chr1:107964443~107994607:+
THCA	cis	rs45544231	1	rs7192828	ENSG00000279344.1	RP11-44F14.7	3.53	0.000449	0.0279	0.15	0.16	Restless legs syndrome;	chr16:52594581	chr16:53478957~53481550:-
THCA	cis	rs78487399	0.808	rs7570242	ENSG00000234936.1	AC010883.5	3.53	0.000449	0.0279	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43478863	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs13395290	ENSG00000234936.1	AC010883.5	3.53	0.000449	0.0279	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43479180	chr2:43229573~43233394:+
THCA	cis	rs862034	0.902	rs862050	ENSG00000270000.1	RP3-449M8.9	-3.53	0.000449	0.0279	-0.16	-0.16	Height;	chr14:74514845	chr14:74471930~74472360:-
THCA	cis	rs12506899	0.903	rs13136437	ENSG00000221639.1	SNORA3	3.53	0.000449	0.0279	0.19	0.16	Tumor biomarkers;	chr4:73293245	chr4:73263960~73264084:+
THCA	cis	rs7824557	0.583	rs2263512	ENSG00000227888.4	FAM66A	-3.53	0.000449	0.0279	-0.2	-0.16	Retinal vascular caliber;	chr8:11375910	chr8:12362019~12388296:+
THCA	cis	rs7824557	0.583	rs6601585	ENSG00000227888.4	FAM66A	-3.53	0.000449	0.0279	-0.2	-0.16	Retinal vascular caliber;	chr8:11376150	chr8:12362019~12388296:+
THCA	cis	rs4568518	0.71	rs6955337	ENSG00000279048.1	RP11-511H23.2	-3.53	0.000449	0.0279	-0.1	-0.16	Measles;	chr7:17974951	chr7:17940503~17942922:+
THCA	cis	rs9595908	0.746	rs9596075	ENSG00000212293.1	SNORA16	3.53	0.000449	0.0279	0.19	0.16	Body mass index;	chr13:32692147	chr13:32420390~32420516:-
THCA	cis	rs1971762	0.583	rs12319789	ENSG00000270175.1	RP11-793H13.11	-3.53	0.000449	0.0279	-0.11	-0.16	Height;	chr12:53696666	chr12:53500162~53500936:-
THCA	cis	rs250518	0.926	rs34749191	ENSG00000251467.1	CTC-250P20.2	3.53	0.000449	0.0279	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72749431	chr5:72996920~72997642:+
THCA	cis	rs1371614	0.632	rs3769134	ENSG00000229122.1	AGBL5-IT1	3.53	0.000449	0.0279	0.12	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928023	chr2:27061038~27061815:+
THCA	cis	rs6479901	0.841	rs10995453	ENSG00000272767.1	JMJD1C-AS1	-3.53	0.000449	0.0279	-0.2	-0.16	Intelligence (multi-trait analysis);	chr10:63174571	chr10:63465229~63466563:+
THCA	cis	rs1953600	0.668	rs751740	ENSG00000242600.5	MBL1P	3.53	0.000449	0.0279	0.13	0.16	Sarcoidosis;	chr10:80152423	chr10:79904898~79950336:+
THCA	cis	rs11175834	0.655	rs11175839	ENSG00000255866.1	RP11-221N13.2	3.53	0.000449	0.0279	0.3	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65613113	chr12:65559591~65560889:+
THCA	cis	rs2880765	0.527	rs35184622	ENSG00000259407.1	RP11-158M2.3	-3.53	0.000449	0.0279	-0.19	-0.16	Coronary artery disease;	chr15:85529804	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.527	rs1483578	ENSG00000259407.1	RP11-158M2.3	-3.53	0.000449	0.0279	-0.19	-0.16	Coronary artery disease;	chr15:85532186	chr15:85744109~85750281:-
THCA	cis	rs67478160	0.643	rs6576005	ENSG00000258534.1	CTD-2134A5.4	-3.53	0.000449	0.0279	-0.16	-0.16	Schizophrenia;	chr14:103826032	chr14:103854366~103880111:-
THCA	cis	rs786425	0.771	rs7135624	ENSG00000270095.1	RP11-214K3.18	-3.53	0.000449	0.0279	-0.19	-0.16	Pubertal anthropometrics;	chr12:123663284	chr12:123971457~123971714:-
THCA	cis	rs4218	0.689	rs12902628	ENSG00000277144.1	RP11-59H7.4	-3.53	0.000449	0.0279	-0.23	-0.16	Social communication problems;	chr15:59100193	chr15:59115547~59116089:-
THCA	cis	rs4742903	0.935	rs9775540	ENSG00000270332.1	SMC2-AS1	3.53	0.000449	0.0279	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104215441	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.74	rs4596709	ENSG00000270332.1	SMC2-AS1	3.53	0.000449	0.0279	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104216475	chr9:104080024~104093073:-
THCA	cis	rs3864663	1	rs3864663	ENSG00000254266.4	RP11-594N15.2	3.53	0.000449	0.028	0.29	0.16	Sudden cardiac arrest;	chr8:77768114	chr8:78426103~78558503:-
THCA	cis	rs911555	0.755	rs11620897	ENSG00000269940.1	RP11-73M18.7	3.53	0.000449	0.028	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103694560~103695170:+
THCA	cis	rs80130819	0.748	rs2732446	ENSG00000226413.2	OR8T1P	3.53	0.000449	0.028	0.24	0.16	Prostate cancer;	chr12:48296394	chr12:48442030~48442947:-
THCA	cis	rs80130819	0.748	rs2258342	ENSG00000226413.2	OR8T1P	3.53	0.000449	0.028	0.24	0.16	Prostate cancer;	chr12:48296580	chr12:48442030~48442947:-
THCA	cis	rs34526934	0.619	rs17336374	ENSG00000279205.1	RP11-632P5.1	3.53	0.000449	0.028	0.24	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176203910	chr2:176822030~176823653:+
THCA	cis	rs763121	0.925	rs1056661	ENSG00000225450.1	RP3-508I15.14	-3.53	0.000449	0.028	-0.12	-0.16	Menopause (age at onset);	chr22:38684240	chr22:38739003~38749041:+
THCA	cis	rs198846	0.542	rs198839	ENSG00000272462.2	U91328.19	-3.53	0.000449	0.028	-0.14	-0.16	Mean corpuscular volume;Mean corpuscular hemoglobin concentration;Hemoglobin levels;Hemoglobin;Glycated hemoglobin levels;Blood pressure;	chr6:26112392	chr6:25992662~26001775:+
THCA	cis	rs9309473	0.95	rs10169213	ENSG00000273245.1	RP11-434P11.2	3.53	0.000449	0.028	0.22	0.16	Metabolite levels;	chr2:73560107	chr2:73750256~73750786:-
THCA	cis	rs2991971	0.933	rs666720	ENSG00000234329.1	RP11-767N6.2	-3.53	0.000449	0.028	-0.15	-0.16	High light scatter reticulocyte count;	chr1:45555123	chr1:45651039~45651826:-
THCA	cis	rs11671005	0.568	rs55987239	ENSG00000267858.4	MZF1-AS1	-3.53	0.000449	0.028	-0.12	-0.16	Mean platelet volume;	chr19:58573678	chr19:58559129~58574797:+
THCA	cis	rs3808502	0.549	rs11991139	ENSG00000255046.1	RP11-297N6.4	3.53	0.000449	0.028	0.17	0.16	Neuroticism;	chr8:11570886	chr8:11797928~11802568:-
THCA	cis	rs791590	0.752	rs3118475	ENSG00000225948.2	RP11-554I8.1	3.53	0.000449	0.028	0.24	0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6065302	chr10:6618716~6625346:+
THCA	cis	rs9532669	0.926	rs8002809	ENSG00000229473.2	RGS17P1	3.53	0.000449	0.028	0.21	0.16	Cervical cancer;	chr13:40872769	chr13:40992779~40993331:-
THCA	cis	rs9532669	0.929	rs7982421	ENSG00000229473.2	RGS17P1	3.53	0.000449	0.028	0.21	0.16	Cervical cancer;	chr13:40872776	chr13:40992779~40993331:-
THCA	cis	rs853679	1	rs6905391	ENSG00000261839.1	RP1-265C24.8	3.53	0.000449	0.028	0.22	0.16	Depression;	chr6:28294909	chr6:28136849~28139678:+
THCA	cis	rs12286929	0.639	rs10891802	ENSG00000255580.1	AP000462.2	3.53	0.000449	0.028	0.15	0.16	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;	chr11:115173168	chr11:115363629~115377931:+
THCA	cis	rs9316337	0.836	rs9580111	ENSG00000236953.1	ZDHHC20-IT1	-3.53	0.000449	0.028	-0.17	-0.16	Schizophrenia;	chr13:21418599	chr13:21376977~21377874:-
THCA	cis	rs3808502	0.509	rs2729940	ENSG00000206014.6	OR7E161P	-3.53	0.000449	0.028	-0.18	-0.16	Neuroticism;	chr8:11524858	chr8:11928597~11929563:-
THCA	cis	rs4356203	0.525	rs111416579	ENSG00000272034.1	SNORD14A	-3.53	0.000449	0.028	-0.16	-0.16	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17227461	chr11:17074654~17074744:-
THCA	cis	rs4845570	1	rs4845570	ENSG00000268288.1	RP11-98D18.16	3.53	0.000449	0.028	0.23	0.16	Coronary artery disease;	chr1:151786628	chr1:151766486~151767000:-
THCA	cis	rs9948	0.881	rs7608621	ENSG00000230606.9	AC159540.1	3.53	0.000449	0.028	0.22	0.16	Erectile dysfunction and prostate cancer treatment;	chr2:96818046	chr2:97416165~97433527:-
THCA	cis	rs11640533	0.901	rs2908790	ENSG00000279344.1	RP11-44F14.7	3.53	0.000449	0.028	0.16	0.16	Intelligence (multi-trait analysis);	chr16:53378249	chr16:53478957~53481550:-
THCA	cis	rs728616	0.558	rs35698456	ENSG00000242600.5	MBL1P	3.53	0.000449	0.028	0.19	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80381806	chr10:79904898~79950336:+
THCA	cis	rs2832191	0.967	rs2832216	ENSG00000232855.5	AF131217.1	-3.53	0.00045	0.028	-0.17	-0.16	Dental caries;	chr21:29149600	chr21:28439346~28674848:-
THCA	cis	rs67340775	0.541	rs200965	ENSG00000272009.1	RP1-313I6.12	-3.53	0.00045	0.028	-0.21	-0.16	Lung cancer in ever smokers;	chr6:27898606	chr6:28078792~28081130:-
THCA	cis	rs7737355	0.853	rs11745955	ENSG00000224431.1	AC063976.7	3.53	0.00045	0.028	0.15	0.16	Life satisfaction;	chr5:131269450	chr5:132199456~132203487:+
THCA	cis	rs273909	0.686	rs77335401	ENSG00000263597.1	MIR3936	-3.53	0.00045	0.028	-0.27	-0.16	Coronary artery disease;	chr5:132424133	chr5:132365490~132365599:-
THCA	cis	rs1654345	0.813	rs1630393	ENSG00000275132.1	Metazoa_SRP	-3.53	0.00045	0.028	-0.18	-0.16	Life satisfaction;Subjective well-being;	chr19:38063417	chr19:38200234~38200532:+
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000281021.1	RP1-12G14.9	-3.53	0.00045	0.028	-0.17	-0.16	Lung cancer;	chr6:149658764	chr6:149576089~149590864:-
THCA	cis	rs2692947	0.77	rs2579552	ENSG00000232931.4	LINC00342	3.53	0.00045	0.028	0.13	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96071335	chr2:95807118~95816215:-
THCA	cis	rs2880765	0.835	rs12708553	ENSG00000218052.5	ADAMTS7P4	3.53	0.00045	0.028	0.18	0.16	Coronary artery disease;	chr15:85503602	chr15:85255369~85330334:-
THCA	cis	rs3095008	0.603	rs2190434	ENSG00000243004.4	AC005062.2	3.53	0.00045	0.028	0.16	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);	chr7:20212410	chr7:19918981~20140453:-
THCA	cis	rs9296092	0.538	rs62405941	ENSG00000272217.1	XXbac-BPG157A10.21	3.53	0.00045	0.028	0.18	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33549520	chr6:33246075~33246856:-
THCA	cis	rs5758511	0.68	rs1107553	ENSG00000182057.4	OGFRP1	-3.53	0.00045	0.028	-0.22	-0.16	Birth weight;	chr22:42271467	chr22:42269753~42275196:+
THCA	cis	rs9902453	0.74	rs2628189	ENSG00000214719.10	AC005562.1	-3.53	0.00045	0.028	-0.15	-0.16	Coffee consumption (cups per day);	chr17:29761795	chr17:30576464~30672789:+
THCA	cis	rs9902453	0.765	rs2729448	ENSG00000214719.10	AC005562.1	-3.53	0.00045	0.028	-0.15	-0.16	Coffee consumption (cups per day);	chr17:29764935	chr17:30576464~30672789:+
THCA	cis	rs7777677	0.925	rs4726544	ENSG00000226660.2	TRBV2	3.53	0.00045	0.028	0.14	0.16	Alcoholic chronic pancreatitis;	chr7:142659616	chr7:142300924~142301432:+
THCA	cis	rs6491750	0.557	rs16962578	ENSG00000276957.1	RP11-29B2.6	-3.53	0.00045	0.028	-0.27	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103511399	chr13:102593338~102593873:-
THCA	cis	rs348196	0.672	rs670876	ENSG00000203761.5	MSTO2P	-3.53	0.00045	0.028	-0.13	-0.16	Breast cancer;	chr1:155701887	chr1:155745829~155750137:+
THCA	cis	rs17507216	0.718	rs17158403	ENSG00000255769.6	GOLGA2P10	-3.53	0.00045	0.028	-0.24	-0.16	Excessive daytime sleepiness;	chr15:82572478	chr15:82472993~82513950:-
THCA	cis	rs6921919	0.789	rs6912584	ENSG00000273712.1	RP5-874C20.7	3.53	0.00045	0.028	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28315613~28315883:-
THCA	cis	rs948562	0.523	rs12362065	ENSG00000280010.1	AP001350.4	3.53	0.00045	0.028	0.26	0.16	Lymphoma;	chr11:58287727	chr11:58627435~58628528:+
THCA	cis	rs7819412	0.775	rs4841490	ENSG00000254839.1	AF131215.6	3.53	0.00045	0.028	0.16	0.16	Triglycerides;	chr8:11079381	chr8:11062647~11067089:-
THCA	cis	rs62621207	0.541	rs41444045	ENSG00000272572.1	RP11-179B2.2	3.53	0.00045	0.028	0.26	0.16	Lung cancer;	chr10:100985749	chr10:100911103~100912739:-
THCA	cis	rs2305707	0.611	rs2445753	ENSG00000273674.3	CTD-2378E12.1	3.53	0.00045	0.028	0.34	0.16	Height;	chr15:51284346	chr15:50839875~50908599:-
THCA	cis	rs5752326	0.51	rs5752336	ENSG00000261188.1	CTA-445C9.14	3.53	0.00045	0.028	0.15	0.16	Ischemic stroke;	chr22:26497946	chr22:26512537~26514568:+
THCA	cis	rs5752326	0.51	rs2187956	ENSG00000261188.1	CTA-445C9.14	3.53	0.00045	0.028	0.15	0.16	Ischemic stroke;	chr22:26499019	chr22:26512537~26514568:+
THCA	cis	rs683250	0.599	rs12789325	ENSG00000254551.1	RP11-727A23.7	-3.53	0.00045	0.028	-0.19	-0.16	Subcortical brain region volumes;	chr11:83366880	chr11:83209431~83213379:-
THCA	cis	rs8023401	0.507	rs626492	ENSG00000259705.1	RP11-227D13.1	3.53	0.00045	0.028	0.19	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48551401	chr15:48645951~48652016:+
THCA	cis	rs7658486	0.661	rs17024223	ENSG00000280219.1	RP11-752L20.3	3.53	0.00045	0.028	0.31	0.16	Immune reponse to smallpox (secreted IL-12p40);	chr4:147967340	chr4:147487971~147496062:+
THCA	cis	rs6494488	0.5	rs8029243	ENSG00000259635.1	AC100830.3	-3.53	0.00045	0.028	-0.37	-0.16	Coronary artery disease;	chr15:64629537	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs7181953	ENSG00000259635.1	AC100830.3	-3.53	0.00045	0.028	-0.37	-0.16	Coronary artery disease;	chr15:64632317	chr15:64701248~64719602:+
THCA	cis	rs875971	0.83	rs427973	ENSG00000230189.5	GS1-124K5.2	3.53	0.00045	0.028	0.11	0.16	Aortic root size;	chr7:66061661	chr7:66409143~66490059:-
THCA	cis	rs73787773	0.644	rs79705195	ENSG00000246859.2	STARD4-AS1	3.53	0.00045	0.028	0.2	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr5:112143132	chr5:111512226~111739726:+
THCA	cis	rs7259376	0.875	rs2116919	ENSG00000269138.1	ZNF209P	3.53	0.00045	0.028	0.16	0.16	Menopause (age at onset);	chr19:22308904	chr19:22463922~22473036:+
THCA	cis	rs301901	0.796	rs62361483	ENSG00000250155.1	CTD-2353F22.1	3.53	0.00045	0.028	0.16	0.16	Height;	chr5:37468413	chr5:36666214~36725195:-
THCA	cis	rs6995541	0.645	rs1544981	ENSG00000248896.2	CTD-2135J3.3	-3.53	0.00045	0.028	-0.24	-0.16	Triglyceride levels;	chr8:10820579	chr8:10729314~10771392:+
THCA	cis	rs4578769	0.765	rs35998712	ENSG00000265939.1	UBE2CP2	-3.53	0.00045	0.028	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22873654	chr18:22900486~22900995:-
THCA	cis	rs67478160	0.643	rs7156697	ENSG00000258534.1	CTD-2134A5.4	-3.53	0.00045	0.028	-0.16	-0.16	Schizophrenia;	chr14:103744799	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.679	rs7156834	ENSG00000258534.1	CTD-2134A5.4	-3.53	0.00045	0.028	-0.16	-0.16	Schizophrenia;	chr14:103744843	chr14:103854366~103880111:-
THCA	cis	rs793571	0.822	rs12443436	ENSG00000245975.2	RP11-30K9.6	3.53	0.00045	0.028	0.19	0.16	Schizophrenia;	chr15:58939022	chr15:58768072~58770974:-
THCA	cis	rs911555	0.692	rs7146215	ENSG00000269940.1	RP11-73M18.7	-3.53	0.00045	0.028	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103694560~103695170:+
THCA	cis	rs9863	0.931	rs11831913	ENSG00000269938.1	RP11-214K3.20	-3.53	0.00045	0.028	-0.19	-0.16	White blood cell count;	chr12:123962351	chr12:123968023~123968579:-
THCA	cis	rs2251188	0.609	rs2249765	ENSG00000198580.7	RP11-611L7.2	-3.53	0.00045	0.028	-0.18	-0.16	Sum basophil neutrophil counts;Neutrophil count;	chr7:6654628	chr7:6673494~6676366:+
THCA	cis	rs3747767	1	rs9352744	ENSG00000233967.5	RP11-250B2.3	-3.53	0.00045	0.028	-0.25	-0.16	Hoarding;	chr6:79507559	chr6:80443344~80465927:+
THCA	cis	rs3105593	0.635	rs3131567	ENSG00000242737.1	RP11-562A8.1	3.53	0.00045	0.028	0.2	0.16	QT interval;	chr15:50465733	chr15:50466738~50467096:+
THCA	cis	rs6963495	0.818	rs6977748	ENSG00000272604.1	RP11-251G23.5	3.53	0.00045	0.028	0.22	0.16	Bipolar disorder (body mass index interaction);	chr7:105527015	chr7:105571083~105573660:+
THCA	cis	rs860295	0.702	rs10796946	ENSG00000236675.1	MTX1P1	-3.53	0.00045	0.028	-0.16	-0.16	Body mass index;	chr1:155459699	chr1:155230975~155234325:+
THCA	cis	rs860295	0.676	rs10908466	ENSG00000236675.1	MTX1P1	-3.53	0.00045	0.028	-0.16	-0.16	Body mass index;	chr1:155459934	chr1:155230975~155234325:+
THCA	cis	rs2823053	0.763	rs73174549	ENSG00000232884.6	AF127936.3	3.53	0.00045	0.028	0.17	0.16	Allergic rhinitis in non-asthmatics;	chr21:15087923	chr21:14746762~14753863:-
THCA	cis	rs208520	0.69	rs7764570	ENSG00000218890.1	NUFIP1P	-3.53	0.00045	0.028	-0.24	-0.16	Exhaled nitric oxide output;	chr6:66117707	chr6:66093431~66094909:-
THCA	cis	rs4869313	0.642	rs2161657	ENSG00000247121.5	CTD-2260A17.2	3.53	0.00045	0.028	0.12	0.16	Pediatric autoimmune diseases;	chr5:96897102	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.55	rs3096168	ENSG00000247121.5	CTD-2260A17.2	3.53	0.00045	0.028	0.12	0.16	Pediatric autoimmune diseases;	chr5:96898508	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs3849750	ENSG00000247121.5	CTD-2260A17.2	3.53	0.00045	0.028	0.12	0.16	Pediatric autoimmune diseases;	chr5:96898874	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.668	rs251342	ENSG00000247121.5	CTD-2260A17.2	3.53	0.00045	0.028	0.12	0.16	Pediatric autoimmune diseases;	chr5:96901139	chr5:96814028~96935809:-
THCA	cis	rs7216064	1	rs1976053	ENSG00000278740.1	RP11-147L13.14	3.53	0.00045	0.028	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836886	chr17:68188547~68189165:+
THCA	cis	rs1864585	0.52	rs73208775	ENSG00000280294.1	RP11-177H2.1	3.53	0.00045	0.028	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10810771	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs57348261	ENSG00000280294.1	RP11-177H2.1	3.53	0.00045	0.028	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10811579	chr8:10856085~10859436:-
THCA	cis	rs2797160	1	rs1418951	ENSG00000226409.1	RP11-735G4.1	-3.53	0.00045	0.028	-0.19	-0.16	Endometrial cancer;	chr6:125675039	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1832980	ENSG00000226409.1	RP11-735G4.1	-3.53	0.00045	0.028	-0.19	-0.16	Endometrial cancer;	chr6:125676298	chr6:125370211~125374324:-
THCA	cis	rs8073060	0.671	rs9894813	ENSG00000255987.1	TOMM20P2	3.53	0.00045	0.028	0.18	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35546829	chr17:35514766~35515186:-
THCA	cis	rs3739034	1	rs34405766	ENSG00000224043.6	CCNT2-AS1	-3.53	0.000451	0.028	-0.2	-0.16	Gut microbiome composition (winter);	chr2:134728619	chr2:134735464~134918710:-
THCA	cis	rs3739034	1	rs34252323	ENSG00000224043.6	CCNT2-AS1	-3.53	0.000451	0.028	-0.2	-0.16	Gut microbiome composition (winter);	chr2:134728732	chr2:134735464~134918710:-
THCA	cis	rs3739034	1	rs35703976	ENSG00000224043.6	CCNT2-AS1	-3.53	0.000451	0.028	-0.2	-0.16	Gut microbiome composition (winter);	chr2:134728780	chr2:134735464~134918710:-
THCA	cis	rs1923539	0.614	rs1923537	ENSG00000244733.5	RP11-506M13.3	3.53	0.000451	0.028	0.17	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935452	chr10:79660891~79677996:+
THCA	cis	rs9990333	0.562	rs73210005	ENSG00000207650.1	MIR570	3.53	0.000451	0.028	0.18	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195699401~195699497:+
THCA	cis	rs10496034	0.541	rs6705193	ENSG00000237887.1	AC092839.1	-3.53	0.000451	0.028	-0.28	-0.16	Refractive astigmatism;	chr2:54688084	chr2:54529343~54529801:+
THCA	cis	rs453301	0.579	rs10096850	ENSG00000253981.4	ALG1L13P	-3.53	0.000451	0.028	-0.17	-0.16	Joint mobility (Beighton score);	chr8:8940712	chr8:8236003~8244667:-
THCA	cis	rs7088591	0.85	rs117491252	ENSG00000276818.1	AC026393.1	3.53	0.000451	0.028	0.32	0.16	Blood pressure;	chr10:57984264	chr10:57095699~57095781:+
THCA	cis	rs12023718	0.588	rs16853133	ENSG00000213057.5	C1orf220	-3.53	0.000451	0.028	-0.16	-0.16	Obesity-related traits;	chr1:178633102	chr1:178542752~178548889:+
THCA	cis	rs786425	0.868	rs786447	ENSG00000278112.1	RP11-972P1.11	-3.53	0.000451	0.028	-0.15	-0.16	Pubertal anthropometrics;	chr12:123585120	chr12:123519390~123519856:-
THCA	cis	rs3198697	0.617	rs11075253	ENSG00000275910.1	RP11-680G24.6	3.53	0.000451	0.0281	0.2	0.16	Triglycerides;	chr16:15054789	chr16:15015828~15016390:-
THCA	cis	rs2885805	0.507	rs1418425	ENSG00000203878.10	CHIAP2	3.53	0.000451	0.0281	0.18	0.16	Cytomegalovirus antibody response;	chr1:110926264	chr1:111280059~111286116:+
THCA	cis	rs10256972	0.758	rs4723649	ENSG00000199023.2	MIR339	-3.53	0.000451	0.0281	-0.17	-0.16	Endometriosis;Longevity;	chr7:1032269	chr7:1022935~1023045:-
THCA	cis	rs4723738	1	rs1019180	ENSG00000227191.5	TRGC2	-3.53	0.000451	0.0281	-0.12	-0.16	Treatment response for severe sepsis;	chr7:38179410	chr7:38239580~38368091:-
THCA	cis	rs875971	0.545	rs2707851	ENSG00000230295.1	RP11-458F8.2	-3.53	0.000451	0.0281	-0.14	-0.16	Aortic root size;	chr7:66624178	chr7:66880708~66882981:+
THCA	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	3.53	0.000451	0.0281	0.19	0.16	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
THCA	cis	rs9863	0.931	rs11057401	ENSG00000269938.1	RP11-214K3.20	-3.53	0.000451	0.0281	-0.19	-0.16	White blood cell count;	chr12:123942759	chr12:123968023~123968579:-
THCA	cis	rs3784262	1	rs12908953	ENSG00000259250.1	RP11-50C13.1	3.53	0.000451	0.0281	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57985614	chr15:58587507~58591676:+
THCA	cis	rs478304	0.593	rs6591188	ENSG00000214659.4	KRT8P26	3.53	0.000451	0.0281	0.15	0.16	Acne (severe);	chr11:65700482	chr11:65726939~65728214:+
THCA	cis	rs7631605	0.845	rs9311149	ENSG00000272334.1	RP11-129K12.1	-3.53	0.000451	0.0281	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36988684	chr3:36973117~36973672:-
THCA	cis	rs10515778	0.948	rs72813995	ENSG00000280834.1	U6	3.53	0.000451	0.0281	0.28	0.16	Inflammatory skin disease;	chr5:159193513	chr5:160072268~160072364:+
THCA	cis	rs10515778	0.948	rs72813999	ENSG00000280834.1	U6	3.53	0.000451	0.0281	0.28	0.16	Inflammatory skin disease;	chr5:159201185	chr5:160072268~160072364:+
THCA	cis	rs10515778	0.948	rs10515777	ENSG00000280834.1	U6	3.53	0.000451	0.0281	0.28	0.16	Inflammatory skin disease;	chr5:159205559	chr5:160072268~160072364:+
THCA	cis	rs7586879	0.575	rs6706316	ENSG00000224165.4	DNAJC27-AS1	-3.53	0.000451	0.0281	-0.09	-0.16	Body mass index;	chr2:24905482	chr2:24971390~25039694:+
THCA	cis	rs12549025	0.838	rs17698981	ENSG00000253390.1	CTC-756D1.2	3.53	0.000451	0.0281	0.28	0.16	Reticulocyte fraction of red cells;	chr8:23538588	chr8:23458601~23484971:+
THCA	cis	rs6691738	0.851	rs3861950	ENSG00000232751.1	RP11-296O14.1	3.53	0.000451	0.0281	0.2	0.16	Asthma;	chr1:173187153	chr1:173351689~173352004:+
THCA	cis	rs6691738	0.851	rs4081545	ENSG00000232751.1	RP11-296O14.1	3.53	0.000451	0.0281	0.2	0.16	Asthma;	chr1:173190377	chr1:173351689~173352004:+
THCA	cis	rs61160187	0.582	rs62372134	ENSG00000272308.1	RP11-231G3.1	-3.53	0.000452	0.0281	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60866457~60866935:-
THCA	cis	rs8030605	0.925	rs72736465	ENSG00000277245.1	RP11-48G14.3	3.53	0.000452	0.0281	0.3	0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56080648	chr15:56447120~56447697:+
THCA	cis	rs13381277	1	rs12608154	ENSG00000263982.1	RP11-504I13.3	3.53	0.000452	0.0281	0.31	0.16	Dental caries;	chr18:76610292	chr18:76372717~76378275:+
THCA	cis	rs13381277	1	rs12605865	ENSG00000263982.1	RP11-504I13.3	3.53	0.000452	0.0281	0.31	0.16	Dental caries;	chr18:76610391	chr18:76372717~76378275:+
THCA	cis	rs9329221	0.686	rs13264580	ENSG00000253641.4	RP11-981G7.2	3.53	0.000452	0.0281	0.16	0.16	Neuroticism;	chr8:10393189	chr8:10474565~10481974:+
THCA	cis	rs713587	0.521	rs35177510	ENSG00000224165.4	DNAJC27-AS1	-3.53	0.000452	0.0281	-0.09	-0.16	Body mass index in non-asthmatics;	chr2:24866725	chr2:24971390~25039694:+
THCA	cis	rs11018874	0.597	rs10765243	ENSG00000280367.1	RP11-121L10.2	3.53	0.000452	0.0281	0.19	0.16	White blood cell types;	chr11:90121950	chr11:90223153~90226538:+
THCA	cis	rs1926657	0.935	rs9524831	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95213645	chr13:95310830~95310955:-
THCA	cis	rs1926657	0.935	rs7983336	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95213813	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs7987653	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95214213	chr13:95310830~95310955:-
THCA	cis	rs1926657	0.935	rs7988494	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95214326	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs9524833	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95214360	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs4334136	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95214524	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs1824913	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95214788	chr13:95310830~95310955:-
THCA	cis	rs1926657	0.825	rs1824911	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95214981	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs7999175	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95215148	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs4773847	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95215755	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs4148467	ENSG00000223298.1	RNY3P8	-3.53	0.000452	0.0281	-0.21	-0.16	Breast cancer;	chr13:95216076	chr13:95310830~95310955:-
THCA	cis	rs11658311	0.85	rs9910747	ENSG00000226478.3	UPF3AP1	-3.53	0.000452	0.0281	-0.38	-0.16	Obsessive-compulsive symptoms;	chr17:17530645	chr17:16745636~16746761:-
THCA	cis	rs2832077	0.943	rs2832091	ENSG00000232855.5	AF131217.1	3.53	0.000452	0.0281	0.2	0.16	Cognitive test performance;	chr21:28790533	chr21:28439346~28674848:-
THCA	cis	rs10090774	1	rs12542138	ENSG00000280303.2	ERICD	3.53	0.000452	0.0281	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140823839	chr8:140636281~140638283:+
THCA	cis	rs1669338	0.588	rs3749360	ENSG00000271870.1	RP11-97C16.1	3.53	0.000452	0.0281	0.15	0.16	White matter integrity;	chr3:3172091	chr3:3152942~3153435:+
THCA	cis	rs2013441	0.613	rs11204422	ENSG00000261033.1	RP11-209D14.2	3.53	0.000452	0.0281	0.2	0.16	Obesity-related traits;	chr17:20093116	chr17:20008051~20009234:-
THCA	cis	rs5770917	1	rs2269381	ENSG00000279182.1	XX-C00717C00720L.1	3.53	0.000452	0.0281	0.27	0.16	Narcolepsy;	chr22:50581640	chr22:50316035~50317025:+
THCA	cis	rs875971	0.965	rs28682868	ENSG00000272831.1	RP11-792A8.4	-3.53	0.000452	0.0281	-0.1	-0.16	Aortic root size;	chr7:66224822	chr7:66739829~66740385:-
THCA	cis	rs801193	1	rs10252765	ENSG00000223473.2	GS1-124K5.3	3.53	0.000452	0.0281	0.11	0.16	Aortic root size;	chr7:66763745	chr7:66491049~66493566:-
THCA	cis	rs1124609	1	rs11635737	ENSG00000244879.4	GABPB1-AS1	3.53	0.000452	0.0281	0.24	0.16	Subjective well-being;	chr15:50148708	chr15:50354959~50372202:+
THCA	cis	rs1124609	1	rs76317808	ENSG00000244879.4	GABPB1-AS1	3.53	0.000452	0.0281	0.24	0.16	Subjective well-being;	chr15:50149023	chr15:50354959~50372202:+
THCA	cis	rs944289	0.616	rs6571735	ENSG00000257520.1	RP11-896J10.3	3.53	0.000452	0.0281	0.16	0.16	Thyroid cancer;	chr14:36089428	chr14:36473207~36519521:-
THCA	cis	rs16975963	0.843	rs73041004	ENSG00000276846.1	CTD-3220F14.3	-3.53	0.000452	0.0281	-0.15	-0.16	Longevity;	chr19:37772790	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.843	rs112628349	ENSG00000276846.1	CTD-3220F14.3	-3.53	0.000452	0.0281	-0.15	-0.16	Longevity;	chr19:37777598	chr19:37314868~37315620:-
THCA	cis	rs7200543	1	rs4985124	ENSG00000260735.1	RP11-72I8.1	-3.53	0.000452	0.0281	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:15094411~15109197:+
THCA	cis	rs1862618	0.853	rs860580	ENSG00000234553.1	AC022431.3	3.53	0.000452	0.0281	0.18	0.16	Initial pursuit acceleration;	chr5:56853602	chr5:56536583~56537826:-
THCA	cis	rs561341	0.709	rs11542477	ENSG00000280033.1	CTD-2095E4.3	3.53	0.000452	0.0281	0.26	0.16	Hip circumference adjusted for BMI;	chr17:31858873	chr17:32159311~32160371:+
THCA	cis	rs2658782	0.901	rs11601056	ENSG00000234106.3	RP11-288E14.2	-3.53	0.000452	0.0281	-0.21	-0.16	Pulmonary function decline;	chr11:93495995	chr11:93535468~93535816:+
THCA	cis	rs7772697	0.508	rs6914925	ENSG00000223701.3	RAET1E-AS1	-3.53	0.000452	0.0281	-0.23	-0.16	Diabetic retinopathy;	chr6:149048849	chr6:149884431~149919508:+
THCA	cis	rs8054556	0.787	rs11649274	ENSG00000183604.13	SMG1P5	-3.53	0.000452	0.0281	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30015148	chr16:30267553~30335374:-
THCA	cis	rs8054556	0.787	rs12935701	ENSG00000183604.13	SMG1P5	-3.53	0.000452	0.0281	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30015427	chr16:30267553~30335374:-
THCA	cis	rs7119	0.679	rs34075648	ENSG00000260776.4	RP11-114H24.2	-3.53	0.000452	0.0281	-0.22	-0.16	Type 2 diabetes;	chr15:77555460	chr15:77914217~77926846:-
THCA	cis	rs8187707	1	rs55672373	ENSG00000233690.1	EBAG9P1	-3.53	0.000452	0.0281	-0.33	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99835096	chr10:99697407~99697949:-
THCA	cis	rs8187707	0.881	rs55804858	ENSG00000233690.1	EBAG9P1	-3.53	0.000452	0.0281	-0.33	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99835308	chr10:99697407~99697949:-
THCA	cis	rs8187707	1	rs17222723	ENSG00000233690.1	EBAG9P1	-3.53	0.000452	0.0281	-0.33	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99836239	chr10:99697407~99697949:-
THCA	cis	rs7403037	0.617	rs35110243	ENSG00000260760.1	PWRN3	3.53	0.000452	0.0281	0.22	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24581421	chr15:24441127~24447967:+
THCA	cis	rs9329221	0.741	rs534523	ENSG00000261451.1	RP11-981G7.1	-3.53	0.000452	0.0281	-0.19	-0.16	Neuroticism;	chr8:10027489	chr8:10433672~10438312:+
THCA	cis	rs11239930	0.538	rs719969	ENSG00000180867.10	PDIA3P1	3.53	0.000452	0.0281	0.15	0.16	AIDS progression;	chr1:147084111	chr1:147178113~147179622:+
THCA	cis	rs3760982	0.585	rs1386502	ENSG00000268601.1	AC115522.3	-3.53	0.000452	0.0281	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789204	chr19:43794309~43795658:-
THCA	cis	rs5015933	0.734	rs10126025	ENSG00000232630.1	PRPS1P2	-3.53	0.000452	0.0281	-0.11	-0.16	Body mass index;	chr9:125383785	chr9:125150653~125151589:+
THCA	cis	rs757978	1	rs7601738	ENSG00000261186.2	RP11-341N2.1	3.53	0.000452	0.0281	0.28	0.16	Chronic lymphocytic leukemia;	chr2:241436398	chr2:242087351~242088457:-
THCA	cis	rs917063	0.716	rs10162332	ENSG00000269927.1	RP6-91H8.3	-3.53	0.000452	0.0281	-0.22	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:71168605	chr14:71141125~71143253:-
THCA	cis	rs917063	0.773	rs7152112	ENSG00000269927.1	RP6-91H8.3	-3.53	0.000452	0.0281	-0.22	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:71169487	chr14:71141125~71143253:-
THCA	cis	rs7520050	0.966	rs11810993	ENSG00000281133.1	AL355480.3	3.53	0.000452	0.0281	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.898	rs34175029	ENSG00000281133.1	AL355480.3	3.53	0.000452	0.0281	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs2275426	ENSG00000281133.1	AL355480.3	3.53	0.000452	0.0281	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45580892~45580996:-
THCA	cis	rs7267979	0.903	rs6050482	ENSG00000276952.1	RP5-965G21.6	3.53	0.000452	0.0281	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.706	rs6037069	ENSG00000276952.1	RP5-965G21.6	3.53	0.000452	0.0281	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25284915~25285588:-
THCA	cis	rs7680126	0.633	rs17389602	ENSG00000261490.1	RP11-448G15.3	-3.53	0.000452	0.0281	-0.14	-0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10205302	chr4:10068089~10073019:-
THCA	cis	rs9595908	0.537	rs7993153	ENSG00000212293.1	SNORA16	3.53	0.000452	0.0281	0.19	0.16	Body mass index;	chr13:32804647	chr13:32420390~32420516:-
THCA	cis	rs875971	1	rs709597	ENSG00000272831.1	RP11-792A8.4	-3.53	0.000452	0.0281	-0.1	-0.16	Aortic root size;	chr7:66360996	chr7:66739829~66740385:-
THCA	cis	rs860295	0.812	rs4278368	ENSG00000203761.5	MSTO2P	-3.53	0.000452	0.0281	-0.13	-0.16	Body mass index;	chr1:155752766	chr1:155745829~155750137:+
THCA	cis	rs57709857	0.801	rs16887273	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000452	0.0281	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38243485	chr8:38382364~38383461:+
THCA	cis	rs669446	0.562	rs3791036	ENSG00000236200.4	KDM4A-AS1	-3.53	0.000452	0.0281	-0.13	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:43689712	chr1:43699765~43708138:-
THCA	cis	rs2288884	0.775	rs7508491	ENSG00000269483.1	AC006272.1	3.53	0.000453	0.0281	0.23	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52001631	chr19:51839924~51843324:-
THCA	cis	rs11884770	0.647	rs6729258	ENSG00000236432.6	AC097662.2	3.53	0.000453	0.0281	0.16	0.16	Advanced age-related macular degeneration;	chr2:227222561	chr2:227221052~227325201:-
THCA	cis	rs7924176	0.521	rs10824142	ENSG00000271848.1	RP11-464F9.21	-3.53	0.000453	0.0281	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:73654039~73674719:+
THCA	cis	rs7924176	0.521	rs11000965	ENSG00000271848.1	RP11-464F9.21	-3.53	0.000453	0.0281	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:73654039~73674719:+
THCA	cis	rs7924176	0.521	rs12357370	ENSG00000271848.1	RP11-464F9.21	-3.53	0.000453	0.0281	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:73654039~73674719:+
THCA	cis	rs8031584	0.541	rs2955797	ENSG00000178081.11	ULK4P3	-3.53	0.000453	0.0281	-0.2	-0.16	Huntington's disease progression;	chr15:30918778	chr15:30103720~30131757:+
THCA	cis	rs4578769	0.681	rs72887615	ENSG00000265939.1	UBE2CP2	-3.53	0.000453	0.0281	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22928638	chr18:22900486~22900995:-
THCA	cis	rs911555	0.755	rs8016676	ENSG00000269940.1	RP11-73M18.7	-3.53	0.000453	0.0281	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103694560~103695170:+
THCA	cis	rs9608946	0.956	rs5749111	ENSG00000279699.1	RP1-102K2.9	3.53	0.000453	0.0281	0.19	0.16	Red cell distribution width;	chr22:30498956	chr22:30275215~30276951:-
THCA	cis	rs1005277	0.54	rs2145487	ENSG00000120555.12	SEPT7P9	3.53	0.000453	0.0281	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38383069~38402916:-
THCA	cis	rs15676	0.783	rs7033070	ENSG00000234771.3	SLC25A25-AS1	-3.53	0.000453	0.0281	-0.14	-0.16	Blood metabolite levels;	chr9:128824095	chr9:128108581~128118693:-
THCA	cis	rs7246657	0.943	rs7257672	ENSG00000268499.1	CTB-102L5.8	3.53	0.000453	0.0281	0.2	0.16	Coronary artery calcification;	chr19:37332957	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.891	rs7257495	ENSG00000268499.1	CTB-102L5.8	3.53	0.000453	0.0281	0.2	0.16	Coronary artery calcification;	chr19:37332974	chr19:38199836~38200934:+
THCA	cis	rs6921919	0.832	rs17312661	ENSG00000273712.1	RP5-874C20.7	3.53	0.000453	0.0281	0.23	0.16	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28315613~28315883:-
THCA	cis	rs972578	0.653	rs5758951	ENSG00000230319.1	AL022476.2	-3.53	0.000453	0.0281	-0.17	-0.16	Mean platelet volume;	chr22:42801028	chr22:43038585~43052366:+
THCA	cis	rs2337406	0.866	rs79901786	ENSG00000280411.1	IGHV1-69-2	-3.53	0.000453	0.0281	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106777623	chr14:106762092~106762588:-
THCA	cis	rs10090774	0.965	rs4961291	ENSG00000280303.2	ERICD	3.53	0.000453	0.0281	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140767676	chr8:140636281~140638283:+
THCA	cis	rs2688608	0.698	rs2633323	ENSG00000271816.1	BMS1P4	3.53	0.000453	0.0281	0.16	0.16	Inflammatory bowel disease;	chr10:73935068	chr10:73699151~73730487:-
THCA	cis	rs9788721	0.967	rs72740955	ENSG00000261762.1	RP11-650L12.2	-3.53	0.000453	0.0281	-0.22	-0.16	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78557437	chr15:78589123~78591276:-
THCA	cis	rs9487051	0.898	rs882072	ENSG00000260273.1	RP11-425D10.10	3.53	0.000453	0.0281	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109290603	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs6924776	ENSG00000260273.1	RP11-425D10.10	3.53	0.000453	0.0281	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109291073	chr6:109382795~109383666:+
THCA	cis	rs13098911	0.54	rs34836513	ENSG00000226074.4	PRSS44	-3.53	0.000453	0.0281	-0.31	-0.16	Celiac disease;	chr3:46004967	chr3:46809359~46812558:-
THCA	cis	rs1876905	0.539	rs62420362	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000453	0.0282	-0.21	-0.16	Mean corpuscular hemoglobin;	chr6:111224167	chr6:111297126~111298510:+
THCA	cis	rs80130819	0.748	rs2732455	ENSG00000226413.2	OR8T1P	3.53	0.000453	0.0282	0.24	0.16	Prostate cancer;	chr12:48284212	chr12:48442030~48442947:-
THCA	cis	rs10102392	0.866	rs12544346	ENSG00000253549.4	RP11-317J10.2	-3.53	0.000453	0.0282	-0.16	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr8:85512387	chr8:85441851~85464915:-
THCA	cis	rs11190604	0.767	rs7392696	ENSG00000273030.1	RP11-285F16.1	3.53	0.000453	0.0282	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100422384	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs11190531	ENSG00000273030.1	RP11-285F16.1	3.53	0.000453	0.0282	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100427553	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs74869390	ENSG00000273030.1	RP11-285F16.1	3.53	0.000453	0.0282	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100429628	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs10509743	ENSG00000273030.1	RP11-285F16.1	3.53	0.000453	0.0282	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100430649	chr10:100412934~100413421:+
THCA	cis	rs9425766	0.888	rs1799876	ENSG00000200674.1	RN7SKP160	3.53	0.000453	0.0282	0.21	0.16	Life satisfaction;	chr1:173909333	chr1:173791548~173791887:+
THCA	cis	rs7267979	0.727	rs4815431	ENSG00000276952.1	RP5-965G21.6	-3.53	0.000453	0.0282	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25284915~25285588:-
THCA	cis	rs7028939	1	rs10988982	ENSG00000255145.2	STX17-AS1	3.53	0.000453	0.0282	0.23	0.16	Preeclampsia;	chr9:100146790	chr9:99886322~99906601:-
THCA	cis	rs354225	0.544	rs10208219	ENSG00000212175.1	SNORA12	-3.53	0.000453	0.0282	-0.2	-0.16	Schizophrenia;	chr2:54578910	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs10208225	ENSG00000212175.1	SNORA12	-3.53	0.000453	0.0282	-0.2	-0.16	Schizophrenia;	chr2:54578912	chr2:55565703~55565850:+
THCA	cis	rs950893	0.729	rs13264439	ENSG00000253837.1	RP11-177H13.2	3.53	0.000453	0.0282	0.16	0.16	Mean corpuscular hemoglobin;	chr8:23607550	chr8:23336171~23366125:+
THCA	cis	rs1560104	0.597	rs4781297	ENSG00000260601.1	RP11-552C15.1	-3.53	0.000453	0.0282	-0.2	-0.16	Obesity-related traits;	chr16:12613347	chr16:12545482~12546684:+
THCA	cis	rs6598955	0.67	rs7520517	ENSG00000236782.4	RP11-96L14.7	-3.53	0.000453	0.0282	-0.19	-0.16	Obesity-related traits;	chr1:26229894	chr1:26169947~26171821:-
THCA	cis	rs9834970	0.566	rs4328757	ENSG00000281100.1	RP11-640L9.2	-3.53	0.000453	0.0282	-0.17	-0.16	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36896689	chr3:36823151~36825158:-
THCA	cis	rs6600671	0.692	rs11249430	ENSG00000226067.5	CH17-118O6.2	3.53	0.000453	0.0282	0.17	0.16	Hip geometry;	chr1:121547115	chr1:120913275~121009291:+
THCA	cis	rs796395	0.701	rs2796822	ENSG00000228208.5	C1orf143	-3.53	0.000453	0.0282	-0.2	-0.16	Post bronchodilator FEV1/FVC ratio;	chr1:218412790	chr1:218510096~218525978:+
THCA	cis	rs9302690	1	rs74809791	ENSG00000205361.7	MT1DP	-3.53	0.000453	0.0282	-0.32	-0.16	Blood protein levels;	chr16:57438948	chr16:56643705~56644786:+
THCA	cis	rs4218	0.681	rs35204615	ENSG00000277144.1	RP11-59H7.4	-3.53	0.000453	0.0282	-0.23	-0.16	Social communication problems;	chr15:59099637	chr15:59115547~59116089:-
THCA	cis	rs12142240	1	rs12142240	ENSG00000232022.5	FAAHP1	-3.53	0.000453	0.0282	-0.18	-0.16	Menopause (age at onset);	chr1:46281629	chr1:46432129~46445521:+
THCA	cis	rs12142240	0.92	rs6697623	ENSG00000232022.5	FAAHP1	-3.53	0.000453	0.0282	-0.18	-0.16	Menopause (age at onset);	chr1:46291870	chr1:46432129~46445521:+
THCA	cis	rs9291683	0.53	rs17246501	ENSG00000261490.1	RP11-448G15.3	3.53	0.000453	0.0282	0.1	0.16	Bone mineral density;	chr4:9984086	chr4:10068089~10073019:-
THCA	cis	rs7829975	0.626	rs907183	ENSG00000248538.5	RP11-10A14.5	3.53	0.000453	0.0282	0.2	0.16	Mood instability;	chr8:8872251	chr8:9189011~9202854:+
THCA	cis	rs1075265	0.518	rs13414393	ENSG00000235937.1	AC008280.1	3.53	0.000453	0.0282	0.19	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54029552~54030682:-
THCA	cis	rs4950322	0.512	rs2353981	ENSG00000180867.10	PDIA3P1	-3.53	0.000453	0.0282	-0.15	-0.16	Protein quantitative trait loci;	chr1:147368365	chr1:147178113~147179622:+
THCA	cis	rs7131987	0.903	rs1991114	ENSG00000257599.1	OVCH1-AS1	-3.53	0.000453	0.0282	-0.2	-0.16	QT interval;	chr12:29239149	chr12:29389294~29487488:+
THCA	cis	rs467650	0.509	rs183628	ENSG00000248489.1	CTD-2007H13.3	3.53	0.000453	0.0282	0.15	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98643787	chr5:98929171~98995013:+
THCA	cis	rs3892630	0.824	rs35700505	ENSG00000267475.1	CTD-2538C1.2	-3.53	0.000454	0.0282	-0.24	-0.16	Red blood cell traits;	chr19:32834100	chr19:32687089~32691750:-
THCA	cis	rs9549260	0.755	rs4941987	ENSG00000275149.1	RP11-427J23.1	-3.53	0.000454	0.0282	-0.21	-0.16	Red blood cell count;	chr13:40621855	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.683	rs4941988	ENSG00000275149.1	RP11-427J23.1	-3.53	0.000454	0.0282	-0.21	-0.16	Red blood cell count;	chr13:40621869	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.64	rs4943796	ENSG00000275149.1	RP11-427J23.1	-3.53	0.000454	0.0282	-0.21	-0.16	Red blood cell count;	chr13:40621879	chr13:40079106~40273509:-
THCA	cis	rs853679	1	rs10456362	ENSG00000273712.1	RP5-874C20.7	-3.53	0.000454	0.0282	-0.24	-0.16	Depression;	chr6:28254038	chr6:28315613~28315883:-
THCA	cis	rs5753618	0.583	rs71324184	ENSG00000224050.1	RP1-90G24.6	-3.53	0.000454	0.0282	-0.21	-0.16	Colorectal cancer;	chr22:31356075	chr22:32273420~32277186:+
THCA	cis	rs2048656	0.54	rs55868514	ENSG00000261451.1	RP11-981G7.1	-3.53	0.000454	0.0282	-0.2	-0.16	Schizophrenia;	chr8:9822890	chr8:10433672~10438312:+
THCA	cis	rs7656342	0.897	rs1967551	ENSG00000249866.1	OR7E83P	3.53	0.000454	0.0282	0.18	0.16	Gut microbiota (bacterial taxa);	chr4:9783510	chr4:9512905~9513874:+
THCA	cis	rs4664293	0.967	rs4665103	ENSG00000230783.1	AC009961.2	-3.53	0.000454	0.0282	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159675801	chr2:159689217~159690291:-
THCA	cis	rs7809950	1	rs2293658	ENSG00000272072.1	CTA-363E19.2	3.53	0.000454	0.0282	0.16	0.16	Coronary artery disease;	chr7:107630122	chr7:107192559~107193300:-
THCA	cis	rs1023500	0.573	rs133378	ENSG00000270083.1	RP1-257I20.14	3.53	0.000454	0.0282	0.18	0.16	Schizophrenia;	chr22:42071691	chr22:42089630~42090028:-
THCA	cis	rs9427116	0.702	rs9427108	ENSG00000236675.1	MTX1P1	-3.53	0.000454	0.0282	-0.15	-0.16	Blood protein levels;	chr1:154635438	chr1:155230975~155234325:+
THCA	cis	rs2625529	0.73	rs2929528	ENSG00000260037.4	CTD-2524L6.3	3.53	0.000454	0.0282	0.21	0.16	Red blood cell count;	chr15:71976996	chr15:71818396~71823384:+
THCA	cis	rs3790515	1	rs12145375	ENSG00000203288.3	RP11-98D18.9	-3.53	0.000454	0.0282	-0.2	-0.16	Depressive symptoms (SSRI exposure interaction);	chr1:151812753	chr1:151790804~151794402:+
THCA	cis	rs3758911	0.861	rs10789593	ENSG00000255353.1	RP11-382M14.1	-3.53	0.000454	0.0282	-0.21	-0.16	Coronary artery disease;	chr11:107286154	chr11:107176286~107177530:+
THCA	cis	rs2562456	0.617	rs34203148	ENSG00000268658.4	LINC00664	3.53	0.000454	0.0282	0.25	0.16	Pain;	chr19:21590743	chr19:21483374~21503238:+
THCA	cis	rs7326068	0.524	rs2497488	ENSG00000238286.1	SLC35E1P1	-3.53	0.000454	0.0282	-0.17	-0.16	Schizophrenia, bipolar disorder and depression (combined);	chr13:20627337	chr13:20607268~20608131:+
THCA	cis	rs2243480	1	rs4718334	ENSG00000237310.1	GS1-124K5.4	-3.53	0.000454	0.0282	-0.19	-0.16	Diabetic kidney disease;	chr7:66324467	chr7:66493706~66495474:+
THCA	cis	rs7474896	0.537	rs2749586	ENSG00000272983.1	RP11-508N22.12	3.53	0.000454	0.0282	0.16	0.16	Obesity (extreme);	chr10:37981286	chr10:38137337~38144399:+
THCA	cis	rs7474896	0.515	rs2749582	ENSG00000272983.1	RP11-508N22.12	3.53	0.000454	0.0282	0.16	0.16	Obesity (extreme);	chr10:37986356	chr10:38137337~38144399:+
THCA	cis	rs6005807	0.64	rs12171099	ENSG00000272858.1	CTA-292E10.8	-3.53	0.000454	0.0282	-0.27	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28680649	chr22:28814914~28815662:+
THCA	cis	rs256438	0.671	rs3813667	ENSG00000243160.1	RP11-342F17.2	3.53	0.000454	0.0282	0.2	0.16	Serum thyroid-stimulating hormone levels;	chr5:80034736	chr5:79529302~79530093:+
THCA	cis	rs7829975	0.593	rs2921077	ENSG00000253130.1	CTD-3023L14.2	-3.53	0.000454	0.0282	-0.17	-0.16	Mood instability;	chr8:8446992	chr8:8561391~8569688:+
THCA	cis	rs10995356	0.844	rs10822089	ENSG00000238280.1	RP11-436D10.3	3.53	0.000454	0.0282	0.19	0.16	Temperament;	chr10:62935383	chr10:62793562~62805887:-
THCA	cis	rs11785400	1	rs6997771	ENSG00000177335.9	C8orf31	3.53	0.000454	0.0282	0.18	0.16	Schizophrenia;	chr8:142666333	chr8:143039209~143059942:+
THCA	cis	rs2694917	0.631	rs2657879	ENSG00000257576.1	RP11-153M3.1	-3.53	0.000454	0.0282	-0.25	-0.16	Blood metabolite ratios;	chr12:56471554	chr12:56511002~56512703:+
THCA	cis	rs911555	0.655	rs10141157	ENSG00000244691.1	RPL10AP1	-3.53	0.000454	0.0282	-0.22	-0.16	Intelligence (multi-trait analysis);	chr14:103551768	chr14:103412119~103412761:-
THCA	cis	rs1874124	0.577	rs2807880	ENSG00000238078.1	LINC01352	3.53	0.000454	0.0282	0.28	0.16	Cholesterol, total;	chr1:220869661	chr1:220829255~220832429:+
THCA	cis	rs6995541	0.553	rs12547146	ENSG00000248896.2	CTD-2135J3.3	-3.53	0.000454	0.0282	-0.22	-0.16	Triglyceride levels;	chr8:10742744	chr8:10729314~10771392:+
THCA	cis	rs9650657	0.572	rs11250098	ENSG00000206014.6	OR7E161P	3.53	0.000454	0.0282	0.18	0.16	Neuroticism;	chr8:10961097	chr8:11928597~11929563:-
THCA	cis	rs17607347	0.505	rs1946768	ENSG00000247324.2	RP11-510M2.2	-3.53	0.000454	0.0282	-0.32	-0.16	Intelligence (multi-trait analysis);	chr16:72300471	chr16:71462278~71465941:+
THCA	cis	rs1348850	0.597	rs4893964	ENSG00000280374.1	RP11-337N6.3	-3.53	0.000454	0.0282	-0.24	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177582930	chr2:177317715~177318471:-
THCA	cis	rs2386661	0.547	rs11259742	ENSG00000231483.1	RP11-336A10.5	3.53	0.000454	0.0282	0.17	0.16	Breast cancer;	chr10:5605115	chr10:5608475~5610793:-
THCA	cis	rs4788570	0.584	rs7204608	ENSG00000260185.1	RP11-432I5.6	3.53	0.000454	0.0282	0.29	0.16	Intelligence (multi-trait analysis);	chr16:71644776	chr16:71655027~71664212:+
THCA	cis	rs9991779	0.657	rs4422400	ENSG00000237125.7	HAND2-AS1	3.53	0.000454	0.0282	0.26	0.16	Pediatric bone mineral content (hip);	chr4:173977637	chr4:173527270~173591324:+
THCA	cis	rs1348850	0.526	rs4893829	ENSG00000280374.1	RP11-337N6.3	3.53	0.000454	0.0282	0.27	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177535082	chr2:177317715~177318471:-
THCA	cis	rs9291683	0.53	rs73227883	ENSG00000261490.1	RP11-448G15.3	3.53	0.000454	0.0282	0.1	0.16	Bone mineral density;	chr4:9977655	chr4:10068089~10073019:-
THCA	cis	rs2408955	0.521	rs10875753	ENSG00000257735.1	RP11-370I10.6	3.53	0.000454	0.0282	0.18	0.16	Glycated hemoglobin levels;	chr12:48163358	chr12:48350945~48442411:+
THCA	cis	rs34783982	0.652	rs12442621	ENSG00000259699.2	HMGB1P8	-3.53	0.000454	0.0282	-0.23	-0.16	Squamous cell lung carcinoma;	chr15:88949970	chr15:89135547~89136495:-
THCA	cis	rs4727027	0.704	rs12535115	ENSG00000244560.5	RP4-800G7.2	-3.53	0.000454	0.0282	-0.1	-0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149197995	chr7:149285281~149297312:+
THCA	cis	rs11098699	0.784	rs4833270	ENSG00000273007.1	RP11-170N16.3	3.53	0.000454	0.0282	0.13	0.16	Mosquito bite size;	chr4:123321407	chr4:122881878~122884712:-
THCA	cis	rs11098699	0.718	rs4833896	ENSG00000273007.1	RP11-170N16.3	3.53	0.000454	0.0282	0.13	0.16	Mosquito bite size;	chr4:123321428	chr4:122881878~122884712:-
THCA	cis	rs875971	1	rs1544549	ENSG00000272831.1	RP11-792A8.4	-3.53	0.000454	0.0282	-0.1	-0.16	Aortic root size;	chr7:66625676	chr7:66739829~66740385:-
THCA	cis	rs34779708	0.733	rs16935948	ENSG00000233200.1	RP11-324I22.2	3.53	0.000454	0.0282	0.2	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35219894~35230598:-
THCA	cis	rs1864585	0.52	rs77559025	ENSG00000280294.1	RP11-177H2.1	3.53	0.000454	0.0282	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10835251	chr8:10856085~10859436:-
THCA	cis	rs61677309	1	rs894677	ENSG00000278376.1	RP11-158I9.8	3.53	0.000454	0.0282	0.12	0.16	Lung cancer in ever smokers;	chr11:118301820	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.964	rs59138930	ENSG00000278376.1	RP11-158I9.8	3.53	0.000454	0.0282	0.12	0.16	Lung cancer in ever smokers;	chr11:118303068	chr11:118791254~118793137:+
THCA	cis	rs10908557	0.758	rs6701341	ENSG00000231416.1	RP11-422P24.9	3.53	0.000454	0.0282	0.2	0.16	Age at first birth;	chr1:154002145	chr1:153995632~153995960:+
THCA	cis	rs875971	0.862	rs1983372	ENSG00000223473.2	GS1-124K5.3	-3.53	0.000454	0.0282	-0.11	-0.16	Aortic root size;	chr7:66146364	chr7:66491049~66493566:-
THCA	cis	rs1950832	0.689	rs8009481	ENSG00000258636.1	CTD-2298J14.2	-3.53	0.000454	0.0282	-0.22	-0.16	Urate levels in obese individuals;	chr14:41667567	chr14:41587861~41604856:-
THCA	cis	rs714027	0.545	rs41161	ENSG00000279699.1	RP1-102K2.9	-3.53	0.000454	0.0282	-0.16	-0.16	Lymphocyte counts;	chr22:30011663	chr22:30275215~30276951:-
THCA	cis	rs6743226	0.626	rs59542139	ENSG00000223374.1	AC005104.3	3.53	0.000455	0.0282	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241274234	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.603	rs60515663	ENSG00000223374.1	AC005104.3	3.53	0.000455	0.0282	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241274843	chr2:241351340~241353104:-
THCA	cis	rs638893	0.853	rs4938549	ENSG00000255422.1	AP002954.4	-3.53	0.000455	0.0282	-0.25	-0.16	Vitiligo;	chr11:118830888	chr11:118704607~118750263:+
THCA	cis	rs1876905	0.597	rs191631	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000455	0.0282	-0.21	-0.16	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111297126~111298510:+
THCA	cis	rs6471393	0.929	rs62525164	ENSG00000261437.1	RP11-22C11.2	3.53	0.000455	0.0282	0.15	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93750084	chr8:94637285~94639467:-
THCA	cis	rs614226	1	rs580016	ENSG00000248008.2	DYNLL1-AS1	3.53	0.000455	0.0282	0.22	0.16	Type 1 diabetes nephropathy;	chr12:120496174	chr12:120490328~120495940:-
THCA	cis	rs12101261	0.813	rs7152373	ENSG00000259167.2	NMNAT1P1	3.53	0.000455	0.0282	0.19	0.16	Graves' disease;	chr14:81003248	chr14:81032529~81033404:+
THCA	cis	rs643472	0.514	rs2341674	ENSG00000241511.1	RPS15AP24	3.53	0.000455	0.0283	0.23	0.16	Corticobasal degeneration;	chr8:29340739	chr8:30117384~30117779:-
THCA	cis	rs2842346	0.568	rs1476586	ENSG00000258623.1	CTD-2325P2.3	-3.53	0.000455	0.0283	-0.21	-0.16	Breast cancer;	chr14:68536787	chr14:68683411~68685565:-
THCA	cis	rs3758911	0.861	rs10890689	ENSG00000255353.1	RP11-382M14.1	-3.53	0.000455	0.0283	-0.21	-0.16	Coronary artery disease;	chr11:107275626	chr11:107176286~107177530:+
THCA	cis	rs875971	0.558	rs4433015	ENSG00000230189.5	GS1-124K5.2	-3.53	0.000455	0.0283	-0.1	-0.16	Aortic root size;	chr7:66174736	chr7:66409143~66490059:-
THCA	cis	rs2798334	0.953	rs528779	ENSG00000273483.1	RP4-671G15.2	3.53	0.000455	0.0283	0.18	0.16	Visceral adipose tissue adjusted for BMI;P wave duration;	chr1:111881455	chr1:112517799~112518441:-
THCA	cis	rs7824557	0.564	rs55758514	ENSG00000261451.1	RP11-981G7.1	-3.53	0.000455	0.0283	-0.2	-0.16	Retinal vascular caliber;	chr8:11372750	chr8:10433672~10438312:+
THCA	cis	rs2821260	0.755	rs2220253	ENSG00000227207.2	RPL31P12	3.53	0.000455	0.0283	0.18	0.16	Intelligence (multi-trait analysis);	chr1:72099777	chr1:72301472~72301829:+
THCA	cis	rs2235649	0.789	rs9929803	ENSG00000260541.1	LA16c-429E7.1	3.53	0.000455	0.0283	0.22	0.16	Blood metabolite levels;	chr16:1802747	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs9939694	ENSG00000260541.1	LA16c-429E7.1	3.53	0.000455	0.0283	0.22	0.16	Blood metabolite levels;	chr16:1802759	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs9939766	ENSG00000260541.1	LA16c-429E7.1	3.53	0.000455	0.0283	0.22	0.16	Blood metabolite levels;	chr16:1802807	chr16:1841020~1843547:-
THCA	cis	rs854765	0.623	rs9893690	ENSG00000281749.1	Y_RNA	-3.53	0.000455	0.0283	-0.2	-0.16	Total body bone mineral density;	chr17:17850532	chr17:18001101~18001195:-
THCA	cis	rs699371	0.557	rs2286412	ENSG00000270000.1	RP3-449M8.9	3.53	0.000455	0.0283	0.15	0.16	Height;	chr14:74502464	chr14:74471930~74472360:-
THCA	cis	rs7809950	0.862	rs58391518	ENSG00000272072.1	CTA-363E19.2	3.53	0.000455	0.0283	0.16	0.16	Coronary artery disease;	chr7:107390342	chr7:107192559~107193300:-
THCA	cis	rs7690839	1	rs7690839	ENSG00000270720.1	RP11-84C13.2	3.53	0.000455	0.0283	0.18	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88898173	chr4:89119284~89119871:+
THCA	cis	rs10967505	0.627	rs10967507	ENSG00000254396.1	RP11-56F10.3	3.53	0.000455	0.0283	0.21	0.16	Schizophrenia;	chr9:26742894	chr9:27102630~27104728:+
THCA	cis	rs7246657	0.654	rs10407568	ENSG00000226686.6	LINC01535	-3.53	0.000455	0.0283	-0.23	-0.16	Coronary artery calcification;	chr19:37632108	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs16958863	ENSG00000226686.6	LINC01535	-3.53	0.000455	0.0283	-0.23	-0.16	Coronary artery calcification;	chr19:37633334	chr19:37251912~37265535:+
THCA	cis	rs768090	0.747	rs2254807	ENSG00000237892.1	KLF7-IT1	3.53	0.000455	0.0283	0.19	0.16	Hemoglobin concentration;Hematocrit;	chr2:207120347	chr2:207120884~207122044:-
THCA	cis	rs12780845	1	rs7912093	ENSG00000273153.1	RP11-406H21.2	3.53	0.000455	0.0283	0.15	0.16	Homocysteine levels;	chr10:17161935	chr10:17137336~17137585:-
THCA	cis	rs12780845	1	rs33993216	ENSG00000273153.1	RP11-406H21.2	3.53	0.000455	0.0283	0.15	0.16	Homocysteine levels;	chr10:17162140	chr10:17137336~17137585:-
THCA	cis	rs6921919	0.848	rs6903652	ENSG00000280107.1	AL022393.9	-3.53	0.000455	0.0283	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28170845~28172521:+
THCA	cis	rs11065706	0.715	rs1265742	ENSG00000278993.1	RP3-424M6.4	-3.53	0.000455	0.0283	-0.25	-0.16	Heart rate;	chr12:110577316	chr12:110501614~110503441:+
THCA	cis	rs1158167	0.518	rs2983640	ENSG00000270001.1	RP11-218C14.8	3.53	0.000455	0.0283	0.2	0.16	Cystatin C;	chr20:23605723	chr20:23631826~23632316:-
THCA	cis	rs860295	0.812	rs3820594	ENSG00000203761.5	MSTO2P	-3.53	0.000455	0.0283	-0.13	-0.16	Body mass index;	chr1:155859720	chr1:155745829~155750137:+
THCA	cis	rs11678584	0.506	rs55772620	ENSG00000276517.1	AL133243.2	-3.53	0.000455	0.0283	-0.21	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32426868	chr2:32526504~32529507:+
THCA	cis	rs7216064	1	rs2365468	ENSG00000278740.1	RP11-147L13.14	3.53	0.000455	0.0283	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845202	chr17:68188547~68189165:+
THCA	cis	rs9393813	0.516	rs4713099	ENSG00000216915.2	RP1-97D16.1	3.53	0.000455	0.0283	0.21	0.16	Bipolar disorder;	chr6:27437423	chr6:27737000~27738494:-
THCA	cis	rs786425	0.866	rs7139193	ENSG00000278112.1	RP11-972P1.11	3.53	0.000455	0.0283	0.15	0.16	Pubertal anthropometrics;	chr12:123686629	chr12:123519390~123519856:-
THCA	cis	rs4845570	0.92	rs1521185	ENSG00000269489.1	RP11-98D18.17	3.53	0.000455	0.0283	0.17	0.16	Coronary artery disease;	chr1:151791573	chr1:151798054~151798602:+
THCA	cis	rs3800688	0.527	rs1648441	ENSG00000236753.4	MKLN1-AS	-3.53	0.000455	0.0283	-0.15	-0.16	Hypertension;	chr7:131462108	chr7:131309744~131328222:-
THCA	cis	rs12549025	0.796	rs2272688	ENSG00000253390.1	CTC-756D1.2	-3.53	0.000455	0.0283	-0.27	-0.16	Reticulocyte fraction of red cells;	chr8:23537766	chr8:23458601~23484971:+
THCA	cis	rs3811273	0.614	rs6572352	ENSG00000211816.2	TRAV38-1	-3.53	0.000455	0.0283	-0.19	-0.16	Periodontal disease-related phenotypes;	chr14:22268440	chr14:22271968~22272563:+
THCA	cis	rs3811273	0.614	rs6572353	ENSG00000211816.2	TRAV38-1	-3.53	0.000455	0.0283	-0.19	-0.16	Periodontal disease-related phenotypes;	chr14:22268461	chr14:22271968~22272563:+
THCA	cis	rs3811273	0.614	rs6572354	ENSG00000211816.2	TRAV38-1	-3.53	0.000455	0.0283	-0.19	-0.16	Periodontal disease-related phenotypes;	chr14:22268462	chr14:22271968~22272563:+
THCA	cis	rs10515778	0.898	rs57720492	ENSG00000280834.1	U6	3.53	0.000455	0.0283	0.27	0.16	Inflammatory skin disease;	chr5:159201695	chr5:160072268~160072364:+
THCA	cis	rs6997458	0.54	rs9329911	ENSG00000253549.4	RP11-317J10.2	3.53	0.000455	0.0283	0.16	0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85495291	chr8:85441851~85464915:-
THCA	cis	rs620729	0.794	rs4713579	ENSG00000272097.1	RP11-421M1.8	3.53	0.000455	0.0283	0.19	0.16	Intelligence (multi-trait analysis);	chr6:11486731	chr6:10743324~10747663:-
THCA	cis	rs2290416	0.892	rs3829012	ENSG00000254973.1	RP11-429J17.7	3.53	0.000455	0.0283	0.32	0.16	Attention deficit hyperactivity disorder;	chr8:143582486	chr8:143758153~143771822:-
THCA	cis	rs2977125	0.815	rs2977156	ENSG00000251468.2	RP11-369K16.1	-3.53	0.000455	0.0283	-0.23	-0.16	Schizophrenia;	chr8:12888269	chr8:12958387~12962200:+
THCA	cis	rs997295	0.554	rs28568344	ENSG00000270964.1	RP11-502I4.3	3.53	0.000455	0.0283	0.13	0.16	Motion sickness;	chr15:67804189	chr15:67541072~67542604:-
THCA	cis	rs972578	1	rs4822247	ENSG00000230319.1	AL022476.2	3.53	0.000455	0.0283	0.17	0.16	Mean platelet volume;	chr22:43007284	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs4822248	ENSG00000230319.1	AL022476.2	3.53	0.000455	0.0283	0.17	0.16	Mean platelet volume;	chr22:43007373	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs4822249	ENSG00000230319.1	AL022476.2	3.53	0.000455	0.0283	0.17	0.16	Mean platelet volume;	chr22:43007500	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs5759086	ENSG00000230319.1	AL022476.2	3.53	0.000455	0.0283	0.17	0.16	Mean platelet volume;	chr22:43008923	chr22:43038585~43052366:+
THCA	cis	rs1876905	0.68	rs395564	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000456	0.0283	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111297126~111298510:+
THCA	cis	rs7474896	0.583	rs10827817	ENSG00000120555.12	SEPT7P9	3.53	0.000456	0.0283	0.21	0.16	Obesity (extreme);	chr10:37709046	chr10:38383069~38402916:-
THCA	cis	rs970548	0.688	rs2082110	ENSG00000230869.1	CTGLF10P	3.53	0.000456	0.0283	0.23	0.16	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435622	chr10:45678692~45700532:+
THCA	cis	rs970548	0.688	rs2082109	ENSG00000230869.1	CTGLF10P	3.53	0.000456	0.0283	0.23	0.16	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435654	chr10:45678692~45700532:+
THCA	cis	rs6929812	0.588	rs6456788	ENSG00000271755.1	RP1-153G14.4	3.53	0.000456	0.0283	0.19	0.16	Neuroticism (multi-trait analysis);	chr6:27454287	chr6:27404010~27406964:-
THCA	cis	rs4295623	0.531	rs2898295	ENSG00000255046.1	RP11-297N6.4	3.53	0.000456	0.0283	0.16	0.16	Morning vs. evening chronotype;	chr8:11738460	chr8:11797928~11802568:-
THCA	cis	rs57709857	0.957	rs10102341	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38303951	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs2280847	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38318669	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs2234549	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38330495	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs11989357	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38337043	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs72630604	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38340685	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs12677788	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38345905	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs10448063	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38352757	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs11774214	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38354895	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs72630614	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38356065	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs72630617	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000456	0.0283	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38373796	chr8:38382364~38383461:+
THCA	cis	rs944289	0.774	rs1958623	ENSG00000212071.1	AL162511.1	3.53	0.000456	0.0283	0.19	0.16	Thyroid cancer;	chr14:36128417	chr14:36196480~36196568:-
THCA	cis	rs6142618	0.562	rs6142617	ENSG00000224452.1	RSL24D1P6	3.53	0.000456	0.0283	0.19	0.16	Inflammatory bowel disease;	chr20:32127959	chr20:32170390~32170790:-
THCA	cis	rs721917	0.506	rs2819098	ENSG00000272489.1	RP11-182L21.5	-3.53	0.000456	0.0283	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79663192~79664786:+
THCA	cis	rs11124272	0.571	rs28383003	ENSG00000276517.1	AL133243.2	-3.53	0.000456	0.0283	-0.16	-0.16	Interleukin-18 levels;	chr2:31578363	chr2:32526504~32529507:+
THCA	cis	rs189798	0.807	rs330905	ENSG00000254153.1	CTA-398F10.2	-3.53	0.000456	0.0283	-0.17	-0.16	Myopia (pathological);	chr8:9136041	chr8:8456909~8461337:-
THCA	cis	rs394563	0.901	rs448874	ENSG00000268592.3	RAET1E-AS1	3.53	0.000456	0.0283	0.21	0.16	Dupuytren's disease;	chr6:149475831	chr6:149863494~149919507:+
THCA	cis	rs2013441	0.613	rs888424	ENSG00000261033.1	RP11-209D14.2	-3.53	0.000456	0.0283	-0.2	-0.16	Obesity-related traits;	chr17:20082114	chr17:20008051~20009234:-
THCA	cis	rs10875746	0.903	rs10875738	ENSG00000258234.1	RP11-370I10.2	3.53	0.000456	0.0283	0.19	0.16	Longevity (90 years and older);	chr12:48079956	chr12:48231098~48284210:-
THCA	cis	rs1928480	1	rs1928480	ENSG00000234618.1	RPSAP9	-3.53	0.000456	0.0283	-0.17	-0.16	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr9:77071521	chr9:76398699~76399586:+
THCA	cis	rs2486012	0.737	rs4660749	ENSG00000237950.1	RP11-7O11.3	3.53	0.000456	0.0283	0.19	0.16	Intelligence (multi-trait analysis);	chr1:43784630	chr1:43944370~43946551:-
THCA	cis	rs972578	0.875	rs5751412	ENSG00000230319.1	AL022476.2	3.53	0.000456	0.0283	0.17	0.16	Mean platelet volume;	chr22:43012251	chr22:43038585~43052366:+
THCA	cis	rs1383484	1	rs7176613	ENSG00000225151.9	GOLGA2P7	3.53	0.000456	0.0283	0.22	0.16	Height;	chr15:83834450	chr15:84199311~84230136:-
THCA	cis	rs9890032	0.509	rs11656986	ENSG00000276250.1	CTD-2349P21.12	-3.53	0.000456	0.0283	-0.14	-0.16	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30803654~30804077:+
THCA	cis	rs2455799	0.573	rs62243672	ENSG00000270409.1	RP11-44D5.1	-3.53	0.000456	0.0283	-0.17	-0.16	Mean platelet volume;	chr3:15895693	chr3:15732252~15733470:+
THCA	cis	rs801193	0.569	rs7782587	ENSG00000223473.2	GS1-124K5.3	3.53	0.000456	0.0283	0.11	0.16	Aortic root size;	chr7:66701485	chr7:66491049~66493566:-
THCA	cis	rs1510272	0.889	rs4680291	ENSG00000243926.1	TIPARP-AS1	-3.53	0.000456	0.0283	-0.17	-0.16	Testicular germ cell tumor;	chr3:156613411	chr3:156671862~156674378:-
THCA	cis	rs8073060	0.586	rs2011897	ENSG00000255987.1	TOMM20P2	3.53	0.000456	0.0283	0.2	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35727389	chr17:35514766~35515186:-
THCA	cis	rs2404602	0.598	rs71405204	ENSG00000196274.5	Metazoa_SRP	-3.53	0.000456	0.0283	-0.19	-0.16	Blood metabolite levels;	chr15:76342964	chr15:76230048~76230390:-
THCA	cis	rs301901	0.766	rs12521993	ENSG00000250155.1	CTD-2353F22.1	3.53	0.000456	0.0283	0.16	0.16	Height;	chr5:37488095	chr5:36666214~36725195:-
THCA	cis	rs6491750	0.557	rs2065548	ENSG00000276957.1	RP11-29B2.6	3.53	0.000456	0.0283	0.24	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103500957	chr13:102593338~102593873:-
THCA	cis	rs1612141	0.744	rs1113993	ENSG00000251363.2	RP11-129M6.1	3.53	0.000456	0.0283	0.23	0.16	QT interval (drug interaction);	chr14:41102162	chr14:40954898~40975877:+
THCA	cis	rs17123764	1	rs113903668	ENSG00000257464.1	RP11-161H23.8	-3.53	0.000456	0.0283	-0.28	-0.16	Intelligence (multi-trait analysis);	chr12:49607725	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.818	rs75222486	ENSG00000257464.1	RP11-161H23.8	-3.53	0.000456	0.0283	-0.28	-0.16	Intelligence (multi-trait analysis);	chr12:49615979	chr12:49442424~49442652:-
THCA	cis	rs13323323	0.696	rs66922431	ENSG00000214820.3	MPRIPP1	3.53	0.000456	0.0283	0.2	0.16	IgG glycosylation;	chr3:44433059	chr3:44579938~44581026:-
THCA	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	3.53	0.000456	0.0283	0.19	0.16	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
THCA	cis	rs10911363	0.592	rs2702180	ENSG00000232860.6	SMG7-AS1	-3.53	0.000456	0.0283	-0.12	-0.16	Systemic lupus erythematosus;	chr1:183548836	chr1:183460874~183472265:-
THCA	cis	rs7439493	0.536	rs763370	ENSG00000247950.5	SEC24B-AS1	3.53	0.000456	0.0283	0.11	0.16	Blood protein levels;	chr4:109667801	chr4:109347475~109433817:-
THCA	cis	rs4081724	0.706	rs11084725	ENSG00000267296.2	CEBPA-AS1	3.53	0.000456	0.0283	0.21	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33343655	chr19:33302857~33305054:+
THCA	cis	rs962856	0.729	rs1483350	ENSG00000236780.4	AC078941.1	3.53	0.000456	0.0283	0.19	0.16	Pancreatic cancer;	chr2:67292771	chr2:67123357~67215319:-
THCA	cis	rs10760158	0.832	rs10760172	ENSG00000235865.2	GSN-AS1	3.53	0.000456	0.0283	0.14	0.16	Pulse pressure;	chr9:121299624	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs4836848	ENSG00000235865.2	GSN-AS1	3.53	0.000456	0.0283	0.14	0.16	Pulse pressure;	chr9:121301074	chr9:121280768~121285530:-
THCA	cis	rs2777491	1	rs7177641	ENSG00000247556.5	OIP5-AS1	3.53	0.000456	0.0283	0.13	0.16	Ulcerative colitis;	chr15:41451228	chr15:41283990~41309737:+
THCA	cis	rs9400467	0.506	rs4639374	ENSG00000255389.1	C6orf3	3.53	0.000456	0.0283	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111137067	chr6:111599875~111602295:+
THCA	cis	rs2290416	0.892	rs62522165	ENSG00000254973.1	RP11-429J17.7	3.53	0.000457	0.0283	0.31	0.16	Attention deficit hyperactivity disorder;	chr8:143593209	chr8:143758153~143771822:-
THCA	cis	rs12544026	0.581	rs472963	ENSG00000253669.3	KB-1732A1.1	-3.53	0.000457	0.0283	-0.18	-0.16	Major depression and alcohol dependence;	chr8:101850891	chr8:102805517~102809971:+
THCA	cis	rs753778	0.667	rs6578153	ENSG00000253210.1	RP11-809O17.1	-3.53	0.000457	0.0283	-0.19	-0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;	chr8:141199444	chr8:141126044~141129961:-
THCA	cis	rs7520050	0.645	rs1768809	ENSG00000280836.1	AL355480.1	3.53	0.000457	0.0284	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45581219~45581321:-
THCA	cis	rs2305707	0.544	rs2445757	ENSG00000273674.3	CTD-2378E12.1	3.53	0.000457	0.0284	0.33	0.16	Height;	chr15:51297568	chr15:50839875~50908599:-
THCA	cis	rs2305707	0.544	rs2470157	ENSG00000273674.3	CTD-2378E12.1	3.53	0.000457	0.0284	0.33	0.16	Height;	chr15:51297703	chr15:50839875~50908599:-
THCA	cis	rs2305707	0.544	rs2470156	ENSG00000273674.3	CTD-2378E12.1	3.53	0.000457	0.0284	0.33	0.16	Height;	chr15:51298216	chr15:50839875~50908599:-
THCA	cis	rs9916302	0.706	rs8073907	ENSG00000266469.1	CTB-131K11.1	-3.53	0.000457	0.0284	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39267896	chr17:39401793~39406233:+
THCA	cis	rs7631605	0.846	rs6768108	ENSG00000224080.1	UBE2FP1	3.53	0.000457	0.0284	0.19	0.16	Cerebrospinal P-tau181p levels;	chr3:36957264	chr3:37143512~37143958:-
THCA	cis	rs12493885	0.697	rs55681402	ENSG00000243069.6	ARHGEF26-AS1	-3.53	0.000457	0.0284	-0.31	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:153942084	chr3:154024401~154121332:-
THCA	cis	rs61776719	0.52	rs12569027	ENSG00000252448.1	SNORA63	-3.53	0.000457	0.0284	-0.19	-0.16	Coronary artery disease;	chr1:37983491	chr1:37884237~37884317:+
THCA	cis	rs11168351	0.75	rs11168366	ENSG00000257735.1	RP11-370I10.6	-3.53	0.000457	0.0284	-0.19	-0.16	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48350945~48442411:+
THCA	cis	rs6788895	1	rs73010965	ENSG00000244265.1	SIAH2-AS1	3.53	0.000457	0.0284	0.35	0.16	Breast cancer;	chr3:150779783	chr3:150761937~150762538:+
THCA	cis	rs4908769	0.735	rs6577497	ENSG00000232912.4	RP5-1115A15.1	3.53	0.000457	0.0284	0.17	0.16	Allergy;	chr1:8545608	chr1:8424645~8434838:+
THCA	cis	rs7819412	0.806	rs2409689	ENSG00000254839.1	AF131215.6	3.53	0.000457	0.0284	0.16	0.16	Triglycerides;	chr8:11075358	chr8:11062647~11067089:-
THCA	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	3.53	0.000457	0.0284	0.18	0.16	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
THCA	cis	rs7551222	0.752	rs4252725	ENSG00000240219.1	RP11-430C7.5	3.53	0.000457	0.0284	0.15	0.16	Schizophrenia;	chr1:204544128	chr1:204626775~204629712:+
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000265443.1	CTD-2349P21.6	-3.53	0.000457	0.0284	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs216433	ENSG00000265443.1	CTD-2349P21.6	-3.53	0.000457	0.0284	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30726305~30727564:-
THCA	cis	rs1858037	0.836	rs17475335	ENSG00000252414.1	RNU6-100P	-3.53	0.000457	0.0284	-0.18	-0.16	Rheumatoid arthritis;	chr2:65378646	chr2:64578892~64578997:+
THCA	cis	rs6586163	1	rs1926196	ENSG00000261438.1	RP11-399O19.9	-3.53	0.000457	0.0284	-0.13	-0.16	Chronic lymphocytic leukemia;	chr10:88993991	chr10:89015836~89017059:+
THCA	cis	rs9596863	1	rs7995218	ENSG00000136149.6	RPL13AP25	-3.53	0.000457	0.0284	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53853739	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.851	rs1379832	ENSG00000136149.6	RPL13AP25	-3.53	0.000457	0.0284	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53855683	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs9568946	ENSG00000136149.6	RPL13AP25	-3.53	0.000457	0.0284	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53856085	chr13:54440704~54441315:-
THCA	cis	rs10795917	0.502	rs1279132	ENSG00000225778.4	PROSER2-AS1	3.53	0.000457	0.0284	0.19	0.16	Prostate cancer (SNP x SNP interaction);	chr10:12044981	chr10:11849608~11894700:-
THCA	cis	rs9427116	0.74	rs11264230	ENSG00000236675.1	MTX1P1	-3.53	0.000457	0.0284	-0.15	-0.16	Blood protein levels;	chr1:154635942	chr1:155230975~155234325:+
THCA	cis	rs9427116	0.702	rs9427109	ENSG00000236675.1	MTX1P1	-3.53	0.000457	0.0284	-0.15	-0.16	Blood protein levels;	chr1:154636533	chr1:155230975~155234325:+
THCA	cis	rs9427116	0.677	rs9426831	ENSG00000236675.1	MTX1P1	3.53	0.000457	0.0284	0.15	0.16	Blood protein levels;	chr1:154637181	chr1:155230975~155234325:+
THCA	cis	rs7819412	0.805	rs4333549	ENSG00000255046.1	RP11-297N6.4	3.53	0.000457	0.0284	0.17	0.16	Triglycerides;	chr8:11122051	chr8:11797928~11802568:-
THCA	cis	rs4272720	0.535	rs35922675	ENSG00000234736.4	FAM170B-AS1	-3.53	0.000457	0.0284	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49081583	chr10:49121839~49151547:+
THCA	cis	rs972578	0.668	rs12106550	ENSG00000230319.1	AL022476.2	3.53	0.000457	0.0284	0.18	0.16	Mean platelet volume;	chr22:42940631	chr22:43038585~43052366:+
THCA	cis	rs972578	0.74	rs9611969	ENSG00000230319.1	AL022476.2	3.53	0.000457	0.0284	0.18	0.16	Mean platelet volume;	chr22:42940679	chr22:43038585~43052366:+
THCA	cis	rs1150668	0.745	rs213238	ENSG00000261839.1	RP1-265C24.8	3.53	0.000457	0.0284	0.16	0.16	Pubertal anthropometrics;	chr6:28354216	chr6:28136849~28139678:+
THCA	cis	rs738722	0.563	rs134551	ENSG00000272858.1	CTA-292E10.8	3.53	0.000457	0.0284	0.16	0.16	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28411637	chr22:28814914~28815662:+
THCA	cis	rs2991971	1	rs606542	ENSG00000234329.1	RP11-767N6.2	-3.53	0.000457	0.0284	-0.15	-0.16	High light scatter reticulocyte count;	chr1:45548261	chr1:45651039~45651826:-
THCA	cis	rs861020	0.563	rs35898529	ENSG00000203706.7	SERTAD4-AS1	3.53	0.000457	0.0284	0.18	0.16	Orofacial clefts;	chr1:209879751	chr1:210231456~210234047:-
THCA	cis	rs7615952	0.546	rs11711150	ENSG00000272840.1	RP11-379B18.6	3.53	0.000457	0.0284	0.26	0.16	Blood pressure (smoking interaction);	chr3:125596819	chr3:125774714~125797953:+
THCA	cis	rs913672	0.637	rs2274950	ENSG00000231742.4	LINC01273	-3.53	0.000457	0.0284	-0.2	-0.16	Monocyte count;	chr20:50277887	chr20:50172550~50176671:+
THCA	cis	rs6687821	0.515	rs7543542	ENSG00000261737.1	RP4-612B15.3	3.53	0.000457	0.0284	0.24	0.16	Yeast infection;	chr1:87069356	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs2390264	ENSG00000261737.1	RP4-612B15.3	3.53	0.000457	0.0284	0.24	0.16	Yeast infection;	chr1:87072743	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs2798674	ENSG00000261737.1	RP4-612B15.3	3.53	0.000457	0.0284	0.24	0.16	Yeast infection;	chr1:87074834	chr1:86703502~86704462:-
THCA	cis	rs10043228	0.826	rs62384461	ENSG00000250015.1	CTC-339F2.2	3.53	0.000457	0.0284	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116283659	chr5:116302354~116304134:-
THCA	cis	rs9307551	0.697	rs7356151	ENSG00000249646.2	OR7E94P	-3.53	0.000457	0.0284	-0.21	-0.16	Refractive error;	chr4:79539532	chr4:79587302~79588130:-
THCA	cis	rs972578	0.936	rs4822237	ENSG00000230319.1	AL022476.2	3.53	0.000457	0.0284	0.17	0.16	Mean platelet volume;	chr22:42968649	chr22:43038585~43052366:+
THCA	cis	rs929354	0.557	rs62491947	ENSG00000224629.1	RP5-1142J19.2	-3.53	0.000457	0.0284	-0.16	-0.16	Body mass index;	chr7:157168119	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs6956046	ENSG00000224629.1	RP5-1142J19.2	-3.53	0.000457	0.0284	-0.16	-0.16	Body mass index;	chr7:157170180	chr7:157263022~157263229:-
THCA	cis	rs929354	0.742	rs2107863	ENSG00000224629.1	RP5-1142J19.2	-3.53	0.000457	0.0284	-0.16	-0.16	Body mass index;	chr7:157171037	chr7:157263022~157263229:-
THCA	cis	rs929354	0.713	rs3802130	ENSG00000224629.1	RP5-1142J19.2	-3.53	0.000457	0.0284	-0.16	-0.16	Body mass index;	chr7:157172543	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs4716460	ENSG00000224629.1	RP5-1142J19.2	-3.53	0.000457	0.0284	-0.16	-0.16	Body mass index;	chr7:157177360	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs3802126	ENSG00000224629.1	RP5-1142J19.2	-3.53	0.000457	0.0284	-0.16	-0.16	Body mass index;	chr7:157177587	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs3802124	ENSG00000224629.1	RP5-1142J19.2	-3.53	0.000457	0.0284	-0.16	-0.16	Body mass index;	chr7:157177915	chr7:157263022~157263229:-
THCA	cis	rs1383484	0.606	rs9329364	ENSG00000259683.1	RP11-182J1.14	3.53	0.000457	0.0284	0.17	0.16	Height;	chr15:83974490	chr15:84389729~84395903:+
THCA	cis	rs9860340	0.77	rs6797527	ENSG00000229729.5	RP11-159G9.5	3.53	0.000457	0.0284	0.11	0.16	Electroencephalographic traits in alcoholism;	chr3:87702740	chr3:88059274~88138973:+
THCA	cis	rs11633886	0.565	rs1402164	ENSG00000259200.1	RP11-718O11.1	3.53	0.000457	0.0284	0.2	0.16	Diisocyanate-induced asthma;	chr15:45779974	chr15:45705078~45931069:+
THCA	cis	rs12893668	0.572	rs11846404	ENSG00000258735.1	LINC00637	-3.53	0.000457	0.0284	-0.21	-0.16	Reticulocyte count;	chr14:103689771	chr14:103847721~103858049:+
THCA	cis	rs10186029	0.68	rs10179425	ENSG00000270659.1	RP11-105N14.1	-3.53	0.000458	0.0284	-0.13	-0.16	Systemic sclerosis;	chr2:213113717	chr2:213152970~213153659:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000232546.1	RP11-458F8.1	3.53	0.000458	0.0284	0.13	0.16	Aortic root size;	chr7:66113790	chr7:66848496~66858136:+
THCA	cis	rs9467773	0.549	rs9467805	ENSG00000228223.2	HCG11	-3.53	0.000458	0.0284	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26523450~26526579:+
THCA	cis	rs763512	0.504	rs6607279	ENSG00000276054.1	RP11-378E13.3	3.53	0.000458	0.0284	0.25	0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37564796	chr17:37386886~37387926:+
THCA	cis	rs6545883	1	rs778762	ENSG00000212978.6	AC016747.3	3.53	0.000458	0.0284	0.18	0.16	Tuberculosis;	chr2:61555786	chr2:61141592~61144969:-
THCA	cis	rs3892630	0.878	rs1061686	ENSG00000267475.1	CTD-2538C1.2	3.53	0.000458	0.0284	0.23	0.16	Red blood cell traits;	chr19:32713638	chr19:32687089~32691750:-
THCA	cis	rs17818399	0.749	rs35625984	ENSG00000279254.1	RP11-536C12.1	-3.53	0.000458	0.0284	-0.18	-0.16	Height;	chr2:46578769	chr2:46668870~46670778:+
THCA	cis	rs755249	0.588	rs2275767	ENSG00000237624.1	OXCT2P1	-3.53	0.000458	0.0284	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39514956~39516490:+
THCA	cis	rs4715166	0.926	rs7749528	ENSG00000272379.1	RP1-257A7.5	3.53	0.000458	0.0284	0.2	0.16	Hip geometry;	chr6:13224591	chr6:13290018~13290490:-
THCA	cis	rs4715166	0.926	rs2840336	ENSG00000272379.1	RP1-257A7.5	3.53	0.000458	0.0284	0.2	0.16	Hip geometry;	chr6:13225563	chr6:13290018~13290490:-
THCA	cis	rs875971	0.528	rs801213	ENSG00000230295.1	RP11-458F8.2	-3.53	0.000458	0.0284	-0.14	-0.16	Aortic root size;	chr7:66549931	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000230295.1	RP11-458F8.2	-3.53	0.000458	0.0284	-0.14	-0.16	Aortic root size;	chr7:66550643	chr7:66880708~66882981:+
THCA	cis	rs801193	0.935	rs11772264	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000458	0.0284	-0.13	-0.16	Aortic root size;	chr7:66711400	chr7:66848496~66858136:+
THCA	cis	rs8028182	0.636	rs4486847	ENSG00000275645.1	RP11-817O13.9	3.53	0.000458	0.0284	0.16	0.16	Sudden cardiac arrest;	chr15:75436190	chr15:75346744~75347161:-
THCA	cis	rs4664293	0.836	rs13032500	ENSG00000230783.1	AC009961.2	-3.53	0.000458	0.0284	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159749740	chr2:159689217~159690291:-
THCA	cis	rs4742903	0.935	rs17237053	ENSG00000270332.1	SMC2-AS1	-3.53	0.000458	0.0284	-0.15	-0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104184078	chr9:104080024~104093073:-
THCA	cis	rs786425	0.932	rs786443	ENSG00000278112.1	RP11-972P1.11	-3.53	0.000458	0.0284	-0.15	-0.16	Pubertal anthropometrics;	chr12:123579344	chr12:123519390~123519856:-
THCA	cis	rs12612435	0.696	rs11683736	ENSG00000231890.6	DARS-AS1	3.53	0.000458	0.0284	0.18	0.16	Takotsubo syndrome;	chr2:136393559	chr2:135985176~136022593:+
THCA	cis	rs6142618	0.52	rs6058669	ENSG00000235217.6	TSPY26P	3.53	0.000458	0.0284	0.15	0.16	Inflammatory bowel disease;	chr20:32382622	chr20:32186477~32190527:-
THCA	cis	rs4907240	0.806	rs4907237	ENSG00000230606.9	AC159540.1	3.53	0.000458	0.0284	0.18	0.16	Event-related brain oscillations;	chr2:96524760	chr2:97416165~97433527:-
THCA	cis	rs6938	0.618	rs12912839	ENSG00000260269.4	CTD-2323K18.1	-3.53	0.000458	0.0284	-0.24	-0.16	Breast cancer;	chr15:74928904	chr15:75527150~75601205:-
THCA	cis	rs721048	0.92	rs1850984	ENSG00000242412.1	DBIL5P2	-3.53	0.000458	0.0284	-0.22	-0.16	Prostate cancer;	chr2:63237807	chr2:63117851~63119542:-
THCA	cis	rs1612141	0.744	rs1113992	ENSG00000251363.2	RP11-129M6.1	3.53	0.000458	0.0284	0.23	0.16	QT interval (drug interaction);	chr14:41101963	chr14:40954898~40975877:+
THCA	cis	rs910873	0.803	rs56238684	ENSG00000269202.1	RP4-614O4.12	-3.53	0.000458	0.0284	-0.3	-0.16	Melanoma;	chr20:34648892	chr20:35201747~35203288:-
THCA	cis	rs3760982	0.585	rs67773424	ENSG00000267058.1	RP11-15A1.3	-3.53	0.000458	0.0284	-0.13	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789842	chr19:43891804~43901805:-
THCA	cis	rs453301	0.624	rs330056	ENSG00000254340.1	RP11-10A14.3	-3.53	0.000458	0.0284	-0.18	-0.16	Joint mobility (Beighton score);	chr8:9232185	chr8:9141424~9145435:+
THCA	cis	rs9608946	1	rs9608944	ENSG00000279699.1	RP1-102K2.9	3.53	0.000458	0.0284	0.19	0.16	Red cell distribution width;	chr22:30495872	chr22:30275215~30276951:-
THCA	cis	rs10411161	0.721	rs10401778	ENSG00000275055.1	CTC-471J1.11	-3.53	0.000458	0.0284	-0.16	-0.16	Breast cancer;	chr19:51881062	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs10402630	ENSG00000275055.1	CTC-471J1.11	-3.53	0.000458	0.0284	-0.16	-0.16	Breast cancer;	chr19:51881317	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.752	rs10402107	ENSG00000275055.1	CTC-471J1.11	-3.53	0.000458	0.0284	-0.16	-0.16	Breast cancer;	chr19:51881347	chr19:52049007~52049754:+
THCA	cis	rs10411161	0.702	rs16983196	ENSG00000275055.1	CTC-471J1.11	-3.53	0.000458	0.0284	-0.16	-0.16	Breast cancer;	chr19:51881526	chr19:52049007~52049754:+
THCA	cis	rs11673344	0.503	rs703531	ENSG00000233527.7	ZNF529-AS1	3.53	0.000458	0.0284	0.14	0.16	Obesity-related traits;	chr19:37010050	chr19:36573070~36594708:+
THCA	cis	rs2832191	0.74	rs2832175	ENSG00000176054.6	RPL23P2	-3.53	0.000458	0.0284	-0.14	-0.16	Dental caries;	chr21:29103285	chr21:28997613~28998033:-
THCA	cis	rs853679	0.567	rs13196606	ENSG00000220721.1	OR1F12	3.53	0.000458	0.0284	0.19	0.16	Depression;	chr6:28402301	chr6:28073316~28074233:+
THCA	cis	rs6546886	0.536	rs828870	ENSG00000217702.2	RP11-287D1.4	-3.53	0.000458	0.0284	-0.2	-0.16	Dialysis-related mortality;	chr2:74095117	chr2:74130583~74135395:+
THCA	cis	rs7246657	0.722	rs3095726	ENSG00000267640.4	CTD-2554C21.2	3.53	0.000459	0.0285	0.15	0.16	Coronary artery calcification;	chr19:37738923	chr19:37817359~37826638:+
THCA	cis	rs9487051	0.836	rs9487036	ENSG00000260273.1	RP11-425D10.10	3.53	0.000459	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109286246	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.836	rs9400270	ENSG00000260273.1	RP11-425D10.10	3.53	0.000459	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109286285	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs7773331	ENSG00000260273.1	RP11-425D10.10	3.53	0.000459	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109288005	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs9374079	ENSG00000260273.1	RP11-425D10.10	3.53	0.000459	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109288416	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.802	rs9487039	ENSG00000260273.1	RP11-425D10.10	3.53	0.000459	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109288960	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs9487042	ENSG00000260273.1	RP11-425D10.10	3.53	0.000459	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109289240	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs9386794	ENSG00000260273.1	RP11-425D10.10	3.53	0.000459	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109290318	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs7772602	ENSG00000260273.1	RP11-425D10.10	-3.53	0.000459	0.0285	-0.19	-0.16	Reticulocyte fraction of red cells;	chr6:109287458	chr6:109382795~109383666:+
THCA	cis	rs34779708	0.931	rs12268745	ENSG00000233200.1	RP11-324I22.2	3.53	0.000459	0.0285	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35219894~35230598:-
THCA	cis	rs11158198	0.599	rs34969541	ENSG00000279636.2	LINC00216	-3.53	0.000459	0.0285	-0.16	-0.16	Dementia and core Alzheimer's disease neuropathologic changes;	chr14:58140288	chr14:58288033~58289158:+
THCA	cis	rs1832871	0.672	rs11751081	ENSG00000213078.3	RP5-933K21.2	-3.53	0.000459	0.0285	-0.24	-0.16	Height;	chr6:158340473	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs13437296	ENSG00000213078.3	RP5-933K21.2	-3.53	0.000459	0.0285	-0.24	-0.16	Height;	chr6:158341787	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs56326208	ENSG00000213078.3	RP5-933K21.2	-3.53	0.000459	0.0285	-0.24	-0.16	Height;	chr6:158341912	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs12529235	ENSG00000213078.3	RP5-933K21.2	-3.53	0.000459	0.0285	-0.24	-0.16	Height;	chr6:158345918	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9457361	ENSG00000213078.3	RP5-933K21.2	-3.53	0.000459	0.0285	-0.24	-0.16	Height;	chr6:158350718	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9457362	ENSG00000213078.3	RP5-933K21.2	-3.53	0.000459	0.0285	-0.24	-0.16	Height;	chr6:158351020	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9456295	ENSG00000213078.3	RP5-933K21.2	-3.53	0.000459	0.0285	-0.24	-0.16	Height;	chr6:158351046	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs56115227	ENSG00000213078.3	RP5-933K21.2	-3.53	0.000459	0.0285	-0.24	-0.16	Height;	chr6:158352852	chr6:157365990~157366923:-
THCA	cis	rs61677309	1	rs55789743	ENSG00000278376.1	RP11-158I9.8	3.53	0.000459	0.0285	0.12	0.16	Lung cancer in ever smokers;	chr11:118301234	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.964	rs56020103	ENSG00000278376.1	RP11-158I9.8	3.53	0.000459	0.0285	0.12	0.16	Lung cancer in ever smokers;	chr11:118301417	chr11:118791254~118793137:+
THCA	cis	rs61677309	1	rs56346212	ENSG00000278376.1	RP11-158I9.8	3.53	0.000459	0.0285	0.12	0.16	Lung cancer in ever smokers;	chr11:118301627	chr11:118791254~118793137:+
THCA	cis	rs6546550	0.901	rs11126251	ENSG00000179818.12	PCBP1-AS1	-3.53	0.000459	0.0285	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69936302	chr2:69962263~70103220:-
THCA	cis	rs4713118	0.869	rs9366700	ENSG00000216915.2	RP1-97D16.1	-3.53	0.000459	0.0285	-0.24	-0.16	Parkinson's disease;	chr6:27729172	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.869	rs6456802	ENSG00000216915.2	RP1-97D16.1	-3.53	0.000459	0.0285	-0.24	-0.16	Parkinson's disease;	chr6:27730576	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.869	rs9393851	ENSG00000216915.2	RP1-97D16.1	-3.53	0.000459	0.0285	-0.24	-0.16	Parkinson's disease;	chr6:27731802	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.869	rs9461400	ENSG00000216915.2	RP1-97D16.1	-3.53	0.000459	0.0285	-0.24	-0.16	Parkinson's disease;	chr6:27732780	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.869	rs9295742	ENSG00000216915.2	RP1-97D16.1	-3.53	0.000459	0.0285	-0.24	-0.16	Parkinson's disease;	chr6:27735053	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.869	rs9461401	ENSG00000216915.2	RP1-97D16.1	-3.53	0.000459	0.0285	-0.24	-0.16	Parkinson's disease;	chr6:27735512	chr6:27737000~27738494:-
THCA	cis	rs12621844	0.638	rs1878081	ENSG00000272663.1	RP11-191L17.1	-3.53	0.000459	0.0285	-0.16	-0.16	Glycated hemoglobin levels;	chr2:48066431	chr2:48440043~48440597:-
THCA	cis	rs1144333	0.655	rs76612182	ENSG00000272855.1	RP5-1102E8.3	-3.53	0.000459	0.0285	-0.33	-0.16	Attention function in attention deficit hyperactive disorder;	chr1:75986204	chr1:76636877~76637339:+
THCA	cis	rs1799949	0.965	rs8071278	ENSG00000279602.1	CTD-3014M21.1	-3.53	0.000459	0.0285	-0.2	-0.16	Menopause (age at onset);	chr17:43041893	chr17:43360041~43361361:-
THCA	cis	rs17310467	0.541	rs764598	ENSG00000126005.14	MMP24-AS1	-3.53	0.000459	0.0285	-0.31	-0.16	Hemostatic factors and hematological phenotypes;	chr20:34573346	chr20:35216462~35278131:-
THCA	cis	rs2695743	0.647	rs4413189	ENSG00000222043.2	AC079305.10	3.53	0.000459	0.0285	0.15	0.16	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177827967	chr2:177264359~177265515:+
THCA	cis	rs909002	0.772	rs6681414	ENSG00000235790.6	RP11-73M7.6	3.53	0.000459	0.0285	0.17	0.16	Intelligence (multi-trait analysis);	chr1:31604633	chr1:31644049~31660162:+
THCA	cis	rs28510890	0.53	rs8032683	ENSG00000258647.4	LINC00930	3.53	0.000459	0.0285	0.18	0.16	Lung cancer in ever smokers;	chr15:92614826	chr15:92567818~92572042:-
THCA	cis	rs6546550	0.901	rs10496174	ENSG00000179818.12	PCBP1-AS1	-3.53	0.000459	0.0285	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69926304	chr2:69962263~70103220:-
THCA	cis	rs59901009	0.954	rs7129531	ENSG00000246273.5	SBF2-AS1	3.53	0.000459	0.0285	0.21	0.16	Hematocrit;Hemoglobin concentration;	chr11:10152900	chr11:9758292~9811319:+
THCA	cis	rs12368653	0.84	rs3816896	ENSG00000270039.1	RP11-571M6.17	3.53	0.000459	0.0285	0.17	0.16	Multiple sclerosis;	chr12:57801990	chr12:57803838~57804415:+
THCA	cis	rs55966801	0.647	rs11605332	ENSG00000277290.1	RP11-326C3.16	-3.53	0.000459	0.0285	-0.2	-0.16	Plateletcrit;	chr11:267250	chr11:243099~243483:-
THCA	cis	rs11250098	0.583	rs66724331	ENSG00000206014.6	OR7E161P	3.53	0.000459	0.0285	0.18	0.16	Morning vs. evening chronotype;	chr8:10931835	chr8:11928597~11929563:-
THCA	cis	rs4262150	0.739	rs17455800	ENSG00000253921.1	CTB-113P19.3	3.53	0.000459	0.0285	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152686229	chr5:151753992~151767247:+
THCA	cis	rs10089	0.953	rs6595807	ENSG00000245937.6	LINC01184	3.53	0.000459	0.0285	0.18	0.16	Ileal carcinoids;	chr5:128195911	chr5:127940426~128083172:-
THCA	cis	rs2180341	0.92	rs1073932	ENSG00000220522.2	RP1-177A13.1	3.53	0.000459	0.0285	0.21	0.16	Breast cancer;	chr6:127360864	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.96	rs7751865	ENSG00000220522.2	RP1-177A13.1	3.53	0.000459	0.0285	0.21	0.16	Breast cancer;	chr6:127361895	chr6:127416535~127416952:-
THCA	cis	rs6792584	0.743	rs9815209	ENSG00000241316.5	SUCLG2-AS1	-3.53	0.000459	0.0285	-0.15	-0.16	Corneal astigmatism;	chr3:67456022	chr3:67654697~67947713:+
THCA	cis	rs965513	0.932	rs10818050	ENSG00000236130.1	PTCSC2	-3.53	0.000459	0.0285	-0.13	-0.16	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97776641	chr9:97805935~97810008:-
THCA	cis	rs13185784	0.784	rs34763496	ENSG00000245060.5	LINC00847	3.53	0.000459	0.0285	0.19	0.16	TRAIL levels;	chr5:180215990	chr5:180830957~180835726:+
THCA	cis	rs6940638	0.662	rs7759694	ENSG00000220721.1	OR1F12	3.53	0.000459	0.0285	0.2	0.16	Intelligence (multi-trait analysis);	chr6:27273177	chr6:28073316~28074233:+
THCA	cis	rs6687821	0.515	rs2390220	ENSG00000261737.1	RP4-612B15.3	3.53	0.000459	0.0285	0.24	0.16	Yeast infection;	chr1:86989235	chr1:86703502~86704462:-
THCA	cis	rs2979481	1	rs9642712	ENSG00000254152.1	CTD-3107M8.2	3.53	0.000459	0.0285	0.2	0.16	Heart rate variability traits;	chr8:30402450	chr8:30349866~30350347:-
THCA	cis	rs11190604	0.767	rs79106148	ENSG00000273030.1	RP11-285F16.1	3.53	0.00046	0.0285	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100424975	chr10:100412934~100413421:+
THCA	cis	rs7082209	0.877	rs3740084	ENSG00000224265.1	RP11-168L22.2	-3.53	0.00046	0.0285	-0.25	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr10:44317984	chr10:43323665~43327932:+
THCA	cis	rs11168618	0.904	rs7137866	ENSG00000240399.1	RP1-228P16.1	3.53	0.00046	0.0285	0.17	0.16	Adiponectin levels;	chr12:48529019	chr12:48054813~48055591:-
THCA	cis	rs11673344	0.526	rs2291001	ENSG00000229481.2	CTD-2554C21.3	-3.53	0.00046	0.0285	-0.15	-0.16	Obesity-related traits;	chr19:37594431	chr19:37829551~37832160:+
THCA	cis	rs11673344	0.518	rs73033134	ENSG00000229481.2	CTD-2554C21.3	-3.53	0.00046	0.0285	-0.15	-0.16	Obesity-related traits;	chr19:37596046	chr19:37829551~37832160:+
THCA	cis	rs1832871	0.655	rs4273715	ENSG00000213078.3	RP5-933K21.2	-3.53	0.00046	0.0285	-0.24	-0.16	Height;	chr6:158301815	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.655	rs4292552	ENSG00000213078.3	RP5-933K21.2	-3.53	0.00046	0.0285	-0.24	-0.16	Height;	chr6:158301856	chr6:157365990~157366923:-
THCA	cis	rs3749237	0.595	rs885592	ENSG00000224424.7	PRKAR2A-AS1	3.53	0.00046	0.0285	0.13	0.16	Resting heart rate;	chr3:49460450	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs3924462	ENSG00000224424.7	PRKAR2A-AS1	3.53	0.00046	0.0285	0.13	0.16	Resting heart rate;	chr3:49486803	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs4855861	ENSG00000224424.7	PRKAR2A-AS1	3.53	0.00046	0.0285	0.13	0.16	Resting heart rate;	chr3:49488529	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs4855859	ENSG00000224424.7	PRKAR2A-AS1	3.53	0.00046	0.0285	0.13	0.16	Resting heart rate;	chr3:49488867	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs7637999	ENSG00000224424.7	PRKAR2A-AS1	3.53	0.00046	0.0285	0.13	0.16	Resting heart rate;	chr3:49497682	chr3:48847572~48851981:+
THCA	cis	rs6901004	0.803	rs11153272	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.00046	0.0285	-0.15	-0.16	Blood metabolite levels;	chr6:111158336	chr6:111297126~111298510:+
THCA	cis	rs7028939	1	rs7350268	ENSG00000255145.2	STX17-AS1	-3.53	0.00046	0.0285	-0.24	-0.16	Preeclampsia;	chr9:100172498	chr9:99886322~99906601:-
THCA	cis	rs7028939	0.892	rs10988996	ENSG00000255145.2	STX17-AS1	-3.53	0.00046	0.0285	-0.24	-0.16	Preeclampsia;	chr9:100176911	chr9:99886322~99906601:-
THCA	cis	rs41271473	0.526	rs10916339	ENSG00000183929.7	DUSP5P1	3.53	0.00046	0.0285	0.23	0.16	Chronic lymphocytic leukemia;	chr1:228529193	chr1:228650241~228651379:+
THCA	cis	rs7932813	0.513	rs11758	ENSG00000176716.4	OR10AB1P	-3.53	0.00046	0.0285	-0.21	-0.16	Waist circumference;	chr11:7665262	chr11:7728400~7729337:+
THCA	cis	rs1433188	0.847	rs17301273	ENSG00000253582.1	RP11-649G15.2	3.53	0.00046	0.0285	0.19	0.16	Subjective well-being;	chr8:107445564	chr8:106520474~106657548:-
THCA	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-3.53	0.00046	0.0285	-0.19	-0.16	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
THCA	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-3.53	0.00046	0.0285	-0.19	-0.16	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-3.53	0.00046	0.0285	-0.19	-0.16	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
THCA	cis	rs17331151	0.541	rs1139106	ENSG00000242142.1	SERBP1P3	-3.53	0.00046	0.0285	-0.26	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52837085	chr3:53064283~53065091:-
THCA	cis	rs11638352	1	rs6493094	ENSG00000166763.7	STRCP1	-3.53	0.00046	0.0285	-0.31	-0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44018592	chr15:43699488~43718184:-
THCA	cis	rs6138458	0.62	rs914314	ENSG00000230772.1	VN1R108P	-3.53	0.00046	0.0285	-0.22	-0.16	Blood protein levels;	chr20:24916719	chr20:25734264~25735093:+
THCA	cis	rs860295	0.775	rs822505	ENSG00000236675.1	MTX1P1	3.53	0.00046	0.0285	0.16	0.16	Body mass index;	chr1:155876737	chr1:155230975~155234325:+
THCA	cis	rs6545883	0.965	rs2305156	ENSG00000212978.6	AC016747.3	3.53	0.00046	0.0285	0.17	0.16	Tuberculosis;	chr2:61502133	chr2:61141592~61144969:-
THCA	cis	rs11593576	0.55	rs1749845	ENSG00000224596.6	ZMIZ1-AS1	-3.53	0.00046	0.0285	-0.18	-0.16	Vitiligo;	chr10:79232143	chr10:78943328~79067895:-
THCA	cis	rs4747241	0.562	rs9416018	ENSG00000272627.1	RP11-354E23.5	-3.53	0.00046	0.0285	-0.23	-0.16	Heschl's gyrus morphology;	chr10:72340884	chr10:72766560~72767052:+
THCA	cis	rs9923856	0.57	rs35919309	ENSG00000263033.2	RP11-396B14.2	-3.53	0.00046	0.0285	-0.16	-0.16	Atopic dermatitis;Adult asthma;	chr16:10951504	chr16:11196177~11224969:+
THCA	cis	rs9425766	0.962	rs941989	ENSG00000270084.1	GAS5-AS1	3.53	0.00046	0.0285	0.16	0.16	Life satisfaction;	chr1:173912733	chr1:173863248~173863941:+
THCA	cis	rs62045849	0.557	rs6500533	ENSG00000261546.1	CTD-2555A7.3	3.53	0.00046	0.0285	0.27	0.16	Red blood cell count;	chr16:89123657	chr16:89113175~89115279:-
THCA	cis	rs11673344	0.543	rs1818748	ENSG00000233527.7	ZNF529-AS1	3.53	0.00046	0.0285	0.14	0.16	Obesity-related traits;	chr19:37065416	chr19:36573070~36594708:+
THCA	cis	rs55661361	1	rs55661361	ENSG00000245498.5	RP11-677M14.7	3.53	0.00046	0.0285	0.11	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124744061	chr11:124800450~124834487:+
THCA	cis	rs1383484	0.798	rs28728297	ENSG00000259728.4	LINC00933	-3.53	0.00046	0.0285	-0.21	-0.16	Height;	chr15:83877660	chr15:84570649~84580175:+
THCA	cis	rs1383484	0.798	rs28578450	ENSG00000259728.4	LINC00933	-3.53	0.00046	0.0285	-0.21	-0.16	Height;	chr15:83877661	chr15:84570649~84580175:+
THCA	cis	rs3853824	0.595	rs7223066	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56839610	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.585	rs7210030	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56841020	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs6503774	ENSG00000263089.1	RP11-166P13.4	-3.53	0.00046	0.0285	-0.16	-0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56841479	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.61	rs3959524	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56841988	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.595	rs9899453	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56842627	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs7225346	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56843583	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs3760157	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56843961	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs3760158	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56844133	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs9913602	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56844665	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.595	rs2049061	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56845296	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs2049062	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56845443	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.595	rs12601782	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56849464	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs4794671	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56850915	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs4794672	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56851225	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs9907968	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56852874	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs9902250	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56855490	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.583	rs8067906	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56857180	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.555	rs8074637	ENSG00000263089.1	RP11-166P13.4	3.53	0.00046	0.0285	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56860306	chr17:57092145~57096425:-
THCA	cis	rs12451471	0.5	rs8077056	ENSG00000279259.1	RP11-334C17.3	-3.53	0.00046	0.0285	-0.17	-0.16	Plateletcrit;Mean corpuscular hemoglobin concentration;	chr17:80102207	chr17:80147250~80148596:+
THCA	cis	rs17095355	0.818	rs12573187	ENSG00000203876.8	ADD3-AS1	-3.53	0.00046	0.0285	-0.19	-0.16	Biliary atresia;	chr10:110096319	chr10:109940104~110008381:-
THCA	cis	rs14027	0.883	rs1433953	ENSG00000279347.1	RP11-85I17.2	-3.53	0.00046	0.0285	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704754	chr8:119838736~119840385:-
THCA	cis	rs4792901	0.802	rs72833136	ENSG00000267151.3	RP11-100E5.2	3.53	0.00046	0.0285	0.18	0.16	Dupuytren's disease;	chr17:43522322	chr17:43444707~43451200:+
THCA	cis	rs2290416	0.892	rs59742520	ENSG00000254973.1	RP11-429J17.7	3.53	0.00046	0.0285	0.31	0.16	Attention deficit hyperactivity disorder;	chr8:143594064	chr8:143758153~143771822:-
THCA	cis	rs1979679	0.608	rs1581075	ENSG00000278733.1	RP11-425D17.1	-3.53	0.00046	0.0285	-0.17	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28570992	chr12:28185625~28186190:-
THCA	cis	rs9487051	0.872	rs9480922	ENSG00000260273.1	RP11-425D10.10	3.53	0.00046	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109286008	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs9480923	ENSG00000260273.1	RP11-425D10.10	3.53	0.00046	0.0285	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109286166	chr6:109382795~109383666:+
THCA	cis	rs721917	0.506	rs1923540	ENSG00000272489.1	RP11-182L21.5	-3.53	0.00046	0.0285	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79663192~79664786:+
THCA	cis	rs721917	0.7	rs2493719	ENSG00000244733.5	RP11-506M13.3	3.53	0.00046	0.0285	0.18	0.16	Chronic obstructive pulmonary disease;	chr10:79896305	chr10:79660891~79677996:+
THCA	cis	rs72634258	0.554	rs4908694	ENSG00000224315.2	RPL7P7	-3.53	0.00046	0.0285	-0.29	-0.16	Inflammatory bowel disease;	chr1:7790838	chr1:8786211~8786913:-
THCA	cis	rs1971762	0.504	rs1843318	ENSG00000270175.1	RP11-793H13.11	-3.53	0.00046	0.0286	-0.1	-0.16	Height;	chr12:53564293	chr12:53500162~53500936:-
THCA	cis	rs2836950	0.52	rs1980407	ENSG00000235701.1	PCBP2P1	-3.53	0.00046	0.0286	-0.18	-0.16	Menarche (age at onset);	chr21:39172035	chr21:39171130~39172106:-
THCA	cis	rs11710088	0.791	rs4481102	ENSG00000240541.2	TM4SF1-AS1	3.53	0.00046	0.0286	0.15	0.16	QRS duration;	chr3:149482843	chr3:149377778~149386583:+
THCA	cis	rs2797160	0.935	rs12717178	ENSG00000226409.1	RP11-735G4.1	3.53	0.00046	0.0286	0.19	0.16	Endometrial cancer;	chr6:125695353	chr6:125370211~125374324:-
THCA	cis	rs9652490	0.646	rs11638387	ENSG00000214646.7	RP11-114H24.4	3.53	0.00046	0.0286	0.28	0.16	Essential tremor;	chr15:77669998	chr15:77941442~77944582:-
THCA	cis	rs9652490	0.646	rs11631120	ENSG00000214646.7	RP11-114H24.4	3.53	0.00046	0.0286	0.28	0.16	Essential tremor;	chr15:77671764	chr15:77941442~77944582:-
THCA	cis	rs2252521	0.524	rs2529480	ENSG00000228421.2	AC005013.5	3.53	0.000461	0.0286	0.21	0.16	Cognitive performance;	chr7:29003504	chr7:28957667~28959345:+
THCA	cis	rs2252521	0.524	rs1719570	ENSG00000228421.2	AC005013.5	3.53	0.000461	0.0286	0.21	0.16	Cognitive performance;	chr7:29003747	chr7:28957667~28959345:+
THCA	cis	rs11673344	0.764	rs16971873	ENSG00000267260.1	CTD-2162K18.4	-3.53	0.000461	0.0286	-0.2	-0.16	Obesity-related traits;	chr19:36978521	chr19:36773153~36777078:+
THCA	cis	rs11216126	0.524	rs61905084	ENSG00000254851.1	RP11-109L13.1	3.53	0.000461	0.0286	0.25	0.16	HDL cholesterol;	chr11:116739578	chr11:117135528~117138582:+
THCA	cis	rs7631605	0.846	rs4678555	ENSG00000224080.1	UBE2FP1	3.53	0.000461	0.0286	0.19	0.16	Cerebrospinal P-tau181p levels;	chr3:36946082	chr3:37143512~37143958:-
THCA	cis	rs7631605	0.846	rs60404305	ENSG00000224080.1	UBE2FP1	3.53	0.000461	0.0286	0.19	0.16	Cerebrospinal P-tau181p levels;	chr3:36946730	chr3:37143512~37143958:-
THCA	cis	rs9435732	0.778	rs6662202	ENSG00000186301.8	MST1P2	-3.53	0.000461	0.0286	-0.16	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17009758	chr1:16645622~16650289:+
THCA	cis	rs758324	0.947	rs56081930	ENSG00000224431.1	AC063976.7	-3.53	0.000461	0.0286	-0.15	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131899581	chr5:132199456~132203487:+
THCA	cis	rs758324	0.947	rs58016983	ENSG00000224431.1	AC063976.7	-3.53	0.000461	0.0286	-0.15	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131899582	chr5:132199456~132203487:+
THCA	cis	rs6121246	0.954	rs73241710	ENSG00000230613.1	HM13-AS1	3.53	0.000461	0.0286	0.18	0.16	Mean corpuscular hemoglobin;	chr20:31837153	chr20:31567707~31573263:-
THCA	cis	rs6060987	1	rs6060987	ENSG00000230613.1	HM13-AS1	3.53	0.000461	0.0286	0.18	0.16	Mean corpuscular volume;	chr20:31839274	chr20:31567707~31573263:-
THCA	cis	rs4845570	1	rs1054479	ENSG00000268288.1	RP11-98D18.16	-3.53	0.000461	0.0286	-0.24	-0.16	Coronary artery disease;	chr1:151773603	chr1:151766486~151767000:-
THCA	cis	rs4845570	1	rs6683364	ENSG00000268288.1	RP11-98D18.16	-3.53	0.000461	0.0286	-0.24	-0.16	Coronary artery disease;	chr1:151773726	chr1:151766486~151767000:-
THCA	cis	rs7501812	0.561	rs62064119	ENSG00000281749.1	Y_RNA	3.53	0.000461	0.0286	0.24	0.16	TB-LM or TBLH-BMD (pleiotropy);	chr17:17838494	chr17:18001101~18001195:-
THCA	cis	rs3096299	0.503	rs9925045	ENSG00000223959.7	AFG3L1P	3.53	0.000461	0.0286	0.09	0.16	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89972586~90002161:+
THCA	cis	rs2354432	0.607	rs894471	ENSG00000237188.3	RP11-337C18.8	-3.53	0.000461	0.0286	-0.31	-0.16	Mitochondrial DNA levels;	chr1:147216343	chr1:147172771~147211568:+
THCA	cis	rs2880765	0.743	rs12906308	ENSG00000218052.5	ADAMTS7P4	3.53	0.000461	0.0286	0.18	0.16	Coronary artery disease;	chr15:85464828	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.743	rs8039049	ENSG00000218052.5	ADAMTS7P4	-3.53	0.000461	0.0286	-0.18	-0.16	Coronary artery disease;	chr15:85464398	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.743	rs8039631	ENSG00000218052.5	ADAMTS7P4	-3.53	0.000461	0.0286	-0.18	-0.16	Coronary artery disease;	chr15:85464700	chr15:85255369~85330334:-
THCA	cis	rs7631605	0.934	rs7610068	ENSG00000272334.1	RP11-129K12.1	-3.53	0.000461	0.0286	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:37216352	chr3:36973117~36973672:-
THCA	cis	rs964611	0.816	rs8030205	ENSG00000259488.2	RP11-154J22.1	-3.53	0.000461	0.0286	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48248739	chr15:48312353~48331856:-
THCA	cis	rs55726902	1	rs55726902	ENSG00000257488.4	RP5-1057I20.2	3.53	0.000461	0.0286	0.27	0.16	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47826854~47837898:+
THCA	cis	rs3617	0.625	rs3774364	ENSG00000243224.1	RP5-1157M23.2	-3.53	0.000461	0.0286	-0.17	-0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52829589	chr3:52239258~52241097:+
THCA	cis	rs6929812	0.691	rs10807024	ENSG00000216915.2	RP1-97D16.1	3.53	0.000461	0.0286	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27460926	chr6:27737000~27738494:-
THCA	cis	rs875971	0.83	rs587360	ENSG00000230189.5	GS1-124K5.2	3.53	0.000461	0.0286	0.11	0.16	Aortic root size;	chr7:66057711	chr7:66409143~66490059:-
THCA	cis	rs7819412	0.807	rs9657519	ENSG00000261451.1	RP11-981G7.1	-3.53	0.000461	0.0286	-0.2	-0.16	Triglycerides;	chr8:11087929	chr8:10433672~10438312:+
THCA	cis	rs2290416	0.892	rs3793369	ENSG00000254973.1	RP11-429J17.7	3.53	0.000461	0.0286	0.32	0.16	Attention deficit hyperactivity disorder;	chr8:143582165	chr8:143758153~143771822:-
THCA	cis	rs4604234	0.614	rs11963923	ENSG00000260645.1	RP11-250B2.5	-3.53	0.000461	0.0286	-0.27	-0.16	Cancer;	chr6:80355099	chr6:80466958~80469080:+
THCA	cis	rs972578	0.74	rs5758972	ENSG00000230319.1	AL022476.2	3.53	0.000461	0.0286	0.17	0.16	Mean platelet volume;	chr22:42836967	chr22:43038585~43052366:+
THCA	cis	rs1005277	0.579	rs1548255	ENSG00000151963.4	RP11-775A3.1	-3.53	0.000461	0.0286	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:37883594~37884109:+
THCA	cis	rs427941	1	rs438635	ENSG00000239486.1	RP11-163E9.1	-3.53	0.000461	0.0286	-0.16	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102210888	chr7:102380465~102382737:-
THCA	cis	rs1864585	0.619	rs73209922	ENSG00000280294.1	RP11-177H2.1	3.53	0.000461	0.0286	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10850999	chr8:10856085~10859436:-
THCA	cis	rs17741873	0.836	rs11000797	ENSG00000271848.1	RP11-464F9.21	-3.53	0.000461	0.0286	-0.2	-0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73868466	chr10:73654039~73674719:+
THCA	cis	rs2228479	0.619	rs77847775	ENSG00000274627.1	RP11-104N10.2	-3.53	0.000461	0.0286	-0.28	-0.16	Skin colour saturation;	chr16:89829835	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.619	rs78001663	ENSG00000274627.1	RP11-104N10.2	-3.53	0.000461	0.0286	-0.28	-0.16	Skin colour saturation;	chr16:89829923	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.572	rs62054252	ENSG00000274627.1	RP11-104N10.2	-3.53	0.000461	0.0286	-0.28	-0.16	Skin colour saturation;	chr16:89830426	chr16:89516797~89522217:+
THCA	cis	rs7246967	0.673	rs28787949	ENSG00000198153.8	ZNF849P	-3.53	0.000461	0.0286	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22647554	chr19:22685167~22686732:+
THCA	cis	rs4915077	0.686	rs17019743	ENSG00000230489.1	VAV3-AS1	3.53	0.000461	0.0286	0.25	0.16	Hypothyroidism;	chr1:107706557	chr1:107964443~107994607:+
THCA	cis	rs2797160	1	rs6934435	ENSG00000226409.1	RP11-735G4.1	3.53	0.000461	0.0286	0.19	0.16	Endometrial cancer;	chr6:125696335	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1739354	ENSG00000226409.1	RP11-735G4.1	3.53	0.000461	0.0286	0.19	0.16	Endometrial cancer;	chr6:125696662	chr6:125370211~125374324:-
THCA	cis	rs3018712	0.532	rs7116363	ENSG00000212093.1	AP000807.1	-3.53	0.000461	0.0286	-0.2	-0.16	Total body bone mineral density;	chr11:68645330	chr11:68506083~68506166:-
THCA	cis	rs2290416	0.892	rs77370907	ENSG00000254973.1	RP11-429J17.7	3.53	0.000461	0.0286	0.32	0.16	Attention deficit hyperactivity disorder;	chr8:143582805	chr8:143758153~143771822:-
THCA	cis	rs4703129	0.967	rs62369077	ENSG00000246763.5	RGMB-AS1	-3.53	0.000461	0.0286	-0.16	-0.16	Asperger disorder;	chr5:98559936	chr5:98769618~98773469:-
THCA	cis	rs3853824	0.636	rs9893721	ENSG00000263089.1	RP11-166P13.4	3.53	0.000462	0.0286	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56866621	chr17:57092145~57096425:-
THCA	cis	rs78487399	0.808	rs17031005	ENSG00000234936.1	AC010883.5	3.53	0.000462	0.0286	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534160	chr2:43229573~43233394:+
THCA	cis	rs5751901	0.614	rs5760485	ENSG00000128262.7	POM121L9P	-3.53	0.000462	0.0286	-0.16	-0.16	Protein quantitative trait loci;	chr22:24590505	chr22:24251828~24265525:+
THCA	cis	rs7095944	0.582	rs2303611	ENSG00000214297.3	ALDOAP2	-3.53	0.000462	0.0286	-0.2	-0.16	Asthma;	chr10:124829420	chr10:125666875~125667950:-
THCA	cis	rs881827	0.851	rs11089082	ENSG00000230982.1	DSTNP1	3.53	0.000462	0.0286	0.16	0.16	Lymphocyte counts;	chr21:46610842	chr21:46653558~46654022:-
THCA	cis	rs6545883	0.894	rs12997538	ENSG00000212978.6	AC016747.3	-3.53	0.000462	0.0286	-0.17	-0.16	Tuberculosis;	chr2:61337114	chr2:61141592~61144969:-
THCA	cis	rs62458065	0.85	rs62458066	ENSG00000231952.3	DPY19L1P2	3.53	0.000462	0.0286	0.27	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32424872	chr7:32812757~32838570:+
THCA	cis	rs8054556	0.787	rs12325400	ENSG00000183604.13	SMG1P5	-3.53	0.000462	0.0286	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30012465	chr16:30267553~30335374:-
THCA	cis	rs1417770	0.895	rs2246574	ENSG00000260971.3	RP11-504A18.1	3.53	0.000462	0.0286	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56236563	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs2487318	ENSG00000260971.3	RP11-504A18.1	3.53	0.000462	0.0286	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56236569	chr1:56248294~56258571:-
THCA	cis	rs7474896	1	rs9417268	ENSG00000276805.1	RP11-291L22.6	3.53	0.000462	0.0286	0.25	0.16	Obesity (extreme);	chr10:37844266	chr10:38451030~38451785:+
THCA	cis	rs929354	0.772	rs10228145	ENSG00000224629.1	RP5-1142J19.2	-3.53	0.000462	0.0286	-0.16	-0.16	Body mass index;	chr7:157214643	chr7:157263022~157263229:-
THCA	cis	rs975752	0.867	rs3808916	ENSG00000227492.1	RP11-316M21.6	3.53	0.000462	0.0286	0.31	0.16	Schizophrenia;	chr10:100187980	chr10:100229667~100234000:+
THCA	cis	rs36093844	0.527	rs4944554	ENSG00000279742.1	RP11-700A24.1	-3.53	0.000462	0.0286	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86046850	chr11:85852557~85854943:-
THCA	cis	rs4578769	0.55	rs6507452	ENSG00000273232.1	RP11-370A5.2	3.53	0.000462	0.0286	0.22	0.16	Eosinophil percentage of white cells;	chr18:23032275	chr18:22882825~22883357:-
THCA	cis	rs60180747	1	rs74581464	ENSG00000261318.1	RP11-653J6.1	3.53	0.000462	0.0286	0.21	0.16	Testicular germ cell tumor;	chr15:66468642	chr15:66278498~66293357:-
THCA	cis	rs6687821	0.515	rs1112998	ENSG00000261737.1	RP4-612B15.3	3.53	0.000462	0.0286	0.24	0.16	Yeast infection;	chr1:86983198	chr1:86703502~86704462:-
THCA	cis	rs12520053	1	rs62376422	ENSG00000248734.2	CTD-2260A17.1	3.53	0.000462	0.0286	0.22	0.16	Blood protein levels;	chr5:96830144	chr5:96784777~96785999:+
THCA	cis	rs793571	0.822	rs28529423	ENSG00000245975.2	RP11-30K9.6	3.53	0.000462	0.0286	0.18	0.16	Schizophrenia;	chr15:58881183	chr15:58768072~58770974:-
THCA	cis	rs793571	0.822	rs28709922	ENSG00000245975.2	RP11-30K9.6	3.53	0.000462	0.0286	0.18	0.16	Schizophrenia;	chr15:58881282	chr15:58768072~58770974:-
THCA	cis	rs6545883	0.894	rs35292974	ENSG00000212978.6	AC016747.3	-3.53	0.000462	0.0286	-0.17	-0.16	Tuberculosis;	chr2:61294912	chr2:61141592~61144969:-
THCA	cis	rs6687821	0.515	rs2798677	ENSG00000261737.1	RP4-612B15.3	3.53	0.000462	0.0286	0.24	0.16	Yeast infection;	chr1:87086740	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs1778012	ENSG00000261737.1	RP4-612B15.3	3.53	0.000462	0.0286	0.24	0.16	Yeast infection;	chr1:87088873	chr1:86703502~86704462:-
THCA	cis	rs785830	0.644	rs1184590	ENSG00000231808.2	LINC01388	-3.53	0.000462	0.0286	-0.18	-0.16	Platelet distribution width;	chr9:262298	chr9:112713~113754:-
THCA	cis	rs858239	0.669	rs6461687	ENSG00000230042.1	AK3P3	-3.53	0.000462	0.0286	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23129178~23129841:+
THCA	cis	rs78487399	0.908	rs76765584	ENSG00000234936.1	AC010883.5	3.53	0.000462	0.0286	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43580895	chr2:43229573~43233394:+
THCA	cis	rs1881509	0.702	rs6578333	ENSG00000233930.3	KRTAP5-AS1	-3.53	0.000462	0.0286	-0.19	-0.16	Heroin dependence;	chr11:1415484	chr11:1571353~1599184:+
THCA	cis	rs4742903	0.935	rs7024069	ENSG00000270332.1	SMC2-AS1	3.53	0.000462	0.0286	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104245895	chr9:104080024~104093073:-
THCA	cis	rs4730276	0.674	rs3801935	ENSG00000250474.1	WBP1LP2	-3.53	0.000462	0.0286	-0.15	-0.16	Ulcerative colitis;	chr7:107896100	chr7:107628553~107629498:+
THCA	cis	rs9863	0.931	rs11831913	ENSG00000270028.1	RP11-380L11.4	3.53	0.000462	0.0286	0.17	0.16	White blood cell count;	chr12:123962351	chr12:123925461~123926083:-
THCA	cis	rs6058526	0.631	rs6119776	ENSG00000235217.6	TSPY26P	-3.53	0.000462	0.0286	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr20:32222297	chr20:32186477~32190527:-
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000264242.2	RP11-271K11.1	3.53	0.000462	0.0286	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30553697~30558962:+
THCA	cis	rs2278702	0.622	rs77924420	ENSG00000259495.2	RP11-210M15.2	-3.53	0.000462	0.0286	-0.24	-0.16	Bipolar disorder;	chr15:80380626	chr15:80344853~80403575:-
THCA	cis	rs5758511	0.68	rs5758667	ENSG00000270083.1	RP1-257I20.14	-3.53	0.000462	0.0286	-0.21	-0.16	Birth weight;	chr22:42237198	chr22:42089630~42090028:-
THCA	cis	rs5758511	0.689	rs56906457	ENSG00000227370.1	RP4-669P10.19	3.53	0.000462	0.0286	0.21	0.16	Birth weight;	chr22:42232329	chr22:42132543~42132998:+
THCA	cis	rs57709857	0.957	rs11985168	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000462	0.0286	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38302525	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs10095753	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000462	0.0286	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38379372	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs72630624	ENSG00000272092.1	RP11-350N15.5	-3.53	0.000462	0.0286	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38382874	chr8:38382364~38383461:+
THCA	cis	rs6696239	0.915	rs10916180	ENSG00000227711.2	RP11-275O4.5	-3.53	0.000462	0.0286	-0.23	-0.16	Height;	chr1:227632822	chr1:227509028~227520477:-
THCA	cis	rs524281	0.729	rs12790034	ENSG00000255038.1	RP11-1167A19.2	3.53	0.000462	0.0286	0.19	0.16	Electroencephalogram traits;	chr11:66018268	chr11:66067277~66069619:-
THCA	cis	rs11671005	0.695	rs12972898	ENSG00000269600.1	AC016629.3	-3.53	0.000462	0.0286	-0.25	-0.16	Mean platelet volume;	chr19:58445521	chr19:58593896~58599355:-
THCA	cis	rs7074356	0.569	rs7090863	ENSG00000225484.5	NUTM2B-AS1	-3.53	0.000462	0.0286	-0.23	-0.16	Borderline personality disorder;	chr10:80261637	chr10:79663088~79826594:-
THCA	cis	rs1417770	0.931	rs4927308	ENSG00000260971.3	RP11-504A18.1	3.53	0.000462	0.0287	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56234702	chr1:56248294~56258571:-
THCA	cis	rs74233809	1	rs12413409	ENSG00000272912.1	RP11-724N1.1	-3.53	0.000462	0.0287	-0.29	-0.16	Birth weight;	chr10:102959339	chr10:102914585~102915404:+
THCA	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	3.53	0.000462	0.0287	0.19	0.16	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
THCA	cis	rs6442522	0.933	rs7622657	ENSG00000249786.6	EAF1-AS1	-3.53	0.000463	0.0287	-0.17	-0.16	Uric acid levels;	chr3:15370385	chr3:15436171~15455940:-
THCA	cis	rs1023500	1	rs1023498	ENSG00000237037.8	NDUFA6-AS1	3.53	0.000463	0.0287	0.15	0.16	Schizophrenia;	chr22:41944565	chr22:42090931~42137742:+
THCA	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-3.53	0.000463	0.0287	-0.15	-0.16	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
THCA	cis	rs9368481	0.729	rs9379948	ENSG00000228223.2	HCG11	-3.53	0.000463	0.0287	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26523450~26526579:+
THCA	cis	rs2039553	0.553	rs4885669	ENSG00000227354.5	RBM26-AS1	-3.53	0.000463	0.0287	-0.15	-0.16	Pancreatic cancer;	chr13:79813615	chr13:79406309~79424328:+
THCA	cis	rs6957923	0.934	rs7788661	ENSG00000234286.1	AC006026.13	-3.53	0.000463	0.0287	-0.21	-0.16	Height;	chr7:23451694	chr7:23680195~23680786:-
THCA	cis	rs10857712	0.521	rs10857714	ENSG00000273336.1	OR7M1P	-3.53	0.000463	0.0287	-0.21	-0.16	Systemic lupus erythematosus;	chr10:133421866	chr10:133481238~133481770:+
THCA	cis	rs34792	0.528	rs222135	ENSG00000255277.3	ABCC6P2	-3.53	0.000463	0.0287	-0.17	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15445470	chr16:14820792~14824702:-
THCA	cis	rs3743162	0.955	rs12442557	ENSG00000225151.9	GOLGA2P7	-3.53	0.000463	0.0287	-0.25	-0.16	Alzheimer's disease (age of onset);	chr15:84887913	chr15:84199311~84230136:-
THCA	cis	rs1850744	0.702	rs116079424	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9591580	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs115282360	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9591752	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.826	rs114657516	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9592233	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs73805540	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9592340	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.826	rs116509172	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9592499	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.59	rs35509001	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9593247	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.793	rs34495260	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9593700	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs9799502	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9594318	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs57171822	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9594831	chr4:9153296~9165451:+
THCA	cis	rs1850744	1	rs76469957	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9595993	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.793	rs75043790	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9596032	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.826	rs76738832	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9596185	chr4:9153296~9165451:+
THCA	cis	rs1850744	1	rs114290083	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9596370	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs114945335	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9596567	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs73802906	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9596824	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs78422890	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9599141	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs11735905	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9600133	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs73802912	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9600873	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs73802915	ENSG00000163612.10	FAM86KP	3.53	0.000463	0.0287	0.37	0.16	Economic and political preferences;	chr4:9601576	chr4:9153296~9165451:+
THCA	cis	rs9326248	0.603	rs7396061	ENSG00000280143.1	AP000892.6	3.53	0.000463	0.0287	0.2	0.16	Blood protein levels;	chr11:116880158	chr11:117204967~117210292:+
THCA	cis	rs11118346	0.64	rs10779361	ENSG00000228536.1	RP11-392O17.1	-3.53	0.000463	0.0287	-0.19	-0.16	Height;	chr1:219569402	chr1:219409681~219411941:-
THCA	cis	rs1200921	0.66	rs1200894	ENSG00000272983.1	RP11-508N22.12	-3.53	0.000463	0.0287	-0.14	-0.16	Breast cancer;	chr10:37198903	chr10:38137337~38144399:+
THCA	cis	rs9450351	0.744	rs9450294	ENSG00000203875.9	SNHG5	-3.53	0.000463	0.0287	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85540712	chr6:85660950~85678736:-
THCA	cis	rs10454142	0.7	rs57537506	ENSG00000202227.1	RNU6-282P	3.53	0.000463	0.0287	0.19	0.16	Sex hormone-binding globulin levels;	chr2:48349409	chr2:48501922~48502024:-
THCA	cis	rs11671005	0.568	rs73068325	ENSG00000267858.4	MZF1-AS1	-3.53	0.000463	0.0287	-0.12	-0.16	Mean platelet volume;	chr19:58567729	chr19:58559129~58574797:+
THCA	cis	rs6806253	0.838	rs2335050	ENSG00000239405.1	TMED10P2	3.53	0.000463	0.0287	0.23	0.16	Pit-and-Fissure caries;	chr3:128559960	chr3:128538020~128538631:+
THCA	cis	rs4869313	0.687	rs10061936	ENSG00000247121.5	CTD-2260A17.2	-3.53	0.000463	0.0287	-0.12	-0.16	Pediatric autoimmune diseases;	chr5:96948117	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.694	rs10069361	ENSG00000247121.5	CTD-2260A17.2	-3.53	0.000463	0.0287	-0.12	-0.16	Pediatric autoimmune diseases;	chr5:96949099	chr5:96814028~96935809:-
THCA	cis	rs620729	0.668	rs17675772	ENSG00000272097.1	RP11-421M1.8	3.53	0.000463	0.0287	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482509	chr6:10743324~10747663:-
THCA	cis	rs620729	0.707	rs34586980	ENSG00000272097.1	RP11-421M1.8	3.53	0.000463	0.0287	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482544	chr6:10743324~10747663:-
THCA	cis	rs1941184	0.5	rs6506925	ENSG00000263823.1	RP11-326K13.4	-3.53	0.000463	0.0287	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31453177	chr18:31942575~31944156:+
THCA	cis	rs7772486	0.905	rs9373486	ENSG00000270638.1	RP3-466P17.1	-3.53	0.000463	0.0287	-0.13	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145735570~145737218:+
THCA	cis	rs7615952	0.8	rs13086460	ENSG00000248787.1	RP11-666A20.4	-3.53	0.000463	0.0287	-0.28	-0.16	Blood pressure (smoking interaction);	chr3:125927574	chr3:125908005~125910272:-
THCA	cis	rs2880765	0.546	rs11637726	ENSG00000259630.2	CTD-2262B20.1	3.53	0.000463	0.0287	0.21	0.16	Coronary artery disease;	chr15:85516040	chr15:85415228~85415633:+
THCA	cis	rs9300255	0.602	rs1569068	ENSG00000235423.7	RP11-282O18.3	-3.53	0.000463	0.0287	-0.17	-0.16	Neutrophil percentage of white cells;	chr12:123147729	chr12:123252030~123261483:-
THCA	cis	rs9925964	0.967	rs2032915	ENSG00000279196.1	RP11-1072A3.3	-3.53	0.000463	0.0287	-0.16	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106092	chr16:30984630~30988270:-
THCA	cis	rs61008539	0.853	rs10950611	ENSG00000273151.1	RP11-449P15.2	-3.53	0.000463	0.0287	-0.11	-0.16	Perceived unattractiveness to mosquitoes;	chr7:821457	chr7:879790~886547:-
THCA	cis	rs301901	0.743	rs301872	ENSG00000250155.1	CTD-2353F22.1	-3.53	0.000463	0.0287	-0.16	-0.16	Height;	chr5:37137756	chr5:36666214~36725195:-
THCA	cis	rs5015933	0.703	rs7037034	ENSG00000232630.1	PRPS1P2	-3.53	0.000463	0.0287	-0.11	-0.16	Body mass index;	chr9:125382358	chr9:125150653~125151589:+
THCA	cis	rs7924176	0.521	rs11000999	ENSG00000271848.1	RP11-464F9.21	-3.53	0.000463	0.0287	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:73654039~73674719:+
THCA	cis	rs911555	0.723	rs7144010	ENSG00000269940.1	RP11-73M18.7	-3.53	0.000463	0.0287	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103694560~103695170:+
THCA	cis	rs7246967	0.736	rs2546463	ENSG00000269364.1	LINC01233	-3.53	0.000463	0.0287	-0.23	-0.16	Bronchopulmonary dysplasia;	chr19:22811804	chr19:22532626~22533494:+
THCA	cis	rs1144333	0.655	rs17097867	ENSG00000272855.1	RP5-1102E8.3	-3.53	0.000463	0.0287	-0.34	-0.16	Attention function in attention deficit hyperactive disorder;	chr1:76005929	chr1:76636877~76637339:+
THCA	cis	rs2562456	0.52	rs582992	ENSG00000268081.1	RP11-678G14.2	-3.53	0.000463	0.0287	-0.27	-0.16	Pain;	chr19:21266744	chr19:21554640~21569237:-
THCA	cis	rs77147124	1	rs2254537	ENSG00000225292.2	RP11-57H14.3	-3.53	0.000463	0.0287	-0.22	-0.16	HDL cholesterol;	chr10:112157327	chr10:112888735~112906111:+
THCA	cis	rs2905347	0.895	rs2905308	ENSG00000179428.2	AC073072.5	3.53	0.000463	0.0287	0.18	0.16	Major depression and alcohol dependence;	chr7:22608575	chr7:22725395~22727620:-
THCA	cis	rs10186029	0.68	rs4673726	ENSG00000270659.1	RP11-105N14.1	-3.53	0.000463	0.0287	-0.13	-0.16	Systemic sclerosis;	chr2:213116391	chr2:213152970~213153659:+
THCA	cis	rs7819412	0.806	rs6980856	ENSG00000254839.1	AF131215.6	-3.53	0.000463	0.0287	-0.17	-0.16	Triglycerides;	chr8:11080750	chr8:11062647~11067089:-
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000264242.2	RP11-271K11.1	3.53	0.000463	0.0287	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30553697~30558962:+
THCA	cis	rs683257	0.81	rs72984118	ENSG00000234147.1	RP3-460G2.2	-3.53	0.000463	0.0287	-0.26	-0.16	Facial emotion recognition (angry faces);	chr6:140695169	chr6:140845958~140852924:-
THCA	cis	rs683257	0.866	rs72984119	ENSG00000234147.1	RP3-460G2.2	-3.53	0.000463	0.0287	-0.26	-0.16	Facial emotion recognition (angry faces);	chr6:140695392	chr6:140845958~140852924:-
THCA	cis	rs683257	0.789	rs72984124	ENSG00000234147.1	RP3-460G2.2	-3.53	0.000463	0.0287	-0.26	-0.16	Facial emotion recognition (angry faces);	chr6:140700308	chr6:140845958~140852924:-
THCA	cis	rs2749097	0.825	rs11208264	ENSG00000244256.3	RN7SL130P	-3.53	0.000464	0.0287	-0.2	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63659401	chr1:63655743~63656047:+
THCA	cis	rs11634944	0.676	rs220028	ENSG00000257647.1	RP11-701H24.3	3.53	0.000464	0.0287	0.09	0.16	Interleukin-8 levels;	chr15:24955890	chr15:25027736~25032047:-
THCA	cis	rs6088590	0.735	rs6060003	ENSG00000126005.14	MMP24-AS1	-3.53	0.000464	0.0287	-0.15	-0.16	Coronary artery disease;	chr20:34707141	chr20:35216462~35278131:-
THCA	cis	rs9467773	0.511	rs17278688	ENSG00000261353.1	CTA-14H9.5	-3.53	0.000464	0.0287	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26527063~26527404:+
THCA	cis	rs2274273	0.87	rs17741542	ENSG00000258469.1	CHMP4BP1	-3.53	0.000464	0.0287	-0.14	-0.16	Protein biomarker;	chr14:55339143	chr14:55298644~55299231:+
THCA	cis	rs7709377	0.808	rs4283832	ENSG00000272265.1	CTD-2287O16.4	3.53	0.000464	0.0287	0.19	0.16	Metabolite levels  (X-11787);	chr5:116232396	chr5:116078110~116078570:-
THCA	cis	rs7959452	0.59	rs7968629	ENSG00000274979.1	RP11-1143G9.5	-3.53	0.000464	0.0287	-0.17	-0.16	Blood protein levels;	chr12:69389077	chr12:69326574~69331882:-
THCA	cis	rs17826219	0.561	rs562840	ENSG00000264242.2	RP11-271K11.1	3.53	0.000464	0.0287	0.23	0.16	Body mass index;	chr17:30622372	chr17:30553697~30558962:+
THCA	cis	rs7246967	0.544	rs420861	ENSG00000198153.8	ZNF849P	-3.53	0.000464	0.0287	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22823102	chr19:22685167~22686732:+
THCA	cis	rs9910816	0.87	rs8075388	ENSG00000207561.1	MIR635	3.53	0.000464	0.0287	0.18	0.16	Bipolar disorder (inflammation and infection response interaction);	chr17:68362723	chr17:68424451~68424548:-
THCA	cis	rs860295	0.702	rs1325908	ENSG00000160766.13	GBAP1	-3.53	0.000464	0.0287	-0.19	-0.16	Body mass index;	chr1:155443513	chr1:155213821~155227422:-
THCA	cis	rs9650657	0.805	rs6982210	ENSG00000255310.2	AF131215.2	-3.53	0.000464	0.0287	-0.13	-0.16	Neuroticism;	chr8:10742484	chr8:11107788~11109726:-
THCA	cis	rs3739034	1	rs34947476	ENSG00000224043.6	CCNT2-AS1	-3.53	0.000464	0.0287	-0.2	-0.16	Gut microbiome composition (winter);	chr2:134728580	chr2:134735464~134918710:-
THCA	cis	rs5758659	0.622	rs6519298	ENSG00000281538.1	RP4-669P10.20	3.53	0.000464	0.0287	0.15	0.16	Cognitive function;	chr22:41968993	chr22:42138060~42139726:+
THCA	cis	rs4792901	0.592	rs57462570	ENSG00000279602.1	CTD-3014M21.1	-3.53	0.000464	0.0287	-0.21	-0.16	Dupuytren's disease;	chr17:43530611	chr17:43360041~43361361:-
THCA	cis	rs17604090	0.793	rs10226095	ENSG00000223813.2	AC007255.8	-3.53	0.000464	0.0287	-0.15	-0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29650443	chr7:29514225~29563670:-
THCA	cis	rs73206853	0.686	rs60439011	ENSG00000257539.2	HSPA8P14	3.53	0.000464	0.0287	0.31	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110471374	chr12:111381867~111385638:+
THCA	cis	rs1799949	0.965	rs8070179	ENSG00000279602.1	CTD-3014M21.1	-3.53	0.000464	0.0287	-0.2	-0.16	Menopause (age at onset);	chr17:43050671	chr17:43360041~43361361:-
THCA	cis	rs1158167	0.518	rs2983636	ENSG00000270001.1	RP11-218C14.8	3.53	0.000464	0.0287	0.2	0.16	Cystatin C;	chr20:23601386	chr20:23631826~23632316:-
THCA	cis	rs875971	0.508	rs10242423	ENSG00000230295.1	RP11-458F8.2	3.53	0.000464	0.0287	0.12	0.16	Aortic root size;	chr7:66594188	chr7:66880708~66882981:+
THCA	cis	rs875971	0.508	rs10253883	ENSG00000230295.1	RP11-458F8.2	3.53	0.000464	0.0287	0.12	0.16	Aortic root size;	chr7:66596151	chr7:66880708~66882981:+
THCA	cis	rs9291683	0.588	rs17246745	ENSG00000261490.1	RP11-448G15.3	3.53	0.000464	0.0287	0.1	0.16	Bone mineral density;	chr4:9992959	chr4:10068089~10073019:-
THCA	cis	rs1858037	0.867	rs876933	ENSG00000252414.1	RNU6-100P	-3.53	0.000464	0.0287	-0.18	-0.16	Rheumatoid arthritis;	chr2:65382303	chr2:64578892~64578997:+
THCA	cis	rs4761470	0.943	rs3803069	ENSG00000258172.1	RP11-1105G2.4	-3.53	0.000464	0.0287	-0.24	-0.16	Estradiol plasma levels (breast cancer);	chr12:94290027	chr12:94272150~94277195:-
THCA	cis	rs7179228	1	rs4777039	ENSG00000260657.2	RP11-315D16.4	3.53	0.000464	0.0287	0.22	0.16	Systolic blood pressure;	chr15:68329110	chr15:68267792~68277994:-
THCA	cis	rs17345786	1	rs3804775	ENSG00000244119.1	PDCL3P4	3.53	0.000464	0.0287	0.15	0.16	Colonoscopy-negative controls vs population controls;	chr3:101587663	chr3:101712472~101713191:+
THCA	cis	rs1975197	0.515	rs2814723	ENSG00000225706.1	PTPRD-AS1	-3.53	0.000464	0.0287	-0.2	-0.16	Restless legs syndrome;	chr9:8846151	chr9:8858130~8862255:+
THCA	cis	rs683250	0.598	rs657824	ENSG00000254551.1	RP11-727A23.7	3.53	0.000464	0.0287	0.2	0.16	Subcortical brain region volumes;	chr11:83257376	chr11:83209431~83213379:-
THCA	cis	rs34779708	0.931	rs17583009	ENSG00000233200.1	RP11-324I22.2	3.53	0.000464	0.0287	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.898	rs11595898	ENSG00000233200.1	RP11-324I22.2	3.53	0.000464	0.0287	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs35886556	ENSG00000233200.1	RP11-324I22.2	3.53	0.000464	0.0287	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35219894~35230598:-
THCA	cis	rs61160187	0.582	rs17419290	ENSG00000272308.1	RP11-231G3.1	3.53	0.000464	0.0287	0.16	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60866457~60866935:-
THCA	cis	rs3808502	0.563	rs12549144	ENSG00000255495.1	AC145124.2	3.53	0.000464	0.0287	0.18	0.16	Neuroticism;	chr8:11565352	chr8:12194467~12196280:+
THCA	cis	rs34119086	1	rs34119086	ENSG00000220721.1	OR1F12	3.53	0.000464	0.0287	0.36	0.16	Breast cancer;	chr6:28594471	chr6:28073316~28074233:+
THCA	cis	rs1417770	0.931	rs2792773	ENSG00000260971.3	RP11-504A18.1	3.53	0.000464	0.0287	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56237724	chr1:56248294~56258571:-
THCA	cis	rs6546550	0.901	rs4144081	ENSG00000179818.12	PCBP1-AS1	-3.53	0.000464	0.0287	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69928350	chr2:69962263~70103220:-
THCA	cis	rs959260	0.925	rs7207506	ENSG00000263843.1	RP11-649A18.12	3.53	0.000464	0.0287	0.17	0.16	Systemic lupus erythematosus;	chr17:75413329	chr17:75271369~75273895:+
THCA	cis	rs804280	0.565	rs2645453	ENSG00000255495.1	AC145124.2	3.53	0.000464	0.0287	0.17	0.16	Myopia (pathological);	chr8:11764492	chr8:12194467~12196280:+
THCA	cis	rs1208285	0.964	rs9389106	ENSG00000227954.5	TARID	3.53	0.000464	0.0287	0.17	0.16	Infantile hypertrophic pyloric stenosis;	chr6:133829318	chr6:133502252~133892802:-
THCA	cis	rs972578	1	rs2284098	ENSG00000274717.1	RP1-47A17.1	-3.53	0.000464	0.0287	-0.17	-0.16	Mean platelet volume;	chr22:43005766	chr22:42791814~42794313:-
THCA	cis	rs972578	1	rs738381	ENSG00000274717.1	RP1-47A17.1	-3.53	0.000464	0.0287	-0.17	-0.16	Mean platelet volume;	chr22:43008101	chr22:42791814~42794313:-
THCA	cis	rs10129255	0.957	rs11847726	ENSG00000211972.2	IGHV3-66	3.53	0.000464	0.0288	0.1	0.16	Kawasaki disease;	chr14:106779116	chr14:106675017~106675544:-
THCA	cis	rs12493885	0.818	rs10935971	ENSG00000238755.3	RP11-23D24.2	-3.53	0.000464	0.0288	-0.35	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154056156	chr3:153384934~153980186:-
THCA	cis	rs12493885	0.818	rs10935972	ENSG00000238755.3	RP11-23D24.2	-3.53	0.000464	0.0288	-0.35	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154056240	chr3:153384934~153980186:-
THCA	cis	rs12493885	0.818	rs62276828	ENSG00000238755.3	RP11-23D24.2	-3.53	0.000464	0.0288	-0.35	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154058152	chr3:153384934~153980186:-
THCA	cis	rs7727544	0.582	rs3792894	ENSG00000263597.1	MIR3936	3.53	0.000464	0.0288	0.15	0.16	Blood metabolite levels;	chr5:132211578	chr5:132365490~132365599:-
THCA	cis	rs2341873	0.542	rs2037040	ENSG00000204588.5	LINC01123	3.53	0.000464	0.0288	0.18	0.16	Neutrophil percentage of white cells;	chr2:110909621	chr2:109987063~109996140:+
THCA	cis	rs77622099	0.843	rs17826430	ENSG00000233426.3	EIF3FP3	-3.53	0.000464	0.0288	-0.41	-0.16	Neuroticism;	chr2:57798459	chr2:58251440~58252525:+
THCA	cis	rs3776081	0.734	rs9324641	ENSG00000254333.1	CTC-367J11.1	-3.53	0.000465	0.0288	-0.19	-0.16	Blood protein levels;	chr5:150148281	chr5:150475531~150485968:-
THCA	cis	rs2292864	0.764	rs3785872	ENSG00000263293.2	RP11-290H9.4	3.53	0.000465	0.0288	0.35	0.16	Left atrial antero-posterior diameter;	chr17:47294709	chr17:47303460~47323613:-
THCA	cis	rs7267979	0.789	rs4815429	ENSG00000276952.1	RP5-965G21.6	-3.53	0.000465	0.0288	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25284915~25285588:-
THCA	cis	rs7959452	0.59	rs28778648	ENSG00000274979.1	RP11-1143G9.5	-3.53	0.000465	0.0288	-0.17	-0.16	Blood protein levels;	chr12:69378131	chr12:69326574~69331882:-
THCA	cis	rs7615952	0.543	rs4645102	ENSG00000248787.1	RP11-666A20.4	-3.53	0.000465	0.0288	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125705597	chr3:125908005~125910272:-
THCA	cis	rs7818688	0.697	rs2904889	ENSG00000253528.2	RP11-347C18.4	-3.53	0.000465	0.0288	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94928370	chr8:94974573~94974853:-
THCA	cis	rs2717559	0.683	rs2717611	ENSG00000253716.4	RP13-582O9.5	-3.53	0.000465	0.0288	-0.11	-0.16	Urinary tract infection frequency;	chr8:142798511	chr8:143280161~143281690:-
THCA	cis	rs2235649	0.789	rs9939680	ENSG00000260541.1	LA16c-429E7.1	3.53	0.000465	0.0288	0.21	0.16	Blood metabolite levels;	chr16:1802719	chr16:1841020~1843547:-
THCA	cis	rs11069062	0.954	rs10851028	ENSG00000270482.1	RP11-131L12.2	3.53	0.000465	0.0288	0.13	0.16	Obesity-related traits;	chr12:118751311	chr12:118375350~118376275:-
THCA	cis	rs990871	0.574	rs10789338	ENSG00000227207.2	RPL31P12	-3.53	0.000465	0.0288	-0.2	-0.16	Subcutaneous adipose tissue;	chr1:72409518	chr1:72301472~72301829:+
THCA	cis	rs9487051	0.872	rs1521908	ENSG00000260273.1	RP11-425D10.10	3.53	0.000465	0.0288	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109292783	chr6:109382795~109383666:+
THCA	cis	rs758324	0.773	rs608834	ENSG00000224431.1	AC063976.7	-3.53	0.000465	0.0288	-0.15	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131935835	chr5:132199456~132203487:+
THCA	cis	rs748404	0.66	rs493377	ENSG00000275601.1	AC011330.13	-3.53	0.000465	0.0288	-0.19	-0.16	Lung cancer;	chr15:43481269	chr15:43642389~43643023:-
THCA	cis	rs708547	0.957	rs781667	ENSG00000269949.1	RP11-738E22.3	3.53	0.000465	0.0288	0.22	0.16	Response to bleomycin (chromatid breaks);	chr4:56932303	chr4:56960927~56961373:-
THCA	cis	rs11671005	0.61	rs8103813	ENSG00000252334.1	RNU6-1337P	3.53	0.000465	0.0288	0.23	0.16	Mean platelet volume;	chr19:58561317	chr19:58483749~58483843:-
THCA	cis	rs2252521	0.553	rs1603907	ENSG00000272568.4	CTB-113D17.1	3.53	0.000465	0.0288	0.18	0.16	Cognitive performance;	chr7:29056647	chr7:28979967~29013367:+
THCA	cis	rs6693017	1	rs7530493	ENSG00000238078.1	LINC01352	-3.53	0.000465	0.0288	-0.25	-0.16	Monocyte early outgrowth colony forming units;	chr1:220816358	chr1:220829255~220832429:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000232559.3	GS1-124K5.12	-3.53	0.000465	0.0288	-0.15	-0.16	Aortic root size;	chr7:66113790	chr7:66554588~66576923:-
THCA	cis	rs427943	0.52	rs2003273	ENSG00000223768.1	LINC00205	3.53	0.000465	0.0288	0.14	0.16	Body mass index;	chr21:45116671	chr21:45293285~45297354:+
THCA	cis	rs10905099	0.505	rs11254967	ENSG00000278982.1	RP5-1031D4.3	3.52	0.000465	0.0288	0.27	0.16	Orofacial clefts;	chr10:7040003	chr10:7411599~7413467:+
THCA	cis	rs1864585	0.52	rs17774398	ENSG00000280294.1	RP11-177H2.1	-3.52	0.000465	0.0288	-0.17	-0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10774986	chr8:10856085~10859436:-
THCA	cis	rs250518	0.926	rs7734796	ENSG00000251467.1	CTC-250P20.2	3.52	0.000465	0.0288	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72781261	chr5:72996920~72997642:+
THCA	cis	rs6088813	0.702	rs6060378	ENSG00000279253.1	RP4-614O4.13	-3.52	0.000465	0.0288	-0.17	-0.16	Height;	chr20:35335198	chr20:35262727~35264187:-
THCA	cis	rs1876905	0.68	rs373526	ENSG00000271789.1	RP5-1112D6.7	3.52	0.000465	0.0288	0.2	0.16	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111297126~111298510:+
THCA	cis	rs12549025	0.945	rs17698956	ENSG00000253390.1	CTC-756D1.2	-3.52	0.000465	0.0288	-0.28	-0.16	Reticulocyte fraction of red cells;	chr8:23538571	chr8:23458601~23484971:+
THCA	cis	rs7819412	0.668	rs2409714	ENSG00000254866.2	DEFB109P3	3.52	0.000465	0.0288	0.22	0.16	Triglycerides;	chr8:11152608	chr8:12150895~12151134:-
THCA	cis	rs11191270	1	rs4919626	ENSG00000269609.4	RPARP-AS1	3.52	0.000465	0.0288	0.19	0.16	Intelligence (multi-trait analysis);	chr10:102320061	chr10:102449817~102461106:+
THCA	cis	rs11191270	0.784	rs11191264	ENSG00000269609.4	RPARP-AS1	3.52	0.000465	0.0288	0.19	0.16	Intelligence (multi-trait analysis);	chr10:102336975	chr10:102449817~102461106:+
THCA	cis	rs7259376	0.875	rs10409520	ENSG00000270947.1	AC025811.3	3.52	0.000465	0.0288	0.17	0.16	Menopause (age at onset);	chr19:22329675	chr19:22455988~22456459:+
THCA	cis	rs911555	0.706	rs10129426	ENSG00000244691.1	RPL10AP1	-3.52	0.000465	0.0288	-0.21	-0.16	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103412119~103412761:-
THCA	cis	rs7546094	0.792	rs6537748	ENSG00000273483.1	RP4-671G15.2	-3.52	0.000465	0.0288	-0.15	-0.16	Platelet distribution width;	chr1:112671759	chr1:112517799~112518441:-
THCA	cis	rs2898290	0.617	rs13273172	ENSG00000227888.4	FAM66A	-3.52	0.000465	0.0288	-0.21	-0.16	Systolic blood pressure;	chr8:11603602	chr8:12362019~12388296:+
THCA	cis	rs13098911	0.54	rs34863575	ENSG00000226074.4	PRSS44	-3.52	0.000465	0.0288	-0.31	-0.16	Celiac disease;	chr3:46052571	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs35772789	ENSG00000226074.4	PRSS44	-3.52	0.000465	0.0288	-0.31	-0.16	Celiac disease;	chr3:46053612	chr3:46809359~46812558:-
THCA	cis	rs755249	0.529	rs3768299	ENSG00000182109.6	RP11-69E11.4	3.52	0.000465	0.0288	0.17	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39522280~39546187:-
THCA	cis	rs9457247	0.602	rs2239827	ENSG00000235272.1	FAM103A2P	3.52	0.000465	0.0288	0.23	0.16	Crohn's disease;	chr6:167077457	chr6:166586124~166586477:-
THCA	cis	rs2880765	0.677	rs7181410	ENSG00000218052.5	ADAMTS7P4	3.52	0.000465	0.0288	0.18	0.16	Coronary artery disease;	chr15:85463104	chr15:85255369~85330334:-
THCA	cis	rs758324	0.679	rs79392931	ENSG00000224431.1	AC063976.7	-3.52	0.000465	0.0288	-0.23	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131949422	chr5:132199456~132203487:+
THCA	cis	rs3758911	0.861	rs11212117	ENSG00000255353.1	RP11-382M14.1	-3.52	0.000465	0.0288	-0.21	-0.16	Coronary artery disease;	chr11:107276757	chr11:107176286~107177530:+
THCA	cis	rs7613875	0.58	rs6808044	ENSG00000281691.1	RBM5-AS1	-3.52	0.000465	0.0288	-0.14	-0.16	Body mass index;	chr3:50098732	chr3:50099603~50100988:-
THCA	cis	rs3825942	1	rs1550437	ENSG00000261801.4	LOXL1-AS1	3.52	0.000465	0.0288	0.2	0.16	Glaucoma (exfoliation);	chr15:73928957	chr15:73908071~73928248:-
THCA	cis	rs9309473	1	rs62151652	ENSG00000273245.1	RP11-434P11.2	3.52	0.000465	0.0288	0.22	0.16	Metabolite levels;	chr2:73473004	chr2:73750256~73750786:-
THCA	cis	rs10975370	0.503	rs2618780	ENSG00000206147.5	RP11-106A1.2	3.52	0.000465	0.0288	0.19	0.16	Breast cancer;	chr9:6033581	chr9:6639139~6639604:+
THCA	cis	rs2652834	1	rs2729780	ENSG00000259459.4	RP11-321G12.1	-3.52	0.000466	0.0288	-0.17	-0.16	HDL cholesterol;	chr15:63112440	chr15:63390136~63438320:+
THCA	cis	rs1065852	0.526	rs2097561	ENSG00000281538.1	RP4-669P10.20	-3.52	0.000466	0.0288	-0.17	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993427	chr22:42138060~42139726:+
THCA	cis	rs1065852	0.526	rs2097562	ENSG00000281538.1	RP4-669P10.20	-3.52	0.000466	0.0288	-0.17	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993496	chr22:42138060~42139726:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000184274.3	LINC00315	-3.52	0.000466	0.0288	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45300245~45305257:-
THCA	cis	rs6545883	0.503	rs1665272	ENSG00000270820.4	RP11-355B11.2	3.52	0.000466	0.0288	0.13	0.16	Tuberculosis;	chr2:61152151	chr2:61471188~61484130:+
THCA	cis	rs9368222	1	rs7766070	ENSG00000280989.1	LINC00581	3.52	0.000466	0.0288	0.21	0.16	Body mass index;Peak insulin response;Acute insulin response;	chr6:20686342	chr6:21486061~21511895:-
THCA	cis	rs2933343	0.621	rs789249	ENSG00000261159.1	RP11-723O4.9	3.52	0.000466	0.0288	0.16	0.16	IgG glycosylation;	chr3:128859610	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.621	rs789241	ENSG00000261159.1	RP11-723O4.9	3.52	0.000466	0.0288	0.16	0.16	IgG glycosylation;	chr3:128866909	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.649	rs2638845	ENSG00000261159.1	RP11-723O4.9	3.52	0.000466	0.0288	0.16	0.16	IgG glycosylation;	chr3:128868526	chr3:128859716~128860526:-
THCA	cis	rs9625935	0.788	rs131296	ENSG00000279159.1	RP3-394A18.1	3.52	0.000466	0.0288	0.13	0.16	Tonsillectomy;	chr22:29778240	chr22:29978950~30028236:-
THCA	cis	rs72843506	0.586	rs79246843	ENSG00000231258.2	ZSWIM5P2	3.52	0.000466	0.0288	0.25	0.16	Schizophrenia;	chr17:19938749	chr17:20583758~20591180:-
THCA	cis	rs7259376	0.84	rs1985135	ENSG00000269138.1	ZNF209P	3.52	0.000466	0.0288	0.17	0.16	Menopause (age at onset);	chr19:22340776	chr19:22463922~22473036:+
THCA	cis	rs6472235	0.749	rs62506641	ENSG00000272192.1	CTD-2532N20.1	3.52	0.000466	0.0288	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65991456	chr8:65842752~65843331:+
THCA	cis	rs950169	0.922	rs4842940	ENSG00000230373.7	GOLGA6L5P	3.52	0.000466	0.0288	0.17	0.16	Schizophrenia;	chr15:84162473	chr15:84507885~84516814:-
THCA	cis	rs950169	0.922	rs4842941	ENSG00000230373.7	GOLGA6L5P	3.52	0.000466	0.0288	0.17	0.16	Schizophrenia;	chr15:84162560	chr15:84507885~84516814:-
THCA	cis	rs950169	0.922	rs12911223	ENSG00000230373.7	GOLGA6L5P	3.52	0.000466	0.0288	0.17	0.16	Schizophrenia;	chr15:84162919	chr15:84507885~84516814:-
THCA	cis	rs11673344	0.504	rs10402907	ENSG00000267260.1	CTD-2162K18.4	-3.52	0.000466	0.0288	-0.19	-0.16	Obesity-related traits;	chr19:37112874	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.563	rs4805199	ENSG00000267260.1	CTD-2162K18.4	-3.52	0.000466	0.0288	-0.19	-0.16	Obesity-related traits;	chr19:37115527	chr19:36773153~36777078:+
THCA	cis	rs4601821	0.895	rs2282511	ENSG00000270179.1	RP11-159N11.4	-3.52	0.000466	0.0288	-0.17	-0.16	Alcoholic chronic pancreatitis;	chr11:113373455	chr11:113368478~113369117:+
THCA	cis	rs6545883	0.868	rs2518932	ENSG00000212978.6	AC016747.3	3.52	0.000466	0.0288	0.17	0.16	Tuberculosis;	chr2:61574142	chr2:61141592~61144969:-
THCA	cis	rs7824557	0.583	rs2736306	ENSG00000261451.1	RP11-981G7.1	3.52	0.000466	0.0288	0.2	0.16	Retinal vascular caliber;	chr8:11382253	chr8:10433672~10438312:+
THCA	cis	rs7246967	0.673	rs2099341	ENSG00000198153.8	ZNF849P	-3.52	0.000466	0.0288	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22651558	chr19:22685167~22686732:+
THCA	cis	rs4845570	1	rs3790514	ENSG00000268288.1	RP11-98D18.16	-3.52	0.000466	0.0288	-0.24	-0.16	Coronary artery disease;	chr1:151771692	chr1:151766486~151767000:-
THCA	cis	rs4578769	0.765	rs3844226	ENSG00000265939.1	UBE2CP2	-3.52	0.000466	0.0288	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22866817	chr18:22900486~22900995:-
THCA	cis	rs6500602	0.647	rs4786519	ENSG00000280063.1	RP11-295D4.3	3.52	0.000466	0.0288	0.09	0.16	Schizophrenia;	chr16:4534405	chr16:4346694~4348648:-
THCA	cis	rs2239557	0.57	rs7157377	ENSG00000259065.1	RP5-1021I20.1	-3.52	0.000466	0.0288	-0.24	-0.16	Common traits (Other);	chr14:73974473	chr14:73787360~73803270:+
THCA	cis	rs9868809	0.772	rs9812977	ENSG00000229759.1	MRPS18AP1	-3.52	0.000466	0.0288	-0.33	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48682870	chr3:48256350~48256938:-
THCA	cis	rs1552172	0.853	rs913513	ENSG00000234222.5	RP11-315I20.1	3.52	0.000466	0.0288	0.2	0.16	Breast cancer;	chr1:145839687	chr1:145926590~145959179:+
THCA	cis	rs10857712	0.904	rs7083614	ENSG00000214279.11	SCART1	-3.52	0.000466	0.0288	-0.13	-0.16	Systemic lupus erythematosus;	chr10:133412732	chr10:133453928~133523558:+
THCA	cis	rs6598541	1	rs12908437	ENSG00000278090.1	RP11-6O2.2	-3.52	0.000466	0.0288	-0.15	-0.16	Urate levels;	chr15:98744146	chr15:99028538~99031053:+
THCA	cis	rs972578	0.776	rs2267464	ENSG00000230319.1	AL022476.2	3.52	0.000466	0.0288	0.17	0.16	Mean platelet volume;	chr22:42902640	chr22:43038585~43052366:+
THCA	cis	rs11098699	0.635	rs2132078	ENSG00000273007.1	RP11-170N16.3	3.52	0.000466	0.0288	0.13	0.16	Mosquito bite size;	chr4:123319274	chr4:122881878~122884712:-
THCA	cis	rs775227	0.574	rs3732809	ENSG00000243849.1	CFAP44-AS1	3.52	0.000466	0.0288	0.3	0.16	Dental caries;	chr3:113326714	chr3:113403991~113433992:+
THCA	cis	rs6929812	0.639	rs726830	ENSG00000271755.1	RP1-153G14.4	3.52	0.000466	0.0288	0.19	0.16	Neuroticism (multi-trait analysis);	chr6:27455411	chr6:27404010~27406964:-
THCA	cis	rs853679	1	rs735765	ENSG00000220721.1	OR1F12	3.52	0.000466	0.0288	0.27	0.16	Depression;	chr6:28202519	chr6:28073316~28074233:+
THCA	cis	rs8177876	0.749	rs12927828	ENSG00000261838.4	RP11-303E16.6	3.52	0.000466	0.0288	0.26	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81069854~81076598:+
THCA	cis	rs72827839	0.846	rs76950846	ENSG00000266601.1	RP11-6N17.3	3.52	0.000466	0.0288	0.19	0.16	Ease of getting up in the morning;	chr17:48024787	chr17:47929682~47933106:-
THCA	cis	rs11098699	0.784	rs11737129	ENSG00000273007.1	RP11-170N16.3	3.52	0.000466	0.0288	0.13	0.16	Mosquito bite size;	chr4:123322266	chr4:122881878~122884712:-
THCA	cis	rs2434529	1	rs514699	ENSG00000245275.6	SAP30L-AS1	3.52	0.000466	0.0288	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154259483	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs534987	ENSG00000245275.6	SAP30L-AS1	3.52	0.000466	0.0288	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154259537	chr5:154329437~154445850:-
THCA	cis	rs853679	0.599	rs149949	ENSG00000272009.1	RP1-313I6.12	-3.52	0.000466	0.0288	-0.22	-0.16	Depression;	chr6:28043738	chr6:28078792~28081130:-
THCA	cis	rs10857712	0.904	rs2265641	ENSG00000214279.11	SCART1	3.52	0.000466	0.0288	0.13	0.16	Systemic lupus erythematosus;	chr10:133408365	chr10:133453928~133523558:+
THCA	cis	rs12681963	0.688	rs16876672	ENSG00000272375.1	RP11-51J9.6	3.52	0.000466	0.0288	0.24	0.16	Migraine;	chr8:30207450	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs7837611	ENSG00000272375.1	RP11-51J9.6	3.52	0.000466	0.0288	0.24	0.16	Migraine;	chr8:30210013	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs7014016	ENSG00000272375.1	RP11-51J9.6	3.52	0.000466	0.0288	0.24	0.16	Migraine;	chr8:30211271	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs73234786	ENSG00000272375.1	RP11-51J9.6	3.52	0.000466	0.0288	0.24	0.16	Migraine;	chr8:30212836	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs12680753	ENSG00000272375.1	RP11-51J9.6	3.52	0.000466	0.0288	0.24	0.16	Migraine;	chr8:30212963	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs55991127	ENSG00000272375.1	RP11-51J9.6	3.52	0.000466	0.0288	0.24	0.16	Migraine;	chr8:30213510	chr8:30197404~30198048:+
THCA	cis	rs7924176	0.521	rs1904062	ENSG00000271848.1	RP11-464F9.21	-3.52	0.000466	0.0288	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:73654039~73674719:+
THCA	cis	rs11237982	0.673	rs72946474	ENSG00000255345.1	CTD-2337I7.1	-3.52	0.000466	0.0288	-0.27	-0.16	Verbal declarative memory;	chr11:79717547	chr11:79092848~79098003:+
THCA	cis	rs56309584	0.883	rs3027247	ENSG00000178977.3	LINC00324	3.52	0.000466	0.0288	0.19	0.16	Initial pursuit acceleration;	chr17:8227549	chr17:8220642~8224043:-
THCA	cis	rs1389724	0.686	rs11102159	ENSG00000259834.1	RP11-284N8.3	-3.52	0.000466	0.0289	-0.13	-0.16	Schizophrenia;	chr1:110782105	chr1:110653560~110657040:-
THCA	cis	rs2562456	0.558	rs62108173	ENSG00000268081.1	RP11-678G14.2	3.52	0.000467	0.0289	0.27	0.16	Pain;	chr19:21244386	chr19:21554640~21569237:-
THCA	cis	rs6840360	0.571	rs62327278	ENSG00000251611.1	RP11-610P16.1	-3.52	0.000467	0.0289	-0.13	-0.16	Intelligence (multi-trait analysis);	chr4:151637638	chr4:151407551~151408835:-
THCA	cis	rs9635324	0.927	rs17733719	ENSG00000259536.4	RP11-111A22.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite ratios;Blood metabolite levels;	chr15:40428587	chr15:40488041~40558019:+
THCA	cis	rs2235649	0.828	rs9925354	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1799865	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.828	rs9938694	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1799871	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.828	rs9936486	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1799887	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.753	rs4316755	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1799915	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs2011088	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1800090	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs7190337	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1800468	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs7189070	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1800812	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs9926962	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1801825	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs9929185	ENSG00000260541.1	LA16c-429E7.1	3.52	0.000467	0.0289	0.21	0.16	Blood metabolite levels;	chr16:1802069	chr16:1841020~1843547:-
THCA	cis	rs12780845	0.931	rs3758418	ENSG00000273153.1	RP11-406H21.2	3.52	0.000467	0.0289	0.15	0.16	Homocysteine levels;	chr10:17203639	chr10:17137336~17137585:-
THCA	cis	rs524281	0.729	rs12790034	ENSG00000255120.4	OVOL1-AS1	3.52	0.000467	0.0289	0.25	0.16	Electroencephalogram traits;	chr11:66018268	chr11:65789051~65790868:-
THCA	cis	rs6942407	0.592	rs886318	ENSG00000224046.1	AC005076.5	-3.52	0.000467	0.0289	-0.15	-0.16	Food allergy;	chr7:87117184	chr7:87151423~87152420:-
THCA	cis	rs4578769	0.765	rs61311054	ENSG00000265939.1	UBE2CP2	-3.52	0.000467	0.0289	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22906406	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs10502430	ENSG00000265939.1	UBE2CP2	-3.52	0.000467	0.0289	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22916946	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs898000	ENSG00000265939.1	UBE2CP2	-3.52	0.000467	0.0289	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22929109	chr18:22900486~22900995:-
THCA	cis	rs3792900	0.509	rs10463951	ENSG00000271824.1	AC009014.3	-3.52	0.000467	0.0289	-0.17	-0.16	Blood protein levels;Insomnia;	chr5:136238423	chr5:136191468~136193134:-
THCA	cis	rs11634944	0.676	rs2732031	ENSG00000257647.1	RP11-701H24.3	3.52	0.000467	0.0289	0.09	0.16	Interleukin-8 levels;	chr15:24997789	chr15:25027736~25032047:-
THCA	cis	rs12807809	0.945	rs1939214	ENSG00000254941.1	RP11-677M14.5	3.52	0.000467	0.0289	0.17	0.16	Schizophrenia;	chr11:124735394	chr11:124807822~124808269:-
THCA	cis	rs10181042	0.535	rs2441465	ENSG00000232713.2	AC010733.5	3.52	0.000467	0.0289	0.14	0.16	Crohn's disease;	chr2:61084052	chr2:60938204~60938604:-
THCA	cis	rs1357692	0.899	rs2030677	ENSG00000238250.1	ST6GAL2-IT1	-3.52	0.000467	0.0289	-0.16	-0.16	Alzheimer's disease;	chr2:107063284	chr2:106822923~106825031:-
THCA	cis	rs2180341	0.782	rs6924274	ENSG00000220522.2	RP1-177A13.1	3.52	0.000467	0.0289	0.19	0.16	Breast cancer;	chr6:127400411	chr6:127416535~127416952:-
THCA	cis	rs972578	0.837	rs4822201	ENSG00000230319.1	AL022476.2	3.52	0.000467	0.0289	0.17	0.16	Mean platelet volume;	chr22:42831266	chr22:43038585~43052366:+
THCA	cis	rs6545883	0.783	rs7355640	ENSG00000270820.4	RP11-355B11.2	3.52	0.000467	0.0289	0.13	0.16	Tuberculosis;	chr2:61618350	chr2:61471188~61484130:+
THCA	cis	rs409045	1	rs456108	ENSG00000271874.1	CTD-2024P10.2	-3.52	0.000467	0.0289	-0.21	-0.16	Left ventricular mass;	chr5:34636885	chr5:34651457~34651888:-
THCA	cis	rs453301	0.631	rs7843369	ENSG00000253981.4	ALG1L13P	-3.52	0.000467	0.0289	-0.16	-0.16	Joint mobility (Beighton score);	chr8:8940276	chr8:8236003~8244667:-
THCA	cis	rs7829975	0.514	rs2920983	ENSG00000248538.5	RP11-10A14.5	-3.52	0.000467	0.0289	-0.19	-0.16	Mood instability;	chr8:8410553	chr8:9189011~9202854:+
THCA	cis	rs7162310	1	rs12898755	ENSG00000259459.4	RP11-321G12.1	3.52	0.000467	0.0289	0.15	0.16	Myopia;	chr15:63282442	chr15:63390136~63438320:+
THCA	cis	rs2692947	0.702	rs7604842	ENSG00000232931.4	LINC00342	-3.52	0.000467	0.0289	-0.13	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96111592	chr2:95807118~95816215:-
THCA	cis	rs4272720	0.562	rs17701186	ENSG00000234736.4	FAM170B-AS1	-3.52	0.000467	0.0289	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49131473	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.562	rs12765281	ENSG00000234736.4	FAM170B-AS1	-3.52	0.000467	0.0289	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49131880	chr10:49121839~49151547:+
THCA	cis	rs10419113	0.641	rs12611312	ENSG00000270804.1	CTD-2583A14.11	-3.52	0.000467	0.0289	-0.13	-0.16	Pediatric bone mineral density (spine);	chr19:57764436	chr19:57867885~57868834:+
THCA	cis	rs10043228	0.702	rs6873096	ENSG00000250015.1	CTC-339F2.2	3.52	0.000467	0.0289	0.19	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116293490	chr5:116302354~116304134:-
THCA	cis	rs2305707	0.544	rs2470153	ENSG00000273674.3	CTD-2378E12.1	3.52	0.000467	0.0289	0.33	0.16	Height;	chr15:51300720	chr15:50839875~50908599:-
THCA	cis	rs875971	0.545	rs73150604	ENSG00000273024.4	INTS4P2	-3.52	0.000467	0.0289	-0.2	-0.16	Aortic root size;	chr7:66480545	chr7:65647864~65715661:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000273024.4	INTS4P2	-3.52	0.000467	0.0289	-0.2	-0.16	Aortic root size;	chr7:66481592	chr7:65647864~65715661:+
THCA	cis	rs8049603	0.504	rs12920681	ENSG00000257838.4	RP11-368J21.3	3.52	0.000467	0.0289	0.2	0.16	Multiple sclerosis;	chr16:23187575	chr16:22545698~22576865:+
THCA	cis	rs9475677	0.953	rs79328757	ENSG00000231441.1	RP11-472M19.2	3.52	0.000467	0.0289	0.2	0.16	Gut microbiota (functional units);	chr6:56360387	chr6:56844002~56864078:+
THCA	cis	rs8064024	0.501	rs28375268	ENSG00000267077.1	RP11-127I20.5	-3.52	0.000467	0.0289	-0.19	-0.16	Cancer;	chr16:4899527	chr16:4795265~4796532:-
THCA	cis	rs10875746	0.551	rs1471997	ENSG00000258273.1	RP11-370I10.4	3.52	0.000467	0.0289	0.23	0.16	Longevity (90 years and older);	chr12:48329812	chr12:48333755~48333901:-
THCA	cis	rs11601239	0.668	rs7102567	ENSG00000254750.1	CASP1P2	-3.52	0.000467	0.0289	-0.13	-0.16	Refractive error;	chr11:105685118	chr11:105063345~105071541:-
THCA	cis	rs6787172	0.651	rs6806702	ENSG00000272087.1	RP11-379F4.7	3.52	0.000467	0.0289	0.14	0.16	Subjective well-being;	chr3:158420939	chr3:158693120~158693768:-
THCA	cis	rs8054556	1	rs4788200	ENSG00000214725.6	CDIPT-AS1	-3.52	0.000467	0.0289	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29959944	chr16:29863593~29868053:+
THCA	cis	rs8054556	1	rs4788201	ENSG00000214725.6	CDIPT-AS1	-3.52	0.000467	0.0289	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29961369	chr16:29863593~29868053:+
THCA	cis	rs8054556	1	rs6565173	ENSG00000214725.6	CDIPT-AS1	-3.52	0.000467	0.0289	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29962846	chr16:29863593~29868053:+
THCA	cis	rs453301	0.624	rs330058	ENSG00000254340.1	RP11-10A14.3	-3.52	0.000467	0.0289	-0.18	-0.16	Joint mobility (Beighton score);	chr8:9232299	chr8:9141424~9145435:+
THCA	cis	rs6840360	0.571	rs4696271	ENSG00000251611.1	RP11-610P16.1	-3.52	0.000467	0.0289	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151587966	chr4:151407551~151408835:-
THCA	cis	rs9875589	0.915	rs9835402	ENSG00000233121.1	VN1R20P	3.52	0.000467	0.0289	0.18	0.16	Ovarian reserve;	chr3:13912899	chr3:13926813~13927778:+
THCA	cis	rs4946260	0.562	rs12527127	ENSG00000216809.1	RP11-57K17.1	3.52	0.000467	0.0289	0.16	0.16	Colorectal cancer;	chr6:117492106	chr6:118452469~118454992:-
THCA	cis	rs4925386	0.625	rs3810550	ENSG00000275437.1	RP5-908M14.10	3.52	0.000467	0.0289	0.17	0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62402236~62405935:-
THCA	cis	rs72827839	0.779	rs72823592	ENSG00000228782.6	CTD-2026D20.3	3.52	0.000467	0.0289	0.19	0.16	Ease of getting up in the morning;	chr17:48045642	chr17:47450568~47492492:-
THCA	cis	rs2948294	0.566	rs13261997	ENSG00000254340.1	RP11-10A14.3	3.52	0.000468	0.0289	0.18	0.16	Red cell distribution width;	chr8:8254773	chr8:9141424~9145435:+
THCA	cis	rs4938303	0.788	rs12799449	ENSG00000254851.1	RP11-109L13.1	3.52	0.000468	0.0289	0.24	0.16	Triglycerides;	chr11:116687809	chr11:117135528~117138582:+
THCA	cis	rs8130944	0.866	rs2839576	ENSG00000225731.1	AP001627.1	3.52	0.000468	0.0289	0.2	0.16	Perceived unattractiveness to mosquitoes;	chr21:42719847	chr21:42733594~42741758:-
THCA	cis	rs8130944	1	rs7278264	ENSG00000225731.1	AP001627.1	3.52	0.000468	0.0289	0.2	0.16	Perceived unattractiveness to mosquitoes;	chr21:42719931	chr21:42733594~42741758:-
THCA	cis	rs2836326	1	rs9975835	ENSG00000231123.1	SPATA20P1	3.52	0.000468	0.0289	0.23	0.16	Metabolite levels (HVA);	chr21:38339020	chr21:38238227~38238664:-
THCA	cis	rs56114371	0.53	rs9357045	ENSG00000220721.1	OR1F12	3.52	0.000468	0.0289	0.22	0.16	Breast cancer;	chr6:27721148	chr6:28073316~28074233:+
THCA	cis	rs860295	0.756	rs7546258	ENSG00000203761.5	MSTO2P	-3.52	0.000468	0.0289	-0.13	-0.16	Body mass index;	chr1:155728854	chr1:155745829~155750137:+
THCA	cis	rs12472274	0.648	rs67102443	ENSG00000279484.1	KLHL30-AS1	3.52	0.000468	0.0289	0.16	0.16	Phospholipid levels (plasma);	chr2:238175961	chr2:238152889~238155994:-
THCA	cis	rs10540	1	rs35811812	ENSG00000279672.1	CMB9-55F22.1	3.52	0.000468	0.0289	0.31	0.16	Body mass index;	chr11:498442	chr11:779617~780755:+
THCA	cis	rs6500602	0.702	rs1051308	ENSG00000280063.1	RP11-295D4.3	-3.52	0.000468	0.0289	-0.09	-0.16	Schizophrenia;	chr16:4510300	chr16:4346694~4348648:-
THCA	cis	rs7403037	0.563	rs2677387	ENSG00000260760.1	PWRN3	3.52	0.000468	0.0289	0.17	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24187648	chr15:24441127~24447967:+
THCA	cis	rs910316	0.967	rs4899550	ENSG00000273565.1	CTD-3075F15.1	-3.52	0.000468	0.0289	-0.19	-0.16	Height;	chr14:75180963	chr14:75176929~75177418:+
THCA	cis	rs6499755	0.932	rs9302665	ENSG00000260135.5	RP11-212I21.2	3.52	0.000468	0.0289	0.18	0.16	Hypospadias;	chr16:55306655	chr16:55426797~55462297:-
THCA	cis	rs9590614	0.872	rs11840816	ENSG00000278390.3	RP11-74J13.8	-3.52	0.000468	0.0289	-0.15	-0.16	Local histogram emphysema pattern;	chr13:41597225	chr13:41132939~41236686:+
THCA	cis	rs9377188	0.619	rs729503	ENSG00000252244.1	RNU7-3P	-3.52	0.000468	0.0289	-0.18	-0.16	Cancer;	chr6:148973440	chr6:149516956~149517017:+
THCA	cis	rs10760158	0.832	rs4837820	ENSG00000235865.2	GSN-AS1	3.52	0.000468	0.0289	0.14	0.16	Pulse pressure;	chr9:121247816	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs4837821	ENSG00000235865.2	GSN-AS1	3.52	0.000468	0.0289	0.14	0.16	Pulse pressure;	chr9:121248241	chr9:121280768~121285530:-
THCA	cis	rs7142002	0.881	rs8013848	ENSG00000271780.1	RP11-1017G21.5	-3.52	0.000468	0.0289	-0.25	-0.16	Autism;	chr14:101935790	chr14:101948347~101949425:+
THCA	cis	rs1876905	0.569	rs354523	ENSG00000271789.1	RP5-1112D6.7	-3.52	0.000468	0.0289	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111297126~111298510:+
THCA	cis	rs7264396	0.635	rs6060696	ENSG00000088340.14	FER1L4	3.52	0.000468	0.0289	0.16	0.16	Total cholesterol levels;	chr20:35934138	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs2064724	ENSG00000088340.14	FER1L4	3.52	0.000468	0.0289	0.16	0.16	Total cholesterol levels;	chr20:35934598	chr20:35558737~35607562:-
THCA	cis	rs7216064	1	rs4791212	ENSG00000278740.1	RP11-147L13.14	3.52	0.000468	0.0289	0.19	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67979269	chr17:68188547~68189165:+
THCA	cis	rs5769765	0.773	rs7290751	ENSG00000260613.1	RP3-522J7.6	-3.52	0.000468	0.0289	-0.21	-0.16	Schizophrenia;	chr22:49924664	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.779	rs12170530	ENSG00000260613.1	RP3-522J7.6	-3.52	0.000468	0.0289	-0.21	-0.16	Schizophrenia;	chr22:49924774	chr22:49832616~49837786:-
THCA	cis	rs2447820	0.588	rs11241669	ENSG00000263432.2	RN7SL689P	-3.52	0.000468	0.0289	-0.2	-0.16	Migraine;	chr5:123033068	chr5:123022487~123022783:-
THCA	cis	rs1799922	0.965	rs4559164	ENSG00000271553.1	RP11-274B21.10	-3.52	0.000468	0.0289	-0.14	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128761756	chr7:128667043~128668156:+
THCA	cis	rs1799922	0.965	rs12534064	ENSG00000271553.1	RP11-274B21.10	-3.52	0.000468	0.0289	-0.14	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128761978	chr7:128667043~128668156:+
THCA	cis	rs17153755	0.796	rs2645456	ENSG00000255046.1	RP11-297N6.4	-3.52	0.000468	0.0289	-0.17	-0.16	Testicular germ cell tumor;	chr8:11757673	chr8:11797928~11802568:-
THCA	cis	rs2357982	0.507	rs59174355	ENSG00000232320.6	AC009299.5	-3.52	0.000468	0.0289	-0.21	-0.16	Presence of antiphospholipid antibodies;	chr2:161023627	chr2:161340816~161341326:-
THCA	cis	rs11711311	0.747	rs11928494	ENSG00000241529.3	RN7SL767P	-3.52	0.000468	0.029	-0.23	-0.16	IgG glycosylation;	chr3:113624372	chr3:113632704~113632998:+
THCA	cis	rs16976116	0.643	rs7181237	ENSG00000279145.1	RP11-547D13.1	3.52	0.000468	0.029	0.15	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55225033	chr15:55171972~55178175:-
THCA	cis	rs13279522	0.908	rs13252592	ENSG00000272192.1	CTD-2532N20.1	3.52	0.000468	0.029	0.2	0.16	Coronary heart disease event reduction (statin therapy interaction);	chr8:66054013	chr8:65842752~65843331:+
THCA	cis	rs478304	0.627	rs11604568	ENSG00000214659.4	KRT8P26	3.52	0.000468	0.029	0.14	0.16	Acne (severe);	chr11:65743865	chr11:65726939~65728214:+
THCA	cis	rs478304	0.651	rs7110576	ENSG00000214659.4	KRT8P26	3.52	0.000468	0.029	0.14	0.16	Acne (severe);	chr11:65744586	chr11:65726939~65728214:+
THCA	cis	rs7259376	0.869	rs6511346	ENSG00000269138.1	ZNF209P	3.52	0.000469	0.029	0.16	0.16	Menopause (age at onset);	chr19:22354772	chr19:22463922~22473036:+
THCA	cis	rs4664304	0.62	rs2357691	ENSG00000226266.5	AC009961.3	3.52	0.000469	0.029	0.19	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159868628	chr2:159670708~159712435:-
THCA	cis	rs17685	0.753	rs2108274	ENSG00000227038.2	AC005077.12	3.52	0.000469	0.029	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76152318	chr7:76090431~76108779:-
THCA	cis	rs11686241	0.872	rs16856226	ENSG00000232485.2	AC098820.3	3.52	0.000469	0.029	0.18	0.16	Cancer;	chr2:216484954	chr2:216479030~216498761:-
THCA	cis	rs987724	0.519	rs9820830	ENSG00000241544.1	RP11-6F2.5	-3.52	0.000469	0.029	-0.2	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824915	chr3:157081841~157088547:+
THCA	cis	rs11168618	0.846	rs11168586	ENSG00000240399.1	RP1-228P16.1	3.52	0.000469	0.029	0.16	0.16	Adiponectin levels;	chr12:48460229	chr12:48054813~48055591:-
THCA	cis	rs7216064	1	rs12452511	ENSG00000265055.1	AC145343.2	3.52	0.000469	0.029	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836460	chr17:68096046~68101474:-
THCA	cis	rs8030605	0.704	rs1087837	ENSG00000277245.1	RP11-48G14.3	-3.52	0.000469	0.029	-0.28	-0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56441441	chr15:56447120~56447697:+
THCA	cis	rs524281	0.773	rs7127808	ENSG00000255038.1	RP11-1167A19.2	-3.52	0.000469	0.029	-0.19	-0.16	Electroencephalogram traits;	chr11:66164448	chr11:66067277~66069619:-
THCA	cis	rs8081187	0.803	rs9898690	ENSG00000263531.1	RP13-753N3.1	3.52	0.000469	0.029	0.37	0.16	Breast cancer;	chr17:30541321	chr17:30863921~30864940:-
THCA	cis	rs7586879	0.575	rs6721750	ENSG00000224165.4	DNAJC27-AS1	-3.52	0.000469	0.029	-0.09	-0.16	Body mass index;	chr2:24905850	chr2:24971390~25039694:+
THCA	cis	rs7586879	0.551	rs7565460	ENSG00000224165.4	DNAJC27-AS1	-3.52	0.000469	0.029	-0.09	-0.16	Body mass index;	chr2:24907204	chr2:24971390~25039694:+
THCA	cis	rs7586879	0.593	rs10198275	ENSG00000224165.4	DNAJC27-AS1	-3.52	0.000469	0.029	-0.09	-0.16	Body mass index;	chr2:24907673	chr2:24971390~25039694:+
THCA	cis	rs7586879	0.593	rs10198356	ENSG00000224165.4	DNAJC27-AS1	-3.52	0.000469	0.029	-0.09	-0.16	Body mass index;	chr2:24907723	chr2:24971390~25039694:+
THCA	cis	rs4792901	0.722	rs12603085	ENSG00000279602.1	CTD-3014M21.1	-3.52	0.000469	0.029	-0.2	-0.16	Dupuytren's disease;	chr17:43468479	chr17:43360041~43361361:-
THCA	cis	rs9650657	0.769	rs1115866	ENSG00000255310.2	AF131215.2	-3.52	0.000469	0.029	-0.13	-0.16	Neuroticism;	chr8:10780823	chr8:11107788~11109726:-
THCA	cis	rs4808199	1	rs4808199	ENSG00000267481.1	CTC-559E9.5	-3.52	0.000469	0.029	-0.17	-0.16	Nonalcoholic fatty liver disease;	chr19:19434290	chr19:19788755~19790531:-
THCA	cis	rs875971	0.545	rs10261710	ENSG00000273142.1	RP11-458F8.4	3.52	0.000469	0.029	0.15	0.16	Aortic root size;	chr7:66249202	chr7:66902857~66906297:+
THCA	cis	rs17685	0.753	rs4398845	ENSG00000227038.2	AC005077.12	3.52	0.000469	0.029	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76087463	chr7:76090431~76108779:-
THCA	cis	rs9400467	0.528	rs1989574	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000469	0.029	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111309203~111313517:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000230295.1	RP11-458F8.2	-3.52	0.000469	0.029	-0.13	-0.16	Aortic root size;	chr7:65963835	chr7:66880708~66882981:+
THCA	cis	rs6456156	0.792	rs4710178	ENSG00000235272.1	FAM103A2P	3.52	0.000469	0.029	0.22	0.16	Primary biliary cholangitis;	chr6:167100044	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.792	rs4710179	ENSG00000235272.1	FAM103A2P	3.52	0.000469	0.029	0.22	0.16	Primary biliary cholangitis;	chr6:167100204	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.792	rs4710181	ENSG00000235272.1	FAM103A2P	3.52	0.000469	0.029	0.22	0.16	Primary biliary cholangitis;	chr6:167100510	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.755	rs4710182	ENSG00000235272.1	FAM103A2P	3.52	0.000469	0.029	0.22	0.16	Primary biliary cholangitis;	chr6:167100573	chr6:166586124~166586477:-
THCA	cis	rs2710103	0.529	rs35814206	ENSG00000264918.1	AC005229.1	-3.52	0.000469	0.029	-0.32	-0.16	Facial morphology (factor 11, projection of the nose);	chr7:147886036	chr7:148730829~148730928:-
THCA	cis	rs757978	0.929	rs111943976	ENSG00000235351.1	AC114730.11	-3.52	0.000469	0.029	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:241439490	chr2:241724615~241725693:-
THCA	cis	rs867371	1	rs1174543	ENSG00000278603.1	RP13-608F4.5	-3.52	0.000469	0.029	-0.21	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472203~82472426:+
THCA	cis	rs722599	0.683	rs8022046	ENSG00000279594.1	RP11-950C14.10	3.52	0.000469	0.029	0.16	0.16	IgG glycosylation;	chr14:74811599	chr14:75011269~75012851:-
THCA	cis	rs722599	0.683	rs8008475	ENSG00000279594.1	RP11-950C14.10	3.52	0.000469	0.029	0.16	0.16	IgG glycosylation;	chr14:74825197	chr14:75011269~75012851:-
THCA	cis	rs2243480	1	rs778729	ENSG00000237310.1	GS1-124K5.4	3.52	0.000469	0.029	0.19	0.16	Diabetic kidney disease;	chr7:66359432	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.901	rs778687	ENSG00000237310.1	GS1-124K5.4	3.52	0.000469	0.029	0.19	0.16	Diabetic kidney disease;	chr7:66370832	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs778679	ENSG00000237310.1	GS1-124K5.4	3.52	0.000469	0.029	0.19	0.16	Diabetic kidney disease;	chr7:66375924	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs778704	ENSG00000237310.1	GS1-124K5.4	3.52	0.000469	0.029	0.19	0.16	Diabetic kidney disease;	chr7:66398480	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.901	rs778693	ENSG00000237310.1	GS1-124K5.4	3.52	0.000469	0.029	0.19	0.16	Diabetic kidney disease;	chr7:66407358	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs778691	ENSG00000237310.1	GS1-124K5.4	3.52	0.000469	0.029	0.19	0.16	Diabetic kidney disease;	chr7:66408105	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs13235972	ENSG00000237310.1	GS1-124K5.4	3.52	0.000469	0.029	0.19	0.16	Diabetic kidney disease;	chr7:66418618	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs34192067	ENSG00000237310.1	GS1-124K5.4	3.52	0.000469	0.029	0.19	0.16	Diabetic kidney disease;	chr7:66422670	chr7:66493706~66495474:+
THCA	cis	rs10129255	0.646	rs55995061	ENSG00000280411.1	IGHV1-69-2	-3.52	0.000469	0.029	-0.1	-0.16	Kawasaki disease;	chr14:106799309	chr14:106762092~106762588:-
THCA	cis	rs72843506	0.586	rs75836592	ENSG00000231258.2	ZSWIM5P2	3.52	0.000469	0.029	0.25	0.16	Schizophrenia;	chr17:19935039	chr17:20583758~20591180:-
THCA	cis	rs11648785	0.522	rs4627348	ENSG00000222019.6	URAHP	3.52	0.000469	0.029	0.13	0.16	Tanning;	chr16:90032208	chr16:90039761~90047773:-
THCA	cis	rs1023500	0.596	rs5751209	ENSG00000270083.1	RP1-257I20.14	3.52	0.000469	0.029	0.19	0.16	Schizophrenia;	chr22:42055599	chr22:42089630~42090028:-
THCA	cis	rs2179367	0.887	rs506268	ENSG00000223701.3	RAET1E-AS1	3.52	0.000469	0.029	0.2	0.16	Dupuytren's disease;	chr6:149364481	chr6:149884431~149919508:+
THCA	cis	rs758324	0.812	rs12653237	ENSG00000224431.1	AC063976.7	3.52	0.000469	0.029	0.15	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131906085	chr5:132199456~132203487:+
THCA	cis	rs2625529	0.824	rs12439900	ENSG00000260037.4	CTD-2524L6.3	-3.52	0.000469	0.029	-0.22	-0.16	Red blood cell count;	chr15:72081299	chr15:71818396~71823384:+
THCA	cis	rs9650657	0.812	rs11250073	ENSG00000269918.1	AF131215.9	-3.52	0.000469	0.029	-0.17	-0.16	Neuroticism;	chr8:10774726	chr8:11104691~11106704:-
THCA	cis	rs9329221	0.662	rs9650650	ENSG00000253641.4	RP11-981G7.2	3.52	0.000469	0.029	0.16	0.16	Neuroticism;	chr8:10390466	chr8:10474565~10481974:+
THCA	cis	rs5006884	0.906	rs71488546	ENSG00000167355.6	AC104389.28	-3.52	0.000469	0.029	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5367530	chr11:5304976~5505652:-
THCA	cis	rs1865760	0.566	rs3752420	ENSG00000272810.1	U91328.22	-3.52	0.000469	0.029	-0.13	-0.16	Height;	chr6:26026907	chr6:26013241~26013757:+
THCA	cis	rs9307551	0.619	rs1440862	ENSG00000249646.2	OR7E94P	-3.52	0.000469	0.029	-0.21	-0.16	Refractive error;	chr4:79503116	chr4:79587302~79588130:-
THCA	cis	rs8054556	0.74	rs4407079	ENSG00000273724.1	RP11-347C12.12	-3.52	0.000469	0.029	-0.15	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29920578	chr16:30336400~30343336:+
THCA	cis	rs12049351	0.774	rs6668018	ENSG00000229367.1	HMGN2P19	3.52	0.000469	0.029	0.24	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229493306	chr1:229570532~229570796:+
THCA	cis	rs503425	1	rs503425	ENSG00000255422.1	AP002954.4	-3.52	0.000469	0.029	-0.2	-0.16	Systemic lupus erythematosus;	chr11:118822018	chr11:118704607~118750263:+
THCA	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	3.52	0.000469	0.029	0.19	0.16	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
THCA	cis	rs57709857	0.957	rs28439472	ENSG00000272092.1	RP11-350N15.5	-3.52	0.000469	0.029	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38297649	chr8:38382364~38383461:+
THCA	cis	rs642858	0.784	rs9376478	ENSG00000234147.1	RP3-460G2.2	3.52	0.000469	0.029	0.2	0.16	Type 2 diabetes;	chr6:139883640	chr6:140845958~140852924:-
THCA	cis	rs7914558	1	rs7067970	ENSG00000272912.1	RP11-724N1.1	-3.52	0.000469	0.029	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:102914585~102915404:+
THCA	cis	rs801193	0.844	rs732465	ENSG00000230295.1	RP11-458F8.2	-3.52	0.000469	0.029	-0.12	-0.16	Aortic root size;	chr7:66533463	chr7:66880708~66882981:+
THCA	cis	rs801193	0.773	rs801207	ENSG00000230295.1	RP11-458F8.2	3.52	0.000469	0.029	0.12	0.16	Aortic root size;	chr7:66555603	chr7:66880708~66882981:+
THCA	cis	rs875971	0.543	rs801191	ENSG00000230295.1	RP11-458F8.2	3.52	0.000469	0.029	0.12	0.16	Aortic root size;	chr7:66567968	chr7:66880708~66882981:+
THCA	cis	rs875971	0.508	rs6947808	ENSG00000230295.1	RP11-458F8.2	3.52	0.000469	0.029	0.12	0.16	Aortic root size;	chr7:66580095	chr7:66880708~66882981:+
THCA	cis	rs3087591	0.708	rs7350943	ENSG00000263535.1	AK4P1	3.52	0.00047	0.029	0.19	0.16	Hip circumference;	chr17:31357535	chr17:31345521~31346187:+
THCA	cis	rs4389656	0.857	rs416847	ENSG00000248677.1	CTD-2044J15.1	3.52	0.00047	0.029	0.16	0.16	Coronary artery disease;	chr5:6739454	chr5:6686325~6707711:-
THCA	cis	rs9488822	0.676	rs873879	ENSG00000237021.2	RP3-486I3.7	3.52	0.00047	0.029	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116070096	chr6:116254207~116256743:+
THCA	cis	rs748404	0.666	rs60018990	ENSG00000166763.7	STRCP1	3.52	0.00047	0.029	0.21	0.16	Lung cancer;	chr15:43504606	chr15:43699488~43718184:-
THCA	cis	rs9427116	0.84	rs9427114	ENSG00000236675.1	MTX1P1	-3.52	0.00047	0.029	-0.15	-0.16	Blood protein levels;	chr1:154654229	chr1:155230975~155234325:+
THCA	cis	rs2014572	0.967	rs10426174	ENSG00000276449.1	AC004076.5	3.52	0.00047	0.029	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57244687	chr19:57449689~57453011:+
THCA	cis	rs2014572	0.967	rs7259978	ENSG00000276449.1	AC004076.5	3.52	0.00047	0.029	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57244761	chr19:57449689~57453011:+
THCA	cis	rs2014572	0.87	rs10426580	ENSG00000276449.1	AC004076.5	3.52	0.00047	0.029	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57244853	chr19:57449689~57453011:+
THCA	cis	rs4919087	0.59	rs793519	ENSG00000237169.1	RP11-452K12.3	-3.52	0.00047	0.029	-0.21	-0.16	Monocyte count;	chr10:97270797	chr10:97309138~97309958:-
THCA	cis	rs867186	1	rs7261167	ENSG00000126005.14	MMP24-AS1	-3.52	0.00047	0.029	-0.24	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34988402	chr20:35216462~35278131:-
THCA	cis	rs9590614	1	rs9590614	ENSG00000278390.3	RP11-74J13.8	3.52	0.00047	0.029	0.15	0.16	Local histogram emphysema pattern;	chr13:41601452	chr13:41132939~41236686:+
THCA	cis	rs7536700	0.908	rs6692298	ENSG00000272030.1	RP1-178F15.4	-3.52	0.00047	0.029	-0.29	-0.16	Multiple myeloma (IgH translocation);	chr1:153659663	chr1:153631438~153634397:-
THCA	cis	rs7536700	1	rs7536700	ENSG00000272030.1	RP1-178F15.4	-3.52	0.00047	0.029	-0.29	-0.16	Multiple myeloma (IgH translocation);	chr1:153668351	chr1:153631438~153634397:-
THCA	cis	rs775227	1	rs35341359	ENSG00000243849.1	CFAP44-AS1	3.52	0.00047	0.029	0.26	0.16	Dental caries;	chr3:113276090	chr3:113403991~113433992:+
THCA	cis	rs3750082	0.785	rs4720085	ENSG00000205763.12	RP9P	-3.52	0.00047	0.029	-0.13	-0.16	Glomerular filtration rate (creatinine);	chr7:32928524	chr7:32916815~32943176:-
THCA	cis	rs5758659	0.652	rs5751195	ENSG00000234009.1	RPL5P34	-3.52	0.00047	0.029	-0.15	-0.16	Cognitive function;	chr22:41983997	chr22:42776406~42777296:-
THCA	cis	rs7631605	0.967	rs9860764	ENSG00000272334.1	RP11-129K12.1	-3.52	0.00047	0.029	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:37217653	chr3:36973117~36973672:-
THCA	cis	rs4664293	0.967	rs2357526	ENSG00000230783.1	AC009961.2	3.52	0.00047	0.029	0.19	0.16	Monocyte percentage of white cells;	chr2:159668085	chr2:159689217~159690291:-
THCA	cis	rs1865760	0.566	rs2032449	ENSG00000272810.1	U91328.22	-3.52	0.00047	0.029	-0.13	-0.16	Height;	chr6:26026371	chr6:26013241~26013757:+
THCA	cis	rs15676	0.733	rs2900269	ENSG00000234771.3	SLC25A25-AS1	3.52	0.00047	0.029	0.14	0.16	Blood metabolite levels;	chr9:128807599	chr9:128108581~128118693:-
THCA	cis	rs12681963	0.61	rs75739606	ENSG00000272375.1	RP11-51J9.6	3.52	0.00047	0.029	0.24	0.16	Migraine;	chr8:30178768	chr8:30197404~30198048:+
THCA	cis	rs7941765	1	rs7927748	ENSG00000255465.3	RP11-264E20.1	-3.52	0.00047	0.029	-0.2	-0.16	Systemic lupus erythematosus;	chr11:128629679	chr11:128615867~128621806:-
THCA	cis	rs561341	0.882	rs563539	ENSG00000265798.5	RP11-271K11.5	3.52	0.00047	0.029	0.23	0.16	Hip circumference adjusted for BMI;	chr17:31980939	chr17:31038575~31059121:-
THCA	cis	rs4656958	0.93	rs1855186	ENSG00000233691.2	RP11-312J18.7	3.52	0.00047	0.029	0.19	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160917102	chr1:160935537~160936126:+
THCA	cis	rs1048886	0.872	rs78892979	ENSG00000271967.1	RP11-134K13.4	-3.52	0.00047	0.029	-0.19	-0.16	Type 2 diabetes;	chr6:70495559	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs77092253	ENSG00000271967.1	RP11-134K13.4	-3.52	0.00047	0.029	-0.19	-0.16	Type 2 diabetes;	chr6:70505156	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs74586626	ENSG00000271967.1	RP11-134K13.4	-3.52	0.00047	0.029	-0.19	-0.16	Type 2 diabetes;	chr6:70514387	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs17635446	ENSG00000271967.1	RP11-134K13.4	-3.52	0.00047	0.029	-0.19	-0.16	Type 2 diabetes;	chr6:70516453	chr6:70596438~70596980:+
THCA	cis	rs478304	0.651	rs11532071	ENSG00000214659.4	KRT8P26	3.52	0.00047	0.029	0.15	0.16	Acne (severe);	chr11:65732727	chr11:65726939~65728214:+
THCA	cis	rs478304	0.651	rs12225620	ENSG00000214659.4	KRT8P26	3.52	0.00047	0.029	0.15	0.16	Acne (severe);	chr11:65737977	chr11:65726939~65728214:+
THCA	cis	rs478304	0.651	rs10896038	ENSG00000214659.4	KRT8P26	3.52	0.00047	0.029	0.15	0.16	Acne (severe);	chr11:65738057	chr11:65726939~65728214:+
THCA	cis	rs7829975	0.577	rs940032	ENSG00000253981.4	ALG1L13P	-3.52	0.00047	0.029	-0.16	-0.16	Mood instability;	chr8:8688833	chr8:8236003~8244667:-
THCA	cis	rs9876781	0.559	rs1903144	ENSG00000228638.1	FCF1P2	-3.52	0.00047	0.029	-0.16	-0.16	Longevity;	chr3:48364907	chr3:48290793~48291375:-
THCA	cis	rs2447820	0.5	rs246278	ENSG00000263432.2	RN7SL689P	3.52	0.00047	0.029	0.2	0.16	Migraine;	chr5:122905343	chr5:123022487~123022783:-
THCA	cis	rs59197085	1	rs3800560	ENSG00000207588.1	MIR593	-3.52	0.00047	0.029	-0.31	-0.16	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);	chr7:128821040	chr7:128081861~128081960:+
THCA	cis	rs59197085	1	rs58845495	ENSG00000207588.1	MIR593	-3.52	0.00047	0.029	-0.31	-0.16	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);	chr7:128822793	chr7:128081861~128081960:+
THCA	cis	rs1198872	0.892	rs1198864	ENSG00000243819.4	RN7SL832P	3.52	0.00047	0.029	0.13	0.16	Cardiac Troponin-T levels;	chr2:10760869	chr2:10690344~10692099:+
THCA	cis	rs732716	0.853	rs72990643	ENSG00000280239.1	CTB-50L17.8	-3.52	0.00047	0.029	-0.13	-0.16	Mean corpuscular volume;	chr19:4454739	chr19:4448810~4450836:+
THCA	cis	rs10876993	0.715	rs2169987	ENSG00000270039.1	RP11-571M6.17	-3.52	0.00047	0.029	-0.17	-0.16	Celiac disease or Rheumatoid arthritis;	chr12:57618328	chr12:57803838~57804415:+
THCA	cis	rs5758659	0.652	rs133303	ENSG00000182057.4	OGFRP1	3.52	0.00047	0.029	0.19	0.16	Cognitive function;	chr22:41999238	chr22:42269753~42275196:+
THCA	cis	rs11319879	1	rs11319879	ENSG00000232709.1	MARK2P9	-3.52	0.00047	0.029	-0.19	-0.16	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;	chr10:92693719	chr10:92418667~92420875:+
THCA	cis	rs72765298	0.79	rs55984238	ENSG00000235332.2	RP11-366O20.5	3.52	0.00047	0.029	0.29	0.16	Pulse pressure;	chr9:125194565	chr9:125194649~125195821:-
THCA	cis	rs6095357	1	rs6095357	ENSG00000230758.1	SNAP23P	-3.52	0.00047	0.029	-0.2	-0.16	Schizophrenia;	chr20:48907328	chr20:49038357~49038602:-
THCA	cis	rs6012564	0.859	rs1997851	ENSG00000230758.1	SNAP23P	-3.52	0.00047	0.029	-0.2	-0.16	Anger;	chr20:48909956	chr20:49038357~49038602:-
THCA	cis	rs7560272	0.723	rs1083919	ENSG00000273245.1	RP11-434P11.2	-3.52	0.00047	0.029	-0.19	-0.16	Schizophrenia;	chr2:73486736	chr2:73750256~73750786:-
THCA	cis	rs4489787	0.527	rs2731085	ENSG00000240399.1	RP1-228P16.1	3.52	0.00047	0.0291	0.18	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48507516	chr12:48054813~48055591:-
THCA	cis	rs3764021	0.527	rs11052426	ENSG00000256069.6	A2MP1	-3.52	0.00047	0.0291	-0.18	-0.16	Type 1 diabetes;	chr12:9688330	chr12:9228533~9275817:-
THCA	cis	rs3764021	0.527	rs17806710	ENSG00000256069.6	A2MP1	-3.52	0.00047	0.0291	-0.18	-0.16	Type 1 diabetes;	chr12:9688368	chr12:9228533~9275817:-
THCA	cis	rs42648	0.623	rs194505	ENSG00000225498.1	AC002064.5	3.52	0.00047	0.0291	0.17	0.16	Homocysteine levels;	chr7:90211993	chr7:90312496~90322592:+
THCA	cis	rs4857855	0.592	rs13098445	ENSG00000239405.1	TMED10P2	3.52	0.00047	0.0291	0.2	0.16	Eosinophil counts;	chr3:128536221	chr3:128538020~128538631:+
THCA	cis	rs8049603	0.524	rs12933261	ENSG00000257838.4	RP11-368J21.3	3.52	0.00047	0.0291	0.2	0.16	Multiple sclerosis;	chr16:23111148	chr16:22545698~22576865:+
THCA	cis	rs2562456	0.641	rs62107468	ENSG00000268278.1	RP11-420K14.1	3.52	0.00047	0.0291	0.22	0.16	Pain;	chr19:21307177	chr19:21637974~21656300:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000230295.1	RP11-458F8.2	-3.52	0.00047	0.0291	-0.12	-0.16	Aortic root size;	chr7:65930047	chr7:66880708~66882981:+
THCA	cis	rs950169	0.922	rs6603022	ENSG00000230373.7	GOLGA6L5P	3.52	0.00047	0.0291	0.18	0.16	Schizophrenia;	chr15:84161418	chr15:84507885~84516814:-
THCA	cis	rs6546550	0.933	rs6546555	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00047	0.0291	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69908628	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs6736408	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00047	0.0291	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69910642	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs6754896	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00047	0.0291	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69911038	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs6546556	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00047	0.0291	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69911869	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs11902198	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00047	0.0291	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69917464	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs6546559	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00047	0.0291	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69918701	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs7419837	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00047	0.0291	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69919493	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.933	rs1454498	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00047	0.0291	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69922093	chr2:69962263~70103220:-
THCA	cis	rs2880765	0.743	rs16940052	ENSG00000218052.5	ADAMTS7P4	-3.52	0.00047	0.0291	-0.18	-0.16	Coronary artery disease;	chr15:85463443	chr15:85255369~85330334:-
THCA	cis	rs2281636	0.691	rs6584306	ENSG00000260475.1	RP11-85A1.3	3.52	0.00047	0.0291	0.17	0.16	Obesity-related traits;	chr10:99662739	chr10:99621055~99621918:+
THCA	cis	rs540425	0.608	rs217362	ENSG00000279853.1	RP5-844F9.1	3.52	0.000471	0.0291	0.2	0.16	Schizophrenia;	chr7:44579000	chr7:44367140~44369292:-
THCA	cis	rs7829975	0.782	rs6990746	ENSG00000254340.1	RP11-10A14.3	-3.52	0.000471	0.0291	-0.17	-0.16	Mood instability;	chr8:8690301	chr8:9141424~9145435:+
THCA	cis	rs7586879	0.598	rs6724772	ENSG00000224165.4	DNAJC27-AS1	-3.52	0.000471	0.0291	-0.09	-0.16	Body mass index;	chr2:24905861	chr2:24971390~25039694:+
THCA	cis	rs2033711	0.503	rs7254299	ENSG00000269054.1	CTD-2619J13.3	-3.52	0.000471	0.0291	-0.12	-0.16	Uric acid clearance;	chr19:58373598	chr19:58362585~58366591:+
THCA	cis	rs7142002	0.568	rs56701068	ENSG00000271780.1	RP11-1017G21.5	-3.52	0.000471	0.0291	-0.19	-0.16	Autism;	chr14:101922903	chr14:101948347~101949425:+
THCA	cis	rs35320143	0.5	rs11075642	ENSG00000246777.1	RP11-61A14.4	-3.52	0.000471	0.0291	-0.15	-0.16	Number of children (6+ vs. 0 or 1);	chr16:66728844	chr16:66751752~66754740:+
THCA	cis	rs9788682	0.895	rs3813570	ENSG00000261143.1	ADAMTS7P3	-3.52	0.000471	0.0291	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78540490	chr15:77976042~77993057:+
THCA	cis	rs6005807	0.719	rs9625509	ENSG00000272858.1	CTA-292E10.8	-3.52	0.000471	0.0291	-0.26	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28593258	chr22:28814914~28815662:+
THCA	cis	rs11633886	0.622	rs4774224	ENSG00000259200.1	RP11-718O11.1	-3.52	0.000471	0.0291	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45837808	chr15:45705078~45931069:+
THCA	cis	rs8058578	1	rs8051050	ENSG00000260911.2	RP11-196G11.2	3.52	0.000471	0.0291	0.14	0.16	Multiple myeloma;	chr16:30676588	chr16:31043150~31049868:+
THCA	cis	rs7031325	0.962	rs7029780	ENSG00000229611.1	RP11-390F4.10	-3.52	0.000471	0.0291	-0.17	-0.16	Systemic lupus erythematosus;	chr9:6652614	chr9:6704471~6707780:+
THCA	cis	rs3760982	0.585	rs67704568	ENSG00000267058.1	RP11-15A1.3	-3.52	0.000471	0.0291	-0.13	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789867	chr19:43891804~43901805:-
THCA	cis	rs3760982	0.585	rs67648499	ENSG00000267058.1	RP11-15A1.3	-3.52	0.000471	0.0291	-0.13	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789903	chr19:43891804~43901805:-
THCA	cis	rs7914558	0.966	rs11191471	ENSG00000272912.1	RP11-724N1.1	-3.52	0.000471	0.0291	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102942293	chr10:102914585~102915404:+
THCA	cis	rs17228156	1	rs17228156	ENSG00000247572.6	CKMT2-AS1	3.52	0.000471	0.0291	0.33	0.16	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure);	chr5:81207084	chr5:81204084~81301560:-
THCA	cis	rs11673344	0.542	rs826324	ENSG00000233527.7	ZNF529-AS1	3.52	0.000471	0.0291	0.13	0.16	Obesity-related traits;	chr19:37014343	chr19:36573070~36594708:+
THCA	cis	rs2235642	0.893	rs2076442	ENSG00000260989.1	LA16c-395F10.2	-3.52	0.000471	0.0291	-0.17	-0.16	Coronary artery disease;	chr16:1541111	chr16:1580527~1610328:+
THCA	cis	rs4389656	0.592	rs187994	ENSG00000248677.1	CTD-2044J15.1	3.52	0.000471	0.0291	0.16	0.16	Coronary artery disease;	chr5:6742055	chr5:6686325~6707711:-
THCA	cis	rs2880765	0.835	rs6497202	ENSG00000218052.5	ADAMTS7P4	-3.52	0.000471	0.0291	-0.18	-0.16	Coronary artery disease;	chr15:85478144	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.566	rs12911430	ENSG00000259407.1	RP11-158M2.3	-3.52	0.000471	0.0291	-0.18	-0.16	Coronary artery disease;	chr15:85468033	chr15:85744109~85750281:-
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000220721.1	OR1F12	3.52	0.000471	0.0291	0.17	0.16	Pubertal anthropometrics;	chr6:28420988	chr6:28073316~28074233:+
THCA	cis	rs11673344	0.566	rs2385180	ENSG00000268499.1	CTB-102L5.8	3.52	0.000471	0.0291	0.17	0.16	Obesity-related traits;	chr19:37431454	chr19:38199836~38200934:+
THCA	cis	rs6981523	0.5	rs4412337	ENSG00000205879.4	FAM90A2P	3.52	0.000471	0.0291	0.2	0.16	Neuroticism;	chr8:11214511	chr8:12172202~12178575:-
THCA	cis	rs61776719	0.764	rs12138115	ENSG00000252448.1	SNORA63	3.52	0.000471	0.0291	0.19	0.16	Coronary artery disease;	chr1:37986909	chr1:37884237~37884317:+
THCA	cis	rs7430456	0.638	rs13071694	ENSG00000231574.4	RP11-91K9.1	3.52	0.000471	0.0291	0.22	0.16	Breast cancer;	chr3:177775198	chr3:177816865~177899224:+
THCA	cis	rs9925964	0.967	rs889548	ENSG00000262766.1	RP11-196G11.4	3.52	0.000471	0.0291	0.11	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31126391	chr16:31118078~31118747:+
THCA	cis	rs972578	1	rs2413737	ENSG00000230319.1	AL022476.2	3.52	0.000471	0.0291	0.17	0.16	Mean platelet volume;	chr22:42965137	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs5759060	ENSG00000230319.1	AL022476.2	3.52	0.000471	0.0291	0.17	0.16	Mean platelet volume;	chr22:42965798	chr22:43038585~43052366:+
THCA	cis	rs972578	0.905	rs56026835	ENSG00000230319.1	AL022476.2	3.52	0.000471	0.0291	0.17	0.16	Mean platelet volume;	chr22:42967116	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs5759062	ENSG00000230319.1	AL022476.2	3.52	0.000471	0.0291	0.17	0.16	Mean platelet volume;	chr22:42967189	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs2267481	ENSG00000230319.1	AL022476.2	3.52	0.000471	0.0291	0.17	0.16	Mean platelet volume;	chr22:42967883	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs11913527	ENSG00000230319.1	AL022476.2	3.52	0.000471	0.0291	0.17	0.16	Mean platelet volume;	chr22:42968628	chr22:43038585~43052366:+
THCA	cis	rs58688157	0.921	rs35600572	ENSG00000269915.1	AP006621.9	-3.52	0.000471	0.0291	-0.18	-0.16	Systemic lupus erythematosus;	chr11:617214	chr11:708564~727047:-
THCA	cis	rs58688157	0.96	rs34449380	ENSG00000269915.1	AP006621.9	-3.52	0.000471	0.0291	-0.18	-0.16	Systemic lupus erythematosus;	chr11:617221	chr11:708564~727047:-
THCA	cis	rs6545883	0.965	rs1562308	ENSG00000212978.6	AC016747.3	3.52	0.000471	0.0291	0.17	0.16	Tuberculosis;	chr2:61541286	chr2:61141592~61144969:-
THCA	cis	rs12893668	0.645	rs35229468	ENSG00000258735.1	LINC00637	-3.52	0.000471	0.0291	-0.21	-0.16	Reticulocyte count;	chr14:103585720	chr14:103847721~103858049:+
THCA	cis	rs2919009	0.607	rs59153085	ENSG00000271670.1	RP11-95I16.4	3.52	0.000471	0.0291	0.19	0.16	Obesity-related traits;	chr10:120931782	chr10:120879256~120880667:-
THCA	cis	rs2919009	0.563	rs55761976	ENSG00000271670.1	RP11-95I16.4	3.52	0.000471	0.0291	0.19	0.16	Obesity-related traits;	chr10:120935030	chr10:120879256~120880667:-
THCA	cis	rs7656342	0.808	rs6835741	ENSG00000249866.1	OR7E83P	3.52	0.000471	0.0291	0.18	0.16	Gut microbiota (bacterial taxa);	chr4:9777287	chr4:9512905~9513874:+
THCA	cis	rs7818688	0.614	rs7834966	ENSG00000253528.2	RP11-347C18.4	3.52	0.000471	0.0291	0.23	0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94834968	chr8:94974573~94974853:-
THCA	cis	rs2880765	0.835	rs7180213	ENSG00000218052.5	ADAMTS7P4	-3.52	0.000471	0.0291	-0.18	-0.16	Coronary artery disease;	chr15:85477956	chr15:85255369~85330334:-
THCA	cis	rs7554511	1	rs35730213	ENSG00000260088.1	RP11-92G12.3	-3.52	0.000471	0.0291	-0.25	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905101	chr1:200669507~200694250:+
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000220721.1	OR1F12	3.52	0.000472	0.0291	0.17	0.16	Pubertal anthropometrics;	chr6:28411584	chr6:28073316~28074233:+
THCA	cis	rs886427	0.517	rs12918697	ENSG00000205890.3	RP11-473M20.5	-3.52	0.000472	0.0291	-0.17	-0.16	Metabolic syndrome;	chr16:2952850	chr16:3032481~3039133:+
THCA	cis	rs10903027	1	rs10903027	ENSG00000224183.1	SDHDP6	3.52	0.000472	0.0291	0.22	0.16	IgG glycosylation;	chr1:25076133	chr1:25294164~25294643:-
THCA	cis	rs6929812	0.664	rs3918438	ENSG00000271755.1	RP1-153G14.4	3.52	0.000472	0.0291	0.18	0.16	Neuroticism (multi-trait analysis);	chr6:27430354	chr6:27404010~27406964:-
THCA	cis	rs10089	0.953	rs1985268	ENSG00000245937.6	LINC01184	3.52	0.000472	0.0291	0.18	0.16	Ileal carcinoids;	chr5:128040239	chr5:127940426~128083172:-
THCA	cis	rs10089	0.953	rs4836358	ENSG00000245937.6	LINC01184	3.52	0.000472	0.0291	0.18	0.16	Ileal carcinoids;	chr5:128041177	chr5:127940426~128083172:-
THCA	cis	rs10089	0.953	rs4836359	ENSG00000245937.6	LINC01184	3.52	0.000472	0.0291	0.18	0.16	Ileal carcinoids;	chr5:128049826	chr5:127940426~128083172:-
THCA	cis	rs10089	0.903	rs6862701	ENSG00000245937.6	LINC01184	3.52	0.000472	0.0291	0.18	0.16	Ileal carcinoids;	chr5:128055557	chr5:127940426~128083172:-
THCA	cis	rs10089	0.953	rs1432615	ENSG00000245937.6	LINC01184	3.52	0.000472	0.0291	0.18	0.16	Ileal carcinoids;	chr5:128059679	chr5:127940426~128083172:-
THCA	cis	rs11658311	0.649	rs8081152	ENSG00000226478.3	UPF3AP1	-3.52	0.000472	0.0291	-0.38	-0.16	Obsessive-compulsive symptoms;	chr17:17531865	chr17:16745636~16746761:-
THCA	cis	rs11658311	0.85	rs7210978	ENSG00000226478.3	UPF3AP1	-3.52	0.000472	0.0291	-0.38	-0.16	Obsessive-compulsive symptoms;	chr17:17533137	chr17:16745636~16746761:-
THCA	cis	rs11658311	0.85	rs7216223	ENSG00000226478.3	UPF3AP1	-3.52	0.000472	0.0291	-0.38	-0.16	Obsessive-compulsive symptoms;	chr17:17533983	chr17:16745636~16746761:-
THCA	cis	rs11190604	1	rs2489034	ENSG00000273030.1	RP11-285F16.1	3.52	0.000472	0.0291	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100559435	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs2489036	ENSG00000273030.1	RP11-285F16.1	3.52	0.000472	0.0291	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100559824	chr10:100412934~100413421:+
THCA	cis	rs2033711	0.87	rs4801583	ENSG00000232098.3	CTD-2619J13.14	3.52	0.000472	0.0291	0.14	0.16	Uric acid clearance;	chr19:58407038	chr19:58404238~58408484:-
THCA	cis	rs714027	0.585	rs737911	ENSG00000279699.1	RP1-102K2.9	-3.52	0.000472	0.0291	-0.17	-0.16	Lymphocyte counts;	chr22:30003428	chr22:30275215~30276951:-
THCA	cis	rs13113518	0.812	rs12500601	ENSG00000272969.1	RP11-528I4.2	3.52	0.000472	0.0291	0.19	0.16	Height;	chr4:55451489	chr4:55547112~55547889:+
THCA	cis	rs7141874	0.541	rs10149004	ENSG00000259078.2	PTBP1P	-3.52	0.000472	0.0291	-0.22	-0.16	Coenzyme Q10 levels;	chr14:65366781	chr14:65279267~65281166:+
THCA	cis	rs3764021	0.527	rs3764022	ENSG00000256069.6	A2MP1	-3.52	0.000472	0.0291	-0.18	-0.16	Type 1 diabetes;	chr12:9680928	chr12:9228533~9275817:-
THCA	cis	rs950893	0.681	rs6992687	ENSG00000253837.1	RP11-177H13.2	3.52	0.000472	0.0291	0.16	0.16	Mean corpuscular hemoglobin;	chr8:23600841	chr8:23336171~23366125:+
THCA	cis	rs12439619	0.508	rs8032033	ENSG00000255769.6	GOLGA2P10	-3.52	0.000472	0.0291	-0.18	-0.16	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472993~82513950:-
THCA	cis	rs910873	1	rs910873	ENSG00000269202.1	RP4-614O4.12	-3.52	0.000472	0.0291	-0.29	-0.16	Melanoma;	chr20:34583968	chr20:35201747~35203288:-
THCA	cis	rs9896933	1	rs9896933	ENSG00000262410.1	RP11-388C12.8	3.52	0.000472	0.0291	0.22	0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82940212	chr17:82745068~82745709:+
THCA	cis	rs6486730	0.508	rs7133440	ENSG00000274695.1	RP11-21K12.3	3.52	0.000472	0.0291	0.19	0.16	Systemic lupus erythematosus;	chr12:128784699	chr12:128826836~128827579:+
THCA	cis	rs1862618	0.671	rs2591956	ENSG00000271828.1	CTD-2310F14.1	-3.52	0.000472	0.0291	-0.22	-0.16	Initial pursuit acceleration;	chr5:56948777	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.671	rs2591955	ENSG00000271828.1	CTD-2310F14.1	-3.52	0.000472	0.0291	-0.22	-0.16	Initial pursuit acceleration;	chr5:56949121	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.641	rs2591954	ENSG00000271828.1	CTD-2310F14.1	-3.52	0.000472	0.0291	-0.22	-0.16	Initial pursuit acceleration;	chr5:56949217	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.671	rs906631	ENSG00000271828.1	CTD-2310F14.1	-3.52	0.000472	0.0291	-0.22	-0.16	Initial pursuit acceleration;	chr5:56949976	chr5:56927874~56929573:+
THCA	cis	rs2076028	0.506	rs9611007	ENSG00000272669.1	RP3-508I15.21	-3.52	0.000472	0.0291	-0.16	-0.16	Resting heart rate;	chr22:38681053	chr22:38742625~38743115:+
THCA	cis	rs7824557	0.564	rs2572394	ENSG00000261451.1	RP11-981G7.1	-3.52	0.000472	0.0291	-0.2	-0.16	Retinal vascular caliber;	chr8:11377884	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs2437152	ENSG00000261451.1	RP11-981G7.1	-3.52	0.000472	0.0291	-0.2	-0.16	Retinal vascular caliber;	chr8:11377988	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs2736300	ENSG00000261451.1	RP11-981G7.1	-3.52	0.000472	0.0291	-0.2	-0.16	Retinal vascular caliber;	chr8:11378070	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs2572392	ENSG00000261451.1	RP11-981G7.1	-3.52	0.000472	0.0291	-0.2	-0.16	Retinal vascular caliber;	chr8:11378096	chr8:10433672~10438312:+
THCA	cis	rs12049351	0.774	rs10916516	ENSG00000229367.1	HMGN2P19	3.52	0.000472	0.0291	0.25	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229564427	chr1:229570532~229570796:+
THCA	cis	rs1412115	0.834	rs10763954	ENSG00000233387.1	RP11-342D11.3	-3.52	0.000472	0.0291	-0.16	-0.16	Schizophrenia;	chr10:33785229	chr10:33096257~33116672:-
THCA	cis	rs2901381	0.701	rs6808695	ENSG00000269984.1	RP11-362K14.5	-3.52	0.000472	0.0291	-0.15	-0.16	Plateletcrit;	chr3:169098067	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs6771815	ENSG00000269984.1	RP11-362K14.5	-3.52	0.000472	0.0291	-0.15	-0.16	Plateletcrit;	chr3:169098575	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs34651932	ENSG00000269984.1	RP11-362K14.5	-3.52	0.000472	0.0291	-0.15	-0.16	Plateletcrit;	chr3:169099332	chr3:169777192~169780334:-
THCA	cis	rs3176789	0.914	rs10844737	ENSG00000256673.1	RP11-599J14.2	3.52	0.000472	0.0291	0.21	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9770056	chr12:9398355~9414851:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000230295.1	RP11-458F8.2	-3.52	0.000472	0.0291	-0.12	-0.16	Calcium levels;	chr7:65974892	chr7:66880708~66882981:+
THCA	cis	rs7412746	0.658	rs11582281	ENSG00000224800.1	RP11-235D19.2	-3.52	0.000472	0.0291	-0.22	-0.16	Melanoma;	chr1:150854355	chr1:150881236~150881683:-
THCA	cis	rs9902453	0.765	rs2259857	ENSG00000214719.10	AC005562.1	-3.52	0.000472	0.0291	-0.15	-0.16	Coffee consumption (cups per day);	chr17:29770762	chr17:30576464~30672789:+
THCA	cis	rs12935229	0.756	rs2077813	ENSG00000260922.1	RP11-538I12.3	-3.52	0.000472	0.0291	-0.24	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77269885	chr16:77234877~77290934:+
THCA	cis	rs2281603	0.52	rs61985663	ENSG00000258824.2	CTD-2555O16.2	-3.52	0.000472	0.0291	-0.14	-0.16	Lymphocyte counts;	chr14:64470986	chr14:64422935~64448557:-
THCA	cis	rs34929064	0.512	rs2157958	ENSG00000179428.2	AC073072.5	3.52	0.000472	0.0291	0.18	0.16	Major depression and alcohol dependence;	chr7:22667088	chr7:22725395~22727620:-
THCA	cis	rs683250	0.568	rs651786	ENSG00000254551.1	RP11-727A23.7	3.52	0.000472	0.0291	0.2	0.16	Subcortical brain region volumes;	chr11:83252105	chr11:83209431~83213379:-
THCA	cis	rs56046484	0.913	rs17611290	ENSG00000218052.5	ADAMTS7P4	-3.52	0.000472	0.0291	-0.25	-0.16	Testicular germ cell tumor;	chr15:85031188	chr15:85255369~85330334:-
THCA	cis	rs503425	0.546	rs540716	ENSG00000255422.1	AP002954.4	3.52	0.000472	0.0291	0.2	0.16	Systemic lupus erythematosus;	chr11:118814306	chr11:118704607~118750263:+
THCA	cis	rs2797160	0.905	rs1418641	ENSG00000226409.1	RP11-735G4.1	-3.52	0.000472	0.0291	-0.19	-0.16	Endometrial cancer;	chr6:125678708	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.905	rs1418640	ENSG00000226409.1	RP11-735G4.1	-3.52	0.000472	0.0291	-0.19	-0.16	Endometrial cancer;	chr6:125678720	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1418639	ENSG00000226409.1	RP11-735G4.1	-3.52	0.000472	0.0291	-0.19	-0.16	Endometrial cancer;	chr6:125678794	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs4895798	ENSG00000226409.1	RP11-735G4.1	-3.52	0.000472	0.0291	-0.19	-0.16	Endometrial cancer;	chr6:125679016	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.967	rs8180614	ENSG00000226409.1	RP11-735G4.1	-3.52	0.000472	0.0291	-0.19	-0.16	Endometrial cancer;	chr6:125679453	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.935	rs60515555	ENSG00000226409.1	RP11-735G4.1	-3.52	0.000472	0.0291	-0.19	-0.16	Endometrial cancer;	chr6:125679492	chr6:125370211~125374324:-
THCA	cis	rs9788721	0.967	rs2036527	ENSG00000261762.1	RP11-650L12.2	-3.52	0.000472	0.0292	-0.21	-0.16	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78559273	chr15:78589123~78591276:-
THCA	cis	rs12105510	1	rs34770028	ENSG00000270996.1	RP11-342K6.4	3.52	0.000472	0.0292	0.14	0.16	Response to platinum-based chemotherapy (cisplatin);	chr2:75637716	chr2:75719120~75720018:+
THCA	cis	rs478304	1	rs478304	ENSG00000214659.4	KRT8P26	-3.52	0.000472	0.0292	-0.14	-0.16	Acne (severe);	chr11:65726789	chr11:65726939~65728214:+
THCA	cis	rs7554511	1	rs12131796	ENSG00000260088.1	RP11-92G12.3	-3.52	0.000472	0.0292	-0.25	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200909599	chr1:200669507~200694250:+
THCA	cis	rs4578769	0.765	rs1584428	ENSG00000265939.1	UBE2CP2	3.52	0.000472	0.0292	0.2	0.16	Eosinophil percentage of white cells;	chr18:22807886	chr18:22900486~22900995:-
THCA	cis	rs7819412	0.775	rs4841489	ENSG00000254839.1	AF131215.6	3.52	0.000473	0.0292	0.16	0.16	Triglycerides;	chr8:11079301	chr8:11062647~11067089:-
THCA	cis	rs250518	0.926	rs34919293	ENSG00000251467.1	CTC-250P20.2	3.52	0.000473	0.0292	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72756687	chr5:72996920~72997642:+
THCA	cis	rs769267	0.965	rs2965198	ENSG00000269131.1	AC004447.2	3.52	0.000473	0.0292	0.1	0.16	Tonsillectomy;	chr19:19362221	chr19:18990893~18993610:+
THCA	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	3.52	0.000473	0.0292	0.18	0.16	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	3.52	0.000473	0.0292	0.18	0.16	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.754	rs10213554	ENSG00000249244.1	RP11-548H18.2	-3.52	0.000473	0.0292	-0.18	-0.16	Corneal astigmatism;	chr4:119339630	chr4:119391831~119395335:-
THCA	cis	rs12188164	1	rs56104584	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000473	0.0292	0.17	0.16	Cystic fibrosis severity;	chr5:437427	chr5:473236~480884:+
THCA	cis	rs12188164	1	rs55842567	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000473	0.0292	0.17	0.16	Cystic fibrosis severity;	chr5:437471	chr5:473236~480884:+
THCA	cis	rs12188164	1	rs56042615	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000473	0.0292	0.17	0.16	Cystic fibrosis severity;	chr5:437552	chr5:473236~480884:+
THCA	cis	rs12188164	1	rs34847072	ENSG00000225138.6	CTD-2228K2.7	3.52	0.000473	0.0292	0.17	0.16	Cystic fibrosis severity;	chr5:437747	chr5:473236~480884:+
THCA	cis	rs2033711	0.503	rs6510141	ENSG00000269054.1	CTD-2619J13.3	3.52	0.000473	0.0292	0.12	0.16	Uric acid clearance;	chr19:58374419	chr19:58362585~58366591:+
THCA	cis	rs6870983	0.749	rs33702	ENSG00000247828.6	TMEM161B-AS1	3.52	0.000473	0.0292	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88194847	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs33701	ENSG00000247828.6	TMEM161B-AS1	3.52	0.000473	0.0292	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88194959	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs33700	ENSG00000247828.6	TMEM161B-AS1	3.52	0.000473	0.0292	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88195091	chr5:88268895~88436685:+
THCA	cis	rs4272720	0.535	rs12776460	ENSG00000234736.4	FAM170B-AS1	-3.52	0.000473	0.0292	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49080886	chr10:49121839~49151547:+
THCA	cis	rs962856	0.729	rs7559393	ENSG00000236780.4	AC078941.1	3.52	0.000473	0.0292	0.19	0.16	Pancreatic cancer;	chr2:67294608	chr2:67123357~67215319:-
THCA	cis	rs7142002	0.667	rs730573	ENSG00000271780.1	RP11-1017G21.5	-3.52	0.000473	0.0292	-0.19	-0.16	Autism;	chr14:101921262	chr14:101948347~101949425:+
THCA	cis	rs7142002	0.568	rs57534774	ENSG00000271780.1	RP11-1017G21.5	-3.52	0.000473	0.0292	-0.19	-0.16	Autism;	chr14:101921803	chr14:101948347~101949425:+
THCA	cis	rs7142002	0.568	rs736449	ENSG00000271780.1	RP11-1017G21.5	-3.52	0.000473	0.0292	-0.19	-0.16	Autism;	chr14:101921845	chr14:101948347~101949425:+
THCA	cis	rs17836934	0.967	rs7959983	ENSG00000271614.1	LINC00936	3.52	0.000473	0.0292	0.14	0.16	Total body bone mineral density;	chr12:90059201	chr12:89708959~89712590:+
THCA	cis	rs3015497	0.616	rs1494181	ENSG00000270062.1	RP11-248J18.3	3.52	0.000473	0.0292	0.18	0.16	Mean platelet volume;	chr14:50589882	chr14:50723777~50724272:-
THCA	cis	rs11782652	1	rs78740005	ENSG00000280193.1	RP13-923O23.7	-3.52	0.000473	0.0292	-0.34	-0.16	Ovarian cancer;Epithelial ovarian cancer;	chr8:81747071	chr8:81696368~81698694:+
THCA	cis	rs7569084	1	rs7569084	ENSG00000214533.3	KRT18P33	-3.52	0.000473	0.0292	-0.2	-0.16	Sum eosinophil basophil counts;	chr2:65429835	chr2:65666695~65667737:+
THCA	cis	rs10186029	0.68	rs10179508	ENSG00000270659.1	RP11-105N14.1	3.52	0.000473	0.0292	0.13	0.16	Systemic sclerosis;	chr2:213113802	chr2:213152970~213153659:+
THCA	cis	rs6121246	0.865	rs6089055	ENSG00000230613.1	HM13-AS1	3.52	0.000473	0.0292	0.18	0.16	Mean corpuscular hemoglobin;	chr20:31736242	chr20:31567707~31573263:-
THCA	cis	rs9796	0.689	rs72737758	ENSG00000247556.5	OIP5-AS1	3.52	0.000473	0.0292	0.13	0.16	Menopause (age at onset);	chr15:41157580	chr15:41283990~41309737:+
THCA	cis	rs950169	0.8	rs34302901	ENSG00000230373.7	GOLGA6L5P	-3.52	0.000473	0.0292	-0.17	-0.16	Schizophrenia;	chr15:84567712	chr15:84507885~84516814:-
THCA	cis	rs9693857	0.518	rs7005065	ENSG00000254153.1	CTA-398F10.2	3.52	0.000473	0.0292	0.19	0.16	Systolic blood pressure;	chr8:9418138	chr8:8456909~8461337:-
THCA	cis	rs17685	0.712	rs28456330	ENSG00000227038.2	AC005077.12	3.52	0.000473	0.0292	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76181224	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs10235086	ENSG00000227038.2	AC005077.12	3.52	0.000473	0.0292	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76203820	chr7:76090431~76108779:-
THCA	cis	rs4664293	0.967	rs9646765	ENSG00000230783.1	AC009961.2	-3.52	0.000473	0.0292	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159709137	chr2:159689217~159690291:-
THCA	cis	rs1908814	0.509	rs13282439	ENSG00000227888.4	FAM66A	3.52	0.000473	0.0292	0.21	0.16	Neuroticism;	chr8:11937392	chr8:12362019~12388296:+
THCA	cis	rs10129255	0.957	rs8005468	ENSG00000280411.1	IGHV1-69-2	-3.52	0.000473	0.0292	-0.1	-0.16	Kawasaki disease;	chr14:106686431	chr14:106762092~106762588:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000232559.3	GS1-124K5.12	-3.52	0.000473	0.0292	-0.15	-0.16	Aortic root size;	chr7:66144830	chr7:66554588~66576923:-
THCA	cis	rs11658311	0.85	rs11654482	ENSG00000128438.9	TBC1D27	3.52	0.000473	0.0292	0.23	0.16	Obsessive-compulsive symptoms;	chr17:17713773	chr17:16922915~16934839:-
THCA	cis	rs13064411	0.696	rs1386336	ENSG00000243849.1	CFAP44-AS1	3.52	0.000473	0.0292	0.26	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113425306	chr3:113403991~113433992:+
THCA	cis	rs2034650	0.525	rs11790	ENSG00000259211.1	RP11-64K12.8	-3.52	0.000473	0.0292	-0.14	-0.16	Interstitial lung disease;	chr15:40420538	chr15:40464193~40466726:-
THCA	cis	rs267567	0.588	rs62239550	ENSG00000235257.7	ITGA9-AS1	3.52	0.000473	0.0292	0.13	0.16	PR interval;	chr3:37536378	chr3:37745432~37861780:-
THCA	cis	rs267567	0.588	rs62239551	ENSG00000235257.7	ITGA9-AS1	3.52	0.000473	0.0292	0.13	0.16	PR interval;	chr3:37536379	chr3:37745432~37861780:-
THCA	cis	rs267567	0.626	rs62239552	ENSG00000235257.7	ITGA9-AS1	3.52	0.000473	0.0292	0.13	0.16	PR interval;	chr3:37536381	chr3:37745432~37861780:-
THCA	cis	rs9488822	0.676	rs13210143	ENSG00000233558.1	RP3-486I3.4	3.52	0.000473	0.0292	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116068473	chr6:116258493~116259115:-
THCA	cis	rs13108904	0.875	rs1564509	ENSG00000254094.1	AC078852.1	-3.52	0.000473	0.0292	-0.18	-0.16	Obesity-related traits;	chr4:1242774	chr4:1356581~1358075:+
THCA	cis	rs3087591	0.708	rs2854311	ENSG00000263535.1	AK4P1	3.52	0.000473	0.0292	0.19	0.16	Hip circumference;	chr17:31344309	chr17:31345521~31346187:+
THCA	cis	rs875971	0.545	rs1267814	ENSG00000230295.1	RP11-458F8.2	-3.52	0.000473	0.0292	-0.14	-0.16	Aortic root size;	chr7:66579422	chr7:66880708~66882981:+
THCA	cis	rs754466	0.58	rs11002294	ENSG00000213514.2	RP11-428P16.2	3.52	0.000473	0.0292	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77780830	chr10:77730766~77734769:+
THCA	cis	rs754466	0.58	rs10824573	ENSG00000213514.2	RP11-428P16.2	3.52	0.000473	0.0292	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77781211	chr10:77730766~77734769:+
THCA	cis	rs2838088	1	rs9974587	ENSG00000226496.2	LINC00323	3.52	0.000473	0.0292	0.25	0.16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr21:41670780	chr21:41141493~41148133:-
THCA	cis	rs4908768	0.539	rs7537982	ENSG00000270282.1	RP5-1115A15.2	3.52	0.000473	0.0292	0.19	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8512653~8513021:+
THCA	cis	rs2290416	0.892	rs76225457	ENSG00000254973.1	RP11-429J17.7	3.52	0.000474	0.0292	0.32	0.16	Attention deficit hyperactivity disorder;	chr8:143583882	chr8:143758153~143771822:-
THCA	cis	rs10089	1	rs7713877	ENSG00000245937.6	LINC01184	3.52	0.000474	0.0292	0.18	0.16	Ileal carcinoids;	chr5:128093133	chr5:127940426~128083172:-
THCA	cis	rs10089	1	rs2898096	ENSG00000245937.6	LINC01184	3.52	0.000474	0.0292	0.18	0.16	Ileal carcinoids;	chr5:128097522	chr5:127940426~128083172:-
THCA	cis	rs4578769	0.513	rs9953640	ENSG00000273232.1	RP11-370A5.2	3.52	0.000474	0.0292	0.22	0.16	Eosinophil percentage of white cells;	chr18:22947856	chr18:22882825~22883357:-
THCA	cis	rs11681884	0.786	rs1992762	ENSG00000272563.1	RP11-480C16.1	-3.52	0.000474	0.0292	-0.36	-0.16	Stroke;	chr2:113052836	chr2:113432600~113436042:+
THCA	cis	rs11039798	0.536	rs112223280	ENSG00000200090.1	Y_RNA	3.52	0.000474	0.0292	0.2	0.16	Axial length;	chr11:48123525	chr11:47726894~47726992:-
THCA	cis	rs12023718	0.588	rs10913585	ENSG00000213057.5	C1orf220	3.52	0.000474	0.0292	0.16	0.16	Obesity-related traits;	chr1:178638559	chr1:178542752~178548889:+
THCA	cis	rs1538970	0.781	rs12049503	ENSG00000280836.1	AL355480.1	-3.52	0.000474	0.0292	-0.22	-0.16	Platelet count;	chr1:45555884	chr1:45581219~45581321:-
THCA	cis	rs7937890	0.559	rs2575838	ENSG00000251991.1	RNU7-49P	3.52	0.000474	0.0292	0.18	0.16	Mitochondrial DNA levels;	chr11:14476675	chr11:14478892~14478953:+
THCA	cis	rs8028182	0.636	rs4886703	ENSG00000275645.1	RP11-817O13.9	3.52	0.000474	0.0292	0.16	0.16	Sudden cardiac arrest;	chr15:75438025	chr15:75346744~75347161:-
THCA	cis	rs112295236	1	rs55763207	ENSG00000255213.1	NPM1P35	-3.52	0.000474	0.0292	-0.4	-0.16	Sex hormone levels;	chr11:63249005	chr11:62330946~62331813:+
THCA	cis	rs755249	0.529	rs604316	ENSG00000228060.1	RP11-69E11.8	-3.52	0.000474	0.0292	-0.15	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39413694	chr1:39565160~39573203:+
THCA	cis	rs862034	0.902	rs862057	ENSG00000270000.1	RP3-449M8.9	-3.52	0.000474	0.0292	-0.16	-0.16	Height;	chr14:74512162	chr14:74471930~74472360:-
THCA	cis	rs9902453	1	rs62070270	ENSG00000250462.7	LRRC37BP1	3.52	0.000474	0.0292	0.13	0.16	Coffee consumption (cups per day);	chr17:29936962	chr17:30629680~30637466:+
THCA	cis	rs924712	0.572	rs6922968	ENSG00000224984.1	RP11-524H19.2	-3.52	0.000474	0.0292	-0.19	-0.16	Breast cancer;	chr6:54842466	chr6:54840118~54840855:-
THCA	cis	rs924712	0.522	rs1503133	ENSG00000224984.1	RP11-524H19.2	-3.52	0.000474	0.0292	-0.19	-0.16	Breast cancer;	chr6:54845113	chr6:54840118~54840855:-
THCA	cis	rs10832963	1	rs2084220	ENSG00000256361.1	RP11-613F22.6	3.52	0.000474	0.0292	0.2	0.16	Breast cancer;	chr11:18635385	chr11:18511043~18511475:-
THCA	cis	rs10483853	0.731	rs11624521	ENSG00000258695.2	RP3-414A15.2	-3.52	0.000474	0.0292	-0.21	-0.16	Coronary artery calcification;	chr14:73294124	chr14:73522878~73530610:+
THCA	cis	rs7487075	0.93	rs11183468	ENSG00000257261.4	RP11-96H19.1	3.52	0.000474	0.0292	0.12	0.16	Itch intensity from mosquito bite;	chr12:46412478	chr12:46383679~46876159:+
THCA	cis	rs7828089	0.582	rs7825938	ENSG00000248738.5	RP11-87E22.2	-3.52	0.000474	0.0292	-0.17	-0.16	Verbal declarative memory;	chr8:22409353	chr8:22877972~22888022:+
THCA	cis	rs7737355	0.947	rs58991576	ENSG00000237714.1	P4HA2-AS1	-3.52	0.000474	0.0292	-0.23	-0.16	Life satisfaction;	chr5:131253847	chr5:132184876~132192808:+
THCA	cis	rs2486012	1	rs3011230	ENSG00000234694.1	RP1-92O14.3	-3.52	0.000474	0.0292	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:43874983	chr1:43354684~43358658:-
THCA	cis	rs7778833	1	rs10266793	ENSG00000229688.6	ISPD-AS1	3.52	0.000474	0.0292	0.33	0.16	Childhood ear infection;	chr7:15734060	chr7:16210488~16270604:+
THCA	cis	rs6832769	0.961	rs1011095	ENSG00000223305.1	RN7SKP30	3.52	0.000474	0.0292	0.2	0.16	Personality dimensions;	chr4:55398774	chr4:55540502~55540835:-
THCA	cis	rs3126085	0.935	rs7550106	ENSG00000237975.5	FLG-AS1	3.52	0.000474	0.0292	0.25	0.16	Atopic dermatitis;	chr1:152224726	chr1:152168125~152445456:+
THCA	cis	rs3176789	0.671	rs7953260	ENSG00000256673.1	RP11-599J14.2	3.52	0.000474	0.0292	0.19	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766067	chr12:9398355~9414851:-
THCA	cis	rs2744375	0.6	rs2237103	ENSG00000261189.1	RP3-512B11.3	3.52	0.000474	0.0292	0.17	0.16	Resting heart rate;	chr6:7551929	chr6:7540451~7541338:-
THCA	cis	rs35740288	0.787	rs2291048	ENSG00000259407.1	RP11-158M2.3	3.52	0.000474	0.0292	0.2	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682427	chr15:85744109~85750281:-
THCA	cis	rs7209700	0.614	rs7225927	ENSG00000262879.4	RP11-156P1.3	3.52	0.000474	0.0292	0.15	0.16	IgG glycosylation;	chr17:47246568	chr17:46984045~47100323:-
THCA	cis	rs1971762	0.583	rs3844370	ENSG00000270175.1	RP11-793H13.11	-3.52	0.000474	0.0292	-0.11	-0.16	Height;	chr12:53692353	chr12:53500162~53500936:-
THCA	cis	rs7760535	0.811	rs1002475	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000474	0.0292	-0.12	-0.16	Metabolic traits;	chr6:111388386	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs11153288	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000474	0.0292	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs11153290	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000474	0.0292	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs11153291	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000474	0.0292	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs11153292	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000474	0.0292	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs12190634	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000474	0.0292	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.508	rs11153294	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000474	0.0292	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111309203~111313517:+
THCA	cis	rs7178375	1	rs28693590	ENSG00000215302.7	CTD-3092A11.1	-3.52	0.000474	0.0292	-0.23	-0.16	Hypertriglyceridemia;	chr15:30902818	chr15:30470779~30507623:+
THCA	cis	rs8030605	0.85	rs1553737	ENSG00000277245.1	RP11-48G14.3	-3.52	0.000474	0.0292	-0.27	-0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56078294	chr15:56447120~56447697:+
THCA	cis	rs9863	0.931	rs3186071	ENSG00000270028.1	RP11-380L11.4	3.52	0.000474	0.0293	0.17	0.16	White blood cell count;	chr12:123944732	chr12:123925461~123926083:-
THCA	cis	rs301901	0.698	rs11948801	ENSG00000250155.1	CTD-2353F22.1	3.52	0.000474	0.0293	0.16	0.16	Height;	chr5:37430113	chr5:36666214~36725195:-
THCA	cis	rs2011503	0.782	rs35545554	ENSG00000271283.1	CTC-412M14.6	-3.52	0.000474	0.0293	-0.24	-0.16	Bipolar disorder;	chr19:19604804	chr19:19699203~19699409:-
THCA	cis	rs1978968	0.707	rs13058527	ENSG00000161103.10	AC008132.13	3.52	0.000474	0.0293	0.2	0.16	Presence of antiphospholipid antibodies;	chr22:17930163	chr22:18846811~18861049:+
THCA	cis	rs2288884	0.541	rs8107827	ENSG00000260160.1	CTC-471J1.2	-3.52	0.000474	0.0293	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51962228	chr19:52058490~52063703:-
THCA	cis	rs2288884	0.505	rs4988334	ENSG00000260160.1	CTC-471J1.2	-3.52	0.000474	0.0293	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965745	chr19:52058490~52063703:-
THCA	cis	rs11237982	0.506	rs12577687	ENSG00000255345.1	CTD-2337I7.1	-3.52	0.000474	0.0293	-0.25	-0.16	Verbal declarative memory;	chr11:79690785	chr11:79092848~79098003:+
THCA	cis	rs975752	0.717	rs7082753	ENSG00000227492.1	RP11-316M21.6	3.52	0.000474	0.0293	0.3	0.16	Schizophrenia;	chr10:100248726	chr10:100229667~100234000:+
THCA	cis	rs6600671	0.934	rs11249429	ENSG00000233029.3	RP11-439A17.9	3.52	0.000474	0.0293	0.18	0.16	Hip geometry;	chr1:121549282	chr1:121090289~121097655:-
THCA	cis	rs929354	0.772	rs7778193	ENSG00000224629.1	RP5-1142J19.2	-3.52	0.000474	0.0293	-0.16	-0.16	Body mass index;	chr7:157187393	chr7:157263022~157263229:-
THCA	cis	rs7665090	0.967	rs13106304	ENSG00000248971.2	KRT8P46	-3.52	0.000475	0.0293	-0.19	-0.16	Primary biliary cholangitis;	chr4:102633818	chr4:102728746~102730171:-
THCA	cis	rs372883	0.648	rs368322	ENSG00000176054.6	RPL23P2	-3.52	0.000475	0.0293	-0.14	-0.16	Pancreatic cancer;	chr21:29344830	chr21:28997613~28998033:-
THCA	cis	rs10804591	1	rs729208	ENSG00000271270.4	TMCC1-AS1	-3.52	0.000475	0.0293	-0.18	-0.16	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;	chr3:129620799	chr3:129893871~129918575:+
THCA	cis	rs17826219	0.733	rs7221691	ENSG00000265443.1	CTD-2349P21.6	3.52	0.000475	0.0293	0.27	0.16	Body mass index;	chr17:30396601	chr17:30726305~30727564:-
THCA	cis	rs116988415	0.636	rs11158561	ENSG00000272909.1	CTD-2555O16.4	3.52	0.000475	0.0293	0.21	0.16	Daytime sleep phenotypes;	chr14:64825952	chr14:64440369~64442238:-
THCA	cis	rs7737355	0.773	rs4706027	ENSG00000224431.1	AC063976.7	3.52	0.000475	0.0293	0.15	0.16	Life satisfaction;	chr5:131597279	chr5:132199456~132203487:+
THCA	cis	rs911555	0.755	rs4143998	ENSG00000269940.1	RP11-73M18.7	3.52	0.000475	0.0293	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs1138400	ENSG00000269940.1	RP11-73M18.7	3.52	0.000475	0.0293	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs7147664	ENSG00000269940.1	RP11-73M18.7	3.52	0.000475	0.0293	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103694560~103695170:+
THCA	cis	rs9303280	0.901	rs7359623	ENSG00000263818.4	CTD-2206N4.4	3.52	0.000475	0.0293	0.21	0.16	Self-reported allergy;	chr17:39893336	chr17:39057019~39113190:+
THCA	cis	rs11992162	1	rs12334769	ENSG00000255046.1	RP11-297N6.4	-3.52	0.000475	0.0293	-0.17	-0.16	Monocyte count;	chr8:11975652	chr8:11797928~11802568:-
THCA	cis	rs972578	0.868	rs2273143	ENSG00000230319.1	AL022476.2	3.52	0.000475	0.0293	0.17	0.16	Mean platelet volume;	chr22:42884644	chr22:43038585~43052366:+
THCA	cis	rs12544026	0.547	rs551295	ENSG00000253669.3	KB-1732A1.1	-3.52	0.000475	0.0293	-0.18	-0.16	Major depression and alcohol dependence;	chr8:101865685	chr8:102805517~102809971:+
THCA	cis	rs7819412	0.774	rs34208825	ENSG00000254866.2	DEFB109P3	3.52	0.000475	0.0293	0.22	0.16	Triglycerides;	chr8:11157106	chr8:12150895~12151134:-
THCA	cis	rs9450351	0.744	rs7741914	ENSG00000280232.1	RP11-321N4.4	3.52	0.000475	0.0293	0.35	0.16	Interferon gamma-induced protein 10 levels;	chr6:86095057	chr6:85498441~85499058:-
THCA	cis	rs4713118	0.869	rs9283880	ENSG00000261839.1	RP1-265C24.8	3.52	0.000475	0.0293	0.18	0.16	Parkinson's disease;	chr6:27747464	chr6:28136849~28139678:+
THCA	cis	rs5006884	0.95	rs35346292	ENSG00000167355.6	AC104389.28	-3.52	0.000475	0.0293	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5368832	chr11:5304976~5505652:-
THCA	cis	rs5006884	1	rs4910775	ENSG00000167355.6	AC104389.28	-3.52	0.000475	0.0293	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5371575	chr11:5304976~5505652:-
THCA	cis	rs5006884	1	rs4910776	ENSG00000167355.6	AC104389.28	-3.52	0.000475	0.0293	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5371654	chr11:5304976~5505652:-
THCA	cis	rs9309711	0.772	rs9752251	ENSG00000271868.1	RP11-1293J14.1	-3.52	0.000475	0.0293	-0.23	-0.16	Neurofibrillary tangles;	chr2:3486098	chr2:3496956~3497428:+
THCA	cis	rs9400467	0.528	rs7451051	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000475	0.0293	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs6913769	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000475	0.0293	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111309203~111313517:+
THCA	cis	rs9788682	1	rs12441426	ENSG00000261143.1	ADAMTS7P3	-3.52	0.000475	0.0293	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78519987	chr15:77976042~77993057:+
THCA	cis	rs7824557	0.591	rs2572452	ENSG00000206014.6	OR7E161P	3.52	0.000475	0.0293	0.18	0.16	Retinal vascular caliber;	chr8:11370745	chr8:11928597~11929563:-
THCA	cis	rs721048	0.834	rs6718609	ENSG00000242412.1	DBIL5P2	-3.52	0.000475	0.0293	-0.21	-0.16	Prostate cancer;	chr2:63232674	chr2:63117851~63119542:-
THCA	cis	rs11089937	1	rs11089937	ENSG00000211638.2	IGLV8-61	-3.52	0.000475	0.0293	-0.12	-0.16	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22098700~22099212:+
THCA	cis	rs4713118	0.869	rs6930992	ENSG00000216915.2	RP1-97D16.1	-3.52	0.000475	0.0293	-0.24	-0.16	Parkinson's disease;	chr6:27744341	chr6:27737000~27738494:-
THCA	cis	rs6885307	0.766	rs6879309	ENSG00000272335.1	RP11-53O19.3	-3.52	0.000475	0.0293	-0.16	-0.16	Age at first birth;	chr5:44975235	chr5:44826076~44828592:+
THCA	cis	rs2554380	0.891	rs2562782	ENSG00000230373.7	GOLGA6L5P	-3.52	0.000475	0.0293	-0.19	-0.16	Height;	chr15:83631329	chr15:84507885~84516814:-
THCA	cis	rs8030605	0.925	rs17238607	ENSG00000277245.1	RP11-48G14.3	3.52	0.000475	0.0293	0.3	0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56103934	chr15:56447120~56447697:+
THCA	cis	rs9911578	0.967	rs8075786	ENSG00000224738.1	AC099850.1	3.52	0.000475	0.0293	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58741855	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.741	rs2611776	ENSG00000224738.1	AC099850.1	3.52	0.000475	0.0293	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58742275	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs7222789	ENSG00000224738.1	AC099850.1	3.52	0.000475	0.0293	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58742492	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs304292	ENSG00000224738.1	AC099850.1	3.52	0.000475	0.0293	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58746762	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs2643119	ENSG00000224738.1	AC099850.1	3.52	0.000475	0.0293	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58750399	chr17:59106598~59118267:+
THCA	cis	rs7927592	0.763	rs7119422	ENSG00000160172.9	FAM86C2P	-3.52	0.000475	0.0293	-0.15	-0.16	Total body bone mineral density;	chr11:68563686	chr11:67791648~67805336:-
THCA	cis	rs6787172	0.622	rs7632059	ENSG00000272087.1	RP11-379F4.7	3.52	0.000475	0.0293	0.14	0.16	Subjective well-being;	chr3:158415518	chr3:158693120~158693768:-
THCA	cis	rs73787773	0.644	rs76177172	ENSG00000246859.2	STARD4-AS1	3.52	0.000475	0.0293	0.2	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr5:112138547	chr5:111512226~111739726:+
THCA	cis	rs73787773	0.644	rs78790140	ENSG00000246859.2	STARD4-AS1	3.52	0.000475	0.0293	0.2	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr5:112140400	chr5:111512226~111739726:+
THCA	cis	rs721917	0.506	rs2758555	ENSG00000272489.1	RP11-182L21.5	-3.52	0.000475	0.0293	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79663192~79664786:+
THCA	cis	rs721917	0.506	rs1923538	ENSG00000272489.1	RP11-182L21.5	-3.52	0.000475	0.0293	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79663192~79664786:+
THCA	cis	rs721917	0.507	rs2819101	ENSG00000272489.1	RP11-182L21.5	-3.52	0.000475	0.0293	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79663192~79664786:+
THCA	cis	rs721917	0.506	rs2819100	ENSG00000272489.1	RP11-182L21.5	-3.52	0.000475	0.0293	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79663192~79664786:+
THCA	cis	rs721917	0.506	rs2758547	ENSG00000272489.1	RP11-182L21.5	-3.52	0.000475	0.0293	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79663192~79664786:+
THCA	cis	rs2280018	0.609	rs2941253	ENSG00000255277.3	ABCC6P2	3.52	0.000475	0.0293	0.18	0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:14820792~14824702:-
THCA	cis	rs2098713	0.599	rs12652658	ENSG00000250155.1	CTD-2353F22.1	3.52	0.000475	0.0293	0.16	0.16	Telomere length;	chr5:37555461	chr5:36666214~36725195:-
THCA	cis	rs11168187	0.528	rs2214526	ENSG00000280054.1	RP1-197B17.7	-3.52	0.000475	0.0293	-0.21	-0.16	Vertical cup-disc ratio;	chr12:47548246	chr12:47728151~47730598:-
THCA	cis	rs9863	0.931	rs11057401	ENSG00000270028.1	RP11-380L11.4	3.52	0.000475	0.0293	0.17	0.16	White blood cell count;	chr12:123942759	chr12:123925461~123926083:-
THCA	cis	rs2014572	1	rs3746231	ENSG00000276449.1	AC004076.5	3.52	0.000475	0.0293	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57248689	chr19:57449689~57453011:+
THCA	cis	rs73193808	0.614	rs2832251	ENSG00000231125.2	AF129075.5	-3.52	0.000475	0.0293	-0.15	-0.16	Coronary artery disease;	chr21:29187231	chr21:29058073~29060095:-
THCA	cis	rs2305707	0.544	rs2470155	ENSG00000273674.3	CTD-2378E12.1	3.52	0.000476	0.0293	0.33	0.16	Height;	chr15:51298556	chr15:50839875~50908599:-
THCA	cis	rs9863	0.828	rs952632	ENSG00000269938.1	RP11-214K3.20	-3.52	0.000476	0.0293	-0.19	-0.16	White blood cell count;	chr12:123985191	chr12:123968023~123968579:-
THCA	cis	rs9863	0.694	rs11837287	ENSG00000269938.1	RP11-214K3.20	-3.52	0.000476	0.0293	-0.19	-0.16	White blood cell count;	chr12:123985512	chr12:123968023~123968579:-
THCA	cis	rs1799922	1	rs17396823	ENSG00000271553.1	RP11-274B21.10	3.52	0.000476	0.0293	0.14	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128744551	chr7:128667043~128668156:+
THCA	cis	rs6832769	1	rs473005	ENSG00000223305.1	RN7SKP30	3.52	0.000476	0.0293	0.2	0.16	Personality dimensions;	chr4:55421958	chr4:55540502~55540835:-
THCA	cis	rs7829975	0.811	rs7011229	ENSG00000254340.1	RP11-10A14.3	-3.52	0.000476	0.0293	-0.17	-0.16	Mood instability;	chr8:8685814	chr8:9141424~9145435:+
THCA	cis	rs7760535	0.763	rs10457240	ENSG00000272356.1	RP5-1112D6.8	-3.52	0.000476	0.0293	-0.12	-0.16	Metabolic traits;	chr6:111527671	chr6:111309203~111313517:+
THCA	cis	rs6802315	0.573	rs7635993	ENSG00000271778.1	RP11-379F4.8	3.52	0.000476	0.0293	0.16	0.16	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158782547~158783124:+
THCA	cis	rs3126085	0.735	rs4845752	ENSG00000237975.5	FLG-AS1	-3.52	0.000476	0.0293	-0.25	-0.16	Atopic dermatitis;	chr1:152254100	chr1:152168125~152445456:+
THCA	cis	rs9487051	0.844	rs9386792	ENSG00000260273.1	RP11-425D10.10	3.52	0.000476	0.0293	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109288772	chr6:109382795~109383666:+
THCA	cis	rs9487051	0.872	rs9398197	ENSG00000260273.1	RP11-425D10.10	3.52	0.000476	0.0293	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109288785	chr6:109382795~109383666:+
THCA	cis	rs3800688	0.527	rs1733862	ENSG00000236753.4	MKLN1-AS	-3.52	0.000476	0.0293	-0.15	-0.16	Hypertension;	chr7:131493567	chr7:131309744~131328222:-
THCA	cis	rs6545883	0.929	rs6705235	ENSG00000212978.6	AC016747.3	3.52	0.000476	0.0293	0.18	0.16	Tuberculosis;	chr2:61486445	chr2:61141592~61144969:-
THCA	cis	rs17655565	0.533	rs12301094	ENSG00000257829.1	RP11-845M18.6	-3.52	0.000476	0.0293	-0.17	-0.16	Plasma amyloid beta peptide concentrations (ABx-42);	chr12:52313826	chr12:52306616~52308371:-
THCA	cis	rs2214442	0.966	rs10232213	ENSG00000271133.4	CTA-293F17.1	-3.52	0.000476	0.0293	-0.16	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20348626	chr7:20328299~20331747:-
THCA	cis	rs2562456	0.833	rs62110428	ENSG00000268521.1	VN1R83P	3.52	0.000476	0.0293	0.16	0.16	Pain;	chr19:21430854	chr19:21289554~21289998:-
THCA	cis	rs9611565	0.694	rs9607816	ENSG00000281538.1	RP4-669P10.20	3.52	0.000476	0.0293	0.18	0.16	Vitiligo;	chr22:41554893	chr22:42138060~42139726:+
THCA	cis	rs6878727	0.545	rs2591383	ENSG00000253807.4	LINC01170	3.52	0.000476	0.0293	0.15	0.16	Breast cancer;	chr5:124351478	chr5:124059794~124405079:-
THCA	cis	rs2228479	0.85	rs62054224	ENSG00000274627.1	RP11-104N10.2	-3.52	0.000476	0.0293	-0.27	-0.16	Skin colour saturation;	chr16:89825663	chr16:89516797~89522217:+
THCA	cis	rs7139978	0.756	rs7995907	ENSG00000223685.4	LINC00571	3.52	0.000476	0.0293	0.16	0.16	Life satisfaction;	chr13:37561643	chr13:38050817~38143232:-
THCA	cis	rs7647973	0.516	rs4955419	ENSG00000228638.1	FCF1P2	-3.52	0.000476	0.0293	-0.16	-0.16	Menarche (age at onset);	chr3:49163259	chr3:48290793~48291375:-
THCA	cis	rs12149695	0.902	rs12924419	ENSG00000259940.2	CTD-3203P2.1	-3.52	0.000476	0.0293	-0.18	-0.16	Gut microbiota (bacterial taxa);	chr16:27243007	chr16:27213308~27214993:-
THCA	cis	rs8057939	0.593	rs27865	ENSG00000260614.1	RP11-491F9.1	3.52	0.000476	0.0293	0.22	0.16	Prostate cancer (SNP x SNP interaction);	chr16:49400971	chr16:49287430~49290227:+
THCA	cis	rs13098911	0.54	rs73833520	ENSG00000226074.4	PRSS44	-3.52	0.000476	0.0293	-0.29	-0.16	Celiac disease;	chr3:46016375	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs35454877	ENSG00000226074.4	PRSS44	-3.52	0.000476	0.0293	-0.29	-0.16	Celiac disease;	chr3:46017992	chr3:46809359~46812558:-
THCA	cis	rs11583043	0.918	rs11581062	ENSG00000233184.5	RP11-421L21.3	-3.52	0.000476	0.0293	-0.17	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100941963	chr1:101025878~101087268:+
THCA	cis	rs11771526	0.901	rs11767773	ENSG00000272905.1	RP11-265E18.1	3.52	0.000476	0.0293	0.21	0.16	Body mass index;	chr7:32232730	chr7:32845394~32846061:+
THCA	cis	rs478304	0.593	rs4645927	ENSG00000214659.4	KRT8P26	3.52	0.000476	0.0293	0.15	0.16	Acne (severe);	chr11:65715356	chr11:65726939~65728214:+
THCA	cis	rs2638953	0.853	rs11049641	ENSG00000247934.4	RP11-967K21.1	-3.52	0.000476	0.0293	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471160	chr12:28163298~28190738:-
THCA	cis	rs738409	0.618	rs16991158	ENSG00000223843.4	EFCAB6-AS1	3.52	0.000476	0.0293	0.23	0.16	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43931299	chr22:43516107~43537117:+
THCA	cis	rs738409	0.657	rs36055245	ENSG00000223843.4	EFCAB6-AS1	3.52	0.000476	0.0293	0.23	0.16	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43931312	chr22:43516107~43537117:+
THCA	cis	rs13279522	0.908	rs6472246	ENSG00000272192.1	CTD-2532N20.1	-3.52	0.000476	0.0293	-0.2	-0.16	Coronary heart disease event reduction (statin therapy interaction);	chr8:66095192	chr8:65842752~65843331:+
THCA	cis	rs721917	0.525	rs2819106	ENSG00000272489.1	RP11-182L21.5	-3.52	0.000476	0.0293	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79663192~79664786:+
THCA	cis	rs11673344	0.566	rs185368	ENSG00000268499.1	CTB-102L5.8	3.52	0.000476	0.0293	0.17	0.16	Obesity-related traits;	chr19:37381827	chr19:38199836~38200934:+
THCA	cis	rs3853824	0.529	rs9892659	ENSG00000263089.1	RP11-166P13.4	3.52	0.000476	0.0294	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56866725	chr17:57092145~57096425:-
THCA	cis	rs73198271	0.74	rs1039910	ENSG00000254340.1	RP11-10A14.3	-3.52	0.000476	0.0294	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:9141424~9145435:+
THCA	cis	rs9309473	0.95	rs10198549	ENSG00000273245.1	RP11-434P11.2	3.52	0.000476	0.0294	0.22	0.16	Metabolite levels;	chr2:73567277	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.848	rs17009159	ENSG00000273245.1	RP11-434P11.2	3.52	0.000476	0.0294	0.22	0.16	Metabolite levels;	chr2:73570635	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs7583255	ENSG00000273245.1	RP11-434P11.2	3.52	0.000476	0.0294	0.22	0.16	Metabolite levels;	chr2:73570869	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs7586463	ENSG00000273245.1	RP11-434P11.2	3.52	0.000476	0.0294	0.22	0.16	Metabolite levels;	chr2:73571349	chr2:73750256~73750786:-
THCA	cis	rs78487399	1	rs78487399	ENSG00000234936.1	AC010883.5	3.52	0.000476	0.0294	0.24	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43582208	chr2:43229573~43233394:+
THCA	cis	rs11733284	0.515	rs10025104	ENSG00000259959.1	RP11-121C2.2	-3.52	0.000476	0.0294	-0.14	-0.16	Gout;Renal underexcretion gout;	chr4:47853982	chr4:47840122~47844339:-
THCA	cis	rs61008539	0.853	rs10950611	ENSG00000229043.2	AC091729.9	-3.52	0.000476	0.0294	-0.18	-0.16	Perceived unattractiveness to mosquitoes;	chr7:821457	chr7:1160374~1165267:+
THCA	cis	rs11673344	0.566	rs2385181	ENSG00000268499.1	CTB-102L5.8	3.52	0.000476	0.0294	0.16	0.16	Obesity-related traits;	chr19:37395428	chr19:38199836~38200934:+
THCA	cis	rs11673344	0.544	rs6508721	ENSG00000268499.1	CTB-102L5.8	3.52	0.000476	0.0294	0.16	0.16	Obesity-related traits;	chr19:37419119	chr19:38199836~38200934:+
THCA	cis	rs11673344	0.566	rs7254009	ENSG00000268499.1	CTB-102L5.8	3.52	0.000476	0.0294	0.16	0.16	Obesity-related traits;	chr19:37427707	chr19:38199836~38200934:+
THCA	cis	rs7267979	0.528	rs34485039	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000476	0.0294	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:25284915~25285588:-
THCA	cis	rs11009175	0.929	rs11009198	ENSG00000233190.1	RPS24P13	-3.52	0.000476	0.0294	-0.25	-0.16	Depression (quantitative trait);	chr10:33053379	chr10:32231849~32232245:-
THCA	cis	rs11009175	0.929	rs11009200	ENSG00000233190.1	RPS24P13	-3.52	0.000476	0.0294	-0.25	-0.16	Depression (quantitative trait);	chr10:33053456	chr10:32231849~32232245:-
THCA	cis	rs11009175	0.929	rs7078479	ENSG00000233190.1	RPS24P13	-3.52	0.000476	0.0294	-0.25	-0.16	Depression (quantitative trait);	chr10:33056273	chr10:32231849~32232245:-
THCA	cis	rs10256972	0.721	rs4720249	ENSG00000199023.2	MIR339	-3.52	0.000476	0.0294	-0.16	-0.16	Endometriosis;Longevity;	chr7:1032927	chr7:1022935~1023045:-
THCA	cis	rs9307551	1	rs3943669	ENSG00000249646.2	OR7E94P	-3.52	0.000477	0.0294	-0.22	-0.16	Refractive error;	chr4:79595389	chr4:79587302~79588130:-
THCA	cis	rs7899106	0.655	rs7903554	ENSG00000270002.1	RP11-93H12.4	3.52	0.000477	0.0294	0.25	0.16	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);	chr10:85595994	chr10:85644073~85648066:+
THCA	cis	rs7031325	0.925	rs2578284	ENSG00000229611.1	RP11-390F4.10	-3.52	0.000477	0.0294	-0.17	-0.16	Systemic lupus erythematosus;	chr9:6651552	chr9:6704471~6707780:+
THCA	cis	rs75422866	0.558	rs73104190	ENSG00000280054.1	RP1-197B17.7	3.52	0.000477	0.0294	0.32	0.16	Pneumonia;	chr12:47716040	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.51	rs73104197	ENSG00000280054.1	RP1-197B17.7	3.52	0.000477	0.0294	0.32	0.16	Pneumonia;	chr12:47717273	chr12:47728151~47730598:-
THCA	cis	rs6840360	0.967	rs7695162	ENSG00000270265.1	RP11-731D1.4	-3.52	0.000477	0.0294	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151589389	chr4:151333775~151353224:-
THCA	cis	rs3800688	0.527	rs9640866	ENSG00000236753.4	MKLN1-AS	3.52	0.000477	0.0294	0.15	0.16	Hypertension;	chr7:131371882	chr7:131309744~131328222:-
THCA	cis	rs9818758	0.607	rs9837237	ENSG00000229759.1	MRPS18AP1	-3.52	0.000477	0.0294	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178150	chr3:48256350~48256938:-
THCA	cis	rs2006933	0.612	rs9894461	ENSG00000267644.1	CTD-2008P7.10	3.52	0.000477	0.0294	0.21	0.16	Amyotrophic lateral sclerosis;	chr17:28158043	chr17:28219285~28220005:+
THCA	cis	rs712039	0.565	rs1714987	ENSG00000277501.1	RP11-697E22.2	3.52	0.000477	0.0294	0.23	0.16	Tuberculosis;	chr17:37386072	chr17:37642947~37684252:+
THCA	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	3.52	0.000477	0.0294	0.19	0.16	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
THCA	cis	rs2228479	0.85	rs79244293	ENSG00000274627.1	RP11-104N10.2	-3.52	0.000477	0.0294	-0.28	-0.16	Skin colour saturation;	chr16:89829812	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.718	rs62054253	ENSG00000274627.1	RP11-104N10.2	-3.52	0.000477	0.0294	-0.28	-0.16	Skin colour saturation;	chr16:89830524	chr16:89516797~89522217:+
THCA	cis	rs2243480	1	rs1546059	ENSG00000237310.1	GS1-124K5.4	-3.52	0.000477	0.0294	-0.18	-0.16	Diabetic kidney disease;	chr7:66189722	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs2420170	ENSG00000237310.1	GS1-124K5.4	-3.52	0.000477	0.0294	-0.18	-0.16	Diabetic kidney disease;	chr7:66191066	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6958289	ENSG00000237310.1	GS1-124K5.4	-3.52	0.000477	0.0294	-0.18	-0.16	Diabetic kidney disease;	chr7:66192124	chr7:66493706~66495474:+
THCA	cis	rs3824488	0.92	rs28448271	ENSG00000271155.1	RP11-435O5.5	-3.52	0.000477	0.0294	-0.27	-0.16	Neuroticism;	chr9:95477448	chr9:95506235~95507636:+
THCA	cis	rs4237845	0.844	rs4628718	ENSG00000270039.1	RP11-571M6.17	-3.52	0.000477	0.0294	-0.17	-0.16	Intelligence (multi-trait analysis);	chr12:57907817	chr12:57803838~57804415:+
THCA	cis	rs881375	0.678	rs2269060	ENSG00000238181.2	AHCYP2	-3.52	0.000477	0.0294	-0.19	-0.16	Rheumatoid arthritis;	chr9:120921291	chr9:120720673~120721972:+
THCA	cis	rs700651	0.789	rs1371663	ENSG00000231621.1	AC013264.2	3.52	0.000477	0.0294	0.17	0.16	Intracranial aneurysm;	chr2:198035581	chr2:197197991~197199273:+
THCA	cis	rs7246967	0.551	rs35740274	ENSG00000198153.8	ZNF849P	-3.52	0.000477	0.0294	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22648611	chr19:22685167~22686732:+
THCA	cis	rs13191038	1	rs13191038	ENSG00000220721.1	OR1F12	3.52	0.000477	0.0294	0.36	0.16	Urinary tract infection frequency;	chr6:28515140	chr6:28073316~28074233:+
THCA	cis	rs9649465	0.561	rs600420	ENSG00000272686.1	RP11-390E23.6	-3.52	0.000477	0.0294	-0.11	-0.16	Migraine;	chr7:123767996	chr7:123749068~123751166:+
THCA	cis	rs7829975	0.511	rs2976906	ENSG00000253981.4	ALG1L13P	3.52	0.000477	0.0294	0.16	0.16	Mood instability;	chr8:8484905	chr8:8236003~8244667:-
THCA	cis	rs1559040	0.929	rs13418039	ENSG00000272156.1	RP11-477N3.1	-3.52	0.000477	0.0294	-0.24	-0.16	Sudden cardiac arrest;	chr2:54093114	chr2:54082554~54085066:+
THCA	cis	rs1559040	1	rs13418839	ENSG00000272156.1	RP11-477N3.1	-3.52	0.000477	0.0294	-0.24	-0.16	Sudden cardiac arrest;	chr2:54093638	chr2:54082554~54085066:+
THCA	cis	rs1559040	0.929	rs13418658	ENSG00000272156.1	RP11-477N3.1	-3.52	0.000477	0.0294	-0.24	-0.16	Sudden cardiac arrest;	chr2:54093662	chr2:54082554~54085066:+
THCA	cis	rs1559040	1	rs61572658	ENSG00000272156.1	RP11-477N3.1	-3.52	0.000477	0.0294	-0.24	-0.16	Sudden cardiac arrest;	chr2:54097606	chr2:54082554~54085066:+
THCA	cis	rs34792	0.554	rs62039131	ENSG00000207425.1	Y_RNA	-3.52	0.000477	0.0294	-0.19	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15528701	chr16:14915457~14915556:-
THCA	cis	rs4794202	0.629	rs2010952	ENSG00000264920.1	RP11-6N17.4	3.52	0.000477	0.0294	0.22	0.16	Alzheimer's disease (cognitive decline);	chr17:47815493	chr17:47891255~47895812:-
THCA	cis	rs883565	0.569	rs7638329	ENSG00000223668.1	EEF1A1P24	-3.52	0.000477	0.0294	-0.14	-0.16	Handedness;	chr3:38978917	chr3:39358545~39359922:+
THCA	cis	rs2880765	0.743	rs11630410	ENSG00000218052.5	ADAMTS7P4	-3.52	0.000477	0.0294	-0.18	-0.16	Coronary artery disease;	chr15:85461510	chr15:85255369~85330334:-
THCA	cis	rs2880765	0.71	rs11630457	ENSG00000218052.5	ADAMTS7P4	-3.52	0.000477	0.0294	-0.18	-0.16	Coronary artery disease;	chr15:85461570	chr15:85255369~85330334:-
THCA	cis	rs3736485	1	rs3736485	ENSG00000259709.1	CTD-2184D3.7	3.52	0.000477	0.0294	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51456413	chr15:52124561~52140246:+
THCA	cis	rs7589561	0.602	rs6543336	ENSG00000272861.1	RP11-332H14.1	-3.52	0.000477	0.0294	-0.21	-0.16	Addiction;	chr2:105785518	chr2:105249404~105249794:-
THCA	cis	rs17683430	0.614	rs2006253	ENSG00000230736.2	RP1-149A16.3	3.52	0.000477	0.0294	0.35	0.16	GIP levels in response to oral glucose tolerance test (120 minutes);	chr22:32134269	chr22:32376664~32384343:+
THCA	cis	rs2446066	0.872	rs11170549	ENSG00000257379.1	RP11-793H13.8	3.52	0.000477	0.0294	0.24	0.16	Red blood cell count;	chr12:53420596	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.872	rs11170550	ENSG00000257379.1	RP11-793H13.8	3.52	0.000477	0.0294	0.24	0.16	Red blood cell count;	chr12:53420930	chr12:53441741~53467528:+
THCA	cis	rs2638953	0.853	rs1355473	ENSG00000247934.4	RP11-967K21.1	-3.52	0.000477	0.0294	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463632	chr12:28163298~28190738:-
THCA	cis	rs3733585	0.781	rs4292328	ENSG00000261490.1	RP11-448G15.3	-3.52	0.000477	0.0294	-0.1	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9969338	chr4:10068089~10073019:-
THCA	cis	rs11190604	0.767	rs3750723	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100413232	chr10:100412934~100413421:+
THCA	cis	rs11242704	0.632	rs3000065	ENSG00000272279.1	RP11-157J24.2	-3.52	0.000477	0.0294	-0.26	-0.16	Response to hepatitis C treatment;	chr6:1536463	chr6:1528364~1528911:-
THCA	cis	rs11673344	0.566	rs256735	ENSG00000268499.1	CTB-102L5.8	3.52	0.000477	0.0294	0.17	0.16	Obesity-related traits;	chr19:37375141	chr19:38199836~38200934:+
THCA	cis	rs11673344	0.566	rs185369	ENSG00000268499.1	CTB-102L5.8	3.52	0.000477	0.0294	0.17	0.16	Obesity-related traits;	chr19:37376137	chr19:38199836~38200934:+
THCA	cis	rs12935229	1	rs17713119	ENSG00000260922.1	RP11-538I12.3	-3.52	0.000477	0.0294	-0.26	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77302529	chr16:77234877~77290934:+
THCA	cis	rs10760158	0.832	rs4837818	ENSG00000235865.2	GSN-AS1	3.52	0.000477	0.0294	0.14	0.16	Pulse pressure;	chr9:121240041	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs10760160	ENSG00000235865.2	GSN-AS1	3.52	0.000477	0.0294	0.14	0.16	Pulse pressure;	chr9:121241048	chr9:121280768~121285530:-
THCA	cis	rs11190604	1	rs11190540	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100442872	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs4919464	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100461438	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs4919465	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100461946	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs10883496	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100462174	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs3793772	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100463068	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs6584379	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100464733	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs11190570	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100467945	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs10883499	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100472431	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs11190572	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100473122	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.945	rs11190573	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100473415	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.943	rs11190574	ENSG00000273030.1	RP11-285F16.1	3.52	0.000477	0.0294	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100474574	chr10:100412934~100413421:+
THCA	cis	rs2014572	0.967	rs10411941	ENSG00000276449.1	AC004076.5	3.52	0.000477	0.0294	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57251518	chr19:57449689~57453011:+
THCA	cis	rs2014572	0.967	rs11667407	ENSG00000276449.1	AC004076.5	3.52	0.000477	0.0294	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57251754	chr19:57449689~57453011:+
THCA	cis	rs2014572	0.967	rs10421632	ENSG00000276449.1	AC004076.5	3.52	0.000477	0.0294	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57253402	chr19:57449689~57453011:+
THCA	cis	rs2014572	0.967	rs8100154	ENSG00000276449.1	AC004076.5	3.52	0.000477	0.0294	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57254064	chr19:57449689~57453011:+
THCA	cis	rs12493885	0.725	rs57740056	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000477	0.0294	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154026741	chr3:154024401~154121332:-
THCA	cis	rs250518	0.926	rs34426717	ENSG00000251467.1	CTC-250P20.2	3.52	0.000477	0.0294	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72752640	chr5:72996920~72997642:+
THCA	cis	rs4886920	0.563	rs4886915	ENSG00000260776.4	RP11-114H24.2	-3.52	0.000477	0.0294	-0.19	-0.16	Neuroticism;	chr15:77782681	chr15:77914217~77926846:-
THCA	cis	rs2014572	0.967	rs8111977	ENSG00000276449.1	AC004076.5	3.52	0.000477	0.0294	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57247790	chr19:57449689~57453011:+
THCA	cis	rs11039798	0.511	rs2047812	ENSG00000200090.1	Y_RNA	-3.52	0.000477	0.0294	-0.14	-0.16	Axial length;	chr11:48140490	chr11:47726894~47726992:-
THCA	cis	rs2919009	0.607	rs56004902	ENSG00000271670.1	RP11-95I16.4	3.52	0.000478	0.0294	0.19	0.16	Obesity-related traits;	chr10:120938378	chr10:120879256~120880667:-
THCA	cis	rs6847067	0.631	rs17009168	ENSG00000180769.7	WDFY3-AS2	3.52	0.000478	0.0294	0.12	0.16	Oropharynx cancer;	chr4:84609643	chr4:84965682~85011277:+
THCA	cis	rs11239930	0.538	rs3011810	ENSG00000180867.10	PDIA3P1	3.52	0.000478	0.0294	0.15	0.16	AIDS progression;	chr1:147082079	chr1:147178113~147179622:+
THCA	cis	rs3758911	0.765	rs10789592	ENSG00000255353.1	RP11-382M14.1	-3.52	0.000478	0.0294	-0.21	-0.16	Coronary artery disease;	chr11:107283589	chr11:107176286~107177530:+
THCA	cis	rs7819412	0.774	rs34208825	ENSG00000254839.1	AF131215.6	3.52	0.000478	0.0294	0.17	0.16	Triglycerides;	chr8:11157106	chr8:11062647~11067089:-
THCA	cis	rs763121	0.853	rs5757187	ENSG00000225450.1	RP3-508I15.14	3.52	0.000478	0.0294	0.12	0.16	Menopause (age at onset);	chr22:38625517	chr22:38739003~38749041:+
THCA	cis	rs897984	0.647	rs8060857	ENSG00000275263.1	RP11-1072A3.4	3.52	0.000478	0.0294	0.19	0.16	Dementia with Lewy bodies;	chr16:30991399	chr16:30956872~30957199:-
THCA	cis	rs11242704	0.925	rs12200037	ENSG00000218027.2	RP11-157J24.1	3.52	0.000478	0.0294	0.21	0.16	Response to hepatitis C treatment;	chr6:1536146	chr6:1513698~1515289:-
THCA	cis	rs17123764	0.892	rs4641552	ENSG00000257464.1	RP11-161H23.8	3.52	0.000478	0.0294	0.3	0.16	Intelligence (multi-trait analysis);	chr12:49653399	chr12:49442424~49442652:-
THCA	cis	rs7097397	0.661	rs2683610	ENSG00000228403.1	RP11-563N6.6	3.52	0.000478	0.0294	0.17	0.16	Systemic lupus erythematosus;	chr10:48769674	chr10:48878022~48878649:+
THCA	cis	rs12506899	0.903	rs7683385	ENSG00000221639.1	SNORA3	3.52	0.000478	0.0294	0.19	0.16	Tumor biomarkers;	chr4:73336604	chr4:73263960~73264084:+
THCA	cis	rs950169	0.92	rs12915390	ENSG00000275120.1	RP11-182J1.17	3.52	0.000478	0.0294	0.19	0.16	Schizophrenia;	chr15:84123317	chr15:84599434~84606463:-
THCA	cis	rs57709857	0.957	rs57984710	ENSG00000272092.1	RP11-350N15.5	-3.52	0.000478	0.0294	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38271610	chr8:38382364~38383461:+
THCA	cis	rs11673344	0.668	rs7248693	ENSG00000267260.1	CTD-2162K18.4	-3.52	0.000478	0.0294	-0.21	-0.16	Obesity-related traits;	chr19:36991864	chr19:36773153~36777078:+
THCA	cis	rs7403037	0.602	rs1878504	ENSG00000260760.1	PWRN3	3.52	0.000478	0.0294	0.17	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24188801	chr15:24441127~24447967:+
THCA	cis	rs1383484	0.64	rs12101685	ENSG00000259683.1	RP11-182J1.14	3.52	0.000478	0.0294	0.17	0.16	Height;	chr15:83974905	chr15:84389729~84395903:+
THCA	cis	rs478304	1	rs478304	ENSG00000255557.1	RP11-770G2.2	-3.52	0.000478	0.0294	-0.17	-0.16	Acne (severe);	chr11:65726789	chr11:65745729~65771585:+
THCA	cis	rs7045881	0.8	rs62544363	ENSG00000254396.1	RP11-56F10.3	3.52	0.000478	0.0294	0.3	0.16	Schizophrenia;	chr9:26804750	chr9:27102630~27104728:+
THCA	cis	rs7045881	0.8	rs62544364	ENSG00000254396.1	RP11-56F10.3	3.52	0.000478	0.0294	0.3	0.16	Schizophrenia;	chr9:26804769	chr9:27102630~27104728:+
THCA	cis	rs7179456	0.593	rs514049	ENSG00000245975.2	RP11-30K9.6	-3.52	0.000478	0.0294	-0.15	-0.16	Asperger disorder;	chr15:58750164	chr15:58768072~58770974:-
THCA	cis	rs9300255	0.543	rs655293	ENSG00000235423.7	RP11-282O18.3	3.52	0.000478	0.0294	0.17	0.16	Neutrophil percentage of white cells;	chr12:123043858	chr12:123252030~123261483:-
THCA	cis	rs9796	0.866	rs544744	ENSG00000247556.5	OIP5-AS1	3.52	0.000478	0.0295	0.13	0.16	Menopause (age at onset);	chr15:41074092	chr15:41283990~41309737:+
THCA	cis	rs478304	0.593	rs4645933	ENSG00000214659.4	KRT8P26	3.52	0.000478	0.0295	0.16	0.16	Acne (severe);	chr11:65717649	chr11:65726939~65728214:+
THCA	cis	rs9796	0.835	rs11856848	ENSG00000247556.5	OIP5-AS1	3.52	0.000478	0.0295	0.13	0.16	Menopause (age at onset);	chr15:41078763	chr15:41283990~41309737:+
THCA	cis	rs9796	0.866	rs516156	ENSG00000247556.5	OIP5-AS1	3.52	0.000478	0.0295	0.13	0.16	Menopause (age at onset);	chr15:41089059	chr15:41283990~41309737:+
THCA	cis	rs3734729	0.702	rs9383747	ENSG00000218358.2	RAET1K	3.52	0.000478	0.0295	0.43	0.16	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150259254	chr6:149998019~150005157:-
THCA	cis	rs11039798	0.588	rs12278284	ENSG00000200090.1	Y_RNA	3.52	0.000478	0.0295	0.13	0.16	Axial length;	chr11:48590511	chr11:47726894~47726992:-
THCA	cis	rs2562456	0.52	rs250001	ENSG00000268081.1	RP11-678G14.2	3.52	0.000478	0.0295	0.27	0.16	Pain;	chr19:21225387	chr19:21554640~21569237:-
THCA	cis	rs7772697	0.508	rs12206419	ENSG00000223701.3	RAET1E-AS1	3.52	0.000478	0.0295	0.23	0.16	Diabetic retinopathy;	chr6:149069829	chr6:149884431~149919508:+
THCA	cis	rs11126435	0.844	rs363691	ENSG00000257702.3	LBX2-AS1	3.52	0.000478	0.0295	0.25	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr2:74614442	chr2:74502595~74504678:+
THCA	cis	rs2179367	0.959	rs2262617	ENSG00000223701.3	RAET1E-AS1	3.52	0.000478	0.0295	0.22	0.16	Dupuytren's disease;	chr6:149438590	chr6:149884431~149919508:+
THCA	cis	rs4664293	0.967	rs35975814	ENSG00000230783.1	AC009961.2	-3.52	0.000478	0.0295	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159691280	chr2:159689217~159690291:-
THCA	cis	rs4913250	0.927	rs36001410	ENSG00000203585.3	RP11-542B15.1	-3.52	0.000478	0.0295	-0.14	-0.16	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr12:67537301	chr12:67519829~67567126:+
THCA	cis	rs17801127	0.748	rs10195910	ENSG00000231969.1	AC144449.1	3.52	0.000478	0.0295	0.3	0.16	Liver enzyme levels (alanine transaminase);	chr2:149787441	chr2:149587196~149848233:+
THCA	cis	rs2522056	0.935	rs757104	ENSG00000237714.1	P4HA2-AS1	-3.52	0.000478	0.0295	-0.23	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132459537	chr5:132184876~132192808:+
THCA	cis	rs7264396	0.709	rs2425073	ENSG00000088340.14	FER1L4	3.52	0.000478	0.0295	0.16	0.16	Total cholesterol levels;	chr20:35705777	chr20:35558737~35607562:-
THCA	cis	rs1971762	0.527	rs784562	ENSG00000270175.1	RP11-793H13.11	3.52	0.000478	0.0295	0.11	0.16	Height;	chr12:53525916	chr12:53500162~53500936:-
THCA	cis	rs6687821	0.515	rs7524526	ENSG00000261737.1	RP4-612B15.3	3.52	0.000478	0.0295	0.24	0.16	Yeast infection;	chr1:87027154	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs4311860	ENSG00000261737.1	RP4-612B15.3	3.52	0.000478	0.0295	0.24	0.16	Yeast infection;	chr1:87031539	chr1:86703502~86704462:-
THCA	cis	rs1926657	1	rs7322825	ENSG00000223298.1	RNY3P8	-3.52	0.000478	0.0295	-0.21	-0.16	Breast cancer;	chr13:95213118	chr13:95310830~95310955:-
THCA	cis	rs12121840	0.79	rs55957417	ENSG00000237463.4	RP11-280O1.2	-3.52	0.000479	0.0295	-0.15	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165575755	chr1:165476841~165582155:-
THCA	cis	rs12121840	0.79	rs58058936	ENSG00000237463.4	RP11-280O1.2	-3.52	0.000479	0.0295	-0.15	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165576449	chr1:165476841~165582155:-
THCA	cis	rs735539	0.521	rs9315905	ENSG00000278291.1	RP11-172H24.4	-3.52	0.000479	0.0295	-0.22	-0.16	Dental caries;	chr13:20830830	chr13:20699307~20703718:-
THCA	cis	rs11039798	0.557	rs683180	ENSG00000200090.1	Y_RNA	-3.52	0.000479	0.0295	-0.13	-0.16	Axial length;	chr11:48442397	chr11:47726894~47726992:-
THCA	cis	rs1654345	0.561	rs10414433	ENSG00000275132.1	Metazoa_SRP	-3.52	0.000479	0.0295	-0.26	-0.16	Life satisfaction;Subjective well-being;	chr19:38053991	chr19:38200234~38200532:+
THCA	cis	rs7737355	0.947	rs6864145	ENSG00000237714.1	P4HA2-AS1	3.52	0.000479	0.0295	0.23	0.16	Life satisfaction;	chr5:131302168	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.898	rs6864413	ENSG00000237714.1	P4HA2-AS1	3.52	0.000479	0.0295	0.23	0.16	Life satisfaction;	chr5:131302175	chr5:132184876~132192808:+
THCA	cis	rs755249	0.51	rs599892	ENSG00000228060.1	RP11-69E11.8	-3.52	0.000479	0.0295	-0.15	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39565160~39573203:+
THCA	cis	rs17122278	1	rs2277295	ENSG00000243431.1	RPL5P30	3.52	0.000479	0.0295	0.16	0.16	Total cholesterol levels;	chr11:118545538	chr11:118560690~118561580:+
THCA	cis	rs911555	0.755	rs35233301	ENSG00000269940.1	RP11-73M18.7	-3.52	0.000479	0.0295	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103694560~103695170:+
THCA	cis	rs524281	0.861	rs12049852	ENSG00000255038.1	RP11-1167A19.2	-3.52	0.000479	0.0295	-0.18	-0.16	Electroencephalogram traits;	chr11:66117231	chr11:66067277~66069619:-
THCA	cis	rs72996113	0.938	rs76578189	ENSG00000248027.1	CTD-2383M3.1	-3.52	0.000479	0.0295	-0.29	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100635541	chr11:100684162~100687955:-
THCA	cis	rs6137726	0.524	rs1203941	ENSG00000237396.1	LINC01384	3.52	0.000479	0.0295	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22615951	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.524	rs1203942	ENSG00000237396.1	LINC01384	3.52	0.000479	0.0295	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22615997	chr20:22587522~22607517:-
THCA	cis	rs58688157	0.96	rs112006329	ENSG00000269915.1	AP006621.9	-3.52	0.000479	0.0295	-0.18	-0.16	Systemic lupus erythematosus;	chr11:617228	chr11:708564~727047:-
THCA	cis	rs16975963	0.793	rs11666497	ENSG00000226686.6	LINC01535	-3.52	0.000479	0.0295	-0.22	-0.16	Longevity;	chr19:37973622	chr19:37251912~37265535:+
THCA	cis	rs2446066	0.728	rs10876444	ENSG00000257379.1	RP11-793H13.8	3.52	0.000479	0.0295	0.24	0.16	Red blood cell count;	chr12:53358697	chr12:53441741~53467528:+
THCA	cis	rs550448	0.755	rs527637	ENSG00000234336.5	JAZF1-AS1	-3.52	0.000479	0.0295	-0.28	-0.16	Type 1 diabetes;	chr7:28215019	chr7:28180322~28243917:+
THCA	cis	rs7028939	0.892	rs10512269	ENSG00000234709.2	UPF3AP3	3.52	0.000479	0.0295	0.29	0.16	Preeclampsia;	chr9:100203100	chr9:99998301~99999069:-
THCA	cis	rs9788682	1	rs7181447	ENSG00000261143.1	ADAMTS7P3	-3.52	0.000479	0.0295	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78522225	chr15:77976042~77993057:+
THCA	cis	rs4800353	0.673	rs1383039	ENSG00000265142.5	MIR133A1HG	-3.52	0.000479	0.0295	-0.22	-0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr18:22034021	chr18:21825487~21831410:-
THCA	cis	rs9549260	0.755	rs7986407	ENSG00000168852.11	TPTE2P5	3.52	0.000479	0.0295	0.12	0.16	Red blood cell count;	chr13:40605661	chr13:40822296~40921749:-
THCA	cis	rs1153858	0.943	rs7402632	ENSG00000275672.1	GATM-AS1	-3.52	0.000479	0.0295	-0.17	-0.16	Homoarginine levels;	chr15:45409715	chr15:45378700~45380123:+
THCA	cis	rs9796	0.87	rs8030306	ENSG00000247556.5	OIP5-AS1	3.52	0.000479	0.0295	0.13	0.16	Menopause (age at onset);	chr15:40969623	chr15:41283990~41309737:+
THCA	cis	rs4073582	0.595	rs801731	ENSG00000245156.1	RP11-867G23.3	3.52	0.000479	0.0295	0.13	0.16	Gout;	chr11:66170975	chr11:66269832~66278525:-
THCA	cis	rs910316	1	rs2300601	ENSG00000259138.1	RP11-950C14.7	3.52	0.000479	0.0295	0.14	0.16	Height;	chr14:75172868	chr14:75127153~75136930:+
THCA	cis	rs2692947	0.537	rs11679899	ENSG00000236750.1	AC009237.16	-3.52	0.000479	0.0295	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712414	chr2:95641634~95641980:-
THCA	cis	rs1993293	0.543	rs11636039	ENSG00000259219.1	CTD-3076O17.2	3.52	0.000479	0.0295	0.19	0.16	Coronary artery calcification;	chr15:99751886	chr15:99976481~99980774:+
THCA	cis	rs9902453	0.808	rs8069669	ENSG00000214719.10	AC005562.1	3.52	0.000479	0.0295	0.15	0.16	Coffee consumption (cups per day);	chr17:29912484	chr17:30576464~30672789:+
THCA	cis	rs11069062	0.683	rs1827175	ENSG00000270482.1	RP11-131L12.2	-3.52	0.000479	0.0295	-0.12	-0.16	Obesity-related traits;	chr12:118734958	chr12:118375350~118376275:-
THCA	cis	rs748404	0.66	rs690012	ENSG00000275601.1	AC011330.13	-3.52	0.000479	0.0295	-0.19	-0.16	Lung cancer;	chr15:43427557	chr15:43642389~43643023:-
THCA	cis	rs9860428	0.844	rs2220397	ENSG00000243795.1	RP11-572M11.3	3.52	0.000479	0.0295	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112895600	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs6807722	ENSG00000243795.1	RP11-572M11.3	3.52	0.000479	0.0295	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896320	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs9846377	ENSG00000243795.1	RP11-572M11.3	3.52	0.000479	0.0295	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112902091	chr3:113142350~113167819:-
THCA	cis	rs66887589	0.967	rs6844263	ENSG00000249244.1	RP11-548H18.2	3.52	0.000479	0.0295	0.16	0.16	Diastolic blood pressure;	chr4:119512652	chr4:119391831~119395335:-
THCA	cis	rs7615952	0.512	rs2979351	ENSG00000243429.1	OR7E29P	3.52	0.000479	0.0295	0.21	0.16	Blood pressure (smoking interaction);	chr3:125644755	chr3:125712139~125713045:+
THCA	cis	rs6751744	0.855	rs7585513	ENSG00000230783.1	AC009961.2	-3.52	0.000479	0.0295	-0.21	-0.16	Dysphagia;	chr2:159550379	chr2:159689217~159690291:-
THCA	cis	rs11992162	0.56	rs13256329	ENSG00000227888.4	FAM66A	-3.52	0.000479	0.0295	-0.2	-0.16	Monocyte count;	chr8:11924705	chr8:12362019~12388296:+
THCA	cis	rs10435719	0.638	rs67146188	ENSG00000227888.4	FAM66A	-3.52	0.000479	0.0295	-0.2	-0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:12362019~12388296:+
THCA	cis	rs7819412	0.669	rs28630509	ENSG00000206014.6	OR7E161P	3.52	0.000479	0.0295	0.19	0.16	Triglycerides;	chr8:11139529	chr8:11928597~11929563:-
THCA	cis	rs7259376	0.837	rs10420149	ENSG00000270947.1	AC025811.3	-3.52	0.000479	0.0295	-0.17	-0.16	Menopause (age at onset);	chr19:22400123	chr19:22455988~22456459:+
THCA	cis	rs3770081	1	rs2303340	ENSG00000272564.1	RP11-548P2.2	-3.52	0.000479	0.0295	-0.3	-0.16	Facial emotion recognition (sad faces);	chr2:86106070	chr2:85904279~85904727:+
THCA	cis	rs561341	0.709	rs8068049	ENSG00000280033.1	CTD-2095E4.3	3.52	0.000479	0.0295	0.26	0.16	Hip circumference adjusted for BMI;	chr17:31856838	chr17:32159311~32160371:+
THCA	cis	rs3087591	0.639	rs734403	ENSG00000263535.1	AK4P1	3.52	0.000479	0.0295	0.19	0.16	Hip circumference;	chr17:31396328	chr17:31345521~31346187:+
THCA	cis	rs7631605	0.874	rs7616160	ENSG00000272334.1	RP11-129K12.1	3.52	0.000479	0.0295	0.19	0.16	Cerebrospinal P-tau181p levels;	chr3:37100486	chr3:36973117~36973672:-
THCA	cis	rs7927592	0.546	rs497261	ENSG00000160172.9	FAM86C2P	3.52	0.000479	0.0295	0.15	0.16	Total body bone mineral density;	chr11:68424776	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.546	rs599083	ENSG00000160172.9	FAM86C2P	3.52	0.000479	0.0295	0.15	0.16	Total body bone mineral density;	chr11:68424878	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.546	rs683978	ENSG00000160172.9	FAM86C2P	3.52	0.000479	0.0295	0.15	0.16	Total body bone mineral density;	chr11:68424953	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.546	rs554734	ENSG00000160172.9	FAM86C2P	3.52	0.000479	0.0295	0.15	0.16	Total body bone mineral density;	chr11:68425050	chr11:67791648~67805336:-
THCA	cis	rs7709377	0.723	rs7717207	ENSG00000248445.4	SEMA6A-AS1	-3.52	0.000479	0.0295	-0.14	-0.16	Metabolite levels  (X-11787);	chr5:116329804	chr5:116447547~116508276:+
THCA	cis	rs67340775	0.541	rs200964	ENSG00000272009.1	RP1-313I6.12	-3.52	0.000479	0.0295	-0.21	-0.16	Lung cancer in ever smokers;	chr6:27899165	chr6:28078792~28081130:-
THCA	cis	rs28830936	0.966	rs28680296	ENSG00000250379.1	RP11-23P13.4	3.52	0.000479	0.0295	0.19	0.16	Diastolic blood pressure;	chr15:41829340	chr15:41825099~41827936:-
THCA	cis	rs72843506	0.586	rs74429763	ENSG00000231258.2	ZSWIM5P2	3.52	0.000479	0.0295	0.25	0.16	Schizophrenia;	chr17:19960206	chr17:20583758~20591180:-
THCA	cis	rs72843506	0.586	rs16960554	ENSG00000231258.2	ZSWIM5P2	3.52	0.000479	0.0295	0.25	0.16	Schizophrenia;	chr17:19966485	chr17:20583758~20591180:-
THCA	cis	rs10108033	0.915	rs9642895	ENSG00000253507.4	CTD-2501M5.1	3.52	0.000479	0.0295	0.22	0.16	IgG glycosylation;	chr8:131327024	chr8:131308545~131317632:+
THCA	cis	rs76382185	0.61	rs34589233	ENSG00000233184.5	RP11-421L21.3	3.52	0.000479	0.0295	0.23	0.16	Lymphocyte counts;	chr1:101098970	chr1:101025878~101087268:+
THCA	cis	rs10010758	1	rs10010758	ENSG00000251332.1	RP11-177C12.4	-3.52	0.000479	0.0295	-0.18	-0.16	Periodontal microbiota;	chr4:37936897	chr4:37995494~37996203:-
THCA	cis	rs78487399	0.665	rs72867023	ENSG00000234936.1	AC010883.5	3.52	0.000479	0.0295	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536027	chr2:43229573~43233394:+
THCA	cis	rs4886920	0.563	rs8037968	ENSG00000260776.4	RP11-114H24.2	-3.52	0.000479	0.0295	-0.19	-0.16	Neuroticism;	chr15:77785420	chr15:77914217~77926846:-
THCA	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	3.52	0.000479	0.0295	0.18	0.16	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
THCA	cis	rs9427116	0.502	rs9426827	ENSG00000236675.1	MTX1P1	-3.52	0.000479	0.0295	-0.15	-0.16	Blood protein levels;	chr1:154617489	chr1:155230975~155234325:+
THCA	cis	rs4800353	0.714	rs4392158	ENSG00000265142.5	MIR133A1HG	3.52	0.000479	0.0295	0.22	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr18:22031132	chr18:21825487~21831410:-
THCA	cis	rs9876781	0.559	rs7630053	ENSG00000244380.1	RP11-24C3.2	3.52	0.00048	0.0295	0.2	0.16	Longevity;	chr3:48357096	chr3:48440352~48446656:-
THCA	cis	rs7005380	0.6	rs13267652	ENSG00000279347.1	RP11-85I17.2	-3.52	0.00048	0.0295	-0.18	-0.16	Interstitial lung disease;	chr8:119878346	chr8:119838736~119840385:-
THCA	cis	rs7005380	0.62	rs13275528	ENSG00000279347.1	RP11-85I17.2	-3.52	0.00048	0.0295	-0.18	-0.16	Interstitial lung disease;	chr8:119878617	chr8:119838736~119840385:-
THCA	cis	rs987724	0.515	rs453219	ENSG00000243926.1	TIPARP-AS1	3.52	0.00048	0.0295	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856463	chr3:156671862~156674378:-
THCA	cis	rs9287719	0.967	rs4669593	ENSG00000243819.4	RN7SL832P	3.52	0.00048	0.0295	0.13	0.16	Prostate cancer;	chr2:10561782	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs3814388	ENSG00000243819.4	RN7SL832P	3.52	0.00048	0.0295	0.13	0.16	Prostate cancer;	chr2:10561973	chr2:10690344~10692099:+
THCA	cis	rs4788570	0.615	rs6499531	ENSG00000260593.1	RP11-432I5.2	-3.52	0.00048	0.0295	-0.26	-0.16	Intelligence (multi-trait analysis);	chr16:71697582	chr16:71623708~71626816:-
THCA	cis	rs9549260	0.755	rs4429172	ENSG00000168852.11	TPTE2P5	3.52	0.00048	0.0295	0.12	0.16	Red blood cell count;	chr13:40615006	chr13:40822296~40921749:-
THCA	cis	rs722599	0.683	rs8011071	ENSG00000279594.1	RP11-950C14.10	3.52	0.00048	0.0295	0.16	0.16	IgG glycosylation;	chr14:74820002	chr14:75011269~75012851:-
THCA	cis	rs950169	1	rs11638297	ENSG00000230373.7	GOLGA6L5P	-3.52	0.00048	0.0295	-0.17	-0.16	Schizophrenia;	chr15:84113665	chr15:84507885~84516814:-
THCA	cis	rs10129255	0.956	rs10137268	ENSG00000280411.1	IGHV1-69-2	-3.52	0.00048	0.0295	-0.1	-0.16	Kawasaki disease;	chr14:106697402	chr14:106762092~106762588:-
THCA	cis	rs972540	1	rs7422054	ENSG00000229647.1	AC007879.7	-3.52	0.00048	0.0295	-0.18	-0.16	Body mass index;	chr2:206383456	chr2:207239650~207245887:+
THCA	cis	rs1971762	0.563	rs3897117	ENSG00000270175.1	RP11-793H13.11	-3.52	0.00048	0.0295	-0.1	-0.16	Height;	chr12:53683623	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.563	rs7958775	ENSG00000270175.1	RP11-793H13.11	-3.52	0.00048	0.0295	-0.1	-0.16	Height;	chr12:53683772	chr12:53500162~53500936:-
THCA	cis	rs1729951	0.575	rs1682333	ENSG00000239213.4	NCK1-AS1	3.52	0.00048	0.0295	0.14	0.16	Neuroticism;	chr3:136969776	chr3:136841726~136862054:-
THCA	cis	rs9410380	1	rs1779307	ENSG00000225385.3	RP11-350E12.4	3.52	0.00048	0.0295	0.16	0.16	Monocyte count;	chr9:88834451	chr9:88066915~88068037:+
THCA	cis	rs9291683	0.609	rs7678012	ENSG00000261490.1	RP11-448G15.3	3.52	0.00048	0.0295	0.1	0.16	Bone mineral density;	chr4:9992148	chr4:10068089~10073019:-
THCA	cis	rs9916302	0.706	rs4795358	ENSG00000266469.1	CTB-131K11.1	-3.52	0.00048	0.0295	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39416812	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs7208252	ENSG00000266469.1	CTB-131K11.1	-3.52	0.00048	0.0295	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39428115	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs9646419	ENSG00000266469.1	CTB-131K11.1	-3.52	0.00048	0.0295	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39440932	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.752	rs12150047	ENSG00000266469.1	CTB-131K11.1	-3.52	0.00048	0.0295	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39445502	chr17:39401793~39406233:+
THCA	cis	rs4262150	0.767	rs4360032	ENSG00000253921.1	CTB-113P19.3	-3.52	0.00048	0.0295	-0.21	-0.16	Bipolar disorder and schizophrenia;	chr5:152583503	chr5:151753992~151767247:+
THCA	cis	rs31872	0.678	rs702390	ENSG00000202515.1	VTRNA1-3	3.52	0.00048	0.0295	0.19	0.16	Visceral adipose tissue adjusted for BMI;	chr5:141062624	chr5:140726158~140726246:+
THCA	cis	rs6546550	0.867	rs7592647	ENSG00000179818.12	PCBP1-AS1	-3.52	0.00048	0.0295	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69912002	chr2:69962263~70103220:-
THCA	cis	rs72928364	0.685	rs1375513	ENSG00000256628.3	ZBTB11-AS1	3.52	0.00048	0.0295	0.22	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101052447	chr3:101676475~101679217:+
THCA	cis	rs714027	0.626	rs7287570	ENSG00000279699.1	RP1-102K2.9	-3.52	0.00048	0.0296	-0.16	-0.16	Lymphocyte counts;	chr22:30111369	chr22:30275215~30276951:-
THCA	cis	rs9911578	1	rs172565	ENSG00000224738.1	AC099850.1	3.52	0.00048	0.0296	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58731635	chr17:59106598~59118267:+
THCA	cis	rs481331	0.866	rs209385	ENSG00000272319.1	AL022345.7	3.52	0.00048	0.0296	0.31	0.16	Systemic juvenile idiopathic arthritis;	chr10:42638913	chr10:42579724~42582772:+
THCA	cis	rs7824557	0.505	rs2572440	ENSG00000255495.1	AC145124.2	3.52	0.00048	0.0296	0.18	0.16	Retinal vascular caliber;	chr8:11391501	chr8:12194467~12196280:+
THCA	cis	rs862034	0.902	rs862051	ENSG00000270000.1	RP3-449M8.9	-3.52	0.00048	0.0296	-0.16	-0.16	Height;	chr14:74514277	chr14:74471930~74472360:-
THCA	cis	rs66887589	0.967	rs13104219	ENSG00000249244.1	RP11-548H18.2	3.52	0.00048	0.0296	0.16	0.16	Diastolic blood pressure;	chr4:119517019	chr4:119391831~119395335:-
THCA	cis	rs3758911	0.861	rs10890690	ENSG00000255353.1	RP11-382M14.1	-3.52	0.00048	0.0296	-0.21	-0.16	Coronary artery disease;	chr11:107276174	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs11212116	ENSG00000255353.1	RP11-382M14.1	-3.52	0.00048	0.0296	-0.21	-0.16	Coronary artery disease;	chr11:107276621	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs10890692	ENSG00000255353.1	RP11-382M14.1	-3.52	0.00048	0.0296	-0.21	-0.16	Coronary artery disease;	chr11:107277053	chr11:107176286~107177530:+
THCA	cis	rs3758911	0.861	rs10749890	ENSG00000255353.1	RP11-382M14.1	-3.52	0.00048	0.0296	-0.21	-0.16	Coronary artery disease;	chr11:107278357	chr11:107176286~107177530:+
THCA	cis	rs6496667	0.865	rs7169196	ENSG00000259262.1	NDUFA3P4	3.52	0.00048	0.0296	0.23	0.16	Rheumatoid arthritis;	chr15:90334252	chr15:90385814~90386063:+
THCA	cis	rs1048886	0.872	rs12200777	ENSG00000271967.1	RP11-134K13.4	-3.52	0.00048	0.0296	-0.19	-0.16	Type 2 diabetes;	chr6:70577251	chr6:70596438~70596980:+
THCA	cis	rs13064411	0.696	rs6773497	ENSG00000243849.1	CFAP44-AS1	3.52	0.00048	0.0296	0.25	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113467667	chr3:113403991~113433992:+
THCA	cis	rs972540	1	rs62195886	ENSG00000229647.1	AC007879.7	-3.52	0.00048	0.0296	-0.18	-0.16	Body mass index;	chr2:206368908	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs56750678	ENSG00000229647.1	AC007879.7	-3.52	0.00048	0.0296	-0.18	-0.16	Body mass index;	chr2:206370570	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs113242332	ENSG00000229647.1	AC007879.7	-3.52	0.00048	0.0296	-0.18	-0.16	Body mass index;	chr2:206372126	chr2:207239650~207245887:+
THCA	cis	rs972540	0.961	rs75388389	ENSG00000229647.1	AC007879.7	-3.52	0.00048	0.0296	-0.18	-0.16	Body mass index;	chr2:206378400	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs62195890	ENSG00000229647.1	AC007879.7	-3.52	0.00048	0.0296	-0.18	-0.16	Body mass index;	chr2:206379210	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs80109481	ENSG00000229647.1	AC007879.7	-3.52	0.00048	0.0296	-0.18	-0.16	Body mass index;	chr2:206382327	chr2:207239650~207245887:+
THCA	cis	rs972540	1	rs1448901	ENSG00000229647.1	AC007879.7	-3.52	0.00048	0.0296	-0.18	-0.16	Body mass index;	chr2:206388916	chr2:207239650~207245887:+
THCA	cis	rs7176527	0.848	rs17600128	ENSG00000176700.18	SCAND2P	3.52	0.00048	0.0296	0.15	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:84631451~84647478:+
THCA	cis	rs12612619	0.689	rs6721395	ENSG00000231636.1	AGBL5-AS1	3.52	0.00048	0.0296	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057259	chr2:27049683~27050264:-
THCA	cis	rs972578	1	rs6002997	ENSG00000230319.1	AL022476.2	3.52	0.00048	0.0296	0.17	0.16	Mean platelet volume;	chr22:42996258	chr22:43038585~43052366:+
THCA	cis	rs9693857	1	rs9693857	ENSG00000254340.1	RP11-10A14.3	-3.52	0.00048	0.0296	-0.18	-0.16	Systolic blood pressure;	chr8:9409607	chr8:9141424~9145435:+
THCA	cis	rs67478160	0.634	rs2368558	ENSG00000258534.1	CTD-2134A5.4	-3.52	0.00048	0.0296	-0.16	-0.16	Schizophrenia;	chr14:103764181	chr14:103854366~103880111:-
THCA	cis	rs67478160	0.634	rs2368559	ENSG00000258534.1	CTD-2134A5.4	-3.52	0.00048	0.0296	-0.16	-0.16	Schizophrenia;	chr14:103764198	chr14:103854366~103880111:-
THCA	cis	rs11681884	0.892	rs56948778	ENSG00000236397.3	DDX11L2	-3.52	0.00048	0.0296	-0.33	-0.16	Stroke;	chr2:113096316	chr2:113599036~113601261:-
THCA	cis	rs11681884	0.892	rs72950867	ENSG00000236397.3	DDX11L2	-3.52	0.00048	0.0296	-0.33	-0.16	Stroke;	chr2:113101094	chr2:113599036~113601261:-
THCA	cis	rs7551222	0.752	rs10900593	ENSG00000240219.1	RP11-430C7.5	3.52	0.000481	0.0296	0.15	0.16	Schizophrenia;	chr1:204500968	chr1:204626775~204629712:+
THCA	cis	rs10844154	0.638	rs326646	ENSG00000277342.1	RP11-843B15.4	-3.52	0.000481	0.0296	-0.19	-0.16	Emphysema-related traits;Weight;	chr12:32250230	chr12:32109076~32109602:+
THCA	cis	rs10186029	0.509	rs6718004	ENSG00000270659.1	RP11-105N14.1	-3.52	0.000481	0.0296	-0.14	-0.16	Systemic sclerosis;	chr2:213080556	chr2:213152970~213153659:+
THCA	cis	rs10911902	0.602	rs1919200	ENSG00000228238.1	GS1-304P7.2	-3.52	0.000481	0.0296	-0.27	-0.16	Schizophrenia;	chr1:186300848	chr1:186578279~186579299:+
THCA	cis	rs713587	0.525	rs11675457	ENSG00000224165.4	DNAJC27-AS1	-3.52	0.000481	0.0296	-0.09	-0.16	Body mass index in non-asthmatics;	chr2:24856901	chr2:24971390~25039694:+
THCA	cis	rs2014572	0.967	rs11084492	ENSG00000276449.1	AC004076.5	3.52	0.000481	0.0296	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57244658	chr19:57449689~57453011:+
THCA	cis	rs862034	0.843	rs862055	ENSG00000270000.1	RP3-449M8.9	-3.52	0.000481	0.0296	-0.16	-0.16	Height;	chr14:74512389	chr14:74471930~74472360:-
THCA	cis	rs12379034	0.611	rs2297454	ENSG00000226752.6	PSMD5-AS1	3.52	0.000481	0.0296	0.21	0.16	Rheumatoid arthritis;	chr9:120409477	chr9:120824828~120854385:+
THCA	cis	rs7765004	0.961	rs9374426	ENSG00000230943.1	RP11-367G18.1	3.52	0.000481	0.0296	0.16	0.16	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113753164	chr6:113623535~113650074:-
THCA	cis	rs7765004	1	rs9387176	ENSG00000230943.1	RP11-367G18.1	3.52	0.000481	0.0296	0.16	0.16	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113753291	chr6:113623535~113650074:-
THCA	cis	rs7765004	1	rs9372374	ENSG00000230943.1	RP11-367G18.1	3.52	0.000481	0.0296	0.16	0.16	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113753457	chr6:113623535~113650074:-
THCA	cis	rs7765004	1	rs9372375	ENSG00000230943.1	RP11-367G18.1	3.52	0.000481	0.0296	0.16	0.16	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113753713	chr6:113623535~113650074:-
THCA	cis	rs7765004	0.961	rs9372376	ENSG00000230943.1	RP11-367G18.1	3.52	0.000481	0.0296	0.16	0.16	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113753763	chr6:113623535~113650074:-
THCA	cis	rs7765004	1	rs9400667	ENSG00000230943.1	RP11-367G18.1	3.52	0.000481	0.0296	0.16	0.16	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113754617	chr6:113623535~113650074:-
THCA	cis	rs4664293	0.967	rs13020365	ENSG00000230783.1	AC009961.2	-3.52	0.000481	0.0296	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159619893	chr2:159689217~159690291:-
THCA	cis	rs7147624	1	rs7160390	ENSG00000276116.2	FUT8-AS1	3.52	0.000481	0.0296	0.23	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65585742	chr14:65411170~65412690:-
THCA	cis	rs7147624	1	rs2411354	ENSG00000276116.2	FUT8-AS1	3.52	0.000481	0.0296	0.23	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65595414	chr14:65411170~65412690:-
THCA	cis	rs854765	0.663	rs1052299	ENSG00000281749.1	Y_RNA	-3.52	0.000481	0.0296	-0.2	-0.16	Total body bone mineral density;	chr17:17847105	chr17:18001101~18001195:-
THCA	cis	rs559555	0.523	rs523349	ENSG00000276517.1	AL133243.2	-3.52	0.000481	0.0296	-0.16	-0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31580636	chr2:32526504~32529507:+
THCA	cis	rs12352279	0.59	rs11506699	ENSG00000227914.3	RP11-130C19.3	-3.52	0.000481	0.0296	-0.26	-0.16	Migraine - clinic-based;	chr9:667680	chr9:673478~685555:-
THCA	cis	rs288326	0.561	rs78177114	ENSG00000272800.1	RP11-438L19.1	3.52	0.000481	0.0296	0.29	0.16	Blood protein levels;	chr2:182865701	chr2:183214319~183215400:+
THCA	cis	rs10916248	0.511	rs10916512	ENSG00000272645.2	RP11-504P24.8	-3.52	0.000481	0.0296	-0.13	-0.16	QT interval (drug interaction);	chr1:224220968	chr1:223951388~223953439:-
THCA	cis	rs11175834	0.655	rs4631931	ENSG00000256915.1	RP11-221N13.4	3.52	0.000481	0.0296	0.29	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65572195	chr12:65644334~65663299:+
THCA	cis	rs4561483	0.673	rs28279	ENSG00000263307.1	RP11-166B2.8	-3.52	0.000481	0.0296	-0.17	-0.16	Testicular germ cell tumor;	chr16:11874698	chr16:11851649~11895611:+
THCA	cis	rs17685	0.632	rs1859793	ENSG00000227038.2	AC005077.12	3.52	0.000481	0.0296	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76191965	chr7:76090431~76108779:-
THCA	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	3.52	0.000481	0.0296	0.15	0.16	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	3.52	0.000481	0.0296	0.15	0.16	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
THCA	cis	rs6472235	0.967	rs59282311	ENSG00000272192.1	CTD-2532N20.1	3.52	0.000481	0.0296	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65974221	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.967	rs7000670	ENSG00000272192.1	CTD-2532N20.1	3.52	0.000481	0.0296	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65975261	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.967	rs56249745	ENSG00000272192.1	CTD-2532N20.1	3.52	0.000481	0.0296	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65976359	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.967	rs7012332	ENSG00000272192.1	CTD-2532N20.1	3.52	0.000481	0.0296	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65977849	chr8:65842752~65843331:+
THCA	cis	rs17301013	0.932	rs332771	ENSG00000270084.1	GAS5-AS1	-3.52	0.000481	0.0296	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174704141	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.861	rs332789	ENSG00000270084.1	GAS5-AS1	-3.52	0.000481	0.0296	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174735754	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs461910	ENSG00000270084.1	GAS5-AS1	-3.52	0.000481	0.0296	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174736351	chr1:173863248~173863941:+
THCA	cis	rs944289	0.646	rs8008989	ENSG00000257520.1	RP11-896J10.3	3.52	0.000481	0.0296	0.16	0.16	Thyroid cancer;	chr14:36088871	chr14:36473207~36519521:-
THCA	cis	rs910316	0.967	rs175502	ENSG00000259138.1	RP11-950C14.7	-3.52	0.000481	0.0296	-0.14	-0.16	Height;	chr14:75066976	chr14:75127153~75136930:+
THCA	cis	rs17194490	0.665	rs71311703	ENSG00000237990.3	CNTN4-AS1	3.52	0.000481	0.0296	0.24	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:2527856	chr3:3039033~3069242:-
THCA	cis	rs7746199	0.668	rs34864796	ENSG00000272009.1	RP1-313I6.12	-3.52	0.000481	0.0296	-0.27	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28078792~28081130:-
THCA	cis	rs8028182	0.636	rs7166737	ENSG00000275645.1	RP11-817O13.9	3.52	0.000481	0.0296	0.16	0.16	Sudden cardiac arrest;	chr15:75390172	chr15:75346744~75347161:-
THCA	cis	rs7259376	0.905	rs62118584	ENSG00000269345.1	VN1R85P	3.52	0.000481	0.0296	0.17	0.16	Menopause (age at onset);	chr19:22358340	chr19:22174766~22175191:-
THCA	cis	rs2933343	0.7	rs789233	ENSG00000261159.1	RP11-723O4.9	3.52	0.000481	0.0296	0.16	0.16	IgG glycosylation;	chr3:128884307	chr3:128859716~128860526:-
THCA	cis	rs950169	0.881	rs150965	ENSG00000230373.7	GOLGA6L5P	-3.52	0.000481	0.0296	-0.17	-0.16	Schizophrenia;	chr15:84537296	chr15:84507885~84516814:-
THCA	cis	rs2839186	0.934	rs2839194	ENSG00000228137.1	AP001469.7	3.52	0.000481	0.0296	0.16	0.16	Testicular germ cell tumor;	chr21:46279523	chr21:46246890~46247682:+
THCA	cis	rs7424096	0.515	rs17497343	ENSG00000279519.1	RP11-288C18.1	3.52	0.000481	0.0296	0.13	0.16	High light scatter reticulocyte percentage of red cells;	chr2:36945889	chr2:36839922~36842539:-
THCA	cis	rs9399599	0.683	rs2786189	ENSG00000233452.5	STXBP5-AS1	-3.52	0.000481	0.0296	-0.17	-0.16	Plasma plasminogen activator levels;	chr6:147209945	chr6:146841901~147204614:-
THCA	cis	rs11098499	0.644	rs10012252	ENSG00000249244.1	RP11-548H18.2	3.52	0.000481	0.0296	0.18	0.16	Corneal astigmatism;	chr4:119637984	chr4:119391831~119395335:-
THCA	cis	rs6479352	0.526	rs10991953	ENSG00000225511.5	LINC00475	-3.52	0.000481	0.0296	-0.17	-0.16	Bipolar disorder (inflammation and infection response interaction);	chr9:91491054	chr9:92141298~92160114:+
THCA	cis	rs7089973	0.523	rs11197017	ENSG00000236799.1	RP11-383C6.2	-3.52	0.000481	0.0296	-0.19	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114977979	chr10:114994657~114996593:+
THCA	cis	rs7089973	0.523	rs7099590	ENSG00000236799.1	RP11-383C6.2	-3.52	0.000481	0.0296	-0.19	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114989947	chr10:114994657~114996593:+
THCA	cis	rs748404	0.56	rs1060939	ENSG00000275601.1	AC011330.13	-3.52	0.000481	0.0296	-0.19	-0.16	Lung cancer;	chr15:43524719	chr15:43642389~43643023:-
THCA	cis	rs3796352	0.764	rs11714902	ENSG00000280417.1	RP11-5O17.1	-3.52	0.000481	0.0296	-0.24	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:53067528	chr3:53046166~53048122:+
THCA	cis	rs853679	0.546	rs200995	ENSG00000220721.1	OR1F12	-3.52	0.000481	0.0296	-0.27	-0.16	Depression;	chr6:27845916	chr6:28073316~28074233:+
THCA	cis	rs913672	0.637	rs2274951	ENSG00000231742.4	LINC01273	3.52	0.000481	0.0296	0.2	0.16	Monocyte count;	chr20:50277933	chr20:50172550~50176671:+
THCA	cis	rs6496667	0.865	rs62019275	ENSG00000259262.1	NDUFA3P4	3.52	0.000481	0.0296	0.23	0.16	Rheumatoid arthritis;	chr15:90331602	chr15:90385814~90386063:+
THCA	cis	rs2274273	0.87	rs2016931	ENSG00000258469.1	CHMP4BP1	3.52	0.000482	0.0296	0.14	0.16	Protein biomarker;	chr14:55375614	chr14:55298644~55299231:+
THCA	cis	rs412658	0.523	rs440597	ENSG00000268119.4	CTD-2561J22.5	-3.52	0.000482	0.0296	-0.18	-0.16	Telomere length;	chr19:21913717	chr19:21444241~21463908:-
THCA	cis	rs495337	0.965	rs12151879	ENSG00000229222.1	KRT18P4	-3.52	0.000482	0.0296	-0.2	-0.16	Psoriasis;	chr20:49932705	chr20:49956745~49958032:+
THCA	cis	rs495337	1	rs4287819	ENSG00000229222.1	KRT18P4	-3.52	0.000482	0.0296	-0.2	-0.16	Psoriasis;	chr20:49935419	chr20:49956745~49958032:+
THCA	cis	rs7550636	0.964	rs10921278	ENSG00000276735.1	Metazoa_SRP	3.52	0.000482	0.0296	0.2	0.16	Coronary artery calcification;	chr1:192846552	chr1:193236794~193237107:-
THCA	cis	rs12621844	0.667	rs990549	ENSG00000234690.5	AC073283.4	-3.52	0.000482	0.0296	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48152283	chr2:47192405~47345074:-
THCA	cis	rs853679	1	rs1679709	ENSG00000261839.1	RP1-265C24.8	-3.52	0.000482	0.0296	-0.22	-0.16	Depression;	chr6:28260564	chr6:28136849~28139678:+
THCA	cis	rs853679	1	rs1778511	ENSG00000261839.1	RP1-265C24.8	-3.52	0.000482	0.0296	-0.22	-0.16	Depression;	chr6:28261633	chr6:28136849~28139678:+
THCA	cis	rs853679	1	rs11965538	ENSG00000261839.1	RP1-265C24.8	3.52	0.000482	0.0296	0.22	0.16	Depression;	chr6:28272137	chr6:28136849~28139678:+
THCA	cis	rs853679	0.882	rs2743555	ENSG00000261839.1	RP1-265C24.8	3.52	0.000482	0.0296	0.22	0.16	Depression;	chr6:28273304	chr6:28136849~28139678:+
THCA	cis	rs853679	1	rs1419183	ENSG00000261839.1	RP1-265C24.8	3.52	0.000482	0.0296	0.22	0.16	Depression;	chr6:28275017	chr6:28136849~28139678:+
THCA	cis	rs853679	1	rs6901575	ENSG00000261839.1	RP1-265C24.8	3.52	0.000482	0.0296	0.22	0.16	Depression;	chr6:28283207	chr6:28136849~28139678:+
THCA	cis	rs7170668	0.862	rs8031902	ENSG00000259134.4	LINC00924	3.52	0.000482	0.0296	0.2	0.16	Motion sickness;	chr15:95488589	chr15:95433095~95507847:+
THCA	cis	rs3126085	0.935	rs4361987	ENSG00000237975.5	FLG-AS1	-3.52	0.000482	0.0296	-0.26	-0.16	Atopic dermatitis;	chr1:152257225	chr1:152168125~152445456:+
THCA	cis	rs2888875	0.894	rs6725776	ENSG00000200924.1	RNU6-1048P	-3.52	0.000482	0.0296	-0.18	-0.16	Glomerular filtration rate (creatinine);	chr2:43556002	chr2:43892690~43892796:+
THCA	cis	rs2888875	0.894	rs1873556	ENSG00000200924.1	RNU6-1048P	-3.52	0.000482	0.0296	-0.18	-0.16	Glomerular filtration rate (creatinine);	chr2:43557064	chr2:43892690~43892796:+
THCA	cis	rs3784262	0.904	rs4646616	ENSG00000259250.1	RP11-50C13.1	3.52	0.000482	0.0296	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57969151	chr15:58587507~58591676:+
THCA	cis	rs12681963	0.688	rs7015750	ENSG00000272375.1	RP11-51J9.6	3.52	0.000482	0.0296	0.24	0.16	Migraine;	chr8:30196499	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs59483213	ENSG00000272375.1	RP11-51J9.6	3.52	0.000482	0.0296	0.24	0.16	Migraine;	chr8:30200085	chr8:30197404~30198048:+
THCA	cis	rs722599	0.683	rs7142898	ENSG00000279594.1	RP11-950C14.10	3.52	0.000482	0.0296	0.16	0.16	IgG glycosylation;	chr14:74787607	chr14:75011269~75012851:-
THCA	cis	rs2904967	0.571	rs1212391	ENSG00000254614.2	AP003068.23	-3.52	0.000482	0.0296	-0.29	-0.16	Mean corpuscular volume;	chr11:65249806	chr11:65177606~65181834:-
THCA	cis	rs7208859	0.673	rs423151	ENSG00000264242.2	RP11-271K11.1	3.52	0.000482	0.0296	0.23	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30553697~30558962:+
THCA	cis	rs1865760	0.566	rs9467663	ENSG00000272810.1	U91328.22	-3.52	0.000482	0.0296	-0.13	-0.16	Height;	chr6:26021228	chr6:26013241~26013757:+
THCA	cis	rs1348850	0.567	rs4893838	ENSG00000271996.1	RP11-337N6.1	3.52	0.000482	0.0296	0.21	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177666708	chr2:177306373~177310572:+
THCA	cis	rs1348850	0.567	rs880897	ENSG00000271996.1	RP11-337N6.1	3.52	0.000482	0.0296	0.21	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177667775	chr2:177306373~177310572:+
THCA	cis	rs1348850	0.567	rs7605493	ENSG00000271996.1	RP11-337N6.1	3.52	0.000482	0.0296	0.21	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177670255	chr2:177306373~177310572:+
THCA	cis	rs9905704	0.918	rs11655808	ENSG00000224738.1	AC099850.1	3.52	0.000482	0.0296	0.22	0.16	Testicular germ cell tumor;	chr17:58777156	chr17:59106598~59118267:+
THCA	cis	rs853679	0.517	rs868987	ENSG00000219891.2	ZSCAN12P1	-3.52	0.000482	0.0296	-0.23	-0.16	Depression;	chr6:28142370	chr6:28091154~28093664:+
THCA	cis	rs1862618	0.853	rs6450408	ENSG00000234553.1	AC022431.3	-3.52	0.000482	0.0296	-0.18	-0.16	Initial pursuit acceleration;	chr5:56802319	chr5:56536583~56537826:-
THCA	cis	rs1612141	0.744	rs11157196	ENSG00000251363.2	RP11-129M6.1	3.52	0.000482	0.0296	0.23	0.16	QT interval (drug interaction);	chr14:41102384	chr14:40954898~40975877:+
THCA	cis	rs2299682	0.826	rs6086917	ENSG00000230506.1	RP11-416N4.4	3.52	0.000482	0.0296	0.26	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9497058	chr20:10173520~10196990:+
THCA	cis	rs2299682	0.826	rs6086919	ENSG00000230506.1	RP11-416N4.4	3.52	0.000482	0.0296	0.26	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9499210	chr20:10173520~10196990:+
THCA	cis	rs7824557	0.592	rs2572371	ENSG00000206014.6	OR7E161P	-3.52	0.000482	0.0296	-0.19	-0.16	Retinal vascular caliber;	chr8:11366284	chr8:11928597~11929563:-
THCA	cis	rs7873102	0.63	rs10973624	ENSG00000213839.4	TMX2P1	-3.52	0.000482	0.0296	-0.12	-0.16	Brain structure;	chr9:37964733	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.654	rs7857446	ENSG00000213839.4	TMX2P1	-3.52	0.000482	0.0296	-0.12	-0.16	Brain structure;	chr9:37965644	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.63	rs4637938	ENSG00000213839.4	TMX2P1	-3.52	0.000482	0.0296	-0.12	-0.16	Brain structure;	chr9:37966134	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.654	rs7862130	ENSG00000213839.4	TMX2P1	-3.52	0.000482	0.0296	-0.12	-0.16	Brain structure;	chr9:37966973	chr9:37885683~37886390:+
THCA	cis	rs7873102	0.654	rs7023815	ENSG00000213839.4	TMX2P1	-3.52	0.000482	0.0296	-0.12	-0.16	Brain structure;	chr9:37967581	chr9:37885683~37886390:+
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000255046.1	RP11-297N6.4	-3.52	0.000482	0.0296	-0.17	-0.16	Neuroticism;	chr8:11989569	chr8:11797928~11802568:-
THCA	cis	rs2040609	0.844	rs9901490	ENSG00000200013.1	RNU6-623P	3.52	0.000482	0.0296	0.19	0.16	Multiple keratinocyte cancers;	chr17:61628494	chr17:60662333~60662437:-
THCA	cis	rs4919087	0.81	rs10736115	ENSG00000237169.1	RP11-452K12.3	-3.52	0.000482	0.0296	-0.2	-0.16	Monocyte count;	chr10:97271928	chr10:97309138~97309958:-
THCA	cis	rs4908760	0.832	rs11121209	ENSG00000270282.1	RP5-1115A15.2	3.52	0.000482	0.0296	0.19	0.16	Vitiligo;	chr1:8626803	chr1:8512653~8513021:+
THCA	cis	rs4908760	0.864	rs6674832	ENSG00000270282.1	RP5-1115A15.2	3.52	0.000482	0.0296	0.19	0.16	Vitiligo;	chr1:8631820	chr1:8512653~8513021:+
THCA	cis	rs4908760	0.864	rs1463052	ENSG00000270282.1	RP5-1115A15.2	3.52	0.000482	0.0296	0.19	0.16	Vitiligo;	chr1:8641172	chr1:8512653~8513021:+
THCA	cis	rs10090774	0.965	rs7461251	ENSG00000280303.2	ERICD	-3.52	0.000482	0.0296	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140711689	chr8:140636281~140638283:+
THCA	cis	rs35123781	0.696	rs13179952	ENSG00000249526.1	CTB-35F21.1	3.52	0.000482	0.0296	0.23	0.16	Schizophrenia;	chr5:139690988	chr5:139684645~139745010:+
THCA	cis	rs35123781	0.696	rs4912755	ENSG00000249526.1	CTB-35F21.1	3.52	0.000482	0.0296	0.23	0.16	Schizophrenia;	chr5:139691066	chr5:139684645~139745010:+
THCA	cis	rs12478296	1	rs60533128	ENSG00000220804.7	AC093642.5	3.52	0.000482	0.0296	0.19	0.16	Obesity-related traits;	chr2:242085937	chr2:242088633~242160153:+
THCA	cis	rs7439493	0.833	rs2237056	ENSG00000247950.5	SEC24B-AS1	-3.52	0.000482	0.0296	-0.1	-0.16	Blood protein levels;	chr4:109702454	chr4:109347475~109433817:-
THCA	cis	rs7127129	0.785	rs10898840	ENSG00000246889.2	AP000487.5	-3.52	0.000482	0.0296	-0.17	-0.16	Aortic root size;	chr11:70193815	chr11:70372246~70398488:-
THCA	cis	rs1023500	0.529	rs133375	ENSG00000270083.1	RP1-257I20.14	3.52	0.000482	0.0296	0.18	0.16	Schizophrenia;	chr22:42070505	chr22:42089630~42090028:-
THCA	cis	rs10256972	0.527	rs28671326	ENSG00000225146.1	AC073957.15	3.52	0.000482	0.0297	0.18	0.16	Endometriosis;Longevity;	chr7:1135337	chr7:1029025~1043891:+
THCA	cis	rs7578982	0.781	rs17041842	ENSG00000227992.1	AC108463.2	3.52	0.000482	0.0297	0.22	0.16	White blood cell types;	chr2:111067882	chr2:111203964~111206215:-
THCA	cis	rs315122	0.588	rs548240	ENSG00000274979.1	RP11-1143G9.5	-3.52	0.000482	0.0297	-0.27	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr12:69362511	chr12:69326574~69331882:-
THCA	cis	rs4908760	0.759	rs6577514	ENSG00000270282.1	RP5-1115A15.2	3.52	0.000482	0.0297	0.19	0.16	Vitiligo;	chr1:8652684	chr1:8512653~8513021:+
THCA	cis	rs7267979	1	rs2257808	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2257809	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2424700	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs910997	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs1077889	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs3002702	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2257982	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2257985	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2257988	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2257432	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2258066	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2258135	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2258201	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2258563	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2258617	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2258769	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2258879	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2257496	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2258884	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2259837	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2259873	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs11100	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs1046073	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2259926	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2259928	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2259956	ENSG00000276952.1	RP5-965G21.6	3.52	0.000482	0.0297	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs2297496	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs7343481	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6115146	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.934	rs6037085	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs6050532	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6083804	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs4815405	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6050542	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25284915~25285588:-
THCA	cis	rs7267979	1	rs6076336	ENSG00000276952.1	RP5-965G21.6	-3.52	0.000482	0.0297	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25284915~25285588:-
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000230189.5	GS1-124K5.2	3.52	0.000482	0.0297	0.11	0.16	Calcium levels;	chr7:65977808	chr7:66409143~66490059:-
THCA	cis	rs1005277	0.579	rs176838	ENSG00000099251.13	HSD17B7P2	-3.51	0.000482	0.0297	-0.14	-0.16	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38356380~38378505:+
THCA	cis	rs9450351	0.744	rs73751283	ENSG00000203875.9	SNHG5	-3.51	0.000482	0.0297	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:86072398	chr6:85660950~85678736:-
THCA	cis	rs913672	0.609	rs8116154	ENSG00000231742.4	LINC01273	3.51	0.000482	0.0297	0.2	0.16	Monocyte count;	chr20:50276198	chr20:50172550~50176671:+
THCA	cis	rs587080	0.624	rs512715	ENSG00000255200.1	AP003068.18	-3.51	0.000482	0.0297	-0.22	-0.16	Plateletcrit;	chr11:65423737	chr11:65174117~65176470:-
THCA	cis	rs9650657	0.812	rs4240669	ENSG00000269918.1	AF131215.9	-3.51	0.000483	0.0297	-0.17	-0.16	Neuroticism;	chr8:10772477	chr8:11104691~11106704:-
THCA	cis	rs4879656	0.966	rs1016674	ENSG00000225693.1	LAGE3P1	3.51	0.000483	0.0297	0.18	0.16	Menopause (age at onset);	chr9:32982689	chr9:33019682~33020165:-
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000281021.1	RP1-12G14.9	3.51	0.000483	0.0297	0.16	0.16	Lung cancer;	chr6:149625336	chr6:149576089~149590864:-
THCA	cis	rs7824557	0.564	rs34964435	ENSG00000261451.1	RP11-981G7.1	-3.51	0.000483	0.0297	-0.2	-0.16	Retinal vascular caliber;	chr8:11372697	chr8:10433672~10438312:+
THCA	cis	rs13182402	1	rs62391531	ENSG00000230929.5	RP11-395C3.1	-3.51	0.000483	0.0297	-0.31	-0.16	Osteoporosis;	chr5:126579034	chr5:126628019~126628319:-
THCA	cis	rs1729951	0.546	rs12054408	ENSG00000239213.4	NCK1-AS1	3.51	0.000483	0.0297	0.14	0.16	Neuroticism;	chr3:136958803	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs35289288	ENSG00000239213.4	NCK1-AS1	3.51	0.000483	0.0297	0.14	0.16	Neuroticism;	chr3:136961726	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs1654904	ENSG00000239213.4	NCK1-AS1	3.51	0.000483	0.0297	0.14	0.16	Neuroticism;	chr3:136962307	chr3:136841726~136862054:-
THCA	cis	rs17181170	0.558	rs1497413	ENSG00000239572.1	RP11-451B8.1	-3.51	0.000483	0.0297	-0.2	-0.16	Prostate cancer;	chr3:87139312	chr3:87731402~87793629:-
THCA	cis	rs1858037	0.867	rs72621551	ENSG00000252414.1	RNU6-100P	-3.51	0.000483	0.0297	-0.18	-0.16	Rheumatoid arthritis;	chr2:65388087	chr2:64578892~64578997:+
THCA	cis	rs6545883	0.525	rs2049747	ENSG00000212978.6	AC016747.3	-3.51	0.000483	0.0297	-0.17	-0.16	Tuberculosis;	chr2:61137019	chr2:61141592~61144969:-
THCA	cis	rs7219021	0.705	rs999475	ENSG00000248278.1	SUMO2P17	-3.51	0.000483	0.0297	-0.21	-0.16	Schizophrenia or bipolar disorder;	chr17:48910682	chr17:48874860~48908983:-
THCA	cis	rs9796	0.87	rs2927061	ENSG00000247556.5	OIP5-AS1	3.51	0.000483	0.0297	0.13	0.16	Menopause (age at onset);	chr15:41010021	chr15:41283990~41309737:+
THCA	cis	rs6885307	0.824	rs61584374	ENSG00000272335.1	RP11-53O19.3	-3.51	0.000483	0.0297	-0.15	-0.16	Age at first birth;	chr5:44963724	chr5:44826076~44828592:+
THCA	cis	rs13256369	0.826	rs7846050	ENSG00000248538.5	RP11-10A14.5	-3.51	0.000483	0.0297	-0.2	-0.16	Obesity-related traits;	chr8:8718159	chr8:9189011~9202854:+
THCA	cis	rs10223402	0.786	rs67365564	ENSG00000233558.1	RP3-486I3.4	3.51	0.000483	0.0297	0.28	0.16	Appendicular lean mass;	chr6:115642309	chr6:116258493~116259115:-
THCA	cis	rs7586879	0.616	rs876186	ENSG00000224165.4	DNAJC27-AS1	-3.51	0.000483	0.0297	-0.09	-0.16	Body mass index;	chr2:24902716	chr2:24971390~25039694:+
THCA	cis	rs7586879	0.575	rs6712981	ENSG00000224165.4	DNAJC27-AS1	-3.51	0.000483	0.0297	-0.09	-0.16	Body mass index;	chr2:24903361	chr2:24971390~25039694:+
THCA	cis	rs9303029	0.611	rs9909476	ENSG00000265458.1	RP13-20L14.6	-3.51	0.000483	0.0297	-0.21	-0.16	Protein quantitative trait loci;	chr17:82481857	chr17:82454273~82458521:-
THCA	cis	rs73206853	0.764	rs61117387	ENSG00000257539.2	HSPA8P14	3.51	0.000483	0.0297	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110429920	chr12:111381867~111385638:+
THCA	cis	rs73206853	0.686	rs73206895	ENSG00000257539.2	HSPA8P14	3.51	0.000483	0.0297	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110442163	chr12:111381867~111385638:+
THCA	cis	rs73206853	0.764	rs76142162	ENSG00000257539.2	HSPA8P14	3.51	0.000483	0.0297	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110446502	chr12:111381867~111385638:+
THCA	cis	rs3784262	0.528	rs4646589	ENSG00000259250.1	RP11-50C13.1	-3.51	0.000483	0.0297	-0.14	-0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58010967	chr15:58587507~58591676:+
THCA	cis	rs10270805	0.667	rs4721503	ENSG00000272537.1	GS1-166A23.1	3.51	0.000483	0.0297	0.29	0.16	Response to statin therapy;	chr7:16454782	chr7:16471184~16471373:+
THCA	cis	rs2836950	0.565	rs3171465	ENSG00000235701.1	PCBP2P1	-3.51	0.000483	0.0297	-0.18	-0.16	Menarche (age at onset);	chr21:39180381	chr21:39171130~39172106:-
THCA	cis	rs763121	0.889	rs1043402	ENSG00000225450.1	RP3-508I15.14	-3.51	0.000483	0.0297	-0.13	-0.16	Menopause (age at onset);	chr22:38483683	chr22:38739003~38749041:+
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000264242.2	RP11-271K11.1	3.51	0.000483	0.0297	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30553697~30558962:+
THCA	cis	rs7131987	0.845	rs7299861	ENSG00000257599.1	OVCH1-AS1	-3.51	0.000483	0.0297	-0.19	-0.16	QT interval;	chr12:29256734	chr12:29389294~29487488:+
THCA	cis	rs7131987	0.934	rs7316004	ENSG00000257599.1	OVCH1-AS1	-3.51	0.000483	0.0297	-0.19	-0.16	QT interval;	chr12:29258765	chr12:29389294~29487488:+
THCA	cis	rs7131987	0.903	rs2216853	ENSG00000257599.1	OVCH1-AS1	-3.51	0.000483	0.0297	-0.19	-0.16	QT interval;	chr12:29260315	chr12:29389294~29487488:+
THCA	cis	rs7131987	0.868	rs10771508	ENSG00000257599.1	OVCH1-AS1	-3.51	0.000483	0.0297	-0.19	-0.16	QT interval;	chr12:29261278	chr12:29389294~29487488:+
THCA	cis	rs2018055	0.692	rs929058	ENSG00000216809.1	RP11-57K17.1	3.51	0.000483	0.0297	0.16	0.16	Diastolic blood pressure;	chr6:117498035	chr6:118452469~118454992:-
THCA	cis	rs73198271	0.74	rs10094270	ENSG00000254340.1	RP11-10A14.3	-3.51	0.000483	0.0297	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:9141424~9145435:+
THCA	cis	rs73198271	0.74	rs28521727	ENSG00000254340.1	RP11-10A14.3	-3.51	0.000483	0.0297	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:9141424~9145435:+
THCA	cis	rs73198271	0.74	rs28402110	ENSG00000254340.1	RP11-10A14.3	-3.51	0.000483	0.0297	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:9141424~9145435:+
THCA	cis	rs73198271	0.74	rs10112989	ENSG00000254340.1	RP11-10A14.3	-3.51	0.000483	0.0297	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:9141424~9145435:+
THCA	cis	rs73198271	0.74	rs10113326	ENSG00000254340.1	RP11-10A14.3	-3.51	0.000483	0.0297	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:9141424~9145435:+
THCA	cis	rs7809950	0.678	rs12670688	ENSG00000272072.1	CTA-363E19.2	-3.51	0.000483	0.0297	-0.18	-0.16	Coronary artery disease;	chr7:107180571	chr7:107192559~107193300:-
THCA	cis	rs1009077	0.904	rs13119468	ENSG00000245958.5	RP11-33B1.1	3.51	0.000483	0.0297	0.2	0.16	Endometriosis;	chr4:119750142	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.951	rs28587671	ENSG00000245958.5	RP11-33B1.1	3.51	0.000483	0.0297	0.2	0.16	Endometriosis;	chr4:119752967	chr4:119454791~119552025:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000219891.2	ZSCAN12P1	3.51	0.000483	0.0297	0.23	0.16	Depression;	chr6:28143758	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000219891.2	ZSCAN12P1	3.51	0.000483	0.0297	0.23	0.16	Depression;	chr6:28144784	chr6:28091154~28093664:+
THCA	cis	rs559555	0.553	rs806645	ENSG00000276517.1	AL133243.2	3.51	0.000483	0.0297	0.15	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31582871	chr2:32526504~32529507:+
THCA	cis	rs9878978	0.722	rs62233832	ENSG00000227588.2	CNTN4-AS2	3.51	0.000483	0.0297	0.21	0.16	Blood pressure (smoking interaction);	chr3:2470415	chr3:2110409~2144241:-
THCA	cis	rs2447820	0.588	rs12055256	ENSG00000263432.2	RN7SL689P	-3.51	0.000483	0.0297	-0.2	-0.16	Migraine;	chr5:123034951	chr5:123022487~123022783:-
THCA	cis	rs7914558	0.933	rs10786729	ENSG00000272912.1	RP11-724N1.1	-3.51	0.000483	0.0297	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102959621	chr10:102914585~102915404:+
THCA	cis	rs16915157	0.557	rs75700446	ENSG00000254271.1	RP11-131N11.4	3.51	0.000483	0.0297	0.33	0.16	Schizophrenia;	chr10:60554780	chr10:60734342~60741828:+
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000273024.4	INTS4P2	3.51	0.000483	0.0297	0.27	0.16	Diabetic kidney disease;	chr7:65951319	chr7:65647864~65715661:+
THCA	cis	rs10497985	0.685	rs6725004	ENSG00000234308.2	AC093381.2	3.51	0.000483	0.0297	0.16	0.16	Cognitive decline (age-related);	chr2:212737324	chr2:212795331~212819264:+
THCA	cis	rs2014572	0.967	rs10427146	ENSG00000276449.1	AC004076.5	3.51	0.000483	0.0297	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57244630	chr19:57449689~57453011:+
THCA	cis	rs10421328	0.821	rs4808976	ENSG00000271283.1	CTC-412M14.6	3.51	0.000483	0.0297	0.22	0.16	Parental longevity (combined parental age at death);	chr19:19648490	chr19:19699203~19699409:-
THCA	cis	rs6847067	0.929	rs12511112	ENSG00000180769.7	WDFY3-AS2	-3.51	0.000483	0.0297	-0.12	-0.16	Oropharynx cancer;	chr4:84754946	chr4:84965682~85011277:+
THCA	cis	rs9911578	1	rs9901114	ENSG00000224738.1	AC099850.1	-3.51	0.000483	0.0297	-0.18	-0.16	Intelligence (multi-trait analysis);	chr17:58497847	chr17:59106598~59118267:+
THCA	cis	rs9903692	0.865	rs7220520	ENSG00000263412.1	RP5-890E16.2	-3.51	0.000483	0.0297	-0.11	-0.16	Pulse pressure;	chr17:48090580	chr17:48045141~48048073:-
THCA	cis	rs2228479	0.85	rs2238532	ENSG00000274627.1	RP11-104N10.2	-3.51	0.000483	0.0297	-0.28	-0.16	Skin colour saturation;	chr16:89797264	chr16:89516797~89522217:+
THCA	cis	rs10895987	1	rs9971407	ENSG00000254614.2	AP003068.23	3.51	0.000484	0.0297	0.26	0.16	Blood protein levels;	chr11:65130754	chr11:65177606~65181834:-
THCA	cis	rs683250	0.598	rs1943748	ENSG00000254551.1	RP11-727A23.7	3.51	0.000484	0.0297	0.19	0.16	Subcortical brain region volumes;	chr11:83410879	chr11:83209431~83213379:-
THCA	cis	rs879324	0.689	rs7193343	ENSG00000280092.1	AC002044.3	3.51	0.000484	0.0297	0.24	0.16	Stroke (ischemic);	chr16:72995261	chr16:73005601~73006141:-
THCA	cis	rs73173548	0.502	rs12187348	ENSG00000247828.6	TMEM161B-AS1	3.51	0.000484	0.0297	0.14	0.16	Macular telangiectasia type 2;	chr5:88424724	chr5:88268895~88436685:+
THCA	cis	rs4888378	0.576	rs8050367	ENSG00000280152.1	RP11-331F4.5	3.51	0.000484	0.0297	0.18	0.16	Coronary artery disease;	chr16:75279360	chr16:75245994~75250077:-
THCA	cis	rs9875589	0.957	rs1108341	ENSG00000233121.1	VN1R20P	3.51	0.000484	0.0297	0.18	0.16	Ovarian reserve;	chr3:13895831	chr3:13926813~13927778:+
THCA	cis	rs9875589	0.957	rs35485647	ENSG00000233121.1	VN1R20P	3.51	0.000484	0.0297	0.18	0.16	Ovarian reserve;	chr3:13896440	chr3:13926813~13927778:+
THCA	cis	rs67478160	0.619	rs12437066	ENSG00000258534.1	CTD-2134A5.4	-3.51	0.000484	0.0297	-0.16	-0.16	Schizophrenia;	chr14:103770507	chr14:103854366~103880111:-
THCA	cis	rs7737355	1	rs6596010	ENSG00000237714.1	P4HA2-AS1	3.51	0.000484	0.0297	0.23	0.16	Life satisfaction;	chr5:131289718	chr5:132184876~132192808:+
THCA	cis	rs78487399	0.808	rs72865297	ENSG00000234936.1	AC010883.5	3.51	0.000484	0.0297	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43516109	chr2:43229573~43233394:+
THCA	cis	rs1125355	0.929	rs11685379	ENSG00000243792.1	OR7E89P	-3.51	0.000484	0.0297	-0.25	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158826845	chr2:158853755~158854576:+
THCA	cis	rs916888	0.738	rs199515	ENSG00000260075.1	NSFP1	3.51	0.000484	0.0297	0.25	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46372855~46487141:+
THCA	cis	rs1580019	0.922	rs1376289	ENSG00000273014.1	RP11-225B17.2	-3.51	0.000484	0.0297	-0.17	-0.16	Cognitive ability;	chr7:32447368	chr7:32758882~32759353:+
THCA	cis	rs12142240	0.77	rs112869704	ENSG00000232022.5	FAAHP1	-3.51	0.000484	0.0297	-0.18	-0.16	Menopause (age at onset);	chr1:46314613	chr1:46432129~46445521:+
THCA	cis	rs721917	0.506	rs2819097	ENSG00000272489.1	RP11-182L21.5	-3.51	0.000484	0.0297	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79663192~79664786:+
THCA	cis	rs9527	0.59	rs1475642	ENSG00000236937.2	PTGES3P4	-3.51	0.000484	0.0297	-0.22	-0.16	Arsenic metabolism;	chr10:102786426	chr10:102845595~102845950:+
THCA	cis	rs6121246	0.697	rs6120970	ENSG00000224628.2	RP5-854E16.2	-3.51	0.000484	0.0297	-0.23	-0.16	Mean corpuscular hemoglobin;	chr20:31644649	chr20:31285317~31286835:-
THCA	cis	rs6121246	0.697	rs7269866	ENSG00000224628.2	RP5-854E16.2	-3.51	0.000484	0.0297	-0.23	-0.16	Mean corpuscular hemoglobin;	chr20:31644701	chr20:31285317~31286835:-
THCA	cis	rs72928364	1	rs62277105	ENSG00000256628.3	ZBTB11-AS1	3.51	0.000484	0.0297	0.29	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100882245	chr3:101676475~101679217:+
THCA	cis	rs7824557	0.564	rs1435275	ENSG00000227888.4	FAM66A	-3.51	0.000484	0.0297	-0.2	-0.16	Retinal vascular caliber;	chr8:11378226	chr8:12362019~12388296:+
THCA	cis	rs1864585	0.52	rs17721089	ENSG00000280294.1	RP11-177H2.1	3.51	0.000484	0.0297	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10847928	chr8:10856085~10859436:-
THCA	cis	rs2386661	0.547	rs4747358	ENSG00000231483.1	RP11-336A10.5	-3.51	0.000484	0.0297	-0.17	-0.16	Breast cancer;	chr10:5608230	chr10:5608475~5610793:-
THCA	cis	rs7264396	1	rs224433	ENSG00000088340.14	FER1L4	3.51	0.000484	0.0297	0.16	0.16	Total cholesterol levels;	chr20:35565933	chr20:35558737~35607562:-
THCA	cis	rs17181170	0.934	rs7642887	ENSG00000239572.1	RP11-451B8.1	-3.51	0.000484	0.0297	-0.18	-0.16	Prostate cancer;	chr3:87123482	chr3:87731402~87793629:-
THCA	cis	rs8040855	0.658	rs11634877	ENSG00000225151.9	GOLGA2P7	-3.51	0.000484	0.0297	-0.23	-0.16	Bulimia nervosa;	chr15:85068246	chr15:84199311~84230136:-
THCA	cis	rs3218092	0.688	rs68017625	ENSG00000213435.3	ATP6V0CP3	3.51	0.000484	0.0297	0.27	0.16	Red cell distribution width;	chr6:41848396	chr6:42727234~42727700:+
THCA	cis	rs14027	0.883	rs13255850	ENSG00000245330.4	KB-1471A8.1	3.51	0.000484	0.0297	0.16	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119705923	chr8:119867419~119874488:-
THCA	cis	rs1612141	0.744	rs8004394	ENSG00000251363.2	RP11-129M6.1	3.51	0.000484	0.0297	0.23	0.16	QT interval (drug interaction);	chr14:41103585	chr14:40954898~40975877:+
THCA	cis	rs78487399	0.908	rs12471686	ENSG00000234936.1	AC010883.5	3.51	0.000484	0.0297	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43603944	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs12467420	ENSG00000234936.1	AC010883.5	3.51	0.000484	0.0297	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43604011	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs72868625	ENSG00000234936.1	AC010883.5	3.51	0.000484	0.0297	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43604047	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.908	rs12475503	ENSG00000234936.1	AC010883.5	3.51	0.000484	0.0297	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43604180	chr2:43229573~43233394:+
THCA	cis	rs6694672	0.867	rs1764800	ENSG00000237861.1	RP11-332L8.1	3.51	0.000484	0.0297	0.35	0.16	Asthma;	chr1:197281485	chr1:197222222~197223255:+
THCA	cis	rs6694672	0.681	rs476390	ENSG00000237861.1	RP11-332L8.1	3.51	0.000484	0.0297	0.35	0.16	Asthma;	chr1:197284137	chr1:197222222~197223255:+
THCA	cis	rs1059312	0.966	rs35907548	ENSG00000279500.1	RP11-21K12.2	-3.51	0.000484	0.0297	-0.11	-0.16	Systemic lupus erythematosus;	chr12:128797635	chr12:128813186~128814750:-
THCA	cis	rs1059312	0.932	rs4760589	ENSG00000279500.1	RP11-21K12.2	-3.51	0.000484	0.0297	-0.11	-0.16	Systemic lupus erythematosus;	chr12:128799837	chr12:128813186~128814750:-
THCA	cis	rs3935996	0.965	rs4589149	ENSG00000233147.1	RP11-90C4.1	-3.51	0.000484	0.0298	-0.14	-0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55850288	chr1:55823807~55868248:+
THCA	cis	rs1737890	0.778	rs2424873	ENSG00000235217.6	TSPY26P	-3.51	0.000484	0.0298	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr20:32351702	chr20:32186477~32190527:-
THCA	cis	rs6870983	0.749	rs358295	ENSG00000247828.6	TMEM161B-AS1	3.51	0.000484	0.0298	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88197940	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs358287	ENSG00000247828.6	TMEM161B-AS1	3.51	0.000484	0.0298	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88199520	chr5:88268895~88436685:+
THCA	cis	rs910316	1	rs11623413	ENSG00000259138.1	RP11-950C14.7	-3.51	0.000484	0.0298	-0.14	-0.16	Height;	chr14:75122121	chr14:75127153~75136930:+
THCA	cis	rs77580281	1	rs5746775	ENSG00000185065.6	AC000068.5	-3.51	0.000484	0.0298	-0.18	-0.16	Pediatric bone mineral density (hip);	chr22:19562820	chr22:19447893~19450105:+
THCA	cis	rs1941184	0.526	rs8092800	ENSG00000263823.1	RP11-326K13.4	-3.51	0.000484	0.0298	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31453965	chr18:31942575~31944156:+
THCA	cis	rs6580649	0.843	rs3803184	ENSG00000273765.1	RP11-370I10.11	3.51	0.000484	0.0298	0.18	0.16	Lung cancer;	chr12:48004219	chr12:48360920~48361377:+
THCA	cis	rs2635047	0.967	rs2576056	ENSG00000280212.1	RP11-49K24.3	-3.51	0.000484	0.0298	-0.15	-0.16	Educational attainment;	chr18:47149091	chr18:47076117~47076594:+
THCA	cis	rs11673344	0.526	rs8101610	ENSG00000229481.2	CTD-2554C21.3	3.51	0.000484	0.0298	0.15	0.16	Obesity-related traits;	chr19:37566604	chr19:37829551~37832160:+
THCA	cis	rs7631605	0.608	rs62239460	ENSG00000224080.1	UBE2FP1	3.51	0.000484	0.0298	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37401419	chr3:37143512~37143958:-
THCA	cis	rs2039553	0.507	rs12873306	ENSG00000227354.5	RBM26-AS1	-3.51	0.000484	0.0298	-0.15	-0.16	Pancreatic cancer;	chr13:79816073	chr13:79406309~79424328:+
THCA	cis	rs11190604	1	rs1417823	ENSG00000273030.1	RP11-285F16.1	-3.51	0.000484	0.0298	-0.18	-0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100468129	chr10:100412934~100413421:+
THCA	cis	rs10089	0.953	rs1036171	ENSG00000245937.6	LINC01184	3.51	0.000484	0.0298	0.18	0.16	Ileal carcinoids;	chr5:128067106	chr5:127940426~128083172:-
THCA	cis	rs3853824	0.636	rs9897759	ENSG00000263089.1	RP11-166P13.4	3.51	0.000484	0.0298	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56863555	chr17:57092145~57096425:-
THCA	cis	rs10090774	0.965	rs11167016	ENSG00000280303.2	ERICD	-3.51	0.000484	0.0298	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140985081	chr8:140636281~140638283:+
THCA	cis	rs9650657	0.535	rs7011756	ENSG00000254839.1	AF131215.6	3.51	0.000484	0.0298	0.17	0.16	Neuroticism;	chr8:11162068	chr8:11062647~11067089:-
THCA	cis	rs73191547	0.641	rs17151318	ENSG00000255310.2	AF131215.2	3.51	0.000484	0.0298	0.13	0.16	Schizophrenia;	chr8:10203173	chr8:11107788~11109726:-
THCA	cis	rs990871	0.574	rs7549534	ENSG00000227207.2	RPL31P12	-3.51	0.000484	0.0298	-0.2	-0.16	Subcutaneous adipose tissue;	chr1:72420286	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs6673910	ENSG00000227207.2	RPL31P12	-3.51	0.000484	0.0298	-0.2	-0.16	Subcutaneous adipose tissue;	chr1:72420876	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs10889951	ENSG00000227207.2	RPL31P12	-3.51	0.000484	0.0298	-0.2	-0.16	Subcutaneous adipose tissue;	chr1:72422203	chr1:72301472~72301829:+
THCA	cis	rs17275866	0.632	rs7672775	ENSG00000237125.7	HAND2-AS1	-3.51	0.000484	0.0298	-0.24	-0.16	Chin dimples;	chr4:174164559	chr4:173527270~173591324:+
THCA	cis	rs2055729	0.634	rs6601390	ENSG00000261451.1	RP11-981G7.1	3.51	0.000484	0.0298	0.22	0.16	Multiple myeloma (hyperdiploidy);	chr8:9883147	chr8:10433672~10438312:+
THCA	cis	rs2055729	0.677	rs6601393	ENSG00000261451.1	RP11-981G7.1	-3.51	0.000484	0.0298	-0.22	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9883525	chr8:10433672~10438312:+
THCA	cis	rs2055729	0.677	rs6990268	ENSG00000261451.1	RP11-981G7.1	-3.51	0.000484	0.0298	-0.22	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9883661	chr8:10433672~10438312:+
THCA	cis	rs12022452	1	rs2184877	ENSG00000237899.1	RP4-739H11.3	-3.51	0.000484	0.0298	-0.25	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40669089~40687588:-
THCA	cis	rs73787773	0.644	rs73227498	ENSG00000246859.2	STARD4-AS1	3.51	0.000484	0.0298	0.22	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr5:112150207	chr5:111512226~111739726:+
THCA	cis	rs467650	0.509	rs27391	ENSG00000248489.1	CTD-2007H13.3	3.51	0.000485	0.0298	0.15	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98644719	chr5:98929171~98995013:+
THCA	cis	rs1005277	0.579	rs2505248	ENSG00000151963.4	RP11-775A3.1	-3.51	0.000485	0.0298	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:37883594~37884109:+
THCA	cis	rs7246967	0.673	rs12978964	ENSG00000198153.8	ZNF849P	-3.51	0.000485	0.0298	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22636442	chr19:22685167~22686732:+
THCA	cis	rs7119	0.635	rs2667767	ENSG00000259362.2	RP11-307C19.1	3.51	0.000485	0.0298	0.21	0.16	Type 2 diabetes;	chr15:77583689	chr15:77525540~77534110:+
THCA	cis	rs8019546	1	rs8019546	ENSG00000259113.1	RP11-406H23.2	3.51	0.000485	0.0298	0.19	0.16	Dietary macronutrient intake;	chr14:50857024	chr14:50448807~50456742:+
THCA	cis	rs10832963	1	rs7943121	ENSG00000256361.1	RP11-613F22.6	3.51	0.000485	0.0298	0.2	0.16	Breast cancer;	chr11:18634515	chr11:18511043~18511475:-
THCA	cis	rs10832963	1	rs10832962	ENSG00000256361.1	RP11-613F22.6	3.51	0.000485	0.0298	0.2	0.16	Breast cancer;	chr11:18634724	chr11:18511043~18511475:-
THCA	cis	rs354225	0.544	rs12713264	ENSG00000212175.1	SNORA12	3.51	0.000485	0.0298	0.2	0.16	Schizophrenia;	chr2:54578081	chr2:55565703~55565850:+
THCA	cis	rs7536700	0.643	rs59770064	ENSG00000272030.1	RP1-178F15.4	-3.51	0.000485	0.0298	-0.28	-0.16	Multiple myeloma (IgH translocation);	chr1:153672987	chr1:153631438~153634397:-
THCA	cis	rs7824557	0.564	rs2043508	ENSG00000261451.1	RP11-981G7.1	-3.51	0.000485	0.0298	-0.2	-0.16	Retinal vascular caliber;	chr8:11369897	chr8:10433672~10438312:+
THCA	cis	rs2455799	0.519	rs2062821	ENSG00000270409.1	RP11-44D5.1	-3.51	0.000485	0.0298	-0.17	-0.16	Mean platelet volume;	chr3:15656137	chr3:15732252~15733470:+
THCA	cis	rs889014	0.933	rs9313638	ENSG00000253959.1	CTB-43E15.1	-3.51	0.000485	0.0298	-0.21	-0.16	Height;	chr5:173573333	chr5:173642519~173658194:+
THCA	cis	rs4713118	0.955	rs9468203	ENSG00000219891.2	ZSCAN12P1	3.51	0.000485	0.0298	0.21	0.16	Parkinson's disease;	chr6:27720888	chr6:28091154~28093664:+
THCA	cis	rs12682352	0.535	rs12677550	ENSG00000254153.1	CTA-398F10.2	3.51	0.000485	0.0298	0.17	0.16	Neuroticism;	chr8:8786812	chr8:8456909~8461337:-
THCA	cis	rs7192750	0.586	rs1981874	ENSG00000260886.1	TAT-AS1	-3.51	0.000485	0.0298	-0.23	-0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71863341	chr16:71565789~71578187:+
THCA	cis	rs4268898	0.932	rs7577964	ENSG00000242628.4	AC009228.1	-3.51	0.000485	0.0298	-0.2	-0.16	Asthma;	chr2:24375410	chr2:24214381~24221516:+
THCA	cis	rs2832191	0.632	rs1984011	ENSG00000176054.6	RPL23P2	-3.51	0.000485	0.0298	-0.14	-0.16	Dental caries;	chr21:28965509	chr21:28997613~28998033:-
THCA	cis	rs7264396	0.573	rs55969606	ENSG00000261582.1	RP4-614O4.11	-3.51	0.000485	0.0298	-0.17	-0.16	Total cholesterol levels;	chr20:35487862	chr20:35267885~35280043:-
THCA	cis	rs12621844	0.67	rs11125165	ENSG00000272663.1	RP11-191L17.1	-3.51	0.000485	0.0298	-0.16	-0.16	Glycated hemoglobin levels;	chr2:48172525	chr2:48440043~48440597:-
THCA	cis	rs9307551	0.584	rs1115518	ENSG00000249646.2	OR7E94P	-3.51	0.000485	0.0298	-0.21	-0.16	Refractive error;	chr4:79491423	chr4:79587302~79588130:-
THCA	cis	rs57709857	0.957	rs55703821	ENSG00000272092.1	RP11-350N15.5	-3.51	0.000485	0.0298	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38296053	chr8:38382364~38383461:+
THCA	cis	rs17023223	0.537	rs12087987	ENSG00000227056.2	RPL6P2	-3.51	0.000485	0.0298	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119219314~119220096:-
THCA	cis	rs11190604	1	rs17113137	ENSG00000273030.1	RP11-285F16.1	3.51	0.000485	0.0298	0.19	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100482241	chr10:100412934~100413421:+
THCA	cis	rs11633886	0.604	rs34965865	ENSG00000259200.1	RP11-718O11.1	-3.51	0.000485	0.0298	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45828976	chr15:45705078~45931069:+
THCA	cis	rs11176749	0.614	rs73126362	ENSG00000203585.3	RP11-542B15.1	3.51	0.000485	0.0298	0.23	0.16	Expressive vocabulary in infants;	chr12:67465562	chr12:67519829~67567126:+
THCA	cis	rs7539542	0.529	rs16850750	ENSG00000234996.3	RP11-480I12.7	3.51	0.000485	0.0298	0.22	0.16	Mean platelet volume;	chr1:202911677	chr1:202861754~202875241:+
THCA	cis	rs72843506	0.586	rs113833946	ENSG00000231258.2	ZSWIM5P2	3.51	0.000485	0.0298	0.25	0.16	Schizophrenia;	chr17:19955593	chr17:20583758~20591180:-
THCA	cis	rs7219021	0.705	rs11079842	ENSG00000248278.1	SUMO2P17	-3.51	0.000485	0.0298	-0.21	-0.16	Schizophrenia or bipolar disorder;	chr17:48925400	chr17:48874860~48908983:-
THCA	cis	rs7975161	0.572	rs7299669	ENSG00000214198.6	RP11-642P15.1	3.51	0.000486	0.0298	0.26	0.16	Toenail selenium levels;	chr12:104175141	chr12:103843749~103930211:-
THCA	cis	rs7975161	0.572	rs11111919	ENSG00000214198.6	RP11-642P15.1	3.51	0.000486	0.0298	0.26	0.16	Toenail selenium levels;	chr12:104176140	chr12:103843749~103930211:-
THCA	cis	rs6500602	0.647	rs3747600	ENSG00000280063.1	RP11-295D4.3	3.51	0.000486	0.0298	0.09	0.16	Schizophrenia;	chr16:4536221	chr16:4346694~4348648:-
THCA	cis	rs2014572	0.933	rs8107516	ENSG00000276449.1	AC004076.5	3.51	0.000486	0.0298	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57247077	chr19:57449689~57453011:+
THCA	cis	rs11118346	0.64	rs4373767	ENSG00000228536.1	RP11-392O17.1	3.51	0.000486	0.0298	0.19	0.16	Height;	chr1:219586340	chr1:219409681~219411941:-
THCA	cis	rs721917	0.525	rs2246111	ENSG00000272489.1	RP11-182L21.5	-3.51	0.000486	0.0298	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79663192~79664786:+
THCA	cis	rs2442825	0.693	rs2255558	ENSG00000254485.4	RP11-380O24.1	-3.51	0.000486	0.0298	-0.15	-0.16	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9292588~9363303:-
THCA	cis	rs2442825	0.72	rs2648561	ENSG00000254485.4	RP11-380O24.1	-3.51	0.000486	0.0298	-0.15	-0.16	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9292588~9363303:-
THCA	cis	rs4713118	0.614	rs9380007	ENSG00000280107.1	AL022393.9	-3.51	0.000486	0.0298	-0.16	-0.16	Parkinson's disease;	chr6:27692729	chr6:28170845~28172521:+
THCA	cis	rs4664304	1	rs4664304	ENSG00000226266.5	AC009961.3	3.51	0.000486	0.0298	0.2	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159937497	chr2:159670708~159712435:-
THCA	cis	rs34783982	0.919	rs12438809	ENSG00000259699.2	HMGB1P8	-3.51	0.000486	0.0298	-0.22	-0.16	Squamous cell lung carcinoma;	chr15:88964073	chr15:89135547~89136495:-
THCA	cis	rs6545883	1	rs6742276	ENSG00000212978.6	AC016747.3	3.51	0.000486	0.0298	0.17	0.16	Tuberculosis;	chr2:61541610	chr2:61141592~61144969:-
THCA	cis	rs9987353	0.544	rs2929469	ENSG00000253981.4	ALG1L13P	3.51	0.000486	0.0298	0.16	0.16	Recombination measurement;	chr8:9205146	chr8:8236003~8244667:-
THCA	cis	rs4073582	0.595	rs801737	ENSG00000245156.1	RP11-867G23.3	3.51	0.000486	0.0298	0.13	0.16	Gout;	chr11:66160722	chr11:66269832~66278525:-
THCA	cis	rs7176527	0.784	rs62021162	ENSG00000259728.4	LINC00933	3.51	0.000486	0.0298	0.24	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84570649~84580175:+
THCA	cis	rs1729951	0.575	rs2163896	ENSG00000239213.4	NCK1-AS1	3.51	0.000486	0.0298	0.14	0.16	Neuroticism;	chr3:136972335	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs1682357	ENSG00000239213.4	NCK1-AS1	3.51	0.000486	0.0298	0.14	0.16	Neuroticism;	chr3:136973167	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs1654923	ENSG00000239213.4	NCK1-AS1	3.51	0.000486	0.0298	0.14	0.16	Neuroticism;	chr3:136973778	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs10935214	ENSG00000239213.4	NCK1-AS1	3.51	0.000486	0.0298	0.14	0.16	Neuroticism;	chr3:136974643	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.545	rs1097288	ENSG00000239213.4	NCK1-AS1	3.51	0.000486	0.0298	0.14	0.16	Neuroticism;	chr3:136974879	chr3:136841726~136862054:-
THCA	cis	rs929354	0.772	rs2023975	ENSG00000224629.1	RP5-1142J19.2	-3.51	0.000486	0.0299	-0.16	-0.16	Body mass index;	chr7:157219402	chr7:157263022~157263229:-
THCA	cis	rs4713118	0.869	rs7773070	ENSG00000216915.2	RP1-97D16.1	-3.51	0.000486	0.0299	-0.24	-0.16	Parkinson's disease;	chr6:27761048	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.869	rs7776351	ENSG00000216915.2	RP1-97D16.1	3.51	0.000486	0.0299	0.24	0.16	Parkinson's disease;	chr6:27758952	chr6:27737000~27738494:-
THCA	cis	rs6600671	0.719	rs9728991	ENSG00000226067.5	CH17-118O6.2	3.51	0.000486	0.0299	0.17	0.16	Hip geometry;	chr1:121522281	chr1:120913275~121009291:+
THCA	cis	rs1832871	0.672	rs6899322	ENSG00000213078.3	RP5-933K21.2	-3.51	0.000486	0.0299	-0.24	-0.16	Height;	chr6:158332637	chr6:157365990~157366923:-
THCA	cis	rs2228479	0.557	rs2293584	ENSG00000274627.1	RP11-104N10.2	-3.51	0.000486	0.0299	-0.28	-0.16	Skin colour saturation;	chr16:89822278	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.557	rs11641726	ENSG00000274627.1	RP11-104N10.2	-3.51	0.000486	0.0299	-0.28	-0.16	Skin colour saturation;	chr16:89825211	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs12599561	ENSG00000274627.1	RP11-104N10.2	-3.51	0.000486	0.0299	-0.28	-0.16	Skin colour saturation;	chr16:89827950	chr16:89516797~89522217:+
THCA	cis	rs4907240	0.961	rs10460601	ENSG00000230606.9	AC159540.1	3.51	0.000486	0.0299	0.18	0.16	Event-related brain oscillations;	chr2:96586707	chr2:97416165~97433527:-
THCA	cis	rs944289	0.646	rs8007617	ENSG00000257520.1	RP11-896J10.3	3.51	0.000486	0.0299	0.16	0.16	Thyroid cancer;	chr14:36088883	chr14:36473207~36519521:-
THCA	cis	rs7216064	0.589	rs7213585	ENSG00000278730.1	RP11-147L13.11	-3.51	0.000486	0.0299	-0.18	-0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68066200	chr17:68126666~68129586:+
THCA	cis	rs301901	0.581	rs292170	ENSG00000250155.1	CTD-2353F22.1	-3.51	0.000486	0.0299	-0.17	-0.16	Height;	chr5:36816559	chr5:36666214~36725195:-
THCA	cis	rs6546550	0.901	rs3732266	ENSG00000179818.12	PCBP1-AS1	-3.51	0.000486	0.0299	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69830316	chr2:69962263~70103220:-
THCA	cis	rs10435719	0.58	rs13260712	ENSG00000227888.4	FAM66A	-3.51	0.000486	0.0299	-0.2	-0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:12362019~12388296:+
THCA	cis	rs11992162	0.551	rs13268217	ENSG00000227888.4	FAM66A	-3.51	0.000486	0.0299	-0.2	-0.16	Monocyte count;	chr8:11925100	chr8:12362019~12388296:+
THCA	cis	rs11992162	0.573	rs13264994	ENSG00000227888.4	FAM66A	-3.51	0.000486	0.0299	-0.2	-0.16	Monocyte count;	chr8:11925250	chr8:12362019~12388296:+
THCA	cis	rs11992162	0.573	rs13275808	ENSG00000227888.4	FAM66A	-3.51	0.000486	0.0299	-0.2	-0.16	Monocyte count;	chr8:11925306	chr8:12362019~12388296:+
THCA	cis	rs4742903	0.935	rs6479225	ENSG00000270332.1	SMC2-AS1	3.51	0.000486	0.0299	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104178049	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.904	rs12380062	ENSG00000270332.1	SMC2-AS1	3.51	0.000486	0.0299	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104179622	chr9:104080024~104093073:-
THCA	cis	rs9863	0.861	rs4765305	ENSG00000269938.1	RP11-214K3.20	-3.51	0.000486	0.0299	-0.18	-0.16	White blood cell count;	chr12:123946065	chr12:123968023~123968579:-
THCA	cis	rs7403037	0.583	rs35463340	ENSG00000260760.1	PWRN3	3.51	0.000486	0.0299	0.22	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24581313	chr15:24441127~24447967:+
THCA	cis	rs3087591	0.683	rs757375	ENSG00000263535.1	AK4P1	3.51	0.000486	0.0299	0.19	0.16	Hip circumference;	chr17:31390861	chr17:31345521~31346187:+
THCA	cis	rs7520050	0.933	rs4504835	ENSG00000281133.1	AL355480.3	3.51	0.000486	0.0299	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45580892~45580996:-
THCA	cis	rs9309473	0.606	rs62149804	ENSG00000273245.1	RP11-434P11.2	3.51	0.000486	0.0299	0.26	0.16	Metabolite levels;	chr2:73609879	chr2:73750256~73750786:-
THCA	cis	rs7131987	0.622	rs7294598	ENSG00000273680.1	RP11-996F15.6	-3.51	0.000487	0.0299	-0.23	-0.16	QT interval;	chr12:29379056	chr12:29332733~29333383:-
THCA	cis	rs854765	0.583	rs5002487	ENSG00000265511.1	RP11-524F11.1	3.51	0.000487	0.0299	0.13	0.16	Total body bone mineral density;	chr17:17929146	chr17:17507351~17508308:+
THCA	cis	rs1556032	0.542	rs10810147	ENSG00000225472.1	RP11-120J1.1	-3.51	0.000487	0.0299	-0.15	-0.16	AIDS;	chr9:14442047	chr9:14317085~14357908:+
THCA	cis	rs8112211	0.731	rs4386247	ENSG00000267291.1	CTB-186G2.1	3.51	0.000487	0.0299	0.18	0.16	Blood protein levels;	chr19:38330834	chr19:38596346~38601694:+
THCA	cis	rs9980	0.576	rs889400	ENSG00000226232.7	RP11-419C5.2	3.51	0.000487	0.0299	0.17	0.16	Blood osmolality (transformed sodium);	chr16:69521973	chr16:69976388~69996188:-
THCA	cis	rs11601239	0.607	rs1002191	ENSG00000254750.1	CASP1P2	-3.51	0.000487	0.0299	-0.12	-0.16	Refractive error;	chr11:105821326	chr11:105063345~105071541:-
THCA	cis	rs427691	0.545	rs25914	ENSG00000249476.1	CTD-2587M2.1	3.51	0.000487	0.0299	0.18	0.16	Autism spectrum disorder or schizophrenia;	chr5:109657320	chr5:109237120~109326369:-
THCA	cis	rs763121	1	rs138464	ENSG00000228274.3	RP3-508I15.9	3.51	0.000487	0.0299	0.17	0.16	Menopause (age at onset);	chr22:38510427	chr22:38667585~38681820:-
THCA	cis	rs6546550	0.933	rs6546554	ENSG00000179818.12	PCBP1-AS1	-3.51	0.000487	0.0299	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69908574	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs1979214	ENSG00000179818.12	PCBP1-AS1	-3.51	0.000487	0.0299	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69910366	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs6739780	ENSG00000179818.12	PCBP1-AS1	-3.51	0.000487	0.0299	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69910979	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.9	rs897122	ENSG00000179818.12	PCBP1-AS1	-3.51	0.000487	0.0299	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69913139	chr2:69962263~70103220:-
THCA	cis	rs9980	0.895	rs56125990	ENSG00000226232.7	RP11-419C5.2	-3.51	0.000487	0.0299	-0.25	-0.16	Blood osmolality (transformed sodium);	chr16:69708484	chr16:69976388~69996188:-
THCA	cis	rs9876781	1	rs13071337	ENSG00000199476.1	Y_RNA	-3.51	0.000487	0.0299	-0.2	-0.16	Longevity;	chr3:48396724	chr3:48288587~48288694:+
THCA	cis	rs6546886	0.536	rs828868	ENSG00000217702.2	RP11-287D1.4	3.51	0.000487	0.0299	0.2	0.16	Dialysis-related mortality;	chr2:74097377	chr2:74130583~74135395:+
THCA	cis	rs2766547	0.647	rs2766541	ENSG00000228559.1	RP3-340B19.3	3.51	0.000487	0.0299	0.18	0.16	Eosinophil percentage of granulocytes;	chr6:35739554	chr6:35544632~35545669:+
THCA	cis	rs786425	0.866	rs7302449	ENSG00000278112.1	RP11-972P1.11	3.51	0.000487	0.0299	0.15	0.16	Pubertal anthropometrics;	chr12:123688199	chr12:123519390~123519856:-
THCA	cis	rs2235649	0.798	rs9932983	ENSG00000260541.1	LA16c-429E7.1	3.51	0.000487	0.0299	0.21	0.16	Blood metabolite levels;	chr16:1798183	chr16:1841020~1843547:-
THCA	cis	rs10875746	0.551	rs1471998	ENSG00000258273.1	RP11-370I10.4	3.51	0.000487	0.0299	0.23	0.16	Longevity (90 years and older);	chr12:48318219	chr12:48333755~48333901:-
THCA	cis	rs16975963	0.793	rs73034929	ENSG00000276846.1	CTD-3220F14.3	-3.51	0.000487	0.0299	-0.15	-0.16	Longevity;	chr19:37966057	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.744	rs11672724	ENSG00000276846.1	CTD-3220F14.3	-3.51	0.000487	0.0299	-0.15	-0.16	Longevity;	chr19:37966848	chr19:37314868~37315620:-
THCA	cis	rs2797160	0.904	rs1418637	ENSG00000226409.1	RP11-735G4.1	-3.51	0.000487	0.0299	-0.19	-0.16	Endometrial cancer;	chr6:125671407	chr6:125370211~125374324:-
THCA	cis	rs2018683	0.707	rs7799357	ENSG00000233517.1	AC005162.5	-3.51	0.000487	0.0299	-0.2	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930501	chr7:28987028~28988899:+
THCA	cis	rs12544026	0.581	rs520880	ENSG00000253669.3	KB-1732A1.1	3.51	0.000487	0.0299	0.18	0.16	Major depression and alcohol dependence;	chr8:101848599	chr8:102805517~102809971:+
THCA	cis	rs913655	1	rs2451514	ENSG00000240291.1	RP11-499P20.2	-3.51	0.000487	0.0299	-0.12	-0.16	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18797280	chr10:18513115~18545651:-
THCA	cis	rs494526	0.871	rs609163	ENSG00000229272.1	RP11-498J9.2	3.51	0.000487	0.0299	0.19	0.16	Alcoholic chronic pancreatitis;	chr10:119025813	chr10:119003536~119003884:-
THCA	cis	rs494526	0.841	rs608660	ENSG00000229272.1	RP11-498J9.2	3.51	0.000487	0.0299	0.19	0.16	Alcoholic chronic pancreatitis;	chr10:119025951	chr10:119003536~119003884:-
THCA	cis	rs9341808	0.754	rs1324121	ENSG00000260645.1	RP11-250B2.5	3.51	0.000487	0.0299	0.14	0.16	Sitting height ratio;	chr6:80236360	chr6:80466958~80469080:+
THCA	cis	rs9911578	1	rs7342903	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58837227	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs7223955	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58839692	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs6503883	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58840182	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs12940681	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58856261	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs4076229	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58859895	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs11079365	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58868069	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs9902994	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58871361	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs9907499	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58871683	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs12944948	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58874113	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs9911578	ENSG00000224738.1	AC099850.1	3.51	0.000487	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58875786	chr17:59106598~59118267:+
THCA	cis	rs10838798	0.523	rs11039593	ENSG00000200090.1	Y_RNA	-3.51	0.000487	0.0299	-0.1	-0.16	Height;	chr11:48218560	chr11:47726894~47726992:-
THCA	cis	rs6840360	0.593	rs2089811	ENSG00000251603.1	RP11-164P12.4	-3.51	0.000487	0.0299	-0.11	-0.16	Intelligence (multi-trait analysis);	chr4:151764019	chr4:151667224~151670502:+
THCA	cis	rs1667255	1	rs1791229	ENSG00000266521.1	RP11-650P15.1	3.51	0.000487	0.0299	0.21	0.16	Retinol levels;	chr18:31602389	chr18:31496645~31497195:-
THCA	cis	rs7824557	0.651	rs6601582	ENSG00000255052.4	FAM66D	-3.51	0.000487	0.0299	-0.21	-0.16	Retinal vascular caliber;	chr8:11349858	chr8:12115782~12177550:+
THCA	cis	rs669446	0.529	rs6697354	ENSG00000236200.4	KDM4A-AS1	-3.51	0.000487	0.0299	-0.13	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:43685344	chr1:43699765~43708138:-
THCA	cis	rs2933343	0.63	rs75824035	ENSG00000231305.3	RP11-723O4.2	3.51	0.000487	0.0299	0.17	0.16	IgG glycosylation;	chr3:128934142	chr3:128861313~128871540:-
THCA	cis	rs721917	0.526	rs2256574	ENSG00000272489.1	RP11-182L21.5	-3.51	0.000487	0.0299	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79663192~79664786:+
THCA	cis	rs9314614	0.789	rs2978887	ENSG00000245857.2	GS1-24F4.2	3.51	0.000487	0.0299	0.21	0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6853357	chr8:6835554~6885276:+
THCA	cis	rs10938353	0.68	rs73191059	ENSG00000273369.1	RP11-700J17.1	3.51	0.000487	0.0299	0.19	0.16	Body mass index;	chr4:44629998	chr4:44693946~44694386:-
THCA	cis	rs6472235	0.837	rs7003160	ENSG00000272192.1	CTD-2532N20.1	3.51	0.000487	0.0299	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66010142	chr8:65842752~65843331:+
THCA	cis	rs2235649	0.798	rs78540053	ENSG00000260541.1	LA16c-429E7.1	3.51	0.000487	0.0299	0.21	0.16	Blood metabolite levels;	chr16:1803274	chr16:1841020~1843547:-
THCA	cis	rs17095355	0.818	rs7071509	ENSG00000203876.8	ADD3-AS1	-3.51	0.000487	0.0299	-0.18	-0.16	Biliary atresia;	chr10:110016091	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.818	rs35096721	ENSG00000203876.8	ADD3-AS1	-3.51	0.000487	0.0299	-0.18	-0.16	Biliary atresia;	chr10:110016149	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.818	rs12571773	ENSG00000203876.8	ADD3-AS1	-3.51	0.000487	0.0299	-0.18	-0.16	Biliary atresia;	chr10:110016246	chr10:109940104~110008381:-
THCA	cis	rs17095355	0.818	rs10884921	ENSG00000203876.8	ADD3-AS1	-3.51	0.000487	0.0299	-0.18	-0.16	Biliary atresia;	chr10:110016490	chr10:109940104~110008381:-
THCA	cis	rs8179	0.7	rs42041	ENSG00000230927.2	TMBIM7P	3.51	0.000487	0.0299	0.23	0.16	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92617430	chr7:92412976~92439562:-
THCA	cis	rs2055729	0.591	rs17150950	ENSG00000261451.1	RP11-981G7.1	3.51	0.000487	0.0299	0.2	0.16	Multiple myeloma (hyperdiploidy);	chr8:10023499	chr8:10433672~10438312:+
THCA	cis	rs10833905	0.938	rs2468560	ENSG00000246225.5	RP11-17A1.3	3.51	0.000487	0.0299	0.23	0.16	Sudden cardiac arrest;	chr11:23067083	chr11:22829380~22945393:+
THCA	cis	rs9911578	0.967	rs6503890	ENSG00000224738.1	AC099850.1	3.51	0.000488	0.0299	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58986806	chr17:59106598~59118267:+
THCA	cis	rs4295623	0.504	rs11250160	ENSG00000251402.3	FAM90A25P	-3.51	0.000488	0.0299	-0.19	-0.16	Morning vs. evening chronotype;	chr8:11735208	chr8:12415080~12418090:-
THCA	cis	rs7989336	0.515	rs6491287	ENSG00000247400.3	DNAJC3-AS1	-3.51	0.000488	0.0299	-0.11	-0.16	Obesity;	chr13:96374769	chr13:95648733~95676925:-
THCA	cis	rs7192750	0.562	rs9302632	ENSG00000260886.1	TAT-AS1	3.51	0.000488	0.0299	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71909608	chr16:71565789~71578187:+
THCA	cis	rs17689437	0.541	rs7189698	ENSG00000260084.1	RP11-615I2.1	3.51	0.000488	0.0299	0.18	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68635062	chr16:68573782~68589512:-
THCA	cis	rs9863	0.794	rs12310367	ENSG00000269938.1	RP11-214K3.20	-3.51	0.000488	0.0299	-0.18	-0.16	White blood cell count;	chr12:124002131	chr12:123968023~123968579:-
THCA	cis	rs2562456	0.833	rs7260065	ENSG00000268278.1	RP11-420K14.1	3.51	0.000488	0.0299	0.22	0.16	Pain;	chr19:21334175	chr19:21637974~21656300:+
THCA	cis	rs1964356	0.967	rs2953802	ENSG00000254340.1	RP11-10A14.3	3.51	0.000488	0.0299	0.17	0.16	Mean corpuscular volume;	chr8:8994371	chr8:9141424~9145435:+
THCA	cis	rs6443245	0.591	rs2542365	ENSG00000227110.5	LMCD1-AS1	-3.51	0.000488	0.0299	-0.19	-0.16	Daytime sleep phenotypes;	chr3:9578664	chr3:7952805~8611924:-
THCA	cis	rs12922040	0.701	rs12149912	ENSG00000263065.1	AF001548.6	-3.51	0.000488	0.0299	-0.19	-0.16	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15741151~15741791:+
THCA	cis	rs9863	0.861	rs11057399	ENSG00000270028.1	RP11-380L11.4	3.51	0.000488	0.0299	0.17	0.16	White blood cell count;	chr12:123940531	chr12:123925461~123926083:-
THCA	cis	rs9635324	0.964	rs11638033	ENSG00000259536.4	RP11-111A22.1	3.51	0.000488	0.03	0.21	0.16	Blood metabolite ratios;Blood metabolite levels;	chr15:40417909	chr15:40488041~40558019:+
THCA	cis	rs2228479	0.557	rs57071566	ENSG00000274627.1	RP11-104N10.2	-3.51	0.000488	0.03	-0.27	-0.16	Skin colour saturation;	chr16:89822919	chr16:89516797~89522217:+
THCA	cis	rs9393777	0.778	rs4452638	ENSG00000226314.6	ZNF192P1	3.51	0.000488	0.03	0.3	0.16	Intelligence (multi-trait analysis);	chr6:27261486	chr6:28161781~28169594:+
THCA	cis	rs7226408	0.6	rs1147765	ENSG00000267707.2	RP11-95O2.5	3.51	0.000488	0.03	0.16	0.16	Obesity-related traits;	chr18:36831639	chr18:37243776~37247506:+
THCA	cis	rs804280	0.509	rs12719915	ENSG00000270154.1	RP11-419I17.1	-3.51	0.000488	0.03	-0.2	-0.16	Myopia (pathological);	chr8:11928746	chr8:12476462~12477122:+
THCA	cis	rs7631605	0.819	rs11129745	ENSG00000272334.1	RP11-129K12.1	-3.51	0.000488	0.03	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36927382	chr3:36973117~36973672:-
THCA	cis	rs939960	1	rs11771827	ENSG00000224016.2	RP11-728K20.1	3.51	0.000488	0.03	0.22	0.16	Neutrophil percentage of white cells;	chr7:150536275	chr7:149891191~149909704:-
THCA	cis	rs59197085	1	rs59197085	ENSG00000207588.1	MIR593	-3.51	0.000488	0.03	-0.31	-0.16	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);	chr7:128820702	chr7:128081861~128081960:+
THCA	cis	rs6878727	0.665	rs161015	ENSG00000253807.4	LINC01170	3.51	0.000488	0.03	0.14	0.16	Breast cancer;	chr5:124318121	chr5:124059794~124405079:-
THCA	cis	rs11603691	0.541	rs118188894	ENSG00000254662.1	RP11-872D17.4	-3.51	0.000488	0.03	-0.39	-0.16	Low high density lipoprotein cholesterol levels;	chr11:57375151	chr11:57325603~57327958:+
THCA	cis	rs2562456	0.754	rs11666213	ENSG00000268521.1	VN1R83P	3.51	0.000488	0.03	0.16	0.16	Pain;	chr19:21422843	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs62110429	ENSG00000268521.1	VN1R83P	3.51	0.000488	0.03	0.16	0.16	Pain;	chr19:21430984	chr19:21289554~21289998:-
THCA	cis	rs365302	1	rs294918	ENSG00000235086.1	FNDC1-IT1	3.51	0.000488	0.03	0.22	0.16	Coronary heart disease;	chr6:159205040	chr6:159240786~159243329:+
THCA	cis	rs181553	0.699	rs8092003	ENSG00000266696.1	RP11-30L3.2	3.51	0.000488	0.03	0.19	0.16	Hip circumference adjusted for BMI;	chr18:49165560	chr18:49205912~49208781:+
THCA	cis	rs8114671	0.904	rs6060197	ENSG00000126005.14	MMP24-AS1	3.51	0.000488	0.03	0.15	0.16	Height;	chr20:35066512	chr20:35216462~35278131:-
THCA	cis	rs8114671	0.839	rs6142290	ENSG00000126005.14	MMP24-AS1	3.51	0.000488	0.03	0.15	0.16	Height;	chr20:35066869	chr20:35216462~35278131:-
THCA	cis	rs8114671	0.869	rs6060199	ENSG00000126005.14	MMP24-AS1	3.51	0.000488	0.03	0.15	0.16	Height;	chr20:35066970	chr20:35216462~35278131:-
THCA	cis	rs293748	0.54	rs12655320	ENSG00000250155.1	CTD-2353F22.1	-3.51	0.000488	0.03	-0.2	-0.16	Obesity-related traits;	chr5:37104756	chr5:36666214~36725195:-
THCA	cis	rs72634258	0.554	rs4908699	ENSG00000224315.2	RPL7P7	-3.51	0.000488	0.03	-0.3	-0.16	Inflammatory bowel disease;	chr1:7845214	chr1:8786211~8786913:-
THCA	cis	rs2426132	0.525	rs2869688	ENSG00000227431.4	CSE1L-AS1	-3.51	0.000488	0.03	-0.21	-0.16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr20:48898344	chr20:49040463~49046044:-
THCA	cis	rs1866631	1	rs1866631	ENSG00000238133.5	MLK7-AS1	3.51	0.000488	0.03	0.21	0.16	Lung cancer in ever smokers;	chr2:173211033	chr2:173166446~173282036:-
THCA	cis	rs2574985	0.53	rs4935727	ENSG00000279863.1	RP11-521C22.2	3.51	0.000488	0.03	0.18	0.16	Subjective well-being;	chr10:50517640	chr10:50334538~50336123:+
THCA	cis	rs2839186	0.9	rs2839196	ENSG00000228137.1	AP001469.7	3.51	0.000488	0.03	0.16	0.16	Testicular germ cell tumor;	chr21:46288123	chr21:46246890~46247682:+
THCA	cis	rs2522056	0.935	rs1981524	ENSG00000263597.1	MIR3936	-3.51	0.000488	0.03	-0.17	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132365490~132365599:-
THCA	cis	rs910316	0.699	rs175039	ENSG00000259138.1	RP11-950C14.7	-3.51	0.000488	0.03	-0.14	-0.16	Height;	chr14:75002247	chr14:75127153~75136930:+
THCA	cis	rs8046148	0.703	rs6500291	ENSG00000279356.1	RP11-429P3.8	-3.51	0.000488	0.03	-0.2	-0.16	Testicular germ cell tumor;	chr16:50120902	chr16:50072862~50074986:+
THCA	cis	rs1005277	0.54	rs1987431	ENSG00000273019.1	RP11-508N22.13	-3.51	0.000488	0.03	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38149968~38150293:+
THCA	cis	rs597539	0.521	rs7943745	ENSG00000250508.1	RP11-757G1.6	3.51	0.000488	0.03	0.18	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68838360	chr11:68870664~68874542:+
THCA	cis	rs479105	0.713	rs12422683	ENSG00000278356.1	RP11-372B4.3	3.51	0.000489	0.03	0.16	0.16	Gut microbiota (bacterial taxa);	chr12:3266733	chr12:2885819~2886329:+
THCA	cis	rs9450351	0.744	rs6919244	ENSG00000203875.9	SNHG5	-3.51	0.000489	0.03	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:86045035	chr6:85660950~85678736:-
THCA	cis	rs73000965	0.837	rs2073846	ENSG00000255129.4	RP11-839D17.3	3.51	0.000489	0.03	0.24	0.16	Platelet count;	chr11:114113595	chr11:113278437~113314437:-
THCA	cis	rs7178375	1	rs10163148	ENSG00000215302.7	CTD-3092A11.1	-3.51	0.000489	0.03	-0.23	-0.16	Hypertriglyceridemia;	chr15:30920481	chr15:30470779~30507623:+
THCA	cis	rs7246657	0.722	rs2972437	ENSG00000226686.6	LINC01535	-3.51	0.000489	0.03	-0.23	-0.16	Coronary artery calcification;	chr19:37719610	chr19:37251912~37265535:+
THCA	cis	rs7089973	0.668	rs7898347	ENSG00000228169.3	PPIAP19	3.51	0.000489	0.03	0.18	0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114884565	chr10:114690143~114690634:-
THCA	cis	rs16975963	0.793	rs12460735	ENSG00000276846.1	CTD-3220F14.3	-3.51	0.000489	0.03	-0.15	-0.16	Longevity;	chr19:37822910	chr19:37314868~37315620:-
THCA	cis	rs1556032	0.521	rs10046863	ENSG00000225472.1	RP11-120J1.1	-3.51	0.000489	0.03	-0.15	-0.16	AIDS;	chr9:14457148	chr9:14317085~14357908:+
THCA	cis	rs7615952	0.546	rs2922194	ENSG00000272840.1	RP11-379B18.6	3.51	0.000489	0.03	0.26	0.16	Blood pressure (smoking interaction);	chr3:125613419	chr3:125774714~125797953:+
THCA	cis	rs8044868	0.887	rs12449073	ENSG00000260886.1	TAT-AS1	3.51	0.000489	0.03	0.19	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72137105	chr16:71565789~71578187:+
THCA	cis	rs7005380	0.733	rs10808505	ENSG00000279347.1	RP11-85I17.2	3.51	0.000489	0.03	0.18	0.16	Interstitial lung disease;	chr8:119927966	chr8:119838736~119840385:-
THCA	cis	rs7932813	0.513	rs12575300	ENSG00000176716.4	OR10AB1P	-3.51	0.000489	0.03	-0.21	-0.16	Waist circumference;	chr11:7664617	chr11:7728400~7729337:+
THCA	cis	rs453301	0.686	rs4840389	ENSG00000253981.4	ALG1L13P	-3.51	0.000489	0.03	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9026993	chr8:8236003~8244667:-
THCA	cis	rs453301	0.658	rs13271797	ENSG00000253981.4	ALG1L13P	-3.51	0.000489	0.03	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9028444	chr8:8236003~8244667:-
THCA	cis	rs4566357	0.615	rs10178098	ENSG00000212391.1	SNORA48	-3.51	0.000489	0.03	-0.17	-0.16	Coronary artery disease;	chr2:227049709	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.595	rs10201538	ENSG00000212391.1	SNORA48	-3.51	0.000489	0.03	-0.17	-0.16	Coronary artery disease;	chr2:227049733	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.615	rs10178260	ENSG00000212391.1	SNORA48	-3.51	0.000489	0.03	-0.17	-0.16	Coronary artery disease;	chr2:227049742	chr2:226968989~226969122:-
THCA	cis	rs2274273	0.84	rs3742569	ENSG00000258469.1	CHMP4BP1	3.51	0.000489	0.03	0.14	0.16	Protein biomarker;	chr14:55351988	chr14:55298644~55299231:+
THCA	cis	rs285757	0.857	rs285766	ENSG00000258741.3	RP11-386M24.4	-3.51	0.000489	0.03	-0.21	-0.16	HIV-1 susceptibility;	chr15:92642899	chr15:92715710~92734195:-
THCA	cis	rs9898058	1	rs77622401	ENSG00000204584.1	RP11-304F15.3	-3.51	0.000489	0.03	-0.18	-0.16	Milk allergy;	chr17:49869222	chr17:49845910~49848837:+
THCA	cis	rs10256972	0.9	rs4388364	ENSG00000225146.1	AC073957.15	3.51	0.000489	0.03	0.17	0.16	Endometriosis;Longevity;	chr7:993409	chr7:1029025~1043891:+
THCA	cis	rs748404	0.69	rs2467737	ENSG00000275601.1	AC011330.13	-3.51	0.000489	0.03	-0.19	-0.16	Lung cancer;	chr15:43444990	chr15:43642389~43643023:-
THCA	cis	rs237743	1	rs238164	ENSG00000222365.1	SNORD12B	-3.51	0.000489	0.03	-0.2	-0.16	Height;	chr20:49227804	chr20:49280319~49280409:+
THCA	cis	rs7660883	0.897	rs236987	ENSG00000251411.1	RP11-397E7.4	3.51	0.000489	0.03	0.15	0.16	HDL cholesterol levels;	chr4:87088627	chr4:86913266~86914817:-
THCA	cis	rs8044868	1	rs10400963	ENSG00000260886.1	TAT-AS1	3.51	0.000489	0.03	0.19	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72151084	chr16:71565789~71578187:+
THCA	cis	rs4767841	0.625	rs2240310	ENSG00000252886.1	RN7SKP197	-3.51	0.000489	0.03	-0.16	-0.16	Urgency urinary incontinence;	chr12:119783832	chr12:119631090~119631386:-
THCA	cis	rs11168618	1	rs12815544	ENSG00000240399.1	RP1-228P16.1	3.51	0.000489	0.03	0.16	0.16	Adiponectin levels;	chr12:48555825	chr12:48054813~48055591:-
THCA	cis	rs7897654	0.61	rs34060850	ENSG00000236937.2	PTGES3P4	3.51	0.000489	0.03	0.24	0.16	Schizophrenia;	chr10:103004308	chr10:102845595~102845950:+
THCA	cis	rs7246657	0.722	rs8100646	ENSG00000226686.6	LINC01535	-3.51	0.000489	0.03	-0.23	-0.16	Coronary artery calcification;	chr19:37617042	chr19:37251912~37265535:+
THCA	cis	rs6995541	0.645	rs2271356	ENSG00000248896.2	CTD-2135J3.3	-3.51	0.000489	0.03	-0.23	-0.16	Triglyceride levels;	chr8:10826266	chr8:10729314~10771392:+
THCA	cis	rs72827839	0.74	rs72825548	ENSG00000278765.1	RP5-890E16.5	-3.51	0.000489	0.03	-0.23	-0.16	Ease of getting up in the morning;	chr17:48153746	chr17:48066704~48067293:-
THCA	cis	rs17331151	0.505	rs7644763	ENSG00000242142.1	SERBP1P3	3.51	0.00049	0.03	0.38	0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52512471	chr3:53064283~53065091:-
THCA	cis	rs7824557	0.583	rs2263511	ENSG00000154316.13	TDH	3.51	0.00049	0.03	0.12	0.16	Retinal vascular caliber;	chr8:11375809	chr8:11339637~11368452:+
THCA	cis	rs9990343	0.513	rs3087253	ENSG00000223552.1	RP11-24F11.2	3.51	0.00049	0.03	0.14	0.16	Brain structure;	chr3:46377198	chr3:46364955~46407059:-
THCA	cis	rs28472312	0.667	rs9937676	ENSG00000259982.1	CDC37P1	-3.51	0.00049	0.03	-0.18	-0.16	Intelligence (multi-trait analysis);	chr16:28958159	chr16:28700294~28701540:-
THCA	cis	rs1124769	0.654	rs35373992	ENSG00000259378.1	DCAF13P3	3.51	0.00049	0.03	0.24	0.16	Cognitive performance;	chr15:51184090	chr15:50944663~50945996:+
THCA	cis	rs853679	0.517	rs9393895	ENSG00000219891.2	ZSCAN12P1	3.51	0.00049	0.03	0.23	0.16	Depression;	chr6:28159843	chr6:28091154~28093664:+
THCA	cis	rs17286411	0.669	rs7206039	ENSG00000260185.1	RP11-432I5.6	-3.51	0.00049	0.03	-0.22	-0.16	Blood protein levels;	chr16:71612011	chr16:71655027~71664212:+
THCA	cis	rs1150668	0.83	rs2023493	ENSG00000220721.1	OR1F12	3.51	0.00049	0.03	0.18	0.16	Pubertal anthropometrics;	chr6:28432385	chr6:28073316~28074233:+
THCA	cis	rs6499755	1	rs6499755	ENSG00000260135.5	RP11-212I21.2	-3.51	0.00049	0.03	-0.18	-0.16	Hypospadias;	chr16:55307223	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.896	rs8058278	ENSG00000260135.5	RP11-212I21.2	-3.51	0.00049	0.03	-0.18	-0.16	Hypospadias;	chr16:55310596	chr16:55426797~55462297:-
THCA	cis	rs2290416	0.892	rs61652493	ENSG00000254973.1	RP11-429J17.7	3.51	0.00049	0.03	0.31	0.16	Attention deficit hyperactivity disorder;	chr8:143586994	chr8:143758153~143771822:-
THCA	cis	rs4889855	0.614	rs6565694	ENSG00000279692.1	RP11-1055B8.1	3.51	0.00049	0.03	0.27	0.16	Fractional excretion of uric acid;	chr17:80527301	chr17:81395609~81397144:-
THCA	cis	rs28643277	0.671	rs4750661	ENSG00000237470.3	DCLRE1CP1	3.51	0.00049	0.03	0.21	0.16	Periodontitis (CDC/AAP);	chr10:15505110	chr10:15015370~15021863:-
THCA	cis	rs4272720	0.562	rs17773851	ENSG00000234736.4	FAM170B-AS1	-3.51	0.00049	0.03	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49132259	chr10:49121839~49151547:+
THCA	cis	rs10911902	0.561	rs78701198	ENSG00000228238.1	GS1-304P7.2	-3.51	0.00049	0.03	-0.25	-0.16	Schizophrenia;	chr1:186380240	chr1:186578279~186579299:+
THCA	cis	rs12882406	1	rs12882406	ENSG00000259321.1	RP11-468E2.5	3.51	0.00049	0.03	0.11	0.16	Body mass index;	chr14:23343028	chr14:24139445~24140444:+
THCA	cis	rs3739034	0.938	rs13018063	ENSG00000224043.6	CCNT2-AS1	-3.51	0.00049	0.0301	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134718238	chr2:134735464~134918710:-
THCA	cis	rs753274	0.65	rs10403233	ENSG00000267147.2	CTC-548K16.1	-3.51	0.00049	0.0301	-0.22	-0.16	Tumor necrosis factor beta levels;	chr19:14309013	chr19:14333743~14343916:+
THCA	cis	rs7819412	0.594	rs60921132	ENSG00000255046.1	RP11-297N6.4	3.51	0.00049	0.0301	0.17	0.16	Triglycerides;	chr8:11107459	chr8:11797928~11802568:-
THCA	cis	rs12780845	0.894	rs7099222	ENSG00000273153.1	RP11-406H21.2	-3.51	0.00049	0.0301	-0.15	-0.16	Homocysteine levels;	chr10:17209431	chr10:17137336~17137585:-
THCA	cis	rs7081476	0.737	rs12571272	ENSG00000262412.1	RP11-85G18.6	-3.51	0.00049	0.0301	-0.36	-0.16	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr10:27219932	chr10:27243130~27250804:+
THCA	cis	rs7081476	0.737	rs7900533	ENSG00000262412.1	RP11-85G18.6	-3.51	0.00049	0.0301	-0.36	-0.16	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr10:27223624	chr10:27243130~27250804:+
THCA	cis	rs2252521	0.553	rs2648659	ENSG00000228421.2	AC005013.5	3.51	0.00049	0.0301	0.21	0.16	Cognitive performance;	chr7:29001336	chr7:28957667~28959345:+
THCA	cis	rs1971762	0.521	rs5009146	ENSG00000270175.1	RP11-793H13.11	-3.51	0.00049	0.0301	-0.11	-0.16	Height;	chr12:53695513	chr12:53500162~53500936:-
THCA	cis	rs8074700	0.539	rs3096649	ENSG00000233101.9	HOXB-AS3	3.51	0.00049	0.0301	0.2	0.16	Body mass index in non-asthmatics;	chr17:48673795	chr17:48549630~48606414:+
THCA	cis	rs1971762	0.522	rs10747680	ENSG00000270175.1	RP11-793H13.11	-3.51	0.00049	0.0301	-0.1	-0.16	Height;	chr12:53683992	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.602	rs4759283	ENSG00000270175.1	RP11-793H13.11	-3.51	0.00049	0.0301	-0.1	-0.16	Height;	chr12:53685459	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.563	rs4759284	ENSG00000270175.1	RP11-793H13.11	-3.51	0.00049	0.0301	-0.1	-0.16	Height;	chr12:53685707	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.523	rs7135101	ENSG00000270175.1	RP11-793H13.11	-3.51	0.00049	0.0301	-0.1	-0.16	Height;	chr12:53686821	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.563	rs10219725	ENSG00000270175.1	RP11-793H13.11	-3.51	0.00049	0.0301	-0.1	-0.16	Height;	chr12:53687081	chr12:53500162~53500936:-
THCA	cis	rs2625529	0.824	rs35112434	ENSG00000260037.4	CTD-2524L6.3	-3.51	0.00049	0.0301	-0.23	-0.16	Red blood cell count;	chr15:72155985	chr15:71818396~71823384:+
THCA	cis	rs6120849	0.663	rs13041792	ENSG00000269202.1	RP4-614O4.12	-3.51	0.00049	0.0301	-0.17	-0.16	Protein C levels;	chr20:34957252	chr20:35201747~35203288:-
THCA	cis	rs2836950	0.561	rs34705151	ENSG00000235701.1	PCBP2P1	-3.51	0.00049	0.0301	-0.18	-0.16	Menarche (age at onset);	chr21:39181418	chr21:39171130~39172106:-
THCA	cis	rs938554	0.692	rs6449213	ENSG00000261490.1	RP11-448G15.3	-3.51	0.00049	0.0301	-0.14	-0.16	Blood metabolite levels;	chr4:9992591	chr4:10068089~10073019:-
THCA	cis	rs10844706	0.699	rs10772079	ENSG00000257027.1	RP11-705C15.3	3.51	0.00049	0.0301	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721798	chr12:9658567~9662085:+
THCA	cis	rs3733585	0.781	rs13103879	ENSG00000250413.1	RP11-448G15.1	3.51	0.00049	0.0301	0.16	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9971255	chr4:10006482~10009725:+
THCA	cis	rs11771526	0.686	rs77847042	ENSG00000272905.1	RP11-265E18.1	3.51	0.00049	0.0301	0.21	0.16	Body mass index;	chr7:32237595	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.901	rs10267589	ENSG00000272905.1	RP11-265E18.1	3.51	0.00049	0.0301	0.21	0.16	Body mass index;	chr7:32240544	chr7:32845394~32846061:+
THCA	cis	rs12121840	0.79	rs12143824	ENSG00000237463.4	RP11-280O1.2	-3.51	0.00049	0.0301	-0.15	-0.16	Interleukin-1-receptor antagonist levels;	chr1:165578069	chr1:165476841~165582155:-
THCA	cis	rs7246657	0.882	rs6508716	ENSG00000268499.1	CTB-102L5.8	3.51	0.00049	0.0301	0.2	0.16	Coronary artery calcification;	chr19:37328108	chr19:38199836~38200934:+
THCA	cis	rs7267979	0.932	rs446649	ENSG00000276952.1	RP5-965G21.6	3.51	0.00049	0.0301	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25284915~25285588:-
THCA	cis	rs12476592	0.602	rs262479	ENSG00000242412.1	DBIL5P2	3.51	0.000491	0.0301	0.2	0.16	Childhood ear infection;	chr2:63645345	chr2:63117851~63119542:-
THCA	cis	rs9863	0.896	rs4765148	ENSG00000270028.1	RP11-380L11.4	3.51	0.000491	0.0301	0.17	0.16	White blood cell count;	chr12:123994090	chr12:123925461~123926083:-
THCA	cis	rs5753037	0.702	rs5752961	ENSG00000273350.1	RP4-539M6.20	-3.51	0.000491	0.0301	-0.18	-0.16	Type 1 diabetes;	chr22:29792095	chr22:30420512~30420912:+
THCA	cis	rs2018683	0.677	rs12531456	ENSG00000233517.1	AC005162.5	-3.51	0.000491	0.0301	-0.2	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930994	chr7:28987028~28988899:+
THCA	cis	rs2018683	0.707	rs2391717	ENSG00000233517.1	AC005162.5	-3.51	0.000491	0.0301	-0.2	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931545	chr7:28987028~28988899:+
THCA	cis	rs2018683	0.707	rs917215	ENSG00000233517.1	AC005162.5	-3.51	0.000491	0.0301	-0.2	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931750	chr7:28987028~28988899:+
THCA	cis	rs11069062	0.71	rs10851027	ENSG00000270482.1	RP11-131L12.2	3.51	0.000491	0.0301	0.12	0.16	Obesity-related traits;	chr12:118748186	chr12:118375350~118376275:-
THCA	cis	rs6840360	0.967	rs4696105	ENSG00000270265.1	RP11-731D1.4	-3.51	0.000491	0.0301	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151685550	chr4:151333775~151353224:-
THCA	cis	rs6968419	1	rs10953813	ENSG00000237870.5	AC073130.1	3.51	0.000491	0.0301	0.17	0.16	Intraocular pressure;	chr7:116183926	chr7:116275606~116286734:-
THCA	cis	rs758324	0.797	rs644713	ENSG00000224431.1	AC063976.7	3.51	0.000491	0.0301	0.16	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:132003396	chr5:132199456~132203487:+
THCA	cis	rs867371	1	rs7181655	ENSG00000278603.1	RP13-608F4.5	3.51	0.000491	0.0301	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472203~82472426:+
THCA	cis	rs867371	1	rs7180584	ENSG00000278603.1	RP13-608F4.5	3.51	0.000491	0.0301	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472203~82472426:+
THCA	cis	rs35343117	1	rs35343117	ENSG00000259407.1	RP11-158M2.3	-3.51	0.000491	0.0301	-0.19	-0.16	Psoriasis;	chr15:85535884	chr15:85744109~85750281:-
THCA	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	3.51	0.000491	0.0301	0.18	0.16	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	3.51	0.000491	0.0301	0.18	0.16	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
THCA	cis	rs8054556	0.656	rs4420550	ENSG00000273724.1	RP11-347C12.12	-3.51	0.000491	0.0301	-0.15	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29927499	chr16:30336400~30343336:+
THCA	cis	rs2638953	0.777	rs10843181	ENSG00000247934.4	RP11-967K21.1	-3.51	0.000491	0.0301	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462824	chr12:28163298~28190738:-
THCA	cis	rs9876781	1	rs28824259	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48384185	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs12487542	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48384586	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs73074358	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48385757	chr3:48288587~48288694:+
THCA	cis	rs9876781	0.967	rs34761139	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48386489	chr3:48288587~48288694:+
THCA	cis	rs9876781	0.868	rs9875280	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48387420	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs6796491	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48388977	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs6804774	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48389129	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs9826195	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48392157	chr3:48288587~48288694:+
THCA	cis	rs9876781	0.967	rs9864815	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48392588	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs9809843	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48392923	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs1563736	ENSG00000199476.1	Y_RNA	-3.51	0.000491	0.0301	-0.2	-0.16	Longevity;	chr3:48395329	chr3:48288587~48288694:+
THCA	cis	rs7818688	1	rs10100089	ENSG00000253528.2	RP11-347C18.4	-3.51	0.000491	0.0301	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95012865	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs10111300	ENSG00000253528.2	RP11-347C18.4	-3.51	0.000491	0.0301	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013403	chr8:94974573~94974853:-
THCA	cis	rs2033711	0.84	rs4801590	ENSG00000269867.1	CTD-2583A14.8	-3.51	0.000491	0.0301	-0.13	-0.16	Uric acid clearance;	chr19:58450446	chr19:57867038~57868172:-
THCA	cis	rs7760535	0.763	rs10457241	ENSG00000272356.1	RP5-1112D6.8	-3.51	0.000491	0.0301	-0.13	-0.16	Metabolic traits;	chr6:111527831	chr6:111309203~111313517:+
THCA	cis	rs1005277	0.577	rs4934906	ENSG00000120555.12	SEPT7P9	3.51	0.000491	0.0301	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38383069~38402916:-
THCA	cis	rs8064029	0.892	rs2660226	ENSG00000267077.1	RP11-127I20.5	-3.51	0.000491	0.0301	-0.25	-0.16	Cancer;	chr16:4876725	chr16:4795265~4796532:-
THCA	cis	rs911555	0.603	rs11626562	ENSG00000269910.1	RP11-73M18.10	3.51	0.000491	0.0301	0.14	0.16	Intelligence (multi-trait analysis);	chr14:103379025	chr14:103694516~103695050:-
THCA	cis	rs4713118	0.525	rs9357042	ENSG00000261839.1	RP1-265C24.8	3.51	0.000491	0.0301	0.16	0.16	Parkinson's disease;	chr6:27615016	chr6:28136849~28139678:+
THCA	cis	rs3785574	0.962	rs2584630	ENSG00000279369.1	RP11-51F16.1	3.51	0.000491	0.0301	0.11	0.16	Height;	chr17:63810201	chr17:63700847~63702670:+
THCA	cis	rs11098499	0.874	rs6851169	ENSG00000249244.1	RP11-548H18.2	3.51	0.000491	0.0301	0.18	0.16	Corneal astigmatism;	chr4:119196355	chr4:119391831~119395335:-
THCA	cis	rs7845127	0.53	rs28860612	ENSG00000253671.1	RP11-806O11.1	3.51	0.000491	0.0301	0.18	0.16	Night sleep phenotypes;	chr8:18247201	chr8:17808941~17820868:+
THCA	cis	rs7829975	0.577	rs17684466	ENSG00000253981.4	ALG1L13P	-3.51	0.000491	0.0301	-0.16	-0.16	Mood instability;	chr8:8687723	chr8:8236003~8244667:-
THCA	cis	rs3935996	0.965	rs10158230	ENSG00000233147.1	RP11-90C4.1	-3.51	0.000491	0.0301	-0.14	-0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55856192	chr1:55823807~55868248:+
THCA	cis	rs4730276	0.674	rs2237685	ENSG00000250474.1	WBP1LP2	3.51	0.000491	0.0301	0.15	0.16	Ulcerative colitis;	chr7:107934339	chr7:107628553~107629498:+
THCA	cis	rs7727544	0.571	rs12521097	ENSG00000263597.1	MIR3936	3.51	0.000491	0.0301	0.16	0.16	Blood metabolite levels;	chr5:132239645	chr5:132365490~132365599:-
THCA	cis	rs8072100	0.512	rs9303533	ENSG00000260075.1	NSFP1	-3.51	0.000491	0.0301	-0.2	-0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:46372855~46487141:+
THCA	cis	rs73206853	0.764	rs73191817	ENSG00000257539.2	HSPA8P14	3.51	0.000491	0.0301	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110480868	chr12:111381867~111385638:+
THCA	cis	rs73206853	0.841	rs56887341	ENSG00000257539.2	HSPA8P14	3.51	0.000491	0.0301	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110509380	chr12:111381867~111385638:+
THCA	cis	rs3749237	0.576	rs62259939	ENSG00000224424.7	PRKAR2A-AS1	3.51	0.000491	0.0301	0.13	0.16	Resting heart rate;	chr3:49348614	chr3:48847572~48851981:+
THCA	cis	rs17122278	1	rs11216910	ENSG00000243431.1	RPL5P30	3.51	0.000491	0.0301	0.16	0.16	Total cholesterol levels;	chr11:118579331	chr11:118560690~118561580:+
THCA	cis	rs1009077	0.716	rs2892870	ENSG00000245958.5	RP11-33B1.1	3.51	0.000491	0.0301	0.25	0.16	Endometriosis;	chr4:119642218	chr4:119454791~119552025:+
THCA	cis	rs240993	0.812	rs4945881	ENSG00000255389.1	C6orf3	3.51	0.000491	0.0301	0.18	0.16	Inflammatory skin disease;Psoriasis;	chr6:111470260	chr6:111599875~111602295:+
THCA	cis	rs7246967	0.673	rs34682021	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22643926	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs60021625	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22646752	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs67631531	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22647664	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.541	rs74169641	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22647774	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs56271774	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22648525	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs4627499	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22649831	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs1835993	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22650235	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.551	rs1835994	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22650243	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs12984634	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22650942	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs12984903	ENSG00000198153.8	ZNF849P	-3.51	0.000491	0.0301	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22651079	chr19:22685167~22686732:+
THCA	cis	rs67073037	0.639	rs1140697	ENSG00000273233.1	RP11-713D19.1	3.51	0.000491	0.0301	0.19	0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28929590	chr2:28810281~28810706:-
THCA	cis	rs7631605	1	rs2302507	ENSG00000272334.1	RP11-129K12.1	-3.51	0.000491	0.0301	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:37103044	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.935	rs6550455	ENSG00000272334.1	RP11-129K12.1	-3.51	0.000491	0.0301	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:37105867	chr3:36973117~36973672:-
THCA	cis	rs2290416	0.892	rs3793372	ENSG00000254973.1	RP11-429J17.7	3.51	0.000491	0.0301	0.32	0.16	Attention deficit hyperactivity disorder;	chr8:143582063	chr8:143758153~143771822:-
THCA	cis	rs4767841	0.565	rs3858710	ENSG00000248636.5	RP11-768F21.1	-3.51	0.000492	0.0301	-0.17	-0.16	Urgency urinary incontinence;	chr12:119801389	chr12:119387987~119668079:-
THCA	cis	rs11633886	0.63	rs8040587	ENSG00000259200.1	RP11-718O11.1	-3.51	0.000492	0.0301	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45822724	chr15:45705078~45931069:+
THCA	cis	rs10411161	0.702	rs8100716	ENSG00000275055.1	CTC-471J1.11	-3.51	0.000492	0.0301	-0.15	-0.16	Breast cancer;	chr19:51880808	chr19:52049007~52049754:+
THCA	cis	rs61160187	0.582	rs4647150	ENSG00000272308.1	RP11-231G3.1	-3.51	0.000492	0.0301	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60866457~60866935:-
THCA	cis	rs2228479	0.717	rs1007932	ENSG00000274627.1	RP11-104N10.2	-3.51	0.000492	0.0301	-0.25	-0.16	Skin colour saturation;	chr16:89772133	chr16:89516797~89522217:+
THCA	cis	rs4805272	1	rs8104550	ENSG00000267799.1	MAN1A2P1	3.51	0.000492	0.0301	0.16	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840826	chr19:28790812~28792871:-
THCA	cis	rs57709857	0.957	rs10101168	ENSG00000272092.1	RP11-350N15.5	-3.51	0.000492	0.0301	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38336000	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.915	rs11777811	ENSG00000272092.1	RP11-350N15.5	-3.51	0.000492	0.0301	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38363950	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.914	rs16887340	ENSG00000272092.1	RP11-350N15.5	-3.51	0.000492	0.0301	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38366179	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs7821392	ENSG00000272092.1	RP11-350N15.5	-3.51	0.000492	0.0301	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38367831	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs72630620	ENSG00000272092.1	RP11-350N15.5	-3.51	0.000492	0.0301	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38376991	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs10099378	ENSG00000272092.1	RP11-350N15.5	-3.51	0.000492	0.0301	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38377869	chr8:38382364~38383461:+
THCA	cis	rs6921919	0.887	rs16894116	ENSG00000273712.1	RP5-874C20.7	3.51	0.000492	0.0301	0.21	0.16	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28315613~28315883:-
THCA	cis	rs7028939	1	rs10988956	ENSG00000255145.2	STX17-AS1	-3.51	0.000492	0.0301	-0.24	-0.16	Preeclampsia;	chr9:100051035	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7867803	ENSG00000255145.2	STX17-AS1	-3.51	0.000492	0.0301	-0.24	-0.16	Preeclampsia;	chr9:100054253	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10988960	ENSG00000255145.2	STX17-AS1	-3.51	0.000492	0.0301	-0.24	-0.16	Preeclampsia;	chr9:100065908	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7849323	ENSG00000255145.2	STX17-AS1	-3.51	0.000492	0.0301	-0.24	-0.16	Preeclampsia;	chr9:100091906	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7868446	ENSG00000255145.2	STX17-AS1	-3.51	0.000492	0.0301	-0.24	-0.16	Preeclampsia;	chr9:100093883	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7870469	ENSG00000255145.2	STX17-AS1	-3.51	0.000492	0.0301	-0.24	-0.16	Preeclampsia;	chr9:100097520	chr9:99886322~99906601:-
THCA	cis	rs10489167	1	rs944940	ENSG00000237899.1	RP4-739H11.3	-3.51	0.000492	0.0301	-0.27	-0.16	Depressive and manic episodes in bipolar disorder;	chr1:40739604	chr1:40669089~40687588:-
THCA	cis	rs4666002	0.636	rs13023194	ENSG00000234072.1	AC074117.10	3.51	0.000492	0.0301	0.16	0.16	Phospholipid levels (plasma);	chr2:27744393	chr2:27356246~27367622:+
THCA	cis	rs897984	0.881	rs12920259	ENSG00000275263.1	RP11-1072A3.4	3.51	0.000492	0.0302	0.19	0.16	Dementia with Lewy bodies;	chr16:30869978	chr16:30956872~30957199:-
THCA	cis	rs4512344	0.509	rs2409784	ENSG00000227888.4	FAM66A	-3.51	0.000492	0.0302	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12362019~12388296:+
THCA	cis	rs860295	0.557	rs12035524	ENSG00000203761.5	MSTO2P	-3.51	0.000492	0.0302	-0.13	-0.16	Body mass index;	chr1:155697311	chr1:155745829~155750137:+
THCA	cis	rs10911902	0.602	rs10494583	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186321363	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs28715477	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186326392	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs74537283	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186328038	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs3736597	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186331918	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs16825183	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186336861	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs3766704	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186342710	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.567	rs76557279	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186344161	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs2272412	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186345817	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs6667940	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186350448	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs6664763	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186357043	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs6689129	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186357078	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs16825243	ENSG00000228238.1	GS1-304P7.2	-3.51	0.000492	0.0302	-0.25	-0.16	Schizophrenia;	chr1:186357769	chr1:186578279~186579299:+
THCA	cis	rs2640806	0.505	rs28375708	ENSG00000253105.4	KB-1448A5.1	3.51	0.000492	0.0302	0.19	0.16	Obesity-related traits;	chr8:96356829	chr8:96371865~96387438:-
THCA	cis	rs9788682	1	rs2036534	ENSG00000261143.1	ADAMTS7P3	-3.51	0.000492	0.0302	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78534606	chr15:77976042~77993057:+
THCA	cis	rs2638953	0.962	rs11049495	ENSG00000247934.4	RP11-967K21.1	-3.51	0.000492	0.0302	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28264795	chr12:28163298~28190738:-
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000230373.7	GOLGA6L5P	-3.51	0.000492	0.0302	-0.15	-0.16	P wave terminal force;	chr15:84632519	chr15:84507885~84516814:-
THCA	cis	rs55788414	0.932	rs9936302	ENSG00000261838.4	RP11-303E16.6	-3.51	0.000492	0.0302	-0.28	-0.16	Left ventricular obstructive tract defect (maternal effect);	chr16:81157185	chr16:81069854~81076598:+
THCA	cis	rs2235573	0.805	rs132934	ENSG00000222044.1	RP5-1039K5.16	3.51	0.000492	0.0302	0.18	0.16	Glioma;Glioblastoma;	chr22:38093551	chr22:38032165~38034228:-
THCA	cis	rs1577917	0.958	rs6454488	ENSG00000220563.1	PKMP3	-3.51	0.000492	0.0302	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85741124	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs2324817	ENSG00000220563.1	PKMP3	-3.51	0.000492	0.0302	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85752936	chr6:85659892~85660606:-
THCA	cis	rs7089973	0.523	rs6585311	ENSG00000236799.1	RP11-383C6.2	-3.51	0.000492	0.0302	-0.19	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114973816	chr10:114994657~114996593:+
THCA	cis	rs7089973	0.523	rs7071789	ENSG00000236799.1	RP11-383C6.2	-3.51	0.000492	0.0302	-0.19	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114975582	chr10:114994657~114996593:+
THCA	cis	rs6687821	0.515	rs4656138	ENSG00000261737.1	RP4-612B15.3	3.51	0.000492	0.0302	0.24	0.16	Yeast infection;	chr1:87045494	chr1:86703502~86704462:-
THCA	cis	rs114858855	1	rs2295835	ENSG00000260273.1	RP11-425D10.10	-3.51	0.000492	0.0302	-0.39	-0.16	Plasma trimethylamine N-oxide levels;	chr6:109714672	chr6:109382795~109383666:+
THCA	cis	rs114858855	1	rs7742066	ENSG00000260273.1	RP11-425D10.10	-3.51	0.000492	0.0302	-0.39	-0.16	Plasma trimethylamine N-oxide levels;	chr6:109714913	chr6:109382795~109383666:+
THCA	cis	rs9990333	0.562	rs55970879	ENSG00000207650.1	MIR570	3.51	0.000492	0.0302	0.18	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195699401~195699497:+
THCA	cis	rs9990333	0.562	rs75681503	ENSG00000207650.1	MIR570	3.51	0.000492	0.0302	0.18	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195699401~195699497:+
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000230295.1	RP11-458F8.2	-3.51	0.000492	0.0302	-0.12	-0.16	Calcium levels;	chr7:65903721	chr7:66880708~66882981:+
THCA	cis	rs72843506	0.656	rs16960678	ENSG00000189423.10	USP32P3	3.51	0.000492	0.0302	0.25	0.16	Schizophrenia;	chr17:20080378	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs73984571	ENSG00000189423.10	USP32P3	3.51	0.000492	0.0302	0.25	0.16	Schizophrenia;	chr17:20080746	chr17:20415547~20431008:+
THCA	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	3.51	0.000492	0.0302	0.18	0.16	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
THCA	cis	rs10435719	0.746	rs58007588	ENSG00000227888.4	FAM66A	3.51	0.000492	0.0302	0.21	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:12362019~12388296:+
THCA	cis	rs6545883	0.826	rs2694617	ENSG00000212978.6	AC016747.3	-3.51	0.000492	0.0302	-0.17	-0.16	Tuberculosis;	chr2:61310079	chr2:61141592~61144969:-
THCA	cis	rs2408955	0.541	rs11168428	ENSG00000257735.1	RP11-370I10.6	-3.51	0.000492	0.0302	-0.18	-0.16	Glycated hemoglobin levels;	chr12:48153345	chr12:48350945~48442411:+
THCA	cis	rs11066679	0.628	rs648791	ENSG00000277566.1	RP11-545P7.9	3.51	0.000493	0.0302	0.19	0.16	Glomerular filtration rate in chronic kidney disease;	chr12:113676159	chr12:113249466~113250042:+
THCA	cis	rs4792901	0.765	rs9892162	ENSG00000279602.1	CTD-3014M21.1	-3.51	0.000493	0.0302	-0.2	-0.16	Dupuytren's disease;	chr17:43523432	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.694	rs9907819	ENSG00000279602.1	CTD-3014M21.1	-3.51	0.000493	0.0302	-0.2	-0.16	Dupuytren's disease;	chr17:43525497	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs9908559	ENSG00000279602.1	CTD-3014M21.1	-3.51	0.000493	0.0302	-0.2	-0.16	Dupuytren's disease;	chr17:43525793	chr17:43360041~43361361:-
THCA	cis	rs8112211	0.637	rs4804046	ENSG00000267291.1	CTB-186G2.1	3.51	0.000493	0.0302	0.18	0.16	Blood protein levels;	chr19:38349092	chr19:38596346~38601694:+
THCA	cis	rs988712	0.921	rs4923455	ENSG00000245573.6	BDNF-AS	3.51	0.000493	0.0302	0.15	0.16	Obesity;	chr11:27572599	chr11:27506838~27698174:+
THCA	cis	rs972578	0.837	rs738386	ENSG00000274717.1	RP1-47A17.1	-3.51	0.000493	0.0302	-0.16	-0.16	Mean platelet volume;	chr22:42932413	chr22:42791814~42794313:-
THCA	cis	rs478304	0.651	rs10896037	ENSG00000255557.1	RP11-770G2.2	3.51	0.000493	0.0302	0.18	0.16	Acne (severe);	chr11:65735953	chr11:65745729~65771585:+
THCA	cis	rs668210	0.793	rs1204011	ENSG00000214659.4	KRT8P26	-3.51	0.000493	0.0302	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr11:65973615	chr11:65726939~65728214:+
THCA	cis	rs4971059	0.608	rs7366138	ENSG00000236675.1	MTX1P1	-3.51	0.000493	0.0302	-0.15	-0.16	Breast cancer;	chr1:155115874	chr1:155230975~155234325:+
THCA	cis	rs962856	0.729	rs11695960	ENSG00000236780.4	AC078941.1	3.51	0.000493	0.0302	0.19	0.16	Pancreatic cancer;	chr2:67294235	chr2:67123357~67215319:-
THCA	cis	rs4767841	0.904	rs278110	ENSG00000252886.1	RN7SKP197	-3.51	0.000493	0.0302	-0.16	-0.16	Urgency urinary incontinence;	chr12:119734722	chr12:119631090~119631386:-
THCA	cis	rs3087591	0.708	rs964288	ENSG00000263535.1	AK4P1	3.51	0.000493	0.0302	0.19	0.16	Hip circumference;	chr17:31352228	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs7406783	ENSG00000263535.1	AK4P1	3.51	0.000493	0.0302	0.19	0.16	Hip circumference;	chr17:31362962	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs10438801	ENSG00000263535.1	AK4P1	3.51	0.000493	0.0302	0.19	0.16	Hip circumference;	chr17:31366767	chr17:31345521~31346187:+
THCA	cis	rs8041227	0.509	rs4779847	ENSG00000270055.1	CTD-3092A11.2	3.51	0.000493	0.0302	0.15	0.16	Eosinophilic esophagitis;	chr15:31236884	chr15:30487963~30490313:+
THCA	cis	rs1612141	0.744	rs2154104	ENSG00000251363.2	RP11-129M6.1	-3.51	0.000493	0.0302	-0.23	-0.16	QT interval (drug interaction);	chr14:41104570	chr14:40954898~40975877:+
THCA	cis	rs1005277	0.579	rs932538	ENSG00000151963.4	RP11-775A3.1	-3.51	0.000493	0.0302	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.541	rs2472177	ENSG00000151963.4	RP11-775A3.1	-3.51	0.000493	0.0302	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2472178	ENSG00000151963.4	RP11-775A3.1	-3.51	0.000493	0.0302	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2474572	ENSG00000151963.4	RP11-775A3.1	-3.51	0.000493	0.0302	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2505198	ENSG00000151963.4	RP11-775A3.1	-3.51	0.000493	0.0302	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:37883594~37884109:+
THCA	cis	rs1144333	0.655	rs12405994	ENSG00000272855.1	RP5-1102E8.3	-3.51	0.000493	0.0302	-0.33	-0.16	Attention function in attention deficit hyperactive disorder;	chr1:75969735	chr1:76636877~76637339:+
THCA	cis	rs8030379	1	rs11259936	ENSG00000176700.18	SCAND2P	3.51	0.000493	0.0302	0.1	0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911830	chr15:84631451~84647478:+
THCA	cis	rs6565180	0.889	rs8051096	ENSG00000274678.1	RP11-2C24.7	-3.51	0.000493	0.0302	-0.15	-0.16	Tonsillectomy;	chr16:30336410	chr16:30821338~30821884:+
THCA	cis	rs2483519	0.511	rs11196872	ENSG00000228169.3	PPIAP19	3.51	0.000493	0.0302	0.18	0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114683402	chr10:114690143~114690634:-
THCA	cis	rs911555	0.755	rs8014013	ENSG00000269940.1	RP11-73M18.7	-3.51	0.000493	0.0302	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103694560~103695170:+
THCA	cis	rs11637445	0.677	rs4386088	ENSG00000260657.2	RP11-315D16.4	-3.51	0.000493	0.0302	-0.21	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67816575	chr15:68267792~68277994:-
THCA	cis	rs11637445	0.64	rs4508380	ENSG00000260657.2	RP11-315D16.4	-3.51	0.000493	0.0302	-0.21	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67816711	chr15:68267792~68277994:-
THCA	cis	rs453301	0.624	rs330060	ENSG00000254340.1	RP11-10A14.3	-3.51	0.000493	0.0302	-0.18	-0.16	Joint mobility (Beighton score);	chr8:9233392	chr8:9141424~9145435:+
THCA	cis	rs308447	0.542	rs10084869	ENSG00000224786.1	CETN4P	3.51	0.000493	0.0302	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr4:122775752	chr4:122730548~122732193:-
THCA	cis	rs5758511	0.689	rs55906806	ENSG00000227370.1	RP4-669P10.19	3.51	0.000493	0.0302	0.22	0.16	Birth weight;	chr22:42248465	chr22:42132543~42132998:+
THCA	cis	rs16857609	0.564	rs13406698	ENSG00000233143.1	DIRC3-AS1	-3.51	0.000493	0.0302	-0.19	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217418362	chr2:217282739~217336120:+
THCA	cis	rs9488822	0.596	rs13192549	ENSG00000233558.1	RP3-486I3.4	3.51	0.000493	0.0302	0.19	0.16	LDL cholesterol;Cholesterol, total;	chr6:116017189	chr6:116258493~116259115:-
THCA	cis	rs9868809	0.881	rs3806694	ENSG00000270441.1	RP11-694I15.7	3.51	0.000493	0.0302	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48634901	chr3:49140086~49160851:-
THCA	cis	rs9868809	1	rs2310997	ENSG00000270441.1	RP11-694I15.7	3.51	0.000493	0.0302	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48640578	chr3:49140086~49160851:-
THCA	cis	rs5006884	1	rs78017006	ENSG00000167355.6	AC104389.28	-3.51	0.000493	0.0302	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5366059	chr11:5304976~5505652:-
THCA	cis	rs10129255	0.912	rs730099	ENSG00000274576.2	IGHV2-70	3.51	0.000493	0.0302	0.11	0.16	Kawasaki disease;	chr14:106711838	chr14:106770577~106771020:-
THCA	cis	rs875971	0.545	rs2420612	ENSG00000230295.1	RP11-458F8.2	3.51	0.000493	0.0302	0.14	0.16	Aortic root size;	chr7:66536825	chr7:66880708~66882981:+
THCA	cis	rs9650657	0.571	rs4240673	ENSG00000206014.6	OR7E161P	3.51	0.000493	0.0302	0.18	0.16	Neuroticism;	chr8:10930102	chr8:11928597~11929563:-
THCA	cis	rs8054556	0.692	rs12716972	ENSG00000273724.1	RP11-347C12.12	-3.51	0.000493	0.0302	-0.15	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29925333	chr16:30336400~30343336:+
THCA	cis	rs7829975	0.511	rs2921028	ENSG00000254153.1	CTA-398F10.2	-3.51	0.000493	0.0302	-0.18	-0.16	Mood instability;	chr8:8482967	chr8:8456909~8461337:-
THCA	cis	rs9878978	0.722	rs2055481	ENSG00000227588.2	CNTN4-AS2	3.51	0.000493	0.0302	0.21	0.16	Blood pressure (smoking interaction);	chr3:2405241	chr3:2110409~2144241:-
THCA	cis	rs910316	0.935	rs11159119	ENSG00000259138.1	RP11-950C14.7	-3.51	0.000493	0.0302	-0.14	-0.16	Height;	chr14:75170264	chr14:75127153~75136930:+
THCA	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	3.51	0.000493	0.0302	0.15	0.16	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
THCA	cis	rs9611565	0.512	rs5751145	ENSG00000237037.8	NDUFA6-AS1	-3.51	0.000494	0.0302	-0.15	-0.16	Vitiligo;	chr22:41737548	chr22:42090931~42137742:+
THCA	cis	rs867186	0.764	rs35291022	ENSG00000279253.1	RP4-614O4.13	-3.51	0.000494	0.0302	-0.27	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34949354	chr20:35262727~35264187:-
THCA	cis	rs656319	0.513	rs1484641	ENSG00000248538.5	RP11-10A14.5	-3.51	0.000494	0.0302	-0.21	-0.16	Myopia (pathological);	chr8:10129014	chr8:9189011~9202854:+
THCA	cis	rs61142792	1	rs335423	ENSG00000272459.1	RP11-1277A3.3	-3.51	0.000494	0.0302	-0.35	-0.16	Alzheimer disease and age of onset;	chr5:177548692	chr5:177554824~177555364:+
THCA	cis	rs61142792	1	rs335422	ENSG00000272459.1	RP11-1277A3.3	-3.51	0.000494	0.0302	-0.35	-0.16	Alzheimer disease and age of onset;	chr5:177550051	chr5:177554824~177555364:+
THCA	cis	rs4218	0.513	rs17302142	ENSG00000259732.1	RP11-59H7.3	-3.51	0.000494	0.0302	-0.21	-0.16	Social communication problems;	chr15:59053813	chr15:59121034~59133250:+
THCA	cis	rs910316	0.874	rs61980828	ENSG00000259138.1	RP11-950C14.7	-3.51	0.000494	0.0302	-0.14	-0.16	Height;	chr14:75163675	chr14:75127153~75136930:+
THCA	cis	rs910316	1	rs910316	ENSG00000259138.1	RP11-950C14.7	3.51	0.000494	0.0302	0.14	0.16	Height;	chr14:75159339	chr14:75127153~75136930:+
THCA	cis	rs2278702	0.848	rs77593396	ENSG00000259495.2	RP11-210M15.2	-3.51	0.000494	0.0302	-0.23	-0.16	Bipolar disorder;	chr15:80387970	chr15:80344853~80403575:-
THCA	cis	rs7192750	0.586	rs2018384	ENSG00000260886.1	TAT-AS1	3.51	0.000494	0.0302	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71906922	chr16:71565789~71578187:+
THCA	cis	rs1941184	0.5	rs55779595	ENSG00000266521.1	RP11-650P15.1	-3.51	0.000494	0.0303	-0.25	-0.16	Parkinson's disease (age of onset);	chr18:31435224	chr18:31496645~31497195:-
THCA	cis	rs786425	0.576	rs10846541	ENSG00000278112.1	RP11-972P1.11	3.51	0.000494	0.0303	0.15	0.16	Pubertal anthropometrics;	chr12:123691739	chr12:123519390~123519856:-
THCA	cis	rs786425	0.866	rs7137946	ENSG00000278112.1	RP11-972P1.11	3.51	0.000494	0.0303	0.15	0.16	Pubertal anthropometrics;	chr12:123692742	chr12:123519390~123519856:-
THCA	cis	rs8130944	0.964	rs1029332	ENSG00000225731.1	AP001627.1	3.51	0.000494	0.0303	0.19	0.16	Perceived unattractiveness to mosquitoes;	chr21:42722869	chr21:42733594~42741758:-
THCA	cis	rs8130944	0.964	rs9653815	ENSG00000225731.1	AP001627.1	3.51	0.000494	0.0303	0.19	0.16	Perceived unattractiveness to mosquitoes;	chr21:42723133	chr21:42733594~42741758:-
THCA	cis	rs113577745	0.616	rs13031635	ENSG00000188525.3	AC010969.1	-3.51	0.000494	0.0303	-0.23	-0.16	Breast cancer;	chr2:9978998	chr2:10003158~10006030:-
THCA	cis	rs2821260	0.703	rs1385912	ENSG00000227207.2	RPL31P12	-3.51	0.000494	0.0303	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:72117692	chr1:72301472~72301829:+
THCA	cis	rs3764021	0.509	rs10772071	ENSG00000257027.1	RP11-705C15.3	3.51	0.000494	0.0303	0.14	0.16	Type 1 diabetes;	chr12:9717324	chr12:9658567~9662085:+
THCA	cis	rs3764021	0.509	rs10772072	ENSG00000257027.1	RP11-705C15.3	3.51	0.000494	0.0303	0.14	0.16	Type 1 diabetes;	chr12:9717335	chr12:9658567~9662085:+
THCA	cis	rs713587	0.525	rs1541984	ENSG00000224165.4	DNAJC27-AS1	-3.51	0.000494	0.0303	-0.09	-0.16	Body mass index in non-asthmatics;	chr2:24859545	chr2:24971390~25039694:+
THCA	cis	rs476633	0.691	rs28568756	ENSG00000247556.5	OIP5-AS1	3.51	0.000494	0.0303	0.12	0.16	Glomerular filtration rate (creatinine);	chr15:41247173	chr15:41283990~41309737:+
THCA	cis	rs6496667	0.865	rs62019277	ENSG00000259262.1	NDUFA3P4	3.51	0.000494	0.0303	0.23	0.16	Rheumatoid arthritis;	chr15:90337206	chr15:90385814~90386063:+
THCA	cis	rs860295	0.676	rs11264374	ENSG00000236675.1	MTX1P1	-3.51	0.000494	0.0303	-0.16	-0.16	Body mass index;	chr1:155451721	chr1:155230975~155234325:+
THCA	cis	rs9450351	0.744	rs6910543	ENSG00000203875.9	SNHG5	-3.51	0.000494	0.0303	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85519023	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs9444353	ENSG00000203875.9	SNHG5	-3.51	0.000494	0.0303	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85566986	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs9351063	ENSG00000203875.9	SNHG5	-3.51	0.000494	0.0303	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85567123	chr6:85660950~85678736:-
THCA	cis	rs2562456	0.833	rs7258099	ENSG00000268278.1	RP11-420K14.1	3.51	0.000494	0.0303	0.22	0.16	Pain;	chr19:21352941	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62109229	ENSG00000268278.1	RP11-420K14.1	3.51	0.000494	0.0303	0.22	0.16	Pain;	chr19:21354380	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs11670815	ENSG00000268278.1	RP11-420K14.1	3.51	0.000494	0.0303	0.22	0.16	Pain;	chr19:21356515	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs11666540	ENSG00000268278.1	RP11-420K14.1	3.51	0.000494	0.0303	0.22	0.16	Pain;	chr19:21356550	chr19:21637974~21656300:+
THCA	cis	rs4081724	0.744	rs3848601	ENSG00000267296.2	CEBPA-AS1	3.51	0.000494	0.0303	0.21	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33334225	chr19:33302857~33305054:+
THCA	cis	rs1862618	0.853	rs1423620	ENSG00000234553.1	AC022431.3	-3.51	0.000494	0.0303	-0.18	-0.16	Initial pursuit acceleration;	chr5:56805169	chr5:56536583~56537826:-
THCA	cis	rs11671005	0.61	rs4756	ENSG00000252334.1	RNU6-1337P	3.51	0.000494	0.0303	0.21	0.16	Mean platelet volume;	chr19:58563286	chr19:58483749~58483843:-
THCA	cis	rs7111546	1	rs76008952	ENSG00000246225.5	RP11-17A1.3	3.51	0.000494	0.0303	0.29	0.16	Dialysis-related mortality;	chr11:22807890	chr11:22829380~22945393:+
THCA	cis	rs4489787	1	rs2705126	ENSG00000240399.1	RP1-228P16.1	3.51	0.000494	0.0303	0.24	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48488779	chr12:48054813~48055591:-
THCA	cis	rs73206853	0.609	rs61582364	ENSG00000257539.2	HSPA8P14	3.51	0.000494	0.0303	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110530042	chr12:111381867~111385638:+
THCA	cis	rs73206853	0.764	rs59527539	ENSG00000257539.2	HSPA8P14	3.51	0.000494	0.0303	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110530314	chr12:111381867~111385638:+
THCA	cis	rs8130944	1	rs4920141	ENSG00000235772.1	AP001625.6	-3.51	0.000494	0.0303	-0.18	-0.16	Perceived unattractiveness to mosquitoes;	chr21:42721519	chr21:42560374~42561934:-
THCA	cis	rs6762	0.692	rs7928925	ENSG00000255284.1	AP006621.5	3.51	0.000494	0.0303	0.11	0.16	Mean platelet volume;	chr11:839155	chr11:777578~784297:+
THCA	cis	rs6762	0.719	rs7936806	ENSG00000255284.1	AP006621.5	3.51	0.000494	0.0303	0.11	0.16	Mean platelet volume;	chr11:839186	chr11:777578~784297:+
THCA	cis	rs35123781	0.654	rs356443	ENSG00000249526.1	CTB-35F21.1	3.51	0.000494	0.0303	0.23	0.16	Schizophrenia;	chr5:139698244	chr5:139684645~139745010:+
THCA	cis	rs1865760	0.964	rs3799373	ENSG00000272810.1	U91328.22	-3.51	0.000494	0.0303	-0.13	-0.16	Height;	chr6:25928945	chr6:26013241~26013757:+
THCA	cis	rs806215	0.526	rs322823	ENSG00000224138.1	AC000123.4	-3.51	0.000494	0.0303	-0.16	-0.16	Type 2 diabetes;	chr7:128087348	chr7:127350128~127351523:+
THCA	cis	rs9987353	0.876	rs329993	ENSG00000248538.5	RP11-10A14.5	3.51	0.000494	0.0303	0.21	0.16	Recombination measurement;	chr8:9265928	chr8:9189011~9202854:+
THCA	cis	rs9650657	0.707	rs4593498	ENSG00000255310.2	AF131215.2	-3.51	0.000494	0.0303	-0.13	-0.16	Neuroticism;	chr8:10797960	chr8:11107788~11109726:-
THCA	cis	rs9650657	0.737	rs4504595	ENSG00000255310.2	AF131215.2	-3.51	0.000494	0.0303	-0.13	-0.16	Neuroticism;	chr8:10797995	chr8:11107788~11109726:-
THCA	cis	rs2115630	0.846	rs8024538	ENSG00000229212.6	RP11-561C5.4	3.51	0.000494	0.0303	0.21	0.16	P wave terminal force;	chr15:84825188	chr15:85205440~85234795:-
THCA	cis	rs1417770	0.579	rs778397	ENSG00000260971.3	RP11-504A18.1	3.51	0.000494	0.0303	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56234783	chr1:56248294~56258571:-
THCA	cis	rs4243849	0.555	rs7838498	ENSG00000279518.1	AC083843.4	3.51	0.000494	0.0303	0.11	0.16	Non-alcoholic fatty liver disease histology (other);	chr8:135749535	chr8:134783694~134785879:-
THCA	cis	rs2039553	0.53	rs12872026	ENSG00000227354.5	RBM26-AS1	-3.51	0.000495	0.0303	-0.15	-0.16	Pancreatic cancer;	chr13:79816007	chr13:79406309~79424328:+
THCA	cis	rs11758351	0.789	rs4496782	ENSG00000216331.1	HIST1H1PS1	3.51	0.000495	0.0303	0.22	0.16	Renal underexcretion gout;Gout;	chr6:26184389	chr6:26195566~26195771:+
THCA	cis	rs926937	0.622	rs6005500	ENSG00000244625.4	MIATNB	-3.51	0.000495	0.0303	-0.34	-0.16	Age-related cataracts;	chr22:27529117	chr22:26672767~26780207:+
THCA	cis	rs55702914	0.652	rs12151726	ENSG00000231621.1	AC013264.2	-3.51	0.000495	0.0303	-0.16	-0.16	Major depression and alcohol dependence;	chr2:197408867	chr2:197197991~197199273:+
THCA	cis	rs36093844	0.626	rs10898431	ENSG00000279742.1	RP11-700A24.1	-3.51	0.000495	0.0303	-0.2	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86036539	chr11:85852557~85854943:-
THCA	cis	rs801193	1	rs2055682	ENSG00000223473.2	GS1-124K5.3	3.51	0.000495	0.0303	0.11	0.16	Aortic root size;	chr7:66795302	chr7:66491049~66493566:-
THCA	cis	rs7959452	0.59	rs56054057	ENSG00000274979.1	RP11-1143G9.5	-3.51	0.000495	0.0303	-0.17	-0.16	Blood protein levels;	chr12:69382192	chr12:69326574~69331882:-
THCA	cis	rs7959452	0.536	rs4761237	ENSG00000274979.1	RP11-1143G9.5	-3.51	0.000495	0.0303	-0.17	-0.16	Blood protein levels;	chr12:69382681	chr12:69326574~69331882:-
THCA	cis	rs889512	0.642	rs28439846	ENSG00000261783.1	RP11-252K23.2	3.51	0.000495	0.0303	0.32	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75246480	chr16:75379818~75381260:-
THCA	cis	rs4533267	1	rs10794478	ENSG00000189419.6	SPATA41	-3.51	0.000495	0.0303	-0.22	-0.16	Height;	chr15:100245695	chr15:100344457~100349655:-
THCA	cis	rs45509595	0.841	rs9368531	ENSG00000220721.1	OR1F12	3.51	0.000495	0.0303	0.28	0.16	Breast cancer;	chr6:27814094	chr6:28073316~28074233:+
THCA	cis	rs45509595	0.749	rs401763	ENSG00000220721.1	OR1F12	3.51	0.000495	0.0303	0.28	0.16	Breast cancer;	chr6:27814750	chr6:28073316~28074233:+
THCA	cis	rs45509595	0.659	rs390764	ENSG00000220721.1	OR1F12	3.51	0.000495	0.0303	0.28	0.16	Breast cancer;	chr6:27814757	chr6:28073316~28074233:+
THCA	cis	rs45509595	0.841	rs401754	ENSG00000220721.1	OR1F12	3.51	0.000495	0.0303	0.28	0.16	Breast cancer;	chr6:27814760	chr6:28073316~28074233:+
THCA	cis	rs45509595	0.841	rs2747054	ENSG00000220721.1	OR1F12	3.51	0.000495	0.0303	0.28	0.16	Breast cancer;	chr6:27815581	chr6:28073316~28074233:+
THCA	cis	rs45509595	0.841	rs200501	ENSG00000220721.1	OR1F12	3.51	0.000495	0.0303	0.28	0.16	Breast cancer;	chr6:27821164	chr6:28073316~28074233:+
THCA	cis	rs4664293	0.899	rs7588710	ENSG00000230783.1	AC009961.2	-3.51	0.000495	0.0303	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159673011	chr2:159689217~159690291:-
THCA	cis	rs10129255	0.912	rs8009135	ENSG00000280411.1	IGHV1-69-2	-3.51	0.000495	0.0303	-0.1	-0.16	Kawasaki disease;	chr14:106777528	chr14:106762092~106762588:-
THCA	cis	rs73206853	0.609	rs55833146	ENSG00000257539.2	HSPA8P14	3.51	0.000495	0.0303	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110434530	chr12:111381867~111385638:+
THCA	cis	rs73206853	0.609	rs7306167	ENSG00000257539.2	HSPA8P14	3.51	0.000495	0.0303	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110454644	chr12:111381867~111385638:+
THCA	cis	rs73206853	0.698	rs73191806	ENSG00000257539.2	HSPA8P14	3.51	0.000495	0.0303	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110462108	chr12:111381867~111385638:+
THCA	cis	rs73206853	0.764	rs56273026	ENSG00000257539.2	HSPA8P14	3.51	0.000495	0.0303	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110463886	chr12:111381867~111385638:+
THCA	cis	rs17604090	0.938	rs10276157	ENSG00000223813.2	AC007255.8	3.51	0.000495	0.0303	0.17	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29625400	chr7:29514225~29563670:-
THCA	cis	rs11673344	0.523	rs2082010	ENSG00000267260.1	CTD-2162K18.4	-3.51	0.000495	0.0303	-0.19	-0.16	Obesity-related traits;	chr19:37039874	chr19:36773153~36777078:+
THCA	cis	rs972578	1	rs714003	ENSG00000230319.1	AL022476.2	3.51	0.000495	0.0303	0.17	0.16	Mean platelet volume;	chr22:42973760	chr22:43038585~43052366:+
THCA	cis	rs13434995	0.513	rs58476959	ENSG00000249700.7	SRD5A3-AS1	-3.51	0.000495	0.0303	-0.22	-0.16	Adiponectin levels;	chr4:55496234	chr4:55363971~55395847:-
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000230295.1	RP11-458F8.2	-3.51	0.000495	0.0303	-0.12	-0.16	Calcium levels;	chr7:65996954	chr7:66880708~66882981:+
THCA	cis	rs1580019	0.922	rs34545272	ENSG00000273014.1	RP11-225B17.2	3.51	0.000495	0.0303	0.17	0.16	Cognitive ability;	chr7:32421018	chr7:32758882~32759353:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-3.51	0.000495	0.0303	-0.18	-0.16	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
THCA	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-3.51	0.000495	0.0303	-0.18	-0.16	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
THCA	cis	rs7474896	0.559	rs10740949	ENSG00000120555.12	SEPT7P9	3.51	0.000495	0.0303	0.21	0.16	Obesity (extreme);	chr10:37689507	chr10:38383069~38402916:-
THCA	cis	rs9911578	0.967	rs686425	ENSG00000224738.1	AC099850.1	3.51	0.000495	0.0303	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58699369	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs405684	ENSG00000224738.1	AC099850.1	3.51	0.000495	0.0303	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58699787	chr17:59106598~59118267:+
THCA	cis	rs77204473	0.744	rs3781985	ENSG00000276505.1	CMB9-94B1.2	-3.51	0.000495	0.0303	-0.3	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117297005~117297328:-
THCA	cis	rs77204473	0.744	rs11606480	ENSG00000276505.1	CMB9-94B1.2	-3.51	0.000495	0.0303	-0.3	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117297005~117297328:-
THCA	cis	rs1062177	1	rs12518722	ENSG00000272112.1	CTB-113P19.5	3.51	0.000495	0.0303	0.14	0.16	Preschool internalizing problems;	chr5:151851899	chr5:151724831~151725356:-
THCA	cis	rs7216064	0.648	rs61676547	ENSG00000278740.1	RP11-147L13.14	3.51	0.000495	0.0303	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896391	chr17:68188547~68189165:+
THCA	cis	rs2252521	0.553	rs317705	ENSG00000272568.4	CTB-113D17.1	3.51	0.000495	0.0303	0.18	0.16	Cognitive performance;	chr7:29057532	chr7:28979967~29013367:+
THCA	cis	rs2252521	0.583	rs317706	ENSG00000272568.4	CTB-113D17.1	3.51	0.000495	0.0303	0.18	0.16	Cognitive performance;	chr7:29057649	chr7:28979967~29013367:+
THCA	cis	rs6840360	1	rs6834095	ENSG00000270265.1	RP11-731D1.4	-3.51	0.000495	0.0303	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151682126	chr4:151333775~151353224:-
THCA	cis	rs7937890	0.504	rs2575847	ENSG00000251991.1	RNU7-49P	3.51	0.000495	0.0303	0.18	0.16	Mitochondrial DNA levels;	chr11:14449626	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2575825	ENSG00000251991.1	RNU7-49P	3.51	0.000495	0.0303	0.18	0.16	Mitochondrial DNA levels;	chr11:14450550	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.532	rs2575827	ENSG00000251991.1	RNU7-49P	3.51	0.000495	0.0303	0.18	0.16	Mitochondrial DNA levels;	chr11:14453969	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2597206	ENSG00000251991.1	RNU7-49P	3.51	0.000495	0.0303	0.18	0.16	Mitochondrial DNA levels;	chr11:14455992	chr11:14478892~14478953:+
THCA	cis	rs58365266	1	rs58365266	ENSG00000226155.1	AC124944.3	-3.51	0.000495	0.0303	-0.26	-0.16	Red cell distribution width;	chr3:196086886	chr3:195912049~195913986:+
THCA	cis	rs1476679	0.962	rs34995835	ENSG00000078319.8	PMS2P1	-3.51	0.000495	0.0303	-0.21	-0.16	Alzheimer's disease (late onset);	chr7:100392741	chr7:100320992~100341908:-
THCA	cis	rs2013441	1	rs972966	ENSG00000261033.1	RP11-209D14.2	-3.51	0.000495	0.0303	-0.21	-0.16	Obesity-related traits;	chr17:20127679	chr17:20008051~20009234:-
THCA	cis	rs1612141	0.64	rs1954451	ENSG00000251363.2	RP11-129M6.1	3.51	0.000495	0.0303	0.23	0.16	QT interval (drug interaction);	chr14:41102533	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs8003326	ENSG00000251363.2	RP11-129M6.1	3.51	0.000495	0.0303	0.23	0.16	QT interval (drug interaction);	chr14:41103254	chr14:40954898~40975877:+
THCA	cis	rs397969	0.607	rs169413	ENSG00000261033.1	RP11-209D14.2	-3.51	0.000495	0.0303	-0.23	-0.16	Platelet count;	chr17:19946432	chr17:20008051~20009234:-
THCA	cis	rs2447820	0.5	rs2024527	ENSG00000263432.2	RN7SL689P	3.51	0.000495	0.0303	0.2	0.16	Migraine;	chr5:122852642	chr5:123022487~123022783:-
THCA	cis	rs748404	0.66	rs694725	ENSG00000275601.1	AC011330.13	-3.51	0.000495	0.0303	-0.19	-0.16	Lung cancer;	chr15:43464012	chr15:43642389~43643023:-
THCA	cis	rs7216064	0.734	rs12942774	ENSG00000278740.1	RP11-147L13.14	-3.51	0.000495	0.0303	-0.17	-0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971446	chr17:68188547~68189165:+
THCA	cis	rs9650657	0.836	rs4841438	ENSG00000269918.1	AF131215.9	-3.51	0.000495	0.0303	-0.17	-0.16	Neuroticism;	chr8:10749246	chr8:11104691~11106704:-
THCA	cis	rs9650657	0.836	rs11250067	ENSG00000269918.1	AF131215.9	-3.51	0.000495	0.0303	-0.17	-0.16	Neuroticism;	chr8:10749444	chr8:11104691~11106704:-
THCA	cis	rs7903847	0.642	rs1537645	ENSG00000225850.3	RP11-452K12.4	3.51	0.000495	0.0303	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97390157	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs7909345	ENSG00000225850.3	RP11-452K12.4	3.51	0.000495	0.0303	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97391037	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10786339	ENSG00000225850.3	RP11-452K12.4	3.51	0.000495	0.0303	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97393319	chr10:97334564~97343203:+
THCA	cis	rs5006884	0.906	rs74494837	ENSG00000167355.6	AC104389.28	-3.51	0.000496	0.0303	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5379702	chr11:5304976~5505652:-
THCA	cis	rs36093924	0.646	rs4822069	ENSG00000270083.1	RP1-257I20.14	-3.51	0.000496	0.0303	-0.18	-0.16	Intelligence;	chr22:41955477	chr22:42089630~42090028:-
THCA	cis	rs478304	0.619	rs10791822	ENSG00000214659.4	KRT8P26	3.51	0.000496	0.0303	0.15	0.16	Acne (severe);	chr11:65661235	chr11:65726939~65728214:+
THCA	cis	rs7989332	0.961	rs4770039	ENSG00000277020.3	RP11-476H16.1	3.51	0.000496	0.0303	0.15	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20474285	chr13:20564708~20567045:-
THCA	cis	rs4908760	0.827	rs6692693	ENSG00000270282.1	RP5-1115A15.2	3.51	0.000496	0.0303	0.19	0.16	Vitiligo;	chr1:8647057	chr1:8512653~8513021:+
THCA	cis	rs4869313	0.721	rs193994	ENSG00000247121.5	CTD-2260A17.2	-3.51	0.000496	0.0303	-0.12	-0.16	Pediatric autoimmune diseases;	chr5:96923019	chr5:96814028~96935809:-
THCA	cis	rs6442522	0.526	rs2124491	ENSG00000249786.6	EAF1-AS1	3.51	0.000496	0.0303	0.16	0.16	Uric acid levels;	chr3:15487898	chr3:15436171~15455940:-
THCA	cis	rs775227	0.574	rs36108475	ENSG00000243849.1	CFAP44-AS1	3.51	0.000496	0.0303	0.29	0.16	Dental caries;	chr3:113319559	chr3:113403991~113433992:+
THCA	cis	rs924712	0.522	rs1910356	ENSG00000224984.1	RP11-524H19.2	-3.51	0.000496	0.0303	-0.19	-0.16	Breast cancer;	chr6:54841345	chr6:54840118~54840855:-
THCA	cis	rs17095355	0.539	rs12260509	ENSG00000203876.8	ADD3-AS1	-3.51	0.000496	0.0303	-0.17	-0.16	Biliary atresia;	chr10:110161237	chr10:109940104~110008381:-
THCA	cis	rs860295	0.812	rs10908481	ENSG00000203761.5	MSTO2P	-3.51	0.000496	0.0303	-0.13	-0.16	Body mass index;	chr1:155743859	chr1:155745829~155750137:+
THCA	cis	rs3845817	0.868	rs702938	ENSG00000281920.1	RP11-418H16.1	3.51	0.000496	0.0303	0.2	0.16	Bipolar disorder;	chr2:65520308	chr2:65623272~65628424:+
THCA	cis	rs3925158	0.51	rs6767007	ENSG00000229589.1	ACVR2B-AS1	-3.51	0.000496	0.0303	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38170766	chr3:38451027~38454820:-
THCA	cis	rs3925158	0.51	rs6799701	ENSG00000229589.1	ACVR2B-AS1	-3.51	0.000496	0.0303	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38178428	chr3:38451027~38454820:-
THCA	cis	rs240993	0.595	rs3777911	ENSG00000220392.1	FCF1P5	3.51	0.000496	0.0303	0.17	0.16	Inflammatory skin disease;Psoriasis;	chr6:111581277	chr6:111353702~111354183:+
THCA	cis	rs7216064	0.906	rs1976052	ENSG00000265055.1	AC145343.2	3.51	0.000496	0.0304	0.24	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834462	chr17:68096046~68101474:-
THCA	cis	rs1009077	0.709	rs10004865	ENSG00000245958.5	RP11-33B1.1	3.51	0.000496	0.0304	0.18	0.16	Endometriosis;	chr4:119745118	chr4:119454791~119552025:+
THCA	cis	rs11671005	0.569	rs73068335	ENSG00000252334.1	RNU6-1337P	3.51	0.000496	0.0304	0.23	0.16	Mean platelet volume;	chr19:58577941	chr19:58483749~58483843:-
THCA	cis	rs3087591	0.708	rs2285894	ENSG00000263535.1	AK4P1	3.51	0.000496	0.0304	0.19	0.16	Hip circumference;	chr17:31327858	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs3815154	ENSG00000263535.1	AK4P1	3.51	0.000496	0.0304	0.19	0.16	Hip circumference;	chr17:31327956	chr17:31345521~31346187:+
THCA	cis	rs10043228	0.826	rs12514785	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116139040	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs77148055	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116174223	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62384213	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116191098	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs35696109	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116192059	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62384215	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116192501	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62384235	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116198537	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62384236	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116198940	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62384238	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116206834	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs77849630	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116221203	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs75080838	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116221770	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62384253	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116227718	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs17139224	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116232496	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs1422500	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116233615	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs1592917	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116233717	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12153717	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116236217	chr5:116302354~116304134:-
THCA	cis	rs10043228	0.59	rs10519448	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116238364	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12521612	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116246908	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs79889615	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116255595	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12520632	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116256069	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62385980	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116257211	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62385993	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116266557	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs17139314	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116271430	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12515251	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116291269	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62384476	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116313812	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12521440	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116334667	chr5:116302354~116304134:-
THCA	cis	rs10043228	0.793	rs62384491	ENSG00000250015.1	CTC-339F2.2	3.51	0.000496	0.0304	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116337061	chr5:116302354~116304134:-
THCA	cis	rs9450351	0.744	rs6901489	ENSG00000280232.1	RP11-321N4.4	3.51	0.000496	0.0304	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:86066343	chr6:85498441~85499058:-
THCA	cis	rs9420	0.528	rs10896632	ENSG00000254602.1	AP000662.4	-3.51	0.000496	0.0304	-0.18	-0.16	Schizophrenia;	chr11:57622829	chr11:57638024~57652790:+
THCA	cis	rs301901	0.772	rs301906	ENSG00000250155.1	CTD-2353F22.1	-3.51	0.000496	0.0304	-0.16	-0.16	Height;	chr5:37105504	chr5:36666214~36725195:-
THCA	cis	rs10223402	0.786	rs9400865	ENSG00000233558.1	RP3-486I3.4	-3.51	0.000496	0.0304	-0.26	-0.16	Appendicular lean mass;	chr6:115643997	chr6:116258493~116259115:-
THCA	cis	rs597539	0.503	rs7131462	ENSG00000250508.1	RP11-757G1.6	3.51	0.000496	0.0304	0.18	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68842675	chr11:68870664~68874542:+
THCA	cis	rs7572733	0.576	rs4850441	ENSG00000231621.1	AC013264.2	3.51	0.000496	0.0304	0.17	0.16	Dermatomyositis;	chr2:198048689	chr2:197197991~197199273:+
THCA	cis	rs7924176	0.564	rs12359146	ENSG00000232342.6	RP11-46O21.2	3.51	0.000496	0.0304	0.2	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74205914	chr10:74506081~74530553:-
THCA	cis	rs7772486	0.875	rs2814863	ENSG00000270638.1	RP3-466P17.1	-3.51	0.000496	0.0304	-0.12	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145735570~145737218:+
THCA	cis	rs3764021	0.527	rs10844456	ENSG00000256069.6	A2MP1	-3.51	0.000496	0.0304	-0.18	-0.16	Type 1 diabetes;	chr12:9689319	chr12:9228533~9275817:-
THCA	cis	rs6560517	0.519	rs2282683	ENSG00000234618.1	RPSAP9	-3.51	0.000496	0.0304	-0.19	-0.16	Dialysis-related mortality;	chr9:76502835	chr9:76398699~76399586:+
THCA	cis	rs11105298	0.891	rs11105319	ENSG00000266347.2	AC068641.1	3.51	0.000496	0.0304	0.21	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89592833~89592927:+
THCA	cis	rs75968099	0.555	rs4425211	ENSG00000272334.1	RP11-129K12.1	-3.51	0.000496	0.0304	-0.2	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:36910407	chr3:36973117~36973672:-
THCA	cis	rs11098499	0.575	rs9996586	ENSG00000249244.1	RP11-548H18.2	3.51	0.000496	0.0304	0.16	0.16	Corneal astigmatism;	chr4:119405787	chr4:119391831~119395335:-
THCA	cis	rs7760535	0.826	rs7753887	ENSG00000272356.1	RP5-1112D6.8	-3.51	0.000496	0.0304	-0.13	-0.16	Metabolic traits;	chr6:111533904	chr6:111309203~111313517:+
THCA	cis	rs1125355	0.69	rs72939206	ENSG00000243792.1	OR7E89P	-3.51	0.000496	0.0304	-0.23	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158785799	chr2:158853755~158854576:+
THCA	cis	rs1125355	0.69	rs72939209	ENSG00000243792.1	OR7E89P	-3.51	0.000496	0.0304	-0.23	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158786291	chr2:158853755~158854576:+
THCA	cis	rs12105510	0.626	rs1990145	ENSG00000270696.1	RP11-342K6.1	3.51	0.000496	0.0304	0.17	0.16	Response to platinum-based chemotherapy (cisplatin);	chr2:75650524	chr2:75660462~75662208:+
THCA	cis	rs479105	0.627	rs12578221	ENSG00000278356.1	RP11-372B4.3	3.51	0.000496	0.0304	0.16	0.16	Gut microbiota (bacterial taxa);	chr12:3263741	chr12:2885819~2886329:+
THCA	cis	rs910316	0.663	rs175034	ENSG00000259138.1	RP11-950C14.7	-3.51	0.000496	0.0304	-0.14	-0.16	Height;	chr14:74996984	chr14:75127153~75136930:+
THCA	cis	rs9611565	0.559	rs1006407	ENSG00000237037.8	NDUFA6-AS1	3.51	0.000496	0.0304	0.16	0.16	Vitiligo;	chr22:41576028	chr22:42090931~42137742:+
THCA	cis	rs9487094	0.644	rs3757230	ENSG00000223537.2	RP5-919F19.5	-3.51	0.000496	0.0304	-0.16	-0.16	Height;	chr6:109383239	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.644	rs3757231	ENSG00000223537.2	RP5-919F19.5	-3.51	0.000496	0.0304	-0.16	-0.16	Height;	chr6:109383248	chr6:109487906~109506800:+
THCA	cis	rs10905099	0.505	rs867454	ENSG00000278982.1	RP5-1031D4.3	-3.51	0.000497	0.0304	-0.27	-0.16	Orofacial clefts;	chr10:7042650	chr10:7411599~7413467:+
THCA	cis	rs3750082	0.855	rs12536402	ENSG00000205763.12	RP9P	-3.51	0.000497	0.0304	-0.14	-0.16	Glomerular filtration rate (creatinine);	chr7:32896807	chr7:32916815~32943176:-
THCA	cis	rs11718455	0.921	rs11130020	ENSG00000271192.1	RP4-555D20.3	-3.51	0.000497	0.0304	-0.22	-0.16	Coronary artery disease;	chr3:43967967	chr3:43996896~43997443:+
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000214533.3	KRT18P33	-3.51	0.000497	0.0304	-0.2	-0.16	Sum eosinophil basophil counts;	chr2:65438139	chr2:65666695~65667737:+
THCA	cis	rs7916697	0.626	rs3858145	ENSG00000233590.1	RP11-153K11.3	-3.51	0.000497	0.0304	-0.2	-0.16	Optic disc area;	chr10:68252081	chr10:68233251~68242379:-
THCA	cis	rs11673344	0.523	rs2891766	ENSG00000267260.1	CTD-2162K18.4	-3.51	0.000497	0.0304	-0.19	-0.16	Obesity-related traits;	chr19:37037057	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs7245453	ENSG00000267260.1	CTD-2162K18.4	-3.51	0.000497	0.0304	-0.19	-0.16	Obesity-related traits;	chr19:37043447	chr19:36773153~36777078:+
THCA	cis	rs9676308	0.737	rs10404731	ENSG00000267549.4	AC006116.17	-3.51	0.000497	0.0304	-0.26	-0.16	Colorectal cancer;	chr19:57077152	chr19:56314703~56341287:+
THCA	cis	rs7615952	0.673	rs16834637	ENSG00000272840.1	RP11-379B18.6	3.51	0.000497	0.0304	0.29	0.16	Blood pressure (smoking interaction);	chr3:125886628	chr3:125774714~125797953:+
THCA	cis	rs1923539	1	rs1923539	ENSG00000272447.1	RP11-182L21.6	3.51	0.000497	0.0304	0.22	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935194	chr10:79825902~79827602:+
THCA	cis	rs6121246	0.697	rs8118150	ENSG00000230613.1	HM13-AS1	3.51	0.000497	0.0304	0.18	0.16	Mean corpuscular hemoglobin;	chr20:31848285	chr20:31567707~31573263:-
THCA	cis	rs4886920	0.563	rs8039011	ENSG00000260776.4	RP11-114H24.2	-3.51	0.000497	0.0304	-0.19	-0.16	Neuroticism;	chr15:77786103	chr15:77914217~77926846:-
THCA	cis	rs775227	0.574	rs79709668	ENSG00000243849.1	CFAP44-AS1	3.51	0.000497	0.0304	0.29	0.16	Dental caries;	chr3:113442418	chr3:113403991~113433992:+
THCA	cis	rs1729951	0.546	rs12054219	ENSG00000239213.4	NCK1-AS1	3.51	0.000497	0.0304	0.14	0.16	Neuroticism;	chr3:136958630	chr3:136841726~136862054:-
THCA	cis	rs8042680	0.784	rs8028856	ENSG00000258725.1	PRC1-AS1	-3.51	0.000497	0.0304	-0.21	-0.16	Type 2 diabetes;	chr15:90987590	chr15:90966345~90988624:+
THCA	cis	rs4218	0.531	rs1374156	ENSG00000259732.1	RP11-59H7.3	-3.51	0.000497	0.0304	-0.21	-0.16	Social communication problems;	chr15:59046746	chr15:59121034~59133250:+
THCA	cis	rs658349	1	rs658349	ENSG00000251332.1	RP11-177C12.4	3.51	0.000497	0.0304	0.19	0.16	Lymphocyte counts;	chr4:38135732	chr4:37995494~37996203:-
THCA	cis	rs2014572	1	rs2014572	ENSG00000276449.1	AC004076.5	3.51	0.000497	0.0304	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57248650	chr19:57449689~57453011:+
THCA	cis	rs7246967	0.611	rs8102927	ENSG00000236312.3	RPL34P34	-3.51	0.000497	0.0304	-0.22	-0.16	Bronchopulmonary dysplasia;	chr19:22696554	chr19:22368599~22368952:-
THCA	cis	rs12931792	0.875	rs58175255	ENSG00000274653.1	RP11-347C12.11	-3.51	0.000497	0.0304	-0.15	-0.16	Tonsillectomy;	chr16:30143969	chr16:30359825~30360336:+
THCA	cis	rs59901009	0.517	rs2403261	ENSG00000246273.5	SBF2-AS1	-3.51	0.000497	0.0304	-0.21	-0.16	Hematocrit;Hemoglobin concentration;	chr11:10000244	chr11:9758292~9811319:+
THCA	cis	rs9840812	0.577	rs503973	ENSG00000273486.1	RP11-731C17.2	-3.51	0.000497	0.0304	-0.16	-0.16	Fibrinogen levels;	chr3:136340695	chr3:136837338~136839021:-
THCA	cis	rs9457247	0.565	rs12193698	ENSG00000235272.1	FAM103A2P	3.51	0.000497	0.0304	0.22	0.16	Crohn's disease;	chr6:167098585	chr6:166586124~166586477:-
THCA	cis	rs9863	0.931	rs6488914	ENSG00000270028.1	RP11-380L11.4	-3.51	0.000497	0.0304	-0.17	-0.16	White blood cell count;	chr12:123963294	chr12:123925461~123926083:-
THCA	cis	rs1125355	0.69	rs17810428	ENSG00000243792.1	OR7E89P	-3.51	0.000497	0.0304	-0.24	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158804939	chr2:158853755~158854576:+
THCA	cis	rs6598541	0.963	rs2137683	ENSG00000278090.1	RP11-6O2.2	-3.51	0.000497	0.0304	-0.14	-0.16	Urate levels;	chr15:98746409	chr15:99028538~99031053:+
THCA	cis	rs711244	0.532	rs2540998	ENSG00000279519.1	RP11-288C18.1	3.51	0.000497	0.0304	0.13	0.16	Mean platelet volume;	chr2:37027872	chr2:36839922~36842539:-
THCA	cis	rs10844706	0.699	rs10844620	ENSG00000257027.1	RP11-705C15.3	3.51	0.000497	0.0304	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9729910	chr12:9658567~9662085:+
THCA	cis	rs763121	0.853	rs138713	ENSG00000228274.3	RP3-508I15.9	-3.51	0.000497	0.0304	-0.18	-0.16	Menopause (age at onset);	chr22:38746610	chr22:38667585~38681820:-
THCA	cis	rs9348440	0.73	rs9465841	ENSG00000280989.1	LINC00581	3.51	0.000497	0.0304	0.25	0.16	Glycemic traits;	chr6:20629477	chr6:21486061~21511895:-
THCA	cis	rs9863	0.896	rs77112003	ENSG00000269938.1	RP11-214K3.20	-3.51	0.000497	0.0304	-0.18	-0.16	White blood cell count;	chr12:124002996	chr12:123968023~123968579:-
THCA	cis	rs11089937	0.597	rs4821774	ENSG00000215456.5	BCRP4	3.51	0.000497	0.0304	0.2	0.16	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22630061~22636153:+
THCA	cis	rs8028182	0.636	rs4886699	ENSG00000275645.1	RP11-817O13.9	3.51	0.000497	0.0304	0.16	0.16	Sudden cardiac arrest;	chr15:75399962	chr15:75346744~75347161:-
THCA	cis	rs972578	1	rs972577	ENSG00000274717.1	RP1-47A17.1	-3.51	0.000497	0.0304	-0.16	-0.16	Mean platelet volume;	chr22:42991639	chr22:42791814~42794313:-
THCA	cis	rs2836950	0.565	rs2836930	ENSG00000235701.1	PCBP2P1	-3.51	0.000497	0.0304	-0.17	-0.16	Menarche (age at onset);	chr21:39173730	chr21:39171130~39172106:-
THCA	cis	rs2836950	0.565	rs2836931	ENSG00000235701.1	PCBP2P1	-3.51	0.000497	0.0304	-0.17	-0.16	Menarche (age at onset);	chr21:39174643	chr21:39171130~39172106:-
THCA	cis	rs5758659	0.967	rs5758670	ENSG00000205702.9	CYP2D7	3.51	0.000497	0.0304	0.12	0.16	Cognitive function;	chr22:42240681	chr22:42140203~42144577:-
THCA	cis	rs13002735	1	rs13002735	ENSG00000224376.1	AC017104.6	3.51	0.000497	0.0304	0.2	0.16	Resting heart rate;	chr2:231404173	chr2:231388976~231394991:+
THCA	cis	rs16975963	0.843	rs7254809	ENSG00000276846.1	CTD-3220F14.3	-3.51	0.000497	0.0304	-0.15	-0.16	Longevity;	chr19:37875055	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.843	rs11672163	ENSG00000276846.1	CTD-3220F14.3	-3.51	0.000497	0.0304	-0.15	-0.16	Longevity;	chr19:37883216	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.843	rs73027451	ENSG00000276846.1	CTD-3220F14.3	-3.51	0.000497	0.0304	-0.15	-0.16	Longevity;	chr19:37885026	chr19:37314868~37315620:-
THCA	cis	rs340849	0.617	rs1991879	ENSG00000274895.1	RP11-478J18.2	-3.51	0.000498	0.0304	-0.14	-0.16	Alzheimer's disease;	chr1:213928698	chr1:213983793~213986419:-
THCA	cis	rs10492096	1	rs11064210	ENSG00000276718.1	RP1-102E24.10	-3.51	0.000498	0.0304	-0.19	-0.16	Hip geometry;	chr12:6467555	chr12:6466537~6467135:+
THCA	cis	rs11785400	1	rs4266629	ENSG00000177335.9	C8orf31	3.51	0.000498	0.0304	0.18	0.16	Schizophrenia;	chr8:142655246	chr8:143039209~143059942:+
THCA	cis	rs12142240	1	rs12146051	ENSG00000232022.5	FAAHP1	-3.51	0.000498	0.0304	-0.19	-0.16	Menopause (age at onset);	chr1:46277280	chr1:46432129~46445521:+
THCA	cis	rs700651	0.675	rs1371665	ENSG00000231621.1	AC013264.2	-3.51	0.000498	0.0304	-0.17	-0.16	Intracranial aneurysm;	chr2:198077844	chr2:197197991~197199273:+
THCA	cis	rs9584850	0.834	rs9584855	ENSG00000231194.1	FARP1-AS1	-3.51	0.000498	0.0304	-0.2	-0.16	Neuroticism;	chr13:98466746	chr13:98435405~98435840:-
THCA	cis	rs875971	0.862	rs11765791	ENSG00000223473.2	GS1-124K5.3	3.51	0.000498	0.0304	0.11	0.16	Aortic root size;	chr7:66471587	chr7:66491049~66493566:-
THCA	cis	rs7671266	0.589	rs10938772	ENSG00000261490.1	RP11-448G15.3	-3.51	0.000498	0.0304	-0.13	-0.16	Cardiovascular disease risk factors;	chr4:10373704	chr4:10068089~10073019:-
THCA	cis	rs7474896	0.583	rs1735621	ENSG00000276805.1	RP11-291L22.6	-3.51	0.000498	0.0304	-0.21	-0.16	Obesity (extreme);	chr10:37878795	chr10:38451030~38451785:+
THCA	cis	rs6546886	0.869	rs6754218	ENSG00000235499.1	AC073046.25	3.51	0.000498	0.0304	0.16	0.16	Dialysis-related mortality;	chr2:74046113	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.912	rs71337722	ENSG00000235499.1	AC073046.25	3.51	0.000498	0.0304	0.16	0.16	Dialysis-related mortality;	chr2:74050800	chr2:73985132~73986343:+
THCA	cis	rs3770081	1	rs57083584	ENSG00000272564.1	RP11-548P2.2	-3.51	0.000498	0.0304	-0.34	-0.16	Facial emotion recognition (sad faces);	chr2:86056525	chr2:85904279~85904727:+
THCA	cis	rs4656958	0.93	rs6703062	ENSG00000233691.2	RP11-312J18.7	3.51	0.000498	0.0304	0.19	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160929453	chr1:160935537~160936126:+
THCA	cis	rs642858	0.784	rs592755	ENSG00000234147.1	RP3-460G2.2	3.51	0.000498	0.0304	0.2	0.16	Type 2 diabetes;	chr6:139916469	chr6:140845958~140852924:-
THCA	cis	rs6957923	0.935	rs13226524	ENSG00000234286.1	AC006026.13	-3.51	0.000498	0.0304	-0.21	-0.16	Height;	chr7:23442258	chr7:23680195~23680786:-
THCA	cis	rs2342371	0.539	rs35959625	ENSG00000243339.3	RN7SL738P	-3.51	0.000498	0.0304	-0.19	-0.16	Fat distribution (HIV);	chr3:196405070	chr3:196399911~196400207:+
THCA	cis	rs690037	0.809	rs690023	ENSG00000272529.1	RP11-415F23.4	3.51	0.000498	0.0304	0.14	0.16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16344847	chr3:16345126~16346440:+
THCA	cis	rs1552244	0.608	rs7615408	ENSG00000269982.1	RP11-1020A11.2	3.51	0.000498	0.0304	0.11	0.16	Alzheimer's disease;	chr3:9958502	chr3:9958717~9962539:+
THCA	cis	rs1832871	0.672	rs111782080	ENSG00000213078.3	RP5-933K21.2	-3.51	0.000498	0.0304	-0.24	-0.16	Height;	chr6:158344353	chr6:157365990~157366923:-
THCA	cis	rs2455799	1	rs2455802	ENSG00000270409.1	RP11-44D5.1	-3.51	0.000498	0.0305	-0.18	-0.16	Mean platelet volume;	chr3:15660789	chr3:15732252~15733470:+
THCA	cis	rs7824557	0.564	rs2572395	ENSG00000261451.1	RP11-981G7.1	-3.51	0.000498	0.0305	-0.2	-0.16	Retinal vascular caliber;	chr8:11377851	chr8:10433672~10438312:+
THCA	cis	rs4925386	0.802	rs6142735	ENSG00000275437.1	RP5-908M14.10	3.51	0.000498	0.0305	0.16	0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62402236~62405935:-
THCA	cis	rs9911578	1	rs2055779	ENSG00000224738.1	AC099850.1	3.51	0.000498	0.0305	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58953200	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs9915935	ENSG00000224738.1	AC099850.1	3.51	0.000498	0.0305	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58765687	chr17:59106598~59118267:+
THCA	cis	rs3013169	0.603	rs4710476	ENSG00000213309.3	RPL9P18	-3.51	0.000498	0.0305	-0.17	-0.16	Schizophrenia;	chr6:64251680	chr6:63615827~63616361:-
THCA	cis	rs7944735	0.517	rs74763661	ENSG00000200090.1	Y_RNA	3.51	0.000498	0.0305	0.15	0.16	Intraocular pressure;	chr11:48212220	chr11:47726894~47726992:-
THCA	cis	rs2243480	1	rs7778911	ENSG00000237310.1	GS1-124K5.4	-3.51	0.000498	0.0305	-0.19	-0.16	Diabetic kidney disease;	chr7:66229519	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1979823	ENSG00000237310.1	GS1-124K5.4	-3.51	0.000498	0.0305	-0.19	-0.16	Diabetic kidney disease;	chr7:66239626	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6964245	ENSG00000237310.1	GS1-124K5.4	-3.51	0.000498	0.0305	-0.19	-0.16	Diabetic kidney disease;	chr7:66253730	chr7:66493706~66495474:+
THCA	cis	rs3781264	0.595	rs10882424	ENSG00000273450.1	RP11-76P2.4	3.51	0.000498	0.0305	0.2	0.16	Esophageal cancer and gastric cancer;	chr10:94326321	chr10:94314907~94315327:-
THCA	cis	rs3781264	0.595	rs7096037	ENSG00000273450.1	RP11-76P2.4	3.51	0.000498	0.0305	0.2	0.16	Esophageal cancer and gastric cancer;	chr10:94329950	chr10:94314907~94315327:-
THCA	cis	rs3781264	0.595	rs11187876	ENSG00000273450.1	RP11-76P2.4	3.51	0.000498	0.0305	0.2	0.16	Esophageal cancer and gastric cancer;	chr10:94330382	chr10:94314907~94315327:-
THCA	cis	rs3781264	0.595	rs10882430	ENSG00000273450.1	RP11-76P2.4	3.51	0.000498	0.0305	0.2	0.16	Esophageal cancer and gastric cancer;	chr10:94330915	chr10:94314907~94315327:-
THCA	cis	rs34638657	0.827	rs3829548	ENSG00000261235.1	RP11-510J16.5	-3.51	0.000498	0.0305	-0.25	-0.16	Lung adenocarcinoma;	chr16:82172633	chr16:82044336~82139631:-
THCA	cis	rs10186029	0.708	rs4672673	ENSG00000270659.1	RP11-105N14.1	-3.51	0.000498	0.0305	-0.13	-0.16	Systemic sclerosis;	chr2:213116739	chr2:213152970~213153659:+
THCA	cis	rs17181170	0.846	rs6797598	ENSG00000239572.1	RP11-451B8.1	-3.51	0.000498	0.0305	-0.19	-0.16	Prostate cancer;	chr3:87133454	chr3:87731402~87793629:-
THCA	cis	rs17181170	0.819	rs17023969	ENSG00000239572.1	RP11-451B8.1	-3.51	0.000498	0.0305	-0.19	-0.16	Prostate cancer;	chr3:87139874	chr3:87731402~87793629:-
THCA	cis	rs4272720	0.562	rs2725184	ENSG00000234736.4	FAM170B-AS1	-3.51	0.000498	0.0305	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49141727	chr10:49121839~49151547:+
THCA	cis	rs7809950	1	rs7809950	ENSG00000272072.1	CTA-363E19.2	-3.51	0.000498	0.0305	-0.16	-0.16	Coronary artery disease;	chr7:107597362	chr7:107192559~107193300:-
THCA	cis	rs4927850	0.521	rs4927679	ENSG00000226155.1	AC124944.3	3.51	0.000498	0.0305	0.17	0.16	Pancreatic cancer;	chr3:195931489	chr3:195912049~195913986:+
THCA	cis	rs6928977	0.66	rs12203875	ENSG00000231028.7	LINC00271	3.51	0.000498	0.0305	0.13	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135539276	chr6:135497801~135716055:+
THCA	cis	rs9549260	0.709	rs2721072	ENSG00000275149.1	RP11-427J23.1	-3.51	0.000498	0.0305	-0.21	-0.16	Red blood cell count;	chr13:40570782	chr13:40079106~40273509:-
THCA	cis	rs6840360	0.571	rs10007653	ENSG00000251611.1	RP11-610P16.1	-3.51	0.000498	0.0305	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151602903	chr4:151407551~151408835:-
THCA	cis	rs78153629	0.92	rs79626713	ENSG00000259330.1	INAFM2	-3.51	0.000498	0.0305	-0.2	-0.16	Heschl's gyrus morphology;	chr15:40430311	chr15:40325216~40326715:+
THCA	cis	rs6473252	0.839	rs7840329	ENSG00000254162.1	RP11-48B3.3	-3.51	0.000498	0.0305	-0.14	-0.16	Breast cancer;	chr8:80890620	chr8:80535006~80539135:-
THCA	cis	rs6473252	0.839	rs2028815	ENSG00000254162.1	RP11-48B3.3	-3.51	0.000498	0.0305	-0.14	-0.16	Breast cancer;	chr8:80891373	chr8:80535006~80539135:-
THCA	cis	rs6473252	0.839	rs4739759	ENSG00000254162.1	RP11-48B3.3	-3.51	0.000498	0.0305	-0.14	-0.16	Breast cancer;	chr8:80895084	chr8:80535006~80539135:-
THCA	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	3.51	0.000498	0.0305	0.18	0.16	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
THCA	cis	rs13064411	0.866	rs35278902	ENSG00000243849.1	CFAP44-AS1	3.51	0.000498	0.0305	0.29	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113520174	chr3:113403991~113433992:+
THCA	cis	rs11751172	0.651	rs1041334	ENSG00000271857.1	RP1-244F24.1	3.51	0.000498	0.0305	0.1	0.16	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45565552	chr6:45421079~45422005:-
THCA	cis	rs17095355	0.818	rs7090570	ENSG00000203876.8	ADD3-AS1	-3.51	0.000498	0.0305	-0.18	-0.16	Biliary atresia;	chr10:110013040	chr10:109940104~110008381:-
THCA	cis	rs2790216	0.901	rs2653506	ENSG00000183055.5	FAM133CP	3.51	0.000499	0.0305	0.25	0.16	Inflammatory bowel disease;	chr10:58206101	chr10:58715554~58716257:+
THCA	cis	rs4857855	0.673	rs4857854	ENSG00000239405.1	TMED10P2	3.51	0.000499	0.0305	0.21	0.16	Eosinophil counts;	chr3:128528996	chr3:128538020~128538631:+
THCA	cis	rs72765298	0.708	rs56346023	ENSG00000235332.2	RP11-366O20.5	3.51	0.000499	0.0305	0.29	0.16	Pulse pressure;	chr9:125195203	chr9:125194649~125195821:-
THCA	cis	rs10858047	0.941	rs72696094	ENSG00000231128.4	RP5-1073O3.2	3.51	0.000499	0.0305	0.23	0.16	Autism;	chr1:114524608	chr1:113812379~113829171:+
THCA	cis	rs7439493	0.874	rs9995011	ENSG00000247950.5	SEC24B-AS1	-3.51	0.000499	0.0305	-0.1	-0.16	Blood protein levels;	chr4:109731578	chr4:109347475~109433817:-
THCA	cis	rs9596863	0.898	rs7328896	ENSG00000136149.6	RPL13AP25	-3.51	0.000499	0.0305	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53760071	chr13:54440704~54441315:-
THCA	cis	rs3749237	0.595	rs1464568	ENSG00000224424.7	PRKAR2A-AS1	3.51	0.000499	0.0305	0.13	0.16	Resting heart rate;	chr3:49420833	chr3:48847572~48851981:+
THCA	cis	rs11098499	0.913	rs13126596	ENSG00000249244.1	RP11-548H18.2	3.51	0.000499	0.0305	0.18	0.16	Corneal astigmatism;	chr4:119219574	chr4:119391831~119395335:-
THCA	cis	rs7809950	0.678	rs2301801	ENSG00000272072.1	CTA-363E19.2	3.51	0.000499	0.0305	0.17	0.16	Coronary artery disease;	chr7:107230301	chr7:107192559~107193300:-
THCA	cis	rs7028939	0.892	rs12379327	ENSG00000255145.2	STX17-AS1	-3.51	0.000499	0.0305	-0.24	-0.16	Preeclampsia;	chr9:100162583	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs73507832	ENSG00000255145.2	STX17-AS1	-3.51	0.000499	0.0305	-0.24	-0.16	Preeclampsia;	chr9:100164569	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10819729	ENSG00000255145.2	STX17-AS1	-3.51	0.000499	0.0305	-0.24	-0.16	Preeclampsia;	chr9:100167173	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10819730	ENSG00000255145.2	STX17-AS1	-3.51	0.000499	0.0305	-0.24	-0.16	Preeclampsia;	chr9:100171654	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10988993	ENSG00000255145.2	STX17-AS1	-3.51	0.000499	0.0305	-0.24	-0.16	Preeclampsia;	chr9:100174223	chr9:99886322~99906601:-
THCA	cis	rs7914558	1	rs12780843	ENSG00000272912.1	RP11-724N1.1	-3.51	0.000499	0.0305	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:102914585~102915404:+
THCA	cis	rs13098911	0.54	rs71327007	ENSG00000226074.4	PRSS44	-3.51	0.000499	0.0305	-0.31	-0.16	Celiac disease;	chr3:46017757	chr3:46809359~46812558:-
THCA	cis	rs478304	0.651	rs11227279	ENSG00000214659.4	KRT8P26	3.51	0.000499	0.0305	0.15	0.16	Acne (severe);	chr11:65727740	chr11:65726939~65728214:+
THCA	cis	rs9878978	1	rs11711499	ENSG00000227588.2	CNTN4-AS2	3.51	0.000499	0.0305	0.19	0.16	Blood pressure (smoking interaction);	chr3:2430661	chr3:2110409~2144241:-
THCA	cis	rs35123781	0.696	rs4912756	ENSG00000253404.1	AC034243.1	-3.51	0.000499	0.0305	-0.21	-0.16	Schizophrenia;	chr5:139691195	chr5:138744434~138753309:-
THCA	cis	rs4648045	0.647	rs72696119	ENSG00000246560.2	RP11-10L12.4	3.51	0.000499	0.0305	0.19	0.16	Lymphocyte percentage of white cells;	chr4:102501347	chr4:102828055~102844075:+
THCA	cis	rs6494488	0.5	rs72744739	ENSG00000259635.1	AC100830.3	-3.51	0.000499	0.0305	-0.4	-0.16	Coronary artery disease;	chr15:64757727	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744741	ENSG00000259635.1	AC100830.3	-3.51	0.000499	0.0305	-0.4	-0.16	Coronary artery disease;	chr15:64758315	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744751	ENSG00000259635.1	AC100830.3	-3.51	0.000499	0.0305	-0.4	-0.16	Coronary artery disease;	chr15:64772458	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs77463022	ENSG00000259635.1	AC100830.3	-3.51	0.000499	0.0305	-0.4	-0.16	Coronary artery disease;	chr15:64772642	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744764	ENSG00000259635.1	AC100830.3	-3.51	0.000499	0.0305	-0.4	-0.16	Coronary artery disease;	chr15:64784688	chr15:64701248~64719602:+
THCA	cis	rs2235649	0.833	rs9927047	ENSG00000260541.1	LA16c-429E7.1	3.51	0.000499	0.0305	0.21	0.16	Blood metabolite levels;	chr16:1801926	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs9929262	ENSG00000260541.1	LA16c-429E7.1	3.51	0.000499	0.0305	0.21	0.16	Blood metabolite levels;	chr16:1801927	chr16:1841020~1843547:-
THCA	cis	rs786425	0.966	rs786422	ENSG00000278112.1	RP11-972P1.11	-3.51	0.000499	0.0305	-0.15	-0.16	Pubertal anthropometrics;	chr12:123599015	chr12:123519390~123519856:-
THCA	cis	rs3748656	1	rs6679	ENSG00000273483.1	RP4-671G15.2	3.51	0.000499	0.0305	0.18	0.16	Hip circumference adjusted for BMI;	chr1:112700426	chr1:112517799~112518441:-
THCA	cis	rs34779708	0.931	rs72789609	ENSG00000233200.1	RP11-324I22.2	3.51	0.000499	0.0305	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs7908573	ENSG00000233200.1	RP11-324I22.2	3.51	0.000499	0.0305	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35219894~35230598:-
THCA	cis	rs7818688	1	rs28496357	ENSG00000253528.2	RP11-347C18.4	-3.51	0.000499	0.0305	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95018283	chr8:94974573~94974853:-
THCA	cis	rs4713118	0.55	rs9368527	ENSG00000280107.1	AL022393.9	-3.51	0.000499	0.0305	-0.16	-0.16	Parkinson's disease;	chr6:27711666	chr6:28170845~28172521:+
THCA	cis	rs75828804	1	rs75258590	ENSG00000260922.1	RP11-538I12.3	-3.51	0.000499	0.0305	-0.35	-0.16	Intraocular pressure;	chr16:77561203	chr16:77234877~77290934:+
THCA	cis	rs2911280	0.536	rs75217481	ENSG00000278985.1	RP11-303E16.9	-3.51	0.000499	0.0305	-0.31	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81542726	chr16:80982319~80984094:-
THCA	cis	rs2911280	0.764	rs13333615	ENSG00000278985.1	RP11-303E16.9	-3.51	0.000499	0.0305	-0.31	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81544499	chr16:80982319~80984094:-
THCA	cis	rs7737355	0.945	rs245801	ENSG00000237714.1	P4HA2-AS1	-3.51	0.000499	0.0305	-0.23	-0.16	Life satisfaction;	chr5:131331262	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.526	rs4705908	ENSG00000263597.1	MIR3936	3.51	0.000499	0.0305	0.16	0.16	Blood metabolite levels;	chr5:132011827	chr5:132365490~132365599:-
THCA	cis	rs2842346	0.568	rs2842331	ENSG00000258623.1	CTD-2325P2.3	-3.51	0.000499	0.0305	-0.21	-0.16	Breast cancer;	chr14:68543973	chr14:68683411~68685565:-
THCA	cis	rs11658311	0.85	rs9910747	ENSG00000266803.1	RP1-77H15.1	3.51	0.000499	0.0305	0.3	0.16	Obsessive-compulsive symptoms;	chr17:17530645	chr17:16557985~16559269:-
THCA	cis	rs7897654	0.571	rs12764049	ENSG00000213061.2	PFN1P11	3.51	0.000499	0.0305	0.21	0.16	Schizophrenia;	chr10:102875199	chr10:102838011~102845473:-
THCA	cis	rs7010267	0.902	rs4242592	ENSG00000254278.1	RP11-278I4.2	-3.51	0.000499	0.0305	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118956736	chr8:119062942~119068782:-
THCA	cis	rs7010267	0.902	rs7006553	ENSG00000254278.1	RP11-278I4.2	-3.51	0.000499	0.0305	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118958540	chr8:119062942~119068782:-
THCA	cis	rs4761638	0.954	rs6538521	ENSG00000241556.1	RP11-490G8.1	-3.51	0.000499	0.0305	-0.17	-0.16	Insulin disposition index;	chr12:94610045	chr12:95467397~95467861:-
THCA	cis	rs11168618	0.846	rs7974213	ENSG00000257763.1	OR5BK1P	-3.51	0.000499	0.0305	-0.14	-0.16	Adiponectin levels;	chr12:48487709	chr12:48355792~48356614:-
THCA	cis	rs9487094	0.644	rs9320288	ENSG00000223537.2	RP5-919F19.5	-3.51	0.000499	0.0305	-0.16	-0.16	Height;	chr6:109446727	chr6:109487906~109506800:+
THCA	cis	rs12681366	0.636	rs1580498	ENSG00000261437.1	RP11-22C11.2	-3.51	0.000499	0.0305	-0.15	-0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94413326	chr8:94637285~94639467:-
THCA	cis	rs7474896	0.559	rs2738185	ENSG00000272983.1	RP11-508N22.12	3.51	0.000499	0.0305	0.16	0.16	Obesity (extreme);	chr10:37958808	chr10:38137337~38144399:+
THCA	cis	rs7819412	0.765	rs7000132	ENSG00000255046.1	RP11-297N6.4	3.51	0.000499	0.0305	0.17	0.16	Triglycerides;	chr8:11173426	chr8:11797928~11802568:-
THCA	cis	rs4841134	0.704	rs2169386	ENSG00000254153.1	CTA-398F10.2	3.51	0.000499	0.0305	0.16	0.16	Age-related disease endophenotypes;	chr8:9340770	chr8:8456909~8461337:-
THCA	cis	rs1075265	0.87	rs10207537	ENSG00000235937.1	AC008280.1	3.51	5e-04	0.0305	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54029552~54030682:-
THCA	cis	rs7713065	0.84	rs59041913	ENSG00000263597.1	MIR3936	-3.51	5e-04	0.0305	-0.2	-0.16	Lung function (FEV1/FVC);	chr5:132452443	chr5:132365490~132365599:-
THCA	cis	rs7713065	0.84	rs10069798	ENSG00000263597.1	MIR3936	-3.51	5e-04	0.0305	-0.2	-0.16	Lung function (FEV1/FVC);	chr5:132452729	chr5:132365490~132365599:-
THCA	cis	rs4915077	1	rs10494075	ENSG00000226822.1	RP11-356N1.2	3.51	5e-04	0.0305	0.31	0.16	Hypothyroidism;	chr1:107787734	chr1:108071482~108074519:+
THCA	cis	rs8187707	1	rs17216282	ENSG00000233690.1	EBAG9P1	3.51	5e-04	0.0305	0.31	0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99845793	chr10:99697407~99697949:-
THCA	cis	rs4845570	1	rs6659705	ENSG00000268288.1	RP11-98D18.16	-3.51	5e-04	0.0305	-0.24	-0.16	Coronary artery disease;	chr1:151797274	chr1:151766486~151767000:-
THCA	cis	rs9309711	0.922	rs11679058	ENSG00000271868.1	RP11-1293J14.1	-3.51	5e-04	0.0305	-0.23	-0.16	Neurofibrillary tangles;	chr2:3480042	chr2:3496956~3497428:+
THCA	cis	rs1577917	1	rs12204015	ENSG00000220563.1	PKMP3	-3.51	5e-04	0.0305	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85888616	chr6:85659892~85660606:-
THCA	cis	rs860295	0.702	rs2048431	ENSG00000236675.1	MTX1P1	-3.51	5e-04	0.0305	-0.16	-0.16	Body mass index;	chr1:155648839	chr1:155230975~155234325:+
THCA	cis	rs2952156	0.684	rs931992	ENSG00000214546.3	AC087491.2	-3.51	5e-04	0.0305	-0.19	-0.16	Asthma;	chr17:39665182	chr17:39619613~39622513:+
THCA	cis	rs11190604	1	rs79831012	ENSG00000273030.1	RP11-285F16.1	3.51	5e-04	0.0305	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100477302	chr10:100412934~100413421:+
THCA	cis	rs9652601	0.691	rs11861236	ENSG00000263033.2	RP11-396B14.2	-3.51	5e-04	0.0305	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11089769	chr16:11196177~11224969:+
THCA	cis	rs2251260	0.685	rs2246609	ENSG00000250548.5	RP11-47I22.2	3.51	5e-04	0.0306	0.24	0.16	Yeast infection;	chr14:61541154	chr14:61556313~61570653:-
THCA	cis	rs2446066	0.659	rs2272002	ENSG00000257379.1	RP11-793H13.8	3.51	5e-04	0.0306	0.27	0.16	Red blood cell count;	chr12:53424132	chr12:53441741~53467528:+
THCA	cis	rs7216064	0.953	rs4791300	ENSG00000278740.1	RP11-147L13.14	3.51	5e-04	0.0306	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934656	chr17:68188547~68189165:+
THCA	cis	rs7520050	0.751	rs2991975	ENSG00000281912.1	LINC01144	3.51	5e-04	0.0306	0.11	0.16	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45303910~45305619:+
THCA	cis	rs913655	1	rs2495824	ENSG00000240291.1	RP11-499P20.2	3.51	5e-04	0.0306	0.12	0.16	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18798521	chr10:18513115~18545651:-
THCA	cis	rs913655	1	rs2493627	ENSG00000240291.1	RP11-499P20.2	3.51	5e-04	0.0306	0.12	0.16	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18799232	chr10:18513115~18545651:-
THCA	cis	rs6762	0.748	rs7928935	ENSG00000255284.1	AP006621.5	3.51	5e-04	0.0306	0.11	0.16	Mean platelet volume;	chr11:839127	chr11:777578~784297:+
THCA	cis	rs763121	0.819	rs5750629	ENSG00000225450.1	RP3-508I15.14	-3.51	5e-04	0.0306	-0.12	-0.16	Menopause (age at onset);	chr22:38589060	chr22:38739003~38749041:+
THCA	cis	rs4907240	1	rs4907240	ENSG00000230606.9	AC159540.1	3.51	5e-04	0.0306	0.18	0.16	Event-related brain oscillations;	chr2:96562302	chr2:97416165~97433527:-
THCA	cis	rs875971	0.862	rs6971059	ENSG00000223473.2	GS1-124K5.3	-3.51	5e-04	0.0306	-0.11	-0.16	Aortic root size;	chr7:66602045	chr7:66491049~66493566:-
THCA	cis	rs875971	0.825	rs7384021	ENSG00000223473.2	GS1-124K5.3	-3.51	5e-04	0.0306	-0.11	-0.16	Aortic root size;	chr7:66612917	chr7:66491049~66493566:-
THCA	cis	rs875971	0.825	rs66981195	ENSG00000223473.2	GS1-124K5.3	-3.51	5e-04	0.0306	-0.11	-0.16	Aortic root size;	chr7:66614048	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs3926380	ENSG00000223473.2	GS1-124K5.3	-3.51	5e-04	0.0306	-0.11	-0.16	Aortic root size;	chr7:66615658	chr7:66491049~66493566:-
THCA	cis	rs875971	0.825	rs1860472	ENSG00000223473.2	GS1-124K5.3	-3.51	5e-04	0.0306	-0.11	-0.16	Aortic root size;	chr7:66617736	chr7:66491049~66493566:-
THCA	cis	rs7192750	0.562	rs9302631	ENSG00000260886.1	TAT-AS1	3.51	5e-04	0.0306	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71909511	chr16:71565789~71578187:+
THCA	cis	rs1930961	1	rs59226697	ENSG00000272942.1	CTA-246H3.12	-3.51	5e-04	0.0306	-0.36	-0.16	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25434324~25435070:-
THCA	cis	rs2562456	0.833	rs62109223	ENSG00000213976.4	CTD-2561J22.2	-3.51	5e-04	0.0306	-0.2	-0.16	Pain;	chr19:21349591	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs62109225	ENSG00000213976.4	CTD-2561J22.2	-3.51	5e-04	0.0306	-0.2	-0.16	Pain;	chr19:21353861	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.754	rs62109226	ENSG00000213976.4	CTD-2561J22.2	-3.51	5e-04	0.0306	-0.2	-0.16	Pain;	chr19:21354111	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.754	rs62109227	ENSG00000213976.4	CTD-2561J22.2	-3.51	5e-04	0.0306	-0.2	-0.16	Pain;	chr19:21354128	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.754	rs62109228	ENSG00000213976.4	CTD-2561J22.2	-3.51	5e-04	0.0306	-0.2	-0.16	Pain;	chr19:21354129	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs8102783	ENSG00000213976.4	CTD-2561J22.2	-3.51	5e-04	0.0306	-0.2	-0.16	Pain;	chr19:21355751	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs2061916	ENSG00000213976.4	CTD-2561J22.2	-3.51	5e-04	0.0306	-0.2	-0.16	Pain;	chr19:21358906	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs4359573	ENSG00000213976.4	CTD-2561J22.2	-3.51	5e-04	0.0306	-0.2	-0.16	Pain;	chr19:21359494	chr19:21382865~21387177:+
THCA	cis	rs2635047	0.935	rs2576031	ENSG00000280212.1	RP11-49K24.3	-3.51	5e-04	0.0306	-0.15	-0.16	Educational attainment;	chr18:47131775	chr18:47076117~47076594:+
THCA	cis	rs962856	0.673	rs11696003	ENSG00000236780.4	AC078941.1	3.51	5e-04	0.0306	0.19	0.16	Pancreatic cancer;	chr2:67294260	chr2:67123357~67215319:-
THCA	cis	rs1850744	0.536	rs114344194	ENSG00000163612.10	FAM86KP	3.51	5e-04	0.0306	0.38	0.16	Economic and political preferences;	chr4:9605096	chr4:9153296~9165451:+
THCA	cis	rs5850	0.602	rs1005786	ENSG00000226816.2	AC005082.12	3.51	5e-04	0.0306	0.22	0.16	Blood protein levels;	chr7:23106218	chr7:23206013~23208045:+
THCA	cis	rs1556032	0.542	rs10124571	ENSG00000225472.1	RP11-120J1.1	-3.51	5e-04	0.0306	-0.15	-0.16	AIDS;	chr9:14442492	chr9:14317085~14357908:+
THCA	cis	rs11124272	0.763	rs558803	ENSG00000276517.1	AL133243.2	-3.51	5e-04	0.0306	-0.15	-0.16	Interleukin-18 levels;	chr2:31619731	chr2:32526504~32529507:+
THCA	cis	rs9549260	0.785	rs6563842	ENSG00000275149.1	RP11-427J23.1	-3.5	5e-04	0.0306	-0.21	-0.16	Red blood cell count;	chr13:40670160	chr13:40079106~40273509:-
THCA	cis	rs17111396	0.826	rs10138781	ENSG00000271656.1	RP11-114N19.5	-3.5	5e-04	0.0306	-0.2	-0.16	Uric acid levels;	chr14:81053518	chr14:81003325~81003645:-
THCA	cis	rs2836950	0.545	rs1888489	ENSG00000235701.1	PCBP2P1	-3.5	5e-04	0.0306	-0.17	-0.16	Menarche (age at onset);	chr21:39161238	chr21:39171130~39172106:-
THCA	cis	rs6929812	0.729	rs6456784	ENSG00000271755.1	RP1-153G14.4	3.5	5e-04	0.0306	0.18	0.16	Neuroticism (multi-trait analysis);	chr6:27422242	chr6:27404010~27406964:-
THCA	cis	rs4372836	0.504	rs6547881	ENSG00000273233.1	RP11-713D19.1	-3.5	5e-04	0.0306	-0.19	-0.16	Body mass index;	chr2:28809880	chr2:28810281~28810706:-
THCA	cis	rs146009840	1	rs146009840	ENSG00000261762.1	RP11-650L12.2	-3.5	5e-04	0.0306	-0.21	-0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78613835	chr15:78589123~78591276:-
THCA	cis	rs524281	0.637	rs7126075	ENSG00000255038.1	RP11-1167A19.2	-3.5	5e-04	0.0306	-0.19	-0.16	Electroencephalogram traits;	chr11:66173092	chr11:66067277~66069619:-
THCA	cis	rs524281	0.861	rs2177054	ENSG00000255038.1	RP11-1167A19.2	-3.5	5e-04	0.0306	-0.19	-0.16	Electroencephalogram traits;	chr11:66177141	chr11:66067277~66069619:-
THCA	cis	rs301901	0.796	rs4869527	ENSG00000250155.1	CTD-2353F22.1	3.5	5e-04	0.0306	0.16	0.16	Height;	chr5:37533964	chr5:36666214~36725195:-
THCA	cis	rs17680741	0.697	rs12264252	ENSG00000242600.5	MBL1P	3.5	5e-04	0.0306	0.17	0.16	Coronary artery disease;	chr10:80517585	chr10:79904898~79950336:+
THCA	cis	rs889398	0.56	rs8057620	ENSG00000226232.7	RP11-419C5.2	-3.5	5e-04	0.0306	-0.16	-0.16	Body mass index;	chr16:69850716	chr16:69976388~69996188:-
THCA	cis	rs11158198	0.559	rs12881190	ENSG00000279636.2	LINC00216	-3.5	5e-04	0.0306	-0.16	-0.16	Dementia and core Alzheimer's disease neuropathologic changes;	chr14:58140566	chr14:58288033~58289158:+
THCA	cis	rs9392556	0.829	rs853417	ENSG00000230648.1	RP3-406P24.3	3.5	0.000501	0.0306	0.2	0.16	Blood metabolite levels;	chr6:4112889	chr6:4018843~4021215:-
THCA	cis	rs9392556	0.829	rs620484	ENSG00000230648.1	RP3-406P24.3	3.5	0.000501	0.0306	0.2	0.16	Blood metabolite levels;	chr6:4113977	chr6:4018843~4021215:-
THCA	cis	rs9392556	0.829	rs7166	ENSG00000230648.1	RP3-406P24.3	3.5	0.000501	0.0306	0.2	0.16	Blood metabolite levels;	chr6:4116028	chr6:4018843~4021215:-
THCA	cis	rs9392556	0.829	rs2783073	ENSG00000230648.1	RP3-406P24.3	3.5	0.000501	0.0306	0.2	0.16	Blood metabolite levels;	chr6:4118440	chr6:4018843~4021215:-
THCA	cis	rs721048	0.85	rs62180324	ENSG00000242412.1	DBIL5P2	-3.5	0.000501	0.0306	-0.22	-0.16	Prostate cancer;	chr2:63189471	chr2:63117851~63119542:-
THCA	cis	rs656900	0.647	rs898436	ENSG00000261229.4	MTHFS	3.5	0.000501	0.0306	0.16	0.16	Cerebrospinal P-tau181p levels;	chr15:79824790	chr15:79843547~79897285:-
THCA	cis	rs9488822	0.676	rs7774952	ENSG00000237021.2	RP3-486I3.7	3.5	0.000501	0.0306	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116059746	chr6:116254207~116256743:+
THCA	cis	rs4218	0.724	rs35168204	ENSG00000277144.1	RP11-59H7.4	-3.5	0.000501	0.0306	-0.23	-0.16	Social communication problems;	chr15:59121354	chr15:59115547~59116089:-
THCA	cis	rs7577696	0.515	rs2300699	ENSG00000276517.1	AL133243.2	-3.5	0.000501	0.0306	-0.15	-0.16	Inflammatory biomarkers;	chr2:31561897	chr2:32526504~32529507:+
THCA	cis	rs1055129	0.655	rs3744006	ENSG00000267801.1	RP11-552F3.9	3.5	0.000501	0.0306	0.18	0.16	White matter hyperintensity burden;	chr17:75842735	chr17:75876372~75879546:+
THCA	cis	rs394563	0.601	rs432582	ENSG00000231760.4	RP11-350J20.5	3.5	0.000501	0.0306	0.22	0.16	Dupuytren's disease;	chr6:149473007	chr6:149796151~149826294:-
THCA	cis	rs7264396	0.635	rs6058375	ENSG00000088340.14	FER1L4	3.5	0.000501	0.0306	0.16	0.16	Total cholesterol levels;	chr20:35944075	chr20:35558737~35607562:-
THCA	cis	rs3737883	1	rs11579558	ENSG00000229652.1	RP11-435P24.2	3.5	0.000501	0.0306	0.17	0.16	Early onset atrial fibrillation;	chr1:203062910	chr1:203353365~203353651:-
THCA	cis	rs6687821	0.515	rs10127488	ENSG00000261737.1	RP4-612B15.3	3.5	0.000501	0.0306	0.24	0.16	Yeast infection;	chr1:87039907	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs6663434	ENSG00000261737.1	RP4-612B15.3	3.5	0.000501	0.0306	0.24	0.16	Yeast infection;	chr1:87042570	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs1573202	ENSG00000261737.1	RP4-612B15.3	3.5	0.000501	0.0306	0.24	0.16	Yeast infection;	chr1:87046037	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs4508067	ENSG00000261737.1	RP4-612B15.3	3.5	0.000501	0.0306	0.24	0.16	Yeast infection;	chr1:87048787	chr1:86703502~86704462:-
THCA	cis	rs34217772	0.83	rs72686548	ENSG00000258636.1	CTD-2298J14.2	3.5	0.000501	0.0306	0.31	0.16	Myopia;	chr14:41742193	chr14:41587861~41604856:-
THCA	cis	rs1858037	0.867	rs1553675	ENSG00000252414.1	RNU6-100P	3.5	0.000501	0.0306	0.18	0.16	Rheumatoid arthritis;	chr2:65343173	chr2:64578892~64578997:+
THCA	cis	rs13098911	0.54	rs71327006	ENSG00000226074.4	PRSS44	-3.5	0.000501	0.0306	-0.31	-0.16	Celiac disease;	chr3:46017416	chr3:46809359~46812558:-
THCA	cis	rs14027	0.961	rs7017279	ENSG00000279347.1	RP11-85I17.2	3.5	0.000501	0.0306	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119838736~119840385:-
THCA	cis	rs2455799	0.573	rs2455834	ENSG00000270409.1	RP11-44D5.1	-3.5	0.000501	0.0306	-0.17	-0.16	Mean platelet volume;	chr3:15712134	chr3:15732252~15733470:+
THCA	cis	rs722599	0.715	rs8008785	ENSG00000279594.1	RP11-950C14.10	-3.5	0.000501	0.0306	-0.16	-0.16	IgG glycosylation;	chr14:74840897	chr14:75011269~75012851:-
THCA	cis	rs12621844	0.7	rs7609124	ENSG00000234690.5	AC073283.4	-3.5	0.000501	0.0306	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48110215	chr2:47192405~47345074:-
THCA	cis	rs4915077	0.686	rs17019843	ENSG00000226822.1	RP11-356N1.2	3.5	0.000501	0.0306	0.3	0.16	Hypothyroidism;	chr1:107730651	chr1:108071482~108074519:+
THCA	cis	rs6546886	0.912	rs13005103	ENSG00000235499.1	AC073046.25	3.5	0.000501	0.0306	0.15	0.16	Dialysis-related mortality;	chr2:74063606	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.912	rs13011961	ENSG00000235499.1	AC073046.25	3.5	0.000501	0.0306	0.15	0.16	Dialysis-related mortality;	chr2:74064234	chr2:73985132~73986343:+
THCA	cis	rs7824557	0.583	rs2263512	ENSG00000154316.13	TDH	3.5	0.000501	0.0306	0.12	0.16	Retinal vascular caliber;	chr8:11375910	chr8:11339637~11368452:+
THCA	cis	rs7824557	0.583	rs6601585	ENSG00000154316.13	TDH	3.5	0.000501	0.0306	0.12	0.16	Retinal vascular caliber;	chr8:11376150	chr8:11339637~11368452:+
THCA	cis	rs2235649	0.833	rs9929264	ENSG00000260541.1	LA16c-429E7.1	3.5	0.000501	0.0306	0.21	0.16	Blood metabolite levels;	chr16:1801933	chr16:1841020~1843547:-
THCA	cis	rs786425	0.509	rs56176939	ENSG00000278112.1	RP11-972P1.11	3.5	0.000501	0.0306	0.15	0.16	Pubertal anthropometrics;	chr12:123700282	chr12:123519390~123519856:-
THCA	cis	rs277939	0.967	rs277978	ENSG00000230847.4	RP11-195E2.1	-3.5	0.000501	0.0306	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71630732	chr5:71074225~71093193:-
THCA	cis	rs1009077	0.716	rs13147817	ENSG00000245958.5	RP11-33B1.1	3.5	0.000501	0.0306	0.26	0.16	Endometriosis;	chr4:119634500	chr4:119454791~119552025:+
THCA	cis	rs7824557	0.545	rs2572380	ENSG00000261451.1	RP11-981G7.1	-3.5	0.000501	0.0306	-0.2	-0.16	Retinal vascular caliber;	chr8:11379968	chr8:10433672~10438312:+
THCA	cis	rs10875746	0.903	rs11168414	ENSG00000275228.1	RP11-370I10.10	3.5	0.000501	0.0306	0.19	0.16	Longevity (90 years and older);	chr12:48118548	chr12:48327942~48328472:-
THCA	cis	rs9608946	1	rs9608941	ENSG00000279699.1	RP1-102K2.9	3.5	0.000501	0.0306	0.19	0.16	Red cell distribution width;	chr22:30490899	chr22:30275215~30276951:-
THCA	cis	rs206966	0.81	rs1179387	ENSG00000277283.1	RP1-267D11.6	3.5	0.000501	0.0306	0.16	0.16	Breast cancer;	chr12:120323108	chr12:120116907~120119000:+
THCA	cis	rs36093844	0.66	rs895256	ENSG00000279742.1	RP11-700A24.1	-3.5	0.000501	0.0306	-0.26	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85824166	chr11:85852557~85854943:-
THCA	cis	rs1433188	0.811	rs3847160	ENSG00000253582.1	RP11-649G15.2	-3.5	0.000501	0.0306	-0.19	-0.16	Subjective well-being;	chr8:107444303	chr8:106520474~106657548:-
THCA	cis	rs61160187	0.582	rs1382917	ENSG00000272308.1	RP11-231G3.1	-3.5	0.000501	0.0306	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.549	rs56031340	ENSG00000272308.1	RP11-231G3.1	-3.5	0.000501	0.0306	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60866457~60866935:-
THCA	cis	rs2830585	1	rs2830586	ENSG00000223563.1	AP001601.2	-3.5	0.000501	0.0306	-0.22	-0.16	Blood protein levels;	chr21:26933158	chr21:26889376~26939742:+
THCA	cis	rs875971	0.793	rs460678	ENSG00000230189.5	GS1-124K5.2	3.5	0.000501	0.0306	0.11	0.16	Aortic root size;	chr7:66062213	chr7:66409143~66490059:-
THCA	cis	rs763121	0.853	rs5750633	ENSG00000225450.1	RP3-508I15.14	-3.5	0.000501	0.0306	-0.12	-0.16	Menopause (age at onset);	chr22:38597462	chr22:38739003~38749041:+
THCA	cis	rs763121	0.853	rs5757166	ENSG00000225450.1	RP3-508I15.14	-3.5	0.000501	0.0306	-0.12	-0.16	Menopause (age at onset);	chr22:38599380	chr22:38739003~38749041:+
THCA	cis	rs12449000	1	rs12449000	ENSG00000274627.1	RP11-104N10.2	-3.5	0.000501	0.0306	-0.16	-0.16	Schizophrenia;	chr16:89806562	chr16:89516797~89522217:+
THCA	cis	rs7166081	1	rs4491456	ENSG00000270964.1	RP11-502I4.3	-3.5	0.000501	0.0306	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67361301	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs12442323	ENSG00000270964.1	RP11-502I4.3	-3.5	0.000501	0.0306	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67362581	chr15:67541072~67542604:-
THCA	cis	rs12915659	1	rs12915659	ENSG00000270964.1	RP11-502I4.3	-3.5	0.000501	0.0306	-0.15	-0.16	Total body bone mineral density;	chr15:67363635	chr15:67541072~67542604:-
THCA	cis	rs7267979	0.966	rs2261795	ENSG00000277938.1	RP5-965G21.3	3.5	0.000501	0.0306	0.13	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25229150~25231933:+
THCA	cis	rs6840360	0.571	rs11944139	ENSG00000251611.1	RP11-610P16.1	-3.5	0.000501	0.0306	-0.13	-0.16	Intelligence (multi-trait analysis);	chr4:151584139	chr4:151407551~151408835:-
THCA	cis	rs13098911	0.54	rs55875328	ENSG00000226074.4	PRSS44	-3.5	0.000502	0.0306	-0.29	-0.16	Celiac disease;	chr3:46010210	chr3:46809359~46812558:-
THCA	cis	rs3743162	1	rs12909280	ENSG00000225151.9	GOLGA2P7	-3.5	0.000502	0.0306	-0.23	-0.16	Alzheimer's disease (age of onset);	chr15:84886125	chr15:84199311~84230136:-
THCA	cis	rs8058578	1	rs56656810	ENSG00000260911.2	RP11-196G11.2	3.5	0.000502	0.0306	0.14	0.16	Multiple myeloma;	chr16:30777438	chr16:31043150~31049868:+
THCA	cis	rs2251301	0.8	rs17153082	ENSG00000154316.13	TDH	3.5	0.000502	0.0306	0.14	0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr8:11267577	chr8:11339637~11368452:+
THCA	cis	rs6600671	1	rs2185281	ENSG00000226067.5	CH17-118O6.2	3.5	0.000502	0.0306	0.16	0.16	Hip geometry;	chr1:121438132	chr1:120913275~121009291:+
THCA	cis	rs9876781	1	rs725310	ENSG00000199476.1	Y_RNA	3.5	0.000502	0.0306	0.2	0.16	Longevity;	chr3:48377081	chr3:48288587~48288694:+
THCA	cis	rs1557488	0.599	rs2874807	ENSG00000260209.1	RP11-680F20.10	-3.5	0.000502	0.0306	-0.22	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126844599	chr11:125873031~125874528:-
THCA	cis	rs910316	0.967	rs175498	ENSG00000259138.1	RP11-950C14.7	-3.5	0.000502	0.0306	-0.14	-0.16	Height;	chr14:75069666	chr14:75127153~75136930:+
THCA	cis	rs4660456	0.913	rs6661855	ENSG00000238287.1	RP11-656D10.3	3.5	0.000502	0.0306	0.2	0.16	Platelet count;	chr1:40703245	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs7542019	ENSG00000238287.1	RP11-656D10.3	3.5	0.000502	0.0306	0.2	0.16	Platelet count;	chr1:40704039	chr1:40493157~40508661:-
THCA	cis	rs972578	1	rs2016623	ENSG00000230319.1	AL022476.2	3.5	0.000502	0.0306	0.17	0.16	Mean platelet volume;	chr22:42974543	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs926351	ENSG00000230319.1	AL022476.2	3.5	0.000502	0.0306	0.17	0.16	Mean platelet volume;	chr22:42975170	chr22:43038585~43052366:+
THCA	cis	rs9860428	0.844	rs9858931	ENSG00000240057.4	RP11-572M11.4	3.5	0.000502	0.0306	0.16	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897933	chr3:113019532~113183301:+
THCA	cis	rs10175706	0.526	rs4614952	ENSG00000256637.5	RP11-76I14.1	-3.5	0.000502	0.0306	-0.14	-0.16	Chin dimples;	chr2:104013691	chr2:103874310~104077778:+
THCA	cis	rs76878669	0.538	rs4930360	ENSG00000255320.1	RP11-755F10.1	-3.5	0.000502	0.0306	-0.2	-0.16	Educational attainment (years of education);	chr11:66375776	chr11:66244840~66246239:-
THCA	cis	rs76878669	0.561	rs55998145	ENSG00000255320.1	RP11-755F10.1	-3.5	0.000502	0.0306	-0.2	-0.16	Educational attainment (years of education);	chr11:66385115	chr11:66244840~66246239:-
THCA	cis	rs755249	0.565	rs12138051	ENSG00000237624.1	OXCT2P1	-3.5	0.000502	0.0306	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39514956~39516490:+
THCA	cis	rs755249	0.564	rs6691194	ENSG00000237624.1	OXCT2P1	-3.5	0.000502	0.0306	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39514956~39516490:+
THCA	cis	rs1005277	0.603	rs1998062	ENSG00000151963.4	RP11-775A3.1	-3.5	0.000502	0.0307	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:37883594~37884109:+
THCA	cis	rs1873147	1	rs1873147	ENSG00000259672.1	RP11-69G7.1	3.5	0.000502	0.0307	0.17	0.16	Orofacial clefts;	chr15:63020433	chr15:63098870~63110403:+
THCA	cis	rs1873147	1	rs12440411	ENSG00000259672.1	RP11-69G7.1	3.5	0.000502	0.0307	0.17	0.16	Orofacial clefts;	chr15:63021382	chr15:63098870~63110403:+
THCA	cis	rs1873147	1	rs12443285	ENSG00000259672.1	RP11-69G7.1	3.5	0.000502	0.0307	0.17	0.16	Orofacial clefts;	chr15:63021397	chr15:63098870~63110403:+
THCA	cis	rs3015497	0.616	rs4901043	ENSG00000270062.1	RP11-248J18.3	-3.5	0.000502	0.0307	-0.18	-0.16	Mean platelet volume;	chr14:50616876	chr14:50723777~50724272:-
THCA	cis	rs7819412	0.54	rs11777355	ENSG00000205879.4	FAM90A2P	-3.5	0.000502	0.0307	-0.2	-0.16	Triglycerides;	chr8:11187180	chr8:12172202~12178575:-
THCA	cis	rs4886920	0.563	rs4442775	ENSG00000260776.4	RP11-114H24.2	-3.5	0.000502	0.0307	-0.19	-0.16	Neuroticism;	chr15:77786778	chr15:77914217~77926846:-
THCA	cis	rs4886920	0.563	rs4509984	ENSG00000260776.4	RP11-114H24.2	-3.5	0.000502	0.0307	-0.19	-0.16	Neuroticism;	chr15:77786925	chr15:77914217~77926846:-
THCA	cis	rs913655	1	rs2987831	ENSG00000240291.1	RP11-499P20.2	-3.5	0.000502	0.0307	-0.12	-0.16	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18813027	chr10:18513115~18545651:-
THCA	cis	rs9878978	1	rs62233806	ENSG00000227588.2	CNTN4-AS2	3.5	0.000502	0.0307	0.19	0.16	Blood pressure (smoking interaction);	chr3:2433794	chr3:2110409~2144241:-
THCA	cis	rs41294858	1	rs76267242	ENSG00000232876.1	CTA-212D2.2	-3.5	0.000502	0.0307	-0.34	-0.16	Red blood cell count;	chr6:135096322	chr6:135055033~135060550:+
THCA	cis	rs3733585	0.605	rs4697926	ENSG00000261490.1	RP11-448G15.3	3.5	0.000502	0.0307	0.11	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10122943	chr4:10068089~10073019:-
THCA	cis	rs9381107	0.591	rs66774072	ENSG00000230939.1	RP11-314C16.1	3.5	0.000502	0.0307	0.26	0.16	Nonsyndromic cleft lip with cleft palate;	chr6:9517372	chr6:8784178~8785445:+
THCA	cis	rs10940346	0.506	rs7721806	ENSG00000271752.1	RP11-269M20.3	3.5	0.000502	0.0307	0.16	0.16	Schizophrenia;	chr5:50576182	chr5:50662859~50663266:-
THCA	cis	rs854765	0.624	rs7501812	ENSG00000281749.1	Y_RNA	-3.5	0.000502	0.0307	-0.2	-0.16	Total body bone mineral density;	chr17:17847593	chr17:18001101~18001195:-
THCA	cis	rs72807343	0.661	rs269462	ENSG00000245317.2	CTC-241N9.1	3.5	0.000502	0.0307	0.28	0.16	Alzheimer's disease (late onset);	chr5:179852949	chr5:179859013~179861283:+
THCA	cis	rs72807343	0.661	rs66959508	ENSG00000245317.2	CTC-241N9.1	3.5	0.000502	0.0307	0.28	0.16	Alzheimer's disease (late onset);	chr5:179856625	chr5:179859013~179861283:+
THCA	cis	rs7712401	0.755	rs27740	ENSG00000263432.2	RN7SL689P	-3.5	0.000502	0.0307	-0.16	-0.16	Mean platelet volume;	chr5:122869077	chr5:123022487~123022783:-
THCA	cis	rs1560104	0.709	rs6498334	ENSG00000259876.1	CTD-3037G24.4	3.5	0.000502	0.0307	0.18	0.16	Obesity-related traits;	chr16:12602789	chr16:12556353~12557694:-
THCA	cis	rs1552244	0.515	rs6768768	ENSG00000186162.9	CIDECP	3.5	0.000502	0.0307	0.16	0.16	Alzheimer's disease;	chr3:10135969	chr3:10014238~10026365:-
THCA	cis	rs4886920	0.563	rs12915515	ENSG00000260776.4	RP11-114H24.2	-3.5	0.000502	0.0307	-0.19	-0.16	Neuroticism;	chr15:77783213	chr15:77914217~77926846:-
THCA	cis	rs17689437	0.505	rs56069138	ENSG00000260084.1	RP11-615I2.1	3.5	0.000502	0.0307	0.18	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68639142	chr16:68573782~68589512:-
THCA	cis	rs889122	0.531	rs918539	ENSG00000267289.1	CTD-2623N2.11	3.5	0.000502	0.0307	0.18	0.16	Menarche (age at onset);	chr19:9903164	chr19:9834079~9835013:-
THCA	cis	rs7631605	0.967	rs7638252	ENSG00000272334.1	RP11-129K12.1	-3.5	0.000503	0.0307	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:37100241	chr3:36973117~36973672:-
THCA	cis	rs8099594	0.565	rs4939846	ENSG00000266696.1	RP11-30L3.2	-3.5	0.000503	0.0307	-0.2	-0.16	Height;	chr18:49189715	chr18:49205912~49208781:+
THCA	cis	rs17689437	0.505	rs12448518	ENSG00000260084.1	RP11-615I2.1	3.5	0.000503	0.0307	0.18	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68632428	chr16:68573782~68589512:-
THCA	cis	rs7726354	0.793	rs74773564	ENSG00000271828.1	CTD-2310F14.1	3.5	0.000503	0.0307	0.36	0.16	Breast cancer (early onset);	chr5:56700042	chr5:56927874~56929573:+
THCA	cis	rs1941184	0.5	rs11873153	ENSG00000266521.1	RP11-650P15.1	-3.5	0.000503	0.0307	-0.25	-0.16	Parkinson's disease (age of onset);	chr18:31432005	chr18:31496645~31497195:-
THCA	cis	rs12722605	0.564	rs12359875	ENSG00000229664.1	RP11-536K7.5	3.5	0.000503	0.0307	0.21	0.16	Inflammatory biomarkers;	chr10:6009144	chr10:6025978~6036427:+
THCA	cis	rs6601450	0.534	rs1133184	ENSG00000253641.4	RP11-981G7.2	-3.5	0.000503	0.0307	-0.15	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10369050	chr8:10474565~10481974:+
THCA	cis	rs3784262	0.669	rs1063666	ENSG00000259250.1	RP11-50C13.1	3.5	0.000503	0.0307	0.13	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57954404	chr15:58587507~58591676:+
THCA	cis	rs853679	0.517	rs4713150	ENSG00000219891.2	ZSCAN12P1	3.5	0.000503	0.0307	0.23	0.16	Depression;	chr6:28168434	chr6:28091154~28093664:+
THCA	cis	rs2115630	0.967	rs7171167	ENSG00000229212.6	RP11-561C5.4	3.5	0.000503	0.0307	0.21	0.16	P wave terminal force;	chr15:84695892	chr15:85205440~85234795:-
THCA	cis	rs2841277	0.708	rs10083490	ENSG00000258701.1	LINC00638	-3.5	0.000503	0.0307	-0.17	-0.16	Rheumatoid arthritis;	chr14:104936081	chr14:104821201~104823718:+
THCA	cis	rs4664304	0.62	rs1039932	ENSG00000226266.5	AC009961.3	-3.5	0.000503	0.0307	-0.19	-0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159856261	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.62	rs11675122	ENSG00000226266.5	AC009961.3	-3.5	0.000503	0.0307	-0.19	-0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159856935	chr2:159670708~159712435:-
THCA	cis	rs4664304	0.62	rs2729705	ENSG00000226266.5	AC009961.3	3.5	0.000503	0.0307	0.19	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159854411	chr2:159670708~159712435:-
THCA	cis	rs2572431	0.505	rs13269118	ENSG00000255310.2	AF131215.2	3.5	0.000503	0.0307	0.14	0.16	Neuroticism;	chr8:11390305	chr8:11107788~11109726:-
THCA	cis	rs7586085	0.966	rs35745544	ENSG00000232411.1	AC009495.3	-3.5	0.000503	0.0307	-0.17	-0.16	Total body bone mineral density;	chr2:165694984	chr2:165833048~165839098:-
THCA	cis	rs7829975	0.593	rs2921051	ENSG00000248538.5	RP11-10A14.5	-3.5	0.000503	0.0307	-0.2	-0.16	Mood instability;	chr8:8462594	chr8:9189011~9202854:+
THCA	cis	rs9488822	0.676	rs7774952	ENSG00000233558.1	RP3-486I3.4	3.5	0.000503	0.0307	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116059746	chr6:116258493~116259115:-
THCA	cis	rs7236492	0.872	rs78226032	ENSG00000267655.1	CTD-2286N8.2	3.5	0.000503	0.0307	0.36	0.16	Inflammatory bowel disease;Crohn's disease;	chr18:79470822	chr18:79117207~79117920:+
THCA	cis	rs9425766	0.679	rs12085290	ENSG00000270084.1	GAS5-AS1	3.5	0.000503	0.0307	0.16	0.16	Life satisfaction;	chr1:174124699	chr1:173863248~173863941:+
THCA	cis	rs11717455	1	rs6798701	ENSG00000232439.1	RPL18AP7	-3.5	0.000503	0.0307	-0.25	-0.16	Systemic lupus erythematosus;	chr3:38815884	chr3:38526802~38527325:-
THCA	cis	rs10090774	0.965	rs11785111	ENSG00000280303.2	ERICD	-3.5	0.000503	0.0307	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140852463	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.932	rs13282141	ENSG00000280303.2	ERICD	-3.5	0.000503	0.0307	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140852692	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs13253993	ENSG00000280303.2	ERICD	-3.5	0.000503	0.0307	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140857417	chr8:140636281~140638283:+
THCA	cis	rs476633	0.691	rs11858115	ENSG00000247556.5	OIP5-AS1	3.5	0.000503	0.0307	0.12	0.16	Glomerular filtration rate (creatinine);	chr15:41250393	chr15:41283990~41309737:+
THCA	cis	rs3110496	1	rs3110496	ENSG00000264290.1	RP11-68I3.4	3.5	0.000503	0.0307	0.12	0.16	Height;	chr17:29590753	chr17:29569580~29570519:+
THCA	cis	rs4808199	1	rs12977524	ENSG00000267481.1	CTC-559E9.5	-3.5	0.000503	0.0307	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19457435	chr19:19788755~19790531:-
THCA	cis	rs7202877	0.656	rs9923834	ENSG00000276408.1	RP11-490B18.5	3.5	0.000503	0.0307	0.29	0.16	Type 1 diabetes;Type 2 diabetes;	chr16:75473355	chr16:75556392~75557059:+
THCA	cis	rs17772222	0.63	rs2778936	ENSG00000222990.1	RNU4-22P	-3.5	0.000503	0.0307	-0.19	-0.16	Coronary artery calcification;	chr14:88505959	chr14:88513498~88513663:+
THCA	cis	rs74233809	0.901	rs1004467	ENSG00000236937.2	PTGES3P4	3.5	0.000503	0.0307	0.3	0.16	Birth weight;	chr10:102834750	chr10:102845595~102845950:+
THCA	cis	rs35065479	1	rs12603880	ENSG00000242889.3	RN7SL449P	3.5	0.000503	0.0307	0.27	0.16	Schizophrenia;	chr17:57668632	chr17:57618108~57618393:+
THCA	cis	rs755249	0.567	rs16826069	ENSG00000182109.6	RP11-69E11.4	3.5	0.000503	0.0307	0.17	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39522280~39546187:-
THCA	cis	rs793571	0.822	rs11636723	ENSG00000245975.2	RP11-30K9.6	3.5	0.000503	0.0307	0.18	0.16	Schizophrenia;	chr15:58914319	chr15:58768072~58770974:-
THCA	cis	rs10043228	0.826	rs77863323	ENSG00000250015.1	CTC-339F2.2	3.5	0.000503	0.0307	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116113415	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs79404901	ENSG00000250015.1	CTC-339F2.2	3.5	0.000503	0.0307	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116113635	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs1876673	ENSG00000250015.1	CTC-339F2.2	3.5	0.000503	0.0307	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116115076	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12516100	ENSG00000250015.1	CTC-339F2.2	3.5	0.000503	0.0307	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116116053	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12520076	ENSG00000250015.1	CTC-339F2.2	3.5	0.000503	0.0307	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116123133	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs12514600	ENSG00000250015.1	CTC-339F2.2	3.5	0.000503	0.0307	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116134958	chr5:116302354~116304134:-
THCA	cis	rs2898290	0.622	rs1382567	ENSG00000270154.1	RP11-419I17.1	-3.5	0.000503	0.0307	-0.2	-0.16	Systolic blood pressure;	chr8:11493390	chr8:12476462~12477122:+
THCA	cis	rs73206853	0.686	rs7139314	ENSG00000257539.2	HSPA8P14	3.5	0.000503	0.0307	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110486066	chr12:111381867~111385638:+
THCA	cis	rs73206853	0.764	rs16940881	ENSG00000257539.2	HSPA8P14	3.5	0.000503	0.0307	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110500013	chr12:111381867~111385638:+
THCA	cis	rs7300001	0.538	rs7968848	ENSG00000257539.2	HSPA8P14	3.5	0.000503	0.0307	0.3	0.16	Headache;	chr12:110503254	chr12:111381867~111385638:+
THCA	cis	rs4568518	0.74	rs11543650	ENSG00000279048.1	RP11-511H23.2	3.5	0.000503	0.0307	0.1	0.16	Measles;	chr7:17970257	chr7:17940503~17942922:+
THCA	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	3.5	0.000503	0.0307	0.18	0.16	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
THCA	cis	rs11239930	0.538	rs17160592	ENSG00000180867.10	PDIA3P1	3.5	0.000503	0.0307	0.15	0.16	AIDS progression;	chr1:147083644	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.538	rs56060937	ENSG00000180867.10	PDIA3P1	3.5	0.000503	0.0307	0.15	0.16	AIDS progression;	chr1:147083854	chr1:147178113~147179622:+
THCA	cis	rs2549003	1	rs10068129	ENSG00000233006.5	AC034220.3	3.5	0.000504	0.0307	0.12	0.16	Asthma (sex interaction);	chr5:132485554	chr5:132311285~132369916:-
THCA	cis	rs7142002	0.881	rs7149063	ENSG00000271780.1	RP11-1017G21.5	-3.5	0.000504	0.0307	-0.25	-0.16	Autism;	chr14:101939262	chr14:101948347~101949425:+
THCA	cis	rs10875746	0.551	rs2054904	ENSG00000258273.1	RP11-370I10.4	3.5	0.000504	0.0307	0.23	0.16	Longevity (90 years and older);	chr12:48330571	chr12:48333755~48333901:-
THCA	cis	rs2842992	0.724	rs2273827	ENSG00000237927.1	RP3-393E18.2	-3.5	0.000504	0.0307	-0.23	-0.16	Age-related macular degeneration (geographic atrophy);	chr6:159790307	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.662	rs2273826	ENSG00000237927.1	RP3-393E18.2	-3.5	0.000504	0.0307	-0.23	-0.16	Age-related macular degeneration (geographic atrophy);	chr6:159790389	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.662	rs2273825	ENSG00000237927.1	RP3-393E18.2	-3.5	0.000504	0.0307	-0.23	-0.16	Age-related macular degeneration (geographic atrophy);	chr6:159790392	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.768	rs2273824	ENSG00000237927.1	RP3-393E18.2	-3.5	0.000504	0.0307	-0.23	-0.16	Age-related macular degeneration (geographic atrophy);	chr6:159790413	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.724	rs2273823	ENSG00000237927.1	RP3-393E18.2	-3.5	0.000504	0.0307	-0.23	-0.16	Age-related macular degeneration (geographic atrophy);	chr6:159790453	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.692	rs1128661	ENSG00000237927.1	RP3-393E18.2	-3.5	0.000504	0.0307	-0.23	-0.16	Age-related macular degeneration (geographic atrophy);	chr6:159790522	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.724	rs1128670	ENSG00000237927.1	RP3-393E18.2	-3.5	0.000504	0.0307	-0.23	-0.16	Age-related macular degeneration (geographic atrophy);	chr6:159790604	chr6:159586955~159589169:-
THCA	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	3.5	0.000504	0.0307	0.15	0.16	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
THCA	cis	rs2486012	1	rs1859726	ENSG00000237950.1	RP11-7O11.3	3.5	0.000504	0.0307	0.19	0.16	Intelligence (multi-trait analysis);	chr1:43930543	chr1:43944370~43946551:-
THCA	cis	rs7829975	0.626	rs332040	ENSG00000254340.1	RP11-10A14.3	3.5	0.000504	0.0307	0.18	0.16	Mood instability;	chr8:8872978	chr8:9141424~9145435:+
THCA	cis	rs950169	0.887	rs35986397	ENSG00000188388.10	GOLGA6L3	3.5	0.000504	0.0307	0.22	0.16	Schizophrenia;	chr15:84400409	chr15:85240472~85247170:+
THCA	cis	rs9487094	0.696	rs1853330	ENSG00000223537.2	RP5-919F19.5	-3.5	0.000504	0.0307	-0.16	-0.16	Height;	chr6:109375548	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.666	rs2211288	ENSG00000223537.2	RP5-919F19.5	-3.5	0.000504	0.0307	-0.16	-0.16	Height;	chr6:109383848	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.666	rs4946970	ENSG00000223537.2	RP5-919F19.5	-3.5	0.000504	0.0307	-0.16	-0.16	Height;	chr6:109384807	chr6:109487906~109506800:+
THCA	cis	rs6545883	0.507	rs4672427	ENSG00000273302.1	RP11-493E12.2	-3.5	0.000504	0.0307	-0.15	-0.16	Tuberculosis;	chr2:61242115	chr2:61199979~61200769:+
THCA	cis	rs2505675	0.887	rs2505676	ENSG00000272465.1	RP1-136B1.1	3.5	0.000504	0.0307	0.2	0.16	Tuberculosis;	chr6:2355141	chr6:2437549~2438249:+
THCA	cis	rs745109	0.7	rs55719944	ENSG00000273080.1	RP11-301O19.1	3.5	0.000504	0.0307	0.28	0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86548181	chr2:86195590~86196049:+
THCA	cis	rs34467563	0.872	rs6986561	ENSG00000253105.4	KB-1448A5.1	3.5	0.000504	0.0307	0.21	0.16	Lobe attachment (rater-scored or self-reported);	chr8:96352337	chr8:96371865~96387438:-
THCA	cis	rs7674212	0.539	rs6854709	ENSG00000230069.3	LRRC37A15P	-3.5	0.000504	0.0307	-0.16	-0.16	Type 2 diabetes;	chr4:103208629	chr4:102727274~102730721:-
THCA	cis	rs12681963	0.748	rs12546409	ENSG00000272375.1	RP11-51J9.6	3.5	0.000504	0.0308	0.18	0.16	Migraine;	chr8:30045440	chr8:30197404~30198048:+
THCA	cis	rs11601321	0.881	rs10893370	ENSG00000187686.4	KRT18P59	-3.5	0.000504	0.0308	-0.26	-0.16	Alzheimer's disease (survival time);	chr11:125321947	chr11:125113161~125126781:+
THCA	cis	rs293748	0.882	rs158802	ENSG00000250155.1	CTD-2353F22.1	-3.5	0.000504	0.0308	-0.22	-0.16	Obesity-related traits;	chr5:36941446	chr5:36666214~36725195:-
THCA	cis	rs354225	0.539	rs6545440	ENSG00000162997.14	PRORSD1P	-3.5	0.000504	0.0308	-0.19	-0.16	Schizophrenia;	chr2:54732725	chr2:55282319~55284522:+
THCA	cis	rs61677309	1	rs1318166	ENSG00000278376.1	RP11-158I9.8	3.5	0.000504	0.0308	0.12	0.16	Lung cancer in ever smokers;	chr11:118300343	chr11:118791254~118793137:+
THCA	cis	rs757081	0.738	rs1073443	ENSG00000260196.1	RP1-239B22.5	-3.5	0.000504	0.0308	-0.2	-0.16	Systolic blood pressure;	chr11:17328847	chr11:17380649~17383531:+
THCA	cis	rs853679	0.517	rs3757187	ENSG00000219891.2	ZSCAN12P1	3.5	0.000504	0.0308	0.23	0.16	Depression;	chr6:28139876	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000219891.2	ZSCAN12P1	3.5	0.000504	0.0308	0.23	0.16	Depression;	chr6:28139998	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.869	rs2056925	ENSG00000216915.2	RP1-97D16.1	-3.5	0.000504	0.0308	-0.24	-0.16	Parkinson's disease;	chr6:27723126	chr6:27737000~27738494:-
THCA	cis	rs2243480	1	rs437889	ENSG00000237310.1	GS1-124K5.4	3.5	0.000504	0.0308	0.18	0.16	Diabetic kidney disease;	chr7:66044247	chr7:66493706~66495474:+
THCA	cis	rs2227564	0.649	rs2948689	ENSG00000271816.1	BMS1P4	3.5	0.000504	0.0308	0.17	0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73898102	chr10:73699151~73730487:-
THCA	cis	rs7216064	1	rs55896768	ENSG00000278740.1	RP11-147L13.14	3.5	0.000504	0.0308	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67917242	chr17:68188547~68189165:+
THCA	cis	rs2227564	0.672	rs10824042	ENSG00000271816.1	BMS1P4	3.5	0.000504	0.0308	0.17	0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73885870	chr10:73699151~73730487:-
THCA	cis	rs860295	0.702	rs11264386	ENSG00000236675.1	MTX1P1	-3.5	0.000504	0.0308	-0.17	-0.16	Body mass index;	chr1:155589379	chr1:155230975~155234325:+
THCA	cis	rs1412115	0.765	rs61845249	ENSG00000233387.1	RP11-342D11.3	-3.5	0.000504	0.0308	-0.16	-0.16	Schizophrenia;	chr10:33782062	chr10:33096257~33116672:-
THCA	cis	rs17181170	0.553	rs1844100	ENSG00000239572.1	RP11-451B8.1	-3.5	0.000504	0.0308	-0.2	-0.16	Prostate cancer;	chr3:87139023	chr3:87731402~87793629:-
THCA	cis	rs9393813	0.528	rs6911865	ENSG00000271755.1	RP1-153G14.4	3.5	0.000504	0.0308	0.18	0.16	Bipolar disorder;	chr6:27502999	chr6:27404010~27406964:-
THCA	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-3.5	0.000504	0.0308	-0.18	-0.16	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
THCA	cis	rs67340775	0.541	rs200979	ENSG00000272009.1	RP1-313I6.12	-3.5	0.000504	0.0308	-0.21	-0.16	Lung cancer in ever smokers;	chr6:27884579	chr6:28078792~28081130:-
THCA	cis	rs2749592	1	rs2749592	ENSG00000226578.1	RP11-258F22.1	-3.5	0.000504	0.0308	-0.2	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37969914	chr10:37775371~37784131:-
THCA	cis	rs8064029	1	rs17631487	ENSG00000267077.1	RP11-127I20.5	3.5	0.000504	0.0308	0.24	0.16	Cancer;	chr16:4856998	chr16:4795265~4796532:-
THCA	cis	rs13113518	0.729	rs11133377	ENSG00000272969.1	RP11-528I4.2	3.5	0.000504	0.0308	0.2	0.16	Height;	chr4:55413708	chr4:55547112~55547889:+
THCA	cis	rs13113518	0.729	rs13120134	ENSG00000272969.1	RP11-528I4.2	3.5	0.000504	0.0308	0.2	0.16	Height;	chr4:55415153	chr4:55547112~55547889:+
THCA	cis	rs2239557	0.508	rs1974582	ENSG00000259065.1	RP5-1021I20.1	-3.5	0.000504	0.0308	-0.24	-0.16	Common traits (Other);	chr14:73900601	chr14:73787360~73803270:+
THCA	cis	rs2239557	0.508	rs11159044	ENSG00000259065.1	RP5-1021I20.1	-3.5	0.000504	0.0308	-0.24	-0.16	Common traits (Other);	chr14:73901158	chr14:73787360~73803270:+
THCA	cis	rs76419734	0.85	rs17036341	ENSG00000251175.4	RP11-45L9.1	3.5	0.000504	0.0308	0.35	0.16	Post bronchodilator FEV1;	chr4:105875672	chr4:105746245~105827172:-
THCA	cis	rs11971779	0.688	rs1862880	ENSG00000252332.1	RNU6-911P	-3.5	0.000504	0.0308	-0.19	-0.16	Diisocyanate-induced asthma;	chr7:139335354	chr7:139448740~139448843:+
THCA	cis	rs34779708	0.931	rs2001893	ENSG00000233200.1	RP11-324I22.2	3.5	0.000505	0.0308	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35219894~35230598:-
THCA	cis	rs1930961	0.558	rs12160908	ENSG00000100058.11	CRYBB2P1	3.5	0.000505	0.0308	0.26	0.16	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25448105~25520854:+
THCA	cis	rs17023223	0.537	rs12083510	ENSG00000227056.2	RPL6P2	-3.5	0.000505	0.0308	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119219314~119220096:-
THCA	cis	rs7412746	0.622	rs72704654	ENSG00000224800.1	RP11-235D19.2	-3.5	0.000505	0.0308	-0.22	-0.16	Melanoma;	chr1:150853934	chr1:150881236~150881683:-
THCA	cis	rs6142618	0.562	rs4911546	ENSG00000224452.1	RSL24D1P6	3.5	0.000505	0.0308	0.18	0.16	Inflammatory bowel disease;	chr20:32130530	chr20:32170390~32170790:-
THCA	cis	rs5753618	0.539	rs695438	ENSG00000224050.1	RP1-90G24.6	-3.5	0.000505	0.0308	-0.2	-0.16	Colorectal cancer;	chr22:31415890	chr22:32273420~32277186:+
THCA	cis	rs7246657	0.55	rs9941475	ENSG00000226686.6	LINC01535	-3.5	0.000505	0.0308	-0.23	-0.16	Coronary artery calcification;	chr19:37573615	chr19:37251912~37265535:+
THCA	cis	rs2463505	0.571	rs3798004	ENSG00000272417.1	CTD-2199O4.6	-3.5	0.000505	0.0308	-0.32	-0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr5:9370833	chr5:10203600~10204040:-
THCA	cis	rs1971762	0.527	rs11170590	ENSG00000270175.1	RP11-793H13.11	-3.5	0.000505	0.0308	-0.1	-0.16	Height;	chr12:53545129	chr12:53500162~53500936:-
THCA	cis	rs1971762	0.527	rs7972401	ENSG00000270175.1	RP11-793H13.11	-3.5	0.000505	0.0308	-0.1	-0.16	Height;	chr12:53546262	chr12:53500162~53500936:-
THCA	cis	rs6982240	0.514	rs892362	ENSG00000253307.1	RP11-10J21.4	-3.5	0.000505	0.0308	-0.23	-0.16	Tonsillectomy;	chr8:141259115	chr8:141252286~141253292:-
THCA	cis	rs7615952	0.543	rs4645102	ENSG00000243429.1	OR7E29P	3.5	0.000505	0.0308	0.2	0.16	Blood pressure (smoking interaction);	chr3:125705597	chr3:125712139~125713045:+
THCA	cis	rs1150668	0.796	rs2531832	ENSG00000220721.1	OR1F12	3.5	0.000505	0.0308	0.18	0.16	Pubertal anthropometrics;	chr6:28421445	chr6:28073316~28074233:+
THCA	cis	rs73198271	0.773	rs66618176	ENSG00000254153.1	CTA-398F10.2	3.5	0.000505	0.0308	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8456909~8461337:-
THCA	cis	rs9911578	1	rs9904879	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58787061	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs8067571	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58791495	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.935	rs6503878	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58807220	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs9807057	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58812591	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs4482353	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58819473	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs12602346	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58824352	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs9897326	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58824936	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.904	rs7209253	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58831626	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs1472288	ENSG00000224738.1	AC099850.1	3.5	0.000505	0.0308	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58833359	chr17:59106598~59118267:+
THCA	cis	rs911555	0.755	rs12432803	ENSG00000269940.1	RP11-73M18.7	-3.5	0.000505	0.0308	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103694560~103695170:+
THCA	cis	rs911555	0.755	rs4906329	ENSG00000269940.1	RP11-73M18.7	-3.5	0.000505	0.0308	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103694560~103695170:+
THCA	cis	rs7819412	0.669	rs6601568	ENSG00000261451.1	RP11-981G7.1	-3.5	0.000505	0.0308	-0.21	-0.16	Triglycerides;	chr8:11215893	chr8:10433672~10438312:+
THCA	cis	rs879324	0.74	rs61078156	ENSG00000280092.1	AC002044.3	3.5	0.000505	0.0308	0.24	0.16	Stroke (ischemic);	chr16:73005232	chr16:73005601~73006141:-
THCA	cis	rs1018326	0.565	rs4508560	ENSG00000238171.1	AC068196.1	-3.5	0.000505	0.0308	-0.18	-0.16	Ankylosing spondylitis;	chr2:181002458	chr2:181076051~181105968:-
THCA	cis	rs72996113	0.702	rs11224402	ENSG00000248027.1	CTD-2383M3.1	-3.5	0.000505	0.0308	-0.31	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100708982	chr11:100684162~100687955:-
THCA	cis	rs1113500	0.548	rs11185271	ENSG00000226822.1	RP11-356N1.2	3.5	0.000505	0.0308	0.18	0.16	Growth-regulated protein alpha levels;	chr1:108117311	chr1:108071482~108074519:+
THCA	cis	rs11190604	0.767	rs10883481	ENSG00000273030.1	RP11-285F16.1	3.5	0.000505	0.0308	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100405264	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs11190513	ENSG00000273030.1	RP11-285F16.1	3.5	0.000505	0.0308	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100405481	chr10:100412934~100413421:+
THCA	cis	rs4792901	0.765	rs12600416	ENSG00000279602.1	CTD-3014M21.1	-3.5	0.000505	0.0308	-0.2	-0.16	Dupuytren's disease;	chr17:43469190	chr17:43360041~43361361:-
THCA	cis	rs11658311	1	rs9911823	ENSG00000232344.2	AC087163.2	3.5	0.000505	0.0308	0.21	0.16	Obsessive-compulsive symptoms;	chr17:17627151	chr17:18010643~18011822:+
THCA	cis	rs11658311	1	rs28454257	ENSG00000232344.2	AC087163.2	3.5	0.000505	0.0308	0.21	0.16	Obsessive-compulsive symptoms;	chr17:17628968	chr17:18010643~18011822:+
THCA	cis	rs11658311	1	rs80300717	ENSG00000232344.2	AC087163.2	3.5	0.000505	0.0308	0.21	0.16	Obsessive-compulsive symptoms;	chr17:17629966	chr17:18010643~18011822:+
THCA	cis	rs7690839	1	rs1458562	ENSG00000270720.1	RP11-84C13.2	3.5	0.000505	0.0308	0.18	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88932447	chr4:89119284~89119871:+
THCA	cis	rs995834	0.869	rs10853719	ENSG00000261770.1	CTC-459F4.1	-3.5	0.000505	0.0308	-0.21	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392287	chr19:27757184~27760849:-
THCA	cis	rs747782	0.527	rs2270993	ENSG00000200090.1	Y_RNA	3.5	0.000505	0.0308	0.15	0.16	Intraocular pressure;	chr11:48123614	chr11:47726894~47726992:-
THCA	cis	rs747782	0.527	rs2279822	ENSG00000200090.1	Y_RNA	3.5	0.000505	0.0308	0.15	0.16	Intraocular pressure;	chr11:48124562	chr11:47726894~47726992:-
THCA	cis	rs747782	0.527	rs7129364	ENSG00000200090.1	Y_RNA	3.5	0.000505	0.0308	0.15	0.16	Intraocular pressure;	chr11:48129024	chr11:47726894~47726992:-
THCA	cis	rs17742757	0.522	rs899364	ENSG00000254527.1	ENPP7P12	-3.5	0.000505	0.0308	-0.2	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11472035	chr8:12205759~12206389:-
THCA	cis	rs7572733	0.935	rs10177758	ENSG00000231621.1	AC013264.2	-3.5	0.000505	0.0308	-0.15	-0.16	Dermatomyositis;	chr2:197994193	chr2:197197991~197199273:+
THCA	cis	rs1862618	0.853	rs3099459	ENSG00000234553.1	AC022431.3	-3.5	0.000505	0.0308	-0.18	-0.16	Initial pursuit acceleration;	chr5:56841343	chr5:56536583~56537826:-
THCA	cis	rs2014572	0.967	rs8112572	ENSG00000276449.1	AC004076.5	3.5	0.000505	0.0308	0.15	0.16	Hyperactive-impulsive symptoms;	chr19:57248244	chr19:57449689~57453011:+
THCA	cis	rs10129255	0.957	rs8009948	ENSG00000280411.1	IGHV1-69-2	-3.5	0.000505	0.0308	-0.1	-0.16	Kawasaki disease;	chr14:106805607	chr14:106762092~106762588:-
THCA	cis	rs17122278	1	rs11216916	ENSG00000243431.1	RPL5P30	3.5	0.000505	0.0308	0.16	0.16	Total cholesterol levels;	chr11:118590890	chr11:118560690~118561580:+
THCA	cis	rs2729354	0.953	rs2649663	ENSG00000254602.1	AP000662.4	-3.5	0.000505	0.0308	-0.2	-0.16	Blood protein levels;	chr11:57589832	chr11:57638024~57652790:+
THCA	cis	rs2486012	0.649	rs9726489	ENSG00000237950.1	RP11-7O11.3	3.5	0.000505	0.0308	0.19	0.16	Intelligence (multi-trait analysis);	chr1:43801997	chr1:43944370~43946551:-
THCA	cis	rs2668423	1	rs2526140	ENSG00000261526.2	CTB-31O20.2	3.5	0.000505	0.0308	0.11	0.16	Nonalcoholic fatty liver disease;	chr19:1374451	chr19:1874871~1876169:-
THCA	cis	rs4575098	0.681	rs11591206	ENSG00000227741.1	RP11-536C5.7	3.5	0.000505	0.0308	0.17	0.16	Monocyte percentage of white cells;	chr1:161141573	chr1:160202199~160208869:-
THCA	cis	rs9863	0.896	rs12829951	ENSG00000270028.1	RP11-380L11.4	3.5	0.000505	0.0308	0.17	0.16	White blood cell count;	chr12:123941294	chr12:123925461~123926083:-
THCA	cis	rs9863	0.861	rs7131882	ENSG00000270028.1	RP11-380L11.4	3.5	0.000505	0.0308	0.17	0.16	White blood cell count;	chr12:123942189	chr12:123925461~123926083:-
THCA	cis	rs6968419	0.963	rs4436065	ENSG00000237870.5	AC073130.1	3.5	0.000506	0.0308	0.17	0.16	Intraocular pressure;	chr7:116181326	chr7:116275606~116286734:-
THCA	cis	rs6787172	0.748	rs7650256	ENSG00000272087.1	RP11-379F4.7	3.5	0.000506	0.0308	0.14	0.16	Subjective well-being;	chr3:158392698	chr3:158693120~158693768:-
THCA	cis	rs271738	0.928	rs907623	ENSG00000231768.1	LINC01354	-3.5	0.000506	0.0308	-0.18	-0.16	Bipolar disorder;	chr1:234527486	chr1:234527891~234531779:-
THCA	cis	rs2841277	0.708	rs2582533	ENSG00000258701.1	LINC00638	3.5	0.000506	0.0308	0.17	0.16	Rheumatoid arthritis;	chr14:104932450	chr14:104821201~104823718:+
THCA	cis	rs6870983	0.749	rs10074764	ENSG00000247828.6	TMEM161B-AS1	3.5	0.000506	0.0308	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88181931	chr5:88268895~88436685:+
THCA	cis	rs6870983	0.749	rs13360207	ENSG00000247828.6	TMEM161B-AS1	3.5	0.000506	0.0308	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88185757	chr5:88268895~88436685:+
THCA	cis	rs7914558	0.966	rs1591915	ENSG00000272912.1	RP11-724N1.1	-3.5	0.000506	0.0308	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102914585~102915404:+
THCA	cis	rs1665050	0.571	rs1446238	ENSG00000259732.1	RP11-59H7.3	-3.5	0.000506	0.0308	-0.21	-0.16	Atopic dermatitis;	chr15:59055558	chr15:59121034~59133250:+
THCA	cis	rs6724465	1	rs56033548	ENSG00000272644.1	RP11-33O4.1	3.5	0.000506	0.0308	0.24	0.16	Height;	chr2:219071772	chr2:219069354~219069809:-
THCA	cis	rs7647973	0.58	rs11130184	ENSG00000228638.1	FCF1P2	-3.5	0.000506	0.0309	-0.16	-0.16	Menarche (age at onset);	chr3:49192497	chr3:48290793~48291375:-
THCA	cis	rs7647973	0.58	rs2334958	ENSG00000228638.1	FCF1P2	-3.5	0.000506	0.0309	-0.16	-0.16	Menarche (age at onset);	chr3:49214931	chr3:48290793~48291375:-
THCA	cis	rs2351088	0.656	rs76115189	ENSG00000231711.2	LINC00899	3.5	0.000506	0.0309	0.2	0.16	Tonsillectomy;	chr22:45776746	chr22:46039907~46044853:-
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000184274.3	LINC00315	-3.5	0.000506	0.0309	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45300245~45305257:-
THCA	cis	rs301901	0.828	rs62361485	ENSG00000250155.1	CTD-2353F22.1	3.5	0.000506	0.0309	0.16	0.16	Height;	chr5:37474739	chr5:36666214~36725195:-
THCA	cis	rs10875746	0.669	rs10875772	ENSG00000226413.2	OR8T1P	3.5	0.000506	0.0309	0.23	0.16	Longevity (90 years and older);	chr12:48215770	chr12:48442030~48442947:-
THCA	cis	rs2067615	0.965	rs4964484	ENSG00000260329.1	RP11-412D9.4	3.5	0.000506	0.0309	0.14	0.16	Heart rate;	chr12:106719246	chr12:106954029~106955497:-
THCA	cis	rs867371	1	rs7173339	ENSG00000278603.1	RP13-608F4.5	3.5	0.000506	0.0309	0.2	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472203~82472426:+
THCA	cis	rs763121	0.853	rs6001188	ENSG00000225450.1	RP3-508I15.14	-3.5	0.000506	0.0309	-0.13	-0.16	Menopause (age at onset);	chr22:38666189	chr22:38739003~38749041:+
THCA	cis	rs11039798	0.511	rs7948129	ENSG00000200090.1	Y_RNA	-3.5	0.000506	0.0309	-0.13	-0.16	Axial length;	chr11:48146276	chr11:47726894~47726992:-
THCA	cis	rs17270561	0.609	rs1185976	ENSG00000272462.2	U91328.19	3.5	0.000506	0.0309	0.13	0.16	Iron status biomarkers;	chr6:25822135	chr6:25992662~26001775:+
THCA	cis	rs1417770	0.931	rs778399	ENSG00000260971.3	RP11-504A18.1	3.5	0.000506	0.0309	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56235311	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs778400	ENSG00000260971.3	RP11-504A18.1	3.5	0.000506	0.0309	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56235495	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs778401	ENSG00000260971.3	RP11-504A18.1	3.5	0.000506	0.0309	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56236714	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs778402	ENSG00000260971.3	RP11-504A18.1	3.5	0.000506	0.0309	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56236772	chr1:56248294~56258571:-
THCA	cis	rs1062177	1	rs2964571	ENSG00000272112.1	CTB-113P19.5	3.5	0.000506	0.0309	0.14	0.16	Preschool internalizing problems;	chr5:151791695	chr5:151724831~151725356:-
THCA	cis	rs1062177	1	rs2915869	ENSG00000272112.1	CTB-113P19.5	3.5	0.000506	0.0309	0.14	0.16	Preschool internalizing problems;	chr5:151791948	chr5:151724831~151725356:-
THCA	cis	rs950027	0.62	rs1145077	ENSG00000259479.5	SORD2P	-3.5	0.000506	0.0309	-0.17	-0.16	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:44826371~44884694:-
THCA	cis	rs755249	0.642	rs28788506	ENSG00000182109.6	RP11-69E11.4	3.5	0.000506	0.0309	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39522280~39546187:-
THCA	cis	rs755249	0.669	rs4660311	ENSG00000182109.6	RP11-69E11.4	3.5	0.000506	0.0309	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39522280~39546187:-
THCA	cis	rs427691	0.625	rs845733	ENSG00000249476.1	CTD-2587M2.1	3.5	0.000506	0.0309	0.18	0.16	Autism spectrum disorder or schizophrenia;	chr5:109687700	chr5:109237120~109326369:-
THCA	cis	rs7119038	0.609	rs11216999	ENSG00000255422.1	AP002954.4	3.5	0.000506	0.0309	0.19	0.16	Sjögren's syndrome;	chr11:118734232	chr11:118704607~118750263:+
THCA	cis	rs3738443	0.904	rs10924968	ENSG00000259865.1	RP11-488L18.10	3.5	0.000506	0.0309	0.17	0.16	Alcohol dependence;	chr1:247236957	chr1:247187281~247188526:-
THCA	cis	rs6101567	0.517	rs2073315	ENSG00000224635.1	RP4-564F22.5	-3.5	0.000506	0.0309	-0.2	-0.16	Nose size;	chr20:39269037	chr20:38406011~38416797:-
THCA	cis	rs1144333	0.655	rs12402347	ENSG00000272855.1	RP5-1102E8.3	-3.5	0.000506	0.0309	-0.34	-0.16	Attention function in attention deficit hyperactive disorder;	chr1:75982301	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs76175698	ENSG00000272855.1	RP5-1102E8.3	-3.5	0.000506	0.0309	-0.34	-0.16	Attention function in attention deficit hyperactive disorder;	chr1:75989107	chr1:76636877~76637339:+
THCA	cis	rs4578769	0.765	rs11082173	ENSG00000265939.1	UBE2CP2	-3.5	0.000506	0.0309	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22858048	chr18:22900486~22900995:-
THCA	cis	rs2455799	0.552	rs1472697	ENSG00000270409.1	RP11-44D5.1	-3.5	0.000506	0.0309	-0.17	-0.16	Mean platelet volume;	chr3:15708761	chr3:15732252~15733470:+
THCA	cis	rs860295	0.557	rs11264371	ENSG00000203761.5	MSTO2P	-3.5	0.000506	0.0309	-0.13	-0.16	Body mass index;	chr1:155442246	chr1:155745829~155750137:+
THCA	cis	rs1876905	0.68	rs402940	ENSG00000271789.1	RP5-1112D6.7	-3.5	0.000506	0.0309	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111297126~111298510:+
THCA	cis	rs1234598	1	rs1234598	ENSG00000271789.1	RP5-1112D6.7	-3.5	0.000506	0.0309	-0.2	-0.16	Mean corpuscular volume;	chr6:111208250	chr6:111297126~111298510:+
THCA	cis	rs1876905	0.68	rs354543	ENSG00000271789.1	RP5-1112D6.7	-3.5	0.000506	0.0309	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111297126~111298510:+
THCA	cis	rs1555322	1	rs2425037	ENSG00000126005.14	MMP24-AS1	3.5	0.000506	0.0309	0.22	0.16	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35216462~35278131:-
THCA	cis	rs12144309	0.58	rs1217403	ENSG00000232450.1	RP4-730K3.3	3.5	0.000506	0.0309	0.21	0.16	Coronary artery disease;	chr1:113846182	chr1:113698884~113699631:-
THCA	cis	rs7439493	0.899	rs4698782	ENSG00000247950.5	SEC24B-AS1	3.5	0.000506	0.0309	0.1	0.16	Blood protein levels;	chr4:109734125	chr4:109347475~109433817:-
THCA	cis	rs748404	0.631	rs6493086	ENSG00000224677.1	PDIA3P2	3.5	0.000506	0.0309	0.19	0.16	Lung cancer;	chr15:43363196	chr15:43649123~43649280:+
THCA	cis	rs16959442	0.816	rs16959182	ENSG00000254912.2	RP11-632K20.2	-3.5	0.000506	0.0309	-0.26	-0.16	Lobe attachment (rater-scored or self-reported);	chr15:32824224	chr15:32494003~32500346:-
THCA	cis	rs12022452	1	rs12034162	ENSG00000272145.1	NFYC-AS1	3.5	0.000506	0.0309	0.14	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40690380~40692066:-
THCA	cis	rs9596863	0.898	rs9591536	ENSG00000136149.6	RPL13AP25	-3.5	0.000506	0.0309	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53803547	chr13:54440704~54441315:-
THCA	cis	rs1050631	1	rs1539822	ENSG00000260552.1	RP11-49I11.1	3.5	0.000506	0.0309	0.19	0.16	Esophageal squamous cell cancer (length of survival);	chr18:36115980	chr18:36179996~36187448:-
THCA	cis	rs1050631	1	rs1785916	ENSG00000260552.1	RP11-49I11.1	3.5	0.000506	0.0309	0.19	0.16	Esophageal squamous cell cancer (length of survival);	chr18:36116193	chr18:36179996~36187448:-
THCA	cis	rs1050631	1	rs1789504	ENSG00000260552.1	RP11-49I11.1	3.5	0.000506	0.0309	0.19	0.16	Esophageal squamous cell cancer (length of survival);	chr18:36116809	chr18:36179996~36187448:-
THCA	cis	rs1417770	0.86	rs1234587	ENSG00000260971.3	RP11-504A18.1	3.5	0.000506	0.0309	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56242190	chr1:56248294~56258571:-
THCA	cis	rs789852	0.867	rs6437391	ENSG00000231770.4	TMEM44-AS1	3.5	0.000506	0.0309	0.22	0.16	QT interval;	chr3:194596097	chr3:194584011~194590260:+
THCA	cis	rs789852	0.764	rs2794668	ENSG00000231770.4	TMEM44-AS1	3.5	0.000506	0.0309	0.22	0.16	QT interval;	chr3:194596166	chr3:194584011~194590260:+
THCA	cis	rs789852	0.867	rs1773175	ENSG00000231770.4	TMEM44-AS1	3.5	0.000506	0.0309	0.22	0.16	QT interval;	chr3:194597003	chr3:194584011~194590260:+
THCA	cis	rs17301013	0.932	rs1653626	ENSG00000270084.1	GAS5-AS1	3.5	0.000507	0.0309	0.16	0.16	Systemic lupus erythematosus;	chr1:174770348	chr1:173863248~173863941:+
THCA	cis	rs2880765	0.835	rs4536419	ENSG00000218052.5	ADAMTS7P4	-3.5	0.000507	0.0309	-0.18	-0.16	Coronary artery disease;	chr15:85496240	chr15:85255369~85330334:-
THCA	cis	rs10946940	0.965	rs9393830	ENSG00000261839.1	RP1-265C24.8	3.5	0.000507	0.0309	0.16	0.16	Systemic lupus erythematosus;	chr6:27619248	chr6:28136849~28139678:+
THCA	cis	rs6430585	0.527	rs7592050	ENSG00000231890.6	DARS-AS1	3.5	0.000507	0.0309	0.19	0.16	Corneal structure;	chr2:135701657	chr2:135985176~136022593:+
THCA	cis	rs11239930	0.517	rs556976	ENSG00000237188.3	RP11-337C18.8	3.5	0.000507	0.0309	0.19	0.16	AIDS progression;	chr1:147073643	chr1:147172771~147211568:+
THCA	cis	rs703410	0.545	rs242962	ENSG00000232139.4	LINC00867	-3.5	0.000507	0.0309	-0.2	-0.16	Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis);	chr10:117553519	chr10:118357108~118365103:+
THCA	cis	rs9876781	1	rs6442118	ENSG00000199476.1	Y_RNA	-3.5	0.000507	0.0309	-0.2	-0.16	Longevity;	chr3:48398582	chr3:48288587~48288694:+
THCA	cis	rs12893668	0.703	rs2403197	ENSG00000258735.1	LINC00637	-3.5	0.000507	0.0309	-0.21	-0.16	Reticulocyte count;	chr14:103587427	chr14:103847721~103858049:+
THCA	cis	rs7005380	0.58	rs1467044	ENSG00000279347.1	RP11-85I17.2	-3.5	0.000507	0.0309	-0.18	-0.16	Interstitial lung disease;	chr8:119874801	chr8:119838736~119840385:-
THCA	cis	rs3758911	0.861	rs10454489	ENSG00000255353.1	RP11-382M14.1	-3.5	0.000507	0.0309	-0.21	-0.16	Coronary artery disease;	chr11:107279206	chr11:107176286~107177530:+
THCA	cis	rs1865760	1	rs9393675	ENSG00000272810.1	U91328.22	-3.5	0.000507	0.0309	-0.13	-0.16	Height;	chr6:25929888	chr6:26013241~26013757:+
THCA	cis	rs7665090	0.603	rs17033015	ENSG00000248971.2	KRT8P46	-3.5	0.000507	0.0309	-0.19	-0.16	Primary biliary cholangitis;	chr4:102625147	chr4:102728746~102730171:-
THCA	cis	rs3845817	0.671	rs840785	ENSG00000281920.1	RP11-418H16.1	-3.5	0.000507	0.0309	-0.19	-0.16	Bipolar disorder;	chr2:65541842	chr2:65623272~65628424:+
THCA	cis	rs3845817	0.703	rs702915	ENSG00000281920.1	RP11-418H16.1	-3.5	0.000507	0.0309	-0.19	-0.16	Bipolar disorder;	chr2:65543462	chr2:65623272~65628424:+
THCA	cis	rs3845817	0.703	rs1673457	ENSG00000281920.1	RP11-418H16.1	-3.5	0.000507	0.0309	-0.19	-0.16	Bipolar disorder;	chr2:65544511	chr2:65623272~65628424:+
THCA	cis	rs3845817	0.703	rs1673458	ENSG00000281920.1	RP11-418H16.1	-3.5	0.000507	0.0309	-0.19	-0.16	Bipolar disorder;	chr2:65544512	chr2:65623272~65628424:+
THCA	cis	rs6545883	0.525	rs1729658	ENSG00000212978.6	AC016747.3	3.5	0.000507	0.0309	0.17	0.16	Tuberculosis;	chr2:61146385	chr2:61141592~61144969:-
THCA	cis	rs1417770	0.931	rs778388	ENSG00000260971.3	RP11-504A18.1	3.5	0.000507	0.0309	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56230485	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs778390	ENSG00000260971.3	RP11-504A18.1	3.5	0.000507	0.0309	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56230930	chr1:56248294~56258571:-
THCA	cis	rs4713118	0.869	rs6914924	ENSG00000216915.2	RP1-97D16.1	-3.5	0.000507	0.0309	-0.24	-0.16	Parkinson's disease;	chr6:27743751	chr6:27737000~27738494:-
THCA	cis	rs115575488	0.778	rs79260622	ENSG00000231365.4	RP11-418J17.1	3.5	0.000507	0.0309	0.26	0.16	Lobe attachment (rater-scored or self-reported);	chr1:119167512	chr1:119140396~119275973:+
THCA	cis	rs143745495	1	rs143745495	ENSG00000231365.4	RP11-418J17.1	3.5	0.000507	0.0309	0.26	0.16	Lobe attachment (rater-scored or self-reported);	chr1:119172555	chr1:119140396~119275973:+
THCA	cis	rs115575488	0.85	rs78641692	ENSG00000231365.4	RP11-418J17.1	3.5	0.000507	0.0309	0.26	0.16	Lobe attachment (rater-scored or self-reported);	chr1:119192896	chr1:119140396~119275973:+
THCA	cis	rs115575488	0.85	rs76997913	ENSG00000231365.4	RP11-418J17.1	3.5	0.000507	0.0309	0.26	0.16	Lobe attachment (rater-scored or self-reported);	chr1:119196322	chr1:119140396~119275973:+
THCA	cis	rs2131877	0.619	rs7639698	ENSG00000238097.1	RP11-513G11.3	-3.5	0.000507	0.0309	-0.18	-0.16	Non-small cell lung cancer;	chr3:195149566	chr3:194247648~194257772:+
THCA	cis	rs6738825	0.565	rs3792158	ENSG00000231621.1	AC013264.2	-3.5	0.000507	0.0309	-0.15	-0.16	Crohn's disease;	chr2:197542453	chr2:197197991~197199273:+
THCA	cis	rs9652601	0.622	rs8045749	ENSG00000263033.2	RP11-396B14.2	-3.5	0.000507	0.0309	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11025796	chr16:11196177~11224969:+
THCA	cis	rs9796	0.689	rs9888718	ENSG00000247556.5	OIP5-AS1	3.5	0.000507	0.0309	0.13	0.16	Menopause (age at onset);	chr15:41154056	chr15:41283990~41309737:+
THCA	cis	rs2882667	0.861	rs13176902	ENSG00000249593.5	CTB-46B19.2	3.5	0.000507	0.0309	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:139012647~139051203:+
THCA	cis	rs2749592	0.513	rs1208708	ENSG00000275858.1	RP11-291L22.8	3.5	0.000507	0.0309	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38450738~38451069:-
THCA	cis	rs11239930	0.538	rs9663073	ENSG00000180867.10	PDIA3P1	3.5	0.000507	0.0309	0.15	0.16	AIDS progression;	chr1:147083022	chr1:147178113~147179622:+
THCA	cis	rs6471393	0.929	rs62525162	ENSG00000261437.1	RP11-22C11.2	3.5	0.000507	0.0309	0.15	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749654	chr8:94637285~94639467:-
THCA	cis	rs12893668	0.667	rs8017628	ENSG00000258735.1	LINC00637	-3.5	0.000507	0.0309	-0.21	-0.16	Reticulocyte count;	chr14:103581091	chr14:103847721~103858049:+
THCA	cis	rs9353324	1	rs9450372	ENSG00000203875.9	SNHG5	-3.5	0.000507	0.0309	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:86027230	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.913	rs68128210	ENSG00000249244.1	RP11-548H18.2	3.5	0.000507	0.0309	0.18	0.16	Corneal astigmatism;	chr4:119216664	chr4:119391831~119395335:-
THCA	cis	rs7020830	0.898	rs12000309	ENSG00000260100.1	RP11-220I1.5	-3.5	0.000507	0.0309	-0.19	-0.16	Schizophrenia;	chr9:37230847	chr9:37078813~37079776:-
THCA	cis	rs7809950	0.817	rs2237671	ENSG00000272072.1	CTA-363E19.2	3.5	0.000507	0.0309	0.16	0.16	Coronary artery disease;	chr7:107491083	chr7:107192559~107193300:-
THCA	cis	rs950169	1	rs35297609	ENSG00000275120.1	RP11-182J1.17	3.5	0.000507	0.0309	0.19	0.16	Schizophrenia;	chr15:84104144	chr15:84599434~84606463:-
THCA	cis	rs72843506	0.656	rs79406817	ENSG00000189423.10	USP32P3	3.5	0.000507	0.0309	0.27	0.16	Schizophrenia;	chr17:20011814	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs77090106	ENSG00000189423.10	USP32P3	3.5	0.000507	0.0309	0.27	0.16	Schizophrenia;	chr17:20044832	chr17:20415547~20431008:+
THCA	cis	rs10089	0.953	rs1432614	ENSG00000245937.6	LINC01184	3.5	0.000508	0.0309	0.18	0.16	Ileal carcinoids;	chr5:128081227	chr5:127940426~128083172:-
THCA	cis	rs12887734	0.546	rs12885509	ENSG00000258735.1	LINC00637	-3.5	0.000508	0.0309	-0.21	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103847721~103858049:+
THCA	cis	rs7781557	0.64	rs2228687	ENSG00000170629.13	DPY19L2P2	3.5	0.000508	0.0309	0.2	0.16	Colorectal adenoma (advanced);	chr7:102976022	chr7:103175133~103280410:-
THCA	cis	rs875971	0.964	rs160635	ENSG00000230189.5	GS1-124K5.2	3.5	0.000508	0.0309	0.11	0.16	Aortic root size;	chr7:66063931	chr7:66409143~66490059:-
THCA	cis	rs939960	0.879	rs36020504	ENSG00000276538.1	RP11-545G3.2	3.5	0.000508	0.0309	0.27	0.16	Neutrophil percentage of white cells;	chr7:150650162	chr7:150047609~150047854:-
THCA	cis	rs7941765	1	rs6590343	ENSG00000255465.3	RP11-264E20.1	-3.5	0.000508	0.031	-0.2	-0.16	Systemic lupus erythematosus;	chr11:128630320	chr11:128615867~128621806:-
THCA	cis	rs6840360	0.571	rs718801	ENSG00000251611.1	RP11-610P16.1	-3.5	0.000508	0.031	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151628095	chr4:151407551~151408835:-
THCA	cis	rs17181170	0.515	rs58388371	ENSG00000239572.1	RP11-451B8.1	-3.5	0.000508	0.031	-0.2	-0.16	Prostate cancer;	chr3:87129107	chr3:87731402~87793629:-
THCA	cis	rs860295	0.702	rs12047756	ENSG00000236675.1	MTX1P1	-3.5	0.000508	0.031	-0.16	-0.16	Body mass index;	chr1:155655153	chr1:155230975~155234325:+
THCA	cis	rs6547705	0.702	rs4832049	ENSG00000266931.1	RP11-1252D15.1	3.5	0.000508	0.031	0.2	0.16	Progressive supranuclear palsy;	chr2:86826596	chr2:87055658~87055800:-
THCA	cis	rs732716	0.813	rs760369	ENSG00000280239.1	CTB-50L17.8	3.5	0.000508	0.031	0.13	0.16	Mean corpuscular volume;	chr19:4449290	chr19:4448810~4450836:+
THCA	cis	rs9859260	0.591	rs3827554	ENSG00000231464.1	AC024937.4	3.5	0.000508	0.031	0.2	0.16	Mean corpuscular volume;	chr3:196082245	chr3:195996738~195998233:+
THCA	cis	rs9450351	0.744	rs6910543	ENSG00000280232.1	RP11-321N4.4	3.5	0.000508	0.031	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85519023	chr6:85498441~85499058:-
THCA	cis	rs9450351	0.744	rs9444353	ENSG00000280232.1	RP11-321N4.4	3.5	0.000508	0.031	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85566986	chr6:85498441~85499058:-
THCA	cis	rs9450351	0.744	rs9351063	ENSG00000280232.1	RP11-321N4.4	3.5	0.000508	0.031	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85567123	chr6:85498441~85499058:-
THCA	cis	rs2209875	0.573	rs74703137	ENSG00000265112.1	MIR3153	-3.5	0.000508	0.031	-0.19	-0.16	Pelvic organ prolapse (moderate/severe);	chr9:89336429	chr9:89312225~89312306:+
THCA	cis	rs4907240	0.921	rs2278563	ENSG00000230606.9	AC159540.1	3.5	0.000508	0.031	0.18	0.16	Event-related brain oscillations;	chr2:96546956	chr2:97416165~97433527:-
THCA	cis	rs875971	0.862	rs11984115	ENSG00000223473.2	GS1-124K5.3	-3.5	0.000508	0.031	-0.11	-0.16	Aortic root size;	chr7:66308872	chr7:66491049~66493566:-
THCA	cis	rs4808199	1	rs60003758	ENSG00000267481.1	CTC-559E9.5	-3.5	0.000508	0.031	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19446544	chr19:19788755~19790531:-
THCA	cis	rs4808199	1	rs12972397	ENSG00000267481.1	CTC-559E9.5	-3.5	0.000508	0.031	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19451540	chr19:19788755~19790531:-
THCA	cis	rs10200159	1	rs6705295	ENSG00000206964.1	Y_RNA	-3.5	0.000508	0.031	-0.36	-0.16	Vitiligo;	chr2:55686874	chr2:55286018~55286128:+
THCA	cis	rs11672691	0.627	rs6508981	ENSG00000268355.1	AC006129.1	-3.5	0.000508	0.031	-0.2	-0.16	Prostate cancer;	chr19:41483668	chr19:41531206~41532174:+
THCA	cis	rs4588572	0.57	rs6453389	ENSG00000245556.2	SCAMP1-AS1	-3.5	0.000508	0.031	-0.12	-0.16	Triglycerides;	chr5:78431179	chr5:78342365~78360507:-
THCA	cis	rs7558911	0.801	rs13004275	ENSG00000183308.6	AC005037.3	3.5	0.000508	0.031	0.18	0.16	Chronic lymphocytic leukemia;	chr2:201236623	chr2:200963263~201009102:+
THCA	cis	rs9900062	1	rs2521879	ENSG00000214176.8	PLEKHM1P	3.5	0.000508	0.031	0.14	0.16	QT interval;	chr17:64746560	chr17:64779259~64837154:-
THCA	cis	rs57709857	0.957	rs6996860	ENSG00000272092.1	RP11-350N15.5	3.5	0.000508	0.031	0.17	0.16	Autism spectrum disorder or schizophrenia;	chr8:38386347	chr8:38382364~38383461:+
THCA	cis	rs10515778	1	rs72815811	ENSG00000280834.1	U6	3.5	0.000508	0.031	0.28	0.16	Inflammatory skin disease;	chr5:159230808	chr5:160072268~160072364:+
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149782897	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149783124	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149783553	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149783956	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149787920	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149787970	chr6:149576089~149590864:-
THCA	cis	rs9322193	1	rs9767077	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149788479	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149788709	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149788941	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000508	0.031	-0.16	-0.16	Lung cancer;	chr6:149788977	chr6:149576089~149590864:-
THCA	cis	rs10896135	0.526	rs484262	ENSG00000255320.1	RP11-755F10.1	-3.5	0.000508	0.031	-0.21	-0.16	Bipolar disorder;	chr11:66632210	chr11:66244840~66246239:-
THCA	cis	rs8058578	1	rs2289442	ENSG00000260911.2	RP11-196G11.2	3.5	0.000508	0.031	0.14	0.16	Multiple myeloma;	chr16:30728598	chr16:31043150~31049868:+
THCA	cis	rs8130944	1	rs2269150	ENSG00000235772.1	AP001625.6	-3.5	0.000508	0.031	-0.18	-0.16	Perceived unattractiveness to mosquitoes;	chr21:42721339	chr21:42560374~42561934:-
THCA	cis	rs1048886	0.872	rs35159719	ENSG00000271967.1	RP11-134K13.4	-3.5	0.000508	0.031	-0.19	-0.16	Type 2 diabetes;	chr6:70561987	chr6:70596438~70596980:+
THCA	cis	rs6101567	0.749	rs743153	ENSG00000224635.1	RP4-564F22.5	-3.5	0.000508	0.031	-0.2	-0.16	Nose size;	chr20:39295324	chr20:38406011~38416797:-
THCA	cis	rs1125355	0.69	rs1515929	ENSG00000243792.1	OR7E89P	-3.5	0.000508	0.031	-0.24	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158773125	chr2:158853755~158854576:+
THCA	cis	rs3126085	0.935	rs11204939	ENSG00000237975.5	FLG-AS1	-3.5	0.000508	0.031	-0.25	-0.16	Atopic dermatitis;	chr1:152228466	chr1:152168125~152445456:+
THCA	cis	rs3770081	1	rs12617717	ENSG00000273080.1	RP11-301O19.1	-3.5	0.000508	0.031	-0.37	-0.16	Facial emotion recognition (sad faces);	chr2:86115180	chr2:86195590~86196049:+
THCA	cis	rs8099594	0.541	rs11082743	ENSG00000266696.1	RP11-30L3.2	-3.5	0.000508	0.031	-0.2	-0.16	Height;	chr18:49243728	chr18:49205912~49208781:+
THCA	cis	rs804280	0.565	rs2645453	ENSG00000254948.1	OR7E158P	-3.5	0.000508	0.031	-0.19	-0.16	Myopia (pathological);	chr8:11764492	chr8:11919900~11920809:-
THCA	cis	rs9650657	0.803	rs13276026	ENSG00000269918.1	AF131215.9	-3.5	0.000508	0.031	-0.16	-0.16	Neuroticism;	chr8:10752445	chr8:11104691~11106704:-
THCA	cis	rs2380205	0.517	rs12774886	ENSG00000232807.2	RP11-536K7.3	3.5	0.000509	0.031	0.16	0.16	Breast cancer;	chr10:5929489	chr10:5934270~5945900:-
THCA	cis	rs9796	0.636	rs1983400	ENSG00000247556.5	OIP5-AS1	3.5	0.000509	0.031	0.13	0.16	Menopause (age at onset);	chr15:41080831	chr15:41283990~41309737:+
THCA	cis	rs9796	0.745	rs2947493	ENSG00000247556.5	OIP5-AS1	3.5	0.000509	0.031	0.13	0.16	Menopause (age at onset);	chr15:41083496	chr15:41283990~41309737:+
THCA	cis	rs9796	0.717	rs2947494	ENSG00000247556.5	OIP5-AS1	3.5	0.000509	0.031	0.13	0.16	Menopause (age at onset);	chr15:41083543	chr15:41283990~41309737:+
THCA	cis	rs9608946	1	rs9608946	ENSG00000279699.1	RP1-102K2.9	3.5	0.000509	0.031	0.19	0.16	Red cell distribution width;	chr22:30496268	chr22:30275215~30276951:-
THCA	cis	rs35123781	0.696	rs7703195	ENSG00000253404.1	AC034243.1	-3.5	0.000509	0.031	-0.21	-0.16	Schizophrenia;	chr5:139692047	chr5:138744434~138753309:-
THCA	cis	rs7246967	0.673	rs11881740	ENSG00000198153.8	ZNF849P	-3.5	0.000509	0.031	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22661042	chr19:22685167~22686732:+
THCA	cis	rs453301	0.605	rs7843024	ENSG00000253981.4	ALG1L13P	-3.5	0.000509	0.031	-0.16	-0.16	Joint mobility (Beighton score);	chr8:8942466	chr8:8236003~8244667:-
THCA	cis	rs453301	0.631	rs7843789	ENSG00000253981.4	ALG1L13P	-3.5	0.000509	0.031	-0.16	-0.16	Joint mobility (Beighton score);	chr8:8943051	chr8:8236003~8244667:-
THCA	cis	rs948562	0.681	rs10750901	ENSG00000280010.1	AP001350.4	3.5	0.000509	0.031	0.22	0.16	Lymphoma;	chr11:58660110	chr11:58627435~58628528:+
THCA	cis	rs4883201	0.572	rs1805735	ENSG00000245105.2	A2M-AS1	3.5	0.000509	0.031	0.15	0.16	Total cholesterol levels;Cholesterol, total;	chr12:8934087	chr12:9065177~9068060:+
THCA	cis	rs2882667	1	rs10064130	ENSG00000249593.5	CTB-46B19.2	3.5	0.000509	0.031	0.2	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:139012647~139051203:+
THCA	cis	rs853679	0.599	rs13193295	ENSG00000272009.1	RP1-313I6.12	-3.5	0.000509	0.031	-0.3	-0.16	Depression;	chr6:28035450	chr6:28078792~28081130:-
THCA	cis	rs11771526	0.551	rs1008540	ENSG00000272905.1	RP11-265E18.1	3.5	0.000509	0.031	0.18	0.16	Body mass index;	chr7:32210010	chr7:32845394~32846061:+
THCA	cis	rs9863	0.896	rs76283024	ENSG00000269938.1	RP11-214K3.20	-3.5	0.000509	0.031	-0.19	-0.16	White blood cell count;	chr12:123982232	chr12:123968023~123968579:-
THCA	cis	rs7701440	0.512	rs40506	ENSG00000251279.1	CTC-436P18.1	-3.5	0.000509	0.031	-0.19	-0.16	Educational attainment;	chr5:61229383	chr5:61162070~61232040:+
THCA	cis	rs7701440	0.512	rs34631	ENSG00000251279.1	CTC-436P18.1	-3.5	0.000509	0.031	-0.19	-0.16	Educational attainment;	chr5:61230499	chr5:61162070~61232040:+
THCA	cis	rs950169	0.92	rs12915390	ENSG00000230373.7	GOLGA6L5P	-3.5	0.000509	0.031	-0.18	-0.16	Schizophrenia;	chr15:84123317	chr15:84507885~84516814:-
THCA	cis	rs9393813	0.805	rs2205829	ENSG00000204789.4	ZNF204P	3.5	0.000509	0.031	0.13	0.16	Bipolar disorder;	chr6:27512448	chr6:27357825~27360221:-
THCA	cis	rs11190604	0.697	rs12355942	ENSG00000273030.1	RP11-285F16.1	-3.5	0.000509	0.031	-0.18	-0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100441563	chr10:100412934~100413421:+
THCA	cis	rs6940638	0.956	rs72838268	ENSG00000224843.5	LINC00240	3.5	0.000509	0.031	0.19	0.16	Intelligence (multi-trait analysis);	chr6:27053394	chr6:26956992~27023924:+
THCA	cis	rs748404	0.66	rs2467738	ENSG00000275601.1	AC011330.13	-3.5	0.000509	0.031	-0.19	-0.16	Lung cancer;	chr15:43447738	chr15:43642389~43643023:-
THCA	cis	rs3800688	0.506	rs12539640	ENSG00000236753.4	MKLN1-AS	-3.5	0.000509	0.031	-0.15	-0.16	Hypertension;	chr7:131468403	chr7:131309744~131328222:-
THCA	cis	rs2018683	0.677	rs12540529	ENSG00000233517.1	AC005162.5	-3.5	0.000509	0.031	-0.2	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929767	chr7:28987028~28988899:+
THCA	cis	rs9878978	0.66	rs62245707	ENSG00000227588.2	CNTN4-AS2	3.5	0.000509	0.031	0.21	0.16	Blood pressure (smoking interaction);	chr3:2396500	chr3:2110409~2144241:-
THCA	cis	rs11239930	0.934	rs10900313	ENSG00000180867.10	PDIA3P1	3.5	0.000509	0.031	0.13	0.16	AIDS progression;	chr1:147089200	chr1:147178113~147179622:+
THCA	cis	rs11098499	0.644	rs10009566	ENSG00000249244.1	RP11-548H18.2	3.5	0.000509	0.031	0.18	0.16	Corneal astigmatism;	chr4:119637453	chr4:119391831~119395335:-
THCA	cis	rs4834770	1	rs878375	ENSG00000249244.1	RP11-548H18.2	3.5	0.000509	0.031	0.17	0.16	Blood protein levels;	chr4:119316419	chr4:119391831~119395335:-
THCA	cis	rs836788	0.535	rs6151850	ENSG00000251050.1	RP11-168A11.4	3.5	0.000509	0.031	0.13	0.16	Glomerular filtration rate (creatinine);	chr5:80793241	chr5:80019609~80019920:+
THCA	cis	rs7116495	1	rs2250866	ENSG00000251143.1	RP11-849H4.4	3.5	0.000509	0.031	0.17	0.16	Severe influenza A (H1N1) infection;	chr11:72093467	chr11:72014291~72020910:+
THCA	cis	rs485497	1	rs485497	ENSG00000244040.4	IL12A-AS1	-3.5	0.000509	0.031	-0.2	-0.16	Sjögren's syndrome;	chr3:160001345	chr3:159913400~160225299:-
THCA	cis	rs6439699	0.825	rs13082187	ENSG00000273486.1	RP11-731C17.2	3.5	0.000509	0.031	0.17	0.16	Intelligence (multi-trait analysis);	chr3:137349060	chr3:136837338~136839021:-
THCA	cis	rs12681366	0.919	rs13248829	ENSG00000253175.1	RP11-267M23.6	3.5	0.000509	0.031	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94476750	chr8:94565036~94565715:+
THCA	cis	rs2243480	1	rs402418	ENSG00000237310.1	GS1-124K5.4	3.5	0.000509	0.031	0.18	0.16	Diabetic kidney disease;	chr7:66044482	chr7:66493706~66495474:+
THCA	cis	rs1832871	0.672	rs1342211	ENSG00000213078.3	RP5-933K21.2	-3.5	0.000509	0.031	-0.24	-0.16	Height;	chr6:158338464	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs11751553	ENSG00000213078.3	RP5-933K21.2	3.5	0.000509	0.031	0.24	0.16	Height;	chr6:158353718	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9457363	ENSG00000213078.3	RP5-933K21.2	-3.5	0.000509	0.031	-0.24	-0.16	Height;	chr6:158356483	chr6:157365990~157366923:-
THCA	cis	rs10411161	0.81	rs17778711	ENSG00000275055.1	CTC-471J1.11	-3.5	0.000509	0.031	-0.19	-0.16	Breast cancer;	chr19:51882047	chr19:52049007~52049754:+
THCA	cis	rs988712	0.921	rs2101467	ENSG00000245573.6	BDNF-AS	-3.5	0.000509	0.031	-0.14	-0.16	Obesity;	chr11:27522812	chr11:27506838~27698174:+
THCA	cis	rs972578	1	rs1569507	ENSG00000274717.1	RP1-47A17.1	3.5	0.000509	0.031	0.17	0.16	Mean platelet volume;	chr22:42960693	chr22:42791814~42794313:-
THCA	cis	rs4295623	0.531	rs2898295	ENSG00000227888.4	FAM66A	-3.5	0.000509	0.031	-0.19	-0.16	Morning vs. evening chronotype;	chr8:11738460	chr8:12362019~12388296:+
THCA	cis	rs9652601	0.665	rs17805769	ENSG00000263033.2	RP11-396B14.2	-3.5	0.000509	0.031	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11092016	chr16:11196177~11224969:+
THCA	cis	rs9611565	0.659	rs4822037	ENSG00000237037.8	NDUFA6-AS1	3.5	0.000509	0.031	0.15	0.16	Vitiligo;	chr22:41549109	chr22:42090931~42137742:+
THCA	cis	rs7873102	0.654	rs7044060	ENSG00000213839.4	TMX2P1	-3.5	0.000509	0.031	-0.12	-0.16	Brain structure;	chr9:37956274	chr9:37885683~37886390:+
THCA	cis	rs1417770	0.931	rs778403	ENSG00000260971.3	RP11-504A18.1	3.5	0.000509	0.031	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56236941	chr1:56248294~56258571:-
THCA	cis	rs9652601	0.622	rs6498143	ENSG00000263033.2	RP11-396B14.2	-3.5	0.000509	0.031	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11001179	chr16:11196177~11224969:+
THCA	cis	rs9652601	0.622	rs7194305	ENSG00000263033.2	RP11-396B14.2	-3.5	0.000509	0.031	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11005850	chr16:11196177~11224969:+
THCA	cis	rs7843479	0.931	rs1031883	ENSG00000208037.1	MIR320A	-3.5	0.000509	0.031	-0.2	-0.16	Mean corpuscular volume;	chr8:21931425	chr8:22244962~22245043:-
THCA	cis	rs3176789	0.647	rs35143542	ENSG00000256673.1	RP11-599J14.2	3.5	0.000509	0.031	0.19	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766925	chr12:9398355~9414851:-
THCA	cis	rs12476592	0.602	rs174485	ENSG00000242412.1	DBIL5P2	3.5	0.000509	0.031	0.2	0.16	Childhood ear infection;	chr2:63630268	chr2:63117851~63119542:-
THCA	cis	rs5758511	0.508	rs28715885	ENSG00000230107.1	CTA-126B4.7	-3.5	0.00051	0.031	-0.22	-0.16	Birth weight;	chr22:42045087	chr22:42438023~42446195:+
THCA	cis	rs5758511	0.508	rs58099562	ENSG00000230107.1	CTA-126B4.7	-3.5	0.00051	0.031	-0.22	-0.16	Birth weight;	chr22:42057768	chr22:42438023~42446195:+
THCA	cis	rs561341	0.941	rs2428338	ENSG00000265798.5	RP11-271K11.5	3.5	0.00051	0.031	0.24	0.16	Hip circumference adjusted for BMI;	chr17:31972610	chr17:31038575~31059121:-
THCA	cis	rs10858047	0.883	rs6701427	ENSG00000231128.4	RP5-1073O3.2	-3.5	0.00051	0.031	-0.24	-0.16	Autism;	chr1:114674265	chr1:113812379~113829171:+
THCA	cis	rs1005277	0.522	rs9417256	ENSG00000273019.1	RP11-508N22.13	-3.5	0.00051	0.031	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38149968~38150293:+
THCA	cis	rs2766547	0.647	rs2766542	ENSG00000228559.1	RP3-340B19.3	3.5	0.00051	0.0311	0.18	0.16	Eosinophil percentage of granulocytes;	chr6:35739913	chr6:35544632~35545669:+
THCA	cis	rs7267979	1	rs2474777	ENSG00000276952.1	RP5-965G21.6	3.5	0.00051	0.0311	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25284915~25285588:-
THCA	cis	rs4879656	0.966	rs7469374	ENSG00000225693.1	LAGE3P1	-3.5	0.00051	0.0311	-0.18	-0.16	Menopause (age at onset);	chr9:33035116	chr9:33019682~33020165:-
THCA	cis	rs4879656	0.966	rs4879661	ENSG00000225693.1	LAGE3P1	-3.5	0.00051	0.0311	-0.18	-0.16	Menopause (age at onset);	chr9:33035248	chr9:33019682~33020165:-
THCA	cis	rs4879656	0.966	rs10971358	ENSG00000225693.1	LAGE3P1	-3.5	0.00051	0.0311	-0.18	-0.16	Menopause (age at onset);	chr9:33038051	chr9:33019682~33020165:-
THCA	cis	rs4879656	0.966	rs7296	ENSG00000225693.1	LAGE3P1	-3.5	0.00051	0.0311	-0.18	-0.16	Menopause (age at onset);	chr9:33039026	chr9:33019682~33020165:-
THCA	cis	rs7709377	0.516	rs7701736	ENSG00000271918.1	CTD-2287O16.5	3.5	0.00051	0.0311	0.15	0.16	Metabolite levels  (X-11787);	chr5:116185318	chr5:116083807~116085416:-
THCA	cis	rs1396485	0.66	rs6874747	ENSG00000271918.1	CTD-2287O16.5	3.5	0.00051	0.0311	0.15	0.16	Inflammatory biomarkers;	chr5:116196852	chr5:116083807~116085416:-
THCA	cis	rs10895987	0.955	rs7113761	ENSG00000197847.11	SLC22A20	-3.5	0.00051	0.0311	-0.2	-0.16	Blood protein levels;	chr11:65159251	chr11:65213840~65242757:+
THCA	cis	rs7264396	0.635	rs6060656	ENSG00000088340.14	FER1L4	3.5	0.00051	0.0311	0.16	0.16	Total cholesterol levels;	chr20:35878460	chr20:35558737~35607562:-
THCA	cis	rs2617170	0.754	rs4763202	ENSG00000245648.1	RP11-277P12.20	3.5	0.00051	0.0311	0.16	0.16	Behcet's disease;	chr12:10474391	chr12:10363769~10398506:+
THCA	cis	rs11673344	0.526	rs17303902	ENSG00000229481.2	CTD-2554C21.3	-3.5	0.00051	0.0311	-0.15	-0.16	Obesity-related traits;	chr19:37551912	chr19:37829551~37832160:+
THCA	cis	rs9488822	0.676	rs12154016	ENSG00000237021.2	RP3-486I3.7	3.5	0.00051	0.0311	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116034025	chr6:116254207~116256743:+
THCA	cis	rs9818758	0.607	rs13087930	ENSG00000229759.1	MRPS18AP1	-3.5	0.00051	0.0311	-0.33	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48924293	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.545	rs11717978	ENSG00000229759.1	MRPS18AP1	-3.5	0.00051	0.0311	-0.33	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48931603	chr3:48256350~48256938:-
THCA	cis	rs3770081	1	rs11899576	ENSG00000273080.1	RP11-301O19.1	-3.5	0.00051	0.0311	-0.32	-0.16	Facial emotion recognition (sad faces);	chr2:86029070	chr2:86195590~86196049:+
THCA	cis	rs801193	1	rs2659915	ENSG00000275400.1	RP4-756H11.5	-3.5	0.00051	0.0311	-0.15	-0.16	Aortic root size;	chr7:66688114	chr7:66553805~66554199:-
THCA	cis	rs55893317	0.526	rs7107916	ENSG00000246273.5	SBF2-AS1	-3.5	0.00051	0.0311	-0.21	-0.16	Red blood cell count;	chr11:9990964	chr11:9758292~9811319:+
THCA	cis	rs615632	0.57	rs17734541	ENSG00000261451.1	RP11-981G7.1	3.5	0.00051	0.0311	0.21	0.16	Neuroticism;	chr8:9850923	chr8:10433672~10438312:+
THCA	cis	rs61142792	1	rs337351	ENSG00000272459.1	RP11-1277A3.3	-3.5	0.00051	0.0311	-0.35	-0.16	Alzheimer disease and age of onset;	chr5:177547018	chr5:177554824~177555364:+
THCA	cis	rs7577696	0.8	rs216544	ENSG00000276334.1	AL133243.1	-3.5	0.00051	0.0311	-0.17	-0.16	Inflammatory biomarkers;	chr2:32093737	chr2:32521927~32523547:+
THCA	cis	rs7656342	0.897	rs7685396	ENSG00000242034.1	RP11-1396O13.1	3.5	0.00051	0.0311	0.19	0.16	Gut microbiota (bacterial taxa);	chr4:9793100	chr4:9553614~9553985:-
THCA	cis	rs2797160	1	rs6910933	ENSG00000226409.1	RP11-735G4.1	3.5	0.00051	0.0311	0.19	0.16	Endometrial cancer;	chr6:125696009	chr6:125370211~125374324:-
THCA	cis	rs4919669	0.777	rs11191375	ENSG00000272912.1	RP11-724N1.1	-3.5	0.00051	0.0311	-0.27	-0.16	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102704900	chr10:102914585~102915404:+
THCA	cis	rs4919669	0.777	rs10883766	ENSG00000272912.1	RP11-724N1.1	-3.5	0.00051	0.0311	-0.27	-0.16	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102705006	chr10:102914585~102915404:+
THCA	cis	rs959260	1	rs4789186	ENSG00000263843.1	RP11-649A18.12	3.5	0.00051	0.0311	0.18	0.16	Systemic lupus erythematosus;	chr17:75390005	chr17:75271369~75273895:+
THCA	cis	rs959260	0.925	rs9901434	ENSG00000263843.1	RP11-649A18.12	3.5	0.00051	0.0311	0.18	0.16	Systemic lupus erythematosus;	chr17:75392689	chr17:75271369~75273895:+
THCA	cis	rs959260	0.925	rs4788890	ENSG00000263843.1	RP11-649A18.12	3.5	0.00051	0.0311	0.18	0.16	Systemic lupus erythematosus;	chr17:75393365	chr17:75271369~75273895:+
THCA	cis	rs959260	0.92	rs4789187	ENSG00000263843.1	RP11-649A18.12	3.5	0.00051	0.0311	0.18	0.16	Systemic lupus erythematosus;	chr17:75398703	chr17:75271369~75273895:+
THCA	cis	rs7903847	0.642	rs11189196	ENSG00000225850.3	RP11-452K12.4	3.5	0.00051	0.0311	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97395322	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.596	rs9787426	ENSG00000225850.3	RP11-452K12.4	3.5	0.00051	0.0311	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97395570	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.62	rs9787454	ENSG00000225850.3	RP11-452K12.4	3.5	0.00051	0.0311	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97395804	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.596	rs7922512	ENSG00000225850.3	RP11-452K12.4	3.5	0.00051	0.0311	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97395928	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs3814553	ENSG00000225850.3	RP11-452K12.4	3.5	0.00051	0.0311	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97396227	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs11189200	ENSG00000225850.3	RP11-452K12.4	3.5	0.00051	0.0311	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97396516	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.602	rs7916665	ENSG00000225850.3	RP11-452K12.4	3.5	0.00051	0.0311	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97397816	chr10:97334564~97343203:+
THCA	cis	rs4699052	1	rs4699055	ENSG00000251288.2	RP11-10L12.2	-3.5	0.00051	0.0311	-0.2	-0.16	Testicular germ cell tumor;	chr4:103233343	chr4:102751401~102752641:+
THCA	cis	rs1862618	0.853	rs190414	ENSG00000234553.1	AC022431.3	-3.5	0.00051	0.0311	-0.18	-0.16	Initial pursuit acceleration;	chr5:56820945	chr5:56536583~56537826:-
THCA	cis	rs16857609	0.564	rs13425215	ENSG00000233143.1	DIRC3-AS1	-3.5	0.00051	0.0311	-0.19	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217423857	chr2:217282739~217336120:+
THCA	cis	rs2486012	0.655	rs2906598	ENSG00000237950.1	RP11-7O11.3	-3.5	0.00051	0.0311	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43906618	chr1:43944370~43946551:-
THCA	cis	rs2486012	0.826	rs2993621	ENSG00000237950.1	RP11-7O11.3	-3.5	0.00051	0.0311	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43906619	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs2486012	ENSG00000237950.1	RP11-7O11.3	-3.5	0.00051	0.0311	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43907737	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs2248305	ENSG00000237950.1	RP11-7O11.3	-3.5	0.00051	0.0311	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43913821	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs1859725	ENSG00000237950.1	RP11-7O11.3	-3.5	0.00051	0.0311	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43913905	chr1:43944370~43946551:-
THCA	cis	rs34779708	0.966	rs2045915	ENSG00000233200.1	RP11-324I22.2	3.5	0.00051	0.0311	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35219894~35230598:-
THCA	cis	rs11157436	0.874	rs35951144	ENSG00000211812.1	TRAV26-2	-3.5	0.00051	0.0311	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149973	chr14:22202583~22203368:+
THCA	cis	rs3749237	0.595	rs7643845	ENSG00000224424.7	PRKAR2A-AS1	3.5	0.00051	0.0311	0.13	0.16	Resting heart rate;	chr3:49493278	chr3:48847572~48851981:+
THCA	cis	rs17711722	0.523	rs313812	ENSG00000230189.5	GS1-124K5.2	-3.5	0.000511	0.0311	-0.1	-0.16	Calcium levels;	chr7:66040056	chr7:66409143~66490059:-
THCA	cis	rs875971	0.895	rs12531677	ENSG00000223473.2	GS1-124K5.3	-3.5	0.000511	0.0311	-0.11	-0.16	Aortic root size;	chr7:66304099	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs7798630	ENSG00000223473.2	GS1-124K5.3	-3.5	0.000511	0.0311	-0.11	-0.16	Aortic root size;	chr7:66306492	chr7:66491049~66493566:-
THCA	cis	rs34792	0.554	rs12933773	ENSG00000262332.1	RP11-517A5.7	3.5	0.000511	0.0311	0.18	0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:16223027~16224261:+
THCA	cis	rs1396485	0.607	rs10477550	ENSG00000250015.1	CTC-339F2.2	3.5	0.000511	0.0311	0.18	0.16	Inflammatory biomarkers;	chr5:116094060	chr5:116302354~116304134:-
THCA	cis	rs6433895	0.601	rs4514840	ENSG00000236153.1	AC104076.3	-3.5	0.000511	0.0311	-0.2	-0.16	Lymphocyte counts;	chr2:181180547	chr2:180979427~180980090:-
THCA	cis	rs2638953	0.924	rs11049575	ENSG00000247934.4	RP11-967K21.1	-3.5	0.000511	0.0311	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28411328	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs2348235	ENSG00000247934.4	RP11-967K21.1	-3.5	0.000511	0.0311	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414019	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.886	rs11049577	ENSG00000247934.4	RP11-967K21.1	-3.5	0.000511	0.0311	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414437	chr12:28163298~28190738:-
THCA	cis	rs2839186	0.934	rs17176520	ENSG00000228137.1	AP001469.7	3.5	0.000511	0.0311	0.16	0.16	Testicular germ cell tumor;	chr21:46262167	chr21:46246890~46247682:+
THCA	cis	rs1556032	0.522	rs4741379	ENSG00000225472.1	RP11-120J1.1	-3.5	0.000511	0.0311	-0.15	-0.16	AIDS;	chr9:14457335	chr9:14317085~14357908:+
THCA	cis	rs6472235	0.586	rs62507386	ENSG00000200714.1	Y_RNA	-3.5	0.000511	0.0311	-0.2	-0.16	Plateletcrit;Myopia (pathological);	chr8:66012724	chr8:65592731~65592820:+
THCA	cis	rs7474896	0.559	rs1208560	ENSG00000272983.1	RP11-508N22.12	3.5	0.000511	0.0311	0.16	0.16	Obesity (extreme);	chr10:37932690	chr10:38137337~38144399:+
THCA	cis	rs2688608	0.672	rs2227576	ENSG00000271816.1	BMS1P4	3.5	0.000511	0.0311	0.16	0.16	Inflammatory bowel disease;	chr10:73918518	chr10:73699151~73730487:-
THCA	cis	rs7763441	1	rs9501843	ENSG00000250903.7	GMDS-AS1	3.5	0.000511	0.0311	0.13	0.16	Monobrow;	chr6:2449638	chr6:2245748~2482022:+
THCA	cis	rs330071	0.549	rs11785593	ENSG00000254153.1	CTA-398F10.2	-3.5	0.000511	0.0311	-0.19	-0.16	Acne (severe);	chr8:9398814	chr8:8456909~8461337:-
THCA	cis	rs7737355	0.812	rs11242083	ENSG00000224431.1	AC063976.7	3.5	0.000511	0.0311	0.15	0.16	Life satisfaction;	chr5:131591833	chr5:132199456~132203487:+
THCA	cis	rs4742903	0.935	rs10991182	ENSG00000270332.1	SMC2-AS1	3.5	0.000511	0.0311	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104221297	chr9:104080024~104093073:-
THCA	cis	rs683250	0.598	rs578842	ENSG00000254551.1	RP11-727A23.7	3.5	0.000511	0.0311	0.2	0.16	Subcortical brain region volumes;	chr11:83263868	chr11:83209431~83213379:-
THCA	cis	rs875971	0.965	rs6971509	ENSG00000272831.1	RP11-792A8.4	-3.5	0.000511	0.0311	-0.1	-0.16	Aortic root size;	chr7:66249983	chr7:66739829~66740385:-
THCA	cis	rs793571	0.822	rs2279719	ENSG00000245975.2	RP11-30K9.6	3.5	0.000511	0.0311	0.18	0.16	Schizophrenia;	chr15:58933619	chr15:58768072~58770974:-
THCA	cis	rs7296418	0.885	rs1790104	ENSG00000256092.2	RP13-942N8.1	3.5	0.000511	0.0311	0.12	0.16	Platelet count;	chr12:123224862	chr12:123363868~123366113:+
THCA	cis	rs7296418	0.816	rs1790096	ENSG00000256092.2	RP13-942N8.1	3.5	0.000511	0.0311	0.12	0.16	Platelet count;	chr12:123225817	chr12:123363868~123366113:+
THCA	cis	rs301901	0.772	rs301863	ENSG00000250155.1	CTD-2353F22.1	-3.5	0.000511	0.0311	-0.16	-0.16	Height;	chr5:37133456	chr5:36666214~36725195:-
THCA	cis	rs7873102	0.542	rs3849927	ENSG00000213839.4	TMX2P1	3.5	0.000511	0.0311	0.13	0.16	Brain structure;	chr9:38055131	chr9:37885683~37886390:+
THCA	cis	rs1538970	0.961	rs4660854	ENSG00000234329.1	RP11-767N6.2	3.5	0.000511	0.0311	0.16	0.16	Platelet count;	chr1:45388415	chr1:45651039~45651826:-
THCA	cis	rs3785309	0.519	rs72763696	ENSG00000268836.1	LA16c-OS12.2	-3.5	0.000511	0.0311	-0.28	-0.16	Immature fraction of reticulocytes;	chr16:212801	chr16:185748~186294:-
THCA	cis	rs3785309	0.519	rs72763698	ENSG00000268836.1	LA16c-OS12.2	-3.5	0.000511	0.0311	-0.28	-0.16	Immature fraction of reticulocytes;	chr16:214794	chr16:185748~186294:-
THCA	cis	rs10487112	0.61	rs6945128	ENSG00000225498.1	AC002064.5	3.5	0.000511	0.0311	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr7:90393765	chr7:90312496~90322592:+
THCA	cis	rs1048886	0.808	rs75589353	ENSG00000271967.1	RP11-134K13.4	-3.5	0.000511	0.0311	-0.19	-0.16	Type 2 diabetes;	chr6:70540228	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs77057748	ENSG00000271967.1	RP11-134K13.4	-3.5	0.000511	0.0311	-0.19	-0.16	Type 2 diabetes;	chr6:70549286	chr6:70596438~70596980:+
THCA	cis	rs6445967	0.506	rs7620197	ENSG00000272360.1	RP11-359I18.5	3.5	0.000511	0.0311	0.2	0.16	Platelet count;	chr3:58483299	chr3:58490830~58491291:-
THCA	cis	rs1005277	0.565	rs2474565	ENSG00000151963.4	RP11-775A3.1	-3.5	0.000511	0.0311	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:37883594~37884109:+
THCA	cis	rs735539	0.874	rs9579927	ENSG00000238286.1	SLC35E1P1	3.5	0.000511	0.0311	0.17	0.16	Dental caries;	chr13:20696062	chr13:20607268~20608131:+
THCA	cis	rs77147124	1	rs2792735	ENSG00000225292.2	RP11-57H14.3	-3.5	0.000511	0.0311	-0.22	-0.16	HDL cholesterol;	chr10:112162067	chr10:112888735~112906111:+
THCA	cis	rs9733	0.65	rs1971378	ENSG00000231073.1	RP11-316M1.3	-3.5	0.000511	0.0311	-0.19	-0.16	Tonsillectomy;	chr1:150624785	chr1:150973123~150975534:+
THCA	cis	rs9925964	0.967	rs889548	ENSG00000279196.1	RP11-1072A3.3	3.5	0.000511	0.0311	0.16	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31126391	chr16:30984630~30988270:-
THCA	cis	rs4753788	0.534	rs7931436	ENSG00000255353.1	RP11-382M14.1	-3.5	0.000511	0.0311	-0.19	-0.16	Coronary artery disease;	chr11:107266386	chr11:107176286~107177530:+
THCA	cis	rs2287641	1	rs60798176	ENSG00000272156.1	RP11-477N3.1	3.5	0.000511	0.0311	0.29	0.16	Cannabis dependence symptom count;	chr2:54142119	chr2:54082554~54085066:+
THCA	cis	rs2287641	0.826	rs56696975	ENSG00000272156.1	RP11-477N3.1	3.5	0.000511	0.0311	0.29	0.16	Cannabis dependence symptom count;	chr2:54142171	chr2:54082554~54085066:+
THCA	cis	rs2287641	1	rs17045536	ENSG00000272156.1	RP11-477N3.1	3.5	0.000511	0.0311	0.29	0.16	Cannabis dependence symptom count;	chr2:54143369	chr2:54082554~54085066:+
THCA	cis	rs2287641	0.826	rs57995357	ENSG00000272156.1	RP11-477N3.1	3.5	0.000511	0.0311	0.29	0.16	Cannabis dependence symptom count;	chr2:54144030	chr2:54082554~54085066:+
THCA	cis	rs34779708	0.931	rs2384283	ENSG00000233200.1	RP11-324I22.2	3.5	0.000511	0.0311	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35219894~35230598:-
THCA	cis	rs9650657	0.617	rs7814795	ENSG00000261451.1	RP11-981G7.1	-3.5	0.000511	0.0311	-0.19	-0.16	Neuroticism;	chr8:10661775	chr8:10433672~10438312:+
THCA	cis	rs11777747	0.891	rs62523972	ENSG00000280303.2	ERICD	-3.5	0.000511	0.0311	-0.2	-0.16	Coronary artery calcification;	chr8:141469763	chr8:140636281~140638283:+
THCA	cis	rs832540	0.898	rs331498	ENSG00000271828.1	CTD-2310F14.1	3.5	0.000511	0.0311	0.22	0.16	Coronary artery disease;	chr5:56954015	chr5:56927874~56929573:+
THCA	cis	rs11583043	0.918	rs58029001	ENSG00000233184.5	RP11-421L21.3	3.5	0.000511	0.0311	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100927853	chr1:101025878~101087268:+
THCA	cis	rs2694528	1	rs929780	ENSG00000250148.1	KRT8P31	3.5	0.000511	0.0311	0.31	0.16	Parkinson's disease;	chr5:60893199	chr5:60743563~60744970:-
THCA	cis	rs1124769	0.719	rs11070833	ENSG00000259378.1	DCAF13P3	3.5	0.000511	0.0311	0.24	0.16	Cognitive performance;	chr15:51087164	chr15:50944663~50945996:+
THCA	cis	rs34779708	0.931	rs10466072	ENSG00000233200.1	RP11-324I22.2	3.5	0.000511	0.0311	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs998658	ENSG00000233200.1	RP11-324I22.2	3.5	0.000511	0.0311	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35219894~35230598:-
THCA	cis	rs2486012	1	rs783301	ENSG00000237950.1	RP11-7O11.3	-3.5	0.000511	0.0311	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43903337	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs2485995	ENSG00000237950.1	RP11-7O11.3	-3.5	0.000511	0.0311	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43903928	chr1:43944370~43946551:-
THCA	cis	rs9457247	0.602	rs17615336	ENSG00000235272.1	FAM103A2P	3.5	0.000511	0.0311	0.22	0.16	Crohn's disease;	chr6:167093246	chr6:166586124~166586477:-
THCA	cis	rs2562456	0.876	rs10424079	ENSG00000268278.1	RP11-420K14.1	3.5	0.000511	0.0311	0.22	0.16	Pain;	chr19:21406377	chr19:21637974~21656300:+
THCA	cis	rs11175834	0.557	rs4444128	ENSG00000277945.1	RP11-677M24.1	3.5	0.000511	0.0311	0.23	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65571793	chr12:65830750~65831050:+
THCA	cis	rs2652822	0.933	rs7170846	ENSG00000259459.4	RP11-321G12.1	-3.5	0.000512	0.0311	-0.13	-0.16	Metabolic traits;	chr15:63157344	chr15:63390136~63438320:+
THCA	cis	rs7737355	0.773	rs3776006	ENSG00000224431.1	AC063976.7	3.5	0.000512	0.0311	0.15	0.16	Life satisfaction;	chr5:131539845	chr5:132199456~132203487:+
THCA	cis	rs6840360	1	rs1366909	ENSG00000270265.1	RP11-731D1.4	-3.5	0.000512	0.0311	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151667269	chr4:151333775~151353224:-
THCA	cis	rs10029851	0.704	rs1436506	ENSG00000234492.4	RPL34-AS1	3.5	0.000512	0.0311	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr4:108709795	chr4:108538190~108620460:-
THCA	cis	rs7166081	1	rs12148134	ENSG00000270964.1	RP11-502I4.3	-3.5	0.000512	0.0311	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67299760	chr15:67541072~67542604:-
THCA	cis	rs8062405	0.964	rs62036614	ENSG00000270424.1	RP11-1348G14.6	3.5	0.000512	0.0311	0.19	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28749959~28750595:-
THCA	cis	rs3845817	0.51	rs6717426	ENSG00000237979.1	AC007389.1	-3.5	0.000512	0.0311	-0.18	-0.16	Bipolar disorder;	chr2:65554277	chr2:65500993~65502138:-
THCA	cis	rs80130819	0.688	rs2732475	ENSG00000273765.1	RP11-370I10.11	3.5	0.000512	0.0311	0.18	0.16	Prostate cancer;	chr12:48306971	chr12:48360920~48361377:+
THCA	cis	rs80130819	0.748	rs2732474	ENSG00000273765.1	RP11-370I10.11	3.5	0.000512	0.0311	0.18	0.16	Prostate cancer;	chr12:48307034	chr12:48360920~48361377:+
THCA	cis	rs73198271	0.74	rs1039911	ENSG00000254340.1	RP11-10A14.3	-3.5	0.000512	0.0311	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:9141424~9145435:+
THCA	cis	rs9811920	0.581	rs793468	ENSG00000273374.1	RP11-383I23.2	-3.5	0.000512	0.0312	-0.14	-0.16	Axial length;	chr3:99819502	chr3:99802699~99806058:-
THCA	cis	rs394563	0.967	rs420099	ENSG00000268592.3	RAET1E-AS1	3.5	0.000512	0.0312	0.21	0.16	Dupuytren's disease;	chr6:149473154	chr6:149863494~149919507:+
THCA	cis	rs9611565	0.625	rs9607819	ENSG00000237037.8	NDUFA6-AS1	3.5	0.000512	0.0312	0.15	0.16	Vitiligo;	chr22:41562858	chr22:42090931~42137742:+
THCA	cis	rs1387259	0.759	rs7960122	ENSG00000275228.1	RP11-370I10.10	3.5	0.000512	0.0312	0.18	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48327942~48328472:-
THCA	cis	rs2729354	0.953	rs2649650	ENSG00000254602.1	AP000662.4	-3.5	0.000512	0.0312	-0.2	-0.16	Blood protein levels;	chr11:57560094	chr11:57638024~57652790:+
THCA	cis	rs10863936	0.519	rs17656362	ENSG00000198468.6	FLVCR1-AS1	-3.5	0.000512	0.0312	-0.19	-0.16	Height;	chr1:212073846	chr1:212852108~212858088:-
THCA	cis	rs964611	0.935	rs2291341	ENSG00000259488.2	RP11-154J22.1	-3.5	0.000512	0.0312	-0.16	-0.16	Metabolite levels (Pyroglutamine);	chr15:48291640	chr15:48312353~48331856:-
THCA	cis	rs4819052	0.59	rs414743	ENSG00000273796.1	LL21NC02-21A1.1	-3.5	0.000512	0.0312	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45092160	chr21:45403809~45404369:-
THCA	cis	rs17507216	0.667	rs13379724	ENSG00000255769.6	GOLGA2P10	-3.5	0.000512	0.0312	-0.22	-0.16	Excessive daytime sleepiness;	chr15:82619892	chr15:82472993~82513950:-
THCA	cis	rs889398	0.537	rs3790086	ENSG00000226232.7	RP11-419C5.2	-3.5	0.000512	0.0312	-0.15	-0.16	Body mass index;	chr16:69853804	chr16:69976388~69996188:-
THCA	cis	rs36093844	0.527	rs4943934	ENSG00000279742.1	RP11-700A24.1	-3.5	0.000512	0.0312	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86023807	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.527	rs17817859	ENSG00000279742.1	RP11-700A24.1	-3.5	0.000512	0.0312	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86029600	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.527	rs10501605	ENSG00000279742.1	RP11-700A24.1	-3.5	0.000512	0.0312	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86032331	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.527	rs10501607	ENSG00000279742.1	RP11-700A24.1	-3.5	0.000512	0.0312	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86032963	chr11:85852557~85854943:-
THCA	cis	rs36093844	0.527	rs17817883	ENSG00000279742.1	RP11-700A24.1	-3.5	0.000512	0.0312	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86033195	chr11:85852557~85854943:-
THCA	cis	rs6496667	0.865	rs7178103	ENSG00000259262.1	NDUFA3P4	3.5	0.000512	0.0312	0.22	0.16	Rheumatoid arthritis;	chr15:90383567	chr15:90385814~90386063:+
THCA	cis	rs3760982	0.585	rs10422108	ENSG00000267058.1	RP11-15A1.3	-3.5	0.000512	0.0312	-0.13	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790716	chr19:43891804~43901805:-
THCA	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-3.5	0.000512	0.0312	-0.18	-0.16	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
THCA	cis	rs4713118	0.614	rs9380007	ENSG00000216915.2	RP1-97D16.1	-3.5	0.000512	0.0312	-0.2	-0.16	Parkinson's disease;	chr6:27692729	chr6:27737000~27738494:-
THCA	cis	rs17211409	1	rs17211409	ENSG00000254731.1	CTD-2005H7.1	3.5	0.000512	0.0312	0.43	0.16	JT interval (sulfonylurea treatment interaction);	chr11:86614845	chr11:86703099~86714092:+
THCA	cis	rs6120849	0.707	rs6088703	ENSG00000269202.1	RP4-614O4.12	-3.5	0.000512	0.0312	-0.18	-0.16	Protein C levels;	chr20:35088246	chr20:35201747~35203288:-
THCA	cis	rs1417770	0.54	rs778127	ENSG00000260971.3	RP11-504A18.1	3.5	0.000512	0.0312	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56138415	chr1:56248294~56258571:-
THCA	cis	rs2318131	0.965	rs12992546	ENSG00000222032.1	AC112721.2	3.5	0.000512	0.0312	0.17	0.16	Motion sickness;	chr2:237009858	chr2:237428920~237434822:-
THCA	cis	rs11992162	0.636	rs11250182	ENSG00000255046.1	RP11-297N6.4	3.5	0.000512	0.0312	0.17	0.16	Monocyte count;	chr8:11950067	chr8:11797928~11802568:-
THCA	cis	rs4699052	1	rs7694190	ENSG00000230069.3	LRRC37A15P	-3.5	0.000512	0.0312	-0.16	-0.16	Testicular germ cell tumor;	chr4:103246860	chr4:102727274~102730721:-
THCA	cis	rs2486012	0.649	rs39722	ENSG00000237950.1	RP11-7O11.3	3.5	0.000512	0.0312	0.19	0.16	Intelligence (multi-trait analysis);	chr1:43819991	chr1:43944370~43946551:-
THCA	cis	rs2832191	0.716	rs1543652	ENSG00000176054.6	RPL23P2	3.5	0.000512	0.0312	0.14	0.16	Dental caries;	chr21:29075679	chr21:28997613~28998033:-
THCA	cis	rs7274963	0.685	rs56039768	ENSG00000236474.1	GCNT1P1	3.5	0.000512	0.0312	0.22	0.16	Body mass index;	chr20:18360253	chr20:18420160~18421454:-
THCA	cis	rs7631605	0.967	rs6806487	ENSG00000272334.1	RP11-129K12.1	-3.5	0.000512	0.0312	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:37079601	chr3:36973117~36973672:-
THCA	cis	rs6545883	0.524	rs2694619	ENSG00000273302.1	RP11-493E12.2	-3.5	0.000512	0.0312	-0.15	-0.16	Tuberculosis;	chr2:61309766	chr2:61199979~61200769:+
THCA	cis	rs11118620	0.622	rs11118618	ENSG00000221571.3	RNU6ATAC35P	3.5	0.000512	0.0312	0.18	0.16	Heart failure;	chr1:220838204	chr1:220825620~220826063:+
THCA	cis	rs1908814	0.516	rs11250178	ENSG00000270154.1	RP11-419I17.1	3.5	0.000512	0.0312	0.2	0.16	Neuroticism;	chr8:11942725	chr8:12476462~12477122:+
THCA	cis	rs875971	0.798	rs6460304	ENSG00000223473.2	GS1-124K5.3	3.5	0.000512	0.0312	0.11	0.16	Aortic root size;	chr7:66499741	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6945775	ENSG00000223473.2	GS1-124K5.3	3.5	0.000512	0.0312	0.11	0.16	Aortic root size;	chr7:66503987	chr7:66491049~66493566:-
THCA	cis	rs285757	0.843	rs413450	ENSG00000259064.2	RP11-386M24.5	-3.5	0.000512	0.0312	-0.24	-0.16	HIV-1 susceptibility;	chr15:92656083	chr15:92627073~92627414:+
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000281021.1	RP1-12G14.9	-3.5	0.000513	0.0312	-0.16	-0.16	Lung cancer;	chr6:149619645	chr6:149576089~149590864:-
THCA	cis	rs9911578	1	rs2567905	ENSG00000224738.1	AC099850.1	3.5	0.000513	0.0312	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58704936	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs304270	ENSG00000224738.1	AC099850.1	-3.5	0.000513	0.0312	-0.18	-0.16	Intelligence (multi-trait analysis);	chr17:58724780	chr17:59106598~59118267:+
THCA	cis	rs1008126	0.64	rs362706	ENSG00000234715.1	CTB-107G13.1	3.5	0.000513	0.0312	0.2	0.16	Metabolite levels (Pyroglutamine);	chr7:103535518	chr7:103445207~103514007:+
THCA	cis	rs17767294	0.612	rs9461425	ENSG00000217539.2	IQCB2P	3.5	0.000513	0.0312	0.33	0.16	Parkinson's disease;	chr6:27951910	chr6:28010723~28012355:+
THCA	cis	rs80130819	0.748	rs1387255	ENSG00000226413.2	OR8T1P	3.5	0.000513	0.0312	0.23	0.16	Prostate cancer;	chr12:48255160	chr12:48442030~48442947:-
THCA	cis	rs7656342	0.721	rs6448996	ENSG00000242034.1	RP11-1396O13.1	-3.5	0.000513	0.0312	-0.18	-0.16	Gut microbiota (bacterial taxa);	chr4:9789630	chr4:9553614~9553985:-
THCA	cis	rs4849303	0.652	rs3789106	ENSG00000204588.5	LINC01123	-3.5	0.000513	0.0312	-0.18	-0.16	Colorectal cancer (diet interaction);	chr2:110963307	chr2:109987063~109996140:+
THCA	cis	rs2358994	0.561	rs11102649	ENSG00000232450.1	RP4-730K3.3	3.5	0.000513	0.0312	0.2	0.16	Type 1 diabetes and autoimmune thyroid diseases;	chr1:113533924	chr1:113698884~113699631:-
THCA	cis	rs8033133	0.56	rs11161166	ENSG00000270523.1	RP11-145P16.3	-3.5	0.000513	0.0312	-0.16	-0.16	Blood osmolality (transformed sodium);	chr15:25079530	chr15:25130978~25131337:+
THCA	cis	rs10266483	0.705	rs1111649	ENSG00000234338.1	RP11-797H7.1	3.5	0.000513	0.0312	0.11	0.16	Response to statin therapy;	chr7:64296435	chr7:64835280~64836882:-
THCA	cis	rs4790333	0.653	rs2447103	ENSG00000263345.1	RP1-59D14.5	-3.5	0.000513	0.0312	-0.08	-0.16	Proinsulin levels;	chr17:2359703	chr17:2375061~2379306:-
THCA	cis	rs911555	0.723	rs7149767	ENSG00000269940.1	RP11-73M18.7	-3.5	0.000513	0.0312	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103694560~103695170:+
THCA	cis	rs911555	0.692	rs7145753	ENSG00000269940.1	RP11-73M18.7	-3.5	0.000513	0.0312	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103694560~103695170:+
THCA	cis	rs740474	0.533	rs3844598	ENSG00000228737.2	AC008781.7	-3.5	0.000513	0.0312	-0.19	-0.16	Allergic disease (asthma, hay fever or eczema);	chr5:141612668	chr5:141618414~141626481:+
THCA	cis	rs7267979	0.932	rs424487	ENSG00000277938.1	RP5-965G21.3	3.5	0.000513	0.0312	0.13	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25229150~25231933:+
THCA	cis	rs10090774	0.965	rs12550497	ENSG00000280303.2	ERICD	3.5	0.000513	0.0312	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140935418	chr8:140636281~140638283:+
THCA	cis	rs638893	0.947	rs1170396	ENSG00000255422.1	AP002954.4	-3.5	0.000513	0.0312	-0.24	-0.16	Vitiligo;	chr11:118833108	chr11:118704607~118750263:+
THCA	cis	rs10411161	0.702	rs7251571	ENSG00000275055.1	CTC-471J1.11	-3.5	0.000513	0.0312	-0.15	-0.16	Breast cancer;	chr19:51885804	chr19:52049007~52049754:+
THCA	cis	rs28830936	1	rs4924575	ENSG00000250379.1	RP11-23P13.4	3.5	0.000513	0.0312	0.18	0.16	Diastolic blood pressure;	chr15:41804728	chr15:41825099~41827936:-
THCA	cis	rs7045881	0.8	rs73433937	ENSG00000234676.1	IFT74-AS1	-3.5	0.000513	0.0312	-0.3	-0.16	Schizophrenia;	chr9:26941606	chr9:26955780~26956295:-
THCA	cis	rs4869313	0.694	rs27296	ENSG00000247121.5	CTD-2260A17.2	3.5	0.000513	0.0312	0.12	0.16	Pediatric autoimmune diseases;	chr5:97025922	chr5:96814028~96935809:-
THCA	cis	rs7851693	1	rs7466269	ENSG00000232172.1	RP11-57C19.2	-3.5	0.000513	0.0312	-0.17	-0.16	Bone mineral density;	chr9:130588697	chr9:130651799~130652383:+
THCA	cis	rs931608	0.585	rs55851405	ENSG00000269138.1	ZNF209P	3.5	0.000513	0.0312	0.24	0.16	Response to statins (LDL cholesterol change);Dental caries;	chr19:22358884	chr19:22463922~22473036:+
THCA	cis	rs12681963	0.545	rs4383929	ENSG00000260253.1	RP4-676L2.1	-3.5	0.000513	0.0312	-0.26	-0.16	Migraine;	chr8:30041288	chr8:29352420~29353170:-
THCA	cis	rs12681963	0.591	rs71506505	ENSG00000260253.1	RP4-676L2.1	-3.5	0.000513	0.0312	-0.26	-0.16	Migraine;	chr8:30043385	chr8:29352420~29353170:-
THCA	cis	rs321358	0.848	rs78087740	ENSG00000271390.1	RP11-89C3.3	3.5	0.000513	0.0312	0.26	0.16	Body mass index;	chr11:111079016	chr11:111089870~111090368:-
THCA	cis	rs321358	0.848	rs73015146	ENSG00000271390.1	RP11-89C3.3	3.5	0.000513	0.0312	0.26	0.16	Body mass index;	chr11:111079143	chr11:111089870~111090368:-
THCA	cis	rs111321694	1	rs111321694	ENSG00000271390.1	RP11-89C3.3	3.5	0.000513	0.0312	0.26	0.16	Educational attainment (years of education);	chr11:111079662	chr11:111089870~111090368:-
THCA	cis	rs321358	0.895	rs17457076	ENSG00000271390.1	RP11-89C3.3	3.5	0.000513	0.0312	0.26	0.16	Body mass index;	chr11:111081030	chr11:111089870~111090368:-
THCA	cis	rs34779708	0.75	rs35032841	ENSG00000233200.1	RP11-324I22.2	3.5	0.000513	0.0312	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.742	rs35912711	ENSG00000233200.1	RP11-324I22.2	3.5	0.000513	0.0312	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs4934702	ENSG00000233200.1	RP11-324I22.2	3.5	0.000513	0.0312	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35219894~35230598:-
THCA	cis	rs1383484	0.506	rs899927	ENSG00000225151.9	GOLGA2P7	3.5	0.000513	0.0312	0.21	0.16	Height;	chr15:83893127	chr15:84199311~84230136:-
THCA	cis	rs11800820	0.538	rs3124113	ENSG00000231612.1	RP11-522M21.3	3.5	0.000513	0.0312	0.22	0.16	Obesity-related traits;	chr1:246542951	chr1:245673732~245676478:-
THCA	cis	rs3093024	0.595	rs4412174	ENSG00000235272.1	FAM103A2P	3.5	0.000513	0.0312	0.22	0.16	Rheumatoid arthritis;	chr6:167062578	chr6:166586124~166586477:-
THCA	cis	rs3093024	0.595	rs4458654	ENSG00000235272.1	FAM103A2P	3.5	0.000513	0.0312	0.22	0.16	Rheumatoid arthritis;	chr6:167062580	chr6:166586124~166586477:-
THCA	cis	rs6598955	0.67	rs6598942	ENSG00000236782.4	RP11-96L14.7	-3.5	0.000513	0.0312	-0.19	-0.16	Obesity-related traits;	chr1:26204543	chr1:26169947~26171821:-
THCA	cis	rs12439619	0.508	rs17354842	ENSG00000255769.6	GOLGA2P10	3.5	0.000513	0.0312	0.18	0.16	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472993~82513950:-
THCA	cis	rs929354	0.772	rs10229630	ENSG00000224629.1	RP5-1142J19.2	-3.5	0.000513	0.0312	-0.16	-0.16	Body mass index;	chr7:157212096	chr7:157263022~157263229:-
THCA	cis	rs7665090	0.967	rs13106304	ENSG00000251288.2	RP11-10L12.2	-3.5	0.000513	0.0312	-0.2	-0.16	Primary biliary cholangitis;	chr4:102633818	chr4:102751401~102752641:+
THCA	cis	rs2214442	0.871	rs3807931	ENSG00000271133.4	CTA-293F17.1	-3.5	0.000513	0.0312	-0.16	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20342051	chr7:20328299~20331747:-
THCA	cis	rs7311936	1	rs7302734	ENSG00000270130.1	RP11-214K3.23	-3.5	0.000513	0.0312	-0.17	-0.16	Vertical cup-disc ratio;	chr12:124151796	chr12:123960717~123961244:-
THCA	cis	rs12101261	0.744	rs59431750	ENSG00000258915.1	BHLHB9P1	-3.5	0.000513	0.0312	-0.2	-0.16	Graves' disease;	chr14:80975725	chr14:80981988~80983638:+
THCA	cis	rs478304	0.593	rs6591188	ENSG00000255120.4	OVOL1-AS1	-3.5	0.000513	0.0312	-0.22	-0.16	Acne (severe);	chr11:65700482	chr11:65789051~65790868:-
THCA	cis	rs17301013	0.932	rs7555533	ENSG00000270084.1	GAS5-AS1	-3.5	0.000513	0.0312	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174589983	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs6671824	ENSG00000270084.1	GAS5-AS1	-3.5	0.000513	0.0312	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174603721	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.861	rs6672148	ENSG00000270084.1	GAS5-AS1	-3.5	0.000513	0.0312	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174604016	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs10912813	ENSG00000270084.1	GAS5-AS1	-3.5	0.000513	0.0312	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174607342	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs67967476	ENSG00000270084.1	GAS5-AS1	-3.5	0.000513	0.0312	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174616119	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs6683602	ENSG00000270084.1	GAS5-AS1	-3.5	0.000513	0.0312	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174617615	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.932	rs6696197	ENSG00000270084.1	GAS5-AS1	-3.5	0.000513	0.0312	-0.17	-0.16	Systemic lupus erythematosus;	chr1:174617860	chr1:173863248~173863941:+
THCA	cis	rs7897654	0.651	rs7922349	ENSG00000236937.2	PTGES3P4	3.5	0.000513	0.0312	0.24	0.16	Schizophrenia;	chr10:102929701	chr10:102845595~102845950:+
THCA	cis	rs7897654	0.651	rs12416441	ENSG00000236937.2	PTGES3P4	3.5	0.000513	0.0312	0.24	0.16	Schizophrenia;	chr10:102930233	chr10:102845595~102845950:+
THCA	cis	rs9308731	0.591	rs60982612	ENSG00000227992.1	AC108463.2	-3.5	0.000513	0.0312	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111183362	chr2:111203964~111206215:-
THCA	cis	rs471144	0.881	rs12089980	ENSG00000237975.5	FLG-AS1	-3.5	0.000514	0.0312	-0.35	-0.16	Inflammatory skin disease;	chr1:152459455	chr1:152168125~152445456:+
THCA	cis	rs700585	0.71	rs13155750	ENSG00000247828.6	TMEM161B-AS1	3.5	0.000514	0.0312	0.14	0.16	Platelet count;	chr5:88871824	chr5:88268895~88436685:+
THCA	cis	rs1417770	0.931	rs778405	ENSG00000260971.3	RP11-504A18.1	3.5	0.000514	0.0312	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56237741	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.895	rs1230036	ENSG00000260971.3	RP11-504A18.1	3.5	0.000514	0.0312	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56238460	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs778411	ENSG00000260971.3	RP11-504A18.1	3.5	0.000514	0.0312	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56240602	chr1:56248294~56258571:-
THCA	cis	rs6840360	1	rs6823194	ENSG00000270265.1	RP11-731D1.4	-3.5	0.000514	0.0313	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151683391	chr4:151333775~151353224:-
THCA	cis	rs7824557	0.564	rs2572386	ENSG00000261451.1	RP11-981G7.1	-3.5	0.000514	0.0313	-0.2	-0.16	Retinal vascular caliber;	chr8:11379466	chr8:10433672~10438312:+
THCA	cis	rs2032366	1	rs10439023	ENSG00000267316.4	RP11-879F14.3	-3.5	0.000514	0.0313	-0.17	-0.16	Obesity-related traits;	chr18:61597073	chr18:61571342~61579456:-
THCA	cis	rs7616559	0.962	rs9842862	ENSG00000240875.4	LINC00886	-3.5	0.000514	0.0313	-0.15	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157018606	chr3:156747346~156817062:-
THCA	cis	rs11180559	0.534	rs1383101	ENSG00000257497.2	RP11-585P4.5	3.5	0.000514	0.0313	0.3	0.16	Daytime sleep phenotypes;	chr12:75607158	chr12:75483454~75489820:-
THCA	cis	rs3087591	0.708	rs7505	ENSG00000263535.1	AK4P1	3.5	0.000514	0.0313	0.19	0.16	Hip circumference;	chr17:31317834	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs2854305	ENSG00000263535.1	AK4P1	3.5	0.000514	0.0313	0.19	0.16	Hip circumference;	chr17:31319985	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.614	rs3785955	ENSG00000263535.1	AK4P1	3.5	0.000514	0.0313	0.19	0.16	Hip circumference;	chr17:31320784	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.683	rs2854306	ENSG00000263535.1	AK4P1	3.5	0.000514	0.0313	0.19	0.16	Hip circumference;	chr17:31321128	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs35109242	ENSG00000263535.1	AK4P1	3.5	0.000514	0.0313	0.19	0.16	Hip circumference;	chr17:31322205	chr17:31345521~31346187:+
THCA	cis	rs3087591	0.708	rs4794887	ENSG00000263535.1	AK4P1	3.5	0.000514	0.0313	0.19	0.16	Hip circumference;	chr17:31322678	chr17:31345521~31346187:+
THCA	cis	rs10129255	1	rs4612959	ENSG00000280411.1	IGHV1-69-2	-3.5	0.000514	0.0313	-0.1	-0.16	Kawasaki disease;	chr14:106767055	chr14:106762092~106762588:-
THCA	cis	rs10129255	1	rs10129407	ENSG00000280411.1	IGHV1-69-2	-3.5	0.000514	0.0313	-0.1	-0.16	Kawasaki disease;	chr14:106767956	chr14:106762092~106762588:-
THCA	cis	rs9875589	0.957	rs1579551	ENSG00000233121.1	VN1R20P	-3.5	0.000514	0.0313	-0.19	-0.16	Ovarian reserve;	chr3:13904074	chr3:13926813~13927778:+
THCA	cis	rs858239	0.712	rs200717	ENSG00000230042.1	AK3P3	-3.5	0.000514	0.0313	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23129178~23129841:+
THCA	cis	rs2223471	0.84	rs2744495	ENSG00000060303.5	RPS17P5	-3.5	0.000514	0.0313	-0.19	-0.16	Subcutaneous adipose tissue;	chr6:50788950	chr6:50857255~50857662:-
THCA	cis	rs409045	0.869	rs457350	ENSG00000271874.1	CTD-2024P10.2	-3.5	0.000514	0.0313	-0.2	-0.16	Left ventricular mass;	chr5:34649996	chr5:34651457~34651888:-
THCA	cis	rs9376098	0.597	rs76577602	ENSG00000232876.1	CTA-212D2.2	-3.5	0.000514	0.0313	-0.23	-0.16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135175976	chr6:135055033~135060550:+
THCA	cis	rs67340775	0.541	rs200966	ENSG00000272009.1	RP1-313I6.12	-3.5	0.000514	0.0313	-0.21	-0.16	Lung cancer in ever smokers;	chr6:27894374	chr6:28078792~28081130:-
THCA	cis	rs7765004	1	rs9374427	ENSG00000230943.1	RP11-367G18.1	3.5	0.000514	0.0313	0.16	0.16	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;	chr6:113753714	chr6:113623535~113650074:-
THCA	cis	rs2797160	0.967	rs1343120	ENSG00000226409.1	RP11-735G4.1	-3.5	0.000514	0.0313	-0.19	-0.16	Endometrial cancer;	chr6:125671664	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.967	rs4897151	ENSG00000226409.1	RP11-735G4.1	-3.5	0.000514	0.0313	-0.19	-0.16	Endometrial cancer;	chr6:125672056	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.935	rs6940748	ENSG00000226409.1	RP11-735G4.1	-3.5	0.000514	0.0313	-0.19	-0.16	Endometrial cancer;	chr6:125672934	chr6:125370211~125374324:-
THCA	cis	rs9891119	1	rs957971	ENSG00000267595.1	RP11-242D8.2	3.5	0.000514	0.0313	0.14	0.16	Multiple sclerosis;Crohn's disease;	chr17:42367907	chr17:43168170~43168249:-
THCA	cis	rs61160187	0.605	rs10068474	ENSG00000272308.1	RP11-231G3.1	3.5	0.000514	0.0313	0.16	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782085	chr5:60866457~60866935:-
THCA	cis	rs2625529	0.591	rs7172158	ENSG00000260037.4	CTD-2524L6.3	3.5	0.000514	0.0313	0.2	0.16	Red blood cell count;	chr15:72112972	chr15:71818396~71823384:+
THCA	cis	rs61160187	0.582	rs4647150	ENSG00000251279.1	CTC-436P18.1	-3.5	0.000514	0.0313	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:61162070~61232040:+
THCA	cis	rs853679	0.517	rs1904841	ENSG00000219891.2	ZSCAN12P1	3.5	0.000514	0.0313	0.23	0.16	Depression;	chr6:28140307	chr6:28091154~28093664:+
THCA	cis	rs7267979	0.844	rs6083851	ENSG00000276952.1	RP5-965G21.6	-3.5	0.000514	0.0313	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.844	rs4423675	ENSG00000276952.1	RP5-965G21.6	-3.5	0.000514	0.0313	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25284915~25285588:-
THCA	cis	rs9527	0.571	rs4917985	ENSG00000272912.1	RP11-724N1.1	-3.5	0.000514	0.0313	-0.19	-0.16	Arsenic metabolism;	chr10:102864315	chr10:102914585~102915404:+
THCA	cis	rs9843304	0.529	rs72996050	ENSG00000243885.1	RP11-278L15.2	3.5	0.000514	0.0313	0.17	0.16	Gallstone disease;	chr3:149484846	chr3:149384179~149385800:-
THCA	cis	rs9329221	1	rs9329221	ENSG00000261451.1	RP11-981G7.1	3.5	0.000514	0.0313	0.19	0.16	Neuroticism;	chr8:10382692	chr8:10433672~10438312:+
THCA	cis	rs1059312	1	rs12814773	ENSG00000279500.1	RP11-21K12.2	-3.5	0.000514	0.0313	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128796241	chr12:128813186~128814750:-
THCA	cis	rs6120849	0.663	rs6088662	ENSG00000269202.1	RP4-614O4.12	-3.5	0.000514	0.0313	-0.17	-0.16	Protein C levels;	chr20:34959830	chr20:35201747~35203288:-
THCA	cis	rs990871	0.574	rs7532281	ENSG00000227207.2	RPL31P12	-3.5	0.000514	0.0313	-0.2	-0.16	Subcutaneous adipose tissue;	chr1:72416660	chr1:72301472~72301829:+
THCA	cis	rs990871	0.539	rs10789339	ENSG00000227207.2	RPL31P12	-3.5	0.000514	0.0313	-0.2	-0.16	Subcutaneous adipose tissue;	chr1:72419029	chr1:72301472~72301829:+
THCA	cis	rs990871	0.545	rs11209964	ENSG00000227207.2	RPL31P12	-3.5	0.000514	0.0313	-0.2	-0.16	Subcutaneous adipose tissue;	chr1:72419404	chr1:72301472~72301829:+
THCA	cis	rs467650	0.509	rs152985	ENSG00000248489.1	CTD-2007H13.3	3.5	0.000514	0.0313	0.14	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98653103	chr5:98929171~98995013:+
THCA	cis	rs10857712	0.754	rs7921041	ENSG00000214279.11	SCART1	-3.5	0.000514	0.0313	-0.13	-0.16	Systemic lupus erythematosus;	chr10:133415735	chr10:133453928~133523558:+
THCA	cis	rs10129255	1	rs10129255	ENSG00000280411.1	IGHV1-69-2	3.5	0.000514	0.0313	0.1	0.16	Kawasaki disease;	chr14:106767970	chr14:106762092~106762588:-
THCA	cis	rs5753037	0.838	rs5763688	ENSG00000279699.1	RP1-102K2.9	-3.5	0.000515	0.0313	-0.16	-0.16	Type 1 diabetes;	chr22:29997514	chr22:30275215~30276951:-
THCA	cis	rs12506899	0.934	rs4270557	ENSG00000221639.1	SNORA3	3.5	0.000515	0.0313	0.19	0.16	Tumor biomarkers;	chr4:73394874	chr4:73263960~73264084:+
THCA	cis	rs7520050	0.966	rs785471	ENSG00000280836.1	AL355480.1	3.5	0.000515	0.0313	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45581219~45581321:-
THCA	cis	rs1005277	0.522	rs289650	ENSG00000273019.1	RP11-508N22.13	-3.5	0.000515	0.0313	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38149968~38150293:+
THCA	cis	rs3800688	0.623	rs1643270	ENSG00000236753.4	MKLN1-AS	-3.5	0.000515	0.0313	-0.15	-0.16	Hypertension;	chr7:131490735	chr7:131309744~131328222:-
THCA	cis	rs860295	0.702	rs12746592	ENSG00000236675.1	MTX1P1	-3.5	0.000515	0.0313	-0.16	-0.16	Body mass index;	chr1:155536176	chr1:155230975~155234325:+
THCA	cis	rs4947019	0.609	rs4946977	ENSG00000223537.2	RP5-919F19.5	-3.5	0.000515	0.0313	-0.29	-0.16	Hematological parameters;	chr6:109454163	chr6:109487906~109506800:+
THCA	cis	rs775227	0.574	rs13086266	ENSG00000243849.1	CFAP44-AS1	3.5	0.000515	0.0313	0.3	0.16	Dental caries;	chr3:113364688	chr3:113403991~113433992:+
THCA	cis	rs11673344	0.704	rs484001	ENSG00000267260.1	CTD-2162K18.4	-3.5	0.000515	0.0313	-0.2	-0.16	Obesity-related traits;	chr19:36931320	chr19:36773153~36777078:+
THCA	cis	rs7737355	1	rs6596010	ENSG00000224431.1	AC063976.7	3.5	0.000515	0.0313	0.15	0.16	Life satisfaction;	chr5:131289718	chr5:132199456~132203487:+
THCA	cis	rs9590614	0.902	rs12876429	ENSG00000278390.3	RP11-74J13.8	-3.5	0.000515	0.0313	-0.15	-0.16	Local histogram emphysema pattern;	chr13:41592832	chr13:41132939~41236686:+
THCA	cis	rs911555	0.755	rs8018400	ENSG00000269940.1	RP11-73M18.7	-3.5	0.000515	0.0313	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103694560~103695170:+
THCA	cis	rs36132109	1	rs36132109	ENSG00000273328.4	RP11-141M3.6	3.5	0.000515	0.0313	0.21	0.16	Monocyte chemoattractant protein-1 levels;	chr3:42985512	chr3:42809414~42908105:+
THCA	cis	rs7973683	0.541	rs6488910	ENSG00000269997.1	RP11-214K3.21	-3.5	0.000515	0.0313	-0.18	-0.16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123909150	chr12:123966077~123966629:-
THCA	cis	rs6674970	0.966	rs10788800	ENSG00000261168.1	RP11-68I18.10	-3.5	0.000515	0.0313	-0.21	-0.16	Childhood ear infection;	chr1:151132474	chr1:151130075~151131610:-
THCA	cis	rs4948275	0.693	rs2650731	ENSG00000233643.2	RP11-491H19.1	-3.5	0.000515	0.0313	-0.18	-0.16	Night sleep phenotypes;	chr10:61579897	chr10:61781745~61821246:-
THCA	cis	rs12493885	0.769	rs57354204	ENSG00000243069.6	ARHGEF26-AS1	-3.5	0.000515	0.0313	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154037929	chr3:154024401~154121332:-
THCA	cis	rs6583331	1	rs12718061	ENSG00000232065.1	LINC01063	-3.5	0.000515	0.0313	-0.18	-0.16	Vitiligo;	chr3:196620566	chr3:196631498~196632587:-
THCA	cis	rs7833790	0.927	rs61020899	ENSG00000254689.1	RP11-354A14.1	-3.5	0.000515	0.0313	-0.2	-0.16	Diastolic blood pressure;	chr8:81844855	chr8:81885377~81923193:+
THCA	cis	rs301901	0.772	rs301878	ENSG00000250155.1	CTD-2353F22.1	-3.5	0.000515	0.0313	-0.16	-0.16	Height;	chr5:37097036	chr5:36666214~36725195:-
THCA	cis	rs301901	0.772	rs301909	ENSG00000250155.1	CTD-2353F22.1	-3.5	0.000515	0.0313	-0.16	-0.16	Height;	chr5:37102525	chr5:36666214~36725195:-
THCA	cis	rs13098911	0.54	rs34718164	ENSG00000226074.4	PRSS44	-3.5	0.000515	0.0313	-0.31	-0.16	Celiac disease;	chr3:46057034	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs13096741	ENSG00000226074.4	PRSS44	-3.5	0.000515	0.0313	-0.31	-0.16	Celiac disease;	chr3:46057662	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34047915	ENSG00000226074.4	PRSS44	-3.5	0.000515	0.0313	-0.31	-0.16	Celiac disease;	chr3:46058999	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs71327014	ENSG00000226074.4	PRSS44	-3.5	0.000515	0.0313	-0.31	-0.16	Celiac disease;	chr3:46059974	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs71327015	ENSG00000226074.4	PRSS44	-3.5	0.000515	0.0313	-0.31	-0.16	Celiac disease;	chr3:46060681	chr3:46809359~46812558:-
THCA	cis	rs13098911	0.54	rs34127208	ENSG00000226074.4	PRSS44	-3.5	0.000515	0.0313	-0.31	-0.16	Celiac disease;	chr3:46062188	chr3:46809359~46812558:-
THCA	cis	rs9307551	0.948	rs2165386	ENSG00000249646.2	OR7E94P	-3.5	0.000515	0.0313	-0.22	-0.16	Refractive error;	chr4:79582248	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.948	rs1440853	ENSG00000249646.2	OR7E94P	-3.5	0.000515	0.0313	-0.22	-0.16	Refractive error;	chr4:79585493	chr4:79587302~79588130:-
THCA	cis	rs9400467	0.506	rs3204954	ENSG00000255389.1	C6orf3	3.5	0.000515	0.0313	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111307394	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.506	rs3204953	ENSG00000255389.1	C6orf3	3.5	0.000515	0.0313	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111307423	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.506	rs10485124	ENSG00000255389.1	C6orf3	3.5	0.000515	0.0313	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111310704	chr6:111599875~111602295:+
THCA	cis	rs910316	0.763	rs175042	ENSG00000259138.1	RP11-950C14.7	-3.5	0.000515	0.0313	-0.14	-0.16	Height;	chr14:75004130	chr14:75127153~75136930:+
THCA	cis	rs7829975	0.56	rs6994131	ENSG00000253981.4	ALG1L13P	-3.5	0.000515	0.0313	-0.16	-0.16	Mood instability;	chr8:8693448	chr8:8236003~8244667:-
THCA	cis	rs7819412	0.668	rs920047	ENSG00000254527.1	ENPP7P12	-3.5	0.000515	0.0313	-0.2	-0.16	Triglycerides;	chr8:11229966	chr8:12205759~12206389:-
THCA	cis	rs2070488	0.965	rs35091896	ENSG00000229589.1	ACVR2B-AS1	3.5	0.000515	0.0313	0.15	0.16	Electrocardiographic conduction measures;	chr3:38401829	chr3:38451027~38454820:-
THCA	cis	rs17211409	1	rs7126717	ENSG00000254731.1	CTD-2005H7.1	3.5	0.000515	0.0313	0.42	0.16	JT interval (sulfonylurea treatment interaction);	chr11:86629016	chr11:86703099~86714092:+
THCA	cis	rs2567519	0.71	rs2714012	ENSG00000265010.1	RP11-661C3.2	-3.5	0.000515	0.0313	-0.18	-0.16	Smoking initiation;	chr17:72787618	chr17:73243093~73244706:+
THCA	cis	rs9876781	1	rs9817615	ENSG00000199476.1	Y_RNA	-3.5	0.000515	0.0313	-0.2	-0.16	Longevity;	chr3:48429347	chr3:48288587~48288694:+
THCA	cis	rs4879656	0.966	rs1016673	ENSG00000225693.1	LAGE3P1	3.5	0.000515	0.0313	0.18	0.16	Menopause (age at onset);	chr9:32982450	chr9:33019682~33020165:-
THCA	cis	rs1555322	1	rs2425031	ENSG00000279253.1	RP4-614O4.13	-3.5	0.000515	0.0313	-0.22	-0.16	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35262727~35264187:-
THCA	cis	rs1059312	0.966	rs2291349	ENSG00000279500.1	RP11-21K12.2	-3.5	0.000515	0.0313	-0.11	-0.16	Systemic lupus erythematosus;	chr12:128799703	chr12:128813186~128814750:-
THCA	cis	rs7307902	1	rs7307902	ENSG00000280054.1	RP1-197B17.7	-3.5	0.000516	0.0313	-0.18	-0.16	Obesity-related traits;	chr12:47529233	chr12:47728151~47730598:-
THCA	cis	rs12234571	0.557	rs11977422	ENSG00000214293.7	APTR	3.5	0.000516	0.0313	0.18	0.16	Obesity-related traits;	chr7:77814598	chr7:77657660~77696265:-
THCA	cis	rs10938353	0.871	rs1439358	ENSG00000273369.1	RP11-700J17.1	-3.5	0.000516	0.0313	-0.18	-0.16	Body mass index;	chr4:44607167	chr4:44693946~44694386:-
THCA	cis	rs7737355	1	rs2158428	ENSG00000224431.1	AC063976.7	-3.5	0.000516	0.0314	-0.15	-0.16	Life satisfaction;	chr5:131415788	chr5:132199456~132203487:+
THCA	cis	rs1062753	0.731	rs11090065	ENSG00000227370.1	RP4-669P10.19	3.5	0.000516	0.0314	0.16	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41988167	chr22:42132543~42132998:+
THCA	cis	rs12915845	1	rs17190166	ENSG00000271997.1	RP11-97O12.6	-3.5	0.000516	0.0314	-0.11	-0.16	Menarche (age at onset);	chr15:88513271	chr15:88501944~88505787:-
THCA	cis	rs4218	0.681	rs4531679	ENSG00000259732.1	RP11-59H7.3	-3.5	0.000516	0.0314	-0.22	-0.16	Social communication problems;	chr15:59083246	chr15:59121034~59133250:+
THCA	cis	rs7487075	0.688	rs12227156	ENSG00000274723.1	RP11-618L22.1	3.5	0.000516	0.0314	0.14	0.16	Itch intensity from mosquito bite;	chr12:46615645	chr12:46970504~46972155:+
THCA	cis	rs34779708	0.931	rs34954932	ENSG00000233200.1	RP11-324I22.2	3.5	0.000516	0.0314	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35219894~35230598:-
THCA	cis	rs6995541	0.645	rs10109550	ENSG00000248896.2	CTD-2135J3.3	-3.5	0.000516	0.0314	-0.23	-0.16	Triglyceride levels;	chr8:10828076	chr8:10729314~10771392:+
THCA	cis	rs6995541	0.645	rs6985890	ENSG00000248896.2	CTD-2135J3.3	-3.5	0.000516	0.0314	-0.23	-0.16	Triglyceride levels;	chr8:10828441	chr8:10729314~10771392:+
THCA	cis	rs6995541	0.645	rs6989846	ENSG00000248896.2	CTD-2135J3.3	-3.5	0.000516	0.0314	-0.23	-0.16	Triglyceride levels;	chr8:10828575	chr8:10729314~10771392:+
THCA	cis	rs72765298	0.848	rs2416954	ENSG00000235332.2	RP11-366O20.5	3.5	0.000516	0.0314	0.24	0.16	Pulse pressure;	chr9:125172071	chr9:125194649~125195821:-
THCA	cis	rs3825942	0.666	rs2304719	ENSG00000261801.4	LOXL1-AS1	3.5	0.000516	0.0314	0.19	0.16	Glaucoma (exfoliation);	chr15:73943159	chr15:73908071~73928248:-
THCA	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	3.5	0.000516	0.0314	0.23	0.16	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
THCA	cis	rs2124969	0.549	rs56296079	ENSG00000226266.5	AC009961.3	-3.5	0.000516	0.0314	-0.26	-0.16	Waist circumference adjusted for body mass index;	chr2:160084950	chr2:159670708~159712435:-
THCA	cis	rs75504410	1	rs78976775	ENSG00000231160.8	KLF3-AS1	-3.5	0.000516	0.0314	-0.18	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38662207	chr4:38612701~38664883:-
THCA	cis	rs75504410	1	rs75067561	ENSG00000231160.8	KLF3-AS1	-3.5	0.000516	0.0314	-0.18	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38674903	chr4:38612701~38664883:-
THCA	cis	rs7208859	0.562	rs216408	ENSG00000264242.2	RP11-271K11.1	-3.5	0.000516	0.0314	-0.23	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30553697~30558962:+
THCA	cis	rs1417770	0.931	rs706369	ENSG00000260971.3	RP11-504A18.1	3.5	0.000516	0.0314	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56224647	chr1:56248294~56258571:-
THCA	cis	rs730566	1	rs730566	ENSG00000228638.1	FCF1P2	3.5	0.000516	0.0314	0.16	0.16	Prion diseases;	chr3:48445644	chr3:48290793~48291375:-
THCA	cis	rs9309473	1	rs6753344	ENSG00000273245.1	RP11-434P11.2	-3.5	0.000516	0.0314	-0.22	-0.16	Metabolite levels;	chr2:73426010	chr2:73750256~73750786:-
THCA	cis	rs2018683	0.739	rs10233884	ENSG00000233517.1	AC005162.5	-3.5	0.000516	0.0314	-0.2	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932690	chr7:28987028~28988899:+
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000184274.3	LINC00315	-3.5	0.000516	0.0314	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000184274.3	LINC00315	-3.5	0.000516	0.0314	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000184274.3	LINC00315	-3.5	0.000516	0.0314	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000184274.3	LINC00315	-3.5	0.000516	0.0314	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000184274.3	LINC00315	-3.5	0.000516	0.0314	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45300245~45305257:-
THCA	cis	rs1560104	0.597	rs11075126	ENSG00000262801.4	U91319.1	-3.5	0.000516	0.0314	-0.18	-0.16	Obesity-related traits;	chr16:12613117	chr16:13246316~13562918:+
THCA	cis	rs853679	0.882	rs9393908	ENSG00000273712.1	RP5-874C20.7	3.5	0.000516	0.0314	0.28	0.16	Depression;	chr6:28223052	chr6:28315613~28315883:-
THCA	cis	rs853679	0.882	rs9366717	ENSG00000273712.1	RP5-874C20.7	3.5	0.000516	0.0314	0.28	0.16	Depression;	chr6:28223279	chr6:28315613~28315883:-
THCA	cis	rs1144333	0.655	rs4949682	ENSG00000272855.1	RP5-1102E8.3	3.5	0.000516	0.0314	0.34	0.16	Attention function in attention deficit hyperactive disorder;	chr1:75977511	chr1:76636877~76637339:+
THCA	cis	rs4915077	0.773	rs17484367	ENSG00000226822.1	RP11-356N1.2	3.5	0.000516	0.0314	0.3	0.16	Hypothyroidism;	chr1:107727031	chr1:108071482~108074519:+
THCA	cis	rs4763879	0.593	rs7960328	ENSG00000278635.1	CTD-2318O12.1	3.5	0.000516	0.0314	0.17	0.16	Type 1 diabetes;	chr12:9699584	chr12:9415641~9416718:+
THCA	cis	rs6982240	0.514	rs10095322	ENSG00000253307.1	RP11-10J21.4	3.5	0.000516	0.0314	0.24	0.16	Tonsillectomy;	chr8:141252228	chr8:141252286~141253292:-
THCA	cis	rs875971	0.862	rs908915	ENSG00000223473.2	GS1-124K5.3	-3.5	0.000516	0.0314	-0.11	-0.16	Aortic root size;	chr7:66149664	chr7:66491049~66493566:-
THCA	cis	rs7819412	0.668	rs2409721	ENSG00000154316.13	TDH	3.5	0.000516	0.0314	0.12	0.16	Triglycerides;	chr8:11180735	chr8:11339637~11368452:+
THCA	cis	rs28510890	0.547	rs12443027	ENSG00000258647.4	LINC00930	3.5	0.000516	0.0314	0.23	0.16	Lung cancer in ever smokers;	chr15:92612013	chr15:92567818~92572042:-
THCA	cis	rs4925386	0.84	rs8124907	ENSG00000275437.1	RP5-908M14.10	3.5	0.000516	0.0314	0.16	0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62402236~62405935:-
THCA	cis	rs321358	0.895	rs17457658	ENSG00000271390.1	RP11-89C3.3	3.5	0.000516	0.0314	0.26	0.16	Body mass index;	chr11:111089448	chr11:111089870~111090368:-
THCA	cis	rs11190604	1	rs57025426	ENSG00000273030.1	RP11-285F16.1	3.5	0.000516	0.0314	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100446111	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs11190552	ENSG00000273030.1	RP11-285F16.1	3.5	0.000516	0.0314	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100446850	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.945	rs11190553	ENSG00000273030.1	RP11-285F16.1	3.5	0.000516	0.0314	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100448202	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs1106565	ENSG00000273030.1	RP11-285F16.1	3.5	0.000516	0.0314	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100451856	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs75063298	ENSG00000273030.1	RP11-285F16.1	3.5	0.000516	0.0314	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100453843	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs12219789	ENSG00000273030.1	RP11-285F16.1	3.5	0.000516	0.0314	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100454021	chr10:100412934~100413421:+
THCA	cis	rs11239930	0.517	rs942689	ENSG00000180867.10	PDIA3P1	3.5	0.000516	0.0314	0.15	0.16	AIDS progression;	chr1:147079231	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.517	rs632861	ENSG00000180867.10	PDIA3P1	3.5	0.000516	0.0314	0.15	0.16	AIDS progression;	chr1:147079826	chr1:147178113~147179622:+
THCA	cis	rs6860806	0.631	rs4705931	ENSG00000263597.1	MIR3936	3.5	0.000516	0.0314	0.15	0.16	Breast cancer;	chr5:132252652	chr5:132365490~132365599:-
THCA	cis	rs7208859	0.673	rs216418	ENSG00000264242.2	RP11-271K11.1	3.5	0.000516	0.0314	0.23	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs216423	ENSG00000264242.2	RP11-271K11.1	3.5	0.000516	0.0314	0.23	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30553697~30558962:+
THCA	cis	rs7122539	0.646	rs569818	ENSG00000275484.1	CTC-1337H24.4	-3.5	0.000516	0.0314	-0.12	-0.16	HIV-1 susceptibility;	chr11:66803278	chr11:67374416~67374932:+
THCA	cis	rs7122539	0.646	rs608248	ENSG00000275484.1	CTC-1337H24.4	3.5	0.000516	0.0314	0.12	0.16	HIV-1 susceptibility;	chr11:66794777	chr11:67374416~67374932:+
THCA	cis	rs804280	0.565	rs1466785	ENSG00000255495.1	AC145124.2	3.5	0.000516	0.0314	0.17	0.16	Myopia (pathological);	chr8:11765947	chr8:12194467~12196280:+
THCA	cis	rs11168618	1	rs11168621	ENSG00000240399.1	RP1-228P16.1	3.5	0.000516	0.0314	0.16	0.16	Adiponectin levels;	chr12:48545188	chr12:48054813~48055591:-
THCA	cis	rs6878727	0.549	rs2561485	ENSG00000253807.4	LINC01170	-3.5	0.000516	0.0314	-0.14	-0.16	Breast cancer;	chr5:124310150	chr5:124059794~124405079:-
THCA	cis	rs2278702	0.568	rs80102939	ENSG00000259495.2	RP11-210M15.2	-3.5	0.000517	0.0314	-0.24	-0.16	Bipolar disorder;	chr15:80383266	chr15:80344853~80403575:-
THCA	cis	rs1003719	0.614	rs1053808	ENSG00000270116.1	AP001429.1	3.5	0.000517	0.0314	0.17	0.16	Eye color traits;	chr21:37153056	chr21:37100814~37101343:+
THCA	cis	rs712039	0.652	rs853232	ENSG00000277501.1	RP11-697E22.2	3.5	0.000517	0.0314	0.23	0.16	Tuberculosis;	chr17:37481076	chr17:37642947~37684252:+
THCA	cis	rs4948275	0.709	rs2249921	ENSG00000233643.2	RP11-491H19.1	3.5	0.000517	0.0314	0.18	0.16	Night sleep phenotypes;	chr10:61487354	chr10:61781745~61821246:-
THCA	cis	rs10090774	0.901	rs11986785	ENSG00000280303.2	ERICD	-3.5	0.000517	0.0314	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140701852	chr8:140636281~140638283:+
THCA	cis	rs1008126	0.6	rs2041006	ENSG00000234715.1	CTB-107G13.1	-3.5	0.000517	0.0314	-0.18	-0.16	Metabolite levels (Pyroglutamine);	chr7:103490358	chr7:103445207~103514007:+
THCA	cis	rs7665090	1	rs5026473	ENSG00000248971.2	KRT8P46	-3.5	0.000517	0.0314	-0.19	-0.16	Primary biliary cholangitis;	chr4:102633636	chr4:102728746~102730171:-
THCA	cis	rs7864204	0.508	rs869950	ENSG00000234506.4	LINC01506	3.5	0.000517	0.0314	0.22	0.16	Body mass index (recreational physical activity interaction);	chr9:68564629	chr9:68543541~68546589:-
THCA	cis	rs2562456	0.917	rs6511253	ENSG00000268278.1	RP11-420K14.1	-3.5	0.000517	0.0314	-0.19	-0.16	Pain;	chr19:21495996	chr19:21637974~21656300:+
THCA	cis	rs1806864	0.565	rs117686039	ENSG00000214908.3	RP11-229M1.2	-3.5	0.000517	0.0314	-0.35	-0.16	Bipolar disorder and schizophrenia;	chr9:87343223	chr9:86374966~86375706:-
THCA	cis	rs3935740	0.73	rs4077833	ENSG00000271983.1	RP11-28H5.2	3.5	0.000517	0.0314	0.2	0.16	Parkinson's disease;	chr15:81340342	chr15:80693216~80693707:-
THCA	cis	rs11800820	0.557	rs55881259	ENSG00000227953.5	LINC01341	3.5	0.000517	0.0314	0.15	0.16	Obesity-related traits;	chr1:246502649	chr1:246776013~246792385:+
THCA	cis	rs11800820	0.557	rs10924755	ENSG00000227953.5	LINC01341	3.5	0.000517	0.0314	0.15	0.16	Obesity-related traits;	chr1:246503045	chr1:246776013~246792385:+
THCA	cis	rs73198271	0.74	rs1039911	ENSG00000254153.1	CTA-398F10.2	3.5	0.000517	0.0314	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8456909~8461337:-
THCA	cis	rs1005277	0.579	rs2474608	ENSG00000151963.4	RP11-775A3.1	-3.5	0.000517	0.0314	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:37883594~37884109:+
THCA	cis	rs3177980	0.534	rs4987369	ENSG00000239494.2	RN7SL333P	-3.5	0.000517	0.0314	-0.15	-0.16	Amyotrophic lateral sclerosis;	chr1:169693601	chr1:169859756~169860052:+
THCA	cis	rs12938	0.846	rs4987367	ENSG00000239494.2	RN7SL333P	-3.5	0.000517	0.0314	-0.15	-0.16	Blood protein levels;	chr1:169693837	chr1:169859756~169860052:+
THCA	cis	rs6598955	0.666	rs12759434	ENSG00000236782.4	RP11-96L14.7	-3.5	0.000517	0.0314	-0.19	-0.16	Obesity-related traits;	chr1:26280632	chr1:26169947~26171821:-
THCA	cis	rs7824557	0.569	rs10106207	ENSG00000261451.1	RP11-981G7.1	-3.5	0.000517	0.0314	-0.2	-0.16	Retinal vascular caliber;	chr8:11157828	chr8:10433672~10438312:+
THCA	cis	rs4819052	0.788	rs2236449	ENSG00000184274.3	LINC00315	-3.5	0.000517	0.0314	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45300245~45305257:-
THCA	cis	rs11175194	0.744	rs57082798	ENSG00000275027.1	AC084357.1	3.5	0.000517	0.0314	0.39	0.16	Epithelial ovarian cancer;	chr12:63837625	chr12:63824238~63824294:+
THCA	cis	rs615552	0.535	rs490005	ENSG00000229298.1	TUBB8P1	-3.5	0.000517	0.0314	-0.17	-0.16	Migraine without aura;	chr9:22020494	chr9:21811621~21812347:-
THCA	cis	rs324126	0.78	rs4802926	ENSG00000269834.4	ZNF528-AS1	-3.5	0.000517	0.0314	-0.12	-0.16	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52388842~52397766:-
THCA	cis	rs7819412	0.66	rs7462931	ENSG00000254839.1	AF131215.6	3.5	0.000517	0.0314	0.16	0.16	Triglycerides;	chr8:11052833	chr8:11062647~11067089:-
THCA	cis	rs453301	0.631	rs11779804	ENSG00000253981.4	ALG1L13P	-3.5	0.000517	0.0314	-0.16	-0.16	Joint mobility (Beighton score);	chr8:8940442	chr8:8236003~8244667:-
THCA	cis	rs4589258	0.644	rs55838813	ENSG00000280367.1	RP11-121L10.2	-3.5	0.000517	0.0314	-0.15	-0.16	Intelligence (multi-trait analysis);	chr11:90677029	chr11:90223153~90226538:+
THCA	cis	rs7577696	0.528	rs160801	ENSG00000276334.1	AL133243.1	-3.5	0.000517	0.0314	-0.17	-0.16	Inflammatory biomarkers;	chr2:31879685	chr2:32521927~32523547:+
THCA	cis	rs465969	1	rs459888	ENSG00000272356.1	RP5-1112D6.8	-3.5	0.000517	0.0314	-0.23	-0.16	Psoriasis;	chr6:111329953	chr6:111309203~111313517:+
THCA	cis	rs2933343	0.729	rs1680781	ENSG00000231305.3	RP11-723O4.2	3.5	0.000517	0.0314	0.17	0.16	IgG glycosylation;	chr3:128893987	chr3:128861313~128871540:-
THCA	cis	rs875971	0.522	rs9530	ENSG00000232546.1	RP11-458F8.1	-3.5	0.000517	0.0314	-0.14	-0.16	Aortic root size;	chr7:65960907	chr7:66848496~66858136:+
THCA	cis	rs2933343	0.7	rs1680779	ENSG00000231305.3	RP11-723O4.2	3.5	0.000517	0.0314	0.17	0.16	IgG glycosylation;	chr3:128895927	chr3:128861313~128871540:-
THCA	cis	rs5758659	0.716	rs5758661	ENSG00000237037.8	NDUFA6-AS1	3.5	0.000517	0.0314	0.12	0.16	Cognitive function;	chr22:42228439	chr22:42090931~42137742:+
THCA	cis	rs6005807	0.719	rs2144922	ENSG00000226471.5	CTA-292E10.6	-3.5	0.000517	0.0314	-0.19	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28527329	chr22:28800683~28848559:+
THCA	cis	rs35740288	0.787	rs11637768	ENSG00000259407.1	RP11-158M2.3	-3.5	0.000517	0.0314	-0.2	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85680179	chr15:85744109~85750281:-
THCA	cis	rs8030605	0.778	rs813267	ENSG00000277245.1	RP11-48G14.3	-3.5	0.000517	0.0314	-0.28	-0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56425349	chr15:56447120~56447697:+
THCA	cis	rs1062177	1	rs41494545	ENSG00000272112.1	CTB-113P19.5	-3.5	0.000517	0.0314	-0.14	-0.16	Preschool internalizing problems;	chr5:151855533	chr5:151724831~151725356:-
THCA	cis	rs4915077	0.892	rs17020104	ENSG00000226822.1	RP11-356N1.2	3.5	0.000517	0.0314	0.26	0.16	Hypothyroidism;	chr1:107811048	chr1:108071482~108074519:+
THCA	cis	rs72634501	0.568	rs590214	ENSG00000182109.6	RP11-69E11.4	3.5	0.000517	0.0314	0.16	0.16	HDL cholesterol;	chr1:39146821	chr1:39522280~39546187:-
THCA	cis	rs1850744	0.702	rs55813730	ENSG00000163612.10	FAM86KP	3.5	0.000518	0.0314	0.37	0.16	Economic and political preferences;	chr4:9593994	chr4:9153296~9165451:+
THCA	cis	rs1154275	0.537	rs6797028	ENSG00000272844.1	RP11-484K9.4	3.5	0.000518	0.0314	0.13	0.16	Takotsubo syndrome;	chr3:112796340	chr3:112990447~112991153:-
THCA	cis	rs3758911	0.765	rs687991	ENSG00000255353.1	RP11-382M14.1	3.5	0.000518	0.0314	0.21	0.16	Coronary artery disease;	chr11:107449918	chr11:107176286~107177530:+
THCA	cis	rs301901	0.772	rs301908	ENSG00000250155.1	CTD-2353F22.1	-3.5	0.000518	0.0314	-0.16	-0.16	Height;	chr5:37103704	chr5:36666214~36725195:-
THCA	cis	rs1012053	0.642	rs1177637	ENSG00000278338.3	VWA8-AS1	3.5	0.000518	0.0314	0.2	0.16	Bipolar disorder;	chr13:42118687	chr13:41955808~41981565:+
THCA	cis	rs1012053	0.642	rs636264	ENSG00000278338.3	VWA8-AS1	3.5	0.000518	0.0314	0.2	0.16	Bipolar disorder;	chr13:42124244	chr13:41955808~41981565:+
THCA	cis	rs7045881	0.576	rs10812521	ENSG00000254396.1	RP11-56F10.3	3.5	0.000518	0.0315	0.2	0.16	Schizophrenia;	chr9:27051814	chr9:27102630~27104728:+
THCA	cis	rs2006933	1	rs12947213	ENSG00000267644.1	CTD-2008P7.10	3.5	0.000518	0.0315	0.2	0.16	Amyotrophic lateral sclerosis;	chr17:28271648	chr17:28219285~28220005:+
THCA	cis	rs9478638	0.507	rs9371882	ENSG00000235381.1	RP11-477D19.2	-3.5	0.000518	0.0315	-0.13	-0.16	Electroencephalogram traits;	chr6:155317607	chr6:155253139~155256724:-
THCA	cis	rs4792901	0.802	rs55989313	ENSG00000279602.1	CTD-3014M21.1	-3.5	0.000518	0.0315	-0.2	-0.16	Dupuytren's disease;	chr17:43528880	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs28581728	ENSG00000279602.1	CTD-3014M21.1	-3.5	0.000518	0.0315	-0.2	-0.16	Dupuytren's disease;	chr17:43531968	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.802	rs28608935	ENSG00000279602.1	CTD-3014M21.1	-3.5	0.000518	0.0315	-0.2	-0.16	Dupuytren's disease;	chr17:43532102	chr17:43360041~43361361:-
THCA	cis	rs1979679	0.842	rs3741760	ENSG00000247934.4	RP11-967K21.1	3.5	0.000518	0.0315	0.15	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28391531	chr12:28163298~28190738:-
THCA	cis	rs4915077	1	rs4915073	ENSG00000226822.1	RP11-356N1.2	3.5	0.000518	0.0315	0.31	0.16	Hypothyroidism;	chr1:107783257	chr1:108071482~108074519:+
THCA	cis	rs8070740	0.559	rs1806263	ENSG00000234327.6	AC012146.7	3.5	0.000518	0.0315	0.13	0.16	Menopause (age at onset);	chr17:5414172	chr17:5111468~5115004:+
THCA	cis	rs7267979	0.866	rs437635	ENSG00000276952.1	RP5-965G21.6	3.5	0.000518	0.0315	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25284915~25285588:-
THCA	cis	rs6840360	1	rs3749561	ENSG00000270265.1	RP11-731D1.4	3.5	0.000518	0.0315	0.15	0.16	Intelligence (multi-trait analysis);	chr4:151688965	chr4:151333775~151353224:-
THCA	cis	rs3784262	0.869	rs12903792	ENSG00000259250.1	RP11-50C13.1	3.5	0.000518	0.0315	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57969082	chr15:58587507~58591676:+
THCA	cis	rs9796	0.87	rs1001341	ENSG00000247556.5	OIP5-AS1	-3.5	0.000518	0.0315	-0.13	-0.16	Menopause (age at onset);	chr15:40969293	chr15:41283990~41309737:+
THCA	cis	rs875971	0.522	rs1880556	ENSG00000230189.5	GS1-124K5.2	3.5	0.000518	0.0315	0.1	0.16	Aortic root size;	chr7:65967557	chr7:66409143~66490059:-
THCA	cis	rs7819412	0.668	rs2409714	ENSG00000206014.6	OR7E161P	3.5	0.000518	0.0315	0.19	0.16	Triglycerides;	chr8:11152608	chr8:11928597~11929563:-
THCA	cis	rs910316	0.737	rs175072	ENSG00000273565.1	CTD-3075F15.1	-3.5	0.000518	0.0315	-0.19	-0.16	Height;	chr14:75036124	chr14:75176929~75177418:+
THCA	cis	rs910316	0.712	rs175074	ENSG00000273565.1	CTD-3075F15.1	-3.5	0.000518	0.0315	-0.19	-0.16	Height;	chr14:75037751	chr14:75176929~75177418:+
THCA	cis	rs944289	0.74	rs1623766	ENSG00000212071.1	AL162511.1	-3.5	0.000518	0.0315	-0.18	-0.16	Thyroid cancer;	chr14:36075632	chr14:36196480~36196568:-
THCA	cis	rs944289	0.74	rs416664	ENSG00000212071.1	AL162511.1	-3.5	0.000518	0.0315	-0.18	-0.16	Thyroid cancer;	chr14:36076319	chr14:36196480~36196568:-
THCA	cis	rs944289	0.74	rs1617130	ENSG00000212071.1	AL162511.1	-3.5	0.000518	0.0315	-0.18	-0.16	Thyroid cancer;	chr14:36077059	chr14:36196480~36196568:-
THCA	cis	rs72772480	0.651	rs4967945	ENSG00000257838.4	RP11-368J21.3	3.5	0.000518	0.0315	0.3	0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr16:23071651	chr16:22545698~22576865:+
THCA	cis	rs4742045	0.532	rs10815070	ENSG00000231967.1	RP11-12D24.6	-3.5	0.000518	0.0315	-0.19	-0.16	Mean corpuscular hemoglobin;	chr9:4760538	chr9:5356312~5356525:-
THCA	cis	rs6545883	0.868	rs2441381	ENSG00000212978.6	AC016747.3	3.5	0.000518	0.0315	0.17	0.16	Tuberculosis;	chr2:61571694	chr2:61141592~61144969:-
THCA	cis	rs7759001	0.744	rs7771590	ENSG00000271755.1	RP1-153G14.4	3.5	0.000518	0.0315	0.19	0.16	Glomerular filtration rate (creatinine);	chr6:27500117	chr6:27404010~27406964:-
THCA	cis	rs9880211	0.528	rs75685279	ENSG00000239213.4	NCK1-AS1	3.5	0.000518	0.0315	0.17	0.16	Height;Body mass index;	chr3:136715991	chr3:136841726~136862054:-
THCA	cis	rs34975555	0.892	rs7464093	ENSG00000253671.1	RP11-806O11.1	-3.5	0.000518	0.0315	-0.27	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17993008	chr8:17808941~17820868:+
THCA	cis	rs1510272	0.961	rs9861440	ENSG00000243926.1	TIPARP-AS1	-3.5	0.000518	0.0315	-0.16	-0.16	Testicular germ cell tumor;	chr3:156599590	chr3:156671862~156674378:-
THCA	cis	rs9693857	0.553	rs10100760	ENSG00000254340.1	RP11-10A14.3	-3.5	0.000518	0.0315	-0.17	-0.16	Systolic blood pressure;	chr8:9513049	chr8:9141424~9145435:+
THCA	cis	rs9828933	1	rs1060897	ENSG00000224479.4	AC136289.1	-3.5	0.000518	0.0315	-0.23	-0.16	Type 2 diabetes;	chr3:64012196	chr3:63742293~63827445:-
THCA	cis	rs8141529	0.509	rs5762853	ENSG00000226471.5	CTA-292E10.6	-3.5	0.000518	0.0315	-0.14	-0.16	Lymphocyte counts;	chr22:28849243	chr22:28800683~28848559:+
THCA	cis	rs2911280	0.764	rs2061679	ENSG00000278985.1	RP11-303E16.9	-3.5	0.000518	0.0315	-0.3	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81540371	chr16:80982319~80984094:-
THCA	cis	rs34638657	0.518	rs2288050	ENSG00000261235.1	RP11-510J16.5	-3.5	0.000518	0.0315	-0.18	-0.16	Lung adenocarcinoma;	chr16:82149798	chr16:82044336~82139631:-
THCA	cis	rs2933343	0.679	rs789221	ENSG00000261159.1	RP11-723O4.9	3.5	0.000518	0.0315	0.16	0.16	IgG glycosylation;	chr3:128872782	chr3:128859716~128860526:-
THCA	cis	rs1436955	0.754	rs2083013	ENSG00000259251.2	RP11-643M14.1	-3.5	0.000519	0.0315	-0.2	-0.16	Type 2 diabetes;	chr15:62109283	chr15:62060503~62062434:+
THCA	cis	rs10089	0.953	rs758179	ENSG00000245937.6	LINC01184	3.5	0.000519	0.0315	0.18	0.16	Ileal carcinoids;	chr5:128018732	chr5:127940426~128083172:-
THCA	cis	rs3015497	0.648	rs10144512	ENSG00000270062.1	RP11-248J18.3	3.5	0.000519	0.0315	0.18	0.16	Mean platelet volume;	chr14:50615553	chr14:50723777~50724272:-
THCA	cis	rs28830936	0.966	rs17733613	ENSG00000250379.1	RP11-23P13.4	3.5	0.000519	0.0315	0.19	0.16	Diastolic blood pressure;	chr15:41625387	chr15:41825099~41827936:-
THCA	cis	rs4713118	0.513	rs156734	ENSG00000176933.5	TOB2P1	-3.5	0.000519	0.0315	-0.19	-0.16	Parkinson's disease;	chr6:28039579	chr6:28217643~28218634:-
THCA	cis	rs7474896	1	rs9418299	ENSG00000276805.1	RP11-291L22.6	3.5	0.000519	0.0315	0.25	0.16	Obesity (extreme);	chr10:37851299	chr10:38451030~38451785:+
THCA	cis	rs8187707	0.881	rs56075687	ENSG00000233690.1	EBAG9P1	-3.5	0.000519	0.0315	-0.33	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99860805	chr10:99697407~99697949:-
THCA	cis	rs738409	0.657	rs12484700	ENSG00000223843.4	EFCAB6-AS1	3.5	0.000519	0.0315	0.23	0.16	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43931393	chr22:43516107~43537117:+
THCA	cis	rs1048886	0.872	rs12191321	ENSG00000271967.1	RP11-134K13.4	-3.5	0.000519	0.0315	-0.19	-0.16	Type 2 diabetes;	chr6:70593484	chr6:70596438~70596980:+
THCA	cis	rs6828577	0.862	rs298974	ENSG00000248280.1	RP11-33B1.2	3.5	0.000519	0.0315	0.14	0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118714879	chr4:119440561~119450157:-
THCA	cis	rs769267	0.929	rs2905424	ENSG00000269131.1	AC004447.2	3.5	0.000519	0.0315	0.1	0.16	Tonsillectomy;	chr19:19362636	chr19:18990893~18993610:+
THCA	cis	rs7166081	1	rs10438355	ENSG00000270964.1	RP11-502I4.3	-3.5	0.000519	0.0315	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67195211	chr15:67541072~67542604:-
THCA	cis	rs67478160	0.634	rs2024669	ENSG00000258534.1	CTD-2134A5.4	-3.5	0.000519	0.0315	-0.16	-0.16	Schizophrenia;	chr14:103809265	chr14:103854366~103880111:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000228022.4	HCG20	-3.5	0.000519	0.0315	-0.25	-0.16	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30766825~30792250:+
THCA	cis	rs2562456	0.752	rs7258562	ENSG00000268278.1	RP11-420K14.1	3.5	0.000519	0.0315	0.22	0.16	Pain;	chr19:21331762	chr19:21637974~21656300:+
THCA	cis	rs9549260	0.709	rs9549240	ENSG00000275149.1	RP11-427J23.1	-3.5	0.000519	0.0315	-0.21	-0.16	Red blood cell count;	chr13:40612507	chr13:40079106~40273509:-
THCA	cis	rs2179367	0.881	rs2744432	ENSG00000216906.2	RP11-350J20.9	-3.5	0.000519	0.0315	-0.19	-0.16	Dupuytren's disease;	chr6:149422735	chr6:149904243~149906418:+
THCA	cis	rs6696239	0.911	rs11580196	ENSG00000227711.2	RP11-275O4.5	-3.5	0.000519	0.0315	-0.26	-0.16	Height;	chr1:227767575	chr1:227509028~227520477:-
THCA	cis	rs2688608	0.62	rs7098444	ENSG00000272140.2	RP11-574K11.29	3.5	0.000519	0.0315	0.13	0.16	Inflammatory bowel disease;	chr10:73820284	chr10:73703735~73713581:-
THCA	cis	rs1003719	0.628	rs2835635	ENSG00000270116.1	AP001429.1	3.5	0.000519	0.0315	0.17	0.16	Eye color traits;	chr21:37156565	chr21:37100814~37101343:+
THCA	cis	rs7804306	1	rs35009545	ENSG00000233264.2	AC006042.8	3.5	0.000519	0.0315	0.3	0.16	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037223	chr7:7980312~7982228:+
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000255052.4	FAM66D	-3.5	0.000519	0.0315	-0.21	-0.16	Neuroticism;	chr8:11991324	chr8:12115782~12177550:+
THCA	cis	rs8114671	0.562	rs6058120	ENSG00000126005.14	MMP24-AS1	-3.5	0.000519	0.0315	-0.15	-0.16	Height;	chr20:34815026	chr20:35216462~35278131:-
THCA	cis	rs2486012	1	rs2485990	ENSG00000237950.1	RP11-7O11.3	-3.5	0.000519	0.0315	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43931118	chr1:43944370~43946551:-
THCA	cis	rs9435732	0.778	rs56047197	ENSG00000268869.4	ESPNP	3.5	0.000519	0.0315	0.17	0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17011965	chr1:16687339~16720157:-
THCA	cis	rs9925964	0.967	rs14235	ENSG00000279196.1	RP11-1072A3.3	-3.5	0.000519	0.0315	-0.16	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31110472	chr16:30984630~30988270:-
THCA	cis	rs879324	0.616	rs7199827	ENSG00000280092.1	AC002044.3	3.5	0.000519	0.0315	0.23	0.16	Stroke (ischemic);	chr16:73011950	chr16:73005601~73006141:-
THCA	cis	rs7615952	0.932	rs13325495	ENSG00000272840.1	RP11-379B18.6	3.5	0.000519	0.0315	0.27	0.16	Blood pressure (smoking interaction);	chr3:125918573	chr3:125774714~125797953:+
THCA	cis	rs9468186	1	rs9468186	ENSG00000216915.2	RP1-97D16.1	-3.5	0.000519	0.0315	-0.23	-0.16	Neuroticism;	chr6:27658852	chr6:27737000~27738494:-
THCA	cis	rs478304	0.593	rs9666878	ENSG00000255120.4	OVOL1-AS1	3.5	0.000519	0.0315	0.22	0.16	Acne (severe);	chr11:65708345	chr11:65789051~65790868:-
THCA	cis	rs11089937	0.626	rs5757017	ENSG00000215456.5	BCRP4	3.49	0.000519	0.0315	0.2	0.16	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22630061~22636153:+
THCA	cis	rs4601292	0.553	rs7017127	ENSG00000200714.1	Y_RNA	-3.49	0.000519	0.0315	-0.23	-0.16	HIV-1 viral setpoint;	chr8:65987692	chr8:65592731~65592820:+
THCA	cis	rs2191566	1	rs2191566	ENSG00000267114.1	CTB-129P6.11	-3.49	0.000519	0.0315	-0.12	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44007237	chr19:44950044~44954007:-
THCA	cis	rs6479901	0.696	rs931972	ENSG00000272767.1	JMJD1C-AS1	-3.49	0.000519	0.0315	-0.19	-0.16	Intelligence (multi-trait analysis);	chr10:63150467	chr10:63465229~63466563:+
THCA	cis	rs773506	0.628	rs10991813	ENSG00000235641.4	LINC00484	3.49	0.000519	0.0315	0.21	0.16	Type 2 diabetes nephropathy;	chr9:91186733	chr9:91159573~91165658:+
THCA	cis	rs4713118	0.869	rs9295743	ENSG00000272009.1	RP1-313I6.12	-3.49	0.000519	0.0315	-0.18	-0.16	Parkinson's disease;	chr6:27747323	chr6:28078792~28081130:-
THCA	cis	rs881375	0.967	rs2109896	ENSG00000270917.1	RP11-27I1.6	-3.49	0.000519	0.0315	-0.22	-0.16	Rheumatoid arthritis;	chr9:120920828	chr9:120812475~120812845:-
THCA	cis	rs7586879	0.593	rs11689543	ENSG00000224165.4	DNAJC27-AS1	-3.49	0.000519	0.0315	-0.09	-0.16	Body mass index;	chr2:24907571	chr2:24971390~25039694:+
THCA	cis	rs7586879	0.593	rs11689546	ENSG00000224165.4	DNAJC27-AS1	-3.49	0.000519	0.0315	-0.09	-0.16	Body mass index;	chr2:24907582	chr2:24971390~25039694:+
THCA	cis	rs10943724	0.917	rs12207977	ENSG00000272129.1	RP11-250B2.6	3.49	0.000519	0.0315	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80518457	chr6:80355424~80356859:+
THCA	cis	rs1065852	0.526	rs9623489	ENSG00000232710.1	RP4-669P10.16	-3.49	0.000519	0.0315	-0.2	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42001022	chr22:42136433~42139927:-
THCA	cis	rs6546886	0.788	rs13003431	ENSG00000235499.1	AC073046.25	3.49	0.000519	0.0315	0.15	0.16	Dialysis-related mortality;	chr2:74025948	chr2:73985132~73986343:+
THCA	cis	rs6546886	0.869	rs35592918	ENSG00000235499.1	AC073046.25	3.49	0.000519	0.0315	0.15	0.16	Dialysis-related mortality;	chr2:74026591	chr2:73985132~73986343:+
THCA	cis	rs658349	0.621	rs605073	ENSG00000251332.1	RP11-177C12.4	-3.49	0.000519	0.0315	-0.18	-0.16	Lymphocyte counts;	chr4:38129634	chr4:37995494~37996203:-
THCA	cis	rs897984	0.806	rs8052245	ENSG00000232748.3	RP11-196G11.6	3.49	0.000519	0.0315	0.19	0.16	Dementia with Lewy bodies;	chr16:30905109	chr16:31056460~31062803:+
THCA	cis	rs7937890	0.559	rs2575829	ENSG00000251991.1	RNU7-49P	3.49	0.000519	0.0315	0.18	0.16	Mitochondrial DNA levels;	chr11:14463475	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2597200	ENSG00000251991.1	RNU7-49P	3.49	0.000519	0.0315	0.18	0.16	Mitochondrial DNA levels;	chr11:14464054	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2575830	ENSG00000251991.1	RNU7-49P	3.49	0.000519	0.0315	0.18	0.16	Mitochondrial DNA levels;	chr11:14464056	chr11:14478892~14478953:+
THCA	cis	rs9291683	0.53	rs998675	ENSG00000250413.1	RP11-448G15.1	-3.49	0.000519	0.0315	-0.16	-0.16	Bone mineral density;	chr4:9947205	chr4:10006482~10009725:+
THCA	cis	rs853679	1	rs2799077	ENSG00000261839.1	RP1-265C24.8	3.49	0.000519	0.0315	0.22	0.16	Depression;	chr6:28266819	chr6:28136849~28139678:+
THCA	cis	rs2880765	0.835	rs56406982	ENSG00000259407.1	RP11-158M2.3	-3.49	0.000519	0.0315	-0.16	-0.16	Coronary artery disease;	chr15:85493148	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.835	rs900573	ENSG00000259407.1	RP11-158M2.3	3.49	0.000519	0.0315	0.16	0.16	Coronary artery disease;	chr15:85494762	chr15:85744109~85750281:-
THCA	cis	rs308403	0.509	rs309376	ENSG00000224786.1	CETN4P	3.49	0.00052	0.0315	0.16	0.16	Blood protein levels;	chr4:122759036	chr4:122730548~122732193:-
THCA	cis	rs4773860	0.601	rs10508018	ENSG00000223298.1	RNY3P8	-3.49	0.00052	0.0315	-0.18	-0.16	Plateletcrit;	chr13:95244162	chr13:95310830~95310955:-
THCA	cis	rs10805346	0.501	rs4604059	ENSG00000261490.1	RP11-448G15.3	-3.49	0.00052	0.0316	-0.1	-0.16	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10113441	chr4:10068089~10073019:-
THCA	cis	rs9902453	0.619	rs2244585	ENSG00000214719.10	AC005562.1	-3.49	0.00052	0.0316	-0.15	-0.16	Coffee consumption (cups per day);	chr17:29745158	chr17:30576464~30672789:+
THCA	cis	rs9902453	0.619	rs2617866	ENSG00000214719.10	AC005562.1	-3.49	0.00052	0.0316	-0.15	-0.16	Coffee consumption (cups per day);	chr17:29749199	chr17:30576464~30672789:+
THCA	cis	rs5758659	0.652	rs129857	ENSG00000182057.4	OGFRP1	-3.49	0.00052	0.0316	-0.18	-0.16	Cognitive function;	chr22:42003682	chr22:42269753~42275196:+
THCA	cis	rs911555	0.547	rs8006994	ENSG00000269910.1	RP11-73M18.10	3.49	0.00052	0.0316	0.14	0.16	Intelligence (multi-trait analysis);	chr14:103374959	chr14:103694516~103695050:-
THCA	cis	rs4664293	1	rs13014418	ENSG00000230783.1	AC009961.2	-3.49	0.00052	0.0316	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159627174	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs3940435	ENSG00000230783.1	AC009961.2	-3.49	0.00052	0.0316	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159638272	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs12999124	ENSG00000230783.1	AC009961.2	-3.49	0.00052	0.0316	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159674817	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs1346325	ENSG00000230783.1	AC009961.2	-3.49	0.00052	0.0316	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159685995	chr2:159689217~159690291:-
THCA	cis	rs6456156	0.792	rs4710183	ENSG00000235272.1	FAM103A2P	-3.49	0.00052	0.0316	-0.22	-0.16	Primary biliary cholangitis;	chr6:167100595	chr6:166586124~166586477:-
THCA	cis	rs7141336	0.607	rs7149722	ENSG00000275198.1	RP11-471B22.3	-3.49	0.00052	0.0316	-0.15	-0.16	Anxiety disorder;	chr14:90750945	chr14:90383365~90387973:+
THCA	cis	rs8062405	0.558	rs151228	ENSG00000261766.1	RP11-22P6.2	-3.49	0.00052	0.0316	-0.15	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28862166~28863340:-
THCA	cis	rs6499755	0.768	rs31095	ENSG00000260135.5	RP11-212I21.2	-3.49	0.00052	0.0316	-0.17	-0.16	Hypospadias;	chr16:55333318	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.768	rs31096	ENSG00000260135.5	RP11-212I21.2	-3.49	0.00052	0.0316	-0.17	-0.16	Hypospadias;	chr16:55333491	chr16:55426797~55462297:-
THCA	cis	rs412658	0.504	rs385774	ENSG00000268119.4	CTD-2561J22.5	-3.49	0.00052	0.0316	-0.18	-0.16	Telomere length;	chr19:21913273	chr19:21444241~21463908:-
THCA	cis	rs9487094	0.689	rs9487070	ENSG00000223537.2	RP5-919F19.5	-3.49	0.00052	0.0316	-0.16	-0.16	Height;	chr6:109361200	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.666	rs974034	ENSG00000223537.2	RP5-919F19.5	-3.49	0.00052	0.0316	-0.16	-0.16	Height;	chr6:109368228	chr6:109487906~109506800:+
THCA	cis	rs1012068	0.695	rs5998152	ENSG00000235989.3	MORC2-AS1	3.49	0.00052	0.0316	0.22	0.16	Chronic hepatitis C infection;	chr22:31867176	chr22:30922308~30932449:+
THCA	cis	rs78487399	0.908	rs73925553	ENSG00000234936.1	AC010883.5	3.49	0.00052	0.0316	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583507	chr2:43229573~43233394:+
THCA	cis	rs9650657	0.812	rs7834466	ENSG00000269918.1	AF131215.9	-3.49	0.00052	0.0316	-0.17	-0.16	Neuroticism;	chr8:10777295	chr8:11104691~11106704:-
THCA	cis	rs4934494	0.525	rs10881611	ENSG00000240996.1	RP11-80H5.7	-3.49	0.00052	0.0316	-0.16	-0.16	Red blood cell count;	chr10:89623664	chr10:89694295~89697928:-
THCA	cis	rs2494663	0.585	rs11264996	ENSG00000231416.1	RP11-422P24.9	3.49	0.00052	0.0316	0.2	0.16	Mean platelet volume;	chr1:154071080	chr1:153995632~153995960:+
THCA	cis	rs10908557	0.709	rs72694300	ENSG00000231416.1	RP11-422P24.9	3.49	0.00052	0.0316	0.2	0.16	Age at first birth;	chr1:154084358	chr1:153995632~153995960:+
THCA	cis	rs9637454	1	rs1477779	ENSG00000231574.4	RP11-91K9.1	3.49	0.00052	0.0316	0.22	0.16	Hippocampal sclerosis;	chr3:178546793	chr3:177816865~177899224:+
THCA	cis	rs15676	0.783	rs4489410	ENSG00000234771.3	SLC25A25-AS1	-3.49	0.00052	0.0316	-0.14	-0.16	Blood metabolite levels;	chr9:128829370	chr9:128108581~128118693:-
THCA	cis	rs11239930	0.56	rs632334	ENSG00000180867.10	PDIA3P1	3.49	0.00052	0.0316	0.15	0.16	AIDS progression;	chr1:147079972	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.538	rs630630	ENSG00000180867.10	PDIA3P1	3.49	0.00052	0.0316	0.15	0.16	AIDS progression;	chr1:147080377	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.538	rs618575	ENSG00000180867.10	PDIA3P1	3.49	0.00052	0.0316	0.15	0.16	AIDS progression;	chr1:147080759	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.517	rs4950354	ENSG00000180867.10	PDIA3P1	3.49	0.00052	0.0316	0.15	0.16	AIDS progression;	chr1:147082674	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.538	rs4950355	ENSG00000180867.10	PDIA3P1	3.49	0.00052	0.0316	0.15	0.16	AIDS progression;	chr1:147082700	chr1:147178113~147179622:+
THCA	cis	rs6870983	0.749	rs42298	ENSG00000247828.6	TMEM161B-AS1	3.49	0.00052	0.0316	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88211623	chr5:88268895~88436685:+
THCA	cis	rs881375	0.678	rs10739581	ENSG00000238181.2	AHCYP2	-3.49	0.00052	0.0316	-0.19	-0.16	Rheumatoid arthritis;	chr9:120934593	chr9:120720673~120721972:+
THCA	cis	rs332034	0.546	rs10091646	ENSG00000254153.1	CTA-398F10.2	3.49	0.00052	0.0316	0.25	0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8830249	chr8:8456909~8461337:-
THCA	cis	rs7131987	0.903	rs11050153	ENSG00000275476.1	RP11-996F15.4	-3.49	0.00052	0.0316	-0.15	-0.16	QT interval;	chr12:29252215	chr12:29277397~29277882:-
THCA	cis	rs7631605	0.819	rs4678922	ENSG00000272334.1	RP11-129K12.1	-3.49	0.00052	0.0316	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36981373	chr3:36973117~36973672:-
THCA	cis	rs714027	0.566	rs4823076	ENSG00000279699.1	RP1-102K2.9	-3.49	0.00052	0.0316	-0.16	-0.16	Lymphocyte counts;	chr22:30123425	chr22:30275215~30276951:-
THCA	cis	rs714027	0.515	rs2412972	ENSG00000279699.1	RP1-102K2.9	-3.49	0.00052	0.0316	-0.16	-0.16	Lymphocyte counts;	chr22:30123836	chr22:30275215~30276951:-
THCA	cis	rs2562456	0.52	rs250001	ENSG00000268117.1	VN1R84P	3.49	0.00052	0.0316	0.25	0.16	Pain;	chr19:21225387	chr19:21719801~21720035:-
THCA	cis	rs3770081	0.59	rs79329534	ENSG00000273080.1	RP11-301O19.1	-3.49	0.00052	0.0316	-0.41	-0.16	Facial emotion recognition (sad faces);	chr2:86231508	chr2:86195590~86196049:+
THCA	cis	rs6479891	1	rs9414788	ENSG00000272767.1	JMJD1C-AS1	-3.49	0.00052	0.0316	-0.22	-0.16	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63465229~63466563:+
THCA	cis	rs208520	1	rs72882100	ENSG00000233859.2	ADH5P4	3.49	0.000521	0.0316	0.25	0.16	Exhaled nitric oxide output;	chr6:66271602	chr6:65836930~65838039:-
THCA	cis	rs7924176	0.521	rs12415957	ENSG00000271848.1	RP11-464F9.21	3.49	0.000521	0.0316	0.17	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:73654039~73674719:+
THCA	cis	rs7264396	0.887	rs1570841	ENSG00000261582.1	RP4-614O4.11	-3.49	0.000521	0.0316	-0.16	-0.16	Total cholesterol levels;	chr20:35460341	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs1886696	ENSG00000261582.1	RP4-614O4.11	-3.49	0.000521	0.0316	-0.16	-0.16	Total cholesterol levels;	chr20:35467881	chr20:35267885~35280043:-
THCA	cis	rs8114671	0.562	rs2889861	ENSG00000126005.14	MMP24-AS1	-3.49	0.000521	0.0316	-0.15	-0.16	Height;	chr20:34817861	chr20:35216462~35278131:-
THCA	cis	rs11069062	0.683	rs10851026	ENSG00000270482.1	RP11-131L12.2	3.49	0.000521	0.0316	0.12	0.16	Obesity-related traits;	chr12:118743512	chr12:118375350~118376275:-
THCA	cis	rs2823962	0.697	rs9637008	ENSG00000270093.1	AP000473.8	-3.49	0.000521	0.0316	-0.14	-0.16	Amyotrophic lateral sclerosis;	chr21:16646119	chr21:16643529~16645065:+
THCA	cis	rs2562456	0.833	rs62110367	ENSG00000268521.1	VN1R83P	3.49	0.000521	0.0316	0.16	0.16	Pain;	chr19:21365829	chr19:21289554~21289998:-
THCA	cis	rs875971	0.862	rs10224872	ENSG00000223473.2	GS1-124K5.3	-3.49	0.000521	0.0316	-0.11	-0.16	Aortic root size;	chr7:66294786	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs949930	ENSG00000223473.2	GS1-124K5.3	-3.49	0.000521	0.0316	-0.11	-0.16	Aortic root size;	chr7:66301835	chr7:66491049~66493566:-
THCA	cis	rs4656958	0.93	rs4656961	ENSG00000233691.2	RP11-312J18.7	3.49	0.000521	0.0316	0.19	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160892811	chr1:160935537~160936126:+
THCA	cis	rs3121446	0.96	rs2354549	ENSG00000229654.1	RP1-60O19.2	3.49	0.000521	0.0316	0.17	0.16	Daytime sleep phenotypes;	chr6:106694448	chr6:106695535~106699994:+
THCA	cis	rs8114671	0.869	rs66535333	ENSG00000126005.14	MMP24-AS1	3.49	0.000521	0.0316	0.15	0.16	Height;	chr20:35068863	chr20:35216462~35278131:-
THCA	cis	rs8114671	0.869	rs1544047	ENSG00000126005.14	MMP24-AS1	3.49	0.000521	0.0316	0.15	0.16	Height;	chr20:35082950	chr20:35216462~35278131:-
THCA	cis	rs8114671	0.836	rs17404569	ENSG00000126005.14	MMP24-AS1	3.49	0.000521	0.0316	0.15	0.16	Height;	chr20:35086274	chr20:35216462~35278131:-
THCA	cis	rs293748	0.713	rs158789	ENSG00000250155.1	CTD-2353F22.1	-3.49	0.000521	0.0316	-0.21	-0.16	Obesity-related traits;	chr5:36834955	chr5:36666214~36725195:-
THCA	cis	rs4742903	0.875	rs1605449	ENSG00000270332.1	SMC2-AS1	3.49	0.000521	0.0316	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104214116	chr9:104080024~104093073:-
THCA	cis	rs6878727	0.85	rs10055879	ENSG00000253807.4	LINC01170	-3.49	0.000521	0.0316	-0.16	-0.16	Breast cancer;	chr5:124368565	chr5:124059794~124405079:-
THCA	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	3.49	0.000521	0.0316	0.14	0.16	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	3.49	0.000521	0.0316	0.14	0.16	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
THCA	cis	rs7671266	0.532	rs4608811	ENSG00000261490.1	RP11-448G15.3	3.49	0.000521	0.0316	0.13	0.16	Cardiovascular disease risk factors;	chr4:10048051	chr4:10068089~10073019:-
THCA	cis	rs875971	0.862	rs2901152	ENSG00000223473.2	GS1-124K5.3	-3.49	0.000521	0.0316	-0.11	-0.16	Aortic root size;	chr7:66300017	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs10263690	ENSG00000223473.2	GS1-124K5.3	-3.49	0.000521	0.0316	-0.11	-0.16	Aortic root size;	chr7:66301466	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs10250544	ENSG00000223473.2	GS1-124K5.3	-3.49	0.000521	0.0316	-0.11	-0.16	Aortic root size;	chr7:66301574	chr7:66491049~66493566:-
THCA	cis	rs13108904	0.87	rs2335855	ENSG00000254094.1	AC078852.1	-3.49	0.000521	0.0316	-0.18	-0.16	Obesity-related traits;	chr4:1244180	chr4:1356581~1358075:+
THCA	cis	rs4272720	0.562	rs34467986	ENSG00000234736.4	FAM170B-AS1	-3.49	0.000521	0.0316	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49130675	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.562	rs34062275	ENSG00000234736.4	FAM170B-AS1	-3.49	0.000521	0.0316	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49130987	chr10:49121839~49151547:+
THCA	cis	rs4321325	0.733	rs13389505	ENSG00000236682.1	AC068282.3	-3.49	0.000521	0.0316	-0.31	-0.16	Protein C levels;	chr2:127177312	chr2:127389130~127400580:+
THCA	cis	rs910316	0.934	rs4903278	ENSG00000259138.1	RP11-950C14.7	3.49	0.000521	0.0316	0.14	0.16	Height;	chr14:75068316	chr14:75127153~75136930:+
THCA	cis	rs10761482	0.813	rs3808942	ENSG00000254271.1	RP11-131N11.4	3.49	0.000521	0.0316	0.21	0.16	Schizophrenia;	chr10:60391090	chr10:60734342~60741828:+
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000184274.3	LINC00315	-3.49	0.000521	0.0316	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000184274.3	LINC00315	-3.49	0.000521	0.0316	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45300245~45305257:-
THCA	cis	rs11644601	1	rs11644601	ENSG00000275910.1	RP11-680G24.6	3.49	0.000521	0.0316	0.2	0.16	Metabolite levels (lipid measures);	chr16:15078261	chr16:15015828~15016390:-
THCA	cis	rs17689437	0.671	rs7195656	ENSG00000260084.1	RP11-615I2.1	3.49	0.000521	0.0316	0.19	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68552888	chr16:68573782~68589512:-
THCA	cis	rs927821	0.68	rs11599868	ENSG00000203886.4	CYP17A1-AS1	-3.49	0.000521	0.0316	-0.19	-0.16	Social autistic-like traits;	chr10:102441624	chr10:102832721~102834516:+
THCA	cis	rs10911902	0.643	rs16825185	ENSG00000233196.2	GS1-304P7.1	-3.49	0.000521	0.0316	-0.24	-0.16	Schizophrenia;	chr1:186337932	chr1:186580515~186581191:-
THCA	cis	rs3026101	0.697	rs1806267	ENSG00000234327.6	AC012146.7	-3.49	0.000521	0.0316	-0.13	-0.16	Body mass index;	chr17:5418786	chr17:5111468~5115004:+
THCA	cis	rs112295236	1	rs111619939	ENSG00000255213.1	NPM1P35	-3.49	0.000521	0.0316	-0.42	-0.16	Sex hormone levels;	chr11:63199188	chr11:62330946~62331813:+
THCA	cis	rs9400467	0.528	rs457492	ENSG00000272356.1	RP5-1112D6.8	-3.49	0.000521	0.0316	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111309203~111313517:+
THCA	cis	rs4575098	0.681	rs10797093	ENSG00000227741.1	RP11-536C5.7	3.49	0.000521	0.0316	0.17	0.16	Monocyte percentage of white cells;	chr1:161133655	chr1:160202199~160208869:-
THCA	cis	rs73198271	0.74	rs10094270	ENSG00000254153.1	CTA-398F10.2	3.49	0.000521	0.0316	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.74	rs28521727	ENSG00000254153.1	CTA-398F10.2	3.49	0.000521	0.0316	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.74	rs28402110	ENSG00000254153.1	CTA-398F10.2	3.49	0.000521	0.0316	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.74	rs10112989	ENSG00000254153.1	CTA-398F10.2	3.49	0.000521	0.0316	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.74	rs10113326	ENSG00000254153.1	CTA-398F10.2	3.49	0.000521	0.0316	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8456909~8461337:-
THCA	cis	rs1971762	0.563	rs11170645	ENSG00000270175.1	RP11-793H13.11	-3.49	0.000521	0.0316	-0.1	-0.16	Height;	chr12:53685296	chr12:53500162~53500936:-
THCA	cis	rs11013210	0.508	rs7099925	ENSG00000261671.1	RP11-573G6.6	3.49	0.000521	0.0316	0.22	0.16	Systemic lupus erythematosus;	chr10:23012118	chr10:22257786~22258548:+
THCA	cis	rs9329221	0.537	rs13282106	ENSG00000261451.1	RP11-981G7.1	3.49	0.000521	0.0316	0.19	0.16	Neuroticism;	chr8:10124390	chr8:10433672~10438312:+
THCA	cis	rs12681366	0.663	rs6980687	ENSG00000253175.1	RP11-267M23.6	3.49	0.000521	0.0316	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94469685	chr8:94565036~94565715:+
THCA	cis	rs4664304	0.62	rs2556086	ENSG00000226266.5	AC009961.3	3.49	0.000521	0.0316	0.18	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159851935	chr2:159670708~159712435:-
THCA	cis	rs7202877	0.706	rs37605	ENSG00000276408.1	RP11-490B18.5	-3.49	0.000521	0.0316	-0.29	-0.16	Type 1 diabetes;Type 2 diabetes;	chr16:75472674	chr16:75556392~75557059:+
THCA	cis	rs250518	0.926	rs3846644	ENSG00000251467.1	CTC-250P20.2	3.49	0.000521	0.0316	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72727276	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs4267846	ENSG00000251467.1	CTC-250P20.2	3.49	0.000521	0.0316	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72735617	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs2338788	ENSG00000251467.1	CTC-250P20.2	3.49	0.000521	0.0316	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72737690	chr5:72996920~72997642:+
THCA	cis	rs9868809	1	rs9868809	ENSG00000270441.1	RP11-694I15.7	3.49	0.000521	0.0316	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48643620	chr3:49140086~49160851:-
THCA	cis	rs7474896	0.583	rs11011341	ENSG00000120555.12	SEPT7P9	3.49	0.000521	0.0316	0.21	0.16	Obesity (extreme);	chr10:37709572	chr10:38383069~38402916:-
THCA	cis	rs3135718	0.935	rs2981584	ENSG00000276742.1	RP11-500G22.4	-3.49	0.000521	0.0316	-0.19	-0.16	Estrogen receptor status in breast cancer;	chr10:121590702	chr10:121956782~121957098:+
THCA	cis	rs2744375	0.6	rs2744372	ENSG00000261189.1	RP3-512B11.3	-3.49	0.000521	0.0316	-0.17	-0.16	Resting heart rate;	chr6:7554233	chr6:7540451~7541338:-
THCA	cis	rs2455799	0.613	rs11706879	ENSG00000224728.1	AC090945.1	-3.49	0.000521	0.0316	-0.18	-0.16	Mean platelet volume;	chr3:15915623	chr3:15878047~15879571:+
THCA	cis	rs2455799	0.613	rs13071161	ENSG00000224728.1	AC090945.1	-3.49	0.000521	0.0316	-0.18	-0.16	Mean platelet volume;	chr3:15916659	chr3:15878047~15879571:+
THCA	cis	rs2455799	0.613	rs13071303	ENSG00000224728.1	AC090945.1	-3.49	0.000521	0.0316	-0.18	-0.16	Mean platelet volume;	chr3:15916696	chr3:15878047~15879571:+
THCA	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	3.49	0.000521	0.0316	0.23	0.16	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
THCA	cis	rs6802315	0.575	rs57932243	ENSG00000271778.1	RP11-379F4.8	3.49	0.000521	0.0316	0.16	0.16	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158782547~158783124:+
THCA	cis	rs6802315	0.604	rs2364927	ENSG00000271778.1	RP11-379F4.8	3.49	0.000521	0.0316	0.16	0.16	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158782547~158783124:+
THCA	cis	rs931608	0.64	rs4932976	ENSG00000269138.1	ZNF209P	-3.49	0.000521	0.0316	-0.22	-0.16	Response to statins (LDL cholesterol change);Dental caries;	chr19:22312076	chr19:22463922~22473036:+
THCA	cis	rs7520050	0.807	rs72688483	ENSG00000281133.1	AL355480.3	-3.49	0.000521	0.0316	-0.18	-0.16	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45580892~45580996:-
THCA	cis	rs9534288	0.797	rs718530	ENSG00000235903.6	CPB2-AS1	3.49	0.000522	0.0316	0.22	0.16	Blood protein levels;	chr13:45989518	chr13:46052806~46113332:+
THCA	cis	rs10129255	0.912	rs61997792	ENSG00000280411.1	IGHV1-69-2	-3.49	0.000522	0.0316	-0.1	-0.16	Kawasaki disease;	chr14:106799304	chr14:106762092~106762588:-
THCA	cis	rs7296418	0.619	rs7139321	ENSG00000256092.2	RP13-942N8.1	3.49	0.000522	0.0316	0.12	0.16	Platelet count;	chr12:123234981	chr12:123363868~123366113:+
THCA	cis	rs4805272	0.512	rs4805278	ENSG00000267799.1	MAN1A2P1	3.49	0.000522	0.0317	0.21	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28845757	chr19:28790812~28792871:-
THCA	cis	rs6687821	0.515	rs2390215	ENSG00000261737.1	RP4-612B15.3	3.49	0.000522	0.0317	0.24	0.16	Yeast infection;	chr1:87023130	chr1:86703502~86704462:-
THCA	cis	rs669446	0.591	rs607062	ENSG00000237950.1	RP11-7O11.3	3.49	0.000522	0.0317	0.14	0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:43667345	chr1:43944370~43946551:-
THCA	cis	rs7208859	0.778	rs6505219	ENSG00000248121.7	SMURF2P1	3.49	0.000522	0.0317	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30600796~30615980:+
THCA	cis	rs9650657	0.572	rs4841465	ENSG00000261451.1	RP11-981G7.1	-3.49	0.000522	0.0317	-0.2	-0.16	Neuroticism;	chr8:10962344	chr8:10433672~10438312:+
THCA	cis	rs6687821	0.515	rs10747338	ENSG00000261737.1	RP4-612B15.3	3.49	0.000522	0.0317	0.24	0.16	Yeast infection;	chr1:87043716	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs4484904	ENSG00000261737.1	RP4-612B15.3	3.49	0.000522	0.0317	0.24	0.16	Yeast infection;	chr1:87048234	chr1:86703502~86704462:-
THCA	cis	rs6449502	0.92	rs11951504	ENSG00000215032.2	GNL3LP1	3.49	0.000522	0.0317	0.26	0.16	Mean platelet volume;	chr5:61076611	chr5:60891935~60893577:-
THCA	cis	rs78487399	0.908	rs17031116	ENSG00000234936.1	AC010883.5	3.49	0.000522	0.0317	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43605874	chr2:43229573~43233394:+
THCA	cis	rs6840360	0.615	rs4696266	ENSG00000251611.1	RP11-610P16.1	-3.49	0.000522	0.0317	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151542269	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs55932132	ENSG00000251611.1	RP11-610P16.1	-3.49	0.000522	0.0317	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151542745	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs6836249	ENSG00000251611.1	RP11-610P16.1	-3.49	0.000522	0.0317	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151544677	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs1561917	ENSG00000251611.1	RP11-610P16.1	-3.49	0.000522	0.0317	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151558081	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.615	rs1561916	ENSG00000251611.1	RP11-610P16.1	-3.49	0.000522	0.0317	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151558082	chr4:151407551~151408835:-
THCA	cis	rs10792665	0.611	rs12277804	ENSG00000255503.1	RP11-113K21.4	-3.49	0.000522	0.0317	-0.16	-0.16	Obesity-related traits;	chr11:82910507	chr11:83072402~83097196:-
THCA	cis	rs2395128	0.705	rs6480764	ENSG00000236842.1	RP11-399K21.10	3.49	0.000522	0.0317	0.25	0.16	Ulcerative colitis;Inflammatory bowel disease;	chr10:74913704	chr10:75430571~75431588:-
THCA	cis	rs12462428	0.911	rs6512119	ENSG00000269427.1	CTC-429P9.1	-3.49	0.000522	0.0317	-0.2	-0.16	Educational attainment (years of education);	chr19:16554404	chr19:16630743~16643942:+
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000281021.1	RP1-12G14.9	-3.49	0.000522	0.0317	-0.16	-0.16	Lung cancer;	chr6:149772542	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000281021.1	RP1-12G14.9	-3.49	0.000522	0.0317	-0.16	-0.16	Lung cancer;	chr6:149775882	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000281021.1	RP1-12G14.9	-3.49	0.000522	0.0317	-0.16	-0.16	Lung cancer;	chr6:149778907	chr6:149576089~149590864:-
THCA	cis	rs1144713	0.6	rs2683489	ENSG00000274964.1	RP11-817I4.1	-3.49	0.000522	0.0317	-0.16	-0.16	Obesity-related traits;	chr12:32098247	chr12:32339368~32340724:+
THCA	cis	rs4947019	0.609	rs2146411	ENSG00000223537.2	RP5-919F19.5	-3.49	0.000522	0.0317	-0.29	-0.16	Hematological parameters;	chr6:109444585	chr6:109487906~109506800:+
THCA	cis	rs17211409	1	rs7116895	ENSG00000254731.1	CTD-2005H7.1	3.49	0.000522	0.0317	0.39	0.16	JT interval (sulfonylurea treatment interaction);	chr11:86610983	chr11:86703099~86714092:+
THCA	cis	rs8022179	0.58	rs8013228	ENSG00000269958.1	RP11-73M18.8	3.49	0.000522	0.0317	0.16	0.16	Monocyte count;	chr14:103376313	chr14:103696353~103697163:+
THCA	cis	rs4308124	1	rs4308124	ENSG00000230499.1	AC108463.1	-3.49	0.000522	0.0317	-0.21	-0.16	Vitiligo;	chr2:111252909	chr2:111195963~111206494:+
THCA	cis	rs7824557	0.564	rs11782430	ENSG00000227888.4	FAM66A	-3.49	0.000522	0.0317	-0.2	-0.16	Retinal vascular caliber;	chr8:11368562	chr8:12362019~12388296:+
THCA	cis	rs7246967	0.673	rs73022717	ENSG00000236312.3	RPL34P34	-3.49	0.000522	0.0317	-0.22	-0.16	Bronchopulmonary dysplasia;	chr19:22694257	chr19:22368599~22368952:-
THCA	cis	rs972578	1	rs4822244	ENSG00000274717.1	RP1-47A17.1	-3.49	0.000522	0.0317	-0.16	-0.16	Mean platelet volume;	chr22:42993022	chr22:42791814~42794313:-
THCA	cis	rs972578	1	rs5759075	ENSG00000274717.1	RP1-47A17.1	-3.49	0.000522	0.0317	-0.16	-0.16	Mean platelet volume;	chr22:42993084	chr22:42791814~42794313:-
THCA	cis	rs972578	1	rs738377	ENSG00000274717.1	RP1-47A17.1	-3.49	0.000522	0.0317	-0.16	-0.16	Mean platelet volume;	chr22:42993564	chr22:42791814~42794313:-
THCA	cis	rs972578	1	rs733139	ENSG00000274717.1	RP1-47A17.1	-3.49	0.000522	0.0317	-0.16	-0.16	Mean platelet volume;	chr22:42994077	chr22:42791814~42794313:-
THCA	cis	rs1816213	1	rs34765129	ENSG00000273466.1	RP11-548H3.1	-3.49	0.000522	0.0317	-0.26	-0.16	Diastolic blood pressure;	chr2:218703524	chr2:218633256~218634014:-
THCA	cis	rs72928364	0.578	rs6441563	ENSG00000256628.3	ZBTB11-AS1	3.49	0.000522	0.0317	0.22	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101058404	chr3:101676475~101679217:+
THCA	cis	rs9796	0.674	rs6492978	ENSG00000247556.5	OIP5-AS1	3.49	0.000522	0.0317	0.13	0.16	Menopause (age at onset);	chr15:41025504	chr15:41283990~41309737:+
THCA	cis	rs9796	0.87	rs2925346	ENSG00000247556.5	OIP5-AS1	-3.49	0.000522	0.0317	-0.13	-0.16	Menopause (age at onset);	chr15:41023497	chr15:41283990~41309737:+
THCA	cis	rs78487399	0.908	rs12463527	ENSG00000234936.1	AC010883.5	3.49	0.000522	0.0317	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43588806	chr2:43229573~43233394:+
THCA	cis	rs6560517	1	rs11144898	ENSG00000234618.1	RPSAP9	-3.49	0.000522	0.0317	-0.18	-0.16	Dialysis-related mortality;	chr9:76431381	chr9:76398699~76399586:+
THCA	cis	rs752590	0.524	rs67237254	ENSG00000227359.1	AC017074.2	3.49	0.000522	0.0317	0.23	0.16	Mucinous ovarian carcinoma;	chr2:113255351	chr2:113677702~113704078:-
THCA	cis	rs964611	0.882	rs3784616	ENSG00000259488.2	RP11-154J22.1	-3.49	0.000522	0.0317	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48278381	chr15:48312353~48331856:-
THCA	cis	rs964611	0.882	rs7175172	ENSG00000259488.2	RP11-154J22.1	-3.49	0.000522	0.0317	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48280021	chr15:48312353~48331856:-
THCA	cis	rs11673344	0.504	rs4805204	ENSG00000233527.7	ZNF529-AS1	3.49	0.000522	0.0317	0.13	0.16	Obesity-related traits;	chr19:37136666	chr19:36573070~36594708:+
THCA	cis	rs9860428	0.808	rs9869058	ENSG00000243795.1	RP11-572M11.3	3.49	0.000522	0.0317	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899522	chr3:113142350~113167819:-
THCA	cis	rs9898058	0.882	rs7208106	ENSG00000253730.1	RP11-893F2.13	-3.49	0.000522	0.0317	-0.29	-0.16	Milk allergy;	chr17:49770630	chr17:50158333~50161276:-
THCA	cis	rs80130819	0.748	rs7953726	ENSG00000226413.2	OR8T1P	3.49	0.000522	0.0317	0.24	0.16	Prostate cancer;	chr12:48217974	chr12:48442030~48442947:-
THCA	cis	rs72843506	0.656	rs73984573	ENSG00000189423.10	USP32P3	3.49	0.000522	0.0317	0.25	0.16	Schizophrenia;	chr17:20082027	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs78408002	ENSG00000189423.10	USP32P3	3.49	0.000522	0.0317	0.25	0.16	Schizophrenia;	chr17:20082601	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs7210439	ENSG00000189423.10	USP32P3	3.49	0.000522	0.0317	0.25	0.16	Schizophrenia;	chr17:20082728	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs7225605	ENSG00000189423.10	USP32P3	3.49	0.000522	0.0317	0.25	0.16	Schizophrenia;	chr17:20083136	chr17:20415547~20431008:+
THCA	cis	rs14027	0.883	rs35449013	ENSG00000279347.1	RP11-85I17.2	-3.49	0.000522	0.0317	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119838736~119840385:-
THCA	cis	rs6471393	0.964	rs2976366	ENSG00000261437.1	RP11-22C11.2	-3.49	0.000522	0.0317	-0.15	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93708829	chr8:94637285~94639467:-
THCA	cis	rs661955	0.845	rs556107	ENSG00000238005.2	RP11-443B7.1	-3.49	0.000522	0.0317	-0.14	-0.16	C-reactive protein levels or LDL-cholesterol levels (pleiotropy);C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:234717312	chr1:234957342~234970062:-
THCA	cis	rs1928480	0.556	rs33998276	ENSG00000234618.1	RPSAP9	-3.49	0.000522	0.0317	-0.19	-0.16	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr9:77072975	chr9:76398699~76399586:+
THCA	cis	rs12101261	0.744	rs12050078	ENSG00000258915.1	BHLHB9P1	3.49	0.000522	0.0317	0.2	0.16	Graves' disease;	chr14:80950010	chr14:80981988~80983638:+
THCA	cis	rs972578	0.967	rs2267477	ENSG00000230319.1	AL022476.2	3.49	0.000522	0.0317	0.17	0.16	Mean platelet volume;	chr22:42938568	chr22:43038585~43052366:+
THCA	cis	rs1417770	0.895	rs7550360	ENSG00000260971.3	RP11-504A18.1	3.49	0.000522	0.0317	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56222670	chr1:56248294~56258571:-
THCA	cis	rs60180747	1	rs79809053	ENSG00000261318.1	RP11-653J6.1	3.49	0.000522	0.0317	0.21	0.16	Testicular germ cell tumor;	chr15:66460830	chr15:66278498~66293357:-
THCA	cis	rs60180747	1	rs11631448	ENSG00000261318.1	RP11-653J6.1	3.49	0.000522	0.0317	0.21	0.16	Testicular germ cell tumor;	chr15:66465623	chr15:66278498~66293357:-
THCA	cis	rs409045	0.9	rs437509	ENSG00000271874.1	CTD-2024P10.2	-3.49	0.000523	0.0317	-0.21	-0.16	Left ventricular mass;	chr5:34638709	chr5:34651457~34651888:-
THCA	cis	rs7819412	0.691	rs73198970	ENSG00000255046.1	RP11-297N6.4	3.49	0.000523	0.0317	0.17	0.16	Triglycerides;	chr8:11182707	chr8:11797928~11802568:-
THCA	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-3.49	0.000523	0.0317	-0.18	-0.16	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
THCA	cis	rs7914558	0.966	rs4532960	ENSG00000272912.1	RP11-724N1.1	-3.49	0.000523	0.0317	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102907649	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs10786724	ENSG00000272912.1	RP11-724N1.1	-3.49	0.000523	0.0317	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102909185	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs2297786	ENSG00000272912.1	RP11-724N1.1	-3.49	0.000523	0.0317	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102920221	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs10786725	ENSG00000272912.1	RP11-724N1.1	-3.49	0.000523	0.0317	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102922600	chr10:102914585~102915404:+
THCA	cis	rs9911578	0.967	rs12938821	ENSG00000224738.1	AC099850.1	3.49	0.000523	0.0317	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58882061	chr17:59106598~59118267:+
THCA	cis	rs4218	0.573	rs4775115	ENSG00000259732.1	RP11-59H7.3	-3.49	0.000523	0.0317	-0.22	-0.16	Social communication problems;	chr15:59076311	chr15:59121034~59133250:+
THCA	cis	rs8030605	0.704	rs72742676	ENSG00000277245.1	RP11-48G14.3	3.49	0.000523	0.0317	0.29	0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56469360	chr15:56447120~56447697:+
THCA	cis	rs6995541	0.524	rs7821812	ENSG00000248896.2	CTD-2135J3.3	-3.49	0.000523	0.0317	-0.25	-0.16	Triglyceride levels;	chr8:10786591	chr8:10729314~10771392:+
THCA	cis	rs11039798	0.588	rs643668	ENSG00000200090.1	Y_RNA	-3.49	0.000523	0.0317	-0.13	-0.16	Axial length;	chr11:48391847	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.588	rs589834	ENSG00000200090.1	Y_RNA	-3.49	0.000523	0.0317	-0.13	-0.16	Axial length;	chr11:48397830	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.588	rs584899	ENSG00000200090.1	Y_RNA	-3.49	0.000523	0.0317	-0.13	-0.16	Axial length;	chr11:48409856	chr11:47726894~47726992:-
THCA	cis	rs6812193	0.761	rs59738370	ENSG00000234036.4	TXNP6	3.49	0.000523	0.0317	0.21	0.16	Parkinson's disease;	chr4:76289234	chr4:76958860~76959169:-
THCA	cis	rs8027587	1	rs35835898	ENSG00000271997.1	RP11-97O12.6	3.49	0.000523	0.0317	0.11	0.16	Obesity-related traits;	chr15:88706763	chr15:88501944~88505787:-
THCA	cis	rs10911902	0.643	rs76057663	ENSG00000233196.2	GS1-304P7.1	-3.49	0.000523	0.0317	-0.26	-0.16	Schizophrenia;	chr1:186325889	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs16825224	ENSG00000233196.2	GS1-304P7.1	-3.49	0.000523	0.0317	-0.26	-0.16	Schizophrenia;	chr1:186349723	chr1:186580515~186581191:-
THCA	cis	rs2664588	0.566	rs6012307	ENSG00000276923.1	RP11-321P16.1	-3.49	0.000523	0.0317	-0.21	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47963425	chr20:48073869~48074188:+
THCA	cis	rs9308731	1	rs6750599	ENSG00000204581.2	AC096670.3	3.49	0.000523	0.0317	0.16	0.16	Chronic lymphocytic leukemia;	chr2:111136292	chr2:111098345~111115588:-
THCA	cis	rs2361701	0.5	rs12601244	ENSG00000275479.1	RP11-334C17.6	3.49	0.000523	0.0317	0.22	0.16	IgG glycosylation;	chr17:80095568	chr17:80149627~80149798:+
THCA	cis	rs911555	0.723	rs12894652	ENSG00000269940.1	RP11-73M18.7	-3.49	0.000523	0.0317	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103694560~103695170:+
THCA	cis	rs10089	1	rs1962291	ENSG00000245937.6	LINC01184	-3.49	0.000523	0.0317	-0.18	-0.16	Ileal carcinoids;	chr5:128109681	chr5:127940426~128083172:-
THCA	cis	rs559928	0.606	rs11605856	ENSG00000236935.1	AP003774.1	3.49	0.000523	0.0317	0.23	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158056	chr11:64325050~64329504:-
THCA	cis	rs559928	0.606	rs11231710	ENSG00000236935.1	AP003774.1	3.49	0.000523	0.0317	0.23	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158271	chr11:64325050~64329504:-
THCA	cis	rs7615952	0.599	rs1875683	ENSG00000248787.1	RP11-666A20.4	-3.49	0.000523	0.0317	-0.25	-0.16	Blood pressure (smoking interaction);	chr3:126013638	chr3:125908005~125910272:-
THCA	cis	rs1881509	0.702	rs4963078	ENSG00000233930.3	KRTAP5-AS1	-3.49	0.000523	0.0317	-0.19	-0.16	Heroin dependence;	chr11:1414099	chr11:1571353~1599184:+
THCA	cis	rs3087591	0.708	rs2189525	ENSG00000263535.1	AK4P1	-3.49	0.000523	0.0317	-0.18	-0.16	Hip circumference;	chr17:31341790	chr17:31345521~31346187:+
THCA	cis	rs3781264	0.595	rs11187881	ENSG00000273450.1	RP11-76P2.4	3.49	0.000523	0.0317	0.2	0.16	Esophageal cancer and gastric cancer;	chr10:94335697	chr10:94314907~94315327:-
THCA	cis	rs972578	0.967	rs5759082	ENSG00000274717.1	RP1-47A17.1	-3.49	0.000523	0.0317	-0.16	-0.16	Mean platelet volume;	chr22:43005073	chr22:42791814~42794313:-
THCA	cis	rs2434529	1	rs520843	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154258659	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs506674	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154258739	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs531293	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154259120	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs490905	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154259190	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs532270	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154259233	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs489770	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154259748	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs2443516	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154260238	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs2434528	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154260334	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs2434529	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154260486	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs2443517	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154260748	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs2434531	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154260788	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs2443518	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154260817	chr5:154329437~154445850:-
THCA	cis	rs2434529	0.956	rs2434532	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154260912	chr5:154329437~154445850:-
THCA	cis	rs2434529	0.955	rs2443520	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154261945	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs2434534	ENSG00000245275.6	SAP30L-AS1	3.49	0.000523	0.0317	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154262230	chr5:154329437~154445850:-
THCA	cis	rs2434529	1	rs2443521	ENSG00000245275.6	SAP30L-AS1	-3.49	0.000523	0.0317	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr5:154262013	chr5:154329437~154445850:-
THCA	cis	rs9788682	0.948	rs28498264	ENSG00000261143.1	ADAMTS7P3	-3.49	0.000523	0.0317	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78545331	chr15:77976042~77993057:+
THCA	cis	rs56309584	0.673	rs11650444	ENSG00000271002.1	RP11-599B13.8	-3.49	0.000523	0.0317	-0.25	-0.16	Initial pursuit acceleration;	chr17:8202999	chr17:8199123~8199437:-
THCA	cis	rs875971	0.628	rs6974355	ENSG00000230189.5	GS1-124K5.2	3.49	0.000523	0.0317	0.1	0.16	Aortic root size;	chr7:66376994	chr7:66409143~66490059:-
THCA	cis	rs4819052	0.788	rs9978857	ENSG00000184274.3	LINC00315	-3.49	0.000524	0.0317	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45300245~45305257:-
THCA	cis	rs9400467	0.506	rs12207616	ENSG00000255389.1	C6orf3	3.49	0.000524	0.0317	0.24	0.16	Amino acid levels;Blood metabolite levels;	chr6:111287594	chr6:111599875~111602295:+
THCA	cis	rs7819412	0.595	rs2409712	ENSG00000154316.13	TDH	3.49	0.000524	0.0317	0.12	0.16	Triglycerides;	chr8:11129327	chr8:11339637~11368452:+
THCA	cis	rs6137726	0.652	rs6082778	ENSG00000237396.1	LINC01384	-3.49	0.000524	0.0317	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22673436	chr20:22587522~22607517:-
THCA	cis	rs6137726	0.652	rs73304707	ENSG00000237396.1	LINC01384	-3.49	0.000524	0.0317	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22673921	chr20:22587522~22607517:-
THCA	cis	rs6828577	0.779	rs419292	ENSG00000248280.1	RP11-33B1.2	3.49	0.000524	0.0317	0.14	0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118712975	chr4:119440561~119450157:-
THCA	cis	rs6828577	0.819	rs368669	ENSG00000248280.1	RP11-33B1.2	3.49	0.000524	0.0317	0.14	0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118713120	chr4:119440561~119450157:-
THCA	cis	rs9911578	1	rs9898916	ENSG00000224738.1	AC099850.1	3.49	0.000524	0.0317	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58971299	chr17:59106598~59118267:+
THCA	cis	rs7819412	0.805	rs2409710	ENSG00000255046.1	RP11-297N6.4	3.49	0.000524	0.0317	0.17	0.16	Triglycerides;	chr8:11122311	chr8:11797928~11802568:-
THCA	cis	rs12506899	0.934	rs4345146	ENSG00000221639.1	SNORA3	-3.49	0.000524	0.0317	-0.19	-0.16	Tumor biomarkers;	chr4:73386175	chr4:73263960~73264084:+
THCA	cis	rs6012953	0.967	rs4496379	ENSG00000232043.1	RP4-530I15.9	-3.49	0.000524	0.0318	-0.11	-0.16	Vitiligo;	chr20:50543407	chr20:50570975~50578041:-
THCA	cis	rs35860234	0.84	rs9533129	ENSG00000231530.1	RP11-187A9.3	-3.49	0.000524	0.0318	-0.19	-0.16	Vitiligo;	chr13:42491981	chr13:42043727~42044247:-
THCA	cis	rs35860234	0.84	rs9533130	ENSG00000231530.1	RP11-187A9.3	-3.49	0.000524	0.0318	-0.19	-0.16	Vitiligo;	chr13:42492387	chr13:42043727~42044247:-
THCA	cis	rs13182402	1	rs35115612	ENSG00000230929.5	RP11-395C3.1	-3.49	0.000524	0.0318	-0.31	-0.16	Osteoporosis;	chr5:126591147	chr5:126628019~126628319:-
THCA	cis	rs7713065	0.836	rs2057657	ENSG00000237714.1	P4HA2-AS1	-3.49	0.000524	0.0318	-0.27	-0.16	Lung function (FEV1/FVC);	chr5:132473624	chr5:132184876~132192808:+
THCA	cis	rs9980	1	rs39999	ENSG00000226232.7	RP11-419C5.2	-3.49	0.000524	0.0318	-0.24	-0.16	Blood osmolality (transformed sodium);	chr16:69619793	chr16:69976388~69996188:-
THCA	cis	rs1478897	0.575	rs12679960	ENSG00000255046.1	RP11-297N6.4	-3.49	0.000524	0.0318	-0.18	-0.16	Systemic lupus erythematosus;	chr8:11573481	chr8:11797928~11802568:-
THCA	cis	rs9878978	0.722	rs13074595	ENSG00000227588.2	CNTN4-AS2	3.49	0.000524	0.0318	0.21	0.16	Blood pressure (smoking interaction);	chr3:2460861	chr3:2110409~2144241:-
THCA	cis	rs9843304	0.772	rs4681515	ENSG00000240541.2	TM4SF1-AS1	-3.49	0.000524	0.0318	-0.15	-0.16	Gallstone disease;	chr3:149494289	chr3:149377778~149386583:+
THCA	cis	rs738409	0.657	rs9625962	ENSG00000223843.4	EFCAB6-AS1	3.49	0.000524	0.0318	0.23	0.16	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43930392	chr22:43516107~43537117:+
THCA	cis	rs738409	0.657	rs11090617	ENSG00000223843.4	EFCAB6-AS1	3.49	0.000524	0.0318	0.23	0.16	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43930820	chr22:43516107~43537117:+
THCA	cis	rs7572733	0.935	rs11692344	ENSG00000231621.1	AC013264.2	-3.49	0.000524	0.0318	-0.15	-0.16	Dermatomyositis;	chr2:197931139	chr2:197197991~197199273:+
THCA	cis	rs4575098	0.626	rs11265557	ENSG00000227741.1	RP11-536C5.7	3.49	0.000524	0.0318	0.17	0.16	Monocyte percentage of white cells;	chr1:161136564	chr1:160202199~160208869:-
THCA	cis	rs860295	0.702	rs10796945	ENSG00000236675.1	MTX1P1	-3.49	0.000524	0.0318	-0.16	-0.16	Body mass index;	chr1:155457897	chr1:155230975~155234325:+
THCA	cis	rs9457247	0.602	rs10484530	ENSG00000235272.1	FAM103A2P	3.49	0.000524	0.0318	0.22	0.16	Crohn's disease;	chr6:167048074	chr6:166586124~166586477:-
THCA	cis	rs61160187	0.673	rs2898288	ENSG00000215032.2	GNL3LP1	-3.49	0.000524	0.0318	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60724662	chr5:60891935~60893577:-
THCA	cis	rs2806731	0.6	rs1932866	ENSG00000136149.6	RPL13AP25	3.49	0.000524	0.0318	0.15	0.16	Obesity-related traits;	chr13:53673027	chr13:54440704~54441315:-
THCA	cis	rs944289	0.774	rs2415313	ENSG00000212071.1	AL162511.1	3.49	0.000524	0.0318	0.19	0.16	Thyroid cancer;	chr14:36115246	chr14:36196480~36196568:-
THCA	cis	rs1908814	0.516	rs11250178	ENSG00000227888.4	FAM66A	3.49	0.000524	0.0318	0.21	0.16	Neuroticism;	chr8:11942725	chr8:12362019~12388296:+
THCA	cis	rs10995356	0.844	rs12218430	ENSG00000238280.1	RP11-436D10.3	-3.49	0.000524	0.0318	-0.19	-0.16	Temperament;	chr10:62931881	chr10:62793562~62805887:-
THCA	cis	rs8054556	0.787	rs12444108	ENSG00000183604.13	SMG1P5	-3.49	0.000524	0.0318	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:30267553~30335374:-
THCA	cis	rs752590	0.614	rs7585510	ENSG00000221055.1	MIR1302-3	3.49	0.000524	0.0318	0.37	0.16	Mucinous ovarian carcinoma;	chr2:113263334	chr2:113582959~113583096:-
THCA	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	3.49	0.000524	0.0318	0.18	0.16	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
THCA	cis	rs7829975	0.539	rs71537846	ENSG00000253981.4	ALG1L13P	-3.49	0.000524	0.0318	-0.16	-0.16	Mood instability;	chr8:8684610	chr8:8236003~8244667:-
THCA	cis	rs9902453	0.765	rs8071576	ENSG00000263603.1	CTD-2349P21.5	3.49	0.000524	0.0318	0.19	0.16	Coffee consumption (cups per day);	chr17:29861536	chr17:30729469~30731202:+
THCA	cis	rs2980439	0.517	rs793753	ENSG00000248538.5	RP11-10A14.5	3.49	0.000524	0.0318	0.2	0.16	Neuroticism;	chr8:8247837	chr8:9189011~9202854:+
THCA	cis	rs7395662	0.853	rs4882054	ENSG00000200090.1	Y_RNA	-3.49	0.000524	0.0318	-0.11	-0.16	HDL cholesterol;	chr11:48378347	chr11:47726894~47726992:-
THCA	cis	rs812925	0.533	rs60997156	ENSG00000270820.4	RP11-355B11.2	3.49	0.000524	0.0318	0.13	0.16	Immature fraction of reticulocytes;	chr2:61169404	chr2:61471188~61484130:+
THCA	cis	rs427943	0.733	rs9637192	ENSG00000223768.1	LINC00205	-3.49	0.000524	0.0318	-0.14	-0.16	Body mass index;	chr21:45217498	chr21:45293285~45297354:+
THCA	cis	rs17301013	0.73	rs12060177	ENSG00000270084.1	GAS5-AS1	-3.49	0.000524	0.0318	-0.16	-0.16	Systemic lupus erythematosus;	chr1:174618545	chr1:173863248~173863941:+
THCA	cis	rs34779708	0.931	rs11010067	ENSG00000233200.1	RP11-324I22.2	-3.49	0.000524	0.0318	-0.19	-0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35219894~35230598:-
THCA	cis	rs929354	0.772	rs1182360	ENSG00000224629.1	RP5-1142J19.2	-3.49	0.000524	0.0318	-0.16	-0.16	Body mass index;	chr7:157227856	chr7:157263022~157263229:-
THCA	cis	rs3784262	0.967	rs12910752	ENSG00000259250.1	RP11-50C13.1	3.49	0.000524	0.0318	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58022481	chr15:58587507~58591676:+
THCA	cis	rs3784262	0.9	rs12911071	ENSG00000259250.1	RP11-50C13.1	3.49	0.000524	0.0318	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58022650	chr15:58587507~58591676:+
THCA	cis	rs3784262	0.904	rs12901462	ENSG00000259250.1	RP11-50C13.1	3.49	0.000524	0.0318	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58024289	chr15:58587507~58591676:+
THCA	cis	rs7871764	0.552	rs13290822	ENSG00000260947.1	RP11-384P7.7	3.49	0.000524	0.0318	0.29	0.16	Height;	chr9:33803044	chr9:33697459~33700986:+
THCA	cis	rs1555322	1	rs2425032	ENSG00000126005.14	MMP24-AS1	-3.49	0.000524	0.0318	-0.22	-0.16	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35216462~35278131:-
THCA	cis	rs12900413	0.842	rs33935448	ENSG00000259561.1	RP11-300G22.2	3.49	0.000524	0.0318	0.18	0.16	Coronary artery aneurysm in Kawasaki disease;	chr15:89765402	chr15:89704665~89705415:+
THCA	cis	rs17739167	0.532	rs8035074	ENSG00000246740.2	PLA2G4E-AS1	-3.49	0.000524	0.0318	-0.18	-0.16	Monocyte count;	chr15:41947581	chr15:41972763~41999094:+
THCA	cis	rs2762353	0.562	rs1165206	ENSG00000272462.2	U91328.19	-3.49	0.000524	0.0318	-0.12	-0.16	Blood metabolite levels;	chr6:25867338	chr6:25992662~26001775:+
THCA	cis	rs7439493	0.903	rs6854876	ENSG00000247950.5	SEC24B-AS1	-3.49	0.000525	0.0318	-0.1	-0.16	Blood protein levels;	chr4:109732284	chr4:109347475~109433817:-
THCA	cis	rs62209	0.752	rs1928720	ENSG00000181800.5	CELF2-AS1	3.49	0.000525	0.0318	0.17	0.16	Alzheimer's disease (late onset);	chr10:10972388	chr10:11316834~11319884:-
THCA	cis	rs4512344	0.509	rs2409784	ENSG00000206014.6	OR7E161P	3.49	0.000525	0.0318	0.18	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11928597~11929563:-
THCA	cis	rs11673344	0.504	rs4805205	ENSG00000233527.7	ZNF529-AS1	3.49	0.000525	0.0318	0.13	0.16	Obesity-related traits;	chr19:37136693	chr19:36573070~36594708:+
THCA	cis	rs12083887	0.505	rs7535961	ENSG00000236866.4	AL157902.3	-3.49	0.000525	0.0318	-0.18	-0.16	Male-pattern baldness;	chr1:118347192	chr1:117596832~117605770:-
THCA	cis	rs9903692	0.648	rs35361214	ENSG00000263412.1	RP5-890E16.2	-3.49	0.000525	0.0318	-0.11	-0.16	Pulse pressure;	chr17:48087729	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.697	rs6504024	ENSG00000263412.1	RP5-890E16.2	-3.49	0.000525	0.0318	-0.11	-0.16	Pulse pressure;	chr17:48088224	chr17:48045141~48048073:-
THCA	cis	rs12935229	0.756	rs8044103	ENSG00000260922.1	RP11-538I12.3	-3.49	0.000525	0.0318	-0.24	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77269073	chr16:77234877~77290934:+
THCA	cis	rs12073359	0.54	rs56892994	ENSG00000253047.1	SNORA40	-3.49	0.000525	0.0318	-0.26	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150211028	chr1:150600539~150600659:-
THCA	cis	rs1876905	0.68	rs1150082	ENSG00000271789.1	RP5-1112D6.7	-3.49	0.000525	0.0318	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111297126~111298510:+
THCA	cis	rs6920965	0.507	rs9385388	ENSG00000226409.1	RP11-735G4.1	-3.49	0.000525	0.0318	-0.2	-0.16	High light scatter reticulocyte count;	chr6:125894150	chr6:125370211~125374324:-
THCA	cis	rs7520050	0.843	rs1707334	ENSG00000234329.1	RP11-767N6.2	-3.49	0.000525	0.0318	-0.14	-0.16	Reticulocyte count;Red blood cell count;	chr1:46140056	chr1:45651039~45651826:-
THCA	cis	rs4713118	0.869	rs9461405	ENSG00000261839.1	RP1-265C24.8	3.49	0.000525	0.0318	0.18	0.16	Parkinson's disease;	chr6:27751596	chr6:28136849~28139678:+
THCA	cis	rs6437740	1	rs6437740	ENSG00000241218.1	RP11-446H18.1	-3.49	0.000525	0.0318	-0.23	-0.16	Smoking behavior;	chr3:107746970	chr3:107327830~107329197:-
THCA	cis	rs7554547	0.69	rs9661078	ENSG00000199347.1	RNU5E-1	3.49	0.000525	0.0318	0.22	0.16	Nonsyndromic cleft lip with cleft palate;	chr1:11876267	chr1:11908152~11908271:+
THCA	cis	rs3784262	1	rs4369598	ENSG00000259250.1	RP11-50C13.1	3.49	0.000525	0.0318	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58026405	chr15:58587507~58591676:+
THCA	cis	rs9611565	0.527	rs73178638	ENSG00000237037.8	NDUFA6-AS1	3.49	0.000525	0.0318	0.15	0.16	Vitiligo;	chr22:41546900	chr22:42090931~42137742:+
THCA	cis	rs6137726	0.652	rs6048241	ENSG00000237396.1	LINC01384	3.49	0.000525	0.0318	0.14	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22669505	chr20:22587522~22607517:-
THCA	cis	rs6952407	1	rs6952407	ENSG00000232546.1	RP11-458F8.1	3.49	0.000525	0.0318	0.13	0.16	Cotinine glucuronidation;	chr7:66580525	chr7:66848496~66858136:+
THCA	cis	rs10207628	0.601	rs6743470	ENSG00000260634.1	RP11-521O16.1	3.49	0.000525	0.0318	0.22	0.16	Psychosis and Alzheimer's disease;	chr2:127110859	chr2:127024252~127025723:-
THCA	cis	rs7142002	0.649	rs10134055	ENSG00000258404.1	RP11-1029J19.5	3.49	0.000525	0.0318	0.4	0.16	Autism;	chr14:102161377	chr14:101634454~101731108:-
THCA	cis	rs3758911	0.861	rs7131522	ENSG00000255353.1	RP11-382M14.1	-3.49	0.000525	0.0318	-0.21	-0.16	Coronary artery disease;	chr11:107293773	chr11:107176286~107177530:+
THCA	cis	rs1560104	0.597	rs12708758	ENSG00000260601.1	RP11-552C15.1	-3.49	0.000525	0.0318	-0.2	-0.16	Obesity-related traits;	chr16:12616844	chr16:12545482~12546684:+
THCA	cis	rs6871536	1	rs1986009	ENSG00000233006.5	AC034220.3	-3.49	0.000525	0.0318	-0.16	-0.16	Asthma (childhood onset);	chr5:132552294	chr5:132311285~132369916:-
THCA	cis	rs2880765	0.835	rs4842887	ENSG00000259407.1	RP11-158M2.3	-3.49	0.000525	0.0318	-0.16	-0.16	Coronary artery disease;	chr15:85492579	chr15:85744109~85750281:-
THCA	cis	rs9911578	1	rs304296	ENSG00000224738.1	AC099850.1	3.49	0.000525	0.0318	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58756868	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs304299	ENSG00000224738.1	AC099850.1	3.49	0.000525	0.0318	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58761111	chr17:59106598~59118267:+
THCA	cis	rs2130392	0.886	rs2077205	ENSG00000250726.1	RP11-616K6.1	-3.49	0.000525	0.0318	-0.19	-0.16	Kawasaki disease;	chr4:184716264	chr4:184072403~184073039:+
THCA	cis	rs11009175	0.929	rs11009199	ENSG00000233190.1	RPS24P13	-3.49	0.000525	0.0318	-0.25	-0.16	Depression (quantitative trait);	chr10:33053400	chr10:32231849~32232245:-
THCA	cis	rs189798	0.807	rs12785	ENSG00000233609.3	RP11-62H7.2	3.49	0.000525	0.0318	0.16	0.16	Myopia (pathological);	chr8:9137426	chr8:8961200~8979025:+
THCA	cis	rs12428035	0.764	rs10508027	ENSG00000247400.3	DNAJC3-AS1	3.49	0.000525	0.0318	0.16	0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95937806	chr13:95648733~95676925:-
THCA	cis	rs10760706	0.962	rs9556	ENSG00000234709.2	UPF3AP3	3.49	0.000525	0.0318	0.21	0.16	Alopecia areata;	chr9:99969955	chr9:99998301~99999069:-
THCA	cis	rs34421088	0.56	rs1478898	ENSG00000270154.1	RP11-419I17.1	-3.49	0.000525	0.0318	-0.2	-0.16	Neuroticism;	chr8:11537570	chr8:12476462~12477122:+
THCA	cis	rs34421088	0.564	rs6983129	ENSG00000270154.1	RP11-419I17.1	3.49	0.000525	0.0318	0.18	0.16	Neuroticism;	chr8:11733627	chr8:12476462~12477122:+
THCA	cis	rs972578	0.905	rs738396	ENSG00000230319.1	AL022476.2	3.49	0.000525	0.0318	0.17	0.16	Mean platelet volume;	chr22:42974785	chr22:43038585~43052366:+
THCA	cis	rs17292804	0.506	rs71417868	ENSG00000258735.1	LINC00637	-3.49	0.000525	0.0318	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103847721~103858049:+
THCA	cis	rs4761470	0.943	rs10450731	ENSG00000258172.1	RP11-1105G2.4	-3.49	0.000526	0.0318	-0.24	-0.16	Estradiol plasma levels (breast cancer);	chr12:94433127	chr12:94272150~94277195:-
THCA	cis	rs910316	0.763	rs4556	ENSG00000259138.1	RP11-950C14.7	3.49	0.000526	0.0318	0.14	0.16	Height;	chr14:75009368	chr14:75127153~75136930:+
THCA	cis	rs4808779	0.884	rs12973608	ENSG00000268650.3	AC068499.10	-3.49	0.000526	0.0318	-0.16	-0.16	Granulocyte percentage of myeloid white cells;	chr19:18287220	chr19:18204730~18220480:+
THCA	cis	rs11239930	0.538	rs4950361	ENSG00000180867.10	PDIA3P1	-3.49	0.000526	0.0318	-0.15	-0.16	AIDS progression;	chr1:147087618	chr1:147178113~147179622:+
THCA	cis	rs4879656	0.864	rs7861851	ENSG00000225693.1	LAGE3P1	-3.49	0.000526	0.0318	-0.18	-0.16	Menopause (age at onset);	chr9:33037351	chr9:33019682~33020165:-
THCA	cis	rs4879656	0.931	rs7875733	ENSG00000225693.1	LAGE3P1	-3.49	0.000526	0.0318	-0.18	-0.16	Menopause (age at onset);	chr9:33037352	chr9:33019682~33020165:-
THCA	cis	rs9348440	0.73	rs6940200	ENSG00000280989.1	LINC00581	3.49	0.000526	0.0318	0.24	0.16	Glycemic traits;	chr6:20635031	chr6:21486061~21511895:-
THCA	cis	rs9353324	1	rs7771366	ENSG00000203875.9	SNHG5	-3.49	0.000526	0.0318	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85582193	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs6902638	ENSG00000203875.9	SNHG5	-3.49	0.000526	0.0318	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85608881	chr6:85660950~85678736:-
THCA	cis	rs10895987	1	rs11227126	ENSG00000254614.2	AP003068.23	3.49	0.000526	0.0319	0.26	0.16	Blood protein levels;	chr11:65140591	chr11:65177606~65181834:-
THCA	cis	rs9487094	0.689	rs1074766	ENSG00000223537.2	RP5-919F19.5	-3.49	0.000526	0.0319	-0.16	-0.16	Height;	chr6:109360263	chr6:109487906~109506800:+
THCA	cis	rs9487094	0.689	rs3818933	ENSG00000223537.2	RP5-919F19.5	-3.49	0.000526	0.0319	-0.16	-0.16	Height;	chr6:109370741	chr6:109487906~109506800:+
THCA	cis	rs12049351	0.774	rs12079612	ENSG00000229367.1	HMGN2P19	3.49	0.000526	0.0319	0.24	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229513625	chr1:229570532~229570796:+
THCA	cis	rs17428076	0.749	rs62182404	ENSG00000228389.1	AC068039.4	-3.49	0.000526	0.0319	-0.22	-0.16	Myopia;	chr2:171891652	chr2:171773482~171775844:+
THCA	cis	rs2549003	1	rs2070723	ENSG00000233006.5	AC034220.3	-3.49	0.000526	0.0319	-0.12	-0.16	Asthma (sex interaction);	chr5:132487495	chr5:132311285~132369916:-
THCA	cis	rs3789045	0.774	rs12039365	ENSG00000235363.1	SNRPGP10	-3.49	0.000526	0.0319	-0.24	-0.16	Educational attainment (college completion);	chr1:204519559	chr1:205351247~205351471:+
THCA	cis	rs3789045	0.774	rs12041243	ENSG00000235363.1	SNRPGP10	-3.49	0.000526	0.0319	-0.24	-0.16	Educational attainment (college completion);	chr1:204521342	chr1:205351247~205351471:+
THCA	cis	rs3789045	0.729	rs12039968	ENSG00000235363.1	SNRPGP10	-3.49	0.000526	0.0319	-0.24	-0.16	Educational attainment (college completion);	chr1:204521546	chr1:205351247~205351471:+
THCA	cis	rs3789045	0.774	rs4252697	ENSG00000235363.1	SNRPGP10	-3.49	0.000526	0.0319	-0.24	-0.16	Educational attainment (college completion);	chr1:204532255	chr1:205351247~205351471:+
THCA	cis	rs3789045	0.774	rs11801299	ENSG00000235363.1	SNRPGP10	-3.49	0.000526	0.0319	-0.24	-0.16	Educational attainment (college completion);	chr1:204559956	chr1:205351247~205351471:+
THCA	cis	rs3789045	0.774	rs12029692	ENSG00000235363.1	SNRPGP10	-3.49	0.000526	0.0319	-0.24	-0.16	Educational attainment (college completion);	chr1:204563195	chr1:205351247~205351471:+
THCA	cis	rs3789045	0.729	rs61817460	ENSG00000235363.1	SNRPGP10	-3.49	0.000526	0.0319	-0.24	-0.16	Educational attainment (college completion);	chr1:204574451	chr1:205351247~205351471:+
THCA	cis	rs1555322	0.818	rs2425022	ENSG00000269202.1	RP4-614O4.12	-3.49	0.000526	0.0319	-0.18	-0.16	Attention deficit hyperactivity disorder;	chr20:35243384	chr20:35201747~35203288:-
THCA	cis	rs2562456	0.833	rs55920089	ENSG00000268278.1	RP11-420K14.1	3.49	0.000526	0.0319	0.22	0.16	Pain;	chr19:21337891	chr19:21637974~21656300:+
THCA	cis	rs2735413	0.709	rs8051521	ENSG00000276007.1	RP11-358L22.3	3.49	0.000526	0.0319	0.13	0.16	Systolic blood pressure (alcohol consumption interaction);	chr16:78054259	chr16:78123243~78124332:+
THCA	cis	rs9475677	0.953	rs3950165	ENSG00000231441.1	RP11-472M19.2	3.49	0.000526	0.0319	0.19	0.16	Gut microbiota (functional units);	chr6:56353385	chr6:56844002~56864078:+
THCA	cis	rs7259376	0.902	rs12610462	ENSG00000270947.1	AC025811.3	3.49	0.000526	0.0319	0.17	0.16	Menopause (age at onset);	chr19:22368660	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs16999064	ENSG00000270947.1	AC025811.3	3.49	0.000526	0.0319	0.17	0.16	Menopause (age at onset);	chr19:22369800	chr19:22455988~22456459:+
THCA	cis	rs6012953	0.845	rs968701	ENSG00000231715.1	COX6CP2	-3.49	0.000526	0.0319	-0.17	-0.16	Vitiligo;	chr20:50578711	chr20:50479767~50479991:+
THCA	cis	rs7665090	1	rs6821119	ENSG00000251288.2	RP11-10L12.2	-3.49	0.000526	0.0319	-0.21	-0.16	Primary biliary cholangitis;	chr4:102634076	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.934	rs6844332	ENSG00000251288.2	RP11-10L12.2	-3.49	0.000526	0.0319	-0.21	-0.16	Primary biliary cholangitis;	chr4:102634095	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.967	rs6821133	ENSG00000251288.2	RP11-10L12.2	-3.49	0.000526	0.0319	-0.21	-0.16	Primary biliary cholangitis;	chr4:102634096	chr4:102751401~102752641:+
THCA	cis	rs56046484	0.956	rs17540501	ENSG00000218052.5	ADAMTS7P4	-3.49	0.000526	0.0319	-0.25	-0.16	Testicular germ cell tumor;	chr15:85094870	chr15:85255369~85330334:-
THCA	cis	rs4081724	0.565	rs73024301	ENSG00000267130.1	CTD-2540B15.9	3.49	0.000526	0.0319	0.25	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33312285	chr19:33305036~33309387:+
THCA	cis	rs950169	0.922	rs4586394	ENSG00000230373.7	GOLGA6L5P	3.49	0.000526	0.0319	0.17	0.16	Schizophrenia;	chr15:84153633	chr15:84507885~84516814:-
THCA	cis	rs17123764	0.892	rs17123927	ENSG00000257464.1	RP11-161H23.8	-3.49	0.000526	0.0319	-0.3	-0.16	Intelligence (multi-trait analysis);	chr12:49755564	chr12:49442424~49442652:-
THCA	cis	rs739525	0.518	rs178268	ENSG00000226287.6	TMEM191A	3.49	0.000526	0.0319	0.16	0.16	Testicular germ cell tumor;	chr22:20975977	chr22:20701114~20704606:+
THCA	cis	rs9376098	0.651	rs7775140	ENSG00000232876.1	CTA-212D2.2	-3.49	0.000526	0.0319	-0.22	-0.16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135170349	chr6:135055033~135060550:+
THCA	cis	rs11673344	0.504	rs2118208	ENSG00000233527.7	ZNF529-AS1	3.49	0.000526	0.0319	0.13	0.16	Obesity-related traits;	chr19:37135573	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.504	rs2118209	ENSG00000233527.7	ZNF529-AS1	3.49	0.000526	0.0319	0.13	0.16	Obesity-related traits;	chr19:37135618	chr19:36573070~36594708:+
THCA	cis	rs12549025	0.796	rs2280860	ENSG00000253390.1	CTC-756D1.2	-3.49	0.000526	0.0319	-0.25	-0.16	Reticulocyte fraction of red cells;	chr8:23547327	chr8:23458601~23484971:+
THCA	cis	rs12549025	0.945	rs2280859	ENSG00000253390.1	CTC-756D1.2	-3.49	0.000526	0.0319	-0.25	-0.16	Reticulocyte fraction of red cells;	chr8:23547453	chr8:23458601~23484971:+
THCA	cis	rs7819412	0.595	rs10503416	ENSG00000206014.6	OR7E161P	-3.49	0.000526	0.0319	-0.19	-0.16	Triglycerides;	chr8:11130043	chr8:11928597~11929563:-
THCA	cis	rs10089	0.953	rs6879970	ENSG00000245937.6	LINC01184	3.49	0.000526	0.0319	0.18	0.16	Ileal carcinoids;	chr5:128051486	chr5:127940426~128083172:-
THCA	cis	rs11168618	0.904	rs7978948	ENSG00000240399.1	RP1-228P16.1	3.49	0.000526	0.0319	0.16	0.16	Adiponectin levels;	chr12:48536240	chr12:48054813~48055591:-
THCA	cis	rs6696239	0.956	rs6656661	ENSG00000227711.2	RP11-275O4.5	-3.49	0.000526	0.0319	-0.22	-0.16	Height;	chr1:227617485	chr1:227509028~227520477:-
THCA	cis	rs7429990	0.932	rs11720151	ENSG00000199476.1	Y_RNA	3.49	0.000526	0.0319	0.21	0.16	Educational attainment (years of education);	chr3:48099144	chr3:48288587~48288694:+
THCA	cis	rs7267979	0.844	rs6115188	ENSG00000276952.1	RP5-965G21.6	3.49	0.000526	0.0319	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25284915~25285588:-
THCA	cis	rs250518	0.926	rs266428	ENSG00000251467.1	CTC-250P20.2	-3.49	0.000526	0.0319	-0.22	-0.16	Mean corpuscular hemoglobin concentration;	chr5:72832940	chr5:72996920~72997642:+
THCA	cis	rs1612141	0.689	rs10782399	ENSG00000251363.2	RP11-129M6.1	3.49	0.000526	0.0319	0.23	0.16	QT interval (drug interaction);	chr14:41101528	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs11157195	ENSG00000251363.2	RP11-129M6.1	3.49	0.000526	0.0319	0.23	0.16	QT interval (drug interaction);	chr14:41101805	chr14:40954898~40975877:+
THCA	cis	rs6929812	0.665	rs10946920	ENSG00000216915.2	RP1-97D16.1	-3.49	0.000526	0.0319	-0.21	-0.16	Neuroticism (multi-trait analysis);	chr6:27461212	chr6:27737000~27738494:-
THCA	cis	rs8030379	1	rs11633301	ENSG00000176700.18	SCAND2P	3.49	0.000527	0.0319	0.1	0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916286	chr15:84631451~84647478:+
THCA	cis	rs7542375	0.683	rs11118626	ENSG00000238078.1	LINC01352	-3.49	0.000527	0.0319	-0.22	-0.16	Obesity-related traits;	chr1:220935570	chr1:220829255~220832429:+
THCA	cis	rs7737355	1	rs6872972	ENSG00000237714.1	P4HA2-AS1	3.49	0.000527	0.0319	0.23	0.16	Life satisfaction;	chr5:131285840	chr5:132184876~132192808:+
THCA	cis	rs409045	0.932	rs457371	ENSG00000271874.1	CTD-2024P10.2	-3.49	0.000527	0.0319	-0.21	-0.16	Left ventricular mass;	chr5:34637103	chr5:34651457~34651888:-
THCA	cis	rs337161	0.605	rs12568838	ENSG00000221571.3	RNU6ATAC35P	-3.49	0.000527	0.0319	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220772349	chr1:220825620~220826063:+
THCA	cis	rs1124769	0.654	rs55712458	ENSG00000259378.1	DCAF13P3	3.49	0.000527	0.0319	0.24	0.16	Cognitive performance;	chr15:51191799	chr15:50944663~50945996:+
THCA	cis	rs1876905	0.68	rs187130	ENSG00000271789.1	RP5-1112D6.7	-3.49	0.000527	0.0319	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111297126~111298510:+
THCA	cis	rs61677309	0.638	rs7940554	ENSG00000278376.1	RP11-158I9.8	3.49	0.000527	0.0319	0.11	0.16	Lung cancer in ever smokers;	chr11:118272215	chr11:118791254~118793137:+
THCA	cis	rs6496932	0.865	rs4843049	ENSG00000259630.2	CTD-2262B20.1	3.49	0.000527	0.0319	0.22	0.16	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85415228~85415633:+
THCA	cis	rs972578	1	rs9611984	ENSG00000230319.1	AL022476.2	3.49	0.000527	0.0319	0.17	0.16	Mean platelet volume;	chr22:43012556	chr22:43038585~43052366:+
THCA	cis	rs7829975	0.511	rs2976902	ENSG00000254340.1	RP11-10A14.3	3.49	0.000527	0.0319	0.18	0.16	Mood instability;	chr8:8483595	chr8:9141424~9145435:+
THCA	cis	rs2032366	1	rs2032366	ENSG00000267316.4	RP11-879F14.3	-3.49	0.000527	0.0319	-0.17	-0.16	Obesity-related traits;	chr18:61599138	chr18:61571342~61579456:-
THCA	cis	rs9911578	0.935	rs304261	ENSG00000224738.1	AC099850.1	3.49	0.000527	0.0319	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58736421	chr17:59106598~59118267:+
THCA	cis	rs6101567	0.749	rs2868508	ENSG00000224635.1	RP4-564F22.5	-3.49	0.000527	0.0319	-0.2	-0.16	Nose size;	chr20:39291433	chr20:38406011~38416797:-
THCA	cis	rs2562456	0.834	rs13346641	ENSG00000268278.1	RP11-420K14.1	3.49	0.000527	0.0319	0.22	0.16	Pain;	chr19:21409481	chr19:21637974~21656300:+
THCA	cis	rs804280	1	rs804281	ENSG00000255046.1	RP11-297N6.4	-3.49	0.000527	0.0319	-0.17	-0.16	Myopia (pathological);	chr8:11754356	chr8:11797928~11802568:-
THCA	cis	rs9308731	1	rs2015454	ENSG00000204581.2	AC096670.3	-3.49	0.000527	0.0319	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:111114571	chr2:111098345~111115588:-
THCA	cis	rs7960884	0.655	rs7960330	ENSG00000177359.16	RP11-551L14.1	3.49	0.000527	0.0319	0.19	0.16	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31230346	chr12:31111652~31206154:-
THCA	cis	rs2408955	0.715	rs1793957	ENSG00000275228.1	RP11-370I10.10	-3.49	0.000527	0.0319	-0.17	-0.16	Glycated hemoglobin levels;	chr12:47999041	chr12:48327942~48328472:-
THCA	cis	rs10760158	0.769	rs7870797	ENSG00000226752.6	PSMD5-AS1	-3.49	0.000527	0.0319	-0.19	-0.16	Pulse pressure;	chr9:121298144	chr9:120824828~120854385:+
THCA	cis	rs12428035	0.764	rs651812	ENSG00000247400.3	DNAJC3-AS1	3.49	0.000527	0.0319	0.15	0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96070978	chr13:95648733~95676925:-
THCA	cis	rs12612435	0.736	rs13015181	ENSG00000231890.6	DARS-AS1	3.49	0.000527	0.0319	0.18	0.16	Takotsubo syndrome;	chr2:136393250	chr2:135985176~136022593:+
THCA	cis	rs1862618	0.853	rs2113078	ENSG00000234553.1	AC022431.3	-3.49	0.000527	0.0319	-0.18	-0.16	Initial pursuit acceleration;	chr5:56791363	chr5:56536583~56537826:-
THCA	cis	rs7919656	0.904	rs2448545	ENSG00000228403.1	RP11-563N6.6	-3.49	0.000527	0.0319	-0.17	-0.16	Clinically amyopathic dermatomyositis;	chr10:48833689	chr10:48878022~48878649:+
THCA	cis	rs72827839	0.739	rs16953235	ENSG00000278765.1	RP5-890E16.5	-3.49	0.000527	0.0319	-0.23	-0.16	Ease of getting up in the morning;	chr17:48167586	chr17:48066704~48067293:-
THCA	cis	rs7031325	0.819	rs7046343	ENSG00000229611.1	RP11-390F4.10	-3.49	0.000527	0.0319	-0.17	-0.16	Systemic lupus erythematosus;	chr9:6652506	chr9:6704471~6707780:+
THCA	cis	rs4578769	0.765	rs8091950	ENSG00000265939.1	UBE2CP2	3.49	0.000527	0.0319	0.2	0.16	Eosinophil percentage of white cells;	chr18:22859136	chr18:22900486~22900995:-
THCA	cis	rs4692589	0.581	rs62344678	ENSG00000229204.3	PTGES3P3	-3.49	0.000527	0.0319	-0.2	-0.16	Anxiety disorder;	chr4:170040157	chr4:169791221~169791702:-
THCA	cis	rs4692589	0.581	rs6817357	ENSG00000229204.3	PTGES3P3	-3.49	0.000527	0.0319	-0.2	-0.16	Anxiety disorder;	chr4:170041365	chr4:169791221~169791702:-
THCA	cis	rs78487399	0.831	rs12469373	ENSG00000234936.1	AC010883.5	3.49	0.000527	0.0319	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43602052	chr2:43229573~43233394:+
THCA	cis	rs11259403	0.558	rs6602820	ENSG00000223784.1	RP11-554I8.2	-3.49	0.000527	0.0319	-0.18	-0.16	Body mass index in asthmatics;	chr10:6554280	chr10:6737382~6739026:+
THCA	cis	rs10832963	0.686	rs11024743	ENSG00000256361.1	RP11-613F22.6	3.49	0.000527	0.0319	0.2	0.16	Breast cancer;	chr11:18632165	chr11:18511043~18511475:-
THCA	cis	rs763121	0.651	rs738249	ENSG00000272669.1	RP3-508I15.21	-3.49	0.000527	0.0319	-0.11	-0.16	Menopause (age at onset);	chr22:38641974	chr22:38742625~38743115:+
THCA	cis	rs3808502	0.549	rs1382563	ENSG00000206014.6	OR7E161P	-3.49	0.000527	0.0319	-0.18	-0.16	Neuroticism;	chr8:11569281	chr8:11928597~11929563:-
THCA	cis	rs208520	1	rs12193164	ENSG00000233859.2	ADH5P4	3.49	0.000528	0.0319	0.25	0.16	Exhaled nitric oxide output;	chr6:66269069	chr6:65836930~65838039:-
THCA	cis	rs208520	0.955	rs28684412	ENSG00000233859.2	ADH5P4	3.49	0.000528	0.0319	0.25	0.16	Exhaled nitric oxide output;	chr6:66269537	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs72882102	ENSG00000233859.2	ADH5P4	3.49	0.000528	0.0319	0.25	0.16	Exhaled nitric oxide output;	chr6:66273515	chr6:65836930~65838039:-
THCA	cis	rs208520	0.954	rs12190073	ENSG00000233859.2	ADH5P4	3.49	0.000528	0.0319	0.25	0.16	Exhaled nitric oxide output;	chr6:66273847	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs12191598	ENSG00000233859.2	ADH5P4	3.49	0.000528	0.0319	0.25	0.16	Exhaled nitric oxide output;	chr6:66274069	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs12192261	ENSG00000233859.2	ADH5P4	3.49	0.000528	0.0319	0.25	0.16	Exhaled nitric oxide output;	chr6:66275375	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs12195505	ENSG00000233859.2	ADH5P4	3.49	0.000528	0.0319	0.25	0.16	Exhaled nitric oxide output;	chr6:66276386	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs12216109	ENSG00000233859.2	ADH5P4	3.49	0.000528	0.0319	0.25	0.16	Exhaled nitric oxide output;	chr6:66277595	chr6:65836930~65838039:-
THCA	cis	rs5752773	0.61	rs695700	ENSG00000272858.1	CTA-292E10.8	-3.49	0.000528	0.0319	-0.14	-0.16	Vertical cup-disc ratio;	chr22:28486854	chr22:28814914~28815662:+
THCA	cis	rs962856	0.575	rs4671801	ENSG00000236780.4	AC078941.1	3.49	0.000528	0.0319	0.22	0.16	Pancreatic cancer;	chr2:67395306	chr2:67123357~67215319:-
THCA	cis	rs1009077	0.716	rs34601943	ENSG00000245958.5	RP11-33B1.1	3.49	0.000528	0.0319	0.25	0.16	Endometriosis;	chr4:119607869	chr4:119454791~119552025:+
THCA	cis	rs9303542	0.729	rs35680046	ENSG00000278765.1	RP5-890E16.5	-3.49	0.000528	0.0319	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48454431	chr17:48066704~48067293:-
THCA	cis	rs6546550	0.935	rs3214007	ENSG00000179818.12	PCBP1-AS1	-3.49	0.000528	0.032	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69871676	chr2:69962263~70103220:-
THCA	cis	rs747782	0.527	rs7113857	ENSG00000200090.1	Y_RNA	3.49	0.000528	0.032	0.15	0.16	Intraocular pressure;	chr11:48120307	chr11:47726894~47726992:-
THCA	cis	rs7264396	0.635	rs6060685	ENSG00000088340.14	FER1L4	3.49	0.000528	0.032	0.16	0.16	Total cholesterol levels;	chr20:35924101	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs6058366	ENSG00000088340.14	FER1L4	3.49	0.000528	0.032	0.16	0.16	Total cholesterol levels;	chr20:35924250	chr20:35558737~35607562:-
THCA	cis	rs2933343	0.649	rs789219	ENSG00000261159.1	RP11-723O4.9	3.49	0.000528	0.032	0.16	0.16	IgG glycosylation;	chr3:128873677	chr3:128859716~128860526:-
THCA	cis	rs61677309	0.558	rs7940047	ENSG00000278376.1	RP11-158I9.8	3.49	0.000528	0.032	0.11	0.16	Lung cancer in ever smokers;	chr11:118271904	chr11:118791254~118793137:+
THCA	cis	rs1023500	1	rs6002548	ENSG00000237037.8	NDUFA6-AS1	3.49	0.000528	0.032	0.15	0.16	Schizophrenia;	chr22:41941036	chr22:42090931~42137742:+
THCA	cis	rs748404	0.66	rs690472	ENSG00000275601.1	AC011330.13	-3.49	0.000528	0.032	-0.19	-0.16	Lung cancer;	chr15:43472170	chr15:43642389~43643023:-
THCA	cis	rs748404	0.69	rs1079309	ENSG00000275601.1	AC011330.13	-3.49	0.000528	0.032	-0.19	-0.16	Lung cancer;	chr15:43490966	chr15:43642389~43643023:-
THCA	cis	rs6600671	1	rs6600669	ENSG00000233029.3	RP11-439A17.9	-3.49	0.000528	0.032	-0.18	-0.16	Hip geometry;	chr1:121471785	chr1:121090289~121097655:-
THCA	cis	rs591584	0.59	rs7126782	ENSG00000255893.1	RP11-685N10.1	-3.49	0.000528	0.032	-0.17	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94590674	chr11:94472908~94473570:-
THCA	cis	rs13064411	0.735	rs722392	ENSG00000243849.1	CFAP44-AS1	3.49	0.000528	0.032	0.25	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113509447	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.627	rs9872168	ENSG00000243849.1	CFAP44-AS1	3.49	0.000528	0.032	0.25	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113514285	chr3:113403991~113433992:+
THCA	cis	rs2228479	0.557	rs11648881	ENSG00000274627.1	RP11-104N10.2	-3.49	0.000528	0.032	-0.27	-0.16	Skin colour saturation;	chr16:89796026	chr16:89516797~89522217:+
THCA	cis	rs6921919	0.789	rs11970439	ENSG00000273712.1	RP5-874C20.7	3.49	0.000528	0.032	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28315613~28315883:-
THCA	cis	rs6788895	1	rs16862842	ENSG00000244265.1	SIAH2-AS1	3.49	0.000528	0.032	0.42	0.16	Breast cancer;	chr3:150767057	chr3:150761937~150762538:+
THCA	cis	rs6788895	1	rs79709238	ENSG00000244265.1	SIAH2-AS1	3.49	0.000528	0.032	0.42	0.16	Breast cancer;	chr3:150770690	chr3:150761937~150762538:+
THCA	cis	rs6788895	1	rs41372346	ENSG00000244265.1	SIAH2-AS1	3.49	0.000528	0.032	0.42	0.16	Breast cancer;	chr3:150771329	chr3:150761937~150762538:+
THCA	cis	rs3770081	1	rs12622009	ENSG00000273080.1	RP11-301O19.1	-3.49	0.000528	0.032	-0.32	-0.16	Facial emotion recognition (sad faces);	chr2:86021202	chr2:86195590~86196049:+
THCA	cis	rs7829975	0.774	rs1703982	ENSG00000233609.3	RP11-62H7.2	-3.49	0.000528	0.032	-0.16	-0.16	Mood instability;	chr8:8740878	chr8:8961200~8979025:+
THCA	cis	rs1823874	0.962	rs12906206	ENSG00000254744.3	CTD-3076O17.1	-3.49	0.000528	0.032	-0.17	-0.16	IgG glycosylation;	chr15:99818921	chr15:99970215~99974010:+
THCA	cis	rs7259376	0.936	rs7256749	ENSG00000270947.1	AC025811.3	-3.49	0.000528	0.032	-0.17	-0.16	Menopause (age at onset);	chr19:22409487	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.869	rs11673228	ENSG00000270947.1	AC025811.3	-3.49	0.000528	0.032	-0.17	-0.16	Menopause (age at onset);	chr19:22413282	chr19:22455988~22456459:+
THCA	cis	rs6687821	0.515	rs10873819	ENSG00000261737.1	RP4-612B15.3	-3.49	0.000528	0.032	-0.24	-0.16	Yeast infection;	chr1:87069512	chr1:86703502~86704462:-
THCA	cis	rs4699052	0.963	rs6533066	ENSG00000230069.3	LRRC37A15P	-3.49	0.000528	0.032	-0.16	-0.16	Testicular germ cell tumor;	chr4:103242450	chr4:102727274~102730721:-
THCA	cis	rs10911902	0.688	rs113019508	ENSG00000228238.1	GS1-304P7.2	-3.49	0.000528	0.032	-0.25	-0.16	Schizophrenia;	chr1:186349685	chr1:186578279~186579299:+
THCA	cis	rs3824488	0.765	rs16909978	ENSG00000237857.2	RP11-435O5.2	-3.49	0.000528	0.032	-0.32	-0.16	Neuroticism;	chr9:95545708	chr9:95414834~95426796:-
THCA	cis	rs947583	0.517	rs6935371	ENSG00000272189.1	RP3-325F22.5	3.49	0.000528	0.032	0.15	0.16	Phosphorus levels;	chr6:135779380	chr6:136550661~136552554:+
THCA	cis	rs10483853	0.887	rs2269967	ENSG00000258695.2	RP3-414A15.2	3.49	0.000528	0.032	0.24	0.16	Coronary artery calcification;	chr14:73271334	chr14:73522878~73530610:+
THCA	cis	rs11633886	0.565	rs28567025	ENSG00000259200.1	RP11-718O11.1	3.49	0.000528	0.032	0.19	0.16	Diisocyanate-induced asthma;	chr15:45767239	chr15:45705078~45931069:+
THCA	cis	rs8046011	0.553	rs4781047	ENSG00000263179.1	HNRNPCP4	-3.49	0.000528	0.032	-0.19	-0.16	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr16:11224680	chr16:11242653~11243552:+
THCA	cis	rs7394190	0.748	rs4746139	ENSG00000272140.2	RP11-574K11.29	-3.49	0.000528	0.032	-0.16	-0.16	Incident atrial fibrillation;	chr10:73647891	chr10:73703735~73713581:-
THCA	cis	rs6499755	0.965	rs2042448	ENSG00000260135.5	RP11-212I21.2	-3.49	0.000528	0.032	-0.18	-0.16	Hypospadias;	chr16:55318151	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.965	rs9888978	ENSG00000260135.5	RP11-212I21.2	-3.49	0.000528	0.032	-0.18	-0.16	Hypospadias;	chr16:55319072	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.965	rs9889178	ENSG00000260135.5	RP11-212I21.2	-3.49	0.000528	0.032	-0.18	-0.16	Hypospadias;	chr16:55319198	chr16:55426797~55462297:-
THCA	cis	rs9788682	1	rs61204066	ENSG00000261143.1	ADAMTS7P3	-3.49	0.000528	0.032	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78522956	chr15:77976042~77993057:+
THCA	cis	rs6496667	0.557	rs2589951	ENSG00000213471.7	TTLL13P	3.49	0.000528	0.032	0.18	0.16	Rheumatoid arthritis;	chr15:90415160	chr15:90249530~90265482:+
THCA	cis	rs6496667	0.557	rs2526002	ENSG00000213471.7	TTLL13P	3.49	0.000528	0.032	0.18	0.16	Rheumatoid arthritis;	chr15:90422423	chr15:90249530~90265482:+
THCA	cis	rs9426935	0.527	rs7521047	ENSG00000231416.1	RP11-422P24.9	-3.49	0.000528	0.032	-0.19	-0.16	Lentiform nucleus volume;	chr1:154103890	chr1:153995632~153995960:+
THCA	cis	rs9300255	0.739	rs1879380	ENSG00000235423.7	RP11-282O18.3	-3.49	0.000528	0.032	-0.18	-0.16	Neutrophil percentage of white cells;	chr12:123254564	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.739	rs6633	ENSG00000235423.7	RP11-282O18.3	-3.49	0.000528	0.032	-0.18	-0.16	Neutrophil percentage of white cells;	chr12:123261262	chr12:123252030~123261483:-
THCA	cis	rs9300255	0.739	rs12824957	ENSG00000235423.7	RP11-282O18.3	-3.49	0.000528	0.032	-0.18	-0.16	Neutrophil percentage of white cells;	chr12:123265681	chr12:123252030~123261483:-
THCA	cis	rs755249	0.53	rs4660475	ENSG00000182109.6	RP11-69E11.4	3.49	0.000528	0.032	0.17	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39522280~39546187:-
THCA	cis	rs755249	0.53	rs66848709	ENSG00000182109.6	RP11-69E11.4	3.49	0.000528	0.032	0.17	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39522280~39546187:-
THCA	cis	rs939960	0.836	rs62491814	ENSG00000276538.1	RP11-545G3.2	3.49	0.000528	0.032	0.25	0.16	Neutrophil percentage of white cells;	chr7:150631112	chr7:150047609~150047854:-
THCA	cis	rs1538970	1	rs17395553	ENSG00000234329.1	RP11-767N6.2	3.49	0.000528	0.032	0.16	0.16	Platelet count;	chr1:45399089	chr1:45651039~45651826:-
THCA	cis	rs1838105	0.64	rs12603447	ENSG00000263142.4	LRRC37A17P	3.49	0.000528	0.032	0.11	0.16	Nonsyndromic cleft lip with cleft palate;	chr17:47068871	chr17:46978481~47054569:+
THCA	cis	rs9858542	0.537	rs4410472	ENSG00000270441.1	RP11-694I15.7	3.49	0.000528	0.032	0.18	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49291657	chr3:49140086~49160851:-
THCA	cis	rs4662750	0.674	rs777437	ENSG00000236682.1	AC068282.3	3.49	0.000528	0.032	0.2	0.16	Renal cell carcinoma;	chr2:127600072	chr2:127389130~127400580:+
THCA	cis	rs6684709	0.638	rs1555027	ENSG00000235052.1	RP1-150O5.3	3.49	0.000529	0.032	0.17	0.16	White blood cell count;	chr1:23522854	chr1:23549139~23550915:-
THCA	cis	rs10792665	0.51	rs7116170	ENSG00000255503.1	RP11-113K21.4	-3.49	0.000529	0.032	-0.16	-0.16	Obesity-related traits;	chr11:82919660	chr11:83072402~83097196:-
THCA	cis	rs7998202	0.667	rs282568	ENSG00000274922.1	RP11-88E10.5	-3.49	0.000529	0.032	-0.22	-0.16	Glycated hemoglobin levels;	chr13:112717624	chr13:112686769~112689815:-
THCA	cis	rs1669338	0.588	rs4684375	ENSG00000271870.1	RP11-97C16.1	3.49	0.000529	0.032	0.15	0.16	White matter integrity;	chr3:3129282	chr3:3152942~3153435:+
THCA	cis	rs7829975	0.514	rs2979139	ENSG00000248538.5	RP11-10A14.5	-3.49	0.000529	0.032	-0.19	-0.16	Mood instability;	chr8:8410803	chr8:9189011~9202854:+
THCA	cis	rs7246657	0.941	rs12982333	ENSG00000267422.1	CTD-2554C21.1	-3.49	0.000529	0.032	-0.18	-0.16	Coronary artery calcification;	chr19:37303822	chr19:37779686~37792865:+
THCA	cis	rs7246657	1	rs10426297	ENSG00000267422.1	CTD-2554C21.1	-3.49	0.000529	0.032	-0.18	-0.16	Coronary artery calcification;	chr19:37307471	chr19:37779686~37792865:+
THCA	cis	rs7246657	1	rs1823061	ENSG00000267422.1	CTD-2554C21.1	-3.49	0.000529	0.032	-0.18	-0.16	Coronary artery calcification;	chr19:37309724	chr19:37779686~37792865:+
THCA	cis	rs12681366	0.663	rs4735294	ENSG00000253175.1	RP11-267M23.6	3.49	0.000529	0.032	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94478313	chr8:94565036~94565715:+
THCA	cis	rs9308731	0.583	rs7567184	ENSG00000227992.1	AC108463.2	-3.49	0.000529	0.032	-0.2	-0.16	Chronic lymphocytic leukemia;	chr2:111173495	chr2:111203964~111206215:-
THCA	cis	rs9308731	0.583	rs2165107	ENSG00000227992.1	AC108463.2	-3.49	0.000529	0.032	-0.2	-0.16	Chronic lymphocytic leukemia;	chr2:111173773	chr2:111203964~111206215:-
THCA	cis	rs9308731	0.583	rs6726007	ENSG00000227992.1	AC108463.2	-3.49	0.000529	0.032	-0.2	-0.16	Chronic lymphocytic leukemia;	chr2:111174545	chr2:111203964~111206215:-
THCA	cis	rs76076331	0.887	rs10184911	ENSG00000271952.1	RP11-245G13.2	-3.49	0.000529	0.032	-0.27	-0.16	Educational attainment (college completion);Educational attainment (years of education);	chr2:10848391	chr2:10878269~10885118:+
THCA	cis	rs76076331	0.887	rs9287724	ENSG00000271952.1	RP11-245G13.2	-3.49	0.000529	0.032	-0.27	-0.16	Educational attainment (college completion);Educational attainment (years of education);	chr2:10848462	chr2:10878269~10885118:+
THCA	cis	rs72482608	0.865	rs7523880	ENSG00000271811.1	RP1-79C4.4	3.49	0.000529	0.032	0.19	0.16	Emphysema imaging phenotypes;	chr1:170800838	chr1:170667381~170669425:+
THCA	cis	rs6012953	0.654	rs6126028	ENSG00000231715.1	COX6CP2	3.49	0.000529	0.032	0.18	0.16	Vitiligo;	chr20:50507757	chr20:50479767~50479991:+
THCA	cis	rs2235649	0.789	rs4567715	ENSG00000260541.1	LA16c-429E7.1	3.49	0.000529	0.032	0.21	0.16	Blood metabolite levels;	chr16:1799362	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs4335769	ENSG00000260541.1	LA16c-429E7.1	3.49	0.000529	0.032	0.21	0.16	Blood metabolite levels;	chr16:1799375	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.753	rs7200472	ENSG00000260541.1	LA16c-429E7.1	3.49	0.000529	0.032	0.21	0.16	Blood metabolite levels;	chr16:1799668	chr16:1841020~1843547:-
THCA	cis	rs13272623	0.502	rs268628	ENSG00000246366.5	RP11-382J12.1	-3.49	0.000529	0.032	-0.19	-0.16	IgG glycosylation;	chr8:70648270	chr8:70608577~70663279:+
THCA	cis	rs7824557	0.836	rs2736378	ENSG00000255495.1	AC145124.2	-3.49	0.000529	0.032	-0.17	-0.16	Retinal vascular caliber;	chr8:11262251	chr8:12194467~12196280:+
THCA	cis	rs7809950	1	rs10258385	ENSG00000272072.1	CTA-363E19.2	-3.49	0.000529	0.032	-0.16	-0.16	Coronary artery disease;	chr7:107602905	chr7:107192559~107193300:-
THCA	cis	rs972578	1	rs5759066	ENSG00000230319.1	AL022476.2	3.49	0.000529	0.032	0.17	0.16	Mean platelet volume;	chr22:42970290	chr22:43038585~43052366:+
THCA	cis	rs2223471	0.905	rs2817414	ENSG00000060303.5	RPS17P5	-3.49	0.000529	0.032	-0.19	-0.16	Subcutaneous adipose tissue;	chr6:50781100	chr6:50857255~50857662:-
THCA	cis	rs9487051	0.872	rs9386790	ENSG00000260273.1	RP11-425D10.10	-3.49	0.000529	0.032	-0.19	-0.16	Reticulocyte fraction of red cells;	chr6:109287257	chr6:109382795~109383666:+
THCA	cis	rs1850744	0.702	rs11724183	ENSG00000163612.10	FAM86KP	3.49	0.000529	0.032	0.38	0.16	Economic and political preferences;	chr4:9608270	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.826	rs11735475	ENSG00000163612.10	FAM86KP	3.49	0.000529	0.032	0.38	0.16	Economic and political preferences;	chr4:9613302	chr4:9153296~9165451:+
THCA	cis	rs2735413	0.709	rs9938043	ENSG00000276007.1	RP11-358L22.3	-3.49	0.000529	0.032	-0.13	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr16:78057529	chr16:78123243~78124332:+
THCA	cis	rs7713065	1	rs7713065	ENSG00000224431.1	AC063976.7	3.49	0.000529	0.032	0.15	0.16	Lung function (FEV1/FVC);	chr5:132452642	chr5:132199456~132203487:+
THCA	cis	rs2898290	0.617	rs13273172	ENSG00000255310.2	AF131215.2	-3.49	0.000529	0.032	-0.14	-0.16	Systolic blood pressure;	chr8:11603602	chr8:11107788~11109726:-
THCA	cis	rs67340775	0.541	rs200975	ENSG00000272009.1	RP1-313I6.12	-3.49	0.000529	0.032	-0.21	-0.16	Lung cancer in ever smokers;	chr6:27887847	chr6:28078792~28081130:-
THCA	cis	rs67340775	0.541	rs200974	ENSG00000272009.1	RP1-313I6.12	-3.49	0.000529	0.032	-0.21	-0.16	Lung cancer in ever smokers;	chr6:27888067	chr6:28078792~28081130:-
THCA	cis	rs7829975	0.627	rs876954	ENSG00000248538.5	RP11-10A14.5	-3.49	0.000529	0.032	-0.2	-0.16	Mood instability;	chr8:8453413	chr8:9189011~9202854:+
THCA	cis	rs10129255	0.744	rs28517388	ENSG00000280411.1	IGHV1-69-2	-3.49	0.000529	0.032	-0.11	-0.16	Kawasaki disease;	chr14:106704323	chr14:106762092~106762588:-
THCA	cis	rs8187707	1	rs72838129	ENSG00000233690.1	EBAG9P1	-3.49	0.000529	0.032	-0.32	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99844724	chr10:99697407~99697949:-
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000264242.2	RP11-271K11.1	3.49	0.000529	0.032	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30553697~30558962:+
THCA	cis	rs9650657	0.812	rs10089615	ENSG00000269918.1	AF131215.9	-3.49	0.000529	0.032	-0.17	-0.16	Neuroticism;	chr8:10776622	chr8:11104691~11106704:-
THCA	cis	rs9487051	1	rs9480924	ENSG00000260273.1	RP11-425D10.10	3.49	0.000529	0.032	0.2	0.16	Reticulocyte fraction of red cells;	chr6:109295867	chr6:109382795~109383666:+
THCA	cis	rs9487051	1	rs9487052	ENSG00000260273.1	RP11-425D10.10	3.49	0.000529	0.032	0.2	0.16	Reticulocyte fraction of red cells;	chr6:109295883	chr6:109382795~109383666:+
THCA	cis	rs4698048	0.506	rs6833292	ENSG00000261490.1	RP11-448G15.3	-3.49	0.000529	0.032	-0.1	-0.16	Skin aging (microtopography measurement);	chr4:10270805	chr4:10068089~10073019:-
THCA	cis	rs11637445	0.677	rs1564278	ENSG00000260657.2	RP11-315D16.4	-3.49	0.000529	0.032	-0.2	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67815050	chr15:68267792~68277994:-
THCA	cis	rs1003719	0.667	rs6517404	ENSG00000270116.1	AP001429.1	-3.49	0.000529	0.032	-0.17	-0.16	Eye color traits;	chr21:37122618	chr21:37100814~37101343:+
THCA	cis	rs4879656	0.835	rs10813927	ENSG00000225693.1	LAGE3P1	-3.49	0.000529	0.032	-0.18	-0.16	Menopause (age at onset);	chr9:33047912	chr9:33019682~33020165:-
THCA	cis	rs2351088	0.611	rs17652545	ENSG00000280383.1	CTA-941F9.10	3.49	0.000529	0.032	0.19	0.16	Tonsillectomy;	chr22:45755538	chr22:45657019~45680130:+
THCA	cis	rs72827839	0.761	rs79541578	ENSG00000266601.1	RP11-6N17.3	3.49	0.000529	0.032	0.19	0.16	Ease of getting up in the morning;	chr17:48025362	chr17:47929682~47933106:-
THCA	cis	rs261967	0.692	rs261984	ENSG00000236882.6	LINC01554	-3.49	0.000529	0.032	-0.19	-0.16	Body mass index;	chr5:96507727	chr5:95852232~95860133:+
THCA	cis	rs3812762	0.868	rs7934519	ENSG00000254860.4	TMEM9B-AS1	-3.49	0.000529	0.032	-0.18	-0.16	Hypospadias;	chr11:8770434	chr11:8964675~8977527:+
THCA	cis	rs9902453	0.765	rs2628185	ENSG00000263603.1	CTD-2349P21.5	-3.49	0.000529	0.032	-0.19	-0.16	Coffee consumption (cups per day);	chr17:29743089	chr17:30729469~30731202:+
THCA	cis	rs7824557	0.527	rs2572369	ENSG00000255046.1	RP11-297N6.4	3.49	0.00053	0.032	0.17	0.16	Retinal vascular caliber;	chr8:11381088	chr8:11797928~11802568:-
THCA	cis	rs1729951	0.575	rs12494558	ENSG00000239213.4	NCK1-AS1	3.49	0.00053	0.032	0.14	0.16	Neuroticism;	chr3:136959939	chr3:136841726~136862054:-
THCA	cis	rs1858037	0.867	rs57913336	ENSG00000252414.1	RNU6-100P	-3.49	0.00053	0.032	-0.18	-0.16	Rheumatoid arthritis;	chr2:65360485	chr2:64578892~64578997:+
THCA	cis	rs36093844	0.527	rs17745248	ENSG00000279742.1	RP11-700A24.1	-3.49	0.00053	0.032	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86042309	chr11:85852557~85854943:-
THCA	cis	rs14027	0.921	rs2289011	ENSG00000279347.1	RP11-85I17.2	3.49	0.00053	0.032	0.19	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119744768	chr8:119838736~119840385:-
THCA	cis	rs7937890	0.559	rs2575837	ENSG00000251991.1	RNU7-49P	3.49	0.00053	0.032	0.18	0.16	Mitochondrial DNA levels;	chr11:14476455	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2167160	ENSG00000251991.1	RNU7-49P	3.49	0.00053	0.032	0.18	0.16	Mitochondrial DNA levels;	chr11:14485903	chr11:14478892~14478953:+
THCA	cis	rs6504108	0.624	rs2305433	ENSG00000264920.1	RP11-6N17.4	3.49	0.00053	0.032	0.13	0.16	Body mass index;	chr17:48188071	chr17:47891255~47895812:-
THCA	cis	rs6517329	0.564	rs879892	ENSG00000214867.3	SRSF9P1	3.49	0.00053	0.032	0.21	0.16	Schizophrenia;	chr21:36136580	chr21:36295173~36295702:-
THCA	cis	rs62045849	0.557	rs9938463	ENSG00000261546.1	CTD-2555A7.3	3.49	0.00053	0.032	0.27	0.16	Red blood cell count;	chr16:89117364	chr16:89113175~89115279:-
THCA	cis	rs714027	0.605	rs5763775	ENSG00000279699.1	RP1-102K2.9	-3.49	0.00053	0.032	-0.16	-0.16	Lymphocyte counts;	chr22:30107018	chr22:30275215~30276951:-
THCA	cis	rs11001765	0.53	rs10824403	ENSG00000237149.5	ZNF503-AS2	-3.49	0.00053	0.0321	-0.22	-0.16	Chin dimples;	chr10:76336768	chr10:75401519~75408982:+
THCA	cis	rs862034	0.902	rs862049	ENSG00000270000.1	RP3-449M8.9	3.49	0.00053	0.0321	0.16	0.16	Height;	chr14:74515179	chr14:74471930~74472360:-
THCA	cis	rs1362756	0.918	rs8059021	ENSG00000260057.4	LINC01571	-3.49	0.00053	0.0321	-0.17	-0.16	Optic disc parameters;Optic disc area;	chr16:51436722	chr16:51762519~51773173:+
THCA	cis	rs4692589	0.581	rs62344679	ENSG00000229204.3	PTGES3P3	-3.49	0.00053	0.0321	-0.2	-0.16	Anxiety disorder;	chr4:170042440	chr4:169791221~169791702:-
THCA	cis	rs13178541	1	rs13178541	ENSG00000250378.1	RP11-119J18.1	-3.49	0.00053	0.0321	-0.19	-0.16	IgG glycosylation;	chr5:135828929	chr5:135812667~135826582:+
THCA	cis	rs34975555	0.557	rs9644600	ENSG00000253671.1	RP11-806O11.1	-3.49	0.00053	0.0321	-0.24	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17933648	chr8:17808941~17820868:+
THCA	cis	rs7246657	0.722	rs1975937	ENSG00000226686.6	LINC01535	-3.49	0.00053	0.0321	-0.23	-0.16	Coronary artery calcification;	chr19:37601031	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs8103647	ENSG00000226686.6	LINC01535	-3.49	0.00053	0.0321	-0.23	-0.16	Coronary artery calcification;	chr19:37609551	chr19:37251912~37265535:+
THCA	cis	rs4666002	0.75	rs13021208	ENSG00000234072.1	AC074117.10	3.49	0.00053	0.0321	0.14	0.16	Phospholipid levels (plasma);	chr2:27678861	chr2:27356246~27367622:+
THCA	cis	rs823156	1	rs823156	ENSG00000226780.1	RP11-38J22.3	3.49	0.00053	0.0321	0.22	0.16	Parkinson's disease;	chr1:205795512	chr1:206117783~206126805:+
THCA	cis	rs758324	0.812	rs11954609	ENSG00000237714.1	P4HA2-AS1	-3.49	0.00053	0.0321	-0.22	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131830045	chr5:132184876~132192808:+
THCA	cis	rs9450351	0.744	rs7772723	ENSG00000203875.9	SNHG5	-3.49	0.00053	0.0321	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85913980	chr6:85660950~85678736:-
THCA	cis	rs10760158	0.8	rs4837829	ENSG00000226752.6	PSMD5-AS1	-3.49	0.00053	0.0321	-0.19	-0.16	Pulse pressure;	chr9:121283680	chr9:120824828~120854385:+
THCA	cis	rs6504622	0.818	rs3851784	ENSG00000238419.1	RNU7-186P	3.49	0.00053	0.0321	0.18	0.16	Orofacial clefts;	chr17:46962751	chr17:47259358~47259420:-
THCA	cis	rs2494663	0.61	rs11588942	ENSG00000231416.1	RP11-422P24.9	3.49	0.00053	0.0321	0.2	0.16	Mean platelet volume;	chr1:154072067	chr1:153995632~153995960:+
THCA	cis	rs2494663	0.61	rs7514662	ENSG00000231416.1	RP11-422P24.9	3.49	0.00053	0.0321	0.2	0.16	Mean platelet volume;	chr1:154072239	chr1:153995632~153995960:+
THCA	cis	rs6430585	0.583	rs3754689	ENSG00000231890.6	DARS-AS1	-3.49	0.00053	0.0321	-0.18	-0.16	Corneal structure;	chr2:135833176	chr2:135985176~136022593:+
THCA	cis	rs1417770	0.579	rs706395	ENSG00000260971.3	RP11-504A18.1	3.49	0.00053	0.0321	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56183306	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.579	rs1149647	ENSG00000260971.3	RP11-504A18.1	3.49	0.00053	0.0321	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56190394	chr1:56248294~56258571:-
THCA	cis	rs332034	0.508	rs1510933	ENSG00000254153.1	CTA-398F10.2	-3.49	0.00053	0.0321	-0.22	-0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8835030	chr8:8456909~8461337:-
THCA	cis	rs867371	1	rs11855089	ENSG00000278603.1	RP13-608F4.5	3.49	0.00053	0.0321	0.2	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472203~82472426:+
THCA	cis	rs7824557	0.518	rs11250094	ENSG00000269899.1	RP11-589N15.2	3.49	0.00053	0.0321	0.18	0.16	Retinal vascular caliber;	chr8:10944491	chr8:11846154~11846391:-
THCA	cis	rs7824557	0.518	rs12546366	ENSG00000269899.1	RP11-589N15.2	3.49	0.00053	0.0321	0.18	0.16	Retinal vascular caliber;	chr8:10944636	chr8:11846154~11846391:-
THCA	cis	rs5752773	0.61	rs695318	ENSG00000272858.1	CTA-292E10.8	-3.49	0.00053	0.0321	-0.14	-0.16	Vertical cup-disc ratio;	chr22:28486985	chr22:28814914~28815662:+
THCA	cis	rs9596863	0.8	rs73197724	ENSG00000136149.6	RPL13AP25	-3.49	0.00053	0.0321	-0.22	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53850005	chr13:54440704~54441315:-
THCA	cis	rs28830936	1	rs9672360	ENSG00000250379.1	RP11-23P13.4	3.49	0.00053	0.0321	0.18	0.16	Diastolic blood pressure;	chr15:41620213	chr15:41825099~41827936:-
THCA	cis	rs11773103	0.786	rs73202985	ENSG00000224046.1	AC005076.5	3.49	0.000531	0.0321	0.2	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87126604	chr7:87151423~87152420:-
THCA	cis	rs11773103	0.786	rs73202988	ENSG00000224046.1	AC005076.5	3.49	0.000531	0.0321	0.2	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87127087	chr7:87151423~87152420:-
THCA	cis	rs11773103	0.786	rs73202994	ENSG00000224046.1	AC005076.5	3.49	0.000531	0.0321	0.2	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87127312	chr7:87151423~87152420:-
THCA	cis	rs11773103	0.786	rs73202997	ENSG00000224046.1	AC005076.5	3.49	0.000531	0.0321	0.2	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87127363	chr7:87151423~87152420:-
THCA	cis	rs2455799	0.574	rs2102212	ENSG00000270409.1	RP11-44D5.1	-3.49	0.000531	0.0321	-0.17	-0.16	Mean platelet volume;	chr3:15662716	chr3:15732252~15733470:+
THCA	cis	rs4763879	0.634	rs12424826	ENSG00000214776.8	RP11-726G1.1	-3.49	0.000531	0.0321	-0.19	-0.16	Type 1 diabetes;	chr12:9701981	chr12:9467552~9576275:+
THCA	cis	rs17607347	0.505	rs8063013	ENSG00000247324.2	RP11-510M2.2	-3.49	0.000531	0.0321	-0.29	-0.16	Intelligence (multi-trait analysis);	chr16:72323000	chr16:71462278~71465941:+
THCA	cis	rs12410462	1	rs75198003	ENSG00000227711.2	RP11-275O4.5	-3.49	0.000531	0.0321	-0.24	-0.16	Major depressive disorder;	chr1:227436152	chr1:227509028~227520477:-
THCA	cis	rs12410462	1	rs75360545	ENSG00000227711.2	RP11-275O4.5	-3.49	0.000531	0.0321	-0.24	-0.16	Major depressive disorder;	chr1:227437718	chr1:227509028~227520477:-
THCA	cis	rs12410462	1	rs16847833	ENSG00000227711.2	RP11-275O4.5	-3.49	0.000531	0.0321	-0.24	-0.16	Major depressive disorder;	chr1:227438961	chr1:227509028~227520477:-
THCA	cis	rs11992162	0.597	rs6996342	ENSG00000227888.4	FAM66A	-3.49	0.000531	0.0321	-0.2	-0.16	Monocyte count;	chr8:11927032	chr8:12362019~12388296:+
THCA	cis	rs62380364	0.727	rs12054920	ENSG00000247828.6	TMEM161B-AS1	-3.49	0.000531	0.0321	-0.12	-0.16	Intelligence (multi-trait analysis);	chr5:88865600	chr5:88268895~88436685:+
THCA	cis	rs9860428	0.787	rs9815002	ENSG00000243795.1	RP11-572M11.3	3.49	0.000531	0.0321	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112903419	chr3:113142350~113167819:-
THCA	cis	rs12188164	0.965	rs41282625	ENSG00000188242.4	PP7080	3.49	0.000531	0.0321	0.15	0.16	Cystic fibrosis severity;	chr5:475511	chr5:466124~473098:-
THCA	cis	rs643506	0.874	rs615642	ENSG00000230911.1	PPIHP1	-3.49	0.000531	0.0321	-0.21	-0.16	Breast cancer;	chr11:111778697	chr11:112029858~112030367:-
THCA	cis	rs9309473	1	rs7582606	ENSG00000273245.1	RP11-434P11.2	3.49	0.000531	0.0321	0.22	0.16	Metabolite levels;	chr2:73586818	chr2:73750256~73750786:-
THCA	cis	rs11583043	0.831	rs6667818	ENSG00000233184.5	RP11-421L21.3	3.49	0.000531	0.0321	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100946757	chr1:101025878~101087268:+
THCA	cis	rs2749592	0.55	rs7917262	ENSG00000275858.1	RP11-291L22.8	-3.49	0.000531	0.0321	-0.19	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38450738~38451069:-
THCA	cis	rs2749592	0.55	rs9733309	ENSG00000275858.1	RP11-291L22.8	-3.49	0.000531	0.0321	-0.19	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38450738~38451069:-
THCA	cis	rs7838490	0.504	rs10504860	ENSG00000253553.4	RP11-586K2.1	3.49	0.000531	0.0321	0.17	0.16	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88537741	chr8:88326836~88737134:+
THCA	cis	rs2486012	1	rs1766964	ENSG00000237950.1	RP11-7O11.3	-3.49	0.000531	0.0321	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43916175	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs61770291	ENSG00000237950.1	RP11-7O11.3	-3.49	0.000531	0.0321	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43917451	chr1:43944370~43946551:-
THCA	cis	rs7819412	0.623	rs7833435	ENSG00000269899.1	RP11-589N15.2	3.49	0.000531	0.0321	0.18	0.16	Triglycerides;	chr8:10943627	chr8:11846154~11846391:-
THCA	cis	rs1941184	0.526	rs3911656	ENSG00000263823.1	RP11-326K13.4	-3.49	0.000531	0.0321	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31453518	chr18:31942575~31944156:+
THCA	cis	rs860295	0.702	rs12039893	ENSG00000236675.1	MTX1P1	-3.49	0.000531	0.0321	-0.16	-0.16	Body mass index;	chr1:155645024	chr1:155230975~155234325:+
THCA	cis	rs9928842	0.823	rs889514	ENSG00000261783.1	RP11-252K23.2	3.49	0.000531	0.0321	0.29	0.16	Alcoholic chronic pancreatitis;	chr16:75238614	chr16:75379818~75381260:-
THCA	cis	rs11884770	0.647	rs6716013	ENSG00000236432.6	AC097662.2	3.49	0.000531	0.0321	0.15	0.16	Advanced age-related macular degeneration;	chr2:227222652	chr2:227221052~227325201:-
THCA	cis	rs4083242	0.524	rs12920630	ENSG00000252311.1	RNU1-103P	3.49	0.000531	0.0321	0.17	0.16	Obesity-related traits;	chr16:86330485	chr16:85781775~85781899:-
THCA	cis	rs74233809	0.901	rs17878846	ENSG00000272912.1	RP11-724N1.1	-3.49	0.000531	0.0321	-0.28	-0.16	Birth weight;	chr10:102870655	chr10:102914585~102915404:+
THCA	cis	rs2625529	0.818	rs2246225	ENSG00000260037.4	CTD-2524L6.3	3.49	0.000531	0.0321	0.22	0.16	Red blood cell count;	chr15:71822889	chr15:71818396~71823384:+
THCA	cis	rs28830936	0.841	rs4923914	ENSG00000250379.1	RP11-23P13.4	3.49	0.000531	0.0321	0.18	0.16	Diastolic blood pressure;	chr15:41827405	chr15:41825099~41827936:-
THCA	cis	rs4808779	0.924	rs12980403	ENSG00000268650.3	AC068499.10	-3.49	0.000531	0.0321	-0.16	-0.16	Granulocyte percentage of myeloid white cells;	chr19:18287329	chr19:18204730~18220480:+
THCA	cis	rs4808779	0.924	rs12610373	ENSG00000268650.3	AC068499.10	-3.49	0.000531	0.0321	-0.16	-0.16	Granulocyte percentage of myeloid white cells;	chr19:18287474	chr19:18204730~18220480:+
THCA	cis	rs2180341	0.782	rs6912196	ENSG00000220522.2	RP1-177A13.1	3.49	0.000531	0.0321	0.19	0.16	Breast cancer;	chr6:127401587	chr6:127416535~127416952:-
THCA	cis	rs9527	0.64	rs7089061	ENSG00000236937.2	PTGES3P4	3.49	0.000531	0.0321	0.22	0.16	Arsenic metabolism;	chr10:102963258	chr10:102845595~102845950:+
THCA	cis	rs9527	0.615	rs7089065	ENSG00000236937.2	PTGES3P4	3.49	0.000531	0.0321	0.22	0.16	Arsenic metabolism;	chr10:102963265	chr10:102845595~102845950:+
THCA	cis	rs9527	0.569	rs10786730	ENSG00000236937.2	PTGES3P4	3.49	0.000531	0.0321	0.22	0.16	Arsenic metabolism;	chr10:102964443	chr10:102845595~102845950:+
THCA	cis	rs12935229	0.756	rs7205038	ENSG00000260922.1	RP11-538I12.3	-3.49	0.000531	0.0321	-0.24	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77268881	chr16:77234877~77290934:+
THCA	cis	rs875971	0.767	rs12668005	ENSG00000223473.2	GS1-124K5.3	3.49	0.000531	0.0321	0.11	0.16	Aortic root size;	chr7:66444034	chr7:66491049~66493566:-
THCA	cis	rs7819412	0.744	rs4841503	ENSG00000254948.1	OR7E158P	3.49	0.000531	0.0321	0.19	0.16	Triglycerides;	chr8:11166817	chr8:11919900~11920809:-
THCA	cis	rs9926296	0.568	rs4420527	ENSG00000275734.1	RP11-368I7.6	3.49	0.000531	0.0321	0.17	0.16	Vitiligo;	chr16:89747780	chr16:89684642~89685304:+
THCA	cis	rs1383484	0.798	rs28645965	ENSG00000259728.4	LINC00933	-3.49	0.000532	0.0321	-0.2	-0.16	Height;	chr15:83869893	chr15:84570649~84580175:+
THCA	cis	rs1383484	0.798	rs28545666	ENSG00000259728.4	LINC00933	-3.49	0.000532	0.0321	-0.2	-0.16	Height;	chr15:83869959	chr15:84570649~84580175:+
THCA	cis	rs3902035	0.765	rs17694991	ENSG00000253194.1	RP11-351A11.1	3.49	0.000532	0.0321	0.28	0.16	QT interval;	chr6:118702649	chr6:118934785~119031541:+
THCA	cis	rs7212590	0.748	rs73315252	ENSG00000267302.4	RP11-178C3.2	3.49	0.000532	0.0321	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59777494	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.748	rs8073489	ENSG00000267302.4	RP11-178C3.2	3.49	0.000532	0.0321	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59784433	chr17:59964832~59996972:+
THCA	cis	rs4906332	0.811	rs2756138	ENSG00000269940.1	RP11-73M18.7	-3.49	0.000532	0.0321	-0.17	-0.16	Coronary artery disease;	chr14:103530396	chr14:103694560~103695170:+
THCA	cis	rs9329221	0.736	rs2001337	ENSG00000253641.4	RP11-981G7.2	3.49	0.000532	0.0321	0.15	0.16	Neuroticism;	chr8:10393644	chr8:10474565~10481974:+
THCA	cis	rs758324	0.504	rs55764014	ENSG00000237714.1	P4HA2-AS1	3.49	0.000532	0.0321	0.22	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131835212	chr5:132184876~132192808:+
THCA	cis	rs453301	0.658	rs6983877	ENSG00000253981.4	ALG1L13P	-3.49	0.000532	0.0321	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9047129	chr8:8236003~8244667:-
THCA	cis	rs1059312	0.932	rs4760593	ENSG00000279500.1	RP11-21K12.2	-3.49	0.000532	0.0321	-0.11	-0.16	Systemic lupus erythematosus;	chr12:128802675	chr12:128813186~128814750:-
THCA	cis	rs10266483	0.739	rs12538943	ENSG00000234585.5	CCT6P3	-3.49	0.000532	0.0321	-0.17	-0.16	Response to statin therapy;	chr7:64395990	chr7:65038354~65074713:+
THCA	cis	rs2348418	0.765	rs6487665	ENSG00000278733.1	RP11-425D17.1	-3.49	0.000532	0.0321	-0.14	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28185625~28186190:-
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000254866.2	DEFB109P3	-3.49	0.000532	0.0321	-0.21	-0.16	Neuroticism;	chr8:11989569	chr8:12150895~12151134:-
THCA	cis	rs6724465	1	rs72967954	ENSG00000272644.1	RP11-33O4.1	3.49	0.000532	0.0321	0.23	0.16	Height;	chr2:219057847	chr2:219069354~219069809:-
THCA	cis	rs11160190	1	rs11160190	ENSG00000258572.1	RP11-1070N10.3	-3.49	0.000532	0.0321	-0.17	-0.16	Vaspin levels;	chr14:94546047	chr14:95516136~95517911:+
THCA	cis	rs2340727	0.524	rs6693980	ENSG00000229808.1	RP11-456P18.2	3.49	0.000532	0.0321	0.22	0.16	White blood cell count;Hematology traits;	chr1:161973412	chr1:161890833~161892196:+
THCA	cis	rs1501138	0.642	rs887648	ENSG00000263327.5	TAPT1-AS1	-3.49	0.000532	0.0321	-0.26	-0.16	Systemic juvenile idiopathic arthritis;	chr4:16294498	chr4:16226685~16320140:+
THCA	cis	rs10857712	1	rs10857712	ENSG00000214279.11	SCART1	-3.49	0.000532	0.0322	-0.13	-0.16	Systemic lupus erythematosus;	chr10:133412162	chr10:133453928~133523558:+
THCA	cis	rs513088	0.681	rs517224	ENSG00000225171.2	DUTP6	-3.49	0.000532	0.0322	-0.23	-0.16	Schizophrenia;	chr1:166677709	chr1:166868748~166869209:+
THCA	cis	rs6471393	0.929	rs62525163	ENSG00000261437.1	RP11-22C11.2	3.49	0.000532	0.0322	0.15	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749824	chr8:94637285~94639467:-
THCA	cis	rs8035452	1	rs12903915	ENSG00000273674.3	CTD-2378E12.1	3.49	0.000532	0.0322	0.2	0.16	Alzheimer's disease (late onset);	chr15:50736551	chr15:50839875~50908599:-
THCA	cis	rs3758911	0.894	rs999984	ENSG00000255353.1	RP11-382M14.1	-3.49	0.000532	0.0322	-0.2	-0.16	Coronary artery disease;	chr11:107321266	chr11:107176286~107177530:+
THCA	cis	rs7116495	0.609	rs10450664	ENSG00000228915.3	OR7E128P	3.49	0.000532	0.0322	0.37	0.16	Severe influenza A (H1N1) infection;	chr11:71925609	chr11:71893410~71894433:+
THCA	cis	rs6494488	0.5	rs72744738	ENSG00000259635.1	AC100830.3	-3.49	0.000532	0.0322	-0.4	-0.16	Coronary artery disease;	chr15:64756135	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744740	ENSG00000259635.1	AC100830.3	-3.49	0.000532	0.0322	-0.4	-0.16	Coronary artery disease;	chr15:64758292	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744749	ENSG00000259635.1	AC100830.3	-3.49	0.000532	0.0322	-0.4	-0.16	Coronary artery disease;	chr15:64770620	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744763	ENSG00000259635.1	AC100830.3	-3.49	0.000532	0.0322	-0.4	-0.16	Coronary artery disease;	chr15:64784453	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744766	ENSG00000259635.1	AC100830.3	-3.49	0.000532	0.0322	-0.4	-0.16	Coronary artery disease;	chr15:64786892	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs111793398	ENSG00000259635.1	AC100830.3	-3.49	0.000532	0.0322	-0.4	-0.16	Coronary artery disease;	chr15:64787155	chr15:64701248~64719602:+
THCA	cis	rs6494488	0.5	rs72744788	ENSG00000259635.1	AC100830.3	-3.49	0.000532	0.0322	-0.4	-0.16	Coronary artery disease;	chr15:64803036	chr15:64701248~64719602:+
THCA	cis	rs10090774	0.71	rs13275969	ENSG00000279766.1	RP11-642A1.2	-3.49	0.000532	0.0322	-0.19	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140663317	chr8:140572142~140572812:-
THCA	cis	rs12621844	0.671	rs6545013	ENSG00000234690.5	AC073283.4	3.49	0.000532	0.0322	0.15	0.16	Glycated hemoglobin levels;	chr2:48024332	chr2:47192405~47345074:-
THCA	cis	rs1865760	0.613	rs9379801	ENSG00000272810.1	U91328.22	-3.49	0.000532	0.0322	-0.12	-0.16	Height;	chr6:25901483	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.613	rs9295674	ENSG00000272810.1	U91328.22	-3.49	0.000532	0.0322	-0.12	-0.16	Height;	chr6:25912114	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.593	rs3903852	ENSG00000272810.1	U91328.22	-3.49	0.000532	0.0322	-0.12	-0.16	Height;	chr6:25914919	chr6:26013241~26013757:+
THCA	cis	rs1050631	1	rs1789550	ENSG00000260552.1	RP11-49I11.1	-3.49	0.000532	0.0322	-0.19	-0.16	Esophageal squamous cell cancer (length of survival);	chr18:36119590	chr18:36179996~36187448:-
THCA	cis	rs9902453	0.619	rs1038088	ENSG00000263370.1	RP11-68I3.5	-3.49	0.000532	0.0322	-0.21	-0.16	Coffee consumption (cups per day);	chr17:29747545	chr17:29639627~29640825:+
THCA	cis	rs7089973	0.564	rs55671354	ENSG00000228169.3	PPIAP19	3.49	0.000532	0.0322	0.19	0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114811522	chr10:114690143~114690634:-
THCA	cis	rs3758911	0.964	rs10789601	ENSG00000255353.1	RP11-382M14.1	-3.49	0.000532	0.0322	-0.2	-0.16	Coronary artery disease;	chr11:107310693	chr11:107176286~107177530:+
THCA	cis	rs9863	0.861	rs4765219	ENSG00000269938.1	RP11-214K3.20	-3.49	0.000532	0.0322	-0.18	-0.16	White blood cell count;	chr12:123955563	chr12:123968023~123968579:-
THCA	cis	rs6762	0.55	rs8672	ENSG00000255284.1	AP006621.5	3.49	0.000532	0.0322	0.11	0.16	Mean platelet volume;	chr11:838634	chr11:777578~784297:+
THCA	cis	rs3736986	1	rs75987339	ENSG00000215283.3	HMGB3P24	-3.49	0.000532	0.0322	-0.29	-0.16	Bipolar disorder (inflammation and infection response interaction);	chr9:36200888	chr9:36303499~36304924:-
THCA	cis	rs3736986	1	rs7036188	ENSG00000215283.3	HMGB3P24	-3.49	0.000532	0.0322	-0.29	-0.16	Bipolar disorder (inflammation and infection response interaction);	chr9:36203316	chr9:36303499~36304924:-
THCA	cis	rs7403037	0.537	rs8028138	ENSG00000260760.1	PWRN3	3.49	0.000532	0.0322	0.18	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24183100	chr15:24441127~24447967:+
THCA	cis	rs11157436	0.83	rs61972214	ENSG00000211812.1	TRAV26-2	-3.49	0.000533	0.0322	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22152416	chr14:22202583~22203368:+
THCA	cis	rs2033711	0.87	rs11084545	ENSG00000269867.1	CTD-2583A14.8	-3.49	0.000533	0.0322	-0.13	-0.16	Uric acid clearance;	chr19:58440326	chr19:57867038~57868172:-
THCA	cis	rs8177876	0.658	rs2911158	ENSG00000261838.4	RP11-303E16.6	-3.49	0.000533	0.0322	-0.25	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057652	chr16:81069854~81076598:+
THCA	cis	rs4073416	0.535	rs7150448	ENSG00000276116.2	FUT8-AS1	3.49	0.000533	0.0322	0.18	0.16	N-glycan levels;	chr14:65404784	chr14:65411170~65412690:-
THCA	cis	rs10858047	0.883	rs72698003	ENSG00000231128.4	RP5-1073O3.2	3.49	0.000533	0.0322	0.24	0.16	Autism;	chr1:114538313	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs12037358	ENSG00000231128.4	RP5-1073O3.2	3.49	0.000533	0.0322	0.24	0.16	Autism;	chr1:114546658	chr1:113812379~113829171:+
THCA	cis	rs3764021	0.506	rs10844468	ENSG00000256069.6	A2MP1	-3.49	0.000533	0.0322	-0.18	-0.16	Type 1 diabetes;	chr12:9690799	chr12:9228533~9275817:-
THCA	cis	rs7833790	0.777	rs7815272	ENSG00000254689.1	RP11-354A14.1	3.49	0.000533	0.0322	0.2	0.16	Diastolic blood pressure;	chr8:81779574	chr8:81885377~81923193:+
THCA	cis	rs7833790	0.777	rs1005850	ENSG00000254689.1	RP11-354A14.1	3.49	0.000533	0.0322	0.2	0.16	Diastolic blood pressure;	chr8:81780020	chr8:81885377~81923193:+
THCA	cis	rs2888875	1	rs1873555	ENSG00000200924.1	RNU6-1048P	-3.49	0.000533	0.0322	-0.18	-0.16	Glomerular filtration rate (creatinine);	chr2:43552526	chr2:43892690~43892796:+
THCA	cis	rs9309711	0.506	rs9284794	ENSG00000271868.1	RP11-1293J14.1	-3.49	0.000533	0.0322	-0.21	-0.16	Neurofibrillary tangles;	chr2:3488281	chr2:3496956~3497428:+
THCA	cis	rs9863	0.861	rs4765528	ENSG00000270061.1	RP11-214K3.19	3.49	0.000533	0.0322	0.22	0.16	White blood cell count;	chr12:123977707	chr12:123969990~123970344:-
THCA	cis	rs11237982	0.6	rs11237961	ENSG00000255345.1	CTD-2337I7.1	-3.49	0.000533	0.0322	-0.25	-0.16	Verbal declarative memory;	chr11:79674857	chr11:79092848~79098003:+
THCA	cis	rs10266483	0.774	rs56055804	ENSG00000234585.5	CCT6P3	-3.49	0.000533	0.0322	-0.16	-0.16	Response to statin therapy;	chr7:64410423	chr7:65038354~65074713:+
THCA	cis	rs7631605	0.967	rs6801864	ENSG00000272334.1	RP11-129K12.1	3.49	0.000533	0.0322	0.19	0.16	Cerebrospinal P-tau181p levels;	chr3:37215751	chr3:36973117~36973672:-
THCA	cis	rs17074492	1	rs7330551	ENSG00000214182.5	PTMAP5	3.49	0.000533	0.0322	0.18	0.16	Sjögren's syndrome;	chr13:81608328	chr13:81689911~81691072:+
THCA	cis	rs4660214	0.671	rs72661956	ENSG00000182109.6	RP11-69E11.4	3.49	0.000533	0.0322	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39319216	chr1:39522280~39546187:-
THCA	cis	rs4660214	0.671	rs16826068	ENSG00000182109.6	RP11-69E11.4	3.49	0.000533	0.0322	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39326204	chr1:39522280~39546187:-
THCA	cis	rs3176789	0.671	rs3176775	ENSG00000256673.1	RP11-599J14.2	3.49	0.000533	0.0322	0.19	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9764486	chr12:9398355~9414851:-
THCA	cis	rs6687821	0.515	rs1199680	ENSG00000261737.1	RP4-612B15.3	3.49	0.000533	0.0322	0.24	0.16	Yeast infection;	chr1:87099993	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs7536241	ENSG00000261737.1	RP4-612B15.3	3.49	0.000533	0.0322	0.24	0.16	Yeast infection;	chr1:87101030	chr1:86703502~86704462:-
THCA	cis	rs9863	0.931	rs35825716	ENSG00000269938.1	RP11-214K3.20	-3.49	0.000533	0.0322	-0.19	-0.16	White blood cell count;	chr12:123942977	chr12:123968023~123968579:-
THCA	cis	rs2821260	0.694	rs1486096	ENSG00000227207.2	RPL31P12	3.49	0.000533	0.0322	0.18	0.16	Intelligence (multi-trait analysis);	chr1:72118501	chr1:72301472~72301829:+
THCA	cis	rs2334880	0.678	rs12922830	ENSG00000260185.1	RP11-432I5.6	3.49	0.000533	0.0322	0.28	0.16	Malaria;	chr16:71413367	chr16:71655027~71664212:+
THCA	cis	rs9309473	1	rs6710438	ENSG00000273245.1	RP11-434P11.2	-3.49	0.000533	0.0322	-0.22	-0.16	Metabolite levels;	chr2:73592981	chr2:73750256~73750786:-
THCA	cis	rs9876781	1	rs2290822	ENSG00000199476.1	Y_RNA	-3.49	0.000533	0.0322	-0.2	-0.16	Longevity;	chr3:48431794	chr3:48288587~48288694:+
THCA	cis	rs11673344	0.523	rs2082010	ENSG00000233527.7	ZNF529-AS1	3.49	0.000533	0.0322	0.13	0.16	Obesity-related traits;	chr19:37039874	chr19:36573070~36594708:+
THCA	cis	rs6691722	0.506	rs12030365	ENSG00000264443.1	RP4-594I10.3	3.49	0.000533	0.0322	0.15	0.16	Response to interferon beta in multiple sclerosis;	chr1:24412730	chr1:24538802~24556024:-
THCA	cis	rs858239	0.796	rs433395	ENSG00000230042.1	AK3P3	-3.49	0.000533	0.0322	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23129178~23129841:+
THCA	cis	rs6456156	0.586	rs720325	ENSG00000235272.1	FAM103A2P	3.49	0.000533	0.0322	0.22	0.16	Primary biliary cholangitis;	chr6:167053861	chr6:166586124~166586477:-
THCA	cis	rs10760158	0.832	rs10818524	ENSG00000235865.2	GSN-AS1	3.49	0.000533	0.0322	0.14	0.16	Pulse pressure;	chr9:121267901	chr9:121280768~121285530:-
THCA	cis	rs10266483	0.739	rs12665990	ENSG00000234585.5	CCT6P3	-3.49	0.000533	0.0322	-0.17	-0.16	Response to statin therapy;	chr7:64404622	chr7:65038354~65074713:+
THCA	cis	rs10863936	0.667	rs17656453	ENSG00000198468.6	FLVCR1-AS1	-3.49	0.000533	0.0322	-0.19	-0.16	Height;	chr1:212077478	chr1:212852108~212858088:-
THCA	cis	rs10863936	0.667	rs7519826	ENSG00000198468.6	FLVCR1-AS1	-3.49	0.000533	0.0322	-0.19	-0.16	Height;	chr1:212084534	chr1:212852108~212858088:-
THCA	cis	rs10863936	0.667	rs56292525	ENSG00000198468.6	FLVCR1-AS1	-3.49	0.000533	0.0322	-0.19	-0.16	Height;	chr1:212089081	chr1:212852108~212858088:-
THCA	cis	rs1832871	0.644	rs56180963	ENSG00000213078.3	RP5-933K21.2	-3.49	0.000533	0.0322	-0.24	-0.16	Height;	chr6:158352958	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.616	rs55675950	ENSG00000213078.3	RP5-933K21.2	-3.49	0.000533	0.0322	-0.24	-0.16	Height;	chr6:158352962	chr6:157365990~157366923:-
THCA	cis	rs720064	0.589	rs10502441	ENSG00000264745.1	TTC39C-AS1	3.49	0.000533	0.0322	0.17	0.16	Strep throat;	chr18:23923207	chr18:23994213~24015339:-
THCA	cis	rs877819	0.697	rs7915340	ENSG00000228403.1	RP11-563N6.6	-3.49	0.000533	0.0322	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48840495	chr10:48878022~48878649:+
THCA	cis	rs267567	0.626	rs267566	ENSG00000235257.7	ITGA9-AS1	-3.49	0.000533	0.0322	-0.13	-0.16	PR interval;	chr3:37532691	chr3:37745432~37861780:-
THCA	cis	rs6743226	0.542	rs62186397	ENSG00000223374.1	AC005104.3	3.49	0.000533	0.0322	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241284497	chr2:241351340~241353104:-
THCA	cis	rs2446066	0.872	rs7300593	ENSG00000257379.1	RP11-793H13.8	3.49	0.000534	0.0322	0.23	0.16	Red blood cell count;	chr12:53396666	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.872	rs7133236	ENSG00000257379.1	RP11-793H13.8	3.49	0.000534	0.0322	0.23	0.16	Red blood cell count;	chr12:53397201	chr12:53441741~53467528:+
THCA	cis	rs10043228	0.826	rs12153778	ENSG00000250015.1	CTC-339F2.2	3.49	0.000534	0.0322	0.25	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116342931	chr5:116302354~116304134:-
THCA	cis	rs9890032	0.934	rs7225461	ENSG00000263603.1	CTD-2349P21.5	-3.49	0.000534	0.0322	-0.2	-0.16	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30729469~30731202:+
THCA	cis	rs9840812	0.769	rs483465	ENSG00000239213.4	NCK1-AS1	3.49	0.000534	0.0322	0.15	0.16	Fibrinogen levels;	chr3:136329135	chr3:136841726~136862054:-
THCA	cis	rs478304	0.58	rs11606947	ENSG00000214659.4	KRT8P26	3.49	0.000534	0.0322	0.15	0.16	Acne (severe);	chr11:65740766	chr11:65726939~65728214:+
THCA	cis	rs944289	0.74	rs884384	ENSG00000212071.1	AL162511.1	3.49	0.000534	0.0322	0.18	0.16	Thyroid cancer;	chr14:36081801	chr14:36196480~36196568:-
THCA	cis	rs944289	0.74	rs884383	ENSG00000212071.1	AL162511.1	3.49	0.000534	0.0322	0.18	0.16	Thyroid cancer;	chr14:36081936	chr14:36196480~36196568:-
THCA	cis	rs13118159	0.801	rs7664474	ENSG00000254094.1	AC078852.1	-3.49	0.000534	0.0322	-0.18	-0.16	Longevity;	chr4:1335328	chr4:1356581~1358075:+
THCA	cis	rs13118159	0.801	rs1128427	ENSG00000254094.1	AC078852.1	-3.49	0.000534	0.0322	-0.18	-0.16	Longevity;	chr4:1336971	chr4:1356581~1358075:+
THCA	cis	rs12474906	0.519	rs13414801	ENSG00000234072.1	AC074117.10	-3.49	0.000534	0.0322	-0.12	-0.16	Schizophrenia;	chr2:28067480	chr2:27356246~27367622:+
THCA	cis	rs11069062	0.683	rs12304903	ENSG00000270482.1	RP11-131L12.2	3.49	0.000534	0.0322	0.12	0.16	Obesity-related traits;	chr12:118746554	chr12:118375350~118376275:-
THCA	cis	rs7554547	0.69	rs4846064	ENSG00000199347.1	RNU5E-1	3.49	0.000534	0.0322	0.22	0.16	Nonsyndromic cleft lip with cleft palate;	chr1:11874785	chr1:11908152~11908271:+
THCA	cis	rs7919656	0.542	rs2620889	ENSG00000228403.1	RP11-563N6.6	3.49	0.000534	0.0322	0.17	0.16	Clinically amyopathic dermatomyositis;	chr10:48768317	chr10:48878022~48878649:+
THCA	cis	rs28830936	0.966	rs17678552	ENSG00000250379.1	RP11-23P13.4	3.49	0.000534	0.0323	0.18	0.16	Diastolic blood pressure;	chr15:41773992	chr15:41825099~41827936:-
THCA	cis	rs4919087	0.59	rs7915926	ENSG00000237169.1	RP11-452K12.3	3.49	0.000534	0.0323	0.21	0.16	Monocyte count;	chr10:97294295	chr10:97309138~97309958:-
THCA	cis	rs9376098	0.571	rs1041479	ENSG00000232876.1	CTA-212D2.2	-3.49	0.000534	0.0323	-0.22	-0.16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135167358	chr6:135055033~135060550:+
THCA	cis	rs7264396	0.79	rs6058288	ENSG00000088340.14	FER1L4	-3.49	0.000534	0.0323	-0.16	-0.16	Total cholesterol levels;	chr20:35640758	chr20:35558737~35607562:-
THCA	cis	rs2180341	1	rs2180341	ENSG00000220522.2	RP1-177A13.1	3.49	0.000534	0.0323	0.21	0.16	Breast cancer;	chr6:127279485	chr6:127416535~127416952:-
THCA	cis	rs9650657	0.65	rs2898248	ENSG00000255310.2	AF131215.2	3.49	0.000534	0.0323	0.13	0.16	Neuroticism;	chr8:10779240	chr8:11107788~11109726:-
THCA	cis	rs2901381	0.701	rs35919673	ENSG00000269984.1	RP11-362K14.5	-3.49	0.000534	0.0323	-0.15	-0.16	Plateletcrit;	chr3:169102481	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs11718015	ENSG00000269984.1	RP11-362K14.5	-3.49	0.000534	0.0323	-0.15	-0.16	Plateletcrit;	chr3:169102938	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs34981912	ENSG00000269984.1	RP11-362K14.5	-3.49	0.000534	0.0323	-0.15	-0.16	Plateletcrit;	chr3:169103951	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs1362521	ENSG00000269984.1	RP11-362K14.5	-3.49	0.000534	0.0323	-0.15	-0.16	Plateletcrit;	chr3:169104653	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs13095581	ENSG00000269984.1	RP11-362K14.5	-3.49	0.000534	0.0323	-0.15	-0.16	Plateletcrit;	chr3:169104964	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs13099881	ENSG00000269984.1	RP11-362K14.5	-3.49	0.000534	0.0323	-0.15	-0.16	Plateletcrit;	chr3:169105108	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs61705229	ENSG00000269984.1	RP11-362K14.5	-3.49	0.000534	0.0323	-0.15	-0.16	Plateletcrit;	chr3:169105171	chr3:169777192~169780334:-
THCA	cis	rs7632954	0.531	rs11720160	ENSG00000227110.5	LMCD1-AS1	-3.49	0.000534	0.0323	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8476246	chr3:7952805~8611924:-
THCA	cis	rs524281	1	rs472518	ENSG00000255120.4	OVOL1-AS1	3.49	0.000534	0.0323	0.22	0.16	Electroencephalogram traits;	chr11:66084431	chr11:65789051~65790868:-
THCA	cis	rs4699052	0.963	rs6816055	ENSG00000251288.2	RP11-10L12.2	-3.49	0.000534	0.0323	-0.2	-0.16	Testicular germ cell tumor;	chr4:103222003	chr4:102751401~102752641:+
THCA	cis	rs4699052	0.963	rs11097801	ENSG00000251288.2	RP11-10L12.2	-3.49	0.000534	0.0323	-0.2	-0.16	Testicular germ cell tumor;	chr4:103229166	chr4:102751401~102752641:+
THCA	cis	rs4699052	0.963	rs56144793	ENSG00000251288.2	RP11-10L12.2	-3.49	0.000534	0.0323	-0.2	-0.16	Testicular germ cell tumor;	chr4:103229496	chr4:102751401~102752641:+
THCA	cis	rs7824557	0.518	rs11777007	ENSG00000269899.1	RP11-589N15.2	3.49	0.000534	0.0323	0.18	0.16	Retinal vascular caliber;	chr8:10944347	chr8:11846154~11846391:-
THCA	cis	rs256438	0.731	rs9293799	ENSG00000251221.1	LINC01337	-3.49	0.000534	0.0323	-0.19	-0.16	Serum thyroid-stimulating hormone levels;	chr5:80049726	chr5:80608623~80622524:-
THCA	cis	rs721917	0.506	rs2758556	ENSG00000272489.1	RP11-182L21.5	3.49	0.000534	0.0323	0.18	0.16	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79663192~79664786:+
THCA	cis	rs7711186	0.786	rs4079111	ENSG00000252464.1	RN7SKP70	3.49	0.000534	0.0323	0.17	0.16	Urate levels in obese individuals;	chr5:178646403	chr5:178619728~178619998:-
THCA	cis	rs7711186	0.786	rs10061883	ENSG00000252464.1	RN7SKP70	3.49	0.000534	0.0323	0.17	0.16	Urate levels in obese individuals;	chr5:178646580	chr5:178619728~178619998:-
THCA	cis	rs7674212	0.537	rs2623060	ENSG00000230069.3	LRRC37A15P	-3.49	0.000534	0.0323	-0.16	-0.16	Type 2 diabetes;	chr4:103126347	chr4:102727274~102730721:-
THCA	cis	rs7809950	1	rs6976607	ENSG00000272072.1	CTA-363E19.2	-3.49	0.000534	0.0323	-0.16	-0.16	Coronary artery disease;	chr7:107582956	chr7:107192559~107193300:-
THCA	cis	rs7809950	0.911	rs7778250	ENSG00000272072.1	CTA-363E19.2	-3.49	0.000534	0.0323	-0.16	-0.16	Coronary artery disease;	chr7:107584120	chr7:107192559~107193300:-
THCA	cis	rs2055729	0.71	rs112406488	ENSG00000261451.1	RP11-981G7.1	3.49	0.000534	0.0323	0.23	0.16	Multiple myeloma (hyperdiploidy);	chr8:9878852	chr8:10433672~10438312:+
THCA	cis	rs7829975	0.688	rs13270194	ENSG00000233609.3	RP11-62H7.2	3.49	0.000534	0.0323	0.16	0.16	Mood instability;	chr8:8520592	chr8:8961200~8979025:+
THCA	cis	rs9488822	0.676	rs11153593	ENSG00000233558.1	RP3-486I3.4	3.49	0.000534	0.0323	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116013968	chr6:116258493~116259115:-
THCA	cis	rs620729	0.794	rs9357151	ENSG00000272097.1	RP11-421M1.8	-3.49	0.000534	0.0323	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:11479203	chr6:10743324~10747663:-
THCA	cis	rs2888875	0.963	rs9973398	ENSG00000200924.1	RNU6-1048P	-3.49	0.000534	0.0323	-0.18	-0.16	Glomerular filtration rate (creatinine);	chr2:43553322	chr2:43892690~43892796:+
THCA	cis	rs9341808	0.754	rs1015158	ENSG00000260645.1	RP11-250B2.5	3.49	0.000534	0.0323	0.14	0.16	Sitting height ratio;	chr6:80236028	chr6:80466958~80469080:+
THCA	cis	rs10844154	0.638	rs326644	ENSG00000277342.1	RP11-843B15.4	-3.49	0.000534	0.0323	-0.19	-0.16	Emphysema-related traits;Weight;	chr12:32248358	chr12:32109076~32109602:+
THCA	cis	rs181553	0.664	rs2166670	ENSG00000266696.1	RP11-30L3.2	3.49	0.000534	0.0323	0.19	0.16	Hip circumference adjusted for BMI;	chr18:49158540	chr18:49205912~49208781:+
THCA	cis	rs453301	0.506	rs476845	ENSG00000248538.5	RP11-10A14.5	3.49	0.000535	0.0323	0.19	0.16	Joint mobility (Beighton score);	chr8:8765367	chr8:9189011~9202854:+
THCA	cis	rs250518	0.926	rs6452683	ENSG00000251467.1	CTC-250P20.2	3.49	0.000535	0.0323	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72787076	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs6875887	ENSG00000251467.1	CTC-250P20.2	3.49	0.000535	0.0323	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72795067	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs6876549	ENSG00000251467.1	CTC-250P20.2	3.49	0.000535	0.0323	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72795463	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs6897422	ENSG00000251467.1	CTC-250P20.2	3.49	0.000535	0.0323	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72795532	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs6452687	ENSG00000251467.1	CTC-250P20.2	3.49	0.000535	0.0323	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72795688	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs6452690	ENSG00000251467.1	CTC-250P20.2	3.49	0.000535	0.0323	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72795785	chr5:72996920~72997642:+
THCA	cis	rs4737732	0.708	rs10096019	ENSG00000272192.1	CTD-2532N20.1	-3.49	0.000535	0.0323	-0.17	-0.16	Stem cell growth factor beta levels;	chr8:65392652	chr8:65842752~65843331:+
THCA	cis	rs1023500	1	rs1023499	ENSG00000237037.8	NDUFA6-AS1	3.49	0.000535	0.0323	0.15	0.16	Schizophrenia;	chr22:41944578	chr22:42090931~42137742:+
THCA	cis	rs3853824	0.636	rs1992554	ENSG00000263089.1	RP11-166P13.4	3.49	0.000535	0.0323	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56864155	chr17:57092145~57096425:-
THCA	cis	rs3853824	0.636	rs9911132	ENSG00000263089.1	RP11-166P13.4	3.49	0.000535	0.0323	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56865362	chr17:57092145~57096425:-
THCA	cis	rs2880765	0.835	rs7163958	ENSG00000259407.1	RP11-158M2.3	-3.49	0.000535	0.0323	-0.16	-0.16	Coronary artery disease;	chr15:85501984	chr15:85744109~85750281:-
THCA	cis	rs7252981	0.632	rs880090	ENSG00000271283.1	CTC-412M14.6	3.49	0.000535	0.0323	0.2	0.16	Perceived unattractiveness to mosquitoes;	chr19:19629920	chr19:19699203~19699409:-
THCA	cis	rs3087591	0.659	rs757377	ENSG00000263535.1	AK4P1	3.49	0.000535	0.0323	0.19	0.16	Hip circumference;	chr17:31393408	chr17:31345521~31346187:+
THCA	cis	rs1556032	0.504	rs7032502	ENSG00000225472.1	RP11-120J1.1	-3.49	0.000535	0.0323	-0.15	-0.16	AIDS;	chr9:14455823	chr9:14317085~14357908:+
THCA	cis	rs34975555	0.557	rs2299585	ENSG00000253671.1	RP11-806O11.1	-3.49	0.000535	0.0323	-0.24	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17933994	chr8:17808941~17820868:+
THCA	cis	rs11089937	0.626	rs5757013	ENSG00000215456.5	BCRP4	3.49	0.000535	0.0323	0.2	0.16	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22630061~22636153:+
THCA	cis	rs6902257	1	rs2503730	ENSG00000233967.5	RP11-250B2.3	-3.49	0.000535	0.0323	-0.31	-0.16	Obesity-related traits;	chr6:80610884	chr6:80443344~80465927:+
THCA	cis	rs10483853	0.806	rs12435797	ENSG00000258891.1	RP5-1021I20.5	3.49	0.000535	0.0323	0.2	0.16	Coronary artery calcification;	chr14:73330961	chr14:73896164~73938114:-
THCA	cis	rs6545883	0.794	rs778152	ENSG00000212978.6	AC016747.3	-3.49	0.000535	0.0323	-0.17	-0.16	Tuberculosis;	chr2:61381405	chr2:61141592~61144969:-
THCA	cis	rs7208859	0.673	rs216440	ENSG00000264242.2	RP11-271K11.1	3.49	0.000535	0.0323	0.23	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30553697~30558962:+
THCA	cis	rs7737355	0.947	rs3776005	ENSG00000224431.1	AC063976.7	3.49	0.000535	0.0323	0.15	0.16	Life satisfaction;	chr5:131543310	chr5:132199456~132203487:+
THCA	cis	rs7246657	0.722	rs2927742	ENSG00000226686.6	LINC01535	3.49	0.000535	0.0323	0.23	0.16	Coronary artery calcification;	chr19:37642717	chr19:37251912~37265535:+
THCA	cis	rs17331151	0.573	rs2276818	ENSG00000242142.1	SERBP1P3	-3.49	0.000535	0.0323	-0.26	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52830619	chr3:53064283~53065091:-
THCA	cis	rs17331151	0.573	rs28552648	ENSG00000242142.1	SERBP1P3	-3.49	0.000535	0.0323	-0.26	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52831577	chr3:53064283~53065091:-
THCA	cis	rs72834846	0.947	rs8080157	ENSG00000236319.2	CTD-2033D24.2	3.49	0.000535	0.0323	0.24	0.16	Red blood cell count;	chr17:55131089	chr17:55526964~55561577:-
THCA	cis	rs34779708	0.897	rs4934529	ENSG00000233200.1	RP11-324I22.2	3.49	0.000535	0.0323	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs7920095	ENSG00000233200.1	RP11-324I22.2	3.49	0.000535	0.0323	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs66887762	ENSG00000233200.1	RP11-324I22.2	3.49	0.000535	0.0323	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35219894~35230598:-
THCA	cis	rs4666002	0.789	rs12998770	ENSG00000234072.1	AC074117.10	3.49	0.000535	0.0323	0.14	0.16	Phospholipid levels (plasma);	chr2:27690321	chr2:27356246~27367622:+
THCA	cis	rs1865760	0.515	rs2003208	ENSG00000272810.1	U91328.22	-3.49	0.000535	0.0323	-0.12	-0.16	Height;	chr6:25940491	chr6:26013241~26013757:+
THCA	cis	rs4713118	0.869	rs6901520	ENSG00000261839.1	RP1-265C24.8	3.49	0.000535	0.0323	0.18	0.16	Parkinson's disease;	chr6:27746796	chr6:28136849~28139678:+
THCA	cis	rs301901	0.828	rs4304095	ENSG00000250155.1	CTD-2353F22.1	3.49	0.000535	0.0323	0.16	0.16	Height;	chr5:37454360	chr5:36666214~36725195:-
THCA	cis	rs2933343	0.621	rs728838	ENSG00000261159.1	RP11-723O4.9	3.49	0.000535	0.0323	0.16	0.16	IgG glycosylation;	chr3:128870170	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.649	rs728839	ENSG00000261159.1	RP11-723O4.9	3.49	0.000535	0.0323	0.16	0.16	IgG glycosylation;	chr3:128870516	chr3:128859716~128860526:-
THCA	cis	rs11678825	0.852	rs11674217	ENSG00000272663.1	RP11-191L17.1	-3.49	0.000535	0.0323	-0.22	-0.16	Reticulocyte fraction of red cells;	chr2:48447352	chr2:48440043~48440597:-
THCA	cis	rs889512	0.642	rs3826110	ENSG00000261783.1	RP11-252K23.2	3.49	0.000535	0.0323	0.32	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr16:75243882	chr16:75379818~75381260:-
THCA	cis	rs9650657	0.675	rs2409658	ENSG00000255310.2	AF131215.2	-3.49	0.000535	0.0323	-0.13	-0.16	Neuroticism;	chr8:10811455	chr8:11107788~11109726:-
THCA	cis	rs6792584	0.598	rs7651649	ENSG00000241316.5	SUCLG2-AS1	3.49	0.000535	0.0323	0.15	0.16	Corneal astigmatism;	chr3:67494257	chr3:67654697~67947713:+
THCA	cis	rs2574985	0.53	rs2092996	ENSG00000279863.1	RP11-521C22.2	-3.49	0.000535	0.0323	-0.18	-0.16	Subjective well-being;	chr10:50521849	chr10:50334538~50336123:+
THCA	cis	rs73108077	0.831	rs2233826	ENSG00000277112.2	RP11-755J8.1	-3.49	0.000535	0.0323	-0.34	-0.16	Red blood cell density in sickle cell anemia;	chr20:31475539	chr20:30681825~30723932:-
THCA	cis	rs6445967	0.53	rs12631656	ENSG00000272360.1	RP11-359I18.5	3.49	0.000535	0.0323	0.19	0.16	Platelet count;	chr3:58423336	chr3:58490830~58491291:-
THCA	cis	rs9527	1	rs4919690	ENSG00000236937.2	PTGES3P4	-3.49	0.000535	0.0323	-0.24	-0.16	Arsenic metabolism;	chr10:102856743	chr10:102845595~102845950:+
THCA	cis	rs911555	0.692	rs60235428	ENSG00000269940.1	RP11-73M18.7	-3.49	0.000535	0.0323	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103694560~103695170:+
THCA	cis	rs8053891	0.673	rs10492824	ENSG00000262140.1	RP11-417N10.3	3.49	0.000535	0.0323	0.22	0.16	Coronary artery disease;	chr16:71984872	chr16:71833787~71835932:+
THCA	cis	rs2692947	0.537	rs12478605	ENSG00000168992.4	OR7E102P	3.49	0.000535	0.0323	0.2	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95711330	chr2:95546531~95547545:+
THCA	cis	rs9307551	1	rs1371989	ENSG00000249646.2	OR7E94P	3.49	0.000535	0.0323	0.22	0.16	Refractive error;	chr4:79600692	chr4:79587302~79588130:-
THCA	cis	rs4713118	0.525	rs9357042	ENSG00000220721.1	OR1F12	3.49	0.000535	0.0323	0.18	0.16	Parkinson's disease;	chr6:27615016	chr6:28073316~28074233:+
THCA	cis	rs9991779	0.58	rs6814121	ENSG00000237125.7	HAND2-AS1	-3.49	0.000535	0.0323	-0.27	-0.16	Pediatric bone mineral content (hip);	chr4:173946728	chr4:173527270~173591324:+
THCA	cis	rs9991779	0.58	rs6815176	ENSG00000237125.7	HAND2-AS1	-3.49	0.000535	0.0323	-0.27	-0.16	Pediatric bone mineral content (hip);	chr4:173947279	chr4:173527270~173591324:+
THCA	cis	rs1858037	0.867	rs964505	ENSG00000252414.1	RNU6-100P	-3.49	0.000535	0.0323	-0.17	-0.16	Rheumatoid arthritis;	chr2:65396055	chr2:64578892~64578997:+
THCA	cis	rs12476592	0.602	rs1374308	ENSG00000242412.1	DBIL5P2	3.49	0.000536	0.0323	0.21	0.16	Childhood ear infection;	chr2:63668302	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs1348805	ENSG00000242412.1	DBIL5P2	3.49	0.000536	0.0323	0.21	0.16	Childhood ear infection;	chr2:63668539	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs1348806	ENSG00000242412.1	DBIL5P2	3.49	0.000536	0.0323	0.21	0.16	Childhood ear infection;	chr2:63668750	chr2:63117851~63119542:-
THCA	cis	rs9911578	1	rs9892062	ENSG00000224738.1	AC099850.1	3.49	0.000536	0.0323	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58899620	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs9894274	ENSG00000224738.1	AC099850.1	3.49	0.000536	0.0323	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58900558	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs7216680	ENSG00000224738.1	AC099850.1	3.49	0.000536	0.0323	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58910882	chr17:59106598~59118267:+
THCA	cis	rs9911578	0.967	rs1588322	ENSG00000224738.1	AC099850.1	3.49	0.000536	0.0323	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58912738	chr17:59106598~59118267:+
THCA	cis	rs6901152	0.895	rs9376743	ENSG00000217648.1	RP1-95L4.4	-3.49	0.000536	0.0323	-0.17	-0.16	Acute lymphoblastic leukemia (childhood);	chr6:143325797	chr6:143342246~143343383:+
THCA	cis	rs748404	0.578	rs478028	ENSG00000224677.1	PDIA3P2	3.49	0.000536	0.0323	0.19	0.16	Lung cancer;	chr15:43318574	chr15:43649123~43649280:+
THCA	cis	rs748404	0.578	rs552701	ENSG00000224677.1	PDIA3P2	3.49	0.000536	0.0323	0.19	0.16	Lung cancer;	chr15:43321612	chr15:43649123~43649280:+
THCA	cis	rs748404	0.578	rs573615	ENSG00000224677.1	PDIA3P2	3.49	0.000536	0.0323	0.19	0.16	Lung cancer;	chr15:43322083	chr15:43649123~43649280:+
THCA	cis	rs924712	0.522	rs7750012	ENSG00000224984.1	RP11-524H19.2	3.49	0.000536	0.0323	0.19	0.16	Breast cancer;	chr6:54837845	chr6:54840118~54840855:-
THCA	cis	rs6995541	0.645	rs60011038	ENSG00000248896.2	CTD-2135J3.3	-3.49	0.000536	0.0323	-0.23	-0.16	Triglyceride levels;	chr8:10819027	chr8:10729314~10771392:+
THCA	cis	rs6545883	0.859	rs2694644	ENSG00000212978.6	AC016747.3	-3.49	0.000536	0.0323	-0.17	-0.16	Tuberculosis;	chr2:61377721	chr2:61141592~61144969:-
THCA	cis	rs76878669	0.606	rs2282531	ENSG00000255320.1	RP11-755F10.1	3.49	0.000536	0.0323	0.2	0.16	Educational attainment (years of education);	chr11:66332023	chr11:66244840~66246239:-
THCA	cis	rs7216064	1	rs9897982	ENSG00000278740.1	RP11-147L13.14	3.49	0.000536	0.0323	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883476	chr17:68188547~68189165:+
THCA	cis	rs877819	0.614	rs2663053	ENSG00000228403.1	RP11-563N6.6	3.49	0.000536	0.0323	0.17	0.16	Systemic lupus erythematosus;	chr10:48776008	chr10:48878022~48878649:+
THCA	cis	rs2562456	0.834	rs2650848	ENSG00000213976.4	CTD-2561J22.2	-3.49	0.000536	0.0323	-0.2	-0.16	Pain;	chr19:21403835	chr19:21382865~21387177:+
THCA	cis	rs4144027	0.875	rs6576010	ENSG00000258534.1	CTD-2134A5.4	3.49	0.000536	0.0323	0.17	0.16	Blood metabolite levels;	chr14:103883265	chr14:103854366~103880111:-
THCA	cis	rs2664588	0.538	rs6018825	ENSG00000276923.1	RP11-321P16.1	-3.49	0.000536	0.0323	-0.21	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47965916	chr20:48073869~48074188:+
THCA	cis	rs10488360	0.762	rs9639772	ENSG00000270822.1	RP11-730B22.1	3.49	0.000536	0.0323	0.2	0.16	Factor VII;	chr7:4375207	chr7:5009164~5009328:-
THCA	cis	rs1124609	1	rs75637446	ENSG00000244879.4	GABPB1-AS1	3.49	0.000536	0.0323	0.24	0.16	Subjective well-being;	chr15:50148330	chr15:50354959~50372202:+
THCA	cis	rs1799922	0.832	rs6954433	ENSG00000271553.1	RP11-274B21.10	3.49	0.000536	0.0323	0.14	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128749813	chr7:128667043~128668156:+
THCA	cis	rs758324	0.504	rs55764014	ENSG00000224431.1	AC063976.7	3.49	0.000536	0.0323	0.15	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131835212	chr5:132199456~132203487:+
THCA	cis	rs3736986	1	rs3780356	ENSG00000215283.3	HMGB3P24	-3.49	0.000536	0.0323	-0.29	-0.16	Bipolar disorder (inflammation and infection response interaction);	chr9:36201254	chr9:36303499~36304924:-
THCA	cis	rs1538970	0.884	rs1771551	ENSG00000234329.1	RP11-767N6.2	3.49	0.000536	0.0324	0.16	0.16	Platelet count;	chr1:45417971	chr1:45651039~45651826:-
THCA	cis	rs7914558	0.966	rs2065977	ENSG00000272912.1	RP11-724N1.1	-3.49	0.000536	0.0324	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs12569617	ENSG00000272912.1	RP11-724N1.1	-3.49	0.000536	0.0324	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102970239	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.933	rs1538204	ENSG00000272912.1	RP11-724N1.1	-3.49	0.000536	0.0324	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102914585~102915404:+
THCA	cis	rs9987353	0.544	rs2929470	ENSG00000253981.4	ALG1L13P	-3.49	0.000536	0.0324	-0.15	-0.16	Recombination measurement;	chr8:9204980	chr8:8236003~8244667:-
THCA	cis	rs35123781	0.696	rs904612	ENSG00000253404.1	AC034243.1	-3.49	0.000536	0.0324	-0.21	-0.16	Schizophrenia;	chr5:139691367	chr5:138744434~138753309:-
THCA	cis	rs9584850	0.834	rs7334078	ENSG00000231194.1	FARP1-AS1	-3.49	0.000536	0.0324	-0.2	-0.16	Neuroticism;	chr13:98468230	chr13:98435405~98435840:-
THCA	cis	rs6687821	0.515	rs4656139	ENSG00000261737.1	RP4-612B15.3	3.49	0.000536	0.0324	0.24	0.16	Yeast infection;	chr1:87059180	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs4431894	ENSG00000261737.1	RP4-612B15.3	3.49	0.000536	0.0324	0.24	0.16	Yeast infection;	chr1:87063801	chr1:86703502~86704462:-
THCA	cis	rs7829975	0.56	rs56094035	ENSG00000254340.1	RP11-10A14.3	-3.49	0.000536	0.0324	-0.19	-0.16	Mood instability;	chr8:8694112	chr8:9141424~9145435:+
THCA	cis	rs7829975	0.539	rs4841012	ENSG00000254340.1	RP11-10A14.3	-3.49	0.000536	0.0324	-0.19	-0.16	Mood instability;	chr8:8694200	chr8:9141424~9145435:+
THCA	cis	rs7829975	0.56	rs4841013	ENSG00000254340.1	RP11-10A14.3	-3.49	0.000536	0.0324	-0.19	-0.16	Mood instability;	chr8:8694503	chr8:9141424~9145435:+
THCA	cis	rs5753037	0.702	rs81800	ENSG00000273350.1	RP4-539M6.20	3.49	0.000536	0.0324	0.18	0.16	Type 1 diabetes;	chr22:29804373	chr22:30420512~30420912:+
THCA	cis	rs806215	0.547	rs322825	ENSG00000224138.1	AC000123.4	-3.49	0.000536	0.0324	-0.16	-0.16	Type 2 diabetes;	chr7:128081455	chr7:127350128~127351523:+
THCA	cis	rs3749237	0.615	rs6792911	ENSG00000224424.7	PRKAR2A-AS1	3.49	0.000536	0.0324	0.13	0.16	Resting heart rate;	chr3:49392423	chr3:48847572~48851981:+
THCA	cis	rs10266483	0.739	rs55747800	ENSG00000234585.5	CCT6P3	-3.49	0.000536	0.0324	-0.16	-0.16	Response to statin therapy;	chr7:64410105	chr7:65038354~65074713:+
THCA	cis	rs7737355	0.812	rs3776013	ENSG00000224431.1	AC063976.7	3.49	0.000536	0.0324	0.15	0.16	Life satisfaction;	chr5:131531711	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.738	rs3776011	ENSG00000224431.1	AC063976.7	3.49	0.000536	0.0324	0.15	0.16	Life satisfaction;	chr5:131533147	chr5:132199456~132203487:+
THCA	cis	rs6938	0.597	rs4886641	ENSG00000260269.4	CTD-2323K18.1	-3.49	0.000536	0.0324	-0.23	-0.16	Breast cancer;	chr15:74936314	chr15:75527150~75601205:-
THCA	cis	rs11001765	0.53	rs11001752	ENSG00000237149.5	ZNF503-AS2	-3.49	0.000536	0.0324	-0.23	-0.16	Chin dimples;	chr10:76366124	chr10:75401519~75408982:+
THCA	cis	rs4713118	0.824	rs9468223	ENSG00000261839.1	RP1-265C24.8	3.49	0.000536	0.0324	0.19	0.16	Parkinson's disease;	chr6:27772887	chr6:28136849~28139678:+
THCA	cis	rs9309473	0.948	rs10173534	ENSG00000273245.1	RP11-434P11.2	3.49	0.000536	0.0324	0.22	0.16	Metabolite levels;	chr2:73586305	chr2:73750256~73750786:-
THCA	cis	rs240993	0.909	rs11153279	ENSG00000255389.1	C6orf3	-3.49	0.000536	0.0324	-0.16	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111599875~111602295:+
THCA	cis	rs354225	0.544	rs12713267	ENSG00000212175.1	SNORA12	-3.49	0.000536	0.0324	-0.19	-0.16	Schizophrenia;	chr2:54578470	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs13403284	ENSG00000212175.1	SNORA12	-3.49	0.000536	0.0324	-0.19	-0.16	Schizophrenia;	chr2:54578612	chr2:55565703~55565850:+
THCA	cis	rs1124769	0.525	rs11070812	ENSG00000259378.1	DCAF13P3	3.49	0.000536	0.0324	0.22	0.16	Cognitive performance;	chr15:50770295	chr15:50944663~50945996:+
THCA	cis	rs853679	0.882	rs4713140	ENSG00000261839.1	RP1-265C24.8	3.49	0.000536	0.0324	0.24	0.16	Depression;	chr6:28129415	chr6:28136849~28139678:+
THCA	cis	rs7819412	0.775	rs34094119	ENSG00000254839.1	AF131215.6	3.49	0.000536	0.0324	0.16	0.16	Triglycerides;	chr8:11078388	chr8:11062647~11067089:-
THCA	cis	rs4660456	0.913	rs656230	ENSG00000238287.1	RP11-656D10.3	3.49	0.000536	0.0324	0.2	0.16	Platelet count;	chr1:40692701	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs2780953	ENSG00000238287.1	RP11-656D10.3	3.49	0.000536	0.0324	0.2	0.16	Platelet count;	chr1:40694105	chr1:40493157~40508661:-
THCA	cis	rs7267979	0.773	rs6132821	ENSG00000276952.1	RP5-965G21.6	3.49	0.000536	0.0324	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.844	rs1555330	ENSG00000276952.1	RP5-965G21.6	3.49	0.000536	0.0324	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.844	rs6107017	ENSG00000276952.1	RP5-965G21.6	3.49	0.000536	0.0324	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.844	rs6132824	ENSG00000276952.1	RP5-965G21.6	3.49	0.000536	0.0324	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25284915~25285588:-
THCA	cis	rs4919087	0.926	rs2861875	ENSG00000237169.1	RP11-452K12.3	3.49	0.000536	0.0324	0.19	0.16	Monocyte count;	chr10:97230382	chr10:97309138~97309958:-
THCA	cis	rs7020830	0.825	rs13297152	ENSG00000260100.1	RP11-220I1.5	-3.49	0.000536	0.0324	-0.2	-0.16	Schizophrenia;	chr9:37075626	chr9:37078813~37079776:-
THCA	cis	rs412658	0.504	rs369128	ENSG00000268119.4	CTD-2561J22.5	-3.49	0.000537	0.0324	-0.18	-0.16	Telomere length;	chr19:21925064	chr19:21444241~21463908:-
THCA	cis	rs412658	0.504	rs17769372	ENSG00000268119.4	CTD-2561J22.5	-3.49	0.000537	0.0324	-0.18	-0.16	Telomere length;	chr19:21931902	chr19:21444241~21463908:-
THCA	cis	rs2252521	0.524	rs719675	ENSG00000228421.2	AC005013.5	3.49	0.000537	0.0324	0.21	0.16	Cognitive performance;	chr7:29002315	chr7:28957667~28959345:+
THCA	cis	rs929354	0.553	rs34498858	ENSG00000224629.1	RP5-1142J19.2	-3.49	0.000537	0.0324	-0.16	-0.16	Body mass index;	chr7:157138643	chr7:157263022~157263229:-
THCA	cis	rs10875746	0.551	rs12322347	ENSG00000258273.1	RP11-370I10.4	3.49	0.000537	0.0324	0.23	0.16	Longevity (90 years and older);	chr12:48313915	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.551	rs12322348	ENSG00000258273.1	RP11-370I10.4	3.49	0.000537	0.0324	0.23	0.16	Longevity (90 years and older);	chr12:48313916	chr12:48333755~48333901:-
THCA	cis	rs11168618	1	rs3961921	ENSG00000240399.1	RP1-228P16.1	3.49	0.000537	0.0324	0.16	0.16	Adiponectin levels;	chr12:48549716	chr12:48054813~48055591:-
THCA	cis	rs11803434	0.601	rs4949224	ENSG00000254545.1	RP11-84A19.3	3.49	0.000537	0.0324	0.17	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr1:31868751	chr1:31789130~31791322:+
THCA	cis	rs643506	0.874	rs645411	ENSG00000230911.1	PPIHP1	-3.49	0.000537	0.0324	-0.22	-0.16	Breast cancer;	chr11:111823766	chr11:112029858~112030367:-
THCA	cis	rs910316	0.726	rs12882664	ENSG00000259138.1	RP11-950C14.7	3.49	0.000537	0.0324	0.14	0.16	Height;	chr14:74980075	chr14:75127153~75136930:+
THCA	cis	rs7259376	0.729	rs3867187	ENSG00000269345.1	VN1R85P	3.49	0.000537	0.0324	0.17	0.16	Menopause (age at onset);	chr19:22387418	chr19:22174766~22175191:-
THCA	cis	rs2562456	0.874	rs2562408	ENSG00000268658.4	LINC00664	-3.49	0.000537	0.0324	-0.23	-0.16	Pain;	chr19:21527079	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.874	rs2562417	ENSG00000268658.4	LINC00664	-3.49	0.000537	0.0324	-0.23	-0.16	Pain;	chr19:21528400	chr19:21483374~21503238:+
THCA	cis	rs2797160	1	rs1777195	ENSG00000226409.1	RP11-735G4.1	3.49	0.000537	0.0324	0.19	0.16	Endometrial cancer;	chr6:125685715	chr6:125370211~125374324:-
THCA	cis	rs12780845	0.931	rs34709865	ENSG00000273153.1	RP11-406H21.2	3.49	0.000537	0.0324	0.15	0.16	Homocysteine levels;	chr10:17203330	chr10:17137336~17137585:-
THCA	cis	rs2289328	0.823	rs35565646	ENSG00000223313.1	RNU6-516P	-3.49	0.000537	0.0324	-0.22	-0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40368314	chr15:40529570~40529673:+
THCA	cis	rs775227	0.574	rs2018912	ENSG00000243849.1	CFAP44-AS1	3.49	0.000537	0.0324	0.29	0.16	Dental caries;	chr3:113341293	chr3:113403991~113433992:+
THCA	cis	rs775227	0.574	rs55693215	ENSG00000243849.1	CFAP44-AS1	3.49	0.000537	0.0324	0.29	0.16	Dental caries;	chr3:113345247	chr3:113403991~113433992:+
THCA	cis	rs775227	0.574	rs60279293	ENSG00000243849.1	CFAP44-AS1	3.49	0.000537	0.0324	0.29	0.16	Dental caries;	chr3:113377240	chr3:113403991~113433992:+
THCA	cis	rs775227	0.574	rs13083453	ENSG00000243849.1	CFAP44-AS1	3.49	0.000537	0.0324	0.29	0.16	Dental caries;	chr3:113378096	chr3:113403991~113433992:+
THCA	cis	rs775227	0.574	rs34049435	ENSG00000243849.1	CFAP44-AS1	3.49	0.000537	0.0324	0.29	0.16	Dental caries;	chr3:113380652	chr3:113403991~113433992:+
THCA	cis	rs34421088	0.56	rs2248699	ENSG00000227888.4	FAM66A	-3.49	0.000537	0.0324	-0.21	-0.16	Neuroticism;	chr8:11536255	chr8:12362019~12388296:+
THCA	cis	rs7560272	0.695	rs13022149	ENSG00000273245.1	RP11-434P11.2	-3.49	0.000537	0.0324	-0.19	-0.16	Schizophrenia;	chr2:73414387	chr2:73750256~73750786:-
THCA	cis	rs7208859	0.673	rs216409	ENSG00000265443.1	CTD-2349P21.6	3.49	0.000537	0.0324	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30726305~30727564:-
THCA	cis	rs7674212	0.865	rs13149311	ENSG00000248971.2	KRT8P46	-3.49	0.000537	0.0324	-0.2	-0.16	Type 2 diabetes;	chr4:103056543	chr4:102728746~102730171:-
THCA	cis	rs656900	0.647	rs600671	ENSG00000261229.4	MTHFS	-3.49	0.000537	0.0324	-0.16	-0.16	Cerebrospinal P-tau181p levels;	chr15:79824890	chr15:79843547~79897285:-
THCA	cis	rs8053891	0.673	rs12444854	ENSG00000262140.1	RP11-417N10.3	3.49	0.000537	0.0324	0.22	0.16	Coronary artery disease;	chr16:71990591	chr16:71833787~71835932:+
THCA	cis	rs875971	0.862	rs4236208	ENSG00000223473.2	GS1-124K5.3	-3.49	0.000537	0.0324	-0.11	-0.16	Aortic root size;	chr7:66284091	chr7:66491049~66493566:-
THCA	cis	rs12959333	0.527	rs12709679	ENSG00000274849.1	RP11-49I11.4	-3.49	0.000537	0.0324	-0.2	-0.16	Post bronchodilator FEV1;	chr18:35689830	chr18:36189824~36190272:+
THCA	cis	rs6691722	0.506	rs11587667	ENSG00000264443.1	RP4-594I10.3	3.49	0.000537	0.0324	0.16	0.16	Response to interferon beta in multiple sclerosis;	chr1:24388945	chr1:24538802~24556024:-
THCA	cis	rs2367725	1	rs2367725	ENSG00000236200.4	KDM4A-AS1	-3.49	0.000537	0.0324	-0.12	-0.16	Aging (time to event);	chr1:43750157	chr1:43699765~43708138:-
THCA	cis	rs10975370	0.527	rs454045	ENSG00000206147.5	RP11-106A1.2	3.49	0.000537	0.0324	0.19	0.16	Breast cancer;	chr9:6032792	chr9:6639139~6639604:+
THCA	cis	rs78487399	0.908	rs6717791	ENSG00000234936.1	AC010883.5	3.49	0.000537	0.0324	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43594867	chr2:43229573~43233394:+
THCA	cis	rs7487075	0.78	rs12296120	ENSG00000272369.1	RP11-446N19.1	3.49	0.000537	0.0324	0.12	0.16	Itch intensity from mosquito bite;	chr12:46343808	chr12:46537502~46652550:+
THCA	cis	rs9303280	0.901	rs12103884	ENSG00000263818.4	CTD-2206N4.4	3.49	0.000537	0.0324	0.2	0.16	Self-reported allergy;	chr17:39889472	chr17:39057019~39113190:+
THCA	cis	rs2638953	0.815	rs1534340	ENSG00000278733.1	RP11-425D17.1	-3.49	0.000537	0.0324	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28515550	chr12:28185625~28186190:-
THCA	cis	rs4561483	0.603	rs62038777	ENSG00000263307.1	RP11-166B2.8	-3.49	0.000537	0.0324	-0.16	-0.16	Testicular germ cell tumor;	chr16:11840319	chr16:11851649~11895611:+
THCA	cis	rs14027	0.921	rs2136374	ENSG00000245330.4	KB-1471A8.1	3.49	0.000537	0.0324	0.16	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119867419~119874488:-
THCA	cis	rs14027	0.881	rs4871578	ENSG00000245330.4	KB-1471A8.1	3.49	0.000537	0.0324	0.16	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119867419~119874488:-
THCA	cis	rs14027	0.921	rs10110601	ENSG00000245330.4	KB-1471A8.1	3.49	0.000537	0.0324	0.16	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119867419~119874488:-
THCA	cis	rs34779708	0.771	rs3867218	ENSG00000233200.1	RP11-324I22.2	3.49	0.000537	0.0324	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35219894~35230598:-
THCA	cis	rs12476592	0.602	rs1255	ENSG00000242412.1	DBIL5P2	3.49	0.000537	0.0324	0.2	0.16	Childhood ear infection;	chr2:63598800	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs964880	ENSG00000242412.1	DBIL5P2	3.49	0.000537	0.0324	0.2	0.16	Childhood ear infection;	chr2:63599798	chr2:63117851~63119542:-
THCA	cis	rs2455799	0.613	rs13071730	ENSG00000270409.1	RP11-44D5.1	-3.49	0.000537	0.0324	-0.17	-0.16	Mean platelet volume;	chr3:15849528	chr3:15732252~15733470:+
THCA	cis	rs4589258	0.788	rs1792616	ENSG00000280367.1	RP11-121L10.2	3.49	0.000538	0.0324	0.15	0.16	Intelligence (multi-trait analysis);	chr11:90719058	chr11:90223153~90226538:+
THCA	cis	rs36132109	0.858	rs13078406	ENSG00000273328.4	RP11-141M3.6	3.49	0.000538	0.0324	0.21	0.16	Monocyte chemoattractant protein-1 levels;	chr3:42982513	chr3:42809414~42908105:+
THCA	cis	rs4262150	0.81	rs72799113	ENSG00000253921.1	CTB-113P19.3	3.49	0.000538	0.0324	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152676302	chr5:151753992~151767247:+
THCA	cis	rs959260	1	rs12604003	ENSG00000263843.1	RP11-649A18.12	3.49	0.000538	0.0324	0.18	0.16	Systemic lupus erythematosus;	chr17:75403517	chr17:75271369~75273895:+
THCA	cis	rs3749237	0.595	rs11130192	ENSG00000224424.7	PRKAR2A-AS1	3.49	0.000538	0.0324	0.13	0.16	Resting heart rate;	chr3:49429773	chr3:48847572~48851981:+
THCA	cis	rs13096760	1	rs13096760	ENSG00000224424.7	PRKAR2A-AS1	3.49	0.000538	0.0324	0.13	0.16	Intelligence (multi-trait analysis);	chr3:49439373	chr3:48847572~48851981:+
THCA	cis	rs12681963	0.688	rs4733444	ENSG00000272375.1	RP11-51J9.6	3.49	0.000538	0.0324	0.23	0.16	Migraine;	chr8:30218739	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs1566741	ENSG00000272375.1	RP11-51J9.6	3.49	0.000538	0.0324	0.23	0.16	Migraine;	chr8:30220913	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs1566738	ENSG00000272375.1	RP11-51J9.6	3.49	0.000538	0.0324	0.23	0.16	Migraine;	chr8:30221355	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs4733447	ENSG00000272375.1	RP11-51J9.6	3.49	0.000538	0.0324	0.23	0.16	Migraine;	chr8:30221526	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs4733451	ENSG00000272375.1	RP11-51J9.6	3.49	0.000538	0.0324	0.23	0.16	Migraine;	chr8:30221825	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.545	rs11994172	ENSG00000272375.1	RP11-51J9.6	3.49	0.000538	0.0324	0.23	0.16	Migraine;	chr8:30222043	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs11994173	ENSG00000272375.1	RP11-51J9.6	3.49	0.000538	0.0324	0.23	0.16	Migraine;	chr8:30222047	chr8:30197404~30198048:+
THCA	cis	rs72675573	0.515	rs1341341	ENSG00000260971.3	RP11-504A18.1	-3.49	0.000538	0.0324	-0.15	-0.16	Monocyte count;	chr1:56266807	chr1:56248294~56258571:-
THCA	cis	rs6982240	0.514	rs72681579	ENSG00000253307.1	RP11-10J21.4	3.49	0.000538	0.0324	0.23	0.16	Tonsillectomy;	chr8:141252975	chr8:141252286~141253292:-
THCA	cis	rs67340775	0.541	rs200973	ENSG00000272009.1	RP1-313I6.12	-3.49	0.000538	0.0325	-0.21	-0.16	Lung cancer in ever smokers;	chr6:27890643	chr6:28078792~28081130:-
THCA	cis	rs4218	0.588	rs9788719	ENSG00000259732.1	RP11-59H7.3	-3.49	0.000538	0.0325	-0.21	-0.16	Social communication problems;	chr15:59028920	chr15:59121034~59133250:+
THCA	cis	rs2115630	0.967	rs11073731	ENSG00000259295.5	CSPG4P12	-3.49	0.000538	0.0325	-0.21	-0.16	P wave terminal force;	chr15:84811882	chr15:85191438~85213905:+
THCA	cis	rs2115630	1	rs8037423	ENSG00000259295.5	CSPG4P12	-3.49	0.000538	0.0325	-0.21	-0.16	P wave terminal force;	chr15:84812263	chr15:85191438~85213905:+
THCA	cis	rs7819412	0.818	rs11989439	ENSG00000261451.1	RP11-981G7.1	-3.49	0.000538	0.0325	-0.2	-0.16	Triglycerides;	chr8:11198088	chr8:10433672~10438312:+
THCA	cis	rs9596863	0.898	rs9568901	ENSG00000136149.6	RPL13AP25	-3.49	0.000538	0.0325	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53747613	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs67601073	ENSG00000136149.6	RPL13AP25	-3.49	0.000538	0.0325	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53748061	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs9596847	ENSG00000136149.6	RPL13AP25	-3.49	0.000538	0.0325	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53748115	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs4573825	ENSG00000136149.6	RPL13AP25	-3.49	0.000538	0.0325	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53750741	chr13:54440704~54441315:-
THCA	cis	rs8114671	0.869	rs2038503	ENSG00000126005.14	MMP24-AS1	3.49	0.000538	0.0325	0.15	0.16	Height;	chr20:35088097	chr20:35216462~35278131:-
THCA	cis	rs6012953	1	rs932420	ENSG00000232043.1	RP4-530I15.9	3.49	0.000538	0.0325	0.11	0.16	Vitiligo;	chr20:50516532	chr20:50570975~50578041:-
THCA	cis	rs3738443	0.678	rs4314914	ENSG00000259865.1	RP11-488L18.10	3.49	0.000538	0.0325	0.14	0.16	Alcohol dependence;	chr1:247210326	chr1:247187281~247188526:-
THCA	cis	rs73222236	0.825	rs9819496	ENSG00000273486.1	RP11-731C17.2	3.49	0.000538	0.0325	0.14	0.16	Coronary artery disease;	chr3:136421036	chr3:136837338~136839021:-
THCA	cis	rs1124769	0.871	rs17646461	ENSG00000259378.1	DCAF13P3	3.49	0.000538	0.0325	0.25	0.16	Cognitive performance;	chr15:50865913	chr15:50944663~50945996:+
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000264242.2	RP11-271K11.1	3.49	0.000538	0.0325	0.24	0.16	Body mass index;	chr17:30752751	chr17:30553697~30558962:+
THCA	cis	rs1876905	0.569	rs354542	ENSG00000271789.1	RP5-1112D6.7	-3.49	0.000538	0.0325	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111297126~111298510:+
THCA	cis	rs1876905	0.68	rs1216020	ENSG00000271789.1	RP5-1112D6.7	-3.49	0.000538	0.0325	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111297126~111298510:+
THCA	cis	rs1876905	0.569	rs354541	ENSG00000271789.1	RP5-1112D6.7	-3.49	0.000538	0.0325	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111297126~111298510:+
THCA	cis	rs1876905	0.68	rs354537	ENSG00000271789.1	RP5-1112D6.7	-3.49	0.000538	0.0325	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111297126~111298510:+
THCA	cis	rs1876905	0.68	rs354536	ENSG00000271789.1	RP5-1112D6.7	-3.49	0.000538	0.0325	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111297126~111298510:+
THCA	cis	rs1876905	0.68	rs1215848	ENSG00000271789.1	RP5-1112D6.7	-3.49	0.000538	0.0325	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111297126~111298510:+
THCA	cis	rs7809615	0.515	rs11772470	ENSG00000274272.1	RP11-44M6.7	3.49	0.000538	0.0325	0.17	0.16	Blood metabolite ratios;	chr7:99583473	chr7:100572232~100578700:-
THCA	cis	rs10861661	0.963	rs10778511	ENSG00000260329.1	RP11-412D9.4	-3.48	0.000538	0.0325	-0.17	-0.16	Triglyceride levels;	chr12:106831553	chr12:106954029~106955497:-
THCA	cis	rs14027	0.883	rs1433953	ENSG00000245330.4	KB-1471A8.1	3.48	0.000538	0.0325	0.16	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704754	chr8:119867419~119874488:-
THCA	cis	rs5762813	0.566	rs4055	ENSG00000272858.1	CTA-292E10.8	-3.48	0.000538	0.0325	-0.2	-0.16	Hematocrit;Hemoglobin concentration;	chr22:28956507	chr22:28814914~28815662:+
THCA	cis	rs755249	0.546	rs7533743	ENSG00000237624.1	OXCT2P1	-3.48	0.000538	0.0325	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39514956~39516490:+
THCA	cis	rs755249	0.565	rs7555699	ENSG00000237624.1	OXCT2P1	-3.48	0.000538	0.0325	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39514956~39516490:+
THCA	cis	rs755249	0.565	rs1809697	ENSG00000237624.1	OXCT2P1	-3.48	0.000538	0.0325	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39493413	chr1:39514956~39516490:+
THCA	cis	rs2281603	0.521	rs6573559	ENSG00000258824.2	CTD-2555O16.2	-3.48	0.000538	0.0325	-0.14	-0.16	Lymphocyte counts;	chr14:64456448	chr14:64422935~64448557:-
THCA	cis	rs7192750	0.586	rs6499551	ENSG00000260886.1	TAT-AS1	3.48	0.000538	0.0325	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71909204	chr16:71565789~71578187:+
THCA	cis	rs345013	0.92	rs56676916	ENSG00000240032.1	RP11-274H2.3	3.48	0.000539	0.0325	0.25	0.16	Prostate cancer;	chr3:145268437	chr3:146066344~146069185:-
THCA	cis	rs4908760	0.827	rs11121210	ENSG00000270282.1	RP5-1115A15.2	3.48	0.000539	0.0325	0.19	0.16	Vitiligo;	chr1:8648470	chr1:8512653~8513021:+
THCA	cis	rs6743226	0.603	rs62186421	ENSG00000223374.1	AC005104.3	3.48	0.000539	0.0325	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241309357	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.58	rs12619620	ENSG00000223374.1	AC005104.3	3.48	0.000539	0.0325	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241310679	chr2:241351340~241353104:-
THCA	cis	rs7208859	0.673	rs216435	ENSG00000265443.1	CTD-2349P21.6	-3.48	0.000539	0.0325	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30726305~30727564:-
THCA	cis	rs877529	0.647	rs139395	ENSG00000280216.1	RP3-333H23.9	-3.48	0.000539	0.0325	-0.18	-0.16	Multiple myeloma;	chr22:39142428	chr22:39379610~39380015:+
THCA	cis	rs1065852	0.526	rs9607869	ENSG00000281538.1	RP4-669P10.20	-3.48	0.000539	0.0325	-0.17	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42022106	chr22:42138060~42139726:+
THCA	cis	rs332034	0.546	rs10094026	ENSG00000254153.1	CTA-398F10.2	3.48	0.000539	0.0325	0.25	0.16	Conduct disorder (maternal expressed emotions interaction);	chr8:8788928	chr8:8456909~8461337:-
THCA	cis	rs17122278	1	rs17092756	ENSG00000243431.1	RPL5P30	3.48	0.000539	0.0325	0.16	0.16	Total cholesterol levels;	chr11:118586915	chr11:118560690~118561580:+
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000184274.3	LINC00315	-3.48	0.000539	0.0325	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45300245~45305257:-
THCA	cis	rs12935418	0.616	rs12446053	ENSG00000261838.4	RP11-303E16.6	-3.48	0.000539	0.0325	-0.21	-0.16	Mean corpuscular volume;	chr16:80930234	chr16:81069854~81076598:+
THCA	cis	rs3864261	0.887	rs268795	ENSG00000249085.1	CTD-2631K10.1	3.48	0.000539	0.0325	0.24	0.16	Discordance in emotional problems in monozygotic twins;	chr5:72904804	chr5:72794405~72816565:-
THCA	cis	rs2797160	1	rs1739378	ENSG00000226409.1	RP11-735G4.1	3.48	0.000539	0.0325	0.19	0.16	Endometrial cancer;	chr6:125691116	chr6:125370211~125374324:-
THCA	cis	rs1873147	0.569	rs58819603	ENSG00000259672.1	RP11-69G7.1	-3.48	0.000539	0.0325	-0.2	-0.16	Orofacial clefts;	chr15:63018667	chr15:63098870~63110403:+
THCA	cis	rs1873147	0.569	rs59418037	ENSG00000259672.1	RP11-69G7.1	-3.48	0.000539	0.0325	-0.2	-0.16	Orofacial clefts;	chr15:63018672	chr15:63098870~63110403:+
THCA	cis	rs6456156	0.586	rs12203510	ENSG00000235272.1	FAM103A2P	3.48	0.000539	0.0325	0.22	0.16	Primary biliary cholangitis;	chr6:167059518	chr6:166586124~166586477:-
THCA	cis	rs1455213	0.544	rs2604555	ENSG00000249252.4	RP11-665G4.1	3.48	0.000539	0.0325	0.21	0.16	Parental longevity (mother's age at death);	chr4:15166612	chr4:15004942~15427914:-
THCA	cis	rs1455213	0.544	rs2702559	ENSG00000249252.4	RP11-665G4.1	3.48	0.000539	0.0325	0.21	0.16	Parental longevity (mother's age at death);	chr4:15167361	chr4:15004942~15427914:-
THCA	cis	rs4808199	0.895	rs2163805	ENSG00000267481.1	CTC-559E9.5	-3.48	0.000539	0.0325	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19465136	chr19:19788755~19790531:-
THCA	cis	rs4808199	0.947	rs2163804	ENSG00000267481.1	CTC-559E9.5	-3.48	0.000539	0.0325	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19465156	chr19:19788755~19790531:-
THCA	cis	rs7560272	0.501	rs11126417	ENSG00000273245.1	RP11-434P11.2	3.48	0.000539	0.0325	0.19	0.16	Schizophrenia;	chr2:73747188	chr2:73750256~73750786:-
THCA	cis	rs8105895	1	rs75167249	ENSG00000269345.1	VN1R85P	3.48	0.000539	0.0325	0.22	0.16	Body mass index (change over time);	chr19:21945853	chr19:22174766~22175191:-
THCA	cis	rs397969	0.646	rs8079923	ENSG00000261033.1	RP11-209D14.2	-3.48	0.000539	0.0325	-0.23	-0.16	Platelet count;	chr17:19966231	chr17:20008051~20009234:-
THCA	cis	rs4730276	0.674	rs34822274	ENSG00000250474.1	WBP1LP2	-3.48	0.000539	0.0325	-0.15	-0.16	Ulcerative colitis;	chr7:107893687	chr7:107628553~107629498:+
THCA	cis	rs4763879	0.634	rs11052582	ENSG00000214776.8	RP11-726G1.1	-3.48	0.000539	0.0325	-0.19	-0.16	Type 1 diabetes;	chr12:9706714	chr12:9467552~9576275:+
THCA	cis	rs12101261	0.744	rs2268458	ENSG00000258915.1	BHLHB9P1	-3.48	0.000539	0.0325	-0.21	-0.16	Graves' disease;	chr14:80996551	chr14:80981988~80983638:+
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000230373.7	GOLGA6L5P	-3.48	0.000539	0.0325	-0.15	-0.16	P wave terminal force;	chr15:84631400	chr15:84507885~84516814:-
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000230373.7	GOLGA6L5P	-3.48	0.000539	0.0325	-0.15	-0.16	P wave terminal force;	chr15:84631524	chr15:84507885~84516814:-
THCA	cis	rs721917	0.506	rs2819102	ENSG00000272489.1	RP11-182L21.5	-3.48	0.000539	0.0325	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79663192~79664786:+
THCA	cis	rs6687821	0.531	rs4357505	ENSG00000261737.1	RP4-612B15.3	-3.48	0.000539	0.0325	-0.25	-0.16	Yeast infection;	chr1:87018785	chr1:86703502~86704462:-
THCA	cis	rs755249	0.614	rs10888798	ENSG00000237624.1	OXCT2P1	-3.48	0.000539	0.0325	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39492408	chr1:39514956~39516490:+
THCA	cis	rs72928364	0.86	rs13086519	ENSG00000256628.3	ZBTB11-AS1	3.48	0.000539	0.0325	0.28	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101085997	chr3:101676475~101679217:+
THCA	cis	rs11800820	0.521	rs3120699	ENSG00000231612.1	RP11-522M21.3	-3.48	0.000539	0.0325	-0.21	-0.16	Obesity-related traits;	chr1:246542207	chr1:245673732~245676478:-
THCA	cis	rs3930017	1	rs7783809	ENSG00000265479.4	DTX2P1-UPK3BP1-PMS2P11	3.48	0.000539	0.0325	0.17	0.16	Body mass index;	chr7:77090234	chr7:76980949~77043775:+
THCA	cis	rs6598541	0.832	rs8032477	ENSG00000278090.1	RP11-6O2.2	-3.48	0.000539	0.0325	-0.14	-0.16	Urate levels;	chr15:98711325	chr15:99028538~99031053:+
THCA	cis	rs62025270	0.547	rs1026722	ENSG00000202081.1	RNU6-1280P	3.48	0.000539	0.0325	0.24	0.16	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85651522~85651628:-
THCA	cis	rs2115630	0.791	rs2008262	ENSG00000259295.5	CSPG4P12	-3.48	0.000539	0.0325	-0.21	-0.16	P wave terminal force;	chr15:84762039	chr15:85191438~85213905:+
THCA	cis	rs8053891	0.673	rs35338546	ENSG00000262140.1	RP11-417N10.3	3.48	0.000539	0.0325	0.21	0.16	Coronary artery disease;	chr16:71988257	chr16:71833787~71835932:+
THCA	cis	rs14027	0.843	rs6469849	ENSG00000279347.1	RP11-85I17.2	-3.48	0.000539	0.0325	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119838736~119840385:-
THCA	cis	rs688181	0.621	rs1885452	ENSG00000271040.1	RP5-933K21.3	3.48	0.000539	0.0325	0.2	0.16	Platelet distribution width;	chr6:157678285	chr6:157323964~157324477:+
THCA	cis	rs1171113	0.657	rs217346	ENSG00000219951.4	RP11-378G13.2	-3.48	0.000539	0.0325	-0.19	-0.16	Bipolar disorder with mood-incongruent psychosis;	chr6:83624641	chr6:83392416~83393409:+
THCA	cis	rs1729951	0.575	rs835641	ENSG00000239213.4	NCK1-AS1	3.48	0.000539	0.0325	0.14	0.16	Neuroticism;	chr3:136984632	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs16844362	ENSG00000239213.4	NCK1-AS1	3.48	0.000539	0.0325	0.14	0.16	Neuroticism;	chr3:136985166	chr3:136841726~136862054:-
THCA	cis	rs2446066	0.872	rs74090765	ENSG00000257379.1	RP11-793H13.8	3.48	0.000539	0.0325	0.23	0.16	Red blood cell count;	chr12:53399130	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.872	rs34148420	ENSG00000257379.1	RP11-793H13.8	3.48	0.000539	0.0325	0.23	0.16	Red blood cell count;	chr12:53405024	chr12:53441741~53467528:+
THCA	cis	rs7129556	0.775	rs17752006	ENSG00000254459.1	RP11-91P24.7	3.48	0.00054	0.0325	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77682948	chr11:77829654~77872262:-
THCA	cis	rs1560104	0.675	rs9927256	ENSG00000259876.1	CTD-3037G24.4	3.48	0.00054	0.0325	0.18	0.16	Obesity-related traits;	chr16:12611158	chr16:12556353~12557694:-
THCA	cis	rs11637445	0.627	rs4776988	ENSG00000260657.2	RP11-315D16.4	-3.48	0.00054	0.0325	-0.2	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67831813	chr15:68267792~68277994:-
THCA	cis	rs4662750	0.536	rs4662744	ENSG00000236682.1	AC068282.3	3.48	0.00054	0.0325	0.2	0.16	Renal cell carcinoma;	chr2:127593390	chr2:127389130~127400580:+
THCA	cis	rs267567	0.647	rs155525	ENSG00000235257.7	ITGA9-AS1	3.48	0.00054	0.0325	0.14	0.16	PR interval;	chr3:37522222	chr3:37745432~37861780:-
THCA	cis	rs5758511	0.68	rs5758698	ENSG00000205702.9	CYP2D7	3.48	0.00054	0.0325	0.14	0.16	Birth weight;	chr22:42288812	chr22:42140203~42144577:-
THCA	cis	rs7216064	0.953	rs4791048	ENSG00000278740.1	RP11-147L13.14	3.48	0.00054	0.0325	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852878	chr17:68188547~68189165:+
THCA	cis	rs720064	0.586	rs9950879	ENSG00000264745.1	TTC39C-AS1	3.48	0.00054	0.0325	0.17	0.16	Strep throat;	chr18:23965115	chr18:23994213~24015339:-
THCA	cis	rs7973719	0.865	rs12228393	ENSG00000205885.6	C1RL-AS1	-3.48	0.00054	0.0325	-0.12	-0.16	IgG glycosylation;	chr12:7215586	chr12:7108052~7122501:+
THCA	cis	rs9374842	1	rs9374842	ENSG00000253194.1	RP11-351A11.1	3.48	0.00054	0.0325	0.25	0.16	Body mass index;	chr6:119864519	chr6:118934785~119031541:+
THCA	cis	rs9905704	0.918	rs9891129	ENSG00000224738.1	AC099850.1	-3.48	0.00054	0.0325	-0.22	-0.16	Testicular germ cell tumor;	chr17:58553113	chr17:59106598~59118267:+
THCA	cis	rs9905704	1	rs9905704	ENSG00000224738.1	AC099850.1	-3.48	0.00054	0.0325	-0.22	-0.16	Testicular germ cell tumor;	chr17:58555182	chr17:59106598~59118267:+
THCA	cis	rs8054556	0.967	rs11150576	ENSG00000214725.6	CDIPT-AS1	-3.48	0.00054	0.0325	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29954175	chr16:29863593~29868053:+
THCA	cis	rs1858037	0.765	rs67404371	ENSG00000252414.1	RNU6-100P	-3.48	0.00054	0.0325	-0.18	-0.16	Rheumatoid arthritis;	chr2:65370137	chr2:64578892~64578997:+
THCA	cis	rs55702914	0.539	rs787990	ENSG00000231621.1	AC013264.2	-3.48	0.00054	0.0325	-0.15	-0.16	Major depression and alcohol dependence;	chr2:197460266	chr2:197197991~197199273:+
THCA	cis	rs7045881	0.736	rs2184740	ENSG00000254396.1	RP11-56F10.3	3.48	0.00054	0.0326	0.25	0.16	Schizophrenia;	chr9:26933294	chr9:27102630~27104728:+
THCA	cis	rs12612619	0.732	rs7560144	ENSG00000231636.1	AGBL5-AS1	3.48	0.00054	0.0326	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057592	chr2:27049683~27050264:-
THCA	cis	rs2227564	0.672	rs2461864	ENSG00000271816.1	BMS1P4	3.48	0.00054	0.0326	0.17	0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73900114	chr10:73699151~73730487:-
THCA	cis	rs6921919	0.789	rs17301128	ENSG00000273712.1	RP5-874C20.7	3.48	0.00054	0.0326	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28315613~28315883:-
THCA	cis	rs4073416	0.542	rs7143318	ENSG00000276116.2	FUT8-AS1	3.48	0.00054	0.0326	0.18	0.16	N-glycan levels;	chr14:65473971	chr14:65411170~65412690:-
THCA	cis	rs8187707	0.568	rs3740065	ENSG00000233690.1	EBAG9P1	3.48	0.00054	0.0326	0.21	0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99845936	chr10:99697407~99697949:-
THCA	cis	rs17689437	0.56	rs12449205	ENSG00000260084.1	RP11-615I2.1	3.48	0.00054	0.0326	0.18	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68632783	chr16:68573782~68589512:-
THCA	cis	rs9596863	0.898	rs35732706	ENSG00000136149.6	RPL13AP25	-3.48	0.00054	0.0326	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53769751	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs8000553	ENSG00000136149.6	RPL13AP25	-3.48	0.00054	0.0326	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53770366	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs8000371	ENSG00000136149.6	RPL13AP25	-3.48	0.00054	0.0326	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53770367	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs7984502	ENSG00000136149.6	RPL13AP25	-3.48	0.00054	0.0326	-0.18	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53770505	chr13:54440704~54441315:-
THCA	cis	rs6957923	0.818	rs7810773	ENSG00000234286.1	AC006026.13	-3.48	0.00054	0.0326	-0.21	-0.16	Height;	chr7:23480485	chr7:23680195~23680786:-
THCA	cis	rs7412746	0.587	rs11204722	ENSG00000224800.1	RP11-235D19.2	3.48	0.00054	0.0326	0.22	0.16	Melanoma;	chr1:150757708	chr1:150881236~150881683:-
THCA	cis	rs6732426	0.55	rs6544647	ENSG00000234936.1	AC010883.5	3.48	0.00054	0.0326	0.13	0.16	Hair morphology;	chr2:43351280	chr2:43229573~43233394:+
THCA	cis	rs4081724	0.638	rs10518275	ENSG00000267296.2	CEBPA-AS1	3.48	0.00054	0.0326	0.2	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33359935	chr19:33302857~33305054:+
THCA	cis	rs773506	0.863	rs2482338	ENSG00000229694.5	RP11-305L7.6	3.48	0.00054	0.0326	0.19	0.16	Type 2 diabetes nephropathy;	chr9:91275591	chr9:91119062~91182762:+
THCA	cis	rs8028182	0.636	rs8028277	ENSG00000275645.1	RP11-817O13.9	3.48	0.00054	0.0326	0.16	0.16	Sudden cardiac arrest;	chr15:75391744	chr15:75346744~75347161:-
THCA	cis	rs3808502	0.526	rs1042701	ENSG00000206014.6	OR7E161P	3.48	0.00054	0.0326	0.19	0.16	Neuroticism;	chr8:11564536	chr8:11928597~11929563:-
THCA	cis	rs3808502	0.526	rs7843987	ENSG00000206014.6	OR7E161P	3.48	0.00054	0.0326	0.19	0.16	Neuroticism;	chr8:11564621	chr8:11928597~11929563:-
THCA	cis	rs59901009	0.577	rs7932484	ENSG00000246273.5	SBF2-AS1	-3.48	0.00054	0.0326	-0.21	-0.16	Hematocrit;Hemoglobin concentration;	chr11:10003336	chr11:9758292~9811319:+
THCA	cis	rs10863936	0.579	rs112948521	ENSG00000198468.6	FLVCR1-AS1	-3.48	0.00054	0.0326	-0.19	-0.16	Height;	chr1:211941324	chr1:212852108~212858088:-
THCA	cis	rs11718502	0.66	rs11717603	ENSG00000232354.6	VIPR1-AS1	3.48	0.00054	0.0326	0.19	0.16	Magnesium levels;	chr3:42451021	chr3:42506465~42533258:-
THCA	cis	rs237743	1	rs237741	ENSG00000222365.1	SNORD12B	-3.48	0.00054	0.0326	-0.2	-0.16	Height;	chr20:49287143	chr20:49280319~49280409:+
THCA	cis	rs237743	1	rs13038621	ENSG00000222365.1	SNORD12B	-3.48	0.00054	0.0326	-0.2	-0.16	Height;	chr20:49291523	chr20:49280319~49280409:+
THCA	cis	rs1832871	0.655	rs6920121	ENSG00000213078.3	RP5-933K21.2	3.48	0.00054	0.0326	0.24	0.16	Height;	chr6:158257472	chr6:157365990~157366923:-
THCA	cis	rs1491818	0.545	rs4923593	ENSG00000249867.4	RP11-115J23.1	3.48	0.00054	0.0326	0.17	0.16	Amyotrophic lateral sclerosis (age of onset);	chr11:29146112	chr11:28702615~29063821:+
THCA	cis	rs7259376	0.875	rs4932755	ENSG00000269138.1	ZNF209P	3.48	0.00054	0.0326	0.16	0.16	Menopause (age at onset);	chr19:22312014	chr19:22463922~22473036:+
THCA	cis	rs11168936	1	rs11168936	ENSG00000257464.1	RP11-161H23.8	-3.48	0.000541	0.0326	-0.17	-0.16	Cancer (pleiotropy);	chr12:49251457	chr12:49442424~49442652:-
THCA	cis	rs7412746	0.658	rs7526489	ENSG00000224800.1	RP11-235D19.2	-3.48	0.000541	0.0326	-0.22	-0.16	Melanoma;	chr1:150753762	chr1:150881236~150881683:-
THCA	cis	rs10938353	0.911	rs4330385	ENSG00000273369.1	RP11-700J17.1	-3.48	0.000541	0.0326	-0.17	-0.16	Body mass index;	chr4:44585482	chr4:44693946~44694386:-
THCA	cis	rs10938353	0.911	rs4504296	ENSG00000273369.1	RP11-700J17.1	-3.48	0.000541	0.0326	-0.17	-0.16	Body mass index;	chr4:44585515	chr4:44693946~44694386:-
THCA	cis	rs1150668	0.764	rs9368565	ENSG00000220721.1	OR1F12	-3.48	0.000541	0.0326	-0.18	-0.16	Pubertal anthropometrics;	chr6:28377433	chr6:28073316~28074233:+
THCA	cis	rs773506	0.692	rs12238485	ENSG00000235641.4	LINC00484	-3.48	0.000541	0.0326	-0.21	-0.16	Type 2 diabetes nephropathy;	chr9:91198670	chr9:91159573~91165658:+
THCA	cis	rs1124769	0.871	rs17646461	ENSG00000244879.4	GABPB1-AS1	-3.48	0.000541	0.0326	-0.17	-0.16	Cognitive performance;	chr15:50865913	chr15:50354959~50372202:+
THCA	cis	rs12817549	0.817	rs7954185	ENSG00000186076.5	RP11-887P2.3	3.48	0.000541	0.0326	0.18	0.16	Hip circumference adjusted for BMI;	chr12:93702397	chr12:93640822~93641586:-
THCA	cis	rs12817549	0.817	rs2033669	ENSG00000186076.5	RP11-887P2.3	-3.48	0.000541	0.0326	-0.18	-0.16	Hip circumference adjusted for BMI;	chr12:93705713	chr12:93640822~93641586:-
THCA	cis	rs12817549	0.817	rs9308296	ENSG00000186076.5	RP11-887P2.3	-3.48	0.000541	0.0326	-0.18	-0.16	Hip circumference adjusted for BMI;	chr12:93708678	chr12:93640822~93641586:-
THCA	cis	rs2797160	1	rs2211418	ENSG00000226409.1	RP11-735G4.1	-3.48	0.000541	0.0326	-0.19	-0.16	Endometrial cancer;	chr6:125674357	chr6:125370211~125374324:-
THCA	cis	rs6427356	1	rs1176546	ENSG00000237189.1	RP11-85G21.2	3.48	0.000541	0.0326	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157164026	chr1:157287703~157288053:-
THCA	cis	rs6427356	0.956	rs1176547	ENSG00000237189.1	RP11-85G21.2	3.48	0.000541	0.0326	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157164036	chr1:157287703~157288053:-
THCA	cis	rs721917	0.525	rs2758545	ENSG00000272489.1	RP11-182L21.5	-3.48	0.000541	0.0326	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79663192~79664786:+
THCA	cis	rs2562456	0.755	rs1879234	ENSG00000268658.4	LINC00664	-3.48	0.000541	0.0326	-0.23	-0.16	Pain;	chr19:21521677	chr19:21483374~21503238:+
THCA	cis	rs1926657	1	rs7139533	ENSG00000223298.1	RNY3P8	-3.48	0.000541	0.0326	-0.21	-0.16	Breast cancer;	chr13:95213321	chr13:95310830~95310955:-
THCA	cis	rs9650657	0.899	rs9650656	ENSG00000255310.2	AF131215.2	-3.48	0.000541	0.0326	-0.13	-0.16	Neuroticism;	chr8:10749744	chr8:11107788~11109726:-
THCA	cis	rs10090774	0.965	rs12680723	ENSG00000280303.2	ERICD	-3.48	0.000541	0.0326	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140984704	chr8:140636281~140638283:+
THCA	cis	rs11157436	0.918	rs1983522	ENSG00000211812.1	TRAV26-2	-3.48	0.000541	0.0326	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150588	chr14:22202583~22203368:+
THCA	cis	rs11157436	0.918	rs12586393	ENSG00000211812.1	TRAV26-2	-3.48	0.000541	0.0326	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150815	chr14:22202583~22203368:+
THCA	cis	rs11157436	0.918	rs2178788	ENSG00000211812.1	TRAV26-2	-3.48	0.000541	0.0326	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150916	chr14:22202583~22203368:+
THCA	cis	rs2980439	0.818	rs2948294	ENSG00000233609.3	RP11-62H7.2	3.48	0.000541	0.0326	0.15	0.16	Neuroticism;	chr8:8237439	chr8:8961200~8979025:+
THCA	cis	rs7147624	0.572	rs2411813	ENSG00000276116.2	FUT8-AS1	3.48	0.000541	0.0326	0.28	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65557188	chr14:65411170~65412690:-
THCA	cis	rs7824557	0.564	rs2572400	ENSG00000227888.4	FAM66A	-3.48	0.000541	0.0326	-0.2	-0.16	Retinal vascular caliber;	chr8:11376858	chr8:12362019~12388296:+
THCA	cis	rs4262150	0.774	rs4958326	ENSG00000253921.1	CTB-113P19.3	3.48	0.000541	0.0326	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152673917	chr5:151753992~151767247:+
THCA	cis	rs7131987	1	rs7131987	ENSG00000275476.1	RP11-996F15.4	-3.48	0.000541	0.0326	-0.15	-0.16	QT interval;	chr12:29253555	chr12:29277397~29277882:-
THCA	cis	rs2919009	0.825	rs7099949	ENSG00000271670.1	RP11-95I16.4	3.48	0.000541	0.0326	0.19	0.16	Obesity-related traits;	chr10:120839119	chr10:120879256~120880667:-
THCA	cis	rs11673344	0.566	rs10419281	ENSG00000268499.1	CTB-102L5.8	3.48	0.000541	0.0326	0.16	0.16	Obesity-related traits;	chr19:37459351	chr19:38199836~38200934:+
THCA	cis	rs16918636	0.541	rs16918760	ENSG00000249867.4	RP11-115J23.1	-3.48	0.000541	0.0326	-0.23	-0.16	Menarche (age at onset);	chr11:29171006	chr11:28702615~29063821:+
THCA	cis	rs13064411	0.696	rs6768648	ENSG00000243849.1	CFAP44-AS1	3.48	0.000541	0.0326	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113515294	chr3:113403991~113433992:+
THCA	cis	rs5006884	1	rs71488545	ENSG00000167355.6	AC104389.28	-3.48	0.000541	0.0326	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5367509	chr11:5304976~5505652:-
THCA	cis	rs5006884	1	rs4910774	ENSG00000167355.6	AC104389.28	-3.48	0.000541	0.0326	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5371314	chr11:5304976~5505652:-
THCA	cis	rs13064773	0.502	rs340250	ENSG00000240207.5	RP11-379F4.4	3.48	0.000541	0.0326	0.18	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158882862	chr3:158732263~158784070:+
THCA	cis	rs13064773	0.546	rs340246	ENSG00000240207.5	RP11-379F4.4	3.48	0.000541	0.0326	0.18	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158884079	chr3:158732263~158784070:+
THCA	cis	rs7824557	0.628	rs11777746	ENSG00000255052.4	FAM66D	-3.48	0.000541	0.0326	-0.21	-0.16	Retinal vascular caliber;	chr8:11347246	chr8:12115782~12177550:+
THCA	cis	rs1665050	0.545	rs59540276	ENSG00000259732.1	RP11-59H7.3	-3.48	0.000541	0.0326	-0.22	-0.16	Atopic dermatitis;	chr15:59037559	chr15:59121034~59133250:+
THCA	cis	rs2055729	0.677	rs6601389	ENSG00000261451.1	RP11-981G7.1	3.48	0.000541	0.0326	0.22	0.16	Multiple myeloma (hyperdiploidy);	chr8:9883126	chr8:10433672~10438312:+
THCA	cis	rs3755605	0.664	rs6809704	ENSG00000242578.1	RP11-469J4.3	3.48	0.000541	0.0326	0.18	0.16	Testicular germ cell tumor;	chr3:170194960	chr3:170410512~170418615:+
THCA	cis	rs10129255	1	rs10134517	ENSG00000280411.1	IGHV1-69-2	-3.48	0.000541	0.0326	-0.1	-0.16	Kawasaki disease;	chr14:106718498	chr14:106762092~106762588:-
THCA	cis	rs10832963	0.924	rs10832950	ENSG00000256361.1	RP11-613F22.6	3.48	0.000541	0.0326	0.2	0.16	Breast cancer;	chr11:18614268	chr11:18511043~18511475:-
THCA	cis	rs10832963	1	rs4757676	ENSG00000256361.1	RP11-613F22.6	3.48	0.000541	0.0326	0.2	0.16	Breast cancer;	chr11:18618930	chr11:18511043~18511475:-
THCA	cis	rs9889262	0.625	rs12150526	ENSG00000248714.5	RP11-1079K10.3	-3.48	0.000541	0.0326	-0.17	-0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49366218	chr17:49361165~49369998:+
THCA	cis	rs10824518	0.744	rs10824537	ENSG00000199664.1	RNU6-1266P	3.48	0.000541	0.0326	0.2	0.16	Myopia;	chr10:77392722	chr10:77776951~77777055:-
THCA	cis	rs6545883	0.929	rs3821222	ENSG00000212978.6	AC016747.3	3.48	0.000541	0.0326	0.18	0.16	Tuberculosis;	chr2:61486391	chr2:61141592~61144969:-
THCA	cis	rs1357692	0.899	rs1357694	ENSG00000238250.1	ST6GAL2-IT1	-3.48	0.000541	0.0326	-0.16	-0.16	Alzheimer's disease;	chr2:107062213	chr2:106822923~106825031:-
THCA	cis	rs1357692	0.836	rs1916920	ENSG00000238250.1	ST6GAL2-IT1	-3.48	0.000541	0.0326	-0.16	-0.16	Alzheimer's disease;	chr2:107062542	chr2:106822923~106825031:-
THCA	cis	rs1357692	0.899	rs2030674	ENSG00000238250.1	ST6GAL2-IT1	-3.48	0.000541	0.0326	-0.16	-0.16	Alzheimer's disease;	chr2:107062780	chr2:106822923~106825031:-
THCA	cis	rs1357692	0.899	rs1916921	ENSG00000238250.1	ST6GAL2-IT1	-3.48	0.000541	0.0326	-0.16	-0.16	Alzheimer's disease;	chr2:107062839	chr2:106822923~106825031:-
THCA	cis	rs7615952	0.866	rs1976459	ENSG00000248787.1	RP11-666A20.4	-3.48	0.000541	0.0326	-0.27	-0.16	Blood pressure (smoking interaction);	chr3:125928643	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.932	rs1976458	ENSG00000248787.1	RP11-666A20.4	-3.48	0.000541	0.0326	-0.27	-0.16	Blood pressure (smoking interaction);	chr3:125928669	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.673	rs3811677	ENSG00000248787.1	RP11-666A20.4	-3.48	0.000541	0.0326	-0.27	-0.16	Blood pressure (smoking interaction);	chr3:125929237	chr3:125908005~125910272:-
THCA	cis	rs934734	0.571	rs7572922	ENSG00000214533.3	KRT18P33	-3.48	0.000541	0.0326	-0.2	-0.16	Rheumatoid arthritis;	chr2:65425022	chr2:65666695~65667737:+
THCA	cis	rs1125355	0.69	rs62183660	ENSG00000243792.1	OR7E89P	-3.48	0.000541	0.0326	-0.23	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158782804	chr2:158853755~158854576:+
THCA	cis	rs2880765	0.835	rs6497206	ENSG00000218052.5	ADAMTS7P4	-3.48	0.000541	0.0326	-0.18	-0.16	Coronary artery disease;	chr15:85485994	chr15:85255369~85330334:-
THCA	cis	rs7989332	0.89	rs4770040	ENSG00000277020.3	RP11-476H16.1	3.48	0.000541	0.0326	0.15	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20474349	chr13:20564708~20567045:-
THCA	cis	rs8040855	0.557	rs9744503	ENSG00000259630.2	CTD-2262B20.1	3.48	0.000542	0.0326	0.18	0.16	Bulimia nervosa;	chr15:85180986	chr15:85415228~85415633:+
THCA	cis	rs6929812	0.665	rs7744110	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27453525	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs2235252	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27454714	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs12199110	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27455789	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs2092121	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27456405	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs2092122	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27456532	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs764460	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27456595	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.594	rs764461	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27456664	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.629	rs10484398	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27457181	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs1883216	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27457406	chr6:27737000~27738494:-
THCA	cis	rs2064219	0.662	rs7761989	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Depressive symptoms;Depressive symptoms (multi-trait analysis);	chr6:27458055	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs7743465	ENSG00000216915.2	RP1-97D16.1	3.48	0.000542	0.0326	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27458938	chr6:27737000~27738494:-
THCA	cis	rs972578	1	rs2256040	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000542	0.0326	-0.16	-0.16	Mean platelet volume;	chr22:43002043	chr22:42791814~42794313:-
THCA	cis	rs17853159	0.541	rs77506398	ENSG00000281912.1	LINC01144	-3.48	0.000542	0.0326	-0.22	-0.16	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45357308	chr1:45303910~45305619:+
THCA	cis	rs867186	0.764	rs78517073	ENSG00000126005.14	MMP24-AS1	-3.48	0.000542	0.0326	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35095627	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs76648234	ENSG00000126005.14	MMP24-AS1	-3.48	0.000542	0.0326	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35102138	chr20:35216462~35278131:-
THCA	cis	rs910316	0.726	rs61979167	ENSG00000273565.1	CTD-3075F15.1	-3.48	0.000542	0.0326	-0.19	-0.16	Height;	chr14:75196907	chr14:75176929~75177418:+
THCA	cis	rs453301	0.606	rs6601279	ENSG00000254340.1	RP11-10A14.3	-3.48	0.000542	0.0326	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9050721	chr8:9141424~9145435:+
THCA	cis	rs453301	0.606	rs6981060	ENSG00000254340.1	RP11-10A14.3	-3.48	0.000542	0.0326	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9050725	chr8:9141424~9145435:+
THCA	cis	rs6088813	0.961	rs878639	ENSG00000261582.1	RP4-614O4.11	-3.48	0.000542	0.0326	-0.15	-0.16	Height;	chr20:35306660	chr20:35267885~35280043:-
THCA	cis	rs11583043	0.708	rs6577227	ENSG00000233184.5	RP11-421L21.3	3.48	0.000542	0.0326	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101096576	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.708	rs12734559	ENSG00000233184.5	RP11-421L21.3	3.48	0.000542	0.0326	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101097445	chr1:101025878~101087268:+
THCA	cis	rs5753037	0.653	rs131286	ENSG00000273350.1	RP4-539M6.20	-3.48	0.000542	0.0327	-0.18	-0.16	Type 1 diabetes;	chr22:29762362	chr22:30420512~30420912:+
THCA	cis	rs4699052	1	rs4699052	ENSG00000251288.2	RP11-10L12.2	-3.48	0.000542	0.0327	-0.2	-0.16	Testicular germ cell tumor;	chr4:103216633	chr4:102751401~102752641:+
THCA	cis	rs758324	0.773	rs6870930	ENSG00000224431.1	AC063976.7	-3.48	0.000542	0.0327	-0.15	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131774432	chr5:132199456~132203487:+
THCA	cis	rs950893	0.595	rs6999833	ENSG00000253837.1	RP11-177H13.2	3.48	0.000542	0.0327	0.16	0.16	Mean corpuscular hemoglobin;	chr8:23596900	chr8:23336171~23366125:+
THCA	cis	rs7246657	0.722	rs2972430	ENSG00000226686.6	LINC01535	3.48	0.000542	0.0327	0.23	0.16	Coronary artery calcification;	chr19:37691210	chr19:37251912~37265535:+
THCA	cis	rs3782774	0.564	rs12580347	ENSG00000278356.1	RP11-372B4.3	3.48	0.000542	0.0327	0.15	0.16	Coronary artery disease;	chr12:3279766	chr12:2885819~2886329:+
THCA	cis	rs972578	0.837	rs2092211	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000542	0.0327	-0.17	-0.16	Mean platelet volume;	chr22:42922759	chr22:42791814~42794313:-
THCA	cis	rs513088	0.515	rs476197	ENSG00000225171.2	DUTP6	3.48	0.000542	0.0327	0.2	0.16	Schizophrenia;	chr1:166704178	chr1:166868748~166869209:+
THCA	cis	rs2446066	0.872	rs10876449	ENSG00000257379.1	RP11-793H13.8	3.48	0.000542	0.0327	0.23	0.16	Red blood cell count;	chr12:53385991	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.872	rs11170525	ENSG00000257379.1	RP11-793H13.8	3.48	0.000542	0.0327	0.23	0.16	Red blood cell count;	chr12:53388844	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.818	rs7315782	ENSG00000257379.1	RP11-793H13.8	3.48	0.000542	0.0327	0.23	0.16	Red blood cell count;	chr12:53391129	chr12:53441741~53467528:+
THCA	cis	rs2446066	0.872	rs11170532	ENSG00000257379.1	RP11-793H13.8	3.48	0.000542	0.0327	0.23	0.16	Red blood cell count;	chr12:53394551	chr12:53441741~53467528:+
THCA	cis	rs7119	0.651	rs12902072	ENSG00000260776.4	RP11-114H24.2	-3.48	0.000542	0.0327	-0.22	-0.16	Type 2 diabetes;	chr15:77556390	chr15:77914217~77926846:-
THCA	cis	rs57709857	1	rs3779921	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000542	0.0327	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38425690	chr8:38382364~38383461:+
THCA	cis	rs57709857	1	rs2293971	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000542	0.0327	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38426493	chr8:38382364~38383461:+
THCA	cis	rs73787773	0.69	rs55641410	ENSG00000246859.2	STARD4-AS1	3.48	0.000542	0.0327	0.2	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr5:112142514	chr5:111512226~111739726:+
THCA	cis	rs12083887	0.505	rs10923554	ENSG00000236866.4	AL157902.3	-3.48	0.000542	0.0327	-0.18	-0.16	Male-pattern baldness;	chr1:118358101	chr1:117596832~117605770:-
THCA	cis	rs12083887	0.505	rs9661709	ENSG00000236866.4	AL157902.3	-3.48	0.000542	0.0327	-0.18	-0.16	Male-pattern baldness;	chr1:118359729	chr1:117596832~117605770:-
THCA	cis	rs12083887	0.505	rs10923556	ENSG00000236866.4	AL157902.3	-3.48	0.000542	0.0327	-0.18	-0.16	Male-pattern baldness;	chr1:118360573	chr1:117596832~117605770:-
THCA	cis	rs684232	0.666	rs1227028	ENSG00000231784.7	DBIL5P	3.48	0.000542	0.0327	0.17	0.16	Prostate cancer;	chr17:670058	chr17:752660~755336:+
THCA	cis	rs684232	0.666	rs425961	ENSG00000231784.7	DBIL5P	3.48	0.000542	0.0327	0.17	0.16	Prostate cancer;	chr17:670474	chr17:752660~755336:+
THCA	cis	rs6570726	0.516	rs9376932	ENSG00000270638.1	RP3-466P17.1	3.48	0.000542	0.0327	0.12	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145408354	chr6:145735570~145737218:+
THCA	cis	rs112295236	0.85	rs58238635	ENSG00000255213.1	NPM1P35	-3.48	0.000542	0.0327	-0.42	-0.16	Sex hormone levels;	chr11:63208439	chr11:62330946~62331813:+
THCA	cis	rs743757	0.878	rs34267788	ENSG00000232352.1	SEMA3B-AS1	3.48	0.000542	0.0327	0.24	0.16	Diastolic blood pressure;	chr3:50507380	chr3:50266641~50267371:-
THCA	cis	rs743757	0.878	rs34434811	ENSG00000232352.1	SEMA3B-AS1	3.48	0.000542	0.0327	0.24	0.16	Diastolic blood pressure;	chr3:50507405	chr3:50266641~50267371:-
THCA	cis	rs743757	0.878	rs35864641	ENSG00000232352.1	SEMA3B-AS1	3.48	0.000542	0.0327	0.24	0.16	Diastolic blood pressure;	chr3:50507432	chr3:50266641~50267371:-
THCA	cis	rs743757	0.878	rs4533647	ENSG00000232352.1	SEMA3B-AS1	3.48	0.000542	0.0327	0.24	0.16	Diastolic blood pressure;	chr3:50508402	chr3:50266641~50267371:-
THCA	cis	rs1023500	0.596	rs5758562	ENSG00000270083.1	RP1-257I20.14	3.48	0.000542	0.0327	0.19	0.16	Schizophrenia;	chr22:42052234	chr22:42089630~42090028:-
THCA	cis	rs4517514	0.509	rs11018870	ENSG00000280367.1	RP11-121L10.2	3.48	0.000543	0.0327	0.2	0.16	Trans fatty acid levels;	chr11:90138241	chr11:90223153~90226538:+
THCA	cis	rs12935418	0.616	rs8047785	ENSG00000261838.4	RP11-303E16.6	3.48	0.000543	0.0327	0.22	0.16	Mean corpuscular volume;	chr16:80935455	chr16:81069854~81076598:+
THCA	cis	rs12935418	0.616	rs11863536	ENSG00000261838.4	RP11-303E16.6	3.48	0.000543	0.0327	0.22	0.16	Mean corpuscular volume;	chr16:80935777	chr16:81069854~81076598:+
THCA	cis	rs11673344	0.704	rs1667384	ENSG00000267260.1	CTD-2162K18.4	-3.48	0.000543	0.0327	-0.2	-0.16	Obesity-related traits;	chr19:36925852	chr19:36773153~36777078:+
THCA	cis	rs13053817	1	rs71329486	ENSG00000279159.1	RP3-394A18.1	3.48	0.000543	0.0327	0.16	0.16	Carotid atherosclerosis in HIV infection;	chr22:29435219	chr22:29978950~30028236:-
THCA	cis	rs2014572	0.904	rs10412465	ENSG00000268379.1	CTC-360J11.4	3.48	0.000543	0.0327	0.19	0.16	Hyperactive-impulsive symptoms;	chr19:57242563	chr19:57175233~57177921:+
THCA	cis	rs2904967	1	rs626555	ENSG00000254614.2	AP003068.23	3.48	0.000543	0.0327	0.29	0.16	Mean corpuscular volume;	chr11:65296082	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.866	rs8638	ENSG00000254614.2	AP003068.23	3.48	0.000543	0.0327	0.29	0.16	Mean corpuscular volume;	chr11:65297447	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.866	rs506280	ENSG00000254614.2	AP003068.23	3.48	0.000543	0.0327	0.29	0.16	Mean corpuscular volume;	chr11:65302063	chr11:65177606~65181834:-
THCA	cis	rs11703808	1	rs11703808	ENSG00000242082.1	RP1-90G24.10	3.48	0.000543	0.0327	0.19	0.16	Intelligence;	chr22:31628994	chr22:32205115~32269666:+
THCA	cis	rs494526	1	rs494469	ENSG00000229272.1	RP11-498J9.2	3.48	0.000543	0.0327	0.17	0.16	Alcoholic chronic pancreatitis;	chr10:119025465	chr10:119003536~119003884:-
THCA	cis	rs2228479	0.702	rs17233868	ENSG00000274627.1	RP11-104N10.2	-3.48	0.000543	0.0327	-0.28	-0.16	Skin colour saturation;	chr16:89737221	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs9282681	ENSG00000274627.1	RP11-104N10.2	-3.48	0.000543	0.0327	-0.28	-0.16	Skin colour saturation;	chr16:89739506	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.717	rs1061647	ENSG00000274627.1	RP11-104N10.2	-3.48	0.000543	0.0327	-0.28	-0.16	Skin colour saturation;	chr16:89739655	chr16:89516797~89522217:+
THCA	cis	rs889312	0.5	rs832566	ENSG00000271828.1	CTD-2310F14.1	-3.48	0.000543	0.0327	-0.21	-0.16	Breast cancer (early onset);Breast cancer;	chr5:56855917	chr5:56927874~56929573:+
THCA	cis	rs9309473	0.519	rs2178154	ENSG00000273245.1	RP11-434P11.2	-3.48	0.000543	0.0327	-0.19	-0.16	Metabolite levels;	chr2:73434610	chr2:73750256~73750786:-
THCA	cis	rs7121800	0.632	rs1870360	ENSG00000242353.1	RP4-710M3.1	-3.48	0.000543	0.0327	-0.14	-0.16	Pit-and-Fissure caries;	chr11:30518717	chr11:30368148~30368646:+
THCA	cis	rs860295	0.702	rs4971095	ENSG00000236675.1	MTX1P1	3.48	0.000543	0.0327	0.16	0.16	Body mass index;	chr1:155636433	chr1:155230975~155234325:+
THCA	cis	rs9393813	0.509	rs10946915	ENSG00000216915.2	RP1-97D16.1	3.48	0.000543	0.0327	0.21	0.16	Bipolar disorder;	chr6:27410051	chr6:27737000~27738494:-
THCA	cis	rs2836950	0.52	rs8130240	ENSG00000235701.1	PCBP2P1	-3.48	0.000543	0.0327	-0.17	-0.16	Menarche (age at onset);	chr21:39166182	chr21:39171130~39172106:-
THCA	cis	rs12621844	0.7	rs990063	ENSG00000234690.5	AC073283.4	-3.48	0.000543	0.0327	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48155896	chr2:47192405~47345074:-
THCA	cis	rs11671005	0.568	rs73068329	ENSG00000252334.1	RNU6-1337P	3.48	0.000543	0.0327	0.23	0.16	Mean platelet volume;	chr19:58568958	chr19:58483749~58483843:-
THCA	cis	rs3808502	0.527	rs2736389	ENSG00000261451.1	RP11-981G7.1	3.48	0.000543	0.0327	0.21	0.16	Neuroticism;	chr8:11303801	chr8:10433672~10438312:+
THCA	cis	rs2658782	0.639	rs2100552	ENSG00000234106.3	RP11-288E14.2	3.48	0.000543	0.0327	0.17	0.16	Pulmonary function decline;	chr11:93449083	chr11:93535468~93535816:+
THCA	cis	rs2442825	0.693	rs2596916	ENSG00000254485.4	RP11-380O24.1	-3.48	0.000543	0.0327	-0.14	-0.16	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9292588~9363303:-
THCA	cis	rs7572733	0.967	rs1318867	ENSG00000231621.1	AC013264.2	3.48	0.000543	0.0327	0.15	0.16	Dermatomyositis;	chr2:198015757	chr2:197197991~197199273:+
THCA	cis	rs285757	0.79	rs373481	ENSG00000259064.2	RP11-386M24.5	3.48	0.000543	0.0327	0.24	0.16	HIV-1 susceptibility;	chr15:92662224	chr15:92627073~92627414:+
THCA	cis	rs1383484	1	rs7172049	ENSG00000225151.9	GOLGA2P7	3.48	0.000543	0.0327	0.21	0.16	Height;	chr15:83834559	chr15:84199311~84230136:-
THCA	cis	rs6137726	0.529	rs8118625	ENSG00000237396.1	LINC01384	3.48	0.000543	0.0327	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22649878	chr20:22587522~22607517:-
THCA	cis	rs11105298	0.891	rs11105287	ENSG00000266347.2	AC068641.1	3.48	0.000543	0.0327	0.2	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89592833~89592927:+
THCA	cis	rs6496667	0.865	rs62019351	ENSG00000259262.1	NDUFA3P4	3.48	0.000543	0.0327	0.22	0.16	Rheumatoid arthritis;	chr15:90383325	chr15:90385814~90386063:+
THCA	cis	rs7572733	0.534	rs1607374	ENSG00000231621.1	AC013264.2	-3.48	0.000543	0.0327	-0.17	-0.16	Dermatomyositis;	chr2:197935716	chr2:197197991~197199273:+
THCA	cis	rs4869313	0.694	rs6870825	ENSG00000247121.5	CTD-2260A17.2	-3.48	0.000543	0.0327	-0.12	-0.16	Pediatric autoimmune diseases;	chr5:96945765	chr5:96814028~96935809:-
THCA	cis	rs3739034	1	rs2276161	ENSG00000224043.6	CCNT2-AS1	-3.48	0.000543	0.0327	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134713165	chr2:134735464~134918710:-
THCA	cis	rs9510795	0.522	rs1121114	ENSG00000205861.10	C1QTNF9B-AS1	-3.48	0.000543	0.0327	-0.19	-0.16	Diabetic kidney disease;	chr13:23649520	chr13:23888889~23897263:+
THCA	cis	rs337161	0.719	rs10863562	ENSG00000221571.3	RNU6ATAC35P	-3.48	0.000543	0.0327	-0.18	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220755813	chr1:220825620~220826063:+
THCA	cis	rs4489787	0.527	rs2731085	ENSG00000273765.1	RP11-370I10.11	3.48	0.000543	0.0327	0.18	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48507516	chr12:48360920~48361377:+
THCA	cis	rs61160187	0.582	rs62367903	ENSG00000251279.1	CTC-436P18.1	-3.48	0.000543	0.0327	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:61162070~61232040:+
THCA	cis	rs17689437	0.881	rs1069286	ENSG00000275383.1	RP11-615I2.6	-3.48	0.000544	0.0327	-0.23	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68523371	chr16:68591382~68594424:+
THCA	cis	rs11673344	0.932	rs76350084	ENSG00000267260.1	CTD-2162K18.4	-3.48	0.000544	0.0327	-0.2	-0.16	Obesity-related traits;	chr19:37187917	chr19:36773153~36777078:+
THCA	cis	rs13178541	0.81	rs4327594	ENSG00000250378.1	RP11-119J18.1	-3.48	0.000544	0.0327	-0.19	-0.16	IgG glycosylation;	chr5:135774638	chr5:135812667~135826582:+
THCA	cis	rs708224	0.713	rs326635	ENSG00000277342.1	RP11-843B15.4	3.48	0.000544	0.0327	0.2	0.16	Pancreatic cancer;	chr12:32243051	chr12:32109076~32109602:+
THCA	cis	rs10223402	0.786	rs4640919	ENSG00000233558.1	RP3-486I3.4	3.48	0.000544	0.0327	0.27	0.16	Appendicular lean mass;	chr6:115632874	chr6:116258493~116259115:-
THCA	cis	rs10223402	0.786	rs6568911	ENSG00000233558.1	RP3-486I3.4	-3.48	0.000544	0.0327	-0.27	-0.16	Appendicular lean mass;	chr6:115636912	chr6:116258493~116259115:-
THCA	cis	rs10223402	0.594	rs9374558	ENSG00000233558.1	RP3-486I3.4	-3.48	0.000544	0.0327	-0.27	-0.16	Appendicular lean mass;	chr6:115640554	chr6:116258493~116259115:-
THCA	cis	rs10223402	0.786	rs9372443	ENSG00000233558.1	RP3-486I3.4	-3.48	0.000544	0.0327	-0.27	-0.16	Appendicular lean mass;	chr6:115641887	chr6:116258493~116259115:-
THCA	cis	rs7711186	0.786	rs4418123	ENSG00000252464.1	RN7SKP70	3.48	0.000544	0.0327	0.17	0.16	Urate levels in obese individuals;	chr5:178646102	chr5:178619728~178619998:-
THCA	cis	rs9392556	0.666	rs1815510	ENSG00000230648.1	RP3-406P24.3	3.48	0.000544	0.0327	0.23	0.16	Blood metabolite levels;	chr6:4108520	chr6:4018843~4021215:-
THCA	cis	rs1816213	1	rs6711592	ENSG00000273466.1	RP11-548H3.1	-3.48	0.000544	0.0327	-0.26	-0.16	Diastolic blood pressure;	chr2:218710704	chr2:218633256~218634014:-
THCA	cis	rs7914558	0.966	rs7096269	ENSG00000272912.1	RP11-724N1.1	-3.48	0.000544	0.0327	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102976964	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.933	rs10883814	ENSG00000272912.1	RP11-724N1.1	-3.48	0.000544	0.0327	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102977647	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs1971589	ENSG00000272912.1	RP11-724N1.1	-3.48	0.000544	0.0327	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102984649	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs1890185	ENSG00000272912.1	RP11-724N1.1	-3.48	0.000544	0.0327	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102914585~102915404:+
THCA	cis	rs1051424	0.642	rs115869798	ENSG00000266701.1	AC005702.4	3.48	0.000544	0.0328	0.25	0.16	Obesity-related traits;	chr17:59815468	chr17:60042546~60042627:-
THCA	cis	rs7010267	0.935	rs10955915	ENSG00000254278.1	RP11-278I4.2	-3.48	0.000544	0.0328	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118951308	chr8:119062942~119068782:-
THCA	cis	rs288326	0.561	rs75936972	ENSG00000272800.1	RP11-438L19.1	3.48	0.000544	0.0328	0.3	0.16	Blood protein levels;	chr2:182892261	chr2:183214319~183215400:+
THCA	cis	rs524281	0.861	rs3953856	ENSG00000255038.1	RP11-1167A19.2	-3.48	0.000544	0.0328	-0.18	-0.16	Electroencephalogram traits;	chr11:66198437	chr11:66067277~66069619:-
THCA	cis	rs524281	0.861	rs2889313	ENSG00000255038.1	RP11-1167A19.2	-3.48	0.000544	0.0328	-0.18	-0.16	Electroencephalogram traits;	chr11:66198595	chr11:66067277~66069619:-
THCA	cis	rs7615952	0.599	rs67566088	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000544	0.0328	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126050130	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.641	rs12495947	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000544	0.0328	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126052855	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.641	rs6805074	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000544	0.0328	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126053431	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.641	rs4422257	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000544	0.0328	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126055520	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.641	rs66520539	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000544	0.0328	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126061531	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.641	rs7632497	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000544	0.0328	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126064243	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.641	rs12487875	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000544	0.0328	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126068381	chr3:125827238~125916384:-
THCA	cis	rs2446066	0.872	rs114075368	ENSG00000257379.1	RP11-793H13.8	3.48	0.000544	0.0328	0.23	0.16	Red blood cell count;	chr12:53407960	chr12:53441741~53467528:+
THCA	cis	rs2286503	0.752	rs59538378	ENSG00000228649.7	AC005682.5	3.48	0.000544	0.0328	0.19	0.16	Fibrinogen;	chr7:22837478	chr7:22854178~22861579:+
THCA	cis	rs5753037	0.653	rs140121	ENSG00000279699.1	RP1-102K2.9	3.48	0.000544	0.0328	0.15	0.16	Type 1 diabetes;	chr22:29742700	chr22:30275215~30276951:-
THCA	cis	rs1865760	0.555	rs2051541	ENSG00000272810.1	U91328.22	3.48	0.000544	0.0328	0.12	0.16	Height;	chr6:25944983	chr6:26013241~26013757:+
THCA	cis	rs7674212	0.512	rs2720462	ENSG00000230069.3	LRRC37A15P	-3.48	0.000544	0.0328	-0.16	-0.16	Type 2 diabetes;	chr4:103135053	chr4:102727274~102730721:-
THCA	cis	rs4788570	0.578	rs9934789	ENSG00000260593.1	RP11-432I5.2	-3.48	0.000544	0.0328	-0.26	-0.16	Intelligence (multi-trait analysis);	chr16:71628564	chr16:71623708~71626816:-
THCA	cis	rs9916302	0.706	rs8069074	ENSG00000266469.1	CTB-131K11.1	3.48	0.000544	0.0328	0.15	0.16	Glomerular filtration rate (creatinine);	chr17:39529148	chr17:39401793~39406233:+
THCA	cis	rs13064773	0.51	rs340302	ENSG00000272247.1	RP11-379F4.9	3.48	0.000544	0.0328	0.17	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158854764	chr3:158801257~158801935:-
THCA	cis	rs5769765	0.908	rs9616396	ENSG00000260613.1	RP3-522J7.6	-3.48	0.000544	0.0328	-0.21	-0.16	Schizophrenia;	chr22:49924177	chr22:49832616~49837786:-
THCA	cis	rs2625529	0.59	rs2607090	ENSG00000260037.4	CTD-2524L6.3	-3.48	0.000544	0.0328	-0.22	-0.16	Red blood cell count;	chr15:72203670	chr15:71818396~71823384:+
THCA	cis	rs7674212	0.541	rs2720471	ENSG00000230069.3	LRRC37A15P	-3.48	0.000544	0.0328	-0.16	-0.16	Type 2 diabetes;	chr4:103102683	chr4:102727274~102730721:-
THCA	cis	rs62025270	0.632	rs7163838	ENSG00000202081.1	RNU6-1280P	-3.48	0.000544	0.0328	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85651522~85651628:-
THCA	cis	rs2115630	1	rs6496452	ENSG00000275120.1	RP11-182J1.17	-3.48	0.000544	0.0328	-0.16	-0.16	P wave terminal force;	chr15:84829414	chr15:84599434~84606463:-
THCA	cis	rs9488822	0.676	rs6918059	ENSG00000237021.2	RP3-486I3.7	3.48	0.000544	0.0328	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116027878	chr6:116254207~116256743:+
THCA	cis	rs72634258	0.554	rs12723500	ENSG00000224315.2	RPL7P7	-3.48	0.000544	0.0328	-0.29	-0.16	Inflammatory bowel disease;	chr1:7797314	chr1:8786211~8786913:-
THCA	cis	rs6001982	0.915	rs73169058	ENSG00000199865.1	RNU6-495P	3.48	0.000544	0.0328	0.28	0.16	Breast cancer;	chr22:40596231	chr22:41377177~41377283:-
THCA	cis	rs6001982	0.915	rs73169060	ENSG00000199865.1	RNU6-495P	3.48	0.000544	0.0328	0.28	0.16	Breast cancer;	chr22:40598740	chr22:41377177~41377283:-
THCA	cis	rs75422866	0.51	rs73105818	ENSG00000280054.1	RP1-197B17.7	3.48	0.000545	0.0328	0.32	0.16	Pneumonia;	chr12:47726538	chr12:47728151~47730598:-
THCA	cis	rs2688608	0.62	rs11000767	ENSG00000272140.2	RP11-574K11.29	3.48	0.000545	0.0328	0.14	0.16	Inflammatory bowel disease;	chr10:73756868	chr10:73703735~73713581:-
THCA	cis	rs7615952	0.512	rs4234285	ENSG00000243429.1	OR7E29P	3.48	0.000545	0.0328	0.2	0.16	Blood pressure (smoking interaction);	chr3:125685633	chr3:125712139~125713045:+
THCA	cis	rs910316	0.789	rs12894419	ENSG00000259138.1	RP11-950C14.7	3.48	0.000545	0.0328	0.14	0.16	Height;	chr14:75005099	chr14:75127153~75136930:+
THCA	cis	rs2839186	0.967	rs2839191	ENSG00000228137.1	AP001469.7	3.48	0.000545	0.0328	0.16	0.16	Testicular germ cell tumor;	chr21:46275481	chr21:46246890~46247682:+
THCA	cis	rs7727544	0.548	rs35696821	ENSG00000263597.1	MIR3936	3.48	0.000545	0.0328	0.15	0.16	Blood metabolite levels;	chr5:132172324	chr5:132365490~132365599:-
THCA	cis	rs3760982	0.585	rs68073292	ENSG00000268601.1	AC115522.3	-3.48	0.000545	0.0328	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787249	chr19:43794309~43795658:-
THCA	cis	rs3760982	0.585	rs62116964	ENSG00000268601.1	AC115522.3	-3.48	0.000545	0.0328	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787834	chr19:43794309~43795658:-
THCA	cis	rs2835345	1	rs2835345	ENSG00000230479.1	AP000695.6	3.48	0.000545	0.0328	0.19	0.16	Pulmonary function;	chr21:36429136	chr21:36430360~36481070:+
THCA	cis	rs972578	1	rs1546861	ENSG00000230319.1	AL022476.2	3.48	0.000545	0.0328	0.16	0.16	Mean platelet volume;	chr22:42959161	chr22:43038585~43052366:+
THCA	cis	rs1046896	0.553	rs1044661	ENSG00000263063.1	RP11-388C12.1	-3.48	0.000545	0.0328	-0.2	-0.16	Glycated hemoglobin levels;	chr17:82943144	chr17:82713908~82716255:-
THCA	cis	rs76070545	0.551	rs10097271	ENSG00000271830.1	RP11-1C8.7	3.48	0.000545	0.0328	0.33	0.16	Alzheimer disease and age of onset;	chr8:103218067	chr8:103481266~103481619:-
THCA	cis	rs7826238	0.623	rs2976893	ENSG00000253981.4	ALG1L13P	-3.48	0.000545	0.0328	-0.16	-0.16	Systolic blood pressure;	chr8:8480709	chr8:8236003~8244667:-
THCA	cis	rs9899728	0.572	rs9915968	ENSG00000263843.1	RP11-649A18.12	-3.48	0.000545	0.0328	-0.18	-0.16	Alzheimer's disease or small vessel stroke;	chr17:75063521	chr17:75271369~75273895:+
THCA	cis	rs875971	0.545	rs73136346	ENSG00000232559.3	GS1-124K5.12	-3.48	0.000545	0.0328	-0.18	-0.16	Aortic root size;	chr7:66101095	chr7:66554588~66576923:-
THCA	cis	rs61677309	0.638	rs57506367	ENSG00000278376.1	RP11-158I9.8	3.48	0.000545	0.0328	0.11	0.16	Lung cancer in ever smokers;	chr11:118271278	chr11:118791254~118793137:+
THCA	cis	rs9475677	1	rs12204179	ENSG00000231441.1	RP11-472M19.2	3.48	0.000545	0.0328	0.2	0.16	Gut microbiota (functional units);	chr6:56344391	chr6:56844002~56864078:+
THCA	cis	rs9475677	1	rs9475677	ENSG00000231441.1	RP11-472M19.2	3.48	0.000545	0.0328	0.2	0.16	Gut microbiota (functional units);	chr6:56344453	chr6:56844002~56864078:+
THCA	cis	rs9475677	1	rs9475678	ENSG00000231441.1	RP11-472M19.2	3.48	0.000545	0.0328	0.2	0.16	Gut microbiota (functional units);	chr6:56344477	chr6:56844002~56864078:+
THCA	cis	rs7191700	0.511	rs8058983	ENSG00000263179.1	HNRNPCP4	3.48	0.000545	0.0328	0.2	0.16	Multiple sclerosis;	chr16:11266992	chr16:11242653~11243552:+
THCA	cis	rs6472235	1	rs60258162	ENSG00000272192.1	CTD-2532N20.1	3.48	0.000545	0.0328	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65933651	chr8:65842752~65843331:+
THCA	cis	rs1383484	1	rs28612730	ENSG00000225151.9	GOLGA2P7	3.48	0.000545	0.0328	0.21	0.16	Height;	chr15:83842454	chr15:84199311~84230136:-
THCA	cis	rs478304	0.514	rs75601653	ENSG00000255120.4	OVOL1-AS1	-3.48	0.000545	0.0328	-0.22	-0.16	Acne (severe);	chr11:65715899	chr11:65789051~65790868:-
THCA	cis	rs2018683	0.649	rs12536605	ENSG00000233517.1	AC005162.5	-3.48	0.000545	0.0328	-0.2	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930883	chr7:28987028~28988899:+
THCA	cis	rs4742903	0.935	rs10116938	ENSG00000270332.1	SMC2-AS1	3.48	0.000545	0.0328	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104214974	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.904	rs4373581	ENSG00000270332.1	SMC2-AS1	3.48	0.000545	0.0328	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104215182	chr9:104080024~104093073:-
THCA	cis	rs4742903	0.935	rs1507509	ENSG00000270332.1	SMC2-AS1	3.48	0.000545	0.0328	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104222621	chr9:104080024~104093073:-
THCA	cis	rs285757	0.79	rs503112	ENSG00000259064.2	RP11-386M24.5	-3.48	0.000545	0.0328	-0.24	-0.16	HIV-1 susceptibility;	chr15:92655283	chr15:92627073~92627414:+
THCA	cis	rs34421088	0.56	rs2618434	ENSG00000251402.3	FAM90A25P	-3.48	0.000545	0.0328	-0.2	-0.16	Neuroticism;	chr8:11541356	chr8:12415080~12418090:-
THCA	cis	rs4731207	0.596	rs6466968	ENSG00000213296.4	RP5-1106E3.1	-3.48	0.000545	0.0328	-0.17	-0.16	Cutaneous malignant melanoma;	chr7:124943303	chr7:124480524~124481395:+
THCA	cis	rs3755605	0.664	rs12493997	ENSG00000242578.1	RP11-469J4.3	3.48	0.000545	0.0328	0.18	0.16	Testicular germ cell tumor;	chr3:170192077	chr3:170410512~170418615:+
THCA	cis	rs321358	0.79	rs73015129	ENSG00000271390.1	RP11-89C3.3	3.48	0.000545	0.0328	0.26	0.16	Body mass index;	chr11:111076157	chr11:111089870~111090368:-
THCA	cis	rs321358	0.79	rs73015134	ENSG00000271390.1	RP11-89C3.3	3.48	0.000545	0.0328	0.26	0.16	Body mass index;	chr11:111076520	chr11:111089870~111090368:-
THCA	cis	rs9916302	0.706	rs1054488	ENSG00000266469.1	CTB-131K11.1	-3.48	0.000545	0.0328	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39531715	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.653	rs11657058	ENSG00000266469.1	CTB-131K11.1	-3.48	0.000545	0.0328	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39543125	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs11657153	ENSG00000266469.1	CTB-131K11.1	-3.48	0.000545	0.0328	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39543476	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.653	rs4239223	ENSG00000266469.1	CTB-131K11.1	-3.48	0.000545	0.0328	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39560751	chr17:39401793~39406233:+
THCA	cis	rs5770820	0.651	rs739365	ENSG00000279182.1	XX-C00717C00720L.1	-3.48	0.000545	0.0328	-0.17	-0.16	Intelligence (multi-trait analysis);	chr22:50701888	chr22:50316035~50317025:+
THCA	cis	rs57709857	0.957	rs7837189	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000545	0.0328	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38290322	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs10958606	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000545	0.0328	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38291886	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs1599918	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000545	0.0328	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38306769	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs16887324	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000545	0.0328	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38308883	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs7841617	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000545	0.0328	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38310131	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs2234555	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000545	0.0328	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38321249	chr8:38382364~38383461:+
THCA	cis	rs1864585	0.754	rs73192809	ENSG00000280294.1	RP11-177H2.1	3.48	0.000545	0.0328	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10917170	chr8:10856085~10859436:-
THCA	cis	rs7949030	0.59	rs12225213	ENSG00000255213.1	NPM1P35	3.48	0.000545	0.0328	0.2	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr11:62330946~62331813:+
THCA	cis	rs2251188	0.632	rs2464877	ENSG00000198580.7	RP11-611L7.2	-3.48	0.000545	0.0328	-0.17	-0.16	Sum basophil neutrophil counts;Neutrophil count;	chr7:6655087	chr7:6673494~6676366:+
THCA	cis	rs721917	0.7	rs2493719	ENSG00000230091.5	TMEM254-AS1	-3.48	0.000545	0.0328	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr10:79896305	chr10:80046860~80078912:-
THCA	cis	rs17604090	0.938	rs73088374	ENSG00000223813.2	AC007255.8	3.48	0.000545	0.0328	0.17	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29615203	chr7:29514225~29563670:-
THCA	cis	rs9859260	0.616	rs9867473	ENSG00000242086.7	LINC00969	3.48	0.000545	0.0328	0.16	0.16	Mean corpuscular volume;	chr3:196104227	chr3:195658062~195739964:+
THCA	cis	rs11168618	0.87	rs7302209	ENSG00000240399.1	RP1-228P16.1	3.48	0.000546	0.0328	0.16	0.16	Adiponectin levels;	chr12:48501601	chr12:48054813~48055591:-
THCA	cis	rs990871	0.574	rs7534013	ENSG00000227207.2	RPL31P12	-3.48	0.000546	0.0328	-0.2	-0.16	Subcutaneous adipose tissue;	chr1:72443328	chr1:72301472~72301829:+
THCA	cis	rs11673344	0.523	rs7255724	ENSG00000267260.1	CTD-2162K18.4	-3.48	0.000546	0.0328	-0.19	-0.16	Obesity-related traits;	chr19:37158675	chr19:36773153~36777078:+
THCA	cis	rs2236295	0.513	rs2393934	ENSG00000238280.1	RP11-436D10.3	-3.48	0.000546	0.0328	-0.19	-0.16	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62885433	chr10:62793562~62805887:-
THCA	cis	rs288326	0.561	rs79221349	ENSG00000272800.1	RP11-438L19.1	3.48	0.000546	0.0328	0.29	0.16	Blood protein levels;	chr2:182886863	chr2:183214319~183215400:+
THCA	cis	rs288326	0.561	rs79775314	ENSG00000272800.1	RP11-438L19.1	3.48	0.000546	0.0328	0.29	0.16	Blood protein levels;	chr2:182888021	chr2:183214319~183215400:+
THCA	cis	rs10875746	0.669	rs17122812	ENSG00000226413.2	OR8T1P	3.48	0.000546	0.0328	0.23	0.16	Longevity (90 years and older);	chr12:48203270	chr12:48442030~48442947:-
THCA	cis	rs1612141	0.744	rs1959882	ENSG00000251363.2	RP11-129M6.1	3.48	0.000546	0.0329	0.23	0.16	QT interval (drug interaction);	chr14:41124707	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs8007750	ENSG00000251363.2	RP11-129M6.1	3.48	0.000546	0.0329	0.23	0.16	QT interval (drug interaction);	chr14:41126590	chr14:40954898~40975877:+
THCA	cis	rs17655565	0.533	rs12825729	ENSG00000257829.1	RP11-845M18.6	-3.48	0.000546	0.0329	-0.17	-0.16	Plasma amyloid beta peptide concentrations (ABx-42);	chr12:52313070	chr12:52306616~52308371:-
THCA	cis	rs910316	0.737	rs175084	ENSG00000259138.1	RP11-950C14.7	-3.48	0.000546	0.0329	-0.14	-0.16	Height;	chr14:75052472	chr14:75127153~75136930:+
THCA	cis	rs9876781	1	rs13076076	ENSG00000199476.1	Y_RNA	-3.48	0.000546	0.0329	-0.2	-0.16	Longevity;	chr3:48437629	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs9849509	ENSG00000199476.1	Y_RNA	-3.48	0.000546	0.0329	-0.2	-0.16	Longevity;	chr3:48442021	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs60512868	ENSG00000199476.1	Y_RNA	-3.48	0.000546	0.0329	-0.2	-0.16	Longevity;	chr3:48442035	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs7636044	ENSG00000199476.1	Y_RNA	-3.48	0.000546	0.0329	-0.2	-0.16	Longevity;	chr3:48443151	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs4490383	ENSG00000199476.1	Y_RNA	-3.48	0.000546	0.0329	-0.2	-0.16	Longevity;	chr3:48443275	chr3:48288587~48288694:+
THCA	cis	rs10875746	1	rs10875746	ENSG00000258234.1	RP11-370I10.2	3.48	0.000546	0.0329	0.18	0.16	Longevity (90 years and older);	chr12:48124481	chr12:48231098~48284210:-
THCA	cis	rs7520050	0.966	rs11579634	ENSG00000280836.1	AL355480.1	-3.48	0.000546	0.0329	-0.19	-0.16	Reticulocyte count;Red blood cell count;	chr1:46000719	chr1:45581219~45581321:-
THCA	cis	rs7089973	0.604	rs11196939	ENSG00000228169.3	PPIAP19	-3.48	0.000546	0.0329	-0.19	-0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114833416	chr10:114690143~114690634:-
THCA	cis	rs10090774	0.965	rs62521905	ENSG00000280303.2	ERICD	3.48	0.000546	0.0329	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140911652	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs6987946	ENSG00000280303.2	ERICD	3.48	0.000546	0.0329	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140917560	chr8:140636281~140638283:+
THCA	cis	rs4660456	0.913	rs2223486	ENSG00000238287.1	RP11-656D10.3	-3.48	0.000546	0.0329	-0.2	-0.16	Platelet count;	chr1:40693557	chr1:40493157~40508661:-
THCA	cis	rs61160187	0.549	rs12518404	ENSG00000272308.1	RP11-231G3.1	-3.48	0.000546	0.0329	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60866457~60866935:-
THCA	cis	rs9878978	0.722	rs13064421	ENSG00000227588.2	CNTN4-AS2	3.48	0.000546	0.0329	0.21	0.16	Blood pressure (smoking interaction);	chr3:2405841	chr3:2110409~2144241:-
THCA	cis	rs4566357	0.521	rs78411533	ENSG00000212391.1	SNORA48	-3.48	0.000546	0.0329	-0.17	-0.16	Coronary artery disease;	chr2:227046091	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.615	rs2272200	ENSG00000212391.1	SNORA48	-3.48	0.000546	0.0329	-0.17	-0.16	Coronary artery disease;	chr2:227047615	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.615	rs10198214	ENSG00000212391.1	SNORA48	-3.48	0.000546	0.0329	-0.17	-0.16	Coronary artery disease;	chr2:227048598	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.615	rs10198406	ENSG00000212391.1	SNORA48	-3.48	0.000546	0.0329	-0.17	-0.16	Coronary artery disease;	chr2:227048823	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.615	rs6436644	ENSG00000212391.1	SNORA48	-3.48	0.000546	0.0329	-0.17	-0.16	Coronary artery disease;	chr2:227049559	chr2:226968989~226969122:-
THCA	cis	rs10419113	0.598	rs12610037	ENSG00000270804.1	CTD-2583A14.11	3.48	0.000546	0.0329	0.13	0.16	Pediatric bone mineral density (spine);	chr19:57752217	chr19:57867885~57868834:+
THCA	cis	rs540425	0.587	rs217357	ENSG00000279853.1	RP5-844F9.1	3.48	0.000546	0.0329	0.2	0.16	Schizophrenia;	chr7:44583317	chr7:44367140~44369292:-
THCA	cis	rs9796	0.87	rs10851402	ENSG00000247556.5	OIP5-AS1	-3.48	0.000546	0.0329	-0.12	-0.16	Menopause (age at onset);	chr15:40971240	chr15:41283990~41309737:+
THCA	cis	rs8035452	0.964	rs2899461	ENSG00000273674.3	CTD-2378E12.1	3.48	0.000546	0.0329	0.2	0.16	Alzheimer's disease (late onset);	chr15:50729481	chr15:50839875~50908599:-
THCA	cis	rs1047014	0.763	rs76175662	ENSG00000226786.2	RP1-167F1.2	-3.48	0.000546	0.0329	-0.16	-0.16	Height;	chr6:19832214	chr6:19534944~19839080:-
THCA	cis	rs7246967	0.551	rs6511367	ENSG00000198153.8	ZNF849P	-3.48	0.000546	0.0329	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22638468	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs7250964	ENSG00000198153.8	ZNF849P	-3.48	0.000546	0.0329	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22639692	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs7250343	ENSG00000198153.8	ZNF849P	-3.48	0.000546	0.0329	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22640043	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.673	rs35007247	ENSG00000198153.8	ZNF849P	-3.48	0.000546	0.0329	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22640121	chr19:22685167~22686732:+
THCA	cis	rs4218	0.648	rs8042896	ENSG00000277144.1	RP11-59H7.4	-3.48	0.000546	0.0329	-0.22	-0.16	Social communication problems;	chr15:59067727	chr15:59115547~59116089:-
THCA	cis	rs13381277	0.764	rs9963875	ENSG00000263982.1	RP11-504I13.3	3.48	0.000546	0.0329	0.26	0.16	Dental caries;	chr18:76612191	chr18:76372717~76378275:+
THCA	cis	rs1865760	1	rs9348698	ENSG00000272810.1	U91328.22	-3.48	0.000546	0.0329	-0.13	-0.16	Height;	chr6:25929461	chr6:26013241~26013757:+
THCA	cis	rs2735413	0.75	rs67126435	ENSG00000276007.1	RP11-358L22.3	3.48	0.000546	0.0329	0.15	0.16	Systolic blood pressure (alcohol consumption interaction);	chr16:78032540	chr16:78123243~78124332:+
THCA	cis	rs10875746	0.729	rs1990028	ENSG00000269514.1	RP11-370I10.12	3.48	0.000546	0.0329	0.16	0.16	Longevity (90 years and older);	chr12:48014230	chr12:48198387~48202031:+
THCA	cis	rs34975555	0.616	rs2285301	ENSG00000253671.1	RP11-806O11.1	-3.48	0.000546	0.0329	-0.24	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17938717	chr8:17808941~17820868:+
THCA	cis	rs2180341	1	rs7776136	ENSG00000220522.2	RP1-177A13.1	3.48	0.000547	0.0329	0.2	0.16	Breast cancer;	chr6:127317203	chr6:127416535~127416952:-
THCA	cis	rs8030605	0.704	rs72742674	ENSG00000277245.1	RP11-48G14.3	3.48	0.000547	0.0329	0.29	0.16	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56467743	chr15:56447120~56447697:+
THCA	cis	rs5993586	1	rs5748172	ENSG00000223461.1	AC004471.9	3.48	0.000547	0.0329	0.35	0.16	Coronary artery disease;	chr22:19389406	chr22:19121529~19124503:+
THCA	cis	rs11048434	0.736	rs12423746	ENSG00000245105.2	A2M-AS1	3.48	0.000547	0.0329	0.12	0.16	Sjögren's syndrome;	chr12:8960406	chr12:9065177~9068060:+
THCA	cis	rs4578769	0.729	rs16973538	ENSG00000265939.1	UBE2CP2	3.48	0.000547	0.0329	0.2	0.16	Eosinophil percentage of white cells;	chr18:22899823	chr18:22900486~22900995:-
THCA	cis	rs721048	0.92	rs62180322	ENSG00000242412.1	DBIL5P2	-3.48	0.000547	0.0329	-0.21	-0.16	Prostate cancer;	chr2:63181174	chr2:63117851~63119542:-
THCA	cis	rs972578	1	rs4822247	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000547	0.0329	-0.16	-0.16	Mean platelet volume;	chr22:43007284	chr22:42791814~42794313:-
THCA	cis	rs972578	1	rs4822248	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000547	0.0329	-0.16	-0.16	Mean platelet volume;	chr22:43007373	chr22:42791814~42794313:-
THCA	cis	rs972578	1	rs4822249	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000547	0.0329	-0.16	-0.16	Mean platelet volume;	chr22:43007500	chr22:42791814~42794313:-
THCA	cis	rs972578	1	rs5759086	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000547	0.0329	-0.16	-0.16	Mean platelet volume;	chr22:43008923	chr22:42791814~42794313:-
THCA	cis	rs10792665	0.735	rs10898064	ENSG00000255503.1	RP11-113K21.4	-3.48	0.000547	0.0329	-0.16	-0.16	Obesity-related traits;	chr11:82964855	chr11:83072402~83097196:-
THCA	cis	rs7212590	0.748	rs62081818	ENSG00000267302.4	RP11-178C3.2	3.48	0.000547	0.0329	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59813268	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.748	rs59685433	ENSG00000267302.4	RP11-178C3.2	3.48	0.000547	0.0329	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59813846	chr17:59964832~59996972:+
THCA	cis	rs13178541	0.593	rs6874289	ENSG00000250167.1	CTC-321K16.1	-3.48	0.000547	0.0329	-0.17	-0.16	IgG glycosylation;	chr5:135708142	chr5:135559577~135634874:+
THCA	cis	rs7560272	0.501	rs2272178	ENSG00000230002.2	ALMS1-IT1	-3.48	0.000547	0.0329	-0.19	-0.16	Schizophrenia;	chr2:73750482	chr2:73456764~73459484:+
THCA	cis	rs7647973	0.6	rs12631989	ENSG00000228638.1	FCF1P2	-3.48	0.000547	0.0329	-0.16	-0.16	Menarche (age at onset);	chr3:49236563	chr3:48290793~48291375:-
THCA	cis	rs7647973	0.6	rs13064780	ENSG00000228638.1	FCF1P2	-3.48	0.000547	0.0329	-0.16	-0.16	Menarche (age at onset);	chr3:49237393	chr3:48290793~48291375:-
THCA	cis	rs9652601	0.622	rs1861548	ENSG00000263033.2	RP11-396B14.2	-3.48	0.000547	0.0329	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11024643	chr16:11196177~11224969:+
THCA	cis	rs9928842	0.771	rs8059190	ENSG00000261783.1	RP11-252K23.2	3.48	0.000547	0.0329	0.29	0.16	Alcoholic chronic pancreatitis;	chr16:75226899	chr16:75379818~75381260:-
THCA	cis	rs4073416	0.542	rs7140695	ENSG00000276116.2	FUT8-AS1	3.48	0.000547	0.0329	0.18	0.16	N-glycan levels;	chr14:65462414	chr14:65411170~65412690:-
THCA	cis	rs4715166	0.798	rs4715169	ENSG00000272379.1	RP1-257A7.5	3.48	0.000547	0.0329	0.19	0.16	Hip geometry;	chr6:13223996	chr6:13290018~13290490:-
THCA	cis	rs1023500	0.573	rs133370	ENSG00000270083.1	RP1-257I20.14	3.48	0.000547	0.0329	0.18	0.16	Schizophrenia;	chr22:42069256	chr22:42089630~42090028:-
THCA	cis	rs1023500	0.551	rs133371	ENSG00000270083.1	RP1-257I20.14	3.48	0.000547	0.0329	0.18	0.16	Schizophrenia;	chr22:42069570	chr22:42089630~42090028:-
THCA	cis	rs1023500	0.573	rs133374	ENSG00000270083.1	RP1-257I20.14	3.48	0.000547	0.0329	0.18	0.16	Schizophrenia;	chr22:42069937	chr22:42089630~42090028:-
THCA	cis	rs925255	0.713	rs9309662	ENSG00000229951.4	FLJ31356	-3.48	0.000547	0.0329	-0.21	-0.16	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28384409~28394672:-
THCA	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	3.48	0.000547	0.0329	0.15	0.16	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
THCA	cis	rs494526	0.641	rs11198781	ENSG00000229272.1	RP11-498J9.2	-3.48	0.000547	0.0329	-0.18	-0.16	Alcoholic chronic pancreatitis;	chr10:119114747	chr10:119003536~119003884:-
THCA	cis	rs929354	0.742	rs7807556	ENSG00000224629.1	RP5-1142J19.2	-3.48	0.000547	0.0329	-0.16	-0.16	Body mass index;	chr7:157141635	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs3802125	ENSG00000224629.1	RP5-1142J19.2	-3.48	0.000547	0.0329	-0.16	-0.16	Body mass index;	chr7:157177869	chr7:157263022~157263229:-
THCA	cis	rs2904967	1	rs487989	ENSG00000254614.2	AP003068.23	3.48	0.000547	0.0329	0.3	0.16	Mean corpuscular volume;	chr11:65297219	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.929	rs655433	ENSG00000254614.2	AP003068.23	3.48	0.000547	0.0329	0.3	0.16	Mean corpuscular volume;	chr11:65301804	chr11:65177606~65181834:-
THCA	cis	rs7709377	0.723	rs7717693	ENSG00000248445.4	SEMA6A-AS1	-3.48	0.000547	0.0329	-0.14	-0.16	Metabolite levels  (X-11787);	chr5:116328266	chr5:116447547~116508276:+
THCA	cis	rs7520050	0.966	rs4073846	ENSG00000280836.1	AL355480.1	-3.48	0.000547	0.0329	-0.19	-0.16	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45581219~45581321:-
THCA	cis	rs3812762	0.871	rs3844100	ENSG00000254860.4	TMEM9B-AS1	-3.48	0.000547	0.0329	-0.18	-0.16	Hypospadias;	chr11:8796261	chr11:8964675~8977527:+
THCA	cis	rs41313321	0.688	rs12005136	ENSG00000272696.1	RP11-339B21.13	-3.48	0.000547	0.0329	-0.12	-0.16	Coenzyme Q10 levels;	chr9:128297551	chr9:128316337~128316909:+
THCA	cis	rs2762353	0.526	rs3936052	ENSG00000272462.2	U91328.19	-3.48	0.000547	0.0329	-0.13	-0.16	Blood metabolite levels;	chr6:25715306	chr6:25992662~26001775:+
THCA	cis	rs4853036	0.951	rs6710444	ENSG00000179818.12	PCBP1-AS1	-3.48	0.000547	0.0329	-0.13	-0.16	Colorectal or endometrial cancer;	chr2:69893500	chr2:69962263~70103220:-
THCA	cis	rs6120849	0.707	rs3746444	ENSG00000269202.1	RP4-614O4.12	-3.48	0.000547	0.0329	-0.17	-0.16	Protein C levels;	chr20:34990448	chr20:35201747~35203288:-
THCA	cis	rs643506	0.817	rs658373	ENSG00000230911.1	PPIHP1	-3.48	0.000547	0.0329	-0.22	-0.16	Breast cancer;	chr11:111812267	chr11:112029858~112030367:-
THCA	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	3.48	0.000547	0.0329	0.21	0.16	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
THCA	cis	rs4788570	0.697	rs2334877	ENSG00000260185.1	RP11-432I5.6	-3.48	0.000547	0.0329	-0.3	-0.16	Intelligence (multi-trait analysis);	chr16:71799429	chr16:71655027~71664212:+
THCA	cis	rs2288884	0.515	rs3752118	ENSG00000269483.1	AC006272.1	3.48	0.000547	0.0329	0.17	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:51839924~51843324:-
THCA	cis	rs7182621	1	rs7182621	ENSG00000182397.13	DNM1P46	-3.48	0.000547	0.0329	-0.17	-0.16	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99790156~99806927:-
THCA	cis	rs7264396	0.79	rs3787164	ENSG00000088340.14	FER1L4	3.48	0.000547	0.0329	0.16	0.16	Total cholesterol levels;	chr20:35640944	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.622	rs3787165	ENSG00000088340.14	FER1L4	3.48	0.000547	0.0329	0.16	0.16	Total cholesterol levels;	chr20:35641024	chr20:35558737~35607562:-
THCA	cis	rs9341808	0.754	rs978814	ENSG00000260645.1	RP11-250B2.5	3.48	0.000548	0.0329	0.14	0.16	Sitting height ratio;	chr6:80250195	chr6:80466958~80469080:+
THCA	cis	rs6427356	0.876	rs1176548	ENSG00000237189.1	RP11-85G21.2	3.48	0.000548	0.0329	0.18	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157164615	chr1:157287703~157288053:-
THCA	cis	rs6012953	1	rs6091173	ENSG00000232043.1	RP4-530I15.9	3.48	0.000548	0.0329	0.11	0.16	Vitiligo;	chr20:50517562	chr20:50570975~50578041:-
THCA	cis	rs6840360	0.615	rs6858483	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000548	0.0329	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151544357	chr4:151407551~151408835:-
THCA	cis	rs7264396	0.887	rs4281980	ENSG00000261582.1	RP4-614O4.11	-3.48	0.000548	0.0329	-0.16	-0.16	Total cholesterol levels;	chr20:35508752	chr20:35267885~35280043:-
THCA	cis	rs9911578	0.967	rs4132925	ENSG00000224738.1	AC099850.1	-3.48	0.000548	0.0329	-0.18	-0.16	Intelligence (multi-trait analysis);	chr17:58860655	chr17:59106598~59118267:+
THCA	cis	rs720064	0.586	rs9958904	ENSG00000264745.1	TTC39C-AS1	-3.48	0.000548	0.0329	-0.17	-0.16	Strep throat;	chr18:23969940	chr18:23994213~24015339:-
THCA	cis	rs911555	0.603	rs11626562	ENSG00000244691.1	RPL10AP1	-3.48	0.000548	0.0329	-0.21	-0.16	Intelligence (multi-trait analysis);	chr14:103379025	chr14:103412119~103412761:-
THCA	cis	rs66561647	0.611	rs7004509	ENSG00000207110.1	RNU1-106P	-3.48	0.000548	0.0329	-0.2	-0.16	Hemoglobin concentration;	chr8:127961419	chr8:127999131~127999294:+
THCA	cis	rs76878669	0.561	rs7948058	ENSG00000255320.1	RP11-755F10.1	3.48	0.000548	0.0329	0.2	0.16	Educational attainment (years of education);	chr11:66380640	chr11:66244840~66246239:-
THCA	cis	rs7615952	0.546	rs4428131	ENSG00000272840.1	RP11-379B18.6	3.48	0.000548	0.0329	0.26	0.16	Blood pressure (smoking interaction);	chr3:125627635	chr3:125774714~125797953:+
THCA	cis	rs6920965	0.509	rs575811	ENSG00000237742.5	RP11-624M8.1	3.48	0.000548	0.0329	0.14	0.16	High light scatter reticulocyte count;	chr6:125841136	chr6:125578558~125749190:-
THCA	cis	rs7824557	0.564	rs6601584	ENSG00000261451.1	RP11-981G7.1	-3.48	0.000548	0.0329	-0.2	-0.16	Retinal vascular caliber;	chr8:11374834	chr8:10433672~10438312:+
THCA	cis	rs9818758	0.607	rs5030795	ENSG00000229759.1	MRPS18AP1	-3.48	0.000548	0.0329	-0.33	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49103683	chr3:48256350~48256938:-
THCA	cis	rs12753569	0.748	rs1013629	ENSG00000272855.1	RP5-1102E8.3	-3.48	0.000548	0.0329	-0.2	-0.16	Personality dimensions;	chr1:76048074	chr1:76636877~76637339:+
THCA	cis	rs337161	0.719	rs10779415	ENSG00000221571.3	RNU6ATAC35P	-3.48	0.000548	0.0329	-0.18	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220762466	chr1:220825620~220826063:+
THCA	cis	rs7220401	0.789	rs4794859	ENSG00000264290.1	RP11-68I3.4	-3.48	0.000548	0.0329	-0.12	-0.16	Coronary artery disease;	chr17:29635375	chr17:29569580~29570519:+
THCA	cis	rs7444	0.941	rs4821116	ENSG00000253120.1	IGLV2-34	3.48	0.000548	0.0329	0.11	0.16	Systemic lupus erythematosus;	chr22:21619030	chr22:22580014~22580296:+
THCA	cis	rs2281558	0.876	rs2274890	ENSG00000276952.1	RP5-965G21.6	3.48	0.000548	0.0329	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:25284915~25285588:-
THCA	cis	rs1124769	0.871	rs2619695	ENSG00000259378.1	DCAF13P3	-3.48	0.000548	0.033	-0.25	-0.16	Cognitive performance;	chr15:50867893	chr15:50944663~50945996:+
THCA	cis	rs3783637	0.558	rs73266060	ENSG00000258413.1	RP11-665C16.6	-3.48	0.000548	0.033	-0.33	-0.16	Rheumatoid arthritis;Obesity-related traits;	chr14:54991516	chr14:55262767~55272075:-
THCA	cis	rs6076960	0.682	rs6054065	ENSG00000233578.1	EIF4EP1	3.48	0.000548	0.033	0.15	0.16	Smooth-surface caries;	chr20:6287273	chr20:5548840~5549481:+
THCA	cis	rs925946	0.899	rs11030119	ENSG00000245573.6	BDNF-AS	-3.48	0.000548	0.033	-0.15	-0.16	Weight;Body mass index;	chr11:27706555	chr11:27506838~27698174:+
THCA	cis	rs7096965	0.958	rs11813925	ENSG00000242147.1	RP13-463N16.6	-3.48	0.000548	0.033	-0.18	-0.16	Major depressive disorder;	chr10:4605360	chr10:5594991~5596118:-
THCA	cis	rs9420	0.528	rs73480556	ENSG00000254602.1	AP000662.4	-3.48	0.000548	0.033	-0.18	-0.16	Schizophrenia;	chr11:57632989	chr11:57638024~57652790:+
THCA	cis	rs3758911	0.894	rs12285491	ENSG00000255353.1	RP11-382M14.1	-3.48	0.000548	0.033	-0.2	-0.16	Coronary artery disease;	chr11:107340319	chr11:107176286~107177530:+
THCA	cis	rs10483853	0.806	rs66498577	ENSG00000258891.1	RP5-1021I20.5	-3.48	0.000548	0.033	-0.21	-0.16	Coronary artery calcification;	chr14:73292012	chr14:73896164~73938114:-
THCA	cis	rs7521902	0.521	rs3765350	ENSG00000218510.5	LINC00339	-3.48	0.000548	0.033	-0.19	-0.16	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22120823	chr1:22025188~22031223:+
THCA	cis	rs11039798	0.66	rs717897	ENSG00000200090.1	Y_RNA	-3.48	0.000548	0.033	-0.13	-0.16	Axial length;	chr11:48354052	chr11:47726894~47726992:-
THCA	cis	rs7903847	0.642	rs9888026	ENSG00000225850.3	RP11-452K12.4	-3.48	0.000548	0.033	-0.16	-0.16	Granulocyte percentage of myeloid white cells;	chr10:97400112	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10882926	ENSG00000225850.3	RP11-452K12.4	-3.48	0.000548	0.033	-0.16	-0.16	Granulocyte percentage of myeloid white cells;	chr10:97400933	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10882923	ENSG00000225850.3	RP11-452K12.4	3.48	0.000548	0.033	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97399261	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.646	rs10882924	ENSG00000225850.3	RP11-452K12.4	3.48	0.000548	0.033	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97399547	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.619	rs9888116	ENSG00000225850.3	RP11-452K12.4	3.48	0.000548	0.033	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97399725	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs9887991	ENSG00000225850.3	RP11-452K12.4	3.48	0.000548	0.033	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97399877	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs9888117	ENSG00000225850.3	RP11-452K12.4	3.48	0.000548	0.033	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97400206	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs2297668	ENSG00000225850.3	RP11-452K12.4	3.48	0.000548	0.033	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97400289	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs1048442	ENSG00000225850.3	RP11-452K12.4	3.48	0.000548	0.033	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97400395	chr10:97334564~97343203:+
THCA	cis	rs7590720	1	rs934156	ENSG00000226276.1	AC093382.1	-3.48	0.000548	0.033	-0.19	-0.16	Alcohol dependence;	chr2:216036759	chr2:215939308~215941719:-
THCA	cis	rs12659144	0.891	rs2909726	ENSG00000249031.1	SUMO2P6	3.48	0.000548	0.033	0.25	0.16	Multiple myeloma (hyperdiploidy);	chr5:174354913	chr5:174561776~174562063:+
THCA	cis	rs2830585	0.677	rs229048	ENSG00000223563.1	AP001601.2	3.48	0.000548	0.033	0.19	0.16	Blood protein levels;	chr21:26941711	chr21:26889376~26939742:+
THCA	cis	rs76878669	0.561	rs2279862	ENSG00000255320.1	RP11-755F10.1	-3.48	0.000548	0.033	-0.2	-0.16	Educational attainment (years of education);	chr11:66367708	chr11:66244840~66246239:-
THCA	cis	rs76878669	0.561	rs12416747	ENSG00000255320.1	RP11-755F10.1	-3.48	0.000548	0.033	-0.2	-0.16	Educational attainment (years of education);	chr11:66368143	chr11:66244840~66246239:-
THCA	cis	rs76878669	0.561	rs7107191	ENSG00000255320.1	RP11-755F10.1	-3.48	0.000548	0.033	-0.2	-0.16	Educational attainment (years of education);	chr11:66372926	chr11:66244840~66246239:-
THCA	cis	rs7577696	0.524	rs12991444	ENSG00000276517.1	AL133243.2	3.48	0.000548	0.033	0.16	0.16	Inflammatory biomarkers;	chr2:32040056	chr2:32526504~32529507:+
THCA	cis	rs2977125	0.815	rs2956757	ENSG00000251468.2	RP11-369K16.1	-3.48	0.000548	0.033	-0.23	-0.16	Schizophrenia;	chr8:12893022	chr8:12958387~12962200:+
THCA	cis	rs875971	0.789	rs7808013	ENSG00000223473.2	GS1-124K5.3	-3.48	0.000548	0.033	-0.11	-0.16	Aortic root size;	chr7:66606209	chr7:66491049~66493566:-
THCA	cis	rs9450351	0.744	rs6902904	ENSG00000280232.1	RP11-321N4.4	3.48	0.000548	0.033	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85492985	chr6:85498441~85499058:-
THCA	cis	rs2664588	0.566	rs6018817	ENSG00000276923.1	RP11-321P16.1	-3.48	0.000548	0.033	-0.21	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47963424	chr20:48073869~48074188:+
THCA	cis	rs806215	0.526	rs322819	ENSG00000224138.1	AC000123.4	-3.48	0.000549	0.033	-0.16	-0.16	Type 2 diabetes;	chr7:128093313	chr7:127350128~127351523:+
THCA	cis	rs1412115	0.871	rs10827285	ENSG00000233387.1	RP11-342D11.3	-3.48	0.000549	0.033	-0.16	-0.16	Schizophrenia;	chr10:33784901	chr10:33096257~33116672:-
THCA	cis	rs3743772	0.5	rs11859135	ENSG00000279344.1	RP11-44F14.7	3.48	0.000549	0.033	0.22	0.16	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53478957~53481550:-
THCA	cis	rs1865760	0.593	rs9393676	ENSG00000272810.1	U91328.22	-3.48	0.000549	0.033	-0.12	-0.16	Height;	chr6:25936716	chr6:26013241~26013757:+
THCA	cis	rs10911902	0.643	rs76469621	ENSG00000228238.1	GS1-304P7.2	-3.48	0.000549	0.033	-0.25	-0.16	Schizophrenia;	chr1:186363848	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs79081972	ENSG00000228238.1	GS1-304P7.2	-3.48	0.000549	0.033	-0.25	-0.16	Schizophrenia;	chr1:186364669	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs75490185	ENSG00000228238.1	GS1-304P7.2	-3.48	0.000549	0.033	-0.25	-0.16	Schizophrenia;	chr1:186366319	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs112738913	ENSG00000228238.1	GS1-304P7.2	-3.48	0.000549	0.033	-0.25	-0.16	Schizophrenia;	chr1:186367231	chr1:186578279~186579299:+
THCA	cis	rs1030877	0.924	rs2250658	ENSG00000235319.1	AC012360.4	-3.48	0.000549	0.033	-0.18	-0.16	Obesity-related traits;	chr2:105273226	chr2:105324210~105330529:+
THCA	cis	rs1030877	1	rs2241797	ENSG00000235319.1	AC012360.4	-3.48	0.000549	0.033	-0.18	-0.16	Obesity-related traits;	chr2:105269504	chr2:105324210~105330529:+
THCA	cis	rs72819454	0.522	rs55921327	ENSG00000280693.1	SH3PXD2A-AS1	-3.48	0.000549	0.033	-0.33	-0.16	Interleukin-9 levels;	chr10:103756584	chr10:103745966~103755423:+
THCA	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	3.48	0.000549	0.033	0.18	0.16	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	3.48	0.000549	0.033	0.18	0.16	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
THCA	cis	rs2665103	0.632	rs3902959	ENSG00000276710.3	CSPG4P8	-3.48	0.000549	0.033	-0.15	-0.16	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82459472~82477258:+
THCA	cis	rs237743	0.896	rs2063710	ENSG00000222365.1	SNORD12B	3.48	0.000549	0.033	0.2	0.16	Height;	chr20:49215517	chr20:49280319~49280409:+
THCA	cis	rs237743	1	rs6012617	ENSG00000222365.1	SNORD12B	3.48	0.000549	0.033	0.2	0.16	Height;	chr20:49220589	chr20:49280319~49280409:+
THCA	cis	rs5770917	1	rs762677	ENSG00000279182.1	XX-C00717C00720L.1	3.48	0.000549	0.033	0.25	0.16	Narcolepsy;	chr22:50579284	chr22:50316035~50317025:+
THCA	cis	rs5770917	1	rs762676	ENSG00000279182.1	XX-C00717C00720L.1	3.48	0.000549	0.033	0.25	0.16	Narcolepsy;	chr22:50579365	chr22:50316035~50317025:+
THCA	cis	rs2562456	0.833	rs11880624	ENSG00000268278.1	RP11-420K14.1	3.48	0.000549	0.033	0.22	0.16	Pain;	chr19:21341028	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs62107547	ENSG00000268278.1	RP11-420K14.1	3.48	0.000549	0.033	0.22	0.16	Pain;	chr19:21341245	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs56187954	ENSG00000268278.1	RP11-420K14.1	3.48	0.000549	0.033	0.22	0.16	Pain;	chr19:21345258	chr19:21637974~21656300:+
THCA	cis	rs7911264	0.967	rs2488087	ENSG00000232709.1	MARK2P9	3.48	0.000549	0.033	0.19	0.16	Inflammatory bowel disease;	chr10:92686284	chr10:92418667~92420875:+
THCA	cis	rs9534288	0.83	rs1548325	ENSG00000235903.6	CPB2-AS1	3.48	0.000549	0.033	0.23	0.16	Blood protein levels;	chr13:46060966	chr13:46052806~46113332:+
THCA	cis	rs1941184	0.526	rs112243414	ENSG00000263823.1	RP11-326K13.4	-3.48	0.000549	0.033	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31454812	chr18:31942575~31944156:+
THCA	cis	rs416603	0.967	rs7191538	ENSG00000263179.1	HNRNPCP4	3.48	0.000549	0.033	0.2	0.16	Type 1 diabetes;	chr16:11269532	chr16:11242653~11243552:+
THCA	cis	rs73198271	0.74	rs10098636	ENSG00000254340.1	RP11-10A14.3	-3.48	0.000549	0.033	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:9141424~9145435:+
THCA	cis	rs13720	0.722	rs163795	ENSG00000225806.6	RP1-309F20.3	-3.48	0.000549	0.033	-0.17	-0.16	Platelet distribution width;	chr20:59002450	chr20:58863528~58888809:-
THCA	cis	rs301901	0.729	rs125682	ENSG00000250155.1	CTD-2353F22.1	-3.48	0.000549	0.033	-0.16	-0.16	Height;	chr5:37337045	chr5:36666214~36725195:-
THCA	cis	rs61160187	0.582	rs12654306	ENSG00000272308.1	RP11-231G3.1	-3.48	0.000549	0.033	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60866457~60866935:-
THCA	cis	rs11212260	0.85	rs536079	ENSG00000261098.1	RP11-819C21.1	-3.48	0.000549	0.033	-0.33	-0.16	IgG glycosylation;	chr11:107493838	chr11:107312132~107316271:-
THCA	cis	rs57709857	0.756	rs57011135	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000549	0.033	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38335493	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.874	rs60312002	ENSG00000272092.1	RP11-350N15.5	-3.48	0.000549	0.033	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38335495	chr8:38382364~38383461:+
THCA	cis	rs4886920	0.563	rs4511491	ENSG00000260776.4	RP11-114H24.2	-3.48	0.000549	0.033	-0.19	-0.16	Neuroticism;	chr15:77786962	chr15:77914217~77926846:-
THCA	cis	rs4886920	0.563	rs4420498	ENSG00000260776.4	RP11-114H24.2	-3.48	0.000549	0.033	-0.19	-0.16	Neuroticism;	chr15:77787083	chr15:77914217~77926846:-
THCA	cis	rs4886920	0.601	rs4589520	ENSG00000260776.4	RP11-114H24.2	-3.48	0.000549	0.033	-0.19	-0.16	Neuroticism;	chr15:77787092	chr15:77914217~77926846:-
THCA	cis	rs2032366	1	rs8088329	ENSG00000267316.4	RP11-879F14.3	-3.48	0.000549	0.033	-0.17	-0.16	Obesity-related traits;	chr18:61595758	chr18:61571342~61579456:-
THCA	cis	rs10129255	0.957	rs10136817	ENSG00000280411.1	IGHV1-69-2	-3.48	0.000549	0.033	-0.1	-0.16	Kawasaki disease;	chr14:106787730	chr14:106762092~106762588:-
THCA	cis	rs7772697	0.508	rs6570927	ENSG00000223701.3	RAET1E-AS1	-3.48	0.000549	0.033	-0.22	-0.16	Diabetic retinopathy;	chr6:149049473	chr6:149884431~149919508:+
THCA	cis	rs12612619	0.689	rs1124649	ENSG00000231636.1	AGBL5-AS1	-3.48	0.000549	0.033	-0.2	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27037601	chr2:27049683~27050264:-
THCA	cis	rs34102591	0.535	rs7964324	ENSG00000270061.1	RP11-214K3.19	-3.48	0.000549	0.033	-0.21	-0.16	Schizophrenia;	chr12:123900978	chr12:123969990~123970344:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000237310.1	GS1-124K5.4	-3.48	0.000549	0.033	-0.19	-0.16	Diabetic kidney disease;	chr7:66253864	chr7:66493706~66495474:+
THCA	cis	rs10844154	0.508	rs2129590	ENSG00000277342.1	RP11-843B15.4	3.48	0.000549	0.033	0.2	0.16	Emphysema-related traits;Weight;	chr12:32273455	chr12:32109076~32109602:+
THCA	cis	rs2447820	0.52	rs12055325	ENSG00000263432.2	RN7SL689P	3.48	0.000549	0.033	0.2	0.16	Migraine;	chr5:123033043	chr5:123022487~123022783:-
THCA	cis	rs3104964	1	rs3104964	ENSG00000253773.2	C8orf37-AS1	-3.48	0.000549	0.033	-0.2	-0.16	Colorectal cancer;	chr8:95583508	chr8:95204456~95810136:+
THCA	cis	rs3790515	1	rs12145375	ENSG00000268288.1	RP11-98D18.16	-3.48	0.00055	0.033	-0.26	-0.16	Depressive symptoms (SSRI exposure interaction);	chr1:151812753	chr1:151766486~151767000:-
THCA	cis	rs911555	0.755	rs17841064	ENSG00000269940.1	RP11-73M18.7	3.48	0.00055	0.033	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103694560~103695170:+
THCA	cis	rs4886920	0.563	rs4542627	ENSG00000260776.4	RP11-114H24.2	3.48	0.00055	0.033	0.19	0.16	Neuroticism;	chr15:77778401	chr15:77914217~77926846:-
THCA	cis	rs4931000	1	rs7302975	ENSG00000255760.1	RP11-428G5.5	-3.48	0.00055	0.033	-0.16	-0.16	Testicular germ cell tumor;	chr12:31985990	chr12:31877079~31887203:-
THCA	cis	rs11665867	0.877	rs66865752	ENSG00000279108.1	CTC-490E21.11	-3.48	0.00055	0.033	-0.24	-0.16	Hematocrit;	chr19:40746270	chr19:40840159~40842039:+
THCA	cis	rs1023500	0.573	rs133382	ENSG00000270083.1	RP1-257I20.14	3.48	0.00055	0.033	0.18	0.16	Schizophrenia;	chr22:42075770	chr22:42089630~42090028:-
THCA	cis	rs1023500	0.573	rs1807494	ENSG00000270083.1	RP1-257I20.14	-3.48	0.00055	0.033	-0.18	-0.16	Schizophrenia;	chr22:42078134	chr22:42089630~42090028:-
THCA	cis	rs875971	0.545	rs35459055	ENSG00000230295.1	RP11-458F8.2	3.48	0.00055	0.033	0.14	0.16	Aortic root size;	chr7:66479399	chr7:66880708~66882981:+
THCA	cis	rs271738	0.642	rs271765	ENSG00000231768.1	LINC01354	3.48	0.00055	0.033	0.18	0.16	Bipolar disorder;	chr1:234538167	chr1:234527891~234531779:-
THCA	cis	rs7395662	1	rs7482528	ENSG00000200090.1	Y_RNA	-3.48	0.00055	0.033	-0.11	-0.16	HDL cholesterol;	chr11:48618500	chr11:47726894~47726992:-
THCA	cis	rs8030379	1	rs1564473	ENSG00000176700.18	SCAND2P	-3.48	0.00055	0.033	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901190	chr15:84631451~84647478:+
THCA	cis	rs495337	1	rs2281216	ENSG00000229222.1	KRT18P4	-3.48	0.00055	0.033	-0.2	-0.16	Psoriasis;	chr20:49951966	chr20:49956745~49958032:+
THCA	cis	rs763121	0.626	rs5750643	ENSG00000225450.1	RP3-508I15.14	-3.48	0.00055	0.033	-0.12	-0.16	Menopause (age at onset);	chr22:38613012	chr22:38739003~38749041:+
THCA	cis	rs9903692	0.779	rs2285863	ENSG00000263412.1	RP5-890E16.2	-3.48	0.00055	0.033	-0.11	-0.16	Pulse pressure;	chr17:48048616	chr17:48045141~48048073:-
THCA	cis	rs8062405	0.688	rs3924376	ENSG00000278665.1	RP11-666O2.4	-3.48	0.00055	0.033	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28599241~28601881:-
THCA	cis	rs172166	0.561	rs149973	ENSG00000261839.1	RP1-265C24.8	3.48	0.00055	0.033	0.15	0.16	Cardiac Troponin-T levels;	chr6:28015835	chr6:28136849~28139678:+
THCA	cis	rs172166	0.561	rs149974	ENSG00000261839.1	RP1-265C24.8	3.48	0.00055	0.033	0.15	0.16	Cardiac Troponin-T levels;	chr6:28017318	chr6:28136849~28139678:+
THCA	cis	rs929354	0.772	rs1182364	ENSG00000224629.1	RP5-1142J19.2	3.48	0.00055	0.033	0.15	0.16	Body mass index;	chr7:157225218	chr7:157263022~157263229:-
THCA	cis	rs929354	0.772	rs1182362	ENSG00000224629.1	RP5-1142J19.2	3.48	0.00055	0.033	0.15	0.16	Body mass index;	chr7:157226841	chr7:157263022~157263229:-
THCA	cis	rs1538970	0.781	rs12049503	ENSG00000281133.1	AL355480.3	-3.48	0.00055	0.0331	-0.2	-0.16	Platelet count;	chr1:45555884	chr1:45580892~45580996:-
THCA	cis	rs7267979	0.844	rs35735333	ENSG00000276952.1	RP5-965G21.6	-3.48	0.00055	0.0331	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25284915~25285588:-
THCA	cis	rs9467773	0.62	rs2101582	ENSG00000228223.2	HCG11	-3.48	0.00055	0.0331	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26523450~26526579:+
THCA	cis	rs6546550	0.867	rs1551374	ENSG00000179818.12	PCBP1-AS1	-3.48	0.00055	0.0331	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69852501	chr2:69962263~70103220:-
THCA	cis	rs11630316	0.632	rs7162712	ENSG00000281264.1	SALRNA3	3.48	0.00055	0.0331	0.18	0.16	Cognitive function;	chr15:70070221	chr15:70615547~70616567:+
THCA	cis	rs11098699	0.614	rs11098707	ENSG00000273007.1	RP11-170N16.3	3.48	0.00055	0.0331	0.13	0.16	Mosquito bite size;	chr4:123348703	chr4:122881878~122884712:-
THCA	cis	rs9450351	0.744	rs6906618	ENSG00000203875.9	SNHG5	-3.48	0.00055	0.0331	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85741719	chr6:85660950~85678736:-
THCA	cis	rs7760535	0.656	rs1883136	ENSG00000231889.6	TRAF3IP2-AS1	3.48	0.00055	0.0331	0.14	0.16	Metabolic traits;	chr6:111585820	chr6:111483511~111598302:+
THCA	cis	rs11069062	0.683	rs7302736	ENSG00000270482.1	RP11-131L12.2	3.48	0.00055	0.0331	0.12	0.16	Obesity-related traits;	chr12:118742861	chr12:118375350~118376275:-
THCA	cis	rs9900062	1	rs9900062	ENSG00000214176.8	PLEKHM1P	3.48	0.00055	0.0331	0.14	0.16	QT interval;	chr17:64743456	chr17:64779259~64837154:-
THCA	cis	rs7267979	0.565	rs4815437	ENSG00000276952.1	RP5-965G21.6	-3.48	0.00055	0.0331	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:25284915~25285588:-
THCA	cis	rs4489787	0.568	rs2705160	ENSG00000273765.1	RP11-370I10.11	3.48	0.00055	0.0331	0.18	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48507373	chr12:48360920~48361377:+
THCA	cis	rs875971	0.597	rs11763224	ENSG00000232559.3	GS1-124K5.12	3.48	0.00055	0.0331	0.17	0.16	Aortic root size;	chr7:66518628	chr7:66554588~66576923:-
THCA	cis	rs4730276	0.674	rs6466206	ENSG00000250474.1	WBP1LP2	-3.48	0.00055	0.0331	-0.15	-0.16	Ulcerative colitis;	chr7:107911314	chr7:107628553~107629498:+
THCA	cis	rs4730276	0.608	rs35765154	ENSG00000250474.1	WBP1LP2	-3.48	0.00055	0.0331	-0.15	-0.16	Ulcerative colitis;	chr7:107912296	chr7:107628553~107629498:+
THCA	cis	rs3734266	0.639	rs7739385	ENSG00000272288.4	RP11-140K17.3	-3.48	0.00055	0.0331	-0.16	-0.16	Systemic lupus erythematosus;	chr6:34899701	chr6:34696317~34697470:+
THCA	cis	rs875971	1	rs2420820	ENSG00000272831.1	RP11-792A8.4	-3.48	0.00055	0.0331	-0.1	-0.16	Aortic root size;	chr7:66626920	chr7:66739829~66740385:-
THCA	cis	rs365302	1	rs294920	ENSG00000235086.1	FNDC1-IT1	3.48	0.00055	0.0331	0.22	0.16	Coronary heart disease;	chr6:159201770	chr6:159240786~159243329:+
THCA	cis	rs9450351	0.744	rs6923017	ENSG00000280232.1	RP11-321N4.4	3.48	0.00055	0.0331	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85592619	chr6:85498441~85499058:-
THCA	cis	rs9353324	1	rs7775788	ENSG00000280232.1	RP11-321N4.4	3.48	0.00055	0.0331	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85595761	chr6:85498441~85499058:-
THCA	cis	rs9876781	1	rs10470686	ENSG00000199476.1	Y_RNA	-3.48	0.00055	0.0331	-0.2	-0.16	Longevity;	chr3:48408549	chr3:48288587~48288694:+
THCA	cis	rs17092148	0.636	rs66535774	ENSG00000269202.1	RP4-614O4.12	-3.48	0.000551	0.0331	-0.16	-0.16	Neuroticism;	chr20:34860757	chr20:35201747~35203288:-
THCA	cis	rs55661361	0.965	rs12293670	ENSG00000245498.5	RP11-677M14.7	3.48	0.000551	0.0331	0.11	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124743036	chr11:124800450~124834487:+
THCA	cis	rs6449502	1	rs6869332	ENSG00000251279.1	CTC-436P18.1	3.48	0.000551	0.0331	0.25	0.16	Mean platelet volume;	chr5:60833534	chr5:61162070~61232040:+
THCA	cis	rs1124769	0.797	rs71471593	ENSG00000259378.1	DCAF13P3	3.48	0.000551	0.0331	0.26	0.16	Cognitive performance;	chr15:51138628	chr15:50944663~50945996:+
THCA	cis	rs11039798	0.588	rs12294395	ENSG00000200090.1	Y_RNA	3.48	0.000551	0.0331	0.13	0.16	Axial length;	chr11:48455308	chr11:47726894~47726992:-
THCA	cis	rs4660456	0.913	rs4660449	ENSG00000238287.1	RP11-656D10.3	3.48	0.000551	0.0331	0.2	0.16	Platelet count;	chr1:40739780	chr1:40493157~40508661:-
THCA	cis	rs1850744	0.826	rs7685513	ENSG00000249767.1	ENPP7P10	3.48	0.000551	0.0331	0.28	0.16	Economic and political preferences;	chr4:9726975	chr4:9079023~9141608:+
THCA	cis	rs1865760	0.593	rs9295678	ENSG00000272810.1	U91328.22	-3.48	0.000551	0.0331	-0.12	-0.16	Height;	chr6:25936805	chr6:26013241~26013757:+
THCA	cis	rs2839627	0.608	rs2001521	ENSG00000225218.1	AP001628.6	3.48	0.000551	0.0331	0.28	0.16	Information processing speed;	chr21:42812070	chr21:42831040~42836477:-
THCA	cis	rs1124769	0.827	rs77725238	ENSG00000259378.1	DCAF13P3	3.48	0.000551	0.0331	0.25	0.16	Cognitive performance;	chr15:50807448	chr15:50944663~50945996:+
THCA	cis	rs2688608	0.653	rs12775558	ENSG00000272140.2	RP11-574K11.29	3.48	0.000551	0.0331	0.14	0.16	Inflammatory bowel disease;	chr10:73811110	chr10:73703735~73713581:-
THCA	cis	rs11681884	0.786	rs34466405	ENSG00000272563.1	RP11-480C16.1	-3.48	0.000551	0.0331	-0.35	-0.16	Stroke;	chr2:113050477	chr2:113432600~113436042:+
THCA	cis	rs1563304	1	rs1563304	ENSG00000261575.2	RP11-259G18.1	3.48	0.000551	0.0331	0.27	0.16	Neuroticism;	chr17:46797087	chr17:46267037~46268694:+
THCA	cis	rs6890684	0.542	rs62366215	ENSG00000251279.1	CTC-436P18.1	-3.48	0.000551	0.0331	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61253693	chr5:61162070~61232040:+
THCA	cis	rs34421088	0.56	rs2618434	ENSG00000270154.1	RP11-419I17.1	-3.48	0.000551	0.0331	-0.2	-0.16	Neuroticism;	chr8:11541356	chr8:12476462~12477122:+
THCA	cis	rs3026101	0.671	rs56190856	ENSG00000234327.6	AC012146.7	-3.48	0.000551	0.0331	-0.13	-0.16	Body mass index;	chr17:5393829	chr17:5111468~5115004:+
THCA	cis	rs78153629	1	rs7166991	ENSG00000259330.1	INAFM2	-3.48	0.000551	0.0331	-0.19	-0.16	Heschl's gyrus morphology;	chr15:40379756	chr15:40325216~40326715:+
THCA	cis	rs2386661	0.516	rs61832676	ENSG00000231483.1	RP11-336A10.5	3.48	0.000551	0.0331	0.17	0.16	Breast cancer;	chr10:5604374	chr10:5608475~5610793:-
THCA	cis	rs7772486	0.875	rs56181683	ENSG00000270638.1	RP3-466P17.1	-3.48	0.000551	0.0331	-0.12	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145735570~145737218:+
THCA	cis	rs10090774	0.76	rs6993266	ENSG00000280303.2	ERICD	3.48	0.000551	0.0331	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140752560	chr8:140636281~140638283:+
THCA	cis	rs6918586	0.565	rs198855	ENSG00000272462.2	U91328.19	-3.48	0.000551	0.0331	-0.14	-0.16	Schizophrenia;	chr6:26103170	chr6:25992662~26001775:+
THCA	cis	rs4713118	0.824	rs9468225	ENSG00000216915.2	RP1-97D16.1	-3.48	0.000551	0.0331	-0.24	-0.16	Parkinson's disease;	chr6:27777940	chr6:27737000~27738494:-
THCA	cis	rs7903456	0.512	rs7083075	ENSG00000200253.1	RNU6-529P	3.48	0.000551	0.0331	0.22	0.16	Gout;Renal underexcretion gout;	chr10:87056203	chr10:87041238~87041341:-
THCA	cis	rs860295	1	rs860295	ENSG00000160766.13	GBAP1	3.48	0.000551	0.0331	0.18	0.16	Body mass index;	chr1:155797917	chr1:155213821~155227422:-
THCA	cis	rs4948275	0.631	rs2606114	ENSG00000233643.2	RP11-491H19.1	3.48	0.000551	0.0331	0.18	0.16	Night sleep phenotypes;	chr10:61589393	chr10:61781745~61821246:-
THCA	cis	rs61160187	0.582	rs4647132	ENSG00000272308.1	RP11-231G3.1	-3.48	0.000551	0.0331	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60866457~60866935:-
THCA	cis	rs4073416	0.542	rs8007497	ENSG00000276116.2	FUT8-AS1	3.48	0.000551	0.0331	0.17	0.16	N-glycan levels;	chr14:65577758	chr14:65411170~65412690:-
THCA	cis	rs2131877	0.528	rs4677809	ENSG00000273009.1	RP11-352G9.1	3.48	0.000551	0.0331	0.17	0.16	Non-small cell lung cancer;	chr3:195115982	chr3:195913078~195913683:-
THCA	cis	rs494526	0.641	rs11198783	ENSG00000229272.1	RP11-498J9.2	-3.48	0.000551	0.0331	-0.18	-0.16	Alcoholic chronic pancreatitis;	chr10:119115358	chr10:119003536~119003884:-
THCA	cis	rs12210905	1	rs12209429	ENSG00000224843.5	LINC00240	3.48	0.000551	0.0331	0.26	0.16	Hip circumference adjusted for BMI;	chr6:27087088	chr6:26956992~27023924:+
THCA	cis	rs7615952	0.599	rs12486459	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000551	0.0331	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126022622	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.599	rs67575510	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000551	0.0331	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126023512	chr3:125827238~125916384:-
THCA	cis	rs7267979	0.844	rs4815413	ENSG00000276952.1	RP5-965G21.6	-3.48	0.000551	0.0331	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.844	rs6083824	ENSG00000276952.1	RP5-965G21.6	-3.48	0.000551	0.0331	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.844	rs6076343	ENSG00000276952.1	RP5-965G21.6	-3.48	0.000551	0.0331	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25284915~25285588:-
THCA	cis	rs5771242	0.518	rs7290465	ENSG00000280567.1	Metazoa_SRP	3.48	0.000551	0.0331	0.21	0.16	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50241329	chr22:49878999~49879242:+
THCA	cis	rs4931000	0.836	rs4930999	ENSG00000255760.1	RP11-428G5.5	-3.48	0.000551	0.0331	-0.16	-0.16	Testicular germ cell tumor;	chr12:31969279	chr12:31877079~31887203:-
THCA	cis	rs1065852	0.526	rs4822079	ENSG00000281538.1	RP4-669P10.20	-3.48	0.000551	0.0331	-0.16	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41998608	chr22:42138060~42139726:+
THCA	cis	rs6598541	0.926	rs4966022	ENSG00000278090.1	RP11-6O2.2	-3.48	0.000551	0.0331	-0.15	-0.16	Urate levels;	chr15:98743055	chr15:99028538~99031053:+
THCA	cis	rs11583043	0.958	rs11583674	ENSG00000233184.5	RP11-421L21.3	3.48	0.000551	0.0331	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100931004	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.874	rs11578366	ENSG00000233184.5	RP11-421L21.3	3.48	0.000551	0.0331	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100931296	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.918	rs56402739	ENSG00000233184.5	RP11-421L21.3	3.48	0.000551	0.0331	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100931577	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.918	rs3850453	ENSG00000233184.5	RP11-421L21.3	3.48	0.000551	0.0331	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100943377	chr1:101025878~101087268:+
THCA	cis	rs867186	0.614	rs17309872	ENSG00000279253.1	RP4-614O4.13	-3.48	0.000551	0.0331	-0.31	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34927985	chr20:35262727~35264187:-
THCA	cis	rs10875746	0.768	rs4760609	ENSG00000258234.1	RP11-370I10.2	-3.48	0.000552	0.0331	-0.18	-0.16	Longevity (90 years and older);	chr12:48021974	chr12:48231098~48284210:-
THCA	cis	rs11039571	0.544	rs7947811	ENSG00000200090.1	Y_RNA	-3.48	0.000552	0.0331	-0.13	-0.16	D-dimer levels;	chr11:48146186	chr11:47726894~47726992:-
THCA	cis	rs12621844	0.706	rs4953557	ENSG00000272663.1	RP11-191L17.1	-3.48	0.000552	0.0331	-0.16	-0.16	Glycated hemoglobin levels;	chr2:48174568	chr2:48440043~48440597:-
THCA	cis	rs7616559	0.606	rs922864	ENSG00000240875.4	LINC00886	-3.48	0.000552	0.0331	-0.12	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157063077	chr3:156747346~156817062:-
THCA	cis	rs2115630	0.691	rs2292462	ENSG00000229212.6	RP11-561C5.4	3.48	0.000552	0.0331	0.2	0.16	P wave terminal force;	chr15:84657523	chr15:85205440~85234795:-
THCA	cis	rs875971	0.508	rs10258739	ENSG00000230295.1	RP11-458F8.2	3.48	0.000552	0.0331	0.12	0.16	Aortic root size;	chr7:66597948	chr7:66880708~66882981:+
THCA	cis	rs4907240	0.961	rs7580048	ENSG00000230606.9	AC159540.1	3.48	0.000552	0.0331	0.18	0.16	Event-related brain oscillations;	chr2:96638443	chr2:97416165~97433527:-
THCA	cis	rs2797160	1	rs1739357	ENSG00000226409.1	RP11-735G4.1	3.48	0.000552	0.0331	0.19	0.16	Endometrial cancer;	chr6:125698509	chr6:125370211~125374324:-
THCA	cis	rs271738	0.64	rs271772	ENSG00000231768.1	LINC01354	3.48	0.000552	0.0331	0.18	0.16	Bipolar disorder;	chr1:234544104	chr1:234527891~234531779:-
THCA	cis	rs440932	0.717	rs330944	ENSG00000254153.1	CTA-398F10.2	-3.48	0.000552	0.0331	-0.17	-0.16	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:8456909~8461337:-
THCA	cis	rs9991779	0.617	rs4453913	ENSG00000237125.7	HAND2-AS1	3.48	0.000552	0.0332	0.26	0.16	Pediatric bone mineral content (hip);	chr4:173983178	chr4:173527270~173591324:+
THCA	cis	rs4568518	0.873	rs13309934	ENSG00000279048.1	RP11-511H23.2	-3.48	0.000552	0.0332	-0.1	-0.16	Measles;	chr7:17991173	chr7:17940503~17942922:+
THCA	cis	rs2729354	1	rs2848630	ENSG00000254602.1	AP000662.4	-3.48	0.000552	0.0332	-0.2	-0.16	Blood protein levels;	chr11:57589434	chr11:57638024~57652790:+
THCA	cis	rs12893668	0.581	rs34843146	ENSG00000258914.1	CTD-2134A5.3	-3.48	0.000552	0.0332	-0.2	-0.16	Reticulocyte count;	chr14:103613527	chr14:103875055~103877478:+
THCA	cis	rs4722166	0.598	rs35658589	ENSG00000179428.2	AC073072.5	-3.48	0.000552	0.0332	-0.18	-0.16	Lung cancer;	chr7:22760816	chr7:22725395~22727620:-
THCA	cis	rs62380364	0.701	rs304136	ENSG00000247828.6	TMEM161B-AS1	3.48	0.000552	0.0332	0.12	0.16	Intelligence (multi-trait analysis);	chr5:88874249	chr5:88268895~88436685:+
THCA	cis	rs11168618	1	rs11168618	ENSG00000240399.1	RP1-228P16.1	3.48	0.000552	0.0332	0.16	0.16	Adiponectin levels;	chr12:48539450	chr12:48054813~48055591:-
THCA	cis	rs6545883	0.894	rs778148	ENSG00000212978.6	AC016747.3	-3.48	0.000552	0.0332	-0.17	-0.16	Tuberculosis;	chr2:61379731	chr2:61141592~61144969:-
THCA	cis	rs751728	0.687	rs4711355	ENSG00000274259.2	XXbac-BPG294E21.9	3.48	0.000552	0.0332	0.18	0.16	Crohn's disease;	chr6:33792129	chr6:33437363~33454453:-
THCA	cis	rs751728	0.687	rs9357164	ENSG00000274259.2	XXbac-BPG294E21.9	3.48	0.000552	0.0332	0.18	0.16	Crohn's disease;	chr6:33793244	chr6:33437363~33454453:-
THCA	cis	rs6445967	0.506	rs7433237	ENSG00000272360.1	RP11-359I18.5	3.48	0.000552	0.0332	0.2	0.16	Platelet count;	chr3:58481137	chr3:58490830~58491291:-
THCA	cis	rs1232027	1	rs1232027	ENSG00000244076.1	CTC-512J14.1	3.48	0.000552	0.0332	0.19	0.16	Huntington's disease progression;	chr5:80619201	chr5:80315671~80315826:+
THCA	cis	rs2229238	0.911	rs59239860	ENSG00000273026.1	RP11-422P24.10	-3.48	0.000552	0.0332	-0.19	-0.16	Coronary heart disease;	chr1:154519631	chr1:153966516~153966930:+
THCA	cis	rs11583043	0.874	rs72734253	ENSG00000233184.5	RP11-421L21.3	3.48	0.000552	0.0332	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100915162	chr1:101025878~101087268:+
THCA	cis	rs34779708	0.931	rs59418206	ENSG00000233200.1	RP11-324I22.2	3.48	0.000552	0.0332	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35219894~35230598:-
THCA	cis	rs524281	1	rs527897	ENSG00000255120.4	OVOL1-AS1	-3.48	0.000552	0.0332	-0.22	-0.16	Electroencephalogram traits;	chr11:66133306	chr11:65789051~65790868:-
THCA	cis	rs10760158	0.832	rs12238702	ENSG00000235865.2	GSN-AS1	3.48	0.000552	0.0332	0.14	0.16	Pulse pressure;	chr9:121237547	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs10985188	ENSG00000235865.2	GSN-AS1	3.48	0.000552	0.0332	0.14	0.16	Pulse pressure;	chr9:121237747	chr9:121280768~121285530:-
THCA	cis	rs35320143	0.5	rs8054044	ENSG00000246777.1	RP11-61A14.4	-3.48	0.000552	0.0332	-0.14	-0.16	Number of children (6+ vs. 0 or 1);	chr16:66780246	chr16:66751752~66754740:+
THCA	cis	rs301901	0.664	rs4504403	ENSG00000250155.1	CTD-2353F22.1	3.48	0.000552	0.0332	0.16	0.16	Height;	chr5:37481330	chr5:36666214~36725195:-
THCA	cis	rs7246657	0.943	rs7252325	ENSG00000266916.4	ZNF793-AS1	-3.48	0.000552	0.0332	-0.15	-0.16	Coronary artery calcification;	chr19:37439743	chr19:37497159~37507046:-
THCA	cis	rs7824557	0.603	rs2246606	ENSG00000255495.1	AC145124.2	3.48	0.000552	0.0332	0.18	0.16	Retinal vascular caliber;	chr8:11361825	chr8:12194467~12196280:+
THCA	cis	rs1150668	0.796	rs1124132	ENSG00000220721.1	OR1F12	3.48	0.000552	0.0332	0.17	0.16	Pubertal anthropometrics;	chr6:28412544	chr6:28073316~28074233:+
THCA	cis	rs1009077	0.582	rs3756155	ENSG00000245958.5	RP11-33B1.1	3.48	0.000552	0.0332	0.25	0.16	Endometriosis;	chr4:119602915	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs78520912	ENSG00000245958.5	RP11-33B1.1	3.48	0.000552	0.0332	0.25	0.16	Endometriosis;	chr4:119604576	chr4:119454791~119552025:+
THCA	cis	rs10875746	0.669	rs61941003	ENSG00000226413.2	OR8T1P	3.48	0.000552	0.0332	0.22	0.16	Longevity (90 years and older);	chr12:48225842	chr12:48442030~48442947:-
THCA	cis	rs10875746	0.579	rs10875778	ENSG00000226413.2	OR8T1P	3.48	0.000552	0.0332	0.22	0.16	Longevity (90 years and older);	chr12:48230872	chr12:48442030~48442947:-
THCA	cis	rs10875746	0.669	rs10875779	ENSG00000226413.2	OR8T1P	3.48	0.000552	0.0332	0.22	0.16	Longevity (90 years and older);	chr12:48236086	chr12:48442030~48442947:-
THCA	cis	rs10875746	0.669	rs11168487	ENSG00000226413.2	OR8T1P	3.48	0.000552	0.0332	0.22	0.16	Longevity (90 years and older);	chr12:48246926	chr12:48442030~48442947:-
THCA	cis	rs9911578	0.935	rs7218105	ENSG00000224738.1	AC099850.1	3.48	0.000552	0.0332	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58963758	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs8076121	ENSG00000224738.1	AC099850.1	3.48	0.000552	0.0332	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58964338	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs12947785	ENSG00000224738.1	AC099850.1	3.48	0.000552	0.0332	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58967799	chr17:59106598~59118267:+
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000265443.1	CTD-2349P21.6	-3.48	0.000553	0.0332	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30726305~30727564:-
THCA	cis	rs9549260	0.604	rs9549273	ENSG00000229456.1	RLIMP1	-3.48	0.000553	0.0332	-0.24	-0.16	Red blood cell count;	chr13:40728011	chr13:40618738~40621348:+
THCA	cis	rs4662750	0.58	rs7558838	ENSG00000236682.1	AC068282.3	3.48	0.000553	0.0332	0.2	0.16	Renal cell carcinoma;	chr2:127593771	chr2:127389130~127400580:+
THCA	cis	rs972578	0.967	rs972579	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000553	0.0332	-0.16	-0.16	Mean platelet volume;	chr22:42991705	chr22:42791814~42794313:-
THCA	cis	rs972578	1	rs4820502	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000553	0.0332	-0.16	-0.16	Mean platelet volume;	chr22:42991909	chr22:42791814~42794313:-
THCA	cis	rs10090774	0.965	rs4440675	ENSG00000280303.2	ERICD	-3.48	0.000553	0.0332	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140965358	chr8:140636281~140638283:+
THCA	cis	rs950169	0.96	rs35159785	ENSG00000230373.7	GOLGA6L5P	-3.48	0.000553	0.0332	-0.18	-0.16	Schizophrenia;	chr15:84135262	chr15:84507885~84516814:-
THCA	cis	rs2243480	0.803	rs423187	ENSG00000237310.1	GS1-124K5.4	3.48	0.000553	0.0332	0.18	0.16	Diabetic kidney disease;	chr7:66044512	chr7:66493706~66495474:+
THCA	cis	rs12506899	0.967	rs6810745	ENSG00000221639.1	SNORA3	3.48	0.000553	0.0332	0.19	0.16	Tumor biomarkers;	chr4:73417134	chr4:73263960~73264084:+
THCA	cis	rs10090774	0.965	rs10111363	ENSG00000280303.2	ERICD	-3.48	0.000553	0.0332	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140918251	chr8:140636281~140638283:+
THCA	cis	rs7572644	0.766	rs1506535	ENSG00000223522.1	AC093690.1	-3.48	0.000553	0.0332	-0.21	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27951214	chr2:28307691~28310459:-
THCA	cis	rs6840360	0.571	rs72728182	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151565875	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696098	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151567901	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.55	rs6816471	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151573717	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.55	rs7683134	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151582210	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs7664663	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151586862	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs1978955	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151588357	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.532	rs4235221	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151590041	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs1473305	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151590569	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs62329101	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151591087	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696100	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151593090	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs62327268	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151601174	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs11723395	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151603039	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs11932059	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151603344	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs875668	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151604509	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs62327269	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151606821	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696273	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151607325	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696274	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151607326	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696101	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151607361	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696275	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151609829	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.55	rs11723438	ENSG00000251611.1	RP11-610P16.1	3.48	0.000553	0.0332	0.12	0.16	Intelligence (multi-trait analysis);	chr4:151610649	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696276	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151611530	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs62327270	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151612466	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs62327271	ENSG00000251611.1	RP11-610P16.1	-3.48	0.000553	0.0332	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151614764	chr4:151407551~151408835:-
THCA	cis	rs9549260	0.785	rs2253001	ENSG00000275149.1	RP11-427J23.1	-3.48	0.000553	0.0332	-0.21	-0.16	Red blood cell count;	chr13:40571193	chr13:40079106~40273509:-
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000237310.1	GS1-124K5.4	3.48	0.000553	0.0332	0.18	0.16	Diabetic kidney disease;	chr7:66136229	chr7:66493706~66495474:+
THCA	cis	rs2838815	0.525	rs2071873	ENSG00000235374.2	SSR4P1	-3.48	0.000553	0.0332	-0.16	-0.16	Pulmonary function;	chr21:45182918	chr21:45070952~45074165:-
THCA	cis	rs256438	0.731	rs10474606	ENSG00000251221.1	LINC01337	3.48	0.000553	0.0332	0.19	0.16	Serum thyroid-stimulating hormone levels;	chr5:80057163	chr5:80608623~80622524:-
THCA	cis	rs10090774	0.965	rs11167015	ENSG00000280303.2	ERICD	-3.48	0.000553	0.0332	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140981341	chr8:140636281~140638283:+
THCA	cis	rs2180341	1	rs2144742	ENSG00000220522.2	RP1-177A13.1	3.48	0.000553	0.0332	0.21	0.16	Breast cancer;	chr6:127274641	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.92	rs6906717	ENSG00000220522.2	RP1-177A13.1	3.48	0.000553	0.0332	0.21	0.16	Breast cancer;	chr6:127275637	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs9385419	ENSG00000220522.2	RP1-177A13.1	3.48	0.000553	0.0332	0.21	0.16	Breast cancer;	chr6:127276446	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs6569478	ENSG00000220522.2	RP1-177A13.1	3.48	0.000553	0.0332	0.21	0.16	Breast cancer;	chr6:127277474	chr6:127416535~127416952:-
THCA	cis	rs11069062	0.683	rs10851024	ENSG00000270482.1	RP11-131L12.2	3.48	0.000553	0.0332	0.12	0.16	Obesity-related traits;	chr12:118736145	chr12:118375350~118376275:-
THCA	cis	rs1557488	0.581	rs7126423	ENSG00000260209.1	RP11-680F20.10	-3.48	0.000553	0.0332	-0.21	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126856287	chr11:125873031~125874528:-
THCA	cis	rs1557488	0.581	rs7110377	ENSG00000260209.1	RP11-680F20.10	-3.48	0.000553	0.0332	-0.21	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126856318	chr11:125873031~125874528:-
THCA	cis	rs763121	0.853	rs2179142	ENSG00000225450.1	RP3-508I15.14	-3.48	0.000553	0.0332	-0.13	-0.16	Menopause (age at onset);	chr22:38641949	chr22:38739003~38749041:+
THCA	cis	rs11175834	0.655	rs4631931	ENSG00000277945.1	RP11-677M24.1	3.48	0.000553	0.0332	0.23	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65572195	chr12:65830750~65831050:+
THCA	cis	rs684232	0.649	rs838369	ENSG00000231784.7	DBIL5P	3.48	0.000553	0.0332	0.17	0.16	Prostate cancer;	chr17:674940	chr17:752660~755336:+
THCA	cis	rs2251260	0.629	rs1088672	ENSG00000250548.5	RP11-47I22.2	3.48	0.000553	0.0332	0.25	0.16	Yeast infection;	chr14:61537581	chr14:61556313~61570653:-
THCA	cis	rs812925	0.533	rs35507645	ENSG00000270820.4	RP11-355B11.2	3.48	0.000553	0.0332	0.13	0.16	Immature fraction of reticulocytes;	chr2:61169631	chr2:61471188~61484130:+
THCA	cis	rs9420	0.961	rs71484468	ENSG00000254602.1	AP000662.4	-3.48	0.000553	0.0332	-0.18	-0.16	Schizophrenia;	chr11:57865327	chr11:57638024~57652790:+
THCA	cis	rs1044826	0.619	rs7375091	ENSG00000178631.7	ACTG1P1	-3.48	0.000553	0.0332	-0.18	-0.16	Obesity-related traits;	chr3:139371547	chr3:139493809~139494937:+
THCA	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-3.48	0.000553	0.0332	-0.19	-0.16	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
THCA	cis	rs721048	0.92	rs62177795	ENSG00000242412.1	DBIL5P2	-3.48	0.000553	0.0332	-0.22	-0.16	Prostate cancer;	chr2:63248505	chr2:63117851~63119542:-
THCA	cis	rs7577696	0.597	rs2280968	ENSG00000276517.1	AL133243.2	3.48	0.000553	0.0332	0.16	0.16	Inflammatory biomarkers;	chr2:32064971	chr2:32526504~32529507:+
THCA	cis	rs7577696	0.597	rs7556942	ENSG00000276517.1	AL133243.2	3.48	0.000553	0.0332	0.16	0.16	Inflammatory biomarkers;	chr2:32070625	chr2:32526504~32529507:+
THCA	cis	rs7577696	0.597	rs17011801	ENSG00000276517.1	AL133243.2	3.48	0.000553	0.0332	0.16	0.16	Inflammatory biomarkers;	chr2:32073003	chr2:32526504~32529507:+
THCA	cis	rs9346455	0.881	rs16881116	ENSG00000233237.5	LINC00472	-3.48	0.000553	0.0332	-0.19	-0.16	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71321785	chr6:71344344~71420769:-
THCA	cis	rs3755605	0.664	rs1705581	ENSG00000242578.1	RP11-469J4.3	3.48	0.000553	0.0332	0.18	0.16	Testicular germ cell tumor;	chr3:170199573	chr3:170410512~170418615:+
THCA	cis	rs7615952	0.641	rs12488180	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000553	0.0332	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126063393	chr3:125827238~125916384:-
THCA	cis	rs7911264	0.967	rs9419741	ENSG00000232709.1	MARK2P9	3.48	0.000553	0.0332	0.19	0.16	Inflammatory bowel disease;	chr10:92670768	chr10:92418667~92420875:+
THCA	cis	rs495337	0.76	rs6125825	ENSG00000229222.1	KRT18P4	-3.48	0.000553	0.0332	-0.2	-0.16	Psoriasis;	chr20:49937166	chr20:49956745~49958032:+
THCA	cis	rs867371	1	rs6495642	ENSG00000278603.1	RP13-608F4.5	3.48	0.000553	0.0332	0.21	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472203~82472426:+
THCA	cis	rs4742903	0.839	rs10761016	ENSG00000270332.1	SMC2-AS1	3.48	0.000553	0.0332	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104245440	chr9:104080024~104093073:-
THCA	cis	rs10175706	0.526	rs4447623	ENSG00000256637.5	RP11-76I14.1	-3.48	0.000554	0.0332	-0.14	-0.16	Chin dimples;	chr2:104046590	chr2:103874310~104077778:+
THCA	cis	rs1876905	0.764	rs9398265	ENSG00000271789.1	RP5-1112D6.7	-3.48	0.000554	0.0332	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111101399	chr6:111297126~111298510:+
THCA	cis	rs10938353	0.871	rs6820273	ENSG00000273369.1	RP11-700J17.1	-3.48	0.000554	0.0332	-0.17	-0.16	Body mass index;	chr4:44581490	chr4:44693946~44694386:-
THCA	cis	rs479105	0.567	rs34592797	ENSG00000278356.1	RP11-372B4.3	3.48	0.000554	0.0332	0.15	0.16	Gut microbiota (bacterial taxa);	chr12:3269985	chr12:2885819~2886329:+
THCA	cis	rs4713118	0.869	rs6922574	ENSG00000261839.1	RP1-265C24.8	3.48	0.000554	0.0332	0.18	0.16	Parkinson's disease;	chr6:27725224	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs9348775	ENSG00000261839.1	RP1-265C24.8	3.48	0.000554	0.0332	0.18	0.16	Parkinson's disease;	chr6:27727550	chr6:28136849~28139678:+
THCA	cis	rs11190604	1	rs4917901	ENSG00000273030.1	RP11-285F16.1	3.48	0.000554	0.0332	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100442016	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs2003284	ENSG00000273030.1	RP11-285F16.1	3.48	0.000554	0.0332	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100442581	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs11190541	ENSG00000273030.1	RP11-285F16.1	3.48	0.000554	0.0332	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100443314	chr10:100412934~100413421:+
THCA	cis	rs9393813	0.529	rs2064093	ENSG00000216915.2	RP1-97D16.1	-3.48	0.000554	0.0332	-0.21	-0.16	Bipolar disorder;	chr6:27474468	chr6:27737000~27738494:-
THCA	cis	rs10911902	0.643	rs3766707	ENSG00000228238.1	GS1-304P7.2	-3.48	0.000554	0.0332	-0.25	-0.16	Schizophrenia;	chr1:186335955	chr1:186578279~186579299:+
THCA	cis	rs11098499	0.71	rs4145952	ENSG00000248280.1	RP11-33B1.2	3.48	0.000554	0.0332	0.13	0.16	Corneal astigmatism;	chr4:119234651	chr4:119440561~119450157:-
THCA	cis	rs911186	0.812	rs6932590	ENSG00000216901.1	AL022393.7	3.48	0.000554	0.0332	0.21	0.16	Autism spectrum disorder or schizophrenia;	chr6:27281152	chr6:28176188~28176674:+
THCA	cis	rs11190604	0.767	rs10883490	ENSG00000273030.1	RP11-285F16.1	3.48	0.000554	0.0332	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100435018	chr10:100412934~100413421:+
THCA	cis	rs4704187	0.687	rs10462513	ENSG00000250889.2	LINC01336	-3.48	0.000554	0.0332	-0.16	-0.16	Response to amphetamines;	chr5:75126782	chr5:75047719~75052843:-
THCA	cis	rs10276381	0.579	rs58696040	ENSG00000234336.5	JAZF1-AS1	-3.48	0.000554	0.0332	-0.29	-0.16	Crohn's disease;	chr7:28108768	chr7:28180322~28243917:+
THCA	cis	rs539514	0.637	rs2025354	ENSG00000261105.4	LMO7-AS1	3.48	0.000554	0.0332	0.18	0.16	Type 1 diabetes;	chr13:75701441	chr13:75604700~75635994:-
THCA	cis	rs10090774	0.965	rs11780104	ENSG00000280303.2	ERICD	-3.48	0.000554	0.0332	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992008	chr8:140636281~140638283:+
THCA	cis	rs11583043	0.667	rs4617425	ENSG00000233184.5	RP11-421L21.3	3.48	0.000554	0.0332	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101077649	chr1:101025878~101087268:+
THCA	cis	rs1799949	1	rs12942277	ENSG00000236383.6	LINC00854	-3.48	0.000554	0.0332	-0.15	-0.16	Menopause (age at onset);	chr17:43035957	chr17:43216941~43305976:-
THCA	cis	rs2832077	0.527	rs1048546	ENSG00000232855.5	AF131217.1	3.48	0.000554	0.0332	0.17	0.16	Cognitive test performance;	chr21:28872555	chr21:28439346~28674848:-
THCA	cis	rs9926296	0.548	rs6500439	ENSG00000275734.1	RP11-368I7.6	-3.48	0.000554	0.0332	-0.17	-0.16	Vitiligo;	chr16:89741867	chr16:89684642~89685304:+
THCA	cis	rs1612141	0.744	rs10144419	ENSG00000251363.2	RP11-129M6.1	3.48	0.000554	0.0332	0.23	0.16	QT interval (drug interaction);	chr14:41104268	chr14:40954898~40975877:+
THCA	cis	rs853679	1	rs853679	ENSG00000261839.1	RP1-265C24.8	3.48	0.000554	0.0333	0.21	0.16	Depression;	chr6:28329086	chr6:28136849~28139678:+
THCA	cis	rs853679	1	rs853678	ENSG00000261839.1	RP1-265C24.8	3.48	0.000554	0.0333	0.21	0.16	Depression;	chr6:28329536	chr6:28136849~28139678:+
THCA	cis	rs559555	0.778	rs765138	ENSG00000272716.1	RP11-563N4.1	3.48	0.000554	0.0333	0.14	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31578869	chr2:32165046~32165757:-
THCA	cis	rs3755605	0.662	rs6797517	ENSG00000242578.1	RP11-469J4.3	3.48	0.000554	0.0333	0.18	0.16	Testicular germ cell tumor;	chr3:170195044	chr3:170410512~170418615:+
THCA	cis	rs13064411	0.696	rs1552432	ENSG00000243849.1	CFAP44-AS1	3.48	0.000554	0.0333	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113506813	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs869342	ENSG00000243849.1	CFAP44-AS1	3.48	0.000554	0.0333	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113507483	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs869343	ENSG00000243849.1	CFAP44-AS1	3.48	0.000554	0.0333	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113507858	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs6438161	ENSG00000243849.1	CFAP44-AS1	3.48	0.000554	0.0333	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113508790	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs9808893	ENSG00000243849.1	CFAP44-AS1	3.48	0.000554	0.0333	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113509597	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.735	rs7631138	ENSG00000243849.1	CFAP44-AS1	3.48	0.000554	0.0333	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113513078	chr3:113403991~113433992:+
THCA	cis	rs763121	0.853	rs1569716	ENSG00000225450.1	RP3-508I15.14	-3.48	0.000554	0.0333	-0.12	-0.16	Menopause (age at onset);	chr22:38602514	chr22:38739003~38749041:+
THCA	cis	rs7572733	0.935	rs938929	ENSG00000231621.1	AC013264.2	3.48	0.000554	0.0333	0.15	0.16	Dermatomyositis;	chr2:197916136	chr2:197197991~197199273:+
THCA	cis	rs17213965	0.925	rs62030569	ENSG00000207425.1	Y_RNA	-3.48	0.000554	0.0333	-0.24	-0.16	Waist-hip ratio;	chr16:15786892	chr16:14915457~14915556:-
THCA	cis	rs11673344	0.504	rs1667378	ENSG00000267260.1	CTD-2162K18.4	-3.48	0.000554	0.0333	-0.19	-0.16	Obesity-related traits;	chr19:37001171	chr19:36773153~36777078:+
THCA	cis	rs34779708	0.832	rs6481946	ENSG00000233200.1	RP11-324I22.2	3.48	0.000554	0.0333	0.2	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35219894~35230598:-
THCA	cis	rs4218	0.813	rs8036907	ENSG00000277144.1	RP11-59H7.4	-3.48	0.000555	0.0333	-0.23	-0.16	Social communication problems;	chr15:59121144	chr15:59115547~59116089:-
THCA	cis	rs754466	0.605	rs10824578	ENSG00000213514.2	RP11-428P16.2	3.48	0.000555	0.0333	0.17	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77818486	chr10:77730766~77734769:+
THCA	cis	rs7615952	0.599	rs7652883	ENSG00000248787.1	RP11-666A20.4	-3.48	0.000555	0.0333	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125989134	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.599	rs6803160	ENSG00000248787.1	RP11-666A20.4	-3.48	0.000555	0.0333	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125990711	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.688	rs12485622	ENSG00000248787.1	RP11-666A20.4	-3.48	0.000555	0.0333	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125991896	chr3:125908005~125910272:-
THCA	cis	rs6968419	1	rs4082046	ENSG00000237870.5	AC073130.1	3.48	0.000555	0.0333	0.17	0.16	Intraocular pressure;	chr7:116177133	chr7:116275606~116286734:-
THCA	cis	rs1046896	1	rs28485881	ENSG00000263063.1	RP11-388C12.1	-3.48	0.000555	0.0333	-0.19	-0.16	Glycated hemoglobin levels;	chr17:82732138	chr17:82713908~82716255:-
THCA	cis	rs10540	1	rs71487296	ENSG00000279672.1	CMB9-55F22.1	3.48	0.000555	0.0333	0.31	0.16	Body mass index;	chr11:500282	chr11:779617~780755:+
THCA	cis	rs9353324	1	rs7745560	ENSG00000280232.1	RP11-321N4.4	-3.48	0.000555	0.0333	-0.33	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85579203	chr6:85498441~85499058:-
THCA	cis	rs9308731	0.591	rs6732491	ENSG00000227992.1	AC108463.2	-3.48	0.000555	0.0333	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111181143	chr2:111203964~111206215:-
THCA	cis	rs1421334	0.715	rs11785152	ENSG00000254109.4	RBPMS-AS1	3.48	0.000555	0.0333	0.16	0.16	Intelligence (multi-trait analysis);	chr8:30987843	chr8:30382119~30385401:-
THCA	cis	rs4704187	0.687	rs7700965	ENSG00000250889.2	LINC01336	-3.48	0.000555	0.0333	-0.16	-0.16	Response to amphetamines;	chr5:75061032	chr5:75047719~75052843:-
THCA	cis	rs12893668	0.572	rs2273175	ENSG00000258735.1	LINC00637	-3.48	0.000555	0.0333	-0.21	-0.16	Reticulocyte count;	chr14:103693804	chr14:103847721~103858049:+
THCA	cis	rs10911902	0.643	rs3766705	ENSG00000228238.1	GS1-304P7.2	-3.48	0.000555	0.0333	-0.26	-0.16	Schizophrenia;	chr1:186342680	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs16825201	ENSG00000228238.1	GS1-304P7.2	-3.48	0.000555	0.0333	-0.26	-0.16	Schizophrenia;	chr1:186344698	chr1:186578279~186579299:+
THCA	cis	rs9816784	0.576	rs12631246	ENSG00000207650.1	MIR570	3.48	0.000555	0.0333	0.18	0.16	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195699401~195699497:+
THCA	cis	rs2179367	0.959	rs585022	ENSG00000223701.3	RAET1E-AS1	3.48	0.000555	0.0333	0.21	0.16	Dupuytren's disease;	chr6:149432168	chr6:149884431~149919508:+
THCA	cis	rs13053817	1	rs78186489	ENSG00000279159.1	RP3-394A18.1	3.48	0.000555	0.0333	0.16	0.16	Carotid atherosclerosis in HIV infection;	chr22:29449714	chr22:29978950~30028236:-
THCA	cis	rs972578	0.837	rs4820496	ENSG00000274717.1	RP1-47A17.1	-3.48	0.000555	0.0333	-0.16	-0.16	Mean platelet volume;	chr22:42924295	chr22:42791814~42794313:-
THCA	cis	rs875971	0.522	rs34973832	ENSG00000230295.1	RP11-458F8.2	-3.48	0.000555	0.0333	-0.12	-0.16	Aortic root size;	chr7:65931217	chr7:66880708~66882981:+
THCA	cis	rs2933343	0.649	rs789214	ENSG00000261159.1	RP11-723O4.9	3.48	0.000555	0.0333	0.16	0.16	IgG glycosylation;	chr3:128876152	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.729	rs789224	ENSG00000261159.1	RP11-723O4.9	3.48	0.000555	0.0333	0.16	0.16	IgG glycosylation;	chr3:128879388	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.761	rs789225	ENSG00000261159.1	RP11-723O4.9	3.48	0.000555	0.0333	0.16	0.16	IgG glycosylation;	chr3:128881386	chr3:128859716~128860526:-
THCA	cis	rs6545883	0.503	rs1665272	ENSG00000212978.6	AC016747.3	3.48	0.000555	0.0333	0.17	0.16	Tuberculosis;	chr2:61152151	chr2:61141592~61144969:-
THCA	cis	rs7554547	0.69	rs10864544	ENSG00000199347.1	RNU5E-1	3.48	0.000555	0.0333	0.22	0.16	Nonsyndromic cleft lip with cleft palate;	chr1:11875666	chr1:11908152~11908271:+
THCA	cis	rs9863	0.828	rs12833624	ENSG00000269938.1	RP11-214K3.20	-3.48	0.000555	0.0333	-0.18	-0.16	White blood cell count;	chr12:123992326	chr12:123968023~123968579:-
THCA	cis	rs9863	0.828	rs34114498	ENSG00000269938.1	RP11-214K3.20	-3.48	0.000555	0.0333	-0.18	-0.16	White blood cell count;	chr12:123995826	chr12:123968023~123968579:-
THCA	cis	rs1799922	1	rs41274152	ENSG00000271553.1	RP11-274B21.10	-3.48	0.000555	0.0333	-0.14	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128759177	chr7:128667043~128668156:+
THCA	cis	rs6546886	0.625	rs76483403	ENSG00000235499.1	AC073046.25	3.48	0.000555	0.0333	0.17	0.16	Dialysis-related mortality;	chr2:74026281	chr2:73985132~73986343:+
THCA	cis	rs9818758	0.505	rs67286839	ENSG00000229759.1	MRPS18AP1	-3.48	0.000555	0.0333	-0.33	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49228311	chr3:48256350~48256938:-
THCA	cis	rs669446	0.533	rs3791041	ENSG00000236200.4	KDM4A-AS1	-3.48	0.000555	0.0333	-0.12	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:43737320	chr1:43699765~43708138:-
THCA	cis	rs4919669	0.777	rs10883765	ENSG00000272912.1	RP11-724N1.1	-3.48	0.000555	0.0333	-0.26	-0.16	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102696929	chr10:102914585~102915404:+
THCA	cis	rs5769765	0.72	rs138820	ENSG00000260613.1	RP3-522J7.6	-3.48	0.000555	0.0333	-0.18	-0.16	Schizophrenia;	chr22:49770430	chr22:49832616~49837786:-
THCA	cis	rs8053891	0.625	rs12921355	ENSG00000262140.1	RP11-417N10.3	3.48	0.000555	0.0333	0.22	0.16	Coronary artery disease;	chr16:71980788	chr16:71833787~71835932:+
THCA	cis	rs7989332	0.662	rs9552200	ENSG00000277020.3	RP11-476H16.1	-3.48	0.000555	0.0333	-0.15	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20487462	chr13:20564708~20567045:-
THCA	cis	rs853679	0.517	rs1904840	ENSG00000219891.2	ZSCAN12P1	3.48	0.000555	0.0333	0.23	0.16	Depression;	chr6:28140454	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000219891.2	ZSCAN12P1	3.48	0.000555	0.0333	0.23	0.16	Depression;	chr6:28141189	chr6:28091154~28093664:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000219891.2	ZSCAN12P1	3.48	0.000555	0.0333	0.23	0.16	Depression;	chr6:28141484	chr6:28091154~28093664:+
THCA	cis	rs16975963	0.644	rs73037036	ENSG00000276846.1	CTD-3220F14.3	-3.48	0.000555	0.0333	-0.15	-0.16	Longevity;	chr19:37670169	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.644	rs111319455	ENSG00000276846.1	CTD-3220F14.3	-3.48	0.000555	0.0333	-0.15	-0.16	Longevity;	chr19:37671746	chr19:37314868~37315620:-
THCA	cis	rs7572733	0.555	rs1837495	ENSG00000231621.1	AC013264.2	3.48	0.000555	0.0333	0.16	0.16	Dermatomyositis;	chr2:198056477	chr2:197197991~197199273:+
THCA	cis	rs11633886	0.529	rs4307893	ENSG00000273972.1	CTD-2306A12.1	-3.48	0.000555	0.0333	-0.19	-0.16	Diisocyanate-induced asthma;	chr15:45805267	chr15:45702640~45703183:+
THCA	cis	rs35320143	0.5	rs12920542	ENSG00000246777.1	RP11-61A14.4	-3.48	0.000555	0.0333	-0.14	-0.16	Number of children (6+ vs. 0 or 1);	chr16:66712648	chr16:66751752~66754740:+
THCA	cis	rs3821902	0.501	rs6799578	ENSG00000271843.1	RP11-245J9.5	-3.48	0.000555	0.0333	-0.24	-0.16	Breast cancer;	chr3:63759992	chr3:64008082~64008692:-
THCA	cis	rs1053338	0.529	rs34003604	ENSG00000271843.1	RP11-245J9.5	-3.48	0.000555	0.0333	-0.24	-0.16	Breast cancer;	chr3:63761852	chr3:64008082~64008692:-
THCA	cis	rs6728302	1	rs73995038	ENSG00000206885.1	SNORA75	3.48	0.000555	0.0333	0.36	0.16	Height;	chr2:231995613	chr2:231455800~231455936:-
THCA	cis	rs13401620	0.827	rs10197579	ENSG00000231013.1	AC013275.2	-3.48	0.000555	0.0333	-0.18	-0.16	Breast size;	chr2:119734728	chr2:119476448~119487346:+
THCA	cis	rs9488822	0.676	rs868943	ENSG00000233558.1	RP3-486I3.4	3.48	0.000555	0.0333	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116016340	chr6:116258493~116259115:-
THCA	cis	rs9488822	0.597	rs12214881	ENSG00000233558.1	RP3-486I3.4	3.48	0.000555	0.0333	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116021024	chr6:116258493~116259115:-
THCA	cis	rs11673344	0.704	rs510757	ENSG00000267260.1	CTD-2162K18.4	3.48	0.000555	0.0333	0.19	0.16	Obesity-related traits;	chr19:36931900	chr19:36773153~36777078:+
THCA	cis	rs4664293	0.902	rs13391919	ENSG00000230783.1	AC009961.2	-3.48	0.000555	0.0333	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159703649	chr2:159689217~159690291:-
THCA	cis	rs7142002	0.764	rs8007118	ENSG00000272444.1	RP11-1017G21.6	-3.48	0.000556	0.0333	-0.23	-0.16	Autism;	chr14:101933556	chr14:101952416~101953063:+
THCA	cis	rs889122	0.513	rs10403584	ENSG00000267289.1	CTD-2623N2.11	-3.48	0.000556	0.0333	-0.18	-0.16	Menarche (age at onset);	chr19:9902764	chr19:9834079~9835013:-
THCA	cis	rs6762	0.748	rs28735718	ENSG00000255284.1	AP006621.5	3.48	0.000556	0.0333	0.11	0.16	Mean platelet volume;	chr11:839629	chr11:777578~784297:+
THCA	cis	rs765787	0.556	rs10851422	ENSG00000259539.1	CTD-2651B20.1	-3.48	0.000556	0.0333	-0.2	-0.16	Uric acid levels;	chr15:45221540	chr15:45152664~45167526:-
THCA	cis	rs1348850	0.526	rs7582179	ENSG00000280374.1	RP11-337N6.3	-3.48	0.000556	0.0333	-0.27	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177505903	chr2:177317715~177318471:-
THCA	cis	rs34779708	0.931	rs17582416	ENSG00000233200.1	RP11-324I22.2	3.48	0.000556	0.0333	0.18	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35219894~35230598:-
THCA	cis	rs1488902	0.785	rs4002152	ENSG00000280385.1	AP000648.5	3.48	0.000556	0.0333	0.14	0.16	Amyotrophic lateral sclerosis;	chr11:89617352	chr11:90193614~90198120:+
THCA	cis	rs72799341	1	rs7185007	ENSG00000232748.3	RP11-196G11.6	-3.48	0.000556	0.0333	-0.22	-0.16	Diastolic blood pressure;	chr16:30916188	chr16:31056460~31062803:+
THCA	cis	rs4262150	0.81	rs4301224	ENSG00000253921.1	CTB-113P19.3	3.48	0.000556	0.0333	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152680684	chr5:151753992~151767247:+
THCA	cis	rs13196561	0.671	rs8180548	ENSG00000270987.1	RP3-467N11.2	3.48	0.000556	0.0333	0.23	0.16	Menarche (age at onset);	chr6:100256270	chr6:100889603~100890338:+
THCA	cis	rs1941184	0.526	rs3911655	ENSG00000263823.1	RP11-326K13.4	-3.48	0.000556	0.0333	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31453763	chr18:31942575~31944156:+
THCA	cis	rs9487051	0.837	rs9480920	ENSG00000260273.1	RP11-425D10.10	3.48	0.000556	0.0333	0.19	0.16	Reticulocyte fraction of red cells;	chr6:109284119	chr6:109382795~109383666:+
THCA	cis	rs1862618	0.802	rs4389648	ENSG00000234553.1	AC022431.3	-3.48	0.000556	0.0333	-0.18	-0.16	Initial pursuit acceleration;	chr5:56807775	chr5:56536583~56537826:-
THCA	cis	rs35740288	0.787	rs2008916	ENSG00000259407.1	RP11-158M2.3	-3.48	0.000556	0.0333	-0.2	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677959	chr15:85744109~85750281:-
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000184274.3	LINC00315	-3.48	0.000556	0.0333	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45300245~45305257:-
THCA	cis	rs2014572	0.967	rs10413037	ENSG00000268379.1	CTC-360J11.4	3.48	0.000556	0.0333	0.18	0.16	Hyperactive-impulsive symptoms;	chr19:57260515	chr19:57175233~57177921:+
THCA	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	3.48	0.000556	0.0333	0.14	0.16	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	3.48	0.000556	0.0333	0.14	0.16	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	3.48	0.000556	0.0333	0.14	0.16	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
THCA	cis	rs9333290	0.93	rs6748509	ENSG00000259915.2	RP11-410E4.1	-3.48	0.000556	0.0333	-0.2	-0.16	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186644937	chr2:186354570~186356773:-
THCA	cis	rs7546094	0.935	rs10776757	ENSG00000273483.1	RP4-671G15.2	3.48	0.000556	0.0333	0.14	0.16	Platelet distribution width;	chr1:112579051	chr1:112517799~112518441:-
THCA	cis	rs7143963	0.636	rs2180393	ENSG00000272444.1	RP11-1017G21.6	3.48	0.000556	0.0333	0.15	0.16	Body mass index;	chr14:102827508	chr14:101952416~101953063:+
THCA	cis	rs16975963	0.793	rs73034946	ENSG00000226686.6	LINC01535	-3.48	0.000556	0.0333	-0.21	-0.16	Longevity;	chr19:37969853	chr19:37251912~37265535:+
THCA	cis	rs9863	0.896	rs7311233	ENSG00000270028.1	RP11-380L11.4	-3.48	0.000556	0.0333	-0.17	-0.16	White blood cell count;	chr12:123991393	chr12:123925461~123926083:-
THCA	cis	rs12144309	0.608	rs1217417	ENSG00000232450.1	RP4-730K3.3	3.48	0.000556	0.0333	0.21	0.16	Coronary artery disease;	chr1:113858282	chr1:113698884~113699631:-
THCA	cis	rs7142002	0.881	rs4900523	ENSG00000271780.1	RP11-1017G21.5	-3.48	0.000556	0.0333	-0.24	-0.16	Autism;	chr14:101934923	chr14:101948347~101949425:+
THCA	cis	rs6747488	0.551	rs223665	ENSG00000276334.1	AL133243.1	3.48	0.000556	0.0333	0.17	0.16	Interleukin-18 levels;	chr2:31794678	chr2:32521927~32523547:+
THCA	cis	rs2562784	0.638	rs2730075	ENSG00000225151.9	GOLGA2P7	-3.48	0.000556	0.0333	-0.29	-0.16	Height;	chr15:83645689	chr15:84199311~84230136:-
THCA	cis	rs1005277	0.54	rs2474598	ENSG00000151963.4	RP11-775A3.1	3.48	0.000556	0.0333	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:37883594~37884109:+
THCA	cis	rs9488822	0.636	rs7745074	ENSG00000237021.2	RP3-486I3.7	3.48	0.000556	0.0333	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116026269	chr6:116254207~116256743:+
THCA	cis	rs700651	0.789	rs5007118	ENSG00000231621.1	AC013264.2	-3.48	0.000556	0.0333	-0.17	-0.16	Intracranial aneurysm;	chr2:198045014	chr2:197197991~197199273:+
THCA	cis	rs700651	0.789	rs10497812	ENSG00000231621.1	AC013264.2	3.48	0.000556	0.0333	0.17	0.16	Intracranial aneurysm;	chr2:198046521	chr2:197197991~197199273:+
THCA	cis	rs8031584	0.678	rs4779496	ENSG00000270015.1	RP11-540B6.6	-3.48	0.000556	0.0334	-0.12	-0.16	Huntington's disease progression;	chr15:30858851	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.678	rs4779497	ENSG00000270015.1	RP11-540B6.6	-3.48	0.000556	0.0334	-0.12	-0.16	Huntington's disease progression;	chr15:30859162	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.678	rs8028173	ENSG00000270015.1	RP11-540B6.6	-3.48	0.000556	0.0334	-0.12	-0.16	Huntington's disease progression;	chr15:30863546	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.706	rs2177670	ENSG00000270015.1	RP11-540B6.6	-3.48	0.000556	0.0334	-0.12	-0.16	Huntington's disease progression;	chr15:30865548	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.678	rs36047941	ENSG00000270015.1	RP11-540B6.6	-3.48	0.000556	0.0334	-0.12	-0.16	Huntington's disease progression;	chr15:30867032	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.678	rs4779790	ENSG00000270015.1	RP11-540B6.6	-3.48	0.000556	0.0334	-0.12	-0.16	Huntington's disease progression;	chr15:30872392	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.678	rs8035703	ENSG00000270015.1	RP11-540B6.6	-3.48	0.000556	0.0334	-0.12	-0.16	Huntington's disease progression;	chr15:30876269	chr15:30926514~30928407:+
THCA	cis	rs8031584	0.578	rs1088473	ENSG00000270015.1	RP11-540B6.6	3.48	0.000556	0.0334	0.12	0.16	Huntington's disease progression;	chr15:30847095	chr15:30926514~30928407:+
THCA	cis	rs6968419	0.963	rs2896175	ENSG00000237870.5	AC073130.1	3.48	0.000556	0.0334	0.17	0.16	Intraocular pressure;	chr7:116171382	chr7:116275606~116286734:-
THCA	cis	rs301901	0.569	rs217846	ENSG00000250155.1	CTD-2353F22.1	3.48	0.000556	0.0334	0.16	0.16	Height;	chr5:37367180	chr5:36666214~36725195:-
THCA	cis	rs59918340	0.936	rs6982449	ENSG00000253307.1	RP11-10J21.4	-3.48	0.000556	0.0334	-0.22	-0.16	Immature fraction of reticulocytes;	chr8:141224543	chr8:141252286~141253292:-
THCA	cis	rs9329221	0.537	rs1484640	ENSG00000261451.1	RP11-981G7.1	3.48	0.000556	0.0334	0.19	0.16	Neuroticism;	chr8:10125733	chr8:10433672~10438312:+
THCA	cis	rs9510787	0.514	rs11843149	ENSG00000205861.10	C1QTNF9B-AS1	-3.48	0.000556	0.0334	-0.2	-0.16	Nasopharyngeal carcinoma;	chr13:23684197	chr13:23888889~23897263:+
THCA	cis	rs2839186	0.605	rs2839170	ENSG00000228137.1	AP001469.7	3.48	0.000556	0.0334	0.16	0.16	Testicular germ cell tumor;	chr21:46251391	chr21:46246890~46247682:+
THCA	cis	rs7737355	1	rs798416	ENSG00000237714.1	P4HA2-AS1	-3.48	0.000556	0.0334	-0.23	-0.16	Life satisfaction;	chr5:131357407	chr5:132184876~132192808:+
THCA	cis	rs7737355	1	rs2549018	ENSG00000237714.1	P4HA2-AS1	-3.48	0.000556	0.0334	-0.23	-0.16	Life satisfaction;	chr5:131363256	chr5:132184876~132192808:+
THCA	cis	rs79243044	0.786	rs16932549	ENSG00000224295.2	AC087380.14	-3.48	0.000556	0.0334	-0.17	-0.16	QRS duration in Tripanosoma cruzi seropositivity;	chr11:5539679	chr11:5518441~5524955:-
THCA	cis	rs61160187	0.582	rs34619	ENSG00000272308.1	RP11-231G3.1	-3.48	0.000556	0.0334	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60866457~60866935:-
THCA	cis	rs860295	0.65	rs28662267	ENSG00000203761.5	MSTO2P	-3.48	0.000556	0.0334	-0.12	-0.16	Body mass index;	chr1:155710658	chr1:155745829~155750137:+
THCA	cis	rs11638815	0.581	rs2870965	ENSG00000259429.4	UBE2Q2P2	-3.48	0.000556	0.0334	-0.13	-0.16	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82632278	chr15:82355142~82420075:+
THCA	cis	rs962856	0.575	rs7597266	ENSG00000236780.4	AC078941.1	3.48	0.000556	0.0334	0.21	0.16	Pancreatic cancer;	chr2:67394509	chr2:67123357~67215319:-
THCA	cis	rs9296092	0.538	rs9461880	ENSG00000272217.1	XXbac-BPG157A10.21	3.48	0.000556	0.0334	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33550937	chr6:33246075~33246856:-
THCA	cis	rs1045529	0.524	rs34251783	ENSG00000253981.4	ALG1L13P	-3.48	0.000556	0.0334	-0.15	-0.16	Myopia (pathological);Myopia;	chr8:9033866	chr8:8236003~8244667:-
THCA	cis	rs4713118	0.662	rs4713120	ENSG00000261839.1	RP1-265C24.8	3.48	0.000556	0.0334	0.16	0.16	Parkinson's disease;	chr6:27754056	chr6:28136849~28139678:+
THCA	cis	rs114858855	0.661	rs9487193	ENSG00000260273.1	RP11-425D10.10	-3.48	0.000556	0.0334	-0.38	-0.16	Plasma trimethylamine N-oxide levels;	chr6:109709376	chr6:109382795~109383666:+
THCA	cis	rs114858855	1	rs73535341	ENSG00000260273.1	RP11-425D10.10	-3.48	0.000556	0.0334	-0.38	-0.16	Plasma trimethylamine N-oxide levels;	chr6:109713795	chr6:109382795~109383666:+
THCA	cis	rs28510890	0.754	rs11074080	ENSG00000258676.4	RP11-386M24.3	3.48	0.000556	0.0334	0.17	0.16	Lung cancer in ever smokers;	chr15:92595272	chr15:92580829~92600545:+
THCA	cis	rs4664293	0.867	rs6720304	ENSG00000230783.1	AC009961.2	-3.48	0.000557	0.0334	-0.21	-0.16	Monocyte percentage of white cells;	chr2:159787321	chr2:159689217~159690291:-
THCA	cis	rs11711311	0.747	rs7638449	ENSG00000241529.3	RN7SL767P	-3.48	0.000557	0.0334	-0.23	-0.16	IgG glycosylation;	chr3:113624799	chr3:113632704~113632998:+
THCA	cis	rs6724465	0.929	rs77945941	ENSG00000272644.1	RP11-33O4.1	3.48	0.000557	0.0334	0.24	0.16	Height;	chr2:219109023	chr2:219069354~219069809:-
THCA	cis	rs972578	1	rs2284097	ENSG00000230319.1	AL022476.2	3.48	0.000557	0.0334	0.17	0.16	Mean platelet volume;	chr22:43004000	chr22:43038585~43052366:+
THCA	cis	rs11671005	0.568	rs55987239	ENSG00000252334.1	RNU6-1337P	3.48	0.000557	0.0334	0.23	0.16	Mean platelet volume;	chr19:58573678	chr19:58483749~58483843:-
THCA	cis	rs4730276	0.674	rs2237682	ENSG00000250474.1	WBP1LP2	-3.48	0.000557	0.0334	-0.15	-0.16	Ulcerative colitis;	chr7:107894791	chr7:107628553~107629498:+
THCA	cis	rs72928364	1	rs17338506	ENSG00000256628.3	ZBTB11-AS1	3.48	0.000557	0.0334	0.28	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100888437	chr3:101676475~101679217:+
THCA	cis	rs7829975	0.742	rs7832968	ENSG00000248538.5	RP11-10A14.5	-3.48	0.000557	0.0334	-0.19	-0.16	Mood instability;	chr8:8795379	chr8:9189011~9202854:+
THCA	cis	rs372883	0.648	rs2832296	ENSG00000176054.6	RPL23P2	-3.48	0.000557	0.0334	-0.14	-0.16	Pancreatic cancer;	chr21:29369133	chr21:28997613~28998033:-
THCA	cis	rs7546094	0.846	rs6537749	ENSG00000273483.1	RP4-671G15.2	-3.48	0.000557	0.0334	-0.15	-0.16	Platelet distribution width;	chr1:112675881	chr1:112517799~112518441:-
THCA	cis	rs12935418	0.561	rs2287991	ENSG00000261061.1	RP11-303E16.2	-3.48	0.000557	0.0334	-0.16	-0.16	Mean corpuscular volume;	chr16:81006950	chr16:81030770~81031485:+
THCA	cis	rs11710088	0.74	rs73152638	ENSG00000244503.1	RP11-278L15.6	3.48	0.000557	0.0334	0.22	0.16	QRS duration;	chr3:149483299	chr3:149494660~149495995:+
THCA	cis	rs9393777	0.844	rs28360634	ENSG00000226314.6	ZNF192P1	-3.48	0.000557	0.0334	-0.32	-0.16	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28161781~28169594:+
THCA	cis	rs7522061	0.546	rs2785663	ENSG00000236731.1	RP4-801G22.2	-3.48	0.000557	0.0334	-0.16	-0.16	Blood protein levels;	chr1:157650968	chr1:157629939~157630728:-
THCA	cis	rs4819052	1	rs2297284	ENSG00000184274.3	LINC00315	-3.48	0.000557	0.0334	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45300245~45305257:-
THCA	cis	rs7614311	0.636	rs66818634	ENSG00000271843.1	RP11-245J9.5	-3.48	0.000557	0.0334	-0.3	-0.16	Lung function (FVC);Lung function (FEV1);	chr3:63927546	chr3:64008082~64008692:-
THCA	cis	rs7614311	0.636	rs66490742	ENSG00000271843.1	RP11-245J9.5	-3.48	0.000557	0.0334	-0.3	-0.16	Lung function (FVC);Lung function (FEV1);	chr3:63927977	chr3:64008082~64008692:-
THCA	cis	rs11637445	0.677	rs3784716	ENSG00000260657.2	RP11-315D16.4	-3.48	0.000557	0.0334	-0.2	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67792112	chr15:68267792~68277994:-
THCA	cis	rs878131	0.804	rs947019	ENSG00000231119.2	RP4-569M23.2	3.48	0.000557	0.0334	0.13	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr20:47045608	chr20:47352561~47354633:+
THCA	cis	rs1062753	0.922	rs9611712	ENSG00000232710.1	RP4-669P10.16	-3.48	0.000557	0.0334	-0.2	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014989	chr22:42136433~42139927:-
THCA	cis	rs6787172	0.622	rs9882274	ENSG00000272087.1	RP11-379F4.7	3.48	0.000557	0.0334	0.14	0.16	Subjective well-being;	chr3:158402644	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs4679827	ENSG00000272087.1	RP11-379F4.7	3.48	0.000557	0.0334	0.14	0.16	Subjective well-being;	chr3:158406754	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs12633594	ENSG00000272087.1	RP11-379F4.7	3.48	0.000557	0.0334	0.14	0.16	Subjective well-being;	chr3:158407155	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs2362968	ENSG00000272087.1	RP11-379F4.7	3.48	0.000557	0.0334	0.14	0.16	Subjective well-being;	chr3:158408157	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs9847045	ENSG00000272087.1	RP11-379F4.7	3.48	0.000557	0.0334	0.14	0.16	Subjective well-being;	chr3:158412014	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs9850856	ENSG00000272087.1	RP11-379F4.7	3.48	0.000557	0.0334	0.14	0.16	Subjective well-being;	chr3:158412066	chr3:158693120~158693768:-
THCA	cis	rs1009077	0.536	rs13124532	ENSG00000248280.1	RP11-33B1.2	3.48	0.000557	0.0334	0.22	0.16	Endometriosis;	chr4:119495290	chr4:119440561~119450157:-
THCA	cis	rs1383484	0.575	rs6603008	ENSG00000259728.4	LINC00933	-3.48	0.000557	0.0334	-0.19	-0.16	Height;	chr15:83935421	chr15:84570649~84580175:+
THCA	cis	rs11168351	0.927	rs10875716	ENSG00000257735.1	RP11-370I10.6	3.48	0.000557	0.0334	0.19	0.16	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48350945~48442411:+
THCA	cis	rs62158211	0.955	rs7556815	ENSG00000231292.6	IGKV1OR2-108	-3.48	0.000557	0.0334	-0.13	-0.16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr2:113406396~113406872:+
THCA	cis	rs17345786	0.798	rs9817043	ENSG00000244119.1	PDCL3P4	3.48	0.000557	0.0334	0.14	0.16	Colonoscopy-negative controls vs population controls;	chr3:101563008	chr3:101712472~101713191:+
THCA	cis	rs9903692	0.954	rs7224014	ENSG00000263412.1	RP5-890E16.2	-3.48	0.000557	0.0334	-0.11	-0.16	Pulse pressure;	chr17:48073499	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs2240122	ENSG00000263412.1	RP5-890E16.2	-3.48	0.000557	0.0334	-0.11	-0.16	Pulse pressure;	chr17:48075197	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.738	rs35202025	ENSG00000263412.1	RP5-890E16.2	-3.48	0.000557	0.0334	-0.11	-0.16	Pulse pressure;	chr17:48075355	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs7217496	ENSG00000263412.1	RP5-890E16.2	-3.48	0.000557	0.0334	-0.11	-0.16	Pulse pressure;	chr17:48076840	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs9747001	ENSG00000263412.1	RP5-890E16.2	-3.48	0.000557	0.0334	-0.11	-0.16	Pulse pressure;	chr17:48077307	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.909	rs12952163	ENSG00000263412.1	RP5-890E16.2	-3.48	0.000557	0.0334	-0.11	-0.16	Pulse pressure;	chr17:48082029	chr17:48045141~48048073:-
THCA	cis	rs6921919	0.789	rs6456814	ENSG00000176933.5	TOB2P1	-3.48	0.000557	0.0334	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28217643~28218634:-
THCA	cis	rs7216064	1	rs73352808	ENSG00000278740.1	RP11-147L13.14	3.48	0.000557	0.0334	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67879041	chr17:68188547~68189165:+
THCA	cis	rs6430585	0.536	rs60397494	ENSG00000231890.6	DARS-AS1	-3.48	0.000557	0.0334	-0.19	-0.16	Corneal structure;	chr2:135712649	chr2:135985176~136022593:+
THCA	cis	rs7843479	0.898	rs4311656	ENSG00000208037.1	MIR320A	-3.48	0.000557	0.0334	-0.2	-0.16	Mean corpuscular volume;	chr8:21944765	chr8:22244962~22245043:-
THCA	cis	rs34975555	0.557	rs916550	ENSG00000253671.1	RP11-806O11.1	-3.48	0.000557	0.0334	-0.23	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17935575	chr8:17808941~17820868:+
THCA	cis	rs10405744	1	rs10409286	ENSG00000271524.1	BNIP3P17	3.48	0.000558	0.0334	0.46	0.16	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);	chr19:19925046	chr19:20221869~20222463:+
THCA	cis	rs911555	0.755	rs34411783	ENSG00000269940.1	RP11-73M18.7	-3.48	0.000558	0.0334	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103694560~103695170:+
THCA	cis	rs10438797	0.52	rs8079438	ENSG00000276995.1	RP11-321A17.6	-3.48	0.000558	0.0334	-0.15	-0.16	Night sleep phenotypes;	chr17:29148337	chr17:29071124~29071594:-
THCA	cis	rs12476592	0.602	rs2121351	ENSG00000242412.1	DBIL5P2	3.48	0.000558	0.0334	0.2	0.16	Childhood ear infection;	chr2:63601227	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.543	rs262470	ENSG00000242412.1	DBIL5P2	3.48	0.000558	0.0334	0.2	0.16	Childhood ear infection;	chr2:63603425	chr2:63117851~63119542:-
THCA	cis	rs2235649	0.798	rs9922462	ENSG00000260541.1	LA16c-429E7.1	3.48	0.000558	0.0334	0.21	0.16	Blood metabolite levels;	chr16:1798010	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.798	rs9932875	ENSG00000260541.1	LA16c-429E7.1	3.48	0.000558	0.0334	0.21	0.16	Blood metabolite levels;	chr16:1798011	chr16:1841020~1843547:-
THCA	cis	rs7005380	1	rs7005380	ENSG00000245330.4	KB-1471A8.1	-3.48	0.000558	0.0334	-0.16	-0.16	Interstitial lung disease;	chr8:119941633	chr8:119867419~119874488:-
THCA	cis	rs75422866	0.51	rs73105819	ENSG00000280054.1	RP1-197B17.7	3.48	0.000558	0.0334	0.31	0.16	Pneumonia;	chr12:47727190	chr12:47728151~47730598:-
THCA	cis	rs6495122	0.644	rs11630087	ENSG00000260269.4	CTD-2323K18.1	-3.48	0.000558	0.0334	-0.22	-0.16	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:74969332	chr15:75527150~75601205:-
THCA	cis	rs6495122	0.644	rs62029217	ENSG00000260269.4	CTD-2323K18.1	-3.48	0.000558	0.0334	-0.22	-0.16	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:74969558	chr15:75527150~75601205:-
THCA	cis	rs6495122	0.618	rs4886413	ENSG00000260269.4	CTD-2323K18.1	-3.48	0.000558	0.0334	-0.22	-0.16	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:74969969	chr15:75527150~75601205:-
THCA	cis	rs2692947	0.566	rs11676901	ENSG00000236750.1	AC009237.16	-3.48	0.000558	0.0334	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95704823	chr2:95641634~95641980:-
THCA	cis	rs944289	0.51	rs2780314	ENSG00000258844.1	RP11-259K15.2	3.48	0.000558	0.0334	0.14	0.16	Thyroid cancer;	chr14:36059286	chr14:36214607~36235608:+
THCA	cis	rs7829975	0.564	rs2921060	ENSG00000248538.5	RP11-10A14.5	3.48	0.000558	0.0334	0.2	0.16	Mood instability;	chr8:8460307	chr8:9189011~9202854:+
THCA	cis	rs14027	0.921	rs16893101	ENSG00000279347.1	RP11-85I17.2	-3.48	0.000558	0.0334	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119838736~119840385:-
THCA	cis	rs2483519	0.584	rs11196864	ENSG00000228169.3	PPIAP19	3.48	0.000558	0.0334	0.19	0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114677324	chr10:114690143~114690634:-
THCA	cis	rs34783982	0.51	rs12438753	ENSG00000259699.2	HMGB1P8	-3.48	0.000558	0.0334	-0.21	-0.16	Squamous cell lung carcinoma;	chr15:88927550	chr15:89135547~89136495:-
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000185485.13	SDHAP1	3.48	0.000558	0.0334	0.13	0.16	Pancreatic cancer;	chr3:196022690	chr3:195959748~195990318:-
THCA	cis	rs9902453	0.619	rs1038088	ENSG00000214719.10	AC005562.1	-3.48	0.000558	0.0334	-0.15	-0.16	Coffee consumption (cups per day);	chr17:29747545	chr17:30576464~30672789:+
THCA	cis	rs4713118	0.662	rs4713120	ENSG00000280107.1	AL022393.9	-3.48	0.000558	0.0334	-0.16	-0.16	Parkinson's disease;	chr6:27754056	chr6:28170845~28172521:+
THCA	cis	rs1348850	0.526	rs2218575	ENSG00000280374.1	RP11-337N6.3	-3.48	0.000558	0.0334	-0.27	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177504269	chr2:177317715~177318471:-
THCA	cis	rs1348850	0.526	rs935426	ENSG00000280374.1	RP11-337N6.3	-3.48	0.000558	0.0334	-0.27	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177504705	chr2:177317715~177318471:-
THCA	cis	rs1059312	1	rs2291350	ENSG00000279500.1	RP11-21K12.2	-3.48	0.000558	0.0334	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128799166	chr12:128813186~128814750:-
THCA	cis	rs17428076	0.831	rs3821093	ENSG00000228389.1	AC068039.4	-3.48	0.000558	0.0334	-0.18	-0.16	Myopia;	chr2:171838077	chr2:171773482~171775844:+
THCA	cis	rs10457678	0.554	rs12205070	ENSG00000225415.2	RP3-509I19.1	-3.48	0.000558	0.0334	-0.22	-0.16	Colorectal or endometrial cancer;	chr6:138833110	chr6:138822747~138823799:+
THCA	cis	rs440932	0.757	rs330943	ENSG00000248538.5	RP11-10A14.5	-3.48	0.000558	0.0334	-0.2	-0.16	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:9189011~9202854:+
THCA	cis	rs11098499	0.754	rs938056	ENSG00000249244.1	RP11-548H18.2	3.48	0.000558	0.0334	0.18	0.16	Corneal astigmatism;	chr4:119316298	chr4:119391831~119395335:-
THCA	cis	rs62400317	0.762	rs11961316	ENSG00000237686.5	RP5-1120P11.1	-3.48	0.000558	0.0335	-0.16	-0.16	Total body bone mineral density;	chr6:45061861	chr6:43995723~44074652:-
THCA	cis	rs210138	0.706	rs3916279	ENSG00000197251.3	LINC00336	3.48	0.000558	0.0335	0.19	0.16	Testicular germ cell tumor;	chr6:33607173	chr6:33586106~33593338:-
THCA	cis	rs2191566	0.691	rs62115513	ENSG00000266921.1	RP11-15A1.7	-3.48	0.000558	0.0335	-0.15	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44083039	chr19:43996896~44002836:-
THCA	cis	rs11723261	0.582	rs4582104	ENSG00000250892.1	RP11-1365D11.1	3.48	0.000558	0.0335	0.22	0.16	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:201409~205009:-
THCA	cis	rs4589258	0.788	rs7126992	ENSG00000280367.1	RP11-121L10.2	3.48	0.000558	0.0335	0.15	0.16	Intelligence (multi-trait analysis);	chr11:90745215	chr11:90223153~90226538:+
THCA	cis	rs4589258	0.788	rs2105797	ENSG00000280367.1	RP11-121L10.2	3.48	0.000558	0.0335	0.15	0.16	Intelligence (multi-trait analysis);	chr11:90745413	chr11:90223153~90226538:+
THCA	cis	rs4589258	0.788	rs2097169	ENSG00000280367.1	RP11-121L10.2	3.48	0.000558	0.0335	0.15	0.16	Intelligence (multi-trait analysis);	chr11:90746256	chr11:90223153~90226538:+
THCA	cis	rs9858542	0.537	rs9818758	ENSG00000270441.1	RP11-694I15.7	3.48	0.000558	0.0335	0.18	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49345492	chr3:49140086~49160851:-
THCA	cis	rs12887734	0.524	rs4906363	ENSG00000258534.1	CTD-2134A5.4	-3.48	0.000558	0.0335	-0.17	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103854366~103880111:-
THCA	cis	rs9925964	0.933	rs56314408	ENSG00000262766.1	RP11-196G11.4	3.47	0.000558	0.0335	0.11	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106068	chr16:31118078~31118747:+
THCA	cis	rs7216064	1	rs56404791	ENSG00000278740.1	RP11-147L13.14	3.47	0.000558	0.0335	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896903	chr17:68188547~68189165:+
THCA	cis	rs7916852	0.717	rs10826398	ENSG00000230500.1	MKX-AS1	3.47	0.000558	0.0335	0.26	0.16	Glaucoma (primary open-angle);	chr10:28104895	chr10:27744786~27767794:+
THCA	cis	rs10938353	0.911	rs7698806	ENSG00000273369.1	RP11-700J17.1	-3.47	0.000558	0.0335	-0.18	-0.16	Body mass index;	chr4:44592146	chr4:44693946~44694386:-
THCA	cis	rs7192750	0.538	rs28594331	ENSG00000260886.1	TAT-AS1	3.47	0.000558	0.0335	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71829579	chr16:71565789~71578187:+
THCA	cis	rs1371614	0.513	rs562311	ENSG00000272148.1	RP11-195B17.1	-3.47	0.000558	0.0335	-0.15	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26875218	chr2:27062428~27062907:-
THCA	cis	rs301901	0.698	rs217845	ENSG00000250155.1	CTD-2353F22.1	3.47	0.000558	0.0335	0.16	0.16	Height;	chr5:37367360	chr5:36666214~36725195:-
THCA	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	3.47	0.000558	0.0335	0.17	0.16	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
THCA	cis	rs11153306	0.844	rs1476044	ENSG00000231889.6	TRAF3IP2-AS1	3.47	0.000558	0.0335	0.14	0.16	Tonsillectomy;	chr6:111628785	chr6:111483511~111598302:+
THCA	cis	rs17853159	0.764	rs11586695	ENSG00000281912.1	LINC01144	-3.47	0.000559	0.0335	-0.22	-0.16	Mean platelet volume;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr1:45354492	chr1:45303910~45305619:+
THCA	cis	rs56318008	0.625	rs10737462	ENSG00000218510.5	LINC00339	-3.47	0.000559	0.0335	-0.2	-0.16	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22118482	chr1:22025188~22031223:+
THCA	cis	rs2386661	0.547	rs57893347	ENSG00000231483.1	RP11-336A10.5	3.47	0.000559	0.0335	0.17	0.16	Breast cancer;	chr10:5604228	chr10:5608475~5610793:-
THCA	cis	rs2882667	0.898	rs12719519	ENSG00000249593.5	CTB-46B19.2	3.47	0.000559	0.0335	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:139012647~139051203:+
THCA	cis	rs9307551	1	rs9307545	ENSG00000249646.2	OR7E94P	-3.47	0.000559	0.0335	-0.21	-0.16	Refractive error;	chr4:79595417	chr4:79587302~79588130:-
THCA	cis	rs875971	1	rs6956179	ENSG00000272831.1	RP11-792A8.4	-3.47	0.000559	0.0335	-0.1	-0.16	Aortic root size;	chr7:66341672	chr7:66739829~66740385:-
THCA	cis	rs11671005	0.735	rs45617039	ENSG00000269600.1	AC016629.3	-3.47	0.000559	0.0335	-0.23	-0.16	Mean platelet volume;	chr19:58439729	chr19:58593896~58599355:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000230189.5	GS1-124K5.2	3.47	0.000559	0.0335	0.1	0.16	Calcium levels;	chr7:65751755	chr7:66409143~66490059:-
THCA	cis	rs301901	0.772	rs6451313	ENSG00000250155.1	CTD-2353F22.1	-3.47	0.000559	0.0335	-0.16	-0.16	Height;	chr5:37182208	chr5:36666214~36725195:-
THCA	cis	rs9549260	0.755	rs7338669	ENSG00000275149.1	RP11-427J23.1	3.47	0.000559	0.0335	0.21	0.16	Red blood cell count;	chr13:40625954	chr13:40079106~40273509:-
THCA	cis	rs1005277	0.579	rs176880	ENSG00000120555.12	SEPT7P9	-3.47	0.000559	0.0335	-0.18	-0.16	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38383069~38402916:-
THCA	cis	rs875971	0.79	rs10257911	ENSG00000223473.2	GS1-124K5.3	-3.47	0.000559	0.0335	-0.11	-0.16	Aortic root size;	chr7:66278783	chr7:66491049~66493566:-
THCA	cis	rs8105895	1	rs8100042	ENSG00000269345.1	VN1R85P	3.47	0.000559	0.0335	0.22	0.16	Body mass index (change over time);	chr19:21945039	chr19:22174766~22175191:-
THCA	cis	rs8105895	1	rs57912102	ENSG00000269345.1	VN1R85P	3.47	0.000559	0.0335	0.22	0.16	Body mass index (change over time);	chr19:21953241	chr19:22174766~22175191:-
THCA	cis	rs6840360	0.571	rs11931934	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000559	0.0335	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151630930	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs55808836	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000559	0.0335	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151633839	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs11726892	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000559	0.0335	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151633954	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696278	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000559	0.0335	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151637826	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696279	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000559	0.0335	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151639297	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.55	rs7689266	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000559	0.0335	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151639896	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs6811676	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000559	0.0335	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151641574	chr4:151407551~151408835:-
THCA	cis	rs9650657	0.836	rs3905581	ENSG00000269918.1	AF131215.9	-3.47	0.000559	0.0335	-0.17	-0.16	Neuroticism;	chr8:10746195	chr8:11104691~11106704:-
THCA	cis	rs4763879	0.634	rs2098298	ENSG00000256594.6	RP11-705C15.2	-3.47	0.000559	0.0335	-0.12	-0.16	Type 1 diabetes;	chr12:9707473	chr12:9633419~9658412:+
THCA	cis	rs12912251	0.591	rs4924291	ENSG00000259225.5	RP11-1008C21.1	3.47	0.000559	0.0335	0.19	0.16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr15:38708283	chr15:37984766~38062340:+
THCA	cis	rs3808502	0.549	rs7831039	ENSG00000255046.1	RP11-297N6.4	3.47	0.000559	0.0335	0.17	0.16	Neuroticism;	chr8:11570128	chr8:11797928~11802568:-
THCA	cis	rs2299587	0.866	rs208765	ENSG00000253671.1	RP11-806O11.1	3.47	0.000559	0.0335	0.19	0.16	Economic and political preferences;	chr8:17947939	chr8:17808941~17820868:+
THCA	cis	rs9300255	0.602	rs1727317	ENSG00000235423.7	RP11-282O18.3	3.47	0.000559	0.0335	0.18	0.16	Neutrophil percentage of white cells;	chr12:123134395	chr12:123252030~123261483:-
THCA	cis	rs2692947	0.74	rs11695514	ENSG00000235959.1	AC009237.17	-3.47	0.000559	0.0335	-0.18	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95882320	chr2:95640181~95640604:-
THCA	cis	rs6715793	0.901	rs12617970	ENSG00000272754.1	AL133245.2	3.47	0.000559	0.0335	0.18	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33178770	chr2:32321638~32323002:+
THCA	cis	rs614226	1	rs616157	ENSG00000278344.1	RP11-18C24.8	-3.47	0.000559	0.0335	-0.22	-0.16	Type 1 diabetes nephropathy;	chr12:120487992	chr12:120500735~120501090:-
THCA	cis	rs1510272	0.889	rs2048336	ENSG00000243926.1	TIPARP-AS1	-3.47	0.000559	0.0335	-0.16	-0.16	Testicular germ cell tumor;	chr3:156610464	chr3:156671862~156674378:-
THCA	cis	rs16857609	0.564	rs13388148	ENSG00000233143.1	DIRC3-AS1	-3.47	0.000559	0.0335	-0.19	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217416777	chr2:217282739~217336120:+
THCA	cis	rs591584	0.59	rs10765689	ENSG00000255893.1	RP11-685N10.1	-3.47	0.000559	0.0335	-0.18	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94589519	chr11:94472908~94473570:-
THCA	cis	rs4908760	0.864	rs6701331	ENSG00000270282.1	RP5-1115A15.2	3.47	0.000559	0.0335	0.19	0.16	Vitiligo;	chr1:8610147	chr1:8512653~8513021:+
THCA	cis	rs79419269	0.643	rs73169654	ENSG00000265810.1	MIR3907	-3.47	0.000559	0.0335	-0.21	-0.16	Immunoglobulin light chain (AL) amyloidosis;	chr7:151212630	chr7:151433489~151433639:-
THCA	cis	rs2919009	0.882	rs2919008	ENSG00000271670.1	RP11-95I16.4	3.47	0.000559	0.0335	0.18	0.16	Obesity-related traits;	chr10:120838163	chr10:120879256~120880667:-
THCA	cis	rs61160187	0.582	rs72757187	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000559	0.0335	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs67490467	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000559	0.0335	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs62367872	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000559	0.0335	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.556	rs55738840	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000559	0.0335	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs58646987	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000559	0.0335	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs11739952	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000559	0.0335	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs4642318	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000559	0.0335	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60866457~60866935:-
THCA	cis	rs6696239	0.84	rs12097239	ENSG00000227711.2	RP11-275O4.5	-3.47	0.000559	0.0335	-0.19	-0.16	Height;	chr1:227724773	chr1:227509028~227520477:-
THCA	cis	rs2840044	0.711	rs225301	ENSG00000255987.1	TOMM20P2	-3.47	0.000559	0.0335	-0.17	-0.16	Response to radiotherapy in cancer (late toxicity);	chr17:35595392	chr17:35514766~35515186:-
THCA	cis	rs4909945	0.506	rs12360799	ENSG00000254554.1	RP11-351I24.1	-3.47	0.000559	0.0335	-0.18	-0.16	Migraine;Headache;	chr11:10633474	chr11:10302657~10303704:-
THCA	cis	rs763121	0.853	rs5757193	ENSG00000225450.1	RP3-508I15.14	3.47	0.000559	0.0335	0.13	0.16	Menopause (age at onset);	chr22:38638862	chr22:38739003~38749041:+
THCA	cis	rs6138458	0.585	rs1007881	ENSG00000274173.1	RP4-568C11.4	3.47	0.000559	0.0335	0.13	0.16	Blood protein levels;	chr20:25033749	chr20:24931840~24932983:+
THCA	cis	rs2243480	1	rs67728539	ENSG00000273024.4	INTS4P2	3.47	0.000559	0.0335	0.27	0.16	Diabetic kidney disease;	chr7:65913137	chr7:65647864~65715661:+
THCA	cis	rs2562456	1	rs2359155	ENSG00000268278.1	RP11-420K14.1	-3.47	0.000559	0.0335	-0.19	-0.16	Pain;	chr19:21489067	chr19:21637974~21656300:+
THCA	cis	rs7129190	0.69	rs1672717	ENSG00000256167.1	ATF4P4	3.47	0.00056	0.0335	0.2	0.16	Chronic kidney disease;	chr11:113942011	chr11:113789231~113791366:+
THCA	cis	rs7520050	0.966	rs1707340	ENSG00000280836.1	AL355480.1	3.47	0.00056	0.0335	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45581219~45581321:-
THCA	cis	rs7520050	1	rs785473	ENSG00000280836.1	AL355480.1	3.47	0.00056	0.0335	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.931	rs785472	ENSG00000280836.1	AL355480.1	3.47	0.00056	0.0335	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45581219~45581321:-
THCA	cis	rs1059312	1	rs9738216	ENSG00000279500.1	RP11-21K12.2	-3.47	0.00056	0.0335	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128797243	chr12:128813186~128814750:-
THCA	cis	rs12101261	0.744	rs2284718	ENSG00000258915.1	BHLHB9P1	-3.47	0.00056	0.0335	-0.2	-0.16	Graves' disease;	chr14:80968545	chr14:80981988~80983638:+
THCA	cis	rs12101261	0.744	rs2284719	ENSG00000258915.1	BHLHB9P1	-3.47	0.00056	0.0335	-0.2	-0.16	Graves' disease;	chr14:80969254	chr14:80981988~80983638:+
THCA	cis	rs12101261	0.744	rs72693057	ENSG00000258915.1	BHLHB9P1	-3.47	0.00056	0.0335	-0.2	-0.16	Graves' disease;	chr14:80970149	chr14:80981988~80983638:+
THCA	cis	rs6125597	0.533	rs6122778	ENSG00000230758.1	SNAP23P	3.47	0.00056	0.0335	0.2	0.16	Intelligence (multi-trait analysis);	chr20:49267405	chr20:49038357~49038602:-
THCA	cis	rs6929812	0.639	rs6456789	ENSG00000216915.2	RP1-97D16.1	3.47	0.00056	0.0335	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27458719	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.629	rs7743443	ENSG00000216915.2	RP1-97D16.1	3.47	0.00056	0.0335	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27458880	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs7748366	ENSG00000216915.2	RP1-97D16.1	3.47	0.00056	0.0335	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27459763	chr6:27737000~27738494:-
THCA	cis	rs9467773	0.62	rs2504571	ENSG00000228223.2	HCG11	-3.47	0.00056	0.0335	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26523450~26526579:+
THCA	cis	rs56309584	0.883	rs9897627	ENSG00000178977.3	LINC00324	-3.47	0.00056	0.0335	-0.19	-0.16	Initial pursuit acceleration;	chr17:8258528	chr17:8220642~8224043:-
THCA	cis	rs62380364	0.754	rs4518438	ENSG00000247828.6	TMEM161B-AS1	-3.47	0.00056	0.0335	-0.12	-0.16	Intelligence (multi-trait analysis);	chr5:88861735	chr5:88268895~88436685:+
THCA	cis	rs10858047	0.883	rs7539721	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114629028	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs9308267	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114632222	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs7556270	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114635420	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs4543788	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114636880	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs6701882	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114638628	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.831	rs11102826	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114638986	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs11102827	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114639222	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs6681386	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114640562	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs975446	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114644740	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs6691804	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114650928	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.7	rs7538880	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114651753	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs7555301	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114657309	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs6537842	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114661846	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs6695699	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114667330	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs6537843	ENSG00000231128.4	RP5-1073O3.2	-3.47	0.00056	0.0335	-0.23	-0.16	Autism;	chr1:114667957	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.831	rs10776787	ENSG00000231128.4	RP5-1073O3.2	3.47	0.00056	0.0335	0.23	0.16	Autism;	chr1:114667540	chr1:113812379~113829171:+
THCA	cis	rs7085104	0.727	rs12773892	ENSG00000213061.2	PFN1P11	3.47	0.00056	0.0335	0.21	0.16	Immature fraction of reticulocytes;Schizophrenia;	chr10:102871420	chr10:102838011~102845473:-
THCA	cis	rs7897654	0.571	rs12767543	ENSG00000213061.2	PFN1P11	3.47	0.00056	0.0335	0.21	0.16	Schizophrenia;	chr10:102871906	chr10:102838011~102845473:-
THCA	cis	rs2638953	0.853	rs11049519	ENSG00000278733.1	RP11-425D17.1	-3.47	0.00056	0.0335	-0.19	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28307285	chr12:28185625~28186190:-
THCA	cis	rs7246967	0.611	rs73030508	ENSG00000198153.8	ZNF849P	-3.47	0.00056	0.0335	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22643230	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs73030511	ENSG00000198153.8	ZNF849P	-3.47	0.00056	0.0335	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22643232	chr19:22685167~22686732:+
THCA	cis	rs28472312	0.667	rs3922668	ENSG00000259982.1	CDC37P1	-3.47	0.00056	0.0335	-0.17	-0.16	Intelligence (multi-trait analysis);	chr16:28981325	chr16:28700294~28701540:-
THCA	cis	rs1510552	0.554	rs2372223	ENSG00000270659.1	RP11-105N14.1	-3.47	0.00056	0.0335	-0.13	-0.16	Contrast sensitivity;	chr2:214122380	chr2:213152970~213153659:+
THCA	cis	rs12681288	0.963	rs7822955	ENSG00000260721.1	AF067845.1	-3.47	0.00056	0.0335	-0.19	-0.16	Schizophrenia;	chr8:1079090	chr8:1368642~1369833:-
THCA	cis	rs9844666	0.512	rs9819440	ENSG00000273486.1	RP11-731C17.2	-3.47	0.00056	0.0335	-0.14	-0.16	Height;	chr3:135944640	chr3:136837338~136839021:-
THCA	cis	rs1023500	0.573	rs8135801	ENSG00000270083.1	RP1-257I20.14	-3.47	0.00056	0.0335	-0.18	-0.16	Schizophrenia;	chr22:42079564	chr22:42089630~42090028:-
THCA	cis	rs10875746	0.768	rs4760676	ENSG00000275228.1	RP11-370I10.10	3.47	0.00056	0.0335	0.19	0.16	Longevity (90 years and older);	chr12:48027880	chr12:48327942~48328472:-
THCA	cis	rs6598955	0.67	rs10902734	ENSG00000236782.4	RP11-96L14.7	3.47	0.00056	0.0335	0.19	0.16	Obesity-related traits;	chr1:26291432	chr1:26169947~26171821:-
THCA	cis	rs6137726	0.568	rs910960	ENSG00000237396.1	LINC01384	3.47	0.00056	0.0335	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22647249	chr20:22587522~22607517:-
THCA	cis	rs9307551	0.948	rs1371993	ENSG00000249646.2	OR7E94P	-3.47	0.00056	0.0335	-0.22	-0.16	Refractive error;	chr4:79560662	chr4:79587302~79588130:-
THCA	cis	rs7246657	0.941	rs67293224	ENSG00000267422.1	CTD-2554C21.1	-3.47	0.00056	0.0335	-0.19	-0.16	Coronary artery calcification;	chr19:37312346	chr19:37779686~37792865:+
THCA	cis	rs7129556	0.702	rs7123080	ENSG00000254459.1	RP11-91P24.7	3.47	0.00056	0.0335	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77788341	chr11:77829654~77872262:-
THCA	cis	rs5769765	0.908	rs9616217	ENSG00000260613.1	RP3-522J7.6	-3.47	0.00056	0.0335	-0.21	-0.16	Schizophrenia;	chr22:49925298	chr22:49832616~49837786:-
THCA	cis	rs6568686	0.786	rs7450789	ENSG00000255389.1	C6orf3	-3.47	0.00056	0.0335	-0.23	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111495772	chr6:111599875~111602295:+
THCA	cis	rs2797160	1	rs1935773	ENSG00000226409.1	RP11-735G4.1	-3.47	0.00056	0.0335	-0.19	-0.16	Endometrial cancer;	chr6:125675329	chr6:125370211~125374324:-
THCA	cis	rs10833905	0.938	rs61892165	ENSG00000246225.5	RP11-17A1.3	-3.47	0.00056	0.0335	-0.23	-0.16	Sudden cardiac arrest;	chr11:23064316	chr11:22829380~22945393:+
THCA	cis	rs11089937	0.626	rs5757014	ENSG00000215456.5	BCRP4	3.47	0.00056	0.0335	0.2	0.16	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22630061~22636153:+
THCA	cis	rs16975963	0.843	rs3848624	ENSG00000276846.1	CTD-3220F14.3	-3.47	0.00056	0.0335	-0.15	-0.16	Longevity;	chr19:37772176	chr19:37314868~37315620:-
THCA	cis	rs7520050	0.966	rs785479	ENSG00000281133.1	AL355480.3	3.47	0.00056	0.0335	0.18	0.16	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45580892~45580996:-
THCA	cis	rs886774	0.565	rs4510766	ENSG00000241764.3	AC002467.7	3.47	0.00056	0.0335	0.13	0.16	Ulcerative colitis;	chr7:107852344	chr7:107742817~107744581:-
THCA	cis	rs1075232	0.522	rs57924788	ENSG00000215302.7	CTD-3092A11.1	-3.47	0.00056	0.0335	-0.28	-0.16	Survival in colorectal cancer (non-distant metastatic);	chr15:31457519	chr15:30470779~30507623:+
THCA	cis	rs10129255	1	rs10129319	ENSG00000280411.1	IGHV1-69-2	-3.47	0.00056	0.0336	-0.1	-0.16	Kawasaki disease;	chr14:106767996	chr14:106762092~106762588:-
THCA	cis	rs4808199	0.947	rs4808960	ENSG00000267481.1	CTC-559E9.5	-3.47	0.00056	0.0336	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19463468	chr19:19788755~19790531:-
THCA	cis	rs763121	0.719	rs138699	ENSG00000225450.1	RP3-508I15.14	-3.47	0.00056	0.0336	-0.14	-0.16	Menopause (age at onset);	chr22:38733703	chr22:38739003~38749041:+
THCA	cis	rs600231	0.598	rs2508712	ENSG00000254614.2	AP003068.23	3.47	0.00056	0.0336	0.21	0.16	Bone mineral density;	chr11:65464790	chr11:65177606~65181834:-
THCA	cis	rs600231	0.708	rs3132767	ENSG00000254614.2	AP003068.23	3.47	0.00056	0.0336	0.21	0.16	Bone mineral density;	chr11:65467389	chr11:65177606~65181834:-
THCA	cis	rs7412746	0.634	rs72704658	ENSG00000224800.1	RP11-235D19.2	-3.47	0.00056	0.0336	-0.22	-0.16	Melanoma;	chr1:150860534	chr1:150881236~150881683:-
THCA	cis	rs3750965	0.919	rs12280942	ENSG00000259799.1	RP11-554A11.9	-3.47	0.00056	0.0336	-0.2	-0.16	Hair color;	chr11:69092215	chr11:69155910~69159752:+
THCA	cis	rs277939	0.967	rs277979	ENSG00000230847.4	RP11-195E2.1	-3.47	0.00056	0.0336	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71631859	chr5:71074225~71093193:-
THCA	cis	rs7911264	0.739	rs4933734	ENSG00000232709.1	MARK2P9	-3.47	0.00056	0.0336	-0.19	-0.16	Inflammatory bowel disease;	chr10:92654810	chr10:92418667~92420875:+
THCA	cis	rs1560104	0.576	rs7186154	ENSG00000262801.4	U91319.1	-3.47	0.000561	0.0336	-0.18	-0.16	Obesity-related traits;	chr16:12615650	chr16:13246316~13562918:+
THCA	cis	rs11190604	0.673	rs10883498	ENSG00000273030.1	RP11-285F16.1	3.47	0.000561	0.0336	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100468952	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.943	rs7900678	ENSG00000273030.1	RP11-285F16.1	3.47	0.000561	0.0336	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100469259	chr10:100412934~100413421:+
THCA	cis	rs78153629	1	rs11557072	ENSG00000259330.1	INAFM2	-3.47	0.000561	0.0336	-0.2	-0.16	Heschl's gyrus morphology;	chr15:40421175	chr15:40325216~40326715:+
THCA	cis	rs36093844	0.527	rs10128700	ENSG00000279742.1	RP11-700A24.1	-3.47	0.000561	0.0336	-0.21	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86043350	chr11:85852557~85854943:-
THCA	cis	rs12612619	0.689	rs6711384	ENSG00000231636.1	AGBL5-AS1	3.47	0.000561	0.0336	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057224	chr2:27049683~27050264:-
THCA	cis	rs860295	0.557	rs12035524	ENSG00000236675.1	MTX1P1	-3.47	0.000561	0.0336	-0.17	-0.16	Body mass index;	chr1:155697311	chr1:155230975~155234325:+
THCA	cis	rs8070624	0.574	rs9914127	ENSG00000281749.1	Y_RNA	3.47	0.000561	0.0336	0.2	0.16	Total body bone mineral density;	chr17:17972522	chr17:18001101~18001195:-
THCA	cis	rs8070624	0.574	rs11078408	ENSG00000281749.1	Y_RNA	3.47	0.000561	0.0336	0.2	0.16	Total body bone mineral density;	chr17:17972697	chr17:18001101~18001195:-
THCA	cis	rs8070624	0.543	rs11078409	ENSG00000281749.1	Y_RNA	3.47	0.000561	0.0336	0.2	0.16	Total body bone mineral density;	chr17:17972982	chr17:18001101~18001195:-
THCA	cis	rs1153858	1	rs61365925	ENSG00000275672.1	GATM-AS1	-3.47	0.000561	0.0336	-0.16	-0.16	Homoarginine levels;	chr15:45358113	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs12101539	ENSG00000275672.1	GATM-AS1	-3.47	0.000561	0.0336	-0.16	-0.16	Homoarginine levels;	chr15:45358468	chr15:45378700~45380123:+
THCA	cis	rs2270204	0.526	rs4734	ENSG00000272696.1	RP11-339B21.13	3.47	0.000561	0.0336	0.13	0.16	Body mass index;	chr9:128256360	chr9:128316337~128316909:+
THCA	cis	rs34421088	0.56	rs2248325	ENSG00000255495.1	AC145124.2	-3.47	0.000561	0.0336	-0.18	-0.16	Neuroticism;	chr8:11539365	chr8:12194467~12196280:+
THCA	cis	rs34421088	0.56	rs2248316	ENSG00000255495.1	AC145124.2	-3.47	0.000561	0.0336	-0.18	-0.16	Neuroticism;	chr8:11539564	chr8:12194467~12196280:+
THCA	cis	rs34421088	0.56	rs2248315	ENSG00000255495.1	AC145124.2	-3.47	0.000561	0.0336	-0.18	-0.16	Neuroticism;	chr8:11539577	chr8:12194467~12196280:+
THCA	cis	rs1153858	0.621	rs2687512	ENSG00000275672.1	GATM-AS1	3.47	0.000561	0.0336	0.17	0.16	Homoarginine levels;	chr15:45289297	chr15:45378700~45380123:+
THCA	cis	rs910316	0.712	rs175015	ENSG00000259138.1	RP11-950C14.7	-3.47	0.000561	0.0336	-0.14	-0.16	Height;	chr14:74990372	chr14:75127153~75136930:+
THCA	cis	rs8070473	1	rs8068353	ENSG00000242660.1	RP11-1094M14.1	-3.47	0.000561	0.0336	-0.24	-0.16	Depression (quantitative trait);	chr17:35513276	chr17:35566517~35566672:+
THCA	cis	rs9923856	0.57	rs1035088	ENSG00000263033.2	RP11-396B14.2	-3.47	0.000561	0.0336	-0.16	-0.16	Atopic dermatitis;Adult asthma;	chr16:10954517	chr16:11196177~11224969:+
THCA	cis	rs67981189	0.727	rs221903	ENSG00000269927.1	RP6-91H8.3	-3.47	0.000561	0.0336	-0.17	-0.16	Schizophrenia;	chr14:71133491	chr14:71141125~71143253:-
THCA	cis	rs9611565	0.559	rs1006407	ENSG00000281538.1	RP4-669P10.20	3.47	0.000561	0.0336	0.19	0.16	Vitiligo;	chr22:41576028	chr22:42138060~42139726:+
THCA	cis	rs11069062	0.683	rs10851025	ENSG00000270482.1	RP11-131L12.2	3.47	0.000561	0.0336	0.12	0.16	Obesity-related traits;	chr12:118739381	chr12:118375350~118376275:-
THCA	cis	rs250518	0.852	rs3846640	ENSG00000251467.1	CTC-250P20.2	3.47	0.000561	0.0336	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72724139	chr5:72996920~72997642:+
THCA	cis	rs250518	0.888	rs6870112	ENSG00000251467.1	CTC-250P20.2	3.47	0.000561	0.0336	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72725093	chr5:72996920~72997642:+
THCA	cis	rs13064411	0.696	rs6799610	ENSG00000243849.1	CFAP44-AS1	-3.47	0.000561	0.0336	-0.25	-0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113529901	chr3:113403991~113433992:+
THCA	cis	rs7020830	0.571	rs7031314	ENSG00000281649.1	EBLN3	3.47	0.000561	0.0336	0.16	0.16	Schizophrenia;	chr9:37376125	chr9:37079857~37090507:+
THCA	cis	rs858239	0.738	rs7807879	ENSG00000226816.2	AC005082.12	3.47	0.000561	0.0336	0.23	0.16	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23206013~23208045:+
THCA	cis	rs8030379	1	rs8024628	ENSG00000176700.18	SCAND2P	-3.47	0.000561	0.0336	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917711	chr15:84631451~84647478:+
THCA	cis	rs8030379	1	rs8029016	ENSG00000176700.18	SCAND2P	-3.47	0.000561	0.0336	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917712	chr15:84631451~84647478:+
THCA	cis	rs10863936	0.667	rs7540968	ENSG00000198468.6	FLVCR1-AS1	-3.47	0.000561	0.0336	-0.19	-0.16	Height;	chr1:212066143	chr1:212852108~212858088:-
THCA	cis	rs757110	0.834	rs1002226	ENSG00000260196.1	RP1-239B22.5	3.47	0.000561	0.0336	0.17	0.16	Type 2 diabetes;	chr11:17384070	chr11:17380649~17383531:+
THCA	cis	rs8028182	0.666	rs9972533	ENSG00000260274.1	RP11-817O13.8	3.47	0.000561	0.0336	0.14	0.16	Sudden cardiac arrest;	chr15:75377738	chr15:75368155~75369584:+
THCA	cis	rs34102591	0.503	rs10846574	ENSG00000270028.1	RP11-380L11.4	3.47	0.000561	0.0336	0.17	0.16	Schizophrenia;	chr12:123900511	chr12:123925461~123926083:-
THCA	cis	rs758324	0.797	rs253948	ENSG00000237714.1	P4HA2-AS1	-3.47	0.000561	0.0336	-0.24	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131986333	chr5:132184876~132192808:+
THCA	cis	rs4673659	0.838	rs7562782	ENSG00000234308.2	AC093381.2	-3.47	0.000561	0.0336	-0.15	-0.16	Asthma (sex interaction);	chr2:212327544	chr2:212795331~212819264:+
THCA	cis	rs114532231	0.661	rs75764836	ENSG00000273080.1	RP11-301O19.1	-3.47	0.000561	0.0336	-0.39	-0.16	Asymmetrical dimethylarginine levels;	chr2:86299740	chr2:86195590~86196049:+
THCA	cis	rs9487094	0.689	rs8465	ENSG00000223537.2	RP5-919F19.5	-3.47	0.000561	0.0336	-0.16	-0.16	Height;	chr6:109367335	chr6:109487906~109506800:+
THCA	cis	rs7674212	0.51	rs55715738	ENSG00000230069.3	LRRC37A15P	-3.47	0.000561	0.0336	-0.16	-0.16	Type 2 diabetes;	chr4:103209032	chr4:102727274~102730721:-
THCA	cis	rs9796	0.689	rs692153	ENSG00000247556.5	OIP5-AS1	3.47	0.000561	0.0336	0.13	0.16	Menopause (age at onset);	chr15:41160483	chr15:41283990~41309737:+
THCA	cis	rs7737355	0.812	rs10041712	ENSG00000237714.1	P4HA2-AS1	-3.47	0.000561	0.0336	-0.22	-0.16	Life satisfaction;	chr5:131429977	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.812	rs6891387	ENSG00000237714.1	P4HA2-AS1	-3.47	0.000561	0.0336	-0.22	-0.16	Life satisfaction;	chr5:131430224	chr5:132184876~132192808:+
THCA	cis	rs683250	0.569	rs10898105	ENSG00000254551.1	RP11-727A23.7	-3.47	0.000561	0.0336	-0.18	-0.16	Subcortical brain region volumes;	chr11:83360862	chr11:83209431~83213379:-
THCA	cis	rs453301	0.579	rs10096850	ENSG00000254153.1	CTA-398F10.2	3.47	0.000562	0.0336	0.18	0.16	Joint mobility (Beighton score);	chr8:8940712	chr8:8456909~8461337:-
THCA	cis	rs7520050	0.865	rs785515	ENSG00000280836.1	AL355480.1	3.47	0.000562	0.0336	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46096990	chr1:45581219~45581321:-
THCA	cis	rs9844666	0.512	rs9836374	ENSG00000239213.4	NCK1-AS1	3.47	0.000562	0.0336	0.16	0.16	Height;	chr3:135989606	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs17250445	ENSG00000239213.4	NCK1-AS1	3.47	0.000562	0.0336	0.16	0.16	Waist circumference adjusted for body mass index;	chr3:135990261	chr3:136841726~136862054:-
THCA	cis	rs2300747	0.932	rs12044852	ENSG00000177173.5	NAP1L4P1	-3.47	0.000562	0.0336	-0.23	-0.16	Primary biliary cholangitis;Multiple sclerosis;	chr1:116545157	chr1:116532936~116534092:-
THCA	cis	rs9788682	0.947	rs7169584	ENSG00000261143.1	ADAMTS7P3	-3.47	0.000562	0.0336	-0.22	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78530318	chr15:77976042~77993057:+
THCA	cis	rs9309473	1	rs9309473	ENSG00000273245.1	RP11-434P11.2	3.47	0.000562	0.0336	0.22	0.16	Metabolite levels;	chr2:73516855	chr2:73750256~73750786:-
THCA	cis	rs7259376	0.775	rs2360621	ENSG00000270947.1	AC025811.3	3.47	0.000562	0.0336	0.17	0.16	Menopause (age at onset);	chr19:22365867	chr19:22455988~22456459:+
THCA	cis	rs929354	0.772	rs3802123	ENSG00000224629.1	RP5-1142J19.2	-3.47	0.000562	0.0336	-0.16	-0.16	Body mass index;	chr7:157177947	chr7:157263022~157263229:-
THCA	cis	rs11239930	0.517	rs2477568	ENSG00000278811.3	LINC00624	-3.47	0.000562	0.0336	-0.18	-0.16	AIDS progression;	chr1:147076244	chr1:147258885~147517875:-
THCA	cis	rs1003719	0.667	rs8127148	ENSG00000270116.1	AP001429.1	-3.47	0.000562	0.0336	-0.17	-0.16	Eye color traits;	chr21:37108992	chr21:37100814~37101343:+
THCA	cis	rs775227	1	rs13094203	ENSG00000243849.1	CFAP44-AS1	3.47	0.000562	0.0336	0.26	0.16	Dental caries;	chr3:113274520	chr3:113403991~113433992:+
THCA	cis	rs7919656	0.662	rs1904605	ENSG00000228403.1	RP11-563N6.6	-3.47	0.000562	0.0336	-0.17	-0.16	Clinically amyopathic dermatomyositis;	chr10:48847335	chr10:48878022~48878649:+
THCA	cis	rs7267979	0.903	rs6107015	ENSG00000276952.1	RP5-965G21.6	3.47	0.000562	0.0336	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25284915~25285588:-
THCA	cis	rs301901	0.675	rs2366274	ENSG00000250155.1	CTD-2353F22.1	-3.47	0.000562	0.0336	-0.16	-0.16	Height;	chr5:37266341	chr5:36666214~36725195:-
THCA	cis	rs6468852	0.602	rs62525269	ENSG00000253669.3	KB-1732A1.1	-3.47	0.000562	0.0336	-0.29	-0.16	Alzheimer's disease (late onset);	chr8:102963799	chr8:102805517~102809971:+
THCA	cis	rs1005277	0.602	rs1831315	ENSG00000151963.4	RP11-775A3.1	-3.47	0.000562	0.0336	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs1780130	ENSG00000151963.4	RP11-775A3.1	-3.47	0.000562	0.0336	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:37883594~37884109:+
THCA	cis	rs943306	0.5	rs10983385	ENSG00000230734.1	RPL10P3	3.47	0.000562	0.0336	0.14	0.16	Lifetime average cigarettes per day in chronic obstructive pulmonary disease;	chr9:116868678	chr9:117180628~117181095:-
THCA	cis	rs9314614	0.789	rs2951859	ENSG00000245857.2	GS1-24F4.2	3.47	0.000562	0.0336	0.21	0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6855631	chr8:6835554~6885276:+
THCA	cis	rs10256972	0.721	rs2030959	ENSG00000199023.2	MIR339	-3.47	0.000562	0.0336	-0.16	-0.16	Endometriosis;Longevity;	chr7:1036270	chr7:1022935~1023045:-
THCA	cis	rs1051424	0.651	rs1292063	ENSG00000266701.1	AC005702.4	-3.47	0.000562	0.0336	-0.25	-0.16	Obesity-related traits;	chr17:59830407	chr17:60042546~60042627:-
THCA	cis	rs3135758	0.52	rs77180105	ENSG00000274461.1	RP11-323P17.2	3.47	0.000562	0.0336	0.41	0.16	Magnesium levels;	chr10:121666143	chr10:120819307~120825311:+
THCA	cis	rs910316	0.737	rs175499	ENSG00000259138.1	RP11-950C14.7	-3.47	0.000562	0.0336	-0.14	-0.16	Height;	chr14:75069224	chr14:75127153~75136930:+
THCA	cis	rs10454142	0.633	rs7559431	ENSG00000202227.1	RNU6-282P	3.47	0.000562	0.0336	0.19	0.16	Sex hormone-binding globulin levels;	chr2:48364468	chr2:48501922~48502024:-
THCA	cis	rs7246657	0.722	rs12974225	ENSG00000226686.6	LINC01535	3.47	0.000562	0.0336	0.23	0.16	Coronary artery calcification;	chr19:37749458	chr19:37251912~37265535:+
THCA	cis	rs7899628	1	rs7899628	ENSG00000273891.1	RP11-500G22.5	-3.47	0.000562	0.0336	-0.15	-0.16	Breast cancer;	chr10:121904429	chr10:121965764~121967700:+
THCA	cis	rs9420	0.961	rs11229148	ENSG00000254602.1	AP000662.4	-3.47	0.000562	0.0336	-0.18	-0.16	Schizophrenia;	chr11:57853988	chr11:57638024~57652790:+
THCA	cis	rs17428076	0.874	rs72885529	ENSG00000228389.1	AC068039.4	-3.47	0.000562	0.0336	-0.18	-0.16	Myopia;	chr2:171827522	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.874	rs72885532	ENSG00000228389.1	AC068039.4	-3.47	0.000562	0.0336	-0.18	-0.16	Myopia;	chr2:171827523	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.836	rs57775770	ENSG00000228389.1	AC068039.4	-3.47	0.000562	0.0336	-0.18	-0.16	Myopia;	chr2:171831221	chr2:171773482~171775844:+
THCA	cis	rs448720	1	rs383144	ENSG00000260657.2	RP11-315D16.4	3.47	0.000562	0.0336	0.2	0.16	Cognitive performance;	chr15:67912243	chr15:68267792~68277994:-
THCA	cis	rs17689437	1	rs17689437	ENSG00000275383.1	RP11-615I2.6	-3.47	0.000562	0.0336	-0.27	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68566448	chr16:68591382~68594424:+
THCA	cis	rs721352	0.684	rs2169282	ENSG00000223621.1	AK4P4	-3.47	0.000562	0.0336	-0.2	-0.16	Chronic sinus infection;	chr9:6350235	chr9:5855781~5856426:-
THCA	cis	rs34779708	0.966	rs7070427	ENSG00000233200.1	RP11-324I22.2	3.47	0.000562	0.0336	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35219894~35230598:-
THCA	cis	rs2018683	0.707	rs917216	ENSG00000233517.1	AC005162.5	-3.47	0.000562	0.0336	-0.2	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931855	chr7:28987028~28988899:+
THCA	cis	rs9652490	0.646	rs12901420	ENSG00000260776.4	RP11-114H24.2	3.47	0.000562	0.0336	0.27	0.16	Essential tremor;	chr15:77674648	chr15:77914217~77926846:-
THCA	cis	rs9300255	0.602	rs10744147	ENSG00000274427.1	RP11-972P1.10	3.47	0.000562	0.0336	0.16	0.16	Neutrophil percentage of white cells;	chr12:123159182	chr12:123515275~123515513:-
THCA	cis	rs9300255	0.602	rs1617434	ENSG00000274427.1	RP11-972P1.10	3.47	0.000562	0.0336	0.16	0.16	Neutrophil percentage of white cells;	chr12:123164939	chr12:123515275~123515513:-
THCA	cis	rs6439699	0.941	rs13068466	ENSG00000273486.1	RP11-731C17.2	3.47	0.000562	0.0336	0.16	0.16	Intelligence (multi-trait analysis);	chr3:137271599	chr3:136837338~136839021:-
THCA	cis	rs2281636	0.66	rs11190184	ENSG00000260475.1	RP11-85A1.3	3.47	0.000562	0.0337	0.17	0.16	Obesity-related traits;	chr10:99608442	chr10:99621055~99621918:+
THCA	cis	rs256438	0.642	rs11738491	ENSG00000251221.1	LINC01337	-3.47	0.000562	0.0337	-0.19	-0.16	Serum thyroid-stimulating hormone levels;	chr5:80039149	chr5:80608623~80622524:-
THCA	cis	rs2033711	0.84	rs3764533	ENSG00000269867.1	CTD-2583A14.8	-3.47	0.000562	0.0337	-0.13	-0.16	Uric acid clearance;	chr19:58417827	chr19:57867038~57868172:-
THCA	cis	rs2274273	0.87	rs8013713	ENSG00000258469.1	CHMP4BP1	-3.47	0.000562	0.0337	-0.14	-0.16	Protein biomarker;	chr14:55374534	chr14:55298644~55299231:+
THCA	cis	rs7819412	0.936	rs7814499	ENSG00000261451.1	RP11-981G7.1	-3.47	0.000562	0.0337	-0.2	-0.16	Triglycerides;	chr8:11183138	chr8:10433672~10438312:+
THCA	cis	rs9392556	0.829	rs7757606	ENSG00000230648.1	RP3-406P24.3	3.47	0.000562	0.0337	0.2	0.16	Blood metabolite levels;	chr6:4119470	chr6:4018843~4021215:-
THCA	cis	rs11785400	0.731	rs4736363	ENSG00000177335.9	C8orf31	3.47	0.000562	0.0337	0.18	0.16	Schizophrenia;	chr8:142660700	chr8:143039209~143059942:+
THCA	cis	rs11098699	0.784	rs6534393	ENSG00000273007.1	RP11-170N16.3	-3.47	0.000563	0.0337	-0.13	-0.16	Mosquito bite size;	chr4:123317792	chr4:122881878~122884712:-
THCA	cis	rs4561483	0.801	rs154148	ENSG00000263307.1	RP11-166B2.8	3.47	0.000563	0.0337	0.17	0.16	Testicular germ cell tumor;	chr16:11862621	chr16:11851649~11895611:+
THCA	cis	rs786425	0.833	rs2222061	ENSG00000278112.1	RP11-972P1.11	3.47	0.000563	0.0337	0.15	0.16	Pubertal anthropometrics;	chr12:123710382	chr12:123519390~123519856:-
THCA	cis	rs10492201	0.529	rs11177004	ENSG00000255733.4	IFNG-AS1	-3.47	0.000563	0.0337	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68015229	chr12:67989445~68234686:+
THCA	cis	rs453301	0.686	rs10217044	ENSG00000253981.4	ALG1L13P	-3.47	0.000563	0.0337	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9037242	chr8:8236003~8244667:-
THCA	cis	rs7267979	0.509	rs6115218	ENSG00000230772.1	VN1R108P	3.47	0.000563	0.0337	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25734264~25735093:+
THCA	cis	rs4533267	1	rs4533267	ENSG00000189419.6	SPATA41	-3.47	0.000563	0.0337	-0.21	-0.16	Height;	chr15:100246066	chr15:100344457~100349655:-
THCA	cis	rs7226408	0.6	rs1246241	ENSG00000267707.2	RP11-95O2.5	-3.47	0.000563	0.0337	-0.16	-0.16	Obesity-related traits;	chr18:36838528	chr18:37243776~37247506:+
THCA	cis	rs7395662	0.963	rs6485900	ENSG00000200090.1	Y_RNA	-3.47	0.000563	0.0337	-0.11	-0.16	HDL cholesterol;	chr11:48615863	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs6485903	ENSG00000200090.1	Y_RNA	-3.47	0.000563	0.0337	-0.11	-0.16	HDL cholesterol;	chr11:48617452	chr11:47726894~47726992:-
THCA	cis	rs17406451	0.759	rs12989996	ENSG00000279873.2	LINC01126	3.47	0.000563	0.0337	0.12	0.16	Mitochondrial DNA levels;	chr2:43425030	chr2:43227210~43228855:+
THCA	cis	rs6137726	0.652	rs7273357	ENSG00000237396.1	LINC01384	-3.47	0.000563	0.0337	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22671324	chr20:22587522~22607517:-
THCA	cis	rs5758659	0.716	rs2143138	ENSG00000237037.8	NDUFA6-AS1	3.47	0.000563	0.0337	0.12	0.16	Cognitive function;	chr22:42222334	chr22:42090931~42137742:+
THCA	cis	rs9341808	0.791	rs1324122	ENSG00000260645.1	RP11-250B2.5	3.47	0.000563	0.0337	0.14	0.16	Sitting height ratio;	chr6:80236344	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.754	rs10806185	ENSG00000260645.1	RP11-250B2.5	3.47	0.000563	0.0337	0.14	0.16	Sitting height ratio;	chr6:80244794	chr6:80466958~80469080:+
THCA	cis	rs7615952	0.599	rs6766327	ENSG00000248787.1	RP11-666A20.4	-3.47	0.000563	0.0337	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126004834	chr3:125908005~125910272:-
THCA	cis	rs28643277	0.671	rs10796304	ENSG00000237470.3	DCLRE1CP1	3.47	0.000563	0.0337	0.2	0.16	Periodontitis (CDC/AAP);	chr10:15504832	chr10:15015370~15021863:-
THCA	cis	rs2283792	0.764	rs2298432	ENSG00000272829.1	XXbac-B135H6.18	3.47	0.000563	0.0337	0.15	0.16	Multiple sclerosis;	chr22:21768900	chr22:20981361~20981755:-
THCA	cis	rs4808779	0.787	rs10406080	ENSG00000268650.3	AC068499.10	-3.47	0.000563	0.0337	-0.16	-0.16	Granulocyte percentage of myeloid white cells;	chr19:18291332	chr19:18204730~18220480:+
THCA	cis	rs4218	0.689	rs28391430	ENSG00000277144.1	RP11-59H7.4	-3.47	0.000563	0.0337	-0.22	-0.16	Social communication problems;	chr15:59100318	chr15:59115547~59116089:-
THCA	cis	rs11673344	0.504	rs11666786	ENSG00000233527.7	ZNF529-AS1	3.47	0.000563	0.0337	0.13	0.16	Obesity-related traits;	chr19:37133947	chr19:36573070~36594708:+
THCA	cis	rs10911902	0.643	rs16825335	ENSG00000228238.1	GS1-304P7.2	-3.47	0.000563	0.0337	-0.25	-0.16	Schizophrenia;	chr1:186418612	chr1:186578279~186579299:+
THCA	cis	rs568617	0.626	rs10896050	ENSG00000245156.1	RP11-867G23.3	-3.47	0.000563	0.0337	-0.18	-0.16	Crohn's disease;	chr11:65810045	chr11:66269832~66278525:-
THCA	cis	rs10483853	0.806	rs10141031	ENSG00000258891.1	RP5-1021I20.5	-3.47	0.000563	0.0337	-0.21	-0.16	Coronary artery calcification;	chr14:73306901	chr14:73896164~73938114:-
THCA	cis	rs7615952	0.599	rs60847438	ENSG00000248787.1	RP11-666A20.4	-3.47	0.000563	0.0337	-0.25	-0.16	Blood pressure (smoking interaction);	chr3:126027162	chr3:125908005~125910272:-
THCA	cis	rs7474896	1	rs11011344	ENSG00000272983.1	RP11-508N22.12	3.47	0.000563	0.0337	0.19	0.16	Obesity (extreme);	chr10:37715918	chr10:38137337~38144399:+
THCA	cis	rs4073416	0.518	rs2184601	ENSG00000276116.2	FUT8-AS1	3.47	0.000563	0.0337	0.18	0.16	N-glycan levels;	chr14:65430650	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.518	rs7157109	ENSG00000276116.2	FUT8-AS1	3.47	0.000563	0.0337	0.18	0.16	N-glycan levels;	chr14:65433715	chr14:65411170~65412690:-
THCA	cis	rs9650657	0.737	rs4841436	ENSG00000269918.1	AF131215.9	3.47	0.000563	0.0337	0.16	0.16	Neuroticism;	chr8:10736964	chr8:11104691~11106704:-
THCA	cis	rs7264396	0.635	rs6060682	ENSG00000088340.14	FER1L4	3.47	0.000563	0.0337	0.16	0.16	Total cholesterol levels;	chr20:35918409	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs6058365	ENSG00000088340.14	FER1L4	3.47	0.000563	0.0337	0.16	0.16	Total cholesterol levels;	chr20:35920170	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs2024854	ENSG00000088340.14	FER1L4	3.47	0.000563	0.0337	0.16	0.16	Total cholesterol levels;	chr20:35923267	chr20:35558737~35607562:-
THCA	cis	rs6547741	0.563	rs10196039	ENSG00000270528.1	RP11-674I16.2	3.47	0.000563	0.0337	0.17	0.16	Oral cavity cancer;	chr2:27748328	chr2:28015777~28016482:-
THCA	cis	rs875971	0.545	rs12670811	ENSG00000222364.1	RNU6-96P	-3.47	0.000563	0.0337	-0.21	-0.16	Aortic root size;	chr7:66358032	chr7:66395191~66395286:+
THCA	cis	rs11771526	0.901	rs11764193	ENSG00000272905.1	RP11-265E18.1	3.47	0.000563	0.0337	0.2	0.16	Body mass index;	chr7:32232588	chr7:32845394~32846061:+
THCA	cis	rs11771526	0.686	rs28399034	ENSG00000272905.1	RP11-265E18.1	3.47	0.000563	0.0337	0.2	0.16	Body mass index;	chr7:32233286	chr7:32845394~32846061:+
THCA	cis	rs9940149	1	rs9934398	ENSG00000277142.1	LINC00235	-3.47	0.000563	0.0337	-0.16	-0.16	Type 2 diabetes;	chr16:250697	chr16:525155~527407:-
THCA	cis	rs7142002	0.881	rs8022268	ENSG00000272444.1	RP11-1017G21.6	-3.47	0.000563	0.0337	-0.23	-0.16	Autism;	chr14:101933650	chr14:101952416~101953063:+
THCA	cis	rs10508774	0.85	rs55780305	ENSG00000217094.2	PPIAP31	3.47	0.000563	0.0337	0.27	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32420640	chr10:32188323~32188817:-
THCA	cis	rs9450351	0.744	rs9450317	ENSG00000280232.1	RP11-321N4.4	3.47	0.000563	0.0337	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85715052	chr6:85498441~85499058:-
THCA	cis	rs1858037	0.836	rs1396209	ENSG00000252414.1	RNU6-100P	-3.47	0.000563	0.0337	-0.18	-0.16	Rheumatoid arthritis;	chr2:65374100	chr2:64578892~64578997:+
THCA	cis	rs4730276	0.674	rs4727692	ENSG00000250474.1	WBP1LP2	-3.47	0.000563	0.0337	-0.14	-0.16	Ulcerative colitis;	chr7:107885569	chr7:107628553~107629498:+
THCA	cis	rs3885907	0.718	rs10162089	ENSG00000224511.1	LINC00365	3.47	0.000563	0.0337	0.2	0.16	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);	chr13:30742601	chr13:30103178~30108875:-
THCA	cis	rs7707921	0.757	rs226198	ENSG00000251374.1	RPS23P5	-3.47	0.000563	0.0337	-0.24	-0.16	Breast cancer;	chr5:82278173	chr5:82265157~82265259:-
THCA	cis	rs12506899	0.934	rs714825	ENSG00000221639.1	SNORA3	3.47	0.000563	0.0337	0.19	0.16	Tumor biomarkers;	chr4:73342482	chr4:73263960~73264084:+
THCA	cis	rs879324	0.689	rs6416747	ENSG00000280092.1	AC002044.3	-3.47	0.000563	0.0337	-0.23	-0.16	Stroke (ischemic);	chr16:72999934	chr16:73005601~73006141:-
THCA	cis	rs4664293	0.967	rs7597482	ENSG00000230783.1	AC009961.2	-3.47	0.000563	0.0337	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159690580	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs7597488	ENSG00000230783.1	AC009961.2	-3.47	0.000563	0.0337	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159690585	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs10803758	ENSG00000230783.1	AC009961.2	-3.47	0.000563	0.0337	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159691708	chr2:159689217~159690291:-
THCA	cis	rs55780018	0.675	rs35860033	ENSG00000224137.1	AC079767.4	3.47	0.000563	0.0337	0.14	0.16	Systolic blood pressure;	chr2:207640954	chr2:207662375~207667024:+
THCA	cis	rs2886497	0.947	rs1511823	ENSG00000224215.1	RP11-371A19.2	-3.47	0.000563	0.0337	-0.2	-0.16	Major depression and alcohol dependence;	chr10:23378594	chr10:23343957~23345181:+
THCA	cis	rs12681366	0.663	rs4735294	ENSG00000261437.1	RP11-22C11.2	3.47	0.000563	0.0337	0.15	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94478313	chr8:94637285~94639467:-
THCA	cis	rs9843304	0.868	rs4681516	ENSG00000240541.2	TM4SF1-AS1	-3.47	0.000563	0.0337	-0.15	-0.16	Gallstone disease;	chr3:149494338	chr3:149377778~149386583:+
THCA	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	3.47	0.000563	0.0337	0.18	0.16	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
THCA	cis	rs1926657	1	rs899495	ENSG00000223298.1	RNY3P8	-3.47	0.000563	0.0337	-0.22	-0.16	Breast cancer;	chr13:95209942	chr13:95310830~95310955:-
THCA	cis	rs12681963	0.688	rs7820490	ENSG00000272375.1	RP11-51J9.6	3.47	0.000563	0.0337	0.23	0.16	Migraine;	chr8:30213634	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs4507726	ENSG00000272375.1	RP11-51J9.6	3.47	0.000563	0.0337	0.23	0.16	Migraine;	chr8:30214491	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs4454242	ENSG00000272375.1	RP11-51J9.6	3.47	0.000563	0.0337	0.23	0.16	Migraine;	chr8:30214804	chr8:30197404~30198048:+
THCA	cis	rs10090774	0.735	rs9324530	ENSG00000279766.1	RP11-642A1.2	-3.47	0.000564	0.0337	-0.19	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140660808	chr8:140572142~140572812:-
THCA	cis	rs11190604	0.767	rs11190533	ENSG00000273030.1	RP11-285F16.1	3.47	0.000564	0.0337	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100431035	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs11190534	ENSG00000273030.1	RP11-285F16.1	3.47	0.000564	0.0337	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100431173	chr10:100412934~100413421:+
THCA	cis	rs1667255	1	rs1611949	ENSG00000266521.1	RP11-650P15.1	3.47	0.000564	0.0337	0.2	0.16	Retinol levels;	chr18:31607203	chr18:31496645~31497195:-
THCA	cis	rs7412746	0.588	rs10305664	ENSG00000224800.1	RP11-235D19.2	-3.47	0.000564	0.0337	-0.22	-0.16	Melanoma;	chr1:150867210	chr1:150881236~150881683:-
THCA	cis	rs4578769	0.691	rs28594790	ENSG00000273232.1	RP11-370A5.2	-3.47	0.000564	0.0337	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22985463	chr18:22882825~22883357:-
THCA	cis	rs4073416	0.542	rs8010726	ENSG00000276116.2	FUT8-AS1	3.47	0.000564	0.0337	0.18	0.16	N-glycan levels;	chr14:65465879	chr14:65411170~65412690:-
THCA	cis	rs683250	0.629	rs685398	ENSG00000254551.1	RP11-727A23.7	3.47	0.000564	0.0337	0.2	0.16	Subcortical brain region volumes;	chr11:83249233	chr11:83209431~83213379:-
THCA	cis	rs5758511	0.689	rs17478227	ENSG00000237037.8	NDUFA6-AS1	3.47	0.000564	0.0337	0.18	0.16	Birth weight;	chr22:42258321	chr22:42090931~42137742:+
THCA	cis	rs7973719	0.509	rs7969508	ENSG00000256967.1	RP11-273B20.1	-3.47	0.000564	0.0337	-0.13	-0.16	IgG glycosylation;	chr12:7217906	chr12:7129079~7131198:-
THCA	cis	rs7973719	0.509	rs7969635	ENSG00000256967.1	RP11-273B20.1	-3.47	0.000564	0.0337	-0.13	-0.16	IgG glycosylation;	chr12:7218016	chr12:7129079~7131198:-
THCA	cis	rs11673344	0.665	rs74435359	ENSG00000267309.1	CTD-2630F21.1	-3.47	0.000564	0.0337	-0.16	-0.16	Obesity-related traits;	chr19:36955252	chr19:36489649~36491040:+
THCA	cis	rs2919009	0.551	rs61872771	ENSG00000271670.1	RP11-95I16.4	3.47	0.000564	0.0337	0.18	0.16	Obesity-related traits;	chr10:120939465	chr10:120879256~120880667:-
THCA	cis	rs1050631	0.96	rs3826603	ENSG00000260552.1	RP11-49I11.1	3.47	0.000564	0.0337	0.2	0.16	Esophageal squamous cell cancer (length of survival);	chr18:36108407	chr18:36179996~36187448:-
THCA	cis	rs2664588	0.538	rs6063188	ENSG00000276923.1	RP11-321P16.1	-3.47	0.000564	0.0337	-0.21	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47964211	chr20:48073869~48074188:+
THCA	cis	rs950169	0.922	rs11635505	ENSG00000230373.7	GOLGA6L5P	3.47	0.000564	0.0337	0.17	0.16	Schizophrenia;	chr15:84553803	chr15:84507885~84516814:-
THCA	cis	rs4272720	0.535	rs58154726	ENSG00000234736.4	FAM170B-AS1	-3.47	0.000564	0.0337	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49082451	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.535	rs68065270	ENSG00000234736.4	FAM170B-AS1	-3.47	0.000564	0.0337	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49082473	chr10:49121839~49151547:+
THCA	cis	rs277939	1	rs410776	ENSG00000251634.2	RP11-1280N14.3	3.47	0.000564	0.0337	0.16	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71585847	chr5:71102898~71128753:-
THCA	cis	rs1555322	0.53	rs2425049	ENSG00000261582.1	RP4-614O4.11	-3.47	0.000564	0.0337	-0.18	-0.16	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35267885~35280043:-
THCA	cis	rs67478160	0.654	rs1535097	ENSG00000258534.1	CTD-2134A5.4	-3.47	0.000564	0.0337	-0.16	-0.16	Schizophrenia;	chr14:103750312	chr14:103854366~103880111:-
THCA	cis	rs10741243	1	rs7895030	ENSG00000230098.1	TCERG1L-AS1	3.47	0.000564	0.0337	0.21	0.16	Type 2 diabetes;	chr10:131143393	chr10:131095218~131095777:+
THCA	cis	rs9309473	1	rs7594511	ENSG00000273245.1	RP11-434P11.2	3.47	0.000564	0.0337	0.22	0.16	Metabolite levels;	chr2:73454512	chr2:73750256~73750786:-
THCA	cis	rs12935418	0.616	rs62054213	ENSG00000261838.4	RP11-303E16.6	3.47	0.000564	0.0337	0.22	0.16	Mean corpuscular volume;	chr16:80934306	chr16:81069854~81076598:+
THCA	cis	rs301901	0.698	rs62360226	ENSG00000250155.1	CTD-2353F22.1	3.47	0.000564	0.0337	0.16	0.16	Height;	chr5:37428489	chr5:36666214~36725195:-
THCA	cis	rs4578769	0.55	rs11082258	ENSG00000273232.1	RP11-370A5.2	3.47	0.000564	0.0337	0.22	0.16	Eosinophil percentage of white cells;	chr18:23037401	chr18:22882825~22883357:-
THCA	cis	rs2055729	0.614	rs10108550	ENSG00000261451.1	RP11-981G7.1	-3.47	0.000564	0.0337	-0.22	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9884123	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.603	rs2250028	ENSG00000255495.1	AC145124.2	3.47	0.000564	0.0337	0.18	0.16	Retinal vascular caliber;	chr8:11356080	chr8:12194467~12196280:+
THCA	cis	rs56091001	0.528	rs9616387	ENSG00000260613.1	RP3-522J7.6	-3.47	0.000564	0.0337	-0.3	-0.16	Acne (severe);	chr22:49919571	chr22:49832616~49837786:-
THCA	cis	rs1959947	0.876	rs1954461	ENSG00000251363.2	RP11-129M6.1	3.47	0.000564	0.0337	0.21	0.16	Hemostatic factors and hematological phenotypes;	chr14:41072285	chr14:40954898~40975877:+
THCA	cis	rs3027234	0.734	rs11650309	ENSG00000271002.1	RP11-599B13.8	-3.47	0.000564	0.0337	-0.23	-0.16	Telomere length;	chr17:8226220	chr17:8199123~8199437:-
THCA	cis	rs524281	0.861	rs10896086	ENSG00000255038.1	RP11-1167A19.2	-3.47	0.000564	0.0337	-0.19	-0.16	Electroencephalogram traits;	chr11:66147293	chr11:66067277~66069619:-
THCA	cis	rs9457247	0.602	rs12209395	ENSG00000235272.1	FAM103A2P	3.47	0.000564	0.0337	0.22	0.16	Crohn's disease;	chr6:167050426	chr6:166586124~166586477:-
THCA	cis	rs17123764	0.892	rs17123970	ENSG00000257464.1	RP11-161H23.8	-3.47	0.000564	0.0337	-0.29	-0.16	Intelligence (multi-trait analysis);	chr12:49766412	chr12:49442424~49442652:-
THCA	cis	rs4218	0.689	rs34338282	ENSG00000277144.1	RP11-59H7.4	-3.47	0.000564	0.0337	-0.22	-0.16	Social communication problems;	chr15:59096897	chr15:59115547~59116089:-
THCA	cis	rs11671005	0.504	rs2305119	ENSG00000268049.1	CTD-2619J13.9	-3.47	0.000564	0.0337	-0.21	-0.16	Mean platelet volume;	chr19:58556256	chr19:58357999~58359603:+
THCA	cis	rs669446	0.533	rs4660261	ENSG00000236200.4	KDM4A-AS1	-3.47	0.000564	0.0337	-0.12	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:43763926	chr1:43699765~43708138:-
THCA	cis	rs2299587	0.932	rs1121879	ENSG00000253671.1	RP11-806O11.1	-3.47	0.000564	0.0337	-0.19	-0.16	Economic and political preferences;	chr8:17992756	chr8:17808941~17820868:+
THCA	cis	rs2135232	0.881	rs72651374	ENSG00000249858.2	SNX5P1	3.47	0.000564	0.0338	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr4:75922771	chr4:76344550~76345590:+
THCA	cis	rs3785574	0.962	rs8066463	ENSG00000279369.1	RP11-51F16.1	3.47	0.000564	0.0338	0.11	0.16	Height;	chr17:63741030	chr17:63700847~63702670:+
THCA	cis	rs2839186	0.5	rs13052701	ENSG00000228137.1	AP001469.7	3.47	0.000564	0.0338	0.17	0.16	Testicular germ cell tumor;	chr21:46240131	chr21:46246890~46247682:+
THCA	cis	rs853679	0.607	rs35749575	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28147040	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs72846780	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28151277	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13205911	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28156336	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13197176	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28161454	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs13201308	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28162311	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34765154	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28162672	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs34505829	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28165461	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs35098436	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28166443	chr6:28073316~28074233:+
THCA	cis	rs853679	0.607	rs72846794	ENSG00000220721.1	OR1F12	3.47	0.000564	0.0338	0.36	0.16	Depression;	chr6:28169721	chr6:28073316~28074233:+
THCA	cis	rs7129556	0.863	rs11237225	ENSG00000254985.1	RSF1-IT2	-3.47	0.000564	0.0338	-0.25	-0.16	Weight loss (gastric bypass surgery);	chr11:77572516	chr11:77717712~77718411:-
THCA	cis	rs1993293	0.569	rs62042315	ENSG00000254744.3	CTD-3076O17.1	-3.47	0.000565	0.0338	-0.21	-0.16	Coronary artery calcification;	chr15:99751724	chr15:99970215~99974010:+
THCA	cis	rs4785204	0.764	rs72794297	ENSG00000279356.1	RP11-429P3.8	-3.47	0.000565	0.0338	-0.29	-0.16	Esophageal cancer (squamous cell);	chr16:50018471	chr16:50072862~50074986:+
THCA	cis	rs4081724	0.638	rs62128266	ENSG00000267296.2	CEBPA-AS1	3.47	0.000565	0.0338	0.2	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33357884	chr19:33302857~33305054:+
THCA	cis	rs59901009	0.577	rs2896514	ENSG00000246273.5	SBF2-AS1	-3.47	0.000565	0.0338	-0.21	-0.16	Hematocrit;Hemoglobin concentration;	chr11:10006354	chr11:9758292~9811319:+
THCA	cis	rs9878978	0.685	rs11711409	ENSG00000227588.2	CNTN4-AS2	3.47	0.000565	0.0338	0.21	0.16	Blood pressure (smoking interaction);	chr3:2460513	chr3:2110409~2144241:-
THCA	cis	rs9878978	0.691	rs11716315	ENSG00000227588.2	CNTN4-AS2	3.47	0.000565	0.0338	0.21	0.16	Blood pressure (smoking interaction);	chr3:2460571	chr3:2110409~2144241:-
THCA	cis	rs9450351	0.744	rs9450299	ENSG00000280232.1	RP11-321N4.4	3.47	0.000565	0.0338	0.36	0.16	Interferon gamma-induced protein 10 levels;	chr6:85562103	chr6:85498441~85499058:-
THCA	cis	rs9450351	0.744	rs6930543	ENSG00000280232.1	RP11-321N4.4	3.47	0.000565	0.0338	0.36	0.16	Interferon gamma-induced protein 10 levels;	chr6:85562658	chr6:85498441~85499058:-
THCA	cis	rs3026101	0.624	rs1806255	ENSG00000234327.6	AC012146.7	-3.47	0.000565	0.0338	-0.13	-0.16	Body mass index;	chr17:5410943	chr17:5111468~5115004:+
THCA	cis	rs12210905	1	rs9348752	ENSG00000224843.5	LINC00240	3.47	0.000565	0.0338	0.23	0.16	Hip circumference adjusted for BMI;	chr6:27107704	chr6:26956992~27023924:+
THCA	cis	rs7819412	0.668	rs920047	ENSG00000255495.1	AC145124.2	-3.47	0.000565	0.0338	-0.18	-0.16	Triglycerides;	chr8:11229966	chr8:12194467~12196280:+
THCA	cis	rs1059312	1	rs7135854	ENSG00000279500.1	RP11-21K12.2	-3.47	0.000565	0.0338	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128795443	chr12:128813186~128814750:-
THCA	cis	rs1059312	0.966	rs7135968	ENSG00000279500.1	RP11-21K12.2	-3.47	0.000565	0.0338	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128795521	chr12:128813186~128814750:-
THCA	cis	rs1059312	1	rs7136092	ENSG00000279500.1	RP11-21K12.2	-3.47	0.000565	0.0338	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128795619	chr12:128813186~128814750:-
THCA	cis	rs11800820	0.557	rs12735611	ENSG00000227953.5	LINC01341	3.47	0.000565	0.0338	0.14	0.16	Obesity-related traits;	chr1:246496895	chr1:246776013~246792385:+
THCA	cis	rs498136	0.734	rs631683	ENSG00000261625.1	RP11-554A11.4	-3.47	0.000565	0.0338	-0.18	-0.16	Cutaneous malignant melanoma;Melanoma;	chr11:69532570	chr11:69000765~69002048:-
THCA	cis	rs4792901	0.659	rs8073121	ENSG00000279602.1	CTD-3014M21.1	-3.47	0.000565	0.0338	-0.2	-0.16	Dupuytren's disease;	chr17:43465554	chr17:43360041~43361361:-
THCA	cis	rs964611	0.816	rs2279365	ENSG00000259488.2	RP11-154J22.1	3.47	0.000565	0.0338	0.14	0.16	Metabolite levels (Pyroglutamine);	chr15:48249503	chr15:48312353~48331856:-
THCA	cis	rs3135718	0.967	rs2912774	ENSG00000276742.1	RP11-500G22.4	-3.47	0.000565	0.0338	-0.18	-0.16	Estrogen receptor status in breast cancer;	chr10:121589148	chr10:121956782~121957098:+
THCA	cis	rs16975963	0.843	rs73041045	ENSG00000276846.1	CTD-3220F14.3	-3.47	0.000565	0.0338	-0.15	-0.16	Longevity;	chr19:37805386	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.843	rs1056405	ENSG00000276846.1	CTD-3220F14.3	-3.47	0.000565	0.0338	-0.15	-0.16	Longevity;	chr19:37822381	chr19:37314868~37315620:-
THCA	cis	rs763121	0.819	rs5757169	ENSG00000225450.1	RP3-508I15.14	-3.47	0.000565	0.0338	-0.12	-0.16	Menopause (age at onset);	chr22:38607490	chr22:38739003~38749041:+
THCA	cis	rs12101261	1	rs12101255	ENSG00000259167.2	NMNAT1P1	3.47	0.000565	0.0338	0.19	0.16	Graves' disease;	chr14:80984708	chr14:81032529~81033404:+
THCA	cis	rs2235573	0.805	rs4821738	ENSG00000222044.1	RP5-1039K5.16	3.47	0.000565	0.0338	0.18	0.16	Glioma;Glioblastoma;	chr22:38104473	chr22:38032165~38034228:-
THCA	cis	rs9296092	0.538	rs75652975	ENSG00000272217.1	XXbac-BPG157A10.21	3.47	0.000565	0.0338	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33548474	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.538	rs9461879	ENSG00000272217.1	XXbac-BPG157A10.21	3.47	0.000565	0.0338	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33549130	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.538	rs9469488	ENSG00000272217.1	XXbac-BPG157A10.21	3.47	0.000565	0.0338	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33549340	chr6:33246075~33246856:-
THCA	cis	rs1059312	0.932	rs11059916	ENSG00000279500.1	RP11-21K12.2	-3.47	0.000565	0.0338	-0.11	-0.16	Systemic lupus erythematosus;	chr12:128803064	chr12:128813186~128814750:-
THCA	cis	rs11168187	0.528	rs2214526	ENSG00000274902.1	RP1-197B17.4	-3.47	0.000565	0.0338	-0.22	-0.16	Vertical cup-disc ratio;	chr12:47548246	chr12:47731908~47732351:+
THCA	cis	rs7246657	0.882	rs13345148	ENSG00000268499.1	CTB-102L5.8	3.47	0.000565	0.0338	0.2	0.16	Coronary artery calcification;	chr19:37328729	chr19:38199836~38200934:+
THCA	cis	rs28374715	0.662	rs10851403	ENSG00000247556.5	OIP5-AS1	3.47	0.000565	0.0338	0.15	0.16	Ulcerative colitis;	chr15:41173889	chr15:41283990~41309737:+
THCA	cis	rs28374715	0.662	rs13329579	ENSG00000247556.5	OIP5-AS1	3.47	0.000565	0.0338	0.15	0.16	Ulcerative colitis;	chr15:41175237	chr15:41283990~41309737:+
THCA	cis	rs2223471	0.87	rs2817422	ENSG00000060303.5	RPS17P5	-3.47	0.000565	0.0338	-0.19	-0.16	Subcutaneous adipose tissue;	chr6:50782527	chr6:50857255~50857662:-
THCA	cis	rs301901	0.734	rs216385	ENSG00000250155.1	CTD-2353F22.1	-3.47	0.000565	0.0338	-0.16	-0.16	Height;	chr5:37275173	chr5:36666214~36725195:-
THCA	cis	rs7572644	0.679	rs36035825	ENSG00000223522.1	AC093690.1	-3.47	0.000565	0.0338	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27795264	chr2:28307691~28310459:-
THCA	cis	rs6580649	0.769	rs60629297	ENSG00000273765.1	RP11-370I10.11	-3.47	0.000565	0.0338	-0.17	-0.16	Lung cancer;	chr12:48044507	chr12:48360920~48361377:+
THCA	cis	rs12452225	0.708	rs72823614	ENSG00000271392.1	RP1-161P9.5	-3.47	0.000565	0.0338	-0.31	-0.16	Night sleep phenotypes;	chr17:34871258	chr17:35757199~35758325:-
THCA	cis	rs11583043	0.874	rs6577222	ENSG00000233184.5	RP11-421L21.3	3.47	0.000565	0.0338	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100954946	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.793	rs3903905	ENSG00000233184.5	RP11-421L21.3	3.47	0.000565	0.0338	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100955401	chr1:101025878~101087268:+
THCA	cis	rs11583043	0.918	rs17525451	ENSG00000233184.5	RP11-421L21.3	3.47	0.000565	0.0338	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100956853	chr1:101025878~101087268:+
THCA	cis	rs1926657	1	rs4771907	ENSG00000223298.1	RNY3P8	-3.47	0.000565	0.0338	-0.21	-0.16	Breast cancer;	chr13:95216726	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs4148463	ENSG00000223298.1	RNY3P8	-3.47	0.000565	0.0338	-0.21	-0.16	Breast cancer;	chr13:95217154	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs4148465	ENSG00000223298.1	RNY3P8	3.47	0.000565	0.0338	0.21	0.16	Breast cancer;	chr13:95216877	chr13:95310830~95310955:-
THCA	cis	rs7772486	0.875	rs2814866	ENSG00000270638.1	RP3-466P17.1	3.47	0.000565	0.0338	0.12	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.875	rs2328712	ENSG00000270638.1	RP3-466P17.1	3.47	0.000565	0.0338	0.12	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145735570~145737218:+
THCA	cis	rs2292864	0.681	rs35735886	ENSG00000263293.2	RP11-290H9.4	3.47	0.000565	0.0338	0.34	0.16	Left atrial antero-posterior diameter;	chr17:47296911	chr17:47303460~47323613:-
THCA	cis	rs4699052	1	rs7661702	ENSG00000251288.2	RP11-10L12.2	-3.47	0.000566	0.0338	-0.2	-0.16	Testicular germ cell tumor;	chr4:103218972	chr4:102751401~102752641:+
THCA	cis	rs4699052	0.928	rs2126473	ENSG00000251288.2	RP11-10L12.2	-3.47	0.000566	0.0338	-0.2	-0.16	Testicular germ cell tumor;	chr4:103220376	chr4:102751401~102752641:+
THCA	cis	rs7111546	1	rs12281140	ENSG00000246225.5	RP11-17A1.3	3.47	0.000566	0.0338	0.27	0.16	Dialysis-related mortality;	chr11:22801788	chr11:22829380~22945393:+
THCA	cis	rs2190422	0.551	rs2711865	ENSG00000234715.1	CTB-107G13.1	-3.47	0.000566	0.0338	-0.23	-0.16	Morning vs. evening chronotype;	chr7:103524969	chr7:103445207~103514007:+
THCA	cis	rs56114371	0.53	rs169262	ENSG00000220721.1	OR1F12	3.47	0.000566	0.0338	0.22	0.16	Breast cancer;	chr6:27803112	chr6:28073316~28074233:+
THCA	cis	rs3770081	1	rs2164879	ENSG00000273080.1	RP11-301O19.1	-3.47	0.000566	0.0338	-0.32	-0.16	Facial emotion recognition (sad faces);	chr2:86034456	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs12328085	ENSG00000273080.1	RP11-301O19.1	-3.47	0.000566	0.0338	-0.32	-0.16	Facial emotion recognition (sad faces);	chr2:86034886	chr2:86195590~86196049:+
THCA	cis	rs3770081	1	rs3770090	ENSG00000273080.1	RP11-301O19.1	-3.47	0.000566	0.0338	-0.32	-0.16	Facial emotion recognition (sad faces);	chr2:86036165	chr2:86195590~86196049:+
THCA	cis	rs2823357	1	rs9981901	ENSG00000281903.1	AF127936.7	-3.47	0.000566	0.0338	-0.17	-0.16	Parkinson's disease;	chr21:15543022	chr21:14819699~14918552:-
THCA	cis	rs1003719	0.667	rs13050226	ENSG00000270116.1	AP001429.1	-3.47	0.000566	0.0338	-0.18	-0.16	Eye color traits;	chr21:37085408	chr21:37100814~37101343:+
THCA	cis	rs1003719	0.667	rs73201942	ENSG00000270116.1	AP001429.1	-3.47	0.000566	0.0338	-0.18	-0.16	Eye color traits;	chr21:37102864	chr21:37100814~37101343:+
THCA	cis	rs17685	0.672	rs6465011	ENSG00000227038.2	AC005077.12	3.47	0.000566	0.0338	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76181979	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs11764119	ENSG00000227038.2	AC005077.12	3.47	0.000566	0.0338	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76183040	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs2158867	ENSG00000227038.2	AC005077.12	3.47	0.000566	0.0338	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76185823	chr7:76090431~76108779:-
THCA	cis	rs17685	0.712	rs1859794	ENSG00000227038.2	AC005077.12	3.47	0.000566	0.0338	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76192226	chr7:76090431~76108779:-
THCA	cis	rs7824557	0.569	rs10106207	ENSG00000254839.1	AF131215.6	3.47	0.000566	0.0338	0.16	0.16	Retinal vascular caliber;	chr8:11157828	chr8:11062647~11067089:-
THCA	cis	rs2736345	0.747	rs1478901	ENSG00000269899.1	RP11-589N15.2	-3.47	0.000566	0.0338	-0.2	-0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11490324	chr8:11846154~11846391:-
THCA	cis	rs2455799	0.613	rs11712323	ENSG00000270409.1	RP11-44D5.1	-3.47	0.000566	0.0338	-0.17	-0.16	Mean platelet volume;	chr3:15849853	chr3:15732252~15733470:+
THCA	cis	rs12722605	0.54	rs11256311	ENSG00000229664.1	RP11-536K7.5	3.47	0.000566	0.0338	0.21	0.16	Inflammatory biomarkers;	chr10:6007350	chr10:6025978~6036427:+
THCA	cis	rs1953600	0.645	rs7071579	ENSG00000242600.5	MBL1P	3.47	0.000566	0.0338	0.13	0.16	Sarcoidosis;	chr10:80150522	chr10:79904898~79950336:+
THCA	cis	rs987724	0.501	rs9851913	ENSG00000243926.1	TIPARP-AS1	3.47	0.000566	0.0338	0.2	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156883165	chr3:156671862~156674378:-
THCA	cis	rs4664293	1	rs6432542	ENSG00000230783.1	AC009961.2	-3.47	0.000566	0.0338	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159624025	chr2:159689217~159690291:-
THCA	cis	rs62380364	0.719	rs56947091	ENSG00000247828.6	TMEM161B-AS1	-3.47	0.000566	0.0338	-0.12	-0.16	Intelligence (multi-trait analysis);	chr5:88864537	chr5:88268895~88436685:+
THCA	cis	rs2434529	1	rs2443519	ENSG00000245275.6	SAP30L-AS1	3.47	0.000566	0.0338	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr5:154261294	chr5:154329437~154445850:-
THCA	cis	rs7403037	0.617	rs11161118	ENSG00000260760.1	PWRN3	3.47	0.000566	0.0338	0.22	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24596584	chr15:24441127~24447967:+
THCA	cis	rs12681963	0.688	rs4733429	ENSG00000272375.1	RP11-51J9.6	3.47	0.000566	0.0338	0.23	0.16	Migraine;	chr8:30203643	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.688	rs4733431	ENSG00000272375.1	RP11-51J9.6	3.47	0.000566	0.0338	0.23	0.16	Migraine;	chr8:30203919	chr8:30197404~30198048:+
THCA	cis	rs12887734	0.524	rs12588797	ENSG00000269958.1	RP11-73M18.8	-3.47	0.000566	0.0338	-0.15	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103696353~103697163:+
THCA	cis	rs9650657	1	rs9650657	ENSG00000255310.2	AF131215.2	-3.47	0.000566	0.0338	-0.13	-0.16	Neuroticism;	chr8:10749890	chr8:11107788~11109726:-
THCA	cis	rs17683430	0.614	rs2006233	ENSG00000230736.2	RP1-149A16.3	3.47	0.000566	0.0338	0.34	0.16	GIP levels in response to oral glucose tolerance test (120 minutes);	chr22:32134861	chr22:32376664~32384343:+
THCA	cis	rs6762	0.642	rs28692469	ENSG00000255284.1	AP006621.5	3.47	0.000566	0.0338	0.11	0.16	Mean platelet volume;	chr11:839675	chr11:777578~784297:+
THCA	cis	rs3749237	0.576	rs3877784	ENSG00000224424.7	PRKAR2A-AS1	3.47	0.000566	0.0338	0.13	0.16	Resting heart rate;	chr3:49501984	chr3:48847572~48851981:+
THCA	cis	rs2055729	0.591	rs6987670	ENSG00000261451.1	RP11-981G7.1	3.47	0.000566	0.0338	0.2	0.16	Multiple myeloma (hyperdiploidy);	chr8:10025667	chr8:10433672~10438312:+
THCA	cis	rs7951911	0.915	rs35433394	ENSG00000254427.1	RP11-430H10.1	3.47	0.000566	0.0338	0.3	0.16	IgG glycosylation;	chr11:45056899	chr11:45355371~45366121:+
THCA	cis	rs708547	0.957	rs2458552	ENSG00000269949.1	RP11-738E22.3	3.47	0.000566	0.0338	0.22	0.16	Response to bleomycin (chromatid breaks);	chr4:56907276	chr4:56960927~56961373:-
THCA	cis	rs4578769	0.55	rs9956087	ENSG00000273232.1	RP11-370A5.2	3.47	0.000566	0.0338	0.22	0.16	Eosinophil percentage of white cells;	chr18:23030538	chr18:22882825~22883357:-
THCA	cis	rs2880765	0.835	rs7169429	ENSG00000259407.1	RP11-158M2.3	-3.47	0.000566	0.0338	-0.16	-0.16	Coronary artery disease;	chr15:85493417	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.835	rs7168860	ENSG00000259407.1	RP11-158M2.3	-3.47	0.000566	0.0338	-0.16	-0.16	Coronary artery disease;	chr15:85493799	chr15:85744109~85750281:-
THCA	cis	rs944289	0.74	rs376927	ENSG00000212071.1	AL162511.1	3.47	0.000566	0.0339	0.18	0.16	Thyroid cancer;	chr14:36078725	chr14:36196480~36196568:-
THCA	cis	rs8113308	1	rs8105440	ENSG00000275055.1	CTC-471J1.11	-3.47	0.000566	0.0339	-0.16	-0.16	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948647	chr19:52049007~52049754:+
THCA	cis	rs862034	0.788	rs862039	ENSG00000270000.1	RP3-449M8.9	-3.47	0.000566	0.0339	-0.16	-0.16	Height;	chr14:74520185	chr14:74471930~74472360:-
THCA	cis	rs7674212	0.507	rs10516495	ENSG00000248971.2	KRT8P46	-3.47	0.000566	0.0339	-0.2	-0.16	Type 2 diabetes;	chr4:102978933	chr4:102728746~102730171:-
THCA	cis	rs9527	0.668	rs7092815	ENSG00000236937.2	PTGES3P4	3.47	0.000566	0.0339	0.22	0.16	Arsenic metabolism;	chr10:102976588	chr10:102845595~102845950:+
THCA	cis	rs2066819	1	rs2066808	ENSG00000257303.1	RP11-977G19.11	-3.47	0.000567	0.0339	-0.22	-0.16	Psoriasis vulgaris;	chr12:56344189	chr12:56300142~56314808:+
THCA	cis	rs7809950	0.773	rs9791733	ENSG00000272072.1	CTA-363E19.2	3.47	0.000567	0.0339	0.17	0.16	Coronary artery disease;	chr7:107401285	chr7:107192559~107193300:-
THCA	cis	rs9911578	1	rs7215808	ENSG00000224738.1	AC099850.1	3.47	0.000567	0.0339	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58863381	chr17:59106598~59118267:+
THCA	cis	rs478304	0.718	rs1144789	ENSG00000245532.5	NEAT1	3.47	0.000567	0.0339	0.11	0.16	Acne (severe);	chr11:65622160	chr11:65422774~65445540:+
THCA	cis	rs8044868	0.548	rs3909541	ENSG00000260886.1	TAT-AS1	-3.47	0.000567	0.0339	-0.19	-0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72167220	chr16:71565789~71578187:+
THCA	cis	rs1062753	0.527	rs62240998	ENSG00000227370.1	RP4-669P10.19	3.47	0.000567	0.0339	0.15	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41958697	chr22:42132543~42132998:+
THCA	cis	rs597539	0.521	rs2060982	ENSG00000250508.1	RP11-757G1.6	-3.47	0.000567	0.0339	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68845459	chr11:68870664~68874542:+
THCA	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	3.47	0.000567	0.0339	0.14	0.16	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
THCA	cis	rs2898681	0.561	rs6855240	ENSG00000248375.1	RP11-177B4.1	-3.47	0.000567	0.0339	-0.32	-0.16	Optic nerve measurement (cup area);	chr4:52874620	chr4:52720081~52720831:-
THCA	cis	rs2898681	0.521	rs6833350	ENSG00000248375.1	RP11-177B4.1	-3.47	0.000567	0.0339	-0.32	-0.16	Optic nerve measurement (cup area);	chr4:52874701	chr4:52720081~52720831:-
THCA	cis	rs1978968	0.717	rs34740481	ENSG00000280007.1	AC008079.10	3.47	0.000567	0.0339	0.16	0.16	Presence of antiphospholipid antibodies;	chr22:17918854	chr22:18110759~18131154:-
THCA	cis	rs471756	0.554	rs2484967	ENSG00000231808.2	LINC01388	-3.47	0.000567	0.0339	-0.18	-0.16	Mean platelet volume;	chr9:221874	chr9:112713~113754:-
THCA	cis	rs9840812	0.61	rs34967300	ENSG00000273486.1	RP11-731C17.2	-3.47	0.000567	0.0339	-0.16	-0.16	Fibrinogen levels;	chr3:136549976	chr3:136837338~136839021:-
THCA	cis	rs7246967	0.611	rs12978511	ENSG00000198153.8	ZNF849P	-3.47	0.000567	0.0339	-0.25	-0.16	Bronchopulmonary dysplasia;	chr19:22636414	chr19:22685167~22686732:+
THCA	cis	rs1580019	0.523	rs13236410	ENSG00000273014.1	RP11-225B17.2	3.47	0.000567	0.0339	0.16	0.16	Cognitive ability;	chr7:32651051	chr7:32758882~32759353:+
THCA	cis	rs364477	0.721	rs279876	ENSG00000227914.3	RP11-130C19.3	-3.47	0.000567	0.0339	-0.27	-0.16	Major depressive disorder;	chr9:996439	chr9:673478~685555:-
THCA	cis	rs1864982	0.681	rs2963076	ENSG00000251556.1	RP11-118M9.3	3.47	0.000567	0.0339	0.25	0.16	Alcohol dependence;	chr5:146911705	chr5:146099406~146120412:+
THCA	cis	rs6860806	0.632	rs4330455	ENSG00000263597.1	MIR3936	3.47	0.000567	0.0339	0.15	0.16	Breast cancer;	chr5:132250656	chr5:132365490~132365599:-
THCA	cis	rs2554380	1	rs2554380	ENSG00000230373.7	GOLGA6L5P	-3.47	0.000567	0.0339	-0.19	-0.16	Height;	chr15:83647132	chr15:84507885~84516814:-
THCA	cis	rs9858542	0.537	rs34514189	ENSG00000270441.1	RP11-694I15.7	3.47	0.000567	0.0339	0.18	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49335612	chr3:49140086~49160851:-
THCA	cis	rs931127	0.505	rs2306362	ENSG00000255120.4	OVOL1-AS1	-3.47	0.000567	0.0339	-0.23	-0.16	Systemic lupus erythematosus;	chr11:65638039	chr11:65789051~65790868:-
THCA	cis	rs3925075	0.515	rs4459557	ENSG00000260911.2	RP11-196G11.2	-3.47	0.000567	0.0339	-0.13	-0.16	IgA nephropathy;	chr16:31350322	chr16:31043150~31049868:+
THCA	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	3.47	0.000567	0.0339	0.18	0.16	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
THCA	cis	rs947211	0.752	rs1572931	ENSG00000206762.1	RNU6-418P	-3.47	0.000567	0.0339	-0.23	-0.16	Parkinson's disease;	chr1:205775090	chr1:205595041~205595147:+
THCA	cis	rs6546886	0.75	rs71406850	ENSG00000235499.1	AC073046.25	3.47	0.000567	0.0339	0.17	0.16	Dialysis-related mortality;	chr2:74016131	chr2:73985132~73986343:+
THCA	cis	rs9329221	0.537	rs6601414	ENSG00000261451.1	RP11-981G7.1	3.47	0.000567	0.0339	0.19	0.16	Neuroticism;	chr8:10119238	chr8:10433672~10438312:+
THCA	cis	rs9329221	0.537	rs6601415	ENSG00000261451.1	RP11-981G7.1	3.47	0.000567	0.0339	0.19	0.16	Neuroticism;	chr8:10119295	chr8:10433672~10438312:+
THCA	cis	rs3026101	0.624	rs1058398	ENSG00000234327.6	AC012146.7	3.47	0.000567	0.0339	0.13	0.16	Body mass index;	chr17:5385440	chr17:5111468~5115004:+
THCA	cis	rs4648045	0.52	rs4456957	ENSG00000246560.2	RP11-10L12.4	3.47	0.000567	0.0339	0.22	0.16	Lymphocyte percentage of white cells;	chr4:102473946	chr4:102828055~102844075:+
THCA	cis	rs7819412	0.744	rs4841503	ENSG00000254839.1	AF131215.6	3.47	0.000567	0.0339	0.16	0.16	Triglycerides;	chr8:11166817	chr8:11062647~11067089:-
THCA	cis	rs11212260	0.737	rs633525	ENSG00000261098.1	RP11-819C21.1	-3.47	0.000567	0.0339	-0.31	-0.16	IgG glycosylation;	chr11:107508275	chr11:107312132~107316271:-
THCA	cis	rs11212260	0.85	rs684209	ENSG00000261098.1	RP11-819C21.1	-3.47	0.000567	0.0339	-0.31	-0.16	IgG glycosylation;	chr11:107508888	chr11:107312132~107316271:-
THCA	cis	rs4800353	0.714	rs11877885	ENSG00000265142.5	MIR133A1HG	-3.47	0.000567	0.0339	-0.21	-0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr18:22033191	chr18:21825487~21831410:-
THCA	cis	rs55661361	0.965	rs12293670	ENSG00000254941.1	RP11-677M14.5	3.47	0.000567	0.0339	0.13	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124743036	chr11:124807822~124808269:-
THCA	cis	rs11630290	0.575	rs7169210	ENSG00000275785.1	RP11-111E14.2	-3.47	0.000567	0.0339	-0.21	-0.16	Iris characteristics;	chr15:63872870	chr15:63890030~63890317:+
THCA	cis	rs7264396	0.887	rs6060431	ENSG00000261582.1	RP4-614O4.11	-3.47	0.000567	0.0339	-0.16	-0.16	Total cholesterol levels;	chr20:35471512	chr20:35267885~35280043:-
THCA	cis	rs881827	0.714	rs12626191	ENSG00000230982.1	DSTNP1	3.47	0.000567	0.0339	0.17	0.16	Lymphocyte counts;	chr21:46656451	chr21:46653558~46654022:-
THCA	cis	rs13232179	1	rs13232179	ENSG00000265810.1	MIR3907	3.47	0.000567	0.0339	0.15	0.16	Coronary heart disease;	chr7:151423862	chr7:151433489~151433639:-
THCA	cis	rs62458065	0.85	rs7808992	ENSG00000231952.3	DPY19L1P2	3.47	0.000567	0.0339	0.27	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32431065	chr7:32812757~32838570:+
THCA	cis	rs62458065	0.85	rs62458098	ENSG00000231952.3	DPY19L1P2	3.47	0.000567	0.0339	0.27	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32431517	chr7:32812757~32838570:+
THCA	cis	rs62458065	0.85	rs73096034	ENSG00000231952.3	DPY19L1P2	3.47	0.000567	0.0339	0.27	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32432436	chr7:32812757~32838570:+
THCA	cis	rs62458065	0.85	rs62458099	ENSG00000231952.3	DPY19L1P2	3.47	0.000567	0.0339	0.27	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32432783	chr7:32812757~32838570:+
THCA	cis	rs62458065	0.85	rs62458100	ENSG00000231952.3	DPY19L1P2	3.47	0.000567	0.0339	0.27	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32433530	chr7:32812757~32838570:+
THCA	cis	rs1023500	0.552	rs5758566	ENSG00000270083.1	RP1-257I20.14	3.47	0.000567	0.0339	0.18	0.16	Schizophrenia;	chr22:42058350	chr22:42089630~42090028:-
THCA	cis	rs4601292	0.553	rs58489131	ENSG00000200714.1	Y_RNA	-3.47	0.000567	0.0339	-0.23	-0.16	HIV-1 viral setpoint;	chr8:65989181	chr8:65592731~65592820:+
THCA	cis	rs11583043	0.874	rs6577219	ENSG00000233184.5	RP11-421L21.3	3.47	0.000568	0.0339	0.17	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:100950151	chr1:101025878~101087268:+
THCA	cis	rs4713118	0.869	rs9468214	ENSG00000216915.2	RP1-97D16.1	-3.47	0.000568	0.0339	-0.24	-0.16	Parkinson's disease;	chr6:27745520	chr6:27737000~27738494:-
THCA	cis	rs478304	0.651	rs78412025	ENSG00000255557.1	RP11-770G2.2	3.47	0.000568	0.0339	0.18	0.16	Acne (severe);	chr11:65728225	chr11:65745729~65771585:+
THCA	cis	rs478304	0.651	rs11227281	ENSG00000255557.1	RP11-770G2.2	3.47	0.000568	0.0339	0.18	0.16	Acne (severe);	chr11:65729087	chr11:65745729~65771585:+
THCA	cis	rs478304	0.651	rs4014192	ENSG00000255557.1	RP11-770G2.2	3.47	0.000568	0.0339	0.18	0.16	Acne (severe);	chr11:65731444	chr11:65745729~65771585:+
THCA	cis	rs478304	0.651	rs4930312	ENSG00000255557.1	RP11-770G2.2	3.47	0.000568	0.0339	0.18	0.16	Acne (severe);	chr11:65732248	chr11:65745729~65771585:+
THCA	cis	rs478304	0.651	rs11537193	ENSG00000255557.1	RP11-770G2.2	3.47	0.000568	0.0339	0.18	0.16	Acne (severe);	chr11:65732532	chr11:65745729~65771585:+
THCA	cis	rs478304	0.651	rs4930313	ENSG00000255557.1	RP11-770G2.2	3.47	0.000568	0.0339	0.18	0.16	Acne (severe);	chr11:65732957	chr11:65745729~65771585:+
THCA	cis	rs17772222	0.651	rs12586714	ENSG00000222990.1	RNU4-22P	3.47	0.000568	0.0339	0.19	0.16	Coronary artery calcification;	chr14:88360497	chr14:88513498~88513663:+
THCA	cis	rs6788895	1	rs6788895	ENSG00000244265.1	SIAH2-AS1	3.47	0.000568	0.0339	0.35	0.16	Breast cancer;	chr3:150750021	chr3:150761937~150762538:+
THCA	cis	rs2880765	0.835	rs730372	ENSG00000218052.5	ADAMTS7P4	3.47	0.000568	0.0339	0.18	0.16	Coronary artery disease;	chr15:85494962	chr15:85255369~85330334:-
THCA	cis	rs9308731	0.591	rs10439396	ENSG00000227992.1	AC108463.2	-3.47	0.000568	0.0339	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111178399	chr2:111203964~111206215:-
THCA	cis	rs7216064	1	rs62085992	ENSG00000265055.1	AC145343.2	3.47	0.000568	0.0339	0.23	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67926967	chr17:68096046~68101474:-
THCA	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	3.47	0.000568	0.0339	0.16	0.16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
THCA	cis	rs4742903	0.935	rs6479228	ENSG00000270332.1	SMC2-AS1	3.47	0.000568	0.0339	0.15	0.16	Breast cancer;High-grade serous ovarian cancer;	chr9:104218631	chr9:104080024~104093073:-
THCA	cis	rs10844706	0.73	rs12317499	ENSG00000257027.1	RP11-705C15.3	3.47	0.000568	0.0339	0.14	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9732764	chr12:9658567~9662085:+
THCA	cis	rs1862618	0.853	rs11739344	ENSG00000234553.1	AC022431.3	-3.47	0.000568	0.0339	-0.18	-0.16	Initial pursuit acceleration;	chr5:56815260	chr5:56536583~56537826:-
THCA	cis	rs17221829	0.521	rs4338531	ENSG00000280385.1	AP000648.5	-3.47	0.000568	0.0339	-0.16	-0.16	Anxiety in major depressive disorder;	chr11:89581964	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.521	rs11018654	ENSG00000280385.1	AP000648.5	-3.47	0.000568	0.0339	-0.16	-0.16	Anxiety in major depressive disorder;	chr11:89584329	chr11:90193614~90198120:+
THCA	cis	rs2227564	0.83	rs2633322	ENSG00000271816.1	BMS1P4	3.47	0.000568	0.0339	0.17	0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73934174	chr10:73699151~73730487:-
THCA	cis	rs7615952	0.546	rs16836896	ENSG00000272840.1	RP11-379B18.6	3.47	0.000568	0.0339	0.26	0.16	Blood pressure (smoking interaction);	chr3:125592418	chr3:125774714~125797953:+
THCA	cis	rs6600671	0.899	rs6674392	ENSG00000226067.5	CH17-118O6.2	3.47	0.000568	0.0339	0.16	0.16	Hip geometry;	chr1:121518864	chr1:120913275~121009291:+
THCA	cis	rs7558911	0.77	rs4616463	ENSG00000183308.6	AC005037.3	3.47	0.000568	0.0339	0.17	0.16	Chronic lymphocytic leukemia;	chr2:201236756	chr2:200963263~201009102:+
THCA	cis	rs7005380	0.62	rs28669275	ENSG00000279347.1	RP11-85I17.2	-3.47	0.000568	0.0339	-0.18	-0.16	Interstitial lung disease;	chr8:119889713	chr8:119838736~119840385:-
THCA	cis	rs2455799	0.896	rs2470533	ENSG00000270409.1	RP11-44D5.1	-3.47	0.000568	0.0339	-0.18	-0.16	Mean platelet volume;	chr3:15656586	chr3:15732252~15733470:+
THCA	cis	rs77204473	1	rs1135663	ENSG00000276505.1	CMB9-94B1.2	-3.47	0.000568	0.0339	-0.32	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116918121	chr11:117297005~117297328:-
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Body mass index;	chr17:30758740	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Body mass index;	chr17:30774046	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs12006	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000264242.2	RP11-271K11.1	3.47	0.000568	0.0339	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30553697~30558962:+
THCA	cis	rs4561483	0.801	rs251723	ENSG00000263307.1	RP11-166B2.8	3.47	0.000568	0.0339	0.17	0.16	Testicular germ cell tumor;	chr16:11859223	chr16:11851649~11895611:+
THCA	cis	rs9860428	0.723	rs1354055	ENSG00000243795.1	RP11-572M11.3	3.47	0.000568	0.0339	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896099	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs6795428	ENSG00000243795.1	RP11-572M11.3	3.47	0.000568	0.0339	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896508	chr3:113142350~113167819:-
THCA	cis	rs7864204	0.508	rs17479209	ENSG00000234506.4	LINC01506	-3.47	0.000568	0.0339	-0.22	-0.16	Body mass index (recreational physical activity interaction);	chr9:68564043	chr9:68543541~68546589:-
THCA	cis	rs3096299	0.586	rs4572400	ENSG00000261118.1	RP11-104N10.1	3.47	0.000568	0.0339	0.13	0.16	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89492017~89504460:-
THCA	cis	rs939960	0.959	rs6950079	ENSG00000224016.2	RP11-728K20.1	3.47	0.000568	0.0339	0.22	0.16	Neutrophil percentage of white cells;	chr7:150586924	chr7:149891191~149909704:-
THCA	cis	rs10483853	0.65	rs17126871	ENSG00000258891.1	RP5-1021I20.5	-3.47	0.000568	0.0339	-0.21	-0.16	Coronary artery calcification;	chr14:73324614	chr14:73896164~73938114:-
THCA	cis	rs656319	0.58	rs13252589	ENSG00000248538.5	RP11-10A14.5	3.47	0.000568	0.0339	0.2	0.16	Myopia (pathological);	chr8:10148016	chr8:9189011~9202854:+
THCA	cis	rs1941184	0.526	rs11081698	ENSG00000263823.1	RP11-326K13.4	-3.47	0.000568	0.0339	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31452694	chr18:31942575~31944156:+
THCA	cis	rs1941184	0.526	rs11081699	ENSG00000263823.1	RP11-326K13.4	-3.47	0.000568	0.0339	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31452707	chr18:31942575~31944156:+
THCA	cis	rs1865760	0.613	rs9379805	ENSG00000272810.1	U91328.22	-3.47	0.000568	0.0339	-0.12	-0.16	Height;	chr6:25938536	chr6:26013241~26013757:+
THCA	cis	rs7226408	0.6	rs719847	ENSG00000267707.2	RP11-95O2.5	-3.47	0.000568	0.0339	-0.16	-0.16	Obesity-related traits;	chr18:36842387	chr18:37243776~37247506:+
THCA	cis	rs7243790	1	rs17473264	ENSG00000277324.1	RP11-850A17.1	-3.47	0.000568	0.0339	-0.17	-0.16	Diastolic blood pressure;	chr18:54436534	chr18:54268346~54270028:-
THCA	cis	rs2447820	0.5	rs42394	ENSG00000263432.2	RN7SL689P	3.47	0.000568	0.034	0.2	0.16	Migraine;	chr5:122968815	chr5:123022487~123022783:-
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000237310.1	GS1-124K5.4	-3.47	0.000568	0.034	-0.18	-0.16	Diabetic kidney disease;	chr7:66158142	chr7:66493706~66495474:+
THCA	cis	rs2882667	0.898	rs2351465	ENSG00000249593.5	CTB-46B19.2	3.47	0.000568	0.034	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:139012647~139051203:+
THCA	cis	rs2692947	0.644	rs1724125	ENSG00000235584.2	AC008268.1	-3.47	0.000568	0.034	-0.16	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96165617	chr2:95666084~95668715:+
THCA	cis	rs17092148	0.636	rs2295096	ENSG00000269202.1	RP4-614O4.12	-3.47	0.000569	0.034	-0.16	-0.16	Neuroticism;	chr20:34876907	chr20:35201747~35203288:-
THCA	cis	rs6471393	1	rs6997642	ENSG00000261437.1	RP11-22C11.2	-3.47	0.000569	0.034	-0.16	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703737	chr8:94637285~94639467:-
THCA	cis	rs10089	0.953	rs758180	ENSG00000245937.6	LINC01184	3.47	0.000569	0.034	0.18	0.16	Ileal carcinoids;	chr5:128018731	chr5:127940426~128083172:-
THCA	cis	rs6787172	0.623	rs4680434	ENSG00000272087.1	RP11-379F4.7	3.47	0.000569	0.034	0.14	0.16	Subjective well-being;	chr3:158435227	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.621	rs9823076	ENSG00000272087.1	RP11-379F4.7	3.47	0.000569	0.034	0.14	0.16	Subjective well-being;	chr3:158435771	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.651	rs9843089	ENSG00000272087.1	RP11-379F4.7	3.47	0.000569	0.034	0.14	0.16	Subjective well-being;	chr3:158436003	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.623	rs9847460	ENSG00000272087.1	RP11-379F4.7	3.47	0.000569	0.034	0.14	0.16	Subjective well-being;	chr3:158436417	chr3:158693120~158693768:-
THCA	cis	rs7824557	0.767	rs10104728	ENSG00000255310.2	AF131215.2	3.47	0.000569	0.034	0.14	0.16	Retinal vascular caliber;	chr8:11313791	chr8:11107788~11109726:-
THCA	cis	rs1200921	0.696	rs1200897	ENSG00000272983.1	RP11-508N22.12	-3.47	0.000569	0.034	-0.14	-0.16	Breast cancer;	chr10:37201961	chr10:38137337~38144399:+
THCA	cis	rs910316	1	rs175443	ENSG00000273565.1	CTD-3075F15.1	-3.47	0.000569	0.034	-0.19	-0.16	Height;	chr14:75135260	chr14:75176929~75177418:+
THCA	cis	rs11800820	0.517	rs12022808	ENSG00000227953.5	LINC01341	3.47	0.000569	0.034	0.14	0.16	Obesity-related traits;	chr1:246495861	chr1:246776013~246792385:+
THCA	cis	rs2562456	0.55	rs4809143	ENSG00000268658.4	LINC00664	3.47	0.000569	0.034	0.25	0.16	Pain;	chr19:21589926	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.583	rs4809144	ENSG00000268658.4	LINC00664	3.47	0.000569	0.034	0.25	0.16	Pain;	chr19:21589928	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.652	rs62110214	ENSG00000268658.4	LINC00664	3.47	0.000569	0.034	0.25	0.16	Pain;	chr19:21592406	chr19:21483374~21503238:+
THCA	cis	rs7246657	0.639	rs3112434	ENSG00000226686.6	LINC01535	3.47	0.000569	0.034	0.23	0.16	Coronary artery calcification;	chr19:37707247	chr19:37251912~37265535:+
THCA	cis	rs6981523	0.532	rs1987190	ENSG00000255495.1	AC145124.2	-3.47	0.000569	0.034	-0.19	-0.16	Neuroticism;	chr8:11196005	chr8:12194467~12196280:+
THCA	cis	rs10496034	0.541	rs7587575	ENSG00000237887.1	AC092839.1	-3.47	0.000569	0.034	-0.27	-0.16	Refractive astigmatism;	chr2:54689492	chr2:54529343~54529801:+
THCA	cis	rs2921036	0.503	rs7817832	ENSG00000253981.4	ALG1L13P	3.47	0.000569	0.034	0.18	0.16	Neuroticism;	chr8:8523311	chr8:8236003~8244667:-
THCA	cis	rs7131987	0.934	rs2216854	ENSG00000257599.1	OVCH1-AS1	-3.47	0.000569	0.034	-0.19	-0.16	QT interval;	chr12:29270527	chr12:29389294~29487488:+
THCA	cis	rs603446	0.901	rs180344	ENSG00000254851.1	RP11-109L13.1	-3.47	0.000569	0.034	-0.21	-0.16	Triglycerides;	chr11:116742468	chr11:117135528~117138582:+
THCA	cis	rs713587	0.563	rs1529897	ENSG00000224165.4	DNAJC27-AS1	-3.47	0.000569	0.034	-0.09	-0.16	Body mass index in non-asthmatics;	chr2:24863958	chr2:24971390~25039694:+
THCA	cis	rs748404	0.66	rs690446	ENSG00000275601.1	AC011330.13	-3.47	0.000569	0.034	-0.19	-0.16	Lung cancer;	chr15:43469066	chr15:43642389~43643023:-
THCA	cis	rs748404	0.631	rs560191	ENSG00000275601.1	AC011330.13	-3.47	0.000569	0.034	-0.19	-0.16	Lung cancer;	chr15:43475576	chr15:43642389~43643023:-
THCA	cis	rs748404	0.69	rs2924369	ENSG00000275601.1	AC011330.13	3.47	0.000569	0.034	0.19	0.16	Lung cancer;	chr15:43485787	chr15:43642389~43643023:-
THCA	cis	rs748404	0.66	rs2444251	ENSG00000275601.1	AC011330.13	-3.47	0.000569	0.034	-0.19	-0.16	Lung cancer;	chr15:43496397	chr15:43642389~43643023:-
THCA	cis	rs748404	0.66	rs548704	ENSG00000275601.1	AC011330.13	-3.47	0.000569	0.034	-0.19	-0.16	Lung cancer;	chr15:43499508	chr15:43642389~43643023:-
THCA	cis	rs1520333	1	rs6982372	ENSG00000254352.1	RP11-578O24.2	-3.47	0.000569	0.034	-0.16	-0.16	Multiple sclerosis;	chr8:78496507	chr8:78723796~78724136:-
THCA	cis	rs10858047	0.883	rs4839384	ENSG00000231128.4	RP5-1073O3.2	3.47	0.000569	0.034	0.24	0.16	Autism;	chr1:114558550	chr1:113812379~113829171:+
THCA	cis	rs10954779	1	rs10954779	ENSG00000127589.4	TUBBP1	-3.47	0.000569	0.034	-0.18	-0.16	Intelligence (multi-trait analysis);	chr8:31162081	chr8:30351873~30353518:+
THCA	cis	rs7656342	0.964	rs13148356	ENSG00000249866.1	OR7E83P	3.47	0.000569	0.034	0.17	0.16	Gut microbiota (bacterial taxa);	chr4:9815446	chr4:9512905~9513874:+
THCA	cis	rs7656342	0.57	rs1980219	ENSG00000250342.1	SNRPCP16	3.47	0.000569	0.034	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9848997	chr4:9051842~9052051:-
THCA	cis	rs36093844	0.654	rs7106460	ENSG00000279742.1	RP11-700A24.1	-3.47	0.000569	0.034	-0.22	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85904506	chr11:85852557~85854943:-
THCA	cis	rs73198271	0.74	rs1039910	ENSG00000254153.1	CTA-398F10.2	3.47	0.000569	0.034	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8456909~8461337:-
THCA	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	3.47	0.000569	0.034	0.21	0.16	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
THCA	cis	rs7212590	0.748	rs7213697	ENSG00000267302.4	RP11-178C3.2	3.47	0.000569	0.034	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59825680	chr17:59964832~59996972:+
THCA	cis	rs4653663	0.533	rs12077115	ENSG00000225518.2	RP11-396C23.2	-3.47	0.000569	0.034	-0.2	-0.16	Neuroticism;	chr1:225737009	chr1:226083639~226090292:+
THCA	cis	rs9450351	0.744	rs56344601	ENSG00000280232.1	RP11-321N4.4	3.47	0.000569	0.034	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:86057967	chr6:85498441~85499058:-
THCA	cis	rs9450351	0.744	rs6913399	ENSG00000280232.1	RP11-321N4.4	3.47	0.000569	0.034	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:86068202	chr6:85498441~85499058:-
THCA	cis	rs7088591	0.867	rs16911467	ENSG00000276818.1	AC026393.1	3.47	0.000569	0.034	0.32	0.16	Blood pressure;	chr10:57981109	chr10:57095699~57095781:+
THCA	cis	rs7819412	0.634	rs6987767	ENSG00000254839.1	AF131215.6	-3.47	0.000569	0.034	-0.16	-0.16	Triglycerides;	chr8:11052556	chr8:11062647~11067089:-
THCA	cis	rs8035452	1	rs12900658	ENSG00000273674.3	CTD-2378E12.1	-3.47	0.00057	0.034	-0.19	-0.16	Alzheimer's disease (late onset);	chr15:50724167	chr15:50839875~50908599:-
THCA	cis	rs7267979	0.873	rs7453	ENSG00000125804.12	FAM182A	-3.47	0.00057	0.034	-0.2	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:26054655~26086917:+
THCA	cis	rs12549025	0.796	rs11135744	ENSG00000253390.1	CTC-756D1.2	-3.47	0.00057	0.034	-0.25	-0.16	Reticulocyte fraction of red cells;	chr8:23543642	chr8:23458601~23484971:+
THCA	cis	rs12549025	0.739	rs7015469	ENSG00000253390.1	CTC-756D1.2	-3.47	0.00057	0.034	-0.25	-0.16	Reticulocyte fraction of red cells;	chr8:23544327	chr8:23458601~23484971:+
THCA	cis	rs7830939	0.586	rs10108359	ENSG00000261451.1	RP11-981G7.1	3.47	0.00057	0.034	0.2	0.16	Neuroticism;	chr8:9469576	chr8:10433672~10438312:+
THCA	cis	rs6479874	0.831	rs2456758	ENSG00000223502.1	RP11-96B5.3	-3.47	0.00057	0.034	-0.18	-0.16	Migraine;	chr10:50978258	chr10:51062579~51068553:-
THCA	cis	rs950169	0.92	rs2135551	ENSG00000230373.7	GOLGA6L5P	-3.47	0.00057	0.034	-0.17	-0.16	Schizophrenia;	chr15:84039099	chr15:84507885~84516814:-
THCA	cis	rs950169	1	rs12902672	ENSG00000230373.7	GOLGA6L5P	-3.47	0.00057	0.034	-0.17	-0.16	Schizophrenia;	chr15:84048234	chr15:84507885~84516814:-
THCA	cis	rs950169	1	rs12903820	ENSG00000230373.7	GOLGA6L5P	-3.47	0.00057	0.034	-0.17	-0.16	Schizophrenia;	chr15:84055068	chr15:84507885~84516814:-
THCA	cis	rs950169	0.919	rs12915589	ENSG00000230373.7	GOLGA6L5P	-3.47	0.00057	0.034	-0.17	-0.16	Schizophrenia;	chr15:84065712	chr15:84507885~84516814:-
THCA	cis	rs950169	0.959	rs66801143	ENSG00000230373.7	GOLGA6L5P	-3.47	0.00057	0.034	-0.17	-0.16	Schizophrenia;	chr15:84067905	chr15:84507885~84516814:-
THCA	cis	rs950169	1	rs35648189	ENSG00000230373.7	GOLGA6L5P	-3.47	0.00057	0.034	-0.17	-0.16	Schizophrenia;	chr15:84071996	chr15:84507885~84516814:-
THCA	cis	rs950169	0.92	rs17300048	ENSG00000230373.7	GOLGA6L5P	-3.47	0.00057	0.034	-0.17	-0.16	Schizophrenia;	chr15:84080725	chr15:84507885~84516814:-
THCA	cis	rs950169	1	rs1848093	ENSG00000230373.7	GOLGA6L5P	-3.47	0.00057	0.034	-0.17	-0.16	Schizophrenia;	chr15:84086775	chr15:84507885~84516814:-
THCA	cis	rs4869313	0.694	rs2910787	ENSG00000247121.5	CTD-2260A17.2	3.47	0.00057	0.034	0.12	0.16	Pediatric autoimmune diseases;	chr5:96938519	chr5:96814028~96935809:-
THCA	cis	rs9889262	0.709	rs12185242	ENSG00000248714.5	RP11-1079K10.3	-3.47	0.00057	0.034	-0.18	-0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49329709	chr17:49361165~49369998:+
THCA	cis	rs75828804	0.826	rs116168751	ENSG00000260922.1	RP11-538I12.3	-3.47	0.00057	0.034	-0.33	-0.16	Intraocular pressure;	chr16:77534005	chr16:77234877~77290934:+
THCA	cis	rs7737355	0.579	rs17171380	ENSG00000237714.1	P4HA2-AS1	-3.47	0.00057	0.034	-0.34	-0.16	Life satisfaction;	chr5:131684402	chr5:132184876~132192808:+
THCA	cis	rs481331	0.866	rs209391	ENSG00000272319.1	AL022345.7	3.47	0.00057	0.034	0.31	0.16	Systemic juvenile idiopathic arthritis;	chr10:42632947	chr10:42579724~42582772:+
THCA	cis	rs465969	1	rs9400478	ENSG00000230177.1	RP5-1112D6.4	-3.47	0.00057	0.034	-0.25	-0.16	Psoriasis;	chr6:111478441	chr6:111277932~111278742:+
THCA	cis	rs4906332	1	rs55731474	ENSG00000259775.1	RP11-45P15.4	-3.47	0.00057	0.034	-0.14	-0.16	Coronary artery disease;	chr14:103412144	chr14:103331674~103332367:-
THCA	cis	rs453301	0.631	rs4840376	ENSG00000253981.4	ALG1L13P	-3.47	0.00057	0.034	-0.16	-0.16	Joint mobility (Beighton score);	chr8:8944591	chr8:8236003~8244667:-
THCA	cis	rs12188164	0.762	rs11745923	ENSG00000188242.4	PP7080	3.47	0.00057	0.034	0.15	0.16	Cystic fibrosis severity;	chr5:475293	chr5:466124~473098:-
THCA	cis	rs791590	0.752	rs62626317	ENSG00000229664.1	RP11-536K7.5	-3.47	0.00057	0.034	-0.24	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6068962	chr10:6025978~6036427:+
THCA	cis	rs2839186	0.708	rs17183123	ENSG00000228137.1	AP001469.7	3.47	0.00057	0.034	0.16	0.16	Testicular germ cell tumor;	chr21:46252047	chr21:46246890~46247682:+
THCA	cis	rs763121	0.776	rs4820346	ENSG00000273076.1	RP3-508I15.22	-3.47	0.00057	0.034	-0.16	-0.16	Menopause (age at onset);	chr22:38729069	chr22:38743495~38743910:+
THCA	cis	rs11992162	0.597	rs7824564	ENSG00000255046.1	RP11-297N6.4	3.47	0.00057	0.034	0.17	0.16	Monocyte count;	chr8:11922671	chr8:11797928~11802568:-
THCA	cis	rs613391	0.702	rs664108	ENSG00000234840.1	LINC01239	-3.47	0.00057	0.034	-0.18	-0.16	Quantitative traits;	chr9:22708380	chr9:22646200~22824213:+
THCA	cis	rs7264396	0.635	rs6058344	ENSG00000088340.14	FER1L4	3.47	0.00057	0.034	0.16	0.16	Total cholesterol levels;	chr20:35887116	chr20:35558737~35607562:-
THCA	cis	rs2562456	0.833	rs11666828	ENSG00000213976.4	CTD-2561J22.2	-3.47	0.00057	0.034	-0.2	-0.16	Pain;	chr19:21342218	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs11671609	ENSG00000213976.4	CTD-2561J22.2	-3.47	0.00057	0.034	-0.2	-0.16	Pain;	chr19:21342769	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.793	rs62109212	ENSG00000213976.4	CTD-2561J22.2	-3.47	0.00057	0.034	-0.2	-0.16	Pain;	chr19:21343716	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs57250002	ENSG00000213976.4	CTD-2561J22.2	-3.47	0.00057	0.034	-0.2	-0.16	Pain;	chr19:21344048	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs62109218	ENSG00000213976.4	CTD-2561J22.2	-3.47	0.00057	0.034	-0.2	-0.16	Pain;	chr19:21346059	chr19:21382865~21387177:+
THCA	cis	rs4372836	0.504	rs6737027	ENSG00000273233.1	RP11-713D19.1	-3.47	0.00057	0.034	-0.19	-0.16	Body mass index;	chr2:28847939	chr2:28810281~28810706:-
THCA	cis	rs9990333	0.562	rs56224853	ENSG00000207650.1	MIR570	3.47	0.00057	0.034	0.18	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195699401~195699497:+
THCA	cis	rs9990333	0.544	rs73210008	ENSG00000207650.1	MIR570	3.47	0.00057	0.034	0.18	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195699401~195699497:+
THCA	cis	rs7129556	0.645	rs684813	ENSG00000254459.1	RP11-91P24.7	3.47	0.00057	0.034	0.22	0.16	Weight loss (gastric bypass surgery);	chr11:77783708	chr11:77829654~77872262:-
THCA	cis	rs3925158	0.51	rs34433145	ENSG00000229589.1	ACVR2B-AS1	-3.47	0.00057	0.034	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38215677	chr3:38451027~38454820:-
THCA	cis	rs1501911	0.53	rs161941	ENSG00000241597.2	CTD-2007H13.1	3.47	0.00057	0.034	0.2	0.16	Lung function (FEV1/FVC);	chr5:98863500	chr5:98954394~98954972:+
THCA	cis	rs8105895	1	rs79846980	ENSG00000269345.1	VN1R85P	3.47	0.00057	0.034	0.22	0.16	Body mass index (change over time);	chr19:21958541	chr19:22174766~22175191:-
THCA	cis	rs8105895	1	rs1849004	ENSG00000269345.1	VN1R85P	3.47	0.00057	0.034	0.22	0.16	Body mass index (change over time);	chr19:21959653	chr19:22174766~22175191:-
THCA	cis	rs8105895	1	rs11882234	ENSG00000269345.1	VN1R85P	3.47	0.00057	0.034	0.22	0.16	Body mass index (change over time);	chr19:21962925	chr19:22174766~22175191:-
THCA	cis	rs1538970	0.884	rs1771551	ENSG00000280836.1	AL355480.1	-3.47	0.00057	0.0341	-0.21	-0.16	Platelet count;	chr1:45417971	chr1:45581219~45581321:-
THCA	cis	rs4073582	0.555	rs521109	ENSG00000245156.1	RP11-867G23.3	3.47	0.00057	0.0341	0.13	0.16	Gout;	chr11:66263477	chr11:66269832~66278525:-
THCA	cis	rs4073582	0.516	rs1151539	ENSG00000245156.1	RP11-867G23.3	3.47	0.00057	0.0341	0.13	0.16	Gout;	chr11:66264189	chr11:66269832~66278525:-
THCA	cis	rs4073582	0.595	rs528842	ENSG00000245156.1	RP11-867G23.3	3.47	0.00057	0.0341	0.13	0.16	Gout;	chr11:66264919	chr11:66269832~66278525:-
THCA	cis	rs4073582	0.595	rs474005	ENSG00000245156.1	RP11-867G23.3	3.47	0.00057	0.0341	0.13	0.16	Gout;	chr11:66265830	chr11:66269832~66278525:-
THCA	cis	rs4073582	0.595	rs2508657	ENSG00000245156.1	RP11-867G23.3	3.47	0.00057	0.0341	0.13	0.16	Gout;	chr11:66276427	chr11:66269832~66278525:-
THCA	cis	rs6416877	0.851	rs7217636	ENSG00000277491.1	RP11-676J12.9	-3.47	0.00057	0.0341	-0.19	-0.16	Myeloid white cell count;	chr17:1419582	chr17:795306~795794:+
THCA	cis	rs7246657	0.882	rs8112610	ENSG00000266916.4	ZNF793-AS1	-3.47	0.00057	0.0341	-0.15	-0.16	Coronary artery calcification;	chr19:37437828	chr19:37497159~37507046:-
THCA	cis	rs11031096	0.516	rs7113845	ENSG00000230593.3	AC090804.1	3.47	0.000571	0.0341	0.2	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:3967996	chr11:3892398~3892887:-
THCA	cis	rs9549260	0.755	rs7333037	ENSG00000275149.1	RP11-427J23.1	-3.47	0.000571	0.0341	-0.21	-0.16	Red blood cell count;	chr13:40641119	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.755	rs7989711	ENSG00000275149.1	RP11-427J23.1	-3.47	0.000571	0.0341	-0.21	-0.16	Red blood cell count;	chr13:40641559	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.755	rs7988604	ENSG00000275149.1	RP11-427J23.1	-3.47	0.000571	0.0341	-0.21	-0.16	Red blood cell count;	chr13:40641665	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.755	rs7990923	ENSG00000275149.1	RP11-427J23.1	-3.47	0.000571	0.0341	-0.21	-0.16	Red blood cell count;	chr13:40641835	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.755	rs4325426	ENSG00000275149.1	RP11-427J23.1	-3.47	0.000571	0.0341	-0.21	-0.16	Red blood cell count;	chr13:40642300	chr13:40079106~40273509:-
THCA	cis	rs853679	0.546	rs175597	ENSG00000220721.1	OR1F12	3.47	0.000571	0.0341	0.27	0.16	Depression;	chr6:27842848	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs200989	ENSG00000220721.1	OR1F12	3.47	0.000571	0.0341	0.27	0.16	Depression;	chr6:27848664	chr6:28073316~28074233:+
THCA	cis	rs2281603	0.57	rs11627387	ENSG00000258824.2	CTD-2555O16.2	-3.47	0.000571	0.0341	-0.14	-0.16	Lymphocyte counts;	chr14:64457259	chr14:64422935~64448557:-
THCA	cis	rs7336332	0.527	rs1475219	ENSG00000261485.1	PAN3-AS1	3.47	0.000571	0.0341	0.15	0.16	Weight;	chr13:27463278	chr13:28136843~28138193:-
THCA	cis	rs4771122	0.697	rs1475220	ENSG00000261485.1	PAN3-AS1	-3.47	0.000571	0.0341	-0.15	-0.16	Body mass index;	chr13:27463311	chr13:28136843~28138193:-
THCA	cis	rs4771122	0.728	rs1475221	ENSG00000261485.1	PAN3-AS1	-3.47	0.000571	0.0341	-0.15	-0.16	Body mass index;	chr13:27463429	chr13:28136843~28138193:-
THCA	cis	rs4763879	0.634	rs7974396	ENSG00000256594.6	RP11-705C15.2	-3.47	0.000571	0.0341	-0.12	-0.16	Type 1 diabetes;	chr12:9708101	chr12:9633419~9658412:+
THCA	cis	rs6921919	0.848	rs56131013	ENSG00000280107.1	AL022393.9	-3.47	0.000571	0.0341	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28170845~28172521:+
THCA	cis	rs7412746	0.658	rs72704652	ENSG00000224800.1	RP11-235D19.2	-3.47	0.000571	0.0341	-0.22	-0.16	Melanoma;	chr1:150846994	chr1:150881236~150881683:-
THCA	cis	rs73198271	0.74	rs1039912	ENSG00000254153.1	CTA-398F10.2	3.47	0.000571	0.0341	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8456909~8461337:-
THCA	cis	rs78487399	0.614	rs7600657	ENSG00000234936.1	AC010883.5	3.47	0.000571	0.0341	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43483305	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs7601093	ENSG00000234936.1	AC010883.5	3.47	0.000571	0.0341	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43483668	chr2:43229573~43233394:+
THCA	cis	rs7216064	1	rs6504549	ENSG00000278740.1	RP11-147L13.14	3.47	0.000571	0.0341	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67892668	chr17:68188547~68189165:+
THCA	cis	rs755249	0.565	rs722357	ENSG00000237624.1	OXCT2P1	-3.47	0.000571	0.0341	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39514956~39516490:+
THCA	cis	rs10457678	0.579	rs12193993	ENSG00000225415.2	RP3-509I19.1	-3.47	0.000571	0.0341	-0.22	-0.16	Colorectal or endometrial cancer;	chr6:138821772	chr6:138822747~138823799:+
THCA	cis	rs5758659	0.652	rs133300	ENSG00000234009.1	RPL5P34	-3.47	0.000571	0.0341	-0.15	-0.16	Cognitive function;	chr22:41993835	chr22:42776406~42777296:-
THCA	cis	rs2898290	0.622	rs7822109	ENSG00000270154.1	RP11-419I17.1	-3.47	0.000571	0.0341	-0.2	-0.16	Systolic blood pressure;	chr8:11491638	chr8:12476462~12477122:+
THCA	cis	rs6545883	0.894	rs778158	ENSG00000212978.6	AC016747.3	-3.47	0.000571	0.0341	-0.17	-0.16	Tuberculosis;	chr2:61328286	chr2:61141592~61144969:-
THCA	cis	rs6560517	1	rs10781361	ENSG00000234618.1	RPSAP9	-3.47	0.000571	0.0341	-0.17	-0.16	Dialysis-related mortality;	chr9:76430149	chr9:76398699~76399586:+
THCA	cis	rs10043228	1	rs78362565	ENSG00000250015.1	CTC-339F2.2	3.47	0.000571	0.0341	0.24	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116228596	chr5:116302354~116304134:-
THCA	cis	rs9650657	0.737	rs4551304	ENSG00000269918.1	AF131215.9	-3.47	0.000571	0.0341	-0.17	-0.16	Neuroticism;	chr8:10807559	chr8:11104691~11106704:-
THCA	cis	rs9650657	0.771	rs4240670	ENSG00000269918.1	AF131215.9	-3.47	0.000571	0.0341	-0.17	-0.16	Neuroticism;	chr8:10808338	chr8:11104691~11106704:-
THCA	cis	rs17074492	1	rs7336463	ENSG00000214182.5	PTMAP5	3.47	0.000571	0.0341	0.18	0.16	Sjögren's syndrome;	chr13:81608856	chr13:81689911~81691072:+
THCA	cis	rs6545883	0.899	rs1562309	ENSG00000212978.6	AC016747.3	3.47	0.000571	0.0341	0.17	0.16	Tuberculosis;	chr2:61542991	chr2:61141592~61144969:-
THCA	cis	rs4660214	0.666	rs11205828	ENSG00000228060.1	RP11-69E11.8	3.47	0.000571	0.0341	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253674	chr1:39565160~39573203:+
THCA	cis	rs6472235	0.837	rs2357579	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66013962	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs11995702	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66014188	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs6992002	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66015002	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.778	rs58967538	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66015548	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs28402886	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66015656	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.807	rs60667481	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66016125	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs60020249	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66016412	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs28605672	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66016959	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs7017618	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66018157	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs6983945	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66018231	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs12114319	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66018681	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs11988360	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66019144	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs10104877	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66020009	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs2884235	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66022532	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs7010679	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66023456	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs10092435	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66023942	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.778	rs2357657	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000571	0.0341	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66024255	chr8:65842752~65843331:+
THCA	cis	rs3176789	0.671	rs3176776	ENSG00000256673.1	RP11-599J14.2	3.47	0.000571	0.0341	0.19	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9764225	chr12:9398355~9414851:-
THCA	cis	rs875971	0.862	rs6460302	ENSG00000223473.2	GS1-124K5.3	3.47	0.000571	0.0341	0.11	0.16	Aortic root size;	chr7:66495270	chr7:66491049~66493566:-
THCA	cis	rs9796	0.84	rs1009913	ENSG00000247556.5	OIP5-AS1	-3.47	0.000571	0.0341	-0.13	-0.16	Menopause (age at onset);	chr15:41038852	chr15:41283990~41309737:+
THCA	cis	rs7616559	0.962	rs9842862	ENSG00000244515.1	KRT18P34	-3.47	0.000571	0.0341	-0.22	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157018606	chr3:157162663~157163932:-
THCA	cis	rs7702057	0.737	rs61632432	ENSG00000271918.1	CTD-2287O16.5	3.47	0.000571	0.0341	0.22	0.16	Amyotrophic lateral sclerosis;	chr5:116076802	chr5:116083807~116085416:-
THCA	cis	rs7615952	0.641	rs12491577	ENSG00000248787.1	RP11-666A20.4	-3.47	0.000571	0.0341	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126012288	chr3:125908005~125910272:-
THCA	cis	rs11711311	0.747	rs2895415	ENSG00000241529.3	RN7SL767P	-3.47	0.000571	0.0341	-0.23	-0.16	IgG glycosylation;	chr3:113626718	chr3:113632704~113632998:+
THCA	cis	rs7824557	0.778	rs3808502	ENSG00000261451.1	RP11-981G7.1	3.47	0.000571	0.0341	0.2	0.16	Retinal vascular caliber;	chr8:11321949	chr8:10433672~10438312:+
THCA	cis	rs564343	0.563	rs1642958	ENSG00000255120.4	OVOL1-AS1	3.47	0.000571	0.0341	0.2	0.16	Obesity (early onset extreme);	chr11:66054502	chr11:65789051~65790868:-
THCA	cis	rs7914558	0.899	rs7913682	ENSG00000272912.1	RP11-724N1.1	-3.47	0.000571	0.0341	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102924635	chr10:102914585~102915404:+
THCA	cis	rs6600671	0.967	rs11249349	ENSG00000226067.5	CH17-118O6.2	3.47	0.000571	0.0341	0.16	0.16	Hip geometry;	chr1:121437310	chr1:120913275~121009291:+
THCA	cis	rs6938	0.618	rs11072514	ENSG00000260269.4	CTD-2323K18.1	-3.47	0.000571	0.0341	-0.23	-0.16	Breast cancer;	chr15:74929524	chr15:75527150~75601205:-
THCA	cis	rs916888	0.821	rs199506	ENSG00000260075.1	NSFP1	3.47	0.000571	0.0341	0.25	0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46372855~46487141:+
THCA	cis	rs7259376	0.875	rs2116919	ENSG00000270947.1	AC025811.3	3.47	0.000571	0.0341	0.17	0.16	Menopause (age at onset);	chr19:22308904	chr19:22455988~22456459:+
THCA	cis	rs2278702	0.568	rs3736420	ENSG00000259495.2	RP11-210M15.2	-3.47	0.000571	0.0341	-0.24	-0.16	Bipolar disorder;	chr15:80373243	chr15:80344853~80403575:-
THCA	cis	rs12935229	0.689	rs1582981	ENSG00000260922.1	RP11-538I12.3	-3.47	0.000571	0.0341	-0.23	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77268430	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.689	rs6564422	ENSG00000260922.1	RP11-538I12.3	-3.47	0.000571	0.0341	-0.23	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77269012	chr16:77234877~77290934:+
THCA	cis	rs9788333	0.792	rs34479949	ENSG00000236953.1	ZDHHC20-IT1	-3.47	0.000572	0.0341	-0.18	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21321435	chr13:21376977~21377874:-
THCA	cis	rs11673344	0.504	rs4806407	ENSG00000267260.1	CTD-2162K18.4	3.47	0.000572	0.0341	0.19	0.16	Obesity-related traits;	chr19:37097849	chr19:36773153~36777078:+
THCA	cis	rs867186	1	rs6579210	ENSG00000126005.14	MMP24-AS1	-3.47	0.000572	0.0341	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35017999	chr20:35216462~35278131:-
THCA	cis	rs3176789	0.957	rs3136559	ENSG00000256673.1	RP11-599J14.2	3.47	0.000572	0.0341	0.21	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9764044	chr12:9398355~9414851:-
THCA	cis	rs10029851	0.645	rs1436504	ENSG00000234492.4	RPL34-AS1	3.47	0.000572	0.0341	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr4:108704028	chr4:108538190~108620460:-
THCA	cis	rs11190604	1	rs11190578	ENSG00000273030.1	RP11-285F16.1	3.47	0.000572	0.0341	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100479196	chr10:100412934~100413421:+
THCA	cis	rs11673344	0.523	rs36096221	ENSG00000267260.1	CTD-2162K18.4	-3.47	0.000572	0.0341	-0.19	-0.16	Obesity-related traits;	chr19:37060838	chr19:36773153~36777078:+
THCA	cis	rs7554547	0.69	rs61402980	ENSG00000199347.1	RNU5E-1	3.47	0.000572	0.0341	0.22	0.16	Nonsyndromic cleft lip with cleft palate;	chr1:11876432	chr1:11908152~11908271:+
THCA	cis	rs6762	0.719	rs1130698	ENSG00000255142.1	AP006621.6	3.47	0.000572	0.0341	0.11	0.16	Mean platelet volume;	chr11:838542	chr11:781645~782105:+
THCA	cis	rs4713118	0.513	rs149945	ENSG00000176933.5	TOB2P1	-3.47	0.000572	0.0341	-0.19	-0.16	Parkinson's disease;	chr6:28035075	chr6:28217643~28218634:-
THCA	cis	rs66887589	0.777	rs4643791	ENSG00000249244.1	RP11-548H18.2	-3.47	0.000572	0.0341	-0.16	-0.16	Diastolic blood pressure;	chr4:119344464	chr4:119391831~119395335:-
THCA	cis	rs16826658	1	rs16826658	ENSG00000218510.5	LINC00339	3.47	0.000572	0.0341	0.17	0.16	Endometriosis;	chr1:22159378	chr1:22025188~22031223:+
THCA	cis	rs71277158	0.688	rs7618919	ENSG00000242578.1	RP11-469J4.3	3.47	0.000572	0.0341	0.24	0.16	Prostate cancer;	chr3:170142451	chr3:170410512~170418615:+
THCA	cis	rs10932886	0.76	rs1463991	ENSG00000224819.1	AC093843.1	3.47	0.000572	0.0341	0.15	0.16	Brain imaging;	chr2:220839026	chr2:220791078~220797893:+
THCA	cis	rs7589561	0.516	rs4851864	ENSG00000272861.1	RP11-332H14.1	3.47	0.000572	0.0341	0.2	0.16	Addiction;	chr2:105774881	chr2:105249404~105249794:-
THCA	cis	rs7259376	0.875	rs10409520	ENSG00000269138.1	ZNF209P	3.47	0.000572	0.0341	0.16	0.16	Menopause (age at onset);	chr19:22329675	chr19:22463922~22473036:+
THCA	cis	rs17045328	1	rs11808746	ENSG00000274245.1	RP11-357P18.2	3.47	0.000572	0.0341	0.3	0.16	Type 2 diabetes;	chr1:207451516	chr1:207372559~207373252:+
THCA	cis	rs975752	0.717	rs2281949	ENSG00000227492.1	RP11-316M21.6	3.47	0.000572	0.0341	0.3	0.16	Schizophrenia;	chr10:100246645	chr10:100229667~100234000:+
THCA	cis	rs975752	0.717	rs7916126	ENSG00000227492.1	RP11-316M21.6	3.47	0.000572	0.0341	0.3	0.16	Schizophrenia;	chr10:100247616	chr10:100229667~100234000:+
THCA	cis	rs6982240	0.569	rs6992278	ENSG00000253307.1	RP11-10J21.4	3.47	0.000572	0.0341	0.22	0.16	Tonsillectomy;	chr8:141269284	chr8:141252286~141253292:-
THCA	cis	rs11168618	0.846	rs11168580	ENSG00000240399.1	RP1-228P16.1	3.47	0.000572	0.0341	0.16	0.16	Adiponectin levels;	chr12:48456641	chr12:48054813~48055591:-
THCA	cis	rs17291845	0.744	rs35422122	ENSG00000260135.5	RP11-212I21.2	3.47	0.000572	0.0341	0.22	0.16	Information processing speed;	chr16:55214015	chr16:55426797~55462297:-
THCA	cis	rs17291845	0.744	rs4284636	ENSG00000260135.5	RP11-212I21.2	3.47	0.000572	0.0341	0.22	0.16	Information processing speed;	chr16:55214022	chr16:55426797~55462297:-
THCA	cis	rs6456156	1	rs7761159	ENSG00000235272.1	FAM103A2P	3.47	0.000572	0.0341	0.22	0.16	Primary biliary cholangitis;	chr6:167106419	chr6:166586124~166586477:-
THCA	cis	rs801193	1	rs17566701	ENSG00000223473.2	GS1-124K5.3	3.47	0.000572	0.0341	0.11	0.16	Aortic root size;	chr7:66728196	chr7:66491049~66493566:-
THCA	cis	rs3096299	0.509	rs4785691	ENSG00000223959.7	AFG3L1P	3.47	0.000572	0.0341	0.09	0.16	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89972586~90002161:+
THCA	cis	rs1580019	0.563	rs13225132	ENSG00000273014.1	RP11-225B17.2	3.47	0.000572	0.0341	0.16	0.16	Cognitive ability;	chr7:32761363	chr7:32758882~32759353:+
THCA	cis	rs1153858	1	rs67831559	ENSG00000275672.1	GATM-AS1	-3.47	0.000572	0.0341	-0.16	-0.16	Homoarginine levels;	chr15:45357109	chr15:45378700~45380123:+
THCA	cis	rs6472235	0.681	rs58881093	ENSG00000272010.1	CTD-3025N20.3	-3.47	0.000572	0.0341	-0.16	-0.16	Plateletcrit;Myopia (pathological);	chr8:65952396	chr8:65591850~65592472:-
THCA	cis	rs7096965	1	rs7096965	ENSG00000242147.1	RP13-463N16.6	-3.47	0.000572	0.0341	-0.18	-0.16	Major depressive disorder;	chr10:4606238	chr10:5594991~5596118:-
THCA	cis	rs7096965	1	rs17369062	ENSG00000242147.1	RP13-463N16.6	-3.47	0.000572	0.0341	-0.18	-0.16	Major depressive disorder;	chr10:4606824	chr10:5594991~5596118:-
THCA	cis	rs7028939	1	rs12000239	ENSG00000255145.2	STX17-AS1	-3.47	0.000572	0.0341	-0.24	-0.16	Preeclampsia;	chr9:100189422	chr9:99886322~99906601:-
THCA	cis	rs9309711	0.922	rs13431788	ENSG00000271868.1	RP11-1293J14.1	-3.47	0.000572	0.0341	-0.22	-0.16	Neurofibrillary tangles;	chr2:3479141	chr2:3496956~3497428:+
THCA	cis	rs7005380	0.733	rs56864850	ENSG00000279347.1	RP11-85I17.2	3.47	0.000572	0.0341	0.18	0.16	Interstitial lung disease;	chr8:119931204	chr8:119838736~119840385:-
THCA	cis	rs7005380	0.785	rs55892034	ENSG00000279347.1	RP11-85I17.2	3.47	0.000572	0.0341	0.18	0.16	Interstitial lung disease;	chr8:119931267	chr8:119838736~119840385:-
THCA	cis	rs2933343	0.601	rs1680758	ENSG00000261159.1	RP11-723O4.9	3.47	0.000572	0.0341	0.16	0.16	IgG glycosylation;	chr3:128876054	chr3:128859716~128860526:-
THCA	cis	rs2486012	0.737	rs37468	ENSG00000237950.1	RP11-7O11.3	-3.47	0.000572	0.0341	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43814709	chr1:43944370~43946551:-
THCA	cis	rs9392556	0.829	rs612022	ENSG00000230648.1	RP3-406P24.3	3.47	0.000572	0.0341	0.2	0.16	Blood metabolite levels;	chr6:4126682	chr6:4018843~4021215:-
THCA	cis	rs9392556	0.829	rs676683	ENSG00000230648.1	RP3-406P24.3	3.47	0.000572	0.0341	0.2	0.16	Blood metabolite levels;	chr6:4127019	chr6:4018843~4021215:-
THCA	cis	rs786425	0.682	rs7136939	ENSG00000278112.1	RP11-972P1.11	3.47	0.000572	0.0341	0.15	0.16	Pubertal anthropometrics;	chr12:123705110	chr12:123519390~123519856:-
THCA	cis	rs889014	0.5	rs2112676	ENSG00000253959.1	CTB-43E15.1	-3.47	0.000572	0.0341	-0.23	-0.16	Height;	chr5:173564570	chr5:173642519~173658194:+
THCA	cis	rs1667255	1	rs1667258	ENSG00000266521.1	RP11-650P15.1	3.47	0.000573	0.0341	0.2	0.16	Retinol levels;	chr18:31609255	chr18:31496645~31497195:-
THCA	cis	rs10461617	0.617	rs79742142	ENSG00000234553.1	AC022431.3	-3.47	0.000573	0.0341	-0.18	-0.16	Type 2 diabetes;	chr5:56808550	chr5:56536583~56537826:-
THCA	cis	rs2287641	1	rs12623320	ENSG00000272156.1	RP11-477N3.1	3.47	0.000573	0.0342	0.28	0.16	Cannabis dependence symptom count;	chr2:54126417	chr2:54082554~54085066:+
THCA	cis	rs9611565	0.659	rs4822037	ENSG00000281538.1	RP4-669P10.20	3.47	0.000573	0.0342	0.18	0.16	Vitiligo;	chr22:41549109	chr22:42138060~42139726:+
THCA	cis	rs9878978	0.89	rs35104429	ENSG00000227588.2	CNTN4-AS2	3.47	0.000573	0.0342	0.19	0.16	Blood pressure (smoking interaction);	chr3:2439875	chr3:2110409~2144241:-
THCA	cis	rs620729	0.874	rs675565	ENSG00000272097.1	RP11-421M1.8	-3.47	0.000573	0.0342	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:11545349	chr6:10743324~10747663:-
THCA	cis	rs950169	1	rs12916348	ENSG00000275120.1	RP11-182J1.17	3.47	0.000573	0.0342	0.19	0.16	Schizophrenia;	chr15:84096775	chr15:84599434~84606463:-
THCA	cis	rs72482608	0.644	rs10753824	ENSG00000271811.1	RP1-79C4.4	3.47	0.000573	0.0342	0.2	0.16	Emphysema imaging phenotypes;	chr1:170830036	chr1:170667381~170669425:+
THCA	cis	rs607541	0.85	rs1017518	ENSG00000259520.4	CTD-2651B20.3	-3.47	0.000573	0.0342	-0.3	-0.16	Obesity-related traits;	chr15:45641109	chr15:45251580~45279251:-
THCA	cis	rs173896	1	rs1213402	ENSG00000246859.2	STARD4-AS1	3.47	0.000573	0.0342	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:111776612	chr5:111512226~111739726:+
THCA	cis	rs6005807	0.668	rs9620808	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28597343	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.668	rs60065194	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28597768	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.719	rs73430179	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28602833	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.719	rs58049055	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28611862	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.582	rs8136767	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28612638	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.719	rs7293232	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28619602	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.563	rs7288792	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28619615	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.64	rs7289534	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28620069	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.719	rs9625512	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28624768	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.719	rs9625513	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28626184	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.719	rs9625514	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28626200	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.64	rs73432205	ENSG00000272858.1	CTA-292E10.8	-3.47	0.000573	0.0342	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28632144	chr22:28814914~28815662:+
THCA	cis	rs2180341	0.842	rs6569476	ENSG00000220694.2	RP3-403A15.1	-3.47	0.000573	0.0342	-0.21	-0.16	Breast cancer;	chr6:127232394	chr6:127435636~127436189:+
THCA	cis	rs8040855	0.627	rs11632658	ENSG00000225151.9	GOLGA2P7	3.47	0.000573	0.0342	0.23	0.16	Bulimia nervosa;	chr15:85062982	chr15:84199311~84230136:-
THCA	cis	rs4601821	0.895	rs2155464	ENSG00000270179.1	RP11-159N11.4	-3.47	0.000573	0.0342	-0.16	-0.16	Alcoholic chronic pancreatitis;	chr11:113371726	chr11:113368478~113369117:+
THCA	cis	rs13113518	0.812	rs12505880	ENSG00000223305.1	RN7SKP30	3.47	0.000573	0.0342	0.2	0.16	Height;	chr4:55440988	chr4:55540502~55540835:-
THCA	cis	rs8070128	0.6	rs8071238	ENSG00000281749.1	Y_RNA	3.47	0.000573	0.0342	0.2	0.16	Total body bone mineral density;	chr17:17997676	chr17:18001101~18001195:-
THCA	cis	rs2348418	0.669	rs7959641	ENSG00000278733.1	RP11-425D17.1	-3.47	0.000573	0.0342	-0.14	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28185625~28186190:-
THCA	cis	rs2562456	0.52	rs250001	ENSG00000268119.4	CTD-2561J22.5	3.47	0.000573	0.0342	0.22	0.16	Pain;	chr19:21225387	chr19:21444241~21463908:-
THCA	cis	rs801193	0.66	rs1962050	ENSG00000230189.5	GS1-124K5.2	-3.47	0.000573	0.0342	-0.1	-0.16	Aortic root size;	chr7:66775021	chr7:66409143~66490059:-
THCA	cis	rs12049351	0.774	rs6662732	ENSG00000229367.1	HMGN2P19	-3.47	0.000573	0.0342	-0.24	-0.16	Circulating myeloperoxidase levels (plasma);	chr1:229493498	chr1:229570532~229570796:+
THCA	cis	rs9902453	0.904	rs8078638	ENSG00000250462.7	LRRC37BP1	3.47	0.000573	0.0342	0.12	0.16	Coffee consumption (cups per day);	chr17:29963340	chr17:30629680~30637466:+
THCA	cis	rs28830936	1	rs17678767	ENSG00000250379.1	RP11-23P13.4	3.47	0.000574	0.0342	0.18	0.16	Diastolic blood pressure;	chr15:41804224	chr15:41825099~41827936:-
THCA	cis	rs7829975	0.742	rs1533059	ENSG00000254340.1	RP11-10A14.3	-3.47	0.000574	0.0342	-0.17	-0.16	Mood instability;	chr8:8827443	chr8:9141424~9145435:+
THCA	cis	rs6088590	0.648	rs6058105	ENSG00000126005.14	MMP24-AS1	-3.47	0.000574	0.0342	-0.15	-0.16	Coronary artery disease;	chr20:34683915	chr20:35216462~35278131:-
THCA	cis	rs16975963	0.843	rs11672257	ENSG00000276846.1	CTD-3220F14.3	-3.47	0.000574	0.0342	-0.15	-0.16	Longevity;	chr19:37948722	chr19:37314868~37315620:-
THCA	cis	rs950169	1	rs12916348	ENSG00000230373.7	GOLGA6L5P	-3.47	0.000574	0.0342	-0.17	-0.16	Schizophrenia;	chr15:84096775	chr15:84507885~84516814:-
THCA	cis	rs4703129	1	rs72771735	ENSG00000246763.5	RGMB-AS1	-3.47	0.000574	0.0342	-0.16	-0.16	Asperger disorder;	chr5:98546570	chr5:98769618~98773469:-
THCA	cis	rs4703129	1	rs72771737	ENSG00000246763.5	RGMB-AS1	-3.47	0.000574	0.0342	-0.16	-0.16	Asperger disorder;	chr5:98546571	chr5:98769618~98773469:-
THCA	cis	rs9916302	0.706	rs4795375	ENSG00000266469.1	CTB-131K11.1	-3.47	0.000574	0.0342	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39506679	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs12937013	ENSG00000266469.1	CTB-131K11.1	-3.47	0.000574	0.0342	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39509318	chr17:39401793~39406233:+
THCA	cis	rs6137726	0.652	rs6048245	ENSG00000237396.1	LINC01384	-3.47	0.000574	0.0342	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22674559	chr20:22587522~22607517:-
THCA	cis	rs4692589	0.606	rs12645495	ENSG00000229204.3	PTGES3P3	-3.47	0.000574	0.0342	-0.21	-0.16	Anxiety disorder;	chr4:170012758	chr4:169791221~169791702:-
THCA	cis	rs950169	1	rs35297609	ENSG00000230373.7	GOLGA6L5P	-3.47	0.000574	0.0342	-0.17	-0.16	Schizophrenia;	chr15:84104144	chr15:84507885~84516814:-
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000185485.13	SDHAP1	3.47	0.000574	0.0342	0.13	0.16	Pancreatic cancer;	chr3:196021659	chr3:195959748~195990318:-
THCA	cis	rs409045	0.9	rs423359	ENSG00000271874.1	CTD-2024P10.2	-3.47	0.000574	0.0342	-0.2	-0.16	Left ventricular mass;	chr5:34638058	chr5:34651457~34651888:-
THCA	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
THCA	cis	rs61160187	0.517	rs7709522	ENSG00000251279.1	CTC-436P18.1	-3.47	0.000574	0.0342	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:61162070~61232040:+
THCA	cis	rs12144309	0.58	rs2040041	ENSG00000232450.1	RP4-730K3.3	-3.47	0.000574	0.0342	-0.21	-0.16	Coronary artery disease;	chr1:113770001	chr1:113698884~113699631:-
THCA	cis	rs2522056	1	rs1003533	ENSG00000263597.1	MIR3936	-3.47	0.000574	0.0342	-0.17	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132365490~132365599:-
THCA	cis	rs10090774	0.965	rs12677559	ENSG00000280303.2	ERICD	3.47	0.000574	0.0342	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140946805	chr8:140636281~140638283:+
THCA	cis	rs7028939	1	rs12377835	ENSG00000255145.2	STX17-AS1	-3.47	0.000574	0.0342	-0.24	-0.16	Preeclampsia;	chr9:100167975	chr9:99886322~99906601:-
THCA	cis	rs8114671	0.562	rs6120739	ENSG00000126005.14	MMP24-AS1	-3.47	0.000574	0.0342	-0.15	-0.16	Height;	chr20:34817424	chr20:35216462~35278131:-
THCA	cis	rs12022452	1	rs75936657	ENSG00000272145.1	NFYC-AS1	3.47	0.000574	0.0342	0.14	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40690380~40692066:-
THCA	cis	rs1969253	0.803	rs843357	ENSG00000205955.4	HSP90AA5P	-3.47	0.000574	0.0342	-0.2	-0.16	Major depressive disorder;	chr3:184143962	chr3:184115352~184117898:+
THCA	cis	rs1008126	0.6	rs6944123	ENSG00000234715.1	CTB-107G13.1	-3.47	0.000574	0.0342	-0.18	-0.16	Metabolite levels (Pyroglutamine);	chr7:103488377	chr7:103445207~103514007:+
THCA	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	3.47	0.000574	0.0342	0.14	0.16	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
THCA	cis	rs1850744	0.702	rs6836184	ENSG00000249767.1	ENPP7P10	-3.47	0.000574	0.0342	-0.31	-0.16	Economic and political preferences;	chr4:9632087	chr4:9079023~9141608:+
THCA	cis	rs1850744	0.536	rs6843869	ENSG00000249767.1	ENPP7P10	-3.47	0.000574	0.0342	-0.31	-0.16	Economic and political preferences;	chr4:9632827	chr4:9079023~9141608:+
THCA	cis	rs9524862	1	rs9524862	ENSG00000223298.1	RNY3P8	3.47	0.000574	0.0342	0.17	0.16	Platelet count;	chr13:95242373	chr13:95310830~95310955:-
THCA	cis	rs2797160	1	rs1777222	ENSG00000226409.1	RP11-735G4.1	3.47	0.000574	0.0342	0.19	0.16	Endometrial cancer;	chr6:125699884	chr6:125370211~125374324:-
THCA	cis	rs669446	0.591	rs586339	ENSG00000237950.1	RP11-7O11.3	3.47	0.000574	0.0342	0.14	0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:43671586	chr1:43944370~43946551:-
THCA	cis	rs8103033	0.786	rs2270028	ENSG00000226025.8	LGALS17A	-3.47	0.000574	0.0342	-0.14	-0.16	Obesity-related traits;	chr19:39642185	chr19:39679374~39686373:+
THCA	cis	rs8103033	0.786	rs2270029	ENSG00000226025.8	LGALS17A	-3.47	0.000574	0.0342	-0.14	-0.16	Obesity-related traits;	chr19:39642360	chr19:39679374~39686373:+
THCA	cis	rs9291683	0.668	rs2241474	ENSG00000261490.1	RP11-448G15.3	3.47	0.000574	0.0342	0.1	0.16	Bone mineral density;	chr4:10084391	chr4:10068089~10073019:-
THCA	cis	rs684232	0.666	rs2657629	ENSG00000231784.7	DBIL5P	3.47	0.000574	0.0342	0.17	0.16	Prostate cancer;	chr17:699021	chr17:752660~755336:+
THCA	cis	rs684232	0.583	rs2657626	ENSG00000231784.7	DBIL5P	3.47	0.000574	0.0342	0.17	0.16	Prostate cancer;	chr17:699812	chr17:752660~755336:+
THCA	cis	rs4660214	0.666	rs10493087	ENSG00000228060.1	RP11-69E11.8	3.47	0.000574	0.0342	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251584	chr1:39565160~39573203:+
THCA	cis	rs57709857	0.957	rs7007097	ENSG00000272092.1	RP11-350N15.5	-3.47	0.000574	0.0342	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38265670	chr8:38382364~38383461:+
THCA	cis	rs10954779	0.728	rs2252480	ENSG00000127589.4	TUBBP1	3.47	0.000574	0.0342	0.19	0.16	Intelligence (multi-trait analysis);	chr8:31132594	chr8:30351873~30353518:+
THCA	cis	rs4272720	0.562	rs7100655	ENSG00000234736.4	FAM170B-AS1	-3.47	0.000574	0.0342	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49130318	chr10:49121839~49151547:+
THCA	cis	rs495337	0.76	rs515686	ENSG00000229222.1	KRT18P4	-3.47	0.000575	0.0342	-0.2	-0.16	Psoriasis;	chr20:49899252	chr20:49956745~49958032:+
THCA	cis	rs3176789	1	rs2071647	ENSG00000256673.1	RP11-599J14.2	3.47	0.000575	0.0343	0.21	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9761409	chr12:9398355~9414851:-
THCA	cis	rs57709857	0.957	rs1488934	ENSG00000272092.1	RP11-350N15.5	-3.47	0.000575	0.0343	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38276094	chr8:38382364~38383461:+
THCA	cis	rs4538475	0.556	rs4613561	ENSG00000273133.1	RP11-799M12.2	-3.47	0.000575	0.0343	-0.21	-0.16	Parkinson's disease;	chr4:15736267	chr4:15563698~15564253:-
THCA	cis	rs2360027	0.662	rs1742854	ENSG00000231365.4	RP11-418J17.1	-3.47	0.000575	0.0343	-0.16	-0.16	Tonsillectomy;	chr1:118614588	chr1:119140396~119275973:+
THCA	cis	rs6600671	1	rs1832558	ENSG00000226067.5	CH17-118O6.2	3.47	0.000575	0.0343	0.16	0.16	Hip geometry;	chr1:121435521	chr1:120913275~121009291:+
THCA	cis	rs1510272	0.806	rs4234313	ENSG00000243926.1	TIPARP-AS1	-3.47	0.000575	0.0343	-0.16	-0.16	Testicular germ cell tumor;	chr3:156611893	chr3:156671862~156674378:-
THCA	cis	rs1510272	0.889	rs2063349	ENSG00000243926.1	TIPARP-AS1	-3.47	0.000575	0.0343	-0.16	-0.16	Testicular germ cell tumor;	chr3:156612356	chr3:156671862~156674378:-
THCA	cis	rs12534093	0.881	rs34033684	ENSG00000234286.1	AC006026.13	-3.47	0.000575	0.0343	-0.25	-0.16	Infant length;Height;	chr7:23445766	chr7:23680195~23680786:-
THCA	cis	rs3816063	0.925	rs35212078	ENSG00000253210.1	RP11-809O17.1	3.47	0.000575	0.0343	0.2	0.16	Obesity-related traits;	chr8:141150730	chr8:141126044~141129961:-
THCA	cis	rs7216064	0.953	rs4791046	ENSG00000278740.1	RP11-147L13.14	3.47	0.000575	0.0343	0.18	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67855857	chr17:68188547~68189165:+
THCA	cis	rs7819412	0.775	rs6601564	ENSG00000255046.1	RP11-297N6.4	3.47	0.000575	0.0343	0.17	0.16	Triglycerides;	chr8:11124541	chr8:11797928~11802568:-
THCA	cis	rs4474742	1	rs4474742	ENSG00000263370.1	RP11-68I3.5	-3.47	0.000575	0.0343	-0.21	-0.16	Monocyte count;	chr17:29738560	chr17:29639627~29640825:+
THCA	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-3.47	0.000575	0.0343	-0.18	-0.16	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-3.47	0.000575	0.0343	-0.18	-0.16	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
THCA	cis	rs34783982	0.529	rs1850324	ENSG00000259699.2	HMGB1P8	-3.47	0.000575	0.0343	-0.21	-0.16	Squamous cell lung carcinoma;	chr15:88929036	chr15:89135547~89136495:-
THCA	cis	rs1412115	0.501	rs7913633	ENSG00000233387.1	RP11-342D11.3	-3.47	0.000575	0.0343	-0.15	-0.16	Schizophrenia;	chr10:33790899	chr10:33096257~33116672:-
THCA	cis	rs11030122	0.547	rs10835333	ENSG00000230593.3	AC090804.1	3.47	0.000575	0.0343	0.19	0.16	Mean platelet volume;Platelet distribution width;	chr11:3936536	chr11:3892398~3892887:-
THCA	cis	rs7824557	0.569	rs10106207	ENSG00000254948.1	OR7E158P	3.47	0.000575	0.0343	0.19	0.16	Retinal vascular caliber;	chr8:11157828	chr8:11919900~11920809:-
THCA	cis	rs7647973	0.516	rs4499638	ENSG00000228638.1	FCF1P2	-3.47	0.000575	0.0343	-0.16	-0.16	Menarche (age at onset);	chr3:49165349	chr3:48290793~48291375:-
THCA	cis	rs17291845	0.744	rs28284	ENSG00000260135.5	RP11-212I21.2	3.47	0.000575	0.0343	0.22	0.16	Information processing speed;	chr16:55240972	chr16:55426797~55462297:-
THCA	cis	rs17291845	0.744	rs30954	ENSG00000260135.5	RP11-212I21.2	3.47	0.000575	0.0343	0.22	0.16	Information processing speed;	chr16:55241304	chr16:55426797~55462297:-
THCA	cis	rs7690839	1	rs10008568	ENSG00000270720.1	RP11-84C13.2	-3.47	0.000575	0.0343	-0.18	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88933041	chr4:89119284~89119871:+
THCA	cis	rs10043228	1	rs62384493	ENSG00000250015.1	CTC-339F2.2	3.47	0.000575	0.0343	0.24	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116337751	chr5:116302354~116304134:-
THCA	cis	rs7395662	1	rs12806328	ENSG00000200090.1	Y_RNA	-3.47	0.000575	0.0343	-0.11	-0.16	HDL cholesterol;	chr11:48626419	chr11:47726894~47726992:-
THCA	cis	rs9878978	0.722	rs35763288	ENSG00000227588.2	CNTN4-AS2	3.47	0.000575	0.0343	0.21	0.16	Blood pressure (smoking interaction);	chr3:2471979	chr3:2110409~2144241:-
THCA	cis	rs2228479	0.702	rs17177891	ENSG00000274627.1	RP11-104N10.2	-3.47	0.000575	0.0343	-0.28	-0.16	Skin colour saturation;	chr16:89733542	chr16:89516797~89522217:+
THCA	cis	rs13437751	0.881	rs10267610	ENSG00000223558.1	TRIM60P17	3.47	0.000575	0.0343	0.33	0.16	QT interval (drug interaction);	chr7:63936733	chr7:64085560~64086576:+
THCA	cis	rs6005807	0.719	rs2881496	ENSG00000226471.5	CTA-292E10.6	3.47	0.000575	0.0343	0.19	0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28525277	chr22:28800683~28848559:+
THCA	cis	rs3733585	0.683	rs3796839	ENSG00000261490.1	RP11-448G15.3	3.47	0.000575	0.0343	0.1	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10008293	chr4:10068089~10073019:-
THCA	cis	rs910316	0.967	rs11624893	ENSG00000273565.1	CTD-3075F15.1	-3.47	0.000575	0.0343	-0.19	-0.16	Height;	chr14:75193421	chr14:75176929~75177418:+
THCA	cis	rs12935418	0.733	rs12448615	ENSG00000261838.4	RP11-303E16.6	3.47	0.000575	0.0343	0.26	0.16	Mean corpuscular volume;	chr16:80947132	chr16:81069854~81076598:+
THCA	cis	rs2797160	0.967	rs1777224	ENSG00000226409.1	RP11-735G4.1	3.47	0.000575	0.0343	0.19	0.16	Endometrial cancer;	chr6:125698381	chr6:125370211~125374324:-
THCA	cis	rs6687821	0.515	rs2764425	ENSG00000261737.1	RP4-612B15.3	3.47	0.000575	0.0343	0.24	0.16	Yeast infection;	chr1:87083076	chr1:86703502~86704462:-
THCA	cis	rs7264396	0.635	rs6058351	ENSG00000088340.14	FER1L4	3.47	0.000576	0.0343	0.16	0.16	Total cholesterol levels;	chr20:35898171	chr20:35558737~35607562:-
THCA	cis	rs11681884	0.786	rs11887249	ENSG00000272563.1	RP11-480C16.1	-3.47	0.000576	0.0343	-0.35	-0.16	Stroke;	chr2:113051689	chr2:113432600~113436042:+
THCA	cis	rs4703129	1	rs2052519	ENSG00000246763.5	RGMB-AS1	-3.47	0.000576	0.0343	-0.15	-0.16	Asperger disorder;	chr5:98535314	chr5:98769618~98773469:-
THCA	cis	rs61160187	0.577	rs34741733	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000576	0.0343	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60866457~60866935:-
THCA	cis	rs910316	0.967	rs4899549	ENSG00000273565.1	CTD-3075F15.1	-3.47	0.000576	0.0343	-0.19	-0.16	Height;	chr14:75180791	chr14:75176929~75177418:+
THCA	cis	rs7139978	0.756	rs4386010	ENSG00000223685.4	LINC00571	-3.47	0.000576	0.0343	-0.16	-0.16	Life satisfaction;	chr13:37551297	chr13:38050817~38143232:-
THCA	cis	rs6095360	0.625	rs2426132	ENSG00000230758.1	SNAP23P	-3.47	0.000576	0.0343	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:49106590	chr20:49038357~49038602:-
THCA	cis	rs751728	0.588	rs7774620	ENSG00000274259.2	XXbac-BPG294E21.9	3.47	0.000576	0.0343	0.18	0.16	Crohn's disease;	chr6:33768508	chr6:33437363~33454453:-
THCA	cis	rs877819	0.697	rs7915025	ENSG00000228403.1	RP11-563N6.6	-3.47	0.000576	0.0343	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48843200	chr10:48878022~48878649:+
THCA	cis	rs7701440	0.512	rs12513581	ENSG00000251279.1	CTC-436P18.1	-3.47	0.000576	0.0343	-0.19	-0.16	Educational attainment;	chr5:61237380	chr5:61162070~61232040:+
THCA	cis	rs9916302	0.706	rs4332770	ENSG00000266469.1	CTB-131K11.1	-3.47	0.000576	0.0343	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39548459	chr17:39401793~39406233:+
THCA	cis	rs7412746	0.611	rs10788794	ENSG00000224800.1	RP11-235D19.2	-3.47	0.000576	0.0343	-0.22	-0.16	Melanoma;	chr1:150756200	chr1:150881236~150881683:-
THCA	cis	rs7412746	0.611	rs10888391	ENSG00000224800.1	RP11-235D19.2	-3.47	0.000576	0.0343	-0.22	-0.16	Melanoma;	chr1:150757507	chr1:150881236~150881683:-
THCA	cis	rs6012564	0.893	rs6012555	ENSG00000230758.1	SNAP23P	-3.47	0.000576	0.0343	-0.2	-0.16	Anger;	chr20:48911205	chr20:49038357~49038602:-
THCA	cis	rs301901	0.698	rs217840	ENSG00000250155.1	CTD-2353F22.1	3.47	0.000576	0.0343	0.16	0.16	Height;	chr5:37373000	chr5:36666214~36725195:-
THCA	cis	rs7737355	0.685	rs74883456	ENSG00000224431.1	AC063976.7	-3.47	0.000576	0.0343	-0.29	-0.16	Life satisfaction;	chr5:131405540	chr5:132199456~132203487:+
THCA	cis	rs13113518	0.513	rs13147861	ENSG00000223305.1	RN7SKP30	3.47	0.000576	0.0343	0.2	0.16	Height;	chr4:55611014	chr4:55540502~55540835:-
THCA	cis	rs9435732	1	rs2076600	ENSG00000268869.4	ESPNP	3.47	0.000576	0.0343	0.17	0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17010896	chr1:16687339~16720157:-
THCA	cis	rs7621331	1	rs35257855	ENSG00000239213.4	NCK1-AS1	3.47	0.000576	0.0343	0.16	0.16	Waist circumference adjusted for body mass index;	chr3:135988919	chr3:136841726~136862054:-
THCA	cis	rs12681963	0.688	rs7010839	ENSG00000272375.1	RP11-51J9.6	-3.47	0.000576	0.0343	-0.23	-0.16	Migraine;	chr8:30223451	chr8:30197404~30198048:+
THCA	cis	rs2288884	0.515	rs11084133	ENSG00000269483.1	AC006272.1	3.47	0.000576	0.0343	0.17	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:51839924~51843324:-
THCA	cis	rs4907240	0.961	rs66727130	ENSG00000230606.9	AC159540.1	3.47	0.000576	0.0343	0.18	0.16	Event-related brain oscillations;	chr2:96659254	chr2:97416165~97433527:-
THCA	cis	rs2089222	1	rs2893685	ENSG00000196668.3	LINC00173	-3.47	0.000576	0.0343	-0.29	-0.16	Acute lymphoblastic leukemia (childhood);	chr12:116563388	chr12:116533422~116536518:+
THCA	cis	rs9796	0.727	rs61203391	ENSG00000247556.5	OIP5-AS1	3.47	0.000576	0.0343	0.13	0.16	Menopause (age at onset);	chr15:41060714	chr15:41283990~41309737:+
THCA	cis	rs9796	0.727	rs12101934	ENSG00000247556.5	OIP5-AS1	3.47	0.000576	0.0343	0.13	0.16	Menopause (age at onset);	chr15:41060881	chr15:41283990~41309737:+
THCA	cis	rs7849270	0.76	rs882616	ENSG00000204055.4	RP11-247A12.2	3.47	0.000576	0.0343	0.2	0.16	Blood metabolite ratios;	chr9:129178586	chr9:129176771~129210548:+
THCA	cis	rs10969557	0.657	rs4741809	ENSG00000231808.2	LINC01388	3.47	0.000576	0.0343	0.17	0.16	Lung cancer;	chr9:328367	chr9:112713~113754:-
THCA	cis	rs393155	0.517	rs330050	ENSG00000254340.1	RP11-10A14.3	-3.47	0.000576	0.0343	-0.17	-0.16	Neuroticism;	chr8:9230169	chr8:9141424~9145435:+
THCA	cis	rs453301	0.571	rs330054	ENSG00000254340.1	RP11-10A14.3	-3.47	0.000576	0.0343	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9230781	chr8:9141424~9145435:+
THCA	cis	rs6979354	0.602	rs56264259	ENSG00000179460.5	EEF1A1P27	-3.47	0.000576	0.0343	-0.18	-0.16	Intelligence (multi-trait analysis);	chr7:21373940	chr7:20582072~20583206:+
THCA	cis	rs12216545	0.961	rs12536876	ENSG00000241134.3	BET1P1	3.47	0.000576	0.0343	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150510677	chr7:150749736~150750094:+
THCA	cis	rs12216545	0.961	rs4529370	ENSG00000241134.3	BET1P1	3.47	0.000576	0.0343	0.2	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150510792	chr7:150749736~150750094:+
THCA	cis	rs1790761	0.505	rs17593068	ENSG00000255318.1	RP11-655M14.13	-3.47	0.000576	0.0343	-0.17	-0.16	Mean corpuscular volume;	chr11:67583461	chr11:67618279~67627304:-
THCA	cis	rs787665	0.891	rs2797581	ENSG00000232709.1	MARK2P9	3.47	0.000576	0.0343	0.24	0.16	Gut microbiome composition (summer);	chr10:93310323	chr10:92418667~92420875:+
THCA	cis	rs7924176	0.668	rs7895133	ENSG00000232342.6	RP11-46O21.2	3.47	0.000576	0.0343	0.2	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74247697	chr10:74506081~74530553:-
THCA	cis	rs755249	0.642	rs11206430	ENSG00000182109.6	RP11-69E11.4	3.47	0.000576	0.0343	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39609695	chr1:39522280~39546187:-
THCA	cis	rs2033711	0.837	rs3764535	ENSG00000269867.1	CTD-2583A14.8	-3.47	0.000576	0.0343	-0.13	-0.16	Uric acid clearance;	chr19:58417685	chr19:57867038~57868172:-
THCA	cis	rs9926296	0.572	rs2079671	ENSG00000274627.1	RP11-104N10.2	-3.47	0.000576	0.0343	-0.16	-0.16	Vitiligo;	chr16:89818573	chr16:89516797~89522217:+
THCA	cis	rs17594362	0.669	rs73181179	ENSG00000264190.1	MIR5006	3.47	0.000576	0.0343	0.26	0.16	Multiple sclerosis;	chr13:41589603	chr13:41568286~41568395:-
THCA	cis	rs7829975	0.545	rs13261926	ENSG00000254153.1	CTA-398F10.2	3.47	0.000576	0.0343	0.18	0.16	Mood instability;	chr8:8694100	chr8:8456909~8461337:-
THCA	cis	rs9329221	0.736	rs2001338	ENSG00000253641.4	RP11-981G7.2	3.47	0.000576	0.0343	0.15	0.16	Neuroticism;	chr8:10393707	chr8:10474565~10481974:+
THCA	cis	rs853679	0.546	rs200996	ENSG00000220721.1	OR1F12	3.47	0.000576	0.0343	0.27	0.16	Depression;	chr6:27844050	chr6:28073316~28074233:+
THCA	cis	rs853679	0.546	rs200990	ENSG00000220721.1	OR1F12	3.47	0.000576	0.0343	0.27	0.16	Depression;	chr6:27848045	chr6:28073316~28074233:+
THCA	cis	rs12101261	0.536	rs2371463	ENSG00000258915.1	BHLHB9P1	-3.47	0.000576	0.0343	-0.16	-0.16	Graves' disease;	chr14:80991444	chr14:80981988~80983638:+
THCA	cis	rs7809950	0.598	rs2283038	ENSG00000272072.1	CTA-363E19.2	3.47	0.000576	0.0343	0.18	0.16	Coronary artery disease;	chr7:107194965	chr7:107192559~107193300:-
THCA	cis	rs7615952	0.546	rs2976733	ENSG00000243429.1	OR7E29P	3.47	0.000576	0.0343	0.2	0.16	Blood pressure (smoking interaction);	chr3:125695294	chr3:125712139~125713045:+
THCA	cis	rs9916302	0.66	rs4795379	ENSG00000266469.1	CTB-131K11.1	-3.47	0.000576	0.0343	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39518430	chr17:39401793~39406233:+
THCA	cis	rs4908760	0.864	rs1953827	ENSG00000270282.1	RP5-1115A15.2	3.47	0.000576	0.0343	0.18	0.16	Vitiligo;	chr1:8619789	chr1:8512653~8513021:+
THCA	cis	rs7259376	0.902	rs8112041	ENSG00000270947.1	AC025811.3	-3.47	0.000576	0.0343	-0.17	-0.16	Menopause (age at onset);	chr19:22421763	chr19:22455988~22456459:+
THCA	cis	rs6472235	0.837	rs60520895	ENSG00000272192.1	CTD-2532N20.1	3.47	0.000577	0.0343	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66018055	chr8:65842752~65843331:+
THCA	cis	rs17607347	0.697	rs62053995	ENSG00000247324.2	RP11-510M2.2	-3.47	0.000577	0.0343	-0.25	-0.16	Intelligence (multi-trait analysis);	chr16:72365020	chr16:71462278~71465941:+
THCA	cis	rs2880765	0.835	rs4842886	ENSG00000259407.1	RP11-158M2.3	-3.47	0.000577	0.0343	-0.16	-0.16	Coronary artery disease;	chr15:85492542	chr15:85744109~85750281:-
THCA	cis	rs8035452	1	rs5022760	ENSG00000273674.3	CTD-2378E12.1	3.47	0.000577	0.0343	0.2	0.16	Alzheimer's disease (late onset);	chr15:50728655	chr15:50839875~50908599:-
THCA	cis	rs8035452	0.964	rs11630054	ENSG00000273674.3	CTD-2378E12.1	3.47	0.000577	0.0343	0.2	0.16	Alzheimer's disease (late onset);	chr15:50723495	chr15:50839875~50908599:-
THCA	cis	rs62158211	1	rs1807282	ENSG00000231292.6	IGKV1OR2-108	-3.47	0.000577	0.0343	-0.13	-0.16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113352459	chr2:113406396~113406872:+
THCA	cis	rs2033711	0.783	rs11671113	ENSG00000269867.1	CTD-2583A14.8	-3.47	0.000577	0.0343	-0.13	-0.16	Uric acid clearance;	chr19:58446720	chr19:57867038~57868172:-
THCA	cis	rs11673344	0.504	rs7258360	ENSG00000267260.1	CTD-2162K18.4	-3.47	0.000577	0.0343	-0.19	-0.16	Obesity-related traits;	chr19:37115015	chr19:36773153~36777078:+
THCA	cis	rs6890684	0.569	rs6864489	ENSG00000251279.1	CTC-436P18.1	-3.47	0.000577	0.0343	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61250143	chr5:61162070~61232040:+
THCA	cis	rs8049603	0.504	rs13339649	ENSG00000257838.4	RP11-368J21.3	3.47	0.000577	0.0343	0.19	0.16	Multiple sclerosis;	chr16:23087101	chr16:22545698~22576865:+
THCA	cis	rs7824557	0.603	rs2736278	ENSG00000255495.1	AC145124.2	3.47	0.000577	0.0343	0.18	0.16	Retinal vascular caliber;	chr8:11362272	chr8:12194467~12196280:+
THCA	cis	rs3784262	0.934	rs7164408	ENSG00000259250.1	RP11-50C13.1	3.47	0.000577	0.0344	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57967138	chr15:58587507~58591676:+
THCA	cis	rs7536700	1	rs61806716	ENSG00000272030.1	RP1-178F15.4	-3.47	0.000577	0.0344	-0.29	-0.16	Multiple myeloma (IgH translocation);	chr1:153676671	chr1:153631438~153634397:-
THCA	cis	rs9916302	0.605	rs12938099	ENSG00000266469.1	CTB-131K11.1	-3.47	0.000577	0.0344	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39456657	chr17:39401793~39406233:+
THCA	cis	rs11710088	0.74	rs11710025	ENSG00000244503.1	RP11-278L15.6	3.47	0.000577	0.0344	0.22	0.16	QRS duration;	chr3:149475307	chr3:149494660~149495995:+
THCA	cis	rs8040855	0.627	rs11632175	ENSG00000225151.9	GOLGA2P7	-3.47	0.000577	0.0344	-0.23	-0.16	Bulimia nervosa;	chr15:85068449	chr15:84199311~84230136:-
THCA	cis	rs3808502	0.516	rs6983727	ENSG00000206014.6	OR7E161P	-3.47	0.000577	0.0344	-0.18	-0.16	Neuroticism;	chr8:11558303	chr8:11928597~11929563:-
THCA	cis	rs17604090	0.877	rs57253003	ENSG00000227855.3	DPY19L2P3	3.47	0.000577	0.0344	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29646940	chr7:29650227~29742594:+
THCA	cis	rs7829975	0.545	rs13261926	ENSG00000253981.4	ALG1L13P	-3.47	0.000577	0.0344	-0.16	-0.16	Mood instability;	chr8:8694100	chr8:8236003~8244667:-
THCA	cis	rs12893668	0.543	rs12147645	ENSG00000258735.1	LINC00637	-3.47	0.000577	0.0344	-0.21	-0.16	Reticulocyte count;	chr14:103633871	chr14:103847721~103858049:+
THCA	cis	rs9527	0.662	rs10883783	ENSG00000203886.4	CYP17A1-AS1	3.47	0.000577	0.0344	0.17	0.16	Arsenic metabolism;	chr10:102831395	chr10:102832721~102834516:+
THCA	cis	rs11640533	0.901	rs2908790	ENSG00000262714.1	RP11-44F14.8	-3.47	0.000577	0.0344	-0.22	-0.16	Intelligence (multi-trait analysis);	chr16:53378249	chr16:53386944~53389085:+
THCA	cis	rs9902453	0.817	rs2617881	ENSG00000214719.10	AC005562.1	-3.47	0.000577	0.0344	-0.14	-0.16	Coffee consumption (cups per day);	chr17:29736257	chr17:30576464~30672789:+
THCA	cis	rs4730276	0.674	rs6466207	ENSG00000250474.1	WBP1LP2	-3.47	0.000577	0.0344	-0.15	-0.16	Ulcerative colitis;	chr7:107914734	chr7:107628553~107629498:+
THCA	cis	rs12506899	0.817	rs4513532	ENSG00000221639.1	SNORA3	-3.47	0.000577	0.0344	-0.19	-0.16	Tumor biomarkers;	chr4:73395059	chr4:73263960~73264084:+
THCA	cis	rs3800688	0.598	rs1615299	ENSG00000236753.4	MKLN1-AS	-3.47	0.000577	0.0344	-0.15	-0.16	Hypertension;	chr7:131459650	chr7:131309744~131328222:-
THCA	cis	rs2115630	0.967	rs10438428	ENSG00000230373.7	GOLGA6L5P	-3.47	0.000577	0.0344	-0.15	-0.16	P wave terminal force;	chr15:84787514	chr15:84507885~84516814:-
THCA	cis	rs6504622	0.557	rs7213526	ENSG00000263142.4	LRRC37A17P	-3.47	0.000577	0.0344	-0.11	-0.16	Orofacial clefts;	chr17:46933791	chr17:46978481~47054569:+
THCA	cis	rs9916302	0.706	rs12947506	ENSG00000266469.1	CTB-131K11.1	-3.47	0.000577	0.0344	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39551339	chr17:39401793~39406233:+
THCA	cis	rs14027	0.883	rs10087723	ENSG00000279347.1	RP11-85I17.2	-3.47	0.000577	0.0344	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711014	chr8:119838736~119840385:-
THCA	cis	rs2880765	0.835	rs4843062	ENSG00000218052.5	ADAMTS7P4	-3.47	0.000577	0.0344	-0.18	-0.16	Coronary artery disease;	chr15:85496906	chr15:85255369~85330334:-
THCA	cis	rs7259376	0.875	rs1991830	ENSG00000270947.1	AC025811.3	3.47	0.000577	0.0344	0.17	0.16	Menopause (age at onset);	chr19:22331928	chr19:22455988~22456459:+
THCA	cis	rs2236295	0.533	rs73279609	ENSG00000238280.1	RP11-436D10.3	-3.47	0.000578	0.0344	-0.19	-0.16	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62889873	chr10:62793562~62805887:-
THCA	cis	rs7395662	1	rs7938880	ENSG00000200090.1	Y_RNA	-3.47	0.000578	0.0344	-0.11	-0.16	HDL cholesterol;	chr11:48620602	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs7925955	ENSG00000200090.1	Y_RNA	-3.47	0.000578	0.0344	-0.11	-0.16	HDL cholesterol;	chr11:48625981	chr11:47726894~47726992:-
THCA	cis	rs757978	1	rs73116394	ENSG00000261186.2	RP11-341N2.1	-3.47	0.000578	0.0344	-0.28	-0.16	Chronic lymphocytic leukemia;	chr2:241428500	chr2:242087351~242088457:-
THCA	cis	rs757978	1	rs73116396	ENSG00000261186.2	RP11-341N2.1	-3.47	0.000578	0.0344	-0.28	-0.16	Chronic lymphocytic leukemia;	chr2:241429278	chr2:242087351~242088457:-
THCA	cis	rs11168618	0.935	rs2114322	ENSG00000257763.1	OR5BK1P	-3.47	0.000578	0.0344	-0.14	-0.16	Adiponectin levels;	chr12:48557824	chr12:48355792~48356614:-
THCA	cis	rs8044868	1	rs4238964	ENSG00000260886.1	TAT-AS1	3.47	0.000578	0.0344	0.19	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72141257	chr16:71565789~71578187:+
THCA	cis	rs10911902	0.643	rs2297226	ENSG00000228238.1	GS1-304P7.2	-3.47	0.000578	0.0344	-0.25	-0.16	Schizophrenia;	chr1:186374627	chr1:186578279~186579299:+
THCA	cis	rs7539542	0.538	rs73091325	ENSG00000234996.3	RP11-480I12.7	3.47	0.000578	0.0344	0.24	0.16	Mean platelet volume;	chr1:202938603	chr1:202861754~202875241:+
THCA	cis	rs4443100	0.67	rs9608071	ENSG00000230701.2	FBXW4P1	3.47	0.000578	0.0344	0.19	0.16	Serum parathyroid hormone levels;	chr22:23065939	chr22:23262767~23265005:+
THCA	cis	rs72482608	0.647	rs10753823	ENSG00000271811.1	RP1-79C4.4	3.47	0.000578	0.0344	0.2	0.16	Emphysema imaging phenotypes;	chr1:170829303	chr1:170667381~170669425:+
THCA	cis	rs9307551	0.619	rs1074134	ENSG00000249646.2	OR7E94P	-3.47	0.000578	0.0344	-0.21	-0.16	Refractive error;	chr4:79503752	chr4:79587302~79588130:-
THCA	cis	rs7772486	0.875	rs1331639	ENSG00000270638.1	RP3-466P17.1	-3.47	0.000578	0.0344	-0.12	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.875	rs7739418	ENSG00000270638.1	RP3-466P17.1	3.47	0.000578	0.0344	0.12	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145735570~145737218:+
THCA	cis	rs60180747	1	rs14303	ENSG00000261318.1	RP11-653J6.1	3.47	0.000578	0.0344	0.21	0.16	Testicular germ cell tumor;	chr15:66490923	chr15:66278498~66293357:-
THCA	cis	rs7010267	0.623	rs13254554	ENSG00000254278.1	RP11-278I4.2	-3.47	0.000578	0.0344	-0.21	-0.16	Total body bone mineral density (age 45-60);	chr8:118998566	chr8:119062942~119068782:-
THCA	cis	rs12468226	0.873	rs76552560	ENSG00000272966.1	RP11-686O6.1	3.47	0.000578	0.0344	0.3	0.16	Urate levels;	chr2:202173123	chr2:202336739~202337200:+
THCA	cis	rs2395128	0.765	rs1880690	ENSG00000236842.1	RP11-399K21.10	3.47	0.000578	0.0344	0.25	0.16	Ulcerative colitis;Inflammatory bowel disease;	chr10:74904924	chr10:75430571~75431588:-
THCA	cis	rs6787172	0.748	rs11710570	ENSG00000272087.1	RP11-379F4.7	3.47	0.000578	0.0344	0.14	0.16	Subjective well-being;	chr3:158338865	chr3:158693120~158693768:-
THCA	cis	rs897984	0.572	rs112906665	ENSG00000275263.1	RP11-1072A3.4	-3.47	0.000578	0.0344	-0.19	-0.16	Dementia with Lewy bodies;	chr16:31028818	chr16:30956872~30957199:-
THCA	cis	rs897984	0.609	rs12445650	ENSG00000275263.1	RP11-1072A3.4	-3.47	0.000578	0.0344	-0.19	-0.16	Dementia with Lewy bodies;	chr16:31033576	chr16:30956872~30957199:-
THCA	cis	rs72843506	0.586	rs56153261	ENSG00000231258.2	ZSWIM5P2	3.47	0.000578	0.0344	0.23	0.16	Schizophrenia;	chr17:19904200	chr17:20583758~20591180:-
THCA	cis	rs7737355	0.812	rs11746227	ENSG00000237714.1	P4HA2-AS1	3.47	0.000578	0.0344	0.22	0.16	Life satisfaction;	chr5:131625543	chr5:132184876~132192808:+
THCA	cis	rs8035452	1	rs9920753	ENSG00000273674.3	CTD-2378E12.1	3.47	0.000578	0.0344	0.2	0.16	Alzheimer's disease (late onset);	chr15:50718881	chr15:50839875~50908599:-
THCA	cis	rs8035452	1	rs7170303	ENSG00000273674.3	CTD-2378E12.1	3.47	0.000578	0.0344	0.2	0.16	Alzheimer's disease (late onset);	chr15:50721589	chr15:50839875~50908599:-
THCA	cis	rs7944735	0.517	rs11039520	ENSG00000200090.1	Y_RNA	3.47	0.000578	0.0344	0.15	0.16	Intraocular pressure;	chr11:48109242	chr11:47726894~47726992:-
THCA	cis	rs3026101	0.599	rs1058381	ENSG00000234327.6	AC012146.7	-3.47	0.000578	0.0344	-0.13	-0.16	Body mass index;	chr17:5384698	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.624	rs1806219	ENSG00000234327.6	AC012146.7	-3.47	0.000578	0.0344	-0.13	-0.16	Body mass index;	chr17:5384753	chr17:5111468~5115004:+
THCA	cis	rs988712	0.921	rs6484317	ENSG00000245573.6	BDNF-AS	3.47	0.000578	0.0344	0.14	0.16	Obesity;	chr11:27576874	chr11:27506838~27698174:+
THCA	cis	rs2180341	1	rs4897207	ENSG00000220522.2	RP1-177A13.1	3.47	0.000578	0.0344	0.21	0.16	Breast cancer;	chr6:127284753	chr6:127416535~127416952:-
THCA	cis	rs836788	0.608	rs863221	ENSG00000251050.1	RP11-168A11.4	-3.47	0.000578	0.0344	-0.12	-0.16	Glomerular filtration rate (creatinine);	chr5:80746456	chr5:80019609~80019920:+
THCA	cis	rs9487051	0.872	rs1111866	ENSG00000260273.1	RP11-425D10.10	-3.47	0.000578	0.0344	-0.19	-0.16	Reticulocyte fraction of red cells;	chr6:109289643	chr6:109382795~109383666:+
THCA	cis	rs2235649	0.663	rs6600167	ENSG00000260541.1	LA16c-429E7.1	3.47	0.000578	0.0344	0.21	0.16	Blood metabolite levels;	chr16:1798911	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.663	rs113908028	ENSG00000260541.1	LA16c-429E7.1	3.47	0.000578	0.0344	0.21	0.16	Blood metabolite levels;	chr16:1798914	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.623	rs8048162	ENSG00000260541.1	LA16c-429E7.1	3.47	0.000578	0.0344	0.21	0.16	Blood metabolite levels;	chr16:1798917	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.663	rs6600168	ENSG00000260541.1	LA16c-429E7.1	3.47	0.000578	0.0344	0.21	0.16	Blood metabolite levels;	chr16:1798926	chr16:1841020~1843547:-
THCA	cis	rs7829975	0.742	rs12547493	ENSG00000248538.5	RP11-10A14.5	3.47	0.000578	0.0344	0.2	0.16	Mood instability;	chr8:8804024	chr8:9189011~9202854:+
THCA	cis	rs7010267	0.935	rs7463176	ENSG00000254278.1	RP11-278I4.2	-3.47	0.000578	0.0344	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118945386	chr8:119062942~119068782:-
THCA	cis	rs7010267	0.935	rs11573829	ENSG00000254278.1	RP11-278I4.2	-3.47	0.000578	0.0344	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118947384	chr8:119062942~119068782:-
THCA	cis	rs7010267	0.935	rs11573824	ENSG00000254278.1	RP11-278I4.2	-3.47	0.000578	0.0344	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118947686	chr8:119062942~119068782:-
THCA	cis	rs7010267	0.935	rs6469789	ENSG00000254278.1	RP11-278I4.2	-3.47	0.000578	0.0344	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118948422	chr8:119062942~119068782:-
THCA	cis	rs524281	0.861	rs7124165	ENSG00000255038.1	RP11-1167A19.2	-3.47	0.000578	0.0344	-0.18	-0.16	Electroencephalogram traits;	chr11:66133747	chr11:66067277~66069619:-
THCA	cis	rs11992162	0.507	rs60902764	ENSG00000255046.1	RP11-297N6.4	3.47	0.000578	0.0344	0.17	0.16	Monocyte count;	chr8:11927482	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.569	rs10106207	ENSG00000255046.1	RP11-297N6.4	3.47	0.000578	0.0344	0.17	0.16	Retinal vascular caliber;	chr8:11157828	chr8:11797928~11802568:-
THCA	cis	rs7088591	0.614	rs59368593	ENSG00000276818.1	AC026393.1	3.47	0.000578	0.0344	0.27	0.16	Blood pressure;	chr10:57996763	chr10:57095699~57095781:+
THCA	cis	rs10938353	0.911	rs13138228	ENSG00000273369.1	RP11-700J17.1	3.47	0.000579	0.0344	0.17	0.16	Body mass index;	chr4:44590043	chr4:44693946~44694386:-
THCA	cis	rs7631605	1	rs6789043	ENSG00000272334.1	RP11-129K12.1	-3.47	0.000579	0.0344	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36984376	chr3:36973117~36973672:-
THCA	cis	rs972578	1	rs2284098	ENSG00000230319.1	AL022476.2	3.47	0.000579	0.0344	0.17	0.16	Mean platelet volume;	chr22:43005766	chr22:43038585~43052366:+
THCA	cis	rs972578	1	rs738381	ENSG00000230319.1	AL022476.2	3.47	0.000579	0.0344	0.17	0.16	Mean platelet volume;	chr22:43008101	chr22:43038585~43052366:+
THCA	cis	rs2214442	0.871	rs3807929	ENSG00000271133.4	CTA-293F17.1	-3.47	0.000579	0.0344	-0.16	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20341946	chr7:20328299~20331747:-
THCA	cis	rs2214442	0.871	rs3807930	ENSG00000271133.4	CTA-293F17.1	-3.47	0.000579	0.0344	-0.16	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20342027	chr7:20328299~20331747:-
THCA	cis	rs7259376	0.84	rs3862494	ENSG00000270947.1	AC025811.3	3.47	0.000579	0.0344	0.17	0.16	Menopause (age at onset);	chr19:22336720	chr19:22455988~22456459:+
THCA	cis	rs9420	0.961	rs79260745	ENSG00000254602.1	AP000662.4	-3.47	0.000579	0.0344	-0.18	-0.16	Schizophrenia;	chr11:57845488	chr11:57638024~57652790:+
THCA	cis	rs2214442	0.756	rs3807934	ENSG00000271133.4	CTA-293F17.1	-3.47	0.000579	0.0344	-0.16	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20343948	chr7:20328299~20331747:-
THCA	cis	rs11671005	0.737	rs11671033	ENSG00000252334.1	RNU6-1337P	3.47	0.000579	0.0344	0.25	0.16	Mean platelet volume;	chr19:58452302	chr19:58483749~58483843:-
THCA	cis	rs7112925	0.932	rs3923203	ENSG00000255517.5	CTD-3074O7.5	3.47	0.000579	0.0344	0.12	0.16	Height;	chr11:67067723	chr11:66473490~66480233:-
THCA	cis	rs16975963	0.895	rs8103383	ENSG00000276846.1	CTD-3220F14.3	-3.47	0.000579	0.0344	-0.15	-0.16	Longevity;	chr19:37837061	chr19:37314868~37315620:-
THCA	cis	rs11800820	0.595	rs3124128	ENSG00000231612.1	RP11-522M21.3	3.47	0.000579	0.0344	0.22	0.16	Obesity-related traits;	chr1:246547890	chr1:245673732~245676478:-
THCA	cis	rs684232	0.666	rs838371	ENSG00000231784.7	DBIL5P	3.47	0.000579	0.0344	0.17	0.16	Prostate cancer;	chr17:706035	chr17:752660~755336:+
THCA	cis	rs6840360	0.571	rs12648420	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000579	0.0344	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151622282	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs72730104	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000579	0.0344	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151622705	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs62327272	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000579	0.0344	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151623938	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.509	rs62327273	ENSG00000251611.1	RP11-610P16.1	-3.47	0.000579	0.0344	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151626442	chr4:151407551~151408835:-
THCA	cis	rs854765	0.583	rs4925125	ENSG00000281749.1	Y_RNA	-3.47	0.000579	0.0344	-0.19	-0.16	Total body bone mineral density;	chr17:17891130	chr17:18001101~18001195:-
THCA	cis	rs61677309	0.638	rs59049611	ENSG00000278376.1	RP11-158I9.8	3.47	0.000579	0.0344	0.12	0.16	Lung cancer in ever smokers;	chr11:118268688	chr11:118791254~118793137:+
THCA	cis	rs354225	0.615	rs12713274	ENSG00000212175.1	SNORA12	3.47	0.000579	0.0345	0.19	0.16	Schizophrenia;	chr2:54621591	chr2:55565703~55565850:+
THCA	cis	rs7631605	0.905	rs3774343	ENSG00000272334.1	RP11-129K12.1	-3.47	0.000579	0.0345	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36994343	chr3:36973117~36973672:-
THCA	cis	rs972578	1	rs2092214	ENSG00000230319.1	AL022476.2	3.47	0.000579	0.0345	0.17	0.16	Mean platelet volume;	chr22:42967917	chr22:43038585~43052366:+
THCA	cis	rs972578	0.967	rs4822238	ENSG00000230319.1	AL022476.2	3.47	0.000579	0.0345	0.17	0.16	Mean platelet volume;	chr22:42968789	chr22:43038585~43052366:+
THCA	cis	rs972578	0.936	rs738394	ENSG00000230319.1	AL022476.2	3.47	0.000579	0.0345	0.17	0.16	Mean platelet volume;	chr22:42970890	chr22:43038585~43052366:+
THCA	cis	rs4908760	0.792	rs10864361	ENSG00000270282.1	RP5-1115A15.2	-3.47	0.000579	0.0345	-0.18	-0.16	Vitiligo;	chr1:8666662	chr1:8512653~8513021:+
THCA	cis	rs6762	0.719	rs28655651	ENSG00000255284.1	AP006621.5	3.47	0.000579	0.0345	0.11	0.16	Mean platelet volume;	chr11:837121	chr11:777578~784297:+
THCA	cis	rs6762	0.748	rs1130663	ENSG00000255284.1	AP006621.5	3.47	0.000579	0.0345	0.11	0.16	Mean platelet volume;	chr11:837582	chr11:777578~784297:+
THCA	cis	rs4533267	0.81	rs4246312	ENSG00000278456.1	RP11-66B24.9	-3.46	0.000579	0.0345	-0.19	-0.16	Height;	chr15:100247600	chr15:100888472~100889106:-
THCA	cis	rs6723226	0.806	rs6543658	ENSG00000276517.1	AL133243.2	-3.46	0.000579	0.0345	-0.15	-0.16	Intelligence (multi-trait analysis);	chr2:32493782	chr2:32526504~32529507:+
THCA	cis	rs6560517	0.747	rs10119532	ENSG00000234618.1	RPSAP9	-3.46	0.000579	0.0345	-0.18	-0.16	Dialysis-related mortality;	chr9:76473607	chr9:76398699~76399586:+
THCA	cis	rs964611	0.938	rs8039653	ENSG00000259488.2	RP11-154J22.1	-3.46	0.000579	0.0345	-0.15	-0.16	Metabolite levels (Pyroglutamine);	chr15:48280438	chr15:48312353~48331856:-
THCA	cis	rs7326068	0.524	rs9506531	ENSG00000238286.1	SLC35E1P1	3.46	0.000579	0.0345	0.16	0.16	Schizophrenia, bipolar disorder and depression (combined);	chr13:20658844	chr13:20607268~20608131:+
THCA	cis	rs73459955	0.712	rs73459912	ENSG00000248441.5	LINC01197	3.46	0.000579	0.0345	0.21	0.16	Major depression and alcohol dependence;	chr15:95088945	chr15:95209099~95327129:-
THCA	cis	rs1065656	0.563	rs391546	ENSG00000259895.1	RP11-715J22.2	-3.46	0.000579	0.0345	-0.18	-0.16	Insulin-like growth factors;	chr16:1865580	chr16:2464950~2468213:-
THCA	cis	rs2664588	0.538	rs6018821	ENSG00000276923.1	RP11-321P16.1	-3.46	0.000579	0.0345	-0.21	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47964482	chr20:48073869~48074188:+
THCA	cis	rs6545883	0.894	rs4672431	ENSG00000212978.6	AC016747.3	-3.46	0.000579	0.0345	-0.17	-0.16	Tuberculosis;	chr2:61292787	chr2:61141592~61144969:-
THCA	cis	rs1065852	0.526	rs2097561	ENSG00000227370.1	RP4-669P10.19	3.46	0.000579	0.0345	0.16	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993427	chr22:42132543~42132998:+
THCA	cis	rs1065852	0.526	rs2097562	ENSG00000227370.1	RP4-669P10.19	3.46	0.000579	0.0345	0.16	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993496	chr22:42132543~42132998:+
THCA	cis	rs3026101	0.671	rs3026145	ENSG00000234327.6	AC012146.7	-3.46	0.000579	0.0345	-0.13	-0.16	Body mass index;	chr17:5413422	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.624	rs55970234	ENSG00000234327.6	AC012146.7	-3.46	0.000579	0.0345	-0.13	-0.16	Body mass index;	chr17:5413445	chr17:5111468~5115004:+
THCA	cis	rs2243480	1	rs422164	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66121618	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316313	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66128561	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316312	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66131504	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs419603	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66132354	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs387676	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66133233	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66133553	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs431076	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66135333	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66136518	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316334	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66137139	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316330	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66140385	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316326	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66144466	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316325	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66144531	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316321	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66146626	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316318	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66147917	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316317	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66148650	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs316304	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66151907	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs2465120	ENSG00000237310.1	GS1-124K5.4	3.46	0.000579	0.0345	0.18	0.16	Diabetic kidney disease;	chr7:66155987	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66157859	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs4718309	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66162777	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6460274	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66163497	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs7787230	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66164112	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66170354	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6974723	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66172952	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs9769882	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66177938	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6966322	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66181767	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs4145008	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66182524	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs4718315	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66183554	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs4718316	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66183744	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1873494	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66184912	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6959002	ENSG00000237310.1	GS1-124K5.4	-3.46	0.000579	0.0345	-0.18	-0.16	Diabetic kidney disease;	chr7:66185509	chr7:66493706~66495474:+
THCA	cis	rs2562456	0.652	rs4809145	ENSG00000268658.4	LINC00664	3.46	0.000579	0.0345	0.25	0.16	Pain;	chr19:21597907	chr19:21483374~21503238:+
THCA	cis	rs10043228	1	rs10079394	ENSG00000250015.1	CTC-339F2.2	3.46	0.000579	0.0345	0.24	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116265222	chr5:116302354~116304134:-
THCA	cis	rs3800688	0.527	rs1684174	ENSG00000236753.4	MKLN1-AS	-3.46	0.000579	0.0345	-0.15	-0.16	Hypertension;	chr7:131482234	chr7:131309744~131328222:-
THCA	cis	rs72765298	0.848	rs10986626	ENSG00000235332.2	RP11-366O20.5	-3.46	0.000579	0.0345	-0.24	-0.16	Pulse pressure;	chr9:125186042	chr9:125194649~125195821:-
THCA	cis	rs12544026	0.679	rs1272384	ENSG00000253669.3	KB-1732A1.1	-3.46	0.000579	0.0345	-0.18	-0.16	Major depression and alcohol dependence;	chr8:101842055	chr8:102805517~102809971:+
THCA	cis	rs3770081	1	rs2289237	ENSG00000273080.1	RP11-301O19.1	3.46	0.00058	0.0345	0.38	0.16	Facial emotion recognition (sad faces);	chr2:86039151	chr2:86195590~86196049:+
THCA	cis	rs7246760	0.881	rs68018725	ENSG00000277587.1	CTD-3116E22.8	-3.46	0.00058	0.0345	-0.38	-0.16	Pursuit maintenance gain;	chr19:9745243	chr19:9721903~9722410:+
THCA	cis	rs3750082	0.817	rs3750078	ENSG00000205763.12	RP9P	-3.46	0.00058	0.0345	-0.13	-0.16	Glomerular filtration rate (creatinine);	chr7:32929877	chr7:32916815~32943176:-
THCA	cis	rs10832963	0.924	rs10500834	ENSG00000256361.1	RP11-613F22.6	3.46	0.00058	0.0345	0.2	0.16	Breast cancer;	chr11:18617165	chr11:18511043~18511475:-
THCA	cis	rs7267979	0.545	rs6050426	ENSG00000274973.1	RP13-401N8.7	-3.46	0.00058	0.0345	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25197629	chr20:25845497~25845862:+
THCA	cis	rs7219021	0.55	rs35929648	ENSG00000248278.1	SUMO2P17	3.46	0.00058	0.0345	0.2	0.16	Schizophrenia or bipolar disorder;	chr17:48925181	chr17:48874860~48908983:-
THCA	cis	rs10805346	0.531	rs12498927	ENSG00000261490.1	RP11-448G15.3	-3.46	0.00058	0.0345	-0.1	-0.16	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10113899	chr4:10068089~10073019:-
THCA	cis	rs2180341	0.814	rs6569488	ENSG00000220522.2	RP1-177A13.1	3.46	0.00058	0.0345	0.19	0.16	Breast cancer;	chr6:127405111	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.814	rs9385424	ENSG00000220522.2	RP1-177A13.1	3.46	0.00058	0.0345	0.19	0.16	Breast cancer;	chr6:127405651	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.814	rs9401958	ENSG00000220522.2	RP1-177A13.1	3.46	0.00058	0.0345	0.19	0.16	Breast cancer;	chr6:127415212	chr6:127416535~127416952:-
THCA	cis	rs5751614	0.537	rs9608093	ENSG00000236611.1	AP000343.2	-3.46	0.00058	0.0345	-0.21	-0.16	Height;	chr22:23271352	chr22:23326616~23328493:+
THCA	cis	rs9527	0.615	rs10883804	ENSG00000236937.2	PTGES3P4	3.46	0.00058	0.0345	0.21	0.16	Arsenic metabolism;	chr10:102946763	chr10:102845595~102845950:+
THCA	cis	rs61160187	0.51	rs4482855	ENSG00000272308.1	RP11-231G3.1	-3.46	0.00058	0.0345	-0.16	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60800670	chr5:60866457~60866935:-
THCA	cis	rs10435719	0.746	rs58007588	ENSG00000255495.1	AC145124.2	3.46	0.00058	0.0345	0.19	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:12194467~12196280:+
THCA	cis	rs2638953	0.924	rs10843169	ENSG00000247934.4	RP11-967K21.1	3.46	0.00058	0.0345	0.16	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430051	chr12:28163298~28190738:-
THCA	cis	rs7241918	0.538	rs6507939	ENSG00000267444.1	SMUG1P1	3.46	0.00058	0.0345	0.21	0.16	Cholesterol, total;HDL cholesterol;	chr18:49649891	chr18:49650350~49651160:+
THCA	cis	rs1185460	0.547	rs1784559	ENSG00000272186.1	RP11-110I1.13	3.46	0.00058	0.0345	0.15	0.16	Coronary artery disease;	chr11:119030904	chr11:119067374~119067698:-
THCA	cis	rs1185460	0.527	rs693619	ENSG00000272186.1	RP11-110I1.13	3.46	0.00058	0.0345	0.15	0.16	Coronary artery disease;	chr11:119031235	chr11:119067374~119067698:-
THCA	cis	rs6600671	1	rs4844380	ENSG00000233029.3	RP11-439A17.9	-3.46	0.00058	0.0345	-0.18	-0.16	Hip geometry;	chr1:121451764	chr1:121090289~121097655:-
THCA	cis	rs9959145	0.866	rs78596711	ENSG00000267199.1	RP11-861E21.2	3.46	0.00058	0.0345	0.2	0.16	Immune response to smallpox vaccine (IL-6);	chr18:12732779	chr18:12438890~12448205:+
THCA	cis	rs2652822	0.525	rs2899691	ENSG00000259459.4	RP11-321G12.1	-3.46	0.00058	0.0345	-0.13	-0.16	Metabolic traits;	chr15:63226889	chr15:63390136~63438320:+
THCA	cis	rs972578	0.837	rs3788601	ENSG00000230319.1	AL022476.2	3.46	0.00058	0.0345	0.16	0.16	Mean platelet volume;	chr22:42931520	chr22:43038585~43052366:+
THCA	cis	rs6561151	0.957	rs2121034	ENSG00000274001.1	RP11-5G9.5	3.46	0.00058	0.0345	0.2	0.16	Crohn's disease;	chr13:43899730	chr13:43877715~43878163:-
THCA	cis	rs3824488	0.79	rs28520225	ENSG00000271384.1	RP11-435O5.7	-3.46	0.00058	0.0345	-0.23	-0.16	Neuroticism;	chr9:95480905	chr9:95406990~95407662:-
THCA	cis	rs4650608	1	rs4650608	ENSG00000235927.4	NEXN-AS1	-3.46	0.00058	0.0345	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;Schizophrenia or bipolar disorder;	chr1:78772330	chr1:77881348~77889539:-
THCA	cis	rs2554380	0.943	rs2585038	ENSG00000230373.7	GOLGA6L5P	-3.46	0.00058	0.0345	-0.19	-0.16	Height;	chr15:83668506	chr15:84507885~84516814:-
THCA	cis	rs494562	0.73	rs9450270	ENSG00000203875.9	SNHG5	-3.46	0.00058	0.0345	-0.25	-0.16	Metabolic traits;Blood metabolite levels;	chr6:85405048	chr6:85660950~85678736:-
THCA	cis	rs1560104	0.597	rs12708757	ENSG00000260601.1	RP11-552C15.1	-3.46	0.00058	0.0345	-0.2	-0.16	Obesity-related traits;	chr16:12616724	chr16:12545482~12546684:+
THCA	cis	rs4869313	0.642	rs2247650	ENSG00000247121.5	CTD-2260A17.2	3.46	0.00058	0.0345	0.12	0.16	Pediatric autoimmune diseases;	chr5:96894046	chr5:96814028~96935809:-
THCA	cis	rs3785309	0.519	rs72765807	ENSG00000268836.1	LA16c-OS12.2	-3.46	0.00058	0.0345	-0.27	-0.16	Immature fraction of reticulocytes;	chr16:229886	chr16:185748~186294:-
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000281021.1	RP1-12G14.9	3.46	0.00058	0.0345	0.16	0.16	Lung cancer;	chr6:149753911	chr6:149576089~149590864:-
THCA	cis	rs9911578	0.765	rs66954617	ENSG00000224738.1	AC099850.1	3.46	0.00058	0.0345	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58922066	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs1971659	ENSG00000224738.1	AC099850.1	3.46	0.00058	0.0345	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58927426	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs8071280	ENSG00000224738.1	AC099850.1	3.46	0.00058	0.0345	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58932864	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs7207693	ENSG00000224738.1	AC099850.1	3.46	0.00058	0.0345	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58939164	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs12936058	ENSG00000224738.1	AC099850.1	3.46	0.00058	0.0345	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58940059	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs9892795	ENSG00000224738.1	AC099850.1	3.46	0.00058	0.0345	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58945693	chr17:59106598~59118267:+
THCA	cis	rs9911578	1	rs6503887	ENSG00000224738.1	AC099850.1	3.46	0.00058	0.0345	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58915959	chr17:59106598~59118267:+
THCA	cis	rs7193343	0.623	rs4140672	ENSG00000280092.1	AC002044.3	3.46	0.00058	0.0345	0.27	0.16	Ischemic stroke (cardioembolic);Atrial fibrillation;	chr16:72974358	chr16:73005601~73006141:-
THCA	cis	rs6598541	0.925	rs1976668	ENSG00000278090.1	RP11-6O2.2	-3.46	0.00058	0.0345	-0.14	-0.16	Urate levels;	chr15:98737963	chr15:99028538~99031053:+
THCA	cis	rs7819412	0.618	rs10105377	ENSG00000255046.1	RP11-297N6.4	3.46	0.00058	0.0345	0.17	0.16	Triglycerides;	chr8:11118223	chr8:11797928~11802568:-
THCA	cis	rs10266483	0.921	rs683510	ENSG00000234338.1	RP11-797H7.1	3.46	0.000581	0.0345	0.11	0.16	Response to statin therapy;	chr7:64288983	chr7:64835280~64836882:-
THCA	cis	rs10266483	0.881	rs665452	ENSG00000234338.1	RP11-797H7.1	3.46	0.000581	0.0345	0.11	0.16	Response to statin therapy;	chr7:64289077	chr7:64835280~64836882:-
THCA	cis	rs6802315	0.604	rs9881462	ENSG00000271778.1	RP11-379F4.8	3.46	0.000581	0.0345	0.16	0.16	Periodontitis (CDC/AAP);	chr3:158763333	chr3:158782547~158783124:+
THCA	cis	rs8077577	0.945	rs9916193	ENSG00000273018.4	CTD-2303H24.2	-3.46	0.000581	0.0345	-0.25	-0.16	Obesity-related traits;	chr17:18153901	chr17:18511221~18551705:-
THCA	cis	rs2034650	0.544	rs2289331	ENSG00000259211.1	RP11-64K12.8	-3.46	0.000581	0.0345	-0.14	-0.16	Interstitial lung disease;	chr15:40407739	chr15:40464193~40466726:-
THCA	cis	rs12935418	0.616	rs11859567	ENSG00000261838.4	RP11-303E16.6	3.46	0.000581	0.0345	0.22	0.16	Mean corpuscular volume;	chr16:80935951	chr16:81069854~81076598:+
THCA	cis	rs964611	0.706	rs4775755	ENSG00000259488.2	RP11-154J22.1	3.46	0.000581	0.0345	0.14	0.16	Metabolite levels (Pyroglutamine);	chr15:48370282	chr15:48312353~48331856:-
THCA	cis	rs7760535	0.711	rs240965	ENSG00000271789.1	RP5-1112D6.7	-3.46	0.000581	0.0345	-0.17	-0.16	Metabolic traits;	chr6:111323321	chr6:111297126~111298510:+
THCA	cis	rs6787172	0.622	rs2362970	ENSG00000272087.1	RP11-379F4.7	3.46	0.000581	0.0345	0.14	0.16	Subjective well-being;	chr3:158412854	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs4679828	ENSG00000272087.1	RP11-379F4.7	3.46	0.000581	0.0345	0.14	0.16	Subjective well-being;	chr3:158414799	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs12629125	ENSG00000272087.1	RP11-379F4.7	3.46	0.000581	0.0345	0.14	0.16	Subjective well-being;	chr3:158415481	chr3:158693120~158693768:-
THCA	cis	rs9457247	0.544	rs6920858	ENSG00000235272.1	FAM103A2P	3.46	0.000581	0.0345	0.22	0.16	Crohn's disease;	chr6:167051142	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.602	rs9459854	ENSG00000235272.1	FAM103A2P	3.46	0.000581	0.0345	0.22	0.16	Crohn's disease;	chr6:167052394	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.624	rs9457260	ENSG00000235272.1	FAM103A2P	3.46	0.000581	0.0345	0.22	0.16	Crohn's disease;	chr6:167053177	chr6:166586124~166586477:-
THCA	cis	rs9457247	0.624	rs17524252	ENSG00000235272.1	FAM103A2P	3.46	0.000581	0.0345	0.22	0.16	Crohn's disease;	chr6:167053490	chr6:166586124~166586477:-
THCA	cis	rs2573652	0.723	rs4577068	ENSG00000254744.3	CTD-3076O17.1	-3.46	0.000581	0.0345	-0.17	-0.16	Height;	chr15:99975754	chr15:99970215~99974010:+
THCA	cis	rs4218	0.517	rs2899640	ENSG00000277144.1	RP11-59H7.4	-3.46	0.000581	0.0345	-0.22	-0.16	Social communication problems;	chr15:59060281	chr15:59115547~59116089:-
THCA	cis	rs2130392	0.886	rs3806796	ENSG00000250726.1	RP11-616K6.1	3.46	0.000581	0.0346	0.19	0.16	Kawasaki disease;	chr4:184730993	chr4:184072403~184073039:+
THCA	cis	rs1928480	0.581	rs35001397	ENSG00000234618.1	RPSAP9	-3.46	0.000581	0.0346	-0.19	-0.16	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr9:77071935	chr9:76398699~76399586:+
THCA	cis	rs9860428	0.844	rs9845041	ENSG00000243795.1	RP11-572M11.3	3.46	0.000581	0.0346	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905212	chr3:113142350~113167819:-
THCA	cis	rs17407555	0.683	rs6833035	ENSG00000250413.1	RP11-448G15.1	-3.46	0.000581	0.0346	-0.17	-0.16	Schizophrenia (age at onset);	chr4:10270645	chr4:10006482~10009725:+
THCA	cis	rs910316	0.967	rs175451	ENSG00000273565.1	CTD-3075F15.1	-3.46	0.000581	0.0346	-0.19	-0.16	Height;	chr14:75123026	chr14:75176929~75177418:+
THCA	cis	rs6546550	0.901	rs6721891	ENSG00000179818.12	PCBP1-AS1	-3.46	0.000581	0.0346	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69918989	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.901	rs6750488	ENSG00000179818.12	PCBP1-AS1	-3.46	0.000581	0.0346	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69918993	chr2:69962263~70103220:-
THCA	cis	rs7824557	0.836	rs765731	ENSG00000255310.2	AF131215.2	-3.46	0.000581	0.0346	-0.13	-0.16	Retinal vascular caliber;	chr8:11263989	chr8:11107788~11109726:-
THCA	cis	rs9532580	0.71	rs9577090	ENSG00000275149.1	RP11-427J23.1	-3.46	0.000581	0.0346	-0.21	-0.16	Mean corpuscular hemoglobin;	chr13:40651091	chr13:40079106~40273509:-
THCA	cis	rs9532580	0.553	rs9549250	ENSG00000275149.1	RP11-427J23.1	-3.46	0.000581	0.0346	-0.21	-0.16	Mean corpuscular hemoglobin;	chr13:40651092	chr13:40079106~40273509:-
THCA	cis	rs4948275	0.742	rs2937153	ENSG00000233643.2	RP11-491H19.1	3.46	0.000581	0.0346	0.18	0.16	Night sleep phenotypes;	chr10:61478029	chr10:61781745~61821246:-
THCA	cis	rs4788570	0.584	rs4788548	ENSG00000260185.1	RP11-432I5.6	-3.46	0.000581	0.0346	-0.29	-0.16	Intelligence (multi-trait analysis);	chr16:71621458	chr16:71655027~71664212:+
THCA	cis	rs1927790	0.643	rs927710	ENSG00000247400.3	DNAJC3-AS1	-3.46	0.000581	0.0346	-0.11	-0.16	Body mass index;	chr13:96352542	chr13:95648733~95676925:-
THCA	cis	rs4660456	0.913	rs12727412	ENSG00000238287.1	RP11-656D10.3	-3.46	0.000581	0.0346	-0.2	-0.16	Platelet count;	chr1:40723243	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs6675886	ENSG00000238287.1	RP11-656D10.3	-3.46	0.000581	0.0346	-0.2	-0.16	Platelet count;	chr1:40727955	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs1494	ENSG00000238287.1	RP11-656D10.3	3.46	0.000581	0.0346	0.2	0.16	Platelet count;	chr1:40706176	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.869	rs7518344	ENSG00000238287.1	RP11-656D10.3	3.46	0.000581	0.0346	0.2	0.16	Platelet count;	chr1:40708327	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.827	rs10736404	ENSG00000238287.1	RP11-656D10.3	3.46	0.000581	0.0346	0.2	0.16	Platelet count;	chr1:40710331	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs2744799	ENSG00000238287.1	RP11-656D10.3	3.46	0.000581	0.0346	0.2	0.16	Platelet count;	chr1:40719862	chr1:40493157~40508661:-
THCA	cis	rs7264396	0.635	rs6119672	ENSG00000088340.14	FER1L4	3.46	0.000581	0.0346	0.16	0.16	Total cholesterol levels;	chr20:35891845	chr20:35558737~35607562:-
THCA	cis	rs3758911	0.894	rs11212156	ENSG00000255353.1	RP11-382M14.1	-3.46	0.000581	0.0346	-0.2	-0.16	Coronary artery disease;	chr11:107323381	chr11:107176286~107177530:+
THCA	cis	rs6546886	0.871	rs13027623	ENSG00000235499.1	AC073046.25	3.46	0.000581	0.0346	0.15	0.16	Dialysis-related mortality;	chr2:74026350	chr2:73985132~73986343:+
THCA	cis	rs4971059	0.629	rs11264333	ENSG00000225855.5	RUSC1-AS1	3.46	0.000581	0.0346	0.1	0.16	Breast cancer;	chr1:155135811	chr1:155316863~155324176:-
THCA	cis	rs4604234	0.803	rs28888768	ENSG00000260645.1	RP11-250B2.5	-3.46	0.000581	0.0346	-0.26	-0.16	Cancer;	chr6:80311913	chr6:80466958~80469080:+
THCA	cis	rs72634258	0.554	rs12061787	ENSG00000224315.2	RPL7P7	-3.46	0.000581	0.0346	-0.29	-0.16	Inflammatory bowel disease;	chr1:7828670	chr1:8786211~8786913:-
THCA	cis	rs11960179	0.892	rs17257792	ENSG00000250066.1	RP11-141O11.1	-3.46	0.000581	0.0346	-0.29	-0.16	Glomerular filtration rate (creatinine);	chr5:68516701	chr5:68963246~68967845:+
THCA	cis	rs2180341	0.961	rs7774468	ENSG00000220522.2	RP1-177A13.1	3.46	0.000582	0.0346	0.21	0.16	Breast cancer;	chr6:127271356	chr6:127416535~127416952:-
THCA	cis	rs2191566	0.96	rs56171514	ENSG00000267114.1	CTB-129P6.11	3.46	0.000582	0.0346	0.12	0.16	Acute lymphoblastic leukemia (childhood);	chr19:44001958	chr19:44950044~44954007:-
THCA	cis	rs3785574	0.962	rs4480868	ENSG00000279369.1	RP11-51F16.1	3.46	0.000582	0.0346	0.11	0.16	Height;	chr17:63711499	chr17:63700847~63702670:+
THCA	cis	rs577676	0.564	rs619699	ENSG00000271811.1	RP1-79C4.4	3.46	0.000582	0.0346	0.2	0.16	Prevalent atrial fibrillation;	chr1:170648238	chr1:170667381~170669425:+
THCA	cis	rs301901	0.772	rs10061157	ENSG00000250155.1	CTD-2353F22.1	3.46	0.000582	0.0346	0.16	0.16	Height;	chr5:37161516	chr5:36666214~36725195:-
THCA	cis	rs2797160	0.935	rs1739372	ENSG00000226409.1	RP11-735G4.1	3.46	0.000582	0.0346	0.19	0.16	Endometrial cancer;	chr6:125690179	chr6:125370211~125374324:-
THCA	cis	rs4081724	0.638	rs1423064	ENSG00000267296.2	CEBPA-AS1	3.46	0.000582	0.0346	0.21	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33355730	chr19:33302857~33305054:+
THCA	cis	rs9487051	1	rs9487051	ENSG00000260273.1	RP11-425D10.10	3.46	0.000582	0.0346	0.2	0.16	Reticulocyte fraction of red cells;	chr6:109295876	chr6:109382795~109383666:+
THCA	cis	rs4699052	1	rs6533060	ENSG00000230069.3	LRRC37A15P	-3.46	0.000582	0.0346	-0.16	-0.16	Testicular germ cell tumor;	chr4:103218839	chr4:102727274~102730721:-
THCA	cis	rs11089937	0.512	rs34963809	ENSG00000215456.5	BCRP4	3.46	0.000582	0.0346	0.2	0.16	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.568	rs35626600	ENSG00000215456.5	BCRP4	3.46	0.000582	0.0346	0.2	0.16	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.539	rs34228957	ENSG00000215456.5	BCRP4	3.46	0.000582	0.0346	0.2	0.16	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22630061~22636153:+
THCA	cis	rs7631605	0.905	rs11129752	ENSG00000224080.1	UBE2FP1	-3.46	0.000582	0.0346	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:37216302	chr3:37143512~37143958:-
THCA	cis	rs9399599	0.902	rs9373523	ENSG00000233452.5	STXBP5-AS1	3.46	0.000582	0.0346	0.16	0.16	Plasma plasminogen activator levels;	chr6:147379997	chr6:146841901~147204614:-
THCA	cis	rs71478720	0.868	rs5744222	ENSG00000214264.4	KCTD9P4	3.46	0.000582	0.0346	0.2	0.16	Interleukin-18 levels;	chr11:112166291	chr11:112180773~112183191:+
THCA	cis	rs71478720	0.953	rs7131094	ENSG00000214264.4	KCTD9P4	3.46	0.000582	0.0346	0.2	0.16	Interleukin-18 levels;	chr11:112174194	chr11:112180773~112183191:+
THCA	cis	rs71478720	0.953	rs7121554	ENSG00000214264.4	KCTD9P4	3.46	0.000582	0.0346	0.2	0.16	Interleukin-18 levels;	chr11:112177328	chr11:112180773~112183191:+
THCA	cis	rs71478720	0.903	rs12797880	ENSG00000214264.4	KCTD9P4	3.46	0.000582	0.0346	0.2	0.16	Interleukin-18 levels;	chr11:112178468	chr11:112180773~112183191:+
THCA	cis	rs938554	0.784	rs4481233	ENSG00000261490.1	RP11-448G15.3	3.46	0.000582	0.0346	0.14	0.16	Blood metabolite levels;	chr4:9954455	chr4:10068089~10073019:-
THCA	cis	rs12129938	0.911	rs12130559	ENSG00000231940.1	RPS7P3	3.46	0.000582	0.0346	0.21	0.16	Thyroid cancer;	chr1:233276358	chr1:233288868~233289447:-
THCA	cis	rs1891275	0.515	rs2153653	ENSG00000232709.1	MARK2P9	3.46	0.000582	0.0346	0.18	0.16	Intelligence (multi-trait analysis);	chr10:91736169	chr10:92418667~92420875:+
THCA	cis	rs1891275	0.508	rs2096079	ENSG00000232709.1	MARK2P9	3.46	0.000582	0.0346	0.18	0.16	Intelligence (multi-trait analysis);	chr10:91736910	chr10:92418667~92420875:+
THCA	cis	rs10043228	1	rs10066259	ENSG00000250015.1	CTC-339F2.2	3.46	0.000582	0.0346	0.24	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116116195	chr5:116302354~116304134:-
THCA	cis	rs8031584	0.672	rs17815726	ENSG00000178081.11	ULK4P3	-3.46	0.000582	0.0346	-0.22	-0.16	Huntington's disease progression;	chr15:31021049	chr15:30103720~30131757:+
THCA	cis	rs9392556	0.829	rs619873	ENSG00000230648.1	RP3-406P24.3	3.46	0.000582	0.0346	0.2	0.16	Blood metabolite levels;	chr6:4107221	chr6:4018843~4021215:-
THCA	cis	rs1729951	0.546	rs361246	ENSG00000239213.4	NCK1-AS1	3.46	0.000582	0.0346	0.14	0.16	Neuroticism;	chr3:136976825	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs361241	ENSG00000239213.4	NCK1-AS1	3.46	0.000582	0.0346	0.14	0.16	Neuroticism;	chr3:136980719	chr3:136841726~136862054:-
THCA	cis	rs9878978	0.691	rs13064000	ENSG00000227588.2	CNTN4-AS2	3.46	0.000582	0.0346	0.21	0.16	Blood pressure (smoking interaction);	chr3:2398387	chr3:2110409~2144241:-
THCA	cis	rs6473252	0.584	rs735839	ENSG00000254162.1	RP11-48B3.3	-3.46	0.000582	0.0346	-0.14	-0.16	Breast cancer;	chr8:80896019	chr8:80535006~80539135:-
THCA	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-3.46	0.000582	0.0346	-0.18	-0.16	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
THCA	cis	rs17331151	0.505	rs35225119	ENSG00000242142.1	SERBP1P3	-3.46	0.000582	0.0346	-0.34	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52589449	chr3:53064283~53065091:-
THCA	cis	rs17331151	0.505	rs71299610	ENSG00000242142.1	SERBP1P3	-3.46	0.000582	0.0346	-0.34	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52607687	chr3:53064283~53065091:-
THCA	cis	rs17331151	0.505	rs13086936	ENSG00000242142.1	SERBP1P3	-3.46	0.000582	0.0346	-0.34	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52625063	chr3:53064283~53065091:-
THCA	cis	rs9843304	0.529	rs34895718	ENSG00000243885.1	RP11-278L15.2	3.46	0.000582	0.0346	0.17	0.16	Gallstone disease;	chr3:149487430	chr3:149384179~149385800:-
THCA	cis	rs5751168	0.598	rs7290828	ENSG00000240160.3	RN7SL263P	3.46	0.000582	0.0346	0.24	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22509461	chr22:23261782~23262071:-
THCA	cis	rs9828933	0.752	rs28675788	ENSG00000224479.4	AC136289.1	3.46	0.000582	0.0346	0.25	0.16	Type 2 diabetes;	chr3:63956512	chr3:63742293~63827445:-
THCA	cis	rs2434529	0.531	rs80336253	ENSG00000245275.6	SAP30L-AS1	3.46	0.000582	0.0346	0.22	0.16	Autism spectrum disorder or schizophrenia;	chr5:154200245	chr5:154329437~154445850:-
THCA	cis	rs12887734	0.524	rs17791722	ENSG00000269958.1	RP11-73M18.8	3.46	0.000582	0.0346	0.15	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103819873	chr14:103696353~103697163:+
THCA	cis	rs929354	0.742	rs3808316	ENSG00000224629.1	RP5-1142J19.2	-3.46	0.000582	0.0346	-0.15	-0.16	Body mass index;	chr7:157152093	chr7:157263022~157263229:-
THCA	cis	rs11083475	0.686	rs73040728	ENSG00000269050.1	CTC-360G5.6	-3.46	0.000582	0.0346	-0.18	-0.16	Heart rate;	chr19:38766961	chr19:38870159~38873763:+
THCA	cis	rs17120471	1	rs17120471	ENSG00000255052.4	FAM66D	3.46	0.000582	0.0346	0.26	0.16	IgG glycosylation;	chr8:12834362	chr8:12115782~12177550:+
THCA	cis	rs3784262	0.565	rs4646606	ENSG00000259250.1	RP11-50C13.1	-3.46	0.000582	0.0346	-0.13	-0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57995328	chr15:58587507~58591676:+
THCA	cis	rs34975555	1	rs35935919	ENSG00000253944.1	RP11-156K13.1	-3.46	0.000582	0.0346	-0.29	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17997270	chr8:17801345~17861069:+
THCA	cis	rs990871	0.61	rs1072882	ENSG00000227207.2	RPL31P12	-3.46	0.000582	0.0346	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72387312	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs1599334	ENSG00000227207.2	RPL31P12	-3.46	0.000582	0.0346	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72400891	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs1838662	ENSG00000227207.2	RPL31P12	-3.46	0.000582	0.0346	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72408574	chr1:72301472~72301829:+
THCA	cis	rs6828577	1	rs6828577	ENSG00000281731.1	RP11-384K6.8	-3.46	0.000583	0.0346	-0.19	-0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118783346	chr4:118664087~118685341:-
THCA	cis	rs9425766	0.679	rs2143114	ENSG00000270084.1	GAS5-AS1	-3.46	0.000583	0.0346	-0.16	-0.16	Life satisfaction;	chr1:174192292	chr1:173863248~173863941:+
THCA	cis	rs7954584	0.635	rs11043242	ENSG00000274292.1	RP11-347I19.7	-3.46	0.000583	0.0346	-0.12	-0.16	Mean corpuscular volume;	chr12:121918387	chr12:121800797~121803403:+
THCA	cis	rs8035452	1	rs12910371	ENSG00000273674.3	CTD-2378E12.1	3.46	0.000583	0.0346	0.2	0.16	Alzheimer's disease (late onset);	chr15:50725380	chr15:50839875~50908599:-
THCA	cis	rs8035452	1	rs11855605	ENSG00000273674.3	CTD-2378E12.1	3.46	0.000583	0.0346	0.2	0.16	Alzheimer's disease (late onset);	chr15:50726920	chr15:50839875~50908599:-
THCA	cis	rs9534288	0.789	rs4942470	ENSG00000235903.6	CPB2-AS1	3.46	0.000583	0.0346	0.24	0.16	Blood protein levels;	chr13:46062517	chr13:46052806~46113332:+
THCA	cis	rs6860806	0.661	rs334902	ENSG00000263597.1	MIR3936	3.46	0.000583	0.0346	0.15	0.16	Breast cancer;	chr5:132250866	chr5:132365490~132365599:-
THCA	cis	rs7176527	0.8	rs56747535	ENSG00000176700.18	SCAND2P	3.46	0.000583	0.0346	0.14	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:84631451~84647478:+
THCA	cis	rs34975555	0.892	rs2285307	ENSG00000253671.1	RP11-806O11.1	-3.46	0.000583	0.0346	-0.25	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17969034	chr8:17808941~17820868:+
THCA	cis	rs9425766	0.679	rs6656188	ENSG00000270084.1	GAS5-AS1	-3.46	0.000583	0.0346	-0.16	-0.16	Life satisfaction;	chr1:174183550	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs12087441	ENSG00000270084.1	GAS5-AS1	-3.46	0.000583	0.0346	-0.16	-0.16	Life satisfaction;	chr1:174188696	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs4652237	ENSG00000270084.1	GAS5-AS1	-3.46	0.000583	0.0346	-0.16	-0.16	Life satisfaction;	chr1:174189718	chr1:173863248~173863941:+
THCA	cis	rs3808502	0.526	rs7823100	ENSG00000206014.6	OR7E161P	3.46	0.000583	0.0346	0.19	0.16	Neuroticism;	chr8:11564982	chr8:11928597~11929563:-
THCA	cis	rs3808502	0.526	rs7823101	ENSG00000206014.6	OR7E161P	3.46	0.000583	0.0346	0.19	0.16	Neuroticism;	chr8:11564983	chr8:11928597~11929563:-
THCA	cis	rs3808502	0.526	rs11985709	ENSG00000206014.6	OR7E161P	3.46	0.000583	0.0346	0.19	0.16	Neuroticism;	chr8:11565574	chr8:11928597~11929563:-
THCA	cis	rs9611565	0.659	rs17367849	ENSG00000237037.8	NDUFA6-AS1	3.46	0.000583	0.0346	0.15	0.16	Vitiligo;	chr22:41527640	chr22:42090931~42137742:+
THCA	cis	rs7829975	0.564	rs2976855	ENSG00000253130.1	CTD-3023L14.2	-3.46	0.000583	0.0346	-0.17	-0.16	Mood instability;	chr8:8444284	chr8:8561391~8569688:+
THCA	cis	rs988712	0.881	rs4923456	ENSG00000245573.6	BDNF-AS	3.46	0.000583	0.0347	0.14	0.16	Obesity;	chr11:27587580	chr11:27506838~27698174:+
THCA	cis	rs7550636	0.658	rs1775686	ENSG00000276735.1	Metazoa_SRP	3.46	0.000583	0.0347	0.19	0.16	Coronary artery calcification;	chr1:192841037	chr1:193236794~193237107:-
THCA	cis	rs7572644	0.723	rs13023003	ENSG00000223522.1	AC093690.1	-3.46	0.000583	0.0347	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27809270	chr2:28307691~28310459:-
THCA	cis	rs7259376	0.807	rs7254434	ENSG00000269138.1	ZNF209P	3.46	0.000583	0.0347	0.16	0.16	Menopause (age at onset);	chr19:22317231	chr19:22463922~22473036:+
THCA	cis	rs10129255	1	rs10134517	ENSG00000274576.2	IGHV2-70	3.46	0.000583	0.0347	0.11	0.16	Kawasaki disease;	chr14:106718498	chr14:106770577~106771020:-
THCA	cis	rs1891275	0.515	rs7911755	ENSG00000232709.1	MARK2P9	3.46	0.000583	0.0347	0.18	0.16	Intelligence (multi-trait analysis);	chr10:91730060	chr10:92418667~92420875:+
THCA	cis	rs4650376	0.789	rs7529603	ENSG00000238015.2	RP4-641G12.3	3.46	0.000583	0.0347	0.27	0.16	IgG glycosylation;	chr1:78768196	chr1:78666272~78666695:+
THCA	cis	rs881375	0.933	rs4837804	ENSG00000270917.1	RP11-27I1.6	-3.46	0.000583	0.0347	-0.22	-0.16	Rheumatoid arthritis;	chr9:120943026	chr9:120812475~120812845:-
THCA	cis	rs561341	0.941	rs112569713	ENSG00000265798.5	RP11-271K11.5	3.46	0.000583	0.0347	0.23	0.16	Hip circumference adjusted for BMI;	chr17:31944719	chr17:31038575~31059121:-
THCA	cis	rs4948275	0.693	rs2787705	ENSG00000233643.2	RP11-491H19.1	3.46	0.000583	0.0347	0.18	0.16	Night sleep phenotypes;	chr10:61554198	chr10:61781745~61821246:-
THCA	cis	rs78487399	0.908	rs17031088	ENSG00000234936.1	AC010883.5	3.46	0.000583	0.0347	0.19	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43579951	chr2:43229573~43233394:+
THCA	cis	rs964611	0.816	rs12438598	ENSG00000259488.2	RP11-154J22.1	-3.46	0.000583	0.0347	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48248812	chr15:48312353~48331856:-
THCA	cis	rs964611	0.816	rs8034192	ENSG00000259488.2	RP11-154J22.1	-3.46	0.000583	0.0347	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48249197	chr15:48312353~48331856:-
THCA	cis	rs964611	0.816	rs8033965	ENSG00000259488.2	RP11-154J22.1	-3.46	0.000583	0.0347	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48249316	chr15:48312353~48331856:-
THCA	cis	rs964611	0.816	rs2279367	ENSG00000259488.2	RP11-154J22.1	-3.46	0.000583	0.0347	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48249907	chr15:48312353~48331856:-
THCA	cis	rs10940346	0.777	rs11744698	ENSG00000271752.1	RP11-269M20.3	3.46	0.000583	0.0347	0.15	0.16	Schizophrenia;	chr5:50586024	chr5:50662859~50663266:-
THCA	cis	rs13201294	1	rs13201294	ENSG00000220721.1	OR1F12	3.46	0.000583	0.0347	0.28	0.16	Squamous cell lung carcinoma;	chr6:27588362	chr6:28073316~28074233:+
THCA	cis	rs6496044	0.963	rs6496050	ENSG00000259276.1	RP11-815J21.3	-3.46	0.000583	0.0347	-0.17	-0.16	Interstitial lung disease;	chr15:85526019	chr15:85621264~85627689:-
THCA	cis	rs5756506	0.758	rs130618	ENSG00000233360.4	Z83844.1	-3.46	0.000583	0.0347	-0.17	-0.16	Hematological parameters;	chr22:37039403	chr22:37641832~37658377:-
THCA	cis	rs2880765	0.805	rs34598679	ENSG00000259407.1	RP11-158M2.3	-3.46	0.000583	0.0347	-0.16	-0.16	Coronary artery disease;	chr15:85498974	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.835	rs4344688	ENSG00000259407.1	RP11-158M2.3	-3.46	0.000583	0.0347	-0.16	-0.16	Coronary artery disease;	chr15:85499776	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.835	rs4280192	ENSG00000259407.1	RP11-158M2.3	-3.46	0.000583	0.0347	-0.16	-0.16	Coronary artery disease;	chr15:85499789	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.835	rs7169632	ENSG00000259407.1	RP11-158M2.3	-3.46	0.000583	0.0347	-0.16	-0.16	Coronary artery disease;	chr15:85501436	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.835	rs12910373	ENSG00000259407.1	RP11-158M2.3	-3.46	0.000583	0.0347	-0.16	-0.16	Coronary artery disease;	chr15:85503571	chr15:85744109~85750281:-
THCA	cis	rs9487051	0.872	rs9487033	ENSG00000260273.1	RP11-425D10.10	-3.46	0.000583	0.0347	-0.19	-0.16	Reticulocyte fraction of red cells;	chr6:109284185	chr6:109382795~109383666:+
THCA	cis	rs11212260	0.737	rs656456	ENSG00000261098.1	RP11-819C21.1	-3.46	0.000583	0.0347	-0.32	-0.16	IgG glycosylation;	chr11:107488594	chr11:107312132~107316271:-
THCA	cis	rs11212260	0.85	rs494034	ENSG00000261098.1	RP11-819C21.1	-3.46	0.000583	0.0347	-0.32	-0.16	IgG glycosylation;	chr11:107489488	chr11:107312132~107316271:-
THCA	cis	rs2797160	1	rs1832979	ENSG00000226409.1	RP11-735G4.1	-3.46	0.000583	0.0347	-0.19	-0.16	Endometrial cancer;	chr6:125676290	chr6:125370211~125374324:-
THCA	cis	rs8053891	0.673	rs11645540	ENSG00000262140.1	RP11-417N10.3	3.46	0.000583	0.0347	0.22	0.16	Coronary artery disease;	chr16:71995031	chr16:71833787~71835932:+
THCA	cis	rs1396485	0.607	rs10076661	ENSG00000250015.1	CTC-339F2.2	3.46	0.000584	0.0347	0.17	0.16	Inflammatory biomarkers;	chr5:116093058	chr5:116302354~116304134:-
THCA	cis	rs7031325	0.962	rs2578283	ENSG00000229611.1	RP11-390F4.10	-3.46	0.000584	0.0347	-0.17	-0.16	Systemic lupus erythematosus;	chr9:6652997	chr9:6704471~6707780:+
THCA	cis	rs7142002	0.881	rs1904298	ENSG00000272444.1	RP11-1017G21.6	3.46	0.000584	0.0347	0.21	0.16	Autism;	chr14:101890138	chr14:101952416~101953063:+
THCA	cis	rs1421334	0.817	rs11783562	ENSG00000254109.4	RBPMS-AS1	3.46	0.000584	0.0347	0.16	0.16	Intelligence (multi-trait analysis);	chr8:30981030	chr8:30382119~30385401:-
THCA	cis	rs7246760	0.867	rs889177	ENSG00000277587.1	CTD-3116E22.8	-3.46	0.000584	0.0347	-0.39	-0.16	Pursuit maintenance gain;	chr19:9735549	chr19:9721903~9722410:+
THCA	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	3.46	0.000584	0.0347	0.18	0.16	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	3.46	0.000584	0.0347	0.18	0.16	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	3.46	0.000584	0.0347	0.18	0.16	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	3.46	0.000584	0.0347	0.18	0.16	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	3.46	0.000584	0.0347	0.18	0.16	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
THCA	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	3.46	0.000584	0.0347	0.18	0.16	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	3.46	0.000584	0.0347	0.18	0.16	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	3.46	0.000584	0.0347	0.18	0.16	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-3.46	0.000584	0.0347	-0.18	-0.16	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-3.46	0.000584	0.0347	-0.18	-0.16	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-3.46	0.000584	0.0347	-0.18	-0.16	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
THCA	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-3.46	0.000584	0.0347	-0.18	-0.16	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
THCA	cis	rs13064773	0.546	rs189303	ENSG00000240207.5	RP11-379F4.4	3.46	0.000584	0.0347	0.18	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158886979	chr3:158732263~158784070:+
THCA	cis	rs13064773	0.546	rs340242	ENSG00000240207.5	RP11-379F4.4	3.46	0.000584	0.0347	0.18	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158887260	chr3:158732263~158784070:+
THCA	cis	rs10916248	0.511	rs10916515	ENSG00000272645.2	RP11-504P24.8	-3.46	0.000584	0.0347	-0.13	-0.16	QT interval (drug interaction);	chr1:224222121	chr1:223951388~223953439:-
THCA	cis	rs10844154	0.638	rs2650124	ENSG00000277342.1	RP11-843B15.4	3.46	0.000584	0.0347	0.19	0.16	Emphysema-related traits;Weight;	chr12:32255044	chr12:32109076~32109602:+
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000184274.3	LINC00315	-3.46	0.000584	0.0347	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45300245~45305257:-
THCA	cis	rs7267979	0.527	rs6076369	ENSG00000276952.1	RP5-965G21.6	-3.46	0.000584	0.0347	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:25284915~25285588:-
THCA	cis	rs301901	0.634	rs4869429	ENSG00000250155.1	CTD-2353F22.1	3.46	0.000584	0.0347	0.16	0.16	Height;	chr5:37407777	chr5:36666214~36725195:-
THCA	cis	rs2034088	0.965	rs4968070	ENSG00000231784.7	DBIL5P	3.46	0.000584	0.0347	0.18	0.16	Hip circumference adjusted for BMI;	chr17:542922	chr17:752660~755336:+
THCA	cis	rs453301	0.686	rs6748	ENSG00000253981.4	ALG1L13P	-3.46	0.000584	0.0347	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9033292	chr8:8236003~8244667:-
THCA	cis	rs9876781	1	rs9311423	ENSG00000199476.1	Y_RNA	-3.46	0.000584	0.0347	-0.2	-0.16	Longevity;	chr3:48378818	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs7634377	ENSG00000199476.1	Y_RNA	-3.46	0.000584	0.0347	-0.2	-0.16	Longevity;	chr3:48379768	chr3:48288587~48288694:+
THCA	cis	rs513088	0.512	rs520343	ENSG00000225171.2	DUTP6	3.46	0.000584	0.0347	0.24	0.16	Schizophrenia;	chr1:166740505	chr1:166868748~166869209:+
THCA	cis	rs854765	0.616	rs8076747	ENSG00000281749.1	Y_RNA	3.46	0.000584	0.0347	0.2	0.16	Total body bone mineral density;	chr17:17950281	chr17:18001101~18001195:-
THCA	cis	rs35306767	0.761	rs11253557	ENSG00000229869.1	RP11-363N22.2	-3.46	0.000584	0.0347	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:997727	chr10:933026~942743:+
THCA	cis	rs3026101	0.671	rs8081480	ENSG00000234327.6	AC012146.7	-3.46	0.000584	0.0347	-0.13	-0.16	Body mass index;	chr17:5379466	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.671	rs8081481	ENSG00000234327.6	AC012146.7	-3.46	0.000584	0.0347	-0.13	-0.16	Body mass index;	chr17:5379468	chr17:5111468~5115004:+
THCA	cis	rs6600671	0.934	rs12131379	ENSG00000226067.5	CH17-118O6.2	3.46	0.000584	0.0347	0.16	0.16	Hip geometry;	chr1:121551639	chr1:120913275~121009291:+
THCA	cis	rs6723226	0.708	rs2710627	ENSG00000276517.1	AL133243.2	-3.46	0.000584	0.0347	-0.15	-0.16	Intelligence (multi-trait analysis);	chr2:32533560	chr2:32526504~32529507:+
THCA	cis	rs786425	0.502	rs7135542	ENSG00000270095.1	RP11-214K3.18	3.46	0.000584	0.0347	0.19	0.16	Pubertal anthropometrics;	chr12:123744882	chr12:123971457~123971714:-
THCA	cis	rs2905347	0.895	rs2961281	ENSG00000232949.1	AC002480.4	-3.46	0.000584	0.0347	-0.2	-0.16	Major depression and alcohol dependence;	chr7:22600673	chr7:22589705~22591622:+
THCA	cis	rs6580649	1	rs3825404	ENSG00000273765.1	RP11-370I10.11	3.46	0.000584	0.0347	0.17	0.16	Lung cancer;	chr12:48006148	chr12:48360920~48361377:+
THCA	cis	rs684232	0.666	rs838373	ENSG00000231784.7	DBIL5P	3.46	0.000584	0.0347	0.17	0.16	Prostate cancer;	chr17:663931	chr17:752660~755336:+
THCA	cis	rs1124769	0.619	rs28637301	ENSG00000259378.1	DCAF13P3	3.46	0.000584	0.0347	0.23	0.16	Cognitive performance;	chr15:51095051	chr15:50944663~50945996:+
THCA	cis	rs1864585	0.52	rs73208778	ENSG00000280294.1	RP11-177H2.1	3.46	0.000584	0.0347	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10812644	chr8:10856085~10859436:-
THCA	cis	rs7339483	0.867	rs7339599	ENSG00000233836.6	RP11-255H23.2	-3.46	0.000584	0.0347	-0.16	-0.16	Discordance in emotional problems in monozygotic twins;	chr19:24244352	chr19:23762944~23833314:+
THCA	cis	rs9650657	0.665	rs7002117	ENSG00000255310.2	AF131215.2	3.46	0.000584	0.0347	0.13	0.16	Neuroticism;	chr8:10758659	chr8:11107788~11109726:-
THCA	cis	rs6049003	0.655	rs6049065	ENSG00000270001.1	RP11-218C14.8	-3.46	0.000584	0.0347	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr20:23746617	chr20:23631826~23632316:-
THCA	cis	rs2652822	0.525	rs58789072	ENSG00000259459.4	RP11-321G12.1	-3.46	0.000584	0.0347	-0.12	-0.16	Metabolic traits;	chr15:63205354	chr15:63390136~63438320:+
THCA	cis	rs1153858	1	rs16952714	ENSG00000275672.1	GATM-AS1	-3.46	0.000584	0.0347	-0.16	-0.16	Homoarginine levels;	chr15:45358160	chr15:45378700~45380123:+
THCA	cis	rs7771547	0.519	rs6917489	ENSG00000224666.3	RP1-50J22.4	3.46	0.000584	0.0347	0.19	0.16	Platelet distribution width;	chr6:36400392	chr6:36386831~36393462:+
THCA	cis	rs7181230	0.845	rs4923852	ENSG00000275636.1	RP11-521C20.5	-3.46	0.000584	0.0347	-0.16	-0.16	Dehydroepiandrosterone sulphate levels;	chr15:40085664	chr15:40078892~40079347:+
THCA	cis	rs8177876	0.658	rs16954513	ENSG00000261838.4	RP11-303E16.6	3.46	0.000584	0.0347	0.33	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043599	chr16:81069854~81076598:+
THCA	cis	rs7267979	0.565	rs958075	ENSG00000276952.1	RP5-965G21.6	-3.46	0.000584	0.0347	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:25284915~25285588:-
THCA	cis	rs4908768	0.501	rs2045820	ENSG00000238249.2	HMGN2P17	-3.46	0.000584	0.0347	-0.18	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8893409~8894151:+
THCA	cis	rs7665090	0.806	rs7674004	ENSG00000248971.2	KRT8P46	-3.46	0.000584	0.0347	-0.18	-0.16	Primary biliary cholangitis;	chr4:102619156	chr4:102728746~102730171:-
THCA	cis	rs6479901	0.895	rs7082066	ENSG00000272767.1	JMJD1C-AS1	-3.46	0.000585	0.0347	-0.19	-0.16	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63465229~63466563:+
THCA	cis	rs2625529	0.668	rs34487006	ENSG00000260037.4	CTD-2524L6.3	-3.46	0.000585	0.0347	-0.22	-0.16	Red blood cell count;	chr15:72170009	chr15:71818396~71823384:+
THCA	cis	rs10940346	0.506	rs11741135	ENSG00000271752.1	RP11-269M20.3	3.46	0.000585	0.0347	0.16	0.16	Schizophrenia;	chr5:50579604	chr5:50662859~50663266:-
THCA	cis	rs860295	0.639	rs10908469	ENSG00000236675.1	MTX1P1	-3.46	0.000585	0.0347	-0.16	-0.16	Body mass index;	chr1:155498941	chr1:155230975~155234325:+
THCA	cis	rs1923243	0.869	rs4650200	ENSG00000223479.3	RP4-788P17.1	3.46	0.000585	0.0347	0.18	0.16	Migraine;	chr1:73186514	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.869	rs4649981	ENSG00000223479.3	RP4-788P17.1	3.46	0.000585	0.0347	0.18	0.16	Migraine;	chr1:73186666	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.869	rs11210176	ENSG00000223479.3	RP4-788P17.1	3.46	0.000585	0.0347	0.18	0.16	Migraine;	chr1:73188860	chr1:73635216~73715214:+
THCA	cis	rs1923243	0.901	rs12142152	ENSG00000223479.3	RP4-788P17.1	3.46	0.000585	0.0347	0.18	0.16	Migraine;	chr1:73189630	chr1:73635216~73715214:+
THCA	cis	rs2692947	0.562	rs11693248	ENSG00000235584.2	AC008268.1	-3.46	0.000585	0.0347	-0.16	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96218815	chr2:95666084~95668715:+
THCA	cis	rs2638953	0.924	rs11049600	ENSG00000247934.4	RP11-967K21.1	-3.46	0.000585	0.0347	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28439061	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.711	rs11049605	ENSG00000247934.4	RP11-967K21.1	-3.46	0.000585	0.0347	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443132	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs9669509	ENSG00000247934.4	RP11-967K21.1	-3.46	0.000585	0.0347	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443507	chr12:28163298~28190738:-
THCA	cis	rs7191700	0.511	rs8043625	ENSG00000263179.1	HNRNPCP4	3.46	0.000585	0.0347	0.2	0.16	Multiple sclerosis;	chr16:11268038	chr16:11242653~11243552:+
THCA	cis	rs12022452	0.591	rs16827359	ENSG00000237899.1	RP4-739H11.3	3.46	0.000585	0.0347	0.23	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40669089~40687588:-
THCA	cis	rs1580019	0.885	rs4580942	ENSG00000231952.3	DPY19L1P2	-3.46	0.000585	0.0347	-0.2	-0.16	Cognitive ability;	chr7:32456823	chr7:32812757~32838570:+
THCA	cis	rs348196	0.672	rs670876	ENSG00000160766.13	GBAP1	-3.46	0.000585	0.0347	-0.2	-0.16	Breast cancer;	chr1:155701887	chr1:155213821~155227422:-
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Body mass index;	chr17:30750419	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Body mass index;	chr17:30753533	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Body mass index;	chr17:30794616	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Body mass index;	chr17:30815122	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Body mass index;	chr17:30815823	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000264242.2	RP11-271K11.1	3.46	0.000585	0.0347	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30553697~30558962:+
THCA	cis	rs12549025	0.836	rs1567667	ENSG00000253390.1	CTC-756D1.2	-3.46	0.000585	0.0348	-0.27	-0.16	Reticulocyte fraction of red cells;	chr8:23560405	chr8:23458601~23484971:+
THCA	cis	rs1590305	0.786	rs7324216	ENSG00000236711.2	SMAD9-IT1	-3.46	0.000585	0.0348	-0.18	-0.16	Hip geometry;	chr13:37485081	chr13:36849366~36850046:-
THCA	cis	rs16957091	0.528	rs8037613	ENSG00000249839.1	AC011330.5	3.46	0.000585	0.0348	0.25	0.16	MGMT methylation in smokers;	chr15:42861247	chr15:43663654~43684339:-
THCA	cis	rs2494663	0.61	rs12048137	ENSG00000231416.1	RP11-422P24.9	3.46	0.000585	0.0348	0.2	0.16	Mean platelet volume;	chr1:154020258	chr1:153995632~153995960:+
THCA	cis	rs875971	0.619	rs2302918	ENSG00000230295.1	RP11-458F8.2	-3.46	0.000585	0.0348	-0.12	-0.16	Aortic root size;	chr7:66535945	chr7:66880708~66882981:+
THCA	cis	rs9911578	1	rs10401050	ENSG00000224738.1	AC099850.1	3.46	0.000585	0.0348	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58876425	chr17:59106598~59118267:+
THCA	cis	rs10515778	1	rs10515778	ENSG00000280834.1	U6	3.46	0.000585	0.0348	0.26	0.16	Inflammatory skin disease;	chr5:159231004	chr5:160072268~160072364:+
THCA	cis	rs9875589	0.957	rs62234598	ENSG00000233121.1	VN1R20P	3.46	0.000585	0.0348	0.18	0.16	Ovarian reserve;	chr3:13923113	chr3:13926813~13927778:+
THCA	cis	rs9875589	0.915	rs13097822	ENSG00000233121.1	VN1R20P	3.46	0.000585	0.0348	0.18	0.16	Ovarian reserve;	chr3:13927899	chr3:13926813~13927778:+
THCA	cis	rs9302752	1	rs9302752	ENSG00000260381.2	RP11-429P3.5	3.46	0.000585	0.0348	0.22	0.16	Leprosy;	chr16:50685192	chr16:50100339~50121943:-
THCA	cis	rs893363	0.559	rs877484	ENSG00000271916.1	RP11-884K10.6	3.46	0.000585	0.0348	0.17	0.16	Axial length;	chr3:53812897	chr3:53797764~53798019:-
THCA	cis	rs7096965	0.958	rs2218386	ENSG00000242147.1	RP13-463N16.6	3.46	0.000585	0.0348	0.18	0.16	Major depressive disorder;	chr10:4597793	chr10:5594991~5596118:-
THCA	cis	rs61008539	0.586	rs6959154	ENSG00000273151.1	RP11-449P15.2	-3.46	0.000585	0.0348	-0.11	-0.16	Perceived unattractiveness to mosquitoes;	chr7:816683	chr7:879790~886547:-
THCA	cis	rs972578	0.967	rs8138930	ENSG00000274717.1	RP1-47A17.1	-3.46	0.000585	0.0348	-0.16	-0.16	Mean platelet volume;	chr22:42940722	chr22:42791814~42794313:-
THCA	cis	rs912593	0.872	rs60740465	ENSG00000225179.1	LINC00457	3.46	0.000585	0.0348	0.25	0.16	Cancer;	chr13:34476704	chr13:34435450~34640685:-
THCA	cis	rs736801	0.521	rs2070729	ENSG00000224431.1	AC063976.7	-3.46	0.000585	0.0348	-0.13	-0.16	Mosquito bite size;Breast cancer;	chr5:132484229	chr5:132199456~132203487:+
THCA	cis	rs3784262	1	rs4646622	ENSG00000259250.1	RP11-50C13.1	3.46	0.000585	0.0348	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57965001	chr15:58587507~58591676:+
THCA	cis	rs7713065	0.765	rs10062371	ENSG00000263597.1	MIR3936	3.46	0.000585	0.0348	0.19	0.16	Lung function (FEV1/FVC);	chr5:132442721	chr5:132365490~132365599:-
THCA	cis	rs6977955	0.838	rs917115	ENSG00000234336.5	JAZF1-AS1	-3.46	0.000585	0.0348	-0.19	-0.16	Allergic disease (asthma, hay fever or eczema);	chr7:28132967	chr7:28180322~28243917:+
THCA	cis	rs6977955	0.838	rs917116	ENSG00000234336.5	JAZF1-AS1	-3.46	0.000585	0.0348	-0.19	-0.16	Allergic disease (asthma, hay fever or eczema);	chr7:28133120	chr7:28180322~28243917:+
THCA	cis	rs73191547	0.69	rs7011281	ENSG00000248538.5	RP11-10A14.5	3.46	0.000585	0.0348	0.19	0.16	Schizophrenia;	chr8:10178525	chr8:9189011~9202854:+
THCA	cis	rs301043	0.559	rs7133095	ENSG00000199172.2	MIR331	3.46	0.000585	0.0348	0.14	0.16	Immature fraction of reticulocytes;	chr12:95441560	chr12:95308410~95308520:+
THCA	cis	rs6472235	0.837	rs10097206	ENSG00000272192.1	CTD-2532N20.1	3.46	0.000586	0.0348	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:66012292	chr8:65842752~65843331:+
THCA	cis	rs2036707	0.744	rs79188719	ENSG00000276740.1	RP11-381O6.1	3.46	0.000586	0.0348	0.33	0.16	Obesity-related traits;	chr13:107834119	chr13:107465984~107466674:-
THCA	cis	rs4845570	1	rs7542898	ENSG00000268288.1	RP11-98D18.16	-3.46	0.000586	0.0348	-0.23	-0.16	Coronary artery disease;	chr1:151781146	chr1:151766486~151767000:-
THCA	cis	rs11098499	0.604	rs2389886	ENSG00000249244.1	RP11-548H18.2	3.46	0.000586	0.0348	0.18	0.16	Corneal astigmatism;	chr4:119649267	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.604	rs2389887	ENSG00000249244.1	RP11-548H18.2	3.46	0.000586	0.0348	0.18	0.16	Corneal astigmatism;	chr4:119649489	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.604	rs34278750	ENSG00000249244.1	RP11-548H18.2	3.46	0.000586	0.0348	0.18	0.16	Corneal astigmatism;	chr4:119649981	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.604	rs10022185	ENSG00000249244.1	RP11-548H18.2	3.46	0.000586	0.0348	0.18	0.16	Corneal astigmatism;	chr4:119650610	chr4:119391831~119395335:-
THCA	cis	rs2180341	0.782	rs6912552	ENSG00000220522.2	RP1-177A13.1	-3.46	0.000586	0.0348	-0.19	-0.16	Breast cancer;	chr6:127401801	chr6:127416535~127416952:-
THCA	cis	rs6546537	0.714	rs17036759	ENSG00000231024.1	AC092431.3	3.46	0.000586	0.0348	0.2	0.16	Serum thyroid-stimulating hormone levels;	chr2:69539897	chr2:69700192~69713847:-
THCA	cis	rs10858047	0.883	rs6537841	ENSG00000231128.4	RP5-1073O3.2	-3.46	0.000586	0.0348	-0.23	-0.16	Autism;	chr1:114658187	chr1:113812379~113829171:+
THCA	cis	rs10186029	0.582	rs1441166	ENSG00000270659.1	RP11-105N14.1	-3.46	0.000586	0.0348	-0.13	-0.16	Systemic sclerosis;	chr2:213145381	chr2:213152970~213153659:+
THCA	cis	rs7264396	0.635	rs6060673	ENSG00000088340.14	FER1L4	-3.46	0.000586	0.0348	-0.16	-0.16	Total cholesterol levels;	chr20:35894474	chr20:35558737~35607562:-
THCA	cis	rs7142002	0.568	rs746781	ENSG00000271780.1	RP11-1017G21.5	-3.46	0.000586	0.0348	-0.19	-0.16	Autism;	chr14:101922138	chr14:101948347~101949425:+
THCA	cis	rs10266483	0.515	rs6948710	ENSG00000234585.5	CCT6P3	-3.46	0.000586	0.0348	-0.16	-0.16	Response to statin therapy;	chr7:64405625	chr7:65038354~65074713:+
THCA	cis	rs987724	0.593	rs9871817	ENSG00000241544.1	RP11-6F2.5	-3.46	0.000586	0.0348	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156893887	chr3:157081841~157088547:+
THCA	cis	rs7010267	0.935	rs6415470	ENSG00000254278.1	RP11-278I4.2	-3.46	0.000586	0.0348	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118942872	chr8:119062942~119068782:-
THCA	cis	rs57709857	1	rs7005874	ENSG00000272092.1	RP11-350N15.5	-3.46	0.000586	0.0348	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38431048	chr8:38382364~38383461:+
THCA	cis	rs6840360	0.593	rs59350867	ENSG00000251603.1	RP11-164P12.4	3.46	0.000586	0.0348	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151774783	chr4:151667224~151670502:+
THCA	cis	rs4713118	0.523	rs2179096	ENSG00000216901.1	AL022393.7	3.46	0.000586	0.0348	0.19	0.16	Parkinson's disease;	chr6:27698141	chr6:28176188~28176674:+
THCA	cis	rs4299518	0.739	rs17279465	ENSG00000223552.1	RP11-24F11.2	-3.46	0.000586	0.0348	-0.15	-0.16	Hirschsprung disease;	chr3:45773256	chr3:46364955~46407059:-
THCA	cis	rs9925964	0.804	rs9926533	ENSG00000279196.1	RP11-1072A3.3	-3.46	0.000586	0.0348	-0.15	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31002858	chr16:30984630~30988270:-
THCA	cis	rs1550115	0.614	rs7574758	ENSG00000224165.4	DNAJC27-AS1	3.46	0.000586	0.0348	0.11	0.16	Coronary artery disease;	chr2:24797231	chr2:24971390~25039694:+
THCA	cis	rs1417770	0.895	rs706366	ENSG00000260971.3	RP11-504A18.1	3.46	0.000586	0.0348	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56225202	chr1:56248294~56258571:-
THCA	cis	rs9450351	0.744	rs9353339	ENSG00000203875.9	SNHG5	3.46	0.000586	0.0348	0.3	0.16	Interferon gamma-induced protein 10 levels;	chr6:85794480	chr6:85660950~85678736:-
THCA	cis	rs4915077	0.686	rs12567695	ENSG00000230489.1	VAV3-AS1	3.46	0.000586	0.0348	0.25	0.16	Hypothyroidism;	chr1:107705961	chr1:107964443~107994607:+
THCA	cis	rs972578	0.747	rs5996242	ENSG00000230319.1	AL022476.2	3.46	0.000586	0.0348	0.17	0.16	Mean platelet volume;	chr22:42834621	chr22:43038585~43052366:+
THCA	cis	rs2055729	0.71	rs13257396	ENSG00000261451.1	RP11-981G7.1	3.46	0.000586	0.0348	0.23	0.16	Multiple myeloma (hyperdiploidy);	chr8:9878873	chr8:10433672~10438312:+
THCA	cis	rs2055729	0.601	rs12546952	ENSG00000261451.1	RP11-981G7.1	-3.46	0.000586	0.0348	-0.22	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9886492	chr8:10433672~10438312:+
THCA	cis	rs7621331	1	rs9864247	ENSG00000239213.4	NCK1-AS1	3.46	0.000586	0.0348	0.16	0.16	Waist circumference adjusted for body mass index;	chr3:135991334	chr3:136841726~136862054:-
THCA	cis	rs3739034	0.938	rs62171395	ENSG00000224043.6	CCNT2-AS1	-3.46	0.000586	0.0348	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134719265	chr2:134735464~134918710:-
THCA	cis	rs2098713	0.535	rs56044522	ENSG00000250155.1	CTD-2353F22.1	3.46	0.000586	0.0348	0.16	0.16	Telomere length;	chr5:37582698	chr5:36666214~36725195:-
THCA	cis	rs28595532	0.623	rs56324414	ENSG00000260404.2	RP11-384K6.6	-3.46	0.000587	0.0348	-0.23	-0.16	Cannabis dependence symptom count;	chr4:118353500	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.623	rs10016452	ENSG00000260404.2	RP11-384K6.6	-3.46	0.000587	0.0348	-0.23	-0.16	Cannabis dependence symptom count;	chr4:118356335	chr4:118591773~118633729:+
THCA	cis	rs28595532	0.623	rs17516540	ENSG00000260404.2	RP11-384K6.6	-3.46	0.000587	0.0348	-0.23	-0.16	Cannabis dependence symptom count;	chr4:118357288	chr4:118591773~118633729:+
THCA	cis	rs853679	0.657	rs1778483	ENSG00000204709.4	LINC01556	3.46	0.000587	0.0348	0.21	0.16	Depression;	chr6:28273214	chr6:28943877~28944537:+
THCA	cis	rs853679	0.657	rs1778482	ENSG00000204709.4	LINC01556	3.46	0.000587	0.0348	0.21	0.16	Depression;	chr6:28273215	chr6:28943877~28944537:+
THCA	cis	rs11671005	0.61	rs3794966	ENSG00000252334.1	RNU6-1337P	3.46	0.000587	0.0348	0.23	0.16	Mean platelet volume;	chr19:58557629	chr19:58483749~58483843:-
THCA	cis	rs4604234	0.711	rs73463560	ENSG00000260645.1	RP11-250B2.5	-3.46	0.000587	0.0348	-0.26	-0.16	Cancer;	chr6:80288806	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.803	rs112533182	ENSG00000260645.1	RP11-250B2.5	-3.46	0.000587	0.0348	-0.26	-0.16	Cancer;	chr6:80295792	chr6:80466958~80469080:+
THCA	cis	rs9650657	0.501	rs3021500	ENSG00000254948.1	OR7E158P	3.46	0.000587	0.0348	0.19	0.16	Neuroticism;	chr8:11166488	chr8:11919900~11920809:-
THCA	cis	rs9910816	0.901	rs7208386	ENSG00000207561.1	MIR635	3.46	0.000587	0.0348	0.18	0.16	Bipolar disorder (inflammation and infection response interaction);	chr17:68353351	chr17:68424451~68424548:-
THCA	cis	rs7781557	0.64	rs73192025	ENSG00000170629.13	DPY19L2P2	-3.46	0.000587	0.0348	-0.21	-0.16	Colorectal adenoma (advanced);	chr7:102951042	chr7:103175133~103280410:-
THCA	cis	rs11153306	0.529	rs11153303	ENSG00000271789.1	RP5-1112D6.7	-3.46	0.000587	0.0348	-0.15	-0.16	Tonsillectomy;	chr6:111616672	chr6:111297126~111298510:+
THCA	cis	rs620729	0.749	rs2177158	ENSG00000272097.1	RP11-421M1.8	3.46	0.000587	0.0348	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480048	chr6:10743324~10747663:-
THCA	cis	rs2191566	0.691	rs55676341	ENSG00000266921.1	RP11-15A1.7	-3.46	0.000587	0.0348	-0.15	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:44083536	chr19:43996896~44002836:-
THCA	cis	rs3736485	1	rs11631408	ENSG00000259709.1	CTD-2184D3.7	3.46	0.000587	0.0348	0.15	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51454039	chr15:52124561~52140246:+
THCA	cis	rs1033962	0.865	rs4319409	ENSG00000273107.1	RP11-165A20.3	3.46	0.000587	0.0348	0.19	0.16	Post-traumatic stress disorder;	chr10:24927024	chr10:24953241~24953513:+
THCA	cis	rs7264396	0.887	rs4911503	ENSG00000261582.1	RP4-614O4.11	-3.46	0.000587	0.0348	-0.16	-0.16	Total cholesterol levels;	chr20:35475270	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs750487	ENSG00000261582.1	RP4-614O4.11	-3.46	0.000587	0.0348	-0.16	-0.16	Total cholesterol levels;	chr20:35478820	chr20:35267885~35280043:-
THCA	cis	rs9991779	0.706	rs6553747	ENSG00000237125.7	HAND2-AS1	3.46	0.000587	0.0348	0.26	0.16	Pediatric bone mineral content (hip);	chr4:173970296	chr4:173527270~173591324:+
THCA	cis	rs4948275	0.693	rs2787708	ENSG00000233643.2	RP11-491H19.1	3.46	0.000587	0.0348	0.18	0.16	Night sleep phenotypes;	chr10:61556326	chr10:61781745~61821246:-
THCA	cis	rs9427116	0.875	rs11264233	ENSG00000236675.1	MTX1P1	-3.46	0.000587	0.0348	-0.14	-0.16	Blood protein levels;	chr1:154653156	chr1:155230975~155234325:+
THCA	cis	rs9304861	1	rs9304861	ENSG00000279329.1	CTD-2553L13.9	-3.46	0.000587	0.0348	-0.19	-0.16	Alzheimer disease and age of onset;	chr19:34780984	chr19:34675717~34677581:-
THCA	cis	rs897984	0.645	rs58726213	ENSG00000275263.1	RP11-1072A3.4	-3.46	0.000587	0.0349	-0.19	-0.16	Dementia with Lewy bodies;	chr16:31033362	chr16:30956872~30957199:-
THCA	cis	rs8130944	1	rs2269151	ENSG00000235772.1	AP001625.6	3.46	0.000587	0.0349	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42721370	chr21:42560374~42561934:-
THCA	cis	rs8130944	0.856	rs4919998	ENSG00000235772.1	AP001625.6	3.46	0.000587	0.0349	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42721490	chr21:42560374~42561934:-
THCA	cis	rs8130944	0.897	rs7277424	ENSG00000235772.1	AP001625.6	3.46	0.000587	0.0349	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42721777	chr21:42560374~42561934:-
THCA	cis	rs72627123	1	rs76553384	ENSG00000259065.1	RP5-1021I20.1	-3.46	0.000587	0.0349	-0.24	-0.16	Morning vs. evening chronotype;	chr14:73916976	chr14:73787360~73803270:+
THCA	cis	rs992969	1	rs1888909	ENSG00000231967.1	RP11-12D24.6	3.46	0.000587	0.0349	0.19	0.16	Asthma;	chr9:6197392	chr9:5356312~5356525:-
THCA	cis	rs1913185	0.787	rs59850864	ENSG00000261051.1	RP11-274H2.5	-3.46	0.000587	0.0349	-0.21	-0.16	Obesity-related traits;	chr3:146111375	chr3:146059585~146061679:-
THCA	cis	rs9828933	0.882	rs3733127	ENSG00000271843.1	RP11-245J9.5	3.46	0.000587	0.0349	0.23	0.16	Type 2 diabetes;	chr3:64002498	chr3:64008082~64008692:-
THCA	cis	rs7818688	1	rs10100842	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013675	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs10103841	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013676	chr8:94974573~94974853:-
THCA	cis	rs875971	0.862	rs778736	ENSG00000223473.2	GS1-124K5.3	3.46	0.000587	0.0349	0.11	0.16	Aortic root size;	chr7:66348861	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs1875057	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000587	0.0349	-0.11	-0.16	Aortic root size;	chr7:66266868	chr7:66491049~66493566:-
THCA	cis	rs875971	0.755	rs10228885	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000587	0.0349	-0.11	-0.16	Aortic root size;	chr7:66315542	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs3893216	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000587	0.0349	-0.11	-0.16	Aortic root size;	chr7:66325720	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6958294	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000587	0.0349	-0.11	-0.16	Aortic root size;	chr7:66329809	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs2088655	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000587	0.0349	-0.11	-0.16	Aortic root size;	chr7:66330724	chr7:66491049~66493566:-
THCA	cis	rs875971	0.895	rs10447522	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000587	0.0349	-0.11	-0.16	Aortic root size;	chr7:66331087	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs7783779	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000587	0.0349	-0.11	-0.16	Aortic root size;	chr7:66331639	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs2088653	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000587	0.0349	-0.11	-0.16	Aortic root size;	chr7:66343621	chr7:66491049~66493566:-
THCA	cis	rs78487399	0.908	rs55921927	ENSG00000234936.1	AC010883.5	3.46	0.000587	0.0349	0.19	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43621796	chr2:43229573~43233394:+
THCA	cis	rs7572644	0.766	rs10495761	ENSG00000223522.1	AC093690.1	-3.46	0.000587	0.0349	-0.21	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28013088	chr2:28307691~28310459:-
THCA	cis	rs412658	0.67	rs1912576	ENSG00000268117.1	VN1R84P	-3.46	0.000587	0.0349	-0.21	-0.16	Telomere length;	chr19:21938491	chr19:21719801~21720035:-
THCA	cis	rs7818688	1	rs73276417	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014084	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs28440026	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014516	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs28712702	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014752	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs28363725	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014880	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs28378156	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014899	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs6989862	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015340	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs6985880	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015371	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs7008542	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000587	0.0349	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015635	chr8:94974573~94974853:-
THCA	cis	rs929354	0.713	rs1034785	ENSG00000224629.1	RP5-1142J19.2	-3.46	0.000587	0.0349	-0.15	-0.16	Body mass index;	chr7:157209689	chr7:157263022~157263229:-
THCA	cis	rs1728400	0.609	rs2178144	ENSG00000252311.1	RNU1-103P	3.46	0.000587	0.0349	0.18	0.16	Breast cancer (survival);	chr16:86387753	chr16:85781775~85781899:-
THCA	cis	rs8180040	0.966	rs3816779	ENSG00000227398.3	KIF9-AS1	3.46	0.000587	0.0349	0.13	0.16	Colorectal cancer;	chr3:47501899	chr3:47164497~47246601:+
THCA	cis	rs620729	0.794	rs9394109	ENSG00000272097.1	RP11-421M1.8	-3.46	0.000587	0.0349	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:11485569	chr6:10743324~10747663:-
THCA	cis	rs11671005	0.611	rs56026876	ENSG00000268912.1	CTD-2619J13.17	-3.46	0.000587	0.0349	-0.15	-0.16	Mean platelet volume;	chr19:58494790	chr19:58428632~58431148:-
THCA	cis	rs944289	0.74	rs12891345	ENSG00000212071.1	AL162511.1	3.46	0.000587	0.0349	0.18	0.16	Thyroid cancer;	chr14:36126977	chr14:36196480~36196568:-
THCA	cis	rs9457247	0.582	rs9459855	ENSG00000235272.1	FAM103A2P	3.46	0.000587	0.0349	0.22	0.16	Crohn's disease;	chr6:167052662	chr6:166586124~166586477:-
THCA	cis	rs7115242	0.702	rs672058	ENSG00000280143.1	AP000892.6	3.46	0.000588	0.0349	0.25	0.16	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117204967~117210292:+
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000230189.5	GS1-124K5.2	-3.46	0.000588	0.0349	-0.1	-0.16	Calcium levels;	chr7:65733651	chr7:66409143~66490059:-
THCA	cis	rs4588572	0.606	rs4290994	ENSG00000245556.2	SCAMP1-AS1	-3.46	0.000588	0.0349	-0.12	-0.16	Triglycerides;	chr5:78446429	chr5:78342365~78360507:-
THCA	cis	rs4588572	0.606	rs6859161	ENSG00000245556.2	SCAMP1-AS1	-3.46	0.000588	0.0349	-0.12	-0.16	Triglycerides;	chr5:78446952	chr5:78342365~78360507:-
THCA	cis	rs4588572	0.644	rs6882191	ENSG00000245556.2	SCAMP1-AS1	-3.46	0.000588	0.0349	-0.12	-0.16	Triglycerides;	chr5:78447274	chr5:78342365~78360507:-
THCA	cis	rs4588572	0.644	rs10061149	ENSG00000245556.2	SCAMP1-AS1	-3.46	0.000588	0.0349	-0.12	-0.16	Triglycerides;	chr5:78448377	chr5:78342365~78360507:-
THCA	cis	rs3784262	1	rs11855259	ENSG00000259250.1	RP11-50C13.1	3.46	0.000588	0.0349	0.14	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57957179	chr15:58587507~58591676:+
THCA	cis	rs875971	1	rs9986696	ENSG00000272831.1	RP11-792A8.4	-3.46	0.000588	0.0349	-0.1	-0.16	Aortic root size;	chr7:66239589	chr7:66739829~66740385:-
THCA	cis	rs2067615	0.929	rs752046	ENSG00000260329.1	RP11-412D9.4	-3.46	0.000588	0.0349	-0.14	-0.16	Heart rate;	chr12:106717782	chr12:106954029~106955497:-
THCA	cis	rs76878669	0.538	rs1546358	ENSG00000255320.1	RP11-755F10.1	-3.46	0.000588	0.0349	-0.2	-0.16	Educational attainment (years of education);	chr11:66407790	chr11:66244840~66246239:-
THCA	cis	rs2766547	0.967	rs2766543	ENSG00000212579.1	SNORA40	-3.46	0.000588	0.0349	-0.17	-0.16	Eosinophil percentage of granulocytes;	chr6:35740857	chr6:35651818~35651945:+
THCA	cis	rs7631605	0.586	rs11718606	ENSG00000224080.1	UBE2FP1	3.46	0.000588	0.0349	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37307449	chr3:37143512~37143958:-
THCA	cis	rs2905347	0.895	rs2961283	ENSG00000232949.1	AC002480.4	3.46	0.000588	0.0349	0.2	0.16	Major depression and alcohol dependence;	chr7:22600879	chr7:22589705~22591622:+
THCA	cis	rs911186	0.812	rs3800316	ENSG00000219392.1	RP1-265C24.5	-3.46	0.000588	0.0349	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr6:27288323	chr6:28115628~28116551:+
THCA	cis	rs2806561	0.929	rs627304	ENSG00000249087.5	ZNF436-AS1	-3.46	0.000588	0.0349	-0.09	-0.16	Height;	chr1:23211062	chr1:23368997~23371839:+
THCA	cis	rs847649	0.692	rs10279449	ENSG00000234715.1	CTB-107G13.1	-3.46	0.000588	0.0349	-0.18	-0.16	Morning vs. evening chronotype;	chr7:102822189	chr7:103445207~103514007:+
THCA	cis	rs721048	0.85	rs7605319	ENSG00000242412.1	DBIL5P2	-3.46	0.000588	0.0349	-0.22	-0.16	Prostate cancer;	chr2:63196360	chr2:63117851~63119542:-
THCA	cis	rs250518	0.926	rs6896898	ENSG00000251467.1	CTC-250P20.2	3.46	0.000588	0.0349	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72795174	chr5:72996920~72997642:+
THCA	cis	rs7924176	0.521	rs10762599	ENSG00000271848.1	RP11-464F9.21	-3.46	0.000588	0.0349	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:73654039~73674719:+
THCA	cis	rs7671266	0.559	rs7681212	ENSG00000261490.1	RP11-448G15.3	3.46	0.000588	0.0349	0.13	0.16	Cardiovascular disease risk factors;	chr4:10357340	chr4:10068089~10073019:-
THCA	cis	rs9307551	1	rs1031005	ENSG00000249646.2	OR7E94P	-3.46	0.000588	0.0349	-0.21	-0.16	Refractive error;	chr4:79595750	chr4:79587302~79588130:-
THCA	cis	rs7188445	0.932	rs17767419	ENSG00000277954.1	RP11-679B19.1	-3.46	0.000588	0.0349	-0.19	-0.16	Urate levels;	chr16:79710651	chr16:79202624~79206739:-
THCA	cis	rs875971	0.558	rs4433015	ENSG00000232559.3	GS1-124K5.12	-3.46	0.000589	0.0349	-0.15	-0.16	Aortic root size;	chr7:66174736	chr7:66554588~66576923:-
THCA	cis	rs1062753	0.731	rs11914200	ENSG00000227370.1	RP4-669P10.19	3.46	0.000589	0.0349	0.16	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41982066	chr22:42132543~42132998:+
THCA	cis	rs1417770	0.931	rs1230033	ENSG00000260971.3	RP11-504A18.1	3.46	0.000589	0.0349	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56224752	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs706358	ENSG00000260971.3	RP11-504A18.1	3.46	0.000589	0.0349	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56228507	chr1:56248294~56258571:-
THCA	cis	rs1417770	0.931	rs706356	ENSG00000260971.3	RP11-504A18.1	3.46	0.000589	0.0349	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56228788	chr1:56248294~56258571:-
THCA	cis	rs11673344	0.562	rs6510580	ENSG00000267260.1	CTD-2162K18.4	-3.46	0.000589	0.0349	-0.19	-0.16	Obesity-related traits;	chr19:37038452	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs2082009	ENSG00000267260.1	CTD-2162K18.4	-3.46	0.000589	0.0349	-0.19	-0.16	Obesity-related traits;	chr19:37039834	chr19:36773153~36777078:+
THCA	cis	rs3734729	0.702	rs9384264	ENSG00000231120.3	BTF3P10	3.46	0.000589	0.0349	0.35	0.16	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150236389	chr6:149977922~149978416:+
THCA	cis	rs45509595	0.841	rs200485	ENSG00000220721.1	OR1F12	3.46	0.000589	0.0349	0.27	0.16	Breast cancer;	chr6:27807919	chr6:28073316~28074233:+
THCA	cis	rs2977125	0.769	rs2956759	ENSG00000251468.2	RP11-369K16.1	-3.46	0.000589	0.0349	-0.23	-0.16	Schizophrenia;	chr8:12897420	chr8:12958387~12962200:+
THCA	cis	rs2977125	0.774	rs2947378	ENSG00000251468.2	RP11-369K16.1	-3.46	0.000589	0.0349	-0.23	-0.16	Schizophrenia;	chr8:12898450	chr8:12958387~12962200:+
THCA	cis	rs875971	0.862	rs10276077	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000589	0.0349	-0.11	-0.16	Aortic root size;	chr7:66263424	chr7:66491049~66493566:-
THCA	cis	rs875971	0.928	rs2036263	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000589	0.0349	-0.11	-0.16	Aortic root size;	chr7:66335210	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs10240949	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000589	0.0349	-0.11	-0.16	Aortic root size;	chr7:66339430	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs7782704	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000589	0.0349	-0.11	-0.16	Aortic root size;	chr7:66340379	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6959268	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000589	0.0349	-0.11	-0.16	Aortic root size;	chr7:66347979	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs12537823	ENSG00000223473.2	GS1-124K5.3	3.46	0.000589	0.0349	0.11	0.16	Aortic root size;	chr7:66255897	chr7:66491049~66493566:-
THCA	cis	rs6787172	0.622	rs11717725	ENSG00000272087.1	RP11-379F4.7	3.46	0.000589	0.0349	0.14	0.16	Subjective well-being;	chr3:158417131	chr3:158693120~158693768:-
THCA	cis	rs7246657	0.943	rs34603719	ENSG00000267422.1	CTD-2554C21.1	-3.46	0.000589	0.0349	-0.19	-0.16	Coronary artery calcification;	chr19:37303626	chr19:37779686~37792865:+
THCA	cis	rs9420	0.528	rs11229080	ENSG00000254602.1	AP000662.4	-3.46	0.000589	0.0349	-0.18	-0.16	Schizophrenia;	chr11:57632038	chr11:57638024~57652790:+
THCA	cis	rs7819412	0.669	rs2409743	ENSG00000255046.1	RP11-297N6.4	3.46	0.000589	0.0349	0.17	0.16	Triglycerides;	chr8:11212851	chr8:11797928~11802568:-
THCA	cis	rs2749592	0.55	rs4934881	ENSG00000275858.1	RP11-291L22.8	-3.46	0.000589	0.0349	-0.18	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:38450738~38451069:-
THCA	cis	rs7819412	0.539	rs11250131	ENSG00000255495.1	AC145124.2	-3.46	0.000589	0.0349	-0.17	-0.16	Triglycerides;	chr8:11393666	chr8:12194467~12196280:+
THCA	cis	rs4730276	0.674	rs66999558	ENSG00000250474.1	WBP1LP2	-3.46	0.000589	0.0349	-0.15	-0.16	Ulcerative colitis;	chr7:107904086	chr7:107628553~107629498:+
THCA	cis	rs4730276	0.674	rs13226236	ENSG00000250474.1	WBP1LP2	-3.46	0.000589	0.0349	-0.15	-0.16	Ulcerative colitis;	chr7:107904297	chr7:107628553~107629498:+
THCA	cis	rs10090774	0.965	rs62521937	ENSG00000280303.2	ERICD	3.46	0.000589	0.0349	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140963425	chr8:140636281~140638283:+
THCA	cis	rs17023223	0.537	rs61319010	ENSG00000227056.2	RPL6P2	-3.46	0.000589	0.0349	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119219314~119220096:-
THCA	cis	rs2836950	0.545	rs11700813	ENSG00000235701.1	PCBP2P1	-3.46	0.000589	0.0349	-0.17	-0.16	Menarche (age at onset);	chr21:39145543	chr21:39171130~39172106:-
THCA	cis	rs11681884	0.892	rs11123159	ENSG00000236397.3	DDX11L2	-3.46	0.000589	0.0349	-0.34	-0.16	Stroke;	chr2:113076453	chr2:113599036~113601261:-
THCA	cis	rs55661361	1	rs55661361	ENSG00000254941.1	RP11-677M14.5	3.46	0.000589	0.0349	0.13	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124744061	chr11:124807822~124808269:-
THCA	cis	rs1923539	0.822	rs1923536	ENSG00000225484.5	NUTM2B-AS1	3.46	0.000589	0.035	0.22	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950053	chr10:79663088~79826594:-
THCA	cis	rs10090774	0.965	rs7005909	ENSG00000280303.2	ERICD	3.46	0.000589	0.035	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140973600	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.83	rs2369409	ENSG00000280303.2	ERICD	3.46	0.000589	0.035	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140979771	chr8:140636281~140638283:+
THCA	cis	rs7432375	0.58	rs4678441	ENSG00000273486.1	RP11-731C17.2	3.46	0.000589	0.035	0.13	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136813986	chr3:136837338~136839021:-
THCA	cis	rs7432375	0.58	rs4678442	ENSG00000273486.1	RP11-731C17.2	3.46	0.000589	0.035	0.13	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136814129	chr3:136837338~136839021:-
THCA	cis	rs4604234	0.803	rs76568328	ENSG00000260645.1	RP11-250B2.5	-3.46	0.000589	0.035	-0.26	-0.16	Cancer;	chr6:80267384	chr6:80466958~80469080:+
THCA	cis	rs7028939	0.818	rs7872556	ENSG00000255145.2	STX17-AS1	-3.46	0.000589	0.035	-0.23	-0.16	Preeclampsia;	chr9:100182574	chr9:99886322~99906601:-
THCA	cis	rs17345786	1	rs3762729	ENSG00000244119.1	PDCL3P4	3.46	0.000589	0.035	0.15	0.16	Colonoscopy-negative controls vs population controls;	chr3:101590030	chr3:101712472~101713191:+
THCA	cis	rs72672639	0.85	rs17735424	ENSG00000253878.4	RP11-347C18.3	-3.46	0.000589	0.035	-0.24	-0.16	Carotid plaque burden;	chr8:94269050	chr8:94950037~94951396:+
THCA	cis	rs804280	0.56	rs10503426	ENSG00000254948.1	OR7E158P	-3.46	0.000589	0.035	-0.19	-0.16	Myopia (pathological);	chr8:11731874	chr8:11919900~11920809:-
THCA	cis	rs79149102	0.522	rs6495104	ENSG00000260103.2	RP11-10O17.1	-3.46	0.000589	0.035	-0.21	-0.16	Lung cancer;	chr15:74475760	chr15:74478070~74490286:-
THCA	cis	rs1790761	0.806	rs35787427	ENSG00000255318.1	RP11-655M14.13	-3.46	0.000589	0.035	-0.18	-0.16	Mean corpuscular volume;	chr11:67488406	chr11:67618279~67627304:-
THCA	cis	rs11960179	0.881	rs78909682	ENSG00000250066.1	RP11-141O11.1	-3.46	0.000589	0.035	-0.33	-0.16	Glomerular filtration rate (creatinine);	chr5:68478272	chr5:68963246~68967845:+
THCA	cis	rs7264396	0.887	rs6120951	ENSG00000261582.1	RP4-614O4.11	-3.46	0.000589	0.035	-0.16	-0.16	Total cholesterol levels;	chr20:35457370	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs58458373	ENSG00000261582.1	RP4-614O4.11	-3.46	0.000589	0.035	-0.16	-0.16	Total cholesterol levels;	chr20:35457790	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs3818441	ENSG00000261582.1	RP4-614O4.11	-3.46	0.000589	0.035	-0.16	-0.16	Total cholesterol levels;	chr20:35458678	chr20:35267885~35280043:-
THCA	cis	rs8054556	0.967	rs7193532	ENSG00000214725.6	CDIPT-AS1	-3.46	0.000589	0.035	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29951481	chr16:29863593~29868053:+
THCA	cis	rs5751614	0.537	rs9624074	ENSG00000236611.1	AP000343.2	-3.46	0.000589	0.035	-0.2	-0.16	Height;	chr22:23283143	chr22:23326616~23328493:+
THCA	cis	rs7998202	0.667	rs282569	ENSG00000274922.1	RP11-88E10.5	-3.46	0.000589	0.035	-0.22	-0.16	Glycated hemoglobin levels;	chr13:112717193	chr13:112686769~112689815:-
THCA	cis	rs2252521	0.524	rs2214973	ENSG00000228421.2	AC005013.5	3.46	0.000589	0.035	0.21	0.16	Cognitive performance;	chr7:29020275	chr7:28957667~28959345:+
THCA	cis	rs12962334	0.555	rs9959556	ENSG00000273232.1	RP11-370A5.2	3.46	0.00059	0.035	0.21	0.16	Breast cancer;	chr18:23011982	chr18:22882825~22883357:-
THCA	cis	rs9902453	0.817	rs2617881	ENSG00000263603.1	CTD-2349P21.5	-3.46	0.00059	0.035	-0.19	-0.16	Coffee consumption (cups per day);	chr17:29736257	chr17:30729469~30731202:+
THCA	cis	rs1229542	1	rs1229542	ENSG00000183444.10	OR7E38P	-3.46	0.00059	0.035	-0.28	-0.16	Myopia (pathological);	chr7:97793614	chr7:97966090~97967074:-
THCA	cis	rs12893668	0.638	rs11851616	ENSG00000258914.1	CTD-2134A5.3	-3.46	0.00059	0.035	-0.2	-0.16	Reticulocyte count;	chr14:103599263	chr14:103875055~103877478:+
THCA	cis	rs12893668	0.667	rs11844466	ENSG00000258914.1	CTD-2134A5.3	-3.46	0.00059	0.035	-0.2	-0.16	Reticulocyte count;	chr14:103600085	chr14:103875055~103877478:+
THCA	cis	rs12893668	0.637	rs12892038	ENSG00000258914.1	CTD-2134A5.3	-3.46	0.00059	0.035	-0.2	-0.16	Reticulocyte count;	chr14:103602292	chr14:103875055~103877478:+
THCA	cis	rs12893668	0.637	rs4525427	ENSG00000258914.1	CTD-2134A5.3	-3.46	0.00059	0.035	-0.2	-0.16	Reticulocyte count;	chr14:103606456	chr14:103875055~103877478:+
THCA	cis	rs7927592	0.731	rs10896350	ENSG00000160172.9	FAM86C2P	3.46	0.00059	0.035	0.15	0.16	Total body bone mineral density;	chr11:68618905	chr11:67791648~67805336:-
THCA	cis	rs7924176	0.502	rs12784355	ENSG00000271848.1	RP11-464F9.21	-3.46	0.00059	0.035	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:73654039~73674719:+
THCA	cis	rs17695224	0.545	rs8109098	ENSG00000275055.1	CTC-471J1.11	-3.46	0.00059	0.035	-0.12	-0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51825363	chr19:52049007~52049754:+
THCA	cis	rs17695224	0.545	rs10853846	ENSG00000275055.1	CTC-471J1.11	-3.46	0.00059	0.035	-0.12	-0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51826595	chr19:52049007~52049754:+
THCA	cis	rs10276381	0.579	rs73072539	ENSG00000234336.5	JAZF1-AS1	-3.46	0.00059	0.035	-0.29	-0.16	Crohn's disease;	chr7:28106636	chr7:28180322~28243917:+
THCA	cis	rs10276381	0.579	rs73072543	ENSG00000234336.5	JAZF1-AS1	-3.46	0.00059	0.035	-0.29	-0.16	Crohn's disease;	chr7:28107231	chr7:28180322~28243917:+
THCA	cis	rs214785	0.932	rs214770	ENSG00000226644.4	RP11-128M1.1	3.46	0.00059	0.035	0.16	0.16	Basal cell carcinoma;	chr20:2298789	chr20:2207217~2213151:+
THCA	cis	rs3764021	0.527	rs11052423	ENSG00000256069.6	A2MP1	3.46	0.00059	0.035	0.18	0.16	Type 1 diabetes;	chr12:9687442	chr12:9228533~9275817:-
THCA	cis	rs9650657	0.769	rs2116094	ENSG00000269918.1	AF131215.9	-3.46	0.00059	0.035	-0.17	-0.16	Neuroticism;	chr8:10741312	chr8:11104691~11106704:-
THCA	cis	rs3749237	0.595	rs4855864	ENSG00000224424.7	PRKAR2A-AS1	3.46	0.00059	0.035	0.13	0.16	Resting heart rate;	chr3:49484541	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs11130199	ENSG00000224424.7	PRKAR2A-AS1	3.46	0.00059	0.035	0.13	0.16	Resting heart rate;	chr3:49501366	chr3:48847572~48851981:+
THCA	cis	rs6840360	0.593	rs6847844	ENSG00000251603.1	RP11-164P12.4	3.46	0.00059	0.035	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151772094	chr4:151667224~151670502:+
THCA	cis	rs2882667	1	rs2060222	ENSG00000249593.5	CTB-46B19.2	3.46	0.00059	0.035	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:139012647~139051203:+
THCA	cis	rs9875589	0.957	rs6778731	ENSG00000228242.5	AC093495.4	-3.46	0.00059	0.035	-0.09	-0.16	Ovarian reserve;	chr3:13906007	chr3:14144637~14165978:+
THCA	cis	rs2583526	0.967	rs2583528	ENSG00000270996.1	RP11-342K6.4	3.46	0.00059	0.035	0.12	0.16	Age of smoking initiation;	chr2:75956949	chr2:75719120~75720018:+
THCA	cis	rs9916302	0.706	rs1874226	ENSG00000266469.1	CTB-131K11.1	3.46	0.00059	0.035	0.15	0.16	Glomerular filtration rate (creatinine);	chr17:39572778	chr17:39401793~39406233:+
THCA	cis	rs6598955	0.724	rs10902731	ENSG00000236782.4	RP11-96L14.7	-3.46	0.00059	0.035	-0.19	-0.16	Obesity-related traits;	chr1:26274302	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.724	rs12732295	ENSG00000236782.4	RP11-96L14.7	-3.46	0.00059	0.035	-0.19	-0.16	Obesity-related traits;	chr1:26275760	chr1:26169947~26171821:-
THCA	cis	rs6598955	0.67	rs3795685	ENSG00000236782.4	RP11-96L14.7	3.46	0.00059	0.035	0.19	0.16	Obesity-related traits;	chr1:26274894	chr1:26169947~26171821:-
THCA	cis	rs6716724	0.671	rs4669700	ENSG00000257135.4	RP11-320M2.1	3.46	0.00059	0.035	0.17	0.16	Sudden cardiac arrest;	chr2:11261412	chr2:10448694~10451327:+
THCA	cis	rs1838105	0.64	rs9889451	ENSG00000263142.4	LRRC37A17P	3.46	0.00059	0.035	0.11	0.16	Nonsyndromic cleft lip with cleft palate;	chr17:47076509	chr17:46978481~47054569:+
THCA	cis	rs4372836	0.504	rs12185717	ENSG00000273233.1	RP11-713D19.1	3.46	0.00059	0.035	0.19	0.16	Body mass index;	chr2:28846685	chr2:28810281~28810706:-
THCA	cis	rs758324	0.812	rs601441	ENSG00000224431.1	AC063976.7	-3.46	0.00059	0.035	-0.14	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131948740	chr5:132199456~132203487:+
THCA	cis	rs4800353	0.673	rs9963751	ENSG00000265142.5	MIR133A1HG	-3.46	0.00059	0.035	-0.21	-0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr18:22022608	chr18:21825487~21831410:-
THCA	cis	rs7824557	0.505	rs2736313	ENSG00000261451.1	RP11-981G7.1	3.46	0.00059	0.035	0.2	0.16	Retinal vascular caliber;	chr8:11229433	chr8:10433672~10438312:+
THCA	cis	rs2562456	0.793	rs627522	ENSG00000268117.1	VN1R84P	3.46	0.00059	0.035	0.21	0.16	Pain;	chr19:21313002	chr19:21719801~21720035:-
THCA	cis	rs7520050	0.966	rs946529	ENSG00000281133.1	AL355480.3	3.46	0.00059	0.035	0.18	0.16	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45580892~45580996:-
THCA	cis	rs1667255	1	rs1791199	ENSG00000266521.1	RP11-650P15.1	3.46	0.00059	0.035	0.2	0.16	Retinol levels;	chr18:31607778	chr18:31496645~31497195:-
THCA	cis	rs7727544	0.618	rs2631367	ENSG00000263597.1	MIR3936	-3.46	0.00059	0.035	-0.15	-0.16	Blood metabolite levels;	chr5:132369766	chr5:132365490~132365599:-
THCA	cis	rs72827839	0.793	rs72823513	ENSG00000266601.1	RP11-6N17.3	3.46	0.00059	0.035	0.19	0.16	Ease of getting up in the morning;	chr17:47971554	chr17:47929682~47933106:-
THCA	cis	rs7917772	0.565	rs61869210	ENSG00000203886.4	CYP17A1-AS1	-3.46	0.00059	0.035	-0.17	-0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102677418	chr10:102832721~102834516:+
THCA	cis	rs3176789	0.671	rs3136563	ENSG00000256673.1	RP11-599J14.2	3.46	0.00059	0.035	0.19	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9762849	chr12:9398355~9414851:-
THCA	cis	rs7432375	0.61	rs28458819	ENSG00000273486.1	RP11-731C17.2	3.46	0.00059	0.035	0.13	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136803472	chr3:136837338~136839021:-
THCA	cis	rs10109025	0.67	rs7825690	ENSG00000255310.2	AF131215.2	-3.46	0.00059	0.035	-0.13	-0.16	Joint mobility (Beighton score);	chr8:11000747	chr8:11107788~11109726:-
THCA	cis	rs7944735	0.545	rs4752805	ENSG00000200090.1	Y_RNA	3.46	0.00059	0.035	0.12	0.16	Intraocular pressure;	chr11:47996803	chr11:47726894~47726992:-
THCA	cis	rs875971	0.862	rs6960446	ENSG00000223473.2	GS1-124K5.3	-3.46	0.00059	0.035	-0.11	-0.16	Aortic root size;	chr7:66268272	chr7:66491049~66493566:-
THCA	cis	rs875971	0.789	rs10260426	ENSG00000223473.2	GS1-124K5.3	-3.46	0.00059	0.035	-0.11	-0.16	Aortic root size;	chr7:66271055	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs7796162	ENSG00000223473.2	GS1-124K5.3	-3.46	0.00059	0.035	-0.11	-0.16	Aortic root size;	chr7:66280771	chr7:66491049~66493566:-
THCA	cis	rs2919009	0.579	rs12258778	ENSG00000271670.1	RP11-95I16.4	-3.46	0.000591	0.035	-0.17	-0.16	Obesity-related traits;	chr10:120868873	chr10:120879256~120880667:-
THCA	cis	rs55702914	0.905	rs787988	ENSG00000231621.1	AC013264.2	3.46	0.000591	0.035	0.15	0.16	Major depression and alcohol dependence;	chr2:197336078	chr2:197197991~197199273:+
THCA	cis	rs185694	0.947	rs169331	ENSG00000279149.1	RP11-374F3.5	3.46	0.000591	0.035	0.23	0.16	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:30304558	chr13:30344672~30347167:+
THCA	cis	rs7521902	0.853	rs72478520	ENSG00000228397.1	RP1-224A6.3	-3.46	0.000591	0.035	-0.28	-0.16	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22163074	chr1:22023994~22024968:-
THCA	cis	rs2243480	1	rs937108	ENSG00000273024.4	INTS4P2	3.46	0.000591	0.035	0.27	0.16	Diabetic kidney disease;	chr7:65963465	chr7:65647864~65715661:+
THCA	cis	rs4713118	0.869	rs9283881	ENSG00000272009.1	RP1-313I6.12	-3.46	0.000591	0.035	-0.18	-0.16	Parkinson's disease;	chr6:27747476	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.869	rs9283882	ENSG00000272009.1	RP1-313I6.12	-3.46	0.000591	0.035	-0.18	-0.16	Parkinson's disease;	chr6:27747479	chr6:28078792~28081130:-
THCA	cis	rs7709377	0.571	rs6886944	ENSG00000272265.1	CTD-2287O16.4	3.46	0.000591	0.035	0.16	0.16	Metabolite levels  (X-11787);	chr5:116077345	chr5:116078110~116078570:-
THCA	cis	rs16975963	0.843	rs73041047	ENSG00000276846.1	CTD-3220F14.3	-3.46	0.000591	0.035	-0.15	-0.16	Longevity;	chr19:37808649	chr19:37314868~37315620:-
THCA	cis	rs2287838	0.967	rs11669872	ENSG00000267370.1	CTD-2623N2.3	3.46	0.000591	0.035	0.15	0.16	Sleep duration;	chr19:9875848	chr19:9756152~9756863:-
THCA	cis	rs7267979	0.527	rs6083891	ENSG00000276952.1	RP5-965G21.6	-3.46	0.000591	0.035	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:25284915~25285588:-
THCA	cis	rs7131987	0.903	rs11050163	ENSG00000257599.1	OVCH1-AS1	-3.46	0.000591	0.035	-0.19	-0.16	QT interval;	chr12:29267465	chr12:29389294~29487488:+
THCA	cis	rs7131987	0.903	rs10843373	ENSG00000257599.1	OVCH1-AS1	-3.46	0.000591	0.035	-0.19	-0.16	QT interval;	chr12:29267675	chr12:29389294~29487488:+
THCA	cis	rs11858159	0.532	rs12898466	ENSG00000259905.4	PWRN1	3.46	0.000591	0.035	0.15	0.16	Platelet thrombus formation;	chr15:24179687	chr15:24493137~24652130:+
THCA	cis	rs17604090	0.756	rs4000290	ENSG00000227855.3	DPY19L2P3	-3.46	0.000591	0.035	-0.19	-0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29667871	chr7:29650227~29742594:+
THCA	cis	rs6121246	0.697	rs6060446	ENSG00000224628.2	RP5-854E16.2	-3.46	0.000591	0.035	-0.22	-0.16	Mean corpuscular hemoglobin;	chr20:31643834	chr20:31285317~31286835:-
THCA	cis	rs9450351	0.744	rs6923017	ENSG00000203875.9	SNHG5	-3.46	0.000591	0.0351	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85592619	chr6:85660950~85678736:-
THCA	cis	rs9353324	1	rs7775788	ENSG00000203875.9	SNHG5	-3.46	0.000591	0.0351	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85595761	chr6:85660950~85678736:-
THCA	cis	rs875971	0.862	rs778686	ENSG00000223473.2	GS1-124K5.3	3.46	0.000591	0.0351	0.11	0.16	Aortic root size;	chr7:66370923	chr7:66491049~66493566:-
THCA	cis	rs7246760	0.867	rs16981648	ENSG00000278611.1	CTC-543D15.8	-3.46	0.000591	0.0351	-0.25	-0.16	Pursuit maintenance gain;	chr19:9693748	chr19:9538733~9539734:+
THCA	cis	rs801193	0.66	rs974239	ENSG00000272831.1	RP11-792A8.4	3.46	0.000591	0.0351	0.1	0.16	Aortic root size;	chr7:66748504	chr7:66739829~66740385:-
THCA	cis	rs875971	0.825	rs4587224	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000591	0.0351	-0.11	-0.16	Aortic root size;	chr7:66271195	chr7:66491049~66493566:-
THCA	cis	rs875971	0.792	rs6971752	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000591	0.0351	-0.11	-0.16	Aortic root size;	chr7:66272999	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs10950033	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000591	0.0351	-0.11	-0.16	Aortic root size;	chr7:66274686	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs11760844	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000591	0.0351	-0.11	-0.16	Aortic root size;	chr7:66274896	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs4149461	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000591	0.0351	-0.11	-0.16	Aortic root size;	chr7:66279745	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs10261398	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000591	0.0351	-0.11	-0.16	Aortic root size;	chr7:66285177	chr7:66491049~66493566:-
THCA	cis	rs758324	0.773	rs630044	ENSG00000224431.1	AC063976.7	3.46	0.000591	0.0351	0.14	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131922685	chr5:132199456~132203487:+
THCA	cis	rs4764124	0.646	rs11610238	ENSG00000261324.2	RP11-174G6.5	-3.46	0.000591	0.0351	-0.11	-0.16	Pubertal anthropometrics;	chr12:14822787	chr12:14762504~14767931:-
THCA	cis	rs12534093	0.804	rs13233614	ENSG00000234286.1	AC006026.13	-3.46	0.000591	0.0351	-0.25	-0.16	Infant length;Height;	chr7:23435767	chr7:23680195~23680786:-
THCA	cis	rs6840360	0.935	rs3919716	ENSG00000270265.1	RP11-731D1.4	-3.46	0.000591	0.0351	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151535235	chr4:151333775~151353224:-
THCA	cis	rs6901004	0.565	rs6900341	ENSG00000219773.1	RP11-506B6.3	3.46	0.000591	0.0351	0.19	0.16	Blood metabolite levels;	chr6:111473206	chr6:112355841~112356714:-
THCA	cis	rs10508774	1	rs72793602	ENSG00000217094.2	PPIAP31	3.46	0.000591	0.0351	0.26	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32459444	chr10:32188323~32188817:-
THCA	cis	rs7978895	0.519	rs11182020	ENSG00000240759.1	RP11-25I15.1	3.46	0.000591	0.0351	0.18	0.16	Type 2 diabetes;	chr12:43332718	chr12:42678873~42679124:-
THCA	cis	rs7045881	0.8	rs1034296	ENSG00000254396.1	RP11-56F10.3	-3.46	0.000591	0.0351	-0.3	-0.16	Schizophrenia;	chr9:26817545	chr9:27102630~27104728:+
THCA	cis	rs337161	0.605	rs7556561	ENSG00000221571.3	RNU6ATAC35P	-3.46	0.000591	0.0351	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220772019	chr1:220825620~220826063:+
THCA	cis	rs337161	0.605	rs7542723	ENSG00000221571.3	RNU6ATAC35P	-3.46	0.000591	0.0351	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220772079	chr1:220825620~220826063:+
THCA	cis	rs337161	0.605	rs7519399	ENSG00000221571.3	RNU6ATAC35P	-3.46	0.000591	0.0351	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220772086	chr1:220825620~220826063:+
THCA	cis	rs337161	0.605	rs7519414	ENSG00000221571.3	RNU6ATAC35P	-3.46	0.000591	0.0351	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220772141	chr1:220825620~220826063:+
THCA	cis	rs337161	0.605	rs11118599	ENSG00000221571.3	RNU6ATAC35P	-3.46	0.000591	0.0351	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220772187	chr1:220825620~220826063:+
THCA	cis	rs10129255	1	rs10137758	ENSG00000280411.1	IGHV1-69-2	-3.46	0.000591	0.0351	-0.1	-0.16	Kawasaki disease;	chr14:106697673	chr14:106762092~106762588:-
THCA	cis	rs6500602	0.702	rs2270366	ENSG00000280063.1	RP11-295D4.3	-3.46	0.000591	0.0351	-0.08	-0.16	Schizophrenia;	chr16:4508614	chr16:4346694~4348648:-
THCA	cis	rs7809950	1	rs4727684	ENSG00000272072.1	CTA-363E19.2	3.46	0.000592	0.0351	0.16	0.16	Coronary artery disease;	chr7:107586025	chr7:107192559~107193300:-
THCA	cis	rs2243480	0.522	rs778717	ENSG00000237310.1	GS1-124K5.4	3.46	0.000592	0.0351	0.23	0.16	Diabetic kidney disease;	chr7:66383164	chr7:66493706~66495474:+
THCA	cis	rs6812193	1	rs1946959	ENSG00000234036.4	TXNP6	-3.46	0.000592	0.0351	-0.23	-0.16	Parkinson's disease;	chr4:76275524	chr4:76958860~76959169:-
THCA	cis	rs7631605	0.625	rs11710131	ENSG00000224080.1	UBE2FP1	3.46	0.000592	0.0351	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37241194	chr3:37143512~37143958:-
THCA	cis	rs7202877	0.706	rs37602	ENSG00000276408.1	RP11-490B18.5	-3.46	0.000592	0.0351	-0.28	-0.16	Type 1 diabetes;Type 2 diabetes;	chr16:75471148	chr16:75556392~75557059:+
THCA	cis	rs1790761	0.658	rs684928	ENSG00000184224.3	C11orf72	3.46	0.000592	0.0351	0.21	0.16	Mean corpuscular volume;	chr11:67562271	chr11:67602880~67606706:-
THCA	cis	rs208520	0.955	rs12204033	ENSG00000218890.1	NUFIP1P	3.46	0.000592	0.0351	0.26	0.16	Exhaled nitric oxide output;	chr6:66291632	chr6:66093431~66094909:-
THCA	cis	rs208520	0.955	rs12202599	ENSG00000218890.1	NUFIP1P	3.46	0.000592	0.0351	0.26	0.16	Exhaled nitric oxide output;	chr6:66291680	chr6:66093431~66094909:-
THCA	cis	rs9860428	0.815	rs9825873	ENSG00000243795.1	RP11-572M11.3	3.46	0.000592	0.0351	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905547	chr3:113142350~113167819:-
THCA	cis	rs4648045	0.565	rs11733749	ENSG00000248971.2	KRT8P46	-3.46	0.000592	0.0351	-0.19	-0.16	Lymphocyte percentage of white cells;	chr4:102625985	chr4:102728746~102730171:-
THCA	cis	rs7074356	0.569	rs17102596	ENSG00000278616.1	BEND3P3	3.46	0.000592	0.0351	0.13	0.16	Borderline personality disorder;	chr10:80275417	chr10:79682997~79685436:+
THCA	cis	rs2302464	1	rs10939630	ENSG00000214846.4	RP11-115L11.1	3.46	0.000592	0.0351	0.35	0.16	Cerebrospinal fluid biomarker levels;	chr4:15656858	chr4:15730962~15731627:-
THCA	cis	rs11785400	1	rs3802232	ENSG00000177335.9	C8orf31	3.46	0.000592	0.0351	0.18	0.16	Schizophrenia;	chr8:142665282	chr8:143039209~143059942:+
THCA	cis	rs2822388	0.744	rs11701640	ENSG00000230965.1	SNX18P13	-3.46	0.000592	0.0351	-0.32	-0.16	Stroke;	chr21:14062617	chr21:13905960~13906488:-
THCA	cis	rs337161	0.543	rs4846662	ENSG00000221571.3	RNU6ATAC35P	3.46	0.000592	0.0351	0.17	0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220778622	chr1:220825620~220826063:+
THCA	cis	rs6787172	0.622	rs12107103	ENSG00000272087.1	RP11-379F4.7	-3.46	0.000592	0.0351	-0.14	-0.16	Subjective well-being;	chr3:158408493	chr3:158693120~158693768:-
THCA	cis	rs2822388	0.59	rs2822387	ENSG00000230965.1	SNX18P13	-3.46	0.000592	0.0351	-0.32	-0.16	Stroke;	chr21:14034842	chr21:13905960~13906488:-
THCA	cis	rs10454142	0.7	rs72820418	ENSG00000202227.1	RNU6-282P	3.46	0.000592	0.0351	0.19	0.16	Sex hormone-binding globulin levels;	chr2:48349548	chr2:48501922~48502024:-
THCA	cis	rs11386980	1	rs11386980	ENSG00000228421.2	AC005013.5	3.46	0.000592	0.0351	0.25	0.16	Lobe attachment (rater-scored or self-reported);	chr7:28965957	chr7:28957667~28959345:+
THCA	cis	rs6929812	0.665	rs10946919	ENSG00000216915.2	RP1-97D16.1	3.46	0.000592	0.0351	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27445188	chr6:27737000~27738494:-
THCA	cis	rs9650657	0.648	rs7833945	ENSG00000248896.2	CTD-2135J3.3	-3.46	0.000592	0.0351	-0.2	-0.16	Neuroticism;	chr8:10842756	chr8:10729314~10771392:+
THCA	cis	rs7246657	0.55	rs10411176	ENSG00000267422.1	CTD-2554C21.1	-3.46	0.000592	0.0351	-0.23	-0.16	Coronary artery calcification;	chr19:37196051	chr19:37779686~37792865:+
THCA	cis	rs6806253	0.73	rs9877627	ENSG00000273174.1	RP11-434H6.6	-3.46	0.000592	0.0351	-0.2	-0.16	Pit-and-Fissure caries;	chr3:128530406	chr3:129123439~129124003:+
THCA	cis	rs6546886	0.711	rs6712566	ENSG00000235499.1	AC073046.25	3.46	0.000592	0.0351	0.17	0.16	Dialysis-related mortality;	chr2:74018194	chr2:73985132~73986343:+
THCA	cis	rs427941	1	rs6465852	ENSG00000239486.1	RP11-163E9.1	3.46	0.000592	0.0351	0.16	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102203618	chr7:102380465~102382737:-
THCA	cis	rs7246967	0.611	rs62118823	ENSG00000198153.8	ZNF849P	-3.46	0.000592	0.0351	-0.26	-0.16	Bronchopulmonary dysplasia;	chr19:22661264	chr19:22685167~22686732:+
THCA	cis	rs9863	0.896	rs4930722	ENSG00000270028.1	RP11-380L11.4	3.46	0.000592	0.0351	0.17	0.16	White blood cell count;	chr12:123938728	chr12:123925461~123926083:-
THCA	cis	rs8040855	0.599	rs4643289	ENSG00000259630.2	CTD-2262B20.1	3.46	0.000592	0.0351	0.17	0.16	Bulimia nervosa;	chr15:85183483	chr15:85415228~85415633:+
THCA	cis	rs6929812	0.702	rs10946918	ENSG00000271755.1	RP1-153G14.4	3.46	0.000592	0.0351	0.18	0.16	Neuroticism (multi-trait analysis);	chr6:27413214	chr6:27404010~27406964:-
THCA	cis	rs7615952	0.599	rs6438953	ENSG00000248787.1	RP11-666A20.4	-3.46	0.000592	0.0351	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126006108	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.599	rs1044215	ENSG00000248787.1	RP11-666A20.4	-3.46	0.000592	0.0351	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126006716	chr3:125908005~125910272:-
THCA	cis	rs4244255	1	rs2864004	ENSG00000260461.1	RP11-541N10.3	-3.46	0.000592	0.0351	-0.35	-0.16	Differentiated thyroid cancer;	chr10:103952090	chr10:103877374~103879761:-
THCA	cis	rs867186	0.614	rs116707649	ENSG00000126005.14	MMP24-AS1	-3.46	0.000593	0.0351	-0.33	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34836868	chr20:35216462~35278131:-
THCA	cis	rs867186	0.614	rs75848331	ENSG00000126005.14	MMP24-AS1	-3.46	0.000593	0.0351	-0.33	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34837186	chr20:35216462~35278131:-
THCA	cis	rs867186	0.614	rs78260746	ENSG00000126005.14	MMP24-AS1	-3.46	0.000593	0.0351	-0.33	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34838312	chr20:35216462~35278131:-
THCA	cis	rs867186	0.614	rs117065834	ENSG00000126005.14	MMP24-AS1	-3.46	0.000593	0.0351	-0.33	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34838765	chr20:35216462~35278131:-
THCA	cis	rs7951870	1	rs61882682	ENSG00000254427.1	RP11-430H10.1	-3.46	0.000593	0.0351	-0.2	-0.16	Schizophrenia;	chr11:46354544	chr11:45355371~45366121:+
THCA	cis	rs2692947	0.832	rs2579550	ENSG00000232931.4	LINC00342	3.46	0.000593	0.0351	0.13	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96076196	chr2:95807118~95816215:-
THCA	cis	rs875971	0.83	rs778711	ENSG00000223473.2	GS1-124K5.3	3.46	0.000593	0.0351	0.11	0.16	Aortic root size;	chr7:66386670	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs1083554	ENSG00000223473.2	GS1-124K5.3	3.46	0.000593	0.0351	0.11	0.16	Aortic root size;	chr7:66387354	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs778707	ENSG00000223473.2	GS1-124K5.3	3.46	0.000593	0.0351	0.11	0.16	Aortic root size;	chr7:66392040	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs778705	ENSG00000223473.2	GS1-124K5.3	3.46	0.000593	0.0351	0.11	0.16	Aortic root size;	chr7:66396128	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs778697	ENSG00000223473.2	GS1-124K5.3	3.46	0.000593	0.0351	0.11	0.16	Aortic root size;	chr7:66405439	chr7:66491049~66493566:-
THCA	cis	rs875971	0.798	rs7789615	ENSG00000223473.2	GS1-124K5.3	3.46	0.000593	0.0351	0.11	0.16	Aortic root size;	chr7:66413674	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6978028	ENSG00000223473.2	GS1-124K5.3	3.46	0.000593	0.0351	0.11	0.16	Aortic root size;	chr7:66421313	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6947339	ENSG00000223473.2	GS1-124K5.3	3.46	0.000593	0.0351	0.11	0.16	Aortic root size;	chr7:66423483	chr7:66491049~66493566:-
THCA	cis	rs6499640	0.643	rs7205986	ENSG00000275191.1	RP11-36I17.2	3.46	0.000593	0.0351	0.2	0.16	Body mass index;Weight;	chr16:53721234	chr16:53628256~53628816:-
THCA	cis	rs643506	0.79	rs688095	ENSG00000230911.1	PPIHP1	-3.46	0.000593	0.0351	-0.21	-0.16	Breast cancer;	chr11:111808047	chr11:112029858~112030367:-
THCA	cis	rs2904967	0.929	rs592050	ENSG00000254614.2	AP003068.23	3.46	0.000593	0.0351	0.28	0.16	Mean corpuscular volume;	chr11:65262718	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.929	rs554122	ENSG00000254614.2	AP003068.23	3.46	0.000593	0.0351	0.28	0.16	Mean corpuscular volume;	chr11:65266403	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.852	rs488289	ENSG00000254614.2	AP003068.23	3.46	0.000593	0.0351	0.28	0.16	Mean corpuscular volume;	chr11:65271793	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.852	rs1858783	ENSG00000254614.2	AP003068.23	3.46	0.000593	0.0351	0.28	0.16	Mean corpuscular volume;	chr11:65275470	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.81	rs507005	ENSG00000254614.2	AP003068.23	3.46	0.000593	0.0351	0.28	0.16	Mean corpuscular volume;	chr11:65278144	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.852	rs668735	ENSG00000254614.2	AP003068.23	3.46	0.000593	0.0351	0.28	0.16	Mean corpuscular volume;	chr11:65278254	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.866	rs526502	ENSG00000254614.2	AP003068.23	-3.46	0.000593	0.0351	-0.28	-0.16	Mean corpuscular volume;	chr11:65259119	chr11:65177606~65181834:-
THCA	cis	rs7264396	0.887	rs2236160	ENSG00000261582.1	RP4-614O4.11	-3.46	0.000593	0.0351	-0.16	-0.16	Total cholesterol levels;	chr20:35513992	chr20:35267885~35280043:-
THCA	cis	rs6942407	0.64	rs4728690	ENSG00000224046.1	AC005076.5	-3.46	0.000593	0.0351	-0.14	-0.16	Food allergy;	chr7:87224688	chr7:87151423~87152420:-
THCA	cis	rs34102591	0.503	rs34587940	ENSG00000270061.1	RP11-214K3.19	-3.46	0.000593	0.0351	-0.21	-0.16	Schizophrenia;	chr12:123906948	chr12:123969990~123970344:-
THCA	cis	rs6545883	0.524	rs12992614	ENSG00000273302.1	RP11-493E12.2	-3.46	0.000593	0.0351	-0.14	-0.16	Tuberculosis;	chr2:61365941	chr2:61199979~61200769:+
THCA	cis	rs1876905	0.68	rs557028	ENSG00000271789.1	RP5-1112D6.7	-3.46	0.000593	0.0351	-0.19	-0.16	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111297126~111298510:+
THCA	cis	rs721917	0.629	rs1304463	ENSG00000225484.5	NUTM2B-AS1	-3.46	0.000593	0.0351	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr10:79969516	chr10:79663088~79826594:-
THCA	cis	rs9863	0.861	rs4930723	ENSG00000270130.1	RP11-214K3.23	-3.46	0.000593	0.0351	-0.19	-0.16	White blood cell count;	chr12:123939053	chr12:123960717~123961244:-
THCA	cis	rs7578199	0.706	rs9973927	ENSG00000228989.1	AC133528.2	3.46	0.000593	0.0352	0.15	0.16	Chronic lymphocytic leukemia;	chr2:241502831	chr2:241690414~241694289:+
THCA	cis	rs735539	0.874	rs9579927	ENSG00000278291.1	RP11-172H24.4	-3.46	0.000593	0.0352	-0.2	-0.16	Dental caries;	chr13:20696062	chr13:20699307~20703718:-
THCA	cis	rs416603	0.901	rs149597	ENSG00000263179.1	HNRNPCP4	3.46	0.000593	0.0352	0.2	0.16	Type 1 diabetes;	chr16:11250085	chr16:11242653~11243552:+
THCA	cis	rs9314614	0.714	rs2980948	ENSG00000245857.2	GS1-24F4.2	-3.46	0.000593	0.0352	-0.21	-0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6856173	chr8:6835554~6885276:+
THCA	cis	rs1065852	0.526	rs9611700	ENSG00000232710.1	RP4-669P10.16	-3.46	0.000593	0.0352	-0.2	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42005510	chr22:42136433~42139927:-
THCA	cis	rs1065852	0.526	rs2413663	ENSG00000232710.1	RP4-669P10.16	-3.46	0.000593	0.0352	-0.2	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42006395	chr22:42136433~42139927:-
THCA	cis	rs12681366	0.537	rs10956914	ENSG00000253175.1	RP11-267M23.6	-3.46	0.000593	0.0352	-0.19	-0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94471495	chr8:94565036~94565715:+
THCA	cis	rs35123781	1	rs35123781	ENSG00000200378.1	RNU5B-4P	3.46	0.000593	0.0352	0.2	0.16	Schizophrenia;	chr5:139685595	chr5:139447907~139448017:+
THCA	cis	rs763121	0.962	rs5757130	ENSG00000228274.3	RP3-508I15.9	-3.46	0.000593	0.0352	-0.16	-0.16	Menopause (age at onset);	chr22:38541789	chr22:38667585~38681820:-
THCA	cis	rs7307902	1	rs11168140	ENSG00000280054.1	RP1-197B17.7	-3.46	0.000594	0.0352	-0.18	-0.16	Obesity-related traits;	chr12:47532925	chr12:47728151~47730598:-
THCA	cis	rs7307902	1	rs12230768	ENSG00000280054.1	RP1-197B17.7	-3.46	0.000594	0.0352	-0.18	-0.16	Obesity-related traits;	chr12:47533201	chr12:47728151~47730598:-
THCA	cis	rs7307902	1	rs10783202	ENSG00000280054.1	RP1-197B17.7	-3.46	0.000594	0.0352	-0.18	-0.16	Obesity-related traits;	chr12:47533922	chr12:47728151~47730598:-
THCA	cis	rs35091702	1	rs35091702	ENSG00000254152.1	CTD-3107M8.2	3.46	0.000594	0.0352	0.23	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr8:30421961	chr8:30349866~30350347:-
THCA	cis	rs11175834	0.655	rs12311233	ENSG00000255866.1	RP11-221N13.2	-3.46	0.000594	0.0352	-0.29	-0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65607333	chr12:65559591~65560889:+
THCA	cis	rs11931598	0.509	rs13140943	ENSG00000245468.3	RP11-367J11.3	3.46	0.000594	0.0352	0.11	0.16	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:6975382	chr4:7094571~7103385:-
THCA	cis	rs1005277	0.579	rs2505194	ENSG00000151963.4	RP11-775A3.1	-3.46	0.000594	0.0352	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:37883594~37884109:+
THCA	cis	rs10761482	0.859	rs1599166	ENSG00000254271.1	RP11-131N11.4	3.46	0.000594	0.0352	0.21	0.16	Schizophrenia;	chr10:60403971	chr10:60734342~60741828:+
THCA	cis	rs10761482	0.861	rs7909961	ENSG00000254271.1	RP11-131N11.4	3.46	0.000594	0.0352	0.21	0.16	Schizophrenia;	chr10:60405820	chr10:60734342~60741828:+
THCA	cis	rs1729951	0.575	rs16844326	ENSG00000239213.4	NCK1-AS1	3.46	0.000594	0.0352	0.14	0.16	Neuroticism;	chr3:136959543	chr3:136841726~136862054:-
THCA	cis	rs10927875	0.632	rs904911	ENSG00000179743.3	FLJ37453	-3.46	0.000594	0.0352	-0.11	-0.16	Dilated cardiomyopathy;	chr1:15800437	chr1:15834479~15848147:-
THCA	cis	rs10927875	0.632	rs1122068	ENSG00000179743.3	FLJ37453	-3.46	0.000594	0.0352	-0.11	-0.16	Dilated cardiomyopathy;	chr1:15800985	chr1:15834479~15848147:-
THCA	cis	rs10927875	0.632	rs4481843	ENSG00000179743.3	FLJ37453	-3.46	0.000594	0.0352	-0.11	-0.16	Dilated cardiomyopathy;	chr1:15801710	chr1:15834479~15848147:-
THCA	cis	rs10927875	0.596	rs1806990	ENSG00000179743.3	FLJ37453	-3.46	0.000594	0.0352	-0.11	-0.16	Dilated cardiomyopathy;	chr1:15802882	chr1:15834479~15848147:-
THCA	cis	rs10927875	0.632	rs7535248	ENSG00000179743.3	FLJ37453	-3.46	0.000594	0.0352	-0.11	-0.16	Dilated cardiomyopathy;	chr1:15803103	chr1:15834479~15848147:-
THCA	cis	rs12701220	0.604	rs34904312	ENSG00000225146.1	AC073957.15	3.46	0.000594	0.0352	0.21	0.16	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1029025~1043891:+
THCA	cis	rs56184018	0.709	rs7856642	ENSG00000222465.1	RNU2-5P	-3.46	0.000594	0.0352	-0.19	-0.16	Mean platelet volume;	chr9:70491437	chr9:70188571~70188750:-
THCA	cis	rs858239	1	rs166663	ENSG00000230042.1	AK3P3	-3.46	0.000594	0.0352	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23129178~23129841:+
THCA	cis	rs2832191	1	rs2832183	ENSG00000232855.5	AF131217.1	3.46	0.000594	0.0352	0.16	0.16	Dental caries;	chr21:29109829	chr21:28439346~28674848:-
THCA	cis	rs78265569	0.786	rs12385717	ENSG00000224387.1	RP3-395M20.2	-3.46	0.000594	0.0352	-0.34	-0.16	Plateletcrit;Platelet count;	chr1:2253416	chr1:2492300~2493258:-
THCA	cis	rs12780845	0.931	rs57751544	ENSG00000273153.1	RP11-406H21.2	3.46	0.000594	0.0352	0.15	0.16	Homocysteine levels;	chr10:17203121	chr10:17137336~17137585:-
THCA	cis	rs9843304	0.501	rs34540967	ENSG00000243885.1	RP11-278L15.2	3.46	0.000594	0.0352	0.17	0.16	Gallstone disease;	chr3:149486594	chr3:149384179~149385800:-
THCA	cis	rs970548	0.908	rs10900229	ENSG00000230869.1	CTGLF10P	3.46	0.000594	0.0352	0.2	0.16	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45625598	chr10:45678692~45700532:+
THCA	cis	rs2726040	0.902	rs33957528	ENSG00000278665.1	RP11-666O2.4	-3.46	0.000594	0.0352	-0.16	-0.16	Hip circumference;	chr16:28296619	chr16:28599241~28601881:-
THCA	cis	rs2124969	0.548	rs7586751	ENSG00000226266.5	AC009961.3	-3.46	0.000594	0.0352	-0.25	-0.16	Waist circumference adjusted for body mass index;	chr2:160101634	chr2:159670708~159712435:-
THCA	cis	rs9990333	0.544	rs73208092	ENSG00000185485.13	SDHAP1	3.46	0.000594	0.0352	0.14	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195959748~195990318:-
THCA	cis	rs4660214	0.666	rs7538300	ENSG00000228060.1	RP11-69E11.8	3.46	0.000594	0.0352	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39187092	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.666	rs11205739	ENSG00000228060.1	RP11-69E11.8	3.46	0.000594	0.0352	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39190729	chr1:39565160~39573203:+
THCA	cis	rs34792	0.554	rs28393495	ENSG00000275910.1	RP11-680G24.6	-3.46	0.000594	0.0352	-0.19	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15516406	chr16:15015828~15016390:-
THCA	cis	rs9487094	0.666	rs12529733	ENSG00000223537.2	RP5-919F19.5	-3.46	0.000594	0.0352	-0.16	-0.16	Height;	chr6:109332929	chr6:109487906~109506800:+
THCA	cis	rs4246307	1	rs4246307	ENSG00000189419.6	SPATA41	3.46	0.000594	0.0352	0.19	0.16	Hip circumference adjusted for BMI;	chr15:100223619	chr15:100344457~100349655:-
THCA	cis	rs16986825	0.57	rs5762879	ENSG00000272858.1	CTA-292E10.8	-3.46	0.000594	0.0352	-0.18	-0.16	Pancreatic cancer;	chr22:28890192	chr22:28814914~28815662:+
THCA	cis	rs6496667	0.908	rs12592935	ENSG00000259262.1	NDUFA3P4	3.46	0.000594	0.0352	0.21	0.16	Rheumatoid arthritis;	chr15:90309205	chr15:90385814~90386063:+
THCA	cis	rs8187707	1	rs72838138	ENSG00000233690.1	EBAG9P1	-3.46	0.000595	0.0352	-0.32	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99848144	chr10:99697407~99697949:-
THCA	cis	rs8187707	1	rs72838146	ENSG00000233690.1	EBAG9P1	-3.46	0.000595	0.0352	-0.32	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99849294	chr10:99697407~99697949:-
THCA	cis	rs1075265	0.901	rs1118618	ENSG00000235937.1	AC008280.1	3.46	0.000595	0.0352	0.19	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54029552~54030682:-
THCA	cis	rs6929812	0.664	rs6938943	ENSG00000216915.2	RP1-97D16.1	3.46	0.000595	0.0352	0.2	0.16	Neuroticism (multi-trait analysis);	chr6:27409131	chr6:27737000~27738494:-
THCA	cis	rs17122278	1	rs7929887	ENSG00000243431.1	RPL5P30	3.46	0.000595	0.0352	0.16	0.16	Total cholesterol levels;	chr11:118558076	chr11:118560690~118561580:+
THCA	cis	rs17666538	1	rs61122136	ENSG00000254207.1	RP11-43A14.1	-3.46	0.000595	0.0352	-0.37	-0.16	IgG glycosylation;	chr8:635027	chr8:725188~725877:-
THCA	cis	rs17666538	0.901	rs73177064	ENSG00000254207.1	RP11-43A14.1	-3.46	0.000595	0.0352	-0.37	-0.16	IgG glycosylation;	chr8:635293	chr8:725188~725877:-
THCA	cis	rs17666538	1	rs73177066	ENSG00000254207.1	RP11-43A14.1	-3.46	0.000595	0.0352	-0.37	-0.16	IgG glycosylation;	chr8:635750	chr8:725188~725877:-
THCA	cis	rs909002	0.772	rs12740754	ENSG00000235790.6	RP11-73M7.6	3.46	0.000595	0.0352	0.16	0.16	Intelligence (multi-trait analysis);	chr1:31617672	chr1:31644049~31660162:+
THCA	cis	rs867186	1	rs35552264	ENSG00000126005.14	MMP24-AS1	-3.46	0.000595	0.0352	-0.27	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34957170	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs17310467	ENSG00000126005.14	MMP24-AS1	-3.46	0.000595	0.0352	-0.27	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34957813	chr20:35216462~35278131:-
THCA	cis	rs564148	1	rs570408	ENSG00000239670.1	RP4-803A2.2	-3.46	0.000595	0.0352	-0.27	-0.16	Response to amphetamines;	chr1:33708824	chr1:32986952~32988233:+
THCA	cis	rs858239	1	rs858239	ENSG00000230042.1	AK3P3	-3.46	0.000595	0.0352	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23129178~23129841:+
THCA	cis	rs5751168	0.834	rs393829	ENSG00000240160.3	RN7SL263P	3.46	0.000595	0.0352	0.25	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22484081	chr22:23261782~23262071:-
THCA	cis	rs3136739	0.614	rs7837168	ENSG00000240395.1	RPL5P23	3.46	0.000595	0.0352	0.27	0.16	Plasma plasminogen activator levels;	chr8:42280646	chr8:42341767~42342634:-
THCA	cis	rs2562456	0.833	rs11667361	ENSG00000268278.1	RP11-420K14.1	3.46	0.000595	0.0352	0.22	0.16	Pain;	chr19:21356580	chr19:21637974~21656300:+
THCA	cis	rs1065852	0.526	rs11090066	ENSG00000227370.1	RP4-669P10.19	3.46	0.000595	0.0352	0.16	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002191	chr22:42132543~42132998:+
THCA	cis	rs7873102	0.967	rs943941	ENSG00000213839.4	TMX2P1	3.46	0.000595	0.0352	0.12	0.16	Brain structure;	chr9:38058305	chr9:37885683~37886390:+
THCA	cis	rs4713118	0.955	rs9380010	ENSG00000219891.2	ZSCAN12P1	3.46	0.000595	0.0352	0.21	0.16	Parkinson's disease;	chr6:27715793	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.955	rs9368528	ENSG00000219891.2	ZSCAN12P1	3.46	0.000595	0.0352	0.21	0.16	Parkinson's disease;	chr6:27716019	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.955	rs9380011	ENSG00000219891.2	ZSCAN12P1	3.46	0.000595	0.0352	0.21	0.16	Parkinson's disease;	chr6:27716145	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.955	rs9368529	ENSG00000219891.2	ZSCAN12P1	3.46	0.000595	0.0352	0.21	0.16	Parkinson's disease;	chr6:27716852	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.955	rs9380012	ENSG00000219891.2	ZSCAN12P1	3.46	0.000595	0.0352	0.21	0.16	Parkinson's disease;	chr6:27716875	chr6:28091154~28093664:+
THCA	cis	rs7989336	0.515	rs61966957	ENSG00000247400.3	DNAJC3-AS1	-3.46	0.000595	0.0352	-0.11	-0.16	Obesity;	chr13:96363111	chr13:95648733~95676925:-
THCA	cis	rs6580649	0.941	rs1635529	ENSG00000273765.1	RP11-370I10.11	3.46	0.000595	0.0352	0.17	0.16	Lung cancer;	chr12:48001319	chr12:48360920~48361377:+
THCA	cis	rs9650657	0.707	rs10097283	ENSG00000255310.2	AF131215.2	-3.46	0.000595	0.0352	-0.13	-0.16	Neuroticism;	chr8:10801896	chr8:11107788~11109726:-
THCA	cis	rs2033711	0.902	rs4801589	ENSG00000268049.1	CTD-2619J13.9	-3.46	0.000595	0.0352	-0.2	-0.16	Uric acid clearance;	chr19:58442031	chr19:58357999~58359603:+
THCA	cis	rs1440410	0.798	rs10026015	ENSG00000250326.1	RP11-284M14.1	-3.46	0.000595	0.0352	-0.14	-0.16	Ischemic stroke;	chr4:143248486	chr4:142933195~143184861:-
THCA	cis	rs4845570	0.92	rs11810571	ENSG00000269489.1	RP11-98D18.17	3.46	0.000595	0.0352	0.16	0.16	Coronary artery disease;	chr1:151789832	chr1:151798054~151798602:+
THCA	cis	rs34217772	0.883	rs61992374	ENSG00000258636.1	CTD-2298J14.2	3.46	0.000595	0.0352	0.3	0.16	Myopia;	chr14:41738042	chr14:41587861~41604856:-
THCA	cis	rs34217772	0.771	rs61992388	ENSG00000258636.1	CTD-2298J14.2	3.46	0.000595	0.0352	0.3	0.16	Myopia;	chr14:41740677	chr14:41587861~41604856:-
THCA	cis	rs758324	0.812	rs13165154	ENSG00000224431.1	AC063976.7	3.46	0.000595	0.0353	0.14	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131819327	chr5:132199456~132203487:+
THCA	cis	rs758324	0.812	rs11750031	ENSG00000224431.1	AC063976.7	3.46	0.000595	0.0353	0.14	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131835558	chr5:132199456~132203487:+
THCA	cis	rs758324	0.773	rs2404777	ENSG00000224431.1	AC063976.7	3.46	0.000595	0.0353	0.14	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131837110	chr5:132199456~132203487:+
THCA	cis	rs758324	0.812	rs2088718	ENSG00000224431.1	AC063976.7	3.46	0.000595	0.0353	0.14	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131843496	chr5:132199456~132203487:+
THCA	cis	rs758324	0.812	rs6893070	ENSG00000224431.1	AC063976.7	-3.46	0.000595	0.0353	-0.14	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131901906	chr5:132199456~132203487:+
THCA	cis	rs6017317	0.696	rs4810417	ENSG00000234271.1	RP1-138B7.4	-3.46	0.000595	0.0353	-0.2	-0.16	Type 2 diabetes;	chr20:44275857	chr20:43523261~43523572:-
THCA	cis	rs12149695	0.966	rs4499236	ENSG00000259940.2	CTD-3203P2.1	-3.46	0.000595	0.0353	-0.17	-0.16	Gut microbiota (bacterial taxa);	chr16:27242810	chr16:27213308~27214993:-
THCA	cis	rs1005277	0.579	rs2505257	ENSG00000120555.12	SEPT7P9	3.46	0.000595	0.0353	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38383069~38402916:-
THCA	cis	rs6687821	0.531	rs6661530	ENSG00000261737.1	RP4-612B15.3	-3.46	0.000595	0.0353	-0.25	-0.16	Yeast infection;	chr1:87020367	chr1:86703502~86704462:-
THCA	cis	rs6600671	0.934	rs12060031	ENSG00000233029.3	RP11-439A17.9	3.46	0.000595	0.0353	0.18	0.16	Hip geometry;	chr1:121501652	chr1:121090289~121097655:-
THCA	cis	rs8058578	0.633	rs113448632	ENSG00000260082.1	RP11-2C24.5	3.46	0.000595	0.0353	0.19	0.16	Multiple myeloma;	chr16:30886898	chr16:30821068~30822110:-
THCA	cis	rs7005380	0.965	rs9918815	ENSG00000279347.1	RP11-85I17.2	3.46	0.000595	0.0353	0.19	0.16	Interstitial lung disease;	chr8:119939370	chr8:119838736~119840385:-
THCA	cis	rs11190604	0.767	rs10883478	ENSG00000273030.1	RP11-285F16.1	3.46	0.000595	0.0353	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100403095	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs7085426	ENSG00000273030.1	RP11-285F16.1	3.46	0.000595	0.0353	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100403883	chr10:100412934~100413421:+
THCA	cis	rs1800795	0.53	rs62449494	ENSG00000225541.1	AC002480.5	-3.46	0.000595	0.0353	-0.17	-0.16	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22718416	chr7:22571607~22661792:-
THCA	cis	rs1823913	0.503	rs6434464	ENSG00000280083.1	RP11-317J9.1	3.46	0.000595	0.0353	0.18	0.16	Obesity-related traits;	chr2:191341120	chr2:191154118~191156070:-
THCA	cis	rs7020830	0.861	rs13295981	ENSG00000260100.1	RP11-220I1.5	-3.46	0.000595	0.0353	-0.19	-0.16	Schizophrenia;	chr9:37330070	chr9:37078813~37079776:-
THCA	cis	rs7131987	0.903	rs918873	ENSG00000274315.1	RP11-996F15.5	3.46	0.000595	0.0353	0.21	0.16	QT interval;	chr12:29237568	chr12:29331434~29331936:-
THCA	cis	rs867186	0.614	rs73902680	ENSG00000126005.14	MMP24-AS1	-3.46	0.000595	0.0353	-0.28	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34706140	chr20:35216462~35278131:-
THCA	cis	rs4561483	0.832	rs171656	ENSG00000263307.1	RP11-166B2.8	3.46	0.000596	0.0353	0.17	0.16	Testicular germ cell tumor;	chr16:11859310	chr16:11851649~11895611:+
THCA	cis	rs7824557	0.564	rs2736304	ENSG00000261451.1	RP11-981G7.1	-3.46	0.000596	0.0353	-0.2	-0.16	Retinal vascular caliber;	chr8:11379455	chr8:10433672~10438312:+
THCA	cis	rs875971	0.825	rs1000464	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000596	0.0353	-0.11	-0.16	Aortic root size;	chr7:66312922	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs10282433	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000596	0.0353	-0.11	-0.16	Aortic root size;	chr7:66256452	chr7:66491049~66493566:-
THCA	cis	rs10911902	0.643	rs3766703	ENSG00000228238.1	GS1-304P7.2	-3.46	0.000596	0.0353	-0.25	-0.16	Schizophrenia;	chr1:186346575	chr1:186578279~186579299:+
THCA	cis	rs972578	0.747	rs5758975	ENSG00000230319.1	AL022476.2	3.46	0.000596	0.0353	0.17	0.16	Mean platelet volume;	chr22:42837259	chr22:43038585~43052366:+
THCA	cis	rs4664293	0.867	rs2357531	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159740907	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs2357532	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159740916	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs16844269	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159742569	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.836	rs4664300	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159743927	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs16822556	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159744392	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs16822558	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159744496	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs1834761	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159745278	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs6432558	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159745397	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.836	rs7567818	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159746186	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs12692563	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159746300	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs12620924	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159746452	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.836	rs13397597	ENSG00000230783.1	AC009961.2	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159747084	chr2:159689217~159690291:-
THCA	cis	rs7631605	0.507	rs7611351	ENSG00000224080.1	UBE2FP1	3.46	0.000596	0.0353	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37364761	chr3:37143512~37143958:-
THCA	cis	rs4727027	0.645	rs12704072	ENSG00000244560.5	RP4-800G7.2	-3.46	0.000596	0.0353	-0.09	-0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149207796	chr7:149285281~149297312:+
THCA	cis	rs12681366	0.881	rs12676373	ENSG00000253175.1	RP11-267M23.6	3.46	0.000596	0.0353	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94349890	chr8:94565036~94565715:+
THCA	cis	rs10405744	0.546	rs59284055	ENSG00000267419.1	CTC-559E9.6	-3.46	0.000596	0.0353	-0.29	-0.16	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);	chr19:19863320	chr19:19776602~19834927:+
THCA	cis	rs1383484	0.798	rs2086441	ENSG00000230373.7	GOLGA6L5P	-3.46	0.000596	0.0353	-0.16	-0.16	Height;	chr15:83881728	chr15:84507885~84516814:-
THCA	cis	rs12428035	0.764	rs4547219	ENSG00000247400.3	DNAJC3-AS1	-3.46	0.000596	0.0353	-0.16	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96089402	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs11616724	ENSG00000247400.3	DNAJC3-AS1	-3.46	0.000596	0.0353	-0.16	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96089416	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs11618108	ENSG00000247400.3	DNAJC3-AS1	-3.46	0.000596	0.0353	-0.16	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96089608	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs72637840	ENSG00000247400.3	DNAJC3-AS1	-3.46	0.000596	0.0353	-0.16	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96090033	chr13:95648733~95676925:-
THCA	cis	rs2692947	0.666	rs10183151	ENSG00000232931.4	LINC00342	-3.46	0.000596	0.0353	-0.13	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96109038	chr2:95807118~95816215:-
THCA	cis	rs62229266	0.626	rs2835268	ENSG00000233393.1	AP000688.29	-3.46	0.000596	0.0353	-0.2	-0.16	Mitral valve prolapse;	chr21:36076838	chr21:36104881~36109690:+
THCA	cis	rs11678825	0.852	rs74318372	ENSG00000272663.1	RP11-191L17.1	-3.46	0.000596	0.0353	-0.23	-0.16	Reticulocyte fraction of red cells;	chr2:48444175	chr2:48440043~48440597:-
THCA	cis	rs1971762	0.563	rs4759285	ENSG00000270175.1	RP11-793H13.11	-3.46	0.000596	0.0353	-0.11	-0.16	Height;	chr12:53685729	chr12:53500162~53500936:-
THCA	cis	rs2299587	0.866	rs208768	ENSG00000253671.1	RP11-806O11.1	-3.46	0.000596	0.0353	-0.19	-0.16	Economic and political preferences;	chr8:17946414	chr8:17808941~17820868:+
THCA	cis	rs2299587	0.866	rs208767	ENSG00000253671.1	RP11-806O11.1	-3.46	0.000596	0.0353	-0.19	-0.16	Economic and political preferences;	chr8:17947891	chr8:17808941~17820868:+
THCA	cis	rs2299587	0.866	rs208766	ENSG00000253671.1	RP11-806O11.1	-3.46	0.000596	0.0353	-0.19	-0.16	Economic and political preferences;	chr8:17947923	chr8:17808941~17820868:+
THCA	cis	rs2562456	0.833	rs2359145	ENSG00000213976.4	CTD-2561J22.2	-3.46	0.000596	0.0353	-0.2	-0.16	Pain;	chr19:21409791	chr19:21382865~21387177:+
THCA	cis	rs10090774	0.965	rs72685787	ENSG00000280303.2	ERICD	3.46	0.000596	0.0353	0.15	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140950016	chr8:140636281~140638283:+
THCA	cis	rs7095944	0.582	rs10901823	ENSG00000214297.3	ALDOAP2	-3.46	0.000596	0.0353	-0.19	-0.16	Asthma;	chr10:124800091	chr10:125666875~125667950:-
THCA	cis	rs9611565	0.512	rs2899347	ENSG00000237037.8	NDUFA6-AS1	-3.46	0.000596	0.0353	-0.15	-0.16	Vitiligo;	chr22:41762200	chr22:42090931~42137742:+
THCA	cis	rs9402682	0.559	rs9321486	ENSG00000232876.1	CTA-212D2.2	-3.46	0.000596	0.0353	-0.21	-0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135126682	chr6:135055033~135060550:+
THCA	cis	rs9676308	0.737	rs78910163	ENSG00000267549.4	AC006116.17	-3.46	0.000596	0.0353	-0.21	-0.16	Colorectal cancer;	chr19:57073776	chr19:56314703~56341287:+
THCA	cis	rs1200921	0.611	rs1200877	ENSG00000272983.1	RP11-508N22.12	-3.46	0.000596	0.0353	-0.14	-0.16	Breast cancer;	chr10:37214821	chr10:38137337~38144399:+
THCA	cis	rs2455799	0.593	rs13078487	ENSG00000270409.1	RP11-44D5.1	-3.46	0.000596	0.0353	-0.17	-0.16	Mean platelet volume;	chr3:15888083	chr3:15732252~15733470:+
THCA	cis	rs4664293	0.769	rs1365798	ENSG00000230783.1	AC009961.2	3.46	0.000596	0.0353	0.2	0.16	Monocyte percentage of white cells;	chr2:159795853	chr2:159689217~159690291:-
THCA	cis	rs720064	0.589	rs12956613	ENSG00000264745.1	TTC39C-AS1	3.46	0.000596	0.0353	0.17	0.16	Strep throat;	chr18:23923151	chr18:23994213~24015339:-
THCA	cis	rs9650657	0.538	rs10111950	ENSG00000261451.1	RP11-981G7.1	-3.46	0.000596	0.0353	-0.2	-0.16	Neuroticism;	chr8:10958244	chr8:10433672~10438312:+
THCA	cis	rs12893668	0.703	rs4906338	ENSG00000258735.1	LINC00637	-3.46	0.000596	0.0353	-0.21	-0.16	Reticulocyte count;	chr14:103584020	chr14:103847721~103858049:+
THCA	cis	rs4908768	0.52	rs4908507	ENSG00000270282.1	RP5-1115A15.2	3.46	0.000596	0.0353	0.18	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678878	chr1:8512653~8513021:+
THCA	cis	rs7572644	0.766	rs13021285	ENSG00000223522.1	AC093690.1	-3.46	0.000596	0.0353	-0.2	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27862480	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.766	rs11902158	ENSG00000223522.1	AC093690.1	-3.46	0.000596	0.0353	-0.2	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27863898	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.766	rs4666028	ENSG00000223522.1	AC093690.1	-3.46	0.000596	0.0353	-0.2	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27865713	chr2:28307691~28310459:-
THCA	cis	rs7903847	0.642	rs7903562	ENSG00000225850.3	RP11-452K12.4	3.46	0.000596	0.0353	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97395025	chr10:97334564~97343203:+
THCA	cis	rs6545883	0.965	rs7591345	ENSG00000212978.6	AC016747.3	3.46	0.000596	0.0353	0.17	0.16	Tuberculosis;	chr2:61502506	chr2:61141592~61144969:-
THCA	cis	rs7474896	0.609	rs11011336	ENSG00000120555.12	SEPT7P9	3.46	0.000596	0.0353	0.21	0.16	Obesity (extreme);	chr10:37696388	chr10:38383069~38402916:-
THCA	cis	rs4568518	0.619	rs13238312	ENSG00000279048.1	RP11-511H23.2	3.46	0.000596	0.0353	0.1	0.16	Measles;	chr7:17968821	chr7:17940503~17942922:+
THCA	cis	rs17301013	0.932	rs6689170	ENSG00000270084.1	GAS5-AS1	-3.46	0.000596	0.0353	-0.16	-0.16	Systemic lupus erythematosus;	chr1:174639596	chr1:173863248~173863941:+
THCA	cis	rs4919087	0.81	rs1572437	ENSG00000237169.1	RP11-452K12.3	-3.46	0.000596	0.0353	-0.2	-0.16	Monocyte count;	chr10:97269521	chr10:97309138~97309958:-
THCA	cis	rs11886999	1	rs61697794	ENSG00000204685.6	STARD7-AS1	-3.46	0.000596	0.0353	-0.17	-0.16	Cardiac Troponin-T levels;	chr2:96236866	chr2:96208416~96242621:+
THCA	cis	rs2233152	0.61	rs10405596	ENSG00000279108.1	CTC-490E21.11	3.46	0.000596	0.0353	0.21	0.16	Kawasaki disease;	chr19:40808815	chr19:40840159~40842039:+
THCA	cis	rs5770917	1	rs2269382	ENSG00000279182.1	XX-C00717C00720L.1	3.46	0.000596	0.0353	0.26	0.16	Narcolepsy;	chr22:50580482	chr22:50316035~50317025:+
THCA	cis	rs7616559	0.649	rs9867766	ENSG00000244515.1	KRT18P34	-3.46	0.000596	0.0353	-0.18	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157014896	chr3:157162663~157163932:-
THCA	cis	rs34975555	0.803	rs2299593	ENSG00000253671.1	RP11-806O11.1	-3.46	0.000597	0.0353	-0.23	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17944861	chr8:17808941~17820868:+
THCA	cis	rs938554	0.612	rs13113918	ENSG00000261490.1	RP11-448G15.3	3.46	0.000597	0.0353	0.13	0.16	Blood metabolite levels;	chr4:9996869	chr4:10068089~10073019:-
THCA	cis	rs938554	0.612	rs28592748	ENSG00000261490.1	RP11-448G15.3	3.46	0.000597	0.0353	0.13	0.16	Blood metabolite levels;	chr4:9996981	chr4:10068089~10073019:-
THCA	cis	rs4908760	0.864	rs12136766	ENSG00000270282.1	RP5-1115A15.2	3.46	0.000597	0.0353	0.18	0.16	Vitiligo;	chr1:8603762	chr1:8512653~8513021:+
THCA	cis	rs10911363	0.592	rs2702182	ENSG00000232860.6	SMG7-AS1	-3.46	0.000597	0.0353	-0.12	-0.16	Systemic lupus erythematosus;	chr1:183547305	chr1:183460874~183472265:-
THCA	cis	rs10911363	0.573	rs2702181	ENSG00000232860.6	SMG7-AS1	-3.46	0.000597	0.0353	-0.12	-0.16	Systemic lupus erythematosus;	chr1:183547850	chr1:183460874~183472265:-
THCA	cis	rs9399599	0.805	rs608147	ENSG00000233452.5	STXBP5-AS1	3.46	0.000597	0.0353	0.16	0.16	Plasma plasminogen activator levels;	chr6:147249587	chr6:146841901~147204614:-
THCA	cis	rs12701220	0.655	rs6463317	ENSG00000225146.1	AC073957.15	3.46	0.000597	0.0353	0.2	0.16	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1029025~1043891:+
THCA	cis	rs1923243	0.649	rs4584349	ENSG00000223479.3	RP4-788P17.1	-3.46	0.000597	0.0353	-0.17	-0.16	Migraine;	chr1:72953974	chr1:73635216~73715214:+
THCA	cis	rs5751168	0.834	rs361676	ENSG00000240160.3	RN7SL263P	3.46	0.000597	0.0353	0.24	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22507724	chr22:23261782~23262071:-
THCA	cis	rs5751168	0.834	rs362184	ENSG00000240160.3	RN7SL263P	3.46	0.000597	0.0353	0.24	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22507744	chr22:23261782~23262071:-
THCA	cis	rs11678584	0.502	rs17011982	ENSG00000276517.1	AL133243.2	-3.46	0.000597	0.0353	-0.18	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32501246	chr2:32526504~32529507:+
THCA	cis	rs972578	0.715	rs2024645	ENSG00000230319.1	AL022476.2	3.46	0.000597	0.0353	0.17	0.16	Mean platelet volume;	chr22:42816775	chr22:43038585~43052366:+
THCA	cis	rs1433188	0.811	rs4100190	ENSG00000253582.1	RP11-649G15.2	3.46	0.000597	0.0353	0.19	0.16	Subjective well-being;	chr8:107444887	chr8:106520474~106657548:-
THCA	cis	rs9796	0.866	rs66818965	ENSG00000247556.5	OIP5-AS1	3.46	0.000597	0.0353	0.12	0.16	Menopause (age at onset);	chr15:41110081	chr15:41283990~41309737:+
THCA	cis	rs9796	0.866	rs1678750	ENSG00000247556.5	OIP5-AS1	3.46	0.000597	0.0353	0.12	0.16	Menopause (age at onset);	chr15:41118507	chr15:41283990~41309737:+
THCA	cis	rs3026101	0.576	rs56188406	ENSG00000234327.6	AC012146.7	-3.46	0.000597	0.0353	-0.13	-0.16	Body mass index;	chr17:5413449	chr17:5111468~5115004:+
THCA	cis	rs6088813	0.635	rs8115394	ENSG00000279253.1	RP4-614O4.13	-3.46	0.000597	0.0353	-0.18	-0.16	Height;	chr20:35302547	chr20:35262727~35264187:-
THCA	cis	rs1557488	0.599	rs7106729	ENSG00000260209.1	RP11-680F20.10	3.46	0.000597	0.0353	0.22	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126839534	chr11:125873031~125874528:-
THCA	cis	rs4915077	0.773	rs17019845	ENSG00000226822.1	RP11-356N1.2	3.46	0.000597	0.0353	0.3	0.16	Hypothyroidism;	chr1:107731203	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.773	rs17019846	ENSG00000226822.1	RP11-356N1.2	3.46	0.000597	0.0353	0.3	0.16	Hypothyroidism;	chr1:107732010	chr1:108071482~108074519:+
THCA	cis	rs975752	0.867	rs7922090	ENSG00000227492.1	RP11-316M21.6	3.46	0.000597	0.0353	0.3	0.16	Schizophrenia;	chr10:100215512	chr10:100229667~100234000:+
THCA	cis	rs9309473	0.948	rs7607892	ENSG00000273245.1	RP11-434P11.2	3.46	0.000597	0.0353	0.22	0.16	Metabolite levels;	chr2:73591580	chr2:73750256~73750786:-
THCA	cis	rs9392556	0.829	rs9328220	ENSG00000230648.1	RP3-406P24.3	3.46	0.000597	0.0353	0.2	0.16	Blood metabolite levels;	chr6:4119947	chr6:4018843~4021215:-
THCA	cis	rs1552172	0.887	rs718942	ENSG00000234222.5	RP11-315I20.1	-3.46	0.000597	0.0353	-0.2	-0.16	Breast cancer;	chr1:145772225	chr1:145926590~145959179:+
THCA	cis	rs1383484	0.798	rs1871731	ENSG00000259728.4	LINC00933	-3.46	0.000597	0.0353	-0.2	-0.16	Height;	chr15:83869280	chr15:84570649~84580175:+
THCA	cis	rs3785574	0.962	rs2247435	ENSG00000279369.1	RP11-51F16.1	3.46	0.000597	0.0353	0.11	0.16	Height;	chr17:63815502	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.924	rs2727292	ENSG00000279369.1	RP11-51F16.1	3.46	0.000597	0.0353	0.11	0.16	Height;	chr17:63816387	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs2597632	ENSG00000279369.1	RP11-51F16.1	3.46	0.000597	0.0353	0.11	0.16	Height;	chr17:63817379	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs2665835	ENSG00000279369.1	RP11-51F16.1	3.46	0.000597	0.0353	0.11	0.16	Height;	chr17:63825898	chr17:63700847~63702670:+
THCA	cis	rs12575480	0.637	rs56204981	ENSG00000233930.3	KRTAP5-AS1	-3.46	0.000597	0.0353	-0.19	-0.16	Pursuit maintenance gain;	chr11:2073622	chr11:1571353~1599184:+
THCA	cis	rs668210	0.793	rs586921	ENSG00000214659.4	KRT8P26	-3.46	0.000597	0.0353	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr11:65980230	chr11:65726939~65728214:+
THCA	cis	rs10911902	0.643	rs3766702	ENSG00000233196.2	GS1-304P7.1	-3.46	0.000597	0.0353	-0.26	-0.16	Schizophrenia;	chr1:186346832	chr1:186580515~186581191:-
THCA	cis	rs2243480	1	rs313809	ENSG00000237310.1	GS1-124K5.4	3.46	0.000597	0.0353	0.18	0.16	Diabetic kidney disease;	chr7:66034996	chr7:66493706~66495474:+
THCA	cis	rs72793342	1	rs72793342	ENSG00000235560.3	AC002310.12	-3.46	0.000597	0.0354	-0.18	-0.16	RANTES levels;	chr16:30537031	chr16:30534752~30537144:+
THCA	cis	rs7192750	0.586	rs2335710	ENSG00000260886.1	TAT-AS1	-3.46	0.000597	0.0354	-0.23	-0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71889278	chr16:71565789~71578187:+
THCA	cis	rs2882667	0.898	rs10045761	ENSG00000249593.5	CTB-46B19.2	3.46	0.000597	0.0354	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:139012647~139051203:+
THCA	cis	rs4907240	0.925	rs11164109	ENSG00000230606.9	AC159540.1	3.46	0.000597	0.0354	0.18	0.16	Event-related brain oscillations;	chr2:96635096	chr2:97416165~97433527:-
THCA	cis	rs6828577	0.862	rs298995	ENSG00000248280.1	RP11-33B1.2	3.46	0.000597	0.0354	0.14	0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118704118	chr4:119440561~119450157:-
THCA	cis	rs354225	0.553	rs7564719	ENSG00000212175.1	SNORA12	-3.46	0.000598	0.0354	-0.2	-0.16	Schizophrenia;	chr2:54602594	chr2:55565703~55565850:+
THCA	cis	rs55692468	0.848	rs55882252	ENSG00000213197.3	AC012066.1	3.46	0.000598	0.0354	0.21	0.16	Intraocular pressure;	chr2:152505186	chr2:152389937~152390630:+
THCA	cis	rs12612435	0.83	rs1515064	ENSG00000230037.1	UBBP1	3.46	0.000598	0.0354	0.2	0.16	Takotsubo syndrome;	chr2:136379446	chr2:136329441~136329913:-
THCA	cis	rs12612435	0.83	rs34608701	ENSG00000230037.1	UBBP1	3.46	0.000598	0.0354	0.2	0.16	Takotsubo syndrome;	chr2:136380051	chr2:136329441~136329913:-
THCA	cis	rs4660456	0.913	rs12567755	ENSG00000238287.1	RP11-656D10.3	-3.46	0.000598	0.0354	-0.2	-0.16	Platelet count;	chr1:40751813	chr1:40493157~40508661:-
THCA	cis	rs9878978	0.691	rs34831690	ENSG00000227588.2	CNTN4-AS2	3.46	0.000598	0.0354	0.2	0.16	Blood pressure (smoking interaction);	chr3:2395959	chr3:2110409~2144241:-
THCA	cis	rs9878978	0.691	rs34078497	ENSG00000227588.2	CNTN4-AS2	3.46	0.000598	0.0354	0.2	0.16	Blood pressure (smoking interaction);	chr3:2395973	chr3:2110409~2144241:-
THCA	cis	rs4578769	0.918	rs4239434	ENSG00000265939.1	UBE2CP2	-3.46	0.000598	0.0354	-0.19	-0.16	Eosinophil percentage of white cells;	chr18:22995160	chr18:22900486~22900995:-
THCA	cis	rs11673344	0.504	rs6510588	ENSG00000267260.1	CTD-2162K18.4	3.46	0.000598	0.0354	0.19	0.16	Obesity-related traits;	chr19:37106493	chr19:36773153~36777078:+
THCA	cis	rs62380364	0.87	rs11749060	ENSG00000247828.6	TMEM161B-AS1	3.46	0.000598	0.0354	0.12	0.16	Intelligence (multi-trait analysis);	chr5:88856757	chr5:88268895~88436685:+
THCA	cis	rs10256972	0.869	rs1007766	ENSG00000199023.2	MIR339	-3.46	0.000598	0.0354	-0.16	-0.16	Endometriosis;Longevity;	chr7:995267	chr7:1022935~1023045:-
THCA	cis	rs17331151	0.573	rs77223362	ENSG00000242142.1	SERBP1P3	-3.46	0.000598	0.0354	-0.26	-0.16	Immune reponse to smallpox (secreted IL-2);	chr3:52831109	chr3:53064283~53065091:-
THCA	cis	rs4568518	0.869	rs6969961	ENSG00000279048.1	RP11-511H23.2	3.46	0.000598	0.0354	0.1	0.16	Measles;	chr7:17990462	chr7:17940503~17942922:+
THCA	cis	rs4568518	0.873	rs6952559	ENSG00000279048.1	RP11-511H23.2	3.46	0.000598	0.0354	0.1	0.16	Measles;	chr7:17990547	chr7:17940503~17942922:+
THCA	cis	rs61160187	0.582	rs62367903	ENSG00000272308.1	RP11-231G3.1	-3.46	0.000598	0.0354	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60866457~60866935:-
THCA	cis	rs206966	0.872	rs1557769	ENSG00000277283.1	RP1-267D11.6	3.46	0.000598	0.0354	0.16	0.16	Breast cancer;	chr12:120362893	chr12:120116907~120119000:+
THCA	cis	rs881375	0.678	rs1930782	ENSG00000238181.2	AHCYP2	-3.46	0.000598	0.0354	-0.19	-0.16	Rheumatoid arthritis;	chr9:120925627	chr9:120720673~120721972:+
THCA	cis	rs2664588	0.561	rs11086233	ENSG00000276923.1	RP11-321P16.1	3.46	0.000598	0.0354	0.21	0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47963748	chr20:48073869~48074188:+
THCA	cis	rs10876993	0.784	rs7314152	ENSG00000270039.1	RP11-571M6.17	-3.46	0.000598	0.0354	-0.17	-0.16	Celiac disease or Rheumatoid arthritis;	chr12:57623918	chr12:57803838~57804415:+
THCA	cis	rs35740288	0.822	rs34734963	ENSG00000259407.1	RP11-158M2.3	-3.46	0.000598	0.0354	-0.2	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85674413	chr15:85744109~85750281:-
THCA	cis	rs7647973	0.516	rs4536858	ENSG00000228638.1	FCF1P2	-3.46	0.000598	0.0354	-0.16	-0.16	Menarche (age at onset);	chr3:49155648	chr3:48290793~48291375:-
THCA	cis	rs7647973	0.516	rs12490393	ENSG00000228638.1	FCF1P2	-3.46	0.000598	0.0354	-0.16	-0.16	Menarche (age at onset);	chr3:49158699	chr3:48290793~48291375:-
THCA	cis	rs758324	0.679	rs17132318	ENSG00000224431.1	AC063976.7	-3.46	0.000598	0.0354	-0.22	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:132021718	chr5:132199456~132203487:+
THCA	cis	rs3808502	0.526	rs1042701	ENSG00000255046.1	RP11-297N6.4	3.46	0.000598	0.0354	0.17	0.16	Neuroticism;	chr8:11564536	chr8:11797928~11802568:-
THCA	cis	rs3808502	0.526	rs7843987	ENSG00000255046.1	RP11-297N6.4	3.46	0.000598	0.0354	0.17	0.16	Neuroticism;	chr8:11564621	chr8:11797928~11802568:-
THCA	cis	rs10043228	1	rs10062350	ENSG00000250015.1	CTC-339F2.2	3.46	0.000598	0.0354	0.24	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116117800	chr5:116302354~116304134:-
THCA	cis	rs2562456	0.833	rs11666447	ENSG00000213976.4	CTD-2561J22.2	-3.46	0.000598	0.0354	-0.2	-0.16	Pain;	chr19:21416270	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs11666525	ENSG00000213976.4	CTD-2561J22.2	-3.46	0.000598	0.0354	-0.2	-0.16	Pain;	chr19:21416503	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.793	rs62110424	ENSG00000213976.4	CTD-2561J22.2	-3.46	0.000598	0.0354	-0.2	-0.16	Pain;	chr19:21416835	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.793	rs3853837	ENSG00000213976.4	CTD-2561J22.2	-3.46	0.000598	0.0354	-0.2	-0.16	Pain;	chr19:21419172	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.793	rs3853838	ENSG00000213976.4	CTD-2561J22.2	-3.46	0.000598	0.0354	-0.2	-0.16	Pain;	chr19:21419192	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs62110426	ENSG00000213976.4	CTD-2561J22.2	-3.46	0.000598	0.0354	-0.2	-0.16	Pain;	chr19:21420124	chr19:21382865~21387177:+
THCA	cis	rs479105	0.872	rs740768	ENSG00000278356.1	RP11-372B4.3	3.46	0.000598	0.0354	0.15	0.16	Gut microbiota (bacterial taxa);	chr12:3264776	chr12:2885819~2886329:+
THCA	cis	rs2991971	0.869	rs2453404	ENSG00000234329.1	RP11-767N6.2	-3.46	0.000598	0.0354	-0.15	-0.16	High light scatter reticulocyte count;	chr1:45549063	chr1:45651039~45651826:-
THCA	cis	rs2991971	1	rs622798	ENSG00000234329.1	RP11-767N6.2	-3.46	0.000598	0.0354	-0.15	-0.16	High light scatter reticulocyte count;	chr1:45549599	chr1:45651039~45651826:-
THCA	cis	rs7824557	0.564	rs34389419	ENSG00000261451.1	RP11-981G7.1	-3.46	0.000598	0.0354	-0.2	-0.16	Retinal vascular caliber;	chr8:11371810	chr8:10433672~10438312:+
THCA	cis	rs6674970	0.933	rs11204772	ENSG00000261168.1	RP11-68I18.10	-3.46	0.000598	0.0354	-0.21	-0.16	Childhood ear infection;	chr1:151083829	chr1:151130075~151131610:-
THCA	cis	rs12780845	0.931	rs2884038	ENSG00000273153.1	RP11-406H21.2	3.46	0.000598	0.0354	0.15	0.16	Homocysteine levels;	chr10:17210159	chr10:17137336~17137585:-
THCA	cis	rs1023500	0.551	rs2854837	ENSG00000270083.1	RP1-257I20.14	3.46	0.000598	0.0354	0.18	0.16	Schizophrenia;	chr22:42062477	chr22:42089630~42090028:-
THCA	cis	rs9309473	0.5	rs6757996	ENSG00000273245.1	RP11-434P11.2	3.46	0.000598	0.0354	0.19	0.16	Metabolite levels;	chr2:73545124	chr2:73750256~73750786:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000264242.2	RP11-271K11.1	3.46	0.000598	0.0354	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000264242.2	RP11-271K11.1	3.46	0.000598	0.0354	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30553697~30558962:+
THCA	cis	rs564148	0.872	rs664727	ENSG00000239670.1	RP4-803A2.2	-3.46	0.000599	0.0354	-0.28	-0.16	Response to amphetamines;	chr1:33691728	chr1:32986952~32988233:+
THCA	cis	rs7192750	0.586	rs6499552	ENSG00000260886.1	TAT-AS1	3.46	0.000599	0.0354	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71909266	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.586	rs13329779	ENSG00000260886.1	TAT-AS1	3.46	0.000599	0.0354	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71910037	chr16:71565789~71578187:+
THCA	cis	rs4919669	1	rs4919669	ENSG00000272912.1	RP11-724N1.1	-3.46	0.000599	0.0354	-0.27	-0.16	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102712218	chr10:102914585~102915404:+
THCA	cis	rs1850744	0.826	rs13101880	ENSG00000249767.1	ENPP7P10	-3.46	0.000599	0.0354	-0.32	-0.16	Economic and political preferences;	chr4:9706203	chr4:9079023~9141608:+
THCA	cis	rs1556032	0.542	rs16931789	ENSG00000225472.1	RP11-120J1.1	-3.46	0.000599	0.0354	-0.15	-0.16	AIDS;	chr9:14443347	chr9:14317085~14357908:+
THCA	cis	rs17428076	0.793	rs7584258	ENSG00000228389.1	AC068039.4	-3.46	0.000599	0.0354	-0.18	-0.16	Myopia;	chr2:171803326	chr2:171773482~171775844:+
THCA	cis	rs1727638	0.837	rs852944	ENSG00000279312.1	RP3-331H24.7	3.46	0.000599	0.0354	0.12	0.16	Cerebrospinal fluid AB1-42 levels;	chr6:71454687	chr6:71373253~71375387:-
THCA	cis	rs7122539	0.722	rs11600959	ENSG00000275484.1	CTC-1337H24.4	-3.46	0.000599	0.0354	-0.13	-0.16	HIV-1 susceptibility;	chr11:66864421	chr11:67374416~67374932:+
THCA	cis	rs10857712	0.551	rs12252576	ENSG00000273336.1	OR7M1P	-3.46	0.000599	0.0354	-0.21	-0.16	Systemic lupus erythematosus;	chr10:133413740	chr10:133481238~133481770:+
THCA	cis	rs11069062	0.633	rs7303575	ENSG00000270482.1	RP11-131L12.2	3.46	0.000599	0.0354	0.12	0.16	Obesity-related traits;	chr12:118742720	chr12:118375350~118376275:-
THCA	cis	rs1371614	0.611	rs540490	ENSG00000272148.1	RP11-195B17.1	-3.46	0.000599	0.0354	-0.15	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26909954	chr2:27062428~27062907:-
THCA	cis	rs2882667	0.898	rs10058347	ENSG00000249593.5	CTB-46B19.2	3.46	0.000599	0.0354	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:139012647~139051203:+
THCA	cis	rs10191559	0.919	rs62180073	ENSG00000238171.1	AC068196.1	-3.46	0.000599	0.0354	-0.2	-0.16	Red blood cell count;	chr2:180969697	chr2:181076051~181105968:-
THCA	cis	rs12073359	0.509	rs12086155	ENSG00000253047.1	SNORA40	-3.46	0.000599	0.0354	-0.27	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150217440	chr1:150600539~150600659:-
THCA	cis	rs7818688	1	rs34700722	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000599	0.0354	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009648	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs4323442	ENSG00000253528.2	RP11-347C18.4	-3.46	0.000599	0.0354	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95010758	chr8:94974573~94974853:-
THCA	cis	rs3935996	0.932	rs12728204	ENSG00000233147.1	RP11-90C4.1	-3.46	0.000599	0.0354	-0.14	-0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55832824	chr1:55823807~55868248:+
THCA	cis	rs4915077	0.892	rs76965144	ENSG00000226822.1	RP11-356N1.2	3.46	0.000599	0.0354	0.27	0.16	Hypothyroidism;	chr1:107807554	chr1:108071482~108074519:+
THCA	cis	rs3736485	0.673	rs8033234	ENSG00000259709.1	CTD-2184D3.7	3.46	0.000599	0.0354	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51663920	chr15:52124561~52140246:+
THCA	cis	rs2228479	0.85	rs11648689	ENSG00000274627.1	RP11-104N10.2	-3.46	0.000599	0.0354	-0.28	-0.16	Skin colour saturation;	chr16:89740324	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs11649162	ENSG00000274627.1	RP11-104N10.2	-3.46	0.000599	0.0354	-0.28	-0.16	Skin colour saturation;	chr16:89740723	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs11640188	ENSG00000274627.1	RP11-104N10.2	-3.46	0.000599	0.0354	-0.28	-0.16	Skin colour saturation;	chr16:89741324	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs11640209	ENSG00000274627.1	RP11-104N10.2	-3.46	0.000599	0.0354	-0.28	-0.16	Skin colour saturation;	chr16:89741420	chr16:89516797~89522217:+
THCA	cis	rs4886920	0.518	rs12902224	ENSG00000260776.4	RP11-114H24.2	-3.46	0.000599	0.0354	-0.22	-0.16	Neuroticism;	chr15:77783930	chr15:77914217~77926846:-
THCA	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-3.46	0.000599	0.0354	-0.15	-0.16	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
THCA	cis	rs1850744	0.702	rs4974858	ENSG00000163612.10	FAM86KP	3.46	0.000599	0.0354	0.37	0.16	Economic and political preferences;	chr4:9605498	chr4:9153296~9165451:+
THCA	cis	rs1941184	0.526	rs67611221	ENSG00000263823.1	RP11-326K13.4	-3.46	0.000599	0.0354	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31455214	chr18:31942575~31944156:+
THCA	cis	rs1941184	0.526	rs16961954	ENSG00000263823.1	RP11-326K13.4	-3.46	0.000599	0.0354	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31455616	chr18:31942575~31944156:+
THCA	cis	rs4272720	0.511	rs7081243	ENSG00000234736.4	FAM170B-AS1	-3.46	0.000599	0.0354	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49133503	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.562	rs34110351	ENSG00000234736.4	FAM170B-AS1	-3.46	0.000599	0.0354	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49133909	chr10:49121839~49151547:+
THCA	cis	rs4272720	0.562	rs67269950	ENSG00000234736.4	FAM170B-AS1	-3.46	0.000599	0.0354	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49135174	chr10:49121839~49151547:+
THCA	cis	rs9303542	0.729	rs8072770	ENSG00000278765.1	RP5-890E16.5	-3.46	0.000599	0.0354	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48456524	chr17:48066704~48067293:-
THCA	cis	rs9368481	0.761	rs12661756	ENSG00000228223.2	HCG11	-3.46	0.000599	0.0354	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26523450~26526579:+
THCA	cis	rs56309584	0.596	rs117854193	ENSG00000271002.1	RP11-599B13.8	-3.46	0.000599	0.0354	-0.24	-0.16	Initial pursuit acceleration;	chr17:8275149	chr17:8199123~8199437:-
THCA	cis	rs256438	0.642	rs9293797	ENSG00000243160.1	RP11-342F17.2	3.46	0.000599	0.0354	0.19	0.16	Serum thyroid-stimulating hormone levels;	chr5:80029041	chr5:79529302~79530093:+
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000273024.4	INTS4P2	3.46	0.000599	0.0355	0.26	0.16	Diabetic kidney disease;	chr7:65892097	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs35391607	ENSG00000273024.4	INTS4P2	3.46	0.000599	0.0355	0.26	0.16	Diabetic kidney disease;	chr7:65895842	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs13220979	ENSG00000273024.4	INTS4P2	3.46	0.000599	0.0355	0.26	0.16	Diabetic kidney disease;	chr7:65898217	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs34974928	ENSG00000273024.4	INTS4P2	3.46	0.000599	0.0355	0.26	0.16	Diabetic kidney disease;	chr7:65899019	chr7:65647864~65715661:+
THCA	cis	rs73198271	0.74	rs10092600	ENSG00000254340.1	RP11-10A14.3	-3.46	0.000599	0.0355	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:9141424~9145435:+
THCA	cis	rs73198271	0.74	rs10105690	ENSG00000254340.1	RP11-10A14.3	-3.46	0.000599	0.0355	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:9141424~9145435:+
THCA	cis	rs324126	0.78	rs2059817	ENSG00000269834.4	ZNF528-AS1	3.46	0.000599	0.0355	0.12	0.16	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52388842~52397766:-
THCA	cis	rs38864	0.744	rs28481622	ENSG00000214188.8	ST7-OT4	3.46	0.000599	0.0355	0.33	0.16	Colonoscopy-negative controls vs population controls;	chr7:117165458	chr7:116953899~117098806:+
THCA	cis	rs38864	1	rs28626669	ENSG00000214188.8	ST7-OT4	3.46	0.000599	0.0355	0.33	0.16	Colonoscopy-negative controls vs population controls;	chr7:117165814	chr7:116953899~117098806:+
THCA	cis	rs9911578	1	rs4636974	ENSG00000224738.1	AC099850.1	3.46	6e-04	0.0355	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58888012	chr17:59106598~59118267:+
THCA	cis	rs7246657	0.943	rs4803347	ENSG00000266916.4	ZNF793-AS1	-3.46	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37357115	chr19:37497159~37507046:-
THCA	cis	rs754466	0.651	rs11002316	ENSG00000213514.2	RP11-428P16.2	3.46	6e-04	0.0355	0.17	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857753	chr10:77730766~77734769:+
THCA	cis	rs7942368	1	rs12282785	ENSG00000255363.1	RP11-672A2.5	-3.46	6e-04	0.0355	-0.22	-0.16	Endometriosis;	chr11:76764986	chr11:76628096~76630363:-
THCA	cis	rs1953600	0.818	rs2152546	ENSG00000242600.5	MBL1P	-3.46	6e-04	0.0355	-0.13	-0.16	Sarcoidosis;	chr10:80146628	chr10:79904898~79950336:+
THCA	cis	rs35306767	0.715	rs1250891	ENSG00000229869.1	RP11-363N22.2	-3.46	6e-04	0.0355	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:994219	chr10:933026~942743:+
THCA	cis	rs9527	0.615	rs10883810	ENSG00000236937.2	PTGES3P4	3.46	6e-04	0.0355	0.21	0.16	Arsenic metabolism;	chr10:102967467	chr10:102845595~102845950:+
THCA	cis	rs9527	0.615	rs10883811	ENSG00000236937.2	PTGES3P4	3.46	6e-04	0.0355	0.21	0.16	Arsenic metabolism;	chr10:102967522	chr10:102845595~102845950:+
THCA	cis	rs2290416	0.786	rs77951814	ENSG00000254973.1	RP11-429J17.7	3.46	6e-04	0.0355	0.32	0.16	Attention deficit hyperactivity disorder;	chr8:143574982	chr8:143758153~143771822:-
THCA	cis	rs2032366	0.606	rs6567225	ENSG00000267316.4	RP11-879F14.3	3.46	6e-04	0.0355	0.18	0.16	Obesity-related traits;	chr18:61607418	chr18:61571342~61579456:-
THCA	cis	rs17345786	0.906	rs12638137	ENSG00000244119.1	PDCL3P4	3.46	6e-04	0.0355	0.16	0.16	Colonoscopy-negative controls vs population controls;	chr3:101432120	chr3:101712472~101713191:+
THCA	cis	rs17345786	0.861	rs79181492	ENSG00000244119.1	PDCL3P4	3.46	6e-04	0.0355	0.16	0.16	Colonoscopy-negative controls vs population controls;	chr3:101497177	chr3:101712472~101713191:+
THCA	cis	rs2692947	0.644	rs772178	ENSG00000236750.1	AC009237.16	3.46	6e-04	0.0355	0.17	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96297946	chr2:95641634~95641980:-
THCA	cis	rs13045180	0.518	rs1936307	ENSG00000224452.1	RSL24D1P6	3.46	6e-04	0.0355	0.21	0.16	Type 1 diabetes nephropathy;	chr20:32941722	chr20:32170390~32170790:-
THCA	cis	rs7647973	0.925	rs4955439	ENSG00000228638.1	FCF1P2	3.46	6e-04	0.0355	0.18	0.16	Menarche (age at onset);	chr3:49208212	chr3:48290793~48291375:-
THCA	cis	rs1612141	1	rs2567023	ENSG00000251363.2	RP11-129M6.1	-3.46	6e-04	0.0355	-0.23	-0.16	QT interval (drug interaction);	chr14:41296007	chr14:40954898~40975877:+
THCA	cis	rs7819412	0.642	rs11250117	ENSG00000254948.1	OR7E158P	3.46	6e-04	0.0355	0.2	0.16	Triglycerides;	chr8:11115230	chr8:11919900~11920809:-
THCA	cis	rs875971	0.545	rs2420456	ENSG00000230295.1	RP11-458F8.2	3.46	6e-04	0.0355	0.14	0.16	Aortic root size;	chr7:66280619	chr7:66880708~66882981:+
THCA	cis	rs427943	0.766	rs446158	ENSG00000215447.6	BX322557.10	-3.45	6e-04	0.0355	-0.13	-0.16	Body mass index;	chr21:45170038	chr21:45288052~45291738:+
THCA	cis	rs301901	0.714	rs301869	ENSG00000250155.1	CTD-2353F22.1	-3.45	6e-04	0.0355	-0.16	-0.16	Height;	chr5:37140495	chr5:36666214~36725195:-
THCA	cis	rs301901	0.772	rs2098713	ENSG00000250155.1	CTD-2353F22.1	-3.45	6e-04	0.0355	-0.16	-0.16	Height;	chr5:37144472	chr5:36666214~36725195:-
THCA	cis	rs9796	0.689	rs11855797	ENSG00000247556.5	OIP5-AS1	3.45	6e-04	0.0355	0.13	0.16	Menopause (age at onset);	chr15:41142481	chr15:41283990~41309737:+
THCA	cis	rs7182621	0.639	rs36069387	ENSG00000182397.13	DNM1P46	3.45	6e-04	0.0355	0.17	0.16	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99790156~99806927:-
THCA	cis	rs2797160	0.967	rs1739355	ENSG00000226409.1	RP11-735G4.1	3.45	6e-04	0.0355	0.19	0.16	Endometrial cancer;	chr6:125696968	chr6:125370211~125374324:-
THCA	cis	rs9902453	0.817	rs880749	ENSG00000264290.1	RP11-68I3.4	-3.45	6e-04	0.0355	-0.12	-0.16	Coffee consumption (cups per day);	chr17:29732952	chr17:29569580~29570519:+
THCA	cis	rs7131987	0.903	rs2194520	ENSG00000257599.1	OVCH1-AS1	-3.45	6e-04	0.0355	-0.19	-0.16	QT interval;	chr12:29270779	chr12:29389294~29487488:+
THCA	cis	rs9650657	0.707	rs1115867	ENSG00000269918.1	AF131215.9	-3.45	6e-04	0.0355	-0.17	-0.16	Neuroticism;	chr8:10781240	chr8:11104691~11106704:-
THCA	cis	rs9475677	0.862	rs7452915	ENSG00000231441.1	RP11-472M19.2	3.45	6e-04	0.0355	0.19	0.16	Gut microbiota (functional units);	chr6:56362905	chr6:56844002~56864078:+
THCA	cis	rs801193	1	rs13239306	ENSG00000230295.1	RP11-458F8.2	3.45	6e-04	0.0355	0.12	0.16	Aortic root size;	chr7:66671030	chr7:66880708~66882981:+
THCA	cis	rs2562456	0.833	rs55875743	ENSG00000213976.4	CTD-2561J22.2	-3.45	6e-04	0.0355	-0.2	-0.16	Pain;	chr19:21383393	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs62110416	ENSG00000213976.4	CTD-2561J22.2	-3.45	6e-04	0.0355	-0.2	-0.16	Pain;	chr19:21401924	chr19:21382865~21387177:+
THCA	cis	rs17359493	0.697	rs73269170	ENSG00000253528.2	RP11-347C18.4	-3.45	6e-04	0.0355	-0.23	-0.16	Type 2 diabetes;	chr8:94817828	chr8:94974573~94974853:-
THCA	cis	rs9981595	1	rs9981595	ENSG00000238141.2	BRWD1-AS1	3.45	6e-04	0.0355	0.28	0.16	Venous thromboembolism (SNP x SNP interaction);	chr21:39188752	chr21:39315707~39323218:+
THCA	cis	rs2797160	0.967	rs926854	ENSG00000226409.1	RP11-735G4.1	3.45	6e-04	0.0355	0.19	0.16	Endometrial cancer;	chr6:125700634	chr6:125370211~125374324:-
THCA	cis	rs11118346	0.64	rs11118343	ENSG00000228536.1	RP11-392O17.1	-3.45	6e-04	0.0355	-0.19	-0.16	Height;	chr1:219566565	chr1:219409681~219411941:-
THCA	cis	rs683250	0.63	rs10898108	ENSG00000254551.1	RP11-727A23.7	-3.45	6e-04	0.0355	-0.19	-0.16	Subcortical brain region volumes;	chr11:83378360	chr11:83209431~83213379:-
THCA	cis	rs7246657	0.943	rs1035479	ENSG00000266916.4	ZNF793-AS1	3.45	6e-04	0.0355	0.15	0.16	Coronary artery calcification;	chr19:37402398	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.882	rs4803539	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37406620	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs10406177	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37417045	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.882	rs28623164	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37422551	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs7252346	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37423780	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs2891699	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37429335	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs9676967	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37437187	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs8109632	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37440223	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs7255407	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37443034	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.941	rs7256130	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37443079	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs2112923	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37449425	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs3760825	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37454699	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs10420754	ENSG00000266916.4	ZNF793-AS1	-3.45	6e-04	0.0355	-0.15	-0.16	Coronary artery calcification;	chr19:37468470	chr19:37497159~37507046:-
THCA	cis	rs4243849	0.555	rs13258178	ENSG00000279518.1	AC083843.4	-3.45	6e-04	0.0355	-0.11	-0.16	Non-alcoholic fatty liver disease histology (other);	chr8:135752992	chr8:134783694~134785879:-
THCA	cis	rs1832871	0.643	rs7750656	ENSG00000213078.3	RP5-933K21.2	-3.45	0.000601	0.0355	-0.24	-0.16	Height;	chr6:158304875	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9457337	ENSG00000213078.3	RP5-933K21.2	-3.45	0.000601	0.0355	-0.24	-0.16	Height;	chr6:158305260	chr6:157365990~157366923:-
THCA	cis	rs3750082	0.582	rs3750079	ENSG00000229358.3	DPY19L1P1	3.45	0.000601	0.0355	0.15	0.16	Glomerular filtration rate (creatinine);	chr7:32929807	chr7:32580949~32761787:-
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000281021.1	RP1-12G14.9	-3.45	0.000601	0.0355	-0.16	-0.16	Lung cancer;	chr6:149787289	chr6:149576089~149590864:-
THCA	cis	rs1629083	0.807	rs55768116	ENSG00000280032.1	RP11-832A4.7	3.45	0.000601	0.0355	0.17	0.16	Lung cancer;	chr11:118237616	chr11:118264593~118266817:+
THCA	cis	rs67981189	0.574	rs2010713	ENSG00000269927.1	RP6-91H8.3	-3.45	0.000601	0.0355	-0.17	-0.16	Schizophrenia;	chr14:70902018	chr14:71141125~71143253:-
THCA	cis	rs67981189	0.593	rs2526883	ENSG00000269927.1	RP6-91H8.3	-3.45	0.000601	0.0355	-0.17	-0.16	Schizophrenia;	chr14:70902858	chr14:71141125~71143253:-
THCA	cis	rs9868809	0.881	rs2276850	ENSG00000270441.1	RP11-694I15.7	3.45	0.000601	0.0355	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48632215	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.881	rs34368826	ENSG00000270441.1	RP11-694I15.7	3.45	0.000601	0.0355	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48633394	chr3:49140086~49160851:-
THCA	cis	rs736408	0.924	rs2535629	ENSG00000243224.1	RP5-1157M23.2	-3.45	0.000601	0.0355	-0.17	-0.16	Bipolar disorder;	chr3:52799203	chr3:52239258~52241097:+
THCA	cis	rs7615952	0.932	rs13321217	ENSG00000272840.1	RP11-379B18.6	3.45	0.000601	0.0355	0.25	0.16	Blood pressure (smoking interaction);	chr3:125912928	chr3:125774714~125797953:+
THCA	cis	rs7809799	0.571	rs740160	ENSG00000242798.1	RP11-506M12.1	-3.45	0.000601	0.0355	-0.32	-0.16	Ulcerative colitis;	chr7:99360257	chr7:100115214~100127139:-
THCA	cis	rs12544026	0.588	rs1264931	ENSG00000253669.3	KB-1732A1.1	3.45	0.000601	0.0355	0.17	0.16	Major depression and alcohol dependence;	chr8:101841925	chr8:102805517~102809971:+
THCA	cis	rs757978	1	rs11681497	ENSG00000235351.1	AC114730.11	-3.45	0.000601	0.0355	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:241404918	chr2:241724615~241725693:-
THCA	cis	rs1560104	0.871	rs4479213	ENSG00000259899.1	CTD-3037G24.3	3.45	0.000601	0.0355	0.19	0.16	Obesity-related traits;	chr16:12618447	chr16:12560756~12611044:-
THCA	cis	rs758324	0.891	rs652839	ENSG00000224431.1	AC063976.7	-3.45	0.000601	0.0355	-0.15	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131945413	chr5:132199456~132203487:+
THCA	cis	rs277939	0.967	rs277986	ENSG00000230847.4	RP11-195E2.1	-3.45	0.000601	0.0355	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71622068	chr5:71074225~71093193:-
THCA	cis	rs1059312	1	rs7135987	ENSG00000279500.1	RP11-21K12.2	-3.45	0.000601	0.0355	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128795572	chr12:128813186~128814750:-
THCA	cis	rs12780845	0.931	rs2884039	ENSG00000273153.1	RP11-406H21.2	3.45	0.000601	0.0355	0.15	0.16	Homocysteine levels;	chr10:17210242	chr10:17137336~17137585:-
THCA	cis	rs2179367	0.919	rs4897124	ENSG00000223701.3	RAET1E-AS1	3.45	0.000601	0.0355	0.21	0.16	Dupuytren's disease;	chr6:149442073	chr6:149884431~149919508:+
THCA	cis	rs9467773	0.836	rs1624440	ENSG00000228223.2	HCG11	3.45	0.000601	0.0355	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26433101	chr6:26523450~26526579:+
THCA	cis	rs11785400	1	rs13266249	ENSG00000177335.9	C8orf31	3.45	0.000601	0.0355	0.18	0.16	Schizophrenia;	chr8:142651049	chr8:143039209~143059942:+
THCA	cis	rs4886920	0.563	rs55726435	ENSG00000260776.4	RP11-114H24.2	-3.45	0.000601	0.0355	-0.19	-0.16	Neuroticism;	chr15:77778741	chr15:77914217~77926846:-
THCA	cis	rs944289	0.74	rs1467794	ENSG00000212071.1	AL162511.1	-3.45	0.000601	0.0355	-0.18	-0.16	Thyroid cancer;	chr14:36097617	chr14:36196480~36196568:-
THCA	cis	rs7616559	0.606	rs931245	ENSG00000240875.4	LINC00886	-3.45	0.000601	0.0355	-0.12	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157063606	chr3:156747346~156817062:-
THCA	cis	rs763121	1	rs763121	ENSG00000225450.1	RP3-508I15.14	3.45	0.000601	0.0355	0.12	0.16	Menopause (age at onset);	chr22:38483935	chr22:38739003~38749041:+
THCA	cis	rs748404	0.666	rs12906481	ENSG00000166763.7	STRCP1	3.45	0.000601	0.0355	0.21	0.16	Lung cancer;	chr15:43467356	chr15:43699488~43718184:-
THCA	cis	rs748404	0.666	rs35958032	ENSG00000166763.7	STRCP1	3.45	0.000601	0.0355	0.21	0.16	Lung cancer;	chr15:43494397	chr15:43699488~43718184:-
THCA	cis	rs9595908	0.606	rs7988462	ENSG00000212293.1	SNORA16	3.45	0.000601	0.0356	0.18	0.16	Body mass index;	chr13:32806701	chr13:32420390~32420516:-
THCA	cis	rs8042680	0.554	rs59278520	ENSG00000258725.1	PRC1-AS1	-3.45	0.000601	0.0356	-0.22	-0.16	Type 2 diabetes;	chr15:90971477	chr15:90966345~90988624:+
THCA	cis	rs6456156	0.792	rs9366089	ENSG00000235272.1	FAM103A2P	3.45	0.000601	0.0356	0.22	0.16	Primary biliary cholangitis;	chr6:167099408	chr6:166586124~166586477:-
THCA	cis	rs6828577	0.819	rs298984	ENSG00000248280.1	RP11-33B1.2	3.45	0.000601	0.0356	0.14	0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118682650	chr4:119440561~119450157:-
THCA	cis	rs6828577	0.862	rs167246	ENSG00000248280.1	RP11-33B1.2	3.45	0.000601	0.0356	0.14	0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118684965	chr4:119440561~119450157:-
THCA	cis	rs7028939	1	rs7868632	ENSG00000255145.2	STX17-AS1	-3.45	0.000601	0.0356	-0.23	-0.16	Preeclampsia;	chr9:100142956	chr9:99886322~99906601:-
THCA	cis	rs7394190	0.748	rs3740293	ENSG00000272599.2	RP11-152N13.16	3.45	0.000602	0.0356	0.2	0.16	Incident atrial fibrillation;	chr10:73646383	chr10:73124573~73125532:-
THCA	cis	rs57709857	0.957	rs11986274	ENSG00000272092.1	RP11-350N15.5	-3.45	0.000602	0.0356	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38401963	chr8:38382364~38383461:+
THCA	cis	rs6690583	0.623	rs61769366	ENSG00000226970.2	RP11-82H13.2	3.45	0.000602	0.0356	0.28	0.16	Serum sulfate level;	chr1:85068379	chr1:84244334~84244577:+
THCA	cis	rs2235649	0.833	rs9927047	ENSG00000260022.1	LA16c-306A4.1	3.45	0.000602	0.0356	0.22	0.16	Blood metabolite levels;	chr16:1801926	chr16:883780~885090:+
THCA	cis	rs2235649	0.833	rs9929262	ENSG00000260022.1	LA16c-306A4.1	3.45	0.000602	0.0356	0.22	0.16	Blood metabolite levels;	chr16:1801927	chr16:883780~885090:+
THCA	cis	rs2327429	0.519	rs4895388	ENSG00000227954.5	TARID	3.45	0.000602	0.0356	0.16	0.16	Coronary artery disease;	chr6:133829423	chr6:133502252~133892802:-
THCA	cis	rs9675999	1	rs9675999	ENSG00000273232.1	RP11-370A5.2	3.45	0.000602	0.0356	0.22	0.16	Breast cancer;	chr18:23047728	chr18:22882825~22883357:-
THCA	cis	rs7246657	0.653	rs10406612	ENSG00000267422.1	CTD-2554C21.1	-3.45	0.000602	0.0356	-0.22	-0.16	Coronary artery calcification;	chr19:37225709	chr19:37779686~37792865:+
THCA	cis	rs114532231	0.661	rs34339158	ENSG00000273080.1	RP11-301O19.1	-3.45	0.000602	0.0356	-0.39	-0.16	Asymmetrical dimethylarginine levels;	chr2:86271451	chr2:86195590~86196049:+
THCA	cis	rs3770081	0.59	rs12623761	ENSG00000273080.1	RP11-301O19.1	-3.45	0.000602	0.0356	-0.39	-0.16	Facial emotion recognition (sad faces);	chr2:86278589	chr2:86195590~86196049:+
THCA	cis	rs4703129	0.967	rs13166458	ENSG00000246763.5	RGMB-AS1	-3.45	0.000602	0.0356	-0.15	-0.16	Asperger disorder;	chr5:98558262	chr5:98769618~98773469:-
THCA	cis	rs7412746	0.658	rs12068264	ENSG00000224800.1	RP11-235D19.2	-3.45	0.000602	0.0356	-0.22	-0.16	Melanoma;	chr1:150754853	chr1:150881236~150881683:-
THCA	cis	rs7412746	0.658	rs2230061	ENSG00000224800.1	RP11-235D19.2	-3.45	0.000602	0.0356	-0.22	-0.16	Melanoma;	chr1:150755063	chr1:150881236~150881683:-
THCA	cis	rs9878978	0.722	rs34953825	ENSG00000227588.2	CNTN4-AS2	3.45	0.000602	0.0356	0.2	0.16	Blood pressure (smoking interaction);	chr3:2395854	chr3:2110409~2144241:-
THCA	cis	rs4218	0.689	rs11853828	ENSG00000277144.1	RP11-59H7.4	-3.45	0.000602	0.0356	-0.22	-0.16	Social communication problems;	chr15:59136031	chr15:59115547~59116089:-
THCA	cis	rs7259376	0.84	rs1985135	ENSG00000270947.1	AC025811.3	3.45	0.000602	0.0356	0.17	0.16	Menopause (age at onset);	chr19:22340776	chr19:22455988~22456459:+
THCA	cis	rs6142618	0.562	rs6061186	ENSG00000224452.1	RSL24D1P6	3.45	0.000602	0.0356	0.18	0.16	Inflammatory bowel disease;	chr20:32143937	chr20:32170390~32170790:-
THCA	cis	rs6921919	0.583	rs9468355	ENSG00000273712.1	RP5-874C20.7	3.45	0.000602	0.0356	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28315613~28315883:-
THCA	cis	rs11785400	1	rs4297023	ENSG00000177335.9	C8orf31	3.45	0.000602	0.0356	0.18	0.16	Schizophrenia;	chr8:142651928	chr8:143039209~143059942:+
THCA	cis	rs11785400	0.963	rs4579507	ENSG00000177335.9	C8orf31	3.45	0.000602	0.0356	0.18	0.16	Schizophrenia;	chr8:142652284	chr8:143039209~143059942:+
THCA	cis	rs9891119	0.965	rs9913597	ENSG00000267595.1	RP11-242D8.2	-3.45	0.000602	0.0356	-0.14	-0.16	Multiple sclerosis;Crohn's disease;	chr17:42358298	chr17:43168170~43168249:-
THCA	cis	rs2820315	0.867	rs2820323	ENSG00000223774.4	RP11-307B6.3	3.45	0.000602	0.0356	0.17	0.16	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201914032	chr1:201893842~201899978:+
THCA	cis	rs9457247	0.624	rs2239826	ENSG00000235272.1	FAM103A2P	3.45	0.000602	0.0356	0.22	0.16	Crohn's disease;	chr6:167091392	chr6:166586124~166586477:-
THCA	cis	rs12236219	0.786	rs79615002	ENSG00000269946.1	RP11-2B6.3	3.45	0.000602	0.0356	0.26	0.16	Body mass index;	chr9:94462780	chr9:94166289~94200627:+
THCA	cis	rs4262150	0.81	rs72797251	ENSG00000253921.1	CTB-113P19.3	3.45	0.000602	0.0356	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152631439	chr5:151753992~151767247:+
THCA	cis	rs6840360	0.615	rs72728179	ENSG00000251611.1	RP11-610P16.1	-3.45	0.000602	0.0356	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151556725	chr4:151407551~151408835:-
THCA	cis	rs10863936	0.667	rs1387815	ENSG00000198468.6	FLVCR1-AS1	-3.45	0.000602	0.0356	-0.19	-0.16	Height;	chr1:212103765	chr1:212852108~212858088:-
THCA	cis	rs4811196	0.871	rs238303	ENSG00000231307.1	RPS3P2	-3.45	0.000602	0.0356	-0.24	-0.16	Bone mineral density;	chr20:37780962	chr20:38537758~38538458:+
THCA	cis	rs6691722	0.506	rs1016209	ENSG00000264443.1	RP4-594I10.3	-3.45	0.000602	0.0356	-0.15	-0.16	Response to interferon beta in multiple sclerosis;	chr1:24419125	chr1:24538802~24556024:-
THCA	cis	rs11722228	1	rs11722228	ENSG00000261490.1	RP11-448G15.3	3.45	0.000602	0.0356	0.1	0.16	Urate levels;Serum uric acid levels;Gout;	chr4:9914117	chr4:10068089~10073019:-
THCA	cis	rs7924176	0.521	rs11000986	ENSG00000271848.1	RP11-464F9.21	-3.45	0.000602	0.0356	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:73654039~73674719:+
THCA	cis	rs7924176	0.521	rs10824147	ENSG00000271848.1	RP11-464F9.21	-3.45	0.000602	0.0356	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:73654039~73674719:+
THCA	cis	rs7924176	0.521	rs12359775	ENSG00000271848.1	RP11-464F9.21	-3.45	0.000602	0.0356	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:73654039~73674719:+
THCA	cis	rs7924176	0.521	rs11516630	ENSG00000271848.1	RP11-464F9.21	-3.45	0.000602	0.0356	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:73654039~73674719:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000214533.3	KRT18P33	-3.45	0.000602	0.0356	-0.2	-0.16	Rheumatoid arthritis;	chr2:65423730	chr2:65666695~65667737:+
THCA	cis	rs9911578	1	rs9901181	ENSG00000224738.1	AC099850.1	3.45	0.000602	0.0356	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58886910	chr17:59106598~59118267:+
THCA	cis	rs6545883	0.783	rs6545888	ENSG00000270820.4	RP11-355B11.2	3.45	0.000602	0.0356	0.13	0.16	Tuberculosis;	chr2:61618080	chr2:61471188~61484130:+
THCA	cis	rs7620503	0.613	rs11715814	ENSG00000228561.2	RP11-114M1.1	3.45	0.000603	0.0356	0.19	0.16	Corneal structure;	chr3:177562207	chr3:177683627~177691250:+
THCA	cis	rs7656342	0.622	rs11726423	ENSG00000250342.1	SNRPCP16	3.45	0.000603	0.0356	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9817948	chr4:9051842~9052051:-
THCA	cis	rs2115630	0.691	rs61322921	ENSG00000254414.1	RP11-182J1.1	-3.45	0.000603	0.0356	-0.19	-0.16	P wave terminal force;	chr15:84620407	chr15:84631898~84633987:-
THCA	cis	rs9876781	1	rs2242150	ENSG00000199476.1	Y_RNA	3.45	0.000603	0.0356	0.2	0.16	Longevity;	chr3:48464565	chr3:48288587~48288694:+
THCA	cis	rs12148329	0.604	rs78657552	ENSG00000259594.4	CTD-2034I4.2	3.45	0.000603	0.0356	0.28	0.16	Immune response to smallpox vaccine (IL-6);	chr15:80716739	chr15:81554003~81696780:+
THCA	cis	rs860295	0.702	rs10752611	ENSG00000236675.1	MTX1P1	-3.45	0.000603	0.0356	-0.16	-0.16	Body mass index;	chr1:155539316	chr1:155230975~155234325:+
THCA	cis	rs9811920	0.609	rs812657	ENSG00000273374.1	RP11-383I23.2	-3.45	0.000603	0.0356	-0.14	-0.16	Axial length;	chr3:99847485	chr3:99802699~99806058:-
THCA	cis	rs9488822	0.636	rs1544155	ENSG00000237021.2	RP3-486I3.7	3.45	0.000603	0.0356	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116025231	chr6:116254207~116256743:+
THCA	cis	rs1978968	0.717	rs28406897	ENSG00000280007.1	AC008079.10	3.45	0.000603	0.0356	0.16	0.16	Presence of antiphospholipid antibodies;	chr22:17919246	chr22:18110759~18131154:-
THCA	cis	rs7924176	0.521	rs10509347	ENSG00000271848.1	RP11-464F9.21	-3.45	0.000603	0.0356	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:73654039~73674719:+
THCA	cis	rs7487075	0.521	rs4768130	ENSG00000257261.4	RP11-96H19.1	3.45	0.000603	0.0356	0.11	0.16	Itch intensity from mosquito bite;	chr12:46713610	chr12:46383679~46876159:+
THCA	cis	rs7829975	0.846	rs1879957	ENSG00000254340.1	RP11-10A14.3	-3.45	0.000603	0.0356	-0.17	-0.16	Mood instability;	chr8:8687298	chr8:9141424~9145435:+
THCA	cis	rs61160187	0.582	rs12652878	ENSG00000272308.1	RP11-231G3.1	-3.45	0.000603	0.0356	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.548	rs17392014	ENSG00000272308.1	RP11-231G3.1	-3.45	0.000603	0.0356	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60866457~60866935:-
THCA	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-3.45	0.000603	0.0356	-0.18	-0.16	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
THCA	cis	rs7308116	0.53	rs10861828	ENSG00000257951.1	RP11-554D14.4	-3.45	0.000603	0.0356	-0.19	-0.16	Pelvic organ prolapse (moderate/severe);	chr12:107892015	chr12:107881242~107883382:+
THCA	cis	rs12807809	1	rs36053597	ENSG00000254941.1	RP11-677M14.5	3.45	0.000603	0.0356	0.17	0.16	Schizophrenia;	chr11:124736588	chr11:124807822~124808269:-
THCA	cis	rs9911578	1	rs4372750	ENSG00000224738.1	AC099850.1	-3.45	0.000603	0.0356	-0.18	-0.16	Intelligence (multi-trait analysis);	chr17:58936442	chr17:59106598~59118267:+
THCA	cis	rs7737355	0.812	rs12513768	ENSG00000224431.1	AC063976.7	3.45	0.000603	0.0356	0.15	0.16	Life satisfaction;	chr5:131281099	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs13173941	ENSG00000224431.1	AC063976.7	3.45	0.000603	0.0356	0.15	0.16	Life satisfaction;	chr5:131287539	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.773	rs13154452	ENSG00000224431.1	AC063976.7	3.45	0.000603	0.0356	0.15	0.16	Life satisfaction;	chr5:131287665	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs13179482	ENSG00000224431.1	AC063976.7	3.45	0.000603	0.0356	0.15	0.16	Life satisfaction;	chr5:131290380	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs11242070	ENSG00000224431.1	AC063976.7	3.45	0.000603	0.0356	0.15	0.16	Life satisfaction;	chr5:131290928	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.738	rs7379696	ENSG00000224431.1	AC063976.7	3.45	0.000603	0.0356	0.15	0.16	Life satisfaction;	chr5:131291767	chr5:132199456~132203487:+
THCA	cis	rs13185787	1	rs13185787	ENSG00000224431.1	AC063976.7	3.45	0.000603	0.0356	0.15	0.16	Subjective well-being;	chr5:131292191	chr5:132199456~132203487:+
THCA	cis	rs7264396	0.635	rs6060709	ENSG00000088340.14	FER1L4	3.45	0.000603	0.0356	0.16	0.16	Total cholesterol levels;	chr20:35948100	chr20:35558737~35607562:-
THCA	cis	rs6546537	0.826	rs2704443	ENSG00000231024.1	AC092431.3	3.45	0.000603	0.0356	0.2	0.16	Serum thyroid-stimulating hormone levels;	chr2:69662206	chr2:69700192~69713847:-
THCA	cis	rs3758911	0.765	rs609821	ENSG00000255353.1	RP11-382M14.1	3.45	0.000603	0.0356	0.2	0.16	Coronary artery disease;	chr11:107468429	chr11:107176286~107177530:+
THCA	cis	rs10129255	0.784	rs7147210	ENSG00000274576.2	IGHV2-70	3.45	0.000603	0.0356	0.11	0.16	Kawasaki disease;	chr14:106705271	chr14:106770577~106771020:-
THCA	cis	rs7824557	0.564	rs13260727	ENSG00000261451.1	RP11-981G7.1	3.45	0.000603	0.0356	0.2	0.16	Retinal vascular caliber;	chr8:11375351	chr8:10433672~10438312:+
THCA	cis	rs1962772	0.532	rs1858713	ENSG00000279903.1	RP11-349F21.5	-3.45	0.000603	0.0356	-0.2	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);	chr8:17517659	chr8:17500012~17500605:+
THCA	cis	rs7474896	1	rs9417263	ENSG00000276805.1	RP11-291L22.6	3.45	0.000603	0.0356	0.24	0.16	Obesity (extreme);	chr10:37825762	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs9417264	ENSG00000276805.1	RP11-291L22.6	3.45	0.000603	0.0356	0.24	0.16	Obesity (extreme);	chr10:37828642	chr10:38451030~38451785:+
THCA	cis	rs7474896	0.945	rs9417265	ENSG00000276805.1	RP11-291L22.6	3.45	0.000603	0.0356	0.24	0.16	Obesity (extreme);	chr10:37829973	chr10:38451030~38451785:+
THCA	cis	rs972578	0.806	rs5751386	ENSG00000274717.1	RP1-47A17.1	-3.45	0.000603	0.0356	-0.16	-0.16	Mean platelet volume;	chr22:42849339	chr22:42791814~42794313:-
THCA	cis	rs6914704	0.702	rs3800038	ENSG00000228718.1	RP11-145H9.3	3.45	0.000603	0.0356	0.2	0.16	Late-onset myasthenia gravis;	chr6:1760553	chr6:2636936~2640001:+
THCA	cis	rs3862188	0.6	rs73132927	ENSG00000230576.1	OR6R1P	-3.45	0.000603	0.0356	-0.13	-0.16	Pre-treatment pain in head and neck squamous cell carcinoma;	chr1:247698297	chr1:247833349~247834288:-
THCA	cis	rs3862188	0.6	rs60749984	ENSG00000230576.1	OR6R1P	-3.45	0.000603	0.0356	-0.13	-0.16	Pre-treatment pain in head and neck squamous cell carcinoma;	chr1:247700672	chr1:247833349~247834288:-
THCA	cis	rs4883201	0.536	rs7974486	ENSG00000245105.2	A2M-AS1	3.45	0.000603	0.0356	0.15	0.16	Total cholesterol levels;Cholesterol, total;	chr12:8979368	chr12:9065177~9068060:+
THCA	cis	rs6545883	0.965	rs2305155	ENSG00000212978.6	AC016747.3	3.45	0.000603	0.0357	0.17	0.16	Tuberculosis;	chr2:61502123	chr2:61141592~61144969:-
THCA	cis	rs7615952	0.641	rs7618515	ENSG00000241288.6	RP11-379B18.5	-3.45	0.000603	0.0357	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126071735	chr3:125827238~125916384:-
THCA	cis	rs4072980	0.527	rs11210825	ENSG00000252448.1	SNORA63	-3.45	0.000604	0.0357	-0.19	-0.16	Coronary artery disease;	chr1:37981314	chr1:37884237~37884317:+
THCA	cis	rs2635047	0.967	rs2668779	ENSG00000280212.1	RP11-49K24.3	-3.45	0.000604	0.0357	-0.16	-0.16	Educational attainment;	chr18:47215695	chr18:47076117~47076594:+
THCA	cis	rs72928364	0.72	rs73145363	ENSG00000256628.3	ZBTB11-AS1	3.45	0.000604	0.0357	0.28	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101091286	chr3:101676475~101679217:+
THCA	cis	rs66561647	0.929	rs67423398	ENSG00000207110.1	RNU1-106P	-3.45	0.000604	0.0357	-0.21	-0.16	Hemoglobin concentration;	chr8:127959974	chr8:127999131~127999294:+
THCA	cis	rs987724	0.593	rs3910072	ENSG00000241544.1	RP11-6F2.5	-3.45	0.000604	0.0357	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156843137	chr3:157081841~157088547:+
THCA	cis	rs987724	0.551	rs9876010	ENSG00000241544.1	RP11-6F2.5	-3.45	0.000604	0.0357	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156845715	chr3:157081841~157088547:+
THCA	cis	rs987724	0.593	rs7652112	ENSG00000241544.1	RP11-6F2.5	-3.45	0.000604	0.0357	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156854774	chr3:157081841~157088547:+
THCA	cis	rs987724	0.593	rs2060015	ENSG00000241544.1	RP11-6F2.5	-3.45	0.000604	0.0357	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856141	chr3:157081841~157088547:+
THCA	cis	rs2839186	0.681	rs13047198	ENSG00000228137.1	AP001469.7	3.45	0.000604	0.0357	0.16	0.16	Testicular germ cell tumor;	chr21:46281921	chr21:46246890~46247682:+
THCA	cis	rs7142002	0.881	rs8013848	ENSG00000272444.1	RP11-1017G21.6	-3.45	0.000604	0.0357	-0.23	-0.16	Autism;	chr14:101935790	chr14:101952416~101953063:+
THCA	cis	rs1044826	0.623	rs4383548	ENSG00000272656.1	RP11-219D15.3	-3.45	0.000604	0.0357	-0.19	-0.16	Obesity-related traits;	chr3:139321673	chr3:139349024~139349371:-
THCA	cis	rs6847067	0.759	rs4533765	ENSG00000180769.7	WDFY3-AS2	3.45	0.000604	0.0357	0.12	0.16	Oropharynx cancer;	chr4:84994417	chr4:84965682~85011277:+
THCA	cis	rs8054556	1	rs3814881	ENSG00000214725.6	CDIPT-AS1	-3.45	0.000604	0.0357	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29989580	chr16:29863593~29868053:+
THCA	cis	rs4604234	0.803	rs79048064	ENSG00000260645.1	RP11-250B2.5	-3.45	0.000604	0.0357	-0.26	-0.16	Cancer;	chr6:80267381	chr6:80466958~80469080:+
THCA	cis	rs7283707	0.748	rs463566	ENSG00000229425.1	AJ006998.2	3.45	0.000604	0.0357	0.22	0.16	QRS complex (12-leadsum);	chr21:15725314	chr21:15370522~15402305:-
THCA	cis	rs62344088	0.59	rs60845955	ENSG00000248925.1	CTD-2083E4.6	3.45	0.000604	0.0357	0.33	0.16	Asthma (childhood onset);	chr5:184979	chr5:269858~271516:-
THCA	cis	rs4730276	0.674	rs10953554	ENSG00000250474.1	WBP1LP2	-3.45	0.000604	0.0357	-0.15	-0.16	Ulcerative colitis;	chr7:107935112	chr7:107628553~107629498:+
THCA	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-3.45	0.000604	0.0357	-0.18	-0.16	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
THCA	cis	rs10435719	0.764	rs10103485	ENSG00000255495.1	AC145124.2	3.45	0.000604	0.0357	0.18	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:12194467~12196280:+
THCA	cis	rs684232	0.666	rs838372	ENSG00000231784.7	DBIL5P	3.45	0.000604	0.0357	0.17	0.16	Prostate cancer;	chr17:663188	chr17:752660~755336:+
THCA	cis	rs1029966	0.541	rs2451	ENSG00000262686.1	GLIS2-AS1	3.45	0.000604	0.0357	0.2	0.16	Cancer;	chr16:4933793	chr16:4324667~4328340:-
THCA	cis	rs7824557	0.843	rs2572418	ENSG00000261451.1	RP11-981G7.1	-3.45	0.000604	0.0357	-0.19	-0.16	Retinal vascular caliber;	chr8:11255580	chr8:10433672~10438312:+
THCA	cis	rs7620503	0.765	rs2133594	ENSG00000228561.2	RP11-114M1.1	-3.45	0.000604	0.0357	-0.18	-0.16	Corneal structure;	chr3:177584329	chr3:177683627~177691250:+
THCA	cis	rs34779708	0.897	rs9665538	ENSG00000233200.1	RP11-324I22.2	3.45	0.000604	0.0357	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35219894~35230598:-
THCA	cis	rs8099594	0.5	rs4491603	ENSG00000266696.1	RP11-30L3.2	3.45	0.000604	0.0357	0.2	0.16	Height;	chr18:49232143	chr18:49205912~49208781:+
THCA	cis	rs2839186	0.605	rs2839173	ENSG00000228137.1	AP001469.7	3.45	0.000604	0.0357	0.16	0.16	Testicular germ cell tumor;	chr21:46256797	chr21:46246890~46247682:+
THCA	cis	rs2485376	0.626	rs61057264	ENSG00000269609.4	RPARP-AS1	-3.45	0.000604	0.0357	-0.25	-0.16	QT interval;	chr10:102235179	chr10:102449817~102461106:+
THCA	cis	rs4713118	1	rs4713118	ENSG00000261839.1	RP1-265C24.8	3.45	0.000604	0.0357	0.17	0.16	Parkinson's disease;	chr6:27709015	chr6:28136849~28139678:+
THCA	cis	rs9818758	0.607	rs61729488	ENSG00000229759.1	MRPS18AP1	-3.45	0.000604	0.0357	-0.34	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49030471	chr3:48256350~48256938:-
THCA	cis	rs2455799	0.613	rs2470547	ENSG00000270409.1	RP11-44D5.1	-3.45	0.000604	0.0357	-0.17	-0.16	Mean platelet volume;	chr3:15696103	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs2470549	ENSG00000270409.1	RP11-44D5.1	-3.45	0.000604	0.0357	-0.17	-0.16	Mean platelet volume;	chr3:15696191	chr3:15732252~15733470:+
THCA	cis	rs12618769	0.504	rs3820942	ENSG00000228970.6	UBTFL6	-3.45	0.000604	0.0357	-0.23	-0.16	Bipolar disorder;	chr2:98556391	chr2:97636780~97637803:-
THCA	cis	rs7615952	0.512	rs2979336	ENSG00000243429.1	OR7E29P	3.45	0.000604	0.0357	0.2	0.16	Blood pressure (smoking interaction);	chr3:125638626	chr3:125712139~125713045:+
THCA	cis	rs2662776	0.967	rs4291481	ENSG00000232995.6	RGS5	3.45	0.000604	0.0357	0.13	0.16	Lead levels in blood;	chr1:163182051	chr1:163244505~163321894:-
THCA	cis	rs1729951	0.575	rs747843	ENSG00000239213.4	NCK1-AS1	3.45	0.000604	0.0357	0.14	0.16	Neuroticism;	chr3:136984288	chr3:136841726~136862054:-
THCA	cis	rs4705962	0.917	rs10066660	ENSG00000230612.2	AC004237.1	3.45	0.000604	0.0357	0.2	0.16	Atopic dermatitis;	chr5:132685298	chr5:132688681~132723725:+
THCA	cis	rs4705962	0.959	rs6885996	ENSG00000230612.2	AC004237.1	3.45	0.000604	0.0357	0.2	0.16	Atopic dermatitis;	chr5:132685604	chr5:132688681~132723725:+
THCA	cis	rs5771242	0.518	rs5771258	ENSG00000273137.1	RP3-402G11.28	-3.45	0.000604	0.0357	-0.13	-0.16	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50237219	chr22:50208461~50209542:-
THCA	cis	rs4820539	0.641	rs5759602	ENSG00000272787.1	KB-226F1.2	3.45	0.000604	0.0357	0.18	0.16	Bone mineral density;	chr22:23147175	chr22:23969211~23969873:+
THCA	cis	rs9634489	0.807	rs413516	ENSG00000247400.3	DNAJC3-AS1	-3.45	0.000604	0.0357	-0.1	-0.16	Body mass index;	chr13:96406819	chr13:95648733~95676925:-
THCA	cis	rs1113500	0.836	rs2801220	ENSG00000230489.1	VAV3-AS1	3.45	0.000605	0.0357	0.15	0.16	Growth-regulated protein alpha levels;	chr1:108042027	chr1:107964443~107994607:+
THCA	cis	rs2235649	0.833	rs9922139	ENSG00000260541.1	LA16c-429E7.1	3.45	0.000605	0.0357	0.21	0.16	Blood metabolite levels;	chr16:1798328	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs9933168	ENSG00000260541.1	LA16c-429E7.1	3.45	0.000605	0.0357	0.21	0.16	Blood metabolite levels;	chr16:1798360	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.746	rs113666107	ENSG00000260541.1	LA16c-429E7.1	3.45	0.000605	0.0357	0.21	0.16	Blood metabolite levels;	chr16:1798641	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.746	rs35104579	ENSG00000260541.1	LA16c-429E7.1	3.45	0.000605	0.0357	0.21	0.16	Blood metabolite levels;	chr16:1798656	chr16:1841020~1843547:-
THCA	cis	rs2235649	0.833	rs55684627	ENSG00000260541.1	LA16c-429E7.1	3.45	0.000605	0.0357	0.21	0.16	Blood metabolite levels;	chr16:1798816	chr16:1841020~1843547:-
THCA	cis	rs7924176	0.54	rs61866073	ENSG00000271848.1	RP11-464F9.21	-3.45	0.000605	0.0357	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:73654039~73674719:+
THCA	cis	rs7924176	0.521	rs7098200	ENSG00000271848.1	RP11-464F9.21	3.45	0.000605	0.0357	0.17	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:73654039~73674719:+
THCA	cis	rs9878978	0.69	rs2874300	ENSG00000227588.2	CNTN4-AS2	3.45	0.000605	0.0357	0.21	0.16	Blood pressure (smoking interaction);	chr3:2406067	chr3:2110409~2144241:-
THCA	cis	rs10200159	0.744	rs6545513	ENSG00000206964.1	Y_RNA	-3.45	0.000605	0.0357	-0.38	-0.16	Vitiligo;	chr2:55657729	chr2:55286018~55286128:+
THCA	cis	rs748404	0.666	rs12911569	ENSG00000166763.7	STRCP1	3.45	0.000605	0.0357	0.21	0.16	Lung cancer;	chr15:43305099	chr15:43699488~43718184:-
THCA	cis	rs1729951	0.575	rs747842	ENSG00000239213.4	NCK1-AS1	3.45	0.000605	0.0357	0.14	0.16	Neuroticism;	chr3:136984279	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs835642	ENSG00000239213.4	NCK1-AS1	3.45	0.000605	0.0357	0.14	0.16	Neuroticism;	chr3:136984523	chr3:136841726~136862054:-
THCA	cis	rs4730276	0.674	rs6944829	ENSG00000250474.1	WBP1LP2	-3.45	0.000605	0.0357	-0.14	-0.16	Ulcerative colitis;	chr7:107885287	chr7:107628553~107629498:+
THCA	cis	rs832540	1	rs252913	ENSG00000271828.1	CTD-2310F14.1	3.45	0.000605	0.0357	0.21	0.16	Coronary artery disease;	chr5:56900019	chr5:56927874~56929573:+
THCA	cis	rs11633886	0.604	rs34042928	ENSG00000259200.1	RP11-718O11.1	-3.45	0.000605	0.0357	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45813179	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.553	rs35116416	ENSG00000259200.1	RP11-718O11.1	-3.45	0.000605	0.0357	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45813559	chr15:45705078~45931069:+
THCA	cis	rs10938353	0.911	rs2348348	ENSG00000273369.1	RP11-700J17.1	-3.45	0.000605	0.0357	-0.18	-0.16	Body mass index;	chr4:44601408	chr4:44693946~44694386:-
THCA	cis	rs11168618	0.567	rs7314569	ENSG00000240399.1	RP1-228P16.1	3.45	0.000605	0.0357	0.16	0.16	Adiponectin levels;	chr12:48423198	chr12:48054813~48055591:-
THCA	cis	rs4262150	0.81	rs17565365	ENSG00000253921.1	CTB-113P19.3	3.45	0.000605	0.0357	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152676674	chr5:151753992~151767247:+
THCA	cis	rs4489787	0.568	rs2705135	ENSG00000273765.1	RP11-370I10.11	3.45	0.000605	0.0357	0.18	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48496773	chr12:48360920~48361377:+
THCA	cis	rs910316	1	rs13099	ENSG00000273565.1	CTD-3075F15.1	-3.45	0.000605	0.0357	-0.19	-0.16	Height;	chr14:75132452	chr14:75176929~75177418:+
THCA	cis	rs2040609	0.753	rs11871330	ENSG00000200013.1	RNU6-623P	3.45	0.000605	0.0357	0.19	0.16	Multiple keratinocyte cancers;	chr17:61637738	chr17:60662333~60662437:-
THCA	cis	rs76419734	0.717	rs72669986	ENSG00000251175.4	RP11-45L9.1	3.45	0.000605	0.0357	0.42	0.16	Post bronchodilator FEV1;	chr4:105629115	chr4:105746245~105827172:-
THCA	cis	rs997295	0.592	rs2899724	ENSG00000245719.1	RP11-34F13.2	3.45	0.000605	0.0357	0.17	0.16	Motion sickness;	chr15:67468470	chr15:67834310~67838879:-
THCA	cis	rs71537559	1	rs71537559	ENSG00000272009.1	RP1-313I6.12	-3.45	0.000605	0.0357	-0.27	-0.16	Squamous cell lung carcinoma;	chr6:27342000	chr6:28078792~28081130:-
THCA	cis	rs7142002	0.881	rs7149063	ENSG00000272444.1	RP11-1017G21.6	-3.45	0.000605	0.0357	-0.23	-0.16	Autism;	chr14:101939262	chr14:101952416~101953063:+
THCA	cis	rs7709377	0.597	rs11241352	ENSG00000272265.1	CTD-2287O16.4	3.45	0.000605	0.0357	0.16	0.16	Metabolite levels  (X-11787);	chr5:116076586	chr5:116078110~116078570:-
THCA	cis	rs7924176	0.521	rs7899920	ENSG00000271848.1	RP11-464F9.21	3.45	0.000605	0.0357	0.17	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:73654039~73674719:+
THCA	cis	rs76793172	0.841	rs111386720	ENSG00000207003.1	RNU6-611P	3.45	0.000606	0.0358	0.3	0.16	Eosinophil counts;	chr19:45798887	chr19:45047458~45047561:+
THCA	cis	rs860295	1	rs860295	ENSG00000236675.1	MTX1P1	3.45	0.000606	0.0358	0.15	0.16	Body mass index;	chr1:155797917	chr1:155230975~155234325:+
THCA	cis	rs4886920	0.694	rs7163336	ENSG00000260776.4	RP11-114H24.2	3.45	0.000606	0.0358	0.18	0.16	Neuroticism;	chr15:77795430	chr15:77914217~77926846:-
THCA	cis	rs2797160	1	rs1777225	ENSG00000226409.1	RP11-735G4.1	3.45	0.000606	0.0358	0.19	0.16	Endometrial cancer;	chr6:125697124	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1739362	ENSG00000226409.1	RP11-735G4.1	3.45	0.000606	0.0358	0.19	0.16	Endometrial cancer;	chr6:125699557	chr6:125370211~125374324:-
THCA	cis	rs7914558	0.966	rs10883817	ENSG00000213061.2	PFN1P11	3.45	0.000606	0.0358	0.19	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:102838011~102845473:-
THCA	cis	rs1063857	0.656	rs216291	ENSG00000207708.1	MIR141	-3.45	0.000606	0.0358	-0.17	-0.16	vWF levels;Coagulation factor levels;	chr12:6042707	chr12:6964097~6964191:+
THCA	cis	rs7809950	0.635	rs62483629	ENSG00000272072.1	CTA-363E19.2	3.45	0.000606	0.0358	0.17	0.16	Coronary artery disease;	chr7:107225733	chr7:107192559~107193300:-
THCA	cis	rs2839619	0.525	rs3737434	ENSG00000233754.1	AP001628.7	-3.45	0.000606	0.0358	-0.17	-0.16	Biochemical measures;	chr21:43017032	chr21:42781074~42782233:-
THCA	cis	rs11190604	1	rs11190551	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100444977	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs10883492	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100446332	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs10883493	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100448431	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs11190555	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100449403	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs11190556	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100449466	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs11190557	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100449612	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs11190558	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100449640	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.943	rs7085261	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100450054	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs7085439	ENSG00000273030.1	RP11-285F16.1	3.45	0.000606	0.0358	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100450343	chr10:100412934~100413421:+
THCA	cis	rs9834970	0.787	rs4789	ENSG00000281100.1	RP11-640L9.2	-3.45	0.000606	0.0358	-0.16	-0.16	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36827948	chr3:36823151~36825158:-
THCA	cis	rs4723738	1	rs11766341	ENSG00000227191.5	TRGC2	-3.45	0.000606	0.0358	-0.12	-0.16	Treatment response for severe sepsis;	chr7:38188147	chr7:38239580~38368091:-
THCA	cis	rs6600671	1	rs4844616	ENSG00000226067.5	CH17-118O6.2	3.45	0.000606	0.0358	0.16	0.16	Hip geometry;	chr1:121429348	chr1:120913275~121009291:+
THCA	cis	rs4763879	0.594	rs12427310	ENSG00000256594.6	RP11-705C15.2	-3.45	0.000606	0.0358	-0.12	-0.16	Type 1 diabetes;	chr12:9707539	chr12:9633419~9658412:+
THCA	cis	rs722414	0.846	rs7310515	ENSG00000258302.2	RP11-981P6.1	3.45	0.000606	0.0358	0.15	0.16	Blood protein levels;	chr12:89505850	chr12:89561129~89594878:+
THCA	cis	rs853679	0.546	rs200949	ENSG00000220721.1	OR1F12	3.45	0.000606	0.0358	0.25	0.16	Depression;	chr6:27867657	chr6:28073316~28074233:+
THCA	cis	rs7129556	0.954	rs10899387	ENSG00000254459.1	RP11-91P24.7	3.45	0.000606	0.0358	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77565143	chr11:77829654~77872262:-
THCA	cis	rs11076221	1	rs27371	ENSG00000261238.1	AC009166.5	-3.45	0.000606	0.0358	-0.28	-0.16	Alcohol dependence;	chr16:51956810	chr16:51149239~51149819:+
THCA	cis	rs736801	0.78	rs12521868	ENSG00000263597.1	MIR3936	-3.45	0.000606	0.0358	-0.16	-0.16	Mosquito bite size;Breast cancer;	chr5:132448701	chr5:132365490~132365599:-
THCA	cis	rs6545883	1	rs778763	ENSG00000212978.6	AC016747.3	3.45	0.000606	0.0358	0.17	0.16	Tuberculosis;	chr2:61558504	chr2:61141592~61144969:-
THCA	cis	rs7495517	0.686	rs4467041	ENSG00000278840.1	RP11-345N11.1	3.45	0.000606	0.0358	0.18	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:27276070	chr15:26557598~26557937:-
THCA	cis	rs1799949	1	rs12944597	ENSG00000236383.6	LINC00854	-3.45	0.000606	0.0358	-0.15	-0.16	Menopause (age at onset);	chr17:43035667	chr17:43216941~43305976:-
THCA	cis	rs1799949	0.965	rs34616041	ENSG00000236383.6	LINC00854	-3.45	0.000606	0.0358	-0.15	-0.16	Menopause (age at onset);	chr17:43036769	chr17:43216941~43305976:-
THCA	cis	rs17270561	0.609	rs1165181	ENSG00000272462.2	U91328.19	-3.45	0.000606	0.0358	-0.13	-0.16	Iron status biomarkers;	chr6:25825162	chr6:25992662~26001775:+
THCA	cis	rs10028773	0.546	rs13117947	ENSG00000249244.1	RP11-548H18.2	3.45	0.000606	0.0358	0.17	0.16	Educational attainment;	chr4:119335905	chr4:119391831~119395335:-
THCA	cis	rs9376098	0.651	rs9402691	ENSG00000232876.1	CTA-212D2.2	-3.45	0.000606	0.0358	-0.22	-0.16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135166364	chr6:135055033~135060550:+
THCA	cis	rs7511006	0.798	rs11703673	ENSG00000272836.1	RP3-402G11.27	3.45	0.000606	0.0358	0.14	0.16	Obesity-related traits;	chr22:50213998	chr22:50205585~50206062:-
THCA	cis	rs6840360	0.55	rs12651635	ENSG00000251611.1	RP11-610P16.1	-3.45	0.000606	0.0358	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151636634	chr4:151407551~151408835:-
THCA	cis	rs67478160	0.654	rs11628240	ENSG00000258534.1	CTD-2134A5.4	-3.45	0.000607	0.0358	-0.16	-0.16	Schizophrenia;	chr14:103751798	chr14:103854366~103880111:-
THCA	cis	rs4650376	0.789	rs1937023	ENSG00000238015.2	RP4-641G12.3	3.45	0.000607	0.0358	0.27	0.16	IgG glycosylation;	chr1:78759941	chr1:78666272~78666695:+
THCA	cis	rs2262909	0.962	rs439574	ENSG00000269364.1	LINC01233	3.45	0.000607	0.0358	0.19	0.16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22049222	chr19:22532626~22533494:+
THCA	cis	rs9902453	0.619	rs2255489	ENSG00000264290.1	RP11-68I3.4	-3.45	0.000607	0.0358	-0.12	-0.16	Coffee consumption (cups per day);	chr17:29757956	chr17:29569580~29570519:+
THCA	cis	rs7631605	0.586	rs13072995	ENSG00000224080.1	UBE2FP1	3.45	0.000607	0.0358	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37287745	chr3:37143512~37143958:-
THCA	cis	rs7631605	0.586	rs11720550	ENSG00000224080.1	UBE2FP1	3.45	0.000607	0.0358	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37291406	chr3:37143512~37143958:-
THCA	cis	rs9650657	0.711	rs10100209	ENSG00000269918.1	AF131215.9	-3.45	0.000607	0.0358	-0.16	-0.16	Neuroticism;	chr8:10726702	chr8:11104691~11106704:-
THCA	cis	rs11212260	0.85	rs639556	ENSG00000261098.1	RP11-819C21.1	3.45	0.000607	0.0358	0.29	0.16	IgG glycosylation;	chr11:107520552	chr11:107312132~107316271:-
THCA	cis	rs8103033	0.781	rs7248699	ENSG00000226025.8	LGALS17A	-3.45	0.000607	0.0358	-0.14	-0.16	Obesity-related traits;	chr19:39649338	chr19:39679374~39686373:+
THCA	cis	rs8103033	0.781	rs7248784	ENSG00000226025.8	LGALS17A	-3.45	0.000607	0.0358	-0.14	-0.16	Obesity-related traits;	chr19:39649347	chr19:39679374~39686373:+
THCA	cis	rs34975555	0.803	rs17126040	ENSG00000253671.1	RP11-806O11.1	3.45	0.000607	0.0358	0.23	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17972171	chr8:17808941~17820868:+
THCA	cis	rs1635	0.655	rs723475	ENSG00000216901.1	AL022393.7	-3.45	0.000607	0.0358	-0.35	-0.16	Schizophrenia;	chr6:28337064	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs16893973	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28334336	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs1416919	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28335107	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs73742535	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28335148	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs73742536	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28335466	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs59598126	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28335823	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs2281041	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28336068	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs58019071	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28336239	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs723476	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28337327	chr6:28176188~28176674:+
THCA	cis	rs1635	0.655	rs73742539	ENSG00000216901.1	AL022393.7	3.45	0.000607	0.0358	0.35	0.16	Schizophrenia;	chr6:28337694	chr6:28176188~28176674:+
THCA	cis	rs7809950	0.599	rs2237658	ENSG00000272072.1	CTA-363E19.2	3.45	0.000607	0.0358	0.17	0.16	Coronary artery disease;	chr7:107197421	chr7:107192559~107193300:-
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000214719.10	AC005562.1	-3.45	0.000607	0.0358	-0.22	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30576464~30672789:+
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000214719.10	AC005562.1	-3.45	0.000607	0.0358	-0.22	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30576464~30672789:+
THCA	cis	rs6545883	0.525	rs1729662	ENSG00000212978.6	AC016747.3	3.45	0.000607	0.0358	0.17	0.16	Tuberculosis;	chr2:61164170	chr2:61141592~61144969:-
THCA	cis	rs17428076	0.831	rs3736499	ENSG00000228389.1	AC068039.4	-3.45	0.000607	0.0358	-0.18	-0.16	Myopia;	chr2:171833908	chr2:171773482~171775844:+
THCA	cis	rs9650657	0.746	rs4841441	ENSG00000269918.1	AF131215.9	-3.45	0.000607	0.0358	-0.16	-0.16	Neuroticism;	chr8:10773388	chr8:11104691~11106704:-
THCA	cis	rs9818758	0.607	rs13068038	ENSG00000229759.1	MRPS18AP1	-3.45	0.000607	0.0358	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49256817	chr3:48256350~48256938:-
THCA	cis	rs2163813	0.788	rs247774	ENSG00000271499.1	CTC-559E9.9	-3.45	0.000607	0.0358	-0.18	-0.16	Toenail selenium levels;	chr19:19732742	chr19:19750618~19752544:+
THCA	cis	rs256438	0.731	rs12332694	ENSG00000251221.1	LINC01337	-3.45	0.000607	0.0358	-0.19	-0.16	Serum thyroid-stimulating hormone levels;	chr5:80046166	chr5:80608623~80622524:-
THCA	cis	rs3793683	1	rs3793683	ENSG00000273980.1	RP13-49I15.6	-3.45	0.000607	0.0358	-0.19	-0.16	Migraine;	chr10:132754883	chr10:133257144~133257551:-
THCA	cis	rs7028939	1	rs10989003	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100184891	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10989004	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100186938	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7859524	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100187078	chr9:99886322~99906601:-
THCA	cis	rs7028939	0.901	rs58197960	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100187755	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs12005668	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100189420	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10819736	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100189493	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7018703	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100190484	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs34407295	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100191044	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs6479004	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100192407	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10989006	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100192814	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10819738	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100193931	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10989010	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100195824	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs6479005	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100197636	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7853497	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100197791	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs6479006	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100199830	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7866669	ENSG00000255145.2	STX17-AS1	-3.45	0.000607	0.0358	-0.24	-0.16	Preeclampsia;	chr9:100201379	chr9:99886322~99906601:-
THCA	cis	rs7631605	0.846	rs4431051	ENSG00000272334.1	RP11-129K12.1	-3.45	0.000607	0.0358	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36950914	chr3:36973117~36973672:-
THCA	cis	rs73459955	0.712	rs76476435	ENSG00000248441.5	LINC01197	3.45	0.000607	0.0358	0.21	0.16	Major depression and alcohol dependence;	chr15:95085578	chr15:95209099~95327129:-
THCA	cis	rs972578	0.84	rs8138151	ENSG00000274717.1	RP1-47A17.1	-3.45	0.000607	0.0358	-0.16	-0.16	Mean platelet volume;	chr22:42989997	chr22:42791814~42794313:-
THCA	cis	rs5758659	0.904	rs5758653	ENSG00000205702.9	CYP2D7	3.45	0.000607	0.0358	0.12	0.16	Cognitive function;	chr22:42217479	chr22:42140203~42144577:-
THCA	cis	rs768090	0.812	rs2300942	ENSG00000237892.1	KLF7-IT1	-3.45	0.000607	0.0358	-0.19	-0.16	Hemoglobin concentration;Hematocrit;	chr2:207125903	chr2:207120884~207122044:-
THCA	cis	rs7829975	0.623	rs7010753	ENSG00000233609.3	RP11-62H7.2	3.45	0.000607	0.0358	0.16	0.16	Mood instability;	chr8:8516446	chr8:8961200~8979025:+
THCA	cis	rs1862618	1	rs1862618	ENSG00000234553.1	AC022431.3	-3.45	0.000607	0.0358	-0.17	-0.16	Initial pursuit acceleration;	chr5:56800488	chr5:56536583~56537826:-
THCA	cis	rs7631605	0.783	rs11129744	ENSG00000272334.1	RP11-129K12.1	-3.45	0.000608	0.0358	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36924958	chr3:36973117~36973672:-
THCA	cis	rs488400	0.571	rs518213	ENSG00000251377.1	RP11-18H21.3	-3.45	0.000608	0.0358	-0.17	-0.16	Trans fatty acid levels;	chr4:151892080	chr4:152207421~152225870:-
THCA	cis	rs7631605	0.586	rs62244335	ENSG00000224080.1	UBE2FP1	3.45	0.000608	0.0358	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37265671	chr3:37143512~37143958:-
THCA	cis	rs6005807	0.719	rs12169071	ENSG00000272858.1	CTA-292E10.8	-3.45	0.000608	0.0358	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28637222	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.719	rs12168765	ENSG00000272858.1	CTA-292E10.8	-3.45	0.000608	0.0358	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28637320	chr22:28814914~28815662:+
THCA	cis	rs6005807	0.719	rs12165893	ENSG00000272858.1	CTA-292E10.8	-3.45	0.000608	0.0358	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28637557	chr22:28814914~28815662:+
THCA	cis	rs9818758	0.607	rs9837625	ENSG00000229759.1	MRPS18AP1	-3.45	0.000608	0.0358	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178533	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs66991555	ENSG00000229759.1	MRPS18AP1	-3.45	0.000608	0.0358	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49191210	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs9855123	ENSG00000229759.1	MRPS18AP1	-3.45	0.000608	0.0358	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49192024	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs34566463	ENSG00000229759.1	MRPS18AP1	-3.45	0.000608	0.0358	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207644	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs11710247	ENSG00000229759.1	MRPS18AP1	-3.45	0.000608	0.0358	-0.32	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49212367	chr3:48256350~48256938:-
THCA	cis	rs7824557	0.603	rs11250130	ENSG00000255495.1	AC145124.2	-3.45	0.000608	0.0358	-0.18	-0.16	Retinal vascular caliber;	chr8:11356946	chr8:12194467~12196280:+
THCA	cis	rs7616559	0.887	rs6441107	ENSG00000244515.1	KRT18P34	-3.45	0.000608	0.0358	-0.21	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:156991418	chr3:157162663~157163932:-
THCA	cis	rs4664293	1	rs2357382	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159636614	chr2:159689217~159690291:-
THCA	cis	rs4664293	1	rs10184034	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159648916	chr2:159689217~159690291:-
THCA	cis	rs4664293	1	rs4664293	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159649241	chr2:159689217~159690291:-
THCA	cis	rs4664293	1	rs10193402	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159651271	chr2:159689217~159690291:-
THCA	cis	rs4664293	1	rs11676412	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159651560	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.934	rs7604482	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159657315	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs10176436	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159658883	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs7559127	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159659424	chr2:159689217~159690291:-
THCA	cis	rs6751744	0.514	rs12386214	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Dysphagia;	chr2:159675012	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs13032135	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159675588	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.932	rs4665104	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159675847	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.967	rs7595639	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159676533	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.934	rs4380179	ENSG00000230783.1	AC009961.2	-3.45	0.000608	0.0358	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159685064	chr2:159689217~159690291:-
THCA	cis	rs875971	0.545	rs13311962	ENSG00000230295.1	RP11-458F8.2	-3.45	0.000608	0.0358	-0.14	-0.16	Aortic root size;	chr7:66603142	chr7:66880708~66882981:+
THCA	cis	rs755107	0.653	rs6013570	ENSG00000201512.1	SNORA71C	-3.45	0.000608	0.0358	-0.21	-0.16	Skin pigmentation;	chr20:37978705	chr20:38429670~38429803:-
THCA	cis	rs722599	0.599	rs8003660	ENSG00000279594.1	RP11-950C14.10	3.45	0.000608	0.0358	0.16	0.16	IgG glycosylation;	chr14:74760395	chr14:75011269~75012851:-
THCA	cis	rs7146395	1	rs7146395	ENSG00000279594.1	RP11-950C14.10	3.45	0.000608	0.0358	0.16	0.16	Platelet count;	chr14:74761944	chr14:75011269~75012851:-
THCA	cis	rs950169	1	rs11638297	ENSG00000275120.1	RP11-182J1.17	3.45	0.000608	0.0358	0.19	0.16	Schizophrenia;	chr15:84113665	chr15:84599434~84606463:-
THCA	cis	rs13393800	1	rs1190447	ENSG00000237126.7	AC073254.1	3.45	0.000608	0.0359	0.14	0.16	Height;	chr2:232555342	chr2:232580948~232611971:-
THCA	cis	rs12520053	1	rs12520053	ENSG00000248734.2	CTD-2260A17.1	3.45	0.000608	0.0359	0.22	0.16	Blood protein levels;	chr5:96831782	chr5:96784777~96785999:+
THCA	cis	rs12520053	1	rs1991011	ENSG00000248734.2	CTD-2260A17.1	3.45	0.000608	0.0359	0.22	0.16	Blood protein levels;	chr5:96832278	chr5:96784777~96785999:+
THCA	cis	rs12520053	1	rs1000555	ENSG00000248734.2	CTD-2260A17.1	3.45	0.000608	0.0359	0.22	0.16	Blood protein levels;	chr5:96832767	chr5:96784777~96785999:+
THCA	cis	rs12520053	1	rs12513660	ENSG00000248734.2	CTD-2260A17.1	3.45	0.000608	0.0359	0.22	0.16	Blood protein levels;	chr5:96834559	chr5:96784777~96785999:+
THCA	cis	rs12520053	0.945	rs12522976	ENSG00000248734.2	CTD-2260A17.1	3.45	0.000608	0.0359	0.22	0.16	Blood protein levels;	chr5:96836073	chr5:96784777~96785999:+
THCA	cis	rs12520053	1	rs12522460	ENSG00000248734.2	CTD-2260A17.1	3.45	0.000608	0.0359	0.22	0.16	Blood protein levels;	chr5:96836126	chr5:96784777~96785999:+
THCA	cis	rs897984	0.646	rs9938088	ENSG00000260911.2	RP11-196G11.2	3.45	0.000608	0.0359	0.13	0.16	Dementia with Lewy bodies;	chr16:30818683	chr16:31043150~31049868:+
THCA	cis	rs7111546	1	rs7111546	ENSG00000246225.5	RP11-17A1.3	3.45	0.000608	0.0359	0.27	0.16	Dialysis-related mortality;	chr11:22808211	chr11:22829380~22945393:+
THCA	cis	rs7264396	0.573	rs58355182	ENSG00000261582.1	RP4-614O4.11	-3.45	0.000608	0.0359	-0.16	-0.16	Total cholesterol levels;	chr20:35487861	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.778	rs6120959	ENSG00000261582.1	RP4-614O4.11	-3.45	0.000608	0.0359	-0.16	-0.16	Total cholesterol levels;	chr20:35490022	chr20:35267885~35280043:-
THCA	cis	rs3789045	0.52	rs2010432	ENSG00000235363.1	SNRPGP10	-3.45	0.000608	0.0359	-0.24	-0.16	Educational attainment (college completion);	chr1:204493491	chr1:205351247~205351471:+
THCA	cis	rs7772486	0.875	rs2748483	ENSG00000270638.1	RP3-466P17.1	-3.45	0.000608	0.0359	-0.12	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145735570~145737218:+
THCA	cis	rs6487679	0.526	rs34362	ENSG00000256427.1	RP11-118B22.4	-3.45	0.000608	0.0359	-0.18	-0.16	Non-alcoholic fatty liver disease histology (AST);	chr12:9232829	chr12:9246497~9257960:+
THCA	cis	rs748404	0.66	rs2467742	ENSG00000275601.1	AC011330.13	-3.45	0.000608	0.0359	-0.19	-0.16	Lung cancer;	chr15:43458039	chr15:43642389~43643023:-
THCA	cis	rs748404	0.69	rs2244981	ENSG00000275601.1	AC011330.13	-3.45	0.000608	0.0359	-0.19	-0.16	Lung cancer;	chr15:43460553	chr15:43642389~43643023:-
THCA	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-3.45	0.000608	0.0359	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
THCA	cis	rs2549003	1	rs2548999	ENSG00000233006.5	AC034220.3	3.45	0.000608	0.0359	0.12	0.16	Asthma (sex interaction);	chr5:132495366	chr5:132311285~132369916:-
THCA	cis	rs9309473	0.948	rs10199224	ENSG00000273245.1	RP11-434P11.2	3.45	0.000608	0.0359	0.22	0.16	Metabolite levels;	chr2:73534319	chr2:73750256~73750786:-
THCA	cis	rs875971	0.545	rs73150604	ENSG00000230295.1	RP11-458F8.2	3.45	0.000608	0.0359	0.14	0.16	Aortic root size;	chr7:66480545	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000230295.1	RP11-458F8.2	3.45	0.000608	0.0359	0.14	0.16	Aortic root size;	chr7:66481592	chr7:66880708~66882981:+
THCA	cis	rs12935229	0.502	rs954044	ENSG00000260922.1	RP11-538I12.3	3.45	0.000608	0.0359	0.22	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77307436	chr16:77234877~77290934:+
THCA	cis	rs7264396	0.887	rs8116304	ENSG00000261582.1	RP4-614O4.11	-3.45	0.000608	0.0359	-0.16	-0.16	Total cholesterol levels;	chr20:35466584	chr20:35267885~35280043:-
THCA	cis	rs17181170	0.789	rs7639047	ENSG00000239572.1	RP11-451B8.1	-3.45	0.000608	0.0359	-0.19	-0.16	Prostate cancer;	chr3:87124581	chr3:87731402~87793629:-
THCA	cis	rs17181170	0.72	rs62257763	ENSG00000239572.1	RP11-451B8.1	-3.45	0.000608	0.0359	-0.19	-0.16	Prostate cancer;	chr3:87125280	chr3:87731402~87793629:-
THCA	cis	rs17181170	0.754	rs62257764	ENSG00000239572.1	RP11-451B8.1	-3.45	0.000608	0.0359	-0.19	-0.16	Prostate cancer;	chr3:87125332	chr3:87731402~87793629:-
THCA	cis	rs9894429	0.7	rs113915083	ENSG00000262049.1	RP13-1032I1.7	-3.45	0.000608	0.0359	-0.1	-0.16	Eye color traits;	chr17:81585670	chr17:81701324~81703300:-
THCA	cis	rs6929812	0.702	rs1569566	ENSG00000216915.2	RP1-97D16.1	3.45	0.000608	0.0359	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27432252	chr6:27737000~27738494:-
THCA	cis	rs656900	0.669	rs665629	ENSG00000261229.4	MTHFS	3.45	0.000608	0.0359	0.16	0.16	Cerebrospinal P-tau181p levels;	chr15:79826889	chr15:79843547~79897285:-
THCA	cis	rs875971	0.862	rs6460293	ENSG00000223473.2	GS1-124K5.3	-3.45	0.000608	0.0359	-0.11	-0.16	Aortic root size;	chr7:66345205	chr7:66491049~66493566:-
THCA	cis	rs5993586	1	rs9306216	ENSG00000223461.1	AC004471.9	3.45	0.000608	0.0359	0.34	0.16	Coronary artery disease;	chr22:19375314	chr22:19121529~19124503:+
THCA	cis	rs5993586	1	rs5748164	ENSG00000223461.1	AC004471.9	3.45	0.000608	0.0359	0.34	0.16	Coronary artery disease;	chr22:19381009	chr22:19121529~19124503:+
THCA	cis	rs1538970	0.781	rs11211139	ENSG00000280836.1	AL355480.1	-3.45	0.000608	0.0359	-0.22	-0.16	Platelet count;	chr1:45550079	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.966	rs10789481	ENSG00000280836.1	AL355480.1	3.45	0.000608	0.0359	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:45581219~45581321:-
THCA	cis	rs2214442	0.871	rs10280712	ENSG00000271133.4	CTA-293F17.1	-3.45	0.000608	0.0359	-0.16	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20344256	chr7:20328299~20331747:-
THCA	cis	rs12428035	0.764	rs72636570	ENSG00000247400.3	DNAJC3-AS1	-3.45	0.000608	0.0359	-0.16	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95955615	chr13:95648733~95676925:-
THCA	cis	rs4218	0.541	rs1374155	ENSG00000259732.1	RP11-59H7.3	-3.45	0.000608	0.0359	-0.21	-0.16	Social communication problems;	chr15:59030630	chr15:59121034~59133250:+
THCA	cis	rs2688608	0.725	rs2688623	ENSG00000271816.1	BMS1P4	3.45	0.000608	0.0359	0.15	0.16	Inflammatory bowel disease;	chr10:73929857	chr10:73699151~73730487:-
THCA	cis	rs10109025	0.701	rs10101292	ENSG00000261451.1	RP11-981G7.1	-3.45	0.000609	0.0359	-0.2	-0.16	Joint mobility (Beighton score);	chr8:10998964	chr8:10433672~10438312:+
THCA	cis	rs4908768	0.52	rs11121216	ENSG00000270282.1	RP5-1115A15.2	3.45	0.000609	0.0359	0.18	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678885	chr1:8512653~8513021:+
THCA	cis	rs8187707	1	rs11816708	ENSG00000233690.1	EBAG9P1	-3.45	0.000609	0.0359	-0.32	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99855258	chr10:99697407~99697949:-
THCA	cis	rs2051773	0.567	rs11024113	ENSG00000184669.7	OR7E14P	-3.45	0.000609	0.0359	-0.22	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17020897	chr11:17013998~17053024:+
THCA	cis	rs2163813	1	rs247778	ENSG00000271283.1	CTC-412M14.6	-3.45	0.000609	0.0359	-0.22	-0.16	Toenail selenium levels;	chr19:19731244	chr19:19699203~19699409:-
THCA	cis	rs6840360	0.967	rs10028410	ENSG00000270265.1	RP11-731D1.4	-3.45	0.000609	0.0359	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151685421	chr4:151333775~151353224:-
THCA	cis	rs6938	0.514	rs56338926	ENSG00000260269.4	CTD-2323K18.1	-3.45	0.000609	0.0359	-0.22	-0.16	Breast cancer;	chr15:74966994	chr15:75527150~75601205:-
THCA	cis	rs875971	0.545	rs10950036	ENSG00000230295.1	RP11-458F8.2	3.45	0.000609	0.0359	0.14	0.16	Aortic root size;	chr7:66353241	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000230295.1	RP11-458F8.2	3.45	0.000609	0.0359	0.14	0.16	Aortic root size;	chr7:66390342	chr7:66880708~66882981:+
THCA	cis	rs16975963	0.843	rs2382624	ENSG00000276846.1	CTD-3220F14.3	-3.45	0.000609	0.0359	-0.15	-0.16	Longevity;	chr19:37928385	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.843	rs11083442	ENSG00000276846.1	CTD-3220F14.3	-3.45	0.000609	0.0359	-0.15	-0.16	Longevity;	chr19:37936888	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.843	rs73031215	ENSG00000276846.1	CTD-3220F14.3	-3.45	0.000609	0.0359	-0.15	-0.16	Longevity;	chr19:37942915	chr19:37314868~37315620:-
THCA	cis	rs7267979	0.718	rs2983489	ENSG00000230772.1	VN1R108P	3.45	0.000609	0.0359	0.14	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25734264~25735093:+
THCA	cis	rs6546550	0.935	rs7563062	ENSG00000179818.12	PCBP1-AS1	-3.45	0.000609	0.0359	-0.13	-0.16	Prevalent atrial fibrillation;	chr2:69823593	chr2:69962263~70103220:-
THCA	cis	rs2797160	1	rs2747717	ENSG00000226409.1	RP11-735G4.1	3.45	0.000609	0.0359	0.19	0.16	Endometrial cancer;	chr6:125687289	chr6:125370211~125374324:-
THCA	cis	rs12681288	0.723	rs35425201	ENSG00000260721.1	AF067845.1	3.45	0.000609	0.0359	0.19	0.16	Schizophrenia;	chr8:1021062	chr8:1368642~1369833:-
THCA	cis	rs860295	0.702	rs10908471	ENSG00000236675.1	MTX1P1	-3.45	0.000609	0.0359	-0.16	-0.16	Body mass index;	chr1:155573151	chr1:155230975~155234325:+
THCA	cis	rs860295	0.702	rs10908472	ENSG00000236675.1	MTX1P1	-3.45	0.000609	0.0359	-0.16	-0.16	Body mass index;	chr1:155574465	chr1:155230975~155234325:+
THCA	cis	rs860295	0.702	rs11264383	ENSG00000236675.1	MTX1P1	-3.45	0.000609	0.0359	-0.16	-0.16	Body mass index;	chr1:155575555	chr1:155230975~155234325:+
THCA	cis	rs990871	0.545	rs1445581	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72433676	chr1:72301472~72301829:+
THCA	cis	rs990871	0.519	rs1373913	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72435890	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs6424471	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72436069	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs1596762	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72437291	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs7531797	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72437435	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs12035943	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72438561	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs1822977	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72440760	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs2121056	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72441103	chr1:72301472~72301829:+
THCA	cis	rs990871	0.546	rs4649956	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72443752	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs12026130	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72444415	chr1:72301472~72301829:+
THCA	cis	rs990871	0.519	rs11209968	ENSG00000227207.2	RPL31P12	-3.45	0.000609	0.0359	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72445634	chr1:72301472~72301829:+
THCA	cis	rs1023500	0.596	rs133352	ENSG00000270083.1	RP1-257I20.14	3.45	0.000609	0.0359	0.18	0.16	Schizophrenia;	chr22:42038018	chr22:42089630~42090028:-
THCA	cis	rs12368653	0.666	rs701007	ENSG00000270039.1	RP11-571M6.17	3.45	0.000609	0.0359	0.17	0.16	Multiple sclerosis;	chr12:57719633	chr12:57803838~57804415:+
THCA	cis	rs1023500	1	rs6002552	ENSG00000237037.8	NDUFA6-AS1	3.45	0.000609	0.0359	0.15	0.16	Schizophrenia;	chr22:41942347	chr22:42090931~42137742:+
THCA	cis	rs7572733	0.935	rs1850633	ENSG00000231621.1	AC013264.2	-3.45	0.000609	0.0359	-0.15	-0.16	Dermatomyositis;	chr2:197964858	chr2:197197991~197199273:+
THCA	cis	rs735539	0.521	rs9552282	ENSG00000278291.1	RP11-172H24.4	3.45	0.000609	0.0359	0.21	0.16	Dental caries;	chr13:20791582	chr13:20699307~20703718:-
THCA	cis	rs735539	0.521	rs2818998	ENSG00000278291.1	RP11-172H24.4	3.45	0.000609	0.0359	0.21	0.16	Dental caries;	chr13:20795772	chr13:20699307~20703718:-
THCA	cis	rs7326068	0.595	rs2762988	ENSG00000278291.1	RP11-172H24.4	3.45	0.000609	0.0359	0.21	0.16	Schizophrenia, bipolar disorder and depression (combined);	chr13:20796641	chr13:20699307~20703718:-
THCA	cis	rs793571	0.784	rs28800895	ENSG00000259250.1	RP11-50C13.1	-3.45	0.000609	0.0359	-0.16	-0.16	Schizophrenia;	chr15:58792837	chr15:58587507~58591676:+
THCA	cis	rs7246657	0.943	rs7253091	ENSG00000266916.4	ZNF793-AS1	-3.45	0.000609	0.0359	-0.15	-0.16	Coronary artery calcification;	chr19:37476312	chr19:37497159~37507046:-
THCA	cis	rs801193	0.66	rs2659914	ENSG00000272831.1	RP11-792A8.4	3.45	0.00061	0.0359	0.1	0.16	Aortic root size;	chr7:66691927	chr7:66739829~66740385:-
THCA	cis	rs12681366	0.592	rs4735291	ENSG00000253175.1	RP11-267M23.6	3.45	0.00061	0.0359	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94394914	chr8:94565036~94565715:+
THCA	cis	rs16857609	0.564	rs12232972	ENSG00000233143.1	DIRC3-AS1	-3.45	0.00061	0.0359	-0.19	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217392549	chr2:217282739~217336120:+
THCA	cis	rs4792901	0.802	rs2242598	ENSG00000279602.1	CTD-3014M21.1	-3.45	0.00061	0.0359	-0.2	-0.16	Dupuytren's disease;	chr17:43533030	chr17:43360041~43361361:-
THCA	cis	rs1005277	0.522	rs1208684	ENSG00000120555.12	SEPT7P9	3.45	0.00061	0.036	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38383069~38402916:-
THCA	cis	rs6545883	0.894	rs2694642	ENSG00000212978.6	AC016747.3	-3.45	0.00061	0.036	-0.17	-0.16	Tuberculosis;	chr2:61369045	chr2:61141592~61144969:-
THCA	cis	rs58123204	1	rs58123204	ENSG00000257379.1	RP11-793H13.8	3.45	0.00061	0.036	0.24	0.16	Mean corpuscular hemoglobin;	chr12:53366378	chr12:53441741~53467528:+
THCA	cis	rs6715284	0.748	rs7597639	ENSG00000183308.6	AC005037.3	3.45	0.00061	0.036	0.34	0.16	Rheumatoid arthritis;	chr2:201338667	chr2:200963263~201009102:+
THCA	cis	rs6715284	0.748	rs7598059	ENSG00000183308.6	AC005037.3	3.45	0.00061	0.036	0.34	0.16	Rheumatoid arthritis;	chr2:201338864	chr2:200963263~201009102:+
THCA	cis	rs6715284	0.748	rs72934957	ENSG00000183308.6	AC005037.3	3.45	0.00061	0.036	0.34	0.16	Rheumatoid arthritis;	chr2:201339100	chr2:200963263~201009102:+
THCA	cis	rs11574514	1	rs14178	ENSG00000280214.1	CTD-2012K14.5	-3.45	0.00061	0.036	-0.27	-0.16	Crohn's disease;	chr16:67935628	chr16:67550815~67552935:-
THCA	cis	rs1799922	0.77	rs77068855	ENSG00000271553.1	RP11-274B21.10	-3.45	0.00061	0.036	-0.14	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128752267	chr7:128667043~128668156:+
THCA	cis	rs4073416	0.518	rs2210805	ENSG00000276116.2	FUT8-AS1	3.45	0.00061	0.036	0.18	0.16	N-glycan levels;	chr14:65426006	chr14:65411170~65412690:-
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000281021.1	RP1-12G14.9	-3.45	0.00061	0.036	-0.16	-0.16	Lung cancer;	chr6:149691226	chr6:149576089~149590864:-
THCA	cis	rs56309584	0.673	rs7219471	ENSG00000271002.1	RP11-599B13.8	-3.45	0.00061	0.036	-0.24	-0.16	Initial pursuit acceleration;	chr17:8218276	chr17:8199123~8199437:-
THCA	cis	rs7927592	0.731	rs11228288	ENSG00000160172.9	FAM86C2P	3.45	0.00061	0.036	0.15	0.16	Total body bone mineral density;	chr11:68586082	chr11:67791648~67805336:-
THCA	cis	rs2625529	0.938	rs4777464	ENSG00000260037.4	CTD-2524L6.3	-3.45	0.00061	0.036	-0.21	-0.16	Red blood cell count;	chr15:71839422	chr15:71818396~71823384:+
THCA	cis	rs301901	0.761	rs1533521	ENSG00000250155.1	CTD-2353F22.1	3.45	0.00061	0.036	0.15	0.16	Height;	chr5:37540355	chr5:36666214~36725195:-
THCA	cis	rs57590327	0.503	rs2372906	ENSG00000241593.4	RP11-520D19.2	3.45	0.00061	0.036	0.19	0.16	Extraversion;	chr3:81455522	chr3:81246579~81297345:-
THCA	cis	rs57590327	0.503	rs9874184	ENSG00000241593.4	RP11-520D19.2	3.45	0.00061	0.036	0.19	0.16	Extraversion;	chr3:81456288	chr3:81246579~81297345:-
THCA	cis	rs57590327	0.503	rs9874464	ENSG00000241593.4	RP11-520D19.2	-3.45	0.00061	0.036	-0.19	-0.16	Extraversion;	chr3:81456337	chr3:81246579~81297345:-
THCA	cis	rs57590327	0.503	rs9880844	ENSG00000241593.4	RP11-520D19.2	3.45	0.00061	0.036	0.19	0.16	Extraversion;	chr3:81458066	chr3:81246579~81297345:-
THCA	cis	rs3849570	0.695	rs9830445	ENSG00000241593.4	RP11-520D19.2	3.45	0.00061	0.036	0.19	0.16	Waist circumference;Body mass index;	chr3:81458912	chr3:81246579~81297345:-
THCA	cis	rs7712401	1	rs7712401	ENSG00000263432.2	RN7SL689P	3.45	0.00061	0.036	0.16	0.16	Mean platelet volume;	chr5:123038764	chr5:123022487~123022783:-
THCA	cis	rs1737890	0.778	rs6119241	ENSG00000235217.6	TSPY26P	-3.45	0.00061	0.036	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr20:32341292	chr20:32186477~32190527:-
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000254414.1	RP11-182J1.1	3.45	0.00061	0.036	0.19	0.16	P wave terminal force;	chr15:84655131	chr15:84631898~84633987:-
THCA	cis	rs267567	0.765	rs267541	ENSG00000270194.1	RP11-259K5.2	3.45	0.00061	0.036	0.11	0.16	PR interval;	chr3:37538243	chr3:37241789~37244177:-
THCA	cis	rs3925158	0.51	rs12054266	ENSG00000229589.1	ACVR2B-AS1	-3.45	0.000611	0.036	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38261421	chr3:38451027~38454820:-
THCA	cis	rs6929812	0.664	rs3918438	ENSG00000216915.2	RP1-97D16.1	3.45	0.000611	0.036	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27430354	chr6:27737000~27738494:-
THCA	cis	rs73108077	0.831	rs118117155	ENSG00000277112.2	RP11-755J8.1	-3.45	0.000611	0.036	-0.34	-0.16	Red blood cell density in sickle cell anemia;	chr20:31468921	chr20:30681825~30723932:-
THCA	cis	rs929354	0.772	rs6969244	ENSG00000224629.1	RP5-1142J19.2	-3.45	0.000611	0.036	-0.15	-0.16	Body mass index;	chr7:157211318	chr7:157263022~157263229:-
THCA	cis	rs6472235	1	rs6981354	ENSG00000272192.1	CTD-2532N20.1	-3.45	0.000611	0.036	-0.15	-0.16	Plateletcrit;Myopia (pathological);	chr8:65952948	chr8:65842752~65843331:+
THCA	cis	rs959260	1	rs9896050	ENSG00000263843.1	RP11-649A18.12	3.45	0.000611	0.036	0.17	0.16	Systemic lupus erythematosus;	chr17:75352874	chr17:75271369~75273895:+
THCA	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-3.45	0.000611	0.036	-0.21	-0.16	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
THCA	cis	rs11250097	0.543	rs68164957	ENSG00000254948.1	OR7E158P	3.45	0.000611	0.036	0.2	0.16	Neuroticism;	chr8:10941979	chr8:11919900~11920809:-
THCA	cis	rs7631605	0.967	rs7632760	ENSG00000272334.1	RP11-129K12.1	-3.45	0.000611	0.036	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36975462	chr3:36973117~36973672:-
THCA	cis	rs4683346	0.731	rs11923822	ENSG00000273328.4	RP11-141M3.6	-3.45	0.000611	0.036	-0.21	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42880685	chr3:42809414~42908105:+
THCA	cis	rs2494663	0.61	rs11265099	ENSG00000231416.1	RP11-422P24.9	-3.45	0.000611	0.036	-0.19	-0.16	Mean platelet volume;	chr1:154108481	chr1:153995632~153995960:+
THCA	cis	rs5753618	0.555	rs5749286	ENSG00000235573.2	RP3-412A9.12	-3.45	0.000611	0.036	-0.18	-0.16	Colorectal cancer;	chr22:31504373	chr22:31113017~31113396:+
THCA	cis	rs6586163	0.872	rs1800682	ENSG00000261438.1	RP11-399O19.9	3.45	0.000611	0.036	0.12	0.16	Chronic lymphocytic leukemia;	chr10:88990206	chr10:89015836~89017059:+
THCA	cis	rs7572733	0.935	rs1607376	ENSG00000231621.1	AC013264.2	-3.45	0.000611	0.036	-0.15	-0.16	Dermatomyositis;	chr2:197963190	chr2:197197991~197199273:+
THCA	cis	rs12887734	0.524	rs17791722	ENSG00000258914.1	CTD-2134A5.3	-3.45	0.000611	0.036	-0.19	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103819873	chr14:103875055~103877478:+
THCA	cis	rs7631605	0.874	rs6806252	ENSG00000272334.1	RP11-129K12.1	-3.45	0.000611	0.036	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:37109497	chr3:36973117~36973672:-
THCA	cis	rs948562	0.947	rs60767173	ENSG00000280010.1	AP001350.4	3.45	0.000611	0.036	0.24	0.16	Lymphoma;	chr11:58634074	chr11:58627435~58628528:+
THCA	cis	rs2880765	0.835	rs7180213	ENSG00000259407.1	RP11-158M2.3	-3.45	0.000611	0.036	-0.16	-0.16	Coronary artery disease;	chr15:85477956	chr15:85744109~85750281:-
THCA	cis	rs4308124	1	rs62160391	ENSG00000230499.1	AC108463.1	-3.45	0.000611	0.036	-0.2	-0.16	Vitiligo;	chr2:111251258	chr2:111195963~111206494:+
THCA	cis	rs76793172	1	rs10406609	ENSG00000207003.1	RNU6-611P	3.45	0.000611	0.036	0.29	0.16	Eosinophil counts;	chr19:45841950	chr19:45047458~45047561:+
THCA	cis	rs7656342	0.665	rs6449090	ENSG00000250342.1	SNRPCP16	3.45	0.000611	0.036	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9882912	chr4:9051842~9052051:-
THCA	cis	rs2447820	0.5	rs246277	ENSG00000263432.2	RN7SL689P	-3.45	0.000611	0.036	-0.19	-0.16	Migraine;	chr5:122904720	chr5:123022487~123022783:-
THCA	cis	rs6489785	0.525	rs584001	ENSG00000258435.1	RP11-711D18.2	3.45	0.000611	0.036	0.18	0.16	Longevity;Allergic disease (asthma, hay fever or eczema);	chr12:120790252	chr12:121391962~121399859:+
THCA	cis	rs3733418	0.929	rs17623445	ENSG00000248632.1	RP11-366M4.11	3.45	0.000611	0.036	0.23	0.16	Obesity-related traits;	chr4:164973506	chr4:164968587~164970002:-
THCA	cis	rs13232179	0.92	rs12703136	ENSG00000265810.1	MIR3907	3.45	0.000611	0.036	0.15	0.16	Coronary heart disease;	chr7:151422194	chr7:151433489~151433639:-
THCA	cis	rs13232179	1	rs1860463	ENSG00000265810.1	MIR3907	3.45	0.000611	0.036	0.15	0.16	Coronary heart disease;	chr7:151422246	chr7:151433489~151433639:-
THCA	cis	rs2299682	0.826	rs73897481	ENSG00000230506.1	RP11-416N4.4	3.45	0.000611	0.036	0.25	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9499949	chr20:10173520~10196990:+
THCA	cis	rs67478160	0.609	rs6576003	ENSG00000258534.1	CTD-2134A5.4	-3.45	0.000611	0.036	-0.16	-0.16	Schizophrenia;	chr14:103824993	chr14:103854366~103880111:-
THCA	cis	rs4512344	0.509	rs2409784	ENSG00000251402.3	FAM90A25P	-3.45	0.000611	0.036	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12415080~12418090:-
THCA	cis	rs684232	0.644	rs870183	ENSG00000231784.7	DBIL5P	3.45	0.000611	0.036	0.17	0.16	Prostate cancer;	chr17:696571	chr17:752660~755336:+
THCA	cis	rs10256972	0.591	rs6968988	ENSG00000225146.1	AC073957.15	3.45	0.000611	0.036	0.17	0.16	Endometriosis;Longevity;	chr7:1129983	chr7:1029025~1043891:+
THCA	cis	rs2733201	1	rs2706487	ENSG00000166763.7	STRCP1	3.45	0.000611	0.036	0.32	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44136687	chr15:43699488~43718184:-
THCA	cis	rs11638352	0.661	rs1820484	ENSG00000166763.7	STRCP1	3.45	0.000611	0.036	0.32	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44137687	chr15:43699488~43718184:-
THCA	cis	rs11638352	0.661	rs2615268	ENSG00000166763.7	STRCP1	-3.45	0.000611	0.036	-0.32	-0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44135599	chr15:43699488~43718184:-
THCA	cis	rs11638352	0.661	rs2555389	ENSG00000166763.7	STRCP1	-3.45	0.000611	0.036	-0.32	-0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44138947	chr15:43699488~43718184:-
THCA	cis	rs2733201	1	rs2162365	ENSG00000166763.7	STRCP1	-3.45	0.000611	0.036	-0.32	-0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44140944	chr15:43699488~43718184:-
THCA	cis	rs11638352	0.661	rs1834641	ENSG00000166763.7	STRCP1	-3.45	0.000611	0.036	-0.32	-0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44142114	chr15:43699488~43718184:-
THCA	cis	rs12922040	1	rs12922040	ENSG00000263065.1	AF001548.6	-3.45	0.000611	0.036	-0.19	-0.16	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15741151~15741791:+
THCA	cis	rs6101567	0.778	rs1009789	ENSG00000224635.1	RP4-564F22.5	-3.45	0.000611	0.036	-0.2	-0.16	Nose size;	chr20:39292481	chr20:38406011~38416797:-
THCA	cis	rs62432346	1	rs62432346	ENSG00000228506.1	RP11-98I9.4	-3.45	0.000611	0.036	-0.3	-0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr6:99541358	chr6:99424922~99431373:+
THCA	cis	rs2832191	1	rs6516891	ENSG00000232855.5	AF131217.1	3.45	0.000611	0.036	0.16	0.16	Dental caries;	chr21:29110749	chr21:28439346~28674848:-
THCA	cis	rs2832191	1	rs2832184	ENSG00000232855.5	AF131217.1	3.45	0.000611	0.036	0.16	0.16	Dental caries;	chr21:29110944	chr21:28439346~28674848:-
THCA	cis	rs964611	0.882	rs12594698	ENSG00000259488.2	RP11-154J22.1	-3.45	0.000611	0.036	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48282759	chr15:48312353~48331856:-
THCA	cis	rs875971	0.862	rs6460290	ENSG00000223473.2	GS1-124K5.3	-3.45	0.000611	0.036	-0.1	-0.16	Aortic root size;	chr7:66344119	chr7:66491049~66493566:-
THCA	cis	rs4578769	0.765	rs12456384	ENSG00000265939.1	UBE2CP2	-3.45	0.000611	0.036	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22841032	chr18:22900486~22900995:-
THCA	cis	rs7142002	0.764	rs8007118	ENSG00000271780.1	RP11-1017G21.5	-3.45	0.000612	0.036	-0.24	-0.16	Autism;	chr14:101933556	chr14:101948347~101949425:+
THCA	cis	rs1865760	0.613	rs9358894	ENSG00000272810.1	U91328.22	-3.45	0.000612	0.036	-0.12	-0.16	Height;	chr6:25923087	chr6:26013241~26013757:+
THCA	cis	rs1113500	0.799	rs1777459	ENSG00000230489.1	VAV3-AS1	3.45	0.000612	0.036	0.15	0.16	Growth-regulated protein alpha levels;	chr1:108042377	chr1:107964443~107994607:+
THCA	cis	rs2766547	1	rs2766544	ENSG00000228559.1	RP3-340B19.3	3.45	0.000612	0.036	0.18	0.16	Eosinophil percentage of granulocytes;	chr6:35743894	chr6:35544632~35545669:+
THCA	cis	rs17604090	0.938	rs850029	ENSG00000223813.2	AC007255.8	3.45	0.000612	0.036	0.16	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29638471	chr7:29514225~29563670:-
THCA	cis	rs3812762	0.871	rs11603335	ENSG00000254860.4	TMEM9B-AS1	-3.45	0.000612	0.036	-0.18	-0.16	Hypospadias;	chr11:8788297	chr11:8964675~8977527:+
THCA	cis	rs1908814	0.509	rs13282439	ENSG00000255495.1	AC145124.2	3.45	0.000612	0.036	0.19	0.16	Neuroticism;	chr8:11937392	chr8:12194467~12196280:+
THCA	cis	rs6802315	0.604	rs2115941	ENSG00000271778.1	RP11-379F4.8	3.45	0.000612	0.036	0.16	0.16	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158782547~158783124:+
THCA	cis	rs773506	0.933	rs773514	ENSG00000229694.5	RP11-305L7.6	-3.45	0.000612	0.036	-0.18	-0.16	Type 2 diabetes nephropathy;	chr9:91219367	chr9:91119062~91182762:+
THCA	cis	rs6940638	0.637	rs13217239	ENSG00000220721.1	OR1F12	3.45	0.000612	0.036	0.18	0.16	Intelligence (multi-trait analysis);	chr6:27287188	chr6:28073316~28074233:+
THCA	cis	rs7631605	0.846	rs6768108	ENSG00000272334.1	RP11-129K12.1	-3.45	0.000612	0.036	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36957264	chr3:36973117~36973672:-
THCA	cis	rs4883201	0.536	rs2377676	ENSG00000245105.2	A2M-AS1	-3.45	0.000612	0.036	-0.15	-0.16	Total cholesterol levels;Cholesterol, total;	chr12:8978211	chr12:9065177~9068060:+
THCA	cis	rs7267979	0.528	rs6076366	ENSG00000276952.1	RP5-965G21.6	-3.45	0.000612	0.0361	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:25284915~25285588:-
THCA	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	3.45	0.000612	0.0361	0.18	0.16	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	3.45	0.000612	0.0361	0.18	0.16	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
THCA	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	3.45	0.000612	0.0361	0.18	0.16	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	3.45	0.000612	0.0361	0.18	0.16	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	3.45	0.000612	0.0361	0.18	0.16	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
THCA	cis	rs9322193	0.961	rs9027	ENSG00000281021.1	RP1-12G14.9	-3.45	0.000612	0.0361	-0.16	-0.16	Lung cancer;	chr6:149594921	chr6:149576089~149590864:-
THCA	cis	rs9322193	1	rs9322193	ENSG00000281021.1	RP1-12G14.9	-3.45	0.000612	0.0361	-0.16	-0.16	Lung cancer;	chr6:149598007	chr6:149576089~149590864:-
THCA	cis	rs934734	0.673	rs754110	ENSG00000214533.3	KRT18P33	3.45	0.000612	0.0361	0.19	0.16	Rheumatoid arthritis;	chr2:65464626	chr2:65666695~65667737:+
THCA	cis	rs11098499	0.913	rs10006304	ENSG00000249244.1	RP11-548H18.2	3.45	0.000612	0.0361	0.18	0.16	Corneal astigmatism;	chr4:119203150	chr4:119391831~119395335:-
THCA	cis	rs2562456	0.917	rs2681392	ENSG00000268658.4	LINC00664	-3.45	0.000612	0.0361	-0.23	-0.16	Pain;	chr19:21513185	chr19:21483374~21503238:+
THCA	cis	rs3096299	0.685	rs4785568	ENSG00000223959.7	AFG3L1P	3.45	0.000612	0.0361	0.09	0.16	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89972586~90002161:+
THCA	cis	rs66887589	0.967	rs56173225	ENSG00000249244.1	RP11-548H18.2	-3.45	0.000612	0.0361	-0.16	-0.16	Diastolic blood pressure;	chr4:119588817	chr4:119391831~119395335:-
THCA	cis	rs66887589	0.967	rs7678973	ENSG00000249244.1	RP11-548H18.2	-3.45	0.000612	0.0361	-0.16	-0.16	Diastolic blood pressure;	chr4:119590662	chr4:119391831~119395335:-
THCA	cis	rs2540552	0.965	rs2540592	ENSG00000221520.1	MIR1285-1	-3.45	0.000612	0.0361	-0.17	-0.16	IgG glycosylation;	chr7:91604154	chr7:92204015~92204098:-
THCA	cis	rs7712401	0.755	rs3213794	ENSG00000263432.2	RN7SL689P	3.45	0.000612	0.0361	0.16	0.16	Mean platelet volume;	chr5:122825943	chr5:123022487~123022783:-
THCA	cis	rs55833108	1	rs55833108	ENSG00000272912.1	RP11-724N1.1	3.45	0.000612	0.0361	0.27	0.16	Schizophrenia;	chr10:102981826	chr10:102914585~102915404:+
THCA	cis	rs78487399	0.908	rs77994584	ENSG00000234936.1	AC010883.5	3.45	0.000612	0.0361	0.2	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43589937	chr2:43229573~43233394:+
THCA	cis	rs11013210	0.508	rs7087200	ENSG00000261671.1	RP11-573G6.6	-3.45	0.000612	0.0361	-0.22	-0.16	Systemic lupus erythematosus;	chr10:23013668	chr10:22257786~22258548:+
THCA	cis	rs34779708	0.966	rs17500582	ENSG00000233200.1	RP11-324I22.2	3.45	0.000612	0.0361	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35219894~35230598:-
THCA	cis	rs4295623	0.816	rs35558975	ENSG00000242607.1	RPS3AP34	-3.45	0.000612	0.0361	-0.18	-0.16	Morning vs. evening chronotype;	chr8:11726967	chr8:12570350~12571130:-
THCA	cis	rs7221595	0.778	rs2727072	ENSG00000280254.1	RP11-81A22.4	-3.45	0.000612	0.0361	-0.16	-0.16	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;	chr17:4015291	chr17:4787057~4789162:+
THCA	cis	rs997295	0.504	rs12905397	ENSG00000270964.1	RP11-502I4.3	-3.45	0.000612	0.0361	-0.13	-0.16	Motion sickness;	chr15:67741812	chr15:67541072~67542604:-
THCA	cis	rs722599	0.651	rs12887044	ENSG00000279594.1	RP11-950C14.10	3.45	0.000612	0.0361	0.16	0.16	IgG glycosylation;	chr14:74788956	chr14:75011269~75012851:-
THCA	cis	rs2832191	0.692	rs2245517	ENSG00000176054.6	RPL23P2	3.45	0.000612	0.0361	0.14	0.16	Dental caries;	chr21:28985647	chr21:28997613~28998033:-
THCA	cis	rs72827839	0.802	rs16953382	ENSG00000278765.1	RP5-890E16.5	-3.45	0.000612	0.0361	-0.23	-0.16	Ease of getting up in the morning;	chr17:48175544	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.79	rs116944299	ENSG00000278765.1	RP5-890E16.5	-3.45	0.000612	0.0361	-0.23	-0.16	Ease of getting up in the morning;	chr17:48190403	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.846	rs74992250	ENSG00000278765.1	RP5-890E16.5	-3.45	0.000612	0.0361	-0.23	-0.16	Ease of getting up in the morning;	chr17:48195624	chr17:48066704~48067293:-
THCA	cis	rs763121	0.889	rs6001209	ENSG00000272669.1	RP3-508I15.21	3.45	0.000612	0.0361	0.11	0.16	Menopause (age at onset);	chr22:38725247	chr22:38742625~38743115:+
THCA	cis	rs620729	0.749	rs34336996	ENSG00000272097.1	RP11-421M1.8	3.45	0.000612	0.0361	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482609	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs36023953	ENSG00000272097.1	RP11-421M1.8	3.45	0.000612	0.0361	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482614	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs35087778	ENSG00000272097.1	RP11-421M1.8	3.45	0.000612	0.0361	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482636	chr6:10743324~10747663:-
THCA	cis	rs11673344	0.523	rs7245520	ENSG00000267260.1	CTD-2162K18.4	-3.45	0.000612	0.0361	-0.19	-0.16	Obesity-related traits;	chr19:37036416	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs7256380	ENSG00000267260.1	CTD-2162K18.4	-3.45	0.000612	0.0361	-0.19	-0.16	Obesity-related traits;	chr19:37041178	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs6510585	ENSG00000267260.1	CTD-2162K18.4	-3.45	0.000612	0.0361	-0.19	-0.16	Obesity-related traits;	chr19:37063081	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs17206540	ENSG00000267260.1	CTD-2162K18.4	-3.45	0.000612	0.0361	-0.19	-0.16	Obesity-related traits;	chr19:37069009	chr19:36773153~36777078:+
THCA	cis	rs2290416	0.892	rs59742520	ENSG00000254338.1	MAFA-AS1	3.45	0.000613	0.0361	0.31	0.16	Attention deficit hyperactivity disorder;	chr8:143594064	chr8:143417679~143419150:+
THCA	cis	rs4713118	0.866	rs2179094	ENSG00000216915.2	RP1-97D16.1	-3.45	0.000613	0.0361	-0.24	-0.16	Parkinson's disease;	chr6:27774046	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.824	rs2179095	ENSG00000216915.2	RP1-97D16.1	3.45	0.000613	0.0361	0.24	0.16	Parkinson's disease;	chr6:27783079	chr6:27737000~27738494:-
THCA	cis	rs7028939	1	rs10988977	ENSG00000255145.2	STX17-AS1	-3.45	0.000613	0.0361	-0.24	-0.16	Preeclampsia;	chr9:100124654	chr9:99886322~99906601:-
THCA	cis	rs1557488	0.581	rs7126443	ENSG00000260209.1	RP11-680F20.10	-3.45	0.000613	0.0361	-0.21	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126858293	chr11:125873031~125874528:-
THCA	cis	rs57590327	0.528	rs4856346	ENSG00000241593.4	RP11-520D19.2	3.45	0.000613	0.0361	0.19	0.16	Extraversion;	chr3:81453504	chr3:81246579~81297345:-
THCA	cis	rs57590327	0.504	rs4856349	ENSG00000241593.4	RP11-520D19.2	3.45	0.000613	0.0361	0.19	0.16	Extraversion;	chr3:81453777	chr3:81246579~81297345:-
THCA	cis	rs57590327	0.503	rs4856350	ENSG00000241593.4	RP11-520D19.2	3.45	0.000613	0.0361	0.19	0.16	Extraversion;	chr3:81454223	chr3:81246579~81297345:-
THCA	cis	rs3736858	1	rs3736858	ENSG00000261105.4	LMO7-AS1	3.45	0.000613	0.0361	0.22	0.16	Interleukin-9 levels;	chr13:75841243	chr13:75604700~75635994:-
THCA	cis	rs35320143	0.5	rs363156	ENSG00000246777.1	RP11-61A14.4	-3.45	0.000613	0.0361	-0.14	-0.16	Number of children (6+ vs. 0 or 1);	chr16:66758811	chr16:66751752~66754740:+
THCA	cis	rs7119	0.667	rs907390	ENSG00000259362.2	RP11-307C19.1	3.45	0.000613	0.0361	0.2	0.16	Type 2 diabetes;	chr15:77610077	chr15:77525540~77534110:+
THCA	cis	rs1510272	0.924	rs6783873	ENSG00000243926.1	TIPARP-AS1	-3.45	0.000613	0.0361	-0.16	-0.16	Testicular germ cell tumor;	chr3:156594525	chr3:156671862~156674378:-
THCA	cis	rs35860234	0.806	rs2324919	ENSG00000231530.1	RP11-187A9.3	3.45	0.000613	0.0361	0.19	0.16	Vitiligo;	chr13:42487648	chr13:42043727~42044247:-
THCA	cis	rs3026101	0.671	rs56018748	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5413619	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.624	rs62072673	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5414349	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.671	rs62072674	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5414486	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.671	rs56061343	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5415182	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.624	rs60691290	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5415183	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.671	rs28619210	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5415733	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.671	rs28409881	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5415780	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.671	rs28437236	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5415894	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.671	rs2301740	ENSG00000234327.6	AC012146.7	-3.45	0.000613	0.0361	-0.13	-0.16	Body mass index;	chr17:5416300	chr17:5111468~5115004:+
THCA	cis	rs4919669	0.697	rs8354	ENSG00000272912.1	RP11-724N1.1	-3.45	0.000613	0.0361	-0.27	-0.16	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102676884	chr10:102914585~102915404:+
THCA	cis	rs2228479	0.85	rs62052212	ENSG00000223959.7	AFG3L1P	-3.45	0.000613	0.0361	-0.15	-0.16	Skin colour saturation;	chr16:89915552	chr16:89972586~90002161:+
THCA	cis	rs250518	0.926	rs11953054	ENSG00000251467.1	CTC-250P20.2	3.45	0.000613	0.0361	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72746876	chr5:72996920~72997642:+
THCA	cis	rs4443100	0.535	rs13055979	ENSG00000230701.2	FBXW4P1	3.45	0.000613	0.0361	0.18	0.16	Serum parathyroid hormone levels;	chr22:23131898	chr22:23262767~23265005:+
THCA	cis	rs503425	0.818	rs2508922	ENSG00000255422.1	AP002954.4	3.45	0.000613	0.0361	0.2	0.16	Systemic lupus erythematosus;	chr11:118810379	chr11:118704607~118750263:+
THCA	cis	rs3960554	0.66	rs55671363	ENSG00000230882.1	AC005077.14	3.45	0.000613	0.0361	0.17	0.16	Eotaxin levels;	chr7:76164087	chr7:76071469~76074963:-
THCA	cis	rs6691738	0.851	rs7518129	ENSG00000227373.4	RP11-160H22.5	3.45	0.000613	0.0361	0.22	0.16	Asthma;	chr1:173194429	chr1:174115300~174160004:-
THCA	cis	rs7246967	0.673	rs34425596	ENSG00000198153.8	ZNF849P	-3.45	0.000613	0.0361	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22716977	chr19:22685167~22686732:+
THCA	cis	rs1858037	0.867	rs4671660	ENSG00000252414.1	RNU6-100P	-3.45	0.000613	0.0361	-0.17	-0.16	Rheumatoid arthritis;	chr2:65349302	chr2:64578892~64578997:+
THCA	cis	rs8020289	1	rs2242625	ENSG00000258301.3	RP11-488C13.5	3.45	0.000613	0.0361	0.16	0.16	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr14:76826299	chr14:76781733~76786724:-
THCA	cis	rs701145	0.585	rs1470664	ENSG00000240068.1	RPL21P42	3.45	0.000613	0.0361	0.31	0.16	Coronary artery disease;	chr3:154147404	chr3:154023835~154024298:+
THCA	cis	rs10895987	0.955	rs7113761	ENSG00000254614.2	AP003068.23	3.45	0.000613	0.0361	0.26	0.16	Blood protein levels;	chr11:65159251	chr11:65177606~65181834:-
THCA	cis	rs2638953	0.853	rs10506037	ENSG00000247934.4	RP11-967K21.1	-3.45	0.000613	0.0361	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498213	chr12:28163298~28190738:-
THCA	cis	rs8114671	0.562	rs6060064	ENSG00000126005.14	MMP24-AS1	3.45	0.000613	0.0361	0.15	0.16	Height;	chr20:34818536	chr20:35216462~35278131:-
THCA	cis	rs35306767	0.761	rs11253560	ENSG00000229869.1	RP11-363N22.2	-3.45	0.000613	0.0361	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:1001286	chr10:933026~942743:+
THCA	cis	rs7849270	0.959	rs3118628	ENSG00000204055.4	RP11-247A12.2	3.45	0.000613	0.0361	0.2	0.16	Blood metabolite ratios;	chr9:129123000	chr9:129176771~129210548:+
THCA	cis	rs6828577	0.862	rs299005	ENSG00000248280.1	RP11-33B1.2	3.45	0.000613	0.0361	0.14	0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118674209	chr4:119440561~119450157:-
THCA	cis	rs2180341	1	rs2326567	ENSG00000220522.2	RP1-177A13.1	3.45	0.000613	0.0361	0.2	0.16	Breast cancer;	chr6:127285015	chr6:127416535~127416952:-
THCA	cis	rs2228479	0.85	rs2238525	ENSG00000274627.1	RP11-104N10.2	-3.45	0.000613	0.0361	-0.27	-0.16	Skin colour saturation;	chr16:89743494	chr16:89516797~89522217:+
THCA	cis	rs9326248	0.581	rs10892063	ENSG00000280143.1	AP000892.6	3.45	0.000613	0.0361	0.19	0.16	Blood protein levels;	chr11:117025439	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.559	rs10892064	ENSG00000280143.1	AP000892.6	3.45	0.000613	0.0361	0.19	0.16	Blood protein levels;	chr11:117025837	chr11:117204967~117210292:+
THCA	cis	rs9326248	0.539	rs10892065	ENSG00000280143.1	AP000892.6	3.45	0.000613	0.0361	0.19	0.16	Blood protein levels;	chr11:117026308	chr11:117204967~117210292:+
THCA	cis	rs9393777	0.778	rs13219354	ENSG00000226314.6	ZNF192P1	-3.45	0.000613	0.0361	-0.3	-0.16	Intelligence (multi-trait analysis);	chr6:27217885	chr6:28161781~28169594:+
THCA	cis	rs9393777	0.778	rs67457459	ENSG00000226314.6	ZNF192P1	-3.45	0.000613	0.0361	-0.3	-0.16	Intelligence (multi-trait analysis);	chr6:27230564	chr6:28161781~28169594:+
THCA	cis	rs7737355	1	rs2551036	ENSG00000237714.1	P4HA2-AS1	3.45	0.000613	0.0361	0.22	0.16	Life satisfaction;	chr5:131313301	chr5:132184876~132192808:+
THCA	cis	rs7737355	1	rs9327608	ENSG00000237714.1	P4HA2-AS1	3.45	0.000613	0.0361	0.22	0.16	Life satisfaction;	chr5:131314441	chr5:132184876~132192808:+
THCA	cis	rs12545912	0.525	rs597910	ENSG00000248538.5	RP11-10A14.5	3.45	0.000613	0.0361	0.25	0.16	Multiple myeloma (hyperdiploidy);	chr8:9937714	chr8:9189011~9202854:+
THCA	cis	rs2055729	0.592	rs7462499	ENSG00000248538.5	RP11-10A14.5	3.45	0.000613	0.0361	0.25	0.16	Multiple myeloma (hyperdiploidy);	chr8:9937753	chr8:9189011~9202854:+
THCA	cis	rs854765	0.583	rs4553680	ENSG00000265511.1	RP11-524F11.1	3.45	0.000613	0.0361	0.13	0.16	Total body bone mineral density;	chr17:17954408	chr17:17507351~17508308:+
THCA	cis	rs854765	0.583	rs8080823	ENSG00000265511.1	RP11-524F11.1	3.45	0.000613	0.0361	0.13	0.16	Total body bone mineral density;	chr17:17960734	chr17:17507351~17508308:+
THCA	cis	rs9393777	0.92	rs66462181	ENSG00000272009.1	RP1-313I6.12	-3.45	0.000613	0.0361	-0.31	-0.16	Intelligence (multi-trait analysis);	chr6:27123882	chr6:28078792~28081130:-
THCA	cis	rs17507216	0.518	rs1877240	ENSG00000255769.6	GOLGA2P10	-3.45	0.000613	0.0361	-0.27	-0.16	Excessive daytime sleepiness;	chr15:82770126	chr15:82472993~82513950:-
THCA	cis	rs7259376	1	rs2163846	ENSG00000269138.1	ZNF209P	3.45	0.000613	0.0361	0.16	0.16	Menopause (age at onset);	chr19:22323042	chr19:22463922~22473036:+
THCA	cis	rs7927592	0.672	rs10501398	ENSG00000160172.9	FAM86C2P	-3.45	0.000613	0.0361	-0.15	-0.16	Total body bone mineral density;	chr11:68564247	chr11:67791648~67805336:-
THCA	cis	rs6870983	0.749	rs152229	ENSG00000247828.6	TMEM161B-AS1	3.45	0.000614	0.0361	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88204861	chr5:88268895~88436685:+
THCA	cis	rs7259376	0.875	rs1091182	ENSG00000270947.1	AC025811.3	-3.45	0.000614	0.0361	-0.17	-0.16	Menopause (age at onset);	chr19:22292820	chr19:22455988~22456459:+
THCA	cis	rs9549260	0.753	rs9532562	ENSG00000168852.11	TPTE2P5	3.45	0.000614	0.0361	0.14	0.16	Red blood cell count;	chr13:40579448	chr13:40822296~40921749:-
THCA	cis	rs5770917	1	rs8137478	ENSG00000279182.1	XX-C00717C00720L.1	3.45	0.000614	0.0361	0.25	0.16	Narcolepsy;	chr22:50578867	chr22:50316035~50317025:+
THCA	cis	rs5770917	1	rs3180872	ENSG00000279182.1	XX-C00717C00720L.1	3.45	0.000614	0.0361	0.25	0.16	Narcolepsy;	chr22:50578965	chr22:50316035~50317025:+
THCA	cis	rs9392556	0.829	rs633290	ENSG00000230648.1	RP3-406P24.3	-3.45	0.000614	0.0361	-0.2	-0.16	Blood metabolite levels;	chr6:4114554	chr6:4018843~4021215:-
THCA	cis	rs1005277	0.54	rs1987431	ENSG00000120555.12	SEPT7P9	3.45	0.000614	0.0361	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38383069~38402916:-
THCA	cis	rs1790761	0.806	rs7114510	ENSG00000255318.1	RP11-655M14.13	3.45	0.000614	0.0361	0.17	0.16	Mean corpuscular volume;	chr11:67457123	chr11:67618279~67627304:-
THCA	cis	rs17689437	0.522	rs11647678	ENSG00000260084.1	RP11-615I2.1	3.45	0.000614	0.0361	0.18	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68636801	chr16:68573782~68589512:-
THCA	cis	rs17689437	0.522	rs60235162	ENSG00000260084.1	RP11-615I2.1	3.45	0.000614	0.0361	0.18	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68638034	chr16:68573782~68589512:-
THCA	cis	rs4907240	0.961	rs4907241	ENSG00000230606.9	AC159540.1	-3.45	0.000614	0.0361	-0.18	-0.16	Event-related brain oscillations;	chr2:96576191	chr2:97416165~97433527:-
THCA	cis	rs997295	0.592	rs7162320	ENSG00000245719.1	RP11-34F13.2	3.45	0.000614	0.0361	0.17	0.16	Motion sickness;	chr15:67473700	chr15:67834310~67838879:-
THCA	cis	rs1922291	0.546	rs3771185	ENSG00000234389.1	AC007278.3	3.45	0.000614	0.0361	0.16	0.16	Blood protein levels;	chr2:102224047	chr2:102438713~102440475:+
THCA	cis	rs4908760	0.827	rs7513420	ENSG00000270282.1	RP5-1115A15.2	3.45	0.000614	0.0361	0.18	0.16	Vitiligo;	chr1:8620985	chr1:8512653~8513021:+
THCA	cis	rs4660456	0.83	rs12742219	ENSG00000238287.1	RP11-656D10.3	-3.45	0.000614	0.0361	-0.2	-0.16	Platelet count;	chr1:40728665	chr1:40493157~40508661:-
THCA	cis	rs4664293	0.867	rs3764968	ENSG00000230783.1	AC009961.2	-3.45	0.000614	0.0362	-0.21	-0.16	Monocyte percentage of white cells;	chr2:159790579	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs6740910	ENSG00000230783.1	AC009961.2	-3.45	0.000614	0.0362	-0.21	-0.16	Monocyte percentage of white cells;	chr2:159792709	chr2:159689217~159690291:-
THCA	cis	rs1005277	0.522	rs9417256	ENSG00000120555.12	SEPT7P9	3.45	0.000614	0.0362	0.17	0.16	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38383069~38402916:-
THCA	cis	rs1979679	0.608	rs1355472	ENSG00000278733.1	RP11-425D17.1	3.45	0.000614	0.0362	0.16	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28568481	chr12:28185625~28186190:-
THCA	cis	rs9902453	0.765	rs2127001	ENSG00000214719.10	AC005562.1	-3.45	0.000614	0.0362	-0.14	-0.16	Coffee consumption (cups per day);	chr17:29771201	chr17:30576464~30672789:+
THCA	cis	rs7131987	0.903	rs67517901	ENSG00000273680.1	RP11-996F15.6	3.45	0.000614	0.0362	0.21	0.16	QT interval;	chr12:29268413	chr12:29332733~29333383:-
THCA	cis	rs5752326	0.558	rs134138	ENSG00000261188.1	CTA-445C9.14	-3.45	0.000614	0.0362	-0.17	-0.16	Ischemic stroke;	chr22:26507993	chr22:26512537~26514568:+
THCA	cis	rs7656342	0.569	rs28591077	ENSG00000250342.1	SNRPCP16	3.45	0.000614	0.0362	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9862054	chr4:9051842~9052051:-
THCA	cis	rs7572644	0.64	rs13027427	ENSG00000223522.1	AC093690.1	-3.45	0.000614	0.0362	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27798176	chr2:28307691~28310459:-
THCA	cis	rs6445967	0.545	rs2271635	ENSG00000272360.1	RP11-359I18.5	3.45	0.000614	0.0362	0.19	0.16	Platelet count;	chr3:58274433	chr3:58490830~58491291:-
THCA	cis	rs6439153	0.933	rs810952	ENSG00000231305.3	RP11-723O4.2	3.45	0.000614	0.0362	0.16	0.16	Pneumococcal bacteremia;	chr3:128967062	chr3:128861313~128871540:-
THCA	cis	rs9584850	0.834	rs9584854	ENSG00000231194.1	FARP1-AS1	3.45	0.000614	0.0362	0.19	0.16	Neuroticism;	chr13:98466336	chr13:98435405~98435840:-
THCA	cis	rs11785400	1	rs3735999	ENSG00000177335.9	C8orf31	3.45	0.000614	0.0362	0.18	0.16	Schizophrenia;	chr8:142664652	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs754957	ENSG00000177335.9	C8orf31	3.45	0.000614	0.0362	0.18	0.16	Schizophrenia;	chr8:142664997	chr8:143039209~143059942:+
THCA	cis	rs7520050	0.778	rs3014218	ENSG00000281912.1	LINC01144	3.45	0.000614	0.0362	0.1	0.16	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45303910~45305619:+
THCA	cis	rs9393777	0.764	rs35565446	ENSG00000272009.1	RP1-313I6.12	-3.45	0.000614	0.0362	-0.31	-0.16	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28078792~28081130:-
THCA	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	3.45	0.000614	0.0362	0.26	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
THCA	cis	rs10515778	0.948	rs17663989	ENSG00000280834.1	U6	3.45	0.000614	0.0362	0.27	0.16	Inflammatory skin disease;	chr5:159199103	chr5:160072268~160072364:+
THCA	cis	rs3925158	0.51	rs34619519	ENSG00000229589.1	ACVR2B-AS1	-3.45	0.000614	0.0362	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38197770	chr3:38451027~38454820:-
THCA	cis	rs3925158	0.51	rs61018091	ENSG00000229589.1	ACVR2B-AS1	-3.45	0.000614	0.0362	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38208402	chr3:38451027~38454820:-
THCA	cis	rs2832191	1	rs8131214	ENSG00000232855.5	AF131217.1	3.45	0.000614	0.0362	0.16	0.16	Dental caries;	chr21:29111065	chr21:28439346~28674848:-
THCA	cis	rs863750	0.528	rs4765015	ENSG00000275389.1	RP11-214K3.24	-3.45	0.000614	0.0362	-0.23	-0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124051265	chr12:124085761~124088598:+
THCA	cis	rs9425766	0.679	rs6691711	ENSG00000270084.1	GAS5-AS1	-3.45	0.000614	0.0362	-0.16	-0.16	Life satisfaction;	chr1:174100283	chr1:173863248~173863941:+
THCA	cis	rs7631605	0.967	rs7643836	ENSG00000272334.1	RP11-129K12.1	-3.45	0.000615	0.0362	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:37107467	chr3:36973117~36973672:-
THCA	cis	rs2334880	0.678	rs7186112	ENSG00000260185.1	RP11-432I5.6	-3.45	0.000615	0.0362	-0.31	-0.16	Malaria;	chr16:71806170	chr16:71655027~71664212:+
THCA	cis	rs1577917	0.518	rs2475787	ENSG00000220563.1	PKMP3	3.45	0.000615	0.0362	0.11	0.16	Response to antipsychotic treatment;	chr6:85705518	chr6:85659892~85660606:-
THCA	cis	rs7656342	0.964	rs2280333	ENSG00000242034.1	RP11-1396O13.1	3.45	0.000615	0.0362	0.18	0.16	Gut microbiota (bacterial taxa);	chr4:9809509	chr4:9553614~9553985:-
THCA	cis	rs2822388	0.744	rs116889051	ENSG00000230965.1	SNX18P13	-3.45	0.000615	0.0362	-0.32	-0.16	Stroke;	chr21:14056106	chr21:13905960~13906488:-
THCA	cis	rs2822388	0.59	rs117422362	ENSG00000230965.1	SNX18P13	-3.45	0.000615	0.0362	-0.32	-0.16	Stroke;	chr21:14063419	chr21:13905960~13906488:-
THCA	cis	rs9875589	0.794	rs2117039	ENSG00000233121.1	VN1R20P	3.45	0.000615	0.0362	0.18	0.16	Ovarian reserve;	chr3:13921833	chr3:13926813~13927778:+
THCA	cis	rs10266483	0.739	rs10949900	ENSG00000271550.1	BNIP3P11	-3.45	0.000615	0.0362	-0.21	-0.16	Response to statin therapy;	chr7:64351751	chr7:64678954~64687393:-
THCA	cis	rs6496932	1	rs35796484	ENSG00000259630.2	CTD-2262B20.1	3.45	0.000615	0.0362	0.21	0.16	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85415228~85415633:+
THCA	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	3.45	0.000615	0.0362	0.19	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
THCA	cis	rs2638953	0.924	rs60703205	ENSG00000247934.4	RP11-967K21.1	-3.45	0.000615	0.0362	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454371	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.85	rs59879751	ENSG00000247934.4	RP11-967K21.1	-3.45	0.000615	0.0362	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454490	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs59193275	ENSG00000247934.4	RP11-967K21.1	-3.45	0.000615	0.0362	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454560	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049620	ENSG00000247934.4	RP11-967K21.1	-3.45	0.000615	0.0362	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454698	chr12:28163298~28190738:-
THCA	cis	rs1113500	0.932	rs1343205	ENSG00000230489.1	VAV3-AS1	-3.45	0.000615	0.0362	-0.15	-0.16	Growth-regulated protein alpha levels;	chr1:108055251	chr1:107964443~107994607:+
THCA	cis	rs6017317	0.696	rs1884611	ENSG00000234271.1	RP1-138B7.4	-3.45	0.000615	0.0362	-0.2	-0.16	Type 2 diabetes;	chr20:44296048	chr20:43523261~43523572:-
THCA	cis	rs4808199	1	rs60321073	ENSG00000267481.1	CTC-559E9.5	-3.45	0.000615	0.0362	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19388789	chr19:19788755~19790531:-
THCA	cis	rs1048886	0.872	rs79128960	ENSG00000271967.1	RP11-134K13.4	-3.45	0.000615	0.0362	-0.19	-0.16	Type 2 diabetes;	chr6:70425140	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs17706833	ENSG00000271967.1	RP11-134K13.4	-3.45	0.000615	0.0362	-0.19	-0.16	Type 2 diabetes;	chr6:70435844	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs78721430	ENSG00000271967.1	RP11-134K13.4	-3.45	0.000615	0.0362	-0.19	-0.16	Type 2 diabetes;	chr6:70520228	chr6:70596438~70596980:+
THCA	cis	rs801193	1	rs2420824	ENSG00000232546.1	RP11-458F8.1	3.45	0.000615	0.0362	0.13	0.16	Aortic root size;	chr7:66666129	chr7:66848496~66858136:+
THCA	cis	rs9392556	0.829	rs689308	ENSG00000230648.1	RP3-406P24.3	3.45	0.000615	0.0362	0.2	0.16	Blood metabolite levels;	chr6:4127496	chr6:4018843~4021215:-
THCA	cis	rs4805834	0.719	rs55977451	ENSG00000267567.1	CTD-2538C1.3	-3.45	0.000615	0.0362	-0.29	-0.16	Creatinine levels;	chr19:32807216	chr19:32718298~32719595:-
THCA	cis	rs45509595	0.841	rs370155	ENSG00000220721.1	OR1F12	3.45	0.000615	0.0362	0.27	0.16	Breast cancer;	chr6:27814253	chr6:28073316~28074233:+
THCA	cis	rs1728400	0.58	rs1687658	ENSG00000252311.1	RNU1-103P	3.45	0.000615	0.0362	0.18	0.16	Breast cancer (survival);	chr16:86386488	chr16:85781775~85781899:-
THCA	cis	rs4295623	0.531	rs2898295	ENSG00000251402.3	FAM90A25P	-3.45	0.000615	0.0362	-0.19	-0.16	Morning vs. evening chronotype;	chr8:11738460	chr8:12415080~12418090:-
THCA	cis	rs9813712	0.855	rs6806152	ENSG00000253540.4	FAM86HP	-3.45	0.000615	0.0362	-0.19	-0.16	Response to amphetamines;	chr3:130245358	chr3:130099092~130111472:-
THCA	cis	rs10969557	0.542	rs1980876	ENSG00000231808.2	LINC01388	3.45	0.000615	0.0362	0.17	0.16	Lung cancer;	chr9:318153	chr9:112713~113754:-
THCA	cis	rs6942407	0.592	rs2057984	ENSG00000224046.1	AC005076.5	-3.45	0.000615	0.0362	-0.15	-0.16	Food allergy;	chr7:87197224	chr7:87151423~87152420:-
THCA	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	3.45	0.000615	0.0362	0.25	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
THCA	cis	rs74181299	0.806	rs2723063	ENSG00000237979.1	AC007389.1	-3.45	0.000615	0.0362	-0.19	-0.16	Pulse pressure;	chr2:65053051	chr2:65500993~65502138:-
THCA	cis	rs7308116	0.967	rs2005101	ENSG00000257951.1	RP11-554D14.4	3.45	0.000615	0.0362	0.18	0.16	Pelvic organ prolapse (moderate/severe);	chr12:107808907	chr12:107881242~107883382:+
THCA	cis	rs2109514	0.602	rs1858810	ENSG00000237813.3	AC002066.1	-3.45	0.000615	0.0362	-0.14	-0.16	Prevalent atrial fibrillation;	chr7:116418805	chr7:116238260~116499465:-
THCA	cis	rs6473252	0.584	rs7825743	ENSG00000254162.1	RP11-48B3.3	-3.45	0.000615	0.0362	-0.13	-0.16	Breast cancer;	chr8:80894863	chr8:80535006~80539135:-
THCA	cis	rs8040855	0.599	rs2342123	ENSG00000259630.2	CTD-2262B20.1	-3.45	0.000615	0.0362	-0.17	-0.16	Bulimia nervosa;	chr15:85181918	chr15:85415228~85415633:+
THCA	cis	rs2002030	0.915	rs11775511	ENSG00000184608.7	FAM167A-AS1	-3.45	0.000615	0.0362	-0.22	-0.16	Cognitive performance;	chr8:11414570	chr8:11368402~11438658:+
THCA	cis	rs7772486	0.875	rs854145	ENSG00000270638.1	RP3-466P17.1	3.45	0.000615	0.0362	0.12	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145735570~145737218:+
THCA	cis	rs1536827	0.698	rs8192766	ENSG00000273336.1	OR7M1P	-3.45	0.000615	0.0362	-0.31	-0.16	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr10:133525881	chr10:133481238~133481770:+
THCA	cis	rs8023401	0.58	rs2466792	ENSG00000259705.1	RP11-227D13.1	-3.45	0.000615	0.0362	-0.18	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48460948	chr15:48645951~48652016:+
THCA	cis	rs2235649	0.833	rs9929264	ENSG00000260022.1	LA16c-306A4.1	3.45	0.000615	0.0362	0.22	0.16	Blood metabolite levels;	chr16:1801933	chr16:883780~885090:+
THCA	cis	rs3739034	0.938	rs6749329	ENSG00000224043.6	CCNT2-AS1	-3.45	0.000615	0.0362	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134716795	chr2:134735464~134918710:-
THCA	cis	rs3739034	0.938	rs4954169	ENSG00000224043.6	CCNT2-AS1	-3.45	0.000615	0.0362	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134717626	chr2:134735464~134918710:-
THCA	cis	rs3739034	0.759	rs62171394	ENSG00000224043.6	CCNT2-AS1	-3.45	0.000615	0.0362	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134719225	chr2:134735464~134918710:-
THCA	cis	rs3739034	0.816	rs62171396	ENSG00000224043.6	CCNT2-AS1	-3.45	0.000615	0.0362	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134719289	chr2:134735464~134918710:-
THCA	cis	rs2749097	1	rs2749096	ENSG00000244256.3	RN7SL130P	-3.45	0.000615	0.0362	-0.22	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63661991	chr1:63655743~63656047:+
THCA	cis	rs801193	0.613	rs2659900	ENSG00000272831.1	RP11-792A8.4	3.45	0.000616	0.0362	0.1	0.16	Aortic root size;	chr7:66719456	chr7:66739829~66740385:-
THCA	cis	rs17407555	0.71	rs10939814	ENSG00000250413.1	RP11-448G15.1	-3.45	0.000616	0.0362	-0.17	-0.16	Schizophrenia (age at onset);	chr4:10271705	chr4:10006482~10009725:+
THCA	cis	rs153852	1	rs153852	ENSG00000243806.1	RPL7P18	3.45	0.000616	0.0362	0.21	0.16	Cancer;	chr5:94840876	chr5:94825961~94826694:-
THCA	cis	rs6499755	0.712	rs31090	ENSG00000260135.5	RP11-212I21.2	-3.45	0.000616	0.0362	-0.17	-0.16	Hypospadias;	chr16:55329716	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.712	rs31091	ENSG00000260135.5	RP11-212I21.2	-3.45	0.000616	0.0362	-0.17	-0.16	Hypospadias;	chr16:55329906	chr16:55426797~55462297:-
THCA	cis	rs1858037	0.867	rs61226353	ENSG00000252414.1	RNU6-100P	-3.45	0.000616	0.0362	-0.17	-0.16	Rheumatoid arthritis;	chr2:65363637	chr2:64578892~64578997:+
THCA	cis	rs9980	0.895	rs4783720	ENSG00000226232.7	RP11-419C5.2	-3.45	0.000616	0.0362	-0.24	-0.16	Blood osmolality (transformed sodium);	chr16:69525793	chr16:69976388~69996188:-
THCA	cis	rs7819412	0.745	rs2898260	ENSG00000261451.1	RP11-981G7.1	-3.45	0.000616	0.0362	-0.2	-0.16	Triglycerides;	chr8:11081980	chr8:10433672~10438312:+
THCA	cis	rs8040855	0.627	rs12905036	ENSG00000225151.9	GOLGA2P7	-3.45	0.000616	0.0362	-0.23	-0.16	Bulimia nervosa;	chr15:85094557	chr15:84199311~84230136:-
THCA	cis	rs721048	0.85	rs13417792	ENSG00000242412.1	DBIL5P2	-3.45	0.000616	0.0362	-0.22	-0.16	Prostate cancer;	chr2:63220065	chr2:63117851~63119542:-
THCA	cis	rs4378999	0.748	rs4974104	ENSG00000273356.1	RP11-804H8.6	-3.45	0.000616	0.0362	-0.18	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51345923	chr3:50669989~50672048:+
THCA	cis	rs4378999	0.748	rs2219890	ENSG00000273356.1	RP11-804H8.6	-3.45	0.000616	0.0362	-0.18	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51346075	chr3:50669989~50672048:+
THCA	cis	rs9611565	0.512	rs1534932	ENSG00000237037.8	NDUFA6-AS1	-3.45	0.000616	0.0362	-0.15	-0.16	Vitiligo;	chr22:41754142	chr22:42090931~42137742:+
THCA	cis	rs6942407	0.546	rs3747807	ENSG00000224046.1	AC005076.5	-3.45	0.000616	0.0362	-0.15	-0.16	Food allergy;	chr7:87171035	chr7:87151423~87152420:-
THCA	cis	rs6832769	1	rs7673908	ENSG00000223305.1	RN7SKP30	-3.45	0.000616	0.0362	-0.2	-0.16	Personality dimensions;	chr4:55528652	chr4:55540502~55540835:-
THCA	cis	rs7959452	0.59	rs11177644	ENSG00000274979.1	RP11-1143G9.5	-3.45	0.000616	0.0362	-0.17	-0.16	Blood protein levels;	chr12:69391968	chr12:69326574~69331882:-
THCA	cis	rs2797160	1	rs6904069	ENSG00000226409.1	RP11-735G4.1	-3.45	0.000616	0.0362	-0.19	-0.16	Endometrial cancer;	chr6:125673988	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs6569435	ENSG00000226409.1	RP11-735G4.1	-3.45	0.000616	0.0362	-0.19	-0.16	Endometrial cancer;	chr6:125677040	chr6:125370211~125374324:-
THCA	cis	rs1124769	0.502	rs12911207	ENSG00000259378.1	DCAF13P3	3.45	0.000616	0.0363	0.22	0.16	Cognitive performance;	chr15:50777099	chr15:50944663~50945996:+
THCA	cis	rs6723226	1	rs6723226	ENSG00000276517.1	AL133243.2	-3.45	0.000616	0.0363	-0.16	-0.16	Intelligence (multi-trait analysis);	chr2:32624140	chr2:32526504~32529507:+
THCA	cis	rs1557488	0.629	rs4936000	ENSG00000260209.1	RP11-680F20.10	-3.45	0.000616	0.0363	-0.21	-0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126865688	chr11:125873031~125874528:-
THCA	cis	rs11168618	0.567	rs56354789	ENSG00000273765.1	RP11-370I10.11	3.45	0.000616	0.0363	0.16	0.16	Adiponectin levels;	chr12:48410160	chr12:48360920~48361377:+
THCA	cis	rs7264396	0.635	rs6060703	ENSG00000088340.14	FER1L4	3.45	0.000616	0.0363	0.16	0.16	Total cholesterol levels;	chr20:35941984	chr20:35558737~35607562:-
THCA	cis	rs9584850	0.834	rs4294654	ENSG00000231194.1	FARP1-AS1	3.45	0.000616	0.0363	0.19	0.16	Neuroticism;	chr13:98467353	chr13:98435405~98435840:-
THCA	cis	rs854765	0.693	rs4924822	ENSG00000281749.1	Y_RNA	-3.45	0.000616	0.0363	-0.2	-0.16	Total body bone mineral density;	chr17:17844699	chr17:18001101~18001195:-
THCA	cis	rs6430585	0.591	rs61187091	ENSG00000231890.6	DARS-AS1	-3.45	0.000616	0.0363	-0.19	-0.16	Corneal structure;	chr2:135710668	chr2:135985176~136022593:+
THCA	cis	rs10805346	0.505	rs35995899	ENSG00000261490.1	RP11-448G15.3	3.45	0.000616	0.0363	0.1	0.16	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10111238	chr4:10068089~10073019:-
THCA	cis	rs950169	1	rs62026530	ENSG00000275120.1	RP11-182J1.17	3.45	0.000616	0.0363	0.19	0.16	Schizophrenia;	chr15:84107088	chr15:84599434~84606463:-
THCA	cis	rs990871	0.61	rs12759396	ENSG00000227207.2	RPL31P12	-3.45	0.000616	0.0363	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72455698	chr1:72301472~72301829:+
THCA	cis	rs13113518	0.812	rs11945371	ENSG00000272969.1	RP11-528I4.2	3.45	0.000616	0.0363	0.19	0.16	Height;	chr4:55409063	chr4:55547112~55547889:+
THCA	cis	rs7403037	0.602	rs2677389	ENSG00000260760.1	PWRN3	3.45	0.000616	0.0363	0.17	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24191053	chr15:24441127~24447967:+
THCA	cis	rs440932	0.747	rs330946	ENSG00000254153.1	CTA-398F10.2	-3.45	0.000616	0.0363	-0.17	-0.16	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8456909~8461337:-
THCA	cis	rs6840360	0.615	rs6535822	ENSG00000251603.1	RP11-164P12.4	3.45	0.000616	0.0363	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151758570	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs6855883	ENSG00000251603.1	RP11-164P12.4	3.45	0.000616	0.0363	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151767845	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.554	rs10222838	ENSG00000251603.1	RP11-164P12.4	3.45	0.000616	0.0363	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151768947	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs10222925	ENSG00000251603.1	RP11-164P12.4	3.45	0.000616	0.0363	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151769063	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.55	rs7675818	ENSG00000251603.1	RP11-164P12.4	3.45	0.000616	0.0363	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151769625	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs7654294	ENSG00000251603.1	RP11-164P12.4	3.45	0.000616	0.0363	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151769823	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs867800	ENSG00000251603.1	RP11-164P12.4	3.45	0.000616	0.0363	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151770318	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs10016160	ENSG00000251603.1	RP11-164P12.4	3.45	0.000616	0.0363	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151772846	chr4:151667224~151670502:+
THCA	cis	rs301901	0.796	rs6872681	ENSG00000250155.1	CTD-2353F22.1	3.45	0.000616	0.0363	0.15	0.16	Height;	chr5:37535278	chr5:36666214~36725195:-
THCA	cis	rs12544026	0.825	rs7838696	ENSG00000253669.3	KB-1732A1.1	3.45	0.000617	0.0363	0.17	0.16	Major depression and alcohol dependence;	chr8:101815313	chr8:102805517~102809971:+
THCA	cis	rs2841277	0.645	rs28380382	ENSG00000258701.1	LINC00638	3.45	0.000617	0.0363	0.17	0.16	Rheumatoid arthritis;	chr14:104944490	chr14:104821201~104823718:+
THCA	cis	rs877819	0.649	rs2928401	ENSG00000228403.1	RP11-563N6.6	-3.45	0.000617	0.0363	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48794512	chr10:48878022~48878649:+
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000264242.2	RP11-271K11.1	3.45	0.000617	0.0363	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30553697~30558962:+
THCA	cis	rs6840360	0.571	rs62327277	ENSG00000251611.1	RP11-610P16.1	-3.45	0.000617	0.0363	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151634753	chr4:151407551~151408835:-
THCA	cis	rs9875589	0.957	rs13077668	ENSG00000228242.5	AC093495.4	3.45	0.000617	0.0363	0.09	0.16	Ovarian reserve;	chr3:13888259	chr3:14144637~14165978:+
THCA	cis	rs2403083	0.505	rs7829240	ENSG00000258256.1	RP11-219B4.5	-3.45	0.000617	0.0363	-0.2	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85231565	chr8:85222446~85245717:-
THCA	cis	rs2734839	0.507	rs2245805	ENSG00000270179.1	RP11-159N11.4	-3.45	0.000617	0.0363	-0.18	-0.16	Information processing speed;	chr11:113419977	chr11:113368478~113369117:+
THCA	cis	rs3091242	0.933	rs3093584	ENSG00000228172.4	RP1-317E23.3	-3.45	0.000617	0.0363	-0.12	-0.16	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25816749~25820797:-
THCA	cis	rs2115630	0.905	rs1975277	ENSG00000229212.6	RP11-561C5.4	3.45	0.000617	0.0363	0.2	0.16	P wave terminal force;	chr15:84786327	chr15:85205440~85234795:-
THCA	cis	rs2904967	0.703	rs2904979	ENSG00000254614.2	AP003068.23	-3.45	0.000617	0.0363	-0.38	-0.16	Mean corpuscular volume;	chr11:65233248	chr11:65177606~65181834:-
THCA	cis	rs13064411	0.735	rs10511326	ENSG00000243849.1	CFAP44-AS1	3.45	0.000617	0.0363	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113497478	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.735	rs6438158	ENSG00000243849.1	CFAP44-AS1	3.45	0.000617	0.0363	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113498443	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs6438159	ENSG00000243849.1	CFAP44-AS1	3.45	0.000617	0.0363	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113498494	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs6769516	ENSG00000243849.1	CFAP44-AS1	3.45	0.000617	0.0363	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113501058	chr3:113403991~113433992:+
THCA	cis	rs2926621	0.732	rs2732224	ENSG00000266312.1	RP11-111H3.3	-3.45	0.000617	0.0363	-0.18	-0.16	Night sleep phenotypes;	chr18:75905714	chr18:76623006~76639011:-
THCA	cis	rs56046484	0.956	rs35204319	ENSG00000218052.5	ADAMTS7P4	-3.45	0.000617	0.0363	-0.24	-0.16	Testicular germ cell tumor;	chr15:85107246	chr15:85255369~85330334:-
THCA	cis	rs7824557	0.737	rs10481445	ENSG00000255046.1	RP11-297N6.4	3.45	0.000617	0.0363	0.16	0.16	Retinal vascular caliber;	chr8:11251760	chr8:11797928~11802568:-
THCA	cis	rs42648	0.869	rs10234301	ENSG00000225498.1	AC002064.5	3.45	0.000617	0.0363	0.16	0.16	Homocysteine levels;	chr7:90288964	chr7:90312496~90322592:+
THCA	cis	rs2131877	0.529	rs1009642	ENSG00000238097.1	RP11-513G11.3	3.45	0.000617	0.0363	0.18	0.16	Non-small cell lung cancer;	chr3:195136857	chr3:194247648~194257772:+
THCA	cis	rs2251260	1	rs1092095	ENSG00000250548.5	RP11-47I22.2	-3.45	0.000617	0.0363	-0.22	-0.16	Yeast infection;	chr14:61551574	chr14:61556313~61570653:-
THCA	cis	rs6456156	0.774	rs1012656	ENSG00000235272.1	FAM103A2P	-3.45	0.000617	0.0363	-0.21	-0.16	Primary biliary cholangitis;	chr6:167111815	chr6:166586124~166586477:-
THCA	cis	rs1926657	0.935	rs7321744	ENSG00000223298.1	RNY3P8	-3.45	0.000617	0.0363	-0.21	-0.16	Breast cancer;	chr13:95217498	chr13:95310830~95310955:-
THCA	cis	rs11051970	0.918	rs12229856	ENSG00000277342.1	RP11-843B15.4	-3.45	0.000617	0.0363	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32378286	chr12:32109076~32109602:+
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000249889.1	ALG1L11P	3.45	0.000617	0.0363	0.18	0.16	Neuroticism;	chr8:11991324	chr8:12178697~12182719:+
THCA	cis	rs7129556	0.701	rs10899399	ENSG00000254459.1	RP11-91P24.7	3.45	0.000617	0.0363	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77698787	chr11:77829654~77872262:-
THCA	cis	rs2290416	0.892	rs34178175	ENSG00000254338.1	MAFA-AS1	3.45	0.000617	0.0363	0.3	0.16	Attention deficit hyperactivity disorder;	chr8:143582517	chr8:143417679~143419150:+
THCA	cis	rs2494663	0.61	rs7521303	ENSG00000231416.1	RP11-422P24.9	3.45	0.000617	0.0363	0.2	0.16	Mean platelet volume;	chr1:154039129	chr1:153995632~153995960:+
THCA	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	3.45	0.000617	0.0363	0.16	0.16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
THCA	cis	rs34779708	0.966	rs1148245	ENSG00000233200.1	RP11-324I22.2	3.45	0.000617	0.0363	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35219894~35230598:-
THCA	cis	rs9309711	0.621	rs7586472	ENSG00000271868.1	RP11-1293J14.1	-3.45	0.000617	0.0363	-0.21	-0.16	Neurofibrillary tangles;	chr2:3469899	chr2:3496956~3497428:+
THCA	cis	rs35320143	0.5	rs11075640	ENSG00000246777.1	RP11-61A14.4	-3.45	0.000617	0.0363	-0.14	-0.16	Number of children (6+ vs. 0 or 1);	chr16:66714709	chr16:66751752~66754740:+
THCA	cis	rs785830	0.521	rs553489	ENSG00000231808.2	LINC01388	-3.45	0.000617	0.0363	-0.18	-0.16	Platelet distribution width;	chr9:259990	chr9:112713~113754:-
THCA	cis	rs7188697	0.775	rs8056620	ENSG00000276259.1	RP11-481J2.4	3.45	0.000617	0.0363	0.11	0.16	QT interval;	chr16:58570483	chr16:58522970~58523842:+
THCA	cis	rs62495153	0.744	rs55993234	ENSG00000254153.1	CTA-398F10.2	-3.45	0.000617	0.0363	-0.37	-0.16	Hippocampal volume;	chr8:8378013	chr8:8456909~8461337:-
THCA	cis	rs62495153	0.744	rs62497498	ENSG00000254153.1	CTA-398F10.2	-3.45	0.000617	0.0363	-0.37	-0.16	Hippocampal volume;	chr8:8378998	chr8:8456909~8461337:-
THCA	cis	rs787665	0.786	rs787684	ENSG00000232709.1	MARK2P9	3.45	0.000617	0.0363	0.24	0.16	Gut microbiome composition (summer);	chr10:93325358	chr10:92418667~92420875:+
THCA	cis	rs9400467	0.506	rs17510789	ENSG00000230177.1	RP5-1112D6.4	-3.45	0.000617	0.0363	-0.18	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111381586	chr6:111277932~111278742:+
THCA	cis	rs7267979	0.932	rs4280527	ENSG00000125804.12	FAM182A	-3.45	0.000617	0.0363	-0.19	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:26054655~26086917:+
THCA	cis	rs11633886	0.656	rs11635738	ENSG00000259200.1	RP11-718O11.1	-3.45	0.000617	0.0363	-0.19	-0.16	Diisocyanate-induced asthma;	chr15:45832805	chr15:45705078~45931069:+
THCA	cis	rs6589219	1	rs6589220	ENSG00000196167.8	COLCA1	-3.45	0.000617	0.0363	-0.17	-0.16	Colorectal cancer;	chr11:111302565	chr11:111290787~111305045:-
THCA	cis	rs10903027	0.963	rs10903028	ENSG00000261349.1	RP3-465N24.5	3.45	0.000618	0.0363	0.18	0.16	IgG glycosylation;	chr1:25076700	chr1:25266102~25267136:-
THCA	cis	rs7131987	0.903	rs7974221	ENSG00000274315.1	RP11-996F15.5	3.45	0.000618	0.0363	0.2	0.16	QT interval;	chr12:29246515	chr12:29331434~29331936:-
THCA	cis	rs7131987	0.868	rs11050151	ENSG00000274315.1	RP11-996F15.5	3.45	0.000618	0.0363	0.2	0.16	QT interval;	chr12:29250075	chr12:29331434~29331936:-
THCA	cis	rs9450351	0.744	rs6913147	ENSG00000203875.9	SNHG5	-3.45	0.000618	0.0363	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85800641	chr6:85660950~85678736:-
THCA	cis	rs7212590	0.748	rs7220187	ENSG00000267302.4	RP11-178C3.2	3.45	0.000618	0.0363	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59820248	chr17:59964832~59996972:+
THCA	cis	rs11153306	0.677	rs10872070	ENSG00000271789.1	RP5-1112D6.7	-3.45	0.000618	0.0363	-0.15	-0.16	Tonsillectomy;	chr6:111600601	chr6:111297126~111298510:+
THCA	cis	rs7246657	0.943	rs13343471	ENSG00000266916.4	ZNF793-AS1	-3.45	0.000618	0.0363	-0.16	-0.16	Coronary artery calcification;	chr19:37441228	chr19:37497159~37507046:-
THCA	cis	rs17689437	0.522	rs8052148	ENSG00000260084.1	RP11-615I2.1	3.45	0.000618	0.0363	0.18	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68638934	chr16:68573782~68589512:-
THCA	cis	rs7626019	0.638	rs60942693	ENSG00000222872.1	RNU4-78P	3.45	0.000618	0.0363	0.21	0.16	Neurofibrillary tangles;	chr3:42230593	chr3:42221840~42221965:+
THCA	cis	rs7626019	0.638	rs12152415	ENSG00000222872.1	RNU4-78P	3.45	0.000618	0.0363	0.21	0.16	Neurofibrillary tangles;	chr3:42232751	chr3:42221840~42221965:+
THCA	cis	rs7626019	0.638	rs12639484	ENSG00000222872.1	RNU4-78P	3.45	0.000618	0.0363	0.21	0.16	Neurofibrillary tangles;	chr3:42234378	chr3:42221840~42221965:+
THCA	cis	rs34217772	0.68	rs61990336	ENSG00000258636.1	CTD-2298J14.2	3.45	0.000618	0.0363	0.27	0.16	Myopia;	chr14:41712728	chr14:41587861~41604856:-
THCA	cis	rs6439153	0.933	rs1871951	ENSG00000231305.3	RP11-723O4.2	3.45	0.000618	0.0363	0.16	0.16	Pneumococcal bacteremia;	chr3:129001644	chr3:128861313~128871540:-
THCA	cis	rs7264396	0.79	rs6121015	ENSG00000088340.14	FER1L4	3.45	0.000618	0.0363	0.16	0.16	Total cholesterol levels;	chr20:35655095	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.79	rs6058290	ENSG00000088340.14	FER1L4	3.45	0.000618	0.0363	0.16	0.16	Total cholesterol levels;	chr20:35659780	chr20:35558737~35607562:-
THCA	cis	rs78153629	1	rs113638727	ENSG00000259330.1	INAFM2	-3.45	0.000618	0.0363	-0.19	-0.16	Heschl's gyrus morphology;	chr15:40413902	chr15:40325216~40326715:+
THCA	cis	rs78153629	0.764	rs112366697	ENSG00000259330.1	INAFM2	-3.45	0.000618	0.0363	-0.19	-0.16	Heschl's gyrus morphology;	chr15:40416445	chr15:40325216~40326715:+
THCA	cis	rs11633886	0.604	rs6493178	ENSG00000259200.1	RP11-718O11.1	-3.45	0.000618	0.0363	-0.2	-0.16	Diisocyanate-induced asthma;	chr15:45812056	chr15:45705078~45931069:+
THCA	cis	rs7914558	0.966	rs11191518	ENSG00000272912.1	RP11-724N1.1	-3.45	0.000618	0.0363	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:102914585~102915404:+
THCA	cis	rs11089937	0.626	rs9622968	ENSG00000215456.5	BCRP4	3.45	0.000618	0.0363	0.2	0.16	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22630061~22636153:+
THCA	cis	rs11673344	0.543	rs12980849	ENSG00000267260.1	CTD-2162K18.4	-3.45	0.000618	0.0363	-0.19	-0.16	Obesity-related traits;	chr19:37160812	chr19:36773153~36777078:+
THCA	cis	rs42648	0.837	rs10262472	ENSG00000225498.1	AC002064.5	3.45	0.000618	0.0363	0.16	0.16	Homocysteine levels;	chr7:90271069	chr7:90312496~90322592:+
THCA	cis	rs2821260	0.729	rs2422137	ENSG00000227207.2	RPL31P12	3.45	0.000618	0.0363	0.18	0.16	Intelligence (multi-trait analysis);	chr1:72154278	chr1:72301472~72301829:+
THCA	cis	rs7631605	0.934	rs9876275	ENSG00000272334.1	RP11-129K12.1	-3.45	0.000618	0.0363	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:37220206	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.87	rs9839105	ENSG00000272334.1	RP11-129K12.1	-3.45	0.000618	0.0363	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:37220795	chr3:36973117~36973672:-
THCA	cis	rs6847067	0.74	rs111481594	ENSG00000180769.7	WDFY3-AS2	3.45	0.000618	0.0363	0.12	0.16	Oropharynx cancer;	chr4:84927622	chr4:84965682~85011277:+
THCA	cis	rs11702966	0.61	rs17654028	ENSG00000231711.2	LINC00899	3.45	0.000618	0.0363	0.2	0.16	Tonsillectomy;	chr22:45839625	chr22:46039907~46044853:-
THCA	cis	rs277939	0.935	rs541035	ENSG00000230847.4	RP11-195E2.1	-3.45	0.000618	0.0364	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71590312	chr5:71074225~71093193:-
THCA	cis	rs12677618	1	rs12677618	ENSG00000253307.1	RP11-10J21.4	3.45	0.000618	0.0364	0.24	0.16	Plateletcrit;	chr8:141291925	chr8:141252286~141253292:-
THCA	cis	rs2898681	0.618	rs79471207	ENSG00000248375.1	RP11-177B4.1	-3.45	0.000618	0.0364	-0.32	-0.16	Optic nerve measurement (cup area);	chr4:52872357	chr4:52720081~52720831:-
THCA	cis	rs12101261	0.58	rs3783950	ENSG00000258915.1	BHLHB9P1	3.45	0.000618	0.0364	0.15	0.16	Graves' disease;	chr14:80981938	chr14:80981988~80983638:+
THCA	cis	rs6496667	0.509	rs6496677	ENSG00000213471.7	TTLL13P	3.45	0.000618	0.0364	0.19	0.16	Rheumatoid arthritis;	chr15:90447126	chr15:90249530~90265482:+
THCA	cis	rs9788682	0.947	rs12439240	ENSG00000261143.1	ADAMTS7P3	-3.45	0.000618	0.0364	-0.22	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78536749	chr15:77976042~77993057:+
THCA	cis	rs17807624	0.78	rs11250152	ENSG00000227888.4	FAM66A	-3.45	0.000618	0.0364	-0.19	-0.16	Systemic lupus erythematosus;	chr8:11596691	chr8:12362019~12388296:+
THCA	cis	rs2832191	1	rs2832185	ENSG00000232855.5	AF131217.1	3.45	0.000618	0.0364	0.16	0.16	Dental caries;	chr21:29111440	chr21:28439346~28674848:-
THCA	cis	rs11098499	0.604	rs2389882	ENSG00000249244.1	RP11-548H18.2	3.45	0.000618	0.0364	0.18	0.16	Corneal astigmatism;	chr4:119645578	chr4:119391831~119395335:-
THCA	cis	rs9868809	0.881	rs13063312	ENSG00000270441.1	RP11-694I15.7	3.45	0.000618	0.0364	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48624552	chr3:49140086~49160851:-
THCA	cis	rs7216064	1	rs12600941	ENSG00000265055.1	AC145343.2	3.45	0.000618	0.0364	0.23	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67922691	chr17:68096046~68101474:-
THCA	cis	rs11168618	0.567	rs12372687	ENSG00000240399.1	RP1-228P16.1	3.45	0.000618	0.0364	0.16	0.16	Adiponectin levels;	chr12:48418016	chr12:48054813~48055591:-
THCA	cis	rs6430585	0.583	rs73957037	ENSG00000231890.6	DARS-AS1	-3.45	0.000618	0.0364	-0.18	-0.16	Corneal structure;	chr2:135830461	chr2:135985176~136022593:+
THCA	cis	rs1153858	1	rs2056493	ENSG00000275672.1	GATM-AS1	-3.45	0.000618	0.0364	-0.16	-0.16	Homoarginine levels;	chr15:45356074	chr15:45378700~45380123:+
THCA	cis	rs6787172	0.653	rs7610691	ENSG00000272087.1	RP11-379F4.7	3.45	0.000618	0.0364	0.14	0.16	Subjective well-being;	chr3:158433054	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.651	rs6441195	ENSG00000272087.1	RP11-379F4.7	3.45	0.000618	0.0364	0.14	0.16	Subjective well-being;	chr3:158433957	chr3:158693120~158693768:-
THCA	cis	rs35791980	0.584	rs1181897	ENSG00000265479.4	DTX2P1-UPK3BP1-PMS2P11	-3.45	0.000619	0.0364	-0.16	-0.16	Pursuit maintenance gain;	chr7:77366149	chr7:76980949~77043775:+
THCA	cis	rs3736986	1	rs3780354	ENSG00000215283.3	HMGB3P24	-3.45	0.000619	0.0364	-0.29	-0.16	Bipolar disorder (inflammation and infection response interaction);	chr9:36208629	chr9:36303499~36304924:-
THCA	cis	rs67478160	0.654	rs4906365	ENSG00000258534.1	CTD-2134A5.4	-3.45	0.000619	0.0364	-0.16	-0.16	Schizophrenia;	chr14:103762893	chr14:103854366~103880111:-
THCA	cis	rs17655565	1	rs60696802	ENSG00000257829.1	RP11-845M18.6	-3.45	0.000619	0.0364	-0.25	-0.16	Plasma amyloid beta peptide concentrations (ABx-42);	chr12:52299392	chr12:52306616~52308371:-
THCA	cis	rs12621844	0.671	rs10167776	ENSG00000234690.5	AC073283.4	-3.45	0.000619	0.0364	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48078599	chr2:47192405~47345074:-
THCA	cis	rs883565	0.528	rs6599271	ENSG00000223668.1	EEF1A1P24	3.45	0.000619	0.0364	0.13	0.16	Handedness;	chr3:38929239	chr3:39358545~39359922:+
THCA	cis	rs150992	0.886	rs161948	ENSG00000246763.5	RGMB-AS1	3.45	0.000619	0.0364	0.16	0.16	Body mass index;	chr5:98932333	chr5:98769618~98773469:-
THCA	cis	rs2554380	1	rs2730076	ENSG00000230373.7	GOLGA6L5P	-3.45	0.000619	0.0364	-0.19	-0.16	Height;	chr15:83647233	chr15:84507885~84516814:-
THCA	cis	rs9303542	0.729	rs55682156	ENSG00000278765.1	RP5-890E16.5	-3.45	0.000619	0.0364	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48435813	chr17:48066704~48067293:-
THCA	cis	rs9878978	0.722	rs35775662	ENSG00000227588.2	CNTN4-AS2	3.45	0.000619	0.0364	0.2	0.16	Blood pressure (smoking interaction);	chr3:2395539	chr3:2110409~2144241:-
THCA	cis	rs524281	0.684	rs7946447	ENSG00000255038.1	RP11-1167A19.2	-3.45	0.000619	0.0364	-0.18	-0.16	Electroencephalogram traits;	chr11:66096867	chr11:66067277~66069619:-
THCA	cis	rs878131	0.685	rs1417450	ENSG00000231119.2	RP4-569M23.2	3.45	0.000619	0.0364	0.13	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr20:47044945	chr20:47352561~47354633:+
THCA	cis	rs2274273	0.84	rs10142448	ENSG00000258469.1	CHMP4BP1	-3.45	0.000619	0.0364	-0.14	-0.16	Protein biomarker;	chr14:55371390	chr14:55298644~55299231:+
THCA	cis	rs9890032	0.934	rs7225461	ENSG00000264538.5	SUZ12P1	-3.45	0.000619	0.0364	-0.11	-0.16	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30709299~30790908:+
THCA	cis	rs6472235	0.681	rs4129057	ENSG00000272010.1	CTD-3025N20.3	-3.45	0.000619	0.0364	-0.16	-0.16	Plateletcrit;Myopia (pathological);	chr8:65943911	chr8:65591850~65592472:-
THCA	cis	rs9800506	0.584	rs6924087	ENSG00000271304.1	DPRXP2	3.45	0.000619	0.0364	0.2	0.16	Neutrophil percentage of granulocytes;	chr6:35563428	chr6:35989515~35990436:-
THCA	cis	rs2688608	0.62	rs7080350	ENSG00000272140.2	RP11-574K11.29	-3.45	0.000619	0.0364	-0.13	-0.16	Inflammatory bowel disease;	chr10:73818085	chr10:73703735~73713581:-
THCA	cis	rs853679	0.538	rs13199081	ENSG00000220721.1	OR1F12	3.45	0.000619	0.0364	0.19	0.16	Depression;	chr6:28364057	chr6:28073316~28074233:+
THCA	cis	rs9923856	0.696	rs11648019	ENSG00000263033.2	RP11-396B14.2	-3.45	0.000619	0.0364	-0.15	-0.16	Atopic dermatitis;Adult asthma;	chr16:11069759	chr16:11196177~11224969:+
THCA	cis	rs7311936	1	rs10773059	ENSG00000270130.1	RP11-214K3.23	-3.45	0.000619	0.0364	-0.17	-0.16	Vertical cup-disc ratio;	chr12:124149940	chr12:123960717~123961244:-
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000264242.2	RP11-271K11.1	3.45	0.000619	0.0364	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30553697~30558962:+
THCA	cis	rs7246967	0.611	rs2617780	ENSG00000198153.8	ZNF849P	-3.45	0.000619	0.0364	-0.29	-0.16	Bronchopulmonary dysplasia;	chr19:22809388	chr19:22685167~22686732:+
THCA	cis	rs11124272	0.638	rs4952203	ENSG00000276517.1	AL133243.2	3.45	0.000619	0.0364	0.17	0.16	Interleukin-18 levels;	chr2:31878620	chr2:32526504~32529507:+
THCA	cis	rs210138	0.706	rs444697	ENSG00000197251.3	LINC00336	3.45	0.000619	0.0364	0.19	0.16	Testicular germ cell tumor;	chr6:33607232	chr6:33586106~33593338:-
THCA	cis	rs9302690	1	rs75700677	ENSG00000205361.7	MT1DP	-3.45	0.000619	0.0364	-0.3	-0.16	Blood protein levels;	chr16:57446403	chr16:56643705~56644786:+
THCA	cis	rs9549260	0.755	rs2151785	ENSG00000275149.1	RP11-427J23.1	-3.45	0.000619	0.0364	-0.21	-0.16	Red blood cell count;	chr13:40669523	chr13:40079106~40273509:-
THCA	cis	rs2280018	0.526	rs2941257	ENSG00000255277.3	ABCC6P2	3.45	0.000619	0.0364	0.18	0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:14820792~14824702:-
THCA	cis	rs10091344	0.561	rs2132167	ENSG00000243181.2	RP11-734J24.1	-3.45	0.000619	0.0364	-0.2	-0.16	Body mass index;	chr8:34250816	chr8:34874159~34874633:+
THCA	cis	rs9818758	0.607	rs73084135	ENSG00000229759.1	MRPS18AP1	-3.45	0.000619	0.0364	-0.34	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49234785	chr3:48256350~48256938:-
THCA	cis	rs1023500	0.956	rs1894713	ENSG00000237037.8	NDUFA6-AS1	3.45	0.000619	0.0364	0.15	0.16	Schizophrenia;	chr22:41939617	chr22:42090931~42137742:+
THCA	cis	rs67981189	0.778	rs2189807	ENSG00000269927.1	RP6-91H8.3	3.45	0.00062	0.0364	0.17	0.16	Schizophrenia;	chr14:70896314	chr14:71141125~71143253:-
THCA	cis	rs2333021	0.77	rs12892806	ENSG00000258376.2	RP4-647C14.2	-3.45	0.00062	0.0364	-0.19	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72936225	chr14:73242651~73245979:-
THCA	cis	rs806215	1	rs698406	ENSG00000279265.1	AC000123.3	-3.45	0.00062	0.0364	-0.19	-0.16	Type 2 diabetes;	chr7:127615231	chr7:127349833~127350293:-
THCA	cis	rs867186	1	rs6060230	ENSG00000126005.14	MMP24-AS1	3.45	0.00062	0.0364	0.23	0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35101505	chr20:35216462~35278131:-
THCA	cis	rs78153629	1	rs11858714	ENSG00000259330.1	INAFM2	-3.45	0.00062	0.0364	-0.19	-0.16	Heschl's gyrus morphology;	chr15:40425248	chr15:40325216~40326715:+
THCA	cis	rs4948275	0.773	rs2787731	ENSG00000233643.2	RP11-491H19.1	3.45	0.00062	0.0364	0.18	0.16	Night sleep phenotypes;	chr10:61487775	chr10:61781745~61821246:-
THCA	cis	rs9796	0.663	rs11853192	ENSG00000247556.5	OIP5-AS1	3.45	0.00062	0.0364	0.13	0.16	Menopause (age at onset);	chr15:41076317	chr15:41283990~41309737:+
THCA	cis	rs4761638	0.677	rs1298698	ENSG00000241556.1	RP11-490G8.1	3.45	0.00062	0.0364	0.17	0.16	Insulin disposition index;	chr12:94604510	chr12:95467397~95467861:-
THCA	cis	rs4948275	0.631	rs2814024	ENSG00000233643.2	RP11-491H19.1	3.45	0.00062	0.0364	0.18	0.16	Night sleep phenotypes;	chr10:61590868	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.598	rs2650742	ENSG00000233643.2	RP11-491H19.1	3.45	0.00062	0.0364	0.18	0.16	Night sleep phenotypes;	chr10:61591188	chr10:61781745~61821246:-
THCA	cis	rs6847067	0.929	rs3098928	ENSG00000180769.7	WDFY3-AS2	-3.45	0.00062	0.0364	-0.11	-0.16	Oropharynx cancer;	chr4:84758650	chr4:84965682~85011277:+
THCA	cis	rs3785574	0.962	rs2584623	ENSG00000279369.1	RP11-51F16.1	3.45	0.00062	0.0364	0.11	0.16	Height;	chr17:63829319	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs13030	ENSG00000279369.1	RP11-51F16.1	3.45	0.00062	0.0364	0.11	0.16	Height;	chr17:63831196	chr17:63700847~63702670:+
THCA	cis	rs9307551	0.619	rs11736348	ENSG00000249646.2	OR7E94P	-3.45	0.00062	0.0364	-0.21	-0.16	Refractive error;	chr4:79498711	chr4:79587302~79588130:-
THCA	cis	rs9307551	0.619	rs1561639	ENSG00000249646.2	OR7E94P	-3.45	0.00062	0.0364	-0.21	-0.16	Refractive error;	chr4:79498986	chr4:79587302~79588130:-
THCA	cis	rs11018904	0.861	rs61903723	ENSG00000280367.1	RP11-121L10.2	3.45	0.00062	0.0364	0.21	0.16	Intelligence (multi-trait analysis);	chr11:90235078	chr11:90223153~90226538:+
THCA	cis	rs917063	0.773	rs12433881	ENSG00000269927.1	RP6-91H8.3	-3.45	0.00062	0.0364	-0.21	-0.16	Gestational age at birth in labor-initiated deliveries (child effect);Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:71167011	chr14:71141125~71143253:-
THCA	cis	rs4295623	0.559	rs2409836	ENSG00000206014.6	OR7E161P	-3.45	0.00062	0.0364	-0.18	-0.16	Morning vs. evening chronotype;	chr8:11831719	chr8:11928597~11929563:-
THCA	cis	rs9308731	0.568	rs28723045	ENSG00000227992.1	AC108463.2	-3.45	0.00062	0.0364	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111178121	chr2:111203964~111206215:-
THCA	cis	rs4698036	0.601	rs4698050	ENSG00000261490.1	RP11-448G15.3	-3.45	0.00062	0.0364	-0.13	-0.16	Cardiovascular disease risk factors;	chr4:10409124	chr4:10068089~10073019:-
THCA	cis	rs4468007	0.865	rs10739599	ENSG00000261534.1	RP11-244O19.1	-3.45	0.00062	0.0364	-0.18	-0.16	Educational attainment;	chr9:121852135	chr9:121815674~121819452:-
THCA	cis	rs524281	0.814	rs1055615	ENSG00000255038.1	RP11-1167A19.2	-3.45	0.00062	0.0365	-0.18	-0.16	Electroencephalogram traits;	chr11:66079451	chr11:66067277~66069619:-
THCA	cis	rs7615952	0.641	rs6438951	ENSG00000248787.1	RP11-666A20.4	-3.45	0.00062	0.0365	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:125978156	chr3:125908005~125910272:-
THCA	cis	rs11065706	0.799	rs2028004	ENSG00000278993.1	RP3-424M6.4	-3.45	0.00062	0.0365	-0.24	-0.16	Heart rate;	chr12:110541734	chr12:110501614~110503441:+
THCA	cis	rs4389656	0.778	rs2290616	ENSG00000248677.1	CTD-2044J15.1	-3.45	0.00062	0.0365	-0.16	-0.16	Coronary artery disease;	chr5:6746991	chr5:6686325~6707711:-
THCA	cis	rs59918340	1	rs59918340	ENSG00000253307.1	RP11-10J21.4	3.45	0.00062	0.0365	0.21	0.16	Immature fraction of reticulocytes;	chr8:141222157	chr8:141252286~141253292:-
THCA	cis	rs66887589	0.967	rs1155577	ENSG00000249244.1	RP11-548H18.2	-3.45	0.00062	0.0365	-0.16	-0.16	Diastolic blood pressure;	chr4:119528655	chr4:119391831~119395335:-
THCA	cis	rs56092632	0.523	rs72728265	ENSG00000253720.1	RP11-473O4.3	3.45	0.000621	0.0365	0.26	0.16	Lobe attachment (rater-scored or self-reported);	chr8:130674898	chr8:129939856~129949394:+
THCA	cis	rs4879656	0.815	rs2774271	ENSG00000225693.1	LAGE3P1	3.45	0.000621	0.0365	0.17	0.16	Menopause (age at onset);	chr9:33098774	chr9:33019682~33020165:-
THCA	cis	rs6006426	1	rs6006426	ENSG00000279699.1	RP1-102K2.9	-3.45	0.000621	0.0365	-0.15	-0.16	Coronary artery disease;	chr22:30273894	chr22:30275215~30276951:-
THCA	cis	rs453301	0.686	rs28482034	ENSG00000233609.3	RP11-62H7.2	-3.45	0.000621	0.0365	-0.16	-0.16	Joint mobility (Beighton score);	chr8:9012154	chr8:8961200~8979025:+
THCA	cis	rs3091242	0.967	rs3093614	ENSG00000228172.4	RP1-317E23.3	-3.45	0.000621	0.0365	-0.12	-0.16	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25816749~25820797:-
THCA	cis	rs11168187	0.714	rs12422983	ENSG00000280054.1	RP1-197B17.7	3.45	0.000621	0.0365	0.26	0.16	Vertical cup-disc ratio;	chr12:47748853	chr12:47728151~47730598:-
THCA	cis	rs7656342	0.57	rs7683831	ENSG00000250342.1	SNRPCP16	3.45	0.000621	0.0365	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9843455	chr4:9051842~9052051:-
THCA	cis	rs9488822	0.636	rs6937104	ENSG00000237021.2	RP3-486I3.7	3.45	0.000621	0.0365	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116054139	chr6:116254207~116256743:+
THCA	cis	rs9488822	0.676	rs1999929	ENSG00000237021.2	RP3-486I3.7	3.45	0.000621	0.0365	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116060831	chr6:116254207~116256743:+
THCA	cis	rs13034020	0.709	rs1821183	ENSG00000271889.1	RP11-493E12.1	3.45	0.000621	0.0365	0.2	0.16	Hodgkin's lymphoma;	chr2:60776368	chr2:61151433~61162105:-
THCA	cis	rs9863	0.896	rs76283024	ENSG00000270028.1	RP11-380L11.4	3.45	0.000621	0.0365	0.17	0.16	White blood cell count;	chr12:123982232	chr12:123925461~123926083:-
THCA	cis	rs2549003	0.674	rs960757	ENSG00000233006.5	AC034220.3	-3.45	0.000621	0.0365	-0.12	-0.16	Asthma (sex interaction);	chr5:132490618	chr5:132311285~132369916:-
THCA	cis	rs73157695	0.676	rs4819168	ENSG00000274248.1	AJ011932.1	3.45	0.000621	0.0365	0.18	0.16	Myopia;	chr21:45917118	chr21:45974489~45974953:+
THCA	cis	rs67539049	1	rs7832089	ENSG00000227888.4	FAM66A	-3.45	0.000621	0.0365	-0.24	-0.16	Itch intensity from mosquito bite;	chr8:11448494	chr8:12362019~12388296:+
THCA	cis	rs9906944	0.933	rs4794018	ENSG00000248278.1	SUMO2P17	-3.45	0.000621	0.0365	-0.19	-0.16	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49016036	chr17:48874860~48908983:-
THCA	cis	rs9906944	0.864	rs9902512	ENSG00000248278.1	SUMO2P17	-3.45	0.000621	0.0365	-0.19	-0.16	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49016912	chr17:48874860~48908983:-
THCA	cis	rs2300747	0.932	rs12038673	ENSG00000177173.5	NAP1L4P1	-3.45	0.000621	0.0365	-0.23	-0.16	Primary biliary cholangitis;Multiple sclerosis;	chr1:116546014	chr1:116532936~116534092:-
THCA	cis	rs12817211	0.699	rs7975894	ENSG00000272368.2	RP4-605O3.4	3.45	0.000621	0.0365	0.13	0.16	Colorectal or endometrial cancer;	chr12:50390529	chr12:50112197~50165618:+
THCA	cis	rs197770	0.542	rs149816	ENSG00000279727.1	RP11-640L9.1	-3.45	0.000621	0.0365	-0.29	-0.16	Phospholipid levels (plasma);	chr3:37469275	chr3:36819276~36822498:-
THCA	cis	rs7487075	0.78	rs1873793	ENSG00000272369.1	RP11-446N19.1	-3.45	0.000621	0.0365	-0.12	-0.16	Itch intensity from mosquito bite;	chr12:46367541	chr12:46537502~46652550:+
THCA	cis	rs4588572	0.644	rs6870646	ENSG00000245556.2	SCAMP1-AS1	-3.45	0.000621	0.0365	-0.12	-0.16	Triglycerides;	chr5:78445258	chr5:78342365~78360507:-
THCA	cis	rs4588572	0.644	rs6873144	ENSG00000245556.2	SCAMP1-AS1	-3.45	0.000621	0.0365	-0.12	-0.16	Triglycerides;	chr5:78445960	chr5:78342365~78360507:-
THCA	cis	rs7818688	0.614	rs79487086	ENSG00000253528.2	RP11-347C18.4	-3.45	0.000621	0.0365	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94863285	chr8:94974573~94974853:-
THCA	cis	rs1383484	0.575	rs1904866	ENSG00000259728.4	LINC00933	-3.45	0.000621	0.0365	-0.19	-0.16	Height;	chr15:83933434	chr15:84570649~84580175:+
THCA	cis	rs6715793	0.868	rs17641062	ENSG00000272754.1	AL133245.2	-3.45	0.000621	0.0365	-0.18	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33189594	chr2:32321638~32323002:+
THCA	cis	rs34864796	0.547	rs200476	ENSG00000220721.1	OR1F12	3.45	0.000621	0.0365	0.22	0.16	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28073316~28074233:+
THCA	cis	rs2447820	0.588	rs1437624	ENSG00000263432.2	RN7SL689P	3.45	0.000621	0.0365	0.2	0.16	Migraine;	chr5:123040636	chr5:123022487~123022783:-
THCA	cis	rs2447820	0.588	rs12653397	ENSG00000263432.2	RN7SL689P	3.45	0.000621	0.0365	0.2	0.16	Migraine;	chr5:123041643	chr5:123022487~123022783:-
THCA	cis	rs9889262	0.561	rs1124881	ENSG00000248714.5	RP11-1079K10.3	3.45	0.000621	0.0365	0.17	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49276125	chr17:49361165~49369998:+
THCA	cis	rs1124769	0.502	rs35088194	ENSG00000259378.1	DCAF13P3	3.45	0.000621	0.0365	0.22	0.16	Cognitive performance;	chr15:50773717	chr15:50944663~50945996:+
THCA	cis	rs686320	1	rs72643572	ENSG00000254614.2	AP003068.23	3.45	0.000621	0.0365	0.28	0.16	Hip circumference adjusted for BMI;	chr11:65483496	chr11:65177606~65181834:-
THCA	cis	rs34792	0.599	rs153791	ENSG00000255277.3	ABCC6P2	-3.45	0.000621	0.0365	-0.16	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15453224	chr16:14820792~14824702:-
THCA	cis	rs7131987	0.874	rs10843366	ENSG00000274315.1	RP11-996F15.5	3.45	0.000621	0.0365	0.2	0.16	QT interval;	chr12:29254970	chr12:29331434~29331936:-
THCA	cis	rs7131987	0.845	rs2042511	ENSG00000274315.1	RP11-996F15.5	3.45	0.000621	0.0365	0.2	0.16	QT interval;	chr12:29255847	chr12:29331434~29331936:-
THCA	cis	rs7131987	0.903	rs10843371	ENSG00000274315.1	RP11-996F15.5	3.45	0.000621	0.0365	0.2	0.16	QT interval;	chr12:29261299	chr12:29331434~29331936:-
THCA	cis	rs3929778	0.675	rs6077004	ENSG00000233578.1	EIF4EP1	3.45	0.000621	0.0365	0.18	0.16	QRS complex (Cornell);	chr20:6462314	chr20:5548840~5549481:+
THCA	cis	rs3925158	0.51	rs77393525	ENSG00000229589.1	ACVR2B-AS1	-3.45	0.000621	0.0365	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38209154	chr3:38451027~38454820:-
THCA	cis	rs3925158	0.51	rs79108376	ENSG00000229589.1	ACVR2B-AS1	-3.45	0.000621	0.0365	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38209503	chr3:38451027~38454820:-
THCA	cis	rs2033711	0.87	rs7259841	ENSG00000269867.1	CTD-2583A14.8	-3.45	0.000621	0.0365	-0.13	-0.16	Uric acid clearance;	chr19:58439756	chr19:57867038~57868172:-
THCA	cis	rs791590	0.752	rs62626325	ENSG00000229664.1	RP11-536K7.5	-3.45	0.000621	0.0365	-0.25	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6079322	chr10:6025978~6036427:+
THCA	cis	rs964611	0.816	rs3784615	ENSG00000259488.2	RP11-154J22.1	-3.45	0.000621	0.0365	-0.14	-0.16	Metabolite levels (Pyroglutamine);	chr15:48248002	chr15:48312353~48331856:-
THCA	cis	rs4683346	0.752	rs4682868	ENSG00000273328.4	RP11-141M3.6	-3.45	0.000621	0.0365	-0.2	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42864023	chr3:42809414~42908105:+
THCA	cis	rs6840360	0.571	rs17360371	ENSG00000251611.1	RP11-610P16.1	-3.45	0.000622	0.0365	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151644222	chr4:151407551~151408835:-
THCA	cis	rs939960	0.959	rs6950421	ENSG00000224016.2	RP11-728K20.1	3.45	0.000622	0.0365	0.22	0.16	Neutrophil percentage of white cells;	chr7:150587112	chr7:149891191~149909704:-
THCA	cis	rs939960	0.918	rs6954709	ENSG00000224016.2	RP11-728K20.1	3.45	0.000622	0.0365	0.22	0.16	Neutrophil percentage of white cells;	chr7:150587154	chr7:149891191~149909704:-
THCA	cis	rs34779708	0.931	rs2244100	ENSG00000233200.1	RP11-324I22.2	-3.45	0.000622	0.0365	-0.19	-0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35219894~35230598:-
THCA	cis	rs7508	0.509	rs441764	ENSG00000253671.1	RP11-806O11.1	-3.45	0.000622	0.0365	-0.2	-0.16	Atrial fibrillation;	chr8:18045648	chr8:17808941~17820868:+
THCA	cis	rs7937890	0.559	rs2597201	ENSG00000251991.1	RNU7-49P	3.45	0.000622	0.0365	0.18	0.16	Mitochondrial DNA levels;	chr11:14463858	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2575831	ENSG00000251991.1	RNU7-49P	3.45	0.000622	0.0365	0.18	0.16	Mitochondrial DNA levels;	chr11:14464648	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.532	rs2575832	ENSG00000251991.1	RNU7-49P	3.45	0.000622	0.0365	0.18	0.16	Mitochondrial DNA levels;	chr11:14467264	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2597197	ENSG00000251991.1	RNU7-49P	3.45	0.000622	0.0365	0.18	0.16	Mitochondrial DNA levels;	chr11:14468286	chr11:14478892~14478953:+
THCA	cis	rs10911902	0.643	rs75906210	ENSG00000228238.1	GS1-304P7.2	-3.45	0.000622	0.0365	-0.26	-0.16	Schizophrenia;	chr1:186365092	chr1:186578279~186579299:+
THCA	cis	rs10199109	0.524	rs3891481	ENSG00000231013.1	AC013275.2	3.45	0.000622	0.0365	0.2	0.16	Platelet count;	chr2:120198176	chr2:119476448~119487346:+
THCA	cis	rs2180341	0.92	rs9401951	ENSG00000220522.2	RP1-177A13.1	3.45	0.000622	0.0365	0.21	0.16	Breast cancer;	chr6:127350487	chr6:127416535~127416952:-
THCA	cis	rs2573652	0.723	rs2573655	ENSG00000259219.1	CTD-3076O17.2	-3.45	0.000622	0.0365	-0.18	-0.16	Height;	chr15:99975504	chr15:99976481~99980774:+
THCA	cis	rs45544231	1	rs3104767	ENSG00000279344.1	RP11-44F14.7	-3.45	0.000622	0.0365	-0.15	-0.16	Restless legs syndrome;	chr16:52590826	chr16:53478957~53481550:-
THCA	cis	rs17217757	0.725	rs58498975	ENSG00000254041.1	RP11-574O7.1	-3.45	0.000622	0.0365	-0.24	-0.16	Tuberculosis;	chr8:105643645	chr8:105142860~105188606:-
THCA	cis	rs6120849	0.754	rs6120793	ENSG00000269202.1	RP4-614O4.12	-3.45	0.000622	0.0365	-0.17	-0.16	Protein C levels;	chr20:35016604	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs6120797	ENSG00000269202.1	RP4-614O4.12	-3.45	0.000622	0.0365	-0.17	-0.16	Protein C levels;	chr20:35018199	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs6119560	ENSG00000269202.1	RP4-614O4.12	-3.45	0.000622	0.0365	-0.17	-0.16	Protein C levels;	chr20:35019174	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.707	rs6120798	ENSG00000269202.1	RP4-614O4.12	-3.45	0.000622	0.0365	-0.17	-0.16	Protein C levels;	chr20:35023019	chr20:35201747~35203288:-
THCA	cis	rs73191547	0.771	rs11777161	ENSG00000248538.5	RP11-10A14.5	-3.45	0.000622	0.0365	-0.19	-0.16	Schizophrenia;	chr8:10185635	chr8:9189011~9202854:+
THCA	cis	rs427941	1	rs423452	ENSG00000239486.1	RP11-163E9.1	-3.45	0.000622	0.0365	-0.16	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102205510	chr7:102380465~102382737:-
THCA	cis	rs16857609	1	rs16857609	ENSG00000233143.1	DIRC3-AS1	-3.45	0.000622	0.0365	-0.17	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217431785	chr2:217282739~217336120:+
THCA	cis	rs1654345	0.561	rs10413751	ENSG00000275132.1	Metazoa_SRP	-3.45	0.000622	0.0365	-0.25	-0.16	Life satisfaction;Subjective well-being;	chr19:38060419	chr19:38200234~38200532:+
THCA	cis	rs2486012	0.737	rs11210928	ENSG00000237950.1	RP11-7O11.3	3.45	0.000622	0.0365	0.18	0.16	Intelligence (multi-trait analysis);	chr1:43802548	chr1:43944370~43946551:-
THCA	cis	rs17122278	0.696	rs562780	ENSG00000243431.1	RPL5P30	-3.45	0.000622	0.0365	-0.17	-0.16	Total cholesterol levels;	chr11:118491699	chr11:118560690~118561580:+
THCA	cis	rs9796	0.866	rs2928148	ENSG00000247556.5	OIP5-AS1	-3.45	0.000622	0.0365	-0.12	-0.16	Menopause (age at onset);	chr15:41109352	chr15:41283990~41309737:+
THCA	cis	rs4578769	0.759	rs12455345	ENSG00000265939.1	UBE2CP2	-3.45	0.000622	0.0365	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:23059491	chr18:22900486~22900995:-
THCA	cis	rs12935418	0.672	rs9925780	ENSG00000261838.4	RP11-303E16.6	3.45	0.000622	0.0365	0.2	0.16	Mean corpuscular volume;	chr16:81011571	chr16:81069854~81076598:+
THCA	cis	rs6840360	0.593	rs1877186	ENSG00000251603.1	RP11-164P12.4	3.45	0.000622	0.0365	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151771266	chr4:151667224~151670502:+
THCA	cis	rs7762018	0.769	rs74838157	ENSG00000236173.1	RP1-182D15.2	3.45	0.000622	0.0365	0.28	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169677227	chr6:169809318~169810102:-
THCA	cis	rs28830936	1	rs12441300	ENSG00000250379.1	RP11-23P13.4	3.45	0.000622	0.0365	0.18	0.16	Diastolic blood pressure;	chr15:41810647	chr15:41825099~41827936:-
THCA	cis	rs270601	0.721	rs270621	ENSG00000263597.1	MIR3936	3.45	0.000622	0.0365	0.15	0.16	Acylcarnitine levels;	chr5:132270128	chr5:132365490~132365599:-
THCA	cis	rs337161	0.64	rs7536276	ENSG00000221571.3	RNU6ATAC35P	3.45	0.000622	0.0365	0.17	0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220787573	chr1:220825620~220826063:+
THCA	cis	rs1612141	0.744	rs2185991	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41104949	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs2185990	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41104990	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs2185989	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41105004	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs4294729	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41105089	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs8021295	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41106698	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs11848997	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41107162	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs3962848	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41107252	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.641	rs2415660	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41107633	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs2415661	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41107766	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs2415662	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41107773	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs2415663	ENSG00000251363.2	RP11-129M6.1	3.45	0.000622	0.0365	0.23	0.16	QT interval (drug interaction);	chr14:41107827	chr14:40954898~40975877:+
THCA	cis	rs6929812	0.664	rs12525255	ENSG00000216915.2	RP1-97D16.1	3.45	0.000622	0.0365	0.2	0.16	Neuroticism (multi-trait analysis);	chr6:27409889	chr6:27737000~27738494:-
THCA	cis	rs5753618	0.583	rs5753632	ENSG00000224050.1	RP1-90G24.6	-3.45	0.000622	0.0366	-0.2	-0.16	Colorectal cancer;	chr22:31467111	chr22:32273420~32277186:+
THCA	cis	rs17122278	0.577	rs537975	ENSG00000255239.1	AP002954.6	3.45	0.000622	0.0366	0.24	0.16	Total cholesterol levels;	chr11:118492154	chr11:118688039~118690600:-
THCA	cis	rs651386	0.506	rs12027180	ENSG00000271811.1	RP1-79C4.4	3.45	0.000622	0.0366	0.2	0.16	Atrial fibrillation;	chr1:170594064	chr1:170667381~170669425:+
THCA	cis	rs11098499	0.954	rs1546505	ENSG00000250950.1	RP11-33B1.3	-3.45	0.000622	0.0366	-0.2	-0.16	Corneal astigmatism;	chr4:119320069	chr4:119456350~119457277:+
THCA	cis	rs4805272	0.512	rs4805279	ENSG00000267799.1	MAN1A2P1	3.44	0.000622	0.0366	0.21	0.16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28846059	chr19:28790812~28792871:-
THCA	cis	rs7565158	0.617	rs11675226	ENSG00000234308.2	AC093381.2	-3.44	0.000622	0.0366	-0.14	-0.16	Body mass index (change over time);	chr2:212736198	chr2:212795331~212819264:+
THCA	cis	rs61841072	0.714	rs2907192	ENSG00000253326.2	RP11-261C10.7	-3.44	0.000622	0.0366	-0.2	-0.16	Schizophrenia;	chr1:242974088	chr1:243054861~243056394:-
THCA	cis	rs2302190	1	rs2302190	ENSG00000224738.1	AC099850.1	3.44	0.000622	0.0366	0.22	0.16	Vitamin D levels;	chr17:58507147	chr17:59106598~59118267:+
THCA	cis	rs7020830	0.825	rs7036132	ENSG00000260100.1	RP11-220I1.5	-3.44	0.000622	0.0366	-0.19	-0.16	Schizophrenia;	chr9:37317244	chr9:37078813~37079776:-
THCA	cis	rs34779708	0.966	rs10508816	ENSG00000233200.1	RP11-324I22.2	3.44	0.000622	0.0366	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35219894~35230598:-
THCA	cis	rs9878978	0.66	rs62245710	ENSG00000227588.2	CNTN4-AS2	3.44	0.000623	0.0366	0.21	0.16	Blood pressure (smoking interaction);	chr3:2410628	chr3:2110409~2144241:-
THCA	cis	rs6565180	1	rs68051857	ENSG00000274678.1	RP11-2C24.7	-3.44	0.000623	0.0366	-0.14	-0.16	Tonsillectomy;	chr16:30348690	chr16:30821338~30821884:+
THCA	cis	rs6565180	1	rs6565180	ENSG00000274678.1	RP11-2C24.7	-3.44	0.000623	0.0366	-0.14	-0.16	Tonsillectomy;	chr16:30350020	chr16:30821338~30821884:+
THCA	cis	rs10411161	0.63	rs76234335	ENSG00000260160.1	CTC-471J1.2	-3.44	0.000623	0.0366	-0.24	-0.16	Breast cancer;	chr19:51954215	chr19:52058490~52063703:-
THCA	cis	rs910316	0.763	rs6574205	ENSG00000259138.1	RP11-950C14.7	3.44	0.000623	0.0366	0.14	0.16	Height;	chr14:74986336	chr14:75127153~75136930:+
THCA	cis	rs1371614	0.523	rs4665924	ENSG00000272148.1	RP11-195B17.1	-3.44	0.000623	0.0366	-0.15	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916437	chr2:27062428~27062907:-
THCA	cis	rs12612619	0.765	rs12615303	ENSG00000272148.1	RP11-195B17.1	-3.44	0.000623	0.0366	-0.15	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26917705	chr2:27062428~27062907:-
THCA	cis	rs1387259	0.723	rs2732488	ENSG00000257735.1	RP11-370I10.6	3.44	0.000623	0.0366	0.18	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48350945~48442411:+
THCA	cis	rs1387259	0.758	rs2634670	ENSG00000257735.1	RP11-370I10.6	3.44	0.000623	0.0366	0.18	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48350945~48442411:+
THCA	cis	rs1005277	0.54	rs4934907	ENSG00000273019.1	RP11-508N22.13	-3.44	0.000623	0.0366	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38149968~38150293:+
THCA	cis	rs1005277	0.54	rs11011351	ENSG00000273019.1	RP11-508N22.13	-3.44	0.000623	0.0366	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38149968~38150293:+
THCA	cis	rs972578	0.791	rs5751392	ENSG00000230319.1	AL022476.2	3.44	0.000623	0.0366	0.17	0.16	Mean platelet volume;	chr22:42865688	chr22:43038585~43052366:+
THCA	cis	rs875971	1	rs875971	ENSG00000272831.1	RP11-792A8.4	-3.44	0.000623	0.0366	-0.1	-0.16	Aortic root size;	chr7:66152608	chr7:66739829~66740385:-
THCA	cis	rs897984	0.806	rs9319588	ENSG00000232748.3	RP11-196G11.6	3.44	0.000623	0.0366	0.19	0.16	Dementia with Lewy bodies;	chr16:30919662	chr16:31056460~31062803:+
THCA	cis	rs897984	0.77	rs12930657	ENSG00000232748.3	RP11-196G11.6	3.44	0.000623	0.0366	0.19	0.16	Dementia with Lewy bodies;	chr16:30920647	chr16:31056460~31062803:+
THCA	cis	rs897984	0.77	rs3813020	ENSG00000232748.3	RP11-196G11.6	3.44	0.000623	0.0366	0.19	0.16	Dementia with Lewy bodies;	chr16:30922754	chr16:31056460~31062803:+
THCA	cis	rs7914558	1	rs4917380	ENSG00000272912.1	RP11-724N1.1	-3.44	0.000623	0.0366	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103015578	chr10:102914585~102915404:+
THCA	cis	rs7914558	1	rs7914558	ENSG00000272912.1	RP11-724N1.1	-3.44	0.000623	0.0366	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103016151	chr10:102914585~102915404:+
THCA	cis	rs2195224	1	rs2195224	ENSG00000273328.4	RP11-141M3.6	-3.44	0.000623	0.0366	-0.19	-0.16	Monocyte count;	chr3:42859508	chr3:42809414~42908105:+
THCA	cis	rs2006933	1	rs9890374	ENSG00000267644.1	CTD-2008P7.10	3.44	0.000623	0.0366	0.2	0.16	Amyotrophic lateral sclerosis;	chr17:28265336	chr17:28219285~28220005:+
THCA	cis	rs467650	0.747	rs36768	ENSG00000246763.5	RGMB-AS1	3.44	0.000623	0.0366	0.16	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98614126	chr5:98769618~98773469:-
THCA	cis	rs9611565	0.568	rs2413656	ENSG00000237037.8	NDUFA6-AS1	-3.44	0.000623	0.0366	-0.14	-0.16	Vitiligo;	chr22:41733353	chr22:42090931~42137742:+
THCA	cis	rs7259376	0.967	rs7252056	ENSG00000269138.1	ZNF209P	3.44	0.000623	0.0366	0.16	0.16	Menopause (age at onset);	chr19:22311250	chr19:22463922~22473036:+
THCA	cis	rs9392556	0.829	rs634698	ENSG00000230648.1	RP3-406P24.3	3.44	0.000623	0.0366	0.2	0.16	Blood metabolite levels;	chr6:4114013	chr6:4018843~4021215:-
THCA	cis	rs7246967	0.673	rs74664155	ENSG00000236312.3	RPL34P34	-3.44	0.000623	0.0366	-0.22	-0.16	Bronchopulmonary dysplasia;	chr19:22697530	chr19:22368599~22368952:-
THCA	cis	rs2882667	0.898	rs11952020	ENSG00000249593.5	CTB-46B19.2	3.44	0.000623	0.0366	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:139012647~139051203:+
THCA	cis	rs7259376	0.869	rs11671804	ENSG00000269345.1	VN1R85P	-3.44	0.000623	0.0366	-0.17	-0.16	Menopause (age at onset);	chr19:22408414	chr19:22174766~22175191:-
THCA	cis	rs72928364	1	rs73137256	ENSG00000256628.3	ZBTB11-AS1	3.44	0.000623	0.0366	0.28	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100882495	chr3:101676475~101679217:+
THCA	cis	rs7264396	0.635	rs6060720	ENSG00000088340.14	FER1L4	3.44	0.000623	0.0366	0.16	0.16	Total cholesterol levels;	chr20:35960414	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.676	rs6060723	ENSG00000088340.14	FER1L4	3.44	0.000623	0.0366	0.16	0.16	Total cholesterol levels;	chr20:35962025	chr20:35558737~35607562:-
THCA	cis	rs9863	0.861	rs4930725	ENSG00000270028.1	RP11-380L11.4	3.44	0.000623	0.0366	0.17	0.16	White blood cell count;	chr12:123943615	chr12:123925461~123926083:-
THCA	cis	rs3617	0.625	rs6445541	ENSG00000243224.1	RP5-1157M23.2	-3.44	0.000623	0.0366	-0.17	-0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52846112	chr3:52239258~52241097:+
THCA	cis	rs7919656	0.626	rs2671694	ENSG00000228403.1	RP11-563N6.6	3.44	0.000623	0.0366	0.17	0.16	Clinically amyopathic dermatomyositis;	chr10:48908030	chr10:48878022~48878649:+
THCA	cis	rs10089	0.953	rs4835940	ENSG00000245937.6	LINC01184	3.44	0.000623	0.0366	0.18	0.16	Ileal carcinoids;	chr5:128070904	chr5:127940426~128083172:-
THCA	cis	rs7713065	0.797	rs3846729	ENSG00000237714.1	P4HA2-AS1	-3.44	0.000623	0.0366	-0.27	-0.16	Lung function (FEV1/FVC);	chr5:132471076	chr5:132184876~132192808:+
THCA	cis	rs1979679	0.573	rs4931087	ENSG00000278733.1	RP11-425D17.1	3.44	0.000623	0.0366	0.16	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582158	chr12:28185625~28186190:-
THCA	cis	rs1421334	0.74	rs55833242	ENSG00000254109.4	RBPMS-AS1	3.44	0.000623	0.0366	0.16	0.16	Intelligence (multi-trait analysis);	chr8:30997515	chr8:30382119~30385401:-
THCA	cis	rs975752	0.717	rs3750709	ENSG00000227492.1	RP11-316M21.6	3.44	0.000623	0.0366	0.3	0.16	Schizophrenia;	chr10:100238295	chr10:100229667~100234000:+
THCA	cis	rs2190422	0.505	rs2711846	ENSG00000234715.1	CTB-107G13.1	-3.44	0.000624	0.0366	-0.19	-0.16	Morning vs. evening chronotype;	chr7:103512050	chr7:103445207~103514007:+
THCA	cis	rs2018683	0.835	rs7782264	ENSG00000272568.4	CTB-113D17.1	-3.44	0.000624	0.0366	-0.15	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28939369	chr7:28979967~29013367:+
THCA	cis	rs57590327	0.503	rs2372905	ENSG00000241593.4	RP11-520D19.2	3.44	0.000624	0.0366	0.19	0.16	Extraversion;	chr3:81455441	chr3:81246579~81297345:-
THCA	cis	rs10954779	0.515	rs1425296	ENSG00000127589.4	TUBBP1	3.44	0.000624	0.0366	0.19	0.16	Intelligence (multi-trait analysis);	chr8:31114472	chr8:30351873~30353518:+
THCA	cis	rs1534238	0.875	rs11884424	ENSG00000259056.1	DUXAP1	3.44	0.000624	0.0366	0.17	0.16	Response to antipsychotic treatment;	chr2:84116269	chr2:84750769~84751231:+
THCA	cis	rs3764021	0.527	rs10772062	ENSG00000256069.6	A2MP1	-3.44	0.000624	0.0366	-0.18	-0.16	Type 1 diabetes;	chr12:9712561	chr12:9228533~9275817:-
THCA	cis	rs1009077	0.627	rs12642735	ENSG00000248280.1	RP11-33B1.2	-3.44	0.000624	0.0366	-0.17	-0.16	Endometriosis;	chr4:119603465	chr4:119440561~119450157:-
THCA	cis	rs1009077	0.627	rs3733526	ENSG00000248280.1	RP11-33B1.2	-3.44	0.000624	0.0366	-0.17	-0.16	Endometriosis;	chr4:119607172	chr4:119440561~119450157:-
THCA	cis	rs7131987	0.903	rs6487796	ENSG00000273680.1	RP11-996F15.6	3.44	0.000624	0.0366	0.21	0.16	QT interval;	chr12:29269831	chr12:29332733~29333383:-
THCA	cis	rs4713118	0.869	rs10214440	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000624	0.0366	-0.17	-0.16	Parkinson's disease;	chr6:27734661	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.869	rs6902689	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000624	0.0366	-0.17	-0.16	Parkinson's disease;	chr6:27741662	chr6:28078792~28081130:-
THCA	cis	rs7246657	0.943	rs34603719	ENSG00000268499.1	CTB-102L5.8	3.44	0.000624	0.0366	0.21	0.16	Coronary artery calcification;	chr19:37303626	chr19:38199836~38200934:+
THCA	cis	rs354225	0.512	rs6753004	ENSG00000162997.14	PRORSD1P	-3.44	0.000624	0.0366	-0.19	-0.16	Schizophrenia;	chr2:54735586	chr2:55282319~55284522:+
THCA	cis	rs277939	1	rs6885523	ENSG00000251634.2	RP11-1280N14.3	3.44	0.000624	0.0366	0.16	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71611668	chr5:71102898~71128753:-
THCA	cis	rs277939	1	rs464182	ENSG00000251634.2	RP11-1280N14.3	3.44	0.000624	0.0366	0.16	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71611711	chr5:71102898~71128753:-
THCA	cis	rs1862618	0.671	rs2255726	ENSG00000271828.1	CTD-2310F14.1	-3.44	0.000624	0.0366	-0.22	-0.16	Initial pursuit acceleration;	chr5:56947301	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.671	rs2591957	ENSG00000271828.1	CTD-2310F14.1	-3.44	0.000624	0.0366	-0.22	-0.16	Initial pursuit acceleration;	chr5:56947319	chr5:56927874~56929573:+
THCA	cis	rs1858037	0.867	rs953312	ENSG00000252414.1	RNU6-100P	-3.44	0.000624	0.0366	-0.17	-0.16	Rheumatoid arthritis;	chr2:65340556	chr2:64578892~64578997:+
THCA	cis	rs1858037	0.867	rs9789444	ENSG00000252414.1	RNU6-100P	-3.44	0.000624	0.0366	-0.17	-0.16	Rheumatoid arthritis;	chr2:65342093	chr2:64578892~64578997:+
THCA	cis	rs13720	0.722	rs163800	ENSG00000225806.6	RP1-309F20.3	3.44	0.000624	0.0366	0.16	0.16	Platelet distribution width;	chr20:59003453	chr20:58863528~58888809:-
THCA	cis	rs4578769	0.797	rs1010800	ENSG00000265939.1	UBE2CP2	3.44	0.000624	0.0366	0.19	0.16	Eosinophil percentage of white cells;	chr18:23027857	chr18:22900486~22900995:-
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000281021.1	RP1-12G14.9	-3.44	0.000624	0.0366	-0.16	-0.16	Lung cancer;	chr6:149629690	chr6:149576089~149590864:-
THCA	cis	rs11168618	0.904	rs7136845	ENSG00000240399.1	RP1-228P16.1	3.44	0.000624	0.0366	0.16	0.16	Adiponectin levels;	chr12:48513246	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs431318	ENSG00000237310.1	GS1-124K5.4	3.44	0.000624	0.0366	0.18	0.16	Diabetic kidney disease;	chr7:66046610	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs313803	ENSG00000237310.1	GS1-124K5.4	3.44	0.000624	0.0366	0.18	0.16	Diabetic kidney disease;	chr7:66049744	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs313802	ENSG00000237310.1	GS1-124K5.4	3.44	0.000624	0.0366	0.18	0.16	Diabetic kidney disease;	chr7:66051386	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000237310.1	GS1-124K5.4	3.44	0.000624	0.0366	0.18	0.16	Diabetic kidney disease;	chr7:66052736	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs458291	ENSG00000237310.1	GS1-124K5.4	3.44	0.000624	0.0366	0.18	0.16	Diabetic kidney disease;	chr7:66055492	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs464895	ENSG00000237310.1	GS1-124K5.4	3.44	0.000624	0.0366	0.18	0.16	Diabetic kidney disease;	chr7:66062119	chr7:66493706~66495474:+
THCA	cis	rs7824557	0.547	rs6601570	ENSG00000206014.6	OR7E161P	3.44	0.000624	0.0366	0.19	0.16	Retinal vascular caliber;	chr8:11221858	chr8:11928597~11929563:-
THCA	cis	rs13064411	0.696	rs6438156	ENSG00000243849.1	CFAP44-AS1	3.44	0.000624	0.0366	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113488082	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs13066742	ENSG00000243849.1	CFAP44-AS1	3.44	0.000624	0.0366	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113489576	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs3732803	ENSG00000243849.1	CFAP44-AS1	3.44	0.000624	0.0366	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113493110	chr3:113403991~113433992:+
THCA	cis	rs2243480	1	rs78803505	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65917585	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65920739	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65922691	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65925107	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65926730	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65928032	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65929575	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65929781	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65929865	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000273024.4	INTS4P2	3.44	0.000624	0.0366	0.26	0.16	Diabetic kidney disease;	chr7:65938222	chr7:65647864~65715661:+
THCA	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	3.44	0.000624	0.0366	0.18	0.16	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
THCA	cis	rs12083887	0.583	rs10802023	ENSG00000236866.4	AL157902.3	-3.44	0.000624	0.0367	-0.19	-0.16	Male-pattern baldness;	chr1:118336033	chr1:117596832~117605770:-
THCA	cis	rs2455799	0.613	rs1345157	ENSG00000270409.1	RP11-44D5.1	-3.44	0.000624	0.0367	-0.17	-0.16	Mean platelet volume;	chr3:15854074	chr3:15732252~15733470:+
THCA	cis	rs7142002	0.527	rs4906164	ENSG00000271780.1	RP11-1017G21.5	-3.44	0.000624	0.0367	-0.2	-0.16	Autism;	chr14:101920694	chr14:101948347~101949425:+
THCA	cis	rs8051431	0.504	rs2335711	ENSG00000260886.1	TAT-AS1	3.44	0.000624	0.0367	0.23	0.16	LDL cholesterol levels;	chr16:71873656	chr16:71565789~71578187:+
THCA	cis	rs4931000	1	rs4931000	ENSG00000255760.1	RP11-428G5.5	-3.44	0.000624	0.0367	-0.15	-0.16	Testicular germ cell tumor;	chr12:31988561	chr12:31877079~31887203:-
THCA	cis	rs11168618	0.904	rs11495273	ENSG00000240399.1	RP1-228P16.1	3.44	0.000624	0.0367	0.15	0.16	Adiponectin levels;	chr12:48535407	chr12:48054813~48055591:-
THCA	cis	rs6443245	0.591	rs2542364	ENSG00000227110.5	LMCD1-AS1	-3.44	0.000624	0.0367	-0.18	-0.16	Daytime sleep phenotypes;	chr3:9578384	chr3:7952805~8611924:-
THCA	cis	rs3734729	0.702	rs6922326	ENSG00000231120.3	BTF3P10	3.44	0.000625	0.0367	0.35	0.16	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150223143	chr6:149977922~149978416:+
THCA	cis	rs748404	0.66	rs509306	ENSG00000275601.1	AC011330.13	-3.44	0.000625	0.0367	-0.19	-0.16	Lung cancer;	chr15:43422973	chr15:43642389~43643023:-
THCA	cis	rs3002131	0.688	rs3008650	ENSG00000272750.1	RP11-378J18.8	-3.44	0.000625	0.0367	-0.23	-0.16	Interleukin-10 levels;	chr1:222589873	chr1:222658867~222661512:-
THCA	cis	rs4713118	1	rs13215072	ENSG00000261839.1	RP1-265C24.8	3.44	0.000625	0.0367	0.17	0.16	Parkinson's disease;	chr6:27709949	chr6:28136849~28139678:+
THCA	cis	rs12908161	0.683	rs12903256	ENSG00000230373.7	GOLGA6L5P	-3.44	0.000625	0.0367	-0.16	-0.16	Schizophrenia;	chr15:84764910	chr15:84507885~84516814:-
THCA	cis	rs9634489	0.678	rs4142189	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000625	0.0367	-0.1	-0.16	Body mass index;	chr13:96404220	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.678	rs9300353	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000625	0.0367	-0.1	-0.16	Body mass index;	chr13:96404830	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.678	rs7995859	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000625	0.0367	-0.1	-0.16	Body mass index;	chr13:96405238	chr13:95648733~95676925:-
THCA	cis	rs9309473	1	rs10184268	ENSG00000273245.1	RP11-434P11.2	3.44	0.000625	0.0367	0.21	0.16	Metabolite levels;	chr2:73399916	chr2:73750256~73750786:-
THCA	cis	rs4325129	0.705	rs10797046	ENSG00000272668.1	RP11-190A12.8	3.44	0.000625	0.0367	0.18	0.16	Obesity-related traits;	chr1:159521290	chr1:159866954~159867685:+
THCA	cis	rs5758659	0.652	rs1063392	ENSG00000281538.1	RP4-669P10.20	-3.44	0.000625	0.0367	-0.14	-0.16	Cognitive function;	chr22:42058946	chr22:42138060~42139726:+
THCA	cis	rs4646450	0.838	rs1589739	ENSG00000274272.1	RP11-44M6.7	3.44	0.000625	0.0367	0.17	0.16	Blood metabolite levels;	chr7:99588124	chr7:100572232~100578700:-
THCA	cis	rs4713118	0.869	rs9283881	ENSG00000261839.1	RP1-265C24.8	3.44	0.000625	0.0367	0.18	0.16	Parkinson's disease;	chr6:27747476	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.869	rs9283882	ENSG00000261839.1	RP1-265C24.8	3.44	0.000625	0.0367	0.18	0.16	Parkinson's disease;	chr6:27747479	chr6:28136849~28139678:+
THCA	cis	rs3770081	0.59	rs34522092	ENSG00000273080.1	RP11-301O19.1	-3.44	0.000625	0.0367	-0.36	-0.16	Facial emotion recognition (sad faces);	chr2:85981182	chr2:86195590~86196049:+
THCA	cis	rs4588572	0.537	rs7705718	ENSG00000245556.2	SCAMP1-AS1	-3.44	0.000625	0.0367	-0.12	-0.16	Triglycerides;	chr5:78434525	chr5:78342365~78360507:-
THCA	cis	rs4588572	0.537	rs7702000	ENSG00000245556.2	SCAMP1-AS1	-3.44	0.000625	0.0367	-0.12	-0.16	Triglycerides;	chr5:78434732	chr5:78342365~78360507:-
THCA	cis	rs4588572	0.537	rs7719228	ENSG00000245556.2	SCAMP1-AS1	-3.44	0.000625	0.0367	-0.12	-0.16	Triglycerides;	chr5:78434752	chr5:78342365~78360507:-
THCA	cis	rs35740288	0.929	rs11073537	ENSG00000259407.1	RP11-158M2.3	-3.44	0.000625	0.0367	-0.19	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85769450	chr15:85744109~85750281:-
THCA	cis	rs12520053	0.943	rs77094181	ENSG00000248734.2	CTD-2260A17.1	3.44	0.000625	0.0367	0.22	0.16	Blood protein levels;	chr5:96831412	chr5:96784777~96785999:+
THCA	cis	rs7621331	0.963	rs9842840	ENSG00000239213.4	NCK1-AS1	3.44	0.000625	0.0367	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136017380	chr3:136841726~136862054:-
THCA	cis	rs2562456	0.876	rs10424079	ENSG00000213976.4	CTD-2561J22.2	-3.44	0.000625	0.0367	-0.19	-0.16	Pain;	chr19:21406377	chr19:21382865~21387177:+
THCA	cis	rs3736858	1	rs9544053	ENSG00000261105.4	LMO7-AS1	-3.44	0.000625	0.0367	-0.22	-0.16	Interleukin-9 levels;	chr13:75853716	chr13:75604700~75635994:-
THCA	cis	rs9990333	0.562	rs55970879	ENSG00000185485.13	SDHAP1	3.44	0.000625	0.0367	0.14	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195959748~195990318:-
THCA	cis	rs9990333	0.562	rs75681503	ENSG00000185485.13	SDHAP1	3.44	0.000625	0.0367	0.14	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195959748~195990318:-
THCA	cis	rs4664293	0.867	rs10194483	ENSG00000230783.1	AC009961.2	-3.44	0.000625	0.0367	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159739883	chr2:159689217~159690291:-
THCA	cis	rs13325613	0.667	rs13060713	ENSG00000223552.1	RP11-24F11.2	-3.44	0.000625	0.0367	-0.29	-0.16	Monocyte count;	chr3:46231218	chr3:46364955~46407059:-
THCA	cis	rs950169	0.922	rs11639244	ENSG00000230373.7	GOLGA6L5P	-3.44	0.000625	0.0367	-0.17	-0.16	Schizophrenia;	chr15:84163898	chr15:84507885~84516814:-
THCA	cis	rs3853824	0.636	rs7209070	ENSG00000263089.1	RP11-166P13.4	3.44	0.000625	0.0367	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr17:56868833	chr17:57092145~57096425:-
THCA	cis	rs10492096	1	rs10849462	ENSG00000276718.1	RP1-102E24.10	-3.44	0.000625	0.0367	-0.19	-0.16	Hip geometry;	chr12:6466826	chr12:6466537~6467135:+
THCA	cis	rs4692589	0.606	rs13127322	ENSG00000229204.3	PTGES3P3	-3.44	0.000625	0.0367	-0.2	-0.16	Anxiety disorder;	chr4:170014018	chr4:169791221~169791702:-
THCA	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	3.44	0.000625	0.0367	0.21	0.16	Depression;	chr6:28399846	chr6:28943877~28944537:+
THCA	cis	rs2692947	0.567	rs4907276	ENSG00000235959.1	AC009237.17	3.44	0.000625	0.0367	0.17	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95725361	chr2:95640181~95640604:-
THCA	cis	rs6458307	0.765	rs58897230	ENSG00000231113.2	RP3-475N16.1	-3.44	0.000625	0.0367	-0.15	-0.16	Bipolar disorder;	chr6:42760285	chr6:42940364~42948360:+
THCA	cis	rs7849270	0.842	rs184457	ENSG00000204055.4	RP11-247A12.2	3.44	0.000625	0.0367	0.2	0.16	Blood metabolite ratios;	chr9:129177740	chr9:129176771~129210548:+
THCA	cis	rs10508774	0.587	rs79318780	ENSG00000217094.2	PPIAP31	3.44	0.000625	0.0367	0.3	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32954823	chr10:32188323~32188817:-
THCA	cis	rs7686660	0.956	rs58945764	ENSG00000250326.1	RP11-284M14.1	-3.44	0.000625	0.0367	-0.16	-0.16	Asthma;	chr4:143028554	chr4:142933195~143184861:-
THCA	cis	rs7686660	1	rs11100765	ENSG00000250326.1	RP11-284M14.1	-3.44	0.000625	0.0367	-0.16	-0.16	Asthma;	chr4:143034007	chr4:142933195~143184861:-
THCA	cis	rs875971	0.52	rs160645	ENSG00000232559.3	GS1-124K5.12	-3.44	0.000625	0.0367	-0.17	-0.16	Aortic root size;	chr7:66091320	chr7:66554588~66576923:-
THCA	cis	rs539514	0.612	rs9573648	ENSG00000261105.4	LMO7-AS1	3.44	0.000625	0.0367	0.18	0.16	Type 1 diabetes;	chr13:75735143	chr13:75604700~75635994:-
THCA	cis	rs74997117	0.793	rs4628222	ENSG00000273183.1	RP11-5C23.2	-3.44	0.000625	0.0367	-0.29	-0.16	Sulfasalazine-induced agranulocytosis;	chr7:155047322	chr7:154956429~154957107:+
THCA	cis	rs9987353	0.544	rs2929470	ENSG00000254153.1	CTA-398F10.2	3.44	0.000625	0.0367	0.17	0.16	Recombination measurement;	chr8:9204980	chr8:8456909~8461337:-
THCA	cis	rs539514	0.664	rs1323712	ENSG00000261105.4	LMO7-AS1	3.44	0.000626	0.0367	0.18	0.16	Type 1 diabetes;	chr13:75725949	chr13:75604700~75635994:-
THCA	cis	rs2006933	1	rs2006933	ENSG00000237575.4	PYY2	3.44	0.000626	0.0367	0.2	0.16	Amyotrophic lateral sclerosis;	chr17:28274107	chr17:28226563~28228065:+
THCA	cis	rs6568686	0.786	rs9387014	ENSG00000255389.1	C6orf3	-3.44	0.000626	0.0367	-0.23	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111529338	chr6:111599875~111602295:+
THCA	cis	rs8014204	0.901	rs2080087	ENSG00000279594.1	RP11-950C14.10	3.44	0.000626	0.0367	0.15	0.16	Caffeine consumption;	chr14:74898359	chr14:75011269~75012851:-
THCA	cis	rs293748	0.54	rs13166829	ENSG00000250155.1	CTD-2353F22.1	-3.44	0.000626	0.0367	-0.19	-0.16	Obesity-related traits;	chr5:37222124	chr5:36666214~36725195:-
THCA	cis	rs12476592	0.602	rs2121353	ENSG00000242412.1	DBIL5P2	3.44	0.000626	0.0367	0.21	0.16	Childhood ear infection;	chr2:63672196	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs262526	ENSG00000242412.1	DBIL5P2	3.44	0.000626	0.0367	0.21	0.16	Childhood ear infection;	chr2:63672344	chr2:63117851~63119542:-
THCA	cis	rs889122	1	rs62104262	ENSG00000267289.1	CTD-2623N2.11	3.44	0.000626	0.0367	0.19	0.16	Menarche (age at onset);	chr19:9885902	chr19:9834079~9835013:-
THCA	cis	rs9573567	0.609	rs9565164	ENSG00000261105.4	LMO7-AS1	-3.44	0.000626	0.0367	-0.34	-0.16	Red blood cell count;Mean corpuscular volume;	chr13:75465240	chr13:75604700~75635994:-
THCA	cis	rs6940638	0.688	rs6921388	ENSG00000224843.5	LINC00240	3.44	0.000626	0.0367	0.14	0.16	Intelligence (multi-trait analysis);	chr6:27112426	chr6:26956992~27023924:+
THCA	cis	rs67478160	0.595	rs2295146	ENSG00000258534.1	CTD-2134A5.4	-3.44	0.000626	0.0367	-0.16	-0.16	Schizophrenia;	chr14:103733019	chr14:103854366~103880111:-
THCA	cis	rs11583043	0.708	rs12754497	ENSG00000233184.5	RP11-421L21.3	-3.44	0.000626	0.0367	-0.17	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101106332	chr1:101025878~101087268:+
THCA	cis	rs13279522	0.908	rs11777972	ENSG00000272192.1	CTD-2532N20.1	3.44	0.000626	0.0367	0.2	0.16	Coronary heart disease event reduction (statin therapy interaction);	chr8:66055927	chr8:65842752~65843331:+
THCA	cis	rs948562	0.744	rs12363774	ENSG00000280010.1	AP001350.4	3.44	0.000626	0.0367	0.24	0.16	Lymphoma;	chr11:58457562	chr11:58627435~58628528:+
THCA	cis	rs6546886	0.869	rs12995468	ENSG00000235499.1	AC073046.25	3.44	0.000626	0.0367	0.15	0.16	Dialysis-related mortality;	chr2:74039651	chr2:73985132~73986343:+
THCA	cis	rs875971	0.862	rs1968126	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000626	0.0367	-0.11	-0.16	Aortic root size;	chr7:66592017	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs6460306	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000626	0.0367	-0.11	-0.16	Aortic root size;	chr7:66595806	chr7:66491049~66493566:-
THCA	cis	rs3737883	1	rs4950913	ENSG00000229652.1	RP11-435P24.2	3.44	0.000626	0.0367	0.17	0.16	Early onset atrial fibrillation;	chr1:203063025	chr1:203353365~203353651:-
THCA	cis	rs56114371	0.777	rs200483	ENSG00000220721.1	OR1F12	3.44	0.000626	0.0367	0.27	0.16	Breast cancer;	chr6:27807046	chr6:28073316~28074233:+
THCA	cis	rs17826219	0.562	rs719600	ENSG00000214719.10	AC005562.1	3.44	0.000626	0.0367	0.21	0.16	Body mass index;	chr17:30404244	chr17:30576464~30672789:+
THCA	cis	rs9437689	0.714	rs7537374	ENSG00000235501.4	RP4-639F20.1	-3.44	0.000626	0.0367	-0.18	-0.16	Phospholipid levels (plasma);	chr1:95019868	chr1:94927566~94963270:+
THCA	cis	rs11760485	0.782	rs10249087	ENSG00000270822.1	RP11-730B22.1	3.44	0.000626	0.0367	0.2	0.16	Early childhood aggressive behavior;	chr7:4364494	chr7:5009164~5009328:-
THCA	cis	rs12621844	0.965	rs2348719	ENSG00000272663.1	RP11-191L17.1	-3.44	0.000626	0.0367	-0.14	-0.16	Glycated hemoglobin levels;	chr2:48181348	chr2:48440043~48440597:-
THCA	cis	rs10029851	0.617	rs6852328	ENSG00000234492.4	RPL34-AS1	3.44	0.000626	0.0367	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr4:108692792	chr4:108538190~108620460:-
THCA	cis	rs13064773	0.51	rs340315	ENSG00000272247.1	RP11-379F4.9	3.44	0.000626	0.0367	0.17	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158857800	chr3:158801257~158801935:-
THCA	cis	rs9296092	0.517	rs62405895	ENSG00000272217.1	XXbac-BPG157A10.21	3.44	0.000626	0.0367	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33504192	chr6:33246075~33246856:-
THCA	cis	rs12156238	0.796	rs28680779	ENSG00000280294.1	RP11-177H2.1	3.44	0.000626	0.0367	0.17	0.16	Cisplatin-induced ototoxicity;	chr8:11430531	chr8:10856085~10859436:-
THCA	cis	rs1862618	0.671	rs2591966	ENSG00000271828.1	CTD-2310F14.1	-3.44	0.000626	0.0368	-0.22	-0.16	Initial pursuit acceleration;	chr5:56937861	chr5:56927874~56929573:+
THCA	cis	rs2209875	0.588	rs7469084	ENSG00000265112.1	MIR3153	-3.44	0.000626	0.0368	-0.18	-0.16	Pelvic organ prolapse (moderate/severe);	chr9:89366248	chr9:89312225~89312306:+
THCA	cis	rs730566	1	rs730566	ENSG00000244380.1	RP11-24C3.2	-3.44	0.000626	0.0368	-0.2	-0.16	Prion diseases;	chr3:48445644	chr3:48440352~48446656:-
THCA	cis	rs910316	0.737	rs108622	ENSG00000259138.1	RP11-950C14.7	-3.44	0.000626	0.0368	-0.13	-0.16	Height;	chr14:75015205	chr14:75127153~75136930:+
THCA	cis	rs910316	0.737	rs424120	ENSG00000259138.1	RP11-950C14.7	-3.44	0.000626	0.0368	-0.13	-0.16	Height;	chr14:75016125	chr14:75127153~75136930:+
THCA	cis	rs7267979	0.966	rs2261790	ENSG00000276952.1	RP5-965G21.6	3.44	0.000626	0.0368	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2261794	ENSG00000276952.1	RP5-965G21.6	3.44	0.000626	0.0368	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2145126	ENSG00000276952.1	RP5-965G21.6	3.44	0.000626	0.0368	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2257705	ENSG00000276952.1	RP5-965G21.6	3.44	0.000626	0.0368	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2227892	ENSG00000276952.1	RP5-965G21.6	3.44	0.000626	0.0368	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2257712	ENSG00000276952.1	RP5-965G21.6	3.44	0.000626	0.0368	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2257461	ENSG00000276952.1	RP5-965G21.6	3.44	0.000626	0.0368	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25284915~25285588:-
THCA	cis	rs3121446	0.692	rs78883518	ENSG00000229654.1	RP1-60O19.2	-3.44	0.000626	0.0368	-0.18	-0.16	Daytime sleep phenotypes;	chr6:106713919	chr6:106695535~106699994:+
THCA	cis	rs7824557	0.505	rs2736313	ENSG00000255495.1	AC145124.2	3.44	0.000626	0.0368	0.18	0.16	Retinal vascular caliber;	chr8:11229433	chr8:12194467~12196280:+
THCA	cis	rs11250097	0.501	rs2409665	ENSG00000280294.1	RP11-177H2.1	3.44	0.000626	0.0368	0.13	0.16	Neuroticism;	chr8:10878723	chr8:10856085~10859436:-
THCA	cis	rs3805389	1	rs3805383	ENSG00000273257.1	RP11-177J6.1	-3.44	0.000626	0.0368	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55609171	chr4:55387949~55388271:+
THCA	cis	rs3805389	0.961	rs62308665	ENSG00000273257.1	RP11-177J6.1	-3.44	0.000626	0.0368	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55611630	chr4:55387949~55388271:+
THCA	cis	rs2882667	0.861	rs10037106	ENSG00000249593.5	CTB-46B19.2	3.44	0.000626	0.0368	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:139012647~139051203:+
THCA	cis	rs2882667	0.898	rs6882583	ENSG00000249593.5	CTB-46B19.2	3.44	0.000626	0.0368	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:139012647~139051203:+
THCA	cis	rs2882667	0.898	rs13182437	ENSG00000249593.5	CTB-46B19.2	3.44	0.000626	0.0368	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:139012647~139051203:+
THCA	cis	rs11030122	0.673	rs10835601	ENSG00000230593.3	AC090804.1	3.44	0.000626	0.0368	0.21	0.16	Mean platelet volume;Platelet distribution width;	chr11:4085186	chr11:3892398~3892887:-
THCA	cis	rs1421334	0.781	rs10954769	ENSG00000254109.4	RBPMS-AS1	3.44	0.000627	0.0368	0.16	0.16	Intelligence (multi-trait analysis);	chr8:30981759	chr8:30382119~30385401:-
THCA	cis	rs1421334	0.781	rs11775011	ENSG00000254109.4	RBPMS-AS1	3.44	0.000627	0.0368	0.16	0.16	Intelligence (multi-trait analysis);	chr8:30981778	chr8:30382119~30385401:-
THCA	cis	rs10089	1	rs13357268	ENSG00000245937.6	LINC01184	3.44	0.000627	0.0368	0.18	0.16	Ileal carcinoids;	chr5:128087359	chr5:127940426~128083172:-
THCA	cis	rs13118159	0.742	rs7679860	ENSG00000254094.1	AC078852.1	-3.44	0.000627	0.0368	-0.18	-0.16	Longevity;	chr4:1340199	chr4:1356581~1358075:+
THCA	cis	rs42648	0.837	rs4728879	ENSG00000225498.1	AC002064.5	3.44	0.000627	0.0368	0.16	0.16	Homocysteine levels;	chr7:90294923	chr7:90312496~90322592:+
THCA	cis	rs42648	0.837	rs12375075	ENSG00000225498.1	AC002064.5	3.44	0.000627	0.0368	0.16	0.16	Homocysteine levels;	chr7:90311017	chr7:90312496~90322592:+
THCA	cis	rs875971	0.571	rs78668714	ENSG00000230295.1	RP11-458F8.2	3.44	0.000627	0.0368	0.14	0.16	Aortic root size;	chr7:66474464	chr7:66880708~66882981:+
THCA	cis	rs2562456	0.793	rs73537884	ENSG00000268278.1	RP11-420K14.1	3.44	0.000627	0.0368	0.22	0.16	Pain;	chr19:21321908	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs78467454	ENSG00000268278.1	RP11-420K14.1	3.44	0.000627	0.0368	0.22	0.16	Pain;	chr19:21321930	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.833	rs55790393	ENSG00000268278.1	RP11-420K14.1	3.44	0.000627	0.0368	0.22	0.16	Pain;	chr19:21323382	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.793	rs11672341	ENSG00000268278.1	RP11-420K14.1	3.44	0.000627	0.0368	0.22	0.16	Pain;	chr19:21324502	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.754	rs11673234	ENSG00000268278.1	RP11-420K14.1	3.44	0.000627	0.0368	0.22	0.16	Pain;	chr19:21324800	chr19:21637974~21656300:+
THCA	cis	rs2562456	0.754	rs11673320	ENSG00000268278.1	RP11-420K14.1	3.44	0.000627	0.0368	0.22	0.16	Pain;	chr19:21324801	chr19:21637974~21656300:+
THCA	cis	rs3739034	1	rs3739036	ENSG00000224043.6	CCNT2-AS1	3.44	0.000627	0.0368	0.19	0.16	Gut microbiome composition (winter);	chr2:134725964	chr2:134735464~134918710:-
THCA	cis	rs6546886	0.871	rs4422181	ENSG00000235499.1	AC073046.25	3.44	0.000627	0.0368	0.15	0.16	Dialysis-related mortality;	chr2:74012459	chr2:73985132~73986343:+
THCA	cis	rs1943345	0.536	rs12269817	ENSG00000254551.1	RP11-727A23.7	3.44	0.000627	0.0368	0.18	0.16	Obesity-related traits;	chr11:83147625	chr11:83209431~83213379:-
THCA	cis	rs2337406	0.866	rs988130	ENSG00000280411.1	IGHV1-69-2	-3.44	0.000627	0.0368	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106777154	chr14:106762092~106762588:-
THCA	cis	rs6968419	0.761	rs7808705	ENSG00000237870.5	AC073130.1	3.44	0.000627	0.0368	0.16	0.16	Intraocular pressure;	chr7:116144284	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.761	rs6964941	ENSG00000237870.5	AC073130.1	3.44	0.000627	0.0368	0.16	0.16	Intraocular pressure;	chr7:116145742	chr7:116275606~116286734:-
THCA	cis	rs5752326	0.558	rs737800	ENSG00000261188.1	CTA-445C9.14	3.44	0.000627	0.0368	0.16	0.16	Ischemic stroke;	chr22:26467593	chr22:26512537~26514568:+
THCA	cis	rs11098499	0.913	rs12186259	ENSG00000249244.1	RP11-548H18.2	3.44	0.000627	0.0368	0.18	0.16	Corneal astigmatism;	chr4:119230884	chr4:119391831~119395335:-
THCA	cis	rs6568686	0.592	rs12202987	ENSG00000255389.1	C6orf3	3.44	0.000627	0.0368	0.22	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111125255	chr6:111599875~111602295:+
THCA	cis	rs13064411	0.66	rs1872747	ENSG00000243849.1	CFAP44-AS1	3.44	0.000627	0.0368	0.26	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113456938	chr3:113403991~113433992:+
THCA	cis	rs7311936	1	rs11057464	ENSG00000270130.1	RP11-214K3.23	-3.44	0.000627	0.0368	-0.17	-0.16	Vertical cup-disc ratio;	chr12:124150010	chr12:123960717~123961244:-
THCA	cis	rs6715793	0.839	rs17567417	ENSG00000272754.1	AL133245.2	-3.44	0.000627	0.0368	-0.18	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33205536	chr2:32321638~32323002:+
THCA	cis	rs364477	0.859	rs279893	ENSG00000227914.3	RP11-130C19.3	3.44	0.000627	0.0368	0.28	0.16	Major depressive disorder;	chr9:969593	chr9:673478~685555:-
THCA	cis	rs4218	0.531	rs12101733	ENSG00000259732.1	RP11-59H7.3	-3.44	0.000627	0.0368	-0.21	-0.16	Social communication problems;	chr15:59047566	chr15:59121034~59133250:+
THCA	cis	rs2665103	0.715	rs11639440	ENSG00000259429.4	UBE2Q2P2	-3.44	0.000627	0.0368	-0.13	-0.16	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82355142~82420075:+
THCA	cis	rs1048886	0.872	rs80232745	ENSG00000271967.1	RP11-134K13.4	-3.44	0.000627	0.0368	-0.19	-0.16	Type 2 diabetes;	chr6:70492385	chr6:70596438~70596980:+
THCA	cis	rs285757	0.895	rs12908852	ENSG00000259064.2	RP11-386M24.5	3.44	0.000627	0.0368	0.24	0.16	HIV-1 susceptibility;	chr15:92648809	chr15:92627073~92627414:+
THCA	cis	rs10911902	0.643	rs3820182	ENSG00000233196.2	GS1-304P7.1	3.44	0.000627	0.0368	0.24	0.16	Schizophrenia;	chr1:186321201	chr1:186580515~186581191:-
THCA	cis	rs6163	0.588	rs12763284	ENSG00000213061.2	PFN1P11	-3.44	0.000627	0.0368	-0.18	-0.16	Waist circumference;Hip circumference;	chr10:102748445	chr10:102838011~102845473:-
THCA	cis	rs875971	0.862	rs1860469	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000627	0.0368	-0.11	-0.16	Aortic root size;	chr7:66641888	chr7:66491049~66493566:-
THCA	cis	rs875971	0.862	rs4718383	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000627	0.0368	-0.11	-0.16	Aortic root size;	chr7:66643422	chr7:66491049~66493566:-
THCA	cis	rs7122539	0.647	rs2167457	ENSG00000275484.1	CTC-1337H24.4	-3.44	0.000627	0.0368	-0.13	-0.16	HIV-1 susceptibility;	chr11:66874925	chr11:67374416~67374932:+
THCA	cis	rs10832963	1	rs11024739	ENSG00000256361.1	RP11-613F22.6	-3.44	0.000627	0.0368	-0.2	-0.16	Breast cancer;	chr11:18624296	chr11:18511043~18511475:-
THCA	cis	rs939960	0.959	rs11769703	ENSG00000276538.1	RP11-545G3.2	3.44	0.000627	0.0368	0.23	0.16	Neutrophil percentage of white cells;	chr7:150569747	chr7:150047609~150047854:-
THCA	cis	rs12101261	0.744	rs55945219	ENSG00000258915.1	BHLHB9P1	-3.44	0.000627	0.0368	-0.2	-0.16	Graves' disease;	chr14:80990269	chr14:80981988~80983638:+
THCA	cis	rs3808502	0.526	rs7822958	ENSG00000206014.6	OR7E161P	3.44	0.000627	0.0368	0.18	0.16	Neuroticism;	chr8:11564933	chr8:11928597~11929563:-
THCA	cis	rs8028182	0.537	rs4371118	ENSG00000260274.1	RP11-817O13.8	-3.44	0.000627	0.0368	-0.13	-0.16	Sudden cardiac arrest;	chr15:75606549	chr15:75368155~75369584:+
THCA	cis	rs718314	0.956	rs4963975	ENSG00000255750.4	RP11-283G6.5	3.44	0.000627	0.0368	0.16	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26290097	chr12:26230819~26319720:-
THCA	cis	rs7824557	0.505	rs2736313	ENSG00000254527.1	ENPP7P12	3.44	0.000627	0.0368	0.2	0.16	Retinal vascular caliber;	chr8:11229433	chr8:12205759~12206389:-
THCA	cis	rs2658782	0.724	rs2248020	ENSG00000234106.3	RP11-288E14.2	3.44	0.000628	0.0368	0.18	0.16	Pulmonary function decline;	chr11:93526799	chr11:93535468~93535816:+
THCA	cis	rs34779708	0.966	rs6481941	ENSG00000233200.1	RP11-324I22.2	3.44	0.000628	0.0368	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35219894~35230598:-
THCA	cis	rs720064	0.557	rs12969459	ENSG00000264745.1	TTC39C-AS1	3.44	0.000628	0.0368	0.17	0.16	Strep throat;	chr18:23922095	chr18:23994213~24015339:-
THCA	cis	rs12681963	0.541	rs7010163	ENSG00000272375.1	RP11-51J9.6	3.44	0.000628	0.0368	0.23	0.16	Migraine;	chr8:30225049	chr8:30197404~30198048:+
THCA	cis	rs55702914	0.628	rs788016	ENSG00000231621.1	AC013264.2	3.44	0.000628	0.0368	0.15	0.16	Major depression and alcohol dependence;	chr2:197487569	chr2:197197991~197199273:+
THCA	cis	rs6840360	1	rs10007167	ENSG00000251611.1	RP11-610P16.1	-3.44	0.000628	0.0368	-0.11	-0.16	Intelligence (multi-trait analysis);	chr4:151682503	chr4:151407551~151408835:-
THCA	cis	rs394563	0.601	rs439495	ENSG00000268592.3	RAET1E-AS1	-3.44	0.000628	0.0368	-0.22	-0.16	Dupuytren's disease;	chr6:149472088	chr6:149863494~149919507:+
THCA	cis	rs7819412	0.669	rs6601568	ENSG00000255046.1	RP11-297N6.4	3.44	0.000628	0.0368	0.17	0.16	Triglycerides;	chr8:11215893	chr8:11797928~11802568:-
THCA	cis	rs7216064	1	rs6504555	ENSG00000278740.1	RP11-147L13.14	-3.44	0.000628	0.0368	-0.18	-0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67944611	chr17:68188547~68189165:+
THCA	cis	rs513088	0.681	rs506349	ENSG00000225171.2	DUTP6	3.44	0.000628	0.0368	0.22	0.16	Schizophrenia;	chr1:166673214	chr1:166868748~166869209:+
THCA	cis	rs513088	0.681	rs12142855	ENSG00000225171.2	DUTP6	3.44	0.000628	0.0368	0.22	0.16	Schizophrenia;	chr1:166685613	chr1:166868748~166869209:+
THCA	cis	rs7081476	0.737	rs4747594	ENSG00000262412.1	RP11-85G18.6	-3.44	0.000628	0.0368	-0.39	-0.16	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr10:27222114	chr10:27243130~27250804:+
THCA	cis	rs9309711	0.961	rs11890651	ENSG00000271868.1	RP11-1293J14.1	-3.44	0.000628	0.0368	-0.21	-0.16	Neurofibrillary tangles;	chr2:3479025	chr2:3496956~3497428:+
THCA	cis	rs57709857	0.957	rs12678205	ENSG00000272092.1	RP11-350N15.5	-3.44	0.000628	0.0368	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38382490	chr8:38382364~38383461:+
THCA	cis	rs7192750	0.586	rs8050488	ENSG00000260886.1	TAT-AS1	3.44	0.000628	0.0368	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71877567	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.586	rs2288029	ENSG00000260886.1	TAT-AS1	3.44	0.000628	0.0368	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71883155	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.517	rs9932922	ENSG00000260886.1	TAT-AS1	3.44	0.000628	0.0368	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71884275	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.586	rs4788570	ENSG00000260886.1	TAT-AS1	3.44	0.000628	0.0368	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71886241	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.562	rs4788573	ENSG00000260886.1	TAT-AS1	3.44	0.000628	0.0368	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71888043	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.586	rs9806882	ENSG00000260886.1	TAT-AS1	3.44	0.000628	0.0368	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71891608	chr16:71565789~71578187:+
THCA	cis	rs7412746	0.611	rs6660084	ENSG00000224800.1	RP11-235D19.2	-3.44	0.000628	0.0368	-0.21	-0.16	Melanoma;	chr1:150776327	chr1:150881236~150881683:-
THCA	cis	rs6449957	0.639	rs251397	ENSG00000249335.1	CTC-340D7.1	3.44	0.000628	0.0368	0.19	0.16	Cleft lip with or without cleft palate;	chr5:68212683	chr5:68832585~68962158:-
THCA	cis	rs1656402	1	rs1190442	ENSG00000263941.2	RN7SL32P	3.44	0.000628	0.0368	0.21	0.16	Non-small cell lung cancer (survival);	chr2:232557495	chr2:233205199~233205479:+
THCA	cis	rs6657613	0.903	rs2871776	ENSG00000186715.9	MST1L	3.44	0.000628	0.0368	0.13	0.16	Hip circumference adjusted for BMI;	chr1:17001806	chr1:16754910~16770237:-
THCA	cis	rs7267979	0.565	rs13040726	ENSG00000277938.1	RP5-965G21.3	-3.44	0.000628	0.0368	-0.13	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:25229150~25231933:+
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000264242.2	RP11-271K11.1	3.44	0.000628	0.0368	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30553697~30558962:+
THCA	cis	rs9392556	0.829	rs7744628	ENSG00000230648.1	RP3-406P24.3	-3.44	0.000628	0.0368	-0.2	-0.16	Blood metabolite levels;	chr6:4119762	chr6:4018843~4021215:-
THCA	cis	rs5167	0.82	rs204468	ENSG00000186019.10	AC084219.4	3.44	0.000628	0.0368	0.18	0.16	Blood protein levels;	chr19:44987378	chr19:44105463~44113145:-
THCA	cis	rs2483519	0.54	rs11196855	ENSG00000228484.1	RP11-106M7.1	3.44	0.000628	0.0368	0.17	0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114670807	chr10:114764788~114779903:+
THCA	cis	rs6921919	0.945	rs7765989	ENSG00000273712.1	RP5-874C20.7	3.44	0.000628	0.0368	0.21	0.16	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28315613~28315883:-
THCA	cis	rs140174	0.763	rs131421	ENSG00000211673.2	IGLV3-1	-3.44	0.000628	0.0368	-0.1	-0.16	Migraine;	chr22:23579015	chr22:22880706~22881396:+
THCA	cis	rs10875746	0.68	rs4760610	ENSG00000275228.1	RP11-370I10.10	3.44	0.000628	0.0368	0.18	0.16	Longevity (90 years and older);	chr12:48024442	chr12:48327942~48328472:-
THCA	cis	rs11637445	0.677	rs3784713	ENSG00000260657.2	RP11-315D16.4	-3.44	0.000628	0.0368	-0.2	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67780675	chr15:68267792~68277994:-
THCA	cis	rs875971	1	rs7792762	ENSG00000272831.1	RP11-792A8.4	3.44	0.000628	0.0368	0.1	0.16	Aortic root size;	chr7:66539151	chr7:66739829~66740385:-
THCA	cis	rs1669338	0.588	rs6784329	ENSG00000271870.1	RP11-97C16.1	3.44	0.000628	0.0368	0.15	0.16	White matter integrity;	chr3:3158329	chr3:3152942~3153435:+
THCA	cis	rs721048	0.85	rs13427868	ENSG00000242412.1	DBIL5P2	-3.44	0.000628	0.0368	-0.21	-0.16	Prostate cancer;	chr2:63198296	chr2:63117851~63119542:-
THCA	cis	rs1959947	0.876	rs1959909	ENSG00000251363.2	RP11-129M6.1	3.44	0.000628	0.0368	0.21	0.16	Hemostatic factors and hematological phenotypes;	chr14:41088123	chr14:40954898~40975877:+
THCA	cis	rs1959947	0.876	rs6572057	ENSG00000251363.2	RP11-129M6.1	3.44	0.000628	0.0368	0.21	0.16	Hemostatic factors and hematological phenotypes;	chr14:41088483	chr14:40954898~40975877:+
THCA	cis	rs7122539	0.646	rs682842	ENSG00000275484.1	CTC-1337H24.4	3.44	0.000628	0.0368	0.11	0.16	HIV-1 susceptibility;	chr11:66801472	chr11:67374416~67374932:+
THCA	cis	rs11992162	0.551	rs35010200	ENSG00000255046.1	RP11-297N6.4	3.44	0.000628	0.0368	0.17	0.16	Monocyte count;	chr8:11928146	chr8:11797928~11802568:-
THCA	cis	rs7615952	0.932	rs3811679	ENSG00000248787.1	RP11-666A20.4	-3.44	0.000628	0.0368	-0.27	-0.16	Blood pressure (smoking interaction);	chr3:125929440	chr3:125908005~125910272:-
THCA	cis	rs9611565	0.592	rs80477	ENSG00000237037.8	NDUFA6-AS1	-3.44	0.000628	0.0368	-0.14	-0.16	Vitiligo;	chr22:41605179	chr22:42090931~42137742:+
THCA	cis	rs939960	0.917	rs6970850	ENSG00000276538.1	RP11-545G3.2	3.44	0.000628	0.0368	0.22	0.16	Neutrophil percentage of white cells;	chr7:150613376	chr7:150047609~150047854:-
THCA	cis	rs939960	0.917	rs6971133	ENSG00000276538.1	RP11-545G3.2	3.44	0.000628	0.0368	0.22	0.16	Neutrophil percentage of white cells;	chr7:150613384	chr7:150047609~150047854:-
THCA	cis	rs2797160	0.904	rs1612274	ENSG00000226409.1	RP11-735G4.1	3.44	0.000628	0.0369	0.18	0.16	Endometrial cancer;	chr6:125693761	chr6:125370211~125374324:-
THCA	cis	rs4767841	0.537	rs413236	ENSG00000252886.1	RN7SKP197	-3.44	0.000628	0.0369	-0.15	-0.16	Urgency urinary incontinence;	chr12:119790268	chr12:119631090~119631386:-
THCA	cis	rs950027	0.62	rs1617984	ENSG00000259479.5	SORD2P	3.44	0.000629	0.0369	0.16	0.16	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:44826371~44884694:-
THCA	cis	rs12476592	0.602	rs2604613	ENSG00000242412.1	DBIL5P2	3.44	0.000629	0.0369	0.2	0.16	Childhood ear infection;	chr2:63605642	chr2:63117851~63119542:-
THCA	cis	rs12476592	0.602	rs262472	ENSG00000242412.1	DBIL5P2	3.44	0.000629	0.0369	0.2	0.16	Childhood ear infection;	chr2:63606482	chr2:63117851~63119542:-
THCA	cis	rs753274	0.65	rs28497965	ENSG00000267147.2	CTC-548K16.1	-3.44	0.000629	0.0369	-0.21	-0.16	Tumor necrosis factor beta levels;	chr19:14306590	chr19:14333743~14343916:+
THCA	cis	rs9487094	0.67	rs1885691	ENSG00000223537.2	RP5-919F19.5	-3.44	0.000629	0.0369	-0.16	-0.16	Height;	chr6:109382188	chr6:109487906~109506800:+
THCA	cis	rs9303542	0.729	rs56655886	ENSG00000278765.1	RP5-890E16.5	-3.44	0.000629	0.0369	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48449529	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs35387091	ENSG00000278765.1	RP5-890E16.5	-3.44	0.000629	0.0369	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48450876	chr17:48066704~48067293:-
THCA	cis	rs17428076	0.83	rs6704590	ENSG00000228389.1	AC068039.4	-3.44	0.000629	0.0369	-0.19	-0.16	Myopia;	chr2:172013647	chr2:171773482~171775844:+
THCA	cis	rs1832871	0.683	rs62437360	ENSG00000213078.3	RP5-933K21.2	-3.44	0.000629	0.0369	-0.23	-0.16	Height;	chr6:158299130	chr6:157365990~157366923:-
THCA	cis	rs931127	0.505	rs2306362	ENSG00000255320.1	RP11-755F10.1	3.44	0.000629	0.0369	0.22	0.16	Systemic lupus erythematosus;	chr11:65638039	chr11:66244840~66246239:-
THCA	cis	rs17376456	0.597	rs1031423	ENSG00000254132.1	MTND6P3	3.44	0.000629	0.0369	0.21	0.16	Diabetic retinopathy;	chr5:93941178	chr5:94568929~94569470:-
THCA	cis	rs2638953	0.814	rs10843164	ENSG00000247934.4	RP11-967K21.1	-3.44	0.000629	0.0369	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416781	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049583	ENSG00000247934.4	RP11-967K21.1	-3.44	0.000629	0.0369	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417238	chr12:28163298~28190738:-
THCA	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	3.44	0.000629	0.0369	0.18	0.16	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
THCA	cis	rs17301013	0.932	rs3737651	ENSG00000270084.1	GAS5-AS1	3.44	0.000629	0.0369	0.16	0.16	Systemic lupus erythematosus;	chr1:174475414	chr1:173863248~173863941:+
THCA	cis	rs708224	0.587	rs2728802	ENSG00000277342.1	RP11-843B15.4	3.44	0.000629	0.0369	0.2	0.16	Pancreatic cancer;	chr12:32252307	chr12:32109076~32109602:+
THCA	cis	rs354225	1	rs354225	ENSG00000162997.14	PRORSD1P	-3.44	0.000629	0.0369	-0.16	-0.16	Schizophrenia;	chr2:54696629	chr2:55282319~55284522:+
THCA	cis	rs354225	0.584	rs10188545	ENSG00000212175.1	SNORA12	-3.44	0.000629	0.0369	-0.2	-0.16	Schizophrenia;	chr2:54604738	chr2:55565703~55565850:+
THCA	cis	rs9549260	0.755	rs1413482	ENSG00000275149.1	RP11-427J23.1	-3.44	0.000629	0.0369	-0.21	-0.16	Red blood cell count;	chr13:40644314	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.755	rs7993233	ENSG00000275149.1	RP11-427J23.1	-3.44	0.000629	0.0369	-0.21	-0.16	Red blood cell count;	chr13:40645297	chr13:40079106~40273509:-
THCA	cis	rs17685	0.753	rs6951943	ENSG00000227038.2	AC005077.12	3.44	0.000629	0.0369	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76143134	chr7:76090431~76108779:-
THCA	cis	rs6432852	0.966	rs6432851	ENSG00000232411.1	AC009495.3	-3.44	0.000629	0.0369	-0.17	-0.16	Diabetic kidney disease;	chr2:165892403	chr2:165833048~165839098:-
THCA	cis	rs2665103	0.715	rs7403041	ENSG00000259429.4	UBE2Q2P2	3.44	0.000629	0.0369	0.13	0.16	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82355142~82420075:+
THCA	cis	rs7616559	0.887	rs7621842	ENSG00000244515.1	KRT18P34	-3.44	0.000629	0.0369	-0.21	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:156993638	chr3:157162663~157163932:-
THCA	cis	rs9488822	0.676	rs12202641	ENSG00000233558.1	RP3-486I3.4	-3.44	0.000629	0.0369	-0.18	-0.16	LDL cholesterol;Cholesterol, total;	chr6:115993471	chr6:116258493~116259115:-
THCA	cis	rs6929812	0.702	rs979352	ENSG00000216915.2	RP1-97D16.1	3.44	0.000629	0.0369	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27433417	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.702	rs6908086	ENSG00000216915.2	RP1-97D16.1	3.44	0.000629	0.0369	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27434244	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.702	rs6914585	ENSG00000216915.2	RP1-97D16.1	3.44	0.000629	0.0369	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27435566	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.702	rs12197858	ENSG00000216915.2	RP1-97D16.1	3.44	0.000629	0.0369	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27436992	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.702	rs10484397	ENSG00000216915.2	RP1-97D16.1	3.44	0.000629	0.0369	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27437904	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.665	rs12200018	ENSG00000216915.2	RP1-97D16.1	3.44	0.000629	0.0369	0.21	0.16	Neuroticism (multi-trait analysis);	chr6:27438377	chr6:27737000~27738494:-
THCA	cis	rs1383484	0.754	rs8038109	ENSG00000225151.9	GOLGA2P7	3.44	0.000629	0.0369	0.22	0.16	Height;	chr15:83913552	chr15:84199311~84230136:-
THCA	cis	rs7216064	0.953	rs11079705	ENSG00000265055.1	AC145343.2	3.44	0.000629	0.0369	0.23	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839336	chr17:68096046~68101474:-
THCA	cis	rs7216064	1	rs11079706	ENSG00000265055.1	AC145343.2	3.44	0.000629	0.0369	0.23	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839354	chr17:68096046~68101474:-
THCA	cis	rs16975963	0.644	rs11666662	ENSG00000276846.1	CTD-3220F14.3	3.44	0.000629	0.0369	0.15	0.16	Longevity;	chr19:37663801	chr19:37314868~37315620:-
THCA	cis	rs12476592	0.543	rs12713494	ENSG00000242412.1	DBIL5P2	3.44	0.000629	0.0369	0.2	0.16	Childhood ear infection;	chr2:63471028	chr2:63117851~63119542:-
THCA	cis	rs11800820	0.521	rs3124109	ENSG00000231612.1	RP11-522M21.3	3.44	0.000629	0.0369	0.21	0.16	Obesity-related traits;	chr1:246542250	chr1:245673732~245676478:-
THCA	cis	rs2115630	1	rs6496452	ENSG00000259295.5	CSPG4P12	-3.44	0.000629	0.0369	-0.2	-0.16	P wave terminal force;	chr15:84829414	chr15:85191438~85213905:+
THCA	cis	rs9488822	0.676	rs868943	ENSG00000237021.2	RP3-486I3.7	3.44	0.000629	0.0369	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116016340	chr6:116254207~116256743:+
THCA	cis	rs9488822	0.597	rs12214881	ENSG00000237021.2	RP3-486I3.7	3.44	0.000629	0.0369	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116021024	chr6:116254207~116256743:+
THCA	cis	rs28510890	0.789	rs10852176	ENSG00000258676.4	RP11-386M24.3	3.44	0.000629	0.0369	0.17	0.16	Lung cancer in ever smokers;	chr15:92588701	chr15:92580829~92600545:+
THCA	cis	rs9488822	0.676	rs13194714	ENSG00000233558.1	RP3-486I3.4	3.44	0.000629	0.0369	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116073656	chr6:116258493~116259115:-
THCA	cis	rs2524276	1	rs2524276	ENSG00000256166.1	XXbac-BPG248L24.13	-3.44	0.000629	0.0369	-0.32	-0.16	Capecitabine sensitivity;	chr6:31440488	chr6:31293908~31301642:-
THCA	cis	rs6565180	0.962	rs35480350	ENSG00000274678.1	RP11-2C24.7	-3.44	0.000629	0.0369	-0.15	-0.16	Tonsillectomy;	chr16:30354718	chr16:30821338~30821884:+
THCA	cis	rs11710088	0.74	rs13092900	ENSG00000244503.1	RP11-278L15.6	3.44	0.000629	0.0369	0.22	0.16	QRS duration;	chr3:149473313	chr3:149494660~149495995:+
THCA	cis	rs11710088	0.74	rs13076896	ENSG00000244503.1	RP11-278L15.6	3.44	0.000629	0.0369	0.22	0.16	QRS duration;	chr3:149474494	chr3:149494660~149495995:+
THCA	cis	rs11710088	0.74	rs10935760	ENSG00000244503.1	RP11-278L15.6	3.44	0.000629	0.0369	0.22	0.16	QRS duration;	chr3:149475636	chr3:149494660~149495995:+
THCA	cis	rs11710088	0.74	rs73152634	ENSG00000244503.1	RP11-278L15.6	3.44	0.000629	0.0369	0.22	0.16	QRS duration;	chr3:149478717	chr3:149494660~149495995:+
THCA	cis	rs867186	0.92	rs6060242	ENSG00000126005.14	MMP24-AS1	-3.44	0.000629	0.0369	-0.23	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35110213	chr20:35216462~35278131:-
THCA	cis	rs11643654	0.745	rs1965024	ENSG00000280344.1	AC009166.7	-3.44	0.000629	0.0369	-0.13	-0.16	Educational attainment (years of education);	chr16:51139648	chr16:51176066~51178898:+
THCA	cis	rs7819412	0.838	rs3021494	ENSG00000255046.1	RP11-297N6.4	3.44	0.000629	0.0369	0.17	0.16	Triglycerides;	chr8:11126024	chr8:11797928~11802568:-
THCA	cis	rs3204270	0.639	rs79193599	ENSG00000266445.1	RP13-991F5.2	3.44	0.000629	0.0369	0.28	0.16	Dental caries;	chr17:81684460	chr17:82476597~82477924:-
THCA	cis	rs9308731	1	rs1980045	ENSG00000204581.2	AC096670.3	-3.44	0.00063	0.0369	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:111146964	chr2:111098345~111115588:-
THCA	cis	rs2797160	1	rs1777226	ENSG00000226409.1	RP11-735G4.1	3.44	0.00063	0.0369	0.19	0.16	Endometrial cancer;	chr6:125696545	chr6:125370211~125374324:-
THCA	cis	rs2821260	0.703	rs2630400	ENSG00000227207.2	RPL31P12	3.44	0.00063	0.0369	0.17	0.16	Intelligence (multi-trait analysis);	chr1:72118080	chr1:72301472~72301829:+
THCA	cis	rs2832191	0.791	rs2832179	ENSG00000176054.6	RPL23P2	-3.44	0.00063	0.0369	-0.13	-0.16	Dental caries;	chr21:29108045	chr21:28997613~28998033:-
THCA	cis	rs2832191	0.791	rs4817270	ENSG00000176054.6	RPL23P2	-3.44	0.00063	0.0369	-0.13	-0.16	Dental caries;	chr21:29108047	chr21:28997613~28998033:-
THCA	cis	rs2832191	0.791	rs2832182	ENSG00000176054.6	RPL23P2	-3.44	0.00063	0.0369	-0.13	-0.16	Dental caries;	chr21:29109291	chr21:28997613~28998033:-
THCA	cis	rs642858	0.956	rs9376483	ENSG00000234147.1	RP3-460G2.2	-3.44	0.00063	0.0369	-0.21	-0.16	Type 2 diabetes;	chr6:139990104	chr6:140845958~140852924:-
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000275400.1	RP4-756H11.5	-3.44	0.00063	0.0369	-0.15	-0.16	Corneal structure;	chr7:66925268	chr7:66553805~66554199:-
THCA	cis	rs9788682	1	rs57064725	ENSG00000261143.1	ADAMTS7P3	-3.44	0.00063	0.0369	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78540694	chr15:77976042~77993057:+
THCA	cis	rs77204473	0.744	rs2269399	ENSG00000276505.1	CMB9-94B1.2	-3.44	0.00063	0.0369	-0.29	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117297005~117297328:-
THCA	cis	rs17122278	0.932	rs11216921	ENSG00000243431.1	RPL5P30	3.44	0.00063	0.0369	0.16	0.16	Total cholesterol levels;	chr11:118594100	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs7115634	ENSG00000243431.1	RPL5P30	3.44	0.00063	0.0369	0.16	0.16	Total cholesterol levels;	chr11:118595534	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs11216924	ENSG00000243431.1	RPL5P30	3.44	0.00063	0.0369	0.16	0.16	Total cholesterol levels;	chr11:118599377	chr11:118560690~118561580:+
THCA	cis	rs476633	0.595	rs11857726	ENSG00000247556.5	OIP5-AS1	3.44	0.00063	0.0369	0.13	0.16	Glomerular filtration rate (creatinine);	chr15:41238161	chr15:41283990~41309737:+
THCA	cis	rs889014	0.5	rs11747139	ENSG00000253959.1	CTB-43E15.1	3.44	0.00063	0.0369	0.22	0.16	Height;	chr5:173567741	chr5:173642519~173658194:+
THCA	cis	rs9921338	0.561	rs11859280	ENSG00000262636.1	CTD-3088G3.4	-3.44	0.00063	0.0369	-0.31	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11376515	chr16:11380859~11381118:-
THCA	cis	rs975752	0.867	rs11190430	ENSG00000227492.1	RP11-316M21.6	3.44	0.00063	0.0369	0.3	0.16	Schizophrenia;	chr10:100224788	chr10:100229667~100234000:+
THCA	cis	rs975752	0.867	rs12247992	ENSG00000227492.1	RP11-316M21.6	3.44	0.00063	0.0369	0.3	0.16	Schizophrenia;	chr10:100225330	chr10:100229667~100234000:+
THCA	cis	rs975752	0.571	rs6584353	ENSG00000227492.1	RP11-316M21.6	3.44	0.00063	0.0369	0.3	0.16	Schizophrenia;	chr10:100227298	chr10:100229667~100234000:+
THCA	cis	rs9828933	0.882	rs3733127	ENSG00000224479.4	AC136289.1	3.44	0.00063	0.0369	0.24	0.16	Type 2 diabetes;	chr3:64002498	chr3:63742293~63827445:-
THCA	cis	rs3902035	0.704	rs62424002	ENSG00000253194.1	RP11-351A11.1	3.44	0.00063	0.0369	0.27	0.16	QT interval;	chr6:118703494	chr6:118934785~119031541:+
THCA	cis	rs42648	0.869	rs6973816	ENSG00000225498.1	AC002064.5	3.44	0.00063	0.0369	0.16	0.16	Homocysteine levels;	chr7:90291758	chr7:90312496~90322592:+
THCA	cis	rs4938303	0.788	rs61906115	ENSG00000254851.1	RP11-109L13.1	3.44	0.00063	0.0369	0.24	0.16	Triglycerides;	chr11:116687529	chr11:117135528~117138582:+
THCA	cis	rs4857855	0.735	rs7631955	ENSG00000273174.1	RP11-434H6.6	-3.44	0.00063	0.0369	-0.2	-0.16	Eosinophil counts;	chr3:128529662	chr3:129123439~129124003:+
THCA	cis	rs6762	0.748	rs7929032	ENSG00000255284.1	AP006621.5	3.44	0.00063	0.0369	0.11	0.16	Mean platelet volume;	chr11:839078	chr11:777578~784297:+
THCA	cis	rs6762	0.748	rs7936838	ENSG00000255284.1	AP006621.5	3.44	0.00063	0.0369	0.11	0.16	Mean platelet volume;	chr11:839093	chr11:777578~784297:+
THCA	cis	rs17689437	0.647	rs1645980	ENSG00000260084.1	RP11-615I2.1	3.44	0.00063	0.0369	0.19	0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68537716	chr16:68573782~68589512:-
THCA	cis	rs17772222	0.675	rs845758	ENSG00000222990.1	RNU4-22P	-3.44	0.00063	0.0369	-0.19	-0.16	Coronary artery calcification;	chr14:88433746	chr14:88513498~88513663:+
THCA	cis	rs10911363	0.592	rs4047798	ENSG00000232860.6	SMG7-AS1	3.44	0.00063	0.0369	0.12	0.16	Systemic lupus erythematosus;	chr1:183452271	chr1:183460874~183472265:-
THCA	cis	rs12230172	0.932	rs11180712	ENSG00000258245.1	RP11-114H23.3	-3.44	0.00063	0.0369	-0.16	-0.16	Glioma;Non-glioblastoma glioma;	chr12:75846951	chr12:75688794~75689096:-
THCA	cis	rs6517329	0.624	rs4817774	ENSG00000230212.5	AP000688.14	-3.44	0.00063	0.0369	-0.19	-0.16	Schizophrenia;	chr21:36112344	chr21:36069642~36126640:-
THCA	cis	rs7520050	0.902	rs9429088	ENSG00000280836.1	AL355480.1	3.44	0.00063	0.0369	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45581219~45581321:-
THCA	cis	rs11958404	0.517	rs35212858	ENSG00000231989.3	PPP1R2P3	-3.44	0.00063	0.0369	-0.39	-0.16	IgG glycosylation;	chr5:157811934	chr5:156850563~156851174:+
THCA	cis	rs11958404	0.517	rs17680818	ENSG00000231989.3	PPP1R2P3	-3.44	0.00063	0.0369	-0.39	-0.16	IgG glycosylation;	chr5:157821540	chr5:156850563~156851174:+
THCA	cis	rs9916302	0.66	rs4795367	ENSG00000266469.1	CTB-131K11.1	-3.44	0.00063	0.037	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39452590	chr17:39401793~39406233:+
THCA	cis	rs10861661	1	rs4964491	ENSG00000260329.1	RP11-412D9.4	-3.44	0.00063	0.037	-0.17	-0.16	Triglyceride levels;	chr12:106828737	chr12:106954029~106955497:-
THCA	cis	rs6743226	0.519	rs12475374	ENSG00000223374.1	AC005104.3	3.44	0.000631	0.037	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241279347	chr2:241351340~241353104:-
THCA	cis	rs11992162	0.967	rs11250185	ENSG00000255046.1	RP11-297N6.4	-3.44	0.000631	0.037	-0.17	-0.16	Monocyte count;	chr8:11975614	chr8:11797928~11802568:-
THCA	cis	rs10911902	0.643	rs16825150	ENSG00000233196.2	GS1-304P7.1	-3.44	0.000631	0.037	-0.24	-0.16	Schizophrenia;	chr1:186306628	chr1:186580515~186581191:-
THCA	cis	rs848087	0.564	rs848112	ENSG00000257826.1	RP11-116N8.4	3.44	0.000631	0.037	0.16	0.16	Breast cancer;	chr14:36784517	chr14:36061026~36067190:-
THCA	cis	rs4081724	0.744	rs12151052	ENSG00000267296.2	CEBPA-AS1	3.44	0.000631	0.037	0.21	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33332746	chr19:33302857~33305054:+
THCA	cis	rs4414128	0.832	rs1573	ENSG00000224251.5	RP11-499O7.7	-3.44	0.000631	0.037	-0.23	-0.16	Breast cancer;	chr10:5638933	chr10:4995488~4997380:+
THCA	cis	rs4713118	0.869	rs6930992	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000631	0.037	-0.17	-0.16	Parkinson's disease;	chr6:27744341	chr6:28078792~28081130:-
THCA	cis	rs1005277	0.54	rs2145487	ENSG00000273019.1	RP11-508N22.13	-3.44	0.000631	0.037	-0.17	-0.16	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38149968~38150293:+
THCA	cis	rs7772697	0.51	rs9498206	ENSG00000223701.3	RAET1E-AS1	-3.44	0.000631	0.037	-0.22	-0.16	Diabetic retinopathy;	chr6:149086029	chr6:149884431~149919508:+
THCA	cis	rs2275620	0.526	rs2146017	ENSG00000274691.1	RP11-310E22.6	-3.44	0.000631	0.037	-0.17	-0.16	Gout;	chr10:94918214	chr10:95173085~95173187:-
THCA	cis	rs7818688	1	rs16917224	ENSG00000253528.2	RP11-347C18.4	-3.44	0.000631	0.037	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017882	chr8:94974573~94974853:-
THCA	cis	rs6589219	0.908	rs7103178	ENSG00000196167.8	COLCA1	-3.44	0.000631	0.037	-0.17	-0.16	Colorectal cancer;	chr11:111294284	chr11:111290787~111305045:-
THCA	cis	rs4761470	0.577	rs35129588	ENSG00000258365.1	RP11-1105G2.3	-3.44	0.000631	0.037	-0.18	-0.16	Estradiol plasma levels (breast cancer);	chr12:94297780	chr12:94277758~94282844:-
THCA	cis	rs829402	0.836	rs853479	ENSG00000187952.9	HS6ST1P1	3.44	0.000631	0.037	0.23	0.16	High light scatter reticulocyte count;	chr1:21663486	chr1:21428303~21429536:+
THCA	cis	rs6473252	0.809	rs12549661	ENSG00000254162.1	RP11-48B3.3	-3.44	0.000631	0.037	-0.14	-0.16	Breast cancer;	chr8:80900044	chr8:80535006~80539135:-
THCA	cis	rs6473252	0.839	rs11786402	ENSG00000254162.1	RP11-48B3.3	-3.44	0.000631	0.037	-0.14	-0.16	Breast cancer;	chr8:80903405	chr8:80535006~80539135:-
THCA	cis	rs7903847	0.596	rs10786340	ENSG00000225850.3	RP11-452K12.4	3.44	0.000631	0.037	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97396806	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs7896100	ENSG00000225850.3	RP11-452K12.4	3.44	0.000631	0.037	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97397237	chr10:97334564~97343203:+
THCA	cis	rs2286503	0.646	rs17147344	ENSG00000226329.2	AC005682.6	3.44	0.000631	0.037	0.21	0.16	Fibrinogen;	chr7:22841237	chr7:22863874~22881350:-
THCA	cis	rs9611565	0.592	rs4481089	ENSG00000237037.8	NDUFA6-AS1	3.44	0.000631	0.037	0.14	0.16	Vitiligo;	chr22:41584888	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.592	rs5996039	ENSG00000237037.8	NDUFA6-AS1	3.44	0.000631	0.037	0.14	0.16	Vitiligo;	chr22:41585953	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.592	rs57102627	ENSG00000237037.8	NDUFA6-AS1	3.44	0.000631	0.037	0.14	0.16	Vitiligo;	chr22:41591623	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.592	rs28750375	ENSG00000237037.8	NDUFA6-AS1	3.44	0.000631	0.037	0.14	0.16	Vitiligo;	chr22:41594640	chr22:42090931~42137742:+
THCA	cis	rs7615952	0.641	rs12491577	ENSG00000241288.6	RP11-379B18.5	-3.44	0.000631	0.037	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126012288	chr3:125827238~125916384:-
THCA	cis	rs875971	0.545	rs67775320	ENSG00000230295.1	RP11-458F8.2	3.44	0.000631	0.037	0.14	0.16	Aortic root size;	chr7:66193792	chr7:66880708~66882981:+
THCA	cis	rs11030122	0.702	rs67300156	ENSG00000230593.3	AC090804.1	3.44	0.000631	0.037	0.21	0.16	Mean platelet volume;Platelet distribution width;	chr11:3932719	chr11:3892398~3892887:-
THCA	cis	rs12428035	0.764	rs72638023	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000631	0.037	-0.16	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96112978	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs72638024	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000631	0.037	-0.16	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96117506	chr13:95648733~95676925:-
THCA	cis	rs38864	1	rs57778199	ENSG00000214188.8	ST7-OT4	3.44	0.000631	0.037	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117162218	chr7:116953899~117098806:+
THCA	cis	rs1371614	0.566	rs11902826	ENSG00000272148.1	RP11-195B17.1	-3.44	0.000631	0.037	-0.14	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26954677	chr2:27062428~27062907:-
THCA	cis	rs2228479	1	rs117406136	ENSG00000223959.7	AFG3L1P	-3.44	0.000631	0.037	-0.15	-0.16	Skin colour saturation;	chr16:89908197	chr16:89972586~90002161:+
THCA	cis	rs6787172	0.651	rs9870802	ENSG00000272087.1	RP11-379F4.7	3.44	0.000631	0.037	0.14	0.16	Subjective well-being;	chr3:158430380	chr3:158693120~158693768:-
THCA	cis	rs950169	1	rs11638394	ENSG00000275120.1	RP11-182J1.17	3.44	0.000631	0.037	0.19	0.16	Schizophrenia;	chr15:84110176	chr15:84599434~84606463:-
THCA	cis	rs950169	1	rs35658069	ENSG00000275120.1	RP11-182J1.17	3.44	0.000631	0.037	0.19	0.16	Schizophrenia;	chr15:84111394	chr15:84599434~84606463:-
THCA	cis	rs453301	0.686	rs6601280	ENSG00000248538.5	RP11-10A14.5	-3.44	0.000631	0.037	-0.19	-0.16	Joint mobility (Beighton score);	chr8:9051726	chr8:9189011~9202854:+
THCA	cis	rs11018904	0.906	rs12793836	ENSG00000280367.1	RP11-121L10.2	3.44	0.000631	0.037	0.21	0.16	Intelligence (multi-trait analysis);	chr11:90220325	chr11:90223153~90226538:+
THCA	cis	rs28830936	1	rs11632424	ENSG00000250379.1	RP11-23P13.4	3.44	0.000631	0.037	0.18	0.16	Diastolic blood pressure;	chr15:41803153	chr15:41825099~41827936:-
THCA	cis	rs1964356	0.967	rs17701675	ENSG00000254340.1	RP11-10A14.3	-3.44	0.000631	0.037	-0.17	-0.16	Mean corpuscular volume;	chr8:8993123	chr8:9141424~9145435:+
THCA	cis	rs5758659	1	rs5751255	ENSG00000205702.9	CYP2D7	3.44	0.000631	0.037	0.12	0.16	Cognitive function;	chr22:42252402	chr22:42140203~42144577:-
THCA	cis	rs7631605	0.967	rs6769734	ENSG00000272334.1	RP11-129K12.1	-3.44	0.000631	0.037	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:36982847	chr3:36973117~36973672:-
THCA	cis	rs765787	0.53	rs12909987	ENSG00000259539.1	CTD-2651B20.1	3.44	0.000631	0.037	0.19	0.16	Uric acid levels;	chr15:45220009	chr15:45152664~45167526:-
THCA	cis	rs2120243	0.874	rs2316706	ENSG00000241770.1	RP11-555M1.3	-3.44	0.000631	0.037	-0.2	-0.16	Hepatocellular carcinoma in hepatitis B infection;	chr3:157442272	chr3:157163452~157169133:+
THCA	cis	rs7412746	0.634	rs7521592	ENSG00000224800.1	RP11-235D19.2	-3.44	0.000632	0.037	-0.22	-0.16	Melanoma;	chr1:150849215	chr1:150881236~150881683:-
THCA	cis	rs7927592	0.731	rs7108376	ENSG00000160172.9	FAM86C2P	-3.44	0.000632	0.037	-0.14	-0.16	Total body bone mineral density;	chr11:68580402	chr11:67791648~67805336:-
THCA	cis	rs3749237	0.595	rs3870338	ENSG00000224424.7	PRKAR2A-AS1	3.44	0.000632	0.037	0.13	0.16	Resting heart rate;	chr3:49519618	chr3:48847572~48851981:+
THCA	cis	rs6017317	0.696	rs4812817	ENSG00000244558.4	KCNK15-AS1	3.44	0.000632	0.037	0.22	0.16	Type 2 diabetes;	chr20:44305381	chr20:44694892~44746021:-
THCA	cis	rs4722166	0.598	rs4722179	ENSG00000179428.2	AC073072.5	-3.44	0.000632	0.037	-0.18	-0.16	Lung cancer;	chr7:22764242	chr7:22725395~22727620:-
THCA	cis	rs324126	0.78	rs2059817	ENSG00000243680.1	RPL37P23	-3.44	0.000632	0.037	-0.14	-0.16	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52143043~52143336:+
THCA	cis	rs42648	0.869	rs42614	ENSG00000225498.1	AC002064.5	3.44	0.000632	0.037	0.16	0.16	Homocysteine levels;	chr7:90321049	chr7:90312496~90322592:+
THCA	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-3.44	0.000632	0.037	-0.18	-0.16	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
THCA	cis	rs7903847	0.642	rs11812223	ENSG00000225850.3	RP11-452K12.4	3.44	0.000632	0.037	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97398698	chr10:97334564~97343203:+
THCA	cis	rs1113500	0.836	rs1618973	ENSG00000230489.1	VAV3-AS1	3.44	0.000632	0.037	0.15	0.16	Growth-regulated protein alpha levels;	chr1:108044145	chr1:107964443~107994607:+
THCA	cis	rs12621844	0.671	rs4952903	ENSG00000234690.5	AC073283.4	-3.44	0.000632	0.037	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48027768	chr2:47192405~47345074:-
THCA	cis	rs7818688	1	rs28406132	ENSG00000253528.2	RP11-347C18.4	-3.44	0.000632	0.037	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95018149	chr8:94974573~94974853:-
THCA	cis	rs1005277	0.579	rs2505194	ENSG00000099251.13	HSD17B7P2	3.44	0.000632	0.037	0.13	0.16	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38356380~38378505:+
THCA	cis	rs7020830	0.823	rs7019699	ENSG00000260100.1	RP11-220I1.5	-3.44	0.000632	0.037	-0.19	-0.16	Schizophrenia;	chr9:37125084	chr9:37078813~37079776:-
THCA	cis	rs7020830	0.931	rs7027473	ENSG00000260100.1	RP11-220I1.5	-3.44	0.000632	0.037	-0.19	-0.16	Schizophrenia;	chr9:37132465	chr9:37078813~37079776:-
THCA	cis	rs13734	0.666	rs7261614	ENSG00000277373.1	RP11-462D18.4	3.44	0.000632	0.037	0.17	0.16	Coronary artery disease;	chr20:17623615	chr20:17565501~17565851:-
THCA	cis	rs2262909	0.962	rs422344	ENSG00000269364.1	LINC01233	-3.44	0.000632	0.037	-0.19	-0.16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22048154	chr19:22532626~22533494:+
THCA	cis	rs755249	0.567	rs61779309	ENSG00000237624.1	OXCT2P1	3.44	0.000632	0.037	0.22	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39514956~39516490:+
THCA	cis	rs16959442	0.816	rs1975678	ENSG00000254912.2	RP11-632K20.2	-3.44	0.000632	0.037	-0.24	-0.16	Lobe attachment (rater-scored or self-reported);	chr15:32828014	chr15:32494003~32500346:-
THCA	cis	rs9863	0.861	rs3789967	ENSG00000269938.1	RP11-214K3.20	-3.44	0.000632	0.037	-0.18	-0.16	White blood cell count;	chr12:123962792	chr12:123968023~123968579:-
THCA	cis	rs1927790	0.667	rs7981845	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000632	0.037	-0.11	-0.16	Body mass index;	chr13:96290279	chr13:95648733~95676925:-
THCA	cis	rs7412746	0.611	rs2864873	ENSG00000224800.1	RP11-235D19.2	-3.44	0.000632	0.037	-0.21	-0.16	Melanoma;	chr1:150841698	chr1:150881236~150881683:-
THCA	cis	rs2239181	0.92	rs2239180	ENSG00000277173.1	CTD-2024F21.1	3.44	0.000632	0.037	0.23	0.16	Gout;	chr12:47862263	chr12:47768529~47769648:+
THCA	cis	rs6901004	0.803	rs9387000	ENSG00000271789.1	RP5-1112D6.7	-3.44	0.000632	0.037	-0.15	-0.16	Blood metabolite levels;	chr6:111138738	chr6:111297126~111298510:+
THCA	cis	rs354225	0.544	rs12713266	ENSG00000212175.1	SNORA12	-3.44	0.000632	0.037	-0.19	-0.16	Schizophrenia;	chr2:54578306	chr2:55565703~55565850:+
THCA	cis	rs354225	0.544	rs11892443	ENSG00000212175.1	SNORA12	-3.44	0.000632	0.037	-0.19	-0.16	Schizophrenia;	chr2:54578639	chr2:55565703~55565850:+
THCA	cis	rs10911902	0.643	rs78468398	ENSG00000233196.2	GS1-304P7.1	-3.44	0.000632	0.037	-0.24	-0.16	Schizophrenia;	chr1:186315149	chr1:186580515~186581191:-
THCA	cis	rs1864585	0.52	rs17776622	ENSG00000280294.1	RP11-177H2.1	3.44	0.000632	0.037	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10818987	chr8:10856085~10859436:-
THCA	cis	rs4666002	0.789	rs13030973	ENSG00000234072.1	AC074117.10	3.44	0.000632	0.037	0.14	0.16	Phospholipid levels (plasma);	chr2:27705930	chr2:27356246~27367622:+
THCA	cis	rs4666002	0.789	rs6727388	ENSG00000234072.1	AC074117.10	3.44	0.000632	0.037	0.14	0.16	Phospholipid levels (plasma);	chr2:27709720	chr2:27356246~27367622:+
THCA	cis	rs4666002	0.789	rs4616435	ENSG00000234072.1	AC074117.10	3.44	0.000632	0.037	0.14	0.16	Phospholipid levels (plasma);	chr2:27710775	chr2:27356246~27367622:+
THCA	cis	rs4666002	0.789	rs6727215	ENSG00000234072.1	AC074117.10	3.44	0.000632	0.037	0.14	0.16	Phospholipid levels (plasma);	chr2:27711864	chr2:27356246~27367622:+
THCA	cis	rs7829975	0.777	rs6989926	ENSG00000254340.1	RP11-10A14.3	-3.44	0.000632	0.037	-0.17	-0.16	Mood instability;	chr8:8689803	chr8:9141424~9145435:+
THCA	cis	rs2562456	0.833	rs4321312	ENSG00000268521.1	VN1R83P	3.44	0.000632	0.037	0.15	0.16	Pain;	chr19:21336614	chr19:21289554~21289998:-
THCA	cis	rs11971779	0.68	rs6947215	ENSG00000252332.1	RNU6-911P	-3.44	0.000632	0.037	-0.17	-0.16	Diisocyanate-induced asthma;	chr7:139341892	chr7:139448740~139448843:+
THCA	cis	rs6997458	0.776	rs1496531	ENSG00000253549.4	RP11-317J10.2	-3.44	0.000632	0.037	-0.15	-0.16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85341833	chr8:85441851~85464915:-
THCA	cis	rs1005277	0.577	rs4934906	ENSG00000151963.4	RP11-775A3.1	-3.44	0.000632	0.037	-0.16	-0.16	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:37883594~37884109:+
THCA	cis	rs11190604	1	rs10883500	ENSG00000273030.1	RP11-285F16.1	3.44	0.000632	0.037	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100478567	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs10883501	ENSG00000273030.1	RP11-285F16.1	3.44	0.000632	0.037	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100478569	chr10:100412934~100413421:+
THCA	cis	rs11190604	1	rs10883502	ENSG00000273030.1	RP11-285F16.1	3.44	0.000632	0.037	0.18	0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100478586	chr10:100412934~100413421:+
THCA	cis	rs2006933	1	rs17792915	ENSG00000237575.4	PYY2	3.44	0.000632	0.037	0.2	0.16	Amyotrophic lateral sclerosis;	chr17:28257661	chr17:28226563~28228065:+
THCA	cis	rs1790761	0.667	rs4147581	ENSG00000184224.3	C11orf72	3.44	0.000633	0.037	0.21	0.16	Mean corpuscular volume;	chr11:67584114	chr11:67602880~67606706:-
THCA	cis	rs7520050	0.966	rs2486447	ENSG00000281133.1	AL355480.3	3.44	0.000633	0.0371	0.18	0.16	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs1085244	ENSG00000281133.1	AL355480.3	3.44	0.000633	0.0371	0.18	0.16	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs6662641	ENSG00000281133.1	AL355480.3	3.44	0.000633	0.0371	0.18	0.16	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.966	rs1707335	ENSG00000281133.1	AL355480.3	3.44	0.000633	0.0371	0.18	0.16	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45580892~45580996:-
THCA	cis	rs9902453	0.704	rs2628179	ENSG00000263370.1	RP11-68I3.5	-3.44	0.000633	0.0371	-0.21	-0.16	Coffee consumption (cups per day);	chr17:29744778	chr17:29639627~29640825:+
THCA	cis	rs10760158	0.769	rs10760162	ENSG00000235865.2	GSN-AS1	3.44	0.000633	0.0371	0.14	0.16	Pulse pressure;	chr9:121242905	chr9:121280768~121285530:-
THCA	cis	rs7246657	0.943	rs9917081	ENSG00000268499.1	CTB-102L5.8	3.44	0.000633	0.0371	0.21	0.16	Coronary artery calcification;	chr19:37385714	chr19:38199836~38200934:+
THCA	cis	rs61008539	0.893	rs4721502	ENSG00000273151.1	RP11-449P15.2	-3.44	0.000633	0.0371	-0.11	-0.16	Perceived unattractiveness to mosquitoes;	chr7:822549	chr7:879790~886547:-
THCA	cis	rs9916302	0.706	rs12950186	ENSG00000266469.1	CTB-131K11.1	-3.44	0.000633	0.0371	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39237142	chr17:39401793~39406233:+
THCA	cis	rs7208859	0.673	rs216418	ENSG00000265443.1	CTD-2349P21.6	-3.44	0.000633	0.0371	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30726305~30727564:-
THCA	cis	rs7208859	0.623	rs216423	ENSG00000265443.1	CTD-2349P21.6	-3.44	0.000633	0.0371	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30726305~30727564:-
THCA	cis	rs17604090	0.938	rs115369413	ENSG00000227855.3	DPY19L2P3	3.44	0.000633	0.0371	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29645424	chr7:29650227~29742594:+
THCA	cis	rs9296092	0.538	rs9461875	ENSG00000272217.1	XXbac-BPG157A10.21	3.44	0.000633	0.0371	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33548867	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.517	rs9461876	ENSG00000272217.1	XXbac-BPG157A10.21	3.44	0.000633	0.0371	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33548880	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.517	rs9461877	ENSG00000272217.1	XXbac-BPG157A10.21	3.44	0.000633	0.0371	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33548890	chr6:33246075~33246856:-
THCA	cis	rs9843304	0.529	rs4681512	ENSG00000243885.1	RP11-278L15.2	3.44	0.000633	0.0371	0.17	0.16	Gallstone disease;	chr3:149485654	chr3:149384179~149385800:-
THCA	cis	rs2281636	0.66	rs61871318	ENSG00000260475.1	RP11-85A1.3	3.44	0.000633	0.0371	0.16	0.16	Obesity-related traits;	chr10:99606784	chr10:99621055~99621918:+
THCA	cis	rs3806843	0.576	rs265316	ENSG00000278901.1	AC005609.17	3.44	0.000633	0.0371	0.18	0.16	Depressive symptoms (multi-trait analysis);	chr5:140911258	chr5:140878073~140882642:-
THCA	cis	rs5753037	0.754	rs41158	ENSG00000273350.1	RP4-539M6.20	-3.44	0.000633	0.0371	-0.17	-0.16	Type 1 diabetes;	chr22:30009994	chr22:30420512~30420912:+
THCA	cis	rs11098499	0.644	rs28787668	ENSG00000249244.1	RP11-548H18.2	3.44	0.000633	0.0371	0.18	0.16	Corneal astigmatism;	chr4:119633532	chr4:119391831~119395335:-
THCA	cis	rs7937890	0.559	rs2575836	ENSG00000251991.1	RNU7-49P	3.44	0.000633	0.0371	0.18	0.16	Mitochondrial DNA levels;	chr11:14476318	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.531	rs2575859	ENSG00000251991.1	RNU7-49P	3.44	0.000633	0.0371	0.18	0.16	Mitochondrial DNA levels;	chr11:14489190	chr11:14478892~14478953:+
THCA	cis	rs4648045	0.565	rs62327181	ENSG00000248971.2	KRT8P46	-3.44	0.000633	0.0371	-0.19	-0.16	Lymphocyte percentage of white cells;	chr4:102624981	chr4:102728746~102730171:-
THCA	cis	rs2243480	1	rs383402	ENSG00000273024.4	INTS4P2	-3.44	0.000633	0.0371	-0.26	-0.16	Diabetic kidney disease;	chr7:66121666	chr7:65647864~65715661:+
THCA	cis	rs6600671	0.966	rs6600664	ENSG00000226067.5	CH17-118O6.2	3.44	0.000633	0.0371	0.16	0.16	Hip geometry;	chr1:121480638	chr1:120913275~121009291:+
THCA	cis	rs6600671	0.932	rs6600663	ENSG00000226067.5	CH17-118O6.2	3.44	0.000633	0.0371	0.16	0.16	Hip geometry;	chr1:121480639	chr1:120913275~121009291:+
THCA	cis	rs77147124	0.959	rs2263608	ENSG00000225292.2	RP11-57H14.3	-3.44	0.000633	0.0371	-0.21	-0.16	HDL cholesterol;	chr10:112185182	chr10:112888735~112906111:+
THCA	cis	rs7028939	1	rs7854689	ENSG00000255145.2	STX17-AS1	-3.44	0.000633	0.0371	-0.24	-0.16	Preeclampsia;	chr9:100197969	chr9:99886322~99906601:-
THCA	cis	rs2911280	0.764	rs13333262	ENSG00000278985.1	RP11-303E16.9	-3.44	0.000633	0.0371	-0.29	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81527442	chr16:80982319~80984094:-
THCA	cis	rs2911280	0.764	rs7196272	ENSG00000278985.1	RP11-303E16.9	-3.44	0.000633	0.0371	-0.29	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81527991	chr16:80982319~80984094:-
THCA	cis	rs9488822	0.702	rs6909746	ENSG00000237021.2	RP3-486I3.7	3.44	0.000633	0.0371	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116031587	chr6:116254207~116256743:+
THCA	cis	rs7267979	0.934	rs2261753	ENSG00000276952.1	RP5-965G21.6	3.44	0.000633	0.0371	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25284915~25285588:-
THCA	cis	rs2830585	0.602	rs233895	ENSG00000223563.1	AP001601.2	3.44	0.000633	0.0371	0.19	0.16	Blood protein levels;	chr21:26952992	chr21:26889376~26939742:+
THCA	cis	rs2130392	0.961	rs2696035	ENSG00000250726.1	RP11-616K6.1	-3.44	0.000633	0.0371	-0.19	-0.16	Kawasaki disease;	chr4:184691799	chr4:184072403~184073039:+
THCA	cis	rs6471393	0.862	rs11994625	ENSG00000261437.1	RP11-22C11.2	3.44	0.000633	0.0371	0.16	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93760149	chr8:94637285~94639467:-
THCA	cis	rs6598955	0.724	rs12754536	ENSG00000236782.4	RP11-96L14.7	-3.44	0.000633	0.0371	-0.19	-0.16	Obesity-related traits;	chr1:26313114	chr1:26169947~26171821:-
THCA	cis	rs17122278	0.577	rs537975	ENSG00000243431.1	RPL5P30	-3.44	0.000633	0.0371	-0.14	-0.16	Total cholesterol levels;	chr11:118492154	chr11:118560690~118561580:+
THCA	cis	rs2835345	1	rs4817797	ENSG00000230479.1	AP000695.6	-3.44	0.000633	0.0371	-0.19	-0.16	Pulmonary function;	chr21:36429098	chr21:36430360~36481070:+
THCA	cis	rs10792665	0.649	rs12271324	ENSG00000255503.1	RP11-113K21.4	-3.44	0.000633	0.0371	-0.16	-0.16	Obesity-related traits;	chr11:83065288	chr11:83072402~83097196:-
THCA	cis	rs524281	0.817	rs10896097	ENSG00000255038.1	RP11-1167A19.2	-3.44	0.000633	0.0371	-0.18	-0.16	Electroencephalogram traits;	chr11:66200482	chr11:66067277~66069619:-
THCA	cis	rs2274273	0.837	rs8008119	ENSG00000258469.1	CHMP4BP1	3.44	0.000633	0.0371	0.14	0.16	Protein biomarker;	chr14:55364510	chr14:55298644~55299231:+
THCA	cis	rs11157436	0.918	rs12437004	ENSG00000211812.1	TRAV26-2	-3.44	0.000633	0.0371	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149461	chr14:22202583~22203368:+
THCA	cis	rs17428076	0.872	rs17428174	ENSG00000228389.1	AC068039.4	-3.44	0.000633	0.0371	-0.19	-0.16	Myopia;	chr2:172021244	chr2:171773482~171775844:+
THCA	cis	rs7954584	0.551	rs1169072	ENSG00000272849.1	RP11-347I19.8	3.44	0.000633	0.0371	0.09	0.16	Mean corpuscular volume;	chr12:121963595	chr12:121797511~121801972:+
THCA	cis	rs7551222	0.716	rs6679717	ENSG00000240219.1	RP11-430C7.5	3.44	0.000633	0.0371	0.14	0.16	Schizophrenia;	chr1:204591549	chr1:204626775~204629712:+
THCA	cis	rs1858037	0.867	rs67453645	ENSG00000252414.1	RNU6-100P	-3.44	0.000633	0.0371	-0.17	-0.16	Rheumatoid arthritis;	chr2:65358908	chr2:64578892~64578997:+
THCA	cis	rs1538970	0.962	rs7532762	ENSG00000234329.1	RP11-767N6.2	3.44	0.000633	0.0371	0.15	0.16	Platelet count;	chr1:45399023	chr1:45651039~45651826:-
THCA	cis	rs875971	0.862	rs11763189	ENSG00000223473.2	GS1-124K5.3	3.44	0.000634	0.0371	0.1	0.16	Aortic root size;	chr7:66518542	chr7:66491049~66493566:-
THCA	cis	rs6957923	0.846	rs6967145	ENSG00000234286.1	AC006026.13	-3.44	0.000634	0.0371	-0.21	-0.16	Height;	chr7:23477849	chr7:23680195~23680786:-
THCA	cis	rs9348440	0.73	rs2328528	ENSG00000280989.1	LINC00581	3.44	0.000634	0.0371	0.24	0.16	Glycemic traits;	chr6:20631314	chr6:21486061~21511895:-
THCA	cis	rs9348440	0.73	rs9460537	ENSG00000280989.1	LINC00581	3.44	0.000634	0.0371	0.24	0.16	Glycemic traits;	chr6:20631879	chr6:21486061~21511895:-
THCA	cis	rs9348440	0.73	rs7768642	ENSG00000280989.1	LINC00581	3.44	0.000634	0.0371	0.24	0.16	Glycemic traits;	chr6:20633676	chr6:21486061~21511895:-
THCA	cis	rs9348440	0.73	rs56241903	ENSG00000280989.1	LINC00581	3.44	0.000634	0.0371	0.24	0.16	Glycemic traits;	chr6:20633896	chr6:21486061~21511895:-
THCA	cis	rs9348440	0.73	rs9465846	ENSG00000280989.1	LINC00581	3.44	0.000634	0.0371	0.24	0.16	Glycemic traits;	chr6:20634110	chr6:21486061~21511895:-
THCA	cis	rs9348440	0.73	rs9465847	ENSG00000280989.1	LINC00581	3.44	0.000634	0.0371	0.24	0.16	Glycemic traits;	chr6:20634197	chr6:21486061~21511895:-
THCA	cis	rs4869313	0.694	rs31398	ENSG00000247121.5	CTD-2260A17.2	3.44	0.000634	0.0371	0.12	0.16	Pediatric autoimmune diseases;	chr5:97020960	chr5:96814028~96935809:-
THCA	cis	rs4869313	0.694	rs27294	ENSG00000247121.5	CTD-2260A17.2	3.44	0.000634	0.0371	0.12	0.16	Pediatric autoimmune diseases;	chr5:97021556	chr5:96814028~96935809:-
THCA	cis	rs4654783	0.671	rs1474647	ENSG00000218510.5	LINC00339	-3.44	0.000634	0.0371	-0.16	-0.16	Endometriosis;	chr1:22115372	chr1:22025188~22031223:+
THCA	cis	rs11651753	0.613	rs4793732	ENSG00000278765.1	RP5-890E16.5	-3.44	0.000634	0.0371	-0.19	-0.16	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:48066704~48067293:-
THCA	cis	rs11658311	1	rs11654553	ENSG00000266803.1	RP1-77H15.1	3.44	0.000634	0.0371	0.31	0.16	Obsessive-compulsive symptoms;	chr17:17558835	chr17:16557985~16559269:-
THCA	cis	rs4262150	0.81	rs72797262	ENSG00000253921.1	CTB-113P19.3	3.44	0.000634	0.0371	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152638728	chr5:151753992~151767247:+
THCA	cis	rs7914558	1	rs7071373	ENSG00000272912.1	RP11-724N1.1	-3.44	0.000634	0.0371	-0.19	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103012165	chr10:102914585~102915404:+
THCA	cis	rs10911363	0.615	rs9286848	ENSG00000232860.6	SMG7-AS1	3.44	0.000634	0.0371	0.12	0.16	Systemic lupus erythematosus;	chr1:183457114	chr1:183460874~183472265:-
THCA	cis	rs6870983	0.749	rs33708	ENSG00000247828.6	TMEM161B-AS1	3.44	0.000634	0.0371	0.14	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88211320	chr5:88268895~88436685:+
THCA	cis	rs721048	0.92	rs77756925	ENSG00000242412.1	DBIL5P2	-3.44	0.000634	0.0371	-0.22	-0.16	Prostate cancer;	chr2:63158846	chr2:63117851~63119542:-
THCA	cis	rs1371614	0.611	rs3843322	ENSG00000229122.1	AGBL5-IT1	3.44	0.000634	0.0371	0.11	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908981	chr2:27061038~27061815:+
THCA	cis	rs10256972	0.567	rs2960850	ENSG00000225146.1	AC073957.15	3.44	0.000634	0.0371	0.17	0.16	Endometriosis;Longevity;	chr7:1172013	chr7:1029025~1043891:+
THCA	cis	rs3750082	0.582	rs7800883	ENSG00000229358.3	DPY19L1P1	3.44	0.000634	0.0371	0.15	0.16	Glomerular filtration rate (creatinine);	chr7:32931670	chr7:32580949~32761787:-
THCA	cis	rs2729354	1	rs2729355	ENSG00000254602.1	AP000662.4	-3.44	0.000634	0.0371	-0.2	-0.16	Blood protein levels;	chr11:57586510	chr11:57638024~57652790:+
THCA	cis	rs12677618	0.623	rs28506950	ENSG00000253307.1	RP11-10J21.4	3.44	0.000634	0.0371	0.23	0.16	Plateletcrit;	chr8:141251868	chr8:141252286~141253292:-
THCA	cis	rs10029851	0.645	rs17039240	ENSG00000234492.4	RPL34-AS1	-3.44	0.000634	0.0371	-0.15	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr4:108703926	chr4:108538190~108620460:-
THCA	cis	rs801193	0.773	rs801207	ENSG00000275400.1	RP4-756H11.5	3.44	0.000634	0.0371	0.14	0.16	Aortic root size;	chr7:66555603	chr7:66553805~66554199:-
THCA	cis	rs875971	0.543	rs801191	ENSG00000275400.1	RP4-756H11.5	3.44	0.000634	0.0371	0.14	0.16	Aortic root size;	chr7:66567968	chr7:66553805~66554199:-
THCA	cis	rs875971	0.508	rs6947808	ENSG00000275400.1	RP4-756H11.5	3.44	0.000634	0.0371	0.14	0.16	Aortic root size;	chr7:66580095	chr7:66553805~66554199:-
THCA	cis	rs801193	0.844	rs732465	ENSG00000275400.1	RP4-756H11.5	-3.44	0.000634	0.0371	-0.14	-0.16	Aortic root size;	chr7:66533463	chr7:66553805~66554199:-
THCA	cis	rs853679	0.527	rs213228	ENSG00000220721.1	OR1F12	3.44	0.000634	0.0371	0.18	0.16	Depression;	chr6:28363475	chr6:28073316~28074233:+
THCA	cis	rs11841001	0.556	rs34083520	ENSG00000261105.4	LMO7-AS1	-3.44	0.000634	0.0371	-0.22	-0.16	Corneal astigmatism;	chr13:75775622	chr13:75604700~75635994:-
THCA	cis	rs2253762	0.736	rs2459082	ENSG00000276742.1	RP11-500G22.4	3.44	0.000634	0.0371	0.19	0.16	Breast cancer;	chr10:122036570	chr10:121956782~121957098:+
THCA	cis	rs4443100	1	rs4443100	ENSG00000240160.3	RN7SL263P	3.44	0.000634	0.0371	0.21	0.16	Serum parathyroid hormone levels;	chr22:23030688	chr22:23261782~23262071:-
THCA	cis	rs7192750	0.563	rs11649672	ENSG00000260886.1	TAT-AS1	3.44	0.000634	0.0371	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71918711	chr16:71565789~71578187:+
THCA	cis	rs9534288	0.716	rs2573304	ENSG00000235903.6	CPB2-AS1	-3.44	0.000634	0.0371	-0.22	-0.16	Blood protein levels;	chr13:45940507	chr13:46052806~46113332:+
THCA	cis	rs6491750	1	rs9558089	ENSG00000276957.1	RP11-29B2.6	-3.44	0.000634	0.0371	-0.27	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr13:103476823	chr13:102593338~102593873:-
THCA	cis	rs11673344	0.523	rs10406110	ENSG00000267260.1	CTD-2162K18.4	-3.44	0.000634	0.0371	-0.19	-0.16	Obesity-related traits;	chr19:37160027	chr19:36773153~36777078:+
THCA	cis	rs9878978	0.754	rs6787193	ENSG00000227588.2	CNTN4-AS2	3.44	0.000634	0.0371	0.2	0.16	Blood pressure (smoking interaction);	chr3:2394450	chr3:2110409~2144241:-
THCA	cis	rs9878978	0.754	rs6774579	ENSG00000227588.2	CNTN4-AS2	3.44	0.000634	0.0371	0.2	0.16	Blood pressure (smoking interaction);	chr3:2394578	chr3:2110409~2144241:-
THCA	cis	rs801193	0.742	rs9969300	ENSG00000272831.1	RP11-792A8.4	-3.44	0.000634	0.0371	-0.1	-0.16	Aortic root size;	chr7:66316659	chr7:66739829~66740385:-
THCA	cis	rs10802047	0.54	rs952591	ENSG00000231365.4	RP11-418J17.1	3.44	0.000634	0.0371	0.16	0.16	Relative hand skill in reading disability;	chr1:118861695	chr1:119140396~119275973:+
THCA	cis	rs997295	0.513	rs11635495	ENSG00000245719.1	RP11-34F13.2	3.44	0.000634	0.0371	0.17	0.16	Motion sickness;	chr15:67512344	chr15:67834310~67838879:-
THCA	cis	rs9650657	0.504	rs10109167	ENSG00000154316.13	TDH	3.44	0.000634	0.0371	0.12	0.16	Neuroticism;	chr8:11176016	chr8:11339637~11368452:+
THCA	cis	rs56104184	0.779	rs17206693	ENSG00000243829.1	CTB-33G10.1	-3.44	0.000635	0.0371	-0.23	-0.16	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48856995	chr19:49719498~49720081:-
THCA	cis	rs7665090	1	rs2125211	ENSG00000248971.2	KRT8P46	3.44	0.000635	0.0371	0.18	0.16	Primary biliary cholangitis;	chr4:102638719	chr4:102728746~102730171:-
THCA	cis	rs4568518	0.772	rs12699946	ENSG00000279048.1	RP11-511H23.2	3.44	0.000635	0.0371	0.1	0.16	Measles;	chr7:17999436	chr7:17940503~17942922:+
THCA	cis	rs2180341	1	rs3798850	ENSG00000220522.2	RP1-177A13.1	3.44	0.000635	0.0371	0.2	0.16	Breast cancer;	chr6:127292821	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.961	rs7775493	ENSG00000220522.2	RP1-177A13.1	3.44	0.000635	0.0371	0.2	0.16	Breast cancer;	chr6:127293855	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.889	rs9321074	ENSG00000220522.2	RP1-177A13.1	3.44	0.000635	0.0371	0.2	0.16	Breast cancer;	chr6:127296874	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs9375499	ENSG00000220522.2	RP1-177A13.1	3.44	0.000635	0.0371	0.2	0.16	Breast cancer;	chr6:127296927	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.961	rs910720	ENSG00000220522.2	RP1-177A13.1	3.44	0.000635	0.0371	0.2	0.16	Breast cancer;	chr6:127297925	chr6:127416535~127416952:-
THCA	cis	rs763121	0.853	rs1013338	ENSG00000225450.1	RP3-508I15.14	-3.44	0.000635	0.0372	-0.12	-0.16	Menopause (age at onset);	chr22:38578149	chr22:38739003~38749041:+
THCA	cis	rs7631605	0.586	rs4574224	ENSG00000224080.1	UBE2FP1	3.44	0.000635	0.0372	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37305659	chr3:37143512~37143958:-
THCA	cis	rs34421088	0.678	rs35928010	ENSG00000254866.2	DEFB109P3	3.44	0.000635	0.0372	0.2	0.16	Neuroticism;	chr8:11734367	chr8:12150895~12151134:-
THCA	cis	rs7028939	1	rs7865483	ENSG00000234709.2	UPF3AP3	-3.44	0.000635	0.0372	-0.28	-0.16	Preeclampsia;	chr9:100205721	chr9:99998301~99999069:-
THCA	cis	rs2434529	1	rs2443522	ENSG00000245275.6	SAP30L-AS1	3.44	0.000635	0.0372	0.18	0.16	Autism spectrum disorder or schizophrenia;	chr5:154262485	chr5:154329437~154445850:-
THCA	cis	rs1348850	0.526	rs4243389	ENSG00000280374.1	RP11-337N6.3	-3.44	0.000635	0.0372	-0.27	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177515055	chr2:177317715~177318471:-
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000261839.1	RP1-265C24.8	3.44	0.000635	0.0372	0.15	0.16	Pubertal anthropometrics;	chr6:28230503	chr6:28136849~28139678:+
THCA	cis	rs72627123	0.867	rs17094045	ENSG00000259065.1	RP5-1021I20.1	-3.44	0.000635	0.0372	-0.28	-0.16	Morning vs. evening chronotype;	chr14:73929548	chr14:73787360~73803270:+
THCA	cis	rs72634258	0.52	rs12078018	ENSG00000224315.2	RPL7P7	-3.44	0.000635	0.0372	-0.28	-0.16	Inflammatory bowel disease;	chr1:7797249	chr1:8786211~8786913:-
THCA	cis	rs7129556	0.954	rs11237220	ENSG00000254985.1	RSF1-IT2	-3.44	0.000635	0.0372	-0.25	-0.16	Weight loss (gastric bypass surgery);	chr11:77557415	chr11:77717712~77718411:-
THCA	cis	rs6500637	0.631	rs12921187	ENSG00000267077.1	RP11-127I20.5	-3.44	0.000635	0.0372	-0.18	-0.16	Cancer;	chr16:4893018	chr16:4795265~4796532:-
THCA	cis	rs409045	1	rs409045	ENSG00000271874.1	CTD-2024P10.2	3.44	0.000635	0.0372	0.21	0.16	Left ventricular mass;	chr5:34628522	chr5:34651457~34651888:-
THCA	cis	rs9837602	0.529	rs793494	ENSG00000273374.1	RP11-383I23.2	-3.44	0.000635	0.0372	-0.14	-0.16	Breast cancer;	chr3:99789924	chr3:99802699~99806058:-
THCA	cis	rs9796	0.689	rs561301	ENSG00000247556.5	OIP5-AS1	3.44	0.000635	0.0372	0.13	0.16	Menopause (age at onset);	chr15:41152525	chr15:41283990~41309737:+
THCA	cis	rs9796	0.689	rs692195	ENSG00000247556.5	OIP5-AS1	3.44	0.000635	0.0372	0.13	0.16	Menopause (age at onset);	chr15:41152696	chr15:41283990~41309737:+
THCA	cis	rs6806253	0.73	rs4431128	ENSG00000273174.1	RP11-434H6.6	-3.44	0.000635	0.0372	-0.21	-0.16	Pit-and-Fissure caries;	chr3:128532835	chr3:129123439~129124003:+
THCA	cis	rs6810798	1	rs6810798	ENSG00000280219.1	RP11-752L20.3	3.44	0.000635	0.0372	0.2	0.16	Coronary artery disease;	chr4:147369666	chr4:147487971~147496062:+
THCA	cis	rs72634501	0.574	rs111623477	ENSG00000182109.6	RP11-69E11.4	3.44	0.000635	0.0372	0.19	0.16	HDL cholesterol;	chr1:39345533	chr1:39522280~39546187:-
THCA	cis	rs4308415	0.934	rs787364	ENSG00000270292.1	RP11-453E17.4	-3.44	0.000635	0.0372	-0.18	-0.16	Educational attainment (years of education);	chr4:67041010	chr4:67725183~67726395:-
THCA	cis	rs9481169	0.85	rs60962769	ENSG00000272356.1	RP5-1112D6.8	3.44	0.000635	0.0372	0.24	0.16	Inflammatory skin disease;	chr6:111598221	chr6:111309203~111313517:+
THCA	cis	rs2625529	0.668	rs35206011	ENSG00000260037.4	CTD-2524L6.3	-3.44	0.000635	0.0372	-0.21	-0.16	Red blood cell count;	chr15:72247153	chr15:71818396~71823384:+
THCA	cis	rs17111396	0.773	rs10147243	ENSG00000271656.1	RP11-114N19.5	-3.44	0.000635	0.0372	-0.2	-0.16	Uric acid levels;	chr14:81044834	chr14:81003325~81003645:-
THCA	cis	rs7131987	0.903	rs7970390	ENSG00000274315.1	RP11-996F15.5	3.44	0.000635	0.0372	0.2	0.16	QT interval;	chr12:29245722	chr12:29331434~29331936:-
THCA	cis	rs3126085	0.935	rs11583524	ENSG00000237975.5	FLG-AS1	3.44	0.000635	0.0372	0.25	0.16	Atopic dermatitis;	chr1:152189181	chr1:152168125~152445456:+
THCA	cis	rs13720	0.722	rs191490	ENSG00000225806.6	RP1-309F20.3	-3.44	0.000636	0.0372	-0.17	-0.16	Platelet distribution width;	chr20:59001125	chr20:58863528~58888809:-
THCA	cis	rs13098911	0.54	rs34283240	ENSG00000226074.4	PRSS44	-3.44	0.000636	0.0372	-0.3	-0.16	Celiac disease;	chr3:46006166	chr3:46809359~46812558:-
THCA	cis	rs9811920	0.638	rs796977	ENSG00000273374.1	RP11-383I23.2	-3.44	0.000636	0.0372	-0.14	-0.16	Axial length;	chr3:99830879	chr3:99802699~99806058:-
THCA	cis	rs1003719	0.591	rs2835618	ENSG00000270116.1	AP001429.1	3.44	0.000636	0.0372	0.17	0.16	Eye color traits;	chr21:37130826	chr21:37100814~37101343:+
THCA	cis	rs9634489	0.843	rs2147688	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96401427	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.843	rs2182067	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96401550	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.843	rs4625590	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96401630	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.843	rs2389669	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96402054	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.786	rs1925123	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96403986	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.843	rs503466	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96406083	chr13:95648733~95676925:-
THCA	cis	rs7713065	0.84	rs10067603	ENSG00000237714.1	P4HA2-AS1	-3.44	0.000636	0.0372	-0.26	-0.16	Lung function (FEV1/FVC);	chr5:132468176	chr5:132184876~132192808:+
THCA	cis	rs7713065	0.84	rs10039559	ENSG00000237714.1	P4HA2-AS1	-3.44	0.000636	0.0372	-0.26	-0.16	Lung function (FEV1/FVC);	chr5:132468815	chr5:132184876~132192808:+
THCA	cis	rs2066819	1	rs2643626	ENSG00000257303.1	RP11-977G19.11	3.44	0.000636	0.0372	0.23	0.16	Psoriasis vulgaris;	chr12:56332734	chr12:56300142~56314808:+
THCA	cis	rs12073359	0.572	rs66773125	ENSG00000253047.1	SNORA40	-3.44	0.000636	0.0372	-0.27	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150202091	chr1:150600539~150600659:-
THCA	cis	rs34779708	0.966	rs11599606	ENSG00000233200.1	RP11-324I22.2	3.44	0.000636	0.0372	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35219894~35230598:-
THCA	cis	rs7200543	1	rs7200543	ENSG00000260735.1	RP11-72I8.1	3.44	0.000636	0.0372	0.18	0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:15094411~15109197:+
THCA	cis	rs7560272	0.723	rs780391	ENSG00000273245.1	RP11-434P11.2	-3.44	0.000636	0.0372	-0.19	-0.16	Schizophrenia;	chr2:73476777	chr2:73750256~73750786:-
THCA	cis	rs4971059	0.629	rs4246529	ENSG00000225855.5	RUSC1-AS1	3.44	0.000636	0.0372	0.1	0.16	Breast cancer;	chr1:155142784	chr1:155316863~155324176:-
THCA	cis	rs4218	0.638	rs8042516	ENSG00000277144.1	RP11-59H7.4	-3.44	0.000636	0.0372	-0.22	-0.16	Social communication problems;	chr15:59067525	chr15:59115547~59116089:-
THCA	cis	rs656900	0.647	rs668641	ENSG00000261229.4	MTHFS	3.44	0.000636	0.0372	0.16	0.16	Cerebrospinal P-tau181p levels;	chr15:79826282	chr15:79843547~79897285:-
THCA	cis	rs494526	0.641	rs7902763	ENSG00000229272.1	RP11-498J9.2	-3.44	0.000636	0.0372	-0.18	-0.16	Alcoholic chronic pancreatitis;	chr10:119101726	chr10:119003536~119003884:-
THCA	cis	rs1737890	0.778	rs2295765	ENSG00000235217.6	TSPY26P	-3.44	0.000636	0.0372	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr20:32431221	chr20:32186477~32190527:-
THCA	cis	rs7474896	1	rs2749564	ENSG00000276805.1	RP11-291L22.6	-3.44	0.000636	0.0372	-0.25	-0.16	Obesity (extreme);	chr10:37889887	chr10:38451030~38451785:+
THCA	cis	rs8049040	0.547	rs12929335	ENSG00000261513.1	RP11-432I5.8	3.44	0.000636	0.0372	0.22	0.16	Blood protein levels;	chr16:71401849	chr16:71723180~71724230:+
THCA	cis	rs9308731	0.591	rs879623	ENSG00000227992.1	AC108463.2	-3.44	0.000636	0.0372	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111189247	chr2:111203964~111206215:-
THCA	cis	rs757978	1	rs80085676	ENSG00000235351.1	AC114730.11	-3.44	0.000636	0.0372	-0.16	-0.16	Chronic lymphocytic leukemia;	chr2:241408492	chr2:241724615~241725693:-
THCA	cis	rs524281	1	rs475805	ENSG00000255120.4	OVOL1-AS1	3.44	0.000636	0.0372	0.22	0.16	Electroencephalogram traits;	chr11:66081267	chr11:65789051~65790868:-
THCA	cis	rs901683	1	rs12779976	ENSG00000230869.1	CTGLF10P	3.44	0.000636	0.0372	0.36	0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45547484	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs17157919	ENSG00000230869.1	CTGLF10P	3.44	0.000636	0.0372	0.36	0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45548644	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs9422440	ENSG00000230869.1	CTGLF10P	-3.44	0.000636	0.0372	-0.36	-0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45549677	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs9422650	ENSG00000230869.1	CTGLF10P	-3.44	0.000636	0.0372	-0.36	-0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45550313	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs78363416	ENSG00000230869.1	CTGLF10P	-3.44	0.000636	0.0372	-0.36	-0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45550686	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs34138033	ENSG00000230869.1	CTGLF10P	-3.44	0.000636	0.0372	-0.36	-0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45551064	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs35036712	ENSG00000230869.1	CTGLF10P	-3.44	0.000636	0.0372	-0.36	-0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45551262	chr10:45678692~45700532:+
THCA	cis	rs769267	0.965	rs2905425	ENSG00000269131.1	AC004447.2	3.44	0.000636	0.0372	0.1	0.16	Tonsillectomy;	chr19:19364908	chr19:18990893~18993610:+
THCA	cis	rs2348418	0.733	rs2019011	ENSG00000278733.1	RP11-425D17.1	-3.44	0.000636	0.0372	-0.14	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28228144	chr12:28185625~28186190:-
THCA	cis	rs9326248	0.574	rs1263173	ENSG00000280143.1	AP000892.6	3.44	0.000636	0.0372	0.2	0.16	Blood protein levels;	chr11:116810292	chr11:117204967~117210292:+
THCA	cis	rs4434872	0.536	rs2297895	ENSG00000228013.1	RP11-350G8.5	-3.44	0.000636	0.0372	-0.28	-0.16	Conduct disorder (symptom count);	chr1:153941208	chr1:154402328~154406564:-
THCA	cis	rs708547	1	rs708547	ENSG00000269949.1	RP11-738E22.3	3.44	0.000636	0.0372	0.22	0.16	Response to bleomycin (chromatid breaks);	chr4:56955143	chr4:56960927~56961373:-
THCA	cis	rs12621844	0.671	rs1483210	ENSG00000272663.1	RP11-191L17.1	-3.44	0.000636	0.0372	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48084451	chr2:48440043~48440597:-
THCA	cis	rs9634489	0.843	rs9513140	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96407525	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.773	rs538416	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96407649	chr13:95648733~95676925:-
THCA	cis	rs9634489	0.843	rs1328058	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96407753	chr13:95648733~95676925:-
THCA	cis	rs76793172	1	rs77461667	ENSG00000207003.1	RNU6-611P	3.44	0.000636	0.0372	0.3	0.16	Eosinophil counts;	chr19:45837919	chr19:45047458~45047561:+
THCA	cis	rs76793172	0.92	rs77799462	ENSG00000207003.1	RNU6-611P	3.44	0.000636	0.0372	0.3	0.16	Eosinophil counts;	chr19:45839242	chr19:45047458~45047561:+
THCA	cis	rs7267979	0.903	rs6132819	ENSG00000276952.1	RP5-965G21.6	3.44	0.000636	0.0372	0.17	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25284915~25285588:-
THCA	cis	rs6432852	0.966	rs13404648	ENSG00000232411.1	AC009495.3	-3.44	0.000636	0.0372	-0.17	-0.16	Diabetic kidney disease;	chr2:165891275	chr2:165833048~165839098:-
THCA	cis	rs11170631	0.507	rs12307701	ENSG00000270175.1	RP11-793H13.11	-3.44	0.000636	0.0372	-0.1	-0.16	Height;	chr12:53696940	chr12:53500162~53500936:-
THCA	cis	rs9634489	0.843	rs7981815	ENSG00000247400.3	DNAJC3-AS1	-3.44	0.000636	0.0372	-0.1	-0.16	Body mass index;	chr13:96408237	chr13:95648733~95676925:-
THCA	cis	rs763512	0.504	rs4573978	ENSG00000276054.1	RP11-378E13.3	-3.44	0.000636	0.0372	-0.24	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37611969	chr17:37386886~37387926:+
THCA	cis	rs6504108	0.507	rs11079816	ENSG00000264920.1	RP11-6N17.4	-3.44	0.000636	0.0372	-0.17	-0.16	Body mass index;	chr17:48210625	chr17:47891255~47895812:-
THCA	cis	rs7656342	0.569	rs4613568	ENSG00000250342.1	SNRPCP16	3.44	0.000636	0.0372	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9861278	chr4:9051842~9052051:-
THCA	cis	rs656319	0.605	rs60278284	ENSG00000248538.5	RP11-10A14.5	3.44	0.000637	0.0372	0.21	0.16	Myopia (pathological);	chr8:10145700	chr8:9189011~9202854:+
THCA	cis	rs1023500	1	rs1023497	ENSG00000237037.8	NDUFA6-AS1	3.44	0.000637	0.0372	0.15	0.16	Schizophrenia;	chr22:41944504	chr22:42090931~42137742:+
THCA	cis	rs7903847	0.642	rs10882910	ENSG00000225850.3	RP11-452K12.4	3.44	0.000637	0.0372	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97378286	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10882911	ENSG00000225850.3	RP11-452K12.4	3.44	0.000637	0.0372	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97378307	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.619	rs10882912	ENSG00000225850.3	RP11-452K12.4	3.44	0.000637	0.0372	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97378320	chr10:97334564~97343203:+
THCA	cis	rs7243790	0.846	rs56053948	ENSG00000277324.1	RP11-850A17.1	-3.44	0.000637	0.0372	-0.16	-0.16	Diastolic blood pressure;	chr18:54434295	chr18:54268346~54270028:-
THCA	cis	rs4218	0.531	rs10431791	ENSG00000259732.1	RP11-59H7.3	-3.44	0.000637	0.0372	-0.2	-0.16	Social communication problems;	chr15:59055159	chr15:59121034~59133250:+
THCA	cis	rs10911363	0.615	rs12024309	ENSG00000232860.6	SMG7-AS1	3.44	0.000637	0.0372	0.12	0.16	Systemic lupus erythematosus;	chr1:183450846	chr1:183460874~183472265:-
THCA	cis	rs7074356	0.569	rs1832683	ENSG00000278616.1	BEND3P3	3.44	0.000637	0.0372	0.13	0.16	Borderline personality disorder;	chr10:80272575	chr10:79682997~79685436:+
THCA	cis	rs17122278	1	rs11216911	ENSG00000243431.1	RPL5P30	-3.44	0.000637	0.0372	-0.16	-0.16	Total cholesterol levels;	chr11:118581186	chr11:118560690~118561580:+
THCA	cis	rs1876905	0.68	rs354540	ENSG00000271789.1	RP5-1112D6.7	-3.44	0.000637	0.0372	-0.19	-0.16	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111297126~111298510:+
THCA	cis	rs7259376	0.714	rs4358065	ENSG00000269138.1	ZNF209P	3.44	0.000637	0.0372	0.16	0.16	Menopause (age at onset);	chr19:22338330	chr19:22463922~22473036:+
THCA	cis	rs9303280	0.836	rs12453507	ENSG00000263818.4	CTD-2206N4.4	3.44	0.000637	0.0373	0.2	0.16	Self-reported allergy;	chr17:39896954	chr17:39057019~39113190:+
THCA	cis	rs1635	0.655	rs2159275	ENSG00000216901.1	AL022393.7	3.44	0.000637	0.0373	0.35	0.16	Schizophrenia;	chr6:28340669	chr6:28176188~28176674:+
THCA	cis	rs708224	0.702	rs813784	ENSG00000277342.1	RP11-843B15.4	3.44	0.000637	0.0373	0.2	0.16	Pancreatic cancer;	chr12:32285823	chr12:32109076~32109602:+
THCA	cis	rs2933343	0.649	rs1683786	ENSG00000261159.1	RP11-723O4.9	3.44	0.000637	0.0373	0.16	0.16	IgG glycosylation;	chr3:128908109	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.7	rs876754	ENSG00000261159.1	RP11-723O4.9	3.44	0.000637	0.0373	0.16	0.16	IgG glycosylation;	chr3:128908910	chr3:128859716~128860526:-
THCA	cis	rs14027	0.883	rs28486074	ENSG00000279347.1	RP11-85I17.2	-3.44	0.000637	0.0373	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720762	chr8:119838736~119840385:-
THCA	cis	rs14027	0.842	rs28634937	ENSG00000279347.1	RP11-85I17.2	-3.44	0.000637	0.0373	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720877	chr8:119838736~119840385:-
THCA	cis	rs11673344	0.526	rs57654288	ENSG00000267470.4	ZNF571-AS1	-3.44	0.000637	0.0373	-0.19	-0.16	Obesity-related traits;	chr19:37587870	chr19:37548914~37587348:+
THCA	cis	rs8022179	0.58	rs58153827	ENSG00000269940.1	RP11-73M18.7	-3.44	0.000637	0.0373	-0.17	-0.16	Monocyte count;	chr14:103378293	chr14:103694560~103695170:+
THCA	cis	rs73198271	0.74	rs10098636	ENSG00000254153.1	CTA-398F10.2	3.44	0.000637	0.0373	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8456909~8461337:-
THCA	cis	rs4808199	0.947	rs7250658	ENSG00000267481.1	CTC-559E9.5	-3.44	0.000637	0.0373	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19460291	chr19:19788755~19790531:-
THCA	cis	rs6137726	0.652	rs6137721	ENSG00000237396.1	LINC01384	-3.44	0.000637	0.0373	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22670000	chr20:22587522~22607517:-
THCA	cis	rs10911902	0.643	rs75158977	ENSG00000233196.2	GS1-304P7.1	-3.44	0.000637	0.0373	-0.25	-0.16	Schizophrenia;	chr1:186324597	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.602	rs3736595	ENSG00000233196.2	GS1-304P7.1	-3.44	0.000637	0.0373	-0.25	-0.16	Schizophrenia;	chr1:186331745	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs3753565	ENSG00000233196.2	GS1-304P7.1	3.44	0.000637	0.0373	0.25	0.16	Schizophrenia;	chr1:186347356	chr1:186580515~186581191:-
THCA	cis	rs972578	0.967	rs2413736	ENSG00000274717.1	RP1-47A17.1	-3.44	0.000637	0.0373	-0.16	-0.16	Mean platelet volume;	chr22:42942833	chr22:42791814~42794313:-
THCA	cis	rs11771526	0.642	rs11762517	ENSG00000272905.1	RP11-265E18.1	3.44	0.000637	0.0373	0.19	0.16	Body mass index;	chr7:32297181	chr7:32845394~32846061:+
THCA	cis	rs1417770	0.931	rs947255	ENSG00000260971.3	RP11-504A18.1	3.44	0.000637	0.0373	0.15	0.16	Lobe attachment (rater-scored or self-reported);	chr1:56223664	chr1:56248294~56258571:-
THCA	cis	rs17604090	0.775	rs73090343	ENSG00000223813.2	AC007255.8	3.44	0.000637	0.0373	0.15	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649152	chr7:29514225~29563670:-
THCA	cis	rs1552244	0.572	rs12107622	ENSG00000180385.7	EMC3-AS1	3.44	0.000637	0.0373	0.2	0.16	Alzheimer's disease;	chr3:10130214	chr3:9986893~10006990:+
THCA	cis	rs1552244	0.572	rs2054478	ENSG00000180385.7	EMC3-AS1	3.44	0.000637	0.0373	0.2	0.16	Alzheimer's disease;	chr3:10130527	chr3:9986893~10006990:+
THCA	cis	rs440932	1	rs440932	ENSG00000254153.1	CTA-398F10.2	-3.44	0.000637	0.0373	-0.17	-0.16	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8456909~8461337:-
THCA	cis	rs6496667	0.865	rs12592226	ENSG00000259262.1	NDUFA3P4	3.44	0.000637	0.0373	0.22	0.16	Rheumatoid arthritis;	chr15:90382958	chr15:90385814~90386063:+
THCA	cis	rs7843479	0.965	rs11135741	ENSG00000208037.1	MIR320A	-3.44	0.000637	0.0373	-0.19	-0.16	Mean corpuscular volume;	chr8:21943580	chr8:22244962~22245043:-
THCA	cis	rs7843479	0.965	rs11135742	ENSG00000208037.1	MIR320A	-3.44	0.000637	0.0373	-0.19	-0.16	Mean corpuscular volume;	chr8:21945399	chr8:22244962~22245043:-
THCA	cis	rs4664293	0.805	rs7593273	ENSG00000230783.1	AC009961.2	-3.44	0.000637	0.0373	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159749349	chr2:159689217~159690291:-
THCA	cis	rs9650657	0.74	rs7002282	ENSG00000269918.1	AF131215.9	-3.44	0.000637	0.0373	-0.17	-0.16	Neuroticism;	chr8:10809483	chr8:11104691~11106704:-
THCA	cis	rs755249	0.567	rs61779308	ENSG00000237624.1	OXCT2P1	3.44	0.000637	0.0373	0.22	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39514956~39516490:+
THCA	cis	rs6142618	0.562	rs4911545	ENSG00000224452.1	RSL24D1P6	3.44	0.000637	0.0373	0.18	0.16	Inflammatory bowel disease;	chr20:32123712	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs6142613	ENSG00000224452.1	RSL24D1P6	3.44	0.000637	0.0373	0.18	0.16	Inflammatory bowel disease;	chr20:32124203	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs6142615	ENSG00000224452.1	RSL24D1P6	3.44	0.000637	0.0373	0.18	0.16	Inflammatory bowel disease;	chr20:32124636	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs6058528	ENSG00000224452.1	RSL24D1P6	3.44	0.000637	0.0373	0.18	0.16	Inflammatory bowel disease;	chr20:32127247	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs6061173	ENSG00000224452.1	RSL24D1P6	3.44	0.000637	0.0373	0.18	0.16	Inflammatory bowel disease;	chr20:32129312	chr20:32170390~32170790:-
THCA	cis	rs8113308	0.515	rs73066981	ENSG00000260160.1	CTC-471J1.2	3.44	0.000638	0.0373	0.24	0.16	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51959146	chr19:52058490~52063703:-
THCA	cis	rs240993	0.516	rs241006	ENSG00000271789.1	RP5-1112D6.7	-3.44	0.000638	0.0373	-0.2	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111279910	chr6:111297126~111298510:+
THCA	cis	rs1560104	0.556	rs59670495	ENSG00000262801.4	U91319.1	-3.44	0.000638	0.0373	-0.18	-0.16	Obesity-related traits;	chr16:12617241	chr16:13246316~13562918:+
THCA	cis	rs9549260	0.755	rs8001443	ENSG00000275149.1	RP11-427J23.1	3.44	0.000638	0.0373	0.21	0.16	Red blood cell count;	chr13:40642509	chr13:40079106~40273509:-
THCA	cis	rs453301	0.658	rs12114954	ENSG00000253981.4	ALG1L13P	-3.44	0.000638	0.0373	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9047352	chr8:8236003~8244667:-
THCA	cis	rs7976269	0.623	rs73063776	ENSG00000257599.1	OVCH1-AS1	-3.44	0.000638	0.0373	-0.37	-0.16	Male-pattern baldness;	chr12:29066066	chr12:29389294~29487488:+
THCA	cis	rs4930561	0.714	rs11228151	ENSG00000184795.9	UNC93B5	-3.44	0.000638	0.0373	-0.2	-0.16	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68181904	chr11:67711702~67716005:-
THCA	cis	rs7246657	1	rs34544865	ENSG00000266916.4	ZNF793-AS1	-3.44	0.000638	0.0373	-0.16	-0.16	Coronary artery calcification;	chr19:37310340	chr19:37497159~37507046:-
THCA	cis	rs9420	0.816	rs674094	ENSG00000254602.1	AP000662.4	3.44	0.000638	0.0373	0.18	0.16	Schizophrenia;	chr11:57897864	chr11:57638024~57652790:+
THCA	cis	rs3864261	0.945	rs266447	ENSG00000249085.1	CTD-2631K10.1	3.44	0.000638	0.0373	0.24	0.16	Discordance in emotional problems in monozygotic twins;	chr5:72886328	chr5:72794405~72816565:-
THCA	cis	rs11051970	0.559	rs11051939	ENSG00000275769.1	RP11-771K4.3	3.44	0.000638	0.0373	0.22	0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32330107	chr12:31443792~31444208:-
THCA	cis	rs11051970	0.559	rs16919727	ENSG00000275769.1	RP11-771K4.3	-3.44	0.000638	0.0373	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32329976	chr12:31443792~31444208:-
THCA	cis	rs11051970	0.559	rs11051940	ENSG00000275769.1	RP11-771K4.3	-3.44	0.000638	0.0373	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32330187	chr12:31443792~31444208:-
THCA	cis	rs11051970	0.559	rs11051941	ENSG00000275769.1	RP11-771K4.3	-3.44	0.000638	0.0373	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32330338	chr12:31443792~31444208:-
THCA	cis	rs11051970	0.559	rs11051942	ENSG00000275769.1	RP11-771K4.3	-3.44	0.000638	0.0373	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32330344	chr12:31443792~31444208:-
THCA	cis	rs11051970	0.559	rs4316592	ENSG00000275769.1	RP11-771K4.3	-3.44	0.000638	0.0373	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32331076	chr12:31443792~31444208:-
THCA	cis	rs5993586	1	rs5992398	ENSG00000223461.1	AC004471.9	3.44	0.000638	0.0373	0.34	0.16	Coronary artery disease;	chr22:19388778	chr22:19121529~19124503:+
THCA	cis	rs2888875	0.963	rs970176	ENSG00000200924.1	RNU6-1048P	-3.44	0.000638	0.0373	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr2:43575208	chr2:43892690~43892796:+
THCA	cis	rs12780845	0.931	rs34665628	ENSG00000229124.5	VIM-AS1	3.44	0.000638	0.0373	0.16	0.16	Homocysteine levels;	chr10:17210297	chr10:17214239~17229985:-
THCA	cis	rs8064029	0.892	rs62036118	ENSG00000267077.1	RP11-127I20.5	3.44	0.000638	0.0373	0.24	0.16	Cancer;	chr16:4851884	chr16:4795265~4796532:-
THCA	cis	rs7246657	0.941	rs67293224	ENSG00000268499.1	CTB-102L5.8	3.44	0.000638	0.0373	0.21	0.16	Coronary artery calcification;	chr19:37312346	chr19:38199836~38200934:+
THCA	cis	rs1008126	0.6	rs2965098	ENSG00000234715.1	CTB-107G13.1	-3.44	0.000638	0.0373	-0.18	-0.16	Metabolite levels (Pyroglutamine);	chr7:103484338	chr7:103445207~103514007:+
THCA	cis	rs765787	0.53	rs12323957	ENSG00000259539.1	CTD-2651B20.1	-3.44	0.000638	0.0373	-0.2	-0.16	Uric acid levels;	chr15:45198575	chr15:45152664~45167526:-
THCA	cis	rs1154275	0.537	rs6789210	ENSG00000272844.1	RP11-484K9.4	3.44	0.000638	0.0373	0.13	0.16	Takotsubo syndrome;	chr3:112797481	chr3:112990447~112991153:-
THCA	cis	rs3800688	0.527	rs10269703	ENSG00000236753.4	MKLN1-AS	-3.44	0.000638	0.0373	-0.15	-0.16	Hypertension;	chr7:131409920	chr7:131309744~131328222:-
THCA	cis	rs10896135	0.526	rs624561	ENSG00000275484.1	CTC-1337H24.4	3.44	0.000638	0.0373	0.12	0.16	Bipolar disorder;	chr11:66647444	chr11:67374416~67374932:+
THCA	cis	rs9400467	0.506	rs12192617	ENSG00000255389.1	C6orf3	3.44	0.000638	0.0373	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111169072	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.537	rs73530977	ENSG00000255389.1	C6orf3	3.44	0.000638	0.0373	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111183616	chr6:111599875~111602295:+
THCA	cis	rs11673344	0.526	rs35153242	ENSG00000180458.2	CTD-3064H18.4	3.44	0.000638	0.0373	0.21	0.16	Obesity-related traits;	chr19:37660841	chr19:37545470~37549171:-
THCA	cis	rs6687821	0.531	rs11161930	ENSG00000261737.1	RP4-612B15.3	3.44	0.000638	0.0373	0.25	0.16	Yeast infection;	chr1:87056097	chr1:86703502~86704462:-
THCA	cis	rs10492201	0.529	rs4913269	ENSG00000255733.4	IFNG-AS1	-3.44	0.000638	0.0373	-0.14	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014065	chr12:67989445~68234686:+
THCA	cis	rs763121	0.853	rs5757231	ENSG00000272669.1	RP3-508I15.21	3.44	0.000638	0.0373	0.11	0.16	Menopause (age at onset);	chr22:38675653	chr22:38742625~38743115:+
THCA	cis	rs1858037	0.836	rs2576923	ENSG00000252414.1	RNU6-100P	3.44	0.000638	0.0373	0.17	0.16	Rheumatoid arthritis;	chr2:65406750	chr2:64578892~64578997:+
THCA	cis	rs11105298	0.891	rs8181784	ENSG00000266347.2	AC068641.1	3.44	0.000638	0.0373	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89592833~89592927:+
THCA	cis	rs447735	0.587	rs258336	ENSG00000274627.1	RP11-104N10.2	3.44	0.000638	0.0373	0.15	0.16	Hemoglobin concentration;	chr16:89654423	chr16:89516797~89522217:+
THCA	cis	rs7267979	0.586	rs6050439	ENSG00000274973.1	RP13-401N8.7	-3.44	0.000638	0.0373	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25845497~25845862:+
THCA	cis	rs4656940	0.574	rs7555286	ENSG00000226889.3	RP11-474I16.8	3.44	0.000638	0.0373	0.18	0.16	Crohn's disease;	chr1:160797459	chr1:161765325~161766227:-
THCA	cis	rs6714900	0.506	rs11893162	ENSG00000234896.1	OR7E62P	3.44	0.000638	0.0373	0.19	0.16	Blood protein levels;	chr2:71136261	chr2:71055527~71056003:+
THCA	cis	rs6714900	0.506	rs13031606	ENSG00000234896.1	OR7E62P	3.44	0.000638	0.0373	0.19	0.16	Blood protein levels;	chr2:71136532	chr2:71055527~71056003:+
THCA	cis	rs9796	0.774	rs28866311	ENSG00000247556.5	OIP5-AS1	3.44	0.000639	0.0373	0.13	0.16	Menopause (age at onset);	chr15:41149997	chr15:41283990~41309737:+
THCA	cis	rs1476679	1	rs1476679	ENSG00000078319.8	PMS2P1	-3.44	0.000639	0.0373	-0.2	-0.16	Alzheimer's disease (late onset);	chr7:100406823	chr7:100320992~100341908:-
THCA	cis	rs9368222	0.613	rs35456723	ENSG00000280989.1	LINC00581	3.44	0.000639	0.0373	0.19	0.16	Body mass index;Peak insulin response;Acute insulin response;	chr6:20661986	chr6:21486061~21511895:-
THCA	cis	rs7119	0.651	rs12902948	ENSG00000260776.4	RP11-114H24.2	-3.44	0.000639	0.0373	-0.22	-0.16	Type 2 diabetes;	chr15:77556912	chr15:77914217~77926846:-
THCA	cis	rs5753618	0.583	rs5753639	ENSG00000235573.2	RP3-412A9.12	3.44	0.000639	0.0373	0.17	0.16	Colorectal cancer;	chr22:31474414	chr22:31113017~31113396:+
THCA	cis	rs2485892	0.619	rs11119431	ENSG00000203706.7	SERTAD4-AS1	3.44	0.000639	0.0373	0.16	0.16	Manic episodes in bipolar disorder;	chr1:210181241	chr1:210231456~210234047:-
THCA	cis	rs7202877	0.656	rs977986	ENSG00000261476.1	RP11-77K12.3	-3.44	0.000639	0.0374	-0.25	-0.16	Type 1 diabetes;Type 2 diabetes;	chr16:75472798	chr16:75458252~75460017:-
THCA	cis	rs8130944	0.964	rs1029332	ENSG00000235772.1	AP001625.6	3.44	0.000639	0.0374	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42722869	chr21:42560374~42561934:-
THCA	cis	rs8130944	0.964	rs9653815	ENSG00000235772.1	AP001625.6	3.44	0.000639	0.0374	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr21:42723133	chr21:42560374~42561934:-
THCA	cis	rs9891119	0.93	rs8073517	ENSG00000267595.1	RP11-242D8.2	-3.44	0.000639	0.0374	-0.14	-0.16	Multiple sclerosis;Crohn's disease;	chr17:42351306	chr17:43168170~43168249:-
THCA	cis	rs10266483	0.774	rs10949901	ENSG00000271550.1	BNIP3P11	-3.44	0.000639	0.0374	-0.21	-0.16	Response to statin therapy;	chr7:64352396	chr7:64678954~64687393:-
THCA	cis	rs10266483	0.774	rs10239221	ENSG00000271550.1	BNIP3P11	-3.44	0.000639	0.0374	-0.21	-0.16	Response to statin therapy;	chr7:64352852	chr7:64678954~64687393:-
THCA	cis	rs9302690	1	rs62037143	ENSG00000205361.7	MT1DP	-3.44	0.000639	0.0374	-0.31	-0.16	Blood protein levels;	chr16:57452671	chr16:56643705~56644786:+
THCA	cis	rs11708578	0.522	rs72996009	ENSG00000237990.3	CNTN4-AS1	3.44	0.000639	0.0374	0.2	0.16	Schizophrenia;	chr3:2387585	chr3:3039033~3069242:-
THCA	cis	rs6142618	0.562	rs2295035	ENSG00000224452.1	RSL24D1P6	3.44	0.000639	0.0374	0.18	0.16	Inflammatory bowel disease;	chr20:32114341	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.543	rs2295036	ENSG00000224452.1	RSL24D1P6	3.44	0.000639	0.0374	0.18	0.16	Inflammatory bowel disease;	chr20:32115793	chr20:32170390~32170790:-
THCA	cis	rs7267979	0.586	rs1007708	ENSG00000274973.1	RP13-401N8.7	-3.44	0.000639	0.0374	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25845497~25845862:+
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000264242.2	RP11-271K11.1	-3.44	0.000639	0.0374	-0.24	-0.16	Body mass index;	chr17:30767864	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Body mass index;	chr17:30756962	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Body mass index;	chr17:30758695	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Body mass index;	chr17:30772984	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Body mass index;	chr17:30779631	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000264242.2	RP11-271K11.1	3.44	0.000639	0.0374	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30553697~30558962:+
THCA	cis	rs8054556	0.74	rs9936474	ENSG00000273724.1	RP11-347C12.12	-3.44	0.000639	0.0374	-0.15	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29921370	chr16:30336400~30343336:+
THCA	cis	rs9860428	0.844	rs9858931	ENSG00000243795.1	RP11-572M11.3	-3.44	0.000639	0.0374	-0.18	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897933	chr3:113142350~113167819:-
THCA	cis	rs10411161	0.58	rs12151287	ENSG00000275055.1	CTC-471J1.11	-3.44	0.000639	0.0374	-0.13	-0.16	Breast cancer;	chr19:51878242	chr19:52049007~52049754:+
THCA	cis	rs17407555	0.862	rs11729685	ENSG00000261490.1	RP11-448G15.3	-3.44	0.000639	0.0374	-0.13	-0.16	Schizophrenia (age at onset);	chr4:10275163	chr4:10068089~10073019:-
THCA	cis	rs4578769	0.55	rs4280358	ENSG00000273232.1	RP11-370A5.2	3.44	0.000639	0.0374	0.22	0.16	Eosinophil percentage of white cells;	chr18:23037844	chr18:22882825~22883357:-
THCA	cis	rs17428076	0.874	rs12619041	ENSG00000228389.1	AC068039.4	3.44	0.000639	0.0374	0.18	0.16	Myopia;	chr2:171744206	chr2:171773482~171775844:+
THCA	cis	rs12545912	0.569	rs616021	ENSG00000248538.5	RP11-10A14.5	3.44	0.00064	0.0374	0.25	0.16	Multiple myeloma (hyperdiploidy);	chr8:9938864	chr8:9189011~9202854:+
THCA	cis	rs11168618	1	rs10875833	ENSG00000258273.1	RP11-370I10.4	-3.44	0.00064	0.0374	-0.21	-0.16	Adiponectin levels;	chr12:48559585	chr12:48333755~48333901:-
THCA	cis	rs10946940	0.897	rs6456801	ENSG00000220721.1	OR1F12	3.44	0.00064	0.0374	0.18	0.16	Systemic lupus erythematosus;	chr6:27657753	chr6:28073316~28074233:+
THCA	cis	rs17604090	1	rs28420551	ENSG00000227855.3	DPY19L2P3	3.44	0.00064	0.0374	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29645737	chr7:29650227~29742594:+
THCA	cis	rs2131877	0.619	rs6794540	ENSG00000238097.1	RP11-513G11.3	-3.44	0.00064	0.0374	-0.18	-0.16	Non-small cell lung cancer;	chr3:195146433	chr3:194247648~194257772:+
THCA	cis	rs2667011	0.512	rs1995950	ENSG00000226266.5	AC009961.3	-3.44	0.00064	0.0374	-0.24	-0.16	Bilirubin levels;	chr2:159944117	chr2:159670708~159712435:-
THCA	cis	rs7542375	0.594	rs2807851	ENSG00000272823.1	RP11-295M18.6	-3.44	0.00064	0.0374	-0.19	-0.16	Obesity-related traits;	chr1:220849203	chr1:220828676~220829211:-
THCA	cis	rs987724	0.593	rs9867621	ENSG00000241544.1	RP11-6F2.5	-3.44	0.00064	0.0374	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156896774	chr3:157081841~157088547:+
THCA	cis	rs987724	0.555	rs12629380	ENSG00000241544.1	RP11-6F2.5	-3.44	0.00064	0.0374	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898291	chr3:157081841~157088547:+
THCA	cis	rs987724	0.555	rs9866373	ENSG00000241544.1	RP11-6F2.5	-3.44	0.00064	0.0374	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901961	chr3:157081841~157088547:+
THCA	cis	rs2562456	0.917	rs2650804	ENSG00000268278.1	RP11-420K14.1	3.44	0.00064	0.0374	0.19	0.16	Pain;	chr19:21497382	chr19:21637974~21656300:+
THCA	cis	rs12935418	1	rs12935418	ENSG00000261838.4	RP11-303E16.6	3.44	0.00064	0.0374	0.24	0.16	Mean corpuscular volume;	chr16:81036403	chr16:81069854~81076598:+
THCA	cis	rs9611565	0.512	rs4820446	ENSG00000237037.8	NDUFA6-AS1	3.44	0.00064	0.0374	0.16	0.16	Vitiligo;	chr22:41819680	chr22:42090931~42137742:+
THCA	cis	rs11088226	0.692	rs1123142	ENSG00000186842.4	LINC00846	-3.44	0.00064	0.0374	-0.2	-0.16	Gastritis;	chr21:32521428	chr21:32572238~32575881:-
THCA	cis	rs4792901	0.959	rs4792998	ENSG00000267151.3	RP11-100E5.2	-3.44	0.00064	0.0374	-0.15	-0.16	Dupuytren's disease;	chr17:43575413	chr17:43444707~43451200:+
THCA	cis	rs9991779	0.657	rs62336581	ENSG00000237125.7	HAND2-AS1	-3.44	0.00064	0.0374	-0.27	-0.16	Pediatric bone mineral content (hip);	chr4:173980447	chr4:173527270~173591324:+
THCA	cis	rs11718502	0.66	rs11717578	ENSG00000232354.6	VIPR1-AS1	3.44	0.00064	0.0374	0.19	0.16	Magnesium levels;	chr3:42450959	chr3:42506465~42533258:-
THCA	cis	rs763512	0.504	rs4573978	ENSG00000277501.1	RP11-697E22.2	-3.44	0.00064	0.0374	-0.22	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37611969	chr17:37642947~37684252:+
THCA	cis	rs13098911	0.54	rs78380307	ENSG00000223552.1	RP11-24F11.2	-3.44	0.00064	0.0374	-0.22	-0.16	Celiac disease;	chr3:46132839	chr3:46364955~46407059:-
THCA	cis	rs939960	0.959	rs11764186	ENSG00000224016.2	RP11-728K20.1	3.44	0.00064	0.0374	0.21	0.16	Neutrophil percentage of white cells;	chr7:150588666	chr7:149891191~149909704:-
THCA	cis	rs939960	0.959	rs13236567	ENSG00000224016.2	RP11-728K20.1	3.44	0.00064	0.0374	0.21	0.16	Neutrophil percentage of white cells;	chr7:150588702	chr7:149891191~149909704:-
THCA	cis	rs4660214	0.568	rs6692769	ENSG00000228060.1	RP11-69E11.8	3.44	0.00064	0.0374	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39217503	chr1:39565160~39573203:+
THCA	cis	rs6687821	0.515	rs6697798	ENSG00000261737.1	RP4-612B15.3	3.44	0.00064	0.0374	0.23	0.16	Yeast infection;	chr1:87020598	chr1:86703502~86704462:-
THCA	cis	rs7824557	0.527	rs2572376	ENSG00000255046.1	RP11-297N6.4	3.44	0.00064	0.0374	0.16	0.16	Retinal vascular caliber;	chr8:11380247	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.527	rs2736305	ENSG00000255046.1	RP11-297N6.4	3.44	0.00064	0.0374	0.16	0.16	Retinal vascular caliber;	chr8:11380264	chr8:11797928~11802568:-
THCA	cis	rs7141336	0.607	rs6575147	ENSG00000275198.1	RP11-471B22.3	-3.44	0.00064	0.0374	-0.14	-0.16	Anxiety disorder;	chr14:90753254	chr14:90383365~90387973:+
THCA	cis	rs17604090	1	rs73297441	ENSG00000227855.3	DPY19L2P3	3.44	0.00064	0.0374	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29644747	chr7:29650227~29742594:+
THCA	cis	rs17604090	0.877	rs28516764	ENSG00000227855.3	DPY19L2P3	3.44	0.00064	0.0374	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29645629	chr7:29650227~29742594:+
THCA	cis	rs17604090	0.938	rs28664977	ENSG00000227855.3	DPY19L2P3	3.44	0.00064	0.0374	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29645753	chr7:29650227~29742594:+
THCA	cis	rs17604090	0.536	rs112165062	ENSG00000227855.3	DPY19L2P3	3.44	0.00064	0.0374	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647976	chr7:29650227~29742594:+
THCA	cis	rs1876905	0.597	rs1215964	ENSG00000271789.1	RP5-1112D6.7	-3.44	0.00064	0.0374	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111297126~111298510:+
THCA	cis	rs948562	0.895	rs7484263	ENSG00000280010.1	AP001350.4	3.44	0.00064	0.0374	0.24	0.16	Lymphoma;	chr11:58608080	chr11:58627435~58628528:+
THCA	cis	rs7246657	0.722	rs16958861	ENSG00000226686.6	LINC01535	-3.44	0.00064	0.0374	-0.23	-0.16	Coronary artery calcification;	chr19:37633278	chr19:37251912~37265535:+
THCA	cis	rs4144027	0.904	rs10438243	ENSG00000258534.1	CTD-2134A5.4	3.44	0.00064	0.0374	0.16	0.16	Blood metabolite levels;	chr14:103879485	chr14:103854366~103880111:-
THCA	cis	rs7914558	1	rs7911789	ENSG00000213061.2	PFN1P11	3.44	0.00064	0.0374	0.19	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs67908413	ENSG00000213061.2	PFN1P11	3.44	0.00064	0.0374	0.19	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102838011~102845473:-
THCA	cis	rs17407555	0.789	rs4348091	ENSG00000250413.1	RP11-448G15.1	3.44	0.00064	0.0374	0.18	0.16	Schizophrenia (age at onset);	chr4:10113739	chr4:10006482~10009725:+
THCA	cis	rs7707921	1	rs17245188	ENSG00000251374.1	RPS23P5	-3.44	0.00064	0.0374	-0.23	-0.16	Breast cancer;	chr5:82173263	chr5:82265157~82265259:-
THCA	cis	rs11634944	0.506	rs765438	ENSG00000257647.1	RP11-701H24.3	3.44	0.00064	0.0374	0.09	0.16	Interleukin-8 levels;	chr15:24990981	chr15:25027736~25032047:-
THCA	cis	rs7621331	1	rs17197552	ENSG00000239213.4	NCK1-AS1	3.44	0.000641	0.0374	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136003422	chr3:136841726~136862054:-
THCA	cis	rs875971	0.706	rs1643374	ENSG00000275400.1	RP4-756H11.5	-3.44	0.000641	0.0374	-0.15	-0.16	Aortic root size;	chr7:66407695	chr7:66553805~66554199:-
THCA	cis	rs2832191	0.755	rs2832193	ENSG00000176054.6	RPL23P2	-3.44	0.000641	0.0374	-0.13	-0.16	Dental caries;	chr21:29121268	chr21:28997613~28998033:-
THCA	cis	rs990871	0.574	rs4649957	ENSG00000227207.2	RPL31P12	-3.44	0.000641	0.0374	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72484065	chr1:72301472~72301829:+
THCA	cis	rs9393777	0.844	rs35909544	ENSG00000220721.1	OR1F12	3.44	0.000641	0.0374	0.3	0.16	Intelligence (multi-trait analysis);	chr6:27195677	chr6:28073316~28074233:+
THCA	cis	rs72634501	0.642	rs67452844	ENSG00000182109.6	RP11-69E11.4	3.44	0.000641	0.0374	0.16	0.16	HDL cholesterol;	chr1:39150610	chr1:39522280~39546187:-
THCA	cis	rs4948275	0.631	rs2606116	ENSG00000233643.2	RP11-491H19.1	3.44	0.000641	0.0374	0.18	0.16	Night sleep phenotypes;	chr10:61591316	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.631	rs2606117	ENSG00000233643.2	RP11-491H19.1	3.44	0.000641	0.0374	0.18	0.16	Night sleep phenotypes;	chr10:61592045	chr10:61781745~61821246:-
THCA	cis	rs559555	0.695	rs12470143	ENSG00000276517.1	AL133243.2	-3.44	0.000641	0.0374	-0.15	-0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31538488	chr2:32526504~32529507:+
THCA	cis	rs12083887	0.505	rs67084635	ENSG00000236866.4	AL157902.3	-3.44	0.000641	0.0374	-0.18	-0.16	Male-pattern baldness;	chr1:118373021	chr1:117596832~117605770:-
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000281021.1	RP1-12G14.9	-3.44	0.000641	0.0374	-0.16	-0.16	Lung cancer;	chr6:149711896	chr6:149576089~149590864:-
THCA	cis	rs6840360	0.615	rs4696094	ENSG00000251611.1	RP11-610P16.1	-3.44	0.000641	0.0375	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151544349	chr4:151407551~151408835:-
THCA	cis	rs73222236	0.75	rs35375192	ENSG00000273486.1	RP11-731C17.2	3.44	0.000641	0.0375	0.14	0.16	Coronary artery disease;	chr3:136456683	chr3:136837338~136839021:-
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000264242.2	RP11-271K11.1	3.44	0.000641	0.0375	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30553697~30558962:+
THCA	cis	rs2617170	0.754	rs12824474	ENSG00000245648.1	RP11-277P12.20	-3.44	0.000641	0.0375	-0.17	-0.16	Behcet's disease;	chr12:10450326	chr12:10363769~10398506:+
THCA	cis	rs12612619	0.689	rs11681145	ENSG00000231636.1	AGBL5-AS1	3.44	0.000641	0.0375	0.19	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27067657	chr2:27049683~27050264:-
THCA	cis	rs6547705	0.858	rs12714202	ENSG00000231259.4	AC125232.1	3.44	0.000641	0.0375	0.22	0.16	Progressive supranuclear palsy;	chr2:86672815	chr2:87031815~87053069:-
THCA	cis	rs7572733	0.592	rs113964240	ENSG00000231621.1	AC013264.2	-3.44	0.000641	0.0375	-0.15	-0.16	Dermatomyositis;	chr2:197591586	chr2:197197991~197199273:+
THCA	cis	rs4568518	0.903	rs10950695	ENSG00000279048.1	RP11-511H23.2	-3.44	0.000641	0.0375	-0.11	-0.16	Measles;	chr7:17995592	chr7:17940503~17942922:+
THCA	cis	rs3800688	0.527	rs7784242	ENSG00000236753.4	MKLN1-AS	-3.44	0.000641	0.0375	-0.15	-0.16	Hypertension;	chr7:131407675	chr7:131309744~131328222:-
THCA	cis	rs3800688	0.527	rs7788446	ENSG00000236753.4	MKLN1-AS	-3.44	0.000641	0.0375	-0.15	-0.16	Hypertension;	chr7:131407886	chr7:131309744~131328222:-
THCA	cis	rs10186029	0.582	rs1992395	ENSG00000270659.1	RP11-105N14.1	3.44	0.000641	0.0375	0.13	0.16	Systemic sclerosis;	chr2:213139147	chr2:213152970~213153659:+
THCA	cis	rs17092148	1	rs6088594	ENSG00000269202.1	RP4-614O4.12	-3.44	0.000641	0.0375	-0.18	-0.16	Neuroticism;	chr20:34755354	chr20:35201747~35203288:-
THCA	cis	rs7712401	0.791	rs4836244	ENSG00000263432.2	RN7SL689P	3.44	0.000641	0.0375	0.16	0.16	Mean platelet volume;	chr5:122780537	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.791	rs4835897	ENSG00000263432.2	RN7SL689P	3.44	0.000641	0.0375	0.16	0.16	Mean platelet volume;	chr5:122785809	chr5:123022487~123022783:-
THCA	cis	rs1612141	0.744	rs8013812	ENSG00000251363.2	RP11-129M6.1	3.44	0.000641	0.0375	0.23	0.16	QT interval (drug interaction);	chr14:41101325	chr14:40954898~40975877:+
THCA	cis	rs875971	0.658	rs432667	ENSG00000230189.5	GS1-124K5.2	3.44	0.000641	0.0375	0.11	0.16	Aortic root size;	chr7:66049646	chr7:66409143~66490059:-
THCA	cis	rs10911902	0.643	rs79080293	ENSG00000228238.1	GS1-304P7.2	-3.44	0.000641	0.0375	-0.26	-0.16	Schizophrenia;	chr1:186379546	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs3766699	ENSG00000228238.1	GS1-304P7.2	-3.44	0.000641	0.0375	-0.26	-0.16	Schizophrenia;	chr1:186381179	chr1:186578279~186579299:+
THCA	cis	rs6788895	1	rs7617507	ENSG00000244265.1	SIAH2-AS1	-3.44	0.000641	0.0375	-0.34	-0.16	Breast cancer;	chr3:150781808	chr3:150761937~150762538:+
THCA	cis	rs9878978	0.554	rs1354241	ENSG00000237990.3	CNTN4-AS1	3.44	0.000641	0.0375	0.16	0.16	Blood pressure (smoking interaction);	chr3:2420893	chr3:3039033~3069242:-
THCA	cis	rs6546886	0.912	rs34136450	ENSG00000235499.1	AC073046.25	3.44	0.000642	0.0375	0.15	0.16	Dialysis-related mortality;	chr2:74079078	chr2:73985132~73986343:+
THCA	cis	rs7246657	0.722	rs10409605	ENSG00000226686.6	LINC01535	-3.44	0.000642	0.0375	-0.23	-0.16	Coronary artery calcification;	chr19:37632236	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs2972447	ENSG00000226686.6	LINC01535	3.44	0.000642	0.0375	0.23	0.16	Coronary artery calcification;	chr19:37638835	chr19:37251912~37265535:+
THCA	cis	rs7147624	0.608	rs4902413	ENSG00000276116.2	FUT8-AS1	3.44	0.000642	0.0375	0.23	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65720373	chr14:65411170~65412690:-
THCA	cis	rs1635	0.655	rs60568488	ENSG00000216901.1	AL022393.7	3.44	0.000642	0.0375	0.35	0.16	Schizophrenia;	chr6:28341734	chr6:28176188~28176674:+
THCA	cis	rs324126	0.78	rs60935857	ENSG00000243680.1	RPL37P23	-3.44	0.000642	0.0375	-0.14	-0.16	Colonoscopy-negative controls vs population controls;	chr19:52382606	chr19:52143043~52143336:+
THCA	cis	rs9475677	0.953	rs6459154	ENSG00000231441.1	RP11-472M19.2	-3.44	0.000642	0.0375	-0.19	-0.16	Gut microbiota (functional units);	chr6:56342539	chr6:56844002~56864078:+
THCA	cis	rs11771526	0.901	rs62456036	ENSG00000272905.1	RP11-265E18.1	3.44	0.000642	0.0375	0.2	0.16	Body mass index;	chr7:32226570	chr7:32845394~32846061:+
THCA	cis	rs6545883	0.931	rs778765	ENSG00000212978.6	AC016747.3	3.44	0.000642	0.0375	0.17	0.16	Tuberculosis;	chr2:61559250	chr2:61141592~61144969:-
THCA	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	3.44	0.000642	0.0375	0.14	0.16	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
THCA	cis	rs9549260	0.755	rs59308928	ENSG00000275149.1	RP11-427J23.1	-3.44	0.000642	0.0375	-0.21	-0.16	Red blood cell count;	chr13:40670942	chr13:40079106~40273509:-
THCA	cis	rs733592	0.507	rs10875739	ENSG00000273765.1	RP11-370I10.11	3.44	0.000642	0.0375	0.14	0.16	Plateletcrit;	chr12:48087136	chr12:48360920~48361377:+
THCA	cis	rs7914558	1	rs3740387	ENSG00000213061.2	PFN1P11	3.44	0.000642	0.0375	0.19	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:102838011~102845473:-
THCA	cis	rs12410462	0.681	rs76191945	ENSG00000227711.2	RP11-275O4.5	-3.44	0.000642	0.0375	-0.29	-0.16	Major depressive disorder;	chr1:227486218	chr1:227509028~227520477:-
THCA	cis	rs5758511	0.573	rs2267438	ENSG00000230107.1	CTA-126B4.7	3.44	0.000642	0.0375	0.16	0.16	Birth weight;	chr22:41841561	chr22:42438023~42446195:+
THCA	cis	rs867186	1	rs2069940	ENSG00000279253.1	RP4-614O4.13	-3.44	0.000642	0.0375	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35171469	chr20:35262727~35264187:-
THCA	cis	rs2180341	0.694	rs2875972	ENSG00000220522.2	RP1-177A13.1	3.44	0.000642	0.0375	0.2	0.16	Breast cancer;	chr6:127264377	chr6:127416535~127416952:-
THCA	cis	rs7520050	0.966	rs1707321	ENSG00000280836.1	AL355480.1	3.44	0.000642	0.0375	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45581219~45581321:-
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000255052.4	FAM66D	-3.44	0.000642	0.0375	-0.2	-0.16	Neuroticism;	chr8:11989569	chr8:12115782~12177550:+
THCA	cis	rs2018683	0.707	rs10279870	ENSG00000233517.1	AC005162.5	-3.44	0.000642	0.0375	-0.19	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929318	chr7:28987028~28988899:+
THCA	cis	rs7940646	0.617	rs1863243	ENSG00000254554.1	RP11-351I24.1	-3.44	0.000642	0.0375	-0.18	-0.16	Platelet aggregation;	chr11:10655826	chr11:10302657~10303704:-
THCA	cis	rs9902453	0.679	rs2054847	ENSG00000263370.1	RP11-68I3.5	3.44	0.000642	0.0375	0.21	0.16	Coffee consumption (cups per day);	chr17:30204995	chr17:29639627~29640825:+
THCA	cis	rs7296418	0.663	rs11057284	ENSG00000256092.2	RP13-942N8.1	3.44	0.000642	0.0375	0.11	0.16	Platelet count;	chr12:123346145	chr12:123363868~123366113:+
THCA	cis	rs9788682	0.706	rs924840	ENSG00000261143.1	ADAMTS7P3	-3.44	0.000642	0.0375	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78439466	chr15:77976042~77993057:+
THCA	cis	rs7430456	0.967	rs6780021	ENSG00000225790.1	RP11-2L8.1	-3.44	0.000642	0.0375	-0.19	-0.16	Breast cancer;	chr3:177739677	chr3:177934823~177937662:+
THCA	cis	rs7246657	0.943	rs6508733	ENSG00000266916.4	ZNF793-AS1	-3.44	0.000642	0.0375	-0.15	-0.16	Coronary artery calcification;	chr19:37509646	chr19:37497159~37507046:-
THCA	cis	rs2130392	1	rs4862406	ENSG00000250726.1	RP11-616K6.1	3.44	0.000642	0.0375	0.19	0.16	Kawasaki disease;	chr4:184708185	chr4:184072403~184073039:+
THCA	cis	rs11992162	0.613	rs6601634	ENSG00000255046.1	RP11-297N6.4	3.44	0.000642	0.0375	0.17	0.16	Monocyte count;	chr8:11948947	chr8:11797928~11802568:-
THCA	cis	rs4814894	0.716	rs4814895	ENSG00000236992.2	RPL12L3	3.44	0.000642	0.0375	0.16	0.16	Breast cancer;	chr20:19772996	chr20:19823443~19823943:-
THCA	cis	rs638893	0.898	rs530646	ENSG00000255422.1	AP002954.4	-3.44	0.000642	0.0375	-0.24	-0.16	Vitiligo;	chr11:118830959	chr11:118704607~118750263:+
THCA	cis	rs638893	0.947	rs12808822	ENSG00000255422.1	AP002954.4	-3.44	0.000642	0.0375	-0.24	-0.16	Vitiligo;	chr11:118831560	chr11:118704607~118750263:+
THCA	cis	rs9475677	0.953	rs17823397	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56345602	chr6:56844002~56864078:+
THCA	cis	rs9475677	0.953	rs17224995	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56345619	chr6:56844002~56864078:+
THCA	cis	rs9475677	0.953	rs78351632	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56345705	chr6:56844002~56864078:+
THCA	cis	rs9475677	0.906	rs78961487	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56345725	chr6:56844002~56864078:+
THCA	cis	rs9475677	0.906	rs17225023	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56345906	chr6:56844002~56864078:+
THCA	cis	rs9475677	0.953	rs12199257	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56345935	chr6:56844002~56864078:+
THCA	cis	rs9475677	0.953	rs9464380	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56346593	chr6:56844002~56864078:+
THCA	cis	rs9475677	0.953	rs17823553	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56346787	chr6:56844002~56864078:+
THCA	cis	rs9475677	0.953	rs1883600	ENSG00000231441.1	RP11-472M19.2	3.44	0.000642	0.0375	0.19	0.16	Gut microbiota (functional units);	chr6:56347336	chr6:56844002~56864078:+
THCA	cis	rs6473252	0.584	rs6989517	ENSG00000254162.1	RP11-48B3.3	-3.44	0.000642	0.0375	-0.14	-0.16	Breast cancer;	chr8:80893971	chr8:80535006~80539135:-
THCA	cis	rs453301	0.606	rs6601279	ENSG00000253981.4	ALG1L13P	-3.44	0.000642	0.0375	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9050721	chr8:8236003~8244667:-
THCA	cis	rs453301	0.606	rs6981060	ENSG00000253981.4	ALG1L13P	-3.44	0.000642	0.0375	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9050725	chr8:8236003~8244667:-
THCA	cis	rs7656342	0.665	rs7696971	ENSG00000250342.1	SNRPCP16	3.44	0.000642	0.0375	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9882904	chr4:9051842~9052051:-
THCA	cis	rs17767294	0.612	rs12332927	ENSG00000219891.2	ZSCAN12P1	3.44	0.000642	0.0375	0.28	0.16	Parkinson's disease;	chr6:27987337	chr6:28091154~28093664:+
THCA	cis	rs7565158	0.581	rs2371706	ENSG00000234308.2	AC093381.2	-3.44	0.000643	0.0375	-0.14	-0.16	Body mass index (change over time);	chr2:212738114	chr2:212795331~212819264:+
THCA	cis	rs12022452	0.73	rs2297755	ENSG00000272145.1	NFYC-AS1	3.44	0.000643	0.0375	0.14	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40690380~40692066:-
THCA	cis	rs12935418	1	rs12935418	ENSG00000278985.1	RP11-303E16.9	3.44	0.000643	0.0375	0.21	0.16	Mean corpuscular volume;	chr16:81036403	chr16:80982319~80984094:-
THCA	cis	rs3026101	0.624	rs7426	ENSG00000234327.6	AC012146.7	-3.44	0.000643	0.0375	-0.13	-0.16	Body mass index;	chr17:5385663	chr17:5111468~5115004:+
THCA	cis	rs748404	0.631	rs11070399	ENSG00000224677.1	PDIA3P2	3.44	0.000643	0.0375	0.19	0.16	Lung cancer;	chr15:43354149	chr15:43649123~43649280:+
THCA	cis	rs4959799	0.655	rs9503520	ENSG00000272248.1	RP3-406P24.4	-3.44	0.000643	0.0375	-0.35	-0.16	Survival in rectal cancer;	chr6:3281507	chr6:4018713~4019202:+
THCA	cis	rs758324	0.812	rs13174462	ENSG00000237714.1	P4HA2-AS1	3.44	0.000643	0.0375	0.22	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131882295	chr5:132184876~132192808:+
THCA	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	3.44	0.000643	0.0375	0.16	0.16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
THCA	cis	rs17607347	1	rs17607347	ENSG00000260593.1	RP11-432I5.2	3.44	0.000643	0.0375	0.22	0.16	Intelligence (multi-trait analysis);	chr16:72347561	chr16:71623708~71626816:-
THCA	cis	rs10129255	0.957	rs8009638	ENSG00000280411.1	IGHV1-69-2	-3.44	0.000643	0.0375	-0.1	-0.16	Kawasaki disease;	chr14:106777570	chr14:106762092~106762588:-
THCA	cis	rs11168187	0.714	rs12424297	ENSG00000280054.1	RP1-197B17.7	3.44	0.000643	0.0375	0.26	0.16	Vertical cup-disc ratio;	chr12:47748560	chr12:47728151~47730598:-
THCA	cis	rs11168187	0.714	rs12423645	ENSG00000280054.1	RP1-197B17.7	3.44	0.000643	0.0375	0.26	0.16	Vertical cup-disc ratio;	chr12:47750195	chr12:47728151~47730598:-
THCA	cis	rs7818688	0.697	rs3802191	ENSG00000253528.2	RP11-347C18.4	3.44	0.000643	0.0376	0.24	0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975356	chr8:94974573~94974853:-
THCA	cis	rs2404602	0.598	rs11855999	ENSG00000196274.5	Metazoa_SRP	-3.44	0.000643	0.0376	-0.18	-0.16	Blood metabolite levels;	chr15:76334992	chr15:76230048~76230390:-
THCA	cis	rs34779708	0.931	rs2384289	ENSG00000233200.1	RP11-324I22.2	3.44	0.000643	0.0376	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs11010082	ENSG00000233200.1	RP11-324I22.2	3.44	0.000643	0.0376	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35219894~35230598:-
THCA	cis	rs10256972	0.758	rs7799391	ENSG00000199023.2	MIR339	-3.44	0.000643	0.0376	-0.16	-0.16	Endometriosis;Longevity;	chr7:1042930	chr7:1022935~1023045:-
THCA	cis	rs4656958	0.93	rs11587040	ENSG00000233691.2	RP11-312J18.7	-3.44	0.000643	0.0376	-0.19	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160929993	chr1:160935537~160936126:+
THCA	cis	rs848087	0.564	rs2774036	ENSG00000257826.1	RP11-116N8.4	3.44	0.000643	0.0376	0.16	0.16	Breast cancer;	chr14:36789499	chr14:36061026~36067190:-
THCA	cis	rs8027587	1	rs12148252	ENSG00000271997.1	RP11-97O12.6	3.44	0.000643	0.0376	0.11	0.16	Obesity-related traits;	chr15:88706799	chr15:88501944~88505787:-
THCA	cis	rs2455799	0.613	rs1976479	ENSG00000270409.1	RP11-44D5.1	-3.44	0.000643	0.0376	-0.17	-0.16	Mean platelet volume;	chr3:15688207	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.613	rs1393969	ENSG00000270409.1	RP11-44D5.1	-3.44	0.000643	0.0376	-0.17	-0.16	Mean platelet volume;	chr3:15688750	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.593	rs2062823	ENSG00000270409.1	RP11-44D5.1	-3.44	0.000643	0.0376	-0.17	-0.16	Mean platelet volume;	chr3:15690749	chr3:15732252~15733470:+
THCA	cis	rs939960	0.959	rs35233281	ENSG00000276538.1	RP11-545G3.2	3.44	0.000643	0.0376	0.23	0.16	Neutrophil percentage of white cells;	chr7:150583856	chr7:150047609~150047854:-
THCA	cis	rs9296092	0.56	rs9469500	ENSG00000272217.1	XXbac-BPG157A10.21	3.44	0.000643	0.0376	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33558419	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.538	rs9461887	ENSG00000272217.1	XXbac-BPG157A10.21	3.44	0.000643	0.0376	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33559050	chr6:33246075~33246856:-
THCA	cis	rs6545883	0.894	rs6709441	ENSG00000212978.6	AC016747.3	-3.44	0.000643	0.0376	-0.17	-0.16	Tuberculosis;	chr2:61209795	chr2:61141592~61144969:-
THCA	cis	rs7267979	0.933	rs2261109	ENSG00000276952.1	RP5-965G21.6	3.44	0.000643	0.0376	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2261698	ENSG00000276952.1	RP5-965G21.6	3.44	0.000643	0.0376	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2261720	ENSG00000276952.1	RP5-965G21.6	3.44	0.000643	0.0376	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.966	rs2227890	ENSG00000276952.1	RP5-965G21.6	3.44	0.000643	0.0376	0.16	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25284915~25285588:-
THCA	cis	rs17604090	0.877	rs68169519	ENSG00000227855.3	DPY19L2P3	3.44	0.000643	0.0376	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29645542	chr7:29650227~29742594:+
THCA	cis	rs1348850	0.561	rs4893956	ENSG00000280374.1	RP11-337N6.3	-3.44	0.000643	0.0376	-0.27	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177508724	chr2:177317715~177318471:-
THCA	cis	rs1348850	0.526	rs2141157	ENSG00000280374.1	RP11-337N6.3	-3.44	0.000643	0.0376	-0.27	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177509384	chr2:177317715~177318471:-
THCA	cis	rs1348850	0.526	rs59972556	ENSG00000280374.1	RP11-337N6.3	-3.44	0.000643	0.0376	-0.27	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177534833	chr2:177317715~177318471:-
THCA	cis	rs829402	0.947	rs829375	ENSG00000187952.9	HS6ST1P1	3.44	0.000643	0.0376	0.23	0.16	High light scatter reticulocyte count;	chr1:21664742	chr1:21428303~21429536:+
THCA	cis	rs6832769	0.885	rs6815516	ENSG00000223305.1	RN7SKP30	-3.44	0.000643	0.0376	-0.2	-0.16	Personality dimensions;	chr4:55533017	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs17085889	ENSG00000223305.1	RN7SKP30	-3.44	0.000643	0.0376	-0.2	-0.16	Personality dimensions;	chr4:55535948	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs10005989	ENSG00000223305.1	RN7SKP30	-3.44	0.000643	0.0376	-0.2	-0.16	Personality dimensions;	chr4:55539039	chr4:55540502~55540835:-
THCA	cis	rs7916852	0.717	rs11006873	ENSG00000230500.1	MKX-AS1	3.44	0.000643	0.0376	0.26	0.16	Glaucoma (primary open-angle);	chr10:28107270	chr10:27744786~27767794:+
THCA	cis	rs11048434	0.736	rs11048338	ENSG00000245105.2	A2M-AS1	3.44	0.000644	0.0376	0.12	0.16	Sjögren's syndrome;	chr12:8968766	chr12:9065177~9068060:+
THCA	cis	rs7243790	1	rs7243790	ENSG00000277324.1	RP11-850A17.1	-3.44	0.000644	0.0376	-0.16	-0.16	Diastolic blood pressure;	chr18:54435393	chr18:54268346~54270028:-
THCA	cis	rs7243790	1	rs55756660	ENSG00000277324.1	RP11-850A17.1	-3.44	0.000644	0.0376	-0.16	-0.16	Diastolic blood pressure;	chr18:54436614	chr18:54268346~54270028:-
THCA	cis	rs7129556	0.859	rs11237215	ENSG00000254459.1	RP11-91P24.7	3.44	0.000644	0.0376	0.19	0.16	Weight loss (gastric bypass surgery);	chr11:77536470	chr11:77829654~77872262:-
THCA	cis	rs4713118	0.869	rs9283883	ENSG00000261839.1	RP1-265C24.8	3.44	0.000644	0.0376	0.18	0.16	Parkinson's disease;	chr6:27747691	chr6:28136849~28139678:+
THCA	cis	rs4533267	0.917	rs4246310	ENSG00000189419.6	SPATA41	3.44	0.000644	0.0376	0.21	0.16	Height;	chr15:100246481	chr15:100344457~100349655:-
THCA	cis	rs7412746	0.658	rs6657388	ENSG00000224800.1	RP11-235D19.2	-3.44	0.000644	0.0376	-0.22	-0.16	Melanoma;	chr1:150776310	chr1:150881236~150881683:-
THCA	cis	rs8040855	0.627	rs17540307	ENSG00000225151.9	GOLGA2P7	-3.44	0.000644	0.0376	-0.23	-0.16	Bulimia nervosa;	chr15:85090614	chr15:84199311~84230136:-
THCA	cis	rs867186	0.541	rs77173268	ENSG00000126005.14	MMP24-AS1	-3.44	0.000644	0.0376	-0.3	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34700198	chr20:35216462~35278131:-
THCA	cis	rs4761470	0.577	rs57925369	ENSG00000258365.1	RP11-1105G2.3	-3.44	0.000644	0.0376	-0.18	-0.16	Estradiol plasma levels (breast cancer);	chr12:94295732	chr12:94277758~94282844:-
THCA	cis	rs67478160	0.643	rs11624184	ENSG00000258534.1	CTD-2134A5.4	-3.44	0.000644	0.0376	-0.16	-0.16	Schizophrenia;	chr14:103774661	chr14:103854366~103880111:-
THCA	cis	rs2901381	0.701	rs71306621	ENSG00000269984.1	RP11-362K14.5	-3.44	0.000644	0.0376	-0.14	-0.16	Plateletcrit;	chr3:169105753	chr3:169777192~169780334:-
THCA	cis	rs2901381	0.701	rs80066785	ENSG00000269984.1	RP11-362K14.5	-3.44	0.000644	0.0376	-0.14	-0.16	Plateletcrit;	chr3:169107514	chr3:169777192~169780334:-
THCA	cis	rs1144333	0.655	rs4949681	ENSG00000272855.1	RP5-1102E8.3	-3.44	0.000644	0.0376	-0.34	-0.16	Attention function in attention deficit hyperactive disorder;	chr1:75944143	chr1:76636877~76637339:+
THCA	cis	rs9875589	0.628	rs62234602	ENSG00000228242.5	AC093495.4	-3.44	0.000644	0.0376	-0.09	-0.16	Ovarian reserve;	chr3:13960670	chr3:14144637~14165978:+
THCA	cis	rs758324	0.947	rs924434	ENSG00000224431.1	AC063976.7	3.44	0.000644	0.0376	0.15	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131807676	chr5:132199456~132203487:+
THCA	cis	rs853679	0.545	rs35949109	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000644	0.0376	-0.21	-0.16	Depression;	chr6:28058148	chr6:28078792~28081130:-
THCA	cis	rs34779708	0.931	rs4934693	ENSG00000233200.1	RP11-324I22.2	3.44	0.000644	0.0376	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35219894~35230598:-
THCA	cis	rs860295	1	rs822490	ENSG00000160766.13	GBAP1	-3.44	0.000644	0.0376	-0.18	-0.16	Body mass index;	chr1:155853180	chr1:155213821~155227422:-
THCA	cis	rs67478160	0.609	rs1547604	ENSG00000258534.1	CTD-2134A5.4	-3.44	0.000644	0.0376	-0.16	-0.16	Schizophrenia;	chr14:103804322	chr14:103854366~103880111:-
THCA	cis	rs8033133	0.56	rs12904560	ENSG00000251896.1	SNORD116-27	-3.44	0.000644	0.0376	-0.18	-0.16	Blood osmolality (transformed sodium);	chr15:25070820	chr15:25101575~25101666:+
THCA	cis	rs2882667	0.898	rs3925110	ENSG00000249593.5	CTB-46B19.2	3.44	0.000644	0.0376	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:139012647~139051203:+
THCA	cis	rs6547705	0.748	rs13010845	ENSG00000231259.4	AC125232.1	-3.44	0.000644	0.0376	-0.21	-0.16	Progressive supranuclear palsy;	chr2:86662353	chr2:87031815~87053069:-
THCA	cis	rs16852403	0.861	rs73049336	ENSG00000224687.1	RASAL2-AS1	3.44	0.000644	0.0376	0.25	0.16	Childhood ear infection;	chr1:178073163	chr1:178091508~178093984:-
THCA	cis	rs7819412	0.654	rs34741518	ENSG00000261451.1	RP11-981G7.1	-3.44	0.000644	0.0376	-0.19	-0.16	Triglycerides;	chr8:10919350	chr8:10433672~10438312:+
THCA	cis	rs471144	0.881	rs12081541	ENSG00000237975.5	FLG-AS1	-3.44	0.000644	0.0376	-0.34	-0.16	Inflammatory skin disease;	chr1:152468890	chr1:152168125~152445456:+
THCA	cis	rs10090774	0.965	rs11785430	ENSG00000280303.2	ERICD	-3.44	0.000644	0.0376	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140999428	chr8:140636281~140638283:+
THCA	cis	rs6547705	0.581	rs1400032	ENSG00000231259.4	AC125232.1	-3.44	0.000644	0.0376	-0.22	-0.16	Progressive supranuclear palsy;	chr2:86696060	chr2:87031815~87053069:-
THCA	cis	rs9902453	0.612	rs2617868	ENSG00000263603.1	CTD-2349P21.5	-3.44	0.000644	0.0376	-0.19	-0.16	Coffee consumption (cups per day);	chr17:29746229	chr17:30729469~30731202:+
THCA	cis	rs4790333	0.715	rs2447110	ENSG00000263345.1	RP1-59D14.5	-3.44	0.000644	0.0376	-0.07	-0.16	Proinsulin levels;	chr17:2358383	chr17:2375061~2379306:-
THCA	cis	rs2299682	0.826	rs6086921	ENSG00000230506.1	RP11-416N4.4	3.44	0.000644	0.0376	0.27	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9499473	chr20:10173520~10196990:+
THCA	cis	rs708224	0.605	rs2442063	ENSG00000274964.1	RP11-817I4.1	3.44	0.000644	0.0376	0.17	0.16	Pancreatic cancer;	chr12:32294789	chr12:32339368~32340724:+
THCA	cis	rs1971762	0.527	rs6580958	ENSG00000270175.1	RP11-793H13.11	-3.44	0.000644	0.0376	-0.11	-0.16	Height;	chr12:53679699	chr12:53500162~53500936:-
THCA	cis	rs2797160	1	rs1832938	ENSG00000226409.1	RP11-735G4.1	-3.44	0.000644	0.0376	-0.18	-0.16	Endometrial cancer;	chr6:125667818	chr6:125370211~125374324:-
THCA	cis	rs9921222	0.5	rs11645742	ENSG00000268836.1	LA16c-OS12.2	3.44	0.000644	0.0376	0.16	0.16	Bone mineral density (spine);Bone mineral density;	chr16:317516	chr16:185748~186294:-
THCA	cis	rs4730276	0.674	rs2237686	ENSG00000250474.1	WBP1LP2	3.44	0.000645	0.0376	0.14	0.16	Ulcerative colitis;	chr7:107934717	chr7:107628553~107629498:+
THCA	cis	rs7246657	0.941	rs7259618	ENSG00000268499.1	CTB-102L5.8	3.44	0.000645	0.0376	0.2	0.16	Coronary artery calcification;	chr19:37259817	chr19:38199836~38200934:+
THCA	cis	rs10802047	0.54	rs2810937	ENSG00000231365.4	RP11-418J17.1	3.44	0.000645	0.0376	0.16	0.16	Relative hand skill in reading disability;	chr1:118859151	chr1:119140396~119275973:+
THCA	cis	rs3784262	0.904	rs4646620	ENSG00000259250.1	RP11-50C13.1	3.44	0.000645	0.0376	0.13	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57966043	chr15:58587507~58591676:+
THCA	cis	rs7927592	0.763	rs2513277	ENSG00000160172.9	FAM86C2P	3.44	0.000645	0.0376	0.14	0.16	Total body bone mineral density;	chr11:68593419	chr11:67791648~67805336:-
THCA	cis	rs7927592	0.763	rs4340059	ENSG00000160172.9	FAM86C2P	3.44	0.000645	0.0376	0.14	0.16	Total body bone mineral density;	chr11:68594965	chr11:67791648~67805336:-
THCA	cis	rs6674176	0.542	rs803679	ENSG00000237950.1	RP11-7O11.3	3.44	0.000645	0.0376	0.15	0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43883733	chr1:43944370~43946551:-
THCA	cis	rs743757	0.878	rs73082948	ENSG00000232352.1	SEMA3B-AS1	3.44	0.000645	0.0376	0.24	0.16	Diastolic blood pressure;	chr3:50506986	chr3:50266641~50267371:-
THCA	cis	rs4948275	0.597	rs2650713	ENSG00000233643.2	RP11-491H19.1	3.44	0.000645	0.0376	0.18	0.16	Night sleep phenotypes;	chr10:61603544	chr10:61781745~61821246:-
THCA	cis	rs10954779	0.511	rs3087417	ENSG00000127589.4	TUBBP1	-3.44	0.000645	0.0376	-0.18	-0.16	Intelligence (multi-trait analysis);	chr8:31124455	chr8:30351873~30353518:+
THCA	cis	rs853679	0.527	rs853693	ENSG00000220721.1	OR1F12	3.44	0.000645	0.0376	0.18	0.16	Depression;	chr6:28314871	chr6:28073316~28074233:+
THCA	cis	rs909002	0.8	rs968335	ENSG00000235790.6	RP11-73M7.6	3.44	0.000645	0.0376	0.16	0.16	Intelligence (multi-trait analysis);	chr1:31620175	chr1:31644049~31660162:+
THCA	cis	rs6441975	0.857	rs1015164	ENSG00000223552.1	RP11-24F11.2	3.43	0.000645	0.0377	0.15	0.16	AIDS progression;	chr3:46410189	chr3:46364955~46407059:-
THCA	cis	rs6840360	0.615	rs4696097	ENSG00000270265.1	RP11-731D1.4	3.43	0.000645	0.0377	0.15	0.16	Intelligence (multi-trait analysis);	chr4:151558613	chr4:151333775~151353224:-
THCA	cis	rs972578	0.905	rs9623736	ENSG00000274717.1	RP1-47A17.1	-3.43	0.000645	0.0377	-0.16	-0.16	Mean platelet volume;	chr22:43010667	chr22:42791814~42794313:-
THCA	cis	rs38864	1	rs2402154	ENSG00000214188.8	ST7-OT4	3.43	0.000645	0.0377	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117155576	chr7:116953899~117098806:+
THCA	cis	rs38864	0.744	rs2188692	ENSG00000214188.8	ST7-OT4	3.43	0.000645	0.0377	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117155804	chr7:116953899~117098806:+
THCA	cis	rs38864	1	rs3808215	ENSG00000214188.8	ST7-OT4	3.43	0.000645	0.0377	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117159118	chr7:116953899~117098806:+
THCA	cis	rs38864	1	rs2402155	ENSG00000214188.8	ST7-OT4	3.43	0.000645	0.0377	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117159386	chr7:116953899~117098806:+
THCA	cis	rs38864	1	rs2402156	ENSG00000214188.8	ST7-OT4	3.43	0.000645	0.0377	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117159396	chr7:116953899~117098806:+
THCA	cis	rs38864	0.744	rs2402157	ENSG00000214188.8	ST7-OT4	3.43	0.000645	0.0377	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117159412	chr7:116953899~117098806:+
THCA	cis	rs38864	1	rs12333554	ENSG00000214188.8	ST7-OT4	3.43	0.000645	0.0377	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117161269	chr7:116953899~117098806:+
THCA	cis	rs38864	1	rs57609520	ENSG00000214188.8	ST7-OT4	3.43	0.000645	0.0377	0.32	0.16	Colonoscopy-negative controls vs population controls;	chr7:117162258	chr7:116953899~117098806:+
THCA	cis	rs1005277	0.579	rs1780137	ENSG00000099251.13	HSD17B7P2	3.43	0.000645	0.0377	0.14	0.16	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38356380~38378505:+
THCA	cis	rs9381107	0.527	rs2294733	ENSG00000230939.1	RP11-314C16.1	3.43	0.000645	0.0377	0.25	0.16	Nonsyndromic cleft lip with cleft palate;	chr6:9516477	chr6:8784178~8785445:+
THCA	cis	rs10207628	0.698	rs10182292	ENSG00000260634.1	RP11-521O16.1	3.43	0.000645	0.0377	0.21	0.16	Psychosis and Alzheimer's disease;	chr2:127111886	chr2:127024252~127025723:-
THCA	cis	rs737008	0.922	rs376374	ENSG00000263080.1	RP11-485G7.5	-3.43	0.000645	0.0377	-0.19	-0.16	Obesity-related traits;	chr16:11276759	chr16:11341809~11345211:-
THCA	cis	rs17023223	0.553	rs56234947	ENSG00000227056.2	RPL6P2	-3.43	0.000645	0.0377	-0.21	-0.16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119219314~119220096:-
THCA	cis	rs2797160	1	rs1418642	ENSG00000226409.1	RP11-735G4.1	-3.43	0.000645	0.0377	-0.18	-0.16	Endometrial cancer;	chr6:125678622	chr6:125370211~125374324:-
THCA	cis	rs7572733	0.935	rs6753450	ENSG00000231621.1	AC013264.2	-3.43	0.000645	0.0377	-0.15	-0.16	Dermatomyositis;	chr2:197870307	chr2:197197991~197199273:+
THCA	cis	rs9376098	0.597	rs6903655	ENSG00000232876.1	CTA-212D2.2	-3.43	0.000646	0.0377	-0.22	-0.16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135171399	chr6:135055033~135060550:+
THCA	cis	rs10089	0.904	rs2195921	ENSG00000245937.6	LINC01184	3.43	0.000646	0.0377	0.18	0.16	Ileal carcinoids;	chr5:128154062	chr5:127940426~128083172:-
THCA	cis	rs10905359	0.591	rs10905362	ENSG00000232591.1	RP5-1031D4.2	-3.43	0.000646	0.0377	-0.14	-0.16	Craniofacial microsomia;	chr10:8416715	chr10:7445558~7471942:-
THCA	cis	rs10905359	0.591	rs10905364	ENSG00000232591.1	RP5-1031D4.2	-3.43	0.000646	0.0377	-0.14	-0.16	Craniofacial microsomia;	chr10:8416992	chr10:7445558~7471942:-
THCA	cis	rs8044868	1	rs16973716	ENSG00000260886.1	TAT-AS1	3.43	0.000646	0.0377	0.18	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72122943	chr16:71565789~71578187:+
THCA	cis	rs990871	0.574	rs2422222	ENSG00000227207.2	RPL31P12	-3.43	0.000646	0.0377	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72447062	chr1:72301472~72301829:+
THCA	cis	rs990871	0.574	rs7535539	ENSG00000227207.2	RPL31P12	-3.43	0.000646	0.0377	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72447816	chr1:72301472~72301829:+
THCA	cis	rs990871	0.545	rs2121055	ENSG00000227207.2	RPL31P12	-3.43	0.000646	0.0377	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72454600	chr1:72301472~72301829:+
THCA	cis	rs990871	0.539	rs4650138	ENSG00000227207.2	RPL31P12	-3.43	0.000646	0.0377	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72459006	chr1:72301472~72301829:+
THCA	cis	rs72843506	0.656	rs10459970	ENSG00000189423.10	USP32P3	3.43	0.000646	0.0377	0.26	0.16	Schizophrenia;	chr17:20034028	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs2385960	ENSG00000189423.10	USP32P3	3.43	0.000646	0.0377	0.26	0.16	Schizophrenia;	chr17:20034904	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs8073875	ENSG00000189423.10	USP32P3	3.43	0.000646	0.0377	0.26	0.16	Schizophrenia;	chr17:20035746	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs57040439	ENSG00000189423.10	USP32P3	3.43	0.000646	0.0377	0.26	0.16	Schizophrenia;	chr17:20036522	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs58313980	ENSG00000189423.10	USP32P3	3.43	0.000646	0.0377	0.26	0.16	Schizophrenia;	chr17:20036737	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs73984559	ENSG00000189423.10	USP32P3	3.43	0.000646	0.0377	0.26	0.16	Schizophrenia;	chr17:20043203	chr17:20415547~20431008:+
THCA	cis	rs6439699	0.941	rs13067731	ENSG00000273486.1	RP11-731C17.2	3.43	0.000646	0.0377	0.16	0.16	Intelligence (multi-trait analysis);	chr3:137271149	chr3:136837338~136839021:-
THCA	cis	rs3126085	0.935	rs2184953	ENSG00000237975.5	FLG-AS1	3.43	0.000646	0.0377	0.25	0.16	Atopic dermatitis;	chr1:152308306	chr1:152168125~152445456:+
THCA	cis	rs34779708	0.897	rs12830	ENSG00000233200.1	RP11-324I22.2	3.43	0.000646	0.0377	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35219894~35230598:-
THCA	cis	rs2839186	0.77	rs2839984	ENSG00000228137.1	AP001469.7	3.43	0.000646	0.0377	0.16	0.16	Testicular germ cell tumor;	chr21:46251776	chr21:46246890~46247682:+
THCA	cis	rs7267979	0.586	rs6050429	ENSG00000274973.1	RP13-401N8.7	-3.43	0.000646	0.0377	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25845497~25845862:+
THCA	cis	rs41308713	0.606	rs77984335	ENSG00000224635.1	RP4-564F22.5	-3.43	0.000646	0.0377	-0.39	-0.16	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38444643	chr20:38406011~38416797:-
THCA	cis	rs12539814	1	rs12539814	ENSG00000244198.4	RP4-545C24.1	3.43	0.000646	0.0377	0.19	0.16	Diastolic blood pressure;	chr7:144433417	chr7:144194858~144280547:+
THCA	cis	rs7809950	0.678	rs2237660	ENSG00000272072.1	CTA-363E19.2	3.43	0.000646	0.0377	0.17	0.16	Coronary artery disease;	chr7:107222518	chr7:107192559~107193300:-
THCA	cis	rs7259376	0.875	rs1991830	ENSG00000269138.1	ZNF209P	3.43	0.000646	0.0377	0.16	0.16	Menopause (age at onset);	chr19:22331928	chr19:22463922~22473036:+
THCA	cis	rs7711186	0.786	rs4413550	ENSG00000252464.1	RN7SKP70	-3.43	0.000646	0.0377	-0.17	-0.16	Urate levels in obese individuals;	chr5:178645634	chr5:178619728~178619998:-
THCA	cis	rs80226907	0.808	rs9323280	ENSG00000258413.1	RP11-665C16.6	-3.43	0.000646	0.0377	-0.39	-0.16	Mean platelet volume;	chr14:55334969	chr14:55262767~55272075:-
THCA	cis	rs2625529	0.73	rs982752	ENSG00000260037.4	CTD-2524L6.3	-3.43	0.000646	0.0377	-0.2	-0.16	Red blood cell count;	chr15:71853596	chr15:71818396~71823384:+
THCA	cis	rs3736986	1	rs3818556	ENSG00000215283.3	HMGB3P24	-3.43	0.000646	0.0377	-0.29	-0.16	Bipolar disorder (inflammation and infection response interaction);	chr9:36204521	chr9:36303499~36304924:-
THCA	cis	rs270601	0.721	rs162894	ENSG00000263597.1	MIR3936	3.43	0.000646	0.0377	0.15	0.16	Acylcarnitine levels;	chr5:132276179	chr5:132365490~132365599:-
THCA	cis	rs875971	0.545	rs1909508	ENSG00000230295.1	RP11-458F8.2	3.43	0.000646	0.0377	0.14	0.16	Aortic root size;	chr7:66301366	chr7:66880708~66882981:+
THCA	cis	rs9948	1	rs59244622	ENSG00000230606.9	AC159540.1	3.43	0.000646	0.0377	0.26	0.16	Erectile dysfunction and prostate cancer treatment;	chr2:96835895	chr2:97416165~97433527:-
THCA	cis	rs9549260	0.62	rs12583418	ENSG00000275149.1	RP11-427J23.1	-3.43	0.000646	0.0377	-0.21	-0.16	Red blood cell count;	chr13:40621274	chr13:40079106~40273509:-
THCA	cis	rs6787172	0.593	rs4680433	ENSG00000272087.1	RP11-379F4.7	-3.43	0.000646	0.0377	-0.14	-0.16	Subjective well-being;	chr3:158419059	chr3:158693120~158693768:-
THCA	cis	rs11685222	0.777	rs745927	ENSG00000229326.3	AC069154.4	3.43	0.000646	0.0377	0.28	0.16	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119724838	chr2:119698623~119700151:+
THCA	cis	rs4218	0.543	rs35658945	ENSG00000259732.1	RP11-59H7.3	-3.43	0.000646	0.0377	-0.21	-0.16	Social communication problems;	chr15:59018053	chr15:59121034~59133250:+
THCA	cis	rs4218	0.543	rs2414618	ENSG00000259732.1	RP11-59H7.3	-3.43	0.000646	0.0377	-0.21	-0.16	Social communication problems;	chr15:59019684	chr15:59121034~59133250:+
THCA	cis	rs4218	0.543	rs12050865	ENSG00000259732.1	RP11-59H7.3	-3.43	0.000646	0.0377	-0.21	-0.16	Social communication problems;	chr15:59020689	chr15:59121034~59133250:+
THCA	cis	rs4984778	0.717	rs2738892	ENSG00000261399.1	LA16c-329F2.1	-3.43	0.000646	0.0377	-0.12	-0.16	Blood protein levels;	chr16:1218758	chr16:1713527~1714208:-
THCA	cis	rs1510272	0.847	rs12492935	ENSG00000243926.1	TIPARP-AS1	-3.43	0.000647	0.0377	-0.16	-0.16	Testicular germ cell tumor;	chr3:156610164	chr3:156671862~156674378:-
THCA	cis	rs1510272	0.842	rs2048337	ENSG00000243926.1	TIPARP-AS1	-3.43	0.000647	0.0377	-0.16	-0.16	Testicular germ cell tumor;	chr3:156610306	chr3:156671862~156674378:-
THCA	cis	rs2292096	1	rs16847180	ENSG00000260088.1	RP11-92G12.3	3.43	0.000647	0.0377	0.31	0.16	Epilepsy;	chr1:200762428	chr1:200669507~200694250:+
THCA	cis	rs5758659	0.716	rs86669	ENSG00000237037.8	NDUFA6-AS1	3.43	0.000647	0.0377	0.12	0.16	Cognitive function;	chr22:42284794	chr22:42090931~42137742:+
THCA	cis	rs4824093	0.61	rs9627798	ENSG00000278869.1	CITF22-49E9.3	3.43	0.000647	0.0377	0.29	0.16	Amyotrophic lateral sclerosis (sporadic);	chr22:49924209	chr22:49933198~49934074:-
THCA	cis	rs4824093	0.61	rs9627799	ENSG00000278869.1	CITF22-49E9.3	3.43	0.000647	0.0377	0.29	0.16	Amyotrophic lateral sclerosis (sporadic);	chr22:49924341	chr22:49933198~49934074:-
THCA	cis	rs875971	0.54	rs736270	ENSG00000230189.5	GS1-124K5.2	3.43	0.000647	0.0377	0.1	0.16	Aortic root size;	chr7:65963835	chr7:66409143~66490059:-
THCA	cis	rs34783982	0.881	rs34031857	ENSG00000259699.2	HMGB1P8	-3.43	0.000647	0.0377	-0.21	-0.16	Squamous cell lung carcinoma;	chr15:88957329	chr15:89135547~89136495:-
THCA	cis	rs6496667	0.865	rs75714371	ENSG00000259262.1	NDUFA3P4	3.43	0.000647	0.0377	0.22	0.16	Rheumatoid arthritis;	chr15:90337370	chr15:90385814~90386063:+
THCA	cis	rs6120849	0.663	rs11698868	ENSG00000269202.1	RP4-614O4.12	-3.43	0.000647	0.0377	-0.17	-0.16	Protein C levels;	chr20:34962143	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.663	rs6119548	ENSG00000269202.1	RP4-614O4.12	-3.43	0.000647	0.0377	-0.17	-0.16	Protein C levels;	chr20:34964809	chr20:35201747~35203288:-
THCA	cis	rs6968419	0.537	rs61487707	ENSG00000237870.5	AC073130.1	3.43	0.000647	0.0377	0.16	0.16	Intraocular pressure;	chr7:116141002	chr7:116275606~116286734:-
THCA	cis	rs2276314	1	rs2298716	ENSG00000267627.4	RP11-905K4.1	-3.43	0.000647	0.0377	-0.2	-0.16	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35951803~35966118:-
THCA	cis	rs683250	0.598	rs7933220	ENSG00000254551.1	RP11-727A23.7	3.43	0.000647	0.0377	0.19	0.16	Subcortical brain region volumes;	chr11:83307732	chr11:83209431~83213379:-
THCA	cis	rs7809799	0.571	rs67546174	ENSG00000242798.1	RP11-506M12.1	-3.43	0.000647	0.0377	-0.31	-0.16	Ulcerative colitis;	chr7:99340631	chr7:100115214~100127139:-
THCA	cis	rs4692589	0.581	rs6821231	ENSG00000229204.3	PTGES3P3	-3.43	0.000647	0.0377	-0.2	-0.16	Anxiety disorder;	chr4:170038837	chr4:169791221~169791702:-
THCA	cis	rs4692589	0.581	rs34149802	ENSG00000229204.3	PTGES3P3	-3.43	0.000647	0.0377	-0.2	-0.16	Anxiety disorder;	chr4:170039133	chr4:169791221~169791702:-
THCA	cis	rs9902453	0.765	rs8079209	ENSG00000263603.1	CTD-2349P21.5	3.43	0.000647	0.0377	0.19	0.16	Coffee consumption (cups per day);	chr17:29859755	chr17:30729469~30731202:+
THCA	cis	rs12817549	0.781	rs7969076	ENSG00000186076.5	RP11-887P2.3	-3.43	0.000647	0.0377	-0.18	-0.16	Hip circumference adjusted for BMI;	chr12:93702266	chr12:93640822~93641586:-
THCA	cis	rs56309584	0.56	rs3027160	ENSG00000271002.1	RP11-599B13.8	-3.43	0.000647	0.0377	-0.24	-0.16	Initial pursuit acceleration;	chr17:8154254	chr17:8199123~8199437:-
THCA	cis	rs467650	0.509	rs29768	ENSG00000248489.1	CTD-2007H13.3	3.43	0.000647	0.0377	0.14	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98645743	chr5:98929171~98995013:+
THCA	cis	rs7074356	0.523	rs7087728	ENSG00000278616.1	BEND3P3	3.43	0.000647	0.0377	0.13	0.16	Borderline personality disorder;	chr10:80273714	chr10:79682997~79685436:+
THCA	cis	rs12912251	0.591	rs3102118	ENSG00000259225.5	RP11-1008C21.1	-3.43	0.000647	0.0377	-0.19	-0.16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr15:38711274	chr15:37984766~38062340:+
THCA	cis	rs11175834	0.655	rs11175839	ENSG00000241749.4	RPSAP52	3.43	0.000647	0.0377	0.25	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65613113	chr12:65758020~65826997:-
THCA	cis	rs4948275	0.631	rs2814023	ENSG00000233643.2	RP11-491H19.1	3.43	0.000647	0.0377	0.18	0.16	Night sleep phenotypes;	chr10:61593649	chr10:61781745~61821246:-
THCA	cis	rs5006884	1	rs12802242	ENSG00000167355.6	AC104389.28	-3.43	0.000647	0.0377	-0.22	-0.16	Fetal hemoglobin levels;	chr11:5369216	chr11:5304976~5505652:-
THCA	cis	rs59901009	0.534	rs7935297	ENSG00000246273.5	SBF2-AS1	-3.43	0.000647	0.0377	-0.2	-0.16	Hematocrit;Hemoglobin concentration;	chr11:10003425	chr11:9758292~9811319:+
THCA	cis	rs1542829	0.614	rs76376162	ENSG00000249846.5	RP11-77P16.4	3.43	0.000647	0.0378	0.28	0.16	Body mass index;	chr3:130423766	chr3:130112550~130120579:+
THCA	cis	rs9650657	0.571	rs11783247	ENSG00000206014.6	OR7E161P	3.43	0.000647	0.0378	0.18	0.16	Neuroticism;	chr8:10931365	chr8:11928597~11929563:-
THCA	cis	rs7656342	0.579	rs6848689	ENSG00000250342.1	SNRPCP16	3.43	0.000647	0.0378	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9882573	chr4:9051842~9052051:-
THCA	cis	rs711830	0.587	rs10188827	ENSG00000279205.1	RP11-632P5.1	3.43	0.000647	0.0378	0.22	0.16	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176142936	chr2:176822030~176823653:+
THCA	cis	rs758324	0.773	rs13183449	ENSG00000224431.1	AC063976.7	3.43	0.000647	0.0378	0.14	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131780389	chr5:132199456~132203487:+
THCA	cis	rs9828933	0.752	rs13434089	ENSG00000224479.4	AC136289.1	-3.43	0.000647	0.0378	-0.25	-0.16	Type 2 diabetes;	chr3:63962890	chr3:63742293~63827445:-
THCA	cis	rs62209	0.8	rs201082	ENSG00000181800.5	CELF2-AS1	3.43	0.000647	0.0378	0.16	0.16	Alzheimer's disease (late onset);	chr10:10963741	chr10:11316834~11319884:-
THCA	cis	rs9911578	0.935	rs302873	ENSG00000224738.1	AC099850.1	3.43	0.000647	0.0378	0.18	0.16	Intelligence (multi-trait analysis);	chr17:58692120	chr17:59106598~59118267:+
THCA	cis	rs6683071	0.54	rs1391558	ENSG00000225265.1	TAF1A-AS1	-3.43	0.000647	0.0378	-0.17	-0.16	Cognitive performance;	chr1:222674687	chr1:222589825~222593032:+
THCA	cis	rs944289	0.74	rs2780302	ENSG00000212071.1	AL162511.1	3.43	0.000647	0.0378	0.18	0.16	Thyroid cancer;	chr14:36079456	chr14:36196480~36196568:-
THCA	cis	rs1005277	0.579	rs1780116	ENSG00000099251.13	HSD17B7P2	3.43	0.000647	0.0378	0.13	0.16	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38356380~38378505:+
THCA	cis	rs1005277	0.579	rs1780121	ENSG00000099251.13	HSD17B7P2	3.43	0.000647	0.0378	0.13	0.16	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38356380~38378505:+
THCA	cis	rs1005277	0.579	rs1780122	ENSG00000099251.13	HSD17B7P2	3.43	0.000647	0.0378	0.13	0.16	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38356380~38378505:+
THCA	cis	rs1005277	0.579	rs1780145	ENSG00000099251.13	HSD17B7P2	3.43	0.000647	0.0378	0.13	0.16	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38356380~38378505:+
THCA	cis	rs9876781	1	rs3214041	ENSG00000199476.1	Y_RNA	-3.43	0.000647	0.0378	-0.2	-0.16	Longevity;	chr3:48413059	chr3:48288587~48288694:+
THCA	cis	rs337161	0.605	rs12562235	ENSG00000221571.3	RNU6ATAC35P	-3.43	0.000647	0.0378	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220772398	chr1:220825620~220826063:+
THCA	cis	rs34779708	0.733	rs11597184	ENSG00000233200.1	RP11-324I22.2	3.43	0.000647	0.0378	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35219894~35230598:-
THCA	cis	rs1417770	0.64	rs947008	ENSG00000260971.3	RP11-504A18.1	-3.43	0.000647	0.0378	-0.14	-0.16	Lobe attachment (rater-scored or self-reported);	chr1:56262212	chr1:56248294~56258571:-
THCA	cis	rs763121	0.853	rs7289577	ENSG00000225450.1	RP3-508I15.14	-3.43	0.000648	0.0378	-0.12	-0.16	Menopause (age at onset);	chr22:38646209	chr22:38739003~38749041:+
THCA	cis	rs9650657	0.501	rs3021500	ENSG00000254839.1	AF131215.6	3.43	0.000648	0.0378	0.16	0.16	Neuroticism;	chr8:11166488	chr8:11062647~11067089:-
THCA	cis	rs9863	0.861	rs7973683	ENSG00000269938.1	RP11-214K3.20	-3.43	0.000648	0.0378	-0.18	-0.16	White blood cell count;	chr12:123964676	chr12:123968023~123968579:-
THCA	cis	rs4889855	0.614	rs7221663	ENSG00000279692.1	RP11-1055B8.1	3.43	0.000648	0.0378	0.26	0.16	Fractional excretion of uric acid;	chr17:80510366	chr17:81395609~81397144:-
THCA	cis	rs4889855	0.578	rs7216808	ENSG00000279692.1	RP11-1055B8.1	3.43	0.000648	0.0378	0.26	0.16	Fractional excretion of uric acid;	chr17:80510387	chr17:81395609~81397144:-
THCA	cis	rs2278702	0.848	rs1446334	ENSG00000259495.2	RP11-210M15.2	-3.43	0.000648	0.0378	-0.23	-0.16	Bipolar disorder;	chr15:80407371	chr15:80344853~80403575:-
THCA	cis	rs67478160	0.634	rs2144079	ENSG00000258534.1	CTD-2134A5.4	-3.43	0.000648	0.0378	-0.16	-0.16	Schizophrenia;	chr14:103792547	chr14:103854366~103880111:-
THCA	cis	rs2549003	0.966	rs2706385	ENSG00000233006.5	AC034220.3	3.43	0.000648	0.0378	0.12	0.16	Asthma (sex interaction);	chr5:132496074	chr5:132311285~132369916:-
THCA	cis	rs10995245	0.84	rs4746525	ENSG00000238280.1	RP11-436D10.3	3.43	0.000648	0.0378	0.19	0.16	Narcolepsy;	chr10:62678511	chr10:62793562~62805887:-
THCA	cis	rs6723226	0.882	rs13035097	ENSG00000276517.1	AL133243.2	3.43	0.000648	0.0378	0.16	0.16	Intelligence (multi-trait analysis);	chr2:32611295	chr2:32526504~32529507:+
THCA	cis	rs301901	0.828	rs10941337	ENSG00000250155.1	CTD-2353F22.1	3.43	0.000648	0.0378	0.15	0.16	Height;	chr5:37474023	chr5:36666214~36725195:-
THCA	cis	rs987724	0.593	rs13322318	ENSG00000241544.1	RP11-6F2.5	-3.43	0.000648	0.0378	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156906481	chr3:157081841~157088547:+
THCA	cis	rs8177876	0.841	rs117310590	ENSG00000261838.4	RP11-303E16.6	3.43	0.000648	0.0378	0.34	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094790	chr16:81069854~81076598:+
THCA	cis	rs2562456	0.917	rs2681376	ENSG00000268658.4	LINC00664	-3.43	0.000648	0.0378	-0.23	-0.16	Pain;	chr19:21532723	chr19:21483374~21503238:+
THCA	cis	rs34779708	0.931	rs2490663	ENSG00000233200.1	RP11-324I22.2	-3.43	0.000648	0.0378	-0.19	-0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35219894~35230598:-
THCA	cis	rs6657613	0.658	rs3738814	ENSG00000235241.1	RP11-108M9.5	3.43	0.000648	0.0378	0.17	0.16	Hip circumference adjusted for BMI;	chr1:17005181	chr1:16889095~16889602:+
THCA	cis	rs754466	0.58	rs2289308	ENSG00000213514.2	RP11-428P16.2	3.43	0.000648	0.0378	0.17	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77819493	chr10:77730766~77734769:+
THCA	cis	rs11785400	1	rs10099892	ENSG00000177335.9	C8orf31	3.43	0.000648	0.0378	0.17	0.16	Schizophrenia;	chr8:142653224	chr8:143039209~143059942:+
THCA	cis	rs7264396	0.887	rs2281849	ENSG00000261582.1	RP4-614O4.11	-3.43	0.000648	0.0378	-0.16	-0.16	Total cholesterol levels;	chr20:35472461	chr20:35267885~35280043:-
THCA	cis	rs4664293	0.802	rs7563417	ENSG00000230783.1	AC009961.2	-3.43	0.000648	0.0378	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159727762	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs13022404	ENSG00000230783.1	AC009961.2	-3.43	0.000648	0.0378	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159732981	chr2:159689217~159690291:-
THCA	cis	rs6545883	0.894	rs2694649	ENSG00000212978.6	AC016747.3	-3.43	0.000648	0.0378	-0.17	-0.16	Tuberculosis;	chr2:61346691	chr2:61141592~61144969:-
THCA	cis	rs2235649	0.663	rs6600167	ENSG00000260022.1	LA16c-306A4.1	3.43	0.000648	0.0378	0.22	0.16	Blood metabolite levels;	chr16:1798911	chr16:883780~885090:+
THCA	cis	rs2235649	0.663	rs113908028	ENSG00000260022.1	LA16c-306A4.1	3.43	0.000648	0.0378	0.22	0.16	Blood metabolite levels;	chr16:1798914	chr16:883780~885090:+
THCA	cis	rs2235649	0.623	rs8048162	ENSG00000260022.1	LA16c-306A4.1	3.43	0.000648	0.0378	0.22	0.16	Blood metabolite levels;	chr16:1798917	chr16:883780~885090:+
THCA	cis	rs2235649	0.663	rs6600168	ENSG00000260022.1	LA16c-306A4.1	3.43	0.000648	0.0378	0.22	0.16	Blood metabolite levels;	chr16:1798926	chr16:883780~885090:+
THCA	cis	rs2307022	0.629	rs2863975	ENSG00000274698.1	RP11-71L14.4	3.43	0.000648	0.0378	0.19	0.16	Body mass index;	chr16:68348544	chr16:68450283~68452318:+
THCA	cis	rs3096299	0.658	rs4291902	ENSG00000223959.7	AFG3L1P	3.43	0.000648	0.0378	0.09	0.16	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89972586~90002161:+
THCA	cis	rs752590	0.524	rs13396369	ENSG00000227359.1	AC017074.2	3.43	0.000648	0.0378	0.22	0.16	Mucinous ovarian carcinoma;	chr2:113254175	chr2:113677702~113704078:-
THCA	cis	rs2302190	1	rs8065388	ENSG00000224738.1	AC099850.1	3.43	0.000648	0.0378	0.21	0.16	Vitamin D levels;	chr17:58484771	chr17:59106598~59118267:+
THCA	cis	rs7166081	0.95	rs8039943	ENSG00000270964.1	RP11-502I4.3	-3.43	0.000648	0.0378	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67364092	chr15:67541072~67542604:-
THCA	cis	rs7166081	1	rs28696998	ENSG00000270964.1	RP11-502I4.3	-3.43	0.000648	0.0378	-0.15	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67364525	chr15:67541072~67542604:-
THCA	cis	rs9296092	0.56	rs9469511	ENSG00000272217.1	XXbac-BPG157A10.21	3.43	0.000649	0.0378	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33563153	chr6:33246075~33246856:-
THCA	cis	rs1048886	0.872	rs55639214	ENSG00000271967.1	RP11-134K13.4	-3.43	0.000649	0.0378	-0.19	-0.16	Type 2 diabetes;	chr6:70577494	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs56114703	ENSG00000271967.1	RP11-134K13.4	-3.43	0.000649	0.0378	-0.19	-0.16	Type 2 diabetes;	chr6:70577594	chr6:70596438~70596980:+
THCA	cis	rs62289301	0.637	rs59684117	ENSG00000273133.1	RP11-799M12.2	3.43	0.000649	0.0378	0.2	0.16	Joint mobility (Beighton score);	chr4:15399890	chr4:15563698~15564253:-
THCA	cis	rs62289301	0.637	rs61240629	ENSG00000273133.1	RP11-799M12.2	3.43	0.000649	0.0378	0.2	0.16	Joint mobility (Beighton score);	chr4:15399910	chr4:15563698~15564253:-
THCA	cis	rs9488822	0.636	rs7745074	ENSG00000233558.1	RP3-486I3.4	3.43	0.000649	0.0378	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:116026269	chr6:116258493~116259115:-
THCA	cis	rs73206853	0.764	rs7312139	ENSG00000257539.2	HSPA8P14	3.43	0.000649	0.0378	0.3	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110547637	chr12:111381867~111385638:+
THCA	cis	rs540425	0.626	rs8580	ENSG00000279853.1	RP5-844F9.1	3.43	0.000649	0.0378	0.2	0.16	Schizophrenia;	chr7:44581237	chr7:44367140~44369292:-
THCA	cis	rs17836934	1	rs55849728	ENSG00000271614.1	LINC00936	3.43	0.000649	0.0378	0.13	0.16	Total body bone mineral density;	chr12:90140138	chr12:89708959~89712590:+
THCA	cis	rs7631605	0.875	rs4678921	ENSG00000272334.1	RP11-129K12.1	-3.43	0.000649	0.0378	-0.19	-0.16	Cerebrospinal P-tau181p levels;	chr3:36981312	chr3:36973117~36973672:-
THCA	cis	rs3805389	0.924	rs2412665	ENSG00000273257.1	RP11-177J6.1	-3.43	0.000649	0.0378	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55606812	chr4:55387949~55388271:+
THCA	cis	rs4699052	0.505	rs3775972	ENSG00000230069.3	LRRC37A15P	-3.43	0.000649	0.0378	-0.21	-0.16	Testicular germ cell tumor;	chr4:103083205	chr4:102727274~102730721:-
THCA	cis	rs8177876	0.822	rs804902	ENSG00000261838.4	RP11-303E16.6	3.43	0.000649	0.0378	0.25	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr16:81069854~81076598:+
THCA	cis	rs74544699	1	rs529312	ENSG00000221639.1	SNORA3	-3.43	0.000649	0.0378	-0.35	-0.16	Growth-regulated protein alpha levels;	chr4:73902265	chr4:73263960~73264084:+
THCA	cis	rs910316	0.763	rs12588981	ENSG00000259138.1	RP11-950C14.7	3.43	0.000649	0.0378	0.13	0.16	Height;	chr14:74993858	chr14:75127153~75136930:+
THCA	cis	rs7737355	0.853	rs31586	ENSG00000224431.1	AC063976.7	3.43	0.000649	0.0378	0.14	0.16	Life satisfaction;	chr5:131665003	chr5:132199456~132203487:+
THCA	cis	rs7474896	0.526	rs1208633	ENSG00000276805.1	RP11-291L22.6	-3.43	0.000649	0.0378	-0.2	-0.16	Obesity (extreme);	chr10:37867945	chr10:38451030~38451785:+
THCA	cis	rs7474896	0.559	rs1779075	ENSG00000276805.1	RP11-291L22.6	-3.43	0.000649	0.0378	-0.2	-0.16	Obesity (extreme);	chr10:37878602	chr10:38451030~38451785:+
THCA	cis	rs7474896	0.559	rs2753880	ENSG00000276805.1	RP11-291L22.6	-3.43	0.000649	0.0378	-0.2	-0.16	Obesity (extreme);	chr10:37884410	chr10:38451030~38451785:+
THCA	cis	rs2636697	0.541	rs28723530	ENSG00000251175.4	RP11-45L9.1	-3.43	0.000649	0.0378	-0.24	-0.16	Response to antipsychotic treatment;	chr4:105505561	chr4:105746245~105827172:-
THCA	cis	rs11239930	0.517	rs590286	ENSG00000180867.10	PDIA3P1	3.43	0.000649	0.0378	0.14	0.16	AIDS progression;	chr1:147074056	chr1:147178113~147179622:+
THCA	cis	rs7819412	0.669	rs35499486	ENSG00000255046.1	RP11-297N6.4	3.43	0.000649	0.0378	0.17	0.16	Triglycerides;	chr8:11216527	chr8:11797928~11802568:-
THCA	cis	rs3135758	0.52	rs11594647	ENSG00000274461.1	RP11-323P17.2	3.43	0.000649	0.0378	0.4	0.16	Magnesium levels;	chr10:121664457	chr10:120819307~120825311:+
THCA	cis	rs9549260	0.604	rs9549281	ENSG00000239827.7	SUGT1P3	-3.43	0.000649	0.0378	-0.21	-0.16	Red blood cell count;	chr13:40756035	chr13:40908159~40921774:-
THCA	cis	rs854765	0.616	rs8070624	ENSG00000265511.1	RP11-524F11.1	3.43	0.000649	0.0378	0.13	0.16	Total body bone mineral density;	chr17:17940082	chr17:17507351~17508308:+
THCA	cis	rs10266483	0.843	rs667644	ENSG00000234338.1	RP11-797H7.1	3.43	0.000649	0.0378	0.11	0.16	Response to statin therapy;	chr7:64290180	chr7:64835280~64836882:-
THCA	cis	rs2243480	1	rs781142	ENSG00000273024.4	INTS4P2	3.43	0.000649	0.0378	0.26	0.16	Diabetic kidney disease;	chr7:65973791	chr7:65647864~65715661:+
THCA	cis	rs76866386	0.786	rs4076834	ENSG00000279873.2	LINC01126	3.43	0.000649	0.0378	0.23	0.16	Cholesterol, total;	chr2:43854488	chr2:43227210~43228855:+
THCA	cis	rs5753037	0.653	rs131285	ENSG00000273350.1	RP4-539M6.20	-3.43	0.000649	0.0378	-0.18	-0.16	Type 1 diabetes;	chr22:29761951	chr22:30420512~30420912:+
THCA	cis	rs4417704	0.551	rs4464265	ENSG00000235151.1	AC114730.2	-3.43	0.000649	0.0378	-0.18	-0.16	Joint mobility (Beighton score);	chr2:240952382	chr2:241844380~241845036:+
THCA	cis	rs6832769	0.925	rs60992571	ENSG00000223305.1	RN7SKP30	-3.43	0.000649	0.0378	-0.2	-0.16	Personality dimensions;	chr4:55574645	chr4:55540502~55540835:-
THCA	cis	rs4956211	0.537	rs12647396	ENSG00000232021.5	LEF1-AS1	3.43	0.000649	0.0379	0.17	0.16	Systemic lupus erythematosus;	chr4:108786573	chr4:108167525~108256836:+
THCA	cis	rs11681884	0.786	rs1992761	ENSG00000272563.1	RP11-480C16.1	-3.43	0.000649	0.0379	-0.33	-0.16	Stroke;	chr2:113052709	chr2:113432600~113436042:+
THCA	cis	rs561341	0.528	rs11650908	ENSG00000214708.4	AC090616.2	-3.43	0.000649	0.0379	-0.17	-0.16	Hip circumference adjusted for BMI;	chr17:31868406	chr17:32141226~32143135:-
THCA	cis	rs2274273	0.934	rs10137307	ENSG00000258469.1	CHMP4BP1	3.43	0.000649	0.0379	0.14	0.16	Protein biomarker;	chr14:55378467	chr14:55298644~55299231:+
THCA	cis	rs9868809	0.649	rs3733086	ENSG00000229759.1	MRPS18AP1	-3.43	0.000649	0.0379	-0.31	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48662086	chr3:48256350~48256938:-
THCA	cis	rs883565	0.528	rs4504116	ENSG00000223668.1	EEF1A1P24	3.43	0.000649	0.0379	0.13	0.16	Handedness;	chr3:38912277	chr3:39358545~39359922:+
THCA	cis	rs10992471	0.56	rs2281715	ENSG00000187984.11	ANKRD19P	-3.43	0.000649	0.0379	-0.1	-0.16	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92885692	chr9:92809388~92888693:+
THCA	cis	rs10875746	0.587	rs9788082	ENSG00000226413.2	OR8T1P	3.43	0.000649	0.0379	0.23	0.16	Longevity (90 years and older);	chr12:48358273	chr12:48442030~48442947:-
THCA	cis	rs12935418	0.83	rs7195459	ENSG00000261838.4	RP11-303E16.6	3.43	0.000649	0.0379	0.23	0.16	Mean corpuscular volume;	chr16:81016376	chr16:81069854~81076598:+
THCA	cis	rs6058526	0.631	rs6087839	ENSG00000235217.6	TSPY26P	-3.43	0.000649	0.0379	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr20:32224976	chr20:32186477~32190527:-
THCA	cis	rs9420	0.528	rs11607122	ENSG00000254602.1	AP000662.4	-3.43	0.000649	0.0379	-0.18	-0.16	Schizophrenia;	chr11:57622264	chr11:57638024~57652790:+
THCA	cis	rs10760158	0.832	rs10985192	ENSG00000235865.2	GSN-AS1	3.43	0.00065	0.0379	0.14	0.16	Pulse pressure;	chr9:121254162	chr9:121280768~121285530:-
THCA	cis	rs11673344	0.523	rs2562609	ENSG00000267260.1	CTD-2162K18.4	-3.43	0.00065	0.0379	-0.19	-0.16	Obesity-related traits;	chr19:37036255	chr19:36773153~36777078:+
THCA	cis	rs757081	0.867	rs2521999	ENSG00000260196.1	RP1-239B22.5	-3.43	0.00065	0.0379	-0.19	-0.16	Systolic blood pressure;	chr11:17311636	chr11:17380649~17383531:+
THCA	cis	rs1669338	0.588	rs55959448	ENSG00000271870.1	RP11-97C16.1	3.43	0.00065	0.0379	0.15	0.16	White matter integrity;	chr3:3162316	chr3:3152942~3153435:+
THCA	cis	rs9650657	0.504	rs10108347	ENSG00000154316.13	TDH	3.43	0.00065	0.0379	0.12	0.16	Neuroticism;	chr8:11176008	chr8:11339637~11368452:+
THCA	cis	rs1957429	0.901	rs8008745	ENSG00000272158.1	RP11-840I19.5	-3.43	0.00065	0.0379	-0.28	-0.16	Pediatric areal bone mineral density (radius);	chr14:64884875	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.808	rs9783609	ENSG00000272158.1	RP11-840I19.5	-3.43	0.00065	0.0379	-0.28	-0.16	Pediatric areal bone mineral density (radius);	chr14:64885564	chr14:65003325~65003767:-
THCA	cis	rs709400	0.832	rs55864158	ENSG00000258534.1	CTD-2134A5.4	3.43	0.00065	0.0379	0.17	0.16	Body mass index;	chr14:103602242	chr14:103854366~103880111:-
THCA	cis	rs7267979	0.727	rs2474765	ENSG00000230772.1	VN1R108P	3.43	0.00065	0.0379	0.14	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25734264~25735093:+
THCA	cis	rs7267979	0.764	rs2474767	ENSG00000230772.1	VN1R108P	3.43	0.00065	0.0379	0.14	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25734264~25735093:+
THCA	cis	rs9878978	1	rs62233805	ENSG00000227588.2	CNTN4-AS2	3.43	0.00065	0.0379	0.19	0.16	Blood pressure (smoking interaction);	chr3:2432701	chr3:2110409~2144241:-
THCA	cis	rs7824557	0.564	rs2736288	ENSG00000261451.1	RP11-981G7.1	-3.43	0.00065	0.0379	-0.2	-0.16	Retinal vascular caliber;	chr8:11370591	chr8:10433672~10438312:+
THCA	cis	rs6471393	0.895	rs58103546	ENSG00000261437.1	RP11-22C11.2	3.43	0.00065	0.0379	0.16	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749483	chr8:94637285~94639467:-
THCA	cis	rs1865760	0.623	rs12216125	ENSG00000272810.1	U91328.22	-3.43	0.00065	0.0379	-0.14	-0.16	Height;	chr6:25997230	chr6:26013241~26013757:+
THCA	cis	rs9307551	0.584	rs13113835	ENSG00000249646.2	OR7E94P	-3.43	0.00065	0.0379	-0.21	-0.16	Refractive error;	chr4:79522945	chr4:79587302~79588130:-
THCA	cis	rs4253772	0.591	rs6008538	ENSG00000277232.2	GTSE1-AS1	-3.43	0.00065	0.0379	-0.18	-0.16	Cholesterol, total;LDL cholesterol;	chr22:46290066	chr22:46295143~46296660:-
THCA	cis	rs4253772	0.591	rs6007795	ENSG00000277232.2	GTSE1-AS1	-3.43	0.00065	0.0379	-0.18	-0.16	Cholesterol, total;LDL cholesterol;	chr22:46290895	chr22:46295143~46296660:-
THCA	cis	rs4253772	0.591	rs73886791	ENSG00000277232.2	GTSE1-AS1	-3.43	0.00065	0.0379	-0.18	-0.16	Cholesterol, total;LDL cholesterol;	chr22:46291315	chr22:46295143~46296660:-
THCA	cis	rs11671005	0.572	rs11669127	ENSG00000252334.1	RNU6-1337P	-3.43	0.00065	0.0379	-0.24	-0.16	Mean platelet volume;	chr19:58492463	chr19:58483749~58483843:-
THCA	cis	rs9402743	0.632	rs4896178	ENSG00000272189.1	RP3-325F22.5	3.43	0.00065	0.0379	0.15	0.16	Systemic lupus erythematosus;	chr6:135783957	chr6:136550661~136552554:+
THCA	cis	rs9402743	0.632	rs7773035	ENSG00000272189.1	RP3-325F22.5	3.43	0.00065	0.0379	0.15	0.16	Systemic lupus erythematosus;	chr6:135784743	chr6:136550661~136552554:+
THCA	cis	rs4908760	0.792	rs10864361	ENSG00000238249.2	HMGN2P17	3.43	0.00065	0.0379	0.18	0.16	Vitiligo;	chr1:8666662	chr1:8893409~8894151:+
THCA	cis	rs2562456	0.558	rs62108173	ENSG00000268119.4	CTD-2561J22.5	3.43	0.00065	0.0379	0.22	0.16	Pain;	chr19:21244386	chr19:21444241~21463908:-
THCA	cis	rs17181170	0.553	rs6795510	ENSG00000239572.1	RP11-451B8.1	-3.43	0.00065	0.0379	-0.19	-0.16	Prostate cancer;	chr3:87125418	chr3:87731402~87793629:-
THCA	cis	rs1383484	0.575	rs28694702	ENSG00000259728.4	LINC00933	-3.43	0.00065	0.0379	-0.19	-0.16	Height;	chr15:83945534	chr15:84570649~84580175:+
THCA	cis	rs9392556	0.829	rs649725	ENSG00000230648.1	RP3-406P24.3	-3.43	0.00065	0.0379	-0.2	-0.16	Blood metabolite levels;	chr6:4109359	chr6:4018843~4021215:-
THCA	cis	rs3785574	0.962	rs8079161	ENSG00000279369.1	RP11-51F16.1	3.43	0.00065	0.0379	0.11	0.16	Height;	chr17:63731201	chr17:63700847~63702670:+
THCA	cis	rs2832191	0.692	rs2245734	ENSG00000176054.6	RPL23P2	3.43	0.00065	0.0379	0.14	0.16	Dental caries;	chr21:28987644	chr21:28997613~28998033:-
THCA	cis	rs6499755	0.768	rs31086	ENSG00000260135.5	RP11-212I21.2	-3.43	0.00065	0.0379	-0.17	-0.16	Hypospadias;	chr16:55328630	chr16:55426797~55462297:-
THCA	cis	rs57590327	0.503	rs7618973	ENSG00000241593.4	RP11-520D19.2	3.43	0.00065	0.0379	0.2	0.16	Extraversion;	chr3:81570437	chr3:81246579~81297345:-
THCA	cis	rs62025270	0.632	rs7181796	ENSG00000202081.1	RNU6-1280P	-3.43	0.00065	0.0379	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85651522~85651628:-
THCA	cis	rs9549260	0.739	rs7330614	ENSG00000275149.1	RP11-427J23.1	-3.43	0.00065	0.0379	-0.21	-0.16	Red blood cell count;	chr13:40625284	chr13:40079106~40273509:-
THCA	cis	rs1971762	0.583	rs7979659	ENSG00000270175.1	RP11-793H13.11	-3.43	0.00065	0.0379	-0.1	-0.16	Height;	chr12:53692795	chr12:53500162~53500936:-
THCA	cis	rs9567307	1	rs9567307	ENSG00000274001.1	RP11-5G9.5	3.43	0.00065	0.0379	0.19	0.16	Leprosy;	chr13:43897741	chr13:43877715~43878163:-
THCA	cis	rs17133449	0.718	rs7923564	ENSG00000205488.7	CALML3-AS1	-3.43	0.00065	0.0379	-0.18	-0.16	Major depressive disorder;	chr10:4711100	chr10:5514244~5526246:-
THCA	cis	rs7267979	0.565	rs13040726	ENSG00000276952.1	RP5-965G21.6	-3.43	0.00065	0.0379	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:25284915~25285588:-
THCA	cis	rs10943724	1	rs10943726	ENSG00000272129.1	RP11-250B2.6	3.43	0.00065	0.0379	0.21	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80594193	chr6:80355424~80356859:+
THCA	cis	rs11681884	0.786	rs1992763	ENSG00000272563.1	RP11-480C16.1	-3.43	0.00065	0.0379	-0.34	-0.16	Stroke;	chr2:113053159	chr2:113432600~113436042:+
THCA	cis	rs6940638	0.715	rs9348751	ENSG00000224843.5	LINC00240	3.43	0.00065	0.0379	0.14	0.16	Intelligence (multi-trait analysis);	chr6:27099411	chr6:26956992~27023924:+
THCA	cis	rs34779708	0.931	rs13377158	ENSG00000233200.1	RP11-324I22.2	-3.43	0.00065	0.0379	-0.18	-0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35219894~35230598:-
THCA	cis	rs1612141	0.744	rs4296175	ENSG00000251363.2	RP11-129M6.1	3.43	0.00065	0.0379	0.22	0.16	QT interval (drug interaction);	chr14:41105323	chr14:40954898~40975877:+
THCA	cis	rs9488822	0.676	rs11153593	ENSG00000237021.2	RP3-486I3.7	3.43	0.00065	0.0379	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116013968	chr6:116254207~116256743:+
THCA	cis	rs4800353	0.516	rs12456978	ENSG00000265142.5	MIR133A1HG	-3.43	0.00065	0.0379	-0.23	-0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr18:21955653	chr18:21825487~21831410:-
THCA	cis	rs6968419	0.504	rs11771585	ENSG00000237870.5	AC073130.1	3.43	0.00065	0.0379	0.17	0.16	Intraocular pressure;	chr7:116164389	chr7:116275606~116286734:-
THCA	cis	rs2880765	0.835	rs4360875	ENSG00000259407.1	RP11-158M2.3	-3.43	0.00065	0.0379	-0.16	-0.16	Coronary artery disease;	chr15:85497163	chr15:85744109~85750281:-
THCA	cis	rs7264396	0.887	rs224360	ENSG00000261582.1	RP4-614O4.11	3.43	0.000651	0.0379	0.16	0.16	Total cholesterol levels;	chr20:35471850	chr20:35267885~35280043:-
THCA	cis	rs8035452	1	rs12440841	ENSG00000273674.3	CTD-2378E12.1	3.43	0.000651	0.0379	0.19	0.16	Alzheimer's disease (late onset);	chr15:50713624	chr15:50839875~50908599:-
THCA	cis	rs10760158	0.8	rs10818520	ENSG00000235865.2	GSN-AS1	3.43	0.000651	0.0379	0.14	0.16	Pulse pressure;	chr9:121256395	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs10818522	ENSG00000235865.2	GSN-AS1	3.43	0.000651	0.0379	0.14	0.16	Pulse pressure;	chr9:121256732	chr9:121280768~121285530:-
THCA	cis	rs10858047	0.883	rs12040800	ENSG00000231128.4	RP5-1073O3.2	3.43	0.000651	0.0379	0.23	0.16	Autism;	chr1:114565956	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.883	rs12040830	ENSG00000231128.4	RP5-1073O3.2	3.43	0.000651	0.0379	0.23	0.16	Autism;	chr1:114566117	chr1:113812379~113829171:+
THCA	cis	rs13230714	0.858	rs2888075	ENSG00000244479.5	OR2A1-AS1	3.43	0.000651	0.0379	0.16	0.16	Breast cancer;	chr7:144456786	chr7:144251264~144356181:-
THCA	cis	rs11089937	0.929	rs5750624	ENSG00000211638.2	IGLV8-61	-3.43	0.000651	0.0379	-0.11	-0.16	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22098700~22099212:+
THCA	cis	rs1927790	0.727	rs9554338	ENSG00000247400.3	DNAJC3-AS1	-3.43	0.000651	0.0379	-0.11	-0.16	Body mass index;	chr13:96314060	chr13:95648733~95676925:-
THCA	cis	rs12780845	1	rs7100163	ENSG00000273153.1	RP11-406H21.2	3.43	0.000651	0.0379	0.15	0.16	Homocysteine levels;	chr10:17139178	chr10:17137336~17137585:-
THCA	cis	rs1978968	0.717	rs34263881	ENSG00000280007.1	AC008079.10	3.43	0.000651	0.0379	0.16	0.16	Presence of antiphospholipid antibodies;	chr22:17918831	chr22:18110759~18131154:-
THCA	cis	rs5753618	0.555	rs5749286	ENSG00000228839.4	PIK3IP1-AS1	-3.43	0.000651	0.0379	-0.18	-0.16	Colorectal cancer;	chr22:31504373	chr22:31292499~31338021:+
THCA	cis	rs751728	0.664	rs943475	ENSG00000274259.2	XXbac-BPG294E21.9	-3.43	0.000651	0.0379	-0.18	-0.16	Crohn's disease;	chr6:33782201	chr6:33437363~33454453:-
THCA	cis	rs34421088	0.56	rs2248699	ENSG00000255495.1	AC145124.2	-3.43	0.000651	0.0379	-0.18	-0.16	Neuroticism;	chr8:11536255	chr8:12194467~12196280:+
THCA	cis	rs6696239	1	rs10799428	ENSG00000227711.2	RP11-275O4.5	-3.43	0.000651	0.0379	-0.23	-0.16	Height;	chr1:227610864	chr1:227509028~227520477:-
THCA	cis	rs76866386	0.786	rs9753033	ENSG00000279873.2	LINC01126	3.43	0.000651	0.0379	0.24	0.16	Cholesterol, total;	chr2:43857461	chr2:43227210~43228855:+
THCA	cis	rs76866386	0.786	rs4507142	ENSG00000279873.2	LINC01126	3.43	0.000651	0.0379	0.24	0.16	Cholesterol, total;	chr2:43859452	chr2:43227210~43228855:+
THCA	cis	rs944289	0.74	rs1537425	ENSG00000212071.1	AL162511.1	-3.43	0.000651	0.0379	-0.18	-0.16	Thyroid cancer;	chr14:36098954	chr14:36196480~36196568:-
THCA	cis	rs9987353	0.566	rs6998368	ENSG00000254153.1	CTA-398F10.2	3.43	0.000651	0.0379	0.18	0.16	Recombination measurement;	chr8:9212778	chr8:8456909~8461337:-
THCA	cis	rs2888875	0.963	rs10164789	ENSG00000200924.1	RNU6-1048P	-3.43	0.000651	0.0379	-0.17	-0.16	Glomerular filtration rate (creatinine);	chr2:43558663	chr2:43892690~43892796:+
THCA	cis	rs2662776	1	rs2662776	ENSG00000232995.6	RGS5	-3.43	0.000651	0.0379	-0.13	-0.16	Lead levels in blood;	chr1:163195239	chr1:163244505~163321894:-
THCA	cis	rs13401620	0.555	rs1437421	ENSG00000236878.1	AC012363.7	-3.43	0.000651	0.038	-0.17	-0.16	Breast size;	chr2:120218255	chr2:120211054~120211715:+
THCA	cis	rs2292096	1	rs16847251	ENSG00000260088.1	RP11-92G12.3	-3.43	0.000651	0.038	-0.32	-0.16	Epilepsy;	chr1:200830953	chr1:200669507~200694250:+
THCA	cis	rs17767294	0.612	rs12332927	ENSG00000217539.2	IQCB2P	3.43	0.000651	0.038	0.3	0.16	Parkinson's disease;	chr6:27987337	chr6:28010723~28012355:+
THCA	cis	rs8040855	0.627	rs12913859	ENSG00000225151.9	GOLGA2P7	-3.43	0.000651	0.038	-0.22	-0.16	Bulimia nervosa;	chr15:85095187	chr15:84199311~84230136:-
THCA	cis	rs6088590	0.542	rs6059956	ENSG00000126005.14	MMP24-AS1	-3.43	0.000651	0.038	-0.14	-0.16	Coronary artery disease;	chr20:34632266	chr20:35216462~35278131:-
THCA	cis	rs4604234	0.901	rs6907326	ENSG00000260645.1	RP11-250B2.5	-3.43	0.000651	0.038	-0.28	-0.16	Cancer;	chr6:80395748	chr6:80466958~80469080:+
THCA	cis	rs58248207	1	rs58248207	ENSG00000200714.1	Y_RNA	-3.43	0.000651	0.038	-0.23	-0.16	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr8:65987352	chr8:65592731~65592820:+
THCA	cis	rs6413860	0.956	rs7417670	ENSG00000260855.1	RP11-439E19.10	-3.43	0.000651	0.038	-0.22	-0.16	Gut microbiome composition (summer);	chr1:246684551	chr1:246772301~246775772:+
THCA	cis	rs11168618	0.967	rs11168619	ENSG00000240399.1	RP1-228P16.1	3.43	0.000651	0.038	0.16	0.16	Adiponectin levels;	chr12:48539822	chr12:48054813~48055591:-
THCA	cis	rs7616559	0.629	rs1482857	ENSG00000240875.4	LINC00886	-3.43	0.000651	0.038	-0.12	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157036748	chr3:156747346~156817062:-
THCA	cis	rs7616559	0.629	rs13082176	ENSG00000240875.4	LINC00886	-3.43	0.000651	0.038	-0.12	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157037439	chr3:156747346~156817062:-
THCA	cis	rs7616559	0.606	rs2220051	ENSG00000240875.4	LINC00886	-3.43	0.000651	0.038	-0.12	-0.16	Carotid artery intima media thickness (sex interaction);	chr3:157046474	chr3:156747346~156817062:-
THCA	cis	rs950169	1	rs12915234	ENSG00000230373.7	GOLGA6L5P	-3.43	0.000652	0.038	-0.17	-0.16	Schizophrenia;	chr15:84089549	chr15:84507885~84516814:-
THCA	cis	rs950169	1	rs34751999	ENSG00000230373.7	GOLGA6L5P	-3.43	0.000652	0.038	-0.17	-0.16	Schizophrenia;	chr15:84089667	chr15:84507885~84516814:-
THCA	cis	rs950169	0.919	rs17300292	ENSG00000230373.7	GOLGA6L5P	-3.43	0.000652	0.038	-0.17	-0.16	Schizophrenia;	chr15:84093816	chr15:84507885~84516814:-
THCA	cis	rs9402743	0.6	rs9376151	ENSG00000272189.1	RP3-325F22.5	3.43	0.000652	0.038	0.15	0.16	Systemic lupus erythematosus;	chr6:135789599	chr6:136550661~136552554:+
THCA	cis	rs17689437	0.874	rs72785112	ENSG00000260084.1	RP11-615I2.1	-3.43	0.000652	0.038	-0.29	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68579398	chr16:68573782~68589512:-
THCA	cis	rs453301	0.686	rs7017868	ENSG00000233609.3	RP11-62H7.2	-3.43	0.000652	0.038	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9015783	chr8:8961200~8979025:+
THCA	cis	rs453301	0.686	rs3895823	ENSG00000233609.3	RP11-62H7.2	-3.43	0.000652	0.038	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9016136	chr8:8961200~8979025:+
THCA	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-3.43	0.000652	0.038	-0.14	-0.16	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
THCA	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
THCA	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
THCA	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	3.43	0.000652	0.038	0.14	0.16	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
THCA	cis	rs747782	0.639	rs17198985	ENSG00000200090.1	Y_RNA	3.43	0.000652	0.038	0.15	0.16	Intraocular pressure;	chr11:48162013	chr11:47726894~47726992:-
THCA	cis	rs13064411	0.627	rs9825827	ENSG00000243849.1	CFAP44-AS1	3.43	0.000652	0.038	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113463384	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs9836396	ENSG00000243849.1	CFAP44-AS1	3.43	0.000652	0.038	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113465435	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs9814395	ENSG00000243849.1	CFAP44-AS1	3.43	0.000652	0.038	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113470038	chr3:113403991~113433992:+
THCA	cis	rs12022452	0.908	rs4660423	ENSG00000272145.1	NFYC-AS1	3.43	0.000652	0.038	0.13	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40690380~40692066:-
THCA	cis	rs2797160	1	rs984040	ENSG00000226409.1	RP11-735G4.1	3.43	0.000652	0.038	0.18	0.16	Endometrial cancer;	chr6:125700131	chr6:125370211~125374324:-
THCA	cis	rs1560104	0.597	rs13338716	ENSG00000262801.4	U91319.1	-3.43	0.000652	0.038	-0.17	-0.16	Obesity-related traits;	chr16:12617477	chr16:13246316~13562918:+
THCA	cis	rs17495987	0.626	rs17494629	ENSG00000219545.8	UMAD1	3.43	0.000652	0.038	0.17	0.16	Tonsillectomy;	chr7:7831900	chr7:7640711~8004059:+
THCA	cis	rs12621844	0.638	rs4953546	ENSG00000234690.5	AC073283.4	-3.43	0.000652	0.038	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48046638	chr2:47192405~47345074:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000652	0.038	-0.16	-0.16	Lung cancer;	chr6:149628899	chr6:149576089~149590864:-
THCA	cis	rs3096299	0.754	rs3096320	ENSG00000260259.1	RP11-368I7.4	3.43	0.000652	0.038	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89336649	chr16:89682620~89686569:-
THCA	cis	rs7246657	1	rs7247672	ENSG00000268499.1	CTB-102L5.8	3.43	0.000652	0.038	0.21	0.16	Coronary artery calcification;	chr19:37253026	chr19:38199836~38200934:+
THCA	cis	rs7246657	1	rs8110011	ENSG00000268499.1	CTB-102L5.8	3.43	0.000652	0.038	0.21	0.16	Coronary artery calcification;	chr19:37254911	chr19:38199836~38200934:+
THCA	cis	rs72934570	0.71	rs76333597	ENSG00000267325.1	LINC01415	3.43	0.000652	0.038	0.25	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr18:55967576	chr18:55776727~55781721:-
THCA	cis	rs9844666	0.512	rs9864656	ENSG00000273486.1	RP11-731C17.2	-3.43	0.000652	0.038	-0.14	-0.16	Height;	chr3:135924696	chr3:136837338~136839021:-
THCA	cis	rs12621844	0.671	rs963133	ENSG00000234690.5	AC073283.4	-3.43	0.000652	0.038	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48081729	chr2:47192405~47345074:-
THCA	cis	rs2228479	0.85	rs62056091	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000652	0.038	-0.26	-0.16	Skin colour saturation;	chr16:89864006	chr16:89516797~89522217:+
THCA	cis	rs1729951	0.575	rs361244	ENSG00000239213.4	NCK1-AS1	3.43	0.000652	0.038	0.13	0.16	Neuroticism;	chr3:136978664	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs361243	ENSG00000239213.4	NCK1-AS1	3.43	0.000652	0.038	0.13	0.16	Neuroticism;	chr3:136978944	chr3:136841726~136862054:-
THCA	cis	rs13161895	1	rs4129403	ENSG00000278970.1	HEIH	3.43	0.000652	0.038	0.15	0.16	LDL cholesterol;	chr5:180049610	chr5:180829954~180831605:-
THCA	cis	rs7833790	0.963	rs28823280	ENSG00000254689.1	RP11-354A14.1	-3.43	0.000652	0.038	-0.19	-0.16	Diastolic blood pressure;	chr8:81865481	chr8:81885377~81923193:+
THCA	cis	rs7632954	0.9	rs6777857	ENSG00000227110.5	LMCD1-AS1	3.43	0.000652	0.038	0.19	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8477643	chr3:7952805~8611924:-
THCA	cis	rs7259376	0.875	rs9304996	ENSG00000269138.1	ZNF209P	3.43	0.000652	0.038	0.16	0.16	Menopause (age at onset);	chr19:22303733	chr19:22463922~22473036:+
THCA	cis	rs7179228	0.788	rs7167822	ENSG00000260657.2	RP11-315D16.4	3.43	0.000652	0.038	0.21	0.16	Systolic blood pressure;	chr15:68331837	chr15:68267792~68277994:-
THCA	cis	rs7192750	0.586	rs12444521	ENSG00000260886.1	TAT-AS1	3.43	0.000652	0.038	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71907795	chr16:71565789~71578187:+
THCA	cis	rs9527	0.641	rs4919684	ENSG00000203886.4	CYP17A1-AS1	3.43	0.000652	0.038	0.16	0.16	Arsenic metabolism;	chr10:102827267	chr10:102832721~102834516:+
THCA	cis	rs765787	0.53	rs12905246	ENSG00000259539.1	CTD-2651B20.1	-3.43	0.000652	0.038	-0.2	-0.16	Uric acid levels;	chr15:45208643	chr15:45152664~45167526:-
THCA	cis	rs2131877	0.573	rs58370605	ENSG00000238097.1	RP11-513G11.3	-3.43	0.000652	0.038	-0.18	-0.16	Non-small cell lung cancer;	chr3:195122148	chr3:194247648~194257772:+
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000182586.6	LINC00334	-3.43	0.000652	0.038	-0.18	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45234340~45258730:+
THCA	cis	rs7737355	0.812	rs10076930	ENSG00000237714.1	P4HA2-AS1	-3.43	0.000652	0.038	-0.22	-0.16	Life satisfaction;	chr5:131428344	chr5:132184876~132192808:+
THCA	cis	rs6017317	0.643	rs4812810	ENSG00000244558.4	KCNK15-AS1	-3.43	0.000652	0.038	-0.22	-0.16	Type 2 diabetes;	chr20:44270892	chr20:44694892~44746021:-
THCA	cis	rs1993293	0.636	rs2168067	ENSG00000259219.1	CTD-3076O17.2	3.43	0.000653	0.038	0.19	0.16	Coronary artery calcification;	chr15:99758972	chr15:99976481~99980774:+
THCA	cis	rs3738443	0.52	rs1771932	ENSG00000227671.4	RP11-488L18.4	-3.43	0.000653	0.038	-0.09	-0.16	Alcohol dependence;	chr1:247218747	chr1:247189851~247210856:-
THCA	cis	rs12468579	0.74	rs12693588	ENSG00000235852.1	AC005540.3	3.43	0.000653	0.038	0.15	0.16	JT interval (sulfonylurea treatment interaction);	chr2:190967766	chr2:190880797~190882059:-
THCA	cis	rs2228479	0.85	rs11639788	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000653	0.038	-0.28	-0.16	Skin colour saturation;	chr16:89741135	chr16:89516797~89522217:+
THCA	cis	rs75920871	0.589	rs67201490	ENSG00000280143.1	AP000892.6	3.43	0.000653	0.038	0.28	0.16	Subjective well-being;	chr11:117212288	chr11:117204967~117210292:+
THCA	cis	rs75920871	0.64	rs4938357	ENSG00000280143.1	AP000892.6	3.43	0.000653	0.038	0.28	0.16	Subjective well-being;	chr11:117213324	chr11:117204967~117210292:+
THCA	cis	rs972578	0.967	rs926353	ENSG00000230319.1	AL022476.2	3.43	0.000653	0.038	0.17	0.16	Mean platelet volume;	chr22:42975501	chr22:43038585~43052366:+
THCA	cis	rs972578	0.905	rs60752002	ENSG00000230319.1	AL022476.2	3.43	0.000653	0.038	0.17	0.16	Mean platelet volume;	chr22:42975622	chr22:43038585~43052366:+
THCA	cis	rs6938	0.534	rs11636892	ENSG00000260269.4	CTD-2323K18.1	-3.43	0.000653	0.038	-0.22	-0.16	Breast cancer;	chr15:74973708	chr15:75527150~75601205:-
THCA	cis	rs74781061	0.722	rs4073149	ENSG00000260103.2	RP11-10O17.1	3.43	0.000653	0.038	0.21	0.16	Endometriosis;	chr15:74606078	chr15:74478070~74490286:-
THCA	cis	rs2179367	0.959	rs4897125	ENSG00000223701.3	RAET1E-AS1	3.43	0.000653	0.038	0.21	0.16	Dupuytren's disease;	chr6:149445072	chr6:149884431~149919508:+
THCA	cis	rs409045	1	rs461277	ENSG00000271874.1	CTD-2024P10.2	-3.43	0.000653	0.038	-0.21	-0.16	Left ventricular mass;	chr5:34633480	chr5:34651457~34651888:-
THCA	cis	rs11249243	0.92	rs4649043	ENSG00000233478.1	RP1-187B23.1	3.43	0.000653	0.038	0.3	0.16	Male-pattern baldness;	chr1:25015765	chr1:25644544~25659111:-
THCA	cis	rs9811920	0.609	rs4928232	ENSG00000273374.1	RP11-383I23.2	-3.43	0.000653	0.038	-0.14	-0.16	Axial length;	chr3:99975373	chr3:99802699~99806058:-
THCA	cis	rs10911902	0.643	rs75008037	ENSG00000228238.1	GS1-304P7.2	-3.43	0.000653	0.038	-0.26	-0.16	Schizophrenia;	chr1:186371380	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs76554103	ENSG00000228238.1	GS1-304P7.2	-3.43	0.000653	0.038	-0.26	-0.16	Schizophrenia;	chr1:186371402	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs7514615	ENSG00000228238.1	GS1-304P7.2	-3.43	0.000653	0.038	-0.26	-0.16	Schizophrenia;	chr1:186373191	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs6425027	ENSG00000228238.1	GS1-304P7.2	-3.43	0.000653	0.038	-0.26	-0.16	Schizophrenia;	chr1:186376034	chr1:186578279~186579299:+
THCA	cis	rs10911902	0.643	rs6425028	ENSG00000228238.1	GS1-304P7.2	-3.43	0.000653	0.038	-0.26	-0.16	Schizophrenia;	chr1:186376149	chr1:186578279~186579299:+
THCA	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	3.43	0.000653	0.038	0.21	0.16	Depression;	chr6:28386473	chr6:28943877~28944537:+
THCA	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	3.43	0.000653	0.038	0.21	0.16	Depression;	chr6:28391932	chr6:28943877~28944537:+
THCA	cis	rs516805	0.748	rs11154078	ENSG00000279114.1	RP3-425C14.5	3.43	0.000653	0.038	0.17	0.16	Lymphocyte counts;	chr6:122387058	chr6:122471923~122484161:+
THCA	cis	rs6840360	1	rs10007167	ENSG00000270265.1	RP11-731D1.4	-3.43	0.000653	0.038	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151682503	chr4:151333775~151353224:-
THCA	cis	rs4889855	0.614	rs9892081	ENSG00000279692.1	RP11-1055B8.1	-3.43	0.000653	0.038	-0.26	-0.16	Fractional excretion of uric acid;	chr17:80510684	chr17:81395609~81397144:-
THCA	cis	rs1560104	0.536	rs12708760	ENSG00000262801.4	U91319.1	-3.43	0.000653	0.038	-0.17	-0.16	Obesity-related traits;	chr16:12617071	chr16:13246316~13562918:+
THCA	cis	rs1560104	0.597	rs13334919	ENSG00000262801.4	U91319.1	-3.43	0.000653	0.038	-0.17	-0.16	Obesity-related traits;	chr16:12617300	chr16:13246316~13562918:+
THCA	cis	rs6413860	0.956	rs6426321	ENSG00000260855.1	RP11-439E19.10	3.43	0.000653	0.038	0.2	0.16	Gut microbiome composition (summer);	chr1:246690388	chr1:246772301~246775772:+
THCA	cis	rs10411936	1	rs873636	ENSG00000279529.1	CTD-3222D19.8	-3.43	0.000653	0.038	-0.11	-0.16	Multiple sclerosis;White blood cell count;	chr19:16403960	chr19:16572624~16575340:+
THCA	cis	rs6723226	0.842	rs1901355	ENSG00000276517.1	AL133243.2	3.43	0.000653	0.038	0.16	0.16	Intelligence (multi-trait analysis);	chr2:32610597	chr2:32526504~32529507:+
THCA	cis	rs950169	0.84	rs72748702	ENSG00000230373.7	GOLGA6L5P	-3.43	0.000653	0.038	-0.17	-0.16	Schizophrenia;	chr15:84246494	chr15:84507885~84516814:-
THCA	cis	rs6787172	0.811	rs4510417	ENSG00000272247.1	RP11-379F4.9	3.43	0.000653	0.038	0.15	0.16	Subjective well-being;	chr3:158491764	chr3:158801257~158801935:-
THCA	cis	rs73076966	1	rs4536713	ENSG00000274269.1	RP4-545L17.12	3.43	0.000653	0.038	0.25	0.16	Plateletcrit;	chr20:1545733	chr20:1186092~1207036:+
THCA	cis	rs4713118	0.513	rs149942	ENSG00000176933.5	TOB2P1	-3.43	0.000653	0.038	-0.19	-0.16	Parkinson's disease;	chr6:28033832	chr6:28217643~28218634:-
THCA	cis	rs1923539	0.822	rs1923536	ENSG00000272447.1	RP11-182L21.6	3.43	0.000653	0.038	0.22	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950053	chr10:79825902~79827602:+
THCA	cis	rs2364403	0.531	rs41264995	ENSG00000225855.5	RUSC1-AS1	3.43	0.000653	0.038	0.16	0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:155947598	chr1:155316863~155324176:-
THCA	cis	rs2006933	1	rs9909055	ENSG00000267644.1	CTD-2008P7.10	3.43	0.000653	0.038	0.2	0.16	Amyotrophic lateral sclerosis;	chr17:28269102	chr17:28219285~28220005:+
THCA	cis	rs7873102	0.967	rs10814646	ENSG00000213839.4	TMX2P1	3.43	0.000653	0.038	0.12	0.16	Brain structure;	chr9:38031033	chr9:37885683~37886390:+
THCA	cis	rs12462428	0.911	rs6512119	ENSG00000279748.1	CTD-3222D19.9	3.43	0.000653	0.038	0.22	0.16	Educational attainment (years of education);	chr19:16554404	chr19:16586905~16589409:+
THCA	cis	rs6940638	1	rs12215241	ENSG00000224843.5	LINC00240	3.43	0.000653	0.0381	0.18	0.16	Intelligence (multi-trait analysis);	chr6:27055302	chr6:26956992~27023924:+
THCA	cis	rs2677744	0.563	rs8024249	ENSG00000214432.8	AC068831.10	-3.43	0.000653	0.0381	-0.16	-0.16	Attention deficit hyperactivity disorder;	chr15:90951019	chr15:91022619~91036611:+
THCA	cis	rs7267979	0.586	rs6050431	ENSG00000274973.1	RP13-401N8.7	-3.43	0.000653	0.0381	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25845497~25845862:+
THCA	cis	rs7267979	0.586	rs6050432	ENSG00000274973.1	RP13-401N8.7	-3.43	0.000653	0.0381	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25845497~25845862:+
THCA	cis	rs5753037	0.543	rs140128	ENSG00000273350.1	RP4-539M6.20	-3.43	0.000653	0.0381	-0.18	-0.16	Type 1 diabetes;	chr22:29754151	chr22:30420512~30420912:+
THCA	cis	rs2280018	0.526	rs1510148	ENSG00000255277.3	ABCC6P2	3.43	0.000654	0.0381	0.18	0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:14820792~14824702:-
THCA	cis	rs1979679	0.578	rs1993936	ENSG00000247934.4	RP11-967K21.1	-3.43	0.000654	0.0381	-0.15	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28120979	chr12:28163298~28190738:-
THCA	cis	rs7949566	0.647	rs4935967	ENSG00000255062.1	RP11-712L6.5	3.43	0.000654	0.0381	0.17	0.16	Platelet distribution width;Mean platelet volume;	chr11:126419061	chr11:126294298~126304318:-
THCA	cis	rs7924176	0.601	rs7896660	ENSG00000232342.6	RP11-46O21.2	3.43	0.000654	0.0381	0.2	0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74170399	chr10:74506081~74530553:-
THCA	cis	rs1552244	0.882	rs7636817	ENSG00000269982.1	RP11-1020A11.2	3.43	0.000654	0.0381	0.12	0.16	Alzheimer's disease;	chr3:9973192	chr3:9958717~9962539:+
THCA	cis	rs4846580	1	rs12134759	ENSG00000230024.1	RP11-95P13.1	-3.43	0.000654	0.0381	-0.18	-0.16	Total body bone mineral density;	chr1:219682434	chr1:219435152~219442642:-
THCA	cis	rs4578769	0.685	rs11659242	ENSG00000265939.1	UBE2CP2	-3.43	0.000654	0.0381	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:23058085	chr18:22900486~22900995:-
THCA	cis	rs9400467	0.506	rs56381513	ENSG00000255389.1	C6orf3	3.43	0.000654	0.0381	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111108482	chr6:111599875~111602295:+
THCA	cis	rs72934570	0.71	rs76035256	ENSG00000267325.1	LINC01415	3.43	0.000654	0.0381	0.25	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr18:55967331	chr18:55776727~55781721:-
THCA	cis	rs72934570	0.71	rs77045199	ENSG00000267325.1	LINC01415	3.43	0.000654	0.0381	0.25	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr18:55967594	chr18:55776727~55781721:-
THCA	cis	rs72934570	0.71	rs75764697	ENSG00000267325.1	LINC01415	3.43	0.000654	0.0381	0.25	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr18:55967605	chr18:55776727~55781721:-
THCA	cis	rs7264396	0.887	rs4911510	ENSG00000261582.1	RP4-614O4.11	-3.43	0.000654	0.0381	-0.16	-0.16	Total cholesterol levels;	chr20:35505325	chr20:35267885~35280043:-
THCA	cis	rs10186029	0.616	rs12616255	ENSG00000270659.1	RP11-105N14.1	-3.43	0.000654	0.0381	-0.12	-0.16	Systemic sclerosis;	chr2:213114171	chr2:213152970~213153659:+
THCA	cis	rs9860428	0.844	rs9820561	ENSG00000243795.1	RP11-572M11.3	3.43	0.000654	0.0381	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897693	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.808	rs6805341	ENSG00000243795.1	RP11-572M11.3	3.43	0.000654	0.0381	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899471	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.808	rs9868922	ENSG00000243795.1	RP11-572M11.3	3.43	0.000654	0.0381	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899503	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs2399437	ENSG00000243795.1	RP11-572M11.3	3.43	0.000654	0.0381	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112900369	chr3:113142350~113167819:-
THCA	cis	rs5758511	0.68	rs5758688	ENSG00000182057.4	OGFRP1	-3.43	0.000654	0.0381	-0.22	-0.16	Birth weight;	chr22:42266495	chr22:42269753~42275196:+
THCA	cis	rs3087591	0.639	rs757379	ENSG00000263535.1	AK4P1	3.43	0.000654	0.0381	0.19	0.16	Hip circumference;	chr17:31397539	chr17:31345521~31346187:+
THCA	cis	rs1864982	0.681	rs319221	ENSG00000251556.1	RP11-118M9.3	-3.43	0.000654	0.0381	-0.24	-0.16	Alcohol dependence;	chr5:146871494	chr5:146099406~146120412:+
THCA	cis	rs8027587	0.925	rs8040181	ENSG00000259699.2	HMGB1P8	3.43	0.000654	0.0381	0.21	0.16	Obesity-related traits;	chr15:88695101	chr15:89135547~89136495:-
THCA	cis	rs7554511	1	rs7522462	ENSG00000260088.1	RP11-92G12.3	3.43	0.000654	0.0381	0.24	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200912467	chr1:200669507~200694250:+
THCA	cis	rs832187	0.629	rs13272	ENSG00000224479.4	AC136289.1	3.43	0.000654	0.0381	0.19	0.16	Schizophrenia;	chr3:64000494	chr3:63742293~63827445:-
THCA	cis	rs7849270	0.959	rs9408986	ENSG00000204055.4	RP11-247A12.2	3.43	0.000654	0.0381	0.2	0.16	Blood metabolite ratios;	chr9:129126156	chr9:129176771~129210548:+
THCA	cis	rs72827839	0.894	rs41336845	ENSG00000278765.1	RP5-890E16.5	3.43	0.000654	0.0381	0.23	0.16	Ease of getting up in the morning;	chr17:48137748	chr17:48066704~48067293:-
THCA	cis	rs7264396	0.635	rs6060692	ENSG00000088340.14	FER1L4	-3.43	0.000654	0.0381	-0.15	-0.16	Total cholesterol levels;	chr20:35930003	chr20:35558737~35607562:-
THCA	cis	rs7818688	0.697	rs80217195	ENSG00000253528.2	RP11-347C18.4	-3.43	0.000654	0.0381	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974625	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.697	rs76215523	ENSG00000253528.2	RP11-347C18.4	-3.43	0.000654	0.0381	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974787	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.697	rs3802192	ENSG00000253528.2	RP11-347C18.4	-3.43	0.000654	0.0381	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975243	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.697	rs11784140	ENSG00000253528.2	RP11-347C18.4	-3.43	0.000654	0.0381	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975252	chr8:94974573~94974853:-
THCA	cis	rs793571	0.779	rs28641638	ENSG00000245975.2	RP11-30K9.6	3.43	0.000654	0.0381	0.17	0.16	Schizophrenia;	chr15:58923034	chr15:58768072~58770974:-
THCA	cis	rs1510272	0.847	rs6441085	ENSG00000243926.1	TIPARP-AS1	-3.43	0.000654	0.0381	-0.16	-0.16	Testicular germ cell tumor;	chr3:156607673	chr3:156671862~156674378:-
THCA	cis	rs2455799	0.613	rs2470536	ENSG00000270409.1	RP11-44D5.1	-3.43	0.000654	0.0381	-0.17	-0.16	Mean platelet volume;	chr3:15673649	chr3:15732252~15733470:+
THCA	cis	rs2455799	0.593	rs2470544	ENSG00000270409.1	RP11-44D5.1	-3.43	0.000654	0.0381	-0.17	-0.16	Mean platelet volume;	chr3:15685727	chr3:15732252~15733470:+
THCA	cis	rs3126085	0.935	rs3126043	ENSG00000237975.5	FLG-AS1	-3.43	0.000654	0.0381	-0.25	-0.16	Atopic dermatitis;	chr1:152283554	chr1:152168125~152445456:+
THCA	cis	rs62045849	0.557	rs4782444	ENSG00000261546.1	CTD-2555A7.3	3.43	0.000654	0.0381	0.27	0.16	Red blood cell count;	chr16:89117565	chr16:89113175~89115279:-
THCA	cis	rs2228479	0.85	rs62054599	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89742442	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.717	rs17233678	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89743554	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17227263	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89744190	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs17233664	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89744220	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.717	rs2074904	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89745138	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.702	rs2074903	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89745255	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs62054601	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89745343	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs1800355	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89746786	chr16:89516797~89522217:+
THCA	cis	rs2228479	0.85	rs11641147	ENSG00000274627.1	RP11-104N10.2	-3.43	0.000654	0.0381	-0.28	-0.16	Skin colour saturation;	chr16:89747181	chr16:89516797~89522217:+
THCA	cis	rs6840360	0.571	rs11939356	ENSG00000251611.1	RP11-610P16.1	-3.43	0.000654	0.0381	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151584082	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs2165789	ENSG00000251611.1	RP11-610P16.1	-3.43	0.000654	0.0381	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151588978	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.55	rs6853955	ENSG00000251611.1	RP11-610P16.1	-3.43	0.000654	0.0381	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151589654	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs17275577	ENSG00000251611.1	RP11-610P16.1	-3.43	0.000654	0.0381	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151598747	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs875667	ENSG00000251611.1	RP11-610P16.1	-3.43	0.000654	0.0381	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151604325	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs4696102	ENSG00000251611.1	RP11-610P16.1	-3.43	0.000654	0.0381	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151608506	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs6833814	ENSG00000251611.1	RP11-610P16.1	-3.43	0.000654	0.0381	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151618527	chr4:151407551~151408835:-
THCA	cis	rs17428076	0.918	rs55864623	ENSG00000228389.1	AC068039.4	-3.43	0.000654	0.0381	-0.2	-0.16	Myopia;	chr2:171892180	chr2:171773482~171775844:+
THCA	cis	rs875971	0.862	rs2909688	ENSG00000223473.2	GS1-124K5.3	3.43	0.000654	0.0381	0.11	0.16	Aortic root size;	chr7:66376625	chr7:66491049~66493566:-
THCA	cis	rs7737355	0.738	rs10051609	ENSG00000224431.1	AC063976.7	3.43	0.000654	0.0381	0.14	0.16	Life satisfaction;	chr5:131541387	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs10059807	ENSG00000224431.1	AC063976.7	3.43	0.000654	0.0381	0.14	0.16	Life satisfaction;	chr5:131541991	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs10515455	ENSG00000224431.1	AC063976.7	3.43	0.000654	0.0381	0.14	0.16	Life satisfaction;	chr5:131543096	chr5:132199456~132203487:+
THCA	cis	rs3809566	0.559	rs4775605	ENSG00000259251.2	RP11-643M14.1	-3.43	0.000654	0.0381	-0.16	-0.16	Platelet count;	chr15:63031849	chr15:62060503~62062434:+
THCA	cis	rs9527	0.501	rs12244388	ENSG00000213277.3	MARCKSL1P1	3.43	0.000654	0.0381	0.17	0.16	Arsenic metabolism;	chr10:102880295	chr10:103175554~103176094:+
THCA	cis	rs2292096	1	rs12736176	ENSG00000260088.1	RP11-92G12.3	3.43	0.000654	0.0381	0.32	0.16	Epilepsy;	chr1:200831900	chr1:200669507~200694250:+
THCA	cis	rs8049040	0.547	rs891131	ENSG00000261513.1	RP11-432I5.8	3.43	0.000654	0.0381	0.22	0.16	Blood protein levels;	chr16:71398514	chr16:71723180~71724230:+
THCA	cis	rs2289328	0.882	rs7164606	ENSG00000223313.1	RNU6-516P	-3.43	0.000654	0.0381	-0.22	-0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40352932	chr15:40529570~40529673:+
THCA	cis	rs2014572	0.967	rs4801452	ENSG00000276449.1	AC004076.5	3.43	0.000654	0.0381	0.14	0.16	Hyperactive-impulsive symptoms;	chr19:57256698	chr19:57449689~57453011:+
THCA	cis	rs683257	0.85	rs72988116	ENSG00000234147.1	RP3-460G2.2	-3.43	0.000654	0.0381	-0.31	-0.16	Facial emotion recognition (angry faces);	chr6:140813529	chr6:140845958~140852924:-
THCA	cis	rs1790761	0.632	rs625978	ENSG00000184224.3	C11orf72	3.43	0.000654	0.0381	0.21	0.16	Mean corpuscular volume;	chr11:67577193	chr11:67602880~67606706:-
THCA	cis	rs10911902	0.643	rs74842753	ENSG00000228238.1	GS1-304P7.2	-3.43	0.000654	0.0381	-0.26	-0.16	Schizophrenia;	chr1:186390059	chr1:186578279~186579299:+
THCA	cis	rs1864585	0.806	rs28566988	ENSG00000280294.1	RP11-177H2.1	3.43	0.000655	0.0381	0.17	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10928869	chr8:10856085~10859436:-
THCA	cis	rs258324	0.79	rs460319	ENSG00000274627.1	RP11-104N10.2	3.43	0.000655	0.0381	0.2	0.16	Height;	chr16:89667685	chr16:89516797~89522217:+
THCA	cis	rs9650657	0.741	rs10100333	ENSG00000255310.2	AF131215.2	-3.43	0.000655	0.0381	-0.13	-0.16	Neuroticism;	chr8:10726778	chr8:11107788~11109726:-
THCA	cis	rs9307551	0.948	rs4975056	ENSG00000249646.2	OR7E94P	-3.43	0.000655	0.0381	-0.22	-0.16	Refractive error;	chr4:79563716	chr4:79587302~79588130:-
THCA	cis	rs683250	0.63	rs10898107	ENSG00000254551.1	RP11-727A23.7	-3.43	0.000655	0.0381	-0.18	-0.16	Subcortical brain region volumes;	chr11:83375811	chr11:83209431~83213379:-
THCA	cis	rs858239	0.614	rs10229956	ENSG00000226816.2	AC005082.12	-3.43	0.000655	0.0381	-0.22	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23206013~23208045:+
THCA	cis	rs5753618	0.583	rs5753639	ENSG00000214076.3	CPSF1P1	3.43	0.000655	0.0381	0.2	0.16	Colorectal cancer;	chr22:31474414	chr22:32269381~32273110:+
THCA	cis	rs11073619	0.616	rs34602083	ENSG00000188388.10	GOLGA6L3	-3.43	0.000655	0.0381	-0.29	-0.16	Positive affect;	chr15:84397156	chr15:85240472~85247170:+
THCA	cis	rs12893668	0.572	rs4906350	ENSG00000258735.1	LINC00637	-3.43	0.000655	0.0381	-0.21	-0.16	Reticulocyte count;	chr14:103645457	chr14:103847721~103858049:+
THCA	cis	rs8054556	1	rs4788195	ENSG00000214725.6	CDIPT-AS1	-3.43	0.000655	0.0381	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29949272	chr16:29863593~29868053:+
THCA	cis	rs237743	1	rs238217	ENSG00000222365.1	SNORD12B	-3.43	0.000655	0.0381	-0.2	-0.16	Height;	chr20:49254902	chr20:49280319~49280409:+
THCA	cis	rs237743	1	rs238174	ENSG00000222365.1	SNORD12B	-3.43	0.000655	0.0381	-0.2	-0.16	Height;	chr20:49262572	chr20:49280319~49280409:+
THCA	cis	rs237743	1	rs6648	ENSG00000222365.1	SNORD12B	-3.43	0.000655	0.0381	-0.2	-0.16	Height;	chr20:49278705	chr20:49280319~49280409:+
THCA	cis	rs237743	1	rs238198	ENSG00000222365.1	SNORD12B	-3.43	0.000655	0.0381	-0.2	-0.16	Height;	chr20:49282523	chr20:49280319~49280409:+
THCA	cis	rs76878669	0.561	rs905770	ENSG00000255320.1	RP11-755F10.1	-3.43	0.000655	0.0381	-0.2	-0.16	Educational attainment (years of education);	chr11:66389294	chr11:66244840~66246239:-
THCA	cis	rs12368653	0.616	rs1027315	ENSG00000270039.1	RP11-571M6.17	3.43	0.000655	0.0381	0.16	0.16	Multiple sclerosis;	chr12:57640409	chr12:57803838~57804415:+
THCA	cis	rs7246657	0.722	rs35863684	ENSG00000226686.6	LINC01535	-3.43	0.000655	0.0381	-0.23	-0.16	Coronary artery calcification;	chr19:37618876	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs10402671	ENSG00000226686.6	LINC01535	-3.43	0.000655	0.0381	-0.23	-0.16	Coronary artery calcification;	chr19:37626185	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs10417576	ENSG00000226686.6	LINC01535	-3.43	0.000655	0.0381	-0.23	-0.16	Coronary artery calcification;	chr19:37628311	chr19:37251912~37265535:+
THCA	cis	rs7430456	0.674	rs13079337	ENSG00000231574.4	RP11-91K9.1	-3.43	0.000655	0.0381	-0.23	-0.16	Breast cancer;	chr3:177776996	chr3:177816865~177899224:+
THCA	cis	rs2048656	0.637	rs10107396	ENSG00000261451.1	RP11-981G7.1	-3.43	0.000655	0.0381	-0.2	-0.16	Schizophrenia;	chr8:9815642	chr8:10433672~10438312:+
THCA	cis	rs12959333	0.527	rs8089199	ENSG00000274849.1	RP11-49I11.4	-3.43	0.000655	0.0381	-0.19	-0.16	Post bronchodilator FEV1;	chr18:35717224	chr18:36189824~36190272:+
THCA	cis	rs10496034	0.541	rs74518232	ENSG00000237887.1	AC092839.1	-3.43	0.000655	0.0381	-0.3	-0.16	Refractive astigmatism;	chr2:54689104	chr2:54529343~54529801:+
THCA	cis	rs57709857	0.957	rs7845284	ENSG00000272092.1	RP11-350N15.5	-3.43	0.000655	0.0381	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38284697	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.681	rs7823681	ENSG00000272092.1	RP11-350N15.5	-3.43	0.000655	0.0381	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38285217	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs10100894	ENSG00000272092.1	RP11-350N15.5	-3.43	0.000655	0.0381	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38285839	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.957	rs10109023	ENSG00000272092.1	RP11-350N15.5	-3.43	0.000655	0.0381	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38286022	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.914	rs10101145	ENSG00000272092.1	RP11-350N15.5	-3.43	0.000655	0.0381	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38286054	chr8:38382364~38383461:+
THCA	cis	rs67478160	0.634	rs941475	ENSG00000258534.1	CTD-2134A5.4	-3.43	0.000655	0.0381	-0.16	-0.16	Schizophrenia;	chr14:103774281	chr14:103854366~103880111:-
THCA	cis	rs1790761	0.607	rs656652	ENSG00000184224.3	C11orf72	3.43	0.000655	0.0381	0.21	0.16	Mean corpuscular volume;	chr11:67576486	chr11:67602880~67606706:-
THCA	cis	rs2688608	0.592	rs13013	ENSG00000272140.2	RP11-574K11.29	3.43	0.000655	0.0381	0.13	0.16	Inflammatory bowel disease;	chr10:73802403	chr10:73703735~73713581:-
THCA	cis	rs10129255	0.957	rs11846893	ENSG00000211972.2	IGHV3-66	3.43	0.000655	0.0381	0.09	0.16	Kawasaki disease;	chr14:106779068	chr14:106675017~106675544:-
THCA	cis	rs12264252	0.623	rs12773636	ENSG00000242600.5	MBL1P	3.43	0.000655	0.0381	0.17	0.16	Coronary artery disease;	chr10:80502651	chr10:79904898~79950336:+
THCA	cis	rs763121	0.853	rs5750630	ENSG00000225450.1	RP3-508I15.14	-3.43	0.000655	0.0381	-0.12	-0.16	Menopause (age at onset);	chr22:38589813	chr22:38739003~38749041:+
THCA	cis	rs73198271	0.694	rs73201840	ENSG00000254153.1	CTA-398F10.2	3.43	0.000655	0.0381	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.694	rs113694763	ENSG00000254153.1	CTA-398F10.2	3.43	0.000655	0.0381	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.694	rs115037021	ENSG00000254153.1	CTA-398F10.2	3.43	0.000655	0.0381	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8456909~8461337:-
THCA	cis	rs73198271	0.694	rs114184516	ENSG00000254153.1	CTA-398F10.2	3.43	0.000655	0.0381	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8456909~8461337:-
THCA	cis	rs7246657	0.722	rs2287229	ENSG00000226686.6	LINC01535	3.43	0.000655	0.0381	0.23	0.16	Coronary artery calcification;	chr19:37697751	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs2075284	ENSG00000226686.6	LINC01535	3.43	0.000655	0.0381	0.23	0.16	Coronary artery calcification;	chr19:37698715	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs968073	ENSG00000226686.6	LINC01535	3.43	0.000655	0.0381	0.23	0.16	Coronary artery calcification;	chr19:37701120	chr19:37251912~37265535:+
THCA	cis	rs6545883	0.524	rs778159	ENSG00000273302.1	RP11-493E12.2	-3.43	0.000655	0.0381	-0.14	-0.16	Tuberculosis;	chr2:61329609	chr2:61199979~61200769:+
THCA	cis	rs7259376	0.714	rs4358065	ENSG00000270947.1	AC025811.3	3.43	0.000655	0.0381	0.17	0.16	Menopause (age at onset);	chr19:22338330	chr19:22455988~22456459:+
THCA	cis	rs773506	1	rs773513	ENSG00000229694.5	RP11-305L7.6	-3.43	0.000655	0.0381	-0.19	-0.16	Type 2 diabetes nephropathy;	chr9:91218561	chr9:91119062~91182762:+
THCA	cis	rs10090774	0.965	rs4543590	ENSG00000280303.2	ERICD	-3.43	0.000655	0.0381	-0.15	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140715735	chr8:140636281~140638283:+
THCA	cis	rs1502337	0.516	rs9652060	ENSG00000278993.1	RP3-424M6.4	-3.43	0.000656	0.0381	-0.24	-0.16	Body mass index;	chr12:110471012	chr12:110501614~110503441:+
THCA	cis	rs467650	0.509	rs152989	ENSG00000248489.1	CTD-2007H13.3	3.43	0.000656	0.0381	0.14	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98654131	chr5:98929171~98995013:+
THCA	cis	rs3790645	1	rs396997	ENSG00000241547.1	RP11-4K3__A.5	-3.43	0.000656	0.0381	-0.18	-0.16	Glucose homeostasis traits;	chr1:26566576	chr1:27325329~27325796:+
THCA	cis	rs7264396	0.887	rs736031	ENSG00000261582.1	RP4-614O4.11	-3.43	0.000656	0.0381	-0.16	-0.16	Total cholesterol levels;	chr20:35460805	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs736032	ENSG00000261582.1	RP4-614O4.11	-3.43	0.000656	0.0381	-0.16	-0.16	Total cholesterol levels;	chr20:35460841	chr20:35267885~35280043:-
THCA	cis	rs73459955	0.712	rs61353661	ENSG00000248441.5	LINC01197	3.43	0.000656	0.0381	0.21	0.16	Major depression and alcohol dependence;	chr15:95084711	chr15:95209099~95327129:-
THCA	cis	rs4698412	0.617	rs35519415	ENSG00000273133.1	RP11-799M12.2	-3.43	0.000656	0.0382	-0.19	-0.16	Parkinson's disease;	chr4:15708707	chr4:15563698~15564253:-
THCA	cis	rs11237982	0.587	rs10899663	ENSG00000255345.1	CTD-2337I7.1	-3.43	0.000656	0.0382	-0.24	-0.16	Verbal declarative memory;	chr11:79678191	chr11:79092848~79098003:+
THCA	cis	rs11168618	0.935	rs2114322	ENSG00000258273.1	RP11-370I10.4	3.43	0.000656	0.0382	0.2	0.16	Adiponectin levels;	chr12:48557824	chr12:48333755~48333901:-
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000255046.1	RP11-297N6.4	3.43	0.000656	0.0382	0.16	0.16	Neuroticism;	chr8:11986249	chr8:11797928~11802568:-
THCA	cis	rs4308415	0.934	rs787362	ENSG00000270292.1	RP11-453E17.4	-3.43	0.000656	0.0382	-0.18	-0.16	Educational attainment (years of education);	chr4:67039213	chr4:67725183~67726395:-
THCA	cis	rs4308415	0.934	rs813104	ENSG00000270292.1	RP11-453E17.4	-3.43	0.000656	0.0382	-0.18	-0.16	Educational attainment (years of education);	chr4:67039773	chr4:67725183~67726395:-
THCA	cis	rs847649	0.842	rs869332	ENSG00000234715.1	CTB-107G13.1	-3.43	0.000656	0.0382	-0.17	-0.16	Morning vs. evening chronotype;	chr7:102991800	chr7:103445207~103514007:+
THCA	cis	rs6806253	0.793	rs4640583	ENSG00000239405.1	TMED10P2	3.43	0.000656	0.0382	0.23	0.16	Pit-and-Fissure caries;	chr3:128559575	chr3:128538020~128538631:+
THCA	cis	rs8037137	0.915	rs79548680	ENSG00000258725.1	PRC1-AS1	-3.43	0.000656	0.0382	-0.24	-0.16	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90962549	chr15:90966345~90988624:+
THCA	cis	rs6921919	0.583	rs11755942	ENSG00000220721.1	OR1F12	3.43	0.000656	0.0382	0.18	0.16	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28073316~28074233:+
THCA	cis	rs34779708	0.931	rs11010077	ENSG00000233200.1	RP11-324I22.2	-3.43	0.000656	0.0382	-0.19	-0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs4934731	ENSG00000233200.1	RP11-324I22.2	3.43	0.000656	0.0382	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs57081218	ENSG00000233200.1	RP11-324I22.2	3.43	0.000656	0.0382	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs12762493	ENSG00000233200.1	RP11-324I22.2	3.43	0.000656	0.0382	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35219894~35230598:-
THCA	cis	rs806215	0.666	rs12672945	ENSG00000224138.1	AC000123.4	3.43	0.000656	0.0382	0.17	0.16	Type 2 diabetes;	chr7:127870436	chr7:127350128~127351523:+
THCA	cis	rs8022179	0.566	rs62006258	ENSG00000269940.1	RP11-73M18.7	-3.43	0.000656	0.0382	-0.17	-0.16	Monocyte count;	chr14:103372572	chr14:103694560~103695170:+
THCA	cis	rs1125355	0.69	rs72937289	ENSG00000243792.1	OR7E89P	-3.43	0.000656	0.0382	-0.24	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr2:158771000	chr2:158853755~158854576:+
THCA	cis	rs11678825	0.852	rs11683202	ENSG00000272663.1	RP11-191L17.1	-3.43	0.000656	0.0382	-0.22	-0.16	Reticulocyte fraction of red cells;	chr2:48437521	chr2:48440043~48440597:-
THCA	cis	rs9650657	0.538	rs10111950	ENSG00000206014.6	OR7E161P	3.43	0.000656	0.0382	0.18	0.16	Neuroticism;	chr8:10958244	chr8:11928597~11929563:-
THCA	cis	rs9650657	0.769	rs1968400	ENSG00000269918.1	AF131215.9	-3.43	0.000656	0.0382	-0.16	-0.16	Neuroticism;	chr8:10757921	chr8:11104691~11106704:-
THCA	cis	rs867186	1	rs867186	ENSG00000279253.1	RP4-614O4.13	3.43	0.000656	0.0382	0.23	0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35176751	chr20:35262727~35264187:-
THCA	cis	rs2228479	0.867	rs62052168	ENSG00000223959.7	AFG3L1P	-3.43	0.000656	0.0382	-0.15	-0.16	Skin colour saturation;	chr16:89880795	chr16:89972586~90002161:+
THCA	cis	rs9584850	0.834	rs745639	ENSG00000231194.1	FARP1-AS1	3.43	0.000656	0.0382	0.19	0.16	Neuroticism;	chr13:98467025	chr13:98435405~98435840:-
THCA	cis	rs9368481	0.761	rs4358615	ENSG00000228223.2	HCG11	-3.43	0.000656	0.0382	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26523450~26526579:+
THCA	cis	rs801193	1	rs2659909	ENSG00000232546.1	RP11-458F8.1	-3.43	0.000656	0.0382	-0.13	-0.16	Aortic root size;	chr7:66695292	chr7:66848496~66858136:+
THCA	cis	rs2228479	0.85	rs62056102	ENSG00000223959.7	AFG3L1P	-3.43	0.000656	0.0382	-0.15	-0.16	Skin colour saturation;	chr16:89875030	chr16:89972586~90002161:+
THCA	cis	rs28530618	0.84	rs11697969	ENSG00000198547.7	C20orf203	3.43	0.000656	0.0382	0.12	0.16	Birth weight;	chr20:32651496	chr20:32631652~32673941:-
THCA	cis	rs3764021	0.509	rs10772073	ENSG00000257027.1	RP11-705C15.3	3.43	0.000656	0.0382	0.14	0.16	Type 1 diabetes;	chr12:9717428	chr12:9658567~9662085:+
THCA	cis	rs7937890	0.559	rs2597196	ENSG00000251991.1	RNU7-49P	-3.43	0.000656	0.0382	-0.18	-0.16	Mitochondrial DNA levels;	chr11:14470055	chr11:14478892~14478953:+
THCA	cis	rs7737355	0.812	rs13158215	ENSG00000224431.1	AC063976.7	3.43	0.000657	0.0382	0.14	0.16	Life satisfaction;	chr5:131293850	chr5:132199456~132203487:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000230295.1	RP11-458F8.2	3.43	0.000657	0.0382	0.14	0.16	Aortic root size;	chr7:66221293	chr7:66880708~66882981:+
THCA	cis	rs9788682	0.747	rs12101809	ENSG00000261143.1	ADAMTS7P3	-3.43	0.000657	0.0382	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78487459	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs28511883	ENSG00000261143.1	ADAMTS7P3	-3.43	0.000657	0.0382	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78491341	chr15:77976042~77993057:+
THCA	cis	rs9435732	0.54	rs9325647	ENSG00000280114.1	RP5-875O13.7	3.43	0.000657	0.0382	0.18	0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17039305	chr1:16681097~16688749:-
THCA	cis	rs9435732	0.504	rs9787230	ENSG00000280114.1	RP5-875O13.7	3.43	0.000657	0.0382	0.18	0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17044475	chr1:16681097~16688749:-
THCA	cis	rs1642645	0.915	rs10890176	ENSG00000228452.1	RP5-994D16.9	-3.43	0.000657	0.0382	-0.19	-0.16	Left ventricular obstructive tract defect (maternal effect);	chr1:42038279	chr1:42775813~42776790:-
THCA	cis	rs7746199	0.736	rs6904596	ENSG00000272009.1	RP1-313I6.12	-3.43	0.000657	0.0382	-0.26	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28078792~28081130:-
THCA	cis	rs73459955	0.641	rs7170213	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95083678	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.667	rs7170969	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95084086	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs73457995	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95085498	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs73457996	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95085629	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.667	rs114868249	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95085653	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs78072287	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95085796	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs61061770	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95086320	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs58747951	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95086367	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs73457999	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95087169	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs73459904	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95087685	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs73459907	ENSG00000248441.5	LINC01197	3.43	0.000657	0.0382	0.2	0.16	Major depression and alcohol dependence;	chr15:95087783	chr15:95209099~95327129:-
THCA	cis	rs354225	0.544	rs12713265	ENSG00000212175.1	SNORA12	-3.43	0.000657	0.0382	-0.19	-0.16	Schizophrenia;	chr2:54578272	chr2:55565703~55565850:+
THCA	cis	rs7520050	0.966	rs1707304	ENSG00000280836.1	AL355480.1	3.43	0.000657	0.0382	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45581219~45581321:-
THCA	cis	rs1062753	0.527	rs6002560	ENSG00000227370.1	RP4-669P10.19	-3.43	0.000657	0.0382	-0.15	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41960882	chr22:42132543~42132998:+
THCA	cis	rs7829975	0.688	rs13270194	ENSG00000253130.1	CTD-3023L14.2	-3.43	0.000657	0.0382	-0.17	-0.16	Mood instability;	chr8:8520592	chr8:8561391~8569688:+
THCA	cis	rs467650	0.529	rs1508791	ENSG00000248489.1	CTD-2007H13.3	-3.43	0.000657	0.0382	-0.14	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98660173	chr5:98929171~98995013:+
THCA	cis	rs10794657	1	rs10794657	ENSG00000232298.2	RP11-10N16.3	-3.43	0.000657	0.0382	-0.21	-0.16	Adiponectin levels;	chr1:24299684	chr1:24307556~24321901:-
THCA	cis	rs516805	0.501	rs564611	ENSG00000279114.1	RP3-425C14.5	-3.43	0.000657	0.0382	-0.14	-0.16	Lymphocyte counts;	chr6:122418178	chr6:122471923~122484161:+
THCA	cis	rs7308116	0.967	rs57379115	ENSG00000257951.1	RP11-554D14.4	3.43	0.000657	0.0382	0.19	0.16	Pelvic organ prolapse (moderate/severe);	chr12:107801985	chr12:107881242~107883382:+
THCA	cis	rs12915845	1	rs13835	ENSG00000271997.1	RP11-97O12.6	-3.43	0.000657	0.0382	-0.11	-0.16	Menarche (age at onset);	chr15:88512809	chr15:88501944~88505787:-
THCA	cis	rs7179228	1	rs2414996	ENSG00000260657.2	RP11-315D16.4	3.43	0.000657	0.0382	0.21	0.16	Systolic blood pressure;	chr15:68323138	chr15:68267792~68277994:-
THCA	cis	rs1371614	0.501	rs6745807	ENSG00000272148.1	RP11-195B17.1	3.43	0.000657	0.0382	0.15	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26962449	chr2:27062428~27062907:-
THCA	cis	rs13401620	0.827	rs1533792	ENSG00000231013.1	AC013275.2	-3.43	0.000657	0.0382	-0.18	-0.16	Breast size;	chr2:119734217	chr2:119476448~119487346:+
THCA	cis	rs6995541	0.662	rs9329231	ENSG00000248896.2	CTD-2135J3.3	-3.43	0.000657	0.0382	-0.19	-0.16	Triglyceride levels;	chr8:10759990	chr8:10729314~10771392:+
THCA	cis	rs4073582	0.595	rs801741	ENSG00000245156.1	RP11-867G23.3	3.43	0.000657	0.0382	0.13	0.16	Gout;	chr11:66149613	chr11:66269832~66278525:-
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000184274.3	LINC00315	-3.43	0.000657	0.0382	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000184274.3	LINC00315	-3.43	0.000657	0.0382	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000184274.3	LINC00315	-3.43	0.000657	0.0382	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000184274.3	LINC00315	-3.43	0.000657	0.0382	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000184274.3	LINC00315	-3.43	0.000657	0.0382	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45300245~45305257:-
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000184274.3	LINC00315	-3.43	0.000657	0.0382	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45300245~45305257:-
THCA	cis	rs1153858	1	rs12440038	ENSG00000275672.1	GATM-AS1	-3.43	0.000657	0.0382	-0.16	-0.16	Homoarginine levels;	chr15:45414541	chr15:45378700~45380123:+
THCA	cis	rs13136331	0.721	rs2732175	ENSG00000249001.4	RP11-742B18.1	3.43	0.000657	0.0382	0.2	0.16	Sitting height ratio;	chr4:87761422	chr4:87568035~87733956:-
THCA	cis	rs11764561	0.604	rs1181944	ENSG00000236018.2	RP4-814D15.1	-3.43	0.000657	0.0382	-0.2	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr7:156209507	chr7:157197600~157198511:-
THCA	cis	rs8030379	1	rs6603004	ENSG00000176700.18	SCAND2P	3.43	0.000657	0.0382	0.1	0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899752	chr15:84631451~84647478:+
THCA	cis	rs6732426	0.792	rs3901678	ENSG00000279873.2	LINC01126	-3.43	0.000657	0.0382	-0.12	-0.16	Hair morphology;	chr2:43360312	chr2:43227210~43228855:+
THCA	cis	rs9329221	0.618	rs73197281	ENSG00000154316.13	TDH	3.43	0.000657	0.0382	0.11	0.16	Neuroticism;	chr8:10405772	chr8:11339637~11368452:+
THCA	cis	rs9400467	0.537	rs73528983	ENSG00000255389.1	C6orf3	3.43	0.000657	0.0382	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111112438	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.537	rs73528998	ENSG00000255389.1	C6orf3	3.43	0.000657	0.0382	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111124427	chr6:111599875~111602295:+
THCA	cis	rs58688157	0.96	rs61877857	ENSG00000269915.1	AP006621.9	-3.43	0.000657	0.0382	-0.18	-0.16	Systemic lupus erythematosus;	chr11:617420	chr11:708564~727047:-
THCA	cis	rs35740288	0.862	rs11637444	ENSG00000259407.1	RP11-158M2.3	-3.43	0.000657	0.0382	-0.19	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85767957	chr15:85744109~85750281:-
THCA	cis	rs412658	0.535	rs1651558	ENSG00000268119.4	CTD-2561J22.5	3.43	0.000657	0.0382	0.18	0.16	Telomere length;	chr19:21906773	chr19:21444241~21463908:-
THCA	cis	rs4713118	1	rs1139226	ENSG00000261839.1	RP1-265C24.8	3.43	0.000658	0.0382	0.17	0.16	Parkinson's disease;	chr6:27707511	chr6:28136849~28139678:+
THCA	cis	rs4713118	1	rs9468195	ENSG00000261839.1	RP1-265C24.8	3.43	0.000658	0.0382	0.17	0.16	Parkinson's disease;	chr6:27708530	chr6:28136849~28139678:+
THCA	cis	rs7824557	0.734	rs2293856	ENSG00000255310.2	AF131215.2	3.43	0.000658	0.0382	0.14	0.16	Retinal vascular caliber;	chr8:11319938	chr8:11107788~11109726:-
THCA	cis	rs42648	0.564	rs39267	ENSG00000225498.1	AC002064.5	3.43	0.000658	0.0382	0.17	0.16	Homocysteine levels;	chr7:90142195	chr7:90312496~90322592:+
THCA	cis	rs42648	0.536	rs39270	ENSG00000225498.1	AC002064.5	3.43	0.000658	0.0382	0.17	0.16	Homocysteine levels;	chr7:90143312	chr7:90312496~90322592:+
THCA	cis	rs11030122	0.702	rs11030276	ENSG00000230593.3	AC090804.1	3.43	0.000658	0.0382	0.21	0.16	Mean platelet volume;Platelet distribution width;	chr11:3924904	chr11:3892398~3892887:-
THCA	cis	rs6938	0.514	rs35556055	ENSG00000260269.4	CTD-2323K18.1	-3.43	0.000658	0.0382	-0.22	-0.16	Breast cancer;	chr15:74961073	chr15:75527150~75601205:-
THCA	cis	rs35860234	0.806	rs9525630	ENSG00000231530.1	RP11-187A9.3	3.43	0.000658	0.0382	0.19	0.16	Vitiligo;	chr13:42486648	chr13:42043727~42044247:-
THCA	cis	rs6832769	1	rs576779	ENSG00000223305.1	RN7SKP30	3.43	0.000658	0.0382	0.2	0.16	Personality dimensions;	chr4:55408140	chr4:55540502~55540835:-
THCA	cis	rs6832769	0.961	rs480479	ENSG00000223305.1	RN7SKP30	3.43	0.000658	0.0382	0.2	0.16	Personality dimensions;	chr4:55408163	chr4:55540502~55540835:-
THCA	cis	rs7394190	0.748	rs12573448	ENSG00000272140.2	RP11-574K11.29	-3.43	0.000658	0.0383	-0.16	-0.16	Incident atrial fibrillation;	chr10:73744754	chr10:73703735~73713581:-
THCA	cis	rs7394190	0.748	rs12572278	ENSG00000272140.2	RP11-574K11.29	-3.43	0.000658	0.0383	-0.16	-0.16	Incident atrial fibrillation;	chr10:73744755	chr10:73703735~73713581:-
THCA	cis	rs2360027	0.662	rs10159155	ENSG00000231365.4	RP11-418J17.1	-3.43	0.000658	0.0383	-0.15	-0.16	Tonsillectomy;	chr1:118611281	chr1:119140396~119275973:+
THCA	cis	rs2360027	0.64	rs10159270	ENSG00000231365.4	RP11-418J17.1	-3.43	0.000658	0.0383	-0.15	-0.16	Tonsillectomy;	chr1:118611356	chr1:119140396~119275973:+
THCA	cis	rs62400317	0.762	rs6909047	ENSG00000237686.5	RP5-1120P11.1	-3.43	0.000658	0.0383	-0.15	-0.16	Total body bone mineral density;	chr6:45031178	chr6:43995723~44074652:-
THCA	cis	rs2483519	0.511	rs10885595	ENSG00000228169.3	PPIAP19	3.43	0.000658	0.0383	0.18	0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114678586	chr10:114690143~114690634:-
THCA	cis	rs7474896	0.559	rs1735629	ENSG00000276805.1	RP11-291L22.6	-3.43	0.000658	0.0383	-0.2	-0.16	Obesity (extreme);	chr10:37889381	chr10:38451030~38451785:+
THCA	cis	rs7586085	1	rs13390528	ENSG00000232411.1	AC009495.3	-3.43	0.000658	0.0383	-0.17	-0.16	Total body bone mineral density;	chr2:165725521	chr2:165833048~165839098:-
THCA	cis	rs11673344	0.504	rs6510593	ENSG00000267260.1	CTD-2162K18.4	-3.43	0.000658	0.0383	-0.19	-0.16	Obesity-related traits;	chr19:37143153	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.504	rs7259332	ENSG00000267260.1	CTD-2162K18.4	-3.43	0.000658	0.0383	-0.19	-0.16	Obesity-related traits;	chr19:37143389	chr19:36773153~36777078:+
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Body mass index;	chr17:30751280	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000264242.2	RP11-271K11.1	3.43	0.000658	0.0383	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30553697~30558962:+
THCA	cis	rs9788682	0.642	rs2568483	ENSG00000261143.1	ADAMTS7P3	-3.43	0.000658	0.0383	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78460001	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs2656069	ENSG00000261143.1	ADAMTS7P3	3.43	0.000658	0.0383	0.23	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78453365	chr15:77976042~77993057:+
THCA	cis	rs7246657	0.943	rs10405064	ENSG00000268499.1	CTB-102L5.8	3.43	0.000658	0.0383	0.21	0.16	Coronary artery calcification;	chr19:37370959	chr19:38199836~38200934:+
THCA	cis	rs4723738	0.967	rs10480164	ENSG00000227191.5	TRGC2	-3.43	0.000658	0.0383	-0.12	-0.16	Treatment response for severe sepsis;	chr7:38206281	chr7:38239580~38368091:-
THCA	cis	rs7712401	0.755	rs965821	ENSG00000263432.2	RN7SL689P	3.43	0.000658	0.0383	0.16	0.16	Mean platelet volume;	chr5:122802013	chr5:123022487~123022783:-
THCA	cis	rs6754311	0.551	rs6739713	ENSG00000231890.6	DARS-AS1	-3.43	0.000658	0.0383	-0.16	-0.16	Mosquito bite size;	chr2:135731408	chr2:135985176~136022593:+
THCA	cis	rs1044826	0.642	rs9859864	ENSG00000178631.7	ACTG1P1	-3.43	0.000658	0.0383	-0.17	-0.16	Obesity-related traits;	chr3:139372377	chr3:139493809~139494937:+
THCA	cis	rs2290416	0.681	rs3793371	ENSG00000254338.1	MAFA-AS1	3.43	0.000658	0.0383	0.31	0.16	Attention deficit hyperactivity disorder;	chr8:143582129	chr8:143417679~143419150:+
THCA	cis	rs73198271	0.751	rs55816468	ENSG00000254153.1	CTA-398F10.2	3.43	0.000658	0.0383	0.19	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748366	chr8:8456909~8461337:-
THCA	cis	rs620729	0.707	rs2177159	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11479533	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs2140109	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11479856	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs6457608	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480086	chr6:10743324~10747663:-
THCA	cis	rs620729	0.75	rs6923613	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480124	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs4713556	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480173	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs6923798	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480258	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs6907900	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480334	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs11751931	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480443	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs35877256	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480495	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs35250180	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480514	chr6:10743324~10747663:-
THCA	cis	rs620729	0.668	rs34630993	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480557	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs34678413	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480674	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs36120363	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480702	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs35491413	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480775	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs35074878	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480837	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs34486680	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480853	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs17607537	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480899	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs17675742	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481009	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs66502560	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481237	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs35100959	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481251	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs17607558	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481292	chr6:10743324~10747663:-
THCA	cis	rs620729	0.707	rs34342746	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481353	chr6:10743324~10747663:-
THCA	cis	rs620729	0.707	rs34363244	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481395	chr6:10743324~10747663:-
THCA	cis	rs620729	0.668	rs67452935	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481470	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs62394921	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481892	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs62394922	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11481914	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs36021289	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482620	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs16871371	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482658	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs3942485	ENSG00000272097.1	RP11-421M1.8	3.43	0.000658	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11482703	chr6:10743324~10747663:-
THCA	cis	rs6471393	0.83	rs6981752	ENSG00000261437.1	RP11-22C11.2	3.43	0.000658	0.0383	0.16	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761046	chr8:94637285~94639467:-
THCA	cis	rs2880765	0.835	rs7161880	ENSG00000259407.1	RP11-158M2.3	-3.43	0.000658	0.0383	-0.16	-0.16	Coronary artery disease;	chr15:85475515	chr15:85744109~85750281:-
THCA	cis	rs9392556	0.829	rs659025	ENSG00000230648.1	RP3-406P24.3	3.43	0.000658	0.0383	0.2	0.16	Blood metabolite levels;	chr6:4118817	chr6:4018843~4021215:-
THCA	cis	rs7632954	0.605	rs6794255	ENSG00000227110.5	LMCD1-AS1	3.43	0.000658	0.0383	0.19	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8481134	chr3:7952805~8611924:-
THCA	cis	rs2073499	0.935	rs2236939	ENSG00000281358.1	RASSF1-AS1	-3.43	0.000658	0.0383	-0.24	-0.16	Schizophrenia;	chr3:50206077	chr3:50337511~50338300:+
THCA	cis	rs6430585	0.527	rs12465544	ENSG00000231890.6	DARS-AS1	-3.43	0.000658	0.0383	-0.18	-0.16	Corneal structure;	chr2:135694106	chr2:135985176~136022593:+
THCA	cis	rs55661361	0.553	rs11219765	ENSG00000245498.5	RP11-677M14.7	-3.43	0.000658	0.0383	-0.11	-0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124732351	chr11:124800450~124834487:+
THCA	cis	rs7656342	0.599	rs6852425	ENSG00000250342.1	SNRPCP16	3.43	0.000658	0.0383	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9855235	chr4:9051842~9052051:-
THCA	cis	rs7656342	0.599	rs9684729	ENSG00000250342.1	SNRPCP16	3.43	0.000658	0.0383	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9860412	chr4:9051842~9052051:-
THCA	cis	rs12908161	0.65	rs182517	ENSG00000254414.1	RP11-182J1.1	3.43	0.000659	0.0383	0.22	0.16	Schizophrenia;	chr15:84846400	chr15:84631898~84633987:-
THCA	cis	rs9863	0.794	rs7978610	ENSG00000269938.1	RP11-214K3.20	3.43	0.000659	0.0383	0.18	0.16	White blood cell count;	chr12:123984025	chr12:123968023~123968579:-
THCA	cis	rs7824557	0.614	rs10503421	ENSG00000255052.4	FAM66D	-3.43	0.000659	0.0383	-0.21	-0.16	Retinal vascular caliber;	chr8:11363804	chr8:12115782~12177550:+
THCA	cis	rs78889164	0.956	rs75826800	ENSG00000239253.1	RPS4XP23	3.43	0.000659	0.0383	0.26	0.16	Lobe attachment (rater-scored or self-reported);	chr19:33383448	chr19:34021659~34021895:+
THCA	cis	rs9584850	0.834	rs12869627	ENSG00000231194.1	FARP1-AS1	3.43	0.000659	0.0383	0.19	0.16	Neuroticism;	chr13:98468198	chr13:98435405~98435840:-
THCA	cis	rs10792665	0.575	rs4625493	ENSG00000255503.1	RP11-113K21.4	3.43	0.000659	0.0383	0.16	0.16	Obesity-related traits;	chr11:82829933	chr11:83072402~83097196:-
THCA	cis	rs950169	0.881	rs34117475	ENSG00000230373.7	GOLGA6L5P	-3.43	0.000659	0.0383	-0.17	-0.16	Schizophrenia;	chr15:84565212	chr15:84507885~84516814:-
THCA	cis	rs8028182	0.636	rs4451914	ENSG00000275645.1	RP11-817O13.9	3.43	0.000659	0.0383	0.15	0.16	Sudden cardiac arrest;	chr15:75447483	chr15:75346744~75347161:-
THCA	cis	rs6762	0.719	rs1130698	ENSG00000255284.1	AP006621.5	3.43	0.000659	0.0383	0.11	0.16	Mean platelet volume;	chr11:838542	chr11:777578~784297:+
THCA	cis	rs2180341	1	rs13218061	ENSG00000220522.2	RP1-177A13.1	3.43	0.000659	0.0383	0.2	0.16	Breast cancer;	chr6:127332613	chr6:127416535~127416952:-
THCA	cis	rs337161	0.573	rs7539769	ENSG00000221571.3	RNU6ATAC35P	-3.43	0.000659	0.0383	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220771358	chr1:220825620~220826063:+
THCA	cis	rs337161	0.605	rs7518916	ENSG00000221571.3	RNU6ATAC35P	-3.43	0.000659	0.0383	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220771641	chr1:220825620~220826063:+
THCA	cis	rs337161	0.605	rs7553948	ENSG00000221571.3	RNU6ATAC35P	-3.43	0.000659	0.0383	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220771798	chr1:220825620~220826063:+
THCA	cis	rs11119805	0.649	rs56318540	ENSG00000225338.1	RP11-384C4.3	-3.43	0.000659	0.0383	-0.27	-0.16	Stearic acid (18:0) levels;	chr1:211885228	chr1:212309051~212309518:-
THCA	cis	rs9549260	0.755	rs9549241	ENSG00000275149.1	RP11-427J23.1	-3.43	0.000659	0.0383	-0.21	-0.16	Red blood cell count;	chr13:40635904	chr13:40079106~40273509:-
THCA	cis	rs11085466	1	rs73552479	ENSG00000268119.4	CTD-2561J22.5	-3.43	0.000659	0.0383	-0.21	-0.16	Colorectal or endometrial cancer;	chr19:21596014	chr19:21444241~21463908:-
THCA	cis	rs75920871	0.589	rs56081989	ENSG00000280143.1	AP000892.6	3.43	0.000659	0.0383	0.28	0.16	Subjective well-being;	chr11:117214589	chr11:117204967~117210292:+
THCA	cis	rs789852	0.867	rs1773177	ENSG00000231770.4	TMEM44-AS1	3.43	0.000659	0.0383	0.21	0.16	QT interval;	chr3:194595452	chr3:194584011~194590260:+
THCA	cis	rs11123170	0.64	rs931472	ENSG00000234997.1	AC016745.3	-3.43	0.000659	0.0383	-0.16	-0.16	Renal function-related traits (BUN);	chr2:113212371	chr2:113424495~113425324:+
THCA	cis	rs7259376	0.902	rs7248242	ENSG00000270947.1	AC025811.3	-3.43	0.000659	0.0383	-0.17	-0.16	Menopause (age at onset);	chr19:22393192	chr19:22455988~22456459:+
THCA	cis	rs11642862	1	rs113454775	ENSG00000275263.1	RP11-1072A3.4	-3.43	0.000659	0.0383	-0.34	-0.16	Tonsillectomy;	chr16:30798213	chr16:30956872~30957199:-
THCA	cis	rs972578	0.837	rs5758980	ENSG00000274717.1	RP1-47A17.1	-3.43	0.000659	0.0383	-0.16	-0.16	Mean platelet volume;	chr22:42847950	chr22:42791814~42794313:-
THCA	cis	rs763121	0.657	rs5995603	ENSG00000272669.1	RP3-508I15.21	-3.43	0.000659	0.0383	-0.12	-0.16	Menopause (age at onset);	chr22:38644728	chr22:38742625~38743115:+
THCA	cis	rs6687821	0.515	rs2798682	ENSG00000261737.1	RP4-612B15.3	3.43	0.000659	0.0383	0.24	0.16	Yeast infection;	chr1:87108280	chr1:86703502~86704462:-
THCA	cis	rs6687821	0.515	rs2798684	ENSG00000261737.1	RP4-612B15.3	3.43	0.000659	0.0383	0.24	0.16	Yeast infection;	chr1:87108534	chr1:86703502~86704462:-
THCA	cis	rs2625529	0.73	rs2957368	ENSG00000260037.4	CTD-2524L6.3	-3.43	0.000659	0.0383	-0.2	-0.16	Red blood cell count;	chr15:72037565	chr15:71818396~71823384:+
THCA	cis	rs11992162	0.967	rs4841661	ENSG00000255046.1	RP11-297N6.4	-3.43	0.000659	0.0383	-0.17	-0.16	Monocyte count;	chr8:11975260	chr8:11797928~11802568:-
THCA	cis	rs11992162	1	rs11994417	ENSG00000255046.1	RP11-297N6.4	-3.43	0.000659	0.0383	-0.17	-0.16	Monocyte count;	chr8:11975753	chr8:11797928~11802568:-
THCA	cis	rs17122278	1	rs57438673	ENSG00000255239.1	AP002954.6	-3.43	0.000659	0.0383	-0.28	-0.16	Total cholesterol levels;	chr11:118588324	chr11:118688039~118690600:-
THCA	cis	rs620729	0.634	rs35408353	ENSG00000272097.1	RP11-421M1.8	3.43	0.00066	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480643	chr6:10743324~10747663:-
THCA	cis	rs620729	0.6	rs35160576	ENSG00000272097.1	RP11-421M1.8	3.43	0.00066	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480645	chr6:10743324~10747663:-
THCA	cis	rs620729	0.707	rs34066851	ENSG00000272097.1	RP11-421M1.8	3.43	0.00066	0.0383	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11480656	chr6:10743324~10747663:-
THCA	cis	rs16857609	0.564	rs6734808	ENSG00000233143.1	DIRC3-AS1	-3.43	0.00066	0.0383	-0.19	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217429848	chr2:217282739~217336120:+
THCA	cis	rs2130392	0.892	rs11728389	ENSG00000250726.1	RP11-616K6.1	3.43	0.00066	0.0383	0.19	0.16	Kawasaki disease;	chr4:184700892	chr4:184072403~184073039:+
THCA	cis	rs11168618	0.715	rs35367885	ENSG00000240399.1	RP1-228P16.1	3.43	0.00066	0.0383	0.16	0.16	Adiponectin levels;	chr12:48525877	chr12:48054813~48055591:-
THCA	cis	rs301901	0.772	rs301873	ENSG00000250155.1	CTD-2353F22.1	-3.43	0.00066	0.0383	-0.16	-0.16	Height;	chr5:37136896	chr5:36666214~36725195:-
THCA	cis	rs875971	0.545	rs11767262	ENSG00000230295.1	RP11-458F8.2	3.43	0.00066	0.0384	0.14	0.16	Aortic root size;	chr7:66302237	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000230295.1	RP11-458F8.2	3.43	0.00066	0.0384	0.14	0.16	Aortic root size;	chr7:66327797	chr7:66880708~66882981:+
THCA	cis	rs1538970	0.884	rs781226	ENSG00000280836.1	AL355480.1	3.43	0.00066	0.0384	0.21	0.16	Platelet count;	chr1:45406990	chr1:45581219~45581321:-
THCA	cis	rs1923243	0.587	rs6667006	ENSG00000223479.3	RP4-788P17.1	3.43	0.00066	0.0384	0.17	0.16	Migraine;	chr1:72970566	chr1:73635216~73715214:+
THCA	cis	rs6840360	0.53	rs12645029	ENSG00000251611.1	RP11-610P16.1	-3.43	0.00066	0.0384	-0.13	-0.16	Intelligence (multi-trait analysis);	chr4:151728880	chr4:151407551~151408835:-
THCA	cis	rs3749237	0.595	rs10865955	ENSG00000224424.7	PRKAR2A-AS1	3.43	0.00066	0.0384	0.13	0.16	Resting heart rate;	chr3:49462396	chr3:48847572~48851981:+
THCA	cis	rs4325129	0.765	rs6687518	ENSG00000272668.1	RP11-190A12.8	3.43	0.00066	0.0384	0.18	0.16	Obesity-related traits;	chr1:159502990	chr1:159866954~159867685:+
THCA	cis	rs4325129	0.705	rs10437324	ENSG00000272668.1	RP11-190A12.8	3.43	0.00066	0.0384	0.18	0.16	Obesity-related traits;	chr1:159504080	chr1:159866954~159867685:+
THCA	cis	rs4325129	0.705	rs10437325	ENSG00000272668.1	RP11-190A12.8	3.43	0.00066	0.0384	0.18	0.16	Obesity-related traits;	chr1:159504587	chr1:159866954~159867685:+
THCA	cis	rs7017914	0.644	rs13258800	ENSG00000246366.5	RP11-382J12.1	3.43	0.00066	0.0384	0.17	0.16	Bone mineral density;	chr8:70819867	chr8:70608577~70663279:+
THCA	cis	rs1440410	0.798	rs11100783	ENSG00000250326.1	RP11-284M14.1	-3.43	0.00066	0.0384	-0.14	-0.16	Ischemic stroke;	chr4:143241047	chr4:142933195~143184861:-
THCA	cis	rs1510552	0.872	rs6715771	ENSG00000270659.1	RP11-105N14.1	3.43	0.00066	0.0384	0.16	0.16	Contrast sensitivity;	chr2:214076010	chr2:213152970~213153659:+
THCA	cis	rs10875746	0.551	rs3751273	ENSG00000258273.1	RP11-370I10.4	3.43	0.00066	0.0384	0.23	0.16	Longevity (90 years and older);	chr12:48345655	chr12:48333755~48333901:-
THCA	cis	rs17772222	0.651	rs1950280	ENSG00000222990.1	RNU4-22P	-3.43	0.00066	0.0384	-0.19	-0.16	Coronary artery calcification;	chr14:88366259	chr14:88513498~88513663:+
THCA	cis	rs250585	1	rs152457	ENSG00000260136.4	CTD-2270L9.4	3.43	0.00066	0.0384	0.14	0.16	Egg allergy;	chr16:23570357	chr16:23452758~23457606:+
THCA	cis	rs250585	1	rs152454	ENSG00000260136.4	CTD-2270L9.4	-3.43	0.00066	0.0384	-0.14	-0.16	Egg allergy;	chr16:23571790	chr16:23452758~23457606:+
THCA	cis	rs11123170	0.64	rs1015754	ENSG00000234997.1	AC016745.3	-3.43	0.000661	0.0384	-0.16	-0.16	Renal function-related traits (BUN);	chr2:113210413	chr2:113424495~113425324:+
THCA	cis	rs8054556	0.765	rs11150574	ENSG00000273724.1	RP11-347C12.12	-3.43	0.000661	0.0384	-0.15	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29923498	chr16:30336400~30343336:+
THCA	cis	rs9860428	0.815	rs9865066	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112858647	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs10934196	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112861497	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs10154832	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112862041	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.76	rs9816107	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112863436	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.733	rs9816110	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112863437	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs6782188	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112864592	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs9878597	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866101	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs2895401	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112867783	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs57371910	ENSG00000243795.1	RP11-572M11.3	3.43	0.000661	0.0384	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112869960	chr3:113142350~113167819:-
THCA	cis	rs34421088	0.56	rs2248325	ENSG00000251402.3	FAM90A25P	-3.43	0.000661	0.0384	-0.2	-0.16	Neuroticism;	chr8:11539365	chr8:12415080~12418090:-
THCA	cis	rs34421088	0.56	rs2248316	ENSG00000251402.3	FAM90A25P	-3.43	0.000661	0.0384	-0.2	-0.16	Neuroticism;	chr8:11539564	chr8:12415080~12418090:-
THCA	cis	rs34421088	0.56	rs2248315	ENSG00000251402.3	FAM90A25P	-3.43	0.000661	0.0384	-0.2	-0.16	Neuroticism;	chr8:11539577	chr8:12415080~12418090:-
THCA	cis	rs7267979	0.789	rs4815429	ENSG00000230772.1	VN1R108P	-3.43	0.000661	0.0384	-0.14	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25734264~25735093:+
THCA	cis	rs8035452	0.964	rs12438878	ENSG00000273674.3	CTD-2378E12.1	3.43	0.000661	0.0384	0.19	0.16	Alzheimer's disease (late onset);	chr15:50714797	chr15:50839875~50908599:-
THCA	cis	rs8035452	1	rs10467994	ENSG00000273674.3	CTD-2378E12.1	3.43	0.000661	0.0384	0.19	0.16	Alzheimer's disease (late onset);	chr15:50716490	chr15:50839875~50908599:-
THCA	cis	rs9400467	0.537	rs12194283	ENSG00000255389.1	C6orf3	3.43	0.000661	0.0384	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111104826	chr6:111599875~111602295:+
THCA	cis	rs14027	0.883	rs13272852	ENSG00000279347.1	RP11-85I17.2	-3.43	0.000661	0.0384	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712921	chr8:119838736~119840385:-
THCA	cis	rs10090774	0.965	rs57416159	ENSG00000280303.2	ERICD	3.43	0.000661	0.0384	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140736896	chr8:140636281~140638283:+
THCA	cis	rs6517329	0.564	rs881712	ENSG00000214867.3	SRSF9P1	3.43	0.000661	0.0384	0.2	0.16	Schizophrenia;	chr21:36135471	chr21:36295173~36295702:-
THCA	cis	rs2351088	0.572	rs61289397	ENSG00000231711.2	LINC00899	3.43	0.000661	0.0384	0.19	0.16	Tonsillectomy;	chr22:45810635	chr22:46039907~46044853:-
THCA	cis	rs71041628	1	rs71041628	ENSG00000254750.1	CASP1P2	3.43	0.000661	0.0384	0.12	0.16	Myopia;	chr11:105794434	chr11:105063345~105071541:-
THCA	cis	rs8192917	0.573	rs10135076	ENSG00000258657.4	RP11-104E19.1	-3.43	0.000661	0.0384	-0.28	-0.16	Vitiligo;	chr14:24652763	chr14:24595723~24657774:+
THCA	cis	rs1552244	0.554	rs6796411	ENSG00000269982.1	RP11-1020A11.2	3.43	0.000661	0.0384	0.11	0.16	Alzheimer's disease;	chr3:9968997	chr3:9958717~9962539:+
THCA	cis	rs3096299	0.503	rs4785677	ENSG00000223959.7	AFG3L1P	3.43	0.000661	0.0384	0.09	0.16	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89972586~90002161:+
THCA	cis	rs2014572	0.967	rs11084492	ENSG00000268379.1	CTC-360J11.4	3.43	0.000661	0.0384	0.18	0.16	Hyperactive-impulsive symptoms;	chr19:57244658	chr19:57175233~57177921:+
THCA	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	3.43	0.000661	0.0384	0.14	0.16	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
THCA	cis	rs941898	0.625	rs6575763	ENSG00000259031.1	CTD-2062F14.3	3.43	0.000661	0.0384	0.21	0.16	White matter hyperintensity burden;	chr14:100105425	chr14:100538939~100540409:+
THCA	cis	rs561341	0.882	rs111484028	ENSG00000265798.5	RP11-271K11.5	3.43	0.000661	0.0384	0.23	0.16	Hip circumference adjusted for BMI;	chr17:31960682	chr17:31038575~31059121:-
THCA	cis	rs561341	0.505	rs548298	ENSG00000265798.5	RP11-271K11.5	3.43	0.000661	0.0384	0.23	0.16	Hip circumference adjusted for BMI;	chr17:31970475	chr17:31038575~31059121:-
THCA	cis	rs561341	0.714	rs547473	ENSG00000265798.5	RP11-271K11.5	3.43	0.000661	0.0384	0.23	0.16	Hip circumference adjusted for BMI;	chr17:31970541	chr17:31038575~31059121:-
THCA	cis	rs561341	1	rs546519	ENSG00000265798.5	RP11-271K11.5	3.43	0.000661	0.0384	0.23	0.16	Hip circumference adjusted for BMI;	chr17:31970663	chr17:31038575~31059121:-
THCA	cis	rs1556032	0.582	rs10125616	ENSG00000225472.1	RP11-120J1.1	-3.43	0.000661	0.0384	-0.15	-0.16	AIDS;	chr9:14443975	chr9:14317085~14357908:+
THCA	cis	rs7246657	0.943	rs6508732	ENSG00000266916.4	ZNF793-AS1	-3.43	0.000661	0.0384	-0.15	-0.16	Coronary artery calcification;	chr19:37509566	chr19:37497159~37507046:-
THCA	cis	rs7188445	0.932	rs3813582	ENSG00000277954.1	RP11-679B19.1	-3.43	0.000661	0.0384	-0.19	-0.16	Urate levels;	chr16:79715456	chr16:79202624~79206739:-
THCA	cis	rs2839186	0.632	rs2839184	ENSG00000215424.8	MCM3AP-AS1	3.43	0.000661	0.0384	0.1	0.16	Testicular germ cell tumor;	chr21:46269099	chr21:46229217~46259390:+
THCA	cis	rs6738825	0.606	rs10931784	ENSG00000231621.1	AC013264.2	-3.43	0.000661	0.0384	-0.15	-0.16	Crohn's disease;	chr2:197540912	chr2:197197991~197199273:+
THCA	cis	rs1062177	1	rs62394155	ENSG00000272112.1	CTB-113P19.5	3.43	0.000661	0.0384	0.14	0.16	Preschool internalizing problems;	chr5:151868508	chr5:151724831~151725356:-
THCA	cis	rs7246760	1	rs58137206	ENSG00000277587.1	CTD-3116E22.8	-3.43	0.000661	0.0384	-0.38	-0.16	Pursuit maintenance gain;	chr19:9745948	chr19:9721903~9722410:+
THCA	cis	rs10956805	0.552	rs1457056	ENSG00000246792.2	RP11-68L18.1	3.43	0.000661	0.0384	0.12	0.16	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);	chr8:91548433	chr8:90646441~90656598:+
THCA	cis	rs7487075	0.619	rs4768725	ENSG00000274723.1	RP11-618L22.1	3.43	0.000661	0.0384	0.15	0.16	Itch intensity from mosquito bite;	chr12:46454695	chr12:46970504~46972155:+
THCA	cis	rs1048886	0.872	rs12529309	ENSG00000271967.1	RP11-134K13.4	-3.43	0.000661	0.0384	-0.19	-0.16	Type 2 diabetes;	chr6:70553931	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs56143128	ENSG00000271967.1	RP11-134K13.4	-3.43	0.000661	0.0384	-0.19	-0.16	Type 2 diabetes;	chr6:70557963	chr6:70596438~70596980:+
THCA	cis	rs4073416	0.594	rs8022080	ENSG00000276116.2	FUT8-AS1	3.43	0.000661	0.0384	0.17	0.16	N-glycan levels;	chr14:65532370	chr14:65411170~65412690:-
THCA	cis	rs2572431	0.505	rs13269118	ENSG00000269918.1	AF131215.9	3.43	0.000661	0.0384	0.17	0.16	Neuroticism;	chr8:11390305	chr8:11104691~11106704:-
THCA	cis	rs6500602	0.702	rs11645519	ENSG00000280063.1	RP11-295D4.3	3.43	0.000662	0.0384	0.08	0.16	Schizophrenia;	chr16:4488988	chr16:4346694~4348648:-
THCA	cis	rs12476592	0.602	rs262533	ENSG00000242412.1	DBIL5P2	3.43	0.000662	0.0384	0.21	0.16	Childhood ear infection;	chr2:63678914	chr2:63117851~63119542:-
THCA	cis	rs6929812	0.702	rs979353	ENSG00000216915.2	RP1-97D16.1	3.43	0.000662	0.0384	0.2	0.16	Neuroticism (multi-trait analysis);	chr6:27433159	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.664	rs6914542	ENSG00000216915.2	RP1-97D16.1	3.43	0.000662	0.0384	0.2	0.16	Neuroticism (multi-trait analysis);	chr6:27435446	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.702	rs57647048	ENSG00000216915.2	RP1-97D16.1	3.43	0.000662	0.0384	0.2	0.16	Neuroticism (multi-trait analysis);	chr6:27441385	chr6:27737000~27738494:-
THCA	cis	rs6929812	0.702	rs55705181	ENSG00000216915.2	RP1-97D16.1	3.43	0.000662	0.0384	0.2	0.16	Neuroticism (multi-trait analysis);	chr6:27441508	chr6:27737000~27738494:-
THCA	cis	rs4927850	1	rs10881563	ENSG00000278820.1	AC024937.1	3.43	0.000662	0.0384	0.16	0.16	Pancreatic cancer;	chr3:196023354	chr3:195960500~195960612:-
THCA	cis	rs3758785	0.597	rs615465	ENSG00000255893.1	RP11-685N10.1	3.43	0.000662	0.0384	0.16	0.16	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94353088	chr11:94472908~94473570:-
THCA	cis	rs3864261	1	rs7706042	ENSG00000249085.1	CTD-2631K10.1	3.43	0.000662	0.0384	0.23	0.16	Discordance in emotional problems in monozygotic twins;	chr5:73064282	chr5:72794405~72816565:-
THCA	cis	rs2494663	0.585	rs7520349	ENSG00000231416.1	RP11-422P24.9	3.43	0.000662	0.0384	0.19	0.16	Mean platelet volume;	chr1:154109173	chr1:153995632~153995960:+
THCA	cis	rs12541437	0.652	rs7013963	ENSG00000253327.2	RAD21-AS1	3.43	0.000662	0.0384	0.19	0.16	Gut microbiome composition (winter);	chr8:116905021	chr8:116874424~116876868:+
THCA	cis	rs7208859	0.562	rs216408	ENSG00000265443.1	CTD-2349P21.6	3.43	0.000662	0.0384	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30726305~30727564:-
THCA	cis	rs17428076	0.756	rs62182432	ENSG00000228389.1	AC068039.4	-3.43	0.000662	0.0384	-0.21	-0.16	Myopia;	chr2:171918221	chr2:171773482~171775844:+
THCA	cis	rs883565	0.654	rs7642737	ENSG00000223668.1	EEF1A1P24	-3.43	0.000662	0.0384	-0.14	-0.16	Handedness;	chr3:38990978	chr3:39358545~39359922:+
THCA	cis	rs2554380	0.891	rs1426164	ENSG00000230373.7	GOLGA6L5P	-3.43	0.000662	0.0384	-0.19	-0.16	Height;	chr15:83633084	chr15:84507885~84516814:-
THCA	cis	rs7819412	0.645	rs4841508	ENSG00000280294.1	RP11-177H2.1	3.43	0.000662	0.0385	0.13	0.16	Triglycerides;	chr8:11207494	chr8:10856085~10859436:-
THCA	cis	rs4561483	0.801	rs8061189	ENSG00000263307.1	RP11-166B2.8	-3.43	0.000662	0.0385	-0.17	-0.16	Testicular germ cell tumor;	chr16:11857892	chr16:11851649~11895611:+
THCA	cis	rs911555	0.603	rs8020912	ENSG00000269958.1	RP11-73M18.8	3.43	0.000662	0.0385	0.15	0.16	Intelligence (multi-trait analysis);	chr14:103380937	chr14:103696353~103697163:+
THCA	cis	rs1864585	0.52	rs12155811	ENSG00000280294.1	RP11-177H2.1	3.43	0.000662	0.0385	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10816003	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs7845731	ENSG00000280294.1	RP11-177H2.1	3.43	0.000662	0.0385	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10817949	chr8:10856085~10859436:-
THCA	cis	rs10421328	0.821	rs4808976	ENSG00000267565.1	CTC-559E9.8	-3.43	0.000662	0.0385	-0.17	-0.16	Parental longevity (combined parental age at death);	chr19:19648490	chr19:19892433~19895847:-
THCA	cis	rs17253792	0.822	rs28481586	ENSG00000186615.9	KTN1-AS1	-3.43	0.000662	0.0385	-0.27	-0.16	Putamen volume;	chr14:55587145	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs10147380	ENSG00000186615.9	KTN1-AS1	-3.43	0.000662	0.0385	-0.27	-0.16	Putamen volume;	chr14:55587636	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs10147688	ENSG00000186615.9	KTN1-AS1	-3.43	0.000662	0.0385	-0.27	-0.16	Putamen volume;	chr14:55587924	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs10135426	ENSG00000186615.9	KTN1-AS1	-3.43	0.000662	0.0385	-0.27	-0.16	Putamen volume;	chr14:55587926	chr14:55499278~55580110:-
THCA	cis	rs2821260	0.534	rs11209921	ENSG00000227207.2	RPL31P12	-3.43	0.000662	0.0385	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:72146688	chr1:72301472~72301829:+
THCA	cis	rs1440410	0.835	rs9790396	ENSG00000250326.1	RP11-284M14.1	-3.43	0.000662	0.0385	-0.14	-0.16	Ischemic stroke;	chr4:143130366	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs7693817	ENSG00000250326.1	RP11-284M14.1	-3.43	0.000662	0.0385	-0.14	-0.16	Ischemic stroke;	chr4:143130372	chr4:142933195~143184861:-
THCA	cis	rs7129556	0.701	rs4945220	ENSG00000254459.1	RP11-91P24.7	-3.43	0.000662	0.0385	-0.2	-0.16	Weight loss (gastric bypass surgery);	chr11:77817115	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.737	rs7951033	ENSG00000254459.1	RP11-91P24.7	-3.43	0.000662	0.0385	-0.2	-0.16	Weight loss (gastric bypass surgery);	chr11:77823398	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.737	rs2154972	ENSG00000254459.1	RP11-91P24.7	3.43	0.000662	0.0385	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77777779	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.775	rs623907	ENSG00000254459.1	RP11-91P24.7	3.43	0.000662	0.0385	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77790402	chr11:77829654~77872262:-
THCA	cis	rs7129556	0.737	rs614495	ENSG00000254459.1	RP11-91P24.7	3.43	0.000662	0.0385	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77825840	chr11:77829654~77872262:-
THCA	cis	rs6546886	0.711	rs6712566	ENSG00000217702.2	RP11-287D1.4	-3.43	0.000662	0.0385	-0.26	-0.16	Dialysis-related mortality;	chr2:74018194	chr2:74130583~74135395:+
THCA	cis	rs1800795	0.553	rs1524099	ENSG00000179428.2	AC073072.5	-3.43	0.000662	0.0385	-0.19	-0.16	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22742038	chr7:22725395~22727620:-
THCA	cis	rs3736858	1	rs61959583	ENSG00000261105.4	LMO7-AS1	-3.43	0.000662	0.0385	-0.22	-0.16	Interleukin-9 levels;	chr13:75854458	chr13:75604700~75635994:-
THCA	cis	rs17092148	0.636	rs6058107	ENSG00000227401.1	RPL37P1	3.43	0.000663	0.0385	0.21	0.16	Neuroticism;	chr20:34700742	chr20:35588324~35588607:+
THCA	cis	rs4743820	0.603	rs1887370	ENSG00000230147.2	RP11-305L7.5	3.43	0.000663	0.0385	0.2	0.16	Ulcerative colitis;Inflammatory bowel disease;	chr9:91164794	chr9:91169585~91170045:-
THCA	cis	rs1200821	0.529	rs2475206	ENSG00000226578.1	RP11-258F22.1	3.43	0.000663	0.0385	0.18	0.16	Hemostatic factors and hematological phenotypes;	chr10:37513604	chr10:37775371~37784131:-
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000663	0.0385	-0.16	-0.16	Lung cancer;	chr6:149763351	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000663	0.0385	-0.16	-0.16	Lung cancer;	chr6:149763714	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000663	0.0385	-0.16	-0.16	Lung cancer;	chr6:149766383	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000663	0.0385	-0.16	-0.16	Lung cancer;	chr6:149766491	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000663	0.0385	-0.16	-0.16	Lung cancer;	chr6:149767481	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000663	0.0385	-0.16	-0.16	Lung cancer;	chr6:149767547	chr6:149576089~149590864:-
THCA	cis	rs9450351	0.744	rs9362225	ENSG00000280232.1	RP11-321N4.4	3.43	0.000663	0.0385	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85500713	chr6:85498441~85499058:-
THCA	cis	rs8031584	1	rs35811129	ENSG00000270015.1	RP11-540B6.6	-3.43	0.000663	0.0385	-0.13	-0.16	Huntington's disease progression;	chr15:30949143	chr15:30926514~30928407:+
THCA	cis	rs10938353	0.911	rs1583729	ENSG00000273369.1	RP11-700J17.1	3.43	0.000663	0.0385	0.17	0.16	Body mass index;	chr4:44583904	chr4:44693946~44694386:-
THCA	cis	rs11157436	0.918	rs1983520	ENSG00000211812.1	TRAV26-2	-3.43	0.000663	0.0385	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150390	chr14:22202583~22203368:+
THCA	cis	rs7487637	0.529	rs56389811	ENSG00000257488.4	RP5-1057I20.2	3.43	0.000663	0.0385	0.28	0.16	Mononucleosis;	chr12:47811575	chr12:47826854~47837898:+
THCA	cis	rs6751744	1	rs6751744	ENSG00000230783.1	AC009961.2	-3.43	0.000663	0.0385	-0.22	-0.16	Dysphagia;	chr2:159550974	chr2:159689217~159690291:-
THCA	cis	rs61160187	0.51	rs10077663	ENSG00000215032.2	GNL3LP1	3.43	0.000663	0.0385	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:60891935~60893577:-
THCA	cis	rs7959452	0.535	rs7133487	ENSG00000274979.1	RP11-1143G9.5	-3.43	0.000663	0.0385	-0.17	-0.16	Blood protein levels;	chr12:69380597	chr12:69326574~69331882:-
THCA	cis	rs10090774	0.965	rs6992780	ENSG00000280303.2	ERICD	3.43	0.000663	0.0385	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140901522	chr8:140636281~140638283:+
THCA	cis	rs911555	0.692	rs7140647	ENSG00000252469.1	RNU7-160P	-3.43	0.000663	0.0385	-0.18	-0.16	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103550345~103550406:+
THCA	cis	rs765787	0.53	rs2413775	ENSG00000259932.1	CTD-2651B20.7	3.43	0.000663	0.0385	0.19	0.16	Uric acid levels;	chr15:45252090	chr15:45198517~45199139:-
THCA	cis	rs2131877	0.599	rs60329099	ENSG00000238097.1	RP11-513G11.3	-3.43	0.000663	0.0385	-0.17	-0.16	Non-small cell lung cancer;	chr3:195154581	chr3:194247648~194257772:+
THCA	cis	rs6860806	0.631	rs7736284	ENSG00000263597.1	MIR3936	3.43	0.000663	0.0385	0.15	0.16	Breast cancer;	chr5:132252458	chr5:132365490~132365599:-
THCA	cis	rs10129255	0.957	rs1056705	ENSG00000274576.2	IGHV2-70	3.43	0.000663	0.0385	0.11	0.16	Kawasaki disease;	chr14:106714323	chr14:106770577~106771020:-
THCA	cis	rs7660883	1	rs72877984	ENSG00000251411.1	RP11-397E7.4	3.43	0.000663	0.0385	0.15	0.16	HDL cholesterol levels;	chr4:87064569	chr4:86913266~86914817:-
THCA	cis	rs7660883	1	rs28677145	ENSG00000251411.1	RP11-397E7.4	3.43	0.000663	0.0385	0.15	0.16	HDL cholesterol levels;	chr4:87065229	chr4:86913266~86914817:-
THCA	cis	rs17407555	0.789	rs12648610	ENSG00000250413.1	RP11-448G15.1	3.43	0.000663	0.0385	0.17	0.16	Schizophrenia (age at onset);	chr4:10113188	chr4:10006482~10009725:+
THCA	cis	rs10256972	0.933	rs35696159	ENSG00000199023.2	MIR339	-3.43	0.000663	0.0385	-0.16	-0.16	Endometriosis;Longevity;	chr7:1007558	chr7:1022935~1023045:-
THCA	cis	rs7829975	0.623	rs10092965	ENSG00000233609.3	RP11-62H7.2	3.43	0.000663	0.0385	0.15	0.16	Mood instability;	chr8:8515975	chr8:8961200~8979025:+
THCA	cis	rs832187	0.813	rs704370	ENSG00000224479.4	AC136289.1	-3.43	0.000663	0.0385	-0.19	-0.16	Schizophrenia;	chr3:63882574	chr3:63742293~63827445:-
THCA	cis	rs832187	0.813	rs704369	ENSG00000224479.4	AC136289.1	-3.43	0.000663	0.0385	-0.19	-0.16	Schizophrenia;	chr3:63882595	chr3:63742293~63827445:-
THCA	cis	rs832187	0.813	rs704368	ENSG00000224479.4	AC136289.1	-3.43	0.000663	0.0385	-0.19	-0.16	Schizophrenia;	chr3:63882661	chr3:63742293~63827445:-
THCA	cis	rs12428035	0.505	rs9590316	ENSG00000247400.3	DNAJC3-AS1	-3.43	0.000663	0.0385	-0.13	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95718515	chr13:95648733~95676925:-
THCA	cis	rs6473252	0.839	rs1982324	ENSG00000254162.1	RP11-48B3.3	3.43	0.000663	0.0385	0.14	0.16	Breast cancer;	chr8:80904405	chr8:80535006~80539135:-
THCA	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-3.43	0.000663	0.0385	-0.17	-0.16	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
THCA	cis	rs875971	0.798	rs57739047	ENSG00000223473.2	GS1-124K5.3	3.43	0.000663	0.0385	0.1	0.16	Aortic root size;	chr7:66507579	chr7:66491049~66493566:-
THCA	cis	rs875971	0.83	rs6950137	ENSG00000223473.2	GS1-124K5.3	3.43	0.000663	0.0385	0.1	0.16	Aortic root size;	chr7:66511623	chr7:66491049~66493566:-
THCA	cis	rs6471393	0.895	rs4255106	ENSG00000261437.1	RP11-22C11.2	3.43	0.000663	0.0385	0.15	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93766367	chr8:94637285~94639467:-
THCA	cis	rs656900	0.647	rs1615963	ENSG00000261229.4	MTHFS	3.43	0.000663	0.0385	0.16	0.16	Cerebrospinal P-tau181p levels;	chr15:79823484	chr15:79843547~79897285:-
THCA	cis	rs4906332	0.834	rs12882130	ENSG00000259775.1	RP11-45P15.4	-3.43	0.000663	0.0385	-0.13	-0.16	Coronary artery disease;	chr14:103412437	chr14:103331674~103332367:-
THCA	cis	rs12681288	0.523	rs11137122	ENSG00000260721.1	AF067845.1	3.43	0.000663	0.0385	0.19	0.16	Schizophrenia;	chr8:1004702	chr8:1368642~1369833:-
THCA	cis	rs9650657	0.836	rs1073913	ENSG00000269918.1	AF131215.9	-3.43	0.000663	0.0385	-0.16	-0.16	Neuroticism;	chr8:10754198	chr8:11104691~11106704:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000230189.5	GS1-124K5.2	3.43	0.000663	0.0385	0.1	0.16	Aortic root size;	chr7:65975357	chr7:66409143~66490059:-
THCA	cis	rs6678639	0.522	rs17102978	ENSG00000224805.2	LINC00853	3.43	0.000663	0.0385	0.23	0.16	Blood metabolite ratios;	chr1:47032907	chr1:47179250~47180339:+
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000264242.2	RP11-271K11.1	3.43	0.000663	0.0385	0.24	0.16	Body mass index;	chr17:30741407	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000264242.2	RP11-271K11.1	3.43	0.000663	0.0385	0.24	0.16	Body mass index;	chr17:30745674	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000264242.2	RP11-271K11.1	3.43	0.000663	0.0385	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30553697~30558962:+
THCA	cis	rs6137726	0.613	rs910956	ENSG00000237396.1	LINC01384	3.43	0.000663	0.0385	0.15	0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22652517	chr20:22587522~22607517:-
THCA	cis	rs7903456	0.648	rs4934290	ENSG00000200253.1	RNU6-529P	3.43	0.000663	0.0385	0.22	0.16	Gout;Renal underexcretion gout;	chr10:87040504	chr10:87041238~87041341:-
THCA	cis	rs1048886	0.872	rs75179941	ENSG00000271967.1	RP11-134K13.4	-3.43	0.000663	0.0385	-0.19	-0.16	Type 2 diabetes;	chr6:70563130	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs7450771	ENSG00000271967.1	RP11-134K13.4	-3.43	0.000663	0.0385	-0.19	-0.16	Type 2 diabetes;	chr6:70565926	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs77665410	ENSG00000271967.1	RP11-134K13.4	-3.43	0.000663	0.0385	-0.19	-0.16	Type 2 diabetes;	chr6:70569676	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs79339185	ENSG00000271967.1	RP11-134K13.4	-3.43	0.000663	0.0385	-0.19	-0.16	Type 2 diabetes;	chr6:70572379	chr6:70596438~70596980:+
THCA	cis	rs9840812	0.773	rs61789601	ENSG00000239213.4	NCK1-AS1	-3.43	0.000663	0.0385	-0.17	-0.16	Fibrinogen levels;	chr3:136236137	chr3:136841726~136862054:-
THCA	cis	rs11051970	0.918	rs11051969	ENSG00000277342.1	RP11-843B15.4	-3.43	0.000663	0.0385	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32384189	chr12:32109076~32109602:+
THCA	cis	rs12362063	1	rs10742217	ENSG00000249867.4	RP11-115J23.1	3.43	0.000663	0.0385	0.16	0.16	Hepatitis B;	chr11:29250533	chr11:28702615~29063821:+
THCA	cis	rs10975370	0.503	rs4742150	ENSG00000206147.5	RP11-106A1.2	3.43	0.000663	0.0385	0.18	0.16	Breast cancer;	chr9:6039679	chr9:6639139~6639604:+
THCA	cis	rs4763879	0.634	rs61915473	ENSG00000214776.8	RP11-726G1.1	-3.43	0.000663	0.0385	-0.19	-0.16	Type 1 diabetes;	chr12:9705282	chr12:9467552~9576275:+
THCA	cis	rs9863	0.861	rs11057399	ENSG00000270130.1	RP11-214K3.23	-3.43	0.000664	0.0385	-0.19	-0.16	White blood cell count;	chr12:123940531	chr12:123960717~123961244:-
THCA	cis	rs62458065	0.568	rs62463963	ENSG00000231952.3	DPY19L1P2	3.43	0.000664	0.0385	0.26	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32447079	chr7:32812757~32838570:+
THCA	cis	rs10509373	0.545	rs17377329	ENSG00000237149.5	ZNF503-AS2	3.43	0.000664	0.0385	0.15	0.16	Response to tamoxifen in breast cancer;	chr10:76311178	chr10:75401519~75408982:+
THCA	cis	rs10509373	0.545	rs7899441	ENSG00000237149.5	ZNF503-AS2	3.43	0.000664	0.0385	0.15	0.16	Response to tamoxifen in breast cancer;	chr10:76311650	chr10:75401519~75408982:+
THCA	cis	rs11673344	0.542	rs826327	ENSG00000233527.7	ZNF529-AS1	3.43	0.000664	0.0385	0.13	0.16	Obesity-related traits;	chr19:37004397	chr19:36573070~36594708:+
THCA	cis	rs3760982	0.585	rs67704568	ENSG00000268601.1	AC115522.3	-3.43	0.000664	0.0385	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789867	chr19:43794309~43795658:-
THCA	cis	rs3760982	0.585	rs67648499	ENSG00000268601.1	AC115522.3	-3.43	0.000664	0.0385	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789903	chr19:43794309~43795658:-
THCA	cis	rs933117	0.892	rs113628239	ENSG00000174680.8	GRIK1-AS1	-3.43	0.000664	0.0385	-0.38	-0.16	Body mass index;	chr21:29684546	chr21:29748175~29764002:+
THCA	cis	rs786425	0.502	rs7301641	ENSG00000270095.1	RP11-214K3.18	-3.43	0.000664	0.0385	-0.19	-0.16	Pubertal anthropometrics;	chr12:123722551	chr12:123971457~123971714:-
THCA	cis	rs8014204	0.967	rs4903266	ENSG00000279594.1	RP11-950C14.10	-3.43	0.000664	0.0385	-0.15	-0.16	Caffeine consumption;	chr14:74878238	chr14:75011269~75012851:-
THCA	cis	rs3750082	0.817	rs2060731	ENSG00000205763.12	RP9P	-3.43	0.000664	0.0385	-0.13	-0.16	Glomerular filtration rate (creatinine);	chr7:32928734	chr7:32916815~32943176:-
THCA	cis	rs73001065	0.551	rs10424702	ENSG00000267481.1	CTC-559E9.5	-3.43	0.000664	0.0385	-0.2	-0.16	LDL cholesterol;	chr19:19397204	chr19:19788755~19790531:-
THCA	cis	rs4703129	1	rs1820767	ENSG00000246763.5	RGMB-AS1	-3.43	0.000664	0.0385	-0.15	-0.16	Asperger disorder;	chr5:98542933	chr5:98769618~98773469:-
THCA	cis	rs591584	0.59	rs7110811	ENSG00000255893.1	RP11-685N10.1	-3.43	0.000664	0.0385	-0.17	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94591245	chr11:94472908~94473570:-
THCA	cis	rs7429990	0.932	rs6766641	ENSG00000199476.1	Y_RNA	3.43	0.000664	0.0385	0.21	0.16	Educational attainment (years of education);	chr3:48103734	chr3:48288587~48288694:+
THCA	cis	rs34779708	0.931	rs4934524	ENSG00000233200.1	RP11-324I22.2	3.43	0.000664	0.0385	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35219894~35230598:-
THCA	cis	rs1153858	1	rs2668747	ENSG00000275672.1	GATM-AS1	-3.43	0.000664	0.0385	-0.16	-0.16	Homoarginine levels;	chr15:45325018	chr15:45378700~45380123:+
THCA	cis	rs7809950	0.817	rs2712195	ENSG00000272072.1	CTA-363E19.2	3.43	0.000664	0.0385	0.16	0.16	Coronary artery disease;	chr7:107487051	chr7:107192559~107193300:-
THCA	cis	rs6598955	0.64	rs4233460	ENSG00000236782.4	RP11-96L14.7	-3.43	0.000664	0.0385	-0.19	-0.16	Obesity-related traits;	chr1:26306896	chr1:26169947~26171821:-
THCA	cis	rs7308116	0.967	rs10861788	ENSG00000257951.1	RP11-554D14.4	3.43	0.000664	0.0385	0.18	0.16	Pelvic organ prolapse (moderate/severe);	chr12:107796502	chr12:107881242~107883382:+
THCA	cis	rs277939	0.935	rs459787	ENSG00000251634.2	RP11-1280N14.3	3.43	0.000664	0.0385	0.16	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71589585	chr5:71102898~71128753:-
THCA	cis	rs6500602	0.826	rs11076831	ENSG00000280063.1	RP11-295D4.3	-3.43	0.000664	0.0385	-0.09	-0.16	Schizophrenia;	chr16:4410132	chr16:4346694~4348648:-
THCA	cis	rs2562456	0.833	rs2154302	ENSG00000268278.1	RP11-420K14.1	3.43	0.000664	0.0386	0.21	0.16	Pain;	chr19:21307609	chr19:21637974~21656300:+
THCA	cis	rs735539	1	rs9579929	ENSG00000238286.1	SLC35E1P1	3.43	0.000664	0.0386	0.17	0.16	Dental caries;	chr13:20708585	chr13:20607268~20608131:+
THCA	cis	rs7474896	0.583	rs4934898	ENSG00000120555.12	SEPT7P9	3.43	0.000664	0.0386	0.21	0.16	Obesity (extreme);	chr10:37701467	chr10:38383069~38402916:-
THCA	cis	rs7267979	0.868	rs6138550	ENSG00000230772.1	VN1R108P	3.43	0.000664	0.0386	0.14	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25734264~25735093:+
THCA	cis	rs7267979	0.903	rs6050481	ENSG00000230772.1	VN1R108P	3.43	0.000664	0.0386	0.14	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25734264~25735093:+
THCA	cis	rs7267979	0.834	rs6115100	ENSG00000230772.1	VN1R108P	3.43	0.000664	0.0386	0.14	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25734264~25735093:+
THCA	cis	rs11658311	0.649	rs16961845	ENSG00000226478.3	UPF3AP1	-3.43	0.000664	0.0386	-0.37	-0.16	Obsessive-compulsive symptoms;	chr17:17529142	chr17:16745636~16746761:-
THCA	cis	rs11658311	0.649	rs9903468	ENSG00000226478.3	UPF3AP1	-3.43	0.000664	0.0386	-0.37	-0.16	Obsessive-compulsive symptoms;	chr17:17529605	chr17:16745636~16746761:-
THCA	cis	rs13064411	0.696	rs6766615	ENSG00000243849.1	CFAP44-AS1	3.43	0.000664	0.0386	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113500495	chr3:113403991~113433992:+
THCA	cis	rs7615952	0.599	rs60847438	ENSG00000241288.6	RP11-379B18.5	-3.43	0.000664	0.0386	-0.18	-0.16	Blood pressure (smoking interaction);	chr3:126027162	chr3:125827238~125916384:-
THCA	cis	rs9650657	0.74	rs6980805	ENSG00000255310.2	AF131215.2	-3.43	0.000664	0.0386	-0.13	-0.16	Neuroticism;	chr8:10822332	chr8:11107788~11109726:-
THCA	cis	rs3892630	0.558	rs4588103	ENSG00000267475.1	CTD-2538C1.2	-3.43	0.000664	0.0386	-0.23	-0.16	Red blood cell traits;	chr19:32861864	chr19:32687089~32691750:-
THCA	cis	rs9549260	0.755	rs2721071	ENSG00000275149.1	RP11-427J23.1	-3.43	0.000664	0.0386	-0.21	-0.16	Red blood cell count;	chr13:40570370	chr13:40079106~40273509:-
THCA	cis	rs881375	0.967	rs7039505	ENSG00000270917.1	RP11-27I1.6	-3.43	0.000664	0.0386	-0.22	-0.16	Rheumatoid arthritis;	chr9:120943667	chr9:120812475~120812845:-
THCA	cis	rs881375	0.902	rs2900180	ENSG00000270917.1	RP11-27I1.6	-3.43	0.000664	0.0386	-0.22	-0.16	Rheumatoid arthritis;	chr9:120944104	chr9:120812475~120812845:-
THCA	cis	rs7119	0.651	rs12904533	ENSG00000260776.4	RP11-114H24.2	-3.43	0.000664	0.0386	-0.22	-0.16	Type 2 diabetes;	chr15:77553586	chr15:77914217~77926846:-
THCA	cis	rs9307551	0.948	rs4389603	ENSG00000249646.2	OR7E94P	-3.43	0.000665	0.0386	-0.22	-0.16	Refractive error;	chr4:79567720	chr4:79587302~79588130:-
THCA	cis	rs442177	0.524	rs2926511	ENSG00000251411.1	RP11-397E7.4	-3.43	0.000665	0.0386	-0.15	-0.16	Triglycerides;Hemoglobin concentration;	chr4:87141459	chr4:86913266~86914817:-
THCA	cis	rs786425	0.966	rs7134896	ENSG00000278112.1	RP11-972P1.11	3.43	0.000665	0.0386	0.15	0.16	Pubertal anthropometrics;	chr12:123617311	chr12:123519390~123519856:-
THCA	cis	rs76878669	0.561	rs7125752	ENSG00000255320.1	RP11-755F10.1	3.43	0.000665	0.0386	0.2	0.16	Educational attainment (years of education);	chr11:66394948	chr11:66244840~66246239:-
THCA	cis	rs559555	0.523	rs12467911	ENSG00000276517.1	AL133243.2	-3.43	0.000665	0.0386	-0.15	-0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31557721	chr2:32526504~32529507:+
THCA	cis	rs6496932	1	rs2002642	ENSG00000259630.2	CTD-2262B20.1	3.43	0.000665	0.0386	0.2	0.16	Central corneal thickness;Corneal structure;	chr15:85284513	chr15:85415228~85415633:+
THCA	cis	rs6496932	1	rs4842872	ENSG00000259630.2	CTD-2262B20.1	3.43	0.000665	0.0386	0.2	0.16	Central corneal thickness;Corneal structure;	chr15:85284825	chr15:85415228~85415633:+
THCA	cis	rs2289328	0.943	rs3803360	ENSG00000223313.1	RNU6-516P	-3.43	0.000665	0.0386	-0.21	-0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40370468	chr15:40529570~40529673:+
THCA	cis	rs10857712	0.851	rs56153177	ENSG00000214279.11	SCART1	-3.43	0.000665	0.0386	-0.13	-0.16	Systemic lupus erythematosus;	chr10:133403471	chr10:133453928~133523558:+
THCA	cis	rs4671400	0.571	rs28480287	ENSG00000270820.4	RP11-355B11.2	-3.43	0.000665	0.0386	-0.14	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61262154	chr2:61471188~61484130:+
THCA	cis	rs7615952	0.673	rs34209763	ENSG00000272840.1	RP11-379B18.6	3.43	0.000665	0.0386	0.28	0.16	Blood pressure (smoking interaction);	chr3:125880752	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.8	rs35390120	ENSG00000272840.1	RP11-379B18.6	3.43	0.000665	0.0386	0.28	0.16	Blood pressure (smoking interaction);	chr3:125880966	chr3:125774714~125797953:+
THCA	cis	rs10419113	0.641	rs12610315	ENSG00000270804.1	CTD-2583A14.11	3.43	0.000665	0.0386	0.13	0.16	Pediatric bone mineral density (spine);	chr19:57765288	chr19:57867885~57868834:+
THCA	cis	rs12304921	0.872	rs17122760	ENSG00000277201.1	AC087884.1	3.43	0.000665	0.0386	0.17	0.16	Type 2 diabetes;	chr12:51125323	chr12:51049921~51050025:+
THCA	cis	rs5758659	0.652	rs133322	ENSG00000234009.1	RPL5P34	-3.43	0.000665	0.0386	-0.15	-0.16	Cognitive function;	chr22:42009655	chr22:42776406~42777296:-
THCA	cis	rs5758659	0.623	rs133328	ENSG00000234009.1	RPL5P34	-3.43	0.000665	0.0386	-0.15	-0.16	Cognitive function;	chr22:42012075	chr22:42776406~42777296:-
THCA	cis	rs34779708	0.931	rs2384275	ENSG00000233200.1	RP11-324I22.2	3.43	0.000665	0.0386	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35219894~35230598:-
THCA	cis	rs7185923	0.74	rs4503789	ENSG00000260818.2	UNGP1	3.43	0.000665	0.0386	0.15	0.16	Weight loss (gastric bypass surgery);	chr16:51220308	chr16:51277852~51279112:+
THCA	cis	rs28595532	0.516	rs28552458	ENSG00000260404.2	RP11-384K6.6	-3.43	0.000665	0.0386	-0.23	-0.16	Cannabis dependence symptom count;	chr4:118367208	chr4:118591773~118633729:+
THCA	cis	rs2486012	0.737	rs6670344	ENSG00000237950.1	RP11-7O11.3	3.43	0.000665	0.0386	0.18	0.16	Intelligence (multi-trait analysis);	chr1:43803537	chr1:43944370~43946551:-
THCA	cis	rs2179367	0.632	rs2341774	ENSG00000216906.2	RP11-350J20.9	3.43	0.000665	0.0386	0.2	0.16	Dupuytren's disease;	chr6:149425014	chr6:149904243~149906418:+
THCA	cis	rs1023500	1	rs6002554	ENSG00000237037.8	NDUFA6-AS1	3.43	0.000665	0.0386	0.15	0.16	Schizophrenia;	chr22:41943091	chr22:42090931~42137742:+
THCA	cis	rs250518	0.926	rs10942402	ENSG00000251467.1	CTC-250P20.2	-3.43	0.000665	0.0386	-0.22	-0.16	Mean corpuscular hemoglobin concentration;	chr5:72760272	chr5:72996920~72997642:+
THCA	cis	rs8073060	0.586	rs225296	ENSG00000255987.1	TOMM20P2	-3.43	0.000665	0.0386	-0.18	-0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35597828	chr17:35514766~35515186:-
THCA	cis	rs2821260	0.66	rs7515320	ENSG00000227207.2	RPL31P12	-3.43	0.000665	0.0386	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:72147925	chr1:72301472~72301829:+
THCA	cis	rs2821260	0.66	rs7541218	ENSG00000227207.2	RPL31P12	-3.43	0.000665	0.0386	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:72148234	chr1:72301472~72301829:+
THCA	cis	rs4262150	0.81	rs4958565	ENSG00000253921.1	CTB-113P19.3	3.43	0.000665	0.0386	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152626527	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs55648729	ENSG00000253921.1	CTB-113P19.3	3.43	0.000665	0.0386	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152629342	chr5:151753992~151767247:+
THCA	cis	rs4808199	0.895	rs6511036	ENSG00000267481.1	CTC-559E9.5	-3.43	0.000665	0.0386	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19471842	chr19:19788755~19790531:-
THCA	cis	rs950027	0.62	rs1719246	ENSG00000259479.5	SORD2P	3.43	0.000665	0.0386	0.16	0.16	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:44826371~44884694:-
THCA	cis	rs6017317	0.696	rs4812817	ENSG00000234271.1	RP1-138B7.4	3.43	0.000666	0.0386	0.2	0.16	Type 2 diabetes;	chr20:44305381	chr20:43523261~43523572:-
THCA	cis	rs12476592	0.543	rs262532	ENSG00000242412.1	DBIL5P2	3.43	0.000666	0.0386	0.2	0.16	Childhood ear infection;	chr2:63678886	chr2:63117851~63119542:-
THCA	cis	rs9837602	0.507	rs1718244	ENSG00000273374.1	RP11-383I23.2	-3.43	0.000666	0.0386	-0.14	-0.16	Breast cancer;	chr3:99793764	chr3:99802699~99806058:-
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000666	0.0386	-0.16	-0.16	Lung cancer;	chr6:149769680	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000666	0.0386	-0.16	-0.16	Lung cancer;	chr6:149775216	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000666	0.0386	-0.16	-0.16	Lung cancer;	chr6:149775303	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000666	0.0386	-0.16	-0.16	Lung cancer;	chr6:149776207	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000666	0.0386	-0.16	-0.16	Lung cancer;	chr6:149776681	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000666	0.0386	-0.16	-0.16	Lung cancer;	chr6:149777561	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000666	0.0386	-0.16	-0.16	Lung cancer;	chr6:149777641	chr6:149576089~149590864:-
THCA	cis	rs9796	0.87	rs2925345	ENSG00000247556.5	OIP5-AS1	-3.43	0.000666	0.0386	-0.12	-0.16	Menopause (age at onset);	chr15:41019601	chr15:41283990~41309737:+
THCA	cis	rs1555322	0.53	rs2425043	ENSG00000269202.1	RP4-614O4.12	-3.43	0.000666	0.0386	-0.16	-0.16	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35201747~35203288:-
THCA	cis	rs2625529	0.59	rs8023703	ENSG00000260037.4	CTD-2524L6.3	3.43	0.000666	0.0386	0.21	0.16	Red blood cell count;	chr15:72211718	chr15:71818396~71823384:+
THCA	cis	rs73228161	0.85	rs17022336	ENSG00000258365.1	RP11-1105G2.3	3.43	0.000666	0.0386	0.34	0.16	Major depressive disorder;	chr12:94271311	chr12:94277758~94282844:-
THCA	cis	rs79478560	0.502	rs10846562	ENSG00000270061.1	RP11-214K3.19	-3.43	0.000666	0.0386	-0.19	-0.16	Lymphocyte counts;	chr12:123855779	chr12:123969990~123970344:-
THCA	cis	rs3770081	1	rs1036554	ENSG00000273080.1	RP11-301O19.1	-3.43	0.000666	0.0386	-0.32	-0.16	Facial emotion recognition (sad faces);	chr2:86008976	chr2:86195590~86196049:+
THCA	cis	rs9860428	0.815	rs11717778	ENSG00000243795.1	RP11-572M11.3	3.43	0.000666	0.0386	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112853801	chr3:113142350~113167819:-
THCA	cis	rs8054556	0.513	rs12596042	ENSG00000273724.1	RP11-347C12.12	-3.43	0.000666	0.0386	-0.15	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29923433	chr16:30336400~30343336:+
THCA	cis	rs12073837	0.5	rs2807845	ENSG00000221571.3	RNU6ATAC35P	-3.43	0.000666	0.0386	-0.14	-0.16	F-cell distribution;	chr1:220822945	chr1:220825620~220826063:+
THCA	cis	rs12368653	0.583	rs7952989	ENSG00000270039.1	RP11-571M6.17	3.43	0.000666	0.0386	0.16	0.16	Multiple sclerosis;	chr12:57702206	chr12:57803838~57804415:+
THCA	cis	rs12368653	0.584	rs7295422	ENSG00000270039.1	RP11-571M6.17	3.43	0.000666	0.0386	0.16	0.16	Multiple sclerosis;	chr12:57705953	chr12:57803838~57804415:+
THCA	cis	rs11073619	0.616	rs2401427	ENSG00000188388.10	GOLGA6L3	-3.43	0.000666	0.0386	-0.29	-0.16	Positive affect;	chr15:84402427	chr15:85240472~85247170:+
THCA	cis	rs3736485	0.808	rs55982453	ENSG00000259709.1	CTD-2184D3.7	3.43	0.000666	0.0386	0.16	0.16	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51659048	chr15:52124561~52140246:+
THCA	cis	rs293748	0.571	rs9632396	ENSG00000250155.1	CTD-2353F22.1	-3.43	0.000666	0.0386	-0.19	-0.16	Obesity-related traits;	chr5:37140229	chr5:36666214~36725195:-
THCA	cis	rs293748	0.571	rs10512664	ENSG00000250155.1	CTD-2353F22.1	-3.43	0.000666	0.0386	-0.19	-0.16	Obesity-related traits;	chr5:37158021	chr5:36666214~36725195:-
THCA	cis	rs2239547	0.521	rs9682464	ENSG00000243224.1	RP5-1157M23.2	-3.43	0.000666	0.0386	-0.18	-0.16	Schizophrenia;	chr3:52854469	chr3:52239258~52241097:+
THCA	cis	rs10129255	0.834	rs10139893	ENSG00000274576.2	IGHV2-70	3.43	0.000666	0.0386	0.11	0.16	Kawasaki disease;	chr14:106711377	chr14:106770577~106771020:-
THCA	cis	rs4869313	0.694	rs38040	ENSG00000247121.5	CTD-2260A17.2	3.43	0.000666	0.0386	0.12	0.16	Pediatric autoimmune diseases;	chr5:96991959	chr5:96814028~96935809:-
THCA	cis	rs6058526	0.631	rs3803989	ENSG00000235217.6	TSPY26P	-3.43	0.000666	0.0386	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr20:32221413	chr20:32186477~32190527:-
THCA	cis	rs9420	0.961	rs11601320	ENSG00000254602.1	AP000662.4	-3.43	0.000666	0.0386	-0.18	-0.16	Schizophrenia;	chr11:57875145	chr11:57638024~57652790:+
THCA	cis	rs12681963	0.688	rs962420	ENSG00000272375.1	RP11-51J9.6	3.43	0.000666	0.0386	0.22	0.16	Migraine;	chr8:30233419	chr8:30197404~30198048:+
THCA	cis	rs3925158	0.51	rs34886276	ENSG00000229589.1	ACVR2B-AS1	-3.43	0.000666	0.0386	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38250226	chr3:38451027~38454820:-
THCA	cis	rs3925158	0.51	rs4955394	ENSG00000229589.1	ACVR2B-AS1	-3.43	0.000666	0.0386	-0.31	-0.16	Gut microbiota (bacterial taxa);	chr3:38251972	chr3:38451027~38454820:-
THCA	cis	rs1737890	0.623	rs6057570	ENSG00000235217.6	TSPY26P	3.43	0.000666	0.0386	0.18	0.16	Chronic obstructive pulmonary disease;	chr20:32400295	chr20:32186477~32190527:-
THCA	cis	rs3758911	0.788	rs10890680	ENSG00000255353.1	RP11-382M14.1	-3.43	0.000666	0.0386	-0.21	-0.16	Coronary artery disease;	chr11:107255139	chr11:107176286~107177530:+
THCA	cis	rs2562456	0.833	rs61035285	ENSG00000268521.1	VN1R83P	3.43	0.000666	0.0386	0.15	0.16	Pain;	chr19:21329475	chr19:21289554~21289998:-
THCA	cis	rs9905704	0.56	rs2680701	ENSG00000265148.4	BZRAP1-AS1	3.43	0.000666	0.0386	0.17	0.16	Testicular germ cell tumor;	chr17:58360940	chr17:58325450~58415766:+
THCA	cis	rs9573567	0.609	rs9573553	ENSG00000261105.4	LMO7-AS1	-3.43	0.000666	0.0387	-0.34	-0.16	Red blood cell count;Mean corpuscular volume;	chr13:75465192	chr13:75604700~75635994:-
THCA	cis	rs858239	0.712	rs199650	ENSG00000230042.1	AK3P3	3.43	0.000666	0.0387	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23129178~23129841:+
THCA	cis	rs9549260	0.755	rs9532571	ENSG00000275149.1	RP11-427J23.1	-3.43	0.000666	0.0387	-0.21	-0.16	Red blood cell count;	chr13:40644533	chr13:40079106~40273509:-
THCA	cis	rs3793683	0.965	rs3829131	ENSG00000273980.1	RP13-49I15.6	-3.43	0.000666	0.0387	-0.19	-0.16	Migraine;	chr10:132751123	chr10:133257144~133257551:-
THCA	cis	rs10932679	0.545	rs11891615	ENSG00000237930.1	AC007563.4	-3.43	0.000666	0.0387	-0.21	-0.16	Pulse pressure;	chr2:216779166	chr2:216785774~216786144:-
THCA	cis	rs7539542	0.529	rs73089386	ENSG00000234996.3	RP11-480I12.7	3.43	0.000667	0.0387	0.22	0.16	Mean platelet volume;	chr1:202900454	chr1:202861754~202875241:+
THCA	cis	rs34779708	0.931	rs11010083	ENSG00000233200.1	RP11-324I22.2	3.43	0.000667	0.0387	0.18	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35219894~35230598:-
THCA	cis	rs9860428	0.808	rs34147006	ENSG00000243795.1	RP11-572M11.3	3.43	0.000667	0.0387	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112903063	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs9819621	ENSG00000243795.1	RP11-572M11.3	3.43	0.000667	0.0387	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904219	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs12490586	ENSG00000243795.1	RP11-572M11.3	3.43	0.000667	0.0387	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904386	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs12487198	ENSG00000243795.1	RP11-572M11.3	3.43	0.000667	0.0387	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904423	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs9863580	ENSG00000243795.1	RP11-572M11.3	3.43	0.000667	0.0387	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905883	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs9877803	ENSG00000243795.1	RP11-572M11.3	3.43	0.000667	0.0387	0.18	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112906290	chr3:113142350~113167819:-
THCA	cis	rs7838490	0.559	rs13274015	ENSG00000253553.4	RP11-586K2.1	3.43	0.000667	0.0387	0.16	0.16	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88588522	chr8:88326836~88737134:+
THCA	cis	rs2919009	1	rs2919009	ENSG00000271670.1	RP11-95I16.4	3.43	0.000667	0.0387	0.17	0.16	Obesity-related traits;	chr10:120831861	chr10:120879256~120880667:-
THCA	cis	rs4141404	0.582	rs5753630	ENSG00000214076.3	CPSF1P1	-3.43	0.000667	0.0387	-0.2	-0.16	Paclitaxel-induced neuropathy;	chr22:31465964	chr22:32269381~32273110:+
THCA	cis	rs860295	0.719	rs490608	ENSG00000160766.13	GBAP1	-3.43	0.000667	0.0387	-0.17	-0.16	Body mass index;	chr1:155713079	chr1:155213821~155227422:-
THCA	cis	rs277939	0.935	rs459787	ENSG00000230847.4	RP11-195E2.1	-3.43	0.000667	0.0387	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71589585	chr5:71074225~71093193:-
THCA	cis	rs4073416	0.518	rs8013442	ENSG00000276116.2	FUT8-AS1	3.43	0.000667	0.0387	0.17	0.16	N-glycan levels;	chr14:65405143	chr14:65411170~65412690:-
THCA	cis	rs9527	0.662	rs10883783	ENSG00000213061.2	PFN1P11	3.43	0.000667	0.0387	0.21	0.16	Arsenic metabolism;	chr10:102831395	chr10:102838011~102845473:-
THCA	cis	rs16975963	0.545	rs12461753	ENSG00000276846.1	CTD-3220F14.3	-3.43	0.000667	0.0387	-0.15	-0.16	Longevity;	chr19:37711614	chr19:37314868~37315620:-
THCA	cis	rs74024059	1	rs2454209	ENSG00000275454.1	CTD-2026K11.4	-3.43	0.000667	0.0387	-0.37	-0.16	Red blood cell count;Hematocrit;	chr15:76021507	chr15:75639760~75640976:+
THCA	cis	rs7246657	0.722	rs3101746	ENSG00000226686.6	LINC01535	3.43	0.000667	0.0387	0.23	0.16	Coronary artery calcification;	chr19:37655499	chr19:37251912~37265535:+
THCA	cis	rs11134654	0.627	rs4868033	ENSG00000253966.1	CTC-455F18.3	-3.43	0.000667	0.0387	-0.23	-0.16	Smooth-surface caries;	chr5:170807260	chr5:170896929~170904461:+
THCA	cis	rs2337406	0.714	rs117798641	ENSG00000280411.1	IGHV1-69-2	-3.43	0.000667	0.0387	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106777984	chr14:106762092~106762588:-
THCA	cis	rs6496667	0.865	rs62019349	ENSG00000259262.1	NDUFA3P4	3.43	0.000667	0.0387	0.22	0.16	Rheumatoid arthritis;	chr15:90378426	chr15:90385814~90386063:+
THCA	cis	rs34792	0.554	rs62039130	ENSG00000207425.1	Y_RNA	-3.43	0.000667	0.0387	-0.18	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15518277	chr16:14915457~14915556:-
THCA	cis	rs6504108	0.624	rs8069263	ENSG00000264920.1	RP11-6N17.4	-3.43	0.000667	0.0387	-0.13	-0.16	Body mass index;	chr17:48209416	chr17:47891255~47895812:-
THCA	cis	rs865483	0.861	rs1063215	ENSG00000273965.1	RP11-378E13.4	-3.43	0.000667	0.0387	-0.2	-0.16	Monocyte count;	chr17:37514833	chr17:37407936~37408594:-
THCA	cis	rs10419113	0.641	rs61333077	ENSG00000270804.1	CTD-2583A14.11	3.43	0.000667	0.0387	0.13	0.16	Pediatric bone mineral density (spine);	chr19:57766589	chr19:57867885~57868834:+
THCA	cis	rs6743226	0.603	rs72484048	ENSG00000223374.1	AC005104.3	3.43	0.000667	0.0387	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241287944	chr2:241351340~241353104:-
THCA	cis	rs875971	0.862	rs6460307	ENSG00000223473.2	GS1-124K5.3	3.43	0.000667	0.0387	0.1	0.16	Aortic root size;	chr7:66595884	chr7:66491049~66493566:-
THCA	cis	rs2736345	0.788	rs2618476	ENSG00000269899.1	RP11-589N15.2	-3.43	0.000667	0.0387	-0.19	-0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11846154~11846391:-
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000281021.1	RP1-12G14.9	-3.43	0.000667	0.0387	-0.16	-0.16	Lung cancer;	chr6:149754363	chr6:149576089~149590864:-
THCA	cis	rs5753037	0.702	rs9614055	ENSG00000273350.1	RP4-539M6.20	-3.43	0.000667	0.0387	-0.17	-0.16	Type 1 diabetes;	chr22:29791713	chr22:30420512~30420912:+
THCA	cis	rs9534288	0.797	rs992631	ENSG00000235903.6	CPB2-AS1	-3.43	0.000667	0.0387	-0.21	-0.16	Blood protein levels;	chr13:46017854	chr13:46052806~46113332:+
THCA	cis	rs735539	1	rs2290143	ENSG00000238286.1	SLC35E1P1	3.43	0.000667	0.0387	0.17	0.16	Dental caries;	chr13:20706224	chr13:20607268~20608131:+
THCA	cis	rs2904297	0.958	rs6448451	ENSG00000261490.1	RP11-448G15.3	-3.43	0.000667	0.0387	-0.11	-0.16	Hashimoto thyroiditis versus Graves' disease;	chr4:11023058	chr4:10068089~10073019:-
THCA	cis	rs2952156	0.684	rs881844	ENSG00000214546.3	AC087491.2	-3.43	0.000667	0.0387	-0.19	-0.16	Asthma;	chr17:39653965	chr17:39619613~39622513:+
THCA	cis	rs9907295	0.901	rs4796120	ENSG00000270871.1	AC015849.19	-3.43	0.000667	0.0387	-0.14	-0.16	Fibroblast growth factor basic levels;	chr17:35873887	chr17:35816717~35830293:-
THCA	cis	rs9860428	0.815	rs10511313	ENSG00000243795.1	RP11-572M11.3	3.43	0.000667	0.0387	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112890642	chr3:113142350~113167819:-
THCA	cis	rs6921919	0.515	rs1339898	ENSG00000220721.1	OR1F12	3.43	0.000667	0.0387	0.17	0.16	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28073316~28074233:+
THCA	cis	rs4815191	0.887	rs1541231	ENSG00000230387.2	RP4-737E23.2	-3.43	0.000667	0.0387	-0.21	-0.16	Obesity-related traits;	chr20:23286176	chr20:23187961~23190307:+
THCA	cis	rs6433895	0.601	rs35110674	ENSG00000236153.1	AC104076.3	-3.43	0.000667	0.0387	-0.21	-0.16	Lymphocyte counts;	chr2:181192292	chr2:180979427~180980090:-
THCA	cis	rs7824557	0.547	rs4512344	ENSG00000261451.1	RP11-981G7.1	-3.43	0.000667	0.0387	-0.2	-0.16	Retinal vascular caliber;	chr8:11221272	chr8:10433672~10438312:+
THCA	cis	rs12407262	0.793	rs17575973	ENSG00000234318.1	RP4-771M4.3	-3.43	0.000667	0.0387	-0.23	-0.16	Stromal-cell-derived factor 1 alpha levels;	chr1:63374246	chr1:62896009~62901639:+
THCA	cis	rs12478296	0.515	rs13412492	ENSG00000220804.7	AC093642.5	3.43	0.000667	0.0387	0.15	0.16	Obesity-related traits;	chr2:242058432	chr2:242088633~242160153:+
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000273024.4	INTS4P2	3.43	0.000668	0.0387	0.26	0.16	Diabetic kidney disease;	chr7:65947955	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000273024.4	INTS4P2	3.43	0.000668	0.0387	0.26	0.16	Diabetic kidney disease;	chr7:65950886	chr7:65647864~65715661:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000273024.4	INTS4P2	3.43	0.000668	0.0387	0.26	0.16	Diabetic kidney disease;	chr7:65951525	chr7:65647864~65715661:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000273024.4	INTS4P2	3.43	0.000668	0.0387	0.26	0.16	Diabetic kidney disease;	chr7:65951549	chr7:65647864~65715661:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000273024.4	INTS4P2	3.43	0.000668	0.0387	0.26	0.16	Diabetic kidney disease;	chr7:65956884	chr7:65647864~65715661:+
THCA	cis	rs1971762	0.563	rs10747679	ENSG00000270175.1	RP11-793H13.11	-3.43	0.000668	0.0387	-0.1	-0.16	Height;	chr12:53683966	chr12:53500162~53500936:-
THCA	cis	rs909002	0.703	rs4949460	ENSG00000223382.3	RP1-65J11.1	-3.43	0.000668	0.0387	-0.16	-0.16	Intelligence (multi-trait analysis);	chr1:31677537	chr1:30824228~30834284:+
THCA	cis	rs801193	1	rs10234018	ENSG00000232546.1	RP11-458F8.1	3.43	0.000668	0.0387	0.13	0.16	Aortic root size;	chr7:66681297	chr7:66848496~66858136:+
THCA	cis	rs62209	0.8	rs17149174	ENSG00000181800.5	CELF2-AS1	3.43	0.000668	0.0387	0.16	0.16	Alzheimer's disease (late onset);	chr10:10960547	chr10:11316834~11319884:-
THCA	cis	rs875971	0.545	rs2279757	ENSG00000230295.1	RP11-458F8.2	3.43	0.000668	0.0387	0.14	0.16	Aortic root size;	chr7:66363676	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000230295.1	RP11-458F8.2	3.43	0.000668	0.0387	0.14	0.16	Aortic root size;	chr7:66374173	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000230295.1	RP11-458F8.2	3.43	0.000668	0.0387	0.14	0.16	Aortic root size;	chr7:66387213	chr7:66880708~66882981:+
THCA	cis	rs758324	0.812	rs12653237	ENSG00000237714.1	P4HA2-AS1	3.43	0.000668	0.0387	0.21	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131906085	chr5:132184876~132192808:+
THCA	cis	rs9532580	0.62	rs2755210	ENSG00000275149.1	RP11-427J23.1	-3.43	0.000668	0.0387	-0.22	-0.16	Mean corpuscular hemoglobin;	chr13:40567145	chr13:40079106~40273509:-
THCA	cis	rs277939	1	rs410776	ENSG00000230847.4	RP11-195E2.1	-3.43	0.000668	0.0387	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71585847	chr5:71074225~71093193:-
THCA	cis	rs56309584	0.673	rs11658322	ENSG00000271002.1	RP11-599B13.8	-3.43	0.000668	0.0387	-0.24	-0.16	Initial pursuit acceleration;	chr17:8268011	chr17:8199123~8199437:-
THCA	cis	rs867186	0.541	rs78449612	ENSG00000279253.1	RP4-614O4.13	-3.43	0.000668	0.0387	-0.31	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34869564	chr20:35262727~35264187:-
THCA	cis	rs2486012	1	rs1766968	ENSG00000237950.1	RP11-7O11.3	-3.43	0.000668	0.0387	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:43937370	chr1:43944370~43946551:-
THCA	cis	rs6657613	0.658	rs3738814	ENSG00000268869.4	ESPNP	3.43	0.000668	0.0387	0.16	0.16	Hip circumference adjusted for BMI;	chr1:17005181	chr1:16687339~16720157:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000232546.1	RP11-458F8.1	3.43	0.000668	0.0387	0.13	0.16	Aortic root size;	chr7:66642265	chr7:66848496~66858136:+
THCA	cis	rs11064837	0.504	rs34500179	ENSG00000248636.5	RP11-768F21.1	3.43	0.000668	0.0387	0.18	0.16	Schizophrenia;	chr12:119631047	chr12:119387987~119668079:-
THCA	cis	rs12931792	0.846	rs9924308	ENSG00000274653.1	RP11-347C12.11	3.43	0.000668	0.0387	0.15	0.16	Tonsillectomy;	chr16:30143419	chr16:30359825~30360336:+
THCA	cis	rs55966801	0.796	rs17655188	ENSG00000277290.1	RP11-326C3.16	-3.43	0.000668	0.0387	-0.21	-0.16	Plateletcrit;	chr11:249408	chr11:243099~243483:-
THCA	cis	rs34779708	0.966	rs12765038	ENSG00000233200.1	RP11-324I22.2	3.43	0.000668	0.0387	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs2045917	ENSG00000233200.1	RP11-324I22.2	3.43	0.000668	0.0387	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35219894~35230598:-
THCA	cis	rs10824518	0.612	rs10824539	ENSG00000199664.1	RNU6-1266P	-3.43	0.000668	0.0387	-0.2	-0.16	Myopia;	chr10:77397375	chr10:77776951~77777055:-
THCA	cis	rs9487051	0.872	rs9386789	ENSG00000260273.1	RP11-425D10.10	3.43	0.000668	0.0387	0.18	0.16	Reticulocyte fraction of red cells;	chr6:109282015	chr6:109382795~109383666:+
THCA	cis	rs4713118	0.739	rs2893931	ENSG00000261839.1	RP1-265C24.8	3.43	0.000668	0.0387	0.18	0.16	Parkinson's disease;	chr6:27780231	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.824	rs2092075	ENSG00000261839.1	RP1-265C24.8	3.43	0.000668	0.0387	0.18	0.16	Parkinson's disease;	chr6:27781551	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.824	rs13211701	ENSG00000261839.1	RP1-265C24.8	3.43	0.000668	0.0387	0.18	0.16	Parkinson's disease;	chr6:27782300	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.824	rs9468229	ENSG00000261839.1	RP1-265C24.8	3.43	0.000668	0.0387	0.18	0.16	Parkinson's disease;	chr6:27782307	chr6:28136849~28139678:+
THCA	cis	rs2018683	0.683	rs12538606	ENSG00000233517.1	AC005162.5	-3.43	0.000668	0.0387	-0.19	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929791	chr7:28987028~28988899:+
THCA	cis	rs4713118	0.869	rs6922574	ENSG00000272009.1	RP1-313I6.12	-3.43	0.000668	0.0387	-0.17	-0.16	Parkinson's disease;	chr6:27725224	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.869	rs9348775	ENSG00000272009.1	RP1-313I6.12	-3.43	0.000668	0.0387	-0.17	-0.16	Parkinson's disease;	chr6:27727550	chr6:28078792~28081130:-
THCA	cis	rs1552244	0.554	rs3774207	ENSG00000269982.1	RP11-1020A11.2	3.43	0.000668	0.0387	0.11	0.16	Alzheimer's disease;	chr3:9943972	chr3:9958717~9962539:+
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000184274.3	LINC00315	-3.43	0.000668	0.0387	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45300245~45305257:-
THCA	cis	rs786425	0.966	rs6488883	ENSG00000278112.1	RP11-972P1.11	3.43	0.000668	0.0387	0.15	0.16	Pubertal anthropometrics;	chr12:123616800	chr12:123519390~123519856:-
THCA	cis	rs2179367	0.6	rs9498356	ENSG00000227660.1	RP11-162J8.2	3.43	0.000669	0.0387	0.21	0.16	Dupuytren's disease;	chr6:149443337	chr6:148955628~148964684:-
THCA	cis	rs11886999	0.953	rs6725867	ENSG00000204685.6	STARD7-AS1	-3.43	0.000669	0.0387	-0.17	-0.16	Cardiac Troponin-T levels;	chr2:96208852	chr2:96208416~96242621:+
THCA	cis	rs11886999	0.953	rs6725872	ENSG00000204685.6	STARD7-AS1	-3.43	0.000669	0.0387	-0.17	-0.16	Cardiac Troponin-T levels;	chr2:96208853	chr2:96208416~96242621:+
THCA	cis	rs6995541	0.583	rs7010926	ENSG00000248896.2	CTD-2135J3.3	-3.43	0.000669	0.0388	-0.21	-0.16	Triglyceride levels;	chr8:10769281	chr8:10729314~10771392:+
THCA	cis	rs7520050	0.771	rs4660882	ENSG00000281133.1	AL355480.3	-3.42	0.000669	0.0388	-0.18	-0.16	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45580892~45580996:-
THCA	cis	rs12681366	0.762	rs6997115	ENSG00000261437.1	RP11-22C11.2	3.42	0.000669	0.0388	0.15	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94353657	chr8:94637285~94639467:-
THCA	cis	rs6121246	0.909	rs6088962	ENSG00000230613.1	HM13-AS1	3.42	0.000669	0.0388	0.18	0.16	Mean corpuscular hemoglobin;	chr20:31680381	chr20:31567707~31573263:-
THCA	cis	rs2841277	0.834	rs2841281	ENSG00000258701.1	LINC00638	-3.42	0.000669	0.0388	-0.17	-0.16	Rheumatoid arthritis;	chr14:104928332	chr14:104821201~104823718:+
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000281021.1	RP1-12G14.9	-3.42	0.000669	0.0388	-0.16	-0.16	Lung cancer;	chr6:149657633	chr6:149576089~149590864:-
THCA	cis	rs790006	0.697	rs11175289	ENSG00000243024.5	RPS11P6	-3.42	0.000669	0.0388	-0.18	-0.16	Response to cytidine analogues (gemcitabine);	chr12:64235371	chr12:64222337~64397065:+
THCA	cis	rs6545883	0.894	rs4672436	ENSG00000212978.6	AC016747.3	-3.42	0.000669	0.0388	-0.17	-0.16	Tuberculosis;	chr2:61376222	chr2:61141592~61144969:-
THCA	cis	rs728616	0.558	rs7097080	ENSG00000278616.1	BEND3P3	3.42	0.000669	0.0388	0.15	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406944	chr10:79682997~79685436:+
THCA	cis	rs2014572	0.967	rs10427146	ENSG00000268379.1	CTC-360J11.4	3.42	0.000669	0.0388	0.18	0.16	Hyperactive-impulsive symptoms;	chr19:57244630	chr19:57175233~57177921:+
THCA	cis	rs2494663	0.52	rs11264873	ENSG00000231416.1	RP11-422P24.9	3.42	0.000669	0.0388	0.2	0.16	Mean platelet volume;	chr1:154018470	chr1:153995632~153995960:+
THCA	cis	rs61160187	0.673	rs10043291	ENSG00000272308.1	RP11-231G3.1	3.42	0.000669	0.0388	0.15	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60763031	chr5:60866457~60866935:-
THCA	cis	rs7394190	0.63	rs4746150	ENSG00000272599.2	RP11-152N13.16	3.42	0.000669	0.0388	0.23	0.16	Incident atrial fibrillation;	chr10:73806177	chr10:73124573~73125532:-
THCA	cis	rs72634258	0.554	rs34020118	ENSG00000224315.2	RPL7P7	-3.42	0.000669	0.0388	-0.29	-0.16	Inflammatory bowel disease;	chr1:7834955	chr1:8786211~8786913:-
THCA	cis	rs72634258	0.554	rs12741937	ENSG00000224315.2	RPL7P7	-3.42	0.000669	0.0388	-0.29	-0.16	Inflammatory bowel disease;	chr1:7837562	chr1:8786211~8786913:-
THCA	cis	rs7824557	0.614	rs2736286	ENSG00000269918.1	AF131215.9	-3.42	0.000669	0.0388	-0.17	-0.16	Retinal vascular caliber;	chr8:11369595	chr8:11104691~11106704:-
THCA	cis	rs372883	0.648	rs1153291	ENSG00000176054.6	RPL23P2	-3.42	0.000669	0.0388	-0.14	-0.16	Pancreatic cancer;	chr21:29316749	chr21:28997613~28998033:-
THCA	cis	rs478304	0.651	rs11600918	ENSG00000214659.4	KRT8P26	3.42	0.000669	0.0388	0.14	0.16	Acne (severe);	chr11:65744494	chr11:65726939~65728214:+
THCA	cis	rs256438	0.642	rs11738491	ENSG00000243160.1	RP11-342F17.2	3.42	0.000669	0.0388	0.19	0.16	Serum thyroid-stimulating hormone levels;	chr5:80039149	chr5:79529302~79530093:+
THCA	cis	rs6696239	0.78	rs10799424	ENSG00000227711.2	RP11-275O4.5	-3.42	0.000669	0.0388	-0.22	-0.16	Height;	chr1:227567774	chr1:227509028~227520477:-
THCA	cis	rs7311936	1	rs7303161	ENSG00000270130.1	RP11-214K3.23	-3.42	0.00067	0.0388	-0.17	-0.16	Vertical cup-disc ratio;	chr12:124151391	chr12:123960717~123961244:-
THCA	cis	rs11717455	1	rs11718422	ENSG00000232439.1	RPL18AP7	-3.42	0.00067	0.0388	-0.26	-0.16	Systemic lupus erythematosus;	chr3:38817695	chr3:38526802~38527325:-
THCA	cis	rs9876781	1	rs4858817	ENSG00000199476.1	Y_RNA	3.42	0.00067	0.0388	0.2	0.16	Longevity;	chr3:48375266	chr3:48288587~48288694:+
THCA	cis	rs9450351	0.744	rs9444371	ENSG00000280232.1	RP11-321N4.4	3.42	0.00067	0.0388	0.34	0.16	Interferon gamma-induced protein 10 levels;	chr6:85950676	chr6:85498441~85499058:-
THCA	cis	rs1590305	0.681	rs17055629	ENSG00000236711.2	SMAD9-IT1	-3.42	0.00067	0.0388	-0.21	-0.16	Hip geometry;	chr13:37445628	chr13:36849366~36850046:-
THCA	cis	rs478304	0.651	rs11604451	ENSG00000255320.1	RP11-755F10.1	3.42	0.00067	0.0388	0.2	0.16	Acne (severe);	chr11:65784239	chr11:66244840~66246239:-
THCA	cis	rs7412746	0.658	rs1027699	ENSG00000224800.1	RP11-235D19.2	-3.42	0.00067	0.0388	-0.21	-0.16	Melanoma;	chr1:150839236	chr1:150881236~150881683:-
THCA	cis	rs11190604	1	rs2489037	ENSG00000273030.1	RP11-285F16.1	-3.42	0.00067	0.0388	-0.19	-0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100560161	chr10:100412934~100413421:+
THCA	cis	rs7236492	0.748	rs11660128	ENSG00000267655.1	CTD-2286N8.2	3.42	0.00067	0.0388	0.35	0.16	Inflammatory bowel disease;Crohn's disease;	chr18:79467950	chr18:79117207~79117920:+
THCA	cis	rs28489187	0.597	rs1001604	ENSG00000223653.4	RP11-131L23.1	-3.42	0.00067	0.0388	-0.18	-0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85413841	chr1:85276715~85448124:+
THCA	cis	rs1003719	0.591	rs1053984	ENSG00000270116.1	AP001429.1	3.42	0.00067	0.0388	0.17	0.16	Eye color traits;	chr21:37201717	chr21:37100814~37101343:+
THCA	cis	rs12438659	1	rs12438659	ENSG00000261143.1	ADAMTS7P3	-3.42	0.00067	0.0388	-0.22	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78532582	chr15:77976042~77993057:+
THCA	cis	rs2243480	0.901	rs313808	ENSG00000237310.1	GS1-124K5.4	3.42	0.00067	0.0388	0.18	0.16	Diabetic kidney disease;	chr7:66034886	chr7:66493706~66495474:+
THCA	cis	rs4704187	0.687	rs4447960	ENSG00000250889.2	LINC01336	-3.42	0.00067	0.0388	-0.16	-0.16	Response to amphetamines;	chr5:75066032	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs9293642	ENSG00000250889.2	LINC01336	-3.42	0.00067	0.0388	-0.16	-0.16	Response to amphetamines;	chr5:75069201	chr5:75047719~75052843:-
THCA	cis	rs7819412	0.703	rs2409713	ENSG00000206014.6	OR7E161P	3.42	0.00067	0.0388	0.18	0.16	Triglycerides;	chr8:11152287	chr8:11928597~11929563:-
THCA	cis	rs1864982	0.681	rs2963078	ENSG00000251556.1	RP11-118M9.3	3.42	0.00067	0.0388	0.25	0.16	Alcohol dependence;	chr5:146866045	chr5:146099406~146120412:+
THCA	cis	rs478304	0.619	rs10896028	ENSG00000255120.4	OVOL1-AS1	-3.42	0.00067	0.0388	-0.21	-0.16	Acne (severe);	chr11:65664716	chr11:65789051~65790868:-
THCA	cis	rs10954779	0.567	rs6990131	ENSG00000127589.4	TUBBP1	-3.42	0.00067	0.0388	-0.18	-0.16	Intelligence (multi-trait analysis);	chr8:31138900	chr8:30351873~30353518:+
THCA	cis	rs1552172	0.853	rs11587821	ENSG00000234222.5	RP11-315I20.1	-3.42	0.00067	0.0388	-0.19	-0.16	Breast cancer;	chr1:145836072	chr1:145926590~145959179:+
THCA	cis	rs9527	0.641	rs4919684	ENSG00000213061.2	PFN1P11	3.42	0.00067	0.0388	0.21	0.16	Arsenic metabolism;	chr10:102827267	chr10:102838011~102845473:-
THCA	cis	rs7914558	0.966	rs3902934	ENSG00000213061.2	PFN1P11	3.42	0.00067	0.0388	0.18	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102986892	chr10:102838011~102845473:-
THCA	cis	rs7914558	1	rs1890184	ENSG00000213061.2	PFN1P11	3.42	0.00067	0.0388	0.18	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988702	chr10:102838011~102845473:-
THCA	cis	rs2797160	0.967	rs984041	ENSG00000226409.1	RP11-735G4.1	3.42	0.00067	0.0388	0.18	0.16	Endometrial cancer;	chr6:125700182	chr6:125370211~125374324:-
THCA	cis	rs7487075	0.578	rs11183486	ENSG00000274723.1	RP11-618L22.1	3.42	0.00067	0.0388	0.15	0.16	Itch intensity from mosquito bite;	chr12:46443921	chr12:46970504~46972155:+
THCA	cis	rs7264396	0.887	rs2236161	ENSG00000261582.1	RP4-614O4.11	-3.42	0.00067	0.0388	-0.16	-0.16	Total cholesterol levels;	chr20:35513802	chr20:35267885~35280043:-
THCA	cis	rs1799949	1	rs915945	ENSG00000236383.6	LINC00854	-3.42	0.00067	0.0388	-0.15	-0.16	Menopause (age at onset);	chr17:43027847	chr17:43216941~43305976:-
THCA	cis	rs9549260	0.753	rs61963266	ENSG00000168852.11	TPTE2P5	3.42	0.00067	0.0388	0.14	0.16	Red blood cell count;	chr13:40596899	chr13:40822296~40921749:-
THCA	cis	rs9549260	0.753	rs4943794	ENSG00000168852.11	TPTE2P5	3.42	0.00067	0.0388	0.14	0.16	Red blood cell count;	chr13:40599271	chr13:40822296~40921749:-
THCA	cis	rs9549260	0.753	rs1986649	ENSG00000168852.11	TPTE2P5	3.42	0.00067	0.0388	0.14	0.16	Red blood cell count;	chr13:40604687	chr13:40822296~40921749:-
THCA	cis	rs9549260	0.753	rs9549238	ENSG00000168852.11	TPTE2P5	3.42	0.00067	0.0388	0.14	0.16	Red blood cell count;	chr13:40605184	chr13:40822296~40921749:-
THCA	cis	rs7520050	0.807	rs4660312	ENSG00000281133.1	AL355480.3	-3.42	0.00067	0.0388	-0.18	-0.16	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.807	rs4468203	ENSG00000281133.1	AL355480.3	-3.42	0.00067	0.0388	-0.18	-0.16	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45580892~45580996:-
THCA	cis	rs9291683	0.588	rs4697705	ENSG00000261490.1	RP11-448G15.3	-3.42	0.00067	0.0388	-0.1	-0.16	Bone mineral density;	chr4:10106503	chr4:10068089~10073019:-
THCA	cis	rs2729354	0.768	rs2848640	ENSG00000254602.1	AP000662.4	-3.42	0.00067	0.0388	-0.2	-0.16	Blood protein levels;	chr11:57495207	chr11:57638024~57652790:+
THCA	cis	rs875971	0.862	rs778734	ENSG00000223473.2	GS1-124K5.3	3.42	0.00067	0.0388	0.1	0.16	Aortic root size;	chr7:66349862	chr7:66491049~66493566:-
THCA	cis	rs4788570	0.697	rs9930015	ENSG00000260185.1	RP11-432I5.6	-3.42	0.00067	0.0388	-0.3	-0.16	Intelligence (multi-trait analysis);	chr16:71767189	chr16:71655027~71664212:+
THCA	cis	rs56318008	0.625	rs10737462	ENSG00000228397.1	RP1-224A6.3	-3.42	0.000671	0.0388	-0.26	-0.16	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22118482	chr1:22023994~22024968:-
THCA	cis	rs7737355	0.812	rs13158295	ENSG00000224431.1	AC063976.7	3.42	0.000671	0.0388	0.14	0.16	Life satisfaction;	chr5:131293699	chr5:132199456~132203487:+
THCA	cis	rs240993	0.595	rs3777910	ENSG00000220392.1	FCF1P5	3.42	0.000671	0.0389	0.17	0.16	Inflammatory skin disease;Psoriasis;	chr6:111581248	chr6:111353702~111354183:+
THCA	cis	rs1059312	1	rs7970815	ENSG00000279500.1	RP11-21K12.2	-3.42	0.000671	0.0389	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128803821	chr12:128813186~128814750:-
THCA	cis	rs11673344	0.583	rs7254411	ENSG00000233527.7	ZNF529-AS1	3.42	0.000671	0.0389	0.13	0.16	Obesity-related traits;	chr19:37034969	chr19:36573070~36594708:+
THCA	cis	rs9291683	0.679	rs2241483	ENSG00000250413.1	RP11-448G15.1	3.42	0.000671	0.0389	0.15	0.16	Bone mineral density;	chr4:10098207	chr4:10006482~10009725:+
THCA	cis	rs9488822	0.676	rs10456902	ENSG00000237021.2	RP3-486I3.7	-3.42	0.000671	0.0389	-0.16	-0.16	LDL cholesterol;Cholesterol, total;	chr6:116012579	chr6:116254207~116256743:+
THCA	cis	rs9652601	0.691	rs9941107	ENSG00000263033.2	RP11-396B14.2	-3.42	0.000671	0.0389	-0.13	-0.16	Systemic lupus erythematosus;	chr16:11102184	chr16:11196177~11224969:+
THCA	cis	rs2841277	0.676	rs10438247	ENSG00000258701.1	LINC00638	3.42	0.000671	0.0389	0.17	0.16	Rheumatoid arthritis;	chr14:104945444	chr14:104821201~104823718:+
THCA	cis	rs73198271	0.74	rs10092720	ENSG00000254340.1	RP11-10A14.3	-3.42	0.000671	0.0389	-0.2	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:9141424~9145435:+
THCA	cis	rs9844985	0.669	rs9880688	ENSG00000243014.1	PTMAP8	3.42	0.000671	0.0389	0.19	0.16	Major depression and alcohol dependence;	chr3:117168577	chr3:117026698~117027039:+
THCA	cis	rs972578	0.765	rs5751391	ENSG00000230319.1	AL022476.2	3.42	0.000671	0.0389	0.16	0.16	Mean platelet volume;	chr22:42865493	chr22:43038585~43052366:+
THCA	cis	rs4073582	0.595	rs1151540	ENSG00000245156.1	RP11-867G23.3	3.42	0.000671	0.0389	0.13	0.16	Gout;	chr11:66274336	chr11:66269832~66278525:-
THCA	cis	rs7626019	0.638	rs13081529	ENSG00000222872.1	RNU4-78P	3.42	0.000671	0.0389	0.21	0.16	Neurofibrillary tangles;	chr3:42231603	chr3:42221840~42221965:+
THCA	cis	rs7626019	0.585	rs12631573	ENSG00000222872.1	RNU4-78P	3.42	0.000671	0.0389	0.21	0.16	Neurofibrillary tangles;	chr3:42234091	chr3:42221840~42221965:+
THCA	cis	rs7626019	0.638	rs34074323	ENSG00000222872.1	RNU4-78P	3.42	0.000671	0.0389	0.21	0.16	Neurofibrillary tangles;	chr3:42235600	chr3:42221840~42221965:+
THCA	cis	rs7626019	0.638	rs36108735	ENSG00000222872.1	RNU4-78P	3.42	0.000671	0.0389	0.21	0.16	Neurofibrillary tangles;	chr3:42236899	chr3:42221840~42221965:+
THCA	cis	rs4664293	0.805	rs6432559	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159750649	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs6432560	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159750758	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs3863924	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159758247	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs11681565	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159760362	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.836	rs11687502	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159760464	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.836	rs13401087	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159760957	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs12692564	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159761326	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs1427328	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159762064	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.613	rs9784044	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159765854	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs4664301	ENSG00000230783.1	AC009961.2	-3.42	0.000671	0.0389	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159766855	chr2:159689217~159690291:-
THCA	cis	rs9296092	0.517	rs55963187	ENSG00000272217.1	XXbac-BPG157A10.21	3.42	0.000671	0.0389	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33556001	chr6:33246075~33246856:-
THCA	cis	rs35740288	0.822	rs10520599	ENSG00000259407.1	RP11-158M2.3	-3.42	0.000671	0.0389	-0.19	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85679866	chr15:85744109~85750281:-
THCA	cis	rs72996113	0.702	rs10431109	ENSG00000248027.1	CTD-2383M3.1	-3.42	0.000671	0.0389	-0.3	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100705866	chr11:100684162~100687955:-
THCA	cis	rs72996113	0.646	rs11224400	ENSG00000248027.1	CTD-2383M3.1	-3.42	0.000671	0.0389	-0.3	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100706137	chr11:100684162~100687955:-
THCA	cis	rs4218	0.689	rs12900369	ENSG00000277144.1	RP11-59H7.4	-3.42	0.000671	0.0389	-0.22	-0.16	Social communication problems;	chr15:59099254	chr15:59115547~59116089:-
THCA	cis	rs4218	0.689	rs28514475	ENSG00000277144.1	RP11-59H7.4	-3.42	0.000671	0.0389	-0.22	-0.16	Social communication problems;	chr15:59099896	chr15:59115547~59116089:-
THCA	cis	rs4218	0.689	rs28610479	ENSG00000277144.1	RP11-59H7.4	-3.42	0.000671	0.0389	-0.22	-0.16	Social communication problems;	chr15:59099906	chr15:59115547~59116089:-
THCA	cis	rs2288884	0.559	rs12611043	ENSG00000269483.1	AC006272.1	3.42	0.000671	0.0389	0.18	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:51839924~51843324:-
THCA	cis	rs2638953	0.927	rs11049630	ENSG00000278733.1	RP11-425D17.1	-3.42	0.000671	0.0389	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460240	chr12:28185625~28186190:-
THCA	cis	rs2911280	0.764	rs77576640	ENSG00000278985.1	RP11-303E16.9	-3.42	0.000671	0.0389	-0.29	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81526386	chr16:80982319~80984094:-
THCA	cis	rs2911280	0.764	rs28410432	ENSG00000278985.1	RP11-303E16.9	-3.42	0.000671	0.0389	-0.29	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81526546	chr16:80982319~80984094:-
THCA	cis	rs2911280	0.764	rs28651456	ENSG00000278985.1	RP11-303E16.9	-3.42	0.000671	0.0389	-0.29	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81526581	chr16:80982319~80984094:-
THCA	cis	rs2911280	0.764	rs28404001	ENSG00000278985.1	RP11-303E16.9	-3.42	0.000671	0.0389	-0.29	-0.16	Dehydroepiandrosterone sulphate levels;	chr16:81526808	chr16:80982319~80984094:-
THCA	cis	rs6715284	0.892	rs8105	ENSG00000183308.6	AC005037.3	3.42	0.000671	0.0389	0.36	0.16	Rheumatoid arthritis;	chr2:201377412	chr2:200963263~201009102:+
THCA	cis	rs2274273	0.84	rs28493647	ENSG00000258469.1	CHMP4BP1	3.42	0.000671	0.0389	0.14	0.16	Protein biomarker;	chr14:55357745	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.84	rs17674463	ENSG00000258469.1	CHMP4BP1	3.42	0.000671	0.0389	0.14	0.16	Protein biomarker;	chr14:55358145	chr14:55298644~55299231:+
THCA	cis	rs56309584	0.673	rs56256903	ENSG00000271002.1	RP11-599B13.8	-3.42	0.000671	0.0389	-0.24	-0.16	Initial pursuit acceleration;	chr17:8219810	chr17:8199123~8199437:-
THCA	cis	rs4568518	0.873	rs4602778	ENSG00000279048.1	RP11-511H23.2	3.42	0.000672	0.0389	0.1	0.16	Measles;	chr7:17989131	chr7:17940503~17942922:+
THCA	cis	rs34421088	0.56	rs2467520	ENSG00000270154.1	RP11-419I17.1	-3.42	0.000672	0.0389	-0.19	-0.16	Neuroticism;	chr8:11541444	chr8:12476462~12477122:+
THCA	cis	rs10971721	0.643	rs7040130	ENSG00000237984.3	PTENP1	3.42	0.000672	0.0389	0.23	0.16	Body mass index;	chr9:33785075	chr9:33673504~33677499:-
THCA	cis	rs615632	0.57	rs17734541	ENSG00000248538.5	RP11-10A14.5	-3.42	0.000672	0.0389	-0.21	-0.16	Neuroticism;	chr8:9850923	chr8:9189011~9202854:+
THCA	cis	rs6545883	0.524	rs811871	ENSG00000273302.1	RP11-493E12.2	-3.42	0.000672	0.0389	-0.14	-0.16	Tuberculosis;	chr2:61350814	chr2:61199979~61200769:+
THCA	cis	rs4727027	0.704	rs12535154	ENSG00000244560.5	RP4-800G7.2	-3.42	0.000672	0.0389	-0.09	-0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149198212	chr7:149285281~149297312:+
THCA	cis	rs4512344	0.509	rs2409784	ENSG00000270154.1	RP11-419I17.1	-3.42	0.000672	0.0389	-0.19	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12476462~12477122:+
THCA	cis	rs11711311	0.668	rs11718061	ENSG00000241529.3	RN7SL767P	3.42	0.000672	0.0389	0.23	0.16	IgG glycosylation;	chr3:113622979	chr3:113632704~113632998:+
THCA	cis	rs1560104	0.597	rs17227492	ENSG00000260601.1	RP11-552C15.1	-3.42	0.000672	0.0389	-0.18	-0.16	Obesity-related traits;	chr16:12620186	chr16:12545482~12546684:+
THCA	cis	rs11992162	0.597	rs7016320	ENSG00000255046.1	RP11-297N6.4	3.42	0.000672	0.0389	0.17	0.16	Monocyte count;	chr8:11923543	chr8:11797928~11802568:-
THCA	cis	rs732716	0.785	rs34080966	ENSG00000280239.1	CTB-50L17.8	3.42	0.000672	0.0389	0.13	0.16	Mean corpuscular volume;	chr19:4417848	chr19:4448810~4450836:+
THCA	cis	rs862034	0.902	rs862056	ENSG00000270000.1	RP3-449M8.9	-3.42	0.000672	0.0389	-0.16	-0.16	Height;	chr14:74512351	chr14:74471930~74472360:-
THCA	cis	rs12286929	0.61	rs12807135	ENSG00000255580.1	AP000462.2	3.42	0.000672	0.0389	0.15	0.16	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;	chr11:115182788	chr11:115363629~115377931:+
THCA	cis	rs853679	0.567	rs7774981	ENSG00000226314.6	ZNF192P1	-3.42	0.000672	0.0389	-0.19	-0.16	Depression;	chr6:28379133	chr6:28161781~28169594:+
THCA	cis	rs853679	0.567	rs7754960	ENSG00000226314.6	ZNF192P1	-3.42	0.000672	0.0389	-0.19	-0.16	Depression;	chr6:28379168	chr6:28161781~28169594:+
THCA	cis	rs513088	0.681	rs503961	ENSG00000225171.2	DUTP6	3.42	0.000672	0.0389	0.22	0.16	Schizophrenia;	chr1:166694494	chr1:166868748~166869209:+
THCA	cis	rs513088	0.681	rs34900988	ENSG00000225171.2	DUTP6	-3.42	0.000672	0.0389	-0.22	-0.16	Schizophrenia;	chr1:166695161	chr1:166868748~166869209:+
THCA	cis	rs2486012	1	rs3011227	ENSG00000237950.1	RP11-7O11.3	3.42	0.000672	0.0389	0.17	0.16	Intelligence (multi-trait analysis);	chr1:43859737	chr1:43944370~43946551:-
THCA	cis	rs9650657	0.738	rs11250078	ENSG00000269918.1	AF131215.9	-3.42	0.000672	0.0389	-0.17	-0.16	Neuroticism;	chr8:10809071	chr8:11104691~11106704:-
THCA	cis	rs2066819	1	rs2371494	ENSG00000257303.1	RP11-977G19.11	-3.42	0.000672	0.0389	-0.22	-0.16	Psoriasis vulgaris;	chr12:56334216	chr12:56300142~56314808:+
THCA	cis	rs10911363	0.592	rs2275675	ENSG00000232860.6	SMG7-AS1	3.42	0.000672	0.0389	0.12	0.16	Systemic lupus erythematosus;	chr1:183470348	chr1:183460874~183472265:-
THCA	cis	rs6500602	0.727	rs4238849	ENSG00000280063.1	RP11-295D4.3	3.42	0.000672	0.0389	0.08	0.16	Schizophrenia;	chr16:4488113	chr16:4346694~4348648:-
THCA	cis	rs950776	0.72	rs11633223	ENSG00000261762.1	RP11-650L12.2	3.42	0.000672	0.0389	0.21	0.16	Sudden cardiac arrest;	chr15:78643134	chr15:78589123~78591276:-
THCA	cis	rs76695126	0.659	rs4791850	ENSG00000271851.1	RP11-565F19.2	3.42	0.000672	0.0389	0.15	0.16	Borderline personality disorder;	chr17:9536244	chr17:9553323~9555696:-
THCA	cis	rs9393777	0.92	rs35768595	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000672	0.0389	-0.31	-0.16	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28078792~28081130:-
THCA	cis	rs1065852	0.526	rs9623490	ENSG00000232710.1	RP4-669P10.16	-3.42	0.000672	0.0389	-0.2	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002262	chr22:42136433~42139927:-
THCA	cis	rs11777747	0.836	rs28368576	ENSG00000280303.2	ERICD	-3.42	0.000672	0.0389	-0.19	-0.16	Coronary artery calcification;	chr8:141469893	chr8:140636281~140638283:+
THCA	cis	rs11777747	0.891	rs28696086	ENSG00000280303.2	ERICD	-3.42	0.000672	0.0389	-0.19	-0.16	Coronary artery calcification;	chr8:141469923	chr8:140636281~140638283:+
THCA	cis	rs11777747	0.891	rs28735440	ENSG00000280303.2	ERICD	-3.42	0.000672	0.0389	-0.19	-0.16	Coronary artery calcification;	chr8:141469946	chr8:140636281~140638283:+
THCA	cis	rs11777747	0.732	rs28417025	ENSG00000280303.2	ERICD	-3.42	0.000672	0.0389	-0.19	-0.16	Coronary artery calcification;	chr8:141470001	chr8:140636281~140638283:+
THCA	cis	rs11777747	0.786	rs28753757	ENSG00000280303.2	ERICD	-3.42	0.000672	0.0389	-0.19	-0.16	Coronary artery calcification;	chr8:141470008	chr8:140636281~140638283:+
THCA	cis	rs1153858	1	rs9783731	ENSG00000275672.1	GATM-AS1	3.42	0.000672	0.0389	0.16	0.16	Homoarginine levels;	chr15:45350686	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs16942000	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45340805	chr15:45378700~45380123:+
THCA	cis	rs1153858	0.945	rs7182300	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45342730	chr15:45378700~45380123:+
THCA	cis	rs1153858	0.887	rs7171163	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45344197	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs56669689	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45345531	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs56806728	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45345616	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs4775906	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45346096	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs7179743	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45346133	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs4775907	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45346449	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs7163720	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45347176	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs7167900	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45347273	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs12591058	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45347974	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs7169587	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45348181	chr15:45378700~45380123:+
THCA	cis	rs1153858	0.943	rs28605551	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45349522	chr15:45378700~45380123:+
THCA	cis	rs1153858	1	rs4775909	ENSG00000275672.1	GATM-AS1	-3.42	0.000672	0.0389	-0.16	-0.16	Homoarginine levels;	chr15:45350844	chr15:45378700~45380123:+
THCA	cis	rs481331	0.741	rs17158044	ENSG00000272319.1	AL022345.7	-3.42	0.000672	0.0389	-0.27	-0.16	Systemic juvenile idiopathic arthritis;	chr10:42689688	chr10:42579724~42582772:+
THCA	cis	rs11673344	0.504	rs35579954	ENSG00000233527.7	ZNF529-AS1	3.42	0.000672	0.0389	0.13	0.16	Obesity-related traits;	chr19:37139308	chr19:36573070~36594708:+
THCA	cis	rs9348440	0.73	rs2328529	ENSG00000280989.1	LINC00581	-3.42	0.000672	0.0389	-0.24	-0.16	Glycemic traits;	chr6:20631722	chr6:21486061~21511895:-
THCA	cis	rs4568518	0.903	rs12154961	ENSG00000279048.1	RP11-511H23.2	3.42	0.000672	0.0389	0.11	0.16	Measles;	chr7:17995715	chr7:17940503~17942922:+
THCA	cis	rs7897654	0.651	rs12783467	ENSG00000236937.2	PTGES3P4	3.42	0.000673	0.0389	0.23	0.16	Schizophrenia;	chr10:102948555	chr10:102845595~102845950:+
THCA	cis	rs2692947	0.673	rs2917662	ENSG00000235584.2	AC008268.1	-3.42	0.000673	0.0389	-0.16	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129218	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.644	rs2969491	ENSG00000235584.2	AC008268.1	-3.42	0.000673	0.0389	-0.16	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129243	chr2:95666084~95668715:+
THCA	cis	rs17689437	0.813	rs10153096	ENSG00000260084.1	RP11-615I2.1	-3.42	0.000673	0.0389	-0.25	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68640005	chr16:68573782~68589512:-
THCA	cis	rs10906466	0.869	rs4424567	ENSG00000237032.1	RP11-398C13.2	3.42	0.000673	0.0389	0.22	0.16	Migraine;	chr10:13759269	chr10:14723171~14724055:-
THCA	cis	rs3096299	0.658	rs4785679	ENSG00000223959.7	AFG3L1P	3.42	0.000673	0.0389	0.09	0.16	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89972586~90002161:+
THCA	cis	rs2692947	0.55	rs4613327	ENSG00000236750.1	AC009237.16	-3.42	0.000673	0.0389	-0.18	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95918075	chr2:95641634~95641980:-
THCA	cis	rs34779708	0.966	rs10827487	ENSG00000233200.1	RP11-324I22.2	3.42	0.000673	0.0389	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35219894~35230598:-
THCA	cis	rs115056730	0.52	rs113247402	ENSG00000230606.9	AC159540.1	3.42	0.000673	0.0389	0.25	0.16	Monocyte chemoattractant protein-3 levels;	chr2:97552110	chr2:97416165~97433527:-
THCA	cis	rs897984	0.647	rs7203999	ENSG00000275263.1	RP11-1072A3.4	3.42	0.000673	0.0389	0.18	0.16	Dementia with Lewy bodies;	chr16:31006233	chr16:30956872~30957199:-
THCA	cis	rs6545883	0.894	rs7566035	ENSG00000212978.6	AC016747.3	-3.42	0.000673	0.0389	-0.17	-0.16	Tuberculosis;	chr2:61293680	chr2:61141592~61144969:-
THCA	cis	rs10911902	0.643	rs3766702	ENSG00000228238.1	GS1-304P7.2	-3.42	0.000673	0.039	-0.26	-0.16	Schizophrenia;	chr1:186346832	chr1:186578279~186579299:+
THCA	cis	rs12935418	0.616	rs62054238	ENSG00000261838.4	RP11-303E16.6	3.42	0.000673	0.039	0.22	0.16	Mean corpuscular volume;	chr16:80965753	chr16:81069854~81076598:+
THCA	cis	rs12935418	0.616	rs62054239	ENSG00000261838.4	RP11-303E16.6	3.42	0.000673	0.039	0.22	0.16	Mean corpuscular volume;	chr16:80966287	chr16:81069854~81076598:+
THCA	cis	rs2180341	1	rs6903878	ENSG00000220522.2	RP1-177A13.1	3.42	0.000673	0.039	0.2	0.16	Breast cancer;	chr6:127317455	chr6:127416535~127416952:-
THCA	cis	rs12887734	0.566	rs3742366	ENSG00000258735.1	LINC00637	-3.42	0.000673	0.039	-0.21	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103847721~103858049:+
THCA	cis	rs11190604	0.697	rs10748795	ENSG00000273030.1	RP11-285F16.1	-3.42	0.000673	0.039	-0.18	-0.16	Palmitoleic acid (16:1n-7) levels;	chr10:100435061	chr10:100412934~100413421:+
THCA	cis	rs12780845	0.931	rs7085460	ENSG00000273153.1	RP11-406H21.2	3.42	0.000673	0.039	0.15	0.16	Homocysteine levels;	chr10:17206668	chr10:17137336~17137585:-
THCA	cis	rs12780845	0.931	rs7089849	ENSG00000273153.1	RP11-406H21.2	3.42	0.000673	0.039	0.15	0.16	Homocysteine levels;	chr10:17207488	chr10:17137336~17137585:-
THCA	cis	rs12780845	0.931	rs67564104	ENSG00000273153.1	RP11-406H21.2	3.42	0.000673	0.039	0.15	0.16	Homocysteine levels;	chr10:17207546	chr10:17137336~17137585:-
THCA	cis	rs12780845	0.931	rs35016603	ENSG00000273153.1	RP11-406H21.2	3.42	0.000673	0.039	0.15	0.16	Homocysteine levels;	chr10:17208262	chr10:17137336~17137585:-
THCA	cis	rs12780845	0.931	rs7095223	ENSG00000273153.1	RP11-406H21.2	3.42	0.000673	0.039	0.15	0.16	Homocysteine levels;	chr10:17208979	chr10:17137336~17137585:-
THCA	cis	rs5770917	1	rs1056964	ENSG00000279182.1	XX-C00717C00720L.1	3.42	0.000673	0.039	0.25	0.16	Narcolepsy;	chr22:50579047	chr22:50316035~50317025:+
THCA	cis	rs2214442	0.817	rs12538581	ENSG00000271133.4	CTA-293F17.1	-3.42	0.000673	0.039	-0.16	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20359494	chr7:20328299~20331747:-
THCA	cis	rs7395662	0.929	rs10838982	ENSG00000200090.1	Y_RNA	-3.42	0.000673	0.039	-0.1	-0.16	HDL cholesterol;	chr11:48618616	chr11:47726894~47726992:-
THCA	cis	rs17221829	0.644	rs12420632	ENSG00000280385.1	AP000648.5	-3.42	0.000673	0.039	-0.16	-0.16	Anxiety in major depressive disorder;	chr11:89633063	chr11:90193614~90198120:+
THCA	cis	rs6691738	0.959	rs6665456	ENSG00000227373.4	RP11-160H22.5	3.42	0.000673	0.039	0.21	0.16	Asthma;	chr1:173171626	chr1:174115300~174160004:-
THCA	cis	rs12681963	0.688	rs7009988	ENSG00000272375.1	RP11-51J9.6	3.42	0.000673	0.039	0.23	0.16	Migraine;	chr8:30224947	chr8:30197404~30198048:+
THCA	cis	rs9652601	0.691	rs3893661	ENSG00000263033.2	RP11-396B14.2	-3.42	0.000673	0.039	-0.12	-0.16	Systemic lupus erythematosus;	chr16:11100023	chr16:11196177~11224969:+
THCA	cis	rs4846580	0.751	rs10863476	ENSG00000230024.1	RP11-95P13.1	-3.42	0.000673	0.039	-0.18	-0.16	Total body bone mineral density;	chr1:219663023	chr1:219435152~219442642:-
THCA	cis	rs3785574	0.962	rs62077483	ENSG00000279369.1	RP11-51F16.1	3.42	0.000673	0.039	0.11	0.16	Height;	chr17:63729020	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs7219920	ENSG00000279369.1	RP11-51F16.1	3.42	0.000673	0.039	0.11	0.16	Height;	chr17:63734282	chr17:63700847~63702670:+
THCA	cis	rs17122278	1	rs11216900	ENSG00000255239.1	AP002954.6	-3.42	0.000673	0.039	-0.28	-0.16	Total cholesterol levels;	chr11:118565364	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000264242.2	RP11-271K11.1	3.42	0.000673	0.039	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30553697~30558962:+
THCA	cis	rs3764021	0.509	rs10772070	ENSG00000257027.1	RP11-705C15.3	3.42	0.000673	0.039	0.14	0.16	Type 1 diabetes;	chr12:9717320	chr12:9658567~9662085:+
THCA	cis	rs910316	1	rs13099	ENSG00000259138.1	RP11-950C14.7	-3.42	0.000673	0.039	-0.14	-0.16	Height;	chr14:75132452	chr14:75127153~75136930:+
THCA	cis	rs9341808	0.718	rs2874829	ENSG00000260645.1	RP11-250B2.5	3.42	0.000673	0.039	0.13	0.16	Sitting height ratio;	chr6:80146380	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.618	rs6916507	ENSG00000260645.1	RP11-250B2.5	3.42	0.000673	0.039	0.13	0.16	Sitting height ratio;	chr6:80152548	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.65	rs6909546	ENSG00000260645.1	RP11-250B2.5	3.42	0.000673	0.039	0.13	0.16	Sitting height ratio;	chr6:80160206	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.69	rs2322634	ENSG00000260645.1	RP11-250B2.5	3.42	0.000673	0.039	0.13	0.16	Sitting height ratio;	chr6:80164297	chr6:80466958~80469080:+
THCA	cis	rs4649295	0.831	rs34949757	ENSG00000231940.1	RPS7P3	3.42	0.000673	0.039	0.18	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr1:233266548	chr1:233288868~233289447:-
THCA	cis	rs4649295	0.898	rs36030979	ENSG00000231940.1	RPS7P3	3.42	0.000673	0.039	0.18	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr1:233266599	chr1:233288868~233289447:-
THCA	cis	rs6499755	0.932	rs1370386	ENSG00000260135.5	RP11-212I21.2	-3.42	0.000673	0.039	-0.17	-0.16	Hypospadias;	chr16:55306255	chr16:55426797~55462297:-
THCA	cis	rs12780845	1	rs35630951	ENSG00000273153.1	RP11-406H21.2	3.42	0.000673	0.039	0.15	0.16	Homocysteine levels;	chr10:17173650	chr10:17137336~17137585:-
THCA	cis	rs3805389	1	rs10026676	ENSG00000273257.1	RP11-177J6.1	-3.42	0.000673	0.039	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55612585	chr4:55387949~55388271:+
THCA	cis	rs3805389	1	rs28564902	ENSG00000273257.1	RP11-177J6.1	-3.42	0.000673	0.039	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55613324	chr4:55387949~55388271:+
THCA	cis	rs651386	0.529	rs2206063	ENSG00000271811.1	RP1-79C4.4	-3.42	0.000673	0.039	-0.19	-0.16	Atrial fibrillation;	chr1:170615956	chr1:170667381~170669425:+
THCA	cis	rs10911902	0.643	rs75235608	ENSG00000233196.2	GS1-304P7.1	-3.42	0.000673	0.039	-0.26	-0.16	Schizophrenia;	chr1:186303471	chr1:186580515~186581191:-
THCA	cis	rs11992162	0.591	rs34123222	ENSG00000255046.1	RP11-297N6.4	3.42	0.000673	0.039	0.17	0.16	Monocyte count;	chr8:11937840	chr8:11797928~11802568:-
THCA	cis	rs17607347	0.697	rs10153187	ENSG00000247324.2	RP11-510M2.2	-3.42	0.000673	0.039	-0.25	-0.16	Intelligence (multi-trait analysis);	chr16:72305891	chr16:71462278~71465941:+
THCA	cis	rs6890270	1	rs6890270	ENSG00000265665.1	AC008391.1	-3.42	0.000674	0.039	-0.19	-0.16	Breast cancer;	chr5:56964779	chr5:56457038~56457138:-
THCA	cis	rs4671400	0.571	rs62152270	ENSG00000270820.4	RP11-355B11.2	-3.42	0.000674	0.039	-0.15	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267125	chr2:61471188~61484130:+
THCA	cis	rs13166814	1	rs13166814	ENSG00000250427.1	CTD-3179P9.2	3.42	0.000674	0.039	0.3	0.16	Subcutaneous adipose tissue;	chr5:118002058	chr5:118282575~118284782:+
THCA	cis	rs172166	0.585	rs149963	ENSG00000261839.1	RP1-265C24.8	3.42	0.000674	0.039	0.15	0.16	Cardiac Troponin-T levels;	chr6:28049354	chr6:28136849~28139678:+
THCA	cis	rs2131877	0.595	rs2172695	ENSG00000238097.1	RP11-513G11.3	-3.42	0.000674	0.039	-0.17	-0.16	Non-small cell lung cancer;	chr3:195134253	chr3:194247648~194257772:+
THCA	cis	rs10411161	0.63	rs12462816	ENSG00000260160.1	CTC-471J1.2	3.42	0.000674	0.039	0.22	0.16	Breast cancer;	chr19:51929462	chr19:52058490~52063703:-
THCA	cis	rs11685222	0.697	rs6708153	ENSG00000229326.3	AC069154.4	3.42	0.000674	0.039	0.26	0.16	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119705377	chr2:119698623~119700151:+
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000264242.2	RP11-271K11.1	3.42	0.000674	0.039	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30553697~30558962:+
THCA	cis	rs7656342	0.791	rs13140817	ENSG00000249866.1	OR7E83P	3.42	0.000674	0.039	0.17	0.16	Gut microbiota (bacterial taxa);	chr4:9761351	chr4:9512905~9513874:+
THCA	cis	rs7824557	0.505	rs2736313	ENSG00000255046.1	RP11-297N6.4	-3.42	0.000674	0.039	-0.16	-0.16	Retinal vascular caliber;	chr8:11229433	chr8:11797928~11802568:-
THCA	cis	rs1858037	0.867	rs2118305	ENSG00000252414.1	RNU6-100P	-3.42	0.000674	0.039	-0.17	-0.16	Rheumatoid arthritis;	chr2:65378086	chr2:64578892~64578997:+
THCA	cis	rs9840812	0.769	rs3755636	ENSG00000239213.4	NCK1-AS1	3.42	0.000674	0.039	0.15	0.16	Fibrinogen levels;	chr3:136249986	chr3:136841726~136862054:-
THCA	cis	rs7039377	0.658	rs7048582	ENSG00000225345.3	SNX18P3	3.42	0.000674	0.039	0.14	0.16	Obesity-related traits;	chr9:38670781	chr9:38566260~38568211:-
THCA	cis	rs2821260	0.967	rs11209896	ENSG00000227207.2	RPL31P12	-3.42	0.000674	0.039	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:72047305	chr1:72301472~72301829:+
THCA	cis	rs9876781	0.874	rs56298324	ENSG00000199476.1	Y_RNA	3.42	0.000674	0.039	0.19	0.16	Longevity;	chr3:48393626	chr3:48288587~48288694:+
THCA	cis	rs9420	0.961	rs7936998	ENSG00000254602.1	AP000662.4	-3.42	0.000674	0.039	-0.18	-0.16	Schizophrenia;	chr11:57871545	chr11:57638024~57652790:+
THCA	cis	rs2243480	1	rs1499614	ENSG00000273024.4	INTS4P2	3.42	0.000674	0.039	0.27	0.16	Diabetic kidney disease;	chr7:66265811	chr7:65647864~65715661:+
THCA	cis	rs7615952	0.576	rs17523380	ENSG00000248787.1	RP11-666A20.4	-3.42	0.000674	0.039	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:126084031	chr3:125908005~125910272:-
THCA	cis	rs453301	0.686	rs11785819	ENSG00000233609.3	RP11-62H7.2	-3.42	0.000674	0.039	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9012868	chr8:8961200~8979025:+
THCA	cis	rs8179	0.7	rs42040	ENSG00000230927.2	TMBIM7P	3.42	0.000674	0.039	0.23	0.16	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92616613	chr7:92412976~92439562:-
THCA	cis	rs7395662	1	rs12366208	ENSG00000200090.1	Y_RNA	-3.42	0.000674	0.039	-0.11	-0.16	HDL cholesterol;	chr11:48541576	chr11:47726894~47726992:-
THCA	cis	rs13077017	0.508	rs12494813	ENSG00000272360.1	RP11-359I18.5	-3.42	0.000674	0.039	-0.16	-0.16	Eating disorders (purging via substances);	chr3:58199868	chr3:58490830~58491291:-
THCA	cis	rs3758141	1	rs3758141	ENSG00000278886.1	RP11-108A14.1	-3.42	0.000674	0.039	-0.25	-0.16	Body mass index (change over time) in gastrointestinal cancer;	chr8:18870439	chr8:18864681~18865247:-
THCA	cis	rs7158214	0.511	rs72702902	ENSG00000227051.5	C14orf132	3.42	0.000674	0.039	0.23	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr14:96138651	chr14:96039324~96094080:+
THCA	cis	rs9287719	0.967	rs6432113	ENSG00000243819.4	RN7SL832P	-3.42	0.000674	0.039	-0.12	-0.16	Prostate cancer;	chr2:10604763	chr2:10690344~10692099:+
THCA	cis	rs950776	1	rs950776	ENSG00000261762.1	RP11-650L12.2	3.42	0.000674	0.039	0.21	0.16	Sudden cardiac arrest;	chr15:78633676	chr15:78589123~78591276:-
THCA	cis	rs7173964	1	rs7173964	ENSG00000259251.2	RP11-643M14.1	-3.42	0.000674	0.039	-0.16	-0.16	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62104743	chr15:62060503~62062434:+
THCA	cis	rs11673344	0.526	rs8101610	ENSG00000180458.2	CTD-3064H18.4	3.42	0.000674	0.039	0.21	0.16	Obesity-related traits;	chr19:37566604	chr19:37545470~37549171:-
THCA	cis	rs12101261	0.536	rs724170	ENSG00000258915.1	BHLHB9P1	-3.42	0.000674	0.039	-0.16	-0.16	Graves' disease;	chr14:80991596	chr14:80981988~80983638:+
THCA	cis	rs11030122	0.547	rs12270732	ENSG00000230593.3	AC090804.1	3.42	0.000674	0.039	0.19	0.16	Mean platelet volume;Platelet distribution width;	chr11:3931671	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.547	rs10767720	ENSG00000230593.3	AC090804.1	3.42	0.000674	0.039	0.19	0.16	Mean platelet volume;Platelet distribution width;	chr11:3932067	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.547	rs10767721	ENSG00000230593.3	AC090804.1	3.42	0.000674	0.039	0.19	0.16	Mean platelet volume;Platelet distribution width;	chr11:3932181	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.547	rs10767723	ENSG00000230593.3	AC090804.1	3.42	0.000674	0.039	0.19	0.16	Mean platelet volume;Platelet distribution width;	chr11:3933796	chr11:3892398~3892887:-
THCA	cis	rs17122278	0.929	rs73023341	ENSG00000243431.1	RPL5P30	3.42	0.000674	0.039	0.16	0.16	Total cholesterol levels;	chr11:118574870	chr11:118560690~118561580:+
THCA	cis	rs7818688	1	rs7002940	ENSG00000253528.2	RP11-347C18.4	-3.42	0.000674	0.039	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015164	chr8:94974573~94974853:-
THCA	cis	rs17286411	0.58	rs2432520	ENSG00000260185.1	RP11-432I5.6	3.42	0.000674	0.039	0.21	0.16	Blood protein levels;	chr16:71573481	chr16:71655027~71664212:+
THCA	cis	rs614226	1	rs12310837	ENSG00000278344.1	RP11-18C24.8	3.42	0.000674	0.039	0.21	0.16	Type 1 diabetes nephropathy;	chr12:120442769	chr12:120500735~120501090:-
THCA	cis	rs9549260	0.755	rs2721069	ENSG00000275149.1	RP11-427J23.1	-3.42	0.000674	0.039	-0.21	-0.16	Red blood cell count;	chr13:40569583	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.755	rs1923249	ENSG00000275149.1	RP11-427J23.1	-3.42	0.000674	0.039	-0.21	-0.16	Red blood cell count;	chr13:40569744	chr13:40079106~40273509:-
THCA	cis	rs3824488	0.79	rs28372566	ENSG00000237857.2	RP11-435O5.2	-3.42	0.000674	0.039	-0.26	-0.16	Neuroticism;	chr9:95482696	chr9:95414834~95426796:-
THCA	cis	rs9990333	0.526	rs11719682	ENSG00000207650.1	MIR570	3.42	0.000674	0.039	0.17	0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196107331	chr3:195699401~195699497:+
THCA	cis	rs789859	0.897	rs1675923	ENSG00000223711.1	AC091633.3	-3.42	0.000674	0.039	-0.18	-0.16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr3:194672479	chr3:195544048~195550581:+
THCA	cis	rs7296418	0.58	rs78455769	ENSG00000256092.2	RP13-942N8.1	3.42	0.000674	0.039	0.11	0.16	Platelet count;	chr12:123371896	chr12:123363868~123366113:+
THCA	cis	rs7737355	0.812	rs4705890	ENSG00000224431.1	AC063976.7	3.42	0.000674	0.039	0.14	0.16	Life satisfaction;	chr5:131519307	chr5:132199456~132203487:+
THCA	cis	rs6687821	0.531	rs4623671	ENSG00000261737.1	RP4-612B15.3	3.42	0.000675	0.039	0.24	0.16	Yeast infection;	chr1:87018537	chr1:86703502~86704462:-
THCA	cis	rs7824557	0.564	rs2572399	ENSG00000227888.4	FAM66A	-3.42	0.000675	0.039	-0.2	-0.16	Retinal vascular caliber;	chr8:11377011	chr8:12362019~12388296:+
THCA	cis	rs7246657	1	rs7247672	ENSG00000267422.1	CTD-2554C21.1	-3.42	0.000675	0.039	-0.18	-0.16	Coronary artery calcification;	chr19:37253026	chr19:37779686~37792865:+
THCA	cis	rs7246657	1	rs8110011	ENSG00000267422.1	CTD-2554C21.1	-3.42	0.000675	0.039	-0.18	-0.16	Coronary artery calcification;	chr19:37254911	chr19:37779686~37792865:+
THCA	cis	rs8014204	0.935	rs10141438	ENSG00000279594.1	RP11-950C14.10	-3.42	0.000675	0.039	-0.15	-0.16	Caffeine consumption;	chr14:74887897	chr14:75011269~75012851:-
THCA	cis	rs2832077	0.943	rs4816332	ENSG00000232855.5	AF131217.1	3.42	0.000675	0.039	0.19	0.16	Cognitive test performance;	chr21:28829384	chr21:28439346~28674848:-
THCA	cis	rs2832077	0.824	rs4816333	ENSG00000232855.5	AF131217.1	3.42	0.000675	0.039	0.19	0.16	Cognitive test performance;	chr21:28829455	chr21:28439346~28674848:-
THCA	cis	rs4578769	0.505	rs4405649	ENSG00000273232.1	RP11-370A5.2	3.42	0.000675	0.039	0.21	0.16	Eosinophil percentage of white cells;	chr18:23007590	chr18:22882825~22883357:-
THCA	cis	rs9963862	1	rs9963862	ENSG00000273232.1	RP11-370A5.2	3.42	0.000675	0.039	0.21	0.16	Late-onset myasthenia gravis;	chr18:23007948	chr18:22882825~22883357:-
THCA	cis	rs1538970	0.748	rs11211137	ENSG00000280836.1	AL355480.1	-3.42	0.000675	0.039	-0.22	-0.16	Platelet count;	chr1:45548220	chr1:45581219~45581321:-
THCA	cis	rs181553	0.664	rs948789	ENSG00000266696.1	RP11-30L3.2	-3.42	0.000675	0.039	-0.19	-0.16	Hip circumference adjusted for BMI;	chr18:49174326	chr18:49205912~49208781:+
THCA	cis	rs4664293	0.867	rs13415025	ENSG00000230783.1	AC009961.2	-3.42	0.000675	0.039	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159729799	chr2:159689217~159690291:-
THCA	cis	rs868036	0.56	rs12443086	ENSG00000270964.1	RP11-502I4.3	3.42	0.000675	0.039	0.13	0.16	Restless legs syndrome;	chr15:67788116	chr15:67541072~67542604:-
THCA	cis	rs6030712	0.723	rs1291144	ENSG00000213979.3	RPL7AP14	3.42	0.000675	0.039	0.25	0.16	Height;	chr20:36899487	chr20:37444733~37445534:-
THCA	cis	rs862034	0.902	rs699371	ENSG00000270000.1	RP3-449M8.9	-3.42	0.000675	0.039	-0.17	-0.16	Height;	chr14:74522730	chr14:74471930~74472360:-
THCA	cis	rs7495517	0.686	rs28537379	ENSG00000278840.1	RP11-345N11.1	3.42	0.000675	0.0391	0.18	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:27270793	chr15:26557598~26557937:-
THCA	cis	rs6768930	0.967	rs62259027	ENSG00000272202.1	RP11-157F20.3	3.42	0.000675	0.0391	0.17	0.16	Obesity-related traits;	chr3:57761662	chr3:57078943~57080101:+
THCA	cis	rs6768930	0.967	rs7631516	ENSG00000272202.1	RP11-157F20.3	3.42	0.000675	0.0391	0.17	0.16	Obesity-related traits;	chr3:57764473	chr3:57078943~57080101:+
THCA	cis	rs3198697	0.663	rs12928099	ENSG00000275910.1	RP11-680G24.6	3.42	0.000675	0.0391	0.19	0.16	Triglycerides;	chr16:15056648	chr16:15015828~15016390:-
THCA	cis	rs11239930	0.517	rs2477568	ENSG00000180867.10	PDIA3P1	-3.42	0.000675	0.0391	-0.15	-0.16	AIDS progression;	chr1:147076244	chr1:147178113~147179622:+
THCA	cis	rs17689437	0.813	rs11643064	ENSG00000260084.1	RP11-615I2.1	-3.42	0.000675	0.0391	-0.25	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68616148	chr16:68573782~68589512:-
THCA	cis	rs3809566	0.676	rs4775607	ENSG00000259459.4	RP11-321G12.1	-3.42	0.000675	0.0391	-0.12	-0.16	Platelet count;	chr15:63035808	chr15:63390136~63438320:+
THCA	cis	rs7631605	0.905	rs17204801	ENSG00000272334.1	RP11-129K12.1	3.42	0.000675	0.0391	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37101943	chr3:36973117~36973672:-
THCA	cis	rs17407555	0.657	rs4698001	ENSG00000250413.1	RP11-448G15.1	-3.42	0.000675	0.0391	-0.17	-0.16	Schizophrenia (age at onset);	chr4:10277789	chr4:10006482~10009725:+
THCA	cis	rs17122278	1	rs4326835	ENSG00000243431.1	RPL5P30	3.42	0.000675	0.0391	0.16	0.16	Total cholesterol levels;	chr11:118561689	chr11:118560690~118561580:+
THCA	cis	rs7621331	0.963	rs1113211	ENSG00000239213.4	NCK1-AS1	3.42	0.000675	0.0391	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:135954635	chr3:136841726~136862054:-
THCA	cis	rs11887277	0.507	rs6743539	ENSG00000231636.1	AGBL5-AS1	-3.42	0.000675	0.0391	-0.18	-0.16	Obesity-related traits;	chr2:26833371	chr2:27049683~27050264:-
THCA	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-3.42	0.000675	0.0391	-0.18	-0.16	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
THCA	cis	rs7923837	0.656	rs2497306	ENSG00000236493.2	EIF2S2P3	-3.42	0.000675	0.0391	-0.16	-0.16	Multiple sclerosis;Body mass index;	chr10:92725454	chr10:92668745~92669743:-
THCA	cis	rs2014572	0.967	rs10426174	ENSG00000268379.1	CTC-360J11.4	3.42	0.000675	0.0391	0.18	0.16	Hyperactive-impulsive symptoms;	chr19:57244687	chr19:57175233~57177921:+
THCA	cis	rs2014572	0.967	rs7259978	ENSG00000268379.1	CTC-360J11.4	3.42	0.000675	0.0391	0.18	0.16	Hyperactive-impulsive symptoms;	chr19:57244761	chr19:57175233~57177921:+
THCA	cis	rs2014572	0.87	rs10426580	ENSG00000268379.1	CTC-360J11.4	3.42	0.000675	0.0391	0.18	0.16	Hyperactive-impulsive symptoms;	chr19:57244853	chr19:57175233~57177921:+
THCA	cis	rs2404602	0.591	rs11635162	ENSG00000196274.5	Metazoa_SRP	-3.42	0.000675	0.0391	-0.19	-0.16	Blood metabolite levels;	chr15:76658764	chr15:76230048~76230390:-
THCA	cis	rs7818688	0.932	rs6471505	ENSG00000253528.2	RP11-347C18.4	-3.42	0.000675	0.0391	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016397	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.932	rs6471506	ENSG00000253528.2	RP11-347C18.4	-3.42	0.000675	0.0391	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016472	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.858	rs7826196	ENSG00000253528.2	RP11-347C18.4	-3.42	0.000675	0.0391	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016774	chr8:94974573~94974853:-
THCA	cis	rs1799949	1	rs12944458	ENSG00000236383.6	LINC00854	-3.42	0.000676	0.0391	-0.15	-0.16	Menopause (age at onset);	chr17:43028755	chr17:43216941~43305976:-
THCA	cis	rs1881396	0.531	rs76586169	ENSG00000223522.1	AC093690.1	-3.42	0.000676	0.0391	-0.22	-0.16	Nonalcoholic fatty liver disease;	chr2:27674968	chr2:28307691~28310459:-
THCA	cis	rs9303542	0.659	rs7214269	ENSG00000278765.1	RP5-890E16.5	-3.42	0.000676	0.0391	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48438121	chr17:48066704~48067293:-
THCA	cis	rs10911902	0.643	rs34585917	ENSG00000233196.2	GS1-304P7.1	-3.42	0.000676	0.0391	-0.24	-0.16	Schizophrenia;	chr1:186317650	chr1:186580515~186581191:-
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000264242.2	RP11-271K11.1	3.42	0.000676	0.0391	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30553697~30558962:+
THCA	cis	rs4959799	0.655	rs6934279	ENSG00000272248.1	RP3-406P24.4	-3.42	0.000676	0.0391	-0.36	-0.16	Survival in rectal cancer;	chr6:3276456	chr6:4018713~4019202:+
THCA	cis	rs4648045	0.594	rs62327180	ENSG00000230069.3	LRRC37A15P	-3.42	0.000676	0.0391	-0.17	-0.16	Lymphocyte percentage of white cells;	chr4:102619605	chr4:102727274~102730721:-
THCA	cis	rs2549003	1	rs2549009	ENSG00000233006.5	AC034220.3	3.42	0.000676	0.0391	0.12	0.16	Asthma (sex interaction);	chr5:132491073	chr5:132311285~132369916:-
THCA	cis	rs7208859	0.623	rs122898	ENSG00000264242.2	RP11-271K11.1	-3.42	0.000676	0.0391	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30553697~30558962:+
THCA	cis	rs2221894	0.616	rs10112345	ENSG00000251191.6	LINC00589	-3.42	0.000676	0.0391	-0.18	-0.16	Obesity-related traits;	chr8:29107153	chr8:29673922~29748109:-
THCA	cis	rs1363605	0.541	rs442253	ENSG00000253955.1	CTB-33O18.3	3.42	0.000676	0.0391	0.22	0.16	Alcohol dependence symptom count;	chr5:173591369	chr5:173579643~173585068:+
THCA	cis	rs9650657	0.529	rs6601521	ENSG00000255310.2	AF131215.2	-3.42	0.000676	0.0391	-0.13	-0.16	Neuroticism;	chr8:10771437	chr8:11107788~11109726:-
THCA	cis	rs7615952	0.599	rs12486459	ENSG00000248787.1	RP11-666A20.4	-3.42	0.000676	0.0391	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126022622	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.599	rs67575510	ENSG00000248787.1	RP11-666A20.4	-3.42	0.000676	0.0391	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126023512	chr3:125908005~125910272:-
THCA	cis	rs2562456	0.917	rs2681389	ENSG00000268658.4	LINC00664	-3.42	0.000676	0.0391	-0.23	-0.16	Pain;	chr19:21509773	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.917	rs6511256	ENSG00000268658.4	LINC00664	-3.42	0.000676	0.0391	-0.23	-0.16	Pain;	chr19:21510513	chr19:21483374~21503238:+
THCA	cis	rs6878727	0.813	rs10063748	ENSG00000253807.4	LINC01170	-3.42	0.000676	0.0391	-0.15	-0.16	Breast cancer;	chr5:124368441	chr5:124059794~124405079:-
THCA	cis	rs6832769	0.961	rs11947623	ENSG00000223305.1	RN7SKP30	3.42	0.000676	0.0391	0.2	0.16	Personality dimensions;	chr4:55483023	chr4:55540502~55540835:-
THCA	cis	rs708224	0.625	rs2261339	ENSG00000277342.1	RP11-843B15.4	3.42	0.000676	0.0391	0.21	0.16	Pancreatic cancer;	chr12:32295462	chr12:32109076~32109602:+
THCA	cis	rs763121	0.853	rs4821798	ENSG00000225450.1	RP3-508I15.14	-3.42	0.000676	0.0391	-0.12	-0.16	Menopause (age at onset);	chr22:38625160	chr22:38739003~38749041:+
THCA	cis	rs7916441	1	rs1769756	ENSG00000230091.5	TMEM254-AS1	3.42	0.000676	0.0391	0.2	0.16	Height;Sitting height ratio;	chr10:79164647	chr10:80046860~80078912:-
THCA	cis	rs7727544	0.548	rs2069614	ENSG00000263597.1	MIR3936	3.42	0.000676	0.0391	0.15	0.16	Blood metabolite levels;	chr5:132071908	chr5:132365490~132365599:-
THCA	cis	rs7727544	0.548	rs2069616	ENSG00000263597.1	MIR3936	3.42	0.000676	0.0391	0.15	0.16	Blood metabolite levels;	chr5:132072384	chr5:132365490~132365599:-
THCA	cis	rs3750082	1	rs3750082	ENSG00000205763.12	RP9P	3.42	0.000676	0.0391	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32880315	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.926	rs11762628	ENSG00000205763.12	RP9P	3.42	0.000676	0.0391	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32886959	chr7:32916815~32943176:-
THCA	cis	rs6890684	0.544	rs194369	ENSG00000251279.1	CTC-436P18.1	-3.42	0.000676	0.0391	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61203358	chr5:61162070~61232040:+
THCA	cis	rs185694	1	rs595449	ENSG00000279149.1	RP11-374F3.5	3.42	0.000676	0.0391	0.22	0.16	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:30322715	chr13:30344672~30347167:+
THCA	cis	rs9309473	0.632	rs11885217	ENSG00000273245.1	RP11-434P11.2	3.42	0.000676	0.0391	0.19	0.16	Metabolite levels;	chr2:73326080	chr2:73750256~73750786:-
THCA	cis	rs1154275	0.563	rs9859168	ENSG00000272844.1	RP11-484K9.4	3.42	0.000676	0.0391	0.13	0.16	Takotsubo syndrome;	chr3:112797059	chr3:112990447~112991153:-
THCA	cis	rs7631605	0.935	rs9831084	ENSG00000272334.1	RP11-129K12.1	-3.42	0.000676	0.0391	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:36984170	chr3:36973117~36973672:-
THCA	cis	rs4730276	0.674	rs3801934	ENSG00000250474.1	WBP1LP2	-3.42	0.000676	0.0391	-0.14	-0.16	Ulcerative colitis;	chr7:107899629	chr7:107628553~107629498:+
THCA	cis	rs4730276	0.674	rs7779923	ENSG00000250474.1	WBP1LP2	-3.42	0.000676	0.0391	-0.14	-0.16	Ulcerative colitis;	chr7:107899799	chr7:107628553~107629498:+
THCA	cis	rs836788	0.633	rs35548549	ENSG00000251221.1	LINC01337	3.42	0.000677	0.0391	0.16	0.16	Glomerular filtration rate (creatinine);	chr5:80686115	chr5:80608623~80622524:-
THCA	cis	rs6723226	0.804	rs17428810	ENSG00000276517.1	AL133243.2	3.42	0.000677	0.0391	0.16	0.16	Intelligence (multi-trait analysis);	chr2:32510976	chr2:32526504~32529507:+
THCA	cis	rs867186	0.841	rs56400038	ENSG00000126005.14	MMP24-AS1	-3.42	0.000677	0.0391	-0.26	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34949868	chr20:35216462~35278131:-
THCA	cis	rs4262150	0.81	rs4473761	ENSG00000253921.1	CTB-113P19.3	3.42	0.000677	0.0391	0.21	0.16	Bipolar disorder and schizophrenia;	chr5:152593947	chr5:151753992~151767247:+
THCA	cis	rs2243480	1	rs466983	ENSG00000237310.1	GS1-124K5.4	3.42	0.000677	0.0391	0.18	0.16	Diabetic kidney disease;	chr7:66055509	chr7:66493706~66495474:+
THCA	cis	rs6479901	0.895	rs1579045	ENSG00000272767.1	JMJD1C-AS1	-3.42	0.000677	0.0391	-0.19	-0.16	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63465229~63466563:+
THCA	cis	rs6479901	0.895	rs7920159	ENSG00000272767.1	JMJD1C-AS1	-3.42	0.000677	0.0391	-0.19	-0.16	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63465229~63466563:+
THCA	cis	rs6479901	0.841	rs10822148	ENSG00000272767.1	JMJD1C-AS1	-3.42	0.000677	0.0391	-0.19	-0.16	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63465229~63466563:+
THCA	cis	rs6479901	0.895	rs10761728	ENSG00000272767.1	JMJD1C-AS1	-3.42	0.000677	0.0391	-0.19	-0.16	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63465229~63466563:+
THCA	cis	rs3739034	0.938	rs4954168	ENSG00000224043.6	CCNT2-AS1	-3.42	0.000677	0.0391	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134707503	chr2:134735464~134918710:-
THCA	cis	rs9868809	0.772	rs13070798	ENSG00000271973.1	RP11-572O6.1	3.42	0.000677	0.0391	0.26	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48668501	chr3:48672455~48672733:+
THCA	cis	rs12744310	0.83	rs12028010	ENSG00000235358.1	RP11-399E6.1	3.42	0.000677	0.0391	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298799	chr1:41242373~41284861:+
THCA	cis	rs62158800	0.598	rs11123670	ENSG00000225588.2	AC096669.1	3.42	0.000677	0.0391	0.15	0.16	Facial morphology (factor 22);	chr2:107674278	chr2:107362282~107407329:+
THCA	cis	rs6691738	0.836	rs10158467	ENSG00000227373.4	RP11-160H22.5	3.42	0.000677	0.0391	0.22	0.16	Asthma;	chr1:173162354	chr1:174115300~174160004:-
THCA	cis	rs1065852	0.526	rs12166549	ENSG00000232710.1	RP4-669P10.16	-3.42	0.000677	0.0391	-0.2	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014415	chr22:42136433~42139927:-
THCA	cis	rs1065852	0.526	rs9611711	ENSG00000232710.1	RP4-669P10.16	-3.42	0.000677	0.0391	-0.2	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014691	chr22:42136433~42139927:-
THCA	cis	rs9450351	0.744	rs9362247	ENSG00000280232.1	RP11-321N4.4	3.42	0.000677	0.0391	0.33	0.16	Interferon gamma-induced protein 10 levels;	chr6:85822546	chr6:85498441~85499058:-
THCA	cis	rs1832871	0.711	rs7747669	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000677	0.0391	-0.24	-0.16	Height;	chr6:158243313	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.683	rs9457224	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000677	0.0391	-0.24	-0.16	Height;	chr6:158245107	chr6:157365990~157366923:-
THCA	cis	rs3809566	0.632	rs9806533	ENSG00000259459.4	RP11-321G12.1	-3.42	0.000677	0.0391	-0.13	-0.16	Platelet count;	chr15:63036099	chr15:63390136~63438320:+
THCA	cis	rs9872440	1	rs9872440	ENSG00000273328.4	RP11-141M3.6	-3.42	0.000677	0.0391	-0.19	-0.16	Granulocyte count;Myeloid white cell count;	chr3:42854959	chr3:42809414~42908105:+
THCA	cis	rs7621331	0.963	rs9846137	ENSG00000239213.4	NCK1-AS1	3.42	0.000677	0.0391	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:135956090	chr3:136841726~136862054:-
THCA	cis	rs1729951	0.575	rs361239	ENSG00000239213.4	NCK1-AS1	3.42	0.000677	0.0392	0.13	0.16	Neuroticism;	chr3:136982453	chr3:136841726~136862054:-
THCA	cis	rs3087591	0.659	rs2525570	ENSG00000263535.1	AK4P1	3.42	0.000677	0.0392	0.19	0.16	Hip circumference;	chr17:31354227	chr17:31345521~31346187:+
THCA	cis	rs564148	1	rs612279	ENSG00000239670.1	RP4-803A2.2	-3.42	0.000677	0.0392	-0.27	-0.16	Response to amphetamines;	chr1:33708373	chr1:32986952~32988233:+
THCA	cis	rs2274089	0.737	rs7747371	ENSG00000272810.1	U91328.22	-3.42	0.000677	0.0392	-0.24	-0.16	Iron status biomarkers;	chr6:25602874	chr6:26013241~26013757:+
THCA	cis	rs722599	0.562	rs2193597	ENSG00000177776.8	RPS2P2	-3.42	0.000677	0.0392	-0.18	-0.16	IgG glycosylation;	chr14:74767626	chr14:74377818~74378418:-
THCA	cis	rs4713118	0.513	rs149972	ENSG00000176933.5	TOB2P1	-3.42	0.000677	0.0392	-0.19	-0.16	Parkinson's disease;	chr6:28015449	chr6:28217643~28218634:-
THCA	cis	rs944289	0.531	rs1169149	ENSG00000188831.4	DPPA3P2	3.42	0.000677	0.0392	0.21	0.16	Thyroid cancer;	chr14:36165019	chr14:36371165~36372383:+
THCA	cis	rs2235649	0.798	rs4100646	ENSG00000260022.1	LA16c-306A4.1	3.42	0.000677	0.0392	0.22	0.16	Blood metabolite levels;	chr16:1800445	chr16:883780~885090:+
THCA	cis	rs9796	0.662	rs8033435	ENSG00000247556.5	OIP5-AS1	3.42	0.000677	0.0392	0.13	0.16	Menopause (age at onset);	chr15:41144281	chr15:41283990~41309737:+
THCA	cis	rs1050631	0.96	rs3826602	ENSG00000260552.1	RP11-49I11.1	-3.42	0.000677	0.0392	-0.19	-0.16	Esophageal squamous cell cancer (length of survival);	chr18:36108400	chr18:36179996~36187448:-
THCA	cis	rs9400467	0.537	rs1150081	ENSG00000255389.1	C6orf3	3.42	0.000677	0.0392	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111157813	chr6:111599875~111602295:+
THCA	cis	rs2292873	1	rs76216798	ENSG00000234949.2	AC104667.3	-3.42	0.000677	0.0392	-0.24	-0.16	Obesity-related traits;	chr2:237589172	chr2:237591020~237595981:+
THCA	cis	rs2292873	1	rs6760287	ENSG00000234949.2	AC104667.3	-3.42	0.000677	0.0392	-0.24	-0.16	Obesity-related traits;	chr2:237590353	chr2:237591020~237595981:+
THCA	cis	rs73191547	0.931	rs6601419	ENSG00000255310.2	AF131215.2	3.42	0.000677	0.0392	0.13	0.16	Schizophrenia;	chr8:10174238	chr8:11107788~11109726:-
THCA	cis	rs35740288	0.929	rs3858927	ENSG00000259407.1	RP11-158M2.3	-3.42	0.000677	0.0392	-0.19	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85758385	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.895	rs3743332	ENSG00000259407.1	RP11-158M2.3	-3.42	0.000677	0.0392	-0.19	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85760520	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.929	rs11635081	ENSG00000259407.1	RP11-158M2.3	-3.42	0.000677	0.0392	-0.19	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85761029	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.685	rs12899481	ENSG00000259407.1	RP11-158M2.3	-3.42	0.000677	0.0392	-0.19	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85765739	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.929	rs1978391	ENSG00000259407.1	RP11-158M2.3	3.42	0.000677	0.0392	0.19	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85768464	chr15:85744109~85750281:-
THCA	cis	rs7572644	0.553	rs4233717	ENSG00000223522.1	AC093690.1	-3.42	0.000677	0.0392	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27811813	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.656	rs4666016	ENSG00000223522.1	AC093690.1	-3.42	0.000677	0.0392	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27814273	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.621	rs4464229	ENSG00000223522.1	AC093690.1	-3.42	0.000677	0.0392	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27815213	chr2:28307691~28310459:-
THCA	cis	rs1612141	1	rs1782164	ENSG00000251363.2	RP11-129M6.1	-3.42	0.000678	0.0392	-0.23	-0.16	QT interval (drug interaction);	chr14:41298721	chr14:40954898~40975877:+
THCA	cis	rs6545883	0.507	rs34668697	ENSG00000273302.1	RP11-493E12.2	-3.42	0.000678	0.0392	-0.14	-0.16	Tuberculosis;	chr2:61341214	chr2:61199979~61200769:+
THCA	cis	rs9596837	0.62	rs9563168	ENSG00000136149.6	RPL13AP25	-3.42	0.000678	0.0392	-0.16	-0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53673692	chr13:54440704~54441315:-
THCA	cis	rs10495907	0.591	rs10199649	ENSG00000234936.1	AC010883.5	3.42	0.000678	0.0392	0.15	0.16	Coronary artery disease;	chr2:43727653	chr2:43229573~43233394:+
THCA	cis	rs7914558	0.966	rs10883805	ENSG00000272912.1	RP11-724N1.1	-3.42	0.000678	0.0392	-0.18	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102948494	chr10:102914585~102915404:+
THCA	cis	rs2243480	0.901	rs2900904	ENSG00000213640.3	EEF1DP4	3.42	0.000678	0.0392	0.29	0.16	Diabetic kidney disease;	chr7:65739282	chr7:64862999~64864370:+
THCA	cis	rs2243480	1	rs6460260	ENSG00000213640.3	EEF1DP4	-3.42	0.000678	0.0392	-0.29	-0.16	Diabetic kidney disease;	chr7:65750468	chr7:64862999~64864370:+
THCA	cis	rs2243480	1	rs6460261	ENSG00000213640.3	EEF1DP4	-3.42	0.000678	0.0392	-0.29	-0.16	Diabetic kidney disease;	chr7:65750593	chr7:64862999~64864370:+
THCA	cis	rs2436845	0.934	rs892485	ENSG00000253320.4	KB-1507C5.2	-3.42	0.000678	0.0392	-0.13	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102862394	chr8:102864300~102977876:+
THCA	cis	rs620729	0.606	rs6926422	ENSG00000215124.2	RP3-420J14.1	3.42	0.000678	0.0392	0.17	0.16	Intelligence (multi-trait analysis);	chr6:11476385	chr6:11861626~11862970:-
THCA	cis	rs7264396	0.635	rs6088971	ENSG00000088340.14	FER1L4	3.42	0.000678	0.0392	0.15	0.16	Total cholesterol levels;	chr20:35947451	chr20:35558737~35607562:-
THCA	cis	rs9595908	0.785	rs4120131	ENSG00000281026.1	N4BP2L2-IT2	3.42	0.000678	0.0392	0.1	0.16	Body mass index;	chr13:32702949	chr13:32504506~32509395:-
THCA	cis	rs3750082	0.852	rs10260000	ENSG00000205763.12	RP9P	3.42	0.000678	0.0392	0.14	0.16	Glomerular filtration rate (creatinine);	chr7:32858622	chr7:32916815~32943176:-
THCA	cis	rs938554	0.744	rs13129697	ENSG00000261490.1	RP11-448G15.3	-3.42	0.000678	0.0392	-0.11	-0.16	Blood metabolite levels;	chr4:9925343	chr4:10068089~10073019:-
THCA	cis	rs3764400	0.507	rs56161855	ENSG00000233101.9	HOXB-AS3	-3.42	0.000678	0.0392	-0.3	-0.16	Body mass index;	chr17:48211287	chr17:48549630~48606414:+
THCA	cis	rs10875746	0.768	rs4760676	ENSG00000258234.1	RP11-370I10.2	3.42	0.000678	0.0392	0.18	0.16	Longevity (90 years and older);	chr12:48027880	chr12:48231098~48284210:-
THCA	cis	rs7737355	0.773	rs3756290	ENSG00000224431.1	AC063976.7	3.42	0.000678	0.0392	0.14	0.16	Life satisfaction;	chr5:131616057	chr5:132199456~132203487:+
THCA	cis	rs3026101	0.671	rs1143206	ENSG00000234327.6	AC012146.7	-3.42	0.000678	0.0392	-0.13	-0.16	Body mass index;	chr17:5381403	chr17:5111468~5115004:+
THCA	cis	rs3026101	0.671	rs1065482	ENSG00000234327.6	AC012146.7	-3.42	0.000678	0.0392	-0.13	-0.16	Body mass index;	chr17:5381424	chr17:5111468~5115004:+
THCA	cis	rs1065852	0.526	rs9611700	ENSG00000281538.1	RP4-669P10.20	-3.42	0.000678	0.0392	-0.16	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42005510	chr22:42138060~42139726:+
THCA	cis	rs1065852	0.526	rs2413663	ENSG00000281538.1	RP4-669P10.20	-3.42	0.000678	0.0392	-0.16	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42006395	chr22:42138060~42139726:+
THCA	cis	rs9650657	0.836	rs2898252	ENSG00000269918.1	AF131215.9	-3.42	0.000678	0.0392	-0.16	-0.16	Neuroticism;	chr8:10746654	chr8:11104691~11106704:-
THCA	cis	rs13102973	0.64	rs11737779	ENSG00000250144.1	RP11-553P9.1	-3.42	0.000678	0.0392	-0.11	-0.16	Subjective well-being;	chr4:134910361	chr4:135045464~135046850:+
THCA	cis	rs4664304	1	rs57771571	ENSG00000226266.5	AC009961.3	3.42	0.000678	0.0392	0.19	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159911293	chr2:159670708~159712435:-
THCA	cis	rs9296092	0.538	rs62407567	ENSG00000274259.2	XXbac-BPG294E21.9	3.42	0.000678	0.0392	0.21	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33569436	chr6:33437363~33454453:-
THCA	cis	rs11771526	0.748	rs4723142	ENSG00000272905.1	RP11-265E18.1	3.42	0.000679	0.0392	0.19	0.16	Body mass index;	chr7:32297957	chr7:32845394~32846061:+
THCA	cis	rs7179228	0.885	rs5016065	ENSG00000260657.2	RP11-315D16.4	-3.42	0.000679	0.0392	-0.21	-0.16	Systolic blood pressure;	chr15:68323084	chr15:68267792~68277994:-
THCA	cis	rs7737355	0.773	rs1019122	ENSG00000237714.1	P4HA2-AS1	3.42	0.000679	0.0392	0.21	0.16	Life satisfaction;	chr5:131763534	chr5:132184876~132192808:+
THCA	cis	rs6545883	0.507	rs2442025	ENSG00000273302.1	RP11-493E12.2	-3.42	0.000679	0.0392	-0.14	-0.16	Tuberculosis;	chr2:61344310	chr2:61199979~61200769:+
THCA	cis	rs6545883	0.524	rs2593631	ENSG00000273302.1	RP11-493E12.2	-3.42	0.000679	0.0392	-0.14	-0.16	Tuberculosis;	chr2:61345151	chr2:61199979~61200769:+
THCA	cis	rs6545883	0.542	rs2593628	ENSG00000273302.1	RP11-493E12.2	-3.42	0.000679	0.0392	-0.14	-0.16	Tuberculosis;	chr2:61346152	chr2:61199979~61200769:+
THCA	cis	rs2483374	1	rs7331734	ENSG00000253771.4	TPTE2P1	3.42	0.000679	0.0392	0.14	0.16	Obesity-related traits;	chr13:24957117	chr13:24924677~24968487:-
THCA	cis	rs6598955	0.694	rs6659387	ENSG00000236782.4	RP11-96L14.7	-3.42	0.000679	0.0392	-0.19	-0.16	Obesity-related traits;	chr1:26307816	chr1:26169947~26171821:-
THCA	cis	rs6921919	0.583	rs6928771	ENSG00000220721.1	OR1F12	3.42	0.000679	0.0392	0.17	0.16	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28073316~28074233:+
THCA	cis	rs28489187	0.706	rs233108	ENSG00000223653.4	RP11-131L23.1	3.42	0.000679	0.0392	0.18	0.16	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85316037	chr1:85276715~85448124:+
THCA	cis	rs12780845	0.929	rs35932553	ENSG00000273153.1	RP11-406H21.2	3.42	0.000679	0.0392	0.15	0.16	Homocysteine levels;	chr10:17171316	chr10:17137336~17137585:-
THCA	cis	rs6687821	0.515	rs7531296	ENSG00000261737.1	RP4-612B15.3	3.42	0.000679	0.0392	0.23	0.16	Yeast infection;	chr1:87005691	chr1:86703502~86704462:-
THCA	cis	rs34102591	0.577	rs3762102	ENSG00000270028.1	RP11-380L11.4	3.42	0.000679	0.0392	0.21	0.16	Schizophrenia;	chr12:123962861	chr12:123925461~123926083:-
THCA	cis	rs720475	0.732	rs7784282	ENSG00000170356.8	OR2A20P	3.42	0.000679	0.0392	0.22	0.16	Breast cancer;	chr7:144431561	chr7:144250045~144252957:-
THCA	cis	rs7656342	0.665	rs10939600	ENSG00000250342.1	SNRPCP16	3.42	0.000679	0.0392	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9885307	chr4:9051842~9052051:-
THCA	cis	rs2749592	0.918	rs11011388	ENSG00000226578.1	RP11-258F22.1	3.42	0.000679	0.0393	0.2	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37866282	chr10:37775371~37784131:-
THCA	cis	rs9307551	0.894	rs6812760	ENSG00000249646.2	OR7E94P	-3.42	0.000679	0.0393	-0.22	-0.16	Refractive error;	chr4:79560702	chr4:79587302~79588130:-
THCA	cis	rs9611565	0.559	rs8139993	ENSG00000237037.8	NDUFA6-AS1	3.42	0.000679	0.0393	0.14	0.16	Vitiligo;	chr22:41599331	chr22:42090931~42137742:+
THCA	cis	rs17428076	0.681	rs62182401	ENSG00000228389.1	AC068039.4	-3.42	0.000679	0.0393	-0.21	-0.16	Myopia;	chr2:171876838	chr2:171773482~171775844:+
THCA	cis	rs465969	0.744	rs574056	ENSG00000230177.1	RP5-1112D6.4	3.42	0.000679	0.0393	0.26	0.16	Psoriasis;	chr6:111305787	chr6:111277932~111278742:+
THCA	cis	rs2997447	0.761	rs2783639	ENSG00000236155.5	RP11-231P20.2	3.42	0.000679	0.0393	0.12	0.16	QRS complex (12-leadsum);	chr1:26102946	chr1:26209741~26229840:+
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000184274.3	LINC00315	-3.42	0.000679	0.0393	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45300245~45305257:-
THCA	cis	rs2864527	0.522	rs72939227	ENSG00000264964.1	RP11-888D10.3	3.42	0.000679	0.0393	0.35	0.16	Dental caries;	chr18:9249119	chr18:9315194~9334441:-
THCA	cis	rs7122539	0.722	rs2380759	ENSG00000275484.1	CTC-1337H24.4	-3.42	0.000679	0.0393	-0.13	-0.16	HIV-1 susceptibility;	chr11:66879959	chr11:67374416~67374932:+
THCA	cis	rs7122539	0.722	rs2380760	ENSG00000275484.1	CTC-1337H24.4	-3.42	0.000679	0.0393	-0.13	-0.16	HIV-1 susceptibility;	chr11:66879960	chr11:67374416~67374932:+
THCA	cis	rs12612619	0.627	rs13391244	ENSG00000231636.1	AGBL5-AS1	-3.42	0.000679	0.0393	-0.2	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27064741	chr2:27049683~27050264:-
THCA	cis	rs6416877	1	rs6416877	ENSG00000277491.1	RP11-676J12.9	-3.42	0.000679	0.0393	-0.19	-0.16	Myeloid white cell count;	chr17:1463828	chr17:795306~795794:+
THCA	cis	rs9828933	0.938	rs9809432	ENSG00000271843.1	RP11-245J9.5	3.42	0.000679	0.0393	0.24	0.16	Type 2 diabetes;	chr3:64017277	chr3:64008082~64008692:-
THCA	cis	rs1050631	1	rs1107840	ENSG00000260552.1	RP11-49I11.1	3.42	0.000679	0.0393	0.19	0.16	Esophageal squamous cell cancer (length of survival);	chr18:36127201	chr18:36179996~36187448:-
THCA	cis	rs11105298	0.891	rs10858864	ENSG00000266347.2	AC068641.1	3.42	0.000679	0.0393	0.2	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs10858865	ENSG00000266347.2	AC068641.1	3.42	0.000679	0.0393	0.2	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89592833~89592927:+
THCA	cis	rs867186	1	rs75165171	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35063650	chr20:35262727~35264187:-
THCA	cis	rs867186	1	rs117573845	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35063818	chr20:35262727~35264187:-
THCA	cis	rs867186	1	rs717593	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35065161	chr20:35262727~35264187:-
THCA	cis	rs867186	1	rs79439610	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35066886	chr20:35262727~35264187:-
THCA	cis	rs867186	1	rs76363448	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35067732	chr20:35262727~35264187:-
THCA	cis	rs867186	1	rs74543591	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35070855	chr20:35262727~35264187:-
THCA	cis	rs867186	0.92	rs78704804	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35078028	chr20:35262727~35264187:-
THCA	cis	rs867186	1	rs76850134	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35083922	chr20:35262727~35264187:-
THCA	cis	rs867186	0.764	rs55993524	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000679	0.0393	-0.25	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35086201	chr20:35262727~35264187:-
THCA	cis	rs6840360	0.571	rs4696099	ENSG00000251611.1	RP11-610P16.1	-3.42	0.000679	0.0393	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151580799	chr4:151407551~151408835:-
THCA	cis	rs620729	0.874	rs606402	ENSG00000272097.1	RP11-421M1.8	3.42	0.000679	0.0393	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11507585	chr6:10743324~10747663:-
THCA	cis	rs12612619	0.732	rs6547401	ENSG00000231636.1	AGBL5-AS1	3.42	0.000679	0.0393	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27061977	chr2:27049683~27050264:-
THCA	cis	rs806215	0.547	rs3757759	ENSG00000224138.1	AC000123.4	-3.42	0.00068	0.0393	-0.16	-0.16	Type 2 diabetes;	chr7:128054762	chr7:127350128~127351523:+
THCA	cis	rs9427116	0.502	rs3766922	ENSG00000236675.1	MTX1P1	-3.42	0.00068	0.0393	-0.14	-0.16	Blood protein levels;	chr1:154604579	chr1:155230975~155234325:+
THCA	cis	rs12724450	0.793	rs11799813	ENSG00000228126.1	FALEC	3.42	0.00068	0.0393	0.3	0.16	Blood protein levels;	chr1:150363264	chr1:150515757~150518032:+
THCA	cis	rs9536318	0.673	rs1323113	ENSG00000273784.3	RP11-78J21.7	-3.42	0.00068	0.0393	-0.21	-0.16	Airflow obstruction;	chr13:52935340	chr13:52600042~52642542:+
THCA	cis	rs11168618	1	rs11168637	ENSG00000258273.1	RP11-370I10.4	-3.42	0.00068	0.0393	-0.2	-0.16	Adiponectin levels;	chr12:48559721	chr12:48333755~48333901:-
THCA	cis	rs7308116	0.967	rs7303096	ENSG00000257951.1	RP11-554D14.4	3.42	0.00068	0.0393	0.18	0.16	Pelvic organ prolapse (moderate/severe);	chr12:107805253	chr12:107881242~107883382:+
THCA	cis	rs7308116	0.967	rs10861791	ENSG00000257951.1	RP11-554D14.4	3.42	0.00068	0.0393	0.18	0.16	Pelvic organ prolapse (moderate/severe);	chr12:107798689	chr12:107881242~107883382:+
THCA	cis	rs1124769	0.778	rs2614787	ENSG00000244879.4	GABPB1-AS1	3.42	0.00068	0.0393	0.17	0.16	Cognitive performance;	chr15:50908021	chr15:50354959~50372202:+
THCA	cis	rs1124769	0.871	rs2614793	ENSG00000244879.4	GABPB1-AS1	3.42	0.00068	0.0393	0.17	0.16	Cognitive performance;	chr15:50917477	chr15:50354959~50372202:+
THCA	cis	rs7264396	0.79	rs3746410	ENSG00000088340.14	FER1L4	3.42	0.00068	0.0393	0.15	0.16	Total cholesterol levels;	chr20:35602948	chr20:35558737~35607562:-
THCA	cis	rs875971	0.545	rs1796217	ENSG00000230295.1	RP11-458F8.2	-3.42	0.00068	0.0393	-0.14	-0.16	Aortic root size;	chr7:66620931	chr7:66880708~66882981:+
THCA	cis	rs1383484	0.575	rs8028946	ENSG00000259728.4	LINC00933	-3.42	0.00068	0.0393	-0.19	-0.16	Height;	chr15:83948325	chr15:84570649~84580175:+
THCA	cis	rs6929812	0.702	rs4713101	ENSG00000216915.2	RP1-97D16.1	3.42	0.00068	0.0393	0.2	0.16	Neuroticism (multi-trait analysis);	chr6:27440019	chr6:27737000~27738494:-
THCA	cis	rs9488822	0.676	rs12196579	ENSG00000237021.2	RP3-486I3.7	3.42	0.00068	0.0393	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116030561	chr6:116254207~116256743:+
THCA	cis	rs9863	0.828	rs12303933	ENSG00000269938.1	RP11-214K3.20	-3.42	0.00068	0.0393	-0.18	-0.16	White blood cell count;	chr12:123997709	chr12:123968023~123968579:-
THCA	cis	rs786425	0.502	rs9787987	ENSG00000270095.1	RP11-214K3.18	3.42	0.00068	0.0393	0.19	0.16	Pubertal anthropometrics;	chr12:123722665	chr12:123971457~123971714:-
THCA	cis	rs4578769	0.765	rs998184	ENSG00000265939.1	UBE2CP2	-3.42	0.00068	0.0393	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22925006	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.765	rs4800440	ENSG00000265939.1	UBE2CP2	-3.42	0.00068	0.0393	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22928158	chr18:22900486~22900995:-
THCA	cis	rs4948275	0.631	rs2650743	ENSG00000233643.2	RP11-491H19.1	3.42	0.00068	0.0393	0.18	0.16	Night sleep phenotypes;	chr10:61590160	chr10:61781745~61821246:-
THCA	cis	rs61160187	0.51	rs10072745	ENSG00000215032.2	GNL3LP1	3.42	0.00068	0.0393	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60787448	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.527	rs6449500	ENSG00000215032.2	GNL3LP1	3.42	0.00068	0.0393	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60788076	chr5:60891935~60893577:-
THCA	cis	rs860295	1	rs822527	ENSG00000236675.1	MTX1P1	3.42	0.00068	0.0393	0.15	0.16	Body mass index;	chr1:155768262	chr1:155230975~155234325:+
THCA	cis	rs1979679	0.578	rs2127316	ENSG00000247934.4	RP11-967K21.1	-3.42	0.00068	0.0393	-0.15	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28121472	chr12:28163298~28190738:-
THCA	cis	rs2243480	1	rs1964692	ENSG00000237310.1	GS1-124K5.4	3.42	0.00068	0.0393	0.18	0.16	Diabetic kidney disease;	chr7:65989196	chr7:66493706~66495474:+
THCA	cis	rs2625529	0.761	rs972029	ENSG00000260037.4	CTD-2524L6.3	-3.42	0.00068	0.0393	-0.22	-0.16	Red blood cell count;	chr15:71880645	chr15:71818396~71823384:+
THCA	cis	rs453301	0.719	rs34004903	ENSG00000253981.4	ALG1L13P	-3.42	0.00068	0.0393	-0.15	-0.16	Joint mobility (Beighton score);	chr8:9035094	chr8:8236003~8244667:-
THCA	cis	rs2574985	0.606	rs1810576	ENSG00000279863.1	RP11-521C22.2	3.42	0.00068	0.0393	0.19	0.16	Subjective well-being;	chr10:50460660	chr10:50334538~50336123:+
THCA	cis	rs1536827	0.688	rs2031922	ENSG00000278518.1	RP11-108K14.12	-3.42	0.00068	0.0393	-0.36	-0.16	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr10:133526589	chr10:133526259~133527513:-
THCA	cis	rs6988985	0.589	rs57219141	ENSG00000253741.1	CTD-2292P10.4	-3.42	0.00068	0.0393	-0.2	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142906203	chr8:142702252~142726973:-
THCA	cis	rs9863	0.896	rs34854841	ENSG00000269938.1	RP11-214K3.20	-3.42	0.00068	0.0393	-0.18	-0.16	White blood cell count;	chr12:123966957	chr12:123968023~123968579:-
THCA	cis	rs7127129	0.842	rs10898832	ENSG00000246889.2	AP000487.5	-3.42	0.00068	0.0393	-0.16	-0.16	Aortic root size;	chr11:70186466	chr11:70372246~70398488:-
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000261839.1	RP1-265C24.8	3.42	0.00068	0.0393	0.15	0.16	Pubertal anthropometrics;	chr6:28128502	chr6:28136849~28139678:+
THCA	cis	rs4841134	0.902	rs6999153	ENSG00000254153.1	CTA-398F10.2	3.42	0.00068	0.0393	0.16	0.16	Age-related disease endophenotypes;	chr8:9335991	chr8:8456909~8461337:-
THCA	cis	rs2735413	0.709	rs4395084	ENSG00000276007.1	RP11-358L22.3	-3.42	0.00068	0.0393	-0.13	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr16:78054114	chr16:78123243~78124332:+
THCA	cis	rs1612141	0.744	rs8017924	ENSG00000251363.2	RP11-129M6.1	3.42	0.00068	0.0393	0.22	0.16	QT interval (drug interaction);	chr14:41112168	chr14:40954898~40975877:+
THCA	cis	rs6743226	0.603	rs11678750	ENSG00000223374.1	AC005104.3	3.42	0.000681	0.0393	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241261504	chr2:241351340~241353104:-
THCA	cis	rs35791980	0.607	rs4729343	ENSG00000265479.4	DTX2P1-UPK3BP1-PMS2P11	3.42	0.000681	0.0393	0.16	0.16	Pursuit maintenance gain;	chr7:77349590	chr7:76980949~77043775:+
THCA	cis	rs9309711	0.922	rs13399524	ENSG00000271868.1	RP11-1293J14.1	-3.42	0.000681	0.0393	-0.21	-0.16	Neurofibrillary tangles;	chr2:3476435	chr2:3496956~3497428:+
THCA	cis	rs939960	0.959	rs13223343	ENSG00000276538.1	RP11-545G3.2	3.42	0.000681	0.0393	0.22	0.16	Neutrophil percentage of white cells;	chr7:150597692	chr7:150047609~150047854:-
THCA	cis	rs11623400	1	rs11623400	ENSG00000258657.4	RP11-104E19.1	3.42	0.000681	0.0393	0.23	0.16	Congenital heart disease (maternal effect);Conotruncal heart defects (maternal effects);	chr14:24575006	chr14:24595723~24657774:+
THCA	cis	rs7216064	1	rs4791299	ENSG00000265055.1	AC145343.2	3.42	0.000681	0.0393	0.22	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934821	chr17:68096046~68101474:-
THCA	cis	rs5758511	0.508	rs2854827	ENSG00000205702.9	CYP2D7	3.42	0.000681	0.0393	0.16	0.16	Birth weight;	chr22:42065914	chr22:42140203~42144577:-
THCA	cis	rs2839186	0.77	rs2839171	ENSG00000228137.1	AP001469.7	-3.42	0.000681	0.0393	-0.15	-0.16	Testicular germ cell tumor;	chr21:46253333	chr21:46246890~46247682:+
THCA	cis	rs9450351	0.744	rs9450304	ENSG00000203875.9	SNHG5	-3.42	0.000681	0.0393	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85620141	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs7749600	ENSG00000203875.9	SNHG5	-3.42	0.000681	0.0393	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85624372	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs9344538	ENSG00000203875.9	SNHG5	-3.42	0.000681	0.0393	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85625243	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs9450307	ENSG00000203875.9	SNHG5	-3.42	0.000681	0.0393	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85634633	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs9450309	ENSG00000203875.9	SNHG5	-3.42	0.000681	0.0393	-0.3	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85639025	chr6:85660950~85678736:-
THCA	cis	rs972578	0.967	rs4822235	ENSG00000274717.1	RP1-47A17.1	-3.42	0.000681	0.0393	-0.16	-0.16	Mean platelet volume;	chr22:42942084	chr22:42791814~42794313:-
THCA	cis	rs4460629	0.71	rs11264318	ENSG00000236675.1	MTX1P1	-3.42	0.000681	0.0393	-0.15	-0.16	Serum magnesium levels;	chr1:155111241	chr1:155230975~155234325:+
THCA	cis	rs3749237	0.595	rs11130196	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000681	0.0393	0.13	0.16	Resting heart rate;	chr3:49452716	chr3:48847572~48851981:+
THCA	cis	rs4601821	0.789	rs7123797	ENSG00000270179.1	RP11-159N11.4	-3.42	0.000681	0.0393	-0.16	-0.16	Alcoholic chronic pancreatitis;	chr11:113391849	chr11:113368478~113369117:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000219891.2	ZSCAN12P1	3.42	0.000681	0.0393	0.22	0.16	Depression;	chr6:28149979	chr6:28091154~28093664:+
THCA	cis	rs13064773	0.528	rs340249	ENSG00000240207.5	RP11-379F4.4	3.42	0.000681	0.0393	0.18	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158883023	chr3:158732263~158784070:+
THCA	cis	rs10089	1	rs59484271	ENSG00000245937.6	LINC01184	3.42	0.000681	0.0393	0.18	0.16	Ileal carcinoids;	chr5:128168089	chr5:127940426~128083172:-
THCA	cis	rs12539814	1	rs12666210	ENSG00000244198.4	RP4-545C24.1	-3.42	0.000681	0.0393	-0.18	-0.16	Diastolic blood pressure;	chr7:144435635	chr7:144194858~144280547:+
THCA	cis	rs7246657	0.722	rs2909093	ENSG00000226686.6	LINC01535	3.42	0.000681	0.0393	0.23	0.16	Coronary artery calcification;	chr19:37708561	chr19:37251912~37265535:+
THCA	cis	rs12893668	0.572	rs34000399	ENSG00000258735.1	LINC00637	-3.42	0.000681	0.0393	-0.21	-0.16	Reticulocyte count;	chr14:103635080	chr14:103847721~103858049:+
THCA	cis	rs950169	0.84	rs62019457	ENSG00000230373.7	GOLGA6L5P	-3.42	0.000681	0.0393	-0.17	-0.16	Schizophrenia;	chr15:84558911	chr15:84507885~84516814:-
THCA	cis	rs950169	0.922	rs67804993	ENSG00000230373.7	GOLGA6L5P	-3.42	0.000681	0.0393	-0.17	-0.16	Schizophrenia;	chr15:84560799	chr15:84507885~84516814:-
THCA	cis	rs4763879	0.593	rs2080206	ENSG00000278635.1	CTD-2318O12.1	3.42	0.000681	0.0393	0.17	0.16	Type 1 diabetes;	chr12:9715370	chr12:9415641~9416718:+
THCA	cis	rs3764021	0.509	rs10772074	ENSG00000257027.1	RP11-705C15.3	3.42	0.000681	0.0394	0.14	0.16	Type 1 diabetes;	chr12:9717686	chr12:9658567~9662085:+
THCA	cis	rs5744897	0.708	rs4883582	ENSG00000277186.1	RP13-554M15.8	3.42	0.000681	0.0394	0.27	0.16	Urate levels in overweight individuals;	chr12:132666147	chr12:132593031~132593698:-
THCA	cis	rs950169	0.84	rs12905223	ENSG00000230373.7	GOLGA6L5P	-3.42	0.000681	0.0394	-0.17	-0.16	Schizophrenia;	chr15:84571037	chr15:84507885~84516814:-
THCA	cis	rs423955	0.619	rs296836	ENSG00000272866.1	RP11-12D24.10	-3.42	0.000681	0.0394	-0.21	-0.16	Platelet count;	chr9:4808456	chr9:5351796~5352410:-
THCA	cis	rs5751168	0.831	rs361901	ENSG00000240160.3	RN7SL263P	-3.42	0.000681	0.0394	-0.24	-0.16	Prostate cancer (SNP x SNP interaction);	chr22:22507676	chr22:23261782~23262071:-
THCA	cis	rs2692947	0.8	rs4332959	ENSG00000235959.1	AC009237.17	-3.42	0.000681	0.0394	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95883373	chr2:95640181~95640604:-
THCA	cis	rs11673344	0.566	rs8109103	ENSG00000268499.1	CTB-102L5.8	-3.42	0.000681	0.0394	-0.16	-0.16	Obesity-related traits;	chr19:37503209	chr19:38199836~38200934:+
THCA	cis	rs7010267	0.596	rs7010043	ENSG00000254278.1	RP11-278I4.2	-3.42	0.000681	0.0394	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118999092	chr8:119062942~119068782:-
THCA	cis	rs2652822	0.504	rs2134263	ENSG00000259459.4	RP11-321G12.1	-3.42	0.000681	0.0394	-0.12	-0.16	Metabolic traits;	chr15:63073195	chr15:63390136~63438320:+
THCA	cis	rs10043228	0.702	rs6873950	ENSG00000250015.1	CTC-339F2.2	3.42	0.000681	0.0394	0.19	0.16	Asthma or chronic obstructive pulmonary disease;	chr5:116293998	chr5:116302354~116304134:-
THCA	cis	rs79149102	0.522	rs950323	ENSG00000260103.2	RP11-10O17.1	-3.42	0.000681	0.0394	-0.22	-0.16	Lung cancer;	chr15:74674188	chr15:74478070~74490286:-
THCA	cis	rs79149102	0.522	rs7170734	ENSG00000260103.2	RP11-10O17.1	-3.42	0.000681	0.0394	-0.22	-0.16	Lung cancer;	chr15:74697065	chr15:74478070~74490286:-
THCA	cis	rs975752	0.764	rs2242052	ENSG00000227492.1	RP11-316M21.6	-3.42	0.000682	0.0394	-0.27	-0.16	Schizophrenia;	chr10:100290757	chr10:100229667~100234000:+
THCA	cis	rs948562	0.744	rs113707421	ENSG00000280010.1	AP001350.4	3.42	0.000682	0.0394	0.24	0.16	Lymphoma;	chr11:58449669	chr11:58627435~58628528:+
THCA	cis	rs5758659	0.622	rs5758527	ENSG00000234009.1	RPL5P34	-3.42	0.000682	0.0394	-0.15	-0.16	Cognitive function;	chr22:41979757	chr22:42776406~42777296:-
THCA	cis	rs3824488	0.92	rs28446116	ENSG00000237857.2	RP11-435O5.2	-3.42	0.000682	0.0394	-0.26	-0.16	Neuroticism;	chr9:95481103	chr9:95414834~95426796:-
THCA	cis	rs17122278	1	rs4326835	ENSG00000255239.1	AP002954.6	-3.42	0.000682	0.0394	-0.28	-0.16	Total cholesterol levels;	chr11:118561689	chr11:118688039~118690600:-
THCA	cis	rs250585	1	rs457964	ENSG00000260136.4	CTD-2270L9.4	3.42	0.000682	0.0394	0.14	0.16	Egg allergy;	chr16:23576603	chr16:23452758~23457606:+
THCA	cis	rs2839186	0.632	rs2839184	ENSG00000228137.1	AP001469.7	3.42	0.000682	0.0394	0.17	0.16	Testicular germ cell tumor;	chr21:46269099	chr21:46246890~46247682:+
THCA	cis	rs478304	0.651	rs10896037	ENSG00000255517.5	CTD-3074O7.5	3.42	0.000682	0.0394	0.12	0.16	Acne (severe);	chr11:65735953	chr11:66473490~66480233:-
THCA	cis	rs6142618	0.562	rs2235902	ENSG00000224452.1	RSL24D1P6	3.42	0.000682	0.0394	0.18	0.16	Inflammatory bowel disease;	chr20:32133547	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs2281358	ENSG00000224452.1	RSL24D1P6	3.42	0.000682	0.0394	0.18	0.16	Inflammatory bowel disease;	chr20:32135545	chr20:32170390~32170790:-
THCA	cis	rs642858	0.784	rs2223966	ENSG00000234147.1	RP3-460G2.2	3.42	0.000682	0.0394	0.2	0.16	Type 2 diabetes;	chr6:139910690	chr6:140845958~140852924:-
THCA	cis	rs12073359	0.509	rs16835254	ENSG00000253047.1	SNORA40	3.42	0.000682	0.0394	0.26	0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150216986	chr1:150600539~150600659:-
THCA	cis	rs7818688	0.929	rs73276439	ENSG00000253528.2	RP11-347C18.4	-3.42	0.000682	0.0394	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95023664	chr8:94974573~94974853:-
THCA	cis	rs8181477	0.764	rs11014484	ENSG00000240291.1	RP11-499P20.2	-3.42	0.000682	0.0394	-0.11	-0.16	Obesity-related traits;	chr10:18490395	chr10:18513115~18545651:-
THCA	cis	rs9876781	1	rs11130171	ENSG00000199476.1	Y_RNA	-3.42	0.000682	0.0394	-0.2	-0.16	Longevity;	chr3:48421052	chr3:48288587~48288694:+
THCA	cis	rs9876781	1	rs9883927	ENSG00000199476.1	Y_RNA	-3.42	0.000682	0.0394	-0.2	-0.16	Longevity;	chr3:48422302	chr3:48288587~48288694:+
THCA	cis	rs324126	0.78	rs34425941	ENSG00000243680.1	RPL37P23	-3.42	0.000682	0.0394	-0.14	-0.16	Colonoscopy-negative controls vs population controls;	chr19:52377359	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs62108318	ENSG00000243680.1	RPL37P23	-3.42	0.000682	0.0394	-0.14	-0.16	Colonoscopy-negative controls vs population controls;	chr19:52380322	chr19:52143043~52143336:+
THCA	cis	rs8064029	0.892	rs77213183	ENSG00000267077.1	RP11-127I20.5	3.42	0.000682	0.0394	0.24	0.16	Cancer;	chr16:4852109	chr16:4795265~4796532:-
THCA	cis	rs4703129	1	rs11954892	ENSG00000246763.5	RGMB-AS1	-3.42	0.000682	0.0394	-0.15	-0.16	Asperger disorder;	chr5:98545297	chr5:98769618~98773469:-
THCA	cis	rs6847067	0.732	rs13124246	ENSG00000180769.7	WDFY3-AS2	3.42	0.000682	0.0394	0.12	0.16	Oropharynx cancer;	chr4:84974368	chr4:84965682~85011277:+
THCA	cis	rs17292804	0.527	rs12887734	ENSG00000258735.1	LINC00637	-3.42	0.000682	0.0394	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103847721~103858049:+
THCA	cis	rs34975555	1	rs2301546	ENSG00000253671.1	RP11-806O11.1	-3.42	0.000682	0.0394	-0.26	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17989996	chr8:17808941~17820868:+
THCA	cis	rs12935229	0.756	rs80216458	ENSG00000260922.1	RP11-538I12.3	-3.42	0.000682	0.0394	-0.24	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77356429	chr16:77234877~77290934:+
THCA	cis	rs987724	0.613	rs1384538	ENSG00000241544.1	RP11-6F2.5	-3.42	0.000682	0.0394	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156977820	chr3:157081841~157088547:+
THCA	cis	rs7081476	0.737	rs113681814	ENSG00000262412.1	RP11-85G18.6	-3.42	0.000682	0.0394	-0.39	-0.16	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr10:27200754	chr10:27243130~27250804:+
THCA	cis	rs7081476	0.737	rs16916444	ENSG00000262412.1	RP11-85G18.6	-3.42	0.000682	0.0394	-0.39	-0.16	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr10:27202719	chr10:27243130~27250804:+
THCA	cis	rs2718812	0.935	rs1006097	ENSG00000242337.4	TFP1	3.42	0.000682	0.0394	0.16	0.16	Iron status biomarkers;	chr3:133692634	chr3:133661998~133754576:+
THCA	cis	rs10129255	0.917	rs7142373	ENSG00000274576.2	IGHV2-70	3.42	0.000682	0.0394	0.11	0.16	Kawasaki disease;	chr14:106708947	chr14:106770577~106771020:-
THCA	cis	rs11671005	0.504	rs7257669	ENSG00000269600.1	AC016629.3	-3.42	0.000682	0.0394	-0.2	-0.16	Mean platelet volume;	chr19:58553572	chr19:58593896~58599355:-
THCA	cis	rs7267979	0.966	rs2257233	ENSG00000276952.1	RP5-965G21.6	-3.42	0.000683	0.0394	-0.16	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25284915~25285588:-
THCA	cis	rs3800688	0.549	rs2398771	ENSG00000236753.4	MKLN1-AS	-3.42	0.000683	0.0394	-0.15	-0.16	Hypertension;	chr7:131419793	chr7:131309744~131328222:-
THCA	cis	rs559555	0.521	rs223631	ENSG00000276334.1	AL133243.1	3.42	0.000683	0.0394	0.17	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31760994	chr2:32521927~32523547:+
THCA	cis	rs12022452	1	rs3738471	ENSG00000272145.1	NFYC-AS1	3.42	0.000683	0.0394	0.14	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40690380~40692066:-
THCA	cis	rs56116382	0.605	rs12715435	ENSG00000270441.1	RP11-694I15.7	3.42	0.000683	0.0394	0.18	0.16	High light scatter reticulocyte count;Intelligence (multi-trait analysis);	chr3:49301559	chr3:49140086~49160851:-
THCA	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-3.42	0.000683	0.0394	-0.19	-0.16	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
THCA	cis	rs2274273	0.868	rs9919926	ENSG00000258469.1	CHMP4BP1	3.42	0.000683	0.0394	0.14	0.16	Protein biomarker;	chr14:55347172	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.934	rs10144418	ENSG00000258469.1	CHMP4BP1	3.42	0.000683	0.0394	0.14	0.16	Protein biomarker;	chr14:55350990	chr14:55298644~55299231:+
THCA	cis	rs4578769	0.729	rs12454969	ENSG00000265939.1	UBE2CP2	-3.42	0.000683	0.0394	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22893042	chr18:22900486~22900995:-
THCA	cis	rs2278702	0.622	rs3848199	ENSG00000259495.2	RP11-210M15.2	-3.42	0.000683	0.0394	-0.23	-0.16	Bipolar disorder;	chr15:80350452	chr15:80344853~80403575:-
THCA	cis	rs7709377	0.597	rs57484726	ENSG00000271918.1	CTD-2287O16.5	3.42	0.000683	0.0394	0.15	0.16	Metabolite levels  (X-11787);	chr5:116178348	chr5:116083807~116085416:-
THCA	cis	rs600231	0.706	rs3782091	ENSG00000197847.11	SLC22A20	3.42	0.000683	0.0394	0.16	0.16	Bone mineral density;	chr11:65569012	chr11:65213840~65242757:+
THCA	cis	rs2237579	0.584	rs28398992	ENSG00000278959.1	RP11-455I9.1	3.42	0.000683	0.0394	0.18	0.16	Body mass index;	chr7:93510936	chr7:93954044~93956519:-
THCA	cis	rs3770081	0.536	rs7562837	ENSG00000272564.1	RP11-548P2.2	-3.42	0.000683	0.0394	-0.22	-0.16	Facial emotion recognition (sad faces);	chr2:86079128	chr2:85904279~85904727:+
THCA	cis	rs7395662	0.963	rs12800770	ENSG00000200090.1	Y_RNA	-3.42	0.000683	0.0394	-0.1	-0.16	HDL cholesterol;	chr11:48583375	chr11:47726894~47726992:-
THCA	cis	rs561341	0.769	rs9899093	ENSG00000280033.1	CTD-2095E4.3	-3.42	0.000683	0.0394	-0.25	-0.16	Hip circumference adjusted for BMI;	chr17:31864935	chr17:32159311~32160371:+
THCA	cis	rs875971	0.862	rs778720	ENSG00000223473.2	GS1-124K5.3	-3.42	0.000683	0.0394	-0.11	-0.16	Aortic root size;	chr7:66381288	chr7:66491049~66493566:-
THCA	cis	rs5758659	0.622	rs6519298	ENSG00000182057.4	OGFRP1	3.42	0.000683	0.0394	0.18	0.16	Cognitive function;	chr22:41968993	chr22:42269753~42275196:+
THCA	cis	rs3764021	0.527	rs10844503	ENSG00000256069.6	A2MP1	-3.42	0.000683	0.0394	-0.18	-0.16	Type 1 diabetes;	chr12:9701660	chr12:9228533~9275817:-
THCA	cis	rs1062753	0.922	rs9611712	ENSG00000281538.1	RP4-669P10.20	-3.42	0.000683	0.0394	-0.16	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014989	chr22:42138060~42139726:+
THCA	cis	rs4713118	0.869	rs9468214	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000683	0.0394	-0.17	-0.16	Parkinson's disease;	chr6:27745520	chr6:28078792~28081130:-
THCA	cis	rs6921919	0.583	rs6928773	ENSG00000220721.1	OR1F12	3.42	0.000683	0.0394	0.17	0.16	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28073316~28074233:+
THCA	cis	rs8131065	1	rs8131065	ENSG00000273199.1	AP000692.10	-3.42	0.000683	0.0395	-0.26	-0.16	Iris color (L* coordinate);	chr21:36639378	chr21:36319792~36320670:-
THCA	cis	rs6012953	0.583	rs6067472	ENSG00000237595.3	RP11-112L6.3	-3.42	0.000683	0.0395	-0.14	-0.16	Vitiligo;	chr20:50515979	chr20:50162765~50166102:-
THCA	cis	rs1003719	0.591	rs2835633	ENSG00000270116.1	AP001429.1	3.42	0.000683	0.0395	0.17	0.16	Eye color traits;	chr21:37152719	chr21:37100814~37101343:+
THCA	cis	rs7819412	0.522	rs4642600	ENSG00000154316.13	TDH	3.42	0.000683	0.0395	0.12	0.16	Triglycerides;	chr8:11155515	chr8:11339637~11368452:+
THCA	cis	rs12101261	0.744	rs72693090	ENSG00000258915.1	BHLHB9P1	-3.42	0.000683	0.0395	-0.2	-0.16	Graves' disease;	chr14:80993409	chr14:80981988~80983638:+
THCA	cis	rs722414	0.846	rs7310238	ENSG00000258302.2	RP11-981P6.1	-3.42	0.000683	0.0395	-0.14	-0.16	Blood protein levels;	chr12:89505925	chr12:89561129~89594878:+
THCA	cis	rs7809950	0.678	rs12672451	ENSG00000272072.1	CTA-363E19.2	3.42	0.000684	0.0395	0.17	0.16	Coronary artery disease;	chr7:107213372	chr7:107192559~107193300:-
THCA	cis	rs1062753	0.961	rs9620007	ENSG00000281538.1	RP4-669P10.20	-3.42	0.000684	0.0395	-0.16	-0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42009653	chr22:42138060~42139726:+
THCA	cis	rs3734729	1	rs3734729	ENSG00000218358.2	RAET1K	-3.42	0.000684	0.0395	-0.42	-0.16	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150249731	chr6:149998019~150005157:-
THCA	cis	rs2348418	0.702	rs10843116	ENSG00000278733.1	RP11-425D17.1	3.42	0.000684	0.0395	0.14	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28162248	chr12:28185625~28186190:-
THCA	cis	rs7937890	0.559	rs2597217	ENSG00000251991.1	RNU7-49P	3.42	0.000684	0.0395	0.18	0.16	Mitochondrial DNA levels;	chr11:14511337	chr11:14478892~14478953:+
THCA	cis	rs4713118	0.869	rs9366700	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000684	0.0395	-0.17	-0.16	Parkinson's disease;	chr6:27729172	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.869	rs6456802	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000684	0.0395	-0.17	-0.16	Parkinson's disease;	chr6:27730576	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.869	rs9393851	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000684	0.0395	-0.17	-0.16	Parkinson's disease;	chr6:27731802	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.869	rs9461400	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000684	0.0395	-0.17	-0.16	Parkinson's disease;	chr6:27732780	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.869	rs9295742	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000684	0.0395	-0.17	-0.16	Parkinson's disease;	chr6:27735053	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.869	rs9461401	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000684	0.0395	-0.17	-0.16	Parkinson's disease;	chr6:27735512	chr6:28078792~28081130:-
THCA	cis	rs7824557	0.806	rs34171564	ENSG00000255046.1	RP11-297N6.4	3.42	0.000684	0.0395	0.16	0.16	Retinal vascular caliber;	chr8:11237837	chr8:11797928~11802568:-
THCA	cis	rs7142002	0.881	rs73343484	ENSG00000272444.1	RP11-1017G21.6	-3.42	0.000684	0.0395	-0.23	-0.16	Autism;	chr14:101941364	chr14:101952416~101953063:+
THCA	cis	rs324126	0.78	rs55748277	ENSG00000243680.1	RPL37P23	-3.42	0.000684	0.0395	-0.14	-0.16	Colonoscopy-negative controls vs population controls;	chr19:52384992	chr19:52143043~52143336:+
THCA	cis	rs4533267	0.956	rs59345658	ENSG00000189419.6	SPATA41	3.42	0.000684	0.0395	0.2	0.16	Height;	chr15:100245077	chr15:100344457~100349655:-
THCA	cis	rs2455826	0.874	rs2455853	ENSG00000270409.1	RP11-44D5.1	-3.42	0.000684	0.0395	-0.18	-0.16	Inflammatory skin disease;	chr3:15648518	chr3:15732252~15733470:+
THCA	cis	rs394563	0.967	rs447025	ENSG00000268592.3	RAET1E-AS1	3.42	0.000684	0.0395	0.21	0.16	Dupuytren's disease;	chr6:149477992	chr6:149863494~149919507:+
THCA	cis	rs9878978	0.722	rs11717960	ENSG00000227588.2	CNTN4-AS2	3.42	0.000684	0.0395	0.21	0.16	Blood pressure (smoking interaction);	chr3:2472183	chr3:2110409~2144241:-
THCA	cis	rs9878978	0.722	rs11717961	ENSG00000227588.2	CNTN4-AS2	3.42	0.000684	0.0395	0.21	0.16	Blood pressure (smoking interaction);	chr3:2472185	chr3:2110409~2144241:-
THCA	cis	rs4947019	0.534	rs13437492	ENSG00000223537.2	RP5-919F19.5	3.42	0.000684	0.0395	0.28	0.16	Hematological parameters;	chr6:109365424	chr6:109487906~109506800:+
THCA	cis	rs6940638	0.662	rs7759694	ENSG00000219392.1	RP1-265C24.5	-3.42	0.000684	0.0395	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:27273177	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.568	rs9468213	ENSG00000216901.1	AL022393.7	3.42	0.000684	0.0395	0.2	0.16	Parkinson's disease;	chr6:27738401	chr6:28176188~28176674:+
THCA	cis	rs1450985	0.932	rs66629090	ENSG00000280620.1	SCAANT1	-3.42	0.000684	0.0395	-0.21	-0.16	Breast cancer;	chr3:64072607	chr3:63911518~63911772:-
THCA	cis	rs1612141	0.744	rs2185988	ENSG00000251363.2	RP11-129M6.1	3.42	0.000684	0.0395	0.22	0.16	QT interval (drug interaction);	chr14:41119150	chr14:40954898~40975877:+
THCA	cis	rs7264396	0.943	rs224395	ENSG00000261582.1	RP4-614O4.11	-3.42	0.000684	0.0395	-0.16	-0.16	Total cholesterol levels;	chr20:35521599	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.943	rs1810742	ENSG00000261582.1	RP4-614O4.11	-3.42	0.000684	0.0395	-0.16	-0.16	Total cholesterol levels;	chr20:35521890	chr20:35267885~35280043:-
THCA	cis	rs643506	0.967	rs2850248	ENSG00000230911.1	PPIHP1	-3.42	0.000684	0.0395	-0.22	-0.16	Breast cancer;	chr11:111774100	chr11:112029858~112030367:-
THCA	cis	rs7631605	0.846	rs11926768	ENSG00000272334.1	RP11-129K12.1	3.42	0.000684	0.0395	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:36926856	chr3:36973117~36973672:-
THCA	cis	rs488400	0.529	rs361131	ENSG00000251377.1	RP11-18H21.3	3.42	0.000684	0.0395	0.17	0.16	Trans fatty acid levels;	chr4:151894661	chr4:152207421~152225870:-
THCA	cis	rs793571	0.915	rs12916751	ENSG00000245975.2	RP11-30K9.6	-3.42	0.000684	0.0395	-0.15	-0.16	Schizophrenia;	chr15:58929542	chr15:58768072~58770974:-
THCA	cis	rs728616	0.867	rs61859763	ENSG00000272447.1	RP11-182L21.6	-3.42	0.000684	0.0395	-0.33	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:79825902~79827602:+
THCA	cis	rs7142002	0.73	rs3742424	ENSG00000271780.1	RP11-1017G21.5	-3.42	0.000684	0.0395	-0.21	-0.16	Autism;	chr14:101925240	chr14:101948347~101949425:+
THCA	cis	rs879324	0.689	rs7192350	ENSG00000280092.1	AC002044.3	-3.42	0.000684	0.0395	-0.23	-0.16	Stroke (ischemic);	chr16:72995296	chr16:73005601~73006141:-
THCA	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-3.42	0.000684	0.0395	-0.14	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
THCA	cis	rs11098499	0.754	rs1980025	ENSG00000249244.1	RP11-548H18.2	-3.42	0.000684	0.0395	-0.18	-0.16	Corneal astigmatism;	chr4:119331651	chr4:119391831~119395335:-
THCA	cis	rs4815191	0.788	rs1541228	ENSG00000230387.2	RP4-737E23.2	-3.42	0.000684	0.0395	-0.22	-0.16	Obesity-related traits;	chr20:23275878	chr20:23187961~23190307:+
THCA	cis	rs4692589	0.581	rs6821641	ENSG00000229204.3	PTGES3P3	-3.42	0.000684	0.0395	-0.2	-0.16	Anxiety disorder;	chr4:170039042	chr4:169791221~169791702:-
THCA	cis	rs1832871	0.711	rs9459887	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158275447	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs62437159	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158276673	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9459946	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158286925	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs12525675	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158287717	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.683	rs11752399	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158290156	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.683	rs6908487	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158292015	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9456266	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158293390	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9457300	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158293577	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9456285	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158311787	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs7745596	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158311959	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9456289	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158319315	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9457343	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158319535	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9457344	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158321011	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs9457345	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158322066	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs56075516	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158324720	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs7750011	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158325770	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.672	rs6933928	ENSG00000213078.3	RP5-933K21.2	-3.42	0.000684	0.0395	-0.23	-0.16	Height;	chr6:158326039	chr6:157365990~157366923:-
THCA	cis	rs987724	0.593	rs12634915	ENSG00000241544.1	RP11-6F2.5	-3.42	0.000684	0.0395	-0.19	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156974446	chr3:157081841~157088547:+
THCA	cis	rs13108904	0.875	rs3822017	ENSG00000254094.1	AC078852.1	-3.42	0.000684	0.0395	-0.18	-0.16	Obesity-related traits;	chr4:1242524	chr4:1356581~1358075:+
THCA	cis	rs6762	0.719	rs28620453	ENSG00000255284.1	AP006621.5	3.42	0.000684	0.0395	0.11	0.16	Mean platelet volume;	chr11:836971	chr11:777578~784297:+
THCA	cis	rs7259376	0.902	rs8112041	ENSG00000269345.1	VN1R85P	-3.42	0.000684	0.0395	-0.17	-0.16	Menopause (age at onset);	chr19:22421763	chr19:22174766~22175191:-
THCA	cis	rs7264396	0.58	rs6119655	ENSG00000088340.14	FER1L4	3.42	0.000684	0.0395	0.16	0.16	Total cholesterol levels;	chr20:35824127	chr20:35558737~35607562:-
THCA	cis	rs4948275	0.773	rs2650738	ENSG00000233643.2	RP11-491H19.1	3.42	0.000684	0.0395	0.17	0.16	Night sleep phenotypes;	chr10:61492554	chr10:61781745~61821246:-
THCA	cis	rs1971762	0.563	rs4759285	ENSG00000257790.1	EIF4A1P4	-3.42	0.000684	0.0395	-0.2	-0.16	Height;	chr12:53685729	chr12:53153272~53154484:+
THCA	cis	rs34779708	0.931	rs4934711	ENSG00000233200.1	RP11-324I22.2	3.42	0.000685	0.0395	0.18	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35219894~35230598:-
THCA	cis	rs2692947	0.727	rs2692950	ENSG00000236750.1	AC009237.16	-3.42	0.000685	0.0395	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007776	chr2:95641634~95641980:-
THCA	cis	rs5742933	0.51	rs10182631	ENSG00000253559.1	OSGEPL1-AS1	-3.42	0.000685	0.0395	-0.21	-0.16	Ferritin levels;	chr2:189635233	chr2:189762704~189765556:+
THCA	cis	rs9400467	0.537	rs73528979	ENSG00000255389.1	C6orf3	3.42	0.000685	0.0395	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111109201	chr6:111599875~111602295:+
THCA	cis	rs5758659	0.967	rs5751250	ENSG00000205702.9	CYP2D7	3.42	0.000685	0.0395	0.12	0.16	Cognitive function;	chr22:42243639	chr22:42140203~42144577:-
THCA	cis	rs10223402	0.786	rs2859772	ENSG00000233558.1	RP3-486I3.4	3.42	0.000685	0.0395	0.27	0.16	Appendicular lean mass;	chr6:115640298	chr6:116258493~116259115:-
THCA	cis	rs74233809	0.901	rs4409766	ENSG00000213061.2	PFN1P11	3.42	0.000685	0.0395	0.27	0.16	Birth weight;	chr10:102856906	chr10:102838011~102845473:-
THCA	cis	rs1124769	0.619	rs4598846	ENSG00000273674.3	CTD-2378E12.1	3.42	0.000685	0.0395	0.21	0.16	Cognitive performance;	chr15:51095918	chr15:50839875~50908599:-
THCA	cis	rs3758911	0.894	rs12286915	ENSG00000255353.1	RP11-382M14.1	-3.42	0.000685	0.0395	-0.2	-0.16	Coronary artery disease;	chr11:107340608	chr11:107176286~107177530:+
THCA	cis	rs6762	0.692	rs5030778	ENSG00000255284.1	AP006621.5	3.42	0.000685	0.0395	0.11	0.16	Mean platelet volume;	chr11:836008	chr11:777578~784297:+
THCA	cis	rs1433188	0.847	rs12541987	ENSG00000253582.1	RP11-649G15.2	3.42	0.000685	0.0395	0.18	0.16	Subjective well-being;	chr8:107441193	chr8:106520474~106657548:-
THCA	cis	rs1150668	0.799	rs853684	ENSG00000261839.1	RP1-265C24.8	3.42	0.000685	0.0395	0.15	0.16	Pubertal anthropometrics;	chr6:28326773	chr6:28136849~28139678:+
THCA	cis	rs4703129	1	rs11241997	ENSG00000246763.5	RGMB-AS1	-3.42	0.000685	0.0395	-0.15	-0.16	Asperger disorder;	chr5:98560725	chr5:98769618~98773469:-
THCA	cis	rs72827839	0.948	rs72827882	ENSG00000228782.6	CTD-2026D20.3	3.42	0.000685	0.0395	0.19	0.16	Ease of getting up in the morning;	chr17:48455262	chr17:47450568~47492492:-
THCA	cis	rs9309473	0.519	rs1815027	ENSG00000273245.1	RP11-434P11.2	-3.42	0.000685	0.0395	-0.19	-0.16	Metabolite levels;	chr2:73604713	chr2:73750256~73750786:-
THCA	cis	rs614226	1	rs616157	ENSG00000248008.2	DYNLL1-AS1	3.42	0.000685	0.0395	0.21	0.16	Type 1 diabetes nephropathy;	chr12:120487992	chr12:120490328~120495940:-
THCA	cis	rs6787172	0.592	rs6767008	ENSG00000272087.1	RP11-379F4.7	3.42	0.000685	0.0395	0.14	0.16	Subjective well-being;	chr3:158383271	chr3:158693120~158693768:-
THCA	cis	rs9527	0.571	rs4917985	ENSG00000213277.3	MARCKSL1P1	3.42	0.000685	0.0395	0.17	0.16	Arsenic metabolism;	chr10:102864315	chr10:103175554~103176094:+
THCA	cis	rs997295	0.592	rs8026627	ENSG00000245719.1	RP11-34F13.2	-3.42	0.000685	0.0395	-0.17	-0.16	Motion sickness;	chr15:67477968	chr15:67834310~67838879:-
THCA	cis	rs1790761	0.692	rs10444362	ENSG00000184224.3	C11orf72	3.42	0.000685	0.0395	0.21	0.16	Mean corpuscular volume;	chr11:67565619	chr11:67602880~67606706:-
THCA	cis	rs1790761	0.692	rs638140	ENSG00000184224.3	C11orf72	3.42	0.000685	0.0395	0.21	0.16	Mean corpuscular volume;	chr11:67566387	chr11:67602880~67606706:-
THCA	cis	rs1790761	0.692	rs1269981	ENSG00000184224.3	C11orf72	3.42	0.000685	0.0395	0.21	0.16	Mean corpuscular volume;	chr11:67567488	chr11:67602880~67606706:-
THCA	cis	rs1790761	0.658	rs666328	ENSG00000184224.3	C11orf72	3.42	0.000685	0.0395	0.21	0.16	Mean corpuscular volume;	chr11:67568067	chr11:67602880~67606706:-
THCA	cis	rs1790761	0.667	rs11227837	ENSG00000184224.3	C11orf72	3.42	0.000685	0.0395	0.21	0.16	Mean corpuscular volume;	chr11:67568953	chr11:67602880~67606706:-
THCA	cis	rs1790761	0.667	rs658768	ENSG00000184224.3	C11orf72	3.42	0.000685	0.0395	0.21	0.16	Mean corpuscular volume;	chr11:67570337	chr11:67602880~67606706:-
THCA	cis	rs1790761	0.667	rs591434	ENSG00000184224.3	C11orf72	3.42	0.000685	0.0395	0.21	0.16	Mean corpuscular volume;	chr11:67570343	chr11:67602880~67606706:-
THCA	cis	rs6787172	0.622	rs67761009	ENSG00000272087.1	RP11-379F4.7	3.42	0.000685	0.0395	0.14	0.16	Subjective well-being;	chr3:158350472	chr3:158693120~158693768:-
THCA	cis	rs4601821	0.823	rs10891546	ENSG00000270179.1	RP11-159N11.4	3.42	0.000685	0.0395	0.16	0.16	Alcoholic chronic pancreatitis;	chr11:113394570	chr11:113368478~113369117:+
THCA	cis	rs6968419	0.537	rs10953809	ENSG00000237870.5	AC073130.1	3.42	0.000685	0.0395	0.16	0.16	Intraocular pressure;	chr7:116127110	chr7:116275606~116286734:-
THCA	cis	rs4295623	0.504	rs11250160	ENSG00000227888.4	FAM66A	-3.42	0.000685	0.0395	-0.19	-0.16	Morning vs. evening chronotype;	chr8:11735208	chr8:12362019~12388296:+
THCA	cis	rs61160187	0.583	rs6449503	ENSG00000272308.1	RP11-231G3.1	3.42	0.000685	0.0396	0.16	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60866457~60866935:-
THCA	cis	rs7010267	0.542	rs4618726	ENSG00000254278.1	RP11-278I4.2	-3.42	0.000685	0.0396	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118997146	chr8:119062942~119068782:-
THCA	cis	rs4533267	0.917	rs4246311	ENSG00000189419.6	SPATA41	3.42	0.000685	0.0396	0.21	0.16	Height;	chr15:100246691	chr15:100344457~100349655:-
THCA	cis	rs2977125	0.769	rs2948373	ENSG00000251468.2	RP11-369K16.1	-3.42	0.000685	0.0396	-0.23	-0.16	Schizophrenia;	chr8:12899398	chr8:12958387~12962200:+
THCA	cis	rs10844706	0.699	rs10844626	ENSG00000257027.1	RP11-705C15.3	3.42	0.000686	0.0396	0.13	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733757	chr12:9658567~9662085:+
THCA	cis	rs10844706	0.699	rs10844630	ENSG00000257027.1	RP11-705C15.3	3.42	0.000686	0.0396	0.13	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734268	chr12:9658567~9662085:+
THCA	cis	rs7216064	0.953	rs4791048	ENSG00000265055.1	AC145343.2	3.42	0.000686	0.0396	0.22	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852878	chr17:68096046~68101474:-
THCA	cis	rs6847067	0.794	rs7675324	ENSG00000180769.7	WDFY3-AS2	3.42	0.000686	0.0396	0.11	0.16	Oropharynx cancer;	chr4:85021460	chr4:84965682~85011277:+
THCA	cis	rs8030379	0.967	rs8028359	ENSG00000176700.18	SCAND2P	-3.42	0.000686	0.0396	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906593	chr15:84631451~84647478:+
THCA	cis	rs1927790	0.643	rs1475296	ENSG00000247400.3	DNAJC3-AS1	-3.42	0.000686	0.0396	-0.1	-0.16	Body mass index;	chr13:96352019	chr13:95648733~95676925:-
THCA	cis	rs3749237	0.595	rs4855873	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000686	0.0396	0.13	0.16	Resting heart rate;	chr3:49421681	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs1464566	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000686	0.0396	0.13	0.16	Resting heart rate;	chr3:49421943	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.537	rs4459909	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000686	0.0396	0.13	0.16	Resting heart rate;	chr3:49431784	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs4855839	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000686	0.0396	0.13	0.16	Resting heart rate;	chr3:49470414	chr3:48847572~48851981:+
THCA	cis	rs9329221	0.512	rs7843924	ENSG00000261451.1	RP11-981G7.1	3.42	0.000686	0.0396	0.18	0.16	Neuroticism;	chr8:10119030	chr8:10433672~10438312:+
THCA	cis	rs2115630	0.967	rs11073702	ENSG00000275120.1	RP11-182J1.17	-3.42	0.000686	0.0396	-0.16	-0.16	P wave terminal force;	chr15:84766840	chr15:84599434~84606463:-
THCA	cis	rs1371614	0.588	rs13017554	ENSG00000231636.1	AGBL5-AS1	3.42	0.000686	0.0396	0.17	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26948114	chr2:27049683~27050264:-
THCA	cis	rs2736337	0.532	rs6998387	ENSG00000154316.13	TDH	-3.42	0.000686	0.0396	-0.11	-0.16	Rheumatoid arthritis;	chr8:11435949	chr8:11339637~11368452:+
THCA	cis	rs948562	0.744	rs12361887	ENSG00000280010.1	AP001350.4	3.42	0.000686	0.0396	0.24	0.16	Lymphoma;	chr11:58488205	chr11:58627435~58628528:+
THCA	cis	rs55780018	0.675	rs59314826	ENSG00000224137.1	AC079767.4	3.42	0.000686	0.0396	0.14	0.16	Systolic blood pressure;	chr2:207638834	chr2:207662375~207667024:+
THCA	cis	rs4788815	0.533	rs12102548	ENSG00000260886.1	TAT-AS1	3.42	0.000686	0.0396	0.23	0.16	Metabolite levels;	chr16:71895860	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.586	rs8062946	ENSG00000260886.1	TAT-AS1	3.42	0.000686	0.0396	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71896904	chr16:71565789~71578187:+
THCA	cis	rs3812762	0.912	rs10769954	ENSG00000254860.4	TMEM9B-AS1	-3.42	0.000686	0.0396	-0.17	-0.16	Hypospadias;	chr11:8762166	chr11:8964675~8977527:+
THCA	cis	rs3749237	0.595	rs4955412	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000686	0.0396	0.13	0.16	Resting heart rate;	chr3:49380735	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.557	rs7631908	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000686	0.0396	0.13	0.16	Resting heart rate;	chr3:49388274	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.615	rs55957735	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000686	0.0396	0.13	0.16	Resting heart rate;	chr3:49400725	chr3:48847572~48851981:+
THCA	cis	rs7631605	0.608	rs11715164	ENSG00000224080.1	UBE2FP1	3.42	0.000686	0.0396	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37399235	chr3:37143512~37143958:-
THCA	cis	rs12476592	1	rs12476592	ENSG00000242412.1	DBIL5P2	-3.42	0.000686	0.0396	-0.23	-0.16	Childhood ear infection;	chr2:63622964	chr2:63117851~63119542:-
THCA	cis	rs4704187	0.687	rs4340901	ENSG00000250889.2	LINC01336	-3.42	0.000686	0.0396	-0.16	-0.16	Response to amphetamines;	chr5:75109080	chr5:75047719~75052843:-
THCA	cis	rs1821002	1	rs1821002	ENSG00000269918.1	AF131215.9	-3.42	0.000686	0.0396	-0.16	-0.16	Systolic blood pressure;	chr8:10782555	chr8:11104691~11106704:-
THCA	cis	rs13401620	0.917	rs11682103	ENSG00000236878.1	AC012363.7	-3.42	0.000686	0.0396	-0.18	-0.16	Breast size;	chr2:119761887	chr2:120211054~120211715:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000230295.1	RP11-458F8.2	3.42	0.000686	0.0396	0.14	0.16	Aortic root size;	chr7:66376216	chr7:66880708~66882981:+
THCA	cis	rs7487075	0.55	rs1472179	ENSG00000275481.1	RP11-474P2.6	3.42	0.000686	0.0396	0.16	0.16	Itch intensity from mosquito bite;	chr12:46416731	chr12:46388856~46392126:+
THCA	cis	rs34421088	0.56	rs1478898	ENSG00000251402.3	FAM90A25P	-3.42	0.000686	0.0396	-0.2	-0.16	Neuroticism;	chr8:11537570	chr8:12415080~12418090:-
THCA	cis	rs7829975	0.777	rs6989926	ENSG00000253981.4	ALG1L13P	-3.42	0.000686	0.0396	-0.15	-0.16	Mood instability;	chr8:8689803	chr8:8236003~8244667:-
THCA	cis	rs2033711	0.87	rs6510152	ENSG00000268049.1	CTD-2619J13.9	-3.42	0.000686	0.0396	-0.2	-0.16	Uric acid clearance;	chr19:58441952	chr19:58357999~58359603:+
THCA	cis	rs2919009	0.607	rs17594946	ENSG00000271670.1	RP11-95I16.4	3.42	0.000686	0.0396	0.18	0.16	Obesity-related traits;	chr10:120953414	chr10:120879256~120880667:-
THCA	cis	rs7621331	1	rs6807242	ENSG00000239213.4	NCK1-AS1	3.42	0.000686	0.0396	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:135975101	chr3:136841726~136862054:-
THCA	cis	rs277939	0.935	rs451229	ENSG00000230847.4	RP11-195E2.1	-3.42	0.000686	0.0396	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71598448	chr5:71074225~71093193:-
THCA	cis	rs57709857	0.915	rs3824289	ENSG00000272092.1	RP11-350N15.5	-3.42	0.000686	0.0396	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38272915	chr8:38382364~38383461:+
THCA	cis	rs1421334	0.715	rs11776713	ENSG00000254109.4	RBPMS-AS1	3.42	0.000686	0.0396	0.16	0.16	Intelligence (multi-trait analysis);	chr8:31004091	chr8:30382119~30385401:-
THCA	cis	rs2832191	0.692	rs8134627	ENSG00000176054.6	RPL23P2	-3.42	0.000686	0.0396	-0.14	-0.16	Dental caries;	chr21:28976747	chr21:28997613~28998033:-
THCA	cis	rs10138297	0.826	rs10142191	ENSG00000278002.1	RP11-596C23.2	-3.42	0.000686	0.0396	-0.31	-0.16	Erythema nodosum in inflammatory bowel disease;	chr14:50020194	chr14:49863072~49864379:+
THCA	cis	rs735539	0.872	rs9509334	ENSG00000238286.1	SLC35E1P1	3.42	0.000686	0.0396	0.16	0.16	Dental caries;	chr13:20694691	chr13:20607268~20608131:+
THCA	cis	rs12612435	0.696	rs16833964	ENSG00000230037.1	UBBP1	3.42	0.000686	0.0396	0.2	0.16	Takotsubo syndrome;	chr2:136388754	chr2:136329441~136329913:-
THCA	cis	rs7246967	0.608	rs433579	ENSG00000198153.8	ZNF849P	-3.42	0.000686	0.0396	-0.23	-0.16	Bronchopulmonary dysplasia;	chr19:22820325	chr19:22685167~22686732:+
THCA	cis	rs11039798	0.545	rs7118670	ENSG00000200090.1	Y_RNA	3.42	0.000687	0.0396	0.13	0.16	Axial length;	chr11:48510504	chr11:47726894~47726992:-
THCA	cis	rs10270805	0.892	rs1921831	ENSG00000272537.1	GS1-166A23.1	3.42	0.000687	0.0396	0.32	0.16	Response to statin therapy;	chr7:16447634	chr7:16471184~16471373:+
THCA	cis	rs17376456	0.597	rs7733142	ENSG00000254132.1	MTND6P3	3.42	0.000687	0.0396	0.2	0.16	Diabetic retinopathy;	chr5:93987090	chr5:94568929~94569470:-
THCA	cis	rs2841277	0.676	rs10438246	ENSG00000258701.1	LINC00638	3.42	0.000687	0.0396	0.17	0.16	Rheumatoid arthritis;	chr14:104943846	chr14:104821201~104823718:+
THCA	cis	rs9894429	0.738	rs8077038	ENSG00000262049.1	RP13-1032I1.7	-3.42	0.000687	0.0396	-0.09	-0.16	Eye color traits;	chr17:81610101	chr17:81701324~81703300:-
THCA	cis	rs9894429	0.789	rs9747336	ENSG00000262049.1	RP13-1032I1.7	3.42	0.000687	0.0396	0.09	0.16	Eye color traits;	chr17:81617163	chr17:81701324~81703300:-
THCA	cis	rs9894429	0.789	rs35887231	ENSG00000262049.1	RP13-1032I1.7	3.42	0.000687	0.0396	0.09	0.16	Eye color traits;	chr17:81620100	chr17:81701324~81703300:-
THCA	cis	rs3749237	0.595	rs2878298	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000687	0.0396	0.13	0.16	Resting heart rate;	chr3:49368647	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs17595772	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000687	0.0396	0.13	0.16	Resting heart rate;	chr3:49372271	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs7621003	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000687	0.0396	0.13	0.16	Resting heart rate;	chr3:49373971	chr3:48847572~48851981:+
THCA	cis	rs3749237	0.595	rs4855877	ENSG00000224424.7	PRKAR2A-AS1	3.42	0.000687	0.0396	0.13	0.16	Resting heart rate;	chr3:49411094	chr3:48847572~48851981:+
THCA	cis	rs7203193	1	rs7203193	ENSG00000241641.1	RPS23P6	3.42	0.000687	0.0396	0.15	0.16	LDL cholesterol;	chr16:11547324	chr16:12081237~12081902:+
THCA	cis	rs34102591	0.53	rs78344382	ENSG00000270061.1	RP11-214K3.19	-3.42	0.000687	0.0396	-0.21	-0.16	Schizophrenia;	chr12:123903856	chr12:123969990~123970344:-
THCA	cis	rs9314614	0.789	rs4840641	ENSG00000245857.2	GS1-24F4.2	3.42	0.000687	0.0396	0.2	0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6855221	chr8:6835554~6885276:+
THCA	cis	rs9314614	0.789	rs4840643	ENSG00000245857.2	GS1-24F4.2	3.42	0.000687	0.0396	0.2	0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6855262	chr8:6835554~6885276:+
THCA	cis	rs7179228	1	rs1533469	ENSG00000260657.2	RP11-315D16.4	3.42	0.000687	0.0396	0.22	0.16	Systolic blood pressure;	chr15:68329368	chr15:68267792~68277994:-
THCA	cis	rs2749592	0.531	rs994804	ENSG00000275858.1	RP11-291L22.8	-3.42	0.000687	0.0396	-0.18	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38450738~38451069:-
THCA	cis	rs9863	0.931	rs11057407	ENSG00000269938.1	RP11-214K3.20	-3.42	0.000687	0.0396	-0.18	-0.16	White blood cell count;	chr12:123965282	chr12:123968023~123968579:-
THCA	cis	rs2305707	0.611	rs28458810	ENSG00000273674.3	CTD-2378E12.1	3.42	0.000687	0.0396	0.32	0.16	Height;	chr15:51278732	chr15:50839875~50908599:-
THCA	cis	rs2033711	0.87	rs11669741	ENSG00000269867.1	CTD-2583A14.8	3.42	0.000687	0.0396	0.13	0.16	Uric acid clearance;	chr19:58449114	chr19:57867038~57868172:-
THCA	cis	rs881375	0.967	rs2239658	ENSG00000270917.1	RP11-27I1.6	-3.42	0.000687	0.0396	-0.22	-0.16	Rheumatoid arthritis;	chr9:120909559	chr9:120812475~120812845:-
THCA	cis	rs4906332	1	rs2065015	ENSG00000259775.1	RP11-45P15.4	3.42	0.000687	0.0396	0.13	0.16	Coronary artery disease;	chr14:103437724	chr14:103331674~103332367:-
THCA	cis	rs586716	0.569	rs62572328	ENSG00000224549.1	RP11-370B11.3	3.42	0.000687	0.0396	0.19	0.16	Tuberculosis;	chr9:22540581	chr9:22767175~22768316:+
THCA	cis	rs35123781	0.654	rs356486	ENSG00000253404.1	AC034243.1	3.42	0.000687	0.0396	0.21	0.16	Schizophrenia;	chr5:139705518	chr5:138744434~138753309:-
THCA	cis	rs189798	0.845	rs330904	ENSG00000254153.1	CTA-398F10.2	3.42	0.000687	0.0396	0.17	0.16	Myopia (pathological);	chr8:9134315	chr8:8456909~8461337:-
THCA	cis	rs11031096	0.542	rs11828337	ENSG00000230593.3	AC090804.1	3.42	0.000687	0.0396	0.19	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:3955744	chr11:3892398~3892887:-
THCA	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-3.42	0.000687	0.0396	-0.18	-0.16	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
THCA	cis	rs10876993	0.855	rs1678520	ENSG00000270039.1	RP11-571M6.17	3.42	0.000687	0.0396	0.17	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57655536	chr12:57803838~57804415:+
THCA	cis	rs867186	0.614	rs77221305	ENSG00000279253.1	RP4-614O4.13	-3.42	0.000687	0.0396	-0.31	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34864237	chr20:35262727~35264187:-
THCA	cis	rs8046148	0.789	rs6500285	ENSG00000279356.1	RP11-429P3.8	-3.42	0.000687	0.0396	-0.2	-0.16	Testicular germ cell tumor;	chr16:50112742	chr16:50072862~50074986:+
THCA	cis	rs6840360	0.571	rs62327274	ENSG00000251611.1	RP11-610P16.1	-3.42	0.000688	0.0396	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151626860	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.571	rs62327275	ENSG00000251611.1	RP11-610P16.1	-3.42	0.000688	0.0396	-0.12	-0.16	Intelligence (multi-trait analysis);	chr4:151627086	chr4:151407551~151408835:-
THCA	cis	rs7395662	1	rs11039819	ENSG00000200090.1	Y_RNA	-3.42	0.000688	0.0396	-0.1	-0.16	HDL cholesterol;	chr11:48540629	chr11:47726894~47726992:-
THCA	cis	rs10085978	0.604	rs7823184	ENSG00000253741.1	CTD-2292P10.4	-3.42	0.000688	0.0396	-0.2	-0.16	Mosquito bite size;	chr8:142138124	chr8:142702252~142726973:-
THCA	cis	rs913655	1	rs1590828	ENSG00000240291.1	RP11-499P20.2	-3.42	0.000688	0.0397	-0.12	-0.16	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18814194	chr10:18513115~18545651:-
THCA	cis	rs913655	0.962	rs1581939	ENSG00000240291.1	RP11-499P20.2	-3.42	0.000688	0.0397	-0.12	-0.16	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18814375	chr10:18513115~18545651:-
THCA	cis	rs6088580	0.634	rs2378133	ENSG00000269202.1	RP4-614O4.12	3.42	0.000688	0.0397	0.13	0.16	Glomerular filtration rate (creatinine);	chr20:34331699	chr20:35201747~35203288:-
THCA	cis	rs57709857	0.957	rs3739252	ENSG00000272092.1	RP11-350N15.5	-3.42	0.000688	0.0397	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr8:38270250	chr8:38382364~38383461:+
THCA	cis	rs9634489	0.843	rs9516685	ENSG00000247400.3	DNAJC3-AS1	-3.42	0.000688	0.0397	-0.1	-0.16	Body mass index;	chr13:96406709	chr13:95648733~95676925:-
THCA	cis	rs2274273	0.934	rs10139337	ENSG00000258469.1	CHMP4BP1	3.42	0.000688	0.0397	0.14	0.16	Protein biomarker;	chr14:55275395	chr14:55298644~55299231:+
THCA	cis	rs7246657	0.943	rs6508732	ENSG00000268499.1	CTB-102L5.8	3.42	0.000688	0.0397	0.2	0.16	Coronary artery calcification;	chr19:37509566	chr19:38199836~38200934:+
THCA	cis	rs6565180	1	rs11862806	ENSG00000274678.1	RP11-2C24.7	-3.42	0.000688	0.0397	-0.14	-0.16	Tonsillectomy;	chr16:30352750	chr16:30821338~30821884:+
THCA	cis	rs561341	0.609	rs739800	ENSG00000263990.1	CTC-542B22.2	3.42	0.000688	0.0397	0.16	0.16	Hip circumference adjusted for BMI;	chr17:31863064	chr17:31873926~31886666:+
THCA	cis	rs561341	0.609	rs7214626	ENSG00000263990.1	CTC-542B22.2	3.42	0.000688	0.0397	0.16	0.16	Hip circumference adjusted for BMI;	chr17:31863970	chr17:31873926~31886666:+
THCA	cis	rs7615952	0.641	rs4490307	ENSG00000248787.1	RP11-666A20.4	-3.42	0.000688	0.0397	-0.23	-0.16	Blood pressure (smoking interaction);	chr3:125993833	chr3:125908005~125910272:-
THCA	cis	rs10911902	0.643	rs1406294	ENSG00000233196.2	GS1-304P7.1	-3.42	0.000688	0.0397	-0.24	-0.16	Schizophrenia;	chr1:186314293	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs76559138	ENSG00000233196.2	GS1-304P7.1	-3.42	0.000688	0.0397	-0.24	-0.16	Schizophrenia;	chr1:186314891	chr1:186580515~186581191:-
THCA	cis	rs7873102	0.933	rs7019689	ENSG00000213839.4	TMX2P1	3.42	0.000688	0.0397	0.12	0.16	Brain structure;	chr9:38028429	chr9:37885683~37886390:+
THCA	cis	rs6901004	0.835	rs1150079	ENSG00000271789.1	RP5-1112D6.7	-3.42	0.000688	0.0397	-0.15	-0.16	Blood metabolite levels;	chr6:111150222	chr6:111297126~111298510:+
THCA	cis	rs11089937	0.597	rs4821772	ENSG00000215456.5	BCRP4	-3.42	0.000688	0.0397	-0.19	-0.16	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22630061~22636153:+
THCA	cis	rs2766547	0.669	rs1831030	ENSG00000228559.1	RP3-340B19.3	3.42	0.000688	0.0397	0.18	0.16	Eosinophil percentage of granulocytes;	chr6:35739156	chr6:35544632~35545669:+
THCA	cis	rs34217772	0.766	rs61992404	ENSG00000258636.1	CTD-2298J14.2	3.42	0.000688	0.0397	0.3	0.16	Myopia;	chr14:41747596	chr14:41587861~41604856:-
THCA	cis	rs13098911	0.54	rs35751180	ENSG00000226074.4	PRSS44	-3.42	0.000688	0.0397	-0.3	-0.16	Celiac disease;	chr3:46014681	chr3:46809359~46812558:-
THCA	cis	rs9303280	0.901	rs12950743	ENSG00000263818.4	CTD-2206N4.4	3.42	0.000688	0.0397	0.2	0.16	Self-reported allergy;	chr17:39892980	chr17:39057019~39113190:+
THCA	cis	rs4389656	0.857	rs274680	ENSG00000248677.1	CTD-2044J15.1	3.42	0.000688	0.0397	0.16	0.16	Coronary artery disease;	chr5:6748972	chr5:6686325~6707711:-
THCA	cis	rs112521149	1	rs112521149	ENSG00000199347.1	RNU5E-1	3.42	0.000688	0.0397	0.32	0.16	Mean corpuscular volume;	chr1:11829758	chr1:11908152~11908271:+
THCA	cis	rs7096965	0.958	rs17368561	ENSG00000242147.1	RP13-463N16.6	-3.42	0.000688	0.0397	-0.18	-0.16	Major depressive disorder;	chr10:4599746	chr10:5594991~5596118:-
THCA	cis	rs4959799	0.655	rs6919570	ENSG00000272248.1	RP3-406P24.4	-3.42	0.000688	0.0397	-0.36	-0.16	Survival in rectal cancer;	chr6:3276783	chr6:4018713~4019202:+
THCA	cis	rs1953600	0.668	rs7091565	ENSG00000242600.5	MBL1P	-3.42	0.000688	0.0397	-0.13	-0.16	Sarcoidosis;	chr10:80153805	chr10:79904898~79950336:+
THCA	cis	rs7818688	1	rs73276437	ENSG00000253528.2	RP11-347C18.4	-3.42	0.000688	0.0397	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95023283	chr8:94974573~94974853:-
THCA	cis	rs35320143	0.5	rs2067040	ENSG00000246777.1	RP11-61A14.4	3.42	0.000688	0.0397	0.14	0.16	Number of children (6+ vs. 0 or 1);	chr16:66730906	chr16:66751752~66754740:+
THCA	cis	rs7819412	0.502	rs4840548	ENSG00000206014.6	OR7E161P	3.42	0.000688	0.0397	0.19	0.16	Triglycerides;	chr8:11135373	chr8:11928597~11929563:-
THCA	cis	rs17798991	0.625	rs34664688	ENSG00000267674.1	RP11-813F20.2	-3.42	0.000688	0.0397	-0.17	-0.16	Obesity-related traits;	chr18:49594616	chr18:49739823~49742063:-
THCA	cis	rs11673344	0.504	rs4239587	ENSG00000233527.7	ZNF529-AS1	3.42	0.000688	0.0397	0.13	0.16	Obesity-related traits;	chr19:37136211	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.504	rs4805202	ENSG00000233527.7	ZNF529-AS1	3.42	0.000688	0.0397	0.13	0.16	Obesity-related traits;	chr19:37136499	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.504	rs4805203	ENSG00000233527.7	ZNF529-AS1	3.42	0.000688	0.0397	0.13	0.16	Obesity-related traits;	chr19:37136586	chr19:36573070~36594708:+
THCA	cis	rs11105298	0.891	rs10777163	ENSG00000266347.2	AC068641.1	3.42	0.000688	0.0397	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89592833~89592927:+
THCA	cis	rs13046373	0.535	rs1354866	ENSG00000174680.8	GRIK1-AS1	-3.42	0.000688	0.0397	-0.19	-0.16	HDL cholesterol;	chr21:30609240	chr21:29748175~29764002:+
THCA	cis	rs7088591	1	rs80056677	ENSG00000276818.1	AC026393.1	3.42	0.000688	0.0397	0.31	0.16	Blood pressure;	chr10:57982809	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs10509083	ENSG00000276818.1	AC026393.1	3.42	0.000688	0.0397	0.31	0.16	Blood pressure;	chr10:57983024	chr10:57095699~57095781:+
THCA	cis	rs7088591	0.867	rs79164980	ENSG00000276818.1	AC026393.1	3.42	0.000688	0.0397	0.31	0.16	Blood pressure;	chr10:57983494	chr10:57095699~57095781:+
THCA	cis	rs2914908	1	rs2914908	ENSG00000250891.1	CTD-2281M20.1	3.42	0.000689	0.0397	0.17	0.16	Common carotid intima-media thickness;Common carotid intima-media thickness in HIV infection;	chr5:118646351	chr5:118468156~118562117:-
THCA	cis	rs600231	0.706	rs10896016	ENSG00000254614.2	AP003068.23	-3.42	0.000689	0.0397	-0.21	-0.16	Bone mineral density;	chr11:65568234	chr11:65177606~65181834:-
THCA	cis	rs9426935	0.58	rs2841102	ENSG00000231416.1	RP11-422P24.9	3.42	0.000689	0.0397	0.18	0.16	Lentiform nucleus volume;	chr1:154045025	chr1:153995632~153995960:+
THCA	cis	rs7119	0.634	rs2682922	ENSG00000259362.2	RP11-307C19.1	3.42	0.000689	0.0397	0.21	0.16	Type 2 diabetes;	chr15:77572664	chr15:77525540~77534110:+
THCA	cis	rs6017317	0.591	rs6017300	ENSG00000234271.1	RP1-138B7.4	-3.42	0.000689	0.0397	-0.2	-0.16	Type 2 diabetes;	chr20:44239415	chr20:43523261~43523572:-
THCA	cis	rs748404	0.631	rs8042688	ENSG00000224677.1	PDIA3P2	3.42	0.000689	0.0397	0.19	0.16	Lung cancer;	chr15:43346327	chr15:43649123~43649280:+
THCA	cis	rs748404	0.631	rs4296223	ENSG00000224677.1	PDIA3P2	3.42	0.000689	0.0397	0.19	0.16	Lung cancer;	chr15:43353048	chr15:43649123~43649280:+
THCA	cis	rs4660456	0.871	rs2274957	ENSG00000238287.1	RP11-656D10.3	-3.42	0.000689	0.0397	-0.2	-0.16	Platelet count;	chr1:40747290	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs4660173	ENSG00000238287.1	RP11-656D10.3	-3.42	0.000689	0.0397	-0.2	-0.16	Platelet count;	chr1:40747876	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs4660452	ENSG00000238287.1	RP11-656D10.3	-3.42	0.000689	0.0397	-0.2	-0.16	Platelet count;	chr1:40748519	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs12567925	ENSG00000238287.1	RP11-656D10.3	-3.42	0.000689	0.0397	-0.2	-0.16	Platelet count;	chr1:40751428	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs12728776	ENSG00000238287.1	RP11-656D10.3	-3.42	0.000689	0.0397	-0.2	-0.16	Platelet count;	chr1:40751718	chr1:40493157~40508661:-
THCA	cis	rs12493885	0.697	rs55955923	ENSG00000243069.6	ARHGEF26-AS1	-3.42	0.000689	0.0397	-0.29	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:153942265	chr3:154024401~154121332:-
THCA	cis	rs9309473	1	rs6755241	ENSG00000273245.1	RP11-434P11.2	3.42	0.000689	0.0397	0.22	0.16	Metabolite levels;	chr2:73414236	chr2:73750256~73750786:-
THCA	cis	rs2635047	1	rs2635049	ENSG00000280212.1	RP11-49K24.3	3.42	0.000689	0.0397	0.15	0.16	Educational attainment;	chr18:47160932	chr18:47076117~47076594:+
THCA	cis	rs17181170	0.553	rs6788255	ENSG00000239572.1	RP11-451B8.1	-3.42	0.000689	0.0397	-0.19	-0.16	Prostate cancer;	chr3:87125486	chr3:87731402~87793629:-
THCA	cis	rs10138297	1	rs10138297	ENSG00000278002.1	RP11-596C23.2	-3.42	0.000689	0.0397	-0.31	-0.16	Erythema nodosum in inflammatory bowel disease;	chr14:50018609	chr14:49863072~49864379:+
THCA	cis	rs7119	0.717	rs12904348	ENSG00000260776.4	RP11-114H24.2	-3.42	0.000689	0.0397	-0.21	-0.16	Type 2 diabetes;	chr15:77523396	chr15:77914217~77926846:-
THCA	cis	rs12049351	0.665	rs12035203	ENSG00000229367.1	HMGN2P19	3.42	0.000689	0.0397	0.24	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229506770	chr1:229570532~229570796:+
THCA	cis	rs1371614	0.632	rs6708148	ENSG00000231636.1	AGBL5-AS1	3.42	0.000689	0.0397	0.18	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944452	chr2:27049683~27050264:-
THCA	cis	rs2292873	1	rs2292873	ENSG00000234949.2	AC104667.3	-3.42	0.000689	0.0397	-0.24	-0.16	Obesity-related traits;	chr2:237590801	chr2:237591020~237595981:+
THCA	cis	rs35851103	0.627	rs58602899	ENSG00000254948.1	OR7E158P	-3.42	0.000689	0.0397	-0.19	-0.16	Neuroticism;	chr8:11991324	chr8:11919900~11920809:-
THCA	cis	rs4245128	0.93	rs4245125	ENSG00000227487.3	NCAM1-AS1	3.42	0.00069	0.0397	0.16	0.16	Life satisfaction;	chr11:112920924	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.897	rs2121680	ENSG00000227487.3	NCAM1-AS1	3.42	0.00069	0.0397	0.16	0.16	Life satisfaction;	chr11:112920928	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.965	rs4245126	ENSG00000227487.3	NCAM1-AS1	3.42	0.00069	0.0397	0.16	0.16	Life satisfaction;	chr11:112921041	chr11:113269532~113273901:-
THCA	cis	rs4245128	1	rs4245128	ENSG00000227487.3	NCAM1-AS1	3.42	0.00069	0.0397	0.16	0.16	Life satisfaction;	chr11:112921260	chr11:113269532~113273901:-
THCA	cis	rs4245128	0.965	rs10789926	ENSG00000227487.3	NCAM1-AS1	3.42	0.00069	0.0397	0.16	0.16	Life satisfaction;	chr11:112921437	chr11:113269532~113273901:-
THCA	cis	rs10895987	1	rs12280510	ENSG00000254614.2	AP003068.23	3.42	0.00069	0.0397	0.26	0.16	Blood protein levels;	chr11:65147076	chr11:65177606~65181834:-
THCA	cis	rs2638953	0.85	rs10843167	ENSG00000247934.4	RP11-967K21.1	-3.42	0.00069	0.0397	-0.16	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28429860	chr12:28163298~28190738:-
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000264242.2	RP11-271K11.1	-3.42	0.00069	0.0397	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30553697~30558962:+
THCA	cis	rs9457247	0.565	rs12178491	ENSG00000235272.1	FAM103A2P	3.42	0.00069	0.0397	0.22	0.16	Crohn's disease;	chr6:167098986	chr6:166586124~166586477:-
THCA	cis	rs2882667	0.898	rs13163536	ENSG00000249593.5	CTB-46B19.2	3.42	0.00069	0.0398	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:139012647~139051203:+
THCA	cis	rs9376098	0.679	rs6903449	ENSG00000232876.1	CTA-212D2.2	-3.42	0.00069	0.0398	-0.21	-0.16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135171270	chr6:135055033~135060550:+
THCA	cis	rs7336933	0.866	rs4147047	ENSG00000278338.3	VWA8-AS1	3.42	0.00069	0.0398	0.25	0.16	Calcium levels;	chr13:41819688	chr13:41955808~41981565:+
THCA	cis	rs41411047	0.826	rs112661097	ENSG00000252172.1	RNU6-720P	3.42	0.00069	0.0398	0.33	0.16	Myocardial infarction;	chr3:149918659	chr3:149917342~149917449:-
THCA	cis	rs7308116	0.967	rs6539360	ENSG00000257951.1	RP11-554D14.4	3.42	0.00069	0.0398	0.18	0.16	Pelvic organ prolapse (moderate/severe);	chr12:107804942	chr12:107881242~107883382:+
THCA	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	3.42	0.00069	0.0398	0.2	0.16	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
THCA	cis	rs11642862	1	rs112691371	ENSG00000275263.1	RP11-1072A3.4	-3.42	0.00069	0.0398	-0.34	-0.16	Tonsillectomy;	chr16:30856895	chr16:30956872~30957199:-
THCA	cis	rs4931000	1	rs2166807	ENSG00000255760.1	RP11-428G5.5	-3.42	0.00069	0.0398	-0.16	-0.16	Testicular germ cell tumor;	chr12:31981704	chr12:31877079~31887203:-
THCA	cis	rs2066819	1	rs116535779	ENSG00000257303.1	RP11-977G19.11	-3.42	0.00069	0.0398	-0.22	-0.16	Psoriasis vulgaris;	chr12:56345477	chr12:56300142~56314808:+
THCA	cis	rs7760535	0.831	rs62420437	ENSG00000272356.1	RP5-1112D6.8	-3.42	0.00069	0.0398	-0.12	-0.16	Metabolic traits;	chr6:111427577	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs4276544	ENSG00000272356.1	RP5-1112D6.8	-3.42	0.00069	0.0398	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.508	rs12211763	ENSG00000272356.1	RP5-1112D6.8	-3.42	0.00069	0.0398	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs10872067	ENSG00000272356.1	RP5-1112D6.8	-3.42	0.00069	0.0398	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs9689727	ENSG00000272356.1	RP5-1112D6.8	-3.42	0.00069	0.0398	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.528	rs12214380	ENSG00000272356.1	RP5-1112D6.8	-3.42	0.00069	0.0398	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111309203~111313517:+
THCA	cis	rs9400467	0.508	rs61269242	ENSG00000272356.1	RP5-1112D6.8	-3.42	0.00069	0.0398	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:111309203~111313517:+
THCA	cis	rs453301	0.686	rs3989373	ENSG00000254340.1	RP11-10A14.3	-3.42	0.00069	0.0398	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9053798	chr8:9141424~9145435:+
THCA	cis	rs6472235	1	rs11986631	ENSG00000272192.1	CTD-2532N20.1	3.42	0.00069	0.0398	0.15	0.16	Plateletcrit;Myopia (pathological);	chr8:65908091	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.872	rs6472236	ENSG00000272192.1	CTD-2532N20.1	3.42	0.00069	0.0398	0.15	0.16	Plateletcrit;Myopia (pathological);	chr8:65920446	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.903	rs7841181	ENSG00000272192.1	CTD-2532N20.1	3.42	0.00069	0.0398	0.15	0.16	Plateletcrit;Myopia (pathological);	chr8:65923319	chr8:65842752~65843331:+
THCA	cis	rs6472235	1	rs11986470	ENSG00000272192.1	CTD-2532N20.1	3.42	0.00069	0.0398	0.15	0.16	Plateletcrit;Myopia (pathological);	chr8:65924048	chr8:65842752~65843331:+
THCA	cis	rs72928364	0.789	rs35856427	ENSG00000256628.3	ZBTB11-AS1	3.42	0.00069	0.0398	0.28	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101086882	chr3:101676475~101679217:+
THCA	cis	rs9549260	0.755	rs9577091	ENSG00000275149.1	RP11-427J23.1	-3.42	0.00069	0.0398	-0.21	-0.16	Red blood cell count;	chr13:40653728	chr13:40079106~40273509:-
THCA	cis	rs2307022	0.541	rs10775303	ENSG00000279649.1	RP11-96D1.8	-3.42	0.00069	0.0398	-0.1	-0.16	Body mass index;	chr16:68327011	chr16:68290087~68292790:-
THCA	cis	rs4081724	0.638	rs17602094	ENSG00000267296.2	CEBPA-AS1	-3.42	0.00069	0.0398	-0.2	-0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33357777	chr19:33302857~33305054:+
THCA	cis	rs6496667	0.533	rs2589949	ENSG00000213471.7	TTLL13P	3.42	0.00069	0.0398	0.18	0.16	Rheumatoid arthritis;	chr15:90411783	chr15:90249530~90265482:+
THCA	cis	rs8179	0.7	rs42043	ENSG00000230927.2	TMBIM7P	3.42	0.00069	0.0398	0.22	0.16	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92618019	chr7:92412976~92439562:-
THCA	cis	rs12912251	0.591	rs3104150	ENSG00000259225.5	RP11-1008C21.1	-3.42	0.00069	0.0398	-0.19	-0.16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr15:38711384	chr15:37984766~38062340:+
THCA	cis	rs7579899	1	rs7579899	ENSG00000226087.1	AC106869.2	-3.42	0.00069	0.0398	-0.19	-0.16	Renal cell carcinoma;	chr2:46310465	chr2:47225794~47239225:+
THCA	cis	rs2337406	0.789	rs112027230	ENSG00000280411.1	IGHV1-69-2	-3.42	0.00069	0.0398	-0.12	-0.16	Alzheimer's disease (late onset);	chr14:106810329	chr14:106762092~106762588:-
THCA	cis	rs7028939	1	rs73507831	ENSG00000255145.2	STX17-AS1	-3.42	0.00069	0.0398	-0.23	-0.16	Preeclampsia;	chr9:100163322	chr9:99886322~99906601:-
THCA	cis	rs1959947	0.876	rs1954456	ENSG00000251363.2	RP11-129M6.1	3.42	0.00069	0.0398	0.21	0.16	Hemostatic factors and hematological phenotypes;	chr14:41086559	chr14:40954898~40975877:+
THCA	cis	rs2904297	0.958	rs1876266	ENSG00000261490.1	RP11-448G15.3	-3.42	0.00069	0.0398	-0.11	-0.16	Hashimoto thyroiditis versus Graves' disease;	chr4:11035790	chr4:10068089~10073019:-
THCA	cis	rs10090774	0.965	rs45613837	ENSG00000280303.2	ERICD	3.42	0.000691	0.0398	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140734818	chr8:140636281~140638283:+
THCA	cis	rs6806253	0.838	rs8179974	ENSG00000239405.1	TMED10P2	3.42	0.000691	0.0398	0.24	0.16	Pit-and-Fissure caries;	chr3:128562858	chr3:128538020~128538631:+
THCA	cis	rs7843479	1	rs67385415	ENSG00000208037.1	MIR320A	-3.42	0.000691	0.0398	-0.19	-0.16	Mean corpuscular volume;	chr8:21996222	chr8:22244962~22245043:-
THCA	cis	rs6981523	0.566	rs34162231	ENSG00000255046.1	RP11-297N6.4	3.42	0.000691	0.0398	0.17	0.16	Neuroticism;	chr8:11145578	chr8:11797928~11802568:-
THCA	cis	rs10457838	0.755	rs11755147	ENSG00000231760.4	RP11-350J20.5	-3.42	0.000691	0.0398	-0.23	-0.16	Post-traumatic stress disorder;	chr6:149090029	chr6:149796151~149826294:-
THCA	cis	rs7112925	1	rs7112925	ENSG00000255517.5	CTD-3074O7.5	3.42	0.000691	0.0398	0.12	0.16	Height;	chr11:67058689	chr11:66473490~66480233:-
THCA	cis	rs4081724	1	rs4081724	ENSG00000267296.2	CEBPA-AS1	3.42	0.000691	0.0398	0.23	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33334040	chr19:33302857~33305054:+
THCA	cis	rs787665	0.836	rs787663	ENSG00000232709.1	MARK2P9	3.42	0.000691	0.0398	0.24	0.16	Gut microbiome composition (summer);	chr10:93311798	chr10:92418667~92420875:+
THCA	cis	rs16975963	0.793	rs1807157	ENSG00000226686.6	LINC01535	-3.42	0.000691	0.0398	-0.21	-0.16	Longevity;	chr19:37974883	chr19:37251912~37265535:+
THCA	cis	rs9907295	0.688	rs9890583	ENSG00000270871.1	AC015849.19	3.42	0.000691	0.0398	0.12	0.16	Fibroblast growth factor basic levels;	chr17:35919389	chr17:35816717~35830293:-
THCA	cis	rs804280	0.509	rs7461273	ENSG00000254948.1	OR7E158P	-3.42	0.000691	0.0398	-0.2	-0.16	Myopia (pathological);	chr8:11920468	chr8:11919900~11920809:-
THCA	cis	rs9611565	0.659	rs73178641	ENSG00000281538.1	RP4-669P10.20	3.42	0.000691	0.0398	0.17	0.16	Vitiligo;	chr22:41556071	chr22:42138060~42139726:+
THCA	cis	rs34779708	0.931	rs11596502	ENSG00000233200.1	RP11-324I22.2	3.42	0.000691	0.0398	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35219894~35230598:-
THCA	cis	rs453301	0.624	rs7014430	ENSG00000254340.1	RP11-10A14.3	3.42	0.000691	0.0398	0.17	0.16	Joint mobility (Beighton score);	chr8:8970227	chr8:9141424~9145435:+
THCA	cis	rs2243480	0.708	rs781141	ENSG00000237310.1	GS1-124K5.4	3.42	0.000691	0.0398	0.18	0.16	Diabetic kidney disease;	chr7:65973566	chr7:66493706~66495474:+
THCA	cis	rs7246657	0.891	rs7253114	ENSG00000268499.1	CTB-102L5.8	3.42	0.000691	0.0398	0.2	0.16	Coronary artery calcification;	chr19:37497823	chr19:38199836~38200934:+
THCA	cis	rs2438150	1	rs2438150	ENSG00000263432.2	RN7SL689P	3.42	0.000691	0.0398	0.16	0.16	Plateletcrit;	chr5:122863501	chr5:123022487~123022783:-
THCA	cis	rs9652601	0.622	rs3901386	ENSG00000263033.2	RP11-396B14.2	-3.42	0.000691	0.0398	-0.12	-0.16	Systemic lupus erythematosus;	chr16:11048863	chr16:11196177~11224969:+
THCA	cis	rs736801	0.808	rs6866614	ENSG00000263597.1	MIR3936	-3.42	0.000691	0.0398	-0.16	-0.16	Mosquito bite size;Breast cancer;	chr5:132451445	chr5:132365490~132365599:-
THCA	cis	rs7129556	0.906	rs72945508	ENSG00000254459.1	RP11-91P24.7	3.42	0.000691	0.0398	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77556492	chr11:77829654~77872262:-
THCA	cis	rs16957091	0.528	rs35538776	ENSG00000249839.1	AC011330.5	3.42	0.000691	0.0398	0.24	0.16	MGMT methylation in smokers;	chr15:42791316	chr15:43663654~43684339:-
THCA	cis	rs61160187	0.582	rs1460961	ENSG00000272308.1	RP11-231G3.1	-3.42	0.000691	0.0398	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60866457~60866935:-
THCA	cis	rs11884770	0.599	rs2178631	ENSG00000236432.6	AC097662.2	3.42	0.000691	0.0398	0.15	0.16	Advanced age-related macular degeneration;	chr2:227222762	chr2:227221052~227325201:-
THCA	cis	rs559928	0.606	rs56311067	ENSG00000236935.1	AP003774.1	3.42	0.000691	0.0398	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164135	chr11:64325050~64329504:-
THCA	cis	rs559928	0.556	rs11607903	ENSG00000236935.1	AP003774.1	3.42	0.000691	0.0398	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164668	chr11:64325050~64329504:-
THCA	cis	rs559928	0.606	rs55942618	ENSG00000236935.1	AP003774.1	3.42	0.000691	0.0398	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168533	chr11:64325050~64329504:-
THCA	cis	rs559928	0.606	rs76653616	ENSG00000236935.1	AP003774.1	3.42	0.000691	0.0398	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168667	chr11:64325050~64329504:-
THCA	cis	rs4919687	0.679	rs12762176	ENSG00000236937.2	PTGES3P4	3.42	0.000691	0.0398	0.22	0.16	Colorectal cancer;	chr10:102739475	chr10:102845595~102845950:+
THCA	cis	rs10911363	0.571	rs6424897	ENSG00000232860.6	SMG7-AS1	3.42	0.000691	0.0398	0.12	0.16	Systemic lupus erythematosus;	chr1:183450068	chr1:183460874~183472265:-
THCA	cis	rs7737355	1	rs12517604	ENSG00000224431.1	AC063976.7	-3.42	0.000691	0.0398	-0.15	-0.16	Life satisfaction;	chr5:131412807	chr5:132199456~132203487:+
THCA	cis	rs9916302	0.706	rs9891892	ENSG00000266469.1	CTB-131K11.1	3.42	0.000691	0.0398	0.15	0.16	Glomerular filtration rate (creatinine);	chr17:39323603	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs7503081	ENSG00000266469.1	CTB-131K11.1	3.42	0.000691	0.0398	0.15	0.16	Glomerular filtration rate (creatinine);	chr17:39326420	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs9944459	ENSG00000266469.1	CTB-131K11.1	3.42	0.000691	0.0398	0.15	0.16	Glomerular filtration rate (creatinine);	chr17:39327932	chr17:39401793~39406233:+
THCA	cis	rs11958404	0.517	rs56344822	ENSG00000231989.3	PPP1R2P3	-3.42	0.000691	0.0398	-0.39	-0.16	IgG glycosylation;	chr5:157792949	chr5:156850563~156851174:+
THCA	cis	rs11958404	0.517	rs17679725	ENSG00000231989.3	PPP1R2P3	-3.42	0.000691	0.0398	-0.39	-0.16	IgG glycosylation;	chr5:157794481	chr5:156850563~156851174:+
THCA	cis	rs7246657	0.943	rs3803895	ENSG00000266916.4	ZNF793-AS1	-3.42	0.000691	0.0398	-0.15	-0.16	Coronary artery calcification;	chr19:37407767	chr19:37497159~37507046:-
THCA	cis	rs6840360	0.615	rs3828546	ENSG00000251603.1	RP11-164P12.4	3.42	0.000691	0.0398	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151758664	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs1429559	ENSG00000251603.1	RP11-164P12.4	3.42	0.000691	0.0398	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151760800	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs1366907	ENSG00000251603.1	RP11-164P12.4	3.42	0.000691	0.0398	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151761597	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs1429558	ENSG00000251603.1	RP11-164P12.4	3.42	0.000691	0.0398	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151764254	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs11723227	ENSG00000251603.1	RP11-164P12.4	3.42	0.000691	0.0398	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151768565	chr4:151667224~151670502:+
THCA	cis	rs6840360	0.593	rs10013612	ENSG00000251603.1	RP11-164P12.4	3.42	0.000691	0.0398	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151772470	chr4:151667224~151670502:+
THCA	cis	rs9527	0.615	rs1556960	ENSG00000236937.2	PTGES3P4	3.42	0.000691	0.0398	0.21	0.16	Arsenic metabolism;	chr10:102966916	chr10:102845595~102845950:+
THCA	cis	rs539096	0.831	rs650729	ENSG00000229348.1	HYI-AS1	3.42	0.000691	0.0398	0.17	0.16	Intelligence (multi-trait analysis);	chr1:43576868	chr1:43453927~43456995:+
THCA	cis	rs2483374	0.725	rs1981053	ENSG00000253771.4	TPTE2P1	-3.42	0.000691	0.0398	-0.14	-0.16	Obesity-related traits;	chr13:24958140	chr13:24924677~24968487:-
THCA	cis	rs80130819	0.748	rs2732477	ENSG00000273765.1	RP11-370I10.11	-3.42	0.000691	0.0398	-0.18	-0.16	Prostate cancer;	chr12:48306499	chr12:48360920~48361377:+
THCA	cis	rs11638352	1	rs2696076	ENSG00000259418.1	RP11-109D20.1	-3.42	0.000692	0.0398	-0.37	-0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44190916	chr15:45041716~45058707:-
THCA	cis	rs6957923	0.755	rs34979424	ENSG00000234286.1	AC006026.13	-3.42	0.000692	0.0398	-0.21	-0.16	Height;	chr7:23480028	chr7:23680195~23680786:-
THCA	cis	rs72634501	0.716	rs67062906	ENSG00000182109.6	RP11-69E11.4	3.42	0.000692	0.0398	0.17	0.16	HDL cholesterol;	chr1:39151018	chr1:39522280~39546187:-
THCA	cis	rs3788317	0.526	rs12168841	ENSG00000232926.1	AC000078.5	-3.42	0.000692	0.0398	-0.18	-0.16	Glaucoma (primary angle closure);	chr22:19897505	chr22:19887289~19887970:+
THCA	cis	rs76793172	1	rs77756656	ENSG00000207003.1	RNU6-611P	3.42	0.000692	0.0398	0.3	0.16	Eosinophil counts;	chr19:45817460	chr19:45047458~45047561:+
THCA	cis	rs1048886	0.808	rs77554252	ENSG00000271967.1	RP11-134K13.4	-3.42	0.000692	0.0399	-0.19	-0.16	Type 2 diabetes;	chr6:70540257	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.808	rs76755006	ENSG00000271967.1	RP11-134K13.4	-3.42	0.000692	0.0399	-0.19	-0.16	Type 2 diabetes;	chr6:70545733	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs12530057	ENSG00000271967.1	RP11-134K13.4	-3.42	0.000692	0.0399	-0.19	-0.16	Type 2 diabetes;	chr6:70551446	chr6:70596438~70596980:+
THCA	cis	rs11658311	1	rs9905032	ENSG00000226478.3	UPF3AP1	-3.42	0.000692	0.0399	-0.4	-0.16	Obsessive-compulsive symptoms;	chr17:17554454	chr17:16745636~16746761:-
THCA	cis	rs12493885	0.818	rs61791545	ENSG00000238755.3	RP11-23D24.2	-3.42	0.000692	0.0399	-0.33	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154051099	chr3:153384934~153980186:-
THCA	cis	rs12493885	0.818	rs73160504	ENSG00000238755.3	RP11-23D24.2	-3.42	0.000692	0.0399	-0.33	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154055595	chr3:153384934~153980186:-
THCA	cis	rs7631605	0.586	rs7612888	ENSG00000224080.1	UBE2FP1	3.42	0.000692	0.0399	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37342070	chr3:37143512~37143958:-
THCA	cis	rs7179456	0.567	rs72745027	ENSG00000259657.1	PIGHP1	-3.42	0.000692	0.0399	-0.18	-0.16	Asperger disorder;	chr15:58802130	chr15:59676757~59677321:+
THCA	cis	rs10938353	0.911	rs1866511	ENSG00000273369.1	RP11-700J17.1	3.42	0.000692	0.0399	0.17	0.16	Body mass index;	chr4:44590153	chr4:44693946~44694386:-
THCA	cis	rs2011503	0.739	rs8108659	ENSG00000271283.1	CTC-412M14.6	-3.42	0.000692	0.0399	-0.23	-0.16	Bipolar disorder;	chr19:19569929	chr19:19699203~19699409:-
THCA	cis	rs758324	0.898	rs11958749	ENSG00000224431.1	AC063976.7	3.42	0.000692	0.0399	0.15	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131830321	chr5:132199456~132203487:+
THCA	cis	rs758324	0.947	rs2404778	ENSG00000224431.1	AC063976.7	3.42	0.000692	0.0399	0.15	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131837193	chr5:132199456~132203487:+
THCA	cis	rs9863	0.828	rs1187415	ENSG00000269938.1	RP11-214K3.20	3.42	0.000692	0.0399	0.17	0.16	White blood cell count;	chr12:124006982	chr12:123968023~123968579:-
THCA	cis	rs7212590	0.881	rs7216675	ENSG00000267302.4	RP11-178C3.2	3.42	0.000692	0.0399	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59805313	chr17:59964832~59996972:+
THCA	cis	rs7212590	1	rs73315284	ENSG00000267302.4	RP11-178C3.2	3.42	0.000692	0.0399	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59807507	chr17:59964832~59996972:+
THCA	cis	rs7212590	1	rs7212590	ENSG00000267302.4	RP11-178C3.2	3.42	0.000692	0.0399	0.29	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808348	chr17:59964832~59996972:+
THCA	cis	rs950169	0.922	rs11631096	ENSG00000230373.7	GOLGA6L5P	-3.42	0.000692	0.0399	-0.17	-0.16	Schizophrenia;	chr15:84557698	chr15:84507885~84516814:-
THCA	cis	rs2460905	0.867	rs6992991	ENSG00000251468.2	RP11-369K16.1	-3.42	0.000692	0.0399	-0.29	-0.16	Post-traumatic stress disorder;	chr8:13008153	chr8:12958387~12962200:+
THCA	cis	rs7631605	0.905	rs7651903	ENSG00000272334.1	RP11-129K12.1	-3.42	0.000692	0.0399	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:36965195	chr3:36973117~36973672:-
THCA	cis	rs9788682	1	rs12441354	ENSG00000261143.1	ADAMTS7P3	-3.42	0.000692	0.0399	-0.22	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78528674	chr15:77976042~77993057:+
THCA	cis	rs7735319	0.51	rs6450946	ENSG00000249572.1	CTD-2203K17.1	3.42	0.000692	0.0399	0.18	0.16	Systolic blood pressure;	chr5:33119942	chr5:33424025~33440619:-
THCA	cis	rs194045	0.609	rs252344	ENSG00000103472.8	RRN3P2	-3.42	0.000692	0.0399	-0.18	-0.16	Yu-Zhi constitution type in type 2 diabetes;	chr16:29173561	chr16:29074976~29116718:+
THCA	cis	rs7096965	0.958	rs61830164	ENSG00000242147.1	RP13-463N16.6	-3.42	0.000692	0.0399	-0.18	-0.16	Major depressive disorder;	chr10:4603313	chr10:5594991~5596118:-
THCA	cis	rs1529711	0.5	rs80091992	ENSG00000267100.1	ILF3-AS1	3.42	0.000692	0.0399	0.16	0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr19:10794226	chr19:10651862~10653844:-
THCA	cis	rs73157695	0.676	rs440207	ENSG00000274248.1	AJ011932.1	3.42	0.000692	0.0399	0.18	0.16	Myopia;	chr21:45914500	chr21:45974489~45974953:+
THCA	cis	rs7216064	0.655	rs8078543	ENSG00000267023.4	LRRC37A16P	3.42	0.000692	0.0399	0.11	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68125777~68152468:-
THCA	cis	rs6472235	0.656	rs16932382	ENSG00000272192.1	CTD-2532N20.1	3.42	0.000692	0.0399	0.16	0.16	Plateletcrit;Myopia (pathological);	chr8:65966241	chr8:65842752~65843331:+
THCA	cis	rs832540	0.931	rs832536	ENSG00000271828.1	CTD-2310F14.1	-3.42	0.000692	0.0399	-0.21	-0.16	Coronary artery disease;	chr5:56916768	chr5:56927874~56929573:+
THCA	cis	rs9611565	0.694	rs5758368	ENSG00000237037.8	NDUFA6-AS1	3.42	0.000692	0.0399	0.14	0.16	Vitiligo;	chr22:41466284	chr22:42090931~42137742:+
THCA	cis	rs11030122	0.673	rs10835596	ENSG00000230593.3	AC090804.1	3.42	0.000692	0.0399	0.21	0.16	Mean platelet volume;Platelet distribution width;	chr11:4078436	chr11:3892398~3892887:-
THCA	cis	rs12472274	0.817	rs34791859	ENSG00000186235.9	AC016757.3	3.42	0.000692	0.0399	0.22	0.16	Phospholipid levels (plasma);	chr2:238162278	chr2:238224552~238231677:-
THCA	cis	rs2839619	0.525	rs11702511	ENSG00000233754.1	AP001628.7	-3.42	0.000692	0.0399	-0.17	-0.16	Biochemical measures;	chr21:43024169	chr21:42781074~42782233:-
THCA	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-3.42	0.000693	0.0399	-0.14	-0.16	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
THCA	cis	rs3790645	1	rs383913	ENSG00000241547.1	RP11-4K3__A.5	-3.42	0.000693	0.0399	-0.18	-0.16	Glucose homeostasis traits;	chr1:26566815	chr1:27325329~27325796:+
THCA	cis	rs1009077	0.716	rs35967840	ENSG00000245958.5	RP11-33B1.1	3.42	0.000693	0.0399	0.24	0.16	Endometriosis;	chr4:119612287	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs13106925	ENSG00000245958.5	RP11-33B1.1	3.42	0.000693	0.0399	0.24	0.16	Endometriosis;	chr4:119617953	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.669	rs11730798	ENSG00000245958.5	RP11-33B1.1	3.42	0.000693	0.0399	0.24	0.16	Endometriosis;	chr4:119618704	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.626	rs11731568	ENSG00000245958.5	RP11-33B1.1	3.42	0.000693	0.0399	0.24	0.16	Endometriosis;	chr4:119618796	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs62319657	ENSG00000245958.5	RP11-33B1.1	3.42	0.000693	0.0399	0.24	0.16	Endometriosis;	chr4:119621367	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs13136296	ENSG00000245958.5	RP11-33B1.1	3.42	0.000693	0.0399	0.24	0.16	Endometriosis;	chr4:119622000	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs62319658	ENSG00000245958.5	RP11-33B1.1	3.42	0.000693	0.0399	0.24	0.16	Endometriosis;	chr4:119623849	chr4:119454791~119552025:+
THCA	cis	rs250518	0.926	rs1912005	ENSG00000251467.1	CTC-250P20.2	-3.42	0.000693	0.0399	-0.21	-0.16	Mean corpuscular hemoglobin concentration;	chr5:72772227	chr5:72996920~72997642:+
THCA	cis	rs7273787	1	rs7273787	ENSG00000226608.3	FTLP3	3.42	0.000693	0.0399	0.17	0.16	Height;	chr20:4117920	chr20:4023917~4024444:+
THCA	cis	rs853679	0.723	rs9366718	ENSG00000261839.1	RP1-265C24.8	3.42	0.000693	0.0399	0.19	0.16	Depression;	chr6:28237724	chr6:28136849~28139678:+
THCA	cis	rs7851693	1	rs10901216	ENSG00000232172.1	RP11-57C19.2	-3.42	0.000693	0.0399	-0.17	-0.16	Bone mineral density;	chr9:130596504	chr9:130651799~130652383:+
THCA	cis	rs73222236	0.737	rs9854328	ENSG00000273486.1	RP11-731C17.2	3.42	0.000693	0.0399	0.13	0.16	Coronary artery disease;	chr3:136350878	chr3:136837338~136839021:-
THCA	cis	rs757282	0.569	rs73107911	ENSG00000268069.2	RP5-1057I20.4	3.42	0.000693	0.0399	0.26	0.16	Optic nerve measurement (cup-to-disc ratio);	chr12:47779822	chr12:47784923~47786002:+
THCA	cis	rs6832769	0.696	rs7660054	ENSG00000223305.1	RN7SKP30	3.42	0.000693	0.0399	0.2	0.16	Personality dimensions;	chr4:55402340	chr4:55540502~55540835:-
THCA	cis	rs9902453	0.765	rs2169810	ENSG00000214719.10	AC005562.1	3.42	0.000693	0.0399	0.14	0.16	Coffee consumption (cups per day);	chr17:29840923	chr17:30576464~30672789:+
THCA	cis	rs7521902	0.853	rs3920498	ENSG00000228397.1	RP1-224A6.3	-3.42	0.000693	0.0399	-0.25	-0.16	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22166394	chr1:22023994~22024968:-
THCA	cis	rs1005277	0.579	rs1614236	ENSG00000151963.4	RP11-775A3.1	-3.42	0.000693	0.0399	-0.16	-0.16	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2749616	ENSG00000151963.4	RP11-775A3.1	-3.42	0.000693	0.0399	-0.16	-0.16	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs1780146	ENSG00000151963.4	RP11-775A3.1	-3.42	0.000693	0.0399	-0.16	-0.16	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:37883594~37884109:+
THCA	cis	rs9425766	0.679	rs4652234	ENSG00000270084.1	GAS5-AS1	-3.42	0.000693	0.0399	-0.16	-0.16	Life satisfaction;	chr1:174181712	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.732	rs6658543	ENSG00000270084.1	GAS5-AS1	-3.42	0.000693	0.0399	-0.16	-0.16	Life satisfaction;	chr1:174183338	chr1:173863248~173863941:+
THCA	cis	rs972578	1	rs5759078	ENSG00000274717.1	RP1-47A17.1	-3.42	0.000693	0.0399	-0.16	-0.16	Mean platelet volume;	chr22:42997036	chr22:42791814~42794313:-
THCA	cis	rs7824557	0.767	rs2060463	ENSG00000255052.4	FAM66D	3.42	0.000693	0.0399	0.25	0.16	Retinal vascular caliber;	chr8:11304101	chr8:12115782~12177550:+
THCA	cis	rs6598955	0.724	rs12132137	ENSG00000236782.4	RP11-96L14.7	-3.42	0.000693	0.0399	-0.19	-0.16	Obesity-related traits;	chr1:26304752	chr1:26169947~26171821:-
THCA	cis	rs35306767	0.761	rs11253558	ENSG00000229869.1	RP11-363N22.2	-3.41	0.000693	0.0399	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:998043	chr10:933026~942743:+
THCA	cis	rs35306767	0.761	rs11253559	ENSG00000229869.1	RP11-363N22.2	-3.41	0.000693	0.0399	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:998869	chr10:933026~942743:+
THCA	cis	rs324126	0.78	rs60935857	ENSG00000269834.4	ZNF528-AS1	3.41	0.000693	0.0399	0.12	0.16	Colonoscopy-negative controls vs population controls;	chr19:52382606	chr19:52388842~52397766:-
THCA	cis	rs7520050	0.778	rs3013597	ENSG00000281133.1	AL355480.3	-3.41	0.000693	0.0399	-0.18	-0.16	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45580892~45580996:-
THCA	cis	rs7577696	0.524	rs545303	ENSG00000276517.1	AL133243.2	-3.41	0.000693	0.0399	-0.14	-0.16	Inflammatory biomarkers;	chr2:31588929	chr2:32526504~32529507:+
THCA	cis	rs7937890	0.535	rs2575857	ENSG00000251991.1	RNU7-49P	3.41	0.000693	0.0399	0.18	0.16	Mitochondrial DNA levels;	chr11:14479750	chr11:14478892~14478953:+
THCA	cis	rs34779708	0.897	rs4934527	ENSG00000233200.1	RP11-324I22.2	3.41	0.000693	0.0399	0.18	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35219894~35230598:-
THCA	cis	rs972578	0.967	rs2267477	ENSG00000274717.1	RP1-47A17.1	-3.41	0.000693	0.0399	-0.16	-0.16	Mean platelet volume;	chr22:42938568	chr22:42791814~42794313:-
THCA	cis	rs867186	0.614	rs76163454	ENSG00000279253.1	RP4-614O4.13	-3.41	0.000693	0.0399	-0.31	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34863903	chr20:35262727~35264187:-
THCA	cis	rs867186	0.614	rs75076672	ENSG00000279253.1	RP4-614O4.13	-3.41	0.000693	0.0399	-0.31	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34863910	chr20:35262727~35264187:-
THCA	cis	rs1048257	0.682	rs2582514	ENSG00000258701.1	LINC00638	3.41	0.000693	0.0399	0.17	0.16	Systemic lupus erythematosus;	chr14:104946867	chr14:104821201~104823718:+
THCA	cis	rs7395662	0.963	rs6485906	ENSG00000200090.1	Y_RNA	-3.41	0.000694	0.0399	-0.1	-0.16	HDL cholesterol;	chr11:48630109	chr11:47726894~47726992:-
THCA	cis	rs966423	0.527	rs6723847	ENSG00000233143.1	DIRC3-AS1	-3.41	0.000694	0.0399	-0.17	-0.16	Thyroid cancer;	chr2:217391766	chr2:217282739~217336120:+
THCA	cis	rs208520	0.69	rs4710311	ENSG00000218890.1	NUFIP1P	-3.41	0.000694	0.0399	-0.23	-0.16	Exhaled nitric oxide output;	chr6:66113330	chr6:66093431~66094909:-
THCA	cis	rs12935418	0.583	rs7186230	ENSG00000261838.4	RP11-303E16.6	3.41	0.000694	0.0399	0.22	0.16	Mean corpuscular volume;	chr16:80930723	chr16:81069854~81076598:+
THCA	cis	rs3808502	0.549	rs4841564	ENSG00000206014.6	OR7E161P	3.41	0.000694	0.0399	0.18	0.16	Neuroticism;	chr8:11568300	chr8:11928597~11929563:-
THCA	cis	rs9652601	0.691	rs9933507	ENSG00000263033.2	RP11-396B14.2	-3.41	0.000694	0.0399	-0.12	-0.16	Systemic lupus erythematosus;	chr16:11107571	chr16:11196177~11224969:+
THCA	cis	rs1499614	1	rs1267817	ENSG00000273024.4	INTS4P2	3.41	0.000694	0.0399	0.27	0.16	Gout;	chr7:66645053	chr7:65647864~65715661:+
THCA	cis	rs786425	0.804	rs10846535	ENSG00000278112.1	RP11-972P1.11	3.41	0.000694	0.0399	0.15	0.16	Pubertal anthropometrics;	chr12:123645841	chr12:123519390~123519856:-
THCA	cis	rs7259376	0.936	rs12459636	ENSG00000269345.1	VN1R85P	-3.41	0.000694	0.0399	-0.17	-0.16	Menopause (age at onset);	chr19:22359637	chr19:22174766~22175191:-
THCA	cis	rs7474896	0.526	rs1208633	ENSG00000272983.1	RP11-508N22.12	3.41	0.000694	0.0399	0.16	0.16	Obesity (extreme);	chr10:37867945	chr10:38137337~38144399:+
THCA	cis	rs7474896	0.559	rs1779075	ENSG00000272983.1	RP11-508N22.12	3.41	0.000694	0.0399	0.16	0.16	Obesity (extreme);	chr10:37878602	chr10:38137337~38144399:+
THCA	cis	rs7474896	0.559	rs2753880	ENSG00000272983.1	RP11-508N22.12	3.41	0.000694	0.0399	0.16	0.16	Obesity (extreme);	chr10:37884410	chr10:38137337~38144399:+
THCA	cis	rs4792901	0.802	rs9903373	ENSG00000279602.1	CTD-3014M21.1	-3.41	0.000694	0.0399	-0.2	-0.16	Dupuytren's disease;	chr17:43480606	chr17:43360041~43361361:-
THCA	cis	rs67478160	0.619	rs12886363	ENSG00000258914.1	CTD-2134A5.3	-3.41	0.000694	0.0399	-0.18	-0.16	Schizophrenia;	chr14:103807449	chr14:103875055~103877478:+
THCA	cis	rs67478160	0.643	rs12880821	ENSG00000258914.1	CTD-2134A5.3	-3.41	0.000694	0.0399	-0.18	-0.16	Schizophrenia;	chr14:103809712	chr14:103875055~103877478:+
THCA	cis	rs11785400	1	rs6988393	ENSG00000177335.9	C8orf31	3.41	0.000694	0.0399	0.17	0.16	Schizophrenia;	chr8:142659184	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs4736365	ENSG00000177335.9	C8orf31	3.41	0.000694	0.0399	0.17	0.16	Schizophrenia;	chr8:142660785	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs3735994	ENSG00000177335.9	C8orf31	3.41	0.000694	0.0399	0.17	0.16	Schizophrenia;	chr8:142661271	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs3824208	ENSG00000177335.9	C8orf31	3.41	0.000694	0.0399	0.17	0.16	Schizophrenia;	chr8:142662241	chr8:143039209~143059942:+
THCA	cis	rs7819412	0.775	rs6601564	ENSG00000261451.1	RP11-981G7.1	-3.41	0.000694	0.0399	-0.2	-0.16	Triglycerides;	chr8:11124541	chr8:10433672~10438312:+
THCA	cis	rs15676	0.838	rs2280841	ENSG00000234771.3	SLC25A25-AS1	3.41	0.000694	0.0399	0.14	0.16	Blood metabolite levels;	chr9:128837832	chr9:128108581~128118693:-
THCA	cis	rs4578769	0.765	rs11082172	ENSG00000265939.1	UBE2CP2	-3.41	0.000694	0.0399	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22857866	chr18:22900486~22900995:-
THCA	cis	rs8192917	0.511	rs7150231	ENSG00000258657.4	RP11-104E19.1	-3.41	0.000694	0.0399	-0.29	-0.16	Vitiligo;	chr14:24592407	chr14:24595723~24657774:+
THCA	cis	rs8192917	0.524	rs12884659	ENSG00000258657.4	RP11-104E19.1	-3.41	0.000694	0.0399	-0.29	-0.16	Vitiligo;	chr14:24595620	chr14:24595723~24657774:+
THCA	cis	rs6929812	0.628	rs2206254	ENSG00000216915.2	RP1-97D16.1	3.41	0.000694	0.04	0.2	0.16	Neuroticism (multi-trait analysis);	chr6:27431852	chr6:27737000~27738494:-
THCA	cis	rs2980439	0.729	rs2955586	ENSG00000233609.3	RP11-62H7.2	3.41	0.000694	0.04	0.15	0.16	Neuroticism;	chr8:8236445	chr8:8961200~8979025:+
THCA	cis	rs6878727	0.815	rs988409	ENSG00000253807.4	LINC01170	-3.41	0.000694	0.04	-0.15	-0.16	Breast cancer;	chr5:124394790	chr5:124059794~124405079:-
THCA	cis	rs76878669	0.561	rs4930177	ENSG00000255320.1	RP11-755F10.1	-3.41	0.000694	0.04	-0.19	-0.16	Educational attainment (years of education);	chr11:66353313	chr11:66244840~66246239:-
THCA	cis	rs9488822	0.676	rs11153594	ENSG00000237021.2	RP3-486I3.7	-3.41	0.000694	0.04	-0.17	-0.16	LDL cholesterol;Cholesterol, total;	chr6:116033428	chr6:116254207~116256743:+
THCA	cis	rs7188445	0.836	rs3813580	ENSG00000277954.1	RP11-679B19.1	-3.41	0.000694	0.04	-0.19	-0.16	Urate levels;	chr16:79715383	chr16:79202624~79206739:-
THCA	cis	rs9788682	0.747	rs2958719	ENSG00000261143.1	ADAMTS7P3	3.41	0.000694	0.04	0.23	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78450687	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs2656072	ENSG00000261143.1	ADAMTS7P3	3.41	0.000694	0.04	0.23	0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78451950	chr15:77976042~77993057:+
THCA	cis	rs8058578	1	rs67128646	ENSG00000274678.1	RP11-2C24.7	3.41	0.000694	0.04	0.15	0.16	Multiple myeloma;	chr16:30660776	chr16:30821338~30821884:+
THCA	cis	rs2274273	0.84	rs66486619	ENSG00000258469.1	CHMP4BP1	3.41	0.000694	0.04	0.13	0.16	Protein biomarker;	chr14:55402837	chr14:55298644~55299231:+
THCA	cis	rs337161	0.573	rs12027850	ENSG00000221571.3	RNU6ATAC35P	-3.41	0.000694	0.04	-0.17	-0.16	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220792567	chr1:220825620~220826063:+
THCA	cis	rs7824557	0.872	rs2572417	ENSG00000255495.1	AC145124.2	-3.41	0.000694	0.04	-0.17	-0.16	Retinal vascular caliber;	chr8:11253953	chr8:12194467~12196280:+
THCA	cis	rs2404602	0.53	rs12915184	ENSG00000196274.5	Metazoa_SRP	-3.41	0.000694	0.04	-0.19	-0.16	Blood metabolite levels;	chr15:76673581	chr15:76230048~76230390:-
THCA	cis	rs1850744	0.702	rs2077679	ENSG00000163612.10	FAM86KP	3.41	0.000694	0.04	0.36	0.16	Economic and political preferences;	chr4:9606465	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs1961552	ENSG00000163612.10	FAM86KP	3.41	0.000694	0.04	0.36	0.16	Economic and political preferences;	chr4:9606682	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs4974816	ENSG00000163612.10	FAM86KP	3.41	0.000694	0.04	0.36	0.16	Economic and political preferences;	chr4:9611443	chr4:9153296~9165451:+
THCA	cis	rs1850744	0.702	rs4974812	ENSG00000163612.10	FAM86KP	3.41	0.000694	0.04	0.36	0.16	Economic and political preferences;	chr4:9612974	chr4:9153296~9165451:+
THCA	cis	rs2228479	0.85	rs62056103	ENSG00000223959.7	AFG3L1P	-3.41	0.000694	0.04	-0.14	-0.16	Skin colour saturation;	chr16:89876373	chr16:89972586~90002161:+
THCA	cis	rs34421088	0.56	rs2618434	ENSG00000255495.1	AC145124.2	-3.41	0.000694	0.04	-0.18	-0.16	Neuroticism;	chr8:11541356	chr8:12194467~12196280:+
THCA	cis	rs910316	1	rs175436	ENSG00000273565.1	CTD-3075F15.1	-3.41	0.000694	0.04	-0.19	-0.16	Height;	chr14:75141980	chr14:75176929~75177418:+
THCA	cis	rs6600671	0.899	rs11249432	ENSG00000226067.5	CH17-118O6.2	3.41	0.000694	0.04	0.15	0.16	Hip geometry;	chr1:121541678	chr1:120913275~121009291:+
THCA	cis	rs8040855	0.599	rs4577058	ENSG00000259630.2	CTD-2262B20.1	3.41	0.000694	0.04	0.17	0.16	Bulimia nervosa;	chr15:85183227	chr15:85415228~85415633:+
THCA	cis	rs860295	0.702	rs12067371	ENSG00000236675.1	MTX1P1	-3.41	0.000694	0.04	-0.16	-0.16	Body mass index;	chr1:155467878	chr1:155230975~155234325:+
THCA	cis	rs10754283	0.967	rs12058749	ENSG00000237505.5	PKN2-AS1	-3.41	0.000694	0.04	-0.19	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:88537513~88685204:-
THCA	cis	rs3935740	1	rs3935740	ENSG00000260619.1	RP11-775C24.3	3.41	0.000695	0.04	0.23	0.16	Parkinson's disease;	chr15:81334384	chr15:80990804~80993258:-
THCA	cis	rs7119	0.604	rs1055691	ENSG00000259362.2	RP11-307C19.1	3.41	0.000695	0.04	0.21	0.16	Type 2 diabetes;	chr15:77572283	chr15:77525540~77534110:+
THCA	cis	rs6449957	0.639	rs251398	ENSG00000249335.1	CTC-340D7.1	-3.41	0.000695	0.04	-0.19	-0.16	Cleft lip with or without cleft palate;	chr5:68213973	chr5:68832585~68962158:-
THCA	cis	rs2115630	0.967	rs10438428	ENSG00000229212.6	RP11-561C5.4	3.41	0.000695	0.04	0.2	0.16	P wave terminal force;	chr15:84787514	chr15:85205440~85234795:-
THCA	cis	rs2074409	0.509	rs2411157	ENSG00000275839.1	CTC-421K24.1	-3.41	0.000695	0.04	-0.19	-0.16	Response to angiotensin II receptor blocker therapy;	chr17:37424298	chr17:37454171~37454931:+
THCA	cis	rs5753037	0.653	rs140102	ENSG00000273350.1	RP4-539M6.20	-3.41	0.000695	0.04	-0.18	-0.16	Type 1 diabetes;	chr22:29732454	chr22:30420512~30420912:+
THCA	cis	rs708547	0.836	rs781554	ENSG00000242083.2	RPL7AP31	-3.41	0.000695	0.04	-0.23	-0.16	Response to bleomycin (chromatid breaks);	chr4:56851371	chr4:56356135~56356932:+
THCA	cis	rs4763879	0.634	rs11052582	ENSG00000256594.6	RP11-705C15.2	-3.41	0.000695	0.04	-0.12	-0.16	Type 1 diabetes;	chr12:9706714	chr12:9633419~9658412:+
THCA	cis	rs6743226	0.603	rs62186406	ENSG00000223374.1	AC005104.3	3.41	0.000695	0.04	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241294041	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.603	rs10933548	ENSG00000223374.1	AC005104.3	3.41	0.000695	0.04	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241295422	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.603	rs62186408	ENSG00000223374.1	AC005104.3	3.41	0.000695	0.04	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241296236	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.603	rs62186410	ENSG00000223374.1	AC005104.3	3.41	0.000695	0.04	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241296443	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.626	rs12612578	ENSG00000223374.1	AC005104.3	3.41	0.000695	0.04	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241297245	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.58	rs11677414	ENSG00000223374.1	AC005104.3	3.41	0.000695	0.04	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241298382	chr2:241351340~241353104:-
THCA	cis	rs6005807	0.719	rs58542867	ENSG00000272858.1	CTA-292E10.8	-3.41	0.000695	0.04	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28592272	chr22:28814914~28815662:+
THCA	cis	rs7264396	0.79	rs3787166	ENSG00000088340.14	FER1L4	3.41	0.000695	0.04	0.16	0.16	Total cholesterol levels;	chr20:35641150	chr20:35558737~35607562:-
THCA	cis	rs1371614	0.552	rs35538505	ENSG00000272148.1	RP11-195B17.1	-3.41	0.000695	0.04	-0.15	-0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26903159	chr2:27062428~27062907:-
THCA	cis	rs9662633	1	rs6695978	ENSG00000227372.9	TP73-AS1	3.41	0.000695	0.04	0.24	0.16	Visceral adipose tissue adjusted for BMI;	chr1:3731781	chr1:3735601~3747336:-
THCA	cis	rs80130819	0.636	rs2732451	ENSG00000273765.1	RP11-370I10.11	3.41	0.000695	0.04	0.18	0.16	Prostate cancer;	chr12:48326163	chr12:48360920~48361377:+
THCA	cis	rs8177876	0.658	rs12444747	ENSG00000261838.4	RP11-303E16.6	3.41	0.000695	0.04	0.32	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041299	chr16:81069854~81076598:+
THCA	cis	rs3785356	0.524	rs3024622	ENSG00000259940.2	CTD-3203P2.1	-3.41	0.000695	0.04	-0.17	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr16:27354132	chr16:27213308~27214993:-
THCA	cis	rs7539542	0.529	rs10800877	ENSG00000234996.3	RP11-480I12.7	3.41	0.000695	0.04	0.22	0.16	Mean platelet volume;	chr1:202914935	chr1:202861754~202875241:+
THCA	cis	rs6427356	1	rs1176542	ENSG00000237189.1	RP11-85G21.2	3.41	0.000695	0.04	0.17	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157163685	chr1:157287703~157288053:-
THCA	cis	rs4664293	0.867	rs13432	ENSG00000230783.1	AC009961.2	-3.41	0.000695	0.04	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159769216	chr2:159689217~159690291:-
THCA	cis	rs10875746	0.768	rs12305182	ENSG00000275228.1	RP11-370I10.10	3.41	0.000695	0.04	0.18	0.16	Longevity (90 years and older);	chr12:48027624	chr12:48327942~48328472:-
THCA	cis	rs6787172	0.622	rs6791431	ENSG00000272087.1	RP11-379F4.7	3.41	0.000695	0.04	0.14	0.16	Subjective well-being;	chr3:158376568	chr3:158693120~158693768:-
THCA	cis	rs6120849	0.754	rs6087667	ENSG00000269202.1	RP4-614O4.12	-3.41	0.000695	0.04	-0.17	-0.16	Protein C levels;	chr20:35064084	chr20:35201747~35203288:-
THCA	cis	rs7665090	1	rs735403	ENSG00000251288.2	RP11-10L12.2	3.41	0.000695	0.04	0.2	0.16	Primary biliary cholangitis;	chr4:102632386	chr4:102751401~102752641:+
THCA	cis	rs9596863	1	rs9536557	ENSG00000136149.6	RPL13AP25	3.41	0.000695	0.04	0.17	0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53859055	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs1545659	ENSG00000136149.6	RPL13AP25	3.41	0.000695	0.04	0.17	0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53859653	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.95	rs6561749	ENSG00000136149.6	RPL13AP25	3.41	0.000695	0.04	0.17	0.16	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53861060	chr13:54440704~54441315:-
THCA	cis	rs34792	0.637	rs2450356	ENSG00000255277.3	ABCC6P2	3.41	0.000695	0.04	0.16	0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:14820792~14824702:-
THCA	cis	rs3768792	0.665	rs56970923	ENSG00000196096.3	AC079610.2	3.41	0.000695	0.04	0.23	0.16	Systemic lupus erythematosus;	chr2:212982032	chr2:213276552~213284205:-
THCA	cis	rs3768792	0.665	rs10497987	ENSG00000196096.3	AC079610.2	3.41	0.000695	0.04	0.23	0.16	Systemic lupus erythematosus;	chr2:212982786	chr2:213276552~213284205:-
THCA	cis	rs3768792	0.665	rs7593134	ENSG00000196096.3	AC079610.2	3.41	0.000695	0.04	0.23	0.16	Systemic lupus erythematosus;	chr2:212983187	chr2:213276552~213284205:-
THCA	cis	rs7916697	0.578	rs61854799	ENSG00000233590.1	RP11-153K11.3	-3.41	0.000695	0.04	-0.21	-0.16	Optic disc area;	chr10:68246902	chr10:68233251~68242379:-
THCA	cis	rs2822388	0.59	rs2822392	ENSG00000230965.1	SNX18P13	-3.41	0.000695	0.04	-0.32	-0.16	Stroke;	chr21:14040510	chr21:13905960~13906488:-
THCA	cis	rs2797160	0.967	rs80303782	ENSG00000226409.1	RP11-735G4.1	-3.41	0.000695	0.04	-0.19	-0.16	Endometrial cancer;	chr6:125683047	chr6:125370211~125374324:-
THCA	cis	rs11671005	0.651	rs55716128	ENSG00000267858.4	MZF1-AS1	-3.41	0.000695	0.04	-0.12	-0.16	Mean platelet volume;	chr19:58537387	chr19:58559129~58574797:+
THCA	cis	rs2749592	0.513	rs1208708	ENSG00000099251.13	HSD17B7P2	3.41	0.000695	0.04	0.13	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38356380~38378505:+
THCA	cis	rs9890514	1	rs7502013	ENSG00000250948.1	RP11-1079K10.2	-3.41	0.000696	0.04	-0.29	-0.16	Platelet thrombus formation;	chr17:48670709	chr17:49375380~49380094:+
THCA	cis	rs5751614	0.967	rs5759663	ENSG00000211649.3	IGLV7-46	-3.41	0.000696	0.04	-0.1	-0.16	Height;	chr22:23247571	chr22:22369614~22370087:+
THCA	cis	rs11089937	0.626	rs5757011	ENSG00000215456.5	BCRP4	3.41	0.000696	0.04	0.19	0.16	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22630061~22636153:+
THCA	cis	rs4660456	0.83	rs12566786	ENSG00000238287.1	RP11-656D10.3	-3.41	0.000696	0.04	-0.2	-0.16	Platelet count;	chr1:40742709	chr1:40493157~40508661:-
THCA	cis	rs5752773	0.513	rs134507	ENSG00000272858.1	CTA-292E10.8	3.41	0.000696	0.04	0.17	0.16	Vertical cup-disc ratio;	chr22:28357845	chr22:28814914~28815662:+
THCA	cis	rs9400467	0.528	rs7752361	ENSG00000272356.1	RP5-1112D6.8	-3.41	0.000696	0.04	-0.12	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:111309203~111313517:+
THCA	cis	rs7760535	0.811	rs7764591	ENSG00000272356.1	RP5-1112D6.8	-3.41	0.000696	0.04	-0.12	-0.16	Metabolic traits;	chr6:111462211	chr6:111309203~111313517:+
THCA	cis	rs11148252	0.774	rs56033750	ENSG00000273784.3	RP11-78J21.7	-3.41	0.000696	0.04	-0.17	-0.16	Lewy body disease;	chr13:52173143	chr13:52600042~52642542:+
THCA	cis	rs3105593	0.965	rs62017197	ENSG00000242737.1	RP11-562A8.1	3.41	0.000696	0.04	0.2	0.16	QT interval;	chr15:50648294	chr15:50466738~50467096:+
THCA	cis	rs2292873	0.818	rs11904188	ENSG00000234949.2	AC104667.3	-3.41	0.000696	0.04	-0.26	-0.16	Obesity-related traits;	chr2:237586496	chr2:237591020~237595981:+
THCA	cis	rs17095355	1	rs9630101	ENSG00000234118.1	RPL13AP6	-3.41	0.000696	0.04	-0.18	-0.16	Biliary atresia;	chr10:109978693	chr10:110936622~110937233:-
THCA	cis	rs875971	0.54	rs35510581	ENSG00000230189.5	GS1-124K5.2	-3.41	0.000696	0.04	-0.1	-0.16	Aortic root size;	chr7:66113790	chr7:66409143~66490059:-
THCA	cis	rs701145	0.537	rs1713819	ENSG00000240068.1	RPL21P42	3.41	0.000696	0.04	0.3	0.16	Coronary artery disease;	chr3:154146685	chr3:154023835~154024298:+
THCA	cis	rs4683346	0.731	rs7623543	ENSG00000273328.4	RP11-141M3.6	-3.41	0.000696	0.04	-0.21	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42880135	chr3:42809414~42908105:+
THCA	cis	rs11105298	0.891	rs10858852	ENSG00000266347.2	AC068641.1	3.41	0.000696	0.04	0.2	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs4842653	ENSG00000266347.2	AC068641.1	3.41	0.000696	0.04	0.2	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89592833~89592927:+
THCA	cis	rs11105298	0.891	rs4842654	ENSG00000266347.2	AC068641.1	3.41	0.000696	0.04	0.2	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89592833~89592927:+
THCA	cis	rs7474896	0.559	rs1735641	ENSG00000276805.1	RP11-291L22.6	-3.41	0.000696	0.04	-0.2	-0.16	Obesity (extreme);	chr10:37895924	chr10:38451030~38451785:+
THCA	cis	rs10186029	0.582	rs1441165	ENSG00000270659.1	RP11-105N14.1	-3.41	0.000696	0.04	-0.13	-0.16	Systemic sclerosis;	chr2:213145107	chr2:213152970~213153659:+
THCA	cis	rs4489787	1	rs4760708	ENSG00000240399.1	RP1-228P16.1	3.41	0.000696	0.04	0.23	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48470055	chr12:48054813~48055591:-
THCA	cis	rs4489787	1	rs10875818	ENSG00000240399.1	RP1-228P16.1	3.41	0.000696	0.04	0.23	0.16	Prostate cancer (SNP x SNP interaction);	chr12:48471429	chr12:48054813~48055591:-
THCA	cis	rs2898279	0.966	rs9693089	ENSG00000242296.2	DEFB109P1	-3.41	0.000696	0.04	-0.21	-0.16	Small cell lung carcinoma;	chr8:11440876	chr8:12393209~12400366:-
THCA	cis	rs17286411	0.671	rs8062477	ENSG00000260185.1	RP11-432I5.6	3.41	0.000696	0.04	0.22	0.16	Blood protein levels;	chr16:71770071	chr16:71655027~71664212:+
THCA	cis	rs4845570	0.85	rs4618976	ENSG00000268288.1	RP11-98D18.16	3.41	0.000696	0.04	0.23	0.16	Coronary artery disease;	chr1:151794112	chr1:151766486~151767000:-
THCA	cis	rs7143963	0.609	rs7140494	ENSG00000272444.1	RP11-1017G21.6	-3.41	0.000696	0.04	-0.15	-0.16	Body mass index;	chr14:102825361	chr14:101952416~101953063:+
THCA	cis	rs9393777	0.528	rs7745603	ENSG00000220721.1	OR1F12	3.41	0.000696	0.0401	0.2	0.16	Intelligence (multi-trait analysis);	chr6:27122625	chr6:28073316~28074233:+
THCA	cis	rs2645424	0.635	rs62495697	ENSG00000255046.1	RP11-297N6.4	3.41	0.000696	0.0401	0.17	0.16	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851498	chr8:11797928~11802568:-
THCA	cis	rs7031325	1	rs7031325	ENSG00000229611.1	RP11-390F4.10	-3.41	0.000696	0.0401	-0.16	-0.16	Systemic lupus erythematosus;	chr9:6655056	chr9:6704471~6707780:+
THCA	cis	rs9488822	0.612	rs13209599	ENSG00000237021.2	RP3-486I3.7	3.41	0.000696	0.0401	0.18	0.16	LDL cholesterol;Cholesterol, total;	chr6:115926231	chr6:116254207~116256743:+
THCA	cis	rs7192750	0.586	rs4788576	ENSG00000260886.1	TAT-AS1	3.41	0.000696	0.0401	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71900202	chr16:71565789~71578187:+
THCA	cis	rs7192750	0.586	rs9937936	ENSG00000260886.1	TAT-AS1	3.41	0.000696	0.0401	0.23	0.16	Total cholesterol levels;LDL cholesterol levels;	chr16:71900516	chr16:71565789~71578187:+
THCA	cis	rs2098713	0.535	rs56288111	ENSG00000250155.1	CTD-2353F22.1	3.41	0.000696	0.0401	0.15	0.16	Telomere length;	chr5:37619340	chr5:36666214~36725195:-
THCA	cis	rs2098713	0.535	rs4869538	ENSG00000250155.1	CTD-2353F22.1	3.41	0.000696	0.0401	0.15	0.16	Telomere length;	chr5:37624065	chr5:36666214~36725195:-
THCA	cis	rs714027	0.585	rs41156	ENSG00000279699.1	RP1-102K2.9	-3.41	0.000696	0.0401	-0.16	-0.16	Lymphocyte counts;	chr22:30008664	chr22:30275215~30276951:-
THCA	cis	rs714027	0.585	rs41157	ENSG00000279699.1	RP1-102K2.9	-3.41	0.000696	0.0401	-0.16	-0.16	Lymphocyte counts;	chr22:30009162	chr22:30275215~30276951:-
THCA	cis	rs6580649	0.943	rs3803183	ENSG00000273765.1	RP11-370I10.11	3.41	0.000696	0.0401	0.17	0.16	Lung cancer;	chr12:48004297	chr12:48360920~48361377:+
THCA	cis	rs2562456	0.833	rs61035285	ENSG00000268278.1	RP11-420K14.1	3.41	0.000696	0.0401	0.22	0.16	Pain;	chr19:21329475	chr19:21637974~21656300:+
THCA	cis	rs7737355	0.812	rs152789	ENSG00000237714.1	P4HA2-AS1	3.41	0.000696	0.0401	0.21	0.16	Life satisfaction;	chr5:131690897	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.773	rs28852	ENSG00000237714.1	P4HA2-AS1	3.41	0.000696	0.0401	0.21	0.16	Life satisfaction;	chr5:131692149	chr5:132184876~132192808:+
THCA	cis	rs2797160	1	rs926853	ENSG00000226409.1	RP11-735G4.1	3.41	0.000696	0.0401	0.18	0.16	Endometrial cancer;	chr6:125700289	chr6:125370211~125374324:-
THCA	cis	rs11960179	1	rs11960179	ENSG00000250066.1	RP11-141O11.1	-3.41	0.000696	0.0401	-0.29	-0.16	Glomerular filtration rate (creatinine);	chr5:68524390	chr5:68963246~68967845:+
THCA	cis	rs2744375	0.6	rs2008748	ENSG00000261189.1	RP3-512B11.3	3.41	0.000696	0.0401	0.16	0.16	Resting heart rate;	chr6:7551445	chr6:7540451~7541338:-
THCA	cis	rs10496034	0.618	rs13399055	ENSG00000237887.1	AC092839.1	-3.41	0.000696	0.0401	-0.32	-0.16	Refractive astigmatism;	chr2:54732271	chr2:54529343~54529801:+
THCA	cis	rs656319	0.513	rs34748716	ENSG00000261451.1	RP11-981G7.1	-3.41	0.000696	0.0401	-0.2	-0.16	Myopia (pathological);	chr8:10116208	chr8:10433672~10438312:+
THCA	cis	rs4664293	0.833	rs3764969	ENSG00000230783.1	AC009961.2	-3.41	0.000696	0.0401	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159764337	chr2:159689217~159690291:-
THCA	cis	rs6968419	0.963	rs10953811	ENSG00000237870.5	AC073130.1	3.41	0.000696	0.0401	0.16	0.16	Intraocular pressure;	chr7:116172451	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.815	rs6977380	ENSG00000237870.5	AC073130.1	3.41	0.000696	0.0401	0.16	0.16	Intraocular pressure;	chr7:116174756	chr7:116275606~116286734:-
THCA	cis	rs11593576	0.55	rs7895110	ENSG00000224596.6	ZMIZ1-AS1	-3.41	0.000697	0.0401	-0.17	-0.16	Vitiligo;	chr10:79234360	chr10:78943328~79067895:-
THCA	cis	rs2573652	0.723	rs2727201	ENSG00000254744.3	CTD-3076O17.1	-3.41	0.000697	0.0401	-0.17	-0.16	Height;	chr15:99975106	chr15:99970215~99974010:+
THCA	cis	rs732072	1	rs72941018	ENSG00000214659.4	KRT8P26	-3.41	0.000697	0.0401	-0.26	-0.16	Inflammatory bowel disease;	chr11:65692616	chr11:65726939~65728214:+
THCA	cis	rs2562456	0.917	rs9304987	ENSG00000268658.4	LINC00664	-3.41	0.000697	0.0401	-0.22	-0.16	Pain;	chr19:21499472	chr19:21483374~21503238:+
THCA	cis	rs1612141	0.744	rs4904249	ENSG00000251363.2	RP11-129M6.1	3.41	0.000697	0.0401	0.22	0.16	QT interval (drug interaction);	chr14:41105681	chr14:40954898~40975877:+
THCA	cis	rs9549260	0.755	rs4943800	ENSG00000275149.1	RP11-427J23.1	-3.41	0.000697	0.0401	-0.21	-0.16	Red blood cell count;	chr13:40642694	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.816	rs7334318	ENSG00000275149.1	RP11-427J23.1	-3.41	0.000697	0.0401	-0.21	-0.16	Red blood cell count;	chr13:40643273	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.755	rs7317254	ENSG00000275149.1	RP11-427J23.1	-3.41	0.000697	0.0401	-0.21	-0.16	Red blood cell count;	chr13:40643712	chr13:40079106~40273509:-
THCA	cis	rs4787491	0.679	rs12933575	ENSG00000275371.1	RP11-455F5.6	-3.41	0.000697	0.0401	-0.14	-0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011243	chr16:30110895~30111955:+
THCA	cis	rs4787491	0.729	rs7191849	ENSG00000275371.1	RP11-455F5.6	-3.41	0.000697	0.0401	-0.14	-0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011836	chr16:30110895~30111955:+
THCA	cis	rs6921919	1	rs6921919	ENSG00000176933.5	TOB2P1	-3.41	0.000697	0.0401	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28217643~28218634:-
THCA	cis	rs9898058	0.825	rs76301358	ENSG00000253730.1	RP11-893F2.13	-3.41	0.000697	0.0401	-0.28	-0.16	Milk allergy;	chr17:49810081	chr17:50158333~50161276:-
THCA	cis	rs7709377	0.516	rs56322212	ENSG00000271918.1	CTD-2287O16.5	3.41	0.000697	0.0401	0.15	0.16	Metabolite levels  (X-11787);	chr5:116161992	chr5:116083807~116085416:-
THCA	cis	rs13064411	0.735	rs6438157	ENSG00000243849.1	CFAP44-AS1	3.41	0.000697	0.0401	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113488469	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs7631082	ENSG00000243849.1	CFAP44-AS1	3.41	0.000697	0.0401	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113490066	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs35860985	ENSG00000243849.1	CFAP44-AS1	3.41	0.000697	0.0401	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113490981	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.735	rs13098166	ENSG00000243849.1	CFAP44-AS1	3.41	0.000697	0.0401	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113491191	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs1486894	ENSG00000243849.1	CFAP44-AS1	3.41	0.000697	0.0401	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113492666	chr3:113403991~113433992:+
THCA	cis	rs947583	0.588	rs9321532	ENSG00000272189.1	RP3-325F22.5	-3.41	0.000697	0.0401	-0.15	-0.16	Phosphorus levels;	chr6:135791078	chr6:136550661~136552554:+
THCA	cis	rs9875589	0.957	rs66716710	ENSG00000228242.5	AC093495.4	-3.41	0.000697	0.0401	-0.09	-0.16	Ovarian reserve;	chr3:13897231	chr3:14144637~14165978:+
THCA	cis	rs7173964	1	rs4775466	ENSG00000259251.2	RP11-643M14.1	-3.41	0.000697	0.0401	-0.16	-0.16	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62104919	chr15:62060503~62062434:+
THCA	cis	rs854765	0.583	rs8075965	ENSG00000265511.1	RP11-524F11.1	3.41	0.000697	0.0401	0.12	0.16	Total body bone mineral density;	chr17:17949866	chr17:17507351~17508308:+
THCA	cis	rs854765	0.583	rs4413022	ENSG00000265511.1	RP11-524F11.1	3.41	0.000697	0.0401	0.12	0.16	Total body bone mineral density;	chr17:17954966	chr17:17507351~17508308:+
THCA	cis	rs763121	0.853	rs5757231	ENSG00000225450.1	RP3-508I15.14	3.41	0.000697	0.0401	0.12	0.16	Menopause (age at onset);	chr22:38675653	chr22:38739003~38749041:+
THCA	cis	rs1656402	1	rs1656400	ENSG00000263941.2	RN7SL32P	-3.41	0.000697	0.0401	-0.19	-0.16	Non-small cell lung cancer (survival);	chr2:232563073	chr2:233205199~233205479:+
THCA	cis	rs853679	0.882	rs9393908	ENSG00000261839.1	RP1-265C24.8	3.41	0.000697	0.0401	0.24	0.16	Depression;	chr6:28223052	chr6:28136849~28139678:+
THCA	cis	rs853679	0.882	rs9366717	ENSG00000261839.1	RP1-265C24.8	3.41	0.000697	0.0401	0.24	0.16	Depression;	chr6:28223279	chr6:28136849~28139678:+
THCA	cis	rs12621844	0.608	rs28460586	ENSG00000234690.5	AC073283.4	-3.41	0.000697	0.0401	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48065558	chr2:47192405~47345074:-
THCA	cis	rs9425766	0.655	rs4652169	ENSG00000270084.1	GAS5-AS1	-3.41	0.000697	0.0401	-0.16	-0.16	Life satisfaction;	chr1:174095343	chr1:173863248~173863941:+
THCA	cis	rs11723261	0.582	rs7679573	ENSG00000250892.1	RP11-1365D11.1	3.41	0.000697	0.0401	0.23	0.16	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:201409~205009:-
THCA	cis	rs6892003	0.903	rs6870098	ENSG00000213376.4	GAPDHP71	3.41	0.000697	0.0401	0.24	0.16	Clopidogrel active metabolite levels;	chr5:174768199	chr5:174513305~174514307:+
THCA	cis	rs2904297	0.798	rs11728636	ENSG00000261490.1	RP11-448G15.3	3.41	0.000697	0.0401	0.11	0.16	Hashimoto thyroiditis versus Graves' disease;	chr4:11021619	chr4:10068089~10073019:-
THCA	cis	rs1383484	0.506	rs4414460	ENSG00000225151.9	GOLGA2P7	3.41	0.000697	0.0401	0.21	0.16	Height;	chr15:83893988	chr15:84199311~84230136:-
THCA	cis	rs6993270	0.512	rs74525403	ENSG00000245330.4	KB-1471A8.1	-3.41	0.000697	0.0401	-0.25	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119862033	chr8:119867419~119874488:-
THCA	cis	rs2736345	0.672	rs2618473	ENSG00000269899.1	RP11-589N15.2	-3.41	0.000697	0.0401	-0.19	-0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486618	chr8:11846154~11846391:-
THCA	cis	rs785830	0.749	rs578216	ENSG00000231808.2	LINC01388	-3.41	0.000697	0.0401	-0.18	-0.16	Platelet distribution width;	chr9:250935	chr9:112713~113754:-
THCA	cis	rs1557488	0.565	rs4937195	ENSG00000260209.1	RP11-680F20.10	3.41	0.000697	0.0401	0.22	0.16	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126836196	chr11:125873031~125874528:-
THCA	cis	rs2131877	0.529	rs3892194	ENSG00000238097.1	RP11-513G11.3	-3.41	0.000697	0.0401	-0.18	-0.16	Non-small cell lung cancer;	chr3:195134946	chr3:194247648~194257772:+
THCA	cis	rs804280	0.544	rs804276	ENSG00000255495.1	AC145124.2	3.41	0.000697	0.0401	0.17	0.16	Myopia (pathological);	chr8:11767499	chr8:12194467~12196280:+
THCA	cis	rs3770081	0.59	rs60785155	ENSG00000273080.1	RP11-301O19.1	-3.41	0.000698	0.0401	-0.39	-0.16	Facial emotion recognition (sad faces);	chr2:86225675	chr2:86195590~86196049:+
THCA	cis	rs3784262	0.565	rs9635350	ENSG00000259250.1	RP11-50C13.1	-3.41	0.000698	0.0401	-0.13	-0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58006214	chr15:58587507~58591676:+
THCA	cis	rs972578	0.967	rs738392	ENSG00000274717.1	RP1-47A17.1	-3.41	0.000698	0.0401	-0.16	-0.16	Mean platelet volume;	chr22:42944273	chr22:42791814~42794313:-
THCA	cis	rs4081724	0.706	rs55814900	ENSG00000267296.2	CEBPA-AS1	3.41	0.000698	0.0401	0.2	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33340175	chr19:33302857~33305054:+
THCA	cis	rs2625529	0.652	rs8040216	ENSG00000260037.4	CTD-2524L6.3	3.41	0.000698	0.0401	0.19	0.16	Red blood cell count;	chr15:71962908	chr15:71818396~71823384:+
THCA	cis	rs9788682	0.747	rs28480606	ENSG00000261143.1	ADAMTS7P3	-3.41	0.000698	0.0401	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78469971	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs7174190	ENSG00000261143.1	ADAMTS7P3	-3.41	0.000698	0.0401	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78471275	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs11072766	ENSG00000261143.1	ADAMTS7P3	-3.41	0.000698	0.0401	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78479204	chr15:77976042~77993057:+
THCA	cis	rs7819412	0.668	rs2409715	ENSG00000254866.2	DEFB109P3	3.41	0.000698	0.0401	0.22	0.16	Triglycerides;	chr8:11152626	chr8:12150895~12151134:-
THCA	cis	rs427943	0.52	rs2838778	ENSG00000223768.1	LINC00205	3.41	0.000698	0.0401	0.14	0.16	Body mass index;	chr21:45094903	chr21:45293285~45297354:+
THCA	cis	rs6472235	1	rs6472232	ENSG00000272192.1	CTD-2532N20.1	3.41	0.000698	0.0401	0.15	0.16	Plateletcrit;Myopia (pathological);	chr8:65880397	chr8:65842752~65843331:+
THCA	cis	rs11992162	0.613	rs56094399	ENSG00000270154.1	RP11-419I17.1	-3.41	0.000698	0.0401	-0.2	-0.16	Monocyte count;	chr8:11939961	chr8:12476462~12477122:+
THCA	cis	rs73198271	0.632	rs57281209	ENSG00000253981.4	ALG1L13P	-3.41	0.000698	0.0401	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8745285	chr8:8236003~8244667:-
THCA	cis	rs73198271	0.632	rs57687880	ENSG00000253981.4	ALG1L13P	-3.41	0.000698	0.0401	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8745400	chr8:8236003~8244667:-
THCA	cis	rs732716	0.785	rs11085073	ENSG00000269318.1	AC007292.3	3.41	0.000698	0.0401	0.22	0.16	Mean corpuscular volume;	chr19:4375165	chr19:4356637~4358448:-
THCA	cis	rs1003719	0.591	rs2018521	ENSG00000270116.1	AP001429.1	3.41	0.000698	0.0401	0.18	0.16	Eye color traits;	chr21:37144964	chr21:37100814~37101343:+
THCA	cis	rs12544026	0.582	rs2155940	ENSG00000253669.3	KB-1732A1.1	-3.41	0.000698	0.0401	-0.17	-0.16	Major depression and alcohol dependence;	chr8:101834900	chr8:102805517~102809971:+
THCA	cis	rs7829975	0.627	rs876954	ENSG00000253130.1	CTD-3023L14.2	-3.41	0.000698	0.0401	-0.17	-0.16	Mood instability;	chr8:8453413	chr8:8561391~8569688:+
THCA	cis	rs4788570	0.615	rs10852502	ENSG00000260185.1	RP11-432I5.6	-3.41	0.000698	0.0401	-0.31	-0.16	Intelligence (multi-trait analysis);	chr16:71618169	chr16:71655027~71664212:+
THCA	cis	rs2304003	0.561	rs13024739	ENSG00000232411.1	AC009495.3	3.41	0.000698	0.0401	0.17	0.16	Social communication problems;	chr2:165795854	chr2:165833048~165839098:-
THCA	cis	rs12621844	0.638	rs2128716	ENSG00000234690.5	AC073283.4	-3.41	0.000698	0.0401	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48044826	chr2:47192405~47345074:-
THCA	cis	rs1009077	0.536	rs35708340	ENSG00000248280.1	RP11-33B1.2	3.41	0.000698	0.0401	0.22	0.16	Endometriosis;	chr4:119442215	chr4:119440561~119450157:-
THCA	cis	rs8044868	0.566	rs3812984	ENSG00000260886.1	TAT-AS1	3.41	0.000698	0.0401	0.18	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72173898	chr16:71565789~71578187:+
THCA	cis	rs2692947	0.683	rs1813381	ENSG00000235584.2	AC008268.1	3.41	0.000698	0.0401	0.17	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95757191	chr2:95666084~95668715:+
THCA	cis	rs7246657	0.943	rs2081096	ENSG00000266916.4	ZNF793-AS1	-3.41	0.000698	0.0402	-0.15	-0.16	Coronary artery calcification;	chr19:37473798	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.941	rs7259618	ENSG00000266916.4	ZNF793-AS1	-3.41	0.000698	0.0402	-0.15	-0.16	Coronary artery calcification;	chr19:37259817	chr19:37497159~37507046:-
THCA	cis	rs7028939	1	rs7858208	ENSG00000255145.2	STX17-AS1	-3.41	0.000698	0.0402	-0.23	-0.16	Preeclampsia;	chr9:100139002	chr9:99886322~99906601:-
THCA	cis	rs9307551	1	rs11098770	ENSG00000249646.2	OR7E94P	-3.41	0.000698	0.0402	-0.21	-0.16	Refractive error;	chr4:79598850	chr4:79587302~79588130:-
THCA	cis	rs7843479	0.965	rs11135763	ENSG00000208037.1	MIR320A	-3.41	0.000698	0.0402	-0.19	-0.16	Mean corpuscular volume;	chr8:21956451	chr8:22244962~22245043:-
THCA	cis	rs867371	0.502	rs2047679	ENSG00000276710.3	CSPG4P8	-3.41	0.000698	0.0402	-0.15	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82459472~82477258:+
THCA	cis	rs9947954	0.866	rs1384226	ENSG00000269365.2	RP11-380M21.4	3.41	0.000698	0.0402	0.18	0.16	IgG glycosylation;	chr18:48709070	chr18:47878295~47882444:+
THCA	cis	rs2288884	0.537	rs7254254	ENSG00000269483.1	AC006272.1	3.41	0.000698	0.0402	0.17	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:51839924~51843324:-
THCA	cis	rs4815191	0.788	rs2096253	ENSG00000230387.2	RP4-737E23.2	-3.41	0.000698	0.0402	-0.22	-0.16	Obesity-related traits;	chr20:23279141	chr20:23187961~23190307:+
THCA	cis	rs1030877	1	rs2576737	ENSG00000235319.1	AC012360.4	-3.41	0.000698	0.0402	-0.18	-0.16	Obesity-related traits;	chr2:105275053	chr2:105324210~105330529:+
THCA	cis	rs524281	0.817	rs10791849	ENSG00000255038.1	RP11-1167A19.2	-3.41	0.000698	0.0402	-0.18	-0.16	Electroencephalogram traits;	chr11:66123126	chr11:66067277~66069619:-
THCA	cis	rs6600671	1	rs1986111	ENSG00000226067.5	CH17-118O6.2	3.41	0.000699	0.0402	0.16	0.16	Hip geometry;	chr1:121462934	chr1:120913275~121009291:+
THCA	cis	rs11681884	1	rs3811054	ENSG00000231747.1	AC079922.2	3.41	0.000699	0.0402	0.19	0.16	Stroke;	chr2:113073363	chr2:112621809~112622167:-
THCA	cis	rs12216125	0.801	rs56107510	ENSG00000272810.1	U91328.22	-3.41	0.000699	0.0402	-0.14	-0.16	Iron status biomarkers;	chr6:25987208	chr6:26013241~26013757:+
THCA	cis	rs1134634	0.52	rs16892152	ENSG00000249252.4	RP11-665G4.1	-3.41	0.000699	0.0402	-0.23	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15004942~15427914:-
THCA	cis	rs80130819	0.515	rs7315258	ENSG00000273765.1	RP11-370I10.11	3.41	0.000699	0.0402	0.17	0.16	Prostate cancer;	chr12:48178887	chr12:48360920~48361377:+
THCA	cis	rs7737355	0.812	rs13172003	ENSG00000237714.1	P4HA2-AS1	3.41	0.000699	0.0402	0.21	0.16	Life satisfaction;	chr5:131751963	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.812	rs2108870	ENSG00000237714.1	P4HA2-AS1	3.41	0.000699	0.0402	0.21	0.16	Life satisfaction;	chr5:131752793	chr5:132184876~132192808:+
THCA	cis	rs925946	0.518	rs12577586	ENSG00000245573.6	BDNF-AS	-3.41	0.000699	0.0402	-0.15	-0.16	Weight;Body mass index;	chr11:27578888	chr11:27506838~27698174:+
THCA	cis	rs944289	0.712	rs12050121	ENSG00000212071.1	AL162511.1	3.41	0.000699	0.0402	0.18	0.16	Thyroid cancer;	chr14:36103742	chr14:36196480~36196568:-
THCA	cis	rs1035491	0.574	rs10461497	ENSG00000248288.1	CTD-2194F4.2	-3.41	0.000699	0.0402	-0.18	-0.16	Body mass index;	chr5:64646571	chr5:65209921~65210948:+
THCA	cis	rs7660883	0.964	rs11097127	ENSG00000251411.1	RP11-397E7.4	3.41	0.000699	0.0402	0.15	0.16	HDL cholesterol levels;	chr4:87069182	chr4:86913266~86914817:-
THCA	cis	rs6499755	0.768	rs31097	ENSG00000260135.5	RP11-212I21.2	3.41	0.000699	0.0402	0.17	0.16	Hypospadias;	chr16:55334723	chr16:55426797~55462297:-
THCA	cis	rs394563	0.601	rs382720	ENSG00000231760.4	RP11-350J20.5	-3.41	0.000699	0.0402	-0.2	-0.16	Dupuytren's disease;	chr6:149474125	chr6:149796151~149826294:-
THCA	cis	rs7621331	1	rs9877082	ENSG00000239213.4	NCK1-AS1	3.41	0.000699	0.0402	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136032494	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs6771224	ENSG00000239213.4	NCK1-AS1	3.41	0.000699	0.0402	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136041892	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs7643661	ENSG00000239213.4	NCK1-AS1	3.41	0.000699	0.0402	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136043056	chr3:136841726~136862054:-
THCA	cis	rs7621331	0.963	rs7621425	ENSG00000239213.4	NCK1-AS1	3.41	0.000699	0.0402	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136043175	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs9812561	ENSG00000239213.4	NCK1-AS1	3.41	0.000699	0.0402	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136043668	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs9875328	ENSG00000239213.4	NCK1-AS1	3.41	0.000699	0.0402	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136046348	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs9880721	ENSG00000239213.4	NCK1-AS1	3.41	0.000699	0.0402	0.15	0.16	Waist circumference adjusted for body mass index;	chr3:136047322	chr3:136841726~136862054:-
THCA	cis	rs2638953	0.893	rs1464011	ENSG00000247934.4	RP11-967K21.1	-3.41	0.000699	0.0402	-0.15	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28516871	chr12:28163298~28190738:-
THCA	cis	rs703842	0.642	rs10876994	ENSG00000270039.1	RP11-571M6.17	-3.41	0.000699	0.0402	-0.19	-0.16	Multiple sclerosis;	chr12:57670954	chr12:57803838~57804415:+
THCA	cis	rs4073416	0.569	rs11158605	ENSG00000276116.2	FUT8-AS1	3.41	0.000699	0.0402	0.17	0.16	N-glycan levels;	chr14:65641202	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.569	rs11158607	ENSG00000276116.2	FUT8-AS1	3.41	0.000699	0.0402	0.17	0.16	N-glycan levels;	chr14:65644079	chr14:65411170~65412690:-
THCA	cis	rs1065852	0.526	rs56234624	ENSG00000227370.1	RP4-669P10.19	3.41	0.000699	0.0402	0.16	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41992822	chr22:42132543~42132998:+
THCA	cis	rs9527	0.615	rs2152915	ENSG00000236937.2	PTGES3P4	3.41	0.000699	0.0402	0.21	0.16	Arsenic metabolism;	chr10:102931975	chr10:102845595~102845950:+
THCA	cis	rs9527	0.615	rs3897401	ENSG00000236937.2	PTGES3P4	3.41	0.000699	0.0402	0.21	0.16	Arsenic metabolism;	chr10:102936622	chr10:102845595~102845950:+
THCA	cis	rs9527	0.615	rs36045108	ENSG00000236937.2	PTGES3P4	3.41	0.000699	0.0402	0.21	0.16	Arsenic metabolism;	chr10:102938172	chr10:102845595~102845950:+
THCA	cis	rs9527	0.568	rs12772775	ENSG00000236937.2	PTGES3P4	3.41	0.000699	0.0402	0.21	0.16	Arsenic metabolism;	chr10:102943242	chr10:102845595~102845950:+
THCA	cis	rs9925964	1	rs9925964	ENSG00000279196.1	RP11-1072A3.3	-3.41	0.000699	0.0402	-0.15	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118574	chr16:30984630~30988270:-
THCA	cis	rs9925964	0.967	rs4889620	ENSG00000279196.1	RP11-1072A3.3	-3.41	0.000699	0.0402	-0.15	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31119853	chr16:30984630~30988270:-
THCA	cis	rs854765	0.693	rs9915776	ENSG00000281749.1	Y_RNA	-3.41	0.000699	0.0402	-0.2	-0.16	Total body bone mineral density;	chr17:17845742	chr17:18001101~18001195:-
THCA	cis	rs8044868	0.893	rs3909543	ENSG00000260886.1	TAT-AS1	3.41	0.000699	0.0402	0.19	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72149644	chr16:71565789~71578187:+
THCA	cis	rs2130392	0.926	rs1107907	ENSG00000250726.1	RP11-616K6.1	-3.41	0.000699	0.0402	-0.19	-0.16	Kawasaki disease;	chr4:184698954	chr4:184072403~184073039:+
THCA	cis	rs836788	0.608	rs26779	ENSG00000251050.1	RP11-168A11.4	-3.41	0.000699	0.0402	-0.12	-0.16	Glomerular filtration rate (creatinine);	chr5:80763384	chr5:80019609~80019920:+
THCA	cis	rs9902453	0.838	rs9646436	ENSG00000264290.1	RP11-68I3.4	3.41	0.000699	0.0402	0.12	0.16	Coffee consumption (cups per day);	chr17:29882041	chr17:29569580~29570519:+
THCA	cis	rs9902453	0.838	rs9646437	ENSG00000264290.1	RP11-68I3.4	3.41	0.000699	0.0402	0.12	0.16	Coffee consumption (cups per day);	chr17:29882047	chr17:29569580~29570519:+
THCA	cis	rs9902453	0.838	rs9646438	ENSG00000264290.1	RP11-68I3.4	3.41	0.000699	0.0402	0.12	0.16	Coffee consumption (cups per day);	chr17:29882073	chr17:29569580~29570519:+
THCA	cis	rs9902453	0.808	rs56216220	ENSG00000264290.1	RP11-68I3.4	3.41	0.000699	0.0402	0.12	0.16	Coffee consumption (cups per day);	chr17:29882164	chr17:29569580~29570519:+
THCA	cis	rs7028939	1	rs10988944	ENSG00000255145.2	STX17-AS1	3.41	0.000699	0.0402	0.22	0.16	Preeclampsia;	chr9:100011933	chr9:99886322~99906601:-
THCA	cis	rs4780401	0.728	rs8057398	ENSG00000274038.1	RP11-66H6.4	-3.41	0.000699	0.0402	-0.18	-0.16	Rheumatoid arthritis;	chr16:11686773	chr16:11056556~11057034:+
THCA	cis	rs2018683	0.835	rs7782264	ENSG00000233517.1	AC005162.5	3.41	0.000699	0.0402	0.19	0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28939369	chr7:28987028~28988899:+
THCA	cis	rs9916302	0.706	rs439537	ENSG00000266469.1	CTB-131K11.1	-3.41	0.000699	0.0402	-0.15	-0.16	Glomerular filtration rate (creatinine);	chr17:39578229	chr17:39401793~39406233:+
THCA	cis	rs3809060	0.571	rs11031767	ENSG00000270903.1	HNRNPA3P9	-3.41	7e-04	0.0402	-0.15	-0.16	Inguinal hernia;	chr11:32405882	chr11:32591793~32592771:-
THCA	cis	rs3809060	0.571	rs3932463	ENSG00000270903.1	HNRNPA3P9	-3.41	7e-04	0.0402	-0.15	-0.16	Inguinal hernia;	chr11:32406277	chr11:32591793~32592771:-
THCA	cis	rs910316	0.967	rs8007539	ENSG00000273565.1	CTD-3075F15.1	-3.41	7e-04	0.0402	-0.18	-0.16	Height;	chr14:75198250	chr14:75176929~75177418:+
THCA	cis	rs9788682	0.792	rs35031105	ENSG00000261143.1	ADAMTS7P3	-3.41	7e-04	0.0402	-0.23	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78480464	chr15:77976042~77993057:+
THCA	cis	rs2262909	0.962	rs401424	ENSG00000269364.1	LINC01233	3.41	7e-04	0.0402	0.19	0.16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22049221	chr19:22532626~22533494:+
THCA	cis	rs7976269	0.573	rs73063745	ENSG00000257599.1	OVCH1-AS1	-3.41	7e-04	0.0402	-0.37	-0.16	Male-pattern baldness;	chr12:29050949	chr12:29389294~29487488:+
THCA	cis	rs10992797	0.523	rs4744258	ENSG00000227603.1	RP11-165J3.6	-3.41	7e-04	0.0402	-0.16	-0.16	Intelligence (multi-trait analysis);	chr9:93599287	chr9:93435332~93437121:-
THCA	cis	rs7173964	1	rs4775467	ENSG00000259251.2	RP11-643M14.1	-3.41	7e-04	0.0402	-0.16	-0.16	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62105199	chr15:62060503~62062434:+
THCA	cis	rs11638815	0.603	rs10162807	ENSG00000259429.4	UBE2Q2P2	-3.41	7e-04	0.0402	-0.13	-0.16	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:82355142~82420075:+
THCA	cis	rs6968419	1	rs10245914	ENSG00000237870.5	AC073130.1	-3.41	7e-04	0.0402	-0.16	-0.16	Intraocular pressure;	chr7:116177531	chr7:116275606~116286734:-
THCA	cis	rs2797160	1	rs1935772	ENSG00000226409.1	RP11-735G4.1	-3.41	7e-04	0.0402	-0.18	-0.16	Endometrial cancer;	chr6:125673562	chr6:125370211~125374324:-
THCA	cis	rs2447820	0.588	rs34953289	ENSG00000263432.2	RN7SL689P	3.41	7e-04	0.0402	0.2	0.16	Migraine;	chr5:123042491	chr5:123022487~123022783:-
THCA	cis	rs7631605	0.586	rs4678564	ENSG00000224080.1	UBE2FP1	-3.41	7e-04	0.0402	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:37395813	chr3:37143512~37143958:-
THCA	cis	rs883565	0.74	rs12631937	ENSG00000223668.1	EEF1A1P24	-3.41	7e-04	0.0402	-0.14	-0.16	Handedness;	chr3:38996161	chr3:39358545~39359922:+
THCA	cis	rs2880765	0.545	rs17553734	ENSG00000259407.1	RP11-158M2.3	3.41	7e-04	0.0402	0.17	0.16	Coronary artery disease;	chr15:85469828	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.566	rs17553790	ENSG00000259407.1	RP11-158M2.3	3.41	7e-04	0.0402	0.17	0.16	Coronary artery disease;	chr15:85470434	chr15:85744109~85750281:-
THCA	cis	rs4218	0.681	rs34977427	ENSG00000277144.1	RP11-59H7.4	-3.41	7e-04	0.0402	-0.22	-0.16	Social communication problems;	chr15:59098172	chr15:59115547~59116089:-
THCA	cis	rs9907295	1	rs11653051	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35909166	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs11653016	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35909756	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9889977	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35910691	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9894799	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35911085	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9903590	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35911286	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9897665	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35911595	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9912049	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35912530	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9911016	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35913349	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9912894	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35913452	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9303693	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35913595	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9914468	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35913727	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9893004	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35913855	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9899215	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35914215	chr17:35816717~35830293:-
THCA	cis	rs9907295	1	rs9907145	ENSG00000270871.1	AC015849.19	3.41	7e-04	0.0402	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35915237	chr17:35816717~35830293:-
THCA	cis	rs875971	0.545	rs6969224	ENSG00000230295.1	RP11-458F8.2	3.41	7e-04	0.0402	0.14	0.16	Aortic root size;	chr7:66370011	chr7:66880708~66882981:+
THCA	cis	rs6940638	1	rs12215773	ENSG00000224843.5	LINC00240	3.41	7e-04	0.0402	0.18	0.16	Intelligence (multi-trait analysis);	chr6:27071454	chr6:26956992~27023924:+
THCA	cis	rs3026445	0.519	rs10492229	ENSG00000278993.1	RP3-424M6.4	-3.41	7e-04	0.0402	-0.23	-0.16	QT interval;	chr12:110164368	chr12:110501614~110503441:+
THCA	cis	rs12022452	1	rs12031278	ENSG00000272145.1	NFYC-AS1	3.41	7e-04	0.0402	0.13	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40690380~40692066:-
THCA	cis	rs13437751	0.649	rs60897208	ENSG00000223558.1	TRIM60P17	3.41	7e-04	0.0402	0.35	0.16	QT interval (drug interaction);	chr7:63887340	chr7:64085560~64086576:+
THCA	cis	rs13437751	0.649	rs10235050	ENSG00000223558.1	TRIM60P17	3.41	7e-04	0.0402	0.35	0.16	QT interval (drug interaction);	chr7:63888405	chr7:64085560~64086576:+
THCA	cis	rs13437751	0.536	rs10238457	ENSG00000223558.1	TRIM60P17	3.41	7e-04	0.0402	0.35	0.16	QT interval (drug interaction);	chr7:63888836	chr7:64085560~64086576:+
THCA	cis	rs910873	0.711	rs62212235	ENSG00000269202.1	RP4-614O4.12	-3.41	7e-04	0.0402	-0.27	-0.16	Melanoma;	chr20:34494366	chr20:35201747~35203288:-
THCA	cis	rs73019876	0.869	rs2522095	ENSG00000269615.1	AC003973.1	3.41	7e-04	0.0402	0.16	0.16	Testicular germ cell tumor;	chr19:21941265	chr19:21940820~21941533:+
THCA	cis	rs7735319	0.528	rs7707609	ENSG00000249572.1	CTD-2203K17.1	3.41	7e-04	0.0402	0.18	0.16	Systolic blood pressure;	chr5:33164460	chr5:33424025~33440619:-
THCA	cis	rs937213	0.712	rs2279580	ENSG00000275636.1	RP11-521C20.5	3.41	7e-04	0.0403	0.16	0.16	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40008013	chr15:40078892~40079347:+
THCA	cis	rs6840360	0.615	rs4696290	ENSG00000251603.1	RP11-164P12.4	3.41	7e-04	0.0403	0.11	0.16	Intelligence (multi-trait analysis);	chr4:151710320	chr4:151667224~151670502:+
THCA	cis	rs7937890	0.532	rs2575833	ENSG00000251991.1	RNU7-49P	3.41	0.000701	0.0403	0.18	0.16	Mitochondrial DNA levels;	chr11:14470959	chr11:14478892~14478953:+
THCA	cis	rs76793172	1	rs74450753	ENSG00000207003.1	RNU6-611P	3.41	0.000701	0.0403	0.29	0.16	Eosinophil counts;	chr19:45814451	chr19:45047458~45047561:+
THCA	cis	rs76793172	0.92	rs77588767	ENSG00000207003.1	RNU6-611P	3.41	0.000701	0.0403	0.29	0.16	Eosinophil counts;	chr19:45823214	chr19:45047458~45047561:+
THCA	cis	rs76793172	1	rs60283385	ENSG00000207003.1	RNU6-611P	3.41	0.000701	0.0403	0.29	0.16	Eosinophil counts;	chr19:45825821	chr19:45047458~45047561:+
THCA	cis	rs76793172	1	rs56006974	ENSG00000207003.1	RNU6-611P	3.41	0.000701	0.0403	0.29	0.16	Eosinophil counts;	chr19:45827378	chr19:45047458~45047561:+
THCA	cis	rs1063857	0.656	rs216292	ENSG00000207708.1	MIR141	-3.41	0.000701	0.0403	-0.17	-0.16	vWF levels;Coagulation factor levels;	chr12:6043810	chr12:6964097~6964191:+
THCA	cis	rs9840812	0.655	rs696516	ENSG00000239213.4	NCK1-AS1	3.41	0.000701	0.0403	0.14	0.16	Fibrinogen levels;	chr3:136348936	chr3:136841726~136862054:-
THCA	cis	rs17122278	0.932	rs11216921	ENSG00000255239.1	AP002954.6	-3.41	0.000701	0.0403	-0.28	-0.16	Total cholesterol levels;	chr11:118594100	chr11:118688039~118690600:-
THCA	cis	rs17122278	1	rs7115634	ENSG00000255239.1	AP002954.6	-3.41	0.000701	0.0403	-0.28	-0.16	Total cholesterol levels;	chr11:118595534	chr11:118688039~118690600:-
THCA	cis	rs17122278	1	rs11216924	ENSG00000255239.1	AP002954.6	-3.41	0.000701	0.0403	-0.28	-0.16	Total cholesterol levels;	chr11:118599377	chr11:118688039~118690600:-
THCA	cis	rs2235649	0.833	rs9922139	ENSG00000260022.1	LA16c-306A4.1	3.41	0.000701	0.0403	0.22	0.16	Blood metabolite levels;	chr16:1798328	chr16:883780~885090:+
THCA	cis	rs2235649	0.833	rs9933168	ENSG00000260022.1	LA16c-306A4.1	3.41	0.000701	0.0403	0.22	0.16	Blood metabolite levels;	chr16:1798360	chr16:883780~885090:+
THCA	cis	rs2235649	0.746	rs113666107	ENSG00000260022.1	LA16c-306A4.1	3.41	0.000701	0.0403	0.22	0.16	Blood metabolite levels;	chr16:1798641	chr16:883780~885090:+
THCA	cis	rs2235649	0.746	rs35104579	ENSG00000260022.1	LA16c-306A4.1	3.41	0.000701	0.0403	0.22	0.16	Blood metabolite levels;	chr16:1798656	chr16:883780~885090:+
THCA	cis	rs2235649	0.833	rs55684627	ENSG00000260022.1	LA16c-306A4.1	3.41	0.000701	0.0403	0.22	0.16	Blood metabolite levels;	chr16:1798816	chr16:883780~885090:+
THCA	cis	rs950169	0.922	rs12915832	ENSG00000230373.7	GOLGA6L5P	-3.41	0.000701	0.0403	-0.17	-0.16	Schizophrenia;	chr15:84568226	chr15:84507885~84516814:-
THCA	cis	rs1765142	0.55	rs667511	ENSG00000242353.1	RP4-710M3.1	-3.41	0.000701	0.0403	-0.13	-0.16	Schizophrenia;	chr11:30404108	chr11:30368148~30368646:+
THCA	cis	rs9876781	1	rs6784322	ENSG00000199476.1	Y_RNA	-3.41	0.000701	0.0403	-0.2	-0.16	Longevity;	chr3:48380745	chr3:48288587~48288694:+
THCA	cis	rs9907295	0.901	rs4796118	ENSG00000270871.1	AC015849.19	3.41	0.000701	0.0403	0.13	0.16	Fibroblast growth factor basic levels;	chr17:35858804	chr17:35816717~35830293:-
THCA	cis	rs6751744	0.924	rs13386318	ENSG00000230783.1	AC009961.2	-3.41	0.000701	0.0403	-0.22	-0.16	Dysphagia;	chr2:159541846	chr2:159689217~159690291:-
THCA	cis	rs17301013	0.896	rs6425292	ENSG00000270084.1	GAS5-AS1	-3.41	0.000701	0.0403	-0.16	-0.16	Systemic lupus erythematosus;	chr1:174618364	chr1:173863248~173863941:+
THCA	cis	rs7662987	0.517	rs1154410	ENSG00000272777.1	RP11-571L19.8	3.41	0.000701	0.0403	0.15	0.16	Smoking initiation;	chr4:99085494	chr4:99067256~99068125:-
THCA	cis	rs722414	0.846	rs7299091	ENSG00000258302.2	RP11-981P6.1	3.41	0.000701	0.0403	0.15	0.16	Blood protein levels;	chr12:89453048	chr12:89561129~89594878:+
THCA	cis	rs7819412	0.502	rs10095003	ENSG00000205879.4	FAM90A2P	-3.41	0.000701	0.0403	-0.21	-0.16	Triglycerides;	chr8:11184940	chr8:12172202~12178575:-
THCA	cis	rs6715793	0.901	rs1065324	ENSG00000272754.1	AL133245.2	-3.41	0.000701	0.0403	-0.18	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33187010	chr2:32321638~32323002:+
THCA	cis	rs7572644	0.581	rs35463245	ENSG00000223522.1	AC093690.1	-3.41	0.000701	0.0403	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27777857	chr2:28307691~28310459:-
THCA	cis	rs2098713	0.562	rs55794983	ENSG00000250155.1	CTD-2353F22.1	3.41	0.000701	0.0403	0.15	0.16	Telomere length;	chr5:37549046	chr5:36666214~36725195:-
THCA	cis	rs6473252	0.839	rs12548739	ENSG00000254162.1	RP11-48B3.3	-3.41	0.000701	0.0403	-0.14	-0.16	Breast cancer;	chr8:80901850	chr8:80535006~80539135:-
THCA	cis	rs950169	0.922	rs4338765	ENSG00000230373.7	GOLGA6L5P	-3.41	0.000701	0.0403	-0.17	-0.16	Schizophrenia;	chr15:84248084	chr15:84507885~84516814:-
THCA	cis	rs72793342	0.651	rs8050463	ENSG00000235560.3	AC002310.12	3.41	0.000701	0.0403	0.17	0.16	RANTES levels;	chr16:30542838	chr16:30534752~30537144:+
THCA	cis	rs10832963	0.961	rs10832954	ENSG00000256361.1	RP11-613F22.6	3.41	0.000701	0.0403	0.19	0.16	Breast cancer;	chr11:18622012	chr11:18511043~18511475:-
THCA	cis	rs9863	0.828	rs4765541	ENSG00000269938.1	RP11-214K3.20	-3.41	0.000701	0.0403	-0.18	-0.16	White blood cell count;	chr12:123981448	chr12:123968023~123968579:-
THCA	cis	rs7824557	0.778	rs6601572	ENSG00000255495.1	AC145124.2	-3.41	0.000701	0.0403	-0.16	-0.16	Retinal vascular caliber;	chr8:11235828	chr8:12194467~12196280:+
THCA	cis	rs7631605	0.598	rs4678961	ENSG00000224080.1	UBE2FP1	3.41	0.000701	0.0403	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37393744	chr3:37143512~37143958:-
THCA	cis	rs2638953	0.815	rs11049684	ENSG00000247934.4	RP11-967K21.1	-3.41	0.000701	0.0403	-0.17	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512426	chr12:28163298~28190738:-
THCA	cis	rs9287719	0.674	rs759399	ENSG00000243819.4	RN7SL832P	-3.41	0.000701	0.0403	-0.12	-0.16	Prostate cancer;	chr2:10656757	chr2:10690344~10692099:+
THCA	cis	rs10905359	0.591	rs7082651	ENSG00000232591.1	RP5-1031D4.2	-3.41	0.000701	0.0403	-0.14	-0.16	Craniofacial microsomia;	chr10:8417405	chr10:7445558~7471942:-
THCA	cis	rs1348850	0.914	rs1975544	ENSG00000280374.1	RP11-337N6.3	3.41	0.000701	0.0403	0.21	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177600695	chr2:177317715~177318471:-
THCA	cis	rs2018683	0.707	rs4722875	ENSG00000233517.1	AC005162.5	-3.41	0.000701	0.0403	-0.19	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930015	chr7:28987028~28988899:+
THCA	cis	rs28510890	0.789	rs10852177	ENSG00000258676.4	RP11-386M24.3	3.41	0.000701	0.0403	0.16	0.16	Lung cancer in ever smokers;	chr15:92594248	chr15:92580829~92600545:+
THCA	cis	rs7129556	0.737	rs537811	ENSG00000254459.1	RP11-91P24.7	3.41	0.000701	0.0403	0.2	0.16	Weight loss (gastric bypass surgery);	chr11:77757043	chr11:77829654~77872262:-
THCA	cis	rs7621331	1	rs73222222	ENSG00000239213.4	NCK1-AS1	3.41	0.000701	0.0403	0.16	0.16	Waist circumference adjusted for body mass index;	chr3:136052883	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs9836758	ENSG00000239213.4	NCK1-AS1	3.41	0.000701	0.0403	0.16	0.16	Waist circumference adjusted for body mass index;	chr3:136053236	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs36039354	ENSG00000239213.4	NCK1-AS1	3.41	0.000701	0.0403	0.16	0.16	Waist circumference adjusted for body mass index;	chr3:136055519	chr3:136841726~136862054:-
THCA	cis	rs3784262	0.669	rs7178598	ENSG00000259250.1	RP11-50C13.1	3.41	0.000701	0.0403	0.13	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58016818	chr15:58587507~58591676:+
THCA	cis	rs17211409	1	rs7115713	ENSG00000254731.1	CTD-2005H7.1	3.41	0.000701	0.0403	0.38	0.16	JT interval (sulfonylurea treatment interaction);	chr11:86623274	chr11:86703099~86714092:+
THCA	cis	rs7819412	0.522	rs3021495	ENSG00000206014.6	OR7E161P	3.41	0.000702	0.0403	0.19	0.16	Triglycerides;	chr8:11137233	chr8:11928597~11929563:-
THCA	cis	rs3800688	0.622	rs15956	ENSG00000236753.4	MKLN1-AS	3.41	0.000702	0.0403	0.15	0.16	Hypertension;	chr7:131496159	chr7:131309744~131328222:-
THCA	cis	rs61160187	0.548	rs68104763	ENSG00000272308.1	RP11-231G3.1	-3.41	0.000702	0.0403	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60866457~60866935:-
THCA	cis	rs7264396	0.887	rs4911502	ENSG00000261582.1	RP4-614O4.11	-3.41	0.000702	0.0403	-0.16	-0.16	Total cholesterol levels;	chr20:35475209	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs6060434	ENSG00000261582.1	RP4-614O4.11	-3.41	0.000702	0.0403	-0.16	-0.16	Total cholesterol levels;	chr20:35480557	chr20:35267885~35280043:-
THCA	cis	rs11992162	0.507	rs60902764	ENSG00000270154.1	RP11-419I17.1	-3.41	0.000702	0.0403	-0.2	-0.16	Monocyte count;	chr8:11927482	chr8:12476462~12477122:+
THCA	cis	rs5877	0.568	rs1951627	ENSG00000270084.1	GAS5-AS1	-3.41	0.000702	0.0403	-0.17	-0.16	Subjective well-being (multi-trait analysis);	chr1:173922679	chr1:173863248~173863941:+
THCA	cis	rs513088	0.681	rs540253	ENSG00000225171.2	DUTP6	-3.41	0.000702	0.0403	-0.22	-0.16	Schizophrenia;	chr1:166691952	chr1:166868748~166869209:+
THCA	cis	rs739496	0.579	rs7956495	ENSG00000234608.6	MAPKAPK5-AS1	3.41	0.000702	0.0403	0.15	0.16	Platelet count;	chr12:111857889	chr12:111839764~111842902:-
THCA	cis	rs4723738	0.934	rs1860522	ENSG00000227191.5	TRGC2	-3.41	0.000702	0.0403	-0.12	-0.16	Treatment response for severe sepsis;	chr7:38200439	chr7:38239580~38368091:-
THCA	cis	rs7520050	0.807	rs6656279	ENSG00000281133.1	AL355480.3	-3.41	0.000702	0.0403	-0.18	-0.16	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45580892~45580996:-
THCA	cis	rs7520050	0.807	rs6671802	ENSG00000281133.1	AL355480.3	-3.41	0.000702	0.0403	-0.18	-0.16	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45580892~45580996:-
THCA	cis	rs939960	0.84	rs35737876	ENSG00000276538.1	RP11-545G3.2	3.41	0.000702	0.0403	0.22	0.16	Neutrophil percentage of white cells;	chr7:150597338	chr7:150047609~150047854:-
THCA	cis	rs12682352	0.535	rs12677550	ENSG00000233609.3	RP11-62H7.2	-3.41	0.000702	0.0403	-0.15	-0.16	Neuroticism;	chr8:8786812	chr8:8961200~8979025:+
THCA	cis	rs2191566	0.839	rs35292176	ENSG00000277806.1	RP11-15A1.8	-3.41	0.000702	0.0403	-0.16	-0.16	Acute lymphoblastic leukemia (childhood);	chr19:43997475	chr19:43976815~43977448:+
THCA	cis	rs2625529	0.824	rs12916951	ENSG00000260037.4	CTD-2524L6.3	-3.41	0.000702	0.0403	-0.21	-0.16	Red blood cell count;	chr15:71960157	chr15:71818396~71823384:+
THCA	cis	rs4664304	0.781	rs6432570	ENSG00000226266.5	AC009961.3	3.41	0.000702	0.0403	0.19	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:159951803	chr2:159670708~159712435:-
THCA	cis	rs112295236	1	rs75254733	ENSG00000255213.1	NPM1P35	-3.41	0.000702	0.0403	-0.38	-0.16	Sex hormone levels;	chr11:63249971	chr11:62330946~62331813:+
THCA	cis	rs12083887	0.505	rs2359837	ENSG00000236866.4	AL157902.3	-3.41	0.000702	0.0403	-0.18	-0.16	Male-pattern baldness;	chr1:118373876	chr1:117596832~117605770:-
THCA	cis	rs11051970	0.559	rs4931012	ENSG00000275769.1	RP11-771K4.3	-3.41	0.000702	0.0403	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32328970	chr12:31443792~31444208:-
THCA	cis	rs6885307	1	rs6889445	ENSG00000272335.1	RP11-53O19.3	-3.41	0.000702	0.0403	-0.15	-0.16	Age at first birth;	chr5:44989465	chr5:44826076~44828592:+
THCA	cis	rs2555155	0.602	rs2555143	ENSG00000254595.1	CTD-2010I16.1	-3.41	0.000702	0.0403	-0.15	-0.16	DNA methylation (variation);	chr11:6520350	chr11:6488186~6489377:-
THCA	cis	rs11681884	0.786	rs17042721	ENSG00000272563.1	RP11-480C16.1	-3.41	0.000702	0.0403	-0.34	-0.16	Stroke;	chr2:113032550	chr2:113432600~113436042:+
THCA	cis	rs12962334	0.555	rs9954649	ENSG00000273232.1	RP11-370A5.2	3.41	0.000702	0.0403	0.21	0.16	Breast cancer;	chr18:23033307	chr18:22882825~22883357:-
THCA	cis	rs4578769	0.505	rs9946743	ENSG00000273232.1	RP11-370A5.2	3.41	0.000702	0.0403	0.21	0.16	Eosinophil percentage of white cells;	chr18:23033394	chr18:22882825~22883357:-
THCA	cis	rs1144333	0.655	rs17097837	ENSG00000272855.1	RP5-1102E8.3	-3.41	0.000702	0.0403	-0.33	-0.16	Attention function in attention deficit hyperactive disorder;	chr1:75996481	chr1:76636877~76637339:+
THCA	cis	rs2562456	0.755	rs11670868	ENSG00000213976.4	CTD-2561J22.2	-3.41	0.000702	0.0403	-0.19	-0.16	Pain;	chr19:21373613	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs55961038	ENSG00000213976.4	CTD-2561J22.2	-3.41	0.000702	0.0403	-0.19	-0.16	Pain;	chr19:21375205	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs2358993	ENSG00000213976.4	CTD-2561J22.2	-3.41	0.000702	0.0403	-0.19	-0.16	Pain;	chr19:21375367	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs11672583	ENSG00000213976.4	CTD-2561J22.2	-3.41	0.000702	0.0403	-0.19	-0.16	Pain;	chr19:21379363	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs17680605	ENSG00000213976.4	CTD-2561J22.2	-3.41	0.000702	0.0403	-0.19	-0.16	Pain;	chr19:21379646	chr19:21382865~21387177:+
THCA	cis	rs1823913	0.525	rs7424440	ENSG00000280083.1	RP11-317J9.1	-3.41	0.000702	0.0403	-0.18	-0.16	Obesity-related traits;	chr2:191337919	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.526	rs35340557	ENSG00000280083.1	RP11-317J9.1	-3.41	0.000702	0.0403	-0.18	-0.16	Obesity-related traits;	chr2:191338688	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.503	rs35562914	ENSG00000280083.1	RP11-317J9.1	-3.41	0.000702	0.0403	-0.18	-0.16	Obesity-related traits;	chr2:191338969	chr2:191154118~191156070:-
THCA	cis	rs7326068	0.524	rs7998500	ENSG00000238286.1	SLC35E1P1	-3.41	0.000702	0.0403	-0.16	-0.16	Schizophrenia, bipolar disorder and depression (combined);	chr13:20584861	chr13:20607268~20608131:+
THCA	cis	rs12544026	0.617	rs1264932	ENSG00000253669.3	KB-1732A1.1	-3.41	0.000702	0.0403	-0.17	-0.16	Major depression and alcohol dependence;	chr8:101840963	chr8:102805517~102809971:+
THCA	cis	rs4601292	0.5	rs7011264	ENSG00000200714.1	Y_RNA	-3.41	0.000702	0.0403	-0.23	-0.16	HIV-1 viral setpoint;	chr8:65986489	chr8:65592731~65592820:+
THCA	cis	rs4601292	0.553	rs62506636	ENSG00000200714.1	Y_RNA	-3.41	0.000702	0.0403	-0.23	-0.16	HIV-1 viral setpoint;	chr8:65986685	chr8:65592731~65592820:+
THCA	cis	rs7737355	0.947	rs40400	ENSG00000237714.1	P4HA2-AS1	-3.41	0.000702	0.0403	-0.22	-0.16	Life satisfaction;	chr5:131495672	chr5:132184876~132192808:+
THCA	cis	rs9860428	0.844	rs9838295	ENSG00000243795.1	RP11-572M11.3	3.41	0.000702	0.0403	0.19	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112909438	chr3:113142350~113167819:-
THCA	cis	rs889122	1	rs10419418	ENSG00000267289.1	CTD-2623N2.11	3.41	0.000702	0.0403	0.19	0.16	Menarche (age at onset);	chr19:9883610	chr19:9834079~9835013:-
THCA	cis	rs11673344	0.74	rs113752815	ENSG00000267309.1	CTD-2630F21.1	-3.41	0.000702	0.0403	-0.16	-0.16	Obesity-related traits;	chr19:37043829	chr19:36489649~36491040:+
THCA	cis	rs365302	0.767	rs364581	ENSG00000235086.1	FNDC1-IT1	3.41	0.000702	0.0403	0.22	0.16	Coronary heart disease;	chr6:159192158	chr6:159240786~159243329:+
THCA	cis	rs11065706	0.752	rs76858926	ENSG00000278993.1	RP3-424M6.4	3.41	0.000703	0.0404	0.24	0.16	Heart rate;	chr12:110296413	chr12:110501614~110503441:+
THCA	cis	rs2486012	1	rs2906461	ENSG00000237950.1	RP11-7O11.3	3.41	0.000703	0.0404	0.19	0.16	Intelligence (multi-trait analysis);	chr1:43868556	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs17474535	ENSG00000237950.1	RP11-7O11.3	-3.41	0.000703	0.0404	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43887412	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs61770286	ENSG00000237950.1	RP11-7O11.3	-3.41	0.000703	0.0404	-0.19	-0.16	Intelligence (multi-trait analysis);	chr1:43890937	chr1:43944370~43946551:-
THCA	cis	rs9634489	0.786	rs449524	ENSG00000247400.3	DNAJC3-AS1	-3.41	0.000703	0.0404	-0.1	-0.16	Body mass index;	chr13:96408650	chr13:95648733~95676925:-
THCA	cis	rs3784262	0.669	rs3204690	ENSG00000259250.1	RP11-50C13.1	3.41	0.000703	0.0404	0.13	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57954570	chr15:58587507~58591676:+
THCA	cis	rs34779708	0.931	rs11010101	ENSG00000233200.1	RP11-324I22.2	3.41	0.000703	0.0404	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs11010102	ENSG00000233200.1	RP11-324I22.2	3.41	0.000703	0.0404	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35219894~35230598:-
THCA	cis	rs17345786	1	rs55641278	ENSG00000244119.1	PDCL3P4	3.41	0.000703	0.0404	0.16	0.16	Colonoscopy-negative controls vs population controls;	chr3:101571733	chr3:101712472~101713191:+
THCA	cis	rs8179	0.645	rs56201652	ENSG00000230927.2	TMBIM7P	3.41	0.000703	0.0404	0.21	0.16	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92648802	chr7:92412976~92439562:-
THCA	cis	rs12931792	0.682	rs12373113	ENSG00000274653.1	RP11-347C12.11	-3.41	0.000703	0.0404	-0.14	-0.16	Tonsillectomy;	chr16:30176192	chr16:30359825~30360336:+
THCA	cis	rs12931792	0.682	rs12373078	ENSG00000274653.1	RP11-347C12.11	-3.41	0.000703	0.0404	-0.14	-0.16	Tonsillectomy;	chr16:30176355	chr16:30359825~30360336:+
THCA	cis	rs620729	0.749	rs4711303	ENSG00000272097.1	RP11-421M1.8	3.41	0.000703	0.0404	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11484894	chr6:10743324~10747663:-
THCA	cis	rs13064411	0.696	rs7624994	ENSG00000243849.1	CFAP44-AS1	3.41	0.000703	0.0404	0.24	0.16	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113509162	chr3:113403991~113433992:+
THCA	cis	rs3849046	0.967	rs154072	ENSG00000253404.1	AC034243.1	-3.41	0.000703	0.0404	-0.17	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138520684	chr5:138744434~138753309:-
THCA	cis	rs11168618	0.904	rs12371700	ENSG00000240399.1	RP1-228P16.1	-3.41	0.000703	0.0404	-0.16	-0.16	Adiponectin levels;	chr12:48525430	chr12:48054813~48055591:-
THCA	cis	rs55702914	0.628	rs2565154	ENSG00000213104.3	NPM1P46	3.41	0.000703	0.0404	0.17	0.16	Major depression and alcohol dependence;	chr2:197445665	chr2:197379701~197380892:-
THCA	cis	rs2797160	1	rs983543	ENSG00000226409.1	RP11-735G4.1	-3.41	0.000703	0.0404	-0.19	-0.16	Endometrial cancer;	chr6:125684621	chr6:125370211~125374324:-
THCA	cis	rs8030379	1	rs10152139	ENSG00000176700.18	SCAND2P	-3.41	0.000703	0.0404	-0.1	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901510	chr15:84631451~84647478:+
THCA	cis	rs7395662	1	rs10742862	ENSG00000200090.1	Y_RNA	-3.41	0.000703	0.0404	-0.1	-0.16	HDL cholesterol;	chr11:48627764	chr11:47726894~47726992:-
THCA	cis	rs2880765	0.566	rs11630381	ENSG00000259407.1	RP11-158M2.3	-3.41	0.000703	0.0404	-0.17	-0.16	Coronary artery disease;	chr15:85469272	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.545	rs11631739	ENSG00000259407.1	RP11-158M2.3	-3.41	0.000703	0.0404	-0.17	-0.16	Coronary artery disease;	chr15:85469347	chr15:85744109~85750281:-
THCA	cis	rs17310467	0.541	rs78522696	ENSG00000126005.14	MMP24-AS1	-3.41	0.000703	0.0404	-0.29	-0.16	Hemostatic factors and hematological phenotypes;	chr20:34594355	chr20:35216462~35278131:-
THCA	cis	rs2361701	0.5	rs12602593	ENSG00000275479.1	RP11-334C17.6	3.41	0.000703	0.0404	0.22	0.16	IgG glycosylation;	chr17:80103080	chr17:80149627~80149798:+
THCA	cis	rs6120849	0.754	rs6120788	ENSG00000269202.1	RP4-614O4.12	-3.41	0.000703	0.0404	-0.17	-0.16	Protein C levels;	chr20:34995913	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs3746436	ENSG00000269202.1	RP4-614O4.12	-3.41	0.000703	0.0404	-0.17	-0.16	Protein C levels;	chr20:34998390	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs3746435	ENSG00000269202.1	RP4-614O4.12	-3.41	0.000703	0.0404	-0.17	-0.16	Protein C levels;	chr20:34999395	chr20:35201747~35203288:-
THCA	cis	rs7976269	0.623	rs55909239	ENSG00000257599.1	OVCH1-AS1	-3.41	0.000703	0.0404	-0.36	-0.16	Male-pattern baldness;	chr12:29016003	chr12:29389294~29487488:+
THCA	cis	rs10858047	0.883	rs6658815	ENSG00000231128.4	RP5-1073O3.2	-3.41	0.000703	0.0404	-0.23	-0.16	Autism;	chr1:114666429	chr1:113812379~113829171:+
THCA	cis	rs10858047	0.783	rs6692475	ENSG00000231128.4	RP5-1073O3.2	-3.41	0.000703	0.0404	-0.23	-0.16	Autism;	chr1:114666521	chr1:113812379~113829171:+
THCA	cis	rs11048434	0.673	rs11611106	ENSG00000245105.2	A2M-AS1	-3.41	0.000703	0.0404	-0.12	-0.16	Sjögren's syndrome;	chr12:8907608	chr12:9065177~9068060:+
THCA	cis	rs9314614	0.789	rs2980950	ENSG00000245857.2	GS1-24F4.2	3.41	0.000704	0.0404	0.2	0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6855285	chr8:6835554~6885276:+
THCA	cis	rs2236521	0.632	rs35265388	ENSG00000226332.2	RP11-157P1.4	3.41	0.000704	0.0404	0.14	0.16	Pelvic organ prolapse;	chr20:62319222	chr20:62305432~62306325:-
THCA	cis	rs875971	0.54	rs781152	ENSG00000230295.1	RP11-458F8.2	-3.41	0.000704	0.0404	-0.12	-0.16	Aortic root size;	chr7:66014585	chr7:66880708~66882981:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000230295.1	RP11-458F8.2	-3.41	0.000704	0.0404	-0.12	-0.16	Calcium levels;	chr7:66014891	chr7:66880708~66882981:+
THCA	cis	rs7246657	0.722	rs12974225	ENSG00000267640.4	CTD-2554C21.2	3.41	0.000704	0.0404	0.14	0.16	Coronary artery calcification;	chr19:37749458	chr19:37817359~37826638:+
THCA	cis	rs12621844	0.7	rs2882003	ENSG00000234690.5	AC073283.4	-3.41	0.000704	0.0404	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48156445	chr2:47192405~47345074:-
THCA	cis	rs4578769	0.765	rs60721147	ENSG00000265939.1	UBE2CP2	-3.41	0.000704	0.0404	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22848569	chr18:22900486~22900995:-
THCA	cis	rs1124769	0.599	rs57262951	ENSG00000244879.4	GABPB1-AS1	-3.41	0.000704	0.0404	-0.16	-0.16	Cognitive performance;	chr15:50788541	chr15:50354959~50372202:+
THCA	cis	rs12931792	0.782	rs12927190	ENSG00000274678.1	RP11-2C24.7	3.41	0.000704	0.0404	0.15	0.16	Tonsillectomy;	chr16:30158072	chr16:30821338~30821884:+
THCA	cis	rs7246657	0.943	rs1382357	ENSG00000266916.4	ZNF793-AS1	-3.41	0.000704	0.0404	-0.15	-0.16	Coronary artery calcification;	chr19:37486707	chr19:37497159~37507046:-
THCA	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	3.41	0.000704	0.0404	0.18	0.16	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
THCA	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	3.41	0.000704	0.0404	0.18	0.16	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
THCA	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	3.41	0.000704	0.0404	0.18	0.16	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	3.41	0.000704	0.0404	0.18	0.16	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
THCA	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	3.41	0.000704	0.0404	0.18	0.16	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
THCA	cis	rs293748	0.571	rs13169211	ENSG00000250155.1	CTD-2353F22.1	-3.41	0.000704	0.0404	-0.19	-0.16	Obesity-related traits;	chr5:37131567	chr5:36666214~36725195:-
THCA	cis	rs6724465	1	rs72967942	ENSG00000272644.1	RP11-33O4.1	3.41	0.000704	0.0404	0.22	0.16	Height;	chr2:219052800	chr2:219069354~219069809:-
THCA	cis	rs8054556	1	rs11901	ENSG00000214725.6	CDIPT-AS1	-3.41	0.000704	0.0404	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29972749	chr16:29863593~29868053:+
THCA	cis	rs944289	0.553	rs1169135	ENSG00000258844.1	RP11-259K15.2	3.41	0.000704	0.0404	0.16	0.16	Thyroid cancer;	chr14:36155696	chr14:36214607~36235608:+
THCA	cis	rs6121246	0.697	rs6088857	ENSG00000224628.2	RP5-854E16.2	-3.41	0.000704	0.0404	-0.22	-0.16	Mean corpuscular hemoglobin;	chr20:31638961	chr20:31285317~31286835:-
THCA	cis	rs7656342	0.599	rs6847858	ENSG00000250342.1	SNRPCP16	3.41	0.000704	0.0404	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9851435	chr4:9051842~9052051:-
THCA	cis	rs7656342	0.599	rs6847871	ENSG00000250342.1	SNRPCP16	3.41	0.000704	0.0404	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9851450	chr4:9051842~9052051:-
THCA	cis	rs7620503	0.613	rs11715627	ENSG00000228561.2	RP11-114M1.1	3.41	0.000704	0.0404	0.18	0.16	Corneal structure;	chr3:177567399	chr3:177683627~177691250:+
THCA	cis	rs12893668	0.703	rs34896432	ENSG00000258735.1	LINC00637	-3.41	0.000704	0.0404	-0.21	-0.16	Reticulocyte count;	chr14:103561658	chr14:103847721~103858049:+
THCA	cis	rs7656342	0.897	rs12507861	ENSG00000242034.1	RP11-1396O13.1	3.41	0.000704	0.0404	0.18	0.16	Gut microbiota (bacterial taxa);	chr4:9775966	chr4:9553614~9553985:-
THCA	cis	rs4601292	0.526	rs1108213	ENSG00000200714.1	Y_RNA	-3.41	0.000704	0.0404	-0.23	-0.16	HIV-1 viral setpoint;	chr8:65985580	chr8:65592731~65592820:+
THCA	cis	rs5758659	0.652	rs133358	ENSG00000182057.4	OGFRP1	3.41	0.000704	0.0404	0.18	0.16	Cognitive function;	chr22:42046535	chr22:42269753~42275196:+
THCA	cis	rs889312	0.5	rs1867731	ENSG00000271828.1	CTD-2310F14.1	-3.41	0.000704	0.0404	-0.21	-0.16	Breast cancer (early onset);Breast cancer;	chr5:56836288	chr5:56927874~56929573:+
THCA	cis	rs9796	0.611	rs691672	ENSG00000247556.5	OIP5-AS1	3.41	0.000704	0.0404	0.13	0.16	Menopause (age at onset);	chr15:41152240	chr15:41283990~41309737:+
THCA	cis	rs6472235	0.934	rs7461470	ENSG00000272192.1	CTD-2532N20.1	3.41	0.000704	0.0404	0.15	0.16	Plateletcrit;Myopia (pathological);	chr8:65914661	chr8:65842752~65843331:+
THCA	cis	rs2130392	0.924	rs873687	ENSG00000250726.1	RP11-616K6.1	3.41	0.000704	0.0404	0.19	0.16	Kawasaki disease;	chr4:184717699	chr4:184072403~184073039:+
THCA	cis	rs1035144	0.606	rs12896769	ENSG00000259167.2	NMNAT1P1	3.41	0.000704	0.0404	0.2	0.16	Male sexual orientation;	chr14:81000708	chr14:81032529~81033404:+
THCA	cis	rs1035144	0.606	rs929630	ENSG00000259167.2	NMNAT1P1	3.41	0.000704	0.0404	0.2	0.16	Male sexual orientation;	chr14:81001114	chr14:81032529~81033404:+
THCA	cis	rs2505675	1	rs2505675	ENSG00000272465.1	RP1-136B1.1	3.41	0.000704	0.0404	0.19	0.16	Tuberculosis;	chr6:2355441	chr6:2437549~2438249:+
THCA	cis	rs7342694	0.541	rs7193967	ENSG00000261218.4	RP11-960L18.1	-3.41	0.000705	0.0404	-0.13	-0.16	Coronary artery disease;	chr16:81872373	chr16:81738248~81767868:+
THCA	cis	rs7674212	0.539	rs6821617	ENSG00000230069.3	LRRC37A15P	-3.41	0.000705	0.0404	-0.16	-0.16	Type 2 diabetes;	chr4:103207253	chr4:102727274~102730721:-
THCA	cis	rs17286411	0.58	rs1477386	ENSG00000260185.1	RP11-432I5.6	3.41	0.000705	0.0404	0.21	0.16	Blood protein levels;	chr16:71566574	chr16:71655027~71664212:+
THCA	cis	rs6993244	1	rs6993244	ENSG00000253981.4	ALG1L13P	3.41	0.000705	0.0405	0.14	0.16	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8236003~8244667:-
THCA	cis	rs7680126	0.596	rs35782983	ENSG00000261490.1	RP11-448G15.3	-3.41	0.000705	0.0405	-0.14	-0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10116104	chr4:10068089~10073019:-
THCA	cis	rs6901004	0.803	rs1022092	ENSG00000271789.1	RP5-1112D6.7	-3.41	0.000705	0.0405	-0.15	-0.16	Blood metabolite levels;	chr6:111106083	chr6:111297126~111298510:+
THCA	cis	rs1348850	0.519	rs4144275	ENSG00000271996.1	RP11-337N6.1	3.41	0.000705	0.0405	0.2	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658640	chr2:177306373~177310572:+
THCA	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	3.41	0.000705	0.0405	0.18	0.16	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
THCA	cis	rs7412746	0.658	rs3768015	ENSG00000224800.1	RP11-235D19.2	-3.41	0.000705	0.0405	-0.21	-0.16	Melanoma;	chr1:150840478	chr1:150881236~150881683:-
THCA	cis	rs9299	0.691	rs10853101	ENSG00000230148.7	HOXB-AS1	3.41	0.000705	0.0405	0.17	0.16	Obesity;	chr17:48599098	chr17:48543551~48551250:+
THCA	cis	rs5758659	0.652	rs1063392	ENSG00000182057.4	OGFRP1	-3.41	0.000705	0.0405	-0.18	-0.16	Cognitive function;	chr22:42058946	chr22:42269753~42275196:+
THCA	cis	rs786425	0.682	rs12829893	ENSG00000278112.1	RP11-972P1.11	-3.41	0.000705	0.0405	-0.15	-0.16	Pubertal anthropometrics;	chr12:123682431	chr12:123519390~123519856:-
THCA	cis	rs2501276	1	rs2501276	ENSG00000218510.5	LINC00339	3.41	0.000705	0.0405	0.34	0.16	Immune response to smallpox vaccine (IL-6);	chr1:22047131	chr1:22025188~22031223:+
THCA	cis	rs17092148	0.945	rs6060042	ENSG00000269202.1	RP4-614O4.12	3.41	0.000705	0.0405	0.18	0.16	Neuroticism;	chr20:34773918	chr20:35201747~35203288:-
THCA	cis	rs875971	0.662	rs448725	ENSG00000230189.5	GS1-124K5.2	3.41	0.000705	0.0405	0.11	0.16	Aortic root size;	chr7:66049641	chr7:66409143~66490059:-
THCA	cis	rs9488822	0.676	rs12196579	ENSG00000233558.1	RP3-486I3.4	3.41	0.000705	0.0405	0.17	0.16	LDL cholesterol;Cholesterol, total;	chr6:116030561	chr6:116258493~116259115:-
THCA	cis	rs6840360	0.593	rs3805356	ENSG00000251603.1	RP11-164P12.4	-3.41	0.000705	0.0405	-0.1	-0.16	Intelligence (multi-trait analysis);	chr4:151759549	chr4:151667224~151670502:+
THCA	cis	rs11048434	0.736	rs2377672	ENSG00000245105.2	A2M-AS1	3.41	0.000705	0.0405	0.12	0.16	Sjögren's syndrome;	chr12:8959818	chr12:9065177~9068060:+
THCA	cis	rs3849046	0.967	rs10077407	ENSG00000253404.1	AC034243.1	-3.41	0.000705	0.0405	-0.17	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138513837	chr5:138744434~138753309:-
THCA	cis	rs3849046	0.967	rs154067	ENSG00000253404.1	AC034243.1	-3.41	0.000705	0.0405	-0.17	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138514370	chr5:138744434~138753309:-
THCA	cis	rs2635047	0.967	rs2571001	ENSG00000280212.1	RP11-49K24.3	-3.41	0.000705	0.0405	-0.15	-0.16	Educational attainment;	chr18:47138712	chr18:47076117~47076594:+
THCA	cis	rs8042680	0.688	rs28404354	ENSG00000214432.8	AC068831.10	-3.41	0.000705	0.0405	-0.22	-0.16	Type 2 diabetes;	chr15:90995820	chr15:91022619~91036611:+
THCA	cis	rs9693857	0.52	rs10107887	ENSG00000261451.1	RP11-981G7.1	3.41	0.000705	0.0405	0.2	0.16	Systolic blood pressure;	chr8:9507154	chr8:10433672~10438312:+
THCA	cis	rs9828933	1	rs9828933	ENSG00000271843.1	RP11-245J9.5	3.41	0.000705	0.0405	0.23	0.16	Type 2 diabetes;	chr3:64017221	chr3:64008082~64008692:-
THCA	cis	rs9828933	0.938	rs7617036	ENSG00000271843.1	RP11-245J9.5	3.41	0.000705	0.0405	0.23	0.16	Type 2 diabetes;	chr3:64017319	chr3:64008082~64008692:-
THCA	cis	rs6496932	1	rs6496932	ENSG00000259630.2	CTD-2262B20.1	3.41	0.000705	0.0405	0.2	0.16	Central corneal thickness;Corneal structure;	chr15:85282336	chr15:85415228~85415633:+
THCA	cis	rs8027587	0.925	rs12443022	ENSG00000259699.2	HMGB1P8	3.41	0.000706	0.0405	0.21	0.16	Obesity-related traits;	chr15:88695397	chr15:89135547~89136495:-
THCA	cis	rs3176789	0.914	rs10772132	ENSG00000256673.1	RP11-599J14.2	-3.41	0.000706	0.0405	-0.21	-0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772316	chr12:9398355~9414851:-
THCA	cis	rs6957923	0.747	rs10950950	ENSG00000234286.1	AC006026.13	-3.41	0.000706	0.0405	-0.2	-0.16	Height;	chr7:23484124	chr7:23680195~23680786:-
THCA	cis	rs6142618	0.562	rs4911197	ENSG00000224452.1	RSL24D1P6	3.41	0.000706	0.0405	0.18	0.16	Inflammatory bowel disease;	chr20:32130490	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs2235898	ENSG00000224452.1	RSL24D1P6	3.41	0.000706	0.0405	0.18	0.16	Inflammatory bowel disease;	chr20:32131259	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs2235899	ENSG00000224452.1	RSL24D1P6	3.41	0.000706	0.0405	0.18	0.16	Inflammatory bowel disease;	chr20:32131732	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs2235901	ENSG00000224452.1	RSL24D1P6	3.41	0.000706	0.0405	0.18	0.16	Inflammatory bowel disease;	chr20:32132233	chr20:32170390~32170790:-
THCA	cis	rs852069	0.539	rs852097	ENSG00000232333.1	RPS27AP2	-3.41	0.000706	0.0405	-0.2	-0.16	Menarche (age at onset);	chr20:17169980	chr20:17516843~17517307:+
THCA	cis	rs7432375	0.61	rs4420814	ENSG00000273486.1	RP11-731C17.2	3.41	0.000706	0.0405	0.13	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136794440	chr3:136837338~136839021:-
THCA	cis	rs76793172	1	rs75504740	ENSG00000207003.1	RNU6-611P	3.41	0.000706	0.0405	0.29	0.16	Eosinophil counts;	chr19:45810118	chr19:45047458~45047561:+
THCA	cis	rs13108904	0.87	rs4974577	ENSG00000254094.1	AC078852.1	-3.41	0.000706	0.0405	-0.19	-0.16	Obesity-related traits;	chr4:1272258	chr4:1356581~1358075:+
THCA	cis	rs13108904	0.87	rs4974578	ENSG00000254094.1	AC078852.1	-3.41	0.000706	0.0405	-0.19	-0.16	Obesity-related traits;	chr4:1272284	chr4:1356581~1358075:+
THCA	cis	rs11751172	0.582	rs13200687	ENSG00000271857.1	RP1-244F24.1	3.41	0.000706	0.0405	0.1	0.16	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45579965	chr6:45421079~45422005:-
THCA	cis	rs11751172	0.654	rs13205082	ENSG00000271857.1	RP1-244F24.1	3.41	0.000706	0.0405	0.1	0.16	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45580867	chr6:45421079~45422005:-
THCA	cis	rs586716	0.506	rs10965366	ENSG00000224549.1	RP11-370B11.3	3.41	0.000706	0.0405	0.19	0.16	Tuberculosis;	chr9:22517034	chr9:22767175~22768316:+
THCA	cis	rs12612435	0.736	rs36035487	ENSG00000231890.6	DARS-AS1	3.41	0.000706	0.0405	0.19	0.16	Takotsubo syndrome;	chr2:136393130	chr2:135985176~136022593:+
THCA	cis	rs613391	0.702	rs584680	ENSG00000234840.1	LINC01239	-3.41	0.000706	0.0405	-0.18	-0.16	Quantitative traits;	chr9:22706598	chr9:22646200~22824213:+
THCA	cis	rs2292873	1	rs6755617	ENSG00000234949.2	AC104667.3	-3.41	0.000706	0.0405	-0.24	-0.16	Obesity-related traits;	chr2:237591084	chr2:237591020~237595981:+
THCA	cis	rs7307902	1	rs10875655	ENSG00000280054.1	RP1-197B17.7	-3.41	0.000706	0.0405	-0.18	-0.16	Obesity-related traits;	chr12:47531424	chr12:47728151~47730598:-
THCA	cis	rs7631605	0.809	rs10849	ENSG00000272334.1	RP11-129K12.1	-3.41	0.000706	0.0405	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:37053579	chr3:36973117~36973672:-
THCA	cis	rs4886920	0.722	rs3935182	ENSG00000260776.4	RP11-114H24.2	-3.41	0.000706	0.0405	-0.18	-0.16	Neuroticism;	chr15:77802465	chr15:77914217~77926846:-
THCA	cis	rs7833790	0.963	rs7836040	ENSG00000254689.1	RP11-354A14.1	3.41	0.000706	0.0405	0.19	0.16	Diastolic blood pressure;	chr8:81786093	chr8:81885377~81923193:+
THCA	cis	rs4272720	0.562	rs2003044	ENSG00000234736.4	FAM170B-AS1	-3.41	0.000706	0.0405	-0.17	-0.16	Platelet count;Plateletcrit;	chr10:49164302	chr10:49121839~49151547:+
THCA	cis	rs6545883	0.929	rs3732171	ENSG00000273302.1	RP11-493E12.2	3.41	0.000706	0.0405	0.14	0.16	Tuberculosis;	chr2:61522555	chr2:61199979~61200769:+
THCA	cis	rs56309584	0.673	rs11078735	ENSG00000265749.4	RP11-849F2.5	3.41	0.000706	0.0405	0.22	0.16	Initial pursuit acceleration;	chr17:8213543	chr17:8365563~8381328:+
THCA	cis	rs9650657	0.741	rs10100333	ENSG00000269918.1	AF131215.9	-3.41	0.000706	0.0405	-0.16	-0.16	Neuroticism;	chr8:10726778	chr8:11104691~11106704:-
THCA	cis	rs1005277	0.579	rs1740737	ENSG00000099251.13	HSD17B7P2	3.41	0.000706	0.0405	0.13	0.16	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38356380~38378505:+
THCA	cis	rs3739034	0.938	rs6747587	ENSG00000224043.6	CCNT2-AS1	-3.41	0.000706	0.0405	-0.19	-0.16	Gut microbiome composition (winter);	chr2:134711944	chr2:134735464~134918710:-
THCA	cis	rs7259376	0.902	rs10409947	ENSG00000270947.1	AC025811.3	3.41	0.000706	0.0405	0.17	0.16	Menopause (age at onset);	chr19:22329716	chr19:22455988~22456459:+
THCA	cis	rs7246657	0.943	rs2126977	ENSG00000266916.4	ZNF793-AS1	3.41	0.000706	0.0405	0.15	0.16	Coronary artery calcification;	chr19:37504845	chr19:37497159~37507046:-
THCA	cis	rs13217239	0.574	rs9366680	ENSG00000224843.5	LINC00240	-3.41	0.000707	0.0405	-0.13	-0.16	Schizophrenia;	chr6:27038344	chr6:26956992~27023924:+
THCA	cis	rs459482	0.587	rs468207	ENSG00000227698.1	AP001619.2	3.41	0.000707	0.0405	0.18	0.16	IgG glycosylation;	chr21:41436088	chr21:41874756~41877613:-
THCA	cis	rs459571	0.959	rs410876	ENSG00000235106.7	LINC00094	3.41	0.000707	0.0405	0.14	0.16	Platelet distribution width;	chr9:134028745	chr9:134025439~134034666:+
THCA	cis	rs7221595	0.778	rs57625058	ENSG00000280254.1	RP11-81A22.4	-3.41	0.000707	0.0405	-0.19	-0.16	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;	chr17:4011219	chr17:4787057~4789162:+
THCA	cis	rs9314614	0.789	rs2951862	ENSG00000245857.2	GS1-24F4.2	3.41	0.000707	0.0405	0.2	0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6853782	chr8:6835554~6885276:+
THCA	cis	rs2652822	0.935	rs12148069	ENSG00000259459.4	RP11-321G12.1	-3.41	0.000707	0.0406	-0.13	-0.16	Metabolic traits;	chr15:63151593	chr15:63390136~63438320:+
THCA	cis	rs2540552	0.965	rs2192803	ENSG00000221520.1	MIR1285-1	-3.41	0.000707	0.0406	-0.16	-0.16	IgG glycosylation;	chr7:91609809	chr7:92204015~92204098:-
THCA	cis	rs416603	0.967	rs11644184	ENSG00000263179.1	HNRNPCP4	3.41	0.000707	0.0406	0.2	0.16	Type 1 diabetes;	chr16:11271247	chr16:11242653~11243552:+
THCA	cis	rs7927592	0.763	rs3740628	ENSG00000160172.9	FAM86C2P	3.41	0.000707	0.0406	0.14	0.16	Total body bone mineral density;	chr11:68613947	chr11:67791648~67805336:-
THCA	cis	rs479105	0.605	rs4766085	ENSG00000278356.1	RP11-372B4.3	3.41	0.000707	0.0406	0.15	0.16	Gut microbiota (bacterial taxa);	chr12:3263990	chr12:2885819~2886329:+
THCA	cis	rs8187707	1	rs7920448	ENSG00000233690.1	EBAG9P1	-3.41	0.000707	0.0406	-0.31	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99846693	chr10:99697407~99697949:-
THCA	cis	rs8187707	1	rs1137968	ENSG00000233690.1	EBAG9P1	-3.41	0.000707	0.0406	-0.31	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr10:99847104	chr10:99697407~99697949:-
THCA	cis	rs6938	0.596	rs11072511	ENSG00000260269.4	CTD-2323K18.1	-3.41	0.000707	0.0406	-0.22	-0.16	Breast cancer;	chr15:74867092	chr15:75527150~75601205:-
THCA	cis	rs2288884	0.505	rs75919042	ENSG00000260160.1	CTC-471J1.2	-3.41	0.000707	0.0406	-0.18	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51973246	chr19:52058490~52063703:-
THCA	cis	rs4604234	0.708	rs73467544	ENSG00000260645.1	RP11-250B2.5	-3.41	0.000707	0.0406	-0.27	-0.16	Cancer;	chr6:80346789	chr6:80466958~80469080:+
THCA	cis	rs7772697	0.508	rs12197040	ENSG00000223701.3	RAET1E-AS1	-3.41	0.000707	0.0406	-0.22	-0.16	Diabetic retinopathy;	chr6:149065177	chr6:149884431~149919508:+
THCA	cis	rs10090774	0.965	rs7843014	ENSG00000280303.2	ERICD	3.41	0.000707	0.0406	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140780382	chr8:140636281~140638283:+
THCA	cis	rs2832191	0.967	rs1999321	ENSG00000232855.5	AF131217.1	-3.41	0.000707	0.0406	-0.16	-0.16	Dental caries;	chr21:29157912	chr21:28439346~28674848:-
THCA	cis	rs2832191	0.967	rs2251377	ENSG00000232855.5	AF131217.1	-3.41	0.000707	0.0406	-0.16	-0.16	Dental caries;	chr21:29158278	chr21:28439346~28674848:-
THCA	cis	rs1396485	0.607	rs4921070	ENSG00000271918.1	CTD-2287O16.5	3.41	0.000707	0.0406	0.15	0.16	Inflammatory biomarkers;	chr5:116176269	chr5:116083807~116085416:-
THCA	cis	rs7208859	0.623	rs609063	ENSG00000264242.2	RP11-271K11.1	3.41	0.000707	0.0406	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs383436	ENSG00000264242.2	RP11-271K11.1	3.41	0.000707	0.0406	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000264242.2	RP11-271K11.1	3.41	0.000707	0.0406	0.25	0.16	Body mass index;	chr17:30641132	chr17:30553697~30558962:+
THCA	cis	rs10876993	0.784	rs10083154	ENSG00000270039.1	RP11-571M6.17	-3.41	0.000707	0.0406	-0.17	-0.16	Celiac disease or Rheumatoid arthritis;	chr12:57627150	chr12:57803838~57804415:+
THCA	cis	rs4788570	0.697	rs11075904	ENSG00000260185.1	RP11-432I5.6	-3.41	0.000707	0.0406	-0.3	-0.16	Intelligence (multi-trait analysis);	chr16:71782996	chr16:71655027~71664212:+
THCA	cis	rs4788570	0.655	rs1392484	ENSG00000260185.1	RP11-432I5.6	-3.41	0.000707	0.0406	-0.3	-0.16	Intelligence (multi-trait analysis);	chr16:71788198	chr16:71655027~71664212:+
THCA	cis	rs4788570	0.697	rs6499540	ENSG00000260185.1	RP11-432I5.6	-3.41	0.000707	0.0406	-0.3	-0.16	Intelligence (multi-trait analysis);	chr16:71788347	chr16:71655027~71664212:+
THCA	cis	rs4788570	0.655	rs7359478	ENSG00000260185.1	RP11-432I5.6	-3.41	0.000707	0.0406	-0.3	-0.16	Intelligence (multi-trait analysis);	chr16:71791542	chr16:71655027~71664212:+
THCA	cis	rs4886920	0.666	rs12591307	ENSG00000260776.4	RP11-114H24.2	-3.41	0.000707	0.0406	-0.18	-0.16	Neuroticism;	chr15:77789187	chr15:77914217~77926846:-
THCA	cis	rs2299682	0.826	rs6086911	ENSG00000230506.1	RP11-416N4.4	3.41	0.000707	0.0406	0.26	0.16	Initial pursuit acceleration in psychotic disorders;Initial pursuit acceleration;	chr20:9488952	chr20:10173520~10196990:+
THCA	cis	rs7824557	0.767	rs7837036	ENSG00000255310.2	AF131215.2	3.41	0.000707	0.0406	0.13	0.16	Retinal vascular caliber;	chr8:11317980	chr8:11107788~11109726:-
THCA	cis	rs860295	0.775	rs822508	ENSG00000236675.1	MTX1P1	-3.41	0.000707	0.0406	-0.15	-0.16	Body mass index;	chr1:155880767	chr1:155230975~155234325:+
THCA	cis	rs6088580	0.634	rs1890002	ENSG00000269202.1	RP4-614O4.12	3.41	0.000707	0.0406	0.13	0.16	Glomerular filtration rate (creatinine);	chr20:34331413	chr20:35201747~35203288:-
THCA	cis	rs35306767	0.715	rs12777801	ENSG00000229869.1	RP11-363N22.2	-3.41	0.000707	0.0406	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:990345	chr10:933026~942743:+
THCA	cis	rs35306767	0.715	rs17221456	ENSG00000229869.1	RP11-363N22.2	-3.41	0.000707	0.0406	-0.25	-0.16	Eosinophil percentage of granulocytes;	chr10:991294	chr10:933026~942743:+
THCA	cis	rs708224	0.713	rs2632360	ENSG00000277342.1	RP11-843B15.4	3.41	0.000708	0.0406	0.2	0.16	Pancreatic cancer;	chr12:32238173	chr12:32109076~32109602:+
THCA	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	3.41	0.000708	0.0406	0.14	0.16	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
THCA	cis	rs9425766	0.962	rs6663875	ENSG00000200674.1	RN7SKP160	3.41	0.000708	0.0406	0.2	0.16	Life satisfaction;	chr1:173894071	chr1:173791548~173791887:+
THCA	cis	rs9863	0.931	rs2178663	ENSG00000270028.1	RP11-380L11.4	3.41	0.000708	0.0406	0.16	0.16	White blood cell count;	chr12:123949358	chr12:123925461~123926083:-
THCA	cis	rs7202877	0.706	rs37605	ENSG00000261476.1	RP11-77K12.3	3.41	0.000708	0.0406	0.25	0.16	Type 1 diabetes;Type 2 diabetes;	chr16:75472674	chr16:75458252~75460017:-
THCA	cis	rs765787	0.505	rs12593605	ENSG00000259539.1	CTD-2651B20.1	-3.41	0.000708	0.0406	-0.19	-0.16	Uric acid levels;	chr15:45205250	chr15:45152664~45167526:-
THCA	cis	rs7631605	0.548	rs4678563	ENSG00000224080.1	UBE2FP1	3.41	0.000708	0.0406	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37330726	chr3:37143512~37143958:-
THCA	cis	rs72827839	0.596	rs885635	ENSG00000266601.1	RP11-6N17.3	3.41	0.000708	0.0406	0.16	0.16	Ease of getting up in the morning;	chr17:47994862	chr17:47929682~47933106:-
THCA	cis	rs1790761	0.692	rs674783	ENSG00000184224.3	C11orf72	3.41	0.000708	0.0406	0.21	0.16	Mean corpuscular volume;	chr11:67571605	chr11:67602880~67606706:-
THCA	cis	rs72799341	1	rs35675346	ENSG00000232748.3	RP11-196G11.6	-3.41	0.000708	0.0406	-0.21	-0.16	Diastolic blood pressure;	chr16:30924760	chr16:31056460~31062803:+
THCA	cis	rs7631605	0.819	rs11129745	ENSG00000224080.1	UBE2FP1	3.41	0.000708	0.0406	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:36927382	chr3:37143512~37143958:-
THCA	cis	rs3767627	0.858	rs12023231	ENSG00000203819.6	HIST2H2BC	-3.41	0.000708	0.0406	-0.22	-0.16	Height;	chr1:150017474	chr1:149850193~149850772:-
THCA	cis	rs6664080	1	rs6664080	ENSG00000227496.1	RP11-145A3.1	3.41	0.000708	0.0406	0.18	0.16	Iris color (L* coordinate);	chr1:226609725	chr1:225700604~225752243:+
THCA	cis	rs11955398	0.501	rs10057004	ENSG00000251279.1	CTC-436P18.1	3.41	0.000708	0.0406	0.19	0.16	Intelligence (multi-trait analysis);	chr5:60745207	chr5:61162070~61232040:+
THCA	cis	rs11673344	0.542	rs1667380	ENSG00000233527.7	ZNF529-AS1	3.41	0.000708	0.0406	0.13	0.16	Obesity-related traits;	chr19:37001848	chr19:36573070~36594708:+
THCA	cis	rs61160187	0.582	rs11740632	ENSG00000272308.1	RP11-231G3.1	-3.41	0.000708	0.0406	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs67555188	ENSG00000272308.1	RP11-231G3.1	-3.41	0.000708	0.0406	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60866457~60866935:-
THCA	cis	rs61160187	0.582	rs67858932	ENSG00000272308.1	RP11-231G3.1	-3.41	0.000708	0.0406	-0.15	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60866457~60866935:-
THCA	cis	rs12621844	0.606	rs4953544	ENSG00000234690.5	AC073283.4	-3.41	0.000708	0.0406	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48019554	chr2:47192405~47345074:-
THCA	cis	rs988712	0.921	rs10767649	ENSG00000245573.6	BDNF-AS	3.41	0.000708	0.0406	0.14	0.16	Obesity;	chr11:27592271	chr11:27506838~27698174:+
THCA	cis	rs7780883	1	rs6946471	ENSG00000273341.1	RP5-899E9.1	-3.41	0.000708	0.0406	-0.18	-0.16	Cervical cancer;	chr7:77432967	chr7:77416673~77425443:+
THCA	cis	rs5993586	1	rs5748165	ENSG00000223461.1	AC004471.9	3.41	0.000708	0.0406	0.34	0.16	Coronary artery disease;	chr22:19381200	chr22:19121529~19124503:+
THCA	cis	rs3218092	0.81	rs10947995	ENSG00000213435.3	ATP6V0CP3	3.41	0.000708	0.0406	0.26	0.16	Red cell distribution width;	chr6:41921485	chr6:42727234~42727700:+
THCA	cis	rs3126085	0.935	rs10749670	ENSG00000237975.5	FLG-AS1	-3.41	0.000708	0.0406	-0.24	-0.16	Atopic dermatitis;	chr1:152247991	chr1:152168125~152445456:+
THCA	cis	rs12823128	0.839	rs10842783	ENSG00000256185.1	RP11-612B6.2	-3.41	0.000708	0.0406	-0.15	-0.16	Birth weight;	chr12:26704293	chr12:26335864~26336950:-
THCA	cis	rs3792900	0.588	rs6872948	ENSG00000271824.1	AC009014.3	-3.41	0.000708	0.0406	-0.16	-0.16	Blood protein levels;Insomnia;	chr5:136189869	chr5:136191468~136193134:-
THCA	cis	rs7005380	0.965	rs11988434	ENSG00000279347.1	RP11-85I17.2	3.41	0.000709	0.0406	0.19	0.16	Interstitial lung disease;	chr8:119932982	chr8:119838736~119840385:-
THCA	cis	rs975752	0.867	rs7911057	ENSG00000227492.1	RP11-316M21.6	3.41	0.000709	0.0406	0.29	0.16	Schizophrenia;	chr10:100197612	chr10:100229667~100234000:+
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000264242.2	RP11-271K11.1	3.41	0.000709	0.0406	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000264242.2	RP11-271K11.1	3.41	0.000709	0.0406	0.25	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30553697~30558962:+
THCA	cis	rs9875589	0.915	rs62234597	ENSG00000233121.1	VN1R20P	3.41	0.000709	0.0406	0.18	0.16	Ovarian reserve;	chr3:13922283	chr3:13926813~13927778:+
THCA	cis	rs6088813	0.635	rs6088792	ENSG00000279253.1	RP4-614O4.13	3.41	0.000709	0.0406	0.17	0.16	Height;	chr20:35321981	chr20:35262727~35264187:-
THCA	cis	rs7083	0.716	rs574603	ENSG00000271412.1	PRR13P3	3.41	0.000709	0.0406	0.2	0.16	Blood protein levels;	chr11:117307025	chr11:117336256~117336631:-
THCA	cis	rs10090774	0.965	rs6578133	ENSG00000280303.2	ERICD	3.41	0.000709	0.0406	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140763753	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs4378011	ENSG00000280303.2	ERICD	3.41	0.000709	0.0406	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140764477	chr8:140636281~140638283:+
THCA	cis	rs9487051	0.872	rs9400269	ENSG00000260273.1	RP11-425D10.10	3.41	0.000709	0.0406	0.18	0.16	Reticulocyte fraction of red cells;	chr6:109284862	chr6:109382795~109383666:+
THCA	cis	rs10515778	0.948	rs61128141	ENSG00000280834.1	U6	3.41	0.000709	0.0407	0.26	0.16	Inflammatory skin disease;	chr5:159205393	chr5:160072268~160072364:+
THCA	cis	rs41411047	1	rs41411047	ENSG00000252172.1	RNU6-720P	-3.41	0.000709	0.0407	-0.32	-0.16	Myocardial infarction;	chr3:149875124	chr3:149917342~149917449:-
THCA	cis	rs479105	0.645	rs740769	ENSG00000278356.1	RP11-372B4.3	3.41	0.000709	0.0407	0.15	0.16	Gut microbiota (bacterial taxa);	chr12:3264708	chr12:2885819~2886329:+
THCA	cis	rs6921919	0.848	rs6903823	ENSG00000280107.1	AL022393.9	-3.41	0.000709	0.0407	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28170845~28172521:+
THCA	cis	rs9329221	0.662	rs35472251	ENSG00000253641.4	RP11-981G7.2	3.41	0.000709	0.0407	0.15	0.16	Neuroticism;	chr8:10389159	chr8:10474565~10481974:+
THCA	cis	rs875971	0.545	rs4718325	ENSG00000230295.1	RP11-458F8.2	3.41	0.000709	0.0407	0.14	0.16	Aortic root size;	chr7:66215323	chr7:66880708~66882981:+
THCA	cis	rs1799922	0.832	rs3778760	ENSG00000271553.1	RP11-274B21.10	-3.41	0.000709	0.0407	-0.14	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128756628	chr7:128667043~128668156:+
THCA	cis	rs7246657	0.943	rs8111782	ENSG00000268499.1	CTB-102L5.8	3.41	0.000709	0.0407	0.21	0.16	Coronary artery calcification;	chr19:37377002	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs10404920	ENSG00000268499.1	CTB-102L5.8	3.41	0.000709	0.0407	0.21	0.16	Coronary artery calcification;	chr19:37390654	chr19:38199836~38200934:+
THCA	cis	rs4683346	0.656	rs4682862	ENSG00000273328.4	RP11-141M3.6	-3.41	0.000709	0.0407	-0.19	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42835921	chr3:42809414~42908105:+
THCA	cis	rs8073060	0.544	rs225258	ENSG00000255987.1	TOMM20P2	-3.41	0.000709	0.0407	-0.18	-0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35629864	chr17:35514766~35515186:-
THCA	cis	rs6995541	0.645	rs77796627	ENSG00000248896.2	CTD-2135J3.3	-3.41	0.000709	0.0407	-0.22	-0.16	Triglyceride levels;	chr8:10831290	chr8:10729314~10771392:+
THCA	cis	rs712039	0.565	rs1714988	ENSG00000277501.1	RP11-697E22.2	3.41	0.000709	0.0407	0.23	0.16	Tuberculosis;	chr17:37387113	chr17:37642947~37684252:+
THCA	cis	rs7674212	0.57	rs2126470	ENSG00000230069.3	LRRC37A15P	-3.41	0.000709	0.0407	-0.15	-0.16	Type 2 diabetes;	chr4:103140605	chr4:102727274~102730721:-
THCA	cis	rs7819412	0.669	rs6601568	ENSG00000254839.1	AF131215.6	3.41	0.00071	0.0407	0.17	0.16	Triglycerides;	chr8:11215893	chr8:11062647~11067089:-
THCA	cis	rs7824557	0.564	rs7814131	ENSG00000255046.1	RP11-297N6.4	3.41	0.00071	0.0407	0.16	0.16	Retinal vascular caliber;	chr8:11241690	chr8:11797928~11802568:-
THCA	cis	rs9309473	0.5	rs11688718	ENSG00000273245.1	RP11-434P11.2	3.41	0.00071	0.0407	0.19	0.16	Metabolite levels;	chr2:73533812	chr2:73750256~73750786:-
THCA	cis	rs9816784	0.525	rs3326	ENSG00000207650.1	MIR570	3.41	0.00071	0.0407	0.17	0.16	Mean corpuscular hemoglobin;	chr3:196054635	chr3:195699401~195699497:+
THCA	cis	rs7246967	0.673	rs4933026	ENSG00000198153.8	ZNF849P	-3.41	0.00071	0.0407	-0.24	-0.16	Bronchopulmonary dysplasia;	chr19:22691690	chr19:22685167~22686732:+
THCA	cis	rs7166081	1	rs4536412	ENSG00000270964.1	RP11-502I4.3	-3.41	0.00071	0.0407	-0.14	-0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67361426	chr15:67541072~67542604:-
THCA	cis	rs7246657	1	rs6508710	ENSG00000267422.1	CTD-2554C21.1	-3.41	0.00071	0.0407	-0.17	-0.16	Coronary artery calcification;	chr19:37258984	chr19:37779686~37792865:+
THCA	cis	rs318719	1	rs318719	ENSG00000267277.1	CTD-2342J14.6	3.41	0.00071	0.0407	0.25	0.16	Coronary artery disease;	chr19:11386305	chr19:11368123~11374935:-
THCA	cis	rs732716	0.889	rs62129355	ENSG00000280239.1	CTB-50L17.8	-3.41	0.00071	0.0407	-0.13	-0.16	Mean corpuscular volume;	chr19:4397037	chr19:4448810~4450836:+
THCA	cis	rs10938353	0.911	rs6447356	ENSG00000273369.1	RP11-700J17.1	-3.41	0.00071	0.0407	-0.17	-0.16	Body mass index;	chr4:44588558	chr4:44693946~44694386:-
THCA	cis	rs10938353	0.911	rs6447357	ENSG00000273369.1	RP11-700J17.1	-3.41	0.00071	0.0407	-0.17	-0.16	Body mass index;	chr4:44588577	chr4:44693946~44694386:-
THCA	cis	rs11758351	1	rs79868973	ENSG00000216331.1	HIST1H1PS1	3.41	0.00071	0.0407	0.25	0.16	Renal underexcretion gout;Gout;	chr6:26189084	chr6:26195566~26195771:+
THCA	cis	rs4648045	0.535	rs4698861	ENSG00000248971.2	KRT8P46	3.41	0.00071	0.0407	0.19	0.16	Lymphocyte percentage of white cells;	chr4:102624330	chr4:102728746~102730171:-
THCA	cis	rs13034020	0.843	rs1432296	ENSG00000271889.1	RP11-493E12.1	-3.41	0.00071	0.0407	-0.22	-0.16	Hodgkin's lymphoma;	chr2:60841032	chr2:61151433~61162105:-
THCA	cis	rs4700393	0.589	rs27565	ENSG00000251279.1	CTC-436P18.1	-3.41	0.00071	0.0407	-0.2	-0.16	Intelligence (multi-trait analysis);	chr5:60541764	chr5:61162070~61232040:+
THCA	cis	rs9652490	0.646	rs11638387	ENSG00000260776.4	RP11-114H24.2	3.41	0.00071	0.0407	0.27	0.16	Essential tremor;	chr15:77669998	chr15:77914217~77926846:-
THCA	cis	rs9652490	0.646	rs11631120	ENSG00000260776.4	RP11-114H24.2	3.41	0.00071	0.0407	0.27	0.16	Essential tremor;	chr15:77671764	chr15:77914217~77926846:-
THCA	cis	rs10896135	0.526	rs484262	ENSG00000275484.1	CTC-1337H24.4	3.41	0.00071	0.0407	0.12	0.16	Bipolar disorder;	chr11:66632210	chr11:67374416~67374932:+
THCA	cis	rs4886920	0.666	rs4595767	ENSG00000260776.4	RP11-114H24.2	-3.41	0.00071	0.0407	-0.18	-0.16	Neuroticism;	chr15:77791373	chr15:77914217~77926846:-
THCA	cis	rs7044106	0.69	rs10739569	ENSG00000235865.2	GSN-AS1	-3.41	0.00071	0.0407	-0.14	-0.16	Hip circumference adjusted for BMI;	chr9:120598749	chr9:121280768~121285530:-
THCA	cis	rs2638953	0.886	rs11049594	ENSG00000247934.4	RP11-967K21.1	3.41	0.00071	0.0407	0.16	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430368	chr12:28163298~28190738:-
THCA	cis	rs9549260	0.755	rs2721044	ENSG00000275149.1	RP11-427J23.1	-3.41	0.00071	0.0407	-0.21	-0.16	Red blood cell count;	chr13:40588088	chr13:40079106~40273509:-
THCA	cis	rs9925964	0.967	rs9936329	ENSG00000279196.1	RP11-1072A3.3	-3.41	0.00071	0.0407	-0.15	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31129478	chr16:30984630~30988270:-
THCA	cis	rs9925964	0.967	rs1549293	ENSG00000279196.1	RP11-1072A3.3	-3.41	0.00071	0.0407	-0.15	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31130672	chr16:30984630~30988270:-
THCA	cis	rs10488360	0.734	rs2107842	ENSG00000270822.1	RP11-730B22.1	3.41	0.00071	0.0407	0.19	0.16	Factor VII;	chr7:4373682	chr7:5009164~5009328:-
THCA	cis	rs6832769	0.961	rs11939815	ENSG00000223305.1	RN7SKP30	3.41	0.000711	0.0407	0.2	0.16	Personality dimensions;	chr4:55492116	chr4:55540502~55540835:-
THCA	cis	rs6832769	0.826	rs58894703	ENSG00000223305.1	RN7SKP30	3.41	0.000711	0.0407	0.2	0.16	Personality dimensions;	chr4:55492371	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs3805157	ENSG00000223305.1	RN7SKP30	3.41	0.000711	0.0407	0.2	0.16	Personality dimensions;	chr4:55497936	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs2177129	ENSG00000223305.1	RN7SKP30	3.41	0.000711	0.0407	0.2	0.16	Personality dimensions;	chr4:55499247	chr4:55540502~55540835:-
THCA	cis	rs6832769	0.89	rs1980273	ENSG00000223305.1	RN7SKP30	3.41	0.000711	0.0407	0.2	0.16	Personality dimensions;	chr4:55501234	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs6819660	ENSG00000223305.1	RN7SKP30	3.41	0.000711	0.0407	0.2	0.16	Personality dimensions;	chr4:55508410	chr4:55540502~55540835:-
THCA	cis	rs6828577	0.955	rs6857117	ENSG00000281731.1	RP11-384K6.8	-3.41	0.000711	0.0407	-0.18	-0.16	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118787409	chr4:118664087~118685341:-
THCA	cis	rs7326068	0.504	rs7983020	ENSG00000238286.1	SLC35E1P1	3.41	0.000711	0.0407	0.16	0.16	Schizophrenia, bipolar disorder and depression (combined);	chr13:20665802	chr13:20607268~20608131:+
THCA	cis	rs6019512	0.563	rs2024594	ENSG00000227431.4	CSE1L-AS1	-3.41	0.000711	0.0407	-0.2	-0.16	Intelligence (multi-trait analysis);	chr20:48901257	chr20:49040463~49046044:-
THCA	cis	rs80130819	0.748	rs2409001	ENSG00000273765.1	RP11-370I10.11	3.41	0.000711	0.0407	0.18	0.16	Prostate cancer;	chr12:48200707	chr12:48360920~48361377:+
THCA	cis	rs7923609	0.54	rs10733789	ENSG00000232075.1	MRPL35P2	3.41	0.000711	0.0407	0.23	0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63188924	chr10:63634317~63634827:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000230189.5	GS1-124K5.2	-3.41	0.000711	0.0407	-0.1	-0.16	Aortic root size;	chr7:66144830	chr7:66409143~66490059:-
THCA	cis	rs17286411	0.701	rs11643690	ENSG00000260185.1	RP11-432I5.6	-3.41	0.000711	0.0407	-0.21	-0.16	Blood protein levels;	chr16:71611735	chr16:71655027~71664212:+
THCA	cis	rs6938	0.534	rs12904897	ENSG00000260269.4	CTD-2323K18.1	-3.41	0.000711	0.0407	-0.22	-0.16	Breast cancer;	chr15:74925345	chr15:75527150~75601205:-
THCA	cis	rs1729951	0.575	rs361248	ENSG00000239213.4	NCK1-AS1	3.41	0.000711	0.0407	0.13	0.16	Neuroticism;	chr3:136990224	chr3:136841726~136862054:-
THCA	cis	rs516805	0.52	rs509596	ENSG00000279114.1	RP3-425C14.5	-3.41	0.000711	0.0407	-0.14	-0.16	Lymphocyte counts;	chr6:122478396	chr6:122471923~122484161:+
THCA	cis	rs7709377	0.671	rs6866454	ENSG00000248445.4	SEMA6A-AS1	-3.41	0.000711	0.0407	-0.14	-0.16	Metabolite levels  (X-11787);	chr5:116121394	chr5:116447547~116508276:+
THCA	cis	rs712039	0.652	rs736424	ENSG00000277501.1	RP11-697E22.2	3.41	0.000711	0.0407	0.22	0.16	Tuberculosis;	chr17:37429263	chr17:37642947~37684252:+
THCA	cis	rs10487112	1	rs10487112	ENSG00000225498.1	AC002064.5	3.41	0.000711	0.0407	0.18	0.16	Perceived unattractiveness to mosquitoes;	chr7:90444092	chr7:90312496~90322592:+
THCA	cis	rs1499614	1	rs1267818	ENSG00000273024.4	INTS4P2	3.41	0.000711	0.0407	0.27	0.16	Gout;	chr7:66642037	chr7:65647864~65715661:+
THCA	cis	rs478304	0.651	rs78412025	ENSG00000255120.4	OVOL1-AS1	-3.41	0.000711	0.0407	-0.2	-0.16	Acne (severe);	chr11:65728225	chr11:65789051~65790868:-
THCA	cis	rs478304	0.651	rs11227281	ENSG00000255120.4	OVOL1-AS1	-3.41	0.000711	0.0407	-0.2	-0.16	Acne (severe);	chr11:65729087	chr11:65789051~65790868:-
THCA	cis	rs478304	0.651	rs4014192	ENSG00000255120.4	OVOL1-AS1	-3.41	0.000711	0.0407	-0.2	-0.16	Acne (severe);	chr11:65731444	chr11:65789051~65790868:-
THCA	cis	rs478304	0.651	rs4930312	ENSG00000255120.4	OVOL1-AS1	-3.41	0.000711	0.0407	-0.2	-0.16	Acne (severe);	chr11:65732248	chr11:65789051~65790868:-
THCA	cis	rs478304	0.651	rs11537193	ENSG00000255120.4	OVOL1-AS1	-3.41	0.000711	0.0407	-0.2	-0.16	Acne (severe);	chr11:65732532	chr11:65789051~65790868:-
THCA	cis	rs478304	0.651	rs4930313	ENSG00000255120.4	OVOL1-AS1	-3.41	0.000711	0.0407	-0.2	-0.16	Acne (severe);	chr11:65732957	chr11:65789051~65790868:-
THCA	cis	rs7296418	0.663	rs11057276	ENSG00000256092.2	RP13-942N8.1	-3.41	0.000711	0.0408	-0.11	-0.16	Platelet count;	chr12:123335850	chr12:123363868~123366113:+
THCA	cis	rs2692947	0.644	rs772175	ENSG00000236750.1	AC009237.16	-3.41	0.000711	0.0408	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96278815	chr2:95641634~95641980:-
THCA	cis	rs9303542	0.729	rs56385452	ENSG00000278765.1	RP5-890E16.5	-3.41	0.000711	0.0408	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48462049	chr17:48066704~48067293:-
THCA	cis	rs3825942	0.587	rs2304720	ENSG00000261801.4	LOXL1-AS1	3.41	0.000711	0.0408	0.19	0.16	Glaucoma (exfoliation);	chr15:73946393	chr15:73908071~73928248:-
THCA	cis	rs11239930	0.517	rs492243	ENSG00000180867.10	PDIA3P1	3.41	0.000711	0.0408	0.15	0.16	AIDS progression;	chr1:147077930	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.517	rs493000	ENSG00000180867.10	PDIA3P1	3.41	0.000711	0.0408	0.15	0.16	AIDS progression;	chr1:147077979	chr1:147178113~147179622:+
THCA	cis	rs9510787	0.947	rs9510785	ENSG00000205861.10	C1QTNF9B-AS1	-3.41	0.000711	0.0408	-0.21	-0.16	Nasopharyngeal carcinoma;	chr13:23615010	chr13:23888889~23897263:+
THCA	cis	rs791590	0.715	rs12722587	ENSG00000212743.2	RP11-563J2.3	-3.41	0.000711	0.0408	-0.19	-0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:6018667	chr10:6350316~6352762:+
THCA	cis	rs9300255	0.679	rs12817892	ENSG00000235423.7	RP11-282O18.3	-3.41	0.000711	0.0408	-0.18	-0.16	Neutrophil percentage of white cells;	chr12:123244155	chr12:123252030~123261483:-
THCA	cis	rs2223471	0.742	rs13213461	ENSG00000060303.5	RPS17P5	3.41	0.000711	0.0408	0.18	0.16	Subcutaneous adipose tissue;	chr6:50692218	chr6:50857255~50857662:-
THCA	cis	rs860295	0.541	rs11264359	ENSG00000236675.1	MTX1P1	-3.41	0.000711	0.0408	-0.15	-0.16	Body mass index;	chr1:155313038	chr1:155230975~155234325:+
THCA	cis	rs7626019	0.638	rs12632746	ENSG00000222872.1	RNU4-78P	3.41	0.000711	0.0408	0.21	0.16	Neurofibrillary tangles;	chr3:42229525	chr3:42221840~42221965:+
THCA	cis	rs76076331	0.887	rs13387062	ENSG00000271952.1	RP11-245G13.2	-3.41	0.000711	0.0408	-0.27	-0.16	Educational attainment (college completion);Educational attainment (years of education);	chr2:10846989	chr2:10878269~10885118:+
THCA	cis	rs12545912	0.569	rs509820	ENSG00000248538.5	RP11-10A14.5	3.41	0.000711	0.0408	0.25	0.16	Multiple myeloma (hyperdiploidy);	chr8:9936583	chr8:9189011~9202854:+
THCA	cis	rs910316	0.737	rs175080	ENSG00000259138.1	RP11-950C14.7	-3.41	0.000711	0.0408	-0.13	-0.16	Height;	chr14:75047125	chr14:75127153~75136930:+
THCA	cis	rs114858855	1	rs9372225	ENSG00000260273.1	RP11-425D10.10	-3.41	0.000711	0.0408	-0.38	-0.16	Plasma trimethylamine N-oxide levels;	chr6:109721577	chr6:109382795~109383666:+
THCA	cis	rs114858855	1	rs17070874	ENSG00000260273.1	RP11-425D10.10	-3.41	0.000711	0.0408	-0.38	-0.16	Plasma trimethylamine N-oxide levels;	chr6:109722161	chr6:109382795~109383666:+
THCA	cis	rs2055375	0.666	rs159544	ENSG00000215032.2	GNL3LP1	3.41	0.000711	0.0408	0.19	0.16	Intelligence (multi-trait analysis);	chr5:61193420	chr5:60891935~60893577:-
THCA	cis	rs67478160	0.584	rs2295148	ENSG00000269940.1	RP11-73M18.7	3.41	0.000711	0.0408	0.15	0.16	Schizophrenia;	chr14:103729273	chr14:103694560~103695170:+
THCA	cis	rs3753275	0.624	rs6577534	ENSG00000230679.1	ENO1-AS1	3.41	0.000711	0.0408	0.16	0.16	Educational attainment;	chr1:8848691	chr1:8878835~8879894:+
THCA	cis	rs76878669	0.561	rs7117630	ENSG00000255320.1	RP11-755F10.1	3.41	0.000712	0.0408	0.2	0.16	Educational attainment (years of education);	chr11:66387306	chr11:66244840~66246239:-
THCA	cis	rs10090774	0.965	rs3923115	ENSG00000280303.2	ERICD	3.41	0.000712	0.0408	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140744352	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs35426024	ENSG00000280303.2	ERICD	3.41	0.000712	0.0408	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140745211	chr8:140636281~140638283:+
THCA	cis	rs10995245	0.879	rs7075349	ENSG00000238280.1	RP11-436D10.3	3.41	0.000712	0.0408	0.19	0.16	Narcolepsy;	chr10:62667889	chr10:62793562~62805887:-
THCA	cis	rs2014572	0.967	rs10418480	ENSG00000276449.1	AC004076.5	3.41	0.000712	0.0408	0.14	0.16	Hyperactive-impulsive symptoms;	chr19:57243687	chr19:57449689~57453011:+
THCA	cis	rs9863	0.896	rs2130382	ENSG00000270028.1	RP11-380L11.4	3.41	0.000712	0.0408	0.17	0.16	White blood cell count;	chr12:124000096	chr12:123925461~123926083:-
THCA	cis	rs6684709	0.638	rs2038027	ENSG00000235052.1	RP1-150O5.3	-3.41	0.000712	0.0408	-0.16	-0.16	White blood cell count;	chr1:23521550	chr1:23549139~23550915:-
THCA	cis	rs11633886	0.677	rs4774198	ENSG00000273972.1	CTD-2306A12.1	-3.41	0.000712	0.0408	-0.17	-0.16	Diisocyanate-induced asthma;	chr15:45754347	chr15:45702640~45703183:+
THCA	cis	rs1555322	0.53	rs2297789	ENSG00000261582.1	RP4-614O4.11	-3.41	0.000712	0.0408	-0.17	-0.16	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35267885~35280043:-
THCA	cis	rs2901381	0.701	rs34336083	ENSG00000269984.1	RP11-362K14.5	-3.41	0.000712	0.0408	-0.14	-0.16	Plateletcrit;	chr3:169098520	chr3:169777192~169780334:-
THCA	cis	rs6083	0.571	rs17190678	ENSG00000245975.2	RP11-30K9.6	-3.41	0.000712	0.0408	-0.14	-0.16	Schizophrenia;	chr15:58555173	chr15:58768072~58770974:-
THCA	cis	rs2286492	0.655	rs117841439	ENSG00000228649.7	AC005682.5	-3.41	0.000712	0.0408	-0.32	-0.16	Bipolar disorder;	chr7:22870922	chr7:22854178~22861579:+
THCA	cis	rs261967	0.692	rs261980	ENSG00000236882.6	LINC01554	-3.41	0.000712	0.0408	-0.19	-0.16	Body mass index;	chr5:96509093	chr5:95852232~95860133:+
THCA	cis	rs4662750	0.58	rs4662745	ENSG00000236682.1	AC068282.3	3.41	0.000712	0.0408	0.19	0.16	Renal cell carcinoma;	chr2:127595288	chr2:127389130~127400580:+
THCA	cis	rs7296418	0.663	rs28450974	ENSG00000256092.2	RP13-942N8.1	3.41	0.000712	0.0408	0.11	0.16	Platelet count;	chr12:123376873	chr12:123363868~123366113:+
THCA	cis	rs7833790	0.724	rs1054078	ENSG00000254689.1	RP11-354A14.1	3.41	0.000712	0.0408	0.17	0.16	Diastolic blood pressure;	chr8:81799918	chr8:81885377~81923193:+
THCA	cis	rs7833790	0.685	rs13255262	ENSG00000254689.1	RP11-354A14.1	3.41	0.000712	0.0408	0.17	0.16	Diastolic blood pressure;	chr8:81815789	chr8:81885377~81923193:+
THCA	cis	rs1003719	0.667	rs28666643	ENSG00000270116.1	AP001429.1	-3.41	0.000712	0.0408	-0.18	-0.16	Eye color traits;	chr21:37083699	chr21:37100814~37101343:+
THCA	cis	rs1003719	0.667	rs3753073	ENSG00000270116.1	AP001429.1	-3.41	0.000712	0.0408	-0.18	-0.16	Eye color traits;	chr21:37094315	chr21:37100814~37101343:+
THCA	cis	rs9435732	0.832	rs7531163	ENSG00000268869.4	ESPNP	3.41	0.000712	0.0408	0.18	0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16986959	chr1:16687339~16720157:-
THCA	cis	rs9435732	0.524	rs9435660	ENSG00000268869.4	ESPNP	3.41	0.000712	0.0408	0.18	0.16	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16987578	chr1:16687339~16720157:-
THCA	cis	rs2635047	1	rs2635043	ENSG00000280212.1	RP11-49K24.3	-3.41	0.000712	0.0408	-0.15	-0.16	Educational attainment;	chr18:47153398	chr18:47076117~47076594:+
THCA	cis	rs2635047	0.875	rs2251948	ENSG00000280212.1	RP11-49K24.3	-3.41	0.000712	0.0408	-0.15	-0.16	Educational attainment;	chr18:47154985	chr18:47076117~47076594:+
THCA	cis	rs7903847	0.642	rs10882922	ENSG00000225850.3	RP11-452K12.4	3.41	0.000712	0.0408	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97398780	chr10:97334564~97343203:+
THCA	cis	rs7903847	0.642	rs10786341	ENSG00000225850.3	RP11-452K12.4	3.41	0.000712	0.0408	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97398850	chr10:97334564~97343203:+
THCA	cis	rs722599	0.651	rs7159354	ENSG00000279594.1	RP11-950C14.10	3.41	0.000712	0.0408	0.15	0.16	IgG glycosylation;	chr14:74787144	chr14:75011269~75012851:-
THCA	cis	rs9923856	0.57	rs36030173	ENSG00000263033.2	RP11-396B14.2	-3.41	0.000712	0.0408	-0.16	-0.16	Atopic dermatitis;Adult asthma;	chr16:10954079	chr16:11196177~11224969:+
THCA	cis	rs2562456	0.874	rs9304986	ENSG00000268658.4	LINC00664	-3.41	0.000712	0.0408	-0.22	-0.16	Pain;	chr19:21499260	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.917	rs2650805	ENSG00000268658.4	LINC00664	-3.41	0.000712	0.0408	-0.22	-0.16	Pain;	chr19:21505137	chr19:21483374~21503238:+
THCA	cis	rs2562456	0.917	rs10420016	ENSG00000268658.4	LINC00664	-3.41	0.000712	0.0408	-0.22	-0.16	Pain;	chr19:21505800	chr19:21483374~21503238:+
THCA	cis	rs6885307	0.824	rs6866995	ENSG00000272335.1	RP11-53O19.3	-3.41	0.000712	0.0408	-0.15	-0.16	Age at first birth;	chr5:44976745	chr5:44826076~44828592:+
THCA	cis	rs2290416	0.892	rs58774517	ENSG00000254973.1	RP11-429J17.7	3.41	0.000712	0.0408	0.32	0.16	Attention deficit hyperactivity disorder;	chr8:143574594	chr8:143758153~143771822:-
THCA	cis	rs28530618	0.84	rs6058783	ENSG00000198547.7	C20orf203	-3.41	0.000712	0.0408	-0.12	-0.16	Birth weight;	chr20:32647980	chr20:32631652~32673941:-
THCA	cis	rs7914558	0.966	rs10883817	ENSG00000272912.1	RP11-724N1.1	-3.41	0.000712	0.0408	-0.18	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:102914585~102915404:+
THCA	cis	rs7010267	0.805	rs6992497	ENSG00000254278.1	RP11-278I4.2	-3.41	0.000712	0.0408	-0.2	-0.16	Total body bone mineral density (age 45-60);	chr8:118967830	chr8:119062942~119068782:-
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000264242.2	RP11-271K11.1	3.41	0.000712	0.0408	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30553697~30558962:+
THCA	cis	rs73459955	0.761	rs12148426	ENSG00000248441.5	LINC01197	3.41	0.000712	0.0408	0.2	0.16	Major depression and alcohol dependence;	chr15:95081834	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs12148542	ENSG00000248441.5	LINC01197	3.41	0.000712	0.0408	0.2	0.16	Major depression and alcohol dependence;	chr15:95082979	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.667	rs60937433	ENSG00000248441.5	LINC01197	3.41	0.000712	0.0408	0.2	0.16	Major depression and alcohol dependence;	chr15:95085215	chr15:95209099~95327129:-
THCA	cis	rs1864585	0.52	rs17774331	ENSG00000280294.1	RP11-177H2.1	3.41	0.000712	0.0408	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10773716	chr8:10856085~10859436:-
THCA	cis	rs6449957	0.607	rs251394	ENSG00000249335.1	CTC-340D7.1	3.41	0.000712	0.0408	0.19	0.16	Cleft lip with or without cleft palate;	chr5:68216172	chr5:68832585~68962158:-
THCA	cis	rs703980	0.745	rs1613295	ENSG00000230091.5	TMEM254-AS1	-3.41	0.000712	0.0408	-0.18	-0.16	Type 2 diabetes;	chr10:79195032	chr10:80046860~80078912:-
THCA	cis	rs7246657	0.653	rs10402050	ENSG00000267422.1	CTD-2554C21.1	-3.41	0.000712	0.0408	-0.22	-0.16	Coronary artery calcification;	chr19:37198056	chr19:37779686~37792865:+
THCA	cis	rs4656958	0.93	rs4656277	ENSG00000233691.2	RP11-312J18.7	3.41	0.000712	0.0408	0.19	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160913978	chr1:160935537~160936126:+
THCA	cis	rs6546550	0.901	rs10167142	ENSG00000179818.12	PCBP1-AS1	-3.41	0.000712	0.0408	-0.12	-0.16	Prevalent atrial fibrillation;	chr2:69835228	chr2:69962263~70103220:-
THCA	cis	rs6546550	0.935	rs10202159	ENSG00000179818.12	PCBP1-AS1	-3.41	0.000712	0.0408	-0.12	-0.16	Prevalent atrial fibrillation;	chr2:69835322	chr2:69962263~70103220:-
THCA	cis	rs6084875	0.733	rs7354668	ENSG00000278595.1	RP5-1068H6.6	-3.41	0.000713	0.0408	-0.18	-0.16	Systemic lupus erythematosus;	chr20:4761064	chr20:4761300~4761696:+
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000281021.1	RP1-12G14.9	-3.41	0.000713	0.0408	-0.16	-0.16	Lung cancer;	chr6:149618465	chr6:149576089~149590864:-
THCA	cis	rs948562	0.744	rs78111333	ENSG00000280010.1	AP001350.4	3.41	0.000713	0.0408	0.24	0.16	Lymphoma;	chr11:58482474	chr11:58627435~58628528:+
THCA	cis	rs2250417	0.504	rs11214093	ENSG00000250303.3	RP11-356J5.12	3.41	0.000713	0.0408	0.19	0.16	Protein quantitative trait loci;Inflammatory biomarkers;	chr11:112121869	chr11:112270749~112362534:+
THCA	cis	rs7586879	0.616	rs10203386	ENSG00000224165.4	DNAJC27-AS1	-3.41	0.000713	0.0408	-0.09	-0.16	Body mass index;	chr2:24913997	chr2:24971390~25039694:+
THCA	cis	rs638893	1	rs649338	ENSG00000255422.1	AP002954.4	-3.41	0.000713	0.0408	-0.24	-0.16	Vitiligo;	chr11:118834945	chr11:118704607~118750263:+
THCA	cis	rs1577917	1	rs16876529	ENSG00000220563.1	PKMP3	-3.41	0.000713	0.0408	-0.12	-0.16	Response to antipsychotic treatment;	chr6:85881484	chr6:85659892~85660606:-
THCA	cis	rs2460905	0.618	rs77155867	ENSG00000251468.2	RP11-369K16.1	-3.41	0.000713	0.0408	-0.3	-0.16	Post-traumatic stress disorder;	chr8:12925188	chr8:12958387~12962200:+
THCA	cis	rs881375	0.678	rs1014530	ENSG00000238181.2	AHCYP2	-3.41	0.000713	0.0408	-0.19	-0.16	Rheumatoid arthritis;	chr9:120922814	chr9:120720673~120721972:+
THCA	cis	rs9296095	1	rs5745568	ENSG00000197251.3	LINC00336	-3.41	0.000713	0.0408	-0.2	-0.16	Platelet count;	chr6:33580617	chr6:33586106~33593338:-
THCA	cis	rs10871290	1	rs10871290	ENSG00000207525.1	Y_RNA	3.41	0.000713	0.0408	0.18	0.16	Breast cancer;	chr16:74438798	chr16:74463888~74463988:-
THCA	cis	rs10858047	0.883	rs6537839	ENSG00000231128.4	RP5-1073O3.2	3.41	0.000713	0.0408	0.23	0.16	Autism;	chr1:114646287	chr1:113812379~113829171:+
THCA	cis	rs3785574	0.962	rs2665799	ENSG00000279369.1	RP11-51F16.1	3.41	0.000713	0.0408	0.11	0.16	Height;	chr17:63842363	chr17:63700847~63702670:+
THCA	cis	rs950169	0.96	rs12905475	ENSG00000230373.7	GOLGA6L5P	-3.41	0.000713	0.0408	-0.18	-0.16	Schizophrenia;	chr15:84131743	chr15:84507885~84516814:-
THCA	cis	rs41419946	1	rs41419946	ENSG00000236206.1	RP11-306I1.2	-3.41	0.000713	0.0408	-0.37	-0.16	Gut microbiome composition (winter);	chr1:165424850	chr1:165598463~165623331:+
THCA	cis	rs950893	0.798	rs907585	ENSG00000253837.1	RP11-177H13.2	-3.41	0.000713	0.0409	-0.16	-0.16	Mean corpuscular hemoglobin;	chr8:23620998	chr8:23336171~23366125:+
THCA	cis	rs10090774	0.965	rs4961236	ENSG00000280303.2	ERICD	3.41	0.000713	0.0409	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140855796	chr8:140636281~140638283:+
THCA	cis	rs1862618	0.853	rs832584	ENSG00000234553.1	AC022431.3	3.41	0.000713	0.0409	0.18	0.16	Initial pursuit acceleration;	chr5:56883385	chr5:56536583~56537826:-
THCA	cis	rs7819412	0.593	rs11778398	ENSG00000269918.1	AF131215.9	-3.41	0.000713	0.0409	-0.18	-0.16	Triglycerides;	chr8:11116733	chr8:11104691~11106704:-
THCA	cis	rs244293	0.765	rs7503269	ENSG00000275710.1	RP11-257O5.4	3.41	0.000713	0.0409	0.18	0.16	Menarche (age at onset);	chr17:54942351	chr17:54964474~54964679:+
THCA	cis	rs1922291	0.546	rs3771187	ENSG00000234389.1	AC007278.3	-3.41	0.000713	0.0409	-0.16	-0.16	Blood protein levels;	chr2:102223898	chr2:102438713~102440475:+
THCA	cis	rs1922291	0.546	rs12472872	ENSG00000234389.1	AC007278.3	-3.41	0.000713	0.0409	-0.16	-0.16	Blood protein levels;	chr2:102224384	chr2:102438713~102440475:+
THCA	cis	rs250518	0.926	rs7723498	ENSG00000251467.1	CTC-250P20.2	3.41	0.000713	0.0409	0.22	0.16	Mean corpuscular hemoglobin concentration;	chr5:72791470	chr5:72996920~72997642:+
THCA	cis	rs7577696	0.568	rs7562653	ENSG00000276334.1	AL133243.1	3.41	0.000713	0.0409	0.18	0.16	Inflammatory biomarkers;	chr2:32253560	chr2:32521927~32523547:+
THCA	cis	rs1552244	0.882	rs6443276	ENSG00000269982.1	RP11-1020A11.2	3.41	0.000714	0.0409	0.12	0.16	Alzheimer's disease;	chr3:9967221	chr3:9958717~9962539:+
THCA	cis	rs478304	0.651	rs10896037	ENSG00000255120.4	OVOL1-AS1	-3.41	0.000714	0.0409	-0.2	-0.16	Acne (severe);	chr11:65735953	chr11:65789051~65790868:-
THCA	cis	rs72717009	0.825	rs7552317	ENSG00000244682.6	FCGR2C	-3.41	0.000714	0.0409	-0.21	-0.16	Rheumatoid arthritis;	chr1:161509648	chr1:161581339~161605662:+
THCA	cis	rs982100	0.63	rs1465475	ENSG00000226856.4	AC093901.1	-3.41	0.000714	0.0409	-0.25	-0.16	Alzheimer disease and age of onset;	chr2:117647234	chr2:118132128~118186386:-
THCA	cis	rs801193	0.839	rs12534943	ENSG00000230295.1	RP11-458F8.2	3.41	0.000714	0.0409	0.12	0.16	Aortic root size;	chr7:66605533	chr7:66880708~66882981:+
THCA	cis	rs6560517	0.519	rs2093839	ENSG00000234618.1	RPSAP9	-3.41	0.000714	0.0409	-0.19	-0.16	Dialysis-related mortality;	chr9:76491736	chr9:76398699~76399586:+
THCA	cis	rs2882667	1	rs10064201	ENSG00000249593.5	CTB-46B19.2	3.41	0.000714	0.0409	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:139012647~139051203:+
THCA	cis	rs11250098	0.642	rs4841460	ENSG00000154316.13	TDH	3.41	0.000714	0.0409	0.11	0.16	Morning vs. evening chronotype;	chr8:10931983	chr8:11339637~11368452:+
THCA	cis	rs1941184	0.526	rs3848485	ENSG00000263823.1	RP11-326K13.4	-3.41	0.000714	0.0409	-0.16	-0.16	Parkinson's disease (age of onset);	chr18:31456353	chr18:31942575~31944156:+
THCA	cis	rs9475677	0.953	rs9475687	ENSG00000231441.1	RP11-472M19.2	3.41	0.000714	0.0409	0.19	0.16	Gut microbiota (functional units);	chr6:56366604	chr6:56844002~56864078:+
THCA	cis	rs933117	0.892	rs8128745	ENSG00000174680.8	GRIK1-AS1	-3.41	0.000714	0.0409	-0.37	-0.16	Body mass index;	chr21:29679216	chr21:29748175~29764002:+
THCA	cis	rs3790645	1	rs369385	ENSG00000241547.1	RP11-4K3__A.5	-3.41	0.000714	0.0409	-0.18	-0.16	Glucose homeostasis traits;	chr1:26566738	chr1:27325329~27325796:+
THCA	cis	rs1150668	0.799	rs9301	ENSG00000261839.1	RP1-265C24.8	3.41	0.000714	0.0409	0.15	0.16	Pubertal anthropometrics;	chr6:28324929	chr6:28136849~28139678:+
THCA	cis	rs832540	0.898	rs702680	ENSG00000271828.1	CTD-2310F14.1	-3.41	0.000714	0.0409	-0.21	-0.16	Coronary artery disease;	chr5:56924555	chr5:56927874~56929573:+
THCA	cis	rs1113500	0.933	rs4593854	ENSG00000230489.1	VAV3-AS1	-3.41	0.000714	0.0409	-0.15	-0.16	Growth-regulated protein alpha levels;	chr1:108095897	chr1:107964443~107994607:+
THCA	cis	rs9875589	0.957	rs6778731	ENSG00000233121.1	VN1R20P	3.41	0.000714	0.0409	0.18	0.16	Ovarian reserve;	chr3:13906007	chr3:13926813~13927778:+
THCA	cis	rs13401620	0.827	rs61160835	ENSG00000231013.1	AC013275.2	-3.41	0.000714	0.0409	-0.18	-0.16	Breast size;	chr2:119729983	chr2:119476448~119487346:+
THCA	cis	rs9291683	0.935	rs1860910	ENSG00000261490.1	RP11-448G15.3	3.41	0.000714	0.0409	0.1	0.16	Bone mineral density;	chr4:10273846	chr4:10068089~10073019:-
THCA	cis	rs5758659	1	rs5758677	ENSG00000205702.9	CYP2D7	3.41	0.000714	0.0409	0.12	0.16	Cognitive function;	chr22:42247033	chr22:42140203~42144577:-
THCA	cis	rs12621844	0.671	rs1483215	ENSG00000272663.1	RP11-191L17.1	3.41	0.000714	0.0409	0.15	0.16	Glycated hemoglobin levels;	chr2:48089589	chr2:48440043~48440597:-
THCA	cis	rs13279522	1	rs13279522	ENSG00000272192.1	CTD-2532N20.1	3.41	0.000714	0.0409	0.19	0.16	Coronary heart disease event reduction (statin therapy interaction);	chr8:66062017	chr8:65842752~65843331:+
THCA	cis	rs5758659	0.652	rs133303	ENSG00000281538.1	RP4-669P10.20	3.41	0.000714	0.0409	0.15	0.16	Cognitive function;	chr22:41999238	chr22:42138060~42139726:+
THCA	cis	rs6743226	0.58	rs11884197	ENSG00000223374.1	AC005104.3	3.41	0.000714	0.0409	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241303371	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.515	rs56061376	ENSG00000223374.1	AC005104.3	3.41	0.000714	0.0409	0.11	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241304020	chr2:241351340~241353104:-
THCA	cis	rs277939	0.905	rs277954	ENSG00000230847.4	RP11-195E2.1	-3.41	0.000714	0.0409	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71618081	chr5:71074225~71093193:-
THCA	cis	rs9307551	0.584	rs2119419	ENSG00000249646.2	OR7E94P	-3.41	0.000714	0.0409	-0.2	-0.16	Refractive error;	chr4:79515828	chr4:79587302~79588130:-
THCA	cis	rs9287719	0.639	rs2357649	ENSG00000243819.4	RN7SL832P	-3.41	0.000714	0.0409	-0.12	-0.16	Prostate cancer;	chr2:10556662	chr2:10690344~10692099:+
THCA	cis	rs787665	0.891	rs787661	ENSG00000232709.1	MARK2P9	3.41	0.000714	0.0409	0.24	0.16	Gut microbiome composition (summer);	chr10:93310769	chr10:92418667~92420875:+
THCA	cis	rs12049351	0.774	rs6657735	ENSG00000229367.1	HMGN2P19	3.41	0.000714	0.0409	0.23	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229491085	chr1:229570532~229570796:+
THCA	cis	rs2180341	1	rs6569477	ENSG00000220522.2	RP1-177A13.1	3.41	0.000714	0.0409	0.2	0.16	Breast cancer;	chr6:127268157	chr6:127416535~127416952:-
THCA	cis	rs7142002	0.536	rs28626353	ENSG00000271780.1	RP11-1017G21.5	-3.41	0.000715	0.0409	-0.29	-0.16	Autism;	chr14:102217225	chr14:101948347~101949425:+
THCA	cis	rs3849046	0.967	rs154073	ENSG00000253404.1	AC034243.1	-3.41	0.000715	0.0409	-0.17	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138522378	chr5:138744434~138753309:-
THCA	cis	rs261967	0.692	rs261961	ENSG00000236882.6	LINC01554	-3.41	0.000715	0.0409	-0.19	-0.16	Body mass index;	chr5:96510047	chr5:95852232~95860133:+
THCA	cis	rs2108225	0.934	rs2301989	ENSG00000233705.5	SLC26A4-AS1	-3.41	0.000715	0.0409	-0.13	-0.16	Ulcerative colitis;	chr7:107803426	chr7:107653968~107662151:-
THCA	cis	rs875971	0.545	rs313828	ENSG00000232559.3	GS1-124K5.12	-3.41	0.000715	0.0409	-0.17	-0.16	Aortic root size;	chr7:66087627	chr7:66554588~66576923:-
THCA	cis	rs875971	0.571	rs160647	ENSG00000232559.3	GS1-124K5.12	-3.41	0.000715	0.0409	-0.17	-0.16	Aortic root size;	chr7:66089365	chr7:66554588~66576923:-
THCA	cis	rs34783982	0.665	rs907782	ENSG00000259699.2	HMGB1P8	-3.41	0.000715	0.0409	-0.2	-0.16	Squamous cell lung carcinoma;	chr15:88950860	chr15:89135547~89136495:-
THCA	cis	rs7631605	1	rs6800554	ENSG00000272334.1	RP11-129K12.1	3.41	0.000715	0.0409	0.18	0.16	Cerebrospinal P-tau181p levels;	chr3:37102388	chr3:36973117~36973672:-
THCA	cis	rs17345786	1	rs73863360	ENSG00000244119.1	PDCL3P4	3.41	0.000715	0.0409	0.15	0.16	Colonoscopy-negative controls vs population controls;	chr3:101597993	chr3:101712472~101713191:+
THCA	cis	rs17345786	0.911	rs10936707	ENSG00000244119.1	PDCL3P4	3.41	0.000715	0.0409	0.15	0.16	Colonoscopy-negative controls vs population controls;	chr3:101605219	chr3:101712472~101713191:+
THCA	cis	rs1113500	0.836	rs1539553	ENSG00000230489.1	VAV3-AS1	3.41	0.000715	0.0409	0.15	0.16	Growth-regulated protein alpha levels;	chr1:108047376	chr1:107964443~107994607:+
THCA	cis	rs875971	0.508	rs10950045	ENSG00000230295.1	RP11-458F8.2	3.41	0.000715	0.0409	0.12	0.16	Aortic root size;	chr7:66601386	chr7:66880708~66882981:+
THCA	cis	rs801193	0.839	rs6968619	ENSG00000230295.1	RP11-458F8.2	3.41	0.000715	0.0409	0.12	0.16	Aortic root size;	chr7:66603880	chr7:66880708~66882981:+
THCA	cis	rs801193	0.805	rs12532355	ENSG00000230295.1	RP11-458F8.2	3.41	0.000715	0.0409	0.12	0.16	Aortic root size;	chr7:66605597	chr7:66880708~66882981:+
THCA	cis	rs12681366	0.806	rs72672679	ENSG00000253175.1	RP11-267M23.6	3.41	0.000715	0.0409	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94368956	chr8:94565036~94565715:+
THCA	cis	rs12681366	0.881	rs12675415	ENSG00000253175.1	RP11-267M23.6	3.41	0.000715	0.0409	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94371332	chr8:94565036~94565715:+
THCA	cis	rs950169	0.922	rs11630507	ENSG00000230373.7	GOLGA6L5P	-3.41	0.000715	0.0409	-0.17	-0.16	Schizophrenia;	chr15:84552494	chr15:84507885~84516814:-
THCA	cis	rs1048886	0.808	rs113870111	ENSG00000271967.1	RP11-134K13.4	-3.41	0.000715	0.0409	-0.19	-0.16	Type 2 diabetes;	chr6:70445856	chr6:70596438~70596980:+
THCA	cis	rs6452524	0.508	rs40214	ENSG00000271862.1	RP11-343L5.2	-3.41	0.000715	0.0409	-0.16	-0.16	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83049376~83050964:-
THCA	cis	rs72781680	0.611	rs78861366	ENSG00000223754.1	AC008073.9	-3.41	0.000715	0.0409	-0.25	-0.16	Lymphocyte counts;	chr2:24131558	chr2:24199839~24201698:-
THCA	cis	rs12664873	0.537	rs3823188	ENSG00000279453.1	RP3-425C14.4	-3.41	0.000715	0.0409	-0.16	-0.16	Atrial fibrillation;	chr6:122422541	chr6:122436789~122439223:-
THCA	cis	rs12780845	0.931	rs11595208	ENSG00000273153.1	RP11-406H21.2	3.41	0.000715	0.0409	0.15	0.16	Homocysteine levels;	chr10:17209637	chr10:17137336~17137585:-
THCA	cis	rs9652490	0.646	rs12914049	ENSG00000260776.4	RP11-114H24.2	3.41	0.000715	0.0409	0.27	0.16	Essential tremor;	chr15:77676783	chr15:77914217~77926846:-
THCA	cis	rs9652490	0.646	rs35971971	ENSG00000260776.4	RP11-114H24.2	3.41	0.000715	0.0409	0.27	0.16	Essential tremor;	chr15:77680108	chr15:77914217~77926846:-
THCA	cis	rs775227	0.528	rs775231	ENSG00000243849.1	CFAP44-AS1	-3.41	0.000715	0.0409	-0.26	-0.16	Dental caries;	chr3:113308367	chr3:113403991~113433992:+
THCA	cis	rs938554	0.57	rs7696983	ENSG00000261490.1	RP11-448G15.3	3.41	0.000715	0.0409	0.13	0.16	Blood metabolite levels;	chr4:9994205	chr4:10068089~10073019:-
THCA	cis	rs10509586	0.522	rs17411458	ENSG00000234452.4	SLC16A12-AS1	3.41	0.000715	0.0409	0.28	0.16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr10:89923992	chr10:89456064~89468140:+
THCA	cis	rs35123781	0.696	rs13154510	ENSG00000253404.1	AC034243.1	-3.41	0.000715	0.0409	-0.2	-0.16	Schizophrenia;	chr5:139691716	chr5:138744434~138753309:-
THCA	cis	rs7631605	0.967	rs4678942	ENSG00000272334.1	RP11-129K12.1	-3.41	0.000715	0.0409	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:37154430	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.905	rs4678944	ENSG00000272334.1	RP11-129K12.1	-3.41	0.000715	0.0409	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:37173194	chr3:36973117~36973672:-
THCA	cis	rs2839186	0.708	rs6518285	ENSG00000225043.1	RPL18AP2	3.41	0.000715	0.041	0.18	0.16	Testicular germ cell tumor;	chr21:46224753	chr21:46420553~46421034:-
THCA	cis	rs10090774	0.83	rs62521902	ENSG00000280303.2	ERICD	3.41	0.000715	0.041	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140901675	chr8:140636281~140638283:+
THCA	cis	rs6452524	0.618	rs6452501	ENSG00000271862.1	RP11-343L5.2	3.41	0.000715	0.041	0.16	0.16	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83049376~83050964:-
THCA	cis	rs12621844	0.671	rs968888	ENSG00000234690.5	AC073283.4	-3.41	0.000715	0.041	-0.15	-0.16	Glycated hemoglobin levels;	chr2:48065818	chr2:47192405~47345074:-
THCA	cis	rs2115630	1	rs56074163	ENSG00000275120.1	RP11-182J1.17	-3.41	0.000715	0.041	-0.16	-0.16	P wave terminal force;	chr15:84808101	chr15:84599434~84606463:-
THCA	cis	rs9400467	0.506	rs10457238	ENSG00000230177.1	RP5-1112D6.4	-3.41	0.000716	0.041	-0.19	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111441390	chr6:111277932~111278742:+
THCA	cis	rs7680126	0.633	rs887732	ENSG00000261490.1	RP11-448G15.3	-3.41	0.000716	0.041	-0.12	-0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10181493	chr4:10068089~10073019:-
THCA	cis	rs7737355	0.812	rs10463886	ENSG00000237714.1	P4HA2-AS1	-3.41	0.000716	0.041	-0.21	-0.16	Life satisfaction;	chr5:131423200	chr5:132184876~132192808:+
THCA	cis	rs7631605	1	rs1990492	ENSG00000272334.1	RP11-129K12.1	-3.41	0.000716	0.041	-0.18	-0.16	Cerebrospinal P-tau181p levels;	chr3:37083129	chr3:36973117~36973672:-
THCA	cis	rs11157436	0.602	rs4982569	ENSG00000211812.1	TRAV26-2	-3.41	0.000716	0.041	-0.13	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22202583~22203368:+
THCA	cis	rs722599	0.683	rs10144845	ENSG00000279594.1	RP11-950C14.10	3.41	0.000716	0.041	0.16	0.16	IgG glycosylation;	chr14:74771067	chr14:75011269~75012851:-
THCA	cis	rs1200921	0.616	rs1200824	ENSG00000272983.1	RP11-508N22.12	3.41	0.000716	0.041	0.14	0.16	Breast cancer;	chr10:37275098	chr10:38137337~38144399:+
THCA	cis	rs988712	0.921	rs6484312	ENSG00000245573.6	BDNF-AS	-3.41	0.000716	0.041	-0.14	-0.16	Obesity;	chr11:27520076	chr11:27506838~27698174:+
THCA	cis	rs988712	0.883	rs6484313	ENSG00000245573.6	BDNF-AS	-3.41	0.000716	0.041	-0.14	-0.16	Obesity;	chr11:27520253	chr11:27506838~27698174:+
THCA	cis	rs988712	0.921	rs901925	ENSG00000245573.6	BDNF-AS	-3.41	0.000716	0.041	-0.14	-0.16	Obesity;	chr11:27520922	chr11:27506838~27698174:+
THCA	cis	rs61160187	0.673	rs4353980	ENSG00000272308.1	RP11-231G3.1	3.41	0.000716	0.041	0.15	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60779501	chr5:60866457~60866935:-
THCA	cis	rs453301	0.631	rs28572014	ENSG00000254340.1	RP11-10A14.3	-3.41	0.000716	0.041	-0.18	-0.16	Joint mobility (Beighton score);	chr8:8936097	chr8:9141424~9145435:+
THCA	cis	rs3784262	0.669	rs4646642	ENSG00000259250.1	RP11-50C13.1	3.41	0.000716	0.041	0.13	0.16	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57954718	chr15:58587507~58591676:+
THCA	cis	rs7851660	0.527	rs7870795	ENSG00000214417.4	KRT18P13	-3.41	0.000716	0.041	-0.14	-0.16	Strep throat;	chr9:97811838	chr9:97698922~97700734:+
THCA	cis	rs7737355	0.812	rs798413	ENSG00000237714.1	P4HA2-AS1	3.41	0.000716	0.041	0.21	0.16	Life satisfaction;	chr5:131360893	chr5:132184876~132192808:+
THCA	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	3.41	0.000716	0.041	0.14	0.16	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
THCA	cis	rs3845817	0.703	rs702919	ENSG00000281920.1	RP11-418H16.1	-3.41	0.000716	0.041	-0.19	-0.16	Bipolar disorder;	chr2:65545157	chr2:65623272~65628424:+
THCA	cis	rs620729	0.749	rs4713562	ENSG00000272097.1	RP11-421M1.8	3.41	0.000716	0.041	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11483286	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs4713569	ENSG00000272097.1	RP11-421M1.8	3.41	0.000716	0.041	0.18	0.16	Intelligence (multi-trait analysis);	chr6:11483585	chr6:10743324~10747663:-
THCA	cis	rs995834	0.826	rs10419909	ENSG00000261770.1	CTC-459F4.1	-3.41	0.000716	0.041	-0.21	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395848	chr19:27757184~27760849:-
THCA	cis	rs995834	0.826	rs8112121	ENSG00000261770.1	CTC-459F4.1	-3.41	0.000716	0.041	-0.21	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396047	chr19:27757184~27760849:-
THCA	cis	rs995834	0.826	rs6508819	ENSG00000261770.1	CTC-459F4.1	-3.41	0.000716	0.041	-0.21	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396068	chr19:27757184~27760849:-
THCA	cis	rs995834	0.869	rs6508821	ENSG00000261770.1	CTC-459F4.1	-3.41	0.000716	0.041	-0.21	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396506	chr19:27757184~27760849:-
THCA	cis	rs2562456	0.752	rs7258562	ENSG00000268521.1	VN1R83P	3.41	0.000716	0.041	0.15	0.16	Pain;	chr19:21331762	chr19:21289554~21289998:-
THCA	cis	rs2985684	0.948	rs4900925	ENSG00000259155.2	RP11-831F12.3	3.41	0.000716	0.041	0.19	0.16	Carotid intima media thickness;	chr14:49545607	chr14:49677369~49677893:+
THCA	cis	rs6754311	0.773	rs4988183	ENSG00000231890.6	DARS-AS1	-3.41	0.000716	0.041	-0.17	-0.16	Mosquito bite size;	chr2:135864476	chr2:135985176~136022593:+
THCA	cis	rs2549003	0.966	rs2070730	ENSG00000233006.5	AC034220.3	-3.41	0.000716	0.041	-0.12	-0.16	Asthma (sex interaction);	chr5:132484108	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs7701588	ENSG00000233006.5	AC034220.3	-3.41	0.000716	0.041	-0.12	-0.16	Asthma (sex interaction);	chr5:132484278	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs2070728	ENSG00000233006.5	AC034220.3	-3.41	0.000716	0.041	-0.12	-0.16	Asthma (sex interaction);	chr5:132484285	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs2070727	ENSG00000233006.5	AC034220.3	-3.41	0.000716	0.041	-0.12	-0.16	Asthma (sex interaction);	chr5:132484583	chr5:132311285~132369916:-
THCA	cis	rs13381277	1	rs9951116	ENSG00000263982.1	RP11-504I13.3	3.41	0.000716	0.041	0.29	0.16	Dental caries;	chr18:76609736	chr18:76372717~76378275:+
THCA	cis	rs7203193	0.966	rs7188633	ENSG00000241641.1	RPS23P6	3.41	0.000716	0.041	0.15	0.16	LDL cholesterol;	chr16:11545517	chr16:12081237~12081902:+
THCA	cis	rs964611	0.938	rs7174204	ENSG00000259488.2	RP11-154J22.1	-3.41	0.000716	0.041	-0.15	-0.16	Metabolite levels (Pyroglutamine);	chr15:48286949	chr15:48312353~48331856:-
THCA	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-3.41	0.000717	0.041	-0.2	-0.16	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
THCA	cis	rs9400467	0.537	rs12215291	ENSG00000255389.1	C6orf3	3.41	0.000717	0.041	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111142317	chr6:111599875~111602295:+
THCA	cis	rs5770917	0.522	rs5770916	ENSG00000273272.1	CTA-384D8.34	-3.41	0.000717	0.041	-0.18	-0.16	Narcolepsy;	chr22:50577669	chr22:50542650~50543011:+
THCA	cis	rs12681963	0.748	rs12546330	ENSG00000272375.1	RP11-51J9.6	-3.41	0.000717	0.041	-0.17	-0.16	Migraine;	chr8:30044958	chr8:30197404~30198048:+
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000261839.1	RP1-265C24.8	3.41	0.000717	0.041	0.15	0.16	Pubertal anthropometrics;	chr6:28219323	chr6:28136849~28139678:+
THCA	cis	rs614226	0.935	rs17431717	ENSG00000248008.2	DYNLL1-AS1	3.41	0.000717	0.041	0.21	0.16	Type 1 diabetes nephropathy;	chr12:120474407	chr12:120490328~120495940:-
THCA	cis	rs9296092	0.538	rs9296094	ENSG00000272217.1	XXbac-BPG157A10.21	3.41	0.000717	0.041	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33552287	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.538	rs9461882	ENSG00000272217.1	XXbac-BPG157A10.21	3.41	0.000717	0.041	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33552444	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.517	rs78978280	ENSG00000272217.1	XXbac-BPG157A10.21	3.41	0.000717	0.041	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33552970	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.5	rs4376348	ENSG00000272217.1	XXbac-BPG157A10.21	3.41	0.000717	0.041	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33553320	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.517	rs62405949	ENSG00000272217.1	XXbac-BPG157A10.21	3.41	0.000717	0.041	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33555023	chr6:33246075~33246856:-
THCA	cis	rs9296092	0.538	rs3916674	ENSG00000272217.1	XXbac-BPG157A10.21	3.41	0.000717	0.041	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33555198	chr6:33246075~33246856:-
THCA	cis	rs6840360	1	rs1105536	ENSG00000270265.1	RP11-731D1.4	-3.41	0.000717	0.041	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151683875	chr4:151333775~151353224:-
THCA	cis	rs6840360	1	rs1105535	ENSG00000270265.1	RP11-731D1.4	-3.41	0.000717	0.041	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151684018	chr4:151333775~151353224:-
THCA	cis	rs11960179	0.764	rs11741085	ENSG00000250066.1	RP11-141O11.1	-3.41	0.000717	0.041	-0.31	-0.16	Glomerular filtration rate (creatinine);	chr5:68469595	chr5:68963246~68967845:+
THCA	cis	rs6723226	0.732	rs390480	ENSG00000276517.1	AL133243.2	3.41	0.000717	0.041	0.15	0.16	Intelligence (multi-trait analysis);	chr2:32285003	chr2:32526504~32529507:+
THCA	cis	rs7937890	0.559	rs2597208	ENSG00000251991.1	RNU7-49P	3.41	0.000717	0.041	0.18	0.16	Mitochondrial DNA levels;	chr11:14450783	chr11:14478892~14478953:+
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000264242.2	RP11-271K11.1	3.41	0.000717	0.041	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30553697~30558962:+
THCA	cis	rs9878978	0.722	rs62233819	ENSG00000227588.2	CNTN4-AS2	3.41	0.000717	0.041	0.21	0.16	Blood pressure (smoking interaction);	chr3:2462545	chr3:2110409~2144241:-
THCA	cis	rs929354	1	rs1182389	ENSG00000224629.1	RP5-1142J19.2	-3.41	0.000717	0.041	-0.15	-0.16	Body mass index;	chr7:157246109	chr7:157263022~157263229:-
THCA	cis	rs7829975	0.744	rs2409092	ENSG00000248538.5	RP11-10A14.5	-3.41	0.000717	0.041	-0.19	-0.16	Mood instability;	chr8:8824682	chr8:9189011~9202854:+
THCA	cis	rs7772486	0.875	rs2224121	ENSG00000270638.1	RP3-466P17.1	3.41	0.000717	0.041	0.12	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145735570~145737218:+
THCA	cis	rs4763879	0.634	rs61915472	ENSG00000278635.1	CTD-2318O12.1	3.41	0.000717	0.041	0.17	0.16	Type 1 diabetes;	chr12:9700995	chr12:9415641~9416718:+
THCA	cis	rs7615952	0.641	rs61048217	ENSG00000248787.1	RP11-666A20.4	-3.41	0.000717	0.041	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126089062	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs60839048	ENSG00000248787.1	RP11-666A20.4	-3.41	0.000717	0.041	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126089095	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs7640158	ENSG00000248787.1	RP11-666A20.4	-3.41	0.000717	0.041	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126089168	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs2365019	ENSG00000248787.1	RP11-666A20.4	-3.41	0.000717	0.041	-0.24	-0.16	Blood pressure (smoking interaction);	chr3:126089292	chr3:125908005~125910272:-
THCA	cis	rs9611565	0.527	rs73178638	ENSG00000281538.1	RP4-669P10.20	3.41	0.000717	0.041	0.18	0.16	Vitiligo;	chr22:41546900	chr22:42138060~42139726:+
THCA	cis	rs853679	0.567	rs7774981	ENSG00000220721.1	OR1F12	3.41	0.000717	0.041	0.19	0.16	Depression;	chr6:28379133	chr6:28073316~28074233:+
THCA	cis	rs853679	0.567	rs7754960	ENSG00000220721.1	OR1F12	3.41	0.000717	0.041	0.19	0.16	Depression;	chr6:28379168	chr6:28073316~28074233:+
THCA	cis	rs877819	0.552	rs2620878	ENSG00000228403.1	RP11-563N6.6	-3.41	0.000717	0.041	-0.16	-0.16	Systemic lupus erythematosus;	chr10:48879727	chr10:48878022~48878649:+
THCA	cis	rs7914558	1	rs11191542	ENSG00000213061.2	PFN1P11	3.41	0.000717	0.041	0.19	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064567	chr10:102838011~102845473:-
THCA	cis	rs17122278	1	rs11216922	ENSG00000243431.1	RPL5P30	3.41	0.000717	0.041	0.16	0.16	Total cholesterol levels;	chr11:118594580	chr11:118560690~118561580:+
THCA	cis	rs2562456	0.526	rs950504	ENSG00000213976.4	CTD-2561J22.2	-3.41	0.000717	0.041	-0.15	-0.16	Pain;	chr19:21601193	chr19:21382865~21387177:+
THCA	cis	rs5743289	0.639	rs62029864	ENSG00000260929.1	RP11-327F22.1	3.41	0.000717	0.041	0.18	0.16	Crohn's disease;Inflammatory bowel disease;	chr16:50718253	chr16:50740910~50742815:-
THCA	cis	rs4683346	0.731	rs35807837	ENSG00000273328.4	RP11-141M3.6	-3.41	0.000717	0.041	-0.21	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42878743	chr3:42809414~42908105:+
THCA	cis	rs8074700	0.539	rs3096648	ENSG00000233101.9	HOXB-AS3	-3.41	0.000718	0.0411	-0.19	-0.16	Body mass index in non-asthmatics;	chr17:48676462	chr17:48549630~48606414:+
THCA	cis	rs2933343	0.672	rs1872545	ENSG00000261159.1	RP11-723O4.9	3.41	0.000718	0.0411	0.16	0.16	IgG glycosylation;	chr3:128926196	chr3:128859716~128860526:-
THCA	cis	rs7188445	0.932	rs73575079	ENSG00000277954.1	RP11-679B19.1	-3.41	0.000718	0.0411	-0.19	-0.16	Urate levels;	chr16:79711344	chr16:79202624~79206739:-
THCA	cis	rs7188445	0.932	rs7203756	ENSG00000277954.1	RP11-679B19.1	3.41	0.000718	0.0411	0.19	0.16	Urate levels;	chr16:79711709	chr16:79202624~79206739:-
THCA	cis	rs883565	0.528	rs9311200	ENSG00000223668.1	EEF1A1P24	-3.41	0.000718	0.0411	-0.13	-0.16	Handedness;	chr3:38912405	chr3:39358545~39359922:+
THCA	cis	rs7572644	0.665	rs4420671	ENSG00000223522.1	AC093690.1	-3.41	0.000718	0.0411	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27816433	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.665	rs4493211	ENSG00000223522.1	AC093690.1	-3.41	0.000718	0.0411	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27816605	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.665	rs4665393	ENSG00000223522.1	AC093690.1	-3.41	0.000718	0.0411	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27817409	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.665	rs4666017	ENSG00000223522.1	AC093690.1	-3.41	0.000718	0.0411	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27817658	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.665	rs12478766	ENSG00000223522.1	AC093690.1	-3.41	0.000718	0.0411	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27818333	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.713	rs13026758	ENSG00000223522.1	AC093690.1	-3.41	0.000718	0.0411	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27818406	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.656	rs4666018	ENSG00000223522.1	AC093690.1	-3.41	0.000718	0.0411	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27819192	chr2:28307691~28310459:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000230295.1	RP11-458F8.2	3.41	0.000718	0.0411	0.12	0.16	Aortic root size;	chr7:66144830	chr7:66880708~66882981:+
THCA	cis	rs8044868	1	rs11075922	ENSG00000260886.1	TAT-AS1	3.41	0.000718	0.0411	0.18	0.16	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72123819	chr16:71565789~71578187:+
THCA	cis	rs4660456	0.913	rs6664044	ENSG00000238287.1	RP11-656D10.3	-3.41	0.000718	0.0411	-0.2	-0.16	Platelet count;	chr1:40735089	chr1:40493157~40508661:-
THCA	cis	rs7246657	0.606	rs2972439	ENSG00000226686.6	LINC01535	3.41	0.000718	0.0411	0.22	0.16	Coronary artery calcification;	chr19:37721680	chr19:37251912~37265535:+
THCA	cis	rs7246657	0.722	rs2909100	ENSG00000226686.6	LINC01535	3.41	0.000718	0.0411	0.22	0.16	Coronary artery calcification;	chr19:37721779	chr19:37251912~37265535:+
THCA	cis	rs478304	0.651	rs11604462	ENSG00000255320.1	RP11-755F10.1	3.41	0.000718	0.0411	0.2	0.16	Acne (severe);	chr11:65784177	chr11:66244840~66246239:-
THCA	cis	rs6496667	0.509	rs57962570	ENSG00000213471.7	TTLL13P	3.41	0.000718	0.0411	0.18	0.16	Rheumatoid arthritis;	chr15:90442364	chr15:90249530~90265482:+
THCA	cis	rs1799949	0.965	rs4239149	ENSG00000279602.1	CTD-3014M21.1	3.41	0.000718	0.0411	0.19	0.16	Menopause (age at onset);	chr17:43176078	chr17:43360041~43361361:-
THCA	cis	rs12541437	0.535	rs2289938	ENSG00000253327.2	RAD21-AS1	3.41	0.000718	0.0411	0.23	0.16	Gut microbiome composition (winter);	chr8:116849277	chr8:116874424~116876868:+
THCA	cis	rs12541437	0.535	rs3816342	ENSG00000253327.2	RAD21-AS1	3.41	0.000718	0.0411	0.23	0.16	Gut microbiome composition (winter);	chr8:116858136	chr8:116874424~116876868:+
THCA	cis	rs6981523	0.553	rs11989369	ENSG00000154316.13	TDH	-3.41	0.000718	0.0411	-0.12	-0.16	Neuroticism;	chr8:11197876	chr8:11339637~11368452:+
THCA	cis	rs2882667	0.894	rs10054478	ENSG00000249593.5	CTB-46B19.2	3.41	0.000718	0.0411	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:139012647~139051203:+
THCA	cis	rs1864585	0.52	rs73200742	ENSG00000280294.1	RP11-177H2.1	3.41	0.000718	0.0411	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10771846	chr8:10856085~10859436:-
THCA	cis	rs9333290	0.897	rs1448424	ENSG00000259915.2	RP11-410E4.1	-3.41	0.000718	0.0411	-0.19	-0.16	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186643245	chr2:186354570~186356773:-
THCA	cis	rs9333290	0.897	rs1839121	ENSG00000259915.2	RP11-410E4.1	-3.41	0.000718	0.0411	-0.19	-0.16	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186643471	chr2:186354570~186356773:-
THCA	cis	rs6500602	0.727	rs3761681	ENSG00000280063.1	RP11-295D4.3	3.41	0.000718	0.0411	0.08	0.16	Schizophrenia;	chr16:4516856	chr16:4346694~4348648:-
THCA	cis	rs6017317	0.696	rs61289351	ENSG00000234271.1	RP1-138B7.4	-3.41	0.000718	0.0411	-0.2	-0.16	Type 2 diabetes;	chr20:44290311	chr20:43523261~43523572:-
THCA	cis	rs6017317	0.696	rs6065715	ENSG00000234271.1	RP1-138B7.4	-3.41	0.000718	0.0411	-0.2	-0.16	Type 2 diabetes;	chr20:44290877	chr20:43523261~43523572:-
THCA	cis	rs6017317	0.696	rs6073396	ENSG00000234271.1	RP1-138B7.4	-3.41	0.000718	0.0411	-0.2	-0.16	Type 2 diabetes;	chr20:44291626	chr20:43523261~43523572:-
THCA	cis	rs6017317	0.731	rs6073397	ENSG00000234271.1	RP1-138B7.4	-3.41	0.000718	0.0411	-0.2	-0.16	Type 2 diabetes;	chr20:44291638	chr20:43523261~43523572:-
THCA	cis	rs6017317	0.731	rs13039300	ENSG00000234271.1	RP1-138B7.4	-3.41	0.000718	0.0411	-0.2	-0.16	Type 2 diabetes;	chr20:44296969	chr20:43523261~43523572:-
THCA	cis	rs2880765	0.835	rs6497206	ENSG00000259407.1	RP11-158M2.3	-3.41	0.000718	0.0411	-0.15	-0.16	Coronary artery disease;	chr15:85485994	chr15:85744109~85750281:-
THCA	cis	rs465969	1	rs9387010	ENSG00000230177.1	RP5-1112D6.4	-3.41	0.000718	0.0411	-0.24	-0.16	Psoriasis;	chr6:111384741	chr6:111277932~111278742:+
THCA	cis	rs2180341	0.814	rs6919277	ENSG00000220522.2	RP1-177A13.1	3.4	0.000718	0.0411	0.19	0.16	Breast cancer;	chr6:127416905	chr6:127416535~127416952:-
THCA	cis	rs354225	0.819	rs241661	ENSG00000237887.1	AC092839.1	-3.4	0.000718	0.0411	-0.2	-0.16	Schizophrenia;	chr2:54697330	chr2:54529343~54529801:+
THCA	cis	rs1864585	0.52	rs73208766	ENSG00000280294.1	RP11-177H2.1	3.4	0.000718	0.0411	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10807027	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.616	rs117478948	ENSG00000280294.1	RP11-177H2.1	3.4	0.000718	0.0411	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10807314	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs714370	ENSG00000280294.1	RP11-177H2.1	3.4	0.000718	0.0411	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10808337	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs73208769	ENSG00000280294.1	RP11-177H2.1	3.4	0.000718	0.0411	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10808474	chr8:10856085~10859436:-
THCA	cis	rs1322639	0.614	rs9364361	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.4	0.000718	0.0411	-0.23	-0.16	Pulse pressure;	chr6:169180404	chr6:169213254~169239565:+
THCA	cis	rs9948	1	rs9948	ENSG00000230606.9	AC159540.1	-3.4	0.000718	0.0411	-0.23	-0.16	Erectile dysfunction and prostate cancer treatment;	chr2:96835063	chr2:97416165~97433527:-
THCA	cis	rs9302752	0.922	rs8063362	ENSG00000260381.2	RP11-429P3.5	3.4	0.000718	0.0411	0.22	0.16	Leprosy;	chr16:50689460	chr16:50100339~50121943:-
THCA	cis	rs7226229	1	rs4985953	ENSG00000261033.1	RP11-209D14.2	-3.4	0.000718	0.0411	-0.22	-0.16	Blood trace element (Se levels);	chr17:20994271	chr17:20008051~20009234:-
THCA	cis	rs9902453	0.765	rs6505143	ENSG00000263603.1	CTD-2349P21.5	3.4	0.000719	0.0411	0.18	0.16	Coffee consumption (cups per day);	chr17:29823567	chr17:30729469~30731202:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65916269	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65918212	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65922114	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65923503	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65925372	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65925938	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65940221	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65943626	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65944004	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000237310.1	GS1-124K5.4	3.4	0.000719	0.0411	0.18	0.16	Diabetic kidney disease;	chr7:65944182	chr7:66493706~66495474:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000237310.1	GS1-124K5.4	-3.4	0.000719	0.0411	-0.18	-0.16	Diabetic kidney disease;	chr7:65928187	chr7:66493706~66495474:+
THCA	cis	rs6921919	0.551	rs13201753	ENSG00000220721.1	OR1F12	3.4	0.000719	0.0411	0.18	0.16	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28073316~28074233:+
THCA	cis	rs11638352	0.661	rs2447333	ENSG00000259418.1	RP11-109D20.1	-3.4	0.000719	0.0411	-0.37	-0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44191166	chr15:45041716~45058707:-
THCA	cis	rs1873147	1	rs12443295	ENSG00000259672.1	RP11-69G7.1	3.4	0.000719	0.0411	0.17	0.16	Orofacial clefts;	chr15:63021467	chr15:63098870~63110403:+
THCA	cis	rs6724465	0.636	rs72951772	ENSG00000272644.1	RP11-33O4.1	3.4	0.000719	0.0411	0.21	0.16	Height;	chr2:219126275	chr2:219069354~219069809:-
THCA	cis	rs2692947	0.727	rs2692950	ENSG00000235959.1	AC009237.17	-3.4	0.000719	0.0411	-0.17	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007776	chr2:95640181~95640604:-
THCA	cis	rs3749237	0.555	rs7637665	ENSG00000224424.7	PRKAR2A-AS1	3.4	0.000719	0.0411	0.13	0.16	Resting heart rate;	chr3:49514862	chr3:48847572~48851981:+
THCA	cis	rs6058526	0.631	rs6119784	ENSG00000235217.6	TSPY26P	-3.4	0.000719	0.0411	-0.18	-0.16	Chronic obstructive pulmonary disease;	chr20:32229979	chr20:32186477~32190527:-
THCA	cis	rs6479901	0.895	rs3211105	ENSG00000272767.1	JMJD1C-AS1	-3.4	0.000719	0.0411	-0.19	-0.16	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63465229~63466563:+
THCA	cis	rs1048886	0.872	rs12203089	ENSG00000271967.1	RP11-134K13.4	-3.4	0.000719	0.0411	-0.19	-0.16	Type 2 diabetes;	chr6:70578956	chr6:70596438~70596980:+
THCA	cis	rs684232	0.644	rs2543781	ENSG00000231784.7	DBIL5P	3.4	0.000719	0.0411	0.17	0.16	Prostate cancer;	chr17:699229	chr17:752660~755336:+
THCA	cis	rs9693857	0.52	rs11249928	ENSG00000261451.1	RP11-981G7.1	3.4	0.000719	0.0411	0.2	0.16	Systolic blood pressure;	chr8:9505750	chr8:10433672~10438312:+
THCA	cis	rs9880211	0.821	rs9832813	ENSG00000239213.4	NCK1-AS1	3.4	0.000719	0.0411	0.14	0.16	Height;Body mass index;	chr3:136346723	chr3:136841726~136862054:-
THCA	cis	rs72819454	0.522	rs56309638	ENSG00000280693.1	SH3PXD2A-AS1	-3.4	0.000719	0.0411	-0.32	-0.16	Interleukin-9 levels;	chr10:103760600	chr10:103745966~103755423:+
THCA	cis	rs12149074	0.901	rs10438631	ENSG00000260876.4	LINC01229	3.4	0.000719	0.0411	0.16	0.16	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80075474	chr16:79676108~79807922:+
THCA	cis	rs1864585	0.552	rs17776497	ENSG00000280294.1	RP11-177H2.1	3.4	0.000719	0.0411	0.16	0.16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10817652	chr8:10856085~10859436:-
THCA	cis	rs4886920	0.694	rs3936093	ENSG00000260776.4	RP11-114H24.2	3.4	0.000719	0.0411	0.18	0.16	Neuroticism;	chr15:77809567	chr15:77914217~77926846:-
THCA	cis	rs11673344	0.542	rs826331	ENSG00000233527.7	ZNF529-AS1	3.4	0.000719	0.0411	0.13	0.16	Obesity-related traits;	chr19:37007360	chr19:36573070~36594708:+
THCA	cis	rs4646404	0.509	rs744925	ENSG00000225442.2	MPRIP-AS1	3.4	0.000719	0.0411	0.19	0.16	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr17:17564187	chr17:17076038~17077752:-
THCA	cis	rs1501138	0.597	rs203443	ENSG00000263327.5	TAPT1-AS1	-3.4	0.000719	0.0411	-0.25	-0.16	Systemic juvenile idiopathic arthritis;	chr4:16247053	chr4:16226685~16320140:+
THCA	cis	rs1267303	0.642	rs11588450	ENSG00000232022.5	FAAHP1	-3.4	0.000719	0.0411	-0.18	-0.16	Monobrow;	chr1:46535324	chr1:46432129~46445521:+
THCA	cis	rs4764124	0.646	rs10744078	ENSG00000261324.2	RP11-174G6.5	3.4	0.000719	0.0411	0.11	0.16	Pubertal anthropometrics;	chr12:14825601	chr12:14762504~14767931:-
THCA	cis	rs4649295	0.833	rs1294329	ENSG00000231940.1	RPS7P3	3.4	0.000719	0.0411	0.17	0.16	Differentiated thyroid cancer;Papillary thyroid cancer;	chr1:233289042	chr1:233288868~233289447:-
THCA	cis	rs12893668	0.703	rs729438	ENSG00000252469.1	RNU7-160P	-3.4	0.00072	0.0411	-0.19	-0.16	Reticulocyte count;	chr14:103626452	chr14:103550345~103550406:+
THCA	cis	rs7188445	0.932	rs17689455	ENSG00000277954.1	RP11-679B19.1	-3.4	0.00072	0.0411	-0.19	-0.16	Urate levels;	chr16:79712438	chr16:79202624~79206739:-
THCA	cis	rs7188445	0.932	rs73575083	ENSG00000277954.1	RP11-679B19.1	-3.4	0.00072	0.0411	-0.19	-0.16	Urate levels;	chr16:79713958	chr16:79202624~79206739:-
THCA	cis	rs7188445	0.932	rs73575085	ENSG00000277954.1	RP11-679B19.1	-3.4	0.00072	0.0411	-0.19	-0.16	Urate levels;	chr16:79714179	chr16:79202624~79206739:-
THCA	cis	rs7188445	0.932	rs73575086	ENSG00000277954.1	RP11-679B19.1	-3.4	0.00072	0.0411	-0.19	-0.16	Urate levels;	chr16:79714588	chr16:79202624~79206739:-
THCA	cis	rs9902453	0.765	rs2628185	ENSG00000214719.10	AC005562.1	-3.4	0.00072	0.0411	-0.14	-0.16	Coffee consumption (cups per day);	chr17:29743089	chr17:30576464~30672789:+
THCA	cis	rs16975963	0.843	rs77895245	ENSG00000276846.1	CTD-3220F14.3	-3.4	0.00072	0.0411	-0.14	-0.16	Longevity;	chr19:37929140	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.843	rs73029180	ENSG00000276846.1	CTD-3220F14.3	-3.4	0.00072	0.0411	-0.14	-0.16	Longevity;	chr19:37929766	chr19:37314868~37315620:-
THCA	cis	rs2749097	0.825	rs35477997	ENSG00000244256.3	RN7SL130P	-3.4	0.00072	0.0411	-0.2	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63656834	chr1:63655743~63656047:+
THCA	cis	rs6762	0.748	rs1130719	ENSG00000255284.1	AP006621.5	3.4	0.00072	0.0411	0.11	0.16	Mean platelet volume;	chr11:838760	chr11:777578~784297:+
THCA	cis	rs7949030	0.626	rs11231145	ENSG00000255213.1	NPM1P35	3.4	0.00072	0.0411	0.19	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr11:62330946~62331813:+
THCA	cis	rs2180341	1	rs9321073	ENSG00000220522.2	RP1-177A13.1	3.4	0.00072	0.0412	0.2	0.16	Breast cancer;	chr6:127288546	chr6:127416535~127416952:-
THCA	cis	rs875971	0.545	rs73146609	ENSG00000230295.1	RP11-458F8.2	3.4	0.00072	0.0412	0.14	0.16	Aortic root size;	chr7:66302477	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000230295.1	RP11-458F8.2	3.4	0.00072	0.0412	0.14	0.16	Aortic root size;	chr7:66305392	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000230295.1	RP11-458F8.2	3.4	0.00072	0.0412	0.14	0.16	Aortic root size;	chr7:66318029	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000230295.1	RP11-458F8.2	3.4	0.00072	0.0412	0.14	0.16	Aortic root size;	chr7:66325577	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000230295.1	RP11-458F8.2	3.4	0.00072	0.0412	0.14	0.16	Aortic root size;	chr7:66339619	chr7:66880708~66882981:+
THCA	cis	rs9329221	0.716	rs11989640	ENSG00000253641.4	RP11-981G7.2	-3.4	0.00072	0.0412	-0.15	-0.16	Neuroticism;	chr8:10398544	chr8:10474565~10481974:+
THCA	cis	rs939960	0.879	rs56412316	ENSG00000276538.1	RP11-545G3.2	3.4	0.00072	0.0412	0.26	0.16	Neutrophil percentage of white cells;	chr7:150652431	chr7:150047609~150047854:-
THCA	cis	rs939960	0.879	rs34396063	ENSG00000276538.1	RP11-545G3.2	3.4	0.00072	0.0412	0.26	0.16	Neutrophil percentage of white cells;	chr7:150658361	chr7:150047609~150047854:-
THCA	cis	rs4073582	1	rs4073582	ENSG00000255320.1	RP11-755F10.1	-3.4	0.00072	0.0412	-0.22	-0.16	Gout;	chr11:66283241	chr11:66244840~66246239:-
THCA	cis	rs11673344	0.832	rs11540540	ENSG00000229481.2	CTD-2554C21.3	-3.4	0.00072	0.0412	-0.14	-0.16	Obesity-related traits;	chr19:37129629	chr19:37829551~37832160:+
THCA	cis	rs34779708	0.966	rs12260130	ENSG00000233200.1	RP11-324I22.2	3.4	0.00072	0.0412	0.18	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35219894~35230598:-
THCA	cis	rs1005277	0.522	rs289650	ENSG00000275858.1	RP11-291L22.8	3.4	0.00072	0.0412	0.18	0.16	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38450738~38451069:-
THCA	cis	rs539096	0.872	rs663618	ENSG00000229348.1	HYI-AS1	3.4	0.00072	0.0412	0.16	0.16	Intelligence (multi-trait analysis);	chr1:43577434	chr1:43453927~43456995:+
THCA	cis	rs4930561	0.714	rs7122250	ENSG00000184795.9	UNC93B5	-3.4	0.00072	0.0412	-0.2	-0.16	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68179005	chr11:67711702~67716005:-
THCA	cis	rs6120849	0.754	rs11167253	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35026646	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.707	rs6120799	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35027152	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs13433216	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35028498	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs6088686	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35035634	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs6120804	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35035898	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs6120812	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35041624	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.707	rs6088690	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35045523	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.754	rs6088691	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35045955	chr20:35201747~35203288:-
THCA	cis	rs6120849	0.518	rs11696652	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00072	0.0412	-0.17	-0.16	Protein C levels;	chr20:35049257	chr20:35201747~35203288:-
THCA	cis	rs6885099	0.527	rs1479563	ENSG00000251400.1	ALDH7A1P1	3.4	0.00072	0.0412	0.19	0.16	Thyroid hormone levels;	chr5:77252974	chr5:77290268~77291800:+
THCA	cis	rs9512730	0.911	rs9579088	ENSG00000234031.1	RPS3AP44	3.4	0.00072	0.0412	0.17	0.16	Schizophrenia;	chr13:27492590	chr13:26576886~26577675:+
THCA	cis	rs765751	0.965	rs12025363	ENSG00000228536.1	RP11-392O17.1	3.4	0.00072	0.0412	0.18	0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219461445	chr1:219409681~219411941:-
THCA	cis	rs13118159	1	rs13118159	ENSG00000254094.1	AC078852.1	-3.4	0.00072	0.0412	-0.19	-0.16	Longevity;	chr4:1371339	chr4:1356581~1358075:+
THCA	cis	rs2933343	0.7	rs2249514	ENSG00000261159.1	RP11-723O4.9	3.4	0.00072	0.0412	0.16	0.16	IgG glycosylation;	chr3:128924969	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.7	rs2630257	ENSG00000261159.1	RP11-723O4.9	3.4	0.00072	0.0412	0.16	0.16	IgG glycosylation;	chr3:128925172	chr3:128859716~128860526:-
THCA	cis	rs853679	0.824	rs34712084	ENSG00000261839.1	RP1-265C24.8	3.4	0.00072	0.0412	0.23	0.16	Depression;	chr6:28076050	chr6:28136849~28139678:+
THCA	cis	rs853679	0.824	rs1321505	ENSG00000261839.1	RP1-265C24.8	3.4	0.00072	0.0412	0.23	0.16	Depression;	chr6:28085045	chr6:28136849~28139678:+
THCA	cis	rs853679	0.882	rs9468287	ENSG00000261839.1	RP1-265C24.8	3.4	0.00072	0.0412	0.23	0.16	Depression;	chr6:28111963	chr6:28136849~28139678:+
THCA	cis	rs12681366	0.881	rs16916760	ENSG00000253175.1	RP11-267M23.6	3.4	0.00072	0.0412	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94356881	chr8:94565036~94565715:+
THCA	cis	rs61863818	0.709	rs10786343	ENSG00000225850.3	RP11-452K12.4	3.4	0.00072	0.0412	0.16	0.16	Monocyte percentage of white cells;	chr10:97399708	chr10:97334564~97343203:+
THCA	cis	rs2635047	0.967	rs2576060	ENSG00000280212.1	RP11-49K24.3	3.4	0.00072	0.0412	0.15	0.16	Educational attainment;	chr18:47110735	chr18:47076117~47076594:+
THCA	cis	rs9693857	1	rs9693857	ENSG00000248538.5	RP11-10A14.5	3.4	0.00072	0.0412	0.2	0.16	Systolic blood pressure;	chr8:9409607	chr8:9189011~9202854:+
THCA	cis	rs1005277	0.54	rs2474598	ENSG00000099251.13	HSD17B7P2	-3.4	0.00072	0.0412	-0.13	-0.16	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38356380~38378505:+
THCA	cis	rs6545883	0.859	rs7561672	ENSG00000212978.6	AC016747.3	-3.4	0.00072	0.0412	-0.17	-0.16	Tuberculosis;	chr2:61291959	chr2:61141592~61144969:-
THCA	cis	rs939960	0.84	rs35873531	ENSG00000276538.1	RP11-545G3.2	3.4	0.00072	0.0412	0.23	0.16	Neutrophil percentage of white cells;	chr7:150597346	chr7:150047609~150047854:-
THCA	cis	rs8054556	1	rs11642046	ENSG00000183604.13	SMG1P5	-3.4	0.00072	0.0412	-0.15	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29981787	chr16:30267553~30335374:-
THCA	cis	rs34779708	0.868	rs2384352	ENSG00000233200.1	RP11-324I22.2	3.4	0.00072	0.0412	0.19	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35219894~35230598:-
THCA	cis	rs8014204	0.935	rs2300596	ENSG00000279594.1	RP11-950C14.10	3.4	0.00072	0.0412	0.15	0.16	Caffeine consumption;	chr14:74887152	chr14:75011269~75012851:-
THCA	cis	rs3758141	0.79	rs6998537	ENSG00000278886.1	RP11-108A14.1	-3.4	0.00072	0.0412	-0.28	-0.16	Body mass index (change over time) in gastrointestinal cancer;	chr8:18871228	chr8:18864681~18865247:-
THCA	cis	rs7311936	1	rs7315555	ENSG00000270130.1	RP11-214K3.23	-3.4	0.000721	0.0412	-0.17	-0.16	Vertical cup-disc ratio;	chr12:124151228	chr12:123960717~123961244:-
THCA	cis	rs6995541	0.553	rs28588745	ENSG00000248896.2	CTD-2135J3.3	-3.4	0.000721	0.0412	-0.25	-0.16	Triglyceride levels;	chr8:10789534	chr8:10729314~10771392:+
THCA	cis	rs3091242	0.935	rs3093632	ENSG00000228172.4	RP1-317E23.3	3.4	0.000721	0.0412	0.12	0.16	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25816749~25820797:-
THCA	cis	rs34975555	1	rs3850749	ENSG00000253671.1	RP11-806O11.1	-3.4	0.000721	0.0412	-0.26	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17993316	chr8:17808941~17820868:+
THCA	cis	rs1510272	0.889	rs2063350	ENSG00000243926.1	TIPARP-AS1	-3.4	0.000721	0.0412	-0.16	-0.16	Testicular germ cell tumor;	chr3:156612398	chr3:156671862~156674378:-
THCA	cis	rs4218	0.505	rs6494064	ENSG00000277144.1	RP11-59H7.4	3.4	0.000721	0.0412	0.2	0.16	Social communication problems;	chr15:59053192	chr15:59115547~59116089:-
THCA	cis	rs758324	0.812	rs6893070	ENSG00000237714.1	P4HA2-AS1	-3.4	0.000721	0.0412	-0.21	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131901906	chr5:132184876~132192808:+
THCA	cis	rs758324	0.812	rs13165154	ENSG00000237714.1	P4HA2-AS1	3.4	0.000721	0.0412	0.21	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131819327	chr5:132184876~132192808:+
THCA	cis	rs758324	0.812	rs11750031	ENSG00000237714.1	P4HA2-AS1	3.4	0.000721	0.0412	0.21	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131835558	chr5:132184876~132192808:+
THCA	cis	rs758324	0.773	rs2404777	ENSG00000237714.1	P4HA2-AS1	3.4	0.000721	0.0412	0.21	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131837110	chr5:132184876~132192808:+
THCA	cis	rs758324	0.812	rs2088718	ENSG00000237714.1	P4HA2-AS1	3.4	0.000721	0.0412	0.21	0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131843496	chr5:132184876~132192808:+
THCA	cis	rs2292096	1	rs12748010	ENSG00000260088.1	RP11-92G12.3	3.4	0.000721	0.0412	0.32	0.16	Epilepsy;	chr1:200804419	chr1:200669507~200694250:+
THCA	cis	rs2292096	1	rs66530521	ENSG00000260088.1	RP11-92G12.3	3.4	0.000721	0.0412	0.32	0.16	Epilepsy;	chr1:200813821	chr1:200669507~200694250:+
THCA	cis	rs4794202	0.579	rs9904503	ENSG00000264920.1	RP11-6N17.4	-3.4	0.000721	0.0412	-0.18	-0.16	Alzheimer's disease (cognitive decline);	chr17:47807006	chr17:47891255~47895812:-
THCA	cis	rs4794202	0.579	rs9896712	ENSG00000264920.1	RP11-6N17.4	-3.4	0.000721	0.0412	-0.18	-0.16	Alzheimer's disease (cognitive decline);	chr17:47807177	chr17:47891255~47895812:-
THCA	cis	rs9425766	0.679	rs2064149	ENSG00000270084.1	GAS5-AS1	-3.4	0.000721	0.0412	-0.16	-0.16	Life satisfaction;	chr1:174255856	chr1:173863248~173863941:+
THCA	cis	rs801193	0.66	rs10950049	ENSG00000272831.1	RP11-792A8.4	3.4	0.000721	0.0412	0.1	0.16	Aortic root size;	chr7:66765873	chr7:66739829~66740385:-
THCA	cis	rs755249	0.567	rs16826069	ENSG00000237624.1	OXCT2P1	3.4	0.000721	0.0412	0.21	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39514956~39516490:+
THCA	cis	rs6921919	0.609	rs9461455	ENSG00000226314.6	ZNF192P1	-3.4	0.000721	0.0412	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28161781~28169594:+
THCA	cis	rs8060686	1	rs8060686	ENSG00000261396.1	CTD-2012K14.2	-3.4	0.000721	0.0412	-0.23	-0.16	HDL cholesterol;Metabolic syndrome;	chr16:67877614	chr16:67538557~67540106:-
THCA	cis	rs72834846	0.947	rs7224432	ENSG00000236319.2	CTD-2033D24.2	3.4	0.000721	0.0412	0.23	0.16	Red blood cell count;	chr17:55099119	chr17:55526964~55561577:-
THCA	cis	rs116095464	1	rs3936676	ENSG00000277812.1	AC021087.1	3.4	0.000721	0.0412	0.38	0.16	Breast cancer;	chr5:353562	chr5:262769~262881:+
THCA	cis	rs3750082	0.889	rs1817050	ENSG00000205763.12	RP9P	3.4	0.000721	0.0412	0.13	0.16	Glomerular filtration rate (creatinine);	chr7:32892294	chr7:32916815~32943176:-
THCA	cis	rs2131877	0.528	rs1494327	ENSG00000273009.1	RP11-352G9.1	3.4	0.000721	0.0412	0.17	0.16	Non-small cell lung cancer;	chr3:195117003	chr3:195913078~195913683:-
THCA	cis	rs11039798	0.588	rs7116858	ENSG00000200090.1	Y_RNA	3.4	0.000721	0.0412	0.13	0.16	Axial length;	chr11:48522368	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.588	rs7946443	ENSG00000200090.1	Y_RNA	3.4	0.000721	0.0412	0.13	0.16	Axial length;	chr11:48523952	chr11:47726894~47726992:-
THCA	cis	rs6569992	0.636	rs55683605	ENSG00000232876.1	CTA-212D2.2	-3.4	0.000721	0.0412	-0.25	-0.16	Red blood cell traits;	chr6:135165969	chr6:135055033~135060550:+
THCA	cis	rs909002	0.8	rs3134718	ENSG00000235790.6	RP11-73M7.6	3.4	0.000721	0.0412	0.16	0.16	Intelligence (multi-trait analysis);	chr1:31624238	chr1:31644049~31660162:+
THCA	cis	rs5770917	1	rs3213445	ENSG00000279182.1	XX-C00717C00720L.1	3.4	0.000721	0.0412	0.24	0.16	Narcolepsy;	chr22:50577409	chr22:50316035~50317025:+
THCA	cis	rs1864982	0.581	rs2963075	ENSG00000251556.1	RP11-118M9.3	-3.4	0.000721	0.0412	-0.25	-0.16	Alcohol dependence;	chr5:146906998	chr5:146099406~146120412:+
THCA	cis	rs256438	0.642	rs9293797	ENSG00000251221.1	LINC01337	-3.4	0.000721	0.0412	-0.19	-0.16	Serum thyroid-stimulating hormone levels;	chr5:80029041	chr5:80608623~80622524:-
THCA	cis	rs11673344	0.504	rs10403728	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000721	0.0412	-0.19	-0.16	Obesity-related traits;	chr19:37091569	chr19:36773153~36777078:+
THCA	cis	rs10090774	0.863	rs7815191	ENSG00000280303.2	ERICD	3.4	0.000721	0.0412	0.14	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140845557	chr8:140636281~140638283:+
THCA	cis	rs7713065	1	rs3857440	ENSG00000224431.1	AC063976.7	-3.4	0.000721	0.0412	-0.15	-0.16	Lung function (FEV1/FVC);	chr5:132458377	chr5:132199456~132203487:+
THCA	cis	rs9296092	0.517	rs76662639	ENSG00000272217.1	XXbac-BPG157A10.21	3.4	0.000721	0.0412	0.17	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33540699	chr6:33246075~33246856:-
THCA	cis	rs721048	0.92	rs62180320	ENSG00000242412.1	DBIL5P2	-3.4	0.000721	0.0412	-0.22	-0.16	Prostate cancer;	chr2:63162115	chr2:63117851~63119542:-
THCA	cis	rs9868809	0.881	rs57334642	ENSG00000270441.1	RP11-694I15.7	3.4	0.000722	0.0412	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629362	chr3:49140086~49160851:-
THCA	cis	rs9868809	0.881	rs3821876	ENSG00000270441.1	RP11-694I15.7	3.4	0.000722	0.0412	0.21	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48630961	chr3:49140086~49160851:-
THCA	cis	rs6545883	0.542	rs10177225	ENSG00000273302.1	RP11-493E12.2	-3.4	0.000722	0.0412	-0.14	-0.16	Tuberculosis;	chr2:61367363	chr2:61199979~61200769:+
THCA	cis	rs748404	0.56	rs1869258	ENSG00000275601.1	AC011330.13	-3.4	0.000722	0.0412	-0.19	-0.16	Lung cancer;	chr15:43511423	chr15:43642389~43643023:-
THCA	cis	rs599083	0.793	rs314750	ENSG00000160172.9	FAM86C2P	-3.4	0.000722	0.0412	-0.15	-0.16	Bone mineral density (spine);	chr11:68414560	chr11:67791648~67805336:-
THCA	cis	rs3788317	0.526	rs879033	ENSG00000232926.1	AC000078.5	-3.4	0.000722	0.0412	-0.18	-0.16	Glaucoma (primary angle closure);	chr22:19896516	chr22:19887289~19887970:+
THCA	cis	rs12701220	0.655	rs10215292	ENSG00000225146.1	AC073957.15	3.4	0.000722	0.0412	0.2	0.16	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1029025~1043891:+
THCA	cis	rs6137726	0.652	rs6082779	ENSG00000237396.1	LINC01384	-3.4	0.000722	0.0412	-0.14	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr20:22675057	chr20:22587522~22607517:-
THCA	cis	rs12438945	0.64	rs1915214	ENSG00000277548.1	RP11-139H15.6	3.4	0.000722	0.0412	0.24	0.16	Glucose homeostasis traits;	chr15:54905963	chr15:55346347~55346752:-
THCA	cis	rs2404602	0.575	rs11633309	ENSG00000196274.5	Metazoa_SRP	-3.4	0.000722	0.0412	-0.19	-0.16	Blood metabolite levels;	chr15:76670008	chr15:76230048~76230390:-
THCA	cis	rs2447820	0.541	rs171546	ENSG00000263432.2	RN7SL689P	3.4	0.000722	0.0412	0.19	0.16	Migraine;	chr5:122915059	chr5:123022487~123022783:-
THCA	cis	rs2447820	0.588	rs246304	ENSG00000263432.2	RN7SL689P	3.4	0.000722	0.0412	0.19	0.16	Migraine;	chr5:122916146	chr5:123022487~123022783:-
THCA	cis	rs7246657	0.722	rs2909098	ENSG00000226686.6	LINC01535	3.4	0.000722	0.0412	0.23	0.16	Coronary artery calcification;	chr19:37713347	chr19:37251912~37265535:+
THCA	cis	rs7264396	0.887	rs6060435	ENSG00000261582.1	RP4-614O4.11	3.4	0.000722	0.0413	0.16	0.16	Total cholesterol levels;	chr20:35481545	chr20:35267885~35280043:-
THCA	cis	rs237743	1	rs67733885	ENSG00000222365.1	SNORD12B	-3.4	0.000722	0.0413	-0.2	-0.16	Height;	chr20:49280020	chr20:49280319~49280409:+
THCA	cis	rs7903847	0.642	rs11814021	ENSG00000225850.3	RP11-452K12.4	3.4	0.000722	0.0413	0.16	0.16	Granulocyte percentage of myeloid white cells;	chr10:97398629	chr10:97334564~97343203:+
THCA	cis	rs58605417	0.509	rs71526945	ENSG00000253553.4	RP11-586K2.1	3.4	0.000722	0.0413	0.17	0.16	Schizophrenia;	chr8:88540072	chr8:88326836~88737134:+
THCA	cis	rs12188164	1	rs34453673	ENSG00000225138.6	CTD-2228K2.7	3.4	0.000722	0.0413	0.16	0.16	Cystic fibrosis severity;	chr5:434607	chr5:473236~480884:+
THCA	cis	rs7020830	0.861	rs13289001	ENSG00000260100.1	RP11-220I1.5	-3.4	0.000722	0.0413	-0.19	-0.16	Schizophrenia;	chr9:37311595	chr9:37078813~37079776:-
THCA	cis	rs453301	0.682	rs2929308	ENSG00000254340.1	RP11-10A14.3	-3.4	0.000722	0.0413	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9226611	chr8:9141424~9145435:+
THCA	cis	rs790006	0.686	rs11175298	ENSG00000243024.5	RPS11P6	-3.4	0.000722	0.0413	-0.18	-0.16	Response to cytidine analogues (gemcitabine);	chr12:64249578	chr12:64222337~64397065:+
THCA	cis	rs6496044	0.963	rs7165300	ENSG00000259276.1	RP11-815J21.3	-3.4	0.000722	0.0413	-0.17	-0.16	Interstitial lung disease;	chr15:85526838	chr15:85621264~85627689:-
THCA	cis	rs11212260	0.85	rs3017611	ENSG00000261098.1	RP11-819C21.1	-3.4	0.000722	0.0413	-0.32	-0.16	IgG glycosylation;	chr11:107485935	chr11:107312132~107316271:-
THCA	cis	rs28830936	1	rs17677199	ENSG00000250379.1	RP11-23P13.4	3.4	0.000722	0.0413	0.18	0.16	Diastolic blood pressure;	chr15:41662415	chr15:41825099~41827936:-
THCA	cis	rs28830936	1	rs11637341	ENSG00000250379.1	RP11-23P13.4	3.4	0.000722	0.0413	0.18	0.16	Diastolic blood pressure;	chr15:41663627	chr15:41825099~41827936:-
THCA	cis	rs2447820	0.588	rs6880211	ENSG00000263432.2	RN7SL689P	3.4	0.000722	0.0413	0.19	0.16	Migraine;	chr5:123055756	chr5:123022487~123022783:-
THCA	cis	rs939960	0.959	rs34534990	ENSG00000224016.2	RP11-728K20.1	3.4	0.000722	0.0413	0.21	0.16	Neutrophil percentage of white cells;	chr7:150586685	chr7:149891191~149909704:-
THCA	cis	rs9902453	0.868	rs12944395	ENSG00000264290.1	RP11-68I3.4	-3.4	0.000722	0.0413	-0.12	-0.16	Coffee consumption (cups per day);	chr17:29996481	chr17:29569580~29570519:+
THCA	cis	rs2797160	0.967	rs2747718	ENSG00000226409.1	RP11-735G4.1	3.4	0.000722	0.0413	0.18	0.16	Endometrial cancer;	chr6:125687963	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs2747719	ENSG00000226409.1	RP11-735G4.1	3.4	0.000722	0.0413	0.18	0.16	Endometrial cancer;	chr6:125688068	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs2797158	ENSG00000226409.1	RP11-735G4.1	3.4	0.000722	0.0413	0.18	0.16	Endometrial cancer;	chr6:125688252	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs2747720	ENSG00000226409.1	RP11-735G4.1	3.4	0.000722	0.0413	0.18	0.16	Endometrial cancer;	chr6:125688312	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.967	rs2797159	ENSG00000226409.1	RP11-735G4.1	3.4	0.000722	0.0413	0.18	0.16	Endometrial cancer;	chr6:125688411	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs2747722	ENSG00000226409.1	RP11-735G4.1	3.4	0.000722	0.0413	0.18	0.16	Endometrial cancer;	chr6:125688483	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs2797160	ENSG00000226409.1	RP11-735G4.1	3.4	0.000722	0.0413	0.18	0.16	Endometrial cancer;	chr6:125688970	chr6:125370211~125374324:-
THCA	cis	rs2797160	0.967	rs2797162	ENSG00000226409.1	RP11-735G4.1	3.4	0.000722	0.0413	0.18	0.16	Endometrial cancer;	chr6:125690235	chr6:125370211~125374324:-
THCA	cis	rs9828933	0.938	rs831691	ENSG00000224479.4	AC136289.1	3.4	0.000722	0.0413	0.22	0.16	Type 2 diabetes;	chr3:64021538	chr3:63742293~63827445:-
THCA	cis	rs7586879	0.575	rs6744205	ENSG00000224165.4	DNAJC27-AS1	-3.4	0.000722	0.0413	-0.09	-0.16	Body mass index;	chr2:24910279	chr2:24971390~25039694:+
THCA	cis	rs735539	0.521	rs2762989	ENSG00000278291.1	RP11-172H24.4	3.4	0.000722	0.0413	0.22	0.16	Dental caries;	chr13:20818382	chr13:20699307~20703718:-
THCA	cis	rs1144333	0.655	rs17097864	ENSG00000272855.1	RP5-1102E8.3	-3.4	0.000722	0.0413	-0.33	-0.16	Attention function in attention deficit hyperactive disorder;	chr1:76003911	chr1:76636877~76637339:+
THCA	cis	rs4142110	1	rs12585865	ENSG00000278338.3	VWA8-AS1	3.4	0.000722	0.0413	0.17	0.16	Nephrolithiasis;	chr13:42177571	chr13:41955808~41981565:+
THCA	cis	rs7246657	0.943	rs7258692	ENSG00000266916.4	ZNF793-AS1	-3.4	0.000723	0.0413	-0.15	-0.16	Coronary artery calcification;	chr19:37327927	chr19:37497159~37507046:-
THCA	cis	rs862034	0.902	rs862053	ENSG00000270000.1	RP3-449M8.9	-3.4	0.000723	0.0413	-0.15	-0.16	Height;	chr14:74513832	chr14:74471930~74472360:-
THCA	cis	rs1858037	0.806	rs12612780	ENSG00000252414.1	RNU6-100P	-3.4	0.000723	0.0413	-0.17	-0.16	Rheumatoid arthritis;	chr2:65355967	chr2:64578892~64578997:+
THCA	cis	rs911555	0.723	rs6575982	ENSG00000269940.1	RP11-73M18.7	-3.4	0.000723	0.0413	-0.16	-0.16	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103694560~103695170:+
THCA	cis	rs9341808	0.718	rs10080237	ENSG00000260645.1	RP11-250B2.5	3.4	0.000723	0.0413	0.13	0.16	Sitting height ratio;	chr6:80144753	chr6:80466958~80469080:+
THCA	cis	rs853679	1	rs2799079	ENSG00000261839.1	RP1-265C24.8	3.4	0.000723	0.0413	0.21	0.16	Depression;	chr6:28267398	chr6:28136849~28139678:+
THCA	cis	rs2386661	0.547	rs11259540	ENSG00000231483.1	RP11-336A10.5	3.4	0.000723	0.0413	0.17	0.16	Breast cancer;	chr10:5604743	chr10:5608475~5610793:-
THCA	cis	rs2386661	0.547	rs11259582	ENSG00000231483.1	RP11-336A10.5	3.4	0.000723	0.0413	0.17	0.16	Breast cancer;	chr10:5604804	chr10:5608475~5610793:-
THCA	cis	rs11711311	0.712	rs3773683	ENSG00000241529.3	RN7SL767P	-3.4	0.000723	0.0413	-0.23	-0.16	IgG glycosylation;	chr3:113622160	chr3:113632704~113632998:+
THCA	cis	rs9907295	0.71	rs9894083	ENSG00000270871.1	AC015849.19	3.4	0.000723	0.0413	0.14	0.16	Fibroblast growth factor basic levels;	chr17:35842151	chr17:35816717~35830293:-
THCA	cis	rs9450351	0.744	rs9450383	ENSG00000203875.9	SNHG5	-3.4	0.000723	0.0413	-0.31	-0.16	Interferon gamma-induced protein 10 levels;	chr6:86073540	chr6:85660950~85678736:-
THCA	cis	rs7129556	0.737	rs484363	ENSG00000254985.1	RSF1-IT2	-3.4	0.000723	0.0413	-0.25	-0.16	Weight loss (gastric bypass surgery);	chr11:77781548	chr11:77717712~77718411:-
THCA	cis	rs7129556	0.728	rs34130561	ENSG00000254985.1	RSF1-IT2	-3.4	0.000723	0.0413	-0.25	-0.16	Weight loss (gastric bypass surgery);	chr11:77785645	chr11:77717712~77718411:-
THCA	cis	rs7129556	0.737	rs623173	ENSG00000254985.1	RSF1-IT2	3.4	0.000723	0.0413	0.25	0.16	Weight loss (gastric bypass surgery);	chr11:77818482	chr11:77717712~77718411:-
THCA	cis	rs758324	0.773	rs804058	ENSG00000224431.1	AC063976.7	-3.4	0.000723	0.0413	-0.14	-0.16	Alzheimer's disease in APOE e4- carriers;	chr5:131930669	chr5:132199456~132203487:+
THCA	cis	rs12908161	1	rs35808647	ENSG00000254414.1	RP11-182J1.1	3.4	0.000723	0.0413	0.21	0.16	Schizophrenia;	chr15:84834210	chr15:84631898~84633987:-
THCA	cis	rs10875746	0.903	rs2158516	ENSG00000275228.1	RP11-370I10.10	3.4	0.000723	0.0413	0.19	0.16	Longevity (90 years and older);	chr12:48097051	chr12:48327942~48328472:-
THCA	cis	rs11960179	0.773	rs16897892	ENSG00000250066.1	RP11-141O11.1	3.4	0.000723	0.0413	0.27	0.16	Glomerular filtration rate (creatinine);	chr5:68509304	chr5:68963246~68967845:+
THCA	cis	rs708224	0.557	rs261874	ENSG00000274964.1	RP11-817I4.1	3.4	0.000723	0.0413	0.17	0.16	Pancreatic cancer;	chr12:32291829	chr12:32339368~32340724:+
THCA	cis	rs7737355	1	rs257389	ENSG00000237714.1	P4HA2-AS1	-3.4	0.000723	0.0413	-0.21	-0.16	Life satisfaction;	chr5:131408570	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.898	rs10079359	ENSG00000237714.1	P4HA2-AS1	-3.4	0.000723	0.0413	-0.21	-0.16	Life satisfaction;	chr5:131422590	chr5:132184876~132192808:+
THCA	cis	rs6545883	0.507	rs12478192	ENSG00000273302.1	RP11-493E12.2	-3.4	0.000723	0.0413	-0.14	-0.16	Tuberculosis;	chr2:61364040	chr2:61199979~61200769:+
THCA	cis	rs7873102	0.702	rs10814634	ENSG00000213839.4	TMX2P1	-3.4	0.000723	0.0413	-0.12	-0.16	Brain structure;	chr9:37964851	chr9:37885683~37886390:+
THCA	cis	rs4788570	0.578	rs9934789	ENSG00000260185.1	RP11-432I5.6	-3.4	0.000723	0.0413	-0.3	-0.16	Intelligence (multi-trait analysis);	chr16:71628564	chr16:71655027~71664212:+
THCA	cis	rs9608946	0.956	rs7287943	ENSG00000279699.1	RP1-102K2.9	3.4	0.000723	0.0413	0.18	0.16	Red cell distribution width;	chr22:30496568	chr22:30275215~30276951:-
THCA	cis	rs62209	0.8	rs201078	ENSG00000181800.5	CELF2-AS1	3.4	0.000723	0.0413	0.16	0.16	Alzheimer's disease (late onset);	chr10:10960789	chr10:11316834~11319884:-
THCA	cis	rs2486012	1	rs3120804	ENSG00000237950.1	RP11-7O11.3	-3.4	0.000723	0.0413	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:43939542	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs3120805	ENSG00000237950.1	RP11-7O11.3	-3.4	0.000723	0.0413	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:43940441	chr1:43944370~43946551:-
THCA	cis	rs2486012	1	rs2906597	ENSG00000237950.1	RP11-7O11.3	-3.4	0.000723	0.0413	-0.18	-0.16	Intelligence (multi-trait analysis);	chr1:43941053	chr1:43944370~43946551:-
THCA	cis	rs6690583	0.623	rs12033900	ENSG00000226970.2	RP11-82H13.2	3.4	0.000723	0.0413	0.26	0.16	Serum sulfate level;	chr1:85012876	chr1:84244334~84244577:+
THCA	cis	rs5769765	0.908	rs4074304	ENSG00000260613.1	RP3-522J7.6	-3.4	0.000723	0.0413	-0.21	-0.16	Schizophrenia;	chr22:49915798	chr22:49832616~49837786:-
THCA	cis	rs1009077	0.761	rs7676589	ENSG00000245958.5	RP11-33B1.1	3.4	0.000723	0.0413	0.24	0.16	Endometriosis;	chr4:119658818	chr4:119454791~119552025:+
THCA	cis	rs6545883	0.507	rs12617371	ENSG00000273302.1	RP11-493E12.2	-3.4	0.000723	0.0413	-0.14	-0.16	Tuberculosis;	chr2:61341999	chr2:61199979~61200769:+
THCA	cis	rs11773103	1	rs73204824	ENSG00000224046.1	AC005076.5	3.4	0.000723	0.0413	0.2	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87144095	chr7:87151423~87152420:-
THCA	cis	rs11773103	0.881	rs73204825	ENSG00000224046.1	AC005076.5	3.4	0.000723	0.0413	0.2	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87144132	chr7:87151423~87152420:-
THCA	cis	rs9400467	0.537	rs111262375	ENSG00000255389.1	C6orf3	3.4	0.000723	0.0413	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111097613	chr6:111599875~111602295:+
THCA	cis	rs6017317	0.696	rs13037113	ENSG00000244558.4	KCNK15-AS1	-3.4	0.000723	0.0413	-0.22	-0.16	Type 2 diabetes;	chr20:44308463	chr20:44694892~44746021:-
THCA	cis	rs6017317	0.696	rs12480669	ENSG00000244558.4	KCNK15-AS1	-3.4	0.000723	0.0413	-0.22	-0.16	Type 2 diabetes;	chr20:44308752	chr20:44694892~44746021:-
THCA	cis	rs7560272	0.501	rs7210	ENSG00000230002.2	ALMS1-IT1	-3.4	0.000723	0.0413	-0.18	-0.16	Schizophrenia;	chr2:73729997	chr2:73456764~73459484:+
THCA	cis	rs8049040	0.502	rs35885273	ENSG00000261513.1	RP11-432I5.8	3.4	0.000723	0.0413	0.22	0.16	Blood protein levels;	chr16:71383880	chr16:71723180~71724230:+
THCA	cis	rs17122278	0.858	rs11216899	ENSG00000255239.1	AP002954.6	3.4	0.000723	0.0413	0.27	0.16	Total cholesterol levels;	chr11:118563706	chr11:118688039~118690600:-
THCA	cis	rs11800820	0.521	rs3120701	ENSG00000231612.1	RP11-522M21.3	3.4	0.000723	0.0413	0.2	0.16	Obesity-related traits;	chr1:246542837	chr1:245673732~245676478:-
THCA	cis	rs11800820	0.521	rs3124114	ENSG00000231612.1	RP11-522M21.3	3.4	0.000723	0.0413	0.2	0.16	Obesity-related traits;	chr1:246543045	chr1:245673732~245676478:-
THCA	cis	rs3785574	0.962	rs2584621	ENSG00000279369.1	RP11-51F16.1	3.4	0.000724	0.0413	0.11	0.16	Height;	chr17:63835076	chr17:63700847~63702670:+
THCA	cis	rs7088591	0.614	rs1930457	ENSG00000276818.1	AC026393.1	3.4	0.000724	0.0413	0.27	0.16	Blood pressure;	chr10:57989471	chr10:57095699~57095781:+
THCA	cis	rs17301013	0.932	rs6664864	ENSG00000270084.1	GAS5-AS1	-3.4	0.000724	0.0413	-0.16	-0.16	Systemic lupus erythematosus;	chr1:174622912	chr1:173863248~173863941:+
THCA	cis	rs5748282	1	rs5748282	ENSG00000185065.6	AC000068.5	-3.4	0.000724	0.0413	-0.17	-0.16	Pediatric bone mineral density (femoral neck);	chr22:19553883	chr22:19447893~19450105:+
THCA	cis	rs10863936	0.667	rs12089230	ENSG00000198468.6	FLVCR1-AS1	-3.4	0.000724	0.0413	-0.18	-0.16	Height;	chr1:212089875	chr1:212852108~212858088:-
THCA	cis	rs832540	0.931	rs331499	ENSG00000271828.1	CTD-2310F14.1	-3.4	0.000724	0.0413	-0.21	-0.16	Coronary artery disease;	chr5:56915096	chr5:56927874~56929573:+
THCA	cis	rs2645424	0.666	rs2272767	ENSG00000255046.1	RP11-297N6.4	3.4	0.000724	0.0413	0.16	0.16	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853550	chr8:11797928~11802568:-
THCA	cis	rs1862618	0.853	rs252887	ENSG00000234553.1	AC022431.3	-3.4	0.000724	0.0413	-0.18	-0.16	Initial pursuit acceleration;	chr5:56870361	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs33322	ENSG00000234553.1	AC022431.3	-3.4	0.000724	0.0413	-0.18	-0.16	Initial pursuit acceleration;	chr5:56879399	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs832582	ENSG00000234553.1	AC022431.3	-3.4	0.000724	0.0413	-0.18	-0.16	Initial pursuit acceleration;	chr5:56881916	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs832551	ENSG00000234553.1	AC022431.3	-3.4	0.000724	0.0413	-0.18	-0.16	Initial pursuit acceleration;	chr5:56884285	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.713	rs832550	ENSG00000234553.1	AC022431.3	-3.4	0.000724	0.0413	-0.18	-0.16	Initial pursuit acceleration;	chr5:56886762	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.756	rs832548	ENSG00000234553.1	AC022431.3	-3.4	0.000724	0.0413	-0.18	-0.16	Initial pursuit acceleration;	chr5:56887810	chr5:56536583~56537826:-
THCA	cis	rs58688157	0.774	rs34889521	ENSG00000269915.1	AP006621.9	-3.4	0.000724	0.0413	-0.17	-0.16	Systemic lupus erythematosus;	chr11:617519	chr11:708564~727047:-
THCA	cis	rs7924176	0.521	rs11001022	ENSG00000271848.1	RP11-464F9.21	-3.4	0.000724	0.0413	-0.17	-0.16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:73654039~73674719:+
THCA	cis	rs7960884	0.655	rs4931471	ENSG00000177359.16	RP11-551L14.1	3.4	0.000724	0.0413	0.18	0.16	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31232160	chr12:31111652~31206154:-
THCA	cis	rs7259376	0.84	rs1808668	ENSG00000270947.1	AC025811.3	3.4	0.000724	0.0413	0.17	0.16	Menopause (age at onset);	chr19:22335855	chr19:22455988~22456459:+
THCA	cis	rs3864261	0.836	rs155425	ENSG00000249085.1	CTD-2631K10.1	-3.4	0.000724	0.0413	-0.24	-0.16	Discordance in emotional problems in monozygotic twins;	chr5:72821457	chr5:72794405~72816565:-
THCA	cis	rs17376456	0.542	rs35672980	ENSG00000254132.1	MTND6P3	3.4	0.000724	0.0414	0.2	0.16	Diabetic retinopathy;	chr5:93949172	chr5:94568929~94569470:-
THCA	cis	rs17376456	0.569	rs7721668	ENSG00000254132.1	MTND6P3	3.4	0.000724	0.0414	0.2	0.16	Diabetic retinopathy;	chr5:93955290	chr5:94568929~94569470:-
THCA	cis	rs7158359	0.955	rs10132850	ENSG00000222990.1	RNU4-22P	-3.4	0.000724	0.0414	-0.21	-0.16	Weight loss (gastric bypass surgery);	chr14:89126231	chr14:88513498~88513663:+
THCA	cis	rs7142002	0.881	rs56872637	ENSG00000272444.1	RP11-1017G21.6	-3.4	0.000724	0.0414	-0.23	-0.16	Autism;	chr14:101941065	chr14:101952416~101953063:+
THCA	cis	rs1864982	0.581	rs496192	ENSG00000251556.1	RP11-118M9.3	-3.4	0.000724	0.0414	-0.24	-0.16	Alcohol dependence;	chr5:146906761	chr5:146099406~146120412:+
THCA	cis	rs684232	0.602	rs379998	ENSG00000231784.7	DBIL5P	3.4	0.000724	0.0414	0.17	0.16	Prostate cancer;	chr17:653644	chr17:752660~755336:+
THCA	cis	rs684232	0.602	rs2543775	ENSG00000231784.7	DBIL5P	3.4	0.000724	0.0414	0.17	0.16	Prostate cancer;	chr17:653883	chr17:752660~755336:+
THCA	cis	rs6433895	0.601	rs34790351	ENSG00000236153.1	AC104076.3	-3.4	0.000724	0.0414	-0.2	-0.16	Lymphocyte counts;	chr2:181191727	chr2:180979427~180980090:-
THCA	cis	rs9788682	1	rs7163730	ENSG00000261143.1	ADAMTS7P3	-3.4	0.000724	0.0414	-0.22	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78522339	chr15:77976042~77993057:+
THCA	cis	rs4578769	0.681	rs4456613	ENSG00000265939.1	UBE2CP2	-3.4	0.000725	0.0414	-0.19	-0.16	Eosinophil percentage of white cells;	chr18:22987266	chr18:22900486~22900995:-
THCA	cis	rs7394190	0.748	rs11000775	ENSG00000272599.2	RP11-152N13.16	3.4	0.000725	0.0414	0.21	0.16	Incident atrial fibrillation;	chr10:73779252	chr10:73124573~73125532:-
THCA	cis	rs2836326	0.954	rs2836315	ENSG00000231231.4	LINC01423	3.4	0.000725	0.0414	0.18	0.16	Metabolite levels (HVA);	chr21:38343205	chr21:38323635~38333421:-
THCA	cis	rs7737355	0.947	rs10478980	ENSG00000237714.1	P4HA2-AS1	3.4	0.000725	0.0414	0.22	0.16	Life satisfaction;	chr5:131282554	chr5:132184876~132192808:+
THCA	cis	rs789852	0.764	rs1773184	ENSG00000231770.4	TMEM44-AS1	3.4	0.000725	0.0414	0.21	0.16	QT interval;	chr3:194593103	chr3:194584011~194590260:+
THCA	cis	rs3805389	0.924	rs10029142	ENSG00000273257.1	RP11-177J6.1	-3.4	0.000725	0.0414	-0.24	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55612967	chr4:55387949~55388271:+
THCA	cis	rs3850625	1	rs3850625	ENSG00000238003.1	RP11-465N4.2	-3.4	0.000725	0.0414	-0.32	-0.16	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr1:201047168	chr1:201978642~201978949:+
THCA	cis	rs813218	0.565	rs4244712	ENSG00000273374.1	RP11-383I23.2	-3.4	0.000725	0.0414	-0.13	-0.16	Orofacial clefts;	chr3:99960617	chr3:99802699~99806058:-
THCA	cis	rs1039766	1	rs268870	ENSG00000237979.1	AC007389.1	3.4	0.000725	0.0414	0.23	0.16	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr2:65500993~65502138:-
THCA	cis	rs5753037	0.838	rs1894474	ENSG00000273350.1	RP4-539M6.20	-3.4	0.000725	0.0414	-0.18	-0.16	Type 1 diabetes;	chr22:29842085	chr22:30420512~30420912:+
THCA	cis	rs8073060	0.544	rs225274	ENSG00000255987.1	TOMM20P2	3.4	0.000725	0.0414	0.19	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35644202	chr17:35514766~35515186:-
THCA	cis	rs990871	0.574	rs7530496	ENSG00000227207.2	RPL31P12	-3.4	0.000725	0.0414	-0.19	-0.16	Subcutaneous adipose tissue;	chr1:72472159	chr1:72301472~72301829:+
THCA	cis	rs7176527	1	rs3762169	ENSG00000259570.1	RP11-671M22.4	-3.4	0.000725	0.0414	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84394512~84395514:+
THCA	cis	rs2040609	1	rs2040609	ENSG00000200013.1	RNU6-623P	3.4	0.000725	0.0414	0.18	0.16	Multiple keratinocyte cancers;	chr17:61617277	chr17:60662333~60662437:-
THCA	cis	rs7267979	0.565	rs4815432	ENSG00000276952.1	RP5-965G21.6	-3.4	0.000725	0.0414	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.565	rs6076364	ENSG00000276952.1	RP5-965G21.6	-3.4	0.000725	0.0414	-0.17	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:25284915~25285588:-
THCA	cis	rs16857609	0.783	rs6706673	ENSG00000233143.1	DIRC3-AS1	-3.4	0.000725	0.0414	-0.17	-0.16	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217386979	chr2:217282739~217336120:+
THCA	cis	rs7809950	0.817	rs11535285	ENSG00000272072.1	CTA-363E19.2	3.4	0.000725	0.0414	0.16	0.16	Coronary artery disease;	chr7:107503421	chr7:107192559~107193300:-
THCA	cis	rs1059312	0.932	rs4760592	ENSG00000279500.1	RP11-21K12.2	-3.4	0.000725	0.0414	-0.1	-0.16	Systemic lupus erythematosus;	chr12:128802604	chr12:128813186~128814750:-
THCA	cis	rs354225	0.626	rs7591204	ENSG00000212175.1	SNORA12	3.4	0.000725	0.0414	0.2	0.16	Schizophrenia;	chr2:54602321	chr2:55565703~55565850:+
THCA	cis	rs972540	0.921	rs6715034	ENSG00000229647.1	AC007879.7	-3.4	0.000725	0.0414	-0.18	-0.16	Body mass index;	chr2:206366445	chr2:207239650~207245887:+
THCA	cis	rs791888	0.929	rs791887	ENSG00000236417.2	CTSLP1	3.4	0.000725	0.0414	0.2	0.16	Magnesium levels;	chr10:87651797	chr10:87386685~87390203:-
THCA	cis	rs1865760	0.566	rs2032445	ENSG00000272810.1	U91328.22	-3.4	0.000725	0.0414	-0.12	-0.16	Height;	chr6:26044584	chr6:26013241~26013757:+
THCA	cis	rs4243849	0.555	rs9324422	ENSG00000279518.1	AC083843.4	-3.4	0.000725	0.0414	-0.1	-0.16	Non-alcoholic fatty liver disease histology (other);	chr8:135749821	chr8:134783694~134785879:-
THCA	cis	rs3020736	0.5	rs7292241	ENSG00000270083.1	RP1-257I20.14	-3.4	0.000725	0.0414	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42089630~42090028:-
THCA	cis	rs17336368	1	rs17336368	ENSG00000237686.5	RP5-1120P11.1	-3.4	0.000725	0.0414	-0.14	-0.16	Chin dimples;	chr6:44783931	chr6:43995723~44074652:-
THCA	cis	rs721048	0.92	rs7568224	ENSG00000242412.1	DBIL5P2	-3.4	0.000725	0.0414	-0.22	-0.16	Prostate cancer;	chr2:63163861	chr2:63117851~63119542:-
THCA	cis	rs3087591	0.708	rs2854320	ENSG00000263535.1	AK4P1	3.4	0.000726	0.0414	0.18	0.16	Hip circumference;	chr17:31367045	chr17:31345521~31346187:+
THCA	cis	rs12428035	0.505	rs9590331	ENSG00000247400.3	DNAJC3-AS1	-3.4	0.000726	0.0414	-0.13	-0.16	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95807816	chr13:95648733~95676925:-
THCA	cis	rs7084402	0.935	rs1896246	ENSG00000180221.6	TPT1P10	-3.4	0.000726	0.0414	-0.18	-0.16	Refractive error;	chr10:58516308	chr10:58212541~58213036:-
THCA	cis	rs7084402	0.87	rs1896245	ENSG00000180221.6	TPT1P10	-3.4	0.000726	0.0414	-0.18	-0.16	Refractive error;	chr10:58516323	chr10:58212541~58213036:-
THCA	cis	rs4808199	0.895	rs4808194	ENSG00000267481.1	CTC-559E9.5	-3.4	0.000726	0.0414	-0.16	-0.16	Nonalcoholic fatty liver disease;	chr19:19324871	chr19:19788755~19790531:-
THCA	cis	rs7474896	0.526	rs1208716	ENSG00000272983.1	RP11-508N22.12	-3.4	0.000726	0.0414	-0.16	-0.16	Obesity (extreme);	chr10:37800345	chr10:38137337~38144399:+
THCA	cis	rs7020830	0.931	rs13293916	ENSG00000260100.1	RP11-220I1.5	-3.4	0.000726	0.0414	-0.19	-0.16	Schizophrenia;	chr9:37136362	chr9:37078813~37079776:-
THCA	cis	rs72996113	0.702	rs78192924	ENSG00000248027.1	CTD-2383M3.1	-3.4	0.000726	0.0414	-0.3	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100660566	chr11:100684162~100687955:-
THCA	cis	rs7129556	0.737	rs643388	ENSG00000254985.1	RSF1-IT2	-3.4	0.000726	0.0414	-0.25	-0.16	Weight loss (gastric bypass surgery);	chr11:77759997	chr11:77717712~77718411:-
THCA	cis	rs17007417	0.568	rs7562979	ENSG00000233971.1	RPS20P10	3.4	0.000726	0.0414	0.24	0.16	Nonalcoholic steatohepatitis-derived hepatocellular carcinoma;	chr2:71817321	chr2:71984182~71984434:-
THCA	cis	rs2098713	0.535	rs11748123	ENSG00000250155.1	CTD-2353F22.1	3.4	0.000726	0.0414	0.15	0.16	Telomere length;	chr5:37575317	chr5:36666214~36725195:-
THCA	cis	rs7267979	0.932	rs928121	ENSG00000125804.12	FAM182A	-3.4	0.000726	0.0414	-0.19	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:26054655~26086917:+
THCA	cis	rs28643277	0.671	rs4750662	ENSG00000237470.3	DCLRE1CP1	-3.4	0.000726	0.0414	-0.2	-0.16	Periodontitis (CDC/AAP);	chr10:15505597	chr10:15015370~15021863:-
THCA	cis	rs875971	0.619	rs2302918	ENSG00000232546.1	RP11-458F8.1	-3.4	0.000726	0.0414	-0.13	-0.16	Aortic root size;	chr7:66535945	chr7:66848496~66858136:+
THCA	cis	rs524281	0.692	rs2254388	ENSG00000255038.1	RP11-1167A19.2	3.4	0.000726	0.0414	0.17	0.16	Electroencephalogram traits;	chr11:66070128	chr11:66067277~66069619:-
THCA	cis	rs7520050	0.966	rs10890361	ENSG00000280836.1	AL355480.1	3.4	0.000726	0.0414	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:45581219~45581321:-
THCA	cis	rs1654345	0.554	rs1654350	ENSG00000275132.1	Metazoa_SRP	-3.4	0.000726	0.0414	-0.23	-0.16	Life satisfaction;Subjective well-being;	chr19:38063828	chr19:38200234~38200532:+
THCA	cis	rs7560272	0.549	rs2421554	ENSG00000273245.1	RP11-434P11.2	3.4	0.000726	0.0414	0.18	0.16	Schizophrenia;	chr2:73579075	chr2:73750256~73750786:-
THCA	cis	rs7220401	0.521	rs2278217	ENSG00000263370.1	RP11-68I3.5	3.4	0.000726	0.0414	0.21	0.16	Coronary artery disease;	chr17:29577599	chr17:29639627~29640825:+
THCA	cis	rs9329221	0.71	rs11779205	ENSG00000253641.4	RP11-981G7.2	3.4	0.000726	0.0414	0.15	0.16	Neuroticism;	chr8:10402590	chr8:10474565~10481974:+
THCA	cis	rs17122278	1	rs11216900	ENSG00000243431.1	RPL5P30	3.4	0.000726	0.0414	0.16	0.16	Total cholesterol levels;	chr11:118565364	chr11:118560690~118561580:+
THCA	cis	rs3808502	0.526	rs7823100	ENSG00000255046.1	RP11-297N6.4	3.4	0.000726	0.0414	0.17	0.16	Neuroticism;	chr8:11564982	chr8:11797928~11802568:-
THCA	cis	rs3808502	0.526	rs7823101	ENSG00000255046.1	RP11-297N6.4	3.4	0.000726	0.0414	0.17	0.16	Neuroticism;	chr8:11564983	chr8:11797928~11802568:-
THCA	cis	rs3808502	0.526	rs11985709	ENSG00000255046.1	RP11-297N6.4	3.4	0.000726	0.0414	0.17	0.16	Neuroticism;	chr8:11565574	chr8:11797928~11802568:-
THCA	cis	rs11157436	0.918	rs1076546	ENSG00000211812.1	TRAV26-2	-3.4	0.000726	0.0415	-0.14	-0.16	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22159015	chr14:22202583~22203368:+
THCA	cis	rs1124769	0.619	rs12904435	ENSG00000244879.4	GABPB1-AS1	-3.4	0.000726	0.0415	-0.16	-0.16	Cognitive performance;	chr15:50818006	chr15:50354959~50372202:+
THCA	cis	rs854765	0.583	rs4534911	ENSG00000265511.1	RP11-524F11.1	3.4	0.000726	0.0415	0.12	0.16	Total body bone mineral density;	chr17:17949016	chr17:17507351~17508308:+
THCA	cis	rs13232179	1	rs12672761	ENSG00000265810.1	MIR3907	-3.4	0.000726	0.0415	-0.15	-0.16	Coronary heart disease;	chr7:151421518	chr7:151433489~151433639:-
THCA	cis	rs8031584	0.918	rs35396566	ENSG00000270015.1	RP11-540B6.6	-3.4	0.000726	0.0415	-0.12	-0.16	Huntington's disease progression;	chr15:30970854	chr15:30926514~30928407:+
THCA	cis	rs8031584	1	rs35607976	ENSG00000270015.1	RP11-540B6.6	-3.4	0.000726	0.0415	-0.12	-0.16	Huntington's disease progression;	chr15:30985585	chr15:30926514~30928407:+
THCA	cis	rs16975963	0.843	rs73025630	ENSG00000276846.1	CTD-3220F14.3	-3.4	0.000726	0.0415	-0.15	-0.16	Longevity;	chr19:37860644	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.793	rs73027418	ENSG00000276846.1	CTD-3220F14.3	-3.4	0.000726	0.0415	-0.15	-0.16	Longevity;	chr19:37870380	chr19:37314868~37315620:-
THCA	cis	rs16975963	0.843	rs113690074	ENSG00000276846.1	CTD-3220F14.3	-3.4	0.000726	0.0415	-0.15	-0.16	Longevity;	chr19:37884753	chr19:37314868~37315620:-
THCA	cis	rs9796	0.689	rs692511	ENSG00000247556.5	OIP5-AS1	3.4	0.000726	0.0415	0.13	0.16	Menopause (age at onset);	chr15:41154054	chr15:41283990~41309737:+
THCA	cis	rs10911902	0.58	rs16825773	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000726	0.0415	-0.25	-0.16	Schizophrenia;	chr1:186699999	chr1:186580515~186581191:-
THCA	cis	rs950169	0.686	rs12906474	ENSG00000230373.7	GOLGA6L5P	-3.4	0.000727	0.0415	-0.17	-0.16	Schizophrenia;	chr15:84566006	chr15:84507885~84516814:-
THCA	cis	rs950169	0.81	rs2879976	ENSG00000230373.7	GOLGA6L5P	-3.4	0.000727	0.0415	-0.17	-0.16	Schizophrenia;	chr15:84566347	chr15:84507885~84516814:-
THCA	cis	rs9307551	1	rs13104009	ENSG00000249646.2	OR7E94P	-3.4	0.000727	0.0415	-0.21	-0.16	Refractive error;	chr4:79609584	chr4:79587302~79588130:-
THCA	cis	rs11785400	0.928	rs750529	ENSG00000177335.9	C8orf31	3.4	0.000727	0.0415	0.17	0.16	Schizophrenia;	chr8:142663460	chr8:143039209~143059942:+
THCA	cis	rs910316	0.737	rs91144	ENSG00000259138.1	RP11-950C14.7	-3.4	0.000727	0.0415	-0.14	-0.16	Height;	chr14:74982814	chr14:75127153~75136930:+
THCA	cis	rs11673344	0.523	rs2562607	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37031358	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs2385415	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37035291	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs7246739	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37040829	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs7260488	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37058883	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.523	rs8110158	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37063491	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.562	rs7257320	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37080933	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.504	rs10403975	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37082172	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.504	rs2385375	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37087620	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.504	rs35162188	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37088908	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.562	rs7250507	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000727	0.0415	-0.18	-0.16	Obesity-related traits;	chr19:37095772	chr19:36773153~36777078:+
THCA	cis	rs11658311	1	rs9903503	ENSG00000226478.3	UPF3AP1	-3.4	0.000727	0.0415	-0.4	-0.16	Obsessive-compulsive symptoms;	chr17:17553913	chr17:16745636~16746761:-
THCA	cis	rs2562456	0.793	rs73537884	ENSG00000268521.1	VN1R83P	3.4	0.000727	0.0415	0.15	0.16	Pain;	chr19:21321908	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.793	rs78467454	ENSG00000268521.1	VN1R83P	3.4	0.000727	0.0415	0.15	0.16	Pain;	chr19:21321930	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs55790393	ENSG00000268521.1	VN1R83P	3.4	0.000727	0.0415	0.15	0.16	Pain;	chr19:21323382	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.793	rs11672341	ENSG00000268521.1	VN1R83P	3.4	0.000727	0.0415	0.15	0.16	Pain;	chr19:21324502	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.754	rs11673234	ENSG00000268521.1	VN1R83P	3.4	0.000727	0.0415	0.15	0.16	Pain;	chr19:21324800	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.754	rs11673320	ENSG00000268521.1	VN1R83P	3.4	0.000727	0.0415	0.15	0.16	Pain;	chr19:21324801	chr19:21289554~21289998:-
THCA	cis	rs9457247	0.565	rs2038580	ENSG00000235272.1	FAM103A2P	3.4	0.000727	0.0415	0.22	0.16	Crohn's disease;	chr6:167043002	chr6:166586124~166586477:-
THCA	cis	rs6500602	0.727	rs11076836	ENSG00000280063.1	RP11-295D4.3	3.4	0.000727	0.0415	0.08	0.16	Schizophrenia;	chr16:4519330	chr16:4346694~4348648:-
THCA	cis	rs6500602	0.727	rs11076837	ENSG00000280063.1	RP11-295D4.3	3.4	0.000727	0.0415	0.08	0.16	Schizophrenia;	chr16:4519439	chr16:4346694~4348648:-
THCA	cis	rs6500602	0.727	rs8051389	ENSG00000280063.1	RP11-295D4.3	3.4	0.000727	0.0415	0.08	0.16	Schizophrenia;	chr16:4520569	chr16:4346694~4348648:-
THCA	cis	rs6500602	0.727	rs4786510	ENSG00000280063.1	RP11-295D4.3	3.4	0.000727	0.0415	0.08	0.16	Schizophrenia;	chr16:4521246	chr16:4346694~4348648:-
THCA	cis	rs6500602	0.702	rs4786511	ENSG00000280063.1	RP11-295D4.3	3.4	0.000727	0.0415	0.08	0.16	Schizophrenia;	chr16:4521644	chr16:4346694~4348648:-
THCA	cis	rs2287838	1	rs11667192	ENSG00000267370.1	CTD-2623N2.3	3.4	0.000727	0.0415	0.14	0.16	Sleep duration;	chr19:9865294	chr19:9756152~9756863:-
THCA	cis	rs7246657	1	rs12709812	ENSG00000267422.1	CTD-2554C21.1	3.4	0.000727	0.0415	0.18	0.16	Coronary artery calcification;	chr19:37303948	chr19:37779686~37792865:+
THCA	cis	rs7656342	0.636	rs9993652	ENSG00000250342.1	SNRPCP16	3.4	0.000727	0.0415	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9887225	chr4:9051842~9052051:-
THCA	cis	rs7005380	0.785	rs7814294	ENSG00000279347.1	RP11-85I17.2	3.4	0.000727	0.0415	0.17	0.16	Interstitial lung disease;	chr8:119927196	chr8:119838736~119840385:-
THCA	cis	rs2228479	0.85	rs11076623	ENSG00000274627.1	RP11-104N10.2	-3.4	0.000727	0.0415	-0.27	-0.16	Skin colour saturation;	chr16:89777712	chr16:89516797~89522217:+
THCA	cis	rs330048	0.545	rs11781008	ENSG00000254340.1	RP11-10A14.3	3.4	0.000727	0.0415	0.17	0.16	Systemic lupus erythematosus;	chr8:9295729	chr8:9141424~9145435:+
THCA	cis	rs883565	0.528	rs9818979	ENSG00000223668.1	EEF1A1P24	3.4	0.000727	0.0415	0.13	0.16	Handedness;	chr3:38922344	chr3:39358545~39359922:+
THCA	cis	rs6598541	0.928	rs8038015	ENSG00000278090.1	RP11-6O2.2	3.4	0.000727	0.0415	0.14	0.16	Urate levels;	chr15:98720045	chr15:99028538~99031053:+
THCA	cis	rs9816784	0.566	rs11720913	ENSG00000207650.1	MIR570	3.4	0.000727	0.0415	0.17	0.16	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195699401~195699497:+
THCA	cis	rs8192917	0.573	rs10139232	ENSG00000258657.4	RP11-104E19.1	-3.4	0.000727	0.0415	-0.28	-0.16	Vitiligo;	chr14:24654597	chr14:24595723~24657774:+
THCA	cis	rs28510890	0.508	rs28664631	ENSG00000258647.4	LINC00930	3.4	0.000727	0.0415	0.17	0.16	Lung cancer in ever smokers;	chr15:92616165	chr15:92567818~92572042:-
THCA	cis	rs875971	0.666	rs13242072	ENSG00000275400.1	RP4-756H11.5	3.4	0.000727	0.0415	0.15	0.16	Aortic root size;	chr7:66301001	chr7:66553805~66554199:-
THCA	cis	rs10911363	0.592	rs2702205	ENSG00000232860.6	SMG7-AS1	-3.4	0.000728	0.0415	-0.12	-0.16	Systemic lupus erythematosus;	chr1:183488063	chr1:183460874~183472265:-
THCA	cis	rs472109	0.565	rs183110	ENSG00000253973.2	RP11-467K18.2	3.4	0.000728	0.0415	0.2	0.16	Coronary artery disease;	chr11:9790069	chr11:9004162~9065154:+
THCA	cis	rs7824557	0.505	rs2572440	ENSG00000227888.4	FAM66A	3.4	0.000728	0.0415	0.19	0.16	Retinal vascular caliber;	chr8:11391501	chr8:12362019~12388296:+
THCA	cis	rs4903031	0.697	rs2239222	ENSG00000258871.1	RP3-514A23.2	-3.4	0.000728	0.0415	-0.16	-0.15	C-reactive protein levels;	chr14:72545177	chr14:72552580~72595125:-
THCA	cis	rs2239181	1	rs2239181	ENSG00000277173.1	CTD-2024F21.1	-3.4	0.000728	0.0415	-0.23	-0.15	Gout;	chr12:47862166	chr12:47768529~47769648:+
THCA	cis	rs714027	0.605	rs5753037	ENSG00000279699.1	RP1-102K2.9	3.4	0.000728	0.0415	0.16	0.15	Lymphocyte counts;	chr22:30185733	chr22:30275215~30276951:-
THCA	cis	rs638893	0.717	rs622690	ENSG00000255422.1	AP002954.4	-3.4	0.000728	0.0415	-0.24	-0.15	Vitiligo;	chr11:118833556	chr11:118704607~118750263:+
THCA	cis	rs2131877	0.529	rs7644208	ENSG00000238097.1	RP11-513G11.3	-3.4	0.000728	0.0415	-0.18	-0.15	Non-small cell lung cancer;	chr3:195135225	chr3:194247648~194257772:+
THCA	cis	rs939960	0.959	rs6954884	ENSG00000224016.2	RP11-728K20.1	3.4	0.000728	0.0415	0.21	0.15	Neutrophil percentage of white cells;	chr7:150587329	chr7:149891191~149909704:-
THCA	cis	rs939960	0.959	rs13232683	ENSG00000224016.2	RP11-728K20.1	3.4	0.000728	0.0415	0.21	0.15	Neutrophil percentage of white cells;	chr7:150587862	chr7:149891191~149909704:-
THCA	cis	rs939960	0.959	rs13232785	ENSG00000224016.2	RP11-728K20.1	3.4	0.000728	0.0415	0.21	0.15	Neutrophil percentage of white cells;	chr7:150587884	chr7:149891191~149909704:-
THCA	cis	rs1198872	0.892	rs1198866	ENSG00000243819.4	RN7SL832P	3.4	0.000728	0.0415	0.12	0.15	Cardiac Troponin-T levels;	chr2:10761664	chr2:10690344~10692099:+
THCA	cis	rs3763267	0.649	rs9505941	ENSG00000226445.1	XXyac-YX65C7_A.2	3.4	0.000728	0.0415	0.28	0.15	Blood protein levels;	chr6:169186477	chr6:169213254~169239565:+
THCA	cis	rs1832871	0.711	rs9459829	ENSG00000213078.3	RP5-933K21.2	-3.4	0.000728	0.0415	-0.23	-0.15	Height;	chr6:158259767	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9457248	ENSG00000213078.3	RP5-933K21.2	-3.4	0.000728	0.0415	-0.23	-0.15	Height;	chr6:158260172	chr6:157365990~157366923:-
THCA	cis	rs7572733	0.935	rs1595824	ENSG00000231621.1	AC013264.2	-3.4	0.000728	0.0415	-0.15	-0.15	Dermatomyositis;	chr2:198009282	chr2:197197991~197199273:+
THCA	cis	rs9902453	0.619	rs2255489	ENSG00000263370.1	RP11-68I3.5	-3.4	0.000728	0.0415	-0.21	-0.15	Coffee consumption (cups per day);	chr17:29757956	chr17:29639627~29640825:+
THCA	cis	rs2933343	0.621	rs789242	ENSG00000261159.1	RP11-723O4.9	3.4	0.000728	0.0415	0.16	0.15	IgG glycosylation;	chr3:128866864	chr3:128859716~128860526:-
THCA	cis	rs2274273	0.84	rs6573014	ENSG00000258469.1	CHMP4BP1	-3.4	0.000728	0.0415	-0.13	-0.15	Protein biomarker;	chr14:55269174	chr14:55298644~55299231:+
THCA	cis	rs732716	0.785	rs62130979	ENSG00000280239.1	CTB-50L17.8	-3.4	0.000728	0.0415	-0.13	-0.15	Mean corpuscular volume;	chr19:4432447	chr19:4448810~4450836:+
THCA	cis	rs1144333	0.655	rs76975224	ENSG00000272855.1	RP5-1102E8.3	-3.4	0.000728	0.0415	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:76005108	chr1:76636877~76637339:+
THCA	cis	rs80130819	0.515	rs1906717	ENSG00000273765.1	RP11-370I10.11	-3.4	0.000728	0.0415	-0.18	-0.15	Prostate cancer;	chr12:48374991	chr12:48360920~48361377:+
THCA	cis	rs9481169	0.717	rs13191781	ENSG00000272356.1	RP5-1112D6.8	3.4	0.000728	0.0415	0.25	0.15	Inflammatory skin disease;	chr6:111620083	chr6:111309203~111313517:+
THCA	cis	rs10483853	0.806	rs7141241	ENSG00000258891.1	RP5-1021I20.5	-3.4	0.000728	0.0415	-0.2	-0.15	Coronary artery calcification;	chr14:73342096	chr14:73896164~73938114:-
THCA	cis	rs10483853	0.806	rs10142258	ENSG00000258891.1	RP5-1021I20.5	-3.4	0.000728	0.0415	-0.2	-0.15	Coronary artery calcification;	chr14:73343509	chr14:73896164~73938114:-
THCA	cis	rs10875746	0.768	rs10875724	ENSG00000258234.1	RP11-370I10.2	3.4	0.000728	0.0415	0.18	0.15	Longevity (90 years and older);	chr12:48026470	chr12:48231098~48284210:-
THCA	cis	rs7208859	0.614	rs216412	ENSG00000264242.2	RP11-271K11.1	-3.4	0.000728	0.0415	-0.22	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30553697~30558962:+
THCA	cis	rs1737890	0.778	rs4911222	ENSG00000235217.6	TSPY26P	3.4	0.000728	0.0415	0.18	0.15	Chronic obstructive pulmonary disease;	chr20:32373397	chr20:32186477~32190527:-
THCA	cis	rs2839186	0.771	rs2280957	ENSG00000225043.1	RPL18AP2	-3.4	0.000728	0.0415	-0.18	-0.15	Testicular germ cell tumor;	chr21:46222358	chr21:46420553~46421034:-
THCA	cis	rs739496	0.579	rs12319315	ENSG00000234608.6	MAPKAPK5-AS1	3.4	0.000728	0.0415	0.15	0.15	Platelet count;	chr12:111903215	chr12:111839764~111842902:-
THCA	cis	rs10946940	0.965	rs9393830	ENSG00000220721.1	OR1F12	3.4	0.000728	0.0415	0.18	0.15	Systemic lupus erythematosus;	chr6:27619248	chr6:28073316~28074233:+
THCA	cis	rs7924176	0.564	rs6480727	ENSG00000232342.6	RP11-46O21.2	3.4	0.000728	0.0416	0.19	0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74506081~74530553:-
THCA	cis	rs2729354	0.768	rs1001956	ENSG00000254602.1	AP000662.4	-3.4	0.000728	0.0416	-0.2	-0.15	Blood protein levels;	chr11:57499476	chr11:57638024~57652790:+
THCA	cis	rs78889164	0.956	rs16968029	ENSG00000239253.1	RPS4XP23	3.4	0.000728	0.0416	0.25	0.15	Lobe attachment (rater-scored or self-reported);	chr19:33378269	chr19:34021659~34021895:+
THCA	cis	rs9596863	1	rs7328595	ENSG00000136149.6	RPL13AP25	3.4	0.000729	0.0416	0.17	0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53849935	chr13:54440704~54441315:-
THCA	cis	rs9596863	1	rs7328970	ENSG00000136149.6	RPL13AP25	3.4	0.000729	0.0416	0.17	0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53850090	chr13:54440704~54441315:-
THCA	cis	rs7924176	0.601	rs10824091	ENSG00000232342.6	RP11-46O21.2	3.4	0.000729	0.0416	0.2	0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74169750	chr10:74506081~74530553:-
THCA	cis	rs4788570	0.615	rs6499526	ENSG00000260185.1	RP11-432I5.6	-3.4	0.000729	0.0416	-0.3	-0.15	Intelligence (multi-trait analysis);	chr16:71614396	chr16:71655027~71664212:+
THCA	cis	rs6499755	0.768	rs31083	ENSG00000260135.5	RP11-212I21.2	-3.4	0.000729	0.0416	-0.17	-0.15	Hypospadias;	chr16:55328219	chr16:55426797~55462297:-
THCA	cis	rs2228479	0.85	rs11647174	ENSG00000223959.7	AFG3L1P	-3.4	0.000729	0.0416	-0.14	-0.15	Skin colour saturation;	chr16:89892130	chr16:89972586~90002161:+
THCA	cis	rs2228479	0.85	rs11648433	ENSG00000223959.7	AFG3L1P	-3.4	0.000729	0.0416	-0.14	-0.15	Skin colour saturation;	chr16:89898647	chr16:89972586~90002161:+
THCA	cis	rs2228479	1	rs62052186	ENSG00000223959.7	AFG3L1P	-3.4	0.000729	0.0416	-0.14	-0.15	Skin colour saturation;	chr16:89903159	chr16:89972586~90002161:+
THCA	cis	rs4664293	0.867	rs12617546	ENSG00000230783.1	AC009961.2	-3.4	0.000729	0.0416	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159767079	chr2:159689217~159690291:-
THCA	cis	rs1322639	0.614	rs9689800	ENSG00000226445.1	XXyac-YX65C7_A.2	3.4	0.000729	0.0416	0.17	0.15	Pulse pressure;	chr6:169172850	chr6:169213254~169239565:+
THCA	cis	rs10954779	0.54	rs2553276	ENSG00000127589.4	TUBBP1	3.4	0.000729	0.0416	0.19	0.15	Intelligence (multi-trait analysis);	chr8:31130048	chr8:30351873~30353518:+
THCA	cis	rs690037	1	rs690037	ENSG00000272529.1	RP11-415F23.4	3.4	0.000729	0.0416	0.14	0.15	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16354161	chr3:16345126~16346440:+
THCA	cis	rs7760535	0.826	rs3777905	ENSG00000272356.1	RP5-1112D6.8	-3.4	0.000729	0.0416	-0.12	-0.15	Metabolic traits;	chr6:111549385	chr6:111309203~111313517:+
THCA	cis	rs7737355	0.812	rs2549011	ENSG00000224431.1	AC063976.7	-3.4	0.000729	0.0416	-0.14	-0.15	Life satisfaction;	chr5:131321725	chr5:132199456~132203487:+
THCA	cis	rs7937890	0.572	rs2597202	ENSG00000251991.1	RNU7-49P	3.4	0.000729	0.0416	0.18	0.15	Mitochondrial DNA levels;	chr11:14463099	chr11:14478892~14478953:+
THCA	cis	rs9425766	0.927	rs9425757	ENSG00000200674.1	RN7SKP160	3.4	0.000729	0.0416	0.2	0.15	Life satisfaction;	chr1:173855675	chr1:173791548~173791887:+
THCA	cis	rs7737355	1	rs30736	ENSG00000237714.1	P4HA2-AS1	-3.4	0.000729	0.0416	-0.22	-0.15	Life satisfaction;	chr5:131388547	chr5:132184876~132192808:+
THCA	cis	rs1005277	0.563	rs2505215	ENSG00000151963.4	RP11-775A3.1	-3.4	0.000729	0.0416	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.563	rs2505216	ENSG00000151963.4	RP11-775A3.1	-3.4	0.000729	0.0416	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs2749612	ENSG00000151963.4	RP11-775A3.1	-3.4	0.000729	0.0416	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:37883594~37884109:+
THCA	cis	rs4664293	0.836	rs13016015	ENSG00000230783.1	AC009961.2	-3.4	0.000729	0.0416	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159790018	chr2:159689217~159690291:-
THCA	cis	rs6083	0.571	rs41294813	ENSG00000245975.2	RP11-30K9.6	-3.4	0.000729	0.0416	-0.14	-0.15	Schizophrenia;	chr15:58555608	chr15:58768072~58770974:-
THCA	cis	rs494526	1	rs592580	ENSG00000229272.1	RP11-498J9.2	3.4	0.000729	0.0416	0.17	0.15	Alcoholic chronic pancreatitis;	chr10:119027192	chr10:119003536~119003884:-
THCA	cis	rs7829975	0.559	rs4841025	ENSG00000254340.1	RP11-10A14.3	-3.4	0.000729	0.0416	-0.17	-0.15	Mood instability;	chr8:8745650	chr8:9141424~9145435:+
THCA	cis	rs11583043	0.918	rs6675403	ENSG00000233184.5	RP11-421L21.3	3.4	0.000729	0.0416	0.17	0.15	Inflammatory bowel disease;Ulcerative colitis;	chr1:100953013	chr1:101025878~101087268:+
THCA	cis	rs7818688	1	rs10093594	ENSG00000253528.2	RP11-347C18.4	3.4	0.000729	0.0416	0.25	0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95021008	chr8:94974573~94974853:-
THCA	cis	rs56283067	0.847	rs12198153	ENSG00000237686.5	RP5-1120P11.1	-3.4	0.000729	0.0416	-0.14	-0.15	Total body bone mineral density;	chr6:44724141	chr6:43995723~44074652:-
THCA	cis	rs56283067	0.811	rs62435997	ENSG00000237686.5	RP5-1120P11.1	-3.4	0.000729	0.0416	-0.14	-0.15	Total body bone mineral density;	chr6:44724432	chr6:43995723~44074652:-
THCA	cis	rs56283067	0.847	rs10456535	ENSG00000237686.5	RP5-1120P11.1	-3.4	0.000729	0.0416	-0.14	-0.15	Total body bone mineral density;	chr6:44725021	chr6:43995723~44074652:-
THCA	cis	rs56283067	0.847	rs10456118	ENSG00000237686.5	RP5-1120P11.1	-3.4	0.000729	0.0416	-0.14	-0.15	Total body bone mineral density;	chr6:44725088	chr6:43995723~44074652:-
THCA	cis	rs9844666	0.512	rs2204259	ENSG00000273486.1	RP11-731C17.2	3.4	0.000729	0.0416	0.14	0.15	Height;	chr3:135934430	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.532	rs9857579	ENSG00000273486.1	RP11-731C17.2	3.4	0.000729	0.0416	0.14	0.15	Height;	chr3:135937654	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9819707	ENSG00000273486.1	RP11-731C17.2	3.4	0.000729	0.0416	0.14	0.15	Height;	chr3:135937664	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9820057	ENSG00000273486.1	RP11-731C17.2	3.4	0.000729	0.0416	0.14	0.15	Height;	chr3:135937896	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs7623721	ENSG00000273486.1	RP11-731C17.2	3.4	0.000729	0.0416	0.14	0.15	Height;	chr3:135938572	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.532	rs12330820	ENSG00000273486.1	RP11-731C17.2	3.4	0.000729	0.0416	0.14	0.15	Height;	chr3:135940543	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs35896773	ENSG00000273486.1	RP11-731C17.2	3.4	0.000729	0.0416	0.14	0.15	Height;	chr3:135940724	chr3:136837338~136839021:-
THCA	cis	rs11673344	0.528	rs578655	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000729	0.0416	-0.19	-0.15	Obesity-related traits;	chr19:36919855	chr19:36773153~36777078:+
THCA	cis	rs17428076	0.801	rs62182392	ENSG00000228389.1	AC068039.4	-3.4	0.000729	0.0416	-0.18	-0.15	Myopia;	chr2:171865252	chr2:171773482~171775844:+
THCA	cis	rs72848980	0.516	rs2296569	ENSG00000272912.1	RP11-724N1.1	3.4	0.000729	0.0416	0.28	0.15	White matter hyperintensity burden;	chr10:103076754	chr10:102914585~102915404:+
THCA	cis	rs7084402	0.967	rs1649057	ENSG00000180221.6	TPT1P10	3.4	0.000729	0.0416	0.18	0.15	Refractive error;	chr10:58558354	chr10:58212541~58213036:-
THCA	cis	rs6993813	0.872	rs4403440	ENSG00000245330.4	KB-1471A8.1	-3.4	0.000729	0.0416	-0.15	-0.15	Bone mineral density (hip);	chr8:119019336	chr8:119867419~119874488:-
THCA	cis	rs34421088	0.576	rs2572436	ENSG00000261451.1	RP11-981G7.1	-3.4	0.000729	0.0416	-0.22	-0.15	Neuroticism;	chr8:11241700	chr8:10433672~10438312:+
THCA	cis	rs7412746	0.658	rs6660845	ENSG00000224800.1	RP11-235D19.2	-3.4	0.000729	0.0416	-0.21	-0.15	Melanoma;	chr1:150868590	chr1:150881236~150881683:-
THCA	cis	rs34779708	0.931	rs7099036	ENSG00000233200.1	RP11-324I22.2	3.4	0.000729	0.0416	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35219894~35230598:-
THCA	cis	rs4713118	0.824	rs742046	ENSG00000272009.1	RP1-313I6.12	-3.4	0.000729	0.0416	-0.18	-0.15	Parkinson's disease;	chr6:27771475	chr6:28078792~28081130:-
THCA	cis	rs12476592	0.602	rs1446563	ENSG00000242412.1	DBIL5P2	3.4	0.000729	0.0416	0.21	0.15	Childhood ear infection;	chr2:63670990	chr2:63117851~63119542:-
THCA	cis	rs6687821	0.531	rs7553360	ENSG00000261737.1	RP4-612B15.3	3.4	0.000729	0.0416	0.24	0.15	Yeast infection;	chr1:87069032	chr1:86703502~86704462:-
THCA	cis	rs6017317	0.643	rs6031489	ENSG00000244558.4	KCNK15-AS1	-3.4	0.000729	0.0416	-0.22	-0.15	Type 2 diabetes;	chr20:44265263	chr20:44694892~44746021:-
THCA	cis	rs6787172	0.592	rs7648196	ENSG00000272087.1	RP11-379F4.7	3.4	0.000729	0.0416	0.14	0.15	Subjective well-being;	chr3:158386917	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs6414388	ENSG00000272087.1	RP11-379F4.7	3.4	0.000729	0.0416	0.14	0.15	Subjective well-being;	chr3:158390300	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.592	rs6414389	ENSG00000272087.1	RP11-379F4.7	3.4	0.000729	0.0416	0.14	0.15	Subjective well-being;	chr3:158390349	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs6414390	ENSG00000272087.1	RP11-379F4.7	3.4	0.000729	0.0416	0.14	0.15	Subjective well-being;	chr3:158390355	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs9880806	ENSG00000272087.1	RP11-379F4.7	3.4	0.000729	0.0416	0.14	0.15	Subjective well-being;	chr3:158398664	chr3:158693120~158693768:-
THCA	cis	rs4218	0.573	rs16940998	ENSG00000259732.1	RP11-59H7.3	3.4	0.000729	0.0416	0.21	0.15	Social communication problems;	chr15:59086095	chr15:59121034~59133250:+
THCA	cis	rs7709377	0.516	rs73257286	ENSG00000271918.1	CTD-2287O16.5	3.4	0.00073	0.0416	0.15	0.15	Metabolite levels  (X-11787);	chr5:116200654	chr5:116083807~116085416:-
THCA	cis	rs111326718	1	rs111326718	ENSG00000272912.1	RP11-724N1.1	-3.4	0.00073	0.0416	-0.18	-0.15	Reticulocyte count;	chr10:103011454	chr10:102914585~102915404:+
THCA	cis	rs944289	0.515	rs1755768	ENSG00000212071.1	AL162511.1	3.4	0.00073	0.0416	0.2	0.15	Thyroid cancer;	chr14:36192691	chr14:36196480~36196568:-
THCA	cis	rs7264396	0.887	rs6060438	ENSG00000261582.1	RP4-614O4.11	-3.4	0.00073	0.0416	-0.16	-0.15	Total cholesterol levels;	chr20:35489577	chr20:35267885~35280043:-
THCA	cis	rs1030877	1	rs2254301	ENSG00000235319.1	AC012360.4	-3.4	0.00073	0.0416	-0.18	-0.15	Obesity-related traits;	chr2:105264277	chr2:105324210~105330529:+
THCA	cis	rs12530	0.651	rs2072816	ENSG00000232218.1	RP1-149A16.16	-3.4	0.00073	0.0416	-0.23	-0.15	IgG glycosylation;	chr22:32394411	chr22:32386668~32386868:+
THCA	cis	rs6754311	0.608	rs3739020	ENSG00000231890.6	DARS-AS1	-3.4	0.00073	0.0416	-0.17	-0.15	Mosquito bite size;	chr2:135844921	chr2:135985176~136022593:+
THCA	cis	rs72819454	0.522	rs4918047	ENSG00000280693.1	SH3PXD2A-AS1	-3.4	0.00073	0.0416	-0.3	-0.15	Interleukin-9 levels;	chr10:103762582	chr10:103745966~103755423:+
THCA	cis	rs11242704	0.632	rs2816291	ENSG00000272279.1	RP11-157J24.2	-3.4	0.00073	0.0416	-0.25	-0.15	Response to hepatitis C treatment;	chr6:1537887	chr6:1528364~1528911:-
THCA	cis	rs11242704	0.632	rs2816292	ENSG00000272279.1	RP11-157J24.2	-3.4	0.00073	0.0416	-0.25	-0.15	Response to hepatitis C treatment;	chr6:1537983	chr6:1528364~1528911:-
THCA	cis	rs754466	0.58	rs10430529	ENSG00000213514.2	RP11-428P16.2	3.4	0.00073	0.0416	0.17	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77822865	chr10:77730766~77734769:+
THCA	cis	rs9860428	0.76	rs9823692	ENSG00000243795.1	RP11-572M11.3	3.4	0.00073	0.0416	0.19	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112910375	chr3:113142350~113167819:-
THCA	cis	rs7829975	0.6	rs1719381	ENSG00000254340.1	RP11-10A14.3	-3.4	0.00073	0.0416	-0.17	-0.15	Mood instability;	chr8:8744834	chr8:9141424~9145435:+
THCA	cis	rs7735319	0.528	rs10037743	ENSG00000249572.1	CTD-2203K17.1	3.4	0.00073	0.0416	0.18	0.15	Systolic blood pressure;	chr5:33163672	chr5:33424025~33440619:-
THCA	cis	rs73198271	0.813	rs56007835	ENSG00000254153.1	CTA-398F10.2	3.4	0.00073	0.0416	0.19	0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8456909~8461337:-
THCA	cis	rs12935418	0.583	rs12446698	ENSG00000261838.4	RP11-303E16.6	3.4	0.00073	0.0416	0.22	0.15	Mean corpuscular volume;	chr16:80930524	chr16:81069854~81076598:+
THCA	cis	rs7259376	0.875	rs4932755	ENSG00000270947.1	AC025811.3	3.4	0.00073	0.0416	0.17	0.15	Menopause (age at onset);	chr19:22312014	chr19:22455988~22456459:+
THCA	cis	rs11673344	0.523	rs2562605	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.00073	0.0416	-0.18	-0.15	Obesity-related traits;	chr19:37029302	chr19:36773153~36777078:+
THCA	cis	rs111756027	0.522	rs9927139	ENSG00000260922.1	RP11-538I12.3	-3.4	0.00073	0.0416	-0.25	-0.15	Bone mineral density (Ward's triangle area);	chr16:77247731	chr16:77234877~77290934:+
THCA	cis	rs3096299	0.809	rs2911264	ENSG00000261118.1	RP11-104N10.1	3.4	0.00073	0.0416	0.14	0.15	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89492017~89504460:-
THCA	cis	rs10760158	0.769	rs10760170	ENSG00000226752.6	PSMD5-AS1	-3.4	0.00073	0.0416	-0.18	-0.15	Pulse pressure;	chr9:121295935	chr9:120824828~120854385:+
THCA	cis	rs10760158	0.832	rs1865542	ENSG00000226752.6	PSMD5-AS1	-3.4	0.00073	0.0416	-0.18	-0.15	Pulse pressure;	chr9:121296521	chr9:120824828~120854385:+
THCA	cis	rs6871536	1	rs10463893	ENSG00000233006.5	AC034220.3	-3.4	0.00073	0.0416	-0.14	-0.15	Asthma (childhood onset);	chr5:132592347	chr5:132311285~132369916:-
THCA	cis	rs8031584	0.678	rs35098644	ENSG00000270015.1	RP11-540B6.6	-3.4	0.00073	0.0416	-0.12	-0.15	Huntington's disease progression;	chr15:30853237	chr15:30926514~30928407:+
THCA	cis	rs708224	0.967	rs1239402	ENSG00000274964.1	RP11-817I4.1	3.4	0.00073	0.0416	0.16	0.15	Pancreatic cancer;	chr12:32287233	chr12:32339368~32340724:+
THCA	cis	rs708224	1	rs1271200	ENSG00000274964.1	RP11-817I4.1	3.4	0.00073	0.0416	0.16	0.15	Pancreatic cancer;	chr12:32288336	chr12:32339368~32340724:+
THCA	cis	rs7246657	0.941	rs7259618	ENSG00000267422.1	CTD-2554C21.1	-3.4	0.00073	0.0416	-0.18	-0.15	Coronary artery calcification;	chr19:37259817	chr19:37779686~37792865:+
THCA	cis	rs2115630	0.755	rs7169629	ENSG00000259295.5	CSPG4P12	3.4	0.00073	0.0416	0.21	0.15	P wave terminal force;	chr15:84648043	chr15:85191438~85213905:+
THCA	cis	rs858239	0.831	rs7796541	ENSG00000226816.2	AC005082.12	3.4	0.00073	0.0416	0.23	0.15	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23206013~23208045:+
THCA	cis	rs13720	0.722	rs163801	ENSG00000225806.6	RP1-309F20.3	-3.4	0.00073	0.0416	-0.16	-0.15	Platelet distribution width;	chr20:59003559	chr20:58863528~58888809:-
THCA	cis	rs939960	0.718	rs73475318	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150602836	chr7:150047609~150047854:-
THCA	cis	rs939960	0.797	rs4367453	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150603360	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs62504165	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150603788	chr7:150047609~150047854:-
THCA	cis	rs939960	0.836	rs12666582	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150610002	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs13225097	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150610079	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs13225393	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150610217	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs13225610	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150610265	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs7788683	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150610670	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs7788885	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150610888	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs9768400	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150611114	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs35432864	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150612117	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs35182796	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150612250	chr7:150047609~150047854:-
THCA	cis	rs939960	0.879	rs13221085	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150612854	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs13236678	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150612981	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs6970561	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150613151	chr7:150047609~150047854:-
THCA	cis	rs939960	0.917	rs6970741	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150613413	chr7:150047609~150047854:-
THCA	cis	rs939960	0.84	rs6971221	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150613699	chr7:150047609~150047854:-
THCA	cis	rs939960	0.918	rs6954076	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150613853	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs6971529	ENSG00000276538.1	RP11-545G3.2	3.4	0.00073	0.0416	0.22	0.15	Neutrophil percentage of white cells;	chr7:150613881	chr7:150047609~150047854:-
THCA	cis	rs3763267	0.649	rs115752978	ENSG00000226445.1	XXyac-YX65C7_A.2	3.4	0.00073	0.0416	0.31	0.15	Blood protein levels;	chr6:169175393	chr6:169213254~169239565:+
THCA	cis	rs2179367	0.887	rs6570965	ENSG00000223701.3	RAET1E-AS1	3.4	0.00073	0.0416	0.2	0.15	Dupuytren's disease;	chr6:149396340	chr6:149884431~149919508:+
THCA	cis	rs2404602	0.552	rs11636612	ENSG00000196274.5	Metazoa_SRP	-3.4	0.00073	0.0416	-0.19	-0.15	Blood metabolite levels;	chr15:76667189	chr15:76230048~76230390:-
THCA	cis	rs642803	0.933	rs644740	ENSG00000255120.4	OVOL1-AS1	3.4	0.00073	0.0416	0.19	0.15	Urate levels;	chr11:65793997	chr11:65789051~65790868:-
THCA	cis	rs6828577	1	rs6822035	ENSG00000281731.1	RP11-384K6.8	-3.4	0.00073	0.0417	-0.18	-0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118789266	chr4:118664087~118685341:-
THCA	cis	rs620729	0.749	rs35658210	ENSG00000272097.1	RP11-421M1.8	3.4	0.000731	0.0417	0.18	0.15	Intelligence (multi-trait analysis);	chr6:11481049	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs35938392	ENSG00000272097.1	RP11-421M1.8	3.4	0.000731	0.0417	0.18	0.15	Intelligence (multi-trait analysis);	chr6:11481076	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs36053861	ENSG00000272097.1	RP11-421M1.8	3.4	0.000731	0.0417	0.18	0.15	Intelligence (multi-trait analysis);	chr6:11481082	chr6:10743324~10747663:-
THCA	cis	rs2180341	1	rs7756336	ENSG00000220522.2	RP1-177A13.1	3.4	0.000731	0.0417	0.2	0.15	Breast cancer;	chr6:127329154	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs9401950	ENSG00000220522.2	RP1-177A13.1	3.4	0.000731	0.0417	0.2	0.15	Breast cancer;	chr6:127334340	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.824	rs9321076	ENSG00000220522.2	RP1-177A13.1	3.4	0.000731	0.0417	0.2	0.15	Breast cancer;	chr6:127334469	chr6:127416535~127416952:-
THCA	cis	rs972578	0.561	rs5759113	ENSG00000274717.1	RP1-47A17.1	-3.4	0.000731	0.0417	-0.17	-0.15	Mean platelet volume;	chr22:43047946	chr22:42791814~42794313:-
THCA	cis	rs10435719	0.718	rs7813935	ENSG00000254527.1	ENPP7P12	3.4	0.000731	0.0417	0.2	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:12205759~12206389:-
THCA	cis	rs1908814	0.504	rs7830734	ENSG00000254527.1	ENPP7P12	3.4	0.000731	0.0417	0.2	0.15	Neuroticism;	chr8:11938130	chr8:12205759~12206389:-
THCA	cis	rs1665050	0.545	rs59540276	ENSG00000277144.1	RP11-59H7.4	-3.4	0.000731	0.0417	-0.21	-0.15	Atopic dermatitis;	chr15:59037559	chr15:59115547~59116089:-
THCA	cis	rs4287000	0.508	rs928368	ENSG00000227603.1	RP11-165J3.6	-3.4	0.000731	0.0417	-0.16	-0.15	Itch intensity from mosquito bite adjusted by bite size;	chr9:93610202	chr9:93435332~93437121:-
THCA	cis	rs7307902	1	rs11531169	ENSG00000280054.1	RP1-197B17.7	-3.4	0.000731	0.0417	-0.18	-0.15	Obesity-related traits;	chr12:47530155	chr12:47728151~47730598:-
THCA	cis	rs7307902	0.966	rs7296532	ENSG00000280054.1	RP1-197B17.7	-3.4	0.000731	0.0417	-0.18	-0.15	Obesity-related traits;	chr12:47530726	chr12:47728151~47730598:-
THCA	cis	rs6058526	0.706	rs35030210	ENSG00000235217.6	TSPY26P	-3.4	0.000731	0.0417	-0.23	-0.15	Chronic obstructive pulmonary disease;	chr20:32444006	chr20:32186477~32190527:-
THCA	cis	rs6963495	0.818	rs6943132	ENSG00000272604.1	RP11-251G23.5	3.4	0.000731	0.0417	0.24	0.15	Bipolar disorder (body mass index interaction);	chr7:105526329	chr7:105571083~105573660:+
THCA	cis	rs12908161	0.959	rs61074241	ENSG00000254414.1	RP11-182J1.1	3.4	0.000731	0.0417	0.22	0.15	Schizophrenia;	chr15:84790165	chr15:84631898~84633987:-
THCA	cis	rs6881280	1	rs255629	ENSG00000249996.1	RP11-359P5.1	3.4	0.000731	0.0417	0.23	0.15	Self-reported allergy;	chr5:123270602	chr5:123036271~123054667:+
THCA	cis	rs9860428	0.844	rs7641119	ENSG00000243795.1	RP11-572M11.3	3.4	0.000731	0.0417	0.18	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112891978	chr3:113142350~113167819:-
THCA	cis	rs6088813	0.961	rs3795159	ENSG00000261582.1	RP4-614O4.11	-3.4	0.000731	0.0417	-0.15	-0.15	Height;	chr20:35308459	chr20:35267885~35280043:-
THCA	cis	rs2572431	0.505	rs13269118	ENSG00000206014.6	OR7E161P	-3.4	0.000731	0.0417	-0.18	-0.15	Neuroticism;	chr8:11390305	chr8:11928597~11929563:-
THCA	cis	rs6921919	0.945	rs16901847	ENSG00000273712.1	RP5-874C20.7	3.4	0.000731	0.0417	0.21	0.15	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28315613~28315883:-
THCA	cis	rs11175194	1	rs17099883	ENSG00000255850.1	TMEM5-AS1	3.4	0.000731	0.0417	0.38	0.15	Epithelial ovarian cancer;	chr12:63867319	chr12:63808845~63822156:-
THCA	cis	rs875971	0.545	rs10950029	ENSG00000230295.1	RP11-458F8.2	3.4	0.000731	0.0417	0.14	0.15	Aortic root size;	chr7:66169334	chr7:66880708~66882981:+
THCA	cis	rs2000999	0.514	rs17604676	ENSG00000271009.2	RP11-346C20.3	-3.4	0.000731	0.0417	-0.18	-0.15	LDL cholesterol levels;Blood protein levels;Total cholesterol levels;LDL cholesterol;Haptoglobin levels;Cholesterol, total;	chr16:72188085	chr16:73060470~73062316:+
THCA	cis	rs7212590	0.581	rs9901254	ENSG00000267302.4	RP11-178C3.2	3.4	0.000731	0.0417	0.29	0.15	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59755556	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.581	rs7209157	ENSG00000267302.4	RP11-178C3.2	3.4	0.000731	0.0417	0.29	0.15	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59756115	chr17:59964832~59996972:+
THCA	cis	rs7212590	0.581	rs6503940	ENSG00000267302.4	RP11-178C3.2	3.4	0.000731	0.0417	0.29	0.15	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59765375	chr17:59964832~59996972:+
THCA	cis	rs453301	0.562	rs1038248	ENSG00000254340.1	RP11-10A14.3	-3.4	0.000731	0.0417	-0.17	-0.15	Joint mobility (Beighton score);	chr8:9183348	chr8:9141424~9145435:+
THCA	cis	rs465969	0.546	rs77990243	ENSG00000230177.1	RP5-1112D6.4	3.4	0.000731	0.0417	0.22	0.15	Psoriasis;	chr6:111513183	chr6:111277932~111278742:+
THCA	cis	rs465969	1	rs4509157	ENSG00000230177.1	RP5-1112D6.4	3.4	0.000731	0.0417	0.22	0.15	Psoriasis;	chr6:111513875	chr6:111277932~111278742:+
THCA	cis	rs7259376	0.807	rs7254434	ENSG00000270947.1	AC025811.3	3.4	0.000731	0.0417	0.17	0.15	Menopause (age at onset);	chr19:22317231	chr19:22455988~22456459:+
THCA	cis	rs2882667	0.858	rs66839813	ENSG00000249593.5	CTB-46B19.2	3.4	0.000731	0.0417	0.19	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:139012647~139051203:+
THCA	cis	rs9368222	1	rs35261542	ENSG00000280989.1	LINC00581	3.4	0.000732	0.0417	0.21	0.15	Body mass index;Peak insulin response;Acute insulin response;	chr6:20675561	chr6:21486061~21511895:-
THCA	cis	rs2901381	0.701	rs71306622	ENSG00000269984.1	RP11-362K14.5	-3.4	0.000732	0.0417	-0.14	-0.15	Plateletcrit;	chr3:169108906	chr3:169777192~169780334:-
THCA	cis	rs12935418	0.83	rs7188549	ENSG00000261838.4	RP11-303E16.6	3.4	0.000732	0.0417	0.23	0.15	Mean corpuscular volume;	chr16:81016371	chr16:81069854~81076598:+
THCA	cis	rs8033133	0.881	rs3803328	ENSG00000257151.1	PWAR6	3.4	0.000732	0.0417	0.12	0.15	Blood osmolality (transformed sodium);	chr15:25085403	chr15:25031873~25036490:+
THCA	cis	rs10090774	0.71	rs10088475	ENSG00000279766.1	RP11-642A1.2	-3.4	0.000732	0.0417	-0.19	-0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140660167	chr8:140572142~140572812:-
THCA	cis	rs7474896	1	rs2295872	ENSG00000276805.1	RP11-291L22.6	3.4	0.000732	0.0417	0.24	0.15	Obesity (extreme);	chr10:37857290	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs2738219	ENSG00000276805.1	RP11-291L22.6	-3.4	0.000732	0.0417	-0.24	-0.15	Obesity (extreme);	chr10:37869332	chr10:38451030~38451785:+
THCA	cis	rs3020736	0.5	rs4147638	ENSG00000270083.1	RP1-257I20.14	-3.4	0.000732	0.0417	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42089630~42090028:-
THCA	cis	rs34779708	0.931	rs2148482	ENSG00000233200.1	RP11-324I22.2	3.4	0.000732	0.0417	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35219894~35230598:-
THCA	cis	rs3176789	0.914	rs724667	ENSG00000256673.1	RP11-599J14.2	3.4	0.000732	0.0417	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9770255	chr12:9398355~9414851:-
THCA	cis	rs4578769	0.802	rs66816194	ENSG00000265939.1	UBE2CP2	-3.4	0.000732	0.0417	-0.2	-0.15	Eosinophil percentage of white cells;	chr18:22895554	chr18:22900486~22900995:-
THCA	cis	rs6142618	0.562	rs6142616	ENSG00000224452.1	RSL24D1P6	3.4	0.000732	0.0417	0.18	0.15	Inflammatory bowel disease;	chr20:32126625	chr20:32170390~32170790:-
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000264242.2	RP11-271K11.1	3.4	0.000732	0.0417	0.25	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30553697~30558962:+
THCA	cis	rs3026101	0.647	rs4790263	ENSG00000234327.6	AC012146.7	-3.4	0.000732	0.0417	-0.13	-0.15	Body mass index;	chr17:5403764	chr17:5111468~5115004:+
THCA	cis	rs12893668	0.572	rs4900590	ENSG00000258735.1	LINC00637	-3.4	0.000732	0.0417	-0.2	-0.15	Reticulocyte count;	chr14:103680084	chr14:103847721~103858049:+
THCA	cis	rs786425	0.801	rs12813346	ENSG00000278112.1	RP11-972P1.11	3.4	0.000732	0.0417	0.15	0.15	Pubertal anthropometrics;	chr12:123716567	chr12:123519390~123519856:-
THCA	cis	rs9902453	0.74	rs2254414	ENSG00000214719.10	AC005562.1	-3.4	0.000732	0.0417	-0.14	-0.15	Coffee consumption (cups per day);	chr17:29734112	chr17:30576464~30672789:+
THCA	cis	rs881375	0.933	rs2239657	ENSG00000270917.1	RP11-27I1.6	3.4	0.000732	0.0417	0.21	0.15	Rheumatoid arthritis;	chr9:120909242	chr9:120812475~120812845:-
THCA	cis	rs684232	0.602	rs2160955	ENSG00000231784.7	DBIL5P	3.4	0.000732	0.0417	0.17	0.15	Prostate cancer;	chr17:657364	chr17:752660~755336:+
THCA	cis	rs7631605	0.967	rs9859086	ENSG00000272334.1	RP11-129K12.1	-3.4	0.000732	0.0417	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:37104700	chr3:36973117~36973672:-
THCA	cis	rs11158198	0.539	rs11626581	ENSG00000279636.2	LINC00216	-3.4	0.000732	0.0417	-0.15	-0.15	Dementia and core Alzheimer's disease neuropathologic changes;	chr14:58137816	chr14:58288033~58289158:+
THCA	cis	rs1552244	0.554	rs9878047	ENSG00000269982.1	RP11-1020A11.2	3.4	0.000732	0.0417	0.11	0.15	Alzheimer's disease;	chr3:9943773	chr3:9958717~9962539:+
THCA	cis	rs6580649	1	rs7305954	ENSG00000273765.1	RP11-370I10.11	3.4	0.000732	0.0417	0.17	0.15	Lung cancer;	chr12:48009747	chr12:48360920~48361377:+
THCA	cis	rs3733585	0.781	rs13103879	ENSG00000261490.1	RP11-448G15.3	-3.4	0.000732	0.0417	-0.1	-0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:9971255	chr4:10068089~10073019:-
THCA	cis	rs758324	0.628	rs61527852	ENSG00000224431.1	AC063976.7	-3.4	0.000732	0.0417	-0.22	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132132376	chr5:132199456~132203487:+
THCA	cis	rs758324	0.628	rs73257828	ENSG00000224431.1	AC063976.7	-3.4	0.000732	0.0417	-0.22	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132136167	chr5:132199456~132203487:+
THCA	cis	rs7819412	0.749	rs11991118	ENSG00000254839.1	AF131215.6	-3.4	0.000732	0.0417	-0.16	-0.15	Triglycerides;	chr8:11081763	chr8:11062647~11067089:-
THCA	cis	rs17181170	0.846	rs1844097	ENSG00000239572.1	RP11-451B8.1	3.4	0.000732	0.0417	0.18	0.15	Prostate cancer;	chr3:87151485	chr3:87731402~87793629:-
THCA	cis	rs860295	0.702	rs2175391	ENSG00000236675.1	MTX1P1	3.4	0.000733	0.0417	0.16	0.15	Body mass index;	chr1:155655811	chr1:155230975~155234325:+
THCA	cis	rs701145	0.585	rs959376	ENSG00000240068.1	RPL21P42	3.4	0.000733	0.0417	0.31	0.15	Coronary artery disease;	chr3:154148918	chr3:154023835~154024298:+
THCA	cis	rs7147624	1	rs7147624	ENSG00000276116.2	FUT8-AS1	-3.4	0.000733	0.0417	-0.22	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr14:65398907	chr14:65411170~65412690:-
THCA	cis	rs2880765	0.743	rs8039049	ENSG00000259407.1	RP11-158M2.3	-3.4	0.000733	0.0417	-0.16	-0.15	Coronary artery disease;	chr15:85464398	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.743	rs8039631	ENSG00000259407.1	RP11-158M2.3	-3.4	0.000733	0.0417	-0.16	-0.15	Coronary artery disease;	chr15:85464700	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.743	rs12906308	ENSG00000259407.1	RP11-158M2.3	3.4	0.000733	0.0417	0.16	0.15	Coronary artery disease;	chr15:85464828	chr15:85744109~85750281:-
THCA	cis	rs17604090	0.55	rs111649163	ENSG00000223813.2	AC007255.8	3.4	0.000733	0.0418	0.15	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649560	chr7:29514225~29563670:-
THCA	cis	rs80130819	0.688	rs1387256	ENSG00000226413.2	OR8T1P	3.4	0.000733	0.0418	0.23	0.15	Prostate cancer;	chr12:48249955	chr12:48442030~48442947:-
THCA	cis	rs3785309	0.519	rs111794747	ENSG00000268836.1	LA16c-OS12.2	-3.4	0.000733	0.0418	-0.27	-0.15	Immature fraction of reticulocytes;	chr16:227007	chr16:185748~186294:-
THCA	cis	rs3785309	0.519	rs72765805	ENSG00000268836.1	LA16c-OS12.2	-3.4	0.000733	0.0418	-0.27	-0.15	Immature fraction of reticulocytes;	chr16:227065	chr16:185748~186294:-
THCA	cis	rs10043228	0.702	rs6866938	ENSG00000250015.1	CTC-339F2.2	3.4	0.000733	0.0418	0.19	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116292420	chr5:116302354~116304134:-
THCA	cis	rs9368481	0.761	rs7775041	ENSG00000228223.2	HCG11	3.4	0.000733	0.0418	0.17	0.15	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26523450~26526579:+
THCA	cis	rs11800820	0.567	rs7527607	ENSG00000231612.1	RP11-522M21.3	-3.4	0.000733	0.0418	-0.21	-0.15	Obesity-related traits;	chr1:246544863	chr1:245673732~245676478:-
THCA	cis	rs7241918	0.832	rs1943973	ENSG00000267444.1	SMUG1P1	3.4	0.000733	0.0418	0.21	0.15	Cholesterol, total;HDL cholesterol;	chr18:49653146	chr18:49650350~49651160:+
THCA	cis	rs1927790	0.727	rs1925122	ENSG00000247400.3	DNAJC3-AS1	-3.4	0.000733	0.0418	-0.11	-0.15	Body mass index;	chr13:96285919	chr13:95648733~95676925:-
THCA	cis	rs7819412	0.522	rs4642600	ENSG00000261451.1	RP11-981G7.1	-3.4	0.000733	0.0418	-0.21	-0.15	Triglycerides;	chr8:11155515	chr8:10433672~10438312:+
THCA	cis	rs3114020	1	rs2622609	ENSG00000246375.2	RP11-10L7.1	-3.4	0.000733	0.0418	-0.21	-0.15	Gout;	chr4:88167323	chr4:88284942~88331421:+
THCA	cis	rs12476592	0.602	rs11125977	ENSG00000242412.1	DBIL5P2	-3.4	0.000733	0.0418	-0.2	-0.15	Childhood ear infection;	chr2:63582415	chr2:63117851~63119542:-
THCA	cis	rs1057510	0.929	rs10849492	ENSG00000269892.1	RP4-761J14.10	-3.4	0.000733	0.0418	-0.15	-0.15	Myopia (pathological);	chr12:6611629	chr12:6742985~6743641:+
THCA	cis	rs643506	1	rs1788955	ENSG00000230911.1	PPIHP1	-3.4	0.000733	0.0418	-0.22	-0.15	Breast cancer;	chr11:111760274	chr11:112029858~112030367:-
THCA	cis	rs11673344	0.523	rs8108509	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000733	0.0418	-0.19	-0.15	Obesity-related traits;	chr19:37060370	chr19:36773153~36777078:+
THCA	cis	rs7712401	0.791	rs154507	ENSG00000263432.2	RN7SL689P	-3.4	0.000733	0.0418	-0.16	-0.15	Mean platelet volume;	chr5:122865212	chr5:123022487~123022783:-
THCA	cis	rs9922134	1	rs6565125	ENSG00000260932.1	RP11-483P21.6	-3.4	0.000733	0.0418	-0.31	-0.15	Maximal oxygen uptake response;	chr16:83106600	chr16:83929796~83931223:-
THCA	cis	rs17286411	0.669	rs4788817	ENSG00000260185.1	RP11-432I5.6	-3.4	0.000733	0.0418	-0.2	-0.15	Blood protein levels;	chr16:71607492	chr16:71655027~71664212:+
THCA	cis	rs748404	0.556	rs10851414	ENSG00000205771.5	CATSPER2P1	3.4	0.000733	0.0418	0.16	0.15	Lung cancer;	chr15:43141734	chr15:43726918~43747094:-
THCA	cis	rs2832191	0.791	rs2832181	ENSG00000176054.6	RPL23P2	-3.4	0.000733	0.0418	-0.13	-0.15	Dental caries;	chr21:29109050	chr21:28997613~28998033:-
THCA	cis	rs4566357	0.576	rs6750845	ENSG00000212391.1	SNORA48	-3.4	0.000733	0.0418	-0.17	-0.15	Coronary artery disease;	chr2:227046321	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.557	rs6707158	ENSG00000212391.1	SNORA48	-3.4	0.000733	0.0418	-0.17	-0.15	Coronary artery disease;	chr2:227046553	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.595	rs6707286	ENSG00000212391.1	SNORA48	-3.4	0.000733	0.0418	-0.17	-0.15	Coronary artery disease;	chr2:227046684	chr2:226968989~226969122:-
THCA	cis	rs17407555	0.683	rs7676442	ENSG00000250413.1	RP11-448G15.1	-3.4	0.000733	0.0418	-0.17	-0.15	Schizophrenia (age at onset);	chr4:10270967	chr4:10006482~10009725:+
THCA	cis	rs987724	0.519	rs1875622	ENSG00000241544.1	RP11-6F2.5	-3.4	0.000733	0.0418	-0.19	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901217	chr3:157081841~157088547:+
THCA	cis	rs911555	0.557	rs8022179	ENSG00000269958.1	RP11-73M18.8	3.4	0.000733	0.0418	0.15	0.15	Intelligence (multi-trait analysis);	chr14:103380950	chr14:103696353~103697163:+
THCA	cis	rs656319	0.629	rs10111315	ENSG00000248538.5	RP11-10A14.5	3.4	0.000733	0.0418	0.2	0.15	Myopia (pathological);	chr8:10008078	chr8:9189011~9202854:+
THCA	cis	rs2223471	0.87	rs2744494	ENSG00000060303.5	RPS17P5	-3.4	0.000733	0.0418	-0.19	-0.15	Subcutaneous adipose tissue;	chr6:50789977	chr6:50857255~50857662:-
THCA	cis	rs6120849	0.617	rs12480442	ENSG00000269202.1	RP4-614O4.12	-3.4	0.000733	0.0418	-0.17	-0.15	Protein C levels;	chr20:35060585	chr20:35201747~35203288:-
THCA	cis	rs17428076	0.756	rs62181743	ENSG00000228389.1	AC068039.4	-3.4	0.000733	0.0418	-0.22	-0.15	Myopia;	chr2:171695491	chr2:171773482~171775844:+
THCA	cis	rs6487679	0.614	rs6487668	ENSG00000256069.6	A2MP1	3.4	0.000734	0.0418	0.21	0.15	Non-alcoholic fatty liver disease histology (AST);	chr12:9200312	chr12:9228533~9275817:-
THCA	cis	rs4815191	0.887	rs6076046	ENSG00000230387.2	RP4-737E23.2	-3.4	0.000734	0.0418	-0.21	-0.15	Obesity-related traits;	chr20:23287107	chr20:23187961~23190307:+
THCA	cis	rs13063635	0.764	rs4683166	ENSG00000226074.4	PRSS44	3.4	0.000734	0.0418	0.26	0.15	Eosinophil percentage of granulocytes;	chr3:46047849	chr3:46809359~46812558:-
THCA	cis	rs4883201	0.536	rs1121401	ENSG00000245105.2	A2M-AS1	3.4	0.000734	0.0418	0.15	0.15	Total cholesterol levels;Cholesterol, total;	chr12:8984026	chr12:9065177~9068060:+
THCA	cis	rs1125355	0.622	rs62183665	ENSG00000243792.1	OR7E89P	-3.4	0.000734	0.0418	-0.24	-0.15	Alzheimer's disease in APOE e4+ carriers;	chr2:158789863	chr2:158853755~158854576:+
THCA	cis	rs12122100	0.526	rs12122534	ENSG00000271721.1	RP11-337C18.9	3.4	0.000734	0.0418	0.15	0.15	HIV-1 control;	chr1:147032846	chr1:147175602~147177740:+
THCA	cis	rs4883201	0.611	rs1805727	ENSG00000245105.2	A2M-AS1	-3.4	0.000734	0.0418	-0.15	-0.15	Total cholesterol levels;Cholesterol, total;	chr12:8944802	chr12:9065177~9068060:+
THCA	cis	rs2991971	0.903	rs2991973	ENSG00000234329.1	RP11-767N6.2	-3.4	0.000734	0.0418	-0.15	-0.15	High light scatter reticulocyte count;	chr1:45554960	chr1:45651039~45651826:-
THCA	cis	rs758324	0.628	rs2405266	ENSG00000224431.1	AC063976.7	-3.4	0.000734	0.0418	-0.23	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132131038	chr5:132199456~132203487:+
THCA	cis	rs758324	0.628	rs13358835	ENSG00000224431.1	AC063976.7	-3.4	0.000734	0.0418	-0.23	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132138477	chr5:132199456~132203487:+
THCA	cis	rs237743	1	rs238200	ENSG00000222365.1	SNORD12B	-3.4	0.000734	0.0418	-0.19	-0.15	Height;	chr20:49283115	chr20:49280319~49280409:+
THCA	cis	rs2252521	0.524	rs317744	ENSG00000228421.2	AC005013.5	3.4	0.000734	0.0418	0.2	0.15	Cognitive performance;	chr7:29027677	chr7:28957667~28959345:+
THCA	cis	rs2252521	0.524	rs317745	ENSG00000228421.2	AC005013.5	3.4	0.000734	0.0418	0.2	0.15	Cognitive performance;	chr7:29028498	chr7:28957667~28959345:+
THCA	cis	rs2252521	0.524	rs2074782	ENSG00000228421.2	AC005013.5	3.4	0.000734	0.0418	0.2	0.15	Cognitive performance;	chr7:29031037	chr7:28957667~28959345:+
THCA	cis	rs12546962	0.92	rs12548931	ENSG00000254153.1	CTA-398F10.2	-3.4	0.000734	0.0418	-0.18	-0.15	Body mass index;	chr8:9343181	chr8:8456909~8461337:-
THCA	cis	rs76076331	0.838	rs55748262	ENSG00000271952.1	RP11-245G13.2	-3.4	0.000734	0.0418	-0.24	-0.15	Educational attainment (college completion);Educational attainment (years of education);	chr2:10842509	chr2:10878269~10885118:+
THCA	cis	rs3764618	1	rs2287754	ENSG00000269420.4	CTD-2265M8.2	3.4	0.000734	0.0418	0.33	0.15	Follicule stimulating hormone;	chr19:48993237	chr19:48061371~48064945:+
THCA	cis	rs9902453	0.619	rs2244585	ENSG00000263370.1	RP11-68I3.5	-3.4	0.000734	0.0418	-0.2	-0.15	Coffee consumption (cups per day);	chr17:29745158	chr17:29639627~29640825:+
THCA	cis	rs9902453	0.619	rs2617866	ENSG00000263370.1	RP11-68I3.5	-3.4	0.000734	0.0418	-0.2	-0.15	Coffee consumption (cups per day);	chr17:29749199	chr17:29639627~29640825:+
THCA	cis	rs758747	0.574	rs12933120	ENSG00000276754.1	RP11-461A8.5	3.4	0.000734	0.0418	0.19	0.15	Body mass index;	chr16:3584745	chr16:3686998~3687380:+
THCA	cis	rs875971	0.862	rs709596	ENSG00000223473.2	GS1-124K5.3	3.4	0.000734	0.0418	0.1	0.15	Aortic root size;	chr7:66360926	chr7:66491049~66493566:-
THCA	cis	rs10875976	0.525	rs4898537	ENSG00000257588.1	RP11-469H8.6	3.4	0.000734	0.0418	0.16	0.15	Obesity;	chr12:49849559	chr12:49951512~49962924:-
THCA	cis	rs7824557	0.569	rs2409718	ENSG00000254948.1	OR7E158P	3.4	0.000734	0.0418	0.19	0.15	Retinal vascular caliber;	chr8:11155467	chr8:11919900~11920809:-
THCA	cis	rs10863936	0.667	rs12076757	ENSG00000198468.6	FLVCR1-AS1	3.4	0.000734	0.0418	0.18	0.15	Height;	chr1:212076009	chr1:212852108~212858088:-
THCA	cis	rs2839186	0.869	rs17176513	ENSG00000228137.1	AP001469.7	3.4	0.000734	0.0418	0.15	0.15	Testicular germ cell tumor;	chr21:46262514	chr21:46246890~46247682:+
THCA	cis	rs10043228	0.702	rs10519454	ENSG00000250015.1	CTC-339F2.2	3.4	0.000734	0.0418	0.19	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116304165	chr5:116302354~116304134:-
THCA	cis	rs2179367	0.632	rs2143075	ENSG00000216906.2	RP11-350J20.9	3.4	0.000734	0.0418	0.2	0.15	Dupuytren's disease;	chr6:149425507	chr6:149904243~149906418:+
THCA	cis	rs7818688	0.697	rs75349998	ENSG00000253528.2	RP11-347C18.4	-3.4	0.000734	0.0418	-0.24	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94978690	chr8:94974573~94974853:-
THCA	cis	rs3753275	0.564	rs6676113	ENSG00000230679.1	ENO1-AS1	3.4	0.000735	0.0418	0.15	0.15	Educational attainment;	chr1:8850485	chr1:8878835~8879894:+
THCA	cis	rs804280	1	rs804280	ENSG00000270154.1	RP11-419I17.1	3.4	0.000735	0.0418	0.19	0.15	Myopia (pathological);	chr8:11755189	chr8:12476462~12477122:+
THCA	cis	rs11681884	0.786	rs34200521	ENSG00000272563.1	RP11-480C16.1	-3.4	0.000735	0.0418	-0.34	-0.15	Stroke;	chr2:113033301	chr2:113432600~113436042:+
THCA	cis	rs34421088	0.531	rs2245232	ENSG00000251402.3	FAM90A25P	-3.4	0.000735	0.0418	-0.2	-0.15	Neuroticism;	chr8:11543435	chr8:12415080~12418090:-
THCA	cis	rs113296370	0.635	rs62138787	ENSG00000226972.2	AC013717.3	-3.4	0.000735	0.0418	-0.21	-0.15	Diabetes in response to antihypertensive drug treatment (treatment strategy interaction);	chr2:43659959	chr2:44270621~44271106:+
THCA	cis	rs9876781	0.933	rs6442124	ENSG00000199476.1	Y_RNA	-3.4	0.000735	0.0418	-0.2	-0.15	Longevity;	chr3:48463903	chr3:48288587~48288694:+
THCA	cis	rs11637445	0.603	rs7183168	ENSG00000260657.2	RP11-315D16.4	-3.4	0.000735	0.0418	-0.2	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr15:67829145	chr15:68267792~68277994:-
THCA	cis	rs7487075	0.619	rs10748450	ENSG00000274723.1	RP11-618L22.1	3.4	0.000735	0.0419	0.15	0.15	Itch intensity from mosquito bite;	chr12:46463319	chr12:46970504~46972155:+
THCA	cis	rs11673344	0.504	rs4806408	ENSG00000267260.1	CTD-2162K18.4	-3.4	0.000735	0.0419	-0.18	-0.15	Obesity-related traits;	chr19:37097875	chr19:36773153~36777078:+
THCA	cis	rs3764021	0.527	rs11052604	ENSG00000257027.1	RP11-705C15.3	3.4	0.000735	0.0419	0.13	0.15	Type 1 diabetes;	chr12:9709952	chr12:9658567~9662085:+
THCA	cis	rs7122539	0.603	rs508443	ENSG00000275484.1	CTC-1337H24.4	3.4	0.000735	0.0419	0.11	0.15	HIV-1 susceptibility;	chr11:66741898	chr11:67374416~67374932:+
THCA	cis	rs786425	1	rs786425	ENSG00000278112.1	RP11-972P1.11	-3.4	0.000735	0.0419	-0.15	-0.15	Pubertal anthropometrics;	chr12:123600955	chr12:123519390~123519856:-
THCA	cis	rs786425	0.682	rs1139320	ENSG00000278112.1	RP11-972P1.11	3.4	0.000735	0.0419	0.15	0.15	Pubertal anthropometrics;	chr12:123712552	chr12:123519390~123519856:-
THCA	cis	rs860295	0.58	rs6672284	ENSG00000236675.1	MTX1P1	-3.4	0.000735	0.0419	-0.16	-0.15	Body mass index;	chr1:155308172	chr1:155230975~155234325:+
THCA	cis	rs2251188	0.632	rs940874	ENSG00000198580.7	RP11-611L7.2	-3.4	0.000735	0.0419	-0.17	-0.15	Sum basophil neutrophil counts;Neutrophil count;	chr7:6656703	chr7:6673494~6676366:+
THCA	cis	rs2239557	0.508	rs12587320	ENSG00000259065.1	RP5-1021I20.1	3.4	0.000735	0.0419	0.23	0.15	Common traits (Other);	chr14:73901591	chr14:73787360~73803270:+
THCA	cis	rs9291683	0.679	rs3756225	ENSG00000250413.1	RP11-448G15.1	3.4	0.000735	0.0419	0.15	0.15	Bone mineral density;	chr4:10092509	chr4:10006482~10009725:+
THCA	cis	rs9291683	0.655	rs3822242	ENSG00000250413.1	RP11-448G15.1	3.4	0.000735	0.0419	0.15	0.15	Bone mineral density;	chr4:10093280	chr4:10006482~10009725:+
THCA	cis	rs4081724	0.565	rs12150908	ENSG00000267130.1	CTD-2540B15.9	3.4	0.000735	0.0419	0.24	0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33317239	chr19:33305036~33309387:+
THCA	cis	rs1062177	0.901	rs1549622	ENSG00000272112.1	CTB-113P19.5	3.4	0.000735	0.0419	0.14	0.15	Preschool internalizing problems;	chr5:151886488	chr5:151724831~151725356:-
THCA	cis	rs6738627	0.895	rs10179126	ENSG00000223318.1	RNA5SP111	3.4	0.000735	0.0419	0.19	0.15	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164655284	chr2:164895677~164895777:-
THCA	cis	rs7394190	0.688	rs3812629	ENSG00000272599.2	RP11-152N13.16	3.4	0.000735	0.0419	0.2	0.15	Incident atrial fibrillation;	chr10:73647532	chr10:73124573~73125532:-
THCA	cis	rs4919087	0.59	rs1253396	ENSG00000237169.1	RP11-452K12.3	3.4	0.000735	0.0419	0.21	0.15	Monocyte count;	chr10:97285473	chr10:97309138~97309958:-
THCA	cis	rs4919087	0.59	rs1253401	ENSG00000237169.1	RP11-452K12.3	3.4	0.000735	0.0419	0.21	0.15	Monocyte count;	chr10:97290513	chr10:97309138~97309958:-
THCA	cis	rs2823053	0.865	rs2823044	ENSG00000232884.6	AF127936.3	-3.4	0.000735	0.0419	-0.16	-0.15	Allergic rhinitis in non-asthmatics;	chr21:15088088	chr21:14746762~14753863:-
THCA	cis	rs7926906	1	rs10741374	ENSG00000280367.1	RP11-121L10.2	3.4	0.000735	0.0419	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90788581	chr11:90223153~90226538:+
THCA	cis	rs7926906	1	rs10741375	ENSG00000280367.1	RP11-121L10.2	3.4	0.000735	0.0419	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90788632	chr11:90223153~90226538:+
THCA	cis	rs4262150	0.81	rs17566118	ENSG00000253921.1	CTB-113P19.3	3.4	0.000735	0.0419	0.2	0.15	Bipolar disorder and schizophrenia;	chr5:152708986	chr5:151753992~151767247:+
THCA	cis	rs4788570	0.667	rs4788557	ENSG00000260185.1	RP11-432I5.6	-3.4	0.000735	0.0419	-0.3	-0.15	Intelligence (multi-trait analysis);	chr16:71770899	chr16:71655027~71664212:+
THCA	cis	rs4788570	0.697	rs9635524	ENSG00000260185.1	RP11-432I5.6	-3.4	0.000735	0.0419	-0.3	-0.15	Intelligence (multi-trait analysis);	chr16:71771053	chr16:71655027~71664212:+
THCA	cis	rs4948275	0.693	rs2253375	ENSG00000233643.2	RP11-491H19.1	3.4	0.000735	0.0419	0.18	0.15	Night sleep phenotypes;	chr10:61565735	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.693	rs2650739	ENSG00000233643.2	RP11-491H19.1	3.4	0.000735	0.0419	0.18	0.15	Night sleep phenotypes;	chr10:61567679	chr10:61781745~61821246:-
THCA	cis	rs7487075	0.578	rs4768119	ENSG00000275481.1	RP11-474P2.6	3.4	0.000735	0.0419	0.16	0.15	Itch intensity from mosquito bite;	chr12:46414119	chr12:46388856~46392126:+
THCA	cis	rs7487075	0.578	rs4258438	ENSG00000275481.1	RP11-474P2.6	3.4	0.000735	0.0419	0.16	0.15	Itch intensity from mosquito bite;	chr12:46415343	chr12:46388856~46392126:+
THCA	cis	rs8040855	0.579	rs4843029	ENSG00000259630.2	CTD-2262B20.1	3.4	0.000735	0.0419	0.17	0.15	Bulimia nervosa;	chr15:85182164	chr15:85415228~85415633:+
THCA	cis	rs8040855	0.599	rs6496792	ENSG00000259630.2	CTD-2262B20.1	3.4	0.000735	0.0419	0.17	0.15	Bulimia nervosa;	chr15:85182514	chr15:85415228~85415633:+
THCA	cis	rs8040855	0.599	rs6496793	ENSG00000259630.2	CTD-2262B20.1	3.4	0.000735	0.0419	0.17	0.15	Bulimia nervosa;	chr15:85182515	chr15:85415228~85415633:+
THCA	cis	rs8040855	0.599	rs6496795	ENSG00000259630.2	CTD-2262B20.1	3.4	0.000735	0.0419	0.17	0.15	Bulimia nervosa;	chr15:85182622	chr15:85415228~85415633:+
THCA	cis	rs10911902	0.643	rs3766703	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000735	0.0419	-0.24	-0.15	Schizophrenia;	chr1:186346575	chr1:186580515~186581191:-
THCA	cis	rs7200786	0.692	rs7206912	ENSG00000274038.1	RP11-66H6.4	-3.4	0.000735	0.0419	-0.19	-0.15	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11150801	chr16:11056556~11057034:+
THCA	cis	rs2243480	1	rs313807	ENSG00000237310.1	GS1-124K5.4	3.4	0.000735	0.0419	0.18	0.15	Diabetic kidney disease;	chr7:66034494	chr7:66493706~66495474:+
THCA	cis	rs14027	0.921	rs6469852	ENSG00000245330.4	KB-1471A8.1	-3.4	0.000736	0.0419	-0.16	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119867419~119874488:-
THCA	cis	rs481331	0.689	rs644175	ENSG00000272319.1	AL022345.7	3.4	0.000736	0.0419	0.27	0.15	Systemic juvenile idiopathic arthritis;	chr10:42703860	chr10:42579724~42582772:+
THCA	cis	rs972578	0.967	rs2038059	ENSG00000230319.1	AL022476.2	3.4	0.000736	0.0419	0.17	0.15	Mean platelet volume;	chr22:42938392	chr22:43038585~43052366:+
THCA	cis	rs12216545	0.662	rs9691288	ENSG00000241134.3	BET1P1	-3.4	0.000736	0.0419	-0.22	-0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150521660	chr7:150749736~150750094:+
THCA	cis	rs72843506	0.656	rs79773274	ENSG00000189423.10	USP32P3	3.4	0.000736	0.0419	0.26	0.15	Schizophrenia;	chr17:20002618	chr17:20415547~20431008:+
THCA	cis	rs7193541	1	rs7193541	ENSG00000262904.1	TMPOP2	3.4	0.000736	0.0419	0.18	0.15	Multiple myeloma;	chr16:74630845	chr16:74667506~74668706:+
THCA	cis	rs181553	0.664	rs11874831	ENSG00000266696.1	RP11-30L3.2	3.4	0.000736	0.0419	0.19	0.15	Hip circumference adjusted for BMI;	chr18:49176221	chr18:49205912~49208781:+
THCA	cis	rs6687821	0.531	rs4518960	ENSG00000261737.1	RP4-612B15.3	3.4	0.000736	0.0419	0.24	0.15	Yeast infection;	chr1:87048746	chr1:86703502~86704462:-
THCA	cis	rs12410462	1	rs75637482	ENSG00000227711.2	RP11-275O4.5	-3.4	0.000736	0.0419	-0.23	-0.15	Major depressive disorder;	chr1:227435243	chr1:227509028~227520477:-
THCA	cis	rs6517329	0.932	rs4817775	ENSG00000230212.5	AP000688.14	-3.4	0.000736	0.0419	-0.19	-0.15	Schizophrenia;	chr21:36112764	chr21:36069642~36126640:-
THCA	cis	rs208520	1	rs12209225	ENSG00000233859.2	ADH5P4	3.4	0.000736	0.0419	0.25	0.15	Exhaled nitric oxide output;	chr6:66286550	chr6:65836930~65838039:-
THCA	cis	rs2486012	1	rs2906467	ENSG00000237950.1	RP11-7O11.3	3.4	0.000736	0.0419	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43854804	chr1:43944370~43946551:-
THCA	cis	rs4713118	0.824	rs9468225	ENSG00000261839.1	RP1-265C24.8	3.4	0.000736	0.0419	0.18	0.15	Parkinson's disease;	chr6:27777940	chr6:28136849~28139678:+
THCA	cis	rs11175194	0.744	rs57082798	ENSG00000255850.1	TMEM5-AS1	3.4	0.000736	0.0419	0.37	0.15	Epithelial ovarian cancer;	chr12:63837625	chr12:63808845~63822156:-
THCA	cis	rs56309584	0.596	rs11649742	ENSG00000271002.1	RP11-599B13.8	-3.4	0.000736	0.0419	-0.24	-0.15	Initial pursuit acceleration;	chr17:8273097	chr17:8199123~8199437:-
THCA	cis	rs1765142	0.55	rs529056	ENSG00000242353.1	RP4-710M3.1	3.4	0.000736	0.0419	0.13	0.15	Schizophrenia;	chr11:30401636	chr11:30368148~30368646:+
THCA	cis	rs975752	0.867	rs73337997	ENSG00000227492.1	RP11-316M21.6	3.4	0.000736	0.0419	0.3	0.15	Schizophrenia;	chr10:100213503	chr10:100229667~100234000:+
THCA	cis	rs61160187	0.65	rs1444237	ENSG00000272308.1	RP11-231G3.1	3.4	0.000736	0.0419	0.15	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60768126	chr5:60866457~60866935:-
THCA	cis	rs2692947	0.567	rs4907276	ENSG00000236750.1	AC009237.16	3.4	0.000736	0.0419	0.17	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95725361	chr2:95641634~95641980:-
THCA	cis	rs57590327	0.503	rs9852235	ENSG00000241593.4	RP11-520D19.2	3.4	0.000736	0.0419	0.19	0.15	Extraversion;	chr3:81459204	chr3:81246579~81297345:-
THCA	cis	rs6499640	0.664	rs8048396	ENSG00000275191.1	RP11-36I17.2	3.4	0.000736	0.0419	0.2	0.15	Body mass index;Weight;	chr16:53736837	chr16:53628256~53628816:-
THCA	cis	rs964611	0.882	rs12442530	ENSG00000259488.2	RP11-154J22.1	-3.4	0.000736	0.0419	-0.14	-0.15	Metabolite levels (Pyroglutamine);	chr15:48288376	chr15:48312353~48331856:-
THCA	cis	rs7129556	0.737	rs72949616	ENSG00000254985.1	RSF1-IT2	-3.4	0.000736	0.0419	-0.25	-0.15	Weight loss (gastric bypass surgery);	chr11:77753325	chr11:77717712~77718411:-
THCA	cis	rs7129556	0.737	rs72949618	ENSG00000254985.1	RSF1-IT2	-3.4	0.000736	0.0419	-0.25	-0.15	Weight loss (gastric bypass surgery);	chr11:77753485	chr11:77717712~77718411:-
THCA	cis	rs7129556	0.737	rs56218634	ENSG00000254985.1	RSF1-IT2	-3.4	0.000736	0.0419	-0.25	-0.15	Weight loss (gastric bypass surgery);	chr11:77753789	chr11:77717712~77718411:-
THCA	cis	rs4773860	0.601	rs4148447	ENSG00000223298.1	RNY3P8	-3.4	0.000736	0.0419	-0.17	-0.15	Plateletcrit;	chr13:95245005	chr13:95310830~95310955:-
THCA	cis	rs911186	0.73	rs2393911	ENSG00000220721.1	OR1F12	3.4	0.000737	0.0419	0.2	0.15	Autism spectrum disorder or schizophrenia;	chr6:27089300	chr6:28073316~28074233:+
THCA	cis	rs9425766	0.888	rs1799876	ENSG00000270084.1	GAS5-AS1	-3.4	0.000737	0.0419	-0.16	-0.15	Life satisfaction;	chr1:173909333	chr1:173863248~173863941:+
THCA	cis	rs11098499	0.739	rs10031033	ENSG00000250950.1	RP11-33B1.3	-3.4	0.000737	0.0419	-0.18	-0.15	Corneal astigmatism;	chr4:119230297	chr4:119456350~119457277:+
THCA	cis	rs17221829	0.521	rs7952498	ENSG00000280385.1	AP000648.5	-3.4	0.000737	0.0419	-0.15	-0.15	Anxiety in major depressive disorder;	chr11:89588897	chr11:90193614~90198120:+
THCA	cis	rs17221829	0.502	rs6483018	ENSG00000280385.1	AP000648.5	-3.4	0.000737	0.0419	-0.15	-0.15	Anxiety in major depressive disorder;	chr11:89590114	chr11:90193614~90198120:+
THCA	cis	rs6142618	0.562	rs2235900	ENSG00000224452.1	RSL24D1P6	3.4	0.000737	0.0419	0.18	0.15	Inflammatory bowel disease;	chr20:32131775	chr20:32170390~32170790:-
THCA	cis	rs11048434	0.736	rs2377673	ENSG00000245105.2	A2M-AS1	3.4	0.000737	0.0419	0.12	0.15	Sjögren's syndrome;	chr12:8959955	chr12:9065177~9068060:+
THCA	cis	rs763121	0.752	rs6001190	ENSG00000272669.1	RP3-508I15.21	-3.4	0.000737	0.0419	-0.11	-0.15	Menopause (age at onset);	chr22:38677806	chr22:38742625~38743115:+
THCA	cis	rs9309473	0.95	rs6740766	ENSG00000273245.1	RP11-434P11.2	3.4	0.000737	0.0419	0.22	0.15	Metabolite levels;	chr2:73553786	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs13431267	ENSG00000273245.1	RP11-434P11.2	3.4	0.000737	0.0419	0.22	0.15	Metabolite levels;	chr2:73555073	chr2:73750256~73750786:-
THCA	cis	rs9309473	1	rs10207220	ENSG00000273245.1	RP11-434P11.2	3.4	0.000737	0.0419	0.22	0.15	Metabolite levels;	chr2:73557919	chr2:73750256~73750786:-
THCA	cis	rs9309473	0.95	rs6735946	ENSG00000273245.1	RP11-434P11.2	3.4	0.000737	0.0419	0.22	0.15	Metabolite levels;	chr2:73562931	chr2:73750256~73750786:-
THCA	cis	rs12188164	0.93	rs11743825	ENSG00000188242.4	PP7080	3.4	0.000737	0.0419	0.15	0.15	Cystic fibrosis severity;	chr5:475348	chr5:466124~473098:-
THCA	cis	rs6840360	0.593	rs2175409	ENSG00000251603.1	RP11-164P12.4	3.4	0.000737	0.0419	0.1	0.15	Intelligence (multi-trait analysis);	chr4:151780504	chr4:151667224~151670502:+
THCA	cis	rs7236492	0.872	rs74949301	ENSG00000267655.1	CTD-2286N8.2	3.4	0.000737	0.0419	0.35	0.15	Inflammatory bowel disease;Crohn's disease;	chr18:79469409	chr18:79117207~79117920:+
THCA	cis	rs6545883	0.931	rs11125885	ENSG00000212978.6	AC016747.3	3.4	0.000737	0.042	0.17	0.15	Tuberculosis;	chr2:61528593	chr2:61141592~61144969:-
THCA	cis	rs6545883	0.965	rs9989775	ENSG00000212978.6	AC016747.3	3.4	0.000737	0.042	0.17	0.15	Tuberculosis;	chr2:61534639	chr2:61141592~61144969:-
THCA	cis	rs2736345	0.788	rs998683	ENSG00000269899.1	RP11-589N15.2	3.4	0.000737	0.042	0.19	0.15	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:11846154~11846391:-
THCA	cis	rs73191547	0.771	rs11787363	ENSG00000248538.5	RP11-10A14.5	-3.4	0.000737	0.042	-0.19	-0.15	Schizophrenia;	chr8:10185845	chr8:9189011~9202854:+
THCA	cis	rs7633075	0.614	rs7648999	ENSG00000228956.7	SATB1-AS1	-3.4	0.000737	0.042	-0.22	-0.15	Symmetrical dimethylarginine levels;	chr3:18537310	chr3:18445024~18920401:+
THCA	cis	rs2361710	0.668	rs4889830	ENSG00000275479.1	RP11-334C17.6	3.4	0.000737	0.042	0.12	0.15	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr17:80140729	chr17:80149627~80149798:+
THCA	cis	rs524281	0.861	rs9736673	ENSG00000255038.1	RP11-1167A19.2	-3.4	0.000737	0.042	-0.18	-0.15	Electroencephalogram traits;	chr11:66156553	chr11:66067277~66069619:-
THCA	cis	rs2436845	0.589	rs2570950	ENSG00000253320.4	KB-1507C5.2	-3.4	0.000737	0.042	-0.13	-0.15	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102871637	chr8:102864300~102977876:+
THCA	cis	rs2018683	0.745	rs917217	ENSG00000233517.1	AC005162.5	3.4	0.000737	0.042	0.19	0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935408	chr7:28987028~28988899:+
THCA	cis	rs7430456	0.674	rs9814974	ENSG00000231574.4	RP11-91K9.1	-3.4	0.000737	0.042	-0.22	-0.15	Breast cancer;	chr3:177774073	chr3:177816865~177899224:+
THCA	cis	rs7246657	0.943	rs713256	ENSG00000268499.1	CTB-102L5.8	3.4	0.000737	0.042	0.21	0.15	Coronary artery calcification;	chr19:37374463	chr19:38199836~38200934:+
THCA	cis	rs11992162	0.55	rs61426048	ENSG00000255046.1	RP11-297N6.4	3.4	0.000737	0.042	0.17	0.15	Monocyte count;	chr8:11927447	chr8:11797928~11802568:-
THCA	cis	rs57709857	0.768	rs10112856	ENSG00000272092.1	RP11-350N15.5	-3.4	0.000737	0.042	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38191921	chr8:38382364~38383461:+
THCA	cis	rs277939	0.935	rs541035	ENSG00000251634.2	RP11-1280N14.3	3.4	0.000737	0.042	0.16	0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71590312	chr5:71102898~71128753:-
THCA	cis	rs9287719	0.967	rs1541573	ENSG00000243819.4	RN7SL832P	3.4	0.000737	0.042	0.13	0.15	Prostate cancer;	chr2:10633259	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.967	rs1541574	ENSG00000243819.4	RN7SL832P	3.4	0.000737	0.042	0.13	0.15	Prostate cancer;	chr2:10633382	chr2:10690344~10692099:+
THCA	cis	rs7959452	0.649	rs4761239	ENSG00000274979.1	RP11-1143G9.5	-3.4	0.000737	0.042	-0.17	-0.15	Blood protein levels;	chr12:69383106	chr12:69326574~69331882:-
THCA	cis	rs9991779	0.58	rs6858266	ENSG00000237125.7	HAND2-AS1	-3.4	0.000737	0.042	-0.26	-0.15	Pediatric bone mineral content (hip);	chr4:173947212	chr4:173527270~173591324:+
THCA	cis	rs721917	0.525	rs4281433	ENSG00000225484.5	NUTM2B-AS1	-3.4	0.000737	0.042	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79663088~79826594:-
THCA	cis	rs7267979	0.549	rs6138537	ENSG00000274973.1	RP13-401N8.7	-3.4	0.000737	0.042	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25203830	chr20:25845497~25845862:+
THCA	cis	rs6598541	0.89	rs28733344	ENSG00000278090.1	RP11-6O2.2	3.4	0.000738	0.042	0.15	0.15	Urate levels;	chr15:98738060	chr15:99028538~99031053:+
THCA	cis	rs1865760	0.566	rs9379825	ENSG00000272810.1	U91328.22	-3.4	0.000738	0.042	-0.12	-0.15	Height;	chr6:26083643	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.566	rs9467672	ENSG00000272810.1	U91328.22	-3.4	0.000738	0.042	-0.12	-0.15	Height;	chr6:26083676	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.566	rs9295688	ENSG00000272810.1	U91328.22	-3.4	0.000738	0.042	-0.12	-0.15	Height;	chr6:26083989	chr6:26013241~26013757:+
THCA	cis	rs6828577	1	rs6854328	ENSG00000281731.1	RP11-384K6.8	-3.4	0.000738	0.042	-0.19	-0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118762337	chr4:118664087~118685341:-
THCA	cis	rs2243480	1	rs1499614	ENSG00000237310.1	GS1-124K5.4	3.4	0.000738	0.042	0.18	0.15	Diabetic kidney disease;	chr7:66265811	chr7:66493706~66495474:+
THCA	cis	rs9425766	0.631	rs10158289	ENSG00000270084.1	GAS5-AS1	-3.4	0.000738	0.042	-0.16	-0.15	Life satisfaction;	chr1:174081529	chr1:173863248~173863941:+
THCA	cis	rs7914558	0.966	rs56946876	ENSG00000272912.1	RP11-724N1.1	-3.4	0.000738	0.042	-0.18	-0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.933	rs12763665	ENSG00000272912.1	RP11-724N1.1	-3.4	0.000738	0.042	-0.18	-0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs10786721	ENSG00000272912.1	RP11-724N1.1	-3.4	0.000738	0.042	-0.18	-0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102914585~102915404:+
THCA	cis	rs7845127	0.53	rs7387217	ENSG00000253671.1	RP11-806O11.1	3.4	0.000738	0.042	0.18	0.15	Night sleep phenotypes;	chr8:18244054	chr8:17808941~17820868:+
THCA	cis	rs6545883	0.929	rs2600663	ENSG00000212978.6	AC016747.3	-3.4	0.000738	0.042	-0.16	-0.15	Tuberculosis;	chr2:61313552	chr2:61141592~61144969:-
THCA	cis	rs2129782	0.51	rs11990735	ENSG00000253553.4	RP11-586K2.1	3.4	0.000738	0.042	0.22	0.15	Electrodermal activity;	chr8:88488954	chr8:88326836~88737134:+
THCA	cis	rs270601	0.69	rs162904	ENSG00000263597.1	MIR3936	-3.4	0.000738	0.042	-0.15	-0.15	Acylcarnitine levels;	chr5:132260091	chr5:132365490~132365599:-
THCA	cis	rs11083475	0.607	rs6508816	ENSG00000269050.1	CTC-360G5.6	-3.4	0.000738	0.042	-0.18	-0.15	Heart rate;	chr19:38777143	chr19:38870159~38873763:+
THCA	cis	rs453301	0.686	rs11787026	ENSG00000254340.1	RP11-10A14.3	3.4	0.000738	0.042	0.17	0.15	Joint mobility (Beighton score);	chr8:9044861	chr8:9141424~9145435:+
THCA	cis	rs1154275	0.743	rs1249887	ENSG00000243795.1	RP11-572M11.3	-3.4	0.000738	0.042	-0.19	-0.15	Takotsubo syndrome;	chr3:112774565	chr3:113142350~113167819:-
THCA	cis	rs1154275	0.743	rs1249888	ENSG00000243795.1	RP11-572M11.3	-3.4	0.000738	0.042	-0.19	-0.15	Takotsubo syndrome;	chr3:112774712	chr3:113142350~113167819:-
THCA	cis	rs1154275	0.743	rs1249889	ENSG00000243795.1	RP11-572M11.3	-3.4	0.000738	0.042	-0.19	-0.15	Takotsubo syndrome;	chr3:112774961	chr3:113142350~113167819:-
THCA	cis	rs1154275	0.743	rs1249891	ENSG00000243795.1	RP11-572M11.3	-3.4	0.000738	0.042	-0.19	-0.15	Takotsubo syndrome;	chr3:112775721	chr3:113142350~113167819:-
THCA	cis	rs3750817	0.537	rs2912778	ENSG00000271670.1	RP11-95I16.4	-3.4	0.000738	0.042	-0.14	-0.15	Breast cancer;	chr10:121579140	chr10:120879256~120880667:-
THCA	cis	rs2360027	0.929	rs1742856	ENSG00000231365.4	RP11-418J17.1	-3.4	0.000738	0.042	-0.15	-0.15	Tonsillectomy;	chr1:118614867	chr1:119140396~119275973:+
THCA	cis	rs17092148	1	rs60789653	ENSG00000269202.1	RP4-614O4.12	-3.4	0.000738	0.042	-0.18	-0.15	Neuroticism;	chr20:34859359	chr20:35201747~35203288:-
THCA	cis	rs910873	0.505	rs67260051	ENSG00000269202.1	RP4-614O4.12	-3.4	0.000738	0.042	-0.18	-0.15	Melanoma;	chr20:34860614	chr20:35201747~35203288:-
THCA	cis	rs12188164	0.965	rs77101200	ENSG00000225138.6	CTD-2228K2.7	3.4	0.000738	0.042	0.16	0.15	Cystic fibrosis severity;	chr5:442944	chr5:473236~480884:+
THCA	cis	rs1790761	0.667	rs4084113	ENSG00000255318.1	RP11-655M14.13	-3.4	0.000738	0.042	-0.18	-0.15	Mean corpuscular volume;	chr11:67489566	chr11:67618279~67627304:-
THCA	cis	rs853679	0.76	rs9357067	ENSG00000261839.1	RP1-265C24.8	3.4	0.000738	0.042	0.19	0.15	Depression;	chr6:28242515	chr6:28136849~28139678:+
THCA	cis	rs853679	0.76	rs967005	ENSG00000261839.1	RP1-265C24.8	3.4	0.000738	0.042	0.19	0.15	Depression;	chr6:28242910	chr6:28136849~28139678:+
THCA	cis	rs7631605	0.586	rs73059487	ENSG00000224080.1	UBE2FP1	3.4	0.000738	0.042	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37266771	chr3:37143512~37143958:-
THCA	cis	rs7819412	0.668	rs2409715	ENSG00000206014.6	OR7E161P	3.4	0.000738	0.042	0.18	0.15	Triglycerides;	chr8:11152626	chr8:11928597~11929563:-
THCA	cis	rs11066679	0.716	rs7967203	ENSG00000277566.1	RP11-545P7.9	3.4	0.000738	0.042	0.19	0.15	Glomerular filtration rate in chronic kidney disease;	chr12:113682786	chr12:113249466~113250042:+
THCA	cis	rs459571	0.92	rs433402	ENSG00000235106.7	LINC00094	3.4	0.000738	0.042	0.14	0.15	Platelet distribution width;	chr9:134033505	chr9:134025439~134034666:+
THCA	cis	rs71478720	0.779	rs34006273	ENSG00000214264.4	KCTD9P4	3.4	0.000739	0.042	0.2	0.15	Interleukin-18 levels;	chr11:112212373	chr11:112180773~112183191:+
THCA	cis	rs9788682	0.747	rs2568490	ENSG00000261143.1	ADAMTS7P3	3.4	0.000739	0.042	0.23	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78446028	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.706	rs2568493	ENSG00000261143.1	ADAMTS7P3	3.4	0.000739	0.042	0.23	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78447891	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs2656074	ENSG00000261143.1	ADAMTS7P3	3.4	0.000739	0.042	0.23	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78449042	chr15:77976042~77993057:+
THCA	cis	rs7829975	0.511	rs2976906	ENSG00000254340.1	RP11-10A14.3	3.4	0.000739	0.042	0.18	0.15	Mood instability;	chr8:8484905	chr8:9141424~9145435:+
THCA	cis	rs7656342	0.758	rs1850732	ENSG00000242034.1	RP11-1396O13.1	-3.4	0.000739	0.042	-0.18	-0.15	Gut microbiota (bacterial taxa);	chr4:9806510	chr4:9553614~9553985:-
THCA	cis	rs9902453	0.689	rs7216948	ENSG00000263603.1	CTD-2349P21.5	3.4	0.000739	0.042	0.19	0.15	Coffee consumption (cups per day);	chr17:29876155	chr17:30729469~30731202:+
THCA	cis	rs6968419	0.721	rs10232544	ENSG00000237870.5	AC073130.1	3.4	0.000739	0.042	0.16	0.15	Intraocular pressure;	chr7:116157131	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.761	rs10236140	ENSG00000237870.5	AC073130.1	3.4	0.000739	0.042	0.16	0.15	Intraocular pressure;	chr7:116157564	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.721	rs7777437	ENSG00000237870.5	AC073130.1	3.4	0.000739	0.042	0.16	0.15	Intraocular pressure;	chr7:116158156	chr7:116275606~116286734:-
THCA	cis	rs9863	0.804	rs80270210	ENSG00000269938.1	RP11-214K3.20	-3.4	0.000739	0.042	-0.18	-0.15	White blood cell count;	chr12:123962850	chr12:123968023~123968579:-
THCA	cis	rs76793172	1	rs28433213	ENSG00000207003.1	RNU6-611P	3.4	0.000739	0.042	0.29	0.15	Eosinophil counts;	chr19:45837910	chr19:45047458~45047561:+
THCA	cis	rs832540	0.931	rs2662040	ENSG00000271828.1	CTD-2310F14.1	3.4	0.000739	0.042	0.21	0.15	Coronary artery disease;	chr5:56950783	chr5:56927874~56929573:+
THCA	cis	rs9590614	0.966	rs66700955	ENSG00000278390.3	RP11-74J13.8	-3.4	0.000739	0.042	-0.14	-0.15	Local histogram emphysema pattern;	chr13:41595824	chr13:41132939~41236686:+
THCA	cis	rs2997447	0.761	rs2802314	ENSG00000236155.5	RP11-231P20.2	-3.4	0.000739	0.042	-0.12	-0.15	QRS complex (12-leadsum);	chr1:26104846	chr1:26209741~26229840:+
THCA	cis	rs3808502	0.527	rs56177149	ENSG00000227888.4	FAM66A	3.4	0.000739	0.042	0.2	0.15	Neuroticism;	chr8:11389789	chr8:12362019~12388296:+
THCA	cis	rs4389656	0.778	rs2279654	ENSG00000248677.1	CTD-2044J15.1	-3.4	0.000739	0.042	-0.16	-0.15	Coronary artery disease;	chr5:6742773	chr5:6686325~6707711:-
THCA	cis	rs35740288	0.731	rs11638407	ENSG00000259407.1	RP11-158M2.3	-3.4	0.000739	0.042	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85551424	chr15:85744109~85750281:-
THCA	cis	rs9308731	0.591	rs6542350	ENSG00000227992.1	AC108463.2	-3.4	0.000739	0.042	-0.18	-0.15	Chronic lymphocytic leukemia;	chr2:111187163	chr2:111203964~111206215:-
THCA	cis	rs2235642	0.582	rs8051374	ENSG00000280231.1	LA16c-380F5.3	-3.4	0.000739	0.042	-0.19	-0.15	Coronary artery disease;	chr16:1516283	chr16:1553655~1554130:-
THCA	cis	rs7264396	0.887	rs2236164	ENSG00000261582.1	RP4-614O4.11	-3.4	0.000739	0.0421	-0.16	-0.15	Total cholesterol levels;	chr20:35509524	chr20:35267885~35280043:-
THCA	cis	rs6545883	0.931	rs7557230	ENSG00000212978.6	AC016747.3	3.4	0.000739	0.0421	0.17	0.15	Tuberculosis;	chr2:61509517	chr2:61141592~61144969:-
THCA	cis	rs13325613	0.834	rs34059564	ENSG00000226074.4	PRSS44	-3.4	0.000739	0.0421	-0.33	-0.15	Monocyte count;	chr3:46184673	chr3:46809359~46812558:-
THCA	cis	rs2494663	0.61	rs7552737	ENSG00000231416.1	RP11-422P24.9	3.4	0.000739	0.0421	0.19	0.15	Mean platelet volume;	chr1:154025328	chr1:153995632~153995960:+
THCA	cis	rs758324	0.891	rs924435	ENSG00000237714.1	P4HA2-AS1	3.4	0.000739	0.0421	0.29	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131807631	chr5:132184876~132192808:+
THCA	cis	rs11574514	1	rs1123072	ENSG00000280214.1	CTD-2012K14.5	-3.4	0.000739	0.0421	-0.28	-0.15	Crohn's disease;	chr16:67864894	chr16:67550815~67552935:-
THCA	cis	rs8099594	0.565	rs7235532	ENSG00000266696.1	RP11-30L3.2	-3.4	0.000739	0.0421	-0.19	-0.15	Height;	chr18:49188326	chr18:49205912~49208781:+
THCA	cis	rs7631605	0.586	rs1040073	ENSG00000224080.1	UBE2FP1	3.4	0.000739	0.0421	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37267041	chr3:37143512~37143958:-
THCA	cis	rs17428076	0.794	rs56133507	ENSG00000228389.1	AC068039.4	-3.4	0.000739	0.0421	-0.21	-0.15	Myopia;	chr2:171961945	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.794	rs62182446	ENSG00000228389.1	AC068039.4	-3.4	0.000739	0.0421	-0.21	-0.15	Myopia;	chr2:171964701	chr2:171773482~171775844:+
THCA	cis	rs7311936	1	rs10744167	ENSG00000270130.1	RP11-214K3.23	-3.4	0.000739	0.0421	-0.17	-0.15	Vertical cup-disc ratio;	chr12:124150567	chr12:123960717~123961244:-
THCA	cis	rs11775334	0.66	rs12543841	ENSG00000261451.1	RP11-981G7.1	3.4	0.000739	0.0421	0.21	0.15	Hypertension;	chr8:10221343	chr8:10433672~10438312:+
THCA	cis	rs4601821	0.823	rs17115439	ENSG00000270179.1	RP11-159N11.4	-3.4	0.00074	0.0421	-0.16	-0.15	Alcoholic chronic pancreatitis;	chr11:113393550	chr11:113368478~113369117:+
THCA	cis	rs11800820	0.521	rs3120700	ENSG00000231612.1	RP11-522M21.3	3.4	0.00074	0.0421	0.2	0.15	Obesity-related traits;	chr1:246542336	chr1:245673732~245676478:-
THCA	cis	rs7709377	0.723	rs10071141	ENSG00000248445.4	SEMA6A-AS1	-3.4	0.00074	0.0421	-0.14	-0.15	Metabolite levels  (X-11787);	chr5:116193923	chr5:116447547~116508276:+
THCA	cis	rs10435719	0.773	rs7842810	ENSG00000227888.4	FAM66A	3.4	0.00074	0.0421	0.2	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:12362019~12388296:+
THCA	cis	rs9596863	0.898	rs9568920	ENSG00000136149.6	RPL13AP25	-3.4	0.00074	0.0421	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53778675	chr13:54440704~54441315:-
THCA	cis	rs950027	0.62	rs1145084	ENSG00000259479.5	SORD2P	3.4	0.00074	0.0421	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:44826371~44884694:-
THCA	cis	rs6445967	0.53	rs57925583	ENSG00000272360.1	RP11-359I18.5	3.4	0.00074	0.0421	0.19	0.15	Platelet count;	chr3:58407426	chr3:58490830~58491291:-
THCA	cis	rs41411047	0.826	rs6769573	ENSG00000252172.1	RNU6-720P	3.4	0.00074	0.0421	0.33	0.15	Myocardial infarction;	chr3:149866457	chr3:149917342~149917449:-
THCA	cis	rs4448343	0.736	rs2297086	ENSG00000271155.1	RP11-435O5.5	-3.4	0.00074	0.0421	-0.16	-0.15	Height;	chr9:95477838	chr9:95506235~95507636:+
THCA	cis	rs2832077	0.943	rs2832100	ENSG00000232855.5	AF131217.1	3.4	0.00074	0.0421	0.19	0.15	Cognitive test performance;	chr21:28803305	chr21:28439346~28674848:-
THCA	cis	rs7978895	0.519	rs1995339	ENSG00000240759.1	RP11-25I15.1	3.4	0.00074	0.0421	0.17	0.15	Type 2 diabetes;	chr12:43325041	chr12:42678873~42679124:-
THCA	cis	rs821367	0.83	rs74281223	ENSG00000229048.5	DUTP1	-3.4	0.00074	0.0421	-0.24	-0.15	Platelet distribution width;	chr3:124704882	chr3:125310881~125311350:+
THCA	cis	rs6860806	0.661	rs3763112	ENSG00000263597.1	MIR3936	3.4	0.00074	0.0421	0.15	0.15	Breast cancer;	chr5:132250787	chr5:132365490~132365599:-
THCA	cis	rs12780845	1	rs2181043	ENSG00000273153.1	RP11-406H21.2	3.4	0.00074	0.0421	0.15	0.15	Homocysteine levels;	chr10:17175804	chr10:17137336~17137585:-
THCA	cis	rs818427	0.964	rs495794	ENSG00000279522.1	CTC-487M23.6	-3.4	0.00074	0.0421	-0.17	-0.15	Total body bone mineral density;	chr5:112865397	chr5:112894933~112896531:+
THCA	cis	rs34779708	0.897	rs9787566	ENSG00000233200.1	RP11-324I22.2	3.4	0.00074	0.0421	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs4351760	ENSG00000233200.1	RP11-324I22.2	3.4	0.00074	0.0421	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.898	rs4934695	ENSG00000233200.1	RP11-324I22.2	3.4	0.00074	0.0421	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs11597483	ENSG00000233200.1	RP11-324I22.2	3.4	0.00074	0.0421	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs35317849	ENSG00000233200.1	RP11-324I22.2	3.4	0.00074	0.0421	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35219894~35230598:-
THCA	cis	rs4660214	0.614	rs11205802	ENSG00000228060.1	RP11-69E11.8	3.4	0.00074	0.0421	0.14	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233442	chr1:39565160~39573203:+
THCA	cis	rs4660214	0.614	rs10888715	ENSG00000228060.1	RP11-69E11.8	3.4	0.00074	0.0421	0.14	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233572	chr1:39565160~39573203:+
THCA	cis	rs875971	0.502	rs2465121	ENSG00000230295.1	RP11-458F8.2	-3.4	0.00074	0.0421	-0.14	-0.15	Aortic root size;	chr7:66156017	chr7:66880708~66882981:+
THCA	cis	rs12780845	0.931	rs11818636	ENSG00000229124.5	VIM-AS1	3.4	0.00074	0.0421	0.16	0.15	Homocysteine levels;	chr10:17202899	chr10:17214239~17229985:-
THCA	cis	rs12780845	0.928	rs11813029	ENSG00000229124.5	VIM-AS1	3.4	0.00074	0.0421	0.16	0.15	Homocysteine levels;	chr10:17202916	chr10:17214239~17229985:-
THCA	cis	rs7709377	0.723	rs6594957	ENSG00000250015.1	CTC-339F2.2	3.4	0.00074	0.0421	0.16	0.15	Metabolite levels  (X-11787);	chr5:116190129	chr5:116302354~116304134:-
THCA	cis	rs7259376	0.905	rs1975172	ENSG00000270947.1	AC025811.3	3.4	0.00074	0.0421	0.17	0.15	Menopause (age at onset);	chr19:22351801	chr19:22455988~22456459:+
THCA	cis	rs2664588	0.561	rs4629214	ENSG00000276923.1	RP11-321P16.1	-3.4	0.00074	0.0421	-0.21	-0.15	Cerebrospinal fluid AB1-42 levels;	chr20:47963104	chr20:48073869~48074188:+
THCA	cis	rs613391	0.631	rs518020	ENSG00000234840.1	LINC01239	-3.4	0.00074	0.0421	-0.18	-0.15	Quantitative traits;	chr9:22698209	chr9:22646200~22824213:+
THCA	cis	rs613391	0.702	rs1448773	ENSG00000234840.1	LINC01239	-3.4	0.00074	0.0421	-0.18	-0.15	Quantitative traits;	chr9:22705548	chr9:22646200~22824213:+
THCA	cis	rs1009077	0.536	rs13116789	ENSG00000245958.5	RP11-33B1.1	3.4	0.00074	0.0421	0.24	0.15	Endometriosis;	chr4:119494057	chr4:119454791~119552025:+
THCA	cis	rs11719291	0.833	rs34037363	ENSG00000229759.1	MRPS18AP1	-3.4	0.00074	0.0421	-0.32	-0.15	Cognitive function;	chr3:48783603	chr3:48256350~48256938:-
THCA	cis	rs950027	0.62	rs2467862	ENSG00000259479.5	SORD2P	3.4	0.00074	0.0421	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:44826371~44884694:-
THCA	cis	rs2898290	0.593	rs2199690	ENSG00000270154.1	RP11-419I17.1	-3.4	0.00074	0.0421	-0.19	-0.15	Systolic blood pressure;	chr8:11482107	chr8:12476462~12477122:+
THCA	cis	rs77106637	0.769	rs11603313	ENSG00000256448.4	RP11-809N8.4	3.4	0.00074	0.0421	0.25	0.15	Type 2 diabetes;	chr11:72877132	chr11:73405297~73410682:+
THCA	cis	rs9637454	1	rs1477778	ENSG00000231574.4	RP11-91K9.1	-3.4	0.00074	0.0421	-0.22	-0.15	Hippocampal sclerosis;	chr3:178546808	chr3:177816865~177899224:+
THCA	cis	rs9637454	1	rs76270853	ENSG00000231574.4	RP11-91K9.1	-3.4	0.00074	0.0421	-0.22	-0.15	Hippocampal sclerosis;	chr3:178546963	chr3:177816865~177899224:+
THCA	cis	rs7647973	0.516	rs4308307	ENSG00000228638.1	FCF1P2	-3.4	0.00074	0.0421	-0.16	-0.15	Menarche (age at onset);	chr3:49155783	chr3:48290793~48291375:-
THCA	cis	rs12801636	0.557	rs3741378	ENSG00000255320.1	RP11-755F10.1	-3.4	0.00074	0.0421	-0.26	-0.15	HDL cholesterol;Coronary artery disease;HDL cholesterol levels;	chr11:65641466	chr11:66244840~66246239:-
THCA	cis	rs2688608	0.592	rs2306328	ENSG00000272140.2	RP11-574K11.29	3.4	0.000741	0.0421	0.13	0.15	Inflammatory bowel disease;	chr10:73819752	chr10:73703735~73713581:-
THCA	cis	rs10911363	0.592	rs2702203	ENSG00000232860.6	SMG7-AS1	-3.4	0.000741	0.0421	-0.12	-0.15	Systemic lupus erythematosus;	chr1:183493378	chr1:183460874~183472265:-
THCA	cis	rs950027	0.62	rs1145093	ENSG00000259479.5	SORD2P	3.4	0.000741	0.0421	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:44826371~44884694:-
THCA	cis	rs950027	0.62	rs1049518	ENSG00000259479.5	SORD2P	3.4	0.000741	0.0421	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:44826371~44884694:-
THCA	cis	rs950027	0.584	rs1145086	ENSG00000259479.5	SORD2P	3.4	0.000741	0.0421	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:44826371~44884694:-
THCA	cis	rs950027	0.62	rs1153857	ENSG00000259479.5	SORD2P	3.4	0.000741	0.0421	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:44826371~44884694:-
THCA	cis	rs950027	0.62	rs1153855	ENSG00000259479.5	SORD2P	3.4	0.000741	0.0421	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:44826371~44884694:-
THCA	cis	rs950027	0.62	rs1145080	ENSG00000259479.5	SORD2P	3.4	0.000741	0.0421	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:44826371~44884694:-
THCA	cis	rs34779708	0.931	rs11597392	ENSG00000233200.1	RP11-324I22.2	3.4	0.000741	0.0421	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35219894~35230598:-
THCA	cis	rs9649465	0.561	rs600081	ENSG00000272686.1	RP11-390E23.6	-3.4	0.000741	0.0421	-0.11	-0.15	Migraine;	chr7:123774537	chr7:123749068~123751166:+
THCA	cis	rs12047808	0.556	rs78183476	ENSG00000227141.2	RP11-545A16.3	-3.4	0.000741	0.0421	-0.33	-0.15	Multiple sclerosis (age of onset);	chr1:179593385	chr1:179586705~179589175:+
THCA	cis	rs7204230	0.921	rs12597502	ENSG00000261291.1	RP11-295M3.2	3.4	0.000741	0.0421	0.22	0.15	Fibrinogen;	chr16:53136157	chr16:53168522~53169450:+
THCA	cis	rs11190604	0.943	rs11190581	ENSG00000273030.1	RP11-285F16.1	3.4	0.000741	0.0421	0.18	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100483630	chr10:100412934~100413421:+
THCA	cis	rs12428035	0.764	rs11619636	ENSG00000247400.3	DNAJC3-AS1	-3.4	0.000741	0.0421	-0.16	-0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96069969	chr13:95648733~95676925:-
THCA	cis	rs7202877	0.656	rs9923834	ENSG00000261476.1	RP11-77K12.3	-3.4	0.000741	0.0421	-0.25	-0.15	Type 1 diabetes;Type 2 diabetes;	chr16:75473355	chr16:75458252~75460017:-
THCA	cis	rs9425766	0.85	rs9425755	ENSG00000200674.1	RN7SKP160	3.4	0.000741	0.0421	0.2	0.15	Life satisfaction;	chr1:173843501	chr1:173791548~173791887:+
THCA	cis	rs9425766	0.85	rs1322770	ENSG00000200674.1	RN7SKP160	3.4	0.000741	0.0421	0.2	0.15	Life satisfaction;	chr1:173863198	chr1:173791548~173791887:+
THCA	cis	rs10751667	0.677	rs9794921	ENSG00000255142.1	AP006621.6	-3.4	0.000741	0.0421	-0.13	-0.15	Alzheimer's disease (late onset);	chr11:1039867	chr11:781645~782105:+
THCA	cis	rs7216064	0.953	rs4790981	ENSG00000265055.1	AC145343.2	3.4	0.000741	0.0421	0.22	0.15	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67925718	chr17:68096046~68101474:-
THCA	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	3.4	0.000741	0.0421	0.17	0.15	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
THCA	cis	rs927821	1	rs927821	ENSG00000203886.4	CYP17A1-AS1	-3.4	0.000741	0.0421	-0.2	-0.15	Social autistic-like traits;	chr10:102448042	chr10:102832721~102834516:+
THCA	cis	rs9860428	0.844	rs7609699	ENSG00000243795.1	RP11-572M11.3	3.4	0.000741	0.0421	0.19	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112902758	chr3:113142350~113167819:-
THCA	cis	rs1832871	0.672	rs9456286	ENSG00000213078.3	RP5-933K21.2	-3.4	0.000741	0.0421	-0.23	-0.15	Height;	chr6:158313283	chr6:157365990~157366923:-
THCA	cis	rs7615952	0.534	rs1503072	ENSG00000248787.1	RP11-666A20.4	-3.4	0.000741	0.0421	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126035848	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.599	rs7631268	ENSG00000248787.1	RP11-666A20.4	-3.4	0.000741	0.0421	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126036821	chr3:125908005~125910272:-
THCA	cis	rs9596863	0.898	rs9568917	ENSG00000136149.6	RPL13AP25	-3.4	0.000741	0.0421	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53776905	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs9568919	ENSG00000136149.6	RPL13AP25	-3.4	0.000741	0.0421	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53778094	chr13:54440704~54441315:-
THCA	cis	rs346291	0.63	rs1742485	ENSG00000279659.1	RP11-177G23.1	3.4	0.000741	0.0421	0.14	0.15	Partial epilepsies;	chr6:79868893	chr6:79573877~79575530:+
THCA	cis	rs7521681	0.877	rs12724195	ENSG00000230489.1	VAV3-AS1	-3.4	0.000741	0.0421	-0.21	-0.15	Asthma and hay fever;	chr1:107818359	chr1:107964443~107994607:+
THCA	cis	rs10911902	0.643	rs3820181	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000741	0.0421	-0.24	-0.15	Schizophrenia;	chr1:186347067	chr1:186580515~186581191:-
THCA	cis	rs3755605	0.728	rs55802818	ENSG00000242578.1	RP11-469J4.3	3.4	0.000741	0.0421	0.17	0.15	Testicular germ cell tumor;	chr3:170065363	chr3:170410512~170418615:+
THCA	cis	rs4730276	0.674	rs4727692	ENSG00000241764.3	AC002467.7	-3.4	0.000741	0.0421	-0.13	-0.15	Ulcerative colitis;	chr7:107885569	chr7:107742817~107744581:-
THCA	cis	rs111756027	0.593	rs11862987	ENSG00000260922.1	RP11-538I12.3	3.4	0.000741	0.0421	0.24	0.15	Bone mineral density (Ward's triangle area);	chr16:77213607	chr16:77234877~77290934:+
THCA	cis	rs950169	0.8	rs4842847	ENSG00000230373.7	GOLGA6L5P	-3.4	0.000741	0.0421	-0.17	-0.15	Schizophrenia;	chr15:84262447	chr15:84507885~84516814:-
THCA	cis	rs7487075	0.619	rs12822345	ENSG00000274723.1	RP11-618L22.1	3.4	0.000741	0.0421	0.15	0.15	Itch intensity from mosquito bite;	chr12:46440894	chr12:46970504~46972155:+
THCA	cis	rs7487075	0.619	rs12824565	ENSG00000274723.1	RP11-618L22.1	3.4	0.000741	0.0421	0.15	0.15	Itch intensity from mosquito bite;	chr12:46440910	chr12:46970504~46972155:+
THCA	cis	rs561341	0.714	rs474455	ENSG00000265798.5	RP11-271K11.5	3.4	0.000741	0.0421	0.23	0.15	Hip circumference adjusted for BMI;	chr17:31985446	chr17:31038575~31059121:-
THCA	cis	rs11992162	0.56	rs13276386	ENSG00000227888.4	FAM66A	3.4	0.000741	0.0421	0.2	0.15	Monocyte count;	chr8:11939912	chr8:12362019~12388296:+
THCA	cis	rs11992162	0.621	rs13268810	ENSG00000227888.4	FAM66A	3.4	0.000741	0.0421	0.2	0.15	Monocyte count;	chr8:11939921	chr8:12362019~12388296:+
THCA	cis	rs11992162	0.636	rs13265816	ENSG00000227888.4	FAM66A	3.4	0.000741	0.0421	0.2	0.15	Monocyte count;	chr8:11939976	chr8:12362019~12388296:+
THCA	cis	rs7487075	0.619	rs4768725	ENSG00000275481.1	RP11-474P2.6	3.4	0.000741	0.0421	0.15	0.15	Itch intensity from mosquito bite;	chr12:46454695	chr12:46388856~46392126:+
THCA	cis	rs7487075	0.619	rs7488450	ENSG00000275481.1	RP11-474P2.6	3.4	0.000741	0.0422	0.16	0.15	Itch intensity from mosquito bite;	chr12:46427255	chr12:46388856~46392126:+
THCA	cis	rs1334893	1	rs1334893	ENSG00000238021.5	ARMC4P1	-3.4	0.000741	0.0422	-0.3	-0.15	Fasting blood insulin (BMI interaction);	chr10:27404376	chr10:27258762~27288824:+
THCA	cis	rs1334893	1	rs2484192	ENSG00000238021.5	ARMC4P1	-3.4	0.000741	0.0422	-0.3	-0.15	Fasting blood insulin (BMI interaction);	chr10:27407165	chr10:27258762~27288824:+
THCA	cis	rs1334893	0.681	rs2429500	ENSG00000238021.5	ARMC4P1	-3.4	0.000741	0.0422	-0.3	-0.15	Fasting blood insulin (BMI interaction);	chr10:27412253	chr10:27258762~27288824:+
THCA	cis	rs972578	0.765	rs4822208	ENSG00000230319.1	AL022476.2	3.4	0.000741	0.0422	0.16	0.15	Mean platelet volume;	chr22:42865217	chr22:43038585~43052366:+
THCA	cis	rs11098499	0.644	rs34835603	ENSG00000249244.1	RP11-548H18.2	3.4	0.000741	0.0422	0.17	0.15	Corneal astigmatism;	chr4:119632273	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.615	rs28850368	ENSG00000249244.1	RP11-548H18.2	3.4	0.000741	0.0422	0.17	0.15	Corneal astigmatism;	chr4:119633158	chr4:119391831~119395335:-
THCA	cis	rs6472235	0.586	rs34464051	ENSG00000200714.1	Y_RNA	-3.4	0.000741	0.0422	-0.2	-0.15	Plateletcrit;Myopia (pathological);	chr8:65989769	chr8:65592731~65592820:+
THCA	cis	rs10208649	0.536	rs13414472	ENSG00000233266.1	HMGB1P31	3.4	0.000741	0.0422	0.27	0.15	Body mass index;	chr2:53738470	chr2:54051334~54051760:+
THCA	cis	rs3785574	1	rs7223257	ENSG00000279369.1	RP11-51F16.1	3.4	0.000741	0.0422	0.11	0.15	Height;	chr17:63710324	chr17:63700847~63702670:+
THCA	cis	rs2505675	0.887	rs2505676	ENSG00000250903.7	GMDS-AS1	3.4	0.000742	0.0422	0.14	0.15	Tuberculosis;	chr6:2355141	chr6:2245748~2482022:+
THCA	cis	rs11992162	1	rs11784499	ENSG00000255046.1	RP11-297N6.4	-3.4	0.000742	0.0422	-0.17	-0.15	Monocyte count;	chr8:11977030	chr8:11797928~11802568:-
THCA	cis	rs16975963	0.843	rs11672257	ENSG00000226686.6	LINC01535	-3.4	0.000742	0.0422	-0.21	-0.15	Longevity;	chr19:37948722	chr19:37251912~37265535:+
THCA	cis	rs4713118	0.513	rs149878	ENSG00000272009.1	RP1-313I6.12	-3.4	0.000742	0.0422	-0.16	-0.15	Parkinson's disease;	chr6:27910960	chr6:28078792~28081130:-
THCA	cis	rs1881509	0.624	rs10833729	ENSG00000233930.3	KRTAP5-AS1	-3.4	0.000742	0.0422	-0.19	-0.15	Heroin dependence;	chr11:1422518	chr11:1571353~1599184:+
THCA	cis	rs6088580	0.634	rs6059867	ENSG00000126005.14	MMP24-AS1	-3.4	0.000742	0.0422	-0.14	-0.15	Glomerular filtration rate (creatinine);	chr20:34490298	chr20:35216462~35278131:-
THCA	cis	rs7829975	0.653	rs13259070	ENSG00000248538.5	RP11-10A14.5	-3.4	0.000742	0.0422	-0.19	-0.15	Mood instability;	chr8:8833277	chr8:9189011~9202854:+
THCA	cis	rs10165862	0.572	rs11674212	ENSG00000230002.2	ALMS1-IT1	3.4	0.000742	0.0422	0.23	0.15	Intelligence (multi-trait analysis);	chr2:73684053	chr2:73456764~73459484:+
THCA	cis	rs72928364	0.728	rs35337386	ENSG00000256628.3	ZBTB11-AS1	3.4	0.000742	0.0422	0.28	0.15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101092204	chr3:101676475~101679217:+
THCA	cis	rs72928364	0.658	rs35252712	ENSG00000256628.3	ZBTB11-AS1	3.4	0.000742	0.0422	0.28	0.15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101092445	chr3:101676475~101679217:+
THCA	cis	rs9649465	0.561	rs2429618	ENSG00000272686.1	RP11-390E23.6	-3.4	0.000742	0.0422	-0.11	-0.15	Migraine;	chr7:123781608	chr7:123749068~123751166:+
THCA	cis	rs6957923	0.846	rs12700443	ENSG00000234286.1	AC006026.13	-3.4	0.000742	0.0422	-0.2	-0.15	Height;	chr7:23475249	chr7:23680195~23680786:-
THCA	cis	rs76878669	0.561	rs1039594	ENSG00000255320.1	RP11-755F10.1	-3.4	0.000742	0.0422	-0.19	-0.15	Educational attainment (years of education);	chr11:66363678	chr11:66244840~66246239:-
THCA	cis	rs76878669	0.515	rs12576299	ENSG00000255320.1	RP11-755F10.1	-3.4	0.000742	0.0422	-0.19	-0.15	Educational attainment (years of education);	chr11:66364815	chr11:66244840~66246239:-
THCA	cis	rs76878669	0.561	rs2279861	ENSG00000255320.1	RP11-755F10.1	-3.4	0.000742	0.0422	-0.19	-0.15	Educational attainment (years of education);	chr11:66365865	chr11:66244840~66246239:-
THCA	cis	rs943466	0.955	rs2894342	ENSG00000274259.2	XXbac-BPG294E21.9	-3.4	0.000742	0.0422	-0.21	-0.15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33806617	chr6:33437363~33454453:-
THCA	cis	rs10911902	0.602	rs10494583	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186321363	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs28715477	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186326392	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs74537283	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186328038	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs3736597	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186331918	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs16825183	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186336861	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs3766704	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186342710	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.567	rs76557279	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186344161	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs2272412	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186345817	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs6667940	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186350448	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs6664763	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186357043	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs6689129	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186357078	chr1:186580515~186581191:-
THCA	cis	rs10911902	0.643	rs16825243	ENSG00000233196.2	GS1-304P7.1	-3.4	0.000742	0.0422	-0.24	-0.15	Schizophrenia;	chr1:186357769	chr1:186580515~186581191:-
THCA	cis	rs3892630	0.588	rs2112917	ENSG00000267567.1	CTD-2538C1.3	3.4	0.000742	0.0422	0.22	0.15	Red blood cell traits;	chr19:32826637	chr19:32718298~32719595:-
THCA	cis	rs7829975	0.511	rs2948286	ENSG00000248538.5	RP11-10A14.5	-3.4	0.000742	0.0422	-0.19	-0.15	Mood instability;	chr8:8272638	chr8:9189011~9202854:+
THCA	cis	rs790006	0.655	rs11175299	ENSG00000243024.5	RPS11P6	-3.4	0.000742	0.0422	-0.18	-0.15	Response to cytidine analogues (gemcitabine);	chr12:64254332	chr12:64222337~64397065:+
THCA	cis	rs7296418	0.961	rs11613937	ENSG00000256092.2	RP13-942N8.1	3.4	0.000742	0.0422	0.11	0.15	Platelet count;	chr12:123035524	chr12:123363868~123366113:+
THCA	cis	rs9990333	1	rs9990333	ENSG00000185485.13	SDHAP1	-3.4	0.000742	0.0422	-0.13	-0.15	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195959748~195990318:-
THCA	cis	rs61160187	0.527	rs10076742	ENSG00000215032.2	GNL3LP1	3.4	0.000742	0.0422	0.2	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795219	chr5:60891935~60893577:-
THCA	cis	rs7173964	0.967	rs7163757	ENSG00000259251.2	RP11-643M14.1	-3.4	0.000742	0.0422	-0.16	-0.15	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62099409	chr15:62060503~62062434:+
THCA	cis	rs7487075	0.619	rs4768709	ENSG00000275481.1	RP11-474P2.6	3.4	0.000742	0.0422	0.16	0.15	Itch intensity from mosquito bite;	chr12:46411982	chr12:46388856~46392126:+
THCA	cis	rs7308116	0.967	rs7133509	ENSG00000257951.1	RP11-554D14.4	3.4	0.000742	0.0422	0.19	0.15	Pelvic organ prolapse (moderate/severe);	chr12:107812344	chr12:107881242~107883382:+
THCA	cis	rs10863936	0.629	rs61830761	ENSG00000198468.6	FLVCR1-AS1	-3.4	0.000742	0.0422	-0.18	-0.15	Height;	chr1:212099088	chr1:212852108~212858088:-
THCA	cis	rs9611565	0.649	rs2413659	ENSG00000237037.8	NDUFA6-AS1	-3.4	0.000742	0.0422	-0.14	-0.15	Vitiligo;	chr22:41768858	chr22:42090931~42137742:+
THCA	cis	rs4723738	1	rs2159501	ENSG00000227191.5	TRGC2	-3.4	0.000742	0.0422	-0.12	-0.15	Treatment response for severe sepsis;	chr7:38199675	chr7:38239580~38368091:-
THCA	cis	rs6715793	0.901	rs726429	ENSG00000272754.1	AL133245.2	-3.4	0.000742	0.0422	-0.18	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33179595	chr2:32321638~32323002:+
THCA	cis	rs786425	0.532	rs34247974	ENSG00000270095.1	RP11-214K3.18	3.4	0.000742	0.0422	0.19	0.15	Pubertal anthropometrics;	chr12:123739664	chr12:123971457~123971714:-
THCA	cis	rs786425	0.502	rs10773032	ENSG00000270095.1	RP11-214K3.18	3.4	0.000742	0.0422	0.19	0.15	Pubertal anthropometrics;	chr12:123741516	chr12:123971457~123971714:-
THCA	cis	rs1012053	0.6	rs611760	ENSG00000278338.3	VWA8-AS1	3.4	0.000742	0.0422	0.19	0.15	Bipolar disorder;	chr13:42105459	chr13:41955808~41981565:+
THCA	cis	rs1012053	0.642	rs1170187	ENSG00000278338.3	VWA8-AS1	3.4	0.000742	0.0422	0.19	0.15	Bipolar disorder;	chr13:42105699	chr13:41955808~41981565:+
THCA	cis	rs1012053	0.688	rs685951	ENSG00000278338.3	VWA8-AS1	3.4	0.000742	0.0422	0.19	0.15	Bipolar disorder;	chr13:42112223	chr13:41955808~41981565:+
THCA	cis	rs1012053	0.642	rs1170174	ENSG00000278338.3	VWA8-AS1	3.4	0.000742	0.0422	0.19	0.15	Bipolar disorder;	chr13:42114075	chr13:41955808~41981565:+
THCA	cis	rs1012053	0.6	rs1170173	ENSG00000278338.3	VWA8-AS1	3.4	0.000742	0.0422	0.19	0.15	Bipolar disorder;	chr13:42114479	chr13:41955808~41981565:+
THCA	cis	rs1012053	0.6	rs1170172	ENSG00000278338.3	VWA8-AS1	3.4	0.000742	0.0422	0.19	0.15	Bipolar disorder;	chr13:42114509	chr13:41955808~41981565:+
THCA	cis	rs7243357	0.824	rs72956135	ENSG00000224367.5	OACYLP	-3.4	0.000742	0.0422	-0.25	-0.15	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;	chr18:59211716	chr18:58996734~59069338:+
THCA	cis	rs7243357	0.824	rs77022464	ENSG00000224367.5	OACYLP	-3.4	0.000742	0.0422	-0.25	-0.15	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;	chr18:59211770	chr18:58996734~59069338:+
THCA	cis	rs6981523	0.553	rs11783045	ENSG00000205879.4	FAM90A2P	-3.4	0.000742	0.0422	-0.19	-0.15	Neuroticism;	chr8:11198666	chr8:12172202~12178575:-
THCA	cis	rs757978	0.733	rs11689496	ENSG00000235351.1	AC114730.11	-3.4	0.000742	0.0422	-0.14	-0.15	Chronic lymphocytic leukemia;	chr2:241486984	chr2:241724615~241725693:-
THCA	cis	rs1005277	0.565	rs2474565	ENSG00000099251.13	HSD17B7P2	3.4	0.000742	0.0422	0.13	0.15	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38356380~38378505:+
THCA	cis	rs7412746	0.658	rs3768016	ENSG00000224800.1	RP11-235D19.2	-3.4	0.000743	0.0422	-0.21	-0.15	Melanoma;	chr1:150837443	chr1:150881236~150881683:-
THCA	cis	rs4660214	0.568	rs967530	ENSG00000228060.1	RP11-69E11.8	3.4	0.000743	0.0422	0.14	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39130465	chr1:39565160~39573203:+
THCA	cis	rs7737355	1	rs12719444	ENSG00000224431.1	AC063976.7	3.4	0.000743	0.0422	0.15	0.15	Life satisfaction;	chr5:131271685	chr5:132199456~132203487:+
THCA	cis	rs853679	0.76	rs9393910	ENSG00000261839.1	RP1-265C24.8	3.4	0.000743	0.0422	0.19	0.15	Depression;	chr6:28240414	chr6:28136849~28139678:+
THCA	cis	rs853679	0.76	rs9368563	ENSG00000261839.1	RP1-265C24.8	3.4	0.000743	0.0422	0.19	0.15	Depression;	chr6:28240780	chr6:28136849~28139678:+
THCA	cis	rs853679	0.76	rs9295768	ENSG00000261839.1	RP1-265C24.8	3.4	0.000743	0.0422	0.19	0.15	Depression;	chr6:28241324	chr6:28136849~28139678:+
THCA	cis	rs13178541	0.688	rs10079688	ENSG00000250378.1	RP11-119J18.1	-3.4	0.000743	0.0422	-0.21	-0.15	IgG glycosylation;	chr5:135858587	chr5:135812667~135826582:+
THCA	cis	rs2839186	0.605	rs2839174	ENSG00000228137.1	AP001469.7	3.4	0.000743	0.0422	0.16	0.15	Testicular germ cell tumor;	chr21:46257020	chr21:46246890~46247682:+
THCA	cis	rs2395128	0.765	rs7909358	ENSG00000236842.1	RP11-399K21.10	-3.4	0.000743	0.0422	-0.26	-0.15	Ulcerative colitis;Inflammatory bowel disease;	chr10:74928324	chr10:75430571~75431588:-
THCA	cis	rs7558911	0.801	rs3769827	ENSG00000183308.6	AC005037.3	3.4	0.000743	0.0422	0.17	0.15	Chronic lymphocytic leukemia;	chr2:201237962	chr2:200963263~201009102:+
THCA	cis	rs613391	0.603	rs10757344	ENSG00000224549.1	RP11-370B11.3	3.4	0.000743	0.0422	0.19	0.15	Quantitative traits;	chr9:22595669	chr9:22767175~22768316:+
THCA	cis	rs718314	0.956	rs11048454	ENSG00000255750.4	RP11-283G6.5	3.4	0.000743	0.0422	0.16	0.15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26307112	chr12:26230819~26319720:-
THCA	cis	rs7560272	0.695	rs780393	ENSG00000273245.1	RP11-434P11.2	-3.4	0.000743	0.0422	-0.19	-0.15	Schizophrenia;	chr2:73474542	chr2:73750256~73750786:-
THCA	cis	rs73019876	0.68	rs807951	ENSG00000269615.1	AC003973.1	-3.4	0.000743	0.0422	-0.16	-0.15	Testicular germ cell tumor;	chr19:21937561	chr19:21940820~21941533:+
THCA	cis	rs9898058	0.943	rs17645899	ENSG00000253730.1	RP11-893F2.13	-3.4	0.000743	0.0422	-0.28	-0.15	Milk allergy;	chr17:49752189	chr17:50158333~50161276:-
THCA	cis	rs16971895	1	rs16971895	ENSG00000271392.1	RP1-161P9.5	-3.4	0.000743	0.0422	-0.38	-0.15	Blood protein levels;	chr17:36059035	chr17:35757199~35758325:-
THCA	cis	rs116095464	1	rs6879758	ENSG00000277812.1	AC021087.1	3.4	0.000743	0.0422	0.38	0.15	Breast cancer;	chr5:350162	chr5:262769~262881:+
THCA	cis	rs6832769	0.961	rs13128582	ENSG00000223305.1	RN7SKP30	3.4	0.000743	0.0422	0.2	0.15	Personality dimensions;	chr4:55462777	chr4:55540502~55540835:-
THCA	cis	rs6832769	0.925	rs6817267	ENSG00000223305.1	RN7SKP30	3.4	0.000743	0.0422	0.2	0.15	Personality dimensions;	chr4:55472374	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs11931061	ENSG00000223305.1	RN7SKP30	3.4	0.000743	0.0422	0.2	0.15	Personality dimensions;	chr4:55472626	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs7668147	ENSG00000223305.1	RN7SKP30	3.4	0.000743	0.0422	0.2	0.15	Personality dimensions;	chr4:55473217	chr4:55540502~55540835:-
THCA	cis	rs6832769	0.961	rs11947476	ENSG00000223305.1	RN7SKP30	3.4	0.000743	0.0422	0.2	0.15	Personality dimensions;	chr4:55473584	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs13102385	ENSG00000223305.1	RN7SKP30	3.4	0.000743	0.0422	0.2	0.15	Personality dimensions;	chr4:55479088	chr4:55540502~55540835:-
THCA	cis	rs4650994	0.525	rs17361286	ENSG00000213057.5	C1orf220	-3.4	0.000743	0.0422	-0.11	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178552781	chr1:178542752~178548889:+
THCA	cis	rs1417770	0.54	rs1230037	ENSG00000260971.3	RP11-504A18.1	3.4	0.000743	0.0422	0.15	0.15	Lobe attachment (rater-scored or self-reported);	chr1:56240215	chr1:56248294~56258571:-
THCA	cis	rs626457	0.503	rs6681131	ENSG00000260971.3	RP11-504A18.1	3.4	0.000743	0.0422	0.14	0.15	Blood protein levels;	chr1:56923519	chr1:56248294~56258571:-
THCA	cis	rs9788682	0.624	rs518425	ENSG00000261143.1	ADAMTS7P3	-3.4	0.000743	0.0422	-0.2	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78591471	chr15:77976042~77993057:+
THCA	cis	rs11931598	0.783	rs28661210	ENSG00000245468.3	RP11-367J11.3	3.4	0.000743	0.0422	0.11	0.15	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7049229	chr4:7094571~7103385:-
THCA	cis	rs7903456	0.648	rs1923938	ENSG00000236417.2	CTSLP1	-3.4	0.000743	0.0422	-0.23	-0.15	Gout;Renal underexcretion gout;	chr10:87077623	chr10:87386685~87390203:-
THCA	cis	rs12900413	0.959	rs12908026	ENSG00000259561.1	RP11-300G22.2	3.4	0.000743	0.0422	0.18	0.15	Coronary artery aneurysm in Kawasaki disease;	chr15:89775653	chr15:89704665~89705415:+
THCA	cis	rs7246967	0.932	rs35706770	ENSG00000269364.1	LINC01233	-3.4	0.000743	0.0422	-0.22	-0.15	Bronchopulmonary dysplasia;	chr19:22876460	chr19:22532626~22533494:+
THCA	cis	rs2292864	1	rs2292864	ENSG00000263293.2	RP11-290H9.4	3.4	0.000743	0.0422	0.32	0.15	Left atrial antero-posterior diameter;	chr17:47290315	chr17:47303460~47323613:-
THCA	cis	rs6545883	0.929	rs2593635	ENSG00000212978.6	AC016747.3	-3.4	0.000743	0.0422	-0.17	-0.15	Tuberculosis;	chr2:61407571	chr2:61141592~61144969:-
THCA	cis	rs55702914	0.655	rs787982	ENSG00000231621.1	AC013264.2	-3.4	0.000743	0.0422	-0.15	-0.15	Major depression and alcohol dependence;	chr2:197450810	chr2:197197991~197199273:+
THCA	cis	rs4815191	0.788	rs6036361	ENSG00000230387.2	RP4-737E23.2	-3.4	0.000744	0.0422	-0.22	-0.15	Obesity-related traits;	chr20:23283408	chr20:23187961~23190307:+
THCA	cis	rs917063	0.773	rs12437099	ENSG00000269927.1	RP6-91H8.3	-3.4	0.000744	0.0423	-0.21	-0.15	Gestational age at birth in labor-initiated deliveries (child effect);Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:71170438	chr14:71141125~71143253:-
THCA	cis	rs11031096	0.542	rs1155146	ENSG00000230593.3	AC090804.1	3.4	0.000744	0.0423	0.19	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:3949790	chr11:3892398~3892887:-
THCA	cis	rs2933343	0.729	rs1683780	ENSG00000231305.3	RP11-723O4.2	3.4	0.000744	0.0423	0.17	0.15	IgG glycosylation;	chr3:128921396	chr3:128861313~128871540:-
THCA	cis	rs10266483	0.774	rs4718067	ENSG00000271550.1	BNIP3P11	3.4	0.000744	0.0423	0.2	0.15	Response to statin therapy;	chr7:64356018	chr7:64678954~64687393:-
THCA	cis	rs7572644	0.766	rs13025314	ENSG00000223522.1	AC093690.1	-3.4	0.000744	0.0423	-0.2	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27857347	chr2:28307691~28310459:-
THCA	cis	rs9818758	0.607	rs67060340	ENSG00000229759.1	MRPS18AP1	-3.4	0.000744	0.0423	-0.32	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48877888	chr3:48256350~48256938:-
THCA	cis	rs4845570	0.749	rs11586446	ENSG00000249602.1	RP11-98D18.3	-3.4	0.000744	0.0423	-0.25	-0.15	Coronary artery disease;	chr1:151740012	chr1:151763384~151769501:-
THCA	cis	rs4649295	0.864	rs2884216	ENSG00000231940.1	RPS7P3	3.4	0.000744	0.0423	0.18	0.15	Differentiated thyroid cancer;Papillary thyroid cancer;	chr1:233260859	chr1:233288868~233289447:-
THCA	cis	rs250518	0.926	rs4321733	ENSG00000251467.1	CTC-250P20.2	3.4	0.000744	0.0423	0.22	0.15	Mean corpuscular hemoglobin concentration;	chr5:72759145	chr5:72996920~72997642:+
THCA	cis	rs250518	0.926	rs4618410	ENSG00000251467.1	CTC-250P20.2	3.4	0.000744	0.0423	0.22	0.15	Mean corpuscular hemoglobin concentration;	chr5:72759146	chr5:72996920~72997642:+
THCA	cis	rs41411047	0.826	rs73155089	ENSG00000252172.1	RNU6-720P	3.4	0.000744	0.0423	0.34	0.15	Myocardial infarction;	chr3:149870421	chr3:149917342~149917449:-
THCA	cis	rs71718386	1	rs71718386	ENSG00000275149.1	RP11-427J23.1	-3.4	0.000744	0.0423	-0.2	-0.15	Eosinophil counts;	chr13:40650154	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.664	rs1360719	ENSG00000275149.1	RP11-427J23.1	-3.4	0.000744	0.0423	-0.2	-0.15	Red blood cell count;	chr13:40651737	chr13:40079106~40273509:-
THCA	cis	rs35791980	0.607	rs2286158	ENSG00000265479.4	DTX2P1-UPK3BP1-PMS2P11	-3.4	0.000744	0.0423	-0.16	-0.15	Pursuit maintenance gain;	chr7:77396723	chr7:76980949~77043775:+
THCA	cis	rs8031584	0.958	rs61997076	ENSG00000270015.1	RP11-540B6.6	-3.4	0.000744	0.0423	-0.12	-0.15	Huntington's disease progression;	chr15:30924022	chr15:30926514~30928407:+
THCA	cis	rs7829975	0.688	rs7826654	ENSG00000253130.1	CTD-3023L14.2	-3.4	0.000744	0.0423	-0.17	-0.15	Mood instability;	chr8:8521596	chr8:8561391~8569688:+
THCA	cis	rs7829975	0.688	rs7826660	ENSG00000253130.1	CTD-3023L14.2	-3.4	0.000744	0.0423	-0.17	-0.15	Mood instability;	chr8:8521597	chr8:8561391~8569688:+
THCA	cis	rs6449957	0.639	rs706711	ENSG00000249335.1	CTC-340D7.1	3.4	0.000744	0.0423	0.19	0.15	Cleft lip with or without cleft palate;	chr5:68224398	chr5:68832585~68962158:-
THCA	cis	rs6547705	0.777	rs4832307	ENSG00000231259.4	AC125232.1	-3.4	0.000744	0.0423	-0.21	-0.15	Progressive supranuclear palsy;	chr2:86682915	chr2:87031815~87053069:-
THCA	cis	rs5758511	0.633	rs5758689	ENSG00000182057.4	OGFRP1	-3.4	0.000744	0.0423	-0.22	-0.15	Birth weight;	chr22:42268966	chr22:42269753~42275196:+
THCA	cis	rs13064773	0.51	rs340277	ENSG00000272247.1	RP11-379F4.9	3.4	0.000744	0.0423	0.17	0.15	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158869942	chr3:158801257~158801935:-
THCA	cis	rs11059919	1	rs11059919	ENSG00000279500.1	RP11-21K12.2	-3.4	0.000744	0.0423	-0.1	-0.15	Systemic lupus erythematosus;	chr12:128804645	chr12:128813186~128814750:-
THCA	cis	rs3809566	0.613	rs16946330	ENSG00000259459.4	RP11-321G12.1	3.4	0.000744	0.0423	0.12	0.15	Platelet count;	chr15:63032302	chr15:63390136~63438320:+
THCA	cis	rs4253772	0.591	rs6007747	ENSG00000277232.2	GTSE1-AS1	-3.4	0.000744	0.0423	-0.17	-0.15	Cholesterol, total;LDL cholesterol;	chr22:46261364	chr22:46295143~46296660:-
THCA	cis	rs9860340	1	rs4356841	ENSG00000229729.5	RP11-159G9.5	3.39	0.000744	0.0423	0.11	0.15	Electroencephalographic traits in alcoholism;	chr3:87715734	chr3:88059274~88138973:+
THCA	cis	rs7647973	0.516	rs4955418	ENSG00000228638.1	FCF1P2	-3.39	0.000744	0.0423	-0.16	-0.15	Menarche (age at onset);	chr3:49163194	chr3:48290793~48291375:-
THCA	cis	rs3824488	0.92	rs28446116	ENSG00000271384.1	RP11-435O5.7	-3.39	0.000745	0.0423	-0.22	-0.15	Neuroticism;	chr9:95481103	chr9:95406990~95407662:-
THCA	cis	rs17689437	0.647	rs821166	ENSG00000260084.1	RP11-615I2.1	3.39	0.000745	0.0423	0.18	0.15	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68544578	chr16:68573782~68589512:-
THCA	cis	rs2944755	0.686	rs6983414	ENSG00000259891.1	CTA-204B4.2	3.39	0.000745	0.0423	0.11	0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140580093	chr8:140505813~140508043:-
THCA	cis	rs1783925	1	rs2845845	ENSG00000254759.1	NAP1L1P1	-3.39	0.000745	0.0423	-0.19	-0.15	Formal thought disorder in schizophrenia;	chr11:125433767	chr11:126067539~126068601:+
THCA	cis	rs66561647	1	rs66561647	ENSG00000207110.1	RNU1-106P	-3.39	0.000745	0.0423	-0.21	-0.15	Hemoglobin concentration;	chr8:127959615	chr8:127999131~127999294:+
THCA	cis	rs7750345	0.83	rs7759802	ENSG00000203808.9	BVES-AS1	3.39	0.000745	0.0423	0.22	0.15	Age-related macular degeneration;	chr6:105802901	chr6:105136308~105169945:+
THCA	cis	rs12701220	0.655	rs10241018	ENSG00000225146.1	AC073957.15	3.39	0.000745	0.0423	0.2	0.15	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1029025~1043891:+
THCA	cis	rs4427176	0.507	rs7822904	ENSG00000254340.1	RP11-10A14.3	-3.39	0.000745	0.0423	-0.18	-0.15	Mosquito bite size;	chr8:9677485	chr8:9141424~9145435:+
THCA	cis	rs768090	0.747	rs3791991	ENSG00000237892.1	KLF7-IT1	-3.39	0.000745	0.0423	-0.18	-0.15	Hemoglobin concentration;Hematocrit;	chr2:207119380	chr2:207120884~207122044:-
THCA	cis	rs950027	0.62	rs2486274	ENSG00000259479.5	SORD2P	3.39	0.000745	0.0423	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:44826371~44884694:-
THCA	cis	rs13178541	0.566	rs6879940	ENSG00000250167.1	CTC-321K16.1	-3.39	0.000745	0.0423	-0.17	-0.15	IgG glycosylation;	chr5:135718040	chr5:135559577~135634874:+
THCA	cis	rs6929812	0.664	rs4711151	ENSG00000271755.1	RP1-153G14.4	3.39	0.000745	0.0423	0.17	0.15	Neuroticism (multi-trait analysis);	chr6:27412322	chr6:27404010~27406964:-
THCA	cis	rs1555322	0.53	rs2250205	ENSG00000261582.1	RP4-614O4.11	-3.39	0.000745	0.0423	-0.17	-0.15	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35267885~35280043:-
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Body mass index;	chr17:30739311	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Body mass index;	chr17:30745415	chr17:30553697~30558962:+
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Body mass index;	chr17:30745654	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000264242.2	RP11-271K11.1	3.39	0.000745	0.0423	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30553697~30558962:+
THCA	cis	rs34421088	0.56	rs2248325	ENSG00000270154.1	RP11-419I17.1	-3.39	0.000745	0.0423	-0.19	-0.15	Neuroticism;	chr8:11539365	chr8:12476462~12477122:+
THCA	cis	rs34421088	0.56	rs2248316	ENSG00000270154.1	RP11-419I17.1	-3.39	0.000745	0.0423	-0.19	-0.15	Neuroticism;	chr8:11539564	chr8:12476462~12477122:+
THCA	cis	rs34421088	0.56	rs2248315	ENSG00000270154.1	RP11-419I17.1	-3.39	0.000745	0.0423	-0.19	-0.15	Neuroticism;	chr8:11539577	chr8:12476462~12477122:+
THCA	cis	rs9402743	0.597	rs9483880	ENSG00000272189.1	RP3-325F22.5	3.39	0.000745	0.0423	0.15	0.15	Systemic lupus erythematosus;	chr6:135781474	chr6:136550661~136552554:+
THCA	cis	rs9402743	0.632	rs4895458	ENSG00000272189.1	RP3-325F22.5	3.39	0.000745	0.0423	0.15	0.15	Systemic lupus erythematosus;	chr6:135783235	chr6:136550661~136552554:+
THCA	cis	rs1047014	0.81	rs60752518	ENSG00000226786.2	RP1-167F1.2	-3.39	0.000745	0.0423	-0.15	-0.15	Height;	chr6:19831899	chr6:19534944~19839080:-
THCA	cis	rs8053891	0.673	rs11645582	ENSG00000262140.1	RP11-417N10.3	3.39	0.000745	0.0423	0.21	0.15	Coronary artery disease;	chr16:71995109	chr16:71833787~71835932:+
THCA	cis	rs2880765	0.743	rs16940052	ENSG00000259407.1	RP11-158M2.3	-3.39	0.000745	0.0423	-0.16	-0.15	Coronary artery disease;	chr15:85463443	chr15:85744109~85750281:-
THCA	cis	rs7838490	0.559	rs6994311	ENSG00000253553.4	RP11-586K2.1	-3.39	0.000745	0.0423	-0.16	-0.15	Body mass index and cholesterol (psychopharmacological treatment);	chr8:88584995	chr8:88326836~88737134:+
THCA	cis	rs6921919	0.832	rs17312661	ENSG00000280107.1	AL022393.9	-3.39	0.000745	0.0423	-0.2	-0.15	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28170845~28172521:+
THCA	cis	rs948562	0.74	rs12361770	ENSG00000280010.1	AP001350.4	3.39	0.000745	0.0423	0.25	0.15	Lymphoma;	chr11:58666759	chr11:58627435~58628528:+
THCA	cis	rs9487094	0.6	rs1885690	ENSG00000223537.2	RP5-919F19.5	-3.39	0.000745	0.0423	-0.16	-0.15	Height;	chr6:109351795	chr6:109487906~109506800:+
THCA	cis	rs7613875	0.6	rs2624832	ENSG00000281691.1	RBM5-AS1	3.39	0.000745	0.0423	0.13	0.15	Body mass index;	chr3:49993425	chr3:50099603~50100988:-
THCA	cis	rs6591182	0.503	rs11227241	ENSG00000245532.5	NEAT1	-3.39	0.000745	0.0423	-0.11	-0.15	Non-alcoholic fatty liver disease histology (lobular);	chr11:65622419	chr11:65422774~65445540:+
THCA	cis	rs11190604	0.731	rs10883480	ENSG00000273030.1	RP11-285F16.1	-3.39	0.000745	0.0423	-0.18	-0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100404064	chr10:100412934~100413421:+
THCA	cis	rs4808199	0.947	rs754255	ENSG00000267481.1	CTC-559E9.5	-3.39	0.000745	0.0423	-0.16	-0.15	Nonalcoholic fatty liver disease;	chr19:19468081	chr19:19788755~19790531:-
THCA	cis	rs950169	0.656	rs748455	ENSG00000254414.1	RP11-182J1.1	3.39	0.000745	0.0423	0.22	0.15	Schizophrenia;	chr15:84606344	chr15:84631898~84633987:-
THCA	cis	rs55702914	0.628	rs2565154	ENSG00000231621.1	AC013264.2	-3.39	0.000746	0.0423	-0.15	-0.15	Major depression and alcohol dependence;	chr2:197445665	chr2:197197991~197199273:+
THCA	cis	rs1799949	0.965	rs6503726	ENSG00000236383.6	LINC00854	-3.39	0.000746	0.0423	-0.15	-0.15	Menopause (age at onset);	chr17:43132725	chr17:43216941~43305976:-
THCA	cis	rs10129255	0.957	rs12590735	ENSG00000211972.2	IGHV3-66	3.39	0.000746	0.0423	0.09	0.15	Kawasaki disease;	chr14:106779660	chr14:106675017~106675544:-
THCA	cis	rs467650	0.549	rs2547958	ENSG00000248489.1	CTD-2007H13.3	-3.39	0.000746	0.0423	-0.14	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:98658249	chr5:98929171~98995013:+
THCA	cis	rs2880765	0.743	rs11630410	ENSG00000259407.1	RP11-158M2.3	-3.39	0.000746	0.0424	-0.16	-0.15	Coronary artery disease;	chr15:85461510	chr15:85744109~85750281:-
THCA	cis	rs2880765	0.71	rs11630457	ENSG00000259407.1	RP11-158M2.3	-3.39	0.000746	0.0424	-0.16	-0.15	Coronary artery disease;	chr15:85461570	chr15:85744109~85750281:-
THCA	cis	rs1005277	0.579	rs2474595	ENSG00000151963.4	RP11-775A3.1	3.39	0.000746	0.0424	0.16	0.15	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:37883594~37884109:+
THCA	cis	rs854765	0.663	rs3183702	ENSG00000281749.1	Y_RNA	-3.39	0.000746	0.0424	-0.2	-0.15	Total body bone mineral density;	chr17:17843975	chr17:18001101~18001195:-
THCA	cis	rs9908102	0.932	rs1044569	ENSG00000277621.1	RP11-597M12.2	-3.39	0.000746	0.0424	-0.16	-0.15	Schizophrenia;	chr17:12992612	chr17:12982613~12983002:-
THCA	cis	rs9392556	0.829	rs617790	ENSG00000230648.1	RP3-406P24.3	3.39	0.000746	0.0424	0.19	0.15	Blood metabolite levels;	chr6:4115524	chr6:4018843~4021215:-
THCA	cis	rs9596863	0.898	rs6561746	ENSG00000136149.6	RPL13AP25	-3.39	0.000746	0.0424	-0.17	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53784233	chr13:54440704~54441315:-
THCA	cis	rs7394190	0.748	rs11000766	ENSG00000272599.2	RP11-152N13.16	3.39	0.000746	0.0424	0.21	0.15	Incident atrial fibrillation;	chr10:73753194	chr10:73124573~73125532:-
THCA	cis	rs12541437	0.535	rs6989717	ENSG00000253327.2	RAD21-AS1	3.39	0.000746	0.0424	0.23	0.15	Gut microbiome composition (winter);	chr8:116845667	chr8:116874424~116876868:+
THCA	cis	rs17695224	0.565	rs28800315	ENSG00000275055.1	CTC-471J1.11	-3.39	0.000746	0.0424	-0.12	-0.15	HDL cholesterol;HDL cholesterol levels;	chr19:51805837	chr19:52049007~52049754:+
THCA	cis	rs1959947	0.793	rs67387018	ENSG00000251363.2	RP11-129M6.1	-3.39	0.000746	0.0424	-0.2	-0.15	Hemostatic factors and hematological phenotypes;	chr14:41047282	chr14:40954898~40975877:+
THCA	cis	rs7843479	1	rs7843479	ENSG00000208037.1	MIR320A	-3.39	0.000746	0.0424	-0.19	-0.15	Mean corpuscular volume;	chr8:21963302	chr8:22244962~22245043:-
THCA	cis	rs9635324	1	rs10518693	ENSG00000259536.4	RP11-111A22.1	3.39	0.000746	0.0424	0.2	0.15	Blood metabolite ratios;Blood metabolite levels;	chr15:40407823	chr15:40488041~40558019:+
THCA	cis	rs6088813	0.961	rs981819	ENSG00000261582.1	RP4-614O4.11	-3.39	0.000746	0.0424	-0.15	-0.15	Height;	chr20:35336309	chr20:35267885~35280043:-
THCA	cis	rs6088813	0.961	rs981818	ENSG00000261582.1	RP4-614O4.11	-3.39	0.000746	0.0424	-0.15	-0.15	Height;	chr20:35336327	chr20:35267885~35280043:-
THCA	cis	rs6088813	0.961	rs2425063	ENSG00000261582.1	RP4-614O4.11	-3.39	0.000746	0.0424	-0.15	-0.15	Height;	chr20:35336470	chr20:35267885~35280043:-
THCA	cis	rs7246657	0.943	rs10424574	ENSG00000268499.1	CTB-102L5.8	3.39	0.000746	0.0424	0.21	0.15	Coronary artery calcification;	chr19:37347491	chr19:38199836~38200934:+
THCA	cis	rs7690839	1	rs4693974	ENSG00000270720.1	RP11-84C13.2	3.39	0.000746	0.0424	0.17	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88889244	chr4:89119284~89119871:+
THCA	cis	rs11671005	0.696	rs73066211	ENSG00000268912.1	CTD-2619J13.17	-3.39	0.000746	0.0424	-0.15	-0.15	Mean platelet volume;	chr19:58485712	chr19:58428632~58431148:-
THCA	cis	rs10911363	0.592	rs2702177	ENSG00000232860.6	SMG7-AS1	-3.39	0.000746	0.0424	-0.12	-0.15	Systemic lupus erythematosus;	chr1:183481487	chr1:183460874~183472265:-
THCA	cis	rs10911363	0.592	rs2702178	ENSG00000232860.6	SMG7-AS1	-3.39	0.000746	0.0424	-0.12	-0.15	Systemic lupus erythematosus;	chr1:183483410	chr1:183460874~183472265:-
THCA	cis	rs2039553	0.553	rs2039556	ENSG00000227354.5	RBM26-AS1	3.39	0.000746	0.0424	0.15	0.15	Pancreatic cancer;	chr13:79811298	chr13:79406309~79424328:+
THCA	cis	rs6678639	0.522	rs74073884	ENSG00000224805.2	LINC00853	-3.39	0.000746	0.0424	-0.23	-0.15	Blood metabolite ratios;	chr1:47034799	chr1:47179250~47180339:+
THCA	cis	rs3824488	0.765	rs10512247	ENSG00000271155.1	RP11-435O5.5	-3.39	0.000746	0.0424	-0.26	-0.15	Neuroticism;	chr9:95534121	chr9:95506235~95507636:+
THCA	cis	rs9634489	0.807	rs9554351	ENSG00000247400.3	DNAJC3-AS1	-3.39	0.000746	0.0424	-0.1	-0.15	Body mass index;	chr13:96400990	chr13:95648733~95676925:-
THCA	cis	rs10091877	0.607	rs12056433	ENSG00000270154.1	RP11-419I17.1	3.39	0.000746	0.0424	0.24	0.15	Lung adenocarcinoma;	chr8:13034363	chr8:12476462~12477122:+
THCA	cis	rs9314614	0.789	rs4840640	ENSG00000245857.2	GS1-24F4.2	3.39	0.000746	0.0424	0.2	0.15	White blood cell count (basophil);IgA nephropathy;	chr8:6855166	chr8:6835554~6885276:+
THCA	cis	rs35934224	0.628	rs2073750	ENSG00000232926.1	AC000078.5	3.39	0.000747	0.0424	0.16	0.15	Glaucoma (primary open-angle);	chr22:19885834	chr22:19887289~19887970:+
THCA	cis	rs2638953	0.924	rs10843162	ENSG00000247934.4	RP11-967K21.1	-3.39	0.000747	0.0424	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28410985	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049579	ENSG00000247934.4	RP11-967K21.1	-3.39	0.000747	0.0424	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414693	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs10843163	ENSG00000247934.4	RP11-967K21.1	-3.39	0.000747	0.0424	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415541	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049582	ENSG00000247934.4	RP11-967K21.1	-3.39	0.000747	0.0424	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416392	chr12:28163298~28190738:-
THCA	cis	rs9300255	0.602	rs1727317	ENSG00000274427.1	RP11-972P1.10	3.39	0.000747	0.0424	0.16	0.15	Neutrophil percentage of white cells;	chr12:123134395	chr12:123515275~123515513:-
THCA	cis	rs55966801	0.898	rs551419	ENSG00000277290.1	RP11-326C3.16	-3.39	0.000747	0.0424	-0.2	-0.15	Plateletcrit;	chr11:240844	chr11:243099~243483:-
THCA	cis	rs7020830	0.867	rs1339553	ENSG00000260100.1	RP11-220I1.5	-3.39	0.000747	0.0424	-0.19	-0.15	Schizophrenia;	chr9:37266126	chr9:37078813~37079776:-
THCA	cis	rs7259376	0.936	rs7255829	ENSG00000270947.1	AC025811.3	3.39	0.000747	0.0424	0.17	0.15	Menopause (age at onset);	chr19:22354509	chr19:22455988~22456459:+
THCA	cis	rs1144333	0.655	rs1438175	ENSG00000272855.1	RP5-1102E8.3	-3.39	0.000747	0.0424	-0.34	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:76009043	chr1:76636877~76637339:+
THCA	cis	rs6715793	0.772	rs62146726	ENSG00000272754.1	AL133245.2	-3.39	0.000747	0.0424	-0.18	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33206462	chr2:32321638~32323002:+
THCA	cis	rs7246967	0.608	rs396440	ENSG00000198153.8	ZNF849P	-3.39	0.000747	0.0424	-0.23	-0.15	Bronchopulmonary dysplasia;	chr19:22820164	chr19:22685167~22686732:+
THCA	cis	rs36093844	0.527	rs72963092	ENSG00000279742.1	RP11-700A24.1	-3.39	0.000747	0.0424	-0.21	-0.15	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86033584	chr11:85852557~85854943:-
THCA	cis	rs638893	1	rs638893	ENSG00000255239.1	AP002954.6	3.39	0.000747	0.0424	0.28	0.15	Vitiligo;	chr11:118827828	chr11:118688039~118690600:-
THCA	cis	rs638893	1	rs28827279	ENSG00000255239.1	AP002954.6	3.39	0.000747	0.0424	0.28	0.15	Vitiligo;	chr11:118830054	chr11:118688039~118690600:-
THCA	cis	rs763512	0.532	rs3094499	ENSG00000277501.1	RP11-697E22.2	3.39	0.000747	0.0424	0.23	0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37531234	chr17:37642947~37684252:+
THCA	cis	rs972578	0.742	rs3788596	ENSG00000230319.1	AL022476.2	3.39	0.000747	0.0424	0.17	0.15	Mean platelet volume;	chr22:42801853	chr22:43038585~43052366:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000278820.1	AC024937.1	3.39	0.000747	0.0424	0.16	0.15	Pancreatic cancer;	chr3:196009869	chr3:195960500~195960612:-
THCA	cis	rs4927850	1	rs4927704	ENSG00000278820.1	AC024937.1	3.39	0.000747	0.0424	0.16	0.15	Pancreatic cancer;	chr3:196011357	chr3:195960500~195960612:-
THCA	cis	rs4927850	1	rs4927848	ENSG00000278820.1	AC024937.1	3.39	0.000747	0.0424	0.16	0.15	Pancreatic cancer;	chr3:196011535	chr3:195960500~195960612:-
THCA	cis	rs6565180	1	rs11863150	ENSG00000274678.1	RP11-2C24.7	3.39	0.000747	0.0424	0.14	0.15	Tonsillectomy;	chr16:30374182	chr16:30821338~30821884:+
THCA	cis	rs13136331	0.721	rs2627721	ENSG00000249001.4	RP11-742B18.1	3.39	0.000747	0.0424	0.2	0.15	Sitting height ratio;	chr4:87762277	chr4:87568035~87733956:-
THCA	cis	rs13136331	0.721	rs2627717	ENSG00000249001.4	RP11-742B18.1	3.39	0.000747	0.0424	0.2	0.15	Sitting height ratio;	chr4:87763593	chr4:87568035~87733956:-
THCA	cis	rs57590327	0.503	rs12497231	ENSG00000241593.4	RP11-520D19.2	3.39	0.000747	0.0424	0.19	0.15	Extraversion;	chr3:81470140	chr3:81246579~81297345:-
THCA	cis	rs1346081	0.758	rs17088071	ENSG00000270292.1	RP11-453E17.4	-3.39	0.000747	0.0424	-0.19	-0.15	Intelligence (multi-trait analysis);	chr4:67183285	chr4:67725183~67726395:-
THCA	cis	rs939960	0.836	rs7788112	ENSG00000276538.1	RP11-545G3.2	3.39	0.000747	0.0424	0.22	0.15	Neutrophil percentage of white cells;	chr7:150610366	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs7788300	ENSG00000276538.1	RP11-545G3.2	3.39	0.000747	0.0424	0.22	0.15	Neutrophil percentage of white cells;	chr7:150610507	chr7:150047609~150047854:-
THCA	cis	rs6433895	0.601	rs13033038	ENSG00000236153.1	AC104076.3	-3.39	0.000747	0.0424	-0.2	-0.15	Lymphocyte counts;	chr2:181187828	chr2:180979427~180980090:-
THCA	cis	rs6691738	0.959	rs10157163	ENSG00000227373.4	RP11-160H22.5	3.39	0.000747	0.0424	0.21	0.15	Asthma;	chr1:173163826	chr1:174115300~174160004:-
THCA	cis	rs9843304	0.967	rs12633863	ENSG00000243885.1	RP11-278L15.2	-3.39	0.000747	0.0424	-0.17	-0.15	Gallstone disease;	chr3:149493725	chr3:149384179~149385800:-
THCA	cis	rs34779708	0.931	rs7079205	ENSG00000233200.1	RP11-324I22.2	3.39	0.000747	0.0424	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35219894~35230598:-
THCA	cis	rs732716	0.785	rs55660045	ENSG00000280239.1	CTB-50L17.8	-3.39	0.000747	0.0424	-0.13	-0.15	Mean corpuscular volume;	chr19:4425308	chr19:4448810~4450836:+
THCA	cis	rs9905704	0.813	rs304269	ENSG00000279069.1	RP11-159D12.6	-3.39	0.000747	0.0424	-0.16	-0.15	Testicular germ cell tumor;	chr17:58724698	chr17:58006674~58008187:+
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000281021.1	RP1-12G14.9	-3.39	0.000747	0.0424	-0.16	-0.15	Lung cancer;	chr6:149622577	chr6:149576089~149590864:-
THCA	cis	rs12476592	0.602	rs1356390	ENSG00000242412.1	DBIL5P2	-3.39	0.000747	0.0424	-0.2	-0.15	Childhood ear infection;	chr2:63442491	chr2:63117851~63119542:-
THCA	cis	rs9733	0.621	rs6669122	ENSG00000231073.1	RP11-316M1.3	-3.39	0.000747	0.0424	-0.19	-0.15	Tonsillectomy;	chr1:150619256	chr1:150973123~150975534:+
THCA	cis	rs35740288	0.577	rs10163090	ENSG00000259295.5	CSPG4P12	3.39	0.000747	0.0424	0.2	0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85650525	chr15:85191438~85213905:+
THCA	cis	rs9307551	0.619	rs998437	ENSG00000249646.2	OR7E94P	-3.39	0.000747	0.0424	-0.2	-0.15	Refractive error;	chr4:79508616	chr4:79587302~79588130:-
THCA	cis	rs897984	0.683	rs13337900	ENSG00000260911.2	RP11-196G11.2	3.39	0.000747	0.0424	0.13	0.15	Dementia with Lewy bodies;	chr16:30811088	chr16:31043150~31049868:+
THCA	cis	rs4443100	0.631	rs13054904	ENSG00000240160.3	RN7SL263P	-3.39	0.000747	0.0424	-0.21	-0.15	Serum parathyroid hormone levels;	chr22:23068739	chr22:23261782~23262071:-
THCA	cis	rs11685222	0.589	rs72965087	ENSG00000229326.3	AC069154.4	3.39	0.000747	0.0424	0.26	0.15	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119671942	chr2:119698623~119700151:+
THCA	cis	rs11685222	0.64	rs72965091	ENSG00000229326.3	AC069154.4	3.39	0.000747	0.0424	0.26	0.15	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119673574	chr2:119698623~119700151:+
THCA	cis	rs78545713	0.649	rs16891464	ENSG00000216331.1	HIST1H1PS1	3.39	0.000748	0.0424	0.27	0.15	Iron status biomarkers (total iron binding capacity);	chr6:26235072	chr6:26195566~26195771:+
THCA	cis	rs1005277	0.579	rs2008449	ENSG00000151963.4	RP11-775A3.1	3.39	0.000748	0.0424	0.16	0.15	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:37883594~37884109:+
THCA	cis	rs73459955	0.712	rs61017442	ENSG00000248441.5	LINC01197	3.39	0.000748	0.0424	0.2	0.15	Major depression and alcohol dependence;	chr15:95079664	chr15:95209099~95327129:-
THCA	cis	rs858239	0.899	rs858271	ENSG00000230042.1	AK3P3	-3.39	0.000748	0.0424	-0.21	-0.15	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23129178~23129841:+
THCA	cis	rs1572312	1	rs1572312	ENSG00000237928.4	NFIA-AS2	3.39	0.000748	0.0424	0.28	0.15	Maximal oxygen uptake response;	chr1:60952057	chr1:60940239~60970776:-
THCA	cis	rs61008539	0.741	rs11767322	ENSG00000273151.1	RP11-449P15.2	-3.39	0.000748	0.0424	-0.11	-0.15	Perceived unattractiveness to mosquitoes;	chr7:827768	chr7:879790~886547:-
THCA	cis	rs7923837	0.634	rs1544210	ENSG00000236493.2	EIF2S2P3	-3.39	0.000748	0.0424	-0.16	-0.15	Multiple sclerosis;Body mass index;	chr10:92728044	chr10:92668745~92669743:-
THCA	cis	rs881375	0.933	rs7021206	ENSG00000270917.1	RP11-27I1.6	3.39	0.000748	0.0424	0.21	0.15	Rheumatoid arthritis;	chr9:120921879	chr9:120812475~120812845:-
THCA	cis	rs11013210	0.508	rs7100499	ENSG00000261671.1	RP11-573G6.6	-3.39	0.000748	0.0424	-0.21	-0.15	Systemic lupus erythematosus;	chr10:23012507	chr10:22257786~22258548:+
THCA	cis	rs4646404	0.509	rs4646368	ENSG00000225442.2	MPRIP-AS1	3.39	0.000748	0.0424	0.19	0.15	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr17:17562144	chr17:17076038~17077752:-
THCA	cis	rs1799949	0.965	rs799910	ENSG00000279602.1	CTD-3014M21.1	-3.39	0.000748	0.0424	-0.19	-0.15	Menopause (age at onset);	chr17:43127544	chr17:43360041~43361361:-
THCA	cis	rs8028182	0.666	rs4886708	ENSG00000275645.1	RP11-817O13.9	3.39	0.000748	0.0424	0.15	0.15	Sudden cardiac arrest;	chr15:75470267	chr15:75346744~75347161:-
THCA	cis	rs12022452	1	rs12022452	ENSG00000272145.1	NFYC-AS1	3.39	0.000748	0.0424	0.13	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40690380~40692066:-
THCA	cis	rs78487399	0.808	rs13416978	ENSG00000234936.1	AC010883.5	-3.39	0.000748	0.0424	-0.2	-0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43478126	chr2:43229573~43233394:+
THCA	cis	rs78487399	0.808	rs13405158	ENSG00000234936.1	AC010883.5	-3.39	0.000748	0.0424	-0.2	-0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43478147	chr2:43229573~43233394:+
THCA	cis	rs922948	0.927	rs6769509	ENSG00000241506.1	PSMC1P1	-3.39	0.000748	0.0424	-0.15	-0.15	Hip geometry;	chr3:69386555	chr3:68635705~68637024:+
THCA	cis	rs5758659	1	rs5758659	ENSG00000205702.9	CYP2D7	3.39	0.000748	0.0424	0.12	0.15	Cognitive function;	chr22:42225997	chr22:42140203~42144577:-
THCA	cis	rs925946	1	rs11030108	ENSG00000245573.6	BDNF-AS	-3.39	0.000748	0.0425	-0.15	-0.15	Weight;Body mass index;	chr11:27673917	chr11:27506838~27698174:+
THCA	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-3.39	0.000748	0.0425	-0.15	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
THCA	cis	rs775227	0.935	rs34239722	ENSG00000243849.1	CFAP44-AS1	3.39	0.000748	0.0425	0.28	0.15	Dental caries;	chr3:113253991	chr3:113403991~113433992:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000272831.1	RP11-792A8.4	3.39	0.000748	0.0425	0.1	0.15	Aortic root size;	chr7:66749580	chr7:66739829~66740385:-
THCA	cis	rs801193	0.66	rs4610622	ENSG00000272831.1	RP11-792A8.4	3.39	0.000748	0.0425	0.1	0.15	Aortic root size;	chr7:66759510	chr7:66739829~66740385:-
THCA	cis	rs12935418	0.616	rs8045512	ENSG00000261838.4	RP11-303E16.6	3.39	0.000748	0.0425	0.22	0.15	Mean corpuscular volume;	chr16:80952410	chr16:81069854~81076598:+
THCA	cis	rs12935418	0.616	rs718954	ENSG00000261838.4	RP11-303E16.6	3.39	0.000748	0.0425	0.22	0.15	Mean corpuscular volume;	chr16:80953219	chr16:81069854~81076598:+
THCA	cis	rs7824557	0.564	rs13268126	ENSG00000261451.1	RP11-981G7.1	-3.39	0.000748	0.0425	-0.2	-0.15	Retinal vascular caliber;	chr8:11373065	chr8:10433672~10438312:+
THCA	cis	rs1850744	0.702	rs7668469	ENSG00000249767.1	ENPP7P10	-3.39	0.000748	0.0425	-0.31	-0.15	Economic and political preferences;	chr4:9742906	chr4:9079023~9141608:+
THCA	cis	rs7395662	0.929	rs7108559	ENSG00000200090.1	Y_RNA	-3.39	0.000748	0.0425	-0.1	-0.15	HDL cholesterol;	chr11:48597599	chr11:47726894~47726992:-
THCA	cis	rs12428035	0.571	rs1788062	ENSG00000247400.3	DNAJC3-AS1	3.39	0.000748	0.0425	0.15	0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95975538	chr13:95648733~95676925:-
THCA	cis	rs6430585	0.583	rs11886852	ENSG00000231890.6	DARS-AS1	-3.39	0.000748	0.0425	-0.17	-0.15	Corneal structure;	chr2:135831809	chr2:135985176~136022593:+
THCA	cis	rs11671005	0.568	rs73068325	ENSG00000252334.1	RNU6-1337P	3.39	0.000748	0.0425	0.23	0.15	Mean platelet volume;	chr19:58567729	chr19:58483749~58483843:-
THCA	cis	rs295490	0.748	rs115673919	ENSG00000272656.1	RP11-219D15.3	3.39	0.000748	0.0425	0.3	0.15	PR interval in Tripanosoma cruzi seropositivity;	chr3:139489239	chr3:139349024~139349371:-
THCA	cis	rs9911578	1	rs999431	ENSG00000224738.1	AC099850.1	3.39	0.000748	0.0425	0.17	0.15	Intelligence (multi-trait analysis);	chr17:58777080	chr17:59106598~59118267:+
THCA	cis	rs58785573	0.504	rs62294474	ENSG00000231160.8	KLF3-AS1	-3.39	0.000748	0.0425	-0.09	-0.15	Lymphocyte percentage of white cells;	chr4:38627104	chr4:38612701~38664883:-
THCA	cis	rs12049351	0.719	rs6587338	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229496891	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs6704265	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229497309	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs4925457	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229497824	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.719	rs10916492	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229498649	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.719	rs10916493	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229498650	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs10916495	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229499774	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs6670553	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229500120	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs754025	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229501550	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs2381108	ENSG00000229367.1	HMGN2P19	3.39	0.000748	0.0425	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229502134	chr1:229570532~229570796:+
THCA	cis	rs459482	0.508	rs461093	ENSG00000227698.1	AP001619.2	3.39	0.000748	0.0425	0.18	0.15	IgG glycosylation;	chr21:41428263	chr21:41874756~41877613:-
THCA	cis	rs7311936	1	rs7303735	ENSG00000270130.1	RP11-214K3.23	-3.39	0.000748	0.0425	-0.17	-0.15	Vertical cup-disc ratio;	chr12:124151757	chr12:123960717~123961244:-
THCA	cis	rs751728	0.544	rs2281820	ENSG00000274259.2	XXbac-BPG294E21.9	3.39	0.000749	0.0425	0.18	0.15	Crohn's disease;	chr6:33801120	chr6:33437363~33454453:-
THCA	cis	rs765787	0.53	rs11070444	ENSG00000259539.1	CTD-2651B20.1	-3.39	0.000749	0.0425	-0.19	-0.15	Uric acid levels;	chr15:45220923	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs11070445	ENSG00000259539.1	CTD-2651B20.1	-3.39	0.000749	0.0425	-0.19	-0.15	Uric acid levels;	chr15:45220965	chr15:45152664~45167526:-
THCA	cis	rs3736986	1	rs7044157	ENSG00000215283.3	HMGB3P24	-3.39	0.000749	0.0425	-0.28	-0.15	Bipolar disorder (inflammation and infection response interaction);	chr9:36215539	chr9:36303499~36304924:-
THCA	cis	rs9637454	1	rs55838081	ENSG00000231574.4	RP11-91K9.1	-3.39	0.000749	0.0425	-0.22	-0.15	Hippocampal sclerosis;	chr3:178551368	chr3:177816865~177899224:+
THCA	cis	rs4262150	0.81	rs72797211	ENSG00000253921.1	CTB-113P19.3	3.39	0.000749	0.0425	0.21	0.15	Bipolar disorder and schizophrenia;	chr5:152579956	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs72797213	ENSG00000253921.1	CTB-113P19.3	3.39	0.000749	0.0425	0.21	0.15	Bipolar disorder and schizophrenia;	chr5:152580953	chr5:151753992~151767247:+
THCA	cis	rs4262150	0.81	rs72797217	ENSG00000253921.1	CTB-113P19.3	3.39	0.000749	0.0425	0.21	0.15	Bipolar disorder and schizophrenia;	chr5:152582078	chr5:151753992~151767247:+
THCA	cis	rs6840360	0.762	rs62327352	ENSG00000251611.1	RP11-610P16.1	-3.39	0.000749	0.0425	-0.11	-0.15	Intelligence (multi-trait analysis);	chr4:151749628	chr4:151407551~151408835:-
THCA	cis	rs1953600	0.668	rs11201879	ENSG00000242600.5	MBL1P	3.39	0.000749	0.0425	0.13	0.15	Sarcoidosis;	chr10:80148817	chr10:79904898~79950336:+
THCA	cis	rs854765	0.663	rs2236513	ENSG00000281749.1	Y_RNA	-3.39	0.000749	0.0425	-0.2	-0.15	Total body bone mineral density;	chr17:17844052	chr17:18001101~18001195:-
THCA	cis	rs7394190	0.63	rs78845904	ENSG00000272599.2	RP11-152N13.16	3.39	0.000749	0.0425	0.21	0.15	Incident atrial fibrillation;	chr10:73757491	chr10:73124573~73125532:-
THCA	cis	rs13064411	0.696	rs6798938	ENSG00000243849.1	CFAP44-AS1	3.39	0.000749	0.0425	0.24	0.15	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113499359	chr3:113403991~113433992:+
THCA	cis	rs67478160	0.584	rs12433009	ENSG00000269940.1	RP11-73M18.7	3.39	0.000749	0.0425	0.15	0.15	Schizophrenia;	chr14:103730068	chr14:103694560~103695170:+
THCA	cis	rs6121246	0.909	rs4518038	ENSG00000224628.2	RP5-854E16.2	-3.39	0.000749	0.0425	-0.23	-0.15	Mean corpuscular hemoglobin;	chr20:31831248	chr20:31285317~31286835:-
THCA	cis	rs66561647	0.895	rs9649959	ENSG00000207110.1	RNU1-106P	3.39	0.000749	0.0425	0.21	0.15	Hemoglobin concentration;	chr8:127960475	chr8:127999131~127999294:+
THCA	cis	rs6449502	0.748	rs10062839	ENSG00000251279.1	CTC-436P18.1	-3.39	0.000749	0.0425	-0.24	-0.15	Mean platelet volume;	chr5:60807625	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.748	rs6449504	ENSG00000251279.1	CTC-436P18.1	-3.39	0.000749	0.0425	-0.24	-0.15	Mean platelet volume;	chr5:60809409	chr5:61162070~61232040:+
THCA	cis	rs6449502	0.748	rs36111624	ENSG00000251279.1	CTC-436P18.1	-3.39	0.000749	0.0425	-0.24	-0.15	Mean platelet volume;	chr5:60810179	chr5:61162070~61232040:+
THCA	cis	rs283610	0.695	rs157554	ENSG00000271714.1	CTD-2377O17.1	-3.39	0.000749	0.0425	-0.14	-0.15	Obesity-related traits;	chr5:73943871	chr5:74865893~74867854:+
THCA	cis	rs910316	1	rs175426	ENSG00000273565.1	CTD-3075F15.1	-3.39	0.000749	0.0425	-0.18	-0.15	Height;	chr14:75157431	chr14:75176929~75177418:+
THCA	cis	rs4073416	0.595	rs10131715	ENSG00000276116.2	FUT8-AS1	3.39	0.000749	0.0425	0.16	0.15	N-glycan levels;	chr14:65690655	chr14:65411170~65412690:-
THCA	cis	rs1864585	0.52	rs6984391	ENSG00000280294.1	RP11-177H2.1	3.39	0.000749	0.0425	0.16	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10788601	chr8:10856085~10859436:-
THCA	cis	rs3788317	0.535	rs5993856	ENSG00000232926.1	AC000078.5	-3.39	0.000749	0.0425	-0.18	-0.15	Glaucoma (primary angle closure);	chr22:19895107	chr22:19887289~19887970:+
THCA	cis	rs703842	0.642	rs73123375	ENSG00000270039.1	RP11-571M6.17	-3.39	0.000749	0.0425	-0.19	-0.15	Multiple sclerosis;	chr12:57669881	chr12:57803838~57804415:+
THCA	cis	rs17604090	0.938	rs28457783	ENSG00000227855.3	DPY19L2P3	3.39	0.000749	0.0425	0.2	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647442	chr7:29650227~29742594:+
THCA	cis	rs17604090	0.818	rs73090342	ENSG00000227855.3	DPY19L2P3	3.39	0.000749	0.0425	0.2	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647924	chr7:29650227~29742594:+
THCA	cis	rs2013441	0.613	rs4925082	ENSG00000261033.1	RP11-209D14.2	3.39	0.000749	0.0425	0.19	0.15	Obesity-related traits;	chr17:20091360	chr17:20008051~20009234:-
THCA	cis	rs11681884	0.892	rs73955151	ENSG00000236397.3	DDX11L2	-3.39	0.000749	0.0425	-0.32	-0.15	Stroke;	chr2:113103648	chr2:113599036~113601261:-
THCA	cis	rs17428076	0.793	rs12622772	ENSG00000228389.1	AC068039.4	-3.39	0.000749	0.0425	-0.18	-0.15	Myopia;	chr2:171769227	chr2:171773482~171775844:+
THCA	cis	rs7412746	0.611	rs16827671	ENSG00000224800.1	RP11-235D19.2	-3.39	0.000749	0.0425	-0.21	-0.15	Melanoma;	chr1:150766283	chr1:150881236~150881683:-
THCA	cis	rs11673344	0.563	rs256744	ENSG00000267470.4	ZNF571-AS1	3.39	0.000749	0.0425	0.17	0.15	Obesity-related traits;	chr19:37364586	chr19:37548914~37587348:+
THCA	cis	rs10911902	0.688	rs113019508	ENSG00000233196.2	GS1-304P7.1	-3.39	0.000749	0.0425	-0.24	-0.15	Schizophrenia;	chr1:186349685	chr1:186580515~186581191:-
THCA	cis	rs2034650	0.506	rs1984793	ENSG00000259211.1	RP11-64K12.8	-3.39	0.000749	0.0425	-0.14	-0.15	Interstitial lung disease;	chr15:40407172	chr15:40464193~40466726:-
THCA	cis	rs78487399	0.908	rs75873078	ENSG00000234936.1	AC010883.5	3.39	0.000749	0.0425	0.23	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43598160	chr2:43229573~43233394:+
THCA	cis	rs12935229	0.808	rs77733020	ENSG00000260922.1	RP11-538I12.3	-3.39	0.000749	0.0425	-0.27	-0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77372878	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.756	rs76693126	ENSG00000260922.1	RP11-538I12.3	-3.39	0.000749	0.0425	-0.27	-0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77376237	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.756	rs77440337	ENSG00000260922.1	RP11-538I12.3	-3.39	0.000749	0.0425	-0.27	-0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77376263	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.808	rs75770460	ENSG00000260922.1	RP11-538I12.3	-3.39	0.000749	0.0425	-0.27	-0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77376405	chr16:77234877~77290934:+
THCA	cis	rs12935229	0.808	rs113233885	ENSG00000260922.1	RP11-538I12.3	-3.39	0.000749	0.0425	-0.27	-0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77376893	chr16:77234877~77290934:+
THCA	cis	rs7162310	1	rs7163368	ENSG00000259459.4	RP11-321G12.1	3.39	0.00075	0.0425	0.14	0.15	Myopia;	chr15:63278922	chr15:63390136~63438320:+
THCA	cis	rs7162310	1	rs7162310	ENSG00000259459.4	RP11-321G12.1	3.39	0.00075	0.0425	0.14	0.15	Myopia;	chr15:63279035	chr15:63390136~63438320:+
THCA	cis	rs721048	0.92	rs17408652	ENSG00000242412.1	DBIL5P2	-3.39	0.00075	0.0425	-0.22	-0.15	Prostate cancer;	chr2:63163355	chr2:63117851~63119542:-
THCA	cis	rs2235642	0.671	rs2235641	ENSG00000260989.1	LA16c-395F10.2	-3.39	0.00075	0.0425	-0.17	-0.15	Coronary artery disease;	chr16:1558176	chr16:1580527~1610328:+
THCA	cis	rs11708578	0.554	rs35498050	ENSG00000237990.3	CNTN4-AS1	3.39	0.00075	0.0425	0.19	0.15	Schizophrenia;	chr3:2387269	chr3:3039033~3069242:-
THCA	cis	rs1560104	0.536	rs9933641	ENSG00000262801.4	U91319.1	-3.39	0.00075	0.0425	-0.17	-0.15	Obesity-related traits;	chr16:12615413	chr16:13246316~13562918:+
THCA	cis	rs7829975	0.658	rs2409096	ENSG00000253981.4	ALG1L13P	3.39	0.00075	0.0425	0.15	0.15	Mood instability;	chr8:8834967	chr8:8236003~8244667:-
THCA	cis	rs6977955	0.526	rs57585717	ENSG00000234336.5	JAZF1-AS1	-3.39	0.00075	0.0425	-0.19	-0.15	Allergic disease (asthma, hay fever or eczema);	chr7:28109636	chr7:28180322~28243917:+
THCA	cis	rs4417704	0.551	rs4606922	ENSG00000235151.1	AC114730.2	-3.39	0.00075	0.0425	-0.17	-0.15	Joint mobility (Beighton score);	chr2:240951790	chr2:241844380~241845036:+
THCA	cis	rs9549260	0.755	rs2755214	ENSG00000275149.1	RP11-427J23.1	-3.39	0.00075	0.0425	-0.2	-0.15	Red blood cell count;	chr13:40575208	chr13:40079106~40273509:-
THCA	cis	rs7572644	0.664	rs4313931	ENSG00000223522.1	AC093690.1	-3.39	0.00075	0.0425	-0.19	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27851834	chr2:28307691~28310459:-
THCA	cis	rs9796	0.689	rs6492983	ENSG00000247556.5	OIP5-AS1	3.39	0.00075	0.0425	0.13	0.15	Menopause (age at onset);	chr15:41143851	chr15:41283990~41309737:+
THCA	cis	rs11955398	0.501	rs4700387	ENSG00000251279.1	CTC-436P18.1	3.39	0.00075	0.0425	0.19	0.15	Intelligence (multi-trait analysis);	chr5:60740924	chr5:61162070~61232040:+
THCA	cis	rs6028446	0.522	rs6129242	ENSG00000224635.1	RP4-564F22.5	-3.39	0.00075	0.0425	-0.19	-0.15	Chin dimples;	chr20:39299679	chr20:38406011~38416797:-
THCA	cis	rs775227	1	rs13093350	ENSG00000243849.1	CFAP44-AS1	-3.39	0.00075	0.0425	-0.25	-0.15	Dental caries;	chr3:113274216	chr3:113403991~113433992:+
THCA	cis	rs8027587	1	rs12148244	ENSG00000271997.1	RP11-97O12.6	3.39	0.00075	0.0425	0.11	0.15	Obesity-related traits;	chr15:88706569	chr15:88501944~88505787:-
THCA	cis	rs409045	1	rs462076	ENSG00000271874.1	CTD-2024P10.2	-3.39	0.00075	0.0425	-0.21	-0.15	Left ventricular mass;	chr5:34633853	chr5:34651457~34651888:-
THCA	cis	rs11030122	0.702	rs7950153	ENSG00000230593.3	AC090804.1	3.39	0.00075	0.0425	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3930107	chr11:3892398~3892887:-
THCA	cis	rs17074492	1	rs58913499	ENSG00000214182.5	PTMAP5	3.39	0.00075	0.0425	0.17	0.15	Sjögren's syndrome;	chr13:81608313	chr13:81689911~81691072:+
THCA	cis	rs1957429	0.731	rs28370916	ENSG00000272158.1	RP11-840I19.5	-3.39	0.00075	0.0425	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64879376	chr14:65003325~65003767:-
THCA	cis	rs2562456	0.876	rs2359144	ENSG00000213976.4	CTD-2561J22.2	-3.39	0.00075	0.0425	-0.19	-0.15	Pain;	chr19:21407834	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.876	rs4638726	ENSG00000213976.4	CTD-2561J22.2	-3.39	0.00075	0.0425	-0.19	-0.15	Pain;	chr19:21409710	chr19:21382865~21387177:+
THCA	cis	rs9596863	0.898	rs28551599	ENSG00000136149.6	RPL13AP25	-3.39	0.00075	0.0425	-0.19	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53768621	chr13:54440704~54441315:-
THCA	cis	rs2098713	0.512	rs13166974	ENSG00000250155.1	CTD-2353F22.1	-3.39	0.00075	0.0425	-0.19	-0.15	Telomere length;	chr5:37171263	chr5:36666214~36725195:-
THCA	cis	rs7709377	0.723	rs2174996	ENSG00000248445.4	SEMA6A-AS1	-3.39	0.00075	0.0426	-0.14	-0.15	Metabolite levels  (X-11787);	chr5:116155111	chr5:116447547~116508276:+
THCA	cis	rs860295	0.871	rs34632540	ENSG00000236675.1	MTX1P1	3.39	0.00075	0.0426	0.15	0.15	Body mass index;	chr1:155642406	chr1:155230975~155234325:+
THCA	cis	rs74781061	0.585	rs1866114	ENSG00000260103.2	RP11-10O17.1	-3.39	0.00075	0.0426	-0.21	-0.15	Endometriosis;	chr15:74441465	chr15:74478070~74490286:-
THCA	cis	rs524281	0.814	rs10896093	ENSG00000255038.1	RP11-1167A19.2	-3.39	0.00075	0.0426	-0.18	-0.15	Electroencephalogram traits;	chr11:66190940	chr11:66067277~66069619:-
THCA	cis	rs4753788	0.534	rs10789590	ENSG00000255353.1	RP11-382M14.1	-3.39	0.00075	0.0426	-0.18	-0.15	Coronary artery disease;	chr11:107266877	chr11:107176286~107177530:+
THCA	cis	rs2638953	0.886	rs11049617	ENSG00000247934.4	RP11-967K21.1	-3.39	0.00075	0.0426	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453344	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.924	rs11049618	ENSG00000247934.4	RP11-967K21.1	-3.39	0.00075	0.0426	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453371	chr12:28163298~28190738:-
THCA	cis	rs12550646	0.585	rs74887565	ENSG00000260588.1	RP11-930P14.2	-3.39	0.00075	0.0426	-0.19	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41824417	chr8:41828165~41829934:-
THCA	cis	rs7578199	0.576	rs2074774	ENSG00000223374.1	AC005104.3	-3.39	0.00075	0.0426	-0.11	-0.15	Chronic lymphocytic leukemia;	chr2:241456672	chr2:241351340~241353104:-
THCA	cis	rs2997447	0.761	rs2783711	ENSG00000236155.5	RP11-231P20.2	-3.39	0.00075	0.0426	-0.12	-0.15	QRS complex (12-leadsum);	chr1:26102373	chr1:26209741~26229840:+
THCA	cis	rs479105	0.567	rs11615232	ENSG00000278356.1	RP11-372B4.3	-3.39	0.000751	0.0426	-0.15	-0.15	Gut microbiota (bacterial taxa);	chr12:3267287	chr12:2885819~2886329:+
THCA	cis	rs80130819	0.636	rs4760623	ENSG00000226413.2	OR8T1P	3.39	0.000751	0.0426	0.23	0.15	Prostate cancer;	chr12:48225473	chr12:48442030~48442947:-
THCA	cis	rs80130819	0.748	rs10747531	ENSG00000226413.2	OR8T1P	3.39	0.000751	0.0426	0.23	0.15	Prostate cancer;	chr12:48238497	chr12:48442030~48442947:-
THCA	cis	rs3824488	0.92	rs28474857	ENSG00000271384.1	RP11-435O5.7	-3.39	0.000751	0.0426	-0.24	-0.15	Neuroticism;	chr9:95484922	chr9:95406990~95407662:-
THCA	cis	rs1552244	0.882	rs68080705	ENSG00000269982.1	RP11-1020A11.2	3.39	0.000751	0.0426	0.12	0.15	Alzheimer's disease;	chr3:9984059	chr3:9958717~9962539:+
THCA	cis	rs77580281	1	rs5748288	ENSG00000185065.6	AC000068.5	-3.39	0.000751	0.0426	-0.17	-0.15	Pediatric bone mineral density (hip);	chr22:19563255	chr22:19447893~19450105:+
THCA	cis	rs12887734	0.566	rs8548	ENSG00000258735.1	LINC00637	-3.39	0.000751	0.0426	-0.21	-0.15	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103847721~103858049:+
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000281021.1	RP1-12G14.9	-3.39	0.000751	0.0426	-0.16	-0.15	Lung cancer;	chr6:149662080	chr6:149576089~149590864:-
THCA	cis	rs9300255	0.506	rs11057251	ENSG00000256092.2	RP13-942N8.1	-3.39	0.000751	0.0426	-0.11	-0.15	Neutrophil percentage of white cells;	chr12:123306680	chr12:123363868~123366113:+
THCA	cis	rs7819412	1	rs2409722	ENSG00000254839.1	AF131215.6	3.39	0.000751	0.0426	0.16	0.15	Triglycerides;	chr8:11182307	chr8:11062647~11067089:-
THCA	cis	rs701145	0.556	rs355756	ENSG00000243069.6	ARHGEF26-AS1	3.39	0.000751	0.0426	0.21	0.15	Coronary artery disease;	chr3:154303274	chr3:154024401~154121332:-
THCA	cis	rs7240205	0.853	rs34288695	ENSG00000265369.3	PCAT18	3.39	0.000751	0.0426	0.17	0.15	Breast cancer;	chr18:26563122	chr18:26687621~26703638:-
THCA	cis	rs17156371	0.803	rs17156367	ENSG00000182531.7	OR7E115P	-3.39	0.000751	0.0426	-0.29	-0.15	Clozapine-induced agranulocytosis;	chr10:15163656	chr10:15007861~15008884:-
THCA	cis	rs11089937	0.597	rs5757024	ENSG00000215456.5	BCRP4	3.39	0.000751	0.0426	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.597	rs5757026	ENSG00000215456.5	BCRP4	3.39	0.000751	0.0426	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.597	rs5750582	ENSG00000215456.5	BCRP4	3.39	0.000751	0.0426	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.626	rs5757028	ENSG00000215456.5	BCRP4	3.39	0.000751	0.0426	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22630061~22636153:+
THCA	cis	rs2235649	0.833	rs9925460	ENSG00000260022.1	LA16c-306A4.1	3.39	0.000751	0.0426	0.22	0.15	Blood metabolite levels;	chr16:1799942	chr16:883780~885090:+
THCA	cis	rs2836950	0.501	rs2056844	ENSG00000235701.1	PCBP2P1	-3.39	0.000751	0.0426	-0.17	-0.15	Menarche (age at onset);	chr21:39298534	chr21:39171130~39172106:-
THCA	cis	rs34390795	1	rs34390795	ENSG00000277186.1	RP13-554M15.8	3.39	0.000751	0.0426	0.2	0.15	Red blood cell count;	chr12:132535810	chr12:132593031~132593698:-
THCA	cis	rs11634944	0.901	rs2855523	ENSG00000251896.1	SNORD116-27	-3.39	0.000751	0.0426	-0.18	-0.15	Interleukin-8 levels;	chr15:24966466	chr15:25101575~25101666:+
THCA	cis	rs9875589	0.957	rs66716710	ENSG00000233121.1	VN1R20P	3.39	0.000751	0.0426	0.18	0.15	Ovarian reserve;	chr3:13897231	chr3:13926813~13927778:+
THCA	cis	rs2205829	0.563	rs4413607	ENSG00000216915.2	RP1-97D16.1	3.39	0.000751	0.0426	0.21	0.15	Bipolar disorder;	chr6:27507341	chr6:27737000~27738494:-
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000281021.1	RP1-12G14.9	-3.39	0.000751	0.0426	-0.16	-0.15	Lung cancer;	chr6:149585576	chr6:149576089~149590864:-
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000227438.1	AP001471.1	3.39	0.000751	0.0426	0.37	0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:46093264~46097530:-
THCA	cis	rs7772486	0.875	rs11755334	ENSG00000270638.1	RP3-466P17.1	3.39	0.000751	0.0426	0.12	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145735570~145737218:+
THCA	cis	rs916888	0.773	rs199445	ENSG00000260075.1	NSFP1	-3.39	0.000751	0.0426	-0.25	-0.15	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46372855~46487141:+
THCA	cis	rs916888	0.773	rs199443	ENSG00000260075.1	NSFP1	-3.39	0.000751	0.0426	-0.25	-0.15	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46372855~46487141:+
THCA	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	3.39	0.000751	0.0426	0.25	0.15	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
THCA	cis	rs4971059	0.654	rs4971076	ENSG00000225855.5	RUSC1-AS1	3.39	0.000751	0.0426	0.1	0.15	Breast cancer;	chr1:155152296	chr1:155316863~155324176:-
THCA	cis	rs4971059	0.654	rs4971052	ENSG00000225855.5	RUSC1-AS1	3.39	0.000751	0.0426	0.1	0.15	Breast cancer;	chr1:155153542	chr1:155316863~155324176:-
THCA	cis	rs453301	0.686	rs7814328	ENSG00000233609.3	RP11-62H7.2	-3.39	0.000751	0.0426	-0.15	-0.15	Joint mobility (Beighton score);	chr8:9018719	chr8:8961200~8979025:+
THCA	cis	rs56283067	0.847	rs12208621	ENSG00000237686.5	RP5-1120P11.1	-3.39	0.000751	0.0426	-0.14	-0.15	Total body bone mineral density;	chr6:44784266	chr6:43995723~44074652:-
THCA	cis	rs9549260	0.755	rs2755216	ENSG00000275149.1	RP11-427J23.1	-3.39	0.000751	0.0426	-0.21	-0.15	Red blood cell count;	chr13:40582801	chr13:40079106~40273509:-
THCA	cis	rs10241079	1	rs10241079	ENSG00000234536.1	AC096582.7	-3.39	0.000751	0.0426	-0.16	-0.15	Lobe attachment (rater-scored or self-reported);	chr7:46680644	chr7:45773595~45783157:+
THCA	cis	rs1560104	0.556	rs7188416	ENSG00000262801.4	U91319.1	-3.39	0.000751	0.0426	-0.17	-0.15	Obesity-related traits;	chr16:12615754	chr16:13246316~13562918:+
THCA	cis	rs910316	0.737	rs175045	ENSG00000273565.1	CTD-3075F15.1	-3.39	0.000751	0.0426	-0.18	-0.15	Height;	chr14:75008572	chr14:75176929~75177418:+
THCA	cis	rs4489787	0.892	rs6580674	ENSG00000240399.1	RP1-228P16.1	3.39	0.000751	0.0426	0.23	0.15	Prostate cancer (SNP x SNP interaction);	chr12:48465353	chr12:48054813~48055591:-
THCA	cis	rs11168618	1	rs3961921	ENSG00000258273.1	RP11-370I10.4	-3.39	0.000751	0.0426	-0.2	-0.15	Adiponectin levels;	chr12:48549716	chr12:48333755~48333901:-
THCA	cis	rs11650494	0.908	rs73340399	ENSG00000262039.1	RP11-81K2.1	3.39	0.000752	0.0426	0.33	0.15	Prostate cancer;	chr17:49295381	chr17:49370740~49476988:+
THCA	cis	rs11650494	0.908	rs57390430	ENSG00000262039.1	RP11-81K2.1	3.39	0.000752	0.0426	0.33	0.15	Prostate cancer;	chr17:49297524	chr17:49370740~49476988:+
THCA	cis	rs4889240	0.74	rs4889242	ENSG00000278985.1	RP11-303E16.9	-3.39	0.000752	0.0426	-0.16	-0.15	Attention deficit hyperactivity disorder and conduct disorder;	chr16:81123916	chr16:80982319~80984094:-
THCA	cis	rs9400467	0.537	rs12195305	ENSG00000255389.1	C6orf3	3.39	0.000752	0.0426	0.22	0.15	Amino acid levels;Blood metabolite levels;	chr6:111128025	chr6:111599875~111602295:+
THCA	cis	rs6723226	0.698	rs13409142	ENSG00000276517.1	AL133243.2	-3.39	0.000752	0.0426	-0.15	-0.15	Intelligence (multi-trait analysis);	chr2:32441069	chr2:32526504~32529507:+
THCA	cis	rs516805	0.52	rs1741820	ENSG00000279114.1	RP3-425C14.5	-3.39	0.000752	0.0426	-0.14	-0.15	Lymphocyte counts;	chr6:122400365	chr6:122471923~122484161:+
THCA	cis	rs860295	0.775	rs822508	ENSG00000160766.13	GBAP1	-3.39	0.000752	0.0426	-0.17	-0.15	Body mass index;	chr1:155880767	chr1:155213821~155227422:-
THCA	cis	rs4578769	0.722	rs55943912	ENSG00000265939.1	UBE2CP2	-3.39	0.000752	0.0426	-0.2	-0.15	Eosinophil percentage of white cells;	chr18:22938388	chr18:22900486~22900995:-
THCA	cis	rs720064	0.525	rs7232062	ENSG00000264745.1	TTC39C-AS1	3.39	0.000752	0.0426	0.17	0.15	Strep throat;	chr18:23970609	chr18:23994213~24015339:-
THCA	cis	rs12935418	0.672	rs9934957	ENSG00000261061.1	RP11-303E16.2	3.39	0.000752	0.0426	0.15	0.15	Mean corpuscular volume;	chr16:81016078	chr16:81030770~81031485:+
THCA	cis	rs55702914	0.628	rs11902195	ENSG00000231621.1	AC013264.2	-3.39	0.000752	0.0426	-0.15	-0.15	Major depression and alcohol dependence;	chr2:197451646	chr2:197197991~197199273:+
THCA	cis	rs4262150	0.81	rs55648940	ENSG00000253921.1	CTB-113P19.3	3.39	0.000752	0.0426	0.21	0.15	Bipolar disorder and schizophrenia;	chr5:152572095	chr5:151753992~151767247:+
THCA	cis	rs2540552	1	rs2710989	ENSG00000221520.1	MIR1285-1	-3.39	0.000752	0.0426	-0.16	-0.15	IgG glycosylation;	chr7:91600458	chr7:92204015~92204098:-
THCA	cis	rs9425766	0.64	rs6685314	ENSG00000270084.1	GAS5-AS1	-3.39	0.000752	0.0426	-0.16	-0.15	Life satisfaction;	chr1:174089905	chr1:173863248~173863941:+
THCA	cis	rs2292096	0.929	rs12729842	ENSG00000260088.1	RP11-92G12.3	3.39	0.000752	0.0426	0.32	0.15	Epilepsy;	chr1:200792678	chr1:200669507~200694250:+
THCA	cis	rs11124272	0.55	rs607294	ENSG00000276517.1	AL133243.2	-3.39	0.000752	0.0426	-0.15	-0.15	Interleukin-18 levels;	chr2:31607738	chr2:32526504~32529507:+
THCA	cis	rs758324	0.738	rs648304	ENSG00000237714.1	P4HA2-AS1	-3.39	0.000752	0.0426	-0.21	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131951015	chr5:132184876~132192808:+
THCA	cis	rs4281086	0.599	rs6601482	ENSG00000272505.1	RP11-981G7.6	-3.39	0.000752	0.0426	-0.13	-0.15	Obesity-related traits;	chr8:10535679	chr8:10486807~10489666:+
THCA	cis	rs56104184	0.83	rs45589039	ENSG00000243829.1	CTB-33G10.1	-3.39	0.000752	0.0426	-0.21	-0.15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48852128	chr19:49719498~49720081:-
THCA	cis	rs56104184	0.83	rs17272658	ENSG00000243829.1	CTB-33G10.1	-3.39	0.000752	0.0426	-0.21	-0.15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48852148	chr19:49719498~49720081:-
THCA	cis	rs1612141	0.554	rs7151006	ENSG00000251363.2	RP11-129M6.1	3.39	0.000752	0.0426	0.22	0.15	QT interval (drug interaction);	chr14:41108350	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.696	rs4632053	ENSG00000251363.2	RP11-129M6.1	3.39	0.000752	0.0426	0.22	0.15	QT interval (drug interaction);	chr14:41108532	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.739	rs4318121	ENSG00000251363.2	RP11-129M6.1	3.39	0.000752	0.0426	0.22	0.15	QT interval (drug interaction);	chr14:41108823	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs4587875	ENSG00000251363.2	RP11-129M6.1	3.39	0.000752	0.0426	0.22	0.15	QT interval (drug interaction);	chr14:41108890	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.689	rs8018821	ENSG00000251363.2	RP11-129M6.1	3.39	0.000752	0.0426	0.22	0.15	QT interval (drug interaction);	chr14:41109194	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs8019667	ENSG00000251363.2	RP11-129M6.1	3.39	0.000752	0.0426	0.22	0.15	QT interval (drug interaction);	chr14:41109756	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs8022444	ENSG00000251363.2	RP11-129M6.1	3.39	0.000752	0.0426	0.22	0.15	QT interval (drug interaction);	chr14:41109808	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs8023215	ENSG00000251363.2	RP11-129M6.1	3.39	0.000752	0.0426	0.22	0.15	QT interval (drug interaction);	chr14:41110022	chr14:40954898~40975877:+
THCA	cis	rs11708578	0.554	rs35415085	ENSG00000237990.3	CNTN4-AS1	3.39	0.000752	0.0426	0.19	0.15	Schizophrenia;	chr3:2387620	chr3:3039033~3069242:-
THCA	cis	rs7020830	0.858	rs67036212	ENSG00000260100.1	RP11-220I1.5	-3.39	0.000752	0.0427	-0.19	-0.15	Schizophrenia;	chr9:37133541	chr9:37078813~37079776:-
THCA	cis	rs1062753	0.771	rs932376	ENSG00000270083.1	RP1-257I20.14	-3.39	0.000752	0.0427	-0.18	-0.15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42218356	chr22:42089630~42090028:-
THCA	cis	rs2447820	0.588	rs11241670	ENSG00000263432.2	RN7SL689P	3.39	0.000752	0.0427	0.19	0.15	Migraine;	chr5:123044804	chr5:123022487~123022783:-
THCA	cis	rs2447820	0.643	rs4637543	ENSG00000263432.2	RN7SL689P	3.39	0.000752	0.0427	0.19	0.15	Migraine;	chr5:123047514	chr5:123022487~123022783:-
THCA	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-3.39	0.000752	0.0427	-0.18	-0.15	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
THCA	cis	rs41411047	0.702	rs73155073	ENSG00000252172.1	RNU6-720P	3.39	0.000752	0.0427	0.34	0.15	Myocardial infarction;	chr3:149849160	chr3:149917342~149917449:-
THCA	cis	rs41411047	0.826	rs73155075	ENSG00000252172.1	RNU6-720P	3.39	0.000752	0.0427	0.34	0.15	Myocardial infarction;	chr3:149850695	chr3:149917342~149917449:-
THCA	cis	rs41411047	0.826	rs73155077	ENSG00000252172.1	RNU6-720P	3.39	0.000752	0.0427	0.34	0.15	Myocardial infarction;	chr3:149857824	chr3:149917342~149917449:-
THCA	cis	rs41411047	0.826	rs73155082	ENSG00000252172.1	RNU6-720P	3.39	0.000752	0.0427	0.34	0.15	Myocardial infarction;	chr3:149861319	chr3:149917342~149917449:-
THCA	cis	rs41411047	0.826	rs73155084	ENSG00000252172.1	RNU6-720P	3.39	0.000752	0.0427	0.34	0.15	Myocardial infarction;	chr3:149864575	chr3:149917342~149917449:-
THCA	cis	rs41411047	0.826	rs73155086	ENSG00000252172.1	RNU6-720P	3.39	0.000752	0.0427	0.34	0.15	Myocardial infarction;	chr3:149866875	chr3:149917342~149917449:-
THCA	cis	rs10895987	0.955	rs7114094	ENSG00000254614.2	AP003068.23	3.39	0.000752	0.0427	0.25	0.15	Blood protein levels;	chr11:65159740	chr11:65177606~65181834:-
THCA	cis	rs3849046	0.967	rs2242599	ENSG00000253404.1	AC034243.1	-3.39	0.000753	0.0427	-0.17	-0.15	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138508585	chr5:138744434~138753309:-
THCA	cis	rs6163	0.508	rs12776506	ENSG00000236937.2	PTGES3P4	3.39	0.000753	0.0427	0.22	0.15	Waist circumference;Hip circumference;	chr10:102773071	chr10:102845595~102845950:+
THCA	cis	rs1667255	1	rs1791198	ENSG00000266521.1	RP11-650P15.1	3.39	0.000753	0.0427	0.2	0.15	Retinol levels;	chr18:31607926	chr18:31496645~31497195:-
THCA	cis	rs910316	0.81	rs77939209	ENSG00000273565.1	CTD-3075F15.1	-3.39	0.000753	0.0427	-0.18	-0.15	Height;	chr14:75203367	chr14:75176929~75177418:+
THCA	cis	rs453301	0.658	rs9650616	ENSG00000233609.3	RP11-62H7.2	-3.39	0.000753	0.0427	-0.15	-0.15	Joint mobility (Beighton score);	chr8:9011689	chr8:8961200~8979025:+
THCA	cis	rs2351088	0.611	rs9614748	ENSG00000280383.1	CTA-941F9.10	3.39	0.000753	0.0427	0.18	0.15	Tonsillectomy;	chr22:45658340	chr22:45657019~45680130:+
THCA	cis	rs2070615	0.545	rs2453478	ENSG00000269514.1	RP11-370I10.12	-3.39	0.000753	0.0427	-0.13	-0.15	Bipolar disorder;	chr12:48808960	chr12:48198387~48202031:+
THCA	cis	rs12887734	0.524	rs4900599	ENSG00000269958.1	RP11-73M18.8	3.39	0.000753	0.0427	0.15	0.15	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103696353~103697163:+
THCA	cis	rs12049351	0.774	rs34405887	ENSG00000229367.1	HMGN2P19	3.39	0.000753	0.0427	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229482887	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.719	rs34804247	ENSG00000229367.1	HMGN2P19	3.39	0.000753	0.0427	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229484938	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs12030128	ENSG00000229367.1	HMGN2P19	3.39	0.000753	0.0427	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229487116	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs6678721	ENSG00000229367.1	HMGN2P19	3.39	0.000753	0.0427	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229487384	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs4925456	ENSG00000229367.1	HMGN2P19	3.39	0.000753	0.0427	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229488149	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.722	rs6703347	ENSG00000229367.1	HMGN2P19	3.39	0.000753	0.0427	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229490419	chr1:229570532~229570796:+
THCA	cis	rs12049351	0.774	rs6701186	ENSG00000229367.1	HMGN2P19	3.39	0.000753	0.0427	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229490739	chr1:229570532~229570796:+
THCA	cis	rs1137	0.694	rs150136	ENSG00000230836.1	LINC01293	-3.39	0.000753	0.0427	-0.21	-0.15	Myopia (pathological);	chr2:74720017	chr2:74940258~74942670:+
THCA	cis	rs1137	0.857	rs150135	ENSG00000230836.1	LINC01293	-3.39	0.000753	0.0427	-0.21	-0.15	Myopia (pathological);	chr2:74721477	chr2:74940258~74942670:+
THCA	cis	rs12032381	1	rs6688377	ENSG00000200033.1	RNU6-403P	3.39	0.000753	0.0427	0.15	0.15	Dupuytren's disease;	chr1:221444065	chr1:221837334~221837437:-
THCA	cis	rs12032381	0.947	rs6688476	ENSG00000200033.1	RNU6-403P	3.39	0.000753	0.0427	0.15	0.15	Dupuytren's disease;	chr1:221444119	chr1:221837334~221837437:-
THCA	cis	rs7705819	0.675	rs254795	ENSG00000253955.1	CTB-33O18.3	3.39	0.000753	0.0427	0.17	0.15	Stroke;	chr5:173497120	chr5:173579643~173585068:+
THCA	cis	rs12428035	0.505	rs9590318	ENSG00000247400.3	DNAJC3-AS1	-3.39	0.000753	0.0427	-0.13	-0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95730448	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.505	rs9590321	ENSG00000247400.3	DNAJC3-AS1	-3.39	0.000753	0.0427	-0.13	-0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95744351	chr13:95648733~95676925:-
THCA	cis	rs394563	0.601	rs391875	ENSG00000223701.3	RAET1E-AS1	3.39	0.000753	0.0427	0.21	0.15	Dupuytren's disease;	chr6:149474000	chr6:149884431~149919508:+
THCA	cis	rs513088	0.681	rs543249	ENSG00000225171.2	DUTP6	3.39	0.000753	0.0427	0.22	0.15	Schizophrenia;	chr1:166699733	chr1:166868748~166869209:+
THCA	cis	rs6499755	0.712	rs31106	ENSG00000260135.5	RP11-212I21.2	-3.39	0.000753	0.0427	-0.16	-0.15	Hypospadias;	chr16:55342447	chr16:55426797~55462297:-
THCA	cis	rs12621844	0.671	rs900510	ENSG00000234690.5	AC073283.4	-3.39	0.000753	0.0427	-0.15	-0.15	Glycated hemoglobin levels;	chr2:48080210	chr2:47192405~47345074:-
THCA	cis	rs9532669	0.89	rs9532593	ENSG00000229473.2	RGS17P1	3.39	0.000753	0.0427	0.2	0.15	Cervical cancer;	chr13:40847717	chr13:40992779~40993331:-
THCA	cis	rs4262150	0.81	rs35124713	ENSG00000253921.1	CTB-113P19.3	3.39	0.000753	0.0427	0.21	0.15	Bipolar disorder and schizophrenia;	chr5:152571547	chr5:151753992~151767247:+
THCA	cis	rs763121	0.853	rs3788545	ENSG00000225450.1	RP3-508I15.14	-3.39	0.000753	0.0427	-0.12	-0.15	Menopause (age at onset);	chr22:38669167	chr22:38739003~38749041:+
THCA	cis	rs3790645	1	rs282175	ENSG00000241547.1	RP11-4K3__A.5	-3.39	0.000753	0.0427	-0.17	-0.15	Glucose homeostasis traits;	chr1:26569311	chr1:27325329~27325796:+
THCA	cis	rs11886999	0.812	rs57251156	ENSG00000204685.6	STARD7-AS1	-3.39	0.000754	0.0427	-0.17	-0.15	Cardiac Troponin-T levels;	chr2:96220962	chr2:96208416~96242621:+
THCA	cis	rs773506	0.933	rs298723	ENSG00000229694.5	RP11-305L7.6	3.39	0.000754	0.0427	0.18	0.15	Type 2 diabetes nephropathy;	chr9:91261060	chr9:91119062~91182762:+
THCA	cis	rs12780845	1	rs7912093	ENSG00000229124.5	VIM-AS1	3.39	0.000754	0.0427	0.16	0.15	Homocysteine levels;	chr10:17161935	chr10:17214239~17229985:-
THCA	cis	rs12780845	1	rs33993216	ENSG00000229124.5	VIM-AS1	3.39	0.000754	0.0427	0.16	0.15	Homocysteine levels;	chr10:17162140	chr10:17214239~17229985:-
THCA	cis	rs9607412	0.536	rs130624	ENSG00000233360.4	Z83844.1	3.39	0.000754	0.0427	0.17	0.15	Mean corpuscular volume;	chr22:37042611	chr22:37641832~37658377:-
THCA	cis	rs9878978	0.754	rs35669246	ENSG00000227588.2	CNTN4-AS2	3.39	0.000754	0.0427	0.2	0.15	Blood pressure (smoking interaction);	chr3:2395509	chr3:2110409~2144241:-
THCA	cis	rs9878978	0.722	rs35472449	ENSG00000227588.2	CNTN4-AS2	3.39	0.000754	0.0427	0.2	0.15	Blood pressure (smoking interaction);	chr3:2395639	chr3:2110409~2144241:-
THCA	cis	rs8113308	1	rs8104737	ENSG00000275055.1	CTC-471J1.11	-3.39	0.000754	0.0427	-0.17	-0.15	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938444	chr19:52049007~52049754:+
THCA	cis	rs2888875	0.889	rs13000971	ENSG00000200924.1	RNU6-1048P	-3.39	0.000754	0.0427	-0.17	-0.15	Glomerular filtration rate (creatinine);	chr2:43553803	chr2:43892690~43892796:+
THCA	cis	rs7824557	0.767	rs3808513	ENSG00000255310.2	AF131215.2	-3.39	0.000754	0.0427	-0.13	-0.15	Retinal vascular caliber;	chr8:11299951	chr8:11107788~11109726:-
THCA	cis	rs11785400	1	rs4484678	ENSG00000177335.9	C8orf31	3.39	0.000754	0.0427	0.17	0.15	Schizophrenia;	chr8:142649412	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs9720653	ENSG00000177335.9	C8orf31	3.39	0.000754	0.0427	0.17	0.15	Schizophrenia;	chr8:142650555	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs13265663	ENSG00000177335.9	C8orf31	3.39	0.000754	0.0427	0.17	0.15	Schizophrenia;	chr8:142650871	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs11780221	ENSG00000177335.9	C8orf31	3.39	0.000754	0.0427	0.17	0.15	Schizophrenia;	chr8:142666796	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs4736368	ENSG00000177335.9	C8orf31	3.39	0.000754	0.0427	0.17	0.15	Schizophrenia;	chr8:142667109	chr8:143039209~143059942:+
THCA	cis	rs34783982	1	rs34783982	ENSG00000259699.2	HMGB1P8	-3.39	0.000754	0.0427	-0.21	-0.15	Squamous cell lung carcinoma;	chr15:88971932	chr15:89135547~89136495:-
THCA	cis	rs1552244	0.832	rs17050674	ENSG00000269982.1	RP11-1020A11.2	3.39	0.000754	0.0427	0.12	0.15	Alzheimer's disease;	chr3:9985574	chr3:9958717~9962539:+
THCA	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	3.39	0.000754	0.0427	0.18	0.15	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
THCA	cis	rs3026101	0.671	rs11868032	ENSG00000234327.6	AC012146.7	-3.39	0.000754	0.0427	-0.13	-0.15	Body mass index;	chr17:5380322	chr17:5111468~5115004:+
THCA	cis	rs7818688	1	rs73276406	ENSG00000253528.2	RP11-347C18.4	-3.39	0.000754	0.0427	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009532	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs9297950	ENSG00000253528.2	RP11-347C18.4	-3.39	0.000754	0.0427	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013431	chr8:94974573~94974853:-
THCA	cis	rs2692947	0.696	rs2969490	ENSG00000233037.2	AC009237.10	3.39	0.000754	0.0427	0.17	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96138165	chr2:95542730~95543230:-
THCA	cis	rs4081724	0.575	rs73030120	ENSG00000267296.2	CEBPA-AS1	3.39	0.000754	0.0427	0.2	0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33389878	chr19:33302857~33305054:+
THCA	cis	rs2933343	0.729	rs1680785	ENSG00000261159.1	RP11-723O4.9	3.39	0.000754	0.0427	0.16	0.15	IgG glycosylation;	chr3:128925973	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.729	rs1680786	ENSG00000261159.1	RP11-723O4.9	3.39	0.000754	0.0427	0.16	0.15	IgG glycosylation;	chr3:128925997	chr3:128859716~128860526:-
THCA	cis	rs5758511	0.68	rs739146	ENSG00000205702.9	CYP2D7	3.39	0.000754	0.0427	0.14	0.15	Birth weight;	chr22:42264408	chr22:42140203~42144577:-
THCA	cis	rs2638953	0.676	rs11049727	ENSG00000247934.4	RP11-967K21.1	-3.39	0.000754	0.0427	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28584864	chr12:28163298~28190738:-
THCA	cis	rs7949030	0.626	rs71490390	ENSG00000255213.1	NPM1P35	3.39	0.000754	0.0427	0.19	0.15	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr11:62330946~62331813:+
THCA	cis	rs13279522	0.572	rs10113415	ENSG00000272192.1	CTD-2532N20.1	3.39	0.000754	0.0427	0.18	0.15	Coronary heart disease event reduction (statin therapy interaction);	chr8:66097405	chr8:65842752~65843331:+
THCA	cis	rs3015497	0.934	rs2934691	ENSG00000270062.1	RP11-248J18.3	3.39	0.000755	0.0428	0.17	0.15	Mean platelet volume;	chr14:50654615	chr14:50723777~50724272:-
THCA	cis	rs972578	0.504	rs7290324	ENSG00000274717.1	RP1-47A17.1	-3.39	0.000755	0.0428	-0.17	-0.15	Mean platelet volume;	chr22:43021793	chr22:42791814~42794313:-
THCA	cis	rs2880765	0.677	rs7181410	ENSG00000259407.1	RP11-158M2.3	3.39	0.000755	0.0428	0.16	0.15	Coronary artery disease;	chr15:85463104	chr15:85744109~85750281:-
THCA	cis	rs10129255	0.789	rs61997796	ENSG00000211967.3	IGHV3-53	-3.39	0.000755	0.0428	-0.09	-0.15	Kawasaki disease;	chr14:106813798	chr14:106592676~106593347:-
THCA	cis	rs1150668	1	rs1150668	ENSG00000261839.1	RP1-265C24.8	3.39	0.000755	0.0428	0.15	0.15	Pubertal anthropometrics;	chr6:28162011	chr6:28136849~28139678:+
THCA	cis	rs9811920	0.638	rs793471	ENSG00000273374.1	RP11-383I23.2	-3.39	0.000755	0.0428	-0.14	-0.15	Axial length;	chr3:99827491	chr3:99802699~99806058:-
THCA	cis	rs4767841	0.868	rs2996028	ENSG00000252886.1	RN7SKP197	-3.39	0.000755	0.0428	-0.15	-0.15	Urgency urinary incontinence;	chr12:119727350	chr12:119631090~119631386:-
THCA	cis	rs7615952	0.546	rs2979307	ENSG00000272840.1	RP11-379B18.6	-3.39	0.000755	0.0428	-0.25	-0.15	Blood pressure (smoking interaction);	chr3:125590730	chr3:125774714~125797953:+
THCA	cis	rs16857609	0.529	rs2373058	ENSG00000233143.1	DIRC3-AS1	-3.39	0.000755	0.0428	-0.19	-0.15	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:217385826	chr2:217282739~217336120:+
THCA	cis	rs9902453	0.765	rs2628167	ENSG00000214719.10	AC005562.1	-3.39	0.000755	0.0428	-0.14	-0.15	Coffee consumption (cups per day);	chr17:29737480	chr17:30576464~30672789:+
THCA	cis	rs11039798	0.623	rs588700	ENSG00000200090.1	Y_RNA	-3.39	0.000755	0.0428	-0.13	-0.15	Axial length;	chr11:48428337	chr11:47726894~47726992:-
THCA	cis	rs5751614	1	rs5996505	ENSG00000211649.3	IGLV7-46	-3.39	0.000755	0.0428	-0.1	-0.15	Height;	chr22:23247296	chr22:22369614~22370087:+
THCA	cis	rs62025270	0.547	rs1026722	ENSG00000259295.5	CSPG4P12	3.39	0.000755	0.0428	0.24	0.15	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85191438~85213905:+
THCA	cis	rs6664080	0.957	rs3738719	ENSG00000227496.1	RP11-145A3.1	3.39	0.000755	0.0428	0.18	0.15	Iris color (L* coordinate);	chr1:226608816	chr1:225700604~225752243:+
THCA	cis	rs7191700	0.511	rs12923756	ENSG00000263179.1	HNRNPCP4	3.39	0.000755	0.0428	0.19	0.15	Multiple sclerosis;	chr16:11265818	chr16:11242653~11243552:+
THCA	cis	rs74233809	1	rs12413409	ENSG00000236937.2	PTGES3P4	3.39	0.000755	0.0428	0.3	0.15	Birth weight;	chr10:102959339	chr10:102845595~102845950:+
THCA	cis	rs2904967	0.852	rs560097	ENSG00000254614.2	AP003068.23	3.39	0.000755	0.0428	0.29	0.15	Mean corpuscular volume;	chr11:65275059	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.929	rs482842	ENSG00000254614.2	AP003068.23	3.39	0.000755	0.0428	0.29	0.15	Mean corpuscular volume;	chr11:65277807	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.852	rs667341	ENSG00000254614.2	AP003068.23	3.39	0.000755	0.0428	0.29	0.15	Mean corpuscular volume;	chr11:65282711	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.866	rs676573	ENSG00000254614.2	AP003068.23	-3.39	0.000755	0.0428	-0.29	-0.15	Mean corpuscular volume;	chr11:65258991	chr11:65177606~65181834:-
THCA	cis	rs755249	0.567	rs3754346	ENSG00000237624.1	OXCT2P1	3.39	0.000755	0.0428	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39514956~39516490:+
THCA	cis	rs755249	0.567	rs16826093	ENSG00000237624.1	OXCT2P1	3.39	0.000755	0.0428	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39514956~39516490:+
THCA	cis	rs755249	0.567	rs41270811	ENSG00000237624.1	OXCT2P1	3.39	0.000755	0.0428	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39514956~39516490:+
THCA	cis	rs755249	0.567	rs61779274	ENSG00000237624.1	OXCT2P1	3.39	0.000755	0.0428	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39514956~39516490:+
THCA	cis	rs755249	0.567	rs17264671	ENSG00000237624.1	OXCT2P1	3.39	0.000755	0.0428	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39514956~39516490:+
THCA	cis	rs755249	0.567	rs4660690	ENSG00000237624.1	OXCT2P1	3.39	0.000755	0.0428	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39514956~39516490:+
THCA	cis	rs755249	0.567	rs61779275	ENSG00000237624.1	OXCT2P1	3.39	0.000755	0.0428	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39514956~39516490:+
THCA	cis	rs4753788	0.511	rs1388168	ENSG00000255353.1	RP11-382M14.1	-3.39	0.000755	0.0428	-0.18	-0.15	Coronary artery disease;	chr11:107267191	chr11:107176286~107177530:+
THCA	cis	rs3096299	0.563	rs4600467	ENSG00000223959.7	AFG3L1P	3.39	0.000755	0.0428	0.09	0.15	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89972586~90002161:+
THCA	cis	rs990871	0.574	rs11209961	ENSG00000227207.2	RPL31P12	3.39	0.000755	0.0428	0.19	0.15	Subcutaneous adipose tissue;	chr1:72409963	chr1:72301472~72301829:+
THCA	cis	rs1862618	0.671	rs2591965	ENSG00000234553.1	AC022431.3	3.39	0.000755	0.0428	0.16	0.15	Initial pursuit acceleration;	chr5:56940349	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.671	rs2591961	ENSG00000234553.1	AC022431.3	3.39	0.000755	0.0428	0.16	0.15	Initial pursuit acceleration;	chr5:56942770	chr5:56536583~56537826:-
THCA	cis	rs950027	0.62	rs1153860	ENSG00000259479.5	SORD2P	-3.39	0.000755	0.0428	-0.16	-0.15	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:44826371~44884694:-
THCA	cis	rs9796	0.87	rs11855248	ENSG00000247556.5	OIP5-AS1	3.39	0.000755	0.0428	0.12	0.15	Menopause (age at onset);	chr15:40983960	chr15:41283990~41309737:+
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000281021.1	RP1-12G14.9	-3.39	0.000755	0.0428	-0.16	-0.15	Lung cancer;	chr6:149618888	chr6:149576089~149590864:-
THCA	cis	rs683250	0.66	rs520291	ENSG00000254551.1	RP11-727A23.7	3.39	0.000755	0.0428	0.19	0.15	Subcortical brain region volumes;	chr11:83246990	chr11:83209431~83213379:-
THCA	cis	rs683250	0.629	rs681367	ENSG00000254551.1	RP11-727A23.7	-3.39	0.000755	0.0428	-0.19	-0.15	Subcortical brain region volumes;	chr11:83250082	chr11:83209431~83213379:-
THCA	cis	rs944289	0.708	rs1958622	ENSG00000212071.1	AL162511.1	3.39	0.000755	0.0428	0.18	0.15	Thyroid cancer;	chr14:36127289	chr14:36196480~36196568:-
THCA	cis	rs793571	0.694	rs12910580	ENSG00000245975.2	RP11-30K9.6	3.39	0.000755	0.0428	0.17	0.15	Schizophrenia;	chr15:58979854	chr15:58768072~58770974:-
THCA	cis	rs7824557	0.843	rs2572418	ENSG00000269918.1	AF131215.9	-3.39	0.000755	0.0428	-0.16	-0.15	Retinal vascular caliber;	chr8:11255580	chr8:11104691~11106704:-
THCA	cis	rs6715793	0.839	rs60558455	ENSG00000272754.1	AL133245.2	-3.39	0.000755	0.0428	-0.18	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33204196	chr2:32321638~32323002:+
THCA	cis	rs3738443	0.678	rs61636449	ENSG00000259865.1	RP11-488L18.10	3.39	0.000755	0.0428	0.14	0.15	Alcohol dependence;	chr1:247213758	chr1:247187281~247188526:-
THCA	cis	rs478304	0.627	rs11604568	ENSG00000255557.1	RP11-770G2.2	3.39	0.000755	0.0428	0.18	0.15	Acne (severe);	chr11:65743865	chr11:65745729~65771585:+
THCA	cis	rs478304	0.651	rs7110576	ENSG00000255557.1	RP11-770G2.2	3.39	0.000755	0.0428	0.18	0.15	Acne (severe);	chr11:65744586	chr11:65745729~65771585:+
THCA	cis	rs539096	0.83	rs2819339	ENSG00000229348.1	HYI-AS1	-3.39	0.000755	0.0428	-0.16	-0.15	Intelligence (multi-trait analysis);	chr1:43552933	chr1:43453927~43456995:+
THCA	cis	rs2888875	1	rs56304210	ENSG00000200924.1	RNU6-1048P	-3.39	0.000755	0.0428	-0.17	-0.15	Glomerular filtration rate (creatinine);	chr2:43552966	chr2:43892690~43892796:+
THCA	cis	rs1062753	0.961	rs9620007	ENSG00000232710.1	RP4-669P10.16	-3.39	0.000755	0.0428	-0.19	-0.15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42009653	chr22:42136433~42139927:-
THCA	cis	rs7737355	0.773	rs4705895	ENSG00000224431.1	AC063976.7	3.39	0.000755	0.0428	0.14	0.15	Life satisfaction;	chr5:131766501	chr5:132199456~132203487:+
THCA	cis	rs1864982	0.581	rs2926164	ENSG00000251556.1	RP11-118M9.3	-3.39	0.000755	0.0428	-0.26	-0.15	Alcohol dependence;	chr5:146892571	chr5:146099406~146120412:+
THCA	cis	rs11673344	0.526	rs17305823	ENSG00000180458.2	CTD-3064H18.4	3.39	0.000755	0.0428	0.21	0.15	Obesity-related traits;	chr19:37644145	chr19:37545470~37549171:-
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000182586.6	LINC00334	-3.39	0.000755	0.0428	-0.17	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45234340~45258730:+
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000182586.6	LINC00334	-3.39	0.000755	0.0428	-0.17	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45234340~45258730:+
THCA	cis	rs801193	0.636	rs2659895	ENSG00000272831.1	RP11-792A8.4	3.39	0.000756	0.0428	0.1	0.15	Aortic root size;	chr7:66731484	chr7:66739829~66740385:-
THCA	cis	rs6049003	0.668	rs4328700	ENSG00000270001.1	RP11-218C14.8	-3.39	0.000756	0.0428	-0.18	-0.15	Cerebrospinal fluid biomarker levels;	chr20:23728908	chr20:23631826~23632316:-
THCA	cis	rs2942194	0.506	rs10503728	ENSG00000253390.1	CTC-756D1.2	3.39	0.000756	0.0428	0.21	0.15	Red cell distribution width;Mean corpuscular volume;	chr8:23563489	chr8:23458601~23484971:+
THCA	cis	rs2625529	0.775	rs4777489	ENSG00000260037.4	CTD-2524L6.3	3.39	0.000756	0.0428	0.21	0.15	Red blood cell count;	chr15:72138093	chr15:71818396~71823384:+
THCA	cis	rs4073582	0.595	rs801736	ENSG00000245156.1	RP11-867G23.3	3.39	0.000756	0.0428	0.13	0.15	Gout;	chr11:66160959	chr11:66269832~66278525:-
THCA	cis	rs4073582	0.595	rs801734	ENSG00000245156.1	RP11-867G23.3	3.39	0.000756	0.0428	0.13	0.15	Gout;	chr11:66163745	chr11:66269832~66278525:-
THCA	cis	rs10085978	0.604	rs10099944	ENSG00000253741.1	CTD-2292P10.4	-3.39	0.000756	0.0428	-0.2	-0.15	Mosquito bite size;	chr8:142153456	chr8:142702252~142726973:-
THCA	cis	rs13053817	1	rs13054354	ENSG00000279159.1	RP3-394A18.1	3.39	0.000756	0.0428	0.15	0.15	Carotid atherosclerosis in HIV infection;	chr22:29444191	chr22:29978950~30028236:-
THCA	cis	rs910316	1	rs175449	ENSG00000273565.1	CTD-3075F15.1	-3.39	0.000756	0.0428	-0.18	-0.15	Height;	chr14:75124143	chr14:75176929~75177418:+
THCA	cis	rs910316	0.935	rs175448	ENSG00000273565.1	CTD-3075F15.1	-3.39	0.000756	0.0428	-0.18	-0.15	Height;	chr14:75124368	chr14:75176929~75177418:+
THCA	cis	rs910316	1	rs175442	ENSG00000273565.1	CTD-3075F15.1	-3.39	0.000756	0.0428	-0.18	-0.15	Height;	chr14:75136861	chr14:75176929~75177418:+
THCA	cis	rs7394190	0.748	rs4746146	ENSG00000272599.2	RP11-152N13.16	3.39	0.000756	0.0428	0.2	0.15	Incident atrial fibrillation;	chr10:73767439	chr10:73124573~73125532:-
THCA	cis	rs925946	0.518	rs10835201	ENSG00000245573.6	BDNF-AS	-3.39	0.000756	0.0428	-0.15	-0.15	Weight;Body mass index;	chr11:27596718	chr11:27506838~27698174:+
THCA	cis	rs9532580	0.619	rs2755211	ENSG00000275149.1	RP11-427J23.1	-3.39	0.000756	0.0428	-0.21	-0.15	Mean corpuscular hemoglobin;	chr13:40568086	chr13:40079106~40273509:-
THCA	cis	rs7674212	0.57	rs2711898	ENSG00000230069.3	LRRC37A15P	-3.39	0.000756	0.0428	-0.15	-0.15	Type 2 diabetes;	chr4:103141914	chr4:102727274~102730721:-
THCA	cis	rs4845570	1	rs6673002	ENSG00000268288.1	RP11-98D18.16	3.39	0.000756	0.0428	0.23	0.15	Coronary artery disease;	chr1:151770799	chr1:151766486~151767000:-
THCA	cis	rs7074356	0.569	rs7090863	ENSG00000278616.1	BEND3P3	3.39	0.000756	0.0428	0.13	0.15	Borderline personality disorder;	chr10:80261637	chr10:79682997~79685436:+
THCA	cis	rs10969557	0.689	rs10813157	ENSG00000231808.2	LINC01388	-3.39	0.000756	0.0428	-0.17	-0.15	Lung cancer;	chr9:307257	chr9:112713~113754:-
THCA	cis	rs10943724	0.959	rs10447324	ENSG00000272129.1	RP11-250B2.6	3.39	0.000756	0.0428	0.2	0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80566598	chr6:80355424~80356859:+
THCA	cis	rs6101567	0.683	rs4812374	ENSG00000224635.1	RP4-564F22.5	-3.39	0.000756	0.0428	-0.2	-0.15	Nose size;	chr20:39300658	chr20:38406011~38416797:-
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000281021.1	RP1-12G14.9	-3.39	0.000756	0.0428	-0.16	-0.15	Lung cancer;	chr6:149664079	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000281021.1	RP1-12G14.9	-3.39	0.000756	0.0428	-0.16	-0.15	Lung cancer;	chr6:149676521	chr6:149576089~149590864:-
THCA	cis	rs73459955	0.712	rs73459908	ENSG00000248441.5	LINC01197	3.39	0.000756	0.0428	0.2	0.15	Major depression and alcohol dependence;	chr15:95087795	chr15:95209099~95327129:-
THCA	cis	rs732072	1	rs72939200	ENSG00000214659.4	KRT8P26	-3.39	0.000756	0.0428	-0.25	-0.15	Inflammatory bowel disease;	chr11:65673811	chr11:65726939~65728214:+
THCA	cis	rs7246967	1	rs62120832	ENSG00000269364.1	LINC01233	-3.39	0.000756	0.0428	-0.23	-0.15	Bronchopulmonary dysplasia;	chr19:22881462	chr19:22532626~22533494:+
THCA	cis	rs13272623	1	rs10087148	ENSG00000246366.5	RP11-382J12.1	3.39	0.000756	0.0428	0.22	0.15	IgG glycosylation;	chr8:70630508	chr8:70608577~70663279:+
THCA	cis	rs13272623	1	rs35557557	ENSG00000246366.5	RP11-382J12.1	3.39	0.000756	0.0428	0.22	0.15	IgG glycosylation;	chr8:70631393	chr8:70608577~70663279:+
THCA	cis	rs13272623	1	rs13272623	ENSG00000246366.5	RP11-382J12.1	3.39	0.000756	0.0428	0.22	0.15	IgG glycosylation;	chr8:70632513	chr8:70608577~70663279:+
THCA	cis	rs13272623	1	rs10504478	ENSG00000246366.5	RP11-382J12.1	3.39	0.000756	0.0428	0.22	0.15	IgG glycosylation;	chr8:70632683	chr8:70608577~70663279:+
THCA	cis	rs787274	0.543	rs1324930	ENSG00000271631.1	RP11-408O19.5	-3.39	0.000756	0.0428	-0.22	-0.15	Age-related hearing impairment (SNP x SNP interaction);	chr9:112872359	chr9:112885158~112885767:+
THCA	cis	rs2209875	0.574	rs2274576	ENSG00000265112.1	MIR3153	-3.39	0.000756	0.0428	-0.18	-0.15	Pelvic organ prolapse (moderate/severe);	chr9:89311531	chr9:89312225~89312306:+
THCA	cis	rs6088580	0.634	rs6059866	ENSG00000269202.1	RP4-614O4.12	-3.39	0.000756	0.0428	-0.13	-0.15	Glomerular filtration rate (creatinine);	chr20:34488005	chr20:35201747~35203288:-
THCA	cis	rs7824557	0.614	rs2736286	ENSG00000255310.2	AF131215.2	-3.39	0.000757	0.0428	-0.13	-0.15	Retinal vascular caliber;	chr8:11369595	chr8:11107788~11109726:-
THCA	cis	rs3789045	0.528	rs61817953	ENSG00000235363.1	SNRPGP10	-3.39	0.000757	0.0428	-0.24	-0.15	Educational attainment (college completion);	chr1:204493484	chr1:205351247~205351471:+
THCA	cis	rs12410462	0.681	rs115959512	ENSG00000227711.2	RP11-275O4.5	-3.39	0.000757	0.0428	-0.3	-0.15	Major depressive disorder;	chr1:227411877	chr1:227509028~227520477:-
THCA	cis	rs9596863	0.898	rs9316660	ENSG00000136149.6	RPL13AP25	-3.39	0.000757	0.0428	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53779427	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.851	rs9568923	ENSG00000136149.6	RPL13AP25	-3.39	0.000757	0.0428	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53783438	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs9568924	ENSG00000136149.6	RPL13AP25	-3.39	0.000757	0.0428	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53786817	chr13:54440704~54441315:-
THCA	cis	rs2839186	0.771	rs13046451	ENSG00000225043.1	RPL18AP2	-3.39	0.000757	0.0428	-0.18	-0.15	Testicular germ cell tumor;	chr21:46221459	chr21:46420553~46421034:-
THCA	cis	rs2839186	0.77	rs2280956	ENSG00000225043.1	RPL18AP2	-3.39	0.000757	0.0428	-0.18	-0.15	Testicular germ cell tumor;	chr21:46222409	chr21:46420553~46421034:-
THCA	cis	rs2839186	0.771	rs2839155	ENSG00000225043.1	RPL18AP2	3.39	0.000757	0.0428	0.18	0.15	Testicular germ cell tumor;	chr21:46220078	chr21:46420553~46421034:-
THCA	cis	rs2839186	0.771	rs2280959	ENSG00000225043.1	RPL18AP2	3.39	0.000757	0.0428	0.18	0.15	Testicular germ cell tumor;	chr21:46222082	chr21:46420553~46421034:-
THCA	cis	rs2839186	0.739	rs2280958	ENSG00000225043.1	RPL18AP2	3.39	0.000757	0.0428	0.18	0.15	Testicular germ cell tumor;	chr21:46222102	chr21:46420553~46421034:-
THCA	cis	rs6901004	0.803	rs4947107	ENSG00000271789.1	RP5-1112D6.7	-3.39	0.000757	0.0428	-0.15	-0.15	Blood metabolite levels;	chr6:111121302	chr6:111297126~111298510:+
THCA	cis	rs5758511	0.508	rs28715885	ENSG00000227370.1	RP4-669P10.19	3.39	0.000757	0.0429	0.2	0.15	Birth weight;	chr22:42045087	chr22:42132543~42132998:+
THCA	cis	rs5758511	0.508	rs58099562	ENSG00000227370.1	RP4-669P10.19	3.39	0.000757	0.0429	0.2	0.15	Birth weight;	chr22:42057768	chr22:42132543~42132998:+
THCA	cis	rs3747767	1	rs9352747	ENSG00000233967.5	RP11-250B2.3	3.39	0.000757	0.0429	0.24	0.15	Hoarding;	chr6:79534831	chr6:80443344~80465927:+
THCA	cis	rs7818688	1	rs7832570	ENSG00000253528.2	RP11-347C18.4	-3.39	0.000757	0.0429	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95011567	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs7818688	ENSG00000253528.2	RP11-347C18.4	-3.39	0.000757	0.0429	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95011854	chr8:94974573~94974853:-
THCA	cis	rs6968419	0.504	rs56038916	ENSG00000237870.5	AC073130.1	3.39	0.000757	0.0429	0.16	0.15	Intraocular pressure;	chr7:116127662	chr7:116275606~116286734:-
THCA	cis	rs6968419	0.537	rs9641558	ENSG00000237870.5	AC073130.1	3.39	0.000757	0.0429	0.16	0.15	Intraocular pressure;	chr7:116129257	chr7:116275606~116286734:-
THCA	cis	rs8030136	0.945	rs8035490	ENSG00000274307.1	RP11-345J18.2	3.39	0.000757	0.0429	0.2	0.15	Periodontitis (DPAL);	chr15:24778208	chr15:25708470~25710869:-
THCA	cis	rs2882667	0.838	rs11958529	ENSG00000249593.5	CTB-46B19.2	3.39	0.000757	0.0429	0.18	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:139012647~139051203:+
THCA	cis	rs6490294	0.571	rs57168159	ENSG00000234608.6	MAPKAPK5-AS1	3.39	0.000757	0.0429	0.17	0.15	Mean platelet volume;	chr12:112189041	chr12:111839764~111842902:-
THCA	cis	rs758324	0.812	rs9327621	ENSG00000237714.1	P4HA2-AS1	3.39	0.000757	0.0429	0.21	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131783250	chr5:132184876~132192808:+
THCA	cis	rs758324	0.898	rs10037928	ENSG00000237714.1	P4HA2-AS1	3.39	0.000757	0.0429	0.21	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131806353	chr5:132184876~132192808:+
THCA	cis	rs758324	0.773	rs11951407	ENSG00000237714.1	P4HA2-AS1	3.39	0.000757	0.0429	0.21	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131806968	chr5:132184876~132192808:+
THCA	cis	rs758324	0.812	rs7709934	ENSG00000237714.1	P4HA2-AS1	3.39	0.000757	0.0429	0.21	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131809517	chr5:132184876~132192808:+
THCA	cis	rs758324	0.812	rs4705840	ENSG00000237714.1	P4HA2-AS1	3.39	0.000757	0.0429	0.21	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131870931	chr5:132184876~132192808:+
THCA	cis	rs758324	0.947	rs11242098	ENSG00000237714.1	P4HA2-AS1	3.39	0.000757	0.0429	0.21	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131871144	chr5:132184876~132192808:+
THCA	cis	rs758324	0.812	rs10045303	ENSG00000237714.1	P4HA2-AS1	-3.39	0.000757	0.0429	-0.21	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131867108	chr5:132184876~132192808:+
THCA	cis	rs2243480	1	rs34970380	ENSG00000237310.1	GS1-124K5.4	3.39	0.000757	0.0429	0.18	0.15	Diabetic kidney disease;	chr7:65966506	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000237310.1	GS1-124K5.4	3.39	0.000757	0.0429	0.18	0.15	Diabetic kidney disease;	chr7:66004843	chr7:66493706~66495474:+
THCA	cis	rs9341808	0.558	rs2490234	ENSG00000272129.1	RP11-250B2.6	3.39	0.000757	0.0429	0.2	0.15	Sitting height ratio;	chr6:80107249	chr6:80355424~80356859:+
THCA	cis	rs7950726	1	rs12805013	ENSG00000167355.6	AC104389.28	3.39	0.000757	0.0429	0.31	0.15	HbA2 levels;	chr11:5203070	chr11:5304976~5505652:-
THCA	cis	rs7950726	1	rs12806120	ENSG00000167355.6	AC104389.28	3.39	0.000757	0.0429	0.31	0.15	HbA2 levels;	chr11:5203254	chr11:5304976~5505652:-
THCA	cis	rs806215	1	rs712701	ENSG00000279265.1	AC000123.3	-3.39	0.000757	0.0429	-0.19	-0.15	Type 2 diabetes;	chr7:127611134	chr7:127349833~127350293:-
THCA	cis	rs2455799	0.613	rs13060772	ENSG00000270409.1	RP11-44D5.1	-3.39	0.000757	0.0429	-0.17	-0.15	Mean platelet volume;	chr3:15855288	chr3:15732252~15733470:+
THCA	cis	rs17376456	0.569	rs7732578	ENSG00000254132.1	MTND6P3	3.39	0.000757	0.0429	0.2	0.15	Diabetic retinopathy;	chr5:94074539	chr5:94568929~94569470:-
THCA	cis	rs9549260	0.755	rs9566553	ENSG00000275149.1	RP11-427J23.1	-3.39	0.000757	0.0429	-0.21	-0.15	Red blood cell count;	chr13:40600094	chr13:40079106~40273509:-
THCA	cis	rs9903692	0.909	rs1468270	ENSG00000263412.1	RP5-890E16.2	-3.39	0.000757	0.0429	-0.11	-0.15	Pulse pressure;	chr17:48047829	chr17:48045141~48048073:-
THCA	cis	rs7560272	0.501	rs11894953	ENSG00000163016.8	ALMS1P	3.39	0.000757	0.0429	0.2	0.15	Schizophrenia;	chr2:73737504	chr2:73644919~73685576:+
THCA	cis	rs867186	0.688	rs6060225	ENSG00000126005.14	MMP24-AS1	-3.39	0.000757	0.0429	-0.23	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35098601	chr20:35216462~35278131:-
THCA	cis	rs11651753	0.935	rs2525109	ENSG00000228782.6	CTD-2026D20.3	3.39	0.000757	0.0429	0.15	0.15	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964961	chr17:47450568~47492492:-
THCA	cis	rs11651753	0.935	rs2525110	ENSG00000228782.6	CTD-2026D20.3	3.39	0.000757	0.0429	0.15	0.15	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964999	chr17:47450568~47492492:-
THCA	cis	rs4948275	0.666	rs2606089	ENSG00000233643.2	RP11-491H19.1	3.39	0.000757	0.0429	0.18	0.15	Night sleep phenotypes;	chr10:61554047	chr10:61781745~61821246:-
THCA	cis	rs7122539	0.722	rs7119426	ENSG00000275484.1	CTC-1337H24.4	-3.39	0.000757	0.0429	-0.13	-0.15	HIV-1 susceptibility;	chr11:66882141	chr11:67374416~67374932:+
THCA	cis	rs7613875	0.641	rs2624845	ENSG00000281691.1	RBM5-AS1	-3.39	0.000758	0.0429	-0.13	-0.15	Body mass index;	chr3:50025004	chr3:50099603~50100988:-
THCA	cis	rs7819412	0.806	rs17723229	ENSG00000254839.1	AF131215.6	3.39	0.000758	0.0429	0.16	0.15	Triglycerides;	chr8:11072559	chr8:11062647~11067089:-
THCA	cis	rs2235573	0.836	rs132932	ENSG00000222044.1	RP5-1039K5.16	3.39	0.000758	0.0429	0.18	0.15	Glioma;Glioblastoma;	chr22:38092609	chr22:38032165~38034228:-
THCA	cis	rs68170813	0.652	rs17403088	ENSG00000241764.3	AC002467.7	3.39	0.000758	0.0429	0.18	0.15	Coronary artery disease;	chr7:107470928	chr7:107742817~107744581:-
THCA	cis	rs4713118	0.824	rs742046	ENSG00000216915.2	RP1-97D16.1	-3.39	0.000758	0.0429	-0.24	-0.15	Parkinson's disease;	chr6:27771475	chr6:27737000~27738494:-
THCA	cis	rs2279440	0.585	rs7651326	ENSG00000212327.1	RNU6-882P	3.39	0.000758	0.0429	0.23	0.15	Glucose homeostasis traits;	chr3:9459629	chr3:9919051~9919153:-
THCA	cis	rs4908760	0.669	rs4908506	ENSG00000270282.1	RP5-1115A15.2	3.39	0.000758	0.0429	0.18	0.15	Vitiligo;	chr1:8668919	chr1:8512653~8513021:+
THCA	cis	rs4845570	1	rs7416415	ENSG00000268288.1	RP11-98D18.16	3.39	0.000758	0.0429	0.23	0.15	Coronary artery disease;	chr1:151785322	chr1:151766486~151767000:-
THCA	cis	rs6479901	0.895	rs10733788	ENSG00000272767.1	JMJD1C-AS1	-3.39	0.000758	0.0429	-0.19	-0.15	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63465229~63466563:+
THCA	cis	rs4853036	0.903	rs13021969	ENSG00000179818.12	PCBP1-AS1	-3.39	0.000758	0.0429	-0.13	-0.15	Colorectal or endometrial cancer;	chr2:69890470	chr2:69962263~70103220:-
THCA	cis	rs3736858	1	rs2120060	ENSG00000261105.4	LMO7-AS1	-3.39	0.000758	0.0429	-0.2	-0.15	Interleukin-9 levels;	chr13:75838764	chr13:75604700~75635994:-
THCA	cis	rs5993586	0.85	rs2097605	ENSG00000223461.1	AC004471.9	3.39	0.000758	0.0429	0.39	0.15	Coronary artery disease;	chr22:19388601	chr22:19121529~19124503:+
THCA	cis	rs7259376	0.775	rs2360621	ENSG00000269345.1	VN1R85P	3.39	0.000758	0.0429	0.17	0.15	Menopause (age at onset);	chr19:22365867	chr19:22174766~22175191:-
THCA	cis	rs35123781	0.696	rs10067965	ENSG00000249526.1	CTB-35F21.1	3.39	0.000758	0.0429	0.22	0.15	Schizophrenia;	chr5:139691768	chr5:139684645~139745010:+
THCA	cis	rs7581030	0.958	rs1804020	ENSG00000281195.1	ZNF638-IT1	-3.39	0.000758	0.0429	-0.13	-0.15	Testicular germ cell tumor;	chr2:71427045	chr2:71373938~71376320:+
THCA	cis	rs6545883	0.965	rs10186325	ENSG00000212978.6	AC016747.3	3.39	0.000758	0.0429	0.17	0.15	Tuberculosis;	chr2:61530586	chr2:61141592~61144969:-
THCA	cis	rs11658311	0.649	rs9889795	ENSG00000226478.3	UPF3AP1	-3.39	0.000758	0.0429	-0.37	-0.15	Obsessive-compulsive symptoms;	chr17:17530900	chr17:16745636~16746761:-
THCA	cis	rs1865760	0.566	rs2032443	ENSG00000272810.1	U91328.22	-3.39	0.000758	0.0429	-0.12	-0.15	Height;	chr6:26046574	chr6:26013241~26013757:+
THCA	cis	rs6137726	0.687	rs6048247	ENSG00000237396.1	LINC01384	-3.39	0.000758	0.0429	-0.14	-0.15	Amyotrophic lateral sclerosis (sporadic);	chr20:22677335	chr20:22587522~22607517:-
THCA	cis	rs11219769	0.607	rs2075713	ENSG00000255045.1	RP11-677M14.2	3.39	0.000758	0.0429	0.15	0.15	Blood protein levels;	chr11:124748043	chr11:124744634~124746337:-
THCA	cis	rs9450351	0.744	rs111533912	ENSG00000203875.9	SNHG5	-3.39	0.000758	0.0429	-0.3	-0.15	Interferon gamma-induced protein 10 levels;	chr6:85622231	chr6:85660950~85678736:-
THCA	cis	rs9450351	0.744	rs9450308	ENSG00000203875.9	SNHG5	-3.39	0.000758	0.0429	-0.3	-0.15	Interferon gamma-induced protein 10 levels;	chr6:85638820	chr6:85660950~85678736:-
THCA	cis	rs11773103	0.881	rs73204826	ENSG00000224046.1	AC005076.5	3.39	0.000758	0.0429	0.2	0.15	Bipolar disorder or major depressive disorder (combined);	chr7:87144942	chr7:87151423~87152420:-
THCA	cis	rs7412746	0.658	rs17660092	ENSG00000224800.1	RP11-235D19.2	-3.39	0.000758	0.0429	-0.21	-0.15	Melanoma;	chr1:150825272	chr1:150881236~150881683:-
THCA	cis	rs7412746	0.658	rs2089082	ENSG00000224800.1	RP11-235D19.2	-3.39	0.000758	0.0429	-0.21	-0.15	Melanoma;	chr1:150827614	chr1:150881236~150881683:-
THCA	cis	rs7412746	0.658	rs10305711	ENSG00000224800.1	RP11-235D19.2	-3.39	0.000758	0.0429	-0.21	-0.15	Melanoma;	chr1:150830520	chr1:150881236~150881683:-
THCA	cis	rs13064773	0.528	rs340281	ENSG00000272247.1	RP11-379F4.9	3.39	0.000758	0.0429	0.16	0.15	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158867414	chr3:158801257~158801935:-
THCA	cis	rs2554380	0.943	rs2401128	ENSG00000230373.7	GOLGA6L5P	-3.39	0.000758	0.0429	-0.19	-0.15	Height;	chr15:83678426	chr15:84507885~84516814:-
THCA	cis	rs2554380	0.943	rs2585061	ENSG00000230373.7	GOLGA6L5P	-3.39	0.000758	0.0429	-0.19	-0.15	Height;	chr15:83678999	chr15:84507885~84516814:-
THCA	cis	rs763121	1	rs138457	ENSG00000225450.1	RP3-508I15.14	3.39	0.000758	0.0429	0.12	0.15	Menopause (age at onset);	chr22:38502046	chr22:38739003~38749041:+
THCA	cis	rs35306767	0.715	rs17221463	ENSG00000229869.1	RP11-363N22.2	-3.39	0.000758	0.0429	-0.25	-0.15	Eosinophil percentage of granulocytes;	chr10:992100	chr10:933026~942743:+
THCA	cis	rs8027587	1	rs8027587	ENSG00000271997.1	RP11-97O12.6	3.39	0.000759	0.0429	0.11	0.15	Obesity-related traits;	chr15:88705908	chr15:88501944~88505787:-
THCA	cis	rs8027587	1	rs62025592	ENSG00000271997.1	RP11-97O12.6	3.39	0.000759	0.0429	0.11	0.15	Obesity-related traits;	chr15:88706100	chr15:88501944~88505787:-
THCA	cis	rs8027587	1	rs12148680	ENSG00000271997.1	RP11-97O12.6	3.39	0.000759	0.0429	0.11	0.15	Obesity-related traits;	chr15:88706438	chr15:88501944~88505787:-
THCA	cis	rs9788333	0.888	rs35880230	ENSG00000236953.1	ZDHHC20-IT1	-3.39	0.000759	0.0429	-0.18	-0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21311833	chr13:21376977~21377874:-
THCA	cis	rs9788333	0.962	rs61951450	ENSG00000236953.1	ZDHHC20-IT1	-3.39	0.000759	0.0429	-0.18	-0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21312215	chr13:21376977~21377874:-
THCA	cis	rs9788333	0.962	rs12584792	ENSG00000236953.1	ZDHHC20-IT1	-3.39	0.000759	0.0429	-0.18	-0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21313069	chr13:21376977~21377874:-
THCA	cis	rs2888875	0.523	rs6708167	ENSG00000279873.2	LINC01126	-3.39	0.000759	0.0429	-0.14	-0.15	Glomerular filtration rate (creatinine);	chr2:43273837	chr2:43227210~43228855:+
THCA	cis	rs2888875	0.505	rs12185704	ENSG00000279873.2	LINC01126	-3.39	0.000759	0.0429	-0.14	-0.15	Glomerular filtration rate (creatinine);	chr2:43315368	chr2:43227210~43228855:+
THCA	cis	rs7824557	0.527	rs11785394	ENSG00000261451.1	RP11-981G7.1	-3.39	0.000759	0.0429	-0.2	-0.15	Retinal vascular caliber;	chr8:11380520	chr8:10433672~10438312:+
THCA	cis	rs1124769	0.523	rs12595051	ENSG00000273674.3	CTD-2378E12.1	3.39	0.000759	0.0429	0.21	0.15	Cognitive performance;	chr15:50808981	chr15:50839875~50908599:-
THCA	cis	rs4948275	0.693	rs2787713	ENSG00000233643.2	RP11-491H19.1	-3.39	0.000759	0.0429	-0.17	-0.15	Night sleep phenotypes;	chr10:61558446	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.693	rs2650732	ENSG00000233643.2	RP11-491H19.1	3.39	0.000759	0.0429	0.17	0.15	Night sleep phenotypes;	chr10:61562549	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.693	rs1456284	ENSG00000233643.2	RP11-491H19.1	3.39	0.000759	0.0429	0.17	0.15	Night sleep phenotypes;	chr10:61563057	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.667	rs2650727	ENSG00000233643.2	RP11-491H19.1	3.39	0.000759	0.0429	0.17	0.15	Night sleep phenotypes;	chr10:61563814	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.693	rs12360246	ENSG00000233643.2	RP11-491H19.1	3.39	0.000759	0.0429	0.17	0.15	Night sleep phenotypes;	chr10:61566059	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.693	rs1824082	ENSG00000233643.2	RP11-491H19.1	3.39	0.000759	0.0429	0.17	0.15	Night sleep phenotypes;	chr10:61566762	chr10:61781745~61821246:-
THCA	cis	rs7267979	0.816	rs422148	ENSG00000276952.1	RP5-965G21.6	3.39	0.000759	0.0429	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25284915~25285588:-
THCA	cis	rs2131877	0.645	rs4677812	ENSG00000238097.1	RP11-513G11.3	-3.39	0.000759	0.0429	-0.17	-0.15	Non-small cell lung cancer;	chr3:195143065	chr3:194247648~194257772:+
THCA	cis	rs8044868	1	rs8052408	ENSG00000260886.1	TAT-AS1	3.39	0.000759	0.0429	0.18	0.15	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72124178	chr16:71565789~71578187:+
THCA	cis	rs4243849	0.526	rs7822885	ENSG00000279518.1	AC083843.4	-3.39	0.000759	0.0429	-0.1	-0.15	Non-alcoholic fatty liver disease histology (other);	chr8:135750332	chr8:134783694~134785879:-
THCA	cis	rs4243849	0.555	rs11784740	ENSG00000279518.1	AC083843.4	-3.39	0.000759	0.0429	-0.1	-0.15	Non-alcoholic fatty liver disease histology (other);	chr8:135750957	chr8:134783694~134785879:-
THCA	cis	rs10043228	1	rs78465528	ENSG00000250015.1	CTC-339F2.2	3.39	0.000759	0.0429	0.23	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116138709	chr5:116302354~116304134:-
THCA	cis	rs10043228	0.826	rs62385219	ENSG00000250015.1	CTC-339F2.2	3.39	0.000759	0.0429	0.23	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116162791	chr5:116302354~116304134:-
THCA	cis	rs12681963	0.748	rs7833115	ENSG00000272375.1	RP11-51J9.6	-3.39	0.000759	0.0429	-0.18	-0.15	Migraine;	chr8:30058676	chr8:30197404~30198048:+
THCA	cis	rs2304003	0.561	rs1465678	ENSG00000232411.1	AC009495.3	-3.39	0.000759	0.0429	-0.17	-0.15	Social communication problems;	chr2:165804360	chr2:165833048~165839098:-
THCA	cis	rs12681963	0.614	rs7013787	ENSG00000272375.1	RP11-51J9.6	3.39	0.000759	0.0429	0.23	0.15	Migraine;	chr8:30203272	chr8:30197404~30198048:+
THCA	cis	rs9309473	0.539	rs6745560	ENSG00000273245.1	RP11-434P11.2	3.39	0.000759	0.0429	0.18	0.15	Metabolite levels;	chr2:73599990	chr2:73750256~73750786:-
THCA	cis	rs4906172	0.838	rs2474681	ENSG00000259230.1	CTD-2555C10.3	-3.39	0.000759	0.0429	-0.23	-0.15	Menopause (age at onset);	chr14:101957992	chr14:102545254~102555826:+
THCA	cis	rs12049351	0.774	rs12033236	ENSG00000229367.1	HMGN2P19	3.39	0.000759	0.043	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229504724	chr1:229570532~229570796:+
THCA	cis	rs7613875	0.62	rs11721204	ENSG00000281691.1	RBM5-AS1	3.39	0.000759	0.043	0.13	0.15	Body mass index;	chr3:49945332	chr3:50099603~50100988:-
THCA	cis	rs2289328	0.882	rs16970633	ENSG00000223313.1	RNU6-516P	-3.39	0.000759	0.043	-0.22	-0.15	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40350676	chr15:40529570~40529673:+
THCA	cis	rs7200786	0.647	rs27965	ENSG00000274038.1	RP11-66H6.4	-3.39	0.000759	0.043	-0.19	-0.15	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11168926	chr16:11056556~11057034:+
THCA	cis	rs721048	0.92	rs13411657	ENSG00000242412.1	DBIL5P2	-3.39	0.000759	0.043	-0.21	-0.15	Prostate cancer;	chr2:63182936	chr2:63117851~63119542:-
THCA	cis	rs9907295	0.579	rs9899866	ENSG00000270871.1	AC015849.19	-3.39	0.000759	0.043	-0.14	-0.15	Fibroblast growth factor basic levels;	chr17:35908466	chr17:35816717~35830293:-
THCA	cis	rs2888875	0.894	rs6756710	ENSG00000200924.1	RNU6-1048P	-3.39	0.000759	0.043	-0.17	-0.15	Glomerular filtration rate (creatinine);	chr2:43563120	chr2:43892690~43892796:+
THCA	cis	rs7119038	0.607	rs12365699	ENSG00000255239.1	AP002954.6	-3.39	0.000759	0.043	-0.27	-0.15	Sjögren's syndrome;	chr11:118872577	chr11:118688039~118690600:-
THCA	cis	rs17111396	0.826	rs10134487	ENSG00000271656.1	RP11-114N19.5	-3.39	0.000759	0.043	-0.19	-0.15	Uric acid levels;	chr14:81057542	chr14:81003325~81003645:-
THCA	cis	rs11098699	0.614	rs871648	ENSG00000273007.1	RP11-170N16.3	3.39	0.000759	0.043	0.13	0.15	Mosquito bite size;	chr4:123346289	chr4:122881878~122884712:-
THCA	cis	rs224278	0.509	rs4746747	ENSG00000238280.1	RP11-436D10.3	3.39	0.000759	0.043	0.22	0.15	Ewing sarcoma;	chr10:62940304	chr10:62793562~62805887:-
THCA	cis	rs324126	0.78	rs62108320	ENSG00000243680.1	RPL37P23	-3.39	0.000759	0.043	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52143043~52143336:+
THCA	cis	rs324126	0.752	rs62108321	ENSG00000243680.1	RPL37P23	-3.39	0.000759	0.043	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52143043~52143336:+
THCA	cis	rs9925964	0.933	rs8050894	ENSG00000262766.1	RP11-196G11.4	-3.39	0.000759	0.043	-0.1	-0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:31118078~31118747:+
THCA	cis	rs758324	0.797	rs247004	ENSG00000224431.1	AC063976.7	3.39	0.000759	0.043	0.15	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132008665	chr5:132199456~132203487:+
THCA	cis	rs10495907	0.556	rs10206389	ENSG00000234936.1	AC010883.5	3.39	0.000759	0.043	0.15	0.15	Coronary artery disease;	chr2:43720621	chr2:43229573~43233394:+
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000184274.3	LINC00315	-3.39	0.000759	0.043	-0.19	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45300245~45305257:-
THCA	cis	rs3026101	0.624	rs17635627	ENSG00000234327.6	AC012146.7	-3.39	0.000759	0.043	-0.13	-0.15	Body mass index;	chr17:5392739	chr17:5111468~5115004:+
THCA	cis	rs743757	0.652	rs2269507	ENSG00000232352.1	SEMA3B-AS1	3.39	0.000759	0.043	0.24	0.15	Diastolic blood pressure;	chr3:50579352	chr3:50266641~50267371:-
THCA	cis	rs743757	0.584	rs2232253	ENSG00000232352.1	SEMA3B-AS1	3.39	0.000759	0.043	0.24	0.15	Diastolic blood pressure;	chr3:50580071	chr3:50266641~50267371:-
THCA	cis	rs683257	0.925	rs116795862	ENSG00000234147.1	RP3-460G2.2	-3.39	0.000759	0.043	-0.26	-0.15	Facial emotion recognition (angry faces);	chr6:140683270	chr6:140845958~140852924:-
THCA	cis	rs61160187	0.582	rs4647132	ENSG00000251279.1	CTC-436P18.1	-3.39	0.000759	0.043	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:61162070~61232040:+
THCA	cis	rs11098499	0.644	rs7676296	ENSG00000249244.1	RP11-548H18.2	3.39	0.000759	0.043	0.17	0.15	Corneal astigmatism;	chr4:119634532	chr4:119391831~119395335:-
THCA	cis	rs11633886	0.622	rs60175246	ENSG00000259200.1	RP11-718O11.1	-3.39	0.000759	0.043	-0.19	-0.15	Diisocyanate-induced asthma;	chr15:45836933	chr15:45705078~45931069:+
THCA	cis	rs11039798	0.588	rs3924476	ENSG00000200090.1	Y_RNA	3.39	0.00076	0.043	0.13	0.15	Axial length;	chr11:48560181	chr11:47726894~47726992:-
THCA	cis	rs6510186	0.963	rs8107804	ENSG00000267662.1	AC007796.1	-3.39	0.00076	0.043	-0.18	-0.15	Total body bone mineral density (age 45-60);	chr19:31167738	chr19:31348881~31417794:+
THCA	cis	rs988712	0.883	rs972096	ENSG00000245573.6	BDNF-AS	-3.39	0.00076	0.043	-0.15	-0.15	Obesity;	chr11:27530835	chr11:27506838~27698174:+
THCA	cis	rs2067615	0.965	rs2204886	ENSG00000260329.1	RP11-412D9.4	-3.39	0.00076	0.043	-0.14	-0.15	Heart rate;	chr12:106734312	chr12:106954029~106955497:-
THCA	cis	rs4664293	0.867	rs7566802	ENSG00000230783.1	AC009961.2	-3.39	0.00076	0.043	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159728480	chr2:159689217~159690291:-
THCA	cis	rs9875589	0.957	rs6778297	ENSG00000228242.5	AC093495.4	-3.39	0.00076	0.043	-0.09	-0.15	Ovarian reserve;	chr3:13890646	chr3:14144637~14165978:+
THCA	cis	rs11030122	0.702	rs17081	ENSG00000230593.3	AC090804.1	-3.39	0.00076	0.043	-0.2	-0.15	Mean platelet volume;Platelet distribution width;	chr11:3966600	chr11:3892398~3892887:-
THCA	cis	rs3026101	0.624	rs12601818	ENSG00000234327.6	AC012146.7	-3.39	0.00076	0.043	-0.13	-0.15	Body mass index;	chr17:5417118	chr17:5111468~5115004:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000234585.5	CCT6P3	-3.39	0.00076	0.043	-0.14	-0.15	Calcium levels;	chr7:66026136	chr7:65038354~65074713:+
THCA	cis	rs10540	1	rs67912009	ENSG00000279672.1	CMB9-55F22.1	3.39	0.00076	0.043	0.29	0.15	Body mass index;	chr11:495057	chr11:779617~780755:+
THCA	cis	rs2228479	0.702	rs78331410	ENSG00000274627.1	RP11-104N10.2	-3.39	0.00076	0.043	-0.27	-0.15	Skin colour saturation;	chr16:89851367	chr16:89516797~89522217:+
THCA	cis	rs8112211	0.731	rs931750	ENSG00000267291.1	CTB-186G2.1	3.39	0.00076	0.043	0.17	0.15	Blood protein levels;	chr19:38328111	chr19:38596346~38601694:+
THCA	cis	rs8112211	0.731	rs73041302	ENSG00000267291.1	CTB-186G2.1	3.39	0.00076	0.043	0.17	0.15	Blood protein levels;	chr19:38328458	chr19:38596346~38601694:+
THCA	cis	rs7772697	0.528	rs9498239	ENSG00000223701.3	RAET1E-AS1	-3.39	0.00076	0.043	-0.21	-0.15	Diabetic retinopathy;	chr6:149164455	chr6:149884431~149919508:+
THCA	cis	rs17217757	0.725	rs1037305	ENSG00000254041.1	RP11-574O7.1	-3.39	0.00076	0.043	-0.23	-0.15	Tuberculosis;	chr8:105615059	chr8:105142860~105188606:-
THCA	cis	rs6479891	0.524	rs61339888	ENSG00000232075.1	MRPL35P2	3.39	0.00076	0.043	0.24	0.15	Arthritis (juvenile idiopathic);	chr10:63102888	chr10:63634317~63634827:-
THCA	cis	rs2018683	0.707	rs2391718	ENSG00000233517.1	AC005162.5	-3.39	0.00076	0.043	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935371	chr7:28987028~28988899:+
THCA	cis	rs61160187	0.582	rs976630	ENSG00000251279.1	CTC-436P18.1	-3.39	0.00076	0.043	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:61162070~61232040:+
THCA	cis	rs6600671	1	rs12047116	ENSG00000233029.3	RP11-439A17.9	-3.39	0.00076	0.043	-0.17	-0.15	Hip geometry;	chr1:121443912	chr1:121090289~121097655:-
THCA	cis	rs6600671	0.967	rs11249347	ENSG00000233029.3	RP11-439A17.9	-3.39	0.00076	0.043	-0.17	-0.15	Hip geometry;	chr1:121446489	chr1:121090289~121097655:-
THCA	cis	rs3809566	0.613	rs16946330	ENSG00000259251.2	RP11-643M14.1	3.39	0.00076	0.043	0.15	0.15	Platelet count;	chr15:63032302	chr15:62060503~62062434:+
THCA	cis	rs2880765	0.835	rs7180923	ENSG00000259407.1	RP11-158M2.3	-3.39	0.00076	0.043	-0.16	-0.15	Coronary artery disease;	chr15:85507659	chr15:85744109~85750281:-
THCA	cis	rs4808199	0.793	rs12459676	ENSG00000267481.1	CTC-559E9.5	-3.39	0.00076	0.043	-0.16	-0.15	Nonalcoholic fatty liver disease;	chr19:19314332	chr19:19788755~19790531:-
THCA	cis	rs11242704	0.962	rs9392303	ENSG00000218027.2	RP11-157J24.1	-3.39	0.00076	0.043	-0.2	-0.15	Response to hepatitis C treatment;	chr6:1530952	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.962	rs6920998	ENSG00000218027.2	RP11-157J24.1	-3.39	0.00076	0.043	-0.2	-0.15	Response to hepatitis C treatment;	chr6:1531029	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.962	rs9405492	ENSG00000218027.2	RP11-157J24.1	-3.39	0.00076	0.043	-0.2	-0.15	Response to hepatitis C treatment;	chr6:1531395	chr6:1513698~1515289:-
THCA	cis	rs7727544	0.548	rs4705938	ENSG00000263597.1	MIR3936	3.39	0.00076	0.043	0.15	0.15	Blood metabolite levels;	chr5:132358384	chr5:132365490~132365599:-
THCA	cis	rs1144333	0.655	rs4949685	ENSG00000272855.1	RP5-1102E8.3	-3.39	0.00076	0.043	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75997585	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs4949619	ENSG00000272855.1	RP5-1102E8.3	-3.39	0.00076	0.043	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75998289	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs1938321	ENSG00000272855.1	RP5-1102E8.3	-3.39	0.00076	0.043	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75998617	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs1938323	ENSG00000272855.1	RP5-1102E8.3	-3.39	0.00076	0.043	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75998807	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs79376884	ENSG00000272855.1	RP5-1102E8.3	-3.39	0.00076	0.043	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75999716	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs75146987	ENSG00000272855.1	RP5-1102E8.3	-3.39	0.00076	0.043	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:76002193	chr1:76636877~76637339:+
THCA	cis	rs10175706	0.501	rs4145979	ENSG00000256637.5	RP11-76I14.1	-3.39	0.00076	0.043	-0.13	-0.15	Chin dimples;	chr2:104036624	chr2:103874310~104077778:+
THCA	cis	rs76419734	0.85	rs10516529	ENSG00000251175.4	RP11-45L9.1	-3.39	0.00076	0.043	-0.35	-0.15	Post bronchodilator FEV1;	chr4:105878159	chr4:105746245~105827172:-
THCA	cis	rs931127	0.658	rs4930305	ENSG00000255557.1	RP11-770G2.2	-3.39	0.00076	0.043	-0.17	-0.15	Systemic lupus erythematosus;	chr11:65696529	chr11:65745729~65771585:+
THCA	cis	rs9807841	0.592	rs7250071	ENSG00000197332.8	ZNF833P	-3.39	0.00076	0.043	-0.14	-0.15	Inflammatory skin disease;	chr19:10655143	chr19:11639776~11686569:+
THCA	cis	rs9889262	0.602	rs57345398	ENSG00000248714.5	RP11-1079K10.3	3.39	0.00076	0.043	0.17	0.15	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49280088	chr17:49361165~49369998:+
THCA	cis	rs9889262	0.602	rs11079868	ENSG00000248714.5	RP11-1079K10.3	3.39	0.00076	0.043	0.17	0.15	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49280607	chr17:49361165~49369998:+
THCA	cis	rs9889262	0.602	rs4794034	ENSG00000248714.5	RP11-1079K10.3	3.39	0.00076	0.043	0.17	0.15	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49281198	chr17:49361165~49369998:+
THCA	cis	rs189798	0.738	rs330908	ENSG00000233609.3	RP11-62H7.2	3.39	0.00076	0.043	0.15	0.15	Myopia (pathological);	chr8:9137656	chr8:8961200~8979025:+
THCA	cis	rs11039798	0.588	rs11039807	ENSG00000200090.1	Y_RNA	3.39	0.00076	0.043	0.13	0.15	Axial length;	chr11:48527839	chr11:47726894~47726992:-
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000264242.2	RP11-271K11.1	3.39	0.000761	0.043	0.23	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000264242.2	RP11-271K11.1	3.39	0.000761	0.043	0.23	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30553697~30558962:+
THCA	cis	rs8062405	0.755	rs62031607	ENSG00000270424.1	RP11-1348G14.6	3.39	0.000761	0.043	0.19	0.15	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28749959~28750595:-
THCA	cis	rs7819412	0.805	rs4333549	ENSG00000254948.1	OR7E158P	3.39	0.000761	0.043	0.19	0.15	Triglycerides;	chr8:11122051	chr8:11919900~11920809:-
THCA	cis	rs11076221	1	rs27630	ENSG00000261238.1	AC009166.5	-3.39	0.000761	0.043	-0.29	-0.15	Alcohol dependence;	chr16:51956679	chr16:51149239~51149819:+
THCA	cis	rs2280018	0.538	rs7404526	ENSG00000207425.1	Y_RNA	3.39	0.000761	0.043	0.17	0.15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:14915457~14915556:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000232546.1	RP11-458F8.1	-3.39	0.000761	0.043	-0.13	-0.15	Aortic root size;	chr7:65975357	chr7:66848496~66858136:+
THCA	cis	rs7246657	0.943	rs7255952	ENSG00000268499.1	CTB-102L5.8	3.39	0.000761	0.043	0.2	0.15	Coronary artery calcification;	chr19:37497895	chr19:38199836~38200934:+
THCA	cis	rs11048434	0.736	rs11048195	ENSG00000245105.2	A2M-AS1	3.39	0.000761	0.043	0.12	0.15	Sjögren's syndrome;	chr12:8953327	chr12:9065177~9068060:+
THCA	cis	rs13326165	0.76	rs61150019	ENSG00000242142.1	SERBP1P3	-3.39	0.000761	0.043	-0.25	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52320360	chr3:53064283~53065091:-
THCA	cis	rs6546550	0.935	rs11673826	ENSG00000179818.12	PCBP1-AS1	-3.39	0.000761	0.043	-0.12	-0.15	Prevalent atrial fibrillation;	chr2:69813901	chr2:69962263~70103220:-
THCA	cis	rs10975370	0.552	rs343472	ENSG00000206147.5	RP11-106A1.2	3.39	0.000761	0.043	0.18	0.15	Breast cancer;	chr9:6043381	chr9:6639139~6639604:+
THCA	cis	rs10833905	0.938	rs2433501	ENSG00000246225.5	RP11-17A1.3	3.39	0.000761	0.043	0.23	0.15	Sudden cardiac arrest;	chr11:23065949	chr11:22829380~22945393:+
THCA	cis	rs6001982	0.915	rs28444678	ENSG00000199865.1	RNU6-495P	3.39	0.000761	0.043	0.28	0.15	Breast cancer;	chr22:40578248	chr22:41377177~41377283:-
THCA	cis	rs6001982	1	rs17002024	ENSG00000199865.1	RNU6-495P	3.39	0.000761	0.043	0.28	0.15	Breast cancer;	chr22:40579264	chr22:41377177~41377283:-
THCA	cis	rs6001982	1	rs6001973	ENSG00000199865.1	RNU6-495P	3.39	0.000761	0.043	0.28	0.15	Breast cancer;	chr22:40581552	chr22:41377177~41377283:-
THCA	cis	rs6001982	0.833	rs73169051	ENSG00000199865.1	RNU6-495P	3.39	0.000761	0.043	0.28	0.15	Breast cancer;	chr22:40583644	chr22:41377177~41377283:-
THCA	cis	rs6001982	1	rs17002026	ENSG00000199865.1	RNU6-495P	3.39	0.000761	0.043	0.28	0.15	Breast cancer;	chr22:40586577	chr22:41377177~41377283:-
THCA	cis	rs467650	0.747	rs461409	ENSG00000246763.5	RGMB-AS1	-3.39	0.000761	0.043	-0.15	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:98594262	chr5:98769618~98773469:-
THCA	cis	rs2191566	0.648	rs4803675	ENSG00000267114.1	CTB-129P6.11	-3.39	0.000761	0.043	-0.12	-0.15	Acute lymphoblastic leukemia (childhood);	chr19:44085563	chr19:44950044~44954007:-
THCA	cis	rs4650994	0.507	rs56229230	ENSG00000213057.5	C1orf220	-3.39	0.000761	0.043	-0.11	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178557428	chr1:178542752~178548889:+
THCA	cis	rs909002	0.8	rs7529064	ENSG00000235790.6	RP11-73M7.6	3.39	0.000761	0.043	0.16	0.15	Intelligence (multi-trait analysis);	chr1:31639591	chr1:31644049~31660162:+
THCA	cis	rs34779708	0.931	rs11592404	ENSG00000233200.1	RP11-324I22.2	3.39	0.000761	0.043	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35219894~35230598:-
THCA	cis	rs7656342	0.729	rs10004319	ENSG00000242034.1	RP11-1396O13.1	3.39	0.000761	0.043	0.18	0.15	Gut microbiota (bacterial taxa);	chr4:9760316	chr4:9553614~9553985:-
THCA	cis	rs6500596	0.506	rs1530088	ENSG00000280063.1	RP11-295D4.3	3.39	0.000761	0.043	0.09	0.15	Schizophrenia;	chr16:4389130	chr16:4346694~4348648:-
THCA	cis	rs8114671	0.836	rs2038504	ENSG00000126005.14	MMP24-AS1	3.39	0.000761	0.043	0.15	0.15	Height;	chr20:35060384	chr20:35216462~35278131:-
THCA	cis	rs8114671	0.836	rs2104083	ENSG00000126005.14	MMP24-AS1	3.39	0.000761	0.043	0.15	0.15	Height;	chr20:35061330	chr20:35216462~35278131:-
THCA	cis	rs8114671	0.839	rs2104084	ENSG00000126005.14	MMP24-AS1	3.39	0.000761	0.043	0.15	0.15	Height;	chr20:35061414	chr20:35216462~35278131:-
THCA	cis	rs35123781	1	rs34510678	ENSG00000200378.1	RNU5B-4P	3.39	0.000761	0.043	0.19	0.15	Schizophrenia;	chr5:139685250	chr5:139447907~139448017:+
THCA	cis	rs4410790	0.515	rs12532771	ENSG00000236039.1	AC019117.2	-3.39	0.000761	0.043	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);Caffeine consumption;Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);	chr7:17302172	chr7:17434477~17460672:-
THCA	cis	rs10508774	1	rs1999534	ENSG00000217094.2	PPIAP31	3.39	0.000761	0.0431	0.26	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32556941	chr10:32188323~32188817:-
THCA	cis	rs6001982	0.915	rs5995875	ENSG00000199865.1	RNU6-495P	3.39	0.000761	0.0431	0.28	0.15	Breast cancer;	chr22:40564688	chr22:41377177~41377283:-
THCA	cis	rs6001982	0.915	rs6001965	ENSG00000199865.1	RNU6-495P	3.39	0.000761	0.0431	0.28	0.15	Breast cancer;	chr22:40564863	chr22:41377177~41377283:-
THCA	cis	rs11673344	0.523	rs10420330	ENSG00000233527.7	ZNF529-AS1	3.39	0.000761	0.0431	0.13	0.15	Obesity-related traits;	chr19:37111269	chr19:36573070~36594708:+
THCA	cis	rs524281	0.692	rs2452681	ENSG00000255120.4	OVOL1-AS1	3.39	0.000761	0.0431	0.22	0.15	Electroencephalogram traits;	chr11:66047371	chr11:65789051~65790868:-
THCA	cis	rs867371	1	rs867370	ENSG00000278603.1	RP13-608F4.5	-3.39	0.000761	0.0431	-0.2	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82472203~82472426:+
THCA	cis	rs867371	1	rs867371	ENSG00000278603.1	RP13-608F4.5	-3.39	0.000761	0.0431	-0.2	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82472203~82472426:+
THCA	cis	rs2562456	0.833	rs2650776	ENSG00000213976.4	CTD-2561J22.2	-3.39	0.000761	0.0431	-0.19	-0.15	Pain;	chr19:21430595	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs2562416	ENSG00000213976.4	CTD-2561J22.2	-3.39	0.000761	0.0431	-0.19	-0.15	Pain;	chr19:21430609	chr19:21382865~21387177:+
THCA	cis	rs6504108	0.624	rs954226	ENSG00000264920.1	RP11-6N17.4	-3.39	0.000762	0.0431	-0.13	-0.15	Body mass index;	chr17:48227450	chr17:47891255~47895812:-
THCA	cis	rs2562456	0.833	rs7258099	ENSG00000213976.4	CTD-2561J22.2	-3.39	0.000762	0.0431	-0.19	-0.15	Pain;	chr19:21352941	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs62109229	ENSG00000213976.4	CTD-2561J22.2	-3.39	0.000762	0.0431	-0.19	-0.15	Pain;	chr19:21354380	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs11670815	ENSG00000213976.4	CTD-2561J22.2	-3.39	0.000762	0.0431	-0.19	-0.15	Pain;	chr19:21356515	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs11666540	ENSG00000213976.4	CTD-2561J22.2	-3.39	0.000762	0.0431	-0.19	-0.15	Pain;	chr19:21356550	chr19:21382865~21387177:+
THCA	cis	rs6929812	0.546	rs2393962	ENSG00000216915.2	RP1-97D16.1	3.39	0.000762	0.0431	0.2	0.15	Neuroticism (multi-trait analysis);	chr6:27495045	chr6:27737000~27738494:-
THCA	cis	rs10780944	0.891	rs13296513	ENSG00000261447.1	RP11-109D9.4	-3.39	0.000762	0.0431	-0.31	-0.15	Pubertal anthropometrics;	chr9:70522445	chr9:69672749~69673713:+
THCA	cis	rs35791980	0.567	rs17805954	ENSG00000273341.1	RP5-899E9.1	3.39	0.000762	0.0431	0.18	0.15	Pursuit maintenance gain;	chr7:77313138	chr7:77416673~77425443:+
THCA	cis	rs11673344	0.796	rs9676450	ENSG00000267260.1	CTD-2162K18.4	-3.39	0.000762	0.0431	-0.19	-0.15	Obesity-related traits;	chr19:36998505	chr19:36773153~36777078:+
THCA	cis	rs72945132	0.638	rs11236127	ENSG00000254604.1	AP000487.6	-3.39	0.000762	0.0431	-0.29	-0.15	Coronary artery disease;	chr11:70395430	chr11:70282367~70363368:-
THCA	cis	rs939960	1	rs12537745	ENSG00000276538.1	RP11-545G3.2	3.39	0.000762	0.0431	0.22	0.15	Neutrophil percentage of white cells;	chr7:150539762	chr7:150047609~150047854:-
THCA	cis	rs7809950	0.906	rs2395907	ENSG00000272072.1	CTA-363E19.2	-3.39	0.000762	0.0431	-0.15	-0.15	Coronary artery disease;	chr7:107612859	chr7:107192559~107193300:-
THCA	cis	rs13232179	1	rs34311452	ENSG00000265810.1	MIR3907	3.39	0.000762	0.0431	0.15	0.15	Coronary heart disease;	chr7:151416057	chr7:151433489~151433639:-
THCA	cis	rs7220401	0.521	rs11080105	ENSG00000263370.1	RP11-68I3.5	3.39	0.000762	0.0431	0.21	0.15	Coronary artery disease;	chr17:29577693	chr17:29639627~29640825:+
THCA	cis	rs722599	0.639	rs2193596	ENSG00000177776.8	RPS2P2	-3.39	0.000762	0.0431	-0.18	-0.15	IgG glycosylation;	chr14:74767398	chr14:74377818~74378418:-
THCA	cis	rs2436845	0.934	rs892486	ENSG00000253320.4	KB-1507C5.2	-3.39	0.000762	0.0431	-0.13	-0.15	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102862401	chr8:102864300~102977876:+
THCA	cis	rs2447820	0.588	rs72798801	ENSG00000263432.2	RN7SL689P	3.39	0.000762	0.0431	0.19	0.15	Migraine;	chr5:123063737	chr5:123022487~123022783:-
THCA	cis	rs2447820	0.588	rs72798802	ENSG00000263432.2	RN7SL689P	3.39	0.000762	0.0431	0.19	0.15	Migraine;	chr5:123063848	chr5:123022487~123022783:-
THCA	cis	rs11233250	0.528	rs58791004	ENSG00000227097.5	RPS28P7	-3.39	0.000762	0.0431	-0.22	-0.15	Glioblastoma;Glioma;	chr11:82691125	chr11:82689559~82689768:+
THCA	cis	rs11233250	0.502	rs59617763	ENSG00000227097.5	RPS28P7	-3.39	0.000762	0.0431	-0.22	-0.15	Glioblastoma;Glioma;	chr11:82691354	chr11:82689559~82689768:+
THCA	cis	rs2274273	0.84	rs10150760	ENSG00000258469.1	CHMP4BP1	-3.39	0.000762	0.0431	-0.14	-0.15	Protein biomarker;	chr14:55354830	chr14:55298644~55299231:+
THCA	cis	rs7772697	0.539	rs9498204	ENSG00000223701.3	RAET1E-AS1	-3.39	0.000762	0.0431	-0.22	-0.15	Diabetic retinopathy;	chr6:149083210	chr6:149884431~149919508:+
THCA	cis	rs7924176	0.521	rs61863363	ENSG00000271848.1	RP11-464F9.21	-3.39	0.000762	0.0431	-0.17	-0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:73654039~73674719:+
THCA	cis	rs2436845	0.934	rs2679758	ENSG00000253320.4	KB-1507C5.2	-3.39	0.000762	0.0431	-0.13	-0.15	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858978	chr8:102864300~102977876:+
THCA	cis	rs1979679	0.578	rs1904387	ENSG00000247934.4	RP11-967K21.1	-3.39	0.000762	0.0431	-0.15	-0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28120723	chr12:28163298~28190738:-
THCA	cis	rs1665050	0.598	rs8041221	ENSG00000259732.1	RP11-59H7.3	-3.39	0.000763	0.0431	-0.2	-0.15	Atopic dermatitis;	chr15:59042609	chr15:59121034~59133250:+
THCA	cis	rs10504130	0.735	rs12679287	ENSG00000272024.1	RP11-546K22.3	-3.39	0.000763	0.0431	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51925568	chr8:51950284~51950690:+
THCA	cis	rs732072	0.826	rs72941004	ENSG00000214659.4	KRT8P26	-3.39	0.000763	0.0431	-0.25	-0.15	Inflammatory bowel disease;	chr11:65682432	chr11:65726939~65728214:+
THCA	cis	rs61677309	0.597	rs112590920	ENSG00000278376.1	RP11-158I9.8	3.39	0.000763	0.0431	0.11	0.15	Lung cancer in ever smokers;	chr11:118272871	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.558	rs4245179	ENSG00000278376.1	RP11-158I9.8	3.39	0.000763	0.0431	0.11	0.15	Lung cancer in ever smokers;	chr11:118273730	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.638	rs4245180	ENSG00000278376.1	RP11-158I9.8	3.39	0.000763	0.0431	0.11	0.15	Lung cancer in ever smokers;	chr11:118273797	chr11:118791254~118793137:+
THCA	cis	rs9788721	0.902	rs951266	ENSG00000261762.1	RP11-650L12.2	-3.39	0.000763	0.0431	-0.2	-0.15	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78586199	chr15:78589123~78591276:-
THCA	cis	rs6545883	0.965	rs3771261	ENSG00000212978.6	AC016747.3	3.39	0.000763	0.0431	0.17	0.15	Tuberculosis;	chr2:61535026	chr2:61141592~61144969:-
THCA	cis	rs6545883	0.718	rs3771260	ENSG00000212978.6	AC016747.3	3.39	0.000763	0.0431	0.17	0.15	Tuberculosis;	chr2:61535249	chr2:61141592~61144969:-
THCA	cis	rs72827839	0.802	rs72825584	ENSG00000278765.1	RP5-890E16.5	-3.39	0.000763	0.0431	-0.23	-0.15	Ease of getting up in the morning;	chr17:48215727	chr17:48066704~48067293:-
THCA	cis	rs74181299	0.712	rs2241161	ENSG00000237979.1	AC007389.1	3.39	0.000763	0.0431	0.19	0.15	Pulse pressure;	chr2:65063708	chr2:65500993~65502138:-
THCA	cis	rs2180341	1	rs6569480	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127300603	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs6904520	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127308657	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs6910763	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127309780	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.924	rs6930849	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127309818	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.924	rs9285459	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127309968	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs6569482	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127310226	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs2144743	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127312665	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs9388561	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127313776	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs9398837	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127314072	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs9398838	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127314140	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs3798852	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127315588	chr6:127416535~127416952:-
THCA	cis	rs6487679	0.526	rs7305336	ENSG00000256427.1	RP11-118B22.4	3.39	0.000763	0.0431	0.18	0.15	Non-alcoholic fatty liver disease histology (AST);	chr12:9222493	chr12:9246497~9257960:+
THCA	cis	rs2776353	0.54	rs2255892	ENSG00000226496.2	LINC00323	-3.39	0.000763	0.0431	-0.25	-0.15	Basal cell carcinoma;	chr21:41667612	chr21:41141493~41148133:-
THCA	cis	rs6545883	0.965	rs7421663	ENSG00000212978.6	AC016747.3	3.39	0.000763	0.0431	0.17	0.15	Tuberculosis;	chr2:61526651	chr2:61141592~61144969:-
THCA	cis	rs113062739	0.808	rs9960460	ENSG00000267515.1	RP11-861E21.3	3.39	0.000763	0.0431	0.24	0.15	Gut microbiota (functional units);	chr18:13309233	chr18:12450447~12451042:+
THCA	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	3.39	0.000763	0.0431	0.17	0.15	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
THCA	cis	rs1873147	1	rs1873149	ENSG00000259672.1	RP11-69G7.1	-3.39	0.000763	0.0431	-0.17	-0.15	Orofacial clefts;	chr15:63020229	chr15:63098870~63110403:+
THCA	cis	rs9811920	0.893	rs9814549	ENSG00000273374.1	RP11-383I23.2	-3.39	0.000763	0.0431	-0.13	-0.15	Axial length;	chr3:100173346	chr3:99802699~99806058:-
THCA	cis	rs8054556	0.647	rs8048433	ENSG00000273724.1	RP11-347C12.12	-3.39	0.000763	0.0431	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30336400~30343336:+
THCA	cis	rs4649295	0.898	rs2177071	ENSG00000231940.1	RPS7P3	3.39	0.000763	0.0431	0.17	0.15	Differentiated thyroid cancer;Papillary thyroid cancer;	chr1:233265156	chr1:233288868~233289447:-
THCA	cis	rs721917	0.544	rs2243639	ENSG00000244733.5	RP11-506M13.3	-3.39	0.000763	0.0431	-0.19	-0.15	Chronic obstructive pulmonary disease;	chr10:79941966	chr10:79660891~79677996:+
THCA	cis	rs7615952	0.932	rs7629977	ENSG00000248787.1	RP11-666A20.4	-3.39	0.000763	0.0431	-0.27	-0.15	Blood pressure (smoking interaction);	chr3:125930730	chr3:125908005~125910272:-
THCA	cis	rs2288884	0.537	rs12151270	ENSG00000269483.1	AC006272.1	3.39	0.000763	0.0431	0.17	0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058984	chr19:51839924~51843324:-
THCA	cis	rs2288884	0.537	rs12151130	ENSG00000269483.1	AC006272.1	3.39	0.000763	0.0431	0.17	0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:51839924~51843324:-
THCA	cis	rs9860428	0.787	rs11713508	ENSG00000243795.1	RP11-572M11.3	3.39	0.000763	0.0431	0.19	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112865339	chr3:113142350~113167819:-
THCA	cis	rs34792	0.524	rs34629185	ENSG00000207425.1	Y_RNA	-3.39	0.000763	0.0431	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517597	chr16:14915457~14915556:-
THCA	cis	rs34792	0.525	rs66651392	ENSG00000207425.1	Y_RNA	-3.39	0.000763	0.0431	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517735	chr16:14915457~14915556:-
THCA	cis	rs8081187	0.803	rs73987935	ENSG00000263531.1	RP13-753N3.1	-3.39	0.000763	0.0431	-0.4	-0.15	Breast cancer;	chr17:30532791	chr17:30863921~30864940:-
THCA	cis	rs4956211	0.56	rs7654111	ENSG00000232021.5	LEF1-AS1	3.39	0.000763	0.0431	0.16	0.15	Systemic lupus erythematosus;	chr4:108787621	chr4:108167525~108256836:+
THCA	cis	rs8020441	0.838	rs72681662	ENSG00000258857.1	RP11-247L20.3	3.39	0.000763	0.0431	0.2	0.15	Cognitive performance;	chr14:50697166	chr14:50397013~50398345:+
THCA	cis	rs931608	0.543	rs1704017	ENSG00000269138.1	ZNF209P	3.39	0.000763	0.0431	0.2	0.15	Response to statins (LDL cholesterol change);Dental caries;	chr19:22447066	chr19:22463922~22473036:+
THCA	cis	rs11931598	0.783	rs28385900	ENSG00000245468.3	RP11-367J11.3	3.39	0.000763	0.0431	0.11	0.15	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7049109	chr4:7094571~7103385:-
THCA	cis	rs2180341	1	rs6937287	ENSG00000220522.2	RP1-177A13.1	3.39	0.000763	0.0431	0.2	0.15	Breast cancer;	chr6:127324574	chr6:127416535~127416952:-
THCA	cis	rs7107174	0.901	rs2511162	ENSG00000254459.1	RP11-91P24.7	-3.39	0.000764	0.0432	-0.2	-0.15	Testicular germ cell tumor;	chr11:78216055	chr11:77829654~77872262:-
THCA	cis	rs6490294	0.904	rs76300790	ENSG00000234608.6	MAPKAPK5-AS1	3.39	0.000764	0.0432	0.15	0.15	Mean platelet volume;	chr12:111964865	chr12:111839764~111842902:-
THCA	cis	rs55692468	0.848	rs2346206	ENSG00000213197.3	AC012066.1	3.39	0.000764	0.0432	0.2	0.15	Intraocular pressure;	chr2:152506465	chr2:152389937~152390630:+
THCA	cis	rs7927592	0.731	rs488381	ENSG00000160172.9	FAM86C2P	-3.39	0.000764	0.0432	-0.14	-0.15	Total body bone mineral density;	chr11:68524225	chr11:67791648~67805336:-
THCA	cis	rs6828577	0.606	rs441216	ENSG00000248280.1	RP11-33B1.2	3.39	0.000764	0.0432	0.15	0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118709247	chr4:119440561~119450157:-
THCA	cis	rs11992162	0.551	rs59191504	ENSG00000227888.4	FAM66A	-3.39	0.000764	0.0432	-0.2	-0.15	Monocyte count;	chr8:11927572	chr8:12362019~12388296:+
THCA	cis	rs2882667	0.898	rs10079634	ENSG00000249593.5	CTB-46B19.2	3.39	0.000764	0.0432	0.18	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:139012647~139051203:+
THCA	cis	rs972540	1	rs6751830	ENSG00000229647.1	AC007879.7	-3.39	0.000764	0.0432	-0.18	-0.15	Body mass index;	chr2:206396246	chr2:207239650~207245887:+
THCA	cis	rs9916302	0.706	rs11655972	ENSG00000266469.1	CTB-131K11.1	-3.39	0.000764	0.0432	-0.15	-0.15	Glomerular filtration rate (creatinine);	chr17:39250819	chr17:39401793~39406233:+
THCA	cis	rs10090774	0.71	rs11166991	ENSG00000279766.1	RP11-642A1.2	-3.39	0.000764	0.0432	-0.19	-0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140656314	chr8:140572142~140572812:-
THCA	cis	rs10508774	0.57	rs56848972	ENSG00000217094.2	PPIAP31	3.39	0.000764	0.0432	0.3	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32946229	chr10:32188323~32188817:-
THCA	cis	rs34792	0.525	rs12708795	ENSG00000275910.1	RP11-680G24.6	-3.39	0.000764	0.0432	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:15015828~15016390:-
THCA	cis	rs73222236	0.825	rs9826146	ENSG00000273486.1	RP11-731C17.2	3.39	0.000764	0.0432	0.13	0.15	Coronary artery disease;	chr3:136264247	chr3:136837338~136839021:-
THCA	cis	rs4646404	0.509	rs897450	ENSG00000225442.2	MPRIP-AS1	3.39	0.000764	0.0432	0.18	0.15	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr17:17572036	chr17:17076038~17077752:-
THCA	cis	rs11992162	0.636	rs4841644	ENSG00000227888.4	FAM66A	3.39	0.000764	0.0432	0.2	0.15	Monocyte count;	chr8:11940924	chr8:12362019~12388296:+
THCA	cis	rs2357982	0.556	rs10490562	ENSG00000232320.6	AC009299.5	-3.39	0.000764	0.0432	-0.2	-0.15	Presence of antiphospholipid antibodies;	chr2:161044292	chr2:161340816~161341326:-
THCA	cis	rs56309584	0.715	rs77224069	ENSG00000265749.4	RP11-849F2.5	3.39	0.000764	0.0432	0.22	0.15	Initial pursuit acceleration;	chr17:8220950	chr17:8365563~8381328:+
THCA	cis	rs2180341	0.751	rs9388553	ENSG00000220522.2	RP1-177A13.1	3.39	0.000764	0.0432	0.2	0.15	Breast cancer;	chr6:127252899	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.722	rs9388555	ENSG00000220522.2	RP1-177A13.1	3.39	0.000764	0.0432	0.2	0.15	Breast cancer;	chr6:127255218	chr6:127416535~127416952:-
THCA	cis	rs7873102	0.872	rs7044173	ENSG00000213839.4	TMX2P1	-3.39	0.000764	0.0432	-0.12	-0.15	Brain structure;	chr9:37956355	chr9:37885683~37886390:+
THCA	cis	rs3176789	0.872	rs7488011	ENSG00000256673.1	RP11-599J14.2	3.39	0.000764	0.0432	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772740	chr12:9398355~9414851:-
THCA	cis	rs4713118	0.513	rs149941	ENSG00000176933.5	TOB2P1	-3.39	0.000764	0.0432	-0.18	-0.15	Parkinson's disease;	chr6:28033255	chr6:28217643~28218634:-
THCA	cis	rs200092657	1	rs200092657	ENSG00000204706.13	MAMDC2-AS1	3.39	0.000764	0.0432	0.12	0.15	Platelet distribution width;	chr9:70458030	chr9:70033921~70175888:-
THCA	cis	rs10875746	0.903	rs17122666	ENSG00000275228.1	RP11-370I10.10	3.39	0.000764	0.0432	0.19	0.15	Longevity (90 years and older);	chr12:48108791	chr12:48327942~48328472:-
THCA	cis	rs240993	0.516	rs173287	ENSG00000271789.1	RP5-1112D6.7	-3.39	0.000764	0.0432	-0.2	-0.15	Inflammatory skin disease;Psoriasis;	chr6:111276236	chr6:111297126~111298510:+
THCA	cis	rs7829975	0.688	rs6601703	ENSG00000254340.1	RP11-10A14.3	3.39	0.000764	0.0432	0.17	0.15	Mood instability;	chr8:8522714	chr8:9141424~9145435:+
THCA	cis	rs875971	0.66	rs2013222	ENSG00000230189.5	GS1-124K5.2	-3.39	0.000764	0.0432	-0.1	-0.15	Aortic root size;	chr7:66570949	chr7:66409143~66490059:-
THCA	cis	rs6084875	0.733	rs6052854	ENSG00000278595.1	RP5-1068H6.6	-3.39	0.000764	0.0432	-0.18	-0.15	Systemic lupus erythematosus;	chr20:4761753	chr20:4761300~4761696:+
THCA	cis	rs11658311	1	rs9896285	ENSG00000232344.2	AC087163.2	-3.39	0.000764	0.0432	-0.18	-0.15	Obsessive-compulsive symptoms;	chr17:17632533	chr17:18010643~18011822:+
THCA	cis	rs7671266	0.532	rs28730480	ENSG00000163612.10	FAM86KP	-3.39	0.000765	0.0432	-0.25	-0.15	Cardiovascular disease risk factors;	chr4:10047243	chr4:9153296~9165451:+
THCA	cis	rs6788895	1	rs78552868	ENSG00000244265.1	SIAH2-AS1	3.39	0.000765	0.0432	0.42	0.15	Breast cancer;	chr3:150793244	chr3:150761937~150762538:+
THCA	cis	rs9393777	0.528	rs7745603	ENSG00000219392.1	RP1-265C24.5	-3.39	0.000765	0.0432	-0.19	-0.15	Intelligence (multi-trait analysis);	chr6:27122625	chr6:28115628~28116551:+
THCA	cis	rs4650994	0.544	rs6664493	ENSG00000213057.5	C1orf220	-3.39	0.000765	0.0432	-0.11	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178525293	chr1:178542752~178548889:+
THCA	cis	rs7914558	1	rs12255047	ENSG00000272912.1	RP11-724N1.1	-3.39	0.000765	0.0432	-0.18	-0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103000995	chr10:102914585~102915404:+
THCA	cis	rs1065852	0.526	rs12166549	ENSG00000281538.1	RP4-669P10.20	-3.39	0.000765	0.0432	-0.16	-0.15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014415	chr22:42138060~42139726:+
THCA	cis	rs1065852	0.526	rs9611711	ENSG00000281538.1	RP4-669P10.20	-3.39	0.000765	0.0432	-0.16	-0.15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014691	chr22:42138060~42139726:+
THCA	cis	rs5751614	1	rs2283805	ENSG00000211649.3	IGLV7-46	-3.39	0.000765	0.0432	-0.1	-0.15	Height;	chr22:23247755	chr22:22369614~22370087:+
THCA	cis	rs12478296	0.534	rs67092377	ENSG00000220804.7	AC093642.5	3.39	0.000765	0.0432	0.15	0.15	Obesity-related traits;	chr2:242060020	chr2:242088633~242160153:+
THCA	cis	rs909002	0.8	rs1056526	ENSG00000235790.6	RP11-73M7.6	3.39	0.000765	0.0432	0.16	0.15	Intelligence (multi-trait analysis);	chr1:31619303	chr1:31644049~31660162:+
THCA	cis	rs34779708	0.966	rs7913615	ENSG00000233200.1	RP11-324I22.2	3.39	0.000765	0.0432	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35219894~35230598:-
THCA	cis	rs7824557	0.778	rs3808502	ENSG00000254866.2	DEFB109P3	-3.39	0.000765	0.0432	-0.21	-0.15	Retinal vascular caliber;	chr8:11321949	chr8:12150895~12151134:-
THCA	cis	rs1612141	1	rs10151454	ENSG00000251363.2	RP11-129M6.1	3.39	0.000765	0.0432	0.22	0.15	QT interval (drug interaction);	chr14:41306797	chr14:40954898~40975877:+
THCA	cis	rs875971	1	rs10244498	ENSG00000272831.1	RP11-792A8.4	3.39	0.000765	0.0432	0.1	0.15	Aortic root size;	chr7:66651069	chr7:66739829~66740385:-
THCA	cis	rs881375	0.678	rs10818488	ENSG00000238181.2	AHCYP2	-3.39	0.000765	0.0432	-0.19	-0.15	Rheumatoid arthritis;	chr9:120942809	chr9:120720673~120721972:+
THCA	cis	rs6017317	0.626	rs73613462	ENSG00000234271.1	RP1-138B7.4	-3.39	0.000765	0.0432	-0.2	-0.15	Type 2 diabetes;	chr20:44224421	chr20:43523261~43523572:-
THCA	cis	rs75422866	0.51	rs73105812	ENSG00000280054.1	RP1-197B17.7	3.39	0.000765	0.0432	0.3	0.15	Pneumonia;	chr12:47724404	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.51	rs74733564	ENSG00000280054.1	RP1-197B17.7	3.39	0.000765	0.0432	0.3	0.15	Pneumonia;	chr12:47724644	chr12:47728151~47730598:-
THCA	cis	rs75422866	0.51	rs73105814	ENSG00000280054.1	RP1-197B17.7	3.39	0.000765	0.0432	0.3	0.15	Pneumonia;	chr12:47725817	chr12:47728151~47730598:-
THCA	cis	rs939960	0.959	rs34534990	ENSG00000276538.1	RP11-545G3.2	3.39	0.000765	0.0432	0.22	0.15	Neutrophil percentage of white cells;	chr7:150586685	chr7:150047609~150047854:-
THCA	cis	rs9650657	0.74	rs7002282	ENSG00000255310.2	AF131215.2	-3.39	0.000765	0.0432	-0.13	-0.15	Neuroticism;	chr8:10809483	chr8:11107788~11109726:-
THCA	cis	rs321358	0.732	rs17535419	ENSG00000271390.1	RP11-89C3.3	3.39	0.000765	0.0432	0.25	0.15	Body mass index;	chr11:111075357	chr11:111089870~111090368:-
THCA	cis	rs197770	0.542	rs169188	ENSG00000279727.1	RP11-640L9.1	-3.39	0.000765	0.0432	-0.28	-0.15	Phospholipid levels (plasma);	chr3:37465958	chr3:36819276~36822498:-
THCA	cis	rs1881396	0.531	rs72613829	ENSG00000223522.1	AC093690.1	-3.39	0.000765	0.0432	-0.21	-0.15	Nonalcoholic fatty liver disease;	chr2:27680120	chr2:28307691~28310459:-
THCA	cis	rs9652601	0.691	rs12922303	ENSG00000263033.2	RP11-396B14.2	-3.39	0.000765	0.0432	-0.12	-0.15	Systemic lupus erythematosus;	chr16:11099608	chr16:11196177~11224969:+
THCA	cis	rs684232	0.602	rs448465	ENSG00000231784.7	DBIL5P	3.39	0.000765	0.0432	0.17	0.15	Prostate cancer;	chr17:656648	chr17:752660~755336:+
THCA	cis	rs1577917	0.771	rs2484355	ENSG00000220563.1	PKMP3	-3.39	0.000765	0.0432	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85684685	chr6:85659892~85660606:-
THCA	cis	rs862034	0.872	rs862045	ENSG00000270000.1	RP3-449M8.9	-3.39	0.000765	0.0432	-0.16	-0.15	Height;	chr14:74517665	chr14:74471930~74472360:-
THCA	cis	rs11955398	0.542	rs2085413	ENSG00000250148.1	KRT8P31	-3.39	0.000765	0.0432	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60729552	chr5:60743563~60744970:-
THCA	cis	rs478304	0.654	rs10896029	ENSG00000245532.5	NEAT1	-3.39	0.000765	0.0432	-0.11	-0.15	Acne (severe);	chr11:65685481	chr11:65422774~65445540:+
THCA	cis	rs478304	0.627	rs11227254	ENSG00000245532.5	NEAT1	-3.39	0.000765	0.0432	-0.11	-0.15	Acne (severe);	chr11:65686529	chr11:65422774~65445540:+
THCA	cis	rs478304	0.637	rs11227255	ENSG00000245532.5	NEAT1	-3.39	0.000765	0.0432	-0.11	-0.15	Acne (severe);	chr11:65686573	chr11:65422774~65445540:+
THCA	cis	rs478304	0.627	rs1073602	ENSG00000245532.5	NEAT1	-3.39	0.000765	0.0432	-0.11	-0.15	Acne (severe);	chr11:65687915	chr11:65422774~65445540:+
THCA	cis	rs478304	0.654	rs6591185	ENSG00000245532.5	NEAT1	-3.39	0.000765	0.0432	-0.11	-0.15	Acne (severe);	chr11:65688271	chr11:65422774~65445540:+
THCA	cis	rs34779708	0.771	rs12098283	ENSG00000233200.1	RP11-324I22.2	3.39	0.000765	0.0432	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35219894~35230598:-
THCA	cis	rs748404	0.578	rs2584701	ENSG00000224677.1	PDIA3P2	3.39	0.000765	0.0432	0.19	0.15	Lung cancer;	chr15:43392741	chr15:43649123~43649280:+
THCA	cis	rs17092148	0.636	rs7273470	ENSG00000250917.1	RP4-785G19.5	-3.39	0.000765	0.0432	-0.21	-0.15	Neuroticism;	chr20:34869118	chr20:34234840~34281173:-
THCA	cis	rs17092148	0.579	rs7265109	ENSG00000250917.1	RP4-785G19.5	-3.39	0.000765	0.0432	-0.21	-0.15	Neuroticism;	chr20:34871551	chr20:34234840~34281173:-
THCA	cis	rs17092148	0.636	rs11697978	ENSG00000250917.1	RP4-785G19.5	-3.39	0.000765	0.0432	-0.21	-0.15	Neuroticism;	chr20:34872563	chr20:34234840~34281173:-
THCA	cis	rs9652601	0.691	rs6498160	ENSG00000263033.2	RP11-396B14.2	-3.39	0.000765	0.0432	-0.12	-0.15	Systemic lupus erythematosus;	chr16:11105590	chr16:11196177~11224969:+
THCA	cis	rs13064411	0.696	rs13325046	ENSG00000243849.1	CFAP44-AS1	3.39	0.000765	0.0432	0.25	0.15	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113385597	chr3:113403991~113433992:+
THCA	cis	rs2749592	0.55	rs7081464	ENSG00000151963.4	RP11-775A3.1	3.39	0.000766	0.0432	0.16	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:37883594~37884109:+
THCA	cis	rs3126085	0.935	rs4845733	ENSG00000237975.5	FLG-AS1	-3.39	0.000766	0.0433	-0.24	-0.15	Atopic dermatitis;	chr1:152190092	chr1:152168125~152445456:+
THCA	cis	rs453301	0.598	rs2921383	ENSG00000253981.4	ALG1L13P	3.39	0.000766	0.0433	0.14	0.15	Joint mobility (Beighton score);	chr8:9034711	chr8:8236003~8244667:-
THCA	cis	rs524281	0.817	rs10896092	ENSG00000255038.1	RP11-1167A19.2	-3.39	0.000766	0.0433	-0.18	-0.15	Electroencephalogram traits;	chr11:66190575	chr11:66067277~66069619:-
THCA	cis	rs4662986	0.535	rs3109319	ENSG00000213225.7	AC018804.7	3.39	0.000766	0.0433	0.3	0.15	Age at smoking initiation in chronic obstructive pulmonary disease;	chr2:129634452	chr2:130229379~130232106:+
THCA	cis	rs738409	0.657	rs2076211	ENSG00000223843.4	EFCAB6-AS1	-3.39	0.000766	0.0433	-0.22	-0.15	Cirrhosis (alcohol related);Nonalcoholic fatty liver disease;Liver enzyme levels (alanine transaminase);Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr22:43933198	chr22:43516107~43537117:+
THCA	cis	rs944289	0.576	rs1169131	ENSG00000258844.1	RP11-259K15.2	3.39	0.000766	0.0433	0.15	0.15	Thyroid cancer;	chr14:36153349	chr14:36214607~36235608:+
THCA	cis	rs10457838	0.742	rs7772696	ENSG00000223701.3	RAET1E-AS1	3.39	0.000766	0.0433	0.22	0.15	Post-traumatic stress disorder;	chr6:149083891	chr6:149884431~149919508:+
THCA	cis	rs10457838	0.742	rs4897078	ENSG00000223701.3	RAET1E-AS1	3.39	0.000766	0.0433	0.22	0.15	Post-traumatic stress disorder;	chr6:149084346	chr6:149884431~149919508:+
THCA	cis	rs250518	0.926	rs34669	ENSG00000251467.1	CTC-250P20.2	-3.39	0.000766	0.0433	-0.22	-0.15	Mean corpuscular hemoglobin concentration;	chr5:72866437	chr5:72996920~72997642:+
THCA	cis	rs3824488	0.92	rs10512249	ENSG00000271384.1	RP11-435O5.7	-3.39	0.000766	0.0433	-0.23	-0.15	Neuroticism;	chr9:95494027	chr9:95406990~95407662:-
THCA	cis	rs3864261	0.774	rs155629	ENSG00000249085.1	CTD-2631K10.1	3.39	0.000766	0.0433	0.25	0.15	Discordance in emotional problems in monozygotic twins;	chr5:72920604	chr5:72794405~72816565:-
THCA	cis	rs9303280	0.901	rs2305479	ENSG00000263818.4	CTD-2206N4.4	3.39	0.000766	0.0433	0.2	0.15	Self-reported allergy;	chr17:39905964	chr17:39057019~39113190:+
THCA	cis	rs7259376	0.902	rs10409947	ENSG00000269138.1	ZNF209P	3.39	0.000766	0.0433	0.16	0.15	Menopause (age at onset);	chr19:22329716	chr19:22463922~22473036:+
THCA	cis	rs786425	0.901	rs11057307	ENSG00000278112.1	RP11-972P1.11	3.39	0.000766	0.0433	0.15	0.15	Pubertal anthropometrics;	chr12:123613666	chr12:123519390~123519856:-
THCA	cis	rs11051970	0.559	rs3789975	ENSG00000275769.1	RP11-771K4.3	-3.39	0.000766	0.0433	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32331469	chr12:31443792~31444208:-
THCA	cis	rs2287926	0.588	rs308362	ENSG00000271862.1	RP11-343L5.2	3.39	0.000766	0.0433	0.21	0.15	Appendicular lean mass;Lean body mass;	chr5:83527972	chr5:83049376~83050964:-
THCA	cis	rs982100	0.591	rs10864957	ENSG00000226856.4	AC093901.1	3.39	0.000766	0.0433	0.25	0.15	Alzheimer disease and age of onset;	chr2:117655366	chr2:118132128~118186386:-
THCA	cis	rs34779708	0.966	rs4934735	ENSG00000233200.1	RP11-324I22.2	-3.39	0.000766	0.0433	-0.18	-0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35219894~35230598:-
THCA	cis	rs12049351	0.774	rs12750869	ENSG00000229367.1	HMGN2P19	3.39	0.000766	0.0433	0.24	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229570467	chr1:229570532~229570796:+
THCA	cis	rs4886920	0.537	rs6495247	ENSG00000260776.4	RP11-114H24.2	3.39	0.000767	0.0433	0.2	0.15	Neuroticism;	chr15:77777089	chr15:77914217~77926846:-
THCA	cis	rs613391	0.702	rs474342	ENSG00000234840.1	LINC01239	-3.39	0.000767	0.0433	-0.18	-0.15	Quantitative traits;	chr9:22711949	chr9:22646200~22824213:+
THCA	cis	rs613391	0.702	rs560220	ENSG00000234840.1	LINC01239	-3.39	0.000767	0.0433	-0.18	-0.15	Quantitative traits;	chr9:22712304	chr9:22646200~22824213:+
THCA	cis	rs7914558	0.966	rs11191438	ENSG00000272912.1	RP11-724N1.1	-3.39	0.000767	0.0433	-0.18	-0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102914585~102915404:+
THCA	cis	rs4141404	0.582	rs5753630	ENSG00000235573.2	RP3-412A9.12	-3.39	0.000767	0.0433	-0.16	-0.15	Paclitaxel-induced neuropathy;	chr22:31465964	chr22:31113017~31113396:+
THCA	cis	rs5770917	1	rs3213446	ENSG00000273272.1	CTA-384D8.34	3.39	0.000767	0.0433	0.23	0.15	Narcolepsy;	chr22:50577245	chr22:50542650~50543011:+
THCA	cis	rs2116941	1	rs2033493	ENSG00000238364.1	RNU7-140P	3.39	0.000767	0.0433	0.23	0.15	Pulse pressure;	chr19:10230178	chr19:10551033~10551092:-
THCA	cis	rs12476592	0.602	rs262507	ENSG00000242412.1	DBIL5P2	3.39	0.000767	0.0433	0.2	0.15	Childhood ear infection;	chr2:63656478	chr2:63117851~63119542:-
THCA	cis	rs35860234	0.806	rs66749983	ENSG00000231530.1	RP11-187A9.3	3.39	0.000767	0.0433	0.19	0.15	Vitiligo;	chr13:42489695	chr13:42043727~42044247:-
THCA	cis	rs2069837	0.636	rs57356541	ENSG00000232949.1	AC002480.4	3.39	0.000767	0.0433	0.27	0.15	Longevity;	chr7:22743764	chr7:22589705~22591622:+
THCA	cis	rs9400467	0.528	rs6568680	ENSG00000272356.1	RP5-1112D6.8	-3.39	0.000767	0.0433	-0.12	-0.15	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111309203~111313517:+
THCA	cis	rs7267979	0.78	rs6050679	ENSG00000277938.1	RP5-965G21.3	3.39	0.000767	0.0433	0.13	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25229150~25231933:+
THCA	cis	rs1125355	0.622	rs62183014	ENSG00000243792.1	OR7E89P	-3.39	0.000767	0.0433	-0.24	-0.15	Alzheimer's disease in APOE e4+ carriers;	chr2:158759029	chr2:158853755~158854576:+
THCA	cis	rs4800353	0.81	rs7229928	ENSG00000265142.5	MIR133A1HG	-3.39	0.000767	0.0433	-0.21	-0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr18:22034167	chr18:21825487~21831410:-
THCA	cis	rs9650657	0.631	rs1124010	ENSG00000255310.2	AF131215.2	-3.39	0.000767	0.0433	-0.13	-0.15	Neuroticism;	chr8:10737992	chr8:11107788~11109726:-
THCA	cis	rs11089937	0.568	rs59356111	ENSG00000215456.5	BCRP4	3.39	0.000767	0.0433	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.626	rs5757019	ENSG00000215456.5	BCRP4	3.39	0.000767	0.0433	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22630061~22636153:+
THCA	cis	rs1560104	0.597	rs17227296	ENSG00000262801.4	U91319.1	-3.39	0.000767	0.0433	-0.17	-0.15	Obesity-related traits;	chr16:12618342	chr16:13246316~13562918:+
THCA	cis	rs1113500	0.933	rs11185259	ENSG00000230489.1	VAV3-AS1	3.39	0.000767	0.0433	0.14	0.15	Growth-regulated protein alpha levels;	chr1:108092440	chr1:107964443~107994607:+
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000281021.1	RP1-12G14.9	-3.39	0.000767	0.0433	-0.16	-0.15	Lung cancer;	chr6:149791063	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000281021.1	RP1-12G14.9	-3.39	0.000767	0.0433	-0.16	-0.15	Lung cancer;	chr6:149791065	chr6:149576089~149590864:-
THCA	cis	rs9326248	0.509	rs533556	ENSG00000280143.1	AP000892.6	3.39	0.000767	0.0433	0.19	0.15	Blood protein levels;	chr11:116870856	chr11:117204967~117210292:+
THCA	cis	rs479105	0.771	rs614616	ENSG00000278356.1	RP11-372B4.3	-3.39	0.000767	0.0433	-0.15	-0.15	Gut microbiota (bacterial taxa);	chr12:3255907	chr12:2885819~2886329:+
THCA	cis	rs3784262	0.669	rs12914455	ENSG00000259250.1	RP11-50C13.1	3.39	0.000767	0.0433	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58019898	chr15:58587507~58591676:+
THCA	cis	rs2540917	0.934	rs173373	ENSG00000237522.1	NONOP2	-3.39	0.000767	0.0433	-0.14	-0.15	Mean corpuscular volume;	chr2:60378784	chr2:60936819~60938049:-
THCA	cis	rs2540917	1	rs243030	ENSG00000237522.1	NONOP2	-3.39	0.000767	0.0433	-0.14	-0.15	Mean corpuscular volume;	chr2:60379436	chr2:60936819~60938049:-
THCA	cis	rs2562456	0.833	rs2562487	ENSG00000268658.4	LINC00664	3.39	0.000768	0.0433	0.23	0.15	Pain;	chr19:21468580	chr19:21483374~21503238:+
THCA	cis	rs801193	0.569	rs6978178	ENSG00000223473.2	GS1-124K5.3	-3.39	0.000768	0.0433	-0.1	-0.15	Aortic root size;	chr7:66658097	chr7:66491049~66493566:-
THCA	cis	rs7656342	0.866	rs10013858	ENSG00000242034.1	RP11-1396O13.1	3.39	0.000768	0.0433	0.18	0.15	Gut microbiota (bacterial taxa);	chr4:9760837	chr4:9553614~9553985:-
THCA	cis	rs3824488	0.765	rs76597087	ENSG00000271155.1	RP11-435O5.5	-3.39	0.000768	0.0433	-0.28	-0.15	Neuroticism;	chr9:95529571	chr9:95506235~95507636:+
THCA	cis	rs9929218	0.529	rs35854485	ENSG00000260459.2	FTLP14	3.39	0.000768	0.0433	0.17	0.15	Colorectal cancer;	chr16:68696952	chr16:68822587~68823070:+
THCA	cis	rs348196	0.767	rs12744132	ENSG00000203761.5	MSTO2P	-3.39	0.000768	0.0433	-0.13	-0.15	Breast cancer;	chr1:155693535	chr1:155745829~155750137:+
THCA	cis	rs78487399	0.908	rs17031095	ENSG00000234936.1	AC010883.5	3.39	0.000768	0.0434	0.19	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43592000	chr2:43229573~43233394:+
THCA	cis	rs13294589	0.838	rs1887224	ENSG00000254396.1	RP11-56F10.3	-3.39	0.000768	0.0434	-0.21	-0.15	Gallbladder cancer;	chr9:26658811	chr9:27102630~27104728:+
THCA	cis	rs1035275	0.507	rs17664296	ENSG00000239926.1	PRDX3P4	-3.39	0.000768	0.0434	-0.18	-0.15	IgG glycosylation;	chr3:64162612	chr3:64174401~64175147:+
THCA	cis	rs6452524	0.618	rs6452506	ENSG00000271862.1	RP11-343L5.2	3.39	0.000768	0.0434	0.16	0.15	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83049376~83050964:-
THCA	cis	rs6452524	0.618	rs1993948	ENSG00000271862.1	RP11-343L5.2	3.39	0.000768	0.0434	0.16	0.15	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83049376~83050964:-
THCA	cis	rs6452524	0.618	rs2075685	ENSG00000271862.1	RP11-343L5.2	3.39	0.000768	0.0434	0.16	0.15	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83049376~83050964:-
THCA	cis	rs9368481	0.743	rs9368480	ENSG00000228223.2	HCG11	-3.39	0.000768	0.0434	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26523450~26526579:+
THCA	cis	rs910316	0.763	rs175044	ENSG00000259138.1	RP11-950C14.7	-3.39	0.000768	0.0434	-0.13	-0.15	Height;	chr14:75005406	chr14:75127153~75136930:+
THCA	cis	rs829402	0.836	rs829373	ENSG00000187952.9	HS6ST1P1	3.39	0.000768	0.0434	0.21	0.15	High light scatter reticulocyte count;	chr1:21662070	chr1:21428303~21429536:+
THCA	cis	rs1881509	0.748	rs10766917	ENSG00000233930.3	KRTAP5-AS1	-3.39	0.000768	0.0434	-0.19	-0.15	Heroin dependence;	chr11:1421325	chr11:1571353~1599184:+
THCA	cis	rs7737355	0.812	rs11750704	ENSG00000224431.1	AC063976.7	3.39	0.000768	0.0434	0.14	0.15	Life satisfaction;	chr5:131575885	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.947	rs11744232	ENSG00000224431.1	AC063976.7	3.39	0.000768	0.0434	0.14	0.15	Life satisfaction;	chr5:131576039	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.947	rs11750739	ENSG00000224431.1	AC063976.7	3.39	0.000768	0.0434	0.14	0.15	Life satisfaction;	chr5:131576050	chr5:132199456~132203487:+
THCA	cis	rs8012947	0.651	rs74055634	ENSG00000257621.6	PSMA3-AS1	3.39	0.000768	0.0434	0.07	0.15	Alcohol consumption in current drinkers;	chr14:58361359	chr14:58265365~58298134:-
THCA	cis	rs4808199	0.947	rs1465695	ENSG00000267481.1	CTC-559E9.5	-3.39	0.000768	0.0434	-0.16	-0.15	Nonalcoholic fatty liver disease;	chr19:19477737	chr19:19788755~19790531:-
THCA	cis	rs832187	1	rs832187	ENSG00000224479.4	AC136289.1	-3.39	0.000768	0.0434	-0.19	-0.15	Schizophrenia;	chr3:63847374	chr3:63742293~63827445:-
THCA	cis	rs2692947	0.526	rs58719199	ENSG00000235959.1	AC009237.17	-3.39	0.000768	0.0434	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95912499	chr2:95640181~95640604:-
THCA	cis	rs2692947	0.655	rs4605406	ENSG00000235959.1	AC009237.17	-3.39	0.000768	0.0434	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95917987	chr2:95640181~95640604:-
THCA	cis	rs112881630	0.585	rs72821200	ENSG00000279368.1	RP1-80N2.4	3.39	0.000768	0.0434	0.29	0.15	Pelvic organ prolapse (moderate/severe);	chr6:6735374	chr6:6685148~6686984:+
THCA	cis	rs3784262	0.74	rs4646582	ENSG00000259250.1	RP11-50C13.1	3.39	0.000768	0.0434	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58015183	chr15:58587507~58591676:+
THCA	cis	rs9889262	0.641	rs3179840	ENSG00000248714.5	RP11-1079K10.3	3.39	0.000768	0.0434	0.18	0.15	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49290174	chr17:49361165~49369998:+
THCA	cis	rs57590327	0.503	rs1461611	ENSG00000241593.4	RP11-520D19.2	3.39	0.000768	0.0434	0.19	0.15	Extraversion;	chr3:81462910	chr3:81246579~81297345:-
THCA	cis	rs57590327	0.503	rs898763	ENSG00000241593.4	RP11-520D19.2	3.39	0.000768	0.0434	0.19	0.15	Extraversion;	chr3:81464257	chr3:81246579~81297345:-
THCA	cis	rs57590327	0.503	rs6776737	ENSG00000241593.4	RP11-520D19.2	3.39	0.000768	0.0434	0.19	0.15	Extraversion;	chr3:81464578	chr3:81246579~81297345:-
THCA	cis	rs1908814	0.516	rs13281315	ENSG00000255046.1	RP11-297N6.4	-3.39	0.000768	0.0434	-0.17	-0.15	Neuroticism;	chr8:11937346	chr8:11797928~11802568:-
THCA	cis	rs7621331	1	rs6810223	ENSG00000239213.4	NCK1-AS1	3.39	0.000768	0.0434	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135975662	chr3:136841726~136862054:-
THCA	cis	rs2692947	0.631	rs2312954	ENSG00000168992.4	OR7E102P	-3.39	0.000768	0.0434	-0.2	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96106699	chr2:95546531~95547545:+
THCA	cis	rs9607412	0.593	rs130619	ENSG00000233360.4	Z83844.1	-3.39	0.000768	0.0434	-0.17	-0.15	Mean corpuscular volume;	chr22:37040308	chr22:37641832~37658377:-
THCA	cis	rs4389656	0.617	rs34596617	ENSG00000248677.1	CTD-2044J15.1	-3.39	0.000768	0.0434	-0.16	-0.15	Coronary artery disease;	chr5:6767132	chr5:6686325~6707711:-
THCA	cis	rs13046373	0.535	rs7276743	ENSG00000174680.8	GRIK1-AS1	-3.39	0.000768	0.0434	-0.19	-0.15	HDL cholesterol;	chr21:30612226	chr21:29748175~29764002:+
THCA	cis	rs10863936	0.667	rs17699790	ENSG00000198468.6	FLVCR1-AS1	-3.39	0.000768	0.0434	-0.18	-0.15	Height;	chr1:211933964	chr1:212852108~212858088:-
THCA	cis	rs7615952	0.599	rs7652883	ENSG00000241288.6	RP11-379B18.5	-3.39	0.000768	0.0434	-0.17	-0.15	Blood pressure (smoking interaction);	chr3:125989134	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.599	rs6803160	ENSG00000241288.6	RP11-379B18.5	-3.39	0.000768	0.0434	-0.17	-0.15	Blood pressure (smoking interaction);	chr3:125990711	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.688	rs12485622	ENSG00000241288.6	RP11-379B18.5	-3.39	0.000768	0.0434	-0.17	-0.15	Blood pressure (smoking interaction);	chr3:125991896	chr3:125827238~125916384:-
THCA	cis	rs4081724	0.671	rs61247826	ENSG00000267296.2	CEBPA-AS1	3.39	0.000768	0.0434	0.2	0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33338547	chr19:33302857~33305054:+
THCA	cis	rs2364403	0.531	rs41264995	ENSG00000160766.13	GBAP1	-3.39	0.000768	0.0434	-0.27	-0.15	Amyotrophic lateral sclerosis (age of onset);	chr1:155947598	chr1:155213821~155227422:-
THCA	cis	rs11088226	0.758	rs2833864	ENSG00000186842.4	LINC00846	-3.39	0.000768	0.0434	-0.21	-0.15	Gastritis;	chr21:32516083	chr21:32572238~32575881:-
THCA	cis	rs714027	0.626	rs4336042	ENSG00000279699.1	RP1-102K2.9	-3.39	0.000768	0.0434	-0.16	-0.15	Lymphocyte counts;	chr22:30156522	chr22:30275215~30276951:-
THCA	cis	rs128738	0.5	rs60168911	ENSG00000224431.1	AC063976.7	-3.39	0.000768	0.0434	-0.16	-0.15	Giant cell arteritis;	chr5:132229767	chr5:132199456~132203487:+
THCA	cis	rs11190604	1	rs9419897	ENSG00000273030.1	RP11-285F16.1	3.39	0.000768	0.0434	0.18	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100486368	chr10:100412934~100413421:+
THCA	cis	rs6496667	0.509	rs2657948	ENSG00000213471.7	TTLL13P	3.39	0.000769	0.0434	0.18	0.15	Rheumatoid arthritis;	chr15:90405385	chr15:90249530~90265482:+
THCA	cis	rs867186	1	rs6060222	ENSG00000126005.14	MMP24-AS1	-3.39	0.000769	0.0434	-0.23	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35094767	chr20:35216462~35278131:-
THCA	cis	rs7924176	0.601	rs10824107	ENSG00000232342.6	RP11-46O21.2	3.39	0.000769	0.0434	0.19	0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.564	rs11000920	ENSG00000232342.6	RP11-46O21.2	3.39	0.000769	0.0434	0.19	0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74506081~74530553:-
THCA	cis	rs9902453	0.817	rs2628170	ENSG00000214719.10	AC005562.1	-3.39	0.000769	0.0434	-0.14	-0.15	Coffee consumption (cups per day);	chr17:29729594	chr17:30576464~30672789:+
THCA	cis	rs12493885	0.654	rs11925207	ENSG00000238755.3	RP11-23D24.2	-3.39	0.000769	0.0434	-0.33	-0.15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:153982097	chr3:153384934~153980186:-
THCA	cis	rs478304	0.619	rs10791822	ENSG00000245532.5	NEAT1	-3.39	0.000769	0.0434	-0.11	-0.15	Acne (severe);	chr11:65661235	chr11:65422774~65445540:+
THCA	cis	rs7824557	0.836	rs2736378	ENSG00000255310.2	AF131215.2	-3.39	0.000769	0.0434	-0.13	-0.15	Retinal vascular caliber;	chr8:11262251	chr8:11107788~11109726:-
THCA	cis	rs939960	0.959	rs13220967	ENSG00000276538.1	RP11-545G3.2	3.39	0.000769	0.0434	0.23	0.15	Neutrophil percentage of white cells;	chr7:150612750	chr7:150047609~150047854:-
THCA	cis	rs939960	0.917	rs12154687	ENSG00000276538.1	RP11-545G3.2	3.39	0.000769	0.0434	0.23	0.15	Neutrophil percentage of white cells;	chr7:150614085	chr7:150047609~150047854:-
THCA	cis	rs1873147	0.569	rs8034365	ENSG00000259672.1	RP11-69G7.1	-3.39	0.000769	0.0434	-0.2	-0.15	Orofacial clefts;	chr15:63017004	chr15:63098870~63110403:+
THCA	cis	rs1348850	0.554	rs1374438	ENSG00000280374.1	RP11-337N6.3	-3.39	0.000769	0.0434	-0.26	-0.15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177511956	chr2:177317715~177318471:-
THCA	cis	rs10515778	1	rs17720568	ENSG00000280834.1	U6	3.39	0.000769	0.0434	0.26	0.15	Inflammatory skin disease;	chr5:159225481	chr5:160072268~160072364:+
THCA	cis	rs6494488	0.5	rs113037933	ENSG00000259635.1	AC100830.3	-3.39	0.000769	0.0434	-0.36	-0.15	Coronary artery disease;	chr15:64606415	chr15:64701248~64719602:+
THCA	cis	rs939960	0.68	rs112634479	ENSG00000276538.1	RP11-545G3.2	3.39	0.000769	0.0434	0.23	0.15	Neutrophil percentage of white cells;	chr7:150601396	chr7:150047609~150047854:-
THCA	cis	rs17428076	1	rs17428076	ENSG00000228389.1	AC068039.4	3.39	0.000769	0.0434	0.19	0.15	Myopia;	chr2:171987022	chr2:171773482~171775844:+
THCA	cis	rs3784262	0.904	rs3784260	ENSG00000259250.1	RP11-50C13.1	3.39	0.000769	0.0434	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57961071	chr15:58587507~58591676:+
THCA	cis	rs7737355	0.947	rs10067982	ENSG00000224431.1	AC063976.7	3.39	0.000769	0.0434	0.15	0.15	Life satisfaction;	chr5:131500247	chr5:132199456~132203487:+
THCA	cis	rs34779708	0.966	rs4934540	ENSG00000233200.1	RP11-324I22.2	3.39	0.000769	0.0434	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35219894~35230598:-
THCA	cis	rs79149102	0.649	rs9788672	ENSG00000260103.2	RP11-10O17.1	-3.39	0.000769	0.0434	-0.21	-0.15	Lung cancer;	chr15:74584012	chr15:74478070~74490286:-
THCA	cis	rs1552244	0.744	rs6763366	ENSG00000269982.1	RP11-1020A11.2	3.39	0.000769	0.0434	0.12	0.15	Alzheimer's disease;	chr3:9991860	chr3:9958717~9962539:+
THCA	cis	rs1908814	0.541	rs7824267	ENSG00000227888.4	FAM66A	3.39	0.000769	0.0434	0.2	0.15	Neuroticism;	chr8:11936770	chr8:12362019~12388296:+
THCA	cis	rs72482608	0.865	rs10919471	ENSG00000271811.1	RP1-79C4.4	3.39	0.000769	0.0434	0.19	0.15	Emphysema imaging phenotypes;	chr1:170794412	chr1:170667381~170669425:+
THCA	cis	rs7819412	0.807	rs10105315	ENSG00000254839.1	AF131215.6	3.39	0.000769	0.0434	0.16	0.15	Triglycerides;	chr8:11074693	chr8:11062647~11067089:-
THCA	cis	rs7665090	0.846	rs4496586	ENSG00000248971.2	KRT8P46	-3.39	0.000769	0.0434	-0.18	-0.15	Primary biliary cholangitis;	chr4:102636154	chr4:102728746~102730171:-
THCA	cis	rs7395662	1	rs10838912	ENSG00000200090.1	Y_RNA	-3.39	0.000769	0.0434	-0.1	-0.15	HDL cholesterol;	chr11:48474925	chr11:47726894~47726992:-
THCA	cis	rs7916852	0.618	rs11006877	ENSG00000230500.1	MKX-AS1	3.39	0.000769	0.0434	0.27	0.15	Glaucoma (primary open-angle);	chr10:28111675	chr10:27744786~27767794:+
THCA	cis	rs6840360	1	rs6840678	ENSG00000270265.1	RP11-731D1.4	3.39	0.000769	0.0434	0.14	0.15	Intelligence (multi-trait analysis);	chr4:151683179	chr4:151333775~151353224:-
THCA	cis	rs1371614	0.635	rs12618836	ENSG00000229122.1	AGBL5-IT1	3.39	0.000769	0.0434	0.11	0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914748	chr2:27061038~27061815:+
THCA	cis	rs12780845	0.894	rs7099222	ENSG00000229124.5	VIM-AS1	-3.39	0.000769	0.0434	-0.15	-0.15	Homocysteine levels;	chr10:17209431	chr10:17214239~17229985:-
THCA	cis	rs10043228	0.826	rs62384691	ENSG00000250015.1	CTC-339F2.2	3.39	0.000769	0.0434	0.23	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116096846	chr5:116302354~116304134:-
THCA	cis	rs10043228	0.826	rs62384692	ENSG00000250015.1	CTC-339F2.2	3.39	0.000769	0.0434	0.23	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116097513	chr5:116302354~116304134:-
THCA	cis	rs10043228	0.826	rs62384695	ENSG00000250015.1	CTC-339F2.2	3.39	0.000769	0.0434	0.23	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116099200	chr5:116302354~116304134:-
THCA	cis	rs10043228	1	rs62384714	ENSG00000250015.1	CTC-339F2.2	3.39	0.000769	0.0434	0.23	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116116900	chr5:116302354~116304134:-
THCA	cis	rs5769765	1	rs5770755	ENSG00000278869.1	CITF22-49E9.3	-3.39	0.00077	0.0434	-0.21	-0.15	Schizophrenia;	chr22:49886488	chr22:49933198~49934074:-
THCA	cis	rs7520050	0.933	rs6661163	ENSG00000281133.1	AL355480.3	3.39	0.00077	0.0434	0.18	0.15	Reticulocyte count;Red blood cell count;	chr1:45789332	chr1:45580892~45580996:-
THCA	cis	rs3785574	0.962	rs2665842	ENSG00000279369.1	RP11-51F16.1	3.39	0.00077	0.0434	0.11	0.15	Height;	chr17:63801175	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs2727332	ENSG00000279369.1	RP11-51F16.1	3.39	0.00077	0.0434	0.11	0.15	Height;	chr17:63801224	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs2584633	ENSG00000279369.1	RP11-51F16.1	3.39	0.00077	0.0434	0.11	0.15	Height;	chr17:63802141	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs2584632	ENSG00000279369.1	RP11-51F16.1	3.39	0.00077	0.0434	0.11	0.15	Height;	chr17:63803281	chr17:63700847~63702670:+
THCA	cis	rs12893668	0.703	rs34186780	ENSG00000258735.1	LINC00637	-3.39	0.00077	0.0434	-0.21	-0.15	Reticulocyte count;	chr14:103561258	chr14:103847721~103858049:+
THCA	cis	rs11992162	0.636	rs4841645	ENSG00000227888.4	FAM66A	-3.39	0.00077	0.0434	-0.2	-0.15	Monocyte count;	chr8:11941175	chr8:12362019~12388296:+
THCA	cis	rs657075	0.55	rs1468199	ENSG00000263597.1	MIR3936	3.39	0.00077	0.0434	0.21	0.15	Rheumatoid arthritis;	chr5:132421320	chr5:132365490~132365599:-
THCA	cis	rs11158609	1	rs2855098	ENSG00000278784.1	RP11-468E2.11	-3.39	0.00077	0.0434	-0.14	-0.15	Systolic blood pressure (cigarette smoking interaction);	chr14:24250334	chr14:24201612~24202811:-
THCA	cis	rs11158609	1	rs2855094	ENSG00000278784.1	RP11-468E2.11	-3.39	0.00077	0.0434	-0.14	-0.15	Systolic blood pressure (cigarette smoking interaction);	chr14:24251167	chr14:24201612~24202811:-
THCA	cis	rs1362756	1	rs8050675	ENSG00000280344.1	AC009166.7	3.39	0.00077	0.0434	0.13	0.15	Optic disc parameters;Optic disc area;	chr16:51432461	chr16:51176066~51178898:+
THCA	cis	rs34779708	0.931	rs7099593	ENSG00000233200.1	RP11-324I22.2	3.39	0.00077	0.0434	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs13376871	ENSG00000233200.1	RP11-324I22.2	3.39	0.00077	0.0434	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs13376801	ENSG00000233200.1	RP11-324I22.2	3.39	0.00077	0.0434	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35219894~35230598:-
THCA	cis	rs9291683	0.704	rs11726271	ENSG00000250413.1	RP11-448G15.1	3.39	0.00077	0.0434	0.15	0.15	Bone mineral density;	chr4:10096568	chr4:10006482~10009725:+
THCA	cis	rs4650994	0.507	rs12141152	ENSG00000213057.5	C1orf220	-3.39	0.00077	0.0435	-0.11	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178545030	chr1:178542752~178548889:+
THCA	cis	rs4650994	0.525	rs4076563	ENSG00000213057.5	C1orf220	-3.39	0.00077	0.0435	-0.11	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178547766	chr1:178542752~178548889:+
THCA	cis	rs4650994	0.525	rs4650996	ENSG00000213057.5	C1orf220	-3.39	0.00077	0.0435	-0.11	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178548230	chr1:178542752~178548889:+
THCA	cis	rs763121	0.925	rs1043312	ENSG00000225450.1	RP3-508I15.14	-3.39	0.00077	0.0435	-0.12	-0.15	Menopause (age at onset);	chr22:38735722	chr22:38739003~38749041:+
THCA	cis	rs8054556	0.692	rs12716973	ENSG00000273724.1	RP11-347C12.12	-3.39	0.00077	0.0435	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29926331	chr16:30336400~30343336:+
THCA	cis	rs67478160	0.643	rs8005225	ENSG00000258534.1	CTD-2134A5.4	3.39	0.00077	0.0435	0.15	0.15	Schizophrenia;	chr14:103833814	chr14:103854366~103880111:-
THCA	cis	rs2842992	0.513	rs7759086	ENSG00000237927.1	RP3-393E18.2	-3.39	0.00077	0.0435	-0.22	-0.15	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159586955~159589169:-
THCA	cis	rs2842992	0.724	rs15982	ENSG00000237927.1	RP3-393E18.2	-3.39	0.00077	0.0435	-0.22	-0.15	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159586955~159589169:-
THCA	cis	rs73019876	0.869	rs2522096	ENSG00000269615.1	AC003973.1	3.39	0.00077	0.0435	0.15	0.15	Testicular germ cell tumor;	chr19:21940615	chr19:21940820~21941533:+
THCA	cis	rs3824488	0.765	rs16909978	ENSG00000271155.1	RP11-435O5.5	-3.39	0.00077	0.0435	-0.28	-0.15	Neuroticism;	chr9:95545708	chr9:95506235~95507636:+
THCA	cis	rs324126	0.78	rs3170100	ENSG00000243680.1	RPL37P23	-3.39	0.00077	0.0435	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52385367	chr19:52143043~52143336:+
THCA	cis	rs7267979	0.816	rs405822	ENSG00000276952.1	RP5-965G21.6	3.39	0.00077	0.0435	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.816	rs6138593	ENSG00000276952.1	RP5-965G21.6	3.39	0.00077	0.0435	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.816	rs409853	ENSG00000276952.1	RP5-965G21.6	3.39	0.00077	0.0435	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25284915~25285588:-
THCA	cis	rs6828577	0.955	rs12513018	ENSG00000281731.1	RP11-384K6.8	-3.39	0.00077	0.0435	-0.18	-0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118791525	chr4:118664087~118685341:-
THCA	cis	rs6828577	0.913	rs2389689	ENSG00000281731.1	RP11-384K6.8	-3.39	0.00077	0.0435	-0.18	-0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118793024	chr4:118664087~118685341:-
THCA	cis	rs9902453	0.704	rs2617874	ENSG00000264290.1	RP11-68I3.4	3.39	0.00077	0.0435	0.12	0.15	Coffee consumption (cups per day);	chr17:29758154	chr17:29569580~29570519:+
THCA	cis	rs12621844	0.671	rs963135	ENSG00000234690.5	AC073283.4	-3.39	0.00077	0.0435	-0.15	-0.15	Glycated hemoglobin levels;	chr2:48081352	chr2:47192405~47345074:-
THCA	cis	rs9840812	0.68	rs17252498	ENSG00000239213.4	NCK1-AS1	-3.39	0.00077	0.0435	-0.17	-0.15	Fibrinogen levels;	chr3:136295356	chr3:136841726~136862054:-
THCA	cis	rs8103033	0.786	rs7245574	ENSG00000226025.8	LGALS17A	-3.39	0.00077	0.0435	-0.14	-0.15	Obesity-related traits;	chr19:39657462	chr19:39679374~39686373:+
THCA	cis	rs478304	0.651	rs11227299	ENSG00000255320.1	RP11-755F10.1	3.39	0.00077	0.0435	0.2	0.15	Acne (severe);	chr11:65782099	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs948494	ENSG00000255320.1	RP11-755F10.1	3.39	0.00077	0.0435	0.2	0.15	Acne (severe);	chr11:65784647	chr11:66244840~66246239:-
THCA	cis	rs478304	0.651	rs948493	ENSG00000255320.1	RP11-755F10.1	3.39	0.00077	0.0435	0.2	0.15	Acne (severe);	chr11:65784683	chr11:66244840~66246239:-
THCA	cis	rs4081724	0.638	rs62128267	ENSG00000267296.2	CEBPA-AS1	3.39	0.00077	0.0435	0.19	0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33366216	chr19:33302857~33305054:+
THCA	cis	rs722599	0.599	rs3825708	ENSG00000177776.8	RPS2P2	-3.39	0.00077	0.0435	-0.18	-0.15	IgG glycosylation;	chr14:74733994	chr14:74377818~74378418:-
THCA	cis	rs6496044	0.547	rs1564719	ENSG00000218052.5	ADAMTS7P4	-3.39	0.00077	0.0435	-0.18	-0.15	Interstitial lung disease;	chr15:85511035	chr15:85255369~85330334:-
THCA	cis	rs9475677	0.906	rs6929994	ENSG00000231441.1	RP11-472M19.2	3.39	0.00077	0.0435	0.19	0.15	Gut microbiota (functional units);	chr6:56368450	chr6:56844002~56864078:+
THCA	cis	rs454217	1	rs454217	ENSG00000277851.1	RP11-756G20.1	3.39	0.00077	0.0435	0.16	0.15	Smoking quantity;	chr12:92324782	chr12:92247756~92363832:-
THCA	cis	rs7737355	0.898	rs1468328	ENSG00000237714.1	P4HA2-AS1	3.39	0.00077	0.0435	0.22	0.15	Life satisfaction;	chr5:131276007	chr5:132184876~132192808:+
THCA	cis	rs8103033	0.793	rs35604304	ENSG00000226025.8	LGALS17A	-3.39	0.000771	0.0435	-0.14	-0.15	Obesity-related traits;	chr19:39631468	chr19:39679374~39686373:+
THCA	cis	rs7119038	0.609	rs11216998	ENSG00000255422.1	AP002954.4	3.39	0.000771	0.0435	0.18	0.15	Sjögren's syndrome;	chr11:118734128	chr11:118704607~118750263:+
THCA	cis	rs1790761	0.505	rs6591256	ENSG00000255318.1	RP11-655M14.13	-3.39	0.000771	0.0435	-0.17	-0.15	Mean corpuscular volume;	chr11:67582428	chr11:67618279~67627304:-
THCA	cis	rs793571	0.915	rs2270664	ENSG00000245975.2	RP11-30K9.6	-3.39	0.000771	0.0435	-0.15	-0.15	Schizophrenia;	chr15:58889786	chr15:58768072~58770974:-
THCA	cis	rs3784262	0.647	rs2414529	ENSG00000259250.1	RP11-50C13.1	3.39	0.000771	0.0435	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58024896	chr15:58587507~58591676:+
THCA	cis	rs7826238	0.594	rs2948285	ENSG00000248538.5	RP11-10A14.5	-3.39	0.000771	0.0435	-0.19	-0.15	Systolic blood pressure;	chr8:8273016	chr8:9189011~9202854:+
THCA	cis	rs4218	0.528	rs57557135	ENSG00000259732.1	RP11-59H7.3	-3.39	0.000771	0.0435	-0.21	-0.15	Social communication problems;	chr15:59054018	chr15:59121034~59133250:+
THCA	cis	rs7621331	0.892	rs9868246	ENSG00000239213.4	NCK1-AS1	3.39	0.000771	0.0435	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135960703	chr3:136841726~136862054:-
THCA	cis	rs7621331	0.963	rs9883808	ENSG00000239213.4	NCK1-AS1	3.39	0.000771	0.0435	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135963372	chr3:136841726~136862054:-
THCA	cis	rs7621331	0.963	rs112781244	ENSG00000239213.4	NCK1-AS1	3.39	0.000771	0.0435	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135966448	chr3:136841726~136862054:-
THCA	cis	rs3790645	1	rs34062688	ENSG00000241547.1	RP11-4K3__A.5	-3.39	0.000771	0.0435	-0.18	-0.15	Glucose homeostasis traits;	chr1:26560659	chr1:27325329~27325796:+
THCA	cis	rs12544026	0.647	rs1264930	ENSG00000253669.3	KB-1732A1.1	3.39	0.000771	0.0435	0.17	0.15	Major depression and alcohol dependence;	chr8:101842182	chr8:102805517~102809971:+
THCA	cis	rs875971	0.545	rs75840613	ENSG00000230295.1	RP11-458F8.2	3.39	0.000771	0.0435	0.14	0.15	Aortic root size;	chr7:66376399	chr7:66880708~66882981:+
THCA	cis	rs250585	1	rs2369007	ENSG00000260136.4	CTD-2270L9.4	-3.39	0.000771	0.0435	-0.14	-0.15	Egg allergy;	chr16:23548884	chr16:23452758~23457606:+
THCA	cis	rs6487679	0.543	rs972110	ENSG00000245105.2	A2M-AS1	3.39	0.000771	0.0435	0.2	0.15	Non-alcoholic fatty liver disease histology (AST);	chr12:9221750	chr12:9065177~9068060:+
THCA	cis	rs17092148	1	rs17092148	ENSG00000269202.1	RP4-614O4.12	3.39	0.000771	0.0435	0.18	0.15	Neuroticism;	chr20:34847358	chr20:35201747~35203288:-
THCA	cis	rs7618501	0.521	rs2352984	ENSG00000281691.1	RBM5-AS1	3.39	0.000771	0.0435	0.13	0.15	Intelligence (multi-trait analysis);	chr3:49911295	chr3:50099603~50100988:-
THCA	cis	rs7618501	0.501	rs35275715	ENSG00000281691.1	RBM5-AS1	3.39	0.000771	0.0435	0.13	0.15	Intelligence (multi-trait analysis);	chr3:49921715	chr3:50099603~50100988:-
THCA	cis	rs7618501	0.521	rs6774354	ENSG00000281691.1	RBM5-AS1	3.39	0.000771	0.0435	0.13	0.15	Intelligence (multi-trait analysis);	chr3:49924347	chr3:50099603~50100988:-
THCA	cis	rs7208859	0.573	rs216442	ENSG00000264242.2	RP11-271K11.1	3.39	0.000771	0.0435	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs216445	ENSG00000264242.2	RP11-271K11.1	3.39	0.000771	0.0435	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs216446	ENSG00000264242.2	RP11-271K11.1	3.39	0.000771	0.0435	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30553697~30558962:+
THCA	cis	rs1557488	0.581	rs1946064	ENSG00000260209.1	RP11-680F20.10	-3.39	0.000771	0.0435	-0.21	-0.15	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126858052	chr11:125873031~125874528:-
THCA	cis	rs7178424	0.967	rs11635980	ENSG00000259251.2	RP11-643M14.1	-3.39	0.000771	0.0435	-0.16	-0.15	Height;	chr15:62078317	chr15:62060503~62062434:+
THCA	cis	rs7084402	0.967	rs1649026	ENSG00000180221.6	TPT1P10	-3.39	0.000771	0.0435	-0.18	-0.15	Refractive error;	chr10:58521640	chr10:58212541~58213036:-
THCA	cis	rs7829975	0.564	rs2921057	ENSG00000254340.1	RP11-10A14.3	3.39	0.000771	0.0435	0.17	0.15	Mood instability;	chr8:8461157	chr8:9141424~9145435:+
THCA	cis	rs17122278	1	rs11216907	ENSG00000255239.1	AP002954.6	-3.39	0.000771	0.0435	-0.27	-0.15	Total cholesterol levels;	chr11:118573810	chr11:118688039~118690600:-
THCA	cis	rs17122278	1	rs55844025	ENSG00000255239.1	AP002954.6	-3.39	0.000771	0.0435	-0.27	-0.15	Total cholesterol levels;	chr11:118575583	chr11:118688039~118690600:-
THCA	cis	rs17122278	1	rs9735449	ENSG00000255239.1	AP002954.6	-3.39	0.000771	0.0435	-0.27	-0.15	Total cholesterol levels;	chr11:118577372	chr11:118688039~118690600:-
THCA	cis	rs6806253	0.838	rs68057450	ENSG00000239405.1	TMED10P2	3.39	0.000771	0.0435	0.22	0.15	Pit-and-Fissure caries;	chr3:128546737	chr3:128538020~128538631:+
THCA	cis	rs4971059	0.617	rs10908458	ENSG00000225855.5	RUSC1-AS1	3.39	0.000771	0.0435	0.1	0.15	Breast cancer;	chr1:155154472	chr1:155316863~155324176:-
THCA	cis	rs1348850	0.519	rs13034781	ENSG00000271996.1	RP11-337N6.1	3.39	0.000771	0.0435	0.2	0.15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658822	chr2:177306373~177310572:+
THCA	cis	rs1348850	0.519	rs1527407	ENSG00000271996.1	RP11-337N6.1	3.39	0.000771	0.0435	0.2	0.15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177660902	chr2:177306373~177310572:+
THCA	cis	rs1348850	0.519	rs1527406	ENSG00000271996.1	RP11-337N6.1	3.39	0.000771	0.0435	0.2	0.15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177660927	chr2:177306373~177310572:+
THCA	cis	rs12541437	0.535	rs1050838	ENSG00000253327.2	RAD21-AS1	3.39	0.000771	0.0435	0.23	0.15	Gut microbiome composition (winter);	chr8:116851978	chr8:116874424~116876868:+
THCA	cis	rs3736485	0.738	rs930920	ENSG00000259709.1	CTD-2184D3.7	3.39	0.000771	0.0435	0.16	0.15	BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr15:51457529	chr15:52124561~52140246:+
THCA	cis	rs13064411	0.696	rs2129434	ENSG00000243849.1	CFAP44-AS1	3.39	0.000771	0.0435	0.25	0.15	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113419916	chr3:113403991~113433992:+
THCA	cis	rs9307551	0.681	rs11098788	ENSG00000250334.4	LINC00989	-3.39	0.000771	0.0435	-0.18	-0.15	Refractive error;	chr4:79629274	chr4:79492416~79576460:+
THCA	cis	rs9307551	0.681	rs11098789	ENSG00000250334.4	LINC00989	-3.39	0.000771	0.0435	-0.18	-0.15	Refractive error;	chr4:79629351	chr4:79492416~79576460:+
THCA	cis	rs11708578	0.554	rs35689887	ENSG00000237990.3	CNTN4-AS1	3.39	0.000771	0.0435	0.19	0.15	Schizophrenia;	chr3:2387494	chr3:3039033~3069242:-
THCA	cis	rs11708578	0.554	rs72996008	ENSG00000237990.3	CNTN4-AS1	3.39	0.000771	0.0435	0.19	0.15	Schizophrenia;	chr3:2387541	chr3:3039033~3069242:-
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000214719.10	AC005562.1	-3.39	0.000771	0.0435	-0.21	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30576464~30672789:+
THCA	cis	rs4325129	0.705	rs11265216	ENSG00000272668.1	RP11-190A12.8	3.39	0.000771	0.0435	0.17	0.15	Obesity-related traits;	chr1:159505857	chr1:159866954~159867685:+
THCA	cis	rs9549260	0.683	rs35594717	ENSG00000275149.1	RP11-427J23.1	-3.39	0.000771	0.0435	-0.24	-0.15	Red blood cell count;	chr13:40666646	chr13:40079106~40273509:-
THCA	cis	rs17092148	0.636	rs59030726	ENSG00000250917.1	RP4-785G19.5	-3.39	0.000771	0.0435	-0.21	-0.15	Neuroticism;	chr20:34866314	chr20:34234840~34281173:-
THCA	cis	rs4671400	0.571	rs6738482	ENSG00000270820.4	RP11-355B11.2	-3.39	0.000771	0.0435	-0.15	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267766	chr2:61471188~61484130:+
THCA	cis	rs61677309	1	rs56785719	ENSG00000278376.1	RP11-158I9.8	3.39	0.000771	0.0435	0.12	0.15	Lung cancer in ever smokers;	chr11:118305908	chr11:118791254~118793137:+
THCA	cis	rs2797160	1	rs2747714	ENSG00000226409.1	RP11-735G4.1	3.38	0.000771	0.0435	0.18	0.15	Endometrial cancer;	chr6:125686474	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs61299898	ENSG00000226409.1	RP11-735G4.1	3.38	0.000771	0.0435	0.18	0.15	Endometrial cancer;	chr6:125686505	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1954361	ENSG00000226409.1	RP11-735G4.1	-3.38	0.000771	0.0435	-0.18	-0.15	Endometrial cancer;	chr6:125680277	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1739367	ENSG00000226409.1	RP11-735G4.1	-3.38	0.000771	0.0435	-0.18	-0.15	Endometrial cancer;	chr6:125683574	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs2747724	ENSG00000226409.1	RP11-735G4.1	-3.38	0.000771	0.0435	-0.18	-0.15	Endometrial cancer;	chr6:125683789	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs2797154	ENSG00000226409.1	RP11-735G4.1	-3.38	0.000771	0.0435	-0.18	-0.15	Endometrial cancer;	chr6:125684051	chr6:125370211~125374324:-
THCA	cis	rs2797160	1	rs1739352	ENSG00000226409.1	RP11-735G4.1	-3.38	0.000771	0.0435	-0.18	-0.15	Endometrial cancer;	chr6:125684164	chr6:125370211~125374324:-
THCA	cis	rs758324	0.717	rs17132324	ENSG00000224431.1	AC063976.7	3.38	0.000771	0.0435	0.16	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132028286	chr5:132199456~132203487:+
THCA	cis	rs2243480	1	rs316322	ENSG00000237310.1	GS1-124K5.4	3.38	0.000771	0.0435	0.17	0.15	Diabetic kidney disease;	chr7:66146246	chr7:66493706~66495474:+
THCA	cis	rs7618915	0.679	rs6802320	ENSG00000239557.1	RP11-168J18.6	3.38	0.000772	0.0435	0.19	0.15	Bipolar disorder;	chr3:52207819	chr3:52373652~52374882:+
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000281021.1	RP1-12G14.9	-3.38	0.000772	0.0435	-0.16	-0.15	Lung cancer;	chr6:149808187	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000281021.1	RP1-12G14.9	-3.38	0.000772	0.0435	-0.16	-0.15	Lung cancer;	chr6:149809506	chr6:149576089~149590864:-
THCA	cis	rs11633886	0.604	rs10153018	ENSG00000259200.1	RP11-718O11.1	-3.38	0.000772	0.0435	-0.19	-0.15	Diisocyanate-induced asthma;	chr15:45831938	chr15:45705078~45931069:+
THCA	cis	rs7829975	0.714	rs12544992	ENSG00000254340.1	RP11-10A14.3	3.38	0.000772	0.0435	0.17	0.15	Mood instability;	chr8:8804171	chr8:9141424~9145435:+
THCA	cis	rs1436955	0.712	rs7164482	ENSG00000259251.2	RP11-643M14.1	-3.38	0.000772	0.0435	-0.19	-0.15	Type 2 diabetes;	chr15:62090684	chr15:62060503~62062434:+
THCA	cis	rs8044868	1	rs8044868	ENSG00000260886.1	TAT-AS1	3.38	0.000772	0.0435	0.18	0.15	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72128203	chr16:71565789~71578187:+
THCA	cis	rs7395662	1	rs7949348	ENSG00000200090.1	Y_RNA	-3.38	0.000772	0.0435	-0.1	-0.15	HDL cholesterol;	chr11:48472249	chr11:47726894~47726992:-
THCA	cis	rs8058578	0.945	rs8058961	ENSG00000260911.2	RP11-196G11.2	3.38	0.000772	0.0435	0.13	0.15	Multiple myeloma;	chr16:30797742	chr16:31043150~31049868:+
THCA	cis	rs7635879	0.583	rs2887143	ENSG00000230102.6	RP11-407B7.1	3.38	0.000772	0.0435	0.13	0.15	Breastfeeding duration;	chr3:194019579	chr3:194005259~194070970:-
THCA	cis	rs28510890	0.828	rs78417563	ENSG00000258676.4	RP11-386M24.3	3.38	0.000772	0.0435	0.16	0.15	Lung cancer in ever smokers;	chr15:92580224	chr15:92580829~92600545:+
THCA	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	3.38	0.000772	0.0435	0.18	0.15	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	3.38	0.000772	0.0435	0.18	0.15	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
THCA	cis	rs2129782	0.51	rs111992066	ENSG00000253553.4	RP11-586K2.1	3.38	0.000772	0.0435	0.23	0.15	Electrodermal activity;	chr8:88335729	chr8:88326836~88737134:+
THCA	cis	rs11175194	1	rs17099883	ENSG00000255642.1	PABPC1P4	3.38	0.000772	0.0435	0.41	0.15	Epithelial ovarian cancer;	chr12:63867319	chr12:63822021~63823895:+
THCA	cis	rs1864585	0.52	rs7826036	ENSG00000280294.1	RP11-177H2.1	3.38	0.000772	0.0435	0.16	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10800310	chr8:10856085~10859436:-
THCA	cis	rs6479352	0.637	rs57339162	ENSG00000225511.5	LINC00475	3.38	0.000772	0.0435	0.16	0.15	Bipolar disorder (inflammation and infection response interaction);	chr9:91510334	chr9:92141298~92160114:+
THCA	cis	rs6479352	0.526	rs56666718	ENSG00000225511.5	LINC00475	3.38	0.000772	0.0435	0.16	0.15	Bipolar disorder (inflammation and infection response interaction);	chr9:91510486	chr9:92141298~92160114:+
THCA	cis	rs6479352	0.609	rs7038274	ENSG00000225511.5	LINC00475	3.38	0.000772	0.0435	0.16	0.15	Bipolar disorder (inflammation and infection response interaction);	chr9:91511052	chr9:92141298~92160114:+
THCA	cis	rs6479352	0.637	rs4744057	ENSG00000225511.5	LINC00475	3.38	0.000772	0.0435	0.16	0.15	Bipolar disorder (inflammation and infection response interaction);	chr9:91512019	chr9:92141298~92160114:+
THCA	cis	rs7631605	0.586	rs4021378	ENSG00000224080.1	UBE2FP1	3.38	0.000772	0.0435	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37412567	chr3:37143512~37143958:-
THCA	cis	rs11168618	0.875	rs7972785	ENSG00000258273.1	RP11-370I10.4	-3.38	0.000772	0.0435	-0.19	-0.15	Adiponectin levels;	chr12:48483273	chr12:48333755~48333901:-
THCA	cis	rs116248771	0.549	rs1548013	ENSG00000240207.5	RP11-379F4.4	3.38	0.000772	0.0435	0.22	0.15	diarrhoeal disease at age 2;	chr3:158713281	chr3:158732263~158784070:+
THCA	cis	rs116248771	0.549	rs9825140	ENSG00000240207.5	RP11-379F4.4	3.38	0.000772	0.0435	0.22	0.15	diarrhoeal disease at age 2;	chr3:158717585	chr3:158732263~158784070:+
THCA	cis	rs6901152	0.861	rs1885649	ENSG00000217648.1	RP1-95L4.4	3.38	0.000772	0.0436	0.17	0.15	Acute lymphoblastic leukemia (childhood);	chr6:143296777	chr6:143342246~143343383:+
THCA	cis	rs11640436	0.565	rs2162957	ENSG00000226348.1	VN2R10P	-3.38	0.000772	0.0436	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr16:77263296	chr16:77220406~77221258:+
THCA	cis	rs6088813	0.961	rs2425062	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000772	0.0436	-0.15	-0.15	Height;	chr20:35335763	chr20:35267885~35280043:-
THCA	cis	rs9426935	0.604	rs2790685	ENSG00000231416.1	RP11-422P24.9	3.38	0.000772	0.0436	0.19	0.15	Lentiform nucleus volume;	chr1:154052717	chr1:153995632~153995960:+
THCA	cis	rs7940646	0.906	rs6484437	ENSG00000254554.1	RP11-351I24.1	-3.38	0.000772	0.0436	-0.18	-0.15	Platelet aggregation;	chr11:10645728	chr11:10302657~10303704:-
THCA	cis	rs2288884	0.943	rs11671792	ENSG00000260160.1	CTC-471J1.2	-3.38	0.000772	0.0436	-0.17	-0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52078430	chr19:52058490~52063703:-
THCA	cis	rs9858542	0.537	rs9873994	ENSG00000270441.1	RP11-694I15.7	3.38	0.000772	0.0436	0.18	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49322510	chr3:49140086~49160851:-
THCA	cis	rs9858542	0.537	rs56038006	ENSG00000270441.1	RP11-694I15.7	3.38	0.000772	0.0436	0.18	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49324936	chr3:49140086~49160851:-
THCA	cis	rs1552244	1	rs35993975	ENSG00000186162.9	CIDECP	3.38	0.000772	0.0436	0.14	0.15	Alzheimer's disease;	chr3:10026110	chr3:10014238~10026365:-
THCA	cis	rs57709857	0.724	rs74302881	ENSG00000272092.1	RP11-350N15.5	-3.38	0.000773	0.0436	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38190081	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.768	rs55885015	ENSG00000272092.1	RP11-350N15.5	-3.38	0.000773	0.0436	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38201122	chr8:38382364~38383461:+
THCA	cis	rs9860428	0.844	rs2399441	ENSG00000240057.4	RP11-572M11.4	-3.38	0.000773	0.0436	-0.16	-0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868165	chr3:113019532~113183301:+
THCA	cis	rs6728642	1	rs73959416	ENSG00000235734.4	HMGN1P36	3.38	0.000773	0.0436	0.25	0.15	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96938781	chr2:97827248~97827545:+
THCA	cis	rs6968419	0.761	rs9691405	ENSG00000237870.5	AC073130.1	3.38	0.000773	0.0436	0.16	0.15	Intraocular pressure;	chr7:116102603	chr7:116275606~116286734:-
THCA	cis	rs972578	0.715	rs5759054	ENSG00000230319.1	AL022476.2	3.38	0.000773	0.0436	0.17	0.15	Mean platelet volume;	chr22:42952172	chr22:43038585~43052366:+
THCA	cis	rs7129556	0.701	rs11237280	ENSG00000254985.1	RSF1-IT2	-3.38	0.000773	0.0436	-0.24	-0.15	Weight loss (gastric bypass surgery);	chr11:77745861	chr11:77717712~77718411:-
THCA	cis	rs6920965	0.545	rs614031	ENSG00000237742.5	RP11-624M8.1	-3.38	0.000773	0.0436	-0.13	-0.15	High light scatter reticulocyte count;	chr6:125844574	chr6:125578558~125749190:-
THCA	cis	rs4648045	0.582	rs2168805	ENSG00000246560.2	RP11-10L12.4	3.38	0.000773	0.0436	0.19	0.15	Lymphocyte percentage of white cells;	chr4:102489877	chr4:102828055~102844075:+
THCA	cis	rs1005277	0.579	rs1740737	ENSG00000151963.4	RP11-775A3.1	-3.38	0.000773	0.0436	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:37883594~37884109:+
THCA	cis	rs41313321	0.564	rs7871866	ENSG00000272696.1	RP11-339B21.13	3.38	0.000773	0.0436	0.13	0.15	Coenzyme Q10 levels;	chr9:128265703	chr9:128316337~128316909:+
THCA	cis	rs941898	0.598	rs7157599	ENSG00000259031.1	CTD-2062F14.3	-3.38	0.000773	0.0436	-0.21	-0.15	White matter hyperintensity burden;	chr14:100159565	chr14:100538939~100540409:+
THCA	cis	rs1124769	0.525	rs8033807	ENSG00000259378.1	DCAF13P3	3.38	0.000773	0.0436	0.21	0.15	Cognitive performance;	chr15:50778531	chr15:50944663~50945996:+
THCA	cis	rs2880765	0.835	rs11638498	ENSG00000218052.5	ADAMTS7P4	-3.38	0.000773	0.0436	-0.17	-0.15	Coronary artery disease;	chr15:85479787	chr15:85255369~85330334:-
THCA	cis	rs997295	0.556	rs10468041	ENSG00000245719.1	RP11-34F13.2	3.38	0.000773	0.0436	0.16	0.15	Motion sickness;	chr15:67480865	chr15:67834310~67838879:-
THCA	cis	rs479105	0.798	rs11615771	ENSG00000278356.1	RP11-372B4.3	3.38	0.000773	0.0436	0.15	0.15	Gut microbiota (bacterial taxa);	chr12:3268128	chr12:2885819~2886329:+
THCA	cis	rs11168351	0.927	rs11168342	ENSG00000257735.1	RP11-370I10.6	3.38	0.000773	0.0436	0.18	0.15	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48350945~48442411:+
THCA	cis	rs6968419	0.802	rs6978849	ENSG00000237870.5	AC073130.1	-3.38	0.000773	0.0436	-0.16	-0.15	Intraocular pressure;	chr7:116169678	chr7:116275606~116286734:-
THCA	cis	rs8187707	1	rs34456559	ENSG00000233690.1	EBAG9P1	-3.38	0.000773	0.0436	-0.31	-0.15	Carboplatin disposition in epthelial ovarian cancer;	chr10:99844249	chr10:99697407~99697949:-
THCA	cis	rs8058578	1	rs13338946	ENSG00000274678.1	RP11-2C24.7	3.38	0.000773	0.0436	0.15	0.15	Multiple myeloma;	chr16:30689537	chr16:30821338~30821884:+
THCA	cis	rs4325129	0.651	rs4656837	ENSG00000272668.1	RP11-190A12.8	3.38	0.000773	0.0436	0.18	0.15	Obesity-related traits;	chr1:159535507	chr1:159866954~159867685:+
THCA	cis	rs3785574	0.962	rs7215915	ENSG00000279369.1	RP11-51F16.1	3.38	0.000773	0.0436	0.11	0.15	Height;	chr17:63751025	chr17:63700847~63702670:+
THCA	cis	rs2888875	0.852	rs12477928	ENSG00000200924.1	RNU6-1048P	-3.38	0.000773	0.0436	-0.17	-0.15	Glomerular filtration rate (creatinine);	chr2:43576673	chr2:43892690~43892796:+
THCA	cis	rs17181170	0.846	rs73142665	ENSG00000239572.1	RP11-451B8.1	-3.38	0.000773	0.0436	-0.18	-0.15	Prostate cancer;	chr3:87147411	chr3:87731402~87793629:-
THCA	cis	rs853679	0.699	rs9468318	ENSG00000272009.1	RP1-313I6.12	-3.38	0.000773	0.0436	-0.19	-0.15	Depression;	chr6:28241753	chr6:28078792~28081130:-
THCA	cis	rs9549260	0.534	rs3812891	ENSG00000239827.7	SUGT1P3	-3.38	0.000773	0.0436	-0.21	-0.15	Red blood cell count;	chr13:40771315	chr13:40908159~40921774:-
THCA	cis	rs28489187	0.683	rs11161607	ENSG00000223653.4	RP11-131L23.1	3.38	0.000773	0.0436	0.18	0.15	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85390172	chr1:85276715~85448124:+
THCA	cis	rs6471393	0.929	rs7016930	ENSG00000261437.1	RP11-22C11.2	3.38	0.000773	0.0436	0.15	0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743185	chr8:94637285~94639467:-
THCA	cis	rs6471393	0.929	rs7017036	ENSG00000261437.1	RP11-22C11.2	3.38	0.000773	0.0436	0.15	0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743216	chr8:94637285~94639467:-
THCA	cis	rs7395662	0.816	rs11039764	ENSG00000200090.1	Y_RNA	-3.38	0.000773	0.0436	-0.1	-0.15	HDL cholesterol;	chr11:48463064	chr11:47726894~47726992:-
THCA	cis	rs5769765	0.908	rs138880	ENSG00000280567.1	Metazoa_SRP	-3.38	0.000773	0.0436	-0.21	-0.15	Schizophrenia;	chr22:49824963	chr22:49878999~49879242:+
THCA	cis	rs1009115	0.551	rs6952620	ENSG00000272745.1	RP5-1007H16.1	-3.38	0.000773	0.0436	-0.2	-0.15	Post bronchodilator FEV1;	chr7:8372976	chr7:7619872~7620543:+
THCA	cis	rs860295	0.529	rs1475766	ENSG00000236675.1	MTX1P1	3.38	0.000774	0.0436	0.15	0.15	Body mass index;	chr1:156011698	chr1:155230975~155234325:+
THCA	cis	rs7737355	0.704	rs11749484	ENSG00000224431.1	AC063976.7	3.38	0.000774	0.0436	0.14	0.15	Life satisfaction;	chr5:131725914	chr5:132199456~132203487:+
THCA	cis	rs8056893	0.917	rs3961283	ENSG00000274698.1	RP11-71L14.4	3.38	0.000774	0.0436	0.21	0.15	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68283733	chr16:68450283~68452318:+
THCA	cis	rs9426935	0.604	rs1819663	ENSG00000231416.1	RP11-422P24.9	3.38	0.000774	0.0436	0.19	0.15	Lentiform nucleus volume;	chr1:154053415	chr1:153995632~153995960:+
THCA	cis	rs10435719	0.899	rs7815595	ENSG00000227888.4	FAM66A	3.38	0.000774	0.0436	0.2	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:12362019~12388296:+
THCA	cis	rs10435719	0.834	rs11250176	ENSG00000227888.4	FAM66A	3.38	0.000774	0.0436	0.2	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:12362019~12388296:+
THCA	cis	rs1908814	0.516	rs4367597	ENSG00000227888.4	FAM66A	3.38	0.000774	0.0436	0.2	0.15	Neuroticism;	chr8:11936020	chr8:12362019~12388296:+
THCA	cis	rs10435719	0.899	rs9329251	ENSG00000227888.4	FAM66A	3.38	0.000774	0.0436	0.2	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:12362019~12388296:+
THCA	cis	rs2115630	0.967	rs12595786	ENSG00000259295.5	CSPG4P12	-3.38	0.000774	0.0436	-0.2	-0.15	P wave terminal force;	chr15:84793439	chr15:85191438~85213905:+
THCA	cis	rs939960	0.959	rs1578916	ENSG00000276538.1	RP11-545G3.2	3.38	0.000774	0.0436	0.23	0.15	Neutrophil percentage of white cells;	chr7:150584887	chr7:150047609~150047854:-
THCA	cis	rs2760061	0.655	rs686533	ENSG00000276255.2	RP5-881P19.7	-3.38	0.000774	0.0436	-0.17	-0.15	Diastolic blood pressure;	chr1:227931903	chr1:228073909~228076550:-
THCA	cis	rs4308124	1	rs56830046	ENSG00000230499.1	AC108463.1	-3.38	0.000774	0.0436	-0.2	-0.15	Vitiligo;	chr2:111252513	chr2:111195963~111206494:+
THCA	cis	rs7615952	0.546	rs11717632	ENSG00000272840.1	RP11-379B18.6	3.38	0.000774	0.0436	0.25	0.15	Blood pressure (smoking interaction);	chr3:125602286	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.546	rs2922197	ENSG00000272840.1	RP11-379B18.6	3.38	0.000774	0.0436	0.25	0.15	Blood pressure (smoking interaction);	chr3:125603188	chr3:125774714~125797953:+
THCA	cis	rs7772486	0.875	rs863820	ENSG00000270638.1	RP3-466P17.1	-3.38	0.000774	0.0436	-0.12	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145735570~145737218:+
THCA	cis	rs6671200	0.573	rs3738171	ENSG00000226026.4	RP11-57H12.3	-3.38	0.000774	0.0436	-0.21	-0.15	Stearic acid (18:0) levels;	chr1:95234038	chr1:95163219~95233982:-
THCA	cis	rs2228479	1	rs12596492	ENSG00000223959.7	AFG3L1P	-3.38	0.000774	0.0436	-0.14	-0.15	Skin colour saturation;	chr16:89890761	chr16:89972586~90002161:+
THCA	cis	rs2228479	1	rs11642267	ENSG00000223959.7	AFG3L1P	-3.38	0.000774	0.0436	-0.14	-0.15	Skin colour saturation;	chr16:89891227	chr16:89972586~90002161:+
THCA	cis	rs6840360	1	rs10049991	ENSG00000270265.1	RP11-731D1.4	-3.38	0.000774	0.0436	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151743011	chr4:151333775~151353224:-
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000214719.10	AC005562.1	-3.38	0.000774	0.0436	-0.21	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30576464~30672789:+
THCA	cis	rs7127129	0.872	rs11607654	ENSG00000246889.2	AP000487.5	-3.38	0.000774	0.0436	-0.16	-0.15	Aortic root size;	chr11:70209615	chr11:70372246~70398488:-
THCA	cis	rs3738443	0.569	rs6704060	ENSG00000227671.4	RP11-488L18.4	-3.38	0.000774	0.0436	-0.09	-0.15	Alcohol dependence;	chr1:247218222	chr1:247189851~247210856:-
THCA	cis	rs17741873	0.779	rs4746154	ENSG00000271848.1	RP11-464F9.21	-3.38	0.000774	0.0436	-0.2	-0.15	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73869638	chr10:73654039~73674719:+
THCA	cis	rs56114371	0.777	rs200482	ENSG00000220721.1	OR1F12	3.38	0.000774	0.0436	0.26	0.15	Breast cancer;	chr6:27806126	chr6:28073316~28074233:+
THCA	cis	rs2098713	0.535	rs1589116	ENSG00000250155.1	CTD-2353F22.1	3.38	0.000774	0.0436	0.15	0.15	Telomere length;	chr5:37629567	chr5:36666214~36725195:-
THCA	cis	rs1790761	0.692	rs614080	ENSG00000184224.3	C11orf72	3.38	0.000774	0.0436	0.21	0.15	Mean corpuscular volume;	chr11:67579816	chr11:67602880~67606706:-
THCA	cis	rs7621331	0.963	rs9862743	ENSG00000239213.4	NCK1-AS1	3.38	0.000774	0.0437	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135968450	chr3:136841726~136862054:-
THCA	cis	rs10792320	0.897	rs10160397	ENSG00000279491.1	RP11-810P12.7	-3.38	0.000774	0.0437	-0.16	-0.15	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61982294	chr11:61967794~61969490:+
THCA	cis	rs3812762	0.871	rs2173999	ENSG00000254860.4	TMEM9B-AS1	-3.38	0.000774	0.0437	-0.17	-0.15	Hypospadias;	chr11:8756530	chr11:8964675~8977527:+
THCA	cis	rs2252521	0.583	rs317763	ENSG00000228421.2	AC005013.5	3.38	0.000774	0.0437	0.21	0.15	Cognitive performance;	chr7:29042687	chr7:28957667~28959345:+
THCA	cis	rs790006	0.697	rs11175287	ENSG00000243024.5	RPS11P6	-3.38	0.000774	0.0437	-0.18	-0.15	Response to cytidine analogues (gemcitabine);	chr12:64230630	chr12:64222337~64397065:+
THCA	cis	rs790006	0.697	rs11175288	ENSG00000243024.5	RPS11P6	-3.38	0.000774	0.0437	-0.18	-0.15	Response to cytidine analogues (gemcitabine);	chr12:64234095	chr12:64222337~64397065:+
THCA	cis	rs790006	0.697	rs11175290	ENSG00000243024.5	RPS11P6	-3.38	0.000774	0.0437	-0.18	-0.15	Response to cytidine analogues (gemcitabine);	chr12:64235422	chr12:64222337~64397065:+
THCA	cis	rs6734118	0.843	rs72792829	ENSG00000225402.1	AC010878.3	3.38	0.000774	0.0437	0.19	0.15	Body mass index;	chr2:37271545	chr2:37816915~37817961:+
THCA	cis	rs6452790	0.502	rs28505226	ENSG00000247828.6	TMEM161B-AS1	3.38	0.000774	0.0437	0.16	0.15	Cognitive function;	chr5:88201795	chr5:88268895~88436685:+
THCA	cis	rs7632954	0.867	rs62235951	ENSG00000227110.5	LMCD1-AS1	3.38	0.000774	0.0437	0.19	0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8476515	chr3:7952805~8611924:-
THCA	cis	rs7632954	0.867	rs59604225	ENSG00000227110.5	LMCD1-AS1	3.38	0.000774	0.0437	0.19	0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8476518	chr3:7952805~8611924:-
THCA	cis	rs7772486	0.875	rs1331644	ENSG00000270638.1	RP3-466P17.1	3.38	0.000774	0.0437	0.12	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145735570~145737218:+
THCA	cis	rs12440869	0.959	rs3743343	ENSG00000270964.1	RP11-502I4.3	3.38	0.000774	0.0437	0.14	0.15	Peak velocity of the mitral A-wave;	chr15:67194437	chr15:67541072~67542604:-
THCA	cis	rs620729	0.708	rs6904209	ENSG00000272097.1	RP11-421M1.8	3.38	0.000774	0.0437	0.18	0.15	Intelligence (multi-trait analysis);	chr6:11477195	chr6:10743324~10747663:-
THCA	cis	rs620729	0.749	rs7752671	ENSG00000272097.1	RP11-421M1.8	3.38	0.000774	0.0437	0.18	0.15	Intelligence (multi-trait analysis);	chr6:11478738	chr6:10743324~10747663:-
THCA	cis	rs34779708	0.931	rs6481935	ENSG00000233200.1	RP11-324I22.2	3.38	0.000775	0.0437	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs12242882	ENSG00000233200.1	RP11-324I22.2	3.38	0.000775	0.0437	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35219894~35230598:-
THCA	cis	rs3782089	0.744	rs11545200	ENSG00000260233.3	SSSCA1-AS1	3.38	0.000775	0.0437	0.23	0.15	Height;	chr11:65552280	chr11:65568482~65570423:-
THCA	cis	rs17428076	0.914	rs72889094	ENSG00000228389.1	AC068039.4	-3.38	0.000775	0.0437	-0.19	-0.15	Myopia;	chr2:171938249	chr2:171773482~171775844:+
THCA	cis	rs4948275	0.693	rs1378889	ENSG00000233643.2	RP11-491H19.1	3.38	0.000775	0.0437	0.17	0.15	Night sleep phenotypes;	chr10:61575134	chr10:61781745~61821246:-
THCA	cis	rs6565180	1	rs11646130	ENSG00000274678.1	RP11-2C24.7	-3.38	0.000775	0.0437	-0.15	-0.15	Tonsillectomy;	chr16:30365638	chr16:30821338~30821884:+
THCA	cis	rs7264396	0.887	rs6120954	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000775	0.0437	-0.16	-0.15	Total cholesterol levels;	chr20:35471711	chr20:35267885~35280043:-
THCA	cis	rs7264396	0.887	rs6060442	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000775	0.0437	-0.16	-0.15	Total cholesterol levels;	chr20:35505928	chr20:35267885~35280043:-
THCA	cis	rs7849270	0.801	rs6478868	ENSG00000204055.4	RP11-247A12.2	3.38	0.000775	0.0437	0.19	0.15	Blood metabolite ratios;	chr9:129164813	chr9:129176771~129210548:+
THCA	cis	rs1383484	0.754	rs8038109	ENSG00000230373.7	GOLGA6L5P	-3.38	0.000775	0.0437	-0.16	-0.15	Height;	chr15:83913552	chr15:84507885~84516814:-
THCA	cis	rs642858	0.784	rs613274	ENSG00000234147.1	RP3-460G2.2	3.38	0.000775	0.0437	0.19	0.15	Type 2 diabetes;	chr6:139921088	chr6:140845958~140852924:-
THCA	cis	rs2179367	0.887	rs2789488	ENSG00000223701.3	RAET1E-AS1	-3.38	0.000775	0.0437	-0.2	-0.15	Dupuytren's disease;	chr6:149404154	chr6:149884431~149919508:+
THCA	cis	rs11039798	0.588	rs11039818	ENSG00000200090.1	Y_RNA	3.38	0.000775	0.0437	0.13	0.15	Axial length;	chr11:48540568	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.588	rs6485869	ENSG00000200090.1	Y_RNA	3.38	0.000775	0.0437	0.13	0.15	Axial length;	chr11:48555351	chr11:47726894~47726992:-
THCA	cis	rs16944613	0.588	rs6496697	ENSG00000259212.1	CTD-3065B20.2	-3.38	0.000775	0.0437	-0.23	-0.15	Colorectal cancer;	chr15:90588600	chr15:90595840~90596447:-
THCA	cis	rs11089937	0.626	rs4821781	ENSG00000215456.5	BCRP4	3.38	0.000775	0.0437	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.626	rs5750589	ENSG00000215456.5	BCRP4	3.38	0.000775	0.0437	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.626	rs5757038	ENSG00000215456.5	BCRP4	3.38	0.000775	0.0437	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22630061~22636153:+
THCA	cis	rs4704187	0.687	rs4704176	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75124771	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs1903839	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75125572	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs4360021	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75126137	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.663	rs4404659	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75126294	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs4404660	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75126385	chr5:75047719~75052843:-
THCA	cis	rs10090774	0.965	rs170068	ENSG00000280303.2	ERICD	3.38	0.000775	0.0437	0.14	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141003373	chr8:140636281~140638283:+
THCA	cis	rs73019876	0.805	rs2522106	ENSG00000269615.1	AC003973.1	3.38	0.000775	0.0437	0.15	0.15	Testicular germ cell tumor;	chr19:21957819	chr19:21940820~21941533:+
THCA	cis	rs7845127	0.53	rs902961	ENSG00000253671.1	RP11-806O11.1	3.38	0.000775	0.0437	0.18	0.15	Night sleep phenotypes;	chr8:18250802	chr8:17808941~17820868:+
THCA	cis	rs7737355	0.812	rs3776013	ENSG00000237714.1	P4HA2-AS1	3.38	0.000775	0.0437	0.21	0.15	Life satisfaction;	chr5:131531711	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.738	rs3776011	ENSG00000237714.1	P4HA2-AS1	3.38	0.000775	0.0437	0.21	0.15	Life satisfaction;	chr5:131533147	chr5:132184876~132192808:+
THCA	cis	rs773506	0.866	rs1972090	ENSG00000229694.5	RP11-305L7.6	3.38	0.000775	0.0437	0.18	0.15	Type 2 diabetes nephropathy;	chr9:91321508	chr9:91119062~91182762:+
THCA	cis	rs950027	0.62	rs35861938	ENSG00000259479.5	SORD2P	3.38	0.000775	0.0437	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:44826371~44884694:-
THCA	cis	rs950027	0.596	rs2467865	ENSG00000259479.5	SORD2P	3.38	0.000775	0.0437	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:44826371~44884694:-
THCA	cis	rs950027	0.62	rs2461700	ENSG00000259479.5	SORD2P	3.38	0.000775	0.0437	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:44826371~44884694:-
THCA	cis	rs950027	0.62	rs2453533	ENSG00000259479.5	SORD2P	3.38	0.000775	0.0437	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:44826371~44884694:-
THCA	cis	rs763121	1	rs86796	ENSG00000225450.1	RP3-508I15.14	3.38	0.000775	0.0437	0.12	0.15	Menopause (age at onset);	chr22:38485449	chr22:38739003~38749041:+
THCA	cis	rs9903692	0.779	rs6504025	ENSG00000263412.1	RP5-890E16.2	-3.38	0.000775	0.0437	-0.11	-0.15	Pulse pressure;	chr17:48088711	chr17:48045141~48048073:-
THCA	cis	rs7615952	0.558	rs7641353	ENSG00000243429.1	OR7E29P	3.38	0.000775	0.0437	0.2	0.15	Blood pressure (smoking interaction);	chr3:125621035	chr3:125712139~125713045:+
THCA	cis	rs10858047	0.883	rs72698008	ENSG00000231128.4	RP5-1073O3.2	3.38	0.000775	0.0437	0.23	0.15	Autism;	chr1:114543643	chr1:113812379~113829171:+
THCA	cis	rs11048434	0.736	rs12821842	ENSG00000245105.2	A2M-AS1	3.38	0.000775	0.0437	0.11	0.15	Sjögren's syndrome;	chr12:8956388	chr12:9065177~9068060:+
THCA	cis	rs11048434	0.736	rs12812913	ENSG00000245105.2	A2M-AS1	3.38	0.000775	0.0437	0.11	0.15	Sjögren's syndrome;	chr12:8958240	chr12:9065177~9068060:+
THCA	cis	rs3176789	0.914	rs4519176	ENSG00000256673.1	RP11-599J14.2	-3.38	0.000775	0.0437	-0.21	-0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772636	chr12:9398355~9414851:-
THCA	cis	rs4596632	0.885	rs6985272	ENSG00000253507.4	CTD-2501M5.1	3.38	0.000775	0.0437	0.17	0.15	Eye color;	chr8:131332123	chr8:131308545~131317632:+
THCA	cis	rs4704187	0.687	rs4621540	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75075378	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs4324655	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75077535	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs6860441	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75093974	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs6453112	ENSG00000250889.2	LINC01336	-3.38	0.000775	0.0437	-0.16	-0.15	Response to amphetamines;	chr5:75094076	chr5:75047719~75052843:-
THCA	cis	rs2638953	0.924	rs12368745	ENSG00000247934.4	RP11-967K21.1	-3.38	0.000775	0.0437	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28396198	chr12:28163298~28190738:-
THCA	cis	rs1941184	0.526	rs1460601	ENSG00000266521.1	RP11-650P15.1	-3.38	0.000775	0.0437	-0.24	-0.15	Parkinson's disease (age of onset);	chr18:31448914	chr18:31496645~31497195:-
THCA	cis	rs1113500	0.933	rs1414674	ENSG00000230489.1	VAV3-AS1	-3.38	0.000776	0.0437	-0.14	-0.15	Growth-regulated protein alpha levels;	chr1:108083325	chr1:107964443~107994607:+
THCA	cis	rs853679	0.55	rs1150692	ENSG00000219891.2	ZSCAN12P1	3.38	0.000776	0.0437	0.22	0.15	Depression;	chr6:28206179	chr6:28091154~28093664:+
THCA	cis	rs8059260	0.524	rs1122185	ENSG00000274038.1	RP11-66H6.4	-3.38	0.000776	0.0437	-0.21	-0.15	Alcohol consumption over the past year;	chr16:11104119	chr16:11056556~11057034:+
THCA	cis	rs1832871	0.711	rs76962726	ENSG00000213078.3	RP5-933K21.2	-3.38	0.000776	0.0437	-0.23	-0.15	Height;	chr6:158253009	chr6:157365990~157366923:-
THCA	cis	rs4664293	0.867	rs7579206	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159715992	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs7565297	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159716008	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs7594329	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159716207	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs7582124	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159716326	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.802	rs13025347	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159721056	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs6432554	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159722573	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs6760485	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159723179	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs6761145	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159725673	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs6732987	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159725918	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs7589941	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159727589	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs7566584	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159728284	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs3732289	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159728887	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs3821299	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159729229	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs13415100	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159729716	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs13389662	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159729926	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs7562060	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159730618	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs4665110	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159731014	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs34893664	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159732266	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs34795915	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159732420	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs10204867	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159732674	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs35196716	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159733266	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs6432557	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159735699	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs7603274	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159736179	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.836	rs13403371	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159736603	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs13428679	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159736687	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs12623283	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159736959	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs2098976	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159737264	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs2081723	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159737649	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs2081722	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159737697	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs10166694	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159738380	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs2357529	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159738922	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs12692562	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159739199	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs12998291	ENSG00000230783.1	AC009961.2	-3.38	0.000776	0.0437	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159739392	chr2:159689217~159690291:-
THCA	cis	rs12122100	0.507	rs1925343	ENSG00000271721.1	RP11-337C18.9	-3.38	0.000776	0.0437	-0.15	-0.15	HIV-1 control;	chr1:147033981	chr1:147175602~147177740:+
THCA	cis	rs6496667	0.865	rs12593879	ENSG00000259262.1	NDUFA3P4	3.38	0.000776	0.0437	0.22	0.15	Rheumatoid arthritis;	chr15:90381276	chr15:90385814~90386063:+
THCA	cis	rs7246967	0.551	rs34897132	ENSG00000198153.8	ZNF849P	-3.38	0.000776	0.0437	-0.24	-0.15	Bronchopulmonary dysplasia;	chr19:22644089	chr19:22685167~22686732:+
THCA	cis	rs74233809	1	rs11191548	ENSG00000272912.1	RP11-724N1.1	3.38	0.000776	0.0437	0.28	0.15	Birth weight;	chr10:103086421	chr10:102914585~102915404:+
THCA	cis	rs716804	0.593	rs12419064	ENSG00000254554.1	RP11-351I24.1	3.38	0.000776	0.0437	0.17	0.15	Neuroticism;	chr11:10299061	chr11:10302657~10303704:-
THCA	cis	rs13108904	0.652	rs2878539	ENSG00000251689.1	RP11-478C6.5	3.38	0.000776	0.0437	0.19	0.15	Obesity-related traits;	chr4:1250089	chr4:269866~270175:-
THCA	cis	rs77580281	1	rs5748278	ENSG00000185065.6	AC000068.5	-3.38	0.000776	0.0437	-0.17	-0.15	Pediatric bone mineral density (hip);	chr22:19548353	chr22:19447893~19450105:+
THCA	cis	rs9291683	0.585	rs12648479	ENSG00000250413.1	RP11-448G15.1	3.38	0.000776	0.0437	0.15	0.15	Bone mineral density;	chr4:10102947	chr4:10006482~10009725:+
THCA	cis	rs4908760	0.73	rs10779704	ENSG00000270282.1	RP5-1115A15.2	3.38	0.000776	0.0437	0.18	0.15	Vitiligo;	chr1:8633478	chr1:8512653~8513021:+
THCA	cis	rs7487075	0.619	rs10748450	ENSG00000275481.1	RP11-474P2.6	3.38	0.000776	0.0437	0.15	0.15	Itch intensity from mosquito bite;	chr12:46463319	chr12:46388856~46392126:+
THCA	cis	rs950893	0.798	rs17089443	ENSG00000253837.1	RP11-177H13.2	-3.38	0.000776	0.0437	-0.16	-0.15	Mean corpuscular hemoglobin;	chr8:23617434	chr8:23336171~23366125:+
THCA	cis	rs950893	0.798	rs11135760	ENSG00000253837.1	RP11-177H13.2	-3.38	0.000776	0.0437	-0.16	-0.15	Mean corpuscular hemoglobin;	chr8:23619730	chr8:23336171~23366125:+
THCA	cis	rs9420	0.961	rs682503	ENSG00000254602.1	AP000662.4	3.38	0.000776	0.0437	0.17	0.15	Schizophrenia;	chr11:57873522	chr11:57638024~57652790:+
THCA	cis	rs3091242	1	rs9689	ENSG00000228172.4	RP1-317E23.3	3.38	0.000776	0.0437	0.12	0.15	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25816749~25820797:-
THCA	cis	rs4879656	0.788	rs10758186	ENSG00000225693.1	LAGE3P1	3.38	0.000776	0.0437	0.16	0.15	Menopause (age at onset);	chr9:33101840	chr9:33019682~33020165:-
THCA	cis	rs2117029	1	rs10783299	ENSG00000239617.1	RP11-302B13.1	-3.38	0.000776	0.0437	-0.18	-0.15	Intelligence (multi-trait analysis);	chr12:48996894	chr12:48903418~48903813:-
THCA	cis	rs62025270	0.632	rs1807309	ENSG00000202081.1	RNU6-1280P	-3.38	0.000776	0.0437	-0.25	-0.15	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85651522~85651628:-
THCA	cis	rs4803480	0.573	rs2302188	ENSG00000270164.1	LINC01480	3.38	0.000776	0.0438	0.13	0.15	Schizophrenia;	chr19:41579520	chr19:41535183~41536904:+
THCA	cis	rs2625529	0.627	rs12902661	ENSG00000260037.4	CTD-2524L6.3	-3.38	0.000777	0.0438	-0.22	-0.15	Red blood cell count;	chr15:72187817	chr15:71818396~71823384:+
THCA	cis	rs5993586	1	rs7284649	ENSG00000223461.1	AC004471.9	3.38	0.000777	0.0438	0.34	0.15	Coronary artery disease;	chr22:19401424	chr22:19121529~19124503:+
THCA	cis	rs34792	0.554	rs4597346	ENSG00000275910.1	RP11-680G24.6	-3.38	0.000777	0.0438	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:15015828~15016390:-
THCA	cis	rs12780845	0.931	rs11818636	ENSG00000273153.1	RP11-406H21.2	3.38	0.000777	0.0438	0.15	0.15	Homocysteine levels;	chr10:17202899	chr10:17137336~17137585:-
THCA	cis	rs12780845	0.928	rs11813029	ENSG00000273153.1	RP11-406H21.2	3.38	0.000777	0.0438	0.15	0.15	Homocysteine levels;	chr10:17202916	chr10:17137336~17137585:-
THCA	cis	rs6545883	0.894	rs2600660	ENSG00000212978.6	AC016747.3	-3.38	0.000777	0.0438	-0.17	-0.15	Tuberculosis;	chr2:61322465	chr2:61141592~61144969:-
THCA	cis	rs4819852	0.723	rs2238790	ENSG00000229107.2	ABHD17AP4	-3.38	0.000777	0.0438	-0.19	-0.15	Pulse pressure;	chr22:19995491	chr22:20667836~20670984:-
THCA	cis	rs7824557	0.585	rs2572385	ENSG00000254866.2	DEFB109P3	-3.38	0.000777	0.0438	-0.22	-0.15	Retinal vascular caliber;	chr8:11351394	chr8:12150895~12151134:-
THCA	cis	rs9296092	0.538	rs75082458	ENSG00000272217.1	XXbac-BPG157A10.21	3.38	0.000777	0.0438	0.17	0.15	Age at smoking initiation in chronic obstructive pulmonary disease;	chr6:33557015	chr6:33246075~33246856:-
THCA	cis	rs17270561	0.779	rs1165200	ENSG00000218281.1	HIST1H2APS3	-3.38	0.000777	0.0438	-0.22	-0.15	Iron status biomarkers;	chr6:25874984	chr6:26233122~26233255:+
THCA	cis	rs881375	1	rs1953126	ENSG00000270917.1	RP11-27I1.6	-3.38	0.000777	0.0438	-0.21	-0.15	Rheumatoid arthritis;	chr9:120878222	chr9:120812475~120812845:-
THCA	cis	rs2692947	0.655	rs2315668	ENSG00000235959.1	AC009237.17	-3.38	0.000777	0.0438	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95763814	chr2:95640181~95640604:-
THCA	cis	rs9450351	0.744	rs9351072	ENSG00000280232.1	RP11-321N4.4	3.38	0.000777	0.0438	0.33	0.15	Interferon gamma-induced protein 10 levels;	chr6:85917611	chr6:85498441~85499058:-
THCA	cis	rs9450351	0.744	rs6912150	ENSG00000280232.1	RP11-321N4.4	3.38	0.000777	0.0438	0.33	0.15	Interferon gamma-induced protein 10 levels;	chr6:85925291	chr6:85498441~85499058:-
THCA	cis	rs7824557	0.564	rs2736293	ENSG00000261451.1	RP11-981G7.1	-3.38	0.000777	0.0438	-0.19	-0.15	Retinal vascular caliber;	chr8:11377104	chr8:10433672~10438312:+
THCA	cis	rs7824557	0.564	rs2736294	ENSG00000261451.1	RP11-981G7.1	-3.38	0.000777	0.0438	-0.19	-0.15	Retinal vascular caliber;	chr8:11377117	chr8:10433672~10438312:+
THCA	cis	rs36093844	0.527	rs4943935	ENSG00000279742.1	RP11-700A24.1	-3.38	0.000777	0.0438	-0.21	-0.15	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86040813	chr11:85852557~85854943:-
THCA	cis	rs10043228	1	rs4286716	ENSG00000248445.4	SEMA6A-AS1	3.38	0.000777	0.0438	0.2	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116184000	chr5:116447547~116508276:+
THCA	cis	rs9650657	0.737	rs2409669	ENSG00000269918.1	AF131215.9	-3.38	0.000777	0.0438	-0.16	-0.15	Neuroticism;	chr8:10766459	chr8:11104691~11106704:-
THCA	cis	rs4660456	0.913	rs4660448	ENSG00000238287.1	RP11-656D10.3	-3.38	0.000777	0.0438	-0.19	-0.15	Platelet count;	chr1:40724682	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs7532802	ENSG00000238287.1	RP11-656D10.3	-3.38	0.000777	0.0438	-0.19	-0.15	Platelet count;	chr1:40725528	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs2361648	ENSG00000238287.1	RP11-656D10.3	-3.38	0.000777	0.0438	-0.19	-0.15	Platelet count;	chr1:40726825	chr1:40493157~40508661:-
THCA	cis	rs7621025	0.617	rs12637102	ENSG00000273486.1	RP11-731C17.2	3.38	0.000777	0.0438	0.14	0.15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136493118	chr3:136837338~136839021:-
THCA	cis	rs28643277	0.671	rs2014825	ENSG00000237470.3	DCLRE1CP1	3.38	0.000777	0.0438	0.2	0.15	Periodontitis (CDC/AAP);	chr10:15506702	chr10:15015370~15021863:-
THCA	cis	rs10256972	0.967	rs4723338	ENSG00000199023.2	MIR339	-3.38	0.000777	0.0438	-0.16	-0.15	Endometriosis;Longevity;	chr7:996605	chr7:1022935~1023045:-
THCA	cis	rs1348850	0.526	rs10803912	ENSG00000280374.1	RP11-337N6.3	3.38	0.000777	0.0438	0.26	0.15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177542448	chr2:177317715~177318471:-
THCA	cis	rs11603020	0.95	rs28362950	ENSG00000265566.2	RN7SL605P	-3.38	0.000777	0.0438	-0.23	-0.15	Blood protein levels;	chr11:57604445	chr11:57528085~57528365:-
THCA	cis	rs1654345	0.561	rs855637	ENSG00000275132.1	Metazoa_SRP	-3.38	0.000777	0.0438	-0.24	-0.15	Life satisfaction;Subjective well-being;	chr19:38057638	chr19:38200234~38200532:+
THCA	cis	rs7474896	0.537	rs1208587	ENSG00000276805.1	RP11-291L22.6	-3.38	0.000777	0.0438	-0.2	-0.15	Obesity (extreme);	chr10:37918831	chr10:38451030~38451785:+
THCA	cis	rs34792	0.525	rs12923446	ENSG00000260872.1	RP11-680G24.5	3.38	0.000777	0.0438	0.16	0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15509723	chr16:15018106~15020488:-
THCA	cis	rs34783982	0.881	rs4627315	ENSG00000259699.2	HMGB1P8	-3.38	0.000777	0.0438	-0.21	-0.15	Squamous cell lung carcinoma;	chr15:88959162	chr15:89135547~89136495:-
THCA	cis	rs2486012	0.649	rs39722	ENSG00000234694.1	RP1-92O14.3	3.38	0.000777	0.0438	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43819991	chr1:43354684~43358658:-
THCA	cis	rs7412746	0.622	rs11552229	ENSG00000224800.1	RP11-235D19.2	-3.38	0.000777	0.0438	-0.21	-0.15	Melanoma;	chr1:150811509	chr1:150881236~150881683:-
THCA	cis	rs10483853	0.731	rs10162414	ENSG00000258891.1	RP5-1021I20.5	3.38	0.000778	0.0438	0.19	0.15	Coronary artery calcification;	chr14:73296524	chr14:73896164~73938114:-
THCA	cis	rs7615952	0.932	rs7630077	ENSG00000248787.1	RP11-666A20.4	-3.38	0.000778	0.0438	-0.27	-0.15	Blood pressure (smoking interaction);	chr3:125930833	chr3:125908005~125910272:-
THCA	cis	rs2287641	1	rs2287641	ENSG00000272156.1	RP11-477N3.1	3.38	0.000778	0.0438	0.27	0.15	Cannabis dependence symptom count;	chr2:54115818	chr2:54082554~54085066:+
THCA	cis	rs877529	0.934	rs139425	ENSG00000279833.1	RP4-742C19.13	-3.38	0.000778	0.0438	-0.1	-0.15	Multiple myeloma;	chr22:39163737	chr22:39133090~39136760:+
THCA	cis	rs6657613	0.903	rs2076601	ENSG00000186715.9	MST1L	3.38	0.000778	0.0438	0.13	0.15	Hip circumference adjusted for BMI;	chr1:17003958	chr1:16754910~16770237:-
THCA	cis	rs11673344	0.642	rs73025481	ENSG00000267470.4	ZNF571-AS1	-3.38	0.000778	0.0438	-0.17	-0.15	Obesity-related traits;	chr19:37346437	chr19:37548914~37587348:+
THCA	cis	rs4971059	0.654	rs7364524	ENSG00000225855.5	RUSC1-AS1	3.38	0.000778	0.0438	0.1	0.15	Breast cancer;	chr1:155149446	chr1:155316863~155324176:-
THCA	cis	rs8031584	0.723	rs711224	ENSG00000270015.1	RP11-540B6.6	3.38	0.000778	0.0438	0.12	0.15	Huntington's disease progression;	chr15:30835718	chr15:30926514~30928407:+
THCA	cis	rs3087591	0.597	rs731759	ENSG00000263535.1	AK4P1	-3.38	0.000778	0.0438	-0.18	-0.15	Hip circumference;	chr17:31395791	chr17:31345521~31346187:+
THCA	cis	rs965513	1	rs10983700	ENSG00000236130.1	PTCSC2	-3.38	0.000778	0.0438	-0.13	-0.15	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97775173	chr9:97805935~97810008:-
THCA	cis	rs965513	1	rs10759927	ENSG00000236130.1	PTCSC2	-3.38	0.000778	0.0438	-0.13	-0.15	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97779894	chr9:97805935~97810008:-
THCA	cis	rs6496667	0.51	rs16944405	ENSG00000213471.7	TTLL13P	3.38	0.000778	0.0438	0.18	0.15	Rheumatoid arthritis;	chr15:90432285	chr15:90249530~90265482:+
THCA	cis	rs1865760	0.964	rs9295677	ENSG00000272810.1	U91328.22	-3.38	0.000778	0.0438	-0.12	-0.15	Height;	chr6:25933484	chr6:26013241~26013757:+
THCA	cis	rs9596863	1	rs9568948	ENSG00000136149.6	RPL13AP25	-3.38	0.000778	0.0438	-0.17	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53863558	chr13:54440704~54441315:-
THCA	cis	rs80130819	0.748	rs2732478	ENSG00000273765.1	RP11-370I10.11	3.38	0.000778	0.0438	0.17	0.15	Prostate cancer;	chr12:48305754	chr12:48360920~48361377:+
THCA	cis	rs1865760	0.516	rs9393684	ENSG00000272810.1	U91328.22	-3.38	0.000778	0.0438	-0.12	-0.15	Height;	chr6:26075303	chr6:26013241~26013757:+
THCA	cis	rs524281	0.861	rs11227426	ENSG00000255038.1	RP11-1167A19.2	-3.38	0.000778	0.0438	-0.18	-0.15	Electroencephalogram traits;	chr11:66204480	chr11:66067277~66069619:-
THCA	cis	rs7737355	0.853	rs245799	ENSG00000224431.1	AC063976.7	-3.38	0.000778	0.0438	-0.14	-0.15	Life satisfaction;	chr5:131337055	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs245796	ENSG00000224431.1	AC063976.7	-3.38	0.000778	0.0438	-0.14	-0.15	Life satisfaction;	chr5:131344491	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs798407	ENSG00000224431.1	AC063976.7	-3.38	0.000778	0.0438	-0.14	-0.15	Life satisfaction;	chr5:131352685	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs798406	ENSG00000224431.1	AC063976.7	-3.38	0.000778	0.0438	-0.14	-0.15	Life satisfaction;	chr5:131353470	chr5:132199456~132203487:+
THCA	cis	rs12621844	0.671	rs1483210	ENSG00000234690.5	AC073283.4	-3.38	0.000778	0.0438	-0.15	-0.15	Glycated hemoglobin levels;	chr2:48084451	chr2:47192405~47345074:-
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000281021.1	RP1-12G14.9	-3.38	0.000778	0.0438	-0.16	-0.15	Lung cancer;	chr6:149752755	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000281021.1	RP1-12G14.9	-3.38	0.000778	0.0438	-0.16	-0.15	Lung cancer;	chr6:149756953	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000281021.1	RP1-12G14.9	-3.38	0.000778	0.0438	-0.16	-0.15	Lung cancer;	chr6:149758502	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000281021.1	RP1-12G14.9	-3.38	0.000778	0.0438	-0.16	-0.15	Lung cancer;	chr6:149758875	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000281021.1	RP1-12G14.9	-3.38	0.000778	0.0438	-0.16	-0.15	Lung cancer;	chr6:149759454	chr6:149576089~149590864:-
THCA	cis	rs3770081	1	rs13390702	ENSG00000273080.1	RP11-301O19.1	-3.38	0.000778	0.0438	-0.31	-0.15	Facial emotion recognition (sad faces);	chr2:86010812	chr2:86195590~86196049:+
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000185485.13	SDHAP1	3.38	0.000778	0.0438	0.15	0.15	Pancreatic cancer;	chr3:196025182	chr3:195959748~195990318:-
THCA	cis	rs1560104	0.597	rs12162027	ENSG00000260601.1	RP11-552C15.1	-3.38	0.000778	0.0438	-0.19	-0.15	Obesity-related traits;	chr16:12616235	chr16:12545482~12546684:+
THCA	cis	rs57709857	0.957	rs13317	ENSG00000272092.1	RP11-350N15.5	-3.38	0.000778	0.0438	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38411996	chr8:38382364~38383461:+
THCA	cis	rs34779708	0.966	rs34776628	ENSG00000233200.1	RP11-324I22.2	3.38	0.000778	0.0438	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs17499247	ENSG00000233200.1	RP11-324I22.2	3.38	0.000778	0.0438	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs10827491	ENSG00000233200.1	RP11-324I22.2	3.38	0.000778	0.0438	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35219894~35230598:-
THCA	cis	rs2832191	0.791	rs8134407	ENSG00000176054.6	RPL23P2	3.38	0.000778	0.0438	0.13	0.15	Dental caries;	chr21:29104265	chr21:28997613~28998033:-
THCA	cis	rs867371	0.502	rs3759800	ENSG00000276710.3	CSPG4P8	3.38	0.000778	0.0438	0.15	0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82459472~82477258:+
THCA	cis	rs858239	0.72	rs10227559	ENSG00000230042.1	AK3P3	-3.38	0.000778	0.0438	-0.21	-0.15	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23129178~23129841:+
THCA	cis	rs524281	0.861	rs10896087	ENSG00000255038.1	RP11-1167A19.2	-3.38	0.000778	0.0438	-0.18	-0.15	Electroencephalogram traits;	chr11:66157078	chr11:66067277~66069619:-
THCA	cis	rs524281	0.861	rs4013917	ENSG00000255038.1	RP11-1167A19.2	-3.38	0.000778	0.0438	-0.18	-0.15	Electroencephalogram traits;	chr11:66158714	chr11:66067277~66069619:-
THCA	cis	rs17122278	1	rs11216907	ENSG00000243431.1	RPL5P30	3.38	0.000778	0.0438	0.16	0.15	Total cholesterol levels;	chr11:118573810	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs55844025	ENSG00000243431.1	RPL5P30	3.38	0.000778	0.0438	0.16	0.15	Total cholesterol levels;	chr11:118575583	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs9735449	ENSG00000243431.1	RPL5P30	3.38	0.000778	0.0438	0.16	0.15	Total cholesterol levels;	chr11:118577372	chr11:118560690~118561580:+
THCA	cis	rs2901381	0.659	rs35787846	ENSG00000269984.1	RP11-362K14.5	-3.38	0.000778	0.0438	-0.14	-0.15	Plateletcrit;	chr3:169097288	chr3:169777192~169780334:-
THCA	cis	rs853679	0.517	rs1340004	ENSG00000219891.2	ZSCAN12P1	3.38	0.000778	0.0438	0.22	0.15	Depression;	chr6:28135913	chr6:28091154~28093664:+
THCA	cis	rs1510272	0.961	rs7644461	ENSG00000243926.1	TIPARP-AS1	-3.38	0.000778	0.0438	-0.16	-0.15	Testicular germ cell tumor;	chr3:156598903	chr3:156671862~156674378:-
THCA	cis	rs2131877	0.554	rs2131876	ENSG00000238097.1	RP11-513G11.3	-3.38	0.000778	0.0438	-0.18	-0.15	Non-small cell lung cancer;	chr3:195134059	chr3:194247648~194257772:+
THCA	cis	rs7713065	0.765	rs11744116	ENSG00000263597.1	MIR3936	-3.38	0.000778	0.0438	-0.19	-0.15	Lung function (FEV1/FVC);	chr5:132444068	chr5:132365490~132365599:-
THCA	cis	rs9859260	0.591	rs3827554	ENSG00000226155.1	AC124944.3	-3.38	0.000779	0.0438	-0.19	-0.15	Mean corpuscular volume;	chr3:196082245	chr3:195912049~195913986:+
THCA	cis	rs2921073	0.605	rs2976933	ENSG00000233609.3	RP11-62H7.2	3.38	0.000779	0.0438	0.15	0.15	Parkinson's disease;	chr8:8397365	chr8:8961200~8979025:+
THCA	cis	rs173896	1	rs192276	ENSG00000246859.2	STARD4-AS1	3.38	0.000779	0.0438	0.21	0.15	Bipolar disorder and schizophrenia;	chr5:111774099	chr5:111512226~111739726:+
THCA	cis	rs34779708	0.966	rs878264	ENSG00000233200.1	RP11-324I22.2	3.38	0.000779	0.0438	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35219894~35230598:-
THCA	cis	rs1144333	0.655	rs3920847	ENSG00000272855.1	RP5-1102E8.3	-3.38	0.000779	0.0439	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75970254	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs7418941	ENSG00000272855.1	RP5-1102E8.3	-3.38	0.000779	0.0439	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75970335	chr1:76636877~76637339:+
THCA	cis	rs7937682	0.593	rs1944121	ENSG00000196167.8	COLCA1	3.38	0.000779	0.0439	0.16	0.15	Primary sclerosing cholangitis;	chr11:111476498	chr11:111290787~111305045:-
THCA	cis	rs13178541	0.593	rs6860305	ENSG00000250167.1	CTC-321K16.1	-3.38	0.000779	0.0439	-0.17	-0.15	IgG glycosylation;	chr5:135710654	chr5:135559577~135634874:+
THCA	cis	rs13178541	0.593	rs5027775	ENSG00000250167.1	CTC-321K16.1	-3.38	0.000779	0.0439	-0.17	-0.15	IgG glycosylation;	chr5:135710995	chr5:135559577~135634874:+
THCA	cis	rs6545883	0.965	rs12713439	ENSG00000212978.6	AC016747.3	3.38	0.000779	0.0439	0.17	0.15	Tuberculosis;	chr2:61525019	chr2:61141592~61144969:-
THCA	cis	rs7560272	0.501	rs12713793	ENSG00000230002.2	ALMS1-IT1	-3.38	0.000779	0.0439	-0.18	-0.15	Schizophrenia;	chr2:73728987	chr2:73456764~73459484:+
THCA	cis	rs41419946	1	rs12072131	ENSG00000236206.1	RP11-306I1.2	-3.38	0.000779	0.0439	-0.35	-0.15	Gut microbiome composition (winter);	chr1:165427788	chr1:165598463~165623331:+
THCA	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-3.38	0.000779	0.0439	-0.14	-0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
THCA	cis	rs11648785	0.526	rs4530137	ENSG00000222019.6	URAHP	3.38	0.000779	0.0439	0.13	0.15	Tanning;	chr16:90028093	chr16:90039761~90047773:-
THCA	cis	rs6449502	0.858	rs4410607	ENSG00000251279.1	CTC-436P18.1	-3.38	0.000779	0.0439	-0.25	-0.15	Mean platelet volume;	chr5:60830439	chr5:61162070~61232040:+
THCA	cis	rs7829975	0.593	rs2921061	ENSG00000253130.1	CTD-3023L14.2	-3.38	0.000779	0.0439	-0.17	-0.15	Mood instability;	chr8:8460105	chr8:8561391~8569688:+
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000264242.2	RP11-271K11.1	3.38	0.000779	0.0439	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30553697~30558962:+
THCA	cis	rs34421088	0.56	rs2245357	ENSG00000270154.1	RP11-419I17.1	-3.38	0.000779	0.0439	-0.19	-0.15	Neuroticism;	chr8:11541975	chr8:12476462~12477122:+
THCA	cis	rs11089937	0.626	rs9619811	ENSG00000215456.5	BCRP4	3.38	0.000779	0.0439	0.2	0.15	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22630061~22636153:+
THCA	cis	rs2034088	0.897	rs12452970	ENSG00000231784.7	DBIL5P	3.38	0.000779	0.0439	0.17	0.15	Hip circumference adjusted for BMI;	chr17:541277	chr17:752660~755336:+
THCA	cis	rs7264396	0.887	rs10359	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000779	0.0439	-0.16	-0.15	Total cholesterol levels;	chr20:35511960	chr20:35267885~35280043:-
THCA	cis	rs2341873	0.595	rs729386	ENSG00000204581.2	AC096670.3	3.38	0.000779	0.0439	0.16	0.15	Neutrophil percentage of white cells;	chr2:110948161	chr2:111098345~111115588:-
THCA	cis	rs13315871	1	rs35792042	ENSG00000272182.1	RP11-802O23.3	3.38	0.000779	0.0439	0.26	0.15	Cholesterol, total;	chr3:58423941	chr3:58428255~58428815:+
THCA	cis	rs9392556	0.829	rs853416	ENSG00000230648.1	RP3-406P24.3	3.38	0.000779	0.0439	0.19	0.15	Blood metabolite levels;	chr6:4112813	chr6:4018843~4021215:-
THCA	cis	rs867186	0.614	rs75401510	ENSG00000279253.1	RP4-614O4.13	-3.38	0.000779	0.0439	-0.31	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34846620	chr20:35262727~35264187:-
THCA	cis	rs7259376	0.905	rs11879791	ENSG00000270947.1	AC025811.3	3.38	0.000779	0.0439	0.16	0.15	Menopause (age at onset);	chr19:22354137	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.936	rs59598661	ENSG00000270947.1	AC025811.3	3.38	0.000779	0.0439	0.16	0.15	Menopause (age at onset);	chr19:22354227	chr19:22455988~22456459:+
THCA	cis	rs4417704	0.502	rs6714289	ENSG00000235151.1	AC114730.2	-3.38	0.000779	0.0439	-0.17	-0.15	Joint mobility (Beighton score);	chr2:240941044	chr2:241844380~241845036:+
THCA	cis	rs1862618	0.853	rs6885541	ENSG00000234553.1	AC022431.3	-3.38	0.000779	0.0439	-0.18	-0.15	Initial pursuit acceleration;	chr5:56815030	chr5:56536583~56537826:-
THCA	cis	rs8028182	0.636	rs8034317	ENSG00000275645.1	RP11-817O13.9	3.38	0.000779	0.0439	0.15	0.15	Sudden cardiac arrest;	chr15:75472002	chr15:75346744~75347161:-
THCA	cis	rs35740288	0.689	rs11630688	ENSG00000259407.1	RP11-158M2.3	-3.38	0.000779	0.0439	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85710048	chr15:85744109~85750281:-
THCA	cis	rs4578769	0.681	rs4517886	ENSG00000265939.1	UBE2CP2	-3.38	0.000779	0.0439	-0.19	-0.15	Eosinophil percentage of white cells;	chr18:22982922	chr18:22900486~22900995:-
THCA	cis	rs2797160	1	rs1739363	ENSG00000226409.1	RP11-735G4.1	3.38	0.000779	0.0439	0.18	0.15	Endometrial cancer;	chr6:125699834	chr6:125370211~125374324:-
THCA	cis	rs620729	0.756	rs9348893	ENSG00000272097.1	RP11-421M1.8	-3.38	0.000779	0.0439	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11491134	chr6:10743324~10747663:-
THCA	cis	rs67981189	0.574	rs2526884	ENSG00000269927.1	RP6-91H8.3	-3.38	0.000779	0.0439	-0.17	-0.15	Schizophrenia;	chr14:70901250	chr14:71141125~71143253:-
THCA	cis	rs7615952	0.546	rs2979340	ENSG00000272840.1	RP11-379B18.6	3.38	0.000779	0.0439	0.25	0.15	Blood pressure (smoking interaction);	chr3:125622540	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.546	rs2979338	ENSG00000272840.1	RP11-379B18.6	3.38	0.000779	0.0439	0.25	0.15	Blood pressure (smoking interaction);	chr3:125624282	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.546	rs2922171	ENSG00000272840.1	RP11-379B18.6	3.38	0.000779	0.0439	0.25	0.15	Blood pressure (smoking interaction);	chr3:125624349	chr3:125774714~125797953:+
THCA	cis	rs7615952	0.546	rs112919177	ENSG00000272840.1	RP11-379B18.6	3.38	0.000779	0.0439	0.25	0.15	Blood pressure (smoking interaction);	chr3:125627226	chr3:125774714~125797953:+
THCA	cis	rs2505675	0.961	rs2450300	ENSG00000272465.1	RP1-136B1.1	-3.38	0.000779	0.0439	-0.2	-0.15	Tuberculosis;	chr6:2322220	chr6:2437549~2438249:+
THCA	cis	rs1552244	0.554	rs7638846	ENSG00000269982.1	RP11-1020A11.2	3.38	0.000779	0.0439	0.11	0.15	Alzheimer's disease;	chr3:10006917	chr3:9958717~9962539:+
THCA	cis	rs61160187	0.549	rs12518404	ENSG00000251279.1	CTC-436P18.1	-3.38	0.000779	0.0439	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:61162070~61232040:+
THCA	cis	rs11679564	0.714	rs10490657	ENSG00000279519.1	RP11-288C18.1	3.38	0.000779	0.0439	0.12	0.15	Immature fraction of reticulocytes;	chr2:36951112	chr2:36839922~36842539:-
THCA	cis	rs17428076	0.874	rs17615262	ENSG00000228389.1	AC068039.4	-3.38	0.000779	0.0439	-0.18	-0.15	Myopia;	chr2:171826971	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.874	rs62182374	ENSG00000228389.1	AC068039.4	-3.38	0.000779	0.0439	-0.18	-0.15	Myopia;	chr2:171829172	chr2:171773482~171775844:+
THCA	cis	rs2991971	0.934	rs2991974	ENSG00000234329.1	RP11-767N6.2	-3.38	0.00078	0.0439	-0.15	-0.15	High light scatter reticulocyte count;	chr1:45554982	chr1:45651039~45651826:-
THCA	cis	rs34792	0.554	rs2067063	ENSG00000207425.1	Y_RNA	-3.38	0.00078	0.0439	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15515106	chr16:14915457~14915556:-
THCA	cis	rs1971762	0.563	rs10747678	ENSG00000270175.1	RP11-793H13.11	3.38	0.00078	0.0439	0.1	0.15	Height;	chr12:53683903	chr12:53500162~53500936:-
THCA	cis	rs929354	0.935	rs1182392	ENSG00000224629.1	RP5-1142J19.2	3.38	0.00078	0.0439	0.15	0.15	Body mass index;	chr7:157243506	chr7:157263022~157263229:-
THCA	cis	rs3785309	0.519	rs7196484	ENSG00000268836.1	LA16c-OS12.2	-3.38	0.00078	0.0439	-0.27	-0.15	Immature fraction of reticulocytes;	chr16:226188	chr16:185748~186294:-
THCA	cis	rs172166	0.694	rs203893	ENSG00000219891.2	ZSCAN12P1	3.38	0.00078	0.0439	0.2	0.15	Cardiac Troponin-T levels;	chr6:28094288	chr6:28091154~28093664:+
THCA	cis	rs7267979	0.873	rs6132822	ENSG00000276952.1	RP5-965G21.6	3.38	0.00078	0.0439	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25284915~25285588:-
THCA	cis	rs853679	0.517	rs4713135	ENSG00000273712.1	RP5-874C20.7	3.38	0.00078	0.0439	0.21	0.15	Depression;	chr6:28071808	chr6:28315613~28315883:-
THCA	cis	rs939960	0.959	rs62502277	ENSG00000276538.1	RP11-545G3.2	3.38	0.00078	0.0439	0.23	0.15	Neutrophil percentage of white cells;	chr7:150583351	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs11764483	ENSG00000276538.1	RP11-545G3.2	3.38	0.00078	0.0439	0.23	0.15	Neutrophil percentage of white cells;	chr7:150583598	chr7:150047609~150047854:-
THCA	cis	rs11190604	1	rs6584383	ENSG00000273030.1	RP11-285F16.1	3.38	0.00078	0.0439	0.18	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100543308	chr10:100412934~100413421:+
THCA	cis	rs3135718	1	rs2420946	ENSG00000276742.1	RP11-500G22.4	-3.38	0.00078	0.0439	-0.18	-0.15	Estrogen receptor status in breast cancer;	chr10:121591810	chr10:121956782~121957098:+
THCA	cis	rs10191559	0.959	rs56209172	ENSG00000238171.1	AC068196.1	-3.38	0.00078	0.0439	-0.19	-0.15	Red blood cell count;	chr2:180972313	chr2:181076051~181105968:-
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000281021.1	RP1-12G14.9	-3.38	0.00078	0.0439	-0.16	-0.15	Lung cancer;	chr6:149760959	chr6:149576089~149590864:-
THCA	cis	rs1124769	0.692	rs3825797	ENSG00000244879.4	GABPB1-AS1	-3.38	0.00078	0.0439	-0.16	-0.15	Cognitive performance;	chr15:50933486	chr15:50354959~50372202:+
THCA	cis	rs7914558	1	rs8139	ENSG00000213061.2	PFN1P11	3.38	0.00078	0.0439	0.18	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:102838011~102845473:-
THCA	cis	rs4722166	0.598	rs7804146	ENSG00000179428.2	AC073072.5	-3.38	0.00078	0.0439	-0.18	-0.15	Lung cancer;	chr7:22761310	chr7:22725395~22727620:-
THCA	cis	rs261967	0.666	rs13358815	ENSG00000236882.6	LINC01554	-3.38	0.00078	0.0439	-0.18	-0.15	Body mass index;	chr5:96519961	chr5:95852232~95860133:+
THCA	cis	rs9878978	1	rs2174019	ENSG00000227588.2	CNTN4-AS2	3.38	0.00078	0.0439	0.18	0.15	Blood pressure (smoking interaction);	chr3:2430983	chr3:2110409~2144241:-
THCA	cis	rs7949030	0.591	rs35156678	ENSG00000255213.1	NPM1P35	3.38	0.00078	0.0439	0.2	0.15	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr11:62330946~62331813:+
THCA	cis	rs9796	0.717	rs476633	ENSG00000247556.5	OIP5-AS1	3.38	0.00078	0.0439	0.12	0.15	Menopause (age at onset);	chr15:41099936	chr15:41283990~41309737:+
THCA	cis	rs10508774	1	rs72780316	ENSG00000217094.2	PPIAP31	3.38	0.00078	0.0439	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32635920	chr10:32188323~32188817:-
THCA	cis	rs73193808	0.804	rs2832276	ENSG00000176054.6	RPL23P2	-3.38	0.00078	0.0439	-0.16	-0.15	Coronary artery disease;	chr21:29236463	chr21:28997613~28998033:-
THCA	cis	rs7560272	0.723	rs7566315	ENSG00000273245.1	RP11-434P11.2	3.38	0.00078	0.0439	0.19	0.15	Schizophrenia;	chr2:73564681	chr2:73750256~73750786:-
THCA	cis	rs1200821	0.529	rs2475206	ENSG00000276805.1	RP11-291L22.6	-3.38	0.00078	0.0439	-0.16	-0.15	Hemostatic factors and hematological phenotypes;	chr10:37513604	chr10:38451030~38451785:+
THCA	cis	rs3770081	0.793	rs58186343	ENSG00000272564.1	RP11-548P2.2	-3.38	0.00078	0.0439	-0.31	-0.15	Facial emotion recognition (sad faces);	chr2:85991277	chr2:85904279~85904727:+
THCA	cis	rs17217757	0.725	rs13277129	ENSG00000254041.1	RP11-574O7.1	-3.38	0.00078	0.0439	-0.23	-0.15	Tuberculosis;	chr8:105628230	chr8:105142860~105188606:-
THCA	cis	rs8033133	0.56	rs12441340	ENSG00000270523.1	RP11-145P16.3	3.38	0.00078	0.0439	0.15	0.15	Blood osmolality (transformed sodium);	chr15:25078817	chr15:25130978~25131337:+
THCA	cis	rs10911902	0.913	rs3131554	ENSG00000233196.2	GS1-304P7.1	-3.38	0.00078	0.0439	-0.22	-0.15	Schizophrenia;	chr1:186482939	chr1:186580515~186581191:-
THCA	cis	rs881827	0.89	rs12152107	ENSG00000230982.1	DSTNP1	-3.38	0.00078	0.0439	-0.15	-0.15	Lymphocyte counts;	chr21:46607967	chr21:46653558~46654022:-
THCA	cis	rs17023223	0.581	rs11811859	ENSG00000227056.2	RPL6P2	-3.38	0.00078	0.0439	-0.2	-0.15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119219314~119220096:-
THCA	cis	rs12724450	0.793	rs71622694	ENSG00000228126.1	FALEC	3.38	0.00078	0.0439	0.3	0.15	Blood protein levels;	chr1:150323754	chr1:150515757~150518032:+
THCA	cis	rs12724450	0.793	rs35437473	ENSG00000228126.1	FALEC	3.38	0.00078	0.0439	0.3	0.15	Blood protein levels;	chr1:150324779	chr1:150515757~150518032:+
THCA	cis	rs1154275	0.743	rs1268971	ENSG00000243795.1	RP11-572M11.3	-3.38	0.00078	0.0439	-0.19	-0.15	Takotsubo syndrome;	chr3:112774459	chr3:113142350~113167819:-
THCA	cis	rs7829975	0.688	rs7837587	ENSG00000253130.1	CTD-3023L14.2	-3.38	0.00078	0.0439	-0.17	-0.15	Mood instability;	chr8:8521482	chr8:8561391~8569688:+
THCA	cis	rs10246939	0.543	rs9640204	ENSG00000270923.1	TAS2R6P	-3.38	0.00078	0.0439	-0.14	-0.15	Bitter taste perception;	chr7:141844300	chr7:141787815~141788640:+
THCA	cis	rs10246939	0.543	rs9640359	ENSG00000270923.1	TAS2R6P	-3.38	0.00078	0.0439	-0.14	-0.15	Bitter taste perception;	chr7:141844399	chr7:141787815~141788640:+
THCA	cis	rs1048886	0.872	rs76920724	ENSG00000271967.1	RP11-134K13.4	-3.38	0.000781	0.0439	-0.19	-0.15	Type 2 diabetes;	chr6:70494450	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.808	rs17635510	ENSG00000271967.1	RP11-134K13.4	-3.38	0.000781	0.0439	-0.19	-0.15	Type 2 diabetes;	chr6:70516932	chr6:70596438~70596980:+
THCA	cis	rs12428035	0.764	rs72637833	ENSG00000247400.3	DNAJC3-AS1	-3.38	0.000781	0.0439	-0.15	-0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96084560	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs72637836	ENSG00000247400.3	DNAJC3-AS1	-3.38	0.000781	0.0439	-0.15	-0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96086373	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs2170813	ENSG00000247400.3	DNAJC3-AS1	-3.38	0.000781	0.0439	-0.15	-0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96087067	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.649	rs2129006	ENSG00000247400.3	DNAJC3-AS1	-3.38	0.000781	0.0439	-0.15	-0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96087324	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.536	rs72637837	ENSG00000247400.3	DNAJC3-AS1	-3.38	0.000781	0.0439	-0.15	-0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96087662	chr13:95648733~95676925:-
THCA	cis	rs2797160	1	rs1739373	ENSG00000226409.1	RP11-735G4.1	3.38	0.000781	0.0439	0.18	0.15	Endometrial cancer;	chr6:125690363	chr6:125370211~125374324:-
THCA	cis	rs2625529	0.504	rs11072349	ENSG00000260037.4	CTD-2524L6.3	3.38	0.000781	0.0439	0.19	0.15	Red blood cell count;	chr15:72172130	chr15:71818396~71823384:+
THCA	cis	rs11168618	0.875	rs11168606	ENSG00000240399.1	RP1-228P16.1	3.38	0.000781	0.0439	0.16	0.15	Adiponectin levels;	chr12:48498906	chr12:48054813~48055591:-
THCA	cis	rs4792901	0.722	rs34558675	ENSG00000279602.1	CTD-3014M21.1	-3.38	0.000781	0.0439	-0.2	-0.15	Dupuytren's disease;	chr17:43473223	chr17:43360041~43361361:-
THCA	cis	rs6472235	0.934	rs56389721	ENSG00000272192.1	CTD-2532N20.1	3.38	0.000781	0.0439	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:65951903	chr8:65842752~65843331:+
THCA	cis	rs10911902	0.643	rs76748438	ENSG00000228238.1	GS1-304P7.2	-3.38	0.000781	0.0439	-0.25	-0.15	Schizophrenia;	chr1:186367379	chr1:186578279~186579299:+
THCA	cis	rs4908768	0.501	rs11121212	ENSG00000238249.2	HMGN2P17	-3.38	0.000781	0.044	-0.18	-0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665934	chr1:8893409~8894151:+
THCA	cis	rs6993813	0.678	rs6469792	ENSG00000254278.1	RP11-278I4.2	-3.38	0.000781	0.044	-0.19	-0.15	Bone mineral density (hip);	chr8:118996132	chr8:119062942~119068782:-
THCA	cis	rs6993813	0.678	rs7824837	ENSG00000254278.1	RP11-278I4.2	-3.38	0.000781	0.044	-0.19	-0.15	Bone mineral density (hip);	chr8:118996497	chr8:119062942~119068782:-
THCA	cis	rs6993813	0.678	rs4416847	ENSG00000254278.1	RP11-278I4.2	-3.38	0.000781	0.044	-0.19	-0.15	Bone mineral density (hip);	chr8:118997019	chr8:119062942~119068782:-
THCA	cis	rs6993813	0.678	rs2062376	ENSG00000254278.1	RP11-278I4.2	-3.38	0.000781	0.044	-0.19	-0.15	Bone mineral density (hip);	chr8:118997770	chr8:119062942~119068782:-
THCA	cis	rs7552393	0.582	rs17520547	ENSG00000233008.4	RP11-475O6.1	-3.38	0.000781	0.044	-0.19	-0.15	Select biomarker traits;	chr1:83782650	chr1:83575776~83861023:-
THCA	cis	rs9902453	1	rs4075623	ENSG00000250462.7	LRRC37BP1	-3.38	0.000781	0.044	-0.12	-0.15	Coffee consumption (cups per day);	chr17:30059508	chr17:30629680~30637466:+
THCA	cis	rs9902453	1	rs4795525	ENSG00000250462.7	LRRC37BP1	-3.38	0.000781	0.044	-0.12	-0.15	Coffee consumption (cups per day);	chr17:30061469	chr17:30629680~30637466:+
THCA	cis	rs9902453	1	rs4239227	ENSG00000250462.7	LRRC37BP1	-3.38	0.000781	0.044	-0.12	-0.15	Coffee consumption (cups per day);	chr17:30062085	chr17:30629680~30637466:+
THCA	cis	rs11673344	0.526	rs17303902	ENSG00000267470.4	ZNF571-AS1	-3.38	0.000781	0.044	-0.19	-0.15	Obesity-related traits;	chr19:37551912	chr19:37548914~37587348:+
THCA	cis	rs947583	0.588	rs6925090	ENSG00000272189.1	RP3-325F22.5	3.38	0.000781	0.044	0.15	0.15	Phosphorus levels;	chr6:135795339	chr6:136550661~136552554:+
THCA	cis	rs2562456	0.754	rs112195516	ENSG00000213976.4	CTD-2561J22.2	-3.38	0.000781	0.044	-0.19	-0.15	Pain;	chr19:21410849	chr19:21382865~21387177:+
THCA	cis	rs9549260	0.785	rs10507484	ENSG00000275149.1	RP11-427J23.1	-3.38	0.000781	0.044	-0.2	-0.15	Red blood cell count;	chr13:40643997	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.709	rs9549247	ENSG00000275149.1	RP11-427J23.1	-3.38	0.000781	0.044	-0.2	-0.15	Red blood cell count;	chr13:40646640	chr13:40079106~40273509:-
THCA	cis	rs6832769	0.961	rs11133379	ENSG00000223305.1	RN7SKP30	3.38	0.000781	0.044	0.19	0.15	Personality dimensions;	chr4:55439944	chr4:55540502~55540835:-
THCA	cis	rs6832769	0.961	rs3736545	ENSG00000223305.1	RN7SKP30	3.38	0.000781	0.044	0.19	0.15	Personality dimensions;	chr4:55444176	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs12643926	ENSG00000223305.1	RN7SKP30	3.38	0.000781	0.044	0.19	0.15	Personality dimensions;	chr4:55444454	chr4:55540502~55540835:-
THCA	cis	rs6832769	0.961	rs12647034	ENSG00000223305.1	RN7SKP30	3.38	0.000781	0.044	0.19	0.15	Personality dimensions;	chr4:55444455	chr4:55540502~55540835:-
THCA	cis	rs2638953	0.853	rs11049635	ENSG00000278733.1	RP11-425D17.1	-3.38	0.000781	0.044	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28464293	chr12:28185625~28186190:-
THCA	cis	rs2299587	0.705	rs208770	ENSG00000253671.1	RP11-806O11.1	-3.38	0.000781	0.044	-0.18	-0.15	Economic and political preferences;	chr8:17943387	chr8:17808941~17820868:+
THCA	cis	rs7824557	0.767	rs6985460	ENSG00000255310.2	AF131215.2	3.38	0.000781	0.044	0.13	0.15	Retinal vascular caliber;	chr8:11313578	chr8:11107788~11109726:-
THCA	cis	rs2638953	0.925	rs10843166	ENSG00000247934.4	RP11-967K21.1	-3.38	0.000781	0.044	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28422811	chr12:28163298~28190738:-
THCA	cis	rs12101261	0.744	rs12050350	ENSG00000258915.1	BHLHB9P1	-3.38	0.000781	0.044	-0.19	-0.15	Graves' disease;	chr14:80951427	chr14:80981988~80983638:+
THCA	cis	rs7246967	0.736	rs436595	ENSG00000198153.8	ZNF849P	-3.38	0.000781	0.044	-0.24	-0.15	Bronchopulmonary dysplasia;	chr19:22810243	chr19:22685167~22686732:+
THCA	cis	rs881375	1	rs10760121	ENSG00000270917.1	RP11-27I1.6	-3.38	0.000781	0.044	-0.22	-0.15	Rheumatoid arthritis;	chr9:120885637	chr9:120812475~120812845:-
THCA	cis	rs3026101	0.671	rs2407	ENSG00000234327.6	AC012146.7	-3.38	0.000781	0.044	-0.12	-0.15	Body mass index;	chr17:5385708	chr17:5111468~5115004:+
THCA	cis	rs2014572	0.933	rs8109882	ENSG00000268379.1	CTC-360J11.4	3.38	0.000781	0.044	0.18	0.15	Hyperactive-impulsive symptoms;	chr19:57244250	chr19:57175233~57177921:+
THCA	cis	rs2014572	0.901	rs35658377	ENSG00000268379.1	CTC-360J11.4	3.38	0.000781	0.044	0.18	0.15	Hyperactive-impulsive symptoms;	chr19:57244259	chr19:57175233~57177921:+
THCA	cis	rs2305707	0.544	rs2470175	ENSG00000273674.3	CTD-2378E12.1	3.38	0.000782	0.044	0.32	0.15	Height;	chr15:51288566	chr15:50839875~50908599:-
THCA	cis	rs721048	0.92	rs2421862	ENSG00000242412.1	DBIL5P2	-3.38	0.000782	0.044	-0.22	-0.15	Prostate cancer;	chr2:63174838	chr2:63117851~63119542:-
THCA	cis	rs1488902	0.669	rs7128536	ENSG00000280385.1	AP000648.5	3.38	0.000782	0.044	0.14	0.15	Amyotrophic lateral sclerosis;	chr11:89623998	chr11:90193614~90198120:+
THCA	cis	rs7129220	0.528	rs11042633	ENSG00000177112.6	MRVI1-AS1	3.38	0.000782	0.044	0.22	0.15	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr11:10120011	chr11:10541272~10599932:+
THCA	cis	rs2667011	0.512	rs1995951	ENSG00000226266.5	AC009961.3	-3.38	0.000782	0.044	-0.23	-0.15	Bilirubin levels;	chr2:159944441	chr2:159670708~159712435:-
THCA	cis	rs61160187	0.555	rs34608	ENSG00000272308.1	RP11-231G3.1	-3.38	0.000782	0.044	-0.15	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:61161807	chr5:60866457~60866935:-
THCA	cis	rs2749592	0.55	rs12255038	ENSG00000275858.1	RP11-291L22.8	-3.38	0.000782	0.044	-0.18	-0.15	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38450738~38451069:-
THCA	cis	rs8030379	1	rs11259933	ENSG00000176700.18	SCAND2P	-3.38	0.000782	0.044	-0.1	-0.15	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911404	chr15:84631451~84647478:+
THCA	cis	rs2692947	0.644	rs1168976	ENSG00000235584.2	AC008268.1	-3.38	0.000782	0.044	-0.16	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96147741	chr2:95666084~95668715:+
THCA	cis	rs2692947	0.644	rs1168974	ENSG00000235584.2	AC008268.1	-3.38	0.000782	0.044	-0.16	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96149189	chr2:95666084~95668715:+
THCA	cis	rs853679	0.76	rs9393910	ENSG00000272009.1	RP1-313I6.12	-3.38	0.000782	0.044	-0.19	-0.15	Depression;	chr6:28240414	chr6:28078792~28081130:-
THCA	cis	rs853679	0.76	rs9368563	ENSG00000272009.1	RP1-313I6.12	-3.38	0.000782	0.044	-0.19	-0.15	Depression;	chr6:28240780	chr6:28078792~28081130:-
THCA	cis	rs853679	0.76	rs9295768	ENSG00000272009.1	RP1-313I6.12	-3.38	0.000782	0.044	-0.19	-0.15	Depression;	chr6:28241324	chr6:28078792~28081130:-
THCA	cis	rs3731570	0.818	rs66730758	ENSG00000231621.1	AC013264.2	-3.38	0.000782	0.044	-0.15	-0.15	Morning vs. evening chronotype;	chr2:197476277	chr2:197197991~197199273:+
THCA	cis	rs55702914	0.628	rs11883902	ENSG00000231621.1	AC013264.2	-3.38	0.000782	0.044	-0.15	-0.15	Major depression and alcohol dependence;	chr2:197476601	chr2:197197991~197199273:+
THCA	cis	rs55702914	0.628	rs6745660	ENSG00000231621.1	AC013264.2	-3.38	0.000782	0.044	-0.15	-0.15	Major depression and alcohol dependence;	chr2:197484812	chr2:197197991~197199273:+
THCA	cis	rs9353324	1	rs9444356	ENSG00000280232.1	RP11-321N4.4	3.38	0.000782	0.044	0.33	0.15	Interferon gamma-induced protein 10 levels;	chr6:85651200	chr6:85498441~85499058:-
THCA	cis	rs1728400	0.61	rs8047465	ENSG00000252311.1	RNU1-103P	3.38	0.000782	0.044	0.17	0.15	Breast cancer (survival);	chr16:86383718	chr16:85781775~85781899:-
THCA	cis	rs2018683	0.707	rs1021689	ENSG00000233517.1	AC005162.5	-3.38	0.000782	0.044	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934606	chr7:28987028~28988899:+
THCA	cis	rs2018683	0.707	rs1021690	ENSG00000233517.1	AC005162.5	-3.38	0.000782	0.044	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934871	chr7:28987028~28988899:+
THCA	cis	rs2018683	0.707	rs1021691	ENSG00000233517.1	AC005162.5	-3.38	0.000782	0.044	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934879	chr7:28987028~28988899:+
THCA	cis	rs6673928	1	rs61815632	ENSG00000234219.1	CDCA4P4	-3.38	0.000782	0.044	-0.22	-0.15	Itch intensity from mosquito bite;	chr1:206765094	chr1:207762584~207763263:+
THCA	cis	rs4723738	1	rs4723738	ENSG00000227191.5	TRGC2	-3.38	0.000782	0.044	-0.12	-0.15	Treatment response for severe sepsis;	chr7:38201307	chr7:38239580~38368091:-
THCA	cis	rs7824557	0.547	rs6601570	ENSG00000254527.1	ENPP7P12	-3.38	0.000782	0.044	-0.2	-0.15	Retinal vascular caliber;	chr8:11221858	chr8:12205759~12206389:-
THCA	cis	rs2287641	1	rs1421619	ENSG00000272156.1	RP11-477N3.1	3.38	0.000782	0.044	0.28	0.15	Cannabis dependence symptom count;	chr2:54139312	chr2:54082554~54085066:+
THCA	cis	rs10090774	0.965	rs55967138	ENSG00000280303.2	ERICD	3.38	0.000782	0.044	0.14	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140944327	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs34496768	ENSG00000280303.2	ERICD	3.38	0.000782	0.044	0.14	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140948091	chr8:140636281~140638283:+
THCA	cis	rs10090774	0.965	rs11167012	ENSG00000280303.2	ERICD	3.38	0.000782	0.044	0.14	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140958309	chr8:140636281~140638283:+
THCA	cis	rs2662776	0.967	rs10753606	ENSG00000232995.6	RGS5	3.38	0.000782	0.044	0.13	0.15	Lead levels in blood;	chr1:163186734	chr1:163244505~163321894:-
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000271064.1	RP11-792A8.3	3.38	0.000782	0.044	0.2	0.15	Corneal structure;	chr7:66801919	chr7:66748838~66749077:-
THCA	cis	rs2013441	0.866	rs2526473	ENSG00000261033.1	RP11-209D14.2	3.38	0.000782	0.044	0.22	0.15	Obesity-related traits;	chr17:20234165	chr17:20008051~20009234:-
THCA	cis	rs3126085	0.935	rs10888466	ENSG00000237975.5	FLG-AS1	3.38	0.000782	0.044	0.24	0.15	Atopic dermatitis;	chr1:152193747	chr1:152168125~152445456:+
THCA	cis	rs7713065	0.84	rs10077785	ENSG00000237714.1	P4HA2-AS1	3.38	0.000783	0.044	0.25	0.15	Lung function (FEV1/FVC);	chr5:132465466	chr5:132184876~132192808:+
THCA	cis	rs7520050	0.778	rs2088102	ENSG00000281912.1	LINC01144	3.38	0.000783	0.044	0.1	0.15	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45303910~45305619:+
THCA	cis	rs6674176	0.551	rs2486003	ENSG00000237950.1	RP11-7O11.3	3.38	0.000783	0.044	0.22	0.15	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43984098	chr1:43944370~43946551:-
THCA	cis	rs881827	0.714	rs9979286	ENSG00000230982.1	DSTNP1	3.38	0.000783	0.044	0.17	0.15	Lymphocyte counts;	chr21:46654751	chr21:46653558~46654022:-
THCA	cis	rs1124769	0.957	rs12443062	ENSG00000259378.1	DCAF13P3	3.38	0.000783	0.044	0.25	0.15	Cognitive performance;	chr15:51080530	chr15:50944663~50945996:+
THCA	cis	rs11751172	0.651	rs7758107	ENSG00000271857.1	RP1-244F24.1	-3.38	0.000783	0.044	-0.1	-0.15	Mosquito bite size;Itch intensity from mosquito bite;	chr6:45568622	chr6:45421079~45422005:-
THCA	cis	rs72634258	0.554	rs7556518	ENSG00000224315.2	RPL7P7	-3.38	0.000783	0.044	-0.28	-0.15	Inflammatory bowel disease;	chr1:7787786	chr1:8786211~8786913:-
THCA	cis	rs6498142	1	rs6498142	ENSG00000263033.2	RP11-396B14.2	3.38	0.000783	0.044	0.16	0.15	Immunoglobulin A;	chr16:10987392	chr16:11196177~11224969:+
THCA	cis	rs1577917	0.56	rs9450288	ENSG00000280232.1	RP11-321N4.4	-3.38	0.000783	0.044	-0.18	-0.15	Response to antipsychotic treatment;	chr6:85511868	chr6:85498441~85499058:-
THCA	cis	rs939960	0.879	rs34118164	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150591734	chr7:150047609~150047854:-
THCA	cis	rs939960	0.797	rs62502300	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150591975	chr7:150047609~150047854:-
THCA	cis	rs939960	0.836	rs35346811	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150592015	chr7:150047609~150047854:-
THCA	cis	rs939960	0.879	rs34803745	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150592303	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs4584065	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150593732	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs2888664	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150594006	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs2373805	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150594047	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs2373806	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150594121	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs35428045	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150594532	chr7:150047609~150047854:-
THCA	cis	rs939960	0.729	rs34990905	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150594648	chr7:150047609~150047854:-
THCA	cis	rs939960	0.879	rs62502326	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150595062	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs6969250	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150595457	chr7:150047609~150047854:-
THCA	cis	rs939960	0.917	rs11981436	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150595679	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs11981515	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150595753	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs12673168	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150596149	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs35512856	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150597203	chr7:150047609~150047854:-
THCA	cis	rs939960	0.614	rs10952276	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150601395	chr7:150047609~150047854:-
THCA	cis	rs939960	0.579	rs10952277	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.044	0.22	0.15	Neutrophil percentage of white cells;	chr7:150601444	chr7:150047609~150047854:-
THCA	cis	rs9329221	0.506	rs17689674	ENSG00000261451.1	RP11-981G7.1	3.38	0.000783	0.044	0.19	0.15	Neuroticism;	chr8:10124344	chr8:10433672~10438312:+
THCA	cis	rs1144333	0.655	rs114457542	ENSG00000272855.1	RP5-1102E8.3	-3.38	0.000783	0.044	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75983629	chr1:76636877~76637339:+
THCA	cis	rs1144333	0.655	rs76735776	ENSG00000272855.1	RP5-1102E8.3	-3.38	0.000783	0.044	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75989526	chr1:76636877~76637339:+
THCA	cis	rs205611	0.769	rs34790684	ENSG00000224646.2	AC007387.2	-3.38	0.000783	0.044	-0.29	-0.15	Iris characteristics;	chr2:74768622	chr2:74754670~74754819:-
THCA	cis	rs7927592	0.626	rs11228279	ENSG00000160172.9	FAM86C2P	-3.38	0.000783	0.044	-0.14	-0.15	Total body bone mineral density;	chr11:68542212	chr11:67791648~67805336:-
THCA	cis	rs7010267	0.593	rs2055101	ENSG00000254278.1	RP11-278I4.2	-3.38	0.000783	0.044	-0.18	-0.15	Total body bone mineral density (age 45-60);	chr8:118874684	chr8:119062942~119068782:-
THCA	cis	rs7208859	0.573	rs73267873	ENSG00000265443.1	CTD-2349P21.6	-3.38	0.000783	0.044	-0.24	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30726305~30727564:-
THCA	cis	rs17826219	0.561	rs4085382	ENSG00000265443.1	CTD-2349P21.6	-3.38	0.000783	0.044	-0.24	-0.15	Body mass index;	chr17:30744184	chr17:30726305~30727564:-
THCA	cis	rs853679	0.567	rs13209596	ENSG00000226314.6	ZNF192P1	-3.38	0.000783	0.044	-0.18	-0.15	Depression;	chr6:28428413	chr6:28161781~28169594:+
THCA	cis	rs853679	0.567	rs9969098	ENSG00000226314.6	ZNF192P1	-3.38	0.000783	0.044	-0.18	-0.15	Depression;	chr6:28430971	chr6:28161781~28169594:+
THCA	cis	rs853679	0.567	rs7740429	ENSG00000226314.6	ZNF192P1	-3.38	0.000783	0.044	-0.18	-0.15	Depression;	chr6:28431469	chr6:28161781~28169594:+
THCA	cis	rs853679	0.567	rs16894106	ENSG00000226314.6	ZNF192P1	-3.38	0.000783	0.044	-0.18	-0.15	Depression;	chr6:28432562	chr6:28161781~28169594:+
THCA	cis	rs7267979	0.789	rs1983974	ENSG00000276952.1	RP5-965G21.6	-3.38	0.000783	0.0441	-0.16	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25284915~25285588:-
THCA	cis	rs9309711	0.737	rs9284795	ENSG00000271868.1	RP11-1293J14.1	-3.38	0.000783	0.0441	-0.22	-0.15	Neurofibrillary tangles;	chr2:3488294	chr2:3496956~3497428:+
THCA	cis	rs939960	0.959	rs34208822	ENSG00000276538.1	RP11-545G3.2	3.38	0.000783	0.0441	0.22	0.15	Neutrophil percentage of white cells;	chr7:150615063	chr7:150047609~150047854:-
THCA	cis	rs8103033	0.676	rs993983	ENSG00000226025.8	LGALS17A	-3.38	0.000783	0.0441	-0.14	-0.15	Obesity-related traits;	chr19:39660840	chr19:39679374~39686373:+
THCA	cis	rs763121	0.853	rs7289577	ENSG00000272669.1	RP3-508I15.21	-3.38	0.000783	0.0441	-0.11	-0.15	Menopause (age at onset);	chr22:38646209	chr22:38742625~38743115:+
THCA	cis	rs1357692	0.899	rs2030675	ENSG00000238250.1	ST6GAL2-IT1	-3.38	0.000783	0.0441	-0.15	-0.15	Alzheimer's disease;	chr2:107063018	chr2:106822923~106825031:-
THCA	cis	rs982100	0.556	rs34109059	ENSG00000226856.4	AC093901.1	3.38	0.000783	0.0441	0.24	0.15	Alzheimer disease and age of onset;	chr2:117649251	chr2:118132128~118186386:-
THCA	cis	rs13126694	0.598	rs10005547	ENSG00000248429.4	RP11-597D13.9	3.38	0.000783	0.0441	0.17	0.15	Blood osmolality (transformed sodium);	chr4:158092407	chr4:158170752~158202877:+
THCA	cis	rs13126694	0.633	rs9993747	ENSG00000248429.4	RP11-597D13.9	3.38	0.000783	0.0441	0.17	0.15	Blood osmolality (transformed sodium);	chr4:158092421	chr4:158170752~158202877:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000230295.1	RP11-458F8.2	-3.38	0.000784	0.0441	-0.14	-0.15	Aortic root size;	chr7:66112359	chr7:66880708~66882981:+
THCA	cis	rs34779708	0.966	rs12775799	ENSG00000233200.1	RP11-324I22.2	3.38	0.000784	0.0441	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs11010122	ENSG00000233200.1	RP11-324I22.2	3.38	0.000784	0.0441	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.9	rs73262807	ENSG00000233200.1	RP11-324I22.2	3.38	0.000784	0.0441	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs4934736	ENSG00000233200.1	RP11-324I22.2	3.38	0.000784	0.0441	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs17591781	ENSG00000233200.1	RP11-324I22.2	3.38	0.000784	0.0441	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs11010125	ENSG00000233200.1	RP11-324I22.2	3.38	0.000784	0.0441	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs7077242	ENSG00000233200.1	RP11-324I22.2	-3.38	0.000784	0.0441	-0.18	-0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs17591857	ENSG00000233200.1	RP11-324I22.2	-3.38	0.000784	0.0441	-0.18	-0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35219894~35230598:-
THCA	cis	rs77147124	1	rs2419604	ENSG00000225292.2	RP11-57H14.3	-3.38	0.000784	0.0441	-0.21	-0.15	HDL cholesterol;	chr10:112184513	chr10:112888735~112906111:+
THCA	cis	rs34779708	0.931	rs35388511	ENSG00000233200.1	RP11-324I22.2	3.38	0.000784	0.0441	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs34815241	ENSG00000233200.1	RP11-324I22.2	3.38	0.000784	0.0441	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35219894~35230598:-
THCA	cis	rs7737355	0.853	rs10051003	ENSG00000237714.1	P4HA2-AS1	3.38	0.000784	0.0441	0.21	0.15	Life satisfaction;	chr5:131736717	chr5:132184876~132192808:+
THCA	cis	rs1908814	0.503	rs34657250	ENSG00000227888.4	FAM66A	-3.38	0.000784	0.0441	-0.2	-0.15	Neuroticism;	chr8:11937864	chr8:12362019~12388296:+
THCA	cis	rs2652822	0.901	rs4775622	ENSG00000259459.4	RP11-321G12.1	-3.38	0.000784	0.0441	-0.13	-0.15	Metabolic traits;	chr15:63115980	chr15:63390136~63438320:+
THCA	cis	rs6929812	0.702	rs4713096	ENSG00000271755.1	RP1-153G14.4	-3.38	0.000784	0.0441	-0.17	-0.15	Neuroticism (multi-trait analysis);	chr6:27411630	chr6:27404010~27406964:-
THCA	cis	rs2436845	0.614	rs2436854	ENSG00000253669.3	KB-1732A1.1	-3.38	0.000784	0.0441	-0.16	-0.15	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813809	chr8:102805517~102809971:+
THCA	cis	rs603446	0.967	rs180375	ENSG00000254851.1	RP11-109L13.1	3.38	0.000784	0.0441	0.2	0.15	Triglycerides;	chr11:116720324	chr11:117135528~117138582:+
THCA	cis	rs34787248	1	rs34787248	ENSG00000261839.1	RP1-265C24.8	3.38	0.000784	0.0441	0.19	0.15	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28136849~28139678:+
THCA	cis	rs2886497	0.947	rs1511824	ENSG00000224215.1	RP11-371A19.2	-3.38	0.000784	0.0441	-0.19	-0.15	Major depression and alcohol dependence;	chr10:23378851	chr10:23343957~23345181:+
THCA	cis	rs9309473	1	rs7564890	ENSG00000273245.1	RP11-434P11.2	3.38	0.000784	0.0441	0.21	0.15	Metabolite levels;	chr2:73414725	chr2:73750256~73750786:-
THCA	cis	rs9925964	0.933	rs9929899	ENSG00000262766.1	RP11-196G11.4	-3.38	0.000784	0.0441	-0.1	-0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31118078~31118747:+
THCA	cis	rs1577917	0.655	rs9342045	ENSG00000280232.1	RP11-321N4.4	-3.38	0.000784	0.0441	-0.18	-0.15	Response to antipsychotic treatment;	chr6:85715430	chr6:85498441~85499058:-
THCA	cis	rs743757	0.652	rs35655236	ENSG00000232352.1	SEMA3B-AS1	3.38	0.000784	0.0441	0.24	0.15	Diastolic blood pressure;	chr3:50560616	chr3:50266641~50267371:-
THCA	cis	rs2288884	0.515	rs2869602	ENSG00000269483.1	AC006272.1	3.38	0.000784	0.0441	0.17	0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:51839924~51843324:-
THCA	cis	rs939960	0.959	rs34035483	ENSG00000224016.2	RP11-728K20.1	3.38	0.000784	0.0441	0.21	0.15	Neutrophil percentage of white cells;	chr7:150597126	chr7:149891191~149909704:-
THCA	cis	rs34375054	0.546	rs4765235	ENSG00000279233.1	RP11-158L12.4	-3.38	0.000784	0.0441	-0.15	-0.15	Post bronchodilator FEV1/FVC ratio;	chr12:125260332	chr12:125138245~125141711:+
THCA	cis	rs3935996	1	rs3935996	ENSG00000233147.1	RP11-90C4.1	-3.38	0.000784	0.0441	-0.14	-0.15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;Reticulocyte fraction of red cells;	chr1:55826667	chr1:55823807~55868248:+
THCA	cis	rs748404	0.646	rs2253268	ENSG00000275601.1	AC011330.13	-3.38	0.000784	0.0441	-0.18	-0.15	Lung cancer;	chr15:43508770	chr15:43642389~43643023:-
THCA	cis	rs208520	0.69	rs4710564	ENSG00000233859.2	ADH5P4	3.38	0.000784	0.0441	0.23	0.15	Exhaled nitric oxide output;	chr6:66113585	chr6:65836930~65838039:-
THCA	cis	rs4886920	0.694	rs12902298	ENSG00000260776.4	RP11-114H24.2	-3.38	0.000784	0.0441	-0.18	-0.15	Neuroticism;	chr15:77793076	chr15:77914217~77926846:-
THCA	cis	rs4886920	0.694	rs62007851	ENSG00000260776.4	RP11-114H24.2	-3.38	0.000784	0.0441	-0.18	-0.15	Neuroticism;	chr15:77794082	chr15:77914217~77926846:-
THCA	cis	rs9329221	0.537	rs6983332	ENSG00000255310.2	AF131215.2	-3.38	0.000784	0.0441	-0.13	-0.15	Neuroticism;	chr8:10120408	chr8:11107788~11109726:-
THCA	cis	rs2447820	0.588	rs55746012	ENSG00000263432.2	RN7SL689P	3.38	0.000784	0.0441	0.19	0.15	Migraine;	chr5:123059150	chr5:123022487~123022783:-
THCA	cis	rs6138458	0.743	rs3746330	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000784	0.0441	-0.2	-0.15	Blood protein levels;	chr20:25019159	chr20:25239007~25245229:-
THCA	cis	rs1383484	0.761	rs28401196	ENSG00000230373.7	GOLGA6L5P	-3.38	0.000785	0.0441	-0.16	-0.15	Height;	chr15:83878609	chr15:84507885~84516814:-
THCA	cis	rs9393777	0.778	rs35526527	ENSG00000220721.1	OR1F12	3.38	0.000785	0.0441	0.3	0.15	Intelligence (multi-trait analysis);	chr6:27074508	chr6:28073316~28074233:+
THCA	cis	rs765751	0.965	rs12403367	ENSG00000228536.1	RP11-392O17.1	-3.38	0.000785	0.0441	-0.18	-0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219454013	chr1:219409681~219411941:-
THCA	cis	rs1765142	0.55	rs640494	ENSG00000242353.1	RP4-710M3.1	3.38	0.000785	0.0441	0.13	0.15	Schizophrenia;	chr11:30386514	chr11:30368148~30368646:+
THCA	cis	rs11018904	0.906	rs10501713	ENSG00000280367.1	RP11-121L10.2	3.38	0.000785	0.0441	0.21	0.15	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90223153~90226538:+
THCA	cis	rs301901	0.734	rs10941321	ENSG00000250155.1	CTD-2353F22.1	-3.38	0.000785	0.0441	-0.15	-0.15	Height;	chr5:37213248	chr5:36666214~36725195:-
THCA	cis	rs2228479	0.85	rs17226428	ENSG00000274627.1	RP11-104N10.2	-3.38	0.000785	0.0441	-0.27	-0.15	Skin colour saturation;	chr16:89776476	chr16:89516797~89522217:+
THCA	cis	rs1799949	0.93	rs34210004	ENSG00000279602.1	CTD-3014M21.1	-3.38	0.000785	0.0441	-0.19	-0.15	Menopause (age at onset);	chr17:43218318	chr17:43360041~43361361:-
THCA	cis	rs7937890	0.598	rs10734225	ENSG00000251991.1	RNU7-49P	3.38	0.000785	0.0441	0.18	0.15	Mitochondrial DNA levels;	chr11:14421448	chr11:14478892~14478953:+
THCA	cis	rs559555	0.612	rs585890	ENSG00000276517.1	AL133243.2	-3.38	0.000785	0.0441	-0.14	-0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31594361	chr2:32526504~32529507:+
THCA	cis	rs76439304	1	rs2046692	ENSG00000247903.1	RP11-421F16.3	-3.38	0.000785	0.0441	-0.23	-0.15	Mean corpuscular volume;	chr12:26912090	chr12:26971586~26979582:+
THCA	cis	rs6561151	0.681	rs17462017	ENSG00000274001.1	RP11-5G9.5	3.38	0.000785	0.0441	0.25	0.15	Crohn's disease;	chr13:43898099	chr13:43877715~43878163:-
THCA	cis	rs6561151	0.681	rs17571812	ENSG00000274001.1	RP11-5G9.5	3.38	0.000785	0.0441	0.25	0.15	Crohn's disease;	chr13:43898326	chr13:43877715~43878163:-
THCA	cis	rs524281	0.861	rs7120326	ENSG00000255038.1	RP11-1167A19.2	-3.38	0.000785	0.0441	-0.18	-0.15	Electroencephalogram traits;	chr11:66081785	chr11:66067277~66069619:-
THCA	cis	rs7937682	0.587	rs611607	ENSG00000196167.8	COLCA1	-3.38	0.000785	0.0441	-0.15	-0.15	Primary sclerosing cholangitis;	chr11:111479040	chr11:111290787~111305045:-
THCA	cis	rs2191566	1	rs384544	ENSG00000267114.1	CTB-129P6.11	-3.38	0.000785	0.0441	-0.12	-0.15	Acute lymphoblastic leukemia (childhood);	chr19:44001103	chr19:44950044~44954007:-
THCA	cis	rs1440410	0.798	rs13128884	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143186669	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.835	rs4582112	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143190579	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.866	rs13139457	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143192647	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs4690779	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143198780	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs13106497	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143199527	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.835	rs4234886	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143203339	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.835	rs6820538	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143207923	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.835	rs10029373	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143208965	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.835	rs11737209	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143211519	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.835	rs11933603	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143212704	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs10001113	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143215252	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.835	rs4513514	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143218559	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs34168479	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143219439	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.835	rs28649839	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143225047	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.798	rs1440416	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143233882	chr4:142933195~143184861:-
THCA	cis	rs1440410	0.666	rs2165302	ENSG00000250326.1	RP11-284M14.1	-3.38	0.000785	0.0441	-0.14	-0.15	Ischemic stroke;	chr4:143234744	chr4:142933195~143184861:-
THCA	cis	rs11634944	1	rs4906940	ENSG00000251896.1	SNORD116-27	-3.38	0.000785	0.0441	-0.18	-0.15	Interleukin-8 levels;	chr15:24956512	chr15:25101575~25101666:+
THCA	cis	rs3784262	1	rs4646629	ENSG00000259250.1	RP11-50C13.1	3.38	0.000785	0.0441	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57963017	chr15:58587507~58591676:+
THCA	cis	rs3784262	1	rs4646627	ENSG00000259250.1	RP11-50C13.1	3.38	0.000785	0.0441	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57963107	chr15:58587507~58591676:+
THCA	cis	rs4704187	0.687	rs12653162	ENSG00000250889.2	LINC01336	-3.38	0.000785	0.0441	-0.16	-0.15	Response to amphetamines;	chr5:75095841	chr5:75047719~75052843:-
THCA	cis	rs77633900	0.803	rs2469564	ENSG00000196274.5	Metazoa_SRP	3.38	0.000785	0.0441	0.27	0.15	Glioma;Non-glioblastoma glioma;	chr15:76197614	chr15:76230048~76230390:-
THCA	cis	rs6901152	0.895	rs9373387	ENSG00000217648.1	RP1-95L4.4	-3.38	0.000785	0.0441	-0.17	-0.15	Acute lymphoblastic leukemia (childhood);	chr6:143313527	chr6:143342246~143343383:+
THCA	cis	rs2235649	0.828	rs9925354	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1799865	chr16:883780~885090:+
THCA	cis	rs2235649	0.828	rs9938694	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1799871	chr16:883780~885090:+
THCA	cis	rs2235649	0.828	rs9936486	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1799887	chr16:883780~885090:+
THCA	cis	rs2235649	0.753	rs4316755	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1799915	chr16:883780~885090:+
THCA	cis	rs2235649	0.833	rs2011088	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1800090	chr16:883780~885090:+
THCA	cis	rs2235649	0.833	rs7190337	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1800468	chr16:883780~885090:+
THCA	cis	rs2235649	0.833	rs7189070	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1800812	chr16:883780~885090:+
THCA	cis	rs2235649	0.833	rs9926962	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1801825	chr16:883780~885090:+
THCA	cis	rs2235649	0.833	rs9929185	ENSG00000260022.1	LA16c-306A4.1	3.38	0.000785	0.0441	0.22	0.15	Blood metabolite levels;	chr16:1802069	chr16:883780~885090:+
THCA	cis	rs11089937	0.667	rs78549985	ENSG00000215456.5	BCRP4	3.38	0.000785	0.0441	0.2	0.15	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22630061~22636153:+
THCA	cis	rs9392556	0.829	rs660560	ENSG00000230648.1	RP3-406P24.3	3.38	0.000785	0.0441	0.19	0.15	Blood metabolite levels;	chr6:4125707	chr6:4018843~4021215:-
THCA	cis	rs321358	0.731	rs494921	ENSG00000271390.1	RP11-89C3.3	-3.38	0.000785	0.0441	-0.24	-0.15	Body mass index;	chr11:111140385	chr11:111089870~111090368:-
THCA	cis	rs12546962	0.654	rs10089120	ENSG00000254153.1	CTA-398F10.2	3.38	0.000785	0.0441	0.17	0.15	Body mass index;	chr8:9351551	chr8:8456909~8461337:-
THCA	cis	rs5751168	0.605	rs5758503	ENSG00000240160.3	RN7SL263P	3.38	0.000785	0.0441	0.25	0.15	Prostate cancer (SNP x SNP interaction);	chr22:22498765	chr22:23261782~23262071:-
THCA	cis	rs858239	0.676	rs3807459	ENSG00000230042.1	AK3P3	-3.38	0.000785	0.0441	-0.2	-0.15	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23129178~23129841:+
THCA	cis	rs728616	0.681	rs56184245	ENSG00000278616.1	BEND3P3	3.38	0.000785	0.0441	0.15	0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80258800	chr10:79682997~79685436:+
THCA	cis	rs7772697	0.508	rs6570926	ENSG00000223701.3	RAET1E-AS1	3.38	0.000785	0.0442	0.22	0.15	Diabetic retinopathy;	chr6:149049246	chr6:149884431~149919508:+
THCA	cis	rs2692947	0.673	rs584811	ENSG00000236750.1	AC009237.16	3.38	0.000785	0.0442	0.16	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96404141	chr2:95641634~95641980:-
THCA	cis	rs1926657	0.877	rs4148464	ENSG00000223298.1	RNY3P8	-3.38	0.000785	0.0442	-0.2	-0.15	Breast cancer;	chr13:95217048	chr13:95310830~95310955:-
THCA	cis	rs11634944	1	rs11632945	ENSG00000251896.1	SNORD116-27	-3.38	0.000785	0.0442	-0.18	-0.15	Interleukin-8 levels;	chr15:24958411	chr15:25101575~25101666:+
THCA	cis	rs72672639	0.85	rs17797394	ENSG00000253878.4	RP11-347C18.3	-3.38	0.000786	0.0442	-0.24	-0.15	Carotid plaque burden;	chr8:94268824	chr8:94950037~94951396:+
THCA	cis	rs1974653	0.672	rs9606231	ENSG00000236499.2	LINC00896	3.38	0.000786	0.0442	0.16	0.15	Schizophrenia;	chr22:20077753	chr22:20206397~20208524:+
THCA	cis	rs7903847	0.692	rs7900255	ENSG00000225850.3	RP11-452K12.4	3.38	0.000786	0.0442	0.16	0.15	Granulocyte percentage of myeloid white cells;	chr10:97397818	chr10:97334564~97343203:+
THCA	cis	rs7551222	0.752	rs10900594	ENSG00000240219.1	RP11-430C7.5	3.38	0.000786	0.0442	0.15	0.15	Schizophrenia;	chr1:204501001	chr1:204626775~204629712:+
THCA	cis	rs7439493	0.903	rs11728699	ENSG00000247950.5	SEC24B-AS1	-3.38	0.000786	0.0442	-0.1	-0.15	Blood protein levels;	chr4:109728735	chr4:109347475~109433817:-
THCA	cis	rs11239930	0.517	rs3011809	ENSG00000180867.10	PDIA3P1	3.38	0.000786	0.0442	0.15	0.15	AIDS progression;	chr1:147077593	chr1:147178113~147179622:+
THCA	cis	rs7615952	0.599	rs16834938	ENSG00000248787.1	RP11-666A20.4	-3.38	0.000786	0.0442	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:125987203	chr3:125908005~125910272:-
THCA	cis	rs6696239	0.794	rs11588850	ENSG00000227711.2	RP11-275O4.5	-3.38	0.000786	0.0442	-0.25	-0.15	Height;	chr1:227739541	chr1:227509028~227520477:-
THCA	cis	rs12295638	0.818	rs12295913	ENSG00000254862.4	RP11-159H22.2	-3.38	0.000786	0.0442	-0.21	-0.15	Obesity (extreme);	chr11:26621113	chr11:27471729~27482433:+
THCA	cis	rs7819412	0.668	rs2409721	ENSG00000206014.6	OR7E161P	3.38	0.000786	0.0442	0.18	0.15	Triglycerides;	chr8:11180735	chr8:11928597~11929563:-
THCA	cis	rs6743226	0.603	rs1106523	ENSG00000223374.1	AC005104.3	3.38	0.000786	0.0442	0.11	0.15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241312124	chr2:241351340~241353104:-
THCA	cis	rs7631605	0.565	rs17206856	ENSG00000224080.1	UBE2FP1	3.38	0.000786	0.0442	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37248719	chr3:37143512~37143958:-
THCA	cis	rs7631605	0.586	rs62244333	ENSG00000224080.1	UBE2FP1	3.38	0.000786	0.0442	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37255171	chr3:37143512~37143958:-
THCA	cis	rs1005277	0.522	rs7090858	ENSG00000273019.1	RP11-508N22.13	3.38	0.000786	0.0442	0.17	0.15	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38149968~38150293:+
THCA	cis	rs7259376	0.807	rs6511348	ENSG00000269345.1	VN1R85P	3.38	0.000786	0.0442	0.17	0.15	Menopause (age at onset);	chr19:22374572	chr19:22174766~22175191:-
THCA	cis	rs4948275	0.773	rs2650709	ENSG00000233643.2	RP11-491H19.1	3.38	0.000786	0.0442	0.17	0.15	Night sleep phenotypes;	chr10:61483034	chr10:61781745~61821246:-
THCA	cis	rs7985	0.595	rs2032576	ENSG00000244625.4	MIATNB	3.38	0.000786	0.0442	0.18	0.15	Electroencephalogram traits;	chr22:26693692	chr22:26672767~26780207:+
THCA	cis	rs9596863	0.898	rs12860689	ENSG00000136149.6	RPL13AP25	-3.38	0.000786	0.0442	-0.17	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53741670	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.747	rs9568899	ENSG00000136149.6	RPL13AP25	-3.38	0.000786	0.0442	-0.17	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53743338	chr13:54440704~54441315:-
THCA	cis	rs4930561	0.714	rs1540209	ENSG00000184795.9	UNC93B5	-3.38	0.000786	0.0442	-0.19	-0.15	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68161053	chr11:67711702~67716005:-
THCA	cis	rs354225	0.544	rs13391522	ENSG00000212175.1	SNORA12	-3.38	0.000786	0.0442	-0.19	-0.15	Schizophrenia;	chr2:54578717	chr2:55565703~55565850:+
THCA	cis	rs11673344	0.526	rs73035160	ENSG00000268499.1	CTB-102L5.8	-3.38	0.000786	0.0442	-0.18	-0.15	Obesity-related traits;	chr19:37655135	chr19:38199836~38200934:+
THCA	cis	rs11673344	0.526	rs1871196	ENSG00000268499.1	CTB-102L5.8	-3.38	0.000786	0.0442	-0.18	-0.15	Obesity-related traits;	chr19:37656022	chr19:38199836~38200934:+
THCA	cis	rs2692947	0.8	rs2692936	ENSG00000232931.4	LINC00342	3.38	0.000786	0.0442	0.13	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96079981	chr2:95807118~95816215:-
THCA	cis	rs15676	0.783	rs7858732	ENSG00000234771.3	SLC25A25-AS1	-3.38	0.000786	0.0442	-0.13	-0.15	Blood metabolite levels;	chr9:128801261	chr9:128108581~128118693:-
THCA	cis	rs3785574	0.962	rs57553639	ENSG00000279369.1	RP11-51F16.1	3.38	0.000786	0.0442	0.11	0.15	Height;	chr17:63771139	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs62077509	ENSG00000279369.1	RP11-51F16.1	3.38	0.000786	0.0442	0.11	0.15	Height;	chr17:63771613	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs56295011	ENSG00000279369.1	RP11-51F16.1	3.38	0.000786	0.0442	0.11	0.15	Height;	chr17:63772999	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs62077512	ENSG00000279369.1	RP11-51F16.1	3.38	0.000786	0.0442	0.11	0.15	Height;	chr17:63774075	chr17:63700847~63702670:+
THCA	cis	rs3785574	0.962	rs58131426	ENSG00000279369.1	RP11-51F16.1	3.38	0.000786	0.0442	0.11	0.15	Height;	chr17:63777015	chr17:63700847~63702670:+
THCA	cis	rs17622252	0.722	rs17695674	ENSG00000280989.1	LINC00581	-3.38	0.000786	0.0442	-0.28	-0.15	Bipolar disorder;	chr6:21354864	chr6:21486061~21511895:-
THCA	cis	rs7960884	0.655	rs7295744	ENSG00000177359.16	RP11-551L14.1	3.38	0.000786	0.0442	0.17	0.15	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31231051	chr12:31111652~31206154:-
THCA	cis	rs10090774	0.932	rs11783270	ENSG00000280303.2	ERICD	-3.38	0.000786	0.0442	-0.14	-0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140725695	chr8:140636281~140638283:+
THCA	cis	rs6142102	0.812	rs6120440	ENSG00000228265.4	RALY-AS1	3.38	0.000786	0.0442	0.15	0.15	Skin pigmentation;	chr20:33929779	chr20:33983052~33994357:-
THCA	cis	rs7119	0.604	rs2271396	ENSG00000259362.2	RP11-307C19.1	3.38	0.000786	0.0442	0.19	0.15	Type 2 diabetes;	chr15:77615193	chr15:77525540~77534110:+
THCA	cis	rs2692947	0.599	rs7561198	ENSG00000232931.4	LINC00342	-3.38	0.000786	0.0442	-0.12	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96109233	chr2:95807118~95816215:-
THCA	cis	rs2692947	0.702	rs2312955	ENSG00000232931.4	LINC00342	-3.38	0.000786	0.0442	-0.12	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96111420	chr2:95807118~95816215:-
THCA	cis	rs10246939	0.543	rs35836873	ENSG00000270923.1	TAS2R6P	-3.38	0.000786	0.0442	-0.14	-0.15	Bitter taste perception;	chr7:141844010	chr7:141787815~141788640:+
THCA	cis	rs10246939	0.543	rs9640358	ENSG00000270923.1	TAS2R6P	-3.38	0.000786	0.0442	-0.14	-0.15	Bitter taste perception;	chr7:141844082	chr7:141787815~141788640:+
THCA	cis	rs524281	0.861	rs10896095	ENSG00000255038.1	RP11-1167A19.2	-3.38	0.000786	0.0442	-0.18	-0.15	Electroencephalogram traits;	chr11:66195089	chr11:66067277~66069619:-
THCA	cis	rs12893668	0.543	rs1799796	ENSG00000258735.1	LINC00637	-3.38	0.000787	0.0442	-0.2	-0.15	Reticulocyte count;	chr14:103699590	chr14:103847721~103858049:+
THCA	cis	rs12893668	0.514	rs3212090	ENSG00000258735.1	LINC00637	-3.38	0.000787	0.0442	-0.2	-0.15	Reticulocyte count;	chr14:103702526	chr14:103847721~103858049:+
THCA	cis	rs10824518	0.866	rs10824534	ENSG00000199664.1	RNU6-1266P	-3.38	0.000787	0.0442	-0.2	-0.15	Myopia;	chr10:77378080	chr10:77776951~77777055:-
THCA	cis	rs2980436	1	rs2980436	ENSG00000248538.5	RP11-10A14.5	3.38	0.000787	0.0442	0.18	0.15	Schizophrenia;	chr8:8234503	chr8:9189011~9202854:+
THCA	cis	rs9333290	0.93	rs12151442	ENSG00000259915.2	RP11-410E4.1	3.38	0.000787	0.0442	0.19	0.15	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186673120	chr2:186354570~186356773:-
THCA	cis	rs9816784	0.576	rs12631246	ENSG00000185485.13	SDHAP1	3.38	0.000787	0.0442	0.14	0.15	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195959748~195990318:-
THCA	cis	rs3809060	0.571	rs5030241	ENSG00000270903.1	HNRNPA3P9	-3.38	0.000787	0.0442	-0.14	-0.15	Inguinal hernia;	chr11:32402750	chr11:32591793~32592771:-
THCA	cis	rs763121	0.853	rs5750622	ENSG00000225450.1	RP3-508I15.14	-3.38	0.000787	0.0442	-0.12	-0.15	Menopause (age at onset);	chr22:38560459	chr22:38739003~38749041:+
THCA	cis	rs2933343	0.7	rs1680778	ENSG00000261159.1	RP11-723O4.9	3.38	0.000787	0.0442	0.16	0.15	IgG glycosylation;	chr3:128895342	chr3:128859716~128860526:-
THCA	cis	rs2446066	0.659	rs34109204	ENSG00000257379.1	RP11-793H13.8	3.38	0.000787	0.0442	0.24	0.15	Red blood cell count;	chr12:53478499	chr12:53441741~53467528:+
THCA	cis	rs7572644	0.766	rs13003383	ENSG00000223522.1	AC093690.1	-3.38	0.000787	0.0442	-0.2	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28012896	chr2:28307691~28310459:-
THCA	cis	rs11069062	0.585	rs10851019	ENSG00000270482.1	RP11-131L12.2	3.38	0.000787	0.0442	0.13	0.15	Obesity-related traits;	chr12:118699777	chr12:118375350~118376275:-
THCA	cis	rs7615952	0.576	rs1127717	ENSG00000248787.1	RP11-666A20.4	-3.38	0.000787	0.0442	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:126107216	chr3:125908005~125910272:-
THCA	cis	rs6142618	0.562	rs6061185	ENSG00000224452.1	RSL24D1P6	-3.38	0.000787	0.0442	-0.18	-0.15	Inflammatory bowel disease;	chr20:32143669	chr20:32170390~32170790:-
THCA	cis	rs3733418	0.929	rs7657444	ENSG00000248632.1	RP11-366M4.11	3.38	0.000787	0.0442	0.23	0.15	Obesity-related traits;	chr4:164965407	chr4:164968587~164970002:-
THCA	cis	rs3733418	0.929	rs13134940	ENSG00000248632.1	RP11-366M4.11	3.38	0.000787	0.0442	0.23	0.15	Obesity-related traits;	chr4:164968460	chr4:164968587~164970002:-
THCA	cis	rs3733418	0.929	rs13110309	ENSG00000248632.1	RP11-366M4.11	3.38	0.000787	0.0442	0.23	0.15	Obesity-related traits;	chr4:164968520	chr4:164968587~164970002:-
THCA	cis	rs9863	0.827	rs12823740	ENSG00000269938.1	RP11-214K3.20	-3.38	0.000787	0.0442	-0.17	-0.15	White blood cell count;	chr12:123973455	chr12:123968023~123968579:-
THCA	cis	rs7646881	0.504	rs61080878	ENSG00000279311.1	RP11-170K4.2	-3.38	0.000787	0.0442	-0.22	-0.15	Tetralogy of Fallot;	chr3:158745108	chr3:158869898~158871821:+
THCA	cis	rs7646881	0.504	rs67305172	ENSG00000279311.1	RP11-170K4.2	-3.38	0.000787	0.0442	-0.22	-0.15	Tetralogy of Fallot;	chr3:158746485	chr3:158869898~158871821:+
THCA	cis	rs453301	0.686	rs3989373	ENSG00000253981.4	ALG1L13P	-3.38	0.000787	0.0442	-0.14	-0.15	Joint mobility (Beighton score);	chr8:9053798	chr8:8236003~8244667:-
THCA	cis	rs11681884	0.892	rs73955148	ENSG00000236397.3	DDX11L2	-3.38	0.000787	0.0442	-0.32	-0.15	Stroke;	chr2:113101200	chr2:113599036~113601261:-
THCA	cis	rs7897654	0.61	rs12569364	ENSG00000236937.2	PTGES3P4	3.38	0.000787	0.0442	0.23	0.15	Schizophrenia;	chr10:102993750	chr10:102845595~102845950:+
THCA	cis	rs7641761	0.539	rs4607155	ENSG00000237978.4	KCNMB2-AS1	3.38	0.000787	0.0442	0.19	0.15	Mean corpuscular hemoglobin;	chr3:179024902	chr3:178526505~178860405:-
THCA	cis	rs7641761	0.539	rs6795238	ENSG00000237978.4	KCNMB2-AS1	3.38	0.000787	0.0442	0.19	0.15	Mean corpuscular hemoglobin;	chr3:179025451	chr3:178526505~178860405:-
THCA	cis	rs7641761	0.539	rs4955810	ENSG00000237978.4	KCNMB2-AS1	3.38	0.000787	0.0442	0.19	0.15	Mean corpuscular hemoglobin;	chr3:179030692	chr3:178526505~178860405:-
THCA	cis	rs2749592	0.55	rs10764135	ENSG00000275858.1	RP11-291L22.8	-3.38	0.000787	0.0442	-0.18	-0.15	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38450738~38451069:-
THCA	cis	rs6433895	0.601	rs34405919	ENSG00000236153.1	AC104076.3	-3.38	0.000787	0.0442	-0.19	-0.15	Lymphocyte counts;	chr2:181178988	chr2:180979427~180980090:-
THCA	cis	rs4325129	0.705	rs11265215	ENSG00000272668.1	RP11-190A12.8	3.38	0.000787	0.0442	0.18	0.15	Obesity-related traits;	chr1:159505816	chr1:159866954~159867685:+
THCA	cis	rs10769945	0.606	rs217236	ENSG00000226416.1	MRPL23-AS1	3.38	0.000787	0.0442	0.16	0.15	DNA methylation (variation);	chr11:1960029	chr11:1983237~1989920:-
THCA	cis	rs55702914	0.628	rs17730989	ENSG00000231621.1	AC013264.2	-3.38	0.000787	0.0442	-0.15	-0.15	Major depression and alcohol dependence;	chr2:197497800	chr2:197197991~197199273:+
THCA	cis	rs858239	0.676	rs274032	ENSG00000230042.1	AK3P3	-3.38	0.000787	0.0442	-0.2	-0.15	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23129178~23129841:+
THCA	cis	rs57709857	0.801	rs56365338	ENSG00000272092.1	RP11-350N15.5	-3.38	0.000787	0.0442	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38243170	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.801	rs16887275	ENSG00000272092.1	RP11-350N15.5	-3.38	0.000787	0.0442	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38243581	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.801	rs28867132	ENSG00000272092.1	RP11-350N15.5	-3.38	0.000787	0.0442	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38244206	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.801	rs7006757	ENSG00000272092.1	RP11-350N15.5	-3.38	0.000787	0.0442	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38245721	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.801	rs10105555	ENSG00000272092.1	RP11-350N15.5	-3.38	0.000787	0.0442	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38246563	chr8:38382364~38383461:+
THCA	cis	rs6496932	1	rs34434405	ENSG00000259630.2	CTD-2262B20.1	3.38	0.000787	0.0442	0.2	0.15	Central corneal thickness;Corneal structure;	chr15:85281437	chr15:85415228~85415633:+
THCA	cis	rs701145	0.585	rs1727945	ENSG00000243069.6	ARHGEF26-AS1	3.38	0.000787	0.0442	0.29	0.15	Coronary artery disease;	chr3:154165076	chr3:154024401~154121332:-
THCA	cis	rs8081187	0.803	rs9897725	ENSG00000263531.1	RP13-753N3.1	3.38	0.000787	0.0442	0.4	0.15	Breast cancer;	chr17:30538643	chr17:30863921~30864940:-
THCA	cis	rs8081187	0.803	rs11650766	ENSG00000263531.1	RP13-753N3.1	-3.38	0.000787	0.0442	-0.4	-0.15	Breast cancer;	chr17:30535249	chr17:30863921~30864940:-
THCA	cis	rs8081187	0.803	rs11655579	ENSG00000263531.1	RP13-753N3.1	-3.38	0.000787	0.0442	-0.4	-0.15	Breast cancer;	chr17:30537695	chr17:30863921~30864940:-
THCA	cis	rs8081187	0.803	rs73987940	ENSG00000263531.1	RP13-753N3.1	-3.38	0.000787	0.0442	-0.4	-0.15	Breast cancer;	chr17:30539025	chr17:30863921~30864940:-
THCA	cis	rs8081187	0.803	rs73987941	ENSG00000263531.1	RP13-753N3.1	-3.38	0.000787	0.0442	-0.4	-0.15	Breast cancer;	chr17:30539093	chr17:30863921~30864940:-
THCA	cis	rs8081187	0.803	rs11658150	ENSG00000263531.1	RP13-753N3.1	-3.38	0.000787	0.0442	-0.4	-0.15	Breast cancer;	chr17:30539572	chr17:30863921~30864940:-
THCA	cis	rs8081187	0.803	rs11657237	ENSG00000263531.1	RP13-753N3.1	-3.38	0.000787	0.0442	-0.4	-0.15	Breast cancer;	chr17:30539632	chr17:30863921~30864940:-
THCA	cis	rs8081187	0.803	rs11653492	ENSG00000263531.1	RP13-753N3.1	-3.38	0.000787	0.0442	-0.4	-0.15	Breast cancer;	chr17:30540135	chr17:30863921~30864940:-
THCA	cis	rs3617	0.573	rs9825230	ENSG00000243224.1	RP5-1157M23.2	-3.38	0.000787	0.0442	-0.17	-0.15	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52867958	chr3:52239258~52241097:+
THCA	cis	rs748404	0.587	rs9920879	ENSG00000224677.1	PDIA3P2	3.38	0.000787	0.0442	0.19	0.15	Lung cancer;	chr15:43347572	chr15:43649123~43649280:+
THCA	cis	rs748404	0.631	rs7166812	ENSG00000224677.1	PDIA3P2	3.38	0.000787	0.0442	0.19	0.15	Lung cancer;	chr15:43352562	chr15:43649123~43649280:+
THCA	cis	rs4662986	0.535	rs11694670	ENSG00000227632.2	AC018804.6	3.38	0.000787	0.0442	0.31	0.15	Age at smoking initiation in chronic obstructive pulmonary disease;	chr2:129656488	chr2:130202312~130212628:+
THCA	cis	rs7160336	0.967	rs10151810	ENSG00000259065.1	RP5-1021I20.1	3.38	0.000787	0.0442	0.18	0.15	Blood protein levels;	chr14:74009093	chr14:73787360~73803270:+
THCA	cis	rs7160336	0.967	rs11159057	ENSG00000259065.1	RP5-1021I20.1	3.38	0.000787	0.0442	0.18	0.15	Blood protein levels;	chr14:74010611	chr14:73787360~73803270:+
THCA	cis	rs6782029	0.583	rs11128561	ENSG00000225026.1	AC091492.2	-3.38	0.000787	0.0442	-0.26	-0.15	Anorexia nervosa;	chr3:11635953	chr3:12328003~12328274:+
THCA	cis	rs10863936	0.667	rs61828547	ENSG00000198468.6	FLVCR1-AS1	-3.38	0.000787	0.0442	-0.18	-0.15	Height;	chr1:212074258	chr1:212852108~212858088:-
THCA	cis	rs10863936	0.667	rs11119843	ENSG00000198468.6	FLVCR1-AS1	-3.38	0.000787	0.0442	-0.18	-0.15	Height;	chr1:212074981	chr1:212852108~212858088:-
THCA	cis	rs293748	0.571	rs10042473	ENSG00000250155.1	CTD-2353F22.1	-3.38	0.000788	0.0442	-0.18	-0.15	Obesity-related traits;	chr5:37243651	chr5:36666214~36725195:-
THCA	cis	rs1933755	1	rs1933755	ENSG00000219776.2	RPL21P67	3.38	0.000788	0.0442	0.25	0.15	Colorectal cancer (calcium intake interaction);	chr6:130604622	chr6:131469059~131469536:+
THCA	cis	rs467650	0.553	rs29771	ENSG00000248489.1	CTD-2007H13.3	3.38	0.000788	0.0442	0.14	0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:98640442	chr5:98929171~98995013:+
THCA	cis	rs7631605	0.571	rs6788554	ENSG00000224080.1	UBE2FP1	3.38	0.000788	0.0442	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37415957	chr3:37143512~37143958:-
THCA	cis	rs61008539	0.893	rs7783487	ENSG00000273151.1	RP11-449P15.2	-3.38	0.000788	0.0443	-0.1	-0.15	Perceived unattractiveness to mosquitoes;	chr7:820523	chr7:879790~886547:-
THCA	cis	rs9902453	0.74	rs2628189	ENSG00000263603.1	CTD-2349P21.5	-3.38	0.000788	0.0443	-0.18	-0.15	Coffee consumption (cups per day);	chr17:29761795	chr17:30729469~30731202:+
THCA	cis	rs9902453	0.765	rs2729448	ENSG00000263603.1	CTD-2349P21.5	-3.38	0.000788	0.0443	-0.18	-0.15	Coffee consumption (cups per day);	chr17:29764935	chr17:30729469~30731202:+
THCA	cis	rs2130392	0.962	rs35613786	ENSG00000250726.1	RP11-616K6.1	3.38	0.000788	0.0443	0.19	0.15	Kawasaki disease;	chr4:184704503	chr4:184072403~184073039:+
THCA	cis	rs76878669	0.561	rs10791876	ENSG00000255320.1	RP11-755F10.1	3.38	0.000788	0.0443	0.19	0.15	Educational attainment (years of education);	chr11:66402175	chr11:66244840~66246239:-
THCA	cis	rs7395662	0.926	rs11039893	ENSG00000200090.1	Y_RNA	-3.38	0.000788	0.0443	-0.1	-0.15	HDL cholesterol;	chr11:48636202	chr11:47726894~47726992:-
THCA	cis	rs7395662	0.75	rs10838985	ENSG00000200090.1	Y_RNA	-3.38	0.000788	0.0443	-0.1	-0.15	HDL cholesterol;	chr11:48623533	chr11:47726894~47726992:-
THCA	cis	rs301901	0.772	rs6887958	ENSG00000250155.1	CTD-2353F22.1	-3.38	0.000788	0.0443	-0.15	-0.15	Height;	chr5:37189717	chr5:36666214~36725195:-
THCA	cis	rs821367	0.83	rs112079112	ENSG00000229048.5	DUTP1	-3.38	0.000788	0.0443	-0.23	-0.15	Platelet distribution width;	chr3:124706041	chr3:125310881~125311350:+
THCA	cis	rs821367	0.785	rs77614255	ENSG00000229048.5	DUTP1	-3.38	0.000788	0.0443	-0.23	-0.15	Platelet distribution width;	chr3:124708475	chr3:125310881~125311350:+
THCA	cis	rs821367	0.83	rs75771831	ENSG00000229048.5	DUTP1	-3.38	0.000788	0.0443	-0.23	-0.15	Platelet distribution width;	chr3:124708748	chr3:125310881~125311350:+
THCA	cis	rs821367	0.789	rs80003343	ENSG00000229048.5	DUTP1	-3.38	0.000788	0.0443	-0.23	-0.15	Platelet distribution width;	chr3:124708761	chr3:125310881~125311350:+
THCA	cis	rs2228479	0.717	rs12917681	ENSG00000274627.1	RP11-104N10.2	-3.38	0.000788	0.0443	-0.24	-0.15	Skin colour saturation;	chr16:89744533	chr16:89516797~89522217:+
THCA	cis	rs73459955	0.712	rs17554431	ENSG00000248441.5	LINC01197	3.38	0.000788	0.0443	0.2	0.15	Major depression and alcohol dependence;	chr15:95074962	chr15:95209099~95327129:-
THCA	cis	rs9303542	0.729	rs6504257	ENSG00000278765.1	RP5-890E16.5	-3.38	0.000788	0.0443	-0.2	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48448660	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs35767434	ENSG00000278765.1	RP5-890E16.5	-3.38	0.000788	0.0443	-0.2	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48451013	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.729	rs34771639	ENSG00000278765.1	RP5-890E16.5	-3.38	0.000788	0.0443	-0.2	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48451167	chr17:48066704~48067293:-
THCA	cis	rs12460587	0.547	rs56244227	ENSG00000269483.1	AC006272.1	3.38	0.000788	0.0443	0.17	0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080439	chr19:51839924~51843324:-
THCA	cis	rs61160187	0.51	rs10077663	ENSG00000251279.1	CTC-436P18.1	-3.38	0.000788	0.0443	-0.2	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:61162070~61232040:+
THCA	cis	rs2034088	0.93	rs2034089	ENSG00000231784.7	DBIL5P	3.38	0.000788	0.0443	0.17	0.15	Hip circumference adjusted for BMI;	chr17:529761	chr17:752660~755336:+
THCA	cis	rs765751	0.965	rs12029812	ENSG00000228536.1	RP11-392O17.1	-3.38	0.000788	0.0443	-0.18	-0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219453655	chr1:219409681~219411941:-
THCA	cis	rs939960	0.876	rs13240099	ENSG00000276538.1	RP11-545G3.2	3.38	0.000788	0.0443	0.23	0.15	Neutrophil percentage of white cells;	chr7:150610497	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs13240106	ENSG00000276538.1	RP11-545G3.2	3.38	0.000788	0.0443	0.23	0.15	Neutrophil percentage of white cells;	chr7:150610512	chr7:150047609~150047854:-
THCA	cis	rs9427116	1	rs9427117	ENSG00000236675.1	MTX1P1	-3.38	0.000788	0.0443	-0.14	-0.15	Blood protein levels;	chr1:154659755	chr1:155230975~155234325:+
THCA	cis	rs9860428	0.844	rs7639603	ENSG00000243795.1	RP11-572M11.3	3.38	0.000788	0.0443	0.19	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112887289	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs9853006	ENSG00000243795.1	RP11-572M11.3	3.38	0.000788	0.0443	0.19	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112887488	chr3:113142350~113167819:-
THCA	cis	rs11002791	0.555	rs3936399	ENSG00000224596.6	ZMIZ1-AS1	-3.38	0.000788	0.0443	-0.16	-0.15	Red blood cell count;	chr10:79020632	chr10:78943328~79067895:-
THCA	cis	rs7615952	0.534	rs1503072	ENSG00000241288.6	RP11-379B18.5	-3.38	0.000788	0.0443	-0.18	-0.15	Blood pressure (smoking interaction);	chr3:126035848	chr3:125827238~125916384:-
THCA	cis	rs7615952	0.599	rs7631268	ENSG00000241288.6	RP11-379B18.5	-3.38	0.000788	0.0443	-0.18	-0.15	Blood pressure (smoking interaction);	chr3:126036821	chr3:125827238~125916384:-
THCA	cis	rs2235642	0.928	rs9932984	ENSG00000280062.1	LA16c-380F5.1	3.38	0.000788	0.0443	0.19	0.15	Coronary artery disease;	chr16:1555050	chr16:1530715~1533301:+
THCA	cis	rs3087591	0.659	rs757376	ENSG00000263535.1	AK4P1	3.38	0.000788	0.0443	0.18	0.15	Hip circumference;	chr17:31390891	chr17:31345521~31346187:+
THCA	cis	rs75504410	0.826	rs931023	ENSG00000231160.8	KLF3-AS1	-3.38	0.000788	0.0443	-0.15	-0.15	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38720959	chr4:38612701~38664883:-
THCA	cis	rs35851103	0.627	rs6601644	ENSG00000254527.1	ENPP7P12	3.38	0.000788	0.0443	0.19	0.15	Neuroticism;	chr8:11989569	chr8:12205759~12206389:-
THCA	cis	rs7315621	0.93	rs7300419	ENSG00000279283.1	RP11-417L19.5	3.38	0.000788	0.0443	0.15	0.15	Longevity;	chr12:131595813	chr12:131896500~131898239:+
THCA	cis	rs7315621	0.93	rs7297317	ENSG00000279283.1	RP11-417L19.5	3.38	0.000788	0.0443	0.15	0.15	Longevity;	chr12:131595814	chr12:131896500~131898239:+
THCA	cis	rs7487075	0.554	rs12229299	ENSG00000274723.1	RP11-618L22.1	3.38	0.000788	0.0443	0.14	0.15	Itch intensity from mosquito bite;	chr12:46691110	chr12:46970504~46972155:+
THCA	cis	rs524281	0.861	rs7931544	ENSG00000255038.1	RP11-1167A19.2	-3.38	0.000788	0.0443	-0.18	-0.15	Electroencephalogram traits;	chr11:66149563	chr11:66067277~66069619:-
THCA	cis	rs2288884	0.505	rs6509602	ENSG00000260160.1	CTC-471J1.2	-3.38	0.000788	0.0443	-0.16	-0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51956892	chr19:52058490~52063703:-
THCA	cis	rs4713118	0.739	rs2893931	ENSG00000272009.1	RP1-313I6.12	-3.38	0.000788	0.0443	-0.17	-0.15	Parkinson's disease;	chr6:27780231	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.824	rs2092075	ENSG00000272009.1	RP1-313I6.12	-3.38	0.000788	0.0443	-0.17	-0.15	Parkinson's disease;	chr6:27781551	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.824	rs13211701	ENSG00000272009.1	RP1-313I6.12	-3.38	0.000788	0.0443	-0.17	-0.15	Parkinson's disease;	chr6:27782300	chr6:28078792~28081130:-
THCA	cis	rs4713118	0.824	rs9468229	ENSG00000272009.1	RP1-313I6.12	-3.38	0.000788	0.0443	-0.17	-0.15	Parkinson's disease;	chr6:27782307	chr6:28078792~28081130:-
THCA	cis	rs7520050	0.966	rs785495	ENSG00000281133.1	AL355480.3	3.38	0.000788	0.0443	0.18	0.15	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45580892~45580996:-
THCA	cis	rs2692947	0.673	rs2229169	ENSG00000232931.4	LINC00342	-3.38	0.000788	0.0443	-0.13	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96114968	chr2:95807118~95816215:-
THCA	cis	rs2692947	0.673	rs2692894	ENSG00000232931.4	LINC00342	-3.38	0.000788	0.0443	-0.13	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96119195	chr2:95807118~95816215:-
THCA	cis	rs4730276	0.674	rs7777259	ENSG00000241764.3	AC002467.7	-3.38	0.000789	0.0443	-0.13	-0.15	Ulcerative colitis;	chr7:107920206	chr7:107742817~107744581:-
THCA	cis	rs8054556	0.539	rs12596543	ENSG00000275371.1	RP11-455F5.6	-3.38	0.000789	0.0443	-0.13	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30017814	chr16:30110895~30111955:+
THCA	cis	rs1728400	0.642	rs1614087	ENSG00000252311.1	RNU1-103P	3.38	0.000789	0.0443	0.17	0.15	Breast cancer (survival);	chr16:86385216	chr16:85781775~85781899:-
THCA	cis	rs7855088	1	rs7855088	ENSG00000236130.1	PTCSC2	-3.38	0.000789	0.0443	-0.12	-0.15	Serum thyroid-stimulating hormone levels;	chr9:97979971	chr9:97805935~97810008:-
THCA	cis	rs4704187	0.595	rs7717337	ENSG00000250889.2	LINC01336	-3.38	0.000789	0.0443	-0.16	-0.15	Response to amphetamines;	chr5:75081176	chr5:75047719~75052843:-
THCA	cis	rs4713118	0.513	rs149962	ENSG00000176933.5	TOB2P1	-3.38	0.000789	0.0443	-0.18	-0.15	Parkinson's disease;	chr6:28048140	chr6:28217643~28218634:-
THCA	cis	rs7620503	0.721	rs6769488	ENSG00000228561.2	RP11-114M1.1	3.38	0.000789	0.0443	0.18	0.15	Corneal structure;	chr3:177590370	chr3:177683627~177691250:+
THCA	cis	rs11048434	0.723	rs1805737	ENSG00000245105.2	A2M-AS1	3.38	0.000789	0.0443	0.12	0.15	Sjögren's syndrome;	chr12:8932074	chr12:9065177~9068060:+
THCA	cis	rs13272623	0.938	rs9918763	ENSG00000246366.5	RP11-382J12.1	3.38	0.000789	0.0443	0.22	0.15	IgG glycosylation;	chr8:70636772	chr8:70608577~70663279:+
THCA	cis	rs13272623	0.938	rs35571096	ENSG00000246366.5	RP11-382J12.1	3.38	0.000789	0.0443	0.22	0.15	IgG glycosylation;	chr8:70637909	chr8:70608577~70663279:+
THCA	cis	rs2494663	0.61	rs6670019	ENSG00000231416.1	RP11-422P24.9	3.38	0.000789	0.0443	0.2	0.15	Mean platelet volume;	chr1:154045516	chr1:153995632~153995960:+
THCA	cis	rs7395662	0.819	rs11039913	ENSG00000200090.1	Y_RNA	-3.38	0.000789	0.0443	-0.1	-0.15	HDL cholesterol;	chr11:48670529	chr11:47726894~47726992:-
THCA	cis	rs7395662	0.864	rs11039917	ENSG00000200090.1	Y_RNA	-3.38	0.000789	0.0443	-0.1	-0.15	HDL cholesterol;	chr11:48673876	chr11:47726894~47726992:-
THCA	cis	rs9291683	0.62	rs717615	ENSG00000250413.1	RP11-448G15.1	-3.38	0.000789	0.0443	-0.15	-0.15	Bone mineral density;	chr4:10103046	chr4:10006482~10009725:+
THCA	cis	rs3781264	0.557	rs7092226	ENSG00000273450.1	RP11-76P2.4	3.38	0.000789	0.0443	0.2	0.15	Esophageal cancer and gastric cancer;	chr10:94352476	chr10:94314907~94315327:-
THCA	cis	rs4648045	0.565	rs4698862	ENSG00000248971.2	KRT8P46	-3.38	0.000789	0.0443	-0.18	-0.15	Lymphocyte percentage of white cells;	chr4:102624640	chr4:102728746~102730171:-
THCA	cis	rs4648045	0.565	rs4698863	ENSG00000248971.2	KRT8P46	-3.38	0.000789	0.0443	-0.18	-0.15	Lymphocyte percentage of white cells;	chr4:102624691	chr4:102728746~102730171:-
THCA	cis	rs2749592	0.505	rs7915670	ENSG00000275858.1	RP11-291L22.8	-3.38	0.000789	0.0443	-0.18	-0.15	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38450738~38451069:-
THCA	cis	rs6487679	0.543	rs34363	ENSG00000256069.6	A2MP1	-3.38	0.000789	0.0443	-0.3	-0.15	Non-alcoholic fatty liver disease histology (AST);	chr12:9238261	chr12:9228533~9275817:-
THCA	cis	rs9650657	0.596	rs2409675	ENSG00000255310.2	AF131215.2	-3.38	0.000789	0.0443	-0.13	-0.15	Neuroticism;	chr8:10737749	chr8:11107788~11109726:-
THCA	cis	rs7520050	0.902	rs4626927	ENSG00000280836.1	AL355480.1	3.38	0.000789	0.0443	0.19	0.15	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45581219~45581321:-
THCA	cis	rs7520050	0.902	rs7514192	ENSG00000280836.1	AL355480.1	3.38	0.000789	0.0443	0.19	0.15	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45581219~45581321:-
THCA	cis	rs285757	0.895	rs2453901	ENSG00000259064.2	RP11-386M24.5	-3.38	0.000789	0.0443	-0.23	-0.15	HIV-1 susceptibility;	chr15:92652572	chr15:92627073~92627414:+
THCA	cis	rs224278	0.509	rs7100320	ENSG00000238280.1	RP11-436D10.3	-3.38	0.000789	0.0443	-0.22	-0.15	Ewing sarcoma;	chr10:62880834	chr10:62793562~62805887:-
THCA	cis	rs224278	0.509	rs6479842	ENSG00000238280.1	RP11-436D10.3	-3.38	0.000789	0.0443	-0.22	-0.15	Ewing sarcoma;	chr10:62881626	chr10:62793562~62805887:-
THCA	cis	rs7712401	0.755	rs13172043	ENSG00000263432.2	RN7SL689P	3.38	0.000789	0.0443	0.16	0.15	Mean platelet volume;	chr5:122849064	chr5:123022487~123022783:-
THCA	cis	rs4713118	0.869	rs9283883	ENSG00000216915.2	RP1-97D16.1	-3.38	0.000789	0.0443	-0.23	-0.15	Parkinson's disease;	chr6:27747691	chr6:27737000~27738494:-
THCA	cis	rs8040855	0.627	rs35668291	ENSG00000225151.9	GOLGA2P7	-3.38	0.000789	0.0443	-0.22	-0.15	Bulimia nervosa;	chr15:85109582	chr15:84199311~84230136:-
THCA	cis	rs656900	0.669	rs7178799	ENSG00000261229.4	MTHFS	-3.38	0.000789	0.0443	-0.15	-0.15	Cerebrospinal P-tau181p levels;	chr15:79826981	chr15:79843547~79897285:-
THCA	cis	rs987724	0.593	rs10212230	ENSG00000241544.1	RP11-6F2.5	-3.38	0.000789	0.0443	-0.18	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973164	chr3:157081841~157088547:+
THCA	cis	rs2252521	0.583	rs1846490	ENSG00000228421.2	AC005013.5	3.38	0.000789	0.0443	0.2	0.15	Cognitive performance;	chr7:29041211	chr7:28957667~28959345:+
THCA	cis	rs9425766	0.679	rs10912761	ENSG00000270084.1	GAS5-AS1	-3.38	0.000789	0.0443	-0.16	-0.15	Life satisfaction;	chr1:174312466	chr1:173863248~173863941:+
THCA	cis	rs2486012	0.579	rs4660750	ENSG00000237950.1	RP11-7O11.3	3.38	0.000789	0.0443	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43784710	chr1:43944370~43946551:-
THCA	cis	rs2933343	0.729	rs813945	ENSG00000231305.3	RP11-723O4.2	3.38	0.000789	0.0443	0.17	0.15	IgG glycosylation;	chr3:128942094	chr3:128861313~128871540:-
THCA	cis	rs7173964	1	rs7167878	ENSG00000259251.2	RP11-643M14.1	-3.38	0.00079	0.0443	-0.16	-0.15	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62103990	chr15:62060503~62062434:+
THCA	cis	rs7903847	0.62	rs2297988	ENSG00000225850.3	RP11-452K12.4	3.38	0.00079	0.0443	0.15	0.15	Granulocyte percentage of myeloid white cells;	chr10:97358625	chr10:97334564~97343203:+
THCA	cis	rs2898290	0.617	rs13278965	ENSG00000254527.1	ENPP7P12	3.38	0.00079	0.0443	0.19	0.15	Systolic blood pressure;	chr8:11609236	chr8:12205759~12206389:-
THCA	cis	rs7267979	0.816	rs3746337	ENSG00000276952.1	RP5-965G21.6	3.38	0.00079	0.0443	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25284915~25285588:-
THCA	cis	rs12497850	1	rs4858831	ENSG00000228638.1	FCF1P2	-3.38	0.00079	0.0443	-0.16	-0.15	Parkinson's disease;	chr3:48698125	chr3:48290793~48291375:-
THCA	cis	rs4656958	0.538	rs4656279	ENSG00000232188.1	RP11-312J18.6	3.38	0.00079	0.0443	0.18	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160916504	chr1:160931739~160934380:-
THCA	cis	rs2243480	1	rs35542501	ENSG00000273024.4	INTS4P2	3.38	0.00079	0.0443	0.26	0.15	Diabetic kidney disease;	chr7:65966228	chr7:65647864~65715661:+
THCA	cis	rs4713118	0.738	rs200465	ENSG00000272009.1	RP1-313I6.12	-3.38	0.00079	0.0443	-0.17	-0.15	Parkinson's disease;	chr6:27789875	chr6:28078792~28081130:-
THCA	cis	rs3096644	0.893	rs3110609	ENSG00000230148.7	HOXB-AS1	-3.38	0.00079	0.0443	-0.16	-0.15	Metabolite levels (Dihydroxy docosatrienoic acid);	chr17:48676181	chr17:48543551~48551250:+
THCA	cis	rs4925114	0.568	rs11656775	ENSG00000281749.1	Y_RNA	-3.38	0.00079	0.0443	-0.19	-0.15	Body mass index;	chr17:17751005	chr17:18001101~18001195:-
THCA	cis	rs4930561	0.714	rs7945995	ENSG00000184795.9	UNC93B5	-3.38	0.00079	0.0443	-0.19	-0.15	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68170835	chr11:67711702~67716005:-
THCA	cis	rs11030122	0.547	rs10835324	ENSG00000230593.3	AC090804.1	3.38	0.00079	0.0443	0.19	0.15	Mean platelet volume;Platelet distribution width;	chr11:3933698	chr11:3892398~3892887:-
THCA	cis	rs11777747	0.891	rs79788097	ENSG00000280303.2	ERICD	-3.38	0.00079	0.0443	-0.19	-0.15	Coronary artery calcification;	chr8:141467417	chr8:140636281~140638283:+
THCA	cis	rs3087591	0.639	rs757378	ENSG00000263535.1	AK4P1	-3.38	0.00079	0.0444	-0.19	-0.15	Hip circumference;	chr17:31395601	chr17:31345521~31346187:+
THCA	cis	rs9400467	0.5	rs1361425	ENSG00000271789.1	RP5-1112D6.7	-3.38	0.00079	0.0444	-0.15	-0.15	Amino acid levels;Blood metabolite levels;	chr6:111151040	chr6:111297126~111298510:+
THCA	cis	rs7487075	0.619	rs11183479	ENSG00000275481.1	RP11-474P2.6	3.38	0.00079	0.0444	0.15	0.15	Itch intensity from mosquito bite;	chr12:46430381	chr12:46388856~46392126:+
THCA	cis	rs7487075	0.656	rs3936214	ENSG00000275481.1	RP11-474P2.6	3.38	0.00079	0.0444	0.15	0.15	Itch intensity from mosquito bite;	chr12:46432029	chr12:46388856~46392126:+
THCA	cis	rs988712	0.921	rs10742178	ENSG00000245573.6	BDNF-AS	3.38	0.00079	0.0444	0.14	0.15	Obesity;	chr11:27592171	chr11:27506838~27698174:+
THCA	cis	rs11216126	0.778	rs17119975	ENSG00000254851.1	RP11-109L13.1	-3.38	0.00079	0.0444	-0.28	-0.15	HDL cholesterol;	chr11:116763841	chr11:117135528~117138582:+
THCA	cis	rs2562456	0.754	rs11666213	ENSG00000213976.4	CTD-2561J22.2	-3.38	0.00079	0.0444	-0.19	-0.15	Pain;	chr19:21422843	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs62110429	ENSG00000213976.4	CTD-2561J22.2	-3.38	0.00079	0.0444	-0.19	-0.15	Pain;	chr19:21430984	chr19:21382865~21387177:+
THCA	cis	rs1050631	1	rs11081934	ENSG00000260552.1	RP11-49I11.1	3.38	0.00079	0.0444	0.19	0.15	Esophageal squamous cell cancer (length of survival);	chr18:36125341	chr18:36179996~36187448:-
THCA	cis	rs6724465	1	rs7600987	ENSG00000272644.1	RP11-33O4.1	3.38	0.00079	0.0444	0.22	0.15	Height;	chr2:219051149	chr2:219069354~219069809:-
THCA	cis	rs2836950	0.509	rs11088466	ENSG00000235701.1	PCBP2P1	-3.38	0.00079	0.0444	-0.17	-0.15	Menarche (age at onset);	chr21:39208091	chr21:39171130~39172106:-
THCA	cis	rs6490294	0.904	rs12423126	ENSG00000234608.6	MAPKAPK5-AS1	3.38	0.00079	0.0444	0.15	0.15	Mean platelet volume;	chr12:111991665	chr12:111839764~111842902:-
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000281021.1	RP1-12G14.9	-3.38	0.00079	0.0444	-0.15	-0.15	Lung cancer;	chr6:149660323	chr6:149576089~149590864:-
THCA	cis	rs7083	0.564	rs536141	ENSG00000254851.1	RP11-109L13.1	3.38	0.00079	0.0444	0.2	0.15	Blood protein levels;	chr11:117233820	chr11:117135528~117138582:+
THCA	cis	rs714027	0.566	rs4820827	ENSG00000279699.1	RP1-102K2.9	-3.38	0.00079	0.0444	-0.16	-0.15	Lymphocyte counts;	chr22:30081600	chr22:30275215~30276951:-
THCA	cis	rs4763879	0.778	rs1044771	ENSG00000278635.1	CTD-2318O12.1	3.38	0.00079	0.0444	0.17	0.15	Type 1 diabetes;	chr12:9699333	chr12:9415641~9416718:+
THCA	cis	rs12893668	0.667	rs71417869	ENSG00000258914.1	CTD-2134A5.3	-3.38	0.00079	0.0444	-0.19	-0.15	Reticulocyte count;	chr14:103611097	chr14:103875055~103877478:+
THCA	cis	rs1150668	0.796	rs213237	ENSG00000261839.1	RP1-265C24.8	3.38	0.00079	0.0444	0.15	0.15	Pubertal anthropometrics;	chr6:28356161	chr6:28136849~28139678:+
THCA	cis	rs7216064	1	rs8072225	ENSG00000265055.1	AC145343.2	3.38	0.00079	0.0444	0.22	0.15	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67916844	chr17:68096046~68101474:-
THCA	cis	rs2797160	1	rs1739371	ENSG00000226409.1	RP11-735G4.1	3.38	0.00079	0.0444	0.18	0.15	Endometrial cancer;	chr6:125690145	chr6:125370211~125374324:-
THCA	cis	rs9916302	0.706	rs3744349	ENSG00000266469.1	CTB-131K11.1	-3.38	0.000791	0.0444	-0.15	-0.15	Glomerular filtration rate (creatinine);	chr17:39258589	chr17:39401793~39406233:+
THCA	cis	rs478304	0.651	rs11604451	ENSG00000255557.1	RP11-770G2.2	3.38	0.000791	0.0444	0.18	0.15	Acne (severe);	chr11:65784239	chr11:65745729~65771585:+
THCA	cis	rs3793683	0.858	rs1571145	ENSG00000273980.1	RP13-49I15.6	-3.38	0.000791	0.0444	-0.19	-0.15	Migraine;	chr10:132770168	chr10:133257144~133257551:-
THCA	cis	rs9860428	0.844	rs9852286	ENSG00000240057.4	RP11-572M11.4	-3.38	0.000791	0.0444	-0.16	-0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896161	chr3:113019532~113183301:+
THCA	cis	rs7520050	0.966	rs785492	ENSG00000281133.1	AL355480.3	3.38	0.000791	0.0444	0.18	0.15	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45580892~45580996:-
THCA	cis	rs2797160	1	rs1935774	ENSG00000226409.1	RP11-735G4.1	3.38	0.000791	0.0444	0.18	0.15	Endometrial cancer;	chr6:125675515	chr6:125370211~125374324:-
THCA	cis	rs6545883	0.859	rs35760550	ENSG00000212978.6	AC016747.3	-3.38	0.000791	0.0444	-0.17	-0.15	Tuberculosis;	chr2:61376730	chr2:61141592~61144969:-
THCA	cis	rs6545883	0.859	rs62149714	ENSG00000212978.6	AC016747.3	-3.38	0.000791	0.0444	-0.17	-0.15	Tuberculosis;	chr2:61376734	chr2:61141592~61144969:-
THCA	cis	rs7824557	0.564	rs35009431	ENSG00000261451.1	RP11-981G7.1	-3.38	0.000791	0.0444	-0.2	-0.15	Retinal vascular caliber;	chr8:11375279	chr8:10433672~10438312:+
THCA	cis	rs6445967	0.569	rs1135089	ENSG00000273493.1	RP11-80H18.4	-3.38	0.000791	0.0444	-0.2	-0.15	Platelet count;	chr3:58318385	chr3:58329965~58330118:+
THCA	cis	rs6445967	0.569	rs2280166	ENSG00000273493.1	RP11-80H18.4	-3.38	0.000791	0.0444	-0.2	-0.15	Platelet count;	chr3:58323875	chr3:58329965~58330118:+
THCA	cis	rs6445967	0.569	rs10687	ENSG00000273493.1	RP11-80H18.4	3.38	0.000791	0.0444	0.2	0.15	Platelet count;	chr3:58319508	chr3:58329965~58330118:+
THCA	cis	rs16975963	0.843	rs11672440	ENSG00000226686.6	LINC01535	-3.38	0.000791	0.0444	-0.22	-0.15	Longevity;	chr19:37760318	chr19:37251912~37265535:+
THCA	cis	rs34779708	0.966	rs4934725	ENSG00000233200.1	RP11-324I22.2	3.38	0.000791	0.0444	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35219894~35230598:-
THCA	cis	rs34779708	1	rs12769189	ENSG00000233200.1	RP11-324I22.2	3.38	0.000791	0.0444	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs12774834	ENSG00000233200.1	RP11-324I22.2	3.38	0.000791	0.0444	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs12775759	ENSG00000233200.1	RP11-324I22.2	3.38	0.000791	0.0444	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs34296409	ENSG00000233200.1	RP11-324I22.2	3.38	0.000791	0.0444	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs35777088	ENSG00000233200.1	RP11-324I22.2	3.38	0.000791	0.0444	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs11592567	ENSG00000233200.1	RP11-324I22.2	3.38	0.000791	0.0444	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35219894~35230598:-
THCA	cis	rs1062177	1	rs12653926	ENSG00000272112.1	CTB-113P19.5	3.38	0.000791	0.0444	0.14	0.15	Preschool internalizing problems;	chr5:151870687	chr5:151724831~151725356:-
THCA	cis	rs8058578	0.943	rs35629860	ENSG00000274678.1	RP11-2C24.7	3.38	0.000791	0.0444	0.15	0.15	Multiple myeloma;	chr16:30660211	chr16:30821338~30821884:+
THCA	cis	rs8031584	0.958	rs61997076	ENSG00000259845.1	HERC2P10	3.38	0.000791	0.0444	0.22	0.15	Huntington's disease progression;	chr15:30924022	chr15:30815271~30844153:+
THCA	cis	rs7829975	0.774	rs13259216	ENSG00000248538.5	RP11-10A14.5	-3.38	0.000791	0.0444	-0.19	-0.15	Mood instability;	chr8:8816091	chr8:9189011~9202854:+
THCA	cis	rs453301	0.658	rs3855900	ENSG00000253981.4	ALG1L13P	-3.38	0.000791	0.0444	-0.15	-0.15	Joint mobility (Beighton score);	chr8:9044411	chr8:8236003~8244667:-
THCA	cis	rs9840812	0.592	rs1711161	ENSG00000273486.1	RP11-731C17.2	3.38	0.000791	0.0444	0.14	0.15	Fibrinogen levels;	chr3:136361695	chr3:136837338~136839021:-
THCA	cis	rs975752	0.867	rs4919440	ENSG00000227492.1	RP11-316M21.6	3.38	0.000791	0.0444	0.3	0.15	Schizophrenia;	chr10:100255162	chr10:100229667~100234000:+
THCA	cis	rs975752	0.867	rs2270962	ENSG00000227492.1	RP11-316M21.6	3.38	0.000791	0.0444	0.3	0.15	Schizophrenia;	chr10:100256287	chr10:100229667~100234000:+
THCA	cis	rs975752	0.867	rs66728174	ENSG00000227492.1	RP11-316M21.6	3.38	0.000791	0.0444	0.3	0.15	Schizophrenia;	chr10:100260869	chr10:100229667~100234000:+
THCA	cis	rs975752	0.867	rs11190443	ENSG00000227492.1	RP11-316M21.6	3.38	0.000791	0.0444	0.3	0.15	Schizophrenia;	chr10:100263981	chr10:100229667~100234000:+
THCA	cis	rs975752	0.867	rs11190444	ENSG00000227492.1	RP11-316M21.6	3.38	0.000791	0.0444	0.3	0.15	Schizophrenia;	chr10:100264595	chr10:100229667~100234000:+
THCA	cis	rs875971	0.545	rs10261710	ENSG00000232559.3	GS1-124K5.12	3.38	0.000791	0.0444	0.17	0.15	Aortic root size;	chr7:66249202	chr7:66554588~66576923:-
THCA	cis	rs11671005	0.504	rs3794963	ENSG00000252334.1	RNU6-1337P	-3.38	0.000791	0.0444	-0.2	-0.15	Mean platelet volume;	chr19:58559684	chr19:58483749~58483843:-
THCA	cis	rs2692947	0.794	rs2692949	ENSG00000236750.1	AC009237.16	-3.38	0.000791	0.0444	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007777	chr2:95641634~95641980:-
THCA	cis	rs34421088	0.56	rs1478898	ENSG00000255495.1	AC145124.2	-3.38	0.000791	0.0444	-0.18	-0.15	Neuroticism;	chr8:11537570	chr8:12194467~12196280:+
THCA	cis	rs8005677	0.611	rs11624528	ENSG00000257285.4	RP11-298I3.1	3.38	0.000791	0.0444	0.17	0.15	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:22929609~22955562:+
THCA	cis	rs12780845	0.931	rs17466418	ENSG00000273153.1	RP11-406H21.2	3.38	0.000791	0.0444	0.15	0.15	Homocysteine levels;	chr10:17202308	chr10:17137336~17137585:-
THCA	cis	rs2228479	0.702	rs62056100	ENSG00000223959.7	AFG3L1P	-3.38	0.000791	0.0444	-0.14	-0.15	Skin colour saturation;	chr16:89873345	chr16:89972586~90002161:+
THCA	cis	rs13064411	0.696	rs7613546	ENSG00000243849.1	CFAP44-AS1	3.38	0.000792	0.0444	0.24	0.15	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113509172	chr3:113403991~113433992:+
THCA	cis	rs2718930	1	rs2718930	ENSG00000277245.1	RP11-48G14.3	3.38	0.000792	0.0444	0.17	0.15	Colonoscopy-negative controls vs population controls;	chr15:56251348	chr15:56447120~56447697:+
THCA	cis	rs6473252	0.839	rs2895689	ENSG00000254162.1	RP11-48B3.3	-3.38	0.000792	0.0444	-0.14	-0.15	Breast cancer;	chr8:80904078	chr8:80535006~80539135:-
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000281021.1	RP1-12G14.9	-3.38	0.000792	0.0444	-0.16	-0.15	Lung cancer;	chr6:149658547	chr6:149576089~149590864:-
THCA	cis	rs4706831	0.647	rs627240	ENSG00000260645.1	RP11-250B2.5	-3.38	0.000792	0.0444	-0.13	-0.15	Joint mobility (Beighton score);	chr6:80276168	chr6:80466958~80469080:+
THCA	cis	rs4705962	0.917	rs10066660	ENSG00000237714.1	P4HA2-AS1	3.38	0.000792	0.0444	0.23	0.15	Atopic dermatitis;	chr5:132685298	chr5:132184876~132192808:+
THCA	cis	rs4705962	0.959	rs6885996	ENSG00000237714.1	P4HA2-AS1	3.38	0.000792	0.0444	0.23	0.15	Atopic dermatitis;	chr5:132685604	chr5:132184876~132192808:+
THCA	cis	rs591584	0.59	rs7120587	ENSG00000255893.1	RP11-685N10.1	-3.38	0.000792	0.0444	-0.17	-0.15	Macrophage Migration Inhibitory Factor levels;	chr11:94586307	chr11:94472908~94473570:-
THCA	cis	rs1979679	0.527	rs12809834	ENSG00000247934.4	RP11-967K21.1	-3.38	0.000792	0.0444	-0.18	-0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28180573	chr12:28163298~28190738:-
THCA	cis	rs9475677	0.861	rs12204391	ENSG00000231441.1	RP11-472M19.2	3.38	0.000792	0.0444	0.19	0.15	Gut microbiota (functional units);	chr6:56344720	chr6:56844002~56864078:+
THCA	cis	rs1426063	0.614	rs75345649	ENSG00000249717.1	RP11-44F21.3	3.38	0.000792	0.0444	0.35	0.15	QT interval;	chr4:75100963	chr4:74955974~74970362:-
THCA	cis	rs1426063	0.614	rs77333523	ENSG00000249717.1	RP11-44F21.3	3.38	0.000792	0.0444	0.35	0.15	QT interval;	chr4:75101024	chr4:74955974~74970362:-
THCA	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-3.38	0.000792	0.0444	-0.17	-0.15	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
THCA	cis	rs2179367	0.959	rs4895789	ENSG00000223701.3	RAET1E-AS1	3.38	0.000792	0.0444	0.21	0.15	Dupuytren's disease;	chr6:149443518	chr6:149884431~149919508:+
THCA	cis	rs832540	0.931	rs832529	ENSG00000271828.1	CTD-2310F14.1	-3.38	0.000792	0.0444	-0.21	-0.15	Coronary artery disease;	chr5:56933461	chr5:56927874~56929573:+
THCA	cis	rs6787172	0.622	rs6797629	ENSG00000272087.1	RP11-379F4.7	3.38	0.000792	0.0444	0.14	0.15	Subjective well-being;	chr3:158347882	chr3:158693120~158693768:-
THCA	cis	rs77147124	0.959	rs2250802	ENSG00000225292.2	RP11-57H14.3	-3.38	0.000792	0.0444	-0.21	-0.15	HDL cholesterol;	chr10:112161596	chr10:112888735~112906111:+
THCA	cis	rs77147124	0.917	rs2803611	ENSG00000225292.2	RP11-57H14.3	-3.38	0.000792	0.0444	-0.21	-0.15	HDL cholesterol;	chr10:112162970	chr10:112888735~112906111:+
THCA	cis	rs2638953	0.924	rs11049619	ENSG00000247934.4	RP11-967K21.1	-3.38	0.000792	0.0444	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453495	chr12:28163298~28190738:-
THCA	cis	rs7712401	0.525	rs193541	ENSG00000276047.1	Metazoa_SRP	3.38	0.000792	0.0444	0.19	0.15	Mean platelet volume;	chr5:122917609	chr5:123070782~123071080:+
THCA	cis	rs7474896	0.537	rs2505255	ENSG00000272983.1	RP11-508N22.12	-3.38	0.000792	0.0444	-0.16	-0.15	Obesity (extreme);	chr10:38070714	chr10:38137337~38144399:+
THCA	cis	rs41419946	1	rs10489747	ENSG00000236206.1	RP11-306I1.2	-3.38	0.000792	0.0444	-0.35	-0.15	Gut microbiome composition (winter);	chr1:165430340	chr1:165598463~165623331:+
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000218358.2	RAET1K	-3.38	0.000792	0.0444	-0.25	-0.15	Lung cancer;	chr6:149875445	chr6:149998019~150005157:-
THCA	cis	rs3785888	0.548	rs11079744	ENSG00000238419.1	RNU7-186P	3.38	0.000792	0.0444	0.18	0.15	Cleft lip with or without cleft palate;	chr17:46949753	chr17:47259358~47259420:-
THCA	cis	rs10129255	0.957	rs67625077	ENSG00000274576.2	IGHV2-70	3.38	0.000792	0.0444	0.11	0.15	Kawasaki disease;	chr14:106715436	chr14:106770577~106771020:-
THCA	cis	rs10129255	0.869	rs72690553	ENSG00000274576.2	IGHV2-70	3.38	0.000792	0.0444	0.11	0.15	Kawasaki disease;	chr14:106715491	chr14:106770577~106771020:-
THCA	cis	rs277939	1	rs6885523	ENSG00000230847.4	RP11-195E2.1	-3.38	0.000792	0.0445	-0.19	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71611668	chr5:71074225~71093193:-
THCA	cis	rs277939	1	rs464182	ENSG00000230847.4	RP11-195E2.1	-3.38	0.000792	0.0445	-0.19	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71611711	chr5:71074225~71093193:-
THCA	cis	rs6743226	0.603	rs3755324	ENSG00000223374.1	AC005104.3	3.38	0.000792	0.0445	0.11	0.15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241263805	chr2:241351340~241353104:-
THCA	cis	rs5771242	0.769	rs4838865	ENSG00000280567.1	Metazoa_SRP	-3.38	0.000792	0.0445	-0.21	-0.15	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50226183	chr22:49878999~49879242:+
THCA	cis	rs2298450	0.717	rs9974041	ENSG00000214867.3	SRSF9P1	3.38	0.000792	0.0445	0.23	0.15	Schizophrenia;	chr21:36262575	chr21:36295173~36295702:-
THCA	cis	rs939960	0.959	rs62502298	ENSG00000224016.2	RP11-728K20.1	3.38	0.000792	0.0445	0.21	0.15	Neutrophil percentage of white cells;	chr7:150589310	chr7:149891191~149909704:-
THCA	cis	rs939960	0.917	rs12671272	ENSG00000224016.2	RP11-728K20.1	3.38	0.000792	0.0445	0.21	0.15	Neutrophil percentage of white cells;	chr7:150589434	chr7:149891191~149909704:-
THCA	cis	rs939960	0.917	rs12671275	ENSG00000224016.2	RP11-728K20.1	3.38	0.000792	0.0445	0.21	0.15	Neutrophil percentage of white cells;	chr7:150589473	chr7:149891191~149909704:-
THCA	cis	rs939960	0.718	rs4339550	ENSG00000224016.2	RP11-728K20.1	3.38	0.000792	0.0445	0.21	0.15	Neutrophil percentage of white cells;	chr7:150590120	chr7:149891191~149909704:-
THCA	cis	rs939960	0.642	rs4382385	ENSG00000224016.2	RP11-728K20.1	3.38	0.000792	0.0445	0.21	0.15	Neutrophil percentage of white cells;	chr7:150590123	chr7:149891191~149909704:-
THCA	cis	rs939960	0.694	rs6942848	ENSG00000224016.2	RP11-728K20.1	3.38	0.000792	0.0445	0.21	0.15	Neutrophil percentage of white cells;	chr7:150590831	chr7:149891191~149909704:-
THCA	cis	rs11673344	0.523	rs6510584	ENSG00000267260.1	CTD-2162K18.4	-3.38	0.000792	0.0445	-0.18	-0.15	Obesity-related traits;	chr19:37058699	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.503	rs7246720	ENSG00000267260.1	CTD-2162K18.4	-3.38	0.000792	0.0445	-0.18	-0.15	Obesity-related traits;	chr19:37073726	chr19:36773153~36777078:+
THCA	cis	rs7923837	0.574	rs2488075	ENSG00000236493.2	EIF2S2P3	-3.38	0.000792	0.0445	-0.16	-0.15	Multiple sclerosis;Body mass index;	chr10:92730417	chr10:92668745~92669743:-
THCA	cis	rs75422866	0.51	rs73105803	ENSG00000280054.1	RP1-197B17.7	3.38	0.000792	0.0445	0.3	0.15	Pneumonia;	chr12:47722135	chr12:47728151~47730598:-
THCA	cis	rs12959333	0.527	rs12963783	ENSG00000274849.1	RP11-49I11.4	-3.38	0.000792	0.0445	-0.19	-0.15	Post bronchodilator FEV1;	chr18:35730027	chr18:36189824~36190272:+
THCA	cis	rs919433	0.857	rs36071109	ENSG00000222017.1	AC011997.1	3.38	0.000792	0.0445	0.16	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318467	chr2:197693106~197774823:+
THCA	cis	rs301901	0.796	rs3941788	ENSG00000250155.1	CTD-2353F22.1	3.38	0.000793	0.0445	0.15	0.15	Height;	chr5:37498809	chr5:36666214~36725195:-
THCA	cis	rs2025345	1	rs12358961	ENSG00000229664.1	RP11-536K7.5	3.38	0.000793	0.0445	0.17	0.15	Self-reported allergy;	chr10:6024232	chr10:6025978~6036427:+
THCA	cis	rs9637454	1	rs4857773	ENSG00000231574.4	RP11-91K9.1	-3.38	0.000793	0.0445	-0.22	-0.15	Hippocampal sclerosis;	chr3:178553608	chr3:177816865~177899224:+
THCA	cis	rs9637454	1	rs56222609	ENSG00000231574.4	RP11-91K9.1	-3.38	0.000793	0.0445	-0.22	-0.15	Hippocampal sclerosis;	chr3:178554192	chr3:177816865~177899224:+
THCA	cis	rs9637454	1	rs12495413	ENSG00000231574.4	RP11-91K9.1	-3.38	0.000793	0.0445	-0.22	-0.15	Hippocampal sclerosis;	chr3:178555136	chr3:177816865~177899224:+
THCA	cis	rs9637454	1	rs12495433	ENSG00000231574.4	RP11-91K9.1	-3.38	0.000793	0.0445	-0.22	-0.15	Hippocampal sclerosis;	chr3:178555172	chr3:177816865~177899224:+
THCA	cis	rs11800820	0.554	rs3124108	ENSG00000231612.1	RP11-522M21.3	3.38	0.000793	0.0445	0.2	0.15	Obesity-related traits;	chr1:246541527	chr1:245673732~245676478:-
THCA	cis	rs9788682	0.668	rs2036529	ENSG00000261143.1	ADAMTS7P3	3.38	0.000793	0.0445	0.23	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78433930	chr15:77976042~77993057:+
THCA	cis	rs12049351	0.774	rs12039754	ENSG00000229367.1	HMGN2P19	3.38	0.000793	0.0445	0.24	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229509149	chr1:229570532~229570796:+
THCA	cis	rs11773103	0.786	rs73203002	ENSG00000224046.1	AC005076.5	3.38	0.000793	0.0445	0.19	0.15	Bipolar disorder or major depressive disorder (combined);	chr7:87129584	chr7:87151423~87152420:-
THCA	cis	rs7824557	0.564	rs7839307	ENSG00000261451.1	RP11-981G7.1	3.38	0.000793	0.0445	0.2	0.15	Retinal vascular caliber;	chr8:11341283	chr8:10433672~10438312:+
THCA	cis	rs752590	0.524	rs45449699	ENSG00000274877.1	RP11-65I12.1	3.38	0.000793	0.0445	0.11	0.15	Mucinous ovarian carcinoma;	chr2:113197656	chr2:113237595~113240825:+
THCA	cis	rs55702914	0.628	rs3731570	ENSG00000231621.1	AC013264.2	-3.38	0.000793	0.0445	-0.15	-0.15	Major depression and alcohol dependence;	chr2:197453059	chr2:197197991~197199273:+
THCA	cis	rs748404	0.56	rs529611	ENSG00000275601.1	AC011330.13	-3.38	0.000793	0.0445	-0.18	-0.15	Lung cancer;	chr15:43513790	chr15:43642389~43643023:-
THCA	cis	rs910316	1	rs8003506	ENSG00000259138.1	RP11-950C14.7	-3.38	0.000793	0.0445	-0.13	-0.15	Height;	chr14:75119585	chr14:75127153~75136930:+
THCA	cis	rs12332430	1	rs35337710	ENSG00000247199.3	RP11-373N22.3	-3.38	0.000793	0.0445	-0.36	-0.15	Post bronchodilator FEV1/FVC ratio in COPD;	chr5:148179629	chr5:148268307~148383783:-
THCA	cis	rs11098499	0.954	rs6847248	ENSG00000250950.1	RP11-33B1.3	-3.38	0.000793	0.0445	-0.19	-0.15	Corneal astigmatism;	chr4:119304800	chr4:119456350~119457277:+
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000273712.1	RP5-874C20.7	3.38	0.000793	0.0445	0.21	0.15	Parkinson's disease;	chr6:28069254	chr6:28315613~28315883:-
THCA	cis	rs13315871	1	rs13060489	ENSG00000272182.1	RP11-802O23.3	3.38	0.000793	0.0445	0.26	0.15	Cholesterol, total;	chr3:58353560	chr3:58428255~58428815:+
THCA	cis	rs12101261	1	rs12101261	ENSG00000258915.1	BHLHB9P1	-3.38	0.000793	0.0445	-0.15	-0.15	Graves' disease;	chr14:80984885	chr14:80981988~80983638:+
THCA	cis	rs6724465	0.714	rs72951802	ENSG00000272644.1	RP11-33O4.1	3.38	0.000793	0.0445	0.2	0.15	Height;	chr2:219141408	chr2:219069354~219069809:-
THCA	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-3.38	0.000793	0.0445	-0.22	-0.15	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
THCA	cis	rs17376456	0.597	rs10866760	ENSG00000254132.1	MTND6P3	3.38	0.000793	0.0445	0.2	0.15	Diabetic retinopathy;	chr5:94002630	chr5:94568929~94569470:-
THCA	cis	rs8114671	0.545	rs2378335	ENSG00000269202.1	RP4-614O4.12	-3.38	0.000793	0.0445	-0.14	-0.15	Height;	chr20:35169027	chr20:35201747~35203288:-
THCA	cis	rs7772486	0.875	rs9390371	ENSG00000270638.1	RP3-466P17.1	3.38	0.000793	0.0445	0.12	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.875	rs6909827	ENSG00000270638.1	RP3-466P17.1	3.38	0.000793	0.0445	0.12	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145735570~145737218:+
THCA	cis	rs7536700	0.915	rs12097725	ENSG00000272030.1	RP1-178F15.4	-3.38	0.000793	0.0445	-0.28	-0.15	Multiple myeloma (IgH translocation);	chr1:153684696	chr1:153631438~153634397:-
THCA	cis	rs773506	0.965	rs9299391	ENSG00000229694.5	RP11-305L7.6	3.38	0.000793	0.0445	0.18	0.15	Type 2 diabetes nephropathy;	chr9:91255361	chr9:91119062~91182762:+
THCA	cis	rs6687821	0.5	rs6702601	ENSG00000261737.1	RP4-612B15.3	3.38	0.000793	0.0445	0.24	0.15	Yeast infection;	chr1:87047875	chr1:86703502~86704462:-
THCA	cis	rs991967	0.58	rs1342586	ENSG00000228208.5	C1orf143	3.38	0.000793	0.0445	0.22	0.15	Hip circumference adjusted for BMI;Height;	chr1:218424517	chr1:218510096~218525978:+
THCA	cis	rs357618	0.581	rs385255	ENSG00000260581.1	CTB-113P19.4	3.38	0.000793	0.0445	0.23	0.15	Basophil percentage of white cells;	chr5:151499453	chr5:151652275~151655449:+
THCA	cis	rs10875746	0.669	rs11168459	ENSG00000275228.1	RP11-370I10.10	3.38	0.000793	0.0445	0.18	0.15	Longevity (90 years and older);	chr12:48202458	chr12:48327942~48328472:-
THCA	cis	rs2070488	0.965	rs13097628	ENSG00000232439.1	RPL18AP7	3.38	0.000793	0.0445	0.19	0.15	Electrocardiographic conduction measures;	chr3:38479665	chr3:38526802~38527325:-
THCA	cis	rs2662776	1	rs10753607	ENSG00000232995.6	RGS5	3.38	0.000793	0.0445	0.13	0.15	Lead levels in blood;	chr1:163189038	chr1:163244505~163321894:-
THCA	cis	rs708547	0.915	rs28605409	ENSG00000269949.1	RP11-738E22.3	3.38	0.000794	0.0445	0.22	0.15	Response to bleomycin (chromatid breaks);	chr4:56900095	chr4:56960927~56961373:-
THCA	cis	rs12621844	0.706	rs4146603	ENSG00000234690.5	AC073283.4	3.38	0.000794	0.0445	0.15	0.15	Glycated hemoglobin levels;	chr2:48172876	chr2:47192405~47345074:-
THCA	cis	rs2447820	0.588	rs12055251	ENSG00000263432.2	RN7SL689P	3.38	0.000794	0.0445	0.19	0.15	Migraine;	chr5:123034581	chr5:123022487~123022783:-
THCA	cis	rs1908814	0.516	rs13281077	ENSG00000227888.4	FAM66A	3.38	0.000794	0.0445	0.2	0.15	Neuroticism;	chr8:11937305	chr8:12362019~12388296:+
THCA	cis	rs7572733	0.935	rs10931797	ENSG00000231621.1	AC013264.2	-3.38	0.000794	0.0445	-0.14	-0.15	Dermatomyositis;	chr2:197976069	chr2:197197991~197199273:+
THCA	cis	rs7619427	0.556	rs9852887	ENSG00000271192.1	RP4-555D20.3	3.38	0.000794	0.0445	0.21	0.15	Schizophrenia;	chr3:44024639	chr3:43996896~43997443:+
THCA	cis	rs7246657	1	rs35398388	ENSG00000267422.1	CTD-2554C21.1	-3.38	0.000794	0.0445	-0.18	-0.15	Coronary artery calcification;	chr19:37249456	chr19:37779686~37792865:+
THCA	cis	rs7763441	0.545	rs9378700	ENSG00000250903.7	GMDS-AS1	-3.38	0.000794	0.0445	-0.14	-0.15	Monobrow;	chr6:2452320	chr6:2245748~2482022:+
THCA	cis	rs6598266	1	rs7166691	ENSG00000182397.13	DNM1P46	-3.38	0.000794	0.0445	-0.25	-0.15	Major depressive disorder;	chr15:99760055	chr15:99790156~99806927:-
THCA	cis	rs7830939	0.586	rs7007562	ENSG00000261451.1	RP11-981G7.1	3.38	0.000794	0.0445	0.2	0.15	Neuroticism;	chr8:9471416	chr8:10433672~10438312:+
THCA	cis	rs11212260	0.649	rs583025	ENSG00000261098.1	RP11-819C21.1	-3.38	0.000794	0.0445	-0.31	-0.15	IgG glycosylation;	chr11:107547820	chr11:107312132~107316271:-
THCA	cis	rs9910816	0.589	rs9284341	ENSG00000207561.1	MIR635	3.38	0.000794	0.0445	0.17	0.15	Bipolar disorder (inflammation and infection response interaction);	chr17:68361311	chr17:68424451~68424548:-
THCA	cis	rs7709377	0.68	rs4921069	ENSG00000250015.1	CTC-339F2.2	3.38	0.000794	0.0445	0.16	0.15	Metabolite levels  (X-11787);	chr5:116176173	chr5:116302354~116304134:-
THCA	cis	rs7709377	0.723	rs1396484	ENSG00000250015.1	CTC-339F2.2	3.38	0.000794	0.0445	0.16	0.15	Metabolite levels  (X-11787);	chr5:116176499	chr5:116302354~116304134:-
THCA	cis	rs6546550	0.935	rs4241261	ENSG00000179818.12	PCBP1-AS1	-3.38	0.000794	0.0445	-0.12	-0.15	Prevalent atrial fibrillation;	chr2:69836528	chr2:69962263~70103220:-
THCA	cis	rs79387448	0.638	rs11465670	ENSG00000281162.1	LINC01127	3.38	0.000794	0.0445	0.19	0.15	Gut microbiota (bacterial taxa);	chr2:102417980	chr2:101962056~101987167:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000232546.1	RP11-458F8.1	3.38	0.000794	0.0445	0.13	0.15	Aortic root size;	chr7:66597493	chr7:66848496~66858136:+
THCA	cis	rs10911902	0.643	rs78088787	ENSG00000228238.1	GS1-304P7.2	-3.38	0.000794	0.0445	-0.24	-0.15	Schizophrenia;	chr1:186364550	chr1:186578279~186579299:+
THCA	cis	rs10029851	0.645	rs9996443	ENSG00000234492.4	RPL34-AS1	3.38	0.000794	0.0446	0.14	0.15	Amyotrophic lateral sclerosis (sporadic);	chr4:108698434	chr4:108538190~108620460:-
THCA	cis	rs9427116	0.84	rs9427113	ENSG00000236675.1	MTX1P1	-3.38	0.000794	0.0446	-0.14	-0.15	Blood protein levels;	chr1:154654001	chr1:155230975~155234325:+
THCA	cis	rs7259376	0.729	rs3867187	ENSG00000270947.1	AC025811.3	3.38	0.000794	0.0446	0.16	0.15	Menopause (age at onset);	chr19:22387418	chr19:22455988~22456459:+
THCA	cis	rs804280	0.509	rs13276433	ENSG00000251402.3	FAM90A25P	3.38	0.000794	0.0446	0.2	0.15	Myopia (pathological);	chr8:11925527	chr8:12415080~12418090:-
THCA	cis	rs806215	0.723	rs1090682	ENSG00000279265.1	AC000123.3	-3.38	0.000795	0.0446	-0.18	-0.15	Type 2 diabetes;	chr7:127605105	chr7:127349833~127350293:-
THCA	cis	rs806215	1	rs712697	ENSG00000279265.1	AC000123.3	-3.38	0.000795	0.0446	-0.18	-0.15	Type 2 diabetes;	chr7:127607078	chr7:127349833~127350293:-
THCA	cis	rs11671005	0.569	rs73068335	ENSG00000267858.4	MZF1-AS1	-3.38	0.000795	0.0446	-0.12	-0.15	Mean platelet volume;	chr19:58577941	chr19:58559129~58574797:+
THCA	cis	rs1542829	0.71	rs1497303	ENSG00000249846.5	RP11-77P16.4	-3.38	0.000795	0.0446	-0.22	-0.15	Body mass index;	chr3:130427887	chr3:130112550~130120579:+
THCA	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-3.38	0.000795	0.0446	-0.15	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
THCA	cis	rs3738443	0.678	rs57861883	ENSG00000259865.1	RP11-488L18.10	3.38	0.000795	0.0446	0.14	0.15	Alcohol dependence;	chr1:247214089	chr1:247187281~247188526:-
THCA	cis	rs1153858	0.725	rs74572151	ENSG00000275672.1	GATM-AS1	-3.38	0.000795	0.0446	-0.16	-0.15	Homoarginine levels;	chr15:45355328	chr15:45378700~45380123:+
THCA	cis	rs11230394	0.715	rs1080719	ENSG00000254477.1	AP000640.10	-3.38	0.000795	0.0446	-0.22	-0.15	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);	chr11:60655418	chr11:59753015~59754975:-
THCA	cis	rs1823913	0.503	rs34716486	ENSG00000280083.1	RP11-317J9.1	-3.38	0.000795	0.0446	-0.18	-0.15	Obesity-related traits;	chr2:191343335	chr2:191154118~191156070:-
THCA	cis	rs7264396	0.635	rs6060660	ENSG00000088340.14	FER1L4	3.38	0.000795	0.0446	0.15	0.15	Total cholesterol levels;	chr20:35888727	chr20:35558737~35607562:-
THCA	cis	rs12724450	0.793	rs35762205	ENSG00000228126.1	FALEC	3.38	0.000795	0.0446	0.3	0.15	Blood protein levels;	chr1:150325460	chr1:150515757~150518032:+
THCA	cis	rs12724450	0.793	rs71515775	ENSG00000228126.1	FALEC	3.38	0.000795	0.0446	0.3	0.15	Blood protein levels;	chr1:150331925	chr1:150515757~150518032:+
THCA	cis	rs12724450	0.793	rs35347210	ENSG00000228126.1	FALEC	3.38	0.000795	0.0446	0.3	0.15	Blood protein levels;	chr1:150347501	chr1:150515757~150518032:+
THCA	cis	rs11673344	0.9	rs11671112	ENSG00000267260.1	CTD-2162K18.4	-3.38	0.000795	0.0446	-0.21	-0.15	Obesity-related traits;	chr19:37169384	chr19:36773153~36777078:+
THCA	cis	rs6871536	1	rs62383710	ENSG00000233006.5	AC034220.3	-3.38	0.000795	0.0446	-0.14	-0.15	Asthma (childhood onset);	chr5:132564905	chr5:132311285~132369916:-
THCA	cis	rs8067354	0.645	rs2102507	ENSG00000266701.1	AC005702.4	3.38	0.000795	0.0446	0.24	0.15	Hemoglobin concentration;	chr17:59798546	chr17:60042546~60042627:-
THCA	cis	rs8067354	0.645	rs2645491	ENSG00000266701.1	AC005702.4	3.38	0.000795	0.0446	0.24	0.15	Hemoglobin concentration;	chr17:59799688	chr17:60042546~60042627:-
THCA	cis	rs8067354	0.645	rs2665400	ENSG00000266701.1	AC005702.4	3.38	0.000795	0.0446	0.24	0.15	Hemoglobin concentration;	chr17:59802840	chr17:60042546~60042627:-
THCA	cis	rs8067354	0.645	rs2645489	ENSG00000266701.1	AC005702.4	3.38	0.000795	0.0446	0.24	0.15	Hemoglobin concentration;	chr17:59806010	chr17:60042546~60042627:-
THCA	cis	rs8067354	0.645	rs2645486	ENSG00000266701.1	AC005702.4	3.38	0.000795	0.0446	0.24	0.15	Hemoglobin concentration;	chr17:59808540	chr17:60042546~60042627:-
THCA	cis	rs8067354	0.645	rs2645487	ENSG00000266701.1	AC005702.4	3.38	0.000795	0.0446	0.24	0.15	Hemoglobin concentration;	chr17:59808764	chr17:60042546~60042627:-
THCA	cis	rs3790645	1	rs3790645	ENSG00000241547.1	RP11-4K3__A.5	-3.38	0.000795	0.0446	-0.18	-0.15	Glucose homeostasis traits;	chr1:26558373	chr1:27325329~27325796:+
THCA	cis	rs8018967	1	rs8018967	ENSG00000258443.1	RP3-414A15.11	-3.38	0.000795	0.0446	-0.19	-0.15	Blood metabolite ratios;	chr14:73510230	chr14:73517233~73520648:-
THCA	cis	rs9300255	0.722	rs67624109	ENSG00000235423.7	RP11-282O18.3	-3.38	0.000795	0.0446	-0.17	-0.15	Neutrophil percentage of white cells;	chr12:123340088	chr12:123252030~123261483:-
THCA	cis	rs2191566	1	rs390369	ENSG00000277806.1	RP11-15A1.8	3.38	0.000795	0.0446	0.16	0.15	Acute lymphoblastic leukemia (childhood);	chr19:44002832	chr19:43976815~43977448:+
THCA	cis	rs2888875	0.963	rs2374551	ENSG00000200924.1	RNU6-1048P	-3.38	0.000795	0.0446	-0.17	-0.15	Glomerular filtration rate (creatinine);	chr2:43575241	chr2:43892690~43892796:+
THCA	cis	rs354225	0.539	rs13428703	ENSG00000162997.14	PRORSD1P	-3.38	0.000795	0.0446	-0.19	-0.15	Schizophrenia;	chr2:54733543	chr2:55282319~55284522:+
THCA	cis	rs713587	0.563	rs7591460	ENSG00000224165.4	DNAJC27-AS1	-3.38	0.000795	0.0446	-0.08	-0.15	Body mass index in non-asthmatics;	chr2:24881098	chr2:24971390~25039694:+
THCA	cis	rs6546550	0.935	rs6546551	ENSG00000179818.12	PCBP1-AS1	-3.38	0.000795	0.0446	-0.12	-0.15	Prevalent atrial fibrillation;	chr2:69846571	chr2:69962263~70103220:-
THCA	cis	rs2662776	1	rs2999967	ENSG00000232995.6	RGS5	-3.38	0.000795	0.0446	-0.13	-0.15	Lead levels in blood;	chr1:163196886	chr1:163244505~163321894:-
THCA	cis	rs2662776	1	rs2999859	ENSG00000232995.6	RGS5	-3.38	0.000795	0.0446	-0.13	-0.15	Lead levels in blood;	chr1:163196933	chr1:163244505~163321894:-
THCA	cis	rs1908814	0.51	rs57655799	ENSG00000255046.1	RP11-297N6.4	-3.38	0.000796	0.0446	-0.16	-0.15	Neuroticism;	chr8:11924908	chr8:11797928~11802568:-
THCA	cis	rs7631605	0.905	rs748766	ENSG00000272334.1	RP11-129K12.1	-3.38	0.000796	0.0446	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:37041383	chr3:36973117~36973672:-
THCA	cis	rs11648785	0.506	rs7191175	ENSG00000222019.6	URAHP	-3.38	0.000796	0.0446	-0.13	-0.15	Tanning;	chr16:90028869	chr16:90039761~90047773:-
THCA	cis	rs4805272	0.539	rs7256211	ENSG00000267799.1	MAN1A2P1	3.38	0.000796	0.0446	0.2	0.15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28842156	chr19:28790812~28792871:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000281831.1	HCP5B	3.38	0.000796	0.0446	0.25	0.15	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29871895~29873783:-
THCA	cis	rs7656342	0.636	rs4697902	ENSG00000242034.1	RP11-1396O13.1	-3.38	0.000796	0.0446	-0.18	-0.15	Gut microbiota (bacterial taxa);	chr4:9862312	chr4:9553614~9553985:-
THCA	cis	rs7395662	1	rs6485888	ENSG00000200090.1	Y_RNA	-3.38	0.000796	0.0446	-0.1	-0.15	HDL cholesterol;	chr11:48583787	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs10838971	ENSG00000200090.1	Y_RNA	-3.38	0.000796	0.0446	-0.1	-0.15	HDL cholesterol;	chr11:48585072	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs7944356	ENSG00000200090.1	Y_RNA	-3.38	0.000796	0.0446	-0.1	-0.15	HDL cholesterol;	chr11:48588602	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs11039857	ENSG00000200090.1	Y_RNA	-3.38	0.000796	0.0446	-0.1	-0.15	HDL cholesterol;	chr11:48589301	chr11:47726894~47726992:-
THCA	cis	rs80130819	0.688	rs1552551	ENSG00000226413.2	OR8T1P	3.38	0.000796	0.0446	0.23	0.15	Prostate cancer;	chr12:48249318	chr12:48442030~48442947:-
THCA	cis	rs1580019	0.885	rs1610141	ENSG00000273014.1	RP11-225B17.2	3.38	0.000796	0.0446	0.17	0.15	Cognitive ability;	chr7:32458823	chr7:32758882~32759353:+
THCA	cis	rs61160187	0.527	rs10076742	ENSG00000251279.1	CTC-436P18.1	-3.38	0.000796	0.0446	-0.2	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795219	chr5:61162070~61232040:+
THCA	cis	rs7395662	0.963	rs4882072	ENSG00000200090.1	Y_RNA	-3.38	0.000796	0.0446	-0.1	-0.15	HDL cholesterol;	chr11:48458339	chr11:47726894~47726992:-
THCA	cis	rs11098499	0.874	rs12509054	ENSG00000249244.1	RP11-548H18.2	3.38	0.000796	0.0446	0.17	0.15	Corneal astigmatism;	chr4:119193920	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.874	rs10022508	ENSG00000249244.1	RP11-548H18.2	3.38	0.000796	0.0446	0.17	0.15	Corneal astigmatism;	chr4:119194073	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.874	rs12502503	ENSG00000249244.1	RP11-548H18.2	3.38	0.000796	0.0446	0.17	0.15	Corneal astigmatism;	chr4:119195100	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.874	rs6832670	ENSG00000249244.1	RP11-548H18.2	3.38	0.000796	0.0446	0.17	0.15	Corneal astigmatism;	chr4:119197637	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.874	rs6822498	ENSG00000249244.1	RP11-548H18.2	3.38	0.000796	0.0446	0.17	0.15	Corneal astigmatism;	chr4:119199028	chr4:119391831~119395335:-
THCA	cis	rs12129938	0.911	rs12140735	ENSG00000231940.1	RPS7P3	3.38	0.000796	0.0446	0.2	0.15	Thyroid cancer;	chr1:233276396	chr1:233288868~233289447:-
THCA	cis	rs1113500	0.836	rs1122158	ENSG00000230489.1	VAV3-AS1	-3.38	0.000796	0.0446	-0.14	-0.15	Growth-regulated protein alpha levels;	chr1:108046046	chr1:107964443~107994607:+
THCA	cis	rs13063635	0.79	rs9845542	ENSG00000223552.1	RP11-24F11.2	-3.38	0.000796	0.0446	-0.19	-0.15	Eosinophil percentage of granulocytes;	chr3:46070377	chr3:46364955~46407059:-
THCA	cis	rs9863	0.828	rs4765562	ENSG00000269938.1	RP11-214K3.20	-3.38	0.000796	0.0446	-0.17	-0.15	White blood cell count;	chr12:123988024	chr12:123968023~123968579:-
THCA	cis	rs939960	1	rs7455366	ENSG00000276538.1	RP11-545G3.2	3.38	0.000796	0.0446	0.22	0.15	Neutrophil percentage of white cells;	chr7:150551113	chr7:150047609~150047854:-
THCA	cis	rs939960	1	rs12535647	ENSG00000276538.1	RP11-545G3.2	3.38	0.000796	0.0446	0.22	0.15	Neutrophil percentage of white cells;	chr7:150552352	chr7:150047609~150047854:-
THCA	cis	rs2018683	0.711	rs2158788	ENSG00000233517.1	AC005162.5	-3.38	0.000796	0.0446	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932341	chr7:28987028~28988899:+
THCA	cis	rs8131065	0.901	rs58358090	ENSG00000230366.8	DSCR9	-3.38	0.000796	0.0446	-0.24	-0.15	Iris color (L* coordinate);	chr21:36634510	chr21:37208503~37221736:+
THCA	cis	rs8131065	1	rs58974617	ENSG00000230366.8	DSCR9	-3.38	0.000796	0.0446	-0.24	-0.15	Iris color (L* coordinate);	chr21:36634567	chr21:37208503~37221736:+
THCA	cis	rs8131065	1	rs66608412	ENSG00000230366.8	DSCR9	-3.38	0.000796	0.0446	-0.24	-0.15	Iris color (L* coordinate);	chr21:36635064	chr21:37208503~37221736:+
THCA	cis	rs8131065	1	rs7277492	ENSG00000230366.8	DSCR9	-3.38	0.000796	0.0446	-0.24	-0.15	Iris color (L* coordinate);	chr21:36635334	chr21:37208503~37221736:+
THCA	cis	rs8131065	1	rs7278590	ENSG00000230366.8	DSCR9	-3.38	0.000796	0.0446	-0.24	-0.15	Iris color (L* coordinate);	chr21:36635379	chr21:37208503~37221736:+
THCA	cis	rs10508774	1	rs72782295	ENSG00000217094.2	PPIAP31	3.38	0.000796	0.0446	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32800861	chr10:32188323~32188817:-
THCA	cis	rs10508774	0.85	rs2152161	ENSG00000217094.2	PPIAP31	3.38	0.000796	0.0446	0.26	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32643857	chr10:32188323~32188817:-
THCA	cis	rs1053338	0.529	rs17069316	ENSG00000271843.1	RP11-245J9.5	3.38	0.000796	0.0446	0.24	0.15	Breast cancer;	chr3:63728293	chr3:64008082~64008692:-
THCA	cis	rs7968440	0.808	rs67934435	ENSG00000200953.1	Y_RNA	3.38	0.000796	0.0446	0.19	0.15	Fibrinogen;	chr12:50823401	chr12:51156868~51156977:-
THCA	cis	rs9907295	0.901	rs9907121	ENSG00000270871.1	AC015849.19	3.38	0.000796	0.0446	0.13	0.15	Fibroblast growth factor basic levels;	chr17:35849074	chr17:35816717~35830293:-
THCA	cis	rs718433	0.501	rs4981387	ENSG00000256379.1	TRAV8-5	-3.38	0.000796	0.0446	-0.17	-0.15	Intraocular pressure;	chr14:21865764	chr14:21903077~21903598:+
THCA	cis	rs80130819	0.515	rs1793956	ENSG00000273765.1	RP11-370I10.11	3.38	0.000796	0.0446	0.17	0.15	Prostate cancer;	chr12:47999131	chr12:48360920~48361377:+
THCA	cis	rs2447820	0.5	rs67324184	ENSG00000263432.2	RN7SL689P	3.38	0.000796	0.0446	0.19	0.15	Migraine;	chr5:122852244	chr5:123022487~123022783:-
THCA	cis	rs721917	1	rs721917	ENSG00000230091.5	TMEM254-AS1	-3.38	0.000796	0.0446	-0.19	-0.15	Chronic obstructive pulmonary disease;	chr10:79946568	chr10:80046860~80078912:-
THCA	cis	rs6049003	0.668	rs6114234	ENSG00000270001.1	RP11-218C14.8	-3.38	0.000796	0.0446	-0.17	-0.15	Cerebrospinal fluid biomarker levels;	chr20:23712088	chr20:23631826~23632316:-
THCA	cis	rs11168351	0.926	rs10875719	ENSG00000257735.1	RP11-370I10.6	3.38	0.000796	0.0447	0.18	0.15	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48350945~48442411:+
THCA	cis	rs478304	0.654	rs7934036	ENSG00000255120.4	OVOL1-AS1	-3.38	0.000796	0.0447	-0.21	-0.15	Acne (severe);	chr11:65683549	chr11:65789051~65790868:-
THCA	cis	rs11030122	0.702	rs10835311	ENSG00000230593.3	AC090804.1	3.38	0.000796	0.0447	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3927797	chr11:3892398~3892887:-
THCA	cis	rs17604090	0.938	rs68158127	ENSG00000227855.3	DPY19L2P3	3.38	0.000796	0.0447	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29645082	chr7:29650227~29742594:+
THCA	cis	rs1978968	0.763	rs9605481	ENSG00000269220.1	LINC00528	-3.38	0.000796	0.0447	-0.17	-0.15	Presence of antiphospholipid antibodies;	chr22:17982911	chr22:17777322~17779481:+
THCA	cis	rs2638953	0.814	rs60960895	ENSG00000247934.4	RP11-967K21.1	-3.38	0.000797	0.0447	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454499	chr12:28163298~28190738:-
THCA	cis	rs9353324	1	rs7745560	ENSG00000203875.9	SNHG5	3.38	0.000797	0.0447	0.29	0.15	Interferon gamma-induced protein 10 levels;	chr6:85579203	chr6:85660950~85678736:-
THCA	cis	rs3785574	0.886	rs62077504	ENSG00000279369.1	RP11-51F16.1	3.38	0.000797	0.0447	0.11	0.15	Height;	chr17:63760374	chr17:63700847~63702670:+
THCA	cis	rs7264396	0.779	rs6087723	ENSG00000088340.14	FER1L4	-3.38	0.000797	0.0447	-0.16	-0.15	Total cholesterol levels;	chr20:35587861	chr20:35558737~35607562:-
THCA	cis	rs2839186	0.708	rs17183123	ENSG00000225043.1	RPL18AP2	3.38	0.000797	0.0447	0.18	0.15	Testicular germ cell tumor;	chr21:46252047	chr21:46420553~46421034:-
THCA	cis	rs9488822	0.702	rs6909746	ENSG00000233558.1	RP3-486I3.4	3.38	0.000797	0.0447	0.17	0.15	LDL cholesterol;Cholesterol, total;	chr6:116031587	chr6:116258493~116259115:-
THCA	cis	rs2997457	0.872	rs298441	ENSG00000261349.1	RP3-465N24.5	-3.38	0.000797	0.0447	-0.22	-0.15	Facial morphology (factor 16);	chr1:25973829	chr1:25266102~25267136:-
THCA	cis	rs12724450	0.793	rs71622688	ENSG00000228126.1	FALEC	3.38	0.000797	0.0447	0.3	0.15	Blood protein levels;	chr1:150306238	chr1:150515757~150518032:+
THCA	cis	rs12724450	0.793	rs34347495	ENSG00000228126.1	FALEC	3.38	0.000797	0.0447	0.3	0.15	Blood protein levels;	chr1:150314058	chr1:150515757~150518032:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000230295.1	RP11-458F8.2	3.38	0.000797	0.0447	0.12	0.15	Aortic root size;	chr7:66113790	chr7:66880708~66882981:+
THCA	cis	rs1122401	0.557	rs1007139	ENSG00000280159.1	CTD-2591A1.1	3.38	0.000797	0.0447	0.17	0.15	Smoking initiation;	chr5:54578442	chr5:54643557~54645987:+
THCA	cis	rs34779708	0.931	rs12767414	ENSG00000233200.1	RP11-324I22.2	3.38	0.000797	0.0447	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35219894~35230598:-
THCA	cis	rs728616	0.558	rs7097080	ENSG00000242600.5	MBL1P	3.38	0.000797	0.0447	0.18	0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406944	chr10:79904898~79950336:+
THCA	cis	rs12927351	1	rs12927351	ENSG00000207525.1	Y_RNA	-3.38	0.000797	0.0447	-0.23	-0.15	Granulocyte percentage of myeloid white cells;	chr16:74562720	chr16:74463888~74463988:-
THCA	cis	rs12927351	1	rs36026517	ENSG00000207525.1	Y_RNA	-3.38	0.000797	0.0447	-0.23	-0.15	Granulocyte percentage of myeloid white cells;	chr16:74563860	chr16:74463888~74463988:-
THCA	cis	rs2832270	1	rs2832270	ENSG00000273017.1	AP000240.9	-3.38	0.000797	0.0447	-0.24	-0.15	Response to mTOR inhibitor (everolimus);	chr21:29222211	chr21:29359002~29359453:+
THCA	cis	rs916888	0.773	rs9896243	ENSG00000260075.1	NSFP1	-3.38	0.000797	0.0447	-0.25	-0.15	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46372855~46487141:+
THCA	cis	rs10489202	0.683	rs2294817	ENSG00000250762.1	RP1-313L4.4	-3.38	0.000797	0.0447	-0.21	-0.15	Schizophrenia;	chr1:168104363	chr1:167819898~167820248:-
THCA	cis	rs9891119	0.965	rs4796791	ENSG00000267595.1	RP11-242D8.2	3.38	0.000797	0.0447	0.14	0.15	Multiple sclerosis;Crohn's disease;	chr17:42378745	chr17:43168170~43168249:-
THCA	cis	rs2997447	0.706	rs1414419	ENSG00000236155.5	RP11-231P20.2	-3.38	0.000797	0.0447	-0.12	-0.15	QRS complex (12-leadsum);	chr1:26104010	chr1:26209741~26229840:+
THCA	cis	rs3126085	0.935	rs10888475	ENSG00000237975.5	FLG-AS1	-3.38	0.000797	0.0447	-0.24	-0.15	Atopic dermatitis;	chr1:152253536	chr1:152168125~152445456:+
THCA	cis	rs9875589	0.957	rs1579551	ENSG00000228242.5	AC093495.4	3.38	0.000797	0.0447	0.09	0.15	Ovarian reserve;	chr3:13904074	chr3:14144637~14165978:+
THCA	cis	rs3805389	0.884	rs62310884	ENSG00000273257.1	RP11-177J6.1	-3.38	0.000797	0.0447	-0.24	-0.15	Waist-to-hip ratio adjusted for body mass index;	chr4:55592233	chr4:55387949~55388271:+
THCA	cis	rs7829975	0.846	rs7005216	ENSG00000233609.3	RP11-62H7.2	-3.38	0.000797	0.0447	-0.15	-0.15	Mood instability;	chr8:8689600	chr8:8961200~8979025:+
THCA	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	3.38	0.000797	0.0447	0.17	0.15	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
THCA	cis	rs7680126	0.53	rs2903827	ENSG00000261490.1	RP11-448G15.3	-3.38	0.000797	0.0447	-0.12	-0.15	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10174248	chr4:10068089~10073019:-
THCA	cis	rs1612141	0.744	rs7159959	ENSG00000251363.2	RP11-129M6.1	3.38	0.000797	0.0447	0.22	0.15	QT interval (drug interaction);	chr14:41112809	chr14:40954898~40975877:+
THCA	cis	rs9902453	0.765	rs2259857	ENSG00000263603.1	CTD-2349P21.5	-3.38	0.000798	0.0447	-0.18	-0.15	Coffee consumption (cups per day);	chr17:29770762	chr17:30729469~30731202:+
THCA	cis	rs972540	1	rs6757124	ENSG00000229647.1	AC007879.7	-3.38	0.000798	0.0447	-0.18	-0.15	Body mass index;	chr2:206366510	chr2:207239650~207245887:+
THCA	cis	rs4671400	0.571	rs12615222	ENSG00000270820.4	RP11-355B11.2	-3.38	0.000798	0.0447	-0.15	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267760	chr2:61471188~61484130:+
THCA	cis	rs4671400	0.543	rs62152274	ENSG00000270820.4	RP11-355B11.2	-3.38	0.000798	0.0447	-0.15	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61272453	chr2:61471188~61484130:+
THCA	cis	rs4671400	0.571	rs62152275	ENSG00000270820.4	RP11-355B11.2	-3.38	0.000798	0.0447	-0.15	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61275103	chr2:61471188~61484130:+
THCA	cis	rs7487075	0.619	rs7489242	ENSG00000275481.1	RP11-474P2.6	3.38	0.000798	0.0447	0.15	0.15	Itch intensity from mosquito bite;	chr12:46434848	chr12:46388856~46392126:+
THCA	cis	rs1538970	0.884	rs781226	ENSG00000234329.1	RP11-767N6.2	-3.38	0.000798	0.0447	-0.15	-0.15	Platelet count;	chr1:45406990	chr1:45651039~45651826:-
THCA	cis	rs256438	0.671	rs17878919	ENSG00000243160.1	RP11-342F17.2	3.38	0.000798	0.0447	0.19	0.15	Serum thyroid-stimulating hormone levels;	chr5:80033715	chr5:79529302~79530093:+
THCA	cis	rs1005277	0.579	rs1548255	ENSG00000099251.13	HSD17B7P2	3.38	0.000798	0.0447	0.13	0.15	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38356380~38378505:+
THCA	cis	rs765787	0.53	rs12592055	ENSG00000259539.1	CTD-2651B20.1	-3.38	0.000798	0.0447	-0.19	-0.15	Uric acid levels;	chr15:45222279	chr15:45152664~45167526:-
THCA	cis	rs747782	0.585	rs1604655	ENSG00000200090.1	Y_RNA	3.38	0.000798	0.0447	0.14	0.15	Intraocular pressure;	chr11:48253226	chr11:47726894~47726992:-
THCA	cis	rs847649	0.692	rs6969054	ENSG00000234715.1	CTB-107G13.1	-3.38	0.000798	0.0447	-0.17	-0.15	Morning vs. evening chronotype;	chr7:102806122	chr7:103445207~103514007:+
THCA	cis	rs847649	0.692	rs6949391	ENSG00000234715.1	CTB-107G13.1	-3.38	0.000798	0.0447	-0.17	-0.15	Morning vs. evening chronotype;	chr7:102806416	chr7:103445207~103514007:+
THCA	cis	rs847649	0.692	rs10257317	ENSG00000234715.1	CTB-107G13.1	-3.38	0.000798	0.0447	-0.17	-0.15	Morning vs. evening chronotype;	chr7:102806609	chr7:103445207~103514007:+
THCA	cis	rs1122401	0.576	rs2161585	ENSG00000280159.1	CTD-2591A1.1	3.38	0.000798	0.0447	0.17	0.15	Smoking initiation;	chr5:54578772	chr5:54643557~54645987:+
THCA	cis	rs763121	0.853	rs8140617	ENSG00000225450.1	RP3-508I15.14	3.38	0.000798	0.0447	0.12	0.15	Menopause (age at onset);	chr22:38574434	chr22:38739003~38749041:+
THCA	cis	rs3784262	0.934	rs4646611	ENSG00000259250.1	RP11-50C13.1	3.38	0.000798	0.0447	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57972885	chr15:58587507~58591676:+
THCA	cis	rs1948632	0.599	rs953350	ENSG00000262583.1	RP11-77K12.5	3.38	0.000798	0.0447	0.2	0.15	Tuberculosis;	chr16:75951111	chr16:75499788~75516280:-
THCA	cis	rs2006933	1	rs2006933	ENSG00000267644.1	CTD-2008P7.10	3.38	0.000798	0.0447	0.2	0.15	Amyotrophic lateral sclerosis;	chr17:28274107	chr17:28219285~28220005:+
THCA	cis	rs9611565	0.592	rs9611612	ENSG00000237037.8	NDUFA6-AS1	3.38	0.000798	0.0447	0.14	0.15	Vitiligo;	chr22:41565185	chr22:42090931~42137742:+
THCA	cis	rs1799949	0.965	rs799910	ENSG00000236383.6	LINC00854	-3.38	0.000798	0.0447	-0.15	-0.15	Menopause (age at onset);	chr17:43127544	chr17:43216941~43305976:-
THCA	cis	rs7631605	0.586	rs4678962	ENSG00000224080.1	UBE2FP1	3.38	0.000798	0.0447	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37413752	chr3:37143512~37143958:-
THCA	cis	rs1552244	0.882	rs3755782	ENSG00000269982.1	RP11-1020A11.2	3.38	0.000798	0.0447	0.12	0.15	Alzheimer's disease;	chr3:9987621	chr3:9958717~9962539:+
THCA	cis	rs1832871	0.711	rs7770047	ENSG00000213078.3	RP5-933K21.2	-3.38	0.000798	0.0447	-0.23	-0.15	Height;	chr6:158264664	chr6:157365990~157366923:-
THCA	cis	rs34792	0.554	rs12708796	ENSG00000275910.1	RP11-680G24.6	-3.38	0.000798	0.0447	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:15015828~15016390:-
THCA	cis	rs7641761	0.514	rs4417911	ENSG00000237978.4	KCNMB2-AS1	3.38	0.000799	0.0447	0.19	0.15	Mean corpuscular hemoglobin;	chr3:179001547	chr3:178526505~178860405:-
THCA	cis	rs854765	0.583	rs8065563	ENSG00000265511.1	RP11-524F11.1	3.38	0.000799	0.0448	0.12	0.15	Total body bone mineral density;	chr17:17879090	chr17:17507351~17508308:+
THCA	cis	rs10504130	0.696	rs60796336	ENSG00000272024.1	RP11-546K22.3	-3.38	0.000799	0.0448	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51950284~51950690:+
THCA	cis	rs9860428	0.844	rs6798395	ENSG00000243795.1	RP11-572M11.3	3.38	0.000799	0.0448	0.18	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897190	chr3:113142350~113167819:-
THCA	cis	rs941207	0.507	rs73337030	ENSG00000258045.2	Metazoa_SRP	3.38	0.000799	0.0448	0.13	0.15	Platelet count;	chr12:56652410	chr12:55731264~55731531:-
THCA	cis	rs524281	0.814	rs2270448	ENSG00000255038.1	RP11-1167A19.2	-3.38	0.000799	0.0448	-0.18	-0.15	Electroencephalogram traits;	chr11:66068460	chr11:66067277~66069619:-
THCA	cis	rs7162310	1	rs12899503	ENSG00000259459.4	RP11-321G12.1	3.38	0.000799	0.0448	0.14	0.15	Myopia;	chr15:63282373	chr15:63390136~63438320:+
THCA	cis	rs7264396	0.635	rs3827030	ENSG00000088340.14	FER1L4	-3.38	0.000799	0.0448	-0.15	-0.15	Total cholesterol levels;	chr20:35887025	chr20:35558737~35607562:-
THCA	cis	rs4305276	0.964	rs4398270	ENSG00000218416.4	PP14571	3.38	0.000799	0.0448	0.19	0.15	Mean platelet volume;	chr2:240525498	chr2:240449315~240456714:-
THCA	cis	rs1799949	0.965	rs8176310	ENSG00000279602.1	CTD-3014M21.1	-3.38	0.000799	0.0448	-0.19	-0.15	Menopause (age at onset);	chr17:43047896	chr17:43360041~43361361:-
THCA	cis	rs2180341	0.855	rs4308584	ENSG00000220522.2	RP1-177A13.1	3.38	0.000799	0.0448	0.19	0.15	Breast cancer;	chr6:127393729	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.855	rs9385422	ENSG00000220522.2	RP1-177A13.1	3.38	0.000799	0.0448	0.19	0.15	Breast cancer;	chr6:127395312	chr6:127416535~127416952:-
THCA	cis	rs12621844	0.706	rs4953557	ENSG00000234690.5	AC073283.4	-3.38	0.000799	0.0448	-0.15	-0.15	Glycated hemoglobin levels;	chr2:48174568	chr2:47192405~47345074:-
THCA	cis	rs10207628	0.738	rs7575209	ENSG00000260634.1	RP11-521O16.1	3.38	0.000799	0.0448	0.21	0.15	Psychosis and Alzheimer's disease;	chr2:127126547	chr2:127024252~127025723:-
THCA	cis	rs6738627	0.766	rs13389219	ENSG00000223318.1	RNA5SP111	3.38	0.000799	0.0448	0.18	0.15	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164672366	chr2:164895677~164895777:-
THCA	cis	rs427943	0.52	rs2838787	ENSG00000237664.1	LINC00316	3.38	0.000799	0.0448	0.14	0.15	Body mass index;	chr21:45119810	chr21:45338590~45341990:-
THCA	cis	rs12612435	0.736	rs16833946	ENSG00000231890.6	DARS-AS1	3.38	0.000799	0.0448	0.18	0.15	Takotsubo syndrome;	chr2:136384141	chr2:135985176~136022593:+
THCA	cis	rs7216064	1	rs12451721	ENSG00000265055.1	AC145343.2	3.38	0.000799	0.0448	0.23	0.15	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942959	chr17:68096046~68101474:-
THCA	cis	rs9309473	0.66	rs62151564	ENSG00000273245.1	RP11-434P11.2	3.38	0.000799	0.0448	0.25	0.15	Metabolite levels;	chr2:73388321	chr2:73750256~73750786:-
THCA	cis	rs7615952	0.599	rs12485717	ENSG00000248787.1	RP11-666A20.4	3.38	0.000799	0.0448	0.24	0.15	Blood pressure (smoking interaction);	chr3:125988232	chr3:125908005~125910272:-
THCA	cis	rs8179	0.514	rs6954290	ENSG00000230927.2	TMBIM7P	3.38	0.000799	0.0448	0.2	0.15	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92653784	chr7:92412976~92439562:-
THCA	cis	rs701145	0.762	rs896014	ENSG00000240068.1	RPL21P42	3.38	0.000799	0.0448	0.31	0.15	Coronary artery disease;	chr3:154124902	chr3:154023835~154024298:+
THCA	cis	rs7119	0.635	rs59745219	ENSG00000259362.2	RP11-307C19.1	3.38	0.000799	0.0448	0.19	0.15	Type 2 diabetes;	chr15:77591788	chr15:77525540~77534110:+
THCA	cis	rs7621331	1	rs13098245	ENSG00000239213.4	NCK1-AS1	3.38	0.000799	0.0448	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135994792	chr3:136841726~136862054:-
THCA	cis	rs2214442	0.528	rs3757727	ENSG00000271133.4	CTA-293F17.1	3.38	0.000799	0.0448	0.17	0.15	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20372274	chr7:20328299~20331747:-
THCA	cis	rs35065479	1	rs35065479	ENSG00000242889.3	RN7SL449P	3.38	0.000799	0.0448	0.25	0.15	Schizophrenia;	chr17:57659374	chr17:57618108~57618393:+
THCA	cis	rs8064024	0.557	rs7193783	ENSG00000267077.1	RP11-127I20.5	-3.38	0.000799	0.0448	-0.18	-0.15	Cancer;	chr16:4899607	chr16:4795265~4796532:-
THCA	cis	rs7236492	0.872	rs78536295	ENSG00000267655.1	CTD-2286N8.2	3.38	0.000799	0.0448	0.35	0.15	Inflammatory bowel disease;Crohn's disease;	chr18:79469738	chr18:79117207~79117920:+
THCA	cis	rs7809950	0.678	rs2237661	ENSG00000272072.1	CTA-363E19.2	3.37	0.000799	0.0448	0.17	0.15	Coronary artery disease;	chr7:107222678	chr7:107192559~107193300:-
THCA	cis	rs394563	0.601	rs376269	ENSG00000223701.3	RAET1E-AS1	3.37	0.000799	0.0448	0.21	0.15	Dupuytren's disease;	chr6:149474018	chr6:149884431~149919508:+
THCA	cis	rs6995541	0.737	rs17152576	ENSG00000248896.2	CTD-2135J3.3	-3.37	0.000799	0.0448	-0.2	-0.15	Triglyceride levels;	chr8:10826478	chr8:10729314~10771392:+
THCA	cis	rs2888875	0.928	rs881477	ENSG00000200924.1	RNU6-1048P	-3.37	0.000799	0.0448	-0.17	-0.15	Glomerular filtration rate (creatinine);	chr2:43564424	chr2:43892690~43892796:+
THCA	cis	rs7809950	1	rs10276604	ENSG00000272072.1	CTA-363E19.2	-3.37	8e-04	0.0448	-0.15	-0.15	Coronary artery disease;	chr7:107576293	chr7:107192559~107193300:-
THCA	cis	rs6724465	1	rs10208728	ENSG00000272644.1	RP11-33O4.1	3.37	8e-04	0.0448	0.22	0.15	Height;	chr2:219052581	chr2:219069354~219069809:-
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000281021.1	RP1-12G14.9	-3.37	8e-04	0.0448	-0.16	-0.15	Lung cancer;	chr6:149667929	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000281021.1	RP1-12G14.9	-3.37	8e-04	0.0448	-0.16	-0.15	Lung cancer;	chr6:149675588	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000281021.1	RP1-12G14.9	-3.37	8e-04	0.0448	-0.16	-0.15	Lung cancer;	chr6:149675847	chr6:149576089~149590864:-
THCA	cis	rs4846580	1	rs4846580	ENSG00000230024.1	RP11-95P13.1	-3.37	8e-04	0.0448	-0.17	-0.15	Total body bone mineral density;	chr1:219724599	chr1:219435152~219442642:-
THCA	cis	rs354225	0.597	rs10176445	ENSG00000212175.1	SNORA12	-3.37	8e-04	0.0448	-0.19	-0.15	Schizophrenia;	chr2:54618639	chr2:55565703~55565850:+
THCA	cis	rs9549260	0.755	rs7335520	ENSG00000275149.1	RP11-427J23.1	-3.37	8e-04	0.0448	-0.2	-0.15	Red blood cell count;	chr13:40622270	chr13:40079106~40273509:-
THCA	cis	rs886774	0.691	rs6965674	ENSG00000273055.1	CTB-13F3.1	-3.37	8e-04	0.0448	-0.13	-0.15	Ulcerative colitis;	chr7:107887657	chr7:107942116~107942740:+
THCA	cis	rs10792665	0.844	rs7125791	ENSG00000255503.1	RP11-113K21.4	-3.37	8e-04	0.0448	-0.16	-0.15	Obesity-related traits;	chr11:82969463	chr11:83072402~83097196:-
THCA	cis	rs34779708	0.966	rs12782948	ENSG00000233200.1	RP11-324I22.2	3.37	8e-04	0.0448	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35219894~35230598:-
THCA	cis	rs12101261	0.744	rs74064796	ENSG00000258915.1	BHLHB9P1	-3.37	8e-04	0.0448	-0.19	-0.15	Graves' disease;	chr14:80984758	chr14:80981988~80983638:+
THCA	cis	rs11764561	0.604	rs1181931	ENSG00000236018.2	RP4-814D15.1	-3.37	8e-04	0.0448	-0.19	-0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr7:156205116	chr7:157197600~157198511:-
THCA	cis	rs72781680	0.611	rs55983206	ENSG00000223754.1	AC008073.9	-3.37	8e-04	0.0448	-0.24	-0.15	Lymphocyte counts;	chr2:24111125	chr2:24199839~24201698:-
THCA	cis	rs1823913	0.614	rs1947457	ENSG00000280083.1	RP11-317J9.1	-3.37	8e-04	0.0448	-0.3	-0.15	Obesity-related traits;	chr2:191298970	chr2:191154118~191156070:-
THCA	cis	rs11190604	0.767	rs4919459	ENSG00000273030.1	RP11-285F16.1	3.37	8e-04	0.0448	0.17	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100440614	chr10:100412934~100413421:+
THCA	cis	rs6750795	0.569	rs1797387	ENSG00000281035.1	AC017104.3	-3.37	8e-04	0.0448	-0.17	-0.15	Height;	chr2:231549981	chr2:231456417~231456557:-
THCA	cis	rs11030122	0.604	rs10835557	ENSG00000230593.3	AC090804.1	3.37	8e-04	0.0448	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:4061891	chr11:3892398~3892887:-
THCA	cis	rs1555322	1	rs2425031	ENSG00000126005.14	MMP24-AS1	-3.37	8e-04	0.0448	-0.21	-0.15	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35216462~35278131:-
THCA	cis	rs4417704	0.551	rs12479396	ENSG00000235151.1	AC114730.2	-3.37	8e-04	0.0448	-0.17	-0.15	Joint mobility (Beighton score);	chr2:240949754	chr2:241844380~241845036:+
THCA	cis	rs4417704	0.551	rs6760411	ENSG00000235151.1	AC114730.2	3.37	8e-04	0.0448	0.17	0.15	Joint mobility (Beighton score);	chr2:240945450	chr2:241844380~241845036:+
THCA	cis	rs7671261	1	rs7671261	ENSG00000270720.1	RP11-84C13.2	3.37	8e-04	0.0448	0.18	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88962667	chr4:89119284~89119871:+
THCA	cis	rs4660456	0.913	rs6668453	ENSG00000238287.1	RP11-656D10.3	-3.37	8e-04	0.0448	-0.2	-0.15	Platelet count;	chr1:40733299	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs35881320	ENSG00000238287.1	RP11-656D10.3	-3.37	8e-04	0.0448	-0.2	-0.15	Platelet count;	chr1:40733893	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.871	rs34512220	ENSG00000238287.1	RP11-656D10.3	-3.37	8e-04	0.0448	-0.2	-0.15	Platelet count;	chr1:40733912	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs6702983	ENSG00000238287.1	RP11-656D10.3	-3.37	8e-04	0.0448	-0.2	-0.15	Platelet count;	chr1:40735585	chr1:40493157~40508661:-
THCA	cis	rs4660456	0.913	rs12566733	ENSG00000238287.1	RP11-656D10.3	-3.37	8e-04	0.0448	-0.2	-0.15	Platelet count;	chr1:40736067	chr1:40493157~40508661:-
THCA	cis	rs7572733	0.935	rs10931796	ENSG00000231621.1	AC013264.2	-3.37	8e-04	0.0448	-0.14	-0.15	Dermatomyositis;	chr2:197975937	chr2:197197991~197199273:+
THCA	cis	rs3770081	1	rs2303339	ENSG00000273080.1	RP11-301O19.1	3.37	8e-04	0.0448	0.35	0.15	Facial emotion recognition (sad faces);	chr2:86119057	chr2:86195590~86196049:+
THCA	cis	rs4076555	0.558	rs12277949	ENSG00000251364.5	CTD-2516F10.2	-3.37	8e-04	0.0448	-0.14	-0.15	IgG glycosylation;	chr11:7454535	chr11:7427266~7512515:-
THCA	cis	rs8031584	0.678	rs3122	ENSG00000215302.7	CTD-3092A11.1	3.37	8e-04	0.0448	0.19	0.15	Huntington's disease progression;	chr15:30878087	chr15:30470779~30507623:+
THCA	cis	rs9923856	0.57	rs34033347	ENSG00000263033.2	RP11-396B14.2	-3.37	8e-04	0.0448	-0.15	-0.15	Atopic dermatitis;Adult asthma;	chr16:10957186	chr16:11196177~11224969:+
THCA	cis	rs1019173	0.627	rs11770440	ENSG00000261455.1	LINC01003	-3.37	8e-04	0.0448	-0.14	-0.15	Kidney function decline traits;	chr7:152005074	chr7:152463786~152465549:+
THCA	cis	rs7978895	0.519	rs7971888	ENSG00000240759.1	RP11-25I15.1	3.37	8e-04	0.0448	0.17	0.15	Type 2 diabetes;	chr12:43327326	chr12:42678873~42679124:-
THCA	cis	rs7246657	0.714	rs12972195	ENSG00000266916.4	ZNF793-AS1	-3.37	8e-04	0.0448	-0.14	-0.15	Coronary artery calcification;	chr19:37261603	chr19:37497159~37507046:-
THCA	cis	rs11785400	1	rs6995314	ENSG00000177335.9	C8orf31	-3.37	8e-04	0.0448	-0.17	-0.15	Schizophrenia;	chr8:142668300	chr8:143039209~143059942:+
THCA	cis	rs9907295	0.818	rs11658222	ENSG00000270871.1	AC015849.19	3.37	8e-04	0.0448	0.13	0.15	Fibroblast growth factor basic levels;	chr17:35825092	chr17:35816717~35830293:-
THCA	cis	rs972578	0.715	rs1807592	ENSG00000230319.1	AL022476.2	3.37	8e-04	0.0448	0.17	0.15	Mean platelet volume;	chr22:42830906	chr22:43038585~43052366:+
THCA	cis	rs9534288	0.83	rs2897027	ENSG00000235903.6	CPB2-AS1	3.37	8e-04	0.0448	0.23	0.15	Blood protein levels;	chr13:46062100	chr13:46052806~46113332:+
THCA	cis	rs7615952	0.576	rs6780025	ENSG00000248787.1	RP11-666A20.4	-3.37	0.000801	0.0448	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126096781	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.576	rs6804482	ENSG00000248787.1	RP11-666A20.4	-3.37	0.000801	0.0448	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126096919	chr3:125908005~125910272:-
THCA	cis	rs7873102	0.654	rs10732212	ENSG00000213839.4	TMX2P1	-3.37	0.000801	0.0448	-0.12	-0.15	Brain structure;	chr9:37957601	chr9:37885683~37886390:+
THCA	cis	rs6545883	0.965	rs1992765	ENSG00000212978.6	AC016747.3	3.37	0.000801	0.0448	0.17	0.15	Tuberculosis;	chr2:61524198	chr2:61141592~61144969:-
THCA	cis	rs1075265	0.933	rs7607066	ENSG00000235937.1	AC008280.1	3.37	0.000801	0.0448	0.18	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54029552~54030682:-
THCA	cis	rs12541437	0.535	rs16888887	ENSG00000253327.2	RAD21-AS1	3.37	0.000801	0.0448	0.23	0.15	Gut microbiome composition (winter);	chr8:116847913	chr8:116874424~116876868:+
THCA	cis	rs66486766	1	rs66486766	ENSG00000230373.7	GOLGA6L5P	-3.37	0.000801	0.0449	-0.18	-0.15	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84507885~84516814:-
THCA	cis	rs875971	0.545	rs313830	ENSG00000232559.3	GS1-124K5.12	-3.37	0.000801	0.0449	-0.17	-0.15	Aortic root size;	chr7:66086944	chr7:66554588~66576923:-
THCA	cis	rs7264396	0.635	rs6058355	ENSG00000088340.14	FER1L4	3.37	0.000801	0.0449	0.15	0.15	Total cholesterol levels;	chr20:35903421	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs6058358	ENSG00000088340.14	FER1L4	3.37	0.000801	0.0449	0.15	0.15	Total cholesterol levels;	chr20:35904638	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs6060675	ENSG00000088340.14	FER1L4	3.37	0.000801	0.0449	0.15	0.15	Total cholesterol levels;	chr20:35905692	chr20:35558737~35607562:-
THCA	cis	rs4763879	0.634	rs11052582	ENSG00000278635.1	CTD-2318O12.1	3.37	0.000801	0.0449	0.17	0.15	Type 1 diabetes;	chr12:9706714	chr12:9415641~9416718:+
THCA	cis	rs337161	0.605	rs17008609	ENSG00000221571.3	RNU6ATAC35P	-3.37	0.000801	0.0449	-0.17	-0.15	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220769818	chr1:220825620~220826063:+
THCA	cis	rs4656958	0.93	rs4017454	ENSG00000233691.2	RP11-312J18.7	3.37	0.000801	0.0449	0.18	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160913460	chr1:160935537~160936126:+
THCA	cis	rs4656958	0.93	rs4017453	ENSG00000233691.2	RP11-312J18.7	3.37	0.000801	0.0449	0.18	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160913461	chr1:160935537~160936126:+
THCA	cis	rs743757	0.652	rs34584636	ENSG00000232352.1	SEMA3B-AS1	3.37	0.000801	0.0449	0.24	0.15	Diastolic blood pressure;	chr3:50569633	chr3:50266641~50267371:-
THCA	cis	rs743757	0.652	rs2355321	ENSG00000232352.1	SEMA3B-AS1	3.37	0.000801	0.0449	0.24	0.15	Diastolic blood pressure;	chr3:50572377	chr3:50266641~50267371:-
THCA	cis	rs743757	0.641	rs2227280	ENSG00000232352.1	SEMA3B-AS1	3.37	0.000801	0.0449	0.24	0.15	Diastolic blood pressure;	chr3:50577257	chr3:50266641~50267371:-
THCA	cis	rs2187895	0.704	rs1476040	ENSG00000271811.1	RP1-79C4.4	3.37	0.000801	0.0449	0.2	0.15	Tonsillectomy;	chr1:170731617	chr1:170667381~170669425:+
THCA	cis	rs8081187	1	rs8081187	ENSG00000240531.1	RPL21P123	3.37	0.000801	0.0449	0.38	0.15	Breast cancer;	chr17:30689342	chr17:29716279~29716685:-
THCA	cis	rs61160187	0.582	rs976631	ENSG00000251279.1	CTC-436P18.1	-3.37	0.000801	0.0449	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:61162070~61232040:+
THCA	cis	rs5762534	0.509	rs134184	ENSG00000235954.5	TTC28-AS1	3.37	0.000801	0.0449	0.15	0.15	Menopause (age at onset);	chr22:28238988	chr22:27919376~28008581:+
THCA	cis	rs13046373	0.535	rs13051529	ENSG00000174680.8	GRIK1-AS1	-3.37	0.000801	0.0449	-0.19	-0.15	HDL cholesterol;	chr21:30657425	chr21:29748175~29764002:+
THCA	cis	rs9450351	0.744	rs7764843	ENSG00000280232.1	RP11-321N4.4	3.37	0.000801	0.0449	0.33	0.15	Interferon gamma-induced protein 10 levels;	chr6:85903875	chr6:85498441~85499058:-
THCA	cis	rs561341	0.609	rs2051810	ENSG00000263990.1	CTC-542B22.2	3.37	0.000801	0.0449	0.16	0.15	Hip circumference adjusted for BMI;	chr17:31868822	chr17:31873926~31886666:+
THCA	cis	rs681383	1	rs656568	ENSG00000264964.1	RP11-888D10.3	3.37	0.000801	0.0449	0.23	0.15	Sitting height ratio;	chr18:8351988	chr18:9315194~9334441:-
THCA	cis	rs3091242	1	rs646867	ENSG00000228172.4	RP1-317E23.3	3.37	0.000802	0.0449	0.12	0.15	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25816749~25820797:-
THCA	cis	rs285757	1	rs285755	ENSG00000258741.3	RP11-386M24.4	-3.37	0.000802	0.0449	-0.22	-0.15	HIV-1 susceptibility;	chr15:92634985	chr15:92715710~92734195:-
THCA	cis	rs285757	1	rs285757	ENSG00000258741.3	RP11-386M24.4	-3.37	0.000802	0.0449	-0.22	-0.15	HIV-1 susceptibility;	chr15:92635945	chr15:92715710~92734195:-
THCA	cis	rs853679	0.723	rs1736904	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000802	0.0449	-0.17	-0.15	Depression;	chr6:28251492	chr6:28078792~28081130:-
THCA	cis	rs875971	0.545	rs73376394	ENSG00000273024.4	INTS4P2	-3.37	0.000802	0.0449	-0.19	-0.15	Aortic root size;	chr7:66172694	chr7:65647864~65715661:+
THCA	cis	rs17331151	0.505	rs71299613	ENSG00000242142.1	SERBP1P3	-3.37	0.000802	0.0449	-0.33	-0.15	Immune reponse to smallpox (secreted IL-2);	chr3:52664789	chr3:53064283~53065091:-
THCA	cis	rs73787773	0.644	rs17134154	ENSG00000246859.2	STARD4-AS1	3.37	0.000802	0.0449	0.19	0.15	Itch intensity from mosquito bite adjusted by bite size;	chr5:112144837	chr5:111512226~111739726:+
THCA	cis	rs2070615	0.833	rs6580695	ENSG00000258017.1	RP11-386G11.10	-3.37	0.000802	0.0449	-0.19	-0.15	Bipolar disorder;	chr12:48807424	chr12:49127782~49147869:+
THCA	cis	rs9889262	0.663	rs2960169	ENSG00000248714.5	RP11-1079K10.3	3.37	0.000802	0.0449	0.17	0.15	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49301007	chr17:49361165~49369998:+
THCA	cis	rs7084402	1	rs7074778	ENSG00000180221.6	TPT1P10	-3.37	0.000802	0.0449	-0.18	-0.15	Refractive error;	chr10:58512488	chr10:58212541~58213036:-
THCA	cis	rs6120849	0.754	rs6120819	ENSG00000269202.1	RP4-614O4.12	-3.37	0.000802	0.0449	-0.17	-0.15	Protein C levels;	chr20:35065235	chr20:35201747~35203288:-
THCA	cis	rs7188445	0.932	rs17689159	ENSG00000277954.1	RP11-679B19.1	-3.37	0.000802	0.0449	-0.19	-0.15	Urate levels;	chr16:79708493	chr16:79202624~79206739:-
THCA	cis	rs889312	0.5	rs702688	ENSG00000271828.1	CTD-2310F14.1	-3.37	0.000802	0.0449	-0.21	-0.15	Breast cancer (early onset);Breast cancer;	chr5:56895159	chr5:56927874~56929573:+
THCA	cis	rs7916441	1	rs1815314	ENSG00000230091.5	TMEM254-AS1	3.37	0.000802	0.0449	0.19	0.15	Height;Sitting height ratio;	chr10:79169036	chr10:80046860~80078912:-
THCA	cis	rs3026101	0.671	rs3026115	ENSG00000234327.6	AC012146.7	-3.37	0.000802	0.0449	-0.12	-0.15	Body mass index;	chr17:5381927	chr17:5111468~5115004:+
THCA	cis	rs495337	0.735	rs528075	ENSG00000229222.1	KRT18P4	-3.37	0.000802	0.0449	-0.19	-0.15	Psoriasis;	chr20:49895107	chr20:49956745~49958032:+
THCA	cis	rs2243480	1	rs35542501	ENSG00000237310.1	GS1-124K5.4	3.37	0.000802	0.0449	0.17	0.15	Diabetic kidney disease;	chr7:65966228	chr7:66493706~66495474:+
THCA	cis	rs17505102	1	rs16864725	ENSG00000225764.1	P3H2-AS1	3.37	0.000802	0.0449	0.33	0.15	Acute lymphoblastic leukemia (childhood);	chr3:189689655	chr3:190120964~190144846:+
THCA	cis	rs6929812	0.729	rs6456784	ENSG00000216915.2	RP1-97D16.1	3.37	0.000802	0.0449	0.2	0.15	Neuroticism (multi-trait analysis);	chr6:27422242	chr6:27737000~27738494:-
THCA	cis	rs8042680	0.666	rs8036430	ENSG00000258725.1	PRC1-AS1	-3.37	0.000802	0.0449	-0.2	-0.15	Type 2 diabetes;	chr15:90976430	chr15:90966345~90988624:+
THCA	cis	rs6662572	0.806	rs56067046	ENSG00000227857.2	RP4-533D7.5	-3.37	0.000802	0.0449	-0.18	-0.15	Blood protein levels;	chr1:45578642	chr1:46134531~46139081:+
THCA	cis	rs7226677	0.901	rs8096537	ENSG00000263006.5	ROCK1P1	3.37	0.000802	0.0449	0.27	0.15	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr18:273216	chr18:109065~122219:+
THCA	cis	rs2662776	1	rs2814372	ENSG00000232995.6	RGS5	-3.37	0.000802	0.0449	-0.13	-0.15	Lead levels in blood;	chr1:163194834	chr1:163244505~163321894:-
THCA	cis	rs7129556	0.701	rs4322421	ENSG00000254459.1	RP11-91P24.7	3.37	0.000802	0.0449	0.19	0.15	Weight loss (gastric bypass surgery);	chr11:77748349	chr11:77829654~77872262:-
THCA	cis	rs3734729	0.702	rs7741317	ENSG00000231120.3	BTF3P10	3.37	0.000802	0.0449	0.32	0.15	Pulmonary function (smoking interaction);Pulmonary function;	chr6:150226008	chr6:149977922~149978416:+
THCA	cis	rs7264396	0.775	rs2296402	ENSG00000261582.1	RP4-614O4.11	-3.37	0.000802	0.0449	-0.16	-0.15	Total cholesterol levels;	chr20:35466904	chr20:35267885~35280043:-
THCA	cis	rs17604090	1	rs114892953	ENSG00000227855.3	DPY19L2P3	3.37	0.000802	0.0449	0.2	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29636682	chr7:29650227~29742594:+
THCA	cis	rs17604090	0.941	rs114036198	ENSG00000227855.3	DPY19L2P3	3.37	0.000802	0.0449	0.2	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29636684	chr7:29650227~29742594:+
THCA	cis	rs397969	0.573	rs203475	ENSG00000270091.1	RP11-78O7.2	-3.37	0.000802	0.0449	-0.14	-0.15	Platelet count;	chr17:19947662	chr17:19896590~19897287:-
THCA	cis	rs9611565	0.559	rs5751160	ENSG00000237037.8	NDUFA6-AS1	-3.37	0.000802	0.0449	-0.15	-0.15	Vitiligo;	chr22:41779691	chr22:42090931~42137742:+
THCA	cis	rs13236243	0.502	rs2237298	ENSG00000236039.1	AC019117.2	-3.37	0.000802	0.0449	-0.16	-0.15	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17308495	chr7:17434477~17460672:-
THCA	cis	rs7220401	0.789	rs3760456	ENSG00000264290.1	RP11-68I3.4	-3.37	0.000802	0.0449	-0.12	-0.15	Coronary artery disease;	chr17:29621826	chr17:29569580~29570519:+
THCA	cis	rs76793172	0.841	rs111386720	ENSG00000267395.4	AC074212.6	3.37	0.000802	0.0449	0.18	0.15	Eosinophil counts;	chr19:45798887	chr19:45767796~45772504:+
THCA	cis	rs478304	0.651	rs78412025	ENSG00000255517.5	CTD-3074O7.5	3.37	0.000802	0.0449	0.11	0.15	Acne (severe);	chr11:65728225	chr11:66473490~66480233:-
THCA	cis	rs478304	0.651	rs11227281	ENSG00000255517.5	CTD-3074O7.5	3.37	0.000802	0.0449	0.11	0.15	Acne (severe);	chr11:65729087	chr11:66473490~66480233:-
THCA	cis	rs478304	0.651	rs4014192	ENSG00000255517.5	CTD-3074O7.5	3.37	0.000802	0.0449	0.11	0.15	Acne (severe);	chr11:65731444	chr11:66473490~66480233:-
THCA	cis	rs478304	0.651	rs4930312	ENSG00000255517.5	CTD-3074O7.5	3.37	0.000802	0.0449	0.11	0.15	Acne (severe);	chr11:65732248	chr11:66473490~66480233:-
THCA	cis	rs478304	0.651	rs11537193	ENSG00000255517.5	CTD-3074O7.5	3.37	0.000802	0.0449	0.11	0.15	Acne (severe);	chr11:65732532	chr11:66473490~66480233:-
THCA	cis	rs478304	0.651	rs4930313	ENSG00000255517.5	CTD-3074O7.5	3.37	0.000802	0.0449	0.11	0.15	Acne (severe);	chr11:65732957	chr11:66473490~66480233:-
THCA	cis	rs7474896	0.832	rs61857912	ENSG00000263064.2	RP11-291L22.7	3.37	0.000802	0.0449	0.25	0.15	Obesity (extreme);	chr10:37633521	chr10:38448689~38448949:+
THCA	cis	rs7176527	0.5	rs895571	ENSG00000229212.6	RP11-561C5.4	3.37	0.000802	0.0449	0.22	0.15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:85205440~85234795:-
THCA	cis	rs7737355	0.738	rs13174592	ENSG00000224431.1	AC063976.7	3.37	0.000803	0.0449	0.14	0.15	Life satisfaction;	chr5:131628007	chr5:132199456~132203487:+
THCA	cis	rs699371	0.545	rs7569	ENSG00000270000.1	RP3-449M8.9	3.37	0.000803	0.0449	0.15	0.15	Height;	chr14:74500060	chr14:74471930~74472360:-
THCA	cis	rs9450351	0.744	rs7741914	ENSG00000203875.9	SNHG5	-3.37	0.000803	0.0449	-0.31	-0.15	Interferon gamma-induced protein 10 levels;	chr6:86095057	chr6:85660950~85678736:-
THCA	cis	rs2018683	0.707	rs2057957	ENSG00000233517.1	AC005162.5	3.37	0.000803	0.0449	0.19	0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935009	chr7:28987028~28988899:+
THCA	cis	rs2275620	0.526	rs1819173	ENSG00000274691.1	RP11-310E22.6	-3.37	0.000803	0.0449	-0.17	-0.15	Gout;	chr10:94920508	chr10:95173085~95173187:-
THCA	cis	rs910316	0.737	rs398896	ENSG00000273565.1	CTD-3075F15.1	-3.37	0.000803	0.0449	-0.18	-0.15	Height;	chr14:75016124	chr14:75176929~75177418:+
THCA	cis	rs7674212	0.57	rs1031804	ENSG00000230069.3	LRRC37A15P	-3.37	0.000803	0.0449	-0.15	-0.15	Type 2 diabetes;	chr4:103144892	chr4:102727274~102730721:-
THCA	cis	rs13064773	0.528	rs340278	ENSG00000272247.1	RP11-379F4.9	3.37	0.000803	0.0449	0.16	0.15	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158869568	chr3:158801257~158801935:-
THCA	cis	rs10207628	0.698	rs7594230	ENSG00000260634.1	RP11-521O16.1	3.37	0.000803	0.0449	0.21	0.15	Psychosis and Alzheimer's disease;	chr2:127115992	chr2:127024252~127025723:-
THCA	cis	rs4566357	0.615	rs2272202	ENSG00000212391.1	SNORA48	3.37	0.000803	0.0449	0.17	0.15	Coronary artery disease;	chr2:227049909	chr2:226968989~226969122:-
THCA	cis	rs972578	0.967	rs9623737	ENSG00000274717.1	RP1-47A17.1	-3.37	0.000803	0.0449	-0.16	-0.15	Mean platelet volume;	chr22:43010674	chr22:42791814~42794313:-
THCA	cis	rs6504622	0.791	rs758392	ENSG00000238419.1	RNU7-186P	-3.37	0.000803	0.0449	-0.17	-0.15	Orofacial clefts;	chr17:46940493	chr17:47259358~47259420:-
THCA	cis	rs11190604	0.767	rs35508946	ENSG00000273030.1	RP11-285F16.1	3.37	0.000803	0.0449	0.17	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100431399	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.652	rs76629555	ENSG00000273030.1	RP11-285F16.1	3.37	0.000803	0.0449	0.17	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100431660	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs7076606	ENSG00000273030.1	RP11-285F16.1	3.37	0.000803	0.0449	0.17	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100432510	chr10:100412934~100413421:+
THCA	cis	rs1009077	0.627	rs7681796	ENSG00000248280.1	RP11-33B1.2	-3.37	0.000803	0.045	-0.17	-0.15	Endometriosis;	chr4:119611992	chr4:119440561~119450157:-
THCA	cis	rs1009077	0.587	rs12502511	ENSG00000248280.1	RP11-33B1.2	-3.37	0.000803	0.045	-0.17	-0.15	Endometriosis;	chr4:119614560	chr4:119440561~119450157:-
THCA	cis	rs1009077	0.627	rs4833622	ENSG00000248280.1	RP11-33B1.2	-3.37	0.000803	0.045	-0.17	-0.15	Endometriosis;	chr4:119625504	chr4:119440561~119450157:-
THCA	cis	rs2018683	0.707	rs4722877	ENSG00000233517.1	AC005162.5	-3.37	0.000803	0.045	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933289	chr7:28987028~28988899:+
THCA	cis	rs2018683	0.707	rs4722878	ENSG00000233517.1	AC005162.5	-3.37	0.000803	0.045	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933414	chr7:28987028~28988899:+
THCA	cis	rs2018683	0.677	rs2057956	ENSG00000233517.1	AC005162.5	-3.37	0.000803	0.045	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933843	chr7:28987028~28988899:+
THCA	cis	rs5769765	1	rs2295408	ENSG00000278869.1	CITF22-49E9.3	-3.37	0.000803	0.045	-0.21	-0.15	Schizophrenia;	chr22:49867403	chr22:49933198~49934074:-
THCA	cis	rs5769765	1	rs2295409	ENSG00000278869.1	CITF22-49E9.3	-3.37	0.000803	0.045	-0.21	-0.15	Schizophrenia;	chr22:49867412	chr22:49933198~49934074:-
THCA	cis	rs7209700	0.692	rs11652097	ENSG00000262879.4	RP11-156P1.3	3.37	0.000803	0.045	0.14	0.15	IgG glycosylation;	chr17:47239351	chr17:46984045~47100323:-
THCA	cis	rs2760061	0.626	rs2527615	ENSG00000276255.2	RP5-881P19.7	-3.37	0.000803	0.045	-0.17	-0.15	Diastolic blood pressure;	chr1:227931582	chr1:228073909~228076550:-
THCA	cis	rs4478858	0.709	rs937786	ENSG00000229447.2	RP11-490K7.4	3.37	0.000803	0.045	0.14	0.15	Alcohol dependence;	chr1:31385022	chr1:31263245~31263681:-
THCA	cis	rs5769765	0.773	rs138834	ENSG00000280567.1	Metazoa_SRP	-3.37	0.000803	0.045	-0.23	-0.15	Schizophrenia;	chr22:49786849	chr22:49878999~49879242:+
THCA	cis	rs7897654	0.59	rs7092593	ENSG00000236937.2	PTGES3P4	3.37	0.000803	0.045	0.24	0.15	Schizophrenia;	chr10:102976594	chr10:102845595~102845950:+
THCA	cis	rs9607412	0.593	rs130619	ENSG00000279738.1	RP5-1014D13.2	-3.37	0.000803	0.045	-0.14	-0.15	Mean corpuscular volume;	chr22:37040308	chr22:37876148~37895563:+
THCA	cis	rs524281	0.954	rs549187	ENSG00000255038.1	RP11-1167A19.2	-3.37	0.000803	0.045	-0.17	-0.15	Electroencephalogram traits;	chr11:66131160	chr11:66067277~66069619:-
THCA	cis	rs3790645	0.874	rs9438508	ENSG00000241547.1	RP11-4K3__A.5	-3.37	0.000803	0.045	-0.17	-0.15	Glucose homeostasis traits;	chr1:26566578	chr1:27325329~27325796:+
THCA	cis	rs2882667	0.858	rs13174479	ENSG00000249593.5	CTB-46B19.2	3.37	0.000803	0.045	0.19	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:139012647~139051203:+
THCA	cis	rs4788570	0.566	rs8056735	ENSG00000261513.1	RP11-432I5.8	3.37	0.000803	0.045	0.27	0.15	Intelligence (multi-trait analysis);	chr16:71468580	chr16:71723180~71724230:+
THCA	cis	rs6580649	1	rs6580649	ENSG00000273765.1	RP11-370I10.11	3.37	0.000803	0.045	0.17	0.15	Lung cancer;	chr12:48016734	chr12:48360920~48361377:+
THCA	cis	rs1923539	0.662	rs7893691	ENSG00000242600.5	MBL1P	-3.37	0.000803	0.045	-0.12	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79931504	chr10:79904898~79950336:+
THCA	cis	rs7829975	0.533	rs35900578	ENSG00000254340.1	RP11-10A14.3	3.37	0.000803	0.045	0.18	0.15	Mood instability;	chr8:8862003	chr8:9141424~9145435:+
THCA	cis	rs1046896	0.562	rs2380172	ENSG00000263063.1	RP11-388C12.1	-3.37	0.000803	0.045	-0.2	-0.15	Glycated hemoglobin levels;	chr17:82929843	chr17:82713908~82716255:-
THCA	cis	rs2662776	1	rs2999965	ENSG00000232995.6	RGS5	-3.37	0.000803	0.045	-0.13	-0.15	Lead levels in blood;	chr1:163198509	chr1:163244505~163321894:-
THCA	cis	rs57709857	0.724	rs16887244	ENSG00000272092.1	RP11-350N15.5	-3.37	0.000803	0.045	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38173827	chr8:38382364~38383461:+
THCA	cis	rs1124769	0.502	rs34354799	ENSG00000259378.1	DCAF13P3	3.37	0.000803	0.045	0.21	0.15	Cognitive performance;	chr15:50774380	chr15:50944663~50945996:+
THCA	cis	rs4824093	0.535	rs9627797	ENSG00000278869.1	CITF22-49E9.3	3.37	0.000803	0.045	0.29	0.15	Amyotrophic lateral sclerosis (sporadic);	chr22:49923921	chr22:49933198~49934074:-
THCA	cis	rs4824093	0.61	rs12168949	ENSG00000278869.1	CITF22-49E9.3	3.37	0.000803	0.045	0.29	0.15	Amyotrophic lateral sclerosis (sporadic);	chr22:49924066	chr22:49933198~49934074:-
THCA	cis	rs708224	0.625	rs2261943	ENSG00000274964.1	RP11-817I4.1	3.37	0.000803	0.045	0.17	0.15	Pancreatic cancer;	chr12:32293610	chr12:32339368~32340724:+
THCA	cis	rs2180341	0.842	rs7739679	ENSG00000220694.2	RP3-403A15.1	-3.37	0.000803	0.045	-0.2	-0.15	Breast cancer;	chr6:127224283	chr6:127435636~127436189:+
THCA	cis	rs11710088	0.74	rs73152645	ENSG00000244503.1	RP11-278L15.6	3.37	0.000803	0.045	0.22	0.15	QRS duration;	chr3:149488309	chr3:149494660~149495995:+
THCA	cis	rs11030122	0.702	rs10835402	ENSG00000230593.3	AC090804.1	3.37	0.000804	0.045	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3969684	chr11:3892398~3892887:-
THCA	cis	rs925550	0.592	rs1026157	ENSG00000224786.1	CETN4P	3.37	0.000804	0.045	0.17	0.15	Primary biliary cholangitis;	chr4:122702738	chr4:122730548~122732193:-
THCA	cis	rs224278	0.509	rs1509952	ENSG00000238280.1	RP11-436D10.3	-3.37	0.000804	0.045	-0.21	-0.15	Ewing sarcoma;	chr10:62979908	chr10:62793562~62805887:-
THCA	cis	rs8177876	0.731	rs4889235	ENSG00000260495.1	RP11-55K13.1	3.37	0.000804	0.045	0.18	0.15	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81110033	chr16:81310731~81313423:-
THCA	cis	rs950169	0.887	rs220333	ENSG00000230373.7	GOLGA6L5P	-3.37	0.000804	0.045	-0.17	-0.15	Schizophrenia;	chr15:84547902	chr15:84507885~84516814:-
THCA	cis	rs9611565	0.659	rs12484694	ENSG00000281538.1	RP4-669P10.20	3.37	0.000804	0.045	0.17	0.15	Vitiligo;	chr22:41523326	chr22:42138060~42139726:+
THCA	cis	rs9650657	0.769	rs1115866	ENSG00000269918.1	AF131215.9	-3.37	0.000804	0.045	-0.16	-0.15	Neuroticism;	chr8:10780823	chr8:11104691~11106704:-
THCA	cis	rs285757	0.895	rs893379	ENSG00000259064.2	RP11-386M24.5	-3.37	0.000804	0.045	-0.22	-0.15	HIV-1 susceptibility;	chr15:92651458	chr15:92627073~92627414:+
THCA	cis	rs76382185	0.756	rs4367796	ENSG00000233184.5	RP11-421L21.3	3.37	0.000804	0.045	0.23	0.15	Lymphocyte counts;	chr1:101118798	chr1:101025878~101087268:+
THCA	cis	rs944289	0.774	rs7147401	ENSG00000212071.1	AL162511.1	3.37	0.000804	0.045	0.18	0.15	Thyroid cancer;	chr14:36089461	chr14:36196480~36196568:-
THCA	cis	rs944289	0.774	rs34081947	ENSG00000212071.1	AL162511.1	3.37	0.000804	0.045	0.18	0.15	Thyroid cancer;	chr14:36090325	chr14:36196480~36196568:-
THCA	cis	rs12621844	0.667	rs10203759	ENSG00000234690.5	AC073283.4	-3.37	0.000804	0.045	-0.14	-0.15	Glycated hemoglobin levels;	chr2:48006911	chr2:47192405~47345074:-
THCA	cis	rs912593	0.872	rs73473547	ENSG00000225179.1	LINC00457	3.37	0.000804	0.045	0.24	0.15	Cancer;	chr13:34464985	chr13:34435450~34640685:-
THCA	cis	rs912593	0.872	rs58055448	ENSG00000225179.1	LINC00457	3.37	0.000804	0.045	0.24	0.15	Cancer;	chr13:34466518	chr13:34435450~34640685:-
THCA	cis	rs912593	0.81	rs79895074	ENSG00000225179.1	LINC00457	3.37	0.000804	0.045	0.24	0.15	Cancer;	chr13:34474387	chr13:34435450~34640685:-
THCA	cis	rs6724465	1	rs72967946	ENSG00000272644.1	RP11-33O4.1	3.37	0.000804	0.045	0.23	0.15	Height;	chr2:219053257	chr2:219069354~219069809:-
THCA	cis	rs1030877	1	rs2576743	ENSG00000235319.1	AC012360.4	-3.37	0.000804	0.045	-0.18	-0.15	Obesity-related traits;	chr2:105284880	chr2:105324210~105330529:+
THCA	cis	rs17767392	0.681	rs4902922	ENSG00000259146.3	RP1-261D10.2	3.37	0.000804	0.045	0.2	0.15	Mitral valve prolapse;	chr14:71221490	chr14:71292729~71321814:-
THCA	cis	rs6832769	1	rs7677526	ENSG00000223305.1	RN7SKP30	3.37	0.000804	0.045	0.19	0.15	Personality dimensions;	chr4:55483741	chr4:55540502~55540835:-
THCA	cis	rs6017317	0.643	rs4810415	ENSG00000244558.4	KCNK15-AS1	-3.37	0.000804	0.045	-0.22	-0.15	Type 2 diabetes;	chr20:44263511	chr20:44694892~44746021:-
THCA	cis	rs6017317	0.664	rs761331	ENSG00000244558.4	KCNK15-AS1	-3.37	0.000804	0.045	-0.22	-0.15	Type 2 diabetes;	chr20:44264990	chr20:44694892~44746021:-
THCA	cis	rs6017317	0.643	rs12481690	ENSG00000244558.4	KCNK15-AS1	-3.37	0.000804	0.045	-0.22	-0.15	Type 2 diabetes;	chr20:44267820	chr20:44694892~44746021:-
THCA	cis	rs12049351	0.774	rs12066463	ENSG00000229367.1	HMGN2P19	3.37	0.000804	0.045	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229533540	chr1:229570532~229570796:+
THCA	cis	rs2638953	0.815	rs11049682	ENSG00000278733.1	RP11-425D17.1	-3.37	0.000805	0.045	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509062	chr12:28185625~28186190:-
THCA	cis	rs3784262	1	rs9325	ENSG00000259250.1	RP11-50C13.1	-3.37	0.000805	0.045	-0.13	-0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57953788	chr15:58587507~58591676:+
THCA	cis	rs701145	0.585	rs1727940	ENSG00000240068.1	RPL21P42	3.37	0.000805	0.045	0.31	0.15	Coronary artery disease;	chr3:154109468	chr3:154023835~154024298:+
THCA	cis	rs1881509	0.66	rs4963080	ENSG00000233930.3	KRTAP5-AS1	-3.37	0.000805	0.045	-0.18	-0.15	Heroin dependence;	chr11:1414623	chr11:1571353~1599184:+
THCA	cis	rs11673344	0.642	rs55926714	ENSG00000267470.4	ZNF571-AS1	-3.37	0.000805	0.045	-0.17	-0.15	Obesity-related traits;	chr19:37307974	chr19:37548914~37587348:+
THCA	cis	rs12621844	0.638	rs1878079	ENSG00000272663.1	RP11-191L17.1	-3.37	0.000805	0.045	-0.15	-0.15	Glycated hemoglobin levels;	chr2:48071244	chr2:48440043~48440597:-
THCA	cis	rs8046148	0.789	rs7206735	ENSG00000279356.1	RP11-429P3.8	3.37	0.000805	0.045	0.2	0.15	Testicular germ cell tumor;	chr16:50114597	chr16:50072862~50074986:+
THCA	cis	rs832540	0.931	rs832534	ENSG00000271828.1	CTD-2310F14.1	-3.37	0.000805	0.045	-0.21	-0.15	Coronary artery disease;	chr5:56917845	chr5:56927874~56929573:+
THCA	cis	rs9300255	0.543	rs1260294	ENSG00000235423.7	RP11-282O18.3	-3.37	0.000805	0.045	-0.18	-0.15	Neutrophil percentage of white cells;	chr12:123075742	chr12:123252030~123261483:-
THCA	cis	rs74781061	0.585	rs7161990	ENSG00000260103.2	RP11-10O17.1	-3.37	0.000805	0.045	-0.21	-0.15	Endometriosis;	chr15:74443323	chr15:74478070~74490286:-
THCA	cis	rs7709377	0.671	rs10478286	ENSG00000250015.1	CTC-339F2.2	-3.37	0.000805	0.045	-0.16	-0.15	Metabolite levels  (X-11787);	chr5:116160166	chr5:116302354~116304134:-
THCA	cis	rs11031096	0.502	rs4910598	ENSG00000230593.3	AC090804.1	3.37	0.000805	0.045	0.21	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4080138	chr11:3892398~3892887:-
THCA	cis	rs7395662	1	rs11039859	ENSG00000200090.1	Y_RNA	-3.37	0.000805	0.045	-0.1	-0.15	HDL cholesterol;	chr11:48590436	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs7928083	ENSG00000200090.1	Y_RNA	-3.37	0.000805	0.045	-0.1	-0.15	HDL cholesterol;	chr11:48591596	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs4882021	ENSG00000200090.1	Y_RNA	-3.37	0.000805	0.045	-0.1	-0.15	HDL cholesterol;	chr11:48594414	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs7129386	ENSG00000200090.1	Y_RNA	-3.37	0.000805	0.045	-0.1	-0.15	HDL cholesterol;	chr11:48595142	chr11:47726894~47726992:-
THCA	cis	rs7395662	1	rs10838975	ENSG00000200090.1	Y_RNA	-3.37	0.000805	0.045	-0.1	-0.15	HDL cholesterol;	chr11:48596063	chr11:47726894~47726992:-
THCA	cis	rs7395662	0.963	rs12418721	ENSG00000200090.1	Y_RNA	-3.37	0.000805	0.045	-0.1	-0.15	HDL cholesterol;	chr11:48596899	chr11:47726894~47726992:-
THCA	cis	rs7395662	0.864	rs7482764	ENSG00000200090.1	Y_RNA	-3.37	0.000805	0.045	-0.1	-0.15	HDL cholesterol;	chr11:48604306	chr11:47726894~47726992:-
THCA	cis	rs7395662	0.929	rs34584314	ENSG00000200090.1	Y_RNA	-3.37	0.000805	0.045	-0.1	-0.15	HDL cholesterol;	chr11:48606134	chr11:47726894~47726992:-
THCA	cis	rs2262909	0.962	rs409439	ENSG00000269364.1	LINC01233	3.37	0.000805	0.045	0.19	0.15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22044630	chr19:22532626~22533494:+
THCA	cis	rs2262909	0.962	rs425781	ENSG00000269364.1	LINC01233	3.37	0.000805	0.045	0.19	0.15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22046504	chr19:22532626~22533494:+
THCA	cis	rs9309473	0.5	rs4852308	ENSG00000273245.1	RP11-434P11.2	-3.37	0.000805	0.045	-0.18	-0.15	Metabolite levels;	chr2:73606908	chr2:73750256~73750786:-
THCA	cis	rs2820315	0.928	rs2678210	ENSG00000223774.4	RP11-307B6.3	3.37	0.000805	0.045	0.18	0.15	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201818812	chr1:201893842~201899978:+
THCA	cis	rs2228479	1	rs117406136	ENSG00000274627.1	RP11-104N10.2	-3.37	0.000805	0.045	-0.25	-0.15	Skin colour saturation;	chr16:89908197	chr16:89516797~89522217:+
THCA	cis	rs9549260	0.753	rs9532578	ENSG00000168852.11	TPTE2P5	3.37	0.000805	0.045	0.14	0.15	Red blood cell count;	chr13:40662270	chr13:40822296~40921749:-
THCA	cis	rs7737355	0.812	rs26010	ENSG00000237714.1	P4HA2-AS1	3.37	0.000805	0.045	0.21	0.15	Life satisfaction;	chr5:131678122	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.812	rs32107	ENSG00000237714.1	P4HA2-AS1	3.37	0.000805	0.045	0.21	0.15	Life satisfaction;	chr5:131703940	chr5:132184876~132192808:+
THCA	cis	rs513088	0.681	rs494467	ENSG00000225171.2	DUTP6	3.37	0.000805	0.045	0.22	0.15	Schizophrenia;	chr1:166692954	chr1:166868748~166869209:+
THCA	cis	rs7665090	1	rs10027437	ENSG00000251288.2	RP11-10L12.2	-3.37	0.000805	0.045	-0.2	-0.15	Primary biliary cholangitis;	chr4:102636094	chr4:102751401~102752641:+
THCA	cis	rs4808199	0.948	rs8108647	ENSG00000267481.1	CTC-559E9.5	-3.37	0.000805	0.045	-0.16	-0.15	Nonalcoholic fatty liver disease;	chr19:19316814	chr19:19788755~19790531:-
THCA	cis	rs6496932	1	rs11638110	ENSG00000259630.2	CTD-2262B20.1	3.37	0.000805	0.045	0.21	0.15	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:85415228~85415633:+
THCA	cis	rs73222236	0.825	rs9812513	ENSG00000273486.1	RP11-731C17.2	3.37	0.000805	0.045	0.13	0.15	Coronary artery disease;	chr3:136335316	chr3:136837338~136839021:-
THCA	cis	rs897984	0.683	rs8050330	ENSG00000260911.2	RP11-196G11.2	3.37	0.000805	0.0451	0.13	0.15	Dementia with Lewy bodies;	chr16:30813649	chr16:31043150~31049868:+
THCA	cis	rs806215	0.526	rs3779522	ENSG00000224138.1	AC000123.4	-3.37	0.000805	0.0451	-0.16	-0.15	Type 2 diabetes;	chr7:128067123	chr7:127350128~127351523:+
THCA	cis	rs806215	0.547	rs322840	ENSG00000224138.1	AC000123.4	-3.37	0.000805	0.0451	-0.16	-0.15	Type 2 diabetes;	chr7:128068923	chr7:127350128~127351523:+
THCA	cis	rs4262150	0.767	rs17550343	ENSG00000253921.1	CTB-113P19.3	3.37	0.000805	0.0451	0.2	0.15	Bipolar disorder and schizophrenia;	chr5:152565805	chr5:151753992~151767247:+
THCA	cis	rs709400	0.859	rs942863	ENSG00000258534.1	CTD-2134A5.4	3.37	0.000805	0.0451	0.17	0.15	Body mass index;	chr14:103554931	chr14:103854366~103880111:-
THCA	cis	rs4262150	0.81	rs17565505	ENSG00000253921.1	CTB-113P19.3	-3.37	0.000805	0.0451	-0.2	-0.15	Bipolar disorder and schizophrenia;	chr5:152684873	chr5:151753992~151767247:+
THCA	cis	rs61008539	0.586	rs6959154	ENSG00000229043.2	AC091729.9	-3.37	0.000805	0.0451	-0.17	-0.15	Perceived unattractiveness to mosquitoes;	chr7:816683	chr7:1160374~1165267:+
THCA	cis	rs2251188	0.609	rs2249765	ENSG00000228010.4	AC073343.13	-3.37	0.000805	0.0451	-0.16	-0.15	Sum basophil neutrophil counts;Neutrophil count;	chr7:6654628	chr7:6663974~6708901:+
THCA	cis	rs10911902	0.643	rs3820182	ENSG00000228238.1	GS1-304P7.2	3.37	0.000805	0.0451	0.24	0.15	Schizophrenia;	chr1:186321201	chr1:186578279~186579299:+
THCA	cis	rs7267979	0.899	rs442834	ENSG00000276952.1	RP5-965G21.6	3.37	0.000805	0.0451	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.932	rs417110	ENSG00000276952.1	RP5-965G21.6	3.37	0.000805	0.0451	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25284915~25285588:-
THCA	cis	rs7267979	0.932	rs449703	ENSG00000276952.1	RP5-965G21.6	3.37	0.000805	0.0451	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25284915~25285588:-
THCA	cis	rs6840360	1	rs6838966	ENSG00000270265.1	RP11-731D1.4	-3.37	0.000805	0.0451	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151682323	chr4:151333775~151353224:-
THCA	cis	rs9573163	0.524	rs192607	ENSG00000226617.1	RPL21P110	-3.37	0.000805	0.0451	-0.24	-0.15	Pancreatic cancer;	chr13:73333635	chr13:72703693~72704138:+
THCA	cis	rs7660760	1	rs7662146	ENSG00000250131.1	RP11-130F10.1	-3.37	0.000805	0.0451	-0.19	-0.15	Left ventricle wall thickness;	chr4:176609642	chr4:177444979~177677126:+
THCA	cis	rs12410462	0.681	rs6670816	ENSG00000227711.2	RP11-275O4.5	3.37	0.000805	0.0451	0.25	0.15	Major depressive disorder;	chr1:227422891	chr1:227509028~227520477:-
THCA	cis	rs1832871	0.683	rs9459852	ENSG00000213078.3	RP5-933K21.2	-3.37	0.000805	0.0451	-0.23	-0.15	Height;	chr6:158266218	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9457264	ENSG00000213078.3	RP5-933K21.2	-3.37	0.000805	0.0451	-0.23	-0.15	Height;	chr6:158268335	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9459877	ENSG00000213078.3	RP5-933K21.2	-3.37	0.000805	0.0451	-0.23	-0.15	Height;	chr6:158271299	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs6906854	ENSG00000213078.3	RP5-933K21.2	-3.37	0.000805	0.0451	-0.23	-0.15	Height;	chr6:158273968	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs6920506	ENSG00000213078.3	RP5-933K21.2	-3.37	0.000805	0.0451	-0.23	-0.15	Height;	chr6:158273985	chr6:157365990~157366923:-
THCA	cis	rs11242704	0.962	rs11962502	ENSG00000218027.2	RP11-157J24.1	3.37	0.000805	0.0451	0.2	0.15	Response to hepatitis C treatment;	chr6:1532119	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.89	rs60442295	ENSG00000218027.2	RP11-157J24.1	3.37	0.000805	0.0451	0.2	0.15	Response to hepatitis C treatment;	chr6:1532135	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.926	rs2317960	ENSG00000218027.2	RP11-157J24.1	3.37	0.000805	0.0451	0.2	0.15	Response to hepatitis C treatment;	chr6:1532631	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.962	rs2317962	ENSG00000218027.2	RP11-157J24.1	3.37	0.000805	0.0451	0.2	0.15	Response to hepatitis C treatment;	chr6:1533058	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.962	rs4959569	ENSG00000218027.2	RP11-157J24.1	3.37	0.000805	0.0451	0.2	0.15	Response to hepatitis C treatment;	chr6:1533212	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.926	rs4959571	ENSG00000218027.2	RP11-157J24.1	3.37	0.000805	0.0451	0.2	0.15	Response to hepatitis C treatment;	chr6:1533367	chr6:1513698~1515289:-
THCA	cis	rs11242704	0.962	rs2873589	ENSG00000218027.2	RP11-157J24.1	3.37	0.000805	0.0451	0.2	0.15	Response to hepatitis C treatment;	chr6:1533513	chr6:1513698~1515289:-
THCA	cis	rs944289	0.74	rs10498332	ENSG00000212071.1	AL162511.1	3.37	0.000806	0.0451	0.18	0.15	Thyroid cancer;	chr14:36102348	chr14:36196480~36196568:-
THCA	cis	rs34792	0.554	rs12919246	ENSG00000275910.1	RP11-680G24.6	-3.37	0.000806	0.0451	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:15015828~15016390:-
THCA	cis	rs17092148	0.636	rs66535774	ENSG00000276073.1	RP5-1125A11.7	3.37	0.000806	0.0451	0.16	0.15	Neuroticism;	chr20:34860757	chr20:33985617~33988989:-
THCA	cis	rs35791980	0.584	rs1181903	ENSG00000265479.4	DTX2P1-UPK3BP1-PMS2P11	-3.37	0.000806	0.0451	-0.16	-0.15	Pursuit maintenance gain;	chr7:77354300	chr7:76980949~77043775:+
THCA	cis	rs1941184	0.526	rs10084010	ENSG00000266521.1	RP11-650P15.1	-3.37	0.000806	0.0451	-0.26	-0.15	Parkinson's disease (age of onset);	chr18:31447782	chr18:31496645~31497195:-
THCA	cis	rs2109514	0.74	rs1476451	ENSG00000237813.3	AC002066.1	3.37	0.000806	0.0451	0.14	0.15	Prevalent atrial fibrillation;	chr7:116429257	chr7:116238260~116499465:-
THCA	cis	rs2109514	0.74	rs7781492	ENSG00000237813.3	AC002066.1	3.37	0.000806	0.0451	0.14	0.15	Prevalent atrial fibrillation;	chr7:116429921	chr7:116238260~116499465:-
THCA	cis	rs10768122	0.551	rs2295756	ENSG00000251194.2	RP1-68D18.2	3.37	0.000806	0.0451	0.14	0.15	Vitiligo;	chr11:35219682	chr11:35212550~35214007:+
THCA	cis	rs11039798	0.588	rs7479642	ENSG00000200090.1	Y_RNA	3.37	0.000806	0.0451	0.13	0.15	Axial length;	chr11:48532256	chr11:47726894~47726992:-
THCA	cis	rs7487075	0.619	rs11183478	ENSG00000275481.1	RP11-474P2.6	3.37	0.000806	0.0451	0.15	0.15	Itch intensity from mosquito bite;	chr12:46430283	chr12:46388856~46392126:+
THCA	cis	rs12780845	0.931	rs1885393	ENSG00000229124.5	VIM-AS1	3.37	0.000806	0.0451	0.15	0.15	Homocysteine levels;	chr10:17205574	chr10:17214239~17229985:-
THCA	cis	rs7818688	1	rs10097930	ENSG00000253528.2	RP11-347C18.4	-3.37	0.000806	0.0451	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013507	chr8:94974573~94974853:-
THCA	cis	rs7737355	0.947	rs58991576	ENSG00000224431.1	AC063976.7	-3.37	0.000806	0.0451	-0.15	-0.15	Life satisfaction;	chr5:131253847	chr5:132199456~132203487:+
THCA	cis	rs6802315	0.604	rs4680467	ENSG00000271778.1	RP11-379F4.8	3.37	0.000806	0.0451	0.15	0.15	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158782547~158783124:+
THCA	cis	rs703980	0.808	rs703966	ENSG00000230091.5	TMEM254-AS1	3.37	0.000806	0.0451	0.18	0.15	Type 2 diabetes;	chr10:79194494	chr10:80046860~80078912:-
THCA	cis	rs765787	0.53	rs12915804	ENSG00000259539.1	CTD-2651B20.1	-3.37	0.000806	0.0451	-0.19	-0.15	Uric acid levels;	chr15:45220364	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs12915027	ENSG00000259539.1	CTD-2651B20.1	-3.37	0.000806	0.0451	-0.19	-0.15	Uric acid levels;	chr15:45220428	chr15:45152664~45167526:-
THCA	cis	rs765787	0.556	rs12915965	ENSG00000259539.1	CTD-2651B20.1	-3.37	0.000806	0.0451	-0.19	-0.15	Uric acid levels;	chr15:45220449	chr15:45152664~45167526:-
THCA	cis	rs9308731	0.568	rs6754736	ENSG00000227992.1	AC108463.2	-3.37	0.000806	0.0451	-0.18	-0.15	Chronic lymphocytic leukemia;	chr2:111190964	chr2:111203964~111206215:-
THCA	cis	rs6489785	0.577	rs2701174	ENSG00000258435.1	RP11-711D18.2	-3.37	0.000806	0.0451	-0.18	-0.15	Longevity;Allergic disease (asthma, hay fever or eczema);	chr12:120888092	chr12:121391962~121399859:+
THCA	cis	rs34779708	0.931	rs4934697	ENSG00000233200.1	RP11-324I22.2	3.37	0.000806	0.0451	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35219894~35230598:-
THCA	cis	rs694739	0.657	rs11231770	ENSG00000236935.1	AP003774.1	3.37	0.000806	0.0451	0.16	0.15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373153	chr11:64325050~64329504:-
THCA	cis	rs694739	0.687	rs11231771	ENSG00000236935.1	AP003774.1	3.37	0.000806	0.0451	0.16	0.15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373170	chr11:64325050~64329504:-
THCA	cis	rs694739	0.628	rs10897487	ENSG00000236935.1	AP003774.1	3.37	0.000806	0.0451	0.16	0.15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373232	chr11:64325050~64329504:-
THCA	cis	rs694739	0.654	rs10897488	ENSG00000236935.1	AP003774.1	3.37	0.000806	0.0451	0.16	0.15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373334	chr11:64325050~64329504:-
THCA	cis	rs17881320	0.51	rs6503699	ENSG00000108785.7	HSD17B1P1	-3.37	0.000806	0.0451	-0.28	-0.15	Atopic dermatitis;	chr17:42402243	chr17:42546764~42548706:+
THCA	cis	rs7246657	0.943	rs10415358	ENSG00000268499.1	CTB-102L5.8	3.37	0.000806	0.0451	0.2	0.15	Coronary artery calcification;	chr19:37317961	chr19:38199836~38200934:+
THCA	cis	rs4713118	0.824	rs742046	ENSG00000261839.1	RP1-265C24.8	3.37	0.000806	0.0451	0.18	0.15	Parkinson's disease;	chr6:27771475	chr6:28136849~28139678:+
THCA	cis	rs8068544	0.606	rs77681389	ENSG00000259623.1	RP11-156E6.1	-3.37	0.000806	0.0451	-0.18	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:42002401	chr17:41848518~41851447:-
THCA	cis	rs8068544	0.748	rs75881902	ENSG00000259623.1	RP11-156E6.1	-3.37	0.000806	0.0451	-0.18	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:42004594	chr17:41848518~41851447:-
THCA	cis	rs8068544	0.818	rs7209012	ENSG00000259623.1	RP11-156E6.1	-3.37	0.000806	0.0451	-0.18	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:42009305	chr17:41848518~41851447:-
THCA	cis	rs8068544	0.818	rs78333491	ENSG00000259623.1	RP11-156E6.1	-3.37	0.000806	0.0451	-0.18	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:42011120	chr17:41848518~41851447:-
THCA	cis	rs6832769	0.925	rs6829182	ENSG00000223305.1	RN7SKP30	3.37	0.000806	0.0451	0.19	0.15	Personality dimensions;	chr4:55587989	chr4:55540502~55540835:-
THCA	cis	rs10858047	0.824	rs222502	ENSG00000231128.4	RP5-1073O3.2	-3.37	0.000806	0.0451	-0.23	-0.15	Autism;	chr1:114622851	chr1:113812379~113829171:+
THCA	cis	rs453301	0.686	rs28665409	ENSG00000233609.3	RP11-62H7.2	-3.37	0.000806	0.0451	-0.15	-0.15	Joint mobility (Beighton score);	chr8:9011767	chr8:8961200~8979025:+
THCA	cis	rs4713118	0.715	rs200480	ENSG00000261839.1	RP1-265C24.8	3.37	0.000806	0.0451	0.16	0.15	Parkinson's disease;	chr6:27805886	chr6:28136849~28139678:+
THCA	cis	rs1862618	0.802	rs832547	ENSG00000234553.1	AC022431.3	-3.37	0.000807	0.0451	-0.18	-0.15	Initial pursuit acceleration;	chr5:56888114	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs866222	ENSG00000234553.1	AC022431.3	-3.37	0.000807	0.0451	-0.18	-0.15	Initial pursuit acceleration;	chr5:56888617	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.853	rs861283	ENSG00000234553.1	AC022431.3	-3.37	0.000807	0.0451	-0.18	-0.15	Initial pursuit acceleration;	chr5:56888783	chr5:56536583~56537826:-
THCA	cis	rs1862618	0.802	rs252900	ENSG00000234553.1	AC022431.3	-3.37	0.000807	0.0451	-0.18	-0.15	Initial pursuit acceleration;	chr5:56889454	chr5:56536583~56537826:-
THCA	cis	rs972578	0.967	rs2068944	ENSG00000230319.1	AL022476.2	3.37	0.000807	0.0451	0.16	0.15	Mean platelet volume;	chr22:42960436	chr22:43038585~43052366:+
THCA	cis	rs10085978	0.565	rs13275116	ENSG00000253741.1	CTD-2292P10.4	3.37	0.000807	0.0451	0.2	0.15	Mosquito bite size;	chr8:142131453	chr8:142702252~142726973:-
THCA	cis	rs897984	0.683	rs72799316	ENSG00000260911.2	RP11-196G11.2	3.37	0.000807	0.0451	0.13	0.15	Dementia with Lewy bodies;	chr16:30815884	chr16:31043150~31049868:+
THCA	cis	rs8054556	1	rs11642046	ENSG00000214725.6	CDIPT-AS1	-3.37	0.000807	0.0451	-0.19	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29981787	chr16:29863593~29868053:+
THCA	cis	rs2228479	0.85	rs2286393	ENSG00000274627.1	RP11-104N10.2	-3.37	0.000807	0.0451	-0.27	-0.15	Skin colour saturation;	chr16:89743140	chr16:89516797~89522217:+
THCA	cis	rs1729951	0.575	rs361245	ENSG00000239213.4	NCK1-AS1	3.37	0.000807	0.0451	0.13	0.15	Neuroticism;	chr3:136976864	chr3:136841726~136862054:-
THCA	cis	rs7608910	0.578	rs2564114	ENSG00000270820.4	RP11-355B11.2	3.37	0.000807	0.0451	0.13	0.15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:61003512	chr2:61471188~61484130:+
THCA	cis	rs17428076	0.749	rs62182439	ENSG00000228389.1	AC068039.4	-3.37	0.000807	0.0451	-0.19	-0.15	Myopia;	chr2:171943275	chr2:171773482~171775844:+
THCA	cis	rs7926906	1	rs7939348	ENSG00000280367.1	RP11-121L10.2	3.37	0.000807	0.0451	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90789233	chr11:90223153~90226538:+
THCA	cis	rs2275620	0.526	rs6583963	ENSG00000274691.1	RP11-310E22.6	-3.37	0.000807	0.0451	-0.17	-0.15	Gout;	chr10:94922558	chr10:95173085~95173187:-
THCA	cis	rs910873	0.901	rs2424995	ENSG00000269202.1	RP4-614O4.12	-3.37	0.000807	0.0451	-0.29	-0.15	Melanoma;	chr20:34576711	chr20:35201747~35203288:-
THCA	cis	rs72781680	0.611	rs2303287	ENSG00000223754.1	AC008073.9	3.37	0.000807	0.0451	0.25	0.15	Lymphocyte counts;	chr2:24079376	chr2:24199839~24201698:-
THCA	cis	rs7737355	0.617	rs245800	ENSG00000224431.1	AC063976.7	-3.37	0.000807	0.0451	-0.14	-0.15	Life satisfaction;	chr5:131341898	chr5:132199456~132203487:+
THCA	cis	rs7119	0.7	rs4886519	ENSG00000259362.2	RP11-307C19.1	3.37	0.000807	0.0451	0.2	0.15	Type 2 diabetes;	chr15:77601543	chr15:77525540~77534110:+
THCA	cis	rs76525880	0.764	rs80052868	ENSG00000266601.1	RP11-6N17.3	-3.37	0.000807	0.0451	-0.23	-0.15	Colorectal or endometrial cancer;	chr17:48489845	chr17:47929682~47933106:-
THCA	cis	rs17092148	1	rs6058112	ENSG00000269202.1	RP4-614O4.12	3.37	0.000807	0.0451	0.17	0.15	Neuroticism;	chr20:34734202	chr20:35201747~35203288:-
THCA	cis	rs17092148	1	rs6060040	ENSG00000269202.1	RP4-614O4.12	3.37	0.000807	0.0451	0.17	0.15	Neuroticism;	chr20:34771251	chr20:35201747~35203288:-
THCA	cis	rs751728	0.664	rs6929696	ENSG00000274259.2	XXbac-BPG294E21.9	-3.37	0.000807	0.0451	-0.18	-0.15	Crohn's disease;	chr6:33791513	chr6:33437363~33454453:-
THCA	cis	rs4656958	0.538	rs7526396	ENSG00000232188.1	RP11-312J18.6	3.37	0.000807	0.0451	0.18	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160930954	chr1:160931739~160934380:-
THCA	cis	rs76419734	1	rs72673821	ENSG00000251175.4	RP11-45L9.1	3.37	0.000807	0.0451	0.39	0.15	Post bronchodilator FEV1;	chr4:105797096	chr4:105746245~105827172:-
THCA	cis	rs4766428	0.506	rs10849900	ENSG00000221246.1	AC144522.1	3.37	0.000807	0.0451	0.16	0.15	Schizophrenia;	chr12:110537085	chr12:110632604~110632693:+
THCA	cis	rs2129782	0.51	rs4559289	ENSG00000253553.4	RP11-586K2.1	-3.37	0.000807	0.0452	-0.23	-0.15	Electrodermal activity;	chr8:88333478	chr8:88326836~88737134:+
THCA	cis	rs620729	0.83	rs9366802	ENSG00000272097.1	RP11-421M1.8	3.37	0.000808	0.0452	0.18	0.15	Intelligence (multi-trait analysis);	chr6:11479365	chr6:10743324~10747663:-
THCA	cis	rs6933660	0.8	rs3800273	ENSG00000219395.2	HSPA8P15	-3.37	0.000808	0.0452	-0.13	-0.15	Menarche (age at onset);	chr6:151437900	chr6:151411259~151413945:-
THCA	cis	rs9987353	0.62	rs34455383	ENSG00000254153.1	CTA-398F10.2	3.37	0.000808	0.0452	0.18	0.15	Recombination measurement;	chr8:9208948	chr8:8456909~8461337:-
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000184274.3	LINC00315	-3.37	0.000808	0.0452	-0.19	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45300245~45305257:-
THCA	cis	rs2359714	0.935	rs12145424	ENSG00000224238.2	WARS2-IT1	3.37	0.000808	0.0452	0.19	0.15	Breast size;	chr1:118244240	chr1:119047405~119064785:+
THCA	cis	rs2359714	0.935	rs1938269	ENSG00000224238.2	WARS2-IT1	3.37	0.000808	0.0452	0.19	0.15	Breast size;	chr1:118244451	chr1:119047405~119064785:+
THCA	cis	rs465969	1	rs459888	ENSG00000230177.1	RP5-1112D6.4	-3.37	0.000808	0.0452	-0.23	-0.15	Psoriasis;	chr6:111329953	chr6:111277932~111278742:+
THCA	cis	rs1958560	0.829	rs2268955	ENSG00000276116.2	FUT8-AS1	3.37	0.000808	0.0452	0.16	0.15	Menarche (age at onset);	chr14:65623291	chr14:65411170~65412690:-
THCA	cis	rs2243480	1	rs4718317	ENSG00000237310.1	GS1-124K5.4	-3.37	0.000808	0.0452	-0.17	-0.15	Diabetic kidney disease;	chr7:66183914	chr7:66493706~66495474:+
THCA	cis	rs465969	0.546	rs7772141	ENSG00000230177.1	RP5-1112D6.4	-3.37	0.000808	0.0452	-0.24	-0.15	Psoriasis;	chr6:111472358	chr6:111277932~111278742:+
THCA	cis	rs465969	0.793	rs7776047	ENSG00000230177.1	RP5-1112D6.4	-3.37	0.000808	0.0452	-0.24	-0.15	Psoriasis;	chr6:111472391	chr6:111277932~111278742:+
THCA	cis	rs972578	0.967	rs5759091	ENSG00000274717.1	RP1-47A17.1	-3.37	0.000808	0.0452	-0.16	-0.15	Mean platelet volume;	chr22:43011458	chr22:42791814~42794313:-
THCA	cis	rs7267979	1	rs10966	ENSG00000277938.1	RP5-965G21.3	3.37	0.000808	0.0452	0.12	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25229150~25231933:+
THCA	cis	rs867371	0.614	rs7183805	ENSG00000255769.6	GOLGA2P10	-3.37	0.000808	0.0452	-0.19	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82472993~82513950:-
THCA	cis	rs875971	0.545	rs2460427	ENSG00000230295.1	RP11-458F8.2	-3.37	0.000808	0.0452	-0.14	-0.15	Aortic root size;	chr7:66154218	chr7:66880708~66882981:+
THCA	cis	rs6889746	1	rs62358259	ENSG00000248898.1	CTD-2288O8.1	-3.37	0.000808	0.0452	-0.18	-0.15	Presence of antiphospholipid antibodies;	chr5:52409669	chr5:52675193~52788026:-
THCA	cis	rs11239930	0.517	rs584107	ENSG00000180867.10	PDIA3P1	-3.37	0.000808	0.0452	-0.14	-0.15	AIDS progression;	chr1:147075862	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.517	rs685741	ENSG00000180867.10	PDIA3P1	3.37	0.000808	0.0452	0.14	0.15	AIDS progression;	chr1:147074503	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.517	rs678111	ENSG00000180867.10	PDIA3P1	3.37	0.000808	0.0452	0.14	0.15	AIDS progression;	chr1:147076613	chr1:147178113~147179622:+
THCA	cis	rs11239930	0.517	rs535827	ENSG00000180867.10	PDIA3P1	3.37	0.000808	0.0452	0.14	0.15	AIDS progression;	chr1:147076642	chr1:147178113~147179622:+
THCA	cis	rs3782089	1	rs11602375	ENSG00000260233.3	SSSCA1-AS1	3.37	0.000808	0.0452	0.23	0.15	Height;	chr11:65529069	chr11:65568482~65570423:-
THCA	cis	rs3782089	1	rs11600543	ENSG00000260233.3	SSSCA1-AS1	3.37	0.000808	0.0452	0.23	0.15	Height;	chr11:65531468	chr11:65568482~65570423:-
THCA	cis	rs8031584	0.697	rs8036176	ENSG00000259845.1	HERC2P10	3.37	0.000808	0.0452	0.21	0.15	Huntington's disease progression;	chr15:30883066	chr15:30815271~30844153:+
THCA	cis	rs3096299	0.746	rs9931120	ENSG00000261118.1	RP11-104N10.1	3.37	0.000808	0.0452	0.13	0.15	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89492017~89504460:-
THCA	cis	rs3096299	0.632	rs8051537	ENSG00000223959.7	AFG3L1P	3.37	0.000808	0.0452	0.09	0.15	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89972586~90002161:+
THCA	cis	rs3176789	0.914	rs10844750	ENSG00000256673.1	RP11-599J14.2	3.37	0.000808	0.0452	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774279	chr12:9398355~9414851:-
THCA	cis	rs972578	0.836	rs5759021	ENSG00000230319.1	AL022476.2	3.37	0.000808	0.0452	0.16	0.15	Mean platelet volume;	chr22:42905894	chr22:43038585~43052366:+
THCA	cis	rs775227	0.574	rs16861158	ENSG00000243849.1	CFAP44-AS1	3.37	0.000808	0.0452	0.27	0.15	Dental caries;	chr3:113542862	chr3:113403991~113433992:+
THCA	cis	rs2280018	0.581	rs7404524	ENSG00000255277.3	ABCC6P2	3.37	0.000808	0.0452	0.17	0.15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:14820792~14824702:-
THCA	cis	rs718314	0.956	rs12814794	ENSG00000255750.4	RP11-283G6.5	-3.37	0.000808	0.0452	-0.15	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26287765	chr12:26230819~26319720:-
THCA	cis	rs7824557	0.815	rs2736372	ENSG00000255495.1	AC145124.2	-3.37	0.000808	0.0452	-0.16	-0.15	Retinal vascular caliber;	chr8:11248532	chr8:12194467~12196280:+
THCA	cis	rs7818688	0.697	rs11781757	ENSG00000253528.2	RP11-347C18.4	-3.37	0.000808	0.0452	-0.24	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975663	chr8:94974573~94974853:-
THCA	cis	rs2342371	0.756	rs28712197	ENSG00000243339.3	RN7SL738P	-3.37	0.000808	0.0452	-0.2	-0.15	Fat distribution (HIV);	chr3:196380343	chr3:196399911~196400207:+
THCA	cis	rs2342371	0.715	rs9846106	ENSG00000243339.3	RN7SL738P	-3.37	0.000808	0.0452	-0.2	-0.15	Fat distribution (HIV);	chr3:196399668	chr3:196399911~196400207:+
THCA	cis	rs4664293	0.867	rs2303550	ENSG00000230783.1	AC009961.2	-3.37	0.000808	0.0452	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159781110	chr2:159689217~159690291:-
THCA	cis	rs317689	0.69	rs317646	ENSG00000251301.5	RP11-81H14.2	-3.37	0.000808	0.0452	-0.15	-0.15	Response to diuretic therapy;	chr12:69263365	chr12:68332888~68451663:-
THCA	cis	rs9916302	0.706	rs4794808	ENSG00000266469.1	CTB-131K11.1	3.37	0.000808	0.0452	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39375663	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.571	rs28799952	ENSG00000266469.1	CTB-131K11.1	3.37	0.000808	0.0452	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39376803	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs9899069	ENSG00000266469.1	CTB-131K11.1	3.37	0.000808	0.0452	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39384519	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs7208487	ENSG00000266469.1	CTB-131K11.1	3.37	0.000808	0.0452	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39387196	chr17:39401793~39406233:+
THCA	cis	rs9607412	0.536	rs130621	ENSG00000279738.1	RP5-1014D13.2	-3.37	0.000808	0.0452	-0.14	-0.15	Mean corpuscular volume;	chr22:37041314	chr22:37876148~37895563:+
THCA	cis	rs11637445	0.677	rs12441598	ENSG00000260657.2	RP11-315D16.4	-3.37	0.000808	0.0452	-0.2	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr15:67780867	chr15:68267792~68277994:-
THCA	cis	rs340849	0.503	rs6697742	ENSG00000274895.1	RP11-478J18.2	3.37	0.000809	0.0452	0.13	0.15	Alzheimer's disease;	chr1:213962579	chr1:213983793~213986419:-
THCA	cis	rs3749237	0.595	rs1568661	ENSG00000224424.7	PRKAR2A-AS1	3.37	0.000809	0.0452	0.13	0.15	Resting heart rate;	chr3:49483525	chr3:48847572~48851981:+
THCA	cis	rs656319	0.729	rs471480	ENSG00000248538.5	RP11-10A14.5	3.37	0.000809	0.0452	0.2	0.15	Myopia (pathological);	chr8:9954952	chr8:9189011~9202854:+
THCA	cis	rs11809443	0.569	rs11800309	ENSG00000276255.2	RP5-881P19.7	3.37	0.000809	0.0452	0.21	0.15	Coronary artery disease;	chr1:228204107	chr1:228073909~228076550:-
THCA	cis	rs7096965	0.958	rs35855341	ENSG00000242147.1	RP13-463N16.6	-3.37	0.000809	0.0452	-0.18	-0.15	Major depressive disorder;	chr10:4604742	chr10:5594991~5596118:-
THCA	cis	rs865483	0.895	rs878520	ENSG00000273965.1	RP11-378E13.4	3.37	0.000809	0.0452	0.19	0.15	Monocyte count;	chr17:37402018	chr17:37407936~37408594:-
THCA	cis	rs34783982	0.881	rs12437678	ENSG00000259699.2	HMGB1P8	-3.37	0.000809	0.0452	-0.2	-0.15	Squamous cell lung carcinoma;	chr15:88953853	chr15:89135547~89136495:-
THCA	cis	rs12681963	0.688	rs2938229	ENSG00000272375.1	RP11-51J9.6	3.37	0.000809	0.0452	0.22	0.15	Migraine;	chr8:30237431	chr8:30197404~30198048:+
THCA	cis	rs12681963	0.614	rs2958740	ENSG00000272375.1	RP11-51J9.6	-3.37	0.000809	0.0452	-0.22	-0.15	Migraine;	chr8:30235218	chr8:30197404~30198048:+
THCA	cis	rs17217757	0.725	rs6989566	ENSG00000254041.1	RP11-574O7.1	3.37	0.000809	0.0452	0.23	0.15	Tuberculosis;	chr8:105640496	chr8:105142860~105188606:-
THCA	cis	rs9611565	0.579	rs73178621	ENSG00000237037.8	NDUFA6-AS1	3.37	0.000809	0.0452	0.15	0.15	Vitiligo;	chr22:41525661	chr22:42090931~42137742:+
THCA	cis	rs970548	0.69	rs11239535	ENSG00000230869.1	CTGLF10P	3.37	0.000809	0.0452	0.17	0.15	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45482939	chr10:45678692~45700532:+
THCA	cis	rs6545883	0.826	rs777593	ENSG00000212978.6	AC016747.3	3.37	0.000809	0.0452	0.17	0.15	Tuberculosis;	chr2:61191968	chr2:61141592~61144969:-
THCA	cis	rs17689437	0.671	rs1728793	ENSG00000260084.1	RP11-615I2.1	3.37	0.000809	0.0452	0.18	0.15	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68568790	chr16:68573782~68589512:-
THCA	cis	rs821367	0.83	rs2289427	ENSG00000229048.5	DUTP1	-3.37	0.000809	0.0452	-0.23	-0.15	Platelet distribution width;	chr3:124699999	chr3:125310881~125311350:+
THCA	cis	rs71277158	0.688	rs73879178	ENSG00000242578.1	RP11-469J4.3	3.37	0.000809	0.0452	0.24	0.15	Prostate cancer;	chr3:170155046	chr3:170410512~170418615:+
THCA	cis	rs4959799	0.655	rs6902992	ENSG00000272248.1	RP3-406P24.4	-3.37	0.000809	0.0452	-0.35	-0.15	Survival in rectal cancer;	chr6:3283459	chr6:4018713~4019202:+
THCA	cis	rs4713118	0.869	rs6914924	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000809	0.0452	-0.17	-0.15	Parkinson's disease;	chr6:27743751	chr6:28078792~28081130:-
THCA	cis	rs6871536	1	rs60490216	ENSG00000233006.5	AC034220.3	-3.37	0.000809	0.0452	-0.14	-0.15	Asthma (childhood onset);	chr5:132586193	chr5:132311285~132369916:-
THCA	cis	rs668210	0.793	rs534201	ENSG00000214659.4	KRT8P26	3.37	0.000809	0.0452	0.17	0.15	Cerebrospinal fluid biomarker levels;	chr11:66009257	chr11:65726939~65728214:+
THCA	cis	rs2926621	1	rs2926621	ENSG00000266312.1	RP11-111H3.3	3.37	0.000809	0.0452	0.18	0.15	Night sleep phenotypes;	chr18:75908215	chr18:76623006~76639011:-
THCA	cis	rs1560104	0.597	rs13338316	ENSG00000262801.4	U91319.1	-3.37	0.000809	0.0452	-0.17	-0.15	Obesity-related traits;	chr16:12617168	chr16:13246316~13562918:+
THCA	cis	rs1560104	0.597	rs13333850	ENSG00000262801.4	U91319.1	-3.37	0.000809	0.0452	-0.17	-0.15	Obesity-related traits;	chr16:12617231	chr16:13246316~13562918:+
THCA	cis	rs1577917	0.958	rs34795473	ENSG00000220563.1	PKMP3	-3.37	0.000809	0.0452	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85752081	chr6:85659892~85660606:-
THCA	cis	rs9916302	0.706	rs9908131	ENSG00000266469.1	CTB-131K11.1	3.37	0.000809	0.0452	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39364196	chr17:39401793~39406233:+
THCA	cis	rs5751168	0.57	rs2051488	ENSG00000236850.4	BMS1P20	-3.37	0.000809	0.0452	-0.2	-0.15	Prostate cancer (SNP x SNP interaction);	chr22:22492858	chr22:22303224~22322847:+
THCA	cis	rs2288884	0.515	rs9676397	ENSG00000269483.1	AC006272.1	3.37	0.000809	0.0452	0.17	0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52076750	chr19:51839924~51843324:-
THCA	cis	rs79149102	0.522	rs6495119	ENSG00000260103.2	RP11-10O17.1	-3.37	0.000809	0.0452	-0.21	-0.15	Lung cancer;	chr15:74642099	chr15:74478070~74490286:-
THCA	cis	rs1730008	0.683	rs1714521	ENSG00000240207.5	RP11-379F4.4	-3.37	0.00081	0.0452	-0.16	-0.15	Lobe attachment (rater-scored or self-reported);	chr3:158567072	chr3:158732263~158784070:+
THCA	cis	rs12935418	0.672	rs9923948	ENSG00000261061.1	RP11-303E16.2	-3.37	0.00081	0.0452	-0.15	-0.15	Mean corpuscular volume;	chr16:81013814	chr16:81030770~81031485:+
THCA	cis	rs7474896	1	rs10827829	ENSG00000276805.1	RP11-291L22.6	3.37	0.00081	0.0452	0.24	0.15	Obesity (extreme);	chr10:37815354	chr10:38451030~38451785:+
THCA	cis	rs7474896	1	rs9418298	ENSG00000276805.1	RP11-291L22.6	3.37	0.00081	0.0452	0.24	0.15	Obesity (extreme);	chr10:37848308	chr10:38451030~38451785:+
THCA	cis	rs8070463	0.515	rs11655943	ENSG00000260075.1	NSFP1	-3.37	0.00081	0.0453	-0.19	-0.15	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:46372855~46487141:+
THCA	cis	rs1800795	0.553	rs1524099	ENSG00000225541.1	AC002480.5	-3.37	0.00081	0.0453	-0.18	-0.15	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22742038	chr7:22571607~22661792:-
THCA	cis	rs72827839	0.625	rs61454280	ENSG00000266601.1	RP11-6N17.3	3.37	0.00081	0.0453	0.16	0.15	Ease of getting up in the morning;	chr17:47972759	chr17:47929682~47933106:-
THCA	cis	rs9818758	0.556	rs116432667	ENSG00000229759.1	MRPS18AP1	-3.37	0.00081	0.0453	-0.32	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48910156	chr3:48256350~48256938:-
THCA	cis	rs4722166	0.598	rs4722180	ENSG00000179428.2	AC073072.5	-3.37	0.00081	0.0453	-0.18	-0.15	Lung cancer;	chr7:22765453	chr7:22725395~22727620:-
THCA	cis	rs34761973	0.569	rs7223411	ENSG00000277200.1	RP11-74E22.8	3.37	0.00081	0.0453	0.24	0.15	Depressive symptoms (multi-trait analysis);Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis);	chr17:2673883	chr17:2720801~2723947:-
THCA	cis	rs12544026	0.581	rs519197	ENSG00000253669.3	KB-1732A1.1	-3.37	0.00081	0.0453	-0.17	-0.15	Major depression and alcohol dependence;	chr8:101848447	chr8:102805517~102809971:+
THCA	cis	rs11633886	0.622	rs4774813	ENSG00000259200.1	RP11-718O11.1	-3.37	0.00081	0.0453	-0.19	-0.15	Diisocyanate-induced asthma;	chr15:45837857	chr15:45705078~45931069:+
THCA	cis	rs494526	0.871	rs10886369	ENSG00000229272.1	RP11-498J9.2	3.37	0.00081	0.0453	0.17	0.15	Alcoholic chronic pancreatitis;	chr10:119024129	chr10:119003536~119003884:-
THCA	cis	rs6968419	0.761	rs6950848	ENSG00000237870.5	AC073130.1	3.37	0.00081	0.0453	0.16	0.15	Intraocular pressure;	chr7:116147238	chr7:116275606~116286734:-
THCA	cis	rs16852403	0.861	rs11583320	ENSG00000224687.1	RASAL2-AS1	3.37	0.00081	0.0453	0.24	0.15	Childhood ear infection;	chr1:178073010	chr1:178091508~178093984:-
THCA	cis	rs758324	0.704	rs493829	ENSG00000224431.1	AC063976.7	-3.37	0.00081	0.0453	-0.14	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131961350	chr5:132199456~132203487:+
THCA	cis	rs7203193	0.966	rs8059354	ENSG00000241641.1	RPS23P6	3.37	0.00081	0.0453	0.15	0.15	LDL cholesterol;	chr16:11546193	chr16:12081237~12081902:+
THCA	cis	rs2945232	1	rs2945232	ENSG00000233609.3	RP11-62H7.2	3.37	0.00081	0.0453	0.15	0.15	Schizophrenia;	chr8:8240516	chr8:8961200~8979025:+
THCA	cis	rs4776059	0.724	rs11633933	ENSG00000259935.1	RP11-519C12.1	3.37	0.00081	0.0453	0.17	0.15	Schizophrenia;	chr15:52656160	chr15:52648634~52649866:-
THCA	cis	rs4713118	0.513	rs149955	ENSG00000176933.5	TOB2P1	-3.37	0.00081	0.0453	-0.19	-0.15	Parkinson's disease;	chr6:28068447	chr6:28217643~28218634:-
THCA	cis	rs9314614	0.789	rs4840642	ENSG00000245857.2	GS1-24F4.2	3.37	0.00081	0.0453	0.2	0.15	White blood cell count (basophil);IgA nephropathy;	chr8:6855243	chr8:6835554~6885276:+
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000264242.2	RP11-271K11.1	-3.37	0.00081	0.0453	-0.24	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30553697~30558962:+
THCA	cis	rs754466	0.724	rs11002318	ENSG00000213514.2	RP11-428P16.2	3.37	0.00081	0.0453	0.17	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77874049	chr10:77730766~77734769:+
THCA	cis	rs8114671	0.562	rs4911161	ENSG00000126005.14	MMP24-AS1	-3.37	0.00081	0.0453	-0.15	-0.15	Height;	chr20:34814428	chr20:35216462~35278131:-
THCA	cis	rs12780845	1	rs35630951	ENSG00000229124.5	VIM-AS1	3.37	0.000811	0.0453	0.16	0.15	Homocysteine levels;	chr10:17173650	chr10:17214239~17229985:-
THCA	cis	rs10754283	0.934	rs10754284	ENSG00000237505.5	PKN2-AS1	-3.37	0.000811	0.0453	-0.18	-0.15	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:88537513~88685204:-
THCA	cis	rs10754283	0.967	rs10801759	ENSG00000237505.5	PKN2-AS1	-3.37	0.000811	0.0453	-0.18	-0.15	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:88537513~88685204:-
THCA	cis	rs10754283	0.967	rs10801760	ENSG00000237505.5	PKN2-AS1	-3.37	0.000811	0.0453	-0.18	-0.15	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:88537513~88685204:-
THCA	cis	rs34792	0.554	rs12918517	ENSG00000207425.1	Y_RNA	-3.37	0.000811	0.0453	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15532974	chr16:14915457~14915556:-
THCA	cis	rs12285326	0.796	rs12418479	ENSG00000280798.1	LINC00294	3.37	0.000811	0.0453	0.14	0.15	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr11:33989285	chr11:33076149~33079454:+
THCA	cis	rs6832769	1	rs28514423	ENSG00000223305.1	RN7SKP30	-3.37	0.000811	0.0453	-0.19	-0.15	Personality dimensions;	chr4:55563072	chr4:55540502~55540835:-
THCA	cis	rs9607412	0.536	rs130621	ENSG00000233360.4	Z83844.1	-3.37	0.000811	0.0453	-0.17	-0.15	Mean corpuscular volume;	chr22:37041314	chr22:37641832~37658377:-
THCA	cis	rs7577696	0.8	rs216544	ENSG00000276517.1	AL133243.2	3.37	0.000811	0.0453	0.14	0.15	Inflammatory biomarkers;	chr2:32093737	chr2:32526504~32529507:+
THCA	cis	rs5753037	0.564	rs131298	ENSG00000279699.1	RP1-102K2.9	-3.37	0.000811	0.0453	-0.15	-0.15	Type 1 diabetes;	chr22:29784012	chr22:30275215~30276951:-
THCA	cis	rs6545883	0.525	rs1177274	ENSG00000270820.4	RP11-355B11.2	3.37	0.000811	0.0453	0.13	0.15	Tuberculosis;	chr2:61141397	chr2:61471188~61484130:+
THCA	cis	rs2692947	0.537	rs12478605	ENSG00000236750.1	AC009237.16	-3.37	0.000811	0.0453	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95711330	chr2:95641634~95641980:-
THCA	cis	rs6870983	0.636	rs12522676	ENSG00000250156.3	CTC-498M16.2	-3.37	0.000811	0.0453	-0.19	-0.15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88149673	chr5:88408982~88439090:-
THCA	cis	rs6870983	0.636	rs12521792	ENSG00000250156.3	CTC-498M16.2	-3.37	0.000811	0.0453	-0.19	-0.15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88151870	chr5:88408982~88439090:-
THCA	cis	rs11685222	0.589	rs17661193	ENSG00000229326.3	AC069154.4	3.37	0.000811	0.0453	0.25	0.15	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119684876	chr2:119698623~119700151:+
THCA	cis	rs2253762	0.68	rs2461212	ENSG00000276742.1	RP11-500G22.4	3.37	0.000811	0.0453	0.18	0.15	Breast cancer;	chr10:122033882	chr10:121956782~121957098:+
THCA	cis	rs9890032	0.934	rs3760318	ENSG00000263603.1	CTD-2349P21.5	-3.37	0.000811	0.0453	-0.19	-0.15	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30729469~30731202:+
THCA	cis	rs7851693	0.963	rs3802342	ENSG00000232172.1	RP11-57C19.2	-3.37	0.000811	0.0453	-0.17	-0.15	Bone mineral density;	chr9:130597916	chr9:130651799~130652383:+
THCA	cis	rs4938174	1	rs4938174	ENSG00000255334.1	RP11-708L7.6	3.37	0.000811	0.0453	0.17	0.15	Corneal structure;	chr11:111042516	chr11:112015307~112016124:+
THCA	cis	rs4924935	0.669	rs9916340	ENSG00000235672.1	AC090286.2	-3.37	0.000811	0.0453	-0.2	-0.15	Pancreatic cancer;	chr17:18849626	chr17:18908279~18908865:+
THCA	cis	rs4924935	0.669	rs7221935	ENSG00000235672.1	AC090286.2	-3.37	0.000811	0.0453	-0.2	-0.15	Pancreatic cancer;	chr17:18857086	chr17:18908279~18908865:+
THCA	cis	rs6472235	0.967	rs11996694	ENSG00000272192.1	CTD-2532N20.1	3.37	0.000811	0.0453	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:65947329	chr8:65842752~65843331:+
THCA	cis	rs9925964	0.869	rs2288004	ENSG00000262766.1	RP11-196G11.4	-3.37	0.000811	0.0453	-0.1	-0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31118078~31118747:+
THCA	cis	rs6938	0.534	rs7495739	ENSG00000260269.4	CTD-2323K18.1	3.37	0.000811	0.0453	0.21	0.15	Breast cancer;	chr15:74893329	chr15:75527150~75601205:-
THCA	cis	rs524281	1	rs524281	ENSG00000255120.4	OVOL1-AS1	3.37	0.000811	0.0453	0.21	0.15	Electroencephalogram traits;	chr11:66119191	chr11:65789051~65790868:-
THCA	cis	rs28830936	1	rs11070343	ENSG00000250379.1	RP11-23P13.4	3.37	0.000811	0.0453	0.18	0.15	Diastolic blood pressure;	chr15:41647948	chr15:41825099~41827936:-
THCA	cis	rs6517329	0.564	rs7282393	ENSG00000214867.3	SRSF9P1	3.37	0.000811	0.0453	0.2	0.15	Schizophrenia;	chr21:36157708	chr21:36295173~36295702:-
THCA	cis	rs453301	0.509	rs7000323	ENSG00000253981.4	ALG1L13P	-3.37	0.000811	0.0453	-0.16	-0.15	Joint mobility (Beighton score);	chr8:8934763	chr8:8236003~8244667:-
THCA	cis	rs9329221	0.621	rs12156350	ENSG00000154316.13	TDH	3.37	0.000811	0.0453	0.11	0.15	Neuroticism;	chr8:10411006	chr8:11339637~11368452:+
THCA	cis	rs11168618	0.875	rs11458	ENSG00000240399.1	RP1-228P16.1	3.37	0.000811	0.0453	0.16	0.15	Adiponectin levels;	chr12:48494811	chr12:48054813~48055591:-
THCA	cis	rs806215	1	rs712700	ENSG00000279265.1	AC000123.3	-3.37	0.000811	0.0453	-0.18	-0.15	Type 2 diabetes;	chr7:127610853	chr7:127349833~127350293:-
THCA	cis	rs6499640	0.664	rs8043738	ENSG00000275191.1	RP11-36I17.2	3.37	0.000811	0.0453	0.2	0.15	Body mass index;Weight;	chr16:53722121	chr16:53628256~53628816:-
THCA	cis	rs6499640	0.664	rs8063472	ENSG00000275191.1	RP11-36I17.2	3.37	0.000811	0.0453	0.2	0.15	Body mass index;Weight;	chr16:53722221	chr16:53628256~53628816:-
THCA	cis	rs6499640	0.643	rs8058460	ENSG00000275191.1	RP11-36I17.2	3.37	0.000811	0.0453	0.2	0.15	Body mass index;Weight;	chr16:53722225	chr16:53628256~53628816:-
THCA	cis	rs9611565	0.649	rs139540	ENSG00000237037.8	NDUFA6-AS1	3.37	0.000811	0.0453	0.14	0.15	Vitiligo;	chr22:41782036	chr22:42090931~42137742:+
THCA	cis	rs965513	1	rs10983701	ENSG00000236130.1	PTCSC2	-3.37	0.000811	0.0453	-0.13	-0.15	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97775295	chr9:97805935~97810008:-
THCA	cis	rs1005277	0.522	rs289647	ENSG00000120555.12	SEPT7P9	3.37	0.000811	0.0453	0.16	0.15	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38383069~38402916:-
THCA	cis	rs12210761	0.85	rs1155672	ENSG00000229950.1	TFAP2A-AS1	-3.37	0.000811	0.0453	-0.28	-0.15	Major depressive disorder;	chr6:10212888	chr6:10409340~10416446:+
THCA	cis	rs17122278	0.858	rs11216899	ENSG00000243431.1	RPL5P30	-3.37	0.000811	0.0453	-0.16	-0.15	Total cholesterol levels;	chr11:118563706	chr11:118560690~118561580:+
THCA	cis	rs7246760	0.867	rs61011126	ENSG00000278611.1	CTC-543D15.8	-3.37	0.000811	0.0453	-0.25	-0.15	Pursuit maintenance gain;	chr19:9703745	chr19:9538733~9539734:+
THCA	cis	rs10871290	1	rs11149710	ENSG00000207525.1	Y_RNA	3.37	0.000812	0.0453	0.18	0.15	Breast cancer;	chr16:74438648	chr16:74463888~74463988:-
THCA	cis	rs9902453	0.845	rs2259855	ENSG00000264290.1	RP11-68I3.4	-3.37	0.000812	0.0453	-0.12	-0.15	Coffee consumption (cups per day);	chr17:29770842	chr17:29569580~29570519:+
THCA	cis	rs8023401	0.529	rs657635	ENSG00000259705.1	RP11-227D13.1	3.37	0.000812	0.0453	0.18	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48590769	chr15:48645951~48652016:+
THCA	cis	rs2486012	1	rs2428953	ENSG00000225721.4	RP11-269F19.2	3.37	0.000812	0.0453	0.26	0.15	Intelligence (multi-trait analysis);	chr1:43977787	chr1:44759037~44775810:-
THCA	cis	rs3015497	0.637	rs6572692	ENSG00000270062.1	RP11-248J18.3	-3.37	0.000812	0.0453	-0.18	-0.15	Mean platelet volume;	chr14:50710021	chr14:50723777~50724272:-
THCA	cis	rs7142002	0.568	rs4906163	ENSG00000271780.1	RP11-1017G21.5	-3.37	0.000812	0.0453	-0.19	-0.15	Autism;	chr14:101920229	chr14:101948347~101949425:+
THCA	cis	rs7142002	0.568	rs4900520	ENSG00000271780.1	RP11-1017G21.5	-3.37	0.000812	0.0453	-0.19	-0.15	Autism;	chr14:101920320	chr14:101948347~101949425:+
THCA	cis	rs7142002	0.568	rs4900521	ENSG00000271780.1	RP11-1017G21.5	-3.37	0.000812	0.0453	-0.19	-0.15	Autism;	chr14:101920357	chr14:101948347~101949425:+
THCA	cis	rs13232179	1	rs1558299	ENSG00000265810.1	MIR3907	3.37	0.000812	0.0453	0.15	0.15	Coronary heart disease;	chr7:151424590	chr7:151433489~151433639:-
THCA	cis	rs972578	1	rs2038062	ENSG00000274717.1	RP1-47A17.1	-3.37	0.000812	0.0453	-0.16	-0.15	Mean platelet volume;	chr22:43001960	chr22:42791814~42794313:-
THCA	cis	rs6885099	0.509	rs832785	ENSG00000250802.5	ZBED3-AS1	3.37	0.000812	0.0453	0.14	0.15	Thyroid hormone levels;	chr5:77254504	chr5:77086740~77166909:+
THCA	cis	rs7308116	0.791	rs57210198	ENSG00000257951.1	RP11-554D14.4	3.37	0.000812	0.0454	0.18	0.15	Pelvic organ prolapse (moderate/severe);	chr12:107811963	chr12:107881242~107883382:+
THCA	cis	rs7308116	1	rs7302313	ENSG00000257951.1	RP11-554D14.4	3.37	0.000812	0.0454	0.18	0.15	Pelvic organ prolapse (moderate/severe);	chr12:107812158	chr12:107881242~107883382:+
THCA	cis	rs9860428	0.815	rs11720045	ENSG00000243795.1	RP11-572M11.3	3.37	0.000812	0.0454	0.18	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112906315	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs9813901	ENSG00000243795.1	RP11-572M11.3	3.37	0.000812	0.0454	0.18	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112908718	chr3:113142350~113167819:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000273024.4	INTS4P2	-3.37	0.000812	0.0454	-0.26	-0.15	Diabetic kidney disease;	chr7:66172773	chr7:65647864~65715661:+
THCA	cis	rs2406342	0.511	rs10469087	ENSG00000278107.1	RP11-162A12.4	3.37	0.000812	0.0454	0.13	0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);	chr18:76863582	chr18:76805151~76805736:-
THCA	cis	rs1322639	0.571	rs13204417	ENSG00000226445.1	XXyac-YX65C7_A.2	3.37	0.000812	0.0454	0.17	0.15	Pulse pressure;	chr6:169175260	chr6:169213254~169239565:+
THCA	cis	rs4808779	0.924	rs11086102	ENSG00000268650.3	AC068499.10	-3.37	0.000812	0.0454	-0.15	-0.15	Granulocyte percentage of myeloid white cells;	chr19:18287818	chr19:18204730~18220480:+
THCA	cis	rs453301	0.571	rs330057	ENSG00000254340.1	RP11-10A14.3	-3.37	0.000812	0.0454	-0.17	-0.15	Joint mobility (Beighton score);	chr8:9232283	chr8:9141424~9145435:+
THCA	cis	rs1555322	1	rs6058219	ENSG00000279253.1	RP4-614O4.13	-3.37	0.000812	0.0454	-0.21	-0.15	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35262727~35264187:-
THCA	cis	rs17120471	1	rs17120712	ENSG00000255052.4	FAM66D	3.37	0.000812	0.0454	0.26	0.15	IgG glycosylation;	chr8:12845730	chr8:12115782~12177550:+
THCA	cis	rs11089937	0.597	rs2213156	ENSG00000215456.5	BCRP4	3.37	0.000812	0.0454	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.626	rs2213157	ENSG00000215456.5	BCRP4	3.37	0.000812	0.0454	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.626	rs9622955	ENSG00000215456.5	BCRP4	3.37	0.000812	0.0454	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22630061~22636153:+
THCA	cis	rs3784262	0.74	rs12917536	ENSG00000259250.1	RP11-50C13.1	3.37	0.000812	0.0454	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57996049	chr15:58587507~58591676:+
THCA	cis	rs12286929	0.679	rs11606814	ENSG00000255580.1	AP000462.2	3.37	0.000812	0.0454	0.14	0.15	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;	chr11:115171793	chr11:115363629~115377931:+
THCA	cis	rs8177876	0.584	rs13185	ENSG00000278985.1	RP11-303E16.9	-3.37	0.000812	0.0454	-0.21	-0.15	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046036	chr16:80982319~80984094:-
THCA	cis	rs7919656	0.874	rs2620898	ENSG00000228403.1	RP11-563N6.6	-3.37	0.000812	0.0454	-0.16	-0.15	Clinically amyopathic dermatomyositis;	chr10:48833231	chr10:48878022~48878649:+
THCA	cis	rs2625529	0.652	rs2930069	ENSG00000260037.4	CTD-2524L6.3	3.37	0.000812	0.0454	0.19	0.15	Red blood cell count;	chr15:71934636	chr15:71818396~71823384:+
THCA	cis	rs7044106	0.648	rs2031369	ENSG00000235865.2	GSN-AS1	-3.37	0.000812	0.0454	-0.14	-0.15	Hip circumference adjusted for BMI;	chr9:120598016	chr9:121280768~121285530:-
THCA	cis	rs35306767	0.715	rs1871622	ENSG00000229869.1	RP11-363N22.2	-3.37	0.000812	0.0454	-0.25	-0.15	Eosinophil percentage of granulocytes;	chr10:1003369	chr10:933026~942743:+
THCA	cis	rs35306767	0.761	rs1871621	ENSG00000229869.1	RP11-363N22.2	-3.37	0.000812	0.0454	-0.25	-0.15	Eosinophil percentage of granulocytes;	chr10:1003656	chr10:933026~942743:+
THCA	cis	rs35306767	0.761	rs12770910	ENSG00000229869.1	RP11-363N22.2	-3.37	0.000812	0.0454	-0.25	-0.15	Eosinophil percentage of granulocytes;	chr10:1004378	chr10:933026~942743:+
THCA	cis	rs35306767	0.761	rs12771539	ENSG00000229869.1	RP11-363N22.2	-3.37	0.000812	0.0454	-0.25	-0.15	Eosinophil percentage of granulocytes;	chr10:1004713	chr10:933026~942743:+
THCA	cis	rs12780845	0.931	rs1885393	ENSG00000273153.1	RP11-406H21.2	3.37	0.000812	0.0454	0.14	0.15	Homocysteine levels;	chr10:17205574	chr10:17137336~17137585:-
THCA	cis	rs12545912	0.569	rs583484	ENSG00000248538.5	RP11-10A14.5	3.37	0.000813	0.0454	0.24	0.15	Multiple myeloma (hyperdiploidy);	chr8:9936859	chr8:9189011~9202854:+
THCA	cis	rs6017317	0.643	rs2903675	ENSG00000234271.1	RP1-138B7.4	-3.37	0.000813	0.0454	-0.2	-0.15	Type 2 diabetes;	chr20:44270574	chr20:43523261~43523572:-
THCA	cis	rs7942368	1	rs1440978	ENSG00000255363.1	RP11-672A2.5	-3.37	0.000813	0.0454	-0.22	-0.15	Endometriosis;	chr11:76765236	chr11:76628096~76630363:-
THCA	cis	rs1923539	0.662	rs2758557	ENSG00000242600.5	MBL1P	-3.37	0.000813	0.0454	-0.12	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928848	chr10:79904898~79950336:+
THCA	cis	rs73242632	0.5	rs1718834	ENSG00000269949.1	RP11-738E22.3	-3.37	0.000813	0.0454	-0.26	-0.15	Congenital heart disease (maternal effect);	chr4:57052738	chr4:56960927~56961373:-
THCA	cis	rs1941184	0.526	rs6506922	ENSG00000266521.1	RP11-650P15.1	-3.37	0.000813	0.0454	-0.23	-0.15	Parkinson's disease (age of onset);	chr18:31441983	chr18:31496645~31497195:-
THCA	cis	rs10200159	1	rs13428382	ENSG00000272606.1	RP11-554J4.1	3.37	0.000813	0.0454	0.28	0.15	Vitiligo;	chr2:55636929	chr2:55617909~55618373:+
THCA	cis	rs15676	0.783	rs13284441	ENSG00000234771.3	SLC25A25-AS1	-3.37	0.000813	0.0454	-0.13	-0.15	Blood metabolite levels;	chr9:128807473	chr9:128108581~128118693:-
THCA	cis	rs7259376	0.807	rs11669254	ENSG00000270947.1	AC025811.3	3.37	0.000813	0.0454	0.17	0.15	Menopause (age at onset);	chr19:22362003	chr19:22455988~22456459:+
THCA	cis	rs6058526	0.631	rs6087835	ENSG00000235217.6	TSPY26P	-3.37	0.000813	0.0454	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr20:32208797	chr20:32186477~32190527:-
THCA	cis	rs5758511	0.573	rs2284082	ENSG00000230107.1	CTA-126B4.7	3.37	0.000813	0.0454	0.16	0.15	Birth weight;	chr22:41844793	chr22:42438023~42446195:+
THCA	cis	rs10804591	1	rs6785282	ENSG00000271270.4	TMCC1-AS1	3.37	0.000813	0.0454	0.17	0.15	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;	chr3:129620657	chr3:129893871~129918575:+
THCA	cis	rs4919087	0.923	rs11189037	ENSG00000237169.1	RP11-452K12.3	-3.37	0.000813	0.0454	-0.18	-0.15	Monocyte count;	chr10:97214950	chr10:97309138~97309958:-
THCA	cis	rs9611565	0.659	rs9611603	ENSG00000281538.1	RP4-669P10.20	3.37	0.000813	0.0454	0.17	0.15	Vitiligo;	chr22:41516746	chr22:42138060~42139726:+
THCA	cis	rs79149102	0.522	rs10459601	ENSG00000260103.2	RP11-10O17.1	-3.37	0.000813	0.0454	-0.21	-0.15	Lung cancer;	chr15:74573068	chr15:74478070~74490286:-
THCA	cis	rs79149102	0.522	rs79811537	ENSG00000260103.2	RP11-10O17.1	-3.37	0.000813	0.0454	-0.21	-0.15	Lung cancer;	chr15:74579474	chr15:74478070~74490286:-
THCA	cis	rs2011013	0.6	rs62027787	ENSG00000259728.4	LINC00933	3.37	0.000813	0.0454	0.27	0.15	Sitting height ratio;	chr15:83924226	chr15:84570649~84580175:+
THCA	cis	rs6832769	1	rs13121235	ENSG00000223305.1	RN7SKP30	3.37	0.000813	0.0454	0.19	0.15	Personality dimensions;	chr4:55445780	chr4:55540502~55540835:-
THCA	cis	rs1501138	0.636	rs203447	ENSG00000263327.5	TAPT1-AS1	-3.37	0.000813	0.0454	-0.25	-0.15	Systemic juvenile idiopathic arthritis;	chr4:16255644	chr4:16226685~16320140:+
THCA	cis	rs4792901	0.802	rs8079750	ENSG00000279602.1	CTD-3014M21.1	-3.37	0.000813	0.0454	-0.19	-0.15	Dupuytren's disease;	chr17:43501129	chr17:43360041~43361361:-
THCA	cis	rs4792901	0.759	rs12601484	ENSG00000279602.1	CTD-3014M21.1	-3.37	0.000813	0.0454	-0.19	-0.15	Dupuytren's disease;	chr17:43501506	chr17:43360041~43361361:-
THCA	cis	rs1040	0.873	rs10280	ENSG00000261039.2	RP11-417E7.2	-3.37	0.000813	0.0454	-0.16	-0.15	Joint mobility (Beighton score);	chr6:169217335	chr6:169175304~169182740:-
THCA	cis	rs786425	0.531	rs7139162	ENSG00000274427.1	RP11-972P1.10	-3.37	0.000813	0.0454	-0.14	-0.15	Pubertal anthropometrics;	chr12:123618342	chr12:123515275~123515513:-
THCA	cis	rs2074409	0.54	rs853202	ENSG00000275839.1	CTC-421K24.1	-3.37	0.000813	0.0454	-0.18	-0.15	Response to angiotensin II receptor blocker therapy;	chr17:37445289	chr17:37454171~37454931:+
THCA	cis	rs2289681	0.524	rs2231648	ENSG00000280022.1	RP11-707O23.1	3.37	0.000813	0.0454	0.33	0.15	Cognitive function;	chr17:44850282	chr17:45592621~45593369:+
THCA	cis	rs2292864	0.764	rs72825627	ENSG00000263293.2	RP11-290H9.4	3.37	0.000813	0.0454	0.33	0.15	Left atrial antero-posterior diameter;	chr17:47308923	chr17:47303460~47323613:-
THCA	cis	rs10043228	0.826	rs12520838	ENSG00000250015.1	CTC-339F2.2	3.37	0.000813	0.0454	0.23	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116161170	chr5:116302354~116304134:-
THCA	cis	rs9368222	1	rs10440833	ENSG00000280989.1	LINC00581	3.37	0.000813	0.0454	0.21	0.15	Body mass index;Peak insulin response;Acute insulin response;	chr6:20687890	chr6:21486061~21511895:-
THCA	cis	rs4773860	0.71	rs4148442	ENSG00000223298.1	RNY3P8	-3.37	0.000813	0.0454	-0.16	-0.15	Plateletcrit;	chr13:95245504	chr13:95310830~95310955:-
THCA	cis	rs854765	0.583	rs9912895	ENSG00000265511.1	RP11-524F11.1	-3.37	0.000813	0.0454	-0.12	-0.15	Total body bone mineral density;	chr17:17922706	chr17:17507351~17508308:+
THCA	cis	rs2120243	0.528	rs62278647	ENSG00000241770.1	RP11-555M1.3	-3.37	0.000813	0.0454	-0.19	-0.15	Hepatocellular carcinoma in hepatitis B infection;	chr3:157431344	chr3:157163452~157169133:+
THCA	cis	rs751728	0.687	rs943479	ENSG00000274259.2	XXbac-BPG294E21.9	3.37	0.000813	0.0454	0.18	0.15	Crohn's disease;	chr6:33784236	chr6:33437363~33454453:-
THCA	cis	rs751728	0.664	rs9394167	ENSG00000274259.2	XXbac-BPG294E21.9	3.37	0.000813	0.0454	0.18	0.15	Crohn's disease;	chr6:33786619	chr6:33437363~33454453:-
THCA	cis	rs751728	0.626	rs6457741	ENSG00000274259.2	XXbac-BPG294E21.9	3.37	0.000813	0.0454	0.18	0.15	Crohn's disease;	chr6:33788249	chr6:33437363~33454453:-
THCA	cis	rs911555	0.755	rs975892	ENSG00000252469.1	RNU7-160P	3.37	0.000813	0.0454	0.18	0.15	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103550345~103550406:+
THCA	cis	rs1908814	0.516	rs4840597	ENSG00000227888.4	FAM66A	3.37	0.000813	0.0454	0.2	0.15	Neuroticism;	chr8:11938559	chr8:12362019~12388296:+
THCA	cis	rs804280	0.509	rs4841639	ENSG00000227888.4	FAM66A	3.37	0.000813	0.0454	0.2	0.15	Myopia (pathological);	chr8:11938584	chr8:12362019~12388296:+
THCA	cis	rs6840360	0.571	rs11940881	ENSG00000251611.1	RP11-610P16.1	-3.37	0.000813	0.0454	-0.12	-0.15	Intelligence (multi-trait analysis);	chr4:151579898	chr4:151407551~151408835:-
THCA	cis	rs9527	0.571	rs7096249	ENSG00000213277.3	MARCKSL1P1	3.37	0.000814	0.0454	0.16	0.15	Arsenic metabolism;	chr10:102858767	chr10:103175554~103176094:+
THCA	cis	rs9527	0.571	rs10786715	ENSG00000213277.3	MARCKSL1P1	3.37	0.000814	0.0454	0.16	0.15	Arsenic metabolism;	chr10:102860978	chr10:103175554~103176094:+
THCA	cis	rs1552244	0.688	rs9875667	ENSG00000186162.9	CIDECP	3.37	0.000814	0.0454	0.13	0.15	Alzheimer's disease;	chr3:10138357	chr3:10014238~10026365:-
THCA	cis	rs11242704	0.632	rs2569829	ENSG00000272279.1	RP11-157J24.2	-3.37	0.000814	0.0454	-0.25	-0.15	Response to hepatitis C treatment;	chr6:1539293	chr6:1528364~1528911:-
THCA	cis	rs4578769	0.759	rs7243797	ENSG00000265939.1	UBE2CP2	3.37	0.000814	0.0454	0.19	0.15	Eosinophil percentage of white cells;	chr18:23014467	chr18:22900486~22900995:-
THCA	cis	rs4578769	0.802	rs7230571	ENSG00000265939.1	UBE2CP2	3.37	0.000814	0.0454	0.19	0.15	Eosinophil percentage of white cells;	chr18:23014493	chr18:22900486~22900995:-
THCA	cis	rs3808502	0.549	rs11991139	ENSG00000206014.6	OR7E161P	3.37	0.000814	0.0454	0.18	0.15	Neuroticism;	chr8:11570886	chr8:11928597~11929563:-
THCA	cis	rs4814894	0.679	rs1884770	ENSG00000236992.2	RPL12L3	3.37	0.000814	0.0454	0.16	0.15	Breast cancer;	chr20:19772430	chr20:19823443~19823943:-
THCA	cis	rs1908814	0.516	rs60176945	ENSG00000227888.4	FAM66A	3.37	0.000814	0.0454	0.2	0.15	Neuroticism;	chr8:11939165	chr8:12362019~12388296:+
THCA	cis	rs1908814	0.516	rs56102998	ENSG00000227888.4	FAM66A	3.37	0.000814	0.0454	0.2	0.15	Neuroticism;	chr8:11939166	chr8:12362019~12388296:+
THCA	cis	rs3808502	0.526	rs7822958	ENSG00000255046.1	RP11-297N6.4	3.37	0.000814	0.0454	0.16	0.15	Neuroticism;	chr8:11564933	chr8:11797928~11802568:-
THCA	cis	rs7927592	0.673	rs498782	ENSG00000160172.9	FAM86C2P	3.37	0.000814	0.0454	0.14	0.15	Total body bone mineral density;	chr11:68508383	chr11:67791648~67805336:-
THCA	cis	rs7630852	0.965	rs4256169	ENSG00000235897.1	TM4SF19-AS1	-3.37	0.000814	0.0454	-0.19	-0.15	Eosinophil counts;	chr3:196785852	chr3:196318330~196325570:+
THCA	cis	rs8179	0.7	rs42039	ENSG00000230927.2	TMBIM7P	-3.37	0.000814	0.0454	-0.22	-0.15	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92615108	chr7:92412976~92439562:-
THCA	cis	rs4073582	0.595	rs1115508	ENSG00000245156.1	RP11-867G23.3	3.37	0.000814	0.0454	0.13	0.15	Gout;	chr11:66155678	chr11:66269832~66278525:-
THCA	cis	rs1577917	0.958	rs12213343	ENSG00000220563.1	PKMP3	-3.37	0.000814	0.0454	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85733301	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs12215265	ENSG00000220563.1	PKMP3	-3.37	0.000814	0.0454	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85734251	chr6:85659892~85660606:-
THCA	cis	rs1577917	0.958	rs13207173	ENSG00000220563.1	PKMP3	-3.37	0.000814	0.0454	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85747804	chr6:85659892~85660606:-
THCA	cis	rs9299	0.502	rs4793944	ENSG00000264920.1	RP11-6N17.4	3.37	0.000814	0.0454	0.13	0.15	Obesity;	chr17:48589942	chr17:47891255~47895812:-
THCA	cis	rs11039798	0.511	rs717896	ENSG00000200090.1	Y_RNA	-3.37	0.000814	0.0454	-0.13	-0.15	Axial length;	chr11:48353783	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.582	rs1483119	ENSG00000200090.1	Y_RNA	-3.37	0.000814	0.0454	-0.13	-0.15	Axial length;	chr11:48360782	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.557	rs4436575	ENSG00000200090.1	Y_RNA	-3.37	0.000814	0.0454	-0.13	-0.15	Axial length;	chr11:48377342	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.623	rs635632	ENSG00000200090.1	Y_RNA	-3.37	0.000814	0.0454	-0.13	-0.15	Axial length;	chr11:48377980	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.623	rs594615	ENSG00000200090.1	Y_RNA	-3.37	0.000814	0.0454	-0.13	-0.15	Axial length;	chr11:48381252	chr11:47726894~47726992:-
THCA	cis	rs9811920	0.609	rs793467	ENSG00000273374.1	RP11-383I23.2	3.37	0.000814	0.0454	0.13	0.15	Axial length;	chr3:99820820	chr3:99802699~99806058:-
THCA	cis	rs634537	0.525	rs496892	ENSG00000229298.1	TUBB8P1	3.37	0.000814	0.0454	0.17	0.15	Glioma;Non-glioblastoma glioma;Glioblastoma;	chr9:22024352	chr9:21811621~21812347:-
THCA	cis	rs7264396	0.836	rs41293080	ENSG00000088340.14	FER1L4	3.37	0.000814	0.0455	0.15	0.15	Total cholesterol levels;	chr20:35599775	chr20:35558737~35607562:-
THCA	cis	rs7166081	1	rs10163040	ENSG00000270964.1	RP11-502I4.3	-3.37	0.000814	0.0455	-0.14	-0.15	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67198148	chr15:67541072~67542604:-
THCA	cis	rs9990333	0.862	rs6806599	ENSG00000185485.13	SDHAP1	-3.37	0.000814	0.0455	-0.13	-0.15	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195959748~195990318:-
THCA	cis	rs3785574	0.962	rs4968660	ENSG00000279369.1	RP11-51F16.1	3.37	0.000814	0.0455	0.11	0.15	Height;	chr17:63714861	chr17:63700847~63702670:+
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000814	0.0455	-0.15	-0.15	Lung cancer;	chr6:149795662	chr6:149576089~149590864:-
THCA	cis	rs1737890	0.778	rs3813921	ENSG00000235217.6	TSPY26P	-3.37	0.000814	0.0455	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr20:32334043	chr20:32186477~32190527:-
THCA	cis	rs6545883	0.524	rs2694618	ENSG00000273302.1	RP11-493E12.2	3.37	0.000814	0.0455	0.14	0.15	Tuberculosis;	chr2:61309849	chr2:61199979~61200769:+
THCA	cis	rs786425	0.53	rs10734904	ENSG00000270095.1	RP11-214K3.18	3.37	0.000814	0.0455	0.18	0.15	Pubertal anthropometrics;	chr12:123719611	chr12:123971457~123971714:-
THCA	cis	rs71277158	0.624	rs16854848	ENSG00000242578.1	RP11-469J4.3	3.37	0.000814	0.0455	0.24	0.15	Prostate cancer;	chr3:170104413	chr3:170410512~170418615:+
THCA	cis	rs9910055	0.53	rs7222349	ENSG00000260793.2	RP5-882C2.2	-3.37	0.000814	0.0455	-0.11	-0.15	Total body bone mineral density;	chr17:44227276	chr17:44221401~44223710:+
THCA	cis	rs7870753	0.578	rs10990768	ENSG00000203279.3	RP11-498P14.5	-3.37	0.000814	0.0455	-0.24	-0.15	Height;	chr9:96373241	chr9:97200475~97238700:-
THCA	cis	rs7937890	0.559	rs2597188	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14495360	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2597187	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14495473	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.504	rs2575822	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14498305	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2575823	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14499808	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2597221	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14505529	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs6486197	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14508328	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2597219	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14509320	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs2575852	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14511822	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.531	rs2597216	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14512370	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.559	rs1548074	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14513279	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.561	rs2575849	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14518093	chr11:14478892~14478953:+
THCA	cis	rs7937890	0.507	rs4463820	ENSG00000251991.1	RNU7-49P	3.37	0.000814	0.0455	0.18	0.15	Mitochondrial DNA levels;	chr11:14534796	chr11:14478892~14478953:+
THCA	cis	rs927821	0.68	rs11597058	ENSG00000203886.4	CYP17A1-AS1	3.37	0.000814	0.0455	0.19	0.15	Social autistic-like traits;	chr10:102442238	chr10:102832721~102834516:+
THCA	cis	rs12534093	0.881	rs12540730	ENSG00000234286.1	AC006026.13	3.37	0.000814	0.0455	0.24	0.15	Infant length;Height;	chr7:23444196	chr7:23680195~23680786:-
THCA	cis	rs9596863	1	rs9971999	ENSG00000136149.6	RPL13AP25	-3.37	0.000814	0.0455	-0.19	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53836181	chr13:54440704~54441315:-
THCA	cis	rs478304	0.651	rs4930319	ENSG00000255120.4	OVOL1-AS1	-3.37	0.000814	0.0455	-0.21	-0.15	Acne (severe);	chr11:65787987	chr11:65789051~65790868:-
THCA	cis	rs12893668	0.572	rs4906356	ENSG00000258735.1	LINC00637	-3.37	0.000814	0.0455	-0.2	-0.15	Reticulocyte count;	chr14:103672364	chr14:103847721~103858049:+
THCA	cis	rs9928842	0.77	rs8048371	ENSG00000261783.1	RP11-252K23.2	3.37	0.000815	0.0455	0.3	0.15	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75379818~75381260:-
THCA	cis	rs1927790	0.727	rs9556554	ENSG00000247400.3	DNAJC3-AS1	-3.37	0.000815	0.0455	-0.1	-0.15	Body mass index;	chr13:96307892	chr13:95648733~95676925:-
THCA	cis	rs2933343	0.649	rs789216	ENSG00000261159.1	RP11-723O4.9	3.37	0.000815	0.0455	0.16	0.15	IgG glycosylation;	chr3:128875660	chr3:128859716~128860526:-
THCA	cis	rs3743772	0.5	rs35346613	ENSG00000279344.1	RP11-44F14.7	3.37	0.000815	0.0455	0.2	0.15	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53478957~53481550:-
THCA	cis	rs3743772	0.5	rs62048485	ENSG00000279344.1	RP11-44F14.7	3.37	0.000815	0.0455	0.2	0.15	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53478957~53481550:-
THCA	cis	rs910316	0.967	rs175498	ENSG00000273565.1	CTD-3075F15.1	-3.37	0.000815	0.0455	-0.18	-0.15	Height;	chr14:75069666	chr14:75176929~75177418:+
THCA	cis	rs7226677	0.901	rs9950805	ENSG00000263006.5	ROCK1P1	-3.37	0.000815	0.0455	-0.27	-0.15	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr18:225964	chr18:109065~122219:+
THCA	cis	rs7226677	0.901	rs7227515	ENSG00000263006.5	ROCK1P1	3.37	0.000815	0.0455	0.27	0.15	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr18:225051	chr18:109065~122219:+
THCA	cis	rs990871	0.574	rs11209972	ENSG00000227207.2	RPL31P12	-3.37	0.000815	0.0455	-0.19	-0.15	Subcutaneous adipose tissue;	chr1:72479031	chr1:72301472~72301829:+
THCA	cis	rs11603020	0.95	rs28362947	ENSG00000265566.2	RN7SL605P	-3.37	0.000815	0.0455	-0.24	-0.15	Blood protein levels;	chr11:57601535	chr11:57528085~57528365:-
THCA	cis	rs11603020	0.95	rs28362948	ENSG00000265566.2	RN7SL605P	-3.37	0.000815	0.0455	-0.24	-0.15	Blood protein levels;	chr11:57601540	chr11:57528085~57528365:-
THCA	cis	rs11673344	0.542	rs2562598	ENSG00000233527.7	ZNF529-AS1	3.37	0.000815	0.0455	0.13	0.15	Obesity-related traits;	chr19:37025318	chr19:36573070~36594708:+
THCA	cis	rs9860428	0.774	rs13324496	ENSG00000243795.1	RP11-572M11.3	3.37	0.000815	0.0455	0.18	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112883013	chr3:113142350~113167819:-
THCA	cis	rs12352279	0.59	rs12338863	ENSG00000227914.3	RP11-130C19.3	-3.37	0.000815	0.0455	-0.26	-0.15	Migraine - clinic-based;	chr9:670538	chr9:673478~685555:-
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149779341	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149780867	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149781649	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149791861	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149792658	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs4816	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149793609	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.926	rs952166	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149798774	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs952165	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149798900	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149801253	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000281021.1	RP1-12G14.9	3.37	0.000815	0.0455	0.15	0.15	Lung cancer;	chr6:149803147	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149805967	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149806304	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000815	0.0455	-0.15	-0.15	Lung cancer;	chr6:149807037	chr6:149576089~149590864:-
THCA	cis	rs561341	0.941	rs2470236	ENSG00000265798.5	RP11-271K11.5	3.37	0.000815	0.0455	0.23	0.15	Hip circumference adjusted for BMI;	chr17:31977921	chr17:31038575~31059121:-
THCA	cis	rs561341	0.941	rs501773	ENSG00000265798.5	RP11-271K11.5	3.37	0.000815	0.0455	0.23	0.15	Hip circumference adjusted for BMI;	chr17:31987416	chr17:31038575~31059121:-
THCA	cis	rs62209	0.752	rs72772071	ENSG00000181800.5	CELF2-AS1	3.37	0.000815	0.0455	0.16	0.15	Alzheimer's disease (late onset);	chr10:10969858	chr10:11316834~11319884:-
THCA	cis	rs73019876	0.901	rs1849001	ENSG00000269615.1	AC003973.1	3.37	0.000815	0.0455	0.15	0.15	Testicular germ cell tumor;	chr19:21947961	chr19:21940820~21941533:+
THCA	cis	rs6714900	0.538	rs357752	ENSG00000234896.1	OR7E62P	-3.37	0.000815	0.0455	-0.19	-0.15	Blood protein levels;	chr2:71143688	chr2:71055527~71056003:+
THCA	cis	rs9902453	1	rs4328498	ENSG00000250462.7	LRRC37BP1	-3.37	0.000815	0.0455	-0.12	-0.15	Coffee consumption (cups per day);	chr17:30017258	chr17:30629680~30637466:+
THCA	cis	rs28830936	0.966	rs2303518	ENSG00000250379.1	RP11-23P13.4	3.37	0.000815	0.0455	0.18	0.15	Diastolic blood pressure;	chr15:41817777	chr15:41825099~41827936:-
THCA	cis	rs7829975	0.774	rs1039915	ENSG00000248538.5	RP11-10A14.5	-3.37	0.000815	0.0455	-0.19	-0.15	Mood instability;	chr8:8822104	chr8:9189011~9202854:+
THCA	cis	rs73019876	0.901	rs2666440	ENSG00000269615.1	AC003973.1	3.37	0.000815	0.0455	0.15	0.15	Testicular germ cell tumor;	chr19:21956543	chr19:21940820~21941533:+
THCA	cis	rs2180341	1	rs9285460	ENSG00000220522.2	RP1-177A13.1	3.37	0.000815	0.0455	0.2	0.15	Breast cancer;	chr6:127319045	chr6:127416535~127416952:-
THCA	cis	rs2180341	1	rs4895822	ENSG00000220522.2	RP1-177A13.1	3.37	0.000815	0.0455	0.2	0.15	Breast cancer;	chr6:127321558	chr6:127416535~127416952:-
THCA	cis	rs931127	0.658	rs12787843	ENSG00000255557.1	RP11-770G2.2	3.37	0.000815	0.0455	0.17	0.15	Systemic lupus erythematosus;	chr11:65709835	chr11:65745729~65771585:+
THCA	cis	rs7737355	0.704	rs984616	ENSG00000224431.1	AC063976.7	3.37	0.000815	0.0455	0.14	0.15	Life satisfaction;	chr5:131555408	chr5:132199456~132203487:+
THCA	cis	rs568617	0.626	rs78028320	ENSG00000245156.1	RP11-867G23.3	-3.37	0.000815	0.0455	-0.18	-0.15	Crohn's disease;	chr11:65814544	chr11:66269832~66278525:-
THCA	cis	rs1144333	0.655	rs79322031	ENSG00000272855.1	RP5-1102E8.3	-3.37	0.000815	0.0455	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75926293	chr1:76636877~76637339:+
THCA	cis	rs1783925	1	rs640364	ENSG00000254759.1	NAP1L1P1	-3.37	0.000815	0.0455	-0.19	-0.15	Formal thought disorder in schizophrenia;	chr11:125430870	chr11:126067539~126068601:+
THCA	cis	rs1007190	0.57	rs8064954	ENSG00000267505.1	CTC-296K1.3	-3.37	0.000815	0.0455	-0.27	-0.15	DNA methylation (variation);	chr17:44790075	chr17:44793199~44794474:+
THCA	cis	rs17428076	0.681	rs62182424	ENSG00000228389.1	AC068039.4	-3.37	0.000815	0.0455	-0.21	-0.15	Myopia;	chr2:171895213	chr2:171773482~171775844:+
THCA	cis	rs7829975	0.564	rs2921060	ENSG00000233609.3	RP11-62H7.2	-3.37	0.000815	0.0455	-0.15	-0.15	Mood instability;	chr8:8460307	chr8:8961200~8979025:+
THCA	cis	rs987724	0.537	rs9847187	ENSG00000241544.1	RP11-6F2.5	-3.37	0.000816	0.0455	-0.18	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156873356	chr3:157081841~157088547:+
THCA	cis	rs987724	0.593	rs2321290	ENSG00000241544.1	RP11-6F2.5	-3.37	0.000816	0.0455	-0.18	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156873765	chr3:157081841~157088547:+
THCA	cis	rs987724	0.574	rs9812895	ENSG00000241544.1	RP11-6F2.5	-3.37	0.000816	0.0455	-0.18	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156886370	chr3:157081841~157088547:+
THCA	cis	rs987724	0.593	rs17382070	ENSG00000241544.1	RP11-6F2.5	-3.37	0.000816	0.0455	-0.18	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156890754	chr3:157081841~157088547:+
THCA	cis	rs7264396	0.887	rs11698935	ENSG00000261582.1	RP4-614O4.11	-3.37	0.000816	0.0455	-0.16	-0.15	Total cholesterol levels;	chr20:35487189	chr20:35267885~35280043:-
THCA	cis	rs2034088	0.965	rs11651340	ENSG00000231784.7	DBIL5P	-3.37	0.000816	0.0455	-0.17	-0.15	Hip circumference adjusted for BMI;	chr17:521859	chr17:752660~755336:+
THCA	cis	rs11168618	0.686	rs11168574	ENSG00000257763.1	OR5BK1P	3.37	0.000816	0.0455	0.13	0.15	Adiponectin levels;	chr12:48445186	chr12:48355792~48356614:-
THCA	cis	rs11168618	0.81	rs35338015	ENSG00000257763.1	OR5BK1P	3.37	0.000816	0.0455	0.13	0.15	Adiponectin levels;	chr12:48445618	chr12:48355792~48356614:-
THCA	cis	rs11168618	0.81	rs6580671	ENSG00000257763.1	OR5BK1P	3.37	0.000816	0.0455	0.13	0.15	Adiponectin levels;	chr12:48447274	chr12:48355792~48356614:-
THCA	cis	rs11168618	0.846	rs11168577	ENSG00000257763.1	OR5BK1P	3.37	0.000816	0.0455	0.13	0.15	Adiponectin levels;	chr12:48448809	chr12:48355792~48356614:-
THCA	cis	rs4601821	0.858	rs2298489	ENSG00000270179.1	RP11-159N11.4	3.37	0.000816	0.0455	0.16	0.15	Alcoholic chronic pancreatitis;	chr11:113364697	chr11:113368478~113369117:+
THCA	cis	rs3770081	1	rs58365138	ENSG00000272564.1	RP11-548P2.2	-3.37	0.000816	0.0455	-0.31	-0.15	Facial emotion recognition (sad faces);	chr2:85985982	chr2:85904279~85904727:+
THCA	cis	rs9611565	0.592	rs5996037	ENSG00000237037.8	NDUFA6-AS1	3.37	0.000816	0.0455	0.14	0.15	Vitiligo;	chr22:41569288	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.592	rs5996038	ENSG00000237037.8	NDUFA6-AS1	3.37	0.000816	0.0455	0.14	0.15	Vitiligo;	chr22:41569296	chr22:42090931~42137742:+
THCA	cis	rs875971	0.66	rs2013222	ENSG00000232546.1	RP11-458F8.1	3.37	0.000816	0.0455	0.13	0.15	Aortic root size;	chr7:66570949	chr7:66848496~66858136:+
THCA	cis	rs13196561	0.671	rs9376816	ENSG00000270987.1	RP3-467N11.2	3.37	0.000816	0.0455	0.23	0.15	Menarche (age at onset);	chr6:100252958	chr6:100889603~100890338:+
THCA	cis	rs7660760	1	rs7660760	ENSG00000250131.1	RP11-130F10.1	-3.37	0.000816	0.0455	-0.19	-0.15	Left ventricle wall thickness;	chr4:176609661	chr4:177444979~177677126:+
THCA	cis	rs62246343	0.541	rs17050396	ENSG00000206573.7	THUMPD3-AS1	-3.37	0.000816	0.0455	-0.11	-0.15	Fibrinogen levels;	chr3:9492652	chr3:9349689~9398579:-
THCA	cis	rs4478858	0.735	rs4494186	ENSG00000229447.2	RP11-490K7.4	3.37	0.000816	0.0455	0.14	0.15	Alcohol dependence;	chr1:31385000	chr1:31263245~31263681:-
THCA	cis	rs61160187	0.582	rs12654306	ENSG00000251279.1	CTC-436P18.1	-3.37	0.000816	0.0455	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:61162070~61232040:+
THCA	cis	rs13064773	0.528	rs340269	ENSG00000240207.5	RP11-379F4.4	3.37	0.000816	0.0455	0.17	0.15	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158876736	chr3:158732263~158784070:+
THCA	cis	rs301901	0.772	rs7735138	ENSG00000250155.1	CTD-2353F22.1	-3.37	0.000816	0.0455	-0.16	-0.15	Height;	chr5:37239138	chr5:36666214~36725195:-
THCA	cis	rs34779708	0.966	rs4934732	ENSG00000233200.1	RP11-324I22.2	3.37	0.000816	0.0455	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35219894~35230598:-
THCA	cis	rs10791097	0.642	rs7107568	ENSG00000255455.2	RP11-890B15.3	-3.37	0.000816	0.0455	-0.14	-0.15	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130909773	chr11:130866254~130870247:-
THCA	cis	rs34783982	0.762	rs34865506	ENSG00000259699.2	HMGB1P8	-3.37	0.000816	0.0455	-0.21	-0.15	Squamous cell lung carcinoma;	chr15:88962501	chr15:89135547~89136495:-
THCA	cis	rs3114020	0.771	rs9631715	ENSG00000246375.2	RP11-10L7.1	3.37	0.000816	0.0455	0.21	0.15	Gout;	chr4:88177579	chr4:88284942~88331421:+
THCA	cis	rs1075265	0.933	rs7562055	ENSG00000235937.1	AC008280.1	3.37	0.000816	0.0455	0.18	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54029552~54030682:-
THCA	cis	rs17689437	0.767	rs11642992	ENSG00000260084.1	RP11-615I2.1	-3.37	0.000816	0.0455	-0.25	-0.15	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68616133	chr16:68573782~68589512:-
THCA	cis	rs1577917	0.655	rs9450311	ENSG00000280232.1	RP11-321N4.4	-3.37	0.000816	0.0455	-0.18	-0.15	Response to antipsychotic treatment;	chr6:85666868	chr6:85498441~85499058:-
THCA	cis	rs17604090	0.818	rs28390296	ENSG00000227855.3	DPY19L2P3	3.37	0.000816	0.0455	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647475	chr7:29650227~29742594:+
THCA	cis	rs860295	0.58	rs2282301	ENSG00000160766.13	GBAP1	3.37	0.000816	0.0455	0.18	0.15	Body mass index;	chr1:155898834	chr1:155213821~155227422:-
THCA	cis	rs7707921	0.522	rs10065463	ENSG00000251374.1	RPS23P5	3.37	0.000816	0.0455	0.18	0.15	Breast cancer;	chr5:82204461	chr5:82265157~82265259:-
THCA	cis	rs8019546	0.924	rs2027343	ENSG00000259113.1	RP11-406H23.2	3.37	0.000816	0.0455	0.19	0.15	Dietary macronutrient intake;	chr14:50858166	chr14:50448807~50456742:+
THCA	cis	rs7829975	0.774	rs57312668	ENSG00000248538.5	RP11-10A14.5	-3.37	0.000816	0.0455	-0.19	-0.15	Mood instability;	chr8:8822967	chr8:9189011~9202854:+
THCA	cis	rs9341808	0.718	rs3812121	ENSG00000260645.1	RP11-250B2.5	3.37	0.000816	0.0455	0.13	0.15	Sitting height ratio;	chr6:80259010	chr6:80466958~80469080:+
THCA	cis	rs6472235	0.837	rs11995587	ENSG00000272010.1	CTD-3025N20.3	-3.37	0.000816	0.0456	-0.15	-0.15	Plateletcrit;Myopia (pathological);	chr8:66013810	chr8:65591850~65592472:-
THCA	cis	rs6472235	0.837	rs11995704	ENSG00000272010.1	CTD-3025N20.3	-3.37	0.000816	0.0456	-0.15	-0.15	Plateletcrit;Myopia (pathological);	chr8:66014193	chr8:65591850~65592472:-
THCA	cis	rs7259376	0.869	rs8110636	ENSG00000270947.1	AC025811.3	-3.37	0.000816	0.0456	-0.16	-0.15	Menopause (age at onset);	chr19:22418025	chr19:22455988~22456459:+
THCA	cis	rs7259376	0.902	rs8100087	ENSG00000270947.1	AC025811.3	-3.37	0.000816	0.0456	-0.16	-0.15	Menopause (age at onset);	chr19:22418557	chr19:22455988~22456459:+
THCA	cis	rs11030122	0.702	rs10835340	ENSG00000230593.3	AC090804.1	-3.37	0.000816	0.0456	-0.2	-0.15	Mean platelet volume;Platelet distribution width;	chr11:3939190	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.702	rs10835407	ENSG00000230593.3	AC090804.1	-3.37	0.000816	0.0456	-0.2	-0.15	Mean platelet volume;Platelet distribution width;	chr11:3972001	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.702	rs1452047	ENSG00000230593.3	AC090804.1	3.37	0.000816	0.0456	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3970418	chr11:3892398~3892887:-
THCA	cis	rs2475553	0.547	rs116760199	ENSG00000213078.3	RP5-933K21.2	-3.37	0.000816	0.0456	-0.25	-0.15	Lipoprotein (a) - cholesterol levels;	chr6:158228686	chr6:157365990~157366923:-
THCA	cis	rs6517329	0.564	rs12626189	ENSG00000233393.1	AP000688.29	3.37	0.000816	0.0456	0.19	0.15	Schizophrenia;	chr21:36137654	chr21:36104881~36109690:+
THCA	cis	rs5753618	0.539	rs695438	ENSG00000214076.3	CPSF1P1	-3.37	0.000816	0.0456	-0.2	-0.15	Colorectal cancer;	chr22:31415890	chr22:32269381~32273110:+
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000281021.1	RP1-12G14.9	-3.37	0.000817	0.0456	-0.15	-0.15	Lung cancer;	chr6:149603650	chr6:149576089~149590864:-
THCA	cis	rs9532580	0.656	rs2721068	ENSG00000275149.1	RP11-427J23.1	-3.37	0.000817	0.0456	-0.21	-0.15	Mean corpuscular hemoglobin;	chr13:40565575	chr13:40079106~40273509:-
THCA	cis	rs1009077	0.761	rs35581370	ENSG00000245958.5	RP11-33B1.1	3.37	0.000817	0.0456	0.24	0.15	Endometriosis;	chr4:119649123	chr4:119454791~119552025:+
THCA	cis	rs1832871	0.672	rs62437361	ENSG00000213078.3	RP5-933K21.2	-3.37	0.000817	0.0456	-0.23	-0.15	Height;	chr6:158307727	chr6:157365990~157366923:-
THCA	cis	rs10129255	0.957	rs8009638	ENSG00000274576.2	IGHV2-70	3.37	0.000817	0.0456	0.1	0.15	Kawasaki disease;	chr14:106777570	chr14:106770577~106771020:-
THCA	cis	rs1048886	1	rs12526787	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000817	0.0456	-0.19	-0.15	Type 2 diabetes;	chr6:70478110	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs75668908	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000817	0.0456	-0.19	-0.15	Type 2 diabetes;	chr6:70483846	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs55778329	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000817	0.0456	-0.19	-0.15	Type 2 diabetes;	chr6:70491271	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs77937573	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000817	0.0456	-0.19	-0.15	Type 2 diabetes;	chr6:70491930	chr6:70596438~70596980:+
THCA	cis	rs4788570	0.584	rs7204608	ENSG00000279592.1	RP11-417N10.4	-3.37	0.000817	0.0456	-0.25	-0.15	Intelligence (multi-trait analysis);	chr16:71644776	chr16:71859680~71860676:+
THCA	cis	rs10911363	0.592	rs10797886	ENSG00000232860.6	SMG7-AS1	-3.37	0.000817	0.0456	-0.12	-0.15	Systemic lupus erythematosus;	chr1:183509955	chr1:183460874~183472265:-
THCA	cis	rs321358	0.895	rs73015175	ENSG00000271390.1	RP11-89C3.3	3.37	0.000817	0.0456	0.25	0.15	Body mass index;	chr11:111088593	chr11:111089870~111090368:-
THCA	cis	rs321358	0.895	rs17536143	ENSG00000271390.1	RP11-89C3.3	3.37	0.000817	0.0456	0.25	0.15	Body mass index;	chr11:111088619	chr11:111089870~111090368:-
THCA	cis	rs321358	0.895	rs12419745	ENSG00000271390.1	RP11-89C3.3	3.37	0.000817	0.0456	0.25	0.15	Body mass index;	chr11:111090741	chr11:111089870~111090368:-
THCA	cis	rs6788895	1	rs73010967	ENSG00000244265.1	SIAH2-AS1	3.37	0.000817	0.0456	0.38	0.15	Breast cancer;	chr3:150780269	chr3:150761937~150762538:+
THCA	cis	rs3808502	0.574	rs4841559	ENSG00000154316.13	TDH	3.37	0.000817	0.0456	0.11	0.15	Neuroticism;	chr8:11559376	chr8:11339637~11368452:+
THCA	cis	rs4144027	0.818	rs881057	ENSG00000258534.1	CTD-2134A5.4	3.37	0.000817	0.0456	0.16	0.15	Blood metabolite levels;	chr14:103887921	chr14:103854366~103880111:-
THCA	cis	rs80130819	0.686	rs78239819	ENSG00000226413.2	OR8T1P	-3.37	0.000817	0.0456	-0.34	-0.15	Prostate cancer;	chr12:48018767	chr12:48442030~48442947:-
THCA	cis	rs7621331	1	rs6786769	ENSG00000239213.4	NCK1-AS1	3.37	0.000817	0.0456	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135994927	chr3:136841726~136862054:-
THCA	cis	rs2098713	0.599	rs12152831	ENSG00000250155.1	CTD-2353F22.1	3.37	0.000817	0.0456	0.15	0.15	Telomere length;	chr5:37555215	chr5:36666214~36725195:-
THCA	cis	rs1577917	0.958	rs12197463	ENSG00000220563.1	PKMP3	-3.37	0.000817	0.0456	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85735524	chr6:85659892~85660606:-
THCA	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-3.37	0.000817	0.0456	-0.18	-0.15	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
THCA	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-3.37	0.000817	0.0456	-0.18	-0.15	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
THCA	cis	rs950893	0.729	rs1858401	ENSG00000253986.1	CTC-756D1.3	-3.37	0.000817	0.0456	-0.19	-0.15	Mean corpuscular hemoglobin;	chr8:23608953	chr8:23493009~23494198:-
THCA	cis	rs8042680	0.784	rs8032722	ENSG00000258725.1	PRC1-AS1	-3.37	0.000817	0.0456	-0.2	-0.15	Type 2 diabetes;	chr15:90978840	chr15:90966345~90988624:+
THCA	cis	rs17604090	0.878	rs4000281	ENSG00000227855.3	DPY19L2P3	3.37	0.000818	0.0456	0.2	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29686671	chr7:29650227~29742594:+
THCA	cis	rs12935418	0.673	rs2549886	ENSG00000261061.1	RP11-303E16.2	3.37	0.000818	0.0456	0.15	0.15	Mean corpuscular volume;	chr16:81027627	chr16:81030770~81031485:+
THCA	cis	rs7045881	0.534	rs7871668	ENSG00000254396.1	RP11-56F10.3	3.37	0.000818	0.0456	0.19	0.15	Schizophrenia;	chr9:27053652	chr9:27102630~27104728:+
THCA	cis	rs9868809	0.881	rs2286652	ENSG00000229759.1	MRPS18AP1	-3.37	0.000818	0.0456	-0.3	-0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48651759	chr3:48256350~48256938:-
THCA	cis	rs3785888	0.569	rs2072317	ENSG00000238419.1	RNU7-186P	-3.37	0.000818	0.0456	-0.18	-0.15	Cleft lip with or without cleft palate;	chr17:46929847	chr17:47259358~47259420:-
THCA	cis	rs1799949	0.965	rs8070179	ENSG00000236383.6	LINC00854	-3.37	0.000818	0.0456	-0.15	-0.15	Menopause (age at onset);	chr17:43050671	chr17:43216941~43305976:-
THCA	cis	rs7851693	0.789	rs7021911	ENSG00000232172.1	RP11-57C19.2	3.37	0.000818	0.0456	0.17	0.15	Bone mineral density;	chr9:130625631	chr9:130651799~130652383:+
THCA	cis	rs7397814	0.558	rs4764447	ENSG00000260423.1	RP13-735L24.1	3.37	0.000818	0.0456	0.18	0.15	IgG glycosylation;	chr12:9426513	chr12:9367464~9397617:+
THCA	cis	rs12887734	0.546	rs12885509	ENSG00000269958.1	RP11-73M18.8	3.37	0.000818	0.0456	0.15	0.15	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103696353~103697163:+
THCA	cis	rs7586879	0.638	rs13035244	ENSG00000224165.4	DNAJC27-AS1	-3.37	0.000818	0.0456	-0.09	-0.15	Body mass index;	chr2:24911140	chr2:24971390~25039694:+
THCA	cis	rs332034	0.591	rs7017739	ENSG00000254153.1	CTA-398F10.2	3.37	0.000818	0.0456	0.23	0.15	Conduct disorder (maternal expressed emotions interaction);	chr8:8850129	chr8:8456909~8461337:-
THCA	cis	rs2318131	0.795	rs2117838	ENSG00000222032.1	AC112721.2	3.37	0.000818	0.0456	0.16	0.15	Motion sickness;	chr2:237011466	chr2:237428920~237434822:-
THCA	cis	rs7702057	0.619	rs7716923	ENSG00000271918.1	CTD-2287O16.5	3.37	0.000818	0.0456	0.21	0.15	Amyotrophic lateral sclerosis;	chr5:116364610	chr5:116083807~116085416:-
THCA	cis	rs12893668	0.572	rs4900591	ENSG00000258735.1	LINC00637	-3.37	0.000818	0.0456	-0.2	-0.15	Reticulocyte count;	chr14:103688541	chr14:103847721~103858049:+
THCA	cis	rs1005277	0.563	rs2800550	ENSG00000151963.4	RP11-775A3.1	-3.37	0.000818	0.0456	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:37883594~37884109:+
THCA	cis	rs17689437	0.625	rs7499785	ENSG00000275383.1	RP11-615I2.6	3.37	0.000818	0.0456	0.17	0.15	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68567382	chr16:68591382~68594424:+
THCA	cis	rs12612435	0.736	rs34253205	ENSG00000230037.1	UBBP1	3.37	0.000818	0.0456	0.22	0.15	Takotsubo syndrome;	chr2:136388689	chr2:136329441~136329913:-
THCA	cis	rs6472235	0.778	rs6472242	ENSG00000272192.1	CTD-2532N20.1	3.37	0.000818	0.0456	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:65998378	chr8:65842752~65843331:+
THCA	cis	rs939960	0.918	rs34176120	ENSG00000276538.1	RP11-545G3.2	3.37	0.000818	0.0456	0.23	0.15	Neutrophil percentage of white cells;	chr7:150586759	chr7:150047609~150047854:-
THCA	cis	rs939960	0.876	rs4573169	ENSG00000276538.1	RP11-545G3.2	3.37	0.000818	0.0456	0.23	0.15	Neutrophil percentage of white cells;	chr7:150590063	chr7:150047609~150047854:-
THCA	cis	rs939960	0.684	rs78148705	ENSG00000276538.1	RP11-545G3.2	3.37	0.000818	0.0456	0.23	0.15	Neutrophil percentage of white cells;	chr7:150591080	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs35659213	ENSG00000276538.1	RP11-545G3.2	3.37	0.000818	0.0456	0.23	0.15	Neutrophil percentage of white cells;	chr7:150594808	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs6951360	ENSG00000276538.1	RP11-545G3.2	3.37	0.000818	0.0456	0.23	0.15	Neutrophil percentage of white cells;	chr7:150595392	chr7:150047609~150047854:-
THCA	cis	rs939960	0.959	rs57729315	ENSG00000276538.1	RP11-545G3.2	3.37	0.000818	0.0456	0.23	0.15	Neutrophil percentage of white cells;	chr7:150596133	chr7:150047609~150047854:-
THCA	cis	rs7973683	0.541	rs7976319	ENSG00000269938.1	RP11-214K3.20	-3.37	0.000819	0.0456	-0.17	-0.15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123903964	chr12:123968023~123968579:-
THCA	cis	rs7578982	0.644	rs10181102	ENSG00000227992.1	AC108463.2	3.37	0.000819	0.0456	0.2	0.15	White blood cell types;	chr2:111077912	chr2:111203964~111206215:-
THCA	cis	rs2911280	0.764	rs7201098	ENSG00000278985.1	RP11-303E16.9	-3.37	0.000819	0.0456	-0.29	-0.15	Dehydroepiandrosterone sulphate levels;	chr16:81525611	chr16:80982319~80984094:-
THCA	cis	rs2911280	0.764	rs7201103	ENSG00000278985.1	RP11-303E16.9	-3.37	0.000819	0.0456	-0.29	-0.15	Dehydroepiandrosterone sulphate levels;	chr16:81525615	chr16:80982319~80984094:-
THCA	cis	rs2911280	0.764	rs7203208	ENSG00000278985.1	RP11-303E16.9	-3.37	0.000819	0.0456	-0.29	-0.15	Dehydroepiandrosterone sulphate levels;	chr16:81525653	chr16:80982319~80984094:-
THCA	cis	rs2911280	0.764	rs13331687	ENSG00000278985.1	RP11-303E16.9	-3.37	0.000819	0.0456	-0.29	-0.15	Dehydroepiandrosterone sulphate levels;	chr16:81525908	chr16:80982319~80984094:-
THCA	cis	rs7665090	1	rs7677509	ENSG00000251288.2	RP11-10L12.2	-3.37	0.000819	0.0456	-0.2	-0.15	Primary biliary cholangitis;	chr4:102628849	chr4:102751401~102752641:+
THCA	cis	rs7665090	0.967	rs7699231	ENSG00000251288.2	RP11-10L12.2	-3.37	0.000819	0.0456	-0.2	-0.15	Primary biliary cholangitis;	chr4:102628918	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs7699678	ENSG00000251288.2	RP11-10L12.2	-3.37	0.000819	0.0456	-0.2	-0.15	Primary biliary cholangitis;	chr4:102628939	chr4:102751401~102752641:+
THCA	cis	rs7665090	1	rs11724614	ENSG00000251288.2	RP11-10L12.2	-3.37	0.000819	0.0456	-0.2	-0.15	Primary biliary cholangitis;	chr4:102629091	chr4:102751401~102752641:+
THCA	cis	rs7439493	0.865	rs9992400	ENSG00000247950.5	SEC24B-AS1	-3.37	0.000819	0.0457	-0.1	-0.15	Blood protein levels;	chr4:109708738	chr4:109347475~109433817:-
THCA	cis	rs2243480	1	rs3885839	ENSG00000189316.3	RP11-797H7.5	3.37	0.000819	0.0457	0.26	0.15	Diabetic kidney disease;	chr7:65825416	chr7:64888527~64890100:-
THCA	cis	rs2243480	1	rs73142122	ENSG00000189316.3	RP11-797H7.5	3.37	0.000819	0.0457	0.26	0.15	Diabetic kidney disease;	chr7:65846311	chr7:64888527~64890100:-
THCA	cis	rs2243480	0.901	rs73142137	ENSG00000189316.3	RP11-797H7.5	3.37	0.000819	0.0457	0.26	0.15	Diabetic kidney disease;	chr7:65878455	chr7:64888527~64890100:-
THCA	cis	rs61160187	0.582	rs3797559	ENSG00000251279.1	CTC-436P18.1	-3.37	0.000819	0.0457	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:61162070~61232040:+
THCA	cis	rs2305707	0.544	rs2470158	ENSG00000273674.3	CTD-2378E12.1	-3.37	0.000819	0.0457	-0.31	-0.15	Height;	chr15:51296198	chr15:50839875~50908599:-
THCA	cis	rs4083242	0.764	rs2353689	ENSG00000270124.1	RP11-118F19.1	-3.37	0.000819	0.0457	-0.15	-0.15	Obesity-related traits;	chr16:86333310	chr16:85580009~85583571:-
THCA	cis	rs4919087	0.884	rs4917762	ENSG00000237169.1	RP11-452K12.3	-3.37	0.000819	0.0457	-0.18	-0.15	Monocyte count;	chr10:97216714	chr10:97309138~97309958:-
THCA	cis	rs2180341	0.814	rs6919082	ENSG00000220522.2	RP1-177A13.1	3.37	0.000819	0.0457	0.19	0.15	Breast cancer;	chr6:127416743	chr6:127416535~127416952:-
THCA	cis	rs3026101	0.671	rs2871210	ENSG00000234327.6	AC012146.7	-3.37	0.000819	0.0457	-0.12	-0.15	Body mass index;	chr17:5401707	chr17:5111468~5115004:+
THCA	cis	rs7166081	0.95	rs8043060	ENSG00000270964.1	RP11-502I4.3	-3.37	0.000819	0.0457	-0.14	-0.15	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67369446	chr15:67541072~67542604:-
THCA	cis	rs73019876	0.502	rs4932954	ENSG00000269364.1	LINC01233	-3.37	0.000819	0.0457	-0.17	-0.15	Testicular germ cell tumor;	chr19:22089652	chr19:22532626~22533494:+
THCA	cis	rs73019876	0.502	rs9304994	ENSG00000269364.1	LINC01233	-3.37	0.000819	0.0457	-0.17	-0.15	Testicular germ cell tumor;	chr19:22089941	chr19:22532626~22533494:+
THCA	cis	rs6589219	1	rs6589219	ENSG00000196167.8	COLCA1	-3.37	0.000819	0.0457	-0.17	-0.15	Colorectal cancer;	chr11:111302186	chr11:111290787~111305045:-
THCA	cis	rs12744221	1	rs12744221	ENSG00000234222.5	RP11-315I20.1	-3.37	0.000819	0.0457	-0.19	-0.15	Epilepsy (remission after treatment);	chr1:145789475	chr1:145926590~145959179:+
THCA	cis	rs867186	1	rs74599371	ENSG00000126005.14	MMP24-AS1	-3.37	0.000819	0.0457	-0.25	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34973692	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs79197732	ENSG00000126005.14	MMP24-AS1	-3.37	0.000819	0.0457	-0.25	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34974673	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs76191812	ENSG00000126005.14	MMP24-AS1	-3.37	0.000819	0.0457	-0.25	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34976108	chr20:35216462~35278131:-
THCA	cis	rs867186	1	rs77437249	ENSG00000126005.14	MMP24-AS1	-3.37	0.000819	0.0457	-0.25	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34976935	chr20:35216462~35278131:-
THCA	cis	rs7487075	0.619	rs1472178	ENSG00000275481.1	RP11-474P2.6	3.37	0.000819	0.0457	0.15	0.15	Itch intensity from mosquito bite;	chr12:46410392	chr12:46388856~46392126:+
THCA	cis	rs11051970	0.918	rs7309115	ENSG00000277342.1	RP11-843B15.4	-3.37	0.000819	0.0457	-0.22	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32388307	chr12:32109076~32109602:+
THCA	cis	rs13401620	0.555	rs2018962	ENSG00000227788.1	AC012363.8	3.37	0.000819	0.0457	0.18	0.15	Breast size;	chr2:120217026	chr2:120211727~120212862:+
THCA	cis	rs74902201	0.649	rs16959907	ENSG00000207688.2	MIR548D2	-3.37	0.000819	0.0457	-0.34	-0.15	Food addiction;	chr17:66665772	chr17:67471489~67471585:+
THCA	cis	rs7927592	0.731	rs2840367	ENSG00000160172.9	FAM86C2P	-3.37	0.000819	0.0457	-0.14	-0.15	Total body bone mineral density;	chr11:68534633	chr11:67791648~67805336:-
THCA	cis	rs4671400	0.543	rs10178135	ENSG00000270820.4	RP11-355B11.2	-3.37	0.000819	0.0457	-0.14	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258132	chr2:61471188~61484130:+
THCA	cis	rs9611565	0.592	rs9611613	ENSG00000237037.8	NDUFA6-AS1	3.37	0.000819	0.0457	0.14	0.15	Vitiligo;	chr22:41565827	chr22:42090931~42137742:+
THCA	cis	rs2071852	0.56	rs2032503	ENSG00000280383.1	CTA-941F9.10	3.37	0.000819	0.0457	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr22:45792917	chr22:45657019~45680130:+
THCA	cis	rs250585	1	rs7196534	ENSG00000260136.4	CTD-2270L9.4	-3.37	0.000819	0.0457	-0.13	-0.15	Egg allergy;	chr16:23546397	chr16:23452758~23457606:+
THCA	cis	rs6490294	0.528	rs7970181	ENSG00000234608.6	MAPKAPK5-AS1	3.37	0.000819	0.0457	0.17	0.15	Mean platelet volume;	chr12:112172194	chr12:111839764~111842902:-
THCA	cis	rs9457247	0.566	rs10946207	ENSG00000235272.1	FAM103A2P	3.37	0.000819	0.0457	0.21	0.15	Crohn's disease;	chr6:167042548	chr6:166586124~166586477:-
THCA	cis	rs7240205	0.816	rs2019480	ENSG00000265369.3	PCAT18	3.37	0.000819	0.0457	0.17	0.15	Breast cancer;	chr18:26545720	chr18:26687621~26703638:-
THCA	cis	rs7081476	0.737	rs111833489	ENSG00000262412.1	RP11-85G18.6	-3.37	0.000819	0.0457	-0.34	-0.15	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr10:27217550	chr10:27243130~27250804:+
THCA	cis	rs6724465	1	rs72951729	ENSG00000272644.1	RP11-33O4.1	3.37	0.00082	0.0457	0.23	0.15	Height;	chr2:219095821	chr2:219069354~219069809:-
THCA	cis	rs9818758	0.607	rs11719220	ENSG00000229759.1	MRPS18AP1	-3.37	0.00082	0.0457	-0.32	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207768	chr3:48256350~48256938:-
THCA	cis	rs9818758	0.607	rs35060561	ENSG00000229759.1	MRPS18AP1	-3.37	0.00082	0.0457	-0.32	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49218070	chr3:48256350~48256938:-
THCA	cis	rs2933343	0.7	rs2624910	ENSG00000261159.1	RP11-723O4.9	3.37	0.00082	0.0457	0.16	0.15	IgG glycosylation;	chr3:128931432	chr3:128859716~128860526:-
THCA	cis	rs17594362	0.581	rs73181180	ENSG00000264190.1	MIR5006	3.37	0.00082	0.0457	0.25	0.15	Multiple sclerosis;	chr13:41589604	chr13:41568286~41568395:-
THCA	cis	rs972578	0.875	rs6519353	ENSG00000230319.1	AL022476.2	3.37	0.00082	0.0457	0.16	0.15	Mean platelet volume;	chr22:42960124	chr22:43038585~43052366:+
THCA	cis	rs6496667	0.865	rs7178854	ENSG00000259262.1	NDUFA3P4	3.37	0.00082	0.0457	0.22	0.15	Rheumatoid arthritis;	chr15:90341402	chr15:90385814~90386063:+
THCA	cis	rs6001482	0.702	rs5757581	ENSG00000279278.1	CH17-264L24.1	-3.37	0.00082	0.0457	-0.13	-0.15	Diastolic blood pressure;	chr22:22234220	chr22:22264601~22273020:+
THCA	cis	rs7980687	0.527	rs28533432	ENSG00000256092.2	RP13-942N8.1	3.37	0.00082	0.0457	0.11	0.15	Head circumference (infant);Educational attainment;Height;	chr12:123388695	chr12:123363868~123366113:+
THCA	cis	rs34779708	0.931	rs79749947	ENSG00000233200.1	RP11-324I22.2	3.37	0.00082	0.0457	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs9663401	ENSG00000233200.1	RP11-324I22.2	3.37	0.00082	0.0457	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35219894~35230598:-
THCA	cis	rs631288	0.793	rs10900331	ENSG00000226015.2	CCT8P1	3.37	0.00082	0.0457	0.27	0.15	PR interval in Tripanosoma cruzi seropositivity;	chr1:147261471	chr1:147203276~147204932:-
THCA	cis	rs763121	0.853	rs5750669	ENSG00000225450.1	RP3-508I15.14	-3.37	0.00082	0.0457	-0.12	-0.15	Menopause (age at onset);	chr22:38684633	chr22:38739003~38749041:+
THCA	cis	rs2486012	0.737	rs4660749	ENSG00000234694.1	RP1-92O14.3	3.37	0.00082	0.0457	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43784630	chr1:43354684~43358658:-
THCA	cis	rs2549003	1	rs17848418	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132485496	chr5:132311285~132369916:-
THCA	cis	rs2549003	0.87	rs61175929	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132485856	chr5:132311285~132369916:-
THCA	cis	rs2549003	0.87	rs10053046	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132485866	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs2070726	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132486046	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs2070725	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132486096	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs10214312	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132486174	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs9282762	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132486363	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs2070724	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132486380	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs9282763	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132486441	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs9282761	ENSG00000233006.5	AC034220.3	-3.37	0.00082	0.0457	-0.12	-0.15	Asthma (sex interaction);	chr5:132486532	chr5:132311285~132369916:-
THCA	cis	rs9425766	0.85	rs7349095	ENSG00000200674.1	RN7SKP160	3.37	0.00082	0.0457	0.2	0.15	Life satisfaction;	chr1:173887899	chr1:173791548~173791887:+
THCA	cis	rs830407	0.661	rs12338580	ENSG00000225693.1	LAGE3P1	3.37	0.00082	0.0457	0.27	0.15	Bipolar disorder and schizophrenia;	chr9:33190241	chr9:33019682~33020165:-
THCA	cis	rs1029966	0.541	rs72633279	ENSG00000262686.1	GLIS2-AS1	-3.37	0.00082	0.0457	-0.2	-0.15	Cancer;	chr16:4936166	chr16:4324667~4328340:-
THCA	cis	rs853679	0.699	rs9468318	ENSG00000261839.1	RP1-265C24.8	3.37	0.00082	0.0457	0.19	0.15	Depression;	chr6:28241753	chr6:28136849~28139678:+
THCA	cis	rs4073582	0.595	rs708472	ENSG00000245156.1	RP11-867G23.3	3.37	0.00082	0.0457	0.13	0.15	Gout;	chr11:66163519	chr11:66269832~66278525:-
THCA	cis	rs4073582	0.595	rs708471	ENSG00000245156.1	RP11-867G23.3	3.37	0.00082	0.0457	0.13	0.15	Gout;	chr11:66163537	chr11:66269832~66278525:-
THCA	cis	rs1005277	0.54	rs1814077	ENSG00000120555.12	SEPT7P9	3.37	0.00082	0.0457	0.17	0.15	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38383069~38402916:-
THCA	cis	rs4243971	0.557	rs1040752	ENSG00000224452.1	RSL24D1P6	3.37	0.00082	0.0457	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr20:32441221	chr20:32170390~32170790:-
THCA	cis	rs748404	0.666	rs8027748	ENSG00000166763.7	STRCP1	3.37	0.00082	0.0457	0.2	0.15	Lung cancer;	chr15:43447622	chr15:43699488~43718184:-
THCA	cis	rs4578769	0.531	rs4800443	ENSG00000273232.1	RP11-370A5.2	3.37	0.00082	0.0457	0.21	0.15	Eosinophil percentage of white cells;	chr18:23015139	chr18:22882825~22883357:-
THCA	cis	rs939960	0.879	rs12154435	ENSG00000276538.1	RP11-545G3.2	3.37	0.00082	0.0457	0.26	0.15	Neutrophil percentage of white cells;	chr7:150646620	chr7:150047609~150047854:-
THCA	cis	rs939960	0.879	rs12154436	ENSG00000276538.1	RP11-545G3.2	3.37	0.00082	0.0457	0.26	0.15	Neutrophil percentage of white cells;	chr7:150646696	chr7:150047609~150047854:-
THCA	cis	rs61160187	0.51	rs10077663	ENSG00000272308.1	RP11-231G3.1	-3.37	0.00082	0.0457	-0.16	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:60866457~60866935:-
THCA	cis	rs2652822	0.525	rs1910094	ENSG00000259459.4	RP11-321G12.1	-3.37	0.00082	0.0457	-0.12	-0.15	Metabolic traits;	chr15:63193328	chr15:63390136~63438320:+
THCA	cis	rs2638953	0.815	rs117066882	ENSG00000247934.4	RP11-967K21.1	-3.37	0.00082	0.0457	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28477287	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049666	ENSG00000247934.4	RP11-967K21.1	-3.37	0.00082	0.0457	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28496138	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.853	rs11049667	ENSG00000247934.4	RP11-967K21.1	-3.37	0.00082	0.0457	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28496942	chr12:28163298~28190738:-
THCA	cis	rs13113518	0.729	rs12641881	ENSG00000272969.1	RP11-528I4.2	3.37	0.00082	0.0457	0.19	0.15	Height;	chr4:55401306	chr4:55547112~55547889:+
THCA	cis	rs9392556	0.829	rs659305	ENSG00000230648.1	RP3-406P24.3	3.37	0.000821	0.0457	0.19	0.15	Blood metabolite levels;	chr6:4125421	chr6:4018843~4021215:-
THCA	cis	rs7267979	0.527	rs6076369	ENSG00000277938.1	RP5-965G21.3	-3.37	0.000821	0.0457	-0.13	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:25229150~25231933:+
THCA	cis	rs7267979	0.844	rs869358	ENSG00000276952.1	RP5-965G21.6	-3.37	0.000821	0.0457	-0.16	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25284915~25285588:-
THCA	cis	rs6968419	0.504	rs11773521	ENSG00000237870.5	AC073130.1	3.37	0.000821	0.0457	0.17	0.15	Intraocular pressure;	chr7:116166470	chr7:116275606~116286734:-
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000230189.5	GS1-124K5.2	3.37	0.000821	0.0457	0.1	0.15	Calcium levels;	chr7:65967580	chr7:66409143~66490059:-
THCA	cis	rs9584850	0.834	rs745638	ENSG00000231194.1	FARP1-AS1	-3.37	0.000821	0.0457	-0.19	-0.15	Neuroticism;	chr13:98467053	chr13:98435405~98435840:-
THCA	cis	rs10844706	1	rs10844706	ENSG00000257027.1	RP11-705C15.3	3.37	0.000821	0.0457	0.13	0.15	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9757536	chr12:9658567~9662085:+
THCA	cis	rs651907	0.617	rs797776	ENSG00000244119.1	PDCL3P4	3.37	0.000821	0.0457	0.12	0.15	Colorectal cancer;	chr3:101891399	chr3:101712472~101713191:+
THCA	cis	rs7809799	0.571	rs73163167	ENSG00000242798.1	RP11-506M12.1	-3.37	0.000821	0.0457	-0.31	-0.15	Ulcerative colitis;	chr7:99345463	chr7:100115214~100127139:-
THCA	cis	rs11777747	1	rs11777747	ENSG00000280303.2	ERICD	-3.37	0.000821	0.0457	-0.19	-0.15	Coronary artery calcification;	chr8:141456721	chr8:140636281~140638283:+
THCA	cis	rs6715793	0.836	rs17568051	ENSG00000272754.1	AL133245.2	-3.37	0.000821	0.0457	-0.18	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33219386	chr2:32321638~32323002:+
THCA	cis	rs73019876	0.869	rs2158107	ENSG00000269615.1	AC003973.1	3.37	0.000821	0.0457	0.15	0.15	Testicular germ cell tumor;	chr19:21968543	chr19:21940820~21941533:+
THCA	cis	rs12428035	0.764	rs537463	ENSG00000247400.3	DNAJC3-AS1	3.37	0.000821	0.0458	0.15	0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96071590	chr13:95648733~95676925:-
THCA	cis	rs2075230	0.866	rs1143015	ENSG00000233223.2	AC113189.5	3.37	0.000821	0.0458	0.15	0.15	Hormone measurements;	chr17:7581888	chr17:7581964~7584072:-
THCA	cis	rs11118346	0.64	rs11806200	ENSG00000228536.1	RP11-392O17.1	-3.37	0.000821	0.0458	-0.18	-0.15	Height;	chr1:219578066	chr1:219409681~219411941:-
THCA	cis	rs11118346	0.64	rs6677960	ENSG00000228536.1	RP11-392O17.1	-3.37	0.000821	0.0458	-0.18	-0.15	Height;	chr1:219581640	chr1:219409681~219411941:-
THCA	cis	rs3737883	1	rs2270543	ENSG00000229652.1	RP11-435P24.2	3.37	0.000821	0.0458	0.16	0.15	Early onset atrial fibrillation;	chr1:203061557	chr1:203353365~203353651:-
THCA	cis	rs831571	0.636	rs831565	ENSG00000239926.1	PRDX3P4	3.37	0.000821	0.0458	0.21	0.15	Type 2 diabetes;	chr3:64090682	chr3:64174401~64175147:+
THCA	cis	rs6600671	1	rs4844381	ENSG00000233029.3	RP11-439A17.9	-3.37	0.000821	0.0458	-0.17	-0.15	Hip geometry;	chr1:121443040	chr1:121090289~121097655:-
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000261839.1	RP1-265C24.8	3.37	0.000821	0.0458	0.15	0.15	Pubertal anthropometrics;	chr6:28298372	chr6:28136849~28139678:+
THCA	cis	rs9970334	0.596	rs709209	ENSG00000226944.1	RP1-120G22.11	3.37	0.000821	0.0458	0.18	0.15	Resting heart rate;	chr1:6218354	chr1:6204840~6205780:-
THCA	cis	rs9596863	0.898	rs35646102	ENSG00000136149.6	RPL13AP25	-3.37	0.000821	0.0458	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53790762	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs9563177	ENSG00000136149.6	RPL13AP25	-3.37	0.000821	0.0458	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53794718	chr13:54440704~54441315:-
THCA	cis	rs9596863	0.898	rs9596850	ENSG00000136149.6	RPL13AP25	-3.37	0.000821	0.0458	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53797578	chr13:54440704~54441315:-
THCA	cis	rs7395662	1	rs6485907	ENSG00000200090.1	Y_RNA	-3.37	0.000821	0.0458	-0.1	-0.15	HDL cholesterol;	chr11:48630143	chr11:47726894~47726992:-
THCA	cis	rs2117029	1	rs2117029	ENSG00000239617.1	RP11-302B13.1	-3.37	0.000821	0.0458	-0.18	-0.15	Intelligence (multi-trait analysis);	chr12:49014657	chr12:48903418~48903813:-
THCA	cis	rs11098499	0.566	rs17051356	ENSG00000249244.1	RP11-548H18.2	3.37	0.000821	0.0458	0.18	0.15	Corneal astigmatism;	chr4:119664153	chr4:119391831~119395335:-
THCA	cis	rs9863	0.828	rs11057412	ENSG00000269938.1	RP11-214K3.20	-3.37	0.000821	0.0458	-0.17	-0.15	White blood cell count;	chr12:124004595	chr12:123968023~123968579:-
THCA	cis	rs17123764	0.892	rs1012874	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000821	0.0458	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49753167	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs11830696	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000821	0.0458	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49757473	chr12:49442424~49442652:-
THCA	cis	rs1440410	0.798	rs11724872	ENSG00000250326.1	RP11-284M14.1	-3.37	0.000821	0.0458	-0.14	-0.15	Ischemic stroke;	chr4:143219512	chr4:142933195~143184861:-
THCA	cis	rs12780845	0.931	rs7085460	ENSG00000229124.5	VIM-AS1	3.37	0.000822	0.0458	0.15	0.15	Homocysteine levels;	chr10:17206668	chr10:17214239~17229985:-
THCA	cis	rs12780845	0.931	rs7089849	ENSG00000229124.5	VIM-AS1	3.37	0.000822	0.0458	0.15	0.15	Homocysteine levels;	chr10:17207488	chr10:17214239~17229985:-
THCA	cis	rs12780845	0.931	rs67564104	ENSG00000229124.5	VIM-AS1	3.37	0.000822	0.0458	0.15	0.15	Homocysteine levels;	chr10:17207546	chr10:17214239~17229985:-
THCA	cis	rs12780845	0.931	rs35016603	ENSG00000229124.5	VIM-AS1	3.37	0.000822	0.0458	0.15	0.15	Homocysteine levels;	chr10:17208262	chr10:17214239~17229985:-
THCA	cis	rs12780845	0.931	rs7095223	ENSG00000229124.5	VIM-AS1	3.37	0.000822	0.0458	0.15	0.15	Homocysteine levels;	chr10:17208979	chr10:17214239~17229985:-
THCA	cis	rs12506899	0.903	rs6820167	ENSG00000221639.1	SNORA3	3.37	0.000822	0.0458	0.18	0.15	Tumor biomarkers;	chr4:73275731	chr4:73263960~73264084:+
THCA	cis	rs1065852	0.526	rs9607869	ENSG00000232710.1	RP4-669P10.16	-3.37	0.000822	0.0458	-0.19	-0.15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42022106	chr22:42136433~42139927:-
THCA	cis	rs17419851	1	rs17419851	ENSG00000272402.1	RP1-30M3.6	3.37	0.000822	0.0458	0.21	0.15	Neutrophil count;	chr6:24749185	chr6:24706747~24707151:+
THCA	cis	rs7954584	0.635	rs3847694	ENSG00000274292.1	RP11-347I19.7	-3.37	0.000822	0.0458	-0.11	-0.15	Mean corpuscular volume;	chr12:121887914	chr12:121800797~121803403:+
THCA	cis	rs8170	0.871	rs13345139	ENSG00000268743.1	CTD-2538G9.5	3.37	0.000822	0.0458	0.2	0.15	Breast cancer (estrogen-receptor negative);Breast cancer;Epithelial ovarian cancer;Ovarian cancer;Breast Cancer in BRCA1 mutation carriers;	chr19:17324224	chr19:16844025~16846473:+
THCA	cis	rs6662572	1	rs3014232	ENSG00000234329.1	RP11-767N6.2	-3.37	0.000822	0.0458	-0.17	-0.15	Blood protein levels;	chr1:45666201	chr1:45651039~45651826:-
THCA	cis	rs10946940	0.965	rs6915266	ENSG00000261839.1	RP1-265C24.8	-3.37	0.000822	0.0458	-0.15	-0.15	Systemic lupus erythematosus;	chr6:27560864	chr6:28136849~28139678:+
THCA	cis	rs4948275	0.693	rs1902427	ENSG00000233643.2	RP11-491H19.1	3.37	0.000822	0.0458	0.17	0.15	Night sleep phenotypes;	chr10:61550282	chr10:61781745~61821246:-
THCA	cis	rs6499755	0.734	rs31117	ENSG00000260135.5	RP11-212I21.2	-3.37	0.000822	0.0458	-0.17	-0.15	Hypospadias;	chr16:55346931	chr16:55426797~55462297:-
THCA	cis	rs1538970	1	rs61791368	ENSG00000280836.1	AL355480.1	-3.37	0.000822	0.0458	-0.21	-0.15	Platelet count;	chr1:45402272	chr1:45581219~45581321:-
THCA	cis	rs11887277	0.507	rs6547274	ENSG00000231636.1	AGBL5-AS1	-3.37	0.000822	0.0458	-0.18	-0.15	Obesity-related traits;	chr2:26841481	chr2:27049683~27050264:-
THCA	cis	rs301901	0.698	rs217838	ENSG00000250155.1	CTD-2353F22.1	3.37	0.000822	0.0458	0.16	0.15	Height;	chr5:37376194	chr5:36666214~36725195:-
THCA	cis	rs966423	0.55	rs13002451	ENSG00000233143.1	DIRC3-AS1	-3.37	0.000822	0.0458	-0.16	-0.15	Thyroid cancer;	chr2:217436618	chr2:217282739~217336120:+
THCA	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	3.37	0.000822	0.0458	0.14	0.15	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
THCA	cis	rs3135718	0.967	rs1219648	ENSG00000276742.1	RP11-500G22.4	3.37	0.000822	0.0458	0.18	0.15	Estrogen receptor status in breast cancer;	chr10:121586676	chr10:121956782~121957098:+
THCA	cis	rs2395128	0.765	rs7097121	ENSG00000236842.1	RP11-399K21.10	3.37	0.000822	0.0458	0.26	0.15	Ulcerative colitis;Inflammatory bowel disease;	chr10:74918890	chr10:75430571~75431588:-
THCA	cis	rs12257961	0.578	rs10796284	ENSG00000237032.1	RP11-398C13.2	-3.37	0.000822	0.0458	-0.2	-0.15	Selective IgA deficiency;	chr10:15350277	chr10:14723171~14724055:-
THCA	cis	rs4948275	0.773	rs2787732	ENSG00000233643.2	RP11-491H19.1	-3.37	0.000822	0.0458	-0.17	-0.15	Night sleep phenotypes;	chr10:61487841	chr10:61781745~61821246:-
THCA	cis	rs476633	0.691	rs28735224	ENSG00000247556.5	OIP5-AS1	3.37	0.000822	0.0458	0.12	0.15	Glomerular filtration rate (creatinine);	chr15:41245341	chr15:41283990~41309737:+
THCA	cis	rs72765298	0.848	rs72767003	ENSG00000235332.2	RP11-366O20.5	3.37	0.000822	0.0458	0.28	0.15	Pulse pressure;	chr9:125150878	chr9:125194649~125195821:-
THCA	cis	rs4578769	0.765	rs57308197	ENSG00000265939.1	UBE2CP2	-3.37	0.000822	0.0458	-0.19	-0.15	Eosinophil percentage of white cells;	chr18:22874272	chr18:22900486~22900995:-
THCA	cis	rs11673344	0.542	rs2562585	ENSG00000233527.7	ZNF529-AS1	3.37	0.000822	0.0458	0.13	0.15	Obesity-related traits;	chr19:37018321	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.523	rs8101392	ENSG00000233527.7	ZNF529-AS1	3.37	0.000822	0.0458	0.13	0.15	Obesity-related traits;	chr19:37024416	chr19:36573070~36594708:+
THCA	cis	rs6445967	0.569	rs3773012	ENSG00000273493.1	RP11-80H18.4	-3.37	0.000822	0.0458	-0.2	-0.15	Platelet count;	chr3:58317342	chr3:58329965~58330118:+
THCA	cis	rs6445967	0.569	rs1913714	ENSG00000273493.1	RP11-80H18.4	-3.37	0.000822	0.0458	-0.2	-0.15	Platelet count;	chr3:58322102	chr3:58329965~58330118:+
THCA	cis	rs13217239	0.646	rs6937880	ENSG00000224843.5	LINC00240	-3.37	0.000822	0.0458	-0.13	-0.15	Schizophrenia;	chr6:27032457	chr6:26956992~27023924:+
THCA	cis	rs13217239	0.621	rs12527231	ENSG00000224843.5	LINC00240	-3.37	0.000822	0.0458	-0.13	-0.15	Schizophrenia;	chr6:27033509	chr6:26956992~27023924:+
THCA	cis	rs13217239	0.646	rs12523820	ENSG00000224843.5	LINC00240	-3.37	0.000822	0.0458	-0.13	-0.15	Schizophrenia;	chr6:27033723	chr6:26956992~27023924:+
THCA	cis	rs6472235	0.814	rs6989099	ENSG00000272192.1	CTD-2532N20.1	3.37	0.000822	0.0458	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:65986027	chr8:65842752~65843331:+
THCA	cis	rs6929812	0.665	rs2235254	ENSG00000216915.2	RP1-97D16.1	3.37	0.000822	0.0458	0.2	0.15	Neuroticism (multi-trait analysis);	chr6:27455015	chr6:27737000~27738494:-
THCA	cis	rs10741243	1	rs11017743	ENSG00000230098.1	TCERG1L-AS1	3.37	0.000822	0.0458	0.21	0.15	Type 2 diabetes;	chr10:131140996	chr10:131095218~131095777:+
THCA	cis	rs10741243	0.867	rs12415758	ENSG00000230098.1	TCERG1L-AS1	3.37	0.000822	0.0458	0.21	0.15	Type 2 diabetes;	chr10:131141044	chr10:131095218~131095777:+
THCA	cis	rs271738	0.674	rs192417	ENSG00000231768.1	LINC01354	-3.37	0.000823	0.0458	-0.17	-0.15	Bipolar disorder;	chr1:234542145	chr1:234527891~234531779:-
THCA	cis	rs2635047	0.935	rs2635050	ENSG00000280212.1	RP11-49K24.3	-3.37	0.000823	0.0458	-0.15	-0.15	Educational attainment;	chr18:47137760	chr18:47076117~47076594:+
THCA	cis	rs2635047	0.967	rs2684820	ENSG00000280212.1	RP11-49K24.3	-3.37	0.000823	0.0458	-0.15	-0.15	Educational attainment;	chr18:47137933	chr18:47076117~47076594:+
THCA	cis	rs11992162	0.597	rs6996342	ENSG00000255046.1	RP11-297N6.4	3.37	0.000823	0.0458	0.16	0.15	Monocyte count;	chr8:11927032	chr8:11797928~11802568:-
THCA	cis	rs9916302	0.706	rs667239	ENSG00000266469.1	CTB-131K11.1	3.37	0.000823	0.0458	0.15	0.15	Glomerular filtration rate (creatinine);	chr17:39285988	chr17:39401793~39406233:+
THCA	cis	rs2562456	0.834	rs13346641	ENSG00000213976.4	CTD-2561J22.2	-3.37	0.000823	0.0458	-0.19	-0.15	Pain;	chr19:21409481	chr19:21382865~21387177:+
THCA	cis	rs4262150	0.739	rs72795394	ENSG00000253921.1	CTB-113P19.3	3.37	0.000823	0.0458	0.2	0.15	Bipolar disorder and schizophrenia;	chr5:152569029	chr5:151753992~151767247:+
THCA	cis	rs3750082	0.852	rs6462425	ENSG00000205763.12	RP9P	3.37	0.000823	0.0458	0.13	0.15	Glomerular filtration rate (creatinine);	chr7:32858983	chr7:32916815~32943176:-
THCA	cis	rs7711186	0.655	rs75315590	ENSG00000252464.1	RN7SKP70	3.37	0.000823	0.0458	0.2	0.15	Urate levels in obese individuals;	chr5:178593817	chr5:178619728~178619998:-
THCA	cis	rs9596863	1	rs9596866	ENSG00000136149.6	RPL13AP25	-3.37	0.000823	0.0458	-0.18	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53885250	chr13:54440704~54441315:-
THCA	cis	rs12440869	0.919	rs2028762	ENSG00000270964.1	RP11-502I4.3	3.37	0.000823	0.0458	0.14	0.15	Peak velocity of the mitral A-wave;	chr15:67189665	chr15:67541072~67542604:-
THCA	cis	rs2933343	0.621	rs4927921	ENSG00000231305.3	RP11-723O4.2	-3.37	0.000823	0.0458	-0.17	-0.15	IgG glycosylation;	chr3:128850025	chr3:128861313~128871540:-
THCA	cis	rs73195822	0.614	rs73194057	ENSG00000249094.2	RP1-7G5.6	3.37	0.000823	0.0458	0.25	0.15	Itch intensity from mosquito bite;	chr12:110779108	chr12:109880676~109888467:+
THCA	cis	rs61160187	0.582	rs62372134	ENSG00000251279.1	CTC-436P18.1	-3.37	0.000823	0.0458	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:61162070~61232040:+
THCA	cis	rs9369640	0.7	rs71562459	ENSG00000212802.4	RPL15P3	3.37	0.000823	0.0458	0.15	0.15	Coronary artery disease;	chr6:12888370	chr6:12514110~12514724:+
THCA	cis	rs7737355	0.773	rs3776006	ENSG00000237714.1	P4HA2-AS1	3.37	0.000823	0.0458	0.21	0.15	Life satisfaction;	chr5:131539845	chr5:132184876~132192808:+
THCA	cis	rs9916302	0.706	rs7212621	ENSG00000266469.1	CTB-131K11.1	3.37	0.000823	0.0458	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39371658	chr17:39401793~39406233:+
THCA	cis	rs11673344	0.864	rs79407399	ENSG00000267309.1	CTD-2630F21.1	-3.37	0.000823	0.0458	-0.16	-0.15	Obesity-related traits;	chr19:37000004	chr19:36489649~36491040:+
THCA	cis	rs2290416	0.579	rs58573550	ENSG00000254973.1	RP11-429J17.7	3.37	0.000823	0.0459	0.3	0.15	Attention deficit hyperactivity disorder;	chr8:143599544	chr8:143758153~143771822:-
THCA	cis	rs9900062	1	rs11871616	ENSG00000214176.8	PLEKHM1P	3.37	0.000823	0.0459	0.13	0.15	QT interval;	chr17:64741484	chr17:64779259~64837154:-
THCA	cis	rs11139399	0.651	rs2086830	ENSG00000233926.1	RP11-154D17.1	-3.37	0.000823	0.0459	-0.19	-0.15	Hippocampal atrophy;	chr9:81730173	chr9:81689713~81776900:+
THCA	cis	rs11139399	0.626	rs2086831	ENSG00000233926.1	RP11-154D17.1	-3.37	0.000823	0.0459	-0.19	-0.15	Hippocampal atrophy;	chr9:81730211	chr9:81689713~81776900:+
THCA	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	3.37	0.000823	0.0459	0.18	0.15	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	3.37	0.000823	0.0459	0.18	0.15	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
THCA	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	3.37	0.000823	0.0459	0.18	0.15	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
THCA	cis	rs757978	0.81	rs1468445	ENSG00000235351.1	AC114730.11	-3.37	0.000823	0.0459	-0.14	-0.15	Chronic lymphocytic leukemia;	chr2:241456139	chr2:241724615~241725693:-
THCA	cis	rs7824557	0.564	rs2572400	ENSG00000255046.1	RP11-297N6.4	3.37	0.000823	0.0459	0.16	0.15	Retinal vascular caliber;	chr8:11376858	chr8:11797928~11802568:-
THCA	cis	rs9649465	0.561	rs609953	ENSG00000272686.1	RP11-390E23.6	-3.37	0.000823	0.0459	-0.1	-0.15	Migraine;	chr7:123782390	chr7:123749068~123751166:+
THCA	cis	rs4253772	0.786	rs4253765	ENSG00000273145.1	CITF22-92A6.1	3.37	0.000823	0.0459	0.19	0.15	Cholesterol, total;LDL cholesterol;	chr22:46226991	chr22:46013606~46015498:+
THCA	cis	rs2562456	0.833	rs62110428	ENSG00000213976.4	CTD-2561J22.2	-3.37	0.000823	0.0459	-0.19	-0.15	Pain;	chr19:21430854	chr19:21382865~21387177:+
THCA	cis	rs5015933	0.734	rs4838261	ENSG00000232630.1	PRPS1P2	-3.37	0.000823	0.0459	-0.1	-0.15	Body mass index;	chr9:125386970	chr9:125150653~125151589:+
THCA	cis	rs71478720	0.903	rs80011693	ENSG00000214264.4	KCTD9P4	3.37	0.000823	0.0459	0.2	0.15	Interleukin-18 levels;	chr11:112134760	chr11:112180773~112183191:+
THCA	cis	rs3087591	0.592	rs2342054	ENSG00000263535.1	AK4P1	3.37	0.000823	0.0459	0.18	0.15	Hip circumference;	chr17:31397690	chr17:31345521~31346187:+
THCA	cis	rs4948275	0.693	rs2814027	ENSG00000233643.2	RP11-491H19.1	-3.37	0.000823	0.0459	-0.17	-0.15	Night sleep phenotypes;	chr10:61582354	chr10:61781745~61821246:-
THCA	cis	rs17428076	0.749	rs788161	ENSG00000228389.1	AC068039.4	-3.37	0.000823	0.0459	-0.19	-0.15	Myopia;	chr2:172061943	chr2:171773482~171775844:+
THCA	cis	rs11800820	0.595	rs7537146	ENSG00000231612.1	RP11-522M21.3	-3.37	0.000823	0.0459	-0.21	-0.15	Obesity-related traits;	chr1:246550848	chr1:245673732~245676478:-
THCA	cis	rs4692589	0.531	rs12650424	ENSG00000229204.3	PTGES3P3	-3.37	0.000823	0.0459	-0.2	-0.15	Anxiety disorder;	chr4:170054053	chr4:169791221~169791702:-
THCA	cis	rs479105	0.567	rs1978239	ENSG00000278356.1	RP11-372B4.3	3.37	0.000823	0.0459	0.15	0.15	Gut microbiota (bacterial taxa);	chr12:3270540	chr12:2885819~2886329:+
THCA	cis	rs11064837	0.55	rs11064849	ENSG00000248636.5	RP11-768F21.1	3.37	0.000824	0.0459	0.18	0.15	Schizophrenia;	chr12:119616782	chr12:119387987~119668079:-
THCA	cis	rs7246657	1	rs7247672	ENSG00000266916.4	ZNF793-AS1	-3.37	0.000824	0.0459	-0.15	-0.15	Coronary artery calcification;	chr19:37253026	chr19:37497159~37507046:-
THCA	cis	rs7246657	1	rs8110011	ENSG00000266916.4	ZNF793-AS1	-3.37	0.000824	0.0459	-0.15	-0.15	Coronary artery calcification;	chr19:37254911	chr19:37497159~37507046:-
THCA	cis	rs13046373	0.507	rs2832969	ENSG00000174680.8	GRIK1-AS1	-3.37	0.000824	0.0459	-0.18	-0.15	HDL cholesterol;	chr21:30647308	chr21:29748175~29764002:+
THCA	cis	rs3748022	1	rs3748022	ENSG00000261000.1	RP11-534L20.5	-3.37	0.000824	0.0459	-0.22	-0.15	Lymphocyte counts;	chr1:206496132	chr1:206503948~206504456:+
THCA	cis	rs6088813	0.961	rs6060371	ENSG00000261582.1	RP4-614O4.11	-3.37	0.000824	0.0459	-0.15	-0.15	Height;	chr20:35325519	chr20:35267885~35280043:-
THCA	cis	rs6088813	0.883	rs2425061	ENSG00000261582.1	RP4-614O4.11	-3.37	0.000824	0.0459	-0.15	-0.15	Height;	chr20:35327768	chr20:35267885~35280043:-
THCA	cis	rs12022452	1	rs12048678	ENSG00000272145.1	NFYC-AS1	3.37	0.000824	0.0459	0.13	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40690380~40692066:-
THCA	cis	rs6427356	1	rs1176543	ENSG00000237189.1	RP11-85G21.2	3.37	0.000824	0.0459	0.17	0.15	Attention deficit hyperactivity disorder and conduct disorder;	chr1:157163804	chr1:157287703~157288053:-
THCA	cis	rs12621844	0.7	rs2348718	ENSG00000234690.5	AC073283.4	-3.37	0.000824	0.0459	-0.15	-0.15	Glycated hemoglobin levels;	chr2:48141461	chr2:47192405~47345074:-
THCA	cis	rs9488822	0.636	rs1544155	ENSG00000233558.1	RP3-486I3.4	3.37	0.000824	0.0459	0.17	0.15	LDL cholesterol;Cholesterol, total;	chr6:116025231	chr6:116258493~116259115:-
THCA	cis	rs7020830	0.505	rs12553878	ENSG00000260100.1	RP11-220I1.5	-3.37	0.000824	0.0459	-0.17	-0.15	Schizophrenia;	chr9:37095708	chr9:37078813~37079776:-
THCA	cis	rs11658311	1	rs28583584	ENSG00000232344.2	AC087163.2	3.37	0.000824	0.0459	0.23	0.15	Obsessive-compulsive symptoms;	chr17:17579983	chr17:18010643~18011822:+
THCA	cis	rs6940638	0.688	rs2022272	ENSG00000224843.5	LINC00240	3.37	0.000824	0.0459	0.14	0.15	Intelligence (multi-trait analysis);	chr6:27135801	chr6:26956992~27023924:+
THCA	cis	rs6580649	1	rs9805048	ENSG00000273765.1	RP11-370I10.11	3.37	0.000824	0.0459	0.17	0.15	Lung cancer;	chr12:48009909	chr12:48360920~48361377:+
THCA	cis	rs7226408	0.6	rs8087932	ENSG00000267707.2	RP11-95O2.5	-3.37	0.000824	0.0459	-0.15	-0.15	Obesity-related traits;	chr18:36845028	chr18:37243776~37247506:+
THCA	cis	rs1552244	0.882	rs17050699	ENSG00000269982.1	RP11-1020A11.2	3.37	0.000824	0.0459	0.12	0.15	Alzheimer's disease;	chr3:9995483	chr3:9958717~9962539:+
THCA	cis	rs7709377	0.723	rs10071141	ENSG00000250015.1	CTC-339F2.2	3.37	0.000824	0.0459	0.16	0.15	Metabolite levels  (X-11787);	chr5:116193923	chr5:116302354~116304134:-
THCA	cis	rs324126	0.78	rs11084153	ENSG00000243680.1	RPL37P23	-3.37	0.000824	0.0459	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs11084154	ENSG00000243680.1	RPL37P23	-3.37	0.000824	0.0459	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs11084155	ENSG00000243680.1	RPL37P23	-3.37	0.000824	0.0459	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52143043~52143336:+
THCA	cis	rs324126	0.752	rs11084156	ENSG00000243680.1	RPL37P23	-3.37	0.000824	0.0459	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs11084157	ENSG00000243680.1	RPL37P23	-3.37	0.000824	0.0459	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs8104808	ENSG00000243680.1	RPL37P23	-3.37	0.000824	0.0459	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs8104812	ENSG00000243680.1	RPL37P23	-3.37	0.000824	0.0459	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52143043~52143336:+
THCA	cis	rs524281	0.861	rs485857	ENSG00000255038.1	RP11-1167A19.2	-3.37	0.000824	0.0459	-0.17	-0.15	Electroencephalogram traits;	chr11:66192048	chr11:66067277~66069619:-
THCA	cis	rs9875589	0.957	rs6778297	ENSG00000233121.1	VN1R20P	3.37	0.000824	0.0459	0.18	0.15	Ovarian reserve;	chr3:13890646	chr3:13926813~13927778:+
THCA	cis	rs11785400	1	rs11785400	ENSG00000177335.9	C8orf31	3.37	0.000824	0.0459	0.17	0.15	Schizophrenia;	chr8:142649072	chr8:143039209~143059942:+
THCA	cis	rs7709377	0.723	rs2174996	ENSG00000250015.1	CTC-339F2.2	3.37	0.000824	0.0459	0.16	0.15	Metabolite levels  (X-11787);	chr5:116155111	chr5:116302354~116304134:-
THCA	cis	rs7772486	0.875	rs1412081	ENSG00000270638.1	RP3-466P17.1	3.37	0.000824	0.0459	0.12	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145735570~145737218:+
THCA	cis	rs7772486	0.875	rs10457792	ENSG00000270638.1	RP3-466P17.1	3.37	0.000824	0.0459	0.12	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145735570~145737218:+
THCA	cis	rs193541	0.626	rs4343835	ENSG00000260686.1	CTB-36H16.2	3.37	0.000824	0.0459	0.14	0.15	Glucose homeostasis traits;	chr5:122753036	chr5:122832356~122834533:+
THCA	cis	rs748404	0.66	rs693510	ENSG00000275601.1	AC011330.13	-3.37	0.000825	0.0459	-0.18	-0.15	Lung cancer;	chr15:43422427	chr15:43642389~43643023:-
THCA	cis	rs748404	0.66	rs690512	ENSG00000275601.1	AC011330.13	-3.37	0.000825	0.0459	-0.18	-0.15	Lung cancer;	chr15:43425480	chr15:43642389~43643023:-
THCA	cis	rs748404	0.66	rs542898	ENSG00000275601.1	AC011330.13	-3.37	0.000825	0.0459	-0.18	-0.15	Lung cancer;	chr15:43427194	chr15:43642389~43643023:-
THCA	cis	rs748404	0.66	rs2249952	ENSG00000275601.1	AC011330.13	-3.37	0.000825	0.0459	-0.18	-0.15	Lung cancer;	chr15:43428335	chr15:43642389~43643023:-
THCA	cis	rs748404	0.66	rs689767	ENSG00000275601.1	AC011330.13	-3.37	0.000825	0.0459	-0.18	-0.15	Lung cancer;	chr15:43429879	chr15:43642389~43643023:-
THCA	cis	rs748404	0.66	rs2439845	ENSG00000275601.1	AC011330.13	-3.37	0.000825	0.0459	-0.18	-0.15	Lung cancer;	chr15:43430412	chr15:43642389~43643023:-
THCA	cis	rs748404	0.631	rs2467745	ENSG00000275601.1	AC011330.13	-3.37	0.000825	0.0459	-0.18	-0.15	Lung cancer;	chr15:43430544	chr15:43642389~43643023:-
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000223473.2	GS1-124K5.3	3.37	0.000825	0.0459	0.11	0.15	Calcium levels;	chr7:65977808	chr7:66491049~66493566:-
THCA	cis	rs71277158	0.688	rs6781454	ENSG00000242578.1	RP11-469J4.3	3.37	0.000825	0.0459	0.24	0.15	Prostate cancer;	chr3:170105308	chr3:170410512~170418615:+
THCA	cis	rs71277158	0.688	rs58417766	ENSG00000242578.1	RP11-469J4.3	3.37	0.000825	0.0459	0.24	0.15	Prostate cancer;	chr3:170115459	chr3:170410512~170418615:+
THCA	cis	rs71277158	0.688	rs7638400	ENSG00000242578.1	RP11-469J4.3	3.37	0.000825	0.0459	0.24	0.15	Prostate cancer;	chr3:170119999	chr3:170410512~170418615:+
THCA	cis	rs71277158	0.688	rs6808506	ENSG00000242578.1	RP11-469J4.3	3.37	0.000825	0.0459	0.24	0.15	Prostate cancer;	chr3:170121451	chr3:170410512~170418615:+
THCA	cis	rs71277158	0.688	rs73879173	ENSG00000242578.1	RP11-469J4.3	3.37	0.000825	0.0459	0.24	0.15	Prostate cancer;	chr3:170127816	chr3:170410512~170418615:+
THCA	cis	rs4671400	0.571	rs4672429	ENSG00000270820.4	RP11-355B11.2	-3.37	0.000825	0.0459	-0.15	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61268334	chr2:61471188~61484130:+
THCA	cis	rs2692947	0.537	rs11682182	ENSG00000168992.4	OR7E102P	3.37	0.000825	0.0459	0.19	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712462	chr2:95546531~95547545:+
THCA	cis	rs9437689	0.69	rs7547662	ENSG00000235501.4	RP4-639F20.1	-3.37	0.000825	0.0459	-0.18	-0.15	Phospholipid levels (plasma);	chr1:94991680	chr1:94927566~94963270:+
THCA	cis	rs4715166	0.859	rs10948546	ENSG00000272379.1	RP1-257A7.5	3.37	0.000825	0.0459	0.19	0.15	Hip geometry;	chr6:13223132	chr6:13290018~13290490:-
THCA	cis	rs925946	1	rs1401635	ENSG00000245573.6	BDNF-AS	3.37	0.000825	0.0459	0.14	0.15	Weight;Body mass index;	chr11:27672444	chr11:27506838~27698174:+
THCA	cis	rs7246967	1	rs936526	ENSG00000269364.1	LINC01233	-3.37	0.000825	0.0459	-0.22	-0.15	Bronchopulmonary dysplasia;	chr19:22873185	chr19:22532626~22533494:+
THCA	cis	rs7246967	1	rs7246967	ENSG00000269364.1	LINC01233	-3.37	0.000825	0.0459	-0.22	-0.15	Bronchopulmonary dysplasia;	chr19:22873544	chr19:22532626~22533494:+
THCA	cis	rs972578	1	rs1569510	ENSG00000230319.1	AL022476.2	-3.37	0.000825	0.0459	-0.16	-0.15	Mean platelet volume;	chr22:42963442	chr22:43038585~43052366:+
THCA	cis	rs3789045	0.688	rs6668637	ENSG00000235363.1	SNRPGP10	-3.37	0.000825	0.0459	-0.23	-0.15	Educational attainment (college completion);	chr1:204483167	chr1:205351247~205351471:+
THCA	cis	rs9399599	0.771	rs617975	ENSG00000233452.5	STXBP5-AS1	-3.37	0.000825	0.0459	-0.16	-0.15	Plasma plasminogen activator levels;	chr6:147257563	chr6:146841901~147204614:-
THCA	cis	rs66887589	0.967	rs2892869	ENSG00000249244.1	RP11-548H18.2	-3.37	0.000825	0.0459	-0.16	-0.15	Diastolic blood pressure;	chr4:119600142	chr4:119391831~119395335:-
THCA	cis	rs11031096	0.542	rs10835337	ENSG00000230593.3	AC090804.1	-3.37	0.000825	0.0459	-0.19	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:3937598	chr11:3892398~3892887:-
THCA	cis	rs2638953	0.815	rs10843186	ENSG00000278733.1	RP11-425D17.1	-3.37	0.000825	0.0459	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482921	chr12:28185625~28186190:-
THCA	cis	rs2638953	0.815	rs1511551	ENSG00000278733.1	RP11-425D17.1	-3.37	0.000825	0.0459	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483897	chr12:28185625~28186190:-
THCA	cis	rs12307997	0.558	rs11055274	ENSG00000256552.2	RP11-113C12.4	-3.37	0.000825	0.0459	-0.3	-0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:7698560	chr12:8320381~8369555:+
THCA	cis	rs17045328	0.744	rs1257575	ENSG00000274245.1	RP11-357P18.2	-3.37	0.000825	0.0459	-0.3	-0.15	Type 2 diabetes;	chr1:207410601	chr1:207372559~207373252:+
THCA	cis	rs2656056	1	rs2656056	ENSG00000261143.1	ADAMTS7P3	3.37	0.000825	0.0459	0.23	0.15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78430177	chr15:77976042~77993057:+
THCA	cis	rs13401620	0.797	rs1046433	ENSG00000236878.1	AC012363.7	-3.37	0.000825	0.0459	-0.18	-0.15	Breast size;	chr2:119980249	chr2:120211054~120211715:+
THCA	cis	rs7267979	0.903	rs6050482	ENSG00000230772.1	VN1R108P	3.37	0.000825	0.0459	0.14	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25734264~25735093:+
THCA	cis	rs7267979	0.706	rs6037069	ENSG00000230772.1	VN1R108P	3.37	0.000825	0.0459	0.14	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25734264~25735093:+
THCA	cis	rs1520333	1	rs10086475	ENSG00000254352.1	RP11-578O24.2	3.37	0.000825	0.046	0.15	0.15	Multiple sclerosis;	chr8:78497114	chr8:78723796~78724136:-
THCA	cis	rs6840360	0.967	rs7695162	ENSG00000251611.1	RP11-610P16.1	-3.37	0.000825	0.046	-0.11	-0.15	Intelligence (multi-trait analysis);	chr4:151589389	chr4:151407551~151408835:-
THCA	cis	rs17123764	0.892	rs11169126	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000825	0.046	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49721831	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs56906356	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000825	0.046	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49724594	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs12313353	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000825	0.046	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49744883	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs12313354	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000825	0.046	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49744884	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs12307828	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000825	0.046	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49745277	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs7968302	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000825	0.046	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49746402	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs7953412	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000825	0.046	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49746483	chr12:49442424~49442652:-
THCA	cis	rs17123764	0.892	rs9805063	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000825	0.046	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49747381	chr12:49442424~49442652:-
THCA	cis	rs7778833	1	rs10249588	ENSG00000229688.6	ISPD-AS1	3.37	0.000825	0.046	0.31	0.15	Childhood ear infection;	chr7:15735470	chr7:16210488~16270604:+
THCA	cis	rs7950726	1	rs35662174	ENSG00000167355.6	AC104389.28	3.37	0.000825	0.046	0.33	0.15	HbA2 levels;	chr11:5203127	chr11:5304976~5505652:-
THCA	cis	rs8187707	0.881	rs72838141	ENSG00000233690.1	EBAG9P1	-3.37	0.000826	0.046	-0.31	-0.15	Carboplatin disposition in epthelial ovarian cancer;	chr10:99848492	chr10:99697407~99697949:-
THCA	cis	rs758324	0.617	rs77938	ENSG00000237714.1	P4HA2-AS1	3.37	0.000826	0.046	0.22	0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131986801	chr5:132184876~132192808:+
THCA	cis	rs13401620	0.827	rs13419800	ENSG00000231013.1	AC013275.2	-3.37	0.000826	0.046	-0.18	-0.15	Breast size;	chr2:119737814	chr2:119476448~119487346:+
THCA	cis	rs9929218	0.529	rs8059194	ENSG00000260459.2	FTLP14	3.37	0.000826	0.046	0.17	0.15	Colorectal cancer;	chr16:68715760	chr16:68822587~68823070:+
THCA	cis	rs910316	0.967	rs175479	ENSG00000259138.1	RP11-950C14.7	-3.37	0.000826	0.046	-0.13	-0.15	Height;	chr14:75095168	chr14:75127153~75136930:+
THCA	cis	rs9341808	0.718	rs2322630	ENSG00000260645.1	RP11-250B2.5	3.37	0.000826	0.046	0.13	0.15	Sitting height ratio;	chr6:80131316	chr6:80466958~80469080:+
THCA	cis	rs6743226	0.59	rs6733962	ENSG00000223374.1	AC005104.3	3.37	0.000826	0.046	0.11	0.15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241280254	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.566	rs59065053	ENSG00000223374.1	AC005104.3	3.37	0.000826	0.046	0.11	0.15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241281151	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.566	rs34006413	ENSG00000223374.1	AC005104.3	3.37	0.000826	0.046	0.11	0.15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241282044	chr2:241351340~241353104:-
THCA	cis	rs6743226	0.566	rs6724257	ENSG00000223374.1	AC005104.3	3.37	0.000826	0.046	0.11	0.15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241282982	chr2:241351340~241353104:-
THCA	cis	rs11960179	0.892	rs7704214	ENSG00000250066.1	RP11-141O11.1	-3.37	0.000826	0.046	-0.26	-0.15	Glomerular filtration rate (creatinine);	chr5:68508264	chr5:68963246~68967845:+
THCA	cis	rs897984	0.644	rs73524556	ENSG00000260911.2	RP11-196G11.2	3.37	0.000826	0.046	0.13	0.15	Dementia with Lewy bodies;	chr16:30811841	chr16:31043150~31049868:+
THCA	cis	rs561341	1	rs8069199	ENSG00000265798.5	RP11-271K11.5	3.37	0.000826	0.046	0.23	0.15	Hip circumference adjusted for BMI;	chr17:31954826	chr17:31038575~31059121:-
THCA	cis	rs6693017	1	rs17008835	ENSG00000238078.1	LINC01352	3.37	0.000826	0.046	0.23	0.15	Monocyte early outgrowth colony forming units;	chr1:220806087	chr1:220829255~220832429:+
THCA	cis	rs931127	0.658	rs4244812	ENSG00000255557.1	RP11-770G2.2	3.37	0.000826	0.046	0.17	0.15	Systemic lupus erythematosus;	chr11:65713297	chr11:65745729~65771585:+
THCA	cis	rs7819412	0.608	rs28417109	ENSG00000255046.1	RP11-297N6.4	3.37	0.000826	0.046	0.17	0.15	Triglycerides;	chr8:11117571	chr8:11797928~11802568:-
THCA	cis	rs10090774	0.965	rs11781807	ENSG00000280303.2	ERICD	-3.37	0.000826	0.046	-0.14	-0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140984294	chr8:140636281~140638283:+
THCA	cis	rs6545883	0.894	rs10177303	ENSG00000212978.6	AC016747.3	-3.37	0.000826	0.046	-0.17	-0.15	Tuberculosis;	chr2:61367324	chr2:61141592~61144969:-
THCA	cis	rs6545883	0.894	rs2694639	ENSG00000212978.6	AC016747.3	-3.37	0.000826	0.046	-0.17	-0.15	Tuberculosis;	chr2:61368156	chr2:61141592~61144969:-
THCA	cis	rs4930561	0.714	rs10896300	ENSG00000184795.9	UNC93B5	3.37	0.000826	0.046	0.19	0.15	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68186305	chr11:67711702~67716005:-
THCA	cis	rs793571	0.822	rs592407	ENSG00000245975.2	RP11-30K9.6	3.37	0.000826	0.046	0.17	0.15	Schizophrenia;	chr15:58865341	chr15:58768072~58770974:-
THCA	cis	rs763121	0.853	rs5757196	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38643850	chr22:38742625~38743115:+
THCA	cis	rs763121	0.785	rs5757199	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38644612	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs9610993	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38646813	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs5757200	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38647486	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs5757203	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38648147	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs2205802	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38650322	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs5757204	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38650695	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs8138996	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38651430	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs6001182	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38651438	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs5757208	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38653225	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs5757211	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38655700	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs6001184	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38656111	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs6001185	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38656150	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs2294296	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38657044	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs2064088	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38657377	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs5757213	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38657883	chr22:38742625~38743115:+
THCA	cis	rs4281086	0.599	rs4591994	ENSG00000272505.1	RP11-981G7.6	-3.37	0.000826	0.046	-0.13	-0.15	Obesity-related traits;	chr8:10534323	chr8:10486807~10489666:+
THCA	cis	rs3736986	1	rs7041383	ENSG00000215283.3	HMGB3P24	3.37	0.000826	0.046	0.29	0.15	Bipolar disorder (inflammation and infection response interaction);	chr9:36204915	chr9:36303499~36304924:-
THCA	cis	rs8081187	0.803	rs9889918	ENSG00000263531.1	RP13-753N3.1	-3.37	0.000826	0.046	-0.43	-0.15	Breast cancer;	chr17:30379979	chr17:30863921~30864940:-
THCA	cis	rs11887277	0.507	rs6547275	ENSG00000231636.1	AGBL5-AS1	-3.37	0.000826	0.046	-0.18	-0.15	Obesity-related traits;	chr2:26841709	chr2:27049683~27050264:-
THCA	cis	rs2635047	1	rs2277717	ENSG00000280212.1	RP11-49K24.3	-3.37	0.000826	0.046	-0.15	-0.15	Educational attainment;	chr18:47176347	chr18:47076117~47076594:+
THCA	cis	rs35306767	0.761	rs11253540	ENSG00000229869.1	RP11-363N22.2	3.37	0.000826	0.046	0.25	0.15	Eosinophil percentage of granulocytes;	chr10:966018	chr10:933026~942743:+
THCA	cis	rs2163813	1	rs12986120	ENSG00000271283.1	CTC-412M14.6	-3.37	0.000826	0.046	-0.21	-0.15	Toenail selenium levels;	chr19:19709330	chr19:19699203~19699409:-
THCA	cis	rs2839186	0.934	rs4819221	ENSG00000228137.1	AP001469.7	-3.37	0.000826	0.046	-0.15	-0.15	Testicular germ cell tumor;	chr21:46275503	chr21:46246890~46247682:+
THCA	cis	rs56283067	0.847	rs10456536	ENSG00000237686.5	RP5-1120P11.1	-3.37	0.000826	0.046	-0.14	-0.15	Total body bone mineral density;	chr6:44725258	chr6:43995723~44074652:-
THCA	cis	rs56283067	0.847	rs60328783	ENSG00000237686.5	RP5-1120P11.1	-3.37	0.000826	0.046	-0.14	-0.15	Total body bone mineral density;	chr6:44725362	chr6:43995723~44074652:-
THCA	cis	rs1005277	0.522	rs1208767	ENSG00000273019.1	RP11-508N22.13	-3.37	0.000826	0.046	-0.17	-0.15	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38149968~38150293:+
THCA	cis	rs763121	0.853	rs3747172	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38671519	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs5750659	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38672784	chr22:38742625~38743115:+
THCA	cis	rs763121	0.819	rs3747173	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38673040	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs3747174	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38673176	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs1065201	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38673505	chr22:38742625~38743115:+
THCA	cis	rs763121	0.853	rs5757226	ENSG00000272669.1	RP3-508I15.21	-3.37	0.000826	0.046	-0.11	-0.15	Menopause (age at onset);	chr22:38674545	chr22:38742625~38743115:+
THCA	cis	rs7686660	1	rs13139088	ENSG00000250326.1	RP11-284M14.1	3.37	0.000826	0.046	0.15	0.15	Asthma;	chr4:143054143	chr4:142933195~143184861:-
THCA	cis	rs7686660	0.956	rs11736977	ENSG00000250326.1	RP11-284M14.1	3.37	0.000826	0.046	0.15	0.15	Asthma;	chr4:143054972	chr4:142933195~143184861:-
THCA	cis	rs73019876	0.869	rs2079062	ENSG00000269615.1	AC003973.1	3.37	0.000826	0.046	0.15	0.15	Testicular germ cell tumor;	chr19:21942410	chr19:21940820~21941533:+
THCA	cis	rs73019876	0.869	rs2522094	ENSG00000269615.1	AC003973.1	3.37	0.000826	0.046	0.15	0.15	Testicular germ cell tumor;	chr19:21942767	chr19:21940820~21941533:+
THCA	cis	rs59482735	1	rs59482735	ENSG00000270917.1	RP11-27I1.6	-3.37	0.000827	0.046	-0.22	-0.15	Prostate-specific antigen levels;	chr9:120881148	chr9:120812475~120812845:-
THCA	cis	rs853679	0.723	rs9366718	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000827	0.046	-0.18	-0.15	Depression;	chr6:28237724	chr6:28078792~28081130:-
THCA	cis	rs11658311	1	rs8074742	ENSG00000226478.3	UPF3AP1	-3.37	0.000827	0.046	-0.39	-0.15	Obsessive-compulsive symptoms;	chr17:17551882	chr17:16745636~16746761:-
THCA	cis	rs11658311	1	rs9897362	ENSG00000226478.3	UPF3AP1	-3.37	0.000827	0.046	-0.39	-0.15	Obsessive-compulsive symptoms;	chr17:17553432	chr17:16745636~16746761:-
THCA	cis	rs683250	0.568	rs671991	ENSG00000254551.1	RP11-727A23.7	3.37	0.000827	0.046	0.19	0.15	Subcortical brain region volumes;	chr11:83295577	chr11:83209431~83213379:-
THCA	cis	rs6801044	0.741	rs2641358	ENSG00000223711.1	AC091633.3	3.37	0.000827	0.046	0.21	0.15	Creatinine levels in ischemic stroke;	chr3:195528068	chr3:195544048~195550581:+
THCA	cis	rs3126085	0.935	rs11204952	ENSG00000237975.5	FLG-AS1	-3.37	0.000827	0.046	-0.24	-0.15	Atopic dermatitis;	chr1:152254845	chr1:152168125~152445456:+
THCA	cis	rs72634258	0.554	rs12092614	ENSG00000224315.2	RPL7P7	-3.37	0.000827	0.046	-0.28	-0.15	Inflammatory bowel disease;	chr1:7805650	chr1:8786211~8786913:-
THCA	cis	rs7173964	1	rs10083587	ENSG00000259251.2	RP11-643M14.1	3.37	0.000827	0.046	0.15	0.15	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62106334	chr15:62060503~62062434:+
THCA	cis	rs2908835	0.576	rs7978928	ENSG00000247157.5	LINC01252	3.37	0.000827	0.046	0.19	0.15	Information processing speed;	chr12:11437697	chr12:11548030~11590369:+
THCA	cis	rs6600671	0.934	rs7528274	ENSG00000233029.3	RP11-439A17.9	-3.37	0.000827	0.046	-0.17	-0.15	Hip geometry;	chr1:121545103	chr1:121090289~121097655:-
THCA	cis	rs9329221	0.638	rs7460436	ENSG00000253641.4	RP11-981G7.2	3.37	0.000827	0.046	0.15	0.15	Neuroticism;	chr8:10396812	chr8:10474565~10481974:+
THCA	cis	rs3853824	0.717	rs4794673	ENSG00000263089.1	RP11-166P13.4	3.37	0.000827	0.046	0.15	0.15	Inflammatory bowel disease;Crohn's disease;	chr17:56870627	chr17:57092145~57096425:-
THCA	cis	rs7283707	0.581	rs2823460	ENSG00000231201.1	AF127577.11	3.37	0.000827	0.046	0.27	0.15	QRS complex (12-leadsum);	chr21:15714437	chr21:14971470~14992854:+
THCA	cis	rs324126	0.78	rs62108319	ENSG00000243680.1	RPL37P23	-3.37	0.000827	0.046	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52143043~52143336:+
THCA	cis	rs7960483	0.929	rs10880811	ENSG00000273015.2	RP11-352M15.2	-3.37	0.000827	0.046	-0.09	-0.15	Hypertension (SNP x SNP interaction);	chr12:45533763	chr12:45718046~45727775:-
THCA	cis	rs6921919	0.638	rs9468344	ENSG00000176933.5	TOB2P1	-3.37	0.000827	0.046	-0.18	-0.15	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28217643~28218634:-
THCA	cis	rs4566357	0.557	rs2272201	ENSG00000212391.1	SNORA48	-3.37	0.000827	0.046	-0.17	-0.15	Coronary artery disease;	chr2:227047835	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.615	rs12474622	ENSG00000212391.1	SNORA48	-3.37	0.000827	0.046	-0.17	-0.15	Coronary artery disease;	chr2:227048077	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.615	rs10174591	ENSG00000212391.1	SNORA48	-3.37	0.000827	0.046	-0.17	-0.15	Coronary artery disease;	chr2:227048424	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.576	rs10187255	ENSG00000212391.1	SNORA48	-3.37	0.000827	0.046	-0.17	-0.15	Coronary artery disease;	chr2:227048726	chr2:226968989~226969122:-
THCA	cis	rs4566357	0.615	rs10177528	ENSG00000212391.1	SNORA48	-3.37	0.000827	0.046	-0.17	-0.15	Coronary artery disease;	chr2:227048990	chr2:226968989~226969122:-
THCA	cis	rs1048886	0.938	rs77408282	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000827	0.046	-0.19	-0.15	Type 2 diabetes;	chr6:70433388	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.938	rs74520771	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000827	0.046	-0.19	-0.15	Type 2 diabetes;	chr6:70444760	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs74716033	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000827	0.046	-0.19	-0.15	Type 2 diabetes;	chr6:70445021	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs75175495	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000827	0.046	-0.19	-0.15	Type 2 diabetes;	chr6:70451869	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs74751032	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000827	0.046	-0.19	-0.15	Type 2 diabetes;	chr6:70458728	chr6:70596438~70596980:+
THCA	cis	rs1048886	0.872	rs75170426	ENSG00000271967.1	RP11-134K13.4	-3.37	0.000827	0.046	-0.19	-0.15	Type 2 diabetes;	chr6:70521415	chr6:70596438~70596980:+
THCA	cis	rs948562	0.947	rs73470773	ENSG00000280010.1	AP001350.4	3.37	0.000827	0.046	0.24	0.15	Lymphoma;	chr11:58648100	chr11:58627435~58628528:+
THCA	cis	rs948562	0.947	rs73470778	ENSG00000280010.1	AP001350.4	3.37	0.000827	0.046	0.24	0.15	Lymphoma;	chr11:58650594	chr11:58627435~58628528:+
THCA	cis	rs478304	0.651	rs11604462	ENSG00000255557.1	RP11-770G2.2	3.37	0.000827	0.046	0.18	0.15	Acne (severe);	chr11:65784177	chr11:65745729~65771585:+
THCA	cis	rs35123781	0.654	rs356486	ENSG00000249526.1	CTB-35F21.1	-3.37	0.000827	0.046	-0.22	-0.15	Schizophrenia;	chr5:139705518	chr5:139684645~139745010:+
THCA	cis	rs35123781	1	rs9687282	ENSG00000200378.1	RNU5B-4P	3.37	0.000827	0.046	0.19	0.15	Schizophrenia;	chr5:139686403	chr5:139447907~139448017:+
THCA	cis	rs7216064	0.861	rs62084252	ENSG00000265055.1	AC145343.2	3.37	0.000827	0.046	0.22	0.15	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883462	chr17:68096046~68101474:-
THCA	cis	rs3824488	0.79	rs28372566	ENSG00000271384.1	RP11-435O5.7	-3.37	0.000827	0.046	-0.22	-0.15	Neuroticism;	chr9:95482696	chr9:95406990~95407662:-
THCA	cis	rs7949030	0.626	rs72927213	ENSG00000255213.1	NPM1P35	3.37	0.000827	0.046	0.19	0.15	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr11:62330946~62331813:+
THCA	cis	rs9650657	0.623	rs10094497	ENSG00000248896.2	CTD-2135J3.3	3.37	0.000827	0.046	0.18	0.15	Neuroticism;	chr8:10745319	chr8:10729314~10771392:+
THCA	cis	rs3892630	0.5	rs35170371	ENSG00000267475.1	CTD-2538C1.2	-3.37	0.000827	0.046	-0.22	-0.15	Red blood cell traits;	chr19:32864175	chr19:32687089~32691750:-
THCA	cis	rs3784262	0.631	rs4646584	ENSG00000259250.1	RP11-50C13.1	3.37	0.000827	0.046	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58013204	chr15:58587507~58591676:+
THCA	cis	rs9863	0.931	rs6488914	ENSG00000269938.1	RP11-214K3.20	3.37	0.000827	0.046	0.18	0.15	White blood cell count;	chr12:123963294	chr12:123968023~123968579:-
THCA	cis	rs324126	0.743	rs34221182	ENSG00000243680.1	RPL37P23	-3.37	0.000828	0.046	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs10445583	ENSG00000243680.1	RPL37P23	-3.37	0.000828	0.046	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52143043~52143336:+
THCA	cis	rs324126	0.752	rs10445584	ENSG00000243680.1	RPL37P23	-3.37	0.000828	0.046	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs10445585	ENSG00000243680.1	RPL37P23	-3.37	0.000828	0.046	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs10445586	ENSG00000243680.1	RPL37P23	-3.37	0.000828	0.046	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs62108317	ENSG00000243680.1	RPL37P23	-3.37	0.000828	0.046	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52143043~52143336:+
THCA	cis	rs1009077	0.536	rs13116789	ENSG00000248280.1	RP11-33B1.2	3.37	0.000828	0.046	0.22	0.15	Endometriosis;	chr4:119494057	chr4:119440561~119450157:-
THCA	cis	rs1552172	0.887	rs12732381	ENSG00000234222.5	RP11-315I20.1	-3.37	0.000828	0.0461	-0.19	-0.15	Breast cancer;	chr1:145804546	chr1:145926590~145959179:+
THCA	cis	rs9607412	0.564	rs25095	ENSG00000233360.4	Z83844.1	-3.37	0.000828	0.0461	-0.17	-0.15	Mean corpuscular volume;	chr22:37037988	chr22:37641832~37658377:-
THCA	cis	rs364477	0.762	rs12238866	ENSG00000227914.3	RP11-130C19.3	-3.37	0.000828	0.0461	-0.25	-0.15	Major depressive disorder;	chr9:1001309	chr9:673478~685555:-
THCA	cis	rs6545883	0.894	rs2600672	ENSG00000212978.6	AC016747.3	3.37	0.000828	0.0461	0.16	0.15	Tuberculosis;	chr2:61309605	chr2:61141592~61144969:-
THCA	cis	rs7560272	0.529	rs2421672	ENSG00000230002.2	ALMS1-IT1	-3.37	0.000828	0.0461	-0.18	-0.15	Schizophrenia;	chr2:73728413	chr2:73456764~73459484:+
THCA	cis	rs813218	0.584	rs1718240	ENSG00000273374.1	RP11-383I23.2	-3.37	0.000828	0.0461	-0.13	-0.15	Orofacial clefts;	chr3:99818093	chr3:99802699~99806058:-
THCA	cis	rs7829975	0.902	rs777707	ENSG00000233609.3	RP11-62H7.2	3.37	0.000828	0.0461	0.15	0.15	Mood instability;	chr8:8726834	chr8:8961200~8979025:+
THCA	cis	rs7688540	0.771	rs7669892	ENSG00000250259.1	RP11-460I19.2	3.37	0.000828	0.0461	0.23	0.15	Facial morphology (factor 6, height of vermillion lower lip);	chr4:315464	chr4:1027678~1028972:+
THCA	cis	rs11673344	0.504	rs6510588	ENSG00000233527.7	ZNF529-AS1	-3.37	0.000828	0.0461	-0.13	-0.15	Obesity-related traits;	chr19:37106493	chr19:36573070~36594708:+
THCA	cis	rs9450351	1	rs7774219	ENSG00000280232.1	RP11-321N4.4	3.37	0.000828	0.0461	0.32	0.15	Interferon gamma-induced protein 10 levels;	chr6:85908837	chr6:85498441~85499058:-
THCA	cis	rs7572644	0.766	rs4233720	ENSG00000223522.1	AC093690.1	-3.37	0.000828	0.0461	-0.2	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27856908	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.766	rs4578808	ENSG00000223522.1	AC093690.1	-3.37	0.000828	0.0461	-0.2	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27858763	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.766	rs4578809	ENSG00000223522.1	AC093690.1	-3.37	0.000828	0.0461	-0.2	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27859627	chr2:28307691~28310459:-
THCA	cis	rs12530	0.715	rs2294311	ENSG00000232218.1	RP1-149A16.16	-3.37	0.000828	0.0461	-0.23	-0.15	IgG glycosylation;	chr22:32397282	chr22:32386668~32386868:+
THCA	cis	rs12530	0.715	rs2294313	ENSG00000232218.1	RP1-149A16.16	-3.37	0.000828	0.0461	-0.23	-0.15	IgG glycosylation;	chr22:32398452	chr22:32386668~32386868:+
THCA	cis	rs853679	0.567	rs6905380	ENSG00000226314.6	ZNF192P1	-3.37	0.000828	0.0461	-0.18	-0.15	Depression;	chr6:28407125	chr6:28161781~28169594:+
THCA	cis	rs7572733	0.967	rs976179	ENSG00000231621.1	AC013264.2	3.37	0.000828	0.0461	0.15	0.15	Dermatomyositis;	chr2:198015654	chr2:197197991~197199273:+
THCA	cis	rs758324	0.661	rs25881	ENSG00000237714.1	P4HA2-AS1	-3.37	0.000828	0.0461	-0.24	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132075445	chr5:132184876~132192808:+
THCA	cis	rs6142618	0.543	rs6142632	ENSG00000224452.1	RSL24D1P6	3.37	0.000828	0.0461	0.18	0.15	Inflammatory bowel disease;	chr20:32182645	chr20:32170390~32170790:-
THCA	cis	rs6504108	0.624	rs882380	ENSG00000264920.1	RP11-6N17.4	-3.37	0.000828	0.0461	-0.13	-0.15	Body mass index;	chr17:48216874	chr17:47891255~47895812:-
THCA	cis	rs8023401	0.507	rs2247876	ENSG00000259705.1	RP11-227D13.1	3.36	0.000828	0.0461	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48639254	chr15:48645951~48652016:+
THCA	cis	rs4081724	0.706	rs12150974	ENSG00000267296.2	CEBPA-AS1	3.36	0.000828	0.0461	0.2	0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33342799	chr19:33302857~33305054:+
THCA	cis	rs150992	1	rs150992	ENSG00000246763.5	RGMB-AS1	3.36	0.000828	0.0461	0.16	0.15	Body mass index;	chr5:98939493	chr5:98769618~98773469:-
THCA	cis	rs701145	0.585	rs62276841	ENSG00000240068.1	RPL21P42	-3.36	0.000828	0.0461	-0.31	-0.15	Coronary artery disease;	chr3:154065856	chr3:154023835~154024298:+
THCA	cis	rs701145	0.585	rs1713846	ENSG00000240068.1	RPL21P42	3.36	0.000828	0.0461	0.31	0.15	Coronary artery disease;	chr3:154069843	chr3:154023835~154024298:+
THCA	cis	rs701145	0.585	rs1727919	ENSG00000240068.1	RPL21P42	3.36	0.000828	0.0461	0.31	0.15	Coronary artery disease;	chr3:154070968	chr3:154023835~154024298:+
THCA	cis	rs701145	0.537	rs1713847	ENSG00000240068.1	RPL21P42	3.36	0.000828	0.0461	0.31	0.15	Coronary artery disease;	chr3:154073318	chr3:154023835~154024298:+
THCA	cis	rs12493885	0.872	rs9840371	ENSG00000240068.1	RPL21P42	3.36	0.000828	0.0461	0.31	0.15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154079040	chr3:154023835~154024298:+
THCA	cis	rs860295	0.775	rs1749410	ENSG00000236675.1	MTX1P1	3.36	0.000828	0.0461	0.15	0.15	Body mass index;	chr1:155874274	chr1:155230975~155234325:+
THCA	cis	rs1864982	0.581	rs2963074	ENSG00000251556.1	RP11-118M9.3	-3.36	0.000828	0.0461	-0.25	-0.15	Alcohol dependence;	chr5:146906210	chr5:146099406~146120412:+
THCA	cis	rs806215	0.826	rs712699	ENSG00000279265.1	AC000123.3	-3.36	0.000828	0.0461	-0.18	-0.15	Type 2 diabetes;	chr7:127610543	chr7:127349833~127350293:-
THCA	cis	rs73459955	0.712	rs58836423	ENSG00000248441.5	LINC01197	3.36	0.000828	0.0461	0.2	0.15	Major depression and alcohol dependence;	chr15:95079649	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs7178707	ENSG00000248441.5	LINC01197	3.36	0.000828	0.0461	0.2	0.15	Major depression and alcohol dependence;	chr15:95080062	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs28613296	ENSG00000248441.5	LINC01197	3.36	0.000828	0.0461	0.2	0.15	Major depression and alcohol dependence;	chr15:95080663	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs56132778	ENSG00000248441.5	LINC01197	3.36	0.000828	0.0461	0.2	0.15	Major depression and alcohol dependence;	chr15:95081230	chr15:95209099~95327129:-
THCA	cis	rs7949030	0.626	rs7124057	ENSG00000255213.1	NPM1P35	3.36	0.000828	0.0461	0.19	0.15	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr11:62330946~62331813:+
THCA	cis	rs11785400	1	rs4518642	ENSG00000177335.9	C8orf31	3.36	0.000828	0.0461	0.17	0.15	Schizophrenia;	chr8:142656005	chr8:143039209~143059942:+
THCA	cis	rs16975963	0.843	rs75802547	ENSG00000226686.6	LINC01535	-3.36	0.000828	0.0461	-0.21	-0.15	Longevity;	chr19:37902681	chr19:37251912~37265535:+
THCA	cis	rs12121840	0.79	rs7535829	ENSG00000237463.4	RP11-280O1.2	-3.36	0.000828	0.0461	-0.15	-0.15	Interleukin-1-receptor antagonist levels;	chr1:165549639	chr1:165476841~165582155:-
THCA	cis	rs11080107	0.542	rs894606	ENSG00000263370.1	RP11-68I3.5	3.36	0.000828	0.0461	0.2	0.15	Coronary artery disease;	chr17:29582334	chr17:29639627~29640825:+
THCA	cis	rs8103033	0.786	rs2190912	ENSG00000226025.8	LGALS17A	-3.36	0.000828	0.0461	-0.14	-0.15	Obesity-related traits;	chr19:39656982	chr19:39679374~39686373:+
THCA	cis	rs8103033	0.786	rs2190913	ENSG00000226025.8	LGALS17A	-3.36	0.000828	0.0461	-0.14	-0.15	Obesity-related traits;	chr19:39656984	chr19:39679374~39686373:+
THCA	cis	rs34779708	0.966	rs34605125	ENSG00000233200.1	RP11-324I22.2	3.36	0.000828	0.0461	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.897	rs16935880	ENSG00000233200.1	RP11-324I22.2	3.36	0.000828	0.0461	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs4934730	ENSG00000233200.1	RP11-324I22.2	3.36	0.000828	0.0461	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs2045918	ENSG00000233200.1	RP11-324I22.2	3.36	0.000828	0.0461	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.966	rs4294520	ENSG00000233200.1	RP11-324I22.2	3.36	0.000828	0.0461	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs34876468	ENSG00000233200.1	RP11-324I22.2	3.36	0.000828	0.0461	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35219894~35230598:-
THCA	cis	rs1009115	0.551	rs10242578	ENSG00000272745.1	RP5-1007H16.1	-3.36	0.000829	0.0461	-0.2	-0.15	Post bronchodilator FEV1;	chr7:8369641	chr7:7619872~7620543:+
THCA	cis	rs944289	0.708	rs7158599	ENSG00000212071.1	AL162511.1	3.36	0.000829	0.0461	0.18	0.15	Thyroid cancer;	chr14:36111976	chr14:36196480~36196568:-
THCA	cis	rs9596863	0.75	rs1971924	ENSG00000136149.6	RPL13AP25	3.36	0.000829	0.0461	0.17	0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53858297	chr13:54440704~54441315:-
THCA	cis	rs7487075	0.619	rs7968897	ENSG00000275481.1	RP11-474P2.6	3.36	0.000829	0.0461	0.15	0.15	Itch intensity from mosquito bite;	chr12:46420041	chr12:46388856~46392126:+
THCA	cis	rs7487075	0.619	rs6582646	ENSG00000275481.1	RP11-474P2.6	3.36	0.000829	0.0461	0.15	0.15	Itch intensity from mosquito bite;	chr12:46420074	chr12:46388856~46392126:+
THCA	cis	rs7129556	0.859	rs11237236	ENSG00000254459.1	RP11-91P24.7	3.36	0.000829	0.0461	0.21	0.15	Weight loss (gastric bypass surgery);	chr11:77601745	chr11:77829654~77872262:-
THCA	cis	rs1612141	0.744	rs7158588	ENSG00000251363.2	RP11-129M6.1	3.36	0.000829	0.0461	0.22	0.15	QT interval (drug interaction);	chr14:41106051	chr14:40954898~40975877:+
THCA	cis	rs1612141	0.744	rs1959904	ENSG00000251363.2	RP11-129M6.1	3.36	0.000829	0.0461	0.22	0.15	QT interval (drug interaction);	chr14:41106065	chr14:40954898~40975877:+
THCA	cis	rs6840360	0.615	rs2120098	ENSG00000251611.1	RP11-610P16.1	-3.36	0.000829	0.0461	-0.12	-0.15	Intelligence (multi-trait analysis);	chr4:151536028	chr4:151407551~151408835:-
THCA	cis	rs6751744	0.513	rs10173538	ENSG00000230783.1	AC009961.2	-3.36	0.000829	0.0461	-0.19	-0.15	Dysphagia;	chr2:159712765	chr2:159689217~159690291:-
THCA	cis	rs4604234	0.803	rs28839510	ENSG00000260645.1	RP11-250B2.5	-3.36	0.000829	0.0461	-0.25	-0.15	Cancer;	chr6:80312266	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.803	rs35629704	ENSG00000260645.1	RP11-250B2.5	-3.36	0.000829	0.0461	-0.25	-0.15	Cancer;	chr6:80319044	chr6:80466958~80469080:+
THCA	cis	rs9788682	0.747	rs2568497	ENSG00000261143.1	ADAMTS7P3	3.36	0.000829	0.0461	0.23	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78429055	chr15:77976042~77993057:+
THCA	cis	rs9788682	0.747	rs2568499	ENSG00000261143.1	ADAMTS7P3	3.36	0.000829	0.0461	0.23	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78430017	chr15:77976042~77993057:+
THCA	cis	rs7737355	0.704	rs11749484	ENSG00000237714.1	P4HA2-AS1	3.36	0.000829	0.0461	0.21	0.15	Life satisfaction;	chr5:131725914	chr5:132184876~132192808:+
THCA	cis	rs524281	0.861	rs3862386	ENSG00000255038.1	RP11-1167A19.2	-3.36	0.000829	0.0461	-0.18	-0.15	Electroencephalogram traits;	chr11:66126953	chr11:66067277~66069619:-
THCA	cis	rs708224	0.625	rs2261943	ENSG00000277342.1	RP11-843B15.4	3.36	0.000829	0.0461	0.2	0.15	Pancreatic cancer;	chr12:32293610	chr12:32109076~32109602:+
THCA	cis	rs4489787	0.568	rs2731066	ENSG00000273765.1	RP11-370I10.11	3.36	0.000829	0.0461	0.17	0.15	Prostate cancer (SNP x SNP interaction);	chr12:48504780	chr12:48360920~48361377:+
THCA	cis	rs17345786	1	rs11715368	ENSG00000244119.1	PDCL3P4	3.36	0.000829	0.0461	0.15	0.15	Colonoscopy-negative controls vs population controls;	chr3:101617536	chr3:101712472~101713191:+
THCA	cis	rs1950832	0.723	rs853238	ENSG00000258636.1	CTD-2298J14.2	3.36	0.000829	0.0461	0.21	0.15	Urate levels in obese individuals;	chr14:41646851	chr14:41587861~41604856:-
THCA	cis	rs5758659	0.652	rs6519301	ENSG00000234009.1	RPL5P34	-3.36	0.000829	0.0461	-0.14	-0.15	Cognitive function;	chr22:41989963	chr22:42776406~42777296:-
THCA	cis	rs7737355	0.812	rs8180462	ENSG00000224431.1	AC063976.7	3.36	0.000829	0.0461	0.14	0.15	Life satisfaction;	chr5:131571496	chr5:132199456~132203487:+
THCA	cis	rs4671400	0.571	rs2421116	ENSG00000270820.4	RP11-355B11.2	-3.36	0.000829	0.0461	-0.14	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61261276	chr2:61471188~61484130:+
THCA	cis	rs7474896	1	rs1322319	ENSG00000276805.1	RP11-291L22.6	3.36	0.000829	0.0461	0.24	0.15	Obesity (extreme);	chr10:37856581	chr10:38451030~38451785:+
THCA	cis	rs4443100	0.67	rs3788338	ENSG00000240160.3	RN7SL263P	3.36	0.000829	0.0461	0.21	0.15	Serum parathyroid hormone levels;	chr22:23069879	chr22:23261782~23262071:-
THCA	cis	rs56309584	0.715	rs77224069	ENSG00000271002.1	RP11-599B13.8	-3.36	0.000829	0.0461	-0.23	-0.15	Initial pursuit acceleration;	chr17:8220950	chr17:8199123~8199437:-
THCA	cis	rs9425766	0.962	rs1322780	ENSG00000200674.1	RN7SKP160	3.36	0.000829	0.0461	0.2	0.15	Life satisfaction;	chr1:173896448	chr1:173791548~173791887:+
THCA	cis	rs9425766	0.962	rs9425435	ENSG00000200674.1	RN7SKP160	3.36	0.000829	0.0461	0.2	0.15	Life satisfaction;	chr1:173896936	chr1:173791548~173791887:+
THCA	cis	rs11681884	0.786	rs11898158	ENSG00000234997.1	AC016745.3	-3.36	0.000829	0.0461	-0.29	-0.15	Stroke;	chr2:113065995	chr2:113424495~113425324:+
THCA	cis	rs2351088	0.611	rs77403416	ENSG00000280383.1	CTA-941F9.10	3.36	0.000829	0.0461	0.17	0.15	Tonsillectomy;	chr22:45666494	chr22:45657019~45680130:+
THCA	cis	rs7631605	0.608	rs11719885	ENSG00000224080.1	UBE2FP1	3.36	0.000829	0.0461	0.17	0.15	Cerebrospinal P-tau181p levels;	chr3:37396550	chr3:37143512~37143958:-
THCA	cis	rs7631605	0.608	rs34829161	ENSG00000224080.1	UBE2FP1	3.36	0.000829	0.0461	0.17	0.15	Cerebrospinal P-tau181p levels;	chr3:37401914	chr3:37143512~37143958:-
THCA	cis	rs2070615	0.525	rs1532365	ENSG00000269514.1	RP11-370I10.12	3.36	0.000829	0.0461	0.13	0.15	Bipolar disorder;	chr12:48810638	chr12:48198387~48202031:+
THCA	cis	rs4646404	0.509	rs4646352	ENSG00000225442.2	MPRIP-AS1	3.36	0.000829	0.0461	0.18	0.15	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr17:17570539	chr17:17076038~17077752:-
THCA	cis	rs7674212	0.539	rs7676041	ENSG00000230069.3	LRRC37A15P	-3.36	0.000829	0.0461	-0.15	-0.15	Type 2 diabetes;	chr4:103205264	chr4:102727274~102730721:-
THCA	cis	rs7028939	1	rs7872897	ENSG00000255145.2	STX17-AS1	-3.36	0.000829	0.0461	-0.23	-0.15	Preeclampsia;	chr9:100147491	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs75781259	ENSG00000255145.2	STX17-AS1	-3.36	0.000829	0.0461	-0.23	-0.15	Preeclampsia;	chr9:100157156	chr9:99886322~99906601:-
THCA	cis	rs9916302	0.706	rs9906612	ENSG00000266469.1	CTB-131K11.1	3.36	0.000829	0.0461	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39391378	chr17:39401793~39406233:+
THCA	cis	rs586716	0.506	rs1603958	ENSG00000224549.1	RP11-370B11.3	3.36	0.000829	0.0461	0.18	0.15	Tuberculosis;	chr9:22518183	chr9:22767175~22768316:+
THCA	cis	rs8037137	0.915	rs2290202	ENSG00000258725.1	PRC1-AS1	-3.36	0.000829	0.0461	-0.24	-0.15	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90969037	chr15:90966345~90988624:+
THCA	cis	rs9650657	0.529	rs10108618	ENSG00000254948.1	OR7E158P	3.36	0.000829	0.0461	0.19	0.15	Neuroticism;	chr8:11095582	chr8:11919900~11920809:-
THCA	cis	rs79839061	0.536	rs3775128	ENSG00000272588.1	RP11-440L14.4	-3.36	0.000829	0.0461	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:892040	chr4:757022~757740:-
THCA	cis	rs3764400	0.506	rs56103412	ENSG00000266821.1	RP11-6N17.2	-3.36	0.000829	0.0461	-0.29	-0.15	Body mass index;	chr17:48464940	chr17:47879472~47882398:-
THCA	cis	rs10207628	1	rs76168490	ENSG00000260634.1	RP11-521O16.1	3.36	0.00083	0.0461	0.21	0.15	Psychosis and Alzheimer's disease;	chr2:127093042	chr2:127024252~127025723:-
THCA	cis	rs10908557	0.758	rs11264865	ENSG00000231416.1	RP11-422P24.9	3.36	0.00083	0.0461	0.19	0.15	Age at first birth;	chr1:154014161	chr1:153995632~153995960:+
THCA	cis	rs2668423	0.922	rs2668417	ENSG00000261526.2	CTB-31O20.2	3.36	0.00083	0.0461	0.11	0.15	Nonalcoholic fatty liver disease;	chr19:1365828	chr19:1874871~1876169:-
THCA	cis	rs6499755	0.712	rs31114	ENSG00000260135.5	RP11-212I21.2	-3.36	0.00083	0.0461	-0.17	-0.15	Hypospadias;	chr16:55346143	chr16:55426797~55462297:-
THCA	cis	rs45544231	1	rs3112626	ENSG00000279344.1	RP11-44F14.7	3.36	0.00083	0.0461	0.14	0.15	Restless legs syndrome;	chr16:52591288	chr16:53478957~53481550:-
THCA	cis	rs7560272	0.723	rs4852927	ENSG00000273245.1	RP11-434P11.2	-3.36	0.00083	0.0461	-0.18	-0.15	Schizophrenia;	chr2:73414429	chr2:73750256~73750786:-
THCA	cis	rs944289	0.774	rs7150539	ENSG00000212071.1	AL162511.1	3.36	0.00083	0.0461	0.18	0.15	Thyroid cancer;	chr14:36086408	chr14:36196480~36196568:-
THCA	cis	rs751728	0.664	rs12196293	ENSG00000274259.2	XXbac-BPG294E21.9	3.36	0.00083	0.0461	0.18	0.15	Crohn's disease;	chr6:33781374	chr6:33437363~33454453:-
THCA	cis	rs11992162	0.56	rs7846248	ENSG00000255495.1	AC145124.2	3.36	0.00083	0.0461	0.18	0.15	Monocyte count;	chr8:11936540	chr8:12194467~12196280:+
THCA	cis	rs11673344	0.504	rs8105065	ENSG00000233527.7	ZNF529-AS1	3.36	0.00083	0.0461	0.13	0.15	Obesity-related traits;	chr19:37141003	chr19:36573070~36594708:+
THCA	cis	rs6142618	0.562	rs6058541	ENSG00000224452.1	RSL24D1P6	3.36	0.00083	0.0462	0.18	0.15	Inflammatory bowel disease;	chr20:32170845	chr20:32170390~32170790:-
THCA	cis	rs3736858	0.8	rs9544059	ENSG00000261553.4	RP11-29G8.3	-3.36	0.00083	0.0462	-0.19	-0.15	Interleukin-9 levels;	chr13:75873062	chr13:75549773~75807120:+
THCA	cis	rs3736858	0.8	rs2165774	ENSG00000261553.4	RP11-29G8.3	-3.36	0.00083	0.0462	-0.19	-0.15	Interleukin-9 levels;	chr13:75873096	chr13:75549773~75807120:+
THCA	cis	rs4648045	0.565	rs11733293	ENSG00000248971.2	KRT8P46	3.36	0.00083	0.0462	0.18	0.15	Lymphocyte percentage of white cells;	chr4:102624096	chr4:102728746~102730171:-
THCA	cis	rs2880765	0.835	rs4843063	ENSG00000259407.1	RP11-158M2.3	-3.36	0.00083	0.0462	-0.15	-0.15	Coronary artery disease;	chr15:85505517	chr15:85744109~85750281:-
THCA	cis	rs847649	0.692	rs1541519	ENSG00000234715.1	CTB-107G13.1	-3.36	0.00083	0.0462	-0.17	-0.15	Morning vs. evening chronotype;	chr7:102826294	chr7:103445207~103514007:+
THCA	cis	rs9733	0.818	rs7520022	ENSG00000231073.1	RP11-316M1.3	-3.36	0.00083	0.0462	-0.18	-0.15	Tonsillectomy;	chr1:150686697	chr1:150973123~150975534:+
THCA	cis	rs17407555	0.683	rs6823180	ENSG00000250413.1	RP11-448G15.1	-3.36	0.00083	0.0462	-0.17	-0.15	Schizophrenia (age at onset);	chr4:10274207	chr4:10006482~10009725:+
THCA	cis	rs36093844	0.698	rs1445498	ENSG00000279742.1	RP11-700A24.1	-3.36	0.00083	0.0462	-0.23	-0.15	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85815647	chr11:85852557~85854943:-
THCA	cis	rs2395128	0.765	rs4745759	ENSG00000236842.1	RP11-399K21.10	3.36	0.00083	0.0462	0.23	0.15	Ulcerative colitis;Inflammatory bowel disease;	chr10:74898448	chr10:75430571~75431588:-
THCA	cis	rs11992162	0.56	rs13256329	ENSG00000255046.1	RP11-297N6.4	3.36	0.00083	0.0462	0.16	0.15	Monocyte count;	chr8:11924705	chr8:11797928~11802568:-
THCA	cis	rs10435719	0.638	rs67146188	ENSG00000255046.1	RP11-297N6.4	3.36	0.00083	0.0462	0.16	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:11797928~11802568:-
THCA	cis	rs2692947	0.832	rs2438978	ENSG00000236750.1	AC009237.16	-3.36	0.00083	0.0462	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96013992	chr2:95641634~95641980:-
THCA	cis	rs2447820	0.588	rs4385206	ENSG00000263432.2	RN7SL689P	3.36	0.00083	0.0462	0.19	0.15	Migraine;	chr5:123039302	chr5:123022487~123022783:-
THCA	cis	rs7615952	0.512	rs1077621	ENSG00000248787.1	RP11-666A20.4	-3.36	0.00083	0.0462	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126100956	chr3:125908005~125910272:-
THCA	cis	rs9302690	1	rs62037100	ENSG00000205361.7	MT1DP	-3.36	0.00083	0.0462	-0.3	-0.15	Blood protein levels;	chr16:57397022	chr16:56643705~56644786:+
THCA	cis	rs12428035	0.764	rs581462	ENSG00000247400.3	DNAJC3-AS1	3.36	0.00083	0.0462	0.15	0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96080961	chr13:95648733~95676925:-
THCA	cis	rs28489187	0.683	rs12047422	ENSG00000223653.4	RP11-131L23.1	3.36	0.00083	0.0462	0.17	0.15	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85383147	chr1:85276715~85448124:+
THCA	cis	rs9584850	0.834	rs17574378	ENSG00000231194.1	FARP1-AS1	3.36	0.00083	0.0462	0.19	0.15	Neuroticism;	chr13:98464130	chr13:98435405~98435840:-
THCA	cis	rs10498546	0.541	rs8022733	ENSG00000259167.2	NMNAT1P1	3.36	0.00083	0.0462	0.23	0.15	Gut microbiome composition (winter);	chr14:80653720	chr14:81032529~81033404:+
THCA	cis	rs7246657	0.943	rs8106839	ENSG00000268499.1	CTB-102L5.8	3.36	0.00083	0.0462	0.2	0.15	Coronary artery calcification;	chr19:37467573	chr19:38199836~38200934:+
THCA	cis	rs11009175	0.929	rs10430560	ENSG00000233190.1	RPS24P13	-3.36	0.000831	0.0462	-0.24	-0.15	Depression (quantitative trait);	chr10:33051403	chr10:32231849~32232245:-
THCA	cis	rs4808199	0.948	rs2301668	ENSG00000267481.1	CTC-559E9.5	-3.36	0.000831	0.0462	-0.16	-0.15	Nonalcoholic fatty liver disease;	chr19:19341440	chr19:19788755~19790531:-
THCA	cis	rs1612141	0.689	rs1954449	ENSG00000251363.2	RP11-129M6.1	3.36	0.000831	0.0462	0.22	0.15	QT interval (drug interaction);	chr14:41117700	chr14:40954898~40975877:+
THCA	cis	rs789859	0.833	rs9834693	ENSG00000223711.1	AC091633.3	-3.36	0.000831	0.0462	-0.18	-0.15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr3:194662758	chr3:195544048~195550581:+
THCA	cis	rs78487399	0.908	rs61271889	ENSG00000234936.1	AC010883.5	3.36	0.000831	0.0462	0.19	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43598297	chr2:43229573~43233394:+
THCA	cis	rs11633886	0.604	rs10153045	ENSG00000259200.1	RP11-718O11.1	-3.36	0.000831	0.0462	-0.19	-0.15	Diisocyanate-induced asthma;	chr15:45832078	chr15:45705078~45931069:+
THCA	cis	rs12541437	0.617	rs16889265	ENSG00000253327.2	RAD21-AS1	3.36	0.000831	0.0462	0.19	0.15	Gut microbiome composition (winter);	chr8:116924243	chr8:116874424~116876868:+
THCA	cis	rs7924176	0.564	rs6480727	ENSG00000271848.1	RP11-464F9.21	-3.36	0.000831	0.0462	-0.16	-0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:73654039~73674719:+
THCA	cis	rs12780845	0.931	rs17466418	ENSG00000229124.5	VIM-AS1	3.36	0.000831	0.0462	0.15	0.15	Homocysteine levels;	chr10:17202308	chr10:17214239~17229985:-
THCA	cis	rs7474896	0.559	rs10740949	ENSG00000276805.1	RP11-291L22.6	3.36	0.000831	0.0462	0.2	0.15	Obesity (extreme);	chr10:37689507	chr10:38451030~38451785:+
THCA	cis	rs6456156	0.774	rs2022001	ENSG00000235272.1	FAM103A2P	-3.36	0.000831	0.0462	-0.21	-0.15	Primary biliary cholangitis;	chr6:167116021	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.774	rs2021999	ENSG00000235272.1	FAM103A2P	-3.36	0.000831	0.0462	-0.21	-0.15	Primary biliary cholangitis;	chr6:167116278	chr6:166586124~166586477:-
THCA	cis	rs6456156	0.806	rs11967165	ENSG00000235272.1	FAM103A2P	-3.36	0.000831	0.0462	-0.21	-0.15	Primary biliary cholangitis;	chr6:167116448	chr6:166586124~166586477:-
THCA	cis	rs6942227	0.947	rs1986731	ENSG00000224164.1	RP3-369A17.4	3.36	0.000831	0.0462	0.24	0.15	Bipolar disorder lithium response (categorical) or schizophrenia;	chr6:25173842	chr6:24742302~24751921:+
THCA	cis	rs13272623	0.502	rs268627	ENSG00000246366.5	RP11-382J12.1	-3.36	0.000831	0.0462	-0.19	-0.15	IgG glycosylation;	chr8:70648806	chr8:70608577~70663279:+
THCA	cis	rs62025270	0.632	rs56153788	ENSG00000202081.1	RNU6-1280P	-3.36	0.000831	0.0462	-0.25	-0.15	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85651522~85651628:-
THCA	cis	rs73173548	0.528	rs16903177	ENSG00000247828.6	TMEM161B-AS1	3.36	0.000831	0.0462	0.14	0.15	Macular telangiectasia type 2;	chr5:88480416	chr5:88268895~88436685:+
THCA	cis	rs73459955	0.761	rs28576636	ENSG00000248441.5	LINC01197	3.36	0.000831	0.0462	0.2	0.15	Major depression and alcohol dependence;	chr15:95086439	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.761	rs28369404	ENSG00000248441.5	LINC01197	3.36	0.000831	0.0462	0.2	0.15	Major depression and alcohol dependence;	chr15:95086442	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs73459903	ENSG00000248441.5	LINC01197	3.36	0.000831	0.0462	0.2	0.15	Major depression and alcohol dependence;	chr15:95087408	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs79908965	ENSG00000248441.5	LINC01197	3.36	0.000831	0.0462	0.2	0.15	Major depression and alcohol dependence;	chr15:95087411	chr15:95209099~95327129:-
THCA	cis	rs9902453	0.904	rs12939344	ENSG00000250462.7	LRRC37BP1	-3.36	0.000831	0.0462	-0.12	-0.15	Coffee consumption (cups per day);	chr17:30001801	chr17:30629680~30637466:+
THCA	cis	rs11718455	0.767	rs13076333	ENSG00000271192.1	RP4-555D20.3	-3.36	0.000832	0.0462	-0.21	-0.15	Coronary artery disease;	chr3:43913578	chr3:43996896~43997443:+
THCA	cis	rs9652601	0.691	rs7203150	ENSG00000263033.2	RP11-396B14.2	-3.36	0.000832	0.0462	-0.12	-0.15	Systemic lupus erythematosus;	chr16:11113865	chr16:11196177~11224969:+
THCA	cis	rs668210	0.793	rs1151514	ENSG00000214659.4	KRT8P26	3.36	0.000832	0.0462	0.17	0.15	Cerebrospinal fluid biomarker levels;	chr11:65991383	chr11:65726939~65728214:+
THCA	cis	rs9316337	0.582	rs3858749	ENSG00000236953.1	ZDHHC20-IT1	-3.36	0.000832	0.0462	-0.18	-0.15	Schizophrenia;	chr13:21434299	chr13:21376977~21377874:-
THCA	cis	rs2572431	0.505	rs13269118	ENSG00000261451.1	RP11-981G7.1	3.36	0.000832	0.0462	0.2	0.15	Neuroticism;	chr8:11390305	chr8:10433672~10438312:+
THCA	cis	rs11031096	0.542	rs6578424	ENSG00000230593.3	AC090804.1	3.36	0.000832	0.0462	0.19	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:3951910	chr11:3892398~3892887:-
THCA	cis	rs2762353	0.779	rs1408273	ENSG00000272462.2	U91328.19	3.36	0.000832	0.0462	0.12	0.15	Blood metabolite levels;	chr6:25840718	chr6:25992662~26001775:+
THCA	cis	rs2014572	0.904	rs10412465	ENSG00000276449.1	AC004076.5	3.36	0.000832	0.0462	0.14	0.15	Hyperactive-impulsive symptoms;	chr19:57242563	chr19:57449689~57453011:+
THCA	cis	rs7737355	0.812	rs10062078	ENSG00000237714.1	P4HA2-AS1	-3.36	0.000832	0.0462	-0.21	-0.15	Life satisfaction;	chr5:131428409	chr5:132184876~132192808:+
THCA	cis	rs10191559	0.552	rs4667082	ENSG00000234663.4	AC104820.2	3.36	0.000832	0.0462	0.14	0.15	Red blood cell count;	chr2:181135250	chr2:181101932~181399559:+
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000184274.3	LINC00315	-3.36	0.000832	0.0462	-0.19	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45300245~45305257:-
THCA	cis	rs10760158	0.832	rs10985194	ENSG00000235865.2	GSN-AS1	3.36	0.000832	0.0462	0.13	0.15	Pulse pressure;	chr9:121265434	chr9:121280768~121285530:-
THCA	cis	rs6500602	0.647	rs1641868	ENSG00000280063.1	RP11-295D4.3	3.36	0.000832	0.0462	0.08	0.15	Schizophrenia;	chr16:4544502	chr16:4346694~4348648:-
THCA	cis	rs7474896	0.616	rs2505239	ENSG00000273019.1	RP11-508N22.13	-3.36	0.000832	0.0462	-0.21	-0.15	Obesity (extreme);	chr10:38151837	chr10:38149968~38150293:+
THCA	cis	rs7474896	0.561	rs2474603	ENSG00000273019.1	RP11-508N22.13	-3.36	0.000832	0.0462	-0.21	-0.15	Obesity (extreme);	chr10:38156754	chr10:38149968~38150293:+
THCA	cis	rs13401620	0.745	rs6542544	ENSG00000236878.1	AC012363.7	-3.36	0.000832	0.0462	-0.18	-0.15	Breast size;	chr2:119712064	chr2:120211054~120211715:+
THCA	cis	rs9902453	0.899	rs1979572	ENSG00000250462.7	LRRC37BP1	3.36	0.000832	0.0462	0.12	0.15	Coffee consumption (cups per day);	chr17:30184960	chr17:30629680~30637466:+
THCA	cis	rs916888	0.821	rs199513	ENSG00000260075.1	NSFP1	3.36	0.000832	0.0462	0.24	0.15	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46372855~46487141:+
THCA	cis	rs2034088	0.965	rs11653961	ENSG00000231784.7	DBIL5P	3.36	0.000832	0.0462	0.17	0.15	Hip circumference adjusted for BMI;	chr17:536868	chr17:752660~755336:+
THCA	cis	rs17027633	0.867	rs7543384	ENSG00000260948.1	RP11-552M11.8	3.36	0.000832	0.0463	0.31	0.15	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405392	chr1:111431046~111433068:-
THCA	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-3.36	0.000832	0.0463	-0.14	-0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
THCA	cis	rs11051970	0.559	rs11051938	ENSG00000275769.1	RP11-771K4.3	-3.36	0.000832	0.0463	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32329882	chr12:31443792~31444208:-
THCA	cis	rs881375	0.692	rs2072438	ENSG00000238181.2	AHCYP2	-3.36	0.000832	0.0463	-0.19	-0.15	Rheumatoid arthritis;	chr9:120889023	chr9:120720673~120721972:+
THCA	cis	rs6439153	0.933	rs6769662	ENSG00000231305.3	RP11-723O4.2	3.36	0.000832	0.0463	0.16	0.15	Pneumococcal bacteremia;	chr3:129002467	chr3:128861313~128871540:-
THCA	cis	rs6439153	0.967	rs12695512	ENSG00000231305.3	RP11-723O4.2	3.36	0.000832	0.0463	0.16	0.15	Pneumococcal bacteremia;	chr3:129003239	chr3:128861313~128871540:-
THCA	cis	rs6439153	0.967	rs12695513	ENSG00000231305.3	RP11-723O4.2	3.36	0.000832	0.0463	0.16	0.15	Pneumococcal bacteremia;	chr3:129003469	chr3:128861313~128871540:-
THCA	cis	rs7259376	0.875	rs1975175	ENSG00000270947.1	AC025811.3	3.36	0.000832	0.0463	0.16	0.15	Menopause (age at onset);	chr19:22332437	chr19:22455988~22456459:+
THCA	cis	rs7474896	1	rs12358094	ENSG00000276805.1	RP11-291L22.6	3.36	0.000832	0.0463	0.25	0.15	Obesity (extreme);	chr10:37726578	chr10:38451030~38451785:+
THCA	cis	rs7315621	0.929	rs10047620	ENSG00000279283.1	RP11-417L19.5	3.36	0.000832	0.0463	0.14	0.15	Longevity;	chr12:131598748	chr12:131896500~131898239:+
THCA	cis	rs7737355	0.578	rs17669718	ENSG00000224431.1	AC063976.7	-3.36	0.000833	0.0463	-0.28	-0.15	Life satisfaction;	chr5:131438683	chr5:132199456~132203487:+
THCA	cis	rs6472235	0.837	rs2357568	ENSG00000272192.1	CTD-2532N20.1	3.36	0.000833	0.0463	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:66004767	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs2357569	ENSG00000272192.1	CTD-2532N20.1	3.36	0.000833	0.0463	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:66004902	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs10098417	ENSG00000272192.1	CTD-2532N20.1	3.36	0.000833	0.0463	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:66006145	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs7465415	ENSG00000272192.1	CTD-2532N20.1	3.36	0.000833	0.0463	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:66008287	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs4380924	ENSG00000272192.1	CTD-2532N20.1	3.36	0.000833	0.0463	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:66008509	chr8:65842752~65843331:+
THCA	cis	rs6472235	0.837	rs11997658	ENSG00000272192.1	CTD-2532N20.1	3.36	0.000833	0.0463	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:66008521	chr8:65842752~65843331:+
THCA	cis	rs11089937	0.637	rs988200	ENSG00000215456.5	BCRP4	3.36	0.000833	0.0463	0.21	0.15	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22630061~22636153:+
THCA	cis	rs1908814	0.516	rs60176945	ENSG00000254527.1	ENPP7P12	3.36	0.000833	0.0463	0.2	0.15	Neuroticism;	chr8:11939165	chr8:12205759~12206389:-
THCA	cis	rs1908814	0.516	rs56102998	ENSG00000254527.1	ENPP7P12	3.36	0.000833	0.0463	0.2	0.15	Neuroticism;	chr8:11939166	chr8:12205759~12206389:-
THCA	cis	rs7631605	0.905	rs7651033	ENSG00000272334.1	RP11-129K12.1	3.36	0.000833	0.0463	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37074551	chr3:36973117~36973672:-
THCA	cis	rs11157436	0.602	rs17255447	ENSG00000211812.1	TRAV26-2	3.36	0.000833	0.0463	0.13	0.15	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22202583~22203368:+
THCA	cis	rs4604234	0.803	rs73463519	ENSG00000260645.1	RP11-250B2.5	-3.36	0.000833	0.0463	-0.25	-0.15	Cancer;	chr6:80266862	chr6:80466958~80469080:+
THCA	cis	rs73193808	0.614	rs2832255	ENSG00000231125.2	AF129075.5	3.36	0.000833	0.0463	0.15	0.15	Coronary artery disease;	chr21:29191846	chr21:29058073~29060095:-
THCA	cis	rs7631605	0.524	rs11129759	ENSG00000224080.1	UBE2FP1	3.36	0.000833	0.0463	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37364762	chr3:37143512~37143958:-
THCA	cis	rs12541437	0.617	rs1584217	ENSG00000253327.2	RAD21-AS1	3.36	0.000833	0.0463	0.19	0.15	Gut microbiome composition (winter);	chr8:116915860	chr8:116874424~116876868:+
THCA	cis	rs12541437	0.617	rs7836868	ENSG00000253327.2	RAD21-AS1	3.36	0.000833	0.0463	0.19	0.15	Gut microbiome composition (winter);	chr8:116916498	chr8:116874424~116876868:+
THCA	cis	rs9488822	0.651	rs3798228	ENSG00000233558.1	RP3-486I3.4	3.36	0.000833	0.0463	0.17	0.15	LDL cholesterol;Cholesterol, total;	chr6:115999993	chr6:116258493~116259115:-
THCA	cis	rs939960	0.879	rs62491812	ENSG00000276538.1	RP11-545G3.2	3.36	0.000833	0.0463	0.25	0.15	Neutrophil percentage of white cells;	chr7:150630336	chr7:150047609~150047854:-
THCA	cis	rs8040855	0.599	rs1964724	ENSG00000259630.2	CTD-2262B20.1	3.36	0.000833	0.0463	0.17	0.15	Bulimia nervosa;	chr15:85183269	chr15:85415228~85415633:+
THCA	cis	rs9369640	0.6	rs1537340	ENSG00000212802.4	RPL15P3	3.36	0.000833	0.0463	0.15	0.15	Coronary artery disease;	chr6:12881623	chr6:12514110~12514724:+
THCA	cis	rs11673344	0.598	rs826326	ENSG00000233527.7	ZNF529-AS1	3.36	0.000833	0.0463	0.13	0.15	Obesity-related traits;	chr19:37003863	chr19:36573070~36594708:+
THCA	cis	rs11673344	0.542	rs826328	ENSG00000233527.7	ZNF529-AS1	3.36	0.000833	0.0463	0.13	0.15	Obesity-related traits;	chr19:37004479	chr19:36573070~36594708:+
THCA	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-3.36	0.000833	0.0463	-0.22	-0.15	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
THCA	cis	rs14027	0.961	rs7017279	ENSG00000245330.4	KB-1471A8.1	-3.36	0.000833	0.0463	-0.15	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119867419~119874488:-
THCA	cis	rs354225	0.584	rs7586311	ENSG00000212175.1	SNORA12	-3.36	0.000833	0.0463	-0.19	-0.15	Schizophrenia;	chr2:54583625	chr2:55565703~55565850:+
THCA	cis	rs9595908	0.709	rs3752476	ENSG00000281026.1	N4BP2L2-IT2	3.36	0.000833	0.0463	0.1	0.15	Body mass index;	chr13:32770965	chr13:32504506~32509395:-
THCA	cis	rs11062040	1	rs11062040	ENSG00000249628.2	LINC00942	-3.36	0.000833	0.0463	-0.15	-0.15	Response to gemcitabine in pancreatic cancer;Survival in pancreatic cancer;	chr12:1982091	chr12:1500525~1507318:-
THCA	cis	rs1765142	0.55	rs475477	ENSG00000242353.1	RP4-710M3.1	3.36	0.000833	0.0463	0.13	0.15	Schizophrenia;	chr11:30387218	chr11:30368148~30368646:+
THCA	cis	rs2486012	0.649	rs9726489	ENSG00000234694.1	RP1-92O14.3	3.36	0.000833	0.0463	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43801997	chr1:43354684~43358658:-
THCA	cis	rs6942756	0.531	rs4731569	ENSG00000271344.1	RP11-274B21.9	3.36	0.000833	0.0463	0.13	0.15	White matter hyperintensity burden;	chr7:129290987	chr7:128690451~128691717:+
THCA	cis	rs1009077	0.716	rs6817975	ENSG00000245958.5	RP11-33B1.1	3.36	0.000833	0.0463	0.23	0.15	Endometriosis;	chr4:119614666	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs4833620	ENSG00000245958.5	RP11-33B1.1	3.36	0.000833	0.0463	0.23	0.15	Endometriosis;	chr4:119617156	chr4:119454791~119552025:+
THCA	cis	rs1009077	0.716	rs2953295	ENSG00000245958.5	RP11-33B1.1	3.36	0.000833	0.0463	0.23	0.15	Endometriosis;	chr4:119627067	chr4:119454791~119552025:+
THCA	cis	rs7176527	0.848	rs72630463	ENSG00000176700.18	SCAND2P	3.36	0.000833	0.0463	0.15	0.15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84750699	chr15:84631451~84647478:+
THCA	cis	rs6940638	1	rs6940638	ENSG00000224843.5	LINC00240	3.36	0.000833	0.0463	0.18	0.15	Intelligence (multi-trait analysis);	chr6:27078471	chr6:26956992~27023924:+
THCA	cis	rs3770081	1	rs3731819	ENSG00000273080.1	RP11-301O19.1	-3.36	0.000833	0.0463	-0.37	-0.15	Facial emotion recognition (sad faces);	chr2:86141518	chr2:86195590~86196049:+
THCA	cis	rs1948632	0.619	rs1391411	ENSG00000262583.1	RP11-77K12.5	3.36	0.000834	0.0463	0.19	0.15	Tuberculosis;	chr16:75951319	chr16:75499788~75516280:-
THCA	cis	rs208520	1	rs12200490	ENSG00000233859.2	ADH5P4	3.36	0.000834	0.0463	0.24	0.15	Exhaled nitric oxide output;	chr6:66266191	chr6:65836930~65838039:-
THCA	cis	rs9291683	0.567	rs12499857	ENSG00000261490.1	RP11-448G15.3	3.36	0.000834	0.0463	0.1	0.15	Bone mineral density;	chr4:9993752	chr4:10068089~10073019:-
THCA	cis	rs4792901	0.802	rs2271958	ENSG00000279602.1	CTD-3014M21.1	-3.36	0.000834	0.0463	-0.2	-0.15	Dupuytren's disease;	chr17:43522015	chr17:43360041~43361361:-
THCA	cis	rs11190604	1	rs10883503	ENSG00000273030.1	RP11-285F16.1	3.36	0.000834	0.0463	0.18	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100515747	chr10:100412934~100413421:+
THCA	cis	rs939960	1	rs12537745	ENSG00000224016.2	RP11-728K20.1	3.36	0.000834	0.0463	0.21	0.15	Neutrophil percentage of white cells;	chr7:150539762	chr7:149891191~149909704:-
THCA	cis	rs111756027	0.522	rs2343041	ENSG00000260922.1	RP11-538I12.3	3.36	0.000834	0.0463	0.26	0.15	Bone mineral density (Ward's triangle area);	chr16:77244419	chr16:77234877~77290934:+
THCA	cis	rs8054556	1	rs8054556	ENSG00000214725.6	CDIPT-AS1	-3.36	0.000834	0.0463	-0.19	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29946895	chr16:29863593~29868053:+
THCA	cis	rs10832963	1	rs10128711	ENSG00000256361.1	RP11-613F22.6	3.36	0.000834	0.0463	0.19	0.15	Breast cancer;	chr11:18611437	chr11:18511043~18511475:-
THCA	cis	rs758324	0.812	rs1875176	ENSG00000224431.1	AC063976.7	-3.36	0.000834	0.0463	-0.14	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131866764	chr5:132199456~132203487:+
THCA	cis	rs620729	0.749	rs6907944	ENSG00000272097.1	RP11-421M1.8	3.36	0.000834	0.0463	0.17	0.15	Intelligence (multi-trait analysis);	chr6:11480397	chr6:10743324~10747663:-
THCA	cis	rs4845570	0.92	rs10788809	ENSG00000268288.1	RP11-98D18.16	3.36	0.000834	0.0463	0.22	0.15	Coronary artery disease;	chr1:151788316	chr1:151766486~151767000:-
THCA	cis	rs7395662	0.784	rs2170661	ENSG00000200090.1	Y_RNA	-3.36	0.000834	0.0463	-0.1	-0.15	HDL cholesterol;	chr11:48356634	chr11:47726894~47726992:-
THCA	cis	rs66887589	0.934	rs56843000	ENSG00000249244.1	RP11-548H18.2	-3.36	0.000834	0.0463	-0.16	-0.15	Diastolic blood pressure;	chr4:119595442	chr4:119391831~119395335:-
THCA	cis	rs765751	0.965	rs6698625	ENSG00000228536.1	RP11-392O17.1	-3.36	0.000834	0.0463	-0.18	-0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219460356	chr1:219409681~219411941:-
THCA	cis	rs42490	0.668	rs42343	ENSG00000251136.7	RP11-37B2.1	-3.36	0.000834	0.0463	-0.13	-0.15	Leprosy;	chr8:89795984	chr8:89609409~89757727:-
THCA	cis	rs73157695	0.676	rs7277160	ENSG00000274248.1	AJ011932.1	3.36	0.000834	0.0463	0.17	0.15	Myopia;	chr21:45913321	chr21:45974489~45974953:+
THCA	cis	rs17428076	0.874	rs17581347	ENSG00000228389.1	AC068039.4	-3.36	0.000834	0.0463	-0.17	-0.15	Myopia;	chr2:171826091	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.874	rs17581361	ENSG00000228389.1	AC068039.4	-3.36	0.000834	0.0463	-0.17	-0.15	Myopia;	chr2:171826102	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.874	rs62182372	ENSG00000228389.1	AC068039.4	-3.36	0.000834	0.0463	-0.17	-0.15	Myopia;	chr2:171827977	chr2:171773482~171775844:+
THCA	cis	rs17428076	0.874	rs62182373	ENSG00000228389.1	AC068039.4	-3.36	0.000834	0.0463	-0.17	-0.15	Myopia;	chr2:171829045	chr2:171773482~171775844:+
THCA	cis	rs4713118	0.513	rs149897	ENSG00000176933.5	TOB2P1	-3.36	0.000834	0.0463	-0.18	-0.15	Parkinson's disease;	chr6:28038872	chr6:28217643~28218634:-
THCA	cis	rs11887277	0.507	rs6547254	ENSG00000231636.1	AGBL5-AS1	-3.36	0.000834	0.0464	-0.18	-0.15	Obesity-related traits;	chr2:26832750	chr2:27049683~27050264:-
THCA	cis	rs7680126	0.632	rs11731464	ENSG00000261490.1	RP11-448G15.3	-3.36	0.000834	0.0464	-0.14	-0.15	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10146752	chr4:10068089~10073019:-
THCA	cis	rs765787	0.53	rs10851423	ENSG00000259539.1	CTD-2651B20.1	-3.36	0.000834	0.0464	-0.19	-0.15	Uric acid levels;	chr15:45223752	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs12913123	ENSG00000259539.1	CTD-2651B20.1	-3.36	0.000834	0.0464	-0.19	-0.15	Uric acid levels;	chr15:45224227	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs12904331	ENSG00000259539.1	CTD-2651B20.1	-3.36	0.000834	0.0464	-0.19	-0.15	Uric acid levels;	chr15:45226095	chr15:45152664~45167526:-
THCA	cis	rs7937890	0.559	rs2575853	ENSG00000251991.1	RNU7-49P	3.36	0.000834	0.0464	0.18	0.15	Mitochondrial DNA levels;	chr11:14512417	chr11:14478892~14478953:+
THCA	cis	rs321358	0.79	rs77820525	ENSG00000271390.1	RP11-89C3.3	3.36	0.000834	0.0464	0.25	0.15	Body mass index;	chr11:111076697	chr11:111089870~111090368:-
THCA	cis	rs321358	0.848	rs73015141	ENSG00000271390.1	RP11-89C3.3	3.36	0.000834	0.0464	0.25	0.15	Body mass index;	chr11:111077556	chr11:111089870~111090368:-
THCA	cis	rs321358	0.848	rs73015142	ENSG00000271390.1	RP11-89C3.3	3.36	0.000834	0.0464	0.25	0.15	Body mass index;	chr11:111078647	chr11:111089870~111090368:-
THCA	cis	rs4683702	0.62	rs11719232	ENSG00000244124.1	ATP1B3-AS1	3.36	0.000834	0.0464	0.14	0.15	Blood protein levels;	chr3:142904187	chr3:141918252~141919021:-
THCA	cis	rs860295	0.775	rs822509	ENSG00000236675.1	MTX1P1	3.36	0.000835	0.0464	0.15	0.15	Body mass index;	chr1:155881020	chr1:155230975~155234325:+
THCA	cis	rs13113518	0.683	rs9761521	ENSG00000272969.1	RP11-528I4.2	3.36	0.000835	0.0464	0.18	0.15	Height;	chr4:55363436	chr4:55547112~55547889:+
THCA	cis	rs11992162	0.597	rs7011924	ENSG00000255046.1	RP11-297N6.4	3.36	0.000835	0.0464	0.17	0.15	Monocyte count;	chr8:11923084	chr8:11797928~11802568:-
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000264242.2	RP11-271K11.1	3.36	0.000835	0.0464	0.23	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30553697~30558962:+
THCA	cis	rs2290416	0.792	rs62522167	ENSG00000254973.1	RP11-429J17.7	3.36	0.000835	0.0464	0.3	0.15	Attention deficit hyperactivity disorder;	chr8:143595864	chr8:143758153~143771822:-
THCA	cis	rs2290416	0.892	rs62522168	ENSG00000254973.1	RP11-429J17.7	3.36	0.000835	0.0464	0.3	0.15	Attention deficit hyperactivity disorder;	chr8:143597606	chr8:143758153~143771822:-
THCA	cis	rs7759001	0.948	rs11966173	ENSG00000216676.2	RP1-15D7.1	-3.36	0.000835	0.0464	-0.2	-0.15	Glomerular filtration rate (creatinine);	chr6:27424083	chr6:27652602~27652825:-
THCA	cis	rs1529711	0.636	rs34464972	ENSG00000267100.1	ILF3-AS1	3.36	0.000835	0.0464	0.16	0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr19:10858458	chr19:10651862~10653844:-
THCA	cis	rs875971	0.545	rs6460276	ENSG00000230295.1	RP11-458F8.2	3.36	0.000835	0.0464	0.14	0.15	Aortic root size;	chr7:66182290	chr7:66880708~66882981:+
THCA	cis	rs11070836	0.711	rs12594395	ENSG00000244879.4	GABPB1-AS1	-3.36	0.000835	0.0464	-0.13	-0.15	Airway wall thickness;	chr15:51191510	chr15:50354959~50372202:+
THCA	cis	rs7737355	0.812	rs257391	ENSG00000237714.1	P4HA2-AS1	3.36	0.000835	0.0464	0.21	0.15	Life satisfaction;	chr5:131404312	chr5:132184876~132192808:+
THCA	cis	rs738144	0.821	rs5757282	ENSG00000235209.1	CTA-150C2.13	-3.36	0.000835	0.0464	-0.26	-0.15	IgG glycosylation;	chr22:38780120	chr22:38921227~38924708:+
THCA	cis	rs7621331	0.963	rs9808979	ENSG00000239213.4	NCK1-AS1	3.36	0.000835	0.0464	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:136000456	chr3:136841726~136862054:-
THCA	cis	rs7621331	1	rs9872542	ENSG00000239213.4	NCK1-AS1	3.36	0.000835	0.0464	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:136001831	chr3:136841726~136862054:-
THCA	cis	rs6828577	0.955	rs13127508	ENSG00000281731.1	RP11-384K6.8	3.36	0.000835	0.0464	0.18	0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118760088	chr4:118664087~118685341:-
THCA	cis	rs524281	0.861	rs10791856	ENSG00000255038.1	RP11-1167A19.2	-3.36	0.000835	0.0464	-0.17	-0.15	Electroencephalogram traits;	chr11:66197179	chr11:66067277~66069619:-
THCA	cis	rs12493885	0.818	rs1521324	ENSG00000238755.3	RP11-23D24.2	-3.36	0.000835	0.0464	-0.33	-0.15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154041074	chr3:153384934~153980186:-
THCA	cis	rs12493885	0.818	rs55681005	ENSG00000238755.3	RP11-23D24.2	-3.36	0.000835	0.0464	-0.33	-0.15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154041468	chr3:153384934~153980186:-
THCA	cis	rs12493885	0.818	rs73158491	ENSG00000238755.3	RP11-23D24.2	-3.36	0.000835	0.0464	-0.33	-0.15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154046323	chr3:153384934~153980186:-
THCA	cis	rs12493885	0.818	rs61791543	ENSG00000238755.3	RP11-23D24.2	-3.36	0.000835	0.0464	-0.33	-0.15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154049008	chr3:153384934~153980186:-
THCA	cis	rs11237982	0.587	rs72944361	ENSG00000255345.1	CTD-2337I7.1	-3.36	0.000835	0.0464	-0.24	-0.15	Verbal declarative memory;	chr11:79677841	chr11:79092848~79098003:+
THCA	cis	rs1926657	0.799	rs9524828	ENSG00000223298.1	RNY3P8	-3.36	0.000835	0.0464	-0.2	-0.15	Breast cancer;	chr13:95211901	chr13:95310830~95310955:-
THCA	cis	rs1926657	1	rs9516537	ENSG00000223298.1	RNY3P8	-3.36	0.000835	0.0464	-0.2	-0.15	Breast cancer;	chr13:95211906	chr13:95310830~95310955:-
THCA	cis	rs4703129	1	rs1550808	ENSG00000246763.5	RGMB-AS1	-3.36	0.000835	0.0464	-0.15	-0.15	Asperger disorder;	chr5:98556562	chr5:98769618~98773469:-
THCA	cis	rs11237982	0.543	rs2154746	ENSG00000255345.1	CTD-2337I7.1	-3.36	0.000835	0.0464	-0.24	-0.15	Verbal declarative memory;	chr11:79690238	chr11:79092848~79098003:+
THCA	cis	rs6017317	0.643	rs6031489	ENSG00000234271.1	RP1-138B7.4	-3.36	0.000835	0.0464	-0.2	-0.15	Type 2 diabetes;	chr20:44265263	chr20:43523261~43523572:-
THCA	cis	rs944289	0.74	rs404131	ENSG00000212071.1	AL162511.1	-3.36	0.000835	0.0464	-0.17	-0.15	Thyroid cancer;	chr14:36075287	chr14:36196480~36196568:-
THCA	cis	rs80130819	0.515	rs1574573	ENSG00000273765.1	RP11-370I10.11	3.36	0.000835	0.0464	0.17	0.15	Prostate cancer;	chr12:48369530	chr12:48360920~48361377:+
THCA	cis	rs7924176	0.564	rs10762588	ENSG00000232342.6	RP11-46O21.2	3.36	0.000835	0.0464	0.19	0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74506081~74530553:-
THCA	cis	rs7924176	0.564	rs4564273	ENSG00000232342.6	RP11-46O21.2	3.36	0.000835	0.0464	0.19	0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74506081~74530553:-
THCA	cis	rs4237845	0.804	rs10877034	ENSG00000270039.1	RP11-571M6.17	-3.36	0.000835	0.0464	-0.17	-0.15	Intelligence (multi-trait analysis);	chr12:57892661	chr12:57803838~57804415:+
THCA	cis	rs524281	1	rs565198	ENSG00000255038.1	RP11-1167A19.2	3.36	0.000835	0.0464	0.17	0.15	Electroencephalogram traits;	chr11:66146037	chr11:66067277~66069619:-
THCA	cis	rs6589219	0.754	rs7105857	ENSG00000196167.8	COLCA1	-3.36	0.000835	0.0464	-0.16	-0.15	Colorectal cancer;	chr11:111300019	chr11:111290787~111305045:-
THCA	cis	rs2281636	0.595	rs11190169	ENSG00000260475.1	RP11-85A1.3	3.36	0.000835	0.0464	0.16	0.15	Obesity-related traits;	chr10:99597878	chr10:99621055~99621918:+
THCA	cis	rs6840360	1	rs3749562	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000835	0.0464	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151675388	chr4:151333775~151353224:-
THCA	cis	rs912593	0.872	rs73473555	ENSG00000225179.1	LINC00457	3.36	0.000835	0.0464	0.24	0.15	Cancer;	chr13:34465752	chr13:34435450~34640685:-
THCA	cis	rs10760158	0.832	rs10513365	ENSG00000235865.2	GSN-AS1	3.36	0.000835	0.0464	0.13	0.15	Pulse pressure;	chr9:121258647	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.768	rs2149805	ENSG00000235865.2	GSN-AS1	3.36	0.000835	0.0464	0.13	0.15	Pulse pressure;	chr9:121259221	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs4837826	ENSG00000235865.2	GSN-AS1	3.36	0.000835	0.0464	0.13	0.15	Pulse pressure;	chr9:121261851	chr9:121280768~121285530:-
THCA	cis	rs8040855	0.597	rs12902942	ENSG00000229212.6	RP11-561C5.4	-3.36	0.000835	0.0464	-0.22	-0.15	Bulimia nervosa;	chr15:85041573	chr15:85205440~85234795:-
THCA	cis	rs9291683	0.527	rs73212848	ENSG00000261490.1	RP11-448G15.3	-3.36	0.000835	0.0464	-0.1	-0.15	Bone mineral density;	chr4:10091675	chr4:10068089~10073019:-
THCA	cis	rs9287719	0.699	rs4669602	ENSG00000234818.1	AC092687.5	3.36	0.000835	0.0464	0.18	0.15	Prostate cancer;	chr2:10647841	chr2:10589166~10604830:+
THCA	cis	rs73193808	0.901	rs8132759	ENSG00000273017.1	AP000240.9	3.36	0.000835	0.0464	0.18	0.15	Coronary artery disease;	chr21:29218630	chr21:29359002~29359453:+
THCA	cis	rs3735398	1	rs867171	ENSG00000271122.1	RP11-379H18.1	-3.36	0.000835	0.0464	-0.16	-0.15	Systolic blood pressure;	chr7:36353431	chr7:35695214~35699413:+
THCA	cis	rs3862188	0.6	rs59589112	ENSG00000230576.1	OR6R1P	-3.36	0.000836	0.0464	-0.13	-0.15	Pre-treatment pain in head and neck squamous cell carcinoma;	chr1:247703592	chr1:247833349~247834288:-
THCA	cis	rs944289	0.708	rs6571736	ENSG00000212071.1	AL162511.1	3.36	0.000836	0.0464	0.18	0.15	Thyroid cancer;	chr14:36111271	chr14:36196480~36196568:-
THCA	cis	rs944289	0.679	rs8016148	ENSG00000212071.1	AL162511.1	3.36	0.000836	0.0464	0.18	0.15	Thyroid cancer;	chr14:36111688	chr14:36196480~36196568:-
THCA	cis	rs944289	0.708	rs2415315	ENSG00000212071.1	AL162511.1	3.36	0.000836	0.0464	0.18	0.15	Thyroid cancer;	chr14:36115338	chr14:36196480~36196568:-
THCA	cis	rs944289	0.708	rs1475716	ENSG00000212071.1	AL162511.1	3.36	0.000836	0.0464	0.18	0.15	Thyroid cancer;	chr14:36116033	chr14:36196480~36196568:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000230295.1	RP11-458F8.2	3.36	0.000836	0.0464	0.12	0.15	Aortic root size;	chr7:66570949	chr7:66880708~66882981:+
THCA	cis	rs3617	0.573	rs12492391	ENSG00000243224.1	RP5-1157M23.2	-3.36	0.000836	0.0464	-0.16	-0.15	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52878280	chr3:52239258~52241097:+
THCA	cis	rs6142618	0.562	rs6142620	ENSG00000224452.1	RSL24D1P6	3.36	0.000836	0.0464	0.18	0.15	Inflammatory bowel disease;	chr20:32147191	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs6061206	ENSG00000224452.1	RSL24D1P6	3.36	0.000836	0.0464	0.18	0.15	Inflammatory bowel disease;	chr20:32174169	chr20:32170390~32170790:-
THCA	cis	rs6142618	0.562	rs67703205	ENSG00000224452.1	RSL24D1P6	3.36	0.000836	0.0464	0.18	0.15	Inflammatory bowel disease;	chr20:32174852	chr20:32170390~32170790:-
THCA	cis	rs7131987	0.903	rs2194519	ENSG00000273680.1	RP11-996F15.6	-3.36	0.000836	0.0464	-0.2	-0.15	QT interval;	chr12:29270650	chr12:29332733~29333383:-
THCA	cis	rs9369640	0.674	rs1332845	ENSG00000212802.4	RPL15P3	-3.36	0.000836	0.0464	-0.15	-0.15	Coronary artery disease;	chr6:12892224	chr6:12514110~12514724:+
THCA	cis	rs708224	0.713	rs326638	ENSG00000277342.1	RP11-843B15.4	3.36	0.000836	0.0464	0.2	0.15	Pancreatic cancer;	chr12:32243846	chr12:32109076~32109602:+
THCA	cis	rs9902453	0.765	rs6505143	ENSG00000214719.10	AC005562.1	3.36	0.000836	0.0464	0.14	0.15	Coffee consumption (cups per day);	chr17:29823567	chr17:30576464~30672789:+
THCA	cis	rs58688157	0.96	rs702966	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:611919	chr11:708564~727047:-
THCA	cis	rs58688157	0.96	rs1055382	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:612182	chr11:708564~727047:-
THCA	cis	rs58688157	0.921	rs12805435	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:612355	chr11:708564~727047:-
THCA	cis	rs58688157	0.96	rs10902178	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:612843	chr11:708564~727047:-
THCA	cis	rs58688157	0.96	rs1051390	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:613165	chr11:708564~727047:-
THCA	cis	rs58688157	0.96	rs12422022	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:613192	chr11:708564~727047:-
THCA	cis	rs58688157	0.96	rs1131665	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:613208	chr11:708564~727047:-
THCA	cis	rs58688157	0.774	rs59115876	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:613757	chr11:708564~727047:-
THCA	cis	rs58688157	0.96	rs1061502	ENSG00000269915.1	AP006621.9	-3.36	0.000836	0.0464	-0.17	-0.15	Systemic lupus erythematosus;	chr11:614318	chr11:708564~727047:-
THCA	cis	rs2115630	1	rs4633690	ENSG00000259295.5	CSPG4P12	-3.36	0.000836	0.0464	-0.2	-0.15	P wave terminal force;	chr15:84818729	chr15:85191438~85213905:+
THCA	cis	rs5753037	0.869	rs41160	ENSG00000279699.1	RP1-102K2.9	-3.36	0.000836	0.0464	-0.15	-0.15	Type 1 diabetes;	chr22:30011399	chr22:30275215~30276951:-
THCA	cis	rs11168187	0.622	rs757355	ENSG00000280054.1	RP1-197B17.7	3.36	0.000836	0.0464	0.19	0.15	Vertical cup-disc ratio;	chr12:47576910	chr12:47728151~47730598:-
THCA	cis	rs3733585	0.631	rs4697924	ENSG00000261490.1	RP11-448G15.3	-3.36	0.000836	0.0464	-0.1	-0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:10122615	chr4:10068089~10073019:-
THCA	cis	rs9611565	0.512	rs964898	ENSG00000237037.8	NDUFA6-AS1	3.36	0.000836	0.0464	0.14	0.15	Vitiligo;	chr22:41746302	chr22:42090931~42137742:+
THCA	cis	rs804280	0.662	rs7826055	ENSG00000254948.1	OR7E158P	3.36	0.000836	0.0464	0.2	0.15	Myopia (pathological);	chr8:11754214	chr8:11919900~11920809:-
THCA	cis	rs409045	1	rs399862	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000836	0.0464	-0.2	-0.15	Left ventricular mass;	chr5:34627728	chr5:34651457~34651888:-
THCA	cis	rs7520050	0.778	rs2934857	ENSG00000281912.1	LINC01144	-3.36	0.000836	0.0464	-0.1	-0.15	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45303910~45305619:+
THCA	cis	rs708224	0.587	rs326640	ENSG00000277342.1	RP11-843B15.4	3.36	0.000836	0.0464	0.2	0.15	Pancreatic cancer;	chr12:32246115	chr12:32109076~32109602:+
THCA	cis	rs835367	1	rs835367	ENSG00000270457.1	RP11-467C18.1	3.36	0.000836	0.0464	0.17	0.15	Obesity-related traits;	chr1:59296796	chr1:59289303~59289640:-
THCA	cis	rs7267979	0.586	rs6037057	ENSG00000274973.1	RP13-401N8.7	-3.36	0.000836	0.0464	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25845497~25845862:+
THCA	cis	rs41411047	0.826	rs112285435	ENSG00000252172.1	RNU6-720P	3.36	0.000836	0.0464	0.33	0.15	Myocardial infarction;	chr3:149829153	chr3:149917342~149917449:-
THCA	cis	rs1957429	0.901	rs3813422	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64880686	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs3813423	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64880757	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.808	rs1467573	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64880865	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs1467571	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64880964	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs1467570	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64881140	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs1467569	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64881268	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.808	rs1957436	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64881489	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs1957435	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64882979	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs1957434	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64883191	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs6573583	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64884493	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.808	rs8009510	ENSG00000272158.1	RP11-840I19.5	-3.36	0.000836	0.0464	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64884620	chr14:65003325~65003767:-
THCA	cis	rs12288023	1	rs34589365	ENSG00000255306.1	RP5-901A4.1	3.36	0.000836	0.0464	0.26	0.15	Serum metabolite levels;	chr11:67668505	chr11:68024809~68030461:-
THCA	cis	rs8056893	0.744	rs2307022	ENSG00000274698.1	RP11-71L14.4	3.36	0.000836	0.0464	0.19	0.15	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68348075	chr16:68450283~68452318:+
THCA	cis	rs62209	0.8	rs11256938	ENSG00000181800.5	CELF2-AS1	3.36	0.000836	0.0464	0.16	0.15	Alzheimer's disease (late onset);	chr10:10967097	chr10:11316834~11319884:-
THCA	cis	rs62209	0.752	rs11256939	ENSG00000181800.5	CELF2-AS1	3.36	0.000836	0.0464	0.16	0.15	Alzheimer's disease (late onset);	chr10:10967203	chr10:11316834~11319884:-
THCA	cis	rs9532580	0.62	rs2701859	ENSG00000275149.1	RP11-427J23.1	-3.36	0.000836	0.0464	-0.21	-0.15	Mean corpuscular hemoglobin;	chr13:40567095	chr13:40079106~40273509:-
THCA	cis	rs1832871	0.711	rs9459769	ENSG00000213078.3	RP5-933K21.2	-3.36	0.000836	0.0464	-0.23	-0.15	Height;	chr6:158245461	chr6:157365990~157366923:-
THCA	cis	rs2290416	0.892	rs76108894	ENSG00000254973.1	RP11-429J17.7	3.36	0.000836	0.0464	0.3	0.15	Attention deficit hyperactivity disorder;	chr8:143591363	chr8:143758153~143771822:-
THCA	cis	rs818427	0.508	rs6867243	ENSG00000270067.1	CTC-487M23.5	3.36	0.000836	0.0464	0.13	0.15	Total body bone mineral density;	chr5:112764330	chr5:112893333~112894001:+
THCA	cis	rs10022260	1	rs10022260	ENSG00000251022.5	THAP9-AS1	-3.36	0.000836	0.0464	-0.18	-0.15	Adult asthma;	chr4:82872768	chr4:82893009~82900960:-
THCA	cis	rs9902453	0.765	rs2264302	ENSG00000263603.1	CTD-2349P21.5	-3.36	0.000836	0.0464	-0.18	-0.15	Coffee consumption (cups per day);	chr17:29730077	chr17:30729469~30731202:+
THCA	cis	rs9902453	0.765	rs2447935	ENSG00000263603.1	CTD-2349P21.5	-3.36	0.000836	0.0464	-0.18	-0.15	Coffee consumption (cups per day);	chr17:29730506	chr17:30729469~30731202:+
THCA	cis	rs642803	0.933	rs644740	ENSG00000255557.1	RP11-770G2.2	-3.36	0.000836	0.0464	-0.17	-0.15	Urate levels;	chr11:65793997	chr11:65745729~65771585:+
THCA	cis	rs16975963	0.843	rs75802547	ENSG00000276846.1	CTD-3220F14.3	-3.36	0.000836	0.0464	-0.14	-0.15	Longevity;	chr19:37902681	chr19:37314868~37315620:-
THCA	cis	rs9549260	0.755	rs9549255	ENSG00000275149.1	RP11-427J23.1	-3.36	0.000836	0.0464	-0.2	-0.15	Red blood cell count;	chr13:40661076	chr13:40079106~40273509:-
THCA	cis	rs2055375	0.594	rs159542	ENSG00000251279.1	CTC-436P18.1	-3.36	0.000836	0.0464	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:61189951	chr5:61162070~61232040:+
THCA	cis	rs3096299	0.542	rs1078578	ENSG00000260259.1	RP11-368I7.4	3.36	0.000836	0.0464	0.17	0.15	Multiple myeloma (IgH translocation);	chr16:89320526	chr16:89682620~89686569:-
THCA	cis	rs34792	0.554	rs12929694	ENSG00000207425.1	Y_RNA	-3.36	0.000836	0.0464	-0.18	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15519840	chr16:14915457~14915556:-
THCA	cis	rs7131987	0.903	rs11050161	ENSG00000273680.1	RP11-996F15.6	3.36	0.000837	0.0464	0.21	0.15	QT interval;	chr12:29267116	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.903	rs11050162	ENSG00000273680.1	RP11-996F15.6	3.36	0.000837	0.0464	0.21	0.15	QT interval;	chr12:29267121	chr12:29332733~29333383:-
THCA	cis	rs9549260	0.755	rs17061503	ENSG00000168852.11	TPTE2P5	-3.36	0.000837	0.0465	-0.11	-0.15	Red blood cell count;	chr13:40672621	chr13:40822296~40921749:-
THCA	cis	rs10506328	0.689	rs4759348	ENSG00000257534.1	RP11-834C11.10	3.36	0.000837	0.0465	0.2	0.15	Mean platelet volume;	chr12:54236733	chr12:54162065~54164452:-
THCA	cis	rs3864261	0.887	rs62363383	ENSG00000249085.1	CTD-2631K10.1	3.36	0.000837	0.0465	0.24	0.15	Discordance in emotional problems in monozygotic twins;	chr5:72883584	chr5:72794405~72816565:-
THCA	cis	rs9923283	0.673	rs1050881	ENSG00000260167.1	RP11-146F11.5	3.36	0.000837	0.0465	0.26	0.15	Plateletcrit;	chr16:29664607	chr16:30585907~30608593:+
THCA	cis	rs7709377	0.516	rs55759160	ENSG00000271918.1	CTD-2287O16.5	3.36	0.000837	0.0465	0.15	0.15	Metabolite levels  (X-11787);	chr5:116145537	chr5:116083807~116085416:-
THCA	cis	rs1396485	0.654	rs11958647	ENSG00000271918.1	CTD-2287O16.5	3.36	0.000837	0.0465	0.15	0.15	Inflammatory biomarkers;	chr5:116146989	chr5:116083807~116085416:-
THCA	cis	rs8077889	0.869	rs11713	ENSG00000267750.4	RUNDC3A-AS1	3.36	0.000837	0.0465	0.19	0.15	Triglycerides;	chr17:43768456	chr17:44299574~44315315:-
THCA	cis	rs7572644	0.664	rs12473340	ENSG00000223522.1	AC093690.1	-3.36	0.000837	0.0465	-0.18	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27800930	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.723	rs13019037	ENSG00000223522.1	AC093690.1	-3.36	0.000837	0.0465	-0.18	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27801775	chr2:28307691~28310459:-
THCA	cis	rs7641761	0.514	rs7612363	ENSG00000237978.4	KCNMB2-AS1	3.36	0.000837	0.0465	0.19	0.15	Mean corpuscular hemoglobin;	chr3:179002440	chr3:178526505~178860405:-
THCA	cis	rs735539	1	rs9506537	ENSG00000238286.1	SLC35E1P1	3.36	0.000837	0.0465	0.17	0.15	Dental caries;	chr13:20706271	chr13:20607268~20608131:+
THCA	cis	rs17123764	0.892	rs12306430	ENSG00000257464.1	RP11-161H23.8	-3.36	0.000837	0.0465	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49730132	chr12:49442424~49442652:-
THCA	cis	rs643506	1	rs4936675	ENSG00000230911.1	PPIHP1	-3.36	0.000837	0.0465	-0.21	-0.15	Breast cancer;	chr11:111752364	chr11:112029858~112030367:-
THCA	cis	rs7246657	0.943	rs10426666	ENSG00000268499.1	CTB-102L5.8	3.36	0.000837	0.0465	0.2	0.15	Coronary artery calcification;	chr19:37337612	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs4969487	ENSG00000268499.1	CTB-102L5.8	3.36	0.000837	0.0465	0.2	0.15	Coronary artery calcification;	chr19:37340137	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs28402338	ENSG00000268499.1	CTB-102L5.8	3.36	0.000837	0.0465	0.2	0.15	Coronary artery calcification;	chr19:37343021	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs10417503	ENSG00000268499.1	CTB-102L5.8	3.36	0.000837	0.0465	0.2	0.15	Coronary artery calcification;	chr19:37351833	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs10403613	ENSG00000268499.1	CTB-102L5.8	3.36	0.000837	0.0465	0.2	0.15	Coronary artery calcification;	chr19:37353404	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs9304566	ENSG00000268499.1	CTB-102L5.8	3.36	0.000837	0.0465	0.2	0.15	Coronary artery calcification;	chr19:37354602	chr19:38199836~38200934:+
THCA	cis	rs7246657	0.943	rs4417644	ENSG00000268499.1	CTB-102L5.8	3.36	0.000837	0.0465	0.2	0.15	Coronary artery calcification;	chr19:37361570	chr19:38199836~38200934:+
THCA	cis	rs722414	0.846	rs7308186	ENSG00000258302.2	RP11-981P6.1	3.36	0.000837	0.0465	0.14	0.15	Blood protein levels;	chr12:89457317	chr12:89561129~89594878:+
THCA	cis	rs722414	0.846	rs1344683	ENSG00000258302.2	RP11-981P6.1	3.36	0.000837	0.0465	0.14	0.15	Blood protein levels;	chr12:89458668	chr12:89561129~89594878:+
THCA	cis	rs722414	0.918	rs1344684	ENSG00000258302.2	RP11-981P6.1	3.36	0.000837	0.0465	0.14	0.15	Blood protein levels;	chr12:89458895	chr12:89561129~89594878:+
THCA	cis	rs722414	0.846	rs3958726	ENSG00000258302.2	RP11-981P6.1	3.36	0.000837	0.0465	0.14	0.15	Blood protein levels;	chr12:89463646	chr12:89561129~89594878:+
THCA	cis	rs722414	0.781	rs7399300	ENSG00000258302.2	RP11-981P6.1	3.36	0.000837	0.0465	0.14	0.15	Blood protein levels;	chr12:89464719	chr12:89561129~89594878:+
THCA	cis	rs722414	0.846	rs9308287	ENSG00000258302.2	RP11-981P6.1	3.36	0.000837	0.0465	0.14	0.15	Blood protein levels;	chr12:89467488	chr12:89561129~89594878:+
THCA	cis	rs9863	0.896	rs7311233	ENSG00000269938.1	RP11-214K3.20	3.36	0.000837	0.0465	0.18	0.15	White blood cell count;	chr12:123991393	chr12:123968023~123968579:-
THCA	cis	rs6832769	0.961	rs13152650	ENSG00000223305.1	RN7SKP30	3.36	0.000837	0.0465	0.19	0.15	Personality dimensions;	chr4:55491691	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs1522110	ENSG00000223305.1	RN7SKP30	3.36	0.000837	0.0465	0.19	0.15	Personality dimensions;	chr4:55514116	chr4:55540502~55540835:-
THCA	cis	rs6715793	0.869	rs4670251	ENSG00000272754.1	AL133245.2	-3.36	0.000837	0.0465	-0.18	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33181717	chr2:32321638~32323002:+
THCA	cis	rs2749592	0.531	rs10764134	ENSG00000275858.1	RP11-291L22.8	-3.36	0.000837	0.0465	-0.18	-0.15	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38450738~38451069:-
THCA	cis	rs889014	1	rs12517986	ENSG00000253959.1	CTB-43E15.1	3.36	0.000837	0.0465	0.2	0.15	Height;	chr5:173568157	chr5:173642519~173658194:+
THCA	cis	rs8112211	0.689	rs8106900	ENSG00000267291.1	CTB-186G2.1	3.36	0.000837	0.0465	0.17	0.15	Blood protein levels;	chr19:38330401	chr19:38596346~38601694:+
THCA	cis	rs2307022	0.671	rs9928605	ENSG00000274698.1	RP11-71L14.4	3.36	0.000837	0.0465	0.18	0.15	Body mass index;	chr16:68340051	chr16:68450283~68452318:+
THCA	cis	rs2617170	0.754	rs2900421	ENSG00000245648.1	RP11-277P12.20	3.36	0.000837	0.0465	0.16	0.15	Behcet's disease;	chr12:10469448	chr12:10363769~10398506:+
THCA	cis	rs17428076	0.681	rs62183776	ENSG00000228389.1	AC068039.4	-3.36	0.000837	0.0465	-0.21	-0.15	Myopia;	chr2:171993206	chr2:171773482~171775844:+
THCA	cis	rs4604234	0.803	rs73463531	ENSG00000260645.1	RP11-250B2.5	-3.36	0.000837	0.0465	-0.25	-0.15	Cancer;	chr6:80274328	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.803	rs11961345	ENSG00000260645.1	RP11-250B2.5	-3.36	0.000837	0.0465	-0.25	-0.15	Cancer;	chr6:80294807	chr6:80466958~80469080:+
THCA	cis	rs3747767	1	rs13206818	ENSG00000233967.5	RP11-250B2.3	3.36	0.000837	0.0465	0.24	0.15	Hoarding;	chr6:79500720	chr6:80443344~80465927:+
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000281021.1	RP1-12G14.9	-3.36	0.000837	0.0465	-0.15	-0.15	Lung cancer;	chr6:149627553	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000281021.1	RP1-12G14.9	-3.36	0.000837	0.0465	-0.15	-0.15	Lung cancer;	chr6:149627691	chr6:149576089~149590864:-
THCA	cis	rs12478296	0.591	rs12719765	ENSG00000220804.7	AC093642.5	3.36	0.000838	0.0465	0.14	0.15	Obesity-related traits;	chr2:242055051	chr2:242088633~242160153:+
THCA	cis	rs2625529	0.627	rs11858015	ENSG00000260037.4	CTD-2524L6.3	-3.36	0.000838	0.0465	-0.21	-0.15	Red blood cell count;	chr15:72260151	chr15:71818396~71823384:+
THCA	cis	rs1737890	0.623	rs6087361	ENSG00000235217.6	TSPY26P	-3.36	0.000838	0.0465	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr20:32286409	chr20:32186477~32190527:-
THCA	cis	rs6902257	0.59	rs2168107	ENSG00000260645.1	RP11-250B2.5	3.36	0.000838	0.0465	0.28	0.15	Obesity-related traits;	chr6:80600723	chr6:80466958~80469080:+
THCA	cis	rs1552244	0.554	rs59465469	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000838	0.0465	0.11	0.15	Alzheimer's disease;	chr3:9949116	chr3:9958717~9962539:+
THCA	cis	rs8014204	0.935	rs3742786	ENSG00000279594.1	RP11-950C14.10	-3.36	0.000838	0.0465	-0.15	-0.15	Caffeine consumption;	chr14:74906308	chr14:75011269~75012851:-
THCA	cis	rs4683346	0.731	rs11129983	ENSG00000273328.4	RP11-141M3.6	-3.36	0.000838	0.0465	-0.21	-0.15	Granulocyte percentage of myeloid white cells;	chr3:42883191	chr3:42809414~42908105:+
THCA	cis	rs10483853	0.747	rs17126867	ENSG00000258891.1	RP5-1021I20.5	-3.36	0.000838	0.0465	-0.2	-0.15	Coronary artery calcification;	chr14:73324563	chr14:73896164~73938114:-
THCA	cis	rs10754283	0.967	rs1320563	ENSG00000237505.5	PKN2-AS1	-3.36	0.000838	0.0465	-0.18	-0.15	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:88537513~88685204:-
THCA	cis	rs688181	0.621	rs9347482	ENSG00000271040.1	RP5-933K21.3	-3.36	0.000838	0.0465	-0.19	-0.15	Platelet distribution width;	chr6:157678704	chr6:157323964~157324477:+
THCA	cis	rs6120849	0.754	rs6088682	ENSG00000269202.1	RP4-614O4.12	-3.36	0.000838	0.0465	-0.17	-0.15	Protein C levels;	chr20:35027899	chr20:35201747~35203288:-
THCA	cis	rs660899	0.857	rs10890280	ENSG00000228452.1	RP5-994D16.9	-3.36	0.000838	0.0465	-0.19	-0.15	Hypertension risk in short sleep duration;	chr1:43772547	chr1:42775813~42776790:-
THCA	cis	rs9863	0.828	rs11057413	ENSG00000269938.1	RP11-214K3.20	-3.36	0.000838	0.0465	-0.18	-0.15	White blood cell count;	chr12:124004615	chr12:123968023~123968579:-
THCA	cis	rs9611519	0.603	rs9607764	ENSG00000184068.2	RP5-821D11.7	3.36	0.000838	0.0465	0.13	0.15	Neuroticism;	chr22:41015800	chr22:41831215~41834665:-
THCA	cis	rs9611519	0.589	rs8138917	ENSG00000184068.2	RP5-821D11.7	3.36	0.000838	0.0465	0.13	0.15	Neuroticism;	chr22:41016421	chr22:41831215~41834665:-
THCA	cis	rs9611519	0.58	rs8138349	ENSG00000184068.2	RP5-821D11.7	3.36	0.000838	0.0465	0.13	0.15	Neuroticism;	chr22:41016719	chr22:41831215~41834665:-
THCA	cis	rs9611519	0.602	rs8138520	ENSG00000184068.2	RP5-821D11.7	3.36	0.000838	0.0465	0.13	0.15	Neuroticism;	chr22:41016924	chr22:41831215~41834665:-
THCA	cis	rs1799949	0.965	rs799917	ENSG00000279602.1	CTD-3014M21.1	-3.36	0.000838	0.0465	-0.19	-0.15	Menopause (age at onset);	chr17:43092919	chr17:43360041~43361361:-
THCA	cis	rs13099587	0.636	rs9880682	ENSG00000279320.1	RP11-329N15.3	-3.36	0.000838	0.0465	-0.25	-0.15	Gut microbiota (beta diversity);	chr3:146532774	chr3:146504570~146506560:-
THCA	cis	rs13099587	0.636	rs60601385	ENSG00000279320.1	RP11-329N15.3	-3.36	0.000838	0.0465	-0.25	-0.15	Gut microbiota (beta diversity);	chr3:146533750	chr3:146504570~146506560:-
THCA	cis	rs11955398	0.563	rs1117676	ENSG00000250148.1	KRT8P31	-3.36	0.000838	0.0465	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60738997	chr5:60743563~60744970:-
THCA	cis	rs4262150	0.81	rs4958562	ENSG00000253921.1	CTB-113P19.3	3.36	0.000838	0.0465	0.2	0.15	Bipolar disorder and schizophrenia;	chr5:152585029	chr5:151753992~151767247:+
THCA	cis	rs4808199	0.847	rs34647936	ENSG00000267481.1	CTC-559E9.5	-3.36	0.000838	0.0465	-0.15	-0.15	Nonalcoholic fatty liver disease;	chr19:19437430	chr19:19788755~19790531:-
THCA	cis	rs11638815	0.603	rs2678448	ENSG00000259429.4	UBE2Q2P2	-3.36	0.000838	0.0465	-0.13	-0.15	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82594655	chr15:82355142~82420075:+
THCA	cis	rs3127553	0.526	rs3905052	ENSG00000242267.5	SKINTL	3.36	0.000838	0.0465	0.21	0.15	Waist circumference;	chr1:48998253	chr1:48096092~48182428:-
THCA	cis	rs13136331	0.641	rs2732174	ENSG00000249001.4	RP11-742B18.1	3.36	0.000838	0.0465	0.2	0.15	Sitting height ratio;	chr4:87761758	chr4:87568035~87733956:-
THCA	cis	rs4853525	0.59	rs10198852	ENSG00000235852.1	AC005540.3	3.36	0.000838	0.0465	0.17	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190863606	chr2:190880797~190882059:-
THCA	cis	rs1334893	0.867	rs619223	ENSG00000215409.4	RP11-748L13.2	3.36	0.000838	0.0465	0.31	0.15	Fasting blood insulin (BMI interaction);	chr10:27429912	chr10:27331357~27341252:-
THCA	cis	rs72781680	0.611	rs56113233	ENSG00000223754.1	AC008073.9	-3.36	0.000838	0.0465	-0.24	-0.15	Lymphocyte counts;	chr2:24118215	chr2:24199839~24201698:-
THCA	cis	rs17407555	0.71	rs7696388	ENSG00000250413.1	RP11-448G15.1	-3.36	0.000838	0.0465	-0.17	-0.15	Schizophrenia (age at onset);	chr4:10271309	chr4:10006482~10009725:+
THCA	cis	rs3930017	1	rs7783809	ENSG00000233448.2	PMS2P9	3.36	0.000839	0.0465	0.18	0.15	Body mass index;	chr7:77090234	chr7:77039944~77043776:+
THCA	cis	rs10863936	0.667	rs7525895	ENSG00000198468.6	FLVCR1-AS1	-3.36	0.000839	0.0465	-0.18	-0.15	Height;	chr1:212097077	chr1:212852108~212858088:-
THCA	cis	rs10863936	0.667	rs1387814	ENSG00000198468.6	FLVCR1-AS1	-3.36	0.000839	0.0465	-0.18	-0.15	Height;	chr1:212103962	chr1:212852108~212858088:-
THCA	cis	rs3747767	0.655	rs66572100	ENSG00000233967.5	RP11-250B2.3	3.36	0.000839	0.0465	0.24	0.15	Hoarding;	chr6:79523799	chr6:80443344~80465927:+
THCA	cis	rs3747767	1	rs72624517	ENSG00000233967.5	RP11-250B2.3	3.36	0.000839	0.0465	0.24	0.15	Hoarding;	chr6:79527970	chr6:80443344~80465927:+
THCA	cis	rs3747767	1	rs9341781	ENSG00000233967.5	RP11-250B2.3	3.36	0.000839	0.0465	0.24	0.15	Hoarding;	chr6:79528879	chr6:80443344~80465927:+
THCA	cis	rs2014572	0.967	rs10412975	ENSG00000268379.1	CTC-360J11.4	3.36	0.000839	0.0465	0.18	0.15	Hyperactive-impulsive symptoms;	chr19:57259186	chr19:57175233~57177921:+
THCA	cis	rs11775334	0.573	rs12547440	ENSG00000261451.1	RP11-981G7.1	3.36	0.000839	0.0465	0.22	0.15	Hypertension;	chr8:10223497	chr8:10433672~10438312:+
THCA	cis	rs9910816	0.614	rs3785602	ENSG00000207561.1	MIR635	-3.36	0.000839	0.0465	-0.18	-0.15	Bipolar disorder (inflammation and infection response interaction);	chr17:68360742	chr17:68424451~68424548:-
THCA	cis	rs1348850	0.526	rs2293475	ENSG00000280374.1	RP11-337N6.3	3.36	0.000839	0.0465	0.26	0.15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177543169	chr2:177317715~177318471:-
THCA	cis	rs8114671	0.967	rs2069945	ENSG00000279253.1	RP4-614O4.13	-3.36	0.000839	0.0466	-0.24	-0.15	Height;	chr20:35174034	chr20:35262727~35264187:-
THCA	cis	rs6586163	1	rs1926195	ENSG00000261438.1	RP11-399O19.9	3.36	0.000839	0.0466	0.12	0.15	Chronic lymphocytic leukemia;	chr10:88994001	chr10:89015836~89017059:+
THCA	cis	rs703842	0.616	rs10783851	ENSG00000270039.1	RP11-571M6.17	3.36	0.000839	0.0466	0.19	0.15	Multiple sclerosis;	chr12:57837372	chr12:57803838~57804415:+
THCA	cis	rs6743226	0.521	rs12474449	ENSG00000223374.1	AC005104.3	3.36	0.000839	0.0466	0.11	0.15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241279274	chr2:241351340~241353104:-
THCA	cis	rs11710088	0.74	rs34394409	ENSG00000244503.1	RP11-278L15.6	3.36	0.000839	0.0466	0.22	0.15	QRS duration;	chr3:149477439	chr3:149494660~149495995:+
THCA	cis	rs4568518	0.587	rs4576329	ENSG00000279048.1	RP11-511H23.2	3.36	0.000839	0.0466	0.1	0.15	Measles;	chr7:17967529	chr7:17940503~17942922:+
THCA	cis	rs7739264	0.602	rs6916251	ENSG00000228412.5	RP4-625H18.2	3.36	0.000839	0.0466	0.19	0.15	Endometriosis;	chr6:19760984	chr6:19802164~19804752:-
THCA	cis	rs7586879	0.616	rs12713422	ENSG00000224165.4	DNAJC27-AS1	-3.36	0.000839	0.0466	-0.09	-0.15	Body mass index;	chr2:24911628	chr2:24971390~25039694:+
THCA	cis	rs758324	0.947	rs72793241	ENSG00000224431.1	AC063976.7	-3.36	0.000839	0.0466	-0.14	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131905192	chr5:132199456~132203487:+
THCA	cis	rs7911264	1	rs10882100	ENSG00000232709.1	MARK2P9	-3.36	0.000839	0.0466	-0.18	-0.15	Inflammatory bowel disease;	chr10:92700930	chr10:92418667~92420875:+
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000281021.1	RP1-12G14.9	-3.36	0.000839	0.0466	-0.15	-0.15	Lung cancer;	chr6:149678086	chr6:149576089~149590864:-
THCA	cis	rs6828577	0.819	rs298975	ENSG00000248280.1	RP11-33B1.2	3.36	0.000839	0.0466	0.13	0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118715240	chr4:119440561~119450157:-
THCA	cis	rs34779708	0.931	rs11010132	ENSG00000233200.1	RP11-324I22.2	3.36	0.000839	0.0466	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35219894~35230598:-
THCA	cis	rs7772697	0.632	rs7742644	ENSG00000223701.3	RAET1E-AS1	-3.36	0.000839	0.0466	-0.21	-0.15	Diabetic retinopathy;	chr6:149105160	chr6:149884431~149919508:+
THCA	cis	rs7542813	1	rs638797	ENSG00000272195.1	RP11-156E8.1	3.36	0.000839	0.0466	0.36	0.15	Post bronchodilator FEV1 in COPD;	chr1:245054228	chr1:244969350~244971088:-
THCA	cis	rs2839186	0.56	rs9975345	ENSG00000228137.1	AP001469.7	-3.36	0.000839	0.0466	-0.16	-0.15	Testicular germ cell tumor;	chr21:46423090	chr21:46246890~46247682:+
THCA	cis	rs1005277	0.579	rs2474571	ENSG00000099251.13	HSD17B7P2	3.36	0.00084	0.0466	0.13	0.15	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38356380~38378505:+
THCA	cis	rs2688608	0.736	rs2227566	ENSG00000271816.1	BMS1P4	3.36	0.00084	0.0466	0.15	0.15	Inflammatory bowel disease;	chr10:73913973	chr10:73699151~73730487:-
THCA	cis	rs2406342	0.511	rs472676	ENSG00000278107.1	RP11-162A12.4	3.36	0.00084	0.0466	0.13	0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);	chr18:76895968	chr18:76805151~76805736:-
THCA	cis	rs775227	0.935	rs56163361	ENSG00000243849.1	CFAP44-AS1	3.36	0.00084	0.0466	0.28	0.15	Dental caries;	chr3:113256674	chr3:113403991~113433992:+
THCA	cis	rs1862618	0.713	rs832549	ENSG00000234553.1	AC022431.3	-3.36	0.00084	0.0466	-0.18	-0.15	Initial pursuit acceleration;	chr5:56887715	chr5:56536583~56537826:-
THCA	cis	rs2318131	0.965	rs2117837	ENSG00000222032.1	AC112721.2	3.36	0.00084	0.0466	0.16	0.15	Motion sickness;	chr2:237011601	chr2:237428920~237434822:-
THCA	cis	rs9650657	0.707	rs2005309	ENSG00000255310.2	AF131215.2	-3.36	0.00084	0.0466	-0.13	-0.15	Neuroticism;	chr8:10794660	chr8:11107788~11109726:-
THCA	cis	rs4730276	0.674	rs2237686	ENSG00000241764.3	AC002467.7	3.36	0.00084	0.0466	0.13	0.15	Ulcerative colitis;	chr7:107934717	chr7:107742817~107744581:-
THCA	cis	rs465969	0.793	rs7752225	ENSG00000230177.1	RP5-1112D6.4	-3.36	0.00084	0.0466	-0.24	-0.15	Psoriasis;	chr6:111459412	chr6:111277932~111278742:+
THCA	cis	rs465969	1	rs35856111	ENSG00000230177.1	RP5-1112D6.4	3.36	0.00084	0.0466	0.24	0.15	Psoriasis;	chr6:111452265	chr6:111277932~111278742:+
THCA	cis	rs465969	0.744	rs13220692	ENSG00000230177.1	RP5-1112D6.4	3.36	0.00084	0.0466	0.24	0.15	Psoriasis;	chr6:111455836	chr6:111277932~111278742:+
THCA	cis	rs12476592	0.602	rs262536	ENSG00000242412.1	DBIL5P2	3.36	0.00084	0.0466	0.2	0.15	Childhood ear infection;	chr2:63679792	chr2:63117851~63119542:-
THCA	cis	rs714027	0.605	rs5753025	ENSG00000279699.1	RP1-102K2.9	-3.36	0.00084	0.0466	-0.15	-0.15	Lymphocyte counts;	chr22:30146168	chr22:30275215~30276951:-
THCA	cis	rs714027	0.605	rs1468176	ENSG00000279699.1	RP1-102K2.9	-3.36	0.00084	0.0466	-0.15	-0.15	Lymphocyte counts;	chr22:30148527	chr22:30275215~30276951:-
THCA	cis	rs12101261	1	rs12101261	ENSG00000259167.2	NMNAT1P1	3.36	0.00084	0.0466	0.17	0.15	Graves' disease;	chr14:80984885	chr14:81032529~81033404:+
THCA	cis	rs7020830	0.931	rs13295115	ENSG00000260100.1	RP11-220I1.5	-3.36	0.00084	0.0466	-0.19	-0.15	Schizophrenia;	chr9:37157967	chr9:37078813~37079776:-
THCA	cis	rs939960	0.959	rs2888662	ENSG00000276538.1	RP11-545G3.2	3.36	0.00084	0.0466	0.22	0.15	Neutrophil percentage of white cells;	chr7:150593085	chr7:150047609~150047854:-
THCA	cis	rs7737355	0.853	rs26004	ENSG00000237714.1	P4HA2-AS1	3.36	0.00084	0.0466	0.21	0.15	Life satisfaction;	chr5:131653262	chr5:132184876~132192808:+
THCA	cis	rs7737355	0.812	rs31591	ENSG00000237714.1	P4HA2-AS1	3.36	0.00084	0.0466	0.21	0.15	Life satisfaction;	chr5:131669945	chr5:132184876~132192808:+
THCA	cis	rs1864585	0.52	rs56109041	ENSG00000280294.1	RP11-177H2.1	3.36	0.00084	0.0466	0.16	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10799644	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs73208756	ENSG00000280294.1	RP11-177H2.1	3.36	0.00084	0.0466	0.16	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10800025	chr8:10856085~10859436:-
THCA	cis	rs1864585	0.52	rs73208757	ENSG00000280294.1	RP11-177H2.1	3.36	0.00084	0.0466	0.16	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10801206	chr8:10856085~10859436:-
THCA	cis	rs7226408	0.6	rs1246627	ENSG00000267707.2	RP11-95O2.5	-3.36	0.00084	0.0466	-0.15	-0.15	Obesity-related traits;	chr18:36889574	chr18:37243776~37247506:+
THCA	cis	rs785830	0.506	rs684092	ENSG00000231808.2	LINC01388	-3.36	0.00084	0.0466	-0.18	-0.15	Platelet distribution width;	chr9:240321	chr9:112713~113754:-
THCA	cis	rs2014572	0.967	rs10413037	ENSG00000276449.1	AC004076.5	3.36	0.00084	0.0466	0.14	0.15	Hyperactive-impulsive symptoms;	chr19:57260515	chr19:57449689~57453011:+
THCA	cis	rs7589561	0.543	rs12470376	ENSG00000272861.1	RP11-332H14.1	-3.36	0.00084	0.0466	-0.2	-0.15	Addiction;	chr2:105779921	chr2:105249404~105249794:-
THCA	cis	rs12612619	0.732	rs11679681	ENSG00000231636.1	AGBL5-AS1	3.36	0.00084	0.0466	0.18	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27075611	chr2:27049683~27050264:-
THCA	cis	rs9925964	0.933	rs4889530	ENSG00000262766.1	RP11-196G11.4	-3.36	0.00084	0.0466	-0.1	-0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31118078~31118747:+
THCA	cis	rs7542375	0.655	rs11590376	ENSG00000238078.1	LINC01352	-3.36	0.00084	0.0466	-0.23	-0.15	Obesity-related traits;	chr1:220913142	chr1:220829255~220832429:+
THCA	cis	rs2638953	0.924	rs11049607	ENSG00000247934.4	RP11-967K21.1	-3.36	0.00084	0.0466	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444574	chr12:28163298~28190738:-
THCA	cis	rs4578769	0.569	rs9955139	ENSG00000273232.1	RP11-370A5.2	3.36	0.00084	0.0466	0.21	0.15	Eosinophil percentage of white cells;	chr18:23048189	chr18:22882825~22883357:-
THCA	cis	rs208520	1	rs12190187	ENSG00000233859.2	ADH5P4	3.36	0.00084	0.0466	0.24	0.15	Exhaled nitric oxide output;	chr6:66263314	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs72882079	ENSG00000233859.2	ADH5P4	3.36	0.00084	0.0466	0.24	0.15	Exhaled nitric oxide output;	chr6:66263985	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs72882086	ENSG00000233859.2	ADH5P4	3.36	0.00084	0.0466	0.24	0.15	Exhaled nitric oxide output;	chr6:66266778	chr6:65836930~65838039:-
THCA	cis	rs12900413	0.879	rs2165072	ENSG00000259561.1	RP11-300G22.2	3.36	0.00084	0.0466	0.18	0.15	Coronary artery aneurysm in Kawasaki disease;	chr15:89759398	chr15:89704665~89705415:+
THCA	cis	rs1580019	0.563	rs13244332	ENSG00000273014.1	RP11-225B17.2	3.36	0.00084	0.0466	0.16	0.15	Cognitive ability;	chr7:32498067	chr7:32758882~32759353:+
THCA	cis	rs7246657	0.943	rs7408563	ENSG00000268499.1	CTB-102L5.8	3.36	0.00084	0.0466	0.2	0.15	Coronary artery calcification;	chr19:37317683	chr19:38199836~38200934:+
THCA	cis	rs7122539	0.647	rs7120256	ENSG00000275484.1	CTC-1337H24.4	-3.36	0.000841	0.0466	-0.13	-0.15	HIV-1 susceptibility;	chr11:66882777	chr11:67374416~67374932:+
THCA	cis	rs7520050	0.902	rs1355642	ENSG00000281133.1	AL355480.3	3.36	0.000841	0.0466	0.18	0.15	Reticulocyte count;Red blood cell count;	chr1:46133231	chr1:45580892~45580996:-
THCA	cis	rs7572733	0.592	rs17731449	ENSG00000231621.1	AC013264.2	-3.36	0.000841	0.0466	-0.14	-0.15	Dermatomyositis;	chr2:197601116	chr2:197197991~197199273:+
THCA	cis	rs2300747	0.872	rs12044773	ENSG00000177173.5	NAP1L4P1	-3.36	0.000841	0.0466	-0.22	-0.15	Primary biliary cholangitis;Multiple sclerosis;	chr1:116544880	chr1:116532936~116534092:-
THCA	cis	rs987724	0.571	rs7641929	ENSG00000241544.1	RP11-6F2.5	-3.36	0.000841	0.0466	-0.19	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:157081841~157088547:+
THCA	cis	rs987724	0.531	rs12492804	ENSG00000241544.1	RP11-6F2.5	-3.36	0.000841	0.0466	-0.19	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:157081841~157088547:+
THCA	cis	rs987724	0.592	rs12497539	ENSG00000241544.1	RP11-6F2.5	-3.36	0.000841	0.0466	-0.19	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:157081841~157088547:+
THCA	cis	rs987724	0.571	rs59717073	ENSG00000241544.1	RP11-6F2.5	-3.36	0.000841	0.0466	-0.19	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:157081841~157088547:+
THCA	cis	rs3768792	0.665	rs67400233	ENSG00000196096.3	AC079610.2	3.36	0.000841	0.0466	0.22	0.15	Systemic lupus erythematosus;	chr2:212982237	chr2:213276552~213284205:-
THCA	cis	rs3768792	0.665	rs66854452	ENSG00000196096.3	AC079610.2	3.36	0.000841	0.0466	0.22	0.15	Systemic lupus erythematosus;	chr2:212982241	chr2:213276552~213284205:-
THCA	cis	rs2179367	1	rs2179367	ENSG00000268592.3	RAET1E-AS1	3.36	0.000841	0.0466	0.2	0.15	Dupuytren's disease;	chr6:149441401	chr6:149863494~149919507:+
THCA	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	3.36	0.000841	0.0466	0.18	0.15	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
THCA	cis	rs2859741	0.546	rs2102087	ENSG00000232273.1	FTH1P1	-3.36	0.000841	0.0466	-0.19	-0.15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);	chr1:37017248	chr1:37544763~37545294:+
THCA	cis	rs7560272	0.501	rs2421676	ENSG00000230002.2	ALMS1-IT1	-3.36	0.000841	0.0466	-0.18	-0.15	Schizophrenia;	chr2:73738960	chr2:73456764~73459484:+
THCA	cis	rs250518	0.692	rs10074296	ENSG00000251467.1	CTC-250P20.2	3.36	0.000841	0.0466	0.21	0.15	Mean corpuscular hemoglobin concentration;	chr5:72791089	chr5:72996920~72997642:+
THCA	cis	rs7631605	0.586	rs11708807	ENSG00000224080.1	UBE2FP1	3.36	0.000841	0.0466	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37370760	chr3:37143512~37143958:-
THCA	cis	rs2486288	0.656	rs2413768	ENSG00000259479.5	SORD2P	-3.36	0.000841	0.0466	-0.16	-0.15	Glomerular filtration rate;	chr15:45269786	chr15:44826371~44884694:-
THCA	cis	rs7200786	0.609	rs12598008	ENSG00000274038.1	RP11-66H6.4	-3.36	0.000841	0.0466	-0.19	-0.15	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10945836	chr16:11056556~11057034:+
THCA	cis	rs7819412	0.74	rs11250119	ENSG00000154316.13	TDH	3.36	0.000841	0.0466	0.11	0.15	Triglycerides;	chr8:11179525	chr8:11339637~11368452:+
THCA	cis	rs3785574	0.924	rs2584641	ENSG00000279369.1	RP11-51F16.1	3.36	0.000841	0.0466	0.11	0.15	Height;	chr17:63785529	chr17:63700847~63702670:+
THCA	cis	rs12101261	0.744	rs72693080	ENSG00000258915.1	BHLHB9P1	-3.36	0.000841	0.0467	-0.19	-0.15	Graves' disease;	chr14:80987375	chr14:80981988~80983638:+
THCA	cis	rs12101261	0.744	rs2024427	ENSG00000258915.1	BHLHB9P1	-3.36	0.000841	0.0467	-0.19	-0.15	Graves' disease;	chr14:80987892	chr14:80981988~80983638:+
THCA	cis	rs13006863	0.527	rs12196	ENSG00000225439.2	BOLA3-AS1	3.36	0.000841	0.0467	0.19	0.15	Immune reponse to smallpox (secreted TNF-alpha);Post-traumatic stress disorder (asjusted for relatedness);	chr2:74214672	chr2:74148009~74150061:+
THCA	cis	rs8027587	1	rs12148772	ENSG00000271997.1	RP11-97O12.6	3.36	0.000841	0.0467	0.1	0.15	Obesity-related traits;	chr15:88706334	chr15:88501944~88505787:-
THCA	cis	rs3758911	0.894	rs10789620	ENSG00000255353.1	RP11-382M14.1	-3.36	0.000841	0.0467	-0.2	-0.15	Coronary artery disease;	chr11:107334700	chr11:107176286~107177530:+
THCA	cis	rs35791980	0.82	rs11764672	ENSG00000273341.1	RP5-899E9.1	-3.36	0.000841	0.0467	-0.17	-0.15	Pursuit maintenance gain;	chr7:77319874	chr7:77416673~77425443:+
THCA	cis	rs5753037	0.585	rs5752962	ENSG00000279699.1	RP1-102K2.9	3.36	0.000841	0.0467	0.14	0.15	Type 1 diabetes;	chr22:29792256	chr22:30275215~30276951:-
THCA	cis	rs7647973	0.925	rs6446257	ENSG00000244380.1	RP11-24C3.2	-3.36	0.000841	0.0467	-0.21	-0.15	Menarche (age at onset);	chr3:49216059	chr3:48440352~48446656:-
THCA	cis	rs340849	0.503	rs12733434	ENSG00000274895.1	RP11-478J18.2	3.36	0.000841	0.0467	0.13	0.15	Alzheimer's disease;	chr1:213962654	chr1:213983793~213986419:-
THCA	cis	rs4578769	0.759	rs9951356	ENSG00000265939.1	UBE2CP2	-3.36	0.000841	0.0467	-0.19	-0.15	Eosinophil percentage of white cells;	chr18:23059786	chr18:22900486~22900995:-
THCA	cis	rs9549260	0.876	rs9549258	ENSG00000229456.1	RLIMP1	3.36	0.000841	0.0467	0.22	0.15	Red blood cell count;	chr13:40673889	chr13:40618738~40621348:+
THCA	cis	rs3015497	0.616	rs6572678	ENSG00000270062.1	RP11-248J18.3	3.36	0.000841	0.0467	0.17	0.15	Mean platelet volume;	chr14:50623397	chr14:50723777~50724272:-
THCA	cis	rs3015497	0.616	rs4901044	ENSG00000270062.1	RP11-248J18.3	3.36	0.000841	0.0467	0.17	0.15	Mean platelet volume;	chr14:50623577	chr14:50723777~50724272:-
THCA	cis	rs72827839	0.802	rs16953925	ENSG00000278765.1	RP5-890E16.5	-3.36	0.000841	0.0467	-0.23	-0.15	Ease of getting up in the morning;	chr17:48217136	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.846	rs16954078	ENSG00000278765.1	RP5-890E16.5	-3.36	0.000841	0.0467	-0.23	-0.15	Ease of getting up in the morning;	chr17:48228765	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.846	rs16954204	ENSG00000278765.1	RP5-890E16.5	-3.36	0.000841	0.0467	-0.23	-0.15	Ease of getting up in the morning;	chr17:48237836	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.74	rs10514938	ENSG00000278765.1	RP5-890E16.5	-3.36	0.000841	0.0467	-0.23	-0.15	Ease of getting up in the morning;	chr17:48245242	chr17:48066704~48067293:-
THCA	cis	rs7871764	0.552	rs13290822	ENSG00000281128.1	PTENP1-AS	3.36	0.000841	0.0467	0.26	0.15	Height;	chr9:33803044	chr9:33677268~33688011:+
THCA	cis	rs12893668	0.603	rs12896171	ENSG00000258735.1	LINC00637	-3.36	0.000841	0.0467	-0.2	-0.15	Reticulocyte count;	chr14:103669629	chr14:103847721~103858049:+
THCA	cis	rs12893668	0.572	rs12590968	ENSG00000258735.1	LINC00637	-3.36	0.000841	0.0467	-0.2	-0.15	Reticulocyte count;	chr14:103670296	chr14:103847721~103858049:+
THCA	cis	rs12893668	0.572	rs11540512	ENSG00000258735.1	LINC00637	-3.36	0.000841	0.0467	-0.2	-0.15	Reticulocyte count;	chr14:103681040	chr14:103847721~103858049:+
THCA	cis	rs12893668	0.572	rs35011804	ENSG00000258735.1	LINC00637	-3.36	0.000841	0.0467	-0.2	-0.15	Reticulocyte count;	chr14:103685063	chr14:103847721~103858049:+
THCA	cis	rs4664293	0.967	rs1006192	ENSG00000230783.1	AC009961.2	-3.36	0.000841	0.0467	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159711078	chr2:159689217~159690291:-
THCA	cis	rs929354	0.772	rs2051876	ENSG00000224629.1	RP5-1142J19.2	3.36	0.000842	0.0467	0.15	0.15	Body mass index;	chr7:157216343	chr7:157263022~157263229:-
THCA	cis	rs4604234	0.803	rs73463522	ENSG00000260645.1	RP11-250B2.5	-3.36	0.000842	0.0467	-0.25	-0.15	Cancer;	chr6:80270041	chr6:80466958~80469080:+
THCA	cis	rs3771570	0.901	rs62190415	ENSG00000223374.1	AC005104.3	-3.36	0.000842	0.0467	-0.15	-0.15	Prostate cancer;	chr2:241487277	chr2:241351340~241353104:-
THCA	cis	rs7833790	1	rs28696138	ENSG00000254689.1	RP11-354A14.1	-3.36	0.000842	0.0467	-0.19	-0.15	Diastolic blood pressure;	chr8:81858559	chr8:81885377~81923193:+
THCA	cis	rs6001982	0.915	rs28567076	ENSG00000199865.1	RNU6-495P	3.36	0.000842	0.0467	0.28	0.15	Breast cancer;	chr22:40588794	chr22:41377177~41377283:-
THCA	cis	rs7005380	0.62	rs7459671	ENSG00000279347.1	RP11-85I17.2	-3.36	0.000842	0.0467	-0.17	-0.15	Interstitial lung disease;	chr8:119896646	chr8:119838736~119840385:-
THCA	cis	rs6137726	0.652	rs6036175	ENSG00000237396.1	LINC01384	3.36	0.000842	0.0467	0.13	0.15	Amyotrophic lateral sclerosis (sporadic);	chr20:22682100	chr20:22587522~22607517:-
THCA	cis	rs73459955	0.712	rs56200331	ENSG00000248441.5	LINC01197	3.36	0.000842	0.0467	0.2	0.15	Major depression and alcohol dependence;	chr15:95074725	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs56293195	ENSG00000248441.5	LINC01197	3.36	0.000842	0.0467	0.2	0.15	Major depression and alcohol dependence;	chr15:95074750	chr15:95209099~95327129:-
THCA	cis	rs73459955	0.712	rs56099352	ENSG00000248441.5	LINC01197	3.36	0.000842	0.0467	0.2	0.15	Major depression and alcohol dependence;	chr15:95074764	chr15:95209099~95327129:-
THCA	cis	rs6471393	0.929	rs4734252	ENSG00000261437.1	RP11-22C11.2	3.36	0.000842	0.0467	0.14	0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744286	chr8:94637285~94639467:-
THCA	cis	rs8073060	0.586	rs8074800	ENSG00000255987.1	TOMM20P2	3.36	0.000842	0.0467	0.17	0.15	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35652129	chr17:35514766~35515186:-
THCA	cis	rs7267979	0.528	rs6076366	ENSG00000277938.1	RP5-965G21.3	-3.36	0.000842	0.0467	-0.13	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:25229150~25231933:+
THCA	cis	rs1908814	0.516	rs7812563	ENSG00000227888.4	FAM66A	3.36	0.000842	0.0467	0.2	0.15	Neuroticism;	chr8:11936979	chr8:12362019~12388296:+
THCA	cis	rs34975555	0.73	rs2299595	ENSG00000253671.1	RP11-806O11.1	-3.36	0.000842	0.0467	-0.22	-0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17945374	chr8:17808941~17820868:+
THCA	cis	rs938554	0.657	rs7660895	ENSG00000163612.10	FAM86KP	-3.36	0.000842	0.0467	-0.21	-0.15	Blood metabolite levels;	chr4:9983821	chr4:9153296~9165451:+
THCA	cis	rs1039766	1	rs268871	ENSG00000237979.1	AC007389.1	3.36	0.000842	0.0467	0.23	0.15	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr2:65500993~65502138:-
THCA	cis	rs7572644	0.723	rs3935148	ENSG00000223522.1	AC093690.1	-3.36	0.000842	0.0467	-0.18	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27798099	chr2:28307691~28310459:-
THCA	cis	rs10946940	0.965	rs6456799	ENSG00000280107.1	AL022393.9	3.36	0.000842	0.0467	0.16	0.15	Systemic lupus erythematosus;	chr6:27605757	chr6:28170845~28172521:+
THCA	cis	rs10824518	0.866	rs11002140	ENSG00000199664.1	RNU6-1266P	-3.36	0.000842	0.0467	-0.2	-0.15	Myopia;	chr10:77381278	chr10:77776951~77777055:-
THCA	cis	rs11168618	0.686	rs11168574	ENSG00000240399.1	RP1-228P16.1	3.36	0.000842	0.0467	0.15	0.15	Adiponectin levels;	chr12:48445186	chr12:48054813~48055591:-
THCA	cis	rs11168618	0.81	rs35338015	ENSG00000240399.1	RP1-228P16.1	3.36	0.000842	0.0467	0.15	0.15	Adiponectin levels;	chr12:48445618	chr12:48054813~48055591:-
THCA	cis	rs11168618	0.81	rs6580671	ENSG00000240399.1	RP1-228P16.1	3.36	0.000842	0.0467	0.15	0.15	Adiponectin levels;	chr12:48447274	chr12:48054813~48055591:-
THCA	cis	rs11168618	0.846	rs11168577	ENSG00000240399.1	RP1-228P16.1	3.36	0.000842	0.0467	0.15	0.15	Adiponectin levels;	chr12:48448809	chr12:48054813~48055591:-
THCA	cis	rs7631605	0.625	rs17199922	ENSG00000224080.1	UBE2FP1	3.36	0.000842	0.0467	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37359383	chr3:37143512~37143958:-
THCA	cis	rs9307551	0.681	rs7687586	ENSG00000250334.4	LINC00989	3.36	0.000842	0.0467	0.18	0.15	Refractive error;	chr4:79640216	chr4:79492416~79576460:+
THCA	cis	rs3739034	1	rs3739034	ENSG00000224043.6	CCNT2-AS1	3.36	0.000842	0.0467	0.18	0.15	Gut microbiome composition (winter);	chr2:134725811	chr2:134735464~134918710:-
THCA	cis	rs9903692	0.954	rs8065670	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48096478	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.908	rs12950402	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48102752	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs11079808	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48102870	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs4794448	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48103445	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs68175794	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48103742	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.862	rs12943543	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48104003	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs4794451	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48107419	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.862	rs4794453	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48107564	chr17:48045141~48048073:-
THCA	cis	rs9903692	0.954	rs8077860	ENSG00000263412.1	RP5-890E16.2	3.36	0.000842	0.0467	0.11	0.15	Pulse pressure;	chr17:48107973	chr17:48045141~48048073:-
THCA	cis	rs6788895	1	rs74950732	ENSG00000244265.1	SIAH2-AS1	3.36	0.000842	0.0467	0.41	0.15	Breast cancer;	chr3:150764834	chr3:150761937~150762538:+
THCA	cis	rs6788895	1	rs76801042	ENSG00000244265.1	SIAH2-AS1	3.36	0.000842	0.0467	0.41	0.15	Breast cancer;	chr3:150764933	chr3:150761937~150762538:+
THCA	cis	rs9652601	0.691	rs12708717	ENSG00000263033.2	RP11-396B14.2	-3.36	0.000842	0.0467	-0.12	-0.15	Systemic lupus erythematosus;	chr16:11098522	chr16:11196177~11224969:+
THCA	cis	rs9652601	0.608	rs8061826	ENSG00000263033.2	RP11-396B14.2	-3.36	0.000842	0.0467	-0.12	-0.15	Systemic lupus erythematosus;	chr16:11098930	chr16:11196177~11224969:+
THCA	cis	rs6565180	0.962	rs6565182	ENSG00000274678.1	RP11-2C24.7	-3.36	0.000842	0.0467	-0.15	-0.15	Tonsillectomy;	chr16:30363060	chr16:30821338~30821884:+
THCA	cis	rs6546886	0.75	rs71406850	ENSG00000217702.2	RP11-287D1.4	-3.36	0.000842	0.0467	-0.26	-0.15	Dialysis-related mortality;	chr2:74016131	chr2:74130583~74135395:+
THCA	cis	rs11001765	0.53	rs11001750	ENSG00000237149.5	ZNF503-AS2	-3.36	0.000843	0.0467	-0.22	-0.15	Chin dimples;	chr10:76361072	chr10:75401519~75408982:+
THCA	cis	rs11001765	0.53	rs11516634	ENSG00000237149.5	ZNF503-AS2	-3.36	0.000843	0.0467	-0.22	-0.15	Chin dimples;	chr10:76367366	chr10:75401519~75408982:+
THCA	cis	rs11001765	0.53	rs79125688	ENSG00000237149.5	ZNF503-AS2	-3.36	0.000843	0.0467	-0.22	-0.15	Chin dimples;	chr10:76370013	chr10:75401519~75408982:+
THCA	cis	rs11001765	0.53	rs10824410	ENSG00000237149.5	ZNF503-AS2	-3.36	0.000843	0.0467	-0.22	-0.15	Chin dimples;	chr10:76372329	chr10:75401519~75408982:+
THCA	cis	rs11001765	0.53	rs11001756	ENSG00000237149.5	ZNF503-AS2	-3.36	0.000843	0.0467	-0.22	-0.15	Chin dimples;	chr10:76373590	chr10:75401519~75408982:+
THCA	cis	rs2919009	0.664	rs57078496	ENSG00000271670.1	RP11-95I16.4	3.36	0.000843	0.0467	0.18	0.15	Obesity-related traits;	chr10:120881877	chr10:120879256~120880667:-
THCA	cis	rs6496667	0.817	rs74528922	ENSG00000259262.1	NDUFA3P4	3.36	0.000843	0.0467	0.21	0.15	Rheumatoid arthritis;	chr15:90377777	chr15:90385814~90386063:+
THCA	cis	rs2292096	1	rs7520780	ENSG00000260088.1	RP11-92G12.3	3.36	0.000843	0.0467	0.32	0.15	Epilepsy;	chr1:200741058	chr1:200669507~200694250:+
THCA	cis	rs267567	0.605	rs1965078	ENSG00000235257.7	ITGA9-AS1	-3.36	0.000843	0.0467	-0.13	-0.15	PR interval;	chr3:37509610	chr3:37745432~37861780:-
THCA	cis	rs7737355	0.628	rs4705893	ENSG00000237714.1	P4HA2-AS1	3.36	0.000843	0.0467	0.33	0.15	Life satisfaction;	chr5:131740228	chr5:132184876~132192808:+
THCA	cis	rs17345786	1	rs17345528	ENSG00000244119.1	PDCL3P4	-3.36	0.000843	0.0467	-0.15	-0.15	Colonoscopy-negative controls vs population controls;	chr3:101575986	chr3:101712472~101713191:+
THCA	cis	rs524281	1	rs472518	ENSG00000255038.1	RP11-1167A19.2	3.36	0.000843	0.0467	0.16	0.15	Electroencephalogram traits;	chr11:66084431	chr11:66067277~66069619:-
THCA	cis	rs4649295	0.737	rs10910121	ENSG00000231940.1	RPS7P3	3.36	0.000843	0.0467	0.17	0.15	Differentiated thyroid cancer;Papillary thyroid cancer;	chr1:233266555	chr1:233288868~233289447:-
THCA	cis	rs6471393	0.929	rs4734251	ENSG00000261437.1	RP11-22C11.2	3.36	0.000843	0.0467	0.14	0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744195	chr8:94637285~94639467:-
THCA	cis	rs184886	0.571	rs12657050	ENSG00000250237.1	CTC-498J12.1	3.36	0.000843	0.0467	0.21	0.15	Breast cancer;	chr5:68283748	chr5:69038518~69043821:-
THCA	cis	rs66887589	0.934	rs2389873	ENSG00000249244.1	RP11-548H18.2	-3.36	0.000843	0.0467	-0.15	-0.15	Diastolic blood pressure;	chr4:119633559	chr4:119391831~119395335:-
THCA	cis	rs66887589	0.934	rs4834792	ENSG00000249244.1	RP11-548H18.2	-3.36	0.000843	0.0467	-0.15	-0.15	Diastolic blood pressure;	chr4:119634541	chr4:119391831~119395335:-
THCA	cis	rs2071852	0.66	rs9626438	ENSG00000280383.1	CTA-941F9.10	-3.36	0.000843	0.0467	-0.16	-0.15	Lobe attachment (rater-scored or self-reported);	chr22:45758018	chr22:45657019~45680130:+
THCA	cis	rs17217757	0.725	rs7464830	ENSG00000254041.1	RP11-574O7.1	-3.36	0.000843	0.0467	-0.23	-0.15	Tuberculosis;	chr8:105605609	chr8:105142860~105188606:-
THCA	cis	rs7713065	0.836	rs2057657	ENSG00000263597.1	MIR3936	-3.36	0.000843	0.0467	-0.19	-0.15	Lung function (FEV1/FVC);	chr5:132473624	chr5:132365490~132365599:-
THCA	cis	rs9309473	0.528	rs7573275	ENSG00000273245.1	RP11-434P11.2	3.36	0.000843	0.0467	0.19	0.15	Metabolite levels;	chr2:73325414	chr2:73750256~73750786:-
THCA	cis	rs2236521	0.617	rs2236520	ENSG00000226332.2	RP11-157P1.4	3.36	0.000843	0.0467	0.13	0.15	Pelvic organ prolapse;	chr20:62317116	chr20:62305432~62306325:-
THCA	cis	rs12049351	0.774	rs34551512	ENSG00000229367.1	HMGN2P19	3.36	0.000843	0.0467	0.24	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229483141	chr1:229570532~229570796:+
THCA	cis	rs11051970	1	rs11051970	ENSG00000277342.1	RP11-843B15.4	-3.36	0.000843	0.0467	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32384554	chr12:32109076~32109602:+
THCA	cis	rs7903456	0.512	rs9420425	ENSG00000200253.1	RNU6-529P	3.36	0.000843	0.0468	0.21	0.15	Gout;Renal underexcretion gout;	chr10:87046682	chr10:87041238~87041341:-
THCA	cis	rs806215	0.547	rs3757754	ENSG00000224138.1	AC000123.4	-3.36	0.000843	0.0468	-0.16	-0.15	Type 2 diabetes;	chr7:128066634	chr7:127350128~127351523:+
THCA	cis	rs4589258	0.788	rs4237552	ENSG00000280367.1	RP11-121L10.2	3.36	0.000844	0.0468	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90725371	chr11:90223153~90226538:+
THCA	cis	rs4589258	0.788	rs10830565	ENSG00000280367.1	RP11-121L10.2	3.36	0.000844	0.0468	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90727649	chr11:90223153~90226538:+
THCA	cis	rs4589258	0.788	rs11019164	ENSG00000280367.1	RP11-121L10.2	3.36	0.000844	0.0468	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90727687	chr11:90223153~90226538:+
THCA	cis	rs4589258	0.788	rs7929571	ENSG00000280367.1	RP11-121L10.2	3.36	0.000844	0.0468	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90728052	chr11:90223153~90226538:+
THCA	cis	rs11168618	0.81	rs11168595	ENSG00000257763.1	OR5BK1P	3.36	0.000844	0.0468	0.13	0.15	Adiponectin levels;	chr12:48474428	chr12:48355792~48356614:-
THCA	cis	rs11168618	0.743	rs12815151	ENSG00000257763.1	OR5BK1P	3.36	0.000844	0.0468	0.13	0.15	Adiponectin levels;	chr12:48481053	chr12:48355792~48356614:-
THCA	cis	rs345013	0.92	rs16856619	ENSG00000240032.1	RP11-274H2.3	-3.36	0.000844	0.0468	-0.24	-0.15	Prostate cancer;	chr3:145292958	chr3:146066344~146069185:-
THCA	cis	rs7020830	0.898	rs7846747	ENSG00000260100.1	RP11-220I1.5	-3.36	0.000844	0.0468	-0.19	-0.15	Schizophrenia;	chr9:37167542	chr9:37078813~37079776:-
THCA	cis	rs9863	0.861	rs4930723	ENSG00000269938.1	RP11-214K3.20	-3.36	0.000844	0.0468	-0.18	-0.15	White blood cell count;	chr12:123939053	chr12:123968023~123968579:-
THCA	cis	rs4511180	0.932	rs3120747	ENSG00000230280.2	HNRNPA1P59	-3.36	0.000844	0.0468	-0.14	-0.15	Post-traumatic stress disorder;	chr1:202194493	chr1:202911812~202912729:+
THCA	cis	rs73459955	0.651	rs73458002	ENSG00000248441.5	LINC01197	3.36	0.000844	0.0468	0.2	0.15	Major depression and alcohol dependence;	chr15:95087373	chr15:95209099~95327129:-
THCA	cis	rs6822297	0.841	rs28704572	ENSG00000240005.4	RP11-293A21.1	3.36	0.000844	0.0468	0.17	0.15	Obesity-related traits;	chr4:26932223	chr4:26859806~26860599:-
THCA	cis	rs7577696	0.509	rs589427	ENSG00000276517.1	AL133243.2	-3.36	0.000844	0.0468	-0.15	-0.15	Inflammatory biomarkers;	chr2:31647444	chr2:32526504~32529507:+
THCA	cis	rs4262150	0.846	rs72799138	ENSG00000253921.1	CTB-113P19.3	3.36	0.000844	0.0468	0.21	0.15	Bipolar disorder and schizophrenia;	chr5:152716955	chr5:151753992~151767247:+
THCA	cis	rs10858047	0.883	rs3789624	ENSG00000231128.4	RP5-1073O3.2	3.36	0.000844	0.0468	0.23	0.15	Autism;	chr1:114573813	chr1:113812379~113829171:+
THCA	cis	rs12428035	0.764	rs672988	ENSG00000247400.3	DNAJC3-AS1	3.36	0.000844	0.0468	0.14	0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96124856	chr13:95648733~95676925:-
THCA	cis	rs3026101	0.534	rs57303034	ENSG00000234327.6	AC012146.7	-3.36	0.000844	0.0468	-0.12	-0.15	Body mass index;	chr17:5415683	chr17:5111468~5115004:+
THCA	cis	rs7829975	0.711	rs4481596	ENSG00000248538.5	RP11-10A14.5	-3.36	0.000844	0.0468	-0.19	-0.15	Mood instability;	chr8:8846820	chr8:9189011~9202854:+
THCA	cis	rs208520	1	rs9453663	ENSG00000218890.1	NUFIP1P	3.36	0.000844	0.0468	0.25	0.15	Exhaled nitric oxide output;	chr6:66266184	chr6:66093431~66094909:-
THCA	cis	rs208520	0.955	rs9453664	ENSG00000218890.1	NUFIP1P	3.36	0.000844	0.0468	0.25	0.15	Exhaled nitric oxide output;	chr6:66266186	chr6:66093431~66094909:-
THCA	cis	rs1552244	0.882	rs13099136	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:9989747	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.51	rs13075308	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:9993241	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.808	rs7615088	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:9994212	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs61429272	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:9995636	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.626	rs2886396	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:9995986	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs9757159	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:9997482	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.816	rs17050701	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:9999870	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs55840655	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:10001006	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.816	rs56387520	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:10001098	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs56224841	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:10002330	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs13088350	ENSG00000269982.1	RP11-1020A11.2	3.36	0.000844	0.0468	0.12	0.15	Alzheimer's disease;	chr3:10002942	chr3:9958717~9962539:+
THCA	cis	rs631288	0.793	rs6681716	ENSG00000226015.2	CCT8P1	3.36	0.000844	0.0468	0.27	0.15	PR interval in Tripanosoma cruzi seropositivity;	chr1:147236176	chr1:147203276~147204932:-
THCA	cis	rs4713118	0.824	rs2179095	ENSG00000261839.1	RP1-265C24.8	-3.36	0.000844	0.0468	-0.18	-0.15	Parkinson's disease;	chr6:27783079	chr6:28136849~28139678:+
THCA	cis	rs4713118	0.866	rs2179094	ENSG00000261839.1	RP1-265C24.8	3.36	0.000844	0.0468	0.18	0.15	Parkinson's disease;	chr6:27774046	chr6:28136849~28139678:+
THCA	cis	rs6921919	0.848	rs6903652	ENSG00000273712.1	RP5-874C20.7	3.36	0.000844	0.0468	0.19	0.15	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28315613~28315883:-
THCA	cis	rs10792665	0.724	rs10898068	ENSG00000255503.1	RP11-113K21.4	-3.36	0.000844	0.0468	-0.16	-0.15	Obesity-related traits;	chr11:82999847	chr11:83072402~83097196:-
THCA	cis	rs10792665	0.724	rs10898069	ENSG00000255503.1	RP11-113K21.4	-3.36	0.000844	0.0468	-0.16	-0.15	Obesity-related traits;	chr11:83000167	chr11:83072402~83097196:-
THCA	cis	rs479105	0.567	rs61907483	ENSG00000278356.1	RP11-372B4.3	3.36	0.000844	0.0468	0.15	0.15	Gut microbiota (bacterial taxa);	chr12:3269910	chr12:2885819~2886329:+
THCA	cis	rs867186	1	rs7270326	ENSG00000126005.14	MMP24-AS1	-3.36	0.000844	0.0468	-0.22	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35105779	chr20:35216462~35278131:-
THCA	cis	rs73193808	0.639	rs2832237	ENSG00000176054.6	RPL23P2	3.36	0.000844	0.0468	0.14	0.15	Coronary artery disease;	chr21:29175362	chr21:28997613~28998033:-
THCA	cis	rs2039553	0.553	rs2039554	ENSG00000227354.5	RBM26-AS1	3.36	0.000844	0.0468	0.15	0.15	Pancreatic cancer;	chr13:79811233	chr13:79406309~79424328:+
THCA	cis	rs2039553	0.553	rs2039555	ENSG00000227354.5	RBM26-AS1	3.36	0.000844	0.0468	0.15	0.15	Pancreatic cancer;	chr13:79811276	chr13:79406309~79424328:+
THCA	cis	rs9611565	0.659	rs12484694	ENSG00000237037.8	NDUFA6-AS1	3.36	0.000844	0.0468	0.14	0.15	Vitiligo;	chr22:41523326	chr22:42090931~42137742:+
THCA	cis	rs9650657	0.515	rs7820860	ENSG00000261451.1	RP11-981G7.1	-3.36	0.000844	0.0468	-0.2	-0.15	Neuroticism;	chr8:11092886	chr8:10433672~10438312:+
THCA	cis	rs440932	0.798	rs330942	ENSG00000254153.1	CTA-398F10.2	-3.36	0.000845	0.0468	-0.16	-0.15	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8456909~8461337:-
THCA	cis	rs6487679	0.526	rs7972426	ENSG00000245105.2	A2M-AS1	3.36	0.000845	0.0468	0.12	0.15	Non-alcoholic fatty liver disease histology (AST);	chr12:9228658	chr12:9065177~9068060:+
THCA	cis	rs72996113	0.702	rs61890762	ENSG00000248027.1	CTD-2383M3.1	-3.36	0.000845	0.0468	-0.31	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;	chr11:100765429	chr11:100684162~100687955:-
THCA	cis	rs2905347	0.757	rs1006509	ENSG00000179428.2	AC073072.5	-3.36	0.000845	0.0468	-0.17	-0.15	Major depression and alcohol dependence;	chr7:22658847	chr7:22725395~22727620:-
THCA	cis	rs1023500	1	rs3752591	ENSG00000205702.9	CYP2D7	-3.36	0.000845	0.0468	-0.14	-0.15	Schizophrenia;	chr22:41943512	chr22:42140203~42144577:-
THCA	cis	rs416603	0.967	rs11640138	ENSG00000263179.1	HNRNPCP4	-3.36	0.000845	0.0468	-0.19	-0.15	Type 1 diabetes;	chr16:11268872	chr16:11242653~11243552:+
THCA	cis	rs12575480	0.672	rs74048171	ENSG00000233930.3	KRTAP5-AS1	-3.36	0.000845	0.0468	-0.18	-0.15	Pursuit maintenance gain;	chr11:2072373	chr11:1571353~1599184:+
THCA	cis	rs11098499	0.644	rs7693919	ENSG00000249244.1	RP11-548H18.2	3.36	0.000845	0.0468	0.17	0.15	Corneal astigmatism;	chr4:119619416	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.57	rs6832740	ENSG00000249244.1	RP11-548H18.2	3.36	0.000845	0.0468	0.17	0.15	Corneal astigmatism;	chr4:119624981	chr4:119391831~119395335:-
THCA	cis	rs11098499	0.644	rs6855918	ENSG00000249244.1	RP11-548H18.2	3.36	0.000845	0.0468	0.17	0.15	Corneal astigmatism;	chr4:119625144	chr4:119391831~119395335:-
THCA	cis	rs987724	0.592	rs1430410	ENSG00000241544.1	RP11-6F2.5	-3.36	0.000845	0.0468	-0.19	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:157081841~157088547:+
THCA	cis	rs7656342	0.93	rs56205495	ENSG00000242034.1	RP11-1396O13.1	3.36	0.000845	0.0468	0.18	0.15	Gut microbiota (bacterial taxa);	chr4:9787877	chr4:9553614~9553985:-
THCA	cis	rs1555322	1	rs2425040	ENSG00000279253.1	RP4-614O4.13	-3.36	0.000845	0.0468	-0.21	-0.15	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35262727~35264187:-
THCA	cis	rs2979489	1	rs2979489	ENSG00000254152.1	CTD-3107M8.2	3.36	0.000845	0.0468	0.22	0.15	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Mean corpuscular hemoglobin;Plateletcrit;Sum neutrophil eosinophil counts;Mean corpuscular volume;	chr8:30423317	chr8:30349866~30350347:-
THCA	cis	rs3784262	0.669	rs2414527	ENSG00000259250.1	RP11-50C13.1	-3.36	0.000845	0.0468	-0.13	-0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57964474	chr15:58587507~58591676:+
THCA	cis	rs11955398	0.692	rs897672	ENSG00000251279.1	CTC-436P18.1	-3.36	0.000845	0.0468	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60700274	chr5:61162070~61232040:+
THCA	cis	rs1927790	0.727	rs9556559	ENSG00000247400.3	DNAJC3-AS1	-3.36	0.000845	0.0468	-0.1	-0.15	Body mass index;	chr13:96322098	chr13:95648733~95676925:-
THCA	cis	rs2223471	0.837	rs2817357	ENSG00000060303.5	RPS17P5	3.36	0.000845	0.0468	0.18	0.15	Subcutaneous adipose tissue;	chr6:50794305	chr6:50857255~50857662:-
THCA	cis	rs4144027	0.904	rs10438242	ENSG00000258534.1	CTD-2134A5.4	3.36	0.000845	0.0468	0.16	0.15	Blood metabolite levels;	chr14:103878738	chr14:103854366~103880111:-
THCA	cis	rs883565	0.569	rs6599273	ENSG00000223668.1	EEF1A1P24	-3.36	0.000845	0.0468	-0.13	-0.15	Handedness;	chr3:38957061	chr3:39358545~39359922:+
THCA	cis	rs684232	0.666	rs366151	ENSG00000231784.7	DBIL5P	3.36	0.000845	0.0468	0.17	0.15	Prostate cancer;	chr17:695071	chr17:752660~755336:+
THCA	cis	rs67478160	0.608	rs11628787	ENSG00000269910.1	RP11-73M18.10	-3.36	0.000845	0.0468	-0.13	-0.15	Schizophrenia;	chr14:103857647	chr14:103694516~103695050:-
THCA	cis	rs9635324	0.893	rs8033249	ENSG00000259536.4	RP11-111A22.1	3.36	0.000845	0.0468	0.2	0.15	Blood metabolite ratios;Blood metabolite levels;	chr15:40429740	chr15:40488041~40558019:+
THCA	cis	rs2334880	0.678	rs16973190	ENSG00000260185.1	RP11-432I5.6	3.36	0.000845	0.0468	0.29	0.15	Malaria;	chr16:71474598	chr16:71655027~71664212:+
THCA	cis	rs875971	1	rs6956179	ENSG00000229180.5	GS1-124K5.11	-3.36	0.000845	0.0468	-0.11	-0.15	Aortic root size;	chr7:66341672	chr7:66526088~66542624:-
THCA	cis	rs72627123	1	rs12050434	ENSG00000259065.1	RP5-1021I20.1	-3.36	0.000845	0.0468	-0.28	-0.15	Morning vs. evening chronotype;	chr14:73874735	chr14:73787360~73803270:+
THCA	cis	rs72627123	0.867	rs17093520	ENSG00000259065.1	RP5-1021I20.1	-3.36	0.000845	0.0468	-0.28	-0.15	Morning vs. evening chronotype;	chr14:73879592	chr14:73787360~73803270:+
THCA	cis	rs72627123	0.867	rs17093546	ENSG00000259065.1	RP5-1021I20.1	-3.36	0.000845	0.0468	-0.28	-0.15	Morning vs. evening chronotype;	chr14:73886317	chr14:73787360~73803270:+
THCA	cis	rs72627123	0.867	rs72627118	ENSG00000259065.1	RP5-1021I20.1	-3.36	0.000845	0.0468	-0.28	-0.15	Morning vs. evening chronotype;	chr14:73888582	chr14:73787360~73803270:+
THCA	cis	rs72627123	0.867	rs74337992	ENSG00000259065.1	RP5-1021I20.1	-3.36	0.000845	0.0468	-0.28	-0.15	Morning vs. evening chronotype;	chr14:73889350	chr14:73787360~73803270:+
THCA	cis	rs9916302	0.706	rs6503500	ENSG00000266469.1	CTB-131K11.1	-3.36	0.000845	0.0468	-0.14	-0.15	Glomerular filtration rate (creatinine);	chr17:39329672	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs28482878	ENSG00000266469.1	CTB-131K11.1	3.36	0.000845	0.0468	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39340847	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs9909304	ENSG00000266469.1	CTB-131K11.1	3.36	0.000845	0.0468	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39344255	chr17:39401793~39406233:+
THCA	cis	rs7520050	0.966	rs12760175	ENSG00000280836.1	AL355480.1	3.36	0.000845	0.0468	0.19	0.15	Reticulocyte count;Red blood cell count;	chr1:45982168	chr1:45581219~45581321:-
THCA	cis	rs7656342	0.79	rs1519097	ENSG00000242034.1	RP11-1396O13.1	-3.36	0.000845	0.0468	-0.17	-0.15	Gut microbiota (bacterial taxa);	chr4:9801229	chr4:9553614~9553985:-
THCA	cis	rs7142002	0.568	rs60184724	ENSG00000271780.1	RP11-1017G21.5	-3.36	0.000846	0.0468	-0.19	-0.15	Autism;	chr14:101919601	chr14:101948347~101949425:+
THCA	cis	rs927675	0.531	rs10763636	ENSG00000213770.3	FAM210CP	-3.36	0.000846	0.0469	-0.19	-0.15	Hippocampal volume;	chr10:28025544	chr10:27349717~27350290:-
THCA	cis	rs7944735	0.832	rs7130876	ENSG00000200090.1	Y_RNA	3.36	0.000846	0.0469	0.14	0.15	Intraocular pressure;	chr11:48029443	chr11:47726894~47726992:-
THCA	cis	rs6500602	0.727	rs4786515	ENSG00000280063.1	RP11-295D4.3	3.36	0.000846	0.0469	0.08	0.15	Schizophrenia;	chr16:4528132	chr16:4346694~4348648:-
THCA	cis	rs6500602	0.727	rs4786516	ENSG00000280063.1	RP11-295D4.3	3.36	0.000846	0.0469	0.08	0.15	Schizophrenia;	chr16:4528640	chr16:4346694~4348648:-
THCA	cis	rs6500602	0.727	rs7193136	ENSG00000280063.1	RP11-295D4.3	3.36	0.000846	0.0469	0.08	0.15	Schizophrenia;	chr16:4530033	chr16:4346694~4348648:-
THCA	cis	rs6500602	0.727	rs10451135	ENSG00000280063.1	RP11-295D4.3	3.36	0.000846	0.0469	0.08	0.15	Schizophrenia;	chr16:4530213	chr16:4346694~4348648:-
THCA	cis	rs7829975	0.846	rs6601724	ENSG00000254340.1	RP11-10A14.3	-3.36	0.000846	0.0469	-0.17	-0.15	Mood instability;	chr8:8687362	chr8:9141424~9145435:+
THCA	cis	rs911555	0.723	rs4906320	ENSG00000252469.1	RNU7-160P	-3.36	0.000846	0.0469	-0.18	-0.15	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103550345~103550406:+
THCA	cis	rs172166	0.538	rs149956	ENSG00000261839.1	RP1-265C24.8	3.36	0.000846	0.0469	0.15	0.15	Cardiac Troponin-T levels;	chr6:28068473	chr6:28136849~28139678:+
THCA	cis	rs6847067	0.794	rs7663580	ENSG00000180769.7	WDFY3-AS2	3.36	0.000846	0.0469	0.11	0.15	Oropharynx cancer;	chr4:85007163	chr4:84965682~85011277:+
THCA	cis	rs1926657	1	rs6492769	ENSG00000223298.1	RNY3P8	-3.36	0.000846	0.0469	-0.2	-0.15	Breast cancer;	chr13:95217768	chr13:95310830~95310955:-
THCA	cis	rs4262150	0.81	rs72799107	ENSG00000253921.1	CTB-113P19.3	3.36	0.000846	0.0469	0.2	0.15	Bipolar disorder and schizophrenia;	chr5:152673844	chr5:151753992~151767247:+
THCA	cis	rs7246657	0.943	rs3745765	ENSG00000266916.4	ZNF793-AS1	-3.36	0.000846	0.0469	-0.14	-0.15	Coronary artery calcification;	chr19:37363333	chr19:37497159~37507046:-
THCA	cis	rs7020830	0.858	rs1492714	ENSG00000260100.1	RP11-220I1.5	-3.36	0.000846	0.0469	-0.19	-0.15	Schizophrenia;	chr9:37141262	chr9:37078813~37079776:-
THCA	cis	rs7020830	0.931	rs13297576	ENSG00000260100.1	RP11-220I1.5	-3.36	0.000846	0.0469	-0.19	-0.15	Schizophrenia;	chr9:37142192	chr9:37078813~37079776:-
THCA	cis	rs6500602	0.634	rs2270365	ENSG00000280063.1	RP11-295D4.3	3.36	0.000846	0.0469	0.08	0.15	Schizophrenia;	chr16:4476757	chr16:4346694~4348648:-
THCA	cis	rs1612141	1	rs1612141	ENSG00000251363.2	RP11-129M6.1	3.36	0.000846	0.0469	0.21	0.15	QT interval (drug interaction);	chr14:41233395	chr14:40954898~40975877:+
THCA	cis	rs2562456	0.833	rs62110367	ENSG00000268658.4	LINC00664	3.36	0.000846	0.0469	0.26	0.15	Pain;	chr19:21365829	chr19:21483374~21503238:+
THCA	cis	rs7737355	0.812	rs30735	ENSG00000224431.1	AC063976.7	-3.36	0.000846	0.0469	-0.14	-0.15	Life satisfaction;	chr5:131373729	chr5:132199456~132203487:+
THCA	cis	rs7772486	0.875	rs7766463	ENSG00000270638.1	RP3-466P17.1	3.36	0.000846	0.0469	0.12	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145735570~145737218:+
THCA	cis	rs11650494	0.634	rs8072520	ENSG00000262039.1	RP11-81K2.1	3.36	0.000847	0.0469	0.33	0.15	Prostate cancer;	chr17:49389278	chr17:49370740~49476988:+
THCA	cis	rs2527866	0.509	rs2706164	ENSG00000234450.1	AC005534.6	3.36	0.000847	0.0469	0.17	0.15	Quantitative traits;	chr7:157292576	chr7:156633355~156633787:+
THCA	cis	rs7615952	0.576	rs4646763	ENSG00000248787.1	RP11-666A20.4	-3.36	0.000847	0.0469	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126103286	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.576	rs4646759	ENSG00000248787.1	RP11-666A20.4	-3.36	0.000847	0.0469	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126104103	chr3:125908005~125910272:-
THCA	cis	rs1927790	0.727	rs12871045	ENSG00000247400.3	DNAJC3-AS1	-3.36	0.000847	0.0469	-0.1	-0.15	Body mass index;	chr13:96319467	chr13:95648733~95676925:-
THCA	cis	rs1927790	0.727	rs9554340	ENSG00000247400.3	DNAJC3-AS1	-3.36	0.000847	0.0469	-0.1	-0.15	Body mass index;	chr13:96321858	chr13:95648733~95676925:-
THCA	cis	rs524281	0.861	rs7941431	ENSG00000255038.1	RP11-1167A19.2	-3.36	0.000847	0.0469	-0.18	-0.15	Electroencephalogram traits;	chr11:66192686	chr11:66067277~66069619:-
THCA	cis	rs5769765	1	rs1033665	ENSG00000278869.1	CITF22-49E9.3	3.36	0.000847	0.0469	0.2	0.15	Schizophrenia;	chr22:49858479	chr22:49933198~49934074:-
THCA	cis	rs8049040	0.5	rs7188475	ENSG00000260593.1	RP11-432I5.2	3.36	0.000847	0.0469	0.18	0.15	Blood protein levels;	chr16:71412455	chr16:71623708~71626816:-
THCA	cis	rs7709377	0.723	rs7716307	ENSG00000250015.1	CTC-339F2.2	3.36	0.000847	0.0469	0.16	0.15	Metabolite levels  (X-11787);	chr5:116163551	chr5:116302354~116304134:-
THCA	cis	rs9333290	0.93	rs13033579	ENSG00000259915.2	RP11-410E4.1	3.36	0.000847	0.0469	0.19	0.15	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186721872	chr2:186354570~186356773:-
THCA	cis	rs6545883	0.894	rs12622458	ENSG00000212978.6	AC016747.3	-3.36	0.000847	0.0469	-0.17	-0.15	Tuberculosis;	chr2:61296419	chr2:61141592~61144969:-
THCA	cis	rs7829975	0.742	rs1533059	ENSG00000233609.3	RP11-62H7.2	-3.36	0.000847	0.0469	-0.15	-0.15	Mood instability;	chr8:8827443	chr8:8961200~8979025:+
THCA	cis	rs2820315	0.867	rs2820319	ENSG00000223774.4	RP11-307B6.3	3.36	0.000847	0.0469	0.17	0.15	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201909522	chr1:201893842~201899978:+
THCA	cis	rs17253792	0.822	rs74968702	ENSG00000186615.9	KTN1-AS1	-3.36	0.000847	0.0469	-0.27	-0.15	Putamen volume;	chr14:55610100	chr14:55499278~55580110:-
THCA	cis	rs2749097	1	rs4643	ENSG00000244256.3	RN7SL130P	-3.36	0.000847	0.0469	-0.22	-0.15	Alcohol consumption (transferrin glycosylation);	chr1:63659768	chr1:63655743~63656047:+
THCA	cis	rs4808199	1	rs17288409	ENSG00000267481.1	CTC-559E9.5	-3.36	0.000847	0.0469	-0.15	-0.15	Nonalcoholic fatty liver disease;	chr19:19393358	chr19:19788755~19790531:-
THCA	cis	rs8130944	0.828	rs2284962	ENSG00000225731.1	AP001627.1	3.36	0.000847	0.0469	0.19	0.15	Perceived unattractiveness to mosquitoes;	chr21:42690922	chr21:42733594~42741758:-
THCA	cis	rs2880765	0.835	rs11638498	ENSG00000259407.1	RP11-158M2.3	-3.36	0.000847	0.0469	-0.15	-0.15	Coronary artery disease;	chr15:85479787	chr15:85744109~85750281:-
THCA	cis	rs7737355	0.579	rs116069962	ENSG00000224431.1	AC063976.7	-3.36	0.000847	0.0469	-0.28	-0.15	Life satisfaction;	chr5:131458302	chr5:132199456~132203487:+
THCA	cis	rs1908814	0.516	rs10113062	ENSG00000227888.4	FAM66A	3.36	0.000847	0.0469	0.2	0.15	Neuroticism;	chr8:11935740	chr8:12362019~12388296:+
THCA	cis	rs1908814	0.516	rs10113145	ENSG00000227888.4	FAM66A	3.36	0.000847	0.0469	0.2	0.15	Neuroticism;	chr8:11935786	chr8:12362019~12388296:+
THCA	cis	rs11638352	1	rs4924729	ENSG00000166763.7	STRCP1	-3.36	0.000847	0.0469	-0.31	-0.15	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43999046	chr15:43699488~43718184:-
THCA	cis	rs1667255	1	rs1667255	ENSG00000266521.1	RP11-650P15.1	3.36	0.000847	0.0469	0.2	0.15	Retinol levels;	chr18:31607316	chr18:31496645~31497195:-
THCA	cis	rs6920965	0.507	rs4285341	ENSG00000226409.1	RP11-735G4.1	-3.36	0.000847	0.0469	-0.19	-0.15	High light scatter reticulocyte count;	chr6:125884443	chr6:125370211~125374324:-
THCA	cis	rs6828577	0.819	rs1064034	ENSG00000248280.1	RP11-33B1.2	3.36	0.000847	0.0469	0.13	0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118710837	chr4:119440561~119450157:-
THCA	cis	rs6828577	0.819	rs366656	ENSG00000248280.1	RP11-33B1.2	3.36	0.000847	0.0469	0.13	0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118713539	chr4:119440561~119450157:-
THCA	cis	rs752590	0.623	rs35836064	ENSG00000227359.1	AC017074.2	3.36	0.000847	0.0469	0.24	0.15	Mucinous ovarian carcinoma;	chr2:113229304	chr2:113677702~113704078:-
THCA	cis	rs6938	0.534	rs4886636	ENSG00000260269.4	CTD-2323K18.1	-3.36	0.000847	0.0469	-0.21	-0.15	Breast cancer;	chr15:74903835	chr15:75527150~75601205:-
THCA	cis	rs10129255	1	rs11621409	ENSG00000280411.1	IGHV1-69-2	-3.36	0.000847	0.0469	-0.1	-0.15	Kawasaki disease;	chr14:106695603	chr14:106762092~106762588:-
THCA	cis	rs154659	1	rs154659	ENSG00000274627.1	RP11-104N10.2	3.36	0.000847	0.0469	0.16	0.15	Tanning;	chr16:89600929	chr16:89516797~89522217:+
THCA	cis	rs7631605	1	rs7631605	ENSG00000272334.1	RP11-129K12.1	-3.36	0.000847	0.0469	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:37193098	chr3:36973117~36973672:-
THCA	cis	rs6589219	0.826	rs10891241	ENSG00000196167.8	COLCA1	-3.36	0.000847	0.0469	-0.17	-0.15	Colorectal cancer;	chr11:111272783	chr11:111290787~111305045:-
THCA	cis	rs12621844	0.621	rs973894	ENSG00000272663.1	RP11-191L17.1	3.36	0.000847	0.0469	0.15	0.15	Glycated hemoglobin levels;	chr2:48176960	chr2:48440043~48440597:-
THCA	cis	rs875971	0.545	rs4441996	ENSG00000230295.1	RP11-458F8.2	-3.36	0.000847	0.0469	-0.13	-0.15	Aortic root size;	chr7:66123233	chr7:66880708~66882981:+
THCA	cis	rs877819	0.697	rs7094742	ENSG00000228403.1	RP11-563N6.6	-3.36	0.000848	0.0469	-0.17	-0.15	Systemic lupus erythematosus;	chr10:48849280	chr10:48878022~48878649:+
THCA	cis	rs8103033	0.786	rs6508898	ENSG00000226025.8	LGALS17A	-3.36	0.000848	0.0469	-0.14	-0.15	Obesity-related traits;	chr19:39661841	chr19:39679374~39686373:+
THCA	cis	rs479105	0.741	rs586841	ENSG00000278356.1	RP11-372B4.3	-3.36	0.000848	0.0469	-0.15	-0.15	Gut microbiota (bacterial taxa);	chr12:3254320	chr12:2885819~2886329:+
THCA	cis	rs9811920	0.893	rs6798114	ENSG00000273374.1	RP11-383I23.2	3.36	0.000848	0.0469	0.13	0.15	Axial length;	chr3:100173981	chr3:99802699~99806058:-
THCA	cis	rs9400467	0.537	rs73530951	ENSG00000255389.1	C6orf3	3.36	0.000848	0.0469	0.21	0.15	Amino acid levels;Blood metabolite levels;	chr6:111163611	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.537	rs73530952	ENSG00000255389.1	C6orf3	3.36	0.000848	0.0469	0.21	0.15	Amino acid levels;Blood metabolite levels;	chr6:111165039	chr6:111599875~111602295:+
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000264242.2	RP11-271K11.1	3.36	0.000848	0.0469	0.22	0.15	Body mass index;	chr17:30690132	chr17:30553697~30558962:+
THCA	cis	rs12639258	0.506	rs6808142	ENSG00000268324.2	LRRC2-AS1	3.36	0.000848	0.0469	0.19	0.15	Eotaxin levels;	chr3:46515345	chr3:46557398~46559694:+
THCA	cis	rs2797160	0.967	rs1739358	ENSG00000226409.1	RP11-735G4.1	3.36	0.000848	0.0469	0.18	0.15	Endometrial cancer;	chr6:125698590	chr6:125370211~125374324:-
THCA	cis	rs768090	0.688	rs10170498	ENSG00000237892.1	KLF7-IT1	-3.36	0.000848	0.0469	-0.18	-0.15	Hemoglobin concentration;Hematocrit;	chr2:207118977	chr2:207120884~207122044:-
THCA	cis	rs8054556	1	rs3814881	ENSG00000183604.13	SMG1P5	-3.36	0.000848	0.0469	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29989580	chr16:30267553~30335374:-
THCA	cis	rs324126	0.78	rs11084150	ENSG00000243680.1	RPL37P23	3.36	0.000848	0.0469	0.14	0.15	Colonoscopy-negative controls vs population controls;	chr19:52381851	chr19:52143043~52143336:+
THCA	cis	rs324126	0.78	rs1993531	ENSG00000243680.1	RPL37P23	-3.36	0.000848	0.0469	-0.14	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52143043~52143336:+
THCA	cis	rs801193	0.636	rs10233806	ENSG00000272831.1	RP11-792A8.4	-3.36	0.000848	0.0469	-0.1	-0.15	Aortic root size;	chr7:66653261	chr7:66739829~66740385:-
THCA	cis	rs11756659	0.505	rs62392761	ENSG00000272810.1	U91328.22	3.36	0.000848	0.0469	0.13	0.15	Mean corpuscular hemoglobin;Red cell distribution width;Mean corpuscular volume;	chr6:25920511	chr6:26013241~26013757:+
THCA	cis	rs62246343	0.719	rs73130116	ENSG00000212327.1	RNU6-882P	3.36	0.000848	0.0469	0.22	0.15	Fibrinogen levels;	chr3:9452827	chr3:9919051~9919153:-
THCA	cis	rs12935418	0.672	rs12446304	ENSG00000261061.1	RP11-303E16.2	-3.36	0.000848	0.0469	-0.15	-0.15	Mean corpuscular volume;	chr16:81012730	chr16:81030770~81031485:+
THCA	cis	rs6715793	0.803	rs11124310	ENSG00000272754.1	AL133245.2	-3.36	0.000848	0.0469	-0.18	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33218992	chr2:32321638~32323002:+
THCA	cis	rs9309711	0.772	rs9309714	ENSG00000271868.1	RP11-1293J14.1	-3.36	0.000848	0.0469	-0.22	-0.15	Neurofibrillary tangles;	chr2:3488059	chr2:3496956~3497428:+
THCA	cis	rs7296418	0.961	rs1790094	ENSG00000256092.2	RP13-942N8.1	3.36	0.000848	0.0469	0.11	0.15	Platelet count;	chr12:123102141	chr12:123363868~123366113:+
THCA	cis	rs10911363	0.659	rs6669960	ENSG00000232860.6	SMG7-AS1	3.36	0.000848	0.047	0.12	0.15	Systemic lupus erythematosus;	chr1:183467442	chr1:183460874~183472265:-
THCA	cis	rs684232	0.623	rs417171	ENSG00000231784.7	DBIL5P	3.36	0.000848	0.047	0.17	0.15	Prostate cancer;	chr17:673701	chr17:752660~755336:+
THCA	cis	rs2832191	0.791	rs7282843	ENSG00000176054.6	RPL23P2	3.36	0.000848	0.047	0.13	0.15	Dental caries;	chr21:29102905	chr21:28997613~28998033:-
THCA	cis	rs2832191	0.74	rs6516890	ENSG00000176054.6	RPL23P2	3.36	0.000848	0.047	0.13	0.15	Dental caries;	chr21:29104491	chr21:28997613~28998033:-
THCA	cis	rs4919687	0.55	rs7904396	ENSG00000203886.4	CYP17A1-AS1	3.36	0.000848	0.047	0.16	0.15	Colorectal cancer;	chr10:102697081	chr10:102832721~102834516:+
THCA	cis	rs6847067	0.763	rs56194765	ENSG00000180769.7	WDFY3-AS2	3.36	0.000848	0.047	0.11	0.15	Oropharynx cancer;	chr4:85004309	chr4:84965682~85011277:+
THCA	cis	rs10438797	0.77	rs9906043	ENSG00000240531.1	RPL21P123	3.36	0.000848	0.047	0.2	0.15	Night sleep phenotypes;	chr17:29177903	chr17:29716279~29716685:-
THCA	cis	rs74925218	1	rs74925218	ENSG00000261143.1	ADAMTS7P3	-3.36	0.000848	0.047	-0.23	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78504390	chr15:77976042~77993057:+
THCA	cis	rs6840360	1	rs6841783	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000848	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151677724	chr4:151333775~151353224:-
THCA	cis	rs6921919	0.583	rs11755942	ENSG00000226314.6	ZNF192P1	-3.36	0.000849	0.047	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28161781~28169594:+
THCA	cis	rs75609241	1	rs2340775	ENSG00000243844.1	RPL17P33	3.36	0.000849	0.047	0.38	0.15	PR interval in Tripanosoma cruzi seropositivity;	chr8:29225094	chr8:29632091~29632644:+
THCA	cis	rs75609241	1	rs936120	ENSG00000243844.1	RPL17P33	3.36	0.000849	0.047	0.38	0.15	PR interval in Tripanosoma cruzi seropositivity;	chr8:29225210	chr8:29632091~29632644:+
THCA	cis	rs75609241	1	rs936119	ENSG00000243844.1	RPL17P33	3.36	0.000849	0.047	0.38	0.15	PR interval in Tripanosoma cruzi seropositivity;	chr8:29225408	chr8:29632091~29632644:+
THCA	cis	rs75609241	1	rs4732670	ENSG00000243844.1	RPL17P33	3.36	0.000849	0.047	0.38	0.15	PR interval in Tripanosoma cruzi seropositivity;	chr8:29225592	chr8:29632091~29632644:+
THCA	cis	rs75609241	0.744	rs60984263	ENSG00000243844.1	RPL17P33	3.36	0.000849	0.047	0.38	0.15	PR interval in Tripanosoma cruzi seropositivity;	chr8:29227954	chr8:29632091~29632644:+
THCA	cis	rs3784262	1	rs4646619	ENSG00000259250.1	RP11-50C13.1	3.36	0.000849	0.047	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57966144	chr15:58587507~58591676:+
THCA	cis	rs9788682	1	rs7164594	ENSG00000261143.1	ADAMTS7P3	-3.36	0.000849	0.047	-0.22	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78510715	chr15:77976042~77993057:+
THCA	cis	rs9590614	0.902	rs12584430	ENSG00000278390.3	RP11-74J13.8	-3.36	0.000849	0.047	-0.14	-0.15	Local histogram emphysema pattern;	chr13:41597686	chr13:41132939~41236686:+
THCA	cis	rs9590614	0.902	rs12584630	ENSG00000278390.3	RP11-74J13.8	-3.36	0.000849	0.047	-0.14	-0.15	Local histogram emphysema pattern;	chr13:41597935	chr13:41132939~41236686:+
THCA	cis	rs1005277	0.54	rs1814077	ENSG00000273019.1	RP11-508N22.13	-3.36	0.000849	0.047	-0.17	-0.15	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38149968~38150293:+
THCA	cis	rs7824557	0.767	rs2060463	ENSG00000255495.1	AC145124.2	3.36	0.000849	0.047	0.17	0.15	Retinal vascular caliber;	chr8:11304101	chr8:12194467~12196280:+
THCA	cis	rs9425766	0.639	rs10798295	ENSG00000270084.1	GAS5-AS1	-3.36	0.000849	0.047	-0.15	-0.15	Life satisfaction;	chr1:173714815	chr1:173863248~173863941:+
THCA	cis	rs7702057	0.619	rs73263082	ENSG00000271918.1	CTD-2287O16.5	3.36	0.000849	0.047	0.21	0.15	Amyotrophic lateral sclerosis;	chr5:116328329	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.619	rs79096984	ENSG00000271918.1	CTD-2287O16.5	3.36	0.000849	0.047	0.21	0.15	Amyotrophic lateral sclerosis;	chr5:116328357	chr5:116083807~116085416:-
THCA	cis	rs7702057	0.619	rs73263087	ENSG00000271918.1	CTD-2287O16.5	3.36	0.000849	0.047	0.21	0.15	Amyotrophic lateral sclerosis;	chr5:116329061	chr5:116083807~116085416:-
THCA	cis	rs929354	1	rs1182452	ENSG00000224629.1	RP5-1142J19.2	3.36	0.000849	0.047	0.15	0.15	Body mass index;	chr7:157260924	chr7:157263022~157263229:-
THCA	cis	rs793571	0.822	rs11856640	ENSG00000245975.2	RP11-30K9.6	-3.36	0.000849	0.047	-0.18	-0.15	Schizophrenia;	chr15:58939841	chr15:58768072~58770974:-
THCA	cis	rs1790761	0.806	rs11601325	ENSG00000255318.1	RP11-655M14.13	-3.36	0.000849	0.047	-0.17	-0.15	Mean corpuscular volume;	chr11:67459535	chr11:67618279~67627304:-
THCA	cis	rs7914558	1	rs10883824	ENSG00000213061.2	PFN1P11	3.36	0.000849	0.047	0.18	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103053140	chr10:102838011~102845473:-
THCA	cis	rs6832769	0.925	rs1965467	ENSG00000223305.1	RN7SKP30	3.36	0.000849	0.047	0.19	0.15	Personality dimensions;	chr4:55456573	chr4:55540502~55540835:-
THCA	cis	rs8113308	0.515	rs113082012	ENSG00000275055.1	CTC-471J1.11	-3.36	0.000849	0.047	-0.22	-0.15	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960980	chr19:52049007~52049754:+
THCA	cis	rs8113308	0.515	rs73066986	ENSG00000275055.1	CTC-471J1.11	-3.36	0.000849	0.047	-0.22	-0.15	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51962805	chr19:52049007~52049754:+
THCA	cis	rs8113308	0.515	rs4986770	ENSG00000275055.1	CTC-471J1.11	-3.36	0.000849	0.047	-0.22	-0.15	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51964781	chr19:52049007~52049754:+
THCA	cis	rs77147124	0.959	rs4917628	ENSG00000225292.2	RP11-57H14.3	-3.36	0.000849	0.047	-0.21	-0.15	HDL cholesterol;	chr10:112187920	chr10:112888735~112906111:+
THCA	cis	rs615632	0.53	rs10092464	ENSG00000261451.1	RP11-981G7.1	-3.36	0.000849	0.047	-0.2	-0.15	Neuroticism;	chr8:9946675	chr8:10433672~10438312:+
THCA	cis	rs910316	0.967	rs8013444	ENSG00000259138.1	RP11-950C14.7	-3.36	0.000849	0.047	-0.13	-0.15	Height;	chr14:75195278	chr14:75127153~75136930:+
THCA	cis	rs2668423	0.922	rs266805	ENSG00000261204.1	AC004449.6	-3.36	0.000849	0.047	-0.18	-0.15	Nonalcoholic fatty liver disease;	chr19:1376724	chr19:637105~637537:-
THCA	cis	rs4919087	0.59	rs2861877	ENSG00000237169.1	RP11-452K12.3	3.36	0.000849	0.047	0.2	0.15	Monocyte count;	chr10:97293559	chr10:97309138~97309958:-
THCA	cis	rs6840360	0.967	rs6535812	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151678222	chr4:151333775~151353224:-
THCA	cis	rs6840360	1	rs6535813	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151678500	chr4:151333775~151353224:-
THCA	cis	rs6840360	1	rs6849050	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151678750	chr4:151333775~151353224:-
THCA	cis	rs6840360	1	rs2007445	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151679218	chr4:151333775~151353224:-
THCA	cis	rs6840360	1	rs4696104	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151679299	chr4:151333775~151353224:-
THCA	cis	rs6840360	1	rs749982	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151680201	chr4:151333775~151353224:-
THCA	cis	rs6840360	1	rs751014	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151680750	chr4:151333775~151353224:-
THCA	cis	rs6840360	1	rs751012	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151681095	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.967	rs10776524	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151681433	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.967	rs6832562	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000849	0.047	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151681646	chr4:151333775~151353224:-
THCA	cis	rs748404	0.666	rs514438	ENSG00000166763.7	STRCP1	3.36	0.000849	0.047	0.19	0.15	Lung cancer;	chr15:43328245	chr15:43699488~43718184:-
THCA	cis	rs2130392	0.962	rs13132498	ENSG00000250726.1	RP11-616K6.1	3.36	0.000849	0.047	0.18	0.15	Kawasaki disease;	chr4:184690300	chr4:184072403~184073039:+
THCA	cis	rs4713118	0.869	rs9283880	ENSG00000216915.2	RP1-97D16.1	-3.36	0.00085	0.047	-0.23	-0.15	Parkinson's disease;	chr6:27747464	chr6:27737000~27738494:-
THCA	cis	rs613391	0.671	rs594958	ENSG00000234840.1	LINC01239	-3.36	0.00085	0.047	-0.17	-0.15	Quantitative traits;	chr9:22714080	chr9:22646200~22824213:+
THCA	cis	rs7474896	1	rs12358108	ENSG00000276805.1	RP11-291L22.6	3.36	0.00085	0.047	0.25	0.15	Obesity (extreme);	chr10:37726679	chr10:38451030~38451785:+
THCA	cis	rs1913185	0.837	rs67154251	ENSG00000243415.2	RP11-274H2.2	-3.36	0.00085	0.047	-0.2	-0.15	Obesity-related traits;	chr3:146157193	chr3:146064042~146105204:+
THCA	cis	rs11048434	0.661	rs34791180	ENSG00000245105.2	A2M-AS1	3.36	0.00085	0.047	0.11	0.15	Sjögren's syndrome;	chr12:8958323	chr12:9065177~9068060:+
THCA	cis	rs4879656	0.525	rs10122739	ENSG00000225693.1	LAGE3P1	-3.36	0.00085	0.047	-0.17	-0.15	Menopause (age at onset);	chr9:33085601	chr9:33019682~33020165:-
THCA	cis	rs1552244	0.882	rs2030564	ENSG00000269982.1	RP11-1020A11.2	3.36	0.00085	0.047	0.12	0.15	Alzheimer's disease;	chr3:9997360	chr3:9958717~9962539:+
THCA	cis	rs12724450	0.793	rs11809332	ENSG00000228126.1	FALEC	3.36	0.00085	0.047	0.3	0.15	Blood protein levels;	chr1:150345342	chr1:150515757~150518032:+
THCA	cis	rs1957429	0.572	rs3813421	ENSG00000272158.1	RP11-840I19.5	-3.36	0.00085	0.047	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64880521	chr14:65003325~65003767:-
THCA	cis	rs929354	0.742	rs10251112	ENSG00000224629.1	RP5-1142J19.2	-3.36	0.00085	0.047	-0.15	-0.15	Body mass index;	chr7:157170830	chr7:157263022~157263229:-
THCA	cis	rs3935740	0.649	rs7167946	ENSG00000260619.1	RP11-775C24.3	3.36	0.00085	0.047	0.27	0.15	Parkinson's disease;	chr15:81336205	chr15:80990804~80993258:-
THCA	cis	rs3935740	0.649	rs7174400	ENSG00000260619.1	RP11-775C24.3	3.36	0.00085	0.047	0.27	0.15	Parkinson's disease;	chr15:81337097	chr15:80990804~80993258:-
THCA	cis	rs3935740	0.649	rs9920579	ENSG00000260619.1	RP11-775C24.3	3.36	0.00085	0.047	0.27	0.15	Parkinson's disease;	chr15:81339185	chr15:80990804~80993258:-
THCA	cis	rs3935740	0.649	rs4077174	ENSG00000260619.1	RP11-775C24.3	3.36	0.00085	0.047	0.27	0.15	Parkinson's disease;	chr15:81339736	chr15:80990804~80993258:-
THCA	cis	rs74181299	0.591	rs10205598	ENSG00000236148.5	AC114752.2	3.36	0.00085	0.047	0.18	0.15	Pulse pressure;	chr2:65152117	chr2:64347193~64347741:-
THCA	cis	rs2692947	0.832	rs2438978	ENSG00000235959.1	AC009237.17	-3.36	0.00085	0.047	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96013992	chr2:95640181~95640604:-
THCA	cis	rs7688540	0.713	rs4624608	ENSG00000250892.1	RP11-1365D11.1	3.36	0.00085	0.047	0.23	0.15	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:201409~205009:-
THCA	cis	rs72766638	0.895	rs55924785	ENSG00000235106.7	LINC00094	3.36	0.00085	0.047	0.16	0.15	Mosquito bite size;	chr9:134064464	chr9:134025439~134034666:+
THCA	cis	rs9816784	0.525	rs555412	ENSG00000207650.1	MIR570	3.36	0.00085	0.047	0.17	0.15	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195699401~195699497:+
THCA	cis	rs9816784	0.525	rs422772	ENSG00000207650.1	MIR570	3.36	0.00085	0.047	0.17	0.15	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195699401~195699497:+
THCA	cis	rs1125355	0.589	rs11681670	ENSG00000243792.1	OR7E89P	-3.36	0.00085	0.047	-0.24	-0.15	Alzheimer's disease in APOE e4+ carriers;	chr2:158753780	chr2:158853755~158854576:+
THCA	cis	rs894638	0.636	rs73126488	ENSG00000263327.5	TAPT1-AS1	-3.36	0.00085	0.0471	-0.19	-0.15	Glomerular filtration rate in chronic kidney disease;	chr4:16118498	chr4:16226685~16320140:+
THCA	cis	rs6471393	0.83	rs57803852	ENSG00000261437.1	RP11-22C11.2	3.36	0.00085	0.0471	0.15	0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761156	chr8:94637285~94639467:-
THCA	cis	rs9860428	0.844	rs9878913	ENSG00000240057.4	RP11-572M11.4	-3.36	0.00085	0.0471	-0.16	-0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866272	chr3:113019532~113183301:+
THCA	cis	rs9860428	0.844	rs2399442	ENSG00000240057.4	RP11-572M11.4	-3.36	0.00085	0.0471	-0.16	-0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866426	chr3:113019532~113183301:+
THCA	cis	rs16975963	0.843	rs11672440	ENSG00000269653.1	CTB-102L5.7	3.36	0.00085	0.0471	0.24	0.15	Longevity;	chr19:37760318	chr19:38184376~38186265:+
THCA	cis	rs4664293	0.867	rs1126842	ENSG00000230783.1	AC009961.2	-3.36	0.00085	0.0471	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159770806	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs3771721	ENSG00000230783.1	AC009961.2	-3.36	0.00085	0.0471	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159771644	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs11681245	ENSG00000230783.1	AC009961.2	-3.36	0.00085	0.0471	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159772882	chr2:159689217~159690291:-
THCA	cis	rs4664293	0.867	rs3771718	ENSG00000230783.1	AC009961.2	-3.36	0.00085	0.0471	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159780397	chr2:159689217~159690291:-
THCA	cis	rs73129298	0.636	rs5014389	ENSG00000259456.3	ADNP-AS1	-3.36	0.00085	0.0471	-0.19	-0.15	Inflammatory skin disease;	chr20:49980743	chr20:50930984~50945134:+
THCA	cis	rs2129782	0.51	rs112441769	ENSG00000253553.4	RP11-586K2.1	3.36	0.00085	0.0471	0.23	0.15	Electrodermal activity;	chr8:88343920	chr8:88326836~88737134:+
THCA	cis	rs1198872	0.892	rs1198862	ENSG00000243819.4	RN7SL832P	3.36	0.00085	0.0471	0.12	0.15	Cardiac Troponin-T levels;	chr2:10760201	chr2:10690344~10692099:+
THCA	cis	rs1198872	0.892	rs1198863	ENSG00000243819.4	RN7SL832P	3.36	0.00085	0.0471	0.12	0.15	Cardiac Troponin-T levels;	chr2:10760349	chr2:10690344~10692099:+
THCA	cis	rs9488822	0.676	rs11757115	ENSG00000237021.2	RP3-486I3.7	3.36	0.00085	0.0471	0.16	0.15	LDL cholesterol;Cholesterol, total;	chr6:116041456	chr6:116254207~116256743:+
THCA	cis	rs12612435	0.869	rs11688500	ENSG00000230037.1	UBBP1	3.36	0.00085	0.0471	0.2	0.15	Takotsubo syndrome;	chr2:136379017	chr2:136329441~136329913:-
THCA	cis	rs12612435	0.83	rs11694468	ENSG00000230037.1	UBBP1	3.36	0.00085	0.0471	0.2	0.15	Takotsubo syndrome;	chr2:136379140	chr2:136329441~136329913:-
THCA	cis	rs34783982	0.748	rs12438134	ENSG00000259699.2	HMGB1P8	-3.36	0.00085	0.0471	-0.21	-0.15	Squamous cell lung carcinoma;	chr15:88944287	chr15:89135547~89136495:-
THCA	cis	rs6496667	0.557	rs2601203	ENSG00000213471.7	TTLL13P	3.36	0.00085	0.0471	0.18	0.15	Rheumatoid arthritis;	chr15:90414897	chr15:90249530~90265482:+
THCA	cis	rs7712401	1	rs7712401	ENSG00000276047.1	Metazoa_SRP	3.36	0.00085	0.0471	0.19	0.15	Mean platelet volume;	chr5:123038764	chr5:123070782~123071080:+
THCA	cis	rs12257961	0.549	rs1955342	ENSG00000237032.1	RP11-398C13.2	-3.36	0.00085	0.0471	-0.2	-0.15	Selective IgA deficiency;	chr10:15335872	chr10:14723171~14724055:-
THCA	cis	rs9287719	0.674	rs6432130	ENSG00000243819.4	RN7SL832P	-3.36	0.000851	0.0471	-0.12	-0.15	Prostate cancer;	chr2:10681431	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.674	rs11691060	ENSG00000243819.4	RN7SL832P	-3.36	0.000851	0.0471	-0.12	-0.15	Prostate cancer;	chr2:10686935	chr2:10690344~10692099:+
THCA	cis	rs9287719	0.674	rs11684157	ENSG00000243819.4	RN7SL832P	-3.36	0.000851	0.0471	-0.12	-0.15	Prostate cancer;	chr2:10687031	chr2:10690344~10692099:+
THCA	cis	rs9916302	0.752	rs8071300	ENSG00000266469.1	CTB-131K11.1	3.36	0.000851	0.0471	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39352271	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs4287601	ENSG00000266469.1	CTB-131K11.1	3.36	0.000851	0.0471	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39357599	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs2338799	ENSG00000266469.1	CTB-131K11.1	3.36	0.000851	0.0471	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39357688	chr17:39401793~39406233:+
THCA	cis	rs9916302	0.706	rs6503504	ENSG00000266469.1	CTB-131K11.1	3.36	0.000851	0.0471	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39358159	chr17:39401793~39406233:+
THCA	cis	rs6517329	0.526	rs2835291	ENSG00000214867.3	SRSF9P1	-3.36	0.000851	0.0471	-0.21	-0.15	Schizophrenia;	chr21:36166622	chr21:36295173~36295702:-
THCA	cis	rs910316	0.763	rs175044	ENSG00000273565.1	CTD-3075F15.1	-3.36	0.000851	0.0471	-0.18	-0.15	Height;	chr14:75005406	chr14:75176929~75177418:+
THCA	cis	rs913655	0.893	rs2480318	ENSG00000240291.1	RP11-499P20.2	-3.36	0.000851	0.0471	-0.11	-0.15	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18808847	chr10:18513115~18545651:-
THCA	cis	rs2034088	0.965	rs28537324	ENSG00000231784.7	DBIL5P	3.36	0.000851	0.0471	0.17	0.15	Hip circumference adjusted for BMI;	chr17:540287	chr17:752660~755336:+
THCA	cis	rs4819052	0.788	rs13049700	ENSG00000184274.3	LINC00315	-3.36	0.000851	0.0471	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45300245~45305257:-
THCA	cis	rs2668423	0.922	rs3826942	ENSG00000261526.2	CTB-31O20.2	-3.36	0.000851	0.0471	-0.11	-0.15	Nonalcoholic fatty liver disease;	chr19:1360576	chr19:1874871~1876169:-
THCA	cis	rs9549260	0.755	rs4943798	ENSG00000275149.1	RP11-427J23.1	-3.36	0.000851	0.0471	-0.2	-0.15	Red blood cell count;	chr13:40628811	chr13:40079106~40273509:-
THCA	cis	rs9549260	0.709	rs4581585	ENSG00000275149.1	RP11-427J23.1	-3.36	0.000851	0.0471	-0.2	-0.15	Red blood cell count;	chr13:40629768	chr13:40079106~40273509:-
THCA	cis	rs8072100	0.512	rs9674670	ENSG00000260075.1	NSFP1	-3.36	0.000851	0.0471	-0.19	-0.15	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:46372855~46487141:+
THCA	cis	rs1440410	0.835	rs11940580	ENSG00000250326.1	RP11-284M14.1	-3.36	0.000851	0.0471	-0.14	-0.15	Ischemic stroke;	chr4:143240372	chr4:142933195~143184861:-
THCA	cis	rs3015497	0.653	rs2356455	ENSG00000270062.1	RP11-248J18.3	3.36	0.000851	0.0471	0.17	0.15	Mean platelet volume;	chr14:50626424	chr14:50723777~50724272:-
THCA	cis	rs11237982	0.543	rs34899775	ENSG00000255345.1	CTD-2337I7.1	-3.36	0.000851	0.0471	-0.24	-0.15	Verbal declarative memory;	chr11:79691721	chr11:79092848~79098003:+
THCA	cis	rs743757	0.536	rs67813889	ENSG00000232352.1	SEMA3B-AS1	3.36	0.000851	0.0471	0.24	0.15	Diastolic blood pressure;	chr3:50592790	chr3:50266641~50267371:-
THCA	cis	rs806215	1	rs806196	ENSG00000279265.1	AC000123.3	-3.36	0.000851	0.0471	-0.18	-0.15	Type 2 diabetes;	chr7:127608360	chr7:127349833~127350293:-
THCA	cis	rs806215	1	rs712698	ENSG00000279265.1	AC000123.3	-3.36	0.000851	0.0471	-0.18	-0.15	Type 2 diabetes;	chr7:127609044	chr7:127349833~127350293:-
THCA	cis	rs806215	0.906	rs806195	ENSG00000279265.1	AC000123.3	-3.36	0.000851	0.0471	-0.18	-0.15	Type 2 diabetes;	chr7:127609124	chr7:127349833~127350293:-
THCA	cis	rs6892003	0.951	rs13172820	ENSG00000213376.4	GAPDHP71	3.36	0.000851	0.0471	0.24	0.15	Clopidogrel active metabolite levels;	chr5:174769539	chr5:174513305~174514307:+
THCA	cis	rs7924176	0.601	rs11000882	ENSG00000232342.6	RP11-46O21.2	3.36	0.000851	0.0471	0.19	0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74130145	chr10:74506081~74530553:-
THCA	cis	rs7713065	0.797	rs3846729	ENSG00000263597.1	MIR3936	-3.36	0.000851	0.0471	-0.19	-0.15	Lung function (FEV1/FVC);	chr5:132471076	chr5:132365490~132365599:-
THCA	cis	rs988712	0.81	rs6484307	ENSG00000245573.6	BDNF-AS	-3.36	0.000851	0.0471	-0.14	-0.15	Obesity;	chr11:27500196	chr11:27506838~27698174:+
THCA	cis	rs6662572	0.906	rs11582058	ENSG00000234329.1	RP11-767N6.2	3.36	0.000851	0.0471	0.17	0.15	Blood protein levels;	chr1:45779751	chr1:45651039~45651826:-
THCA	cis	rs409045	0.965	rs406210	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000851	0.0471	-0.21	-0.15	Left ventricular mass;	chr5:34634285	chr5:34651457~34651888:-
THCA	cis	rs1504749	0.569	rs1007256	ENSG00000254608.1	RP11-56A10.1	-3.36	0.000851	0.0471	-0.21	-0.15	Intracranial aneurysm;	chr8:54379276	chr8:54648993~54869903:+
THCA	cis	rs7264396	0.79	rs1040695	ENSG00000088340.14	FER1L4	3.36	0.000851	0.0471	0.15	0.15	Total cholesterol levels;	chr20:35656907	chr20:35558737~35607562:-
THCA	cis	rs35791980	0.56	rs4729347	ENSG00000273341.1	RP5-899E9.1	-3.36	0.000851	0.0471	-0.17	-0.15	Pursuit maintenance gain;	chr7:77353163	chr7:77416673~77425443:+
THCA	cis	rs735539	0.598	rs2290144	ENSG00000238286.1	SLC35E1P1	-3.36	0.000851	0.0471	-0.17	-0.15	Dental caries;	chr13:20691519	chr13:20607268~20608131:+
THCA	cis	rs748404	0.631	rs6493084	ENSG00000224677.1	PDIA3P2	3.36	0.000851	0.0471	0.19	0.15	Lung cancer;	chr15:43355429	chr15:43649123~43649280:+
THCA	cis	rs748404	0.631	rs12905772	ENSG00000224677.1	PDIA3P2	3.36	0.000851	0.0471	0.19	0.15	Lung cancer;	chr15:43356246	chr15:43649123~43649280:+
THCA	cis	rs748404	0.676	rs4401024	ENSG00000224677.1	PDIA3P2	3.36	0.000851	0.0471	0.19	0.15	Lung cancer;	chr15:43358137	chr15:43649123~43649280:+
THCA	cis	rs806215	0.547	rs11772303	ENSG00000224138.1	AC000123.4	3.36	0.000851	0.0471	0.16	0.15	Type 2 diabetes;	chr7:127758908	chr7:127350128~127351523:+
THCA	cis	rs9926296	0.607	rs2079672	ENSG00000260259.1	RP11-368I7.4	3.36	0.000851	0.0471	0.16	0.15	Vitiligo;	chr16:89818509	chr16:89682620~89686569:-
THCA	cis	rs12633726	0.515	rs7640298	ENSG00000214192.3	UBE2V1P2	-3.36	0.000851	0.0471	-0.27	-0.15	Influenza A (H1N1) severity;	chr3:175032049	chr3:175718231~175718670:-
THCA	cis	rs7028939	1	rs7860660	ENSG00000255145.2	STX17-AS1	-3.36	0.000851	0.0471	-0.23	-0.15	Preeclampsia;	chr9:100134922	chr9:99886322~99906601:-
THCA	cis	rs4763879	0.752	rs10772083	ENSG00000256673.1	RP11-599J14.2	-3.36	0.000851	0.0471	-0.19	-0.15	Type 1 diabetes;	chr12:9722302	chr12:9398355~9414851:-
THCA	cis	rs6601530	0.525	rs736668	ENSG00000255310.2	AF131215.2	-3.36	0.000851	0.0471	-0.13	-0.15	Carotid intima media thickness;	chr8:10764125	chr8:11107788~11109726:-
THCA	cis	rs7809950	0.817	rs2712224	ENSG00000272072.1	CTA-363E19.2	3.36	0.000851	0.0471	0.16	0.15	Coronary artery disease;	chr7:107540790	chr7:107192559~107193300:-
THCA	cis	rs7809950	0.861	rs10264412	ENSG00000272072.1	CTA-363E19.2	3.36	0.000851	0.0471	0.16	0.15	Coronary artery disease;	chr7:107543432	chr7:107192559~107193300:-
THCA	cis	rs7246657	1	rs12709812	ENSG00000268499.1	CTB-102L5.8	-3.36	0.000852	0.0471	-0.2	-0.15	Coronary artery calcification;	chr19:37303948	chr19:38199836~38200934:+
THCA	cis	rs1401543	0.891	rs17196097	ENSG00000239213.4	NCK1-AS1	-3.36	0.000852	0.0471	-0.17	-0.15	Anticoagulant levels;	chr3:135889065	chr3:136841726~136862054:-
THCA	cis	rs3750082	0.855	rs6462430	ENSG00000205763.12	RP9P	3.36	0.000852	0.0471	0.13	0.15	Glomerular filtration rate (creatinine);	chr7:32882219	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.889	rs7781915	ENSG00000205763.12	RP9P	3.36	0.000852	0.0471	0.13	0.15	Glomerular filtration rate (creatinine);	chr7:32883547	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.889	rs12154586	ENSG00000205763.12	RP9P	3.36	0.000852	0.0471	0.13	0.15	Glomerular filtration rate (creatinine);	chr7:32883759	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.889	rs970673	ENSG00000205763.12	RP9P	3.36	0.000852	0.0471	0.13	0.15	Glomerular filtration rate (creatinine);	chr7:32888115	chr7:32916815~32943176:-
THCA	cis	rs3750082	0.889	rs3750081	ENSG00000205763.12	RP9P	3.36	0.000852	0.0471	0.13	0.15	Glomerular filtration rate (creatinine);	chr7:32891264	chr7:32916815~32943176:-
THCA	cis	rs7709377	0.723	rs7720518	ENSG00000250015.1	CTC-339F2.2	3.36	0.000852	0.0471	0.16	0.15	Metabolite levels  (X-11787);	chr5:116177106	chr5:116302354~116304134:-
THCA	cis	rs7709377	0.723	rs7702975	ENSG00000250015.1	CTC-339F2.2	3.36	0.000852	0.0471	0.16	0.15	Metabolite levels  (X-11787);	chr5:116177123	chr5:116302354~116304134:-
THCA	cis	rs72843506	0.656	rs78325601	ENSG00000189423.10	USP32P3	3.36	0.000852	0.0471	0.26	0.15	Schizophrenia;	chr17:20018486	chr17:20415547~20431008:+
THCA	cis	rs72843506	0.656	rs74648067	ENSG00000189423.10	USP32P3	3.36	0.000852	0.0471	0.26	0.15	Schizophrenia;	chr17:20022938	chr17:20415547~20431008:+
THCA	cis	rs9796	0.87	rs3986311	ENSG00000247556.5	OIP5-AS1	3.36	0.000852	0.0471	0.12	0.15	Menopause (age at onset);	chr15:40972141	chr15:41283990~41309737:+
THCA	cis	rs6545883	0.525	rs1177274	ENSG00000212978.6	AC016747.3	3.36	0.000852	0.0471	0.16	0.15	Tuberculosis;	chr2:61141397	chr2:61141592~61144969:-
THCA	cis	rs867186	1	rs7263253	ENSG00000279253.1	RP4-614O4.13	-3.36	0.000852	0.0471	-0.25	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35061573	chr20:35262727~35264187:-
THCA	cis	rs867186	1	rs7268447	ENSG00000279253.1	RP4-614O4.13	-3.36	0.000852	0.0471	-0.25	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35061790	chr20:35262727~35264187:-
THCA	cis	rs867186	0.92	rs2145558	ENSG00000279253.1	RP4-614O4.13	-3.36	0.000852	0.0471	-0.25	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35062266	chr20:35262727~35264187:-
THCA	cis	rs10435719	0.58	rs13260712	ENSG00000255046.1	RP11-297N6.4	3.36	0.000852	0.0471	0.16	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:11797928~11802568:-
THCA	cis	rs11992162	0.551	rs13268217	ENSG00000255046.1	RP11-297N6.4	3.36	0.000852	0.0471	0.16	0.15	Monocyte count;	chr8:11925100	chr8:11797928~11802568:-
THCA	cis	rs11992162	0.573	rs13264994	ENSG00000255046.1	RP11-297N6.4	3.36	0.000852	0.0471	0.16	0.15	Monocyte count;	chr8:11925250	chr8:11797928~11802568:-
THCA	cis	rs11992162	0.573	rs13275808	ENSG00000255046.1	RP11-297N6.4	3.36	0.000852	0.0471	0.16	0.15	Monocyte count;	chr8:11925306	chr8:11797928~11802568:-
THCA	cis	rs513088	0.681	rs558843	ENSG00000225171.2	DUTP6	3.36	0.000852	0.0471	0.22	0.15	Schizophrenia;	chr1:166664979	chr1:166868748~166869209:+
THCA	cis	rs6687821	0.531	rs4656135	ENSG00000261737.1	RP4-612B15.3	3.36	0.000852	0.0471	0.24	0.15	Yeast infection;	chr1:87023404	chr1:86703502~86704462:-
THCA	cis	rs2562456	0.52	rs582992	ENSG00000268119.4	CTD-2561J22.5	-3.36	0.000852	0.0471	-0.22	-0.15	Pain;	chr19:21266744	chr19:21444241~21463908:-
THCA	cis	rs10109025	0.701	rs10101292	ENSG00000269899.1	RP11-589N15.2	3.36	0.000852	0.0471	0.17	0.15	Joint mobility (Beighton score);	chr8:10998964	chr8:11846154~11846391:-
THCA	cis	rs7631605	0.586	rs4336065	ENSG00000224080.1	UBE2FP1	3.36	0.000852	0.0471	0.17	0.15	Cerebrospinal P-tau181p levels;	chr3:37288163	chr3:37143512~37143958:-
THCA	cis	rs1799949	0.965	rs799912	ENSG00000236383.6	LINC00854	-3.36	0.000852	0.0471	-0.15	-0.15	Menopause (age at onset);	chr17:43105117	chr17:43216941~43305976:-
THCA	cis	rs3864261	1	rs62362241	ENSG00000249085.1	CTD-2631K10.1	3.36	0.000852	0.0471	0.23	0.15	Discordance in emotional problems in monozygotic twins;	chr5:73095266	chr5:72794405~72816565:-
THCA	cis	rs2486012	0.737	rs37468	ENSG00000234694.1	RP1-92O14.3	-3.36	0.000852	0.0471	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43814709	chr1:43354684~43358658:-
THCA	cis	rs1050631	1	rs1785914	ENSG00000260552.1	RP11-49I11.1	-3.36	0.000852	0.0471	-0.19	-0.15	Esophageal squamous cell cancer (length of survival);	chr18:36120833	chr18:36179996~36187448:-
THCA	cis	rs2180341	0.889	rs2000909	ENSG00000220522.2	RP1-177A13.1	3.36	0.000852	0.0471	0.19	0.15	Breast cancer;	chr6:127390028	chr6:127416535~127416952:-
THCA	cis	rs8028182	0.636	rs28432989	ENSG00000275645.1	RP11-817O13.9	3.36	0.000852	0.0471	0.15	0.15	Sudden cardiac arrest;	chr15:75475956	chr15:75346744~75347161:-
THCA	cis	rs758324	0.812	rs11954609	ENSG00000224431.1	AC063976.7	-3.36	0.000852	0.0471	-0.14	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131830045	chr5:132199456~132203487:+
THCA	cis	rs10908557	0.758	rs11264866	ENSG00000231416.1	RP11-422P24.9	3.36	0.000852	0.0471	0.19	0.15	Age at first birth;	chr1:154014574	chr1:153995632~153995960:+
THCA	cis	rs10908557	0.716	rs6679907	ENSG00000231416.1	RP11-422P24.9	3.36	0.000852	0.0471	0.19	0.15	Age at first birth;	chr1:154015676	chr1:153995632~153995960:+
THCA	cis	rs478304	0.654	rs11601509	ENSG00000245532.5	NEAT1	-3.36	0.000852	0.0471	-0.11	-0.15	Acne (severe);	chr11:65689393	chr11:65422774~65445540:+
THCA	cis	rs1362756	0.958	rs1073990	ENSG00000280344.1	AC009166.7	-3.36	0.000852	0.0471	-0.13	-0.15	Optic disc parameters;Optic disc area;	chr16:51446038	chr16:51176066~51178898:+
THCA	cis	rs3091242	0.933	rs9645452	ENSG00000228172.4	RP1-317E23.3	-3.36	0.000852	0.0471	-0.12	-0.15	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25816749~25820797:-
THCA	cis	rs7631605	0.905	rs58129217	ENSG00000272334.1	RP11-129K12.1	-3.36	0.000852	0.0471	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:36970133	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.905	rs7622170	ENSG00000272334.1	RP11-129K12.1	-3.36	0.000852	0.0471	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:36975085	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.905	rs7611106	ENSG00000272334.1	RP11-129K12.1	-3.36	0.000852	0.0471	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:36975533	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.875	rs56198917	ENSG00000272334.1	RP11-129K12.1	-3.36	0.000852	0.0471	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:36976307	chr3:36973117~36973672:-
THCA	cis	rs10943724	1	rs1454446	ENSG00000272129.1	RP11-250B2.6	3.36	0.000852	0.0472	0.2	0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80588971	chr6:80355424~80356859:+
THCA	cis	rs2434529	1	rs1833734	ENSG00000245275.6	SAP30L-AS1	3.36	0.000853	0.0472	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr5:154276758	chr5:154329437~154445850:-
THCA	cis	rs10504130	0.696	rs12677407	ENSG00000272024.1	RP11-546K22.3	-3.36	0.000853	0.0472	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51920718	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs59602923	ENSG00000272024.1	RP11-546K22.3	-3.36	0.000853	0.0472	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51923565	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs113096282	ENSG00000272024.1	RP11-546K22.3	-3.36	0.000853	0.0472	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51924206	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.735	rs77362085	ENSG00000272024.1	RP11-546K22.3	-3.36	0.000853	0.0472	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51924398	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.735	rs12681203	ENSG00000272024.1	RP11-546K22.3	-3.36	0.000853	0.0472	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51925292	chr8:51950284~51950690:+
THCA	cis	rs10504130	0.696	rs79069311	ENSG00000272024.1	RP11-546K22.3	-3.36	0.000853	0.0472	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51950284~51950690:+
THCA	cis	rs11673344	0.523	rs2562609	ENSG00000233527.7	ZNF529-AS1	3.36	0.000853	0.0472	0.13	0.15	Obesity-related traits;	chr19:37036255	chr19:36573070~36594708:+
THCA	cis	rs7181649	0.679	rs11539008	ENSG00000259924.1	RP11-16E23.4	3.36	0.000853	0.0472	0.23	0.15	Mean corpuscular hemoglobin;	chr15:65564315	chr15:65771176~65772139:-
THCA	cis	rs4589258	0.737	rs1783798	ENSG00000280367.1	RP11-121L10.2	-3.36	0.000853	0.0472	-0.15	-0.15	Intelligence (multi-trait analysis);	chr11:90710178	chr11:90223153~90226538:+
THCA	cis	rs4700393	0.967	rs921897	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Intelligence (multi-trait analysis);	chr5:60793310	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.51	rs10076679	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795124	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.527	rs6890201	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795365	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.51	rs6875456	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795503	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.51	rs6894750	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795729	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.51	rs6876335	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795991	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.51	rs6449501	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60796860	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.51	rs4235481	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797560	chr5:60891935~60893577:-
THCA	cis	rs61160187	0.505	rs4235482	ENSG00000215032.2	GNL3LP1	3.36	0.000853	0.0472	0.19	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797785	chr5:60891935~60893577:-
THCA	cis	rs7439493	0.865	rs17512351	ENSG00000247950.5	SEC24B-AS1	-3.36	0.000853	0.0472	-0.1	-0.15	Blood protein levels;	chr4:109724039	chr4:109347475~109433817:-
THCA	cis	rs61160187	0.673	rs4527549	ENSG00000272308.1	RP11-231G3.1	3.36	0.000853	0.0472	0.15	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60766918	chr5:60866457~60866935:-
THCA	cis	rs2652834	1	rs2729785	ENSG00000259459.4	RP11-321G12.1	-3.36	0.000853	0.0472	-0.16	-0.15	HDL cholesterol;	chr15:63110375	chr15:63390136~63438320:+
THCA	cis	rs2652834	1	rs2729784	ENSG00000259459.4	RP11-321G12.1	-3.36	0.000853	0.0472	-0.16	-0.15	HDL cholesterol;	chr15:63110536	chr15:63390136~63438320:+
THCA	cis	rs2652834	1	rs2729781	ENSG00000259459.4	RP11-321G12.1	-3.36	0.000853	0.0472	-0.16	-0.15	HDL cholesterol;	chr15:63112066	chr15:63390136~63438320:+
THCA	cis	rs4794202	0.629	rs62076106	ENSG00000264920.1	RP11-6N17.4	-3.36	0.000853	0.0472	-0.21	-0.15	Alzheimer's disease (cognitive decline);	chr17:47813113	chr17:47891255~47895812:-
THCA	cis	rs7586879	0.639	rs6722022	ENSG00000224165.4	DNAJC27-AS1	-3.36	0.000853	0.0472	-0.09	-0.15	Body mass index;	chr2:24875990	chr2:24971390~25039694:+
THCA	cis	rs412658	0.504	rs369128	ENSG00000268117.1	VN1R84P	-3.36	0.000853	0.0472	-0.19	-0.15	Telomere length;	chr19:21925064	chr19:21719801~21720035:-
THCA	cis	rs412658	0.504	rs17769372	ENSG00000268117.1	VN1R84P	-3.36	0.000853	0.0472	-0.19	-0.15	Telomere length;	chr19:21931902	chr19:21719801~21720035:-
THCA	cis	rs41419946	1	rs114251281	ENSG00000236206.1	RP11-306I1.2	-3.36	0.000853	0.0472	-0.39	-0.15	Gut microbiome composition (winter);	chr1:165439309	chr1:165598463~165623331:+
THCA	cis	rs9925964	0.804	rs4889606	ENSG00000279196.1	RP11-1072A3.3	3.36	0.000853	0.0472	0.15	0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30999862	chr16:30984630~30988270:-
THCA	cis	rs6788895	1	rs60523415	ENSG00000244265.1	SIAH2-AS1	3.36	0.000853	0.0472	0.41	0.15	Breast cancer;	chr3:150759215	chr3:150761937~150762538:+
THCA	cis	rs6788895	1	rs75942495	ENSG00000244265.1	SIAH2-AS1	3.36	0.000853	0.0472	0.41	0.15	Breast cancer;	chr3:150760090	chr3:150761937~150762538:+
THCA	cis	rs9818758	0.556	rs9835439	ENSG00000229759.1	MRPS18AP1	-3.36	0.000853	0.0472	-0.31	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49182897	chr3:48256350~48256938:-
THCA	cis	rs4589258	0.788	rs7942155	ENSG00000280367.1	RP11-121L10.2	3.36	0.000853	0.0472	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90734350	chr11:90223153~90226538:+
THCA	cis	rs9902453	0.904	rs12936302	ENSG00000250462.7	LRRC37BP1	-3.36	0.000853	0.0472	-0.12	-0.15	Coffee consumption (cups per day);	chr17:30022458	chr17:30629680~30637466:+
THCA	cis	rs9400467	0.528	rs11153280	ENSG00000272356.1	RP5-1112D6.8	-3.36	0.000853	0.0472	-0.12	-0.15	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111309203~111313517:+
THCA	cis	rs1789	0.706	rs7696938	ENSG00000251379.1	RP11-484O2.1	3.36	0.000853	0.0472	0.21	0.15	Blood protein levels;	chr4:15701954	chr4:15358141~15420032:-
THCA	cis	rs7005380	0.733	rs10107579	ENSG00000279347.1	RP11-85I17.2	3.36	0.000853	0.0472	0.17	0.15	Interstitial lung disease;	chr8:119922329	chr8:119838736~119840385:-
THCA	cis	rs9402743	0.632	rs6570038	ENSG00000272189.1	RP3-325F22.5	3.36	0.000853	0.0472	0.15	0.15	Systemic lupus erythematosus;	chr6:135775465	chr6:136550661~136552554:+
THCA	cis	rs944289	0.718	rs12878623	ENSG00000212071.1	AL162511.1	3.36	0.000853	0.0472	0.17	0.15	Thyroid cancer;	chr14:36081499	chr14:36196480~36196568:-
THCA	cis	rs6545883	0.894	rs2694643	ENSG00000212978.6	AC016747.3	3.36	0.000853	0.0472	0.17	0.15	Tuberculosis;	chr2:61377248	chr2:61141592~61144969:-
THCA	cis	rs2243480	0.901	rs778730	ENSG00000237310.1	GS1-124K5.4	3.36	0.000853	0.0472	0.18	0.15	Diabetic kidney disease;	chr7:66358338	chr7:66493706~66495474:+
THCA	cis	rs12468579	0.77	rs13395505	ENSG00000235852.1	AC005540.3	-3.36	0.000854	0.0472	-0.15	-0.15	JT interval (sulfonylurea treatment interaction);	chr2:190973788	chr2:190880797~190882059:-
THCA	cis	rs786425	0.966	rs3748269	ENSG00000278112.1	RP11-972P1.11	3.36	0.000854	0.0472	0.14	0.15	Pubertal anthropometrics;	chr12:123615378	chr12:123519390~123519856:-
THCA	cis	rs2239547	0.603	rs2276825	ENSG00000243224.1	RP5-1157M23.2	-3.36	0.000854	0.0472	-0.18	-0.15	Schizophrenia;	chr3:52852589	chr3:52239258~52241097:+
THCA	cis	rs7737355	0.853	rs11745955	ENSG00000237714.1	P4HA2-AS1	3.36	0.000854	0.0472	0.21	0.15	Life satisfaction;	chr5:131269450	chr5:132184876~132192808:+
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000281021.1	RP1-12G14.9	-3.36	0.000854	0.0472	-0.15	-0.15	Lung cancer;	chr6:149669173	chr6:149576089~149590864:-
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000281021.1	RP1-12G14.9	-3.36	0.000854	0.0472	-0.15	-0.15	Lung cancer;	chr6:149669447	chr6:149576089~149590864:-
THCA	cis	rs2977125	0.815	rs2956745	ENSG00000251468.2	RP11-369K16.1	-3.36	0.000854	0.0472	-0.22	-0.15	Schizophrenia;	chr8:12881190	chr8:12958387~12962200:+
THCA	cis	rs7395662	1	rs11039890	ENSG00000200090.1	Y_RNA	-3.36	0.000854	0.0472	-0.1	-0.15	HDL cholesterol;	chr11:48631916	chr11:47726894~47726992:-
THCA	cis	rs1799949	0.773	rs2137990	ENSG00000236383.6	LINC00854	3.36	0.000854	0.0472	0.15	0.15	Menopause (age at onset);	chr17:43165879	chr17:43216941~43305976:-
THCA	cis	rs116988415	0.551	rs2269294	ENSG00000272909.1	CTD-2555O16.4	3.36	0.000854	0.0472	0.18	0.15	Daytime sleep phenotypes;	chr14:64819466	chr14:64440369~64442238:-
THCA	cis	rs7252981	0.632	rs8113682	ENSG00000271283.1	CTC-412M14.6	-3.36	0.000854	0.0472	-0.2	-0.15	Perceived unattractiveness to mosquitoes;	chr19:19632921	chr19:19699203~19699409:-
THCA	cis	rs7252981	0.632	rs11878202	ENSG00000271283.1	CTC-412M14.6	-3.36	0.000854	0.0472	-0.2	-0.15	Perceived unattractiveness to mosquitoes;	chr19:19633270	chr19:19699203~19699409:-
THCA	cis	rs701145	0.556	rs355771	ENSG00000243069.6	ARHGEF26-AS1	3.36	0.000854	0.0472	0.2	0.15	Coronary artery disease;	chr3:154321596	chr3:154024401~154121332:-
THCA	cis	rs7028939	1	rs10988954	ENSG00000255145.2	STX17-AS1	-3.36	0.000854	0.0472	-0.23	-0.15	Preeclampsia;	chr9:100048927	chr9:99886322~99906601:-
THCA	cis	rs2933343	0.7	rs789239	ENSG00000261159.1	RP11-723O4.9	3.36	0.000854	0.0472	0.16	0.15	IgG glycosylation;	chr3:128914965	chr3:128859716~128860526:-
THCA	cis	rs7620503	0.729	rs13082698	ENSG00000228561.2	RP11-114M1.1	3.36	0.000854	0.0472	0.18	0.15	Corneal structure;	chr3:177588160	chr3:177683627~177691250:+
THCA	cis	rs7487075	0.619	rs10880969	ENSG00000275481.1	RP11-474P2.6	3.36	0.000854	0.0472	0.15	0.15	Itch intensity from mosquito bite;	chr12:46433240	chr12:46388856~46392126:+
THCA	cis	rs9876781	0.559	rs7610524	ENSG00000228638.1	FCF1P2	-3.36	0.000854	0.0472	-0.15	-0.15	Longevity;	chr3:48353882	chr3:48290793~48291375:-
THCA	cis	rs34421088	0.56	rs2245357	ENSG00000255495.1	AC145124.2	-3.36	0.000854	0.0472	-0.18	-0.15	Neuroticism;	chr8:11541975	chr8:12194467~12196280:+
THCA	cis	rs11190604	0.767	rs12360395	ENSG00000273030.1	RP11-285F16.1	3.36	0.000854	0.0472	0.17	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100434317	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs10883489	ENSG00000273030.1	RP11-285F16.1	3.36	0.000854	0.0472	0.17	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100434775	chr10:100412934~100413421:+
THCA	cis	rs11190604	0.767	rs10883491	ENSG00000273030.1	RP11-285F16.1	3.36	0.000854	0.0472	0.17	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100436314	chr10:100412934~100413421:+
THCA	cis	rs11168618	0.846	rs11168586	ENSG00000257763.1	OR5BK1P	3.36	0.000854	0.0472	0.13	0.15	Adiponectin levels;	chr12:48460229	chr12:48355792~48356614:-
THCA	cis	rs4713118	0.955	rs9393848	ENSG00000219891.2	ZSCAN12P1	3.36	0.000854	0.0472	0.2	0.15	Parkinson's disease;	chr6:27720590	chr6:28091154~28093664:+
THCA	cis	rs7394190	0.748	rs2306325	ENSG00000272599.2	RP11-152N13.16	3.36	0.000854	0.0472	0.2	0.15	Incident atrial fibrillation;	chr10:73746916	chr10:73124573~73125532:-
THCA	cis	rs7394190	0.748	rs11000764	ENSG00000272599.2	RP11-152N13.16	3.36	0.000854	0.0472	0.2	0.15	Incident atrial fibrillation;	chr10:73747106	chr10:73124573~73125532:-
THCA	cis	rs7191700	0.578	rs243327	ENSG00000263179.1	HNRNPCP4	3.36	0.000854	0.0472	0.19	0.15	Multiple sclerosis;	chr16:11259447	chr16:11242653~11243552:+
THCA	cis	rs11030122	0.632	rs10835556	ENSG00000230593.3	AC090804.1	3.36	0.000854	0.0472	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:4061783	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.632	rs4910596	ENSG00000230593.3	AC090804.1	3.36	0.000854	0.0472	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:4063374	chr11:3892398~3892887:-
THCA	cis	rs982100	0.556	rs11123439	ENSG00000226856.4	AC093901.1	3.36	0.000854	0.0472	0.24	0.15	Alzheimer disease and age of onset;	chr2:117655519	chr2:118132128~118186386:-
THCA	cis	rs982100	0.63	rs13031912	ENSG00000226856.4	AC093901.1	3.36	0.000854	0.0472	0.24	0.15	Alzheimer disease and age of onset;	chr2:117655703	chr2:118132128~118186386:-
THCA	cis	rs982100	0.63	rs13032818	ENSG00000226856.4	AC093901.1	3.36	0.000854	0.0472	0.24	0.15	Alzheimer disease and age of onset;	chr2:117656105	chr2:118132128~118186386:-
THCA	cis	rs6445967	0.554	rs62259824	ENSG00000272360.1	RP11-359I18.5	3.36	0.000854	0.0472	0.19	0.15	Platelet count;	chr3:58475938	chr3:58490830~58491291:-
THCA	cis	rs1362756	1	rs1362756	ENSG00000280344.1	AC009166.7	3.36	0.000854	0.0472	0.13	0.15	Optic disc parameters;Optic disc area;	chr16:51424379	chr16:51176066~51178898:+
THCA	cis	rs2934442	0.611	rs11632811	ENSG00000276772.1	CTD-2515H24.2	3.36	0.000854	0.0472	0.18	0.15	Bipolar disorder (age of onset and psychotic symptoms);	chr15:57471789	chr15:57553955~57555680:+
THCA	cis	rs6546886	0.625	rs12991192	ENSG00000235499.1	AC073046.25	3.36	0.000854	0.0472	0.17	0.15	Dialysis-related mortality;	chr2:74082539	chr2:73985132~73986343:+
THCA	cis	rs35851103	0.6	rs4841662	ENSG00000255495.1	AC145124.2	-3.36	0.000854	0.0472	-0.17	-0.15	Neuroticism;	chr8:11986249	chr8:12194467~12196280:+
THCA	cis	rs1113500	0.524	rs11185270	ENSG00000230489.1	VAV3-AS1	-3.36	0.000854	0.0472	-0.14	-0.15	Growth-regulated protein alpha levels;	chr1:108111740	chr1:107964443~107994607:+
THCA	cis	rs1113500	0.548	rs17020971	ENSG00000230489.1	VAV3-AS1	-3.36	0.000854	0.0472	-0.14	-0.15	Growth-regulated protein alpha levels;	chr1:108112666	chr1:107964443~107994607:+
THCA	cis	rs6546886	0.536	rs7589197	ENSG00000235499.1	AC073046.25	3.36	0.000854	0.0472	0.13	0.15	Dialysis-related mortality;	chr2:74095342	chr2:73985132~73986343:+
THCA	cis	rs9902453	0.933	rs7221154	ENSG00000250462.7	LRRC37BP1	-3.36	0.000854	0.0472	-0.12	-0.15	Coffee consumption (cups per day);	chr17:30178006	chr17:30629680~30637466:+
THCA	cis	rs6988985	0.647	rs28459852	ENSG00000253741.1	CTD-2292P10.4	-3.36	0.000854	0.0472	-0.19	-0.15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905020	chr8:142702252~142726973:-
THCA	cis	rs710913	0.774	rs2695319	ENSG00000182109.6	RP11-69E11.4	3.36	0.000854	0.0472	0.15	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39591028	chr1:39522280~39546187:-
THCA	cis	rs8058578	1	rs8051050	ENSG00000274678.1	RP11-2C24.7	3.36	0.000855	0.0472	0.15	0.15	Multiple myeloma;	chr16:30676588	chr16:30821338~30821884:+
THCA	cis	rs11089937	0.609	rs9622980	ENSG00000215456.5	BCRP4	3.36	0.000855	0.0472	0.21	0.15	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.667	rs10483107	ENSG00000215456.5	BCRP4	3.36	0.000855	0.0472	0.21	0.15	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.667	rs11704024	ENSG00000215456.5	BCRP4	3.36	0.000855	0.0472	0.21	0.15	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22630061~22636153:+
THCA	cis	rs17122278	1	rs11216909	ENSG00000255239.1	AP002954.6	-3.36	0.000855	0.0473	-0.27	-0.15	Total cholesterol levels;	chr11:118579031	chr11:118688039~118690600:-
THCA	cis	rs2098713	0.561	rs4869440	ENSG00000250155.1	CTD-2353F22.1	3.36	0.000855	0.0473	0.15	0.15	Telomere length;	chr5:37600839	chr5:36666214~36725195:-
THCA	cis	rs12049351	0.774	rs2145395	ENSG00000229367.1	HMGN2P19	3.36	0.000855	0.0473	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229535234	chr1:229570532~229570796:+
THCA	cis	rs11030122	0.702	rs1349583	ENSG00000230593.3	AC090804.1	3.36	0.000855	0.0473	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3951006	chr11:3892398~3892887:-
THCA	cis	rs11168618	0.846	rs11168586	ENSG00000258273.1	RP11-370I10.4	-3.36	0.000855	0.0473	-0.19	-0.15	Adiponectin levels;	chr12:48460229	chr12:48333755~48333901:-
THCA	cis	rs864537	0.584	rs7523907	ENSG00000273160.1	RP11-104L21.3	3.36	0.000855	0.0473	0.16	0.15	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167458010	chr1:167457742~167459891:-
THCA	cis	rs9488822	0.702	rs10872141	ENSG00000233558.1	RP3-486I3.4	3.36	0.000855	0.0473	0.17	0.15	LDL cholesterol;Cholesterol, total;	chr6:116002083	chr6:116258493~116259115:-
THCA	cis	rs3770081	1	rs58365138	ENSG00000273080.1	RP11-301O19.1	-3.36	0.000855	0.0473	-0.36	-0.15	Facial emotion recognition (sad faces);	chr2:85985982	chr2:86195590~86196049:+
THCA	cis	rs2549003	1	rs6873426	ENSG00000233006.5	AC034220.3	-3.36	0.000855	0.0473	-0.12	-0.15	Asthma (sex interaction);	chr5:132482939	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs6894655	ENSG00000233006.5	AC034220.3	-3.36	0.000855	0.0473	-0.12	-0.15	Asthma (sex interaction);	chr5:132482957	chr5:132311285~132369916:-
THCA	cis	rs2549003	0.966	rs839	ENSG00000233006.5	AC034220.3	-3.36	0.000855	0.0473	-0.12	-0.15	Asthma (sex interaction);	chr5:132483434	chr5:132311285~132369916:-
THCA	cis	rs7760535	0.757	rs10456875	ENSG00000272356.1	RP5-1112D6.8	-3.36	0.000855	0.0473	-0.12	-0.15	Metabolic traits;	chr6:111428522	chr6:111309203~111313517:+
THCA	cis	rs12549025	0.836	rs2004645	ENSG00000253390.1	CTC-756D1.2	-3.36	0.000855	0.0473	-0.26	-0.15	Reticulocyte fraction of red cells;	chr8:23559578	chr8:23458601~23484971:+
THCA	cis	rs6847067	0.727	rs17009341	ENSG00000180769.7	WDFY3-AS2	3.36	0.000855	0.0473	0.12	0.15	Oropharynx cancer;	chr4:84923963	chr4:84965682~85011277:+
THCA	cis	rs6847067	0.8	rs72664952	ENSG00000180769.7	WDFY3-AS2	3.36	0.000855	0.0473	0.12	0.15	Oropharynx cancer;	chr4:84925938	chr4:84965682~85011277:+
THCA	cis	rs1113500	1	rs1777483	ENSG00000230489.1	VAV3-AS1	3.36	0.000855	0.0473	0.14	0.15	Growth-regulated protein alpha levels;	chr1:108066786	chr1:107964443~107994607:+
THCA	cis	rs1667255	1	rs1667237	ENSG00000266521.1	RP11-650P15.1	3.36	0.000855	0.0473	0.2	0.15	Retinol levels;	chr18:31574082	chr18:31496645~31497195:-
THCA	cis	rs27524	0.734	rs27037	ENSG00000272109.1	CTD-2260A17.3	-3.36	0.000856	0.0473	-0.2	-0.15	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96804353~96806105:+
THCA	cis	rs2242330	0.705	rs7670716	ENSG00000250075.4	RP11-584P21.2	3.36	0.000856	0.0473	0.21	0.15	Parkinson's disease;	chr4:67582656	chr4:67417305~67468251:-
THCA	cis	rs7173743	0.525	rs7166501	ENSG00000252061.1	RNU6-415P	3.36	0.000856	0.0473	0.19	0.15	Coronary artery disease;	chr15:78841397	chr15:78898840~78898936:-
THCA	cis	rs3864261	1	rs6452815	ENSG00000249085.1	CTD-2631K10.1	-3.36	0.000856	0.0473	-0.23	-0.15	Discordance in emotional problems in monozygotic twins;	chr5:73102324	chr5:72794405~72816565:-
THCA	cis	rs73076966	0.941	rs17794135	ENSG00000274269.1	RP4-545L17.12	3.36	0.000856	0.0473	0.24	0.15	Plateletcrit;	chr20:1555714	chr20:1186092~1207036:+
THCA	cis	rs73076966	1	rs11697395	ENSG00000274269.1	RP4-545L17.12	3.36	0.000856	0.0473	0.24	0.15	Plateletcrit;	chr20:1557620	chr20:1186092~1207036:+
THCA	cis	rs6546550	0.935	rs1377995	ENSG00000179818.12	PCBP1-AS1	-3.36	0.000856	0.0473	-0.12	-0.15	Prevalent atrial fibrillation;	chr2:69837023	chr2:69962263~70103220:-
THCA	cis	rs73198271	0.563	rs74556999	ENSG00000253981.4	ALG1L13P	-3.36	0.000856	0.0473	-0.2	-0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8690949	chr8:8236003~8244667:-
THCA	cis	rs7809950	0.817	rs2222845	ENSG00000272072.1	CTA-363E19.2	-3.36	0.000856	0.0473	-0.16	-0.15	Coronary artery disease;	chr7:107641384	chr7:107192559~107193300:-
THCA	cis	rs5994176	0.897	rs9306247	ENSG00000253691.2	IGKV2OR22-4	3.36	0.000856	0.0473	0.09	0.15	Blood protein levels;	chr22:17135825	chr22:16914235~16914981:-
THCA	cis	rs990871	0.546	rs12035763	ENSG00000227207.2	RPL31P12	-3.36	0.000856	0.0473	-0.19	-0.15	Subcutaneous adipose tissue;	chr1:72464952	chr1:72301472~72301829:+
THCA	cis	rs524281	0.648	rs10896089	ENSG00000255038.1	RP11-1167A19.2	-3.36	0.000856	0.0473	-0.18	-0.15	Electroencephalogram traits;	chr11:66168821	chr11:66067277~66069619:-
THCA	cis	rs13046373	0.535	rs2226377	ENSG00000174680.8	GRIK1-AS1	-3.36	0.000856	0.0473	-0.19	-0.15	HDL cholesterol;	chr21:30659597	chr21:29748175~29764002:+
THCA	cis	rs7107174	0.901	rs10899473	ENSG00000254459.1	RP11-91P24.7	-3.36	0.000856	0.0473	-0.21	-0.15	Testicular germ cell tumor;	chr11:78331937	chr11:77829654~77872262:-
THCA	cis	rs9348440	0.615	rs13437429	ENSG00000280989.1	LINC00581	3.36	0.000856	0.0473	0.23	0.15	Glycemic traits;	chr6:20626420	chr6:21486061~21511895:-
THCA	cis	rs10760158	0.832	rs10818523	ENSG00000235865.2	GSN-AS1	3.36	0.000856	0.0473	0.13	0.15	Pulse pressure;	chr9:121265809	chr9:121280768~121285530:-
THCA	cis	rs10760158	0.832	rs963003	ENSG00000235865.2	GSN-AS1	3.36	0.000856	0.0473	0.13	0.15	Pulse pressure;	chr9:121272531	chr9:121280768~121285530:-
THCA	cis	rs76419734	0.85	rs17036066	ENSG00000251175.4	RP11-45L9.1	3.36	0.000856	0.0473	0.42	0.15	Post bronchodilator FEV1;	chr4:105646060	chr4:105746245~105827172:-
THCA	cis	rs1005277	0.522	rs11011343	ENSG00000273019.1	RP11-508N22.13	-3.36	0.000856	0.0473	-0.17	-0.15	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38149968~38150293:+
THCA	cis	rs409045	0.965	rs409078	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34628764	chr5:34651457~34651888:-
THCA	cis	rs409045	0.965	rs440827	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34629846	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs402954	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34629926	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs436061	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34630619	chr5:34651457~34651888:-
THCA	cis	rs409045	0.965	rs422402	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34630746	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs457451	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34631255	chr5:34651457~34651888:-
THCA	cis	rs409045	0.965	rs457361	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34631573	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs467222	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34631769	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs455613	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34632561	chr5:34651457~34651888:-
THCA	cis	rs409045	0.965	rs436961	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34633066	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs408815	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34633094	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs416207	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34633104	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs367167	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34633287	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs466261	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34633650	chr5:34651457~34651888:-
THCA	cis	rs409045	1	rs458995	ENSG00000271874.1	CTD-2024P10.2	-3.36	0.000856	0.0473	-0.2	-0.15	Left ventricular mass;	chr5:34633804	chr5:34651457~34651888:-
THCA	cis	rs12887734	0.524	rs4906363	ENSG00000269958.1	RP11-73M18.8	3.36	0.000856	0.0473	0.15	0.15	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103696353~103697163:+
THCA	cis	rs7542375	0.594	rs2807852	ENSG00000272823.1	RP11-295M18.6	-3.36	0.000856	0.0473	-0.19	-0.15	Obesity-related traits;	chr1:220850814	chr1:220828676~220829211:-
THCA	cis	rs4789693	0.872	rs28612648	ENSG00000279744.1	RP13-20L14.10	-3.36	0.000856	0.0473	-0.14	-0.15	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82462601~82464255:+
THCA	cis	rs3739034	0.877	rs4953923	ENSG00000224043.6	CCNT2-AS1	-3.36	0.000856	0.0473	-0.19	-0.15	Gut microbiome composition (winter);	chr2:134688376	chr2:134735464~134918710:-
THCA	cis	rs3176789	0.914	rs1029992	ENSG00000256673.1	RP11-599J14.2	3.36	0.000856	0.0473	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773162	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.914	rs1029991	ENSG00000256673.1	RP11-599J14.2	3.36	0.000856	0.0473	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773468	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.914	rs1029990	ENSG00000256673.1	RP11-599J14.2	3.36	0.000856	0.0473	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773801	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.914	rs10844749	ENSG00000256673.1	RP11-599J14.2	3.36	0.000856	0.0473	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774028	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.914	rs1540356	ENSG00000256673.1	RP11-599J14.2	3.36	0.000856	0.0473	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774188	chr12:9398355~9414851:-
THCA	cis	rs3176789	0.914	rs1540355	ENSG00000256673.1	RP11-599J14.2	3.36	0.000856	0.0473	0.21	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774272	chr12:9398355~9414851:-
THCA	cis	rs7578982	0.821	rs56226558	ENSG00000227992.1	AC108463.2	3.36	0.000856	0.0473	0.2	0.15	White blood cell types;	chr2:111078756	chr2:111203964~111206215:-
THCA	cis	rs16971802	1	rs16971802	ENSG00000273687.1	RP5-837J1.6	-3.36	0.000856	0.0473	-0.31	-0.15	Blood protein levels;	chr17:35984351	chr17:35018660~35018991:+
THCA	cis	rs4660456	0.913	rs556875	ENSG00000238287.1	RP11-656D10.3	-3.36	0.000856	0.0473	-0.19	-0.15	Platelet count;	chr1:40688571	chr1:40493157~40508661:-
THCA	cis	rs71277158	0.624	rs61493476	ENSG00000242578.1	RP11-469J4.3	3.36	0.000857	0.0473	0.24	0.15	Prostate cancer;	chr3:170170043	chr3:170410512~170418615:+
THCA	cis	rs8112211	0.731	rs2368484	ENSG00000267291.1	CTB-186G2.1	3.36	0.000857	0.0473	0.18	0.15	Blood protein levels;	chr19:38334807	chr19:38596346~38601694:+
THCA	cis	rs4141404	0.582	rs5753630	ENSG00000224050.1	RP1-90G24.6	-3.36	0.000857	0.0473	-0.19	-0.15	Paclitaxel-induced neuropathy;	chr22:31465964	chr22:32273420~32277186:+
THCA	cis	rs7439493	0.58	rs2107050	ENSG00000247950.5	SEC24B-AS1	3.36	0.000857	0.0473	0.1	0.15	Blood protein levels;	chr4:109658630	chr4:109347475~109433817:-
THCA	cis	rs1048886	0.872	rs12201029	ENSG00000271967.1	RP11-134K13.4	-3.36	0.000857	0.0473	-0.18	-0.15	Type 2 diabetes;	chr6:70599019	chr6:70596438~70596980:+
THCA	cis	rs9450351	0.744	rs7738777	ENSG00000280232.1	RP11-321N4.4	3.36	0.000857	0.0473	0.33	0.15	Interferon gamma-induced protein 10 levels;	chr6:85923468	chr6:85498441~85499058:-
THCA	cis	rs818427	0.508	rs10076641	ENSG00000270067.1	CTC-487M23.5	3.36	0.000857	0.0473	0.13	0.15	Total body bone mineral density;	chr5:112721403	chr5:112893333~112894001:+
THCA	cis	rs755249	0.567	rs41270821	ENSG00000237624.1	OXCT2P1	3.36	0.000857	0.0473	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39514956~39516490:+
THCA	cis	rs755249	0.567	rs2296175	ENSG00000237624.1	OXCT2P1	3.36	0.000857	0.0473	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39514956~39516490:+
THCA	cis	rs9534288	0.671	rs4942465	ENSG00000235903.6	CPB2-AS1	3.36	0.000857	0.0473	0.21	0.15	Blood protein levels;	chr13:45988552	chr13:46052806~46113332:+
THCA	cis	rs11030122	0.702	rs10835312	ENSG00000230593.3	AC090804.1	3.36	0.000857	0.0473	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3929023	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.702	rs4910866	ENSG00000230593.3	AC090804.1	3.36	0.000857	0.0473	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3929324	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.702	rs10767715	ENSG00000230593.3	AC090804.1	3.36	0.000857	0.0473	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3930179	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.702	rs1013351	ENSG00000230593.3	AC090804.1	3.36	0.000857	0.0473	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3931073	chr11:3892398~3892887:-
THCA	cis	rs6715793	0.901	rs6707904	ENSG00000272754.1	AL133245.2	-3.36	0.000857	0.0473	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33180265	chr2:32321638~32323002:+
THCA	cis	rs6715793	0.901	rs5006126	ENSG00000272754.1	AL133245.2	-3.36	0.000857	0.0473	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33180398	chr2:32321638~32323002:+
THCA	cis	rs10438797	0.838	rs6505112	ENSG00000240531.1	RPL21P123	3.36	0.000857	0.0473	0.2	0.15	Night sleep phenotypes;	chr17:29165615	chr17:29716279~29716685:-
THCA	cis	rs9467773	0.869	rs1796521	ENSG00000228223.2	HCG11	3.36	0.000857	0.0473	0.17	0.15	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26523450~26526579:+
THCA	cis	rs793571	0.822	rs10518991	ENSG00000245975.2	RP11-30K9.6	3.36	0.000857	0.0473	0.17	0.15	Schizophrenia;	chr15:58898731	chr15:58768072~58770974:-
THCA	cis	rs1232027	0.545	rs1650742	ENSG00000251221.1	LINC01337	3.36	0.000857	0.0473	0.18	0.15	Huntington's disease progression;	chr5:80695064	chr5:80608623~80622524:-
THCA	cis	rs2486012	0.737	rs2906470	ENSG00000237950.1	RP11-7O11.3	3.36	0.000857	0.0473	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43840887	chr1:43944370~43946551:-
THCA	cis	rs4819052	0.851	rs8126930	ENSG00000184274.3	LINC00315	-3.36	0.000857	0.0473	-0.18	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45300245~45305257:-
THCA	cis	rs11085466	1	rs4399664	ENSG00000268119.4	CTD-2561J22.5	-3.36	0.000857	0.0473	-0.2	-0.15	Colorectal or endometrial cancer;	chr19:21595224	chr19:21444241~21463908:-
THCA	cis	rs2098713	0.561	rs57015453	ENSG00000250155.1	CTD-2353F22.1	3.36	0.000857	0.0474	0.15	0.15	Telomere length;	chr5:37596878	chr5:36666214~36725195:-
THCA	cis	rs6832769	0.961	rs2412646	ENSG00000223305.1	RN7SKP30	3.36	0.000857	0.0474	0.19	0.15	Personality dimensions;	chr4:55452605	chr4:55540502~55540835:-
THCA	cis	rs6832769	1	rs11733864	ENSG00000223305.1	RN7SKP30	3.36	0.000857	0.0474	0.19	0.15	Personality dimensions;	chr4:55455363	chr4:55540502~55540835:-
THCA	cis	rs6840360	1	rs6846114	ENSG00000270265.1	RP11-731D1.4	3.36	0.000857	0.0474	0.14	0.15	Intelligence (multi-trait analysis);	chr4:151683406	chr4:151333775~151353224:-
THCA	cis	rs524281	0.861	rs918299	ENSG00000255038.1	RP11-1167A19.2	-3.36	0.000857	0.0474	-0.17	-0.15	Electroencephalogram traits;	chr11:66160136	chr11:66067277~66069619:-
THCA	cis	rs2434529	1	rs528184	ENSG00000245275.6	SAP30L-AS1	3.36	0.000857	0.0474	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr5:154265368	chr5:154329437~154445850:-
THCA	cis	rs6088580	0.634	rs6142153	ENSG00000126005.14	MMP24-AS1	3.36	0.000857	0.0474	0.14	0.15	Glomerular filtration rate (creatinine);	chr20:34380941	chr20:35216462~35278131:-
THCA	cis	rs8046148	0.789	rs4785383	ENSG00000279356.1	RP11-429P3.8	-3.36	0.000857	0.0474	-0.2	-0.15	Testicular germ cell tumor;	chr16:50113891	chr16:50072862~50074986:+
THCA	cis	rs8046148	0.789	rs4785384	ENSG00000279356.1	RP11-429P3.8	-3.36	0.000857	0.0474	-0.2	-0.15	Testicular germ cell tumor;	chr16:50114082	chr16:50072862~50074986:+
THCA	cis	rs2832191	0.935	rs11910475	ENSG00000232855.5	AF131217.1	3.36	0.000857	0.0474	0.16	0.15	Dental caries;	chr21:29147381	chr21:28439346~28674848:-
THCA	cis	rs12621844	0.833	rs11695011	ENSG00000272663.1	RP11-191L17.1	-3.36	0.000857	0.0474	-0.14	-0.15	Glycated hemoglobin levels;	chr2:48180338	chr2:48440043~48440597:-
THCA	cis	rs7474896	0.609	rs11011336	ENSG00000276805.1	RP11-291L22.6	3.36	0.000857	0.0474	0.2	0.15	Obesity (extreme);	chr10:37696388	chr10:38451030~38451785:+
THCA	cis	rs2395128	0.705	rs7072392	ENSG00000236842.1	RP11-399K21.10	3.36	0.000857	0.0474	0.23	0.15	Ulcerative colitis;Inflammatory bowel disease;	chr10:74943294	chr10:75430571~75431588:-
THCA	cis	rs1865760	0.568	rs2032450	ENSG00000272810.1	U91328.22	-3.36	0.000857	0.0474	-0.12	-0.15	Height;	chr6:25992886	chr6:26013241~26013757:+
THCA	cis	rs1865760	0.713	rs2013063	ENSG00000272810.1	U91328.22	-3.36	0.000857	0.0474	-0.12	-0.15	Height;	chr6:25993870	chr6:26013241~26013757:+
THCA	cis	rs66515264	0.912	rs4147827	ENSG00000230439.2	RP11-488P3.1	3.36	0.000857	0.0474	0.24	0.15	Orofacial clefts;Cleft lip with or without cleft palate;	chr1:94082524	chr1:93752924~93775444:-
THCA	cis	rs751728	0.648	rs6922275	ENSG00000274259.2	XXbac-BPG294E21.9	3.36	0.000857	0.0474	0.17	0.15	Crohn's disease;	chr6:33781962	chr6:33437363~33454453:-
THCA	cis	rs751728	0.664	rs943474	ENSG00000274259.2	XXbac-BPG294E21.9	3.36	0.000857	0.0474	0.17	0.15	Crohn's disease;	chr6:33782057	chr6:33437363~33454453:-
THCA	cis	rs751728	0.664	rs943478	ENSG00000274259.2	XXbac-BPG294E21.9	3.36	0.000857	0.0474	0.17	0.15	Crohn's disease;	chr6:33783163	chr6:33437363~33454453:-
THCA	cis	rs7978895	0.519	rs1995340	ENSG00000240759.1	RP11-25I15.1	3.36	0.000857	0.0474	0.17	0.15	Type 2 diabetes;	chr12:43325135	chr12:42678873~42679124:-
THCA	cis	rs17181170	0.553	rs2341251	ENSG00000239572.1	RP11-451B8.1	-3.36	0.000857	0.0474	-0.19	-0.15	Prostate cancer;	chr3:87130180	chr3:87731402~87793629:-
THCA	cis	rs17181170	0.574	rs9873581	ENSG00000239572.1	RP11-451B8.1	-3.36	0.000857	0.0474	-0.19	-0.15	Prostate cancer;	chr3:87136352	chr3:87731402~87793629:-
THCA	cis	rs17181170	0.553	rs1039154	ENSG00000239572.1	RP11-451B8.1	-3.36	0.000857	0.0474	-0.19	-0.15	Prostate cancer;	chr3:87136510	chr3:87731402~87793629:-
THCA	cis	rs1150668	0.796	rs728122	ENSG00000220721.1	OR1F12	3.36	0.000858	0.0474	0.16	0.15	Pubertal anthropometrics;	chr6:28431347	chr6:28073316~28074233:+
THCA	cis	rs9596863	0.821	rs4884722	ENSG00000136149.6	RPL13AP25	3.36	0.000858	0.0474	0.17	0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53855686	chr13:54440704~54441315:-
THCA	cis	rs453301	0.686	rs2409120	ENSG00000253981.4	ALG1L13P	-3.36	0.000858	0.0474	-0.15	-0.15	Joint mobility (Beighton score);	chr8:9025061	chr8:8236003~8244667:-
THCA	cis	rs11642862	1	rs74483355	ENSG00000275263.1	RP11-1072A3.4	-3.36	0.000858	0.0474	-0.33	-0.15	Tonsillectomy;	chr16:30825109	chr16:30956872~30957199:-
THCA	cis	rs944289	0.74	rs950319	ENSG00000212071.1	AL162511.1	3.36	0.000858	0.0474	0.17	0.15	Thyroid cancer;	chr14:36096786	chr14:36196480~36196568:-
THCA	cis	rs3771529	1	rs3771529	ENSG00000231024.1	AC092431.3	-3.36	0.000858	0.0474	-0.23	-0.15	Mean platelet volume;	chr2:69937708	chr2:69700192~69713847:-
THCA	cis	rs6456156	0.586	rs2001114	ENSG00000235272.1	FAM103A2P	3.36	0.000858	0.0474	0.21	0.15	Primary biliary cholangitis;	chr6:167073090	chr6:166586124~166586477:-
THCA	cis	rs7903456	0.648	rs9421561	ENSG00000200253.1	RNU6-529P	-3.36	0.000858	0.0474	-0.22	-0.15	Gout;Renal underexcretion gout;	chr10:87039315	chr10:87041238~87041341:-
THCA	cis	rs4948275	0.773	rs2787736	ENSG00000233643.2	RP11-491H19.1	3.36	0.000858	0.0474	0.17	0.15	Night sleep phenotypes;	chr10:61490694	chr10:61781745~61821246:-
THCA	cis	rs11048434	0.687	rs12814670	ENSG00000245105.2	A2M-AS1	3.36	0.000858	0.0474	0.12	0.15	Sjögren's syndrome;	chr12:8907429	chr12:9065177~9068060:+
THCA	cis	rs6840360	0.55	rs4696288	ENSG00000251611.1	RP11-610P16.1	-3.36	0.000858	0.0474	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151699998	chr4:151407551~151408835:-
THCA	cis	rs6840360	0.55	rs4696289	ENSG00000251611.1	RP11-610P16.1	-3.36	0.000858	0.0474	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151700085	chr4:151407551~151408835:-
THCA	cis	rs7394190	0.748	rs4746147	ENSG00000272599.2	RP11-152N13.16	3.35	0.000858	0.0474	0.2	0.15	Incident atrial fibrillation;	chr10:73767950	chr10:73124573~73125532:-
THCA	cis	rs7394190	0.748	rs3088070	ENSG00000272599.2	RP11-152N13.16	3.35	0.000858	0.0474	0.2	0.15	Incident atrial fibrillation;	chr10:73770255	chr10:73124573~73125532:-
THCA	cis	rs7394190	0.748	rs11541237	ENSG00000272599.2	RP11-152N13.16	3.35	0.000858	0.0474	0.2	0.15	Incident atrial fibrillation;	chr10:73771204	chr10:73124573~73125532:-
THCA	cis	rs7394190	0.748	rs11000772	ENSG00000272599.2	RP11-152N13.16	3.35	0.000858	0.0474	0.2	0.15	Incident atrial fibrillation;	chr10:73774230	chr10:73124573~73125532:-
THCA	cis	rs7394190	0.748	rs11000773	ENSG00000272599.2	RP11-152N13.16	3.35	0.000858	0.0474	0.2	0.15	Incident atrial fibrillation;	chr10:73774357	chr10:73124573~73125532:-
THCA	cis	rs7394190	0.688	rs76033784	ENSG00000272599.2	RP11-152N13.16	3.35	0.000858	0.0474	0.2	0.15	Incident atrial fibrillation;	chr10:73776212	chr10:73124573~73125532:-
THCA	cis	rs10829156	0.699	rs4747353	ENSG00000225527.1	RP11-383B4.4	-3.35	0.000858	0.0474	-0.22	-0.15	Sudden cardiac arrest;	chr10:18548028	chr10:18531849~18533336:-
THCA	cis	rs1065852	0.526	rs1062753	ENSG00000281538.1	RP4-669P10.20	-3.35	0.000858	0.0474	-0.16	-0.15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41996807	chr22:42138060~42139726:+
THCA	cis	rs806215	1	rs2106186	ENSG00000279265.1	AC000123.3	-3.35	0.000858	0.0474	-0.18	-0.15	Type 2 diabetes;	chr7:127601298	chr7:127349833~127350293:-
THCA	cis	rs17607347	0.738	rs806732	ENSG00000247324.2	RP11-510M2.2	-3.35	0.000858	0.0474	-0.24	-0.15	Intelligence (multi-trait analysis);	chr16:72375057	chr16:71462278~71465941:+
THCA	cis	rs9392556	0.666	rs2326403	ENSG00000230648.1	RP3-406P24.3	3.35	0.000858	0.0474	0.22	0.15	Blood metabolite levels;	chr6:4108698	chr6:4018843~4021215:-
THCA	cis	rs6683071	0.501	rs3002146	ENSG00000225265.1	TAF1A-AS1	-3.35	0.000858	0.0474	-0.17	-0.15	Cognitive performance;	chr1:222636066	chr1:222589825~222593032:+
THCA	cis	rs67180937	0.553	rs1391557	ENSG00000225265.1	TAF1A-AS1	-3.35	0.000858	0.0474	-0.17	-0.15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222589825~222593032:+
THCA	cis	rs34779708	0.931	rs1926556	ENSG00000233200.1	RP11-324I22.2	3.35	0.000858	0.0474	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs1926554	ENSG00000233200.1	RP11-324I22.2	3.35	0.000858	0.0474	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs4934710	ENSG00000233200.1	RP11-324I22.2	3.35	0.000858	0.0474	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.897	rs35784065	ENSG00000233200.1	RP11-324I22.2	3.35	0.000858	0.0474	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35219894~35230598:-
THCA	cis	rs757978	1	rs2074771	ENSG00000261186.2	RP11-341N2.1	-3.35	0.000858	0.0474	-0.27	-0.15	Chronic lymphocytic leukemia;	chr2:241411529	chr2:242087351~242088457:-
THCA	cis	rs7259376	0.875	rs9304996	ENSG00000270947.1	AC025811.3	3.35	0.000858	0.0474	0.16	0.15	Menopause (age at onset);	chr19:22303733	chr19:22455988~22456459:+
THCA	cis	rs26595	0.549	rs26594	ENSG00000249249.1	AC010226.4	-3.35	0.000858	0.0474	-0.13	-0.15	Wegener's granulomatosis;	chr5:116440056	chr5:115602057~115620659:+
THCA	cis	rs10792665	0.541	rs7106519	ENSG00000255503.1	RP11-113K21.4	3.35	0.000858	0.0474	0.16	0.15	Obesity-related traits;	chr11:82916988	chr11:83072402~83097196:-
THCA	cis	rs17689437	1	rs11641652	ENSG00000260084.1	RP11-615I2.1	-3.35	0.000858	0.0474	-0.24	-0.15	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68554909	chr16:68573782~68589512:-
THCA	cis	rs17689437	1	rs11860220	ENSG00000260084.1	RP11-615I2.1	-3.35	0.000858	0.0474	-0.24	-0.15	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68557812	chr16:68573782~68589512:-
THCA	cis	rs2494663	0.585	rs7531051	ENSG00000231416.1	RP11-422P24.9	3.35	0.000859	0.0474	0.19	0.15	Mean platelet volume;	chr1:154047541	chr1:153995632~153995960:+
THCA	cis	rs2562456	0.839	rs2562411	ENSG00000213976.4	CTD-2561J22.2	-3.35	0.000859	0.0474	-0.19	-0.15	Pain;	chr19:21419181	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.876	rs2562413	ENSG00000213976.4	CTD-2561J22.2	-3.35	0.000859	0.0474	-0.19	-0.15	Pain;	chr19:21420084	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.916	rs1967182	ENSG00000213976.4	CTD-2561J22.2	-3.35	0.000859	0.0474	-0.19	-0.15	Pain;	chr19:21420337	chr19:21382865~21387177:+
THCA	cis	rs2885056	0.83	rs2018810	ENSG00000267544.1	AC007229.3	3.35	0.000859	0.0474	0.23	0.15	Red cell distribution width;	chr19:10558496	chr19:10841839~10842250:+
THCA	cis	rs2395128	0.705	rs2395121	ENSG00000236842.1	RP11-399K21.10	-3.35	0.000859	0.0474	-0.24	-0.15	Ulcerative colitis;Inflammatory bowel disease;	chr10:74911091	chr10:75430571~75431588:-
THCA	cis	rs7136259	0.545	rs11105369	ENSG00000258302.2	RP11-981P6.1	-3.35	0.000859	0.0474	-0.15	-0.15	Coronary heart disease;	chr12:89684845	chr12:89561129~89594878:+
THCA	cis	rs250585	0.764	rs4967958	ENSG00000260136.4	CTD-2270L9.4	-3.35	0.000859	0.0474	-0.13	-0.15	Egg allergy;	chr16:23516802	chr16:23452758~23457606:+
THCA	cis	rs6751744	0.889	rs12692553	ENSG00000230783.1	AC009961.2	-3.35	0.000859	0.0474	-0.21	-0.15	Dysphagia;	chr2:159534337	chr2:159689217~159690291:-
THCA	cis	rs1971762	0.561	rs4759288	ENSG00000270175.1	RP11-793H13.11	-3.35	0.000859	0.0474	-0.1	-0.15	Height;	chr12:53690222	chr12:53500162~53500936:-
THCA	cis	rs11975235	0.818	rs11976977	ENSG00000272905.1	RP11-265E18.1	-3.35	0.000859	0.0474	-0.12	-0.15	Presence of antiphospholipid antibodies;	chr7:32157336	chr7:32845394~32846061:+
THCA	cis	rs7028939	1	rs10760719	ENSG00000255145.2	STX17-AS1	-3.35	0.000859	0.0474	-0.23	-0.15	Preeclampsia;	chr9:100175251	chr9:99886322~99906601:-
THCA	cis	rs4704187	0.687	rs9293643	ENSG00000250889.2	LINC01336	3.35	0.000859	0.0474	0.16	0.15	Response to amphetamines;	chr5:75069228	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs4621537	ENSG00000250889.2	LINC01336	-3.35	0.000859	0.0474	-0.16	-0.15	Response to amphetamines;	chr5:75066397	chr5:75047719~75052843:-
THCA	cis	rs4704187	0.687	rs7709707	ENSG00000250889.2	LINC01336	-3.35	0.000859	0.0474	-0.16	-0.15	Response to amphetamines;	chr5:75067750	chr5:75047719~75052843:-
THCA	cis	rs7615952	0.576	rs12497295	ENSG00000248787.1	RP11-666A20.4	-3.35	0.000859	0.0474	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126099807	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.512	rs4646765	ENSG00000248787.1	RP11-666A20.4	-3.35	0.000859	0.0474	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126101864	chr3:125908005~125910272:-
THCA	cis	rs2357982	0.531	rs4664032	ENSG00000232320.6	AC009299.5	-3.35	0.000859	0.0474	-0.2	-0.15	Presence of antiphospholipid antibodies;	chr2:161040057	chr2:161340816~161341326:-
THCA	cis	rs2357982	0.556	rs16845493	ENSG00000232320.6	AC009299.5	-3.35	0.000859	0.0474	-0.2	-0.15	Presence of antiphospholipid antibodies;	chr2:161040273	chr2:161340816~161341326:-
THCA	cis	rs3739034	0.877	rs10928510	ENSG00000224043.6	CCNT2-AS1	-3.35	0.000859	0.0474	-0.18	-0.15	Gut microbiome composition (winter);	chr2:134686370	chr2:134735464~134918710:-
THCA	cis	rs2395128	0.681	rs10465981	ENSG00000236842.1	RP11-399K21.10	3.35	0.000859	0.0474	0.23	0.15	Ulcerative colitis;Inflammatory bowel disease;	chr10:74945563	chr10:75430571~75431588:-
THCA	cis	rs909002	0.72	rs4949459	ENSG00000223382.3	RP1-65J11.1	3.35	0.000859	0.0474	0.16	0.15	Intelligence (multi-trait analysis);	chr1:31676753	chr1:30824228~30834284:+
THCA	cis	rs763121	0.962	rs138711	ENSG00000280527.1	AL031587.1	3.35	0.000859	0.0474	0.18	0.15	Menopause (age at onset);	chr22:38743908	chr22:37946326~37946426:+
THCA	cis	rs6066084	0.533	rs3092581	ENSG00000215452.3	ZNF663P	3.35	0.000859	0.0474	0.18	0.15	Quantitative traits;	chr20:46825846	chr20:46414228~46459276:-
THCA	cis	rs73191547	0.782	rs11786117	ENSG00000248538.5	RP11-10A14.5	-3.35	0.000859	0.0475	-0.18	-0.15	Schizophrenia;	chr8:10180964	chr8:9189011~9202854:+
THCA	cis	rs9693857	0.52	rs7821875	ENSG00000261451.1	RP11-981G7.1	3.35	0.000859	0.0475	0.2	0.15	Systolic blood pressure;	chr8:9501802	chr8:10433672~10438312:+
THCA	cis	rs13113518	0.678	rs13149568	ENSG00000272969.1	RP11-528I4.2	3.35	0.000859	0.0475	0.18	0.15	Height;	chr4:55370412	chr4:55547112~55547889:+
THCA	cis	rs9875589	0.957	rs1433358	ENSG00000233121.1	VN1R20P	3.35	0.000859	0.0475	0.18	0.15	Ovarian reserve;	chr3:13902365	chr3:13926813~13927778:+
THCA	cis	rs854765	0.663	rs3744115	ENSG00000281749.1	Y_RNA	-3.35	0.000859	0.0475	-0.19	-0.15	Total body bone mineral density;	chr17:17846508	chr17:18001101~18001195:-
THCA	cis	rs12575480	0.637	rs73398080	ENSG00000233930.3	KRTAP5-AS1	-3.35	0.000859	0.0475	-0.18	-0.15	Pursuit maintenance gain;	chr11:2073369	chr11:1571353~1599184:+
THCA	cis	rs853679	0.769	rs7752448	ENSG00000272009.1	RP1-313I6.12	-3.35	0.000859	0.0475	-0.24	-0.15	Depression;	chr6:28333322	chr6:28078792~28081130:-
THCA	cis	rs6589219	0.866	rs4477469	ENSG00000196167.8	COLCA1	-3.35	0.000859	0.0475	-0.17	-0.15	Colorectal cancer;	chr11:111290028	chr11:111290787~111305045:-
THCA	cis	rs12550646	0.652	rs10090395	ENSG00000260588.1	RP11-930P14.2	3.35	0.000859	0.0475	0.19	0.15	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41809356	chr8:41828165~41829934:-
THCA	cis	rs728616	0.614	rs56147535	ENSG00000278616.1	BEND3P3	3.35	0.000859	0.0475	0.15	0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80267869	chr10:79682997~79685436:+
THCA	cis	rs2736345	0.755	rs2736340	ENSG00000270154.1	RP11-419I17.1	3.35	0.000859	0.0475	0.21	0.15	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:12476462~12477122:+
THCA	cis	rs7746199	0.736	rs17693963	ENSG00000220721.1	OR1F12	3.35	0.000859	0.0475	0.32	0.15	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28073316~28074233:+
THCA	cis	rs17695224	0.565	rs7253182	ENSG00000275055.1	CTC-471J1.11	-3.35	0.00086	0.0475	-0.12	-0.15	HDL cholesterol;HDL cholesterol levels;	chr19:51808838	chr19:52049007~52049754:+
THCA	cis	rs6499755	0.712	rs31085	ENSG00000260135.5	RP11-212I21.2	-3.35	0.00086	0.0475	-0.16	-0.15	Hypospadias;	chr16:55328590	chr16:55426797~55462297:-
THCA	cis	rs668210	0.739	rs1151511	ENSG00000214659.4	KRT8P26	3.35	0.00086	0.0475	0.17	0.15	Cerebrospinal fluid biomarker levels;	chr11:65988812	chr11:65726939~65728214:+
THCA	cis	rs2776353	0.846	rs2776348	ENSG00000226496.2	LINC00323	-3.35	0.00086	0.0475	-0.2	-0.15	Basal cell carcinoma;	chr21:41666784	chr21:41141493~41148133:-
THCA	cis	rs909002	0.8	rs2176807	ENSG00000235790.6	RP11-73M7.6	3.35	0.00086	0.0475	0.16	0.15	Intelligence (multi-trait analysis);	chr1:31627134	chr1:31644049~31660162:+
THCA	cis	rs9863	0.896	rs2130382	ENSG00000269938.1	RP11-214K3.20	-3.35	0.00086	0.0475	-0.18	-0.15	White blood cell count;	chr12:124000096	chr12:123968023~123968579:-
THCA	cis	rs758324	0.812	rs601441	ENSG00000237714.1	P4HA2-AS1	-3.35	0.00086	0.0475	-0.21	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131948740	chr5:132184876~132192808:+
THCA	cis	rs12904129	0.564	rs12439268	ENSG00000214432.8	AC068831.10	-3.35	0.00086	0.0475	-0.15	-0.15	Gait speed in old age;	chr15:91666413	chr15:91022619~91036611:+
THCA	cis	rs9860428	0.844	rs28782232	ENSG00000243795.1	RP11-572M11.3	3.35	0.00086	0.0475	0.19	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112849314	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs6806976	ENSG00000243795.1	RP11-572M11.3	3.35	0.00086	0.0475	0.19	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112852143	chr3:113142350~113167819:-
THCA	cis	rs9860428	0.844	rs6765575	ENSG00000243795.1	RP11-572M11.3	3.35	0.00086	0.0475	0.19	0.15	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112854322	chr3:113142350~113167819:-
THCA	cis	rs10489202	0.657	rs3767479	ENSG00000250762.1	RP1-313L4.4	-3.35	0.00086	0.0475	-0.21	-0.15	Schizophrenia;	chr1:168100602	chr1:167819898~167820248:-
THCA	cis	rs6847067	0.8	rs11730981	ENSG00000180769.7	WDFY3-AS2	3.35	0.00086	0.0475	0.12	0.15	Oropharynx cancer;	chr4:84928846	chr4:84965682~85011277:+
THCA	cis	rs6847067	0.8	rs9684737	ENSG00000180769.7	WDFY3-AS2	3.35	0.00086	0.0475	0.12	0.15	Oropharynx cancer;	chr4:84930812	chr4:84965682~85011277:+
THCA	cis	rs4780401	0.728	rs7188511	ENSG00000274038.1	RP11-66H6.4	-3.35	0.00086	0.0475	-0.18	-0.15	Rheumatoid arthritis;	chr16:11679887	chr16:11056556~11057034:+
THCA	cis	rs7631605	0.967	rs7639607	ENSG00000272334.1	RP11-129K12.1	-3.35	0.00086	0.0475	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:37227548	chr3:36973117~36973672:-
THCA	cis	rs4144027	0.74	rs10150898	ENSG00000258534.1	CTD-2134A5.4	3.35	0.00086	0.0475	0.16	0.15	Blood metabolite levels;	chr14:103888288	chr14:103854366~103880111:-
THCA	cis	rs9549260	0.753	rs9532562	ENSG00000229456.1	RLIMP1	3.35	0.00086	0.0475	0.21	0.15	Red blood cell count;	chr13:40579448	chr13:40618738~40621348:+
THCA	cis	rs15676	0.783	rs11515530	ENSG00000234771.3	SLC25A25-AS1	-3.35	0.00086	0.0475	-0.13	-0.15	Blood metabolite levels;	chr9:128814088	chr9:128108581~128118693:-
THCA	cis	rs4948275	0.667	rs2814030	ENSG00000233643.2	RP11-491H19.1	-3.35	0.00086	0.0475	-0.18	-0.15	Night sleep phenotypes;	chr10:61578035	chr10:61781745~61821246:-
THCA	cis	rs7503807	0.688	rs7503203	ENSG00000262585.1	RP11-353N14.5	-3.35	0.00086	0.0475	-0.17	-0.15	Obesity;	chr17:80616728	chr17:79915252~79926725:-
THCA	cis	rs7487075	0.619	rs6582658	ENSG00000275481.1	RP11-474P2.6	3.35	0.00086	0.0475	0.14	0.15	Itch intensity from mosquito bite;	chr12:46462312	chr12:46388856~46392126:+
THCA	cis	rs8044868	1	rs6499562	ENSG00000260886.1	TAT-AS1	3.35	0.00086	0.0475	0.18	0.15	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72128956	chr16:71565789~71578187:+
THCA	cis	rs752590	0.623	rs67802835	ENSG00000274877.1	RP11-65I12.1	3.35	0.00086	0.0475	0.11	0.15	Mucinous ovarian carcinoma;	chr2:113221583	chr2:113237595~113240825:+
THCA	cis	rs56283067	0.887	rs62437968	ENSG00000237686.5	RP5-1120P11.1	-3.35	0.00086	0.0475	-0.14	-0.15	Total body bone mineral density;	chr6:44761758	chr6:43995723~44074652:-
THCA	cis	rs801193	0.591	rs4506088	ENSG00000223473.2	GS1-124K5.3	-3.35	0.000861	0.0475	-0.1	-0.15	Aortic root size;	chr7:66670470	chr7:66491049~66493566:-
THCA	cis	rs801193	0.569	rs2659908	ENSG00000223473.2	GS1-124K5.3	3.35	0.000861	0.0475	0.1	0.15	Aortic root size;	chr7:66695835	chr7:66491049~66493566:-
THCA	cis	rs801193	0.569	rs4717315	ENSG00000223473.2	GS1-124K5.3	3.35	0.000861	0.0475	0.1	0.15	Aortic root size;	chr7:66713338	chr7:66491049~66493566:-
THCA	cis	rs801193	0.527	rs2707837	ENSG00000223473.2	GS1-124K5.3	3.35	0.000861	0.0475	0.1	0.15	Aortic root size;	chr7:66716086	chr7:66491049~66493566:-
THCA	cis	rs7246760	0.867	rs58461110	ENSG00000278611.1	CTC-543D15.8	-3.35	0.000861	0.0475	-0.25	-0.15	Pursuit maintenance gain;	chr19:9722714	chr19:9538733~9539734:+
THCA	cis	rs7246760	0.867	rs55800282	ENSG00000278611.1	CTC-543D15.8	-3.35	0.000861	0.0475	-0.25	-0.15	Pursuit maintenance gain;	chr19:9722854	chr19:9538733~9539734:+
THCA	cis	rs7246760	0.867	rs8107594	ENSG00000278611.1	CTC-543D15.8	-3.35	0.000861	0.0475	-0.25	-0.15	Pursuit maintenance gain;	chr19:9725281	chr19:9538733~9539734:+
THCA	cis	rs13064411	0.696	rs6808394	ENSG00000243849.1	CFAP44-AS1	3.35	0.000861	0.0475	0.25	0.15	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113403677	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.627	rs28536176	ENSG00000243849.1	CFAP44-AS1	3.35	0.000861	0.0475	0.25	0.15	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113424778	chr3:113403991~113433992:+
THCA	cis	rs13064411	0.696	rs9869318	ENSG00000243849.1	CFAP44-AS1	3.35	0.000861	0.0475	0.25	0.15	Response to simvastatin treatment (PCSK9 protein level change);	chr3:113427424	chr3:113403991~113433992:+
THCA	cis	rs7474896	0.945	rs2749561	ENSG00000276805.1	RP11-291L22.6	-3.35	0.000861	0.0475	-0.24	-0.15	Obesity (extreme);	chr10:37909119	chr10:38451030~38451785:+
THCA	cis	rs10483853	0.806	rs7156451	ENSG00000258891.1	RP5-1021I20.5	-3.35	0.000861	0.0475	-0.2	-0.15	Coronary artery calcification;	chr14:73393919	chr14:73896164~73938114:-
THCA	cis	rs10483853	0.806	rs11159017	ENSG00000258891.1	RP5-1021I20.5	-3.35	0.000861	0.0475	-0.2	-0.15	Coronary artery calcification;	chr14:73396220	chr14:73896164~73938114:-
THCA	cis	rs9420	0.961	rs708228	ENSG00000254602.1	AP000662.4	-3.35	0.000861	0.0475	-0.17	-0.15	Schizophrenia;	chr11:57818190	chr11:57638024~57652790:+
THCA	cis	rs7944735	0.607	rs34895872	ENSG00000200090.1	Y_RNA	3.35	0.000861	0.0475	0.12	0.15	Intraocular pressure;	chr11:48000226	chr11:47726894~47726992:-
THCA	cis	rs9902453	0.933	rs8080343	ENSG00000250462.7	LRRC37BP1	3.35	0.000861	0.0475	0.12	0.15	Coffee consumption (cups per day);	chr17:30129740	chr17:30629680~30637466:+
THCA	cis	rs832540	0.931	rs832399	ENSG00000271828.1	CTD-2310F14.1	-3.35	0.000861	0.0475	-0.21	-0.15	Coronary artery disease;	chr5:56926531	chr5:56927874~56929573:+
THCA	cis	rs11642862	1	rs11645175	ENSG00000275263.1	RP11-1072A3.4	-3.35	0.000861	0.0475	-0.33	-0.15	Tonsillectomy;	chr16:30791978	chr16:30956872~30957199:-
THCA	cis	rs7395662	0.929	rs11039903	ENSG00000200090.1	Y_RNA	-3.35	0.000861	0.0475	-0.1	-0.15	HDL cholesterol;	chr11:48658153	chr11:47726894~47726992:-
THCA	cis	rs11098699	0.784	rs1048476	ENSG00000273007.1	RP11-170N16.3	3.35	0.000861	0.0475	0.12	0.15	Mosquito bite size;	chr4:123318648	chr4:122881878~122884712:-
THCA	cis	rs9902453	0.868	rs8066602	ENSG00000250462.7	LRRC37BP1	3.35	0.000861	0.0475	0.12	0.15	Coffee consumption (cups per day);	chr17:30196067	chr17:30629680~30637466:+
THCA	cis	rs9902453	0.868	rs8066731	ENSG00000250462.7	LRRC37BP1	3.35	0.000861	0.0475	0.12	0.15	Coffee consumption (cups per day);	chr17:30196103	chr17:30629680~30637466:+
THCA	cis	rs71277158	0.688	rs879161	ENSG00000242578.1	RP11-469J4.3	3.35	0.000861	0.0475	0.24	0.15	Prostate cancer;	chr3:170094327	chr3:170410512~170418615:+
THCA	cis	rs9652601	0.622	rs1003603	ENSG00000263033.2	RP11-396B14.2	-3.35	0.000861	0.0475	-0.12	-0.15	Systemic lupus erythematosus;	chr16:11020766	chr16:11196177~11224969:+
THCA	cis	rs35740288	0.731	rs12913556	ENSG00000259407.1	RP11-158M2.3	-3.35	0.000861	0.0475	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85558965	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.731	rs35085180	ENSG00000259407.1	RP11-158M2.3	-3.35	0.000861	0.0475	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85559381	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.77	rs75039806	ENSG00000259407.1	RP11-158M2.3	-3.35	0.000861	0.0475	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561813	chr15:85744109~85750281:-
THCA	cis	rs2734839	0.507	rs2005313	ENSG00000270179.1	RP11-159N11.4	-3.35	0.000861	0.0475	-0.18	-0.15	Information processing speed;	chr11:113419327	chr11:113368478~113369117:+
THCA	cis	rs7709377	0.671	rs10056927	ENSG00000250015.1	CTC-339F2.2	3.35	0.000861	0.0475	0.16	0.15	Metabolite levels  (X-11787);	chr5:116160906	chr5:116302354~116304134:-
THCA	cis	rs1510272	0.889	rs4680286	ENSG00000243926.1	TIPARP-AS1	-3.35	0.000861	0.0475	-0.16	-0.15	Testicular germ cell tumor;	chr3:156601298	chr3:156671862~156674378:-
THCA	cis	rs11168618	0.626	rs7310960	ENSG00000257763.1	OR5BK1P	-3.35	0.000861	0.0475	-0.13	-0.15	Adiponectin levels;	chr12:48466334	chr12:48355792~48356614:-
THCA	cis	rs7631605	0.967	rs4678949	ENSG00000272334.1	RP11-129K12.1	-3.35	0.000861	0.0475	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:37211786	chr3:36973117~36973672:-
THCA	cis	rs7631605	0.967	rs4678950	ENSG00000272334.1	RP11-129K12.1	-3.35	0.000861	0.0475	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:37212191	chr3:36973117~36973672:-
THCA	cis	rs6995541	0.583	rs765658	ENSG00000248896.2	CTD-2135J3.3	-3.35	0.000861	0.0475	-0.21	-0.15	Triglyceride levels;	chr8:10740520	chr8:10729314~10771392:+
THCA	cis	rs5758511	0.573	rs4501042	ENSG00000230107.1	CTA-126B4.7	3.35	0.000861	0.0475	0.16	0.15	Birth weight;	chr22:41849759	chr22:42438023~42446195:+
THCA	cis	rs9425766	0.962	rs1322777	ENSG00000200674.1	RN7SKP160	3.35	0.000861	0.0475	0.2	0.15	Life satisfaction;	chr1:173889962	chr1:173791548~173791887:+
THCA	cis	rs2066819	1	rs2066808	ENSG00000276272.1	RP11-121C6.5	-3.35	0.000861	0.0475	-0.32	-0.15	Psoriasis vulgaris;	chr12:56344189	chr12:56411944~56413190:-
THCA	cis	rs7737355	0.812	rs798414	ENSG00000224431.1	AC063976.7	-3.35	0.000861	0.0475	-0.14	-0.15	Life satisfaction;	chr5:131360757	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.842	rs30733	ENSG00000224431.1	AC063976.7	-3.35	0.000861	0.0475	-0.14	-0.15	Life satisfaction;	chr5:131369263	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs42256	ENSG00000224431.1	AC063976.7	-3.35	0.000861	0.0475	-0.14	-0.15	Life satisfaction;	chr5:131370213	chr5:132199456~132203487:+
THCA	cis	rs1113500	0.575	rs1781070	ENSG00000226822.1	RP11-356N1.2	-3.35	0.000861	0.0475	-0.16	-0.15	Growth-regulated protein alpha levels;	chr1:108027076	chr1:108071482~108074519:+
THCA	cis	rs10654220	1	rs10654220	ENSG00000235423.7	RP11-282O18.3	3.35	0.000861	0.0475	0.18	0.15	Platelet count;	chr12:123218875	chr12:123252030~123261483:-
THCA	cis	rs9828933	0.678	rs704366	ENSG00000224479.4	AC136289.1	-3.35	0.000861	0.0475	-0.23	-0.15	Type 2 diabetes;	chr3:63885972	chr3:63742293~63827445:-
THCA	cis	rs877819	0.649	rs2620903	ENSG00000228403.1	RP11-563N6.6	-3.35	0.000861	0.0475	-0.17	-0.15	Systemic lupus erythematosus;	chr10:48802169	chr10:48878022~48878649:+
THCA	cis	rs11673344	0.77	rs7257135	ENSG00000267470.4	ZNF571-AS1	-3.35	0.000861	0.0476	-0.18	-0.15	Obesity-related traits;	chr19:37088726	chr19:37548914~37587348:+
THCA	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-3.35	0.000861	0.0476	-0.14	-0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
THCA	cis	rs4938642	0.731	rs3802885	ENSG00000255239.1	AP002954.6	3.35	0.000862	0.0476	0.28	0.15	Platelet count;	chr11:119161980	chr11:118688039~118690600:-
THCA	cis	rs7778833	1	rs7778833	ENSG00000229688.6	ISPD-AS1	3.35	0.000862	0.0476	0.32	0.15	Childhood ear infection;	chr7:15734513	chr7:16210488~16270604:+
THCA	cis	rs2016266	0.855	rs6580941	ENSG00000270175.1	RP11-793H13.11	-3.35	0.000862	0.0476	-0.11	-0.15	Bone mineral density;Bone mineral density (spine);	chr12:53268415	chr12:53500162~53500936:-
THCA	cis	rs4388249	0.706	rs17162326	ENSG00000249476.1	CTD-2587M2.1	3.35	0.000862	0.0476	0.19	0.15	Schizophrenia;	chr5:109842615	chr5:109237120~109326369:-
THCA	cis	rs4388249	0.706	rs3797676	ENSG00000249476.1	CTD-2587M2.1	3.35	0.000862	0.0476	0.19	0.15	Schizophrenia;	chr5:109843539	chr5:109237120~109326369:-
THCA	cis	rs12612435	0.793	rs16833925	ENSG00000230037.1	UBBP1	3.35	0.000862	0.0476	0.19	0.15	Takotsubo syndrome;	chr2:136380343	chr2:136329441~136329913:-
THCA	cis	rs2279440	0.759	rs9845420	ENSG00000254485.4	RP11-380O24.1	3.35	0.000862	0.0476	0.18	0.15	Glucose homeostasis traits;	chr3:9460779	chr3:9292588~9363303:-
THCA	cis	rs913655	0.72	rs2451519	ENSG00000240291.1	RP11-499P20.2	-3.35	0.000862	0.0476	-0.11	-0.15	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18791718	chr10:18513115~18545651:-
THCA	cis	rs6095360	0.517	rs237700	ENSG00000222365.1	SNORD12B	-3.35	0.000862	0.0476	-0.19	-0.15	Intelligence (multi-trait analysis);	chr20:49293285	chr20:49280319~49280409:+
THCA	cis	rs6012953	0.583	rs6067472	ENSG00000231715.1	COX6CP2	-3.35	0.000862	0.0476	-0.17	-0.15	Vitiligo;	chr20:50515979	chr20:50479767~50479991:+
THCA	cis	rs7173964	1	rs7167932	ENSG00000259251.2	RP11-643M14.1	-3.35	0.000862	0.0476	-0.15	-0.15	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62104079	chr15:62060503~62062434:+
THCA	cis	rs7173964	1	rs7172432	ENSG00000259251.2	RP11-643M14.1	-3.35	0.000862	0.0476	-0.15	-0.15	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62104190	chr15:62060503~62062434:+
THCA	cis	rs9796	0.558	rs6492993	ENSG00000247556.5	OIP5-AS1	3.35	0.000862	0.0476	0.12	0.15	Menopause (age at onset);	chr15:41233906	chr15:41283990~41309737:+
THCA	cis	rs6662572	0.737	rs72677530	ENSG00000234329.1	RP11-767N6.2	-3.35	0.000862	0.0476	-0.17	-0.15	Blood protein levels;	chr1:46064005	chr1:45651039~45651826:-
THCA	cis	rs6662572	0.737	rs72677533	ENSG00000234329.1	RP11-767N6.2	-3.35	0.000862	0.0476	-0.17	-0.15	Blood protein levels;	chr1:46070886	chr1:45651039~45651826:-
THCA	cis	rs10911902	0.643	rs75235608	ENSG00000228238.1	GS1-304P7.2	-3.35	0.000862	0.0476	-0.26	-0.15	Schizophrenia;	chr1:186303471	chr1:186578279~186579299:+
THCA	cis	rs74181299	0.806	rs2723063	ENSG00000281920.1	RP11-418H16.1	-3.35	0.000862	0.0476	-0.2	-0.15	Pulse pressure;	chr2:65053051	chr2:65623272~65628424:+
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000182586.6	LINC00334	-3.35	0.000862	0.0476	-0.16	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45234340~45258730:+
THCA	cis	rs2692947	0.8	rs2692948	ENSG00000235959.1	AC009237.17	-3.35	0.000862	0.0476	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007817	chr2:95640181~95640604:-
THCA	cis	rs5769765	0.773	rs7410291	ENSG00000278869.1	CITF22-49E9.3	3.35	0.000862	0.0476	0.2	0.15	Schizophrenia;	chr22:49906430	chr22:49933198~49934074:-
THCA	cis	rs5769765	0.955	rs9616366	ENSG00000278869.1	CITF22-49E9.3	3.35	0.000862	0.0476	0.2	0.15	Schizophrenia;	chr22:49907530	chr22:49933198~49934074:-
THCA	cis	rs7572644	0.709	rs7592580	ENSG00000223522.1	AC093690.1	-3.35	0.000862	0.0476	-0.2	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27898323	chr2:28307691~28310459:-
THCA	cis	rs660899	0.857	rs3791047	ENSG00000228452.1	RP5-994D16.9	-3.35	0.000862	0.0476	-0.18	-0.15	Hypertension risk in short sleep duration;	chr1:43770443	chr1:42775813~42776790:-
THCA	cis	rs4805272	0.512	rs765484	ENSG00000267799.1	MAN1A2P1	3.35	0.000862	0.0476	0.2	0.15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28853756	chr19:28790812~28792871:-
THCA	cis	rs7028939	1	rs10989007	ENSG00000234709.2	UPF3AP3	3.35	0.000862	0.0476	0.27	0.15	Preeclampsia;	chr9:100192956	chr9:99998301~99999069:-
THCA	cis	rs4568518	0.616	rs10950691	ENSG00000279048.1	RP11-511H23.2	3.35	0.000862	0.0476	0.1	0.15	Measles;	chr7:17966511	chr7:17940503~17942922:+
THCA	cis	rs10109025	0.67	rs7825690	ENSG00000254839.1	AF131215.6	3.35	0.000862	0.0476	0.15	0.15	Joint mobility (Beighton score);	chr8:11000747	chr8:11062647~11067089:-
THCA	cis	rs4788570	0.615	rs6499526	ENSG00000260593.1	RP11-432I5.2	-3.35	0.000862	0.0476	-0.25	-0.15	Intelligence (multi-trait analysis);	chr16:71614396	chr16:71623708~71626816:-
THCA	cis	rs12410462	0.892	rs75757169	ENSG00000227711.2	RP11-275O4.5	-3.35	0.000862	0.0476	-0.23	-0.15	Major depressive disorder;	chr1:227442154	chr1:227509028~227520477:-
THCA	cis	rs3864261	1	rs57213367	ENSG00000249085.1	CTD-2631K10.1	3.35	0.000862	0.0476	0.23	0.15	Discordance in emotional problems in monozygotic twins;	chr5:73056078	chr5:72794405~72816565:-
THCA	cis	rs17033621	0.549	rs7593367	ENSG00000238250.1	ST6GAL2-IT1	3.35	0.000862	0.0476	0.14	0.15	Intelligence (multi-trait analysis);	chr2:106972689	chr2:106822923~106825031:-
THCA	cis	rs7615952	0.599	rs2279821	ENSG00000248787.1	RP11-666A20.4	-3.35	0.000862	0.0476	-0.24	-0.15	Blood pressure (smoking interaction);	chr3:126015465	chr3:125908005~125910272:-
THCA	cis	rs11233413	0.874	rs12422142	ENSG00000246067.6	RAB30-AS1	3.35	0.000862	0.0476	0.16	0.15	Economic and political preferences (feminism/equality);	chr11:83043119	chr11:83072066~83106719:+
THCA	cis	rs11233413	0.874	rs11233440	ENSG00000246067.6	RAB30-AS1	3.35	0.000862	0.0476	0.16	0.15	Economic and political preferences (feminism/equality);	chr11:83047195	chr11:83072066~83106719:+
THCA	cis	rs72834846	0.797	rs17745654	ENSG00000236319.2	CTD-2033D24.2	3.35	0.000862	0.0476	0.23	0.15	Red blood cell count;	chr17:55095029	chr17:55526964~55561577:-
THCA	cis	rs934734	0.571	rs7565437	ENSG00000214533.3	KRT18P33	-3.35	0.000862	0.0476	-0.19	-0.15	Rheumatoid arthritis;	chr2:65419832	chr2:65666695~65667737:+
THCA	cis	rs1160351	0.929	rs11845070	ENSG00000244053.1	RPL13AP2	3.35	0.000862	0.0476	0.18	0.15	Sexual dysfunction (SSRI/SNRI-related);	chr14:47587007	chr14:47200575~47201104:-
THCA	cis	rs11212260	0.85	rs636820	ENSG00000261098.1	RP11-819C21.1	3.35	0.000862	0.0476	0.29	0.15	IgG glycosylation;	chr11:107521100	chr11:107312132~107316271:-
THCA	cis	rs11212260	0.85	rs668143	ENSG00000261098.1	RP11-819C21.1	-3.35	0.000862	0.0476	-0.29	-0.15	IgG glycosylation;	chr11:107518725	chr11:107312132~107316271:-
THCA	cis	rs11212260	0.649	rs666373	ENSG00000261098.1	RP11-819C21.1	-3.35	0.000862	0.0476	-0.29	-0.15	IgG glycosylation;	chr11:107519122	chr11:107312132~107316271:-
THCA	cis	rs11212260	0.85	rs546646	ENSG00000261098.1	RP11-819C21.1	-3.35	0.000862	0.0476	-0.29	-0.15	IgG glycosylation;	chr11:107521376	chr11:107312132~107316271:-
THCA	cis	rs6017317	0.696	rs4276083	ENSG00000244558.4	KCNK15-AS1	-3.35	0.000862	0.0476	-0.22	-0.15	Type 2 diabetes;	chr20:44299870	chr20:44694892~44746021:-
THCA	cis	rs12621844	0.671	rs6706664	ENSG00000234690.5	AC073283.4	-3.35	0.000862	0.0476	-0.14	-0.15	Glycated hemoglobin levels;	chr2:48068915	chr2:47192405~47345074:-
THCA	cis	rs2486012	0.737	rs37457	ENSG00000234694.1	RP1-92O14.3	3.35	0.000862	0.0476	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43825519	chr1:43354684~43358658:-
THCA	cis	rs2638953	0.886	rs11049615	ENSG00000247934.4	RP11-967K21.1	-3.35	0.000862	0.0476	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452152	chr12:28163298~28190738:-
THCA	cis	rs1580019	0.922	rs59938271	ENSG00000273014.1	RP11-225B17.2	3.35	0.000862	0.0476	0.17	0.15	Cognitive ability;	chr7:32445232	chr7:32758882~32759353:+
THCA	cis	rs7246657	0.943	rs28373708	ENSG00000266916.4	ZNF793-AS1	-3.35	0.000863	0.0476	-0.14	-0.15	Coronary artery calcification;	chr19:37485757	chr19:37497159~37507046:-
THCA	cis	rs6748734	0.548	rs12618707	ENSG00000235151.1	AC114730.2	3.35	0.000863	0.0476	0.17	0.15	Urinary metabolites;	chr2:240935142	chr2:241844380~241845036:+
THCA	cis	rs6445967	0.689	rs11714574	ENSG00000272360.1	RP11-359I18.5	3.35	0.000863	0.0476	0.16	0.15	Platelet count;	chr3:58394738	chr3:58490830~58491291:-
THCA	cis	rs2055729	0.71	rs10104236	ENSG00000261451.1	RP11-981G7.1	-3.35	0.000863	0.0476	-0.21	-0.15	Multiple myeloma (hyperdiploidy);	chr8:9882782	chr8:10433672~10438312:+
THCA	cis	rs2732480	0.577	rs2634684	ENSG00000275228.1	RP11-370I10.10	3.35	0.000863	0.0476	0.17	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48327942~48328472:-
THCA	cis	rs7520050	0.966	rs1707336	ENSG00000281133.1	AL355480.3	3.35	0.000863	0.0476	0.18	0.15	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45580892~45580996:-
THCA	cis	rs7824557	0.564	rs2572379	ENSG00000255046.1	RP11-297N6.4	3.35	0.000863	0.0476	0.16	0.15	Retinal vascular caliber;	chr8:11379971	chr8:11797928~11802568:-
THCA	cis	rs3789045	0.779	rs12043569	ENSG00000235363.1	SNRPGP10	-3.35	0.000863	0.0476	-0.21	-0.15	Educational attainment (college completion);	chr1:204590876	chr1:205351247~205351471:+
THCA	cis	rs6545883	0.965	rs766447	ENSG00000212978.6	AC016747.3	3.35	0.000863	0.0476	0.17	0.15	Tuberculosis;	chr2:61508434	chr2:61141592~61144969:-
THCA	cis	rs11590090	0.817	rs12133247	ENSG00000231246.1	RP5-965F6.2	-3.35	0.000863	0.0476	-0.19	-0.15	Hyperactive-impulsive symptoms;	chr1:112761096	chr1:112177234~112360528:-
THCA	cis	rs2574985	0.738	rs3011770	ENSG00000279863.1	RP11-521C22.2	-3.35	0.000863	0.0476	-0.19	-0.15	Subjective well-being;	chr10:50511625	chr10:50334538~50336123:+
THCA	cis	rs7173964	0.967	rs8037894	ENSG00000259251.2	RP11-643M14.1	-3.35	0.000863	0.0476	-0.15	-0.15	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62102065	chr15:62060503~62062434:+
THCA	cis	rs58722170	0.659	rs61776209	ENSG00000252448.1	SNORA63	-3.35	0.000863	0.0476	-0.19	-0.15	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37624651	chr1:37884237~37884317:+
THCA	cis	rs2098713	0.561	rs11949124	ENSG00000250155.1	CTD-2353F22.1	3.35	0.000863	0.0476	0.15	0.15	Telomere length;	chr5:37590362	chr5:36666214~36725195:-
THCA	cis	rs4073416	0.569	rs2092914	ENSG00000276116.2	FUT8-AS1	3.35	0.000863	0.0476	0.16	0.15	N-glycan levels;	chr14:65612397	chr14:65411170~65412690:-
THCA	cis	rs8103033	0.748	rs8101868	ENSG00000226025.8	LGALS17A	-3.35	0.000863	0.0476	-0.14	-0.15	Obesity-related traits;	chr19:39646090	chr19:39679374~39686373:+
THCA	cis	rs950169	0.922	rs62028133	ENSG00000230373.7	GOLGA6L5P	-3.35	0.000863	0.0476	-0.17	-0.15	Schizophrenia;	chr15:84250623	chr15:84507885~84516814:-
THCA	cis	rs950169	0.723	rs17589320	ENSG00000230373.7	GOLGA6L5P	-3.35	0.000863	0.0476	-0.17	-0.15	Schizophrenia;	chr15:84251244	chr15:84507885~84516814:-
THCA	cis	rs4713118	0.869	rs9461405	ENSG00000216915.2	RP1-97D16.1	-3.35	0.000863	0.0476	-0.23	-0.15	Parkinson's disease;	chr6:27751596	chr6:27737000~27738494:-
THCA	cis	rs1669338	0.588	rs3931974	ENSG00000271870.1	RP11-97C16.1	-3.35	0.000863	0.0476	-0.14	-0.15	White matter integrity;	chr3:3145210	chr3:3152942~3153435:+
THCA	cis	rs913655	0.508	rs12245924	ENSG00000240291.1	RP11-499P20.2	3.35	0.000863	0.0476	0.12	0.15	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18720830	chr10:18513115~18545651:-
THCA	cis	rs913655	0.508	rs7921519	ENSG00000240291.1	RP11-499P20.2	3.35	0.000863	0.0476	0.12	0.15	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18721540	chr10:18513115~18545651:-
THCA	cis	rs76878669	0.561	rs6591217	ENSG00000255320.1	RP11-755F10.1	3.35	0.000863	0.0476	0.2	0.15	Educational attainment (years of education);	chr11:66407182	chr11:66244840~66246239:-
THCA	cis	rs4243971	0.516	rs4911229	ENSG00000224452.1	RSL24D1P6	-3.35	0.000863	0.0476	-0.18	-0.15	Inflammatory bowel disease;Crohn's disease;	chr20:32426173	chr20:32170390~32170790:-
THCA	cis	rs7028939	1	rs7870701	ENSG00000255145.2	STX17-AS1	-3.35	0.000863	0.0476	-0.23	-0.15	Preeclampsia;	chr9:100134862	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7021923	ENSG00000255145.2	STX17-AS1	-3.35	0.000863	0.0476	-0.23	-0.15	Preeclampsia;	chr9:100136443	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10988979	ENSG00000255145.2	STX17-AS1	-3.35	0.000863	0.0476	-0.23	-0.15	Preeclampsia;	chr9:100136789	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10819725	ENSG00000255145.2	STX17-AS1	-3.35	0.000863	0.0476	-0.23	-0.15	Preeclampsia;	chr9:100137357	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs7847149	ENSG00000255145.2	STX17-AS1	-3.35	0.000863	0.0476	-0.23	-0.15	Preeclampsia;	chr9:100138384	chr9:99886322~99906601:-
THCA	cis	rs7028939	1	rs10819726	ENSG00000255145.2	STX17-AS1	-3.35	0.000863	0.0476	-0.23	-0.15	Preeclampsia;	chr9:100139942	chr9:99886322~99906601:-
THCA	cis	rs4948275	0.693	rs2246190	ENSG00000233643.2	RP11-491H19.1	3.35	0.000863	0.0476	0.17	0.15	Night sleep phenotypes;	chr10:61580354	chr10:61781745~61821246:-
THCA	cis	rs8112211	0.731	rs3745952	ENSG00000267291.1	CTB-186G2.1	3.35	0.000863	0.0476	0.17	0.15	Blood protein levels;	chr19:38327659	chr19:38596346~38601694:+
THCA	cis	rs8112211	0.731	rs931749	ENSG00000267291.1	CTB-186G2.1	3.35	0.000863	0.0476	0.17	0.15	Blood protein levels;	chr19:38328285	chr19:38596346~38601694:+
THCA	cis	rs931608	0.565	rs10405452	ENSG00000269138.1	ZNF209P	3.35	0.000863	0.0476	0.2	0.15	Response to statins (LDL cholesterol change);Dental caries;	chr19:22347066	chr19:22463922~22473036:+
THCA	cis	rs925255	0.591	rs7559046	ENSG00000229951.4	FLJ31356	3.35	0.000863	0.0476	0.2	0.15	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28384409~28394672:-
THCA	cis	rs56309584	0.673	rs56256903	ENSG00000265749.4	RP11-849F2.5	3.35	0.000863	0.0476	0.21	0.15	Initial pursuit acceleration;	chr17:8219810	chr17:8365563~8381328:+
THCA	cis	rs2180341	1	rs2057223	ENSG00000220522.2	RP1-177A13.1	3.35	0.000863	0.0476	0.2	0.15	Breast cancer;	chr6:127316229	chr6:127416535~127416952:-
THCA	cis	rs3784262	1	rs12903551	ENSG00000259250.1	RP11-50C13.1	3.35	0.000864	0.0476	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57976174	chr15:58587507~58591676:+
THCA	cis	rs3784262	0.967	rs11630835	ENSG00000259250.1	RP11-50C13.1	3.35	0.000864	0.0476	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57977264	chr15:58587507~58591676:+
THCA	cis	rs763121	1	rs138457	ENSG00000228274.3	RP3-508I15.9	3.35	0.000864	0.0476	0.16	0.15	Menopause (age at onset);	chr22:38502046	chr22:38667585~38681820:-
THCA	cis	rs73019876	0.901	rs1848998	ENSG00000269615.1	AC003973.1	3.35	0.000864	0.0476	0.15	0.15	Testicular germ cell tumor;	chr19:21952478	chr19:21940820~21941533:+
THCA	cis	rs854765	0.929	rs854766	ENSG00000281749.1	Y_RNA	3.35	0.000864	0.0476	0.2	0.15	Total body bone mineral density;	chr17:18109461	chr17:18001101~18001195:-
THCA	cis	rs6840360	0.55	rs4696269	ENSG00000251611.1	RP11-610P16.1	-3.35	0.000864	0.0477	-0.12	-0.15	Intelligence (multi-trait analysis);	chr4:151560552	chr4:151407551~151408835:-
THCA	cis	rs17159640	0.826	rs10274016	ENSG00000226851.1	AC004112.4	-3.35	0.000864	0.0477	-0.32	-0.15	Mortality in heart failure;	chr7:112353894	chr7:112328189~112409623:-
THCA	cis	rs854765	0.583	rs950966	ENSG00000265511.1	RP11-524F11.1	-3.35	0.000864	0.0477	-0.12	-0.15	Total body bone mineral density;	chr17:17880434	chr17:17507351~17508308:+
THCA	cis	rs7631605	1	rs6550450	ENSG00000272334.1	RP11-129K12.1	-3.35	0.000864	0.0477	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:37081608	chr3:36973117~36973672:-
THCA	cis	rs7781557	0.696	rs55849741	ENSG00000170629.13	DPY19L2P2	-3.35	0.000864	0.0477	-0.2	-0.15	Colorectal adenoma (advanced);	chr7:102943622	chr7:103175133~103280410:-
THCA	cis	rs7824557	0.564	rs2736290	ENSG00000255046.1	RP11-297N6.4	3.35	0.000864	0.0477	0.16	0.15	Retinal vascular caliber;	chr8:11376789	chr8:11797928~11802568:-
THCA	cis	rs10207628	0.698	rs7566991	ENSG00000260634.1	RP11-521O16.1	3.35	0.000864	0.0477	0.21	0.15	Psychosis and Alzheimer's disease;	chr2:127123357	chr2:127024252~127025723:-
THCA	cis	rs10207628	0.653	rs7601287	ENSG00000260634.1	RP11-521O16.1	3.35	0.000864	0.0477	0.21	0.15	Psychosis and Alzheimer's disease;	chr2:127123667	chr2:127024252~127025723:-
THCA	cis	rs3737883	1	rs7538696	ENSG00000229652.1	RP11-435P24.2	3.35	0.000864	0.0477	0.17	0.15	Early onset atrial fibrillation;	chr1:203065181	chr1:203353365~203353651:-
THCA	cis	rs440932	0.757	rs330943	ENSG00000254153.1	CTA-398F10.2	-3.35	0.000864	0.0477	-0.16	-0.15	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:8456909~8461337:-
THCA	cis	rs7914558	0.966	rs10786719	ENSG00000272912.1	RP11-724N1.1	3.35	0.000864	0.0477	0.18	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878235	chr10:102914585~102915404:+
THCA	cis	rs8187707	1	rs72838136	ENSG00000233690.1	EBAG9P1	-3.35	0.000864	0.0477	-0.31	-0.15	Carboplatin disposition in epthelial ovarian cancer;	chr10:99847958	chr10:99697407~99697949:-
THCA	cis	rs8187707	1	rs72838149	ENSG00000233690.1	EBAG9P1	-3.35	0.000864	0.0477	-0.31	-0.15	Carboplatin disposition in epthelial ovarian cancer;	chr10:99849816	chr10:99697407~99697949:-
THCA	cis	rs8187707	1	rs72838150	ENSG00000233690.1	EBAG9P1	-3.35	0.000864	0.0477	-0.31	-0.15	Carboplatin disposition in epthelial ovarian cancer;	chr10:99849905	chr10:99697407~99697949:-
THCA	cis	rs8187707	0.764	rs56333232	ENSG00000233690.1	EBAG9P1	-3.35	0.000864	0.0477	-0.31	-0.15	Carboplatin disposition in epthelial ovarian cancer;	chr10:99850346	chr10:99697407~99697949:-
THCA	cis	rs708547	1	rs10003229	ENSG00000269949.1	RP11-738E22.3	-3.35	0.000864	0.0477	-0.21	-0.15	Response to bleomycin (chromatid breaks);	chr4:56943432	chr4:56960927~56961373:-
THCA	cis	rs7308116	1	rs7308116	ENSG00000257951.1	RP11-554D14.4	3.35	0.000864	0.0477	0.18	0.15	Pelvic organ prolapse (moderate/severe);	chr12:107806819	chr12:107881242~107883382:+
THCA	cis	rs1005277	0.505	rs200910	ENSG00000273019.1	RP11-508N22.13	-3.35	0.000864	0.0477	-0.17	-0.15	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38149968~38150293:+
THCA	cis	rs2098713	0.535	rs2176478	ENSG00000250155.1	CTD-2353F22.1	3.35	0.000864	0.0477	0.15	0.15	Telomere length;	chr5:37626939	chr5:36666214~36725195:-
THCA	cis	rs11048434	0.736	rs7957321	ENSG00000245105.2	A2M-AS1	3.35	0.000864	0.0477	0.12	0.15	Sjögren's syndrome;	chr12:8967558	chr12:9065177~9068060:+
THCA	cis	rs910316	0.967	rs175432	ENSG00000259138.1	RP11-950C14.7	-3.35	0.000864	0.0477	-0.13	-0.15	Height;	chr14:75148543	chr14:75127153~75136930:+
THCA	cis	rs4533267	0.843	rs4471661	ENSG00000278456.1	RP11-66B24.9	-3.35	0.000864	0.0477	-0.18	-0.15	Height;	chr15:100254415	chr15:100888472~100889106:-
THCA	cis	rs2305707	0.544	rs936307	ENSG00000273674.3	CTD-2378E12.1	3.35	0.000865	0.0477	0.32	0.15	Height;	chr15:51287778	chr15:50839875~50908599:-
THCA	cis	rs7005380	0.62	rs13282901	ENSG00000279347.1	RP11-85I17.2	-3.35	0.000865	0.0477	-0.17	-0.15	Interstitial lung disease;	chr8:119881561	chr8:119838736~119840385:-
THCA	cis	rs763121	0.853	rs5750668	ENSG00000225450.1	RP3-508I15.14	-3.35	0.000865	0.0477	-0.12	-0.15	Menopause (age at onset);	chr22:38683959	chr22:38739003~38749041:+
THCA	cis	rs9303542	0.694	rs7222593	ENSG00000278765.1	RP5-890E16.5	-3.35	0.000865	0.0477	-0.19	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48253072	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs7211607	ENSG00000278765.1	RP5-890E16.5	-3.35	0.000865	0.0477	-0.19	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48258937	chr17:48066704~48067293:-
THCA	cis	rs9303542	0.694	rs12941754	ENSG00000278765.1	RP5-890E16.5	-3.35	0.000865	0.0477	-0.19	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48259674	chr17:48066704~48067293:-
THCA	cis	rs7824557	0.737	rs2293855	ENSG00000255310.2	AF131215.2	3.35	0.000865	0.0477	0.13	0.15	Retinal vascular caliber;	chr8:11319901	chr8:11107788~11109726:-
THCA	cis	rs7587476	0.768	rs9789462	ENSG00000229267.2	AC072062.1	-3.35	0.000865	0.0477	-0.17	-0.15	Neuroblastoma;	chr2:214778216	chr2:214810229~214963274:+
THCA	cis	rs4589258	0.788	rs4463819	ENSG00000280367.1	RP11-121L10.2	3.35	0.000865	0.0477	0.14	0.15	Intelligence (multi-trait analysis);	chr11:90729376	chr11:90223153~90226538:+
THCA	cis	rs10508774	1	rs61299190	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32570591	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs72795557	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32581579	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs117817425	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32590266	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs72795564	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32599372	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs72795567	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32607581	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs1333221	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32614495	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs1829545	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32617449	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs58783140	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32620675	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs58339739	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32620706	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs72795571	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32621005	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs72795572	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32621058	chr10:32188323~32188817:-
THCA	cis	rs10508774	1	rs117557786	ENSG00000217094.2	PPIAP31	3.35	0.000865	0.0477	0.27	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32641148	chr10:32188323~32188817:-
THCA	cis	rs13323323	0.728	rs1004631	ENSG00000214820.3	MPRIPP1	3.35	0.000865	0.0477	0.18	0.15	IgG glycosylation;	chr3:44551487	chr3:44579938~44581026:-
THCA	cis	rs769267	0.93	rs2315022	ENSG00000269131.1	AC004447.2	-3.35	0.000865	0.0477	-0.1	-0.15	Tonsillectomy;	chr19:19302572	chr19:18990893~18993610:+
THCA	cis	rs787665	0.786	rs2259185	ENSG00000232709.1	MARK2P9	3.35	0.000865	0.0477	0.24	0.15	Gut microbiome composition (summer);	chr10:93323968	chr10:92418667~92420875:+
THCA	cis	rs12049351	0.719	rs2145394	ENSG00000229367.1	HMGN2P19	3.35	0.000865	0.0477	0.23	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229535217	chr1:229570532~229570796:+
THCA	cis	rs2486012	1	rs2906456	ENSG00000234694.1	RP1-92O14.3	-3.35	0.000865	0.0477	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43875248	chr1:43354684~43358658:-
THCA	cis	rs10895987	0.955	rs7114094	ENSG00000197847.11	SLC22A20	-3.35	0.000865	0.0477	-0.19	-0.15	Blood protein levels;	chr11:65159740	chr11:65213840~65242757:+
THCA	cis	rs9816784	0.525	rs41301371	ENSG00000207650.1	MIR570	3.35	0.000865	0.0477	0.17	0.15	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195699401~195699497:+
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000261839.1	RP1-265C24.8	3.35	0.000865	0.0477	0.15	0.15	Pubertal anthropometrics;	chr6:28259100	chr6:28136849~28139678:+
THCA	cis	rs9425766	0.679	rs9787001	ENSG00000270084.1	GAS5-AS1	-3.35	0.000865	0.0477	-0.16	-0.15	Life satisfaction;	chr1:174222556	chr1:173863248~173863941:+
THCA	cis	rs9425766	0.679	rs972361	ENSG00000270084.1	GAS5-AS1	-3.35	0.000865	0.0477	-0.16	-0.15	Life satisfaction;	chr1:174228270	chr1:173863248~173863941:+
THCA	cis	rs12101261	0.813	rs58266067	ENSG00000271656.1	RP11-114N19.5	-3.35	0.000865	0.0477	-0.18	-0.15	Graves' disease;	chr14:81002132	chr14:81003325~81003645:-
THCA	cis	rs7680126	0.672	rs4697957	ENSG00000261490.1	RP11-448G15.3	-3.35	0.000865	0.0477	-0.12	-0.15	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10180630	chr4:10068089~10073019:-
THCA	cis	rs9425766	0.924	rs9286895	ENSG00000200674.1	RN7SKP160	3.35	0.000865	0.0477	0.2	0.15	Life satisfaction;	chr1:173873329	chr1:173791548~173791887:+
THCA	cis	rs847649	0.731	rs7785272	ENSG00000234715.1	CTB-107G13.1	-3.35	0.000865	0.0477	-0.17	-0.15	Morning vs. evening chronotype;	chr7:103030576	chr7:103445207~103514007:+
THCA	cis	rs1737890	0.778	rs1129012	ENSG00000235217.6	TSPY26P	-3.35	0.000865	0.0477	-0.17	-0.15	Chronic obstructive pulmonary disease;	chr20:32327658	chr20:32186477~32190527:-
THCA	cis	rs2625529	0.73	rs35713471	ENSG00000260037.4	CTD-2524L6.3	-3.35	0.000865	0.0477	-0.21	-0.15	Red blood cell count;	chr15:72167630	chr15:71818396~71823384:+
THCA	cis	rs4857855	0.673	rs9878263	ENSG00000239405.1	TMED10P2	3.35	0.000866	0.0477	0.2	0.15	Eosinophil counts;	chr3:128530824	chr3:128538020~128538631:+
THCA	cis	rs4857855	0.673	rs6803295	ENSG00000239405.1	TMED10P2	3.35	0.000866	0.0477	0.2	0.15	Eosinophil counts;	chr3:128531112	chr3:128538020~128538631:+
THCA	cis	rs11048434	0.649	rs11613650	ENSG00000245105.2	A2M-AS1	3.35	0.000866	0.0477	0.12	0.15	Sjögren's syndrome;	chr12:8907800	chr12:9065177~9068060:+
THCA	cis	rs2797501	1	rs61836362	ENSG00000272764.1	RP11-318E3.9	-3.35	0.000866	0.0477	-0.22	-0.15	Osteosarcoma;	chr10:5768495	chr10:5813985~5814441:+
THCA	cis	rs67539049	1	rs67539049	ENSG00000227888.4	FAM66A	-3.35	0.000866	0.0477	-0.23	-0.15	Itch intensity from mosquito bite;	chr8:11449802	chr8:12362019~12388296:+
THCA	cis	rs11603020	0.95	rs28362949	ENSG00000265566.2	RN7SL605P	-3.35	0.000866	0.0477	-0.23	-0.15	Blood protein levels;	chr11:57604438	chr11:57528085~57528365:-
THCA	cis	rs728616	0.571	rs113030473	ENSG00000272447.1	RP11-182L21.6	-3.35	0.000866	0.0477	-0.32	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79889275	chr10:79825902~79827602:+
THCA	cis	rs757110	0.933	rs4148646	ENSG00000260196.1	RP1-239B22.5	3.35	0.000866	0.0477	0.18	0.15	Type 2 diabetes;	chr11:17393643	chr11:17380649~17383531:+
THCA	cis	rs7809950	0.53	rs34021916	ENSG00000272072.1	CTA-363E19.2	3.35	0.000866	0.0477	0.17	0.15	Coronary artery disease;	chr7:107177456	chr7:107192559~107193300:-
THCA	cis	rs9907295	0.901	rs3760326	ENSG00000270871.1	AC015849.19	3.35	0.000866	0.0477	0.14	0.15	Fibroblast growth factor basic levels;	chr17:35853493	chr17:35816717~35830293:-
THCA	cis	rs7702057	0.619	rs4920913	ENSG00000271918.1	CTD-2287O16.5	-3.35	0.000866	0.0477	-0.21	-0.15	Amyotrophic lateral sclerosis;	chr5:116329560	chr5:116083807~116085416:-
THCA	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	3.35	0.000866	0.0478	0.14	0.15	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
THCA	cis	rs8046148	0.737	rs4074655	ENSG00000279356.1	RP11-429P3.8	3.35	0.000866	0.0478	0.19	0.15	Testicular germ cell tumor;	chr16:50112333	chr16:50072862~50074986:+
THCA	cis	rs285757	0.895	rs16974307	ENSG00000259064.2	RP11-386M24.5	3.35	0.000866	0.0478	0.22	0.15	HIV-1 susceptibility;	chr15:92652232	chr15:92627073~92627414:+
THCA	cis	rs613391	0.612	rs618109	ENSG00000234840.1	LINC01239	-3.35	0.000866	0.0478	-0.17	-0.15	Quantitative traits;	chr9:22698066	chr9:22646200~22824213:+
THCA	cis	rs7131987	0.903	rs2194519	ENSG00000257599.1	OVCH1-AS1	3.35	0.000866	0.0478	0.18	0.15	QT interval;	chr12:29270650	chr12:29389294~29487488:+
THCA	cis	rs56114371	0.568	rs200468	ENSG00000216915.2	RP1-97D16.1	-3.35	0.000866	0.0478	-0.25	-0.15	Breast cancer;	chr6:27790076	chr6:27737000~27738494:-
THCA	cis	rs4930561	0.69	rs6591334	ENSG00000184795.9	UNC93B5	-3.35	0.000866	0.0478	-0.2	-0.15	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68157092	chr11:67711702~67716005:-
THCA	cis	rs9880211	0.606	rs28576629	ENSG00000239213.4	NCK1-AS1	3.35	0.000866	0.0478	0.17	0.15	Height;Body mass index;	chr3:136054819	chr3:136841726~136862054:-
THCA	cis	rs9611519	0.542	rs8139770	ENSG00000184068.2	RP5-821D11.7	3.35	0.000866	0.0478	0.13	0.15	Neuroticism;	chr22:41020177	chr22:41831215~41834665:-
THCA	cis	rs2239557	0.508	rs12588108	ENSG00000259065.1	RP5-1021I20.1	-3.35	0.000866	0.0478	-0.23	-0.15	Common traits (Other);	chr14:73865775	chr14:73787360~73803270:+
THCA	cis	rs2239557	0.508	rs34774275	ENSG00000259065.1	RP5-1021I20.1	-3.35	0.000866	0.0478	-0.23	-0.15	Common traits (Other);	chr14:73867013	chr14:73787360~73803270:+
THCA	cis	rs620729	0.749	rs62394918	ENSG00000272097.1	RP11-421M1.8	3.35	0.000866	0.0478	0.17	0.15	Intelligence (multi-trait analysis);	chr6:11481764	chr6:10743324~10747663:-
THCA	cis	rs2734839	0.507	rs2002453	ENSG00000270179.1	RP11-159N11.4	-3.35	0.000866	0.0478	-0.18	-0.15	Information processing speed;	chr11:113418576	chr11:113368478~113369117:+
THCA	cis	rs7267979	0.844	rs6083845	ENSG00000276952.1	RP5-965G21.6	-3.35	0.000866	0.0478	-0.16	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25284915~25285588:-
THCA	cis	rs11603020	1	rs11603020	ENSG00000265566.2	RN7SL605P	3.35	0.000866	0.0478	0.23	0.15	Blood protein levels;	chr11:57606859	chr11:57528085~57528365:-
THCA	cis	rs7020830	0.894	rs13300951	ENSG00000260100.1	RP11-220I1.5	-3.35	0.000866	0.0478	-0.19	-0.15	Schizophrenia;	chr9:37146630	chr9:37078813~37079776:-
THCA	cis	rs2274089	0.826	rs17318575	ENSG00000272810.1	U91328.22	-3.35	0.000867	0.0478	-0.24	-0.15	Iron status biomarkers;	chr6:25493010	chr6:26013241~26013757:+
THCA	cis	rs73459955	0.712	rs55830969	ENSG00000248441.5	LINC01197	3.35	0.000867	0.0478	0.2	0.15	Major depression and alcohol dependence;	chr15:95078852	chr15:95209099~95327129:-
THCA	cis	rs7737355	0.812	rs6868007	ENSG00000224431.1	AC063976.7	3.35	0.000867	0.0478	0.14	0.15	Life satisfaction;	chr5:131489117	chr5:132199456~132203487:+
THCA	cis	rs1322639	0.614	rs7751131	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.35	0.000867	0.0478	-0.23	-0.15	Pulse pressure;	chr6:169178615	chr6:169213254~169239565:+
THCA	cis	rs1322639	0.574	rs9364360	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.35	0.000867	0.0478	-0.23	-0.15	Pulse pressure;	chr6:169180079	chr6:169213254~169239565:+
THCA	cis	rs7709909	0.553	rs26782	ENSG00000249655.1	CTC-325J23.2	3.35	0.000867	0.0478	0.18	0.15	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80756600	chr5:80630313~80631590:-
THCA	cis	rs7709909	0.532	rs26781	ENSG00000249655.1	CTC-325J23.2	3.35	0.000867	0.0478	0.18	0.15	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80756947	chr5:80630313~80631590:-
THCA	cis	rs7709909	0.532	rs26780	ENSG00000249655.1	CTC-325J23.2	3.35	0.000867	0.0478	0.18	0.15	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80757436	chr5:80630313~80631590:-
THCA	cis	rs1040	1	rs10945405	ENSG00000261039.2	RP11-417E7.2	3.35	0.000867	0.0478	0.16	0.15	Joint mobility (Beighton score);	chr6:169221041	chr6:169175304~169182740:-
THCA	cis	rs73198271	0.74	rs10105920	ENSG00000254340.1	RP11-10A14.3	3.35	0.000867	0.0478	0.19	0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:9141424~9145435:+
THCA	cis	rs1040	1	rs1040	ENSG00000261039.2	RP11-417E7.2	-3.35	0.000867	0.0478	-0.16	-0.15	Joint mobility (Beighton score);	chr6:169216252	chr6:169175304~169182740:-
THCA	cis	rs9376098	0.737	rs9402694	ENSG00000232876.1	CTA-212D2.2	-3.35	0.000867	0.0478	-0.21	-0.15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135177595	chr6:135055033~135060550:+
THCA	cis	rs11678825	0.852	rs11676078	ENSG00000272663.1	RP11-191L17.1	-3.35	0.000867	0.0478	-0.21	-0.15	Reticulocyte fraction of red cells;	chr2:48443067	chr2:48440043~48440597:-
THCA	cis	rs7520050	0.966	rs11589562	ENSG00000232022.5	FAAHP1	3.35	0.000867	0.0478	0.15	0.15	Reticulocyte count;Red blood cell count;	chr1:46001049	chr1:46432129~46445521:+
THCA	cis	rs6715284	1	rs6711127	ENSG00000183308.6	AC005037.3	3.35	0.000867	0.0478	0.33	0.15	Rheumatoid arthritis;	chr2:201348792	chr2:200963263~201009102:+
THCA	cis	rs6715284	1	rs72934973	ENSG00000183308.6	AC005037.3	3.35	0.000867	0.0478	0.33	0.15	Rheumatoid arthritis;	chr2:201349211	chr2:200963263~201009102:+
THCA	cis	rs4948275	0.679	rs10994772	ENSG00000233643.2	RP11-491H19.1	3.35	0.000867	0.0478	0.17	0.15	Night sleep phenotypes;	chr10:61456117	chr10:61781745~61821246:-
THCA	cis	rs910316	0.763	rs175014	ENSG00000273565.1	CTD-3075F15.1	-3.35	0.000867	0.0478	-0.18	-0.15	Height;	chr14:74990224	chr14:75176929~75177418:+
THCA	cis	rs4771996	0.508	rs9554404	ENSG00000276573.1	RP11-128N14.5	-3.35	0.000867	0.0478	-0.23	-0.15	Obesity-related traits;	chr13:97597110	chr13:97435946~97436168:+
THCA	cis	rs2888875	0.523	rs11891936	ENSG00000279873.2	LINC01126	3.35	0.000867	0.0478	0.14	0.15	Glomerular filtration rate (creatinine);	chr2:43305163	chr2:43227210~43228855:+
THCA	cis	rs9303029	0.611	rs2306753	ENSG00000265458.1	RP13-20L14.6	3.35	0.000867	0.0478	0.2	0.15	Protein quantitative trait loci;	chr17:82469114	chr17:82454273~82458521:-
THCA	cis	rs12210905	0.764	rs72835248	ENSG00000224843.5	LINC00240	3.35	0.000867	0.0478	0.26	0.15	Hip circumference adjusted for BMI;	chr6:26964038	chr6:26956992~27023924:+
THCA	cis	rs2821260	0.729	rs727726	ENSG00000227207.2	RPL31P12	3.35	0.000867	0.0478	0.17	0.15	Intelligence (multi-trait analysis);	chr1:72094057	chr1:72301472~72301829:+
THCA	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	3.35	0.000867	0.0478	0.17	0.15	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
THCA	cis	rs775227	0.574	rs34286076	ENSG00000243849.1	CFAP44-AS1	3.35	0.000867	0.0478	0.27	0.15	Dental caries;	chr3:113550848	chr3:113403991~113433992:+
THCA	cis	rs1232027	0.656	rs1677655	ENSG00000244076.1	CTC-512J14.1	3.35	0.000867	0.0478	0.19	0.15	Huntington's disease progression;	chr5:80672677	chr5:80315671~80315826:+
THCA	cis	rs2562456	0.833	rs11880624	ENSG00000213976.4	CTD-2561J22.2	-3.35	0.000867	0.0478	-0.19	-0.15	Pain;	chr19:21341028	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs62107547	ENSG00000213976.4	CTD-2561J22.2	-3.35	0.000867	0.0478	-0.19	-0.15	Pain;	chr19:21341245	chr19:21382865~21387177:+
THCA	cis	rs2562456	0.833	rs56187954	ENSG00000213976.4	CTD-2561J22.2	-3.35	0.000867	0.0478	-0.19	-0.15	Pain;	chr19:21345258	chr19:21382865~21387177:+
THCA	cis	rs9303542	0.694	rs66529852	ENSG00000278765.1	RP5-890E16.5	-3.35	0.000867	0.0478	-0.2	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48443838	chr17:48066704~48067293:-
THCA	cis	rs9650657	0.74	rs11250077	ENSG00000255310.2	AF131215.2	-3.35	0.000867	0.0478	-0.13	-0.15	Neuroticism;	chr8:10798927	chr8:11107788~11109726:-
THCA	cis	rs4915077	0.803	rs76698933	ENSG00000226822.1	RP11-356N1.2	3.35	0.000867	0.0478	0.26	0.15	Hypothyroidism;	chr1:107835331	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.803	rs77705025	ENSG00000226822.1	RP11-356N1.2	3.35	0.000867	0.0478	0.26	0.15	Hypothyroidism;	chr1:107836350	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.803	rs74399981	ENSG00000226822.1	RP11-356N1.2	3.35	0.000867	0.0478	0.26	0.15	Hypothyroidism;	chr1:107836535	chr1:108071482~108074519:+
THCA	cis	rs4915077	0.803	rs4915080	ENSG00000226822.1	RP11-356N1.2	3.35	0.000867	0.0478	0.26	0.15	Hypothyroidism;	chr1:107838145	chr1:108071482~108074519:+
THCA	cis	rs72827839	0.846	rs72825517	ENSG00000278765.1	RP5-890E16.5	-3.35	0.000867	0.0478	-0.22	-0.15	Ease of getting up in the morning;	chr17:48094462	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.841	rs16952265	ENSG00000278765.1	RP5-890E16.5	-3.35	0.000867	0.0478	-0.22	-0.15	Ease of getting up in the morning;	chr17:48107521	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.894	rs112306902	ENSG00000278765.1	RP5-890E16.5	-3.35	0.000867	0.0478	-0.22	-0.15	Ease of getting up in the morning;	chr17:48113670	chr17:48066704~48067293:-
THCA	cis	rs256438	0.671	rs17878919	ENSG00000251221.1	LINC01337	-3.35	0.000867	0.0478	-0.18	-0.15	Serum thyroid-stimulating hormone levels;	chr5:80033715	chr5:80608623~80622524:-
THCA	cis	rs9376098	0.668	rs210962	ENSG00000232876.1	CTA-212D2.2	-3.35	0.000867	0.0478	-0.21	-0.15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135182647	chr6:135055033~135060550:+
THCA	cis	rs7315621	0.965	rs6598194	ENSG00000279283.1	RP11-417L19.5	3.35	0.000867	0.0478	0.14	0.15	Longevity;	chr12:131596042	chr12:131896500~131898239:+
THCA	cis	rs12452225	0.708	rs72823612	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34871186	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.643	rs72823616	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34873549	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.708	rs10512466	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34878866	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.708	rs62064811	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34883994	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.708	rs7223630	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34892571	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.708	rs7210677	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34894192	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.582	rs12452723	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34896741	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.582	rs12449962	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34899205	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.708	rs56138114	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34900603	chr17:35757199~35758325:-
THCA	cis	rs12452225	0.656	rs7223121	ENSG00000271392.1	RP1-161P9.5	-3.35	0.000867	0.0478	-0.3	-0.15	Night sleep phenotypes;	chr17:34912631	chr17:35757199~35758325:-
THCA	cis	rs7621331	1	rs9862264	ENSG00000239213.4	NCK1-AS1	3.35	0.000867	0.0478	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135975654	chr3:136841726~136862054:-
THCA	cis	rs6452524	0.618	rs255561	ENSG00000271862.1	RP11-343L5.2	3.35	0.000867	0.0478	0.16	0.15	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83049376~83050964:-
THCA	cis	rs1922291	0.546	rs17637748	ENSG00000234389.1	AC007278.3	-3.35	0.000867	0.0478	-0.15	-0.15	Blood protein levels;	chr2:102225255	chr2:102438713~102440475:+
THCA	cis	rs9677476	1	rs9677476	ENSG00000224376.1	AC017104.6	-3.35	0.000867	0.0478	-0.16	-0.15	Food antigen IgG levels;	chr2:231261577	chr2:231388976~231394991:+
THCA	cis	rs13287066	0.603	rs10739948	ENSG00000203364.2	RP11-370F5.4	-3.35	0.000867	0.0478	-0.14	-0.15	Intelligence (multi-trait analysis);	chr9:93387990	chr9:93147040~93148556:+
THCA	cis	rs7924176	0.521	rs10824137	ENSG00000271848.1	RP11-464F9.21	3.35	0.000867	0.0478	0.17	0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:73654039~73674719:+
THCA	cis	rs4660214	0.666	rs7554206	ENSG00000228060.1	RP11-69E11.8	3.35	0.000868	0.0478	0.15	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39565160~39573203:+
THCA	cis	rs10483853	0.806	rs11159015	ENSG00000258891.1	RP5-1021I20.5	-3.35	0.000868	0.0478	-0.2	-0.15	Coronary artery calcification;	chr14:73364720	chr14:73896164~73938114:-
THCA	cis	rs10483853	0.806	rs8015790	ENSG00000258891.1	RP5-1021I20.5	-3.35	0.000868	0.0478	-0.2	-0.15	Coronary artery calcification;	chr14:73366297	chr14:73896164~73938114:-
THCA	cis	rs7631605	0.586	rs13085190	ENSG00000224080.1	UBE2FP1	3.35	0.000868	0.0478	0.17	0.15	Cerebrospinal P-tau181p levels;	chr3:37368426	chr3:37143512~37143958:-
THCA	cis	rs9898058	0.941	rs17646883	ENSG00000204584.1	RP11-304F15.3	-3.35	0.000868	0.0478	-0.18	-0.15	Milk allergy;	chr17:49873710	chr17:49845910~49848837:+
THCA	cis	rs442177	0.524	rs342435	ENSG00000251411.1	RP11-397E7.4	-3.35	0.000868	0.0478	-0.15	-0.15	Triglycerides;Hemoglobin concentration;	chr4:87122054	chr4:86913266~86914817:-
THCA	cis	rs897984	0.609	rs35468353	ENSG00000275263.1	RP11-1072A3.4	-3.35	0.000868	0.0478	-0.18	-0.15	Dementia with Lewy bodies;	chr16:31045112	chr16:30956872~30957199:-
THCA	cis	rs897984	0.609	rs11862744	ENSG00000275263.1	RP11-1072A3.4	-3.35	0.000868	0.0478	-0.18	-0.15	Dementia with Lewy bodies;	chr16:31046479	chr16:30956872~30957199:-
THCA	cis	rs7503807	0.701	rs1485329	ENSG00000262585.1	RP11-353N14.5	-3.35	0.000868	0.0478	-0.17	-0.15	Obesity;	chr17:80669761	chr17:79915252~79926725:-
THCA	cis	rs2250417	0.647	rs4937123	ENSG00000250303.3	RP11-356J5.12	3.35	0.000868	0.0478	0.2	0.15	Protein quantitative trait loci;Inflammatory biomarkers;	chr11:112172306	chr11:112270749~112362534:+
THCA	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	3.35	0.000868	0.0478	0.18	0.15	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
THCA	cis	rs7028939	0.892	rs10989013	ENSG00000255145.2	STX17-AS1	-3.35	0.000868	0.0478	-0.23	-0.15	Preeclampsia;	chr9:100200585	chr9:99886322~99906601:-
THCA	cis	rs7226408	0.6	rs9948487	ENSG00000267707.2	RP11-95O2.5	-3.35	0.000868	0.0478	-0.15	-0.15	Obesity-related traits;	chr18:36979916	chr18:37243776~37247506:+
THCA	cis	rs494526	0.579	rs10886385	ENSG00000229272.1	RP11-498J9.2	-3.35	0.000868	0.0478	-0.17	-0.15	Alcoholic chronic pancreatitis;	chr10:119109866	chr10:119003536~119003884:-
THCA	cis	rs6832769	1	rs6853192	ENSG00000223305.1	RN7SKP30	-3.35	0.000868	0.0478	-0.19	-0.15	Personality dimensions;	chr4:55543087	chr4:55540502~55540835:-
THCA	cis	rs11673344	0.504	rs7252940	ENSG00000233527.7	ZNF529-AS1	3.35	0.000868	0.0478	0.13	0.15	Obesity-related traits;	chr19:37138589	chr19:36573070~36594708:+
THCA	cis	rs1927790	0.727	rs7323056	ENSG00000247400.3	DNAJC3-AS1	-3.35	0.000868	0.0478	-0.1	-0.15	Body mass index;	chr13:96303946	chr13:95648733~95676925:-
THCA	cis	rs8114671	0.562	rs1018447	ENSG00000126005.14	MMP24-AS1	3.35	0.000868	0.0478	0.15	0.15	Height;	chr20:34813904	chr20:35216462~35278131:-
THCA	cis	rs1552244	0.816	rs13059144	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9968513	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs66559400	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9970867	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs68153882	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9971426	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs35056669	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9972487	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs3732967	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9973753	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs3732966	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9974056	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs13062917	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9975348	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.816	rs13076197	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9978089	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs34779351	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9980117	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs13077641	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9981251	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs13074282	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9983015	chr3:9958717~9962539:+
THCA	cis	rs1552244	0.882	rs67895180	ENSG00000269982.1	RP11-1020A11.2	3.35	0.000868	0.0478	0.12	0.15	Alzheimer's disease;	chr3:9984395	chr3:9958717~9962539:+
THCA	cis	rs660899	0.752	rs7511800	ENSG00000228452.1	RP5-994D16.9	-3.35	0.000868	0.0478	-0.19	-0.15	Hypertension risk in short sleep duration;	chr1:43748598	chr1:42775813~42776790:-
THCA	cis	rs922948	0.89	rs11128128	ENSG00000241506.1	PSMC1P1	3.35	0.000868	0.0478	0.15	0.15	Hip geometry;	chr3:69390580	chr3:68635705~68637024:+
THCA	cis	rs9807841	0.723	rs1965767	ENSG00000267100.1	ILF3-AS1	3.35	0.000868	0.0478	0.2	0.15	Inflammatory skin disease;	chr19:10749539	chr19:10651862~10653844:-
THCA	cis	rs3749237	0.576	rs4241406	ENSG00000224424.7	PRKAR2A-AS1	3.35	0.000868	0.0478	0.13	0.15	Resting heart rate;	chr3:49562993	chr3:48847572~48851981:+
THCA	cis	rs7818688	1	rs11786380	ENSG00000253528.2	RP11-347C18.4	-3.35	0.000868	0.0478	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015908	chr8:94974573~94974853:-
THCA	cis	rs7089973	0.604	rs12218498	ENSG00000228169.3	PPIAP19	3.35	0.000868	0.0478	0.18	0.15	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114818730	chr10:114690143~114690634:-
THCA	cis	rs2905347	0.895	rs2961280	ENSG00000179428.2	AC073072.5	3.35	0.000868	0.0478	0.17	0.15	Major depression and alcohol dependence;	chr7:22600098	chr7:22725395~22727620:-
THCA	cis	rs7315621	0.965	rs6598193	ENSG00000279283.1	RP11-417L19.5	3.35	0.000868	0.0478	0.14	0.15	Longevity;	chr12:131595924	chr12:131896500~131898239:+
THCA	cis	rs7772697	0.508	rs9498199	ENSG00000223701.3	RAET1E-AS1	-3.35	0.000868	0.0478	-0.21	-0.15	Diabetic retinopathy;	chr6:149057786	chr6:149884431~149919508:+
THCA	cis	rs7772697	0.537	rs9322165	ENSG00000223701.3	RAET1E-AS1	-3.35	0.000868	0.0478	-0.21	-0.15	Diabetic retinopathy;	chr6:149058219	chr6:149884431~149919508:+
THCA	cis	rs9916302	0.706	rs8182252	ENSG00000266469.1	CTB-131K11.1	3.35	0.000868	0.0478	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39571697	chr17:39401793~39406233:+
THCA	cis	rs853679	0.506	rs1150693	ENSG00000219891.2	ZSCAN12P1	3.35	0.000868	0.0479	0.21	0.15	Depression;	chr6:28206812	chr6:28091154~28093664:+
THCA	cis	rs12083887	0.583	rs12139966	ENSG00000236866.4	AL157902.3	-3.35	0.000868	0.0479	-0.18	-0.15	Male-pattern baldness;	chr1:118339823	chr1:117596832~117605770:-
THCA	cis	rs9652601	0.622	rs2286974	ENSG00000263033.2	RP11-396B14.2	-3.35	0.000868	0.0479	-0.12	-0.15	Systemic lupus erythematosus;	chr16:11020655	chr16:11196177~11224969:+
THCA	cis	rs7044106	0.708	rs1324472	ENSG00000235865.2	GSN-AS1	-3.35	0.000869	0.0479	-0.14	-0.15	Hip circumference adjusted for BMI;	chr9:120612832	chr9:121280768~121285530:-
THCA	cis	rs964611	0.816	rs1426722	ENSG00000259488.2	RP11-154J22.1	-3.35	0.000869	0.0479	-0.14	-0.15	Metabolite levels (Pyroglutamine);	chr15:48277212	chr15:48312353~48331856:-
THCA	cis	rs7631605	0.809	rs3774327	ENSG00000272334.1	RP11-129K12.1	-3.35	0.000869	0.0479	-0.18	-0.15	Cerebrospinal P-tau181p levels;	chr3:37057876	chr3:36973117~36973672:-
THCA	cis	rs4794202	0.629	rs16948424	ENSG00000264920.1	RP11-6N17.4	-3.35	0.000869	0.0479	-0.21	-0.15	Alzheimer's disease (cognitive decline);	chr17:47812346	chr17:47891255~47895812:-
THCA	cis	rs71277158	0.688	rs76146702	ENSG00000242578.1	RP11-469J4.3	3.35	0.000869	0.0479	0.24	0.15	Prostate cancer;	chr3:170150932	chr3:170410512~170418615:+
THCA	cis	rs5769765	0.955	rs9616204	ENSG00000260613.1	RP3-522J7.6	-3.35	0.000869	0.0479	-0.19	-0.15	Schizophrenia;	chr22:49909882	chr22:49832616~49837786:-
THCA	cis	rs5769765	0.955	rs9616368	ENSG00000260613.1	RP3-522J7.6	-3.35	0.000869	0.0479	-0.19	-0.15	Schizophrenia;	chr22:49909885	chr22:49832616~49837786:-
THCA	cis	rs1881509	0.702	rs7102832	ENSG00000233930.3	KRTAP5-AS1	-3.35	0.000869	0.0479	-0.18	-0.15	Heroin dependence;	chr11:1413913	chr11:1571353~1599184:+
THCA	cis	rs78487399	0.764	rs12473987	ENSG00000234936.1	AC010883.5	3.35	0.000869	0.0479	0.18	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43585041	chr2:43229573~43233394:+
THCA	cis	rs4295623	0.504	rs11250160	ENSG00000270154.1	RP11-419I17.1	-3.35	0.000869	0.0479	-0.18	-0.15	Morning vs. evening chronotype;	chr8:11735208	chr8:12476462~12477122:+
THCA	cis	rs1005277	0.505	rs1208689	ENSG00000273019.1	RP11-508N22.13	-3.35	0.000869	0.0479	-0.17	-0.15	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38149968~38150293:+
THCA	cis	rs10435719	0.902	rs6601633	ENSG00000255046.1	RP11-297N6.4	3.35	0.000869	0.0479	0.16	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11797928~11802568:-
THCA	cis	rs8054556	1	rs4788195	ENSG00000183604.13	SMG1P5	-3.35	0.000869	0.0479	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29949272	chr16:30267553~30335374:-
THCA	cis	rs3758785	0.641	rs10831207	ENSG00000255893.1	RP11-685N10.1	3.35	0.000869	0.0479	0.16	0.15	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94356197	chr11:94472908~94473570:-
THCA	cis	rs2051773	0.567	rs12293395	ENSG00000272034.1	SNORD14A	3.35	0.000869	0.0479	0.17	0.15	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17026114	chr11:17074654~17074744:-
THCA	cis	rs853679	0.76	rs9357067	ENSG00000272009.1	RP1-313I6.12	-3.35	0.000869	0.0479	-0.19	-0.15	Depression;	chr6:28242515	chr6:28078792~28081130:-
THCA	cis	rs853679	0.76	rs967005	ENSG00000272009.1	RP1-313I6.12	-3.35	0.000869	0.0479	-0.19	-0.15	Depression;	chr6:28242910	chr6:28078792~28081130:-
THCA	cis	rs9907295	0.818	rs4796109	ENSG00000270871.1	AC015849.19	3.35	0.000869	0.0479	0.13	0.15	Fibroblast growth factor basic levels;	chr17:35811904	chr17:35816717~35830293:-
THCA	cis	rs34783982	0.881	rs36116028	ENSG00000259699.2	HMGB1P8	-3.35	0.000869	0.0479	-0.2	-0.15	Squamous cell lung carcinoma;	chr15:88957398	chr15:89135547~89136495:-
THCA	cis	rs9844666	0.512	rs16843509	ENSG00000273486.1	RP11-731C17.2	3.35	0.000869	0.0479	0.13	0.15	Height;	chr3:135923662	chr3:136837338~136839021:-
THCA	cis	rs1873147	1	rs4774470	ENSG00000259672.1	RP11-69G7.1	3.35	0.000869	0.0479	0.16	0.15	Orofacial clefts;	chr15:63019920	chr15:63098870~63110403:+
THCA	cis	rs12946454	0.521	rs66827053	ENSG00000233175.2	CTD-2020K17.3	3.35	0.000869	0.0479	0.16	0.15	Systolic blood pressure;	chr17:45173286	chr17:45238028~45241734:-
THCA	cis	rs7246967	0.673	rs2885221	ENSG00000198153.8	ZNF849P	-3.35	0.000869	0.0479	-0.24	-0.15	Bronchopulmonary dysplasia;	chr19:22656585	chr19:22685167~22686732:+
THCA	cis	rs7246967	0.611	rs2885222	ENSG00000198153.8	ZNF849P	-3.35	0.000869	0.0479	-0.24	-0.15	Bronchopulmonary dysplasia;	chr19:22657142	chr19:22685167~22686732:+
THCA	cis	rs3126085	0.877	rs1969019	ENSG00000237975.5	FLG-AS1	-3.35	0.000869	0.0479	-0.24	-0.15	Atopic dermatitis;	chr1:152239026	chr1:152168125~152445456:+
THCA	cis	rs1941184	0.526	rs7351033	ENSG00000266521.1	RP11-650P15.1	-3.35	0.000869	0.0479	-0.23	-0.15	Parkinson's disease (age of onset);	chr18:31442407	chr18:31496645~31497195:-
THCA	cis	rs200972	1	rs200972	ENSG00000176933.5	TOB2P1	-3.35	0.00087	0.0479	-0.18	-0.15	Urinary tract infection frequency;	chr6:27891059	chr6:28217643~28218634:-
THCA	cis	rs9393777	0.528	rs9467989	ENSG00000220721.1	OR1F12	3.35	0.00087	0.0479	0.2	0.15	Intelligence (multi-trait analysis);	chr6:27096496	chr6:28073316~28074233:+
THCA	cis	rs5771242	0.776	rs6010198	ENSG00000280567.1	Metazoa_SRP	3.35	0.00087	0.0479	0.21	0.15	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50172199	chr22:49878999~49879242:+
THCA	cis	rs10824518	0.738	rs71475646	ENSG00000199664.1	RNU6-1266P	-3.35	0.00087	0.0479	-0.2	-0.15	Myopia;	chr10:77311024	chr10:77776951~77777055:-
THCA	cis	rs2486012	1	rs17474535	ENSG00000234694.1	RP1-92O14.3	-3.35	0.00087	0.0479	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43887412	chr1:43354684~43358658:-
THCA	cis	rs2486012	1	rs61770286	ENSG00000234694.1	RP1-92O14.3	-3.35	0.00087	0.0479	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43890937	chr1:43354684~43358658:-
THCA	cis	rs2486012	1	rs2906461	ENSG00000234694.1	RP1-92O14.3	3.35	0.00087	0.0479	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43868556	chr1:43354684~43358658:-
THCA	cis	rs2692947	0.644	rs1168975	ENSG00000235584.2	AC008268.1	-3.35	0.00087	0.0479	-0.16	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96148336	chr2:95666084~95668715:+
THCA	cis	rs1057510	1	rs1057510	ENSG00000207708.1	MIR141	3.35	0.00087	0.0479	0.22	0.15	Myopia (pathological);	chr12:6574121	chr12:6964097~6964191:+
THCA	cis	rs1865760	0.713	rs1130000	ENSG00000272810.1	U91328.22	-3.35	0.00087	0.0479	-0.12	-0.15	Height;	chr6:25985168	chr6:26013241~26013757:+
THCA	cis	rs10421328	1	rs10421328	ENSG00000270402.1	CTC-412M14.5	3.35	0.00087	0.0479	0.24	0.15	Parental longevity (combined parental age at death);	chr19:19666005	chr19:19708965~19710465:+
THCA	cis	rs12544026	0.617	rs2155941	ENSG00000253669.3	KB-1732A1.1	-3.35	0.00087	0.0479	-0.17	-0.15	Major depression and alcohol dependence;	chr8:101834819	chr8:102805517~102809971:+
THCA	cis	rs7737355	1	rs257390	ENSG00000224431.1	AC063976.7	-3.35	0.00087	0.0479	-0.14	-0.15	Life satisfaction;	chr5:131404924	chr5:132199456~132203487:+
THCA	cis	rs3925075	0.531	rs7206295	ENSG00000260911.2	RP11-196G11.2	-3.35	0.00087	0.0479	-0.13	-0.15	IgA nephropathy;	chr16:31325198	chr16:31043150~31049868:+
THCA	cis	rs12744310	0.945	rs72665696	ENSG00000235358.1	RP11-399E6.1	3.35	0.00087	0.0479	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309757	chr1:41242373~41284861:+
THCA	cis	rs12744310	0.943	rs12751511	ENSG00000235358.1	RP11-399E6.1	3.35	0.00087	0.0479	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41310731	chr1:41242373~41284861:+
THCA	cis	rs12744310	1	rs34073585	ENSG00000235358.1	RP11-399E6.1	3.35	0.00087	0.0479	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311527	chr1:41242373~41284861:+
THCA	cis	rs6832769	0.89	rs564762	ENSG00000223305.1	RN7SKP30	3.35	0.00087	0.0479	0.19	0.15	Personality dimensions;	chr4:55418464	chr4:55540502~55540835:-
THCA	cis	rs5770917	1	rs17848459	ENSG00000273272.1	CTA-384D8.34	3.35	0.00087	0.0479	0.22	0.15	Narcolepsy;	chr22:50573882	chr22:50542650~50543011:+
THCA	cis	rs62103177	0.584	rs9956207	ENSG00000267251.2	AC139100.3	3.35	0.00087	0.0479	0.2	0.15	Opioid sensitivity;	chr18:80210509	chr18:80183680~80202992:+
THCA	cis	rs11678825	0.85	rs115289925	ENSG00000272663.1	RP11-191L17.1	-3.35	0.00087	0.0479	-0.2	-0.15	Reticulocyte fraction of red cells;	chr2:48440744	chr2:48440043~48440597:-
THCA	cis	rs7201408	0.908	rs12922185	ENSG00000261465.5	RP11-626G11.5	-3.35	0.00087	0.0479	-0.19	-0.15	Attention deficit hyperactivity disorder (inattention symptoms);	chr16:20060288	chr16:19062499~19067691:-
THCA	cis	rs7201408	0.908	rs12926562	ENSG00000261465.5	RP11-626G11.5	-3.35	0.00087	0.0479	-0.19	-0.15	Attention deficit hyperactivity disorder (inattention symptoms);	chr16:20060808	chr16:19062499~19067691:-
THCA	cis	rs9902453	0.765	rs2127001	ENSG00000263603.1	CTD-2349P21.5	-3.35	0.00087	0.0479	-0.18	-0.15	Coffee consumption (cups per day);	chr17:29771201	chr17:30729469~30731202:+
THCA	cis	rs7709909	0.553	rs41097	ENSG00000249655.1	CTC-325J23.2	3.35	0.00087	0.0479	0.18	0.15	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80723353	chr5:80630313~80631590:-
THCA	cis	rs7709909	0.553	rs32951	ENSG00000249655.1	CTC-325J23.2	3.35	0.00087	0.0479	0.18	0.15	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80725349	chr5:80630313~80631590:-
THCA	cis	rs7709909	0.553	rs151886	ENSG00000249655.1	CTC-325J23.2	3.35	0.00087	0.0479	0.18	0.15	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80728258	chr5:80630313~80631590:-
THCA	cis	rs7709909	0.553	rs245014	ENSG00000249655.1	CTC-325J23.2	3.35	0.00087	0.0479	0.18	0.15	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80728615	chr5:80630313~80631590:-
THCA	cis	rs7998202	0.667	rs282584	ENSG00000274922.1	RP11-88E10.5	3.35	0.00087	0.0479	0.22	0.15	Glycated hemoglobin levels;	chr13:112695505	chr13:112686769~112689815:-
THCA	cis	rs2645424	0.866	rs2645426	ENSG00000254556.1	AF131215.4	3.35	0.00087	0.0479	0.18	0.15	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11825262	chr8:11136898~11138607:-
THCA	cis	rs9525927	0.817	rs6561169	ENSG00000227258.4	SMIM2-AS1	-3.35	0.00087	0.0479	-0.17	-0.15	Dupuytren's disease;	chr13:44270102	chr13:44110451~44240517:+
THCA	cis	rs1144333	0.51	rs12408897	ENSG00000272855.1	RP5-1102E8.3	-3.35	0.00087	0.0479	-0.33	-0.15	Attention function in attention deficit hyperactive disorder;	chr1:75982417	chr1:76636877~76637339:+
THCA	cis	rs11031096	0.542	rs10835390	ENSG00000230593.3	AC090804.1	3.35	0.00087	0.0479	0.19	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:3960258	chr11:3892398~3892887:-
THCA	cis	rs7267979	1	rs6115153	ENSG00000277938.1	RP5-965G21.3	-3.35	0.00087	0.0479	-0.12	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25229150~25231933:+
THCA	cis	rs7267979	1	rs7268053	ENSG00000277938.1	RP5-965G21.3	-3.35	0.00087	0.0479	-0.12	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25229150~25231933:+
THCA	cis	rs7267979	1	rs6083809	ENSG00000277938.1	RP5-965G21.3	-3.35	0.00087	0.0479	-0.12	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25229150~25231933:+
THCA	cis	rs7615952	0.611	rs2971298	ENSG00000272840.1	RP11-379B18.6	3.35	0.00087	0.0479	0.28	0.15	Blood pressure (smoking interaction);	chr3:125883870	chr3:125774714~125797953:+
THCA	cis	rs6456156	0.774	rs968333	ENSG00000235272.1	FAM103A2P	3.35	0.00087	0.0479	0.21	0.15	Primary biliary cholangitis;	chr6:167112710	chr6:166586124~166586477:-
THCA	cis	rs5769765	0.913	rs8135071	ENSG00000278869.1	CITF22-49E9.3	3.35	0.00087	0.0479	0.2	0.15	Schizophrenia;	chr22:49905939	chr22:49933198~49934074:-
THCA	cis	rs801193	0.901	rs4273746	ENSG00000275400.1	RP4-756H11.5	3.35	0.000871	0.0479	0.15	0.15	Aortic root size;	chr7:66836124	chr7:66553805~66554199:-
THCA	cis	rs972578	1	rs6002997	ENSG00000274717.1	RP1-47A17.1	-3.35	0.000871	0.0479	-0.16	-0.15	Mean platelet volume;	chr22:42996258	chr22:42791814~42794313:-
THCA	cis	rs944289	0.684	rs8016315	ENSG00000212071.1	AL162511.1	3.35	0.000871	0.048	0.18	0.15	Thyroid cancer;	chr14:36101158	chr14:36196480~36196568:-
THCA	cis	rs944289	0.74	rs4982334	ENSG00000212071.1	AL162511.1	3.35	0.000871	0.048	0.18	0.15	Thyroid cancer;	chr14:36101396	chr14:36196480~36196568:-
THCA	cis	rs80130819	0.688	rs2054902	ENSG00000226413.2	OR8T1P	3.35	0.000871	0.048	0.23	0.15	Prostate cancer;	chr12:48330995	chr12:48442030~48442947:-
THCA	cis	rs4805272	0.512	rs12373558	ENSG00000267799.1	MAN1A2P1	3.35	0.000871	0.048	0.2	0.15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28846785	chr19:28790812~28792871:-
THCA	cis	rs7772697	0.508	rs1934223	ENSG00000223701.3	RAET1E-AS1	-3.35	0.000871	0.048	-0.21	-0.15	Diabetic retinopathy;	chr6:149053915	chr6:149884431~149919508:+
THCA	cis	rs13401620	0.555	rs1437421	ENSG00000227788.1	AC012363.8	-3.35	0.000871	0.048	-0.18	-0.15	Breast size;	chr2:120218255	chr2:120211727~120212862:+
THCA	cis	rs975752	0.867	rs7924284	ENSG00000227492.1	RP11-316M21.6	-3.35	0.000871	0.048	-0.29	-0.15	Schizophrenia;	chr10:100258332	chr10:100229667~100234000:+
THCA	cis	rs9450351	0.744	rs1447157	ENSG00000280232.1	RP11-321N4.4	3.35	0.000871	0.048	0.34	0.15	Interferon gamma-induced protein 10 levels;	chr6:85879434	chr6:85498441~85499058:-
THCA	cis	rs478304	0.651	rs11604451	ENSG00000255120.4	OVOL1-AS1	-3.35	0.000871	0.048	-0.2	-0.15	Acne (severe);	chr11:65784239	chr11:65789051~65790868:-
THCA	cis	rs12681963	0.688	rs4733159	ENSG00000272375.1	RP11-51J9.6	-3.35	0.000871	0.048	-0.23	-0.15	Migraine;	chr8:30202344	chr8:30197404~30198048:+
THCA	cis	rs755249	0.565	rs2695324	ENSG00000182109.6	RP11-69E11.4	3.35	0.000871	0.048	0.15	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39522280~39546187:-
THCA	cis	rs76695126	0.659	rs8075234	ENSG00000271851.1	RP11-565F19.2	-3.35	0.000871	0.048	-0.15	-0.15	Borderline personality disorder;	chr17:9530365	chr17:9553323~9555696:-
THCA	cis	rs35791980	0.534	rs1181904	ENSG00000273341.1	RP5-899E9.1	3.35	0.000871	0.048	0.17	0.15	Pursuit maintenance gain;	chr7:77353997	chr7:77416673~77425443:+
THCA	cis	rs1557488	0.581	rs7942644	ENSG00000260209.1	RP11-680F20.10	-3.35	0.000871	0.048	-0.21	-0.15	Attention deficit hyperactivity disorder and conduct disorder;	chr11:126860403	chr11:125873031~125874528:-
THCA	cis	rs2486012	0.737	rs1502907	ENSG00000237950.1	RP11-7O11.3	3.35	0.000871	0.048	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43792369	chr1:43944370~43946551:-
THCA	cis	rs2486012	0.737	rs3791055	ENSG00000237950.1	RP11-7O11.3	3.35	0.000871	0.048	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43799984	chr1:43944370~43946551:-
THCA	cis	rs7487075	0.578	rs4072304	ENSG00000275481.1	RP11-474P2.6	3.35	0.000871	0.048	0.15	0.15	Itch intensity from mosquito bite;	chr12:46432404	chr12:46388856~46392126:+
THCA	cis	rs975752	0.867	rs11190421	ENSG00000227492.1	RP11-316M21.6	3.35	0.000871	0.048	0.29	0.15	Schizophrenia;	chr10:100195855	chr10:100229667~100234000:+
THCA	cis	rs975752	0.717	rs6584350	ENSG00000227492.1	RP11-316M21.6	3.35	0.000871	0.048	0.29	0.15	Schizophrenia;	chr10:100197458	chr10:100229667~100234000:+
THCA	cis	rs3770081	1	rs76297018	ENSG00000273080.1	RP11-301O19.1	-3.35	0.000871	0.048	-0.35	-0.15	Facial emotion recognition (sad faces);	chr2:85999884	chr2:86195590~86196049:+
THCA	cis	rs12780845	1	rs12783490	ENSG00000229124.5	VIM-AS1	3.35	0.000871	0.048	0.15	0.15	Homocysteine levels;	chr10:17181717	chr10:17214239~17229985:-
THCA	cis	rs17123764	0.892	rs7967073	ENSG00000257464.1	RP11-161H23.8	-3.35	0.000871	0.048	-0.3	-0.15	Intelligence (multi-trait analysis);	chr12:49728425	chr12:49442424~49442652:-
THCA	cis	rs7223966	0.691	rs9893518	ENSG00000228979.4	CTD-2501B8.5	-3.35	0.000871	0.048	-0.21	-0.15	Hip circumference adjusted for BMI;Body mass index;	chr17:63929637	chr17:63471604~63472093:+
THCA	cis	rs478304	0.627	rs11604568	ENSG00000255517.5	CTD-3074O7.5	3.35	0.000871	0.048	0.11	0.15	Acne (severe);	chr11:65743865	chr11:66473490~66480233:-
THCA	cis	rs478304	0.651	rs7110576	ENSG00000255517.5	CTD-3074O7.5	3.35	0.000871	0.048	0.11	0.15	Acne (severe);	chr11:65744586	chr11:66473490~66480233:-
THCA	cis	rs9947954	1	rs8095199	ENSG00000269365.2	RP11-380M21.4	-3.35	0.000871	0.048	-0.18	-0.15	IgG glycosylation;	chr18:48712037	chr18:47878295~47882444:+
THCA	cis	rs913655	0.759	rs2495818	ENSG00000240291.1	RP11-499P20.2	-3.35	0.000872	0.048	-0.11	-0.15	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18814788	chr10:18513115~18545651:-
THCA	cis	rs1555322	0.53	rs2425044	ENSG00000269202.1	RP4-614O4.12	-3.35	0.000872	0.048	-0.16	-0.15	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35201747~35203288:-
THCA	cis	rs17711722	0.523	rs365896	ENSG00000230189.5	GS1-124K5.2	-3.35	0.000872	0.048	-0.1	-0.15	Calcium levels;	chr7:66045710	chr7:66409143~66490059:-
THCA	cis	rs2243480	1	rs410128	ENSG00000237310.1	GS1-124K5.4	3.35	0.000872	0.048	0.18	0.15	Diabetic kidney disease;	chr7:66138186	chr7:66493706~66495474:+
THCA	cis	rs3788317	0.526	rs5993855	ENSG00000232926.1	AC000078.5	-3.35	0.000872	0.048	-0.18	-0.15	Glaucoma (primary angle closure);	chr22:19894592	chr22:19887289~19887970:+
THCA	cis	rs465969	1	rs7750803	ENSG00000230177.1	RP5-1112D6.4	-3.35	0.000872	0.048	-0.24	-0.15	Psoriasis;	chr6:111478910	chr6:111277932~111278742:+
THCA	cis	rs11711311	0.712	rs3773684	ENSG00000241529.3	RN7SL767P	3.35	0.000872	0.048	0.22	0.15	IgG glycosylation;	chr3:113615641	chr3:113632704~113632998:+
THCA	cis	rs7824557	0.564	rs1435275	ENSG00000255046.1	RP11-297N6.4	3.35	0.000872	0.048	0.16	0.15	Retinal vascular caliber;	chr8:11378226	chr8:11797928~11802568:-
THCA	cis	rs3015497	0.637	rs28888411	ENSG00000270062.1	RP11-248J18.3	3.35	0.000872	0.048	0.17	0.15	Mean platelet volume;	chr14:50708951	chr14:50723777~50724272:-
THCA	cis	rs7824557	0.736	rs10107010	ENSG00000255310.2	AF131215.2	-3.35	0.000872	0.048	-0.13	-0.15	Retinal vascular caliber;	chr8:11275203	chr8:11107788~11109726:-
THCA	cis	rs713587	0.563	rs10865315	ENSG00000224165.4	DNAJC27-AS1	-3.35	0.000872	0.048	-0.08	-0.15	Body mass index in non-asthmatics;	chr2:24877869	chr2:24971390~25039694:+
THCA	cis	rs911555	0.755	rs35233301	ENSG00000252469.1	RNU7-160P	-3.35	0.000872	0.048	-0.17	-0.15	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103550345~103550406:+
THCA	cis	rs1023500	0.596	rs133369	ENSG00000270083.1	RP1-257I20.14	3.35	0.000872	0.048	0.17	0.15	Schizophrenia;	chr22:42067810	chr22:42089630~42090028:-
THCA	cis	rs7267979	0.934	rs2257464	ENSG00000276952.1	RP5-965G21.6	3.35	0.000872	0.048	0.16	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25284915~25285588:-
THCA	cis	rs2227564	0.729	rs2633306	ENSG00000271816.1	BMS1P4	-3.35	0.000872	0.048	-0.16	-0.15	Crohn's disease;Inflammatory bowel disease;	chr10:73892689	chr10:73699151~73730487:-
THCA	cis	rs9303029	0.551	rs72859131	ENSG00000265458.1	RP13-20L14.6	3.35	0.000872	0.048	0.21	0.15	Protein quantitative trait loci;	chr17:82471977	chr17:82454273~82458521:-
THCA	cis	rs2638953	0.925	rs61920563	ENSG00000278733.1	RP11-425D17.1	-3.35	0.000872	0.048	-0.19	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28332760	chr12:28185625~28186190:-
THCA	cis	rs10863936	0.6	rs2358436	ENSG00000198468.6	FLVCR1-AS1	-3.35	0.000872	0.048	-0.18	-0.15	Height;	chr1:212054407	chr1:212852108~212858088:-
THCA	cis	rs6993449	0.77	rs1954736	ENSG00000253676.1	TAGLN2P1	3.35	0.000872	0.048	0.16	0.15	IgG glycosylation;	chr8:107219887	chr8:106697427~106698013:-
THCA	cis	rs9549260	0.755	rs17061503	ENSG00000275149.1	RP11-427J23.1	3.35	0.000872	0.048	0.2	0.15	Red blood cell count;	chr13:40672621	chr13:40079106~40273509:-
THCA	cis	rs9859260	1	rs2239641	ENSG00000242086.7	LINC00969	3.35	0.000872	0.048	0.15	0.15	Mean corpuscular volume;	chr3:196062543	chr3:195658062~195739964:+
THCA	cis	rs1005277	0.579	rs1780116	ENSG00000151963.4	RP11-775A3.1	-3.35	0.000872	0.048	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs1780121	ENSG00000151963.4	RP11-775A3.1	-3.35	0.000872	0.048	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs1780122	ENSG00000151963.4	RP11-775A3.1	-3.35	0.000872	0.048	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:37883594~37884109:+
THCA	cis	rs1005277	0.579	rs1780145	ENSG00000151963.4	RP11-775A3.1	-3.35	0.000872	0.048	-0.16	-0.15	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:37883594~37884109:+
THCA	cis	rs12692119	0.649	rs75729306	ENSG00000273950.1	Metazoa_SRP	3.35	0.000872	0.048	0.29	0.15	Pelvic organ prolapse (moderate/severe);	chr2:126857674	chr2:127856890~127857147:+
THCA	cis	rs7809950	0.954	rs2894466	ENSG00000272072.1	CTA-363E19.2	-3.35	0.000872	0.048	-0.15	-0.15	Coronary artery disease;	chr7:107602464	chr7:107192559~107193300:-
THCA	cis	rs7809950	0.834	rs3801946	ENSG00000272072.1	CTA-363E19.2	-3.35	0.000872	0.048	-0.15	-0.15	Coronary artery disease;	chr7:107602550	chr7:107192559~107193300:-
THCA	cis	rs9843304	1	rs9843304	ENSG00000243885.1	RP11-278L15.2	-3.35	0.000872	0.048	-0.17	-0.15	Gallstone disease;	chr3:149493600	chr3:149384179~149385800:-
THCA	cis	rs9916302	0.706	rs4795385	ENSG00000266469.1	CTB-131K11.1	3.35	0.000872	0.048	0.14	0.15	Glomerular filtration rate (creatinine);	chr17:39576895	chr17:39401793~39406233:+
THCA	cis	rs867186	1	rs17092297	ENSG00000126005.14	MMP24-AS1	3.35	0.000873	0.048	0.22	0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35115331	chr20:35216462~35278131:-
THCA	cis	rs3809566	0.597	rs9806545	ENSG00000259459.4	RP11-321G12.1	-3.35	0.000873	0.048	-0.12	-0.15	Platelet count;	chr15:63036291	chr15:63390136~63438320:+
THCA	cis	rs4713118	0.513	rs200971	ENSG00000216915.2	RP1-97D16.1	-3.35	0.000873	0.048	-0.22	-0.15	Parkinson's disease;	chr6:27891126	chr6:27737000~27738494:-
THCA	cis	rs76917914	1	rs4742711	ENSG00000236130.1	PTCSC2	-3.35	0.000873	0.048	-0.15	-0.15	Immature fraction of reticulocytes;	chr9:98018508	chr9:97805935~97810008:-
THCA	cis	rs2080501	0.601	rs12919799	ENSG00000275155.1	CTD-2595P9.4	3.35	0.000873	0.048	0.14	0.15	IgG glycosylation;	chr16:49635044	chr16:49847018~49847632:-
THCA	cis	rs2289328	0.825	rs35777573	ENSG00000223313.1	RNU6-516P	-3.35	0.000873	0.048	-0.22	-0.15	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40352045	chr15:40529570~40529673:+
THCA	cis	rs10421328	0.784	rs8107058	ENSG00000267565.1	CTC-559E9.8	-3.35	0.000873	0.048	-0.16	-0.15	Parental longevity (combined parental age at death);	chr19:19648842	chr19:19892433~19895847:-
THCA	cis	rs3789045	0.729	rs16853822	ENSG00000235363.1	SNRPGP10	-3.35	0.000873	0.048	-0.23	-0.15	Educational attainment (college completion);	chr1:204481213	chr1:205351247~205351471:+
THCA	cis	rs6416877	0.655	rs11653564	ENSG00000277491.1	RP11-676J12.9	-3.35	0.000873	0.048	-0.16	-0.15	Myeloid white cell count;	chr17:1460224	chr17:795306~795794:+
THCA	cis	rs651907	0.505	rs2926540	ENSG00000256628.3	ZBTB11-AS1	3.35	0.000873	0.048	0.16	0.15	Colorectal cancer;	chr3:101867885	chr3:101676475~101679217:+
THCA	cis	rs6580649	1	rs6580647	ENSG00000273765.1	RP11-370I10.11	-3.35	0.000873	0.0481	-0.16	-0.15	Lung cancer;	chr12:48009446	chr12:48360920~48361377:+
THCA	cis	rs16918636	0.704	rs2356863	ENSG00000249867.4	RP11-115J23.1	-3.35	0.000873	0.0481	-0.19	-0.15	Menarche (age at onset);	chr11:29105548	chr11:28702615~29063821:+
THCA	cis	rs7267979	0.527	rs6083891	ENSG00000277938.1	RP5-965G21.3	-3.35	0.000873	0.0481	-0.13	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:25229150~25231933:+
THCA	cis	rs2921036	0.503	rs7817832	ENSG00000253130.1	CTD-3023L14.2	-3.35	0.000873	0.0481	-0.2	-0.15	Neuroticism;	chr8:8523311	chr8:8561391~8569688:+
THCA	cis	rs7020830	0.825	rs10973248	ENSG00000260100.1	RP11-220I1.5	-3.35	0.000873	0.0481	-0.19	-0.15	Schizophrenia;	chr9:37197771	chr9:37078813~37079776:-
THCA	cis	rs12780845	1	rs67505314	ENSG00000229124.5	VIM-AS1	3.35	0.000873	0.0481	0.15	0.15	Homocysteine levels;	chr10:17198135	chr10:17214239~17229985:-
THCA	cis	rs911555	0.692	rs7146215	ENSG00000252469.1	RNU7-160P	-3.35	0.000873	0.0481	-0.17	-0.15	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103550345~103550406:+
THCA	cis	rs9487094	0.689	rs2884037	ENSG00000223537.2	RP5-919F19.5	-3.35	0.000873	0.0481	-0.15	-0.15	Height;	chr6:109354092	chr6:109487906~109506800:+
THCA	cis	rs17139672	0.609	rs12659063	ENSG00000248445.4	SEMA6A-AS1	3.35	0.000873	0.0481	0.16	0.15	Facial morphology (factor 18);	chr5:116388589	chr5:116447547~116508276:+
THCA	cis	rs11085466	1	rs73552468	ENSG00000268119.4	CTD-2561J22.5	-3.35	0.000873	0.0481	-0.2	-0.15	Colorectal or endometrial cancer;	chr19:21589295	chr19:21444241~21463908:-
THCA	cis	rs7192750	0.586	rs12447045	ENSG00000260886.1	TAT-AS1	3.35	0.000873	0.0481	0.22	0.15	Total cholesterol levels;LDL cholesterol levels;	chr16:71880714	chr16:71565789~71578187:+
THCA	cis	rs6871536	1	rs2706334	ENSG00000233006.5	AC034220.3	3.35	0.000873	0.0481	0.13	0.15	Asthma (childhood onset);	chr5:132554779	chr5:132311285~132369916:-
THCA	cis	rs786425	0.585	rs10744160	ENSG00000270095.1	RP11-214K3.18	3.35	0.000873	0.0481	0.18	0.15	Pubertal anthropometrics;	chr12:123740995	chr12:123971457~123971714:-
THCA	cis	rs853679	0.76	rs11967137	ENSG00000261839.1	RP1-265C24.8	3.35	0.000873	0.0481	0.18	0.15	Depression;	chr6:28231986	chr6:28136849~28139678:+
THCA	cis	rs758324	0.583	rs61009979	ENSG00000224431.1	AC063976.7	-3.35	0.000873	0.0481	-0.22	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132028834	chr5:132199456~132203487:+
THCA	cis	rs7709377	0.595	rs803967	ENSG00000272265.1	CTD-2287O16.4	3.35	0.000873	0.0481	0.16	0.15	Metabolite levels  (X-11787);	chr5:116269422	chr5:116078110~116078570:-
THCA	cis	rs524281	0.861	rs7937281	ENSG00000255038.1	RP11-1167A19.2	-3.35	0.000873	0.0481	-0.17	-0.15	Electroencephalogram traits;	chr11:66182603	chr11:66067277~66069619:-
THCA	cis	rs478304	0.619	rs10896028	ENSG00000214659.4	KRT8P26	3.35	0.000873	0.0481	0.14	0.15	Acne (severe);	chr11:65664716	chr11:65726939~65728214:+
THCA	cis	rs7273787	0.961	rs57674902	ENSG00000226608.3	FTLP3	-3.35	0.000873	0.0481	-0.17	-0.15	Height;	chr20:4116094	chr20:4023917~4024444:+
THCA	cis	rs9858542	0.537	rs115753735	ENSG00000270441.1	RP11-694I15.7	3.35	0.000874	0.0481	0.17	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49317572	chr3:49140086~49160851:-
THCA	cis	rs7208859	0.623	rs170051	ENSG00000264242.2	RP11-271K11.1	3.35	0.000874	0.0481	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.51	rs216402	ENSG00000264242.2	RP11-271K11.1	3.35	0.000874	0.0481	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs216434	ENSG00000264242.2	RP11-271K11.1	3.35	0.000874	0.0481	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs216436	ENSG00000264242.2	RP11-271K11.1	3.35	0.000874	0.0481	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000264242.2	RP11-271K11.1	3.35	0.000874	0.0481	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs216439	ENSG00000264242.2	RP11-271K11.1	3.35	0.000874	0.0481	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30553697~30558962:+
THCA	cis	rs2013231	1	rs2013231	ENSG00000259959.1	RP11-121C2.2	3.35	0.000874	0.0481	0.14	0.15	Platelet distribution width;	chr4:48087441	chr4:47840122~47844339:-
THCA	cis	rs2625529	0.73	rs3759900	ENSG00000260037.4	CTD-2524L6.3	3.35	0.000874	0.0481	0.19	0.15	Red blood cell count;	chr15:72159486	chr15:71818396~71823384:+
THCA	cis	rs1971762	0.563	rs7975862	ENSG00000270175.1	RP11-793H13.11	3.35	0.000874	0.0481	0.1	0.15	Height;	chr12:53684643	chr12:53500162~53500936:-
THCA	cis	rs17123764	0.892	rs12306481	ENSG00000257464.1	RP11-161H23.8	-3.35	0.000874	0.0481	-0.29	-0.15	Intelligence (multi-trait analysis);	chr12:49730293	chr12:49442424~49442652:-
THCA	cis	rs524281	0.861	rs10896077	ENSG00000255038.1	RP11-1167A19.2	-3.35	0.000874	0.0481	-0.17	-0.15	Electroencephalogram traits;	chr11:66084262	chr11:66067277~66069619:-
THCA	cis	rs524281	0.817	rs7115081	ENSG00000255038.1	RP11-1167A19.2	-3.35	0.000874	0.0481	-0.17	-0.15	Electroencephalogram traits;	chr11:66086070	chr11:66067277~66069619:-
THCA	cis	rs524281	0.861	rs11227403	ENSG00000255038.1	RP11-1167A19.2	-3.35	0.000874	0.0481	-0.17	-0.15	Electroencephalogram traits;	chr11:66090957	chr11:66067277~66069619:-
THCA	cis	rs524281	0.861	rs7935336	ENSG00000255038.1	RP11-1167A19.2	-3.35	0.000874	0.0481	-0.17	-0.15	Electroencephalogram traits;	chr11:66097854	chr11:66067277~66069619:-
THCA	cis	rs524281	0.861	rs11227409	ENSG00000255038.1	RP11-1167A19.2	-3.35	0.000874	0.0481	-0.17	-0.15	Electroencephalogram traits;	chr11:66103467	chr11:66067277~66069619:-
THCA	cis	rs524281	0.861	rs11227410	ENSG00000255038.1	RP11-1167A19.2	-3.35	0.000874	0.0481	-0.17	-0.15	Electroencephalogram traits;	chr11:66105925	chr11:66067277~66069619:-
THCA	cis	rs9910816	0.837	rs2041982	ENSG00000207561.1	MIR635	3.35	0.000874	0.0481	0.17	0.15	Bipolar disorder (inflammation and infection response interaction);	chr17:68356470	chr17:68424451~68424548:-
THCA	cis	rs2638953	0.925	rs11049598	ENSG00000247934.4	RP11-967K21.1	-3.35	0.000874	0.0481	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28436160	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049611	ENSG00000247934.4	RP11-967K21.1	-3.35	0.000874	0.0481	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28447311	chr12:28163298~28190738:-
THCA	cis	rs10129255	0.879	rs7160512	ENSG00000224373.3	IGHV4-59	3.35	0.000874	0.0481	0.09	0.15	Kawasaki disease;	chr14:106694574	chr14:106627249~106627825:-
THCA	cis	rs10129255	0.879	rs7159157	ENSG00000224373.3	IGHV4-59	3.35	0.000874	0.0481	0.09	0.15	Kawasaki disease;	chr14:106694578	chr14:106627249~106627825:-
THCA	cis	rs2574985	0.702	rs3011793	ENSG00000231345.3	BEND3P1	-3.35	0.000874	0.0481	-0.24	-0.15	Subjective well-being;	chr10:50556712	chr10:50655967~50660472:+
THCA	cis	rs11633886	0.748	rs10519035	ENSG00000273972.1	CTD-2306A12.1	-3.35	0.000874	0.0481	-0.17	-0.15	Diisocyanate-induced asthma;	chr15:45781393	chr15:45702640~45703183:+
THCA	cis	rs972578	0.806	rs8137128	ENSG00000274717.1	RP1-47A17.1	-3.35	0.000874	0.0481	-0.16	-0.15	Mean platelet volume;	chr22:42989990	chr22:42791814~42794313:-
THCA	cis	rs7116495	0.529	rs575871	ENSG00000227467.3	LINC01537	-3.35	0.000874	0.0481	-0.28	-0.15	Severe influenza A (H1N1) infection;	chr11:72067776	chr11:72570660~72573229:+
THCA	cis	rs9611565	0.512	rs964899	ENSG00000237037.8	NDUFA6-AS1	-3.35	0.000874	0.0481	-0.15	-0.15	Vitiligo;	chr22:41746382	chr22:42090931~42137742:+
THCA	cis	rs9859260	1	rs2284890	ENSG00000242086.7	LINC00969	3.35	0.000874	0.0481	0.15	0.15	Mean corpuscular volume;	chr3:196061276	chr3:195658062~195739964:+
THCA	cis	rs9859260	1	rs2284889	ENSG00000242086.7	LINC00969	3.35	0.000874	0.0481	0.15	0.15	Mean corpuscular volume;	chr3:196061376	chr3:195658062~195739964:+
THCA	cis	rs9859260	0.961	rs2300780	ENSG00000242086.7	LINC00969	3.35	0.000874	0.0481	0.15	0.15	Mean corpuscular volume;	chr3:196063420	chr3:195658062~195739964:+
THCA	cis	rs1729951	0.575	rs361242	ENSG00000239213.4	NCK1-AS1	3.35	0.000874	0.0481	0.13	0.15	Neuroticism;	chr3:136979488	chr3:136841726~136862054:-
THCA	cis	rs6494488	0.5	rs79939025	ENSG00000259635.1	AC100830.3	-3.35	0.000874	0.0481	-0.35	-0.15	Coronary artery disease;	chr15:64568786	chr15:64701248~64719602:+
THCA	cis	rs6840360	0.571	rs12650655	ENSG00000270265.1	RP11-731D1.4	-3.35	0.000874	0.0481	-0.15	-0.15	Intelligence (multi-trait analysis);	chr4:151634923	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.571	rs7685697	ENSG00000270265.1	RP11-731D1.4	-3.35	0.000874	0.0481	-0.15	-0.15	Intelligence (multi-trait analysis);	chr4:151637697	chr4:151333775~151353224:-
THCA	cis	rs6840360	0.593	rs10022023	ENSG00000270265.1	RP11-731D1.4	-3.35	0.000874	0.0481	-0.15	-0.15	Intelligence (multi-trait analysis);	chr4:151639579	chr4:151333775~151353224:-
THCA	cis	rs2236231	0.55	rs4902496	ENSG00000259648.1	RP11-643G16.4	-3.35	0.000874	0.0481	-0.19	-0.15	Plasma kynurenine levels in major depressive disorder;	chr14:67588896	chr14:67614929~67616626:+
THCA	cis	rs6715793	0.901	rs4670928	ENSG00000272754.1	AL133245.2	-3.35	0.000874	0.0481	-0.18	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33192043	chr2:32321638~32323002:+
THCA	cis	rs11673344	0.543	rs1818748	ENSG00000267260.1	CTD-2162K18.4	-3.35	0.000874	0.0481	-0.18	-0.15	Obesity-related traits;	chr19:37065416	chr19:36773153~36777078:+
THCA	cis	rs2554380	0.943	rs979543	ENSG00000230373.7	GOLGA6L5P	-3.35	0.000874	0.0481	-0.18	-0.15	Height;	chr15:83683812	chr15:84507885~84516814:-
THCA	cis	rs2074409	0.572	rs4074605	ENSG00000276054.1	RP11-378E13.3	-3.35	0.000874	0.0481	-0.24	-0.15	Response to angiotensin II receptor blocker therapy;	chr17:37562341	chr17:37386886~37387926:+
THCA	cis	rs17217757	0.725	rs35330171	ENSG00000254041.1	RP11-574O7.1	-3.35	0.000874	0.0481	-0.23	-0.15	Tuberculosis;	chr8:105604390	chr8:105142860~105188606:-
THCA	cis	rs1122401	0.576	rs2962552	ENSG00000280159.1	CTD-2591A1.1	3.35	0.000874	0.0481	0.17	0.15	Smoking initiation;	chr5:54582004	chr5:54643557~54645987:+
THCA	cis	rs7781557	0.64	rs6968036	ENSG00000170629.13	DPY19L2P2	-3.35	0.000874	0.0481	-0.2	-0.15	Colorectal adenoma (advanced);	chr7:102915473	chr7:103175133~103280410:-
THCA	cis	rs1908814	0.516	rs13281315	ENSG00000227888.4	FAM66A	3.35	0.000874	0.0481	0.2	0.15	Neuroticism;	chr8:11937346	chr8:12362019~12388296:+
THCA	cis	rs10186029	0.524	rs10932471	ENSG00000270659.1	RP11-105N14.1	-3.35	0.000874	0.0481	-0.13	-0.15	Systemic sclerosis;	chr2:213144943	chr2:213152970~213153659:+
THCA	cis	rs2239557	0.508	rs9646165	ENSG00000259065.1	RP5-1021I20.1	-3.35	0.000874	0.0481	-0.23	-0.15	Common traits (Other);	chr14:73858104	chr14:73787360~73803270:+
THCA	cis	rs12705054	0.588	rs7798877	ENSG00000238109.1	AC004893.10	-3.35	0.000874	0.0481	-0.29	-0.15	Facial emotion recognition (sad faces);	chr7:99219070	chr7:98998538~98999930:-
THCA	cis	rs1383484	0.575	rs8024422	ENSG00000259728.4	LINC00933	-3.35	0.000874	0.0481	-0.18	-0.15	Height;	chr15:83951228	chr15:84570649~84580175:+
THCA	cis	rs2018683	0.711	rs917213	ENSG00000233517.1	AC005162.5	-3.35	0.000874	0.0481	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928587	chr7:28987028~28988899:+
THCA	cis	rs2018683	0.711	rs917214	ENSG00000233517.1	AC005162.5	-3.35	0.000874	0.0481	-0.19	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928676	chr7:28987028~28988899:+
THCA	cis	rs1538970	0.781	rs34768551	ENSG00000280836.1	AL355480.1	-3.35	0.000874	0.0481	-0.21	-0.15	Platelet count;	chr1:45554736	chr1:45581219~45581321:-
THCA	cis	rs6674176	0.597	rs9326136	ENSG00000236200.4	KDM4A-AS1	3.35	0.000875	0.0481	0.12	0.15	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43924720	chr1:43699765~43708138:-
THCA	cis	rs2549003	1	rs13170412	ENSG00000233006.5	AC034220.3	-3.35	0.000875	0.0481	-0.12	-0.15	Asthma (sex interaction);	chr5:132487827	chr5:132311285~132369916:-
THCA	cis	rs61160187	0.582	rs1021005	ENSG00000251279.1	CTC-436P18.1	-3.35	0.000875	0.0481	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.517	rs6884966	ENSG00000251279.1	CTC-436P18.1	-3.35	0.000875	0.0481	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:61162070~61232040:+
THCA	cis	rs7824557	0.527	rs4634600	ENSG00000255046.1	RP11-297N6.4	3.35	0.000875	0.0481	0.16	0.15	Retinal vascular caliber;	chr8:11381508	chr8:11797928~11802568:-
THCA	cis	rs7824557	0.527	rs4631425	ENSG00000255046.1	RP11-297N6.4	3.35	0.000875	0.0481	0.16	0.15	Retinal vascular caliber;	chr8:11381545	chr8:11797928~11802568:-
THCA	cis	rs3808502	0.585	rs4549730	ENSG00000255046.1	RP11-297N6.4	3.35	0.000875	0.0481	0.16	0.15	Neuroticism;	chr8:11381569	chr8:11797928~11802568:-
THCA	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	3.35	0.000875	0.0481	0.14	0.15	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
THCA	cis	rs620729	0.874	rs598907	ENSG00000272097.1	RP11-421M1.8	-3.35	0.000875	0.0481	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11586202	chr6:10743324~10747663:-
THCA	cis	rs5758659	1	rs134869	ENSG00000205702.9	CYP2D7	3.35	0.000875	0.0481	0.11	0.15	Cognitive function;	chr22:42256068	chr22:42140203~42144577:-
THCA	cis	rs709400	0.859	rs7154948	ENSG00000258735.1	LINC00637	3.35	0.000875	0.0481	0.2	0.15	Body mass index;	chr14:103556607	chr14:103847721~103858049:+
THCA	cis	rs34779708	0.966	rs12775548	ENSG00000233200.1	RP11-324I22.2	3.35	0.000875	0.0481	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35219894~35230598:-
THCA	cis	rs9929218	0.529	rs11075694	ENSG00000260459.2	FTLP14	3.35	0.000875	0.0481	0.17	0.15	Colorectal cancer;	chr16:68696463	chr16:68822587~68823070:+
THCA	cis	rs9907295	0.688	rs2376287	ENSG00000270871.1	AC015849.19	3.35	0.000875	0.0481	0.12	0.15	Fibroblast growth factor basic levels;	chr17:35919865	chr17:35816717~35830293:-
THCA	cis	rs9907295	0.688	rs4796133	ENSG00000270871.1	AC015849.19	3.35	0.000875	0.0481	0.12	0.15	Fibroblast growth factor basic levels;	chr17:35920505	chr17:35816717~35830293:-
THCA	cis	rs9907295	0.688	rs7213636	ENSG00000270871.1	AC015849.19	3.35	0.000875	0.0481	0.12	0.15	Fibroblast growth factor basic levels;	chr17:35920944	chr17:35816717~35830293:-
THCA	cis	rs9907295	0.688	rs28722787	ENSG00000270871.1	AC015849.19	3.35	0.000875	0.0481	0.12	0.15	Fibroblast growth factor basic levels;	chr17:35922795	chr17:35816717~35830293:-
THCA	cis	rs7572733	0.935	rs13394871	ENSG00000231621.1	AC013264.2	-3.35	0.000875	0.0481	-0.14	-0.15	Dermatomyositis;	chr2:197981613	chr2:197197991~197199273:+
THCA	cis	rs74544699	1	rs353028	ENSG00000221639.1	SNORA3	-3.35	0.000875	0.0481	-0.32	-0.15	Growth-regulated protein alpha levels;	chr4:73911506	chr4:73263960~73264084:+
THCA	cis	rs17122278	1	rs11216906	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118573229	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs9736327	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118576865	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs9735421	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118576882	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs73023350	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118578681	chr11:118560690~118561580:+
THCA	cis	rs17122278	0.929	rs7126175	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118580160	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs11216912	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118581619	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs17842763	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118583462	chr11:118560690~118561580:+
THCA	cis	rs17122278	0.929	rs11216917	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118591445	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs11216925	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118600708	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs10892245	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118601639	chr11:118560690~118561580:+
THCA	cis	rs17122278	1	rs17742	ENSG00000243431.1	RPL5P30	3.35	0.000875	0.0481	0.16	0.15	Total cholesterol levels;	chr11:118602670	chr11:118560690~118561580:+
THCA	cis	rs11992162	0.529	rs6995037	ENSG00000255046.1	RP11-297N6.4	3.35	0.000875	0.0482	0.17	0.15	Monocyte count;	chr8:11923378	chr8:11797928~11802568:-
THCA	cis	rs11673344	0.504	rs12984458	ENSG00000233527.7	ZNF529-AS1	-3.35	0.000875	0.0482	-0.13	-0.15	Obesity-related traits;	chr19:37138189	chr19:36573070~36594708:+
THCA	cis	rs11048434	0.636	rs11614970	ENSG00000245105.2	A2M-AS1	3.35	0.000875	0.0482	0.12	0.15	Sjögren's syndrome;	chr12:8907457	chr12:9065177~9068060:+
THCA	cis	rs9907295	0.901	rs78905197	ENSG00000270871.1	AC015849.19	3.35	0.000875	0.0482	0.14	0.15	Fibroblast growth factor basic levels;	chr17:35850189	chr17:35816717~35830293:-
THCA	cis	rs11031096	0.502	rs1442726	ENSG00000230593.3	AC090804.1	3.35	0.000875	0.0482	0.2	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4073518	chr11:3892398~3892887:-
THCA	cis	rs4713118	0.824	rs9468223	ENSG00000216915.2	RP1-97D16.1	-3.35	0.000875	0.0482	-0.24	-0.15	Parkinson's disease;	chr6:27772887	chr6:27737000~27738494:-
THCA	cis	rs7737355	0.738	rs3776016	ENSG00000224431.1	AC063976.7	3.35	0.000875	0.0482	0.14	0.15	Life satisfaction;	chr5:131519659	chr5:132199456~132203487:+
THCA	cis	rs2933343	0.7	rs6787833	ENSG00000261159.1	RP11-723O4.9	3.35	0.000875	0.0482	0.15	0.15	IgG glycosylation;	chr3:128937341	chr3:128859716~128860526:-
THCA	cis	rs701145	0.585	rs4680125	ENSG00000238755.3	RP11-23D24.2	-3.35	0.000875	0.0482	-0.33	-0.15	Coronary artery disease;	chr3:154066909	chr3:153384934~153980186:-
THCA	cis	rs1832871	0.711	rs9459826	ENSG00000213078.3	RP5-933K21.2	3.35	0.000876	0.0482	0.23	0.15	Height;	chr6:158259364	chr6:157365990~157366923:-
THCA	cis	rs4656958	0.964	rs4656959	ENSG00000233691.2	RP11-312J18.7	3.35	0.000876	0.0482	0.18	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:160889171	chr1:160935537~160936126:+
THCA	cis	rs714027	0.526	rs73164755	ENSG00000279699.1	RP1-102K2.9	3.35	0.000876	0.0482	0.15	0.15	Lymphocyte counts;	chr22:30194026	chr22:30275215~30276951:-
THCA	cis	rs9902453	0.933	rs9303628	ENSG00000250462.7	LRRC37BP1	3.35	0.000876	0.0482	0.12	0.15	Coffee consumption (cups per day);	chr17:30200210	chr17:30629680~30637466:+
THCA	cis	rs7914558	1	rs10509757	ENSG00000213061.2	PFN1P11	3.35	0.000876	0.0482	0.18	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102838011~102845473:-
THCA	cis	rs7246760	0.867	rs68041339	ENSG00000278611.1	CTC-543D15.8	-3.35	0.000876	0.0482	-0.25	-0.15	Pursuit maintenance gain;	chr19:9708175	chr19:9538733~9539734:+
THCA	cis	rs7246760	0.867	rs56377135	ENSG00000278611.1	CTC-543D15.8	-3.35	0.000876	0.0482	-0.25	-0.15	Pursuit maintenance gain;	chr19:9709440	chr19:9538733~9539734:+
THCA	cis	rs7246760	0.867	rs55914342	ENSG00000278611.1	CTC-543D15.8	-3.35	0.000876	0.0482	-0.25	-0.15	Pursuit maintenance gain;	chr19:9713771	chr19:9538733~9539734:+
THCA	cis	rs2904967	0.929	rs1783486	ENSG00000254614.2	AP003068.23	-3.35	0.000876	0.0482	-0.28	-0.15	Mean corpuscular volume;	chr11:65241446	chr11:65177606~65181834:-
THCA	cis	rs2904967	0.852	rs1633466	ENSG00000254614.2	AP003068.23	-3.35	0.000876	0.0482	-0.28	-0.15	Mean corpuscular volume;	chr11:65248702	chr11:65177606~65181834:-
THCA	cis	rs7615952	1	rs7615952	ENSG00000248787.1	RP11-666A20.4	3.35	0.000876	0.0482	0.26	0.15	Blood pressure (smoking interaction);	chr3:125930560	chr3:125908005~125910272:-
THCA	cis	rs10946940	0.965	rs4713112	ENSG00000261839.1	RP1-265C24.8	-3.35	0.000876	0.0482	-0.15	-0.15	Systemic lupus erythematosus;	chr6:27549054	chr6:28136849~28139678:+
THCA	cis	rs12462428	1	rs12462428	ENSG00000268087.1	CTC-429P9.2	3.35	0.000876	0.0482	0.13	0.15	Educational attainment (years of education);	chr19:16583799	chr19:16610411~16636531:+
THCA	cis	rs2486288	0.656	rs11632419	ENSG00000259479.5	SORD2P	-3.35	0.000876	0.0482	-0.16	-0.15	Glomerular filtration rate;	chr15:45265258	chr15:44826371~44884694:-
THCA	cis	rs2486288	0.656	rs2271438	ENSG00000259479.5	SORD2P	-3.35	0.000876	0.0482	-0.16	-0.15	Glomerular filtration rate;	chr15:45265270	chr15:44826371~44884694:-
THCA	cis	rs2486288	0.656	rs11854365	ENSG00000259479.5	SORD2P	-3.35	0.000876	0.0482	-0.16	-0.15	Glomerular filtration rate;	chr15:45265885	chr15:44826371~44884694:-
THCA	cis	rs7819412	0.703	rs2409713	ENSG00000254866.2	DEFB109P3	3.35	0.000876	0.0482	0.21	0.15	Triglycerides;	chr8:11152287	chr8:12150895~12151134:-
THCA	cis	rs4141404	0.604	rs5753625	ENSG00000235573.2	RP3-412A9.12	3.35	0.000876	0.0482	0.16	0.15	Paclitaxel-induced neuropathy;	chr22:31458860	chr22:31113017~31113396:+
THCA	cis	rs2760061	0.598	rs673726	ENSG00000276255.2	RP5-881P19.7	-3.35	0.000876	0.0482	-0.17	-0.15	Diastolic blood pressure;	chr1:227932472	chr1:228073909~228076550:-
THCA	cis	rs2760061	0.626	rs672977	ENSG00000276255.2	RP5-881P19.7	-3.35	0.000876	0.0482	-0.17	-0.15	Diastolic blood pressure;	chr1:227932587	chr1:228073909~228076550:-
THCA	cis	rs2760061	0.626	rs672907	ENSG00000276255.2	RP5-881P19.7	-3.35	0.000876	0.0482	-0.17	-0.15	Diastolic blood pressure;	chr1:227932644	chr1:228073909~228076550:-
THCA	cis	rs71520386	0.846	rs61997069	ENSG00000228649.7	AC005682.5	-3.35	0.000876	0.0482	-0.24	-0.15	Fibrinogen levels;	chr7:22773966	chr7:22854178~22861579:+
THCA	cis	rs5758511	0.633	rs5751258	ENSG00000182057.4	OGFRP1	-3.35	0.000876	0.0482	-0.21	-0.15	Birth weight;	chr22:42267865	chr22:42269753~42275196:+
THCA	cis	rs3806843	0.518	rs2563310	ENSG00000278901.1	AC005609.17	-3.35	0.000876	0.0482	-0.16	-0.15	Depressive symptoms (multi-trait analysis);	chr5:140636156	chr5:140878073~140882642:-
THCA	cis	rs2562456	0.833	rs7260065	ENSG00000268521.1	VN1R83P	3.35	0.000876	0.0482	0.15	0.15	Pain;	chr19:21334175	chr19:21289554~21289998:-
THCA	cis	rs2191566	0.761	rs446016	ENSG00000277806.1	RP11-15A1.8	-3.35	0.000876	0.0482	-0.16	-0.15	Acute lymphoblastic leukemia (childhood);	chr19:43997366	chr19:43976815~43977448:+
THCA	cis	rs1737890	0.778	rs3903368	ENSG00000235217.6	TSPY26P	-3.35	0.000876	0.0482	-0.17	-0.15	Chronic obstructive pulmonary disease;	chr20:32374383	chr20:32186477~32190527:-
THCA	cis	rs4713118	0.911	rs2394000	ENSG00000219891.2	ZSCAN12P1	3.35	0.000876	0.0482	0.2	0.15	Parkinson's disease;	chr6:27719212	chr6:28091154~28093664:+
THCA	cis	rs4713118	0.955	rs9393847	ENSG00000219891.2	ZSCAN12P1	3.35	0.000876	0.0482	0.2	0.15	Parkinson's disease;	chr6:27720194	chr6:28091154~28093664:+
THCA	cis	rs9510787	0.563	rs3829349	ENSG00000205861.10	C1QTNF9B-AS1	-3.35	0.000876	0.0482	-0.21	-0.15	Nasopharyngeal carcinoma;	chr13:23667472	chr13:23888889~23897263:+
THCA	cis	rs668210	0.793	rs522553	ENSG00000214659.4	KRT8P26	3.35	0.000876	0.0482	0.17	0.15	Cerebrospinal fluid biomarker levels;	chr11:66004198	chr11:65726939~65728214:+
THCA	cis	rs668210	0.643	rs549334	ENSG00000214659.4	KRT8P26	3.35	0.000876	0.0482	0.17	0.15	Cerebrospinal fluid biomarker levels;	chr11:66007188	chr11:65726939~65728214:+
THCA	cis	rs7680126	0.627	rs9291642	ENSG00000261490.1	RP11-448G15.3	3.35	0.000877	0.0482	0.15	0.15	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10005651	chr4:10068089~10073019:-
THCA	cis	rs9921338	0.923	rs17233387	ENSG00000262636.1	CTD-3088G3.4	-3.35	0.000877	0.0482	-0.2	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11295191	chr16:11380859~11381118:-
THCA	cis	rs7737355	0.812	rs26010	ENSG00000224431.1	AC063976.7	3.35	0.000877	0.0482	0.14	0.15	Life satisfaction;	chr5:131678122	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.812	rs32107	ENSG00000224431.1	AC063976.7	3.35	0.000877	0.0482	0.14	0.15	Life satisfaction;	chr5:131703940	chr5:132199456~132203487:+
THCA	cis	rs12295638	0.818	rs11029624	ENSG00000254862.4	RP11-159H22.2	3.35	0.000877	0.0482	0.2	0.15	Obesity (extreme);	chr11:26587987	chr11:27471729~27482433:+
THCA	cis	rs12295638	0.818	rs12294962	ENSG00000254862.4	RP11-159H22.2	3.35	0.000877	0.0482	0.2	0.15	Obesity (extreme);	chr11:26588590	chr11:27471729~27482433:+
THCA	cis	rs1858037	0.867	rs4671658	ENSG00000252414.1	RNU6-100P	3.35	0.000877	0.0482	0.17	0.15	Rheumatoid arthritis;	chr2:65334258	chr2:64578892~64578997:+
THCA	cis	rs780094	0.585	rs7586601	ENSG00000270528.1	RP11-674I16.2	3.35	0.000877	0.0482	0.17	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:28015777~28016482:-
THCA	cis	rs80067372	0.671	rs116600817	ENSG00000233223.2	AC113189.5	-3.35	0.000877	0.0482	-0.16	-0.15	Chin dimples;	chr17:7555478	chr17:7581964~7584072:-
THCA	cis	rs59901009	0.517	rs7926141	ENSG00000246273.5	SBF2-AS1	-3.35	0.000877	0.0482	-0.2	-0.15	Hematocrit;Hemoglobin concentration;	chr11:9996883	chr11:9758292~9811319:+
THCA	cis	rs59901009	0.517	rs7940348	ENSG00000246273.5	SBF2-AS1	-3.35	0.000877	0.0482	-0.2	-0.15	Hematocrit;Hemoglobin concentration;	chr11:9997295	chr11:9758292~9811319:+
THCA	cis	rs72766638	0.895	rs11795079	ENSG00000235106.7	LINC00094	3.35	0.000877	0.0482	0.16	0.15	Mosquito bite size;	chr9:134065012	chr9:134025439~134034666:+
THCA	cis	rs9326248	0.581	rs7120963	ENSG00000280143.1	AP000892.6	-3.35	0.000877	0.0482	-0.19	-0.15	Blood protein levels;	chr11:116959545	chr11:117204967~117210292:+
THCA	cis	rs10457838	0.568	rs4897080	ENSG00000231760.4	RP11-350J20.5	3.35	0.000877	0.0482	0.22	0.15	Post-traumatic stress disorder;	chr6:149102092	chr6:149796151~149826294:-
THCA	cis	rs6499755	0.712	rs31100	ENSG00000260135.5	RP11-212I21.2	-3.35	0.000877	0.0482	-0.16	-0.15	Hypospadias;	chr16:55337611	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.712	rs31101	ENSG00000260135.5	RP11-212I21.2	-3.35	0.000877	0.0482	-0.16	-0.15	Hypospadias;	chr16:55337766	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.686	rs31102	ENSG00000260135.5	RP11-212I21.2	-3.35	0.000877	0.0482	-0.16	-0.15	Hypospadias;	chr16:55338610	chr16:55426797~55462297:-
THCA	cis	rs6499755	0.712	rs31105	ENSG00000260135.5	RP11-212I21.2	-3.35	0.000877	0.0482	-0.16	-0.15	Hypospadias;	chr16:55341811	chr16:55426797~55462297:-
THCA	cis	rs947583	0.573	rs9494336	ENSG00000272189.1	RP3-325F22.5	3.35	0.000877	0.0482	0.16	0.15	Phosphorus levels;	chr6:135694749	chr6:136550661~136552554:+
THCA	cis	rs7572644	0.713	rs4666020	ENSG00000223522.1	AC093690.1	3.35	0.000877	0.0482	0.19	0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27823161	chr2:28307691~28310459:-
THCA	cis	rs11098499	0.644	rs10050092	ENSG00000249244.1	RP11-548H18.2	3.35	0.000877	0.0482	0.17	0.15	Corneal astigmatism;	chr4:119610930	chr4:119391831~119395335:-
THCA	cis	rs12493050	1	rs12493050	ENSG00000234371.6	RPSAP31	-3.35	0.000877	0.0482	-0.22	-0.15	Subjective response to lithium treatment;	chr3:183147285	chr3:183884924~183888449:+
THCA	cis	rs7937127	0.6	rs3781803	ENSG00000246250.2	RP11-613D13.5	3.35	0.000877	0.0482	0.17	0.15	Fibrinogen levels;	chr11:43417813	chr11:43829709~43880726:-
THCA	cis	rs7045881	0.8	rs59175724	ENSG00000234676.1	IFT74-AS1	-3.35	0.000877	0.0482	-0.3	-0.15	Schizophrenia;	chr9:26924486	chr9:26955780~26956295:-
THCA	cis	rs2842992	0.724	rs4709368	ENSG00000237927.1	RP3-393E18.2	3.35	0.000877	0.0482	0.22	0.15	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159586955~159589169:-
THCA	cis	rs7819412	0.549	rs28887839	ENSG00000255052.4	FAM66D	3.35	0.000877	0.0482	0.21	0.15	Triglycerides;	chr8:11142903	chr8:12115782~12177550:+
THCA	cis	rs9596863	0.898	rs34617186	ENSG00000136149.6	RPL13AP25	-3.35	0.000877	0.0482	-0.17	-0.15	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53796459	chr13:54440704~54441315:-
THCA	cis	rs1150668	0.796	rs2247002	ENSG00000220721.1	OR1F12	3.35	0.000877	0.0483	0.16	0.15	Pubertal anthropometrics;	chr6:28430174	chr6:28073316~28074233:+
THCA	cis	rs9844666	0.512	rs13434196	ENSG00000273486.1	RP11-731C17.2	3.35	0.000877	0.0483	0.14	0.15	Height;	chr3:135924461	chr3:136837338~136839021:-
THCA	cis	rs7621331	0.714	rs9844478	ENSG00000273486.1	RP11-731C17.2	3.35	0.000877	0.0483	0.14	0.15	Waist circumference adjusted for body mass index;	chr3:135924473	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs9849088	ENSG00000273486.1	RP11-731C17.2	3.35	0.000877	0.0483	0.14	0.15	Height;	chr3:135925060	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs56807950	ENSG00000273486.1	RP11-731C17.2	3.35	0.000877	0.0483	0.14	0.15	Height;	chr3:135925531	chr3:136837338~136839021:-
THCA	cis	rs9844666	0.512	rs59063369	ENSG00000273486.1	RP11-731C17.2	3.35	0.000877	0.0483	0.14	0.15	Height;	chr3:135925636	chr3:136837338~136839021:-
THCA	cis	rs7520050	0.898	rs4660885	ENSG00000280836.1	AL355480.1	3.35	0.000877	0.0483	0.18	0.15	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45581219~45581321:-
THCA	cis	rs73198271	0.92	rs11781542	ENSG00000253981.4	ALG1L13P	-3.35	0.000878	0.0483	-0.19	-0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8759671	chr8:8236003~8244667:-
THCA	cis	rs7809799	0.571	rs11977673	ENSG00000242798.1	RP11-506M12.1	3.35	0.000878	0.0483	0.29	0.15	Ulcerative colitis;	chr7:99296312	chr7:100115214~100127139:-
THCA	cis	rs9859260	1	rs2300778	ENSG00000242086.7	LINC00969	3.35	0.000878	0.0483	0.15	0.15	Mean corpuscular volume;	chr3:196063866	chr3:195658062~195739964:+
THCA	cis	rs9859260	1	rs2300777	ENSG00000242086.7	LINC00969	3.35	0.000878	0.0483	0.15	0.15	Mean corpuscular volume;	chr3:196063940	chr3:195658062~195739964:+
THCA	cis	rs7833790	0.724	rs6473309	ENSG00000254689.1	RP11-354A14.1	3.35	0.000878	0.0483	0.17	0.15	Diastolic blood pressure;	chr8:81795645	chr8:81885377~81923193:+
THCA	cis	rs2434529	1	rs475851	ENSG00000245275.6	SAP30L-AS1	3.35	0.000878	0.0483	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr5:154267103	chr5:154329437~154445850:-
THCA	cis	rs1005277	0.579	rs2505241	ENSG00000099251.13	HSD17B7P2	3.35	0.000878	0.0483	0.13	0.15	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38356380~38378505:+
THCA	cis	rs1161098	1	rs1161098	ENSG00000256037.1	MRPL40P1	3.35	0.000878	0.0483	0.22	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67453680	chr12:67351436~67352039:+
THCA	cis	rs11031096	0.542	rs1452048	ENSG00000230593.3	AC090804.1	3.35	0.000878	0.0483	0.19	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:3944198	chr11:3892398~3892887:-
THCA	cis	rs4144027	0.935	rs8008020	ENSG00000258534.1	CTD-2134A5.4	3.35	0.000878	0.0483	0.16	0.15	Blood metabolite levels;	chr14:103889546	chr14:103854366~103880111:-
THCA	cis	rs10857712	0.851	rs7913420	ENSG00000214279.11	SCART1	-3.35	0.000878	0.0483	-0.13	-0.15	Systemic lupus erythematosus;	chr10:133400350	chr10:133453928~133523558:+
THCA	cis	rs2638953	0.815	rs61922546	ENSG00000247934.4	RP11-967K21.1	-3.35	0.000878	0.0483	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28524632	chr12:28163298~28190738:-
THCA	cis	rs6517329	0.544	rs9305578	ENSG00000233393.1	AP000688.29	3.35	0.000878	0.0483	0.19	0.15	Schizophrenia;	chr21:36141857	chr21:36104881~36109690:+
THCA	cis	rs6517329	0.585	rs2242803	ENSG00000233393.1	AP000688.29	3.35	0.000878	0.0483	0.19	0.15	Schizophrenia;	chr21:36143725	chr21:36104881~36109690:+
THCA	cis	rs7641761	0.539	rs6794956	ENSG00000237978.4	KCNMB2-AS1	3.35	0.000878	0.0483	0.19	0.15	Mean corpuscular hemoglobin;	chr3:179025432	chr3:178526505~178860405:-
THCA	cis	rs13326165	0.543	rs1769	ENSG00000243224.1	RP5-1157M23.2	-3.35	0.000878	0.0483	-0.24	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52256534	chr3:52239258~52241097:+
THCA	cis	rs17445240	1	rs78506209	ENSG00000234423.1	LINC01250	-3.35	0.000878	0.0483	-0.33	-0.15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);	chr2:3652125	chr2:2895048~3126026:-
THCA	cis	rs72843506	0.586	rs75128113	ENSG00000189423.10	USP32P3	3.35	0.000878	0.0483	0.26	0.15	Schizophrenia;	chr17:20000172	chr17:20415547~20431008:+
THCA	cis	rs61142792	1	rs75192957	ENSG00000249109.1	RP11-1026M7.2	3.35	0.000879	0.0483	0.36	0.15	Alzheimer disease and age of onset;	chr5:177551966	chr5:177782197~177794396:+
THCA	cis	rs12935418	0.616	rs7184568	ENSG00000261838.4	RP11-303E16.6	3.35	0.000879	0.0483	0.21	0.15	Mean corpuscular volume;	chr16:80930951	chr16:81069854~81076598:+
THCA	cis	rs10754283	0.967	rs6663363	ENSG00000237505.5	PKN2-AS1	-3.35	0.000879	0.0483	-0.18	-0.15	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:88537513~88685204:-
THCA	cis	rs7439493	0.772	rs7694620	ENSG00000247950.5	SEC24B-AS1	-3.35	0.000879	0.0483	-0.1	-0.15	Blood protein levels;	chr4:109707163	chr4:109347475~109433817:-
THCA	cis	rs7439493	0.865	rs7674356	ENSG00000247950.5	SEC24B-AS1	-3.35	0.000879	0.0483	-0.1	-0.15	Blood protein levels;	chr4:109711039	chr4:109347475~109433817:-
THCA	cis	rs2549003	0.933	rs3846731	ENSG00000233006.5	AC034220.3	-3.35	0.000879	0.0483	-0.12	-0.15	Asthma (sex interaction);	chr5:132478572	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs7734334	ENSG00000233006.5	AC034220.3	-3.35	0.000879	0.0483	-0.12	-0.15	Asthma (sex interaction);	chr5:132479312	chr5:132311285~132369916:-
THCA	cis	rs2549003	1	rs7735073	ENSG00000233006.5	AC034220.3	-3.35	0.000879	0.0483	-0.12	-0.15	Asthma (sex interaction);	chr5:132479665	chr5:132311285~132369916:-
THCA	cis	rs9925964	0.967	rs749767	ENSG00000262766.1	RP11-196G11.4	3.35	0.000879	0.0483	0.1	0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31113086	chr16:31118078~31118747:+
THCA	cis	rs2965280	1	rs2910413	ENSG00000267219.1	AC010504.2	3.35	0.000879	0.0483	0.29	0.15	Colorectal cancer;	chr19:34458127	chr19:34348356~34359412:-
THCA	cis	rs75828804	0.85	rs79473335	ENSG00000260922.1	RP11-538I12.3	-3.35	0.000879	0.0483	-0.32	-0.15	Intraocular pressure;	chr16:77580888	chr16:77234877~77290934:+
THCA	cis	rs6496667	0.865	rs7161929	ENSG00000259262.1	NDUFA3P4	3.35	0.000879	0.0483	0.22	0.15	Rheumatoid arthritis;	chr15:90340777	chr15:90385814~90386063:+
THCA	cis	rs3747767	1	rs6915859	ENSG00000233967.5	RP11-250B2.3	3.35	0.000879	0.0483	0.24	0.15	Hoarding;	chr6:79497528	chr6:80443344~80465927:+
THCA	cis	rs258324	0.79	rs8062346	ENSG00000274627.1	RP11-104N10.2	-3.35	0.000879	0.0483	-0.21	-0.15	Height;	chr16:89666260	chr16:89516797~89522217:+
THCA	cis	rs9450351	0.744	rs111533912	ENSG00000280232.1	RP11-321N4.4	3.35	0.000879	0.0483	0.33	0.15	Interferon gamma-induced protein 10 levels;	chr6:85622231	chr6:85498441~85499058:-
THCA	cis	rs9450351	0.744	rs9450308	ENSG00000280232.1	RP11-321N4.4	3.35	0.000879	0.0483	0.33	0.15	Interferon gamma-induced protein 10 levels;	chr6:85638820	chr6:85498441~85499058:-
THCA	cis	rs1627020	1	rs1540157	ENSG00000254645.1	RP11-396O20.2	3.35	0.000879	0.0483	0.21	0.15	Gestational age at birth (maternal effect);	chr11:15167863	chr11:15701963~15758898:-
THCA	cis	rs11089937	0.597	rs4821768	ENSG00000215456.5	BCRP4	3.35	0.000879	0.0483	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.597	rs4821770	ENSG00000215456.5	BCRP4	3.35	0.000879	0.0483	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.568	rs4821771	ENSG00000215456.5	BCRP4	3.35	0.000879	0.0483	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22630061~22636153:+
THCA	cis	rs11089937	0.597	rs4821773	ENSG00000215456.5	BCRP4	3.35	0.000879	0.0483	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22630061~22636153:+
THCA	cis	rs6981523	0.532	rs1987190	ENSG00000205879.4	FAM90A2P	-3.35	0.000879	0.0483	-0.2	-0.15	Neuroticism;	chr8:11196005	chr8:12172202~12178575:-
THCA	cis	rs972578	0.837	rs1018448	ENSG00000230319.1	AL022476.2	3.35	0.000879	0.0483	0.16	0.15	Mean platelet volume;	chr22:42810944	chr22:43038585~43052366:+
THCA	cis	rs950169	1	rs1818950	ENSG00000230373.7	GOLGA6L5P	-3.35	0.000879	0.0483	-0.17	-0.15	Schizophrenia;	chr15:84053769	chr15:84507885~84516814:-
THCA	cis	rs8187707	1	rs113741841	ENSG00000233690.1	EBAG9P1	-3.35	0.000879	0.0483	-0.31	-0.15	Carboplatin disposition in epthelial ovarian cancer;	chr10:99854376	chr10:99697407~99697949:-
THCA	cis	rs4589258	0.737	rs2226919	ENSG00000280367.1	RP11-121L10.2	3.35	0.000879	0.0483	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90731273	chr11:90223153~90226538:+
THCA	cis	rs11673344	0.642	rs55755939	ENSG00000267470.4	ZNF571-AS1	-3.35	0.000879	0.0483	-0.17	-0.15	Obesity-related traits;	chr19:37353723	chr19:37548914~37587348:+
THCA	cis	rs2652822	0.935	rs2292038	ENSG00000259459.4	RP11-321G12.1	3.35	0.000879	0.0483	0.13	0.15	Metabolic traits;	chr15:63157481	chr15:63390136~63438320:+
THCA	cis	rs17301013	0.93	rs6425279	ENSG00000270084.1	GAS5-AS1	3.35	0.000879	0.0483	0.16	0.15	Systemic lupus erythematosus;	chr1:174418717	chr1:173863248~173863941:+
THCA	cis	rs11673344	0.67	rs73039188	ENSG00000267470.4	ZNF571-AS1	-3.35	0.000879	0.0483	-0.18	-0.15	Obesity-related traits;	chr19:36922449	chr19:37548914~37587348:+
THCA	cis	rs4705962	0.959	rs2227282	ENSG00000230612.2	AC004237.1	3.35	0.000879	0.0483	0.2	0.15	Atopic dermatitis;	chr5:132677487	chr5:132688681~132723725:+
THCA	cis	rs862034	0.662	rs12893681	ENSG00000270000.1	RP3-449M8.9	3.35	0.000879	0.0483	0.15	0.15	Height;	chr14:74537927	chr14:74471930~74472360:-
THCA	cis	rs7089973	0.604	rs1359079	ENSG00000228169.3	PPIAP19	3.35	0.000879	0.0483	0.18	0.15	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114822743	chr10:114690143~114690634:-
THCA	cis	rs939960	0.959	rs62502298	ENSG00000276538.1	RP11-545G3.2	3.35	0.000879	0.0483	0.22	0.15	Neutrophil percentage of white cells;	chr7:150589310	chr7:150047609~150047854:-
THCA	cis	rs939960	0.917	rs12671272	ENSG00000276538.1	RP11-545G3.2	3.35	0.000879	0.0483	0.22	0.15	Neutrophil percentage of white cells;	chr7:150589434	chr7:150047609~150047854:-
THCA	cis	rs939960	0.917	rs12671275	ENSG00000276538.1	RP11-545G3.2	3.35	0.000879	0.0483	0.22	0.15	Neutrophil percentage of white cells;	chr7:150589473	chr7:150047609~150047854:-
THCA	cis	rs939960	0.718	rs4339550	ENSG00000276538.1	RP11-545G3.2	3.35	0.000879	0.0483	0.22	0.15	Neutrophil percentage of white cells;	chr7:150590120	chr7:150047609~150047854:-
THCA	cis	rs939960	0.642	rs4382385	ENSG00000276538.1	RP11-545G3.2	3.35	0.000879	0.0483	0.22	0.15	Neutrophil percentage of white cells;	chr7:150590123	chr7:150047609~150047854:-
THCA	cis	rs939960	0.694	rs6942848	ENSG00000276538.1	RP11-545G3.2	3.35	0.000879	0.0483	0.22	0.15	Neutrophil percentage of white cells;	chr7:150590831	chr7:150047609~150047854:-
THCA	cis	rs10787903	0.521	rs11198773	ENSG00000229272.1	RP11-498J9.2	-3.35	0.000879	0.0483	-0.17	-0.15	Alcoholic chronic pancreatitis;	chr10:119103593	chr10:119003536~119003884:-
THCA	cis	rs494526	0.641	rs11198774	ENSG00000229272.1	RP11-498J9.2	-3.35	0.000879	0.0483	-0.17	-0.15	Alcoholic chronic pancreatitis;	chr10:119103720	chr10:119003536~119003884:-
THCA	cis	rs931127	0.747	rs11820062	ENSG00000255517.5	CTD-3074O7.5	3.35	0.000879	0.0483	0.11	0.15	Systemic lupus erythematosus;	chr11:65662465	chr11:66473490~66480233:-
THCA	cis	rs256438	0.731	rs13181102	ENSG00000251221.1	LINC01337	-3.35	0.000879	0.0483	-0.18	-0.15	Serum thyroid-stimulating hormone levels;	chr5:80041334	chr5:80608623~80622524:-
THCA	cis	rs6840360	1	rs4696285	ENSG00000270265.1	RP11-731D1.4	-3.35	0.000879	0.0483	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151684297	chr4:151333775~151353224:-
THCA	cis	rs12135894	0.562	rs6688969	ENSG00000272153.1	RP1-286D6.5	-3.35	0.000879	0.0483	-0.12	-0.15	Mean corpuscular volume;	chr1:3826827	chr1:3785008~3785538:+
THCA	cis	rs6885099	0.509	rs251428	ENSG00000251400.1	ALDH7A1P1	3.35	0.000879	0.0483	0.18	0.15	Thyroid hormone levels;	chr5:77257249	chr5:77290268~77291800:+
THCA	cis	rs12677618	1	rs10092931	ENSG00000253307.1	RP11-10J21.4	3.35	0.000879	0.0483	0.23	0.15	Plateletcrit;	chr8:141297102	chr8:141252286~141253292:-
THCA	cis	rs10191559	0.919	rs62180074	ENSG00000238171.1	AC068196.1	-3.35	0.000879	0.0483	-0.19	-0.15	Red blood cell count;	chr2:180973282	chr2:181076051~181105968:-
THCA	cis	rs2032366	0.967	rs6650736	ENSG00000267316.4	RP11-879F14.3	-3.35	0.000879	0.0483	-0.16	-0.15	Obesity-related traits;	chr18:61601711	chr18:61571342~61579456:-
THCA	cis	rs2032366	0.967	rs9965804	ENSG00000267316.4	RP11-879F14.3	-3.35	0.000879	0.0483	-0.16	-0.15	Obesity-related traits;	chr18:61602021	chr18:61571342~61579456:-
THCA	cis	rs2032366	1	rs1894095	ENSG00000267316.4	RP11-879F14.3	-3.35	0.000879	0.0483	-0.16	-0.15	Obesity-related traits;	chr18:61605988	chr18:61571342~61579456:-
THCA	cis	rs1974653	0.672	rs28610569	ENSG00000236499.2	LINC00896	3.35	0.000879	0.0483	0.15	0.15	Schizophrenia;	chr22:20083828	chr22:20206397~20208524:+
THCA	cis	rs9329221	0.662	rs4240645	ENSG00000253641.4	RP11-981G7.2	-3.35	0.000879	0.0483	-0.15	-0.15	Neuroticism;	chr8:10396953	chr8:10474565~10481974:+
THCA	cis	rs7916697	0.54	rs4551651	ENSG00000233590.1	RP11-153K11.3	-3.35	0.00088	0.0483	-0.19	-0.15	Optic disc area;	chr10:68264772	chr10:68233251~68242379:-
THCA	cis	rs12144309	0.554	rs12119076	ENSG00000232450.1	RP4-730K3.3	3.35	0.00088	0.0483	0.19	0.15	Coronary artery disease;	chr1:113667853	chr1:113698884~113699631:-
THCA	cis	rs7621331	1	rs34311570	ENSG00000239213.4	NCK1-AS1	3.35	0.00088	0.0483	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:135990140	chr3:136841726~136862054:-
THCA	cis	rs3784262	0.967	rs12148907	ENSG00000259250.1	RP11-50C13.1	3.35	0.00088	0.0483	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58004252	chr15:58587507~58591676:+
THCA	cis	rs3784262	1	rs1372368	ENSG00000259250.1	RP11-50C13.1	3.35	0.00088	0.0483	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58005165	chr15:58587507~58591676:+
THCA	cis	rs9309473	0.514	rs62149659	ENSG00000273245.1	RP11-434P11.2	3.35	0.00088	0.0484	0.24	0.15	Metabolite levels;	chr2:73358068	chr2:73750256~73750786:-
THCA	cis	rs620729	0.874	rs821443	ENSG00000272097.1	RP11-421M1.8	-3.35	0.00088	0.0484	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11538301	chr6:10743324~10747663:-
THCA	cis	rs4763879	0.634	rs61915472	ENSG00000214776.8	RP11-726G1.1	-3.35	0.00088	0.0484	-0.18	-0.15	Type 1 diabetes;	chr12:9700995	chr12:9467552~9576275:+
THCA	cis	rs944289	0.74	rs885535	ENSG00000212071.1	AL162511.1	3.35	0.00088	0.0484	0.17	0.15	Thyroid cancer;	chr14:36082574	chr14:36196480~36196568:-
THCA	cis	rs11785400	1	rs6997670	ENSG00000177335.9	C8orf31	3.35	0.00088	0.0484	0.17	0.15	Schizophrenia;	chr8:142656502	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs4557682	ENSG00000177335.9	C8orf31	3.35	0.00088	0.0484	0.17	0.15	Schizophrenia;	chr8:142656769	chr8:143039209~143059942:+
THCA	cis	rs11785400	1	rs7002932	ENSG00000177335.9	C8orf31	3.35	0.00088	0.0484	0.17	0.15	Schizophrenia;	chr8:142657402	chr8:143039209~143059942:+
THCA	cis	rs9435732	0.559	rs11203280	ENSG00000186301.8	MST1P2	-3.35	0.00088	0.0484	-0.12	-0.15	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17016288	chr1:16645622~16650289:+
THCA	cis	rs7572733	0.84	rs10497807	ENSG00000231621.1	AC013264.2	3.35	0.00088	0.0484	0.14	0.15	Dermatomyositis;	chr2:197720363	chr2:197197991~197199273:+
THCA	cis	rs8067287	0.634	rs7225344	ENSG00000265511.1	RP11-524F11.1	3.35	0.00088	0.0484	0.12	0.15	Diabetic kidney disease;	chr17:16937184	chr17:17507351~17508308:+
THCA	cis	rs10090774	0.93	rs2369410	ENSG00000280303.2	ERICD	3.35	0.00088	0.0484	0.14	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140900541	chr8:140636281~140638283:+
THCA	cis	rs4704187	0.687	rs4361493	ENSG00000250889.2	LINC01336	-3.35	0.00088	0.0484	-0.16	-0.15	Response to amphetamines;	chr5:75109272	chr5:75047719~75052843:-
THCA	cis	rs7142002	0.881	rs8006108	ENSG00000271780.1	RP11-1017G21.5	-3.35	0.00088	0.0484	-0.23	-0.15	Autism;	chr14:101933189	chr14:101948347~101949425:+
THCA	cis	rs481331	0.866	rs2505893	ENSG00000272319.1	AL022345.7	3.35	0.00088	0.0484	0.28	0.15	Systemic juvenile idiopathic arthritis;	chr10:42709533	chr10:42579724~42582772:+
THCA	cis	rs11773103	0.786	rs17161323	ENSG00000224046.1	AC005076.5	3.35	0.00088	0.0484	0.19	0.15	Bipolar disorder or major depressive disorder (combined);	chr7:87129922	chr7:87151423~87152420:-
THCA	cis	rs2652834	1	rs2729783	ENSG00000259459.4	RP11-321G12.1	-3.35	0.00088	0.0484	-0.16	-0.15	HDL cholesterol;	chr15:63111117	chr15:63390136~63438320:+
THCA	cis	rs9333290	0.93	rs11678190	ENSG00000259915.2	RP11-410E4.1	3.35	0.00088	0.0484	0.18	0.15	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186695581	chr2:186354570~186356773:-
THCA	cis	rs11048434	0.626	rs1805736	ENSG00000245105.2	A2M-AS1	-3.35	0.00088	0.0484	-0.12	-0.15	Sjögren's syndrome;	chr12:8932335	chr12:9065177~9068060:+
THCA	cis	rs4648045	0.647	rs11097787	ENSG00000246560.2	RP11-10L12.4	3.35	0.00088	0.0484	0.19	0.15	Lymphocyte percentage of white cells;	chr4:102486185	chr4:102828055~102844075:+
THCA	cis	rs17604090	1	rs10272065	ENSG00000223813.2	AC007255.8	3.35	0.00088	0.0484	0.16	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29654620	chr7:29514225~29563670:-
THCA	cis	rs6452524	0.618	rs7722924	ENSG00000271862.1	RP11-343L5.2	3.35	0.00088	0.0484	0.16	0.15	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83049376~83050964:-
THCA	cis	rs9400467	0.506	rs12195578	ENSG00000255389.1	C6orf3	3.35	0.00088	0.0484	0.21	0.15	Amino acid levels;Blood metabolite levels;	chr6:111293583	chr6:111599875~111602295:+
THCA	cis	rs10435719	0.744	rs11250175	ENSG00000227888.4	FAM66A	3.35	0.00088	0.0484	0.2	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:12362019~12388296:+
THCA	cis	rs1908814	0.516	rs13252853	ENSG00000227888.4	FAM66A	3.35	0.00088	0.0484	0.2	0.15	Neuroticism;	chr8:11935465	chr8:12362019~12388296:+
THCA	cis	rs1908814	0.516	rs13252854	ENSG00000227888.4	FAM66A	3.35	0.00088	0.0484	0.2	0.15	Neuroticism;	chr8:11935469	chr8:12362019~12388296:+
THCA	cis	rs1908814	0.516	rs13279577	ENSG00000227888.4	FAM66A	3.35	0.00088	0.0484	0.2	0.15	Neuroticism;	chr8:11935587	chr8:12362019~12388296:+
THCA	cis	rs1908814	0.516	rs10112958	ENSG00000227888.4	FAM66A	3.35	0.00088	0.0484	0.2	0.15	Neuroticism;	chr8:11935631	chr8:12362019~12388296:+
THCA	cis	rs4144027	0.935	rs881056	ENSG00000258534.1	CTD-2134A5.4	3.35	0.00088	0.0484	0.16	0.15	Blood metabolite levels;	chr14:103887888	chr14:103854366~103880111:-
THCA	cis	rs321358	0.731	rs17460781	ENSG00000271390.1	RP11-89C3.3	3.35	0.00088	0.0484	0.24	0.15	Body mass index;	chr11:111169966	chr11:111089870~111090368:-
THCA	cis	rs5997397	0.967	rs5762777	ENSG00000226471.5	CTA-292E10.6	-3.35	0.000881	0.0484	-0.12	-0.15	Red cell distribution width;	chr22:28754056	chr22:28800683~28848559:+
THCA	cis	rs35740288	0.822	rs4843090	ENSG00000259407.1	RP11-158M2.3	-3.35	0.000881	0.0484	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677398	chr15:85744109~85750281:-
THCA	cis	rs7903456	0.512	rs9420426	ENSG00000200253.1	RNU6-529P	3.35	0.000881	0.0484	0.21	0.15	Gout;Renal underexcretion gout;	chr10:87046781	chr10:87041238~87041341:-
THCA	cis	rs7226229	1	rs4985954	ENSG00000261033.1	RP11-209D14.2	-3.35	0.000881	0.0484	-0.21	-0.15	Blood trace element (Se levels);	chr17:20994639	chr17:20008051~20009234:-
THCA	cis	rs7558911	0.899	rs13013222	ENSG00000183308.6	AC005037.3	3.35	0.000881	0.0484	0.17	0.15	Chronic lymphocytic leukemia;	chr2:201167461	chr2:200963263~201009102:+
THCA	cis	rs6573604	1	rs7151301	ENSG00000276116.2	FUT8-AS1	-3.35	0.000881	0.0484	-0.18	-0.15	N-glycan levels;	chr14:65314778	chr14:65411170~65412690:-
THCA	cis	rs9635324	0.605	rs62018005	ENSG00000259536.4	RP11-111A22.1	3.35	0.000881	0.0484	0.2	0.15	Blood metabolite ratios;Blood metabolite levels;	chr15:40398851	chr15:40488041~40558019:+
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000281021.1	RP1-12G14.9	-3.35	0.000881	0.0484	-0.15	-0.15	Lung cancer;	chr6:149789350	chr6:149576089~149590864:-
THCA	cis	rs34779708	0.966	rs10827493	ENSG00000233200.1	RP11-324I22.2	3.35	0.000881	0.0484	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35219894~35230598:-
THCA	cis	rs2688608	0.698	rs2227578	ENSG00000271816.1	BMS1P4	3.35	0.000881	0.0484	0.15	0.15	Inflammatory bowel disease;	chr10:73918957	chr10:73699151~73730487:-
THCA	cis	rs56104184	0.83	rs73061617	ENSG00000243829.1	CTB-33G10.1	-3.35	0.000881	0.0484	-0.21	-0.15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48847727	chr19:49719498~49720081:-
THCA	cis	rs6601327	0.578	rs4075359	ENSG00000261451.1	RP11-981G7.1	-3.35	0.000881	0.0484	-0.18	-0.15	Multiple myeloma (hyperdiploidy);	chr8:9630303	chr8:10433672~10438312:+
THCA	cis	rs6121246	0.865	rs77130187	ENSG00000224628.2	RP5-854E16.2	-3.35	0.000881	0.0484	-0.23	-0.15	Mean corpuscular hemoglobin;	chr20:31681257	chr20:31285317~31286835:-
THCA	cis	rs6787172	0.622	rs939114	ENSG00000272087.1	RP11-379F4.7	3.35	0.000881	0.0484	0.14	0.15	Subjective well-being;	chr3:158397464	chr3:158693120~158693768:-
THCA	cis	rs9878978	0.722	rs11719351	ENSG00000227588.2	CNTN4-AS2	3.35	0.000881	0.0484	0.2	0.15	Blood pressure (smoking interaction);	chr3:2418188	chr3:2110409~2144241:-
THCA	cis	rs4924935	0.624	rs9902467	ENSG00000235672.1	AC090286.2	-3.35	0.000881	0.0484	-0.19	-0.15	Pancreatic cancer;	chr17:18851614	chr17:18908279~18908865:+
THCA	cis	rs1865760	0.566	rs2858993	ENSG00000272810.1	U91328.22	-3.35	0.000881	0.0484	-0.12	-0.15	Height;	chr6:26087628	chr6:26013241~26013757:+
THCA	cis	rs2625529	0.627	rs1037680	ENSG00000260037.4	CTD-2524L6.3	-3.35	0.000881	0.0484	-0.21	-0.15	Red blood cell count;	chr15:72221978	chr15:71818396~71823384:+
THCA	cis	rs5751614	1	rs5759664	ENSG00000211649.3	IGLV7-46	-3.35	0.000881	0.0484	-0.1	-0.15	Height;	chr22:23249536	chr22:22369614~22370087:+
THCA	cis	rs4441609	0.816	rs4678914	ENSG00000281100.1	RP11-640L9.2	-3.35	0.000881	0.0484	-0.16	-0.15	Interleukin-1-receptor antagonist levels;	chr3:36906926	chr3:36823151~36825158:-
THCA	cis	rs875971	0.564	rs313804	ENSG00000230189.5	GS1-124K5.2	3.35	0.000881	0.0484	0.1	0.15	Aortic root size;	chr7:66049635	chr7:66409143~66490059:-
THCA	cis	rs7089973	0.584	rs4752255	ENSG00000228169.3	PPIAP19	3.35	0.000881	0.0484	0.18	0.15	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114817031	chr10:114690143~114690634:-
THCA	cis	rs620729	0.834	rs9394115	ENSG00000272097.1	RP11-421M1.8	-3.35	0.000881	0.0484	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11493371	chr6:10743324~10747663:-
THCA	cis	rs620729	0.874	rs628980	ENSG00000272097.1	RP11-421M1.8	-3.35	0.000881	0.0484	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11497103	chr6:10743324~10747663:-
THCA	cis	rs620729	0.874	rs687163	ENSG00000272097.1	RP11-421M1.8	-3.35	0.000881	0.0484	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11499503	chr6:10743324~10747663:-
THCA	cis	rs620729	0.874	rs478147	ENSG00000272097.1	RP11-421M1.8	-3.35	0.000881	0.0484	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11507106	chr6:10743324~10747663:-
THCA	cis	rs620729	0.834	rs552681	ENSG00000272097.1	RP11-421M1.8	-3.35	0.000881	0.0484	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11554752	chr6:10743324~10747663:-
THCA	cis	rs620729	0.794	rs471560	ENSG00000272097.1	RP11-421M1.8	-3.35	0.000881	0.0484	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11555679	chr6:10743324~10747663:-
THCA	cis	rs620729	0.83	rs578507	ENSG00000272097.1	RP11-421M1.8	-3.35	0.000881	0.0484	-0.18	-0.15	Intelligence (multi-trait analysis);	chr6:11563568	chr6:10743324~10747663:-
THCA	cis	rs7989332	0.961	rs4770041	ENSG00000277020.3	RP11-476H16.1	3.35	0.000881	0.0484	0.14	0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20474430	chr13:20564708~20567045:-
THCA	cis	rs1865760	0.963	rs9356991	ENSG00000272810.1	U91328.22	-3.35	0.000881	0.0484	-0.12	-0.15	Height;	chr6:25901530	chr6:26013241~26013757:+
THCA	cis	rs12210761	1	rs9295450	ENSG00000229950.1	TFAP2A-AS1	-3.35	0.000882	0.0484	-0.29	-0.15	Major depressive disorder;	chr6:10209962	chr6:10409340~10416446:+
THCA	cis	rs13113518	0.812	rs12500601	ENSG00000223305.1	RN7SKP30	3.35	0.000882	0.0484	0.19	0.15	Height;	chr4:55451489	chr4:55540502~55540835:-
THCA	cis	rs73787773	0.644	rs17134156	ENSG00000246859.2	STARD4-AS1	3.35	0.000882	0.0484	0.19	0.15	Itch intensity from mosquito bite adjusted by bite size;	chr5:112146040	chr5:111512226~111739726:+
THCA	cis	rs897984	0.571	rs7184567	ENSG00000275263.1	RP11-1072A3.4	-3.35	0.000882	0.0484	-0.18	-0.15	Dementia with Lewy bodies;	chr16:31009757	chr16:30956872~30957199:-
THCA	cis	rs7824557	0.545	rs2572380	ENSG00000255046.1	RP11-297N6.4	3.35	0.000882	0.0484	0.16	0.15	Retinal vascular caliber;	chr8:11379968	chr8:11797928~11802568:-
THCA	cis	rs1005277	0.579	rs1614236	ENSG00000099251.13	HSD17B7P2	3.35	0.000882	0.0484	0.13	0.15	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38356380~38378505:+
THCA	cis	rs1005277	0.579	rs2749616	ENSG00000099251.13	HSD17B7P2	3.35	0.000882	0.0484	0.13	0.15	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38356380~38378505:+
THCA	cis	rs1005277	0.579	rs1780146	ENSG00000099251.13	HSD17B7P2	3.35	0.000882	0.0484	0.13	0.15	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38356380~38378505:+
THCA	cis	rs11039798	0.623	rs6485879	ENSG00000200090.1	Y_RNA	3.35	0.000882	0.0484	0.13	0.15	Axial length;	chr11:48566432	chr11:47726894~47726992:-
THCA	cis	rs45544231	0.966	rs3104786	ENSG00000279344.1	RP11-44F14.7	3.35	0.000882	0.0484	0.14	0.15	Restless legs syndrome;	chr16:52603451	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs3104787	ENSG00000279344.1	RP11-44F14.7	3.35	0.000882	0.0484	0.14	0.15	Restless legs syndrome;	chr16:52603631	chr16:53478957~53481550:-
THCA	cis	rs6120849	0.707	rs6088694	ENSG00000269202.1	RP4-614O4.12	-3.35	0.000882	0.0484	-0.17	-0.15	Protein C levels;	chr20:35064568	chr20:35201747~35203288:-
THCA	cis	rs1560104	0.597	rs7187433	ENSG00000262801.4	U91319.1	-3.35	0.000882	0.0484	-0.17	-0.15	Obesity-related traits;	chr16:12615251	chr16:13246316~13562918:+
THCA	cis	rs972578	0.967	rs6002985	ENSG00000230319.1	AL022476.2	3.35	0.000882	0.0484	0.16	0.15	Mean platelet volume;	chr22:42937421	chr22:43038585~43052366:+
THCA	cis	rs7824557	0.843	rs2572418	ENSG00000255046.1	RP11-297N6.4	3.35	0.000882	0.0484	0.16	0.15	Retinal vascular caliber;	chr8:11255580	chr8:11797928~11802568:-
THCA	cis	rs9303542	0.729	rs1533057	ENSG00000278765.1	RP5-890E16.5	-3.35	0.000882	0.0484	-0.2	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48441743	chr17:48066704~48067293:-
THCA	cis	rs9309473	0.519	rs6746971	ENSG00000273245.1	RP11-434P11.2	3.35	0.000882	0.0484	0.18	0.15	Metabolite levels;	chr2:73442334	chr2:73750256~73750786:-
THCA	cis	rs62458065	0.713	rs921406	ENSG00000231952.3	DPY19L1P2	3.35	0.000882	0.0484	0.26	0.15	Metabolite levels (HVA/MHPG ratio);	chr7:32446593	chr7:32812757~32838570:+
THCA	cis	rs345013	0.92	rs9851966	ENSG00000240032.1	RP11-274H2.3	3.35	0.000882	0.0484	0.24	0.15	Prostate cancer;	chr3:145277976	chr3:146066344~146069185:-
THCA	cis	rs345013	0.92	rs9838827	ENSG00000240032.1	RP11-274H2.3	3.35	0.000882	0.0484	0.24	0.15	Prostate cancer;	chr3:145278536	chr3:146066344~146069185:-
THCA	cis	rs4713118	0.513	rs202908	ENSG00000176933.5	TOB2P1	-3.35	0.000882	0.0484	-0.18	-0.15	Parkinson's disease;	chr6:28043773	chr6:28217643~28218634:-
THCA	cis	rs4713118	0.513	rs156739	ENSG00000176933.5	TOB2P1	-3.35	0.000882	0.0484	-0.18	-0.15	Parkinson's disease;	chr6:28045632	chr6:28217643~28218634:-
THCA	cis	rs4713118	0.513	rs149958	ENSG00000176933.5	TOB2P1	-3.35	0.000882	0.0484	-0.18	-0.15	Parkinson's disease;	chr6:28045839	chr6:28217643~28218634:-
THCA	cis	rs3087591	0.659	rs8065496	ENSG00000263535.1	AK4P1	3.35	0.000882	0.0485	0.18	0.15	Hip circumference;	chr17:31393122	chr17:31345521~31346187:+
THCA	cis	rs1412115	0.501	rs10763952	ENSG00000233387.1	RP11-342D11.3	-3.35	0.000882	0.0485	-0.15	-0.15	Schizophrenia;	chr10:33779428	chr10:33096257~33116672:-
THCA	cis	rs11051970	0.527	rs7309590	ENSG00000275769.1	RP11-771K4.3	-3.35	0.000882	0.0485	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32337915	chr12:31443792~31444208:-
THCA	cis	rs2638953	0.777	rs11049689	ENSG00000247934.4	RP11-967K21.1	-3.35	0.000882	0.0485	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28519177	chr12:28163298~28190738:-
THCA	cis	rs237743	1	rs68014903	ENSG00000222365.1	SNORD12B	-3.35	0.000882	0.0485	-0.19	-0.15	Height;	chr20:49295502	chr20:49280319~49280409:+
THCA	cis	rs7178424	0.79	rs17271305	ENSG00000259251.2	RP11-643M14.1	-3.35	0.000882	0.0485	-0.16	-0.15	Height;	chr15:62040781	chr15:62060503~62062434:+
THCA	cis	rs34779708	0.966	rs12773647	ENSG00000233200.1	RP11-324I22.2	3.35	0.000882	0.0485	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35219894~35230598:-
THCA	cis	rs9811920	0.609	rs6765027	ENSG00000273374.1	RP11-383I23.2	-3.35	0.000882	0.0485	-0.13	-0.15	Axial length;	chr3:99968886	chr3:99802699~99806058:-
THCA	cis	rs9393777	0.557	rs9358949	ENSG00000124549.13	BTN2A3P	-3.35	0.000882	0.0485	-0.2	-0.15	Intelligence (multi-trait analysis);	chr6:26485489	chr6:26421391~26432383:+
THCA	cis	rs763121	0.853	rs4820345	ENSG00000225450.1	RP3-508I15.14	-3.35	0.000882	0.0485	-0.12	-0.15	Menopause (age at onset);	chr22:38695146	chr22:38739003~38749041:+
THCA	cis	rs10191559	0.919	rs7599958	ENSG00000238171.1	AC068196.1	-3.35	0.000882	0.0485	-0.19	-0.15	Red blood cell count;	chr2:180973939	chr2:181076051~181105968:-
THCA	cis	rs2274273	0.934	rs17740741	ENSG00000258469.1	CHMP4BP1	3.35	0.000882	0.0485	0.14	0.15	Protein biomarker;	chr14:55295994	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.901	rs68046603	ENSG00000258469.1	CHMP4BP1	3.35	0.000882	0.0485	0.14	0.15	Protein biomarker;	chr14:55296085	chr14:55298644~55299231:+
THCA	cis	rs2274273	0.901	rs12050099	ENSG00000258469.1	CHMP4BP1	3.35	0.000882	0.0485	0.14	0.15	Protein biomarker;	chr14:55297613	chr14:55298644~55299231:+
THCA	cis	rs3801203	0.617	rs3823729	ENSG00000224116.5	INHBA-AS1	-3.35	0.000882	0.0485	-0.21	-0.15	Language performance in older adults (adjusted for episodic memory);	chr7:42158875	chr7:41693916~41779388:+
THCA	cis	rs9844666	0.512	rs9813082	ENSG00000273486.1	RP11-731C17.2	3.35	0.000882	0.0485	0.13	0.15	Height;	chr3:135918615	chr3:136837338~136839021:-
THCA	cis	rs2251188	0.632	rs2464877	ENSG00000228010.4	AC073343.13	-3.35	0.000882	0.0485	-0.16	-0.15	Sum basophil neutrophil counts;Neutrophil count;	chr7:6655087	chr7:6663974~6708901:+
THCA	cis	rs11098499	0.604	rs12642411	ENSG00000249244.1	RP11-548H18.2	3.35	0.000882	0.0485	0.18	0.15	Corneal astigmatism;	chr4:119659370	chr4:119391831~119395335:-
THCA	cis	rs72753537	0.872	rs111699285	ENSG00000214417.4	KRT18P13	3.35	0.000883	0.0485	0.19	0.15	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97843903	chr9:97698922~97700734:+
THCA	cis	rs4568518	0.903	rs12699940	ENSG00000279048.1	RP11-511H23.2	3.35	0.000883	0.0485	0.1	0.15	Measles;	chr7:17997414	chr7:17940503~17942922:+
THCA	cis	rs911186	0.812	rs35454259	ENSG00000220721.1	OR1F12	3.35	0.000883	0.0485	0.21	0.15	Autism spectrum disorder or schizophrenia;	chr6:27286696	chr6:28073316~28074233:+
THCA	cis	rs9393777	0.502	rs3823427	ENSG00000220721.1	OR1F12	3.35	0.000883	0.0485	0.21	0.15	Intelligence (multi-trait analysis);	chr6:27288567	chr6:28073316~28074233:+
THCA	cis	rs7246657	0.765	rs10402455	ENSG00000267422.1	CTD-2554C21.1	-3.35	0.000883	0.0485	-0.19	-0.15	Coronary artery calcification;	chr19:37237805	chr19:37779686~37792865:+
THCA	cis	rs6902257	1	rs2496676	ENSG00000260645.1	RP11-250B2.5	3.35	0.000883	0.0485	0.28	0.15	Obesity-related traits;	chr6:80595953	chr6:80466958~80469080:+
THCA	cis	rs17301013	0.932	rs2987869	ENSG00000270084.1	GAS5-AS1	3.35	0.000883	0.0485	0.16	0.15	Systemic lupus erythematosus;	chr1:174820269	chr1:173863248~173863941:+
THCA	cis	rs17301013	0.827	rs1793309	ENSG00000270084.1	GAS5-AS1	3.35	0.000883	0.0485	0.16	0.15	Systemic lupus erythematosus;	chr1:174826199	chr1:173863248~173863941:+
THCA	cis	rs6472235	1	rs6994725	ENSG00000272192.1	CTD-2532N20.1	3.35	0.000883	0.0485	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:65932508	chr8:65842752~65843331:+
THCA	cis	rs6472235	1	rs11984566	ENSG00000272192.1	CTD-2532N20.1	3.35	0.000883	0.0485	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:65939237	chr8:65842752~65843331:+
THCA	cis	rs6472235	1	rs7817474	ENSG00000272192.1	CTD-2532N20.1	3.35	0.000883	0.0485	0.15	0.15	Plateletcrit;Myopia (pathological);	chr8:65939683	chr8:65842752~65843331:+
THCA	cis	rs131777	0.577	rs5770928	ENSG00000272836.1	RP3-402G11.27	-3.35	0.000883	0.0485	-0.14	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50205585~50206062:-
THCA	cis	rs10266483	0.774	rs11765812	ENSG00000234338.1	RP11-797H7.1	-3.35	0.000883	0.0485	-0.12	-0.15	Response to statin therapy;	chr7:64385366	chr7:64835280~64836882:-
THCA	cis	rs6495122	0.662	rs12898997	ENSG00000260269.4	CTD-2323K18.1	-3.35	0.000883	0.0485	-0.22	-0.15	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:74798008	chr15:75527150~75601205:-
THCA	cis	rs7131987	0.903	rs7308125	ENSG00000273680.1	RP11-996F15.6	3.35	0.000883	0.0485	0.2	0.15	QT interval;	chr12:29272278	chr12:29332733~29333383:-
THCA	cis	rs7829975	0.623	rs10092965	ENSG00000253130.1	CTD-3023L14.2	-3.35	0.000883	0.0485	-0.17	-0.15	Mood instability;	chr8:8515975	chr8:8561391~8569688:+
THCA	cis	rs588177	1	rs588177	ENSG00000236935.1	AP003774.1	3.35	0.000883	0.0485	0.16	0.15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64256584	chr11:64325050~64329504:-
THCA	cis	rs11039798	0.588	rs12284168	ENSG00000200090.1	Y_RNA	3.35	0.000883	0.0485	0.13	0.15	Axial length;	chr11:48534075	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.588	rs6485857	ENSG00000200090.1	Y_RNA	3.35	0.000883	0.0485	0.13	0.15	Axial length;	chr11:48534959	chr11:47726894~47726992:-
THCA	cis	rs2153219	0.685	rs674919	ENSG00000268592.3	RAET1E-AS1	-3.35	0.000883	0.0485	-0.29	-0.15	Coronary artery disease;	chr6:149427275	chr6:149863494~149919507:+
THCA	cis	rs8040855	0.599	rs8037195	ENSG00000259630.2	CTD-2262B20.1	3.35	0.000883	0.0485	0.17	0.15	Bulimia nervosa;	chr15:85181455	chr15:85415228~85415633:+
THCA	cis	rs1150668	0.83	rs2859365	ENSG00000220721.1	OR1F12	-3.35	0.000883	0.0485	-0.16	-0.15	Pubertal anthropometrics;	chr6:28423688	chr6:28073316~28074233:+
THCA	cis	rs2554380	0.943	rs2585042	ENSG00000230373.7	GOLGA6L5P	-3.35	0.000883	0.0485	-0.19	-0.15	Height;	chr15:83672996	chr15:84507885~84516814:-
THCA	cis	rs7264396	0.836	rs6058276	ENSG00000088340.14	FER1L4	3.35	0.000883	0.0485	0.15	0.15	Total cholesterol levels;	chr20:35599806	chr20:35558737~35607562:-
THCA	cis	rs9534288	0.797	rs1134071	ENSG00000235903.6	CPB2-AS1	3.35	0.000883	0.0485	0.21	0.15	Blood protein levels;	chr13:45988800	chr13:46052806~46113332:+
THCA	cis	rs7185923	0.74	rs4445901	ENSG00000260818.2	UNGP1	3.35	0.000883	0.0485	0.14	0.15	Weight loss (gastric bypass surgery);	chr16:51225814	chr16:51277852~51279112:+
THCA	cis	rs2048656	0.6	rs1976671	ENSG00000261451.1	RP11-981G7.1	3.35	0.000883	0.0485	0.19	0.15	Schizophrenia;	chr8:9822124	chr8:10433672~10438312:+
THCA	cis	rs73019876	0.869	rs1859093	ENSG00000269615.1	AC003973.1	3.35	0.000883	0.0485	0.15	0.15	Testicular germ cell tumor;	chr19:21960537	chr19:21940820~21941533:+
THCA	cis	rs7005380	0.746	rs1464276	ENSG00000279347.1	RP11-85I17.2	3.35	0.000883	0.0485	0.17	0.15	Interstitial lung disease;	chr8:119924801	chr8:119838736~119840385:-
THCA	cis	rs1850744	1	rs10939507	ENSG00000249767.1	ENPP7P10	-3.35	0.000883	0.0485	-0.32	-0.15	Economic and political preferences;	chr4:9767199	chr4:9079023~9141608:+
THCA	cis	rs6940638	0.688	rs9348750	ENSG00000224843.5	LINC00240	3.35	0.000883	0.0485	0.14	0.15	Intelligence (multi-trait analysis);	chr6:27090166	chr6:26956992~27023924:+
THCA	cis	rs7577696	0.554	rs34835885	ENSG00000276517.1	AL133243.2	3.35	0.000883	0.0485	0.15	0.15	Inflammatory biomarkers;	chr2:32100345	chr2:32526504~32529507:+
THCA	cis	rs57709857	0.957	rs56300324	ENSG00000272092.1	RP11-350N15.5	-3.35	0.000883	0.0485	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38323043	chr8:38382364~38383461:+
THCA	cis	rs858239	0.799	rs10279941	ENSG00000230042.1	AK3P3	-3.35	0.000883	0.0485	-0.21	-0.15	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23129178~23129841:+
THCA	cis	rs73019876	0.868	rs2262908	ENSG00000269615.1	AC003973.1	3.35	0.000883	0.0485	0.15	0.15	Testicular germ cell tumor;	chr19:21951998	chr19:21940820~21941533:+
THCA	cis	rs721917	0.544	rs2243639	ENSG00000272489.1	RP11-182L21.5	-3.35	0.000884	0.0485	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr10:79941966	chr10:79663192~79664786:+
THCA	cis	rs913655	1	rs2480328	ENSG00000240291.1	RP11-499P20.2	-3.35	0.000884	0.0485	-0.11	-0.15	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18813927	chr10:18513115~18545651:-
THCA	cis	rs17213965	1	rs17213965	ENSG00000207425.1	Y_RNA	-3.35	0.000884	0.0485	-0.24	-0.15	Waist-hip ratio;	chr16:15788110	chr16:14915457~14915556:-
THCA	cis	rs7112925	0.687	rs5006007	ENSG00000255517.5	CTD-3074O7.5	3.35	0.000884	0.0485	0.12	0.15	Height;	chr11:67063091	chr11:66473490~66480233:-
THCA	cis	rs67478160	0.634	rs2024669	ENSG00000269910.1	RP11-73M18.10	3.35	0.000884	0.0485	0.13	0.15	Schizophrenia;	chr14:103809265	chr14:103694516~103695050:-
THCA	cis	rs12101261	0.744	rs55751898	ENSG00000258915.1	BHLHB9P1	-3.35	0.000884	0.0485	-0.18	-0.15	Graves' disease;	chr14:80952919	chr14:80981988~80983638:+
THCA	cis	rs6806253	0.73	rs56954786	ENSG00000273174.1	RP11-434H6.6	-3.35	0.000884	0.0485	-0.21	-0.15	Pit-and-Fissure caries;	chr3:128540870	chr3:129123439~129124003:+
THCA	cis	rs6806253	0.689	rs59420157	ENSG00000273174.1	RP11-434H6.6	-3.35	0.000884	0.0485	-0.21	-0.15	Pit-and-Fissure caries;	chr3:128540981	chr3:129123439~129124003:+
THCA	cis	rs7264396	0.832	rs224371	ENSG00000088340.14	FER1L4	3.35	0.000884	0.0485	0.14	0.15	Total cholesterol levels;	chr20:35487005	chr20:35558737~35607562:-
THCA	cis	rs12286929	0.639	rs4938180	ENSG00000255580.1	AP000462.2	3.35	0.000884	0.0485	0.14	0.15	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;	chr11:115170292	chr11:115363629~115377931:+
THCA	cis	rs11785400	1	rs10108059	ENSG00000177335.9	C8orf31	-3.35	0.000884	0.0485	-0.17	-0.15	Schizophrenia;	chr8:142668610	chr8:143039209~143059942:+
THCA	cis	rs2074409	0.509	rs853193	ENSG00000275839.1	CTC-421K24.1	-3.35	0.000884	0.0485	-0.18	-0.15	Response to angiotensin II receptor blocker therapy;	chr17:37463009	chr17:37454171~37454931:+
THCA	cis	rs2074409	0.509	rs853205	ENSG00000275839.1	CTC-421K24.1	-3.35	0.000884	0.0485	-0.18	-0.15	Response to angiotensin II receptor blocker therapy;	chr17:37464292	chr17:37454171~37454931:+
THCA	cis	rs2074409	0.509	rs2074412	ENSG00000275839.1	CTC-421K24.1	-3.35	0.000884	0.0485	-0.18	-0.15	Response to angiotensin II receptor blocker therapy;	chr17:37478961	chr17:37454171~37454931:+
THCA	cis	rs3816183	0.626	rs4953529	ENSG00000236090.2	LDHAP3	-3.35	0.000884	0.0486	-0.21	-0.15	Hypospadias;	chr2:42643300	chr2:41819747~41820754:+
THCA	cis	rs17742757	0.521	rs2736324	ENSG00000254556.1	AF131215.4	-3.35	0.000884	0.0486	-0.19	-0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11470673	chr8:11136898~11138607:-
THCA	cis	rs2838088	1	rs9647274	ENSG00000226496.2	LINC00323	3.35	0.000884	0.0486	0.23	0.15	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr21:41671615	chr21:41141493~41148133:-
THCA	cis	rs786425	0.53	rs7397745	ENSG00000270095.1	RP11-214K3.18	3.35	0.000884	0.0486	0.18	0.15	Pubertal anthropometrics;	chr12:123733479	chr12:123971457~123971714:-
THCA	cis	rs8040855	0.627	rs12909130	ENSG00000229212.6	RP11-561C5.4	-3.35	0.000884	0.0486	-0.22	-0.15	Bulimia nervosa;	chr15:85047270	chr15:85205440~85234795:-
THCA	cis	rs1598856	0.715	rs1598861	ENSG00000248161.4	RP11-499E18.1	3.35	0.000884	0.0486	0.16	0.15	Primary biliary cholangitis;	chr4:102565540	chr4:102418602~102450010:-
THCA	cis	rs11673344	0.704	rs1644710	ENSG00000267260.1	CTD-2162K18.4	-3.35	0.000884	0.0486	-0.19	-0.15	Obesity-related traits;	chr19:36926160	chr19:36773153~36777078:+
THCA	cis	rs613391	0.671	rs488729	ENSG00000234840.1	LINC01239	-3.35	0.000884	0.0486	-0.18	-0.15	Quantitative traits;	chr9:22699124	chr9:22646200~22824213:+
THCA	cis	rs613391	0.702	rs1448775	ENSG00000234840.1	LINC01239	-3.35	0.000884	0.0486	-0.18	-0.15	Quantitative traits;	chr9:22704376	chr9:22646200~22824213:+
THCA	cis	rs7394190	0.748	rs3781216	ENSG00000272599.2	RP11-152N13.16	3.35	0.000884	0.0486	0.2	0.15	Incident atrial fibrillation;	chr10:73762646	chr10:73124573~73125532:-
THCA	cis	rs2434529	0.531	rs75582905	ENSG00000245275.6	SAP30L-AS1	3.35	0.000884	0.0486	0.21	0.15	Autism spectrum disorder or schizophrenia;	chr5:154196751	chr5:154329437~154445850:-
THCA	cis	rs16957091	0.647	rs3759792	ENSG00000275601.1	AC011330.13	-3.35	0.000885	0.0486	-0.21	-0.15	MGMT methylation in smokers;	chr15:42960566	chr15:43642389~43643023:-
THCA	cis	rs1933755	0.92	rs9375746	ENSG00000219776.2	RPL21P67	-3.35	0.000885	0.0486	-0.24	-0.15	Colorectal cancer (calcium intake interaction);	chr6:130592658	chr6:131469059~131469536:+
THCA	cis	rs7539542	0.529	rs10920519	ENSG00000234996.3	RP11-480I12.7	3.35	0.000885	0.0486	0.21	0.15	Mean platelet volume;	chr1:202897203	chr1:202861754~202875241:+
THCA	cis	rs9341808	0.727	rs1324120	ENSG00000260645.1	RP11-250B2.5	3.35	0.000885	0.0486	0.13	0.15	Sitting height ratio;	chr6:80266408	chr6:80466958~80469080:+
THCA	cis	rs9650657	0.572	rs4841465	ENSG00000269899.1	RP11-589N15.2	3.35	0.000885	0.0486	0.17	0.15	Neuroticism;	chr8:10962344	chr8:11846154~11846391:-
THCA	cis	rs10824518	0.866	rs7918140	ENSG00000199664.1	RNU6-1266P	-3.35	0.000885	0.0486	-0.2	-0.15	Myopia;	chr10:77354362	chr10:77776951~77777055:-
THCA	cis	rs8054556	1	rs4788197	ENSG00000183604.13	SMG1P5	-3.35	0.000885	0.0486	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29959513	chr16:30267553~30335374:-
THCA	cis	rs8054556	1	rs4788198	ENSG00000183604.13	SMG1P5	-3.35	0.000885	0.0486	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29959514	chr16:30267553~30335374:-
THCA	cis	rs1950832	0.723	rs853239	ENSG00000258636.1	CTD-2298J14.2	3.35	0.000885	0.0486	0.21	0.15	Urate levels in obese individuals;	chr14:41646463	chr14:41587861~41604856:-
THCA	cis	rs786425	0.531	rs35708602	ENSG00000274427.1	RP11-972P1.10	-3.35	0.000885	0.0486	-0.14	-0.15	Pubertal anthropometrics;	chr12:123615157	chr12:123515275~123515513:-
THCA	cis	rs7824557	0.547	rs2409749	ENSG00000206014.6	OR7E161P	3.35	0.000885	0.0486	0.18	0.15	Retinal vascular caliber;	chr8:11221440	chr8:11928597~11929563:-
THCA	cis	rs950169	1	rs79318564	ENSG00000275120.1	RP11-182J1.17	3.35	0.000885	0.0486	0.18	0.15	Schizophrenia;	chr15:84117398	chr15:84599434~84606463:-
THCA	cis	rs950169	1	rs1911155	ENSG00000275120.1	RP11-182J1.17	3.35	0.000885	0.0486	0.18	0.15	Schizophrenia;	chr15:84118883	chr15:84599434~84606463:-
THCA	cis	rs7949030	0.626	rs11231141	ENSG00000255213.1	NPM1P35	3.35	0.000885	0.0486	0.19	0.15	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr11:62330946~62331813:+
THCA	cis	rs11030122	0.61	rs7952083	ENSG00000223756.5	TSSC2	3.35	0.000885	0.0486	0.18	0.15	Mean platelet volume;Platelet distribution width;	chr11:3869730	chr11:3380961~3408978:+
THCA	cis	rs324126	0.78	rs1993530	ENSG00000269834.4	ZNF528-AS1	-3.35	0.000885	0.0486	-0.12	-0.15	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52388842~52397766:-
THCA	cis	rs2836950	0.509	rs4816618	ENSG00000235701.1	PCBP2P1	-3.35	0.000885	0.0486	-0.17	-0.15	Menarche (age at onset);	chr21:39227603	chr21:39171130~39172106:-
THCA	cis	rs2836950	0.527	rs2836948	ENSG00000235701.1	PCBP2P1	-3.35	0.000885	0.0486	-0.17	-0.15	Menarche (age at onset);	chr21:39227751	chr21:39171130~39172106:-
THCA	cis	rs4919669	0.777	rs5011218	ENSG00000272912.1	RP11-724N1.1	-3.35	0.000885	0.0486	-0.26	-0.15	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102641461	chr10:102914585~102915404:+
THCA	cis	rs4919669	0.668	rs4146429	ENSG00000272912.1	RP11-724N1.1	-3.35	0.000885	0.0486	-0.26	-0.15	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102641875	chr10:102914585~102915404:+
THCA	cis	rs4919669	0.668	rs4146428	ENSG00000272912.1	RP11-724N1.1	-3.35	0.000885	0.0486	-0.26	-0.15	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102641964	chr10:102914585~102915404:+
THCA	cis	rs972578	0.837	rs6002963	ENSG00000230319.1	AL022476.2	3.35	0.000885	0.0486	0.16	0.15	Mean platelet volume;	chr22:42850140	chr22:43038585~43052366:+
THCA	cis	rs9638182	0.623	rs13246490	ENSG00000274080.1	CTA-315H11.2	3.35	0.000886	0.0486	0.23	0.15	Triglycerides;	chr7:73578020	chr7:73609262~73611502:-
THCA	cis	rs11089937	0.568	rs5756988	ENSG00000215456.5	BCRP4	-3.35	0.000886	0.0486	-0.19	-0.15	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22630061~22636153:+
THCA	cis	rs34779708	0.832	rs12764283	ENSG00000233200.1	RP11-324I22.2	3.35	0.000886	0.0486	0.19	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35241532	chr10:35219894~35230598:-
THCA	cis	rs2243480	0.908	rs4718273	ENSG00000213640.3	EEF1DP4	-3.35	0.000886	0.0486	-0.28	-0.15	Diabetic kidney disease;	chr7:65751112	chr7:64862999~64864370:+
THCA	cis	rs208520	1	rs12189683	ENSG00000233859.2	ADH5P4	-3.35	0.000886	0.0486	-0.24	-0.15	Exhaled nitric oxide output;	chr6:66267823	chr6:65836930~65838039:-
THCA	cis	rs208520	1	rs12191403	ENSG00000233859.2	ADH5P4	3.35	0.000886	0.0486	0.24	0.15	Exhaled nitric oxide output;	chr6:66268244	chr6:65836930~65838039:-
THCA	cis	rs3742264	0.656	rs4460970	ENSG00000235903.6	CPB2-AS1	-3.35	0.000886	0.0486	-0.19	-0.15	Blood protein levels;	chr13:45966158	chr13:46052806~46113332:+
THCA	cis	rs41271473	0.75	rs17352829	ENSG00000183929.7	DUSP5P1	3.35	0.000886	0.0486	0.2	0.15	Chronic lymphocytic leukemia;	chr1:228753917	chr1:228650241~228651379:+
THCA	cis	rs6988985	0.765	rs4379428	ENSG00000253741.1	CTD-2292P10.4	-3.35	0.000886	0.0486	-0.2	-0.15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142906632	chr8:142702252~142726973:-
THCA	cis	rs41308713	0.681	rs8116426	ENSG00000224635.1	RP4-564F22.5	-3.35	0.000886	0.0486	-0.4	-0.15	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38405996	chr20:38406011~38416797:-
THCA	cis	rs41308713	0.786	rs8116471	ENSG00000224635.1	RP4-564F22.5	-3.35	0.000886	0.0486	-0.4	-0.15	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38406047	chr20:38406011~38416797:-
THCA	cis	rs10043228	1	rs77856716	ENSG00000250015.1	CTC-339F2.2	3.35	0.000886	0.0486	0.24	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116229963	chr5:116302354~116304134:-
THCA	cis	rs4646404	0.526	rs11867345	ENSG00000225442.2	MPRIP-AS1	3.35	0.000886	0.0486	0.18	0.15	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr17:17575076	chr17:17076038~17077752:-
THCA	cis	rs9402682	0.596	rs9321485	ENSG00000232876.1	CTA-212D2.2	-3.35	0.000886	0.0486	-0.21	-0.15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135126635	chr6:135055033~135060550:+
THCA	cis	rs9309473	1	rs1403284	ENSG00000273245.1	RP11-434P11.2	-3.35	0.000886	0.0486	-0.21	-0.15	Metabolite levels;	chr2:73499535	chr2:73750256~73750786:-
THCA	cis	rs2562456	0.833	rs11880624	ENSG00000268521.1	VN1R83P	3.35	0.000886	0.0486	0.15	0.15	Pain;	chr19:21341028	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs62107547	ENSG00000268521.1	VN1R83P	3.35	0.000886	0.0486	0.15	0.15	Pain;	chr19:21341245	chr19:21289554~21289998:-
THCA	cis	rs2562456	0.833	rs56187954	ENSG00000268521.1	VN1R83P	3.35	0.000886	0.0486	0.15	0.15	Pain;	chr19:21345258	chr19:21289554~21289998:-
THCA	cis	rs3784262	0.565	rs9635346	ENSG00000259250.1	RP11-50C13.1	-3.35	0.000886	0.0486	-0.13	-0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:58005920	chr15:58587507~58591676:+
THCA	cis	rs758324	0.812	rs4280859	ENSG00000237714.1	P4HA2-AS1	-3.35	0.000886	0.0486	-0.21	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131911248	chr5:132184876~132192808:+
THCA	cis	rs9341808	0.718	rs9343978	ENSG00000260645.1	RP11-250B2.5	3.35	0.000886	0.0486	0.13	0.15	Sitting height ratio;	chr6:80262261	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.754	rs9341810	ENSG00000260645.1	RP11-250B2.5	3.35	0.000886	0.0486	0.13	0.15	Sitting height ratio;	chr6:80265121	chr6:80466958~80469080:+
THCA	cis	rs9341808	0.7	rs12215236	ENSG00000260645.1	RP11-250B2.5	3.35	0.000886	0.0486	0.13	0.15	Sitting height ratio;	chr6:80265341	chr6:80466958~80469080:+
THCA	cis	rs2180341	0.814	rs6905553	ENSG00000220522.2	RP1-177A13.1	3.35	0.000886	0.0486	0.18	0.15	Breast cancer;	chr6:127406262	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.782	rs6569490	ENSG00000220522.2	RP1-177A13.1	3.35	0.000886	0.0486	0.18	0.15	Breast cancer;	chr6:127408470	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.814	rs9321085	ENSG00000220522.2	RP1-177A13.1	3.35	0.000886	0.0486	0.18	0.15	Breast cancer;	chr6:127414216	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.814	rs9401959	ENSG00000220522.2	RP1-177A13.1	3.35	0.000886	0.0486	0.18	0.15	Breast cancer;	chr6:127415319	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.814	rs7768435	ENSG00000220522.2	RP1-177A13.1	3.35	0.000886	0.0486	0.18	0.15	Breast cancer;	chr6:127415893	chr6:127416535~127416952:-
THCA	cis	rs4764124	0.646	rs10846062	ENSG00000261324.2	RP11-174G6.5	-3.35	0.000886	0.0486	-0.11	-0.15	Pubertal anthropometrics;	chr12:14812847	chr12:14762504~14767931:-
THCA	cis	rs13178541	0.593	rs6862956	ENSG00000250167.1	CTC-321K16.1	-3.35	0.000886	0.0486	-0.17	-0.15	IgG glycosylation;	chr5:135706119	chr5:135559577~135634874:+
THCA	cis	rs4787491	0.679	rs7204852	ENSG00000275371.1	RP11-455F5.6	-3.35	0.000886	0.0486	-0.13	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028857	chr16:30110895~30111955:+
THCA	cis	rs4787491	0.729	rs12446378	ENSG00000275371.1	RP11-455F5.6	-3.35	0.000886	0.0486	-0.13	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30031789	chr16:30110895~30111955:+
THCA	cis	rs4787491	0.729	rs8043883	ENSG00000275371.1	RP11-455F5.6	-3.35	0.000886	0.0486	-0.13	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30033260	chr16:30110895~30111955:+
THCA	cis	rs4787491	0.765	rs8054507	ENSG00000275371.1	RP11-455F5.6	-3.35	0.000886	0.0486	-0.13	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30034721	chr16:30110895~30111955:+
THCA	cis	rs4787491	0.729	rs4788215	ENSG00000275371.1	RP11-455F5.6	-3.35	0.000886	0.0486	-0.13	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036609	chr16:30110895~30111955:+
THCA	cis	rs7844233	0.826	rs9657108	ENSG00000254023.1	PKMP4	3.35	0.000886	0.0486	0.31	0.15	Breast cancer;	chr8:75678477	chr8:75376709~75377014:+
THCA	cis	rs4919087	0.926	rs953097	ENSG00000237169.1	RP11-452K12.3	-3.35	0.000886	0.0487	-0.18	-0.15	Monocyte count;	chr10:97222157	chr10:97309138~97309958:-
THCA	cis	rs4919087	0.962	rs3814164	ENSG00000237169.1	RP11-452K12.3	-3.35	0.000886	0.0487	-0.18	-0.15	Monocyte count;	chr10:97222992	chr10:97309138~97309958:-
THCA	cis	rs9450351	0.744	rs7752222	ENSG00000280232.1	RP11-321N4.4	3.35	0.000886	0.0487	0.32	0.15	Interferon gamma-induced protein 10 levels;	chr6:85913874	chr6:85498441~85499058:-
THCA	cis	rs939960	0.876	rs58391005	ENSG00000224016.2	RP11-728K20.1	3.35	0.000886	0.0487	0.21	0.15	Neutrophil percentage of white cells;	chr7:150521049	chr7:149891191~149909704:-
THCA	cis	rs939960	0.917	rs12530578	ENSG00000224016.2	RP11-728K20.1	3.35	0.000886	0.0487	0.21	0.15	Neutrophil percentage of white cells;	chr7:150521218	chr7:149891191~149909704:-
THCA	cis	rs4820792	1	rs714191	ENSG00000235954.5	TTC28-AS1	-3.35	0.000887	0.0487	-0.13	-0.15	Breast size;	chr22:28749423	chr22:27919376~28008581:+
THCA	cis	rs227275	0.53	rs3960788	ENSG00000248971.2	KRT8P46	-3.35	0.000887	0.0487	-0.18	-0.15	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102728746~102730171:-
THCA	cis	rs7927592	0.789	rs2291467	ENSG00000160172.9	FAM86C2P	3.35	0.000887	0.0487	0.16	0.15	Total body bone mineral density;	chr11:68449288	chr11:67791648~67805336:-
THCA	cis	rs6997458	0.902	rs1472360	ENSG00000253549.4	RP11-317J10.2	3.35	0.000887	0.0487	0.16	0.15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85392969	chr8:85441851~85464915:-
THCA	cis	rs11800820	0.567	rs3124116	ENSG00000231612.1	RP11-522M21.3	3.35	0.000887	0.0487	0.2	0.15	Obesity-related traits;	chr1:246543749	chr1:245673732~245676478:-
THCA	cis	rs11800820	0.567	rs3124119	ENSG00000231612.1	RP11-522M21.3	3.35	0.000887	0.0487	0.2	0.15	Obesity-related traits;	chr1:246544514	chr1:245673732~245676478:-
THCA	cis	rs11800820	0.567	rs3129568	ENSG00000231612.1	RP11-522M21.3	3.35	0.000887	0.0487	0.2	0.15	Obesity-related traits;	chr1:246544556	chr1:245673732~245676478:-
THCA	cis	rs6012953	1	rs6012953	ENSG00000237595.3	RP11-112L6.3	3.35	0.000887	0.0487	0.14	0.15	Vitiligo;	chr20:50506506	chr20:50162765~50166102:-
THCA	cis	rs7264396	0.779	rs2425162	ENSG00000088340.14	FER1L4	3.35	0.000887	0.0487	0.15	0.15	Total cholesterol levels;	chr20:35842052	chr20:35558737~35607562:-
THCA	cis	rs11088226	0.692	rs8127603	ENSG00000186842.4	LINC00846	-3.35	0.000887	0.0487	-0.19	-0.15	Gastritis;	chr21:32514348	chr21:32572238~32575881:-
THCA	cis	rs76878669	0.538	rs1785633	ENSG00000255320.1	RP11-755F10.1	-3.35	0.000887	0.0487	-0.19	-0.15	Educational attainment (years of education);	chr11:66340056	chr11:66244840~66246239:-
THCA	cis	rs76878669	0.515	rs947978	ENSG00000255320.1	RP11-755F10.1	-3.35	0.000887	0.0487	-0.19	-0.15	Educational attainment (years of education);	chr11:66341189	chr11:66244840~66246239:-
THCA	cis	rs9420	0.961	rs7117205	ENSG00000254602.1	AP000662.4	-3.35	0.000887	0.0487	-0.17	-0.15	Schizophrenia;	chr11:57874411	chr11:57638024~57652790:+
THCA	cis	rs6840360	1	rs1877187	ENSG00000270265.1	RP11-731D1.4	-3.35	0.000887	0.0487	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151684469	chr4:151333775~151353224:-
THCA	cis	rs9426935	0.816	rs12133492	ENSG00000272030.1	RP1-178F15.4	3.35	0.000887	0.0487	0.16	0.15	Lentiform nucleus volume;	chr1:153859689	chr1:153631438~153634397:-
THCA	cis	rs2652822	0.935	rs12594313	ENSG00000259459.4	RP11-321G12.1	-3.35	0.000887	0.0487	-0.13	-0.15	Metabolic traits;	chr15:63144463	chr15:63390136~63438320:+
THCA	cis	rs5997397	0.967	rs5752791	ENSG00000226471.5	CTA-292E10.6	3.35	0.000887	0.0487	0.12	0.15	Red cell distribution width;	chr22:28757559	chr22:28800683~28848559:+
THCA	cis	rs9369640	0.674	rs4714951	ENSG00000212802.4	RPL15P3	3.35	0.000887	0.0487	0.15	0.15	Coronary artery disease;	chr6:12897075	chr6:12514110~12514724:+
THCA	cis	rs2180341	0.924	rs877661	ENSG00000220522.2	RP1-177A13.1	3.35	0.000887	0.0487	0.2	0.15	Breast cancer;	chr6:127266770	chr6:127416535~127416952:-
THCA	cis	rs11018904	0.906	rs36177012	ENSG00000280367.1	RP11-121L10.2	3.35	0.000887	0.0487	0.21	0.15	Intelligence (multi-trait analysis);	chr11:90200151	chr11:90223153~90226538:+
THCA	cis	rs11018904	0.906	rs7925507	ENSG00000280367.1	RP11-121L10.2	3.35	0.000887	0.0487	0.21	0.15	Intelligence (multi-trait analysis);	chr11:90206978	chr11:90223153~90226538:+
THCA	cis	rs6787172	0.566	rs11719188	ENSG00000272087.1	RP11-379F4.7	3.35	0.000887	0.0487	0.14	0.15	Subjective well-being;	chr3:158388975	chr3:158693120~158693768:-
THCA	cis	rs8030379	1	rs1480823	ENSG00000176700.18	SCAND2P	-3.35	0.000887	0.0487	-0.1	-0.15	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916994	chr15:84631451~84647478:+
THCA	cis	rs2933343	0.729	rs1680794	ENSG00000261159.1	RP11-723O4.9	3.35	0.000887	0.0487	0.16	0.15	IgG glycosylation;	chr3:128901547	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.7	rs1683777	ENSG00000261159.1	RP11-723O4.9	3.35	0.000887	0.0487	0.16	0.15	IgG glycosylation;	chr3:128906037	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.7	rs1680788	ENSG00000261159.1	RP11-723O4.9	3.35	0.000887	0.0487	0.16	0.15	IgG glycosylation;	chr3:128906475	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.7	rs789240	ENSG00000261159.1	RP11-723O4.9	3.35	0.000887	0.0487	0.16	0.15	IgG glycosylation;	chr3:128911792	chr3:128859716~128860526:-
THCA	cis	rs2933343	0.7	rs789238	ENSG00000261159.1	RP11-723O4.9	3.35	0.000887	0.0487	0.16	0.15	IgG glycosylation;	chr3:128917872	chr3:128859716~128860526:-
THCA	cis	rs1823913	0.503	rs35672076	ENSG00000280083.1	RP11-317J9.1	-3.35	0.000887	0.0487	-0.18	-0.15	Obesity-related traits;	chr2:191343907	chr2:191154118~191156070:-
THCA	cis	rs1823913	0.503	rs35282329	ENSG00000280083.1	RP11-317J9.1	-3.35	0.000887	0.0487	-0.18	-0.15	Obesity-related traits;	chr2:191343925	chr2:191154118~191156070:-
THCA	cis	rs2882667	0.898	rs11749944	ENSG00000249593.5	CTB-46B19.2	3.35	0.000887	0.0487	0.18	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:139012647~139051203:+
THCA	cis	rs9457247	0.565	rs2239824	ENSG00000235272.1	FAM103A2P	3.35	0.000887	0.0487	0.21	0.15	Crohn's disease;	chr6:167098311	chr6:166586124~166586477:-
THCA	cis	rs701145	0.556	rs355758	ENSG00000243069.6	ARHGEF26-AS1	-3.35	0.000887	0.0487	-0.2	-0.15	Coronary artery disease;	chr3:154289893	chr3:154024401~154121332:-
THCA	cis	rs7395662	0.963	rs4882146	ENSG00000200090.1	Y_RNA	-3.35	0.000888	0.0487	-0.1	-0.15	HDL cholesterol;	chr11:48638617	chr11:47726894~47726992:-
THCA	cis	rs11673344	0.796	rs16971886	ENSG00000267260.1	CTD-2162K18.4	-3.35	0.000888	0.0487	-0.19	-0.15	Obesity-related traits;	chr19:36997073	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.83	rs3745770	ENSG00000267260.1	CTD-2162K18.4	-3.35	0.000888	0.0487	-0.19	-0.15	Obesity-related traits;	chr19:36997663	chr19:36773153~36777078:+
THCA	cis	rs11673344	0.797	rs3745768	ENSG00000267260.1	CTD-2162K18.4	-3.35	0.000888	0.0487	-0.19	-0.15	Obesity-related traits;	chr19:36997907	chr19:36773153~36777078:+
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000281021.1	RP1-12G14.9	-3.35	0.000888	0.0487	-0.15	-0.15	Lung cancer;	chr6:149641481	chr6:149576089~149590864:-
THCA	cis	rs758324	0.533	rs25882	ENSG00000224431.1	AC063976.7	-3.35	0.000888	0.0487	-0.15	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132075767	chr5:132199456~132203487:+
THCA	cis	rs910316	0.687	rs175059	ENSG00000259138.1	RP11-950C14.7	-3.35	0.000888	0.0487	-0.13	-0.15	Height;	chr14:75023964	chr14:75127153~75136930:+
THCA	cis	rs950169	0.922	rs11630760	ENSG00000230373.7	GOLGA6L5P	-3.35	0.000888	0.0487	-0.17	-0.15	Schizophrenia;	chr15:84570106	chr15:84507885~84516814:-
THCA	cis	rs17818399	0.501	rs13413254	ENSG00000279254.1	RP11-536C12.1	-3.35	0.000888	0.0487	-0.14	-0.15	Height;	chr2:46575795	chr2:46668870~46670778:+
THCA	cis	rs6918152	0.646	rs2473488	ENSG00000270937.1	RP5-856G1.1	-3.35	0.000888	0.0487	-0.21	-0.15	Black vs. red hair color;Black vs. blond hair color;	chr6:544239	chr6:1026494~1027225:-
THCA	cis	rs7185923	0.74	rs7206884	ENSG00000260818.2	UNGP1	3.35	0.000888	0.0487	0.14	0.15	Weight loss (gastric bypass surgery);	chr16:51225045	chr16:51277852~51279112:+
THCA	cis	rs7219021	0.705	rs11869991	ENSG00000248278.1	SUMO2P17	-3.35	0.000888	0.0487	-0.2	-0.15	Schizophrenia or bipolar disorder;	chr17:48950401	chr17:48874860~48908983:-
THCA	cis	rs4604234	0.803	rs11968568	ENSG00000260645.1	RP11-250B2.5	-3.35	0.000888	0.0487	-0.25	-0.15	Cancer;	chr6:80276577	chr6:80466958~80469080:+
THCA	cis	rs4604234	0.803	rs3805893	ENSG00000260645.1	RP11-250B2.5	-3.35	0.000888	0.0487	-0.25	-0.15	Cancer;	chr6:80285761	chr6:80466958~80469080:+
THCA	cis	rs61869271	0.805	rs7086663	ENSG00000236799.1	RP11-383C6.2	-3.35	0.000888	0.0487	-0.18	-0.15	Tonsillectomy;	chr10:115006577	chr10:114994657~114996593:+
THCA	cis	rs9828933	0.752	rs73117082	ENSG00000224479.4	AC136289.1	3.35	0.000888	0.0487	0.24	0.15	Type 2 diabetes;	chr3:63961889	chr3:63742293~63827445:-
THCA	cis	rs6545883	0.791	rs4672445	ENSG00000212978.6	AC016747.3	-3.35	0.000888	0.0487	-0.17	-0.15	Tuberculosis;	chr2:61427873	chr2:61141592~61144969:-
THCA	cis	rs2797160	0.904	rs1739370	ENSG00000226409.1	RP11-735G4.1	3.35	0.000888	0.0487	0.18	0.15	Endometrial cancer;	chr6:125690085	chr6:125370211~125374324:-
THCA	cis	rs10792665	0.541	rs1318423	ENSG00000255503.1	RP11-113K21.4	-3.35	0.000888	0.0487	-0.16	-0.15	Obesity-related traits;	chr11:82904460	chr11:83072402~83097196:-
THCA	cis	rs4730276	0.64	rs8721	ENSG00000241764.3	AC002467.7	-3.35	0.000888	0.0487	-0.13	-0.15	Ulcerative colitis;	chr7:107919277	chr7:107742817~107744581:-
THCA	cis	rs9573567	0.609	rs79938109	ENSG00000261105.4	LMO7-AS1	-3.35	0.000888	0.0487	-0.34	-0.15	Red blood cell count;Mean corpuscular volume;	chr13:75467476	chr13:75604700~75635994:-
THCA	cis	rs12935418	0.887	rs2873310	ENSG00000261838.4	RP11-303E16.6	-3.35	0.000888	0.0487	-0.23	-0.15	Mean corpuscular volume;	chr16:81038540	chr16:81069854~81076598:+
THCA	cis	rs972578	0.837	rs2413720	ENSG00000230319.1	AL022476.2	3.35	0.000888	0.0487	0.16	0.15	Mean platelet volume;	chr22:42802253	chr22:43038585~43052366:+
THCA	cis	rs939960	0.84	rs34940374	ENSG00000276538.1	RP11-545G3.2	3.35	0.000888	0.0487	0.24	0.15	Neutrophil percentage of white cells;	chr7:150634289	chr7:150047609~150047854:-
THCA	cis	rs11190604	1	rs9420782	ENSG00000273030.1	RP11-285F16.1	3.35	0.000888	0.0487	0.17	0.15	Palmitoleic acid (16:1n-7) levels;	chr10:100475258	chr10:100412934~100413421:+
THCA	cis	rs2921036	0.529	rs2979192	ENSG00000253981.4	ALG1L13P	3.35	0.000888	0.0487	0.15	0.15	Neuroticism;	chr8:8480637	chr8:8236003~8244667:-
THCA	cis	rs1075265	0.547	rs7557799	ENSG00000272156.1	RP11-477N3.1	-3.35	0.000888	0.0487	-0.16	-0.15	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54082554~54085066:+
THCA	cis	rs5758659	0.652	rs133340	ENSG00000182057.4	OGFRP1	-3.35	0.000888	0.0487	-0.17	-0.15	Cognitive function;	chr22:42021683	chr22:42269753~42275196:+
THCA	cis	rs7707921	0.69	rs6870335	ENSG00000251374.1	RPS23P5	3.35	0.000889	0.0487	0.2	0.15	Breast cancer;	chr5:82294251	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.767	rs862244	ENSG00000251374.1	RPS23P5	-3.35	0.000889	0.0487	-0.2	-0.15	Breast cancer;	chr5:82290982	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.801	rs862243	ENSG00000251374.1	RPS23P5	-3.35	0.000889	0.0487	-0.2	-0.15	Breast cancer;	chr5:82291010	chr5:82265157~82265259:-
THCA	cis	rs7707921	0.767	rs862241	ENSG00000251374.1	RPS23P5	-3.35	0.000889	0.0487	-0.2	-0.15	Breast cancer;	chr5:82292192	chr5:82265157~82265259:-
THCA	cis	rs7131987	0.845	rs7299861	ENSG00000274315.1	RP11-996F15.5	3.35	0.000889	0.0487	0.2	0.15	QT interval;	chr12:29256734	chr12:29331434~29331936:-
THCA	cis	rs7131987	0.934	rs7316004	ENSG00000274315.1	RP11-996F15.5	3.35	0.000889	0.0487	0.2	0.15	QT interval;	chr12:29258765	chr12:29331434~29331936:-
THCA	cis	rs7131987	0.903	rs2216853	ENSG00000274315.1	RP11-996F15.5	3.35	0.000889	0.0487	0.2	0.15	QT interval;	chr12:29260315	chr12:29331434~29331936:-
THCA	cis	rs7131987	0.868	rs10771508	ENSG00000274315.1	RP11-996F15.5	3.35	0.000889	0.0487	0.2	0.15	QT interval;	chr12:29261278	chr12:29331434~29331936:-
THCA	cis	rs2251188	0.544	rs2464873	ENSG00000207217.1	SNORA42	-3.35	0.000889	0.0487	-0.19	-0.15	Sum basophil neutrophil counts;Neutrophil count;	chr7:6648120	chr7:6016877~6017011:+
THCA	cis	rs591584	0.617	rs608972	ENSG00000255893.1	RP11-685N10.1	3.35	0.000889	0.0487	0.16	0.15	Macrophage Migration Inhibitory Factor levels;	chr11:94602964	chr11:94472908~94473570:-
THCA	cis	rs755249	0.567	rs72661940	ENSG00000182109.6	RP11-69E11.4	3.35	0.000889	0.0487	0.17	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39262975	chr1:39522280~39546187:-
THCA	cis	rs6599077	0.616	rs9883358	ENSG00000223797.4	ENTPD3-AS1	3.35	0.000889	0.0487	0.14	0.15	Sleep-related phenotypes;	chr3:40134140	chr3:40313802~40453329:-
THCA	cis	rs5754733	0.555	rs2051554	ENSG00000273082.1	LL22NC03-32F9.1	-3.34	0.000889	0.0488	-0.21	-0.15	Eotaxin levels;	chr22:33845874	chr22:33922422~33922766:+
THCA	cis	rs513088	0.681	rs523900	ENSG00000225171.2	DUTP6	3.34	0.000889	0.0488	0.21	0.15	Schizophrenia;	chr1:166680370	chr1:166868748~166869209:+
THCA	cis	rs765787	0.53	rs7167731	ENSG00000259539.1	CTD-2651B20.1	-3.34	0.000889	0.0488	-0.19	-0.15	Uric acid levels;	chr15:45218702	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs12910270	ENSG00000259539.1	CTD-2651B20.1	-3.34	0.000889	0.0488	-0.19	-0.15	Uric acid levels;	chr15:45219888	chr15:45152664~45167526:-
THCA	cis	rs765787	0.53	rs12440238	ENSG00000259539.1	CTD-2651B20.1	-3.34	0.000889	0.0488	-0.19	-0.15	Uric acid levels;	chr15:45220707	chr15:45152664~45167526:-
THCA	cis	rs668210	0.793	rs502363	ENSG00000214659.4	KRT8P26	3.34	0.000889	0.0488	0.17	0.15	Cerebrospinal fluid biomarker levels;	chr11:66008121	chr11:65726939~65728214:+
THCA	cis	rs77580281	1	rs5748284	ENSG00000185065.6	AC000068.5	-3.34	0.000889	0.0488	-0.17	-0.15	Pediatric bone mineral density (hip);	chr22:19555028	chr22:19447893~19450105:+
THCA	cis	rs478304	0.654	rs11227260	ENSG00000255557.1	RP11-770G2.2	3.34	0.000889	0.0488	0.19	0.15	Acne (severe);	chr11:65693687	chr11:65745729~65771585:+
THCA	cis	rs2070488	0.965	rs7640050	ENSG00000232439.1	RPL18AP7	3.34	0.000889	0.0488	0.19	0.15	Electrocardiographic conduction measures;	chr3:38484373	chr3:38526802~38527325:-
THCA	cis	rs2292096	1	rs72746858	ENSG00000260088.1	RP11-92G12.3	3.34	0.000889	0.0488	0.31	0.15	Epilepsy;	chr1:200814025	chr1:200669507~200694250:+
THCA	cis	rs8054556	1	rs11150579	ENSG00000214725.6	CDIPT-AS1	-3.34	0.000889	0.0488	-0.19	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29989009	chr16:29863593~29868053:+
THCA	cis	rs8054556	1	rs9924686	ENSG00000214725.6	CDIPT-AS1	-3.34	0.000889	0.0488	-0.19	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29991755	chr16:29863593~29868053:+
THCA	cis	rs8054556	1	rs4788209	ENSG00000214725.6	CDIPT-AS1	-3.34	0.000889	0.0488	-0.19	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30001945	chr16:29863593~29868053:+
THCA	cis	rs8054556	1	rs4788210	ENSG00000214725.6	CDIPT-AS1	-3.34	0.000889	0.0488	-0.19	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30002353	chr16:29863593~29868053:+
THCA	cis	rs8054556	1	rs11150580	ENSG00000214725.6	CDIPT-AS1	-3.34	0.000889	0.0488	-0.19	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30003243	chr16:29863593~29868053:+
THCA	cis	rs11671005	0.736	rs11668201	ENSG00000269600.1	AC016629.3	-3.34	0.000889	0.0488	-0.22	-0.15	Mean platelet volume;	chr19:58492265	chr19:58593896~58599355:-
THCA	cis	rs45544231	1	rs3104768	ENSG00000279344.1	RP11-44F14.7	3.34	0.000889	0.0488	0.14	0.15	Restless legs syndrome;	chr16:52592484	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs3112624	ENSG00000279344.1	RP11-44F14.7	3.34	0.000889	0.0488	0.14	0.15	Restless legs syndrome;	chr16:52592639	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs3104769	ENSG00000279344.1	RP11-44F14.7	3.34	0.000889	0.0488	0.14	0.15	Restless legs syndrome;	chr16:52593319	chr16:53478957~53481550:-
THCA	cis	rs45544231	0.966	rs3104773	ENSG00000279344.1	RP11-44F14.7	3.34	0.000889	0.0488	0.14	0.15	Restless legs syndrome;	chr16:52595524	chr16:53478957~53481550:-
THCA	cis	rs12681366	0.839	rs2931632	ENSG00000261437.1	RP11-22C11.2	3.34	0.000889	0.0488	0.16	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:94637285~94639467:-
THCA	cis	rs2901381	0.659	rs10513659	ENSG00000269984.1	RP11-362K14.5	3.34	0.000889	0.0488	0.14	0.15	Plateletcrit;	chr3:169091528	chr3:169777192~169780334:-
THCA	cis	rs478304	0.651	rs11227299	ENSG00000255557.1	RP11-770G2.2	3.34	0.000889	0.0488	0.18	0.15	Acne (severe);	chr11:65782099	chr11:65745729~65771585:+
THCA	cis	rs478304	0.651	rs948494	ENSG00000255557.1	RP11-770G2.2	3.34	0.000889	0.0488	0.18	0.15	Acne (severe);	chr11:65784647	chr11:65745729~65771585:+
THCA	cis	rs478304	0.651	rs948493	ENSG00000255557.1	RP11-770G2.2	3.34	0.000889	0.0488	0.18	0.15	Acne (severe);	chr11:65784683	chr11:65745729~65771585:+
THCA	cis	rs2070488	0.965	rs1058945	ENSG00000232439.1	RPL18AP7	-3.34	0.000889	0.0488	-0.19	-0.15	Electrocardiographic conduction measures;	chr3:38491020	chr3:38526802~38527325:-
THCA	cis	rs2070488	0.965	rs4679053	ENSG00000232439.1	RPL18AP7	3.34	0.000889	0.0488	0.19	0.15	Electrocardiographic conduction measures;	chr3:38482004	chr3:38526802~38527325:-
THCA	cis	rs2070488	0.965	rs1046048	ENSG00000232439.1	RPL18AP7	3.34	0.000889	0.0488	0.19	0.15	Electrocardiographic conduction measures;	chr3:38483251	chr3:38526802~38527325:-
THCA	cis	rs2070488	0.965	rs7642472	ENSG00000232439.1	RPL18AP7	3.34	0.000889	0.0488	0.19	0.15	Electrocardiographic conduction measures;	chr3:38484076	chr3:38526802~38527325:-
THCA	cis	rs2070488	0.93	rs928813	ENSG00000232439.1	RPL18AP7	3.34	0.000889	0.0488	0.19	0.15	Electrocardiographic conduction measures;	chr3:38487046	chr3:38526802~38527325:-
THCA	cis	rs2070488	0.965	rs7433277	ENSG00000232439.1	RPL18AP7	3.34	0.000889	0.0488	0.19	0.15	Electrocardiographic conduction measures;	chr3:38488327	chr3:38526802~38527325:-
THCA	cis	rs1862618	0.671	rs252897	ENSG00000271828.1	CTD-2310F14.1	3.34	0.000889	0.0488	0.21	0.15	Initial pursuit acceleration;	chr5:56927173	chr5:56927874~56929573:+
THCA	cis	rs12083887	0.505	rs7541204	ENSG00000236866.4	AL157902.3	-3.34	0.000889	0.0488	-0.18	-0.15	Male-pattern baldness;	chr1:118369123	chr1:117596832~117605770:-
THCA	cis	rs67478160	0.643	rs8004408	ENSG00000258534.1	CTD-2134A5.4	-3.34	0.000889	0.0488	-0.15	-0.15	Schizophrenia;	chr14:103737601	chr14:103854366~103880111:-
THCA	cis	rs11098699	0.784	rs6832894	ENSG00000273007.1	RP11-170N16.3	3.34	0.000889	0.0488	0.12	0.15	Mosquito bite size;	chr4:123318370	chr4:122881878~122884712:-
THCA	cis	rs7558370	0.52	rs76221161	ENSG00000234423.1	LINC01250	-3.34	0.000889	0.0488	-0.33	-0.15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);	chr2:3652533	chr2:2895048~3126026:-
THCA	cis	rs17445240	1	rs77719803	ENSG00000234423.1	LINC01250	-3.34	0.000889	0.0488	-0.33	-0.15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);	chr2:3653486	chr2:2895048~3126026:-
THCA	cis	rs1200821	0.535	rs1208783	ENSG00000276805.1	RP11-291L22.6	3.34	0.000889	0.0488	0.16	0.15	Hemostatic factors and hematological phenotypes;	chr10:37478539	chr10:38451030~38451785:+
THCA	cis	rs7914558	0.966	rs10748836	ENSG00000272912.1	RP11-724N1.1	-3.34	0.000889	0.0488	-0.18	-0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102934160	chr10:102914585~102915404:+
THCA	cis	rs7914558	0.966	rs10786727	ENSG00000272912.1	RP11-724N1.1	-3.34	0.000889	0.0488	-0.18	-0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102938766	chr10:102914585~102915404:+
THCA	cis	rs6496667	0.821	rs79731978	ENSG00000259262.1	NDUFA3P4	3.34	0.000889	0.0488	0.22	0.15	Rheumatoid arthritis;	chr15:90332781	chr15:90385814~90386063:+
THCA	cis	rs9348440	0.667	rs4515379	ENSG00000280989.1	LINC00581	3.34	0.000889	0.0488	0.23	0.15	Glycemic traits;	chr6:20627210	chr6:21486061~21511895:-
THCA	cis	rs6439153	0.933	rs6799008	ENSG00000231305.3	RP11-723O4.2	3.34	0.000889	0.0488	0.16	0.15	Pneumococcal bacteremia;	chr3:128998544	chr3:128861313~128871540:-
THCA	cis	rs2880765	0.835	rs6496027	ENSG00000218052.5	ADAMTS7P4	-3.34	0.000889	0.0488	-0.17	-0.15	Coronary artery disease;	chr15:85506757	chr15:85255369~85330334:-
THCA	cis	rs3020736	0.5	rs6002605	ENSG00000270083.1	RP1-257I20.14	-3.34	0.00089	0.0488	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42089630~42090028:-
THCA	cis	rs28489187	0.706	rs233066	ENSG00000223653.4	RP11-131L23.1	3.34	0.00089	0.0488	0.17	0.15	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85339247	chr1:85276715~85448124:+
THCA	cis	rs79419269	0.572	rs1122979	ENSG00000265810.1	MIR3907	-3.34	0.00089	0.0488	-0.2	-0.15	Immunoglobulin light chain (AL) amyloidosis;	chr7:151217985	chr7:151433489~151433639:-
THCA	cis	rs256438	0.731	rs7723567	ENSG00000251221.1	LINC01337	-3.34	0.00089	0.0488	-0.18	-0.15	Serum thyroid-stimulating hormone levels;	chr5:80048466	chr5:80608623~80622524:-
THCA	cis	rs13046373	0.508	rs1507393	ENSG00000174680.8	GRIK1-AS1	-3.34	0.00089	0.0488	-0.18	-0.15	HDL cholesterol;	chr21:30620460	chr21:29748175~29764002:+
THCA	cis	rs13046373	0.508	rs2253516	ENSG00000174680.8	GRIK1-AS1	-3.34	0.00089	0.0488	-0.18	-0.15	HDL cholesterol;	chr21:30620998	chr21:29748175~29764002:+
THCA	cis	rs13046373	0.508	rs1012969	ENSG00000174680.8	GRIK1-AS1	-3.34	0.00089	0.0488	-0.18	-0.15	HDL cholesterol;	chr21:30623789	chr21:29748175~29764002:+
THCA	cis	rs13046373	0.508	rs13048637	ENSG00000174680.8	GRIK1-AS1	-3.34	0.00089	0.0488	-0.18	-0.15	HDL cholesterol;	chr21:30626736	chr21:29748175~29764002:+
THCA	cis	rs1520333	1	rs1520333	ENSG00000254352.1	RP11-578O24.2	-3.34	0.00089	0.0488	-0.16	-0.15	Multiple sclerosis;	chr8:78488803	chr8:78723796~78724136:-
THCA	cis	rs12893668	0.572	rs1606	ENSG00000258735.1	LINC00637	-3.34	0.00089	0.0488	-0.2	-0.15	Reticulocyte count;	chr14:103694944	chr14:103847721~103858049:+
THCA	cis	rs714027	0.585	rs41171	ENSG00000279699.1	RP1-102K2.9	-3.34	0.00089	0.0488	-0.16	-0.15	Lymphocyte counts;	chr22:30026118	chr22:30275215~30276951:-
THCA	cis	rs11673344	0.801	rs17707446	ENSG00000267470.4	ZNF571-AS1	3.34	0.00089	0.0488	0.18	0.15	Obesity-related traits;	chr19:37092140	chr19:37548914~37587348:+
THCA	cis	rs12999542	0.5	rs13001301	ENSG00000234389.1	AC007278.3	3.34	0.00089	0.0488	0.24	0.15	Serum protein levels (sST2);	chr2:102322538	chr2:102438713~102440475:+
THCA	cis	rs12999542	0.5	rs17695648	ENSG00000234389.1	AC007278.3	3.34	0.00089	0.0488	0.24	0.15	Serum protein levels (sST2);	chr2:102331721	chr2:102438713~102440475:+
THCA	cis	rs4705962	0.918	rs11242122	ENSG00000237714.1	P4HA2-AS1	-3.34	0.00089	0.0488	-0.22	-0.15	Atopic dermatitis;	chr5:132689016	chr5:132184876~132192808:+
THCA	cis	rs2395128	0.705	rs16931866	ENSG00000236842.1	RP11-399K21.10	3.34	0.00089	0.0488	0.23	0.15	Ulcerative colitis;Inflammatory bowel disease;	chr10:74948000	chr10:75430571~75431588:-
THCA	cis	rs2822388	1	rs2822388	ENSG00000230965.1	SNX18P13	3.34	0.00089	0.0488	0.31	0.15	Stroke;	chr21:14035713	chr21:13905960~13906488:-
THCA	cis	rs7142002	0.614	rs7152695	ENSG00000272444.1	RP11-1017G21.6	-3.34	0.00089	0.0488	-0.17	-0.15	Autism;	chr14:101923757	chr14:101952416~101953063:+
THCA	cis	rs17364464	1	rs17364464	ENSG00000228649.7	AC005682.5	3.34	0.00089	0.0488	0.24	0.15	Dialysis-related mortality;	chr7:22474434	chr7:22854178~22861579:+
THCA	cis	rs8114671	0.562	rs2424999	ENSG00000126005.14	MMP24-AS1	-3.34	0.00089	0.0488	-0.15	-0.15	Height;	chr20:34798627	chr20:35216462~35278131:-
THCA	cis	rs9399599	0.805	rs474990	ENSG00000233452.5	STXBP5-AS1	-3.34	0.00089	0.0488	-0.15	-0.15	Plasma plasminogen activator levels;	chr6:147251244	chr6:146841901~147204614:-
THCA	cis	rs10985070	0.504	rs2296077	ENSG00000243738.3	RN7SL181P	3.34	0.00089	0.0488	0.15	0.15	Rheumatoid arthritis;	chr9:121182665	chr9:121203159~121203435:+
THCA	cis	rs13437751	0.764	rs10282573	ENSG00000223558.1	TRIM60P17	-3.34	0.00089	0.0488	-0.29	-0.15	QT interval (drug interaction);	chr7:63960261	chr7:64085560~64086576:+
THCA	cis	rs55882075	0.535	rs67484565	ENSG00000225051.5	HMGB3P22	-3.34	0.00089	0.0488	-0.14	-0.15	Monocyte percentage of white cells;	chr5:179683573	chr5:179679032~179694768:+
THCA	cis	rs11658311	1	rs74609824	ENSG00000232344.2	AC087163.2	3.34	0.00089	0.0488	0.21	0.15	Obsessive-compulsive symptoms;	chr17:17578039	chr17:18010643~18011822:+
THCA	cis	rs4561483	0.771	rs7202234	ENSG00000263307.1	RP11-166B2.8	-3.34	0.00089	0.0488	-0.15	-0.15	Testicular germ cell tumor;	chr16:11848465	chr16:11851649~11895611:+
THCA	cis	rs11702966	0.61	rs17654028	ENSG00000235159.1	RP6-109B7.4	3.34	0.00089	0.0488	0.2	0.15	Tonsillectomy;	chr22:45839625	chr22:46067356~46069891:-
THCA	cis	rs7192750	0.586	rs2335713	ENSG00000260886.1	TAT-AS1	3.34	0.00089	0.0488	0.22	0.15	Total cholesterol levels;LDL cholesterol levels;	chr16:71870388	chr16:71565789~71578187:+
THCA	cis	rs453301	0.686	rs6601280	ENSG00000253981.4	ALG1L13P	3.34	0.00089	0.0488	0.15	0.15	Joint mobility (Beighton score);	chr8:9051726	chr8:8236003~8244667:-
THCA	cis	rs7826238	0.623	rs2976893	ENSG00000254340.1	RP11-10A14.3	-3.34	0.00089	0.0488	-0.17	-0.15	Systolic blood pressure;	chr8:8480709	chr8:9141424~9145435:+
THCA	cis	rs1538970	0.924	rs4660851	ENSG00000234329.1	RP11-767N6.2	3.34	0.00089	0.0488	0.15	0.15	Platelet count;	chr1:45378138	chr1:45651039~45651826:-
THCA	cis	rs9426935	0.604	rs3001365	ENSG00000231416.1	RP11-422P24.9	3.34	0.00089	0.0488	0.18	0.15	Lentiform nucleus volume;	chr1:154046706	chr1:153995632~153995960:+
THCA	cis	rs1005277	0.522	rs289649	ENSG00000120555.12	SEPT7P9	3.34	0.00089	0.0488	0.17	0.15	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38383069~38402916:-
THCA	cis	rs266717	0.844	rs266728	ENSG00000234197.1	ETV5-AS1	-3.34	0.00089	0.0488	-0.12	-0.15	Adiponectin levels;	chr3:186805512	chr3:186079170~186080947:+
THCA	cis	rs12083887	0.505	rs6672951	ENSG00000236866.4	AL157902.3	-3.34	0.00089	0.0488	-0.18	-0.15	Male-pattern baldness;	chr1:118369453	chr1:117596832~117605770:-
THCA	cis	rs6138458	0.717	rs2179732	ENSG00000274414.1	RP5-965G21.4	-3.34	0.00089	0.0488	-0.2	-0.15	Blood protein levels;	chr20:25019810	chr20:25239007~25245229:-
THCA	cis	rs7772486	0.875	rs9403765	ENSG00000270638.1	RP3-466P17.1	-3.34	0.00089	0.0488	-0.12	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145735570~145737218:+
THCA	cis	rs7439493	0.58	rs2107051	ENSG00000247950.5	SEC24B-AS1	3.34	0.00089	0.0488	0.1	0.15	Blood protein levels;	chr4:109658680	chr4:109347475~109433817:-
THCA	cis	rs7439493	0.58	rs12646055	ENSG00000247950.5	SEC24B-AS1	3.34	0.00089	0.0488	0.1	0.15	Blood protein levels;	chr4:109659760	chr4:109347475~109433817:-
THCA	cis	rs7439493	0.58	rs11098040	ENSG00000247950.5	SEC24B-AS1	3.34	0.00089	0.0488	0.1	0.15	Blood protein levels;	chr4:109659856	chr4:109347475~109433817:-
THCA	cis	rs10191559	0.919	rs72883527	ENSG00000238171.1	AC068196.1	-3.34	0.00089	0.0488	-0.19	-0.15	Red blood cell count;	chr2:180993442	chr2:181076051~181105968:-
THCA	cis	rs10191559	0.919	rs72883544	ENSG00000238171.1	AC068196.1	-3.34	0.00089	0.0488	-0.19	-0.15	Red blood cell count;	chr2:180998625	chr2:181076051~181105968:-
THCA	cis	rs7028939	0.892	rs10988966	ENSG00000255145.2	STX17-AS1	-3.34	0.00089	0.0488	-0.23	-0.15	Preeclampsia;	chr9:100087069	chr9:99886322~99906601:-
THCA	cis	rs7737355	1	rs7719126	ENSG00000237714.1	P4HA2-AS1	3.34	0.00089	0.0488	0.22	0.15	Life satisfaction;	chr5:131278056	chr5:132184876~132192808:+
THCA	cis	rs2275620	0.501	rs1853208	ENSG00000274691.1	RP11-310E22.6	-3.34	0.00089	0.0488	-0.17	-0.15	Gout;	chr10:94904062	chr10:95173085~95173187:-
THCA	cis	rs17122278	1	rs17122278	ENSG00000243431.1	RPL5P30	-3.34	0.000891	0.0488	-0.16	-0.15	Total cholesterol levels;	chr11:118578655	chr11:118560690~118561580:+
THCA	cis	rs12049351	0.774	rs1020353	ENSG00000229367.1	HMGN2P19	3.34	0.000891	0.0488	0.24	0.15	Circulating myeloperoxidase levels (plasma);	chr1:229561571	chr1:229570532~229570796:+
THCA	cis	rs12701220	0.553	rs9639882	ENSG00000225146.1	AC073957.15	3.34	0.000891	0.0488	0.2	0.15	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1029025~1043891:+
THCA	cis	rs747782	0.528	rs16905753	ENSG00000200090.1	Y_RNA	3.34	0.000891	0.0488	0.14	0.15	Intraocular pressure;	chr11:48264354	chr11:47726894~47726992:-
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000281021.1	RP1-12G14.9	-3.34	0.000891	0.0488	-0.15	-0.15	Lung cancer;	chr6:149650996	chr6:149576089~149590864:-
THCA	cis	rs9353324	1	rs58334368	ENSG00000280232.1	RP11-321N4.4	3.34	0.000891	0.0489	0.32	0.15	Interferon gamma-induced protein 10 levels;	chr6:85971591	chr6:85498441~85499058:-
THCA	cis	rs72827839	0.793	rs72823527	ENSG00000266601.1	RP11-6N17.3	3.34	0.000891	0.0489	0.18	0.15	Ease of getting up in the morning;	chr17:48021444	chr17:47929682~47933106:-
THCA	cis	rs224278	0.531	rs1999477	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000891	0.0489	-0.21	-0.15	Ewing sarcoma;	chr10:62886538	chr10:62793562~62805887:-
THCA	cis	rs2223471	0.776	rs10948570	ENSG00000060303.5	RPS17P5	3.34	0.000891	0.0489	0.18	0.15	Subcutaneous adipose tissue;	chr6:50678462	chr6:50857255~50857662:-
THCA	cis	rs7818688	1	rs10092003	ENSG00000253528.2	RP11-347C18.4	-3.34	0.000891	0.0489	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95024194	chr8:94974573~94974853:-
THCA	cis	rs7818688	1	rs11776189	ENSG00000253528.2	RP11-347C18.4	-3.34	0.000891	0.0489	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95024513	chr8:94974573~94974853:-
THCA	cis	rs1440410	0.965	rs57168887	ENSG00000250326.1	RP11-284M14.1	-3.34	0.000891	0.0489	-0.14	-0.15	Ischemic stroke;	chr4:143193042	chr4:142933195~143184861:-
THCA	cis	rs62025270	0.632	rs62022915	ENSG00000202081.1	RNU6-1280P	-3.34	0.000891	0.0489	-0.25	-0.15	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85651522~85651628:-
THCA	cis	rs4704187	0.687	rs6885887	ENSG00000250889.2	LINC01336	-3.34	0.000891	0.0489	-0.16	-0.15	Response to amphetamines;	chr5:75202017	chr5:75047719~75052843:-
THCA	cis	rs9428238	0.583	rs6664452	ENSG00000233154.4	RP4-655J12.4	3.34	0.000891	0.0489	0.19	0.15	Heart rate variability traits (SDNN);	chr1:115830305	chr1:116423724~116478842:-
THCA	cis	rs7702057	0.521	rs12654903	ENSG00000248445.4	SEMA6A-AS1	3.34	0.000891	0.0489	0.16	0.15	Amyotrophic lateral sclerosis;	chr5:116388669	chr5:116447547~116508276:+
THCA	cis	rs7615952	0.688	rs7624806	ENSG00000272840.1	RP11-379B18.6	3.34	0.000891	0.0489	0.25	0.15	Blood pressure (smoking interaction);	chr3:125880231	chr3:125774714~125797953:+
THCA	cis	rs77204473	0.744	rs2046149	ENSG00000276505.1	CMB9-94B1.2	-3.34	0.000891	0.0489	-0.29	-0.15	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117297005~117297328:-
THCA	cis	rs250585	0.79	rs2285521	ENSG00000260136.4	CTD-2270L9.4	-3.34	0.000891	0.0489	-0.14	-0.15	Egg allergy;	chr16:23510459	chr16:23452758~23457606:+
THCA	cis	rs7560272	0.512	rs2421677	ENSG00000230002.2	ALMS1-IT1	-3.34	0.000891	0.0489	-0.18	-0.15	Schizophrenia;	chr2:73738790	chr2:73456764~73459484:+
THCA	cis	rs7176527	0.579	rs366717	ENSG00000259570.1	RP11-671M22.4	-3.34	0.000891	0.0489	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84394512~84395514:+
THCA	cis	rs7713065	0.765	rs4371745	ENSG00000263597.1	MIR3936	3.34	0.000891	0.0489	0.19	0.15	Lung function (FEV1/FVC);	chr5:132444263	chr5:132365490~132365599:-
THCA	cis	rs6997458	0.576	rs10099251	ENSG00000254208.1	RP11-219B4.3	-3.34	0.000892	0.0489	-0.17	-0.15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85313204	chr8:85177522~85178150:-
THCA	cis	rs4788570	0.667	rs8052910	ENSG00000260185.1	RP11-432I5.6	-3.34	0.000892	0.0489	-0.3	-0.15	Intelligence (multi-trait analysis);	chr16:71756318	chr16:71655027~71664212:+
THCA	cis	rs11601239	0.535	rs2155045	ENSG00000254750.1	CASP1P2	-3.34	0.000892	0.0489	-0.12	-0.15	Refractive error;	chr11:105767804	chr11:105063345~105071541:-
THCA	cis	rs7246657	0.943	rs7252325	ENSG00000268499.1	CTB-102L5.8	3.34	0.000892	0.0489	0.19	0.15	Coronary artery calcification;	chr19:37439743	chr19:38199836~38200934:+
THCA	cis	rs1823913	0.538	rs11892998	ENSG00000280083.1	RP11-317J9.1	-3.34	0.000892	0.0489	-0.17	-0.15	Obesity-related traits;	chr2:191340159	chr2:191154118~191156070:-
THCA	cis	rs879324	0.689	rs12931021	ENSG00000280092.1	AC002044.3	-3.34	0.000892	0.0489	-0.23	-0.15	Stroke (ischemic);	chr16:72997275	chr16:73005601~73006141:-
THCA	cis	rs78487399	0.808	rs13414619	ENSG00000234936.1	AC010883.5	3.34	0.000892	0.0489	0.2	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43472267	chr2:43229573~43233394:+
THCA	cis	rs7520050	0.966	rs10890383	ENSG00000280836.1	AL355480.1	3.34	0.000892	0.0489	0.19	0.15	Reticulocyte count;Red blood cell count;	chr1:46122831	chr1:45581219~45581321:-
THCA	cis	rs17772222	0.63	rs12433739	ENSG00000222990.1	RNU4-22P	3.34	0.000892	0.0489	0.2	0.15	Coronary artery calcification;	chr14:88331704	chr14:88513498~88513663:+
THCA	cis	rs4073582	0.595	rs10896104	ENSG00000245156.1	RP11-867G23.3	3.34	0.000892	0.0489	0.13	0.15	Gout;	chr11:66234398	chr11:66269832~66278525:-
THCA	cis	rs6691738	0.959	rs61826341	ENSG00000227373.4	RP11-160H22.5	3.34	0.000892	0.0489	0.21	0.15	Asthma;	chr1:173173355	chr1:174115300~174160004:-
THCA	cis	rs11960179	0.764	rs10515085	ENSG00000250066.1	RP11-141O11.1	-3.34	0.000892	0.0489	-0.3	-0.15	Glomerular filtration rate (creatinine);	chr5:68466573	chr5:68963246~68967845:+
THCA	cis	rs12935229	0.709	rs7192938	ENSG00000260922.1	RP11-538I12.3	3.34	0.000892	0.0489	0.24	0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77362393	chr16:77234877~77290934:+
THCA	cis	rs66561647	0.853	rs66824612	ENSG00000207110.1	RNU1-106P	-3.34	0.000892	0.0489	-0.21	-0.15	Hemoglobin concentration;	chr8:127955573	chr8:127999131~127999294:+
THCA	cis	rs11711311	0.712	rs10804510	ENSG00000241529.3	RN7SL767P	-3.34	0.000892	0.0489	-0.22	-0.15	IgG glycosylation;	chr3:113621853	chr3:113632704~113632998:+
THCA	cis	rs13401620	0.917	rs6542549	ENSG00000236878.1	AC012363.7	-3.34	0.000892	0.0489	-0.18	-0.15	Breast size;	chr2:119769256	chr2:120211054~120211715:+
THCA	cis	rs12935418	0.561	rs2287991	ENSG00000261838.4	RP11-303E16.6	3.34	0.000892	0.0489	0.19	0.15	Mean corpuscular volume;	chr16:81006950	chr16:81069854~81076598:+
THCA	cis	rs6687821	0.531	rs6576861	ENSG00000261737.1	RP4-612B15.3	3.34	0.000892	0.0489	0.24	0.15	Yeast infection;	chr1:87030538	chr1:86703502~86704462:-
THCA	cis	rs561341	1	rs537166	ENSG00000265798.5	RP11-271K11.5	3.34	0.000892	0.0489	0.22	0.15	Hip circumference adjusted for BMI;	chr17:31999808	chr17:31038575~31059121:-
THCA	cis	rs2120243	0.539	rs988588	ENSG00000243176.4	RP11-550I24.2	3.34	0.000892	0.0489	0.15	0.15	Hepatocellular carcinoma in hepatitis B infection;	chr3:157336227	chr3:157175223~157381265:+
THCA	cis	rs852069	0.539	rs852097	ENSG00000212232.1	SNORD17	3.34	0.000892	0.0489	0.22	0.15	Menarche (age at onset);	chr20:17169980	chr20:17962710~17962946:-
THCA	cis	rs9326248	0.581	rs10892061	ENSG00000280143.1	AP000892.6	3.34	0.000892	0.0489	0.19	0.15	Blood protein levels;	chr11:117015398	chr11:117204967~117210292:+
THCA	cis	rs8030605	0.778	rs72740524	ENSG00000277245.1	RP11-48G14.3	3.34	0.000892	0.0489	0.28	0.15	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56265517	chr15:56447120~56447697:+
THCA	cis	rs894638	0.577	rs16868298	ENSG00000263327.5	TAPT1-AS1	-3.34	0.000892	0.0489	-0.18	-0.15	Glomerular filtration rate in chronic kidney disease;	chr4:16121197	chr4:16226685~16320140:+
THCA	cis	rs61160187	0.667	rs7722373	ENSG00000251279.1	CTC-436P18.1	-3.34	0.000892	0.0489	-0.18	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:61162070~61232040:+
THCA	cis	rs11673344	0.528	rs476194	ENSG00000267260.1	CTD-2162K18.4	-3.34	0.000892	0.0489	-0.19	-0.15	Obesity-related traits;	chr19:36919831	chr19:36773153~36777078:+
THCA	cis	rs7829975	0.509	rs2945269	ENSG00000248538.5	RP11-10A14.5	-3.34	0.000892	0.0489	-0.19	-0.15	Mood instability;	chr8:8258056	chr8:9189011~9202854:+
THCA	cis	rs2572431	0.505	rs13269118	ENSG00000255046.1	RP11-297N6.4	-3.34	0.000892	0.0489	-0.16	-0.15	Neuroticism;	chr8:11390305	chr8:11797928~11802568:-
THCA	cis	rs9309473	0.5	rs12996463	ENSG00000273245.1	RP11-434P11.2	-3.34	0.000892	0.0489	-0.18	-0.15	Metabolite levels;	chr2:73428368	chr2:73750256~73750786:-
THCA	cis	rs3770081	0.59	rs60838463	ENSG00000273080.1	RP11-301O19.1	-3.34	0.000892	0.0489	-0.39	-0.15	Facial emotion recognition (sad faces);	chr2:86216409	chr2:86195590~86196049:+
THCA	cis	rs10129255	0.957	rs61997760	ENSG00000280411.1	IGHV1-69-2	-3.34	0.000893	0.0489	-0.1	-0.15	Kawasaki disease;	chr14:106716993	chr14:106762092~106762588:-
THCA	cis	rs72928364	0.656	rs13096071	ENSG00000256628.3	ZBTB11-AS1	-3.34	0.000893	0.0489	-0.32	-0.15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101082799	chr3:101676475~101679217:+
THCA	cis	rs7219021	0.743	rs575556	ENSG00000248278.1	SUMO2P17	3.34	0.000893	0.0489	0.19	0.15	Schizophrenia or bipolar disorder;	chr17:48780125	chr17:48874860~48908983:-
THCA	cis	rs2274089	0.85	rs78975171	ENSG00000272810.1	U91328.22	-3.34	0.000893	0.0489	-0.24	-0.15	Iron status biomarkers;	chr6:25554683	chr6:26013241~26013757:+
THCA	cis	rs11030122	0.661	rs12290747	ENSG00000230593.3	AC090804.1	3.34	0.000893	0.0489	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3918420	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.702	rs7128762	ENSG00000230593.3	AC090804.1	3.34	0.000893	0.0489	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3922047	chr11:3892398~3892887:-
THCA	cis	rs11030122	0.702	rs7102215	ENSG00000230593.3	AC090804.1	3.34	0.000893	0.0489	0.2	0.15	Mean platelet volume;Platelet distribution width;	chr11:3922740	chr11:3892398~3892887:-
THCA	cis	rs9399186	1	rs12164028	ENSG00000272189.1	RP3-325F22.5	3.34	0.000893	0.0489	0.29	0.15	Pursuit maintenance gain;	chr6:136608797	chr6:136550661~136552554:+
THCA	cis	rs11638352	0.661	rs2615281	ENSG00000166763.7	STRCP1	3.34	0.000893	0.0489	0.26	0.15	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44158391	chr15:43699488~43718184:-
THCA	cis	rs791590	0.752	rs41295105	ENSG00000229664.1	RP11-536K7.5	-3.34	0.000893	0.0489	-0.24	-0.15	Soluble interleukin-2 receptor subunit alpha;	chr10:6080711	chr10:6025978~6036427:+
THCA	cis	rs2991971	0.933	rs666720	ENSG00000281133.1	AL355480.3	3.34	0.000893	0.0489	0.19	0.15	High light scatter reticulocyte count;	chr1:45555123	chr1:45580892~45580996:-
THCA	cis	rs9437689	0.714	rs7533303	ENSG00000235501.4	RP4-639F20.1	-3.34	0.000893	0.0489	-0.17	-0.15	Phospholipid levels (plasma);	chr1:94997415	chr1:94927566~94963270:+
THCA	cis	rs854765	0.929	rs2955360	ENSG00000281749.1	Y_RNA	-3.34	0.000893	0.0489	-0.2	-0.15	Total body bone mineral density;	chr17:18071573	chr17:18001101~18001195:-
THCA	cis	rs7647973	0.925	rs6446257	ENSG00000228638.1	FCF1P2	3.34	0.000893	0.0489	0.17	0.15	Menarche (age at onset);	chr3:49216059	chr3:48290793~48291375:-
THCA	cis	rs2117029	0.555	rs7958241	ENSG00000239617.1	RP11-302B13.1	3.34	0.000893	0.0489	0.18	0.15	Intelligence (multi-trait analysis);	chr12:49115479	chr12:48903418~48903813:-
THCA	cis	rs12893668	0.703	rs729438	ENSG00000244691.1	RPL10AP1	3.34	0.000893	0.0489	0.22	0.15	Reticulocyte count;	chr14:103626452	chr14:103412119~103412761:-
THCA	cis	rs8064029	0.881	rs72633271	ENSG00000267077.1	RP11-127I20.5	3.34	0.000893	0.0489	0.24	0.15	Cancer;	chr16:4853320	chr16:4795265~4796532:-
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000261839.1	RP1-265C24.8	3.34	0.000893	0.0489	0.15	0.15	Pubertal anthropometrics;	chr6:28271903	chr6:28136849~28139678:+
THCA	cis	rs2242330	0.651	rs7692528	ENSG00000250075.4	RP11-584P21.2	3.34	0.000893	0.0489	0.21	0.15	Parkinson's disease;	chr4:67589584	chr4:67417305~67468251:-
THCA	cis	rs2692947	0.832	rs2692954	ENSG00000235959.1	AC009237.17	-3.34	0.000893	0.049	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96017630	chr2:95640181~95640604:-
THCA	cis	rs17331151	0.505	rs13066389	ENSG00000242142.1	SERBP1P3	-3.34	0.000893	0.049	-0.32	-0.15	Immune reponse to smallpox (secreted IL-2);	chr3:52531301	chr3:53064283~53065091:-
THCA	cis	rs17331151	0.505	rs7614424	ENSG00000242142.1	SERBP1P3	-3.34	0.000893	0.049	-0.32	-0.15	Immune reponse to smallpox (secreted IL-2);	chr3:52532338	chr3:53064283~53065091:-
THCA	cis	rs293748	0.571	rs13177573	ENSG00000250155.1	CTD-2353F22.1	3.34	0.000893	0.049	0.18	0.15	Obesity-related traits;	chr5:37233335	chr5:36666214~36725195:-
THCA	cis	rs13113518	0.51	rs10049561	ENSG00000249700.7	SRD5A3-AS1	3.34	0.000893	0.049	0.19	0.15	Height;	chr4:55426623	chr4:55363971~55395847:-
THCA	cis	rs4919087	0.923	rs12357266	ENSG00000237169.1	RP11-452K12.3	-3.34	0.000893	0.049	-0.18	-0.15	Monocyte count;	chr10:97218288	chr10:97309138~97309958:-
THCA	cis	rs301901	0.796	rs4869520	ENSG00000250155.1	CTD-2353F22.1	3.34	0.000893	0.049	0.15	0.15	Height;	chr5:37508981	chr5:36666214~36725195:-
THCA	cis	rs4924935	0.646	rs8070707	ENSG00000235672.1	AC090286.2	3.34	0.000894	0.049	0.19	0.15	Pancreatic cancer;	chr17:18917144	chr17:18908279~18908865:+
THCA	cis	rs61677309	0.638	rs57461652	ENSG00000278376.1	RP11-158I9.8	3.34	0.000894	0.049	0.11	0.15	Lung cancer in ever smokers;	chr11:118275482	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.638	rs58162302	ENSG00000278376.1	RP11-158I9.8	3.34	0.000894	0.049	0.11	0.15	Lung cancer in ever smokers;	chr11:118275484	chr11:118791254~118793137:+
THCA	cis	rs61677309	0.638	rs58507982	ENSG00000278376.1	RP11-158I9.8	3.34	0.000894	0.049	0.11	0.15	Lung cancer in ever smokers;	chr11:118275795	chr11:118791254~118793137:+
THCA	cis	rs258324	0.79	rs258318	ENSG00000274627.1	RP11-104N10.2	3.34	0.000894	0.049	0.2	0.15	Height;	chr16:89665642	chr16:89516797~89522217:+
THCA	cis	rs12797204	1	rs35248605	ENSG00000246067.6	RAB30-AS1	-3.34	0.000894	0.049	-0.29	-0.15	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr11:83735059	chr11:83072066~83106719:+
THCA	cis	rs6694672	0.867	rs1764629	ENSG00000237861.1	RP11-332L8.1	3.34	0.000894	0.049	0.33	0.15	Asthma;	chr1:197247502	chr1:197222222~197223255:+
THCA	cis	rs11665867	0.941	rs112646411	ENSG00000237118.2	CYP2F2P	-3.34	0.000894	0.049	-0.28	-0.15	Hematocrit;	chr19:40812744	chr19:40818721~40826772:-
THCA	cis	rs12780845	1	rs3752950	ENSG00000273153.1	RP11-406H21.2	3.34	0.000894	0.049	0.15	0.15	Homocysteine levels;	chr10:17161357	chr10:17137336~17137585:-
THCA	cis	rs5753618	0.561	rs5753609	ENSG00000224050.1	RP1-90G24.6	-3.34	0.000894	0.049	-0.2	-0.15	Colorectal cancer;	chr22:31423226	chr22:32273420~32277186:+
THCA	cis	rs2832191	0.933	rs2832236	ENSG00000232855.5	AF131217.1	3.34	0.000894	0.049	0.16	0.15	Dental caries;	chr21:29175281	chr21:28439346~28674848:-
THCA	cis	rs11048434	0.736	rs12823100	ENSG00000245105.2	A2M-AS1	3.34	0.000894	0.049	0.11	0.15	Sjögren's syndrome;	chr12:8956312	chr12:9065177~9068060:+
THCA	cis	rs11048434	0.736	rs12424026	ENSG00000245105.2	A2M-AS1	3.34	0.000894	0.049	0.11	0.15	Sjögren's syndrome;	chr12:8958397	chr12:9065177~9068060:+
THCA	cis	rs11048434	0.736	rs2041624	ENSG00000245105.2	A2M-AS1	3.34	0.000894	0.049	0.11	0.15	Sjögren's syndrome;	chr12:8959259	chr12:9065177~9068060:+
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000188388.10	GOLGA6L3	-3.34	0.000894	0.049	-0.18	-0.15	P wave terminal force;	chr15:84631400	chr15:85240472~85247170:+
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000188388.10	GOLGA6L3	-3.34	0.000894	0.049	-0.18	-0.15	P wave terminal force;	chr15:84631524	chr15:85240472~85247170:+
THCA	cis	rs8040855	0.599	rs6496800	ENSG00000259630.2	CTD-2262B20.1	3.34	0.000894	0.049	0.17	0.15	Bulimia nervosa;	chr15:85185055	chr15:85415228~85415633:+
THCA	cis	rs3847153	1	rs3843553	ENSG00000228224.3	NACAP1	3.34	0.000894	0.049	0.25	0.15	Premature ovarian failure;	chr8:100802608	chr8:101361794~101372707:+
THCA	cis	rs8070740	0.559	rs58351927	ENSG00000234327.6	AC012146.7	-3.34	0.000894	0.049	-0.13	-0.15	Menopause (age at onset);	chr17:5393718	chr17:5111468~5115004:+
THCA	cis	rs651907	0.505	rs688058	ENSG00000256628.3	ZBTB11-AS1	3.34	0.000894	0.049	0.16	0.15	Colorectal cancer;	chr3:101866623	chr3:101676475~101679217:+
THCA	cis	rs3770081	0.793	rs58186343	ENSG00000273080.1	RP11-301O19.1	-3.34	0.000894	0.049	-0.36	-0.15	Facial emotion recognition (sad faces);	chr2:85991277	chr2:86195590~86196049:+
THCA	cis	rs7819412	0.645	rs4841508	ENSG00000206014.6	OR7E161P	3.34	0.000894	0.049	0.18	0.15	Triglycerides;	chr8:11207494	chr8:11928597~11929563:-
THCA	cis	rs2486012	1	rs2485989	ENSG00000237950.1	RP11-7O11.3	-3.34	0.000894	0.049	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43942782	chr1:43944370~43946551:-
THCA	cis	rs17275866	0.59	rs57897166	ENSG00000237125.7	HAND2-AS1	-3.34	0.000894	0.049	-0.23	-0.15	Chin dimples;	chr4:174159415	chr4:173527270~173591324:+
THCA	cis	rs17275866	0.632	rs55675569	ENSG00000237125.7	HAND2-AS1	-3.34	0.000894	0.049	-0.23	-0.15	Chin dimples;	chr4:174159443	chr4:173527270~173591324:+
THCA	cis	rs5993586	1	rs5746734	ENSG00000223461.1	AC004471.9	3.34	0.000894	0.049	0.33	0.15	Coronary artery disease;	chr22:19400145	chr22:19121529~19124503:+
THCA	cis	rs12753569	0.748	rs1013630	ENSG00000272855.1	RP5-1102E8.3	-3.34	0.000894	0.049	-0.19	-0.15	Personality dimensions;	chr1:76048134	chr1:76636877~76637339:+
THCA	cis	rs9329221	0.71	rs11785061	ENSG00000253641.4	RP11-981G7.2	3.34	0.000894	0.049	0.15	0.15	Neuroticism;	chr8:10402018	chr8:10474565~10481974:+
THCA	cis	rs910873	0.803	rs1885120	ENSG00000269202.1	RP4-614O4.12	-3.34	0.000894	0.049	-0.27	-0.15	Melanoma;	chr20:34989186	chr20:35201747~35203288:-
THCA	cis	rs7173964	1	rs8038040	ENSG00000259251.2	RP11-643M14.1	-3.34	0.000894	0.049	-0.15	-0.15	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr15:62102140	chr15:62060503~62062434:+
THCA	cis	rs7772486	0.875	rs2073287	ENSG00000270638.1	RP3-466P17.1	3.34	0.000894	0.049	0.12	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145735570~145737218:+
THCA	cis	rs911555	0.603	rs8016326	ENSG00000269910.1	RP11-73M18.10	3.34	0.000895	0.049	0.14	0.15	Intelligence (multi-trait analysis);	chr14:103380379	chr14:103694516~103695050:-
THCA	cis	rs12935418	0.616	rs9936366	ENSG00000261061.1	RP11-303E16.2	-3.34	0.000895	0.049	-0.15	-0.15	Mean corpuscular volume;	chr16:81011657	chr16:81030770~81031485:+
THCA	cis	rs62458065	0.713	rs62463968	ENSG00000231952.3	DPY19L1P2	3.34	0.000895	0.049	0.26	0.15	Metabolite levels (HVA/MHPG ratio);	chr7:32461630	chr7:32812757~32838570:+
THCA	cis	rs1891275	0.515	rs1418161	ENSG00000232709.1	MARK2P9	3.34	0.000895	0.049	0.17	0.15	Intelligence (multi-trait analysis);	chr10:91724898	chr10:92418667~92420875:+
THCA	cis	rs17331151	0.505	rs79979130	ENSG00000242142.1	SERBP1P3	-3.34	0.000895	0.049	-0.36	-0.15	Immune reponse to smallpox (secreted IL-2);	chr3:52516994	chr3:53064283~53065091:-
THCA	cis	rs45544231	1	rs3104777	ENSG00000279344.1	RP11-44F14.7	3.34	0.000895	0.049	0.14	0.15	Restless legs syndrome;	chr16:52598719	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs45500599	ENSG00000279344.1	RP11-44F14.7	-3.34	0.000895	0.049	-0.14	-0.15	Restless legs syndrome;	chr16:52598985	chr16:53478957~53481550:-
THCA	cis	rs9991779	0.666	rs6822061	ENSG00000237125.7	HAND2-AS1	-3.34	0.000895	0.049	-0.24	-0.15	Pediatric bone mineral content (hip);	chr4:173982163	chr4:173527270~173591324:+
THCA	cis	rs6496044	0.547	rs1564719	ENSG00000259407.1	RP11-158M2.3	-3.34	0.000895	0.049	-0.16	-0.15	Interstitial lung disease;	chr15:85511035	chr15:85744109~85750281:-
THCA	cis	rs17181170	0.532	rs6769886	ENSG00000239572.1	RP11-451B8.1	-3.34	0.000895	0.049	-0.19	-0.15	Prostate cancer;	chr3:87134733	chr3:87731402~87793629:-
THCA	cis	rs17291845	0.744	rs28675148	ENSG00000260135.5	RP11-212I21.2	3.34	0.000895	0.049	0.21	0.15	Information processing speed;	chr16:55214115	chr16:55426797~55462297:-
THCA	cis	rs11673344	0.504	rs1667378	ENSG00000233527.7	ZNF529-AS1	3.34	0.000895	0.049	0.13	0.15	Obesity-related traits;	chr19:37001171	chr19:36573070~36594708:+
THCA	cis	rs9549260	0.727	rs4603422	ENSG00000275149.1	RP11-427J23.1	-3.34	0.000895	0.049	-0.2	-0.15	Red blood cell count;	chr13:40574216	chr13:40079106~40273509:-
THCA	cis	rs10768122	0.524	rs7116432	ENSG00000255443.1	RP1-68D18.4	3.34	0.000895	0.049	0.13	0.15	Vitiligo;	chr11:35222511	chr11:35210343~35214985:-
THCA	cis	rs28510890	0.658	rs12442454	ENSG00000258647.4	LINC00930	3.34	0.000895	0.049	0.18	0.15	Lung cancer in ever smokers;	chr15:92615762	chr15:92567818~92572042:-
THCA	cis	rs76793172	1	rs16980027	ENSG00000207003.1	RNU6-611P	3.34	0.000895	0.049	0.28	0.15	Eosinophil counts;	chr19:45809847	chr19:45047458~45047561:+
THCA	cis	rs758324	0.812	rs1875176	ENSG00000237714.1	P4HA2-AS1	-3.34	0.000895	0.049	-0.21	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131866764	chr5:132184876~132192808:+
THCA	cis	rs14027	0.921	rs16893077	ENSG00000245330.4	KB-1471A8.1	3.34	0.000895	0.049	0.16	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119867419~119874488:-
THCA	cis	rs7819412	0.811	rs2409691	ENSG00000261451.1	RP11-981G7.1	-3.34	0.000895	0.049	-0.19	-0.15	Triglycerides;	chr8:11085766	chr8:10433672~10438312:+
THCA	cis	rs3087591	0.553	rs2854334	ENSG00000263535.1	AK4P1	3.34	0.000895	0.049	0.18	0.15	Hip circumference;	chr17:31388482	chr17:31345521~31346187:+
THCA	cis	rs2243480	0.901	rs3813708	ENSG00000273024.4	INTS4P2	3.34	0.000895	0.049	0.26	0.15	Diabetic kidney disease;	chr7:65840645	chr7:65647864~65715661:+
THCA	cis	rs1048886	0.872	rs10945231	ENSG00000271967.1	RP11-134K13.4	-3.34	0.000895	0.049	-0.18	-0.15	Type 2 diabetes;	chr6:70588060	chr6:70596438~70596980:+
THCA	cis	rs9608946	0.515	rs3804078	ENSG00000272689.1	RP4-539M6.21	3.34	0.000895	0.049	0.22	0.15	Red cell distribution width;	chr22:30457895	chr22:30421206~30421536:-
THCA	cis	rs12724450	0.793	rs34233130	ENSG00000228126.1	FALEC	3.34	0.000895	0.0491	0.31	0.15	Blood protein levels;	chr1:150477290	chr1:150515757~150518032:+
THCA	cis	rs2276314	0.857	rs4799408	ENSG00000267627.4	RP11-905K4.1	3.34	0.000896	0.0491	0.19	0.15	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35951803~35966118:-
THCA	cis	rs3096299	0.583	rs889574	ENSG00000260259.1	RP11-368I7.4	3.34	0.000896	0.0491	0.17	0.15	Multiple myeloma (IgH translocation);	chr16:89320400	chr16:89682620~89686569:-
THCA	cis	rs2120243	0.598	rs1500916	ENSG00000243176.4	RP11-550I24.2	3.34	0.000896	0.0491	0.15	0.15	Hepatocellular carcinoma in hepatitis B infection;	chr3:157370253	chr3:157175223~157381265:+
THCA	cis	rs7809950	0.954	rs3779494	ENSG00000272072.1	CTA-363E19.2	-3.34	0.000896	0.0491	-0.15	-0.15	Coronary artery disease;	chr7:107609910	chr7:107192559~107193300:-
THCA	cis	rs34421088	0.531	rs2245232	ENSG00000270154.1	RP11-419I17.1	-3.34	0.000896	0.0491	-0.19	-0.15	Neuroticism;	chr8:11543435	chr8:12476462~12477122:+
THCA	cis	rs972578	1	rs5759067	ENSG00000230319.1	AL022476.2	3.34	0.000896	0.0491	0.16	0.15	Mean platelet volume;	chr22:42976793	chr22:43038585~43052366:+
THCA	cis	rs10419113	0.522	rs6510102	ENSG00000269794.1	AC010642.2	-3.34	0.000896	0.0491	-0.16	-0.15	Pediatric bone mineral density (spine);	chr19:57797273	chr19:58319277~58320489:+
THCA	cis	rs10266483	0.774	rs10253630	ENSG00000234338.1	RP11-797H7.1	-3.34	0.000896	0.0491	-0.11	-0.15	Response to statin therapy;	chr7:64366962	chr7:64835280~64836882:-
THCA	cis	rs45544231	1	rs3104772	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52595414	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs3112622	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52595591	chr16:53478957~53481550:-
THCA	cis	rs45544231	0.966	rs3104775	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52595915	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs3112618	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52597274	chr16:53478957~53481550:-
THCA	cis	rs45544231	0.966	rs3104776	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52597550	chr16:53478957~53481550:-
THCA	cis	rs45544231	0.932	rs3112616	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52597835	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs11075551	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52598052	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs3112615	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52598438	chr16:53478957~53481550:-
THCA	cis	rs45544231	0.966	rs3104778	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52599740	chr16:53478957~53481550:-
THCA	cis	rs45544231	0.932	rs3104779	ENSG00000279344.1	RP11-44F14.7	3.34	0.000896	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52599745	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs11860998	ENSG00000279344.1	RP11-44F14.7	-3.34	0.000896	0.0491	-0.14	-0.15	Restless legs syndrome;	chr16:52594506	chr16:53478957~53481550:-
THCA	cis	rs45544231	1	rs11861036	ENSG00000279344.1	RP11-44F14.7	-3.34	0.000896	0.0491	-0.14	-0.15	Restless legs syndrome;	chr16:52594652	chr16:53478957~53481550:-
THCA	cis	rs6495122	0.699	rs34862454	ENSG00000260269.4	CTD-2323K18.1	-3.34	0.000896	0.0491	-0.22	-0.15	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:74809189	chr15:75527150~75601205:-
THCA	cis	rs936229	0.511	rs12591513	ENSG00000260269.4	CTD-2323K18.1	-3.34	0.000896	0.0491	-0.22	-0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr15:74810373	chr15:75527150~75601205:-
THCA	cis	rs10435719	0.867	rs6999030	ENSG00000227888.4	FAM66A	3.34	0.000896	0.0491	0.2	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:12362019~12388296:+
THCA	cis	rs10435719	0.834	rs6985792	ENSG00000227888.4	FAM66A	3.34	0.000896	0.0491	0.2	0.15	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:12362019~12388296:+
THCA	cis	rs13046373	0.535	rs9977510	ENSG00000174680.8	GRIK1-AS1	-3.34	0.000896	0.0491	-0.18	-0.15	HDL cholesterol;	chr21:30655602	chr21:29748175~29764002:+
THCA	cis	rs9987353	0.522	rs2929466	ENSG00000254340.1	RP11-10A14.3	-3.34	0.000896	0.0491	-0.17	-0.15	Recombination measurement;	chr8:9206389	chr8:9141424~9145435:+
THCA	cis	rs4703129	0.934	rs1978419	ENSG00000246763.5	RGMB-AS1	-3.34	0.000896	0.0491	-0.15	-0.15	Asperger disorder;	chr5:98532166	chr5:98769618~98773469:-
THCA	cis	rs4703129	1	rs6865579	ENSG00000246763.5	RGMB-AS1	-3.34	0.000896	0.0491	-0.15	-0.15	Asperger disorder;	chr5:98532425	chr5:98769618~98773469:-
THCA	cis	rs4703129	1	rs1345572	ENSG00000246763.5	RGMB-AS1	-3.34	0.000896	0.0491	-0.15	-0.15	Asperger disorder;	chr5:98536662	chr5:98769618~98773469:-
THCA	cis	rs2357982	0.556	rs7605436	ENSG00000232320.6	AC009299.5	-3.34	0.000896	0.0491	-0.2	-0.15	Presence of antiphospholipid antibodies;	chr2:161032879	chr2:161340816~161341326:-
THCA	cis	rs4773860	0.717	rs9556466	ENSG00000223298.1	RNY3P8	-3.34	0.000896	0.0491	-0.18	-0.15	Plateletcrit;	chr13:95247817	chr13:95310830~95310955:-
THCA	cis	rs6840360	1	rs7663045	ENSG00000251611.1	RP11-610P16.1	-3.34	0.000896	0.0491	-0.11	-0.15	Intelligence (multi-trait analysis);	chr4:151755198	chr4:151407551~151408835:-
THCA	cis	rs4948275	0.606	rs2787719	ENSG00000233643.2	RP11-491H19.1	3.34	0.000896	0.0491	0.17	0.15	Night sleep phenotypes;	chr10:61573465	chr10:61781745~61821246:-
THCA	cis	rs3135718	0.967	rs1219651	ENSG00000276742.1	RP11-500G22.4	3.34	0.000896	0.0491	0.18	0.15	Estrogen receptor status in breast cancer;	chr10:121584987	chr10:121956782~121957098:+
THCA	cis	rs739496	0.579	rs57427612	ENSG00000234608.6	MAPKAPK5-AS1	3.34	0.000896	0.0491	0.14	0.15	Platelet count;	chr12:111856192	chr12:111839764~111842902:-
THCA	cis	rs3105593	1	rs4775897	ENSG00000242737.1	RP11-562A8.1	3.34	0.000896	0.0491	0.2	0.15	QT interval;	chr15:50651869	chr15:50466738~50467096:+
THCA	cis	rs7631605	0.608	rs62241903	ENSG00000224080.1	UBE2FP1	3.34	0.000896	0.0491	0.18	0.15	Cerebrospinal P-tau181p levels;	chr3:37388000	chr3:37143512~37143958:-
THCA	cis	rs7264396	0.635	rs7263302	ENSG00000088340.14	FER1L4	3.34	0.000896	0.0491	0.15	0.15	Total cholesterol levels;	chr20:35957936	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs6060719	ENSG00000088340.14	FER1L4	3.34	0.000896	0.0491	0.15	0.15	Total cholesterol levels;	chr20:35958091	chr20:35558737~35607562:-
THCA	cis	rs7264396	0.635	rs6058378	ENSG00000088340.14	FER1L4	3.34	0.000896	0.0491	0.15	0.15	Total cholesterol levels;	chr20:35958736	chr20:35558737~35607562:-
THCA	cis	rs8070740	0.559	rs12600578	ENSG00000234327.6	AC012146.7	-3.34	0.000896	0.0491	-0.13	-0.15	Menopause (age at onset);	chr17:5396630	chr17:5111468~5115004:+
THCA	cis	rs3750082	0.852	rs34724897	ENSG00000205763.12	RP9P	-3.34	0.000896	0.0491	-0.13	-0.15	Glomerular filtration rate (creatinine);	chr7:32859914	chr7:32916815~32943176:-
THCA	cis	rs56046484	0.912	rs12914674	ENSG00000218052.5	ADAMTS7P4	-3.34	0.000896	0.0491	-0.23	-0.15	Testicular germ cell tumor;	chr15:85119829	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.956	rs34889576	ENSG00000218052.5	ADAMTS7P4	-3.34	0.000896	0.0491	-0.23	-0.15	Testicular germ cell tumor;	chr15:85121445	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.956	rs34076898	ENSG00000218052.5	ADAMTS7P4	-3.34	0.000896	0.0491	-0.23	-0.15	Testicular germ cell tumor;	chr15:85121569	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.956	rs35533990	ENSG00000218052.5	ADAMTS7P4	-3.34	0.000896	0.0491	-0.23	-0.15	Testicular germ cell tumor;	chr15:85121590	chr15:85255369~85330334:-
THCA	cis	rs56046484	0.956	rs35045545	ENSG00000218052.5	ADAMTS7P4	-3.34	0.000896	0.0491	-0.23	-0.15	Testicular germ cell tumor;	chr15:85121720	chr15:85255369~85330334:-
THCA	cis	rs7474896	0.583	rs11011346	ENSG00000120555.12	SEPT7P9	3.34	0.000896	0.0491	0.2	0.15	Obesity (extreme);	chr10:37720555	chr10:38383069~38402916:-
THCA	cis	rs3020736	0.5	rs5996111	ENSG00000270083.1	RP1-257I20.14	-3.34	0.000896	0.0491	-0.18	-0.15	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42089630~42090028:-
THCA	cis	rs854765	0.583	rs9913724	ENSG00000265511.1	RP11-524F11.1	3.34	0.000896	0.0491	0.12	0.15	Total body bone mineral density;	chr17:17915787	chr17:17507351~17508308:+
THCA	cis	rs854765	0.583	rs7207043	ENSG00000265511.1	RP11-524F11.1	3.34	0.000896	0.0491	0.12	0.15	Total body bone mineral density;	chr17:17915874	chr17:17507351~17508308:+
THCA	cis	rs854765	0.583	rs6502622	ENSG00000265511.1	RP11-524F11.1	3.34	0.000896	0.0491	0.12	0.15	Total body bone mineral density;	chr17:17931377	chr17:17507351~17508308:+
THCA	cis	rs11702966	0.61	rs78873334	ENSG00000231711.2	LINC00899	3.34	0.000896	0.0491	0.2	0.15	Tonsillectomy;	chr22:45837862	chr22:46039907~46044853:-
THCA	cis	rs944801	0.587	rs7049105	ENSG00000229298.1	TUBB8P1	-3.34	0.000896	0.0491	-0.16	-0.15	Type 2 diabetes;	chr9:22028802	chr9:21811621~21812347:-
THCA	cis	rs7914558	1	rs10883826	ENSG00000213061.2	PFN1P11	3.34	0.000896	0.0491	0.18	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:102838011~102845473:-
THCA	cis	rs34975555	0.892	rs13266666	ENSG00000253671.1	RP11-806O11.1	-3.34	0.000896	0.0491	-0.26	-0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17999839	chr8:17808941~17820868:+
THCA	cis	rs34975555	0.892	rs13256296	ENSG00000253671.1	RP11-806O11.1	-3.34	0.000896	0.0491	-0.26	-0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17999907	chr8:17808941~17820868:+
THCA	cis	rs3126085	0.935	rs4595369	ENSG00000237975.5	FLG-AS1	-3.34	0.000896	0.0491	-0.24	-0.15	Atopic dermatitis;	chr1:152275717	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs4634913	ENSG00000237975.5	FLG-AS1	-3.34	0.000896	0.0491	-0.24	-0.15	Atopic dermatitis;	chr1:152277456	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs4534386	ENSG00000237975.5	FLG-AS1	-3.34	0.000896	0.0491	-0.24	-0.15	Atopic dermatitis;	chr1:152279238	chr1:152168125~152445456:+
THCA	cis	rs3126085	1	rs11485508	ENSG00000237975.5	FLG-AS1	-3.34	0.000896	0.0491	-0.24	-0.15	Atopic dermatitis;	chr1:152280691	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs12027807	ENSG00000237975.5	FLG-AS1	-3.34	0.000896	0.0491	-0.24	-0.15	Atopic dermatitis;	chr1:152281250	chr1:152168125~152445456:+
THCA	cis	rs3126085	1	rs4845756	ENSG00000237975.5	FLG-AS1	-3.34	0.000896	0.0491	-0.24	-0.15	Atopic dermatitis;	chr1:152282443	chr1:152168125~152445456:+
THCA	cis	rs2235642	0.582	rs11643891	ENSG00000280231.1	LA16c-380F5.3	-3.34	0.000897	0.0491	-0.19	-0.15	Coronary artery disease;	chr16:1515539	chr16:1553655~1554130:-
THCA	cis	rs3087591	0.708	rs17885030	ENSG00000263535.1	AK4P1	3.34	0.000897	0.0491	0.18	0.15	Hip circumference;	chr17:31328200	chr17:31345521~31346187:+
THCA	cis	rs9309711	0.643	rs10188449	ENSG00000235078.1	AC142528.1	-3.34	0.000897	0.0491	-0.14	-0.15	Neurofibrillary tangles;	chr2:3476595	chr2:3519275~3523197:+
THCA	cis	rs4589258	0.788	rs10765377	ENSG00000280367.1	RP11-121L10.2	3.34	0.000897	0.0491	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90721525	chr11:90223153~90226538:+
THCA	cis	rs4589258	0.788	rs10830563	ENSG00000280367.1	RP11-121L10.2	3.34	0.000897	0.0491	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90721581	chr11:90223153~90226538:+
THCA	cis	rs67981189	0.537	rs917067	ENSG00000269927.1	RP6-91H8.3	-3.34	0.000897	0.0491	-0.17	-0.15	Schizophrenia;	chr14:70905187	chr14:71141125~71143253:-
THCA	cis	rs4792901	0.765	rs35557239	ENSG00000279602.1	CTD-3014M21.1	-3.34	0.000897	0.0491	-0.2	-0.15	Dupuytren's disease;	chr17:43470907	chr17:43360041~43361361:-
THCA	cis	rs12544026	0.581	rs1148497	ENSG00000253669.3	KB-1732A1.1	-3.34	0.000897	0.0491	-0.17	-0.15	Major depression and alcohol dependence;	chr8:101844289	chr8:102805517~102809971:+
THCA	cis	rs6517329	0.564	rs67013231	ENSG00000233393.1	AP000688.29	3.34	0.000897	0.0491	0.19	0.15	Schizophrenia;	chr21:36133804	chr21:36104881~36109690:+
THCA	cis	rs6847067	0.8	rs12506456	ENSG00000180769.7	WDFY3-AS2	3.34	0.000897	0.0491	0.11	0.15	Oropharynx cancer;	chr4:84937095	chr4:84965682~85011277:+
THCA	cis	rs6847067	0.8	rs12503215	ENSG00000180769.7	WDFY3-AS2	3.34	0.000897	0.0491	0.11	0.15	Oropharynx cancer;	chr4:84937335	chr4:84965682~85011277:+
THCA	cis	rs12612619	0.732	rs1078809	ENSG00000231636.1	AGBL5-AS1	3.34	0.000897	0.0491	0.18	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27066047	chr2:27049683~27050264:-
THCA	cis	rs12612619	0.732	rs10865461	ENSG00000231636.1	AGBL5-AS1	3.34	0.000897	0.0491	0.18	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27069783	chr2:27049683~27050264:-
THCA	cis	rs12612619	0.732	rs1053609	ENSG00000231636.1	AGBL5-AS1	3.34	0.000897	0.0491	0.18	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27070282	chr2:27049683~27050264:-
THCA	cis	rs2486012	1	rs2428963	ENSG00000237950.1	RP11-7O11.3	-3.34	0.000897	0.0491	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43907767	chr1:43944370~43946551:-
THCA	cis	rs3824488	0.92	rs80155616	ENSG00000271384.1	RP11-435O5.7	-3.34	0.000897	0.0491	-0.25	-0.15	Neuroticism;	chr9:95481586	chr9:95406990~95407662:-
THCA	cis	rs3824488	0.92	rs28510415	ENSG00000271384.1	RP11-435O5.7	-3.34	0.000897	0.0491	-0.25	-0.15	Neuroticism;	chr9:95482744	chr9:95406990~95407662:-
THCA	cis	rs10504130	0.696	rs79740712	ENSG00000272024.1	RP11-546K22.3	-3.34	0.000897	0.0491	-0.17	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51925750	chr8:51950284~51950690:+
THCA	cis	rs7216064	0.531	rs62084683	ENSG00000267023.4	LRRC37A16P	3.34	0.000897	0.0491	0.11	0.15	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68035609	chr17:68125777~68152468:-
THCA	cis	rs1023500	1	rs7293091	ENSG00000237037.8	NDUFA6-AS1	3.34	0.000897	0.0491	0.15	0.15	Schizophrenia;	chr22:41945304	chr22:42090931~42137742:+
THCA	cis	rs2806561	0.929	rs6694445	ENSG00000249087.5	ZNF436-AS1	-3.34	0.000897	0.0491	-0.09	-0.15	Height;	chr1:23213935	chr1:23368997~23371839:+
THCA	cis	rs45544231	1	rs3104789	ENSG00000279344.1	RP11-44F14.7	3.34	0.000897	0.0491	0.14	0.15	Restless legs syndrome;	chr16:52604636	chr16:53478957~53481550:-
THCA	cis	rs2150410	0.833	rs2735310	ENSG00000255568.3	BRWD1-AS2	3.34	0.000897	0.0491	0.19	0.15	Temperament (bipolar disorder);	chr21:39345574	chr21:39313935~39314962:+
THCA	cis	rs683250	0.661	rs2507854	ENSG00000254551.1	RP11-727A23.7	-3.34	0.000897	0.0491	-0.18	-0.15	Subcortical brain region volumes;	chr11:83417189	chr11:83209431~83213379:-
THCA	cis	rs5769765	0.778	rs4574208	ENSG00000278869.1	CITF22-49E9.3	-3.34	0.000897	0.0491	-0.2	-0.15	Schizophrenia;	chr22:49863090	chr22:49933198~49934074:-
THCA	cis	rs1832871	0.711	rs12525147	ENSG00000213078.3	RP5-933K21.2	-3.34	0.000897	0.0491	-0.23	-0.15	Height;	chr6:158262477	chr6:157365990~157366923:-
THCA	cis	rs11048434	0.736	rs11048344	ENSG00000245105.2	A2M-AS1	3.34	0.000897	0.0491	0.11	0.15	Sjögren's syndrome;	chr12:8970013	chr12:9065177~9068060:+
THCA	cis	rs11048434	0.736	rs11048345	ENSG00000245105.2	A2M-AS1	3.34	0.000897	0.0491	0.11	0.15	Sjögren's syndrome;	chr12:8970460	chr12:9065177~9068060:+
THCA	cis	rs7474896	0.515	rs675628	ENSG00000272983.1	RP11-508N22.12	3.34	0.000897	0.0491	0.16	0.15	Obesity (extreme);	chr10:38016403	chr10:38137337~38144399:+
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000281021.1	RP1-12G14.9	-3.34	0.000897	0.0491	-0.15	-0.15	Lung cancer;	chr6:149637911	chr6:149576089~149590864:-
THCA	cis	rs2292096	1	rs12733378	ENSG00000260088.1	RP11-92G12.3	3.34	0.000897	0.0491	0.31	0.15	Epilepsy;	chr1:200858678	chr1:200669507~200694250:+
THCA	cis	rs7141336	0.607	rs7158495	ENSG00000275198.1	RP11-471B22.3	-3.34	0.000897	0.0491	-0.14	-0.15	Anxiety disorder;	chr14:90745531	chr14:90383365~90387973:+
THCA	cis	rs45544231	1	rs3104774	ENSG00000279344.1	RP11-44F14.7	-3.34	0.000897	0.0491	-0.14	-0.15	Restless legs syndrome;	chr16:52595790	chr16:53478957~53481550:-
THCA	cis	rs9907295	1	rs9901195	ENSG00000270871.1	AC015849.19	3.34	0.000897	0.0491	0.13	0.15	Fibroblast growth factor basic levels;	chr17:35915576	chr17:35816717~35830293:-
THCA	cis	rs11782517	0.924	rs35222693	ENSG00000261451.1	RP11-981G7.1	3.34	0.000897	0.0491	0.2	0.15	Nose size;	chr8:10251280	chr8:10433672~10438312:+
THCA	cis	rs6088813	0.961	rs6060373	ENSG00000261582.1	RP4-614O4.11	3.34	0.000897	0.0491	0.14	0.15	Height;	chr20:35326405	chr20:35267885~35280043:-
THCA	cis	rs9858542	0.537	rs34915642	ENSG00000270441.1	RP11-694I15.7	3.34	0.000897	0.0491	0.17	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49321213	chr3:49140086~49160851:-
THCA	cis	rs4703129	1	rs11740633	ENSG00000246763.5	RGMB-AS1	-3.34	0.000897	0.0491	-0.15	-0.15	Asperger disorder;	chr5:98511897	chr5:98769618~98773469:-
THCA	cis	rs4857855	0.673	rs7610175	ENSG00000239405.1	TMED10P2	3.34	0.000897	0.0491	0.2	0.15	Eosinophil counts;	chr3:128530149	chr3:128538020~128538631:+
THCA	cis	rs4857855	0.673	rs9860081	ENSG00000239405.1	TMED10P2	3.34	0.000897	0.0491	0.2	0.15	Eosinophil counts;	chr3:128530430	chr3:128538020~128538631:+
THCA	cis	rs7208859	0.673	rs1347360	ENSG00000265443.1	CTD-2349P21.6	-3.34	0.000897	0.0491	-0.25	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30726305~30727564:-
THCA	cis	rs13053817	1	rs73405097	ENSG00000279159.1	RP3-394A18.1	3.34	0.000897	0.0491	0.15	0.15	Carotid atherosclerosis in HIV infection;	chr22:29459847	chr22:29978950~30028236:-
THCA	cis	rs13053817	1	rs7290684	ENSG00000279159.1	RP3-394A18.1	3.34	0.000897	0.0491	0.15	0.15	Carotid atherosclerosis in HIV infection;	chr22:29461675	chr22:29978950~30028236:-
THCA	cis	rs13053817	0.898	rs7291001	ENSG00000279159.1	RP3-394A18.1	3.34	0.000897	0.0491	0.15	0.15	Carotid atherosclerosis in HIV infection;	chr22:29461870	chr22:29978950~30028236:-
THCA	cis	rs10995356	0.772	rs10822093	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000897	0.0491	-0.18	-0.15	Temperament;	chr10:62945379	chr10:62793562~62805887:-
THCA	cis	rs10995356	0.872	rs2065449	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000897	0.0491	-0.18	-0.15	Temperament;	chr10:62949281	chr10:62793562~62805887:-
THCA	cis	rs1153858	1	rs12439274	ENSG00000275672.1	GATM-AS1	-3.34	0.000897	0.0491	-0.16	-0.15	Homoarginine levels;	chr15:45344469	chr15:45378700~45380123:+
THCA	cis	rs877529	0.967	rs139411	ENSG00000279833.1	RP4-742C19.13	-3.34	0.000897	0.0491	-0.1	-0.15	Multiple myeloma;	chr22:39156883	chr22:39133090~39136760:+
THCA	cis	rs3757458	1	rs17135348	ENSG00000078319.8	PMS2P1	3.34	0.000897	0.0491	0.31	0.15	QT interval;	chr7:101237799	chr7:100320992~100341908:-
THCA	cis	rs8031584	0.918	rs35396566	ENSG00000259845.1	HERC2P10	3.34	0.000897	0.0491	0.22	0.15	Huntington's disease progression;	chr15:30970854	chr15:30815271~30844153:+
THCA	cis	rs8031584	1	rs35607976	ENSG00000259845.1	HERC2P10	3.34	0.000897	0.0491	0.22	0.15	Huntington's disease progression;	chr15:30985585	chr15:30815271~30844153:+
THCA	cis	rs854765	0.583	rs11078404	ENSG00000265511.1	RP11-524F11.1	3.34	0.000897	0.0491	0.12	0.15	Total body bone mineral density;	chr17:17917173	chr17:17507351~17508308:+
THCA	cis	rs11678825	0.852	rs11692537	ENSG00000272663.1	RP11-191L17.1	-3.34	0.000897	0.0491	-0.21	-0.15	Reticulocyte fraction of red cells;	chr2:48443032	chr2:48440043~48440597:-
THCA	cis	rs11678825	0.852	rs76984715	ENSG00000272663.1	RP11-191L17.1	-3.34	0.000897	0.0491	-0.21	-0.15	Reticulocyte fraction of red cells;	chr2:48443863	chr2:48440043~48440597:-
THCA	cis	rs11678825	0.852	rs77961213	ENSG00000272663.1	RP11-191L17.1	-3.34	0.000897	0.0491	-0.21	-0.15	Reticulocyte fraction of red cells;	chr2:48445228	chr2:48440043~48440597:-
THCA	cis	rs11678825	0.852	rs75150625	ENSG00000272663.1	RP11-191L17.1	-3.34	0.000897	0.0491	-0.21	-0.15	Reticulocyte fraction of red cells;	chr2:48445234	chr2:48440043~48440597:-
THCA	cis	rs3737883	1	rs11579055	ENSG00000229652.1	RP11-435P24.2	3.34	0.000897	0.0491	0.16	0.15	Early onset atrial fibrillation;	chr1:203062187	chr1:203353365~203353651:-
THCA	cis	rs755249	0.53	rs16826087	ENSG00000237624.1	OXCT2P1	3.34	0.000898	0.0491	0.21	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39514956~39516490:+
THCA	cis	rs12701220	0.655	rs7778968	ENSG00000225146.1	AC073957.15	3.34	0.000898	0.0491	0.2	0.15	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1029025~1043891:+
THCA	cis	rs11708578	0.554	rs72996019	ENSG00000237990.3	CNTN4-AS1	3.34	0.000898	0.0491	0.19	0.15	Schizophrenia;	chr3:2388112	chr3:3039033~3069242:-
THCA	cis	rs4753788	0.511	rs12224337	ENSG00000255353.1	RP11-382M14.1	-3.34	0.000898	0.0491	-0.18	-0.15	Coronary artery disease;	chr11:107269351	chr11:107176286~107177530:+
THCA	cis	rs7819412	0.635	rs4841501	ENSG00000255052.4	FAM66D	3.34	0.000898	0.0491	0.21	0.15	Triglycerides;	chr8:11143466	chr8:12115782~12177550:+
THCA	cis	rs7209700	0.963	rs1000232	ENSG00000262879.4	RP11-156P1.3	3.34	0.000898	0.0491	0.15	0.15	IgG glycosylation;	chr17:47279195	chr17:46984045~47100323:-
THCA	cis	rs8041447	0.896	rs11635027	ENSG00000259248.4	USP3-AS1	-3.34	0.000898	0.0491	-0.11	-0.15	Immature fraction of reticulocytes;	chr15:62775339	chr15:63544247~63601589:-
THCA	cis	rs12428035	0.764	rs568170	ENSG00000247400.3	DNAJC3-AS1	3.34	0.000898	0.0492	0.15	0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96112539	chr13:95648733~95676925:-
THCA	cis	rs12428035	0.764	rs493423	ENSG00000247400.3	DNAJC3-AS1	3.34	0.000898	0.0492	0.15	0.15	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96117228	chr13:95648733~95676925:-
THCA	cis	rs964611	0.938	rs8026751	ENSG00000259488.2	RP11-154J22.1	-3.34	0.000898	0.0492	-0.14	-0.15	Metabolite levels (Pyroglutamine);	chr15:48290648	chr15:48312353~48331856:-
THCA	cis	rs8054556	1	rs4318227	ENSG00000214725.6	CDIPT-AS1	-3.34	0.000898	0.0492	-0.19	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29973518	chr16:29863593~29868053:+
THCA	cis	rs7246967	0.866	rs115497901	ENSG00000269364.1	LINC01233	-3.34	0.000898	0.0492	-0.22	-0.15	Bronchopulmonary dysplasia;	chr19:22859959	chr19:22532626~22533494:+
THCA	cis	rs237743	1	rs13038202	ENSG00000222365.1	SNORD12B	-3.34	0.000898	0.0492	-0.19	-0.15	Height;	chr20:49219081	chr20:49280319~49280409:+
THCA	cis	rs237743	1	rs9753608	ENSG00000222365.1	SNORD12B	-3.34	0.000898	0.0492	-0.19	-0.15	Height;	chr20:49220669	chr20:49280319~49280409:+
THCA	cis	rs237743	1	rs2273145	ENSG00000222365.1	SNORD12B	-3.34	0.000898	0.0492	-0.19	-0.15	Height;	chr20:49223054	chr20:49280319~49280409:+
THCA	cis	rs237743	1	rs11553387	ENSG00000222365.1	SNORD12B	-3.34	0.000898	0.0492	-0.19	-0.15	Height;	chr20:49225123	chr20:49280319~49280409:+
THCA	cis	rs919433	1	rs919433	ENSG00000222017.1	AC011997.1	3.34	0.000898	0.0492	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301841	chr2:197693106~197774823:+
THCA	cis	rs13108904	0.905	rs34490749	ENSG00000254094.1	AC078852.1	-3.34	0.000898	0.0492	-0.18	-0.15	Obesity-related traits;	chr4:1224193	chr4:1356581~1358075:+
THCA	cis	rs875971	0.545	rs316324	ENSG00000230295.1	RP11-458F8.2	-3.34	0.000898	0.0492	-0.13	-0.15	Aortic root size;	chr7:66145627	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000230295.1	RP11-458F8.2	-3.34	0.000898	0.0492	-0.13	-0.15	Aortic root size;	chr7:66146002	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000230295.1	RP11-458F8.2	-3.34	0.000898	0.0492	-0.13	-0.15	Aortic root size;	chr7:66152984	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000230295.1	RP11-458F8.2	3.34	0.000898	0.0492	0.13	0.15	Aortic root size;	chr7:66158946	chr7:66880708~66882981:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000230295.1	RP11-458F8.2	3.34	0.000898	0.0492	0.13	0.15	Aortic root size;	chr7:66160135	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000230295.1	RP11-458F8.2	3.34	0.000898	0.0492	0.13	0.15	Aortic root size;	chr7:66161064	chr7:66880708~66882981:+
THCA	cis	rs10208649	0.536	rs13423576	ENSG00000233266.1	HMGB1P31	3.34	0.000898	0.0492	0.27	0.15	Body mass index;	chr2:53737028	chr2:54051334~54051760:+
THCA	cis	rs10208649	0.536	rs13414183	ENSG00000233266.1	HMGB1P31	3.34	0.000898	0.0492	0.27	0.15	Body mass index;	chr2:53738387	chr2:54051334~54051760:+
THCA	cis	rs7615952	0.576	rs66671308	ENSG00000241288.6	RP11-379B18.5	-3.34	0.000898	0.0492	-0.17	-0.15	Blood pressure (smoking interaction);	chr3:126074683	chr3:125827238~125916384:-
THCA	cis	rs3617	0.573	rs12638968	ENSG00000243224.1	RP5-1157M23.2	3.34	0.000898	0.0492	0.16	0.15	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52885431	chr3:52239258~52241097:+
THCA	cis	rs743757	0.701	rs34202063	ENSG00000232352.1	SEMA3B-AS1	3.34	0.000898	0.0492	0.23	0.15	Diastolic blood pressure;	chr3:50593383	chr3:50266641~50267371:-
THCA	cis	rs743757	0.652	rs13094336	ENSG00000232352.1	SEMA3B-AS1	3.34	0.000898	0.0492	0.23	0.15	Diastolic blood pressure;	chr3:50595439	chr3:50266641~50267371:-
THCA	cis	rs1577917	0.876	rs66986937	ENSG00000220563.1	PKMP3	-3.34	0.000898	0.0492	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85822473	chr6:85659892~85660606:-
THCA	cis	rs11089937	0.568	rs5756989	ENSG00000215456.5	BCRP4	3.34	0.000898	0.0492	0.19	0.15	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22630061~22636153:+
THCA	cis	rs1823913	0.503	rs35868016	ENSG00000280083.1	RP11-317J9.1	-3.34	0.000898	0.0492	-0.18	-0.15	Obesity-related traits;	chr2:191344082	chr2:191154118~191156070:-
THCA	cis	rs7586085	1	rs777358	ENSG00000232411.1	AC009495.3	-3.34	0.000899	0.0492	-0.16	-0.15	Total body bone mineral density;	chr2:165699162	chr2:165833048~165839098:-
THCA	cis	rs939960	0.959	rs73163513	ENSG00000276538.1	RP11-545G3.2	3.34	0.000899	0.0492	0.22	0.15	Neutrophil percentage of white cells;	chr7:150596729	chr7:150047609~150047854:-
THCA	cis	rs345013	0.92	rs9828282	ENSG00000240032.1	RP11-274H2.3	3.34	0.000899	0.0492	0.24	0.15	Prostate cancer;	chr3:145290291	chr3:146066344~146069185:-
THCA	cis	rs345013	0.92	rs9854020	ENSG00000240032.1	RP11-274H2.3	3.34	0.000899	0.0492	0.24	0.15	Prostate cancer;	chr3:145291725	chr3:146066344~146069185:-
THCA	cis	rs345013	0.92	rs1562208	ENSG00000240032.1	RP11-274H2.3	3.34	0.000899	0.0492	0.24	0.15	Prostate cancer;	chr3:145300437	chr3:146066344~146069185:-
THCA	cis	rs345013	0.92	rs73151053	ENSG00000240032.1	RP11-274H2.3	3.34	0.000899	0.0492	0.24	0.15	Prostate cancer;	chr3:145301973	chr3:146066344~146069185:-
THCA	cis	rs345013	0.92	rs2218484	ENSG00000240032.1	RP11-274H2.3	3.34	0.000899	0.0492	0.24	0.15	Prostate cancer;	chr3:145304950	chr3:146066344~146069185:-
THCA	cis	rs2882667	0.861	rs10043676	ENSG00000249593.5	CTB-46B19.2	3.34	0.000899	0.0492	0.18	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:139012647~139051203:+
THCA	cis	rs2882667	0.898	rs10038121	ENSG00000249593.5	CTB-46B19.2	3.34	0.000899	0.0492	0.18	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:139012647~139051203:+
THCA	cis	rs2882667	0.861	rs10075541	ENSG00000249593.5	CTB-46B19.2	3.34	0.000899	0.0492	0.18	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:139012647~139051203:+
THCA	cis	rs524281	0.692	rs10896076	ENSG00000255038.1	RP11-1167A19.2	-3.34	0.000899	0.0492	-0.17	-0.15	Electroencephalogram traits;	chr11:66073197	chr11:66067277~66069619:-
THCA	cis	rs11633886	0.569	rs72719097	ENSG00000259200.1	RP11-718O11.1	-3.34	0.000899	0.0492	-0.19	-0.15	Diisocyanate-induced asthma;	chr15:45836883	chr15:45705078~45931069:+
THCA	cis	rs11633886	0.569	rs72719098	ENSG00000259200.1	RP11-718O11.1	-3.34	0.000899	0.0492	-0.19	-0.15	Diisocyanate-induced asthma;	chr15:45836884	chr15:45705078~45931069:+
THCA	cis	rs17217757	0.725	rs2343299	ENSG00000254041.1	RP11-574O7.1	-3.34	0.000899	0.0492	-0.23	-0.15	Tuberculosis;	chr8:105605772	chr8:105142860~105188606:-
THCA	cis	rs2486288	0.656	rs11637838	ENSG00000259479.5	SORD2P	-3.34	0.000899	0.0492	-0.16	-0.15	Glomerular filtration rate;	chr15:45258459	chr15:44826371~44884694:-
THCA	cis	rs901683	1	rs12781186	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45517990	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs12779198	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45518099	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs12762495	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45518167	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs17157880	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45519040	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs35131026	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45519311	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs17157884	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45520494	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs78913745	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45524463	chr10:45678692~45700532:+
THCA	cis	rs901683	0.867	rs17157885	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45524646	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs17157887	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45524900	chr10:45678692~45700532:+
THCA	cis	rs901683	1	rs71496609	ENSG00000230869.1	CTGLF10P	-3.34	0.000899	0.0492	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45525583	chr10:45678692~45700532:+
THCA	cis	rs6545883	0.507	rs62149712	ENSG00000273302.1	RP11-493E12.2	-3.34	0.000899	0.0492	-0.14	-0.15	Tuberculosis;	chr2:61374137	chr2:61199979~61200769:+
THCA	cis	rs5993586	0.51	rs9606038	ENSG00000273032.1	DGCR9	-3.34	0.000899	0.0492	-0.3	-0.15	Coronary artery disease;	chr22:19499669	chr22:19017834~19020248:+
THCA	cis	rs2486012	1	rs61770287	ENSG00000237950.1	RP11-7O11.3	-3.34	0.000899	0.0492	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43893533	chr1:43944370~43946551:-
THCA	cis	rs2486012	0.826	rs17533707	ENSG00000237950.1	RP11-7O11.3	-3.34	0.000899	0.0492	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43895861	chr1:43944370~43946551:-
THCA	cis	rs2562456	0.833	rs2650801	ENSG00000268278.1	RP11-420K14.1	3.34	0.000899	0.0492	0.2	0.15	Pain;	chr19:21452553	chr19:21637974~21656300:+
THCA	cis	rs11673344	0.966	rs56330606	ENSG00000267260.1	CTD-2162K18.4	-3.34	0.000899	0.0492	-0.19	-0.15	Obesity-related traits;	chr19:37183051	chr19:36773153~36777078:+
THCA	cis	rs911186	0.812	rs6932590	ENSG00000220721.1	OR1F12	3.34	0.000899	0.0492	0.19	0.15	Autism spectrum disorder or schizophrenia;	chr6:27281152	chr6:28073316~28074233:+
THCA	cis	rs6120849	0.707	rs6120826	ENSG00000269202.1	RP4-614O4.12	-3.34	0.000899	0.0492	-0.17	-0.15	Protein C levels;	chr20:35084028	chr20:35201747~35203288:-
THCA	cis	rs3784262	0.631	rs4646625	ENSG00000259250.1	RP11-50C13.1	3.34	0.000899	0.0492	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57964098	chr15:58587507~58591676:+
THCA	cis	rs448720	0.526	rs451917	ENSG00000260657.2	RP11-315D16.4	-3.34	0.000899	0.0492	-0.18	-0.15	Cognitive performance;	chr15:67940714	chr15:68267792~68277994:-
THCA	cis	rs478304	0.53	rs11568300	ENSG00000255120.4	OVOL1-AS1	-3.34	0.000899	0.0492	-0.21	-0.15	Acne (severe);	chr11:65657696	chr11:65789051~65790868:-
THCA	cis	rs10043228	0.826	rs11241356	ENSG00000250015.1	CTC-339F2.2	3.34	0.000899	0.0492	0.23	0.15	Asthma or chronic obstructive pulmonary disease;	chr5:116110826	chr5:116302354~116304134:-
THCA	cis	rs6662572	0.737	rs11584814	ENSG00000234329.1	RP11-767N6.2	-3.34	0.000899	0.0492	-0.17	-0.15	Blood protein levels;	chr1:46038717	chr1:45651039~45651826:-
THCA	cis	rs1005277	0.579	rs176838	ENSG00000151963.4	RP11-775A3.1	3.34	0.000899	0.0492	0.16	0.15	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:37883594~37884109:+
THCA	cis	rs7615952	0.599	rs67566088	ENSG00000248787.1	RP11-666A20.4	-3.34	0.000899	0.0492	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:126050130	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs12495947	ENSG00000248787.1	RP11-666A20.4	-3.34	0.000899	0.0492	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:126052855	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs6805074	ENSG00000248787.1	RP11-666A20.4	-3.34	0.000899	0.0492	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:126053431	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs4422257	ENSG00000248787.1	RP11-666A20.4	-3.34	0.000899	0.0492	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:126055520	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs66520539	ENSG00000248787.1	RP11-666A20.4	-3.34	0.000899	0.0492	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:126061531	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs7632497	ENSG00000248787.1	RP11-666A20.4	-3.34	0.000899	0.0492	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:126064243	chr3:125908005~125910272:-
THCA	cis	rs7615952	0.641	rs12487875	ENSG00000248787.1	RP11-666A20.4	-3.34	0.000899	0.0492	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:126068381	chr3:125908005~125910272:-
THCA	cis	rs11992162	0.636	rs4841642	ENSG00000227888.4	FAM66A	3.34	0.000899	0.0492	0.2	0.15	Monocyte count;	chr8:11940825	chr8:12362019~12388296:+
THCA	cis	rs11992162	0.636	rs4841646	ENSG00000227888.4	FAM66A	3.34	0.000899	0.0492	0.2	0.15	Monocyte count;	chr8:11941198	chr8:12362019~12388296:+
THCA	cis	rs11030122	0.547	rs4910865	ENSG00000230593.3	AC090804.1	3.34	0.000899	0.0492	0.19	0.15	Mean platelet volume;Platelet distribution width;	chr11:3929316	chr11:3892398~3892887:-
THCA	cis	rs6787172	0.622	rs6798940	ENSG00000272087.1	RP11-379F4.7	3.34	0.000899	0.0492	0.14	0.15	Subjective well-being;	chr3:158375232	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs6774676	ENSG00000272087.1	RP11-379F4.7	3.34	0.000899	0.0492	0.14	0.15	Subjective well-being;	chr3:158375252	chr3:158693120~158693768:-
THCA	cis	rs867186	0.925	rs73905030	ENSG00000126005.14	MMP24-AS1	-3.34	0.000899	0.0492	-0.24	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34994476	chr20:35216462~35278131:-
THCA	cis	rs7656342	0.619	rs7688167	ENSG00000250342.1	SNRPCP16	3.34	0.000899	0.0492	0.2	0.15	Gut microbiota (bacterial taxa);	chr4:9891882	chr4:9051842~9052051:-
THCA	cis	rs7641761	0.539	rs6790867	ENSG00000237978.4	KCNMB2-AS1	3.34	0.000899	0.0492	0.19	0.15	Mean corpuscular hemoglobin;	chr3:179020644	chr3:178526505~178860405:-
THCA	cis	rs11039798	0.544	rs114343057	ENSG00000200090.1	Y_RNA	3.34	0.000899	0.0492	0.13	0.15	Axial length;	chr11:48536620	chr11:47726894~47726992:-
THCA	cis	rs11039798	0.588	rs10838970	ENSG00000200090.1	Y_RNA	3.34	0.000899	0.0492	0.13	0.15	Axial length;	chr11:48584715	chr11:47726894~47726992:-
THCA	cis	rs7819412	0.715	rs35223712	ENSG00000270076.1	AF131215.8	3.34	0.000899	0.0492	0.16	0.15	Triglycerides;	chr8:11186417	chr8:11202965~11203671:+
THCA	cis	rs7005380	0.733	rs6469878	ENSG00000279347.1	RP11-85I17.2	3.34	0.000899	0.0492	0.17	0.15	Interstitial lung disease;	chr8:119926208	chr8:119838736~119840385:-
THCA	cis	rs2692947	0.673	rs3111873	ENSG00000236750.1	AC009237.16	3.34	0.000899	0.0492	0.17	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96116247	chr2:95641634~95641980:-
THCA	cis	rs7851660	0.527	rs7859751	ENSG00000214417.4	KRT18P13	-3.34	9e-04	0.0492	-0.14	-0.15	Strep throat;	chr9:97813606	chr9:97698922~97700734:+
THCA	cis	rs11018904	0.817	rs11601793	ENSG00000280367.1	RP11-121L10.2	3.34	9e-04	0.0492	0.2	0.15	Intelligence (multi-trait analysis);	chr11:90213186	chr11:90223153~90226538:+
THCA	cis	rs9649465	0.561	rs631445	ENSG00000272686.1	RP11-390E23.6	3.34	9e-04	0.0492	0.1	0.15	Migraine;	chr7:123773653	chr7:123749068~123751166:+
THCA	cis	rs6995541	0.583	rs17152302	ENSG00000248896.2	CTD-2135J3.3	3.34	9e-04	0.0492	0.21	0.15	Triglyceride levels;	chr8:10762516	chr8:10729314~10771392:+
THCA	cis	rs2128382	0.519	rs10956503	ENSG00000253720.1	RP11-473O4.3	-3.34	9e-04	0.0492	-0.26	-0.15	Colorectal cancer;	chr8:129901508	chr8:129939856~129949394:+
THCA	cis	rs9309473	0.514	rs62149630	ENSG00000273245.1	RP11-434P11.2	3.34	9e-04	0.0492	0.24	0.15	Metabolite levels;	chr2:73354627	chr2:73750256~73750786:-
THCA	cis	rs8077577	0.945	rs62073649	ENSG00000273018.4	CTD-2303H24.2	-3.34	9e-04	0.0492	-0.25	-0.15	Obesity-related traits;	chr17:18177208	chr17:18511221~18551705:-
THCA	cis	rs67478160	0.643	rs6576005	ENSG00000269910.1	RP11-73M18.10	3.34	9e-04	0.0492	0.13	0.15	Schizophrenia;	chr14:103826032	chr14:103694516~103695050:-
THCA	cis	rs1559040	0.932	rs28368466	ENSG00000233266.1	HMGB1P31	-3.34	9e-04	0.0492	-0.31	-0.15	Sudden cardiac arrest;	chr2:54061824	chr2:54051334~54051760:+
THCA	cis	rs6001982	0.915	rs6001980	ENSG00000199865.1	RNU6-495P	3.34	9e-04	0.0492	0.27	0.15	Breast cancer;	chr22:40608380	chr22:41377177~41377283:-
THCA	cis	rs6787172	0.622	rs11709804	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158371944	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs10936133	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158372184	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs10936134	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158372334	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.592	rs11714104	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158375680	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs9853566	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158376081	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.565	rs9816143	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158376336	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs28578723	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158377431	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs56387731	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158379931	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.592	rs9867152	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158380374	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.651	rs9809952	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158380655	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs4680431	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158381130	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs7639867	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158381387	chr3:158693120~158693768:-
THCA	cis	rs6787172	0.622	rs9873426	ENSG00000272087.1	RP11-379F4.7	3.34	9e-04	0.0492	0.14	0.15	Subjective well-being;	chr3:158381993	chr3:158693120~158693768:-
THCA	cis	rs9549260	0.709	rs12585870	ENSG00000275149.1	RP11-427J23.1	-3.34	9e-04	0.0492	-0.2	-0.15	Red blood cell count;	chr13:40625350	chr13:40079106~40273509:-
THCA	cis	rs6137726	0.652	rs2209796	ENSG00000237396.1	LINC01384	-3.34	9e-04	0.0492	-0.14	-0.15	Amyotrophic lateral sclerosis (sporadic);	chr20:22678812	chr20:22587522~22607517:-
THCA	cis	rs4792901	1	rs1010049	ENSG00000267151.3	RP11-100E5.2	-3.34	9e-04	0.0492	-0.15	-0.15	Dupuytren's disease;	chr17:43578311	chr17:43444707~43451200:+
THCA	cis	rs11634944	0.673	rs1549474	ENSG00000257647.1	RP11-701H24.3	3.34	9e-04	0.0492	0.09	0.15	Interleukin-8 levels;	chr15:25000886	chr15:25027736~25032047:-
THCA	cis	rs9859260	0.961	rs9846149	ENSG00000242086.7	LINC00969	3.34	9e-04	0.0492	0.15	0.15	Mean corpuscular volume;	chr3:196060437	chr3:195658062~195739964:+
THCA	cis	rs1832871	0.711	rs62439861	ENSG00000213078.3	RP5-933K21.2	-3.34	9e-04	0.0492	-0.23	-0.15	Height;	chr6:158279499	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9459904	ENSG00000213078.3	RP5-933K21.2	-3.34	9e-04	0.0492	-0.23	-0.15	Height;	chr6:158279950	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9459918	ENSG00000213078.3	RP5-933K21.2	-3.34	9e-04	0.0492	-0.23	-0.15	Height;	chr6:158282572	chr6:157365990~157366923:-
THCA	cis	rs1832871	0.711	rs9459924	ENSG00000213078.3	RP5-933K21.2	-3.34	9e-04	0.0492	-0.23	-0.15	Height;	chr6:158282870	chr6:157365990~157366923:-
THCA	cis	rs728616	0.51	rs7074356	ENSG00000278616.1	BEND3P3	3.34	9e-04	0.0492	0.14	0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80431578	chr10:79682997~79685436:+
THCA	cis	rs1832871	0.683	rs11756200	ENSG00000213078.3	RP5-933K21.2	-3.34	9e-04	0.0492	-0.23	-0.15	Height;	chr6:158236704	chr6:157365990~157366923:-
THCA	cis	rs3785574	0.962	rs16947051	ENSG00000279369.1	RP11-51F16.1	3.34	9e-04	0.0492	0.11	0.15	Height;	chr17:63713557	chr17:63700847~63702670:+
THCA	cis	rs897984	0.537	rs8045637	ENSG00000260911.2	RP11-196G11.2	3.34	9e-04	0.0492	0.13	0.15	Dementia with Lewy bodies;	chr16:30807341	chr16:31043150~31049868:+
THCA	cis	rs4948275	0.693	rs2814031	ENSG00000233643.2	RP11-491H19.1	3.34	9e-04	0.0492	0.17	0.15	Night sleep phenotypes;	chr10:61577762	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.693	rs2814028	ENSG00000233643.2	RP11-491H19.1	3.34	9e-04	0.0492	0.17	0.15	Night sleep phenotypes;	chr10:61578535	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.693	rs2606103	ENSG00000233643.2	RP11-491H19.1	3.34	9e-04	0.0492	0.17	0.15	Night sleep phenotypes;	chr10:61578805	chr10:61781745~61821246:-
THCA	cis	rs4948275	0.658	rs1933444	ENSG00000233643.2	RP11-491H19.1	3.34	9e-04	0.0492	0.17	0.15	Night sleep phenotypes;	chr10:61579286	chr10:61781745~61821246:-
THCA	cis	rs1799922	0.77	rs62479590	ENSG00000271553.1	RP11-274B21.10	-3.34	9e-04	0.0492	-0.14	-0.15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr7:128766759	chr7:128667043~128668156:+
THCA	cis	rs1865760	0.713	rs6928951	ENSG00000272810.1	U91328.22	-3.34	9e-04	0.0492	-0.12	-0.15	Height;	chr6:25995326	chr6:26013241~26013757:+
THCA	cis	rs2034650	0.563	rs11070270	ENSG00000259211.1	RP11-64K12.8	3.34	9e-04	0.0492	0.14	0.15	Interstitial lung disease;	chr15:40416223	chr15:40464193~40466726:-
THCA	cis	rs9400467	0.506	rs77097930	ENSG00000255389.1	C6orf3	3.34	9e-04	0.0492	0.21	0.15	Amino acid levels;Blood metabolite levels;	chr6:111294276	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.506	rs118071464	ENSG00000255389.1	C6orf3	3.34	9e-04	0.0492	0.21	0.15	Amino acid levels;Blood metabolite levels;	chr6:111305469	chr6:111599875~111602295:+
THCA	cis	rs9400467	0.506	rs12209435	ENSG00000255389.1	C6orf3	3.34	9e-04	0.0492	0.21	0.15	Amino acid levels;Blood metabolite levels;	chr6:111321834	chr6:111599875~111602295:+
THCA	cis	rs7819412	0.669	rs7823349	ENSG00000206014.6	OR7E161P	3.34	9e-04	0.0492	0.18	0.15	Triglycerides;	chr8:11141120	chr8:11928597~11929563:-
THCA	cis	rs7819412	0.669	rs4840549	ENSG00000206014.6	OR7E161P	3.34	9e-04	0.0492	0.18	0.15	Triglycerides;	chr8:11141445	chr8:11928597~11929563:-
THCA	cis	rs62158211	1	rs62158211	ENSG00000231292.6	IGKV1OR2-108	-3.34	9e-04	0.0493	-0.12	-0.15	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348562	chr2:113406396~113406872:+
THCA	cis	rs4835473	0.932	rs2323200	ENSG00000248890.1	HHIP-AS1	-3.34	9e-04	0.0493	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143765448	chr4:144642922~144661357:-
THCA	cis	rs12681963	0.688	rs2958746	ENSG00000272375.1	RP11-51J9.6	-3.34	9e-04	0.0493	-0.22	-0.15	Migraine;	chr8:30231554	chr8:30197404~30198048:+
THCA	cis	rs12893668	0.603	rs61637848	ENSG00000258735.1	LINC00637	-3.34	9e-04	0.0493	-0.2	-0.15	Reticulocyte count;	chr14:103629694	chr14:103847721~103858049:+
THCA	cis	rs2018683	0.621	rs10261556	ENSG00000233517.1	AC005162.5	-3.34	9e-04	0.0493	-0.18	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28937019	chr7:28987028~28988899:+
THCA	cis	rs7474896	0.515	rs688608	ENSG00000272983.1	RP11-508N22.12	3.34	9e-04	0.0493	0.16	0.15	Obesity (extreme);	chr10:38042696	chr10:38137337~38144399:+
THCA	cis	rs4792901	0.759	rs12948043	ENSG00000279602.1	CTD-3014M21.1	-3.34	9e-04	0.0493	-0.19	-0.15	Dupuytren's disease;	chr17:43538462	chr17:43360041~43361361:-
THCA	cis	rs2797160	0.967	rs28629380	ENSG00000226409.1	RP11-735G4.1	-3.34	9e-04	0.0493	-0.18	-0.15	Endometrial cancer;	chr6:125683051	chr6:125370211~125374324:-
THCA	cis	rs643506	1	rs643506	ENSG00000230911.1	PPIHP1	-3.34	9e-04	0.0493	-0.21	-0.15	Breast cancer;	chr11:111765903	chr11:112029858~112030367:-
THCA	cis	rs7246657	0.943	rs7255785	ENSG00000266916.4	ZNF793-AS1	-3.34	9e-04	0.0493	-0.14	-0.15	Coronary artery calcification;	chr19:37480781	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs7255996	ENSG00000266916.4	ZNF793-AS1	-3.34	9e-04	0.0493	-0.14	-0.15	Coronary artery calcification;	chr19:37480797	chr19:37497159~37507046:-
THCA	cis	rs9549260	0.755	rs2721045	ENSG00000275149.1	RP11-427J23.1	-3.34	9e-04	0.0493	-0.2	-0.15	Red blood cell count;	chr13:40588495	chr13:40079106~40273509:-
THCA	cis	rs6589219	0.721	rs7944895	ENSG00000196167.8	COLCA1	-3.34	9e-04	0.0493	-0.16	-0.15	Colorectal cancer;	chr11:111297051	chr11:111290787~111305045:-
THCA	cis	rs2130392	0.926	rs7680323	ENSG00000250726.1	RP11-616K6.1	3.34	9e-04	0.0493	0.19	0.15	Kawasaki disease;	chr4:184731717	chr4:184072403~184073039:+
THCA	cis	rs7818688	1	rs28651964	ENSG00000253528.2	RP11-347C18.4	-3.34	0.000901	0.0493	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014553	chr8:94974573~94974853:-
THCA	cis	rs6084875	0.733	rs6037959	ENSG00000278595.1	RP5-1068H6.6	-3.34	0.000901	0.0493	-0.18	-0.15	Systemic lupus erythematosus;	chr20:4761077	chr20:4761300~4761696:+
THCA	cis	rs7131987	0.874	rs10843366	ENSG00000273680.1	RP11-996F15.6	3.34	0.000901	0.0493	0.2	0.15	QT interval;	chr12:29254970	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.845	rs2042511	ENSG00000273680.1	RP11-996F15.6	3.34	0.000901	0.0493	0.2	0.15	QT interval;	chr12:29255847	chr12:29332733~29333383:-
THCA	cis	rs7131987	0.903	rs10843371	ENSG00000273680.1	RP11-996F15.6	3.34	0.000901	0.0493	0.2	0.15	QT interval;	chr12:29261299	chr12:29332733~29333383:-
THCA	cis	rs1891275	0.515	rs7092745	ENSG00000232709.1	MARK2P9	3.34	0.000901	0.0493	0.17	0.15	Intelligence (multi-trait analysis);	chr10:91724063	chr10:92418667~92420875:+
THCA	cis	rs301901	0.796	rs1517789	ENSG00000250155.1	CTD-2353F22.1	3.34	0.000901	0.0493	0.15	0.15	Height;	chr5:37510578	chr5:36666214~36725195:-
THCA	cis	rs862034	1	rs862031	ENSG00000270000.1	RP3-449M8.9	3.34	0.000901	0.0493	0.16	0.15	Height;	chr14:74525152	chr14:74471930~74472360:-
THCA	cis	rs2436845	1	rs1138	ENSG00000253320.4	KB-1507C5.2	-3.34	0.000901	0.0493	-0.12	-0.15	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102856258	chr8:102864300~102977876:+
THCA	cis	rs9549260	0.755	rs12585875	ENSG00000275149.1	RP11-427J23.1	-3.34	0.000901	0.0493	-0.2	-0.15	Red blood cell count;	chr13:40625394	chr13:40079106~40273509:-
THCA	cis	rs10992797	0.527	rs10821172	ENSG00000227603.1	RP11-165J3.6	-3.34	0.000901	0.0493	-0.16	-0.15	Intelligence (multi-trait analysis);	chr9:93599969	chr9:93435332~93437121:-
THCA	cis	rs4287000	0.508	rs62574558	ENSG00000227603.1	RP11-165J3.6	-3.34	0.000901	0.0493	-0.16	-0.15	Itch intensity from mosquito bite adjusted by bite size;	chr9:93600380	chr9:93435332~93437121:-
THCA	cis	rs4287000	0.508	rs4744259	ENSG00000227603.1	RP11-165J3.6	-3.34	0.000901	0.0493	-0.16	-0.15	Itch intensity from mosquito bite adjusted by bite size;	chr9:93600636	chr9:93435332~93437121:-
THCA	cis	rs4287000	0.508	rs2254712	ENSG00000227603.1	RP11-165J3.6	-3.34	0.000901	0.0493	-0.16	-0.15	Itch intensity from mosquito bite adjusted by bite size;	chr9:93601577	chr9:93435332~93437121:-
THCA	cis	rs10992797	0.504	rs2994369	ENSG00000227603.1	RP11-165J3.6	-3.34	0.000901	0.0493	-0.16	-0.15	Intelligence (multi-trait analysis);	chr9:93604231	chr9:93435332~93437121:-
THCA	cis	rs2904967	1	rs636928	ENSG00000254614.2	AP003068.23	3.34	0.000901	0.0493	0.29	0.15	Mean corpuscular volume;	chr11:65326013	chr11:65177606~65181834:-
THCA	cis	rs1765142	0.55	rs808152	ENSG00000242353.1	RP4-710M3.1	3.34	0.000901	0.0493	0.13	0.15	Schizophrenia;	chr11:30397414	chr11:30368148~30368646:+
THCA	cis	rs950169	1	rs1818950	ENSG00000275120.1	RP11-182J1.17	3.34	0.000901	0.0493	0.18	0.15	Schizophrenia;	chr15:84053769	chr15:84599434~84606463:-
THCA	cis	rs854765	0.583	rs7503334	ENSG00000265511.1	RP11-524F11.1	-3.34	0.000901	0.0493	-0.12	-0.15	Total body bone mineral density;	chr17:17876144	chr17:17507351~17508308:+
THCA	cis	rs854765	0.583	rs6502619	ENSG00000265511.1	RP11-524F11.1	-3.34	0.000901	0.0493	-0.12	-0.15	Total body bone mineral density;	chr17:17876390	chr17:17507351~17508308:+
THCA	cis	rs10489202	0.644	rs11584210	ENSG00000250762.1	RP1-313L4.4	-3.34	0.000901	0.0493	-0.27	-0.15	Schizophrenia;	chr1:167877615	chr1:167819898~167820248:-
THCA	cis	rs173896	1	rs255887	ENSG00000246859.2	STARD4-AS1	3.34	0.000901	0.0493	0.22	0.15	Bipolar disorder and schizophrenia;	chr5:111767724	chr5:111512226~111739726:+
THCA	cis	rs6545883	0.524	rs7561697	ENSG00000273302.1	RP11-493E12.2	-3.34	0.000901	0.0493	-0.14	-0.15	Tuberculosis;	chr2:61292030	chr2:61199979~61200769:+
THCA	cis	rs804280	0.509	rs7461273	ENSG00000251402.3	FAM90A25P	3.34	0.000901	0.0493	0.2	0.15	Myopia (pathological);	chr8:11920468	chr8:12415080~12418090:-
THCA	cis	rs34779708	0.931	rs7084196	ENSG00000233200.1	RP11-324I22.2	3.34	0.000901	0.0493	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35219894~35230598:-
THCA	cis	rs4713118	0.869	rs6901520	ENSG00000216915.2	RP1-97D16.1	-3.34	0.000901	0.0493	-0.23	-0.15	Parkinson's disease;	chr6:27746796	chr6:27737000~27738494:-
THCA	cis	rs7219021	0.705	rs2270576	ENSG00000248278.1	SUMO2P17	-3.34	0.000901	0.0493	-0.2	-0.15	Schizophrenia or bipolar disorder;	chr17:48930601	chr17:48874860~48908983:-
THCA	cis	rs7474896	0.583	rs1735621	ENSG00000272983.1	RP11-508N22.12	3.34	0.000901	0.0493	0.16	0.15	Obesity (extreme);	chr10:37878795	chr10:38137337~38144399:+
THCA	cis	rs6995541	0.583	rs7826180	ENSG00000248896.2	CTD-2135J3.3	3.34	0.000901	0.0493	0.21	0.15	Triglyceride levels;	chr8:10770334	chr8:10729314~10771392:+
THCA	cis	rs11048434	0.673	rs1124402	ENSG00000245105.2	A2M-AS1	3.34	0.000902	0.0493	0.12	0.15	Sjögren's syndrome;	chr12:8910010	chr12:9065177~9068060:+
THCA	cis	rs6929812	0.628	rs4713097	ENSG00000271755.1	RP1-153G14.4	3.34	0.000902	0.0493	0.17	0.15	Neuroticism (multi-trait analysis);	chr6:27411768	chr6:27404010~27406964:-
THCA	cis	rs7551222	0.749	rs11240761	ENSG00000240219.1	RP11-430C7.5	3.34	0.000902	0.0493	0.14	0.15	Schizophrenia;	chr1:204597572	chr1:204626775~204629712:+
THCA	cis	rs6599077	0.616	rs11706943	ENSG00000223797.4	ENTPD3-AS1	3.34	0.000902	0.0493	0.14	0.15	Sleep-related phenotypes;	chr3:40132418	chr3:40313802~40453329:-
THCA	cis	rs3824488	0.92	rs60417486	ENSG00000271155.1	RP11-435O5.5	-3.34	0.000902	0.0493	-0.27	-0.15	Neuroticism;	chr9:95499896	chr9:95506235~95507636:+
THCA	cis	rs6510186	0.887	rs10419200	ENSG00000267662.1	AC007796.1	-3.34	0.000902	0.0493	-0.18	-0.15	Total body bone mineral density (age 45-60);	chr19:31172971	chr19:31348881~31417794:+
THCA	cis	rs11073619	0.572	rs35984335	ENSG00000188388.10	GOLGA6L3	-3.34	0.000902	0.0493	-0.28	-0.15	Positive affect;	chr15:84393638	chr15:85240472~85247170:+
THCA	cis	rs337161	0.605	rs11118600	ENSG00000221571.3	RNU6ATAC35P	-3.34	0.000902	0.0493	-0.16	-0.15	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220772371	chr1:220825620~220826063:+
THCA	cis	rs2287641	0.826	rs76134249	ENSG00000272156.1	RP11-477N3.1	3.34	0.000902	0.0493	0.29	0.15	Cannabis dependence symptom count;	chr2:54041977	chr2:54082554~54085066:+
THCA	cis	rs4773860	0.71	rs9302051	ENSG00000223298.1	RNY3P8	3.34	0.000902	0.0493	0.16	0.15	Plateletcrit;	chr13:95242669	chr13:95310830~95310955:-
THCA	cis	rs3176789	0.914	rs4385980	ENSG00000256673.1	RP11-599J14.2	3.34	0.000902	0.0493	0.2	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772596	chr12:9398355~9414851:-
THCA	cis	rs8031584	1	rs35811129	ENSG00000259845.1	HERC2P10	3.34	0.000902	0.0493	0.22	0.15	Huntington's disease progression;	chr15:30949143	chr15:30815271~30844153:+
THCA	cis	rs2486012	1	rs61770289	ENSG00000234694.1	RP1-92O14.3	-3.34	0.000902	0.0493	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43898038	chr1:43354684~43358658:-
THCA	cis	rs12101261	0.744	rs2239610	ENSG00000258915.1	BHLHB9P1	-3.34	0.000902	0.0493	-0.18	-0.15	Graves' disease;	chr14:80955913	chr14:80981988~80983638:+
THCA	cis	rs7259376	0.775	rs7257134	ENSG00000269345.1	VN1R85P	3.34	0.000902	0.0493	0.17	0.15	Menopause (age at onset);	chr19:22358055	chr19:22174766~22175191:-
THCA	cis	rs4787491	0.729	rs4788213	ENSG00000275371.1	RP11-455F5.6	-3.34	0.000902	0.0493	-0.13	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023203	chr16:30110895~30111955:+
THCA	cis	rs758324	0.628	rs2073506	ENSG00000237714.1	P4HA2-AS1	-3.34	0.000902	0.0493	-0.32	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132059045	chr5:132184876~132192808:+
THCA	cis	rs4849845	0.522	rs11893187	ENSG00000231013.1	AC013275.2	3.34	0.000902	0.0493	0.16	0.15	Mean platelet volume;	chr2:120260961	chr2:119476448~119487346:+
THCA	cis	rs7225537	0.738	rs7501848	ENSG00000260328.1	RP11-416I2.1	-3.34	0.000902	0.0493	-0.12	-0.15	Mean platelet volume;	chr17:17001098	chr17:17011914~17014990:-
THCA	cis	rs2486012	0.85	rs246774	ENSG00000237950.1	RP11-7O11.3	3.34	0.000902	0.0493	0.18	0.15	Intelligence (multi-trait analysis);	chr1:43834023	chr1:43944370~43946551:-
THCA	cis	rs72799341	1	rs72799341	ENSG00000232748.3	RP11-196G11.6	-3.34	0.000902	0.0493	-0.21	-0.15	Diastolic blood pressure;	chr16:30925422	chr16:31056460~31062803:+
THCA	cis	rs34779708	0.966	rs1213392	ENSG00000233200.1	RP11-324I22.2	3.34	0.000902	0.0493	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35219894~35230598:-
THCA	cis	rs4417704	0.551	rs10933524	ENSG00000235151.1	AC114730.2	-3.34	0.000902	0.0493	-0.17	-0.15	Joint mobility (Beighton score);	chr2:240940378	chr2:241844380~241845036:+
THCA	cis	rs57709857	0.801	rs10113411	ENSG00000272092.1	RP11-350N15.5	-3.34	0.000902	0.0493	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38249259	chr8:38382364~38383461:+
THCA	cis	rs57709857	0.801	rs10958567	ENSG00000272092.1	RP11-350N15.5	-3.34	0.000902	0.0493	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr8:38250615	chr8:38382364~38383461:+
THCA	cis	rs896655	0.629	rs10965144	ENSG00000229835.2	KHSRPP1	-3.34	0.000902	0.0493	-0.19	-0.15	Coronary artery disease;	chr9:21808914	chr9:21695176~21696943:+
THCA	cis	rs2214442	0.902	rs10241490	ENSG00000271133.4	CTA-293F17.1	-3.34	0.000903	0.0494	-0.15	-0.15	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr7:20354367	chr7:20328299~20331747:-
THCA	cis	rs2736337	0.532	rs6998387	ENSG00000227888.4	FAM66A	3.34	0.000903	0.0494	0.19	0.15	Rheumatoid arthritis;	chr8:11435949	chr8:12362019~12388296:+
THCA	cis	rs3790645	0.958	rs12723936	ENSG00000241547.1	RP11-4K3__A.5	-3.34	0.000903	0.0494	-0.18	-0.15	Glucose homeostasis traits;	chr1:26546063	chr1:27325329~27325796:+
THCA	cis	rs3087591	0.639	rs2342053	ENSG00000263535.1	AK4P1	3.34	0.000903	0.0494	0.18	0.15	Hip circumference;	chr17:31395178	chr17:31345521~31346187:+
THCA	cis	rs12893668	0.603	rs61637848	ENSG00000244691.1	RPL10AP1	-3.34	0.000903	0.0494	-0.21	-0.15	Reticulocyte count;	chr14:103629694	chr14:103412119~103412761:-
THCA	cis	rs7158359	0.955	rs1957839	ENSG00000222990.1	RNU4-22P	-3.34	0.000903	0.0494	-0.21	-0.15	Weight loss (gastric bypass surgery);	chr14:89125283	chr14:88513498~88513663:+
THCA	cis	rs6871536	0.806	rs2522411	ENSG00000233006.5	AC034220.3	3.34	0.000903	0.0494	0.14	0.15	Asthma (childhood onset);	chr5:132548075	chr5:132311285~132369916:-
THCA	cis	rs7259376	0.936	rs11085524	ENSG00000270947.1	AC025811.3	3.34	0.000903	0.0494	0.16	0.15	Menopause (age at onset);	chr19:22353620	chr19:22455988~22456459:+
THCA	cis	rs11634944	0.643	rs975698	ENSG00000257647.1	RP11-701H24.3	3.34	0.000903	0.0494	0.09	0.15	Interleukin-8 levels;	chr15:25015360	chr15:25027736~25032047:-
THCA	cis	rs2830585	1	rs2830585	ENSG00000223563.1	AP001601.2	3.34	0.000903	0.0494	0.21	0.15	Blood protein levels;	chr21:26932893	chr21:26889376~26939742:+
THCA	cis	rs813218	0.584	rs11711935	ENSG00000273374.1	RP11-383I23.2	3.34	0.000903	0.0494	0.12	0.15	Orofacial clefts;	chr3:100089960	chr3:99802699~99806058:-
THCA	cis	rs5753037	0.586	rs140120	ENSG00000279699.1	RP1-102K2.9	3.34	0.000903	0.0494	0.15	0.15	Type 1 diabetes;	chr22:29742559	chr22:30275215~30276951:-
THCA	cis	rs2692947	0.526	rs4907225	ENSG00000235959.1	AC009237.17	-3.34	0.000903	0.0494	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95910922	chr2:95640181~95640604:-
THCA	cis	rs73198271	1	rs11775821	ENSG00000254153.1	CTA-398F10.2	3.34	0.000903	0.0494	0.2	0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8456909~8461337:-
THCA	cis	rs61160187	0.582	rs72757187	ENSG00000251279.1	CTC-436P18.1	-3.34	0.000903	0.0494	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.582	rs67490467	ENSG00000251279.1	CTC-436P18.1	-3.34	0.000903	0.0494	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.582	rs62367872	ENSG00000251279.1	CTC-436P18.1	-3.34	0.000903	0.0494	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.556	rs55738840	ENSG00000251279.1	CTC-436P18.1	-3.34	0.000903	0.0494	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.582	rs58646987	ENSG00000251279.1	CTC-436P18.1	-3.34	0.000903	0.0494	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.582	rs11739952	ENSG00000251279.1	CTC-436P18.1	-3.34	0.000903	0.0494	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:61162070~61232040:+
THCA	cis	rs61160187	0.582	rs4642318	ENSG00000251279.1	CTC-436P18.1	-3.34	0.000903	0.0494	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:61162070~61232040:+
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000261839.1	RP1-265C24.8	3.34	0.000903	0.0494	0.14	0.15	Pubertal anthropometrics;	chr6:28411584	chr6:28136849~28139678:+
THCA	cis	rs4141404	0.604	rs2103853	ENSG00000235573.2	RP3-412A9.12	-3.34	0.000903	0.0494	-0.16	-0.15	Paclitaxel-induced neuropathy;	chr22:31459489	chr22:31113017~31113396:+
THCA	cis	rs61677309	0.638	rs4938493	ENSG00000278376.1	RP11-158I9.8	3.34	0.000903	0.0494	0.11	0.15	Lung cancer in ever smokers;	chr11:118274089	chr11:118791254~118793137:+
THCA	cis	rs9300255	0.602	rs2695476	ENSG00000235423.7	RP11-282O18.3	3.34	0.000903	0.0494	0.17	0.15	Neutrophil percentage of white cells;	chr12:123209659	chr12:123252030~123261483:-
THCA	cis	rs688181	0.568	rs661983	ENSG00000271040.1	RP5-933K21.3	-3.34	0.000903	0.0494	-0.19	-0.15	Platelet distribution width;	chr6:157679666	chr6:157323964~157324477:+
THCA	cis	rs763121	1	rs86796	ENSG00000228274.3	RP3-508I15.9	3.34	0.000903	0.0494	0.16	0.15	Menopause (age at onset);	chr22:38485449	chr22:38667585~38681820:-
THCA	cis	rs881375	0.933	rs4837799	ENSG00000270917.1	RP11-27I1.6	-3.34	0.000903	0.0494	-0.21	-0.15	Rheumatoid arthritis;	chr9:120906048	chr9:120812475~120812845:-
THCA	cis	rs9369640	0.7	rs34944538	ENSG00000212802.4	RPL15P3	3.34	0.000903	0.0494	0.15	0.15	Coronary artery disease;	chr6:12888913	chr6:12514110~12514724:+
THCA	cis	rs801193	0.591	rs721717	ENSG00000223473.2	GS1-124K5.3	-3.34	0.000903	0.0494	-0.1	-0.15	Aortic root size;	chr7:66665305	chr7:66491049~66493566:-
THCA	cis	rs801193	0.569	rs6951302	ENSG00000223473.2	GS1-124K5.3	-3.34	0.000903	0.0494	-0.1	-0.15	Aortic root size;	chr7:66667525	chr7:66491049~66493566:-
THCA	cis	rs6832769	1	rs28582059	ENSG00000223305.1	RN7SKP30	-3.34	0.000903	0.0494	-0.19	-0.15	Personality dimensions;	chr4:55542237	chr4:55540502~55540835:-
THCA	cis	rs6084875	0.733	rs4143674	ENSG00000278595.1	RP5-1068H6.6	-3.34	0.000903	0.0494	-0.18	-0.15	Systemic lupus erythematosus;	chr20:4760658	chr20:4761300~4761696:+
THCA	cis	rs943466	1	rs943461	ENSG00000274259.2	XXbac-BPG294E21.9	-3.34	0.000903	0.0494	-0.22	-0.15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33801632	chr6:33437363~33454453:-
THCA	cis	rs943466	1	rs943462	ENSG00000274259.2	XXbac-BPG294E21.9	-3.34	0.000903	0.0494	-0.22	-0.15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33801801	chr6:33437363~33454453:-
THCA	cis	rs1436955	0.959	rs920177	ENSG00000259251.2	RP11-643M14.1	-3.34	0.000903	0.0494	-0.17	-0.15	Type 2 diabetes;	chr15:62121543	chr15:62060503~62062434:+
THCA	cis	rs6499755	0.932	rs12928690	ENSG00000260135.5	RP11-212I21.2	-3.34	0.000903	0.0494	-0.17	-0.15	Hypospadias;	chr16:55309653	chr16:55426797~55462297:-
THCA	cis	rs9907295	0.748	rs4795091	ENSG00000270871.1	AC015849.19	3.34	0.000903	0.0494	0.14	0.15	Fibroblast growth factor basic levels;	chr17:35814874	chr17:35816717~35830293:-
THCA	cis	rs9907295	0.71	rs4795092	ENSG00000270871.1	AC015849.19	3.34	0.000903	0.0494	0.14	0.15	Fibroblast growth factor basic levels;	chr17:35814967	chr17:35816717~35830293:-
THCA	cis	rs9907295	0.605	rs11652192	ENSG00000270871.1	AC015849.19	3.34	0.000903	0.0494	0.14	0.15	Fibroblast growth factor basic levels;	chr17:35833174	chr17:35816717~35830293:-
THCA	cis	rs6601327	0.571	rs7820675	ENSG00000261451.1	RP11-981G7.1	3.34	0.000903	0.0494	0.18	0.15	Multiple myeloma (hyperdiploidy);	chr8:9790238	chr8:10433672~10438312:+
THCA	cis	rs6871536	1	rs10079653	ENSG00000233006.5	AC034220.3	-3.34	0.000903	0.0494	-0.13	-0.15	Asthma (childhood onset);	chr5:132559819	chr5:132311285~132369916:-
THCA	cis	rs8054556	0.787	rs12921753	ENSG00000183604.13	SMG1P5	-3.34	0.000903	0.0494	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30007399	chr16:30267553~30335374:-
THCA	cis	rs2117029	0.619	rs10747562	ENSG00000239617.1	RP11-302B13.1	-3.34	0.000904	0.0494	-0.18	-0.15	Intelligence (multi-trait analysis);	chr12:49111401	chr12:48903418~48903813:-
THCA	cis	rs2117029	0.619	rs11168862	ENSG00000239617.1	RP11-302B13.1	-3.34	0.000904	0.0494	-0.18	-0.15	Intelligence (multi-trait analysis);	chr12:49112175	chr12:48903418~48903813:-
THCA	cis	rs6828577	0.955	rs13134170	ENSG00000281731.1	RP11-384K6.8	-3.34	0.000904	0.0494	-0.18	-0.15	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118760720	chr4:118664087~118685341:-
THCA	cis	rs17607347	0.738	rs62053998	ENSG00000247324.2	RP11-510M2.2	-3.34	0.000904	0.0494	-0.24	-0.15	Intelligence (multi-trait analysis);	chr16:72368519	chr16:71462278~71465941:+
THCA	cis	rs7572644	0.713	rs7560060	ENSG00000223522.1	AC093690.1	-3.34	0.000904	0.0494	-0.19	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27834657	chr2:28307691~28310459:-
THCA	cis	rs7572644	0.713	rs4233718	ENSG00000223522.1	AC093690.1	-3.34	0.000904	0.0494	-0.19	-0.15	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:27843493	chr2:28307691~28310459:-
THCA	cis	rs7869524	0.549	rs2885045	ENSG00000231808.2	LINC01388	-3.34	0.000904	0.0494	-0.17	-0.15	Mean platelet volume;	chr9:331183	chr9:112713~113754:-
THCA	cis	rs939960	0.959	rs13222892	ENSG00000224016.2	RP11-728K20.1	3.34	0.000904	0.0494	0.21	0.15	Neutrophil percentage of white cells;	chr7:150588016	chr7:149891191~149909704:-
THCA	cis	rs939960	0.758	rs13235632	ENSG00000224016.2	RP11-728K20.1	3.34	0.000904	0.0494	0.21	0.15	Neutrophil percentage of white cells;	chr7:150588042	chr7:149891191~149909704:-
THCA	cis	rs35791980	0.564	rs1181898	ENSG00000265479.4	DTX2P1-UPK3BP1-PMS2P11	-3.34	0.000904	0.0494	-0.15	-0.15	Pursuit maintenance gain;	chr7:77364260	chr7:76980949~77043775:+
THCA	cis	rs877819	0.552	rs2671712	ENSG00000228403.1	RP11-563N6.6	3.34	0.000904	0.0494	0.16	0.15	Systemic lupus erythematosus;	chr10:48883000	chr10:48878022~48878649:+
THCA	cis	rs2494663	0.585	rs7547663	ENSG00000231416.1	RP11-422P24.9	3.34	0.000904	0.0494	0.19	0.15	Mean platelet volume;	chr1:154057763	chr1:153995632~153995960:+
THCA	cis	rs9818758	0.556	rs9872660	ENSG00000270441.1	RP11-694I15.7	3.34	0.000904	0.0494	0.17	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49341399	chr3:49140086~49160851:-
THCA	cis	rs9818758	0.882	rs74926817	ENSG00000270441.1	RP11-694I15.7	3.34	0.000904	0.0494	0.17	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49341400	chr3:49140086~49160851:-
THCA	cis	rs9858542	0.537	rs67882627	ENSG00000270441.1	RP11-694I15.7	3.34	0.000904	0.0494	0.17	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49343008	chr3:49140086~49160851:-
THCA	cis	rs867186	1	rs2889873	ENSG00000279253.1	RP4-614O4.13	-3.34	0.000904	0.0494	-0.25	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35059038	chr20:35262727~35264187:-
THCA	cis	rs13098911	0.54	rs13068572	ENSG00000223552.1	RP11-24F11.2	-3.34	0.000904	0.0494	-0.22	-0.15	Celiac disease;	chr3:46135604	chr3:46364955~46407059:-
THCA	cis	rs35359187	0.557	rs4473573	ENSG00000229912.1	AC128709.4	3.34	0.000904	0.0494	0.29	0.15	Facial morphology (factor 22);	chr3:197535361	chr3:197450327~197456654:-
THCA	cis	rs6471393	1	rs6471393	ENSG00000261437.1	RP11-22C11.2	-3.34	0.000904	0.0494	-0.15	-0.15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703063	chr8:94637285~94639467:-
THCA	cis	rs8032315	0.965	rs7497304	ENSG00000278370.1	RP11-387D10.4	3.34	0.000904	0.0494	0.19	0.15	Autism spectrum disorder or schizophrenia;	chr15:90885946	chr15:90650631~90651103:+
THCA	cis	rs944289	0.774	rs12589124	ENSG00000212071.1	AL162511.1	3.34	0.000904	0.0494	0.17	0.15	Thyroid cancer;	chr14:36094718	chr14:36196480~36196568:-
THCA	cis	rs944289	0.74	rs2183451	ENSG00000212071.1	AL162511.1	3.34	0.000904	0.0494	0.17	0.15	Thyroid cancer;	chr14:36095227	chr14:36196480~36196568:-
THCA	cis	rs944289	0.774	rs884090	ENSG00000212071.1	AL162511.1	3.34	0.000904	0.0494	0.17	0.15	Thyroid cancer;	chr14:36095741	chr14:36196480~36196568:-
THCA	cis	rs701145	0.585	rs1727958	ENSG00000238755.3	RP11-23D24.2	3.34	0.000904	0.0494	0.33	0.15	Coronary artery disease;	chr3:154107011	chr3:153384934~153980186:-
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000264242.2	RP11-271K11.1	3.34	0.000904	0.0494	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30553697~30558962:+
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000264242.2	RP11-271K11.1	3.34	0.000904	0.0494	0.24	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30553697~30558962:+
THCA	cis	rs12543645	0.598	rs17767186	ENSG00000253641.4	RP11-981G7.2	3.34	0.000904	0.0494	0.15	0.15	Schizophrenia;	chr8:10419984	chr8:10474565~10481974:+
THCA	cis	rs751728	0.664	rs2296744	ENSG00000274259.2	XXbac-BPG294E21.9	3.34	0.000904	0.0494	0.17	0.15	Crohn's disease;	chr6:33772605	chr6:33437363~33454453:-
THCA	cis	rs2288884	0.537	rs4145658	ENSG00000269483.1	AC006272.1	3.34	0.000904	0.0494	0.17	0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:51839924~51843324:-
THCA	cis	rs11018904	0.861	rs12786959	ENSG00000280367.1	RP11-121L10.2	3.34	0.000904	0.0494	0.2	0.15	Intelligence (multi-trait analysis);	chr11:90210508	chr11:90223153~90226538:+
THCA	cis	rs11018904	0.861	rs12787117	ENSG00000280367.1	RP11-121L10.2	3.34	0.000904	0.0494	0.2	0.15	Intelligence (multi-trait analysis);	chr11:90210513	chr11:90223153~90226538:+
THCA	cis	rs11018904	0.906	rs35129016	ENSG00000280367.1	RP11-121L10.2	3.34	0.000904	0.0494	0.2	0.15	Intelligence (multi-trait analysis);	chr11:90215521	chr11:90223153~90226538:+
THCA	cis	rs1958560	0.867	rs2185454	ENSG00000276116.2	FUT8-AS1	3.34	0.000904	0.0494	0.17	0.15	Menarche (age at onset);	chr14:65403876	chr14:65411170~65412690:-
THCA	cis	rs4713118	0.739	rs2893931	ENSG00000216915.2	RP1-97D16.1	-3.34	0.000904	0.0494	-0.24	-0.15	Parkinson's disease;	chr6:27780231	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.824	rs2092075	ENSG00000216915.2	RP1-97D16.1	-3.34	0.000904	0.0494	-0.24	-0.15	Parkinson's disease;	chr6:27781551	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.824	rs13211701	ENSG00000216915.2	RP1-97D16.1	-3.34	0.000904	0.0494	-0.24	-0.15	Parkinson's disease;	chr6:27782300	chr6:27737000~27738494:-
THCA	cis	rs4713118	0.824	rs9468229	ENSG00000216915.2	RP1-97D16.1	-3.34	0.000904	0.0494	-0.24	-0.15	Parkinson's disease;	chr6:27782307	chr6:27737000~27738494:-
THCA	cis	rs9376098	0.651	rs9494167	ENSG00000232876.1	CTA-212D2.2	3.34	0.000905	0.0494	0.21	0.15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135167931	chr6:135055033~135060550:+
THCA	cis	rs4434872	1	rs10796958	ENSG00000223599.1	RP11-216N14.7	3.34	0.000905	0.0494	0.25	0.15	Conduct disorder (symptom count);	chr1:153838891	chr1:153852106~153853414:-
THCA	cis	rs9527	0.615	rs10883781	ENSG00000236937.2	PTGES3P4	3.34	0.000905	0.0494	0.21	0.15	Arsenic metabolism;	chr10:102821373	chr10:102845595~102845950:+
THCA	cis	rs35123781	0.533	rs7728485	ENSG00000253404.1	AC034243.1	-3.34	0.000905	0.0494	-0.2	-0.15	Schizophrenia;	chr5:139697559	chr5:138744434~138753309:-
THCA	cis	rs10266483	0.739	rs11765764	ENSG00000234338.1	RP11-797H7.1	-3.34	0.000905	0.0494	-0.12	-0.15	Response to statin therapy;	chr7:64368163	chr7:64835280~64836882:-
THCA	cis	rs250585	0.736	rs2040574	ENSG00000260136.4	CTD-2270L9.4	-3.34	0.000905	0.0494	-0.14	-0.15	Egg allergy;	chr16:23499005	chr16:23452758~23457606:+
THCA	cis	rs250585	1	rs3785408	ENSG00000260136.4	CTD-2270L9.4	-3.34	0.000905	0.0494	-0.14	-0.15	Egg allergy;	chr16:23508665	chr16:23452758~23457606:+
THCA	cis	rs250585	0.538	rs7186729	ENSG00000260136.4	CTD-2270L9.4	-3.34	0.000905	0.0494	-0.14	-0.15	Egg allergy;	chr16:23514773	chr16:23452758~23457606:+
THCA	cis	rs250585	0.92	rs8046051	ENSG00000260136.4	CTD-2270L9.4	-3.34	0.000905	0.0494	-0.14	-0.15	Egg allergy;	chr16:23527345	chr16:23452758~23457606:+
THCA	cis	rs250585	1	rs4968018	ENSG00000260136.4	CTD-2270L9.4	-3.34	0.000905	0.0494	-0.14	-0.15	Egg allergy;	chr16:23531810	chr16:23452758~23457606:+
THCA	cis	rs250585	1	rs6497672	ENSG00000260136.4	CTD-2270L9.4	-3.34	0.000905	0.0494	-0.14	-0.15	Egg allergy;	chr16:23532974	chr16:23452758~23457606:+
THCA	cis	rs11678584	0.686	rs72787505	ENSG00000276517.1	AL133243.2	-3.34	0.000905	0.0494	-0.27	-0.15	Reticulocyte fraction of red cells;Reticulocyte count;	chr2:32583604	chr2:32526504~32529507:+
THCA	cis	rs4144027	0.904	rs55696130	ENSG00000258534.1	CTD-2134A5.4	3.34	0.000905	0.0494	0.16	0.15	Blood metabolite levels;	chr14:103875527	chr14:103854366~103880111:-
THCA	cis	rs45544231	1	rs3112612	ENSG00000279344.1	RP11-44F14.7	3.34	0.000905	0.0494	0.14	0.15	Restless legs syndrome;	chr16:52601252	chr16:53478957~53481550:-
THCA	cis	rs7246657	1	rs35398388	ENSG00000268499.1	CTB-102L5.8	3.34	0.000905	0.0494	0.2	0.15	Coronary artery calcification;	chr19:37249456	chr19:38199836~38200934:+
THCA	cis	rs7572733	0.935	rs11675025	ENSG00000231621.1	AC013264.2	-3.34	0.000905	0.0494	-0.14	-0.15	Dermatomyositis;	chr2:197973591	chr2:197197991~197199273:+
THCA	cis	rs7824557	0.806	rs10503418	ENSG00000255495.1	AC145124.2	-3.34	0.000905	0.0494	-0.16	-0.15	Retinal vascular caliber;	chr8:11261474	chr8:12194467~12196280:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000230295.1	RP11-458F8.2	3.34	0.000905	0.0494	0.13	0.15	Aortic root size;	chr7:66164012	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000230295.1	RP11-458F8.2	3.34	0.000905	0.0494	0.13	0.15	Aortic root size;	chr7:66166374	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000230295.1	RP11-458F8.2	3.34	0.000905	0.0494	0.13	0.15	Aortic root size;	chr7:66168318	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000230295.1	RP11-458F8.2	3.34	0.000905	0.0494	0.13	0.15	Aortic root size;	chr7:66169164	chr7:66880708~66882981:+
THCA	cis	rs2047076	0.785	rs62365099	ENSG00000225407.3	CTD-2384B11.2	-3.34	0.000905	0.0494	-0.24	-0.15	Monocyte count;	chr5:76798478	chr5:76691439~76716215:-
THCA	cis	rs11158609	0.941	rs1997996	ENSG00000278784.1	RP11-468E2.11	-3.34	0.000905	0.0495	-0.14	-0.15	Systolic blood pressure (cigarette smoking interaction);	chr14:24214842	chr14:24201612~24202811:-
THCA	cis	rs11158609	1	rs11158609	ENSG00000278784.1	RP11-468E2.11	-3.34	0.000905	0.0495	-0.14	-0.15	Systolic blood pressure (cigarette smoking interaction);	chr14:24219608	chr14:24201612~24202811:-
THCA	cis	rs11158609	1	rs7157595	ENSG00000278784.1	RP11-468E2.11	-3.34	0.000905	0.0495	-0.14	-0.15	Systolic blood pressure (cigarette smoking interaction);	chr14:24227032	chr14:24201612~24202811:-
THCA	cis	rs36132109	0.826	rs13081156	ENSG00000273328.4	RP11-141M3.6	3.34	0.000905	0.0495	0.2	0.15	Monocyte chemoattractant protein-1 levels;	chr3:42963725	chr3:42809414~42908105:+
THCA	cis	rs76439304	1	rs12425210	ENSG00000247903.1	RP11-421F16.3	-3.34	0.000905	0.0495	-0.23	-0.15	Mean corpuscular volume;	chr12:26896398	chr12:26971586~26979582:+
THCA	cis	rs76439304	1	rs12425228	ENSG00000247903.1	RP11-421F16.3	-3.34	0.000905	0.0495	-0.23	-0.15	Mean corpuscular volume;	chr12:26896423	chr12:26971586~26979582:+
THCA	cis	rs34779708	0.931	rs12240347	ENSG00000233200.1	RP11-324I22.2	3.34	0.000905	0.0495	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35219894~35230598:-
THCA	cis	rs34779708	0.931	rs12248333	ENSG00000233200.1	RP11-324I22.2	3.34	0.000905	0.0495	0.18	0.15	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35219894~35230598:-
THCA	cis	rs6058526	0.631	rs6119778	ENSG00000235217.6	TSPY26P	-3.34	0.000905	0.0495	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr20:32225986	chr20:32186477~32190527:-
THCA	cis	rs6058526	0.631	rs3818219	ENSG00000235217.6	TSPY26P	-3.34	0.000905	0.0495	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr20:32231239	chr20:32186477~32190527:-
THCA	cis	rs10908557	0.758	rs113165037	ENSG00000231416.1	RP11-422P24.9	3.34	0.000905	0.0495	0.19	0.15	Age at first birth;	chr1:154017260	chr1:153995632~153995960:+
THCA	cis	rs4925114	0.568	rs941448	ENSG00000281749.1	Y_RNA	-3.34	0.000905	0.0495	-0.19	-0.15	Body mass index;	chr17:17751228	chr17:18001101~18001195:-
THCA	cis	rs9859260	1	rs2239640	ENSG00000242086.7	LINC00969	3.34	0.000905	0.0495	0.15	0.15	Mean corpuscular volume;	chr3:196062837	chr3:195658062~195739964:+
THCA	cis	rs6049003	0.668	rs6132652	ENSG00000270001.1	RP11-218C14.8	-3.34	0.000905	0.0495	-0.17	-0.15	Cerebrospinal fluid biomarker levels;	chr20:23723628	chr20:23631826~23632316:-
THCA	cis	rs708224	0.605	rs2442063	ENSG00000277342.1	RP11-843B15.4	3.34	0.000905	0.0495	0.2	0.15	Pancreatic cancer;	chr12:32294789	chr12:32109076~32109602:+
THCA	cis	rs5770917	1	rs12627787	ENSG00000273272.1	CTA-384D8.34	3.34	0.000905	0.0495	0.22	0.15	Narcolepsy;	chr22:50573952	chr22:50542650~50543011:+
THCA	cis	rs7395662	0.927	rs12793888	ENSG00000200090.1	Y_RNA	-3.34	0.000905	0.0495	-0.1	-0.15	HDL cholesterol;	chr11:48466504	chr11:47726894~47726992:-
THCA	cis	rs6088580	0.634	rs6059875	ENSG00000126005.14	MMP24-AS1	-3.34	0.000905	0.0495	-0.14	-0.15	Glomerular filtration rate (creatinine);	chr20:34498285	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.634	rs6088512	ENSG00000126005.14	MMP24-AS1	-3.34	0.000905	0.0495	-0.14	-0.15	Glomerular filtration rate (creatinine);	chr20:34508086	chr20:35216462~35278131:-
THCA	cis	rs6088580	0.634	rs6058070	ENSG00000126005.14	MMP24-AS1	-3.34	0.000905	0.0495	-0.14	-0.15	Glomerular filtration rate (creatinine);	chr20:34515716	chr20:35216462~35278131:-
THCA	cis	rs4434872	0.536	rs12033532	ENSG00000228013.1	RP11-350G8.5	-3.34	0.000905	0.0495	-0.27	-0.15	Conduct disorder (symptom count);	chr1:153916344	chr1:154402328~154406564:-
THCA	cis	rs9300255	0.664	rs7306755	ENSG00000235423.7	RP11-282O18.3	-3.34	0.000905	0.0495	-0.18	-0.15	Neutrophil percentage of white cells;	chr12:123283382	chr12:123252030~123261483:-
THCA	cis	rs7216064	0.7	rs4791295	ENSG00000267023.4	LRRC37A16P	-3.34	0.000906	0.0495	-0.12	-0.15	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68001201	chr17:68125777~68152468:-
THCA	cis	rs172166	0.694	rs203876	ENSG00000219891.2	ZSCAN12P1	3.34	0.000906	0.0495	0.19	0.15	Cardiac Troponin-T levels;	chr6:28078895	chr6:28091154~28093664:+
THCA	cis	rs172166	0.694	rs203877	ENSG00000219891.2	ZSCAN12P1	3.34	0.000906	0.0495	0.19	0.15	Cardiac Troponin-T levels;	chr6:28080846	chr6:28091154~28093664:+
THCA	cis	rs172166	0.652	rs476167	ENSG00000219891.2	ZSCAN12P1	3.34	0.000906	0.0495	0.19	0.15	Cardiac Troponin-T levels;	chr6:28098110	chr6:28091154~28093664:+
THCA	cis	rs172166	0.694	rs203892	ENSG00000219891.2	ZSCAN12P1	3.34	0.000906	0.0495	0.19	0.15	Cardiac Troponin-T levels;	chr6:28099418	chr6:28091154~28093664:+
THCA	cis	rs791888	0.929	rs2755431	ENSG00000236417.2	CTSLP1	3.34	0.000906	0.0495	0.19	0.15	Magnesium levels;	chr10:87655347	chr10:87386685~87390203:-
THCA	cis	rs910316	0.763	rs175014	ENSG00000259138.1	RP11-950C14.7	-3.34	0.000906	0.0495	-0.13	-0.15	Height;	chr14:74990224	chr14:75127153~75136930:+
THCA	cis	rs62289301	0.571	rs10461112	ENSG00000273133.1	RP11-799M12.2	-3.34	0.000906	0.0495	-0.19	-0.15	Joint mobility (Beighton score);	chr4:15455676	chr4:15563698~15564253:-
THCA	cis	rs7107174	1	rs4944198	ENSG00000254459.1	RP11-91P24.7	-3.34	0.000906	0.0495	-0.21	-0.15	Testicular germ cell tumor;	chr11:78321559	chr11:77829654~77872262:-
THCA	cis	rs7709377	0.671	rs7707320	ENSG00000250015.1	CTC-339F2.2	3.34	0.000906	0.0495	0.16	0.15	Metabolite levels  (X-11787);	chr5:116156564	chr5:116302354~116304134:-
THCA	cis	rs17133449	0.718	rs2167695	ENSG00000205488.7	CALML3-AS1	-3.34	0.000906	0.0495	-0.18	-0.15	Major depressive disorder;	chr10:4711788	chr10:5514244~5526246:-
THCA	cis	rs1737890	0.778	rs6087868	ENSG00000235217.6	TSPY26P	-3.34	0.000906	0.0495	-0.17	-0.15	Chronic obstructive pulmonary disease;	chr20:32300072	chr20:32186477~32190527:-
THCA	cis	rs877529	0.934	rs139419	ENSG00000279833.1	RP4-742C19.13	-3.34	0.000906	0.0495	-0.1	-0.15	Multiple myeloma;	chr22:39161335	chr22:39133090~39136760:+
THCA	cis	rs10760158	0.832	rs13292100	ENSG00000235865.2	GSN-AS1	3.34	0.000906	0.0495	0.13	0.15	Pulse pressure;	chr9:121278719	chr9:121280768~121285530:-
THCA	cis	rs832540	0.931	rs1445996	ENSG00000271828.1	CTD-2310F14.1	3.34	0.000906	0.0495	0.21	0.15	Coronary artery disease;	chr5:56939721	chr5:56927874~56929573:+
THCA	cis	rs755249	1	rs4660293	ENSG00000182109.6	RP11-69E11.4	-3.34	0.000906	0.0495	-0.17	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39522280~39546187:-
THCA	cis	rs1790761	0.692	rs10896179	ENSG00000184224.3	C11orf72	3.34	0.000906	0.0495	0.2	0.15	Mean corpuscular volume;	chr11:67549457	chr11:67602880~67606706:-
THCA	cis	rs7084402	0.967	rs1649025	ENSG00000180221.6	TPT1P10	-3.34	0.000906	0.0495	-0.18	-0.15	Refractive error;	chr10:58521824	chr10:58212541~58213036:-
THCA	cis	rs7084402	0.967	rs1658490	ENSG00000180221.6	TPT1P10	-3.34	0.000906	0.0495	-0.18	-0.15	Refractive error;	chr10:58521856	chr10:58212541~58213036:-
THCA	cis	rs1850744	0.51	rs2280203	ENSG00000250942.1	ENPP7P11	3.34	0.000906	0.0495	0.2	0.15	Economic and political preferences;	chr4:9907935	chr4:9677308~9677934:+
THCA	cis	rs6988985	0.728	rs10105643	ENSG00000247317.3	RP11-273G15.2	-3.34	0.000906	0.0495	-0.17	-0.15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142876470	chr8:142981738~143018437:-
THCA	cis	rs867186	0.764	rs35291022	ENSG00000126005.14	MMP24-AS1	-3.34	0.000906	0.0495	-0.26	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34949354	chr20:35216462~35278131:-
THCA	cis	rs9487051	0.872	rs9487043	ENSG00000260273.1	RP11-425D10.10	3.34	0.000906	0.0495	0.18	0.15	Reticulocyte fraction of red cells;	chr6:109289271	chr6:109382795~109383666:+
THCA	cis	rs2950393	0.929	rs7980835	ENSG00000258045.2	Metazoa_SRP	-3.34	0.000906	0.0495	-0.13	-0.15	Platelet distribution width;	chr12:56676847	chr12:55731264~55731531:-
THCA	cis	rs2950393	0.929	rs10747769	ENSG00000258045.2	Metazoa_SRP	-3.34	0.000906	0.0495	-0.13	-0.15	Platelet distribution width;	chr12:56677056	chr12:55731264~55731531:-
THCA	cis	rs7911264	0.628	rs7921040	ENSG00000236493.2	EIF2S2P3	3.34	0.000906	0.0495	0.16	0.15	Inflammatory bowel disease;	chr10:92658668	chr10:92668745~92669743:-
THCA	cis	rs8014204	0.839	rs6574197	ENSG00000279594.1	RP11-950C14.10	-3.34	0.000906	0.0495	-0.15	-0.15	Caffeine consumption;	chr14:74864784	chr14:75011269~75012851:-
THCA	cis	rs524281	0.861	rs7943911	ENSG00000255038.1	RP11-1167A19.2	-3.34	0.000907	0.0495	-0.17	-0.15	Electroencephalogram traits;	chr11:66175583	chr11:66067277~66069619:-
THCA	cis	rs10515778	0.948	rs17719770	ENSG00000280834.1	U6	3.34	0.000907	0.0495	0.26	0.15	Inflammatory skin disease;	chr5:159169981	chr5:160072268~160072364:+
THCA	cis	rs10515778	0.948	rs12188266	ENSG00000280834.1	U6	3.34	0.000907	0.0495	0.26	0.15	Inflammatory skin disease;	chr5:159171955	chr5:160072268~160072364:+
THCA	cis	rs10515778	0.898	rs17720062	ENSG00000280834.1	U6	3.34	0.000907	0.0495	0.26	0.15	Inflammatory skin disease;	chr5:159177376	chr5:160072268~160072364:+
THCA	cis	rs10515778	0.948	rs72813991	ENSG00000280834.1	U6	3.34	0.000907	0.0495	0.26	0.15	Inflammatory skin disease;	chr5:159178579	chr5:160072268~160072364:+
THCA	cis	rs10515778	0.898	rs55931437	ENSG00000280834.1	U6	3.34	0.000907	0.0495	0.26	0.15	Inflammatory skin disease;	chr5:159182608	chr5:160072268~160072364:+
THCA	cis	rs13326165	0.76	rs9844183	ENSG00000280417.1	RP11-5O17.1	-3.34	0.000907	0.0495	-0.19	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52281176	chr3:53046166~53048122:+
THCA	cis	rs972578	0.651	rs5759002	ENSG00000230319.1	AL022476.2	-3.34	0.000907	0.0495	-0.16	-0.15	Mean platelet volume;	chr22:42867426	chr22:43038585~43052366:+
THCA	cis	rs74400468	0.529	rs11239742	ENSG00000277479.1	AL022345.10	3.34	0.000907	0.0495	0.29	0.15	Cannabis dependence symptom count;	chr10:42710205	chr10:42578500~42578727:+
THCA	cis	rs2013441	0.786	rs4003797	ENSG00000261033.1	RP11-209D14.2	3.34	0.000907	0.0495	0.21	0.15	Obesity-related traits;	chr17:20385587	chr17:20008051~20009234:-
THCA	cis	rs55702914	0.628	rs67657812	ENSG00000231621.1	AC013264.2	-3.34	0.000907	0.0495	-0.14	-0.15	Major depression and alcohol dependence;	chr2:197522677	chr2:197197991~197199273:+
THCA	cis	rs9844985	0.669	rs6806238	ENSG00000243014.1	PTMAP8	3.34	0.000907	0.0495	0.18	0.15	Major depression and alcohol dependence;	chr3:117166511	chr3:117026698~117027039:+
THCA	cis	rs793571	0.784	rs8029301	ENSG00000259250.1	RP11-50C13.1	-3.34	0.000907	0.0495	-0.15	-0.15	Schizophrenia;	chr15:58829637	chr15:58587507~58591676:+
THCA	cis	rs58688157	0.705	rs12290989	ENSG00000269915.1	AP006621.9	-3.34	0.000907	0.0495	-0.17	-0.15	Systemic lupus erythematosus;	chr11:615010	chr11:708564~727047:-
THCA	cis	rs10807026	1	rs10807026	ENSG00000216901.1	AL022393.7	-3.34	0.000907	0.0495	-0.2	-0.15	Lung adenocarcinoma;	chr6:27587740	chr6:28176188~28176674:+
THCA	cis	rs2638953	0.962	rs11049488	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259439	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs57618147	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259902	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs716687	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261517	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.925	rs11049491	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28262340	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049493	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28263115	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049496	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28267327	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.819	rs10843146	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28268352	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.889	rs2045887	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28270825	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs2172299	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28280180	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049503	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28282714	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs61922974	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283302	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs61922975	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283705	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs61922976	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283837	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs61922977	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28286889	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049505	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28288087	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049509	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000907	0.0495	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290055	chr12:28163298~28190738:-
THCA	cis	rs72675573	0.567	rs10888955	ENSG00000260971.3	RP11-504A18.1	3.34	0.000907	0.0495	0.14	0.15	Monocyte count;	chr1:56108684	chr1:56248294~56258571:-
THCA	cis	rs7621331	1	rs13097946	ENSG00000239213.4	NCK1-AS1	-3.34	0.000907	0.0495	-0.15	-0.15	Waist circumference adjusted for body mass index;	chr3:135994780	chr3:136841726~136862054:-
THCA	cis	rs6600671	0.967	rs4844613	ENSG00000226067.5	CH17-118O6.2	3.34	0.000907	0.0496	0.15	0.15	Hip geometry;	chr1:121431913	chr1:120913275~121009291:+
THCA	cis	rs6445967	0.53	rs3922711	ENSG00000272360.1	RP11-359I18.5	3.34	0.000907	0.0496	0.18	0.15	Platelet count;	chr3:58398516	chr3:58490830~58491291:-
THCA	cis	rs10905099	0.505	rs7897607	ENSG00000278982.1	RP5-1031D4.3	3.34	0.000907	0.0496	0.26	0.15	Orofacial clefts;	chr10:7042390	chr10:7411599~7413467:+
THCA	cis	rs712039	0.652	rs8069062	ENSG00000277501.1	RP11-697E22.2	3.34	0.000907	0.0496	0.22	0.15	Tuberculosis;	chr17:37469202	chr17:37642947~37684252:+
THCA	cis	rs712039	0.652	rs60112577	ENSG00000277501.1	RP11-697E22.2	3.34	0.000907	0.0496	0.22	0.15	Tuberculosis;	chr17:37473105	chr17:37642947~37684252:+
THCA	cis	rs45544231	1	rs3104791	ENSG00000279344.1	RP11-44F14.7	3.34	0.000907	0.0496	0.14	0.15	Restless legs syndrome;	chr16:52605050	chr16:53478957~53481550:-
THCA	cis	rs4788196	1	rs4788196	ENSG00000183604.13	SMG1P5	-3.34	0.000907	0.0496	-0.15	-0.15	Pubertal anthropometrics;	chr16:29956113	chr16:30267553~30335374:-
THCA	cis	rs6580649	0.831	rs4760620	ENSG00000273765.1	RP11-370I10.11	3.34	0.000907	0.0496	0.16	0.15	Lung cancer;	chr12:48165859	chr12:48360920~48361377:+
THCA	cis	rs7474896	0.513	rs11011248	ENSG00000276805.1	RP11-291L22.6	-3.34	0.000907	0.0496	-0.3	-0.15	Obesity (extreme);	chr10:37552381	chr10:38451030~38451785:+
THCA	cis	rs6600671	1	rs1591882	ENSG00000233029.3	RP11-439A17.9	-3.34	0.000907	0.0496	-0.17	-0.15	Hip geometry;	chr1:121441455	chr1:121090289~121097655:-
THCA	cis	rs7028939	0.535	rs78818503	ENSG00000234709.2	UPF3AP3	-3.34	0.000907	0.0496	-0.24	-0.15	Preeclampsia;	chr9:100395391	chr9:99998301~99999069:-
THCA	cis	rs4081724	0.608	rs62126646	ENSG00000267296.2	CEBPA-AS1	3.34	0.000908	0.0496	0.18	0.15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33337377	chr19:33302857~33305054:+
THCA	cis	rs6545883	0.929	rs9679557	ENSG00000212978.6	AC016747.3	3.34	0.000908	0.0496	0.17	0.15	Tuberculosis;	chr2:61482214	chr2:61141592~61144969:-
THCA	cis	rs6107848	0.586	rs6133327	ENSG00000233578.1	EIF4EP1	-3.34	0.000908	0.0496	-0.15	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr20:6509082	chr20:5548840~5549481:+
THCA	cis	rs668210	0.739	rs543952	ENSG00000214659.4	KRT8P26	3.34	0.000908	0.0496	0.17	0.15	Cerebrospinal fluid biomarker levels;	chr11:65976804	chr11:65726939~65728214:+
THCA	cis	rs577676	0.564	rs644784	ENSG00000271811.1	RP1-79C4.4	3.34	0.000908	0.0496	0.19	0.15	Prevalent atrial fibrillation;	chr1:170636945	chr1:170667381~170669425:+
THCA	cis	rs7045881	0.8	rs62544435	ENSG00000234676.1	IFT74-AS1	-3.34	0.000908	0.0496	-0.3	-0.15	Schizophrenia;	chr9:26900096	chr9:26955780~26956295:-
THCA	cis	rs7045881	0.8	rs10511792	ENSG00000234676.1	IFT74-AS1	-3.34	0.000908	0.0496	-0.3	-0.15	Schizophrenia;	chr9:26901070	chr9:26955780~26956295:-
THCA	cis	rs889122	0.683	rs7245830	ENSG00000267289.1	CTD-2623N2.11	3.34	0.000908	0.0496	0.19	0.15	Menarche (age at onset);	chr19:9890337	chr19:9834079~9835013:-
THCA	cis	rs28643277	0.532	rs10737103	ENSG00000237470.3	DCLRE1CP1	3.34	0.000908	0.0496	0.2	0.15	Periodontitis (CDC/AAP);	chr10:15506839	chr10:15015370~15021863:-
THCA	cis	rs1913185	0.891	rs67325724	ENSG00000243415.2	RP11-274H2.2	-3.34	0.000908	0.0496	-0.2	-0.15	Obesity-related traits;	chr3:146156940	chr3:146064042~146105204:+
THCA	cis	rs7665090	0.84	rs7674640	ENSG00000248971.2	KRT8P46	-3.34	0.000908	0.0496	-0.18	-0.15	Primary biliary cholangitis;	chr4:102619623	chr4:102728746~102730171:-
THCA	cis	rs12210905	1	rs115268625	ENSG00000224843.5	LINC00240	3.34	0.000908	0.0496	0.25	0.15	Hip circumference adjusted for BMI;	chr6:26980450	chr6:26956992~27023924:+
THCA	cis	rs12210905	1	rs12192446	ENSG00000224843.5	LINC00240	3.34	0.000908	0.0496	0.25	0.15	Hip circumference adjusted for BMI;	chr6:27027859	chr6:26956992~27023924:+
THCA	cis	rs12210905	1	rs76889265	ENSG00000224843.5	LINC00240	3.34	0.000908	0.0496	0.25	0.15	Hip circumference adjusted for BMI;	chr6:27041056	chr6:26956992~27023924:+
THCA	cis	rs2061333	1	rs2061333	ENSG00000277806.1	RP11-15A1.8	3.34	0.000908	0.0496	0.18	0.15	Alzheimer's disease;	chr19:44110055	chr19:43976815~43977448:+
THCA	cis	rs17470137	0.592	rs337098	ENSG00000263432.2	RN7SL689P	-3.34	0.000908	0.0496	-0.17	-0.15	Aortic root size;	chr5:123233822	chr5:123022487~123022783:-
THCA	cis	rs1336149	0.509	rs2766079	ENSG00000211581.1	MIR765	3.34	0.000908	0.0496	0.21	0.15	Chin dimples;	chr1:157081952	chr1:156936131~156936244:-
THCA	cis	rs588177	0.919	rs2244625	ENSG00000236935.1	AP003774.1	3.34	0.000908	0.0496	0.16	0.15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64258672	chr11:64325050~64329504:-
THCA	cis	rs950893	0.729	rs13264439	ENSG00000253986.1	CTC-756D1.3	-3.34	0.000908	0.0496	-0.19	-0.15	Mean corpuscular hemoglobin;	chr8:23607550	chr8:23493009~23494198:-
THCA	cis	rs6074022	0.912	rs4810485	ENSG00000225849.1	RP5-981L23.2	3.34	0.000908	0.0496	0.16	0.15	Inflammatory bowel disease;Crohn's disease;Multiple sclerosis;	chr20:46119308	chr20:46463902~46465124:-
THCA	cis	rs3809566	0.676	rs11071719	ENSG00000259459.4	RP11-321G12.1	-3.34	0.000908	0.0496	-0.12	-0.15	Platelet count;	chr15:63037676	chr15:63390136~63438320:+
THCA	cis	rs7520050	0.778	rs2991985	ENSG00000281912.1	LINC01144	3.34	0.000908	0.0496	0.1	0.15	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45303910~45305619:+
THCA	cis	rs409045	1	rs456329	ENSG00000271874.1	CTD-2024P10.2	-3.34	0.000908	0.0496	-0.2	-0.15	Left ventricular mass;	chr5:34632496	chr5:34651457~34651888:-
THCA	cis	rs1914816	0.941	rs2469544	ENSG00000260269.4	CTD-2323K18.1	-3.34	0.000908	0.0496	-0.27	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr15:76192606	chr15:75527150~75601205:-
THCA	cis	rs16915157	0.557	rs72822817	ENSG00000254271.1	RP11-131N11.4	3.34	0.000908	0.0496	0.31	0.15	Schizophrenia;	chr10:60551986	chr10:60734342~60741828:+
THCA	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	3.34	0.000908	0.0496	0.2	0.15	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
THCA	cis	rs12780845	1	rs7082376	ENSG00000229124.5	VIM-AS1	3.34	0.000908	0.0496	0.15	0.15	Homocysteine levels;	chr10:17190224	chr10:17214239~17229985:-
THCA	cis	rs683250	0.566	rs610062	ENSG00000254551.1	RP11-727A23.7	3.34	0.000908	0.0496	0.18	0.15	Subcortical brain region volumes;	chr11:83292247	chr11:83209431~83213379:-
THCA	cis	rs79149102	0.522	rs6495112	ENSG00000260103.2	RP11-10O17.1	-3.34	0.000908	0.0496	-0.21	-0.15	Lung cancer;	chr15:74540457	chr15:74478070~74490286:-
THCA	cis	rs79149102	0.522	rs7175512	ENSG00000260103.2	RP11-10O17.1	-3.34	0.000908	0.0496	-0.21	-0.15	Lung cancer;	chr15:74540640	chr15:74478070~74490286:-
THCA	cis	rs801193	0.569	rs35070132	ENSG00000223473.2	GS1-124K5.3	3.34	0.000908	0.0496	0.11	0.15	Aortic root size;	chr7:66773096	chr7:66491049~66493566:-
THCA	cis	rs2933343	0.7	rs883602	ENSG00000261159.1	RP11-723O4.9	3.34	0.000908	0.0496	0.15	0.15	IgG glycosylation;	chr3:128935109	chr3:128859716~128860526:-
THCA	cis	rs11719291	0.833	rs11713694	ENSG00000229759.1	MRPS18AP1	-3.34	0.000908	0.0496	-0.32	-0.15	Cognitive function;	chr3:48796182	chr3:48256350~48256938:-
THCA	cis	rs11719291	0.833	rs11709246	ENSG00000229759.1	MRPS18AP1	-3.34	0.000908	0.0496	-0.32	-0.15	Cognitive function;	chr3:48822065	chr3:48256350~48256938:-
THCA	cis	rs11719291	0.504	rs71324924	ENSG00000229759.1	MRPS18AP1	-3.34	0.000908	0.0496	-0.32	-0.15	Cognitive function;	chr3:48828011	chr3:48256350~48256938:-
THCA	cis	rs7737355	0.853	rs1468453	ENSG00000224431.1	AC063976.7	3.34	0.000908	0.0496	0.15	0.15	Life satisfaction;	chr5:131251766	chr5:132199456~132203487:+
THCA	cis	rs7737355	0.947	rs6895586	ENSG00000224431.1	AC063976.7	3.34	0.000908	0.0496	0.15	0.15	Life satisfaction;	chr5:131252315	chr5:132199456~132203487:+
THCA	cis	rs11971779	0.68	rs4728467	ENSG00000252332.1	RNU6-911P	-3.34	0.000908	0.0496	-0.18	-0.15	Diisocyanate-induced asthma;	chr7:139435816	chr7:139448740~139448843:+
THCA	cis	rs76793172	1	rs16980059	ENSG00000207003.1	RNU6-611P	3.34	0.000909	0.0496	0.29	0.15	Eosinophil counts;	chr19:45850376	chr19:45047458~45047561:+
THCA	cis	rs1864982	0.581	rs1630123	ENSG00000251556.1	RP11-118M9.3	-3.34	0.000909	0.0496	-0.24	-0.15	Alcohol dependence;	chr5:146899720	chr5:146099406~146120412:+
THCA	cis	rs30388	0.585	rs12448350	ENSG00000261390.4	RP11-345M22.2	-3.34	0.000909	0.0496	-0.17	-0.15	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr16:79580564	chr16:79715232~79770563:-
THCA	cis	rs10995356	0.844	rs10822099	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000909	0.0496	-0.18	-0.15	Temperament;	chr10:62962272	chr10:62793562~62805887:-
THCA	cis	rs10995356	0.844	rs10822100	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000909	0.0496	-0.18	-0.15	Temperament;	chr10:62962646	chr10:62793562~62805887:-
THCA	cis	rs11048434	0.761	rs12824380	ENSG00000245105.2	A2M-AS1	3.34	0.000909	0.0496	0.12	0.15	Sjögren's syndrome;	chr12:8979421	chr12:9065177~9068060:+
THCA	cis	rs950027	0.62	rs1153862	ENSG00000259479.5	SORD2P	3.34	0.000909	0.0496	0.16	0.15	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:44826371~44884694:-
THCA	cis	rs7577696	0.637	rs693918	ENSG00000276334.1	AL133243.1	3.34	0.000909	0.0496	0.16	0.15	Inflammatory biomarkers;	chr2:31643808	chr2:32521927~32523547:+
THCA	cis	rs9982086	0.793	rs57502095	ENSG00000260583.1	AP000223.42	-3.34	0.000909	0.0496	-0.36	-0.15	Carboplatin disposition in epthelial ovarian cancer;	chr21:25525039	chr21:25582770~25583326:-
THCA	cis	rs12285276	0.636	rs7120031	ENSG00000205106.4	DKFZp779M0652	3.34	0.000909	0.0496	0.17	0.15	Visceral fat;	chr11:45794469	chr11:45771432~45772358:+
THCA	cis	rs1023500	1	rs1047997	ENSG00000237037.8	NDUFA6-AS1	3.34	0.000909	0.0496	0.15	0.15	Schizophrenia;	chr22:41938949	chr22:42090931~42137742:+
THCA	cis	rs2360027	0.622	rs10157240	ENSG00000231365.4	RP11-418J17.1	-3.34	0.000909	0.0496	-0.15	-0.15	Tonsillectomy;	chr1:118611330	chr1:119140396~119275973:+
THCA	cis	rs504458	0.618	rs6682490	ENSG00000241975.1	TCEB1P19	-3.34	0.000909	0.0496	-0.17	-0.15	Childhood ear infection;	chr1:88359607	chr1:88829102~88829419:+
THCA	cis	rs8022179	0.566	rs62006258	ENSG00000269958.1	RP11-73M18.8	-3.34	0.000909	0.0496	-0.15	-0.15	Monocyte count;	chr14:103372572	chr14:103696353~103697163:+
THCA	cis	rs10751667	0.601	rs10902272	ENSG00000255142.1	AP006621.6	-3.34	0.000909	0.0496	-0.13	-0.15	Alzheimer's disease (late onset);	chr11:1040821	chr11:781645~782105:+
THCA	cis	rs375066	0.62	rs10401170	ENSG00000176761.7	ZNF285B	3.34	0.000909	0.0496	0.18	0.15	Breast cancer;	chr19:43795471	chr19:44467641~44473227:+
THCA	cis	rs7246657	0.943	rs7258692	ENSG00000268499.1	CTB-102L5.8	3.34	0.000909	0.0496	0.2	0.15	Coronary artery calcification;	chr19:37327927	chr19:38199836~38200934:+
THCA	cis	rs854765	0.663	rs9915248	ENSG00000281749.1	Y_RNA	-3.34	0.000909	0.0496	-0.19	-0.15	Total body bone mineral density;	chr17:17844200	chr17:18001101~18001195:-
THCA	cis	rs10489202	0.657	rs3767478	ENSG00000250762.1	RP1-313L4.4	-3.34	0.000909	0.0496	-0.21	-0.15	Schizophrenia;	chr1:168100388	chr1:167819898~167820248:-
THCA	cis	rs7824557	0.564	rs12550129	ENSG00000255046.1	RP11-297N6.4	3.34	0.000909	0.0496	0.16	0.15	Retinal vascular caliber;	chr8:11376408	chr8:11797928~11802568:-
THCA	cis	rs10208649	0.505	rs9309252	ENSG00000233266.1	HMGB1P31	3.34	0.000909	0.0496	0.25	0.15	Body mass index;	chr2:53938635	chr2:54051334~54051760:+
THCA	cis	rs2882667	0.861	rs7703288	ENSG00000249593.5	CTB-46B19.2	3.34	0.000909	0.0496	0.18	0.15	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:139012647~139051203:+
THCA	cis	rs9933309	1	rs9933309	ENSG00000260121.1	RP5-1142A6.9	3.34	0.000909	0.0496	0.13	0.15	Glycated hemoglobin levels;	chr16:88778524	chr16:88718615~88720459:+
THCA	cis	rs7665090	0.967	rs5026469	ENSG00000230069.3	LRRC37A15P	-3.34	0.000909	0.0496	-0.15	-0.15	Primary biliary cholangitis;	chr4:102633556	chr4:102727274~102730721:-
THCA	cis	rs7665090	0.967	rs5026470	ENSG00000230069.3	LRRC37A15P	-3.34	0.000909	0.0496	-0.15	-0.15	Primary biliary cholangitis;	chr4:102633565	chr4:102727274~102730721:-
THCA	cis	rs7665090	0.967	rs5026471	ENSG00000230069.3	LRRC37A15P	-3.34	0.000909	0.0496	-0.15	-0.15	Primary biliary cholangitis;	chr4:102633576	chr4:102727274~102730721:-
THCA	cis	rs4906172	1	rs2403015	ENSG00000259230.1	CTD-2555C10.3	-3.34	0.000909	0.0496	-0.23	-0.15	Menopause (age at onset);	chr14:101961223	chr14:102545254~102555826:+
THCA	cis	rs12621844	0.671	rs963135	ENSG00000272663.1	RP11-191L17.1	-3.34	0.000909	0.0496	-0.15	-0.15	Glycated hemoglobin levels;	chr2:48081352	chr2:48440043~48440597:-
THCA	cis	rs1862618	0.853	rs832583	ENSG00000234553.1	AC022431.3	-3.34	0.000909	0.0496	-0.18	-0.15	Initial pursuit acceleration;	chr5:56882390	chr5:56536583~56537826:-
THCA	cis	rs6017317	0.696	rs1884611	ENSG00000244558.4	KCNK15-AS1	-3.34	0.000909	0.0496	-0.22	-0.15	Type 2 diabetes;	chr20:44296048	chr20:44694892~44746021:-
THCA	cis	rs80168506	0.748	rs7574907	ENSG00000234308.2	AC093381.2	3.34	0.000909	0.0496	0.18	0.15	Selective IgA deficiency;	chr2:213221535	chr2:212795331~212819264:+
THCA	cis	rs13437751	0.649	rs60897208	ENSG00000224458.3	GUSBP6	3.34	0.000909	0.0496	0.33	0.15	QT interval (drug interaction);	chr7:63887340	chr7:64100305~64150721:+
THCA	cis	rs13437751	0.649	rs10235050	ENSG00000224458.3	GUSBP6	3.34	0.000909	0.0496	0.33	0.15	QT interval (drug interaction);	chr7:63888405	chr7:64100305~64150721:+
THCA	cis	rs13437751	0.536	rs10238457	ENSG00000224458.3	GUSBP6	3.34	0.000909	0.0496	0.33	0.15	QT interval (drug interaction);	chr7:63888836	chr7:64100305~64150721:+
THCA	cis	rs7615952	0.688	rs7624806	ENSG00000241278.1	ENPP7P4	3.34	0.000909	0.0496	0.22	0.15	Blood pressure (smoking interaction);	chr3:125880231	chr3:125848223~125909372:+
THCA	cis	rs9494145	0.526	rs9389272	ENSG00000232876.1	CTA-212D2.2	-3.34	0.000909	0.0497	-0.23	-0.15	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135138699	chr6:135055033~135060550:+
THCA	cis	rs6840360	1	rs6535821	ENSG00000251611.1	RP11-610P16.1	-3.34	0.000909	0.0497	-0.11	-0.15	Intelligence (multi-trait analysis);	chr4:151757822	chr4:151407551~151408835:-
THCA	cis	rs76439304	1	rs17485072	ENSG00000247903.1	RP11-421F16.3	-3.34	0.000909	0.0497	-0.23	-0.15	Mean corpuscular volume;	chr12:26909926	chr12:26971586~26979582:+
THCA	cis	rs36132109	0.858	rs13081266	ENSG00000273328.4	RP11-141M3.6	3.34	0.000909	0.0497	0.19	0.15	Monocyte chemoattractant protein-1 levels;	chr3:42963598	chr3:42809414~42908105:+
THCA	cis	rs561341	0.609	rs739800	ENSG00000214708.4	AC090616.2	-3.34	0.00091	0.0497	-0.18	-0.15	Hip circumference adjusted for BMI;	chr17:31863064	chr17:32141226~32143135:-
THCA	cis	rs561341	0.609	rs7214626	ENSG00000214708.4	AC090616.2	-3.34	0.00091	0.0497	-0.18	-0.15	Hip circumference adjusted for BMI;	chr17:31863970	chr17:32141226~32143135:-
THCA	cis	rs7819412	0.703	rs2409713	ENSG00000255046.1	RP11-297N6.4	3.34	0.00091	0.0497	0.16	0.15	Triglycerides;	chr8:11152287	chr8:11797928~11802568:-
THCA	cis	rs867186	1	rs112777695	ENSG00000279253.1	RP4-614O4.13	-3.34	0.00091	0.0497	-0.23	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35105374	chr20:35262727~35264187:-
THCA	cis	rs7495517	0.686	rs7168033	ENSG00000278840.1	RP11-345N11.1	3.34	0.00091	0.0497	0.17	0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:27274506	chr15:26557598~26557937:-
THCA	cis	rs38864	1	rs193569	ENSG00000231210.2	LINC01510	3.34	0.00091	0.0497	0.22	0.15	Colonoscopy-negative controls vs population controls;	chr7:117175103	chr7:116570960~116614820:-
THCA	cis	rs12780845	1	rs10490958	ENSG00000229124.5	VIM-AS1	-3.34	0.00091	0.0497	-0.15	-0.15	Homocysteine levels;	chr10:17191451	chr10:17214239~17229985:-
THCA	cis	rs11125529	0.585	rs10205866	ENSG00000233266.1	HMGB1P31	3.34	0.00091	0.0497	0.26	0.15	Telomere length;	chr2:54266113	chr2:54051334~54051760:+
THCA	cis	rs2638953	0.889	rs11049481	ENSG00000247934.4	RP11-967K21.1	-3.34	0.00091	0.0497	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252087	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049482	ENSG00000247934.4	RP11-967K21.1	-3.34	0.00091	0.0497	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252088	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049484	ENSG00000247934.4	RP11-967K21.1	-3.34	0.00091	0.0497	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252254	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs11049485	ENSG00000247934.4	RP11-967K21.1	-3.34	0.00091	0.0497	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252522	chr12:28163298~28190738:-
THCA	cis	rs2638953	0.962	rs10843143	ENSG00000247934.4	RP11-967K21.1	-3.34	0.00091	0.0497	-0.16	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28253484	chr12:28163298~28190738:-
THCA	cis	rs17253792	0.822	rs79022053	ENSG00000186615.9	KTN1-AS1	-3.34	0.00091	0.0497	-0.26	-0.15	Putamen volume;	chr14:55605003	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs76555508	ENSG00000186615.9	KTN1-AS1	-3.34	0.00091	0.0497	-0.26	-0.15	Putamen volume;	chr14:55605150	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.908	rs9972177	ENSG00000186615.9	KTN1-AS1	-3.34	0.00091	0.0497	-0.26	-0.15	Putamen volume;	chr14:55606488	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs9972178	ENSG00000186615.9	KTN1-AS1	-3.34	0.00091	0.0497	-0.26	-0.15	Putamen volume;	chr14:55606762	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs9972180	ENSG00000186615.9	KTN1-AS1	-3.34	0.00091	0.0497	-0.26	-0.15	Putamen volume;	chr14:55607014	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs10142757	ENSG00000186615.9	KTN1-AS1	-3.34	0.00091	0.0497	-0.26	-0.15	Putamen volume;	chr14:55607493	chr14:55499278~55580110:-
THCA	cis	rs17253792	0.822	rs10143002	ENSG00000186615.9	KTN1-AS1	-3.34	0.00091	0.0497	-0.26	-0.15	Putamen volume;	chr14:55607560	chr14:55499278~55580110:-
THCA	cis	rs17092148	1	rs62211617	ENSG00000269202.1	RP4-614O4.12	-3.34	0.00091	0.0497	-0.17	-0.15	Neuroticism;	chr20:34812552	chr20:35201747~35203288:-
THCA	cis	rs17092148	1	rs11699062	ENSG00000269202.1	RP4-614O4.12	-3.34	0.00091	0.0497	-0.17	-0.15	Neuroticism;	chr20:34812576	chr20:35201747~35203288:-
THCA	cis	rs3126085	0.935	rs3126046	ENSG00000237975.5	FLG-AS1	3.34	0.00091	0.0497	0.24	0.15	Atopic dermatitis;	chr1:152284449	chr1:152168125~152445456:+
THCA	cis	rs3126085	0.935	rs3120660	ENSG00000237975.5	FLG-AS1	3.34	0.00091	0.0497	0.24	0.15	Atopic dermatitis;	chr1:152286225	chr1:152168125~152445456:+
THCA	cis	rs7626019	0.516	rs61296186	ENSG00000222872.1	RNU4-78P	3.34	0.00091	0.0497	0.21	0.15	Neurofibrillary tangles;	chr3:42229003	chr3:42221840~42221965:+
THCA	cis	rs7412746	0.611	rs12085336	ENSG00000224800.1	RP11-235D19.2	-3.34	0.00091	0.0497	-0.2	-0.15	Melanoma;	chr1:150803304	chr1:150881236~150881683:-
THCA	cis	rs10940346	0.807	rs6898102	ENSG00000271752.1	RP11-269M20.3	3.34	0.00091	0.0497	0.15	0.15	Schizophrenia;	chr5:50578496	chr5:50662859~50663266:-
THCA	cis	rs74781061	0.722	rs77102700	ENSG00000260103.2	RP11-10O17.1	-3.34	0.00091	0.0497	-0.21	-0.15	Endometriosis;	chr15:74604600	chr15:74478070~74490286:-
THCA	cis	rs11142387	0.621	rs7873409	ENSG00000204706.13	MAMDC2-AS1	3.34	0.00091	0.0497	0.11	0.15	Body mass index (SNP x SNP interaction);Body mass index;Intelligence (multi-trait analysis);	chr9:70465451	chr9:70033921~70175888:-
THCA	cis	rs875971	0.862	rs11773628	ENSG00000223473.2	GS1-124K5.3	-3.34	0.00091	0.0497	-0.1	-0.15	Aortic root size;	chr7:66517644	chr7:66491049~66493566:-
THCA	cis	rs321358	0.731	rs7926634	ENSG00000271390.1	RP11-89C3.3	-3.34	0.00091	0.0497	-0.24	-0.15	Body mass index;	chr11:111149618	chr11:111089870~111090368:-
THCA	cis	rs453301	0.686	rs11787026	ENSG00000248538.5	RP11-10A14.5	-3.34	0.00091	0.0497	-0.19	-0.15	Joint mobility (Beighton score);	chr8:9044861	chr8:9189011~9202854:+
THCA	cis	rs9611565	0.649	rs9623450	ENSG00000237037.8	NDUFA6-AS1	-3.34	0.00091	0.0497	-0.14	-0.15	Vitiligo;	chr22:41779227	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.568	rs5751159	ENSG00000237037.8	NDUFA6-AS1	-3.34	0.00091	0.0497	-0.14	-0.15	Vitiligo;	chr22:41779361	chr22:42090931~42137742:+
THCA	cis	rs9611565	0.649	rs5758466	ENSG00000237037.8	NDUFA6-AS1	-3.34	0.00091	0.0497	-0.14	-0.15	Vitiligo;	chr22:41780055	chr22:42090931~42137742:+
THCA	cis	rs7081476	0.737	rs7919198	ENSG00000262412.1	RP11-85G18.6	-3.34	0.00091	0.0497	-0.38	-0.15	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr10:27208556	chr10:27243130~27250804:+
THCA	cis	rs7081476	0.737	rs4747592	ENSG00000262412.1	RP11-85G18.6	-3.34	0.00091	0.0497	-0.38	-0.15	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;	chr10:27209828	chr10:27243130~27250804:+
THCA	cis	rs2806561	0.619	rs7543975	ENSG00000249087.5	ZNF436-AS1	-3.34	0.00091	0.0497	-0.11	-0.15	Height;	chr1:23054623	chr1:23368997~23371839:+
THCA	cis	rs7412746	0.658	rs11589458	ENSG00000224800.1	RP11-235D19.2	-3.34	0.00091	0.0497	-0.21	-0.15	Melanoma;	chr1:150820140	chr1:150881236~150881683:-
THCA	cis	rs4808199	0.948	rs757000	ENSG00000267481.1	CTC-559E9.5	-3.34	0.00091	0.0497	-0.16	-0.15	Nonalcoholic fatty liver disease;	chr19:19337492	chr19:19788755~19790531:-
THCA	cis	rs4808199	0.948	rs757001	ENSG00000267481.1	CTC-559E9.5	-3.34	0.00091	0.0497	-0.16	-0.15	Nonalcoholic fatty liver disease;	chr19:19337999	chr19:19788755~19790531:-
THCA	cis	rs9860340	0.853	rs6797501	ENSG00000229729.5	RP11-159G9.5	3.34	0.00091	0.0497	0.1	0.15	Electroencephalographic traits in alcoholism;	chr3:87702661	chr3:88059274~88138973:+
THCA	cis	rs11085466	1	rs2292986	ENSG00000268119.4	CTD-2561J22.5	3.34	0.00091	0.0497	0.2	0.15	Colorectal or endometrial cancer;	chr19:21593530	chr19:21444241~21463908:-
THCA	cis	rs9650657	0.504	rs7813802	ENSG00000255046.1	RP11-297N6.4	-3.34	0.000911	0.0497	-0.16	-0.15	Neuroticism;	chr8:11176467	chr8:11797928~11802568:-
THCA	cis	rs763512	0.532	rs3110626	ENSG00000277501.1	RP11-697E22.2	-3.34	0.000911	0.0497	-0.23	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37536300	chr17:37642947~37684252:+
THCA	cis	rs45544231	1	rs3104790	ENSG00000279344.1	RP11-44F14.7	3.34	0.000911	0.0497	0.14	0.15	Restless legs syndrome;	chr16:52604751	chr16:53478957~53481550:-
THCA	cis	rs6430585	0.527	rs62168833	ENSG00000231890.6	DARS-AS1	-3.34	0.000911	0.0497	-0.18	-0.15	Corneal structure;	chr2:135691684	chr2:135985176~136022593:+
THCA	cis	rs758324	0.717	rs3916444	ENSG00000224431.1	AC063976.7	-3.34	0.000911	0.0497	-0.15	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:132019259	chr5:132199456~132203487:+
THCA	cis	rs9400467	0.528	rs7750792	ENSG00000272356.1	RP5-1112D6.8	-3.34	0.000911	0.0497	-0.12	-0.15	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:111309203~111313517:+
THCA	cis	rs2836950	0.565	rs2836934	ENSG00000235701.1	PCBP2P1	-3.34	0.000911	0.0497	-0.17	-0.15	Menarche (age at onset);	chr21:39192959	chr21:39171130~39172106:-
THCA	cis	rs8022179	0.58	rs6575979	ENSG00000269958.1	RP11-73M18.8	3.34	0.000911	0.0497	0.15	0.15	Monocyte count;	chr14:103374681	chr14:103696353~103697163:+
THCA	cis	rs73198271	0.751	rs617813	ENSG00000254153.1	CTA-398F10.2	3.34	0.000911	0.0497	0.17	0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8456909~8461337:-
THCA	cis	rs2692947	0.644	rs1168970	ENSG00000236750.1	AC009237.16	-3.34	0.000911	0.0497	-0.17	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96150867	chr2:95641634~95641980:-
THCA	cis	rs3015497	0.586	rs12587821	ENSG00000270062.1	RP11-248J18.3	3.34	0.000911	0.0497	0.17	0.15	Mean platelet volume;	chr14:50625836	chr14:50723777~50724272:-
THCA	cis	rs3015497	0.586	rs12587842	ENSG00000270062.1	RP11-248J18.3	3.34	0.000911	0.0497	0.17	0.15	Mean platelet volume;	chr14:50625844	chr14:50723777~50724272:-
THCA	cis	rs8054556	1	rs7190185	ENSG00000183604.13	SMG1P5	-3.34	0.000911	0.0497	-0.15	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29951031	chr16:30267553~30335374:-
THCA	cis	rs67539049	1	rs73546310	ENSG00000227888.4	FAM66A	-3.34	0.000911	0.0497	-0.23	-0.15	Itch intensity from mosquito bite;	chr8:11444992	chr8:12362019~12388296:+
THCA	cis	rs909116	0.509	rs569550	ENSG00000226416.1	MRPL23-AS1	-3.34	0.000911	0.0497	-0.17	-0.15	Breast cancer;	chr11:1865838	chr11:1983237~1989920:-
THCA	cis	rs1005277	0.603	rs1998062	ENSG00000099251.13	HSD17B7P2	3.34	0.000911	0.0497	0.13	0.15	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38356380~38378505:+
THCA	cis	rs8077577	0.943	rs62073603	ENSG00000273018.4	CTD-2303H24.2	-3.34	0.000911	0.0497	-0.25	-0.15	Obesity-related traits;	chr17:18161002	chr17:18511221~18551705:-
THCA	cis	rs1729951	0.514	rs75977	ENSG00000239213.4	NCK1-AS1	3.34	0.000911	0.0497	0.13	0.15	Neuroticism;	chr3:136981707	chr3:136841726~136862054:-
THCA	cis	rs2277862	0.635	rs2378356	ENSG00000261582.1	RP4-614O4.11	-3.34	0.000911	0.0497	-0.18	-0.15	Cholesterol, total;	chr20:35513324	chr20:35267885~35280043:-
THCA	cis	rs10483853	0.806	rs8009393	ENSG00000258891.1	RP5-1021I20.5	-3.34	0.000911	0.0497	-0.2	-0.15	Coronary artery calcification;	chr14:73372872	chr14:73896164~73938114:-
THCA	cis	rs10483853	0.806	rs12589279	ENSG00000258891.1	RP5-1021I20.5	-3.34	0.000911	0.0497	-0.2	-0.15	Coronary artery calcification;	chr14:73386429	chr14:73896164~73938114:-
THCA	cis	rs61160187	0.61	rs4700397	ENSG00000272308.1	RP11-231G3.1	3.34	0.000911	0.0497	0.15	0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60866457~60866935:-
THCA	cis	rs1577917	0.958	rs10944144	ENSG00000220563.1	PKMP3	-3.34	0.000911	0.0497	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85828037	chr6:85659892~85660606:-
THCA	cis	rs1124769	0.654	rs12592344	ENSG00000259378.1	DCAF13P3	3.34	0.000911	0.0497	0.23	0.15	Cognitive performance;	chr15:51188447	chr15:50944663~50945996:+
THCA	cis	rs4589258	0.713	rs1792614	ENSG00000280367.1	RP11-121L10.2	3.34	0.000911	0.0497	0.15	0.15	Intelligence (multi-trait analysis);	chr11:90719344	chr11:90223153~90226538:+
THCA	cis	rs4589258	0.698	rs1792617	ENSG00000280367.1	RP11-121L10.2	-3.34	0.000911	0.0497	-0.15	-0.15	Intelligence (multi-trait analysis);	chr11:90715996	chr11:90223153~90226538:+
THCA	cis	rs4076555	0.558	rs11041393	ENSG00000251364.5	CTD-2516F10.2	-3.34	0.000911	0.0497	-0.14	-0.15	IgG glycosylation;	chr11:7455303	chr11:7427266~7512515:-
THCA	cis	rs8056893	0.513	rs3743742	ENSG00000274698.1	RP11-71L14.4	3.34	0.000911	0.0497	0.18	0.15	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68311133	chr16:68450283~68452318:+
THCA	cis	rs1790761	0.967	rs12573992	ENSG00000255318.1	RP11-655M14.13	-3.34	0.000911	0.0497	-0.17	-0.15	Mean corpuscular volume;	chr11:67430286	chr11:67618279~67627304:-
THCA	cis	rs1790761	0.967	rs4930427	ENSG00000255318.1	RP11-655M14.13	-3.34	0.000911	0.0497	-0.17	-0.15	Mean corpuscular volume;	chr11:67433348	chr11:67618279~67627304:-
THCA	cis	rs4845570	0.92	rs6694952	ENSG00000268288.1	RP11-98D18.16	3.34	0.000911	0.0497	0.22	0.15	Coronary artery disease;	chr1:151787655	chr1:151766486~151767000:-
THCA	cis	rs950169	0.887	rs71395453	ENSG00000230373.7	GOLGA6L5P	-3.34	0.000911	0.0497	-0.17	-0.15	Schizophrenia;	chr15:84570259	chr15:84507885~84516814:-
THCA	cis	rs2284219	0.894	rs1076291	ENSG00000226874.1	AC005154.8	-3.34	0.000911	0.0497	-0.16	-0.15	Type 2 diabetes;	chr7:30672979	chr7:30544053~30544431:+
THCA	cis	rs2284219	0.894	rs1076292	ENSG00000226874.1	AC005154.8	-3.34	0.000911	0.0497	-0.16	-0.15	Type 2 diabetes;	chr7:30673085	chr7:30544053~30544431:+
THCA	cis	rs2284219	0.894	rs2251002	ENSG00000226874.1	AC005154.8	-3.34	0.000911	0.0497	-0.16	-0.15	Type 2 diabetes;	chr7:30673228	chr7:30544053~30544431:+
THCA	cis	rs4434872	1	rs6690242	ENSG00000223599.1	RP11-216N14.7	3.34	0.000911	0.0497	0.25	0.15	Conduct disorder (symptom count);	chr1:153828622	chr1:153852106~153853414:-
THCA	cis	rs3742264	0.656	rs9534261	ENSG00000235903.6	CPB2-AS1	-3.34	0.000911	0.0497	-0.19	-0.15	Blood protein levels;	chr13:45959923	chr13:46052806~46113332:+
THCA	cis	rs28510890	0.51	rs3825982	ENSG00000258647.4	LINC00930	3.34	0.000911	0.0497	0.23	0.15	Lung cancer in ever smokers;	chr15:92617015	chr15:92567818~92572042:-
THCA	cis	rs9634489	0.542	rs9513139	ENSG00000247400.3	DNAJC3-AS1	3.34	0.000911	0.0497	0.1	0.15	Body mass index;	chr13:96405892	chr13:95648733~95676925:-
THCA	cis	rs6443245	0.611	rs2648385	ENSG00000227110.5	LMCD1-AS1	-3.34	0.000911	0.0497	-0.18	-0.15	Daytime sleep phenotypes;	chr3:9577083	chr3:7952805~8611924:-
THCA	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	3.34	0.000911	0.0497	0.17	0.15	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
THCA	cis	rs748404	0.516	rs523156	ENSG00000275601.1	AC011330.13	3.34	0.000912	0.0497	0.18	0.15	Lung cancer;	chr15:43519645	chr15:43642389~43643023:-
THCA	cis	rs2692947	0.794	rs2692893	ENSG00000273265.1	RP11-353K11.1	-3.34	0.000912	0.0497	-0.14	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96090799	chr2:96812239~96813657:-
THCA	cis	rs7122539	0.734	rs9971487	ENSG00000275484.1	CTC-1337H24.4	-3.34	0.000912	0.0497	-0.13	-0.15	HIV-1 susceptibility;	chr11:66899525	chr11:67374416~67374932:+
THCA	cis	rs4787491	0.729	rs11544328	ENSG00000275371.1	RP11-455F5.6	-3.34	0.000912	0.0497	-0.13	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30025807	chr16:30110895~30111955:+
THCA	cis	rs7201929	1	rs11644151	ENSG00000278665.1	RP11-666O2.4	-3.34	0.000912	0.0498	-0.19	-0.15	QT interval;	chr16:28884339	chr16:28599241~28601881:-
THCA	cis	rs4703129	1	rs7732536	ENSG00000246763.5	RGMB-AS1	-3.34	0.000912	0.0498	-0.15	-0.15	Asperger disorder;	chr5:98523215	chr5:98769618~98773469:-
THCA	cis	rs4703129	1	rs1478455	ENSG00000246763.5	RGMB-AS1	-3.34	0.000912	0.0498	-0.15	-0.15	Asperger disorder;	chr5:98523448	chr5:98769618~98773469:-
THCA	cis	rs4703129	1	rs1156556	ENSG00000246763.5	RGMB-AS1	-3.34	0.000912	0.0498	-0.15	-0.15	Asperger disorder;	chr5:98523586	chr5:98769618~98773469:-
THCA	cis	rs4703129	1	rs4703106	ENSG00000246763.5	RGMB-AS1	-3.34	0.000912	0.0498	-0.15	-0.15	Asperger disorder;	chr5:98524458	chr5:98769618~98773469:-
THCA	cis	rs56104184	0.887	rs55869333	ENSG00000243829.1	CTB-33G10.1	-3.34	0.000912	0.0498	-0.19	-0.15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48838888	chr19:49719498~49720081:-
THCA	cis	rs77106637	0.932	rs3814730	ENSG00000256448.4	RP11-809N8.4	3.34	0.000912	0.0498	0.25	0.15	Type 2 diabetes;	chr11:72844508	chr11:73405297~73410682:+
THCA	cis	rs1958560	0.932	rs6573615	ENSG00000276116.2	FUT8-AS1	3.34	0.000912	0.0498	0.16	0.15	Menarche (age at onset);	chr14:65579816	chr14:65411170~65412690:-
THCA	cis	rs17364464	0.945	rs7795410	ENSG00000228649.7	AC005682.5	-3.34	0.000912	0.0498	-0.24	-0.15	Dialysis-related mortality;	chr7:22476976	chr7:22854178~22861579:+
THCA	cis	rs7709377	0.672	rs73253250	ENSG00000250015.1	CTC-339F2.2	3.34	0.000912	0.0498	0.16	0.15	Metabolite levels  (X-11787);	chr5:116145100	chr5:116302354~116304134:-
THCA	cis	rs9402743	0.632	rs9399167	ENSG00000272189.1	RP3-325F22.5	3.34	0.000912	0.0498	0.15	0.15	Systemic lupus erythematosus;	chr6:135792678	chr6:136550661~136552554:+
THCA	cis	rs2729354	0.768	rs2848635	ENSG00000254602.1	AP000662.4	-3.34	0.000912	0.0498	-0.2	-0.15	Blood protein levels;	chr11:57486458	chr11:57638024~57652790:+
THCA	cis	rs1577917	0.958	rs12198876	ENSG00000220563.1	PKMP3	-3.34	0.000912	0.0498	-0.12	-0.15	Response to antipsychotic treatment;	chr6:85815758	chr6:85659892~85660606:-
THCA	cis	rs950169	0.887	rs35986397	ENSG00000230373.7	GOLGA6L5P	-3.34	0.000912	0.0498	-0.17	-0.15	Schizophrenia;	chr15:84400409	chr15:84507885~84516814:-
THCA	cis	rs10207628	1	rs10207628	ENSG00000260634.1	RP11-521O16.1	3.34	0.000912	0.0498	0.21	0.15	Psychosis and Alzheimer's disease;	chr2:127094445	chr2:127024252~127025723:-
THCA	cis	rs35740288	0.929	rs11630585	ENSG00000259407.1	RP11-158M2.3	-3.34	0.000912	0.0498	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762773	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.929	rs11636821	ENSG00000259407.1	RP11-158M2.3	-3.34	0.000912	0.0498	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762774	chr15:85744109~85750281:-
THCA	cis	rs35740288	0.929	rs11630684	ENSG00000259407.1	RP11-158M2.3	-3.34	0.000912	0.0498	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85763025	chr15:85744109~85750281:-
THCA	cis	rs8028182	0.636	rs28623700	ENSG00000275645.1	RP11-817O13.9	3.34	0.000912	0.0498	0.15	0.15	Sudden cardiac arrest;	chr15:75557373	chr15:75346744~75347161:-
THCA	cis	rs8028182	0.577	rs28693593	ENSG00000275645.1	RP11-817O13.9	3.34	0.000912	0.0498	0.15	0.15	Sudden cardiac arrest;	chr15:75557435	chr15:75346744~75347161:-
THCA	cis	rs7631605	0.573	rs6772967	ENSG00000224080.1	UBE2FP1	3.34	0.000912	0.0498	0.17	0.15	Cerebrospinal P-tau181p levels;	chr3:37402643	chr3:37143512~37143958:-
THCA	cis	rs7631605	0.573	rs4021347	ENSG00000224080.1	UBE2FP1	3.34	0.000912	0.0498	0.17	0.15	Cerebrospinal P-tau181p levels;	chr3:37403410	chr3:37143512~37143958:-
THCA	cis	rs2228479	0.85	rs62056091	ENSG00000223959.7	AFG3L1P	-3.34	0.000912	0.0498	-0.15	-0.15	Skin colour saturation;	chr16:89864006	chr16:89972586~90002161:+
THCA	cis	rs939960	0.959	rs13232989	ENSG00000224016.2	RP11-728K20.1	-3.34	0.000912	0.0498	-0.21	-0.15	Neutrophil percentage of white cells;	chr7:150587812	chr7:149891191~149909704:-
THCA	cis	rs291671	0.558	rs17305657	ENSG00000260536.1	RP5-1085F17.4	3.34	0.000912	0.0498	0.37	0.15	Hair color;	chr20:33218782	chr20:32843128~32854257:-
THCA	cis	rs423955	1	rs296847	ENSG00000272866.1	RP11-12D24.10	3.34	0.000912	0.0498	0.21	0.15	Platelet count;	chr9:4793798	chr9:5351796~5352410:-
THCA	cis	rs9811920	0.609	rs793501	ENSG00000273374.1	RP11-383I23.2	3.34	0.000912	0.0498	0.13	0.15	Axial length;	chr3:99872794	chr3:99802699~99806058:-
THCA	cis	rs8067342	0.723	rs12602504	ENSG00000189423.10	USP32P3	-3.34	0.000912	0.0498	-0.19	-0.15	Red cell distribution width;Immature fraction of reticulocytes;	chr17:21266324	chr17:20415547~20431008:+
THCA	cis	rs8062405	0.558	rs3743963	ENSG00000261766.1	RP11-22P6.2	-3.34	0.000912	0.0498	-0.14	-0.15	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28593365	chr16:28862166~28863340:-
THCA	cis	rs3736858	1	rs2296093	ENSG00000261105.4	LMO7-AS1	-3.34	0.000912	0.0498	-0.21	-0.15	Interleukin-9 levels;	chr13:75856325	chr13:75604700~75635994:-
THCA	cis	rs4664293	0.867	rs1427329	ENSG00000230783.1	AC009961.2	-3.34	0.000912	0.0498	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159748301	chr2:159689217~159690291:-
THCA	cis	rs9307551	0.584	rs7697359	ENSG00000249646.2	OR7E94P	-3.34	0.000913	0.0498	-0.2	-0.15	Refractive error;	chr4:79546982	chr4:79587302~79588130:-
THCA	cis	rs6715793	0.839	rs4670828	ENSG00000272754.1	AL133245.2	-3.34	0.000913	0.0498	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33180968	chr2:32321638~32323002:+
THCA	cis	rs6715793	0.869	rs58786532	ENSG00000272754.1	AL133245.2	-3.34	0.000913	0.0498	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33180983	chr2:32321638~32323002:+
THCA	cis	rs6715793	0.839	rs4670836	ENSG00000272754.1	AL133245.2	-3.34	0.000913	0.0498	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33181305	chr2:32321638~32323002:+
THCA	cis	rs6715793	0.809	rs4670849	ENSG00000272754.1	AL133245.2	-3.34	0.000913	0.0498	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33181511	chr2:32321638~32323002:+
THCA	cis	rs6715793	0.901	rs6720405	ENSG00000272754.1	AL133245.2	-3.34	0.000913	0.0498	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33183304	chr2:32321638~32323002:+
THCA	cis	rs6715793	0.901	rs17566780	ENSG00000272754.1	AL133245.2	-3.34	0.000913	0.0498	-0.17	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr2:33185021	chr2:32321638~32323002:+
THCA	cis	rs337161	0.654	rs3795536	ENSG00000221571.3	RNU6ATAC35P	-3.34	0.000913	0.0498	-0.17	-0.15	Response to antipsychotic therapy (extrapyramidal side effects);	chr1:220762635	chr1:220825620~220826063:+
THCA	cis	rs6743226	0.603	rs55659209	ENSG00000223374.1	AC005104.3	3.34	0.000913	0.0498	0.11	0.15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241314902	chr2:241351340~241353104:-
THCA	cis	rs4841134	1	rs4841134	ENSG00000254153.1	CTA-398F10.2	-3.34	0.000913	0.0498	-0.16	-0.15	Age-related disease endophenotypes;	chr8:9329014	chr8:8456909~8461337:-
THCA	cis	rs7246657	0.943	rs10414904	ENSG00000266916.4	ZNF793-AS1	-3.34	0.000913	0.0498	-0.14	-0.15	Coronary artery calcification;	chr19:37339186	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs10417844	ENSG00000266916.4	ZNF793-AS1	-3.34	0.000913	0.0498	-0.14	-0.15	Coronary artery calcification;	chr19:37346685	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs1373991	ENSG00000266916.4	ZNF793-AS1	-3.34	0.000913	0.0498	-0.14	-0.15	Coronary artery calcification;	chr19:37348009	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs10405407	ENSG00000266916.4	ZNF793-AS1	-3.34	0.000913	0.0498	-0.14	-0.15	Coronary artery calcification;	chr19:37348262	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs12709813	ENSG00000266916.4	ZNF793-AS1	-3.34	0.000913	0.0498	-0.14	-0.15	Coronary artery calcification;	chr19:37354081	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.943	rs13345116	ENSG00000266916.4	ZNF793-AS1	-3.34	0.000913	0.0498	-0.14	-0.15	Coronary artery calcification;	chr19:37356196	chr19:37497159~37507046:-
THCA	cis	rs7246657	0.765	rs7247259	ENSG00000266916.4	ZNF793-AS1	-3.34	0.000913	0.0498	-0.14	-0.15	Coronary artery calcification;	chr19:37360188	chr19:37497159~37507046:-
THCA	cis	rs17286411	0.671	rs11641873	ENSG00000260185.1	RP11-432I5.6	-3.34	0.000913	0.0498	-0.21	-0.15	Blood protein levels;	chr16:71740993	chr16:71655027~71664212:+
THCA	cis	rs73198271	1	rs11776513	ENSG00000254153.1	CTA-398F10.2	3.34	0.000913	0.0498	0.2	0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8456909~8461337:-
THCA	cis	rs10200159	1	rs6712314	ENSG00000206964.1	Y_RNA	-3.34	0.000913	0.0498	-0.36	-0.15	Vitiligo;	chr2:55626901	chr2:55286018~55286128:+
THCA	cis	rs1957429	0.808	rs1951492	ENSG00000272158.1	RP11-840I19.5	-3.34	0.000913	0.0498	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64880177	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs1951491	ENSG00000272158.1	RP11-840I19.5	-3.34	0.000913	0.0498	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64880232	chr14:65003325~65003767:-
THCA	cis	rs1957429	0.901	rs1951490	ENSG00000272158.1	RP11-840I19.5	-3.34	0.000913	0.0498	-0.27	-0.15	Pediatric areal bone mineral density (radius);	chr14:64880239	chr14:65003325~65003767:-
THCA	cis	rs28830936	1	rs28830936	ENSG00000250379.1	RP11-23P13.4	3.34	0.000913	0.0498	0.18	0.15	Diastolic blood pressure;	chr15:41614210	chr15:41825099~41827936:-
THCA	cis	rs28830936	1	rs4923905	ENSG00000250379.1	RP11-23P13.4	3.34	0.000913	0.0498	0.18	0.15	Diastolic blood pressure;	chr15:41617691	chr15:41825099~41827936:-
THCA	cis	rs28830936	1	rs9672298	ENSG00000250379.1	RP11-23P13.4	3.34	0.000913	0.0498	0.18	0.15	Diastolic blood pressure;	chr15:41620170	chr15:41825099~41827936:-
THCA	cis	rs28830936	0.967	rs9672671	ENSG00000250379.1	RP11-23P13.4	3.34	0.000913	0.0498	0.18	0.15	Diastolic blood pressure;	chr15:41624877	chr15:41825099~41827936:-
THCA	cis	rs6445967	0.5	rs1554126	ENSG00000272360.1	RP11-359I18.5	3.34	0.000913	0.0498	0.19	0.15	Platelet count;	chr3:58291809	chr3:58490830~58491291:-
THCA	cis	rs6657613	0.967	rs7550758	ENSG00000186715.9	MST1L	-3.34	0.000913	0.0498	-0.13	-0.15	Hip circumference adjusted for BMI;	chr1:17000934	chr1:16754910~16770237:-
THCA	cis	rs6657613	1	rs6657613	ENSG00000186715.9	MST1L	-3.34	0.000913	0.0498	-0.13	-0.15	Hip circumference adjusted for BMI;	chr1:17001705	chr1:16754910~16770237:-
THCA	cis	rs427943	0.75	rs8126717	ENSG00000223768.1	LINC00205	-3.34	0.000913	0.0498	-0.14	-0.15	Body mass index;	chr21:45189195	chr21:45293285~45297354:+
THCA	cis	rs755249	0.761	rs3768321	ENSG00000182109.6	RP11-69E11.4	3.34	0.000913	0.0498	0.18	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39522280~39546187:-
THCA	cis	rs17807624	0.78	rs11250152	ENSG00000255495.1	AC145124.2	-3.34	0.000913	0.0498	-0.17	-0.15	Systemic lupus erythematosus;	chr8:11596691	chr8:12194467~12196280:+
THCA	cis	rs76439304	1	rs7397665	ENSG00000247903.1	RP11-421F16.3	-3.34	0.000913	0.0498	-0.23	-0.15	Mean corpuscular volume;	chr12:26905630	chr12:26971586~26979582:+
THCA	cis	rs2018683	0.707	rs10279610	ENSG00000233517.1	AC005162.5	3.34	0.000913	0.0498	0.19	0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936079	chr7:28987028~28988899:+
THCA	cis	rs791590	0.715	rs7093069	ENSG00000229664.1	RP11-536K7.5	-3.34	0.000913	0.0498	-0.22	-0.15	Soluble interleukin-2 receptor subunit alpha;	chr10:6021356	chr10:6025978~6036427:+
THCA	cis	rs7028939	0.681	rs10819733	ENSG00000255145.2	STX17-AS1	-3.34	0.000913	0.0498	-0.23	-0.15	Preeclampsia;	chr9:100178495	chr9:99886322~99906601:-
THCA	cis	rs2180341	1	rs2038378	ENSG00000220522.2	RP1-177A13.1	3.34	0.000913	0.0498	0.2	0.15	Breast cancer;	chr6:127269255	chr6:127416535~127416952:-
THCA	cis	rs11242704	0.962	rs7776141	ENSG00000218027.2	RP11-157J24.1	-3.34	0.000913	0.0498	-0.2	-0.15	Response to hepatitis C treatment;	chr6:1531711	chr6:1513698~1515289:-
THCA	cis	rs5770917	1	rs2269385	ENSG00000273272.1	CTA-384D8.34	3.34	0.000913	0.0498	0.22	0.15	Narcolepsy;	chr22:50572510	chr22:50542650~50543011:+
THCA	cis	rs5770917	1	rs2269384	ENSG00000273272.1	CTA-384D8.34	3.34	0.000913	0.0498	0.22	0.15	Narcolepsy;	chr22:50572686	chr22:50542650~50543011:+
THCA	cis	rs5770917	1	rs115743514	ENSG00000273272.1	CTA-384D8.34	3.34	0.000913	0.0498	0.22	0.15	Narcolepsy;	chr22:50573504	chr22:50542650~50543011:+
THCA	cis	rs73019876	0.502	rs28456336	ENSG00000269364.1	LINC01233	-3.34	0.000913	0.0498	-0.17	-0.15	Testicular germ cell tumor;	chr19:22085977	chr19:22532626~22533494:+
THCA	cis	rs10089	1	rs72794392	ENSG00000245937.6	LINC01184	3.34	0.000914	0.0498	0.18	0.15	Ileal carcinoids;	chr5:128154369	chr5:127940426~128083172:-
THCA	cis	rs875971	0.545	rs1547529	ENSG00000230295.1	RP11-458F8.2	3.34	0.000914	0.0498	0.13	0.15	Aortic root size;	chr7:66258859	chr7:66880708~66882981:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000230295.1	RP11-458F8.2	3.34	0.000914	0.0498	0.13	0.15	Aortic root size;	chr7:66283366	chr7:66880708~66882981:+
THCA	cis	rs1881509	0.623	rs7101802	ENSG00000233930.3	KRTAP5-AS1	-3.34	0.000914	0.0498	-0.18	-0.15	Heroin dependence;	chr11:1416552	chr11:1571353~1599184:+
THCA	cis	rs1881509	0.66	rs7102167	ENSG00000233930.3	KRTAP5-AS1	-3.34	0.000914	0.0498	-0.18	-0.15	Heroin dependence;	chr11:1416873	chr11:1571353~1599184:+
THCA	cis	rs6499755	0.712	rs31113	ENSG00000260135.5	RP11-212I21.2	-3.34	0.000914	0.0498	-0.16	-0.15	Hypospadias;	chr16:55345721	chr16:55426797~55462297:-
THCA	cis	rs11785400	0.928	rs10100287	ENSG00000177335.9	C8orf31	3.34	0.000914	0.0498	0.17	0.15	Schizophrenia;	chr8:142653452	chr8:143039209~143059942:+
THCA	cis	rs9916302	0.706	rs57933226	ENSG00000266469.1	CTB-131K11.1	-3.34	0.000914	0.0498	-0.14	-0.15	Glomerular filtration rate (creatinine);	chr17:39256576	chr17:39401793~39406233:+
THCA	cis	rs12780845	1	rs7096692	ENSG00000273153.1	RP11-406H21.2	3.34	0.000914	0.0498	0.15	0.15	Homocysteine levels;	chr10:17138829	chr10:17137336~17137585:-
THCA	cis	rs8028313	0.63	rs3784700	ENSG00000245719.1	RP11-34F13.2	-3.34	0.000914	0.0498	-0.17	-0.15	Obesity;	chr15:67725414	chr15:67834310~67838879:-
THCA	cis	rs224278	0.509	rs7073383	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000914	0.0498	-0.21	-0.15	Ewing sarcoma;	chr10:62961149	chr10:62793562~62805887:-
THCA	cis	rs4489787	1	rs2705126	ENSG00000258273.1	RP11-370I10.4	-3.34	0.000914	0.0498	-0.3	-0.15	Prostate cancer (SNP x SNP interaction);	chr12:48488779	chr12:48333755~48333901:-
THCA	cis	rs440932	1	rs365309	ENSG00000254153.1	CTA-398F10.2	3.34	0.000914	0.0498	0.16	0.15	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8456909~8461337:-
THCA	cis	rs9549260	0.561	rs9549297	ENSG00000239827.7	SUGT1P3	-3.34	0.000914	0.0498	-0.2	-0.15	Red blood cell count;	chr13:40823346	chr13:40908159~40921774:-
THCA	cis	rs7621331	1	rs7621331	ENSG00000239213.4	NCK1-AS1	3.34	0.000914	0.0499	0.15	0.15	Waist circumference adjusted for body mass index;	chr3:136043085	chr3:136841726~136862054:-
THCA	cis	rs35851103	0.506	rs4841659	ENSG00000251402.3	FAM90A25P	3.34	0.000914	0.0499	0.19	0.15	Neuroticism;	chr8:11970691	chr8:12415080~12418090:-
THCA	cis	rs10938353	0.906	rs6852413	ENSG00000273369.1	RP11-700J17.1	-3.34	0.000914	0.0499	-0.18	-0.15	Body mass index;	chr4:44591329	chr4:44693946~44694386:-
THCA	cis	rs17604090	1	rs17661938	ENSG00000223813.2	AC007255.8	3.34	0.000914	0.0499	0.16	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29653762	chr7:29514225~29563670:-
THCA	cis	rs10208649	0.505	rs2287512	ENSG00000233266.1	HMGB1P31	3.34	0.000914	0.0499	0.28	0.15	Body mass index;	chr2:53670895	chr2:54051334~54051760:+
THCA	cis	rs9309473	0.519	rs2421545	ENSG00000273245.1	RP11-434P11.2	-3.34	0.000914	0.0499	-0.18	-0.15	Metabolite levels;	chr2:73412348	chr2:73750256~73750786:-
THCA	cis	rs7560272	0.723	rs12995433	ENSG00000273245.1	RP11-434P11.2	-3.34	0.000914	0.0499	-0.18	-0.15	Schizophrenia;	chr2:73414198	chr2:73750256~73750786:-
THCA	cis	rs2581828	0.656	rs2336723	ENSG00000280417.1	RP11-5O17.1	3.34	0.000914	0.0499	0.14	0.15	Crohn's disease;	chr3:53072031	chr3:53046166~53048122:+
THCA	cis	rs72928364	0.728	rs35573711	ENSG00000256628.3	ZBTB11-AS1	3.34	0.000914	0.0499	0.27	0.15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101092823	chr3:101676475~101679217:+
THCA	cis	rs3784262	0.869	rs4646628	ENSG00000259250.1	RP11-50C13.1	3.34	0.000914	0.0499	0.13	0.15	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Barrett's esophagus;	chr15:57963084	chr15:58587507~58591676:+
THCA	cis	rs888194	0.966	rs6606725	ENSG00000249094.2	RP1-7G5.6	-3.34	0.000914	0.0499	-0.19	-0.15	Neuroticism;	chr12:109467563	chr12:109880676~109888467:+
THCA	cis	rs7940646	0.679	rs11603178	ENSG00000254554.1	RP11-351I24.1	3.34	0.000914	0.0499	0.19	0.15	Platelet aggregation;	chr11:10638520	chr11:10302657~10303704:-
THCA	cis	rs714027	0.605	rs2899147	ENSG00000279699.1	RP1-102K2.9	-3.34	0.000914	0.0499	-0.15	-0.15	Lymphocyte counts;	chr22:30137076	chr22:30275215~30276951:-
THCA	cis	rs6921919	0.609	rs9461455	ENSG00000220721.1	OR1F12	3.34	0.000915	0.0499	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28073316~28074233:+
THCA	cis	rs775227	0.574	rs35765657	ENSG00000243849.1	CFAP44-AS1	3.34	0.000915	0.0499	0.28	0.15	Dental caries;	chr3:113359537	chr3:113403991~113433992:+
THCA	cis	rs1950832	0.689	rs12880770	ENSG00000258636.1	CTD-2298J14.2	-3.34	0.000915	0.0499	-0.21	-0.15	Urate levels in obese individuals;	chr14:41693207	chr14:41587861~41604856:-
THCA	cis	rs1950832	0.689	rs11627839	ENSG00000258636.1	CTD-2298J14.2	-3.34	0.000915	0.0499	-0.21	-0.15	Urate levels in obese individuals;	chr14:41695101	chr14:41587861~41604856:-
THCA	cis	rs3806843	0.52	rs265312	ENSG00000278901.1	AC005609.17	3.34	0.000915	0.0499	0.17	0.15	Depressive symptoms (multi-trait analysis);	chr5:140916687	chr5:140878073~140882642:-
THCA	cis	rs3806843	0.576	rs155358	ENSG00000278901.1	AC005609.17	3.34	0.000915	0.0499	0.17	0.15	Depressive symptoms (multi-trait analysis);	chr5:140917447	chr5:140878073~140882642:-
THCA	cis	rs7631605	0.586	rs6550466	ENSG00000224080.1	UBE2FP1	3.34	0.000915	0.0499	0.17	0.15	Cerebrospinal P-tau181p levels;	chr3:37263989	chr3:37143512~37143958:-
THCA	cis	rs4218	0.689	rs35555888	ENSG00000277144.1	RP11-59H7.4	-3.34	0.000915	0.0499	-0.21	-0.15	Social communication problems;	chr15:59093935	chr15:59115547~59116089:-
THCA	cis	rs2180341	0.843	rs4895821	ENSG00000220522.2	RP1-177A13.1	3.34	0.000915	0.0499	0.2	0.15	Breast cancer;	chr6:127251616	chr6:127416535~127416952:-
THCA	cis	rs2180341	0.92	rs9398836	ENSG00000220522.2	RP1-177A13.1	3.34	0.000915	0.0499	0.2	0.15	Breast cancer;	chr6:127255352	chr6:127416535~127416952:-
THCA	cis	rs13048019	1	rs13050704	ENSG00000237594.2	AP000251.3	3.34	0.000915	0.0499	0.21	0.15	Amyotrophic lateral sclerosis;	chr21:31535487	chr21:31559245~31560487:+
THCA	cis	rs1383484	0.754	rs906425	ENSG00000225151.9	GOLGA2P7	3.34	0.000915	0.0499	0.21	0.15	Height;	chr15:83920070	chr15:84199311~84230136:-
THCA	cis	rs9303542	0.729	rs8067857	ENSG00000278765.1	RP5-890E16.5	-3.34	0.000915	0.0499	-0.2	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48464878	chr17:48066704~48067293:-
THCA	cis	rs250567	0.609	rs80096684	ENSG00000260136.4	CTD-2270L9.4	-3.34	0.000915	0.0499	-0.13	-0.15	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:23513783	chr16:23452758~23457606:+
THCA	cis	rs9450351	0.744	rs35510369	ENSG00000280232.1	RP11-321N4.4	3.34	0.000915	0.0499	0.33	0.15	Interferon gamma-induced protein 10 levels;	chr6:85556411	chr6:85498441~85499058:-
THCA	cis	rs2667011	0.759	rs2715931	ENSG00000226266.5	AC009961.3	3.34	0.000915	0.0499	0.24	0.15	Bilirubin levels;	chr2:159991127	chr2:159670708~159712435:-
THCA	cis	rs524281	0.861	rs10791855	ENSG00000255038.1	RP11-1167A19.2	-3.34	0.000915	0.0499	-0.18	-0.15	Electroencephalogram traits;	chr11:66196266	chr11:66067277~66069619:-
THCA	cis	rs2014572	0.967	rs10412975	ENSG00000276449.1	AC004076.5	3.34	0.000915	0.0499	0.14	0.15	Hyperactive-impulsive symptoms;	chr19:57259186	chr19:57449689~57453011:+
THCA	cis	rs8058578	1	rs2289442	ENSG00000274678.1	RP11-2C24.7	3.34	0.000915	0.0499	0.15	0.15	Multiple myeloma;	chr16:30728598	chr16:30821338~30821884:+
THCA	cis	rs2243480	1	rs7794661	ENSG00000237310.1	GS1-124K5.4	3.34	0.000915	0.0499	0.17	0.15	Diabetic kidney disease;	chr7:65924743	chr7:66493706~66495474:+
THCA	cis	rs4237845	0.761	rs11172378	ENSG00000270039.1	RP11-571M6.17	-3.34	0.000915	0.0499	-0.16	-0.15	Intelligence (multi-trait analysis);	chr12:57904378	chr12:57803838~57804415:+
THCA	cis	rs2836950	0.52	rs2836966	ENSG00000235701.1	PCBP2P1	-3.34	0.000915	0.0499	-0.17	-0.15	Menarche (age at onset);	chr21:39265595	chr21:39171130~39172106:-
THCA	cis	rs11710088	0.711	rs35884523	ENSG00000244503.1	RP11-278L15.6	3.34	0.000915	0.0499	0.21	0.15	QRS duration;	chr3:149470430	chr3:149494660~149495995:+
THCA	cis	rs2944755	0.723	rs13274041	ENSG00000259891.1	CTA-204B4.2	3.34	0.000915	0.0499	0.11	0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140577816	chr8:140505813~140508043:-
THCA	cis	rs2944755	0.723	rs13274321	ENSG00000259891.1	CTA-204B4.2	3.34	0.000915	0.0499	0.11	0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578107	chr8:140505813~140508043:-
THCA	cis	rs2944755	0.723	rs13273553	ENSG00000259891.1	CTA-204B4.2	3.34	0.000915	0.0499	0.11	0.15	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578166	chr8:140505813~140508043:-
THCA	cis	rs79478560	0.541	rs11057391	ENSG00000270061.1	RP11-214K3.19	-3.34	0.000915	0.0499	-0.2	-0.15	Lymphocyte counts;	chr12:123910806	chr12:123969990~123970344:-
THCA	cis	rs787665	0.891	rs2761286	ENSG00000232709.1	MARK2P9	3.34	0.000916	0.0499	0.24	0.15	Gut microbiome composition (summer);	chr10:93310280	chr10:92418667~92420875:+
THCA	cis	rs758324	0.812	rs494349	ENSG00000237714.1	P4HA2-AS1	-3.34	0.000916	0.0499	-0.21	-0.15	Alzheimer's disease in APOE e4- carriers;	chr5:131924759	chr5:132184876~132192808:+
THCA	cis	rs972578	0.702	rs2092212	ENSG00000230319.1	AL022476.2	3.34	0.000916	0.0499	0.16	0.15	Mean platelet volume;	chr22:42922942	chr22:43038585~43052366:+
THCA	cis	rs4578769	0.759	rs9947828	ENSG00000265939.1	UBE2CP2	-3.34	0.000916	0.0499	-0.19	-0.15	Eosinophil percentage of white cells;	chr18:23058592	chr18:22900486~22900995:-
THCA	cis	rs1124769	0.502	rs8042982	ENSG00000259378.1	DCAF13P3	3.34	0.000916	0.0499	0.21	0.15	Cognitive performance;	chr15:50774816	chr15:50944663~50945996:+
THCA	cis	rs1124769	0.502	rs737031	ENSG00000259378.1	DCAF13P3	3.34	0.000916	0.0499	0.21	0.15	Cognitive performance;	chr15:50775340	chr15:50944663~50945996:+
THCA	cis	rs9788682	0.948	rs905739	ENSG00000261143.1	ADAMTS7P3	-3.34	0.000916	0.0499	-0.22	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78552768	chr15:77976042~77993057:+
THCA	cis	rs67478160	0.643	rs2024667	ENSG00000258534.1	CTD-2134A5.4	-3.34	0.000916	0.0499	-0.15	-0.15	Schizophrenia;	chr14:103745192	chr14:103854366~103880111:-
THCA	cis	rs790006	0.667	rs11175295	ENSG00000243024.5	RPS11P6	-3.34	0.000916	0.0499	-0.17	-0.15	Response to cytidine analogues (gemcitabine);	chr12:64243570	chr12:64222337~64397065:+
THCA	cis	rs17597773	0.674	rs984676	ENSG00000272823.1	RP11-295M18.6	3.34	0.000916	0.0499	0.2	0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220835080	chr1:220828676~220829211:-
THCA	cis	rs6840360	0.869	rs55668815	ENSG00000251611.1	RP11-610P16.1	-3.34	0.000916	0.0499	-0.11	-0.15	Intelligence (multi-trait analysis);	chr4:151552676	chr4:151407551~151408835:-
THCA	cis	rs1876905	0.597	rs354526	ENSG00000271789.1	RP5-1112D6.7	-3.34	0.000916	0.0499	-0.2	-0.15	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111297126~111298510:+
THCA	cis	rs10091877	0.607	rs7816868	ENSG00000270154.1	RP11-419I17.1	-3.34	0.000916	0.0499	-0.23	-0.15	Lung adenocarcinoma;	chr8:13033465	chr8:12476462~12477122:+
THCA	cis	rs901683	1	rs71496608	ENSG00000230869.1	CTGLF10P	-3.34	0.000916	0.0499	-0.37	-0.15	Mean corpuscular volume;Red blood cell traits;	chr10:45521684	chr10:45678692~45700532:+
THCA	cis	rs7216064	1	rs2365468	ENSG00000265055.1	AC145343.2	3.34	0.000916	0.0499	0.22	0.15	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845202	chr17:68096046~68101474:-
THCA	cis	rs7647973	0.961	rs7626076	ENSG00000228638.1	FCF1P2	-3.34	0.000916	0.0499	-0.17	-0.15	Menarche (age at onset);	chr3:49260706	chr3:48290793~48291375:-
THCA	cis	rs7731390	0.541	rs112385424	ENSG00000237714.1	P4HA2-AS1	-3.34	0.000916	0.0499	-0.33	-0.15	IgG glycosylation;	chr5:132243152	chr5:132184876~132192808:+
THCA	cis	rs4908760	0.827	rs10864360	ENSG00000238249.2	HMGN2P17	-3.34	0.000916	0.0499	-0.18	-0.15	Vitiligo;	chr1:8664463	chr1:8893409~8894151:+
THCA	cis	rs72827839	0.846	rs72823599	ENSG00000278765.1	RP5-890E16.5	-3.34	0.000916	0.0499	-0.22	-0.15	Ease of getting up in the morning;	chr17:48055062	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.846	rs72823601	ENSG00000278765.1	RP5-890E16.5	-3.34	0.000916	0.0499	-0.22	-0.15	Ease of getting up in the morning;	chr17:48057846	chr17:48066704~48067293:-
THCA	cis	rs72827839	0.846	rs72825504	ENSG00000278765.1	RP5-890E16.5	-3.34	0.000916	0.0499	-0.22	-0.15	Ease of getting up in the morning;	chr17:48062117	chr17:48066704~48067293:-
THCA	cis	rs12935418	0.672	rs9938541	ENSG00000261061.1	RP11-303E16.2	-3.34	0.000916	0.0499	-0.15	-0.15	Mean corpuscular volume;	chr16:81011623	chr16:81030770~81031485:+
THCA	cis	rs7737355	0.812	rs12655240	ENSG00000237714.1	P4HA2-AS1	-3.34	0.000916	0.0499	-0.21	-0.15	Life satisfaction;	chr5:131416313	chr5:132184876~132192808:+
THCA	cis	rs4683346	0.752	rs2114883	ENSG00000273328.4	RP11-141M3.6	-3.34	0.000916	0.0499	-0.19	-0.15	Granulocyte percentage of myeloid white cells;	chr3:42841176	chr3:42809414~42908105:+
THCA	cis	rs9300255	0.679	rs12829456	ENSG00000235423.7	RP11-282O18.3	-3.34	0.000916	0.05	-0.18	-0.15	Neutrophil percentage of white cells;	chr12:123240848	chr12:123252030~123261483:-
THCA	cis	rs6724465	0.714	rs72951802	ENSG00000237281.1	CATIP-AS2	-3.34	0.000916	0.05	-0.2	-0.15	Height;	chr2:219141408	chr2:218326889~218357966:-
THCA	cis	rs2664588	0.503	rs6012309	ENSG00000276923.1	RP11-321P16.1	-3.34	0.000916	0.05	-0.21	-0.15	Cerebrospinal fluid AB1-42 levels;	chr20:47968726	chr20:48073869~48074188:+
THCA	cis	rs17428076	0.794	rs62183763	ENSG00000228389.1	AC068039.4	-3.34	0.000916	0.05	-0.21	-0.15	Myopia;	chr2:171973172	chr2:171773482~171775844:+
THCA	cis	rs4474742	1	rs4474742	ENSG00000264290.1	RP11-68I3.4	-3.34	0.000916	0.05	-0.12	-0.15	Monocyte count;	chr17:29738560	chr17:29569580~29570519:+
THCA	cis	rs17122278	1	rs11216904	ENSG00000243431.1	RPL5P30	3.34	0.000917	0.05	0.16	0.15	Total cholesterol levels;	chr11:118570148	chr11:118560690~118561580:+
THCA	cis	rs2115630	1	rs11073730	ENSG00000275120.1	RP11-182J1.17	-3.34	0.000917	0.05	-0.16	-0.15	P wave terminal force;	chr15:84811365	chr15:84599434~84606463:-
THCA	cis	rs10938353	0.911	rs1439356	ENSG00000273369.1	RP11-700J17.1	-3.34	0.000917	0.05	-0.17	-0.15	Body mass index;	chr4:44600669	chr4:44693946~44694386:-
THCA	cis	rs10938353	0.911	rs10805128	ENSG00000273369.1	RP11-700J17.1	-3.34	0.000917	0.05	-0.17	-0.15	Body mass index;	chr4:44601014	chr4:44693946~44694386:-
THCA	cis	rs754466	0.651	rs11818687	ENSG00000213514.2	RP11-428P16.2	3.34	0.000917	0.05	0.17	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77877951	chr10:77730766~77734769:+
THCA	cis	rs9322193	1	rs9377229	ENSG00000281021.1	RP1-12G14.9	-3.34	0.000917	0.05	-0.15	-0.15	Lung cancer;	chr6:149607655	chr6:149576089~149590864:-
THCA	cis	rs11763147	1	rs11763147	ENSG00000232546.1	RP11-458F8.1	3.34	0.000917	0.05	0.13	0.15	Corneal structure;	chr7:65861834	chr7:66848496~66858136:+
THCA	cis	rs11233250	0.502	rs11233261	ENSG00000227097.5	RPS28P7	-3.34	0.000917	0.05	-0.21	-0.15	Glioblastoma;Glioma;	chr11:82690642	chr11:82689559~82689768:+
THCA	cis	rs6940638	0.662	rs7759694	ENSG00000224843.5	LINC00240	3.34	0.000917	0.05	0.14	0.15	Intelligence (multi-trait analysis);	chr6:27273177	chr6:26956992~27023924:+
THCA	cis	rs9291683	0.546	rs13146686	ENSG00000261490.1	RP11-448G15.3	3.34	0.000917	0.05	0.1	0.15	Bone mineral density;	chr4:10033309	chr4:10068089~10073019:-
THCA	cis	rs9650657	0.711	rs7007318	ENSG00000255310.2	AF131215.2	-3.34	0.000917	0.05	-0.13	-0.15	Neuroticism;	chr8:10734768	chr8:11107788~11109726:-
THCA	cis	rs12210905	1	rs72838266	ENSG00000224843.5	LINC00240	3.34	0.000917	0.05	0.25	0.15	Hip circumference adjusted for BMI;	chr6:27047273	chr6:26956992~27023924:+
THCA	cis	rs12210905	1	rs12201498	ENSG00000224843.5	LINC00240	3.34	0.000917	0.05	0.25	0.15	Hip circumference adjusted for BMI;	chr6:27062305	chr6:26956992~27023924:+
THCA	cis	rs12210905	1	rs12203728	ENSG00000224843.5	LINC00240	3.34	0.000917	0.05	0.25	0.15	Hip circumference adjusted for BMI;	chr6:27083971	chr6:26956992~27023924:+
THCA	cis	rs10938353	0.834	rs13135313	ENSG00000273369.1	RP11-700J17.1	-3.34	0.000917	0.05	-0.17	-0.15	Body mass index;	chr4:44600199	chr4:44693946~44694386:-
THCA	cis	rs9921222	0.521	rs62032884	ENSG00000268836.1	LA16c-OS12.2	3.34	0.000917	0.05	0.15	0.15	Bone mineral density (spine);Bone mineral density;	chr16:313415	chr16:185748~186294:-
THCA	cis	rs7818688	0.929	rs7812312	ENSG00000253528.2	RP11-347C18.4	-3.34	0.000917	0.05	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95008172	chr8:94974573~94974853:-
THCA	cis	rs7818688	0.929	rs28419772	ENSG00000253528.2	RP11-347C18.4	-3.34	0.000917	0.05	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009208	chr8:94974573~94974853:-
THCA	cis	rs2239557	0.539	rs2302117	ENSG00000258603.3	RP3-414A15.10	3.34	0.000917	0.05	0.18	0.15	Common traits (Other);	chr14:73988110	chr14:73616700~73633941:-
THCA	cis	rs2239557	0.539	rs62005063	ENSG00000258603.3	RP3-414A15.10	3.34	0.000917	0.05	0.18	0.15	Common traits (Other);	chr14:73989276	chr14:73616700~73633941:-
THCA	cis	rs950169	0.84	rs62029595	ENSG00000230373.7	GOLGA6L5P	-3.34	0.000917	0.05	-0.17	-0.15	Schizophrenia;	chr15:84400603	chr15:84507885~84516814:-
THCA	cis	rs757978	0.777	rs11693232	ENSG00000261186.2	RP11-341N2.1	-3.34	0.000917	0.05	-0.27	-0.15	Chronic lymphocytic leukemia;	chr2:241422825	chr2:242087351~242088457:-
THCA	cis	rs1865760	0.566	rs2051544	ENSG00000272810.1	U91328.22	-3.34	0.000917	0.05	-0.12	-0.15	Height;	chr6:26070865	chr6:26013241~26013757:+
THCA	cis	rs45544231	1	rs3104796	ENSG00000279344.1	RP11-44F14.7	3.34	0.000917	0.05	0.14	0.15	Restless legs syndrome;	chr16:52608465	chr16:53478957~53481550:-
THCA	cis	rs733592	0.931	rs765260	ENSG00000275228.1	RP11-370I10.10	3.34	0.000917	0.05	0.15	0.15	Plateletcrit;	chr12:48038153	chr12:48327942~48328472:-
THCA	cis	rs7129556	0.954	rs10899386	ENSG00000254459.1	RP11-91P24.7	3.34	0.000917	0.05	0.19	0.15	Weight loss (gastric bypass surgery);	chr11:77535381	chr11:77829654~77872262:-
THCA	cis	rs910316	1	rs4903289	ENSG00000259138.1	RP11-950C14.7	-3.34	0.000917	0.05	-0.13	-0.15	Height;	chr14:75157285	chr14:75127153~75136930:+
THCA	cis	rs10256972	1	rs10256972	ENSG00000199023.2	MIR339	3.34	0.000917	0.05	0.16	0.15	Endometriosis;Longevity;	chr7:999367	chr7:1022935~1023045:-
THCA	cis	rs489332	0.512	rs489045	ENSG00000234618.1	RPSAP9	-3.34	0.000917	0.05	-0.17	-0.15	Schizophrenia;	chr9:75423904	chr9:76398699~76399586:+
THCA	cis	rs71444571	1	rs71444571	ENSG00000235423.7	RP11-282O18.3	-3.34	0.000917	0.05	-0.18	-0.15	Lymphocyte percentage of white cells;	chr12:123286468	chr12:123252030~123261483:-
THCA	cis	rs7246657	0.943	rs10405325	ENSG00000268499.1	CTB-102L5.8	3.34	0.000917	0.05	0.2	0.15	Coronary artery calcification;	chr19:37392575	chr19:38199836~38200934:+
THCA	cis	rs72834846	0.947	rs8076086	ENSG00000236319.2	CTD-2033D24.2	3.34	0.000917	0.05	0.22	0.15	Red blood cell count;	chr17:55098341	chr17:55526964~55561577:-
THCA	cis	rs11800820	0.566	rs3129571	ENSG00000231612.1	RP11-522M21.3	3.34	0.000917	0.05	0.21	0.15	Obesity-related traits;	chr1:246547350	chr1:245673732~245676478:-
THCA	cis	rs7737355	0.947	rs6879005	ENSG00000237714.1	P4HA2-AS1	3.34	0.000917	0.05	0.22	0.15	Life satisfaction;	chr5:131279752	chr5:132184876~132192808:+
THCA	cis	rs6847067	0.794	rs10856852	ENSG00000180769.7	WDFY3-AS2	3.34	0.000917	0.05	0.11	0.15	Oropharynx cancer;	chr4:84976382	chr4:84965682~85011277:+
THCA	cis	rs1627020	0.935	rs1792528	ENSG00000254645.1	RP11-396O20.2	3.34	0.000917	0.05	0.21	0.15	Gestational age at birth (maternal effect);	chr11:15171851	chr11:15701963~15758898:-
THCA	cis	rs11665867	0.887	rs73048915	ENSG00000237118.2	CYP2F2P	-3.34	0.000917	0.05	-0.28	-0.15	Hematocrit;	chr19:40813886	chr19:40818721~40826772:-
THCA	cis	rs7555668	1	rs7555668	ENSG00000226419.5	SLC16A1-AS1	-3.34	0.000917	0.05	-0.17	-0.15	Cognitive performance;	chr1:112313948	chr1:112956415~112999496:+
THCA	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	38.49	2.22e-147	8.78e-139	1.22	0.87	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	38.49	2.22e-147	8.78e-139	1.22	0.87	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	38.27	1.6e-146	6.2e-138	1.22	0.87	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	38.09	8.72e-146	3.28e-137	1.23	0.87	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	38.09	8.72e-146	3.28e-137	1.23	0.87	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	38.09	8.72e-146	3.28e-137	1.23	0.87	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
THCA	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	38.01	1.89e-145	6.96e-137	1.23	0.87	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
THCA	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	37.98	2.47e-145	9.08e-137	1.22	0.87	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	37.97	2.6e-145	9.49e-137	1.23	0.87	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	37.95	3.34e-145	1.21e-136	1.22	0.87	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	37.83	1.04e-144	3.7e-136	1.22	0.87	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	37.83	1.04e-144	3.7e-136	1.22	0.87	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
THCA	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	37.43	4.11e-143	1.43e-134	1.13	0.87	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
THCA	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	37.1	9.41e-142	3.14e-133	1.22	0.86	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
THCA	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	36.95	4.13e-141	1.36e-132	1.12	0.86	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
THCA	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	36.92	5.09e-141	1.52e-132	1.06	0.86	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	36.92	5.49e-141	1.62e-132	1.06	0.86	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	36.92	5.49e-141	1.62e-132	1.06	0.86	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	36.89	7.22e-141	2.12e-132	1.06	0.86	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	36.88	7.88e-141	2.3e-132	1.06	0.86	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-36.85	1.02e-140	2.97e-132	-1.06	-0.86	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	36.8	1.73e-140	4.99e-132	1.06	0.86	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	36.68	5.38e-140	1.54e-131	1.06	0.86	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	36.6	1.12e-139	3.05e-131	1.06	0.86	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	36.6	1.12e-139	3.05e-131	1.06	0.86	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	36.6	1.12e-139	3.05e-131	1.06	0.86	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	36.6	1.12e-139	3.05e-131	1.06	0.86	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	36.6	1.12e-139	3.05e-131	1.06	0.86	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	36.6	1.12e-139	3.05e-131	1.06	0.86	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	36.6	1.12e-139	3.05e-131	1.06	0.86	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	36.54	1.92e-139	5.18e-131	1.06	0.86	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
THCA	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	36.53	2.13e-139	5.73e-131	1.22	0.86	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
THCA	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	36.46	4.27e-139	1.14e-130	1.12	0.86	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
THCA	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	36.12	1.04e-137	2.79e-129	1.07	0.86	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
THCA	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	36.12	1.06e-137	2.83e-129	1.12	0.86	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
THCA	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	35.72	5.03e-136	1.29e-127	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
THCA	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-35.7	6.02e-136	1.52e-127	-1.19	-0.85	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	35.58	1.95e-135	4.88e-127	1.19	0.85	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
THCA	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	35.54	2.81e-135	6.84e-127	1.06	0.85	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	35.54	2.81e-135	6.84e-127	1.06	0.85	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	35.54	2.81e-135	6.84e-127	1.06	0.85	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	35.54	2.81e-135	6.84e-127	1.06	0.85	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	35.54	2.81e-135	6.84e-127	1.06	0.85	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	35.42	9.31e-135	2.25e-126	1.06	0.85	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
THCA	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	35.25	4.84e-134	1.16e-125	1.17	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
THCA	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	35.12	1.57e-133	3.67e-125	1.06	0.85	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
THCA	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	35.02	4.48e-133	1.04e-124	1.17	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
THCA	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	34.96	7.7e-133	1.77e-124	1.2	0.85	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
THCA	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	34.92	1.1e-132	2.52e-124	1.19	0.85	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
THCA	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	34.9	1.34e-132	3.05e-124	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	34.9	1.37e-132	3.11e-124	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	34.79	4.08e-132	9.18e-124	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
THCA	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	34.78	4.38e-132	9.81e-124	1.2	0.85	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
THCA	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	34.74	6.43e-132	1.43e-123	1.19	0.85	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
THCA	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	34.71	9.26e-132	2.05e-123	1.19	0.85	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
THCA	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	34.65	1.53e-131	3.38e-123	1.05	0.85	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
THCA	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	34.6	2.72e-131	5.96e-123	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
THCA	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	34.42	1.51e-130	3.31e-122	1.12	0.85	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
THCA	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	34.38	2.15e-130	4.66e-122	1.2	0.85	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
THCA	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	34.05	5.61e-129	1.2e-120	1.05	0.84	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	34.05	5.61e-129	1.2e-120	1.05	0.84	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	34.05	5.61e-129	1.2e-120	1.05	0.84	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
THCA	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	34.05	5.93e-129	1.26e-120	1.17	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	34.01	8.56e-129	1.81e-120	1.18	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
THCA	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	33.95	1.49e-128	3.14e-120	1.05	0.84	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	33.93	1.78e-128	3.73e-120	1.06	0.84	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	33.92	1.99e-128	4.16e-120	1.06	0.84	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
THCA	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-33.83	4.76e-128	9.87e-120	-1.12	-0.84	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
THCA	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	33.81	5.98e-128	1.23e-119	1.05	0.84	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	33.81	6.33e-128	1.3e-119	1.05	0.84	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
THCA	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	33.77	9.17e-128	1.88e-119	1.18	0.84	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
THCA	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	33.59	5.07e-127	1.02e-118	1.05	0.84	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
THCA	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	33.48	1.52e-126	3.05e-118	1.2	0.84	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
THCA	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	33.45	2.03e-126	4.03e-118	1.04	0.84	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	33.45	2.03e-126	4.03e-118	1.04	0.84	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	33.25	1.62e-125	3.19e-117	1.04	0.84	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	32.99	2.08e-124	4.03e-116	1.05	0.84	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	32.92	4.07e-124	7.85e-116	1.03	0.84	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	32.91	4.47e-124	8.61e-116	1.03	0.84	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	32.86	7.56e-124	1.45e-115	1.03	0.83	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
THCA	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	32.73	2.68e-123	5.07e-115	1.18	0.83	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
THCA	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	32.71	3.19e-123	5.95e-115	1.04	0.83	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	32.71	3.19e-123	5.95e-115	1.04	0.83	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	32.71	3.19e-123	5.95e-115	1.04	0.83	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	32.65	5.97e-123	1.11e-114	1.04	0.83	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	32.55	1.6e-122	2.95e-114	1.04	0.83	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
THCA	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	32.51	2.45e-122	4.48e-114	1.15	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	32.33	1.43e-121	2.59e-113	1.17	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	32.07	2.01e-120	3.57e-112	1.18	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
THCA	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-31.9	1.14e-119	2.01e-111	-1.04	-0.83	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	31.88	1.33e-119	2.32e-111	1.02	0.83	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	31.88	1.33e-119	2.32e-111	1.02	0.83	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	31.88	1.33e-119	2.32e-111	1.02	0.83	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	31.84	2.02e-119	3.51e-111	1.02	0.83	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-31.77	4.27e-119	7.36e-111	-1.03	-0.83	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
THCA	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	31.71	7.55e-119	1.28e-110	1.18	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	31.71	7.55e-119	1.28e-110	1.18	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	31.71	7.55e-119	1.28e-110	1.18	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	31.71	7.55e-119	1.28e-110	1.18	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
THCA	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	31.69	9.86e-119	1.65e-110	1.05	0.83	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
THCA	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	31.67	1.21e-118	2e-110	1.12	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	31.59	2.51e-118	4.1e-110	1.15	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
THCA	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	31.56	3.36e-118	5.44e-110	1.03	0.82	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	31.56	3.36e-118	5.44e-110	1.03	0.82	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
THCA	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	31.5	6.25e-118	1.01e-109	1.33	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
THCA	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	31.46	9.69e-118	1.56e-109	1.01	0.82	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
THCA	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-31.46	9.77e-118	1.57e-109	-1.15	-0.82	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
THCA	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-31.46	9.9e-118	1.58e-109	-1.03	-0.82	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-31.44	1.23e-117	1.95e-109	-1.04	-0.82	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-31.31	4.47e-117	7.06e-109	-1.04	-0.82	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-31.28	6.2e-117	8.82e-109	-1.03	-0.82	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-31.28	6.2e-117	8.82e-109	-1.03	-0.82	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-31.28	6.2e-117	8.82e-109	-1.03	-0.82	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-31.28	6.2e-117	8.82e-109	-1.03	-0.82	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-31.28	6.2e-117	8.82e-109	-1.03	-0.82	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	31.28	6.2e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	31.28	6.21e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	31.28	6.21e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	31.28	6.21e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	31.28	6.21e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	31.28	6.21e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	31.28	6.21e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	31.28	6.21e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	31.28	6.21e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	31.28	6.22e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	31.28	6.22e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	31.28	6.22e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	31.28	6.22e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	31.28	6.24e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	31.28	6.26e-117	8.82e-109	1.03	0.82	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	31.28	6.27e-117	8.82e-109	1.02	0.82	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
THCA	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	31.24	9.15e-117	1.28e-108	1.31	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	31.22	1.12e-116	1.56e-108	1.32	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	31.22	1.12e-116	1.56e-108	1.32	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
THCA	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-31.22	1.15e-116	1.6e-108	-1.03	-0.82	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	31.21	1.28e-116	1.76e-108	1.05	0.82	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	31.2	1.38e-116	1.89e-108	1.02	0.82	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	31.2	1.38e-116	1.89e-108	1.02	0.82	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
THCA	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	31.2	1.39e-116	1.89e-108	1.15	0.82	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
THCA	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	31.18	1.65e-116	2.24e-108	1.03	0.82	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	31.18	1.68e-116	2.27e-108	1.03	0.82	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	31.18	1.68e-116	2.27e-108	1.03	0.82	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	31.18	1.68e-116	2.27e-108	1.03	0.82	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	31.18	1.71e-116	2.31e-108	1.34	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
THCA	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	31.18	1.74e-116	2.34e-108	1.04	0.82	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	31.17	1.81e-116	2.42e-108	1.01	0.82	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	31.11	3.29e-116	4.37e-108	1.03	0.82	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
THCA	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	31.11	3.31e-116	4.38e-108	1.03	0.82	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-31.11	3.33e-116	4.39e-108	-1.03	-0.82	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-31.11	3.33e-116	4.39e-108	-1.03	-0.82	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	31.08	4.83e-116	6.25e-108	1.03	0.82	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	31.08	4.83e-116	6.25e-108	1.03	0.82	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	31.08	4.83e-116	6.25e-108	1.03	0.82	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	31.06	5.61e-116	7.22e-108	1.03	0.82	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
THCA	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	31.05	5.99e-116	7.7e-108	1.02	0.82	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-31.02	8.75e-116	1.12e-107	-1.03	-0.82	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	30.99	1.11e-115	1.42e-107	1.32	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	30.98	1.34e-115	1.69e-107	1.33	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	30.98	1.34e-115	1.69e-107	1.33	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
THCA	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	30.93	2.03e-115	2.51e-107	1.14	0.82	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
THCA	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	30.93	2.23e-115	2.74e-107	1.03	0.82	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	30.91	2.73e-115	3.26e-107	1.02	0.82	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	30.91	2.73e-115	3.26e-107	1.02	0.82	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	30.91	2.73e-115	3.26e-107	1.02	0.82	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	30.91	2.73e-115	3.26e-107	1.02	0.82	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	30.91	2.73e-115	3.26e-107	1.02	0.82	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	30.91	2.73e-115	3.26e-107	1.02	0.82	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	30.91	2.73e-115	3.26e-107	1.02	0.82	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	30.91	2.73e-115	3.26e-107	1.02	0.82	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
THCA	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	30.9	3.05e-115	3.64e-107	1.08	0.82	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
THCA	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	30.89	3.27e-115	3.88e-107	1.03	0.82	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	30.85	4.72e-115	5.57e-107	1.03	0.82	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	30.85	4.75e-115	5.6e-107	1.03	0.82	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	30.81	7.19e-115	8.42e-107	1.02	0.82	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
THCA	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-30.76	1.21e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-30.76	1.21e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-30.76	1.21e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-30.76	1.21e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-30.76	1.21e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-30.76	1.22e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-30.76	1.22e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-30.76	1.22e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-30.76	1.22e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-30.76	1.22e-114	1.37e-106	-1.03	-0.82	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	30.73	1.58e-114	1.77e-106	1.02	0.82	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	30.71	2e-114	2.23e-106	1.03	0.82	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
THCA	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-30.7	2.14e-114	2.39e-106	-1.03	-0.82	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.602	rs4975977	ENSG00000231752.4	EMBP1	-30.66	3.39e-114	3.76e-106	-1.03	-0.82	Schizophrenia;	chr5:46307988	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-30.63	4.39e-114	4.72e-106	-1.02	-0.82	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-30.63	4.39e-114	4.72e-106	-1.02	-0.82	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-30.63	4.39e-114	4.72e-106	-1.02	-0.82	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-30.62	5.25e-114	5.53e-106	-1.03	-0.82	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-30.62	5.25e-114	5.53e-106	-1.03	-0.82	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-30.62	5.25e-114	5.53e-106	-1.03	-0.82	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	30.6	5.99e-114	6.23e-106	1.03	0.82	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
THCA	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-30.6	6.39e-114	6.61e-106	-1.02	-0.82	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	30.57	8.22e-114	8.48e-106	1.02	0.82	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	30.57	8.65e-114	8.88e-106	1.02	0.82	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	30.57	8.65e-114	8.88e-106	1.02	0.82	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-30.55	1.06e-113	1.08e-105	-1.03	-0.82	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	30.53	1.22e-113	1.24e-105	1.01	0.82	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-30.52	1.36e-113	1.38e-105	-1.03	-0.82	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-30.5	1.73e-113	1.73e-105	-1.02	-0.82	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-30.5	1.73e-113	1.73e-105	-1.02	-0.82	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-30.5	1.73e-113	1.73e-105	-1.02	-0.82	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-30.5	1.74e-113	1.73e-105	-1.02	-0.82	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-30.5	1.74e-113	1.73e-105	-1.02	-0.82	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	30.48	2.07e-113	2.05e-105	1.02	0.81	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-30.46	2.72e-113	2.67e-105	-1.02	-0.81	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
THCA	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-30.45	2.8e-113	2.75e-105	-1.08	-0.81	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
THCA	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	30.45	3.04e-113	2.94e-105	1.02	0.81	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	30.45	3.04e-113	2.94e-105	1.02	0.81	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	30.45	3.04e-113	2.94e-105	1.02	0.81	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	30.45	3.04e-113	2.94e-105	1.02	0.81	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	30.45	3.04e-113	2.94e-105	1.02	0.81	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	30.45	3.04e-113	2.94e-105	1.02	0.81	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	30.45	3.04e-113	2.94e-105	1.02	0.81	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-30.44	3.13e-113	3.03e-105	-1.02	-0.81	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	30.44	3.16e-113	3.04e-105	1.02	0.81	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	30.44	3.16e-113	3.04e-105	1.02	0.81	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	30.44	3.18e-113	3.06e-105	1.02	0.81	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-30.44	3.23e-113	3.1e-105	-1.02	-0.81	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-30.44	3.24e-113	3.11e-105	-1.02	-0.81	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	30.38	6.16e-113	5.85e-105	1.02	0.81	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
THCA	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-30.37	6.63e-113	6.27e-105	-1.02	-0.81	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
THCA	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-30.36	7.29e-113	6.83e-105	-1.08	-0.81	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
THCA	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-30.36	7.29e-113	6.83e-105	-1.08	-0.81	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
THCA	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	30.36	7.5e-113	7.01e-105	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	30.35	8.12e-113	7.55e-105	1.02	0.81	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	30.35	8.12e-113	7.55e-105	1.02	0.81	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	30.35	8.12e-113	7.55e-105	1.02	0.81	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
THCA	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-30.33	9.9e-113	9.16e-105	-1.08	-0.81	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
THCA	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-30.29	1.52e-112	1.4e-104	-1.02	-0.81	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	30.29	1.56e-112	1.43e-104	1.02	0.81	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-30.26	1.94e-112	1.77e-104	-1.02	-0.81	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
THCA	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-30.25	2.16e-112	1.97e-104	-1.13	-0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
THCA	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-30.25	2.25e-112	2.04e-104	-1.02	-0.81	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	30.25	2.3e-112	2.09e-104	1.32	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	30.23	2.71e-112	2.45e-104	1.02	0.81	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	30.23	2.83e-112	2.56e-104	1.32	0.81	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
THCA	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	30.2	3.65e-112	3.27e-104	1.01	0.81	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	30.2	3.68e-112	3.3e-104	1.01	0.81	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	30.19	4e-112	3.58e-104	1.32	0.81	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
THCA	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-30.18	4.58e-112	4.03e-104	-1.04	-0.81	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-30.18	4.58e-112	4.03e-104	-1.04	-0.81	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-30.18	4.58e-112	4.03e-104	-1.04	-0.81	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	30.18	4.58e-112	4.03e-104	1.04	0.81	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	30.18	4.6e-112	4.03e-104	1.04	0.81	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-30.17	5.23e-112	4.56e-104	-1.03	-0.81	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	30.13	7.87e-112	6.84e-104	1.01	0.81	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
THCA	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	30.12	8.61e-112	7.47e-104	1.17	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
THCA	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	30.08	1.31e-111	1.13e-103	1.02	0.81	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
THCA	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-30.07	1.38e-111	1.19e-103	-1.03	-0.81	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	30.03	2.14e-111	1.82e-103	1.32	0.81	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
THCA	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	30.03	2.14e-111	1.82e-103	1.32	0.81	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
THCA	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	30.03	2.14e-111	1.82e-103	1.32	0.81	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
THCA	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	30.03	2.14e-111	1.82e-103	1.32	0.81	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
THCA	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-30.02	2.52e-111	2.14e-103	-1.04	-0.81	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-29.99	3.31e-111	2.8e-103	-1.04	-0.81	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	29.99	3.37e-111	2.85e-103	1.32	0.81	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
THCA	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	29.98	3.54e-111	2.97e-103	1.01	0.81	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	29.98	3.54e-111	2.97e-103	1.01	0.81	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	29.98	3.54e-111	2.97e-103	1.01	0.81	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-29.98	3.6e-111	3.02e-103	-1.02	-0.81	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-29.98	3.6e-111	3.02e-103	-1.02	-0.81	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	29.97	4.05e-111	3.37e-103	1.03	0.81	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	29.94	5.46e-111	4.53e-103	1.04	0.81	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	29.94	5.53e-111	4.56e-103	1.02	0.81	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	29.94	5.53e-111	4.56e-103	1.02	0.81	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	29.94	5.53e-111	4.56e-103	1.02	0.81	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
THCA	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	29.92	6.47e-111	5.3e-103	1.02	0.81	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
THCA	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	29.92	6.73e-111	5.51e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	29.91	7.54e-111	6.16e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
THCA	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-29.91	7.58e-111	6.17e-103	-1.03	-0.81	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	29.9	8.64e-111	6.87e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	29.89	9.57e-111	7.59e-103	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
THCA	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-29.88	9.97e-111	7.89e-103	-1.08	-0.81	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
THCA	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-29.88	1e-110	7.94e-103	-1.03	-0.81	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	29.87	1.18e-110	9.27e-103	1.31	0.81	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
THCA	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	29.87	1.19e-110	9.27e-103	1.02	0.81	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	29.87	1.19e-110	9.27e-103	1.02	0.81	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	29.87	1.19e-110	9.27e-103	1.02	0.81	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	29.87	1.19e-110	9.27e-103	1.02	0.81	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	29.87	1.19e-110	9.27e-103	1.02	0.81	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	29.86	1.27e-110	9.92e-103	1.02	0.81	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	29.84	1.56e-110	1.21e-102	1.04	0.81	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
THCA	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-29.83	1.69e-110	1.31e-102	-1.01	-0.81	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-29.83	1.69e-110	1.31e-102	-1.01	-0.81	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	29.82	1.98e-110	1.53e-102	1.09	0.81	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
THCA	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	29.81	2.15e-110	1.65e-102	1.32	0.81	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
THCA	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	29.78	2.81e-110	2.16e-102	1.03	0.81	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	29.78	2.85e-110	2.17e-102	1.02	0.81	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	29.78	2.85e-110	2.17e-102	1.02	0.81	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	29.78	2.85e-110	2.17e-102	1.02	0.81	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
THCA	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	29.77	3.33e-110	2.53e-102	1.09	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
THCA	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	29.76	3.49e-110	2.65e-102	1.09	0.81	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	29.76	3.66e-110	2.78e-102	1.3	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
THCA	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	29.75	3.75e-110	2.84e-102	1.02	0.81	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-29.75	3.76e-110	2.85e-102	-1.02	-0.81	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
THCA	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	29.74	4.45e-110	3.37e-102	1.13	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
THCA	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	29.72	5.21e-110	3.92e-102	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
THCA	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	29.72	5.23e-110	3.94e-102	1.02	0.81	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	29.69	7.01e-110	5.25e-102	1.31	0.81	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
THCA	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-29.62	1.48e-109	1.09e-101	-1.03	-0.81	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	29.56	2.83e-109	2.07e-101	1.02	0.81	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	29.55	2.97e-109	2.17e-101	1.1	0.81	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
THCA	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	29.54	3.31e-109	2.4e-101	1.01	0.81	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	29.54	3.31e-109	2.4e-101	1.01	0.81	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	29.54	3.31e-109	2.4e-101	1.01	0.81	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
THCA	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	29.54	3.47e-109	2.46e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-29.53	3.83e-109	2.72e-101	-1.03	-0.81	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	29.53	3.93e-109	2.78e-101	1.32	0.81	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
THCA	trans	rs1816752	1	rs9511272	ENSG00000237917.1	PARP4P1	29.5	5e-109	3.53e-101	1.02	0.81	Obesity-related traits;	chr13:24446495	chrY:26594851~26634652:-
THCA	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	29.5	5.3e-109	3.74e-101	1.01	0.81	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-29.5	5.43e-109	3.81e-101	-1.03	-0.81	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	29.47	7.14e-109	5e-101	1.01	0.81	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	29.47	7.19e-109	5.03e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
THCA	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-29.45	8.96e-109	6.19e-101	-1.02	-0.81	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	29.44	9.77e-109	6.75e-101	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
THCA	trans	rs10940346	0.728	rs12655271	ENSG00000231752.4	EMBP1	-29.42	1.15e-108	7.92e-101	-1.02	-0.81	Schizophrenia;	chr5:50212921	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	29.42	1.15e-108	7.93e-101	1.01	0.81	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	29.42	1.18e-108	8.11e-101	1.01	0.81	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
THCA	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	29.42	1.23e-108	8.44e-101	1.31	0.8	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	29.41	1.25e-108	8.54e-101	1.09	0.8	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	29.41	1.25e-108	8.54e-101	1.09	0.8	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	29.41	1.25e-108	8.54e-101	1.09	0.8	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
THCA	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	29.38	1.81e-108	1.23e-100	1.33	0.8	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
THCA	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	29.36	2.12e-108	1.44e-100	1.31	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
THCA	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	29.31	3.53e-108	2.39e-100	1	0.8	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
THCA	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	29.31	3.67e-108	2.48e-100	1.14	0.8	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
THCA	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	29.29	4.49e-108	3.02e-100	1.32	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
THCA	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	29.25	7.21e-108	4.82e-100	1.09	0.8	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
THCA	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-29.24	7.42e-108	4.95e-100	-1.29	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
THCA	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	29.24	8.05e-108	5.36e-100	1.08	0.8	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	29.24	8.05e-108	5.36e-100	1.08	0.8	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
THCA	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	29.23	8.17e-108	5.43e-100	1.14	0.8	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
THCA	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	29.19	1.26e-107	8.26e-100	1.09	0.8	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	29.19	1.26e-107	8.26e-100	1.09	0.8	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	29.19	1.26e-107	8.26e-100	1.09	0.8	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	29.19	1.26e-107	8.26e-100	1.09	0.8	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	29.19	1.26e-107	8.26e-100	1.09	0.8	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	29.19	1.26e-107	8.26e-100	1.09	0.8	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
THCA	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	29.14	2.09e-107	1.37e-99	1.1	0.8	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
THCA	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	29.07	4.36e-107	2.84e-99	1.3	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
THCA	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	29.06	5.02e-107	3.27e-99	1.3	0.8	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	29.06	5.22e-107	3.38e-99	1.09	0.8	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	29.06	5.22e-107	3.38e-99	1.09	0.8	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
THCA	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-29.03	6.98e-107	4.51e-99	-1.06	-0.8	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	29.01	8.75e-107	5.63e-99	1.09	0.8	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	29	8.92e-107	5.74e-99	1.02	0.8	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
THCA	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-28.98	1.2e-106	7.67e-99	-1.09	-0.8	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	28.98	1.2e-106	7.67e-99	1.09	0.8	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	28.98	1.2e-106	7.67e-99	1.09	0.8	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
THCA	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-28.94	1.79e-106	1.14e-98	-1.3	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
THCA	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-28.93	1.88e-106	1.2e-98	-1.04	-0.8	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	28.9	2.69e-106	1.72e-98	1.02	0.8	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.652	rs8185385	ENSG00000231752.4	EMBP1	-28.88	3.12e-106	1.99e-98	-1.02	-0.8	Schizophrenia;	chr5:46318532	chr1:121519112~121571892:+
THCA	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-28.88	3.27e-106	2.08e-98	-1.1	-0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-28.88	3.27e-106	2.08e-98	-1.1	-0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
THCA	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	28.84	4.94e-106	3.13e-98	1.33	0.8	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
THCA	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-28.81	6.77e-106	4.28e-98	-1.1	-0.8	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
THCA	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	28.81	7.05e-106	4.45e-98	1.32	0.8	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
THCA	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-28.78	9.59e-106	6.04e-98	-1.03	-0.8	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs56387400	ENSG00000231752.4	EMBP1	-28.77	1.01e-105	6.38e-98	-1.03	-0.8	Schizophrenia;	chr5:50517577	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.694	rs2219454	ENSG00000231752.4	EMBP1	-28.75	1.22e-105	7.61e-98	-1.02	-0.8	Schizophrenia;	chr5:50212798	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs12520874	ENSG00000231752.4	EMBP1	-28.75	1.24e-105	7.75e-98	-1.03	-0.8	Schizophrenia;	chr5:50523857	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs7708897	ENSG00000231752.4	EMBP1	-28.75	1.29e-105	8.04e-98	-1.03	-0.8	Schizophrenia;	chr5:50528209	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	28.74	1.35e-105	8.4e-98	1.3	0.8	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
THCA	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	28.73	1.5e-105	9.33e-98	1.08	0.8	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
THCA	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-28.73	1.57e-105	9.79e-98	-1.06	-0.8	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
THCA	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	28.72	1.74e-105	1.08e-97	1.29	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
THCA	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	28.72	1.8e-105	1.12e-97	1.06	0.8	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
THCA	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	28.69	2.34e-105	1.45e-97	1.05	0.8	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
THCA	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	28.68	2.61e-105	1.61e-97	1.12	0.8	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
THCA	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	28.67	2.89e-105	1.78e-97	1.08	0.8	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
THCA	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	28.66	3.06e-105	1.88e-97	1.09	0.8	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
THCA	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	28.66	3.06e-105	1.88e-97	1.09	0.8	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
THCA	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-28.64	3.9e-105	2.38e-97	-1.08	-0.8	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	28.63	4.23e-105	2.57e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	28.63	4.23e-105	2.57e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	28.63	4.23e-105	2.57e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	28.63	4.23e-105	2.57e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	28.63	4.44e-105	2.66e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	28.62	4.85e-105	2.9e-97	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	28.6	5.99e-105	3.57e-97	1.01	0.8	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-28.59	6.61e-105	3.93e-97	-1.1	-0.8	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-28.59	6.8e-105	4.04e-97	-1.04	-0.8	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
THCA	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	28.56	9.4e-105	5.55e-97	1.09	0.8	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
THCA	trans	rs4276421	0.714	rs8185016	ENSG00000231752.4	EMBP1	28.55	1.02e-104	6.01e-97	1	0.8	P wave duration;	chr5:46121704	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.713	rs8188193	ENSG00000231752.4	EMBP1	28.55	1.02e-104	6.01e-97	1	0.8	P wave duration;	chr5:46122428	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.565	rs7720870	ENSG00000231752.4	EMBP1	28.54	1.07e-104	6.31e-97	1.01	0.8	P wave duration;	chr5:46139574	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	28.54	1.14e-104	6.68e-97	1.32	0.8	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
THCA	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	28.54	1.14e-104	6.68e-97	1.32	0.8	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	28.52	1.33e-104	7.79e-97	1.08	0.8	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	28.5	1.76e-104	1.03e-96	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	28.5	1.76e-104	1.03e-96	1.1	0.8	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
THCA	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	28.47	2.32e-104	1.35e-96	1.09	0.8	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
THCA	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	28.46	2.51e-104	1.46e-96	1.1	0.8	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
THCA	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	28.46	2.51e-104	1.46e-96	1.28	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	28.46	2.51e-104	1.46e-96	1.28	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
THCA	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	28.43	3.46e-104	2.01e-96	1.13	0.8	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
THCA	trans	rs4276421	0.774	rs6884716	ENSG00000231752.4	EMBP1	28.41	4.22e-104	2.44e-96	1	0.8	P wave duration;	chr5:46115267	chr1:121519112~121571892:+
THCA	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	28.38	5.91e-104	3.41e-96	1.09	0.79	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
THCA	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	28.36	7.46e-104	4.26e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	28.36	7.46e-104	4.26e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	28.36	7.46e-104	4.26e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	28.36	7.46e-104	4.26e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	28.36	7.46e-104	4.26e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	28.36	7.46e-104	4.26e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	28.36	7.46e-104	4.26e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	28.36	7.46e-104	4.26e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	28.36	7.67e-104	4.37e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.661	rs10059426	ENSG00000231752.4	EMBP1	-28.35	8.63e-104	4.89e-96	-1	-0.79	P wave duration;	chr5:46090412	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.774	rs7720482	ENSG00000231752.4	EMBP1	-28.34	9.32e-104	5.28e-96	-1	-0.79	P wave duration;	chr5:46106061	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	28.34	9.37e-104	5.31e-96	1.3	0.79	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
THCA	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	28.34	9.58e-104	5.42e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	28.34	9.58e-104	5.42e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	28.31	1.3e-103	7.35e-96	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.774	rs13361118	ENSG00000231752.4	EMBP1	-28.3	1.46e-103	8.19e-96	-1	-0.79	P wave duration;	chr5:46078308	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.774	rs10050829	ENSG00000231752.4	EMBP1	-28.29	1.47e-103	8.23e-96	-1	-0.79	P wave duration;	chr5:46072628	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs10067655	ENSG00000231752.4	EMBP1	-28.29	1.47e-103	8.23e-96	-1	-0.79	P wave duration;	chr5:46072803	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.745	rs13354272	ENSG00000231752.4	EMBP1	-28.29	1.47e-103	8.23e-96	-1	-0.79	P wave duration;	chr5:46078020	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.695	rs4498260	ENSG00000231752.4	EMBP1	-28.29	1.53e-103	8.55e-96	-1	-0.79	P wave duration;	chr5:46079235	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.683	rs4484447	ENSG00000231752.4	EMBP1	28.28	1.77e-103	9.9e-96	0.99	0.79	P wave duration;	chr5:46048757	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.774	rs4370277	ENSG00000231752.4	EMBP1	28.27	1.81e-103	1.01e-95	0.99	0.79	P wave duration;	chr5:46048566	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	28.25	2.46e-103	1.37e-95	1.06	0.79	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
THCA	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-28.24	2.48e-103	1.38e-95	-1.06	-0.79	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
THCA	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	28.19	4.54e-103	2.52e-95	1	0.79	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	28.19	4.54e-103	2.52e-95	1	0.79	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
THCA	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	28.17	5.7e-103	3.15e-95	1.02	0.79	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
THCA	trans	rs4276421	0.662	rs4367307	ENSG00000231752.4	EMBP1	-28.16	6.26e-103	3.45e-95	-1	-0.79	P wave duration;	chr5:46065857	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.774	rs10066479	ENSG00000231752.4	EMBP1	-28.15	6.95e-103	3.83e-95	-0.99	-0.79	P wave duration;	chr5:46097385	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.774	rs12515804	ENSG00000231752.4	EMBP1	-28.15	6.95e-103	3.83e-95	-0.99	-0.79	P wave duration;	chr5:46098504	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	28.12	9.36e-103	5.14e-95	1	0.79	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	28.12	9.36e-103	5.14e-95	1	0.79	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
THCA	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	28.11	9.86e-103	5.41e-95	1.06	0.79	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
THCA	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	28.11	1e-102	5.49e-95	1.13	0.79	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
THCA	trans	rs4276421	0.774	rs10042199	ENSG00000231752.4	EMBP1	-28.1	1.16e-102	6.35e-95	-1	-0.79	P wave duration;	chr5:46103946	chr1:121519112~121571892:+
THCA	trans	rs12291225	0.585	rs4757250	ENSG00000236360.2	RP11-334A14.2	28.09	1.24e-102	6.8e-95	1.09	0.79	Sense of smell;	chr11:14354137	chr1:52993201~52993702:-
THCA	trans	rs4276421	0.774	rs8188064	ENSG00000231752.4	EMBP1	28.09	1.27e-102	6.96e-95	1	0.79	P wave duration;	chr5:46045249	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-28.06	1.64e-102	8.91e-95	-1.11	-0.79	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
THCA	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	28.06	1.71e-102	9.31e-95	1.11	0.79	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
THCA	trans	rs10940346	1	rs10940359	ENSG00000231752.4	EMBP1	-28.04	2.16e-102	1.17e-94	-1.03	-0.79	Schizophrenia;	chr5:50538645	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-28.04	2.2e-102	1.2e-94	-1.07	-0.79	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.744	rs4431354	ENSG00000231752.4	EMBP1	28.03	2.4e-102	1.3e-94	1	0.79	P wave duration;	chr5:46051284	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	28	3.3e-102	1.79e-94	1.1	0.79	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.774	rs72755668	ENSG00000231752.4	EMBP1	-27.99	3.73e-102	2.02e-94	-1	-0.79	P wave duration;	chr5:46102658	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.745	rs10941722	ENSG00000231752.4	EMBP1	-27.98	3.97e-102	2.14e-94	-1	-0.79	P wave duration;	chr5:46067527	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.745	rs4441886	ENSG00000231752.4	EMBP1	-27.98	4.04e-102	2.18e-94	-1	-0.79	P wave duration;	chr5:46063034	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	27.94	6.01e-102	3.24e-94	1.31	0.79	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-27.93	7.04e-102	3.79e-94	-1.06	-0.79	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
THCA	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	27.92	7.78e-102	4.18e-94	1.29	0.79	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
THCA	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	27.88	1.13e-101	6.05e-94	1.08	0.79	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
THCA	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	27.88	1.15e-101	6.17e-94	1.3	0.79	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
THCA	trans	rs4276421	0.774	rs4499842	ENSG00000231752.4	EMBP1	27.85	1.59e-101	8.53e-94	1	0.79	P wave duration;	chr5:46034390	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	27.84	1.68e-101	8.98e-94	1.33	0.79	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
THCA	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	27.82	2.13e-101	1.14e-93	1.09	0.79	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.774	rs4302598	ENSG00000231752.4	EMBP1	27.82	2.19e-101	1.17e-93	0.99	0.79	P wave duration;	chr5:46019065	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.682	rs10054419	ENSG00000231752.4	EMBP1	27.81	2.28e-101	1.21e-93	0.99	0.79	P wave duration;	chr5:46036863	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.623	rs12654375	ENSG00000231752.4	EMBP1	27.81	2.4e-101	1.28e-93	1	0.79	P wave duration;	chr5:46036452	chr1:121519112~121571892:+
THCA	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	27.78	3.24e-101	1.72e-93	1.11	0.79	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
THCA	trans	rs941207	1	rs941207	ENSG00000121089.4	NACA3P	-27.76	4.06e-101	2.15e-93	-1.06	-0.79	Platelet count;	chr12:56629500	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	27.75	4.32e-101	2.28e-93	1.07	0.79	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.704	rs57407363	ENSG00000231752.4	EMBP1	-27.74	4.76e-101	2.51e-93	-1	-0.79	P wave duration;	chr5:46073845	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.712	rs4389698	ENSG00000231752.4	EMBP1	27.72	6.41e-101	3.38e-93	1	0.79	P wave duration;	chr5:46051566	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.6	rs4426925	ENSG00000231752.4	EMBP1	27.72	6.41e-101	3.38e-93	1	0.79	P wave duration;	chr5:46055499	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-27.67	1.07e-100	5.6e-93	-1.06	-0.79	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.805	rs13168838	ENSG00000231752.4	EMBP1	27.62	1.71e-100	8.92e-93	1	0.79	P wave duration;	chr5:46016815	chr1:121519112~121571892:+
THCA	trans	rs7949030	0.588	rs2509982	ENSG00000186676.3	EEF1GP1	27.62	1.8e-100	9.39e-93	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62544846	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.588	rs2509961	ENSG00000186676.3	EEF1GP1	27.62	1.84e-100	9.53e-93	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62543437	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.588	rs2512563	ENSG00000186676.3	EEF1GP1	27.62	1.84e-100	9.53e-93	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62543777	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.588	rs2428548	ENSG00000186676.3	EEF1GP1	27.62	1.84e-100	9.53e-93	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62543990	chr7:125033453~125035301:+
THCA	trans	rs7949030	0.588	rs2512562	ENSG00000186676.3	EEF1GP1	27.62	1.84e-100	9.53e-93	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62544684	chr7:125033453~125035301:+
THCA	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	27.6	2.13e-100	1.1e-92	1.3	0.79	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
THCA	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	27.6	2.24e-100	1.16e-92	1.29	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
THCA	trans	rs76329678	1	rs76329678	ENSG00000231752.4	EMBP1	-27.57	3.06e-100	1.58e-92	-1.03	-0.79	Schizophrenia;	chr5:50534452	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.807	rs12520938	ENSG00000231752.4	EMBP1	-27.54	3.91e-100	2.01e-92	-0.99	-0.79	P wave duration;	chr5:46098683	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.807	rs10941740	ENSG00000231752.4	EMBP1	-27.54	3.91e-100	2.01e-92	-0.99	-0.79	P wave duration;	chr5:46100208	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	27.53	4.64e-100	2.38e-92	1.01	0.79	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	27.52	4.92e-100	2.52e-92	1.07	0.79	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	27.52	4.92e-100	2.52e-92	1.07	0.79	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.904	rs4489075	ENSG00000231752.4	EMBP1	27.46	9.46e-100	4.83e-92	1	0.78	P wave duration;	chr5:46018903	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-27.45	1.05e-99	5.37e-92	-1	-0.78	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.623	rs4409106	ENSG00000231752.4	EMBP1	27.45	1.08e-99	5.53e-92	0.99	0.78	P wave duration;	chr5:46038004	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	27.45	1.1e-99	5.59e-92	1.3	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.874	rs4501347	ENSG00000231752.4	EMBP1	27.41	1.56e-99	7.93e-92	1	0.78	P wave duration;	chr5:45974779	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	27.28	6.59e-99	3.33e-91	1.25	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
THCA	trans	rs4276421	0.904	rs4569880	ENSG00000231752.4	EMBP1	27.27	6.84e-99	3.45e-91	1	0.78	P wave duration;	chr5:46011373	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.874	rs4569881	ENSG00000231752.4	EMBP1	27.27	6.84e-99	3.45e-91	1	0.78	P wave duration;	chr5:46011667	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.816	rs13362078	ENSG00000231752.4	EMBP1	27.27	6.84e-99	3.45e-91	1	0.78	P wave duration;	chr5:46013351	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	27.26	7.71e-99	3.88e-91	1.29	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
THCA	trans	rs4276421	0.695	rs4421114	ENSG00000231752.4	EMBP1	-27.26	7.98e-99	4.01e-91	-0.99	-0.78	P wave duration;	chr5:46069241	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.845	rs62372987	ENSG00000231752.4	EMBP1	27.25	8.92e-99	4.46e-91	1	0.78	P wave duration;	chr5:45979889	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.659	rs8188026	ENSG00000231752.4	EMBP1	27.24	1.02e-98	5.08e-91	1	0.78	P wave duration;	chr5:46053462	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	27.21	1.37e-98	6.82e-91	1.3	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.845	rs4492122	ENSG00000231752.4	EMBP1	27.21	1.4e-98	7.01e-91	1	0.78	P wave duration;	chr5:45982952	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	27.2	1.46e-98	7.29e-91	1.26	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
THCA	trans	rs4276421	0.904	rs7293482	ENSG00000231752.4	EMBP1	27.19	1.62e-98	8.05e-91	1	0.78	P wave duration;	chr5:46003984	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.967	rs4866979	ENSG00000231752.4	EMBP1	-27.11	3.86e-98	1.91e-90	-0.99	-0.78	P wave duration;	chr5:45804745	chr1:121519112~121571892:+
THCA	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	27.1	4.09e-98	2.03e-90	1.08	0.78	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
THCA	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-27.05	7.47e-98	3.69e-90	-1.07	-0.78	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
THCA	trans	rs12291225	0.546	rs11023199	ENSG00000236360.2	RP11-334A14.2	27.05	7.62e-98	3.76e-90	1.08	0.78	Sense of smell;	chr11:14372712	chr1:52993201~52993702:-
THCA	trans	rs4276421	0.874	rs34501453	ENSG00000231752.4	EMBP1	27	1.24e-97	6.13e-90	0.99	0.78	P wave duration;	chr5:45947338	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.904	rs6862657	ENSG00000231752.4	EMBP1	-26.99	1.42e-97	6.97e-90	-1	-0.78	P wave duration;	chr5:45905895	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	26.96	1.82e-97	8.96e-90	1.07	0.78	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	26.96	1.82e-97	8.96e-90	1.07	0.78	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	26.96	1.83e-97	8.98e-90	1.07	0.78	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	26.96	1.84e-97	9.02e-90	1.03	0.78	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.904	rs10067132	ENSG00000231752.4	EMBP1	26.95	2.08e-97	1.02e-89	0.99	0.78	P wave duration;	chr5:46027600	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.837	rs6451829	ENSG00000231752.4	EMBP1	26.94	2.46e-97	1.2e-89	0.98	0.78	P wave duration;	chr5:45893260	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.904	rs7716296	ENSG00000231752.4	EMBP1	26.94	2.46e-97	1.2e-89	0.98	0.78	P wave duration;	chr5:45895783	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.935	rs6882139	ENSG00000231752.4	EMBP1	26.94	2.46e-97	1.2e-89	0.98	0.78	P wave duration;	chr5:45897149	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	26.88	4.49e-97	2.18e-89	1.03	0.78	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	26.84	6.74e-97	3.27e-89	1.06	0.78	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.934	rs6451838	ENSG00000231752.4	EMBP1	26.82	8.38e-97	4.05e-89	0.98	0.78	P wave duration;	chr5:45935060	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.874	rs7727331	ENSG00000231752.4	EMBP1	26.82	8.49e-97	4.1e-89	0.98	0.78	P wave duration;	chr5:45945199	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	26.82	8.79e-97	4.24e-89	1.02	0.78	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
THCA	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	26.8	1.05e-96	5.06e-89	1.3	0.78	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
THCA	trans	rs4276421	0.638	rs4551075	ENSG00000231752.4	EMBP1	26.72	2.46e-96	1.18e-88	1	0.78	P wave duration;	chr5:46011710	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-26.72	2.49e-96	1.19e-88	-1.05	-0.78	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.967	rs10069793	ENSG00000231752.4	EMBP1	26.71	2.62e-96	1.25e-88	0.99	0.78	P wave duration;	chr5:45803049	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-26.71	2.71e-96	1.3e-88	-1.04	-0.78	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.904	rs57299032	ENSG00000231752.4	EMBP1	26.7	3.09e-96	1.47e-88	1	0.78	P wave duration;	chr5:45998162	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.935	rs35163964	ENSG00000231752.4	EMBP1	26.67	4.06e-96	1.93e-88	0.98	0.78	P wave duration;	chr5:45904860	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	26.59	9.44e-96	4.47e-88	1.24	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	26.59	9.58e-96	4.53e-88	1.25	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.904	rs6451843	ENSG00000231752.4	EMBP1	26.59	9.68e-96	4.58e-88	0.99	0.78	P wave duration;	chr5:45946683	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-26.58	1.09e-95	5.14e-88	-1.25	-0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	26.54	1.63e-95	7.57e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
THCA	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	26.53	1.77e-95	8.19e-88	1.3	0.77	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
THCA	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	26.53	1.8e-95	8.35e-88	1.3	0.77	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
THCA	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	26.53	1.92e-95	8.89e-88	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
THCA	trans	rs4276421	0.736	rs7445572	ENSG00000231752.4	EMBP1	26.49	2.92e-95	1.35e-87	0.99	0.77	P wave duration;	chr5:45920315	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.7	rs10070274	ENSG00000231752.4	EMBP1	26.48	2.98e-95	1.37e-87	0.99	0.77	P wave duration;	chr5:46030675	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	26.48	3.18e-95	1.46e-87	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
THCA	trans	rs10940346	1	rs7704686	ENSG00000231752.4	EMBP1	-26.47	3.54e-95	1.63e-87	-1.01	-0.77	Schizophrenia;	chr5:50548995	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.904	rs4274988	ENSG00000231752.4	EMBP1	26.43	5.37e-95	2.45e-87	0.98	0.77	P wave duration;	chr5:45926339	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.935	rs7725537	ENSG00000231752.4	EMBP1	26.43	5.37e-95	2.45e-87	0.98	0.77	P wave duration;	chr5:45927191	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.935	rs35730142	ENSG00000231752.4	EMBP1	26.43	5.37e-95	2.45e-87	0.98	0.77	P wave duration;	chr5:45927453	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.967	rs4541666	ENSG00000231752.4	EMBP1	26.43	5.51e-95	2.52e-87	0.99	0.77	P wave duration;	chr5:45857027	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs11748089	ENSG00000231752.4	EMBP1	-26.43	5.55e-95	2.53e-87	-0.99	-0.77	P wave duration;	chr5:45810733	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs10037766	ENSG00000231752.4	EMBP1	-26.43	5.55e-95	2.53e-87	-0.99	-0.77	P wave duration;	chr5:45813215	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs13175559	ENSG00000231752.4	EMBP1	26.42	5.6e-95	2.55e-87	0.99	0.77	P wave duration;	chr5:45854525	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.816	rs6451835	ENSG00000231752.4	EMBP1	26.42	5.83e-95	2.65e-87	0.98	0.77	P wave duration;	chr5:45928735	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.904	rs7444405	ENSG00000231752.4	EMBP1	26.4	7.05e-95	3.2e-87	0.98	0.77	P wave duration;	chr5:45915373	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs4276421	ENSG00000231752.4	EMBP1	-26.4	7.33e-95	3.33e-87	-0.99	-0.77	P wave duration;	chr5:45801977	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-26.38	9.12e-95	4.12e-87	-1.03	-0.77	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-26.38	9.12e-95	4.12e-87	-1.03	-0.77	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	26.34	1.31e-94	5.92e-87	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
THCA	trans	rs4276421	0.904	rs34462057	ENSG00000231752.4	EMBP1	26.34	1.39e-94	6.26e-87	0.98	0.77	P wave duration;	chr5:45900215	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	26.33	1.59e-94	7.18e-87	1.09	0.77	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.967	rs10755272	ENSG00000231752.4	EMBP1	-26.32	1.65e-94	7.42e-87	-0.98	-0.77	P wave duration;	chr5:45815434	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs4866982	ENSG00000231752.4	EMBP1	-26.32	1.65e-94	7.42e-87	-0.98	-0.77	P wave duration;	chr5:45816754	chr1:121519112~121571892:+
THCA	trans	rs10940346	1	rs1423645	ENSG00000231752.4	EMBP1	-26.3	2.11e-94	9.46e-87	-1.02	-0.77	Schizophrenia;	chr5:50540881	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	26.3	2.17e-94	9.69e-87	0.98	0.77	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.935	rs6898824	ENSG00000231752.4	EMBP1	-26.3	2.17e-94	9.69e-87	-0.98	-0.77	P wave duration;	chr5:45842058	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	26.3	2.21e-94	9.89e-87	1.25	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
THCA	trans	rs4276421	0.839	rs7719401	ENSG00000231752.4	EMBP1	26.29	2.26e-94	1.01e-86	0.98	0.77	P wave duration;	chr5:45938713	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.967	rs35648163	ENSG00000231752.4	EMBP1	26.28	2.73e-94	1.22e-86	0.98	0.77	P wave duration;	chr5:45945778	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.934	rs6451840	ENSG00000231752.4	EMBP1	26.26	3.07e-94	1.35e-86	0.98	0.77	P wave duration;	chr5:45935584	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.87	rs6451842	ENSG00000231752.4	EMBP1	26.26	3.07e-94	1.35e-86	0.98	0.77	P wave duration;	chr5:45936431	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.744	rs4541667	ENSG00000231752.4	EMBP1	26.23	4.25e-94	1.87e-86	1	0.77	P wave duration;	chr5:46060767	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.935	rs6451827	ENSG00000231752.4	EMBP1	26.22	4.75e-94	2.08e-86	0.98	0.77	P wave duration;	chr5:45879496	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	26.22	4.85e-94	2.13e-86	1.05	0.77	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	26.21	5.3e-94	2.32e-86	1.02	0.77	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	26.21	5.3e-94	2.32e-86	1.02	0.77	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	26.21	5.3e-94	2.32e-86	1.02	0.77	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	26.21	5.53e-94	2.41e-86	1.02	0.77	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	26.21	5.53e-94	2.41e-86	1.02	0.77	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.845	rs4371763	ENSG00000231752.4	EMBP1	26.2	6.3e-94	2.74e-86	0.99	0.77	P wave duration;	chr5:45983120	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs10039283	ENSG00000231752.4	EMBP1	26.15	1.04e-93	4.51e-86	0.98	0.77	P wave duration;	chr5:45864741	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.967	rs4282324	ENSG00000231752.4	EMBP1	26.15	1.04e-93	4.51e-86	0.98	0.77	P wave duration;	chr5:45865330	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.901	rs10056175	ENSG00000231752.4	EMBP1	26.15	1.08e-93	4.68e-86	0.98	0.77	P wave duration;	chr5:45934503	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs6895191	ENSG00000231752.4	EMBP1	26.13	1.25e-93	5.4e-86	0.98	0.77	P wave duration;	chr5:45877572	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	26.13	1.33e-93	5.73e-86	1.24	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
THCA	trans	rs4276421	0.935	rs6451834	ENSG00000231752.4	EMBP1	26.12	1.41e-93	6.09e-86	0.98	0.77	P wave duration;	chr5:45927208	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs13340341	ENSG00000231752.4	EMBP1	26.12	1.44e-93	6.2e-86	0.98	0.77	P wave duration;	chr5:45860834	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.874	rs6451830	ENSG00000231752.4	EMBP1	26.11	1.56e-93	6.71e-86	0.97	0.77	P wave duration;	chr5:45893354	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.688	rs7713759	ENSG00000231752.4	EMBP1	26.1	1.84e-93	7.91e-86	0.97	0.77	P wave duration;	chr5:46143447	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-26.09	2.04e-93	8.73e-86	-1.01	-0.77	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
THCA	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	26.09	2.05e-93	8.78e-86	0.95	0.77	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
THCA	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-26.04	3.34e-93	1.43e-85	-0.99	-0.77	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
THCA	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-26.04	3.52e-93	1.5e-85	-1.02	-0.77	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.935	rs12109652	ENSG00000231752.4	EMBP1	26.04	3.56e-93	1.52e-85	0.97	0.77	P wave duration;	chr5:45878206	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs28657933	ENSG00000231752.4	EMBP1	26.02	4.34e-93	1.84e-85	0.97	0.77	P wave duration;	chr5:45863597	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-25.91	1.38e-92	5.8e-85	-1.02	-0.77	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.934	rs7443410	ENSG00000231752.4	EMBP1	25.9	1.47e-92	6.2e-85	0.98	0.77	P wave duration;	chr5:45960831	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-25.88	1.91e-92	8e-85	-1.02	-0.77	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-25.88	1.91e-92	8e-85	-1.02	-0.77	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-25.88	1.91e-92	8e-85	-1.02	-0.77	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	25.86	2.27e-92	9.52e-85	1.01	0.77	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.762	rs10043270	ENSG00000231752.4	EMBP1	25.84	2.78e-92	1.16e-84	0.98	0.77	P wave duration;	chr5:45967846	chr1:121519112~121571892:+
THCA	trans	rs4276421	1	rs4331911	ENSG00000231752.4	EMBP1	25.84	2.88e-92	1.2e-84	0.97	0.77	P wave duration;	chr5:45859273	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-25.84	2.98e-92	1.25e-84	-1.02	-0.77	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.935	rs4502836	ENSG00000231752.4	EMBP1	25.79	4.68e-92	1.95e-84	0.98	0.77	P wave duration;	chr5:45956617	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-25.77	6.36e-92	2.62e-84	-1.01	-0.77	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.967	rs7725171	ENSG00000231752.4	EMBP1	25.69	1.42e-91	5.7e-84	0.97	0.76	P wave duration;	chr5:45923684	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-25.69	1.5e-91	5.99e-84	-1.05	-0.76	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-25.65	2.08e-91	8.3e-84	-1.01	-0.76	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
THCA	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	25.65	2.19e-91	8.76e-84	1.09	0.76	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
THCA	trans	rs10940346	1	rs11739291	ENSG00000231752.4	EMBP1	-25.64	2.33e-91	9.29e-84	-1	-0.76	Schizophrenia;	chr5:50550394	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-25.62	3.05e-91	1.21e-83	-0.96	-0.76	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	25.62	3.08e-91	1.22e-83	1.24	0.76	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-25.61	3.46e-91	1.37e-83	-1.04	-0.76	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-25.47	1.54e-90	6.03e-83	-0.96	-0.76	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	25.43	2.24e-90	8.71e-83	0.97	0.76	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	25.42	2.47e-90	9.6e-83	1	0.76	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.967	rs10062508	ENSG00000231752.4	EMBP1	25.38	3.96e-90	1.53e-82	0.98	0.76	P wave duration;	chr5:45961764	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs6451814	ENSG00000231752.4	EMBP1	25.33	6.5e-90	2.51e-82	0.96	0.76	P wave duration;	chr5:45734981	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-25.31	8.63e-90	3.32e-82	-0.96	-0.76	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-25.31	8.63e-90	3.32e-82	-0.96	-0.76	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	25.31	8.63e-90	3.32e-82	0.96	0.76	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-25.27	1.22e-89	4.7e-82	-1.03	-0.76	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-25.26	1.41e-89	5.41e-82	-0.96	-0.76	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-25.26	1.41e-89	5.41e-82	-0.96	-0.76	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.874	rs71618219	ENSG00000231752.4	EMBP1	25.23	1.91e-89	7.28e-82	0.98	0.76	P wave duration;	chr5:45950598	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-25.23	1.94e-89	7.39e-82	-0.96	-0.76	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-25.21	2.57e-89	9.77e-82	-1.05	-0.76	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.869	rs10036065	ENSG00000231752.4	EMBP1	-25.2	2.59e-89	9.85e-82	-0.96	-0.76	P wave duration;	chr5:45701926	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.776	rs10473392	ENSG00000231752.4	EMBP1	25.2	2.59e-89	9.85e-82	0.96	0.76	P wave duration;	chr5:45709959	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.745	rs10079238	ENSG00000231752.4	EMBP1	-25.2	2.81e-89	1.07e-81	-0.96	-0.76	P wave duration;	chr5:46066531	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-25.18	3.29e-89	1.24e-81	-0.98	-0.76	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.935	rs4473777	ENSG00000231752.4	EMBP1	25.18	3.37e-89	1.27e-81	0.98	0.76	P wave duration;	chr5:45968760	chr1:121519112~121571892:+
THCA	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-25.17	3.63e-89	1.37e-81	-0.95	-0.76	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
THCA	trans	rs4276421	0.869	rs7736561	ENSG00000231752.4	EMBP1	25.16	4.01e-89	1.51e-81	0.95	0.76	P wave duration;	chr5:45716294	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs6892627	ENSG00000231752.4	EMBP1	25.16	4.37e-89	1.65e-81	0.96	0.76	P wave duration;	chr5:45722892	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs2337951	ENSG00000231752.4	EMBP1	25.14	5.07e-89	1.91e-81	0.95	0.76	P wave duration;	chr5:45717834	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs6451812	ENSG00000231752.4	EMBP1	25.14	5.12e-89	1.93e-81	0.95	0.76	P wave duration;	chr5:45692206	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs2337952	ENSG00000231752.4	EMBP1	25.14	5.23e-89	1.97e-81	0.95	0.76	P wave duration;	chr5:45722022	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.901	rs10044479	ENSG00000231752.4	EMBP1	25.13	5.62e-89	2.11e-81	0.96	0.76	P wave duration;	chr5:45751434	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.87	rs7706116	ENSG00000231752.4	EMBP1	25.12	6.2e-89	2.32e-81	0.96	0.76	P wave duration;	chr5:45742522	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs7718785	ENSG00000231752.4	EMBP1	25.08	9.37e-89	3.51e-81	0.96	0.76	P wave duration;	chr5:45725495	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs13187565	ENSG00000231752.4	EMBP1	25.08	9.5e-89	3.55e-81	0.95	0.76	P wave duration;	chr5:45707436	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.901	rs7447717	ENSG00000231752.4	EMBP1	-25.06	1.17e-88	4.38e-81	-0.95	-0.76	P wave duration;	chr5:45770150	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-25.05	1.39e-88	5.19e-81	-1.1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
THCA	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	25.04	1.45e-88	5.4e-81	0.98	0.76	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-25.04	1.5e-88	5.59e-81	-1.04	-0.76	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
THCA	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-25.04	1.58e-88	5.86e-81	-1.1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
THCA	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-25.04	1.58e-88	5.86e-81	-1.1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
THCA	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-25.03	1.65e-88	6.12e-81	-1.1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
THCA	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	25.03	1.68e-88	6.22e-81	1.24	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
THCA	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-24.99	2.52e-88	9.29e-81	-1.03	-0.76	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.901	rs9687260	ENSG00000231752.4	EMBP1	24.99	2.57e-88	9.47e-81	0.95	0.76	P wave duration;	chr5:45759774	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.901	rs4455566	ENSG00000231752.4	EMBP1	24.99	2.6e-88	9.57e-81	0.95	0.76	P wave duration;	chr5:45752760	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-24.99	2.6e-88	9.58e-81	-1.1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
THCA	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-24.99	2.6e-88	9.58e-81	-1.1	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
THCA	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	24.97	3.34e-88	1.23e-80	0.95	0.76	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.556	rs10213679	ENSG00000231752.4	EMBP1	24.96	3.53e-88	1.29e-80	0.98	0.75	P wave duration;	chr5:45954206	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.904	rs4289566	ENSG00000231752.4	EMBP1	24.96	3.53e-88	1.29e-80	0.98	0.75	P wave duration;	chr5:45955499	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.837	rs10078625	ENSG00000231752.4	EMBP1	24.91	6.28e-88	2.29e-80	0.95	0.75	P wave duration;	chr5:45707015	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs7705696	ENSG00000231752.4	EMBP1	24.91	6.28e-88	2.29e-80	0.95	0.75	P wave duration;	chr5:45712387	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	24.89	7.65e-88	2.78e-80	0.99	0.75	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.869	rs1527831	ENSG00000231752.4	EMBP1	24.87	9.55e-88	3.47e-80	0.95	0.75	P wave duration;	chr5:45656821	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	24.84	1.34e-87	4.86e-80	1.24	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
THCA	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	24.8	2.03e-87	7.34e-80	0.96	0.75	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	24.78	2.52e-87	9.11e-80	0.98	0.75	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	24.76	3.2e-87	1.15e-79	0.96	0.75	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs2879074	ENSG00000231752.4	EMBP1	24.75	3.3e-87	1.19e-79	0.94	0.75	P wave duration;	chr5:45716107	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.682	rs10067983	ENSG00000231752.4	EMBP1	24.72	4.65e-87	1.67e-79	0.95	0.75	P wave duration;	chr5:46064294	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-24.7	6.01e-87	2.15e-79	-1.01	-0.75	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	24.69	6.44e-87	2.31e-79	1.06	0.75	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-24.69	6.49e-87	2.32e-79	-1.02	-0.75	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.81	rs10213756	ENSG00000231752.4	EMBP1	24.68	7.6e-87	2.72e-79	0.97	0.75	P wave duration;	chr5:45952498	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.55	rs34812524	ENSG00000231752.4	EMBP1	24.66	8.75e-87	3.12e-79	0.96	0.75	P wave duration;	chr5:46054030	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.715	rs10043248	ENSG00000231752.4	EMBP1	24.66	9.19e-87	3.27e-79	0.96	0.75	P wave duration;	chr5:46025930	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	24.66	9.22e-87	3.28e-79	0.98	0.75	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-24.62	1.39e-86	4.94e-79	-0.99	-0.75	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-24.62	1.39e-86	4.94e-79	-0.99	-0.75	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-24.62	1.45e-86	5.15e-79	-0.98	-0.75	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-24.62	1.45e-86	5.15e-79	-0.98	-0.75	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-24.62	1.45e-86	5.15e-79	-0.98	-0.75	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	24.61	1.56e-86	5.51e-79	0.99	0.75	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	24.61	1.56e-86	5.51e-79	0.99	0.75	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	24.61	1.56e-86	5.51e-79	0.99	0.75	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	24.6	1.72e-86	6.05e-79	1	0.75	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
THCA	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	24.6	1.72e-86	6.05e-79	1	0.75	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
THCA	trans	rs2589161	1	rs2589161	ENSG00000231752.4	EMBP1	24.56	2.68e-86	9.43e-79	0.95	0.75	Breast cancer;	chr5:45653810	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs1405918	ENSG00000231752.4	EMBP1	24.56	2.68e-86	9.43e-79	0.95	0.75	P wave duration;	chr5:45654968	chr1:121519112~121571892:+
THCA	trans	rs2885056	0.83	rs7259124	ENSG00000227534.1	RP3-323B6.1	24.54	3.18e-86	1.12e-78	1.05	0.75	Red cell distribution width;	chr19:10560988	chrX:65469087~65470380:+
THCA	trans	rs4276421	0.967	rs6865429	ENSG00000231752.4	EMBP1	-24.54	3.42e-86	1.2e-78	-0.95	-0.75	P wave duration;	chr5:45830406	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	24.53	3.84e-86	1.34e-78	0.98	0.75	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	24.53	3.84e-86	1.34e-78	0.98	0.75	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-24.51	4.66e-86	1.62e-78	-1.01	-0.75	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-24.51	4.66e-86	1.62e-78	-1.01	-0.75	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-24.51	4.66e-86	1.62e-78	-1.01	-0.75	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
THCA	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-24.51	4.74e-86	1.65e-78	-1.08	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
THCA	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-24.49	5.77e-86	2e-78	-0.99	-0.75	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-24.48	5.99e-86	2.08e-78	-0.98	-0.75	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	24.48	6.25e-86	2.16e-78	0.97	0.75	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	24.47	6.64e-86	2.29e-78	0.99	0.75	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
THCA	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	24.47	6.64e-86	2.29e-78	0.98	0.75	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	24.47	6.64e-86	2.29e-78	0.98	0.75	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.837	rs2580260	ENSG00000231752.4	EMBP1	24.45	8.67e-86	2.98e-78	0.94	0.75	P wave duration;	chr5:45638527	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	24.45	9.08e-86	3.12e-78	1	0.75	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	24.44	1.01e-85	3.48e-78	0.99	0.75	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
THCA	trans	rs2885056	0.783	rs12459941	ENSG00000227534.1	RP3-323B6.1	-24.43	1.07e-85	3.68e-78	-1.01	-0.75	Red cell distribution width;	chr19:10555436	chrX:65469087~65470380:+
THCA	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-24.43	1.13e-85	3.87e-78	-1	-0.75	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.901	rs12110137	ENSG00000231752.4	EMBP1	24.41	1.36e-85	4.67e-78	0.94	0.75	P wave duration;	chr5:45727764	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.635	rs12186454	ENSG00000231752.4	EMBP1	-24.4	1.45e-85	4.97e-78	-0.96	-0.75	P wave duration;	chr5:46067621	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.87	rs4257782	ENSG00000231752.4	EMBP1	24.39	1.73e-85	5.91e-78	0.94	0.75	P wave duration;	chr5:45750292	chr1:121519112~121571892:+
THCA	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-24.37	2.09e-85	7.11e-78	-1.12	-0.75	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
THCA	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	24.34	2.75e-85	9.35e-78	0.97	0.75	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	24.34	2.75e-85	9.35e-78	0.97	0.75	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-24.34	2.94e-85	9.98e-78	-1	-0.75	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	24.32	3.6e-85	1.22e-77	1.05	0.75	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	24.3	4.61e-85	1.56e-77	0.95	0.75	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-24.26	7.07e-85	2.39e-77	-1	-0.75	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-24.26	7.09e-85	2.39e-77	-1	-0.75	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-24.23	9.45e-85	3.18e-77	-1	-0.75	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-24.23	9.45e-85	3.18e-77	-1	-0.75	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.805	rs6451810	ENSG00000231752.4	EMBP1	24.22	1.03e-84	3.45e-77	0.94	0.75	P wave duration;	chr5:45633898	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	24.21	1.18e-84	3.97e-77	1.19	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
THCA	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-24.19	1.44e-84	4.81e-77	-1	-0.74	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
THCA	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	24.19	1.46e-84	4.88e-77	1.06	0.74	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	24.17	1.81e-84	5.99e-77	0.97	0.74	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	24.17	1.81e-84	5.99e-77	0.97	0.74	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	24.17	1.81e-84	5.99e-77	0.97	0.74	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	24.17	1.81e-84	5.99e-77	0.97	0.74	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	24.17	1.81e-84	5.99e-77	0.97	0.74	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	24.17	1.81e-84	5.99e-77	0.97	0.74	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
THCA	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	24.16	1.91e-84	6.33e-77	1.11	0.74	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
THCA	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-24.16	1.93e-84	6.39e-77	-0.99	-0.74	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.837	rs2696013	ENSG00000231752.4	EMBP1	24.16	1.96e-84	6.49e-77	0.94	0.74	P wave duration;	chr5:45603104	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-24.16	1.97e-84	6.51e-77	-1	-0.74	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
THCA	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-24.16	1.99e-84	6.58e-77	-1.1	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
THCA	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	24.15	2.15e-84	7.09e-77	1	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	24.15	2.15e-84	7.09e-77	1	0.74	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	24.15	2.3e-84	7.54e-77	0.97	0.74	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.837	rs1483303	ENSG00000231752.4	EMBP1	24.13	2.87e-84	9.36e-77	0.94	0.74	P wave duration;	chr5:45571997	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-24.13	2.88e-84	9.4e-77	-0.97	-0.74	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.845	rs34040576	ENSG00000231752.4	EMBP1	24.12	2.94e-84	9.6e-77	0.96	0.74	P wave duration;	chr5:46005596	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.904	rs13360955	ENSG00000231752.4	EMBP1	24.12	2.94e-84	9.6e-77	0.96	0.74	P wave duration;	chr5:46005842	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.774	rs4428422	ENSG00000231752.4	EMBP1	24.12	3.16e-84	1.03e-76	0.95	0.74	P wave duration;	chr5:46017216	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-24.11	3.28e-84	1.07e-76	-1.01	-0.74	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	24.1	3.83e-84	1.25e-76	1	0.74	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	24.09	4.06e-84	1.32e-76	1.01	0.74	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
THCA	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
THCA	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
THCA	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
THCA	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
THCA	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	24.08	4.56e-84	1.47e-76	1	0.74	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	24.08	4.76e-84	1.53e-76	1.05	0.74	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	24.08	4.82e-84	1.55e-76	0.97	0.74	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.736	rs8188290	ENSG00000231752.4	EMBP1	24.08	4.9e-84	1.57e-76	0.96	0.74	P wave duration;	chr5:46047215	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs2589162	ENSG00000231752.4	EMBP1	-24.03	7.9e-84	2.53e-76	-0.94	-0.74	P wave duration;	chr5:45655791	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	24.03	8.23e-84	2.64e-76	0.97	0.74	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.904	rs10070596	ENSG00000231752.4	EMBP1	24.02	8.77e-84	2.81e-76	0.96	0.74	P wave duration;	chr5:46004129	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	24.02	9.02e-84	2.88e-76	0.97	0.74	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	24.02	9.02e-84	2.88e-76	0.97	0.74	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.837	rs6893773	ENSG00000231752.4	EMBP1	24	1.1e-83	3.51e-76	0.94	0.74	P wave duration;	chr5:45622394	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-24	1.15e-83	3.65e-76	-1.09	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
THCA	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-23.98	1.34e-83	4.28e-76	-0.99	-0.74	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.901	rs35381866	ENSG00000231752.4	EMBP1	23.97	1.58e-83	5.03e-76	0.94	0.74	P wave duration;	chr5:45690085	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.837	rs2337483	ENSG00000231752.4	EMBP1	23.96	1.76e-83	5.58e-76	0.94	0.74	P wave duration;	chr5:45608220	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	23.94	2.05e-83	6.48e-76	1	0.74	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-23.94	2.05e-83	6.5e-76	-0.99	-0.74	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.839	rs28885449	ENSG00000231752.4	EMBP1	23.94	2.16e-83	6.82e-76	0.95	0.74	P wave duration;	chr5:45994103	chr1:121519112~121571892:+
THCA	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-23.91	2.92e-83	9.21e-76	-1.07	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
THCA	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-23.91	2.92e-83	9.21e-76	-1.07	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
THCA	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	23.86	5.12e-83	1.61e-75	1	0.74	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	23.85	5.62e-83	1.77e-75	1.01	0.74	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
THCA	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	23.85	5.9e-83	1.85e-75	1.12	0.74	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
THCA	trans	rs4276421	0.845	rs10434580	ENSG00000231752.4	EMBP1	23.84	6.36e-83	2e-75	0.96	0.74	P wave duration;	chr5:46010910	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	23.82	7.79e-83	2.43e-75	1	0.74	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	23.82	7.79e-83	2.43e-75	1	0.74	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	23.82	7.79e-83	2.43e-75	1	0.74	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
THCA	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	23.82	7.79e-83	2.43e-75	1	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.81	rs13190242	ENSG00000231752.4	EMBP1	23.78	1.16e-82	3.6e-75	0.96	0.74	P wave duration;	chr5:46054443	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.967	rs4541665	ENSG00000231752.4	EMBP1	-23.77	1.31e-82	4.06e-75	-0.95	-0.74	P wave duration;	chr5:45796444	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-23.76	1.57e-82	4.89e-75	-0.97	-0.74	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	23.73	2.17e-82	6.71e-75	1.01	0.74	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.837	rs6451807	ENSG00000231752.4	EMBP1	23.72	2.37e-82	7.34e-75	0.93	0.74	P wave duration;	chr5:45534321	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	23.7	2.83e-82	8.73e-75	0.99	0.74	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
THCA	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	23.7	3e-82	9.22e-75	0.9	0.74	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-23.68	3.43e-82	1.05e-74	-0.98	-0.74	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-23.67	4.06e-82	1.25e-74	-0.95	-0.74	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.837	rs2049656	ENSG00000231752.4	EMBP1	-23.67	4.14e-82	1.27e-74	-0.95	-0.74	P wave duration;	chr5:45579590	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	23.65	4.82e-82	1.47e-74	1.04	0.74	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.837	rs1384732	ENSG00000231752.4	EMBP1	23.65	4.83e-82	1.48e-74	0.93	0.74	P wave duration;	chr5:45553285	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs2580258	ENSG00000231752.4	EMBP1	23.62	6.88e-82	2.09e-74	0.93	0.74	P wave duration;	chr5:45586815	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-23.56	1.26e-81	3.82e-74	-0.98	-0.74	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-23.55	1.5e-81	4.52e-74	-0.98	-0.74	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-23.55	1.5e-81	4.52e-74	-0.98	-0.74	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
THCA	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	23.54	1.56e-81	4.7e-74	1.12	0.74	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
THCA	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	23.53	1.76e-81	5.28e-74	1.01	0.74	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
THCA	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-23.52	2.06e-81	6.16e-74	-0.99	-0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.837	rs755048	ENSG00000231752.4	EMBP1	-23.51	2.33e-81	6.87e-74	-0.94	-0.74	P wave duration;	chr5:45596256	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.837	rs10069510	ENSG00000231752.4	EMBP1	-23.51	2.33e-81	6.87e-74	-0.94	-0.74	P wave duration;	chr5:45596937	chr1:121519112~121571892:+
THCA	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	23.48	3.05e-81	8.91e-74	1.11	0.73	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
THCA	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-23.48	3.07e-81	8.97e-74	-1.05	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
THCA	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-23.48	3.07e-81	8.97e-74	-1.05	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
THCA	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	23.48	3.2e-81	9.35e-74	1	0.73	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	23.47	3.36e-81	9.78e-74	0.99	0.73	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-23.46	3.99e-81	1.16e-73	-0.98	-0.73	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-23.46	3.99e-81	1.16e-73	-0.98	-0.73	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-23.46	3.99e-81	1.16e-73	-0.98	-0.73	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-23.44	4.59e-81	1.33e-73	-1.01	-0.73	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	23.42	5.82e-81	1.69e-73	0.95	0.73	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-23.4	7.49e-81	2.16e-73	-1.01	-0.73	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-23.4	7.49e-81	2.16e-73	-1.01	-0.73	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
THCA	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	23.37	1e-80	2.88e-73	1.13	0.73	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
THCA	trans	rs2885056	0.783	rs73007347	ENSG00000227534.1	RP3-323B6.1	23.36	1.17e-80	3.38e-73	1	0.73	Red cell distribution width;	chr19:10539973	chrX:65469087~65470380:+
THCA	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	23.33	1.61e-80	4.62e-73	1.12	0.73	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
THCA	trans	rs2885056	0.83	rs2018810	ENSG00000227534.1	RP3-323B6.1	23.31	1.85e-80	5.3e-73	1.01	0.73	Red cell distribution width;	chr19:10558496	chrX:65469087~65470380:+
THCA	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	23.3	2.18e-80	6.23e-73	1	0.73	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-23.3	2.2e-80	6.28e-73	-1	-0.73	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	23.29	2.46e-80	7.03e-73	1.1	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
THCA	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-23.26	3.2e-80	9.12e-73	-0.97	-0.73	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-23.26	3.47e-80	9.87e-73	-0.97	-0.73	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	23.25	3.63e-80	1.03e-72	1.04	0.73	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	23.25	3.79e-80	1.07e-72	0.94	0.73	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
THCA	trans	rs10940346	1	rs6874016	ENSG00000231752.4	EMBP1	-23.24	4.3e-80	1.22e-72	-0.96	-0.73	Schizophrenia;	chr5:50549640	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-23.23	4.78e-80	1.35e-72	-0.95	-0.73	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-23.22	5.01e-80	1.41e-72	-0.97	-0.73	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	23.21	5.77e-80	1.63e-72	1.1	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
THCA	trans	rs4276421	0.967	rs10941703	ENSG00000231752.4	EMBP1	-23.2	6.2e-80	1.74e-72	-0.93	-0.73	P wave duration;	chr5:45781770	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-23.12	1.52e-79	4.24e-72	-1.02	-0.73	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-23.11	1.77e-79	4.93e-72	-0.96	-0.73	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
THCA	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-23.07	2.56e-79	7.11e-72	-0.9	-0.73	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-23.07	2.6e-79	7.23e-72	-0.98	-0.73	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-23.07	2.72e-79	7.56e-72	-1.01	-0.73	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	23.06	2.96e-79	8.19e-72	1.09	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	23.05	3.11e-79	8.6e-72	1.09	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	23.05	3.11e-79	8.6e-72	1.09	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	23.01	5.17e-79	1.42e-71	1.09	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
THCA	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-23.01	5.27e-79	1.45e-71	-1.06	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
THCA	trans	rs4276421	0.753	rs7443976	ENSG00000231752.4	EMBP1	23	5.59e-79	1.53e-71	0.92	0.73	P wave duration;	chr5:45936323	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	22.97	7.77e-79	2.12e-71	1.01	0.73	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.869	rs1351720	ENSG00000231752.4	EMBP1	22.96	8.88e-79	2.42e-71	0.92	0.73	P wave duration;	chr5:45561801	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-22.94	1.12e-78	3.05e-71	-1.01	-0.73	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	22.92	1.27e-78	3.43e-71	1.09	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
THCA	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	22.91	1.44e-78	3.88e-71	0.93	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-22.9	1.63e-78	4.39e-71	-1.01	-0.73	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	22.89	1.8e-78	4.83e-71	1.01	0.73	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
THCA	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	22.86	2.43e-78	6.5e-71	0.98	0.73	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
THCA	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-22.8	4.84e-78	1.29e-70	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
THCA	trans	rs4276421	0.967	rs7443384	ENSG00000231752.4	EMBP1	22.8	4.89e-78	1.3e-70	0.93	0.72	P wave duration;	chr5:45960791	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-22.74	9.56e-78	2.54e-70	-0.99	-0.72	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	22.7	1.38e-77	3.63e-70	0.96	0.72	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
THCA	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	22.69	1.6e-77	4.22e-70	0.97	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-22.65	2.45e-77	6.42e-70	-1.01	-0.72	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
THCA	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-22.65	2.56e-77	6.71e-70	-0.82	-0.72	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
THCA	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-22.63	3.12e-77	8.12e-70	-1.01	-0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-22.62	3.54e-77	9.21e-70	-0.93	-0.72	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-22.6	4.23e-77	1.1e-69	-0.96	-0.72	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	22.6	4.4e-77	1.14e-69	0.97	0.72	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
THCA	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-22.59	4.91e-77	1.27e-69	-1.08	-0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
THCA	trans	rs3947	1	rs2645425	ENSG00000229857.1	RP11-159H20.3	22.55	7.23e-77	1.87e-69	1.06	0.72	Blood protein levels;	chr8:11843769	chr9:76992099~76993108:+
THCA	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	22.5	1.23e-76	3.14e-69	0.96	0.72	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	22.5	1.27e-76	3.25e-69	0.97	0.72	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
THCA	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	22.48	1.64e-76	4.18e-69	1.01	0.72	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-22.47	1.84e-76	4.69e-69	-0.96	-0.72	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
THCA	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	22.46	2e-76	5.09e-69	0.97	0.72	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
THCA	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-22.45	2.17e-76	5.51e-69	-1	-0.72	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
THCA	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	22.44	2.35e-76	5.96e-69	0.96	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	22.43	2.58e-76	6.54e-69	1.01	0.72	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	22.42	2.87e-76	7.26e-69	0.96	0.72	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
THCA	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	22.42	2.87e-76	7.26e-69	0.96	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
THCA	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-22.4	3.65e-76	9.23e-69	-1.01	-0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-22.39	4.01e-76	1.01e-68	-0.97	-0.72	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
THCA	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	22.37	5.39e-76	1.35e-68	0.87	0.72	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
THCA	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	22.37	5.39e-76	1.35e-68	0.87	0.72	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
THCA	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	22.37	5.39e-76	1.35e-68	0.87	0.72	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-22.36	5.81e-76	1.46e-68	-0.93	-0.72	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.806	rs6414906	ENSG00000231752.4	EMBP1	22.35	6.29e-76	1.57e-68	0.91	0.72	P wave duration;	chr5:45406219	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-22.32	8.95e-76	2.24e-68	-1.01	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
THCA	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-22.3	1.15e-75	2.87e-68	-1.01	-0.72	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
THCA	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-22.28	1.37e-75	3.42e-68	-0.88	-0.72	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
THCA	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-22.28	1.45e-75	3.6e-68	-1.04	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
THCA	trans	rs4276421	0.776	rs4133429	ENSG00000231752.4	EMBP1	22.27	1.52e-75	3.77e-68	0.91	0.72	P wave duration;	chr5:45403633	chr1:121519112~121571892:+
THCA	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	22.27	1.58e-75	3.93e-68	0.87	0.72	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-22.26	1.65e-75	4.1e-68	-0.93	-0.72	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
THCA	trans	rs3947	0.95	rs2740592	ENSG00000229857.1	RP11-159H20.3	22.26	1.72e-75	4.28e-68	1.06	0.72	Blood protein levels;	chr8:11843744	chr9:76992099~76993108:+
THCA	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-22.24	2.23e-75	5.54e-68	-0.93	-0.72	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
THCA	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	22.23	2.35e-75	5.81e-68	0.87	0.72	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	22.22	2.6e-75	6.43e-68	0.88	0.72	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
THCA	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	22.22	2.7e-75	6.67e-68	0.96	0.72	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-22.21	2.84e-75	7.02e-68	-0.97	-0.72	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	22.18	3.96e-75	9.76e-68	0.97	0.72	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.776	rs7723380	ENSG00000231752.4	EMBP1	22.17	4.38e-75	1.08e-67	0.9	0.72	P wave duration;	chr5:45428433	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.806	rs12520124	ENSG00000231752.4	EMBP1	22.17	4.38e-75	1.08e-67	0.9	0.72	P wave duration;	chr5:45434917	chr1:121519112~121571892:+
THCA	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	22.17	4.65e-75	1.14e-67	1.1	0.71	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
THCA	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	22.17	4.65e-75	1.14e-67	1.1	0.71	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
THCA	trans	rs4276421	0.776	rs13175193	ENSG00000231752.4	EMBP1	22.16	4.96e-75	1.22e-67	0.9	0.71	P wave duration;	chr5:45408894	chr1:121519112~121571892:+
THCA	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	22.16	5.35e-75	1.31e-67	0.97	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-22.15	5.56e-75	1.36e-67	-1	-0.71	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
THCA	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	22.14	6.07e-75	1.48e-67	1.09	0.71	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
THCA	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	22.14	6.07e-75	1.48e-67	1.09	0.71	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
THCA	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	22.14	6.07e-75	1.48e-67	1.09	0.71	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
THCA	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	22.14	6.07e-75	1.48e-67	1.09	0.71	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
THCA	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	22.14	6.07e-75	1.48e-67	1.09	0.71	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
THCA	trans	rs4276421	0.806	rs6892290	ENSG00000231752.4	EMBP1	22.14	6.07e-75	1.48e-67	0.91	0.71	P wave duration;	chr5:45427035	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	22.14	6.62e-75	1.61e-67	0.97	0.71	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.806	rs13162651	ENSG00000231752.4	EMBP1	22.14	6.67e-75	1.62e-67	0.9	0.71	P wave duration;	chr5:45409798	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.837	rs10073636	ENSG00000231752.4	EMBP1	-22.13	7.22e-75	1.76e-67	-0.91	-0.71	P wave duration;	chr5:45537197	chr1:121519112~121571892:+
THCA	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	22.12	7.83e-75	1.91e-67	0.96	0.71	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.806	rs6451804	ENSG00000231752.4	EMBP1	22.1	9.81e-75	2.38e-67	0.91	0.71	P wave duration;	chr5:45492103	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	22.07	1.34e-74	3.24e-67	0.98	0.71	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
THCA	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	22.06	1.43e-74	3.47e-67	1.09	0.71	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
THCA	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	22.05	1.6e-74	3.87e-67	1.09	0.71	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
THCA	trans	rs4276421	0.806	rs2337412	ENSG00000231752.4	EMBP1	22.05	1.61e-74	3.89e-67	0.91	0.71	P wave duration;	chr5:45483410	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.869	rs11741075	ENSG00000231752.4	EMBP1	-22.03	2.01e-74	4.86e-67	-0.91	-0.71	P wave duration;	chr5:45556276	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	21.98	3.76e-74	9.01e-67	1	0.71	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.806	rs6451801	ENSG00000231752.4	EMBP1	21.97	4.02e-74	9.65e-67	0.9	0.71	P wave duration;	chr5:45439331	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	21.97	4.06e-74	9.74e-67	0.88	0.71	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
THCA	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	21.96	4.62e-74	1.11e-66	1.09	0.71	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
THCA	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	21.95	5.02e-74	1.2e-66	0.89	0.71	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
THCA	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	21.95	5.25e-74	1.25e-66	1.1	0.71	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
THCA	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	21.94	5.41e-74	1.29e-66	0.88	0.71	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
THCA	trans	rs4276421	0.806	rs34666220	ENSG00000231752.4	EMBP1	21.92	6.91e-74	1.65e-66	0.9	0.71	P wave duration;	chr5:45435884	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	21.92	6.98e-74	1.66e-66	1.03	0.71	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
THCA	trans	rs13253073	0.545	rs13265660	ENSG00000260318.1	COX6CP1	21.91	7.82e-74	1.86e-66	1.28	0.71	Glucose homeostasis traits;	chr8:99815931	chr16:11903923~11904137:-
THCA	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	21.9	8.43e-74	2.01e-66	1.08	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	21.89	9.34e-74	2.21e-66	1.08	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.806	rs13169726	ENSG00000231752.4	EMBP1	21.85	1.53e-73	3.61e-66	0.9	0.71	P wave duration;	chr5:45444967	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.806	rs6892594	ENSG00000231752.4	EMBP1	21.84	1.62e-73	3.8e-66	0.89	0.71	P wave duration;	chr5:45427071	chr1:121519112~121571892:+
THCA	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-21.82	2.12e-73	4.97e-66	-0.86	-0.71	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
THCA	trans	rs4276421	0.806	rs7732970	ENSG00000231752.4	EMBP1	21.81	2.34e-73	5.48e-66	0.89	0.71	P wave duration;	chr5:45452044	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	21.81	2.39e-73	5.61e-66	0.94	0.71	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	21.79	2.69e-73	6.31e-66	0.9	0.71	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
THCA	trans	rs3947	0.855	rs1296026	ENSG00000229857.1	RP11-159H20.3	21.78	3.12e-73	7.31e-66	1.04	0.71	Blood protein levels;	chr8:11839933	chr9:76992099~76993108:+
THCA	trans	rs3947	0.95	rs1293331	ENSG00000229857.1	RP11-159H20.3	21.77	3.37e-73	7.89e-66	1.04	0.71	Blood protein levels;	chr8:11840927	chr9:76992099~76993108:+
THCA	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	21.76	3.76e-73	8.79e-66	0.9	0.71	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
THCA	trans	rs4276421	0.806	rs6860200	ENSG00000231752.4	EMBP1	21.75	4.4e-73	1.03e-65	0.89	0.71	P wave duration;	chr5:45440241	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	21.74	5.14e-73	1.2e-65	1.07	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	21.71	6.42e-73	1.49e-65	1.07	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
THCA	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	21.71	6.43e-73	1.49e-65	0.94	0.71	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	21.71	6.43e-73	1.49e-65	0.94	0.71	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	21.7	7.65e-73	1.77e-65	1.07	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	21.7	7.65e-73	1.77e-65	1.07	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
THCA	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-21.65	1.26e-72	2.91e-65	-0.99	-0.71	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-21.65	1.26e-72	2.91e-65	-0.99	-0.71	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	21.65	1.32e-72	3.04e-65	1.07	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.845	rs4426926	ENSG00000231752.4	EMBP1	21.64	1.42e-72	3.28e-65	0.92	0.71	P wave duration;	chr5:45994241	chr1:121519112~121571892:+
THCA	trans	rs2885056	0.739	rs4363951	ENSG00000227534.1	RP3-323B6.1	21.64	1.47e-72	3.38e-65	0.96	0.71	Red cell distribution width;	chr19:10538797	chrX:65469087~65470380:+
THCA	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	21.64	1.5e-72	3.45e-65	1.01	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
THCA	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	21.63	1.54e-72	3.53e-65	0.9	0.71	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
THCA	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	21.61	1.95e-72	4.46e-65	0.94	0.71	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
THCA	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	21.61	1.95e-72	4.46e-65	0.94	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	21.6	2.21e-72	5.06e-65	0.91	0.71	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
THCA	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-21.58	2.62e-72	6e-65	-0.86	-0.71	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-21.55	3.79e-72	8.63e-65	-1	-0.71	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-21.55	3.96e-72	8.99e-65	-0.9	-0.7	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
THCA	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-21.52	5.61e-72	1.27e-64	-0.84	-0.7	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	21.51	5.66e-72	1.28e-64	0.9	0.7	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
THCA	trans	rs4276421	0.837	rs7706140	ENSG00000231752.4	EMBP1	21.51	6.23e-72	1.41e-64	0.89	0.7	P wave duration;	chr5:45474712	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.837	rs7727890	ENSG00000231752.4	EMBP1	21.51	6.23e-72	1.41e-64	0.89	0.7	P wave duration;	chr5:45478669	chr1:121519112~121571892:+
THCA	trans	rs3947	1	rs3947	ENSG00000229857.1	RP11-159H20.3	21.48	7.93e-72	1.79e-64	1.04	0.7	Blood protein levels;	chr8:11844866	chr9:76992099~76993108:+
THCA	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-21.45	1.19e-71	2.68e-64	-0.97	-0.7	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.776	rs7717787	ENSG00000231752.4	EMBP1	21.44	1.32e-71	2.98e-64	0.89	0.7	P wave duration;	chr5:45466514	chr1:121519112~121571892:+
THCA	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-21.39	2.08e-71	4.65e-64	-0.85	-0.7	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	21.38	2.51e-71	5.62e-64	0.96	0.7	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
THCA	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	21.37	2.69e-71	6e-64	0.93	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.805	rs13354798	ENSG00000231752.4	EMBP1	21.36	2.96e-71	6.61e-64	0.89	0.7	P wave duration;	chr5:45456975	chr1:121519112~121571892:+
THCA	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	21.35	3.44e-71	7.66e-64	0.97	0.7	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
THCA	trans	rs3947	0.855	rs1293327	ENSG00000229857.1	RP11-159H20.3	21.35	3.47e-71	7.73e-64	1.03	0.7	Blood protein levels;	chr8:11837477	chr9:76992099~76993108:+
THCA	trans	rs2885056	0.699	rs34275421	ENSG00000227534.1	RP3-323B6.1	21.35	3.48e-71	7.75e-64	0.96	0.7	Red cell distribution width;	chr19:10534136	chrX:65469087~65470380:+
THCA	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-21.33	4.18e-71	9.23e-64	-0.98	-0.7	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
THCA	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	21.32	4.88e-71	1.08e-63	1.22	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
THCA	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	21.32	4.88e-71	1.08e-63	1.22	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
THCA	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	21.32	4.88e-71	1.08e-63	1.22	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
THCA	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	21.31	5.23e-71	1.15e-63	0.89	0.7	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
THCA	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-21.31	5.47e-71	1.2e-63	-0.98	-0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
THCA	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-21.31	5.47e-71	1.2e-63	-0.98	-0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-21.31	5.47e-71	1.2e-63	-0.98	-0.7	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
THCA	trans	rs3947	0.865	rs1296028	ENSG00000229857.1	RP11-159H20.3	21.28	7.06e-71	1.55e-63	1.01	0.7	Blood protein levels;	chr8:11841238	chr9:76992099~76993108:+
THCA	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-21.28	7.33e-71	1.61e-63	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-21.28	7.33e-71	1.61e-63	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
THCA	trans	rs4276421	0.776	rs56908114	ENSG00000231752.4	EMBP1	21.27	8.02e-71	1.76e-63	0.89	0.7	P wave duration;	chr5:45416692	chr1:121519112~121571892:+
THCA	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	21.25	1.04e-70	2.26e-63	0.89	0.7	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
THCA	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	21.25	1.04e-70	2.26e-63	0.89	0.7	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
THCA	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	21.25	1.04e-70	2.26e-63	0.89	0.7	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
THCA	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	21.25	1.04e-70	2.26e-63	0.89	0.7	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
THCA	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	21.23	1.2e-70	2.62e-63	0.96	0.7	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
THCA	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-21.22	1.32e-70	2.87e-63	-0.93	-0.7	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-21.2	1.64e-70	3.54e-63	-0.89	-0.7	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
THCA	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-21.2	1.69e-70	3.65e-63	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
THCA	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	21.2	1.75e-70	3.78e-63	1.22	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
THCA	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	21.18	2.18e-70	4.69e-63	0.89	0.7	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
THCA	trans	rs3947	1	rs4839	ENSG00000229857.1	RP11-159H20.3	21.15	2.82e-70	6.04e-63	1.01	0.7	Blood protein levels;	chr8:11844424	chr9:76992099~76993108:+
THCA	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-21.15	2.84e-70	6.08e-63	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
THCA	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	21.15	2.99e-70	6.41e-63	1.21	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
THCA	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	21.15	2.99e-70	6.41e-63	1.21	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
THCA	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	21.15	2.99e-70	6.41e-63	1.21	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
THCA	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-21.15	3.06e-70	6.56e-63	-0.97	-0.7	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
THCA	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-21.14	3.19e-70	6.82e-63	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
THCA	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-21.13	3.78e-70	8.06e-63	-0.91	-0.7	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
THCA	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-21.12	4.18e-70	8.91e-63	-1.17	-0.7	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-21.12	4.18e-70	8.91e-63	-1.17	-0.7	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
THCA	trans	rs3947	0.756	rs1613883	ENSG00000229857.1	RP11-159H20.3	21.12	4.3e-70	9.17e-63	1	0.7	Blood protein levels;	chr8:11842123	chr9:76992099~76993108:+
THCA	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	21.11	4.44e-70	9.45e-63	1.21	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
THCA	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	21.11	4.74e-70	1.01e-62	0.96	0.7	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
THCA	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	21.1	4.97e-70	1.06e-62	0.81	0.7	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
THCA	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	21.1	4.97e-70	1.06e-62	0.81	0.7	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
THCA	trans	rs7554547	0.871	rs6661289	ENSG00000261819.1	RP11-680G24.4	21.1	5.27e-70	1.12e-62	0.93	0.7	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr16:14988259~14990160:-
THCA	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	21.07	7.14e-70	1.5e-62	0.94	0.7	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	21.07	7.14e-70	1.5e-62	0.94	0.7	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.719	rs6451802	ENSG00000231752.4	EMBP1	21.06	7.55e-70	1.59e-62	0.89	0.7	P wave duration;	chr5:45440925	chr1:121519112~121571892:+
THCA	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	21.05	8.3e-70	1.74e-62	0.99	0.7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
THCA	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	21.02	1.17e-69	2.45e-62	1.17	0.7	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
THCA	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	21.02	1.26e-69	2.64e-62	0.9	0.7	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
THCA	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-21.01	1.35e-69	2.83e-62	-0.86	-0.7	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
THCA	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	20.96	2.38e-69	4.96e-62	0.8	0.7	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
THCA	trans	rs4276421	0.837	rs7446182	ENSG00000231752.4	EMBP1	-20.94	2.79e-69	5.82e-62	-0.89	-0.69	P wave duration;	chr5:45401715	chr1:121519112~121571892:+
THCA	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	20.94	3.04e-69	6.32e-62	1	0.69	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
THCA	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	20.93	3.06e-69	6.35e-62	0.8	0.69	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
THCA	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-20.93	3.12e-69	6.48e-62	-0.85	-0.69	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-20.93	3.21e-69	6.65e-62	-0.89	-0.69	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	20.91	3.96e-69	8.18e-62	0.87	0.69	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
THCA	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	20.91	4.16e-69	8.59e-62	0.87	0.69	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
THCA	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	20.9	4.5e-69	9.27e-62	0.9	0.69	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	20.9	4.5e-69	9.27e-62	0.9	0.69	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
THCA	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	20.89	5.24e-69	1.08e-61	0.8	0.69	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
THCA	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	20.89	5.24e-69	1.08e-61	0.8	0.69	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
THCA	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	20.89	5.24e-69	1.08e-61	0.8	0.69	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
THCA	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	20.87	6.07e-69	1.25e-61	0.8	0.69	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
THCA	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	20.87	6.37e-69	1.31e-61	0.8	0.69	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
THCA	trans	rs941207	0.547	rs56183434	ENSG00000121089.4	NACA3P	20.86	6.55e-69	1.34e-61	0.84	0.69	Platelet count;	chr12:56676145	chr4:164943290~164943937:+
THCA	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	20.86	7.08e-69	1.45e-61	1.17	0.69	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
THCA	trans	rs3947	1	rs709821	ENSG00000229857.1	RP11-159H20.3	20.83	9.84e-69	2e-61	1.01	0.69	Blood protein levels;	chr8:11845085	chr9:76992099~76993108:+
THCA	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-20.81	1.25e-68	2.54e-61	-0.85	-0.69	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
THCA	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	20.8	1.27e-68	2.58e-61	0.97	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
THCA	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	20.8	1.38e-68	2.81e-61	0.81	0.69	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
THCA	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-20.79	1.48e-68	3e-61	-1.01	-0.69	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
THCA	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	20.79	1.56e-68	3.15e-61	0.81	0.69	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
THCA	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	20.78	1.56e-68	3.17e-61	0.97	0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
THCA	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	20.78	1.6e-68	3.25e-61	0.79	0.69	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-20.78	1.71e-68	3.45e-61	-0.88	-0.69	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-20.78	1.71e-68	3.45e-61	-0.88	-0.69	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-20.78	1.71e-68	3.45e-61	-0.88	-0.69	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-20.77	1.92e-68	3.88e-61	-0.88	-0.69	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
THCA	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-20.76	2.13e-68	4.29e-61	-0.86	-0.69	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
THCA	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	20.75	2.26e-68	4.55e-61	0.98	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
THCA	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	20.75	2.26e-68	4.55e-61	0.98	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
THCA	trans	rs10940346	0.644	rs62365309	ENSG00000231752.4	EMBP1	-20.74	2.45e-68	4.92e-61	-0.91	-0.69	Schizophrenia;	chr5:50568902	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.807	rs4865843	ENSG00000231752.4	EMBP1	-20.74	2.45e-68	4.92e-61	-0.91	-0.69	Schizophrenia;	chr5:50569681	chr1:121519112~121571892:+
THCA	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-20.74	2.63e-68	5.27e-61	-0.87	-0.69	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-20.74	2.63e-68	5.27e-61	-0.87	-0.69	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
THCA	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	20.71	3.52e-68	7.03e-61	1.01	0.69	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
THCA	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-20.7	3.73e-68	7.46e-61	-0.88	-0.69	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	20.69	4.14e-68	8.28e-61	0.87	0.69	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
THCA	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	20.67	5.14e-68	1.03e-60	0.97	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
THCA	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	20.67	5.33e-68	1.06e-60	1.23	0.69	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
THCA	trans	rs3947	0.688	rs1293326	ENSG00000229857.1	RP11-159H20.3	20.67	5.38e-68	1.07e-60	0.99	0.69	Blood protein levels;	chr8:11837256	chr9:76992099~76993108:+
THCA	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-20.67	5.52e-68	1.1e-60	-0.87	-0.69	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
THCA	trans	rs3947	0.687	rs1736065	ENSG00000229857.1	RP11-159H20.3	20.67	5.71e-68	1.13e-60	1.01	0.69	Blood protein levels;	chr8:11827944	chr9:76992099~76993108:+
THCA	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	20.66	5.77e-68	1.14e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	20.66	5.77e-68	1.14e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
THCA	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	20.65	6.65e-68	1.31e-60	0.93	0.69	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-20.65	6.66e-68	1.31e-60	-0.89	-0.69	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
THCA	trans	rs2657294	0.603	rs11543	ENSG00000172974.11	AC007318.5	20.64	7.13e-68	1.4e-60	0.87	0.69	Pneumonia;	chr10:75210855	chr2:65205108~65205988:+
THCA	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-20.63	8.09e-68	1.58e-60	-0.81	-0.69	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
THCA	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	20.63	8.51e-68	1.66e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	20.63	8.51e-68	1.66e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	20.63	8.51e-68	1.66e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	20.63	8.51e-68	1.66e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	20.63	8.51e-68	1.66e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	20.63	8.51e-68	1.66e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
THCA	trans	rs7554547	0.871	rs11588551	ENSG00000261819.1	RP11-680G24.4	-20.63	8.83e-68	1.72e-60	-0.91	-0.69	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr16:14988259~14990160:-
THCA	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-20.62	9.82e-68	1.91e-60	-1.01	-0.69	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
THCA	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	20.59	1.23e-67	2.39e-60	1.04	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
THCA	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	20.59	1.34e-67	2.6e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	20.59	1.34e-67	2.6e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
THCA	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-20.58	1.42e-67	2.75e-60	-0.92	-0.69	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
THCA	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-20.58	1.49e-67	2.87e-60	-1.16	-0.69	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
THCA	trans	rs3947	1	rs1736081	ENSG00000229857.1	RP11-159H20.3	20.57	1.53e-67	2.96e-60	1.01	0.69	Blood protein levels;	chr8:11845331	chr9:76992099~76993108:+
THCA	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	20.57	1.63e-67	3.15e-60	0.97	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
THCA	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	20.56	1.73e-67	3.33e-60	1.16	0.69	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
THCA	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	20.56	1.79e-67	3.45e-60	1.06	0.69	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
THCA	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	20.56	1.88e-67	3.62e-60	0.97	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
THCA	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	20.56	1.88e-67	3.62e-60	0.97	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
THCA	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	20.56	1.88e-67	3.62e-60	0.97	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
THCA	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	20.55	2e-67	3.85e-60	0.86	0.69	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
THCA	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	20.55	2e-67	3.85e-60	0.98	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
THCA	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	20.54	2.28e-67	4.37e-60	1.17	0.69	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
THCA	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-20.53	2.35e-67	4.51e-60	-1.16	-0.69	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
THCA	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-20.53	2.44e-67	4.67e-60	-1	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
THCA	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-20.53	2.6e-67	4.97e-60	-1.2	-0.69	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
THCA	trans	rs3947	0.738	rs1293328	ENSG00000229857.1	RP11-159H20.3	20.52	2.64e-67	5.04e-60	0.98	0.69	Blood protein levels;	chr8:11837551	chr9:76992099~76993108:+
THCA	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	20.52	2.67e-67	5.11e-60	1.22	0.69	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-20.5	3.46e-67	6.6e-60	-0.98	-0.69	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
THCA	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	20.49	3.86e-67	7.34e-60	0.97	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
THCA	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	20.49	3.86e-67	7.34e-60	0.97	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
THCA	trans	rs13177918	0.911	rs12186451	ENSG00000239528.1	RPS14P8	20.48	4.06e-67	7.7e-60	1.22	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150432625	chr5:116562562~116562930:+
THCA	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-20.48	4.33e-67	8.22e-60	-1.15	-0.69	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
THCA	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-20.48	4.44e-67	8.42e-60	-0.87	-0.69	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
THCA	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	20.46	5.09e-67	9.64e-60	1.22	0.69	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
THCA	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	20.46	5.16e-67	9.76e-60	1.03	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
THCA	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	20.44	6.4e-67	1.21e-59	1.22	0.69	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
THCA	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	20.44	6.81e-67	1.29e-59	0.84	0.69	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
THCA	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	20.44	6.94e-67	1.31e-59	0.97	0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
THCA	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	20.43	7.33e-67	1.38e-59	1.22	0.69	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
THCA	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	20.42	8.02e-67	1.51e-59	0.95	0.69	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
THCA	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	20.42	8.26e-67	1.55e-59	0.88	0.69	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
THCA	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	20.42	8.26e-67	1.55e-59	0.88	0.69	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
THCA	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	20.42	8.5e-67	1.6e-59	0.81	0.69	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-20.42	8.56e-67	1.61e-59	-0.91	-0.69	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
THCA	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	20.41	9.13e-67	1.71e-59	1.06	0.69	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
THCA	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	20.41	9.31e-67	1.74e-59	1.17	0.69	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
THCA	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	20.4	1.05e-66	1.97e-59	0.98	0.69	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
THCA	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	20.4	1.07e-66	1.99e-59	0.94	0.69	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
THCA	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	20.38	1.21e-66	2.25e-59	0.97	0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
THCA	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-20.38	1.33e-66	2.47e-59	-1.16	-0.68	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
THCA	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	20.36	1.53e-66	2.85e-59	1.21	0.68	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-20.36	1.62e-66	3.01e-59	-0.89	-0.68	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-20.36	1.62e-66	3.01e-59	-0.89	-0.68	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
THCA	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	20.35	1.75e-66	3.24e-59	0.97	0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
THCA	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	20.33	2.15e-66	3.98e-59	0.82	0.68	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
THCA	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-20.32	2.32e-66	4.29e-59	-1.13	-0.68	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-20.32	2.32e-66	4.29e-59	-1.13	-0.68	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-20.32	2.32e-66	4.29e-59	-1.13	-0.68	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
THCA	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	20.32	2.39e-66	4.42e-59	1.02	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
THCA	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	20.32	2.4e-66	4.44e-59	1.19	0.68	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
THCA	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	20.32	2.44e-66	4.5e-59	1.27	0.68	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
THCA	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	20.31	2.66e-66	4.9e-59	0.8	0.68	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
THCA	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	20.29	3.38e-66	6.24e-59	1.03	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
THCA	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-20.28	3.57e-66	6.56e-59	-0.88	-0.68	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
THCA	trans	rs3947	0.95	rs1692811	ENSG00000229857.1	RP11-159H20.3	20.28	3.64e-66	6.69e-59	1.01	0.68	Blood protein levels;	chr8:11845539	chr9:76992099~76993108:+
THCA	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	20.28	3.72e-66	6.85e-59	0.79	0.68	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
THCA	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	20.28	3.72e-66	6.85e-59	0.79	0.68	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-20.28	3.76e-66	6.92e-59	-0.88	-0.68	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
THCA	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-20.26	4.43e-66	8.14e-59	-1.13	-0.68	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	20.26	4.52e-66	8.29e-59	1.12	0.68	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
THCA	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	20.26	4.71e-66	8.63e-59	0.96	0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
THCA	trans	rs9876781	1	rs9838618	ENSG00000235912.1	RP1-159A19.3	-20.25	5.08e-66	9.29e-59	-0.83	-0.68	Longevity;	chr3:48445949	chr1:27649419~27649610:+
THCA	trans	rs13190036	1	rs351862	ENSG00000217325.2	PRELID1P1	-20.25	5.27e-66	9.64e-59	-0.97	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr6:126643488~126644390:+
THCA	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	20.23	6.34e-66	1.16e-58	0.81	0.68	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
THCA	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-20.23	6.72e-66	1.23e-58	-0.95	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
THCA	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	20.22	7.12e-66	1.3e-58	0.88	0.68	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
THCA	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	20.22	7.33e-66	1.33e-58	1.27	0.68	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
THCA	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	20.21	7.99e-66	1.45e-58	1.23	0.68	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
THCA	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-20.21	8.17e-66	1.49e-58	-0.86	-0.68	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
THCA	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	20.2	8.66e-66	1.58e-58	1.02	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
THCA	trans	rs3947	1	rs1736083	ENSG00000229857.1	RP11-159H20.3	20.2	8.84e-66	1.61e-58	1.02	0.68	Blood protein levels;	chr8:11845988	chr9:76992099~76993108:+
THCA	trans	rs3947	1	rs1692812	ENSG00000229857.1	RP11-159H20.3	20.2	8.84e-66	1.61e-58	1.02	0.68	Blood protein levels;	chr8:11846014	chr9:76992099~76993108:+
THCA	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-20.2	8.89e-66	1.61e-58	-0.88	-0.68	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-20.2	8.89e-66	1.61e-58	-0.88	-0.68	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
THCA	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	20.2	8.96e-66	1.62e-58	1.12	0.68	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	20.2	8.96e-66	1.62e-58	1.12	0.68	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
THCA	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-20.19	1.01e-65	1.82e-58	-0.83	-0.68	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-20.17	1.2e-65	2.18e-58	-0.88	-0.68	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-20.17	1.2e-65	2.18e-58	-0.88	-0.68	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	20.17	1.22e-65	2.21e-58	1.02	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	20.17	1.22e-65	2.21e-58	1.02	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
THCA	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	20.17	1.25e-65	2.25e-58	0.95	0.68	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	20.17	1.25e-65	2.25e-58	0.95	0.68	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	20.17	1.25e-65	2.25e-58	0.95	0.68	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	20.17	1.25e-65	2.25e-58	0.95	0.68	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
THCA	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-20.16	1.33e-65	2.41e-58	-0.97	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
THCA	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-20.16	1.39e-65	2.5e-58	-1.12	-0.68	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-20.16	1.39e-65	2.5e-58	-1.12	-0.68	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
THCA	trans	rs3947	0.789	rs1293322	ENSG00000229857.1	RP11-159H20.3	20.15	1.54e-65	2.77e-58	0.97	0.68	Blood protein levels;	chr8:11835129	chr9:76992099~76993108:+
THCA	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	20.14	1.62e-65	2.91e-58	0.94	0.68	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
THCA	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	20.14	1.69e-65	3.03e-58	0.82	0.68	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	20.14	1.74e-65	3.13e-58	0.82	0.68	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
THCA	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-20.14	1.77e-65	3.18e-58	-0.86	-0.68	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-20.14	1.77e-65	3.18e-58	-0.86	-0.68	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
THCA	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-20.13	1.85e-65	3.33e-58	-0.82	-0.68	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
THCA	trans	rs13177918	0.911	rs12186451	ENSG00000213058.3	RP4-765C7.2	20.12	2.08e-65	3.73e-58	1.19	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150432625	chr1:178411616~178411972:+
THCA	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	20.12	2.22e-65	3.98e-58	1.23	0.68	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
THCA	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	20.1	2.56e-65	4.58e-58	0.81	0.68	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
THCA	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	20.1	2.68e-65	4.78e-58	0.79	0.68	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
THCA	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-20.09	2.83e-65	5.05e-58	-1.13	-0.68	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
THCA	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-20.09	3.04e-65	5.42e-58	-0.94	-0.68	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
THCA	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-20.08	3.15e-65	5.62e-58	-0.96	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
THCA	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	20.07	3.78e-65	6.74e-58	0.79	0.68	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
THCA	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-20.06	3.83e-65	6.83e-58	-0.97	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
THCA	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-20.04	4.93e-65	8.71e-58	-0.98	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
THCA	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	20.04	5.07e-65	8.94e-58	1.12	0.68	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	20.04	5.07e-65	8.94e-58	1.12	0.68	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
THCA	trans	rs8081395	0.729	rs12453125	ENSG00000187870.7	RNFT1P3	-20.04	5.12e-65	9.03e-58	-0.88	-0.68	White blood cell count;	chr17:59968715	chr17:20743333~20754501:-
THCA	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-20.03	5.52e-65	9.72e-58	-1.12	-0.68	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-20.02	6.52e-65	1.15e-57	-1.16	-0.68	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
THCA	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-20.01	6.69e-65	1.17e-57	-0.94	-0.68	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
THCA	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	20	7.5e-65	1.31e-57	0.85	0.68	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
THCA	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	20	7.84e-65	1.37e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	20	7.84e-65	1.37e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	20	7.84e-65	1.37e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	20	7.84e-65	1.37e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	20	7.84e-65	1.37e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
THCA	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-19.98	9.22e-65	1.61e-57	-0.87	-0.68	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
THCA	trans	rs13190036	1	rs351864	ENSG00000217325.2	PRELID1P1	-19.98	9.87e-65	1.72e-57	-0.96	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr6:126643488~126644390:+
THCA	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	19.97	1.09e-64	1.9e-57	0.94	0.68	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	19.97	1.09e-64	1.9e-57	0.94	0.68	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
THCA	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	19.96	1.18e-64	2.05e-57	0.85	0.68	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
THCA	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-19.95	1.26e-64	2.2e-57	-0.98	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
THCA	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	19.95	1.27e-64	2.21e-57	1.13	0.68	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-19.94	1.5e-64	2.6e-57	-1.11	-0.68	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	19.94	1.5e-64	2.6e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	19.94	1.5e-64	2.6e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
THCA	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	19.94	1.5e-64	2.6e-57	1.14	0.68	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
THCA	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-19.94	1.55e-64	2.68e-57	-0.84	-0.68	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
THCA	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	19.93	1.62e-64	2.8e-57	0.93	0.68	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	19.93	1.62e-64	2.8e-57	0.93	0.68	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
THCA	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	19.92	1.82e-64	3.13e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	19.92	1.82e-64	3.13e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	19.92	1.82e-64	3.13e-57	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-19.91	1.98e-64	3.4e-57	-1.11	-0.68	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
THCA	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-19.9	2.37e-64	4.07e-57	-0.82	-0.68	Longevity;	chr3:48452692	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-19.9	2.37e-64	4.07e-57	-0.82	-0.68	Longevity;	chr3:48455358	chr1:27649419~27649610:+
THCA	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-19.9	2.38e-64	4.09e-57	-0.85	-0.68	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
THCA	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-19.88	2.85e-64	4.89e-57	-0.83	-0.68	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
THCA	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	19.88	2.9e-64	4.96e-57	0.94	0.68	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
THCA	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	19.88	2.94e-64	5.03e-57	0.94	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
THCA	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	19.87	3.22e-64	5.49e-57	0.78	0.68	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
THCA	trans	rs9876781	1	rs6442119	ENSG00000235912.1	RP1-159A19.3	-19.87	3.24e-64	5.53e-57	-0.82	-0.68	Longevity;	chr3:48398713	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-19.86	3.48e-64	5.93e-57	-0.82	-0.68	Longevity;	chr3:48457056	chr1:27649419~27649610:+
THCA	trans	rs10940346	0.777	rs11744698	ENSG00000231752.4	EMBP1	-19.85	3.76e-64	6.41e-57	-0.88	-0.68	Schizophrenia;	chr5:50586024	chr1:121519112~121571892:+
THCA	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-19.85	3.88e-64	6.6e-57	-0.85	-0.68	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
THCA	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	19.85	3.88e-64	6.61e-57	0.93	0.68	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
THCA	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	19.85	3.97e-64	6.76e-57	0.85	0.68	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
THCA	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-19.85	4.03e-64	6.85e-57	-0.96	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
THCA	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-19.85	4.03e-64	6.85e-57	-0.96	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
THCA	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-19.85	4.03e-64	6.85e-57	-0.96	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
THCA	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-19.85	4.03e-64	6.85e-57	-0.96	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
THCA	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-19.85	4.03e-64	6.85e-57	-0.96	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
THCA	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-19.85	4.03e-64	6.85e-57	-0.96	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
THCA	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	19.85	4.1e-64	6.95e-57	0.93	0.68	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	19.85	4.1e-64	6.95e-57	0.93	0.68	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	19.85	4.1e-64	6.95e-57	0.93	0.68	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	19.85	4.1e-64	6.95e-57	0.93	0.68	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
THCA	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	19.84	4.28e-64	7.26e-57	1.22	0.68	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
THCA	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-19.82	5.21e-64	8.79e-57	-0.85	-0.67	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-19.82	5.21e-64	8.79e-57	-0.85	-0.67	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
THCA	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-19.82	5.52e-64	9.31e-57	-0.85	-0.67	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
THCA	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	19.82	5.59e-64	9.43e-57	0.85	0.67	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
THCA	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	19.8	6.53e-64	1.1e-56	0.93	0.67	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	19.8	6.6e-64	1.11e-56	0.93	0.67	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
THCA	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-19.8	6.64e-64	1.11e-56	-0.96	-0.67	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
THCA	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	19.8	6.81e-64	1.14e-56	0.94	0.67	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	19.8	6.81e-64	1.14e-56	0.94	0.67	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
THCA	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	19.8	6.99e-64	1.17e-56	0.93	0.67	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
THCA	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	19.8	6.99e-64	1.17e-56	1	0.67	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
THCA	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	19.8	7.12e-64	1.19e-56	0.93	0.67	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	19.79	7.19e-64	1.2e-56	0.93	0.67	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
THCA	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-19.79	7.46e-64	1.25e-56	-0.82	-0.67	Longevity;	chr3:48446507	chr1:27649419~27649610:+
THCA	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-19.79	7.82e-64	1.31e-56	-0.85	-0.67	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-19.79	7.82e-64	1.31e-56	-0.85	-0.67	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
THCA	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-19.79	7.84e-64	1.31e-56	-0.85	-0.67	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-19.79	7.84e-64	1.31e-56	-0.85	-0.67	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-19.79	7.84e-64	1.31e-56	-0.85	-0.67	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
THCA	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-19.79	7.84e-64	1.31e-56	-0.85	-0.67	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
THCA	trans	rs3947	0.951	rs1692819	ENSG00000229857.1	RP11-159H20.3	19.77	9.11e-64	1.52e-56	1.01	0.67	Blood protein levels;	chr8:11847939	chr9:76992099~76993108:+
THCA	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	19.76	1.01e-63	1.68e-56	0.94	0.67	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
THCA	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	19.76	1.02e-63	1.7e-56	0.81	0.67	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
THCA	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	19.76	1.07e-63	1.78e-56	1.11	0.67	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
THCA	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	19.75	1.16e-63	1.93e-56	1.18	0.67	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	19.75	1.22e-63	2.02e-56	0.85	0.67	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
THCA	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	19.74	1.26e-63	2.08e-56	1.11	0.67	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	19.74	1.26e-63	2.08e-56	1.11	0.67	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	19.74	1.26e-63	2.08e-56	1.11	0.67	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
THCA	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	19.74	1.33e-63	2.21e-56	0.85	0.67	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
THCA	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-19.74	1.36e-63	2.24e-56	-1.23	-0.67	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
THCA	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	19.73	1.45e-63	2.4e-56	0.92	0.67	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
THCA	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	19.72	1.67e-63	2.75e-56	1.11	0.67	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
THCA	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-19.72	1.69e-63	2.79e-56	-0.96	-0.67	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
THCA	trans	rs7949030	0.964	rs2957122	ENSG00000186676.3	EEF1GP1	-19.71	1.72e-63	2.83e-56	-0.93	-0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62624628	chr7:125033453~125035301:+
THCA	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-19.71	1.77e-63	2.91e-56	-0.85	-0.67	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
THCA	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	19.71	1.78e-63	2.93e-56	0.92	0.67	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
THCA	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	19.71	1.78e-63	2.93e-56	0.94	0.67	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
THCA	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-19.71	1.78e-63	2.94e-56	-1.11	-0.67	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
THCA	trans	rs4276421	0.806	rs10079739	ENSG00000231752.4	EMBP1	-19.71	1.85e-63	3.05e-56	-0.89	-0.67	P wave duration;	chr5:45607597	chr1:121519112~121571892:+
THCA	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	19.7	1.92e-63	3.15e-56	0.92	0.67	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	19.7	1.92e-63	3.15e-56	0.92	0.67	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	19.7	1.92e-63	3.15e-56	0.92	0.67	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	19.7	1.92e-63	3.15e-56	0.92	0.67	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	19.7	1.92e-63	3.15e-56	0.92	0.67	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	19.7	1.92e-63	3.15e-56	0.92	0.67	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	19.7	1.92e-63	3.15e-56	0.92	0.67	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	19.7	1.92e-63	3.15e-56	0.92	0.67	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	19.7	1.93e-63	3.16e-56	0.92	0.67	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	19.7	1.93e-63	3.16e-56	0.92	0.67	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	19.7	1.93e-63	3.16e-56	0.92	0.67	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
THCA	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-19.7	2.09e-63	3.41e-56	-0.95	-0.67	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
THCA	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	19.68	2.58e-63	4.21e-56	1.16	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
THCA	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	19.68	2.58e-63	4.21e-56	1.16	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
THCA	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	19.68	2.58e-63	4.21e-56	1.16	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
THCA	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-19.67	2.8e-63	4.57e-56	-1.02	-0.67	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
THCA	trans	rs10940346	0.807	rs6898102	ENSG00000231752.4	EMBP1	-19.66	3.09e-63	5.04e-56	-0.87	-0.67	Schizophrenia;	chr5:50578496	chr1:121519112~121571892:+
THCA	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	19.65	3.29e-63	5.36e-56	0.92	0.67	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	19.65	3.29e-63	5.36e-56	0.92	0.67	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
THCA	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-19.65	3.31e-63	5.39e-56	-0.85	-0.67	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-19.64	3.78e-63	6.14e-56	-0.81	-0.67	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
THCA	trans	rs3947	1	rs1736082	ENSG00000229857.1	RP11-159H20.3	19.64	3.79e-63	6.16e-56	1.01	0.67	Blood protein levels;	chr8:11845911	chr9:76992099~76993108:+
THCA	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-19.63	4.45e-63	7.22e-56	-0.81	-0.67	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	19.61	5.2e-63	8.42e-56	0.86	0.67	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
THCA	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	19.61	5.52e-63	8.94e-56	0.79	0.67	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
THCA	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	19.61	5.52e-63	8.94e-56	0.79	0.67	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
THCA	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	19.59	6.23e-63	1.01e-55	0.85	0.67	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
THCA	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	19.59	6.23e-63	1.01e-55	0.85	0.67	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
THCA	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	19.59	6.23e-63	1.01e-55	0.85	0.67	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
THCA	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-19.59	6.75e-63	1.09e-55	-0.85	-0.67	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
THCA	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	19.59	6.87e-63	1.11e-55	0.93	0.67	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
THCA	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	19.58	7.22e-63	1.16e-55	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	19.57	7.78e-63	1.25e-55	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	19.57	7.78e-63	1.25e-55	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	19.57	7.78e-63	1.25e-55	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
THCA	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	19.56	8.65e-63	1.39e-55	0.8	0.67	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
THCA	trans	rs7949030	1	rs3018561	ENSG00000186676.3	EEF1GP1	-19.56	8.94e-63	1.44e-55	-0.93	-0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62624757	chr7:125033453~125035301:+
THCA	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-19.55	1.03e-62	1.64e-55	-0.82	-0.67	Longevity;	chr3:48426493	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-19.55	1.03e-62	1.64e-55	-0.82	-0.67	Longevity;	chr3:48432839	chr1:27649419~27649610:+
THCA	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-19.54	1.13e-62	1.81e-55	-0.96	-0.67	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
THCA	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	19.53	1.23e-62	1.96e-55	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
THCA	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	19.52	1.38e-62	2.21e-55	1.16	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
THCA	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-19.52	1.39e-62	2.22e-55	-0.78	-0.67	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
THCA	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	19.51	1.5e-62	2.38e-55	0.79	0.67	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	19.5	1.64e-62	2.62e-55	0.79	0.67	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
THCA	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	19.49	1.92e-62	3.05e-55	1.21	0.67	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
THCA	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-19.48	2.22e-62	3.52e-55	-0.83	-0.67	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
THCA	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-19.48	2.26e-62	3.58e-55	-0.85	-0.67	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	19.47	2.3e-62	3.64e-55	0.85	0.67	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
THCA	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	19.47	2.35e-62	3.73e-55	1.1	0.67	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
THCA	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	19.46	2.72e-62	4.31e-55	1.02	0.67	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
THCA	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	19.46	2.77e-62	4.38e-55	0.91	0.67	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
THCA	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-19.45	3.11e-62	4.92e-55	-0.84	-0.67	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
THCA	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-19.44	3.35e-62	5.28e-55	-0.81	-0.67	Longevity;	chr3:48422209	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-19.44	3.35e-62	5.28e-55	-0.81	-0.67	Longevity;	chr3:48423094	chr1:27649419~27649610:+
THCA	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	19.41	4.75e-62	7.49e-55	0.9	0.67	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
THCA	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-19.39	5.64e-62	8.87e-55	-0.92	-0.67	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
THCA	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	19.39	5.9e-62	9.28e-55	0.9	0.67	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
THCA	trans	rs9876781	1	rs28824259	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48384185	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs12487542	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48384586	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs73074358	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48385757	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.967	rs34761139	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48386489	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.868	rs9875280	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48387420	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs6796491	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48388977	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs6804774	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48389129	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs9826195	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48392157	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.967	rs9864815	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48392588	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs9809843	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48392923	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs1563736	ENSG00000235912.1	RP1-159A19.3	-19.38	6.04e-62	9.48e-55	-0.81	-0.67	Longevity;	chr3:48395329	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-19.38	6.06e-62	9.51e-55	-0.81	-0.67	Longevity;	chr3:48440237	chr1:27649419~27649610:+
THCA	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	19.38	6.19e-62	9.69e-55	0.94	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
THCA	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	19.38	6.49e-62	1.02e-54	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
THCA	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	19.38	6.67e-62	1.05e-54	0.91	0.67	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	19.36	7.52e-62	1.18e-54	0.91	0.67	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	19.36	7.52e-62	1.18e-54	0.91	0.67	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
THCA	trans	rs9876781	1	rs13071337	ENSG00000235912.1	RP1-159A19.3	-19.36	7.64e-62	1.19e-54	-0.81	-0.67	Longevity;	chr3:48396724	chr1:27649419~27649610:+
THCA	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-19.36	7.88e-62	1.23e-54	-0.91	-0.67	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
THCA	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	19.36	7.92e-62	1.24e-54	0.79	0.67	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
THCA	trans	rs9876781	1	rs9311423	ENSG00000235912.1	RP1-159A19.3	-19.35	8.38e-62	1.31e-54	-0.81	-0.67	Longevity;	chr3:48378818	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs7634377	ENSG00000235912.1	RP1-159A19.3	-19.35	8.38e-62	1.31e-54	-0.81	-0.67	Longevity;	chr3:48379768	chr1:27649419~27649610:+
THCA	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	19.35	8.93e-62	1.39e-54	0.9	0.67	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
THCA	trans	rs9876781	1	rs9864371	ENSG00000235912.1	RP1-159A19.3	-19.34	9.74e-62	1.51e-54	-0.81	-0.67	Longevity;	chr3:48385276	chr1:27649419~27649610:+
THCA	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	19.34	9.95e-62	1.54e-54	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
THCA	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-19.34	1.02e-61	1.58e-54	-0.81	-0.67	Longevity;	chr3:48437797	chr1:27649419~27649610:+
THCA	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	19.33	1.1e-61	1.71e-54	1.11	0.67	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
THCA	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-19.32	1.22e-61	1.89e-54	-0.81	-0.67	Longevity;	chr3:48440024	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs7630741	ENSG00000235912.1	RP1-159A19.3	-19.32	1.22e-61	1.89e-54	-0.81	-0.67	Longevity;	chr3:48378233	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs6784322	ENSG00000235912.1	RP1-159A19.3	-19.31	1.35e-61	2.08e-54	-0.81	-0.67	Longevity;	chr3:48380745	chr1:27649419~27649610:+
THCA	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	19.31	1.36e-61	2.11e-54	0.91	0.67	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
THCA	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	19.3	1.51e-61	2.33e-54	0.9	0.66	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
THCA	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	19.29	1.61e-61	2.49e-54	0.98	0.66	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
THCA	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-19.29	1.73e-61	2.67e-54	-0.91	-0.66	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
THCA	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	19.29	1.75e-61	2.7e-54	0.95	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	19.29	1.75e-61	2.7e-54	0.95	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
THCA	trans	rs7554547	0.778	rs2008113	ENSG00000261819.1	RP11-680G24.4	-19.28	1.88e-61	2.89e-54	-0.85	-0.66	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr16:14988259~14990160:-
THCA	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	19.28	1.89e-61	2.91e-54	0.9	0.66	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
THCA	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	19.28	1.95e-61	3.01e-54	1.24	0.66	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
THCA	trans	rs3947	0.813	rs1293316	ENSG00000229857.1	RP11-159H20.3	19.28	1.96e-61	3.01e-54	0.95	0.66	Blood protein levels;	chr8:11833406	chr9:76992099~76993108:+
THCA	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	19.27	2.05e-61	3.15e-54	0.92	0.66	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
THCA	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	19.27	2.1e-61	3.23e-54	0.79	0.66	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
THCA	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	19.27	2.13e-61	3.27e-54	0.99	0.66	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
THCA	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	19.27	2.16e-61	3.32e-54	0.95	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
THCA	trans	rs9876781	1	rs9815103	ENSG00000235912.1	RP1-159A19.3	-19.26	2.23e-61	3.42e-54	-0.81	-0.66	Longevity;	chr3:48372725	chr1:27649419~27649610:+
THCA	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-19.26	2.39e-61	3.67e-54	-0.89	-0.66	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
THCA	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	19.24	2.93e-61	4.49e-54	0.84	0.66	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
THCA	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	19.23	3.08e-61	4.72e-54	0.83	0.66	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
THCA	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-19.23	3.1e-61	4.75e-54	-0.9	-0.66	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
THCA	trans	rs3947	1	rs1736084	ENSG00000229857.1	RP11-159H20.3	19.22	3.43e-61	5.25e-54	0.99	0.66	Blood protein levels;	chr8:11846148	chr9:76992099~76993108:+
THCA	trans	rs9876781	1	rs725309	ENSG00000235912.1	RP1-159A19.3	19.21	3.88e-61	5.93e-54	0.8	0.66	Longevity;	chr3:48377218	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs6442118	ENSG00000235912.1	RP1-159A19.3	-19.21	3.96e-61	6.05e-54	-0.81	-0.66	Longevity;	chr3:48398582	chr1:27649419~27649610:+
THCA	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	19.2	4.32e-61	6.59e-54	0.79	0.66	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
THCA	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	19.2	4.62e-61	7.04e-54	0.89	0.66	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
THCA	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	19.2	4.62e-61	7.04e-54	0.89	0.66	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
THCA	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	19.2	4.62e-61	7.04e-54	0.89	0.66	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
THCA	trans	rs3947	1	rs1736085	ENSG00000229857.1	RP11-159H20.3	19.17	5.83e-61	8.86e-54	0.99	0.66	Blood protein levels;	chr8:11846150	chr9:76992099~76993108:+
THCA	trans	rs9876781	1	rs2885510	ENSG00000235912.1	RP1-159A19.3	19.17	5.9e-61	8.96e-54	0.8	0.66	Longevity;	chr3:48376736	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs7653691	ENSG00000235912.1	RP1-159A19.3	19.17	5.92e-61	8.98e-54	0.8	0.66	Longevity;	chr3:48378199	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs6442117	ENSG00000235912.1	RP1-159A19.3	19.17	5.92e-61	8.98e-54	0.8	0.66	Longevity;	chr3:48378407	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.967	rs2885509	ENSG00000235912.1	RP1-159A19.3	19.17	6.03e-61	9.16e-54	0.8	0.66	Longevity;	chr3:48376729	chr1:27649419~27649610:+
THCA	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-19.17	6.07e-61	9.2e-54	-0.93	-0.66	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
THCA	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	19.15	7.94e-61	1.2e-53	0.85	0.66	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
THCA	trans	rs9876781	1	rs725310	ENSG00000235912.1	RP1-159A19.3	19.14	8.19e-61	1.24e-53	0.8	0.66	Longevity;	chr3:48377081	chr1:27649419~27649610:+
THCA	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	19.12	9.97e-61	1.5e-53	0.91	0.66	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
THCA	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	19.11	1.16e-60	1.74e-53	0.84	0.66	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
THCA	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	19.1	1.27e-60	1.91e-53	0.76	0.66	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
THCA	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-19.1	1.29e-60	1.93e-53	-0.82	-0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
THCA	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	19.1	1.29e-60	1.94e-53	0.92	0.66	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	19.1	1.34e-60	2.01e-53	0.9	0.66	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
THCA	trans	rs7949030	0.78	rs3017666	ENSG00000186676.3	EEF1GP1	-19.08	1.6e-60	2.4e-53	-0.91	-0.66	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62636945	chr7:125033453~125035301:+
THCA	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-19.08	1.64e-60	2.45e-53	-0.91	-0.66	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
THCA	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	19.08	1.64e-60	2.46e-53	0.91	0.66	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
THCA	trans	rs9876781	1	rs3214041	ENSG00000235912.1	RP1-159A19.3	-19.06	2.05e-60	3.06e-53	-0.81	-0.66	Longevity;	chr3:48413059	chr1:27649419~27649610:+
THCA	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	19.05	2.18e-60	3.25e-53	0.84	0.66	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
THCA	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	19.04	2.6e-60	3.88e-53	1.08	0.66	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
THCA	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	19.02	3.23e-60	4.8e-53	0.9	0.66	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
THCA	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-19.02	3.24e-60	4.8e-53	-0.8	-0.66	Longevity;	chr3:48408549	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs11712561	ENSG00000235912.1	RP1-159A19.3	-18.99	4.16e-60	6.17e-53	-0.8	-0.66	Longevity;	chr3:48393807	chr1:27649419~27649610:+
THCA	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	18.98	4.91e-60	7.26e-53	0.91	0.66	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
THCA	trans	rs3947	0.951	rs1692813	ENSG00000229857.1	RP11-159H20.3	18.97	5.21e-60	7.7e-53	0.97	0.66	Blood protein levels;	chr8:11846787	chr9:76992099~76993108:+
THCA	trans	rs3947	0.951	rs1692814	ENSG00000229857.1	RP11-159H20.3	18.97	5.21e-60	7.7e-53	0.97	0.66	Blood protein levels;	chr8:11846789	chr9:76992099~76993108:+
THCA	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-18.97	5.32e-60	7.86e-53	-0.8	-0.66	Longevity;	chr3:48408490	chr1:27649419~27649610:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	18.96	5.62e-60	8.3e-53	0.83	0.66	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
THCA	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	18.96	5.78e-60	8.53e-53	0.88	0.66	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
THCA	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-18.96	5.81e-60	8.58e-53	-0.8	-0.66	Longevity;	chr3:48445934	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs1459242	ENSG00000235912.1	RP1-159A19.3	18.95	6.42e-60	9.47e-53	0.8	0.66	Longevity;	chr3:48372047	chr1:27649419~27649610:+
THCA	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	18.95	6.44e-60	9.48e-53	0.9	0.66	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	18.95	6.44e-60	9.48e-53	0.9	0.66	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
THCA	trans	rs9876781	1	rs6442123	ENSG00000235912.1	RP1-159A19.3	-18.93	7.76e-60	1.14e-52	-0.8	-0.66	Longevity;	chr3:48458887	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs2242150	ENSG00000235912.1	RP1-159A19.3	18.93	8.15e-60	1.2e-52	0.8	0.66	Longevity;	chr3:48464565	chr1:27649419~27649610:+
THCA	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-18.93	8.45e-60	1.24e-52	-0.77	-0.66	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
THCA	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	18.91	9.9e-60	1.45e-52	0.9	0.66	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
THCA	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	18.91	9.9e-60	1.45e-52	0.9	0.66	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
THCA	trans	rs3947	0.951	rs1736086	ENSG00000229857.1	RP11-159H20.3	18.91	1e-59	1.47e-52	0.96	0.66	Blood protein levels;	chr8:11847388	chr9:76992099~76993108:+
THCA	trans	rs9876781	1	rs7651407	ENSG00000235912.1	RP1-159A19.3	-18.91	1.06e-59	1.55e-52	-0.8	-0.66	Longevity;	chr3:48402409	chr1:27649419~27649610:+
THCA	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	18.9	1.06e-59	1.56e-52	0.9	0.66	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
THCA	trans	rs9611565	0.694	rs4822032	ENSG00000268568.1	AC007228.9	-18.88	1.33e-59	1.94e-52	-0.8	-0.66	Vitiligo;	chr22:41529531	chr19:56672574~56673901:-
THCA	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	18.87	1.6e-59	2.34e-52	0.9	0.66	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	18.87	1.6e-59	2.34e-52	0.9	0.66	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	18.87	1.6e-59	2.34e-52	0.9	0.66	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	18.87	1.6e-59	2.34e-52	0.9	0.66	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	18.87	1.6e-59	2.34e-52	0.9	0.66	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
THCA	trans	rs3947	0.789	rs6990033	ENSG00000229857.1	RP11-159H20.3	-18.86	1.65e-59	2.41e-52	-0.92	-0.66	Blood protein levels;	chr8:11835869	chr9:76992099~76993108:+
THCA	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	18.86	1.65e-59	2.41e-52	0.83	0.66	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
THCA	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	18.86	1.67e-59	2.43e-52	0.9	0.66	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
THCA	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-18.86	1.68e-59	2.44e-52	-1.09	-0.66	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
THCA	trans	rs9876781	1	rs898225	ENSG00000235912.1	RP1-159A19.3	18.85	1.84e-59	2.67e-52	0.8	0.66	Longevity;	chr3:48371689	chr1:27649419~27649610:+
THCA	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	18.85	1.97e-59	2.86e-52	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
THCA	trans	rs7949030	1	rs2956993	ENSG00000186676.3	EEF1GP1	-18.85	2e-59	2.91e-52	-0.91	-0.66	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62638690	chr7:125033453~125035301:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000243403.1	RP11-330L19.1	18.84	2.15e-59	3.12e-52	0.78	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr15:64592979~64593326:+
THCA	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	18.83	2.42e-59	3.51e-52	0.82	0.66	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.911	rs12186451	ENSG00000224114.1	RP11-343H5.4	18.82	2.57e-59	3.72e-52	1.15	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150432625	chr1:206695837~206696269:-
THCA	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	18.82	2.71e-59	3.92e-52	0.91	0.66	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	18.82	2.71e-59	3.93e-52	0.9	0.66	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
THCA	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	18.8	3.3e-59	4.77e-52	0.83	0.66	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
THCA	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	18.8	3.42e-59	4.94e-52	0.84	0.66	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
THCA	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	18.8	3.44e-59	4.96e-52	0.8	0.66	Longevity;	chr3:48407742	chr1:27649419~27649610:+
THCA	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	18.79	3.57e-59	5.15e-52	0.9	0.66	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
THCA	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-18.79	3.61e-59	5.21e-52	-0.8	-0.65	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
THCA	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-18.76	4.97e-59	7.16e-52	-0.88	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
THCA	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	18.73	6.99e-59	1.01e-51	0.9	0.65	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
THCA	trans	rs2885056	0.8	rs8105074	ENSG00000227534.1	RP3-323B6.1	18.72	7.45e-59	1.07e-51	0.9	0.65	Red cell distribution width;	chr19:10598016	chrX:65469087~65470380:+
THCA	trans	rs13190036	1	rs625882	ENSG00000217325.2	PRELID1P1	-18.72	7.47e-59	1.07e-51	-0.92	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr6:126643488~126644390:+
THCA	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-18.7	9.3e-59	1.33e-51	-0.83	-0.65	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
THCA	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	18.69	1.02e-58	1.46e-51	0.94	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	18.69	1.02e-58	1.46e-51	0.94	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
THCA	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-18.68	1.18e-58	1.7e-51	-0.78	-0.65	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
THCA	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	18.67	1.37e-58	1.96e-51	0.91	0.65	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
THCA	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	18.65	1.6e-58	2.28e-51	0.84	0.65	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
THCA	trans	rs9876781	1	rs2290822	ENSG00000235912.1	RP1-159A19.3	-18.65	1.63e-58	2.33e-51	-0.8	-0.65	Longevity;	chr3:48431794	chr1:27649419~27649610:+
THCA	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	18.65	1.69e-58	2.41e-51	0.77	0.65	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
THCA	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-18.64	1.82e-58	2.59e-51	-0.8	-0.65	Longevity;	chr3:48421052	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-18.64	1.82e-58	2.59e-51	-0.8	-0.65	Longevity;	chr3:48422302	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs13076076	ENSG00000235912.1	RP1-159A19.3	-18.64	1.84e-58	2.63e-51	-0.79	-0.65	Longevity;	chr3:48437629	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs9849509	ENSG00000235912.1	RP1-159A19.3	-18.64	1.84e-58	2.63e-51	-0.79	-0.65	Longevity;	chr3:48442021	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs60512868	ENSG00000235912.1	RP1-159A19.3	-18.64	1.84e-58	2.63e-51	-0.79	-0.65	Longevity;	chr3:48442035	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-18.64	1.84e-58	2.63e-51	-0.79	-0.65	Longevity;	chr3:48443151	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-18.64	1.84e-58	2.63e-51	-0.79	-0.65	Longevity;	chr3:48443275	chr1:27649419~27649610:+
THCA	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	18.63	1.99e-58	2.84e-51	0.9	0.65	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
THCA	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-18.63	2.01e-58	2.86e-51	-0.78	-0.65	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.607	rs132792	ENSG00000268568.1	AC007228.9	18.61	2.56e-58	3.63e-51	0.82	0.65	Vitiligo;	chr22:41666818	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	18.61	2.57e-58	3.66e-51	0.94	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
THCA	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-18.6	2.74e-58	3.88e-51	-0.88	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
THCA	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	18.59	3.06e-58	4.34e-51	0.78	0.65	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.918	rs6002351	ENSG00000268568.1	AC007228.9	-18.59	3.09e-58	4.38e-51	-0.8	-0.65	Vitiligo;	chr22:41361219	chr19:56672574~56673901:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-18.59	3.23e-58	4.58e-51	-0.79	-0.65	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
THCA	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-18.59	3.23e-58	4.58e-51	-0.79	-0.65	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
THCA	trans	rs9611565	0.879	rs5758307	ENSG00000268568.1	AC007228.9	-18.58	3.38e-58	4.78e-51	-0.8	-0.65	Vitiligo;	chr22:41354215	chr19:56672574~56673901:-
THCA	trans	rs9876781	1	rs6810060	ENSG00000235912.1	RP1-159A19.3	-18.57	3.71e-58	5.25e-51	-0.79	-0.65	Longevity;	chr3:48393284	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs6770470	ENSG00000235912.1	RP1-159A19.3	-18.57	3.71e-58	5.25e-51	-0.79	-0.65	Longevity;	chr3:48393659	chr1:27649419~27649610:+
THCA	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	18.57	3.78e-58	5.34e-51	0.82	0.65	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	18.57	3.78e-58	5.34e-51	0.82	0.65	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-18.57	3.8e-58	5.37e-51	-0.77	-0.65	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
THCA	trans	rs9876781	1	rs4858817	ENSG00000235912.1	RP1-159A19.3	18.56	4.23e-58	5.96e-51	0.79	0.65	Longevity;	chr3:48375266	chr1:27649419~27649610:+
THCA	trans	rs9611565	0.592	rs4481089	ENSG00000268568.1	AC007228.9	-18.55	4.6e-58	6.47e-51	-0.83	-0.65	Vitiligo;	chr22:41584888	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs5996039	ENSG00000268568.1	AC007228.9	-18.55	4.6e-58	6.47e-51	-0.83	-0.65	Vitiligo;	chr22:41585953	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs57102627	ENSG00000268568.1	AC007228.9	-18.55	4.6e-58	6.47e-51	-0.83	-0.65	Vitiligo;	chr22:41591623	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.592	rs28750375	ENSG00000268568.1	AC007228.9	-18.55	4.6e-58	6.47e-51	-0.83	-0.65	Vitiligo;	chr22:41594640	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-18.55	4.8e-58	6.75e-51	-0.83	-0.65	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
THCA	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-18.55	4.8e-58	6.75e-51	-0.83	-0.65	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
THCA	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	18.54	5.57e-58	7.82e-51	0.82	0.65	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	18.54	5.57e-58	7.82e-51	0.82	0.65	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	18.53	6.2e-58	8.7e-51	0.83	0.65	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
THCA	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-18.51	7.52e-58	1.05e-50	-0.78	-0.65	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
THCA	trans	rs7554547	0.838	rs885770	ENSG00000261819.1	RP11-680G24.4	18.51	7.81e-58	1.09e-50	0.88	0.65	Nonsyndromic cleft lip with cleft palate;	chr1:11878699	chr16:14988259~14990160:-
THCA	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-18.5	8.5e-58	1.19e-50	-0.82	-0.65	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
THCA	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-18.5	8.5e-58	1.19e-50	-0.82	-0.65	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
THCA	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-18.48	9.92e-58	1.39e-50	-0.74	-0.65	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
THCA	trans	rs9876781	1	rs9817615	ENSG00000235912.1	RP1-159A19.3	-18.48	1.07e-57	1.49e-50	-0.79	-0.65	Longevity;	chr3:48429347	chr1:27649419~27649610:+
THCA	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	18.46	1.23e-57	1.72e-50	0.86	0.65	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
THCA	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-18.46	1.33e-57	1.85e-50	-0.8	-0.65	Longevity;	chr3:48414217	chr1:27649419~27649610:+
THCA	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-18.45	1.4e-57	1.95e-50	-0.86	-0.65	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
THCA	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-18.45	1.41e-57	1.97e-50	-0.83	-0.65	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
THCA	trans	rs10242455	0.702	rs112475236	ENSG00000228834.1	RP11-249L21.4	18.45	1.49e-57	2.08e-50	1.81	0.65	Blood metabolite levels;	chr7:99447056	chr6:108907615~108907873:-
THCA	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	18.44	1.5e-57	2.09e-50	1.28	0.65	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
THCA	trans	rs55665837	0.524	rs61884009	ENSG00000236360.2	RP11-334A14.2	18.44	1.63e-57	2.27e-50	0.92	0.65	Vitamin D levels;	chr11:14404916	chr1:52993201~52993702:-
THCA	trans	rs10242455	0.557	rs45529541	ENSG00000228834.1	RP11-249L21.4	18.44	1.66e-57	2.31e-50	1.81	0.65	Blood metabolite levels;	chr7:99450520	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs3528	ENSG00000228834.1	RP11-249L21.4	18.44	1.66e-57	2.31e-50	1.81	0.65	Blood metabolite levels;	chr7:99458317	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs55927283	ENSG00000228834.1	RP11-249L21.4	18.44	1.66e-57	2.31e-50	1.81	0.65	Blood metabolite levels;	chr7:99459568	chr6:108907615~108907873:-
THCA	trans	rs3947	0.951	rs1692817	ENSG00000229857.1	RP11-159H20.3	18.43	1.81e-57	2.52e-50	0.94	0.65	Blood protein levels;	chr8:11847210	chr9:76992099~76993108:+
THCA	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-18.42	1.97e-57	2.73e-50	-0.82	-0.65	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
THCA	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-18.42	1.97e-57	2.74e-50	-0.87	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
THCA	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	18.41	2.17e-57	3.01e-50	0.89	0.65	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
THCA	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	18.41	2.25e-57	3.12e-50	0.86	0.65	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
THCA	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-18.37	3.24e-57	4.49e-50	-0.82	-0.65	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
THCA	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	18.36	3.92e-57	5.43e-50	0.87	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-18.35	4.25e-57	5.89e-50	-0.79	-0.65	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
THCA	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	18.32	5.58e-57	7.72e-50	0.77	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
THCA	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-18.3	7.11e-57	9.82e-50	-0.77	-0.65	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
THCA	trans	rs10242455	0.85	rs57367781	ENSG00000228834.1	RP11-249L21.4	18.3	7.18e-57	9.92e-50	1.82	0.65	Blood metabolite levels;	chr7:99519196	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs6974831	ENSG00000228834.1	RP11-249L21.4	18.3	7.18e-57	9.92e-50	1.82	0.65	Blood metabolite levels;	chr7:99533982	chr6:108907615~108907873:-
THCA	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-18.28	8.35e-57	1.15e-49	-0.87	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
THCA	trans	rs9611565	0.559	rs8139993	ENSG00000268568.1	AC007228.9	-18.26	1.05e-56	1.45e-49	-0.82	-0.64	Vitiligo;	chr22:41599331	chr19:56672574~56673901:-
THCA	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-18.21	1.88e-56	2.58e-49	-0.82	-0.64	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
THCA	trans	rs13190036	1	rs13175695	ENSG00000217325.2	PRELID1P1	18.2	2.15e-56	2.95e-49	0.86	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr6:126643488~126644390:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	18.18	2.66e-56	3.65e-49	0.82	0.64	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
THCA	trans	rs13190036	0.901	rs6898107	ENSG00000217325.2	PRELID1P1	18.17	2.73e-56	3.74e-49	0.87	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr6:126643488~126644390:+
THCA	trans	rs941207	0.507	rs2958124	ENSG00000121089.4	NACA3P	-18.17	2.82e-56	3.86e-49	-0.77	-0.64	Platelet count;	chr12:56633837	chr4:164943290~164943937:+
THCA	trans	rs13190036	0.901	rs6556309	ENSG00000217325.2	PRELID1P1	18.16	3.03e-56	4.15e-49	0.86	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr6:126643488~126644390:+
THCA	trans	rs4276421	0.597	rs8188245	ENSG00000231752.4	EMBP1	-18.15	3.53e-56	4.82e-49	-0.89	-0.64	P wave duration;	chr5:46174762	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.574	rs839418	ENSG00000230849.2	GOT2P2	18.13	4.24e-56	5.79e-49	0.86	0.64	Blood metabolite ratios;	chr16:58705426	chr1:173141100~173142350:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	18.13	4.32e-56	5.9e-49	0.76	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
THCA	trans	rs9611565	0.592	rs80477	ENSG00000268568.1	AC007228.9	18.06	8.88e-56	1.2e-48	0.82	0.64	Vitiligo;	chr22:41605179	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	18.06	9.19e-56	1.24e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-18.05	1.02e-55	1.38e-48	-0.89	-0.64	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	18.05	1.02e-55	1.38e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	18.04	1.1e-55	1.49e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
THCA	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	18.04	1.15e-55	1.54e-48	0.99	0.64	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
THCA	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	18.04	1.18e-55	1.58e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-18.03	1.32e-55	1.77e-48	-0.89	-0.64	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-18.02	1.35e-55	1.81e-48	-0.91	-0.64	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
THCA	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	18.01	1.61e-55	2.16e-48	1.79	0.64	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	18	1.72e-55	2.3e-48	1.79	0.64	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	18	1.72e-55	2.3e-48	1.79	0.64	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
THCA	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	18	1.72e-55	2.3e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	18	1.72e-55	2.3e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	18	1.72e-55	2.3e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	18	1.72e-55	2.3e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	18	1.72e-55	2.3e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	18	1.72e-55	2.3e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	18	1.72e-55	2.3e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	18	1.72e-55	2.3e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
THCA	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	18	1.77e-55	2.37e-48	1.79	0.64	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	17.99	1.89e-55	2.53e-48	1.79	0.64	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	17.99	1.89e-55	2.53e-48	1.79	0.64	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	17.99	1.95e-55	2.6e-48	1.79	0.64	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
THCA	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	17.99	2.02e-55	2.7e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
THCA	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	17.99	2.03e-55	2.71e-48	0.95	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
THCA	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	17.97	2.3e-55	3.06e-48	0.79	0.64	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	17.97	2.36e-55	3.14e-48	0.82	0.64	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	17.97	2.36e-55	3.14e-48	0.82	0.64	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	17.97	2.36e-55	3.14e-48	0.82	0.64	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
THCA	trans	rs8175379	0.521	rs10037109	ENSG00000231752.4	EMBP1	17.97	2.37e-55	3.15e-48	0.84	0.64	Interleukin-7 levels;	chr5:46328343	chr1:121519112~121571892:+
THCA	trans	rs2950393	0.804	rs7295862	ENSG00000121089.4	NACA3P	-17.96	2.65e-55	3.51e-48	-0.75	-0.64	Platelet distribution width;	chr12:56775374	chr4:164943290~164943937:+
THCA	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	17.96	2.82e-55	3.73e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	17.96	2.82e-55	3.73e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	17.96	2.82e-55	3.73e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
THCA	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	17.95	2.95e-55	3.9e-48	0.85	0.64	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
THCA	trans	rs1816752	0.704	rs7995968	ENSG00000237917.1	PARP4P1	-17.95	2.98e-55	3.93e-48	-0.8	-0.64	Obesity-related traits;	chr13:24392754	chrY:26594851~26634652:-
THCA	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	17.95	3.1e-55	4.09e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	17.94	3.23e-55	4.27e-48	0.88	0.64	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	17.94	3.23e-55	4.27e-48	0.88	0.64	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	17.94	3.24e-55	4.27e-48	0.88	0.64	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
THCA	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-17.94	3.34e-55	4.4e-48	-0.78	-0.64	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
THCA	trans	rs8175379	0.575	rs8185283	ENSG00000231752.4	EMBP1	-17.94	3.36e-55	4.42e-48	-0.84	-0.64	Interleukin-7 levels;	chr5:46337706	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-17.94	3.41e-55	4.48e-48	-0.77	-0.64	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-17.94	3.41e-55	4.48e-48	-0.77	-0.64	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-17.94	3.41e-55	4.48e-48	-0.77	-0.64	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
THCA	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	17.94	3.44e-55	4.52e-48	0.88	0.64	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
THCA	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	17.94	3.48e-55	4.58e-48	0.8	0.64	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
THCA	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-17.93	3.66e-55	4.8e-48	-0.82	-0.64	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
THCA	trans	rs9876781	1	rs4858793	ENSG00000235912.1	RP1-159A19.3	17.93	3.7e-55	4.85e-48	0.77	0.64	Longevity;	chr3:48373517	chr1:27649419~27649610:+
THCA	trans	rs13190036	0.681	rs28461408	ENSG00000217325.2	PRELID1P1	17.92	4.27e-55	5.59e-48	0.98	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr6:126643488~126644390:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-17.91	4.37e-55	5.72e-48	-0.81	-0.64	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
THCA	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-17.91	4.37e-55	5.72e-48	-0.81	-0.64	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
THCA	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	17.91	4.44e-55	5.8e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-17.91	4.83e-55	6.31e-48	-0.81	-0.64	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
THCA	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	17.88	6.63e-55	8.61e-48	0.97	0.64	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
THCA	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	17.87	6.71e-55	8.71e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	17.87	6.71e-55	8.71e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
THCA	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	17.87	6.71e-55	8.71e-48	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
THCA	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-17.87	6.9e-55	8.94e-48	-0.8	-0.64	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
THCA	trans	rs3947	0.906	rs1692821	ENSG00000229857.1	RP11-159H20.3	17.87	7.4e-55	9.58e-48	0.89	0.64	Blood protein levels;	chr8:11842479	chr9:76992099~76993108:+
THCA	trans	rs9876781	0.872	rs11797	ENSG00000235912.1	RP1-159A19.3	-17.86	7.53e-55	9.76e-48	-0.79	-0.64	Longevity;	chr3:48467186	chr1:27649419~27649610:+
THCA	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-17.86	7.86e-55	1.02e-47	-0.75	-0.64	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
THCA	trans	rs7554547	0.818	rs4993566	ENSG00000261819.1	RP11-680G24.4	17.85	8.79e-55	1.14e-47	0.83	0.64	Nonsyndromic cleft lip with cleft palate;	chr1:11909937	chr16:14988259~14990160:-
THCA	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	17.85	8.89e-55	1.15e-47	1.79	0.64	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
THCA	trans	rs9876781	0.933	rs6442124	ENSG00000235912.1	RP1-159A19.3	-17.84	9.88e-55	1.27e-47	-0.78	-0.64	Longevity;	chr3:48463903	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	17.84	1.01e-54	1.3e-47	0.78	0.64	Longevity;	chr3:48407507	chr1:27649419~27649610:+
THCA	trans	rs8175379	0.515	rs8185067	ENSG00000231752.4	EMBP1	-17.83	1.13e-54	1.44e-47	-0.84	-0.64	Interleukin-7 levels;	chr5:46337722	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.511	rs34101830	ENSG00000231752.4	EMBP1	-17.82	1.14e-54	1.46e-47	-0.83	-0.64	Schizophrenia;	chr5:46349001	chr1:121519112~121571892:+
THCA	trans	rs8175379	0.522	rs8185256	ENSG00000231752.4	EMBP1	-17.82	1.17e-54	1.49e-47	-0.84	-0.64	Interleukin-7 levels;	chr5:46298301	chr1:121519112~121571892:+
THCA	trans	rs8175379	0.584	rs8185180	ENSG00000231752.4	EMBP1	-17.82	1.17e-54	1.49e-47	-0.84	-0.64	Interleukin-7 levels;	chr5:46300291	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-17.81	1.33e-54	1.69e-47	-0.76	-0.63	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-17.81	1.33e-54	1.69e-47	-0.76	-0.63	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-17.81	1.33e-54	1.69e-47	-0.76	-0.63	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-17.81	1.33e-54	1.69e-47	-0.76	-0.63	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-17.81	1.33e-54	1.69e-47	-0.76	-0.63	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-17.81	1.35e-54	1.72e-47	-0.77	-0.63	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-17.81	1.35e-54	1.72e-47	-0.77	-0.63	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-17.81	1.35e-54	1.72e-47	-0.77	-0.63	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-17.79	1.57e-54	1.98e-47	-0.81	-0.63	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
THCA	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	17.79	1.59e-54	2.01e-47	0.85	0.63	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
THCA	trans	rs10242455	0.702	rs73403290	ENSG00000228834.1	RP11-249L21.4	17.79	1.68e-54	2.12e-47	1.78	0.63	Blood metabolite levels;	chr7:99560205	chr6:108907615~108907873:-
THCA	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-17.79	1.69e-54	2.13e-47	-0.78	-0.63	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-17.79	1.73e-54	2.18e-47	-0.77	-0.63	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-17.79	1.74e-54	2.19e-47	-0.77	-0.63	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
THCA	trans	rs8175379	0.551	rs4975969	ENSG00000231752.4	EMBP1	-17.78	1.84e-54	2.31e-47	-0.84	-0.63	Interleukin-7 levels;	chr5:46295887	chr1:121519112~121571892:+
THCA	trans	rs8175379	0.509	rs7293427	ENSG00000231752.4	EMBP1	17.78	1.9e-54	2.38e-47	0.83	0.63	Interleukin-7 levels;	chr5:46253335	chr1:121519112~121571892:+
THCA	trans	rs8175379	0.509	rs4128583	ENSG00000231752.4	EMBP1	17.77	2.01e-54	2.51e-47	0.83	0.63	Interleukin-7 levels;	chr5:46251985	chr1:121519112~121571892:+
THCA	trans	rs9611565	1	rs1109151	ENSG00000268568.1	AC007228.9	-17.77	2.04e-54	2.55e-47	-0.79	-0.63	Vitiligo;	chr22:41356940	chr19:56672574~56673901:-
THCA	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-17.75	2.53e-54	3.12e-47	-0.77	-0.63	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-17.75	2.59e-54	3.2e-47	-0.76	-0.63	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-17.75	2.6e-54	3.21e-47	-0.76	-0.63	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
THCA	trans	rs9611565	0.879	rs4820437	ENSG00000268568.1	AC007228.9	-17.74	2.68e-54	3.31e-47	-0.78	-0.63	Vitiligo;	chr22:41365286	chr19:56672574~56673901:-
THCA	trans	rs8175379	0.506	rs10035927	ENSG00000231752.4	EMBP1	-17.74	2.88e-54	3.55e-47	-0.83	-0.63	Interleukin-7 levels;	chr5:46404107	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	17.73	3.16e-54	3.9e-47	0.76	0.63	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
THCA	trans	rs8175379	0.542	rs12657764	ENSG00000231752.4	EMBP1	-17.72	3.51e-54	4.31e-47	-0.83	-0.63	Interleukin-7 levels;	chr5:46281165	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-17.72	3.6e-54	4.42e-47	-0.77	-0.63	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
THCA	trans	rs13358908	0.503	rs10073687	ENSG00000231752.4	EMBP1	-17.71	3.72e-54	4.57e-47	-0.83	-0.63	Schizophrenia;	chr5:46352187	chr1:121519112~121571892:+
THCA	trans	rs13358908	0.526	rs4975974	ENSG00000231752.4	EMBP1	-17.71	3.81e-54	4.67e-47	-0.83	-0.63	Schizophrenia;	chr5:46307464	chr1:121519112~121571892:+
THCA	trans	rs8175379	0.501	rs12514178	ENSG00000231752.4	EMBP1	-17.71	3.81e-54	4.67e-47	-0.83	-0.63	Interleukin-7 levels;	chr5:46309072	chr1:121519112~121571892:+
THCA	trans	rs8175379	0.501	rs8185192	ENSG00000231752.4	EMBP1	-17.71	3.81e-54	4.67e-47	-0.83	-0.63	Interleukin-7 levels;	chr5:46309722	chr1:121519112~121571892:+
THCA	trans	rs10242455	0.557	rs77997620	ENSG00000228834.1	RP11-249L21.4	17.7	4.29e-54	5.24e-47	1.76	0.63	Blood metabolite levels;	chr7:99472792	chr6:108907615~108907873:-
THCA	trans	rs13253073	0.883	rs12545602	ENSG00000260318.1	COX6CP1	17.7	4.29e-54	5.24e-47	1.21	0.63	Glucose homeostasis traits;	chr8:99834612	chr16:11903923~11904137:-
THCA	trans	rs13358908	0.507	rs12521357	ENSG00000231752.4	EMBP1	-17.7	4.38e-54	5.33e-47	-0.83	-0.63	Schizophrenia;	chr5:46403146	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-17.7	4.45e-54	5.42e-47	-0.76	-0.63	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
THCA	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	17.69	4.62e-54	5.61e-47	1.76	0.63	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	17.69	4.62e-54	5.61e-47	1.76	0.63	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
THCA	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-17.69	5e-54	6.08e-47	-0.78	-0.63	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
THCA	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	17.69	5.06e-54	6.14e-47	0.87	0.63	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
THCA	trans	rs8081395	0.834	rs11650106	ENSG00000187870.7	RNFT1P3	-17.68	5.19e-54	6.29e-47	-0.81	-0.63	White blood cell count;	chr17:59772890	chr17:20743333~20754501:-
THCA	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-17.68	5.24e-54	6.36e-47	-0.89	-0.63	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
THCA	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-17.68	5.54e-54	6.67e-47	-0.76	-0.63	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
THCA	trans	rs8081395	0.899	rs2645477	ENSG00000187870.7	RNFT1P3	-17.67	6.22e-54	7.46e-47	-0.82	-0.63	White blood cell count;	chr17:59768263	chr17:20743333~20754501:-
THCA	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-17.66	6.27e-54	7.51e-47	-0.77	-0.63	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-17.66	6.66e-54	7.96e-47	-0.76	-0.63	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-17.66	6.66e-54	7.96e-47	-0.76	-0.63	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-17.66	6.66e-54	7.96e-47	-0.76	-0.63	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-17.66	6.66e-54	7.96e-47	-0.76	-0.63	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-17.66	6.66e-54	7.96e-47	-0.76	-0.63	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
THCA	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	17.65	7.03e-54	8.37e-47	1.13	0.63	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
THCA	trans	rs13358908	0.556	rs55638678	ENSG00000231752.4	EMBP1	-17.65	7.46e-54	8.89e-47	-0.83	-0.63	Schizophrenia;	chr5:46332618	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-17.64	7.86e-54	9.36e-47	-0.76	-0.63	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-17.64	7.86e-54	9.36e-47	-0.76	-0.63	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-17.64	7.86e-54	9.36e-47	-0.76	-0.63	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-17.64	7.86e-54	9.36e-47	-0.76	-0.63	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
THCA	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	17.64	8.33e-54	9.89e-47	1.76	0.63	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
THCA	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-17.63	9.23e-54	1.08e-46	-0.76	-0.63	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
THCA	trans	rs13190036	0.901	rs10056655	ENSG00000217325.2	PRELID1P1	17.63	9.46e-54	1.1e-46	0.85	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr6:126643488~126644390:+
THCA	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-17.61	1.16e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-17.61	1.16e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-17.61	1.16e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-17.61	1.16e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-17.61	1.16e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-17.61	1.17e-53	1.35e-46	-0.76	-0.63	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-17.61	1.18e-53	1.37e-46	-0.76	-0.63	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
THCA	trans	rs9876781	1	rs922075	ENSG00000235912.1	RP1-159A19.3	17.6	1.21e-53	1.4e-46	0.75	0.63	Longevity;	chr3:48447994	chr1:27649419~27649610:+
THCA	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-17.6	1.28e-53	1.49e-46	-0.87	-0.63	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
THCA	trans	rs8175379	0.502	rs8185361	ENSG00000231752.4	EMBP1	-17.58	1.53e-53	1.77e-46	-0.83	-0.63	Interleukin-7 levels;	chr5:46300238	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-17.58	1.61e-53	1.86e-46	-0.78	-0.63	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-17.57	1.76e-53	2.04e-46	-0.78	-0.63	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
THCA	trans	rs9876781	1	rs2045554	ENSG00000235912.1	RP1-159A19.3	17.55	2.17e-53	2.5e-46	0.75	0.63	Longevity;	chr3:48453142	chr1:27649419~27649610:+
THCA	trans	rs10941710	0.579	rs8188241	ENSG00000231752.4	EMBP1	17.54	2.36e-53	2.72e-46	0.89	0.63	Neuroticism;	chr5:46204646	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-17.52	2.85e-53	3.27e-46	-0.77	-0.63	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
THCA	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-17.52	2.87e-53	3.3e-46	-1.12	-0.63	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
THCA	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-17.52	2.89e-53	3.32e-46	-0.78	-0.63	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
THCA	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	17.49	4.21e-53	4.81e-46	1.13	0.63	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
THCA	trans	rs9876781	1	rs13069724	ENSG00000235912.1	RP1-159A19.3	-17.48	4.43e-53	5.05e-46	-0.76	-0.63	Longevity;	chr3:48436629	chr1:27649419~27649610:+
THCA	trans	rs12709013	0.591	rs30834	ENSG00000230849.2	GOT2P2	17.48	4.46e-53	5.09e-46	0.84	0.63	Blood metabolite ratios;	chr16:58715394	chr1:173141100~173142350:-
THCA	trans	rs10242455	0.702	rs73403286	ENSG00000228834.1	RP11-249L21.4	17.45	6.35e-53	7.22e-46	1.78	0.63	Blood metabolite levels;	chr7:99557242	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs73405247	ENSG00000228834.1	RP11-249L21.4	17.45	6.35e-53	7.22e-46	1.78	0.63	Blood metabolite levels;	chr7:99561551	chr6:108907615~108907873:-
THCA	trans	rs7503168	0.558	rs71381460	ENSG00000234130.2	RP13-88F20.1	17.44	6.51e-53	7.38e-46	1.12	0.63	Plateletcrit;	chr17:35564602	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs11655098	ENSG00000234130.2	RP13-88F20.1	17.44	6.51e-53	7.38e-46	1.12	0.63	Plateletcrit;	chr17:35567831	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs17638076	ENSG00000234130.2	RP13-88F20.1	17.44	6.51e-53	7.38e-46	1.12	0.63	Plateletcrit;	chr17:35569254	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs12939138	ENSG00000234130.2	RP13-88F20.1	17.44	6.51e-53	7.38e-46	1.12	0.63	Plateletcrit;	chr17:35574559	chrX:93222220~93225015:-
THCA	trans	rs73990293	0.737	rs12951703	ENSG00000234130.2	RP13-88F20.1	17.44	6.51e-53	7.38e-46	1.12	0.63	Clopidogrel active metabolite levels;	chr17:35586035	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs79468963	ENSG00000234130.2	RP13-88F20.1	17.44	6.51e-53	7.38e-46	1.12	0.63	Plateletcrit;	chr17:35590408	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs71381461	ENSG00000234130.2	RP13-88F20.1	17.44	6.51e-53	7.38e-46	1.12	0.63	Plateletcrit;	chr17:35593601	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs34937989	ENSG00000234130.2	RP13-88F20.1	17.44	6.51e-53	7.38e-46	1.12	0.63	Plateletcrit;	chr17:35594744	chrX:93222220~93225015:-
THCA	trans	rs13190036	0.792	rs6874206	ENSG00000217325.2	PRELID1P1	-17.43	7.22e-53	8.18e-46	-0.84	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr6:126643488~126644390:+
THCA	trans	rs13190036	0.901	rs10072499	ENSG00000217325.2	PRELID1P1	-17.43	7.22e-53	8.18e-46	-0.84	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr6:126643488~126644390:+
THCA	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-17.43	7.34e-53	8.31e-46	-0.77	-0.63	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-17.43	7.64e-53	8.65e-46	-0.77	-0.63	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
THCA	trans	rs9876781	1	rs7636782	ENSG00000235912.1	RP1-159A19.3	-17.43	7.9e-53	8.95e-46	-0.75	-0.63	Longevity;	chr3:48379897	chr1:27649419~27649610:+
THCA	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-17.42	8.56e-53	9.69e-46	-0.76	-0.63	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
THCA	trans	rs9876781	0.967	rs1870444	ENSG00000235912.1	RP1-159A19.3	-17.39	1.13e-52	1.27e-45	-0.75	-0.63	Longevity;	chr3:48445369	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.967	rs1459249	ENSG00000235912.1	RP1-159A19.3	-17.39	1.14e-52	1.29e-45	-0.75	-0.63	Longevity;	chr3:48438208	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs2362450	ENSG00000235912.1	RP1-159A19.3	-17.39	1.16e-52	1.31e-45	-0.75	-0.63	Longevity;	chr3:48419904	chr1:27649419~27649610:+
THCA	trans	rs9876781	1	rs2362452	ENSG00000235912.1	RP1-159A19.3	17.39	1.19e-52	1.34e-45	0.75	0.63	Longevity;	chr3:48376724	chr1:27649419~27649610:+
THCA	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-17.38	1.27e-52	1.43e-45	-0.77	-0.63	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-17.38	1.27e-52	1.43e-45	-0.77	-0.63	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-17.38	1.27e-52	1.44e-45	-0.77	-0.63	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
THCA	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-17.38	1.33e-52	1.49e-45	-0.76	-0.63	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
THCA	trans	rs12291225	0.883	rs1864658	ENSG00000236360.2	RP11-334A14.2	-17.38	1.33e-52	1.5e-45	-0.89	-0.63	Sense of smell;	chr11:14234898	chr1:52993201~52993702:-
THCA	trans	rs8175379	0.506	rs8188256	ENSG00000231752.4	EMBP1	-17.38	1.35e-52	1.52e-45	-0.82	-0.63	Interleukin-7 levels;	chr5:46372404	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.798	rs12516161	ENSG00000239528.1	RPS14P8	17.38	1.35e-52	1.52e-45	1.03	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	17.38	1.35e-52	1.52e-45	0.91	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	17.36	1.65e-52	1.85e-45	0.77	0.62	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
THCA	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-17.35	1.72e-52	1.93e-45	-0.76	-0.62	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
THCA	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	17.35	1.73e-52	1.93e-45	0.77	0.62	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
THCA	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-17.35	1.78e-52	1.99e-45	-0.85	-0.62	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
THCA	trans	rs13190036	1	rs6880798	ENSG00000217325.2	PRELID1P1	17.34	1.89e-52	2.11e-45	0.89	0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr6:126643488~126644390:+
THCA	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-17.34	1.9e-52	2.12e-45	-0.77	-0.62	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
THCA	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	17.34	1.92e-52	2.15e-45	1.11	0.62	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
THCA	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	17.34	1.95e-52	2.18e-45	0.77	0.62	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
THCA	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	17.34	2.07e-52	2.31e-45	0.87	0.62	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
THCA	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-17.34	2.08e-52	2.32e-45	-0.76	-0.62	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.601	rs7712849	ENSG00000231752.4	EMBP1	17.33	2.16e-52	2.41e-45	0.82	0.62	Schizophrenia;	chr5:50407774	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	17.33	2.25e-52	2.51e-45	0.91	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
THCA	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	17.31	2.65e-52	2.95e-45	1.13	0.62	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	17.31	2.65e-52	2.95e-45	1.13	0.62	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
THCA	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	17.31	2.65e-52	2.95e-45	1.13	0.62	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
THCA	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-17.31	2.78e-52	3.09e-45	-0.75	-0.62	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.562	rs1674514	ENSG00000231752.4	EMBP1	-17.3	2.87e-52	3.19e-45	-0.82	-0.62	Schizophrenia;	chr5:50269291	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-17.3	2.96e-52	3.29e-45	-0.75	-0.62	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
THCA	trans	rs13358908	0.51	rs4975991	ENSG00000231752.4	EMBP1	-17.3	3.06e-52	3.4e-45	-0.83	-0.62	Schizophrenia;	chr5:46328545	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.834	rs13163277	ENSG00000239528.1	RPS14P8	17.29	3.32e-52	3.69e-45	1.03	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr5:116562562~116562930:+
THCA	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	17.29	3.42e-52	3.79e-45	1.13	0.62	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	17.29	3.42e-52	3.79e-45	1.13	0.62	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	17.28	3.86e-52	4.27e-45	1.13	0.62	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
THCA	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-17.25	5.38e-52	5.93e-45	-0.76	-0.62	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-17.24	5.77e-52	6.35e-45	-0.75	-0.62	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-17.24	5.77e-52	6.35e-45	-0.75	-0.62	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
THCA	trans	rs10242455	0.702	rs73397481	ENSG00000228834.1	RP11-249L21.4	17.22	7.27e-52	7.99e-45	1.77	0.62	Blood metabolite levels;	chr7:99432485	chr6:108907615~108907873:-
THCA	trans	rs13253073	0.883	rs2305290	ENSG00000260318.1	COX6CP1	17.22	7.36e-52	8.09e-45	1.16	0.62	Glucose homeostasis traits;	chr8:99819066	chr16:11903923~11904137:-
THCA	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-17.22	7.38e-52	8.11e-45	-0.76	-0.62	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
THCA	trans	rs13177918	0.822	rs62382255	ENSG00000239528.1	RPS14P8	17.21	7.49e-52	8.22e-45	1.03	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459154	chr5:116562562~116562930:+
THCA	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	17.19	9.28e-52	1.02e-44	1.13	0.62	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-17.17	1.24e-51	1.36e-44	-0.72	-0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
THCA	trans	rs10940346	0.601	rs552892	ENSG00000231752.4	EMBP1	-17.16	1.31e-51	1.44e-44	-0.82	-0.62	Schizophrenia;	chr5:50269093	chr1:121519112~121571892:+
THCA	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-17.16	1.36e-51	1.49e-44	-0.77	-0.62	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
THCA	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	17.16	1.38e-51	1.51e-44	0.77	0.62	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
THCA	trans	rs12709013	0.591	rs149479	ENSG00000230849.2	GOT2P2	-17.15	1.42e-51	1.56e-44	-0.85	-0.62	Blood metabolite ratios;	chr16:58703171	chr1:173141100~173142350:-
THCA	trans	rs10940346	0.524	rs1458763	ENSG00000231752.4	EMBP1	-17.15	1.5e-51	1.64e-44	-0.82	-0.62	Schizophrenia;	chr5:50265531	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1458765	ENSG00000231752.4	EMBP1	-17.15	1.5e-51	1.64e-44	-0.82	-0.62	Schizophrenia;	chr5:50266141	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4865675	ENSG00000231752.4	EMBP1	-17.15	1.51e-51	1.65e-44	-0.82	-0.62	Schizophrenia;	chr5:50279300	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs506919	ENSG00000231752.4	EMBP1	-17.15	1.51e-51	1.65e-44	-0.82	-0.62	Schizophrenia;	chr5:50279635	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1858343	ENSG00000231752.4	EMBP1	-17.15	1.51e-51	1.65e-44	-0.82	-0.62	Schizophrenia;	chr5:50290180	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs1858344	ENSG00000231752.4	EMBP1	-17.15	1.51e-51	1.65e-44	-0.82	-0.62	Schizophrenia;	chr5:50290345	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6449802	ENSG00000231752.4	EMBP1	-17.15	1.51e-51	1.65e-44	-0.82	-0.62	Schizophrenia;	chr5:50299390	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs2137129	ENSG00000231752.4	EMBP1	-17.15	1.51e-51	1.65e-44	-0.82	-0.62	Schizophrenia;	chr5:50300962	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs549751	ENSG00000231752.4	EMBP1	-17.14	1.58e-51	1.72e-44	-0.82	-0.62	Schizophrenia;	chr5:50262114	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-17.14	1.64e-51	1.79e-44	-0.76	-0.62	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.562	rs555704	ENSG00000231752.4	EMBP1	-17.13	1.92e-51	2.08e-44	-0.82	-0.62	Schizophrenia;	chr5:50277066	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-17.12	1.98e-51	2.15e-44	-0.76	-0.62	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.601	rs496230	ENSG00000231752.4	EMBP1	-17.12	2.01e-51	2.19e-44	-0.82	-0.62	Schizophrenia;	chr5:50275179	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	17.12	2.08e-51	2.26e-44	0.83	0.62	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
THCA	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-17.11	2.27e-51	2.47e-44	-0.75	-0.62	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
THCA	trans	rs9611565	1	rs5758314	ENSG00000268568.1	AC007228.9	-17.1	2.42e-51	2.63e-44	-0.76	-0.62	Vitiligo;	chr22:41366519	chr19:56672574~56673901:-
THCA	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	17.1	2.44e-51	2.65e-44	0.82	0.62	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	17.1	2.44e-51	2.65e-44	0.82	0.62	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
THCA	trans	rs13177918	0.871	rs11745133	ENSG00000239528.1	RPS14P8	17.1	2.5e-51	2.71e-44	1.01	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr5:116562562~116562930:+
THCA	trans	rs13177918	0.871	rs11745194	ENSG00000239528.1	RPS14P8	17.1	2.5e-51	2.71e-44	1.01	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr5:116562562~116562930:+
THCA	trans	rs10940346	0.537	rs7293378	ENSG00000231752.4	EMBP1	-17.09	2.79e-51	3.02e-44	-0.82	-0.62	Schizophrenia;	chr5:50192402	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs524184	ENSG00000231752.4	EMBP1	-17.09	2.91e-51	3.15e-44	-0.81	-0.62	Schizophrenia;	chr5:50276256	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-17.08	2.95e-51	3.2e-44	-0.75	-0.62	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
THCA	trans	rs3947	0.789	rs8005	ENSG00000229857.1	RP11-159H20.3	-17.07	3.35e-51	3.62e-44	-0.82	-0.62	Blood protein levels;	chr8:11843587	chr9:76992099~76993108:+
THCA	trans	rs10940346	0.668	rs11746545	ENSG00000231752.4	EMBP1	-17.07	3.48e-51	3.76e-44	-0.87	-0.62	Schizophrenia;	chr5:50531238	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-17.07	3.52e-51	3.8e-44	-0.74	-0.62	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-17.07	3.52e-51	3.8e-44	-0.74	-0.62	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
THCA	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-17.07	3.59e-51	3.87e-44	-0.74	-0.62	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
THCA	trans	rs10940346	0.58	rs10940533	ENSG00000231752.4	EMBP1	-17.06	3.85e-51	4.14e-44	-0.82	-0.62	Schizophrenia;	chr5:50146552	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-17.04	4.76e-51	5.11e-44	-0.81	-0.62	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-17.03	5.33e-51	5.71e-44	-0.78	-0.62	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
THCA	trans	rs10242455	0.702	rs74416635	ENSG00000228834.1	RP11-249L21.4	17.03	5.42e-51	5.8e-44	1.78	0.62	Blood metabolite levels;	chr7:99582946	chr6:108907615~108907873:-
THCA	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	17.03	5.56e-51	5.95e-44	0.82	0.62	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	17.03	5.56e-51	5.95e-44	0.82	0.62	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
THCA	trans	rs9876781	1	rs7635522	ENSG00000235912.1	RP1-159A19.3	-17.02	5.96e-51	6.37e-44	-0.75	-0.62	Longevity;	chr3:48382166	chr1:27649419~27649610:+
THCA	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	17.02	6.18e-51	6.6e-44	0.76	0.62	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
THCA	trans	rs13177918	0.798	rs12516161	ENSG00000213058.3	RP4-765C7.2	17.01	6.32e-51	6.75e-44	1.01	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:178411616~178411972:+
THCA	trans	rs10940346	0.562	rs563750	ENSG00000231752.4	EMBP1	-17.01	6.37e-51	6.81e-44	-0.81	-0.62	Schizophrenia;	chr5:50278004	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7724645	ENSG00000231752.4	EMBP1	-17.01	6.41e-51	6.85e-44	-0.81	-0.62	Schizophrenia;	chr5:50299846	chr1:121519112~121571892:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000212994.5	RPS26P6	17.01	6.52e-51	6.96e-44	0.77	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:100895771~100896118:+
THCA	trans	rs10940346	0.58	rs4865801	ENSG00000231752.4	EMBP1	-17.01	6.66e-51	7.11e-44	-0.82	-0.62	Schizophrenia;	chr5:50163364	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs507761	ENSG00000231752.4	EMBP1	-17.01	6.75e-51	7.18e-44	-0.81	-0.62	Schizophrenia;	chr5:50279558	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs494540	ENSG00000231752.4	EMBP1	-17.01	6.75e-51	7.18e-44	-0.81	-0.62	Schizophrenia;	chr5:50280228	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.51	rs10038023	ENSG00000231752.4	EMBP1	-17.01	6.75e-51	7.18e-44	-0.81	-0.62	Schizophrenia;	chr5:50280387	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs471455	ENSG00000231752.4	EMBP1	-17.01	6.75e-51	7.18e-44	-0.81	-0.62	Schizophrenia;	chr5:50280427	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs13360551	ENSG00000231752.4	EMBP1	-17.01	6.75e-51	7.18e-44	-0.81	-0.62	Schizophrenia;	chr5:50287350	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4865685	ENSG00000231752.4	EMBP1	-17.01	6.75e-51	7.18e-44	-0.81	-0.62	Schizophrenia;	chr5:50290682	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6449779	ENSG00000231752.4	EMBP1	-17.01	6.75e-51	7.18e-44	-0.81	-0.62	Schizophrenia;	chr5:50290876	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs2353221	ENSG00000231752.4	EMBP1	-17.01	6.75e-51	7.18e-44	-0.81	-0.62	Schizophrenia;	chr5:50299085	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs62365901	ENSG00000231752.4	EMBP1	17.01	6.77e-51	7.2e-44	0.81	0.62	Schizophrenia;	chr5:50434497	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs28500170	ENSG00000231752.4	EMBP1	17.01	6.77e-51	7.2e-44	0.81	0.62	Schizophrenia;	chr5:50441594	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs13157992	ENSG00000231752.4	EMBP1	17.01	6.77e-51	7.2e-44	0.81	0.62	Schizophrenia;	chr5:50444074	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs57300567	ENSG00000231752.4	EMBP1	17.01	6.77e-51	7.2e-44	0.81	0.62	Schizophrenia;	chr5:50467359	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs7736775	ENSG00000231752.4	EMBP1	-17.01	6.77e-51	7.2e-44	-0.81	-0.62	Schizophrenia;	chr5:50472463	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1841103	ENSG00000231752.4	EMBP1	-17	6.91e-51	7.33e-44	-0.81	-0.62	Schizophrenia;	chr5:50263913	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs504773	ENSG00000231752.4	EMBP1	-17	6.91e-51	7.33e-44	-0.81	-0.62	Schizophrenia;	chr5:50264656	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1458766	ENSG00000231752.4	EMBP1	-17	6.91e-51	7.33e-44	-0.81	-0.62	Schizophrenia;	chr5:50266457	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs514195	ENSG00000231752.4	EMBP1	-17	6.91e-51	7.33e-44	-0.81	-0.62	Schizophrenia;	chr5:50267123	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs12513730	ENSG00000231752.4	EMBP1	-17	7.11e-51	7.54e-44	-0.81	-0.62	Schizophrenia;	chr5:50302800	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.56	rs2137134	ENSG00000231752.4	EMBP1	17	7.53e-51	7.97e-44	0.81	0.62	Schizophrenia;	chr5:50354188	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.54	rs57137858	ENSG00000231752.4	EMBP1	17	7.53e-51	7.97e-44	0.81	0.62	Schizophrenia;	chr5:50369737	chr1:121519112~121571892:+
THCA	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-17	7.58e-51	8.02e-44	-0.74	-0.62	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
THCA	trans	rs10940346	0.623	rs7736990	ENSG00000231752.4	EMBP1	-16.99	7.85e-51	8.3e-44	-0.81	-0.62	Schizophrenia;	chr5:50300008	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10079897	ENSG00000231752.4	EMBP1	-16.99	7.85e-51	8.3e-44	-0.81	-0.62	Schizophrenia;	chr5:50300032	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs2005573	ENSG00000231752.4	EMBP1	-16.99	7.88e-51	8.33e-44	-0.81	-0.62	Schizophrenia;	chr5:50301614	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs2011540	ENSG00000231752.4	EMBP1	-16.99	7.88e-51	8.33e-44	-0.81	-0.62	Schizophrenia;	chr5:50301634	chr1:121519112~121571892:+
THCA	trans	rs73990293	0.737	rs4531775	ENSG00000234130.2	RP13-88F20.1	16.99	8.23e-51	8.69e-44	1.11	0.62	Clopidogrel active metabolite levels;	chr17:35559919	chrX:93222220~93225015:-
THCA	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-16.98	8.7e-51	9.19e-44	-0.74	-0.62	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
THCA	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-16.98	9.43e-51	9.94e-44	-0.74	-0.62	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
THCA	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-16.97	1.02e-50	1.07e-43	-0.73	-0.62	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
THCA	trans	rs10940346	0.541	rs4865914	ENSG00000231752.4	EMBP1	-16.96	1.09e-50	1.14e-43	-0.82	-0.62	Schizophrenia;	chr5:50173322	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs559096	ENSG00000231752.4	EMBP1	-16.96	1.09e-50	1.14e-43	-0.82	-0.62	Schizophrenia;	chr5:50226512	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.623	rs4865519	ENSG00000231752.4	EMBP1	-16.96	1.11e-50	1.16e-43	-0.81	-0.62	Schizophrenia;	chr5:50293002	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-16.95	1.21e-50	1.26e-43	-0.74	-0.62	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.601	rs526329	ENSG00000231752.4	EMBP1	-16.95	1.29e-50	1.34e-43	-0.81	-0.62	Schizophrenia;	chr5:50276141	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs6868713	ENSG00000231752.4	EMBP1	-16.95	1.29e-50	1.34e-43	-0.81	-0.62	Schizophrenia;	chr5:50276741	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.834	rs13163277	ENSG00000213058.3	RP4-765C7.2	16.93	1.48e-50	1.54e-43	1.01	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr1:178411616~178411972:+
THCA	trans	rs13190036	0.551	rs7732930	ENSG00000217325.2	PRELID1P1	-16.93	1.54e-50	1.59e-43	-0.79	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr6:126643488~126644390:+
THCA	trans	rs10940346	0.601	rs13174293	ENSG00000231752.4	EMBP1	16.93	1.59e-50	1.65e-43	0.81	0.62	Schizophrenia;	chr5:50352191	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4865699	ENSG00000231752.4	EMBP1	-16.92	1.72e-50	1.77e-43	-0.81	-0.62	Schizophrenia;	chr5:50303347	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-16.92	1.74e-50	1.79e-43	-0.75	-0.62	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
THCA	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	16.92	1.77e-50	1.82e-43	0.82	0.62	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	16.92	1.77e-50	1.82e-43	0.82	0.62	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	16.92	1.77e-50	1.82e-43	0.82	0.62	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
THCA	trans	rs10940346	0.601	rs11960276	ENSG00000231752.4	EMBP1	-16.91	1.83e-50	1.88e-43	-0.82	-0.62	Schizophrenia;	chr5:50265194	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6861461	ENSG00000231752.4	EMBP1	16.91	1.88e-50	1.93e-43	0.81	0.62	Schizophrenia;	chr5:50348493	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs13175165	ENSG00000231752.4	EMBP1	-16.91	1.9e-50	1.95e-43	-0.81	-0.62	Schizophrenia;	chr5:50151463	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1674512	ENSG00000231752.4	EMBP1	16.91	1.93e-50	1.98e-43	0.81	0.61	Schizophrenia;	chr5:50268794	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs4379243	ENSG00000231752.4	EMBP1	-16.9	2.18e-50	2.23e-43	-0.81	-0.61	Schizophrenia;	chr5:50149933	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.541	rs10041893	ENSG00000231752.4	EMBP1	16.89	2.21e-50	2.26e-43	0.81	0.61	Schizophrenia;	chr5:50460740	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4865698	ENSG00000231752.4	EMBP1	-16.89	2.22e-50	2.27e-43	-0.81	-0.61	Schizophrenia;	chr5:50303332	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4865700	ENSG00000231752.4	EMBP1	-16.89	2.22e-50	2.27e-43	-0.81	-0.61	Schizophrenia;	chr5:50303862	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs13178993	ENSG00000231752.4	EMBP1	-16.89	2.22e-50	2.27e-43	-0.81	-0.61	Schizophrenia;	chr5:50305256	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.56	rs6892613	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50353678	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6450056	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50356692	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4637546	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50358359	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10073591	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50359010	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.521	rs7730857	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50361516	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs10071725	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50361986	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7732000	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50364779	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs11959569	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50369429	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6450063	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50374147	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10042504	ENSG00000231752.4	EMBP1	16.89	2.41e-50	2.44e-43	0.81	0.61	Schizophrenia;	chr5:50386329	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10054503	ENSG00000231752.4	EMBP1	16.88	2.56e-50	2.59e-43	0.81	0.61	Schizophrenia;	chr5:50326746	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.623	rs6863840	ENSG00000231752.4	EMBP1	16.88	2.56e-50	2.59e-43	0.81	0.61	Schizophrenia;	chr5:50328070	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs6871761	ENSG00000231752.4	EMBP1	16.88	2.56e-50	2.59e-43	0.81	0.61	Schizophrenia;	chr5:50328134	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6877713	ENSG00000231752.4	EMBP1	16.88	2.56e-50	2.59e-43	0.81	0.61	Schizophrenia;	chr5:50329254	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4337857	ENSG00000231752.4	EMBP1	16.88	2.56e-50	2.59e-43	0.81	0.61	Schizophrenia;	chr5:50329735	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs6876902	ENSG00000231752.4	EMBP1	16.88	2.61e-50	2.64e-43	0.81	0.61	Schizophrenia;	chr5:50320934	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.822	rs62382255	ENSG00000213058.3	RP4-765C7.2	16.88	2.63e-50	2.66e-43	1.01	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459154	chr1:178411616~178411972:+
THCA	trans	rs10940346	0.562	rs34601168	ENSG00000231752.4	EMBP1	16.88	2.67e-50	2.69e-43	0.81	0.61	Schizophrenia;	chr5:50330561	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs35740733	ENSG00000231752.4	EMBP1	16.88	2.67e-50	2.69e-43	0.81	0.61	Schizophrenia;	chr5:50330771	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.502	rs77189370	ENSG00000231752.4	EMBP1	16.88	2.67e-50	2.69e-43	0.81	0.61	Schizophrenia;	chr5:50334920	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.54	rs10039622	ENSG00000231752.4	EMBP1	16.88	2.67e-50	2.69e-43	0.81	0.61	Schizophrenia;	chr5:50336720	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10064702	ENSG00000231752.4	EMBP1	16.88	2.67e-50	2.69e-43	0.81	0.61	Schizophrenia;	chr5:50336928	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs13160697	ENSG00000231752.4	EMBP1	16.88	2.67e-50	2.69e-43	0.81	0.61	Schizophrenia;	chr5:50339822	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.56	rs6450107	ENSG00000231752.4	EMBP1	16.87	2.72e-50	2.74e-43	0.81	0.61	Schizophrenia;	chr5:50430069	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs35815956	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50350905	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6450098	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50420076	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs62365896	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50422243	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs58756661	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50436837	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.56	rs16879094	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50442603	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7720960	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50450489	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6863108	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50451450	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.56	rs13180267	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50452300	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs10044979	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50464074	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10045034	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50464323	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.54	rs59940663	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50467345	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs34586987	ENSG00000231752.4	EMBP1	16.87	2.8e-50	2.8e-43	0.81	0.61	Schizophrenia;	chr5:50467574	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.525	rs7728419	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50474238	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4029989	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50474501	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.584	rs10061339	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50475952	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1016620	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50490763	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs2353961	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50491604	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7379514	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50492052	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10755228	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50493498	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs34371354	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50494203	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs55843201	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50494254	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs56251178	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50494837	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.645	rs6450162	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50498547	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7706105	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50501745	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs11948302	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50502317	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10940335	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50502595	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1833900	ENSG00000231752.4	EMBP1	-16.87	2.8e-50	2.8e-43	-0.81	-0.61	Schizophrenia;	chr5:50504668	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs34950042	ENSG00000231752.4	EMBP1	-16.87	2.88e-50	2.87e-43	-0.81	-0.61	Schizophrenia;	chr5:50479299	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs3845167	ENSG00000231752.4	EMBP1	-16.87	2.88e-50	2.87e-43	-0.81	-0.61	Schizophrenia;	chr5:50480297	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.56	rs7293410	ENSG00000231752.4	EMBP1	-16.86	3.09e-50	3.07e-43	-0.81	-0.61	Schizophrenia;	chr5:50163036	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs12332500	ENSG00000231752.4	EMBP1	16.86	3.14e-50	3.11e-43	0.8	0.61	Schizophrenia;	chr5:50349021	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7723480	ENSG00000231752.4	EMBP1	16.86	3.14e-50	3.11e-43	0.8	0.61	Schizophrenia;	chr5:50350324	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs13357429	ENSG00000231752.4	EMBP1	16.86	3.29e-50	3.26e-43	0.81	0.61	Schizophrenia;	chr5:50413616	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs4495185	ENSG00000231752.4	EMBP1	16.86	3.29e-50	3.26e-43	0.81	0.61	Schizophrenia;	chr5:50415453	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.871	rs11745133	ENSG00000213058.3	RP4-765C7.2	16.86	3.29e-50	3.26e-43	1	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr1:178411616~178411972:+
THCA	trans	rs13177918	0.871	rs11745194	ENSG00000213058.3	RP4-765C7.2	16.86	3.29e-50	3.26e-43	1	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr1:178411616~178411972:+
THCA	trans	rs10940346	0.58	rs9292005	ENSG00000231752.4	EMBP1	16.86	3.32e-50	3.29e-43	0.81	0.61	Schizophrenia;	chr5:50430521	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7378969	ENSG00000231752.4	EMBP1	-16.85	3.42e-50	3.38e-43	-0.81	-0.61	Schizophrenia;	chr5:50471925	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1511737	ENSG00000231752.4	EMBP1	-16.85	3.48e-50	3.44e-43	-0.81	-0.61	Schizophrenia;	chr5:50312308	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-16.85	3.51e-50	3.47e-43	-0.75	-0.61	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.601	rs2036902	ENSG00000231752.4	EMBP1	16.85	3.52e-50	3.49e-43	0.81	0.61	Schizophrenia;	chr5:50401098	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7448495	ENSG00000231752.4	EMBP1	-16.85	3.57e-50	3.53e-43	-0.81	-0.61	Schizophrenia;	chr5:50300238	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs62365902	ENSG00000231752.4	EMBP1	16.85	3.58e-50	3.54e-43	0.81	0.61	Schizophrenia;	chr5:50434594	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs9291925	ENSG00000231752.4	EMBP1	16.85	3.71e-50	3.67e-43	0.81	0.61	Schizophrenia;	chr5:50320129	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7722742	ENSG00000231752.4	EMBP1	16.85	3.71e-50	3.67e-43	0.81	0.61	Schizophrenia;	chr5:50320312	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs6449961	ENSG00000231752.4	EMBP1	16.85	3.71e-50	3.67e-43	0.81	0.61	Schizophrenia;	chr5:50320867	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs7705284	ENSG00000231752.4	EMBP1	16.85	3.71e-50	3.67e-43	0.81	0.61	Schizophrenia;	chr5:50325574	chr1:121519112~121571892:+
THCA	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	16.84	3.73e-50	3.68e-43	0.77	0.61	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
THCA	trans	rs10940346	0.56	rs10039233	ENSG00000231752.4	EMBP1	16.84	3.77e-50	3.72e-43	0.81	0.61	Schizophrenia;	chr5:50351630	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs7447926	ENSG00000231752.4	EMBP1	-16.84	3.97e-50	3.92e-43	-0.81	-0.61	Schizophrenia;	chr5:50310902	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10940242	ENSG00000231752.4	EMBP1	16.84	4e-50	3.94e-43	0.81	0.61	Schizophrenia;	chr5:50351018	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs10940336	ENSG00000231752.4	EMBP1	-16.83	4.19e-50	4.12e-43	-0.81	-0.61	Schizophrenia;	chr5:50505020	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.584	rs7293449	ENSG00000231752.4	EMBP1	-16.83	4.32e-50	4.25e-43	-0.81	-0.61	Schizophrenia;	chr5:50259959	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7710841	ENSG00000231752.4	EMBP1	16.83	4.46e-50	4.39e-43	0.81	0.61	Schizophrenia;	chr5:50349986	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7722623	ENSG00000231752.4	EMBP1	16.83	4.46e-50	4.39e-43	0.81	0.61	Schizophrenia;	chr5:50350496	chr1:121519112~121571892:+
THCA	trans	rs9876781	0.874	rs56298324	ENSG00000235912.1	RP1-159A19.3	16.83	4.48e-50	4.4e-43	0.73	0.61	Longevity;	chr3:48393626	chr1:27649419~27649610:+
THCA	trans	rs10940346	0.601	rs579279	ENSG00000231752.4	EMBP1	-16.83	4.57e-50	4.49e-43	-0.81	-0.61	Schizophrenia;	chr5:50277308	chr1:121519112~121571892:+
THCA	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	16.82	4.79e-50	4.71e-43	0.77	0.61	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
THCA	trans	rs1816752	0.669	rs4770699	ENSG00000237917.1	PARP4P1	-16.82	4.94e-50	4.84e-43	-0.75	-0.61	Obesity-related traits;	chr13:24488234	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.54	rs2199089	ENSG00000231752.4	EMBP1	-16.82	4.95e-50	4.84e-43	-0.82	-0.61	Schizophrenia;	chr5:50199332	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1511738	ENSG00000231752.4	EMBP1	-16.82	4.97e-50	4.84e-43	-0.81	-0.61	Schizophrenia;	chr5:50313444	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7446951	ENSG00000231752.4	EMBP1	-16.82	4.97e-50	4.84e-43	-0.81	-0.61	Schizophrenia;	chr5:50314949	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10062032	ENSG00000231752.4	EMBP1	-16.82	4.97e-50	4.84e-43	-0.81	-0.61	Schizophrenia;	chr5:50316138	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10074359	ENSG00000231752.4	EMBP1	-16.82	4.97e-50	4.84e-43	-0.81	-0.61	Schizophrenia;	chr5:50316423	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1606224	ENSG00000231752.4	EMBP1	-16.82	4.97e-50	4.84e-43	-0.81	-0.61	Schizophrenia;	chr5:50317405	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7341010	ENSG00000231752.4	EMBP1	-16.82	4.97e-50	4.84e-43	-0.81	-0.61	Schizophrenia;	chr5:50317811	chr1:121519112~121571892:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	16.81	5.5e-50	5.36e-43	0.78	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
THCA	trans	rs10940346	0.601	rs4865676	ENSG00000231752.4	EMBP1	16.8	6e-50	5.83e-43	0.81	0.61	Schizophrenia;	chr5:50279343	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.679	rs7999480	ENSG00000237917.1	PARP4P1	-16.8	6.12e-50	5.95e-43	-0.78	-0.61	Obesity-related traits;	chr13:24397865	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.601	rs7717982	ENSG00000231752.4	EMBP1	16.8	6.14e-50	5.97e-43	0.81	0.61	Schizophrenia;	chr5:50401488	chr1:121519112~121571892:+
THCA	trans	rs10037055	0.685	rs10039241	ENSG00000217325.2	PRELID1P1	-16.79	6.88e-50	6.68e-43	-0.78	-0.61	Migraine without aura;	chr5:177151071	chr6:126643488~126644390:+
THCA	trans	rs6477998	1	rs6477998	ENSG00000238072.1	RP11-305M3.2	-16.78	7.38e-50	7.15e-43	-0.8	-0.61	Hematology traits;	chr9:113234969	chr7:129410113~129410370:-
THCA	trans	rs7503168	0.558	rs117414856	ENSG00000234130.2	RP13-88F20.1	16.78	7.77e-50	7.51e-43	1.11	0.61	Plateletcrit;	chr17:35604168	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	16.78	7.77e-50	7.51e-43	1.11	0.61	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
THCA	trans	rs10940346	0.601	rs12697055	ENSG00000231752.4	EMBP1	16.77	7.81e-50	7.55e-43	0.81	0.61	Schizophrenia;	chr5:50317827	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	16.77	8.32e-50	8.03e-43	0.79	0.61	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
THCA	trans	rs10940346	0.601	rs4398636	ENSG00000231752.4	EMBP1	16.76	9.41e-50	9.07e-43	0.81	0.61	Schizophrenia;	chr5:50391957	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	16.74	1.11e-49	1.07e-42	0.87	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	16.74	1.12e-49	1.07e-42	0.88	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	16.74	1.12e-49	1.07e-42	0.88	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
THCA	trans	rs10940346	0.601	rs4145844	ENSG00000231752.4	EMBP1	-16.74	1.13e-49	1.08e-42	-0.81	-0.61	Schizophrenia;	chr5:50478019	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	16.73	1.2e-49	1.14e-42	0.82	0.61	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
THCA	trans	rs13190036	0.551	rs11955537	ENSG00000217325.2	PRELID1P1	-16.73	1.21e-49	1.15e-42	-0.78	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.636	rs13166688	ENSG00000217325.2	PRELID1P1	-16.73	1.21e-49	1.15e-42	-0.78	-0.61	Migraine without aura;	chr5:177156965	chr6:126643488~126644390:+
THCA	trans	rs4276421	0.904	rs4388219	ENSG00000231752.4	EMBP1	16.73	1.26e-49	1.21e-42	0.78	0.61	P wave duration;	chr5:45780648	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.505	rs2219453	ENSG00000231752.4	EMBP1	-16.7	1.7e-49	1.62e-42	-0.82	-0.61	Schizophrenia;	chr5:50212774	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10940075	ENSG00000231752.4	EMBP1	-16.7	1.75e-49	1.67e-42	-0.81	-0.61	Schizophrenia;	chr5:50304547	chr1:121519112~121571892:+
THCA	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	16.69	1.98e-49	1.89e-42	1.66	0.61	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
THCA	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-16.68	2.05e-49	1.96e-42	-0.73	-0.61	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
THCA	trans	rs3947	0.789	rs9009	ENSG00000229857.1	RP11-159H20.3	-16.67	2.32e-49	2.21e-42	-0.82	-0.61	Blood protein levels;	chr8:11844497	chr9:76992099~76993108:+
THCA	trans	rs3947	0.906	rs709822	ENSG00000229857.1	RP11-159H20.3	16.67	2.41e-49	2.29e-42	0.85	0.61	Blood protein levels;	chr8:11844804	chr9:76992099~76993108:+
THCA	trans	rs10940346	0.56	rs10073530	ENSG00000231752.4	EMBP1	16.65	2.82e-49	2.68e-42	0.81	0.61	Schizophrenia;	chr5:50358823	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs567248	ENSG00000231752.4	EMBP1	-16.64	3.26e-49	3.1e-42	-0.81	-0.61	Schizophrenia;	chr5:50277650	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.519	rs10940514	ENSG00000231752.4	EMBP1	-16.63	3.56e-49	3.38e-42	-0.81	-0.61	Schizophrenia;	chr5:50146166	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.509	rs10042628	ENSG00000231752.4	EMBP1	16.63	3.71e-49	3.52e-42	0.83	0.61	P wave duration;	chr5:46004627	chr1:121519112~121571892:+
THCA	trans	rs10037055	1	rs10037055	ENSG00000217325.2	PRELID1P1	-16.62	4.03e-49	3.82e-42	-0.77	-0.61	Migraine without aura;	chr5:177264278	chr6:126643488~126644390:+
THCA	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	16.62	4.12e-49	3.91e-42	0.86	0.61	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	16.62	4.12e-49	3.91e-42	0.86	0.61	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	16.62	4.12e-49	3.91e-42	0.86	0.61	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
THCA	trans	rs10940346	0.601	rs6892142	ENSG00000231752.4	EMBP1	-16.6	4.77e-49	4.51e-42	-0.81	-0.61	Schizophrenia;	chr5:50276518	chr1:121519112~121571892:+
THCA	trans	rs10037055	1	rs6886255	ENSG00000217325.2	PRELID1P1	16.6	4.82e-49	4.56e-42	0.77	0.61	Migraine without aura;	chr5:177291360	chr6:126643488~126644390:+
THCA	trans	rs10940346	0.58	rs9688065	ENSG00000231752.4	EMBP1	-16.6	4.9e-49	4.63e-42	-0.81	-0.61	Schizophrenia;	chr5:50147444	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs1039798	ENSG00000231752.4	EMBP1	16.6	5e-49	4.72e-42	0.81	0.61	Schizophrenia;	chr5:50355909	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs10072182	ENSG00000231752.4	EMBP1	16.6	5e-49	4.72e-42	0.81	0.61	Schizophrenia;	chr5:50356818	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs7442762	ENSG00000231752.4	EMBP1	16.6	5e-49	4.72e-42	0.81	0.61	Schizophrenia;	chr5:50358137	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	16.59	5.2e-49	4.91e-42	0.89	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
THCA	trans	rs4276421	0.571	rs59968174	ENSG00000231752.4	EMBP1	16.59	5.28e-49	4.99e-42	0.82	0.61	P wave duration;	chr5:46027939	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-16.58	6.06e-49	5.71e-42	-0.79	-0.61	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
THCA	trans	rs9611565	0.572	rs139569	ENSG00000268568.1	AC007228.9	-16.57	7.07e-49	6.66e-42	-0.76	-0.61	Vitiligo;	chr22:41815137	chr19:56672574~56673901:-
THCA	trans	rs7503168	0.558	rs75787089	ENSG00000234130.2	RP13-88F20.1	16.56	7.1e-49	6.69e-42	1.11	0.61	Plateletcrit;	chr17:35598042	chrX:93222220~93225015:-
THCA	trans	rs13190036	0.551	rs7710269	ENSG00000217325.2	PRELID1P1	-16.56	7.2e-49	6.78e-42	-0.78	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr6:126643488~126644390:+
THCA	trans	rs13190036	0.515	rs2878686	ENSG00000217325.2	PRELID1P1	-16.56	7.2e-49	6.78e-42	-0.78	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr6:126643488~126644390:+
THCA	trans	rs10940346	0.601	rs16879414	ENSG00000231752.4	EMBP1	16.56	7.53e-49	7.09e-42	0.81	0.61	Schizophrenia;	chr5:50337969	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.668	rs6884426	ENSG00000231752.4	EMBP1	-16.55	7.85e-49	7.39e-42	-0.81	-0.61	Schizophrenia;	chr5:50492782	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.52	rs7293339	ENSG00000231752.4	EMBP1	-16.54	9.14e-49	8.59e-42	-0.81	-0.61	Schizophrenia;	chr5:50207465	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.607	rs8188210	ENSG00000231752.4	EMBP1	-16.53	9.72e-49	9.12e-42	-0.81	-0.61	Schizophrenia;	chr5:50211664	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs10051529	ENSG00000231752.4	EMBP1	-16.53	9.94e-49	9.32e-42	-0.8	-0.61	Schizophrenia;	chr5:50303103	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.562	rs13182357	ENSG00000231752.4	EMBP1	16.53	1.06e-48	9.97e-42	0.81	0.61	Schizophrenia;	chr5:50404060	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6860503	ENSG00000231752.4	EMBP1	16.52	1.1e-48	1.03e-41	0.81	0.61	Schizophrenia;	chr5:50446340	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs13172932	ENSG00000231752.4	EMBP1	16.51	1.2e-48	1.12e-41	0.8	0.61	Schizophrenia;	chr5:50345364	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6868380	ENSG00000231752.4	EMBP1	16.51	1.21e-48	1.13e-41	0.8	0.61	Schizophrenia;	chr5:50328473	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs34185098	ENSG00000231752.4	EMBP1	16.51	1.28e-48	1.19e-41	0.8	0.61	Schizophrenia;	chr5:50330100	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs34616519	ENSG00000231752.4	EMBP1	16.51	1.3e-48	1.21e-41	0.81	0.61	Schizophrenia;	chr5:50353638	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.54	rs12109228	ENSG00000231752.4	EMBP1	16.51	1.3e-48	1.21e-41	0.81	0.61	Schizophrenia;	chr5:50383135	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	16.51	1.3e-48	1.21e-41	0.76	0.61	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
THCA	trans	rs10940346	0.601	rs1841104	ENSG00000231752.4	EMBP1	-16.51	1.32e-48	1.22e-41	-0.81	-0.61	Schizophrenia;	chr5:50263930	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.58	rs28528780	ENSG00000231752.4	EMBP1	16.5	1.41e-48	1.31e-41	0.81	0.61	Schizophrenia;	chr5:50441293	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-16.5	1.45e-48	1.35e-41	-0.74	-0.61	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
THCA	trans	rs10940346	0.524	rs35601537	ENSG00000231752.4	EMBP1	-16.48	1.67e-48	1.54e-41	-0.8	-0.61	Schizophrenia;	chr5:50509460	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.54	rs34645496	ENSG00000231752.4	EMBP1	16.48	1.67e-48	1.55e-41	0.8	0.61	Schizophrenia;	chr5:50322419	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs35330444	ENSG00000231752.4	EMBP1	16.48	1.67e-48	1.55e-41	0.8	0.61	Schizophrenia;	chr5:50322606	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.601	rs6875734	ENSG00000231752.4	EMBP1	16.48	1.67e-48	1.55e-41	0.8	0.61	Schizophrenia;	chr5:50323203	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-16.47	1.85e-48	1.71e-41	-0.78	-0.61	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-16.47	1.85e-48	1.71e-41	-0.78	-0.61	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
THCA	trans	rs10940346	0.601	rs7709906	ENSG00000231752.4	EMBP1	16.47	1.92e-48	1.78e-41	0.8	0.6	Schizophrenia;	chr5:50299936	chr1:121519112~121571892:+
THCA	trans	rs7554547	0.716	rs34954501	ENSG00000261819.1	RP11-680G24.4	16.47	1.95e-48	1.81e-41	0.82	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11878146	chr16:14988259~14990160:-
THCA	trans	rs10940346	0.562	rs7380318	ENSG00000231752.4	EMBP1	-16.47	1.96e-48	1.81e-41	-0.8	-0.6	Schizophrenia;	chr5:50510557	chr1:121519112~121571892:+
THCA	trans	rs13190036	0.551	rs9313751	ENSG00000217325.2	PRELID1P1	-16.47	1.97e-48	1.82e-41	-0.78	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr6:126643488~126644390:+
THCA	trans	rs10940346	0.601	rs12651834	ENSG00000231752.4	EMBP1	16.46	2.04e-48	1.89e-41	0.8	0.6	Schizophrenia;	chr5:50351199	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	16.46	2.12e-48	1.96e-41	0.81	0.6	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
THCA	trans	rs10940346	0.601	rs10042601	ENSG00000231752.4	EMBP1	-16.45	2.31e-48	2.13e-41	-0.8	-0.6	Schizophrenia;	chr5:50315248	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-16.44	2.51e-48	2.32e-41	-0.76	-0.6	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
THCA	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	16.43	2.96e-48	2.72e-41	1.12	0.6	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
THCA	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	16.43	2.96e-48	2.72e-41	1.12	0.6	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000234513.1	AC073072.7	16.4	4.19e-48	3.83e-41	0.74	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:22773646~22773993:-
THCA	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	16.39	4.3e-48	3.93e-41	0.83	0.6	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
THCA	trans	rs13190036	0.551	rs11957608	ENSG00000217325.2	PRELID1P1	-16.38	5.09e-48	4.63e-41	-0.77	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr6:126643488~126644390:+
THCA	trans	rs4276421	0.509	rs4504391	ENSG00000231752.4	EMBP1	16.37	5.34e-48	4.86e-41	0.82	0.6	P wave duration;	chr5:46035678	chr1:121519112~121571892:+
THCA	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-16.28	1.42e-47	1.28e-40	-0.74	-0.6	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
THCA	trans	rs1816752	0.603	rs9551099	ENSG00000237917.1	PARP4P1	-16.27	1.49e-47	1.34e-40	-0.76	-0.6	Obesity-related traits;	chr13:24410978	chrY:26594851~26634652:-
THCA	trans	rs4276421	0.593	rs7448901	ENSG00000231752.4	EMBP1	16.27	1.52e-47	1.36e-40	0.82	0.6	P wave duration;	chr5:45941482	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.615	rs7445658	ENSG00000231752.4	EMBP1	16.27	1.52e-47	1.36e-40	0.82	0.6	P wave duration;	chr5:45941513	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs10076636	ENSG00000231752.4	EMBP1	16.27	1.52e-47	1.36e-40	0.82	0.6	P wave duration;	chr5:45942052	chr1:121519112~121571892:+
THCA	trans	rs916888	0.779	rs199526	ENSG00000214425.5	LRRC37A4P	16.26	1.66e-47	1.49e-40	0.77	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45506741~45550335:-
THCA	trans	rs10940346	0.601	rs5011669	ENSG00000231752.4	EMBP1	-16.26	1.74e-47	1.56e-40	-0.81	-0.6	Schizophrenia;	chr5:50311788	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.519	rs7293422	ENSG00000231752.4	EMBP1	-16.23	2.29e-47	2.05e-40	-0.8	-0.6	Schizophrenia;	chr5:50146010	chr1:121519112~121571892:+
THCA	trans	rs9467773	0.935	rs11752946	ENSG00000242375.1	RP11-498P14.3	16.2	3.11e-47	2.78e-40	0.83	0.6	Intelligence (multi-trait analysis);	chr6:26560136	chr9:97195351~97197687:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	16.2	3.32e-47	2.97e-40	0.76	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
THCA	trans	rs10940346	0.601	rs1344339	ENSG00000231752.4	EMBP1	-16.19	3.62e-47	3.23e-40	-0.79	-0.6	Schizophrenia;	chr5:50327987	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	16.18	3.87e-47	3.45e-40	0.88	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
THCA	trans	rs4276421	0.571	rs6414908	ENSG00000231752.4	EMBP1	16.18	3.95e-47	3.52e-40	0.8	0.6	P wave duration;	chr5:45879332	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-16.15	5.57e-47	4.95e-40	-0.75	-0.6	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-16.15	5.57e-47	4.95e-40	-0.75	-0.6	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
THCA	trans	rs9611519	0.78	rs1535048	ENSG00000268568.1	AC007228.9	-16.15	5.72e-47	5.08e-40	-0.7	-0.6	Neuroticism;	chr22:41288089	chr19:56672574~56673901:-
THCA	trans	rs13190036	0.748	rs28395268	ENSG00000217325.2	PRELID1P1	16.14	5.96e-47	5.3e-40	0.78	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr6:126643488~126644390:+
THCA	trans	rs10940346	0.54	rs12521033	ENSG00000231752.4	EMBP1	-16.14	6.21e-47	5.51e-40	-0.79	-0.6	Schizophrenia;	chr5:50145974	chr1:121519112~121571892:+
THCA	trans	rs10037055	0.947	rs10063803	ENSG00000217325.2	PRELID1P1	16.13	6.86e-47	6.08e-40	0.76	0.6	Migraine without aura;	chr5:177240326	chr6:126643488~126644390:+
THCA	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	16.13	7.02e-47	6.23e-40	0.8	0.6	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
THCA	trans	rs10940346	0.601	rs3849669	ENSG00000231752.4	EMBP1	16.11	8.33e-47	7.38e-40	0.79	0.6	Schizophrenia;	chr5:50365710	chr1:121519112~121571892:+
THCA	trans	rs10242455	0.557	rs73403272	ENSG00000228834.1	RP11-249L21.4	16.11	8.44e-47	7.48e-40	1.62	0.6	Blood metabolite levels;	chr7:99536585	chr6:108907615~108907873:-
THCA	trans	rs4240897	0.561	rs12043045	ENSG00000261819.1	RP11-680G24.4	16.08	1.09e-46	9.64e-40	0.79	0.6	Tuberculosis;	chr1:11900294	chr16:14988259~14990160:-
THCA	trans	rs8175379	0.521	rs8175430	ENSG00000231752.4	EMBP1	-16.08	1.1e-46	9.67e-40	-0.79	-0.6	Interleukin-7 levels;	chr5:46305095	chr1:121519112~121571892:+
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	16.08	1.14e-46	1e-39	0.75	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
THCA	trans	rs4240897	0.544	rs7542773	ENSG00000261819.1	RP11-680G24.4	16.07	1.2e-46	1.06e-39	0.79	0.6	Tuberculosis;	chr1:11901073	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.508	rs7520898	ENSG00000261819.1	RP11-680G24.4	16.07	1.2e-46	1.06e-39	0.79	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11901078	chr16:14988259~14990160:-
THCA	trans	rs10242455	0.702	rs1045012	ENSG00000228834.1	RP11-249L21.4	16.05	1.51e-46	1.33e-39	1.64	0.6	Blood metabolite levels;	chr7:99386731	chr6:108907615~108907873:-
THCA	trans	rs7121616	0.961	rs11218976	ENSG00000234176.1	HSPA8P1	16.05	1.53e-46	1.34e-39	0.75	0.6	Breast cancer;	chr11:123090950	chrX:121203182~121205014:-
THCA	trans	rs10242455	0.702	rs10251282	ENSG00000228834.1	RP11-249L21.4	16.05	1.53e-46	1.34e-39	1.64	0.6	Blood metabolite levels;	chr7:99392613	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs28460612	ENSG00000228834.1	RP11-249L21.4	16.05	1.53e-46	1.34e-39	1.64	0.6	Blood metabolite levels;	chr7:99395582	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs28753399	ENSG00000228834.1	RP11-249L21.4	16.05	1.53e-46	1.34e-39	1.64	0.6	Blood metabolite levels;	chr7:99399636	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs28668326	ENSG00000228834.1	RP11-249L21.4	16.05	1.53e-46	1.34e-39	1.64	0.6	Blood metabolite levels;	chr7:99400530	chr6:108907615~108907873:-
THCA	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	16.03	1.97e-46	1.72e-39	0.87	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
THCA	trans	rs7121616	0.92	rs7109445	ENSG00000234176.1	HSPA8P1	16.01	2.43e-46	2.12e-39	0.75	0.59	Breast cancer;	chr11:123094779	chrX:121203182~121205014:-
THCA	trans	rs4276421	0.507	rs7293474	ENSG00000231752.4	EMBP1	-15.99	2.82e-46	2.46e-39	-0.79	-0.59	P wave duration;	chr5:46286705	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	15.99	2.95e-46	2.57e-39	0.8	0.59	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
THCA	trans	rs7121616	1	rs7121616	ENSG00000234176.1	HSPA8P1	15.98	3.19e-46	2.78e-39	0.75	0.59	Breast cancer;	chr11:123095918	chrX:121203182~121205014:-
THCA	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	15.97	3.41e-46	2.97e-39	0.8	0.59	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
THCA	trans	rs9467773	0.935	rs1884947	ENSG00000242375.1	RP11-498P14.3	15.96	3.89e-46	3.38e-39	0.82	0.59	Intelligence (multi-trait analysis);	chr6:26553045	chr9:97195351~97197687:-
THCA	trans	rs10940346	0.58	rs12188257	ENSG00000231752.4	EMBP1	-15.94	4.8e-46	4.16e-39	-0.79	-0.59	Schizophrenia;	chr5:50147242	chr1:121519112~121571892:+
THCA	trans	rs7121616	0.96	rs7122306	ENSG00000234176.1	HSPA8P1	15.94	4.98e-46	4.31e-39	0.75	0.59	Breast cancer;	chr11:123096254	chrX:121203182~121205014:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	15.93	5.48e-46	4.74e-39	0.74	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
THCA	trans	rs10940346	0.542	rs2219452	ENSG00000231752.4	EMBP1	-15.92	5.85e-46	5.06e-39	-0.8	-0.59	Schizophrenia;	chr5:50209813	chr1:121519112~121571892:+
THCA	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	15.92	5.98e-46	5.18e-39	0.73	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
THCA	trans	rs9611565	0.506	rs7364221	ENSG00000268568.1	AC007228.9	-15.91	6.5e-46	5.62e-39	-0.69	-0.59	Vitiligo;	chr22:41254186	chr19:56672574~56673901:-
THCA	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	15.9	7.33e-46	6.33e-39	0.8	0.59	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	15.9	7.33e-46	6.33e-39	0.8	0.59	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	15.89	8.53e-46	7.36e-39	0.8	0.59	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
THCA	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-15.88	8.6e-46	7.42e-39	-0.84	-0.59	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
THCA	trans	rs10242455	0.702	rs7794068	ENSG00000228834.1	RP11-249L21.4	15.86	1.11e-45	9.55e-39	1.59	0.59	Blood metabolite levels;	chr7:99549250	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs17161726	ENSG00000228834.1	RP11-249L21.4	15.85	1.22e-45	1.05e-38	1.61	0.59	Blood metabolite levels;	chr7:99410772	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs73397447	ENSG00000228834.1	RP11-249L21.4	15.85	1.22e-45	1.05e-38	1.61	0.59	Blood metabolite levels;	chr7:99413326	chr6:108907615~108907873:-
THCA	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	15.85	1.28e-45	1.1e-38	0.94	0.59	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
THCA	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	15.84	1.3e-45	1.12e-38	0.79	0.59	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000235459.5	RPS26P31	15.83	1.53e-45	1.31e-38	0.73	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:122681315~122681662:+
THCA	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	15.8	1.98e-45	1.7e-38	0.79	0.59	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
THCA	trans	rs7730934	1	rs11742271	ENSG00000227018.1	IL6STP1	15.8	2.07e-45	1.77e-38	0.97	0.59	Blood protein levels;	chr5:55967454	chr17:15783288~15784307:+
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	15.8	2.08e-45	1.77e-38	0.73	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
THCA	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	15.79	2.36e-45	2.01e-38	0.8	0.59	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	15.79	2.36e-45	2.01e-38	0.8	0.59	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
THCA	trans	rs7730934	1	rs2408157	ENSG00000227018.1	IL6STP1	15.78	2.41e-45	2.06e-38	0.92	0.59	Blood protein levels;	chr5:55974940	chr17:15783288~15784307:+
THCA	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	15.78	2.65e-45	2.26e-38	0.79	0.59	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	15.78	2.67e-45	2.28e-38	0.72	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
THCA	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	15.75	3.34e-45	2.84e-38	0.71	0.59	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
THCA	trans	rs9611565	0.614	rs4822053	ENSG00000268568.1	AC007228.9	-15.75	3.46e-45	2.94e-38	-0.74	-0.59	Vitiligo;	chr22:41816932	chr19:56672574~56673901:-
THCA	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	15.75	3.55e-45	3.02e-38	0.79	0.59	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-15.72	4.79e-45	4.07e-38	-0.71	-0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
THCA	trans	rs10242455	0.702	rs58348977	ENSG00000228834.1	RP11-249L21.4	15.71	5.41e-45	4.59e-38	1.7	0.59	Blood metabolite levels;	chr7:99590391	chr6:108907615~108907873:-
THCA	trans	rs9467773	0.933	rs35355150	ENSG00000242375.1	RP11-498P14.3	15.7	5.59e-45	4.74e-38	0.83	0.59	Intelligence (multi-trait analysis);	chr6:26525811	chr9:97195351~97197687:-
THCA	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	15.69	6.35e-45	5.37e-38	0.79	0.59	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
THCA	trans	rs13177918	0.798	rs12516161	ENSG00000224114.1	RP11-343H5.4	15.69	6.73e-45	5.69e-38	0.96	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:206695837~206696269:-
THCA	trans	rs12709013	0.636	rs1646256	ENSG00000230849.2	GOT2P2	15.66	8.64e-45	7.28e-38	0.76	0.59	Blood metabolite ratios;	chr16:58712114	chr1:173141100~173142350:-
THCA	trans	rs13177918	0.834	rs13163277	ENSG00000224114.1	RP11-343H5.4	15.66	8.87e-45	7.47e-38	0.96	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr1:206695837~206696269:-
THCA	trans	rs4276421	0.638	rs10061699	ENSG00000231752.4	EMBP1	15.65	9.53e-45	8.03e-38	0.79	0.59	P wave duration;	chr5:45864788	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.638	rs4282323	ENSG00000231752.4	EMBP1	15.65	9.53e-45	8.03e-38	0.79	0.59	P wave duration;	chr5:45865241	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.638	rs4283798	ENSG00000231752.4	EMBP1	15.65	9.53e-45	8.03e-38	0.79	0.59	P wave duration;	chr5:45866041	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-15.65	9.83e-45	8.27e-38	-0.74	-0.59	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
THCA	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	15.65	1.02e-44	8.59e-38	0.77	0.59	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
THCA	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-15.63	1.2e-44	1.01e-37	-0.73	-0.58	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
THCA	trans	rs13177918	0.822	rs62382255	ENSG00000224114.1	RP11-343H5.4	15.63	1.21e-44	1.02e-37	0.96	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459154	chr1:206695837~206696269:-
THCA	trans	rs7730934	1	rs6875155	ENSG00000227018.1	IL6STP1	-15.61	1.48e-44	1.24e-37	-0.96	-0.58	Blood protein levels;	chr5:55975226	chr17:15783288~15784307:+
THCA	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	15.57	2.13e-44	1.77e-37	0.79	0.58	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
THCA	trans	rs4276421	0.638	rs6895453	ENSG00000231752.4	EMBP1	15.56	2.45e-44	2.04e-37	0.78	0.58	P wave duration;	chr5:45850134	chr1:121519112~121571892:+
THCA	trans	rs9611565	0.571	rs7364123	ENSG00000268568.1	AC007228.9	-15.56	2.49e-44	2.07e-37	-0.74	-0.58	Vitiligo;	chr22:41820322	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.871	rs11745133	ENSG00000224114.1	RP11-343H5.4	15.55	2.69e-44	2.23e-37	0.95	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr1:206695837~206696269:-
THCA	trans	rs13177918	0.871	rs11745194	ENSG00000224114.1	RP11-343H5.4	15.55	2.69e-44	2.23e-37	0.95	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr1:206695837~206696269:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-15.55	2.79e-44	2.32e-37	-0.74	-0.58	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
THCA	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-15.55	2.79e-44	2.32e-37	-0.74	-0.58	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
THCA	trans	rs10242455	0.571	rs56167514	ENSG00000228834.1	RP11-249L21.4	15.54	2.91e-44	2.42e-37	1.58	0.58	Blood metabolite levels;	chr7:99563724	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.571	rs7805661	ENSG00000228834.1	RP11-249L21.4	15.54	2.91e-44	2.42e-37	1.58	0.58	Blood metabolite levels;	chr7:99573899	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs917152	ENSG00000228834.1	RP11-249L21.4	15.53	3.34e-44	2.77e-37	1.61	0.58	Blood metabolite levels;	chr7:99406874	chr6:108907615~108907873:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	15.51	4.16e-44	3.44e-37	0.72	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
THCA	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	15.5	4.36e-44	3.6e-37	0.76	0.58	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
THCA	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	15.49	4.85e-44	4e-37	0.91	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
THCA	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	15.49	4.86e-44	4.01e-37	0.77	0.58	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	15.49	4.86e-44	4.01e-37	0.77	0.58	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	15.49	4.86e-44	4.01e-37	0.77	0.58	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	15.49	4.86e-44	4.01e-37	0.77	0.58	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	15.49	4.86e-44	4.01e-37	0.77	0.58	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	15.49	4.86e-44	4.01e-37	0.77	0.58	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	15.48	5.76e-44	4.73e-37	0.76	0.58	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
THCA	trans	rs4240897	0.548	rs10746496	ENSG00000261819.1	RP11-680G24.4	15.46	6.81e-44	5.59e-37	0.76	0.58	Tuberculosis;	chr1:11904090	chr16:14988259~14990160:-
THCA	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	15.43	9.83e-44	8.03e-37	0.77	0.58	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	15.43	9.83e-44	8.03e-37	0.77	0.58	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-15.43	9.88e-44	8.07e-37	-0.77	-0.58	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-15.41	1.16e-43	9.49e-37	-0.72	-0.58	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
THCA	trans	rs10940346	0.601	rs1033108	ENSG00000231752.4	EMBP1	15.39	1.4e-43	1.14e-36	0.78	0.58	Schizophrenia;	chr5:50327764	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	15.39	1.49e-43	1.21e-36	0.76	0.58	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	15.39	1.49e-43	1.21e-36	0.76	0.58	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
THCA	trans	rs55665837	0.778	rs11023212	ENSG00000236360.2	RP11-334A14.2	15.39	1.49e-43	1.21e-36	0.8	0.58	Vitamin D levels;	chr11:14410163	chr1:52993201~52993702:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-15.38	1.51e-43	1.23e-36	-0.71	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
THCA	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	15.36	1.87e-43	1.52e-36	0.76	0.58	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	15.36	1.87e-43	1.52e-36	0.76	0.58	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	15.36	1.87e-43	1.52e-36	0.76	0.58	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
THCA	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	15.36	1.89e-43	1.53e-36	0.86	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
THCA	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	15.36	1.96e-43	1.59e-36	0.76	0.58	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
THCA	trans	rs7730934	1	rs6894414	ENSG00000227018.1	IL6STP1	15.36	1.98e-43	1.61e-36	0.96	0.58	Blood protein levels;	chr5:55956667	chr17:15783288~15784307:+
THCA	trans	rs26067	0.643	rs693082	ENSG00000231752.4	EMBP1	15.35	2.1e-43	1.7e-36	0.79	0.58	Breast cancer;	chr5:50808537	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	15.34	2.38e-43	1.92e-36	0.78	0.58	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
THCA	trans	rs7730934	1	rs11739016	ENSG00000227018.1	IL6STP1	15.34	2.45e-43	1.98e-36	0.96	0.58	Blood protein levels;	chr5:55967545	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs11741953	ENSG00000227018.1	IL6STP1	15.34	2.45e-43	1.98e-36	0.96	0.58	Blood protein levels;	chr5:55971986	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs6450357	ENSG00000227018.1	IL6STP1	15.34	2.45e-43	1.98e-36	0.96	0.58	Blood protein levels;	chr5:55974168	chr17:15783288~15784307:+
THCA	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	15.33	2.61e-43	2.11e-36	0.76	0.58	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	15.32	3.02e-43	2.44e-36	0.76	0.58	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	15.32	3.02e-43	2.44e-36	0.76	0.58	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	15.3	3.41e-43	2.75e-36	0.76	0.58	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
THCA	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	15.3	3.58e-43	2.89e-36	0.9	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
THCA	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	15.29	3.92e-43	3.14e-36	0.76	0.58	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	15.29	4.06e-43	3.26e-36	0.77	0.58	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	15.28	4.47e-43	3.58e-36	0.76	0.58	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
THCA	trans	rs7730934	1	rs7726239	ENSG00000227018.1	IL6STP1	15.27	4.63e-43	3.71e-36	0.96	0.58	Blood protein levels;	chr5:55999478	chr17:15783288~15784307:+
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	15.27	4.7e-43	3.76e-36	0.71	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
THCA	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	15.27	4.76e-43	3.81e-36	0.76	0.58	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	15.27	5.02e-43	4.01e-36	0.77	0.58	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	15.26	5.35e-43	4.28e-36	0.75	0.58	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	15.26	5.35e-43	4.28e-36	0.75	0.58	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
THCA	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-15.25	5.7e-43	4.55e-36	-0.79	-0.58	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
THCA	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	15.24	6.76e-43	5.38e-36	0.76	0.58	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	15.23	7.21e-43	5.74e-36	0.76	0.57	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
THCA	trans	rs26067	0.689	rs152839	ENSG00000231752.4	EMBP1	-15.22	8.3e-43	6.59e-36	-0.79	-0.57	Breast cancer;	chr5:50849432	chr1:121519112~121571892:+
THCA	trans	rs10037055	0.741	rs4976640	ENSG00000217325.2	PRELID1P1	-15.21	8.59e-43	6.82e-36	-0.72	-0.57	Migraine without aura;	chr5:177125006	chr6:126643488~126644390:+
THCA	trans	rs928391	0.572	rs11264548	ENSG00000227183.3	HDGFP1	-15.21	9.04e-43	7.17e-36	-0.8	-0.57	Platelet count;	chr1:156779339	chrX:131646639~131646890:+
THCA	trans	rs10242455	0.702	rs57832867	ENSG00000228834.1	RP11-249L21.4	15.21	9.16e-43	7.27e-36	1.58	0.57	Blood metabolite levels;	chr7:99368773	chr6:108907615~108907873:-
THCA	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	15.21	9.36e-43	7.43e-36	0.85	0.57	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
THCA	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	15.2	1.01e-42	8e-36	0.75	0.57	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
THCA	trans	rs7730934	1	rs2228043	ENSG00000227018.1	IL6STP1	15.18	1.21e-42	9.62e-36	0.88	0.57	Blood protein levels;	chr5:55956103	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs10471960	ENSG00000227018.1	IL6STP1	15.16	1.43e-42	1.13e-35	0.9	0.57	Blood protein levels;	chr5:55940546	chr17:15783288~15784307:+
THCA	trans	rs7730934	0.892	rs11745285	ENSG00000227018.1	IL6STP1	15.16	1.43e-42	1.13e-35	0.9	0.57	Blood protein levels;	chr5:55967513	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs2228044	ENSG00000227018.1	IL6STP1	15.16	1.43e-42	1.13e-35	0.9	0.57	Blood protein levels;	chr5:55968325	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs7730934	ENSG00000227018.1	IL6STP1	15.16	1.43e-42	1.13e-35	0.9	0.57	Blood protein levels;	chr5:55970684	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs6450358	ENSG00000227018.1	IL6STP1	15.16	1.43e-42	1.13e-35	0.9	0.57	Blood protein levels;	chr5:55974176	chr17:15783288~15784307:+
THCA	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-15.16	1.49e-42	1.18e-35	-0.79	-0.57	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	15.14	1.85e-42	1.46e-35	0.72	0.57	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
THCA	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	15.14	1.87e-42	1.48e-35	0.76	0.57	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
THCA	trans	rs10242455	0.702	rs17161700	ENSG00000228834.1	RP11-249L21.4	15.12	2.25e-42	1.77e-35	1.64	0.57	Blood metabolite levels;	chr7:99379444	chr6:108907615~108907873:-
THCA	trans	rs4276421	0.577	rs10054424	ENSG00000231752.4	EMBP1	15.12	2.26e-42	1.77e-35	0.76	0.57	P wave duration;	chr5:45748769	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	15.12	2.35e-42	1.85e-35	0.76	0.57	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	15.12	2.35e-42	1.85e-35	0.76	0.57	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
THCA	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	15.11	2.44e-42	1.91e-35	0.75	0.57	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
THCA	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	15.11	2.44e-42	1.91e-35	0.75	0.57	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
THCA	trans	rs3947	0.653	rs1293296	ENSG00000229857.1	RP11-159H20.3	15.1	2.64e-42	2.07e-35	0.83	0.57	Blood protein levels;	chr8:11853648	chr9:76992099~76993108:+
THCA	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-15.09	3.11e-42	2.42e-35	-0.79	-0.57	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
THCA	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	15.08	3.28e-42	2.56e-35	0.84	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
THCA	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-15.07	3.92e-42	3.05e-35	-0.79	-0.57	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
THCA	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-15.02	6.31e-42	4.88e-35	-0.9	-0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
THCA	trans	rs10037055	0.853	rs10036193	ENSG00000217325.2	PRELID1P1	-15.02	6.54e-42	5.05e-35	-0.71	-0.57	Migraine without aura;	chr5:177141519	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.853	rs9885210	ENSG00000217325.2	PRELID1P1	-15.02	6.54e-42	5.05e-35	-0.71	-0.57	Migraine without aura;	chr5:177142187	chr6:126643488~126644390:+
THCA	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-15.01	6.64e-42	5.13e-35	-0.79	-0.57	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
THCA	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	15.01	6.87e-42	5.3e-35	0.83	0.57	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
THCA	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	15	7.79e-42	6e-35	0.75	0.57	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
THCA	trans	rs4276421	0.53	rs13356313	ENSG00000231752.4	EMBP1	14.99	8.34e-42	6.42e-35	0.78	0.57	P wave duration;	chr5:45963787	chr1:121519112~121571892:+
THCA	trans	rs10037055	0.812	rs11949435	ENSG00000217325.2	PRELID1P1	14.99	8.44e-42	6.49e-35	0.71	0.57	Migraine without aura;	chr5:177287931	chr6:126643488~126644390:+
THCA	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-14.99	8.71e-42	6.69e-35	-0.66	-0.57	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
THCA	trans	rs10037055	0.853	rs12660023	ENSG00000217325.2	PRELID1P1	14.99	8.88e-42	6.82e-35	0.7	0.57	Migraine without aura;	chr5:177273884	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.853	rs4976680	ENSG00000217325.2	PRELID1P1	14.99	8.88e-42	6.82e-35	0.7	0.57	Migraine without aura;	chr5:177275745	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.853	rs4976681	ENSG00000217325.2	PRELID1P1	14.99	8.88e-42	6.82e-35	0.7	0.57	Migraine without aura;	chr5:177277662	chr6:126643488~126644390:+
THCA	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-14.97	1.07e-41	8.17e-35	-0.88	-0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
THCA	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	14.94	1.39e-41	1.06e-34	0.96	0.57	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
THCA	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-14.93	1.59e-41	1.21e-34	-0.71	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
THCA	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-14.93	1.59e-41	1.21e-34	-0.71	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
THCA	trans	rs8010715	0.52	rs12435994	ENSG00000248988.1	RP11-815N9.2	14.92	1.65e-41	1.25e-34	0.75	0.57	IgG glycosylation;	chr14:24120252	chr4:159007119~159007835:+
THCA	trans	rs8010715	0.596	rs12435995	ENSG00000248988.1	RP11-815N9.2	14.92	1.65e-41	1.25e-34	0.75	0.57	IgG glycosylation;	chr14:24120255	chr4:159007119~159007835:+
THCA	trans	rs9611519	0.78	rs2284079	ENSG00000268568.1	AC007228.9	-14.92	1.68e-41	1.27e-34	-0.63	-0.57	Neuroticism;	chr22:41262628	chr19:56672574~56673901:-
THCA	trans	rs7121616	0.774	rs74693612	ENSG00000234176.1	HSPA8P1	14.9	2.07e-41	1.56e-34	0.72	0.57	Breast cancer;	chr11:123092310	chrX:121203182~121205014:-
THCA	trans	rs9611519	0.808	rs5751074	ENSG00000268568.1	AC007228.9	-14.9	2.15e-41	1.61e-34	-0.63	-0.57	Neuroticism;	chr22:41269718	chr19:56672574~56673901:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-14.9	2.22e-41	1.67e-34	-0.67	-0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
THCA	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-14.89	2.45e-41	1.84e-34	-0.71	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
THCA	trans	rs10037055	0.853	rs10056008	ENSG00000217325.2	PRELID1P1	-14.89	2.45e-41	1.84e-34	-0.7	-0.57	Migraine without aura;	chr5:177194147	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.853	rs10476219	ENSG00000217325.2	PRELID1P1	-14.89	2.45e-41	1.84e-34	-0.7	-0.57	Migraine without aura;	chr5:177201547	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.853	rs10035180	ENSG00000217325.2	PRELID1P1	-14.88	2.54e-41	1.91e-34	-0.7	-0.57	Migraine without aura;	chr5:177171501	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.853	rs1546363	ENSG00000217325.2	PRELID1P1	-14.88	2.54e-41	1.91e-34	-0.7	-0.57	Migraine without aura;	chr5:177174030	chr6:126643488~126644390:+
THCA	trans	rs4276421	0.571	rs7293493	ENSG00000231752.4	EMBP1	14.88	2.72e-41	2.04e-34	0.77	0.57	P wave duration;	chr5:46028749	chr1:121519112~121571892:+
THCA	trans	rs9611519	0.761	rs35445172	ENSG00000268568.1	AC007228.9	-14.87	2.89e-41	2.17e-34	-0.63	-0.57	Neuroticism;	chr22:41264297	chr19:56672574~56673901:-
THCA	trans	rs4276421	0.55	rs4478331	ENSG00000231752.4	EMBP1	14.87	2.91e-41	2.18e-34	0.78	0.57	P wave duration;	chr5:46005323	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	14.87	2.96e-41	2.21e-34	0.75	0.57	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
THCA	trans	rs8175379	0.509	rs8185010	ENSG00000231752.4	EMBP1	-14.86	3.28e-41	2.45e-34	-0.77	-0.57	Interleukin-7 levels;	chr5:46306373	chr1:121519112~121571892:+
THCA	trans	rs7121616	1	rs7113273	ENSG00000234176.1	HSPA8P1	-14.85	3.55e-41	2.65e-34	-0.72	-0.57	Breast cancer;	chr11:123092192	chrX:121203182~121205014:-
THCA	trans	rs9611519	0.78	rs5751071	ENSG00000268568.1	AC007228.9	-14.85	3.65e-41	2.72e-34	-0.63	-0.57	Neuroticism;	chr22:41260328	chr19:56672574~56673901:-
THCA	trans	rs1816752	0.646	rs9511291	ENSG00000224976.2	PARP4P2	14.85	3.7e-41	2.76e-34	0.65	0.56	Obesity-related traits;	chr13:24467609	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9511292	ENSG00000224976.2	PARP4P2	14.85	3.7e-41	2.76e-34	0.65	0.56	Obesity-related traits;	chr13:24467623	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9511293	ENSG00000224976.2	PARP4P2	14.85	3.7e-41	2.76e-34	0.65	0.56	Obesity-related traits;	chr13:24467747	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9511294	ENSG00000224976.2	PARP4P2	14.85	3.7e-41	2.76e-34	0.65	0.56	Obesity-related traits;	chr13:24467773	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9511296	ENSG00000224976.2	PARP4P2	14.85	3.7e-41	2.76e-34	0.65	0.56	Obesity-related traits;	chr13:24467962	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.583	rs9553311	ENSG00000224976.2	PARP4P2	14.83	4.31e-41	3.21e-34	0.65	0.56	Obesity-related traits;	chr13:24474016	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs4480642	ENSG00000224976.2	PARP4P2	14.83	4.34e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24471358	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9551108	ENSG00000224976.2	PARP4P2	14.83	4.34e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24471434	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.603	rs4238178	ENSG00000224976.2	PARP4P2	14.83	4.34e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24472344	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs2862903	ENSG00000224976.2	PARP4P2	14.83	4.34e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24473169	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs7319207	ENSG00000224976.2	PARP4P2	14.83	4.34e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24473220	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9634401	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24468072	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.624	rs9634402	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24468119	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9634403	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24468211	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9581064	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24468251	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs4769361	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24468834	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs4770693	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24468835	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs4770695	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24468895	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs7337981	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24469245	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs7328391	ENSG00000224976.2	PARP4P2	14.83	4.35e-41	3.22e-34	0.65	0.56	Obesity-related traits;	chr13:24470325	chr13:19349137~19407962:+
THCA	trans	rs9611519	0.78	rs2235850	ENSG00000268568.1	AC007228.9	-14.82	4.58e-41	3.39e-34	-0.63	-0.56	Neuroticism;	chr22:41261622	chr19:56672574~56673901:-
THCA	trans	rs7121616	1	rs7123187	ENSG00000234176.1	HSPA8P1	14.81	5.27e-41	3.9e-34	0.72	0.56	Breast cancer;	chr11:123090915	chrX:121203182~121205014:-
THCA	trans	rs3740713	0.669	rs2896526	ENSG00000235847.2	LDHAP7	14.8	5.81e-41	4.29e-34	0.98	0.56	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:84777259~84778223:-
THCA	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	14.79	6.42e-41	4.74e-34	0.7	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
THCA	trans	rs10037055	0.898	rs4976636	ENSG00000217325.2	PRELID1P1	-14.79	6.63e-41	4.89e-34	-0.71	-0.56	Migraine without aura;	chr5:177118091	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.898	rs4976637	ENSG00000217325.2	PRELID1P1	-14.79	6.63e-41	4.89e-34	-0.71	-0.56	Migraine without aura;	chr5:177118141	chr6:126643488~126644390:+
THCA	trans	rs3740713	0.748	rs35292478	ENSG00000235847.2	LDHAP7	14.78	6.98e-41	5.14e-34	0.98	0.56	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:84777259~84778223:-
THCA	trans	rs1816752	0.646	rs9578740	ENSG00000224976.2	PARP4P2	14.78	7.35e-41	5.41e-34	0.65	0.56	Obesity-related traits;	chr13:24466692	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.631	rs4769358	ENSG00000224976.2	PARP4P2	14.78	7.35e-41	5.41e-34	0.65	0.56	Obesity-related traits;	chr13:24466940	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.608	rs4769359	ENSG00000224976.2	PARP4P2	14.78	7.35e-41	5.41e-34	0.65	0.56	Obesity-related traits;	chr13:24466966	chr13:19349137~19407962:+
THCA	trans	rs616147	0.627	rs816510	ENSG00000183298.5	RP11-556K13.1	-14.77	7.69e-41	5.66e-34	-0.76	-0.56	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr1:101786340~101787219:-
THCA	trans	rs10037055	0.853	rs6890580	ENSG00000217325.2	PRELID1P1	-14.77	7.98e-41	5.87e-34	-0.7	-0.56	Migraine without aura;	chr5:177226519	chr6:126643488~126644390:+
THCA	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	14.77	8.28e-41	6.09e-34	0.82	0.56	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
THCA	trans	rs1816752	0.646	rs2862902	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24461965	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs734715	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24462041	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs730030	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24462509	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs7992667	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24462821	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs7995958	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24462895	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs8002741	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24462918	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs7998198	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24462979	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs7998203	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24462989	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs7998600	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24463222	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.624	rs9511282	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24463597	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.583	rs9511283	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24463656	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9507351	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24465118	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs4770688	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24466007	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs4770689	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24466008	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs12431171	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24466380	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs12854523	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24466460	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.608	rs4769360	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24467016	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.608	rs9511290	ENSG00000224976.2	PARP4P2	14.76	8.91e-41	6.52e-34	0.64	0.56	Obesity-related traits;	chr13:24467189	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.669	rs9553309	ENSG00000224976.2	PARP4P2	14.73	1.21e-40	8.78e-34	0.65	0.56	Obesity-related traits;	chr13:24471476	chr13:19349137~19407962:+
THCA	trans	rs10037055	0.853	rs2336237	ENSG00000217325.2	PRELID1P1	14.72	1.31e-40	9.52e-34	0.7	0.56	Migraine without aura;	chr5:177238878	chr6:126643488~126644390:+
THCA	trans	rs10037055	0.853	rs1363405	ENSG00000217325.2	PRELID1P1	14.72	1.38e-40	1.01e-33	0.7	0.56	Migraine without aura;	chr5:177209881	chr6:126643488~126644390:+
THCA	trans	rs2288327	0.557	rs60488846	ENSG00000269800.1	PLEKHA3P1	14.71	1.44e-40	1.05e-33	0.76	0.56	Atrial fibrillation;	chr2:178493115	chr19:41521043~41521989:-
THCA	trans	rs1816752	0.646	rs9511295	ENSG00000224976.2	PARP4P2	14.7	1.56e-40	1.13e-33	0.65	0.56	Obesity-related traits;	chr13:24467794	chr13:19349137~19407962:+
THCA	trans	rs10037055	0.687	rs6556308	ENSG00000217325.2	PRELID1P1	-14.7	1.64e-40	1.19e-33	-0.7	-0.56	Migraine without aura;	chr5:177219700	chr6:126643488~126644390:+
THCA	trans	rs4276421	0.615	rs7733616	ENSG00000231752.4	EMBP1	-14.7	1.66e-40	1.21e-33	-0.76	-0.56	P wave duration;	chr5:45798621	chr1:121519112~121571892:+
THCA	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	14.69	1.71e-40	1.24e-33	0.7	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
THCA	trans	rs9611519	0.78	rs9611527	ENSG00000268568.1	AC007228.9	-14.69	1.72e-40	1.25e-33	-0.67	-0.56	Neuroticism;	chr22:41248424	chr19:56672574~56673901:-
THCA	trans	rs9467773	0.935	rs1056668	ENSG00000242375.1	RP11-498P14.3	14.69	1.75e-40	1.27e-33	0.78	0.56	Intelligence (multi-trait analysis);	chr6:26510377	chr9:97195351~97197687:-
THCA	trans	rs1816752	0.609	rs4770692	ENSG00000224976.2	PARP4P2	14.69	1.84e-40	1.33e-33	0.65	0.56	Obesity-related traits;	chr13:24468689	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.609	rs4770694	ENSG00000224976.2	PARP4P2	14.69	1.84e-40	1.33e-33	0.65	0.56	Obesity-related traits;	chr13:24468891	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.624	rs9507354	ENSG00000224976.2	PARP4P2	14.69	1.84e-40	1.33e-33	0.65	0.56	Obesity-related traits;	chr13:24469227	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.624	rs9553312	ENSG00000224976.2	PARP4P2	14.69	1.84e-40	1.33e-33	0.65	0.56	Obesity-related traits;	chr13:24474055	chr13:19349137~19407962:+
THCA	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-14.69	1.86e-40	1.35e-33	-0.69	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
THCA	trans	rs10037055	0.741	rs2336405	ENSG00000217325.2	PRELID1P1	-14.68	2.05e-40	1.48e-33	-0.7	-0.56	Migraine without aura;	chr5:177230288	chr6:126643488~126644390:+
THCA	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	14.67	2.13e-40	1.54e-33	0.69	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
THCA	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	14.67	2.19e-40	1.58e-33	0.92	0.56	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
THCA	trans	rs1816752	0.624	rs2096093	ENSG00000224976.2	PARP4P2	14.66	2.37e-40	1.71e-33	0.65	0.56	Obesity-related traits;	chr13:24472753	chr13:19349137~19407962:+
THCA	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	14.66	2.43e-40	1.75e-33	0.94	0.56	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	14.66	2.43e-40	1.75e-33	0.94	0.56	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	14.66	2.43e-40	1.75e-33	0.94	0.56	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
THCA	trans	rs116095464	0.558	rs6872854	ENSG00000185986.11	SDHAP3	14.65	2.57e-40	1.85e-33	0.6	0.56	Breast cancer;	chr5:208923	chr5:1572222~1594620:-
THCA	trans	rs1816752	0.646	rs6490937	ENSG00000224976.2	PARP4P2	14.65	2.74e-40	1.98e-33	0.64	0.56	Obesity-related traits;	chr13:24475834	chr13:19349137~19407962:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000233778.3	RP11-777J24.1	-14.65	2.75e-40	1.98e-33	-0.69	-0.56	Cognitive function;	chr12:56083910	chr8:92144088~92144435:-
THCA	trans	rs1816752	0.524	rs7996445	ENSG00000224976.2	PARP4P2	14.65	2.75e-40	1.98e-33	0.64	0.56	Obesity-related traits;	chr13:24475329	chr13:19349137~19407962:+
THCA	trans	rs116095464	0.619	rs2303741	ENSG00000185986.11	SDHAP3	14.64	2.83e-40	2.04e-33	0.6	0.56	Breast cancer;	chr5:218241	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.614	rs56299325	ENSG00000185986.11	SDHAP3	14.64	2.83e-40	2.04e-33	0.6	0.56	Breast cancer;	chr5:220479	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs62346526	ENSG00000185986.11	SDHAP3	14.64	2.83e-40	2.04e-33	0.6	0.56	Breast cancer;	chr5:220499	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs56043030	ENSG00000185986.11	SDHAP3	14.64	2.83e-40	2.04e-33	0.6	0.56	Breast cancer;	chr5:220802	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10067021	ENSG00000185986.11	SDHAP3	14.64	2.83e-40	2.04e-33	0.6	0.56	Breast cancer;	chr5:221375	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9312977	ENSG00000185986.11	SDHAP3	14.64	2.83e-40	2.04e-33	0.6	0.56	Breast cancer;	chr5:221801	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6881920	ENSG00000185986.11	SDHAP3	14.64	2.83e-40	2.04e-33	0.6	0.56	Breast cancer;	chr5:222296	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6878061	ENSG00000185986.11	SDHAP3	14.64	2.83e-40	2.04e-33	0.6	0.56	Breast cancer;	chr5:222957	chr5:1572222~1594620:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-14.64	2.99e-40	2.15e-33	-0.72	-0.56	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
THCA	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	14.63	3.22e-40	2.31e-33	0.94	0.56	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
THCA	trans	rs8175379	0.53	rs12516847	ENSG00000231752.4	EMBP1	-14.63	3.23e-40	2.31e-33	-0.76	-0.56	Interleukin-7 levels;	chr5:46300736	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.646	rs9511279	ENSG00000224976.2	PARP4P2	14.63	3.31e-40	2.37e-33	0.65	0.56	Obesity-related traits;	chr13:24463348	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9511280	ENSG00000224976.2	PARP4P2	14.63	3.31e-40	2.37e-33	0.65	0.56	Obesity-related traits;	chr13:24463364	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9511281	ENSG00000224976.2	PARP4P2	14.63	3.31e-40	2.37e-33	0.65	0.56	Obesity-related traits;	chr13:24463441	chr13:19349137~19407962:+
THCA	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	14.63	3.32e-40	2.38e-33	0.92	0.56	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
THCA	trans	rs116095464	0.614	rs10067482	ENSG00000185986.11	SDHAP3	14.63	3.36e-40	2.41e-33	0.59	0.56	Breast cancer;	chr5:219213	chr5:1572222~1594620:-
THCA	trans	rs4276421	0.615	rs10064278	ENSG00000231752.4	EMBP1	-14.62	3.57e-40	2.55e-33	-0.76	-0.56	P wave duration;	chr5:45786496	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.583	rs9511284	ENSG00000224976.2	PARP4P2	14.62	3.67e-40	2.63e-33	0.64	0.56	Obesity-related traits;	chr13:24463660	chr13:19349137~19407962:+
THCA	trans	rs7258465	1	rs7252707	ENSG00000267533.1	RP11-815J4.7	14.61	3.87e-40	2.77e-33	0.77	0.56	Breast cancer;	chr19:18501447	chr18:12067173~12068417:-
THCA	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-14.61	3.98e-40	2.85e-33	-0.87	-0.56	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
THCA	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	14.6	4.23e-40	3.02e-33	0.94	0.56	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
THCA	trans	rs26067	0.74	rs26079	ENSG00000231752.4	EMBP1	-14.6	4.34e-40	3.1e-33	-0.77	-0.56	Breast cancer;	chr5:50863180	chr1:121519112~121571892:+
THCA	trans	rs116095464	0.558	rs6555055	ENSG00000185986.11	SDHAP3	14.6	4.47e-40	3.19e-33	0.6	0.56	Breast cancer;	chr5:226045	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6555056	ENSG00000185986.11	SDHAP3	14.6	4.47e-40	3.19e-33	0.6	0.56	Breast cancer;	chr5:226107	chr5:1572222~1594620:-
THCA	trans	rs1816752	0.608	rs4770690	ENSG00000224976.2	PARP4P2	14.6	4.61e-40	3.28e-33	0.64	0.56	Obesity-related traits;	chr13:24467049	chr13:19349137~19407962:+
THCA	trans	rs3740713	0.592	rs73434674	ENSG00000235847.2	LDHAP7	14.6	4.61e-40	3.28e-33	0.97	0.56	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:84777259~84778223:-
THCA	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	14.59	4.74e-40	3.38e-33	0.67	0.56	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
THCA	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	14.59	5.06e-40	3.6e-33	0.94	0.56	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
THCA	trans	rs116095464	0.558	rs10036253	ENSG00000185986.11	SDHAP3	14.59	5.07e-40	3.61e-33	0.6	0.56	Breast cancer;	chr5:238404	chr5:1572222~1594620:-
THCA	trans	rs7258465	1	rs2007981	ENSG00000267533.1	RP11-815J4.7	14.57	6.09e-40	4.33e-33	0.77	0.56	Breast cancer;	chr19:18456745	chr18:12067173~12068417:-
THCA	trans	rs1816752	0.669	rs4770699	ENSG00000224976.2	PARP4P2	14.57	6.17e-40	4.38e-33	0.65	0.56	Obesity-related traits;	chr13:24488234	chr13:19349137~19407962:+
THCA	trans	rs116095464	0.558	rs7703803	ENSG00000185986.11	SDHAP3	14.56	6.4e-40	4.53e-33	0.61	0.56	Breast cancer;	chr5:292196	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9654452	ENSG00000185986.11	SDHAP3	14.56	6.4e-40	4.53e-33	0.61	0.56	Breast cancer;	chr5:299446	chr5:1572222~1594620:-
THCA	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	14.55	7.28e-40	5.15e-33	0.78	0.56	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
THCA	trans	rs916888	0.61	rs199530	ENSG00000214425.5	LRRC37A4P	14.55	7.29e-40	5.15e-33	0.69	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45506741~45550335:-
THCA	trans	rs7258465	1	rs10164319	ENSG00000267533.1	RP11-815J4.7	14.55	7.32e-40	5.17e-33	0.77	0.56	Breast cancer;	chr19:18459023	chr18:12067173~12068417:-
THCA	trans	rs7258465	0.965	rs1560118	ENSG00000267533.1	RP11-815J4.7	14.55	7.32e-40	5.17e-33	0.77	0.56	Breast cancer;	chr19:18459225	chr18:12067173~12068417:-
THCA	trans	rs3740713	0.669	rs113003553	ENSG00000235847.2	LDHAP7	14.54	7.76e-40	5.48e-33	0.97	0.56	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr2:84777259~84778223:-
THCA	trans	rs9467773	0.935	rs4573	ENSG00000242375.1	RP11-498P14.3	14.54	7.81e-40	5.51e-33	0.78	0.56	Intelligence (multi-trait analysis);	chr6:26546580	chr9:97195351~97197687:-
THCA	trans	rs7258465	1	rs8107367	ENSG00000267533.1	RP11-815J4.7	14.54	7.83e-40	5.53e-33	0.78	0.56	Breast cancer;	chr19:18453895	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	14.54	7.93e-40	5.6e-33	0.76	0.56	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
THCA	trans	rs116095464	0.558	rs6882584	ENSG00000185986.11	SDHAP3	14.54	7.99e-40	5.63e-33	0.6	0.56	Breast cancer;	chr5:223296	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs3213838	ENSG00000185986.11	SDHAP3	14.54	7.99e-40	5.63e-33	0.6	0.56	Breast cancer;	chr5:223775	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6555052	ENSG00000185986.11	SDHAP3	14.54	7.99e-40	5.63e-33	0.6	0.56	Breast cancer;	chr5:224153	chr5:1572222~1594620:-
THCA	trans	rs7258465	1	rs34171762	ENSG00000267533.1	RP11-815J4.7	14.54	8.36e-40	5.89e-33	0.78	0.56	Breast cancer;	chr19:18448600	chr18:12067173~12068417:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000233778.3	RP11-777J24.1	-14.53	8.98e-40	6.32e-33	-0.67	-0.56	Cognitive function;	chr12:56080024	chr8:92144088~92144435:-
THCA	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-14.53	9.34e-40	6.57e-33	-0.86	-0.56	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
THCA	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-14.52	9.66e-40	6.79e-33	-0.69	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
THCA	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	14.52	1.02e-39	7.19e-33	0.92	0.56	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
THCA	trans	rs116095464	0.51	rs7723883	ENSG00000185986.11	SDHAP3	14.52	1.03e-39	7.24e-33	0.6	0.56	Breast cancer;	chr5:270683	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs28558836	ENSG00000185986.11	SDHAP3	14.52	1.03e-39	7.24e-33	0.6	0.56	Breast cancer;	chr5:285633	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs62347678	ENSG00000185986.11	SDHAP3	14.51	1.07e-39	7.53e-33	0.6	0.56	Breast cancer;	chr5:227381	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs73031482	ENSG00000185986.11	SDHAP3	14.51	1.07e-39	7.53e-33	0.6	0.56	Breast cancer;	chr5:227479	chr5:1572222~1594620:-
THCA	trans	rs1816752	0.646	rs7995190	ENSG00000224976.2	PARP4P2	14.51	1.15e-39	8.05e-33	0.64	0.56	Obesity-related traits;	chr13:24475709	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.608	rs7326664	ENSG00000224976.2	PARP4P2	14.51	1.15e-39	8.05e-33	0.64	0.56	Obesity-related traits;	chr13:24475868	chr13:19349137~19407962:+
THCA	trans	rs116095464	0.558	rs61689490	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:224789	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs61492827	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:225659	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs56342538	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:225681	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs1541822	ENSG00000185986.11	SDHAP3	-14.5	1.16e-39	8.05e-33	-0.6	-0.56	Breast cancer;	chr5:269119	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7708182	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:234673	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10058428	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:235493	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10076655	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:239349	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10057492	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:239388	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs28418643	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:240744	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.614	rs62344339	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:252880	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9687898	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:253837	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9688045	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:253920	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs112343653	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:257059	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs73024831	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:257077	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs62344345	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:257305	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs57335027	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:262792	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6869925	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:263921	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6875291	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:264077	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6866776	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:264380	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6874745	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:264412	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7715108	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:264546	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7730700	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:264598	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10057674	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:266698	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs1812843	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:267543	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs12173244	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:269409	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs56127718	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:270158	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.614	rs10061564	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:271214	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs55776650	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:273711	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.614	rs28736753	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:273966	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs59113266	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:279850	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs11959126	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:283765	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7356696	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:284136	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7356561	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:284266	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs59284383	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:284410	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7731089	ENSG00000185986.11	SDHAP3	14.5	1.16e-39	8.05e-33	0.6	0.56	Breast cancer;	chr5:290307	chr5:1572222~1594620:-
THCA	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	14.5	1.17e-39	8.09e-33	0.77	0.56	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
THCA	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	14.5	1.17e-39	8.09e-33	0.77	0.56	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	14.5	1.17e-39	8.09e-33	0.77	0.56	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
THCA	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	14.5	1.17e-39	8.09e-33	0.77	0.56	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
THCA	trans	rs116095464	0.558	rs10043002	ENSG00000185986.11	SDHAP3	14.5	1.21e-39	8.4e-33	0.6	0.56	Breast cancer;	chr5:226638	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs2162870	ENSG00000185986.11	SDHAP3	14.5	1.21e-39	8.4e-33	0.6	0.56	Breast cancer;	chr5:228014	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs28729548	ENSG00000185986.11	SDHAP3	14.5	1.21e-39	8.4e-33	0.6	0.56	Breast cancer;	chr5:228910	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.681	rs9687745	ENSG00000185986.11	SDHAP3	14.5	1.21e-39	8.4e-33	0.6	0.56	Breast cancer;	chr5:229194	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9688136	ENSG00000185986.11	SDHAP3	14.5	1.21e-39	8.4e-33	0.6	0.56	Breast cancer;	chr5:229233	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.51	rs55750776	ENSG00000185986.11	SDHAP3	14.5	1.21e-39	8.4e-33	0.6	0.56	Breast cancer;	chr5:230352	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.764	rs10069197	ENSG00000185986.11	SDHAP3	14.5	1.21e-39	8.4e-33	0.6	0.56	Breast cancer;	chr5:230707	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.867	rs10074958	ENSG00000185986.11	SDHAP3	14.5	1.21e-39	8.4e-33	0.6	0.56	Breast cancer;	chr5:230713	chr5:1572222~1594620:-
THCA	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	14.49	1.36e-39	9.38e-33	0.68	0.56	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
THCA	trans	rs7258465	0.965	rs7254249	ENSG00000267533.1	RP11-815J4.7	14.48	1.46e-39	1.01e-32	0.77	0.56	Breast cancer;	chr19:18480935	chr18:12067173~12068417:-
THCA	trans	rs1816752	0.646	rs750388	ENSG00000224976.2	PARP4P2	14.48	1.48e-39	1.02e-32	0.64	0.56	Obesity-related traits;	chr13:24461690	chr13:19349137~19407962:+
THCA	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-14.48	1.5e-39	1.04e-32	-0.66	-0.56	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
THCA	trans	rs26067	0.689	rs282546	ENSG00000231752.4	EMBP1	-14.48	1.53e-39	1.06e-32	-0.77	-0.56	Breast cancer;	chr5:50762209	chr1:121519112~121571892:+
THCA	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	14.48	1.54e-39	1.06e-32	0.68	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
THCA	trans	rs116095464	0.558	rs55664502	ENSG00000185986.11	SDHAP3	14.47	1.65e-39	1.14e-32	0.6	0.56	Breast cancer;	chr5:270370	chr5:1572222~1594620:-
THCA	trans	rs9611519	0.78	rs5751072	ENSG00000268568.1	AC007228.9	-14.47	1.68e-39	1.16e-32	-0.61	-0.56	Neuroticism;	chr22:41260505	chr19:56672574~56673901:-
THCA	trans	rs1816752	0.646	rs9511301	ENSG00000224976.2	PARP4P2	14.47	1.7e-39	1.17e-32	0.63	0.56	Obesity-related traits;	chr13:24477034	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs7332220	ENSG00000224976.2	PARP4P2	14.47	1.7e-39	1.17e-32	0.63	0.56	Obesity-related traits;	chr13:24477081	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.624	rs11149109	ENSG00000224976.2	PARP4P2	14.47	1.7e-39	1.17e-32	0.63	0.56	Obesity-related traits;	chr13:24477290	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs9511302	ENSG00000224976.2	PARP4P2	14.47	1.7e-39	1.17e-32	0.63	0.56	Obesity-related traits;	chr13:24477580	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs8002599	ENSG00000224976.2	PARP4P2	14.47	1.7e-39	1.17e-32	0.63	0.56	Obesity-related traits;	chr13:24478486	chr13:19349137~19407962:+
THCA	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	14.47	1.7e-39	1.17e-32	0.69	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
THCA	trans	rs4276421	0.555	rs2589181	ENSG00000231752.4	EMBP1	14.47	1.72e-39	1.18e-32	0.74	0.56	P wave duration;	chr5:45611931	chr1:121519112~121571892:+
THCA	trans	rs7258465	0.897	rs1043327	ENSG00000267533.1	RP11-815J4.7	14.47	1.72e-39	1.19e-32	0.77	0.56	Breast cancer;	chr19:18444162	chr18:12067173~12068417:-
THCA	trans	rs1816752	0.646	rs750389	ENSG00000224976.2	PARP4P2	14.46	1.75e-39	1.21e-32	0.64	0.55	Obesity-related traits;	chr13:24461677	chr13:19349137~19407962:+
THCA	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	14.45	1.95e-39	1.34e-32	1.02	0.55	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
THCA	trans	rs7258465	1	rs10413237	ENSG00000267533.1	RP11-815J4.7	14.45	1.98e-39	1.36e-32	0.79	0.55	Breast cancer;	chr19:18437439	chr18:12067173~12068417:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-14.45	1.98e-39	1.36e-32	-0.71	-0.55	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-14.45	1.98e-39	1.36e-32	-0.71	-0.55	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
THCA	trans	rs7258465	1	rs2303697	ENSG00000267533.1	RP11-815J4.7	14.45	2.05e-39	1.41e-32	0.77	0.55	Breast cancer;	chr19:18435868	chr18:12067173~12068417:-
THCA	trans	rs116095464	0.558	rs2288459	ENSG00000185986.11	SDHAP3	14.45	2.07e-39	1.42e-32	0.6	0.55	Breast cancer;	chr5:231028	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs2288458	ENSG00000185986.11	SDHAP3	14.45	2.07e-39	1.42e-32	0.6	0.55	Breast cancer;	chr5:231145	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs2288457	ENSG00000185986.11	SDHAP3	14.45	2.07e-39	1.42e-32	0.6	0.55	Breast cancer;	chr5:231155	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.614	rs4371799	ENSG00000185986.11	SDHAP3	14.45	2.07e-39	1.42e-32	0.6	0.55	Breast cancer;	chr5:268077	chr5:1572222~1594620:-
THCA	trans	rs1816752	0.646	rs9507355	ENSG00000224976.2	PARP4P2	-14.44	2.33e-39	1.59e-32	-0.63	-0.55	Obesity-related traits;	chr13:24476819	chr13:19349137~19407962:+
THCA	trans	rs116095464	0.558	rs1971229	ENSG00000185986.11	SDHAP3	14.44	2.33e-39	1.6e-32	0.6	0.55	Breast cancer;	chr5:268072	chr5:1572222~1594620:-
THCA	trans	rs7554547	0.905	rs4993564	ENSG00000261819.1	RP11-680G24.4	14.43	2.37e-39	1.62e-32	0.72	0.55	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr16:14988259~14990160:-
THCA	trans	rs4276421	0.577	rs4367308	ENSG00000231752.4	EMBP1	-14.43	2.44e-39	1.67e-32	-0.74	-0.55	P wave duration;	chr5:45715651	chr1:121519112~121571892:+
THCA	trans	rs7730934	0.818	rs6873896	ENSG00000227018.1	IL6STP1	14.42	2.65e-39	1.81e-32	0.86	0.55	Blood protein levels;	chr5:56017121	chr17:15783288~15784307:+
THCA	trans	rs116095464	0.558	rs10075018	ENSG00000185986.11	SDHAP3	14.42	2.73e-39	1.87e-32	0.6	0.55	Breast cancer;	chr5:239060	chr5:1572222~1594620:-
THCA	trans	rs4276421	0.638	rs62371967	ENSG00000231752.4	EMBP1	14.42	2.75e-39	1.88e-32	0.75	0.55	P wave duration;	chr5:45897706	chr1:121519112~121571892:+
THCA	trans	rs116095464	0.558	rs7736600	ENSG00000185986.11	SDHAP3	14.41	2.87e-39	1.96e-32	0.6	0.55	Breast cancer;	chr5:231222	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7725227	ENSG00000185986.11	SDHAP3	14.41	2.87e-39	1.96e-32	0.6	0.55	Breast cancer;	chr5:233402	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7710005	ENSG00000185986.11	SDHAP3	14.41	2.87e-39	1.96e-32	0.6	0.55	Breast cancer;	chr5:233457	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs55838121	ENSG00000185986.11	SDHAP3	14.41	3e-39	2.05e-32	0.6	0.55	Breast cancer;	chr5:266775	chr5:1572222~1594620:-
THCA	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	14.41	3.04e-39	2.07e-32	0.83	0.55	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
THCA	trans	rs916888	0.531	rs183211	ENSG00000214425.5	LRRC37A4P	-14.41	3.08e-39	2.1e-32	-0.68	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45506741~45550335:-
THCA	trans	rs7937890	0.904	rs67623158	ENSG00000236360.2	RP11-334A14.2	-14.4	3.22e-39	2.19e-32	-0.72	-0.55	Mitochondrial DNA levels;	chr11:14273650	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs7121171	ENSG00000236360.2	RP11-334A14.2	14.4	3.41e-39	2.31e-32	0.75	0.55	Vitamin D levels;	chr11:14424874	chr1:52993201~52993702:-
THCA	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	14.39	3.66e-39	2.48e-32	0.76	0.55	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
THCA	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	14.39	3.66e-39	2.48e-32	0.76	0.55	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs7258465	ENSG00000267533.1	RP11-815J4.7	14.38	3.86e-39	2.62e-32	0.76	0.55	Breast cancer;	chr19:18422832	chr18:12067173~12068417:-
THCA	trans	rs3779195	0.627	rs6950023	ENSG00000225169.1	BRI3P1	14.38	3.87e-39	2.62e-32	0.86	0.55	Sex hormone-binding globulin levels;	chr7:98286323	chr1:100213293~100213670:+
THCA	trans	rs3779195	0.627	rs6967728	ENSG00000225169.1	BRI3P1	14.38	3.87e-39	2.62e-32	0.86	0.55	Sex hormone-binding globulin levels;	chr7:98286325	chr1:100213293~100213670:+
THCA	trans	rs116095464	0.558	rs28635197	ENSG00000185986.11	SDHAP3	14.37	4.5e-39	3.04e-32	0.6	0.55	Breast cancer;	chr5:278956	chr5:1572222~1594620:-
THCA	trans	rs7258465	1	rs28572537	ENSG00000267533.1	RP11-815J4.7	14.37	4.54e-39	3.07e-32	0.77	0.55	Breast cancer;	chr19:18441398	chr18:12067173~12068417:-
THCA	trans	rs1816752	0.646	rs2902359	ENSG00000224976.2	PARP4P2	14.36	4.85e-39	3.28e-32	0.64	0.55	Obesity-related traits;	chr13:24461783	chr13:19349137~19407962:+
THCA	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	14.36	4.87e-39	3.29e-32	0.82	0.55	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
THCA	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-14.36	5.15e-39	3.47e-32	-0.93	-0.55	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
THCA	trans	rs7258465	1	rs8103622	ENSG00000267533.1	RP11-815J4.7	14.35	5.51e-39	3.71e-32	0.77	0.55	Breast cancer;	chr19:18462024	chr18:12067173~12068417:-
THCA	trans	rs4276421	0.593	rs10223123	ENSG00000231752.4	EMBP1	14.34	5.79e-39	3.9e-32	0.74	0.55	P wave duration;	chr5:45893554	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs9292929	ENSG00000231752.4	EMBP1	14.34	5.79e-39	3.9e-32	0.74	0.55	P wave duration;	chr5:45894168	chr1:121519112~121571892:+
THCA	trans	rs3740713	0.669	rs78098319	ENSG00000235847.2	LDHAP7	14.34	5.93e-39	3.99e-32	0.97	0.55	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr2:84777259~84778223:-
THCA	trans	rs116095464	0.558	rs13357299	ENSG00000185986.11	SDHAP3	14.34	6.16e-39	4.14e-32	0.6	0.55	Breast cancer;	chr5:242096	chr5:1572222~1594620:-
THCA	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	14.34	6.28e-39	4.22e-32	0.66	0.55	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
THCA	trans	rs2288327	0.557	rs7588593	ENSG00000269800.1	PLEKHA3P1	14.34	6.34e-39	4.26e-32	0.75	0.55	Atrial fibrillation;	chr2:178487723	chr19:41521043~41521989:-
THCA	trans	rs2288327	0.557	rs7577862	ENSG00000269800.1	PLEKHA3P1	14.34	6.34e-39	4.26e-32	0.75	0.55	Atrial fibrillation;	chr2:178488130	chr19:41521043~41521989:-
THCA	trans	rs116095464	0.558	rs13354585	ENSG00000185986.11	SDHAP3	14.34	6.34e-39	4.26e-32	0.6	0.55	Breast cancer;	chr5:242148	chr5:1572222~1594620:-
THCA	trans	rs1816752	0.646	rs750390	ENSG00000224976.2	PARP4P2	14.33	6.48e-39	4.35e-32	0.64	0.55	Obesity-related traits;	chr13:24461603	chr13:19349137~19407962:+
THCA	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-14.33	6.6e-39	4.43e-32	-0.67	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
THCA	trans	rs12709013	0.591	rs30834	ENSG00000233719.3	GOT2P3	14.33	6.87e-39	4.61e-32	0.73	0.55	Blood metabolite ratios;	chr16:58715394	chr12:9641802~9643007:+
THCA	trans	rs7258465	1	rs10409483	ENSG00000267533.1	RP11-815J4.7	14.33	6.89e-39	4.63e-32	0.77	0.55	Breast cancer;	chr19:18479413	chr18:12067173~12068417:-
THCA	trans	rs116095464	0.558	rs113796397	ENSG00000185986.11	SDHAP3	14.33	6.91e-39	4.64e-32	0.6	0.55	Breast cancer;	chr5:246388	chr5:1572222~1594620:-
THCA	trans	rs7258465	1	rs10427083	ENSG00000267533.1	RP11-815J4.7	14.33	6.92e-39	4.64e-32	0.77	0.55	Breast cancer;	chr19:18439466	chr18:12067173~12068417:-
THCA	trans	rs116095464	0.558	rs62347683	ENSG00000185986.11	SDHAP3	14.33	7.01e-39	4.7e-32	0.6	0.55	Breast cancer;	chr5:230216	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.681	rs10060016	ENSG00000185986.11	SDHAP3	14.32	7.15e-39	4.78e-32	0.6	0.55	Breast cancer;	chr5:240985	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10057299	ENSG00000185986.11	SDHAP3	14.32	7.15e-39	4.78e-32	0.6	0.55	Breast cancer;	chr5:242020	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs13356367	ENSG00000185986.11	SDHAP3	14.32	7.15e-39	4.78e-32	0.6	0.55	Breast cancer;	chr5:242280	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.85	rs10055295	ENSG00000185986.11	SDHAP3	14.32	7.15e-39	4.78e-32	0.6	0.55	Breast cancer;	chr5:243634	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10055354	ENSG00000185986.11	SDHAP3	14.32	7.15e-39	4.78e-32	0.6	0.55	Breast cancer;	chr5:243679	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs60251075	ENSG00000185986.11	SDHAP3	14.32	7.15e-39	4.78e-32	0.6	0.55	Breast cancer;	chr5:245177	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs62344300	ENSG00000185986.11	SDHAP3	14.32	7.15e-39	4.78e-32	0.6	0.55	Breast cancer;	chr5:246221	chr5:1572222~1594620:-
THCA	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	14.32	7.19e-39	4.81e-32	0.66	0.55	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
THCA	trans	rs7730934	1	rs1445872	ENSG00000227018.1	IL6STP1	14.32	7.77e-39	5.19e-32	0.97	0.55	Blood protein levels;	chr5:55962032	chr17:15783288~15784307:+
THCA	trans	rs7258465	0.965	rs8100767	ENSG00000267533.1	RP11-815J4.7	14.31	8.06e-39	5.38e-32	0.77	0.55	Breast cancer;	chr19:18478278	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs3810429	ENSG00000267533.1	RP11-815J4.7	14.31	8.44e-39	5.64e-32	0.77	0.55	Breast cancer;	chr19:18432460	chr18:12067173~12068417:-
THCA	trans	rs7730934	1	rs35682251	ENSG00000227018.1	IL6STP1	14.31	8.5e-39	5.67e-32	0.97	0.55	Blood protein levels;	chr5:56011217	chr17:15783288~15784307:+
THCA	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	14.3	9.12e-39	6.08e-32	0.81	0.55	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
THCA	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-14.3	9.27e-39	6.17e-32	-0.75	-0.55	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
THCA	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	14.29	9.53e-39	6.34e-32	0.76	0.55	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
THCA	trans	rs1816752	0.646	rs2862905	ENSG00000224976.2	PARP4P2	14.29	9.66e-39	6.43e-32	0.64	0.55	Obesity-related traits;	chr13:24485142	chr13:19349137~19407962:+
THCA	trans	rs7258465	1	rs10409505	ENSG00000267533.1	RP11-815J4.7	14.29	9.69e-39	6.45e-32	0.77	0.55	Breast cancer;	chr19:18479441	chr18:12067173~12068417:-
THCA	trans	rs4276421	0.571	rs4368738	ENSG00000231752.4	EMBP1	14.29	9.84e-39	6.54e-32	0.74	0.55	P wave duration;	chr5:45892686	chr1:121519112~121571892:+
THCA	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	14.29	1.02e-38	6.81e-32	0.76	0.55	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
THCA	trans	rs10037055	0.853	rs9313749	ENSG00000217325.2	PRELID1P1	-14.29	1.03e-38	6.85e-32	-0.68	-0.55	Migraine without aura;	chr5:177170693	chr6:126643488~126644390:+
THCA	trans	rs7258465	0.965	rs7253990	ENSG00000267533.1	RP11-815J4.7	14.28	1.05e-38	6.99e-32	0.76	0.55	Breast cancer;	chr19:18493275	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs2303695	ENSG00000267533.1	RP11-815J4.7	14.28	1.08e-38	7.18e-32	0.77	0.55	Breast cancer;	chr19:18451814	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	14.28	1.09e-38	7.23e-32	0.76	0.55	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
THCA	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	14.28	1.12e-38	7.4e-32	0.76	0.55	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
THCA	trans	rs10940346	0.601	rs1033109	ENSG00000231752.4	EMBP1	14.27	1.16e-38	7.71e-32	0.69	0.55	Schizophrenia;	chr5:50327705	chr1:121519112~121571892:+
THCA	trans	rs116095464	0.558	rs10462754	ENSG00000185986.11	SDHAP3	14.27	1.21e-38	7.99e-32	0.59	0.55	Breast cancer;	chr5:246554	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10462755	ENSG00000185986.11	SDHAP3	14.27	1.21e-38	7.99e-32	0.59	0.55	Breast cancer;	chr5:246633	chr5:1572222~1594620:-
THCA	trans	rs10242455	0.702	rs76840929	ENSG00000228834.1	RP11-249L21.4	14.27	1.21e-38	8.04e-32	1.54	0.55	Blood metabolite levels;	chr7:99348235	chr6:108907615~108907873:-
THCA	trans	rs116095464	0.542	rs28650039	ENSG00000185986.11	SDHAP3	14.27	1.22e-38	8.09e-32	0.6	0.55	Breast cancer;	chr5:273839	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs6866632	ENSG00000185986.11	SDHAP3	14.26	1.37e-38	9.05e-32	0.6	0.55	Breast cancer;	chr5:264314	chr5:1572222~1594620:-
THCA	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	14.26	1.37e-38	9.05e-32	0.92	0.55	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
THCA	trans	rs7258465	1	rs34256197	ENSG00000267533.1	RP11-815J4.7	14.26	1.39e-38	9.2e-32	0.76	0.55	Breast cancer;	chr19:18495662	chr18:12067173~12068417:-
THCA	trans	rs2896526	0.736	rs78950598	ENSG00000235847.2	LDHAP7	14.25	1.43e-38	9.44e-32	0.99	0.55	Amyloid A serum levels;	chr11:18375599	chr2:84777259~84778223:-
THCA	trans	rs7258465	1	rs10442	ENSG00000267533.1	RP11-815J4.7	14.25	1.44e-38	9.51e-32	0.77	0.55	Breast cancer;	chr19:18434531	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs4595905	ENSG00000267533.1	RP11-815J4.7	14.25	1.44e-38	9.51e-32	0.77	0.55	Breast cancer;	chr19:18436495	chr18:12067173~12068417:-
THCA	trans	rs3740713	0.719	rs78515595	ENSG00000235847.2	LDHAP7	14.25	1.46e-38	9.67e-32	0.97	0.55	Amyotrophic lateral sclerosis (sporadic);	chr11:18409830	chr2:84777259~84778223:-
THCA	trans	rs9611519	0.78	rs2235849	ENSG00000268568.1	AC007228.9	-14.25	1.47e-38	9.74e-32	-0.6	-0.55	Neuroticism;	chr22:41257536	chr19:56672574~56673901:-
THCA	trans	rs10242455	0.702	rs73713531	ENSG00000228834.1	RP11-249L21.4	14.24	1.65e-38	1.09e-31	1.55	0.55	Blood metabolite levels;	chr7:99624756	chr6:108907615~108907873:-
THCA	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	14.24	1.72e-38	1.14e-31	0.66	0.55	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000233778.3	RP11-777J24.1	-14.23	1.76e-38	1.16e-31	-0.67	-0.55	Cognitive function;	chr12:56084218	chr8:92144088~92144435:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000233778.3	RP11-777J24.1	-14.23	1.76e-38	1.16e-31	-0.67	-0.55	Cognitive function;	chr12:56084874	chr8:92144088~92144435:-
THCA	trans	rs116095464	0.558	rs7713524	ENSG00000185986.11	SDHAP3	-14.23	1.82e-38	1.2e-31	-0.59	-0.55	Breast cancer;	chr5:276085	chr5:1572222~1594620:-
THCA	trans	rs7258465	1	rs34746918	ENSG00000267533.1	RP11-815J4.7	14.23	1.89e-38	1.25e-31	0.77	0.55	Breast cancer;	chr19:18428934	chr18:12067173~12068417:-
THCA	trans	rs55665837	1	rs10832257	ENSG00000236360.2	RP11-334A14.2	14.22	2.01e-38	1.32e-31	0.73	0.55	Vitamin D levels;	chr11:14421770	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	14.22	2.01e-38	1.32e-31	0.73	0.55	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
THCA	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	14.22	2.01e-38	1.32e-31	0.94	0.55	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	14.22	2.01e-38	1.32e-31	0.94	0.55	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
THCA	trans	rs616147	0.616	rs1768234	ENSG00000183298.5	RP11-556K13.1	-14.22	2.01e-38	1.32e-31	-0.77	-0.55	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr1:101786340~101787219:-
THCA	trans	rs8081395	0.58	rs180515	ENSG00000187870.7	RNFT1P3	14.22	2.09e-38	1.37e-31	0.72	0.55	White blood cell count;	chr17:59946914	chr17:20743333~20754501:-
THCA	trans	rs7730934	1	rs11574777	ENSG00000227018.1	IL6STP1	-14.21	2.29e-38	1.5e-31	-0.95	-0.55	Blood protein levels;	chr5:55953115	chr17:15783288~15784307:+
THCA	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	14.21	2.31e-38	1.51e-31	0.83	0.55	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	14.21	2.31e-38	1.51e-31	0.83	0.55	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
THCA	trans	rs3740713	0.669	rs34740438	ENSG00000235847.2	LDHAP7	14.2	2.38e-38	1.56e-31	0.96	0.55	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr2:84777259~84778223:-
THCA	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	14.2	2.4e-38	1.57e-31	0.82	0.55	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
THCA	trans	rs4276421	0.615	rs4626346	ENSG00000231752.4	EMBP1	14.2	2.4e-38	1.57e-31	0.73	0.55	P wave duration;	chr5:45857435	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.615	rs7730617	ENSG00000231752.4	EMBP1	14.2	2.5e-38	1.64e-31	0.74	0.55	P wave duration;	chr5:45840201	chr1:121519112~121571892:+
THCA	trans	rs55665837	1	rs2305306	ENSG00000236360.2	RP11-334A14.2	14.19	2.67e-38	1.74e-31	0.73	0.55	Vitamin D levels;	chr11:14513453	chr1:52993201~52993702:-
THCA	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-14.19	2.68e-38	1.75e-31	-0.87	-0.55	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
THCA	trans	rs10242455	0.702	rs6977165	ENSG00000228834.1	RP11-249L21.4	14.19	2.69e-38	1.76e-31	1.55	0.55	Blood metabolite levels;	chr7:99671774	chr6:108907615~108907873:-
THCA	trans	rs116095464	0.867	rs7726582	ENSG00000185986.11	SDHAP3	14.19	2.71e-38	1.77e-31	0.59	0.55	Breast cancer;	chr5:215234	chr5:1572222~1594620:-
THCA	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	14.18	2.94e-38	1.92e-31	0.82	0.55	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
THCA	trans	rs10242455	0.571	rs13438288	ENSG00000228834.1	RP11-249L21.4	14.18	3.06e-38	2e-31	1.57	0.55	Blood metabolite levels;	chr7:99318791	chr6:108907615~108907873:-
THCA	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	14.18	3.13e-38	2.04e-31	0.76	0.55	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	14.18	3.13e-38	2.04e-31	0.76	0.55	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
THCA	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	14.18	3.13e-38	2.04e-31	0.76	0.55	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
THCA	trans	rs1816752	0.716	rs7995304	ENSG00000224976.2	PARP4P2	14.18	3.15e-38	2.06e-31	0.64	0.55	Obesity-related traits;	chr13:24514284	chr13:19349137~19407962:+
THCA	trans	rs10242455	0.702	rs59574285	ENSG00000228834.1	RP11-249L21.4	14.17	3.25e-38	2.12e-31	1.55	0.55	Blood metabolite levels;	chr7:99638528	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs6956305	ENSG00000228834.1	RP11-249L21.4	14.17	3.25e-38	2.12e-31	1.55	0.55	Blood metabolite levels;	chr7:99643687	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs73713580	ENSG00000228834.1	RP11-249L21.4	14.17	3.25e-38	2.12e-31	1.55	0.55	Blood metabolite levels;	chr7:99643987	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs6976017	ENSG00000228834.1	RP11-249L21.4	14.17	3.25e-38	2.12e-31	1.55	0.55	Blood metabolite levels;	chr7:99652376	chr6:108907615~108907873:-
THCA	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	14.17	3.42e-38	2.23e-31	0.76	0.55	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-
THCA	trans	rs7730934	0.818	rs6450361	ENSG00000227018.1	IL6STP1	14.16	3.6e-38	2.35e-31	0.84	0.55	Blood protein levels;	chr5:56004698	chr17:15783288~15784307:+
THCA	trans	rs77688320	0.517	rs2270315	ENSG00000235105.1	RP11-329A14.1	14.16	3.63e-38	2.36e-31	0.61	0.55	Breast cancer;	chr2:201452542	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.517	rs2287054	ENSG00000235105.1	RP11-329A14.1	14.16	3.63e-38	2.36e-31	0.61	0.55	Breast cancer;	chr2:201454315	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.5	rs10931948	ENSG00000235105.1	RP11-329A14.1	14.16	3.63e-38	2.36e-31	0.61	0.55	Breast cancer;	chr2:201459199	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs6435084	ENSG00000235105.1	RP11-329A14.1	14.16	3.63e-38	2.36e-31	0.61	0.55	Breast cancer;	chr2:201461274	chr1:48435967~48437223:+
THCA	trans	rs4276421	0.555	rs2247112	ENSG00000231752.4	EMBP1	14.16	3.83e-38	2.49e-31	0.73	0.55	P wave duration;	chr5:45628908	chr1:121519112~121571892:+
THCA	trans	rs77688320	0.535	rs2540441	ENSG00000235105.1	RP11-329A14.1	-14.15	3.88e-38	2.52e-31	-0.61	-0.55	Breast cancer;	chr2:201481946	chr1:48435967~48437223:+
THCA	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	14.15	4.1e-38	2.67e-31	0.82	0.55	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.627	rs10114381	ENSG00000238072.1	RP11-305M3.2	14.14	4.29e-38	2.79e-31	0.82	0.55	Hematology traits;	chr9:113213692	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.651	rs10114423	ENSG00000238072.1	RP11-305M3.2	14.14	4.29e-38	2.79e-31	0.82	0.55	Hematology traits;	chr9:113213751	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.676	rs10817460	ENSG00000238072.1	RP11-305M3.2	14.14	4.29e-38	2.79e-31	0.82	0.55	Hematology traits;	chr9:113214118	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.603	rs7859189	ENSG00000238072.1	RP11-305M3.2	14.14	4.29e-38	2.79e-31	0.82	0.55	Hematology traits;	chr9:113217389	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.676	rs6477997	ENSG00000238072.1	RP11-305M3.2	14.14	4.29e-38	2.79e-31	0.82	0.55	Hematology traits;	chr9:113218833	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.627	rs3810914	ENSG00000238072.1	RP11-305M3.2	14.14	4.29e-38	2.79e-31	0.82	0.55	Hematology traits;	chr9:113219441	chr7:129410113~129410370:-
THCA	trans	rs6477998	0.676	rs4978536	ENSG00000238072.1	RP11-305M3.2	14.14	4.29e-38	2.79e-31	0.82	0.55	Hematology traits;	chr9:113220123	chr7:129410113~129410370:-
THCA	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	14.14	4.36e-38	2.83e-31	0.99	0.55	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	14.14	4.38e-38	2.84e-31	1	0.55	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
THCA	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	14.13	4.75e-38	3.08e-31	0.68	0.55	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
THCA	trans	rs7730934	0.818	rs10076283	ENSG00000227018.1	IL6STP1	14.13	4.81e-38	3.12e-31	0.84	0.55	Blood protein levels;	chr5:55994618	chr17:15783288~15784307:+
THCA	trans	rs116095464	0.51	rs7714944	ENSG00000185986.11	SDHAP3	14.13	4.88e-38	3.16e-31	0.59	0.55	Breast cancer;	chr5:231650	chr5:1572222~1594620:-
THCA	trans	rs7730934	0.818	rs10066245	ENSG00000227018.1	IL6STP1	14.13	5e-38	3.24e-31	0.84	0.55	Blood protein levels;	chr5:55975457	chr17:15783288~15784307:+
THCA	trans	rs7730934	0.818	rs6861772	ENSG00000227018.1	IL6STP1	14.13	5e-38	3.24e-31	0.84	0.55	Blood protein levels;	chr5:55975793	chr17:15783288~15784307:+
THCA	trans	rs7730934	0.818	rs6873542	ENSG00000227018.1	IL6STP1	14.13	5e-38	3.24e-31	0.84	0.55	Blood protein levels;	chr5:55986790	chr17:15783288~15784307:+
THCA	trans	rs116095464	0.558	rs7708515	ENSG00000185986.11	SDHAP3	14.12	5.62e-38	3.63e-31	0.57	0.55	Breast cancer;	chr5:234874	chr5:1572222~1594620:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-14.12	5.74e-38	3.7e-31	-0.66	-0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
THCA	trans	rs616147	0.671	rs674192	ENSG00000183298.5	RP11-556K13.1	-14.11	5.97e-38	3.85e-31	-0.76	-0.55	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr1:101786340~101787219:-
THCA	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	14.11	6.14e-38	3.96e-31	0.93	0.55	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	14.11	6.14e-38	3.96e-31	0.93	0.55	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	14.11	6.14e-38	3.96e-31	0.93	0.55	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
THCA	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	14.1	6.42e-38	4.14e-31	0.72	0.55	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
THCA	trans	rs3947	0.615	rs2088346	ENSG00000229857.1	RP11-159H20.3	14.1	6.45e-38	4.16e-31	0.85	0.55	Blood protein levels;	chr8:11796875	chr9:76992099~76993108:+
THCA	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	14.1	6.53e-38	4.21e-31	0.75	0.55	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
THCA	trans	rs1816752	0.716	rs1441058	ENSG00000224976.2	PARP4P2	14.1	6.58e-38	4.24e-31	0.64	0.55	Obesity-related traits;	chr13:24516275	chr13:19349137~19407962:+
THCA	trans	rs116095464	0.558	rs10079760	ENSG00000185986.11	SDHAP3	14.1	6.59e-38	4.24e-31	0.58	0.55	Breast cancer;	chr5:230663	chr5:1572222~1594620:-
THCA	trans	rs7730934	0.818	rs16884703	ENSG00000227018.1	IL6STP1	14.1	6.61e-38	4.26e-31	0.84	0.55	Blood protein levels;	chr5:55993468	chr17:15783288~15784307:+
THCA	trans	rs9611519	0.78	rs1983631	ENSG00000268568.1	AC007228.9	-14.1	6.8e-38	4.38e-31	-0.64	-0.55	Neuroticism;	chr22:41248070	chr19:56672574~56673901:-
THCA	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-14.09	7.31e-38	4.7e-31	-0.68	-0.54	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
THCA	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	14.09	7.43e-38	4.77e-31	0.98	0.54	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	14.09	7.43e-38	4.77e-31	0.98	0.54	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
THCA	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	14.09	7.43e-38	4.77e-31	0.98	0.54	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
THCA	trans	rs1816752	0.646	rs7322329	ENSG00000224976.2	PARP4P2	14.08	7.75e-38	4.98e-31	0.63	0.54	Obesity-related traits;	chr13:24479193	chr13:19349137~19407962:+
THCA	trans	rs55665837	1	rs11023227	ENSG00000236360.2	RP11-334A14.2	14.08	7.81e-38	5.02e-31	0.72	0.54	Vitamin D levels;	chr11:14437541	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs11023229	ENSG00000236360.2	RP11-334A14.2	14.08	7.81e-38	5.02e-31	0.72	0.54	Vitamin D levels;	chr11:14439455	chr1:52993201~52993702:-
THCA	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	14.08	7.87e-38	5.06e-31	0.82	0.54	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
THCA	trans	rs7730934	1	rs11739853	ENSG00000227018.1	IL6STP1	14.08	8.27e-38	5.31e-31	0.95	0.54	Blood protein levels;	chr5:55961688	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs11574769	ENSG00000227018.1	IL6STP1	14.08	8.27e-38	5.31e-31	0.95	0.54	Blood protein levels;	chr5:55962393	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs13170520	ENSG00000227018.1	IL6STP1	14.08	8.27e-38	5.31e-31	0.95	0.54	Blood protein levels;	chr5:55978014	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs11744301	ENSG00000227018.1	IL6STP1	14.08	8.27e-38	5.31e-31	0.95	0.54	Blood protein levels;	chr5:55978776	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs11748421	ENSG00000227018.1	IL6STP1	14.08	8.27e-38	5.31e-31	0.95	0.54	Blood protein levels;	chr5:55978844	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs11744523	ENSG00000227018.1	IL6STP1	14.08	8.27e-38	5.31e-31	0.95	0.54	Blood protein levels;	chr5:55980088	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs11574765	ENSG00000227018.1	IL6STP1	14.08	8.27e-38	5.31e-31	0.95	0.54	Blood protein levels;	chr5:55983139	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs35354044	ENSG00000227018.1	IL6STP1	14.08	8.27e-38	5.31e-31	0.95	0.54	Blood protein levels;	chr5:55986809	chr17:15783288~15784307:+
THCA	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs3923294	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14419856	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs12283797	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14420716	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs10832256	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14421329	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.961	rs12795972	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14422229	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs12287715	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14423029	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	14.08	8.46e-38	5.42e-31	0.72	0.54	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
THCA	trans	rs116095464	0.51	rs73016876	ENSG00000185986.11	SDHAP3	14.08	8.54e-38	5.47e-31	0.6	0.54	Breast cancer;	chr5:244360	chr5:1572222~1594620:-
THCA	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	14.07	8.63e-38	5.51e-31	0.73	0.54	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	14.07	8.63e-38	5.51e-31	0.73	0.54	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	14.07	8.63e-38	5.51e-31	0.73	0.54	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.961	rs12576926	ENSG00000236360.2	RP11-334A14.2	14.07	8.63e-38	5.51e-31	0.73	0.54	Vitamin D levels;	chr11:14458746	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs34382046	ENSG00000236360.2	RP11-334A14.2	14.07	8.7e-38	5.53e-31	0.72	0.54	Vitamin D levels;	chr11:14429772	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs7945167	ENSG00000236360.2	RP11-334A14.2	14.07	8.7e-38	5.53e-31	0.72	0.54	Vitamin D levels;	chr11:14430274	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.961	rs60622588	ENSG00000236360.2	RP11-334A14.2	14.07	8.7e-38	5.53e-31	0.72	0.54	Vitamin D levels;	chr11:14435452	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs11023223	ENSG00000236360.2	RP11-334A14.2	14.07	8.7e-38	5.53e-31	0.72	0.54	Vitamin D levels;	chr11:14435566	chr1:52993201~52993702:-
THCA	trans	rs116095464	0.51	rs10057501	ENSG00000185986.11	SDHAP3	14.07	8.92e-38	5.67e-31	0.59	0.54	Breast cancer;	chr5:239430	chr5:1572222~1594620:-
THCA	trans	rs7258465	0.965	rs10408290	ENSG00000267533.1	RP11-815J4.7	14.06	9.48e-38	6.02e-31	0.76	0.54	Breast cancer;	chr19:18431891	chr18:12067173~12068417:-
THCA	trans	rs7258465	0.965	rs10409003	ENSG00000267533.1	RP11-815J4.7	14.06	9.48e-38	6.02e-31	0.76	0.54	Breast cancer;	chr19:18432244	chr18:12067173~12068417:-
THCA	trans	rs7937890	0.9	rs7118682	ENSG00000236360.2	RP11-334A14.2	-14.06	9.57e-38	6.08e-31	-0.72	-0.54	Mitochondrial DNA levels;	chr11:14253004	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.922	rs12287212	ENSG00000236360.2	RP11-334A14.2	14.06	1.01e-37	6.43e-31	0.72	0.54	Vitamin D levels;	chr11:14428315	chr1:52993201~52993702:-
THCA	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	14.06	1.03e-37	6.53e-31	0.75	0.54	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
THCA	trans	rs8081395	0.627	rs12952730	ENSG00000187870.7	RNFT1P3	14.06	1.04e-37	6.57e-31	0.71	0.54	White blood cell count;	chr17:59901475	chr17:20743333~20754501:-
THCA	trans	rs8081395	0.627	rs180536	ENSG00000187870.7	RNFT1P3	14.06	1.04e-37	6.57e-31	0.71	0.54	White blood cell count;	chr17:59919445	chr17:20743333~20754501:-
THCA	trans	rs55665837	1	rs10832275	ENSG00000236360.2	RP11-334A14.2	14.05	1.05e-37	6.64e-31	0.72	0.54	Vitamin D levels;	chr11:14456678	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs12276938	ENSG00000236360.2	RP11-334A14.2	14.05	1.09e-37	6.87e-31	0.72	0.54	Vitamin D levels;	chr11:14441942	chr1:52993201~52993702:-
THCA	trans	rs7730934	1	rs35450255	ENSG00000227018.1	IL6STP1	14.05	1.09e-37	6.89e-31	0.95	0.54	Blood protein levels;	chr5:56006116	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs13177475	ENSG00000227018.1	IL6STP1	14.05	1.09e-37	6.89e-31	0.95	0.54	Blood protein levels;	chr5:56006580	chr17:15783288~15784307:+
THCA	trans	rs7730934	1	rs13166487	ENSG00000227018.1	IL6STP1	14.05	1.09e-37	6.89e-31	0.95	0.54	Blood protein levels;	chr5:56008123	chr17:15783288~15784307:+
THCA	trans	rs12709013	0.569	rs30837	ENSG00000233719.3	GOT2P3	14.05	1.09e-37	6.92e-31	0.72	0.54	Blood metabolite ratios;	chr16:58711942	chr12:9641802~9643007:+
THCA	trans	rs13177918	0.798	rs2343805	ENSG00000213058.3	RP4-765C7.2	14.05	1.1e-37	6.94e-31	0.83	0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr1:178411616~178411972:+
THCA	trans	rs7730934	0.818	rs6863337	ENSG00000227018.1	IL6STP1	14.05	1.11e-37	6.99e-31	0.85	0.54	Blood protein levels;	chr5:55993318	chr17:15783288~15784307:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	14.05	1.13e-37	7.11e-31	0.69	0.54	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
THCA	trans	rs7811142	0.83	rs28495773	ENSG00000228546.2	CTA-313A17.3	14.05	1.13e-37	7.15e-31	0.94	0.54	Platelet count;	chr7:100345960	chr7:102337316~102339115:+
THCA	trans	rs7258465	1	rs10411009	ENSG00000267533.1	RP11-815J4.7	14.05	1.14e-37	7.2e-31	0.75	0.54	Breast cancer;	chr19:18495456	chr18:12067173~12068417:-
THCA	trans	rs12709013	0.636	rs1646256	ENSG00000233719.3	GOT2P3	14.05	1.14e-37	7.23e-31	0.7	0.54	Blood metabolite ratios;	chr16:58712114	chr12:9641802~9643007:+
THCA	trans	rs1816752	0.646	rs3783073	ENSG00000224976.2	PARP4P2	14.04	1.18e-37	7.45e-31	0.63	0.54	Obesity-related traits;	chr13:24493222	chr13:19349137~19407962:+
THCA	trans	rs928391	0.541	rs1888863	ENSG00000227183.3	HDGFP1	-14.03	1.29e-37	8.15e-31	-0.86	-0.54	Platelet count;	chr1:156828046	chrX:131646639~131646890:+
THCA	trans	rs2657294	0.73	rs1259505	ENSG00000172974.11	AC007318.5	14.03	1.31e-37	8.25e-31	0.66	0.54	Pneumonia;	chr10:75237183	chr2:65205108~65205988:+
THCA	trans	rs10242455	0.702	rs116671616	ENSG00000228834.1	RP11-249L21.4	14.03	1.33e-37	8.37e-31	1.53	0.54	Blood metabolite levels;	chr7:99356935	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.702	rs75156180	ENSG00000228834.1	RP11-249L21.4	14.03	1.33e-37	8.37e-31	1.53	0.54	Blood metabolite levels;	chr7:99366477	chr6:108907615~108907873:-
THCA	trans	rs7730934	0.711	rs3827618	ENSG00000227018.1	IL6STP1	14.02	1.42e-37	8.95e-31	0.84	0.54	Blood protein levels;	chr5:55993325	chr17:15783288~15784307:+
THCA	trans	rs7258465	1	rs271623	ENSG00000267533.1	RP11-815J4.7	14.02	1.45e-37	9.09e-31	0.76	0.54	Breast cancer;	chr19:18518137	chr18:12067173~12068417:-
THCA	trans	rs55665837	1	rs10466412	ENSG00000236360.2	RP11-334A14.2	14.02	1.45e-37	9.1e-31	0.72	0.54	Vitamin D levels;	chr11:14483643	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs11023224	ENSG00000236360.2	RP11-334A14.2	14.02	1.47e-37	9.26e-31	0.72	0.54	Vitamin D levels;	chr11:14436193	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.961	rs11023226	ENSG00000236360.2	RP11-334A14.2	14.02	1.47e-37	9.26e-31	0.72	0.54	Vitamin D levels;	chr11:14437271	chr1:52993201~52993702:-
THCA	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	14.02	1.48e-37	9.27e-31	0.75	0.54	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000233778.3	RP11-777J24.1	-14.01	1.57e-37	9.85e-31	-0.63	-0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:92144088~92144435:-
THCA	trans	rs928391	0.592	rs1888861	ENSG00000227183.3	HDGFP1	-14.01	1.59e-37	9.97e-31	-0.86	-0.54	Platelet count;	chr1:156828169	chrX:131646639~131646890:+
THCA	trans	rs7258465	0.965	rs271622	ENSG00000267533.1	RP11-815J4.7	14.01	1.67e-37	1.05e-30	0.76	0.54	Breast cancer;	chr19:18518467	chr18:12067173~12068417:-
THCA	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	14.01	1.71e-37	1.07e-30	0.72	0.54	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
THCA	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	14	1.71e-37	1.07e-30	0.93	0.54	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	14	1.71e-37	1.07e-30	0.93	0.54	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	14	1.71e-37	1.07e-30	0.93	0.54	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	14	1.71e-37	1.07e-30	0.93	0.54	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	14	1.71e-37	1.07e-30	0.93	0.54	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	14	1.71e-37	1.07e-30	0.93	0.54	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
THCA	trans	rs55665837	0.961	rs11023237	ENSG00000236360.2	RP11-334A14.2	14	1.75e-37	1.09e-30	0.72	0.54	Vitamin D levels;	chr11:14478788	chr1:52993201~52993702:-
THCA	trans	rs12709013	0.591	rs30838	ENSG00000233719.3	GOT2P3	14	1.77e-37	1.11e-30	0.72	0.54	Blood metabolite ratios;	chr16:58711513	chr12:9641802~9643007:+
THCA	trans	rs55665837	1	rs12364959	ENSG00000236360.2	RP11-334A14.2	14	1.78e-37	1.11e-30	0.72	0.54	Vitamin D levels;	chr11:14485889	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs2305305	ENSG00000236360.2	RP11-334A14.2	14	1.78e-37	1.11e-30	0.72	0.54	Vitamin D levels;	chr11:14519396	chr1:52993201~52993702:-
THCA	trans	rs3779195	0.697	rs13232861	ENSG00000225169.1	BRI3P1	13.99	1.91e-37	1.19e-30	0.83	0.54	Sex hormone-binding globulin levels;	chr7:98299769	chr1:100213293~100213670:+
THCA	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-13.99	2.01e-37	1.25e-30	-0.81	-0.54	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
THCA	trans	rs7937890	0.904	rs11023169	ENSG00000236360.2	RP11-334A14.2	-13.99	2.03e-37	1.27e-30	-0.71	-0.54	Mitochondrial DNA levels;	chr11:14269439	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs10766182	ENSG00000236360.2	RP11-334A14.2	13.98	2.15e-37	1.34e-30	0.72	0.54	Vitamin D levels;	chr11:14477990	chr1:52993201~52993702:-
THCA	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	13.98	2.18e-37	1.36e-30	0.81	0.54	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
THCA	trans	rs8081395	0.603	rs1292047	ENSG00000187870.7	RNFT1P3	13.98	2.18e-37	1.36e-30	0.71	0.54	White blood cell count;	chr17:59877805	chr17:20743333~20754501:-
THCA	trans	rs1816752	0.646	rs1361578	ENSG00000224976.2	PARP4P2	13.98	2.19e-37	1.36e-30	0.63	0.54	Obesity-related traits;	chr13:24491117	chr13:19349137~19407962:+
THCA	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-13.97	2.32e-37	1.44e-30	-0.65	-0.54	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
THCA	trans	rs55665837	1	rs34980103	ENSG00000236360.2	RP11-334A14.2	13.97	2.32e-37	1.44e-30	0.72	0.54	Vitamin D levels;	chr11:14491339	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs55665837	ENSG00000236360.2	RP11-334A14.2	13.97	2.44e-37	1.52e-30	0.72	0.54	Vitamin D levels;	chr11:14473503	chr1:52993201~52993702:-
THCA	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	13.96	2.55e-37	1.59e-30	0.91	0.54	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
THCA	trans	rs928391	0.592	rs7516856	ENSG00000227183.3	HDGFP1	-13.96	2.56e-37	1.59e-30	-0.86	-0.54	Platelet count;	chr1:156828324	chrX:131646639~131646890:+
THCA	trans	rs9876781	0.624	rs12491849	ENSG00000235912.1	RP1-159A19.3	-13.96	2.62e-37	1.62e-30	-0.69	-0.54	Longevity;	chr3:48489975	chr1:27649419~27649610:+
THCA	trans	rs9899728	0.572	rs4365317	ENSG00000234925.2	ATP5HP4	13.96	2.72e-37	1.69e-30	0.84	0.54	Alzheimer's disease or small vessel stroke;	chr17:75063725	chr12:68642519~68642993:-
THCA	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	13.96	2.76e-37	1.71e-30	0.67	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
THCA	trans	rs7258465	0.931	rs271626	ENSG00000267533.1	RP11-815J4.7	-13.96	2.78e-37	1.72e-30	-0.75	-0.54	Breast cancer;	chr19:18516257	chr18:12067173~12068417:-
THCA	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	13.95	3.05e-37	1.89e-30	0.66	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
THCA	trans	rs1816752	0.646	rs7322323	ENSG00000224976.2	PARP4P2	13.95	3.11e-37	1.92e-30	0.62	0.54	Obesity-related traits;	chr13:24479189	chr13:19349137~19407962:+
THCA	trans	rs55665837	1	rs10832264	ENSG00000236360.2	RP11-334A14.2	13.94	3.2e-37	1.98e-30	0.72	0.54	Vitamin D levels;	chr11:14438436	chr1:52993201~52993702:-
THCA	trans	rs3779195	0.929	rs10953259	ENSG00000225169.1	BRI3P1	-13.94	3.31e-37	2.05e-30	-0.83	-0.54	Sex hormone-binding globulin levels;	chr7:98383795	chr1:100213293~100213670:+
THCA	trans	rs116095464	0.558	rs10052012	ENSG00000185986.11	SDHAP3	13.94	3.43e-37	2.12e-30	0.59	0.54	Breast cancer;	chr5:231793	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10077076	ENSG00000185986.11	SDHAP3	13.94	3.43e-37	2.12e-30	0.59	0.54	Breast cancer;	chr5:231825	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10080225	ENSG00000185986.11	SDHAP3	13.94	3.43e-37	2.12e-30	0.59	0.54	Breast cancer;	chr5:232060	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10475136	ENSG00000185986.11	SDHAP3	13.94	3.43e-37	2.12e-30	0.59	0.54	Breast cancer;	chr5:232681	chr5:1572222~1594620:-
THCA	trans	rs4276421	0.555	rs10041767	ENSG00000231752.4	EMBP1	13.93	3.58e-37	2.21e-30	0.71	0.54	P wave duration;	chr5:45767317	chr1:121519112~121571892:+
THCA	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	13.93	3.64e-37	2.25e-30	0.92	0.54	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
THCA	trans	rs55665837	1	rs10832278	ENSG00000236360.2	RP11-334A14.2	13.93	3.75e-37	2.32e-30	0.72	0.54	Vitamin D levels;	chr11:14475073	chr1:52993201~52993702:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-13.92	3.79e-37	2.35e-30	-0.67	-0.54	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
THCA	trans	rs616147	0.655	rs1707981	ENSG00000183298.5	RP11-556K13.1	-13.92	3.8e-37	2.35e-30	-0.76	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr1:101786340~101787219:-
THCA	trans	rs3779195	0.929	rs2906184	ENSG00000225169.1	BRI3P1	-13.92	3.93e-37	2.43e-30	-0.83	-0.54	Sex hormone-binding globulin levels;	chr7:98310675	chr1:100213293~100213670:+
THCA	trans	rs7811142	0.943	rs67196635	ENSG00000228546.2	CTA-313A17.3	13.92	3.99e-37	2.46e-30	0.92	0.54	Platelet count;	chr7:100427941	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs6962151	ENSG00000228546.2	CTA-313A17.3	13.92	3.99e-37	2.46e-30	0.92	0.54	Platelet count;	chr7:100430861	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.943	rs67483801	ENSG00000228546.2	CTA-313A17.3	13.92	3.99e-37	2.46e-30	0.92	0.54	Platelet count;	chr7:100434135	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs11761784	ENSG00000228546.2	CTA-313A17.3	13.92	3.99e-37	2.46e-30	0.92	0.54	Platelet count;	chr7:100442347	chr7:102337316~102339115:+
THCA	trans	rs116095464	0.558	rs6879656	ENSG00000185986.11	SDHAP3	13.92	4e-37	2.47e-30	0.61	0.54	Breast cancer;	chr5:264313	chr5:1572222~1594620:-
THCA	trans	rs7730934	0.818	rs6891628	ENSG00000227018.1	IL6STP1	13.92	4.04e-37	2.49e-30	0.84	0.54	Blood protein levels;	chr5:56000710	chr17:15783288~15784307:+
THCA	trans	rs3779195	0.86	rs12704986	ENSG00000225169.1	BRI3P1	13.92	4.13e-37	2.55e-30	0.82	0.54	Sex hormone-binding globulin levels;	chr7:98357118	chr1:100213293~100213670:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-13.91	4.31e-37	2.66e-30	-0.67	-0.54	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
THCA	trans	rs7258465	0.965	rs748609	ENSG00000267533.1	RP11-815J4.7	13.91	4.36e-37	2.69e-30	0.76	0.54	Breast cancer;	chr19:18449472	chr18:12067173~12068417:-
THCA	trans	rs7811142	1	rs11766752	ENSG00000228546.2	CTA-313A17.3	13.91	4.47e-37	2.75e-30	0.93	0.54	Platelet count;	chr7:100475669	chr7:102337316~102339115:+
THCA	trans	rs616147	0.72	rs2965067	ENSG00000183298.5	RP11-556K13.1	-13.9	4.63e-37	2.85e-30	-0.76	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr1:101786340~101787219:-
THCA	trans	rs4276421	0.615	rs12109205	ENSG00000231752.4	EMBP1	13.9	4.71e-37	2.9e-30	0.73	0.54	P wave duration;	chr5:45876576	chr1:121519112~121571892:+
THCA	trans	rs616147	0.72	rs1768209	ENSG00000183298.5	RP11-556K13.1	-13.9	4.73e-37	2.91e-30	-0.76	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr1:101786340~101787219:-
THCA	trans	rs7811142	1	rs4472444	ENSG00000228546.2	CTA-313A17.3	13.9	4.76e-37	2.93e-30	0.93	0.54	Platelet count;	chr7:100473135	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs7809801	ENSG00000228546.2	CTA-313A17.3	13.9	4.76e-37	2.93e-30	0.93	0.54	Platelet count;	chr7:100474408	chr7:102337316~102339115:+
THCA	trans	rs7258465	0.896	rs8103660	ENSG00000267533.1	RP11-815J4.7	13.9	4.86e-37	2.99e-30	0.76	0.54	Breast cancer;	chr19:18455585	chr18:12067173~12068417:-
THCA	trans	rs7258465	0.965	rs2385088	ENSG00000267533.1	RP11-815J4.7	13.9	5.01e-37	3.08e-30	0.75	0.54	Breast cancer;	chr19:18434730	chr18:12067173~12068417:-
THCA	trans	rs55665837	1	rs10832276	ENSG00000236360.2	RP11-334A14.2	13.89	5.13e-37	3.15e-30	0.73	0.54	Vitamin D levels;	chr11:14461728	chr1:52993201~52993702:-
THCA	trans	rs7730934	0.818	rs13179290	ENSG00000227018.1	IL6STP1	13.89	5.18e-37	3.18e-30	0.84	0.54	Blood protein levels;	chr5:56007013	chr17:15783288~15784307:+
THCA	trans	rs55665837	1	rs11023246	ENSG00000236360.2	RP11-334A14.2	13.89	5.41e-37	3.32e-30	0.72	0.54	Vitamin D levels;	chr11:14515410	chr1:52993201~52993702:-
THCA	trans	rs616147	0.671	rs675595	ENSG00000183298.5	RP11-556K13.1	-13.89	5.53e-37	3.37e-30	-0.76	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr1:101786340~101787219:-
THCA	trans	rs9899728	0.572	rs9915968	ENSG00000234925.2	ATP5HP4	13.88	6.14e-37	3.73e-30	0.84	0.54	Alzheimer's disease or small vessel stroke;	chr17:75063521	chr12:68642519~68642993:-
THCA	trans	rs1816752	0.624	rs7330766	ENSG00000224976.2	PARP4P2	13.87	6.24e-37	3.79e-30	0.63	0.54	Obesity-related traits;	chr13:24495579	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.603	rs7984094	ENSG00000224976.2	PARP4P2	13.87	6.24e-37	3.79e-30	0.63	0.54	Obesity-related traits;	chr13:24496212	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs4770700	ENSG00000224976.2	PARP4P2	13.87	6.24e-37	3.79e-30	0.63	0.54	Obesity-related traits;	chr13:24494796	chr13:19349137~19407962:+
THCA	trans	rs7811142	0.943	rs28660238	ENSG00000228546.2	CTA-313A17.3	13.87	6.25e-37	3.8e-30	0.91	0.54	Platelet count;	chr7:100425685	chr7:102337316~102339115:+
THCA	trans	rs4276421	0.555	rs10041772	ENSG00000231752.4	EMBP1	13.87	6.57e-37	3.99e-30	0.7	0.54	P wave duration;	chr5:45767386	chr1:121519112~121571892:+
THCA	trans	rs7937890	0.904	rs7484197	ENSG00000236360.2	RP11-334A14.2	13.87	6.6e-37	4.01e-30	0.72	0.54	Mitochondrial DNA levels;	chr11:14262108	chr1:52993201~52993702:-
THCA	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	13.86	6.94e-37	4.21e-30	0.92	0.54	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	13.86	6.94e-37	4.21e-30	0.92	0.54	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
THCA	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	13.86	7.14e-37	4.33e-30	0.71	0.54	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	13.86	7.14e-37	4.33e-30	0.71	0.54	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
THCA	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	13.86	7.14e-37	4.33e-30	0.71	0.54	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
THCA	trans	rs7258465	1	rs8105994	ENSG00000267533.1	RP11-815J4.7	13.86	7.49e-37	4.55e-30	0.76	0.54	Breast cancer;	chr19:18482743	chr18:12067173~12068417:-
THCA	trans	rs6477998	0.647	rs10981704	ENSG00000238072.1	RP11-305M3.2	-13.85	7.89e-37	4.78e-30	-0.73	-0.54	Hematology traits;	chr9:113253989	chr7:129410113~129410370:-
THCA	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	13.85	8.1e-37	4.91e-30	0.92	0.54	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs112317829	ENSG00000228546.2	CTA-313A17.3	13.85	8.21e-37	4.97e-30	0.92	0.54	Platelet count;	chr7:100445550	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	13.85	8.21e-37	4.97e-30	0.92	0.54	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs67239991	ENSG00000228546.2	CTA-313A17.3	13.85	8.21e-37	4.97e-30	0.92	0.54	Platelet count;	chr7:100448881	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.943	rs111493473	ENSG00000228546.2	CTA-313A17.3	13.85	8.21e-37	4.97e-30	0.92	0.54	Platelet count;	chr7:100452119	chr7:102337316~102339115:+
THCA	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	13.85	8.23e-37	4.98e-30	0.64	0.54	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	13.85	8.23e-37	4.98e-30	0.64	0.54	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
THCA	trans	rs3779195	0.697	rs1688606	ENSG00000225169.1	BRI3P1	13.84	8.55e-37	5.17e-30	0.82	0.54	Sex hormone-binding globulin levels;	chr7:98345539	chr1:100213293~100213670:+
THCA	trans	rs3779195	0.858	rs3779196	ENSG00000225169.1	BRI3P1	13.84	8.67e-37	5.25e-30	0.82	0.54	Sex hormone-binding globulin levels;	chr7:98360794	chr1:100213293~100213670:+
THCA	trans	rs3779195	0.789	rs6965424	ENSG00000225169.1	BRI3P1	13.84	8.67e-37	5.25e-30	0.82	0.54	Sex hormone-binding globulin levels;	chr7:98361813	chr1:100213293~100213670:+
THCA	trans	rs4276421	0.571	rs7703405	ENSG00000231752.4	EMBP1	-13.84	8.69e-37	5.25e-30	-0.71	-0.54	P wave duration;	chr5:45872218	chr1:121519112~121571892:+
THCA	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	13.84	9.19e-37	5.55e-30	0.81	0.54	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000227887.1	RPS26P13	13.83	9.54e-37	5.76e-30	0.67	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:208697369~208697698:-
THCA	trans	rs7258465	1	rs76194	ENSG00000267533.1	RP11-815J4.7	13.83	9.77e-37	5.9e-30	0.75	0.54	Breast cancer;	chr19:18519770	chr18:12067173~12068417:-
THCA	trans	rs7258465	1	rs271621	ENSG00000267533.1	RP11-815J4.7	13.83	9.77e-37	5.9e-30	0.75	0.54	Breast cancer;	chr19:18520522	chr18:12067173~12068417:-
THCA	trans	rs116095464	0.558	rs62347677	ENSG00000185986.11	SDHAP3	13.83	1.01e-36	6.12e-30	0.59	0.54	Breast cancer;	chr5:227338	chr5:1572222~1594620:-
THCA	trans	rs9611519	0.78	rs3171692	ENSG00000268568.1	AC007228.9	-13.82	1.05e-36	6.32e-30	-0.64	-0.54	Neuroticism;	chr22:41246208	chr19:56672574~56673901:-
THCA	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	13.82	1.1e-36	6.6e-30	0.64	0.54	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
THCA	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	13.81	1.13e-36	6.81e-30	0.91	0.54	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
THCA	trans	rs1816752	0.669	rs3783072	ENSG00000224976.2	PARP4P2	13.81	1.2e-36	7.21e-30	0.62	0.54	Obesity-related traits;	chr13:24493258	chr13:19349137~19407962:+
THCA	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-13.81	1.23e-36	7.42e-30	-0.67	-0.54	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
THCA	trans	rs1816752	0.716	rs9553330	ENSG00000224976.2	PARP4P2	13.8	1.25e-36	7.5e-30	0.63	0.54	Obesity-related traits;	chr13:24516018	chr13:19349137~19407962:+
THCA	trans	rs7811142	1	rs60844404	ENSG00000228546.2	CTA-313A17.3	13.8	1.28e-36	7.67e-30	0.93	0.54	Platelet count;	chr7:100482851	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs113738841	ENSG00000228546.2	CTA-313A17.3	13.8	1.28e-36	7.67e-30	0.93	0.54	Platelet count;	chr7:100483683	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs11763511	ENSG00000228546.2	CTA-313A17.3	13.8	1.28e-36	7.67e-30	0.93	0.54	Platelet count;	chr7:100484321	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs2897358	ENSG00000228546.2	CTA-313A17.3	13.8	1.28e-36	7.67e-30	0.93	0.54	Platelet count;	chr7:100491017	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs7787620	ENSG00000228546.2	CTA-313A17.3	13.8	1.28e-36	7.67e-30	0.93	0.54	Platelet count;	chr7:100491611	chr7:102337316~102339115:+
THCA	trans	rs3779195	1	rs3779195	ENSG00000225169.1	BRI3P1	-13.8	1.3e-36	7.82e-30	-0.84	-0.54	Sex hormone-binding globulin levels;	chr7:98364050	chr1:100213293~100213670:+
THCA	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	13.8	1.34e-36	8.02e-30	0.67	0.54	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
THCA	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	13.8	1.34e-36	8.02e-30	0.67	0.54	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
THCA	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-13.8	1.35e-36	8.13e-30	-0.85	-0.54	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
THCA	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	13.79	1.41e-36	8.48e-30	0.73	0.54	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
THCA	trans	rs7730934	1	rs11742754	ENSG00000227018.1	IL6STP1	13.79	1.44e-36	8.63e-30	1	0.54	Blood protein levels;	chr5:56002665	chr17:15783288~15784307:+
THCA	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	13.79	1.49e-36	8.92e-30	0.73	0.54	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
THCA	trans	rs7811142	1	rs6953107	ENSG00000228546.2	CTA-313A17.3	13.78	1.51e-36	9.08e-30	0.94	0.54	Platelet count;	chr7:100498041	chr7:102337316~102339115:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000233778.3	RP11-777J24.1	13.78	1.53e-36	9.16e-30	0.64	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:92144088~92144435:-
THCA	trans	rs9611519	0.78	rs9611528	ENSG00000268568.1	AC007228.9	-13.78	1.54e-36	9.2e-30	-0.6	-0.54	Neuroticism;	chr22:41252498	chr19:56672574~56673901:-
THCA	trans	rs116095464	0.614	rs62344292	ENSG00000185986.11	SDHAP3	13.78	1.58e-36	9.47e-30	0.59	0.54	Breast cancer;	chr5:244515	chr5:1572222~1594620:-
THCA	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-13.77	1.8e-36	1.08e-29	-0.66	-0.54	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
THCA	trans	rs7312770	0.612	rs773114	ENSG00000227887.1	RPS26P13	13.77	1.81e-36	1.08e-29	0.67	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:208697369~208697698:-
THCA	trans	rs116095464	0.558	rs7714335	ENSG00000185986.11	SDHAP3	13.76	1.86e-36	1.11e-29	0.59	0.54	Breast cancer;	chr5:263398	chr5:1572222~1594620:-
THCA	trans	rs12709013	0.591	rs30840	ENSG00000233719.3	GOT2P3	13.76	1.87e-36	1.12e-29	0.7	0.54	Blood metabolite ratios;	chr16:58710165	chr12:9641802~9643007:+
THCA	trans	rs7811142	0.945	rs6978739	ENSG00000228546.2	CTA-313A17.3	13.76	1.91e-36	1.14e-29	0.95	0.54	Platelet count;	chr7:100501057	chr7:102337316~102339115:+
THCA	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	13.76	1.99e-36	1.19e-29	0.67	0.54	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
THCA	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-13.75	2.07e-36	1.23e-29	-0.74	-0.54	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
THCA	trans	rs7811142	0.943	rs111757992	ENSG00000228546.2	CTA-313A17.3	13.74	2.27e-36	1.35e-29	0.9	0.54	Platelet count;	chr7:100418731	chr7:102337316~102339115:+
THCA	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	13.74	2.3e-36	1.37e-29	0.67	0.54	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
THCA	trans	rs8175379	0.509	rs7293453	ENSG00000231752.4	EMBP1	13.74	2.37e-36	1.41e-29	0.73	0.54	Interleukin-7 levels;	chr5:46253007	chr1:121519112~121571892:+
THCA	trans	rs7811142	1	rs68116612	ENSG00000228546.2	CTA-313A17.3	13.73	2.55e-36	1.52e-29	0.9	0.54	Platelet count;	chr7:100408870	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs11559117	ENSG00000228546.2	CTA-313A17.3	13.73	2.59e-36	1.54e-29	0.92	0.54	Platelet count;	chr7:100478991	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs2406253	ENSG00000228546.2	CTA-313A17.3	13.73	2.59e-36	1.54e-29	0.92	0.54	Platelet count;	chr7:100479650	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs4463351	ENSG00000228546.2	CTA-313A17.3	13.73	2.59e-36	1.54e-29	0.92	0.54	Platelet count;	chr7:100480603	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs11769700	ENSG00000228546.2	CTA-313A17.3	13.73	2.59e-36	1.54e-29	0.92	0.54	Platelet count;	chr7:100492426	chr7:102337316~102339115:+
THCA	trans	rs116095464	0.614	rs78905930	ENSG00000185986.11	SDHAP3	13.72	2.92e-36	1.74e-29	0.58	0.53	Breast cancer;	chr5:246445	chr5:1572222~1594620:-
THCA	trans	rs12709013	0.591	rs30841	ENSG00000233719.3	GOT2P3	13.71	3.13e-36	1.86e-29	0.7	0.53	Blood metabolite ratios;	chr16:58709819	chr12:9641802~9643007:+
THCA	trans	rs7811142	0.945	rs6974282	ENSG00000228546.2	CTA-313A17.3	13.71	3.28e-36	1.95e-29	0.94	0.53	Platelet count;	chr7:100500672	chr7:102337316~102339115:+
THCA	trans	rs7730934	1	rs11574770	ENSG00000227018.1	IL6STP1	13.7	3.64e-36	2.16e-29	0.94	0.53	Blood protein levels;	chr5:55956788	chr17:15783288~15784307:+
THCA	trans	rs7937890	0.874	rs2303972	ENSG00000236360.2	RP11-334A14.2	-13.69	3.77e-36	2.23e-29	-0.72	-0.53	Mitochondrial DNA levels;	chr11:14281736	chr1:52993201~52993702:-
THCA	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	13.69	3.83e-36	2.27e-29	0.91	0.53	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	13.69	3.83e-36	2.27e-29	0.91	0.53	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
THCA	trans	rs8175379	0.509	rs10078317	ENSG00000231752.4	EMBP1	13.69	3.86e-36	2.28e-29	0.73	0.53	Interleukin-7 levels;	chr5:46254038	chr1:121519112~121571892:+
THCA	trans	rs7258465	1	rs4808804	ENSG00000267533.1	RP11-815J4.7	13.66	5.17e-36	3.06e-29	0.75	0.53	Breast cancer;	chr19:18474515	chr18:12067173~12068417:-
THCA	trans	rs12709013	0.591	rs30842	ENSG00000233719.3	GOT2P3	-13.66	5.3e-36	3.13e-29	-0.7	-0.53	Blood metabolite ratios;	chr16:58709550	chr12:9641802~9643007:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-13.65	5.48e-36	3.24e-29	-0.66	-0.53	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
THCA	trans	rs9876781	0.563	rs4858821	ENSG00000235912.1	RP1-159A19.3	13.64	6.14e-36	3.62e-29	0.69	0.53	Longevity;	chr3:48512515	chr1:27649419~27649610:+
THCA	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	13.63	7.02e-36	4.13e-29	0.94	0.53	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.945	rs34989573	ENSG00000228546.2	CTA-313A17.3	13.63	7.06e-36	4.16e-29	0.94	0.53	Platelet count;	chr7:100500272	chr7:102337316~102339115:+
THCA	trans	rs1816752	0.716	rs9553331	ENSG00000224976.2	PARP4P2	13.62	7.53e-36	4.44e-29	0.62	0.53	Obesity-related traits;	chr13:24516030	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.646	rs7997248	ENSG00000224976.2	PARP4P2	13.62	7.92e-36	4.66e-29	0.62	0.53	Obesity-related traits;	chr13:24507050	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.669	rs2862906	ENSG00000224976.2	PARP4P2	13.61	8.37e-36	4.92e-29	0.63	0.53	Obesity-related traits;	chr13:24494482	chr13:19349137~19407962:+
THCA	trans	rs7258465	0.965	rs2561043	ENSG00000267533.1	RP11-815J4.7	13.61	8.44e-36	4.96e-29	0.73	0.53	Breast cancer;	chr19:18511873	chr18:12067173~12068417:-
THCA	trans	rs7730934	1	rs11741161	ENSG00000227018.1	IL6STP1	13.6	9.06e-36	5.32e-29	0.91	0.53	Blood protein levels;	chr5:56018420	chr17:15783288~15784307:+
THCA	trans	rs3779195	0.929	rs1635612	ENSG00000225169.1	BRI3P1	13.59	1.03e-35	6.01e-29	0.79	0.53	Sex hormone-binding globulin levels;	chr7:98385737	chr1:100213293~100213670:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000196933.5	RPS26P11	13.59	1.06e-35	6.18e-29	0.67	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:72044545~72044892:+
THCA	trans	rs9611519	1	rs9611519	ENSG00000268568.1	AC007228.9	-13.58	1.09e-35	6.36e-29	-0.65	-0.53	Neuroticism;	chr22:41217184	chr19:56672574~56673901:-
THCA	trans	rs9611519	1	rs9611520	ENSG00000268568.1	AC007228.9	-13.58	1.09e-35	6.36e-29	-0.65	-0.53	Neuroticism;	chr22:41217299	chr19:56672574~56673901:-
THCA	trans	rs10242455	0.702	rs76702117	ENSG00000228834.1	RP11-249L21.4	13.58	1.18e-35	6.88e-29	1.53	0.53	Blood metabolite levels;	chr7:99319156	chr6:108907615~108907873:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000233778.3	RP11-777J24.1	13.57	1.28e-35	7.45e-29	0.63	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:92144088~92144435:-
THCA	trans	rs7730934	0.818	rs7719246	ENSG00000227018.1	IL6STP1	13.56	1.33e-35	7.73e-29	0.81	0.53	Blood protein levels;	chr5:55948949	chr17:15783288~15784307:+
THCA	trans	rs7730934	0.818	rs11739048	ENSG00000227018.1	IL6STP1	13.56	1.33e-35	7.73e-29	0.81	0.53	Blood protein levels;	chr5:55967667	chr17:15783288~15784307:+
THCA	trans	rs4276421	0.571	rs7724350	ENSG00000231752.4	EMBP1	-13.56	1.37e-35	7.97e-29	-0.73	-0.53	P wave duration;	chr5:45939572	chr1:121519112~121571892:+
THCA	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	13.56	1.39e-35	8.09e-29	0.91	0.53	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
THCA	trans	rs13177918	0.798	rs2343805	ENSG00000239528.1	RPS14P8	13.56	1.39e-35	8.09e-29	0.82	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr5:116562562~116562930:+
THCA	trans	rs7258465	1	rs34010330	ENSG00000267533.1	RP11-815J4.7	13.56	1.41e-35	8.24e-29	0.74	0.53	Breast cancer;	chr19:18448847	chr18:12067173~12068417:-
THCA	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	13.55	1.48e-35	8.64e-29	0.83	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
THCA	trans	rs7811142	1	rs7811142	ENSG00000228546.2	CTA-313A17.3	13.55	1.5e-35	8.74e-29	0.91	0.53	Platelet count;	chr7:100467820	chr7:102337316~102339115:+
THCA	trans	rs1816752	0.716	rs1539096	ENSG00000224976.2	PARP4P2	13.54	1.61e-35	9.38e-29	0.62	0.53	Obesity-related traits;	chr13:24501721	chr13:19349137~19407962:+
THCA	trans	rs7730934	0.818	rs6888334	ENSG00000227018.1	IL6STP1	13.54	1.69e-35	9.81e-29	0.81	0.53	Blood protein levels;	chr5:55955329	chr17:15783288~15784307:+
THCA	trans	rs7730934	0.818	rs10471419	ENSG00000227018.1	IL6STP1	13.54	1.69e-35	9.81e-29	0.81	0.53	Blood protein levels;	chr5:55955395	chr17:15783288~15784307:+
THCA	trans	rs7730934	0.818	rs62363895	ENSG00000227018.1	IL6STP1	13.54	1.69e-35	9.81e-29	0.81	0.53	Blood protein levels;	chr5:55958708	chr17:15783288~15784307:+
THCA	trans	rs77688320	0.517	rs10497868	ENSG00000235105.1	RP11-329A14.1	-13.52	1.96e-35	1.14e-28	-0.59	-0.53	Breast cancer;	chr2:201439317	chr1:48435967~48437223:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-13.52	1.98e-35	1.15e-28	-0.66	-0.53	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-13.52	1.98e-35	1.15e-28	-0.66	-0.53	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
THCA	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	13.52	1.99e-35	1.16e-28	0.9	0.53	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
THCA	trans	rs116095464	0.558	rs6878087	ENSG00000185986.11	SDHAP3	-13.52	2.08e-35	1.21e-28	-0.57	-0.53	Breast cancer;	chr5:223002	chr5:1572222~1594620:-
THCA	trans	rs2288327	0.643	rs16866334	ENSG00000269800.1	PLEKHA3P1	13.52	2.11e-35	1.22e-28	0.69	0.53	Atrial fibrillation;	chr2:178471945	chr19:41521043~41521989:-
THCA	trans	rs10242455	0.571	rs11972210	ENSG00000228834.1	RP11-249L21.4	13.51	2.29e-35	1.33e-28	1.39	0.53	Blood metabolite levels;	chr7:99609320	chr6:108907615~108907873:-
THCA	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-13.51	2.34e-35	1.36e-28	-0.68	-0.53	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
THCA	trans	rs1816752	0.692	rs6490944	ENSG00000224976.2	PARP4P2	13.5	2.37e-35	1.37e-28	0.62	0.53	Obesity-related traits;	chr13:24513866	chr13:19349137~19407962:+
THCA	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	13.49	2.82e-35	1.63e-28	0.71	0.53	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
THCA	trans	rs7258465	1	rs271624	ENSG00000267533.1	RP11-815J4.7	13.49	2.87e-35	1.66e-28	0.74	0.53	Breast cancer;	chr19:18517143	chr18:12067173~12068417:-
THCA	trans	rs4276421	0.55	rs6898825	ENSG00000231752.4	EMBP1	-13.48	2.94e-35	1.7e-28	-0.78	-0.53	P wave duration;	chr5:45842061	chr1:121519112~121571892:+
THCA	trans	rs7730934	0.818	rs1373998	ENSG00000227018.1	IL6STP1	13.48	3e-35	1.74e-28	0.81	0.53	Blood protein levels;	chr5:55959737	chr17:15783288~15784307:+
THCA	trans	rs1816752	0.692	rs2282409	ENSG00000224976.2	PARP4P2	13.48	3.13e-35	1.81e-28	0.62	0.53	Obesity-related traits;	chr13:24512388	chr13:19349137~19407962:+
THCA	trans	rs7811142	1	rs6972167	ENSG00000228546.2	CTA-313A17.3	13.47	3.21e-35	1.85e-28	0.92	0.53	Platelet count;	chr7:100482390	chr7:102337316~102339115:+
THCA	trans	rs26067	0.74	rs27683	ENSG00000231752.4	EMBP1	13.47	3.29e-35	1.9e-28	0.74	0.53	Breast cancer;	chr5:50865708	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.624	rs4770701	ENSG00000224976.2	PARP4P2	13.47	3.31e-35	1.91e-28	0.61	0.53	Obesity-related traits;	chr13:24508806	chr13:19349137~19407962:+
THCA	trans	rs7937890	0.967	rs963212	ENSG00000236360.2	RP11-334A14.2	-13.47	3.38e-35	1.95e-28	-0.7	-0.53	Mitochondrial DNA levels;	chr11:14303186	chr1:52993201~52993702:-
THCA	trans	rs7937890	1	rs2970334	ENSG00000236360.2	RP11-334A14.2	-13.47	3.38e-35	1.95e-28	-0.7	-0.53	Mitochondrial DNA levels;	chr11:14307809	chr1:52993201~52993702:-
THCA	trans	rs12709013	0.574	rs839418	ENSG00000233719.3	GOT2P3	13.47	3.5e-35	2.02e-28	0.7	0.53	Blood metabolite ratios;	chr16:58705426	chr12:9641802~9643007:+
THCA	trans	rs7811142	0.943	rs66958101	ENSG00000228546.2	CTA-313A17.3	13.46	3.52e-35	2.03e-28	0.91	0.53	Platelet count;	chr7:100476397	chr7:102337316~102339115:+
THCA	trans	rs26067	0.689	rs285529	ENSG00000231752.4	EMBP1	-13.44	4.37e-35	2.52e-28	-0.71	-0.53	Breast cancer;	chr5:50843452	chr1:121519112~121571892:+
THCA	trans	rs7811142	1	rs74460138	ENSG00000228546.2	CTA-313A17.3	13.44	4.66e-35	2.68e-28	0.9	0.53	Platelet count;	chr7:100429716	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs6975729	ENSG00000228546.2	CTA-313A17.3	13.44	4.66e-35	2.68e-28	0.9	0.53	Platelet count;	chr7:100430564	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs1073	ENSG00000228546.2	CTA-313A17.3	13.44	4.66e-35	2.68e-28	0.9	0.53	Platelet count;	chr7:100433989	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs4989959	ENSG00000228546.2	CTA-313A17.3	13.44	4.66e-35	2.68e-28	0.9	0.53	Platelet count;	chr7:100434665	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.887	rs4074838	ENSG00000228546.2	CTA-313A17.3	13.44	4.66e-35	2.68e-28	0.9	0.53	Platelet count;	chr7:100435042	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.945	rs6955362	ENSG00000228546.2	CTA-313A17.3	13.44	4.66e-35	2.68e-28	0.9	0.53	Platelet count;	chr7:100458543	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs6975514	ENSG00000228546.2	CTA-313A17.3	13.44	4.66e-35	2.68e-28	0.9	0.53	Platelet count;	chr7:100458597	chr7:102337316~102339115:+
THCA	trans	rs7258465	1	rs8111708	ENSG00000267533.1	RP11-815J4.7	13.42	5.35e-35	3.08e-28	0.74	0.53	Breast cancer;	chr19:18448066	chr18:12067173~12068417:-
THCA	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	13.42	5.57e-35	3.2e-28	0.93	0.53	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	13.42	5.57e-35	3.2e-28	0.93	0.53	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
THCA	trans	rs12709013	0.536	rs1646260	ENSG00000233719.3	GOT2P3	13.42	5.63e-35	3.23e-28	0.7	0.53	Blood metabolite ratios;	chr16:58734951	chr12:9641802~9643007:+
THCA	trans	rs8175379	0.509	rs10074483	ENSG00000231752.4	EMBP1	13.41	5.89e-35	3.39e-28	0.72	0.53	Interleukin-7 levels;	chr5:46238631	chr1:121519112~121571892:+
THCA	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	13.41	5.99e-35	3.44e-28	0.82	0.53	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
THCA	trans	rs8175379	0.509	rs8185053	ENSG00000231752.4	EMBP1	-13.41	6.07e-35	3.49e-28	-0.72	-0.53	Interleukin-7 levels;	chr5:46261842	chr1:121519112~121571892:+
THCA	trans	rs8175379	1	rs8175379	ENSG00000231752.4	EMBP1	-13.41	6.07e-35	3.49e-28	-0.72	-0.53	Interleukin-7 levels;	chr5:46263441	chr1:121519112~121571892:+
THCA	trans	rs7811142	1	rs11773661	ENSG00000228546.2	CTA-313A17.3	13.41	6.1e-35	3.5e-28	0.91	0.53	Platelet count;	chr7:100475446	chr7:102337316~102339115:+
THCA	trans	rs8175379	0.509	rs8185235	ENSG00000231752.4	EMBP1	13.4	6.57e-35	3.77e-28	0.72	0.53	Interleukin-7 levels;	chr5:46252306	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.613	rs4238801	ENSG00000233719.3	GOT2P3	13.4	6.58e-35	3.77e-28	0.69	0.53	Blood metabolite ratios;	chr16:58738275	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs4575523	ENSG00000233719.3	GOT2P3	13.4	6.58e-35	3.77e-28	0.69	0.53	Blood metabolite ratios;	chr16:58738559	chr12:9641802~9643007:+
THCA	trans	rs8175379	0.505	rs12189292	ENSG00000231752.4	EMBP1	-13.4	6.69e-35	3.84e-28	-0.72	-0.53	Interleukin-7 levels;	chr5:46340498	chr1:121519112~121571892:+
THCA	trans	rs7554547	0.667	rs59952418	ENSG00000261819.1	RP11-680G24.4	13.4	6.73e-35	3.86e-28	0.72	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11878153	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.703	rs7543258	ENSG00000261819.1	RP11-680G24.4	13.39	6.97e-35	4e-28	0.7	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11901599	chr16:14988259~14990160:-
THCA	trans	rs8175379	0.509	rs4128582	ENSG00000231752.4	EMBP1	13.39	6.99e-35	4.01e-28	0.72	0.53	Interleukin-7 levels;	chr5:46252001	chr1:121519112~121571892:+
THCA	trans	rs7811142	1	rs1000215	ENSG00000228546.2	CTA-313A17.3	13.39	7.26e-35	4.16e-28	0.88	0.53	Platelet count;	chr7:100406920	chr7:102337316~102339115:+
THCA	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	13.39	7.27e-35	4.16e-28	0.82	0.53	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	13.39	7.27e-35	4.16e-28	0.82	0.53	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	13.39	7.27e-35	4.16e-28	0.82	0.53	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	13.39	7.27e-35	4.16e-28	0.82	0.53	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	13.39	7.27e-35	4.16e-28	0.82	0.53	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	13.39	7.27e-35	4.16e-28	0.82	0.53	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	13.39	7.27e-35	4.16e-28	0.82	0.53	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs11600486	ENSG00000234176.1	HSPA8P1	13.38	8.18e-35	4.68e-28	0.82	0.53	Breast cancer;	chr11:123047060	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	13.38	8.18e-35	4.68e-28	0.82	0.53	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
THCA	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	13.37	8.71e-35	4.98e-28	0.92	0.52	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
THCA	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	13.37	8.71e-35	4.98e-28	0.82	0.52	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	13.37	8.71e-35	4.98e-28	0.82	0.52	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	13.37	8.71e-35	4.98e-28	0.82	0.52	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	13.37	8.71e-35	4.98e-28	0.82	0.52	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
THCA	trans	rs7811142	1	rs11764818	ENSG00000228546.2	CTA-313A17.3	13.37	9.12e-35	5.21e-28	0.9	0.52	Platelet count;	chr7:100445432	chr7:102337316~102339115:+
THCA	trans	rs1816752	0.646	rs9511309	ENSG00000224976.2	PARP4P2	13.36	9.31e-35	5.32e-28	0.61	0.52	Obesity-related traits;	chr13:24515435	chr13:19349137~19407962:+
THCA	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	13.36	9.75e-35	5.56e-28	0.82	0.52	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-13.36	9.8e-35	5.59e-28	-0.82	-0.52	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
THCA	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	13.36	9.82e-35	5.6e-28	0.92	0.52	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
THCA	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	13.36	1e-34	5.71e-28	0.82	0.52	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
THCA	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	13.35	1.09e-34	6.2e-28	0.92	0.52	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs60257855	ENSG00000228546.2	CTA-313A17.3	13.35	1.1e-34	6.27e-28	0.9	0.52	Platelet count;	chr7:100429157	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs66632384	ENSG00000228546.2	CTA-313A17.3	13.34	1.22e-34	6.93e-28	0.89	0.52	Platelet count;	chr7:100421281	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs67163493	ENSG00000228546.2	CTA-313A17.3	13.34	1.22e-34	6.93e-28	0.89	0.52	Platelet count;	chr7:100426215	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.943	rs73403312	ENSG00000228546.2	CTA-313A17.3	13.34	1.22e-34	6.93e-28	0.89	0.52	Platelet count;	chr7:100426530	chr7:102337316~102339115:+
THCA	trans	rs8175379	0.509	rs8188019	ENSG00000231752.4	EMBP1	13.34	1.22e-34	6.94e-28	0.71	0.52	Interleukin-7 levels;	chr5:46130910	chr1:121519112~121571892:+
THCA	trans	rs7811142	0.887	rs111972532	ENSG00000228546.2	CTA-313A17.3	13.33	1.27e-34	7.24e-28	0.9	0.52	Platelet count;	chr7:100471465	chr7:102337316~102339115:+
THCA	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	13.33	1.28e-34	7.28e-28	0.66	0.52	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
THCA	trans	rs7811142	1	rs60478351	ENSG00000228546.2	CTA-313A17.3	13.33	1.37e-34	7.76e-28	0.9	0.52	Platelet count;	chr7:100491394	chr7:102337316~102339115:+
THCA	trans	rs12709013	0.646	rs8046154	ENSG00000233719.3	GOT2P3	-13.32	1.39e-34	7.86e-28	-0.68	-0.52	Blood metabolite ratios;	chr16:58773978	chr12:9641802~9643007:+
THCA	trans	rs7554547	0.685	rs12724129	ENSG00000261819.1	RP11-680G24.4	13.32	1.48e-34	8.39e-28	0.68	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11897582	chr16:14988259~14990160:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-13.31	1.58e-34	8.92e-28	-0.67	-0.52	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
THCA	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-13.31	1.58e-34	8.92e-28	-0.67	-0.52	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
THCA	trans	rs8175379	0.501	rs10064455	ENSG00000231752.4	EMBP1	-13.3	1.75e-34	9.89e-28	-0.73	-0.52	Interleukin-7 levels;	chr5:46293430	chr1:121519112~121571892:+
THCA	trans	rs8175379	0.505	rs10073477	ENSG00000231752.4	EMBP1	-13.3	1.81e-34	1.03e-27	-0.72	-0.52	Interleukin-7 levels;	chr5:46338025	chr1:121519112~121571892:+
THCA	trans	rs877636	0.702	rs773112	ENSG00000234513.1	AC073072.7	13.29	1.86e-34	1.05e-27	0.68	0.52	Cognitive function;	chr12:55982097	chr7:22773646~22773993:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000233778.3	RP11-777J24.1	13.29	1.89e-34	1.07e-27	0.62	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:92144088~92144435:-
THCA	trans	rs26067	0.689	rs27266	ENSG00000231752.4	EMBP1	-13.29	2.01e-34	1.14e-27	-0.73	-0.52	Breast cancer;	chr5:50865793	chr1:121519112~121571892:+
THCA	trans	rs877636	0.702	rs773110	ENSG00000234513.1	AC073072.7	13.28	2.06e-34	1.16e-27	0.68	0.52	Cognitive function;	chr12:55981353	chr7:22773646~22773993:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000234513.1	AC073072.7	13.28	2.06e-34	1.16e-27	0.68	0.52	Cognitive function;	chr12:55981956	chr7:22773646~22773993:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000243403.1	RP11-330L19.1	13.28	2.17e-34	1.22e-27	0.67	0.52	Cognitive function;	chr12:55976127	chr15:64592979~64593326:+
THCA	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	13.28	2.2e-34	1.24e-27	0.66	0.52	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
THCA	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-13.28	2.21e-34	1.25e-27	-0.67	-0.52	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
THCA	trans	rs877636	0.702	rs61937249	ENSG00000234513.1	AC073072.7	13.27	2.23e-34	1.26e-27	0.68	0.52	Cognitive function;	chr12:55988132	chr7:22773646~22773993:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-13.26	2.48e-34	1.39e-27	-0.7	-0.52	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-13.26	2.48e-34	1.39e-27	-0.7	-0.52	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
THCA	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-13.26	2.58e-34	1.45e-27	-0.68	-0.52	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
THCA	trans	rs2288327	0.643	rs1559908	ENSG00000269800.1	PLEKHA3P1	-13.26	2.59e-34	1.46e-27	-0.68	-0.52	Atrial fibrillation;	chr2:178471620	chr19:41521043~41521989:-
THCA	trans	rs7811142	1	rs11763414	ENSG00000228546.2	CTA-313A17.3	13.26	2.63e-34	1.48e-27	0.89	0.52	Platelet count;	chr7:100419221	chr7:102337316~102339115:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	13.26	2.65e-34	1.49e-27	0.69	0.52	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
THCA	trans	rs116095464	0.558	rs6555058	ENSG00000185986.11	SDHAP3	-13.25	2.73e-34	1.53e-27	-0.55	-0.52	Breast cancer;	chr5:226261	chr5:1572222~1594620:-
THCA	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	13.25	2.86e-34	1.61e-27	0.64	0.52	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
THCA	trans	rs7937890	1	rs2970335	ENSG00000236360.2	RP11-334A14.2	13.25	2.91e-34	1.63e-27	0.69	0.52	Mitochondrial DNA levels;	chr11:14303855	chr1:52993201~52993702:-
THCA	trans	rs7811142	1	rs73161759	ENSG00000228546.2	CTA-313A17.3	13.25	2.97e-34	1.67e-27	0.89	0.52	Platelet count;	chr7:100412371	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs67315960	ENSG00000228546.2	CTA-313A17.3	13.25	2.97e-34	1.67e-27	0.89	0.52	Platelet count;	chr7:100417501	chr7:102337316~102339115:+
THCA	trans	rs13358908	0.506	rs7293471	ENSG00000231752.4	EMBP1	-13.24	3e-34	1.68e-27	-0.72	-0.52	Schizophrenia;	chr5:46404446	chr1:121519112~121571892:+
THCA	trans	rs877636	1	rs705696	ENSG00000212994.5	RPS26P6	13.24	3.1e-34	1.74e-27	0.7	0.52	Cognitive function;	chr12:56086864	chr8:100895771~100896118:+
THCA	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	13.24	3.27e-34	1.83e-27	0.93	0.52	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
THCA	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-13.21	4.09e-34	2.29e-27	-0.64	-0.52	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
THCA	trans	rs7811142	1	rs11771419	ENSG00000228546.2	CTA-313A17.3	13.21	4.21e-34	2.35e-27	0.88	0.52	Platelet count;	chr7:100390780	chr7:102337316~102339115:+
THCA	trans	rs7554547	0.791	rs6665662	ENSG00000261819.1	RP11-680G24.4	13.21	4.36e-34	2.44e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11891804	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs34117126	ENSG00000261819.1	RP11-680G24.4	13.21	4.36e-34	2.44e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11892138	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs17037520	ENSG00000261819.1	RP11-680G24.4	13.21	4.36e-34	2.44e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11892349	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs12749498	ENSG00000261819.1	RP11-680G24.4	13.21	4.36e-34	2.44e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11892570	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs12036266	ENSG00000261819.1	RP11-680G24.4	13.21	4.36e-34	2.44e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11893257	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs2065611	ENSG00000261819.1	RP11-680G24.4	13.21	4.36e-34	2.44e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11893469	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs4492637	ENSG00000261819.1	RP11-680G24.4	13.21	4.36e-34	2.44e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11895787	chr16:14988259~14990160:-
THCA	trans	rs55665837	1	rs11023215	ENSG00000236360.2	RP11-334A14.2	13.2	4.41e-34	2.46e-27	0.7	0.52	Vitamin D levels;	chr11:14415424	chr1:52993201~52993702:-
THCA	trans	rs7811142	1	rs67471932	ENSG00000228546.2	CTA-313A17.3	13.2	4.74e-34	2.65e-27	0.88	0.52	Platelet count;	chr7:100412362	chr7:102337316~102339115:+
THCA	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-13.19	4.97e-34	2.77e-27	-0.81	-0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
THCA	trans	rs7811142	0.943	rs3900792	ENSG00000228546.2	CTA-313A17.3	13.19	5.09e-34	2.84e-27	0.87	0.52	Platelet count;	chr7:100406954	chr7:102337316~102339115:+
THCA	trans	rs7554547	0.791	rs4846074	ENSG00000261819.1	RP11-680G24.4	13.19	5.19e-34	2.89e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11896172	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs2064614	ENSG00000261819.1	RP11-680G24.4	13.19	5.22e-34	2.91e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11893883	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.765	rs34175640	ENSG00000261819.1	RP11-680G24.4	-13.18	5.42e-34	3.02e-27	-0.69	-0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11892155	chr16:14988259~14990160:-
THCA	trans	rs9611519	1	rs9611510	ENSG00000268568.1	AC007228.9	-13.18	5.47e-34	3.04e-27	-0.64	-0.52	Neuroticism;	chr22:41173120	chr19:56672574~56673901:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-13.18	5.67e-34	3.16e-27	-0.65	-0.52	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
THCA	trans	rs7554547	0.791	rs4846076	ENSG00000261819.1	RP11-680G24.4	13.17	6.22e-34	3.46e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11896708	chr16:14988259~14990160:-
THCA	trans	rs12709013	0.613	rs1618602	ENSG00000233719.3	GOT2P3	13.17	6.29e-34	3.49e-27	0.68	0.52	Blood metabolite ratios;	chr16:58756080	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs8045466	ENSG00000233719.3	GOT2P3	13.17	6.29e-34	3.49e-27	0.68	0.52	Blood metabolite ratios;	chr16:58765113	chr12:9641802~9643007:+
THCA	trans	rs7554547	0.69	rs9661078	ENSG00000261819.1	RP11-680G24.4	13.16	6.5e-34	3.61e-27	0.71	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11876267	chr16:14988259~14990160:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-13.16	6.64e-34	3.69e-27	-0.68	-0.52	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
THCA	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	13.16	6.79e-34	3.77e-27	0.82	0.52	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
THCA	trans	rs916888	0.687	rs199456	ENSG00000204650.12	CRHR1-IT1	13.16	6.98e-34	3.88e-27	0.6	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45620328~45648216:+
THCA	trans	rs916888	0.773	rs199451	ENSG00000204650.12	CRHR1-IT1	13.16	6.98e-34	3.88e-27	0.6	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45620328~45648216:+
THCA	trans	rs7312770	0.612	rs773114	ENSG00000196933.5	RPS26P11	13.16	7.01e-34	3.89e-27	0.65	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:72044545~72044892:+
THCA	trans	rs916888	0.773	rs199534	ENSG00000204650.12	CRHR1-IT1	13.15	7.25e-34	4.02e-27	0.6	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45620328~45648216:+
THCA	trans	rs9611519	0.964	rs20551	ENSG00000268568.1	AC007228.9	-13.13	8.91e-34	4.93e-27	-0.65	-0.52	Neuroticism;	chr22:41152004	chr19:56672574~56673901:-
THCA	trans	rs7554547	0.791	rs1321073	ENSG00000261819.1	RP11-680G24.4	13.13	8.94e-34	4.94e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr16:14988259~14990160:-
THCA	trans	rs7614738	1	rs7614738	ENSG00000197582.5	GPX1P1	13.12	1.03e-33	5.7e-27	0.71	0.52	Red cell distribution width;	chr3:49273698	chrX:13378735~13379340:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000234513.1	AC073072.7	13.11	1.06e-33	5.88e-27	0.67	0.52	Cognitive function;	chr12:55996580	chr7:22773646~22773993:-
THCA	trans	rs1816752	0.524	rs1965154	ENSG00000237917.1	PARP4P1	-13.11	1.07e-33	5.91e-27	-0.66	-0.52	Obesity-related traits;	chr13:24498062	chrY:26594851~26634652:-
THCA	trans	rs12709013	0.636	rs1646281	ENSG00000233719.3	GOT2P3	13.11	1.09e-33	5.99e-27	0.68	0.52	Blood metabolite ratios;	chr16:58750512	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.613	rs8049462	ENSG00000233719.3	GOT2P3	13.11	1.09e-33	5.99e-27	0.68	0.52	Blood metabolite ratios;	chr16:58757654	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.66	rs257629	ENSG00000233719.3	GOT2P3	13.11	1.09e-33	5.99e-27	0.68	0.52	Blood metabolite ratios;	chr16:58758044	chr12:9641802~9643007:+
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	13.1	1.24e-33	6.85e-27	0.64	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	13.1	1.27e-33	7e-27	0.64	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000223416.3	RPS26P15	13.09	1.36e-33	7.5e-27	0.63	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:58056133~58056480:-
THCA	trans	rs10242455	0.571	rs45532337	ENSG00000228834.1	RP11-249L21.4	13.08	1.41e-33	7.77e-27	1.29	0.52	Blood metabolite levels;	chr7:99712696	chr6:108907615~108907873:-
THCA	trans	rs7811142	1	rs11771241	ENSG00000228546.2	CTA-313A17.3	13.08	1.49e-33	8.2e-27	0.87	0.52	Platelet count;	chr7:100397162	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.943	rs10241492	ENSG00000228546.2	CTA-313A17.3	13.08	1.49e-33	8.2e-27	0.87	0.52	Platelet count;	chr7:100397190	chr7:102337316~102339115:+
THCA	trans	rs916888	0.773	rs199457	ENSG00000204650.12	CRHR1-IT1	13.07	1.62e-33	8.89e-27	0.6	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45620328~45648216:+
THCA	trans	rs7554547	0.69	rs7516708	ENSG00000261819.1	RP11-680G24.4	13.07	1.63e-33	8.93e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11890148	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.739	rs4846073	ENSG00000261819.1	RP11-680G24.4	13.07	1.63e-33	8.93e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11890521	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs57678332	ENSG00000261819.1	RP11-680G24.4	13.07	1.63e-33	8.93e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11890834	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.765	rs57176983	ENSG00000261819.1	RP11-680G24.4	13.07	1.63e-33	8.93e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11891041	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs1321072	ENSG00000261819.1	RP11-680G24.4	13.07	1.63e-33	8.93e-27	0.69	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11891261	chr16:14988259~14990160:-
THCA	trans	rs9467773	0.933	rs2024970	ENSG00000242375.1	RP11-498P14.3	13.06	1.73e-33	9.5e-27	0.74	0.52	Intelligence (multi-trait analysis);	chr6:26497292	chr9:97195351~97197687:-
THCA	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-13.06	1.81e-33	9.9e-27	-0.66	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
THCA	trans	rs7811142	1	rs76913697	ENSG00000228546.2	CTA-313A17.3	13.06	1.82e-33	9.98e-27	0.88	0.52	Platelet count;	chr7:100405149	chr7:102337316~102339115:+
THCA	trans	rs7730934	0.818	rs7736703	ENSG00000227018.1	IL6STP1	13.05	1.97e-33	1.08e-26	0.84	0.52	Blood protein levels;	chr5:56016434	chr17:15783288~15784307:+
THCA	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-13.05	1.97e-33	1.08e-26	-0.63	-0.52	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
THCA	trans	rs10242455	0.571	rs45593341	ENSG00000228834.1	RP11-249L21.4	13.04	2.24e-33	1.22e-26	1.33	0.52	Blood metabolite levels;	chr7:99707288	chr6:108907615~108907873:-
THCA	trans	rs9467773	0.838	rs3734540	ENSG00000242375.1	RP11-498P14.3	13.03	2.28e-33	1.24e-26	0.74	0.52	Intelligence (multi-trait analysis);	chr6:26463093	chr9:97195351~97197687:-
THCA	trans	rs916888	0.773	rs199448	ENSG00000204650.12	CRHR1-IT1	13.03	2.37e-33	1.29e-26	0.6	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45620328~45648216:+
THCA	trans	rs916888	0.773	rs199447	ENSG00000204650.12	CRHR1-IT1	13.03	2.37e-33	1.29e-26	0.6	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45620328~45648216:+
THCA	trans	rs7811142	1	rs73405353	ENSG00000228546.2	CTA-313A17.3	13.03	2.38e-33	1.3e-26	0.91	0.52	Platelet count;	chr7:100493592	chr7:102337316~102339115:+
THCA	trans	rs7554547	0.69	rs10864544	ENSG00000261819.1	RP11-680G24.4	13.02	2.53e-33	1.38e-26	0.7	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11875666	chr16:14988259~14990160:-
THCA	trans	rs7937890	1	rs7937890	ENSG00000236360.2	RP11-334A14.2	13.02	2.54e-33	1.38e-26	0.69	0.51	Mitochondrial DNA levels;	chr11:14374939	chr1:52993201~52993702:-
THCA	trans	rs7554547	0.765	rs4845886	ENSG00000261819.1	RP11-680G24.4	13.02	2.75e-33	1.5e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11888603	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs4846069	ENSG00000261819.1	RP11-680G24.4	13.02	2.75e-33	1.5e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11888974	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.791	rs11121837	ENSG00000261819.1	RP11-680G24.4	13.02	2.75e-33	1.5e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11889414	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.765	rs4846070	ENSG00000261819.1	RP11-680G24.4	13.02	2.75e-33	1.5e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11889464	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.739	rs61527718	ENSG00000261819.1	RP11-680G24.4	13.02	2.75e-33	1.5e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11889583	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.714	rs4846071	ENSG00000261819.1	RP11-680G24.4	13.02	2.75e-33	1.5e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11889612	chr16:14988259~14990160:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000234513.1	AC073072.7	13.01	2.76e-33	1.5e-26	0.67	0.51	Cognitive function;	chr12:55980911	chr7:22773646~22773993:-
THCA	trans	rs4240897	0.935	rs2236055	ENSG00000261819.1	RP11-680G24.4	13	3.1e-33	1.69e-26	0.67	0.51	Tuberculosis;	chr1:11982204	chr16:14988259~14990160:-
THCA	trans	rs10242455	0.702	rs2293256	ENSG00000228834.1	RP11-249L21.4	-12.99	3.43e-33	1.86e-26	-1.2	-0.51	Blood metabolite levels;	chr7:99460078	chr6:108907615~108907873:-
THCA	trans	rs13253073	1	rs12550092	ENSG00000260318.1	COX6CP1	12.99	3.61e-33	1.96e-26	1.27	0.51	Glucose homeostasis traits;	chr8:99886954	chr16:11903923~11904137:-
THCA	trans	rs12709013	0.591	rs149479	ENSG00000233719.3	GOT2P3	-12.98	3.87e-33	2.1e-26	-0.7	-0.51	Blood metabolite ratios;	chr16:58703171	chr12:9641802~9643007:+
THCA	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	12.97	4.12e-33	2.23e-26	0.9	0.51	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
THCA	trans	rs7811142	1	rs6979335	ENSG00000228546.2	CTA-313A17.3	12.96	4.48e-33	2.43e-26	0.91	0.51	Platelet count;	chr7:100492237	chr7:102337316~102339115:+
THCA	trans	rs877636	0.74	rs705702	ENSG00000234513.1	AC073072.7	-12.96	4.67e-33	2.53e-26	-0.66	-0.51	Cognitive function;	chr12:55996852	chr7:22773646~22773993:-
THCA	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	12.94	5.67e-33	3.06e-26	0.81	0.51	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-12.94	5.84e-33	3.15e-26	-0.66	-0.51	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
THCA	trans	rs9611519	1	rs9611505	ENSG00000268568.1	AC007228.9	-12.93	6.32e-33	3.41e-26	-0.64	-0.51	Neuroticism;	chr22:41144275	chr19:56672574~56673901:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-12.92	6.56e-33	3.54e-26	-0.69	-0.51	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
THCA	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	12.92	6.7e-33	3.61e-26	0.7	0.51	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
THCA	trans	rs9611519	0.964	rs5995992	ENSG00000268568.1	AC007228.9	-12.92	7.17e-33	3.86e-26	-0.63	-0.51	Neuroticism;	chr22:41091214	chr19:56672574~56673901:-
THCA	trans	rs3779195	0.929	rs4268041	ENSG00000225169.1	BRI3P1	-12.91	7.41e-33	3.99e-26	-0.78	-0.51	Sex hormone-binding globulin levels;	chr7:98376226	chr1:100213293~100213670:+
THCA	trans	rs12709013	0.576	rs2432622	ENSG00000233719.3	GOT2P3	12.91	7.47e-33	4.02e-26	0.67	0.51	Blood metabolite ratios;	chr16:58749681	chr12:9641802~9643007:+
THCA	trans	rs9611519	0.828	rs4822008	ENSG00000268568.1	AC007228.9	-12.91	7.55e-33	4.06e-26	-0.64	-0.51	Neuroticism;	chr22:41143202	chr19:56672574~56673901:-
THCA	trans	rs116095464	0.558	rs28636067	ENSG00000185986.11	SDHAP3	12.9	8.16e-33	4.39e-26	0.62	0.51	Breast cancer;	chr5:199300	chr5:1572222~1594620:-
THCA	trans	rs7811142	1	rs7794485	ENSG00000228546.2	CTA-313A17.3	12.9	8.66e-33	4.65e-26	0.91	0.51	Platelet count;	chr7:100471313	chr7:102337316~102339115:+
THCA	trans	rs4240897	0.835	rs4845891	ENSG00000261819.1	RP11-680G24.4	12.88	9.59e-33	5.14e-26	0.67	0.51	Tuberculosis;	chr1:11982449	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.69	rs4846064	ENSG00000261819.1	RP11-680G24.4	12.88	9.68e-33	5.19e-26	0.69	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11874785	chr16:14988259~14990160:-
THCA	trans	rs7258465	0.931	rs76195	ENSG00000267533.1	RP11-815J4.7	12.88	9.97e-33	5.35e-26	0.71	0.51	Breast cancer;	chr19:18519020	chr18:12067173~12068417:-
THCA	trans	rs116095464	0.558	rs34629844	ENSG00000185986.11	SDHAP3	12.88	1.04e-32	5.59e-26	0.61	0.51	Breast cancer;	chr5:200714	chr5:1572222~1594620:-
THCA	trans	rs916888	0.773	rs199533	ENSG00000204650.12	CRHR1-IT1	12.88	1.04e-32	5.59e-26	0.59	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45620328~45648216:+
THCA	trans	rs116095464	1	rs28416084	ENSG00000185986.11	SDHAP3	12.88	1.05e-32	5.65e-26	0.61	0.51	Breast cancer;	chr5:217525	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9312978	ENSG00000185986.11	SDHAP3	12.88	1.05e-32	5.65e-26	0.61	0.51	Breast cancer;	chr5:221815	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9312979	ENSG00000185986.11	SDHAP3	12.88	1.05e-32	5.65e-26	0.61	0.51	Breast cancer;	chr5:221942	chr5:1572222~1594620:-
THCA	trans	rs4240897	0.935	rs1474868	ENSG00000261819.1	RP11-680G24.4	-12.87	1.09e-32	5.84e-26	-0.67	-0.51	Tuberculosis;	chr1:11984107	chr16:14988259~14990160:-
THCA	trans	rs116095464	0.558	rs10055993	ENSG00000185986.11	SDHAP3	12.86	1.17e-32	6.29e-26	0.62	0.51	Breast cancer;	chr5:264181	chr5:1572222~1594620:-
THCA	trans	rs9899728	0.539	rs56267297	ENSG00000234925.2	ATP5HP4	12.86	1.2e-32	6.43e-26	1.01	0.51	Alzheimer's disease or small vessel stroke;	chr17:75050901	chr12:68642519~68642993:-
THCA	trans	rs7811142	1	rs67040465	ENSG00000228546.2	CTA-313A17.3	12.85	1.29e-32	6.91e-26	0.9	0.51	Platelet count;	chr7:100485455	chr7:102337316~102339115:+
THCA	trans	rs916888	0.773	rs199445	ENSG00000204650.12	CRHR1-IT1	12.83	1.59e-32	8.51e-26	0.58	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45620328~45648216:+
THCA	trans	rs916888	0.773	rs199443	ENSG00000204650.12	CRHR1-IT1	12.83	1.59e-32	8.51e-26	0.58	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45620328~45648216:+
THCA	trans	rs116095464	0.558	rs10056628	ENSG00000185986.11	SDHAP3	12.83	1.67e-32	8.9e-26	0.6	0.51	Breast cancer;	chr5:279397	chr5:1572222~1594620:-
THCA	trans	rs10242455	0.571	rs73713594	ENSG00000228834.1	RP11-249L21.4	12.82	1.8e-32	9.58e-26	1.29	0.51	Blood metabolite levels;	chr7:99728875	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.571	rs73713595	ENSG00000228834.1	RP11-249L21.4	12.82	1.8e-32	9.58e-26	1.29	0.51	Blood metabolite levels;	chr7:99729036	chr6:108907615~108907873:-
THCA	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	12.82	1.81e-32	9.65e-26	0.63	0.51	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
THCA	trans	rs116095464	0.558	rs10068203	ENSG00000185986.11	SDHAP3	12.82	1.82e-32	9.73e-26	0.61	0.51	Breast cancer;	chr5:206503	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9654453	ENSG00000185986.11	SDHAP3	12.82	1.87e-32	9.94e-26	0.61	0.51	Breast cancer;	chr5:299506	chr5:1572222~1594620:-
THCA	trans	rs9611519	0.929	rs2064560	ENSG00000268568.1	AC007228.9	-12.8	2.14e-32	1.14e-25	-0.63	-0.51	Neuroticism;	chr22:41134036	chr19:56672574~56673901:-
THCA	trans	rs9611519	1	rs2057070	ENSG00000268568.1	AC007228.9	-12.8	2.14e-32	1.14e-25	-0.63	-0.51	Neuroticism;	chr22:41168283	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.929	rs9611509	ENSG00000268568.1	AC007228.9	-12.8	2.14e-32	1.14e-25	-0.63	-0.51	Neuroticism;	chr22:41169823	chr19:56672574~56673901:-
THCA	trans	rs7811142	1	rs11761725	ENSG00000228546.2	CTA-313A17.3	12.79	2.44e-32	1.3e-25	0.9	0.51	Platelet count;	chr7:100442192	chr7:102337316~102339115:+
THCA	trans	rs116095464	0.558	rs73029475	ENSG00000185986.11	SDHAP3	12.79	2.48e-32	1.32e-25	0.6	0.51	Breast cancer;	chr5:206854	chr5:1572222~1594620:-
THCA	trans	rs9467773	0.649	rs2145318	ENSG00000242375.1	RP11-498P14.3	12.78	2.51e-32	1.34e-25	0.72	0.51	Intelligence (multi-trait analysis);	chr6:26496375	chr9:97195351~97197687:-
THCA	trans	rs10242455	0.571	rs45527841	ENSG00000228834.1	RP11-249L21.4	12.78	2.57e-32	1.37e-25	1.29	0.51	Blood metabolite levels;	chr7:99713342	chr6:108907615~108907873:-
THCA	trans	rs7121616	0.576	rs73608699	ENSG00000234176.1	HSPA8P1	12.78	2.59e-32	1.38e-25	0.8	0.51	Breast cancer;	chr11:123044718	chrX:121203182~121205014:-
THCA	trans	rs7811142	1	rs7783550	ENSG00000228546.2	CTA-313A17.3	-12.78	2.61e-32	1.39e-25	-0.86	-0.51	Platelet count;	chr7:100390182	chr7:102337316~102339115:+
THCA	trans	rs12709013	0.636	rs1646284	ENSG00000233719.3	GOT2P3	12.77	2.78e-32	1.48e-25	0.67	0.51	Blood metabolite ratios;	chr16:58752093	chr12:9641802~9643007:+
THCA	trans	rs10242455	0.571	rs117370443	ENSG00000228834.1	RP11-249L21.4	12.77	2.93e-32	1.55e-25	1.43	0.51	Blood metabolite levels;	chr7:99377635	chr6:108907615~108907873:-
THCA	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	12.77	3.01e-32	1.59e-25	0.8	0.51	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
THCA	trans	rs9611519	1	rs6002271	ENSG00000268568.1	AC007228.9	-12.76	3.11e-32	1.65e-25	-0.63	-0.51	Neuroticism;	chr22:41170591	chr19:56672574~56673901:-
THCA	trans	rs877636	1	rs4759229	ENSG00000234513.1	AC073072.7	-12.76	3.25e-32	1.72e-25	-0.65	-0.51	Cognitive function;	chr12:56080696	chr7:22773646~22773993:-
THCA	trans	rs7554547	0.644	rs57077193	ENSG00000261819.1	RP11-680G24.4	12.76	3.29e-32	1.74e-25	0.7	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11878154	chr16:14988259~14990160:-
THCA	trans	rs9611519	0.964	rs2092563	ENSG00000268568.1	AC007228.9	-12.75	3.53e-32	1.87e-25	-0.63	-0.51	Neuroticism;	chr22:41196673	chr19:56672574~56673901:-
THCA	trans	rs7554547	0.69	rs7364817	ENSG00000261819.1	RP11-680G24.4	12.75	3.56e-32	1.89e-25	0.7	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11877060	chr16:14988259~14990160:-
THCA	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-12.73	4.03e-32	2.13e-25	-0.94	-0.51	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
THCA	trans	rs116095464	0.558	rs62346506	ENSG00000185986.11	SDHAP3	12.73	4.29e-32	2.27e-25	0.6	0.51	Breast cancer;	chr5:201479	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs9312956	ENSG00000185986.11	SDHAP3	12.73	4.29e-32	2.27e-25	0.6	0.51	Breast cancer;	chr5:201697	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs62346508	ENSG00000185986.11	SDHAP3	12.73	4.29e-32	2.27e-25	0.6	0.51	Breast cancer;	chr5:203553	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10059907	ENSG00000185986.11	SDHAP3	12.73	4.29e-32	2.27e-25	0.6	0.51	Breast cancer;	chr5:205245	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10060089	ENSG00000185986.11	SDHAP3	12.73	4.29e-32	2.27e-25	0.6	0.51	Breast cancer;	chr5:205450	chr5:1572222~1594620:-
THCA	trans	rs7811142	1	rs2406255	ENSG00000228546.2	CTA-313A17.3	12.72	4.47e-32	2.36e-25	0.9	0.51	Platelet count;	chr7:100456067	chr7:102337316~102339115:+
THCA	trans	rs4276421	0.533	rs34930360	ENSG00000231752.4	EMBP1	12.72	4.76e-32	2.51e-25	0.78	0.51	P wave duration;	chr5:46120740	chr1:121519112~121571892:+
THCA	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	12.71	5.13e-32	2.7e-25	0.65	0.51	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
THCA	trans	rs7121616	0.576	rs60405069	ENSG00000234176.1	HSPA8P1	12.71	5.19e-32	2.73e-25	0.8	0.51	Breast cancer;	chr11:123043616	chrX:121203182~121205014:-
THCA	trans	rs9611519	0.929	rs11090039	ENSG00000268568.1	AC007228.9	-12.7	5.35e-32	2.82e-25	-0.64	-0.51	Neuroticism;	chr22:41100796	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.798	rs2343805	ENSG00000224114.1	RP11-343H5.4	12.7	5.44e-32	2.86e-25	0.77	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr1:206695837~206696269:-
THCA	trans	rs112721625	1	rs112721625	ENSG00000187870.7	RNFT1P3	12.7	5.52e-32	2.91e-25	0.66	0.51	Monocyte count;	chr17:59850066	chr17:20743333~20754501:-
THCA	trans	rs7554547	0.739	rs2050269	ENSG00000261819.1	RP11-680G24.4	12.7	5.64e-32	2.97e-25	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886432	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.765	rs2050268	ENSG00000261819.1	RP11-680G24.4	12.7	5.64e-32	2.97e-25	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886487	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.765	rs2050267	ENSG00000261819.1	RP11-680G24.4	12.7	5.64e-32	2.97e-25	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886516	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.69	rs4846066	ENSG00000261819.1	RP11-680G24.4	12.7	5.71e-32	3e-25	0.69	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11877993	chr16:14988259~14990160:-
THCA	trans	rs2657294	0.965	rs4746270	ENSG00000172974.11	AC007318.5	12.7	5.84e-32	3.07e-25	0.6	0.51	Pneumonia;	chr10:75185189	chr2:65205108~65205988:+
THCA	trans	rs7730934	0.892	rs35257381	ENSG00000227018.1	IL6STP1	12.69	6.31e-32	3.32e-25	0.94	0.51	Blood protein levels;	chr5:56022784	chr17:15783288~15784307:+
THCA	trans	rs116095464	0.558	rs9687621	ENSG00000185986.11	SDHAP3	12.68	6.68e-32	3.51e-25	0.6	0.5	Breast cancer;	chr5:229079	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs56081398	ENSG00000185986.11	SDHAP3	12.68	6.71e-32	3.52e-25	0.6	0.5	Breast cancer;	chr5:247203	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs10065584	ENSG00000185986.11	SDHAP3	12.68	6.71e-32	3.52e-25	0.6	0.5	Breast cancer;	chr5:253882	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs56298907	ENSG00000185986.11	SDHAP3	12.68	6.71e-32	3.52e-25	0.6	0.5	Breast cancer;	chr5:283165	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs7356535	ENSG00000185986.11	SDHAP3	12.68	6.71e-32	3.52e-25	0.6	0.5	Breast cancer;	chr5:284002	chr5:1572222~1594620:-
THCA	trans	rs116095464	0.558	rs55833259	ENSG00000185986.11	SDHAP3	12.68	6.71e-32	3.52e-25	0.6	0.5	Breast cancer;	chr5:286613	chr5:1572222~1594620:-
THCA	trans	rs10242455	0.557	rs57830676	ENSG00000228834.1	RP11-249L21.4	12.68	6.78e-32	3.56e-25	1.33	0.5	Blood metabolite levels;	chr7:99683740	chr6:108907615~108907873:-
THCA	trans	rs12709013	0.591	rs899375	ENSG00000233719.3	GOT2P3	12.68	6.96e-32	3.65e-25	0.67	0.5	Blood metabolite ratios;	chr16:58792325	chr12:9641802~9643007:+
THCA	trans	rs9876781	1	rs9838618	ENSG00000225528.1	RP3-370M22.8	-12.68	7.02e-32	3.68e-25	-0.6	-0.5	Longevity;	chr3:48445949	chr22:39960397~39964683:+
THCA	trans	rs916888	0.773	rs199439	ENSG00000204650.12	CRHR1-IT1	12.67	7.35e-32	3.85e-25	0.58	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45620328~45648216:+
THCA	trans	rs7554547	0.765	rs2050270	ENSG00000261819.1	RP11-680G24.4	12.66	8.09e-32	4.23e-25	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11886399	chr16:14988259~14990160:-
THCA	trans	rs2657294	0.965	rs10824286	ENSG00000172974.11	AC007318.5	12.66	8.58e-32	4.49e-25	0.59	0.5	Pneumonia;	chr10:75172251	chr2:65205108~65205988:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000234513.1	AC073072.7	-12.65	9.28e-32	4.85e-25	-0.64	-0.5	Cognitive function;	chr12:56080595	chr7:22773646~22773993:-
THCA	trans	rs9467773	0.869	rs9295689	ENSG00000242375.1	RP11-498P14.3	12.65	9.41e-32	4.92e-25	0.72	0.5	Intelligence (multi-trait analysis);	chr6:26455583	chr9:97195351~97197687:-
THCA	trans	rs2657294	0.965	rs2657285	ENSG00000172974.11	AC007318.5	12.64	9.8e-32	5.12e-25	0.6	0.5	Pneumonia;	chr10:75164166	chr2:65205108~65205988:+
THCA	trans	rs9611519	0.964	rs4820428	ENSG00000268568.1	AC007228.9	12.64	1.03e-31	5.37e-25	0.63	0.5	Neuroticism;	chr22:41141585	chr19:56672574~56673901:-
THCA	trans	rs116095464	0.558	rs9312957	ENSG00000185986.11	SDHAP3	12.63	1.08e-31	5.66e-25	0.59	0.5	Breast cancer;	chr5:202079	chr5:1572222~1594620:-
THCA	trans	rs916888	0.773	rs199535	ENSG00000204650.12	CRHR1-IT1	12.63	1.14e-31	5.96e-25	0.57	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45620328~45648216:+
THCA	trans	rs2657294	1	rs2657294	ENSG00000172974.11	AC007318.5	12.62	1.18e-31	6.18e-25	0.6	0.5	Pneumonia;	chr10:75193267	chr2:65205108~65205988:+
THCA	trans	rs9899728	0.539	rs12938889	ENSG00000234925.2	ATP5HP4	-12.62	1.2e-31	6.26e-25	-1	-0.5	Alzheimer's disease or small vessel stroke;	chr17:75043834	chr12:68642519~68642993:-
THCA	trans	rs7811142	0.887	rs35111986	ENSG00000228546.2	CTA-313A17.3	12.62	1.21e-31	6.31e-25	0.88	0.5	Platelet count;	chr7:100402651	chr7:102337316~102339115:+
THCA	trans	rs10242455	0.571	rs55830753	ENSG00000228834.1	RP11-249L21.4	12.62	1.22e-31	6.35e-25	1.32	0.5	Blood metabolite levels;	chr7:99694599	chr6:108907615~108907873:-
THCA	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	12.61	1.31e-31	6.82e-25	0.64	0.5	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
THCA	trans	rs12709013	0.613	rs6499984	ENSG00000233719.3	GOT2P3	12.6	1.45e-31	7.56e-25	0.67	0.5	Blood metabolite ratios;	chr16:58810209	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.574	rs9302706	ENSG00000233719.3	GOT2P3	12.6	1.45e-31	7.56e-25	0.67	0.5	Blood metabolite ratios;	chr16:58812060	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.591	rs2086206	ENSG00000233719.3	GOT2P3	12.6	1.48e-31	7.7e-25	0.67	0.5	Blood metabolite ratios;	chr16:58802094	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.591	rs6499980	ENSG00000233719.3	GOT2P3	12.6	1.48e-31	7.7e-25	0.67	0.5	Blood metabolite ratios;	chr16:58787972	chr12:9641802~9643007:+
THCA	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	12.59	1.56e-31	8.1e-25	0.61	0.5	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
THCA	trans	rs877636	0.702	rs773108	ENSG00000234513.1	AC073072.7	12.59	1.56e-31	8.12e-25	0.67	0.5	Cognitive function;	chr12:55976127	chr7:22773646~22773993:-
THCA	trans	rs9611519	0.894	rs8136923	ENSG00000268568.1	AC007228.9	-12.59	1.57e-31	8.19e-25	-0.61	-0.5	Neuroticism;	chr22:41074518	chr19:56672574~56673901:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-12.59	1.61e-31	8.39e-25	-0.62	-0.5	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
THCA	trans	rs2657294	0.965	rs7079694	ENSG00000172974.11	AC007318.5	12.59	1.62e-31	8.41e-25	0.59	0.5	Pneumonia;	chr10:75136804	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs2395140	ENSG00000172974.11	AC007318.5	12.58	1.69e-31	8.75e-25	0.59	0.5	Pneumonia;	chr10:75139253	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs2997754	ENSG00000172974.11	AC007318.5	12.58	1.69e-31	8.75e-25	0.59	0.5	Pneumonia;	chr10:75144379	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs10824285	ENSG00000172974.11	AC007318.5	12.58	1.69e-31	8.75e-25	0.59	0.5	Pneumonia;	chr10:75153271	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs2047951	ENSG00000172974.11	AC007318.5	12.58	1.69e-31	8.75e-25	0.59	0.5	Pneumonia;	chr10:75161310	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs2804523	ENSG00000172974.11	AC007318.5	12.58	1.69e-31	8.75e-25	0.59	0.5	Pneumonia;	chr10:75161584	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs7899946	ENSG00000172974.11	AC007318.5	12.58	1.69e-31	8.75e-25	0.59	0.5	Pneumonia;	chr10:75166013	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs4746264	ENSG00000172974.11	AC007318.5	12.58	1.7e-31	8.81e-25	0.59	0.5	Pneumonia;	chr10:75114194	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs9299525	ENSG00000172974.11	AC007318.5	12.58	1.7e-31	8.81e-25	0.59	0.5	Pneumonia;	chr10:75118267	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs10762658	ENSG00000172974.11	AC007318.5	12.58	1.7e-31	8.81e-25	0.59	0.5	Pneumonia;	chr10:75119804	chr2:65205108~65205988:+
THCA	trans	rs77688320	0.573	rs2714480	ENSG00000235105.1	RP11-329A14.1	-12.58	1.72e-31	8.94e-25	-0.58	-0.5	Breast cancer;	chr2:201486286	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2908763	ENSG00000235105.1	RP11-329A14.1	-12.58	1.73e-31	8.98e-25	-0.58	-0.5	Breast cancer;	chr2:201503860	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs60148247	ENSG00000235105.1	RP11-329A14.1	-12.58	1.73e-31	8.98e-25	-0.58	-0.5	Breast cancer;	chr2:201513770	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2080324	ENSG00000235105.1	RP11-329A14.1	-12.58	1.73e-31	8.98e-25	-0.58	-0.5	Breast cancer;	chr2:201514089	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2080323	ENSG00000235105.1	RP11-329A14.1	-12.58	1.73e-31	8.98e-25	-0.58	-0.5	Breast cancer;	chr2:201514126	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2080322	ENSG00000235105.1	RP11-329A14.1	-12.58	1.73e-31	8.98e-25	-0.58	-0.5	Breast cancer;	chr2:201514317	chr1:48435967~48437223:+
THCA	trans	rs10242455	0.571	rs41258334	ENSG00000228834.1	RP11-249L21.4	12.58	1.75e-31	9.06e-25	1.37	0.5	Blood metabolite levels;	chr7:99674185	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.571	rs28365067	ENSG00000228834.1	RP11-249L21.4	12.58	1.75e-31	9.06e-25	1.37	0.5	Blood metabolite levels;	chr7:99674687	chr6:108907615~108907873:-
THCA	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	12.58	1.76e-31	9.11e-25	0.8	0.5	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
THCA	trans	rs77688320	0.553	rs2080320	ENSG00000235105.1	RP11-329A14.1	12.58	1.77e-31	9.16e-25	0.58	0.5	Breast cancer;	chr2:201514450	chr1:48435967~48437223:+
THCA	trans	rs116095464	0.558	rs10065239	ENSG00000185986.11	SDHAP3	12.58	1.82e-31	9.42e-25	0.6	0.5	Breast cancer;	chr5:275173	chr5:1572222~1594620:-
THCA	trans	rs916888	0.779	rs199528	ENSG00000204650.12	CRHR1-IT1	12.57	1.84e-31	9.53e-25	0.58	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45620328~45648216:+
THCA	trans	rs916888	0.821	rs199525	ENSG00000204650.12	CRHR1-IT1	12.57	1.84e-31	9.53e-25	0.58	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45620328~45648216:+
THCA	trans	rs2657294	0.929	rs6480771	ENSG00000172974.11	AC007318.5	12.57	1.92e-31	9.94e-25	0.6	0.5	Pneumonia;	chr10:75101922	chr2:65205108~65205988:+
THCA	trans	rs3740713	1	rs73438686	ENSG00000235847.2	LDHAP7	12.57	1.97e-31	1.02e-24	0.96	0.5	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr2:84777259~84778223:-
THCA	trans	rs77688320	0.553	rs2540432	ENSG00000235105.1	RP11-329A14.1	-12.56	2.06e-31	1.06e-24	-0.58	-0.5	Breast cancer;	chr2:201500171	chr1:48435967~48437223:+
THCA	trans	rs12709013	0.591	rs9932967	ENSG00000233719.3	GOT2P3	12.56	2.1e-31	1.09e-24	0.67	0.5	Blood metabolite ratios;	chr16:58805583	chr12:9641802~9643007:+
THCA	trans	rs7312770	1	rs7312770	ENSG00000196933.5	RPS26P11	-12.56	2.12e-31	1.1e-24	-0.61	-0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:72044545~72044892:+
THCA	trans	rs12709013	0.591	rs4410065	ENSG00000233719.3	GOT2P3	12.56	2.18e-31	1.13e-24	0.67	0.5	Blood metabolite ratios;	chr16:58800968	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.591	rs2406234	ENSG00000233719.3	GOT2P3	12.56	2.18e-31	1.13e-24	0.67	0.5	Blood metabolite ratios;	chr16:58801840	chr12:9641802~9643007:+
THCA	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	12.55	2.35e-31	1.21e-24	0.69	0.5	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
THCA	trans	rs12709013	0.636	rs967852	ENSG00000233719.3	GOT2P3	12.55	2.36e-31	1.22e-24	0.67	0.5	Blood metabolite ratios;	chr16:58807313	chr12:9641802~9643007:+
THCA	trans	rs9467773	0.901	rs1407045	ENSG00000242375.1	RP11-498P14.3	12.55	2.37e-31	1.22e-24	0.71	0.5	Intelligence (multi-trait analysis);	chr6:26475927	chr9:97195351~97197687:-
THCA	trans	rs12709013	0.536	rs9930758	ENSG00000233719.3	GOT2P3	12.55	2.42e-31	1.25e-24	0.67	0.5	Blood metabolite ratios;	chr16:58803167	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.535	rs9924136	ENSG00000233719.3	GOT2P3	12.54	2.57e-31	1.33e-24	0.67	0.5	Blood metabolite ratios;	chr16:58779573	chr12:9641802~9643007:+
THCA	trans	rs7312770	0.612	rs773114	ENSG00000223416.3	RPS26P15	12.54	2.63e-31	1.35e-24	0.61	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:58056133~58056480:-
THCA	trans	rs116095464	0.614	rs10059220	ENSG00000185986.11	SDHAP3	12.53	2.86e-31	1.47e-24	0.6	0.5	Breast cancer;	chr5:242698	chr5:1572222~1594620:-
THCA	trans	rs7937890	1	rs6486190	ENSG00000236360.2	RP11-334A14.2	12.52	2.96e-31	1.52e-24	0.67	0.5	Mitochondrial DNA levels;	chr11:14379670	chr1:52993201~52993702:-
THCA	trans	rs12709013	0.591	rs7184377	ENSG00000233719.3	GOT2P3	12.51	3.35e-31	1.72e-24	0.67	0.5	Blood metabolite ratios;	chr16:58808765	chr12:9641802~9643007:+
THCA	trans	rs916888	0.773	rs169201	ENSG00000204650.12	CRHR1-IT1	12.51	3.39e-31	1.74e-24	0.59	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45620328~45648216:+
THCA	trans	rs9876781	1	rs6442119	ENSG00000225528.1	RP3-370M22.8	-12.51	3.43e-31	1.76e-24	-0.59	-0.5	Longevity;	chr3:48398713	chr22:39960397~39964683:+
THCA	trans	rs12709013	0.514	rs8062639	ENSG00000233719.3	GOT2P3	12.51	3.52e-31	1.8e-24	0.66	0.5	Blood metabolite ratios;	chr16:58800264	chr12:9641802~9643007:+
THCA	trans	rs10242455	0.571	rs80045298	ENSG00000228834.1	RP11-249L21.4	12.5	3.69e-31	1.89e-24	1.31	0.5	Blood metabolite levels;	chr7:99709830	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.571	rs41279866	ENSG00000228834.1	RP11-249L21.4	12.5	3.69e-31	1.89e-24	1.31	0.5	Blood metabolite levels;	chr7:99717653	chr6:108907615~108907873:-
THCA	trans	rs9611519	0.894	rs4821998	ENSG00000268568.1	AC007228.9	-12.49	3.96e-31	2.03e-24	-0.61	-0.5	Neuroticism;	chr22:41072269	chr19:56672574~56673901:-
THCA	trans	rs77688320	0.553	rs2243791	ENSG00000235105.1	RP11-329A14.1	-12.49	4.23e-31	2.17e-24	-0.57	-0.5	Breast cancer;	chr2:201478079	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2540449	ENSG00000235105.1	RP11-329A14.1	-12.49	4.28e-31	2.19e-24	-0.57	-0.5	Breast cancer;	chr2:201451036	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.573	rs2080327	ENSG00000235105.1	RP11-329A14.1	-12.49	4.28e-31	2.19e-24	-0.57	-0.5	Breast cancer;	chr2:201461495	chr1:48435967~48437223:+
THCA	trans	rs916888	0.773	rs1378358	ENSG00000204650.12	CRHR1-IT1	12.48	4.61e-31	2.36e-24	0.59	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45620328~45648216:+
THCA	trans	rs877636	1	rs705696	ENSG00000234513.1	AC073072.7	12.48	4.66e-31	2.38e-24	0.66	0.5	Cognitive function;	chr12:56086864	chr7:22773646~22773993:-
THCA	trans	rs77688320	0.529	rs2540438	ENSG00000235105.1	RP11-329A14.1	-12.48	4.71e-31	2.4e-24	-0.58	-0.5	Breast cancer;	chr2:201485833	chr1:48435967~48437223:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	12.47	4.89e-31	2.49e-24	0.65	0.5	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000196656.7	AC004057.1	12.46	5.19e-31	2.65e-24	0.61	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr4:113214046~113217170:-
THCA	trans	rs7554547	0.69	rs61402980	ENSG00000261819.1	RP11-680G24.4	12.46	5.2e-31	2.65e-24	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11876432	chr16:14988259~14990160:-
THCA	trans	rs4276421	0.509	rs10067206	ENSG00000231752.4	EMBP1	12.46	5.48e-31	2.79e-24	0.71	0.5	P wave duration;	chr5:46027737	chr1:121519112~121571892:+
THCA	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-12.43	7.13e-31	3.62e-24	-0.65	-0.5	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
THCA	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-12.43	7.26e-31	3.68e-24	-0.65	-0.5	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
THCA	trans	rs12709013	0.66	rs30839	ENSG00000230849.2	GOT2P2	12.43	7.46e-31	3.79e-24	0.65	0.5	Blood metabolite ratios;	chr16:58711437	chr1:173141100~173142350:-
THCA	trans	rs7811142	1	rs7803454	ENSG00000228546.2	CTA-313A17.3	12.42	7.78e-31	3.94e-24	0.88	0.5	Platelet count;	chr7:100393925	chr7:102337316~102339115:+
THCA	trans	rs7811142	0.943	rs11769886	ENSG00000228546.2	CTA-313A17.3	12.42	7.78e-31	3.94e-24	0.88	0.5	Platelet count;	chr7:100400984	chr7:102337316~102339115:+
THCA	trans	rs13253073	0.544	rs10955223	ENSG00000260318.1	COX6CP1	12.42	7.83e-31	3.97e-24	0.95	0.5	Glucose homeostasis traits;	chr8:99903454	chr16:11903923~11904137:-
THCA	trans	rs2657294	0.931	rs2804522	ENSG00000172974.11	AC007318.5	12.41	8.55e-31	4.33e-24	0.59	0.5	Pneumonia;	chr10:75159132	chr2:65205108~65205988:+
THCA	trans	rs77688320	0.553	rs12473387	ENSG00000235105.1	RP11-329A14.1	12.41	8.84e-31	4.47e-24	0.57	0.5	Breast cancer;	chr2:201415778	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs4507084	ENSG00000235105.1	RP11-329A14.1	12.41	8.84e-31	4.47e-24	0.57	0.5	Breast cancer;	chr2:201420377	chr1:48435967~48437223:+
THCA	trans	rs12709013	0.574	rs35321124	ENSG00000233719.3	GOT2P3	12.41	8.86e-31	4.48e-24	0.66	0.5	Blood metabolite ratios;	chr16:58786561	chr12:9641802~9643007:+
THCA	trans	rs7811142	1	rs7783159	ENSG00000228546.2	CTA-313A17.3	12.4	9.51e-31	4.81e-24	0.89	0.5	Platelet count;	chr7:100419831	chr7:102337316~102339115:+
THCA	trans	rs4276421	0.571	rs12386473	ENSG00000231752.4	EMBP1	12.4	9.67e-31	4.88e-24	0.71	0.5	P wave duration;	chr5:45961509	chr1:121519112~121571892:+
THCA	trans	rs12200782	0.505	rs9295696	ENSG00000242375.1	RP11-498P14.3	12.39	1.02e-30	5.15e-24	0.84	0.5	Small cell lung carcinoma;	chr6:26550060	chr9:97195351~97197687:-
THCA	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-12.39	1.05e-30	5.3e-24	-0.65	-0.5	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
THCA	trans	rs3740713	1	rs79199586	ENSG00000235847.2	LDHAP7	12.38	1.14e-30	5.77e-24	0.96	0.5	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr2:84777259~84778223:-
THCA	trans	rs4276421	0.55	rs62372979	ENSG00000231752.4	EMBP1	12.38	1.19e-30	5.98e-24	0.71	0.5	P wave duration;	chr5:45964899	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.55	rs62372974	ENSG00000231752.4	EMBP1	12.37	1.27e-30	6.4e-24	0.7	0.5	P wave duration;	chr5:45960277	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.571	rs13361098	ENSG00000231752.4	EMBP1	12.36	1.39e-30	7.01e-24	0.7	0.5	P wave duration;	chr5:45967499	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs538628	ENSG00000204650.12	CRHR1-IT1	12.36	1.45e-30	7.32e-24	0.57	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45620328~45648216:+
THCA	trans	rs12709013	0.755	rs1424245	ENSG00000233719.3	GOT2P3	12.35	1.57e-30	7.9e-24	0.6	0.49	Blood metabolite ratios;	chr16:58729926	chr12:9641802~9643007:+
THCA	trans	rs9611519	0.894	rs9623320	ENSG00000268568.1	AC007228.9	-12.33	1.79e-30	8.98e-24	-0.6	-0.49	Neuroticism;	chr22:41082478	chr19:56672574~56673901:-
THCA	trans	rs10242455	0.702	rs41385645	ENSG00000228834.1	RP11-249L21.4	12.32	1.94e-30	9.72e-24	1.31	0.49	Blood metabolite levels;	chr7:99376415	chr6:108907615~108907873:-
THCA	trans	rs4276421	0.55	rs10038082	ENSG00000231752.4	EMBP1	12.32	1.98e-30	9.93e-24	0.7	0.49	P wave duration;	chr5:45963148	chr1:121519112~121571892:+
THCA	trans	rs916888	0.61	rs199529	ENSG00000204650.12	CRHR1-IT1	12.32	2.02e-30	1.01e-23	0.55	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45620328~45648216:+
THCA	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	12.32	2.07e-30	1.04e-23	0.66	0.49	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
THCA	trans	rs77688320	0.553	rs2540430	ENSG00000235105.1	RP11-329A14.1	-12.3	2.35e-30	1.18e-23	-0.57	-0.49	Breast cancer;	chr2:201503791	chr1:48435967~48437223:+
THCA	trans	rs8081395	0.651	rs1292067	ENSG00000187870.7	RNFT1P3	-12.29	2.67e-30	1.33e-23	-0.65	-0.49	White blood cell count;	chr17:59853285	chr17:20743333~20754501:-
THCA	trans	rs77688320	0.553	rs2244438	ENSG00000235105.1	RP11-329A14.1	-12.28	2.87e-30	1.43e-23	-0.57	-0.49	Breast cancer;	chr2:201387816	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2540330	ENSG00000235105.1	RP11-329A14.1	-12.28	2.87e-30	1.43e-23	-0.57	-0.49	Breast cancer;	chr2:201388133	chr1:48435967~48437223:+
THCA	trans	rs916888	0.773	rs199439	ENSG00000280022.1	RP11-707O23.1	-12.28	2.89e-30	1.43e-23	-0.62	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45592621~45593369:+
THCA	trans	rs4276421	0.571	rs10214057	ENSG00000231752.4	EMBP1	12.27	3.11e-30	1.55e-23	0.7	0.49	P wave duration;	chr5:45954403	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.55	rs62372041	ENSG00000231752.4	EMBP1	12.27	3.26e-30	1.62e-23	0.7	0.49	P wave duration;	chr5:45954946	chr1:121519112~121571892:+
THCA	trans	rs77688320	0.553	rs2540331	ENSG00000235105.1	RP11-329A14.1	-12.27	3.36e-30	1.67e-23	-0.57	-0.49	Breast cancer;	chr2:201388150	chr1:48435967~48437223:+
THCA	trans	rs3740713	1	rs73438604	ENSG00000235847.2	LDHAP7	12.27	3.38e-30	1.68e-23	0.92	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr2:84777259~84778223:-
THCA	trans	rs4276421	0.53	rs62371973	ENSG00000231752.4	EMBP1	12.26	3.48e-30	1.72e-23	0.75	0.49	P wave duration;	chr5:45907824	chr1:121519112~121571892:+
THCA	trans	rs2657294	0.895	rs4746262	ENSG00000172974.11	AC007318.5	12.26	3.62e-30	1.79e-23	0.6	0.49	Pneumonia;	chr10:75093631	chr2:65205108~65205988:+
THCA	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-12.26	3.66e-30	1.81e-23	-0.58	-0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
THCA	trans	rs12709013	0.591	rs4784986	ENSG00000233719.3	GOT2P3	12.25	3.75e-30	1.86e-23	0.65	0.49	Blood metabolite ratios;	chr16:58803007	chr12:9641802~9643007:+
THCA	trans	rs877636	1	rs877636	ENSG00000234513.1	AC073072.7	-12.25	3.93e-30	1.95e-23	-0.63	-0.49	Cognitive function;	chr12:56086799	chr7:22773646~22773993:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	12.24	4.32e-30	2.13e-23	0.65	0.49	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	12.24	4.44e-30	2.19e-23	0.64	0.49	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
THCA	trans	rs7554547	0.69	rs4314892	ENSG00000261819.1	RP11-680G24.4	12.22	5.28e-30	2.6e-23	0.68	0.49	Nonsyndromic cleft lip with cleft palate;	chr1:11889780	chr16:14988259~14990160:-
THCA	trans	rs10940346	0.506	rs10454829	ENSG00000231752.4	EMBP1	-12.22	5.4e-30	2.66e-23	-0.67	-0.49	Schizophrenia;	chr5:50585120	chr1:121519112~121571892:+
THCA	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	12.21	5.43e-30	2.67e-23	0.65	0.49	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
THCA	trans	rs13253073	0.544	rs13280341	ENSG00000260318.1	COX6CP1	12.21	5.53e-30	2.72e-23	0.99	0.49	Glucose homeostasis traits;	chr8:99908840	chr16:11903923~11904137:-
THCA	trans	rs2657294	0.965	rs7088974	ENSG00000172974.11	AC007318.5	12.21	5.59e-30	2.75e-23	0.58	0.49	Pneumonia;	chr10:75131338	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.965	rs2657286	ENSG00000172974.11	AC007318.5	-12.21	5.61e-30	2.76e-23	-0.58	-0.49	Pneumonia;	chr10:75145940	chr2:65205108~65205988:+
THCA	trans	rs7811142	0.83	rs118119933	ENSG00000228546.2	CTA-313A17.3	12.21	5.7e-30	2.8e-23	0.9	0.49	Platelet count;	chr7:100341427	chr7:102337316~102339115:+
THCA	trans	rs4276421	0.593	rs10214362	ENSG00000231752.4	EMBP1	12.2	5.99e-30	2.95e-23	0.7	0.49	P wave duration;	chr5:45952814	chr1:121519112~121571892:+
THCA	trans	rs9876781	1	rs9881491	ENSG00000225528.1	RP3-370M22.8	-12.2	6.02e-30	2.96e-23	-0.58	-0.49	Longevity;	chr3:48446507	chr22:39960397~39964683:+
THCA	trans	rs4240897	0.935	rs3766744	ENSG00000261819.1	RP11-680G24.4	12.2	6.12e-30	3.01e-23	0.63	0.49	Tuberculosis;	chr1:11983660	chr16:14988259~14990160:-
THCA	trans	rs2657294	0.895	rs3088142	ENSG00000172974.11	AC007318.5	12.19	6.73e-30	3.29e-23	0.6	0.49	Pneumonia;	chr10:75094806	chr2:65205108~65205988:+
THCA	trans	rs7121616	0.531	rs12573932	ENSG00000234176.1	HSPA8P1	12.19	7.12e-30	3.48e-23	0.76	0.49	Breast cancer;	chr11:123040995	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.576	rs9665920	ENSG00000234176.1	HSPA8P1	12.19	7.12e-30	3.48e-23	0.76	0.49	Breast cancer;	chr11:123041700	chrX:121203182~121205014:-
THCA	trans	rs7937890	0.681	rs4756784	ENSG00000236360.2	RP11-334A14.2	-12.18	7.3e-30	3.57e-23	-0.66	-0.49	Mitochondrial DNA levels;	chr11:14249358	chr1:52993201~52993702:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	12.18	7.32e-30	3.58e-23	0.6	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
THCA	trans	rs10940346	0.506	rs12187591	ENSG00000231752.4	EMBP1	-12.18	7.39e-30	3.61e-23	-0.67	-0.49	Schizophrenia;	chr5:50586789	chr1:121519112~121571892:+
THCA	trans	rs9876781	1	rs11712561	ENSG00000225528.1	RP3-370M22.8	-12.18	7.43e-30	3.63e-23	-0.58	-0.49	Longevity;	chr3:48393807	chr22:39960397~39964683:+
THCA	trans	rs10940346	0.506	rs7721806	ENSG00000231752.4	EMBP1	-12.18	7.57e-30	3.7e-23	-0.66	-0.49	Schizophrenia;	chr5:50576182	chr1:121519112~121571892:+
THCA	trans	rs9611519	0.894	rs9611488	ENSG00000268568.1	AC007228.9	-12.18	7.84e-30	3.83e-23	-0.6	-0.49	Neuroticism;	chr22:41066588	chr19:56672574~56673901:-
THCA	trans	rs916888	0.773	rs538628	ENSG00000280022.1	RP11-707O23.1	-12.17	7.91e-30	3.86e-23	-0.62	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45592621~45593369:+
THCA	trans	rs9876781	1	rs9864371	ENSG00000225528.1	RP3-370M22.8	-12.17	8.09e-30	3.95e-23	-0.58	-0.49	Longevity;	chr3:48385276	chr22:39960397~39964683:+
THCA	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	12.17	8.33e-30	4.06e-23	0.61	0.49	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	12.17	8.48e-30	4.13e-23	0.65	0.49	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	12.17	8.48e-30	4.13e-23	0.65	0.49	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000242970.2	AC068522.4	-12.16	8.67e-30	4.22e-23	-0.63	-0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:58588420~58588764:-
THCA	trans	rs916888	0.821	rs70600	ENSG00000204650.12	CRHR1-IT1	12.16	8.74e-30	4.26e-23	0.56	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45620328~45648216:+
THCA	trans	rs13014235	0.667	rs2540328	ENSG00000235105.1	RP11-329A14.1	-12.15	9.54e-30	4.64e-23	-0.56	-0.49	Basal cell carcinoma;	chr2:201384337	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.509	rs2714487	ENSG00000235105.1	RP11-329A14.1	-12.15	9.54e-30	4.64e-23	-0.56	-0.49	Breast cancer;	chr2:201384837	chr1:48435967~48437223:+
THCA	trans	rs10940346	0.517	rs12659073	ENSG00000231752.4	EMBP1	-12.15	1e-29	4.88e-23	-0.67	-0.49	Schizophrenia;	chr5:50558564	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000204652.6	RPS26P8	-12.14	1.12e-29	5.45e-23	-0.64	-0.49	Cognitive function;	chr12:56083910	chr17:45608571~45608918:+
THCA	trans	rs3740713	1	rs3740713	ENSG00000235847.2	LDHAP7	12.14	1.12e-29	5.45e-23	0.96	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr2:84777259~84778223:-
THCA	trans	rs77688320	0.535	rs10186894	ENSG00000235105.1	RP11-329A14.1	12.14	1.13e-29	5.46e-23	0.56	0.49	Breast cancer;	chr2:201440909	chr1:48435967~48437223:+
THCA	trans	rs4240897	0.935	rs4846082	ENSG00000261819.1	RP11-680G24.4	12.13	1.17e-29	5.66e-23	0.63	0.49	Tuberculosis;	chr1:11982386	chr16:14988259~14990160:-
THCA	trans	rs9876781	1	rs7630741	ENSG00000225528.1	RP3-370M22.8	-12.13	1.18e-29	5.72e-23	-0.58	-0.49	Longevity;	chr3:48378233	chr22:39960397~39964683:+
THCA	trans	rs7121616	0.5	rs12574868	ENSG00000234176.1	HSPA8P1	12.12	1.25e-29	6.07e-23	0.76	0.49	Breast cancer;	chr11:123040824	chrX:121203182~121205014:-
THCA	trans	rs7121616	0.531	rs11826861	ENSG00000234176.1	HSPA8P1	12.12	1.25e-29	6.07e-23	0.76	0.49	Breast cancer;	chr11:123041207	chrX:121203182~121205014:-
THCA	trans	rs4276421	0.53	rs72751925	ENSG00000231752.4	EMBP1	12.12	1.28e-29	6.21e-23	0.7	0.49	P wave duration;	chr5:45962607	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs199445	ENSG00000280022.1	RP11-707O23.1	-12.12	1.31e-29	6.35e-23	-0.6	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45592621~45593369:+
THCA	trans	rs916888	0.773	rs199443	ENSG00000280022.1	RP11-707O23.1	-12.12	1.31e-29	6.35e-23	-0.6	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45592621~45593369:+
THCA	trans	rs4276421	0.55	rs7722380	ENSG00000231752.4	EMBP1	-12.11	1.39e-29	6.7e-23	-0.74	-0.49	P wave duration;	chr5:45678276	chr1:121519112~121571892:+
THCA	trans	rs77688320	0.553	rs7582946	ENSG00000235105.1	RP11-329A14.1	12.11	1.4e-29	6.76e-23	0.56	0.49	Breast cancer;	chr2:201423969	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2540339	ENSG00000235105.1	RP11-329A14.1	-12.11	1.4e-29	6.76e-23	-0.56	-0.49	Breast cancer;	chr2:201415725	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2540340	ENSG00000235105.1	RP11-329A14.1	-12.11	1.4e-29	6.76e-23	-0.56	-0.49	Breast cancer;	chr2:201416477	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs1558637	ENSG00000235105.1	RP11-329A14.1	-12.11	1.42e-29	6.84e-23	-0.56	-0.49	Breast cancer;	chr2:201398651	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs10804114	ENSG00000235105.1	RP11-329A14.1	12.11	1.43e-29	6.91e-23	0.56	0.49	Breast cancer;	chr2:201402139	chr1:48435967~48437223:+
THCA	trans	rs7364180	0.582	rs139568	ENSG00000268568.1	AC007228.9	12.1	1.57e-29	7.59e-23	0.55	0.49	Alzheimer's disease biomarkers;	chr22:41814981	chr19:56672574~56673901:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	12.1	1.6e-29	7.71e-23	0.65	0.49	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-12.09	1.71e-29	8.22e-23	-0.61	-0.49	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
THCA	trans	rs7937890	0.732	rs7946902	ENSG00000236360.2	RP11-334A14.2	-12.09	1.73e-29	8.32e-23	-0.65	-0.49	Mitochondrial DNA levels;	chr11:14251762	chr1:52993201~52993702:-
THCA	trans	rs3740713	1	rs73436638	ENSG00000235847.2	LDHAP7	12.09	1.73e-29	8.33e-23	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73436642	ENSG00000235847.2	LDHAP7	12.09	1.73e-29	8.33e-23	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73436666	ENSG00000235847.2	LDHAP7	12.09	1.73e-29	8.33e-23	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438611	ENSG00000235847.2	LDHAP7	12.09	1.73e-29	8.33e-23	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs2643872	ENSG00000235847.2	LDHAP7	12.09	1.73e-29	8.33e-23	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs75381502	ENSG00000235847.2	LDHAP7	12.09	1.73e-29	8.33e-23	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr2:84777259~84778223:-
THCA	trans	rs4925166	1	rs4925166	ENSG00000263946.1	RP11-434D2.11	12.09	1.79e-29	8.59e-23	0.61	0.49	Multiple sclerosis;	chr17:18307496	chr17:20554971~20559410:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000196656.7	AC004057.1	12.08	1.84e-29	8.83e-23	0.6	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr4:113214046~113217170:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	12.08	1.99e-29	9.54e-23	0.59	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
THCA	trans	rs4276421	0.593	rs6898646	ENSG00000231752.4	EMBP1	12.07	2.08e-29	9.97e-23	0.67	0.49	P wave duration;	chr5:45841837	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000204652.6	RPS26P8	-12.07	2.09e-29	1e-22	-0.64	-0.49	Cognitive function;	chr12:56084218	chr17:45608571~45608918:+
THCA	trans	rs877636	0.692	rs7971751	ENSG00000204652.6	RPS26P8	-12.07	2.09e-29	1e-22	-0.64	-0.49	Cognitive function;	chr12:56084874	chr17:45608571~45608918:+
THCA	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	12.07	2.15e-29	1.03e-22	0.66	0.49	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
THCA	trans	rs916888	0.773	rs199448	ENSG00000280022.1	RP11-707O23.1	-12.06	2.19e-29	1.05e-22	-0.61	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45592621~45593369:+
THCA	trans	rs916888	0.773	rs199447	ENSG00000280022.1	RP11-707O23.1	-12.06	2.19e-29	1.05e-22	-0.61	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45592621~45593369:+
THCA	trans	rs9876781	1	rs9815103	ENSG00000225528.1	RP3-370M22.8	-12.06	2.21e-29	1.06e-22	-0.58	-0.49	Longevity;	chr3:48372725	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	12.06	2.3e-29	1.1e-22	0.66	0.49	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
THCA	trans	rs9876781	1	rs28824259	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48384185	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs12487542	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48384586	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs73074358	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48385757	chr22:39960397~39964683:+
THCA	trans	rs9876781	0.967	rs34761139	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48386489	chr22:39960397~39964683:+
THCA	trans	rs9876781	0.868	rs9875280	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48387420	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs6796491	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48388977	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs6804774	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48389129	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs9826195	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48392157	chr22:39960397~39964683:+
THCA	trans	rs9876781	0.967	rs9864815	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48392588	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs9809843	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48392923	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs1563736	ENSG00000225528.1	RP3-370M22.8	-12.06	2.32e-29	1.11e-22	-0.58	-0.49	Longevity;	chr3:48395329	chr22:39960397~39964683:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-12.06	2.39e-29	1.14e-22	-0.64	-0.49	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-12.06	2.39e-29	1.14e-22	-0.64	-0.49	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
THCA	trans	rs10940346	0.506	rs7704183	ENSG00000231752.4	EMBP1	-12.05	2.45e-29	1.17e-22	-0.66	-0.49	Schizophrenia;	chr5:50576738	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.74	rs6490924	ENSG00000224976.2	PARP4P2	12.05	2.45e-29	1.17e-22	0.57	0.49	Obesity-related traits;	chr13:24432914	chr13:19349137~19407962:+
THCA	trans	rs916888	0.773	rs169201	ENSG00000280022.1	RP11-707O23.1	-12.05	2.46e-29	1.17e-22	-0.62	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45592621~45593369:+
THCA	trans	rs9876781	1	rs13071337	ENSG00000225528.1	RP3-370M22.8	-12.05	2.46e-29	1.18e-22	-0.58	-0.49	Longevity;	chr3:48396724	chr22:39960397~39964683:+
THCA	trans	rs10940346	0.506	rs4605740	ENSG00000231752.4	EMBP1	-12.05	2.63e-29	1.25e-22	-0.66	-0.49	Schizophrenia;	chr5:50574869	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	12.04	2.67e-29	1.27e-22	0.66	0.49	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	12.04	2.67e-29	1.27e-22	0.66	0.49	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
THCA	trans	rs9876781	1	rs1109227	ENSG00000225528.1	RP3-370M22.8	-12.04	2.68e-29	1.28e-22	-0.58	-0.49	Longevity;	chr3:48437797	chr22:39960397~39964683:+
THCA	trans	rs916888	0.773	rs1378358	ENSG00000280022.1	RP11-707O23.1	-12.04	2.75e-29	1.31e-22	-0.62	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45592621~45593369:+
THCA	trans	rs916888	0.773	rs199457	ENSG00000280022.1	RP11-707O23.1	-12.04	2.76e-29	1.31e-22	-0.61	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45592621~45593369:+
THCA	trans	rs2657294	0.796	rs7082123	ENSG00000172974.11	AC007318.5	12.04	2.77e-29	1.32e-22	0.59	0.49	Pneumonia;	chr10:75091101	chr2:65205108~65205988:+
THCA	trans	rs916888	0.687	rs199456	ENSG00000280022.1	RP11-707O23.1	-12.04	2.78e-29	1.32e-22	-0.61	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45592621~45593369:+
THCA	trans	rs916888	0.773	rs199451	ENSG00000280022.1	RP11-707O23.1	-12.04	2.78e-29	1.32e-22	-0.61	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45592621~45593369:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	12.04	2.8e-29	1.33e-22	0.62	0.49	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
THCA	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	12.04	2.82e-29	1.34e-22	0.66	0.49	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
THCA	trans	rs9876781	1	rs13091785	ENSG00000225528.1	RP3-370M22.8	-12.03	2.91e-29	1.38e-22	-0.58	-0.49	Longevity;	chr3:48452692	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs6776700	ENSG00000225528.1	RP3-370M22.8	-12.03	2.91e-29	1.38e-22	-0.58	-0.49	Longevity;	chr3:48455358	chr22:39960397~39964683:+
THCA	trans	rs3740713	1	rs73436645	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr2:84777259~84778223:-
THCA	trans	rs3740713	0.925	rs73436650	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73436655	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr2:84777259~84778223:-
THCA	trans	rs3740713	0.92	rs80254575	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73436662	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs113725670	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73436682	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73436685	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs2056781	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73436701	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438607	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs75010364	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438627	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438634	ENSG00000235847.2	LDHAP7	12.03	3.02e-29	1.43e-22	0.91	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr2:84777259~84778223:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000225071.1	GS1-184P14.2	12.03	3.02e-29	1.44e-22	0.66	0.49	Cognitive function;	chr12:55976127	chrX:24429573~24429920:-
THCA	trans	rs9876781	0.967	rs7618883	ENSG00000225528.1	RP3-370M22.8	-12.03	3.16e-29	1.5e-22	-0.58	-0.49	Longevity;	chr3:48457056	chr22:39960397~39964683:+
THCA	trans	rs10940346	0.506	rs12659667	ENSG00000231752.4	EMBP1	-12.02	3.21e-29	1.52e-22	-0.66	-0.49	Schizophrenia;	chr5:50566091	chr1:121519112~121571892:+
THCA	trans	rs6477998	0.702	rs7861707	ENSG00000238072.1	RP11-305M3.2	12.02	3.38e-29	1.6e-22	0.7	0.48	Hematology traits;	chr9:113251428	chr7:129410113~129410370:-
THCA	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	12.01	3.48e-29	1.65e-22	0.66	0.48	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	12.01	3.48e-29	1.65e-22	0.66	0.48	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
THCA	trans	rs9876781	1	rs9311423	ENSG00000225528.1	RP3-370M22.8	-12.01	3.49e-29	1.65e-22	-0.58	-0.48	Longevity;	chr3:48378818	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs7634377	ENSG00000225528.1	RP3-370M22.8	-12.01	3.49e-29	1.65e-22	-0.58	-0.48	Longevity;	chr3:48379768	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	12.01	3.5e-29	1.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	12.01	3.5e-29	1.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	12.01	3.5e-29	1.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	12.01	3.5e-29	1.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	12.01	3.5e-29	1.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	12.01	3.5e-29	1.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	12.01	3.5e-29	1.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
THCA	trans	rs2657294	0.861	rs6480769	ENSG00000172974.11	AC007318.5	12.01	3.57e-29	1.69e-22	0.59	0.48	Pneumonia;	chr10:75091745	chr2:65205108~65205988:+
THCA	trans	rs77688320	0.553	rs2714488	ENSG00000235105.1	RP11-329A14.1	-12.01	3.65e-29	1.72e-22	-0.56	-0.48	Breast cancer;	chr2:201405050	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs2249868	ENSG00000235105.1	RP11-329A14.1	-12.01	3.65e-29	1.72e-22	-0.56	-0.48	Breast cancer;	chr2:201412503	chr1:48435967~48437223:+
THCA	trans	rs9876781	1	rs4858793	ENSG00000225528.1	RP3-370M22.8	12.01	3.71e-29	1.76e-22	0.57	0.48	Longevity;	chr3:48373517	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	12	3.92e-29	1.85e-22	0.67	0.48	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
THCA	trans	rs9876781	1	rs3774808	ENSG00000225528.1	RP3-370M22.8	-12	3.92e-29	1.85e-22	-0.58	-0.48	Longevity;	chr3:48440237	chr22:39960397~39964683:+
THCA	trans	rs9876781	0.872	rs11797	ENSG00000225528.1	RP3-370M22.8	-12	4.04e-29	1.9e-22	-0.59	-0.48	Longevity;	chr3:48467186	chr22:39960397~39964683:+
THCA	trans	rs3740713	1	rs73438631	ENSG00000235847.2	LDHAP7	12	4.05e-29	1.91e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr2:84777259~84778223:-
THCA	trans	rs9876781	0.9	rs1037773	ENSG00000225528.1	RP3-370M22.8	-12	4.12e-29	1.94e-22	-0.58	-0.48	Longevity;	chr3:48426493	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs2279077	ENSG00000225528.1	RP3-370M22.8	-12	4.12e-29	1.94e-22	-0.58	-0.48	Longevity;	chr3:48432839	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs9883759	ENSG00000225528.1	RP3-370M22.8	-11.99	4.22e-29	1.99e-22	-0.58	-0.48	Longevity;	chr3:48422209	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs6442120	ENSG00000225528.1	RP3-370M22.8	-11.99	4.22e-29	1.99e-22	-0.58	-0.48	Longevity;	chr3:48423094	chr22:39960397~39964683:+
THCA	trans	rs4276421	0.593	rs10941704	ENSG00000231752.4	EMBP1	-11.99	4.35e-29	2.05e-22	-0.72	-0.48	P wave duration;	chr5:45783404	chr1:121519112~121571892:+
THCA	trans	rs7364180	0.515	rs6002503	ENSG00000268568.1	AC007228.9	-11.99	4.49e-29	2.12e-22	-0.55	-0.48	Alzheimer's disease biomarkers;	chr22:41812668	chr19:56672574~56673901:-
THCA	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	11.99	4.55e-29	2.14e-22	0.66	0.48	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-11.98	4.59e-29	2.16e-22	-0.64	-0.48	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
THCA	trans	rs3740713	1	rs73436668	ENSG00000235847.2	LDHAP7	11.98	4.7e-29	2.21e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr2:84777259~84778223:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	11.98	4.76e-29	2.23e-22	0.64	0.48	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
THCA	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	11.98	4.77e-29	2.23e-22	0.66	0.48	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	11.98	4.91e-29	2.3e-22	0.66	0.48	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
THCA	trans	rs916888	0.821	rs199506	ENSG00000204650.12	CRHR1-IT1	-11.98	4.99e-29	2.34e-22	-0.55	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45620328~45648216:+
THCA	trans	rs77688320	0.573	rs59674665	ENSG00000235105.1	RP11-329A14.1	-11.97	5.09e-29	2.38e-22	-0.57	-0.48	Breast cancer;	chr2:201514881	chr1:48435967~48437223:+
THCA	trans	rs9611519	1	rs2273085	ENSG00000268568.1	AC007228.9	-11.97	5.27e-29	2.46e-22	-0.57	-0.48	Neuroticism;	chr22:41219372	chr19:56672574~56673901:-
THCA	trans	rs9876781	1	rs3214041	ENSG00000225528.1	RP3-370M22.8	-11.97	5.38e-29	2.51e-22	-0.58	-0.48	Longevity;	chr3:48413059	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs13314659	ENSG00000225528.1	RP3-370M22.8	11.96	5.58e-29	2.61e-22	0.58	0.48	Longevity;	chr3:48407742	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	11.96	5.69e-29	2.65e-22	0.66	0.48	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	11.96	5.71e-29	2.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
THCA	trans	rs9899728	0.539	rs11077772	ENSG00000234925.2	ATP5HP4	11.96	5.95e-29	2.77e-22	0.95	0.48	Alzheimer's disease or small vessel stroke;	chr17:75039603	chr12:68642519~68642993:-
THCA	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-11.96	5.99e-29	2.79e-22	-0.62	-0.48	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
THCA	trans	rs9876781	1	rs11130170	ENSG00000225528.1	RP3-370M22.8	-11.96	6.01e-29	2.8e-22	-0.58	-0.48	Longevity;	chr3:48408490	chr22:39960397~39964683:+
THCA	trans	rs916888	0.773	rs199533	ENSG00000280022.1	RP11-707O23.1	-11.95	6.24e-29	2.9e-22	-0.61	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45592621~45593369:+
THCA	trans	rs13190036	1	rs4976682	ENSG00000226986.4	RP11-543B16.2	11.95	6.34e-29	2.95e-22	0.68	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	11.95	6.56e-29	3.05e-22	0.66	0.48	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
THCA	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-11.95	6.58e-29	3.06e-22	-0.62	-0.48	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
THCA	trans	rs3740713	1	rs12289603	ENSG00000235847.2	LDHAP7	11.95	6.63e-29	3.08e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr2:84777259~84778223:-
THCA	trans	rs8010715	0.816	rs6573565	ENSG00000238000.1	RP11-274E7.2	-11.94	6.82e-29	3.17e-22	-0.51	-0.48	IgG glycosylation;	chr14:24125524	chr5:98213402~98214121:+
THCA	trans	rs7811142	1	rs73161762	ENSG00000228546.2	CTA-313A17.3	11.94	6.87e-29	3.19e-22	0.86	0.48	Platelet count;	chr7:100417223	chr7:102337316~102339115:+
THCA	trans	rs8010715	0.816	rs762093	ENSG00000238000.1	RP11-274E7.2	11.94	6.97e-29	3.24e-22	0.51	0.48	IgG glycosylation;	chr14:24122709	chr5:98213402~98214121:+
THCA	trans	rs8010715	0.785	rs2877611	ENSG00000238000.1	RP11-274E7.2	11.94	7.2e-29	3.34e-22	0.51	0.48	IgG glycosylation;	chr14:24126221	chr5:98213402~98214121:+
THCA	trans	rs12709013	0.636	rs30835	ENSG00000230849.2	GOT2P2	11.93	7.32e-29	3.4e-22	0.62	0.48	Blood metabolite ratios;	chr16:58714117	chr1:173141100~173142350:-
THCA	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	11.93	7.38e-29	3.43e-22	0.66	0.48	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs73440625	ENSG00000235847.2	LDHAP7	11.93	7.42e-29	3.45e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-11.93	7.53e-29	3.5e-22	-0.67	-0.48	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.55	rs34423213	ENSG00000231752.4	EMBP1	11.93	7.56e-29	3.51e-22	0.73	0.48	P wave duration;	chr5:45680866	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs4569882	ENSG00000231752.4	EMBP1	11.93	7.65e-29	3.55e-22	0.7	0.48	P wave duration;	chr5:46011875	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	11.93	7.75e-29	3.59e-22	0.66	0.48	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	11.93	7.75e-29	3.59e-22	0.66	0.48	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	11.93	7.75e-29	3.59e-22	0.66	0.48	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	11.93	7.75e-29	3.59e-22	0.66	0.48	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	11.93	7.75e-29	3.59e-22	0.66	0.48	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	11.93	7.75e-29	3.59e-22	0.66	0.48	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	11.93	7.75e-29	3.59e-22	0.66	0.48	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs75740864	ENSG00000235847.2	LDHAP7	11.93	7.88e-29	3.65e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr2:84777259~84778223:-
THCA	trans	rs9876781	1	rs7651407	ENSG00000225528.1	RP3-370M22.8	-11.92	8.31e-29	3.85e-22	-0.57	-0.48	Longevity;	chr3:48402409	chr22:39960397~39964683:+
THCA	trans	rs10940346	0.506	rs12657678	ENSG00000231752.4	EMBP1	11.92	8.41e-29	3.89e-22	0.65	0.48	Schizophrenia;	chr5:50564284	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-11.92	8.56e-29	3.96e-22	-0.66	-0.48	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.55	rs62367712	ENSG00000231752.4	EMBP1	11.91	8.83e-29	4.08e-22	0.72	0.48	P wave duration;	chr5:45766262	chr1:121519112~121571892:+
THCA	trans	rs77688320	0.553	rs6722889	ENSG00000235105.1	RP11-329A14.1	-11.91	8.99e-29	4.16e-22	-0.56	-0.48	Breast cancer;	chr2:201439359	chr1:48435967~48437223:+
THCA	trans	rs877636	0.702	rs773110	ENSG00000212994.5	RPS26P6	11.91	9.28e-29	4.29e-22	0.63	0.48	Cognitive function;	chr12:55981353	chr8:100895771~100896118:+
THCA	trans	rs877636	0.702	rs773111	ENSG00000212994.5	RPS26P6	11.91	9.28e-29	4.29e-22	0.63	0.48	Cognitive function;	chr12:55981956	chr8:100895771~100896118:+
THCA	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	11.91	9.54e-29	4.41e-22	0.66	0.48	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	11.91	9.54e-29	4.41e-22	0.66	0.48	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	11.91	9.54e-29	4.41e-22	0.66	0.48	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	11.91	9.54e-29	4.41e-22	0.66	0.48	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	11.91	9.54e-29	4.41e-22	0.66	0.48	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	11.91	9.54e-29	4.41e-22	0.66	0.48	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs1848048	ENSG00000235847.2	LDHAP7	11.9	9.88e-29	4.56e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs16935432	ENSG00000235847.2	LDHAP7	11.9	9.88e-29	4.56e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs76599129	ENSG00000235847.2	LDHAP7	11.9	9.88e-29	4.56e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr2:84777259~84778223:-
THCA	trans	rs2657294	0.895	rs2395137	ENSG00000172974.11	AC007318.5	11.9	1.03e-28	4.75e-22	0.58	0.48	Pneumonia;	chr10:75088235	chr2:65205108~65205988:+
THCA	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	11.9	1.03e-28	4.77e-22	0.66	0.48	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	11.9	1.03e-28	4.77e-22	0.66	0.48	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs76586692	ENSG00000235847.2	LDHAP7	11.89	1.06e-28	4.91e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs76062966	ENSG00000235847.2	LDHAP7	11.89	1.06e-28	4.91e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	11.89	1.08e-28	4.99e-22	0.66	0.48	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	11.89	1.08e-28	4.99e-22	0.66	0.48	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs57311859	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr2:84777259~84778223:-
THCA	trans	rs3740713	0.92	rs112973292	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr2:84777259~84778223:-
THCA	trans	rs3740713	0.92	rs73438656	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr2:84777259~84778223:-
THCA	trans	rs3740713	0.92	rs73438659	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438666	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs16935424	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438674	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438690	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438695	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73440606	ENSG00000235847.2	LDHAP7	11.89	1.09e-28	5.02e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr2:84777259~84778223:-
THCA	trans	rs4276421	0.55	rs10473403	ENSG00000231752.4	EMBP1	11.89	1.12e-28	5.16e-22	0.68	0.48	P wave duration;	chr5:45921272	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.669	rs7984513	ENSG00000224976.2	PARP4P2	11.88	1.16e-28	5.35e-22	0.56	0.48	Obesity-related traits;	chr13:24445117	chr13:19349137~19407962:+
THCA	trans	rs4276421	0.55	rs4242126	ENSG00000231752.4	EMBP1	-11.88	1.19e-28	5.5e-22	-0.71	-0.48	P wave duration;	chr5:45826271	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.583	rs6490918	ENSG00000224976.2	PARP4P2	11.87	1.28e-28	5.9e-22	0.56	0.48	Obesity-related traits;	chr13:24427977	chr13:19349137~19407962:+
THCA	trans	rs3740713	1	rs73440636	ENSG00000235847.2	LDHAP7	11.87	1.31e-28	6.04e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	11.87	1.34e-28	6.14e-22	0.66	0.48	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs73440634	ENSG00000235847.2	LDHAP7	11.87	1.34e-28	6.16e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18451999	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73440615	ENSG00000235847.2	LDHAP7	11.87	1.35e-28	6.21e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	11.87	1.39e-28	6.36e-22	0.66	0.48	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
THCA	trans	rs9611519	1	rs5758264	ENSG00000268568.1	AC007228.9	-11.86	1.39e-28	6.39e-22	-0.57	-0.48	Neuroticism;	chr22:41220280	chr19:56672574~56673901:-
THCA	trans	rs9876781	1	rs6442118	ENSG00000225528.1	RP3-370M22.8	-11.86	1.41e-28	6.45e-22	-0.57	-0.48	Longevity;	chr3:48398582	chr22:39960397~39964683:+
THCA	trans	rs4276421	0.55	rs1852598	ENSG00000231752.4	EMBP1	11.86	1.45e-28	6.64e-22	0.73	0.48	P wave duration;	chr5:45602874	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	11.86	1.48e-28	6.79e-22	0.66	0.48	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	11.86	1.48e-28	6.79e-22	0.66	0.48	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
THCA	trans	rs116095464	0.558	rs12173015	ENSG00000185986.11	SDHAP3	-11.85	1.54e-28	7.04e-22	-0.5	-0.48	Breast cancer;	chr5:269852	chr5:1572222~1594620:-
THCA	trans	rs2657294	0.965	rs2657291	ENSG00000172974.11	AC007318.5	11.85	1.56e-28	7.13e-22	0.58	0.48	Pneumonia;	chr10:75166945	chr2:65205108~65205988:+
THCA	trans	rs9611519	0.894	rs13053242	ENSG00000268568.1	AC007228.9	-11.85	1.57e-28	7.2e-22	-0.6	-0.48	Neuroticism;	chr22:41063482	chr19:56672574~56673901:-
THCA	trans	rs9876781	1	rs6784322	ENSG00000225528.1	RP3-370M22.8	-11.85	1.59e-28	7.26e-22	-0.57	-0.48	Longevity;	chr3:48380745	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	11.85	1.6e-28	7.32e-22	0.66	0.48	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000212994.5	RPS26P6	11.85	1.61e-28	7.35e-22	0.63	0.48	Cognitive function;	chr12:55982097	chr8:100895771~100896118:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-11.85	1.63e-28	7.46e-22	-0.6	-0.48	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-11.85	1.63e-28	7.46e-22	-0.6	-0.48	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000196656.7	AC004057.1	-11.85	1.66e-28	7.56e-22	-0.57	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr4:113214046~113217170:-
THCA	trans	rs9876781	1	rs10470686	ENSG00000225528.1	RP3-370M22.8	-11.85	1.66e-28	7.6e-22	-0.57	-0.48	Longevity;	chr3:48408549	chr22:39960397~39964683:+
THCA	trans	rs916888	0.773	rs199534	ENSG00000280022.1	RP11-707O23.1	-11.84	1.68e-28	7.66e-22	-0.6	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45592621~45593369:+
THCA	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	11.84	1.68e-28	7.66e-22	0.66	0.48	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-11.84	1.68e-28	7.66e-22	-0.63	-0.48	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	11.84	1.68e-28	7.67e-22	0.64	0.48	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
THCA	trans	rs3740713	1	rs75487138	ENSG00000235847.2	LDHAP7	11.84	1.7e-28	7.76e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	11.84	1.77e-28	8.08e-22	0.67	0.48	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs78549183	ENSG00000235847.2	LDHAP7	11.84	1.77e-28	8.09e-22	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	11.84	1.79e-28	8.16e-22	0.66	0.48	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	11.84	1.79e-28	8.16e-22	0.66	0.48	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	11.84	1.79e-28	8.16e-22	0.66	0.48	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs113497813	ENSG00000235847.2	LDHAP7	11.83	1.9e-28	8.65e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438697	ENSG00000235847.2	LDHAP7	11.83	1.9e-28	8.65e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs114330751	ENSG00000235847.2	LDHAP7	11.83	1.9e-28	8.65e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	11.83	1.9e-28	8.66e-22	0.65	0.48	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.509	rs8185343	ENSG00000231752.4	EMBP1	11.83	1.91e-28	8.69e-22	0.69	0.48	P wave duration;	chr5:46012100	chr1:121519112~121571892:+
THCA	trans	rs3740713	1	rs61081934	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr2:84777259~84778223:-
THCA	trans	rs3740713	0.92	rs112818034	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs76708296	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438668	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs75647856	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438687	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs74663287	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73438699	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73440604	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs73440610	ENSG00000235847.2	LDHAP7	11.83	1.94e-28	8.83e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	11.83	1.99e-28	9.02e-22	0.65	0.48	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.53	rs4552614	ENSG00000231752.4	EMBP1	11.82	2.06e-28	9.36e-22	0.69	0.48	P wave duration;	chr5:46017620	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	11.82	2.11e-28	9.56e-22	0.65	0.48	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	11.82	2.11e-28	9.58e-22	0.66	0.48	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	11.82	2.11e-28	9.58e-22	0.66	0.48	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	11.82	2.11e-28	9.58e-22	0.66	0.48	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	11.82	2.11e-28	9.58e-22	0.66	0.48	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	11.82	2.11e-28	9.58e-22	0.66	0.48	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs113036885	ENSG00000235847.2	LDHAP7	11.82	2.13e-28	9.64e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs112410494	ENSG00000235847.2	LDHAP7	11.82	2.13e-28	9.64e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr2:84777259~84778223:-
THCA	trans	rs3740713	1	rs74741949	ENSG00000235847.2	LDHAP7	11.82	2.13e-28	9.64e-22	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr2:84777259~84778223:-
THCA	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-11.82	2.19e-28	9.94e-22	-0.62	-0.48	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
THCA	trans	rs4276421	0.55	rs62373044	ENSG00000231752.4	EMBP1	11.81	2.2e-28	9.96e-22	0.7	0.48	P wave duration;	chr5:46005052	chr1:121519112~121571892:+
THCA	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	11.81	2.21e-28	1e-21	0.63	0.48	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
THCA	trans	rs3740713	1	rs60376560	ENSG00000235847.2	LDHAP7	11.81	2.22e-28	1.01e-21	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr2:84777259~84778223:-
THCA	trans	rs8010715	0.816	rs1134340	ENSG00000238000.1	RP11-274E7.2	11.81	2.24e-28	1.01e-21	0.5	0.48	IgG glycosylation;	chr14:24125004	chr5:98213402~98214121:+
THCA	trans	rs3740713	1	rs73440614	ENSG00000235847.2	LDHAP7	11.81	2.29e-28	1.04e-21	0.91	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr2:84777259~84778223:-
THCA	trans	rs916888	0.773	rs199535	ENSG00000280022.1	RP11-707O23.1	-11.81	2.34e-28	1.06e-21	-0.59	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45592621~45593369:+
THCA	trans	rs8010715	0.816	rs7153156	ENSG00000238000.1	RP11-274E7.2	11.8	2.49e-28	1.13e-21	0.5	0.48	IgG glycosylation;	chr14:24129637	chr5:98213402~98214121:+
THCA	trans	rs8010715	0.816	rs6573572	ENSG00000238000.1	RP11-274E7.2	11.8	2.49e-28	1.13e-21	0.5	0.48	IgG glycosylation;	chr14:24130021	chr5:98213402~98214121:+
THCA	trans	rs8010715	0.816	rs8015168	ENSG00000238000.1	RP11-274E7.2	11.8	2.49e-28	1.13e-21	0.5	0.48	IgG glycosylation;	chr14:24130663	chr5:98213402~98214121:+
THCA	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	11.8	2.49e-28	1.13e-21	0.66	0.48	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
THCA	trans	rs8010715	0.816	rs11574503	ENSG00000238000.1	RP11-274E7.2	-11.8	2.5e-28	1.13e-21	-0.5	-0.48	IgG glycosylation;	chr14:24132109	chr5:98213402~98214121:+
THCA	trans	rs4276421	0.55	rs1405916	ENSG00000231752.4	EMBP1	11.8	2.51e-28	1.14e-21	0.73	0.48	P wave duration;	chr5:45673782	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	11.8	2.56e-28	1.16e-21	0.65	0.48	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
THCA	trans	rs12709013	0.613	rs1657178	ENSG00000233719.3	GOT2P3	11.79	2.66e-28	1.2e-21	0.62	0.48	Blood metabolite ratios;	chr16:58735300	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.585	rs7188608	ENSG00000233719.3	GOT2P3	11.79	2.66e-28	1.2e-21	0.62	0.48	Blood metabolite ratios;	chr16:58736236	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1657176	ENSG00000233719.3	GOT2P3	11.79	2.66e-28	1.2e-21	0.62	0.48	Blood metabolite ratios;	chr16:58736833	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1646282	ENSG00000233719.3	GOT2P3	11.79	2.66e-28	1.2e-21	0.62	0.48	Blood metabolite ratios;	chr16:58741296	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs4784977	ENSG00000233719.3	GOT2P3	11.79	2.66e-28	1.2e-21	0.62	0.48	Blood metabolite ratios;	chr16:58742120	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1646269	ENSG00000233719.3	GOT2P3	11.79	2.66e-28	1.2e-21	0.62	0.48	Blood metabolite ratios;	chr16:58743412	chr12:9641802~9643007:+
THCA	trans	rs3740713	1	rs35593189	ENSG00000235847.2	LDHAP7	11.79	2.66e-28	1.2e-21	0.9	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr2:84777259~84778223:-
THCA	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	11.79	2.69e-28	1.21e-21	0.66	0.48	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
THCA	trans	rs2657294	0.895	rs2002023	ENSG00000172974.11	AC007318.5	11.79	2.73e-28	1.23e-21	0.58	0.48	Pneumonia;	chr10:75088766	chr2:65205108~65205988:+
THCA	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	11.79	2.75e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000227887.1	RPS26P13	-11.79	2.76e-28	1.24e-21	-0.58	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:208697369~208697698:-
THCA	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	11.79	2.77e-28	1.24e-21	0.66	0.48	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	11.79	2.79e-28	1.25e-21	0.66	0.48	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.571	rs10074470	ENSG00000231752.4	EMBP1	11.79	2.81e-28	1.26e-21	0.68	0.48	P wave duration;	chr5:45940922	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs61012768	ENSG00000231752.4	EMBP1	11.79	2.81e-28	1.26e-21	0.68	0.48	P wave duration;	chr5:45941000	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs7448897	ENSG00000231752.4	EMBP1	11.79	2.81e-28	1.26e-21	0.68	0.48	P wave duration;	chr5:45941347	chr1:121519112~121571892:+
THCA	trans	rs9611519	0.894	rs9611486	ENSG00000268568.1	AC007228.9	-11.78	2.92e-28	1.31e-21	-0.59	-0.48	Neuroticism;	chr22:41062780	chr19:56672574~56673901:-
THCA	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	11.78	2.94e-28	1.32e-21	0.66	0.48	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	11.78	3.07e-28	1.37e-21	0.66	0.48	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	11.78	3.07e-28	1.37e-21	0.66	0.48	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	11.78	3.1e-28	1.39e-21	0.66	0.48	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	11.78	3.16e-28	1.41e-21	0.66	0.48	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	11.77	3.26e-28	1.46e-21	0.66	0.48	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
THCA	trans	rs8010715	0.816	rs2332224	ENSG00000238000.1	RP11-274E7.2	11.77	3.29e-28	1.47e-21	0.51	0.48	IgG glycosylation;	chr14:24129335	chr5:98213402~98214121:+
THCA	trans	rs12709013	0.597	rs8051078	ENSG00000233719.3	GOT2P3	11.77	3.3e-28	1.47e-21	0.62	0.48	Blood metabolite ratios;	chr16:58774200	chr12:9641802~9643007:+
THCA	trans	rs9611519	1	rs4820433	ENSG00000268568.1	AC007228.9	-11.77	3.31e-28	1.48e-21	-0.55	-0.48	Neuroticism;	chr22:41211061	chr19:56672574~56673901:-
THCA	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	11.76	3.58e-28	1.6e-21	0.65	0.48	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
THCA	trans	rs9876781	0.967	rs9876891	ENSG00000225528.1	RP3-370M22.8	-11.76	3.65e-28	1.63e-21	-0.57	-0.48	Longevity;	chr3:48440024	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-11.76	3.69e-28	1.64e-21	-0.65	-0.48	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
THCA	trans	rs77688320	0.517	rs12991600	ENSG00000235105.1	RP11-329A14.1	11.76	3.71e-28	1.65e-21	0.51	0.48	Breast cancer;	chr2:201472513	chr1:48435967~48437223:+
THCA	trans	rs13190036	1	rs28580074	ENSG00000226986.4	RP11-543B16.2	11.76	3.75e-28	1.67e-21	0.68	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	11.76	3.75e-28	1.67e-21	0.65	0.48	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.593	rs6871250	ENSG00000231752.4	EMBP1	-11.76	3.78e-28	1.69e-21	-0.67	-0.48	P wave duration;	chr5:45801662	chr1:121519112~121571892:+
THCA	trans	rs9876781	1	rs2242150	ENSG00000225528.1	RP3-370M22.8	11.75	3.87e-28	1.72e-21	0.57	0.48	Longevity;	chr3:48464565	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	11.75	3.89e-28	1.73e-21	0.66	0.48	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	11.75	3.92e-28	1.75e-21	0.62	0.48	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
THCA	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	11.75	3.93e-28	1.75e-21	0.66	0.48	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
THCA	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-11.74	4.21e-28	1.88e-21	-0.62	-0.48	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
THCA	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-11.74	4.22e-28	1.88e-21	-0.61	-0.48	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
THCA	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	11.74	4.29e-28	1.91e-21	0.66	0.48	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	11.74	4.29e-28	1.91e-21	0.66	0.48	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000242970.2	AC068522.4	11.74	4.35e-28	1.93e-21	0.63	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:58588420~58588764:-
THCA	trans	rs9876781	1	rs6810060	ENSG00000225528.1	RP3-370M22.8	-11.74	4.45e-28	1.98e-21	-0.57	-0.48	Longevity;	chr3:48393284	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs6770470	ENSG00000225528.1	RP3-370M22.8	-11.74	4.45e-28	1.98e-21	-0.57	-0.48	Longevity;	chr3:48393659	chr22:39960397~39964683:+
THCA	trans	rs4276421	0.593	rs7719703	ENSG00000231752.4	EMBP1	-11.74	4.5e-28	2e-21	-0.67	-0.48	P wave duration;	chr5:45781860	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs9896243	ENSG00000204650.12	CRHR1-IT1	11.73	4.62e-28	2.06e-21	0.55	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45620328~45648216:+
THCA	trans	rs9611519	1	rs3818003	ENSG00000268568.1	AC007228.9	-11.73	4.75e-28	2.11e-21	-0.55	-0.48	Neuroticism;	chr22:41213686	chr19:56672574~56673901:-
THCA	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	11.73	4.78e-28	2.12e-21	0.65	0.48	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	11.73	4.78e-28	2.12e-21	0.65	0.48	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	11.73	4.78e-28	2.12e-21	0.65	0.48	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	11.73	4.78e-28	2.12e-21	0.65	0.48	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	11.73	4.78e-28	2.12e-21	0.65	0.48	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
THCA	trans	rs9876781	0.56	rs4558783	ENSG00000235912.1	RP1-159A19.3	11.73	4.8e-28	2.13e-21	0.6	0.48	Longevity;	chr3:48365972	chr1:27649419~27649610:+
THCA	trans	rs12709013	0.636	rs9937713	ENSG00000233719.3	GOT2P3	11.73	4.88e-28	2.17e-21	0.62	0.48	Blood metabolite ratios;	chr16:58771921	chr12:9641802~9643007:+
THCA	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	11.73	4.91e-28	2.18e-21	0.7	0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
THCA	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	11.72	5.03e-28	2.23e-21	0.65	0.48	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
THCA	trans	rs9876781	1	rs7653691	ENSG00000225528.1	RP3-370M22.8	11.72	5.07e-28	2.25e-21	0.56	0.48	Longevity;	chr3:48378199	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs6442117	ENSG00000225528.1	RP3-370M22.8	11.72	5.07e-28	2.25e-21	0.56	0.48	Longevity;	chr3:48378407	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs725309	ENSG00000225528.1	RP3-370M22.8	11.72	5.19e-28	2.3e-21	0.56	0.48	Longevity;	chr3:48377218	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	11.72	5.2e-28	2.3e-21	0.65	0.48	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	11.72	5.2e-28	2.3e-21	0.65	0.48	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.571	rs62371974	ENSG00000231752.4	EMBP1	11.72	5.46e-28	2.42e-21	0.68	0.48	P wave duration;	chr5:45910184	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs6451820	ENSG00000231752.4	EMBP1	-11.71	5.94e-28	2.63e-21	-0.67	-0.48	P wave duration;	chr5:45775207	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.55	rs16902186	ENSG00000231752.4	EMBP1	11.71	6e-28	2.65e-21	0.72	0.48	P wave duration;	chr5:45611886	chr1:121519112~121571892:+
THCA	trans	rs9876781	0.967	rs2885509	ENSG00000225528.1	RP3-370M22.8	11.7	6.07e-28	2.69e-21	0.56	0.48	Longevity;	chr3:48376729	chr22:39960397~39964683:+
THCA	trans	rs12709013	0.636	rs1646268	ENSG00000233719.3	GOT2P3	11.7	6.15e-28	2.72e-21	0.62	0.48	Blood metabolite ratios;	chr16:58743292	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1646272	ENSG00000233719.3	GOT2P3	11.7	6.16e-28	2.72e-21	0.62	0.47	Blood metabolite ratios;	chr16:58746508	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.66	rs1657163	ENSG00000233719.3	GOT2P3	11.7	6.16e-28	2.72e-21	0.62	0.47	Blood metabolite ratios;	chr16:58746688	chr12:9641802~9643007:+
THCA	trans	rs4276421	0.593	rs2337954	ENSG00000231752.4	EMBP1	11.7	6.16e-28	2.72e-21	0.67	0.47	P wave duration;	chr5:45651767	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs13178796	ENSG00000231752.4	EMBP1	11.7	6.16e-28	2.72e-21	0.67	0.47	P wave duration;	chr5:45684414	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.509	rs10041094	ENSG00000231752.4	EMBP1	11.7	6.18e-28	2.73e-21	0.68	0.47	P wave duration;	chr5:45996800	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	11.7	6.19e-28	2.73e-21	0.65	0.47	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.593	rs72750046	ENSG00000231752.4	EMBP1	11.7	6.23e-28	2.75e-21	0.67	0.47	P wave duration;	chr5:45930775	chr1:121519112~121571892:+
THCA	trans	rs9876781	1	rs2885510	ENSG00000225528.1	RP3-370M22.8	11.7	6.29e-28	2.78e-21	0.56	0.47	Longevity;	chr3:48376736	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	11.7	6.42e-28	2.84e-21	0.65	0.47	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	11.7	6.42e-28	2.84e-21	0.65	0.47	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	11.7	6.42e-28	2.84e-21	0.65	0.47	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-11.7	6.55e-28	2.89e-21	-0.65	-0.47	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	11.69	6.79e-28	3e-21	0.65	0.47	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
THCA	trans	rs3740713	1	rs73440637	ENSG00000235847.2	LDHAP7	11.69	6.9e-28	3.04e-21	0.91	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr2:84777259~84778223:-
THCA	trans	rs4276421	0.593	rs10462095	ENSG00000231752.4	EMBP1	-11.68	7.22e-28	3.18e-21	-0.67	-0.47	P wave duration;	chr5:45797500	chr1:121519112~121571892:+
THCA	trans	rs9876781	1	rs898225	ENSG00000225528.1	RP3-370M22.8	11.68	7.48e-28	3.29e-21	0.57	0.47	Longevity;	chr3:48371689	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	11.68	7.5e-28	3.3e-21	0.65	0.47	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
THCA	trans	rs8010715	0.816	rs6573573	ENSG00000238000.1	RP11-274E7.2	11.68	7.52e-28	3.3e-21	0.5	0.47	IgG glycosylation;	chr14:24130048	chr5:98213402~98214121:+
THCA	trans	rs4276421	0.593	rs4551074	ENSG00000231752.4	EMBP1	-11.68	7.52e-28	3.31e-21	-0.67	-0.47	P wave duration;	chr5:45792651	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs4866978	ENSG00000231752.4	EMBP1	-11.68	7.75e-28	3.41e-21	-0.66	-0.47	P wave duration;	chr5:45800636	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	11.67	8e-28	3.52e-21	0.65	0.47	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.593	rs9687374	ENSG00000231752.4	EMBP1	-11.67	8.1e-28	3.56e-21	-0.67	-0.47	P wave duration;	chr5:45796838	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	11.67	8.15e-28	3.58e-21	0.65	0.47	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.53	rs16902217	ENSG00000231752.4	EMBP1	11.67	8.48e-28	3.72e-21	0.67	0.47	P wave duration;	chr5:45719223	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs7706676	ENSG00000231752.4	EMBP1	-11.67	8.53e-28	3.74e-21	-0.67	-0.47	P wave duration;	chr5:45784368	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.571	rs12109155	ENSG00000231752.4	EMBP1	11.66	9.44e-28	4.13e-21	0.67	0.47	P wave duration;	chr5:45727897	chr1:121519112~121571892:+
THCA	trans	rs77688320	0.5	rs7603584	ENSG00000235105.1	RP11-329A14.1	11.65	9.51e-28	4.17e-21	0.51	0.47	Breast cancer;	chr2:201440422	chr1:48435967~48437223:+
THCA	trans	rs9876781	1	rs6442123	ENSG00000225528.1	RP3-370M22.8	-11.64	1.05e-27	4.58e-21	-0.57	-0.47	Longevity;	chr3:48458887	chr22:39960397~39964683:+
THCA	trans	rs4276421	0.593	rs28473745	ENSG00000231752.4	EMBP1	11.64	1.05e-27	4.6e-21	0.67	0.47	P wave duration;	chr5:45740468	chr1:121519112~121571892:+
THCA	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-11.64	1.05e-27	4.6e-21	-0.62	-0.47	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000242970.2	AC068522.4	11.64	1.06e-27	4.63e-21	0.62	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:58588420~58588764:-
THCA	trans	rs4276421	0.615	rs60927048	ENSG00000231752.4	EMBP1	11.64	1.08e-27	4.73e-21	0.66	0.47	P wave duration;	chr5:45854618	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs6872194	ENSG00000231752.4	EMBP1	-11.64	1.09e-27	4.77e-21	-0.66	-0.47	P wave duration;	chr5:45792959	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.636	rs72792430	ENSG00000233719.3	GOT2P3	-11.64	1.1e-27	4.82e-21	-0.62	-0.47	Blood metabolite ratios;	chr16:58746990	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1657161	ENSG00000233719.3	GOT2P3	11.64	1.11e-27	4.84e-21	0.62	0.47	Blood metabolite ratios;	chr16:58743234	chr12:9641802~9643007:+
THCA	trans	rs877636	0.702	rs773109	ENSG00000212994.5	RPS26P6	11.63	1.14e-27	4.97e-21	0.62	0.47	Cognitive function;	chr12:55980911	chr8:100895771~100896118:+
THCA	trans	rs4276421	0.593	rs13359915	ENSG00000231752.4	EMBP1	-11.63	1.15e-27	5.04e-21	-0.66	-0.47	P wave duration;	chr5:45769816	chr1:121519112~121571892:+
THCA	trans	rs77688320	0.517	rs10931949	ENSG00000235105.1	RP11-329A14.1	11.62	1.26e-27	5.5e-21	0.51	0.47	Breast cancer;	chr2:201459730	chr1:48435967~48437223:+
THCA	trans	rs4276421	0.571	rs4560554	ENSG00000231752.4	EMBP1	11.62	1.29e-27	5.62e-21	0.66	0.47	P wave duration;	chr5:45867574	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs4132311	ENSG00000231752.4	EMBP1	11.62	1.29e-27	5.62e-21	0.66	0.47	P wave duration;	chr5:45867992	chr1:121519112~121571892:+
THCA	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	11.62	1.29e-27	5.64e-21	0.7	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
THCA	trans	rs12709013	0.636	rs4538000	ENSG00000233719.3	GOT2P3	11.61	1.41e-27	6.14e-21	0.62	0.47	Blood metabolite ratios;	chr16:58744506	chr12:9641802~9643007:+
THCA	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	11.61	1.42e-27	6.16e-21	0.62	0.47	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
THCA	trans	rs9876781	1	rs9817615	ENSG00000225528.1	RP3-370M22.8	-11.61	1.42e-27	6.18e-21	-0.56	-0.47	Longevity;	chr3:48429347	chr22:39960397~39964683:+
THCA	trans	rs4276421	0.593	rs10062641	ENSG00000231752.4	EMBP1	11.61	1.44e-27	6.27e-21	0.67	0.47	P wave duration;	chr5:45930240	chr1:121519112~121571892:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000212829.8	RPS26P3	11.61	1.48e-27	6.45e-21	0.59	0.47	Cognitive function;	chr12:56076841	chr9:9090898~9091245:+
THCA	trans	rs12709013	0.636	rs10852565	ENSG00000233719.3	GOT2P3	11.6	1.53e-27	6.65e-21	0.61	0.47	Blood metabolite ratios;	chr16:58771277	chr12:9641802~9643007:+
THCA	trans	rs916888	0.697	rs199516	ENSG00000204650.12	CRHR1-IT1	-11.6	1.62e-27	7.03e-21	-0.53	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45620328~45648216:+
THCA	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	11.59	1.66e-27	7.2e-21	0.63	0.47	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
THCA	trans	rs959695	1	rs959695	ENSG00000260318.1	COX6CP1	11.59	1.68e-27	7.28e-21	0.64	0.47	Hippocampal atrophy;	chr8:99822954	chr16:11903923~11904137:-
THCA	trans	rs9876781	1	rs6794875	ENSG00000225528.1	RP3-370M22.8	-11.59	1.68e-27	7.3e-21	-0.57	-0.47	Longevity;	chr3:48414217	chr22:39960397~39964683:+
THCA	trans	rs7312770	0.612	rs773114	ENSG00000242970.2	AC068522.4	11.59	1.75e-27	7.58e-21	0.62	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:58588420~58588764:-
THCA	trans	rs3740713	0.925	rs55727925	ENSG00000235847.2	LDHAP7	11.59	1.75e-27	7.59e-21	0.88	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr2:84777259~84778223:-
THCA	trans	rs916888	0.738	rs199515	ENSG00000204650.12	CRHR1-IT1	-11.59	1.76e-27	7.61e-21	-0.53	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45620328~45648216:+
THCA	trans	rs9876781	1	rs725310	ENSG00000225528.1	RP3-370M22.8	11.59	1.77e-27	7.69e-21	0.56	0.47	Longevity;	chr3:48377081	chr22:39960397~39964683:+
THCA	trans	rs4276421	0.571	rs6894273	ENSG00000231752.4	EMBP1	11.58	1.91e-27	8.27e-21	0.67	0.47	P wave duration;	chr5:45701407	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs4866973	ENSG00000231752.4	EMBP1	-11.57	1.99e-27	8.61e-21	-0.65	-0.47	P wave duration;	chr5:45816584	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs6886950	ENSG00000231752.4	EMBP1	11.57	1.99e-27	8.62e-21	0.66	0.47	P wave duration;	chr5:45742867	chr1:121519112~121571892:+
THCA	trans	rs877636	1	rs2292239	ENSG00000234513.1	AC073072.7	11.57	2.04e-27	8.83e-21	0.6	0.47	Cognitive function;	chr12:56088396	chr7:22773646~22773993:-
THCA	trans	rs4276421	0.593	rs10056041	ENSG00000231752.4	EMBP1	-11.57	2.11e-27	9.14e-21	-0.66	-0.47	P wave duration;	chr5:45786075	chr1:121519112~121571892:+
THCA	trans	rs9876781	1	rs9876781	ENSG00000225528.1	RP3-370M22.8	-11.57	2.13e-27	9.19e-21	-0.56	-0.47	Longevity;	chr3:48445934	chr22:39960397~39964683:+
THCA	trans	rs4276421	0.554	rs35304078	ENSG00000231752.4	EMBP1	11.56	2.16e-27	9.31e-21	0.66	0.47	P wave duration;	chr5:45685489	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs10066821	ENSG00000231752.4	EMBP1	11.56	2.23e-27	9.64e-21	0.65	0.47	P wave duration;	chr5:45844236	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.615	rs12108961	ENSG00000231752.4	EMBP1	11.56	2.23e-27	9.64e-21	0.65	0.47	P wave duration;	chr5:45845859	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.54	rs4242125	ENSG00000231752.4	EMBP1	-11.56	2.31e-27	9.95e-21	-0.65	-0.47	P wave duration;	chr5:45820055	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs6898480	ENSG00000231752.4	EMBP1	-11.56	2.31e-27	9.95e-21	-0.65	-0.47	P wave duration;	chr5:45825479	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.636	rs6499976	ENSG00000233719.3	GOT2P3	11.55	2.36e-27	1.02e-20	0.61	0.47	Blood metabolite ratios;	chr16:58770330	chr12:9641802~9643007:+
THCA	trans	rs4276421	0.593	rs16902199	ENSG00000231752.4	EMBP1	11.55	2.43e-27	1.05e-20	0.66	0.47	P wave duration;	chr5:45648655	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs4437383	ENSG00000231752.4	EMBP1	11.55	2.43e-27	1.05e-20	0.66	0.47	P wave duration;	chr5:45679534	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs7718780	ENSG00000231752.4	EMBP1	-11.54	2.59e-27	1.12e-20	-0.65	-0.47	P wave duration;	chr5:45804191	chr1:121519112~121571892:+
THCA	trans	rs10940346	0.506	rs11741135	ENSG00000231752.4	EMBP1	-11.54	2.61e-27	1.13e-20	-0.64	-0.47	Schizophrenia;	chr5:50579604	chr1:121519112~121571892:+
THCA	trans	rs916888	0.821	rs199514	ENSG00000204650.12	CRHR1-IT1	-11.54	2.64e-27	1.14e-20	-0.53	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45620328~45648216:+
THCA	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	11.54	2.67e-27	1.15e-20	0.68	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
THCA	trans	rs9876781	1	rs9812647	ENSG00000225528.1	RP3-370M22.8	11.54	2.67e-27	1.15e-20	0.56	0.47	Longevity;	chr3:48407507	chr22:39960397~39964683:+
THCA	trans	rs12709013	0.636	rs4499224	ENSG00000233719.3	GOT2P3	11.54	2.72e-27	1.17e-20	0.61	0.47	Blood metabolite ratios;	chr16:58770364	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1595180	ENSG00000233719.3	GOT2P3	11.54	2.72e-27	1.17e-20	0.61	0.47	Blood metabolite ratios;	chr16:58770545	chr12:9641802~9643007:+
THCA	trans	rs4276421	0.593	rs10058269	ENSG00000231752.4	EMBP1	11.54	2.72e-27	1.17e-20	0.66	0.47	P wave duration;	chr5:45750039	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.636	rs257628	ENSG00000233719.3	GOT2P3	11.54	2.75e-27	1.18e-20	0.61	0.47	Blood metabolite ratios;	chr16:58758924	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs257627	ENSG00000233719.3	GOT2P3	11.54	2.75e-27	1.18e-20	0.61	0.47	Blood metabolite ratios;	chr16:58758956	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.597	rs1616072	ENSG00000233719.3	GOT2P3	11.54	2.79e-27	1.2e-20	0.61	0.47	Blood metabolite ratios;	chr16:58747194	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs2575374	ENSG00000233719.3	GOT2P3	11.54	2.79e-27	1.2e-20	0.61	0.47	Blood metabolite ratios;	chr16:58747494	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1657164	ENSG00000233719.3	GOT2P3	11.54	2.79e-27	1.2e-20	0.61	0.47	Blood metabolite ratios;	chr16:58747949	chr12:9641802~9643007:+
THCA	trans	rs877636	1	rs4759229	ENSG00000233778.3	RP11-777J24.1	-11.53	2.86e-27	1.23e-20	-0.58	-0.47	Cognitive function;	chr12:56080696	chr8:92144088~92144435:-
THCA	trans	rs9876781	1	rs1459242	ENSG00000225528.1	RP3-370M22.8	11.53	2.87e-27	1.24e-20	0.56	0.47	Longevity;	chr3:48372047	chr22:39960397~39964683:+
THCA	trans	rs877636	0.74	rs705698	ENSG00000234513.1	AC073072.7	11.53	2.9e-27	1.25e-20	0.61	0.47	Cognitive function;	chr12:55990903	chr7:22773646~22773993:-
THCA	trans	rs77688320	0.517	rs7573536	ENSG00000235105.1	RP11-329A14.1	11.53	2.92e-27	1.25e-20	0.5	0.47	Breast cancer;	chr2:201469676	chr1:48435967~48437223:+
THCA	trans	rs4276421	0.53	rs10078485	ENSG00000231752.4	EMBP1	11.53	2.94e-27	1.26e-20	0.66	0.47	P wave duration;	chr5:45879307	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.571	rs62371969	ENSG00000231752.4	EMBP1	11.53	2.94e-27	1.26e-20	0.66	0.47	P wave duration;	chr5:45904700	chr1:121519112~121571892:+
THCA	trans	rs959695	0.864	rs7844422	ENSG00000260318.1	COX6CP1	11.53	2.97e-27	1.27e-20	0.63	0.47	Hippocampal atrophy;	chr8:99837782	chr16:11903923~11904137:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	11.53	2.97e-27	1.28e-20	0.61	0.47	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
THCA	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	11.53	2.97e-27	1.28e-20	0.61	0.47	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
THCA	trans	rs4276421	0.593	rs6873359	ENSG00000231752.4	EMBP1	11.53	2.97e-27	1.28e-20	0.66	0.47	P wave duration;	chr5:45694473	chr1:121519112~121571892:+
THCA	trans	rs13190036	0.901	rs28684504	ENSG00000226986.4	RP11-543B16.2	11.53	3.03e-27	1.3e-20	0.67	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr1:211207239~211207897:+
THCA	trans	rs2657294	0.796	rs6480770	ENSG00000172974.11	AC007318.5	11.53	3.04e-27	1.31e-20	0.58	0.47	Pneumonia;	chr10:75098799	chr2:65205108~65205988:+
THCA	trans	rs13190036	0.901	rs6898107	ENSG00000226986.4	RP11-543B16.2	11.52	3.1e-27	1.33e-20	0.64	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr1:211207239~211207897:+
THCA	trans	rs4276421	0.593	rs10074312	ENSG00000231752.4	EMBP1	11.52	3.11e-27	1.33e-20	0.66	0.47	P wave duration;	chr5:45671565	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	11.52	3.21e-27	1.37e-20	0.64	0.47	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
THCA	trans	rs916888	0.779	rs199528	ENSG00000280022.1	RP11-707O23.1	-11.52	3.22e-27	1.38e-20	-0.59	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45592621~45593369:+
THCA	trans	rs916888	0.821	rs199525	ENSG00000280022.1	RP11-707O23.1	-11.52	3.22e-27	1.38e-20	-0.59	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45592621~45593369:+
THCA	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	11.52	3.31e-27	1.42e-20	0.64	0.47	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
THCA	trans	rs77688320	0.535	rs10460403	ENSG00000235105.1	RP11-329A14.1	11.52	3.32e-27	1.42e-20	0.5	0.47	Breast cancer;	chr2:201478014	chr1:48435967~48437223:+
THCA	trans	rs959695	1	rs2442756	ENSG00000260318.1	COX6CP1	11.52	3.37e-27	1.44e-20	0.62	0.47	Hippocampal atrophy;	chr8:99816910	chr16:11903923~11904137:-
THCA	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	11.52	3.37e-27	1.44e-20	0.65	0.47	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000212994.5	RPS26P6	11.51	3.38e-27	1.45e-20	0.63	0.47	Cognitive function;	chr12:55976127	chr8:100895771~100896118:+
THCA	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-11.51	3.45e-27	1.47e-20	-0.59	-0.47	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
THCA	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-11.51	3.52e-27	1.5e-20	-0.6	-0.47	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
THCA	trans	rs12709013	0.537	rs1657167	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58748955	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs8054414	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58749772	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.597	rs11076259	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58749860	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1646278	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58750084	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1646280	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58750420	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.597	rs1646286	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58752651	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1624301	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58753491	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1626006	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58753691	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.684	rs1646287	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58753774	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.671	rs1369933	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58753927	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1369934	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58754124	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.613	rs1646288	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58755576	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.561	rs727484	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58756568	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs191783	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58759994	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs257624	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58760994	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.559	rs8060721	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58765581	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs8044542	ENSG00000233719.3	GOT2P3	11.51	3.57e-27	1.52e-20	0.61	0.47	Blood metabolite ratios;	chr16:58765620	chr12:9641802~9643007:+
THCA	trans	rs916888	0.821	rs415430	ENSG00000204650.12	CRHR1-IT1	-11.51	3.58e-27	1.53e-20	-0.53	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45620328~45648216:+
THCA	trans	rs916888	0.779	rs430685	ENSG00000204650.12	CRHR1-IT1	-11.51	3.58e-27	1.53e-20	-0.53	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45620328~45648216:+
THCA	trans	rs77688320	0.517	rs6717641	ENSG00000235105.1	RP11-329A14.1	11.51	3.62e-27	1.54e-20	0.51	0.47	Breast cancer;	chr2:201450484	chr1:48435967~48437223:+
THCA	trans	rs4276421	0.571	rs4431353	ENSG00000231752.4	EMBP1	11.51	3.65e-27	1.55e-20	0.66	0.47	P wave duration;	chr5:45926171	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.571	rs7712920	ENSG00000231752.4	EMBP1	11.51	3.69e-27	1.56e-20	0.67	0.47	P wave duration;	chr5:45589104	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.636	rs1646279	ENSG00000233719.3	GOT2P3	11.5	3.81e-27	1.61e-20	0.61	0.47	Blood metabolite ratios;	chr16:58750235	chr12:9641802~9643007:+
THCA	trans	rs9876781	1	rs4858817	ENSG00000225528.1	RP3-370M22.8	11.5	3.82e-27	1.61e-20	0.56	0.47	Longevity;	chr3:48375266	chr22:39960397~39964683:+
THCA	trans	rs916888	0.821	rs199512	ENSG00000204650.12	CRHR1-IT1	-11.5	3.88e-27	1.63e-20	-0.53	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45620328~45648216:+
THCA	trans	rs916888	0.821	rs199509	ENSG00000204650.12	CRHR1-IT1	-11.5	3.88e-27	1.63e-20	-0.53	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45620328~45648216:+
THCA	trans	rs916888	0.821	rs199507	ENSG00000204650.12	CRHR1-IT1	-11.5	3.88e-27	1.63e-20	-0.53	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45620328~45648216:+
THCA	trans	rs4276421	0.593	rs6451822	ENSG00000231752.4	EMBP1	-11.5	3.97e-27	1.67e-20	-0.65	-0.47	P wave duration;	chr5:45804888	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs6894784	ENSG00000231752.4	EMBP1	11.49	4.05e-27	1.71e-20	0.66	0.47	P wave duration;	chr5:45710935	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.571	rs28405556	ENSG00000231752.4	EMBP1	11.49	4.05e-27	1.71e-20	0.66	0.47	P wave duration;	chr5:45636684	chr1:121519112~121571892:+
THCA	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	11.49	4.1e-27	1.73e-20	0.64	0.47	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
THCA	trans	rs4276421	0.533	rs35197327	ENSG00000231752.4	EMBP1	11.49	4.14e-27	1.74e-20	0.67	0.47	P wave duration;	chr5:45616911	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.561	rs1657174	ENSG00000233719.3	GOT2P3	11.49	4.25e-27	1.79e-20	0.61	0.47	Blood metabolite ratios;	chr16:58755139	chr12:9641802~9643007:+
THCA	trans	rs13190036	1	rs7714695	ENSG00000226986.4	RP11-543B16.2	-11.49	4.32e-27	1.82e-20	-0.68	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr1:211207239~211207897:+
THCA	trans	rs13190036	0.901	rs28563911	ENSG00000226986.4	RP11-543B16.2	11.49	4.36e-27	1.83e-20	0.67	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr1:211207239~211207897:+
THCA	trans	rs13190036	1	rs59737888	ENSG00000226986.4	RP11-543B16.2	-11.49	4.4e-27	1.85e-20	-0.68	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-11.48	4.47e-27	1.88e-20	-0.65	-0.47	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.509	rs10062391	ENSG00000231752.4	EMBP1	11.48	4.61e-27	1.93e-20	0.68	0.47	P wave duration;	chr5:45994818	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.593	rs7719500	ENSG00000231752.4	EMBP1	11.48	4.62e-27	1.94e-20	0.66	0.47	P wave duration;	chr5:45577870	chr1:121519112~121571892:+
THCA	trans	rs13190036	1	rs13175695	ENSG00000226986.4	RP11-543B16.2	11.48	4.8e-27	2.01e-20	0.63	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr1:211207239~211207897:+
THCA	trans	rs9876781	1	rs13076076	ENSG00000225528.1	RP3-370M22.8	-11.47	4.9e-27	2.05e-20	-0.56	-0.47	Longevity;	chr3:48437629	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs9849509	ENSG00000225528.1	RP3-370M22.8	-11.47	4.9e-27	2.05e-20	-0.56	-0.47	Longevity;	chr3:48442021	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs60512868	ENSG00000225528.1	RP3-370M22.8	-11.47	4.9e-27	2.05e-20	-0.56	-0.47	Longevity;	chr3:48442035	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs7636044	ENSG00000225528.1	RP3-370M22.8	-11.47	4.9e-27	2.05e-20	-0.56	-0.47	Longevity;	chr3:48443151	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs4490383	ENSG00000225528.1	RP3-370M22.8	-11.47	4.9e-27	2.05e-20	-0.56	-0.47	Longevity;	chr3:48443275	chr22:39960397~39964683:+
THCA	trans	rs2731664	0.792	rs335435	ENSG00000215571.5	GRK6P1	11.47	4.99e-27	2.09e-20	0.62	0.47	Intelligence (multi-trait analysis);	chr5:177440942	chr13:21319156~21320866:+
THCA	trans	rs4276421	0.593	rs13361609	ENSG00000231752.4	EMBP1	11.47	5.13e-27	2.15e-20	0.66	0.47	P wave duration;	chr5:45697360	chr1:121519112~121571892:+
THCA	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	11.47	5.24e-27	2.19e-20	0.61	0.47	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
THCA	trans	rs4276421	0.55	rs1534392	ENSG00000231752.4	EMBP1	11.47	5.28e-27	2.21e-20	0.66	0.47	P wave duration;	chr5:45633255	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	11.46	5.31e-27	2.22e-20	0.63	0.47	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
THCA	trans	rs9876781	1	rs2290822	ENSG00000225528.1	RP3-370M22.8	-11.46	5.36e-27	2.24e-20	-0.56	-0.47	Longevity;	chr3:48431794	chr22:39960397~39964683:+
THCA	trans	rs12709013	0.636	rs8060717	ENSG00000233719.3	GOT2P3	11.46	5.56e-27	2.32e-20	0.6	0.47	Blood metabolite ratios;	chr16:58765574	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.621	rs6499974	ENSG00000233719.3	GOT2P3	11.46	5.56e-27	2.32e-20	0.6	0.47	Blood metabolite ratios;	chr16:58769642	chr12:9641802~9643007:+
THCA	trans	rs9876781	1	rs11130171	ENSG00000225528.1	RP3-370M22.8	-11.45	5.83e-27	2.43e-20	-0.56	-0.47	Longevity;	chr3:48421052	chr22:39960397~39964683:+
THCA	trans	rs9876781	1	rs9883927	ENSG00000225528.1	RP3-370M22.8	-11.45	5.83e-27	2.43e-20	-0.56	-0.47	Longevity;	chr3:48422302	chr22:39960397~39964683:+
THCA	trans	rs13253073	0.556	rs13279371	ENSG00000260318.1	COX6CP1	11.45	6.15e-27	2.56e-20	1.15	0.47	Glucose homeostasis traits;	chr8:99407006	chr16:11903923~11904137:-
THCA	trans	rs4276421	0.593	rs16902221	ENSG00000231752.4	EMBP1	11.45	6.19e-27	2.58e-20	0.66	0.47	P wave duration;	chr5:45739938	chr1:121519112~121571892:+
THCA	trans	rs13190036	0.901	rs28715668	ENSG00000226986.4	RP11-543B16.2	11.45	6.35e-27	2.64e-20	0.67	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr1:211207239~211207897:+
THCA	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	11.44	6.38e-27	2.66e-20	0.61	0.47	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
THCA	trans	rs4276421	0.593	rs13176359	ENSG00000231752.4	EMBP1	-11.44	6.44e-27	2.68e-20	-0.65	-0.47	P wave duration;	chr5:45814173	chr1:121519112~121571892:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000233778.3	RP11-777J24.1	-11.44	6.47e-27	2.7e-20	-0.58	-0.47	Cognitive function;	chr12:56080595	chr8:92144088~92144435:-
THCA	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	11.44	6.52e-27	2.71e-20	0.62	0.47	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
THCA	trans	rs616147	0.671	rs674192	ENSG00000214263.2	RPSAP53	-11.44	6.57e-27	2.73e-20	-0.6	-0.47	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr13:67266845~67267706:-
THCA	trans	rs12709013	0.636	rs11076260	ENSG00000233719.3	GOT2P3	11.44	6.79e-27	2.82e-20	0.61	0.47	Blood metabolite ratios;	chr16:58749942	chr12:9641802~9643007:+
THCA	trans	rs4276421	0.55	rs10214369	ENSG00000231752.4	EMBP1	-11.43	6.98e-27	2.9e-20	-0.66	-0.47	P wave duration;	chr5:45638409	chr1:121519112~121571892:+
THCA	trans	rs2645424	0.671	rs2294138	ENSG00000256560.1	LINC01486	11.43	7.15e-27	2.97e-20	0.59	0.47	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847630	chr12:109354083~109359488:-
THCA	trans	rs77688320	0.5	rs4129010	ENSG00000235105.1	RP11-329A14.1	11.43	7.26e-27	3.02e-20	0.51	0.47	Breast cancer;	chr2:201443602	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.5	rs4129011	ENSG00000235105.1	RP11-329A14.1	11.43	7.26e-27	3.02e-20	0.51	0.47	Breast cancer;	chr2:201443863	chr1:48435967~48437223:+
THCA	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	11.43	7.29e-27	3.03e-20	0.61	0.47	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
THCA	trans	rs12200782	0.53	rs9379892	ENSG00000242375.1	RP11-498P14.3	11.43	7.3e-27	3.03e-20	0.84	0.47	Small cell lung carcinoma;	chr6:26582186	chr9:97195351~97197687:-
THCA	trans	rs4276421	0.554	rs7724971	ENSG00000231752.4	EMBP1	-11.43	7.38e-27	3.06e-20	-0.65	-0.47	P wave duration;	chr5:45814638	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	11.43	7.6e-27	3.15e-20	0.65	0.47	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	11.43	7.6e-27	3.15e-20	0.65	0.47	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.615	rs6877477	ENSG00000231752.4	EMBP1	11.42	7.65e-27	3.17e-20	0.65	0.47	P wave duration;	chr5:45825707	chr1:121519112~121571892:+
THCA	trans	rs1816752	0.716	rs9553289	ENSG00000224976.2	PARP4P2	11.42	7.9e-27	3.27e-20	0.55	0.47	Obesity-related traits;	chr13:24400640	chr13:19349137~19407962:+
THCA	trans	rs12709013	0.636	rs12325516	ENSG00000233719.3	GOT2P3	11.42	7.95e-27	3.29e-20	0.61	0.47	Blood metabolite ratios;	chr16:58749899	chr12:9641802~9643007:+
THCA	trans	rs9876781	0.933	rs6442124	ENSG00000225528.1	RP3-370M22.8	-11.41	8.38e-27	3.47e-20	-0.56	-0.47	Longevity;	chr3:48463903	chr22:39960397~39964683:+
THCA	trans	rs4276421	0.511	rs62371976	ENSG00000231752.4	EMBP1	11.41	8.64e-27	3.58e-20	0.65	0.47	P wave duration;	chr5:45914178	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	11.41	9.03e-27	3.74e-20	0.64	0.47	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000212994.5	RPS26P6	11.4	9.43e-27	3.9e-20	0.61	0.47	Cognitive function;	chr12:55990903	chr8:100895771~100896118:+
THCA	trans	rs12200782	0.505	rs1535275	ENSG00000242375.1	RP11-498P14.3	11.4	9.63e-27	3.98e-20	0.82	0.47	Small cell lung carcinoma;	chr6:26520539	chr9:97195351~97197687:-
THCA	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-11.4	9.64e-27	3.98e-20	-0.62	-0.47	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
THCA	trans	rs1816752	0.905	rs3818938	ENSG00000224976.2	PARP4P2	-11.4	9.68e-27	4e-20	-0.55	-0.47	Obesity-related traits;	chr13:24454945	chr13:19349137~19407962:+
THCA	trans	rs4276421	0.593	rs4380674	ENSG00000231752.4	EMBP1	11.4	9.75e-27	4.03e-20	0.65	0.47	P wave duration;	chr5:45769295	chr1:121519112~121571892:+
THCA	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-11.39	1.07e-26	4.41e-20	-0.6	-0.47	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
THCA	trans	rs9611519	0.828	rs28814423	ENSG00000268568.1	AC007228.9	-11.38	1.1e-26	4.55e-20	-0.57	-0.46	Neuroticism;	chr22:41056297	chr19:56672574~56673901:-
THCA	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	11.38	1.1e-26	4.55e-20	0.68	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000212829.8	RPS26P3	-11.37	1.21e-26	4.99e-20	-0.59	-0.46	Cognitive function;	chr12:56084218	chr9:9090898~9091245:+
THCA	trans	rs877636	0.692	rs7971751	ENSG00000212829.8	RPS26P3	-11.37	1.21e-26	4.99e-20	-0.59	-0.46	Cognitive function;	chr12:56084874	chr9:9090898~9091245:+
THCA	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	11.37	1.23e-26	5.08e-20	0.62	0.46	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
THCA	trans	rs13253073	0.556	rs35194538	ENSG00000260318.1	COX6CP1	11.37	1.24e-26	5.12e-20	1.15	0.46	Glucose homeostasis traits;	chr8:99397627	chr16:11903923~11904137:-
THCA	trans	rs13190036	1	rs6889220	ENSG00000226986.4	RP11-543B16.2	11.37	1.25e-26	5.16e-20	0.66	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr1:211207239~211207897:+
THCA	trans	rs5022636	0.525	rs7539584	ENSG00000180764.13	PIPSL	11.37	1.29e-26	5.29e-20	0.54	0.46	Gut microbiota (functional units);	chr1:151210477	chr10:93958191~93961540:-
THCA	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	11.36	1.32e-26	5.45e-20	0.63	0.46	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.593	rs7706959	ENSG00000231752.4	EMBP1	-11.36	1.35e-26	5.53e-20	-0.66	-0.46	P wave duration;	chr5:45793689	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-11.36	1.39e-26	5.7e-20	-0.64	-0.46	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-11.36	1.39e-26	5.7e-20	-0.64	-0.46	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	11.36	1.39e-26	5.7e-20	0.64	0.46	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
THCA	trans	rs13190036	0.792	rs6874206	ENSG00000226986.4	RP11-543B16.2	-11.35	1.48e-26	6.09e-20	-0.63	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr1:211207239~211207897:+
THCA	trans	rs13190036	0.901	rs10072499	ENSG00000226986.4	RP11-543B16.2	-11.35	1.48e-26	6.09e-20	-0.63	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	11.35	1.56e-26	6.38e-20	0.64	0.46	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
THCA	trans	rs7554547	0.714	rs926269	ENSG00000261819.1	RP11-680G24.4	11.34	1.63e-26	6.68e-20	0.63	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11909691	chr16:14988259~14990160:-
THCA	trans	rs7554547	0.714	rs2878679	ENSG00000261819.1	RP11-680G24.4	11.34	1.63e-26	6.68e-20	0.63	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11915586	chr16:14988259~14990160:-
THCA	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	11.34	1.65e-26	6.75e-20	0.64	0.46	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
THCA	trans	rs7554547	0.714	rs4845890	ENSG00000261819.1	RP11-680G24.4	11.34	1.65e-26	6.76e-20	0.62	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11912612	chr16:14988259~14990160:-
THCA	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	11.34	1.69e-26	6.89e-20	0.62	0.46	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
THCA	trans	rs9611519	0.894	rs4821990	ENSG00000268568.1	AC007228.9	-11.33	1.72e-26	7.03e-20	-0.57	-0.46	Neuroticism;	chr22:41042706	chr19:56672574~56673901:-
THCA	trans	rs13190036	1	rs17078781	ENSG00000226986.4	RP11-543B16.2	-11.33	1.77e-26	7.22e-20	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	11.33	1.78e-26	7.24e-20	0.63	0.46	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	11.33	1.78e-26	7.24e-20	0.63	0.46	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	11.33	1.78e-26	7.24e-20	0.63	0.46	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	11.33	1.78e-26	7.24e-20	0.63	0.46	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
THCA	trans	rs13190036	0.892	rs71601339	ENSG00000226986.4	RP11-543B16.2	-11.32	1.89e-26	7.67e-20	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr1:211207239~211207897:+
THCA	trans	rs12709013	0.636	rs1865836	ENSG00000233719.3	GOT2P3	11.32	1.91e-26	7.77e-20	0.6	0.46	Blood metabolite ratios;	chr16:58768143	chr12:9641802~9643007:+
THCA	trans	rs77688320	0.5	rs6755428	ENSG00000235105.1	RP11-329A14.1	11.32	1.95e-26	7.94e-20	0.5	0.46	Breast cancer;	chr2:201431043	chr1:48435967~48437223:+
THCA	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	11.32	1.97e-26	7.99e-20	0.63	0.46	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
THCA	trans	rs9611519	0.929	rs9611469	ENSG00000268568.1	AC007228.9	-11.32	1.99e-26	8.07e-20	-0.57	-0.46	Neuroticism;	chr22:41037315	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.929	rs73174657	ENSG00000268568.1	AC007228.9	-11.32	1.99e-26	8.07e-20	-0.57	-0.46	Neuroticism;	chr22:41038154	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.929	rs9611474	ENSG00000268568.1	AC007228.9	-11.32	1.99e-26	8.07e-20	-0.57	-0.46	Neuroticism;	chr22:41038854	chr19:56672574~56673901:-
THCA	trans	rs13190036	0.901	rs6556309	ENSG00000226986.4	RP11-543B16.2	11.32	2.04e-26	8.3e-20	0.62	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr1:211207239~211207897:+
THCA	trans	rs616147	1	rs1768208	ENSG00000183298.5	RP11-556K13.1	-11.31	2.09e-26	8.47e-20	-0.67	-0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr1:101786340~101787219:-
THCA	trans	rs916888	0.821	rs199505	ENSG00000204650.12	CRHR1-IT1	-11.31	2.1e-26	8.5e-20	-0.52	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45620328~45648216:+
THCA	trans	rs916888	0.821	rs70602	ENSG00000204650.12	CRHR1-IT1	-11.31	2.1e-26	8.5e-20	-0.52	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45620328~45648216:+
THCA	trans	rs2645424	0.762	rs2294139	ENSG00000256560.1	LINC01486	11.31	2.17e-26	8.79e-20	0.59	0.46	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847933	chr12:109354083~109359488:-
THCA	trans	rs9876781	1	rs7636782	ENSG00000225528.1	RP3-370M22.8	-11.31	2.22e-26	8.99e-20	-0.54	-0.46	Longevity;	chr3:48379897	chr22:39960397~39964683:+
THCA	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	11.3	2.26e-26	9.16e-20	0.65	0.46	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	11.3	2.26e-26	9.16e-20	0.65	0.46	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
THCA	trans	rs7554547	0.667	rs12065911	ENSG00000261819.1	RP11-680G24.4	11.3	2.27e-26	9.21e-20	0.63	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11908323	chr16:14988259~14990160:-
THCA	trans	rs12709013	0.601	rs2432621	ENSG00000233719.3	GOT2P3	11.3	2.32e-26	9.39e-20	0.6	0.46	Blood metabolite ratios;	chr16:58749676	chr12:9641802~9643007:+
THCA	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	11.3	2.34e-26	9.49e-20	0.62	0.46	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	11.3	2.34e-26	9.49e-20	0.62	0.46	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	11.3	2.34e-26	9.49e-20	0.62	0.46	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000234354.3	RPS26P47	11.3	2.36e-26	9.55e-20	0.6	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr13:100539901~100540248:-
THCA	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	11.3	2.42e-26	9.79e-20	0.64	0.46	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	11.3	2.42e-26	9.79e-20	0.64	0.46	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	11.3	2.42e-26	9.79e-20	0.64	0.46	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	11.3	2.42e-26	9.79e-20	0.64	0.46	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
THCA	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	11.3	2.43e-26	9.82e-20	0.62	0.46	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
THCA	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	11.29	2.62e-26	1.06e-19	0.64	0.46	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
THCA	trans	rs916888	0.61	rs199529	ENSG00000280022.1	RP11-707O23.1	-11.29	2.63e-26	1.06e-19	-0.55	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45592621~45593369:+
THCA	trans	rs4276421	0.571	rs10473389	ENSG00000231752.4	EMBP1	11.29	2.64e-26	1.07e-19	0.66	0.46	P wave duration;	chr5:45561699	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	11.28	2.68e-26	1.08e-19	0.64	0.46	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	11.28	2.68e-26	1.08e-19	0.64	0.46	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	11.28	2.68e-26	1.08e-19	0.64	0.46	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	11.28	2.68e-26	1.08e-19	0.64	0.46	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	11.28	2.68e-26	1.08e-19	0.64	0.46	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	11.28	2.73e-26	1.1e-19	0.64	0.46	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	11.28	2.73e-26	1.1e-19	0.64	0.46	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	11.28	2.73e-26	1.1e-19	0.64	0.46	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	11.28	2.73e-26	1.1e-19	0.64	0.46	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
THCA	trans	rs877636	1	rs4759229	ENSG00000196656.7	AC004057.1	-11.28	2.74e-26	1.11e-19	-0.59	-0.46	Cognitive function;	chr12:56080696	chr4:113214046~113217170:-
THCA	trans	rs2731664	0.792	rs2630767	ENSG00000215571.5	GRK6P1	11.28	2.77e-26	1.12e-19	0.61	0.46	Intelligence (multi-trait analysis);	chr5:177443699	chr13:21319156~21320866:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000212829.8	RPS26P3	-11.28	2.81e-26	1.13e-19	-0.58	-0.46	Cognitive function;	chr12:56083910	chr9:9090898~9091245:+
THCA	trans	rs77688320	0.517	rs7605375	ENSG00000235105.1	RP11-329A14.1	11.27	3.14e-26	1.26e-19	0.5	0.46	Breast cancer;	chr2:201465907	chr1:48435967~48437223:+
THCA	trans	rs9467773	0.836	rs1624440	ENSG00000242375.1	RP11-498P14.3	-11.27	3.15e-26	1.27e-19	-0.64	-0.46	Intelligence (multi-trait analysis);	chr6:26433101	chr9:97195351~97197687:-
THCA	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	11.27	3.18e-26	1.28e-19	0.64	0.46	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	11.27	3.18e-26	1.28e-19	0.64	0.46	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	11.27	3.18e-26	1.28e-19	0.64	0.46	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
THCA	trans	rs12200782	0.53	rs6929908	ENSG00000242375.1	RP11-498P14.3	11.26	3.25e-26	1.31e-19	0.82	0.46	Small cell lung carcinoma;	chr6:26555061	chr9:97195351~97197687:-
THCA	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	11.26	3.3e-26	1.33e-19	0.63	0.46	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	11.26	3.3e-26	1.33e-19	0.61	0.46	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
THCA	trans	rs9876781	1	rs7635522	ENSG00000225528.1	RP3-370M22.8	-11.26	3.39e-26	1.36e-19	-0.55	-0.46	Longevity;	chr3:48382166	chr22:39960397~39964683:+
THCA	trans	rs616147	1	rs616147	ENSG00000183298.5	RP11-556K13.1	-11.26	3.39e-26	1.36e-19	-0.66	-0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr1:101786340~101787219:-
THCA	trans	rs11098499	0.818	rs55825515	ENSG00000275858.1	RP11-291L22.8	11.26	3.42e-26	1.37e-19	0.64	0.46	Corneal astigmatism;	chr4:119565247	chr10:38450738~38451069:-
THCA	trans	rs13190036	1	rs351862	ENSG00000226986.4	RP11-543B16.2	-11.26	3.44e-26	1.38e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr1:211207239~211207897:+
THCA	trans	rs9467773	0.869	rs742090	ENSG00000242375.1	RP11-498P14.3	-11.25	3.63e-26	1.46e-19	-0.64	-0.46	Intelligence (multi-trait analysis);	chr6:26415409	chr9:97195351~97197687:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000204652.6	RPS26P8	11.23	4.28e-26	1.71e-19	0.59	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:45608571~45608918:+
THCA	trans	rs616147	0.85	rs631312	ENSG00000183298.5	RP11-556K13.1	-11.23	4.47e-26	1.79e-19	-0.66	-0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr1:101786340~101787219:-
THCA	trans	rs9467773	0.869	rs1796520	ENSG00000242375.1	RP11-498P14.3	-11.22	4.58e-26	1.83e-19	-0.64	-0.46	Intelligence (multi-trait analysis);	chr6:26410572	chr9:97195351~97197687:-
THCA	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	11.22	4.89e-26	1.95e-19	0.61	0.46	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-11.21	5.1e-26	2.04e-19	-0.61	-0.46	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
THCA	trans	rs10242455	0.571	rs11734	ENSG00000228834.1	RP11-249L21.4	-11.21	5.2e-26	2.07e-19	-1.19	-0.46	Blood metabolite levels;	chr7:99632145	chr6:108907615~108907873:-
THCA	trans	rs13190036	0.901	rs55741473	ENSG00000226986.4	RP11-543B16.2	-11.21	5.21e-26	2.08e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr1:211207239~211207897:+
THCA	trans	rs7312770	1	rs7312770	ENSG00000234354.3	RPS26P47	-11.2	5.46e-26	2.18e-19	-0.57	-0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr13:100539901~100540248:-
THCA	trans	rs13190036	1	rs34446750	ENSG00000226986.4	RP11-543B16.2	-11.2	5.5e-26	2.19e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	11.2	5.58e-26	2.22e-19	0.63	0.46	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
THCA	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	11.2	5.61e-26	2.23e-19	0.61	0.46	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	11.2	5.61e-26	2.23e-19	0.61	0.46	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
THCA	trans	rs7833986	0.501	rs2953911	ENSG00000244245.1	RP11-120B7.1	11.2	5.67e-26	2.25e-19	0.6	0.46	Height;	chr8:56035450	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2667999	ENSG00000244245.1	RP11-120B7.1	11.2	5.67e-26	2.25e-19	0.6	0.46	Height;	chr8:56037915	chr5:108593609~108593967:+
THCA	trans	rs13190036	1	rs13177748	ENSG00000226986.4	RP11-543B16.2	-11.2	5.85e-26	2.33e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr1:211207239~211207897:+
THCA	trans	rs13190036	1	rs13157667	ENSG00000226986.4	RP11-543B16.2	-11.2	5.91e-26	2.35e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr1:211207239~211207897:+
THCA	trans	rs13190036	1	rs13167431	ENSG00000226986.4	RP11-543B16.2	-11.2	5.91e-26	2.35e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr1:211207239~211207897:+
THCA	trans	rs13190036	1	rs35535623	ENSG00000226986.4	RP11-543B16.2	-11.2	5.91e-26	2.35e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr1:211207239~211207897:+
THCA	trans	rs13190036	1	rs71601343	ENSG00000226986.4	RP11-543B16.2	-11.2	5.91e-26	2.35e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr1:211207239~211207897:+
THCA	trans	rs13190036	1	rs71601344	ENSG00000226986.4	RP11-543B16.2	-11.2	5.91e-26	2.35e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr1:211207239~211207897:+
THCA	trans	rs13190036	1	rs3733875	ENSG00000226986.4	RP11-543B16.2	-11.2	5.91e-26	2.35e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr1:211207239~211207897:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000196656.7	AC004057.1	-11.19	6.06e-26	2.41e-19	-0.59	-0.46	Cognitive function;	chr12:56080595	chr4:113214046~113217170:-
THCA	trans	rs916888	0.821	rs199504	ENSG00000204650.12	CRHR1-IT1	-11.19	6.2e-26	2.46e-19	-0.52	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45620328~45648216:+
THCA	trans	rs2731664	0.792	rs2731662	ENSG00000215571.5	GRK6P1	-11.19	6.22e-26	2.47e-19	-0.6	-0.46	Intelligence (multi-trait analysis);	chr5:177445493	chr13:21319156~21320866:+
THCA	trans	rs959695	1	rs35845479	ENSG00000260318.1	COX6CP1	11.19	6.33e-26	2.51e-19	0.63	0.46	Hippocampal atrophy;	chr8:99834273	chr16:11903923~11904137:-
THCA	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	11.19	6.51e-26	2.59e-19	0.63	0.46	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	11.19	6.51e-26	2.59e-19	0.63	0.46	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
THCA	trans	rs12709013	0.597	rs1657171	ENSG00000233719.3	GOT2P3	11.18	6.55e-26	2.6e-19	0.6	0.46	Blood metabolite ratios;	chr16:58752083	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.636	rs1646285	ENSG00000233719.3	GOT2P3	11.18	6.55e-26	2.6e-19	0.6	0.46	Blood metabolite ratios;	chr16:58752102	chr12:9641802~9643007:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000224553.1	AC008065.1	11.18	6.61e-26	2.62e-19	0.55	0.46	Cognitive function;	chr12:56076841	chr2:171374931~171375278:-
THCA	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	11.18	6.72e-26	2.67e-19	0.63	0.46	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
THCA	trans	rs8067354	0.789	rs1292068	ENSG00000187870.7	RNFT1P3	11.18	6.88e-26	2.73e-19	0.62	0.46	Hemoglobin concentration;	chr17:59851958	chr17:20743333~20754501:-
THCA	trans	rs13190036	0.901	rs10056655	ENSG00000226986.4	RP11-543B16.2	11.18	7.03e-26	2.79e-19	0.62	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr1:211207239~211207897:+
THCA	trans	rs8010715	0.771	rs2277481	ENSG00000238000.1	RP11-274E7.2	11.18	7.09e-26	2.81e-19	0.48	0.46	IgG glycosylation;	chr14:24118336	chr5:98213402~98214121:+
THCA	trans	rs9876781	0.874	rs56298324	ENSG00000225528.1	RP3-370M22.8	11.17	7.18e-26	2.84e-19	0.53	0.46	Longevity;	chr3:48393626	chr22:39960397~39964683:+
THCA	trans	rs877636	1	rs877636	ENSG00000223416.3	RPS26P15	-11.17	7.25e-26	2.87e-19	-0.58	-0.46	Cognitive function;	chr12:56086799	chr1:58056133~58056480:-
THCA	trans	rs13190036	1	rs13185316	ENSG00000226986.4	RP11-543B16.2	-11.17	7.6e-26	3.01e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr1:211207239~211207897:+
THCA	trans	rs9876781	1	rs2362452	ENSG00000225528.1	RP3-370M22.8	11.17	7.66e-26	3.03e-19	0.54	0.46	Longevity;	chr3:48376724	chr22:39960397~39964683:+
THCA	trans	rs7833986	0.501	rs2719257	ENSG00000244245.1	RP11-120B7.1	11.16	7.87e-26	3.11e-19	0.6	0.46	Height;	chr8:56027614	chr5:108593609~108593967:+
THCA	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-11.16	8.04e-26	3.18e-19	-0.64	-0.46	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-11.16	8.26e-26	3.26e-19	-0.63	-0.46	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
THCA	trans	rs2731664	0.819	rs449351	ENSG00000215571.5	GRK6P1	11.16	8.28e-26	3.27e-19	0.62	0.46	Intelligence (multi-trait analysis);	chr5:177445590	chr13:21319156~21320866:+
THCA	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	11.16	8.34e-26	3.29e-19	0.63	0.46	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	11.16	8.44e-26	3.33e-19	0.63	0.46	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
THCA	trans	rs62079673	0.527	rs9788998	ENSG00000265574.1	WDR45BP1	11.15	8.63e-26	3.41e-19	0.54	0.46	Breast cancer;	chr17:82647768	chr17:32111562~32112590:-
THCA	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-11.15	9.06e-26	3.57e-19	-0.63	-0.46	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
THCA	trans	rs2731664	0.756	rs335433	ENSG00000215571.5	GRK6P1	11.15	9.12e-26	3.6e-19	0.62	0.46	Intelligence (multi-trait analysis);	chr5:177440206	chr13:21319156~21320866:+
THCA	trans	rs4276421	0.593	rs12659948	ENSG00000231752.4	EMBP1	-11.15	9.19e-26	3.62e-19	-0.64	-0.46	P wave duration;	chr5:45739534	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	11.14	9.4e-26	3.71e-19	0.63	0.46	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
THCA	trans	rs2731664	0.792	rs2630765	ENSG00000215571.5	GRK6P1	11.14	9.47e-26	3.73e-19	0.6	0.46	Intelligence (multi-trait analysis);	chr5:177449824	chr13:21319156~21320866:+
THCA	trans	rs9611519	1	rs5758268	ENSG00000268568.1	AC007228.9	-11.14	9.69e-26	3.82e-19	-0.54	-0.46	Neuroticism;	chr22:41226415	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.929	rs73174660	ENSG00000268568.1	AC007228.9	-11.14	9.86e-26	3.88e-19	-0.56	-0.46	Neuroticism;	chr22:41041300	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.78	rs2235852	ENSG00000268568.1	AC007228.9	-11.14	1.01e-25	3.99e-19	-0.5	-0.46	Neuroticism;	chr22:41265150	chr19:56672574~56673901:-
THCA	trans	rs2731664	0.792	rs466256	ENSG00000215571.5	GRK6P1	11.13	1.04e-25	4.11e-19	0.6	0.46	Intelligence (multi-trait analysis);	chr5:177448955	chr13:21319156~21320866:+
THCA	trans	rs9467773	0.869	rs1796521	ENSG00000242375.1	RP11-498P14.3	-11.13	1.07e-25	4.22e-19	-0.64	-0.46	Intelligence (multi-trait analysis);	chr6:26421164	chr9:97195351~97197687:-
THCA	trans	rs2731664	0.792	rs335466	ENSG00000215571.5	GRK6P1	11.13	1.08e-25	4.26e-19	0.61	0.46	Intelligence (multi-trait analysis);	chr5:177462529	chr13:21319156~21320866:+
THCA	trans	rs7554547	0.667	rs11121839	ENSG00000261819.1	RP11-680G24.4	11.13	1.11e-25	4.34e-19	0.62	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11908280	chr16:14988259~14990160:-
THCA	trans	rs9611519	0.929	rs12484971	ENSG00000268568.1	AC007228.9	-11.12	1.14e-25	4.48e-19	-0.56	-0.46	Neuroticism;	chr22:41043300	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.929	rs13055800	ENSG00000268568.1	AC007228.9	-11.12	1.14e-25	4.48e-19	-0.56	-0.46	Neuroticism;	chr22:41044420	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.929	rs4821991	ENSG00000268568.1	AC007228.9	-11.12	1.14e-25	4.48e-19	-0.56	-0.46	Neuroticism;	chr22:41044679	chr19:56672574~56673901:-
THCA	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	11.12	1.16e-25	4.55e-19	0.62	0.46	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
THCA	trans	rs2731664	0.792	rs335432	ENSG00000215571.5	GRK6P1	11.12	1.2e-25	4.71e-19	0.62	0.46	Intelligence (multi-trait analysis);	chr5:177439257	chr13:21319156~21320866:+
THCA	trans	rs9611519	0.964	rs2179744	ENSG00000268568.1	AC007228.9	-11.11	1.22e-25	4.77e-19	-0.54	-0.46	Neuroticism;	chr22:41225710	chr19:56672574~56673901:-
THCA	trans	rs13190036	1	rs34832871	ENSG00000226986.4	RP11-543B16.2	-11.11	1.26e-25	4.93e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr1:211207239~211207897:+
THCA	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	11.11	1.28e-25	5.01e-19	0.61	0.46	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	11.11	1.3e-25	5.08e-19	0.61	0.46	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
THCA	trans	rs5022636	0.525	rs6587559	ENSG00000180764.13	PIPSL	11.11	1.3e-25	5.1e-19	0.52	0.46	Gut microbiota (functional units);	chr1:151245262	chr10:93958191~93961540:-
THCA	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	11.11	1.32e-25	5.16e-19	0.62	0.46	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
THCA	trans	rs616147	0.671	rs675595	ENSG00000214263.2	RPSAP53	-11.1	1.38e-25	5.41e-19	-0.59	-0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr13:67266845~67267706:-
THCA	trans	rs9876781	0.539	rs9809695	ENSG00000235912.1	RP1-159A19.3	11.1	1.44e-25	5.66e-19	0.57	0.46	Longevity;	chr3:48364654	chr1:27649419~27649610:+
THCA	trans	rs7833986	0.501	rs2719261	ENSG00000244245.1	RP11-120B7.1	11.09	1.47e-25	5.76e-19	0.58	0.46	Height;	chr8:56029423	chr5:108593609~108593967:+
THCA	trans	rs12200782	0.505	rs7765920	ENSG00000242375.1	RP11-498P14.3	11.09	1.51e-25	5.9e-19	0.8	0.46	Small cell lung carcinoma;	chr6:26514543	chr9:97195351~97197687:-
THCA	trans	rs1816752	0.875	rs59686377	ENSG00000224976.2	PARP4P2	-11.08	1.61e-25	6.29e-19	-0.53	-0.46	Obesity-related traits;	chr13:24475869	chr13:19349137~19407962:+
THCA	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-11.07	1.75e-25	6.83e-19	-0.67	-0.45	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
THCA	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-11.07	1.76e-25	6.89e-19	-0.64	-0.45	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	11.07	1.81e-25	7.08e-19	0.62	0.45	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
THCA	trans	rs7833986	0.501	rs72653941	ENSG00000244245.1	RP11-120B7.1	11.07	1.81e-25	7.08e-19	0.58	0.45	Height;	chr8:56029688	chr5:108593609~108593967:+
THCA	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	11.07	1.86e-25	7.26e-19	0.6	0.45	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
THCA	trans	rs9611519	0.929	rs9611465	ENSG00000268568.1	AC007228.9	-11.06	1.96e-25	7.63e-19	-0.57	-0.45	Neuroticism;	chr22:41030135	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.929	rs9611466	ENSG00000268568.1	AC007228.9	-11.06	1.96e-25	7.63e-19	-0.57	-0.45	Neuroticism;	chr22:41030295	chr19:56672574~56673901:-
THCA	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	11.06	1.99e-25	7.77e-19	0.62	0.45	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	11.06	1.99e-25	7.77e-19	0.62	0.45	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
THCA	trans	rs7833986	0.501	rs2953909	ENSG00000244245.1	RP11-120B7.1	11.06	2e-25	7.8e-19	0.59	0.45	Height;	chr8:56055641	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2953910	ENSG00000244245.1	RP11-120B7.1	11.06	2e-25	7.8e-19	0.59	0.45	Height;	chr8:56056202	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2976012	ENSG00000244245.1	RP11-120B7.1	11.06	2e-25	7.8e-19	0.59	0.45	Height;	chr8:56061784	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2953922	ENSG00000244245.1	RP11-120B7.1	11.06	2e-25	7.8e-19	0.59	0.45	Height;	chr8:56064926	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2953897	ENSG00000244245.1	RP11-120B7.1	11.06	2e-25	7.8e-19	0.59	0.45	Height;	chr8:56068010	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2953898	ENSG00000244245.1	RP11-120B7.1	11.06	2e-25	7.8e-19	0.59	0.45	Height;	chr8:56068244	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2953901	ENSG00000244245.1	RP11-120B7.1	11.06	2e-25	7.8e-19	0.59	0.45	Height;	chr8:56069265	chr5:108593609~108593967:+
THCA	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	11.06	2e-25	7.8e-19	0.59	0.45	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
THCA	trans	rs877636	0.692	rs11171739	ENSG00000244604.1	RP11-713H12.1	11.06	2.01e-25	7.85e-19	0.57	0.45	Cognitive function;	chr12:56076841	chr17:8561230~8561576:+
THCA	trans	rs7833986	0.501	rs2719258	ENSG00000244245.1	RP11-120B7.1	11.06	2.06e-25	8.01e-19	0.58	0.45	Height;	chr8:56028830	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2719259	ENSG00000244245.1	RP11-120B7.1	11.06	2.06e-25	8.01e-19	0.58	0.45	Height;	chr8:56029071	chr5:108593609~108593967:+
THCA	trans	rs9611519	0.929	rs12484477	ENSG00000268568.1	AC007228.9	-11.05	2.07e-25	8.06e-19	-0.57	-0.45	Neuroticism;	chr22:41033080	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.929	rs4820425	ENSG00000268568.1	AC007228.9	-11.05	2.1e-25	8.17e-19	-0.57	-0.45	Neuroticism;	chr22:41035338	chr19:56672574~56673901:-
THCA	trans	rs9876781	1	rs922075	ENSG00000225528.1	RP3-370M22.8	11.05	2.22e-25	8.65e-19	0.53	0.45	Longevity;	chr3:48447994	chr22:39960397~39964683:+
THCA	trans	rs877636	1	rs877636	ENSG00000233778.3	RP11-777J24.1	-11.05	2.24e-25	8.71e-19	-0.56	-0.45	Cognitive function;	chr12:56086799	chr8:92144088~92144435:-
THCA	trans	rs2731664	0.756	rs4976695	ENSG00000215571.5	GRK6P1	11.04	2.29e-25	8.91e-19	0.61	0.45	Intelligence (multi-trait analysis);	chr5:177435962	chr13:21319156~21320866:+
THCA	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	11.04	2.29e-25	8.92e-19	0.63	0.45	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
THCA	trans	rs9611519	0.929	rs4820423	ENSG00000268568.1	AC007228.9	-11.04	2.31e-25	8.97e-19	-0.57	-0.45	Neuroticism;	chr22:41034334	chr19:56672574~56673901:-
THCA	trans	rs7399018	0.739	rs7399073	ENSG00000223825.5	DAZAP2P1	11.04	2.34e-25	9.11e-19	0.6	0.45	Cisplatin-induced ototoxicity;	chr12:51220266	chr2:202201384~202201886:-
THCA	trans	rs12709013	0.66	rs30839	ENSG00000233719.3	GOT2P3	11.04	2.39e-25	9.26e-19	0.59	0.45	Blood metabolite ratios;	chr16:58711437	chr12:9641802~9643007:+
THCA	trans	rs7833986	0.534	rs17813240	ENSG00000244245.1	RP11-120B7.1	11.04	2.44e-25	9.45e-19	0.6	0.45	Height;	chr8:56013232	chr5:108593609~108593967:+
THCA	trans	rs2731664	0.792	rs652242	ENSG00000215571.5	GRK6P1	11.03	2.63e-25	1.02e-18	0.61	0.45	Intelligence (multi-trait analysis);	chr5:177446009	chr13:21319156~21320866:+
THCA	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	11.03	2.68e-25	1.04e-18	0.62	0.45	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
THCA	trans	rs13190036	1	rs351864	ENSG00000226986.4	RP11-543B16.2	-11.02	2.7e-25	1.05e-18	-0.65	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr1:211207239~211207897:+
THCA	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	11.02	2.72e-25	1.06e-18	0.6	0.45	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
THCA	trans	rs2731664	0.765	rs2630766	ENSG00000215571.5	GRK6P1	11.02	2.74e-25	1.06e-18	0.6	0.45	Intelligence (multi-trait analysis);	chr5:177447940	chr13:21319156~21320866:+
THCA	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	11.02	2.74e-25	1.06e-18	0.62	0.45	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
THCA	trans	rs13190036	0.551	rs7710269	ENSG00000226986.4	RP11-543B16.2	-11.02	2.83e-25	1.1e-18	-0.58	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr1:211207239~211207897:+
THCA	trans	rs13190036	0.515	rs2878686	ENSG00000226986.4	RP11-543B16.2	-11.02	2.83e-25	1.1e-18	-0.58	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr1:211207239~211207897:+
THCA	trans	rs13190036	0.551	rs9313751	ENSG00000226986.4	RP11-543B16.2	-11.02	2.92e-25	1.13e-18	-0.59	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	11.01	2.96e-25	1.15e-18	0.62	0.45	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
THCA	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	11.01	2.97e-25	1.15e-18	0.6	0.45	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
THCA	trans	rs13190036	0.551	rs11957608	ENSG00000226986.4	RP11-543B16.2	-11.01	3e-25	1.16e-18	-0.59	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr1:211207239~211207897:+
THCA	trans	rs8067354	0.872	rs2645466	ENSG00000187870.7	RNFT1P3	11.01	3.01e-25	1.17e-18	0.61	0.45	Hemoglobin concentration;	chr17:59775853	chr17:20743333~20754501:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000204652.6	RPS26P8	11.01	3.02e-25	1.17e-18	0.58	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:45608571~45608918:+
THCA	trans	rs2731664	0.756	rs2545796	ENSG00000215571.5	GRK6P1	11.01	3.06e-25	1.18e-18	0.61	0.45	Intelligence (multi-trait analysis);	chr5:177437268	chr13:21319156~21320866:+
THCA	trans	rs1816752	0.875	rs17384871	ENSG00000224976.2	PARP4P2	-11.01	3.12e-25	1.21e-18	-0.53	-0.45	Obesity-related traits;	chr13:24484959	chr13:19349137~19407962:+
THCA	trans	rs7833986	0.501	rs72653948	ENSG00000244245.1	RP11-120B7.1	11	3.29e-25	1.27e-18	0.57	0.45	Height;	chr8:56043130	chr5:108593609~108593967:+
THCA	trans	rs9876781	0.507	rs1824362	ENSG00000235912.1	RP1-159A19.3	11	3.29e-25	1.27e-18	0.56	0.45	Longevity;	chr3:48360459	chr1:27649419~27649610:+
THCA	trans	rs13190036	0.551	rs11955537	ENSG00000226986.4	RP11-543B16.2	-11	3.3e-25	1.28e-18	-0.58	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr1:211207239~211207897:+
THCA	trans	rs10037055	0.636	rs13166688	ENSG00000226986.4	RP11-543B16.2	-11	3.3e-25	1.28e-18	-0.58	-0.45	Migraine without aura;	chr5:177156965	chr1:211207239~211207897:+
THCA	trans	rs9876781	1	rs13069724	ENSG00000225528.1	RP3-370M22.8	-11	3.34e-25	1.29e-18	-0.54	-0.45	Longevity;	chr3:48436629	chr22:39960397~39964683:+
THCA	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	11	3.36e-25	1.3e-18	0.58	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
THCA	trans	rs7833986	0.501	rs72653953	ENSG00000244245.1	RP11-120B7.1	11	3.36e-25	1.3e-18	0.59	0.45	Height;	chr8:56058236	chr5:108593609~108593967:+
THCA	trans	rs1355223	0.506	rs11032898	ENSG00000225531.1	RP11-196I18.3	10.99	3.66e-25	1.41e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848564	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.506	rs1828299	ENSG00000225531.1	RP11-196I18.3	10.99	3.66e-25	1.41e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848871	chr9:107116829~107117557:+
THCA	trans	rs616147	0.72	rs2965067	ENSG00000214263.2	RPSAP53	-10.99	3.76e-25	1.45e-18	-0.59	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr13:67266845~67267706:-
THCA	trans	rs7833986	0.501	rs72653951	ENSG00000244245.1	RP11-120B7.1	10.98	3.87e-25	1.49e-18	0.57	0.45	Height;	chr8:56049278	chr5:108593609~108593967:+
THCA	trans	rs13190036	0.591	rs78523677	ENSG00000226986.4	RP11-543B16.2	-10.98	4.07e-25	1.57e-18	-0.61	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	10.97	4.21e-25	1.62e-18	0.62	0.45	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
THCA	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	10.97	4.38e-25	1.69e-18	0.6	0.45	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
THCA	trans	rs877636	0.74	rs705698	ENSG00000225071.1	GS1-184P14.2	10.97	4.41e-25	1.7e-18	0.61	0.45	Cognitive function;	chr12:55990903	chrX:24429573~24429920:-
THCA	trans	rs10037055	0.685	rs10039241	ENSG00000226986.4	RP11-543B16.2	-10.97	4.52e-25	1.74e-18	-0.58	-0.45	Migraine without aura;	chr5:177151071	chr1:211207239~211207897:+
THCA	trans	rs1355223	0.506	rs11032899	ENSG00000225531.1	RP11-196I18.3	10.96	4.68e-25	1.8e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848687	chr9:107116829~107117557:+
THCA	trans	rs10908521	0.685	rs1998977	ENSG00000227183.3	HDGFP1	-10.96	4.81e-25	1.85e-18	-0.58	-0.45	Uric acid clearance;	chr1:156834329	chrX:131646639~131646890:+
THCA	trans	rs2645424	0.635	rs62495697	ENSG00000256560.1	LINC01486	10.96	4.85e-25	1.86e-18	0.57	0.45	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851498	chr12:109354083~109359488:-
THCA	trans	rs9876781	0.967	rs1870444	ENSG00000225528.1	RP3-370M22.8	-10.95	5.05e-25	1.94e-18	-0.53	-0.45	Longevity;	chr3:48445369	chr22:39960397~39964683:+
THCA	trans	rs877636	0.702	rs773108	ENSG00000235459.5	RPS26P31	10.95	5.06e-25	1.95e-18	0.61	0.45	Cognitive function;	chr12:55976127	chr7:122681315~122681662:+
THCA	trans	rs9876781	0.967	rs1459249	ENSG00000225528.1	RP3-370M22.8	-10.95	5.15e-25	1.98e-18	-0.53	-0.45	Longevity;	chr3:48438208	chr22:39960397~39964683:+
THCA	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	10.95	5.18e-25	1.99e-18	0.51	0.45	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
THCA	trans	rs7121616	0.96	rs12361252	ENSG00000234176.1	HSPA8P1	10.95	5.2e-25	2e-18	0.63	0.45	Breast cancer;	chr11:123091564	chrX:121203182~121205014:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000212829.8	RPS26P3	-10.95	5.42e-25	2.08e-18	-0.55	-0.45	Cognitive function;	chr12:56080024	chr9:9090898~9091245:+
THCA	trans	rs959695	1	rs60891426	ENSG00000260318.1	COX6CP1	10.94	5.48e-25	2.1e-18	0.62	0.45	Hippocampal atrophy;	chr8:99831798	chr16:11903923~11904137:-
THCA	trans	rs1816752	0.704	rs7995968	ENSG00000224976.2	PARP4P2	10.94	5.6e-25	2.15e-18	0.54	0.45	Obesity-related traits;	chr13:24392754	chr13:19349137~19407962:+
THCA	trans	rs9876781	1	rs2362450	ENSG00000225528.1	RP3-370M22.8	-10.94	5.67e-25	2.18e-18	-0.53	-0.45	Longevity;	chr3:48419904	chr22:39960397~39964683:+
THCA	trans	rs7833986	0.501	rs17814658	ENSG00000244245.1	RP11-120B7.1	10.94	5.69e-25	2.18e-18	0.59	0.45	Height;	chr8:56076571	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs72653957	ENSG00000244245.1	RP11-120B7.1	10.94	5.69e-25	2.18e-18	0.59	0.45	Height;	chr8:56077489	chr5:108593609~108593967:+
THCA	trans	rs12709013	0.636	rs30835	ENSG00000233719.3	GOT2P3	10.94	5.78e-25	2.22e-18	0.58	0.45	Blood metabolite ratios;	chr16:58714117	chr12:9641802~9643007:+
THCA	trans	rs2731664	0.792	rs2630764	ENSG00000215571.5	GRK6P1	10.93	6.1e-25	2.34e-18	0.6	0.45	Intelligence (multi-trait analysis);	chr5:177453084	chr13:21319156~21320866:+
THCA	trans	rs2731664	0.792	rs2544809	ENSG00000215571.5	GRK6P1	10.93	6.2e-25	2.37e-18	0.59	0.45	Intelligence (multi-trait analysis);	chr5:177458498	chr13:21319156~21320866:+
THCA	trans	rs8010715	1	rs3742500	ENSG00000238000.1	RP11-274E7.2	10.93	6.22e-25	2.38e-18	0.51	0.45	IgG glycosylation;	chr14:24142769	chr5:98213402~98214121:+
THCA	trans	rs10908521	0.611	rs7516736	ENSG00000227183.3	HDGFP1	-10.93	6.29e-25	2.41e-18	-0.59	-0.45	Uric acid clearance;	chr1:156825994	chrX:131646639~131646890:+
THCA	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-10.93	6.33e-25	2.42e-18	-0.65	-0.45	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
THCA	trans	rs1816752	0.524	rs1965154	ENSG00000224976.2	PARP4P2	10.93	6.36e-25	2.43e-18	0.55	0.45	Obesity-related traits;	chr13:24498062	chr13:19349137~19407962:+
THCA	trans	rs1355223	0.506	rs7131229	ENSG00000225531.1	RP11-196I18.3	-10.93	6.42e-25	2.46e-18	-0.61	-0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847781	chr9:107116829~107117557:+
THCA	trans	rs74781061	1	rs74781061	ENSG00000227288.3	RP5-837I24.1	10.92	6.74e-25	2.58e-18	0.6	0.45	Endometriosis;	chr15:74595855	chr1:81501794~81503468:+
THCA	trans	rs2731664	0.792	rs335420	ENSG00000215571.5	GRK6P1	-10.92	6.87e-25	2.63e-18	-0.59	-0.45	Intelligence (multi-trait analysis);	chr5:177471618	chr13:21319156~21320866:+
THCA	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-10.92	6.87e-25	2.63e-18	-0.57	-0.45	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
THCA	trans	rs7833986	0.501	rs72653981	ENSG00000244245.1	RP11-120B7.1	10.92	6.9e-25	2.64e-18	0.59	0.45	Height;	chr8:56115255	chr5:108593609~108593967:+
THCA	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	10.91	7.36e-25	2.81e-18	0.57	0.45	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
THCA	trans	rs2731664	0.792	rs1130857	ENSG00000215571.5	GRK6P1	10.9	8.06e-25	3.07e-18	0.6	0.45	Intelligence (multi-trait analysis);	chr5:177436518	chr13:21319156~21320866:+
THCA	trans	rs877636	0.74	rs772920	ENSG00000196656.7	AC004057.1	10.9	8.24e-25	3.14e-18	0.58	0.45	Cognitive function;	chr12:55996580	chr4:113214046~113217170:-
THCA	trans	rs1355223	0.525	rs7129533	ENSG00000225531.1	RP11-196I18.3	10.9	8.45e-25	3.22e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850745	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.525	rs55796371	ENSG00000225531.1	RP11-196I18.3	10.9	8.45e-25	3.22e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851222	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.525	rs12280958	ENSG00000225531.1	RP11-196I18.3	10.9	8.45e-25	3.22e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851252	chr9:107116829~107117557:+
THCA	trans	rs55665837	0.539	rs12794714	ENSG00000236360.2	RP11-334A14.2	10.89	8.59e-25	3.27e-18	0.58	0.45	Vitamin D levels;	chr11:14892029	chr1:52993201~52993702:-
THCA	trans	rs9611519	1	rs5758267	ENSG00000268568.1	AC007228.9	10.89	8.72e-25	3.32e-18	0.53	0.45	Neuroticism;	chr22:41223346	chr19:56672574~56673901:-
THCA	trans	rs13190036	1	rs628506	ENSG00000226986.4	RP11-543B16.2	-10.89	8.75e-25	3.33e-18	-0.61	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr1:211207239~211207897:+
THCA	trans	rs7833986	0.501	rs2719226	ENSG00000244245.1	RP11-120B7.1	10.89	8.86e-25	3.37e-18	0.59	0.45	Height;	chr8:56131507	chr5:108593609~108593967:+
THCA	trans	rs55665837	0.539	rs10766196	ENSG00000236360.2	RP11-334A14.2	10.88	9.3e-25	3.54e-18	0.58	0.45	Vitamin D levels;	chr11:14891585	chr1:52993201~52993702:-
THCA	trans	rs1355223	0.525	rs10836316	ENSG00000225531.1	RP11-196I18.3	10.88	9.32e-25	3.54e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34852748	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.545	rs7123029	ENSG00000225531.1	RP11-196I18.3	10.88	9.32e-25	3.54e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853268	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.545	rs7111695	ENSG00000225531.1	RP11-196I18.3	10.88	9.32e-25	3.54e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853359	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.507	rs11032903	ENSG00000225531.1	RP11-196I18.3	10.88	9.32e-25	3.54e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854629	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.545	rs12278318	ENSG00000225531.1	RP11-196I18.3	10.88	9.32e-25	3.54e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854960	chr9:107116829~107117557:+
THCA	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	10.88	9.37e-25	3.56e-18	0.6	0.45	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
THCA	trans	rs916888	0.821	rs199506	ENSG00000280022.1	RP11-707O23.1	10.88	9.53e-25	3.62e-18	0.56	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45592621~45593369:+
THCA	trans	rs7833986	0.501	rs2976038	ENSG00000244245.1	RP11-120B7.1	10.88	9.64e-25	3.66e-18	0.58	0.45	Height;	chr8:56116305	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2976036	ENSG00000244245.1	RP11-120B7.1	10.88	9.64e-25	3.66e-18	0.58	0.45	Height;	chr8:56119162	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.534	rs17759244	ENSG00000244245.1	RP11-120B7.1	10.88	9.64e-25	3.66e-18	0.58	0.45	Height;	chr8:56121209	chr5:108593609~108593967:+
THCA	trans	rs616147	0.655	rs1707981	ENSG00000214263.2	RPSAP53	-10.88	9.82e-25	3.73e-18	-0.59	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr13:67266845~67267706:-
THCA	trans	rs8010715	1	rs8010715	ENSG00000238000.1	RP11-274E7.2	10.87	1.02e-24	3.85e-18	0.51	0.45	IgG glycosylation;	chr14:24139938	chr5:98213402~98214121:+
THCA	trans	rs7113874	0.659	rs7935453	ENSG00000266891.1	RP11-692N5.2	10.87	1.02e-24	3.87e-18	0.67	0.45	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625216	chr18:9734882~9735602:-
THCA	trans	rs9876781	0.53	rs11708617	ENSG00000235912.1	RP1-159A19.3	-10.87	1.05e-24	3.99e-18	-0.58	-0.45	Longevity;	chr3:48354819	chr1:27649419~27649610:+
THCA	trans	rs2731664	0.792	rs465670	ENSG00000215571.5	GRK6P1	10.87	1.09e-24	4.15e-18	0.6	0.45	Intelligence (multi-trait analysis);	chr5:177450623	chr13:21319156~21320866:+
THCA	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-10.86	1.1e-24	4.18e-18	-0.51	-0.45	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
THCA	trans	rs1355223	0.545	rs7106831	ENSG00000225531.1	RP11-196I18.3	10.86	1.13e-24	4.29e-18	0.61	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34857995	chr9:107116829~107117557:+
THCA	trans	rs616147	0.616	rs1768234	ENSG00000214263.2	RPSAP53	-10.86	1.14e-24	4.32e-18	-0.59	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr13:67266845~67267706:-
THCA	trans	rs13190036	0.551	rs4976639	ENSG00000226986.4	RP11-543B16.2	10.86	1.17e-24	4.43e-18	0.6	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr1:211207239~211207897:+
THCA	trans	rs7833986	0.501	rs17815934	ENSG00000244245.1	RP11-120B7.1	10.86	1.18e-24	4.46e-18	0.59	0.45	Height;	chr8:56125836	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2719255	ENSG00000244245.1	RP11-120B7.1	10.86	1.19e-24	4.52e-18	0.59	0.45	Height;	chr8:56124099	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs72653990	ENSG00000244245.1	RP11-120B7.1	10.86	1.19e-24	4.52e-18	0.59	0.45	Height;	chr8:56124556	chr5:108593609~108593967:+
THCA	trans	rs7937890	0.874	rs6486191	ENSG00000236360.2	RP11-334A14.2	10.86	1.19e-24	4.52e-18	0.61	0.45	Mitochondrial DNA levels;	chr11:14382193	chr1:52993201~52993702:-
THCA	trans	rs9876781	1	rs2045554	ENSG00000225528.1	RP3-370M22.8	10.84	1.33e-24	5.01e-18	0.52	0.45	Longevity;	chr3:48453142	chr22:39960397~39964683:+
THCA	trans	rs877636	1	rs877636	ENSG00000227887.1	RPS26P13	-10.84	1.34e-24	5.07e-18	-0.58	-0.45	Cognitive function;	chr12:56086799	chr1:208697369~208697698:-
THCA	trans	rs916888	0.821	rs70600	ENSG00000280022.1	RP11-707O23.1	-10.84	1.38e-24	5.21e-18	-0.56	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45592621~45593369:+
THCA	trans	rs9611519	0.929	rs926914	ENSG00000268568.1	AC007228.9	-10.84	1.39e-24	5.25e-18	-0.56	-0.45	Neuroticism;	chr22:41022150	chr19:56672574~56673901:-
THCA	trans	rs2645424	0.666	rs2272767	ENSG00000256560.1	LINC01486	10.84	1.4e-24	5.28e-18	0.55	0.45	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853550	chr12:109354083~109359488:-
THCA	trans	rs13190036	0.551	rs28932178	ENSG00000226986.4	RP11-543B16.2	-10.84	1.43e-24	5.39e-18	-0.61	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr1:211207239~211207897:+
THCA	trans	rs74781061	0.932	rs74025818	ENSG00000227288.3	RP5-837I24.1	10.83	1.44e-24	5.43e-18	0.6	0.45	Endometriosis;	chr15:74618287	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs2198843	ENSG00000227288.3	RP5-837I24.1	10.83	1.5e-24	5.64e-18	0.59	0.45	Endometriosis;	chr15:74708889	chr1:81501794~81503468:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000244604.1	RP11-713H12.1	-10.83	1.53e-24	5.76e-18	-0.57	-0.45	Cognitive function;	chr12:56084218	chr17:8561230~8561576:+
THCA	trans	rs877636	0.692	rs7971751	ENSG00000244604.1	RP11-713H12.1	-10.83	1.53e-24	5.76e-18	-0.57	-0.45	Cognitive function;	chr12:56084874	chr17:8561230~8561576:+
THCA	trans	rs2731664	0.792	rs2545795	ENSG00000215571.5	GRK6P1	10.83	1.53e-24	5.78e-18	0.59	0.45	Intelligence (multi-trait analysis);	chr5:177460105	chr13:21319156~21320866:+
THCA	trans	rs1355223	0.525	rs7129517	ENSG00000225531.1	RP11-196I18.3	10.82	1.58e-24	5.94e-18	0.62	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850689	chr9:107116829~107117557:+
THCA	trans	rs7833986	0.501	rs72653986	ENSG00000244245.1	RP11-120B7.1	10.82	1.65e-24	6.21e-18	0.58	0.45	Height;	chr8:56122489	chr5:108593609~108593967:+
THCA	trans	rs55665837	0.539	rs10500804	ENSG00000236360.2	RP11-334A14.2	10.82	1.7e-24	6.4e-18	0.58	0.45	Vitamin D levels;	chr11:14888727	chr1:52993201~52993702:-
THCA	trans	rs11098499	0.954	rs6857105	ENSG00000275858.1	RP11-291L22.8	10.81	1.7e-24	6.41e-18	0.61	0.45	Corneal astigmatism;	chr4:119301143	chr10:38450738~38451069:-
THCA	trans	rs9876781	0.559	rs1903144	ENSG00000235912.1	RP1-159A19.3	-10.81	1.71e-24	6.45e-18	-0.56	-0.45	Longevity;	chr3:48364907	chr1:27649419~27649610:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000223416.3	RPS26P15	-10.8	1.98e-24	7.45e-18	-0.56	-0.45	Cognitive function;	chr12:56080595	chr1:58056133~58056480:-
THCA	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	10.8	1.99e-24	7.49e-18	0.5	0.45	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
THCA	trans	rs74781061	0.932	rs7161903	ENSG00000227288.3	RP5-837I24.1	10.8	2.01e-24	7.54e-18	0.59	0.45	Endometriosis;	chr15:74647929	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs7497342	ENSG00000227288.3	RP5-837I24.1	10.8	2.01e-24	7.54e-18	0.59	0.45	Endometriosis;	chr15:74655722	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs11072497	ENSG00000227288.3	RP5-837I24.1	10.8	2.01e-24	7.54e-18	0.59	0.45	Endometriosis;	chr15:74659016	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs11072498	ENSG00000227288.3	RP5-837I24.1	10.8	2.01e-24	7.54e-18	0.59	0.45	Endometriosis;	chr15:74661846	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs2415245	ENSG00000227288.3	RP5-837I24.1	10.8	2.01e-24	7.54e-18	0.59	0.45	Endometriosis;	chr15:74678091	chr1:81501794~81503468:+
THCA	trans	rs616147	0.962	rs545397	ENSG00000183298.5	RP11-556K13.1	10.79	2.13e-24	7.97e-18	0.63	0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr1:101786340~101787219:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000196656.7	AC004057.1	-10.79	2.19e-24	8.19e-18	-0.57	-0.45	Cognitive function;	chr12:55996852	chr4:113214046~113217170:-
THCA	trans	rs7833986	0.501	rs72653978	ENSG00000244245.1	RP11-120B7.1	10.79	2.2e-24	8.25e-18	0.58	0.45	Height;	chr8:56105834	chr5:108593609~108593967:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000244604.1	RP11-713H12.1	-10.78	2.25e-24	8.43e-18	-0.57	-0.45	Cognitive function;	chr12:56083910	chr17:8561230~8561576:+
THCA	trans	rs2731664	0.721	rs2450333	ENSG00000215571.5	GRK6P1	10.78	2.34e-24	8.76e-18	0.59	0.45	Intelligence (multi-trait analysis);	chr5:177472545	chr13:21319156~21320866:+
THCA	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	10.78	2.35e-24	8.79e-18	0.51	0.45	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
THCA	trans	rs8067354	0.872	rs7224006	ENSG00000187870.7	RNFT1P3	-10.78	2.37e-24	8.86e-18	-0.6	-0.45	Hemoglobin concentration;	chr17:59818977	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.872	rs1295925	ENSG00000187870.7	RNFT1P3	-10.78	2.37e-24	8.86e-18	-0.6	-0.45	Hemoglobin concentration;	chr17:59832902	chr17:20743333~20754501:-
THCA	trans	rs616147	0.962	rs1513219	ENSG00000183298.5	RP11-556K13.1	10.77	2.57e-24	9.62e-18	0.63	0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr1:101786340~101787219:-
THCA	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	10.76	2.71e-24	1.01e-17	0.5	0.44	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
THCA	trans	rs4295623	0.556	rs10903343	ENSG00000229857.1	RP11-159H20.3	-10.76	2.73e-24	1.02e-17	-0.56	-0.44	Morning vs. evening chronotype;	chr8:11838363	chr9:76992099~76993108:+
THCA	trans	rs877636	0.669	rs7297175	ENSG00000204652.6	RPS26P8	-10.76	2.74e-24	1.02e-17	-0.57	-0.44	Cognitive function;	chr12:56080024	chr17:45608571~45608918:+
THCA	trans	rs1355223	0.506	rs7130774	ENSG00000225531.1	RP11-196I18.3	10.76	2.76e-24	1.03e-17	0.61	0.44	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847720	chr9:107116829~107117557:+
THCA	trans	rs616147	0.72	rs1768209	ENSG00000214263.2	RPSAP53	-10.76	2.76e-24	1.03e-17	-0.58	-0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr13:67266845~67267706:-
THCA	trans	rs1816752	0.679	rs7999480	ENSG00000224976.2	PARP4P2	10.76	2.81e-24	1.05e-17	0.54	0.44	Obesity-related traits;	chr13:24397865	chr13:19349137~19407962:+
THCA	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	10.76	2.82e-24	1.05e-17	0.5	0.44	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
THCA	trans	rs916888	0.821	rs199513	ENSG00000204650.12	CRHR1-IT1	-10.75	2.9e-24	1.08e-17	-0.5	-0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45620328~45648216:+
THCA	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	10.75	2.91e-24	1.09e-17	0.5	0.44	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
THCA	trans	rs7833986	0.501	rs72653959	ENSG00000244245.1	RP11-120B7.1	10.75	3.03e-24	1.13e-17	0.58	0.44	Height;	chr8:56083957	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs72653962	ENSG00000244245.1	RP11-120B7.1	10.75	3.03e-24	1.13e-17	0.58	0.44	Height;	chr8:56084946	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs72653967	ENSG00000244245.1	RP11-120B7.1	10.75	3.03e-24	1.13e-17	0.58	0.44	Height;	chr8:56086873	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.534	rs10504198	ENSG00000244245.1	RP11-120B7.1	10.75	3.03e-24	1.13e-17	0.58	0.44	Height;	chr8:56093695	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.534	rs2976022	ENSG00000244245.1	RP11-120B7.1	10.75	3.03e-24	1.13e-17	0.58	0.44	Height;	chr8:56095284	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2976018	ENSG00000244245.1	RP11-120B7.1	10.75	3.03e-24	1.13e-17	0.58	0.44	Height;	chr8:56102193	chr5:108593609~108593967:+
THCA	trans	rs8067354	0.831	rs2333617	ENSG00000187870.7	RNFT1P3	-10.75	3.11e-24	1.16e-17	-0.6	-0.44	Hemoglobin concentration;	chr17:59818859	chr17:20743333~20754501:-
THCA	trans	rs616147	0.816	rs1768190	ENSG00000183298.5	RP11-556K13.1	10.74	3.2e-24	1.19e-17	0.63	0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr1:101786340~101787219:-
THCA	trans	rs1355223	0.506	rs1509660	ENSG00000225531.1	RP11-196I18.3	10.74	3.22e-24	1.2e-17	0.61	0.44	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843470	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.506	rs1509659	ENSG00000225531.1	RP11-196I18.3	10.74	3.22e-24	1.2e-17	0.61	0.44	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843586	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.506	rs11032894	ENSG00000225531.1	RP11-196I18.3	10.74	3.22e-24	1.2e-17	0.61	0.44	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843997	chr9:107116829~107117557:+
THCA	trans	rs1355223	0.506	rs7947848	ENSG00000225531.1	RP11-196I18.3	10.74	3.22e-24	1.2e-17	0.61	0.44	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34844673	chr9:107116829~107117557:+
THCA	trans	rs877636	1	rs705696	ENSG00000227887.1	RPS26P13	10.74	3.25e-24	1.21e-17	0.6	0.44	Cognitive function;	chr12:56086864	chr1:208697369~208697698:-
THCA	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	10.74	3.38e-24	1.26e-17	0.51	0.44	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
THCA	trans	rs74781061	0.932	rs11072496	ENSG00000227288.3	RP5-837I24.1	10.73	3.42e-24	1.27e-17	0.59	0.44	Endometriosis;	chr15:74628191	chr1:81501794~81503468:+
THCA	trans	rs877636	1	rs705696	ENSG00000223416.3	RPS26P15	10.73	3.6e-24	1.34e-17	0.58	0.44	Cognitive function;	chr12:56086864	chr1:58056133~58056480:-
THCA	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	10.73	3.67e-24	1.36e-17	0.59	0.44	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
THCA	trans	rs55665837	0.54	rs4144487	ENSG00000236360.2	RP11-334A14.2	10.73	3.71e-24	1.38e-17	0.58	0.44	Vitamin D levels;	chr11:14728905	chr1:52993201~52993702:-
THCA	trans	rs2731664	0.792	rs335452	ENSG00000215571.5	GRK6P1	10.73	3.72e-24	1.38e-17	0.6	0.44	Intelligence (multi-trait analysis);	chr5:177452670	chr13:21319156~21320866:+
THCA	trans	rs2731664	0.792	rs385981	ENSG00000215571.5	GRK6P1	10.73	3.72e-24	1.38e-17	0.6	0.44	Intelligence (multi-trait analysis);	chr5:177459538	chr13:21319156~21320866:+
THCA	trans	rs877636	1	rs4759229	ENSG00000227887.1	RPS26P13	-10.72	3.74e-24	1.39e-17	-0.58	-0.44	Cognitive function;	chr12:56080696	chr1:208697369~208697698:-
THCA	trans	rs7833986	0.534	rs17814089	ENSG00000244245.1	RP11-120B7.1	-10.72	3.87e-24	1.43e-17	-0.58	-0.44	Height;	chr8:56053004	chr5:108593609~108593967:+
THCA	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	10.71	4.21e-24	1.56e-17	0.6	0.44	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	10.71	4.37e-24	1.62e-17	0.59	0.44	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
THCA	trans	rs877636	0.702	rs773110	ENSG00000227887.1	RPS26P13	10.71	4.4e-24	1.63e-17	0.58	0.44	Cognitive function;	chr12:55981353	chr1:208697369~208697698:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000227887.1	RPS26P13	10.71	4.4e-24	1.63e-17	0.58	0.44	Cognitive function;	chr12:55981956	chr1:208697369~208697698:-
THCA	trans	rs916888	0.821	rs199505	ENSG00000280022.1	RP11-707O23.1	10.7	4.7e-24	1.74e-17	0.54	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45592621~45593369:+
THCA	trans	rs916888	0.821	rs70602	ENSG00000280022.1	RP11-707O23.1	10.7	4.7e-24	1.74e-17	0.54	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45592621~45593369:+
THCA	trans	rs7121616	0.733	rs10790554	ENSG00000234176.1	HSPA8P1	10.7	4.82e-24	1.78e-17	0.55	0.44	Breast cancer;	chr11:123130376	chrX:121203182~121205014:-
THCA	trans	rs12709013	0.729	rs1657179	ENSG00000230849.2	GOT2P2	10.69	4.86e-24	1.79e-17	0.53	0.44	Blood metabolite ratios;	chr16:58735115	chr1:173141100~173142350:-
THCA	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	10.69	5.06e-24	1.87e-17	0.6	0.44	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
THCA	trans	rs55665837	0.54	rs10832294	ENSG00000236360.2	RP11-334A14.2	10.69	5.08e-24	1.87e-17	0.58	0.44	Vitamin D levels;	chr11:14725881	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.54	rs10219313	ENSG00000236360.2	RP11-334A14.2	10.69	5.08e-24	1.87e-17	0.58	0.44	Vitamin D levels;	chr11:14728303	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.519	rs10832297	ENSG00000236360.2	RP11-334A14.2	10.69	5.08e-24	1.87e-17	0.58	0.44	Vitamin D levels;	chr11:14736191	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.54	rs12788030	ENSG00000236360.2	RP11-334A14.2	10.69	5.08e-24	1.87e-17	0.58	0.44	Vitamin D levels;	chr11:14743138	chr1:52993201~52993702:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000243538.1	CTB-55B8.1	10.69	5.11e-24	1.88e-17	0.53	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr5:16902294~16902641:-
THCA	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	10.69	5.2e-24	1.92e-17	0.63	0.44	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
THCA	trans	rs12709013	0.792	rs1473206	ENSG00000230849.2	GOT2P2	10.68	5.32e-24	1.96e-17	0.53	0.44	Blood metabolite ratios;	chr16:58737529	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs1473205	ENSG00000230849.2	GOT2P2	10.68	5.32e-24	1.96e-17	0.53	0.44	Blood metabolite ratios;	chr16:58737547	chr1:173141100~173142350:-
THCA	trans	rs2731664	0.792	rs163199	ENSG00000215571.5	GRK6P1	10.68	5.33e-24	1.96e-17	0.59	0.44	Intelligence (multi-trait analysis);	chr5:177463066	chr13:21319156~21320866:+
THCA	trans	rs616147	0.962	rs1708104	ENSG00000183298.5	RP11-556K13.1	-10.68	5.65e-24	2.08e-17	-0.62	-0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr1:101786340~101787219:-
THCA	trans	rs55665837	0.54	rs3206554	ENSG00000236360.2	RP11-334A14.2	10.68	5.71e-24	2.1e-17	0.57	0.44	Vitamin D levels;	chr11:14776399	chr1:52993201~52993702:-
THCA	trans	rs4276421	0.571	rs1527833	ENSG00000231752.4	EMBP1	-10.67	5.84e-24	2.15e-17	-0.62	-0.44	P wave duration;	chr5:45570915	chr1:121519112~121571892:+
THCA	trans	rs55665837	0.54	rs10832299	ENSG00000236360.2	RP11-334A14.2	10.67	5.84e-24	2.15e-17	0.57	0.44	Vitamin D levels;	chr11:14747846	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.52	rs10766189	ENSG00000236360.2	RP11-334A14.2	10.67	5.87e-24	2.16e-17	0.57	0.44	Vitamin D levels;	chr11:14712377	chr1:52993201~52993702:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000227887.1	RPS26P13	10.67	5.88e-24	2.16e-17	0.58	0.44	Cognitive function;	chr12:55982097	chr1:208697369~208697698:-
THCA	trans	rs55665837	0.54	rs4757261	ENSG00000236360.2	RP11-334A14.2	10.67	6.08e-24	2.23e-17	0.57	0.44	Vitamin D levels;	chr11:14648256	chr1:52993201~52993702:-
THCA	trans	rs3808502	0.503	rs34190028	ENSG00000253893.2	FAM85B	10.67	6.13e-24	2.25e-17	0.58	0.44	Neuroticism;	chr8:11559641	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	10.67	6.16e-24	2.26e-17	0.63	0.44	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
THCA	trans	rs13014235	0.562	rs2080325	ENSG00000235105.1	RP11-329A14.1	-10.67	6.27e-24	2.3e-17	-0.48	-0.44	Basal cell carcinoma;	chr2:201513640	chr1:48435967~48437223:+
THCA	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	10.66	6.33e-24	2.33e-17	0.63	0.44	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
THCA	trans	rs9876781	0.559	rs11130167	ENSG00000235912.1	RP1-159A19.3	-10.66	6.41e-24	2.35e-17	-0.56	-0.44	Longevity;	chr3:48358570	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.559	rs13073692	ENSG00000235912.1	RP1-159A19.3	-10.66	6.41e-24	2.35e-17	-0.56	-0.44	Longevity;	chr3:48361812	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.559	rs7611415	ENSG00000235912.1	RP1-159A19.3	-10.66	6.41e-24	2.35e-17	-0.56	-0.44	Longevity;	chr3:48363659	chr1:27649419~27649610:+
THCA	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	10.66	6.43e-24	2.36e-17	0.6	0.44	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
THCA	trans	rs9876781	0.56	rs2362451	ENSG00000235912.1	RP1-159A19.3	10.66	6.47e-24	2.38e-17	0.54	0.44	Longevity;	chr3:48358338	chr1:27649419~27649610:+
THCA	trans	rs9876781	0.53	rs35516531	ENSG00000235912.1	RP1-159A19.3	-10.66	6.49e-24	2.38e-17	-0.56	-0.44	Longevity;	chr3:48364275	chr1:27649419~27649610:+
THCA	trans	rs7833986	0.501	rs2976044	ENSG00000244245.1	RP11-120B7.1	10.66	6.62e-24	2.43e-17	0.54	0.44	Height;	chr8:56074178	chr5:108593609~108593967:+
THCA	trans	rs55665837	0.519	rs1451677	ENSG00000236360.2	RP11-334A14.2	10.66	6.64e-24	2.44e-17	0.58	0.44	Vitamin D levels;	chr11:14724466	chr1:52993201~52993702:-
THCA	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	10.66	6.76e-24	2.48e-17	0.61	0.44	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
THCA	trans	rs916888	0.821	rs199504	ENSG00000280022.1	RP11-707O23.1	10.66	6.79e-24	2.49e-17	0.54	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45592621~45593369:+
THCA	trans	rs7833986	0.534	rs72653928	ENSG00000244245.1	RP11-120B7.1	10.65	6.86e-24	2.52e-17	0.6	0.44	Height;	chr8:55995176	chr5:108593609~108593967:+
THCA	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	10.65	6.89e-24	2.53e-17	0.63	0.44	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	10.65	6.89e-24	2.53e-17	0.63	0.44	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
THCA	trans	rs7554547	0.714	rs6671723	ENSG00000261819.1	RP11-680G24.4	10.64	8.14e-24	2.98e-17	0.61	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11908021	chr16:14988259~14990160:-
THCA	trans	rs1355223	0.506	rs7131272	ENSG00000225531.1	RP11-196I18.3	-10.63	8.18e-24	2.99e-17	-0.6	-0.44	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848001	chr9:107116829~107117557:+
THCA	trans	rs55665837	0.54	rs11023302	ENSG00000236360.2	RP11-334A14.2	10.63	8.3e-24	3.03e-17	0.57	0.44	Vitamin D levels;	chr11:14672389	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.54	rs10128681	ENSG00000236360.2	RP11-334A14.2	10.63	8.3e-24	3.03e-17	0.57	0.44	Vitamin D levels;	chr11:14680030	chr1:52993201~52993702:-
THCA	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	10.63	8.76e-24	3.2e-17	0.6	0.44	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	10.63	8.76e-24	3.2e-17	0.6	0.44	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000227887.1	RPS26P13	10.62	8.93e-24	3.26e-17	0.58	0.44	Cognitive function;	chr12:55980911	chr1:208697369~208697698:-
THCA	trans	rs9876781	0.559	rs7610524	ENSG00000235912.1	RP1-159A19.3	-10.62	8.95e-24	3.27e-17	-0.56	-0.44	Longevity;	chr3:48353882	chr1:27649419~27649610:+
THCA	trans	rs3808502	0.563	rs12541800	ENSG00000253893.2	FAM85B	-10.62	9.06e-24	3.31e-17	-0.58	-0.44	Neuroticism;	chr8:11565563	chr8:8167819~8226614:-
THCA	trans	rs55665837	0.54	rs7938266	ENSG00000236360.2	RP11-334A14.2	10.62	9.12e-24	3.33e-17	0.57	0.44	Vitamin D levels;	chr11:14687778	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.54	rs10766192	ENSG00000236360.2	RP11-334A14.2	10.62	9.35e-24	3.41e-17	0.57	0.44	Vitamin D levels;	chr11:14790140	chr1:52993201~52993702:-
THCA	trans	rs916888	0.697	rs199516	ENSG00000280022.1	RP11-707O23.1	10.62	9.39e-24	3.43e-17	0.54	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45592621~45593369:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000227887.1	RPS26P13	-10.62	9.43e-24	3.44e-17	-0.57	-0.44	Cognitive function;	chr12:56080595	chr1:208697369~208697698:-
THCA	trans	rs13190036	0.551	rs1052432	ENSG00000226986.4	RP11-543B16.2	-10.62	9.56e-24	3.49e-17	-0.6	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr1:211207239~211207897:+
THCA	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	10.61	1.01e-23	3.69e-17	0.63	0.44	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
THCA	trans	rs2645424	0.55	rs28577034	ENSG00000256560.1	LINC01486	10.61	1.03e-23	3.75e-17	0.54	0.44	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851206	chr12:109354083~109359488:-
THCA	trans	rs55665837	0.54	rs12290926	ENSG00000236360.2	RP11-334A14.2	10.6	1.06e-23	3.87e-17	0.57	0.44	Vitamin D levels;	chr11:14673500	chr1:52993201~52993702:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000227887.1	RPS26P13	10.6	1.08e-23	3.94e-17	0.58	0.44	Cognitive function;	chr12:55988132	chr1:208697369~208697698:-
THCA	trans	rs74781061	0.932	rs7178568	ENSG00000227288.3	RP5-837I24.1	10.6	1.08e-23	3.94e-17	0.58	0.44	Endometriosis;	chr15:74559075	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs8023479	ENSG00000227288.3	RP5-837I24.1	10.6	1.08e-23	3.94e-17	0.58	0.44	Endometriosis;	chr15:74561337	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs12437519	ENSG00000227288.3	RP5-837I24.1	10.6	1.08e-23	3.94e-17	0.58	0.44	Endometriosis;	chr15:74562109	chr1:81501794~81503468:+
THCA	trans	rs877636	0.74	rs705698	ENSG00000235459.5	RPS26P31	10.6	1.09e-23	3.96e-17	0.58	0.44	Cognitive function;	chr12:55990903	chr7:122681315~122681662:+
THCA	trans	rs5022636	0.525	rs4971021	ENSG00000180764.13	PIPSL	10.6	1.1e-23	4.01e-17	0.5	0.44	Gut microbiota (functional units);	chr1:151246152	chr10:93958191~93961540:-
THCA	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	10.6	1.15e-23	4.17e-17	0.6	0.44	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
THCA	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	10.59	1.18e-23	4.28e-17	0.63	0.44	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
THCA	trans	rs55665837	0.54	rs1007392	ENSG00000236360.2	RP11-334A14.2	10.59	1.18e-23	4.3e-17	0.57	0.44	Vitamin D levels;	chr11:14753045	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.523	rs10832301	ENSG00000236360.2	RP11-334A14.2	10.59	1.18e-23	4.3e-17	0.57	0.44	Vitamin D levels;	chr11:14767418	chr1:52993201~52993702:-
THCA	trans	rs877636	1	rs877636	ENSG00000196656.7	AC004057.1	-10.59	1.19e-23	4.32e-17	-0.56	-0.44	Cognitive function;	chr12:56086799	chr4:113214046~113217170:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	10.59	1.19e-23	4.33e-17	0.56	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
THCA	trans	rs55665837	0.54	rs12416696	ENSG00000236360.2	RP11-334A14.2	10.59	1.22e-23	4.43e-17	0.57	0.44	Vitamin D levels;	chr11:14769343	chr1:52993201~52993702:-
THCA	trans	rs4276421	0.571	rs10805694	ENSG00000231752.4	EMBP1	-10.59	1.23e-23	4.46e-17	-0.62	-0.44	P wave duration;	chr5:45539757	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	10.58	1.26e-23	4.57e-17	0.58	0.44	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
THCA	trans	rs8067354	0.83	rs2453913	ENSG00000187870.7	RNFT1P3	10.58	1.27e-23	4.6e-17	0.59	0.44	Hemoglobin concentration;	chr17:59782789	chr17:20743333~20754501:-
THCA	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-10.58	1.32e-23	4.8e-17	-0.6	-0.44	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
THCA	trans	rs7833986	0.501	rs9650314	ENSG00000244245.1	RP11-120B7.1	10.58	1.35e-23	4.9e-17	0.6	0.44	Height;	chr8:55991051	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.534	rs72653924	ENSG00000244245.1	RP11-120B7.1	10.58	1.35e-23	4.9e-17	0.6	0.44	Height;	chr8:55993529	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.534	rs2667972	ENSG00000244245.1	RP11-120B7.1	10.58	1.35e-23	4.9e-17	0.6	0.44	Height;	chr8:55994102	chr5:108593609~108593967:+
THCA	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-10.57	1.37e-23	4.97e-17	-0.6	-0.44	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
THCA	trans	rs74781061	0.932	rs6495121	ENSG00000227288.3	RP5-837I24.1	10.57	1.4e-23	5.08e-17	0.59	0.44	Endometriosis;	chr15:74711167	chr1:81501794~81503468:+
THCA	trans	rs9425766	0.639	rs10798295	ENSG00000213331.4	RP11-713C19.2	10.57	1.43e-23	5.17e-17	0.54	0.44	Life satisfaction;	chr1:173714815	chr4:187970273~187971284:+
THCA	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	10.57	1.46e-23	5.28e-17	0.61	0.44	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
THCA	trans	rs916888	0.821	rs199514	ENSG00000280022.1	RP11-707O23.1	10.57	1.47e-23	5.33e-17	0.53	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45592621~45593369:+
THCA	trans	rs3808502	0.526	rs36048422	ENSG00000253893.2	FAM85B	10.57	1.48e-23	5.38e-17	0.58	0.44	Neuroticism;	chr8:11559635	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.526	rs11783065	ENSG00000253893.2	FAM85B	10.57	1.48e-23	5.38e-17	0.58	0.44	Neuroticism;	chr8:11559748	chr8:8167819~8226614:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000224553.1	AC008065.1	-10.56	1.53e-23	5.56e-17	-0.53	-0.44	Cognitive function;	chr12:56083910	chr2:171374931~171375278:-
THCA	trans	rs7647973	0.58	rs12637576	ENSG00000197582.5	GPX1P1	10.56	1.58e-23	5.7e-17	0.63	0.44	Menarche (age at onset);	chr3:49199901	chrX:13378735~13379340:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000224553.1	AC008065.1	-10.56	1.58e-23	5.71e-17	-0.53	-0.44	Cognitive function;	chr12:56084218	chr2:171374931~171375278:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000224553.1	AC008065.1	-10.56	1.58e-23	5.71e-17	-0.53	-0.44	Cognitive function;	chr12:56084874	chr2:171374931~171375278:-
THCA	trans	rs3808502	0.574	rs4841559	ENSG00000253893.2	FAM85B	10.56	1.58e-23	5.72e-17	0.57	0.44	Neuroticism;	chr8:11559376	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.929	rs11072493	ENSG00000227288.3	RP5-837I24.1	10.56	1.6e-23	5.78e-17	0.58	0.44	Endometriosis;	chr15:74536881	chr1:81501794~81503468:+
THCA	trans	rs877636	0.702	rs61937249	ENSG00000196656.7	AC004057.1	10.56	1.6e-23	5.78e-17	0.57	0.44	Cognitive function;	chr12:55988132	chr4:113214046~113217170:-
THCA	trans	rs8067354	0.872	rs2645488	ENSG00000187870.7	RNFT1P3	10.56	1.6e-23	5.79e-17	0.59	0.44	Hemoglobin concentration;	chr17:59812044	chr17:20743333~20754501:-
THCA	trans	rs877636	1	rs705696	ENSG00000233778.3	RP11-777J24.1	10.56	1.62e-23	5.85e-17	0.56	0.44	Cognitive function;	chr12:56086864	chr8:92144088~92144435:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000227887.1	RPS26P13	10.55	1.66e-23	6.02e-17	0.59	0.44	Cognitive function;	chr12:55976127	chr1:208697369~208697698:-
THCA	trans	rs9876781	0.559	rs7630053	ENSG00000235912.1	RP1-159A19.3	-10.55	1.7e-23	6.13e-17	-0.55	-0.44	Longevity;	chr3:48357096	chr1:27649419~27649610:+
THCA	trans	rs11023332	1	rs11023332	ENSG00000236360.2	RP11-334A14.2	10.55	1.7e-23	6.15e-17	0.57	0.44	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr1:52993201~52993702:-
THCA	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-10.55	1.73e-23	6.26e-17	-0.62	-0.44	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
THCA	trans	rs2731664	0.792	rs2630763	ENSG00000215571.5	GRK6P1	10.54	1.87e-23	6.75e-17	0.58	0.44	Intelligence (multi-trait analysis);	chr5:177474004	chr13:21319156~21320866:+
THCA	trans	rs8067354	0.789	rs4622571	ENSG00000187870.7	RNFT1P3	10.54	1.91e-23	6.88e-17	0.59	0.44	Hemoglobin concentration;	chr17:59807036	chr17:20743333~20754501:-
THCA	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	10.53	1.93e-23	6.97e-17	0.63	0.44	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
THCA	trans	rs12145833	0.596	rs12043646	ENSG00000154608.12	CEP170P1	-10.53	1.95e-23	7.03e-17	-0.63	-0.44	Obesity (early onset extreme);	chr1:243118690	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.596	rs12123491	ENSG00000154608.12	CEP170P1	-10.53	1.95e-23	7.03e-17	-0.63	-0.44	Obesity (early onset extreme);	chr1:243134622	chr4:118467590~118554204:+
THCA	trans	rs2731664	0.792	rs335434	ENSG00000215571.5	GRK6P1	10.53	1.96e-23	7.07e-17	0.59	0.44	Intelligence (multi-trait analysis);	chr5:177440275	chr13:21319156~21320866:+
THCA	trans	rs916888	0.821	rs415430	ENSG00000280022.1	RP11-707O23.1	10.53	2e-23	7.2e-17	0.53	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45592621~45593369:+
THCA	trans	rs916888	0.779	rs430685	ENSG00000280022.1	RP11-707O23.1	10.53	2e-23	7.2e-17	0.53	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45592621~45593369:+
THCA	trans	rs74781061	0.932	rs11629946	ENSG00000227288.3	RP5-837I24.1	-10.53	2.08e-23	7.49e-17	-0.58	-0.44	Endometriosis;	chr15:74579550	chr1:81501794~81503468:+
THCA	trans	rs13190036	0.551	rs7732930	ENSG00000226986.4	RP11-543B16.2	-10.53	2.08e-23	7.5e-17	-0.56	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr1:211207239~211207897:+
THCA	trans	rs1355223	0.506	rs7130678	ENSG00000225531.1	RP11-196I18.3	10.53	2.09e-23	7.52e-17	0.6	0.44	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847634	chr9:107116829~107117557:+
THCA	trans	rs3779195	0.585	rs56694862	ENSG00000225169.1	BRI3P1	-10.52	2.12e-23	7.63e-17	-0.72	-0.44	Sex hormone-binding globulin levels;	chr7:98267808	chr1:100213293~100213670:+
THCA	trans	rs55665837	0.539	rs10832310	ENSG00000236360.2	RP11-334A14.2	10.52	2.13e-23	7.68e-17	0.57	0.44	Vitamin D levels;	chr11:14856896	chr1:52993201~52993702:-
THCA	trans	rs12709013	0.694	rs1616798	ENSG00000230849.2	GOT2P2	10.52	2.25e-23	8.1e-17	0.52	0.44	Blood metabolite ratios;	chr16:58739433	chr1:173141100~173142350:-
THCA	trans	rs8067354	0.872	rs1292060	ENSG00000187870.7	RNFT1P3	10.51	2.45e-23	8.82e-17	0.59	0.44	Hemoglobin concentration;	chr17:59836488	chr17:20743333~20754501:-
THCA	trans	rs916888	0.773	rs9896243	ENSG00000280022.1	RP11-707O23.1	-10.51	2.46e-23	8.84e-17	-0.55	-0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45592621~45593369:+
THCA	trans	rs916888	0.821	rs199512	ENSG00000280022.1	RP11-707O23.1	10.5	2.69e-23	9.66e-17	0.53	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45592621~45593369:+
THCA	trans	rs916888	0.821	rs199509	ENSG00000280022.1	RP11-707O23.1	10.5	2.69e-23	9.66e-17	0.53	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45592621~45593369:+
THCA	trans	rs916888	0.821	rs199507	ENSG00000280022.1	RP11-707O23.1	10.5	2.69e-23	9.66e-17	0.53	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45592621~45593369:+
THCA	trans	rs877636	0.702	rs773110	ENSG00000196656.7	AC004057.1	10.5	2.71e-23	9.72e-17	0.56	0.44	Cognitive function;	chr12:55981353	chr4:113214046~113217170:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000196656.7	AC004057.1	10.5	2.71e-23	9.72e-17	0.56	0.44	Cognitive function;	chr12:55981956	chr4:113214046~113217170:-
THCA	trans	rs74781061	0.872	rs6495106	ENSG00000227288.3	RP5-837I24.1	10.49	2.72e-23	9.77e-17	0.58	0.44	Endometriosis;	chr15:74487006	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs7176491	ENSG00000227288.3	RP5-837I24.1	10.49	2.72e-23	9.77e-17	0.58	0.44	Endometriosis;	chr15:74514875	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs61168092	ENSG00000227288.3	RP5-837I24.1	10.49	2.72e-23	9.77e-17	0.58	0.44	Endometriosis;	chr15:74517619	chr1:81501794~81503468:+
THCA	trans	rs74781061	1	rs8040745	ENSG00000227288.3	RP5-837I24.1	10.49	2.72e-23	9.77e-17	0.58	0.44	Endometriosis;	chr15:74525791	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.872	rs4886598	ENSG00000227288.3	RP5-837I24.1	10.49	2.75e-23	9.87e-17	0.58	0.44	Endometriosis;	chr15:74484441	chr1:81501794~81503468:+
THCA	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-10.49	2.85e-23	1.02e-16	-0.58	-0.44	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	10.49	2.85e-23	1.02e-16	0.58	0.44	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	10.49	2.85e-23	1.02e-16	0.58	0.44	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
THCA	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	10.48	3.02e-23	1.08e-16	0.58	0.44	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
THCA	trans	rs7833986	0.501	rs2667983	ENSG00000244245.1	RP11-120B7.1	10.48	3.07e-23	1.1e-16	0.6	0.44	Height;	chr8:55981528	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2667981	ENSG00000244245.1	RP11-120B7.1	10.48	3.07e-23	1.1e-16	0.6	0.44	Height;	chr8:55981744	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs2719245	ENSG00000244245.1	RP11-120B7.1	10.48	3.07e-23	1.1e-16	0.6	0.44	Height;	chr8:55981800	chr5:108593609~108593967:+
THCA	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	10.48	3.07e-23	1.1e-16	0.58	0.44	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	10.48	3.07e-23	1.1e-16	0.58	0.44	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000227887.1	RPS26P13	-10.48	3.1e-23	1.11e-16	-0.57	-0.44	Cognitive function;	chr12:55996852	chr1:208697369~208697698:-
THCA	trans	rs3808502	0.563	rs12549144	ENSG00000253893.2	FAM85B	-10.48	3.17e-23	1.13e-16	-0.57	-0.44	Neuroticism;	chr8:11565352	chr8:8167819~8226614:-
THCA	trans	rs3779195	0.524	rs76976120	ENSG00000225169.1	BRI3P1	-10.48	3.21e-23	1.15e-16	-0.72	-0.44	Sex hormone-binding globulin levels;	chr7:98264860	chr1:100213293~100213670:+
THCA	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-10.47	3.4e-23	1.21e-16	-0.64	-0.43	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
THCA	trans	rs2731664	0.74	rs2731670	ENSG00000215571.5	GRK6P1	-10.47	3.44e-23	1.23e-16	-0.57	-0.43	Intelligence (multi-trait analysis);	chr5:177421018	chr13:21319156~21320866:+
THCA	trans	rs55665837	0.502	rs12795794	ENSG00000236360.2	RP11-334A14.2	10.46	3.57e-23	1.27e-16	0.57	0.43	Vitamin D levels;	chr11:14825327	chr1:52993201~52993702:-
THCA	trans	rs916888	0.738	rs199515	ENSG00000280022.1	RP11-707O23.1	10.46	3.71e-23	1.32e-16	0.53	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45592621~45593369:+
THCA	trans	rs2898290	0.5	rs11998678	ENSG00000253893.2	FAM85B	10.46	3.81e-23	1.36e-16	0.58	0.43	Systolic blood pressure;	chr8:11972641	chr8:8167819~8226614:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000227887.1	RPS26P13	10.46	3.82e-23	1.36e-16	0.57	0.43	Cognitive function;	chr12:55996580	chr1:208697369~208697698:-
THCA	trans	rs35851103	0.627	rs6601644	ENSG00000253893.2	FAM85B	-10.45	3.87e-23	1.38e-16	-0.57	-0.43	Neuroticism;	chr8:11989569	chr8:8167819~8226614:-
THCA	trans	rs9876781	0.559	rs1841178	ENSG00000235912.1	RP1-159A19.3	-10.45	3.87e-23	1.38e-16	-0.55	-0.43	Longevity;	chr3:48355556	chr1:27649419~27649610:+
THCA	trans	rs2645424	0.604	rs9644756	ENSG00000256560.1	LINC01486	10.45	4e-23	1.43e-16	0.54	0.43	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11857591	chr12:109354083~109359488:-
THCA	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	10.45	4.09e-23	1.46e-16	0.52	0.43	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
THCA	trans	rs2645424	0.55	rs12338	ENSG00000256560.1	LINC01486	10.44	4.17e-23	1.49e-16	0.52	0.43	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853379	chr12:109354083~109359488:-
THCA	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	10.44	4.32e-23	1.54e-16	0.59	0.43	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-10.44	4.49e-23	1.6e-16	-0.53	-0.43	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-10.44	4.49e-23	1.6e-16	-0.53	-0.43	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
THCA	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	10.43	4.64e-23	1.65e-16	0.62	0.43	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
THCA	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	10.43	4.64e-23	1.65e-16	0.62	0.43	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
THCA	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	10.43	4.64e-23	1.65e-16	0.62	0.43	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
THCA	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	10.43	4.64e-23	1.65e-16	0.62	0.43	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	10.43	4.64e-23	1.65e-16	0.62	0.43	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	10.43	4.69e-23	1.67e-16	0.57	0.43	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000204652.6	RPS26P8	10.43	4.89e-23	1.74e-16	0.55	0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:45608571~45608918:+
THCA	trans	rs7554547	0.69	rs57044570	ENSG00000261819.1	RP11-680G24.4	10.43	4.9e-23	1.74e-16	0.6	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11899181	chr16:14988259~14990160:-
THCA	trans	rs7647973	0.58	rs2117938	ENSG00000197582.5	GPX1P1	-10.42	5.06e-23	1.8e-16	-0.61	-0.43	Menarche (age at onset);	chr3:49226417	chrX:13378735~13379340:-
THCA	trans	rs66887589	0.592	rs28580295	ENSG00000275858.1	RP11-291L22.8	10.42	5.16e-23	1.83e-16	0.54	0.43	Diastolic blood pressure;	chr4:119357718	chr10:38450738~38451069:-
THCA	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	10.42	5.17e-23	1.83e-16	0.64	0.43	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	10.42	5.17e-23	1.83e-16	0.64	0.43	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	10.42	5.17e-23	1.83e-16	0.64	0.43	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
THCA	trans	rs12145833	0.538	rs4658547	ENSG00000154608.12	CEP170P1	10.42	5.27e-23	1.87e-16	0.6	0.43	Obesity (early onset extreme);	chr1:243227829	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.538	rs9803701	ENSG00000154608.12	CEP170P1	10.42	5.27e-23	1.87e-16	0.6	0.43	Obesity (early onset extreme);	chr1:243228332	chr4:118467590~118554204:+
THCA	trans	rs877636	0.702	rs773110	ENSG00000233778.3	RP11-777J24.1	10.41	5.78e-23	2.05e-16	0.54	0.43	Cognitive function;	chr12:55981353	chr8:92144088~92144435:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000233778.3	RP11-777J24.1	10.41	5.78e-23	2.05e-16	0.54	0.43	Cognitive function;	chr12:55981956	chr8:92144088~92144435:-
THCA	trans	rs74781061	0.86	rs1456432	ENSG00000227288.3	RP5-837I24.1	10.4	5.97e-23	2.11e-16	0.58	0.43	Endometriosis;	chr15:74710710	chr1:81501794~81503468:+
THCA	trans	rs3779195	0.585	rs73709460	ENSG00000225169.1	BRI3P1	-10.4	6.16e-23	2.18e-16	-0.71	-0.43	Sex hormone-binding globulin levels;	chr7:98265942	chr1:100213293~100213670:+
THCA	trans	rs877636	1	rs2292239	ENSG00000196656.7	AC004057.1	10.4	6.35e-23	2.24e-16	0.55	0.43	Cognitive function;	chr12:56088396	chr4:113214046~113217170:-
THCA	trans	rs55665837	0.539	rs10832311	ENSG00000236360.2	RP11-334A14.2	10.39	6.61e-23	2.33e-16	0.56	0.43	Vitamin D levels;	chr11:14860380	chr1:52993201~52993702:-
THCA	trans	rs2645424	0.519	rs17154027	ENSG00000256560.1	LINC01486	-10.38	7.48e-23	2.64e-16	-0.53	-0.43	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856343	chr12:109354083~109359488:-
THCA	trans	rs12709013	0.729	rs1657179	ENSG00000233719.3	GOT2P3	10.37	7.63e-23	2.69e-16	0.51	0.43	Blood metabolite ratios;	chr16:58735115	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs1473206	ENSG00000233719.3	GOT2P3	10.37	7.65e-23	2.69e-16	0.51	0.43	Blood metabolite ratios;	chr16:58737529	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs1473205	ENSG00000233719.3	GOT2P3	10.37	7.65e-23	2.69e-16	0.51	0.43	Blood metabolite ratios;	chr16:58737547	chr12:9641802~9643007:+
THCA	trans	rs12145833	0.538	rs12026408	ENSG00000154608.12	CEP170P1	-10.37	7.89e-23	2.78e-16	-0.63	-0.43	Obesity (early onset extreme);	chr1:243203503	chr4:118467590~118554204:+
THCA	trans	rs1816752	0.875	rs3783076	ENSG00000224976.2	PARP4P2	-10.37	8.05e-23	2.83e-16	-0.5	-0.43	Obesity-related traits;	chr13:24490319	chr13:19349137~19407962:+
THCA	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	10.37	8.18e-23	2.88e-16	0.61	0.43	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
THCA	trans	rs7554547	0.69	rs17037526	ENSG00000261819.1	RP11-680G24.4	10.37	8.22e-23	2.89e-16	0.6	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11899305	chr16:14988259~14990160:-
THCA	trans	rs55665837	0.539	rs731042	ENSG00000236360.2	RP11-334A14.2	10.36	8.39e-23	2.95e-16	0.56	0.43	Vitamin D levels;	chr11:14853429	chr1:52993201~52993702:-
THCA	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	10.36	8.43e-23	2.96e-16	0.61	0.43	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
THCA	trans	rs1816752	0.679	rs8181826	ENSG00000224976.2	PARP4P2	10.36	8.44e-23	2.97e-16	0.5	0.43	Obesity-related traits;	chr13:24396570	chr13:19349137~19407962:+
THCA	trans	rs10908521	0.685	rs12746582	ENSG00000227183.3	HDGFP1	-10.36	8.47e-23	2.98e-16	-0.57	-0.43	Uric acid clearance;	chr1:156836231	chrX:131646639~131646890:+
THCA	trans	rs7121616	0.733	rs10892967	ENSG00000234176.1	HSPA8P1	10.36	8.51e-23	2.99e-16	0.54	0.43	Breast cancer;	chr11:123130350	chrX:121203182~121205014:-
THCA	trans	rs13190036	1	rs655623	ENSG00000226986.4	RP11-543B16.2	10.36	8.76e-23	3.08e-16	0.6	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr1:211207239~211207897:+
THCA	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	10.35	9.1e-23	3.2e-16	0.58	0.43	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000224553.1	AC008065.1	-10.35	9.18e-23	3.22e-16	-0.51	-0.43	Cognitive function;	chr12:56080024	chr2:171374931~171375278:-
THCA	trans	rs2645424	0.639	rs35581201	ENSG00000256560.1	LINC01486	10.35	9.21e-23	3.23e-16	0.53	0.43	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11849325	chr12:109354083~109359488:-
THCA	trans	rs1816752	0.875	rs59531061	ENSG00000224976.2	PARP4P2	-10.35	9.59e-23	3.36e-16	-0.51	-0.43	Obesity-related traits;	chr13:24507297	chr13:19349137~19407962:+
THCA	trans	rs7647973	0.516	rs4308307	ENSG00000197582.5	GPX1P1	10.35	9.79e-23	3.43e-16	0.61	0.43	Menarche (age at onset);	chr3:49155783	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.526	rs10026625	ENSG00000275858.1	RP11-291L22.8	10.34	1e-22	3.52e-16	0.54	0.43	Corneal astigmatism;	chr4:119358981	chr10:38450738~38451069:-
THCA	trans	rs10908521	0.685	rs7534418	ENSG00000227183.3	HDGFP1	-10.34	1.01e-22	3.54e-16	-0.56	-0.43	Uric acid clearance;	chr1:156836011	chrX:131646639~131646890:+
THCA	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	10.34	1.01e-22	3.54e-16	0.58	0.43	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000243538.1	CTB-55B8.1	10.34	1.04e-22	3.65e-16	0.51	0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr5:16902294~16902641:-
THCA	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	10.34	1.05e-22	3.69e-16	0.64	0.43	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	10.34	1.05e-22	3.69e-16	0.64	0.43	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
THCA	trans	rs1816752	0.603	rs9511278	ENSG00000224976.2	PARP4P2	10.33	1.08e-22	3.78e-16	0.51	0.43	Obesity-related traits;	chr13:24455766	chr13:19349137~19407962:+
THCA	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	10.33	1.11e-22	3.88e-16	0.58	0.43	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.509	rs4532370	ENSG00000231752.4	EMBP1	-10.33	1.12e-22	3.91e-16	-0.63	-0.43	P wave duration;	chr5:45506716	chr1:121519112~121571892:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000242970.2	AC068522.4	-10.33	1.12e-22	3.93e-16	-0.59	-0.43	Cognitive function;	chr12:56080595	chr8:58588420~58588764:-
THCA	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-10.33	1.16e-22	4.06e-16	-0.57	-0.43	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
THCA	trans	rs877636	1	rs2292239	ENSG00000233778.3	RP11-777J24.1	10.32	1.17e-22	4.1e-16	0.53	0.43	Cognitive function;	chr12:56088396	chr8:92144088~92144435:-
THCA	trans	rs4276421	0.571	rs1483308	ENSG00000231752.4	EMBP1	-10.32	1.19e-22	4.16e-16	-0.6	-0.43	P wave duration;	chr5:45538282	chr1:121519112~121571892:+
THCA	trans	rs4606360	1	rs4606360	ENSG00000213331.4	RP11-713C19.2	10.32	1.2e-22	4.19e-16	0.53	0.43	Subjective well-being;	chr1:173729868	chr4:187970273~187971284:+
THCA	trans	rs877636	0.702	rs773112	ENSG00000233778.3	RP11-777J24.1	10.32	1.24e-22	4.35e-16	0.54	0.43	Cognitive function;	chr12:55982097	chr8:92144088~92144435:-
THCA	trans	rs10908521	0.685	rs11264568	ENSG00000227183.3	HDGFP1	-10.31	1.27e-22	4.45e-16	-0.57	-0.43	Uric acid clearance;	chr1:156836077	chrX:131646639~131646890:+
THCA	trans	rs10908521	0.685	rs11264569	ENSG00000227183.3	HDGFP1	-10.31	1.27e-22	4.45e-16	-0.57	-0.43	Uric acid clearance;	chr1:156836098	chrX:131646639~131646890:+
THCA	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	10.31	1.3e-22	4.55e-16	0.58	0.43	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
THCA	trans	rs7833986	0.501	rs72653917	ENSG00000244245.1	RP11-120B7.1	10.31	1.3e-22	4.55e-16	0.58	0.43	Height;	chr8:55980285	chr5:108593609~108593967:+
THCA	trans	rs7819412	1	rs2409722	ENSG00000253893.2	FAM85B	10.31	1.31e-22	4.57e-16	0.56	0.43	Triglycerides;	chr8:11182307	chr8:8167819~8226614:-
THCA	trans	rs6732160	0.596	rs7605923	ENSG00000236165.1	PRADC1P1	10.31	1.33e-22	4.64e-16	0.58	0.43	Intelligence (multi-trait analysis);	chr2:73175205	chr3:36976316~36976840:+
THCA	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	10.3	1.39e-22	4.84e-16	0.62	0.43	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000196656.7	AC004057.1	10.3	1.41e-22	4.92e-16	0.55	0.43	Cognitive function;	chr12:55982097	chr4:113214046~113217170:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000233778.3	RP11-777J24.1	10.29	1.51e-22	5.27e-16	0.54	0.43	Cognitive function;	chr12:55980911	chr8:92144088~92144435:-
THCA	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	10.29	1.52e-22	5.3e-16	0.62	0.43	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	10.29	1.52e-22	5.3e-16	0.62	0.43	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
THCA	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	10.29	1.52e-22	5.3e-16	0.62	0.43	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
THCA	trans	rs7833986	0.534	rs2667980	ENSG00000244245.1	RP11-120B7.1	10.29	1.55e-22	5.39e-16	0.6	0.43	Height;	chr8:55983982	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.501	rs72653921	ENSG00000244245.1	RP11-120B7.1	10.29	1.55e-22	5.39e-16	0.6	0.43	Height;	chr8:55984598	chr5:108593609~108593967:+
THCA	trans	rs7833986	0.534	rs2458083	ENSG00000244245.1	RP11-120B7.1	10.29	1.55e-22	5.39e-16	0.6	0.43	Height;	chr8:55986226	chr5:108593609~108593967:+
THCA	trans	rs7819412	0.745	rs6601569	ENSG00000253893.2	FAM85B	10.29	1.57e-22	5.47e-16	0.57	0.43	Triglycerides;	chr8:11216069	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-10.28	1.66e-22	5.79e-16	-0.58	-0.43	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
THCA	trans	rs12145833	0.538	rs61833885	ENSG00000154608.12	CEP170P1	-10.28	1.66e-22	5.8e-16	-0.62	-0.43	Obesity (early onset extreme);	chr1:243233886	chr4:118467590~118554204:+
THCA	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	10.28	1.71e-22	5.94e-16	0.61	0.43	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000196656.7	AC004057.1	10.27	1.79e-22	6.23e-16	0.56	0.43	Cognitive function;	chr12:55980911	chr4:113214046~113217170:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000233778.3	RP11-777J24.1	10.27	1.84e-22	6.41e-16	0.54	0.43	Cognitive function;	chr12:55988132	chr8:92144088~92144435:-
THCA	trans	rs7833986	0.501	rs2667978	ENSG00000244245.1	RP11-120B7.1	10.27	1.87e-22	6.51e-16	0.57	0.43	Height;	chr8:55985392	chr5:108593609~108593967:+
THCA	trans	rs55665837	0.502	rs4757269	ENSG00000236360.2	RP11-334A14.2	10.27	1.89e-22	6.58e-16	0.56	0.43	Vitamin D levels;	chr11:14814646	chr1:52993201~52993702:-
THCA	trans	rs2731664	0.792	rs337374	ENSG00000215571.5	GRK6P1	-10.27	1.9e-22	6.61e-16	-0.58	-0.43	Intelligence (multi-trait analysis);	chr5:177463415	chr13:21319156~21320866:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000212829.8	RPS26P3	10.27	1.92e-22	6.66e-16	0.53	0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr9:9090898~9091245:+
THCA	trans	rs7647973	0.516	rs4955419	ENSG00000197582.5	GPX1P1	10.26	1.93e-22	6.71e-16	0.61	0.43	Menarche (age at onset);	chr3:49163259	chrX:13378735~13379340:-
THCA	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	10.26	1.94e-22	6.75e-16	0.61	0.43	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	10.26	1.96e-22	6.8e-16	0.62	0.43	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	10.26	1.96e-22	6.8e-16	0.62	0.43	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
THCA	trans	rs10908521	0.717	rs11264572	ENSG00000227183.3	HDGFP1	-10.26	1.98e-22	6.86e-16	-0.57	-0.43	Uric acid clearance;	chr1:156836245	chrX:131646639~131646890:+
THCA	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-10.26	2.02e-22	7.01e-16	-0.61	-0.43	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
THCA	trans	rs10908521	0.626	rs11264570	ENSG00000227183.3	HDGFP1	-10.25	2.16e-22	7.48e-16	-0.57	-0.43	Uric acid clearance;	chr1:156836167	chrX:131646639~131646890:+
THCA	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	10.25	2.28e-22	7.91e-16	0.61	0.43	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	10.25	2.28e-22	7.91e-16	0.61	0.43	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
THCA	trans	rs4276421	0.509	rs17293295	ENSG00000231752.4	EMBP1	10.24	2.39e-22	8.27e-16	0.63	0.43	P wave duration;	chr5:45509473	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.509	rs12656485	ENSG00000231752.4	EMBP1	10.24	2.39e-22	8.27e-16	0.63	0.43	P wave duration;	chr5:45513518	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.509	rs1483311	ENSG00000231752.4	EMBP1	10.24	2.39e-22	8.27e-16	0.63	0.43	P wave duration;	chr5:45514872	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.509	rs1483312	ENSG00000231752.4	EMBP1	10.24	2.39e-22	8.27e-16	0.63	0.43	P wave duration;	chr5:45514982	chr1:121519112~121571892:+
THCA	trans	rs4276421	0.509	rs1483313	ENSG00000231752.4	EMBP1	10.24	2.39e-22	8.27e-16	0.63	0.43	P wave duration;	chr5:45515322	chr1:121519112~121571892:+
THCA	trans	rs2731664	0.792	rs335468	ENSG00000215571.5	GRK6P1	-10.24	2.42e-22	8.39e-16	-0.57	-0.43	Intelligence (multi-trait analysis);	chr5:177465348	chr13:21319156~21320866:+
THCA	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-10.23	2.59e-22	8.94e-16	-0.57	-0.43	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
THCA	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
THCA	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	10.23	2.59e-22	8.94e-16	0.57	0.43	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
THCA	trans	rs35851103	0.627	rs58602899	ENSG00000253893.2	FAM85B	-10.23	2.61e-22	9e-16	-0.56	-0.43	Neuroticism;	chr8:11991324	chr8:8167819~8226614:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000233778.3	RP11-777J24.1	10.23	2.71e-22	9.32e-16	0.54	0.43	Cognitive function;	chr12:55996580	chr8:92144088~92144435:-
THCA	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	10.22	2.79e-22	9.59e-16	0.57	0.43	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
THCA	trans	rs13190036	0.681	rs28461408	ENSG00000226986.4	RP11-543B16.2	10.22	2.83e-22	9.74e-16	0.66	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr1:211207239~211207897:+
THCA	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	10.21	3.07e-22	1.05e-15	0.64	0.43	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
THCA	trans	rs55665837	0.539	rs11023350	ENSG00000236360.2	RP11-334A14.2	10.21	3.12e-22	1.07e-15	0.56	0.43	Vitamin D levels;	chr11:14839971	chr1:52993201~52993702:-
THCA	trans	rs74781061	0.872	rs3826041	ENSG00000227288.3	RP5-837I24.1	10.21	3.2e-22	1.1e-15	0.57	0.43	Endometriosis;	chr15:74726549	chr1:81501794~81503468:+
THCA	trans	rs877636	0.74	rs705702	ENSG00000233778.3	RP11-777J24.1	-10.2	3.25e-22	1.12e-15	-0.53	-0.43	Cognitive function;	chr12:55996852	chr8:92144088~92144435:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-10.2	3.45e-22	1.18e-15	-0.52	-0.43	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
THCA	trans	rs7647973	0.58	rs12629759	ENSG00000197582.5	GPX1P1	10.19	3.49e-22	1.2e-15	0.61	0.43	Menarche (age at onset);	chr3:49199961	chrX:13378735~13379340:-
THCA	trans	rs66887589	0.592	rs62320740	ENSG00000275858.1	RP11-291L22.8	10.19	3.55e-22	1.22e-15	0.53	0.43	Diastolic blood pressure;	chr4:119358331	chr10:38450738~38451069:-
THCA	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	10.19	3.59e-22	1.23e-15	0.61	0.43	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	10.19	3.59e-22	1.23e-15	0.61	0.43	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
THCA	trans	rs77688320	0.535	rs7579617	ENSG00000235105.1	RP11-329A14.1	10.19	3.71e-22	1.27e-15	0.47	0.43	Breast cancer;	chr2:201384065	chr1:48435967~48437223:+
THCA	trans	rs7833986	0.501	rs2668007	ENSG00000244245.1	RP11-120B7.1	10.18	3.88e-22	1.33e-15	0.59	0.43	Height;	chr8:56031552	chr5:108593609~108593967:+
THCA	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	10.18	3.89e-22	1.33e-15	0.61	0.43	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
THCA	trans	rs877636	1	rs4759229	ENSG00000242970.2	AC068522.4	-10.18	3.9e-22	1.33e-15	-0.58	-0.43	Cognitive function;	chr12:56080696	chr8:58588420~58588764:-
THCA	trans	rs7819412	0.669	rs2409743	ENSG00000253893.2	FAM85B	10.18	4.09e-22	1.4e-15	0.57	0.42	Triglycerides;	chr8:11212851	chr8:8167819~8226614:-
THCA	trans	rs77688320	0.535	rs2241118	ENSG00000235105.1	RP11-329A14.1	10.18	4.1e-22	1.4e-15	0.47	0.42	Breast cancer;	chr2:201388993	chr1:48435967~48437223:+
THCA	trans	rs7662987	0.793	rs7669660	ENSG00000228407.2	RP4-800M22.1	10.18	4.11e-22	1.41e-15	0.82	0.42	Smoking initiation;	chr4:99071451	chr1:52160261~52160600:-
THCA	trans	rs12145833	0.538	rs10754798	ENSG00000154608.12	CEP170P1	10.18	4.11e-22	1.41e-15	0.58	0.42	Obesity (early onset extreme);	chr1:243146656	chr4:118467590~118554204:+
THCA	trans	rs77688320	0.535	rs13001194	ENSG00000235105.1	RP11-329A14.1	10.18	4.11e-22	1.41e-15	0.47	0.42	Breast cancer;	chr2:201396452	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs7597850	ENSG00000235105.1	RP11-329A14.1	10.18	4.11e-22	1.41e-15	0.47	0.42	Breast cancer;	chr2:201396679	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs7571761	ENSG00000235105.1	RP11-329A14.1	10.18	4.11e-22	1.41e-15	0.47	0.42	Breast cancer;	chr2:201396837	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs10931944	ENSG00000235105.1	RP11-329A14.1	10.18	4.11e-22	1.41e-15	0.47	0.42	Breast cancer;	chr2:201398875	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs11681526	ENSG00000235105.1	RP11-329A14.1	10.18	4.11e-22	1.41e-15	0.47	0.42	Breast cancer;	chr2:201399037	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs13022344	ENSG00000235105.1	RP11-329A14.1	10.18	4.11e-22	1.41e-15	0.47	0.42	Breast cancer;	chr2:201399433	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs6732993	ENSG00000235105.1	RP11-329A14.1	10.18	4.11e-22	1.41e-15	0.47	0.42	Breast cancer;	chr2:201399593	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.553	rs6761777	ENSG00000235105.1	RP11-329A14.1	10.18	4.11e-22	1.41e-15	0.47	0.42	Breast cancer;	chr2:201399879	chr1:48435967~48437223:+
THCA	trans	rs3808502	0.549	rs4841564	ENSG00000253893.2	FAM85B	10.17	4.16e-22	1.42e-15	0.56	0.42	Neuroticism;	chr8:11568300	chr8:8167819~8226614:-
THCA	trans	rs877636	1	rs705696	ENSG00000196656.7	AC004057.1	10.17	4.22e-22	1.44e-15	0.56	0.42	Cognitive function;	chr12:56086864	chr4:113214046~113217170:-
THCA	trans	rs77688320	0.535	rs13027669	ENSG00000235105.1	RP11-329A14.1	10.17	4.29e-22	1.47e-15	0.47	0.42	Breast cancer;	chr2:201382596	chr1:48435967~48437223:+
THCA	trans	rs9425766	0.511	rs10912676	ENSG00000213331.4	RP11-713C19.2	10.17	4.4e-22	1.5e-15	0.53	0.42	Life satisfaction;	chr1:173740477	chr4:187970273~187971284:+
THCA	trans	rs7819412	0.936	rs7814499	ENSG00000253893.2	FAM85B	10.16	4.59e-22	1.57e-15	0.56	0.42	Triglycerides;	chr8:11183138	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	10.16	4.6e-22	1.57e-15	0.6	0.42	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
THCA	trans	rs4646450	0.636	rs2003499	ENSG00000228834.1	RP11-249L21.4	10.16	4.64e-22	1.58e-15	0.82	0.42	Blood metabolite levels;	chr7:99417361	chr6:108907615~108907873:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000224553.1	AC008065.1	10.16	4.72e-22	1.61e-15	0.5	0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr2:171374931~171375278:-
THCA	trans	rs12145833	0.596	rs10737887	ENSG00000154608.12	CEP170P1	10.15	4.9e-22	1.67e-15	0.59	0.42	Obesity (early onset extreme);	chr1:243260844	chr4:118467590~118554204:+
THCA	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	10.15	4.91e-22	1.68e-15	0.56	0.42	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
THCA	trans	rs77688320	0.535	rs10804115	ENSG00000235105.1	RP11-329A14.1	10.15	5.27e-22	1.8e-15	0.47	0.42	Breast cancer;	chr2:201415510	chr1:48435967~48437223:+
THCA	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	10.14	5.37e-22	1.83e-15	0.63	0.42	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
THCA	trans	rs3808502	0.525	rs13280813	ENSG00000253893.2	FAM85B	10.14	5.58e-22	1.9e-15	0.56	0.42	Neuroticism;	chr8:11567596	chr8:8167819~8226614:-
THCA	trans	rs12145833	0.538	rs10926977	ENSG00000154608.12	CEP170P1	-10.14	5.63e-22	1.91e-15	-0.62	-0.42	Obesity (early onset extreme);	chr1:243248065	chr4:118467590~118554204:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000224553.1	AC008065.1	10.13	5.79e-22	1.97e-15	0.5	0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr2:171374931~171375278:-
THCA	trans	rs12709013	0.694	rs1616798	ENSG00000233719.3	GOT2P3	10.13	5.81e-22	1.98e-15	0.5	0.42	Blood metabolite ratios;	chr16:58739433	chr12:9641802~9643007:+
THCA	trans	rs77688320	0.535	rs6751543	ENSG00000235105.1	RP11-329A14.1	10.13	6.16e-22	2.09e-15	0.47	0.42	Breast cancer;	chr2:201400210	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs34625194	ENSG00000235105.1	RP11-329A14.1	10.13	6.16e-22	2.09e-15	0.47	0.42	Breast cancer;	chr2:201406815	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs11691859	ENSG00000235105.1	RP11-329A14.1	10.13	6.16e-22	2.09e-15	0.47	0.42	Breast cancer;	chr2:201407268	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.517	rs11691865	ENSG00000235105.1	RP11-329A14.1	10.13	6.16e-22	2.09e-15	0.47	0.42	Breast cancer;	chr2:201407309	chr1:48435967~48437223:+
THCA	trans	rs73110464	0.505	rs2638503	ENSG00000254285.3	KRT8P3	-10.12	6.32e-22	2.15e-15	-0.56	-0.42	Cancer (pleiotropy);	chr12:52913585	chr8:61578220~61579668:+
THCA	trans	rs77688320	0.535	rs7579853	ENSG00000235105.1	RP11-329A14.1	10.12	6.33e-22	2.15e-15	0.46	0.42	Breast cancer;	chr2:201384256	chr1:48435967~48437223:+
THCA	trans	rs5877	0.568	rs1951627	ENSG00000213331.4	RP11-713C19.2	10.12	6.44e-22	2.19e-15	0.59	0.42	Subjective well-being (multi-trait analysis);	chr1:173922679	chr4:187970273~187971284:+
THCA	trans	rs77688320	0.553	rs3795966	ENSG00000235105.1	RP11-329A14.1	10.12	6.51e-22	2.21e-15	0.46	0.42	Breast cancer;	chr2:201380521	chr1:48435967~48437223:+
THCA	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	10.12	6.57e-22	2.23e-15	0.62	0.42	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
THCA	trans	rs7554547	0.69	rs1474576	ENSG00000261819.1	RP11-680G24.4	10.12	6.75e-22	2.29e-15	0.58	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11887572	chr16:14988259~14990160:-
THCA	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	10.11	6.85e-22	2.32e-15	0.56	0.42	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	10.11	6.85e-22	2.32e-15	0.56	0.42	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	10.11	6.85e-22	2.32e-15	0.57	0.42	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	10.11	6.85e-22	2.32e-15	0.57	0.42	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	10.11	6.85e-22	2.32e-15	0.57	0.42	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
THCA	trans	rs9425766	0.679	rs7552939	ENSG00000213331.4	RP11-713C19.2	10.11	6.96e-22	2.36e-15	0.53	0.42	Life satisfaction;	chr1:173798305	chr4:187970273~187971284:+
THCA	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-10.11	7.05e-22	2.39e-15	-0.57	-0.42	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
THCA	trans	rs7662987	0.793	rs12106	ENSG00000228407.2	RP4-800M22.1	10.11	7.16e-22	2.43e-15	0.81	0.42	Smoking initiation;	chr4:99072199	chr1:52160261~52160600:-
THCA	trans	rs7662987	0.793	rs28730632	ENSG00000228407.2	RP4-800M22.1	10.11	7.16e-22	2.43e-15	0.81	0.42	Smoking initiation;	chr4:99074552	chr1:52160261~52160600:-
THCA	trans	rs7662987	0.793	rs4699700	ENSG00000228407.2	RP4-800M22.1	10.11	7.16e-22	2.43e-15	0.81	0.42	Smoking initiation;	chr4:99077184	chr1:52160261~52160600:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000243403.1	RP11-330L19.1	-10.11	7.23e-22	2.45e-15	-0.58	-0.42	Asthma;	chr12:55970537	chr15:64592979~64593326:+
THCA	trans	rs10242455	0.717	rs58649180	ENSG00000228834.1	RP11-249L21.4	10.11	7.38e-22	2.5e-15	0.87	0.42	Blood metabolite levels;	chr7:99738422	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.717	rs72494455	ENSG00000228834.1	RP11-249L21.4	10.11	7.38e-22	2.5e-15	0.87	0.42	Blood metabolite levels;	chr7:99739154	chr6:108907615~108907873:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000233778.3	RP11-777J24.1	10.11	7.38e-22	2.5e-15	0.55	0.42	Cognitive function;	chr12:55976127	chr8:92144088~92144435:-
THCA	trans	rs7554547	0.667	rs12567187	ENSG00000261819.1	RP11-680G24.4	10.1	7.57e-22	2.56e-15	0.58	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11896095	chr16:14988259~14990160:-
THCA	trans	rs4276421	0.509	rs1351719	ENSG00000231752.4	EMBP1	10.1	7.76e-22	2.63e-15	0.62	0.42	P wave duration;	chr5:45520383	chr1:121519112~121571892:+
THCA	trans	rs7554547	0.69	rs6669571	ENSG00000261819.1	RP11-680G24.4	10.1	8.06e-22	2.73e-15	0.58	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11887253	chr16:14988259~14990160:-
THCA	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	10.09	8.15e-22	2.75e-15	0.61	0.42	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
THCA	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	10.09	8.15e-22	2.75e-15	0.61	0.42	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
THCA	trans	rs7554547	0.622	rs28455075	ENSG00000261819.1	RP11-680G24.4	10.09	8.2e-22	2.77e-15	0.6	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11879663	chr16:14988259~14990160:-
THCA	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	10.09	8.53e-22	2.88e-15	0.59	0.42	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
THCA	trans	rs7819412	0.775	rs4840551	ENSG00000253893.2	FAM85B	10.09	8.55e-22	2.89e-15	0.57	0.42	Triglycerides;	chr8:11171530	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.525	rs9650661	ENSG00000253893.2	FAM85B	10.08	8.8e-22	2.97e-15	0.56	0.42	Neuroticism;	chr8:11569624	chr8:8167819~8226614:-
THCA	trans	rs77688320	0.535	rs7575721	ENSG00000235105.1	RP11-329A14.1	10.08	8.9e-22	3.01e-15	0.46	0.42	Breast cancer;	chr2:201392055	chr1:48435967~48437223:+
THCA	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	10.08	8.93e-22	3.01e-15	0.58	0.42	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
THCA	trans	rs7819412	0.669	rs35499486	ENSG00000253893.2	FAM85B	10.08	9.01e-22	3.04e-15	0.58	0.42	Triglycerides;	chr8:11216527	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.799	rs4372642	ENSG00000227288.3	RP5-837I24.1	10.08	9.19e-22	3.1e-15	0.56	0.42	Endometriosis;	chr15:74460095	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs6495102	ENSG00000227288.3	RP5-837I24.1	10.08	9.19e-22	3.1e-15	0.56	0.42	Endometriosis;	chr15:74470337	chr1:81501794~81503468:+
THCA	trans	rs35851103	0.506	rs4841659	ENSG00000253893.2	FAM85B	-10.08	9.21e-22	3.11e-15	-0.56	-0.42	Neuroticism;	chr8:11970691	chr8:8167819~8226614:-
THCA	trans	rs77688320	0.535	rs3815515	ENSG00000235105.1	RP11-329A14.1	10.08	9.5e-22	3.2e-15	0.46	0.42	Breast cancer;	chr2:201393207	chr1:48435967~48437223:+
THCA	trans	rs11098499	0.865	rs10213221	ENSG00000275858.1	RP11-291L22.8	10.08	9.51e-22	3.2e-15	0.56	0.42	Corneal astigmatism;	chr4:119334771	chr10:38450738~38451069:-
THCA	trans	rs77688320	0.535	rs11691118	ENSG00000235105.1	RP11-329A14.1	10.06	1.07e-21	3.6e-15	0.46	0.42	Breast cancer;	chr2:201405121	chr1:48435967~48437223:+
THCA	trans	rs9611519	0.929	rs71327107	ENSG00000268568.1	AC007228.9	-10.05	1.13e-21	3.8e-15	-0.54	-0.42	Neuroticism;	chr22:41022225	chr19:56672574~56673901:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000244604.1	RP11-713H12.1	-10.05	1.15e-21	3.87e-15	-0.53	-0.42	Cognitive function;	chr12:56080024	chr17:8561230~8561576:+
THCA	trans	rs9650657	0.504	rs2409724	ENSG00000253893.2	FAM85B	10.05	1.15e-21	3.87e-15	0.55	0.42	Neuroticism;	chr8:11184133	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.549	rs1382563	ENSG00000253893.2	FAM85B	-10.05	1.17e-21	3.91e-15	-0.55	-0.42	Neuroticism;	chr8:11569281	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.669	rs6601568	ENSG00000253893.2	FAM85B	10.05	1.23e-21	4.11e-15	0.57	0.42	Triglycerides;	chr8:11215893	chr8:8167819~8226614:-
THCA	trans	rs9611519	0.828	rs9611460	ENSG00000268568.1	AC007228.9	-10.04	1.23e-21	4.12e-15	-0.54	-0.42	Neuroticism;	chr22:41022293	chr19:56672574~56673901:-
THCA	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	10.04	1.29e-21	4.33e-15	0.62	0.42	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
THCA	trans	rs1355223	0.506	rs12294339	ENSG00000225531.1	RP11-196I18.3	10.04	1.33e-21	4.44e-15	0.57	0.42	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34838652	chr9:107116829~107117557:+
THCA	trans	rs3808502	0.516	rs6983727	ENSG00000253893.2	FAM85B	-10.03	1.35e-21	4.52e-15	-0.56	-0.42	Neuroticism;	chr8:11558303	chr8:8167819~8226614:-
THCA	trans	rs35851103	0.6	rs4841662	ENSG00000253893.2	FAM85B	10.03	1.37e-21	4.6e-15	0.55	0.42	Neuroticism;	chr8:11986249	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.635	rs6993	ENSG00000233719.3	GOT2P3	10.03	1.38e-21	4.62e-15	0.55	0.42	Blood metabolite ratios;	chr16:58707463	chr12:9641802~9643007:+
THCA	trans	rs77688320	0.517	rs12623282	ENSG00000235105.1	RP11-329A14.1	10.03	1.43e-21	4.79e-15	0.46	0.42	Breast cancer;	chr2:201382734	chr1:48435967~48437223:+
THCA	trans	rs77688320	0.535	rs7561048	ENSG00000235105.1	RP11-329A14.1	10.03	1.45e-21	4.85e-15	0.46	0.42	Breast cancer;	chr2:201388316	chr1:48435967~48437223:+
THCA	trans	rs7554547	0.69	rs12087996	ENSG00000261819.1	RP11-680G24.4	10.02	1.47e-21	4.92e-15	0.58	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11897152	chr16:14988259~14990160:-
THCA	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	10.02	1.48e-21	4.96e-15	0.56	0.42	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	10.02	1.48e-21	4.96e-15	0.56	0.42	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
THCA	trans	rs7554547	0.69	rs6667637	ENSG00000261819.1	RP11-680G24.4	10.02	1.49e-21	4.99e-15	0.58	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11887900	chr16:14988259~14990160:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000196656.7	AC004057.1	10.02	1.56e-21	5.23e-15	0.56	0.42	Cognitive function;	chr12:55976127	chr4:113214046~113217170:-
THCA	trans	rs7554547	0.69	rs7524721	ENSG00000261819.1	RP11-680G24.4	10.01	1.58e-21	5.28e-15	0.58	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11890119	chr16:14988259~14990160:-
THCA	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	10.01	1.61e-21	5.37e-15	0.63	0.42	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
THCA	trans	rs77688320	0.535	rs11680694	ENSG00000235105.1	RP11-329A14.1	10.01	1.62e-21	5.42e-15	0.46	0.42	Breast cancer;	chr2:201393498	chr1:48435967~48437223:+
THCA	trans	rs8067354	0.958	rs8081468	ENSG00000187870.7	RNFT1P3	10.01	1.63e-21	5.45e-15	0.58	0.42	Hemoglobin concentration;	chr17:59759563	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.958	rs2333563	ENSG00000187870.7	RNFT1P3	10.01	1.63e-21	5.45e-15	0.58	0.42	Hemoglobin concentration;	chr17:59762207	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.872	rs2645483	ENSG00000187870.7	RNFT1P3	10.01	1.63e-21	5.45e-15	0.58	0.42	Hemoglobin concentration;	chr17:59770823	chr17:20743333~20754501:-
THCA	trans	rs7554547	0.69	rs1474577	ENSG00000261819.1	RP11-680G24.4	10.01	1.68e-21	5.62e-15	0.58	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11887712	chr16:14988259~14990160:-
THCA	trans	rs13014235	0.592	rs55860809	ENSG00000235105.1	RP11-329A14.1	10.01	1.69e-21	5.63e-15	0.46	0.42	Basal cell carcinoma;	chr2:201394347	chr1:48435967~48437223:+
THCA	trans	rs9650657	0.572	rs4841465	ENSG00000253893.2	FAM85B	10.01	1.7e-21	5.66e-15	0.54	0.42	Neuroticism;	chr8:10962344	chr8:8167819~8226614:-
THCA	trans	rs10242455	0.717	rs2741872	ENSG00000228834.1	RP11-249L21.4	-10.01	1.7e-21	5.67e-15	-0.8	-0.42	Blood metabolite levels;	chr7:99742153	chr6:108907615~108907873:-
THCA	trans	rs3749237	1	rs9819511	ENSG00000197582.5	GPX1P1	10	1.72e-21	5.75e-15	0.63	0.42	Resting heart rate;	chr3:49846828	chrX:13378735~13379340:-
THCA	trans	rs3749237	1	rs1317140	ENSG00000197582.5	GPX1P1	10	1.77e-21	5.89e-15	0.63	0.42	Resting heart rate;	chr3:49841219	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	10	1.79e-21	5.96e-15	0.55	0.42	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
THCA	trans	rs4646450	0.636	rs10279308	ENSG00000228834.1	RP11-249L21.4	9.98	2.03e-21	6.76e-15	0.81	0.42	Blood metabolite levels;	chr7:99407883	chr6:108907615~108907873:-
THCA	trans	rs4295623	0.559	rs4841600	ENSG00000229857.1	RP11-159H20.3	-9.98	2.08e-21	6.93e-15	-0.54	-0.42	Morning vs. evening chronotype;	chr8:11830639	chr9:76992099~76993108:+
THCA	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	9.98	2.17e-21	7.21e-15	0.61	0.42	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
THCA	trans	rs13190036	0.901	rs6898107	ENSG00000228305.2	AC016734.2	9.97	2.26e-21	7.51e-15	0.49	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr2:63622178~63622831:-
THCA	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	9.97	2.33e-21	7.75e-15	0.62	0.42	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
THCA	trans	rs6477998	0.603	rs12338803	ENSG00000238072.1	RP11-305M3.2	9.96	2.4e-21	7.97e-15	0.69	0.42	Hematology traits;	chr9:113263148	chr7:129410113~129410370:-
THCA	trans	rs7121616	1	rs75228513	ENSG00000234176.1	HSPA8P1	9.96	2.43e-21	8.08e-15	0.57	0.42	Breast cancer;	chr11:123096160	chrX:121203182~121205014:-
THCA	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	9.96	2.47e-21	8.19e-15	0.55	0.42	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	9.96	2.47e-21	8.2e-15	0.56	0.42	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	9.96	2.51e-21	8.32e-15	0.55	0.42	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	9.96	2.52e-21	8.35e-15	0.56	0.42	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000227887.1	RPS26P13	9.96	2.52e-21	8.35e-15	0.55	0.42	Cognitive function;	chr12:55990903	chr1:208697369~208697698:-
THCA	trans	rs9650657	0.504	rs6986032	ENSG00000253893.2	FAM85B	9.96	2.59e-21	8.58e-15	0.56	0.42	Neuroticism;	chr8:11174731	chr8:8167819~8226614:-
THCA	trans	rs13190036	0.901	rs4631	ENSG00000226986.4	RP11-543B16.2	9.95	2.6e-21	8.62e-15	0.62	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr1:211207239~211207897:+
THCA	trans	rs3749237	0.964	rs10865959	ENSG00000197582.5	GPX1P1	9.95	2.63e-21	8.7e-15	0.61	0.42	Resting heart rate;	chr3:49853569	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	9.95	2.63e-21	8.72e-15	0.55	0.42	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	9.95	2.63e-21	8.72e-15	0.55	0.42	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	9.95	2.63e-21	8.72e-15	0.55	0.42	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000212829.8	RPS26P3	9.95	2.69e-21	8.91e-15	0.51	0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:9090898~9091245:+
THCA	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	9.95	2.75e-21	9.09e-15	0.55	0.42	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
THCA	trans	rs13190036	1	rs625882	ENSG00000226986.4	RP11-543B16.2	-9.95	2.78e-21	9.21e-15	-0.59	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr1:211207239~211207897:+
THCA	trans	rs7121616	1	rs79401687	ENSG00000234176.1	HSPA8P1	9.94	2.98e-21	9.86e-15	0.57	0.42	Breast cancer;	chr11:123096264	chrX:121203182~121205014:-
THCA	trans	rs3808502	0.549	rs11991139	ENSG00000253893.2	FAM85B	9.94	2.99e-21	9.89e-15	0.55	0.42	Neuroticism;	chr8:11570886	chr8:8167819~8226614:-
THCA	trans	rs877636	0.692	rs11171739	ENSG00000227586.5	RP11-162A23.5	9.94	3.03e-21	1e-14	0.52	0.42	Cognitive function;	chr12:56076841	chr10:123171535~123171875:-
THCA	trans	rs877636	1	rs2292239	ENSG00000223416.3	RPS26P15	9.93	3.14e-21	1.04e-14	0.52	0.42	Cognitive function;	chr12:56088396	chr1:58056133~58056480:-
THCA	trans	rs73110464	0.505	rs2682296	ENSG00000254285.3	KRT8P3	-9.93	3.23e-21	1.07e-14	-0.56	-0.42	Cancer (pleiotropy);	chr12:52914481	chr8:61578220~61579668:+
THCA	trans	rs3808502	0.549	rs7831039	ENSG00000253893.2	FAM85B	9.93	3.28e-21	1.08e-14	0.55	0.42	Neuroticism;	chr8:11570128	chr8:8167819~8226614:-
THCA	trans	rs13016963	0.546	rs11691602	ENSG00000235105.1	RP11-329A14.1	9.93	3.3e-21	1.09e-14	0.45	0.42	Esophageal squamous cell carcinoma;Melanoma;	chr2:201362976	chr1:48435967~48437223:+
THCA	trans	rs13190036	0.792	rs6874206	ENSG00000228305.2	AC016734.2	-9.93	3.32e-21	1.1e-14	-0.48	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr2:63622178~63622831:-
THCA	trans	rs13190036	0.901	rs10072499	ENSG00000228305.2	AC016734.2	-9.93	3.32e-21	1.1e-14	-0.48	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr2:63622178~63622831:-
THCA	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	9.93	3.33e-21	1.1e-14	0.54	0.42	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
THCA	trans	rs7662987	0.793	rs7684735	ENSG00000228407.2	RP4-800M22.1	9.92	3.37e-21	1.11e-14	0.8	0.42	Smoking initiation;	chr4:99070355	chr1:52160261~52160600:-
THCA	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	9.92	3.52e-21	1.16e-14	0.55	0.42	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	9.92	3.52e-21	1.16e-14	0.55	0.42	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
THCA	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	9.92	3.54e-21	1.17e-14	0.6	0.42	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
THCA	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	9.91	3.64e-21	1.2e-14	0.6	0.42	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000242970.2	AC068522.4	9.91	3.69e-21	1.22e-14	0.58	0.42	Cognitive function;	chr12:55996580	chr8:58588420~58588764:-
THCA	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	9.91	3.79e-21	1.25e-14	0.54	0.42	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
THCA	trans	rs10037055	1	rs6886255	ENSG00000226986.4	RP11-543B16.2	9.91	3.86e-21	1.27e-14	0.53	0.42	Migraine without aura;	chr5:177291360	chr1:211207239~211207897:+
THCA	trans	rs10435719	0.805	rs13269417	ENSG00000253893.2	FAM85B	-9.91	3.91e-21	1.29e-14	-0.57	-0.42	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:8167819~8226614:-
THCA	trans	rs4295623	0.559	rs2409836	ENSG00000229857.1	RP11-159H20.3	-9.91	3.92e-21	1.29e-14	-0.53	-0.42	Morning vs. evening chronotype;	chr8:11831719	chr9:76992099~76993108:+
THCA	trans	rs877636	0.74	rs772920	ENSG00000223416.3	RPS26P15	9.9	3.97e-21	1.31e-14	0.53	0.42	Cognitive function;	chr12:55996580	chr1:58056133~58056480:-
THCA	trans	rs10037055	1	rs10037055	ENSG00000226986.4	RP11-543B16.2	-9.9	3.97e-21	1.31e-14	-0.53	-0.42	Migraine without aura;	chr5:177264278	chr1:211207239~211207897:+
THCA	trans	rs74781061	0.932	rs2012008	ENSG00000227288.3	RP5-837I24.1	9.9	4.01e-21	1.32e-14	0.57	0.42	Endometriosis;	chr15:74441827	chr1:81501794~81503468:+
THCA	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	9.9	4.07e-21	1.34e-14	0.55	0.42	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
THCA	trans	rs13177918	0.677	rs3797622	ENSG00000226396.1	RP5-1056L3.3	9.89	4.27e-21	1.4e-14	0.42	0.42	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:19608114~19608568:+
THCA	trans	rs9650657	0.538	rs10111950	ENSG00000253893.2	FAM85B	9.89	4.29e-21	1.41e-14	0.54	0.42	Neuroticism;	chr8:10958244	chr8:8167819~8226614:-
THCA	trans	rs1816752	1	rs9511272	ENSG00000224976.2	PARP4P2	-9.89	4.3e-21	1.41e-14	-0.5	-0.42	Obesity-related traits;	chr13:24446495	chr13:19349137~19407962:+
THCA	trans	rs7819412	0.537	rs2127127	ENSG00000253893.2	FAM85B	9.89	4.33e-21	1.42e-14	0.54	0.42	Triglycerides;	chr8:11577283	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.524	rs10088408	ENSG00000253893.2	FAM85B	9.89	4.38e-21	1.44e-14	0.54	0.42	Neuroticism;	chr8:10959687	chr8:8167819~8226614:-
THCA	trans	rs7554547	0.622	rs2179110	ENSG00000261819.1	RP11-680G24.4	9.89	4.49e-21	1.47e-14	0.58	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11912754	chr16:14988259~14990160:-
THCA	trans	rs3808502	0.526	rs1042701	ENSG00000253893.2	FAM85B	9.89	4.53e-21	1.49e-14	0.56	0.41	Neuroticism;	chr8:11564536	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.526	rs7843987	ENSG00000253893.2	FAM85B	9.89	4.53e-21	1.49e-14	0.56	0.41	Neuroticism;	chr8:11564621	chr8:8167819~8226614:-
THCA	trans	rs4512344	0.514	rs13255193	ENSG00000253893.2	FAM85B	9.89	4.57e-21	1.5e-14	0.54	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11451683	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.535	rs7671759	ENSG00000275858.1	RP11-291L22.8	9.88	4.93e-21	1.62e-14	0.56	0.41	Corneal astigmatism;	chr4:119326939	chr10:38450738~38451069:-
THCA	trans	rs74781061	0.929	rs4886601	ENSG00000227288.3	RP5-837I24.1	9.88	5.01e-21	1.64e-14	0.58	0.41	Endometriosis;	chr15:74591510	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs9635320	ENSG00000227288.3	RP5-837I24.1	9.87	5.08e-21	1.66e-14	0.59	0.41	Endometriosis;	chr15:74592750	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs7176095	ENSG00000227288.3	RP5-837I24.1	9.87	5.08e-21	1.66e-14	0.59	0.41	Endometriosis;	chr15:74594070	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs11072494	ENSG00000227288.3	RP5-837I24.1	9.87	5.08e-21	1.66e-14	0.59	0.41	Endometriosis;	chr15:74596822	chr1:81501794~81503468:+
THCA	trans	rs3808502	0.526	rs7822958	ENSG00000253893.2	FAM85B	9.87	5.13e-21	1.68e-14	0.56	0.41	Neuroticism;	chr8:11564933	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	9.87	5.14e-21	1.69e-14	0.55	0.41	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000227586.5	RP11-162A23.5	9.87	5.15e-21	1.69e-14	0.51	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr10:123171535~123171875:-
THCA	trans	rs77688320	0.535	rs12468504	ENSG00000235105.1	RP11-329A14.1	-9.87	5.36e-21	1.75e-14	-0.46	-0.41	Breast cancer;	chr2:201393746	chr1:48435967~48437223:+
THCA	trans	rs13190036	0.901	rs6556309	ENSG00000228305.2	AC016734.2	9.86	5.47e-21	1.79e-14	0.48	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr2:63622178~63622831:-
THCA	trans	rs2645424	0.635	rs6980952	ENSG00000256560.1	LINC01486	-9.86	5.49e-21	1.8e-14	-0.5	-0.41	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11858964	chr12:109354083~109359488:-
THCA	trans	rs3808502	0.526	rs7823100	ENSG00000253893.2	FAM85B	9.86	5.85e-21	1.91e-14	0.56	0.41	Neuroticism;	chr8:11564982	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.526	rs7823101	ENSG00000253893.2	FAM85B	9.86	5.85e-21	1.91e-14	0.56	0.41	Neuroticism;	chr8:11564983	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.526	rs11985709	ENSG00000253893.2	FAM85B	9.86	5.85e-21	1.91e-14	0.56	0.41	Neuroticism;	chr8:11565574	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.504	rs10109167	ENSG00000253893.2	FAM85B	9.85	5.98e-21	1.95e-14	0.55	0.41	Neuroticism;	chr8:11176016	chr8:8167819~8226614:-
THCA	trans	rs7819412	1	rs7819412	ENSG00000253893.2	FAM85B	-9.85	6.17e-21	2.02e-14	-0.55	-0.41	Triglycerides;	chr8:11187652	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	9.85	6.39e-21	2.09e-14	0.54	0.41	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000227586.5	RP11-162A23.5	9.84	6.54e-21	2.13e-14	0.51	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:123171535~123171875:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000243538.1	CTB-55B8.1	9.84	6.78e-21	2.21e-14	0.49	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr5:16902294~16902641:-
THCA	trans	rs5022636	0.79	rs10399679	ENSG00000180764.13	PIPSL	9.84	6.83e-21	2.23e-14	0.47	0.41	Gut microbiota (functional units);	chr1:151278361	chr10:93958191~93961540:-
THCA	trans	rs9650657	0.504	rs10108347	ENSG00000253893.2	FAM85B	9.84	6.91e-21	2.25e-14	0.55	0.41	Neuroticism;	chr8:11176008	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000223416.3	RPS26P15	9.84	6.93e-21	2.26e-14	0.53	0.41	Cognitive function;	chr12:55988132	chr1:58056133~58056480:-
THCA	trans	rs74781061	0.929	rs11072495	ENSG00000227288.3	RP5-837I24.1	9.83	7.14e-21	2.33e-14	0.58	0.41	Endometriosis;	chr15:74598790	chr1:81501794~81503468:+
THCA	trans	rs11023332	0.832	rs10832289	ENSG00000236360.2	RP11-334A14.2	-9.83	7.16e-21	2.33e-14	-0.53	-0.41	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.81	rs10734224	ENSG00000236360.2	RP11-334A14.2	9.83	7.27e-21	2.37e-14	0.56	0.41	Mitochondrial DNA levels;	chr11:14402578	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.593	rs2597189	ENSG00000236360.2	RP11-334A14.2	9.83	7.52e-21	2.45e-14	0.58	0.41	Mitochondrial DNA levels;	chr11:14490514	chr1:52993201~52993702:-
THCA	trans	rs3749237	0.964	rs2352975	ENSG00000197582.5	GPX1P1	9.83	7.54e-21	2.45e-14	0.61	0.41	Resting heart rate;	chr3:49854452	chrX:13378735~13379340:-
THCA	trans	rs3749237	1	rs13316065	ENSG00000197582.5	GPX1P1	9.82	7.68e-21	2.5e-14	0.63	0.41	Resting heart rate;	chr3:49847480	chrX:13378735~13379340:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000244604.1	RP11-713H12.1	-9.82	7.71e-21	2.51e-14	-0.5	-0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:8561230~8561576:+
THCA	trans	rs7554547	0.622	rs72864769	ENSG00000261819.1	RP11-680G24.4	9.82	7.89e-21	2.57e-14	0.59	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11881264	chr16:14988259~14990160:-
THCA	trans	rs13177918	0.677	rs3857421	ENSG00000226396.1	RP5-1056L3.3	-9.82	7.99e-21	2.6e-14	-0.41	-0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:19608114~19608568:+
THCA	trans	rs3947	0.544	rs8191604	ENSG00000229857.1	RP11-159H20.3	9.81	8.3e-21	2.7e-14	0.65	0.41	Blood protein levels;	chr8:11779375	chr9:76992099~76993108:+
THCA	trans	rs877636	0.702	rs773109	ENSG00000242970.2	AC068522.4	9.81	8.75e-21	2.84e-14	0.58	0.41	Cognitive function;	chr12:55980911	chr8:58588420~58588764:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000242970.2	AC068522.4	9.81	8.81e-21	2.86e-14	0.57	0.41	Cognitive function;	chr12:55981353	chr8:58588420~58588764:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000242970.2	AC068522.4	9.81	8.81e-21	2.86e-14	0.57	0.41	Cognitive function;	chr12:55981956	chr8:58588420~58588764:-
THCA	trans	rs4240897	1	rs4240897	ENSG00000261819.1	RP11-680G24.4	-9.8	9.36e-21	3.04e-14	-0.54	-0.41	Tuberculosis;	chr1:11982698	chr16:14988259~14990160:-
THCA	trans	rs13177918	0.677	rs4841	ENSG00000226396.1	RP5-1056L3.3	9.8	9.43e-21	3.06e-14	0.42	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs13183077	ENSG00000226396.1	RP5-1056L3.3	9.8	9.43e-21	3.06e-14	0.42	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:19608114~19608568:+
THCA	trans	rs877636	0.74	rs705702	ENSG00000242970.2	AC068522.4	-9.8	9.6e-21	3.11e-14	-0.57	-0.41	Cognitive function;	chr12:55996852	chr8:58588420~58588764:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000242970.2	AC068522.4	9.79	9.74e-21	3.16e-14	0.57	0.41	Cognitive function;	chr12:55988132	chr8:58588420~58588764:-
THCA	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-9.79	9.75e-21	3.16e-14	-0.57	-0.41	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
THCA	trans	rs9650657	0.513	rs4314618	ENSG00000253893.2	FAM85B	9.79	9.82e-21	3.18e-14	0.53	0.41	Neuroticism;	chr8:10959262	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	9.79	9.94e-21	3.22e-14	0.56	0.41	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
THCA	trans	rs13190036	1	rs13175695	ENSG00000228305.2	AC016734.2	9.79	9.99e-21	3.24e-14	0.48	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr2:63622178~63622831:-
THCA	trans	rs7819412	0.744	rs4841503	ENSG00000253893.2	FAM85B	9.79	1e-20	3.24e-14	0.55	0.41	Triglycerides;	chr8:11166817	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.572	rs2597218	ENSG00000236360.2	RP11-334A14.2	9.79	1.01e-20	3.27e-14	0.58	0.41	Mitochondrial DNA levels;	chr11:14510792	chr1:52993201~52993702:-
THCA	trans	rs1908814	0.516	rs13281315	ENSG00000253893.2	FAM85B	-9.79	1.04e-20	3.37e-14	-0.56	-0.41	Neuroticism;	chr8:11937346	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	9.78	1.07e-20	3.48e-14	0.54	0.41	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
THCA	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	9.78	1.07e-20	3.48e-14	0.54	0.41	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
THCA	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	9.78	1.07e-20	3.48e-14	0.54	0.41	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
THCA	trans	rs4295623	0.553	rs11250163	ENSG00000253893.2	FAM85B	-9.78	1.08e-20	3.49e-14	-0.55	-0.41	Morning vs. evening chronotype;	chr8:11738928	chr8:8167819~8226614:-
THCA	trans	rs13177918	0.677	rs2073472	ENSG00000226396.1	RP5-1056L3.3	9.78	1.1e-20	3.57e-14	0.42	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:19608114~19608568:+
THCA	trans	rs1908814	0.516	rs7825529	ENSG00000253893.2	FAM85B	-9.78	1.12e-20	3.62e-14	-0.56	-0.41	Neuroticism;	chr8:11936935	chr8:8167819~8226614:-
THCA	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	9.78	1.13e-20	3.64e-14	0.6	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000204652.6	RPS26P8	-9.78	1.13e-20	3.65e-14	-0.51	-0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:45608571~45608918:+
THCA	trans	rs10242455	0.717	rs2687133	ENSG00000228834.1	RP11-249L21.4	-9.77	1.15e-20	3.71e-14	-0.79	-0.41	Blood metabolite levels;	chr7:99734460	chr6:108907615~108907873:-
THCA	trans	rs804280	0.517	rs7815179	ENSG00000253893.2	FAM85B	-9.77	1.17e-20	3.78e-14	-0.56	-0.41	Myopia (pathological);	chr8:11934539	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.871	rs7815186	ENSG00000253893.2	FAM85B	-9.77	1.17e-20	3.78e-14	-0.56	-0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs7833079	ENSG00000253893.2	FAM85B	-9.77	1.17e-20	3.78e-14	-0.56	-0.41	Neuroticism;	chr8:11934620	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.812	rs11949435	ENSG00000226986.4	RP11-543B16.2	9.77	1.2e-20	3.87e-14	0.51	0.41	Migraine without aura;	chr5:177287931	chr1:211207239~211207897:+
THCA	trans	rs877636	0.74	rs705698	ENSG00000196656.7	AC004057.1	9.77	1.21e-20	3.91e-14	0.53	0.41	Cognitive function;	chr12:55990903	chr4:113214046~113217170:-
THCA	trans	rs74781061	0.929	rs8025976	ENSG00000227288.3	RP5-837I24.1	9.77	1.21e-20	3.92e-14	0.58	0.41	Endometriosis;	chr15:74577697	chr1:81501794~81503468:+
THCA	trans	rs877636	0.702	rs773112	ENSG00000242970.2	AC068522.4	9.77	1.22e-20	3.95e-14	0.57	0.41	Cognitive function;	chr12:55982097	chr8:58588420~58588764:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000227586.5	RP11-162A23.5	-9.76	1.25e-20	4.03e-14	-0.52	-0.41	Cognitive function;	chr12:56084218	chr10:123171535~123171875:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000227586.5	RP11-162A23.5	-9.76	1.25e-20	4.03e-14	-0.52	-0.41	Cognitive function;	chr12:56084874	chr10:123171535~123171875:-
THCA	trans	rs13190036	0.901	rs10056655	ENSG00000228305.2	AC016734.2	9.76	1.29e-20	4.17e-14	0.48	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr2:63622178~63622831:-
THCA	trans	rs12145833	0.596	rs1060643	ENSG00000154608.12	CEP170P1	-9.76	1.3e-20	4.19e-14	-0.6	-0.41	Obesity (early onset extreme);	chr1:243266674	chr4:118467590~118554204:+
THCA	trans	rs877636	0.692	rs2271194	ENSG00000227586.5	RP11-162A23.5	-9.76	1.3e-20	4.2e-14	-0.52	-0.41	Cognitive function;	chr12:56083910	chr10:123171535~123171875:-
THCA	trans	rs7819412	0.875	rs11250121	ENSG00000253893.2	FAM85B	9.76	1.32e-20	4.26e-14	0.55	0.41	Triglycerides;	chr8:11202802	chr8:8167819~8226614:-
THCA	trans	rs7554547	0.667	rs4304595	ENSG00000261819.1	RP11-680G24.4	9.76	1.33e-20	4.27e-14	0.58	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11886332	chr16:14988259~14990160:-
THCA	trans	rs7503168	0.908	rs9911863	ENSG00000234130.2	RP13-88F20.1	9.76	1.33e-20	4.28e-14	0.56	0.41	Plateletcrit;	chr17:35612880	chrX:93222220~93225015:-
THCA	trans	rs864643	0.513	rs1768149	ENSG00000188856.6	RPSAP47	9.76	1.33e-20	4.29e-14	0.61	0.41	Attention deficit hyperactivity disorder;	chr3:39466089	chr8:80558870~80559757:+
THCA	trans	rs74781061	0.932	rs4886605	ENSG00000227288.3	RP5-837I24.1	9.75	1.38e-20	4.45e-14	0.53	0.41	Endometriosis;	chr15:74733647	chr1:81501794~81503468:+
THCA	trans	rs13177918	0.677	rs57890152	ENSG00000226396.1	RP5-1056L3.3	9.75	1.38e-20	4.46e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:19608114~19608568:+
THCA	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	9.75	1.43e-20	4.59e-14	0.57	0.41	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
THCA	trans	rs12145833	0.596	rs61833913	ENSG00000154608.12	CEP170P1	-9.75	1.45e-20	4.67e-14	-0.6	-0.41	Obesity (early onset extreme);	chr1:243276726	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.596	rs12026068	ENSG00000154608.12	CEP170P1	-9.75	1.45e-20	4.67e-14	-0.6	-0.41	Obesity (early onset extreme);	chr1:243277050	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.596	rs12134228	ENSG00000154608.12	CEP170P1	-9.75	1.45e-20	4.67e-14	-0.6	-0.41	Obesity (early onset extreme);	chr1:243284316	chr4:118467590~118554204:+
THCA	trans	rs1908814	0.516	rs13281077	ENSG00000253893.2	FAM85B	-9.75	1.46e-20	4.7e-14	-0.56	-0.41	Neuroticism;	chr8:11937305	chr8:8167819~8226614:-
THCA	trans	rs13177918	0.686	rs12654827	ENSG00000226396.1	RP5-1056L3.3	9.75	1.46e-20	4.71e-14	0.42	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:19608114~19608568:+
THCA	trans	rs1908814	0.541	rs7824267	ENSG00000253893.2	FAM85B	-9.75	1.46e-20	4.71e-14	-0.56	-0.41	Neuroticism;	chr8:11936770	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.501	rs3021500	ENSG00000253893.2	FAM85B	9.74	1.5e-20	4.81e-14	0.54	0.41	Neuroticism;	chr8:11166488	chr8:8167819~8226614:-
THCA	trans	rs7554547	0.667	rs6666533	ENSG00000261819.1	RP11-680G24.4	9.74	1.51e-20	4.85e-14	0.57	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11889068	chr16:14988259~14990160:-
THCA	trans	rs10037055	0.853	rs12660023	ENSG00000226986.4	RP11-543B16.2	9.74	1.51e-20	4.86e-14	0.51	0.41	Migraine without aura;	chr5:177273884	chr1:211207239~211207897:+
THCA	trans	rs10037055	0.853	rs4976680	ENSG00000226986.4	RP11-543B16.2	9.74	1.51e-20	4.86e-14	0.51	0.41	Migraine without aura;	chr5:177275745	chr1:211207239~211207897:+
THCA	trans	rs10037055	0.853	rs4976681	ENSG00000226986.4	RP11-543B16.2	9.74	1.51e-20	4.86e-14	0.51	0.41	Migraine without aura;	chr5:177277662	chr1:211207239~211207897:+
THCA	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	9.74	1.51e-20	4.87e-14	0.54	0.41	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
THCA	trans	rs12145833	0.596	rs3926866	ENSG00000154608.12	CEP170P1	-9.74	1.53e-20	4.91e-14	-0.63	-0.41	Obesity (early onset extreme);	chr1:243274330	chr4:118467590~118554204:+
THCA	trans	rs7824557	0.547	rs6601570	ENSG00000253893.2	FAM85B	9.74	1.54e-20	4.94e-14	0.55	0.41	Retinal vascular caliber;	chr8:11221858	chr8:8167819~8226614:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000212829.8	RPS26P3	9.74	1.55e-20	4.99e-14	0.5	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:9090898~9091245:+
THCA	trans	rs10435719	0.899	rs7815595	ENSG00000253893.2	FAM85B	-9.74	1.56e-20	5e-14	-0.56	-0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.834	rs11250176	ENSG00000253893.2	FAM85B	-9.74	1.56e-20	5e-14	-0.56	-0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs4367597	ENSG00000253893.2	FAM85B	-9.74	1.56e-20	5e-14	-0.56	-0.41	Neuroticism;	chr8:11936020	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.899	rs9329251	ENSG00000253893.2	FAM85B	-9.74	1.56e-20	5e-14	-0.56	-0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:8167819~8226614:-
THCA	trans	rs5022636	0.74	rs11204795	ENSG00000180764.13	PIPSL	9.74	1.57e-20	5.04e-14	0.46	0.41	Gut microbiota (functional units);	chr1:151275522	chr10:93958191~93961540:-
THCA	trans	rs6477998	0.58	rs7851623	ENSG00000238072.1	RP11-305M3.2	9.74	1.58e-20	5.07e-14	0.67	0.41	Hematology traits;	chr9:113240285	chr7:129410113~129410370:-
THCA	trans	rs804280	0.542	rs36100659	ENSG00000253893.2	FAM85B	-9.74	1.58e-20	5.09e-14	-0.56	-0.41	Myopia (pathological);	chr8:11934144	chr8:8167819~8226614:-
THCA	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	9.73	1.61e-20	5.16e-14	0.47	0.41	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
THCA	trans	rs10435719	0.773	rs7842810	ENSG00000253893.2	FAM85B	-9.73	1.61e-20	5.17e-14	-0.55	-0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.947	rs10063803	ENSG00000226986.4	RP11-543B16.2	9.73	1.65e-20	5.29e-14	0.52	0.41	Migraine without aura;	chr5:177240326	chr1:211207239~211207897:+
THCA	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	9.73	1.72e-20	5.53e-14	0.54	0.41	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
THCA	trans	rs7121616	0.515	rs11218966	ENSG00000234176.1	HSPA8P1	9.72	1.73e-20	5.54e-14	0.72	0.41	Breast cancer;	chr11:123086510	chrX:121203182~121205014:-
THCA	trans	rs8010715	0.848	rs8009511	ENSG00000238000.1	RP11-274E7.2	9.72	1.73e-20	5.56e-14	0.45	0.41	IgG glycosylation;	chr14:24124771	chr5:98213402~98214121:+
THCA	trans	rs8010715	0.804	rs1134334	ENSG00000238000.1	RP11-274E7.2	9.72	1.73e-20	5.56e-14	0.45	0.41	IgG glycosylation;	chr14:24124905	chr5:98213402~98214121:+
THCA	trans	rs12497850	0.864	rs3212	ENSG00000197582.5	GPX1P1	9.72	1.75e-20	5.62e-14	0.61	0.41	Parkinson's disease;	chr3:49108308	chrX:13378735~13379340:-
THCA	trans	rs4295623	0.553	rs34962960	ENSG00000253893.2	FAM85B	9.72	1.78e-20	5.7e-14	0.54	0.41	Morning vs. evening chronotype;	chr8:11737088	chr8:8167819~8226614:-
THCA	trans	rs13177918	0.677	rs13161099	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs13161417	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs13161156	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs13181401	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs4541646	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs3900644	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs2070844	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.629	rs2070842	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs13171800	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs2070841	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs13177951	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs13177970	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.677	rs13164105	ENSG00000226396.1	RP5-1056L3.3	9.72	1.82e-20	5.81e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:19608114~19608568:+
THCA	trans	rs8010715	0.848	rs927494	ENSG00000238000.1	RP11-274E7.2	9.72	1.87e-20	5.98e-14	0.45	0.41	IgG glycosylation;	chr14:24131181	chr5:98213402~98214121:+
THCA	trans	rs3779195	0.585	rs58699591	ENSG00000225169.1	BRI3P1	-9.71	1.89e-20	6.04e-14	-0.66	-0.41	Sex hormone-binding globulin levels;	chr7:98247392	chr1:100213293~100213670:+
THCA	trans	rs10435719	0.764	rs10103485	ENSG00000253893.2	FAM85B	-9.71	1.91e-20	6.09e-14	-0.55	-0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000223416.3	RPS26P15	9.71	1.94e-20	6.2e-14	0.52	0.41	Cognitive function;	chr12:55981353	chr1:58056133~58056480:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000223416.3	RPS26P15	9.71	1.94e-20	6.2e-14	0.52	0.41	Cognitive function;	chr12:55981956	chr1:58056133~58056480:-
THCA	trans	rs9898641	1	rs9898641	ENSG00000187870.7	RNFT1P3	9.71	1.94e-20	6.21e-14	0.52	0.41	Interleukin-1-beta levels;	chr17:59493672	chr17:20743333~20754501:-
THCA	trans	rs2645424	0.686	rs2294140	ENSG00000256560.1	LINC01486	-9.71	2.03e-20	6.48e-14	-0.49	-0.41	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr12:109354083~109359488:-
THCA	trans	rs13177918	0.677	rs13160685	ENSG00000226396.1	RP5-1056L3.3	9.71	2.03e-20	6.48e-14	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:19608114~19608568:+
THCA	trans	rs9650657	0.504	rs10093053	ENSG00000253893.2	FAM85B	9.7	2.04e-20	6.51e-14	0.54	0.41	Neuroticism;	chr8:11179678	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000223416.3	RPS26P15	9.7	2.05e-20	6.55e-14	0.52	0.41	Cognitive function;	chr12:55982097	chr1:58056133~58056480:-
THCA	trans	rs74781061	1	rs4887166	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.57	0.41	Endometriosis;	chr15:74605257	chr1:81501794~81503468:+
THCA	trans	rs74781061	1	rs6495117	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.57	0.41	Endometriosis;	chr15:74607159	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs7177407	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.58	0.41	Endometriosis;	chr15:74551444	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs8043082	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.58	0.41	Endometriosis;	chr15:74564896	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs8026923	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.58	0.41	Endometriosis;	chr15:74565721	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs7171838	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.58	0.41	Endometriosis;	chr15:74571778	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs6495115	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.58	0.41	Endometriosis;	chr15:74578122	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.858	rs4887162	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.58	0.41	Endometriosis;	chr15:74580159	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs4887163	ENSG00000227288.3	RP5-837I24.1	9.7	2.11e-20	6.74e-14	0.58	0.41	Endometriosis;	chr15:74580405	chr1:81501794~81503468:+
THCA	trans	rs7554547	0.667	rs2050266	ENSG00000261819.1	RP11-680G24.4	9.7	2.2e-20	7e-14	0.58	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11886531	chr16:14988259~14990160:-
THCA	trans	rs7824557	0.507	rs7010590	ENSG00000253893.2	FAM85B	-9.69	2.22e-20	7.06e-14	-0.54	-0.41	Retinal vascular caliber;	chr8:11205373	chr8:8167819~8226614:-
THCA	trans	rs55665837	0.701	rs11023265	ENSG00000236360.2	RP11-334A14.2	9.69	2.26e-20	7.19e-14	0.55	0.41	Vitamin D levels;	chr11:14594492	chr1:52993201~52993702:-
THCA	trans	rs7824557	0.505	rs2736313	ENSG00000253893.2	FAM85B	-9.69	2.34e-20	7.44e-14	-0.54	-0.41	Retinal vascular caliber;	chr8:11229433	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000223416.3	RPS26P15	9.69	2.34e-20	7.45e-14	0.54	0.41	Cognitive function;	chr12:55976127	chr1:58056133~58056480:-
THCA	trans	rs7937890	0.599	rs2597204	ENSG00000236360.2	RP11-334A14.2	9.69	2.36e-20	7.52e-14	0.57	0.41	Mitochondrial DNA levels;	chr11:14459471	chr1:52993201~52993702:-
THCA	trans	rs13177918	0.651	rs13184111	ENSG00000226396.1	RP5-1056L3.3	9.69	2.37e-20	7.55e-14	0.42	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:19608114~19608568:+
THCA	trans	rs7937890	0.572	rs2597202	ENSG00000236360.2	RP11-334A14.2	9.68	2.41e-20	7.66e-14	0.57	0.41	Mitochondrial DNA levels;	chr11:14463099	chr1:52993201~52993702:-
THCA	trans	rs7819412	0.875	rs6981523	ENSG00000253893.2	FAM85B	9.68	2.46e-20	7.82e-14	0.54	0.41	Triglycerides;	chr8:11204283	chr8:8167819~8226614:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-9.68	2.56e-20	8.12e-14	-0.49	-0.41	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
THCA	trans	rs5022636	0.927	rs4522000	ENSG00000180764.13	PIPSL	9.68	2.57e-20	8.17e-14	0.46	0.41	Gut microbiota (functional units);	chr1:151283612	chr10:93958191~93961540:-
THCA	trans	rs1816752	0.905	rs4769348	ENSG00000224976.2	PARP4P2	-9.67	2.7e-20	8.56e-14	-0.49	-0.41	Obesity-related traits;	chr13:24400975	chr13:19349137~19407962:+
THCA	trans	rs12145833	0.596	rs61833906	ENSG00000154608.12	CEP170P1	-9.67	2.71e-20	8.59e-14	-0.6	-0.41	Obesity (early onset extreme);	chr1:243256404	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.665	rs78871868	ENSG00000154608.12	CEP170P1	-9.67	2.71e-20	8.59e-14	-0.6	-0.41	Obesity (early onset extreme);	chr1:243259020	chr4:118467590~118554204:+
THCA	trans	rs1908814	0.516	rs7812563	ENSG00000253893.2	FAM85B	-9.67	2.71e-20	8.6e-14	-0.55	-0.41	Neuroticism;	chr8:11936979	chr8:8167819~8226614:-
THCA	trans	rs4295623	0.585	rs13259242	ENSG00000253893.2	FAM85B	9.67	2.72e-20	8.64e-14	0.54	0.41	Morning vs. evening chronotype;	chr8:11735524	chr8:8167819~8226614:-
THCA	trans	rs10242455	0.717	rs2687134	ENSG00000228834.1	RP11-249L21.4	-9.67	2.77e-20	8.77e-14	-0.78	-0.41	Blood metabolite levels;	chr7:99733419	chr6:108907615~108907873:-
THCA	trans	rs58106596	0.66	rs62197212	ENSG00000259020.3	RP11-529H20.3	9.66	2.85e-20	9.02e-14	0.71	0.41	Lymphocyte counts;White blood cell count;	chr2:231698017	chr14:92026566~92026887:+
THCA	trans	rs12497850	0.864	rs4279134	ENSG00000197582.5	GPX1P1	9.66	2.88e-20	9.11e-14	0.61	0.41	Parkinson's disease;	chr3:49119243	chrX:13378735~13379340:-
THCA	trans	rs1908814	0.516	rs10113062	ENSG00000253893.2	FAM85B	-9.66	2.88e-20	9.14e-14	-0.55	-0.41	Neuroticism;	chr8:11935740	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs10113145	ENSG00000253893.2	FAM85B	-9.66	2.88e-20	9.14e-14	-0.55	-0.41	Neuroticism;	chr8:11935786	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.929	rs8041807	ENSG00000227288.3	RP5-837I24.1	9.66	2.89e-20	9.15e-14	0.58	0.41	Endometriosis;	chr15:74534590	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs12594447	ENSG00000227288.3	RP5-837I24.1	9.66	2.89e-20	9.15e-14	0.58	0.41	Endometriosis;	chr15:74536392	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs1821848	ENSG00000227288.3	RP5-837I24.1	9.66	2.89e-20	9.15e-14	0.58	0.41	Endometriosis;	chr15:74541443	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs8043032	ENSG00000227288.3	RP5-837I24.1	9.66	2.89e-20	9.15e-14	0.58	0.41	Endometriosis;	chr15:74543975	chr1:81501794~81503468:+
THCA	trans	rs13177918	0.626	rs12186649	ENSG00000226396.1	RP5-1056L3.3	9.65	3.07e-20	9.72e-14	0.42	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:19608114~19608568:+
THCA	trans	rs13190036	1	rs6889220	ENSG00000228305.2	AC016734.2	9.65	3.17e-20	1e-13	0.5	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr2:63622178~63622831:-
THCA	trans	rs916888	0.61	rs199530	ENSG00000280022.1	RP11-707O23.1	9.65	3.22e-20	1.02e-13	0.44	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45592621~45593369:+
THCA	trans	rs1355223	0.506	rs6484738	ENSG00000225531.1	RP11-196I18.3	9.65	3.28e-20	1.04e-13	0.53	0.41	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34839311	chr9:107116829~107117557:+
THCA	trans	rs7121616	0.515	rs76088419	ENSG00000234176.1	HSPA8P1	9.64	3.32e-20	1.05e-13	0.72	0.41	Breast cancer;	chr11:123066813	chrX:121203182~121205014:-
THCA	trans	rs616147	0.962	rs545397	ENSG00000214263.2	RPSAP53	9.64	3.32e-20	1.05e-13	0.54	0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr13:67266845~67267706:-
THCA	trans	rs9650657	0.504	rs6601565	ENSG00000253893.2	FAM85B	9.64	3.37e-20	1.07e-13	0.54	0.41	Neuroticism;	chr8:11174719	chr8:8167819~8226614:-
THCA	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	9.64	3.37e-20	1.07e-13	0.53	0.41	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	9.64	3.42e-20	1.08e-13	0.54	0.41	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	9.64	3.42e-20	1.08e-13	0.54	0.41	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-9.64	3.47e-20	1.1e-13	-0.53	-0.41	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
THCA	trans	rs11951515	0.509	rs12521249	ENSG00000174977.8	AC026271.5	9.64	3.48e-20	1.1e-13	0.46	0.41	Metabolite levels  (X-11787);	chr5:43558527	chr17:18650195~18651542:+
THCA	trans	rs10435719	0.744	rs11250175	ENSG00000253893.2	FAM85B	-9.64	3.57e-20	1.12e-13	-0.55	-0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs13252853	ENSG00000253893.2	FAM85B	-9.64	3.57e-20	1.12e-13	-0.55	-0.41	Neuroticism;	chr8:11935465	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs13252854	ENSG00000253893.2	FAM85B	-9.64	3.57e-20	1.12e-13	-0.55	-0.41	Neuroticism;	chr8:11935469	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs13279577	ENSG00000253893.2	FAM85B	-9.64	3.57e-20	1.12e-13	-0.55	-0.41	Neuroticism;	chr8:11935587	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs10112958	ENSG00000253893.2	FAM85B	-9.64	3.57e-20	1.12e-13	-0.55	-0.41	Neuroticism;	chr8:11935631	chr8:8167819~8226614:-
THCA	trans	rs1079467	0.735	rs75941265	ENSG00000233426.3	EIF3FP3	-9.63	3.61e-20	1.14e-13	-0.7	-0.41	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7949542	chr2:58251440~58252525:+
THCA	trans	rs12497850	0.864	rs4521268	ENSG00000197582.5	GPX1P1	9.63	3.66e-20	1.15e-13	0.6	0.41	Parkinson's disease;	chr3:49100471	chrX:13378735~13379340:-
THCA	trans	rs7617480	0.61	rs4955420	ENSG00000197582.5	GPX1P1	9.63	3.66e-20	1.15e-13	0.59	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chrX:13378735~13379340:-
THCA	trans	rs877636	1	rs2292239	ENSG00000227887.1	RPS26P13	9.63	3.71e-20	1.17e-13	0.52	0.41	Cognitive function;	chr12:56088396	chr1:208697369~208697698:-
THCA	trans	rs7937890	0.869	rs2915404	ENSG00000236360.2	RP11-334A14.2	9.63	3.76e-20	1.18e-13	0.56	0.41	Mitochondrial DNA levels;	chr11:14383279	chr1:52993201~52993702:-
THCA	trans	rs13177918	0.629	rs13161261	ENSG00000226396.1	RP5-1056L3.3	9.63	3.81e-20	1.2e-13	0.41	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:19608114~19608568:+
THCA	trans	rs1908814	0.516	rs35391955	ENSG00000253893.2	FAM85B	-9.63	3.81e-20	1.2e-13	-0.55	-0.41	Neuroticism;	chr8:11939219	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.684	rs12799007	ENSG00000236360.2	RP11-334A14.2	9.63	3.82e-20	1.2e-13	0.56	0.41	Mitochondrial DNA levels;	chr11:14404938	chr1:52993201~52993702:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000223416.3	RPS26P15	-9.63	3.85e-20	1.21e-13	-0.52	-0.41	Cognitive function;	chr12:55996852	chr1:58056133~58056480:-
THCA	trans	rs916888	0.821	rs199513	ENSG00000280022.1	RP11-707O23.1	9.62	4.03e-20	1.27e-13	0.49	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45592621~45593369:+
THCA	trans	rs13190036	0.901	rs28684504	ENSG00000228305.2	AC016734.2	9.62	4.05e-20	1.27e-13	0.5	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr2:63622178~63622831:-
THCA	trans	rs7937890	0.56	rs2597194	ENSG00000236360.2	RP11-334A14.2	9.62	4.09e-20	1.29e-13	0.57	0.41	Mitochondrial DNA levels;	chr11:14475723	chr1:52993201~52993702:-
THCA	trans	rs13190036	1	rs4976682	ENSG00000228305.2	AC016734.2	9.62	4.15e-20	1.3e-13	0.49	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr2:63622178~63622831:-
THCA	trans	rs5022636	0.891	rs4971027	ENSG00000180764.13	PIPSL	9.61	4.29e-20	1.35e-13	0.46	0.41	Gut microbiota (functional units);	chr1:151277945	chr10:93958191~93961540:-
THCA	trans	rs7617480	0.61	rs10865954	ENSG00000197582.5	GPX1P1	9.61	4.44e-20	1.39e-13	0.59	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chrX:13378735~13379340:-
THCA	trans	rs877636	1	rs2292239	ENSG00000242970.2	AC068522.4	9.61	4.46e-20	1.4e-13	0.55	0.41	Cognitive function;	chr12:56088396	chr8:58588420~58588764:-
THCA	trans	rs10242455	0.717	rs4646461	ENSG00000228834.1	RP11-249L21.4	9.61	4.48e-20	1.41e-13	0.81	0.41	Blood metabolite levels;	chr7:99733850	chr6:108907615~108907873:-
THCA	trans	rs72615157	0.561	rs113401658	ENSG00000228546.2	CTA-313A17.3	9.6	4.66e-20	1.46e-13	0.69	0.41	Lung function (FEV1/FVC);	chr7:100260882	chr7:102337316~102339115:+
THCA	trans	rs72615157	0.561	rs113844570	ENSG00000228546.2	CTA-313A17.3	9.6	4.66e-20	1.46e-13	0.69	0.41	Lung function (FEV1/FVC);	chr7:100276155	chr7:102337316~102339115:+
THCA	trans	rs804280	0.543	rs13261205	ENSG00000253893.2	FAM85B	-9.6	4.67e-20	1.46e-13	-0.55	-0.41	Myopia (pathological);	chr8:11933707	chr8:8167819~8226614:-
THCA	trans	rs804280	0.518	rs34266352	ENSG00000253893.2	FAM85B	-9.6	4.67e-20	1.46e-13	-0.55	-0.41	Myopia (pathological);	chr8:11933953	chr8:8167819~8226614:-
THCA	trans	rs804280	0.542	rs34117651	ENSG00000253893.2	FAM85B	-9.6	4.67e-20	1.46e-13	-0.55	-0.41	Myopia (pathological);	chr8:11934108	chr8:8167819~8226614:-
THCA	trans	rs8010715	0.848	rs2277483	ENSG00000238000.1	RP11-274E7.2	9.6	4.82e-20	1.51e-13	0.44	0.4	IgG glycosylation;	chr14:24122683	chr5:98213402~98214121:+
THCA	trans	rs55665837	0.701	rs1522633	ENSG00000236360.2	RP11-334A14.2	9.6	4.88e-20	1.53e-13	0.56	0.4	Vitamin D levels;	chr11:14623692	chr1:52993201~52993702:-
THCA	trans	rs1908814	0.516	rs60176945	ENSG00000253893.2	FAM85B	-9.6	4.94e-20	1.55e-13	-0.55	-0.4	Neuroticism;	chr8:11939165	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs56102998	ENSG00000253893.2	FAM85B	-9.6	4.94e-20	1.55e-13	-0.55	-0.4	Neuroticism;	chr8:11939166	chr8:8167819~8226614:-
THCA	trans	rs877636	1	rs877636	ENSG00000242970.2	AC068522.4	-9.59	5.04e-20	1.58e-13	-0.55	-0.4	Cognitive function;	chr12:56086799	chr8:58588420~58588764:-
THCA	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	9.59	5.05e-20	1.58e-13	0.54	0.4	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
THCA	trans	rs74781061	0.929	rs8025915	ENSG00000227288.3	RP5-837I24.1	9.59	5.21e-20	1.63e-13	0.57	0.4	Endometriosis;	chr15:74578188	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs16969612	ENSG00000227288.3	RP5-837I24.1	-9.59	5.25e-20	1.64e-13	-0.57	-0.4	Endometriosis;	chr15:74514096	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.79	rs6495105	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74480512	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.858	rs12592906	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74481811	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs11855521	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74488038	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs55662551	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74488745	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.858	rs79923136	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74492219	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs12439505	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74494021	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.858	rs35752918	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74494240	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs79534854	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74494257	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.858	rs4278699	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74500057	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs8038730	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74501003	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs7178219	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74502552	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs6495109	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74504720	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs8037436	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74506167	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs4887155	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74512119	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs11072490	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74515169	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs1821847	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74516873	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs7173006	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74517792	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs78796673	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74520186	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs4261483	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74520993	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs8041030	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74525726	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs8028163	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74530360	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs11072492	ENSG00000227288.3	RP5-837I24.1	9.59	5.25e-20	1.64e-13	0.57	0.4	Endometriosis;	chr15:74531782	chr1:81501794~81503468:+
THCA	trans	rs10037055	0.853	rs9313749	ENSG00000226986.4	RP11-543B16.2	-9.58	5.46e-20	1.71e-13	-0.5	-0.4	Migraine without aura;	chr5:177170693	chr1:211207239~211207897:+
THCA	trans	rs1908814	0.516	rs58869268	ENSG00000253893.2	FAM85B	-9.58	5.52e-20	1.72e-13	-0.55	-0.4	Neuroticism;	chr8:11939586	chr8:8167819~8226614:-
THCA	trans	rs6732160	0.845	rs13413175	ENSG00000236165.1	PRADC1P1	9.57	5.91e-20	1.84e-13	0.53	0.4	Intelligence (multi-trait analysis);	chr2:73162788	chr3:36976316~36976840:+
THCA	trans	rs74781061	0.929	rs6495118	ENSG00000227288.3	RP5-837I24.1	9.57	6.17e-20	1.92e-13	0.56	0.4	Endometriosis;	chr15:74619671	chr1:81501794~81503468:+
THCA	trans	rs10435719	0.899	rs11250177	ENSG00000253893.2	FAM85B	-9.57	6.29e-20	1.96e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:8167819~8226614:-
THCA	trans	rs916888	0.61	rs142167	ENSG00000280022.1	RP11-707O23.1	9.57	6.31e-20	1.96e-13	0.43	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45592621~45593369:+
THCA	trans	rs4295623	0.585	rs34421088	ENSG00000253893.2	FAM85B	9.57	6.31e-20	1.97e-13	0.53	0.4	Morning vs. evening chronotype;	chr8:11731533	chr8:8167819~8226614:-
THCA	trans	rs12497850	0.931	rs4974082	ENSG00000197582.5	GPX1P1	9.57	6.32e-20	1.97e-13	0.6	0.4	Parkinson's disease;	chr3:48961890	chrX:13378735~13379340:-
THCA	trans	rs9876781	0.624	rs12491849	ENSG00000225528.1	RP3-370M22.8	-9.57	6.33e-20	1.97e-13	-0.5	-0.4	Longevity;	chr3:48489975	chr22:39960397~39964683:+
THCA	trans	rs1908814	0.516	rs4840597	ENSG00000253893.2	FAM85B	-9.56	6.38e-20	1.99e-13	-0.55	-0.4	Neuroticism;	chr8:11938559	chr8:8167819~8226614:-
THCA	trans	rs804280	0.509	rs4841639	ENSG00000253893.2	FAM85B	-9.56	6.38e-20	1.99e-13	-0.55	-0.4	Myopia (pathological);	chr8:11938584	chr8:8167819~8226614:-
THCA	trans	rs3779195	0.524	rs80195155	ENSG00000225169.1	BRI3P1	-9.56	6.39e-20	1.99e-13	-0.66	-0.4	Sex hormone-binding globulin levels;	chr7:98248841	chr1:100213293~100213670:+
THCA	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
THCA	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	9.56	6.42e-20	1.99e-13	0.52	0.4	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
THCA	trans	rs7833986	0.501	rs2719227	ENSG00000244245.1	RP11-120B7.1	-9.56	6.45e-20	2e-13	-0.52	-0.4	Height;	chr8:56131235	chr5:108593609~108593967:+
THCA	trans	rs10435719	0.753	rs9694940	ENSG00000253893.2	FAM85B	-9.56	6.47e-20	2.01e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs10113042	ENSG00000253893.2	FAM85B	-9.56	6.49e-20	2.01e-13	-0.54	-0.4	Neuroticism;	chr8:11935669	chr8:8167819~8226614:-
THCA	trans	rs55665837	0.701	rs10160597	ENSG00000236360.2	RP11-334A14.2	9.56	6.59e-20	2.05e-13	0.54	0.4	Vitamin D levels;	chr11:14582446	chr1:52993201~52993702:-
THCA	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	9.56	6.76e-20	2.1e-13	0.52	0.4	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
THCA	trans	rs10435719	0.867	rs34465618	ENSG00000253893.2	FAM85B	-9.55	6.94e-20	2.15e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.867	rs34583868	ENSG00000253893.2	FAM85B	-9.55	6.94e-20	2.15e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	9.55	7.07e-20	2.19e-13	0.52	0.4	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
THCA	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	9.55	7.1e-20	2.2e-13	0.63	0.4	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
THCA	trans	rs9650657	0.572	rs11250098	ENSG00000253893.2	FAM85B	9.55	7.17e-20	2.22e-13	0.52	0.4	Neuroticism;	chr8:10961097	chr8:8167819~8226614:-
THCA	trans	rs1045902	0.583	rs2303904	ENSG00000236165.1	PRADC1P1	-9.54	7.53e-20	2.33e-13	-0.54	-0.4	Intelligence (multi-trait analysis);	chr2:73220647	chr3:36976316~36976840:+
THCA	trans	rs10435719	0.867	rs6999030	ENSG00000253893.2	FAM85B	-9.54	7.56e-20	2.34e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.834	rs6985792	ENSG00000253893.2	FAM85B	-9.54	7.56e-20	2.34e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000242970.2	AC068522.4	9.54	7.63e-20	2.36e-13	0.57	0.4	Cognitive function;	chr12:55976127	chr8:58588420~58588764:-
THCA	trans	rs916888	0.61	rs199438	ENSG00000280022.1	RP11-707O23.1	-9.54	7.67e-20	2.37e-13	-0.43	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45592621~45593369:+
THCA	trans	rs1040555	0.516	rs242547	ENSG00000253915.1	MAPRE1P1	9.54	7.69e-20	2.38e-13	0.53	0.4	Lymphocyte percentage of white cells;	chr20:32830775	chr8:135625185~135625981:-
THCA	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	9.54	7.7e-20	2.38e-13	0.52	0.4	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000223416.3	RPS26P15	9.54	7.76e-20	2.4e-13	0.52	0.4	Cognitive function;	chr12:55980911	chr1:58056133~58056480:-
THCA	trans	rs7824557	0.569	rs2409718	ENSG00000253893.2	FAM85B	9.54	7.99e-20	2.47e-13	0.53	0.4	Retinal vascular caliber;	chr8:11155467	chr8:8167819~8226614:-
THCA	trans	rs916888	0.61	rs199453	ENSG00000280022.1	RP11-707O23.1	-9.54	8.07e-20	2.49e-13	-0.43	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45592621~45593369:+
THCA	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	9.53	8.1e-20	2.5e-13	0.53	0.4	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
THCA	trans	rs7819412	0.805	rs2409710	ENSG00000253893.2	FAM85B	9.53	8.2e-20	2.53e-13	0.54	0.4	Triglycerides;	chr8:11122311	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	9.53	8.23e-20	2.54e-13	0.52	0.4	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
THCA	trans	rs74781061	0.929	rs12439113	ENSG00000227288.3	RP5-837I24.1	9.53	8.26e-20	2.55e-13	0.57	0.4	Endometriosis;	chr15:74563806	chr1:81501794~81503468:+
THCA	trans	rs55665837	0.701	rs11023272	ENSG00000236360.2	RP11-334A14.2	9.53	8.27e-20	2.55e-13	0.54	0.4	Vitamin D levels;	chr11:14608824	chr1:52993201~52993702:-
THCA	trans	rs55665837	0.665	rs11023273	ENSG00000236360.2	RP11-334A14.2	9.53	8.27e-20	2.55e-13	0.54	0.4	Vitamin D levels;	chr11:14609273	chr1:52993201~52993702:-
THCA	trans	rs6477998	0.58	rs10817467	ENSG00000238072.1	RP11-305M3.2	9.53	8.3e-20	2.56e-13	0.66	0.4	Hematology traits;	chr9:113246803	chr7:129410113~129410370:-
THCA	trans	rs12497850	0.931	rs7628719	ENSG00000197582.5	GPX1P1	9.53	8.35e-20	2.58e-13	0.6	0.4	Parkinson's disease;	chr3:48958054	chrX:13378735~13379340:-
THCA	trans	rs10435719	0.867	rs62493601	ENSG00000253893.2	FAM85B	-9.53	8.58e-20	2.65e-13	-0.54	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:8167819~8226614:-
THCA	trans	rs804280	0.509	rs13268030	ENSG00000253893.2	FAM85B	-9.53	8.62e-20	2.66e-13	-0.54	-0.4	Myopia (pathological);	chr8:11925564	chr8:8167819~8226614:-
THCA	trans	rs13190036	1	rs625882	ENSG00000228305.2	AC016734.2	-9.53	8.7e-20	2.68e-13	-0.49	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr2:63622178~63622831:-
THCA	trans	rs11098499	0.954	rs6820115	ENSG00000275858.1	RP11-291L22.8	9.52	8.88e-20	2.74e-13	0.51	0.4	Corneal astigmatism;	chr4:119477027	chr10:38450738~38451069:-
THCA	trans	rs5022636	0.927	rs10788803	ENSG00000180764.13	PIPSL	9.52	8.9e-20	2.74e-13	0.45	0.4	Gut microbiota (functional units);	chr1:151291306	chr10:93958191~93961540:-
THCA	trans	rs10435719	0.78	rs9692662	ENSG00000253893.2	FAM85B	-9.52	8.94e-20	2.75e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.899	rs9693925	ENSG00000253893.2	FAM85B	-9.52	8.94e-20	2.75e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:8167819~8226614:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000244604.1	RP11-713H12.1	9.52	9.18e-20	2.83e-13	0.51	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:8561230~8561576:+
THCA	trans	rs1039766	1	rs7558347	ENSG00000224334.1	AP000357.4	9.52	9.33e-20	2.87e-13	0.63	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65245666	chr22:24686923~24688087:+
THCA	trans	rs12497850	0.931	rs7626445	ENSG00000197582.5	GPX1P1	9.52	9.39e-20	2.89e-13	0.6	0.4	Parkinson's disease;	chr3:49077111	chrX:13378735~13379340:-
THCA	trans	rs10435719	0.902	rs7459983	ENSG00000253893.2	FAM85B	-9.52	9.41e-20	2.9e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.929	rs59946128	ENSG00000227288.3	RP5-837I24.1	9.51	9.65e-20	2.97e-13	0.57	0.4	Endometriosis;	chr15:74493006	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs60777494	ENSG00000227288.3	RP5-837I24.1	9.51	9.65e-20	2.97e-13	0.57	0.4	Endometriosis;	chr15:74493007	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs57271230	ENSG00000227288.3	RP5-837I24.1	9.51	9.65e-20	2.97e-13	0.57	0.4	Endometriosis;	chr15:74493018	chr1:81501794~81503468:+
THCA	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	9.51	9.71e-20	2.98e-13	0.46	0.4	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
THCA	trans	rs1816752	1	rs7988810	ENSG00000224976.2	PARP4P2	-9.51	9.9e-20	3.04e-13	-0.48	-0.4	Obesity-related traits;	chr13:24444958	chr13:19349137~19407962:+
THCA	trans	rs10435719	0.718	rs7813935	ENSG00000253893.2	FAM85B	-9.51	1e-19	3.08e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.504	rs7830734	ENSG00000253893.2	FAM85B	-9.51	1e-19	3.08e-13	-0.55	-0.4	Neuroticism;	chr8:11938130	chr8:8167819~8226614:-
THCA	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	9.51	1e-19	3.09e-13	0.46	0.4	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
THCA	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	9.51	1e-19	3.09e-13	0.46	0.4	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
THCA	trans	rs5022636	1	rs5022636	ENSG00000180764.13	PIPSL	9.51	1.01e-19	3.11e-13	0.46	0.4	Gut microbiota (functional units);	chr1:151322585	chr10:93958191~93961540:-
THCA	trans	rs6732160	0.845	rs72807999	ENSG00000236165.1	PRADC1P1	9.51	1.02e-19	3.12e-13	0.53	0.4	Intelligence (multi-trait analysis);	chr2:73164567	chr3:36976316~36976840:+
THCA	trans	rs2898290	0.617	rs13273172	ENSG00000253893.2	FAM85B	9.5	1.03e-19	3.17e-13	0.54	0.4	Systolic blood pressure;	chr8:11603602	chr8:8167819~8226614:-
THCA	trans	rs66887589	0.592	rs11731571	ENSG00000275858.1	RP11-291L22.8	9.5	1.04e-19	3.19e-13	0.5	0.4	Diastolic blood pressure;	chr4:119300030	chr10:38450738~38451069:-
THCA	trans	rs7819412	0.838	rs3021494	ENSG00000253893.2	FAM85B	9.5	1.05e-19	3.22e-13	0.54	0.4	Triglycerides;	chr8:11126024	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.929	rs2068982	ENSG00000227288.3	RP5-837I24.1	-9.5	1.05e-19	3.22e-13	-0.56	-0.4	Endometriosis;	chr15:74623547	chr1:81501794~81503468:+
THCA	trans	rs10435719	0.902	rs6601633	ENSG00000253893.2	FAM85B	9.5	1.07e-19	3.27e-13	0.54	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:8167819~8226614:-
THCA	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	9.5	1.09e-19	3.33e-13	0.53	0.4	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	9.5	1.09e-19	3.33e-13	0.53	0.4	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
THCA	trans	rs74781061	0.929	rs4886599	ENSG00000227288.3	RP5-837I24.1	9.5	1.1e-19	3.37e-13	0.57	0.4	Endometriosis;	chr15:74484442	chr1:81501794~81503468:+
THCA	trans	rs1039766	1	rs268870	ENSG00000224334.1	AP000357.4	9.49	1.14e-19	3.49e-13	0.62	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr22:24686923~24688087:+
THCA	trans	rs7312770	1	rs7312770	ENSG00000212829.8	RPS26P3	-9.49	1.16e-19	3.54e-13	-0.48	-0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:9090898~9091245:+
THCA	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	9.49	1.16e-19	3.55e-13	0.53	0.4	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
THCA	trans	rs1816752	0.935	rs3816219	ENSG00000224976.2	PARP4P2	-9.49	1.19e-19	3.63e-13	-0.48	-0.4	Obesity-related traits;	chr13:24442995	chr13:19349137~19407962:+
THCA	trans	rs13190036	1	rs6880798	ENSG00000226986.4	RP11-543B16.2	9.48	1.22e-19	3.73e-13	0.57	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr1:211207239~211207897:+
THCA	trans	rs10435719	0.647	rs10092605	ENSG00000253893.2	FAM85B	-9.48	1.22e-19	3.74e-13	-0.54	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.867	rs35778860	ENSG00000253893.2	FAM85B	-9.48	1.24e-19	3.8e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.631	rs7118886	ENSG00000236360.2	RP11-334A14.2	9.48	1.27e-19	3.88e-13	0.55	0.4	Mitochondrial DNA levels;	chr11:14405971	chr1:52993201~52993702:-
THCA	trans	rs864643	0.513	rs1398666	ENSG00000188856.6	RPSAP47	9.48	1.27e-19	3.88e-13	0.59	0.4	Attention deficit hyperactivity disorder;	chr3:39475540	chr8:80558870~80559757:+
THCA	trans	rs864643	0.513	rs1768202	ENSG00000188856.6	RPSAP47	9.48	1.27e-19	3.88e-13	0.59	0.4	Attention deficit hyperactivity disorder;	chr3:39476053	chr8:80558870~80559757:+
THCA	trans	rs1039766	1	rs268871	ENSG00000224334.1	AP000357.4	9.48	1.29e-19	3.94e-13	0.61	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr22:24686923~24688087:+
THCA	trans	rs10435719	0.902	rs7459545	ENSG00000253893.2	FAM85B	-9.48	1.3e-19	3.98e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.775	rs6601564	ENSG00000253893.2	FAM85B	9.47	1.32e-19	4.03e-13	0.54	0.4	Triglycerides;	chr8:11124541	chr8:8167819~8226614:-
THCA	trans	rs73110464	0.505	rs2638503	ENSG00000220378.3	KRT8P42	-9.47	1.36e-19	4.15e-13	-0.55	-0.4	Cancer (pleiotropy);	chr12:52913585	chr6:134296997~134298695:-
THCA	trans	rs3779195	0.591	rs77968419	ENSG00000225169.1	BRI3P1	-9.47	1.36e-19	4.15e-13	-0.65	-0.4	Sex hormone-binding globulin levels;	chr7:98237168	chr1:100213293~100213670:+
THCA	trans	rs7937890	0.598	rs10734225	ENSG00000236360.2	RP11-334A14.2	9.47	1.37e-19	4.17e-13	0.56	0.4	Mitochondrial DNA levels;	chr11:14421448	chr1:52993201~52993702:-
THCA	trans	rs1039766	1	rs268861	ENSG00000224334.1	AP000357.4	9.47	1.37e-19	4.19e-13	0.61	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr22:24686923~24688087:+
THCA	trans	rs1039766	1	rs268862	ENSG00000224334.1	AP000357.4	9.47	1.37e-19	4.19e-13	0.61	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr22:24686923~24688087:+
THCA	trans	rs616147	0.85	rs631312	ENSG00000214263.2	RPSAP53	-9.47	1.39e-19	4.24e-13	-0.53	-0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr13:67266845~67267706:-
THCA	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	9.47	1.39e-19	4.25e-13	0.51	0.4	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
THCA	trans	rs4276421	0.509	rs6451806	ENSG00000231752.4	EMBP1	-9.47	1.42e-19	4.33e-13	-0.58	-0.4	P wave duration;	chr5:45530059	chr1:121519112~121571892:+
THCA	trans	rs12497850	0.931	rs9311434	ENSG00000197582.5	GPX1P1	9.46	1.46e-19	4.44e-13	0.59	0.4	Parkinson's disease;	chr3:48846714	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs7623023	ENSG00000197582.5	GPX1P1	9.46	1.46e-19	4.44e-13	0.59	0.4	Parkinson's disease;	chr3:48876805	chrX:13378735~13379340:-
THCA	trans	rs4295623	0.559	rs4841600	ENSG00000253893.2	FAM85B	-9.46	1.5e-19	4.56e-13	-0.53	-0.4	Morning vs. evening chronotype;	chr8:11830639	chr8:8167819~8226614:-
THCA	trans	rs8010715	0.52	rs12435994	ENSG00000238000.1	RP11-274E7.2	9.46	1.52e-19	4.62e-13	0.44	0.4	IgG glycosylation;	chr14:24120252	chr5:98213402~98214121:+
THCA	trans	rs8010715	0.596	rs12435995	ENSG00000238000.1	RP11-274E7.2	9.46	1.52e-19	4.62e-13	0.44	0.4	IgG glycosylation;	chr14:24120255	chr5:98213402~98214121:+
THCA	trans	rs12497850	1	rs1352420	ENSG00000197582.5	GPX1P1	9.46	1.52e-19	4.63e-13	0.6	0.4	Parkinson's disease;	chr3:48719858	chrX:13378735~13379340:-
THCA	trans	rs877636	1	rs705696	ENSG00000242970.2	AC068522.4	9.45	1.56e-19	4.74e-13	0.57	0.4	Cognitive function;	chr12:56086864	chr8:58588420~58588764:-
THCA	trans	rs73110464	0.505	rs2682296	ENSG00000220378.3	KRT8P42	-9.45	1.57e-19	4.78e-13	-0.55	-0.4	Cancer (pleiotropy);	chr12:52914481	chr6:134296997~134298695:-
THCA	trans	rs916888	0.61	rs199454	ENSG00000280022.1	RP11-707O23.1	9.45	1.58e-19	4.79e-13	0.43	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45592621~45593369:+
THCA	trans	rs13190036	0.748	rs28395268	ENSG00000226986.4	RP11-543B16.2	9.45	1.6e-19	4.87e-13	0.52	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr1:211207239~211207897:+
THCA	trans	rs10435719	0.509	rs13248956	ENSG00000253893.2	FAM85B	-9.45	1.62e-19	4.91e-13	-0.54	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932259	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.528	rs13250020	ENSG00000253893.2	FAM85B	-9.45	1.62e-19	4.91e-13	-0.54	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932260	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.929	rs4887153	ENSG00000227288.3	RP5-837I24.1	9.45	1.62e-19	4.93e-13	0.56	0.4	Endometriosis;	chr15:74484701	chr1:81501794~81503468:+
THCA	trans	rs12497850	0.931	rs7431710	ENSG00000197582.5	GPX1P1	9.45	1.64e-19	4.99e-13	0.59	0.4	Parkinson's disease;	chr3:48898150	chrX:13378735~13379340:-
THCA	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	9.45	1.66e-19	5.03e-13	0.53	0.4	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
THCA	trans	rs616147	0.962	rs1513219	ENSG00000214263.2	RPSAP53	9.44	1.67e-19	5.08e-13	0.53	0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr13:67266845~67267706:-
THCA	trans	rs916888	0.61	rs199444	ENSG00000280022.1	RP11-707O23.1	-9.44	1.69e-19	5.12e-13	-0.43	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45592621~45593369:+
THCA	trans	rs916888	0.61	rs199442	ENSG00000280022.1	RP11-707O23.1	-9.44	1.69e-19	5.12e-13	-0.43	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45592621~45593369:+
THCA	trans	rs13190036	1	rs28580074	ENSG00000228305.2	AC016734.2	9.44	1.75e-19	5.3e-13	0.49	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr2:63622178~63622831:-
THCA	trans	rs867371	0.722	rs8033050	ENSG00000235370.6	DNM1P51	-9.44	1.75e-19	5.31e-13	-0.5	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:84398316~84411701:-
THCA	trans	rs4911253	0.509	rs66499347	ENSG00000253915.1	MAPRE1P1	-9.44	1.75e-19	5.31e-13	-0.53	-0.4	Lymphocyte counts;	chr20:32860890	chr8:135625185~135625981:-
THCA	trans	rs10435719	0.902	rs4840599	ENSG00000253893.2	FAM85B	9.44	1.76e-19	5.33e-13	0.54	0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:8167819~8226614:-
THCA	trans	rs616147	0.816	rs1768190	ENSG00000214263.2	RPSAP53	9.44	1.78e-19	5.39e-13	0.53	0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr13:67266845~67267706:-
THCA	trans	rs7662987	1	rs17595424	ENSG00000233859.2	ADH5P4	9.44	1.78e-19	5.41e-13	0.82	0.4	Smoking initiation;	chr4:99072718	chr6:65836930~65838039:-
THCA	trans	rs1079467	0.73	rs74933956	ENSG00000233426.3	EIF3FP3	-9.44	1.79e-19	5.42e-13	-0.69	-0.4	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950507	chr2:58251440~58252525:+
THCA	trans	rs1079467	0.73	rs77880011	ENSG00000233426.3	EIF3FP3	-9.44	1.79e-19	5.42e-13	-0.69	-0.4	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950656	chr2:58251440~58252525:+
THCA	trans	rs1816752	0.746	rs9511270	ENSG00000224976.2	PARP4P2	-9.43	1.82e-19	5.5e-13	-0.47	-0.4	Obesity-related traits;	chr13:24444542	chr13:19349137~19407962:+
THCA	trans	rs864643	0.513	rs481523	ENSG00000188856.6	RPSAP47	9.43	1.82e-19	5.52e-13	0.59	0.4	Attention deficit hyperactivity disorder;	chr3:39477849	chr8:80558870~80559757:+
THCA	trans	rs12497850	0.931	rs6791542	ENSG00000197582.5	GPX1P1	9.43	1.82e-19	5.52e-13	0.59	0.4	Parkinson's disease;	chr3:48749786	chrX:13378735~13379340:-
THCA	trans	rs7662987	1	rs13119035	ENSG00000233859.2	ADH5P4	9.43	1.83e-19	5.52e-13	0.83	0.4	Smoking initiation;	chr4:99077979	chr6:65836930~65838039:-
THCA	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	9.43	1.85e-19	5.59e-13	0.52	0.4	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
THCA	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	9.43	1.87e-19	5.66e-13	0.51	0.4	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
THCA	trans	rs916888	0.61	rs199446	ENSG00000280022.1	RP11-707O23.1	9.43	1.89e-19	5.7e-13	0.43	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45592621~45593369:+
THCA	trans	rs66887589	0.87	rs10518336	ENSG00000275858.1	RP11-291L22.8	9.43	1.91e-19	5.78e-13	0.49	0.4	Diastolic blood pressure;	chr4:119601779	chr10:38450738~38451069:-
THCA	trans	rs55665837	0.701	rs12787709	ENSG00000236360.2	RP11-334A14.2	9.43	1.92e-19	5.81e-13	0.54	0.4	Vitamin D levels;	chr11:14617711	chr1:52993201~52993702:-
THCA	trans	rs13190036	1	rs59737888	ENSG00000228305.2	AC016734.2	-9.42	1.99e-19	6.01e-13	-0.5	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr2:63622178~63622831:-
THCA	trans	rs13190036	1	rs34832871	ENSG00000228305.2	AC016734.2	-9.42	2e-19	6.03e-13	-0.5	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr2:63622178~63622831:-
THCA	trans	rs66887589	0.72	rs2036858	ENSG00000275858.1	RP11-291L22.8	9.42	2.01e-19	6.07e-13	0.49	0.4	Diastolic blood pressure;	chr4:119328082	chr10:38450738~38451069:-
THCA	trans	rs74781061	0.929	rs12442097	ENSG00000227288.3	RP5-837I24.1	9.42	2.02e-19	6.1e-13	0.56	0.4	Endometriosis;	chr15:74554792	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs8029215	ENSG00000227288.3	RP5-837I24.1	9.42	2.02e-19	6.1e-13	0.56	0.4	Endometriosis;	chr15:74561147	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs4887159	ENSG00000227288.3	RP5-837I24.1	9.42	2.02e-19	6.1e-13	0.56	0.4	Endometriosis;	chr15:74573541	chr1:81501794~81503468:+
THCA	trans	rs72615157	0.612	rs7786505	ENSG00000228546.2	CTA-313A17.3	9.42	2.05e-19	6.18e-13	0.62	0.4	Lung function (FEV1/FVC);	chr7:100219962	chr7:102337316~102339115:+
THCA	trans	rs72615157	0.613	rs56089143	ENSG00000228546.2	CTA-313A17.3	9.42	2.05e-19	6.18e-13	0.62	0.4	Lung function (FEV1/FVC);	chr7:100222221	chr7:102337316~102339115:+
THCA	trans	rs72615157	0.664	rs6953580	ENSG00000228546.2	CTA-313A17.3	9.42	2.05e-19	6.18e-13	0.62	0.4	Lung function (FEV1/FVC);	chr7:100227652	chr7:102337316~102339115:+
THCA	trans	rs7662987	1	rs11547772	ENSG00000233859.2	ADH5P4	9.42	2.06e-19	6.2e-13	0.82	0.4	Smoking initiation;	chr4:99071642	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs28730640	ENSG00000233859.2	ADH5P4	9.42	2.06e-19	6.2e-13	0.82	0.4	Smoking initiation;	chr4:99072902	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs7658118	ENSG00000233859.2	ADH5P4	9.42	2.06e-19	6.2e-13	0.82	0.4	Smoking initiation;	chr4:99073457	chr6:65836930~65838039:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000224553.1	AC008065.1	9.42	2.1e-19	6.32e-13	0.47	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr2:171374931~171375278:-
THCA	trans	rs916888	0.647	rs199449	ENSG00000280022.1	RP11-707O23.1	-9.42	2.1e-19	6.33e-13	-0.43	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45592621~45593369:+
THCA	trans	rs66887589	0.72	rs11724758	ENSG00000275858.1	RP11-291L22.8	9.42	2.1e-19	6.34e-13	0.49	0.4	Diastolic blood pressure;	chr4:119318723	chr10:38450738~38451069:-
THCA	trans	rs867371	0.762	rs12905578	ENSG00000235370.6	DNM1P51	9.42	2.11e-19	6.37e-13	0.5	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:84398316~84411701:-
THCA	trans	rs867371	0.762	rs1846910	ENSG00000235370.6	DNM1P51	-9.42	2.11e-19	6.37e-13	-0.5	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:84398316~84411701:-
THCA	trans	rs3806843	0.735	rs2563335	ENSG00000231043.3	AC007238.1	-9.42	2.12e-19	6.39e-13	-0.46	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr2:58460292~58462032:-
THCA	trans	rs9329221	0.682	rs6982308	ENSG00000253893.2	FAM85B	9.41	2.14e-19	6.45e-13	0.51	0.4	Neuroticism;	chr8:10336262	chr8:8167819~8226614:-
THCA	trans	rs5022636	0.927	rs10888409	ENSG00000180764.13	PIPSL	9.41	2.15e-19	6.47e-13	0.45	0.4	Gut microbiota (functional units);	chr1:151299306	chr10:93958191~93961540:-
THCA	trans	rs7662987	1	rs7662987	ENSG00000233859.2	ADH5P4	9.41	2.17e-19	6.55e-13	0.83	0.4	Smoking initiation;	chr4:99070491	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs7658127	ENSG00000233859.2	ADH5P4	9.41	2.17e-19	6.55e-13	0.83	0.4	Smoking initiation;	chr4:99073471	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs4699699	ENSG00000233859.2	ADH5P4	9.41	2.17e-19	6.55e-13	0.83	0.4	Smoking initiation;	chr4:99076028	chr6:65836930~65838039:-
THCA	trans	rs7662987	0.938	rs13118409	ENSG00000233859.2	ADH5P4	9.41	2.17e-19	6.55e-13	0.83	0.4	Smoking initiation;	chr4:99077585	chr6:65836930~65838039:-
THCA	trans	rs1816752	0.806	rs3816218	ENSG00000224976.2	PARP4P2	-9.41	2.2e-19	6.61e-13	-0.47	-0.4	Obesity-related traits;	chr13:24443033	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.666	rs7994022	ENSG00000224976.2	PARP4P2	-9.41	2.2e-19	6.61e-13	-0.47	-0.4	Obesity-related traits;	chr13:24443092	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.776	rs7998843	ENSG00000224976.2	PARP4P2	-9.41	2.2e-19	6.61e-13	-0.47	-0.4	Obesity-related traits;	chr13:24443147	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.712	rs6490932	ENSG00000224976.2	PARP4P2	-9.41	2.2e-19	6.61e-13	-0.47	-0.4	Obesity-related traits;	chr13:24443313	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.713	rs7336357	ENSG00000224976.2	PARP4P2	-9.41	2.2e-19	6.61e-13	-0.47	-0.4	Obesity-related traits;	chr13:24443452	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.683	rs7330532	ENSG00000224976.2	PARP4P2	-9.41	2.2e-19	6.61e-13	-0.47	-0.4	Obesity-related traits;	chr13:24443453	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.59	rs61947036	ENSG00000224976.2	PARP4P2	-9.41	2.2e-19	6.61e-13	-0.47	-0.4	Obesity-related traits;	chr13:24443544	chr13:19349137~19407962:+
THCA	trans	rs12709013	0.792	rs12928733	ENSG00000233719.3	GOT2P3	9.41	2.21e-19	6.66e-13	0.49	0.4	Blood metabolite ratios;	chr16:58807216	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs62066381	ENSG00000233719.3	GOT2P3	9.41	2.23e-19	6.69e-13	0.49	0.4	Blood metabolite ratios;	chr16:58807981	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs36098613	ENSG00000233719.3	GOT2P3	9.41	2.23e-19	6.69e-13	0.49	0.4	Blood metabolite ratios;	chr16:58810562	chr12:9641802~9643007:+
THCA	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	9.41	2.23e-19	6.7e-13	0.52	0.4	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	9.41	2.23e-19	6.7e-13	0.52	0.4	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	9.41	2.23e-19	6.7e-13	0.52	0.4	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
THCA	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	9.41	2.23e-19	6.7e-13	0.52	0.4	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
THCA	trans	rs4911253	0.527	rs853859	ENSG00000253915.1	MAPRE1P1	9.41	2.23e-19	6.71e-13	0.52	0.4	Lymphocyte counts;	chr20:32814463	chr8:135625185~135625981:-
THCA	trans	rs7662987	1	rs6852848	ENSG00000233859.2	ADH5P4	-9.41	2.24e-19	6.74e-13	-0.83	-0.4	Smoking initiation;	chr4:99080781	chr6:65836930~65838039:-
THCA	trans	rs1816752	0.805	rs61614647	ENSG00000224976.2	PARP4P2	-9.41	2.24e-19	6.75e-13	-0.47	-0.4	Obesity-related traits;	chr13:24441829	chr13:19349137~19407962:+
THCA	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	9.41	2.28e-19	6.86e-13	0.63	0.4	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	9.41	2.28e-19	6.86e-13	0.63	0.4	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
THCA	trans	rs9581094	0.505	rs6490945	ENSG00000237917.1	PARP4P1	9.41	2.29e-19	6.88e-13	0.54	0.4	Sudden cardiac arrest;	chr13:24514056	chrY:26594851~26634652:-
THCA	trans	rs12497850	0.931	rs11920534	ENSG00000197582.5	GPX1P1	9.4	2.34e-19	7.03e-13	0.59	0.4	Parkinson's disease;	chr3:48900328	chrX:13378735~13379340:-
THCA	trans	rs10037055	0.853	rs10056008	ENSG00000226986.4	RP11-543B16.2	-9.4	2.35e-19	7.07e-13	-0.5	-0.4	Migraine without aura;	chr5:177194147	chr1:211207239~211207897:+
THCA	trans	rs10037055	0.853	rs10476219	ENSG00000226986.4	RP11-543B16.2	-9.4	2.35e-19	7.07e-13	-0.5	-0.4	Migraine without aura;	chr5:177201547	chr1:211207239~211207897:+
THCA	trans	rs2898290	0.592	rs2736342	ENSG00000253893.2	FAM85B	9.4	2.36e-19	7.08e-13	0.53	0.4	Systolic blood pressure;	chr8:11489780	chr8:8167819~8226614:-
THCA	trans	rs804280	0.542	rs35647515	ENSG00000253893.2	FAM85B	-9.4	2.37e-19	7.12e-13	-0.55	-0.4	Myopia (pathological);	chr8:11934120	chr8:8167819~8226614:-
THCA	trans	rs13190036	0.901	rs28715668	ENSG00000228305.2	AC016734.2	9.4	2.39e-19	7.18e-13	0.49	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr2:63622178~63622831:-
THCA	trans	rs12138950	0.681	rs10917472	ENSG00000224237.1	MINOS1P3	9.4	2.4e-19	7.2e-13	0.56	0.4	Hypothyroidism;Thyroid volume;	chr1:19524218	chr3:27214816~27215018:-
THCA	trans	rs9650657	0.547	rs11250099	ENSG00000253893.2	FAM85B	-9.4	2.4e-19	7.21e-13	-0.51	-0.4	Neuroticism;	chr8:10961147	chr8:8167819~8226614:-
THCA	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	9.4	2.41e-19	7.24e-13	0.52	0.4	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
THCA	trans	rs1908814	0.516	rs13275143	ENSG00000253893.2	FAM85B	-9.4	2.43e-19	7.28e-13	-0.55	-0.4	Neuroticism;	chr8:11939481	chr8:8167819~8226614:-
THCA	trans	rs616147	1	rs616147	ENSG00000214263.2	RPSAP53	-9.4	2.44e-19	7.33e-13	-0.53	-0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr13:67266845~67267706:-
THCA	trans	rs864643	0.513	rs1707956	ENSG00000188856.6	RPSAP47	-9.4	2.47e-19	7.39e-13	-0.59	-0.4	Attention deficit hyperactivity disorder;	chr3:39482025	chr8:80558870~80559757:+
THCA	trans	rs864643	0.588	rs604869	ENSG00000188856.6	RPSAP47	9.4	2.47e-19	7.39e-13	0.59	0.4	Attention deficit hyperactivity disorder;	chr3:39486307	chr8:80558870~80559757:+
THCA	trans	rs1816752	0.905	rs8002309	ENSG00000224976.2	PARP4P2	-9.39	2.5e-19	7.5e-13	-0.48	-0.4	Obesity-related traits;	chr13:24402217	chr13:19349137~19407962:+
THCA	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-9.39	2.52e-19	7.54e-13	-0.63	-0.4	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-9.39	2.52e-19	7.54e-13	-0.63	-0.4	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-9.39	2.52e-19	7.54e-13	-0.63	-0.4	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	9.39	2.52e-19	7.54e-13	0.63	0.4	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
THCA	trans	rs13177918	0.557	rs12520101	ENSG00000226396.1	RP5-1056L3.3	9.39	2.53e-19	7.57e-13	0.4	0.4	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:19608114~19608568:+
THCA	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	9.39	2.54e-19	7.61e-13	0.52	0.4	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
THCA	trans	rs804280	0.509	rs7461273	ENSG00000253893.2	FAM85B	-9.39	2.54e-19	7.61e-13	-0.54	-0.4	Myopia (pathological);	chr8:11920468	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.853	rs10036193	ENSG00000226986.4	RP11-543B16.2	-9.39	2.55e-19	7.64e-13	-0.5	-0.4	Migraine without aura;	chr5:177141519	chr1:211207239~211207897:+
THCA	trans	rs10037055	0.853	rs9885210	ENSG00000226986.4	RP11-543B16.2	-9.39	2.55e-19	7.64e-13	-0.5	-0.4	Migraine without aura;	chr5:177142187	chr1:211207239~211207897:+
THCA	trans	rs877636	0.669	rs7297175	ENSG00000227586.5	RP11-162A23.5	-9.39	2.55e-19	7.65e-13	-0.49	-0.4	Cognitive function;	chr12:56080024	chr10:123171535~123171875:-
THCA	trans	rs916888	0.531	rs183211	ENSG00000280022.1	RP11-707O23.1	-9.39	2.61e-19	7.81e-13	-0.42	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45592621~45593369:+
THCA	trans	rs10435719	0.809	rs77601743	ENSG00000253893.2	FAM85B	-9.39	2.65e-19	7.92e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933060	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.678	rs74724594	ENSG00000253893.2	FAM85B	-9.39	2.65e-19	7.92e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933067	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.702	rs77055881	ENSG00000253893.2	FAM85B	-9.39	2.65e-19	7.92e-13	-0.55	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933072	chr8:8167819~8226614:-
THCA	trans	rs13190036	1	rs13177748	ENSG00000228305.2	AC016734.2	-9.39	2.65e-19	7.92e-13	-0.49	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr2:63622178~63622831:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000223416.3	RPS26P15	9.39	2.66e-19	7.95e-13	0.51	0.4	Cognitive function;	chr12:55990903	chr1:58056133~58056480:-
THCA	trans	rs10037055	0.687	rs6556308	ENSG00000226986.4	RP11-543B16.2	-9.39	2.68e-19	8.01e-13	-0.5	-0.4	Migraine without aura;	chr5:177219700	chr1:211207239~211207897:+
THCA	trans	rs12709013	0.792	rs12600201	ENSG00000233719.3	GOT2P3	9.39	2.68e-19	8.01e-13	0.48	0.4	Blood metabolite ratios;	chr16:58773132	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs12600206	ENSG00000233719.3	GOT2P3	9.39	2.68e-19	8.01e-13	0.48	0.4	Blood metabolite ratios;	chr16:58773169	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs11076263	ENSG00000233719.3	GOT2P3	9.39	2.68e-19	8.01e-13	0.48	0.4	Blood metabolite ratios;	chr16:58773295	chr12:9641802~9643007:+
THCA	trans	rs13190036	1	rs7714695	ENSG00000228305.2	AC016734.2	-9.39	2.7e-19	8.06e-13	-0.5	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr2:63622178~63622831:-
THCA	trans	rs74781061	0.929	rs76160708	ENSG00000227288.3	RP5-837I24.1	9.38	2.71e-19	8.08e-13	0.56	0.4	Endometriosis;	chr15:74636901	chr1:81501794~81503468:+
THCA	trans	rs1908814	0.516	rs11250178	ENSG00000253893.2	FAM85B	-9.38	2.73e-19	8.16e-13	-0.55	-0.4	Neuroticism;	chr8:11942725	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.929	rs8027066	ENSG00000227288.3	RP5-837I24.1	9.38	2.74e-19	8.17e-13	0.56	0.4	Endometriosis;	chr15:74535682	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs2415242	ENSG00000227288.3	RP5-837I24.1	9.38	2.74e-19	8.17e-13	0.56	0.4	Endometriosis;	chr15:74546765	chr1:81501794~81503468:+
THCA	trans	rs1816752	0.774	rs55888616	ENSG00000224976.2	PARP4P2	-9.38	2.74e-19	8.18e-13	-0.47	-0.4	Obesity-related traits;	chr13:24441954	chr13:19349137~19407962:+
THCA	trans	rs10037055	0.853	rs6890580	ENSG00000226986.4	RP11-543B16.2	-9.38	2.75e-19	8.2e-13	-0.5	-0.4	Migraine without aura;	chr5:177226519	chr1:211207239~211207897:+
THCA	trans	rs10037055	0.853	rs10035180	ENSG00000226986.4	RP11-543B16.2	-9.38	2.89e-19	8.63e-13	-0.49	-0.4	Migraine without aura;	chr5:177171501	chr1:211207239~211207897:+
THCA	trans	rs10037055	0.853	rs1546363	ENSG00000226986.4	RP11-543B16.2	-9.38	2.89e-19	8.63e-13	-0.49	-0.4	Migraine without aura;	chr5:177174030	chr1:211207239~211207897:+
THCA	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-9.37	2.95e-19	8.79e-13	-0.63	-0.4	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
THCA	trans	rs804280	0.509	rs9886639	ENSG00000253893.2	FAM85B	-9.37	2.97e-19	8.86e-13	-0.54	-0.4	Myopia (pathological);	chr8:11927020	chr8:8167819~8226614:-
THCA	trans	rs616147	0.962	rs1708104	ENSG00000214263.2	RPSAP53	-9.37	2.99e-19	8.9e-13	-0.52	-0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr13:67266845~67267706:-
THCA	trans	rs13190036	0.901	rs28563911	ENSG00000228305.2	AC016734.2	9.37	3.01e-19	8.98e-13	0.49	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr2:63622178~63622831:-
THCA	trans	rs3806843	0.741	rs2563293	ENSG00000231043.3	AC007238.1	9.37	3.03e-19	9.01e-13	0.47	0.4	Depressive symptoms (multi-trait analysis);	chr5:140730951	chr2:58460292~58462032:-
THCA	trans	rs7824557	0.547	rs2409745	ENSG00000253893.2	FAM85B	-9.37	3.05e-19	9.08e-13	-0.53	-0.4	Retinal vascular caliber;	chr8:11219126	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.686	rs244919	ENSG00000230849.2	GOT2P2	-9.37	3.07e-19	9.13e-13	-0.48	-0.4	Blood metabolite ratios;	chr16:58704146	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.686	rs151817	ENSG00000230849.2	GOT2P2	-9.37	3.07e-19	9.14e-13	-0.48	-0.4	Blood metabolite ratios;	chr16:58704014	chr1:173141100~173142350:-
THCA	trans	rs12497850	0.931	rs3774628	ENSG00000197582.5	GPX1P1	9.37	3.09e-19	9.19e-13	0.59	0.4	Parkinson's disease;	chr3:48764407	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.705	rs35614340	ENSG00000231043.3	AC007238.1	9.37	3.1e-19	9.21e-13	0.46	0.4	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr2:58460292~58462032:-
THCA	trans	rs916888	0.61	rs199536	ENSG00000280022.1	RP11-707O23.1	9.36	3.17e-19	9.44e-13	0.43	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45592621~45593369:+
THCA	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	9.36	3.23e-19	9.6e-13	0.52	0.4	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
THCA	trans	rs1039766	1	rs10116	ENSG00000224334.1	AP000357.4	9.36	3.25e-19	9.65e-13	0.61	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr22:24686923~24688087:+
THCA	trans	rs1039766	1	rs268878	ENSG00000224334.1	AP000357.4	9.36	3.25e-19	9.65e-13	0.61	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr22:24686923~24688087:+
THCA	trans	rs1039766	0.929	rs268881	ENSG00000224334.1	AP000357.4	9.36	3.25e-19	9.65e-13	0.61	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr22:24686923~24688087:+
THCA	trans	rs916888	0.61	rs199438	ENSG00000204650.12	CRHR1-IT1	9.36	3.26e-19	9.68e-13	0.39	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45620328~45648216:+
THCA	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	9.36	3.3e-19	9.8e-13	0.51	0.4	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
THCA	trans	rs1908814	0.51	rs57655799	ENSG00000253893.2	FAM85B	-9.36	3.3e-19	9.81e-13	-0.53	-0.4	Neuroticism;	chr8:11924908	chr8:8167819~8226614:-
THCA	trans	rs916888	0.61	rs199453	ENSG00000204650.12	CRHR1-IT1	9.36	3.31e-19	9.82e-13	0.39	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45620328~45648216:+
THCA	trans	rs12709013	0.792	rs8049572	ENSG00000233719.3	GOT2P3	9.36	3.32e-19	9.85e-13	0.48	0.4	Blood metabolite ratios;	chr16:58809672	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.766	rs34438483	ENSG00000233719.3	GOT2P3	9.36	3.32e-19	9.85e-13	0.48	0.4	Blood metabolite ratios;	chr16:58810530	chr12:9641802~9643007:+
THCA	trans	rs74781061	0.929	rs8029099	ENSG00000227288.3	RP5-837I24.1	9.36	3.33e-19	9.87e-13	0.56	0.4	Endometriosis;	chr15:74474429	chr1:81501794~81503468:+
THCA	trans	rs916888	0.61	rs199436	ENSG00000280022.1	RP11-707O23.1	9.36	3.35e-19	9.94e-13	0.42	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45592621~45593369:+
THCA	trans	rs804280	0.509	rs10109241	ENSG00000253893.2	FAM85B	-9.36	3.39e-19	1.01e-12	-0.54	-0.4	Myopia (pathological);	chr8:11927476	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	9.36	3.4e-19	1.01e-12	0.51	0.4	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
THCA	trans	rs13014235	0.532	rs6729982	ENSG00000235105.1	RP11-329A14.1	9.35	3.44e-19	1.02e-12	0.42	0.4	Basal cell carcinoma;	chr2:201416413	chr1:48435967~48437223:+
THCA	trans	rs13014235	0.532	rs10497867	ENSG00000235105.1	RP11-329A14.1	9.35	3.44e-19	1.02e-12	0.42	0.4	Basal cell carcinoma;	chr2:201420144	chr1:48435967~48437223:+
THCA	trans	rs12709013	0.693	rs1627257	ENSG00000233719.3	GOT2P3	9.35	3.5e-19	1.04e-12	0.48	0.4	Blood metabolite ratios;	chr16:58763764	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs12926512	ENSG00000233719.3	GOT2P3	9.35	3.5e-19	1.04e-12	0.48	0.4	Blood metabolite ratios;	chr16:58768317	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs12595974	ENSG00000233719.3	GOT2P3	9.35	3.5e-19	1.04e-12	0.48	0.4	Blood metabolite ratios;	chr16:58769132	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs1836877	ENSG00000233719.3	GOT2P3	9.35	3.5e-19	1.04e-12	0.48	0.4	Blood metabolite ratios;	chr16:58769821	chr12:9641802~9643007:+
THCA	trans	rs55665837	0.701	rs10766188	ENSG00000236360.2	RP11-334A14.2	9.35	3.51e-19	1.04e-12	0.54	0.4	Vitamin D levels;	chr11:14639280	chr1:52993201~52993702:-
THCA	trans	rs10435719	0.902	rs7006538	ENSG00000253893.2	FAM85B	-9.35	3.53e-19	1.05e-12	-0.54	-0.4	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:8167819~8226614:-
THCA	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-9.35	3.56e-19	1.05e-12	-0.52	-0.4	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
THCA	trans	rs1816752	1	rs9511265	ENSG00000224976.2	PARP4P2	-9.35	3.58e-19	1.06e-12	-0.47	-0.4	Obesity-related traits;	chr13:24438221	chr13:19349137~19407962:+
THCA	trans	rs74781061	0.86	rs7163775	ENSG00000227288.3	RP5-837I24.1	9.35	3.59e-19	1.06e-12	0.56	0.4	Endometriosis;	chr15:74452760	chr1:81501794~81503468:+
THCA	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-9.35	3.59e-19	1.06e-12	-0.62	-0.4	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-9.35	3.59e-19	1.06e-12	-0.62	-0.4	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-9.35	3.59e-19	1.06e-12	-0.62	-0.4	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
THCA	trans	rs66887589	0.616	rs6843509	ENSG00000275858.1	RP11-291L22.8	9.35	3.63e-19	1.08e-12	0.49	0.4	Diastolic blood pressure;	chr4:119299041	chr10:38450738~38451069:-
THCA	trans	rs10037055	0.853	rs2336237	ENSG00000226986.4	RP11-543B16.2	9.35	3.64e-19	1.08e-12	0.5	0.4	Migraine without aura;	chr5:177238878	chr1:211207239~211207897:+
THCA	trans	rs867371	0.717	rs3858954	ENSG00000235370.6	DNM1P51	-9.35	3.7e-19	1.1e-12	-0.5	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:84398316~84411701:-
THCA	trans	rs1816752	0.776	rs9511268	ENSG00000224976.2	PARP4P2	-9.35	3.7e-19	1.1e-12	-0.47	-0.4	Obesity-related traits;	chr13:24444182	chr13:19349137~19407962:+
THCA	trans	rs864643	0.513	rs1707944	ENSG00000188856.6	RPSAP47	9.34	3.72e-19	1.1e-12	0.59	0.4	Attention deficit hyperactivity disorder;	chr3:39487141	chr8:80558870~80559757:+
THCA	trans	rs13190036	0.901	rs55741473	ENSG00000228305.2	AC016734.2	-9.34	3.73e-19	1.1e-12	-0.49	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr2:63622178~63622831:-
THCA	trans	rs12709013	0.792	rs1646277	ENSG00000233719.3	GOT2P3	9.34	3.73e-19	1.1e-12	0.48	0.4	Blood metabolite ratios;	chr16:58750037	chr12:9641802~9643007:+
THCA	trans	rs13190036	1	rs17078781	ENSG00000228305.2	AC016734.2	-9.34	3.74e-19	1.11e-12	-0.49	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr2:63622178~63622831:-
THCA	trans	rs13014235	0.532	rs11681592	ENSG00000235105.1	RP11-329A14.1	9.34	3.78e-19	1.12e-12	0.42	0.4	Basal cell carcinoma;	chr2:201399178	chr1:48435967~48437223:+
THCA	trans	rs1816752	1	rs1816752	ENSG00000224976.2	PARP4P2	-9.34	3.85e-19	1.14e-12	-0.49	-0.4	Obesity-related traits;	chr13:24406811	chr13:19349137~19407962:+
THCA	trans	rs66887589	0.616	rs1052633	ENSG00000275858.1	RP11-291L22.8	9.34	3.85e-19	1.14e-12	0.49	0.4	Diastolic blood pressure;	chr4:119294159	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.592	rs2175383	ENSG00000275858.1	RP11-291L22.8	9.34	3.85e-19	1.14e-12	0.49	0.4	Diastolic blood pressure;	chr4:119294681	chr10:38450738~38451069:-
THCA	trans	rs7819412	0.765	rs17783634	ENSG00000253893.2	FAM85B	9.34	3.88e-19	1.15e-12	0.53	0.4	Triglycerides;	chr8:11196588	chr8:8167819~8226614:-
THCA	trans	rs7503168	1	rs16971217	ENSG00000234130.2	RP13-88F20.1	9.34	3.95e-19	1.17e-12	0.52	0.4	Plateletcrit;	chr17:35617036	chrX:93222220~93225015:-
THCA	trans	rs12709013	0.792	rs11646756	ENSG00000233719.3	GOT2P3	9.34	3.97e-19	1.17e-12	0.48	0.4	Blood metabolite ratios;	chr16:58773598	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs62066815	ENSG00000233719.3	GOT2P3	9.34	4e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58751577	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.766	rs1657175	ENSG00000233719.3	GOT2P3	9.34	4e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58755527	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs1646290	ENSG00000233719.3	GOT2P3	9.34	4e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58755807	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs1364346	ENSG00000233719.3	GOT2P3	9.34	4e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58756420	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs257626	ENSG00000233719.3	GOT2P3	9.34	4e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58759574	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs257625	ENSG00000233719.3	GOT2P3	9.34	4e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58759978	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs1646262	ENSG00000233719.3	GOT2P3	9.34	4e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58760593	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs257623	ENSG00000233719.3	GOT2P3	9.34	4e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58761247	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs11649387	ENSG00000233719.3	GOT2P3	9.34	4.01e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58803176	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs11649133	ENSG00000233719.3	GOT2P3	9.34	4.01e-19	1.18e-12	0.48	0.4	Blood metabolite ratios;	chr16:58803275	chr12:9641802~9643007:+
THCA	trans	rs5022636	0.927	rs10888410	ENSG00000180764.13	PIPSL	9.33	4.03e-19	1.19e-12	0.44	0.4	Gut microbiota (functional units);	chr1:151299975	chr10:93958191~93961540:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000224553.1	AC008065.1	-9.33	4.03e-19	1.19e-12	-0.45	-0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr2:171374931~171375278:-
THCA	trans	rs12709013	0.792	rs1646289	ENSG00000233719.3	GOT2P3	9.33	4.03e-19	1.19e-12	0.48	0.4	Blood metabolite ratios;	chr16:58755689	chr12:9641802~9643007:+
THCA	trans	rs1816752	1	rs7326932	ENSG00000224976.2	PARP4P2	-9.33	4.12e-19	1.21e-12	-0.48	-0.4	Obesity-related traits;	chr13:24430355	chr13:19349137~19407962:+
THCA	trans	rs9329221	0.592	rs7832708	ENSG00000253893.2	FAM85B	-9.33	4.14e-19	1.22e-12	-0.52	-0.4	Neuroticism;	chr8:10332530	chr8:8167819~8226614:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000243538.1	CTB-55B8.1	-9.33	4.22e-19	1.24e-12	-0.46	-0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr5:16902294~16902641:-
THCA	trans	rs10037055	0.741	rs2336405	ENSG00000226986.4	RP11-543B16.2	-9.33	4.25e-19	1.25e-12	-0.49	-0.4	Migraine without aura;	chr5:177230288	chr1:211207239~211207897:+
THCA	trans	rs13190036	0.892	rs71601339	ENSG00000228305.2	AC016734.2	-9.33	4.34e-19	1.28e-12	-0.49	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr2:63622178~63622831:-
THCA	trans	rs74781061	0.929	rs79600165	ENSG00000227288.3	RP5-837I24.1	9.32	4.43e-19	1.3e-12	0.55	0.4	Endometriosis;	chr15:74648650	chr1:81501794~81503468:+
THCA	trans	rs3806843	0.735	rs2530242	ENSG00000231043.3	AC007238.1	9.32	4.54e-19	1.34e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140673766	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs2530241	ENSG00000231043.3	AC007238.1	9.32	4.54e-19	1.34e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140674900	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs2530235	ENSG00000231043.3	AC007238.1	9.32	4.54e-19	1.34e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140693062	chr2:58460292~58462032:-
THCA	trans	rs74781061	0.929	rs4324083	ENSG00000227288.3	RP5-837I24.1	9.32	4.59e-19	1.35e-12	0.55	0.39	Endometriosis;	chr15:74479139	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs117379081	ENSG00000227288.3	RP5-837I24.1	9.32	4.59e-19	1.35e-12	0.55	0.39	Endometriosis;	chr15:74480106	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs79600239	ENSG00000227288.3	RP5-837I24.1	9.32	4.59e-19	1.35e-12	0.55	0.39	Endometriosis;	chr15:74481987	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.929	rs16969247	ENSG00000227288.3	RP5-837I24.1	9.32	4.59e-19	1.35e-12	0.55	0.39	Endometriosis;	chr15:74486541	chr1:81501794~81503468:+
THCA	trans	rs12709013	0.686	rs151817	ENSG00000233719.3	GOT2P3	-9.32	4.59e-19	1.35e-12	-0.47	-0.39	Blood metabolite ratios;	chr16:58704014	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.686	rs244919	ENSG00000233719.3	GOT2P3	-9.32	4.61e-19	1.35e-12	-0.47	-0.39	Blood metabolite ratios;	chr16:58704146	chr12:9641802~9643007:+
THCA	trans	rs13190036	1	rs13185316	ENSG00000228305.2	AC016734.2	-9.32	4.62e-19	1.36e-12	-0.49	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr2:63622178~63622831:-
THCA	trans	rs7113874	0.592	rs34009921	ENSG00000266891.1	RP11-692N5.2	9.31	5e-19	1.47e-12	0.6	0.39	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8597314	chr18:9734882~9735602:-
THCA	trans	rs3806843	0.657	rs2563283	ENSG00000231043.3	AC007238.1	9.31	5.02e-19	1.47e-12	0.47	0.39	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.771	rs2563336	ENSG00000231043.3	AC007238.1	9.31	5.02e-19	1.47e-12	0.47	0.39	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr2:58460292~58462032:-
THCA	trans	rs864643	0.513	rs6599028	ENSG00000188856.6	RPSAP47	9.31	5.03e-19	1.48e-12	0.59	0.39	Attention deficit hyperactivity disorder;	chr3:39492344	chr8:80558870~80559757:+
THCA	trans	rs66887589	0.616	rs11731675	ENSG00000275858.1	RP11-291L22.8	9.31	5.05e-19	1.48e-12	0.48	0.39	Diastolic blood pressure;	chr4:119291359	chr10:38450738~38451069:-
THCA	trans	rs916888	0.61	rs199452	ENSG00000280022.1	RP11-707O23.1	-9.31	5.05e-19	1.48e-12	-0.42	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45592621~45593369:+
THCA	trans	rs80033912	0.713	rs7629936	ENSG00000197582.5	GPX1P1	9.3	5.12e-19	1.5e-12	0.61	0.39	Intelligence (multi-trait analysis);	chr3:49799274	chrX:13378735~13379340:-
THCA	trans	rs66887589	0.616	rs11732621	ENSG00000275858.1	RP11-291L22.8	9.3	5.15e-19	1.51e-12	0.48	0.39	Diastolic blood pressure;	chr4:119291728	chr10:38450738~38451069:-
THCA	trans	rs3806843	0.735	rs6849	ENSG00000231043.3	AC007238.1	9.3	5.25e-19	1.54e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr2:58460292~58462032:-
THCA	trans	rs864643	0.513	rs614823	ENSG00000188856.6	RPSAP47	9.3	5.26e-19	1.54e-12	0.59	0.39	Attention deficit hyperactivity disorder;	chr3:39493267	chr8:80558870~80559757:+
THCA	trans	rs7819412	0.582	rs2409685	ENSG00000253893.2	FAM85B	9.3	5.28e-19	1.55e-12	0.52	0.39	Triglycerides;	chr8:11051683	chr8:8167819~8226614:-
THCA	trans	rs1039766	0.925	rs268863	ENSG00000224334.1	AP000357.4	9.3	5.3e-19	1.55e-12	0.6	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr22:24686923~24688087:+
THCA	trans	rs2929278	0.617	rs694461	ENSG00000180867.10	PDIA3P1	9.3	5.35e-19	1.57e-12	0.35	0.39	Schizophrenia;	chr15:43803865	chr1:147178113~147179622:+
THCA	trans	rs3806843	0.706	rs2563302	ENSG00000231043.3	AC007238.1	9.3	5.41e-19	1.58e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs801168	ENSG00000231043.3	AC007238.1	9.3	5.41e-19	1.58e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs801167	ENSG00000231043.3	AC007238.1	-9.3	5.41e-19	1.58e-12	-0.46	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs809635	ENSG00000231043.3	AC007238.1	9.3	5.41e-19	1.58e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.648	rs2530233	ENSG00000231043.3	AC007238.1	9.3	5.41e-19	1.58e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs702394	ENSG00000231043.3	AC007238.1	9.3	5.41e-19	1.58e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs801183	ENSG00000231043.3	AC007238.1	-9.3	5.41e-19	1.58e-12	-0.46	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs801180	ENSG00000231043.3	AC007238.1	9.3	5.41e-19	1.58e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr2:58460292~58462032:-
THCA	trans	rs13014235	0.532	rs13029007	ENSG00000235105.1	RP11-329A14.1	9.3	5.44e-19	1.59e-12	0.42	0.39	Basal cell carcinoma;	chr2:201400154	chr1:48435967~48437223:+
THCA	trans	rs7824557	0.569	rs10106207	ENSG00000253893.2	FAM85B	9.3	5.49e-19	1.61e-12	0.52	0.39	Retinal vascular caliber;	chr8:11157828	chr8:8167819~8226614:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000234513.1	AC073072.7	-9.3	5.52e-19	1.61e-12	-0.56	-0.39	Asthma;	chr12:55970537	chr7:22773646~22773993:-
THCA	trans	rs66887589	0.616	rs6822808	ENSG00000275858.1	RP11-291L22.8	9.29	5.55e-19	1.62e-12	0.49	0.39	Diastolic blood pressure;	chr4:119296210	chr10:38450738~38451069:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000227586.5	RP11-162A23.5	9.29	5.56e-19	1.63e-12	0.48	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:123171535~123171875:-
THCA	trans	rs74781061	1	rs11072488	ENSG00000227288.3	RP5-837I24.1	9.29	5.66e-19	1.65e-12	0.55	0.39	Endometriosis;	chr15:74494017	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.932	rs11857328	ENSG00000227288.3	RP5-837I24.1	9.29	5.66e-19	1.65e-12	0.55	0.39	Endometriosis;	chr15:74510550	chr1:81501794~81503468:+
THCA	trans	rs13014235	0.644	rs10201587	ENSG00000235105.1	RP11-329A14.1	9.29	5.66e-19	1.66e-12	0.43	0.39	Basal cell carcinoma;	chr2:201338068	chr1:48435967~48437223:+
THCA	trans	rs7833986	0.501	rs17812659	ENSG00000244245.1	RP11-120B7.1	9.29	5.74e-19	1.68e-12	0.54	0.39	Height;	chr8:55977303	chr5:108593609~108593967:+
THCA	trans	rs11098499	0.532	rs4504231	ENSG00000275858.1	RP11-291L22.8	9.29	5.74e-19	1.68e-12	0.53	0.39	Corneal astigmatism;	chr4:119665736	chr10:38450738~38451069:-
THCA	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	9.29	5.76e-19	1.68e-12	0.52	0.39	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
THCA	trans	rs12497850	0.931	rs62262517	ENSG00000197582.5	GPX1P1	9.29	5.81e-19	1.7e-12	0.59	0.39	Parkinson's disease;	chr3:49097481	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.735	rs2563306	ENSG00000231043.3	AC007238.1	9.29	5.88e-19	1.72e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs813897	ENSG00000231043.3	AC007238.1	9.29	5.88e-19	1.72e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr2:58460292~58462032:-
THCA	trans	rs55665837	0.701	rs11023278	ENSG00000236360.2	RP11-334A14.2	9.29	5.9e-19	1.72e-12	0.53	0.39	Vitamin D levels;	chr11:14619638	chr1:52993201~52993702:-
THCA	trans	rs6424115	0.691	rs4341315	ENSG00000228217.1	AL390877.1	-9.29	5.92e-19	1.73e-12	-0.52	-0.39	Immature fraction of reticulocytes;	chr1:23878193	chr1:117778087~117778506:-
THCA	trans	rs12709013	0.792	rs12596434	ENSG00000233719.3	GOT2P3	9.29	5.93e-19	1.73e-12	0.48	0.39	Blood metabolite ratios;	chr16:58792309	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs62064940	ENSG00000233719.3	GOT2P3	9.29	5.93e-19	1.73e-12	0.48	0.39	Blood metabolite ratios;	chr16:58796560	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs11644344	ENSG00000233719.3	GOT2P3	9.29	5.93e-19	1.73e-12	0.48	0.39	Blood metabolite ratios;	chr16:58803080	chr12:9641802~9643007:+
THCA	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-9.29	5.96e-19	1.74e-12	-0.62	-0.39	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
THCA	trans	rs7819412	0.837	rs17724467	ENSG00000253893.2	FAM85B	9.28	6.08e-19	1.77e-12	0.53	0.39	Triglycerides;	chr8:11118172	chr8:8167819~8226614:-
THCA	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	9.28	6.11e-19	1.78e-12	0.53	0.39	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
THCA	trans	rs1816752	0.87	rs7320102	ENSG00000224976.2	PARP4P2	-9.28	6.23e-19	1.82e-12	-0.46	-0.39	Obesity-related traits;	chr13:24437435	chr13:19349137~19407962:+
THCA	trans	rs7819412	0.74	rs28633434	ENSG00000253893.2	FAM85B	9.28	6.24e-19	1.82e-12	0.53	0.39	Triglycerides;	chr8:11196413	chr8:8167819~8226614:-
THCA	trans	rs3806843	0.735	rs2563314	ENSG00000231043.3	AC007238.1	9.28	6.28e-19	1.83e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs2530240	ENSG00000231043.3	AC007238.1	9.28	6.28e-19	1.83e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs801189	ENSG00000231043.3	AC007238.1	9.28	6.28e-19	1.83e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.706	rs1089305	ENSG00000231043.3	AC007238.1	9.28	6.28e-19	1.83e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs801185	ENSG00000231043.3	AC007238.1	9.28	6.28e-19	1.83e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.676	rs2563304	ENSG00000231043.3	AC007238.1	9.28	6.28e-19	1.83e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs3776129	ENSG00000231043.3	AC007238.1	9.28	6.28e-19	1.83e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr2:58460292~58462032:-
THCA	trans	rs1816752	0.905	rs7339140	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24437764	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs9511266	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24438366	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.817	rs7985394	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24438714	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.789	rs7986037	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24438715	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs7995909	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24439159	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs6490927	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24439802	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs6490928	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24439921	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs6490929	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24440114	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs3825449	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24440303	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs7998797	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24440850	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs7981337	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24440915	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs7981480	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24440966	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.837	rs4769355	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24441059	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs4770680	ENSG00000224976.2	PARP4P2	-9.28	6.31e-19	1.84e-12	-0.46	-0.39	Obesity-related traits;	chr13:24441110	chr13:19349137~19407962:+
THCA	trans	rs2898290	0.622	rs1478890	ENSG00000253893.2	FAM85B	9.28	6.32e-19	1.84e-12	0.53	0.39	Systolic blood pressure;	chr8:11498093	chr8:8167819~8226614:-
THCA	trans	rs916888	0.647	rs199523	ENSG00000280022.1	RP11-707O23.1	9.28	6.34e-19	1.85e-12	0.42	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45592621~45593369:+
THCA	trans	rs74781061	0.86	rs6495103	ENSG00000227288.3	RP5-837I24.1	9.28	6.42e-19	1.87e-12	0.56	0.39	Endometriosis;	chr15:74470507	chr1:81501794~81503468:+
THCA	trans	rs1816752	0.87	rs9511261	ENSG00000224976.2	PARP4P2	-9.28	6.42e-19	1.87e-12	-0.46	-0.39	Obesity-related traits;	chr13:24437880	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs9511262	ENSG00000224976.2	PARP4P2	-9.28	6.42e-19	1.87e-12	-0.46	-0.39	Obesity-related traits;	chr13:24437885	chr13:19349137~19407962:+
THCA	trans	rs12709013	0.792	rs1615326	ENSG00000233719.3	GOT2P3	9.28	6.47e-19	1.88e-12	0.48	0.39	Blood metabolite ratios;	chr16:58747148	chr12:9641802~9643007:+
THCA	trans	rs1816752	0.638	rs9578730	ENSG00000224976.2	PARP4P2	-9.28	6.48e-19	1.89e-12	-0.48	-0.39	Obesity-related traits;	chr13:24425545	chr13:19349137~19407962:+
THCA	trans	rs55665837	0.701	rs12286408	ENSG00000236360.2	RP11-334A14.2	9.27	6.54e-19	1.9e-12	0.53	0.39	Vitamin D levels;	chr11:14557830	chr1:52993201~52993702:-
THCA	trans	rs74781061	0.929	rs8028430	ENSG00000227288.3	RP5-837I24.1	9.27	6.64e-19	1.93e-12	0.56	0.39	Endometriosis;	chr15:74553404	chr1:81501794~81503468:+
THCA	trans	rs9650657	0.513	rs7005884	ENSG00000253893.2	FAM85B	9.27	6.71e-19	1.95e-12	0.5	0.39	Neuroticism;	chr8:10938962	chr8:8167819~8226614:-
THCA	trans	rs6424115	0.83	rs6424119	ENSG00000228217.1	AL390877.1	-9.27	6.72e-19	1.95e-12	-0.52	-0.39	Immature fraction of reticulocytes;	chr1:23877653	chr1:117778087~117778506:-
THCA	trans	rs55665837	0.701	rs2007361	ENSG00000236360.2	RP11-334A14.2	9.27	6.8e-19	1.98e-12	0.54	0.39	Vitamin D levels;	chr11:14641176	chr1:52993201~52993702:-
THCA	trans	rs3806843	0.771	rs801174	ENSG00000231043.3	AC007238.1	9.27	6.8e-19	1.98e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140733127	chr2:58460292~58462032:-
THCA	trans	rs1908814	0.516	rs4841641	ENSG00000253893.2	FAM85B	-9.27	6.81e-19	1.98e-12	-0.54	-0.39	Neuroticism;	chr8:11940718	chr8:8167819~8226614:-
THCA	trans	rs1816752	0.819	rs7316961	ENSG00000224976.2	PARP4P2	-9.27	6.82e-19	1.98e-12	-0.46	-0.39	Obesity-related traits;	chr13:24411039	chr13:19349137~19407962:+
THCA	trans	rs74781061	0.932	rs11629749	ENSG00000227288.3	RP5-837I24.1	9.27	6.93e-19	2.01e-12	0.51	0.39	Endometriosis;	chr15:74627252	chr1:81501794~81503468:+
THCA	trans	rs7662987	1	rs7683802	ENSG00000233859.2	ADH5P4	9.27	7.01e-19	2.04e-12	0.81	0.39	Smoking initiation;	chr4:99073987	chr6:65836930~65838039:-
THCA	trans	rs7662987	0.818	rs4699701	ENSG00000233859.2	ADH5P4	9.27	7.01e-19	2.04e-12	0.81	0.39	Smoking initiation;	chr4:99077296	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs13146416	ENSG00000233859.2	ADH5P4	9.27	7.01e-19	2.04e-12	0.81	0.39	Smoking initiation;	chr4:99078009	chr6:65836930~65838039:-
THCA	trans	rs916888	0.779	rs199526	ENSG00000280022.1	RP11-707O23.1	9.26	7.03e-19	2.04e-12	0.44	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45592621~45593369:+
THCA	trans	rs13014235	0.532	rs3731709	ENSG00000235105.1	RP11-329A14.1	9.26	7.05e-19	2.05e-12	0.42	0.39	Basal cell carcinoma;	chr2:201381311	chr1:48435967~48437223:+
THCA	trans	rs74781061	0.86	rs2289187	ENSG00000227288.3	RP5-837I24.1	9.26	7.08e-19	2.05e-12	0.56	0.39	Endometriosis;	chr15:74452058	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs7166701	ENSG00000227288.3	RP5-837I24.1	9.26	7.08e-19	2.05e-12	0.56	0.39	Endometriosis;	chr15:74456674	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs77655065	ENSG00000227288.3	RP5-837I24.1	9.26	7.08e-19	2.05e-12	0.56	0.39	Endometriosis;	chr15:74462699	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.858	rs12592493	ENSG00000227288.3	RP5-837I24.1	9.26	7.08e-19	2.05e-12	0.56	0.39	Endometriosis;	chr15:74466999	chr1:81501794~81503468:+
THCA	trans	rs13190036	1	rs6880798	ENSG00000228305.2	AC016734.2	9.26	7.11e-19	2.06e-12	0.48	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr2:63622178~63622831:-
THCA	trans	rs1039766	0.866	rs2160263	ENSG00000224334.1	AP000357.4	9.26	7.12e-19	2.07e-12	0.61	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65282104	chr22:24686923~24688087:+
THCA	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	9.26	7.15e-19	2.07e-12	0.51	0.39	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	9.26	7.15e-19	2.07e-12	0.51	0.39	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
THCA	trans	rs1908814	0.516	rs11996277	ENSG00000253893.2	FAM85B	-9.26	7.16e-19	2.08e-12	-0.54	-0.39	Neuroticism;	chr8:11942522	chr8:8167819~8226614:-
THCA	trans	rs10816533	1	rs7859307	ENSG00000232063.1	RP11-307E17.8	9.26	7.18e-19	2.08e-12	0.93	0.39	Height;	chr9:96842489	chr9:94332476~94360948:+
THCA	trans	rs1039766	1	rs268864	ENSG00000224334.1	AP000357.4	-9.26	7.2e-19	2.09e-12	-0.61	-0.39	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr22:24686923~24688087:+
THCA	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-9.26	7.24e-19	2.1e-12	-0.61	-0.39	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-9.26	7.24e-19	2.1e-12	-0.61	-0.39	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-9.26	7.24e-19	2.1e-12	-0.61	-0.39	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-9.26	7.24e-19	2.1e-12	-0.61	-0.39	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-9.26	7.24e-19	2.1e-12	-0.61	-0.39	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
THCA	trans	rs74781061	0.858	rs8023865	ENSG00000227288.3	RP5-837I24.1	9.26	7.27e-19	2.1e-12	0.55	0.39	Endometriosis;	chr15:74561263	chr1:81501794~81503468:+
THCA	trans	rs12709013	0.766	rs11648511	ENSG00000233719.3	GOT2P3	9.26	7.29e-19	2.11e-12	0.47	0.39	Blood metabolite ratios;	chr16:58798171	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.716	rs11647582	ENSG00000233719.3	GOT2P3	9.26	7.29e-19	2.11e-12	0.47	0.39	Blood metabolite ratios;	chr16:58801474	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs35684307	ENSG00000233719.3	GOT2P3	9.26	7.29e-19	2.11e-12	0.47	0.39	Blood metabolite ratios;	chr16:58801651	chr12:9641802~9643007:+
THCA	trans	rs1816752	0.837	rs7139748	ENSG00000224976.2	PARP4P2	-9.26	7.33e-19	2.12e-12	-0.47	-0.39	Obesity-related traits;	chr13:24411531	chr13:19349137~19407962:+
THCA	trans	rs12709013	0.59	rs982848	ENSG00000233719.3	GOT2P3	9.26	7.42e-19	2.15e-12	0.47	0.39	Blood metabolite ratios;	chr16:58704294	chr12:9641802~9643007:+
THCA	trans	rs10816533	1	rs7032889	ENSG00000232063.1	RP11-307E17.8	9.26	7.5e-19	2.17e-12	0.93	0.39	Height;	chr9:96859520	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs12236179	ENSG00000232063.1	RP11-307E17.8	9.26	7.5e-19	2.17e-12	0.93	0.39	Height;	chr9:96863448	chr9:94332476~94360948:+
THCA	trans	rs12709013	0.766	rs12599331	ENSG00000233719.3	GOT2P3	9.26	7.5e-19	2.17e-12	0.48	0.39	Blood metabolite ratios;	chr16:58805307	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs1646276	ENSG00000233719.3	GOT2P3	9.25	7.73e-19	2.23e-12	0.48	0.39	Blood metabolite ratios;	chr16:58749654	chr12:9641802~9643007:+
THCA	trans	rs72615157	0.645	rs76281814	ENSG00000228546.2	CTA-313A17.3	9.25	7.73e-19	2.23e-12	0.66	0.39	Lung function (FEV1/FVC);	chr7:100248791	chr7:102337316~102339115:+
THCA	trans	rs72615157	0.595	rs112241539	ENSG00000228546.2	CTA-313A17.3	9.25	7.73e-19	2.23e-12	0.66	0.39	Lung function (FEV1/FVC);	chr7:100249614	chr7:102337316~102339115:+
THCA	trans	rs10435719	0.902	rs12681142	ENSG00000253893.2	FAM85B	-9.25	7.84e-19	2.26e-12	-0.54	-0.39	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.741	rs4976640	ENSG00000228305.2	AC016734.2	-9.25	7.86e-19	2.27e-12	-0.42	-0.39	Migraine without aura;	chr5:177125006	chr2:63622178~63622831:-
THCA	trans	rs1079467	0.73	rs72846600	ENSG00000233426.3	EIF3FP3	-9.25	8.04e-19	2.32e-12	-0.66	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7952994	chr2:58251440~58252525:+
THCA	trans	rs74781061	1	rs6495116	ENSG00000227288.3	RP5-837I24.1	9.25	8.1e-19	2.34e-12	0.55	0.39	Endometriosis;	chr15:74593607	chr1:81501794~81503468:+
THCA	trans	rs66887589	0.616	rs7659403	ENSG00000275858.1	RP11-291L22.8	9.25	8.15e-19	2.35e-12	0.48	0.39	Diastolic blood pressure;	chr4:119286099	chr10:38450738~38451069:-
THCA	trans	rs804280	0.509	rs13276433	ENSG00000253893.2	FAM85B	-9.25	8.16e-19	2.35e-12	-0.53	-0.39	Myopia (pathological);	chr8:11925527	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.902	rs11250179	ENSG00000253893.2	FAM85B	-9.25	8.17e-19	2.36e-12	-0.54	-0.39	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:8167819~8226614:-
THCA	trans	rs10908521	1	rs10908521	ENSG00000227183.3	HDGFP1	9.25	8.2e-19	2.37e-12	0.55	0.39	Uric acid clearance;	chr1:156843858	chrX:131646639~131646890:+
THCA	trans	rs74781061	0.86	rs4077703	ENSG00000227288.3	RP5-837I24.1	9.24	8.55e-19	2.47e-12	0.56	0.39	Endometriosis;	chr15:74469821	chr1:81501794~81503468:+
THCA	trans	rs13190036	1	rs13157667	ENSG00000228305.2	AC016734.2	-9.24	8.59e-19	2.47e-12	-0.49	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr2:63622178~63622831:-
THCA	trans	rs13190036	1	rs13167431	ENSG00000228305.2	AC016734.2	-9.24	8.59e-19	2.47e-12	-0.49	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr2:63622178~63622831:-
THCA	trans	rs13190036	1	rs35535623	ENSG00000228305.2	AC016734.2	-9.24	8.59e-19	2.47e-12	-0.49	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr2:63622178~63622831:-
THCA	trans	rs13190036	1	rs71601343	ENSG00000228305.2	AC016734.2	-9.24	8.59e-19	2.47e-12	-0.49	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr2:63622178~63622831:-
THCA	trans	rs13190036	1	rs71601344	ENSG00000228305.2	AC016734.2	-9.24	8.59e-19	2.47e-12	-0.49	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr2:63622178~63622831:-
THCA	trans	rs13190036	1	rs3733875	ENSG00000228305.2	AC016734.2	-9.24	8.59e-19	2.47e-12	-0.49	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr2:63622178~63622831:-
THCA	trans	rs11098499	1	rs1011054	ENSG00000275858.1	RP11-291L22.8	-9.24	8.68e-19	2.5e-12	-0.53	-0.39	Corneal astigmatism;	chr4:119281232	chr10:38450738~38451069:-
THCA	trans	rs12709013	0.792	rs1646270	ENSG00000233719.3	GOT2P3	9.24	8.69e-19	2.5e-12	0.48	0.39	Blood metabolite ratios;	chr16:58745823	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs12325054	ENSG00000233719.3	GOT2P3	9.24	8.73e-19	2.51e-12	0.48	0.39	Blood metabolite ratios;	chr16:58749804	chr12:9641802~9643007:+
THCA	trans	rs11098499	0.866	rs7665125	ENSG00000275858.1	RP11-291L22.8	9.24	8.81e-19	2.54e-12	0.5	0.39	Corneal astigmatism;	chr4:119480924	chr10:38450738~38451069:-
THCA	trans	rs1816752	0.819	rs4770664	ENSG00000224976.2	PARP4P2	-9.24	8.85e-19	2.55e-12	-0.46	-0.39	Obesity-related traits;	chr13:24414695	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.935	rs4770676	ENSG00000224976.2	PARP4P2	-9.24	8.86e-19	2.55e-12	-0.47	-0.39	Obesity-related traits;	chr13:24429745	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs7995492	ENSG00000224976.2	PARP4P2	-9.24	8.87e-19	2.55e-12	-0.46	-0.39	Obesity-related traits;	chr13:24438885	chr13:19349137~19407962:+
THCA	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	9.23	9.12e-19	2.62e-12	0.5	0.39	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
THCA	trans	rs6424115	0.83	rs6673210	ENSG00000228217.1	AL390877.1	-9.23	9.18e-19	2.64e-12	-0.52	-0.39	Immature fraction of reticulocytes;	chr1:23877044	chr1:117778087~117778506:-
THCA	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	9.23	9.23e-19	2.65e-12	0.61	0.39	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	9.23	9.23e-19	2.65e-12	0.61	0.39	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
THCA	trans	rs1816752	0.783	rs7317439	ENSG00000224976.2	PARP4P2	-9.23	9.25e-19	2.66e-12	-0.46	-0.39	Obesity-related traits;	chr13:24410939	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.819	rs7317504	ENSG00000224976.2	PARP4P2	-9.23	9.25e-19	2.66e-12	-0.46	-0.39	Obesity-related traits;	chr13:24411287	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.783	rs7317712	ENSG00000224976.2	PARP4P2	-9.23	9.25e-19	2.66e-12	-0.46	-0.39	Obesity-related traits;	chr13:24411365	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.783	rs7139527	ENSG00000224976.2	PARP4P2	-9.23	9.25e-19	2.66e-12	-0.46	-0.39	Obesity-related traits;	chr13:24411374	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.819	rs9511240	ENSG00000224976.2	PARP4P2	-9.23	9.25e-19	2.66e-12	-0.46	-0.39	Obesity-related traits;	chr13:24411768	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.819	rs7988388	ENSG00000224976.2	PARP4P2	-9.23	9.25e-19	2.66e-12	-0.46	-0.39	Obesity-related traits;	chr13:24412675	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.875	rs7993132	ENSG00000224976.2	PARP4P2	-9.23	9.25e-19	2.66e-12	-0.46	-0.39	Obesity-related traits;	chr13:24412903	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.792	rs7330956	ENSG00000224976.2	PARP4P2	-9.23	9.25e-19	2.66e-12	-0.46	-0.39	Obesity-related traits;	chr13:24413174	chr13:19349137~19407962:+
THCA	trans	rs1039766	1	rs12104748	ENSG00000224334.1	AP000357.4	-9.23	9.27e-19	2.66e-12	-0.61	-0.39	Lung adenocarcinoma;Lung cancer;	chr2:65290112	chr22:24686923~24688087:+
THCA	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	9.23	9.27e-19	2.66e-12	0.51	0.39	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
THCA	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	9.23	9.34e-19	2.68e-12	0.51	0.39	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
THCA	trans	rs330048	0.561	rs330088	ENSG00000253893.2	FAM85B	-9.23	9.34e-19	2.68e-12	-0.51	-0.39	Systemic lupus erythematosus;	chr8:9292236	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.547	rs4512344	ENSG00000253893.2	FAM85B	9.23	9.44e-19	2.71e-12	0.53	0.39	Retinal vascular caliber;	chr8:11221272	chr8:8167819~8226614:-
THCA	trans	rs7833986	0.501	rs2719233	ENSG00000244245.1	RP11-120B7.1	9.23	9.44e-19	2.71e-12	0.54	0.39	Height;	chr8:55973597	chr5:108593609~108593967:+
THCA	trans	rs1816752	1	rs7999554	ENSG00000224976.2	PARP4P2	-9.23	9.61e-19	2.76e-12	-0.47	-0.39	Obesity-related traits;	chr13:24435631	chr13:19349137~19407962:+
THCA	trans	rs2243480	1	rs7456042	ENSG00000273142.1	RP11-458F8.4	-9.22	9.67e-19	2.77e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65834791	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs73142121	ENSG00000273142.1	RP11-458F8.4	-9.22	9.67e-19	2.77e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65846219	chr7:66902857~66906297:+
THCA	trans	rs13177918	0.75	rs59354956	ENSG00000226396.1	RP5-1056L3.3	9.22	9.67e-19	2.77e-12	0.39	0.39	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:19608114~19608568:+
THCA	trans	rs1816752	0.712	rs2862898	ENSG00000224976.2	PARP4P2	-9.22	9.73e-19	2.79e-12	-0.46	-0.39	Obesity-related traits;	chr13:24414323	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.652	rs2902356	ENSG00000224976.2	PARP4P2	-9.22	9.73e-19	2.79e-12	-0.46	-0.39	Obesity-related traits;	chr13:24414333	chr13:19349137~19407962:+
THCA	trans	rs2243480	1	rs34702770	ENSG00000273142.1	RP11-458F8.4	-9.22	9.83e-19	2.82e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65879836	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs34637256	ENSG00000273142.1	RP11-458F8.4	-9.22	9.83e-19	2.82e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65895144	chr7:66902857~66906297:+
THCA	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	9.22	9.92e-19	2.84e-12	0.51	0.39	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	9.22	9.92e-19	2.84e-12	0.51	0.39	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	9.22	9.92e-19	2.84e-12	0.51	0.39	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	9.22	9.92e-19	2.84e-12	0.51	0.39	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	9.22	9.92e-19	2.84e-12	0.51	0.39	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	9.22	9.92e-19	2.84e-12	0.51	0.39	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
THCA	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	9.22	9.92e-19	2.84e-12	0.51	0.39	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
THCA	trans	rs10037055	0.898	rs4976636	ENSG00000226986.4	RP11-543B16.2	-9.22	9.95e-19	2.85e-12	-0.49	-0.39	Migraine without aura;	chr5:177118091	chr1:211207239~211207897:+
THCA	trans	rs10037055	0.898	rs4976637	ENSG00000226986.4	RP11-543B16.2	-9.22	9.95e-19	2.85e-12	-0.49	-0.39	Migraine without aura;	chr5:177118141	chr1:211207239~211207897:+
THCA	trans	rs74781061	0.86	rs8033841	ENSG00000227288.3	RP5-837I24.1	9.22	1e-18	2.86e-12	0.55	0.39	Endometriosis;	chr15:74471540	chr1:81501794~81503468:+
THCA	trans	rs12497850	1	rs4858828	ENSG00000197582.5	GPX1P1	9.22	1.01e-18	2.88e-12	0.57	0.39	Parkinson's disease;	chr3:48687378	chrX:13378735~13379340:-
THCA	trans	rs12497850	1	rs4858798	ENSG00000197582.5	GPX1P1	9.22	1.01e-18	2.88e-12	0.57	0.39	Parkinson's disease;	chr3:48689679	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.741	rs4912597	ENSG00000231043.3	AC007238.1	9.21	1.05e-18	2.99e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140727272	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.771	rs2563334	ENSG00000231043.3	AC007238.1	9.21	1.05e-18	2.99e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140727480	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs778597	ENSG00000231043.3	AC007238.1	-9.21	1.07e-18	3.05e-12	-0.46	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140661080	chr2:58460292~58462032:-
THCA	trans	rs9650657	0.571	rs4240673	ENSG00000253893.2	FAM85B	9.21	1.07e-18	3.06e-12	0.5	0.39	Neuroticism;	chr8:10930102	chr8:8167819~8226614:-
THCA	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	9.21	1.09e-18	3.11e-12	0.51	0.39	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
THCA	trans	rs12497850	0.931	rs9840050	ENSG00000197582.5	GPX1P1	9.21	1.09e-18	3.12e-12	0.58	0.39	Parkinson's disease;	chr3:49095877	chrX:13378735~13379340:-
THCA	trans	rs13014235	0.579	rs6745435	ENSG00000235105.1	RP11-329A14.1	9.21	1.1e-18	3.13e-12	0.43	0.39	Basal cell carcinoma;	chr2:201337840	chr1:48435967~48437223:+
THCA	trans	rs916888	0.647	rs199449	ENSG00000204650.12	CRHR1-IT1	9.21	1.1e-18	3.14e-12	0.39	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45620328~45648216:+
THCA	trans	rs7662987	1	rs7684986	ENSG00000233859.2	ADH5P4	9.21	1.1e-18	3.14e-12	0.82	0.39	Smoking initiation;	chr4:99070525	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs1061187	ENSG00000233859.2	ADH5P4	9.21	1.1e-18	3.14e-12	0.82	0.39	Smoking initiation;	chr4:99071702	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs13145727	ENSG00000233859.2	ADH5P4	9.21	1.1e-18	3.14e-12	0.82	0.39	Smoking initiation;	chr4:99077715	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs13125919	ENSG00000233859.2	ADH5P4	9.21	1.1e-18	3.14e-12	0.82	0.39	Smoking initiation;	chr4:99078697	chr6:65836930~65838039:-
THCA	trans	rs1816752	0.777	rs6490915	ENSG00000224976.2	PARP4P2	-9.21	1.1e-18	3.14e-12	-0.47	-0.39	Obesity-related traits;	chr13:24413724	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.774	rs7986162	ENSG00000224976.2	PARP4P2	-9.21	1.1e-18	3.15e-12	-0.46	-0.39	Obesity-related traits;	chr13:24425941	chr13:19349137~19407962:+
THCA	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	9.21	1.11e-18	3.16e-12	0.51	0.39	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
THCA	trans	rs13190036	1	rs34446750	ENSG00000228305.2	AC016734.2	-9.2	1.14e-18	3.24e-12	-0.48	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr2:63622178~63622831:-
THCA	trans	rs6424115	0.83	rs6658703	ENSG00000228217.1	AL390877.1	-9.2	1.15e-18	3.28e-12	-0.52	-0.39	Immature fraction of reticulocytes;	chr1:23876926	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs2501434	ENSG00000228217.1	AL390877.1	-9.2	1.15e-18	3.28e-12	-0.52	-0.39	Immature fraction of reticulocytes;	chr1:23876935	chr1:117778087~117778506:-
THCA	trans	rs7819412	0.807	rs4840542	ENSG00000253893.2	FAM85B	9.2	1.15e-18	3.28e-12	0.52	0.39	Triglycerides;	chr8:11087299	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.755	rs1628029	ENSG00000233719.3	GOT2P3	9.2	1.17e-18	3.33e-12	0.47	0.39	Blood metabolite ratios;	chr16:58763846	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs1657165	ENSG00000233719.3	GOT2P3	9.2	1.17e-18	3.33e-12	0.47	0.39	Blood metabolite ratios;	chr16:58747980	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.818	rs1646273	ENSG00000233719.3	GOT2P3	9.2	1.17e-18	3.33e-12	0.47	0.39	Blood metabolite ratios;	chr16:58748318	chr12:9641802~9643007:+
THCA	trans	rs10816533	1	rs10816600	ENSG00000232063.1	RP11-307E17.8	9.2	1.18e-18	3.36e-12	0.92	0.39	Height;	chr9:96814142	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10979212	ENSG00000232063.1	RP11-307E17.8	9.2	1.18e-18	3.36e-12	0.92	0.39	Height;	chr9:96829446	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10979329	ENSG00000232063.1	RP11-307E17.8	9.2	1.18e-18	3.36e-12	0.92	0.39	Height;	chr9:96854542	chr9:94332476~94360948:+
THCA	trans	rs2243480	1	rs3885839	ENSG00000273142.1	RP11-458F8.4	-9.2	1.19e-18	3.38e-12	-0.5	-0.39	Diabetic kidney disease;	chr7:65825416	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs73142122	ENSG00000273142.1	RP11-458F8.4	-9.2	1.19e-18	3.38e-12	-0.5	-0.39	Diabetic kidney disease;	chr7:65846311	chr7:66902857~66906297:+
THCA	trans	rs2243480	0.901	rs73142137	ENSG00000273142.1	RP11-458F8.4	-9.2	1.19e-18	3.38e-12	-0.5	-0.39	Diabetic kidney disease;	chr7:65878455	chr7:66902857~66906297:+
THCA	trans	rs11098499	0.532	rs4833624	ENSG00000275858.1	RP11-291L22.8	9.2	1.19e-18	3.39e-12	0.52	0.39	Corneal astigmatism;	chr4:119664342	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.532	rs12512646	ENSG00000275858.1	RP11-291L22.8	9.2	1.19e-18	3.39e-12	0.52	0.39	Corneal astigmatism;	chr4:119664578	chr10:38450738~38451069:-
THCA	trans	rs10037055	0.853	rs6890580	ENSG00000228305.2	AC016734.2	-9.2	1.19e-18	3.4e-12	-0.42	-0.39	Migraine without aura;	chr5:177226519	chr2:63622178~63622831:-
THCA	trans	rs2243480	1	rs13247184	ENSG00000273142.1	RP11-458F8.4	-9.2	1.21e-18	3.45e-12	-0.5	-0.39	Diabetic kidney disease;	chr7:65893941	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs35283677	ENSG00000273142.1	RP11-458F8.4	-9.2	1.21e-18	3.45e-12	-0.5	-0.39	Diabetic kidney disease;	chr7:65894246	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs35421653	ENSG00000273142.1	RP11-458F8.4	-9.2	1.21e-18	3.45e-12	-0.5	-0.39	Diabetic kidney disease;	chr7:65898442	chr7:66902857~66906297:+
THCA	trans	rs74781061	0.929	rs9672559	ENSG00000227288.3	RP5-837I24.1	9.2	1.21e-18	3.45e-12	0.55	0.39	Endometriosis;	chr15:74698995	chr1:81501794~81503468:+
THCA	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	9.19	1.22e-18	3.47e-12	0.51	0.39	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
THCA	trans	rs13177918	0.75	rs58256223	ENSG00000226396.1	RP5-1056L3.3	9.19	1.23e-18	3.49e-12	0.39	0.39	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:19608114~19608568:+
THCA	trans	rs3806843	0.932	rs2563269	ENSG00000231043.3	AC007238.1	9.19	1.23e-18	3.51e-12	0.44	0.39	Depressive symptoms (multi-trait analysis);	chr5:140756883	chr2:58460292~58462032:-
THCA	trans	rs1039766	1	rs268882	ENSG00000224334.1	AP000357.4	-9.19	1.24e-18	3.52e-12	-0.59	-0.39	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr22:24686923~24688087:+
THCA	trans	rs1045902	0.583	rs36106493	ENSG00000236165.1	PRADC1P1	9.19	1.25e-18	3.54e-12	0.52	0.39	Intelligence (multi-trait analysis);	chr2:73215211	chr3:36976316~36976840:+
THCA	trans	rs1816752	0.905	rs4769352	ENSG00000224976.2	PARP4P2	-9.19	1.26e-18	3.59e-12	-0.46	-0.39	Obesity-related traits;	chr13:24426237	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.805	rs4769353	ENSG00000224976.2	PARP4P2	-9.19	1.26e-18	3.59e-12	-0.46	-0.39	Obesity-related traits;	chr13:24426318	chr13:19349137~19407962:+
THCA	trans	rs12138950	0.625	rs12041608	ENSG00000224237.1	MINOS1P3	-9.19	1.28e-18	3.63e-12	-0.53	-0.39	Hypothyroidism;Thyroid volume;	chr1:19515431	chr3:27214816~27215018:-
THCA	trans	rs1039766	0.929	rs55843720	ENSG00000224334.1	AP000357.4	9.19	1.28e-18	3.65e-12	0.61	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr22:24686923~24688087:+
THCA	trans	rs3806843	0.801	rs2531358	ENSG00000231043.3	AC007238.1	9.18	1.32e-18	3.76e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.735	rs778595	ENSG00000231043.3	AC007238.1	9.18	1.34e-18	3.8e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140657096	chr2:58460292~58462032:-
THCA	trans	rs10435719	0.61	rs76311455	ENSG00000253893.2	FAM85B	-9.18	1.35e-18	3.83e-12	-0.54	-0.39	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933017	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.61	rs80269926	ENSG00000253893.2	FAM85B	-9.18	1.35e-18	3.83e-12	-0.54	-0.39	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933018	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.792	rs62064901	ENSG00000233719.3	GOT2P3	9.18	1.36e-18	3.86e-12	0.47	0.39	Blood metabolite ratios;	chr16:58776758	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs12935488	ENSG00000233719.3	GOT2P3	9.18	1.37e-18	3.87e-12	0.47	0.39	Blood metabolite ratios;	chr16:58766320	chr12:9641802~9643007:+
THCA	trans	rs916888	0.61	rs199436	ENSG00000204650.12	CRHR1-IT1	-9.18	1.37e-18	3.89e-12	-0.38	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45620328~45648216:+
THCA	trans	rs7819412	0.775	rs34094119	ENSG00000253893.2	FAM85B	9.18	1.37e-18	3.89e-12	0.5	0.39	Triglycerides;	chr8:11078388	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.853	rs1363405	ENSG00000226986.4	RP11-543B16.2	9.18	1.38e-18	3.91e-12	0.49	0.39	Migraine without aura;	chr5:177209881	chr1:211207239~211207897:+
THCA	trans	rs12709013	0.59	rs982848	ENSG00000230849.2	GOT2P2	9.18	1.39e-18	3.94e-12	0.47	0.39	Blood metabolite ratios;	chr16:58704294	chr1:173141100~173142350:-
THCA	trans	rs5022636	0.964	rs1056847	ENSG00000180764.13	PIPSL	9.18	1.41e-18	4e-12	0.44	0.39	Gut microbiota (functional units);	chr1:151315696	chr10:93958191~93961540:-
THCA	trans	rs66887589	0.616	rs11098498	ENSG00000275858.1	RP11-291L22.8	9.18	1.43e-18	4.04e-12	0.48	0.39	Diastolic blood pressure;	chr4:119265964	chr10:38450738~38451069:-
THCA	trans	rs1816752	0.837	rs9318530	ENSG00000224976.2	PARP4P2	9.17	1.44e-18	4.07e-12	0.46	0.39	Obesity-related traits;	chr13:24424419	chr13:19349137~19407962:+
THCA	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	9.17	1.46e-18	4.12e-12	0.6	0.39	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
THCA	trans	rs10037055	0.741	rs2336405	ENSG00000228305.2	AC016734.2	-9.17	1.46e-18	4.14e-12	-0.42	-0.39	Migraine without aura;	chr5:177230288	chr2:63622178~63622831:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000225071.1	GS1-184P14.2	-9.17	1.47e-18	4.14e-12	-0.57	-0.39	Asthma;	chr12:55970537	chrX:24429573~24429920:-
THCA	trans	rs7662987	0.793	rs12697	ENSG00000228407.2	RP4-800M22.1	-9.17	1.47e-18	4.16e-12	-0.74	-0.39	Smoking initiation;	chr4:99072225	chr1:52160261~52160600:-
THCA	trans	rs7647973	0.961	rs7638750	ENSG00000197582.5	GPX1P1	-9.17	1.48e-18	4.19e-12	-0.62	-0.39	Menarche (age at onset);	chr3:49415524	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.705	rs2530230	ENSG00000231043.3	AC007238.1	9.17	1.52e-18	4.3e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140708546	chr2:58460292~58462032:-
THCA	trans	rs12709013	0.792	rs12325510	ENSG00000233719.3	GOT2P3	9.17	1.54e-18	4.35e-12	0.48	0.39	Blood metabolite ratios;	chr16:58749707	chr12:9641802~9643007:+
THCA	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-9.16	1.55e-18	4.39e-12	-0.51	-0.39	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
THCA	trans	rs1039766	1	rs268853	ENSG00000224334.1	AP000357.4	9.16	1.56e-18	4.39e-12	0.61	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65250869	chr22:24686923~24688087:+
THCA	trans	rs916888	0.647	rs199524	ENSG00000280022.1	RP11-707O23.1	9.16	1.56e-18	4.4e-12	0.41	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45592621~45593369:+
THCA	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	9.16	1.58e-18	4.46e-12	0.51	0.39	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
THCA	trans	rs4295623	0.531	rs2898295	ENSG00000253893.2	FAM85B	9.16	1.64e-18	4.61e-12	0.49	0.39	Morning vs. evening chronotype;	chr8:11738460	chr8:8167819~8226614:-
THCA	trans	rs1816752	0.905	rs13428	ENSG00000224976.2	PARP4P2	-9.16	1.65e-18	4.63e-12	-0.46	-0.39	Obesity-related traits;	chr13:24435303	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs8000215	ENSG00000224976.2	PARP4P2	-9.16	1.65e-18	4.63e-12	-0.46	-0.39	Obesity-related traits;	chr13:24435648	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs2033955	ENSG00000224976.2	PARP4P2	-9.16	1.65e-18	4.63e-12	-0.46	-0.39	Obesity-related traits;	chr13:24436406	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs2033954	ENSG00000224976.2	PARP4P2	-9.16	1.65e-18	4.63e-12	-0.46	-0.39	Obesity-related traits;	chr13:24436429	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs9511260	ENSG00000224976.2	PARP4P2	-9.16	1.65e-18	4.63e-12	-0.46	-0.39	Obesity-related traits;	chr13:24437038	chr13:19349137~19407962:+
THCA	trans	rs66887589	0.616	rs10032299	ENSG00000275858.1	RP11-291L22.8	9.16	1.66e-18	4.68e-12	0.48	0.39	Diastolic blood pressure;	chr4:119285264	chr10:38450738~38451069:-
THCA	trans	rs7503168	1	rs12604067	ENSG00000234130.2	RP13-88F20.1	9.15	1.69e-18	4.76e-12	0.51	0.39	Plateletcrit;	chr17:35625084	chrX:93222220~93225015:-
THCA	trans	rs7503168	0.73	rs11655803	ENSG00000234130.2	RP13-88F20.1	9.15	1.69e-18	4.76e-12	0.51	0.39	Plateletcrit;	chr17:35625677	chrX:93222220~93225015:-
THCA	trans	rs12497850	0.543	rs6446218	ENSG00000197582.5	GPX1P1	9.15	1.69e-18	4.77e-12	0.58	0.39	Parkinson's disease;	chr3:49038080	chrX:13378735~13379340:-
THCA	trans	rs10037055	0.853	rs2336237	ENSG00000228305.2	AC016734.2	9.15	1.69e-18	4.77e-12	0.42	0.39	Migraine without aura;	chr5:177238878	chr2:63622178~63622831:-
THCA	trans	rs916888	0.61	rs199444	ENSG00000204650.12	CRHR1-IT1	9.15	1.72e-18	4.84e-12	0.39	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45620328~45648216:+
THCA	trans	rs916888	0.61	rs199442	ENSG00000204650.12	CRHR1-IT1	9.15	1.72e-18	4.84e-12	0.39	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45620328~45648216:+
THCA	trans	rs12497850	0.931	rs13064784	ENSG00000197582.5	GPX1P1	9.15	1.73e-18	4.87e-12	0.58	0.39	Parkinson's disease;	chr3:49098528	chrX:13378735~13379340:-
THCA	trans	rs10037055	0.853	rs1363405	ENSG00000228305.2	AC016734.2	9.15	1.73e-18	4.87e-12	0.42	0.39	Migraine without aura;	chr5:177209881	chr2:63622178~63622831:-
THCA	trans	rs6743068	0.541	rs7578456	ENSG00000235105.1	RP11-329A14.1	9.15	1.74e-18	4.88e-12	0.44	0.39	Lymphocyte percentage of white cells;	chr2:201370625	chr1:48435967~48437223:+
THCA	trans	rs3806843	0.735	rs801188	ENSG00000231043.3	AC007238.1	9.15	1.78e-18	5e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140687331	chr2:58460292~58462032:-
THCA	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-9.15	1.79e-18	5.03e-12	-0.61	-0.39	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-9.15	1.79e-18	5.03e-12	-0.61	-0.39	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.863	rs4974084	ENSG00000197582.5	GPX1P1	9.15	1.79e-18	5.04e-12	0.58	0.39	Parkinson's disease;	chr3:48901647	chrX:13378735~13379340:-
THCA	trans	rs1816752	0.875	rs1050110	ENSG00000224976.2	PARP4P2	-9.15	1.8e-18	5.05e-12	-0.46	-0.39	Obesity-related traits;	chr13:24435347	chr13:19349137~19407962:+
THCA	trans	rs7819412	0.775	rs4841489	ENSG00000253893.2	FAM85B	9.14	1.83e-18	5.13e-12	0.5	0.39	Triglycerides;	chr8:11079301	chr8:8167819~8226614:-
THCA	trans	rs12497850	0.931	rs13316620	ENSG00000197582.5	GPX1P1	9.14	1.83e-18	5.14e-12	0.57	0.39	Parkinson's disease;	chr3:49007922	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.735	rs778596	ENSG00000231043.3	AC007238.1	9.14	1.84e-18	5.16e-12	0.46	0.39	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr2:58460292~58462032:-
THCA	trans	rs4295623	0.559	rs2409836	ENSG00000253893.2	FAM85B	-9.14	1.84e-18	5.16e-12	-0.52	-0.39	Morning vs. evening chronotype;	chr8:11831719	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.687	rs6556308	ENSG00000228305.2	AC016734.2	-9.14	1.84e-18	5.16e-12	-0.42	-0.39	Migraine without aura;	chr5:177219700	chr2:63622178~63622831:-
THCA	trans	rs11098499	0.657	rs10434028	ENSG00000275858.1	RP11-291L22.8	9.14	1.84e-18	5.17e-12	0.5	0.39	Corneal astigmatism;	chr4:119373309	chr10:38450738~38451069:-
THCA	trans	rs1816752	0.905	rs7991450	ENSG00000224976.2	PARP4P2	-9.14	1.89e-18	5.3e-12	-0.46	-0.39	Obesity-related traits;	chr13:24425898	chr13:19349137~19407962:+
THCA	trans	rs13190036	0.551	rs11957608	ENSG00000228305.2	AC016734.2	-9.14	1.92e-18	5.38e-12	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr2:63622178~63622831:-
THCA	trans	rs13016963	0.546	rs11898821	ENSG00000235105.1	RP11-329A14.1	9.14	1.95e-18	5.48e-12	0.42	0.39	Esophageal squamous cell carcinoma;Melanoma;	chr2:201334965	chr1:48435967~48437223:+
THCA	trans	rs12497850	0.931	rs6446205	ENSG00000197582.5	GPX1P1	9.13	1.96e-18	5.5e-12	0.58	0.39	Parkinson's disease;	chr3:48997778	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.897	rs6795025	ENSG00000197582.5	GPX1P1	9.13	1.96e-18	5.5e-12	0.58	0.39	Parkinson's disease;	chr3:49043814	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.897	rs7432989	ENSG00000197582.5	GPX1P1	9.13	1.96e-18	5.5e-12	0.58	0.39	Parkinson's disease;	chr3:49067703	chrX:13378735~13379340:-
THCA	trans	rs9329221	0.905	rs10283145	ENSG00000253893.2	FAM85B	9.13	1.97e-18	5.52e-12	0.51	0.39	Neuroticism;	chr8:10383901	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.806	rs6980856	ENSG00000253893.2	FAM85B	-9.13	1.98e-18	5.56e-12	-0.51	-0.39	Triglycerides;	chr8:11080750	chr8:8167819~8226614:-
THCA	trans	rs12497850	0.931	rs7621015	ENSG00000197582.5	GPX1P1	9.13	2.01e-18	5.63e-12	0.58	0.39	Parkinson's disease;	chr3:48978623	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs4072859	ENSG00000197582.5	GPX1P1	9.13	2.01e-18	5.63e-12	0.58	0.39	Parkinson's disease;	chr3:48994772	chrX:13378735~13379340:-
THCA	trans	rs6424115	0.83	rs2501431	ENSG00000228217.1	AL390877.1	-9.13	2.02e-18	5.66e-12	-0.51	-0.39	Immature fraction of reticulocytes;	chr1:23875153	chr1:117778087~117778506:-
THCA	trans	rs1816752	0.905	rs1050112	ENSG00000224976.2	PARP4P2	-9.13	2.03e-18	5.7e-12	-0.46	-0.39	Obesity-related traits;	chr13:24435159	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs9511264	ENSG00000224976.2	PARP4P2	9.13	2.05e-18	5.74e-12	0.46	0.39	Obesity-related traits;	chr13:24438079	chr13:19349137~19407962:+
THCA	trans	rs1079467	1	rs1079467	ENSG00000233426.3	EIF3FP3	-9.13	2.06e-18	5.78e-12	-0.61	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7948164	chr2:58251440~58252525:+
THCA	trans	rs11098499	0.821	rs56155624	ENSG00000275858.1	RP11-291L22.8	9.13	2.07e-18	5.8e-12	0.5	0.39	Corneal astigmatism;	chr4:119369871	chr10:38450738~38451069:-
THCA	trans	rs7819412	0.806	rs17723229	ENSG00000253893.2	FAM85B	9.13	2.08e-18	5.82e-12	0.52	0.39	Triglycerides;	chr8:11072559	chr8:8167819~8226614:-
THCA	trans	rs6424115	0.83	rs2502991	ENSG00000228217.1	AL390877.1	-9.13	2.11e-18	5.92e-12	-0.51	-0.39	Immature fraction of reticulocytes;	chr1:23875828	chr1:117778087~117778506:-
THCA	trans	rs13190036	1	rs628506	ENSG00000228305.2	AC016734.2	-9.12	2.15e-18	6.01e-12	-0.45	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr2:63622178~63622831:-
THCA	trans	rs6424115	0.83	rs2502992	ENSG00000228217.1	AL390877.1	-9.12	2.16e-18	6.03e-12	-0.51	-0.39	Immature fraction of reticulocytes;	chr1:23875429	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.867	rs2501432	ENSG00000228217.1	AL390877.1	-9.12	2.16e-18	6.03e-12	-0.51	-0.39	Immature fraction of reticulocytes;	chr1:23875430	chr1:117778087~117778506:-
THCA	trans	rs10037055	0.685	rs10039241	ENSG00000228305.2	AC016734.2	-9.12	2.16e-18	6.03e-12	-0.43	-0.39	Migraine without aura;	chr5:177151071	chr2:63622178~63622831:-
THCA	trans	rs7819412	0.818	rs11989439	ENSG00000253893.2	FAM85B	9.12	2.18e-18	6.09e-12	0.52	0.39	Triglycerides;	chr8:11198088	chr8:8167819~8226614:-
THCA	trans	rs12497850	0.931	rs4974080	ENSG00000197582.5	GPX1P1	9.12	2.18e-18	6.1e-12	0.58	0.39	Parkinson's disease;	chr3:48993395	chrX:13378735~13379340:-
THCA	trans	rs3779195	0.52	rs17169479	ENSG00000225169.1	BRI3P1	9.12	2.24e-18	6.26e-12	0.62	0.39	Sex hormone-binding globulin levels;	chr7:98238721	chr1:100213293~100213670:+
THCA	trans	rs12497850	0.931	rs7636057	ENSG00000197582.5	GPX1P1	9.12	2.26e-18	6.31e-12	0.58	0.39	Parkinson's disease;	chr3:48955149	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs7643368	ENSG00000197582.5	GPX1P1	9.12	2.26e-18	6.31e-12	0.58	0.39	Parkinson's disease;	chr3:48955422	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.866	rs6791234	ENSG00000197582.5	GPX1P1	9.12	2.26e-18	6.31e-12	0.58	0.39	Parkinson's disease;	chr3:48958704	chrX:13378735~13379340:-
THCA	trans	rs7503168	1	rs35237539	ENSG00000234130.2	RP13-88F20.1	9.12	2.26e-18	6.31e-12	0.5	0.39	Plateletcrit;	chr17:35602563	chrX:93222220~93225015:-
THCA	trans	rs9650657	0.589	rs12542037	ENSG00000253893.2	FAM85B	-9.11	2.29e-18	6.4e-12	-0.48	-0.39	Neuroticism;	chr8:10900986	chr8:8167819~8226614:-
THCA	trans	rs2243480	1	rs34815098	ENSG00000273142.1	RP11-458F8.4	-9.11	2.32e-18	6.46e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65827267	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs35735127	ENSG00000273142.1	RP11-458F8.4	-9.11	2.32e-18	6.46e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65835436	chr7:66902857~66906297:+
THCA	trans	rs2243480	0.901	rs35256305	ENSG00000273142.1	RP11-458F8.4	-9.11	2.32e-18	6.46e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65841418	chr7:66902857~66906297:+
THCA	trans	rs2243480	0.803	rs34004500	ENSG00000273142.1	RP11-458F8.4	-9.11	2.32e-18	6.46e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65847191	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs35825738	ENSG00000273142.1	RP11-458F8.4	-9.11	2.32e-18	6.46e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65853040	chr7:66902857~66906297:+
THCA	trans	rs7819412	0.807	rs9657519	ENSG00000253893.2	FAM85B	9.11	2.32e-18	6.48e-12	0.51	0.39	Triglycerides;	chr8:11087929	chr8:8167819~8226614:-
THCA	trans	rs11023332	0.706	rs10766197	ENSG00000236360.2	RP11-334A14.2	9.11	2.36e-18	6.58e-12	0.5	0.39	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr1:52993201~52993702:-
THCA	trans	rs2898290	0.622	rs7822109	ENSG00000253893.2	FAM85B	9.11	2.36e-18	6.58e-12	0.53	0.39	Systolic blood pressure;	chr8:11491638	chr8:8167819~8226614:-
THCA	trans	rs2243480	0.803	rs35480979	ENSG00000273142.1	RP11-458F8.4	-9.11	2.37e-18	6.6e-12	-0.48	-0.39	Diabetic kidney disease;	chr7:65892097	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs35391607	ENSG00000273142.1	RP11-458F8.4	-9.11	2.37e-18	6.6e-12	-0.48	-0.39	Diabetic kidney disease;	chr7:65895842	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs13220979	ENSG00000273142.1	RP11-458F8.4	-9.11	2.37e-18	6.6e-12	-0.48	-0.39	Diabetic kidney disease;	chr7:65898217	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs34974928	ENSG00000273142.1	RP11-458F8.4	-9.11	2.37e-18	6.6e-12	-0.48	-0.39	Diabetic kidney disease;	chr7:65899019	chr7:66902857~66906297:+
THCA	trans	rs13190036	0.551	rs9313751	ENSG00000228305.2	AC016734.2	-9.11	2.38e-18	6.63e-12	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr2:63622178~63622831:-
THCA	trans	rs916888	0.61	rs199452	ENSG00000204650.12	CRHR1-IT1	9.11	2.39e-18	6.67e-12	0.38	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45620328~45648216:+
THCA	trans	rs10037055	0.853	rs10035180	ENSG00000228305.2	AC016734.2	-9.11	2.41e-18	6.73e-12	-0.42	-0.39	Migraine without aura;	chr5:177171501	chr2:63622178~63622831:-
THCA	trans	rs10037055	0.853	rs1546363	ENSG00000228305.2	AC016734.2	-9.11	2.41e-18	6.73e-12	-0.42	-0.39	Migraine without aura;	chr5:177174030	chr2:63622178~63622831:-
THCA	trans	rs7819412	0.774	rs34208825	ENSG00000253893.2	FAM85B	9.1	2.49e-18	6.93e-12	0.51	0.39	Triglycerides;	chr8:11157106	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.853	rs10036193	ENSG00000228305.2	AC016734.2	-9.1	2.5e-18	6.95e-12	-0.42	-0.39	Migraine without aura;	chr5:177141519	chr2:63622178~63622831:-
THCA	trans	rs10037055	0.853	rs9885210	ENSG00000228305.2	AC016734.2	-9.1	2.5e-18	6.95e-12	-0.42	-0.39	Migraine without aura;	chr5:177142187	chr2:63622178~63622831:-
THCA	trans	rs12709013	0.792	rs7185513	ENSG00000233719.3	GOT2P3	9.1	2.54e-18	7.06e-12	0.47	0.39	Blood metabolite ratios;	chr16:58794889	chr12:9641802~9643007:+
THCA	trans	rs66887589	0.616	rs11098497	ENSG00000275858.1	RP11-291L22.8	9.1	2.56e-18	7.14e-12	0.48	0.39	Diastolic blood pressure;	chr4:119265913	chr10:38450738~38451069:-
THCA	trans	rs916888	0.531	rs183211	ENSG00000204650.12	CRHR1-IT1	9.1	2.62e-18	7.29e-12	0.38	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45620328~45648216:+
THCA	trans	rs13190036	0.551	rs7732930	ENSG00000228305.2	AC016734.2	-9.1	2.63e-18	7.32e-12	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr2:63622178~63622831:-
THCA	trans	rs9329221	0.905	rs13252982	ENSG00000253893.2	FAM85B	9.1	2.65e-18	7.37e-12	0.5	0.39	Neuroticism;	chr8:10397595	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.87	rs11777976	ENSG00000253893.2	FAM85B	9.1	2.65e-18	7.37e-12	0.5	0.39	Neuroticism;	chr8:10397892	chr8:8167819~8226614:-
THCA	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	9.1	2.67e-18	7.42e-12	0.51	0.39	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
THCA	trans	rs1816752	0.905	rs7571	ENSG00000224976.2	PARP4P2	-9.09	2.68e-18	7.46e-12	-0.46	-0.39	Obesity-related traits;	chr13:24426479	chr13:19349137~19407962:+
THCA	trans	rs7647973	1	rs3866330	ENSG00000197582.5	GPX1P1	9.09	2.71e-18	7.53e-12	0.61	0.39	Menarche (age at onset);	chr3:49545561	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs3870341	ENSG00000197582.5	GPX1P1	9.09	2.71e-18	7.53e-12	0.61	0.39	Menarche (age at onset);	chr3:49547312	chrX:13378735~13379340:-
THCA	trans	rs9650657	0.535	rs7011756	ENSG00000253893.2	FAM85B	9.09	2.71e-18	7.53e-12	0.51	0.39	Neuroticism;	chr8:11162068	chr8:8167819~8226614:-
THCA	trans	rs1816752	0.87	rs9581025	ENSG00000224976.2	PARP4P2	-9.09	2.73e-18	7.59e-12	-0.46	-0.39	Obesity-related traits;	chr13:24423687	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs9581027	ENSG00000224976.2	PARP4P2	-9.09	2.73e-18	7.59e-12	-0.46	-0.39	Obesity-related traits;	chr13:24423790	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs9318529	ENSG00000224976.2	PARP4P2	-9.09	2.73e-18	7.59e-12	-0.46	-0.39	Obesity-related traits;	chr13:24424190	chr13:19349137~19407962:+
THCA	trans	rs10037055	0.853	rs12660023	ENSG00000228305.2	AC016734.2	9.09	2.74e-18	7.6e-12	0.42	0.39	Migraine without aura;	chr5:177273884	chr2:63622178~63622831:-
THCA	trans	rs10037055	0.853	rs4976680	ENSG00000228305.2	AC016734.2	9.09	2.74e-18	7.6e-12	0.42	0.39	Migraine without aura;	chr5:177275745	chr2:63622178~63622831:-
THCA	trans	rs10037055	0.853	rs4976681	ENSG00000228305.2	AC016734.2	9.09	2.74e-18	7.6e-12	0.42	0.39	Migraine without aura;	chr5:177277662	chr2:63622178~63622831:-
THCA	trans	rs10037055	0.853	rs10056008	ENSG00000228305.2	AC016734.2	-9.09	2.75e-18	7.64e-12	-0.42	-0.39	Migraine without aura;	chr5:177194147	chr2:63622178~63622831:-
THCA	trans	rs10037055	0.853	rs10476219	ENSG00000228305.2	AC016734.2	-9.09	2.75e-18	7.64e-12	-0.42	-0.39	Migraine without aura;	chr5:177201547	chr2:63622178~63622831:-
THCA	trans	rs7819412	0.775	rs11773990	ENSG00000253893.2	FAM85B	9.09	2.77e-18	7.69e-12	0.5	0.39	Triglycerides;	chr8:11077572	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.775	rs4545055	ENSG00000253893.2	FAM85B	9.09	2.77e-18	7.69e-12	0.5	0.39	Triglycerides;	chr8:11077856	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.775	rs2898257	ENSG00000253893.2	FAM85B	9.09	2.77e-18	7.69e-12	0.5	0.39	Triglycerides;	chr8:11077858	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.905	rs13254263	ENSG00000253893.2	FAM85B	9.09	2.78e-18	7.72e-12	0.5	0.39	Neuroticism;	chr8:10397671	chr8:8167819~8226614:-
THCA	trans	rs7662987	0.793	rs78790289	ENSG00000228407.2	RP4-800M22.1	9.09	2.79e-18	7.75e-12	0.75	0.39	Smoking initiation;	chr4:99066736	chr1:52160261~52160600:-
THCA	trans	rs6424115	0.83	rs2502993	ENSG00000228217.1	AL390877.1	-9.09	2.8e-18	7.77e-12	-0.51	-0.39	Immature fraction of reticulocytes;	chr1:23874772	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs4649124	ENSG00000228217.1	AL390877.1	-9.09	2.8e-18	7.77e-12	-0.51	-0.39	Immature fraction of reticulocytes;	chr1:23874867	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs3003336	ENSG00000228217.1	AL390877.1	-9.09	2.8e-18	7.77e-12	-0.51	-0.39	Immature fraction of reticulocytes;	chr1:23874958	chr1:117778087~117778506:-
THCA	trans	rs74781061	0.929	rs6495108	ENSG00000227288.3	RP5-837I24.1	9.09	2.81e-18	7.8e-12	0.55	0.39	Endometriosis;	chr15:74502186	chr1:81501794~81503468:+
THCA	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	7.87e-12	0.5	0.39	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	9.09	2.84e-18	7.87e-12	0.5	0.39	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
THCA	trans	rs1816752	0.87	rs73469543	ENSG00000224976.2	PARP4P2	-9.09	2.84e-18	7.89e-12	-0.46	-0.39	Obesity-related traits;	chr13:24424832	chr13:19349137~19407962:+
THCA	trans	rs9650657	0.538	rs11250093	ENSG00000253893.2	FAM85B	-9.09	2.84e-18	7.89e-12	-0.51	-0.39	Neuroticism;	chr8:10941318	chr8:8167819~8226614:-
THCA	trans	rs12497850	0.931	rs6414613	ENSG00000197582.5	GPX1P1	9.09	2.86e-18	7.94e-12	0.57	0.39	Parkinson's disease;	chr3:48998452	chrX:13378735~13379340:-
THCA	trans	rs916888	0.61	rs142167	ENSG00000204650.12	CRHR1-IT1	-9.09	2.87e-18	7.96e-12	-0.38	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45620328~45648216:+
THCA	trans	rs6743068	0.541	rs6761514	ENSG00000235105.1	RP11-329A14.1	9.09	2.88e-18	7.98e-12	0.43	0.39	Lymphocyte percentage of white cells;	chr2:201362826	chr1:48435967~48437223:+
THCA	trans	rs12497850	0.897	rs9884022	ENSG00000197582.5	GPX1P1	9.09	2.88e-18	7.99e-12	0.58	0.39	Parkinson's disease;	chr3:48919429	chrX:13378735~13379340:-
THCA	trans	rs7819412	0.775	rs4841490	ENSG00000253893.2	FAM85B	9.08	2.91e-18	8.07e-12	0.5	0.39	Triglycerides;	chr8:11079381	chr8:8167819~8226614:-
THCA	trans	rs7647973	1	rs3905330	ENSG00000197582.5	GPX1P1	9.08	2.98e-18	8.25e-12	0.6	0.39	Menarche (age at onset);	chr3:49513341	chrX:13378735~13379340:-
THCA	trans	rs7503168	1	rs16971227	ENSG00000234130.2	RP13-88F20.1	9.08	2.98e-18	8.26e-12	0.5	0.39	Plateletcrit;	chr17:35622203	chrX:93222220~93225015:-
THCA	trans	rs12497850	0.931	rs6446196	ENSG00000197582.5	GPX1P1	9.08	2.99e-18	8.27e-12	0.57	0.39	Parkinson's disease;	chr3:48967290	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.805	rs6446198	ENSG00000197582.5	GPX1P1	9.08	2.99e-18	8.27e-12	0.57	0.39	Parkinson's disease;	chr3:48970205	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	9.08	3e-18	8.31e-12	0.49	0.39	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
THCA	trans	rs13190036	1	rs351862	ENSG00000228305.2	AC016734.2	-9.08	3.01e-18	8.34e-12	-0.48	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr2:63622178~63622831:-
THCA	trans	rs1816752	0.819	rs6490917	ENSG00000224976.2	PARP4P2	-9.08	3.02e-18	8.35e-12	-0.45	-0.39	Obesity-related traits;	chr13:24423119	chr13:19349137~19407962:+
THCA	trans	rs2898290	0.617	rs13278965	ENSG00000253893.2	FAM85B	-9.08	3.04e-18	8.41e-12	-0.52	-0.39	Systolic blood pressure;	chr8:11609236	chr8:8167819~8226614:-
THCA	trans	rs7662987	0.877	rs13120000	ENSG00000233859.2	ADH5P4	9.08	3.04e-18	8.41e-12	0.83	0.39	Smoking initiation;	chr4:99065196	chr6:65836930~65838039:-
THCA	trans	rs12497850	0.829	rs8926	ENSG00000197582.5	GPX1P1	9.08	3.04e-18	8.42e-12	0.57	0.39	Parkinson's disease;	chr3:49015352	chrX:13378735~13379340:-
THCA	trans	rs10816533	1	rs10124033	ENSG00000232063.1	RP11-307E17.8	-9.08	3.1e-18	8.57e-12	-0.93	-0.39	Height;	chr9:96851822	chr9:94332476~94360948:+
THCA	trans	rs7819412	0.745	rs4841498	ENSG00000253893.2	FAM85B	9.08	3.1e-18	8.57e-12	0.51	0.39	Triglycerides;	chr8:11127922	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.812	rs11949435	ENSG00000228305.2	AC016734.2	9.08	3.11e-18	8.61e-12	0.42	0.39	Migraine without aura;	chr5:177287931	chr2:63622178~63622831:-
THCA	trans	rs12497850	1	rs12497850	ENSG00000197582.5	GPX1P1	9.08	3.12e-18	8.63e-12	0.56	0.39	Parkinson's disease;	chr3:48711556	chrX:13378735~13379340:-
THCA	trans	rs12497850	1	rs6788650	ENSG00000197582.5	GPX1P1	9.08	3.12e-18	8.63e-12	0.56	0.39	Parkinson's disease;	chr3:48712110	chrX:13378735~13379340:-
THCA	trans	rs877636	1	rs877636	ENSG00000212829.8	RPS26P3	-9.08	3.13e-18	8.65e-12	-0.49	-0.39	Cognitive function;	chr12:56086799	chr9:9090898~9091245:+
THCA	trans	rs2243480	1	rs4718269	ENSG00000273142.1	RP11-458F8.4	9.07	3.15e-18	8.71e-12	0.49	0.39	Diabetic kidney disease;	chr7:65735810	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs4718270	ENSG00000273142.1	RP11-458F8.4	-9.07	3.15e-18	8.71e-12	-0.49	-0.39	Diabetic kidney disease;	chr7:65737415	chr7:66902857~66906297:+
THCA	trans	rs2243480	0.908	rs4718273	ENSG00000273142.1	RP11-458F8.4	9.07	3.15e-18	8.71e-12	0.49	0.39	Diabetic kidney disease;	chr7:65751112	chr7:66902857~66906297:+
THCA	trans	rs9650657	0.538	rs6984496	ENSG00000253893.2	FAM85B	9.07	3.15e-18	8.72e-12	0.49	0.39	Neuroticism;	chr8:10938583	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.805	rs4333549	ENSG00000253893.2	FAM85B	9.07	3.16e-18	8.75e-12	0.51	0.39	Triglycerides;	chr8:11122051	chr8:8167819~8226614:-
THCA	trans	rs3806843	0.9	rs2337983	ENSG00000231043.3	AC007238.1	9.07	3.2e-18	8.85e-12	0.44	0.39	Depressive symptoms (multi-trait analysis);	chr5:140757223	chr2:58460292~58462032:-
THCA	trans	rs1816752	0.837	rs7324645	ENSG00000224976.2	PARP4P2	-9.07	3.27e-18	9.03e-12	-0.45	-0.39	Obesity-related traits;	chr13:24426717	chr13:19349137~19407962:+
THCA	trans	rs2243480	1	rs1404147	ENSG00000273142.1	RP11-458F8.4	-9.07	3.28e-18	9.07e-12	-0.46	-0.39	Diabetic kidney disease;	chr7:65799537	chr7:66902857~66906297:+
THCA	trans	rs1039766	0.925	rs268850	ENSG00000224334.1	AP000357.4	9.07	3.3e-18	9.12e-12	0.59	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr22:24686923~24688087:+
THCA	trans	rs12497850	0.931	rs13315711	ENSG00000197582.5	GPX1P1	9.07	3.35e-18	9.25e-12	0.57	0.39	Parkinson's disease;	chr3:48948966	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs7430198	ENSG00000197582.5	GPX1P1	9.07	3.35e-18	9.25e-12	0.57	0.39	Parkinson's disease;	chr3:48951327	chrX:13378735~13379340:-
THCA	trans	rs7824557	0.737	rs10481445	ENSG00000253893.2	FAM85B	9.07	3.35e-18	9.25e-12	0.51	0.39	Retinal vascular caliber;	chr8:11251760	chr8:8167819~8226614:-
THCA	trans	rs9876781	0.563	rs4858821	ENSG00000225528.1	RP3-370M22.8	9.06	3.39e-18	9.37e-12	0.49	0.39	Longevity;	chr3:48512515	chr22:39960397~39964683:+
THCA	trans	rs9650657	0.537	rs4841457	ENSG00000253893.2	FAM85B	9.06	3.45e-18	9.51e-12	0.48	0.39	Neuroticism;	chr8:10916001	chr8:8167819~8226614:-
THCA	trans	rs7503168	0.818	rs9902765	ENSG00000234130.2	RP13-88F20.1	9.06	3.56e-18	9.81e-12	0.5	0.39	Plateletcrit;	chr17:35586124	chrX:93222220~93225015:-
THCA	trans	rs11653357	1	rs11653357	ENSG00000234130.2	RP13-88F20.1	9.06	3.56e-18	9.81e-12	0.5	0.39	Platelet count;Platelet distribution width;	chr17:35596588	chrX:93222220~93225015:-
THCA	trans	rs12709013	0.792	rs1657170	ENSG00000233719.3	GOT2P3	9.06	3.57e-18	9.83e-12	0.47	0.39	Blood metabolite ratios;	chr16:58752082	chr12:9641802~9643007:+
THCA	trans	rs4295623	0.504	rs11250160	ENSG00000253893.2	FAM85B	9.06	3.58e-18	9.85e-12	0.49	0.39	Morning vs. evening chronotype;	chr8:11735208	chr8:8167819~8226614:-
THCA	trans	rs2243480	1	rs34703416	ENSG00000273142.1	RP11-458F8.4	-9.06	3.58e-18	9.86e-12	-0.48	-0.39	Diabetic kidney disease;	chr7:65835655	chr7:66902857~66906297:+
THCA	trans	rs7824557	0.724	rs2251473	ENSG00000253893.2	FAM85B	-9.06	3.62e-18	9.97e-12	-0.51	-0.39	Retinal vascular caliber;	chr8:11319617	chr8:8167819~8226614:-
THCA	trans	rs12497850	0.897	rs7373778	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48798959	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9876848	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48806626	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.805	rs11130176	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48806644	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9311430	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48807818	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9311432	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48813010	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9682444	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48815206	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9835307	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48820372	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9311433	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48826402	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9755490	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48834231	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs7430501	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48852686	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs10780033	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48853842	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9840684	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48856347	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.864	rs7431857	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48862914	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs4974079	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48869036	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.897	rs6446252	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48873692	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs4974087	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48881799	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs4974085	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48887467	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs28642807	ENSG00000197582.5	GPX1P1	9.06	3.62e-18	9.97e-12	0.57	0.39	Parkinson's disease;	chr3:48889383	chrX:13378735~13379340:-
THCA	trans	rs13190036	0.551	rs11955537	ENSG00000228305.2	AC016734.2	-9.05	3.71e-18	1.02e-11	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr2:63622178~63622831:-
THCA	trans	rs10037055	0.636	rs13166688	ENSG00000228305.2	AC016734.2	-9.05	3.71e-18	1.02e-11	-0.43	-0.39	Migraine without aura;	chr5:177156965	chr2:63622178~63622831:-
THCA	trans	rs12497850	1	rs10865952	ENSG00000197582.5	GPX1P1	9.05	3.8e-18	1.04e-11	0.56	0.39	Parkinson's disease;	chr3:48707051	chrX:13378735~13379340:-
THCA	trans	rs9611519	0.565	rs8135524	ENSG00000268568.1	AC007228.9	-9.05	3.81e-18	1.05e-11	-0.44	-0.39	Neuroticism;	chr22:41040438	chr19:56672574~56673901:-
THCA	trans	rs7554547	0.622	rs4846067	ENSG00000261819.1	RP11-680G24.4	9.05	3.81e-18	1.05e-11	0.55	0.39	Nonsyndromic cleft lip with cleft palate;	chr1:11880209	chr16:14988259~14990160:-
THCA	trans	rs877636	0.859	rs3741499	ENSG00000196933.5	RPS26P11	-9.05	3.84e-18	1.05e-11	-0.5	-0.39	Cognitive function;	chr12:56080595	chrX:72044545~72044892:+
THCA	trans	rs12138950	0.681	rs60066365	ENSG00000224237.1	MINOS1P3	9.05	3.85e-18	1.06e-11	0.53	0.39	Hypothyroidism;Thyroid volume;	chr1:19512191	chr3:27214816~27215018:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000233778.3	RP11-777J24.1	9.05	3.93e-18	1.08e-11	0.49	0.39	Cognitive function;	chr12:55990903	chr8:92144088~92144435:-
THCA	trans	rs12497850	0.931	rs12493289	ENSG00000197582.5	GPX1P1	9.05	3.95e-18	1.09e-11	0.57	0.39	Parkinson's disease;	chr3:48867728	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.865	rs7649458	ENSG00000197582.5	GPX1P1	9.05	3.95e-18	1.09e-11	0.57	0.39	Parkinson's disease;	chr3:48882694	chrX:13378735~13379340:-
THCA	trans	rs453301	0.682	rs2929451	ENSG00000253893.2	FAM85B	-9.04	3.98e-18	1.09e-11	-0.48	-0.39	Joint mobility (Beighton score);	chr8:9227785	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.932	rs11854461	ENSG00000227288.3	RP5-837I24.1	9.04	4.04e-18	1.11e-11	0.54	0.38	Endometriosis;	chr15:74447400	chr1:81501794~81503468:+
THCA	trans	rs7647973	1	rs7619789	ENSG00000197582.5	GPX1P1	9.04	4.05e-18	1.11e-11	0.59	0.38	Menarche (age at onset);	chr3:49438830	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.922	rs57273516	ENSG00000197582.5	GPX1P1	9.04	4.05e-18	1.11e-11	0.59	0.38	Menarche (age at onset);	chr3:49445641	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs1009051	ENSG00000197582.5	GPX1P1	9.04	4.05e-18	1.11e-11	0.59	0.38	Menarche (age at onset);	chr3:49484116	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs3870339	ENSG00000197582.5	GPX1P1	9.04	4.05e-18	1.11e-11	0.59	0.38	Menarche (age at onset);	chr3:49499430	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9846123	ENSG00000197582.5	GPX1P1	-9.04	4.07e-18	1.12e-11	-0.57	-0.38	Parkinson's disease;	chr3:49050679	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs7647813	ENSG00000197582.5	GPX1P1	9.04	4.1e-18	1.12e-11	0.57	0.38	Parkinson's disease;	chr3:48795915	chrX:13378735~13379340:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000244604.1	RP11-713H12.1	9.04	4.11e-18	1.13e-11	0.48	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:8561230~8561576:+
THCA	trans	rs12138950	0.681	rs9783019	ENSG00000224237.1	MINOS1P3	9.04	4.11e-18	1.13e-11	0.52	0.38	Hypothyroidism;Thyroid volume;	chr1:19523162	chr3:27214816~27215018:-
THCA	trans	rs13190036	1	rs655623	ENSG00000228305.2	AC016734.2	9.04	4.11e-18	1.13e-11	0.46	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr2:63622178~63622831:-
THCA	trans	rs3806843	0.75	rs2563285	ENSG00000231043.3	AC007238.1	9.04	4.12e-18	1.13e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140746552	chr2:58460292~58462032:-
THCA	trans	rs12138950	0.711	rs10799821	ENSG00000224237.1	MINOS1P3	9.04	4.22e-18	1.16e-11	0.52	0.38	Hypothyroidism;Thyroid volume;	chr1:19511475	chr3:27214816~27215018:-
THCA	trans	rs12497850	0.865	rs13072911	ENSG00000197582.5	GPX1P1	9.04	4.23e-18	1.16e-11	0.57	0.38	Parkinson's disease;	chr3:48924695	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	9.04	4.23e-18	1.16e-11	0.51	0.38	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	9.04	4.23e-18	1.16e-11	0.51	0.38	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	9.04	4.23e-18	1.16e-11	0.51	0.38	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	9.04	4.23e-18	1.16e-11	0.51	0.38	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	9.04	4.23e-18	1.16e-11	0.51	0.38	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
THCA	trans	rs12497850	0.931	rs7627404	ENSG00000197582.5	GPX1P1	9.03	4.39e-18	1.2e-11	0.58	0.38	Parkinson's disease;	chr3:48782235	chrX:13378735~13379340:-
THCA	trans	rs7662987	0.793	rs7669660	ENSG00000233859.2	ADH5P4	9.03	4.4e-18	1.2e-11	0.71	0.38	Smoking initiation;	chr4:99071451	chr6:65836930~65838039:-
THCA	trans	rs7647973	1	rs11130189	ENSG00000197582.5	GPX1P1	9.03	4.44e-18	1.21e-11	0.62	0.38	Menarche (age at onset);	chr3:49309924	chrX:13378735~13379340:-
THCA	trans	rs7503168	1	rs9894057	ENSG00000234130.2	RP13-88F20.1	9.03	4.58e-18	1.25e-11	0.49	0.38	Plateletcrit;	chr17:35562904	chrX:93222220~93225015:-
THCA	trans	rs74781061	0.789	rs1078011	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74442521	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs4887147	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74443863	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs4887151	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74445126	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.789	rs2289188	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74450127	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.789	rs12440654	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74453008	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs7169985	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74453437	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs8037211	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74455061	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.789	rs11852291	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74457624	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs4887152	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74464013	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.86	rs4544202	ENSG00000227288.3	RP5-837I24.1	9.03	4.61e-18	1.26e-11	0.54	0.38	Endometriosis;	chr15:74468654	chr1:81501794~81503468:+
THCA	trans	rs916888	0.61	rs199454	ENSG00000204650.12	CRHR1-IT1	-9.02	4.79e-18	1.31e-11	-0.38	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45620328~45648216:+
THCA	trans	rs11023332	0.617	rs1879888	ENSG00000236360.2	RP11-334A14.2	9.02	4.79e-18	1.31e-11	0.49	0.38	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr1:52993201~52993702:-
THCA	trans	rs12497850	0.931	rs11705888	ENSG00000197582.5	GPX1P1	9.02	4.82e-18	1.31e-11	0.58	0.38	Parkinson's disease;	chr3:48779856	chrX:13378735~13379340:-
THCA	trans	rs7819412	0.538	rs4523214	ENSG00000253893.2	FAM85B	9.02	4.87e-18	1.33e-11	0.51	0.38	Triglycerides;	chr8:11113263	chr8:8167819~8226614:-
THCA	trans	rs7647973	1	rs11928090	ENSG00000197582.5	GPX1P1	9.02	4.89e-18	1.33e-11	0.6	0.38	Menarche (age at onset);	chr3:49567471	chrX:13378735~13379340:-
THCA	trans	rs9329221	0.905	rs4433149	ENSG00000253893.2	FAM85B	9.02	4.89e-18	1.33e-11	0.5	0.38	Neuroticism;	chr8:10391758	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.792	rs12598527	ENSG00000233719.3	GOT2P3	9.02	4.9e-18	1.34e-11	0.46	0.38	Blood metabolite ratios;	chr16:58772987	chr12:9641802~9643007:+
THCA	trans	rs13190036	1	rs351864	ENSG00000228305.2	AC016734.2	-9.02	4.96e-18	1.35e-11	-0.47	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr2:63622178~63622831:-
THCA	trans	rs35851103	0.507	rs6601649	ENSG00000253893.2	FAM85B	9.01	5.05e-18	1.38e-11	0.52	0.38	Neuroticism;	chr8:11999808	chr8:8167819~8226614:-
THCA	trans	rs12497850	0.931	rs11924597	ENSG00000197582.5	GPX1P1	9.01	5.06e-18	1.38e-11	0.57	0.38	Parkinson's disease;	chr3:48900357	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.897	rs9850134	ENSG00000197582.5	GPX1P1	9.01	5.06e-18	1.38e-11	0.57	0.38	Parkinson's disease;	chr3:48919714	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs9867373	ENSG00000197582.5	GPX1P1	9.01	5.06e-18	1.38e-11	0.57	0.38	Parkinson's disease;	chr3:48923505	chrX:13378735~13379340:-
THCA	trans	rs7824557	0.524	rs7835318	ENSG00000253893.2	FAM85B	9.01	5.12e-18	1.4e-11	0.51	0.38	Retinal vascular caliber;	chr8:11096364	chr8:8167819~8226614:-
THCA	trans	rs11951515	0.508	rs11958046	ENSG00000174977.8	AC026271.5	-9.01	5.22e-18	1.42e-11	-0.43	-0.38	Metabolite levels  (X-11787);	chr5:43583287	chr17:18650195~18651542:+
THCA	trans	rs7662987	0.793	rs12106	ENSG00000233859.2	ADH5P4	9.01	5.31e-18	1.44e-11	0.71	0.38	Smoking initiation;	chr4:99072199	chr6:65836930~65838039:-
THCA	trans	rs7662987	0.793	rs28730632	ENSG00000233859.2	ADH5P4	9.01	5.31e-18	1.44e-11	0.71	0.38	Smoking initiation;	chr4:99074552	chr6:65836930~65838039:-
THCA	trans	rs7662987	0.793	rs4699700	ENSG00000233859.2	ADH5P4	9.01	5.31e-18	1.44e-11	0.71	0.38	Smoking initiation;	chr4:99077184	chr6:65836930~65838039:-
THCA	trans	rs12497850	0.897	rs6781790	ENSG00000197582.5	GPX1P1	9.01	5.35e-18	1.46e-11	0.57	0.38	Parkinson's disease;	chr3:49007334	chrX:13378735~13379340:-
THCA	trans	rs1816752	0.721	rs7399656	ENSG00000224976.2	PARP4P2	-9.01	5.38e-18	1.46e-11	-0.45	-0.38	Obesity-related traits;	chr13:24415708	chr13:19349137~19407962:+
THCA	trans	rs13190036	0.551	rs7710269	ENSG00000228305.2	AC016734.2	-9.01	5.39e-18	1.47e-11	-0.43	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr2:63622178~63622831:-
THCA	trans	rs13190036	0.515	rs2878686	ENSG00000228305.2	AC016734.2	-9.01	5.39e-18	1.47e-11	-0.43	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr2:63622178~63622831:-
THCA	trans	rs11098499	1	rs13435802	ENSG00000275858.1	RP11-291L22.8	-9	5.41e-18	1.47e-11	-0.5	-0.38	Corneal astigmatism;	chr4:119256805	chr10:38450738~38451069:-
THCA	trans	rs12497850	0.863	rs4858799	ENSG00000197582.5	GPX1P1	9	5.45e-18	1.48e-11	0.56	0.38	Parkinson's disease;	chr3:48690771	chrX:13378735~13379340:-
THCA	trans	rs12709013	0.792	rs12600201	ENSG00000230849.2	GOT2P2	9	5.58e-18	1.52e-11	0.47	0.38	Blood metabolite ratios;	chr16:58773132	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs12600206	ENSG00000230849.2	GOT2P2	9	5.58e-18	1.52e-11	0.47	0.38	Blood metabolite ratios;	chr16:58773169	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs11076263	ENSG00000230849.2	GOT2P2	9	5.58e-18	1.52e-11	0.47	0.38	Blood metabolite ratios;	chr16:58773295	chr1:173141100~173142350:-
THCA	trans	rs3806843	0.868	rs2563291	ENSG00000231043.3	AC007238.1	9	5.64e-18	1.53e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140740014	chr2:58460292~58462032:-
THCA	trans	rs877636	1	rs4759229	ENSG00000196933.5	RPS26P11	-9	5.68e-18	1.54e-11	-0.5	-0.38	Cognitive function;	chr12:56080696	chrX:72044545~72044892:+
THCA	trans	rs74781061	0.86	rs6495101	ENSG00000227288.3	RP5-837I24.1	9	5.68e-18	1.54e-11	0.54	0.38	Endometriosis;	chr15:74450411	chr1:81501794~81503468:+
THCA	trans	rs12497850	0.931	rs7616815	ENSG00000197582.5	GPX1P1	9	5.69e-18	1.55e-11	0.57	0.38	Parkinson's disease;	chr3:48742282	chrX:13378735~13379340:-
THCA	trans	rs3779195	0.585	rs7777991	ENSG00000225169.1	BRI3P1	-9	5.73e-18	1.56e-11	-0.62	-0.38	Sex hormone-binding globulin levels;	chr7:98236445	chr1:100213293~100213670:+
THCA	trans	rs1816752	0.905	rs1348110	ENSG00000224976.2	PARP4P2	-9	5.74e-18	1.56e-11	-0.46	-0.38	Obesity-related traits;	chr13:24406537	chr13:19349137~19407962:+
THCA	trans	rs74781061	0.86	rs4887150	ENSG00000227288.3	RP5-837I24.1	9	5.74e-18	1.56e-11	0.54	0.38	Endometriosis;	chr15:74444683	chr1:81501794~81503468:+
THCA	trans	rs1816752	0.875	rs8001187	ENSG00000224976.2	PARP4P2	-9	5.79e-18	1.57e-11	-0.46	-0.38	Obesity-related traits;	chr13:24402276	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.783	rs9507333	ENSG00000224976.2	PARP4P2	-9	5.79e-18	1.57e-11	-0.46	-0.38	Obesity-related traits;	chr13:24404172	chr13:19349137~19407962:+
THCA	trans	rs7503168	1	rs1037590	ENSG00000234130.2	RP13-88F20.1	9	5.82e-18	1.58e-11	0.5	0.38	Plateletcrit;	chr17:35575616	chrX:93222220~93225015:-
THCA	trans	rs66887589	0.616	rs13113885	ENSG00000275858.1	RP11-291L22.8	9	5.82e-18	1.58e-11	0.48	0.38	Diastolic blood pressure;	chr4:119300021	chr10:38450738~38451069:-
THCA	trans	rs12497850	1	rs4858831	ENSG00000197582.5	GPX1P1	8.99	5.91e-18	1.6e-11	0.56	0.38	Parkinson's disease;	chr3:48698125	chrX:13378735~13379340:-
THCA	trans	rs74781061	0.86	rs3985310	ENSG00000227288.3	RP5-837I24.1	8.99	5.95e-18	1.61e-11	0.54	0.38	Endometriosis;	chr15:74442826	chr1:81501794~81503468:+
THCA	trans	rs7819412	0.634	rs4841485	ENSG00000253893.2	FAM85B	-8.99	5.99e-18	1.63e-11	-0.5	-0.38	Triglycerides;	chr8:11052426	chr8:8167819~8226614:-
THCA	trans	rs804280	0.509	rs12719915	ENSG00000256560.1	LINC01486	-8.99	6e-18	1.63e-11	-0.49	-0.38	Myopia (pathological);	chr8:11928746	chr12:109354083~109359488:-
THCA	trans	rs7662987	1	rs28730587	ENSG00000233859.2	ADH5P4	8.99	6.07e-18	1.65e-11	0.81	0.38	Smoking initiation;	chr4:99083190	chr6:65836930~65838039:-
THCA	trans	rs2243480	1	rs4548056	ENSG00000273142.1	RP11-458F8.4	-8.99	6.08e-18	1.65e-11	-0.48	-0.38	Diabetic kidney disease;	chr7:65833886	chr7:66902857~66906297:+
THCA	trans	rs1039766	1	rs72822431	ENSG00000224334.1	AP000357.4	-8.99	6.11e-18	1.66e-11	-0.59	-0.38	Lung adenocarcinoma;Lung cancer;	chr2:65294682	chr22:24686923~24688087:+
THCA	trans	rs5022636	0.821	rs4246525	ENSG00000180764.13	PIPSL	8.99	6.24e-18	1.69e-11	0.44	0.38	Gut microbiota (functional units);	chr1:151285263	chr10:93958191~93961540:-
THCA	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-8.98	6.38e-18	1.73e-11	-0.56	-0.38	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
THCA	trans	rs7819412	0.645	rs4841508	ENSG00000253893.2	FAM85B	8.98	6.57e-18	1.78e-11	0.52	0.38	Triglycerides;	chr8:11207494	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.504	rs6601566	ENSG00000253893.2	FAM85B	8.98	6.65e-18	1.8e-11	0.52	0.38	Neuroticism;	chr8:11185465	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.515	rs7820860	ENSG00000253893.2	FAM85B	8.98	6.73e-18	1.82e-11	0.51	0.38	Neuroticism;	chr8:11092886	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.531	rs2575828	ENSG00000236360.2	RP11-334A14.2	8.98	6.74e-18	1.82e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14462646	chr1:52993201~52993702:-
THCA	trans	rs7503168	0.908	rs9907772	ENSG00000234130.2	RP13-88F20.1	8.98	6.75e-18	1.83e-11	0.5	0.38	Plateletcrit;	chr17:35673609	chrX:93222220~93225015:-
THCA	trans	rs7824557	0.547	rs2409749	ENSG00000253893.2	FAM85B	8.97	7.05e-18	1.91e-11	0.52	0.38	Retinal vascular caliber;	chr8:11221440	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.634	rs6987767	ENSG00000253893.2	FAM85B	-8.97	7.12e-18	1.93e-11	-0.5	-0.38	Triglycerides;	chr8:11052556	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.515	rs6601560	ENSG00000253893.2	FAM85B	8.97	7.15e-18	1.93e-11	0.51	0.38	Neuroticism;	chr8:11093356	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.559	rs2034480	ENSG00000236360.2	RP11-334A14.2	8.97	7.28e-18	1.97e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14445377	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.532	rs2256884	ENSG00000236360.2	RP11-334A14.2	8.97	7.28e-18	1.97e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14454856	chr1:52993201~52993702:-
THCA	trans	rs1816752	0.905	rs7317850	ENSG00000224976.2	PARP4P2	-8.97	7.33e-18	1.98e-11	-0.46	-0.38	Obesity-related traits;	chr13:24419899	chr13:19349137~19407962:+
THCA	trans	rs7819412	0.66	rs7462931	ENSG00000253893.2	FAM85B	8.97	7.35e-18	1.99e-11	0.5	0.38	Triglycerides;	chr8:11052833	chr8:8167819~8226614:-
THCA	trans	rs12138950	0.681	rs10799822	ENSG00000224237.1	MINOS1P3	8.96	7.41e-18	2e-11	0.52	0.38	Hypothyroidism;Thyroid volume;	chr1:19513327	chr3:27214816~27215018:-
THCA	trans	rs7937890	0.559	rs2597217	ENSG00000236360.2	RP11-334A14.2	8.96	7.46e-18	2.01e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14511337	chr1:52993201~52993702:-
THCA	trans	rs12709013	0.792	rs62066815	ENSG00000230849.2	GOT2P2	8.96	7.53e-18	2.03e-11	0.47	0.38	Blood metabolite ratios;	chr16:58751577	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.766	rs1657175	ENSG00000230849.2	GOT2P2	8.96	7.53e-18	2.03e-11	0.47	0.38	Blood metabolite ratios;	chr16:58755527	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs1646290	ENSG00000230849.2	GOT2P2	8.96	7.53e-18	2.03e-11	0.47	0.38	Blood metabolite ratios;	chr16:58755807	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs1364346	ENSG00000230849.2	GOT2P2	8.96	7.53e-18	2.03e-11	0.47	0.38	Blood metabolite ratios;	chr16:58756420	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs257626	ENSG00000230849.2	GOT2P2	8.96	7.53e-18	2.03e-11	0.47	0.38	Blood metabolite ratios;	chr16:58759574	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs257625	ENSG00000230849.2	GOT2P2	8.96	7.53e-18	2.03e-11	0.47	0.38	Blood metabolite ratios;	chr16:58759978	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs1646262	ENSG00000230849.2	GOT2P2	8.96	7.53e-18	2.03e-11	0.47	0.38	Blood metabolite ratios;	chr16:58760593	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs257623	ENSG00000230849.2	GOT2P2	8.96	7.53e-18	2.03e-11	0.47	0.38	Blood metabolite ratios;	chr16:58761247	chr1:173141100~173142350:-
THCA	trans	rs1816752	0.905	rs9581026	ENSG00000224976.2	PARP4P2	-8.96	7.57e-18	2.04e-11	-0.45	-0.38	Obesity-related traits;	chr13:24423788	chr13:19349137~19407962:+
THCA	trans	rs12709013	0.792	rs1646277	ENSG00000230849.2	GOT2P2	8.96	7.63e-18	2.06e-11	0.47	0.38	Blood metabolite ratios;	chr16:58750037	chr1:173141100~173142350:-
THCA	trans	rs10037055	1	rs10037055	ENSG00000228305.2	AC016734.2	-8.96	7.66e-18	2.07e-11	-0.42	-0.38	Migraine without aura;	chr5:177264278	chr2:63622178~63622831:-
THCA	trans	rs9329221	0.905	rs6601451	ENSG00000253893.2	FAM85B	8.96	7.7e-18	2.08e-11	0.49	0.38	Neuroticism;	chr8:10386171	chr8:8167819~8226614:-
THCA	trans	rs1816752	0.905	rs9511242	ENSG00000224976.2	PARP4P2	-8.96	7.83e-18	2.11e-11	-0.46	-0.38	Obesity-related traits;	chr13:24419261	chr13:19349137~19407962:+
THCA	trans	rs3806843	0.838	rs2563289	ENSG00000231043.3	AC007238.1	8.96	7.93e-18	2.14e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140743181	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs2563260	ENSG00000231043.3	AC007238.1	8.96	7.94e-18	2.14e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140758282	chr2:58460292~58462032:-
THCA	trans	rs9329221	0.905	rs4610752	ENSG00000253893.2	FAM85B	8.96	7.95e-18	2.14e-11	0.49	0.38	Neuroticism;	chr8:10391452	chr8:8167819~8226614:-
THCA	trans	rs5022636	0.964	rs7545392	ENSG00000180764.13	PIPSL	8.95	8.08e-18	2.18e-11	0.44	0.38	Gut microbiota (functional units);	chr1:151337779	chr10:93958191~93961540:-
THCA	trans	rs12709013	0.792	rs1646289	ENSG00000230849.2	GOT2P2	8.95	8.2e-18	2.21e-11	0.47	0.38	Blood metabolite ratios;	chr16:58755689	chr1:173141100~173142350:-
THCA	trans	rs864643	0.524	rs9822783	ENSG00000188856.6	RPSAP47	8.95	8.37e-18	2.25e-11	0.7	0.38	Attention deficit hyperactivity disorder;	chr3:39463311	chr8:80558870~80559757:+
THCA	trans	rs1816752	0.905	rs4770666	ENSG00000224976.2	PARP4P2	-8.95	8.41e-18	2.26e-11	-0.45	-0.38	Obesity-related traits;	chr13:24414891	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs7400631	ENSG00000224976.2	PARP4P2	-8.95	8.41e-18	2.26e-11	-0.45	-0.38	Obesity-related traits;	chr13:24415927	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs8002215	ENSG00000224976.2	PARP4P2	-8.95	8.41e-18	2.26e-11	-0.45	-0.38	Obesity-related traits;	chr13:24416229	chr13:19349137~19407962:+
THCA	trans	rs12138950	0.681	rs4362008	ENSG00000224237.1	MINOS1P3	8.95	8.54e-18	2.3e-11	0.52	0.38	Hypothyroidism;Thyroid volume;	chr1:19511064	chr3:27214816~27215018:-
THCA	trans	rs730566	1	rs730566	ENSG00000235912.1	RP1-159A19.3	8.94	8.65e-18	2.33e-11	0.5	0.38	Prion diseases;	chr3:48445644	chr1:27649419~27649610:+
THCA	trans	rs7113874	0.545	rs72855149	ENSG00000266891.1	RP11-692N5.2	8.94	8.72e-18	2.35e-11	0.58	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8586160	chr18:9734882~9735602:-
THCA	trans	rs7937890	0.535	rs2575857	ENSG00000236360.2	RP11-334A14.2	8.94	8.98e-18	2.41e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14479750	chr1:52993201~52993702:-
THCA	trans	rs7824557	0.724	rs2572398	ENSG00000253893.2	FAM85B	-8.94	8.98e-18	2.42e-11	-0.5	-0.38	Retinal vascular caliber;	chr8:11320584	chr8:8167819~8226614:-
THCA	trans	rs12497850	0.931	rs13064911	ENSG00000197582.5	GPX1P1	8.94	9.05e-18	2.43e-11	0.57	0.38	Parkinson's disease;	chr3:48914952	chrX:13378735~13379340:-
THCA	trans	rs1816752	0.819	rs7985478	ENSG00000224976.2	PARP4P2	-8.94	9.1e-18	2.44e-11	-0.45	-0.38	Obesity-related traits;	chr13:24417135	chr13:19349137~19407962:+
THCA	trans	rs9329221	0.905	rs17765901	ENSG00000253893.2	FAM85B	8.94	9.14e-18	2.46e-11	0.49	0.38	Neuroticism;	chr8:10391970	chr8:8167819~8226614:-
THCA	trans	rs3806843	0.966	rs2563267	ENSG00000231043.3	AC007238.1	8.93	9.29e-18	2.5e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140757328	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs2563266	ENSG00000231043.3	AC007238.1	8.93	9.29e-18	2.5e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140757330	chr2:58460292~58462032:-
THCA	trans	rs1816752	0.905	rs11839006	ENSG00000224976.2	PARP4P2	-8.93	9.32e-18	2.5e-11	-0.45	-0.38	Obesity-related traits;	chr13:24435893	chr13:19349137~19407962:+
THCA	trans	rs7819412	0.668	rs4841507	ENSG00000253893.2	FAM85B	8.93	9.34e-18	2.51e-11	0.52	0.38	Triglycerides;	chr8:11188885	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.513	rs4841459	ENSG00000253893.2	FAM85B	8.93	9.36e-18	2.51e-11	0.48	0.38	Neuroticism;	chr8:10924932	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.741	rs4976640	ENSG00000226986.4	RP11-543B16.2	-8.93	9.44e-18	2.53e-11	-0.48	-0.38	Migraine without aura;	chr5:177125006	chr1:211207239~211207897:+
THCA	trans	rs7503168	1	rs7503168	ENSG00000234130.2	RP13-88F20.1	8.93	9.46e-18	2.54e-11	0.48	0.38	Plateletcrit;	chr17:35558885	chrX:93222220~93225015:-
THCA	trans	rs877636	1	rs877636	ENSG00000234354.3	RPS26P47	-8.93	9.48e-18	2.54e-11	-0.51	-0.38	Cognitive function;	chr12:56086799	chr13:100539901~100540248:-
THCA	trans	rs9329221	0.905	rs4841329	ENSG00000253893.2	FAM85B	8.93	9.51e-18	2.55e-11	0.49	0.38	Neuroticism;	chr8:10395588	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.559	rs2575838	ENSG00000236360.2	RP11-334A14.2	8.93	9.67e-18	2.59e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14476675	chr1:52993201~52993702:-
THCA	trans	rs2929278	0.617	rs3087657	ENSG00000180867.10	PDIA3P1	-8.93	9.7e-18	2.6e-11	-0.34	-0.38	Schizophrenia;	chr15:43771661	chr1:147178113~147179622:+
THCA	trans	rs7937890	0.559	rs2575829	ENSG00000236360.2	RP11-334A14.2	8.93	9.8e-18	2.63e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14463475	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2597200	ENSG00000236360.2	RP11-334A14.2	8.93	9.8e-18	2.63e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14464054	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2575830	ENSG00000236360.2	RP11-334A14.2	8.93	9.8e-18	2.63e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14464056	chr1:52993201~52993702:-
THCA	trans	rs2929278	0.617	rs12908467	ENSG00000180867.10	PDIA3P1	8.93	9.86e-18	2.64e-11	0.34	0.38	Schizophrenia;	chr15:43755232	chr1:147178113~147179622:+
THCA	trans	rs7113874	0.578	rs1026021	ENSG00000266891.1	RP11-692N5.2	-8.93	9.89e-18	2.65e-11	-0.58	-0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8543231	chr18:9734882~9735602:-
THCA	trans	rs1816752	0.905	rs2000153	ENSG00000224976.2	PARP4P2	-8.92	1e-17	2.69e-11	-0.46	-0.38	Obesity-related traits;	chr13:24405752	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.755	rs1981277	ENSG00000224976.2	PARP4P2	-8.92	1.01e-17	2.7e-11	-0.45	-0.38	Obesity-related traits;	chr13:24409375	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.712	rs9507335	ENSG00000224976.2	PARP4P2	-8.92	1.01e-17	2.7e-11	-0.45	-0.38	Obesity-related traits;	chr13:24409766	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.811	rs9507337	ENSG00000224976.2	PARP4P2	-8.92	1.01e-17	2.7e-11	-0.45	-0.38	Obesity-related traits;	chr13:24410807	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.905	rs9511249	ENSG00000224976.2	PARP4P2	-8.92	1.02e-17	2.72e-11	-0.45	-0.38	Obesity-related traits;	chr13:24425457	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.819	rs4770665	ENSG00000224976.2	PARP4P2	-8.92	1.04e-17	2.78e-11	-0.45	-0.38	Obesity-related traits;	chr13:24414810	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.749	rs77832754	ENSG00000224976.2	PARP4P2	-8.92	1.04e-17	2.78e-11	-0.45	-0.38	Obesity-related traits;	chr13:24416016	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.633	rs8002387	ENSG00000224976.2	PARP4P2	-8.92	1.04e-17	2.78e-11	-0.45	-0.38	Obesity-related traits;	chr13:24416306	chr13:19349137~19407962:+
THCA	trans	rs12497850	0.897	rs9681717	ENSG00000197582.5	GPX1P1	8.92	1.06e-17	2.85e-11	0.57	0.38	Parkinson's disease;	chr3:48835565	chrX:13378735~13379340:-
THCA	trans	rs12709013	0.792	rs12325510	ENSG00000230849.2	GOT2P2	8.91	1.1e-17	2.93e-11	0.47	0.38	Blood metabolite ratios;	chr16:58749707	chr1:173141100~173142350:-
THCA	trans	rs74781061	0.858	rs58473469	ENSG00000227288.3	RP5-837I24.1	8.91	1.1e-17	2.95e-11	0.54	0.38	Endometriosis;	chr15:74592722	chr1:81501794~81503468:+
THCA	trans	rs7662987	0.793	rs7684735	ENSG00000233859.2	ADH5P4	8.91	1.12e-17	3e-11	0.7	0.38	Smoking initiation;	chr4:99070355	chr6:65836930~65838039:-
THCA	trans	rs7819412	0.691	rs73198970	ENSG00000253893.2	FAM85B	8.91	1.15e-17	3.07e-11	0.51	0.38	Triglycerides;	chr8:11182707	chr8:8167819~8226614:-
THCA	trans	rs7647973	1	rs892974	ENSG00000197582.5	GPX1P1	8.91	1.15e-17	3.08e-11	0.61	0.38	Menarche (age at onset);	chr3:49361081	chrX:13378735~13379340:-
THCA	trans	rs74781061	0.86	rs1866113	ENSG00000227288.3	RP5-837I24.1	8.91	1.15e-17	3.08e-11	0.54	0.38	Endometriosis;	chr15:74437262	chr1:81501794~81503468:+
THCA	trans	rs3806843	0.898	rs3756335	ENSG00000231043.3	AC007238.1	-8.9	1.17e-17	3.13e-11	-0.44	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140833925	chr2:58460292~58462032:-
THCA	trans	rs9650657	0.589	rs10107145	ENSG00000253893.2	FAM85B	8.9	1.2e-17	3.2e-11	0.48	0.38	Neuroticism;	chr8:10900703	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.62	rs6601427	ENSG00000253893.2	FAM85B	8.9	1.2e-17	3.21e-11	0.5	0.38	Neuroticism;	chr8:10298515	chr8:8167819~8226614:-
THCA	trans	rs804280	0.509	rs12719915	ENSG00000253893.2	FAM85B	8.9	1.21e-17	3.23e-11	0.52	0.38	Myopia (pathological);	chr8:11928746	chr8:8167819~8226614:-
THCA	trans	rs3806843	0.766	rs801176	ENSG00000231043.3	AC007238.1	-8.9	1.21e-17	3.23e-11	-0.44	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140707425	chr2:58460292~58462032:-
THCA	trans	rs7937890	0.559	rs2575837	ENSG00000236360.2	RP11-334A14.2	8.9	1.21e-17	3.23e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14476455	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2167160	ENSG00000236360.2	RP11-334A14.2	8.9	1.21e-17	3.23e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14485903	chr1:52993201~52993702:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000244604.1	RP11-713H12.1	8.9	1.21e-17	3.23e-11	0.47	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:8561230~8561576:+
THCA	trans	rs7824557	0.688	rs2572397	ENSG00000253893.2	FAM85B	-8.9	1.22e-17	3.26e-11	-0.5	-0.38	Retinal vascular caliber;	chr8:11318894	chr8:8167819~8226614:-
THCA	trans	rs1816752	0.748	rs6490912	ENSG00000224976.2	PARP4P2	-8.9	1.25e-17	3.33e-11	-0.45	-0.38	Obesity-related traits;	chr13:24408941	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.819	rs1981276	ENSG00000224976.2	PARP4P2	-8.9	1.25e-17	3.33e-11	-0.45	-0.38	Obesity-related traits;	chr13:24409361	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.837	rs57052031	ENSG00000224976.2	PARP4P2	-8.9	1.25e-17	3.33e-11	-0.45	-0.38	Obesity-related traits;	chr13:24409730	chr13:19349137~19407962:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000212829.8	RPS26P3	-8.9	1.26e-17	3.35e-11	-0.49	-0.38	Cognitive function;	chr12:56080595	chr9:9090898~9091245:+
THCA	trans	rs2929278	0.589	rs2411284	ENSG00000180867.10	PDIA3P1	8.89	1.27e-17	3.37e-11	0.33	0.38	Schizophrenia;	chr15:43746701	chr1:147178113~147179622:+
THCA	trans	rs7662987	0.793	rs28730602	ENSG00000228407.2	RP4-800M22.1	8.89	1.27e-17	3.39e-11	0.71	0.38	Smoking initiation;	chr4:99080531	chr1:52160261~52160600:-
THCA	trans	rs4295623	0.556	rs10903343	ENSG00000253893.2	FAM85B	-8.89	1.29e-17	3.43e-11	-0.5	-0.38	Morning vs. evening chronotype;	chr8:11838363	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.693	rs1627257	ENSG00000230849.2	GOT2P2	8.89	1.3e-17	3.45e-11	0.47	0.38	Blood metabolite ratios;	chr16:58763764	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs12926512	ENSG00000230849.2	GOT2P2	8.89	1.3e-17	3.45e-11	0.47	0.38	Blood metabolite ratios;	chr16:58768317	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs12595974	ENSG00000230849.2	GOT2P2	8.89	1.3e-17	3.45e-11	0.47	0.38	Blood metabolite ratios;	chr16:58769132	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs1836877	ENSG00000230849.2	GOT2P2	8.89	1.3e-17	3.45e-11	0.47	0.38	Blood metabolite ratios;	chr16:58769821	chr1:173141100~173142350:-
THCA	trans	rs864643	0.524	rs80322842	ENSG00000188856.6	RPSAP47	8.89	1.31e-17	3.49e-11	0.71	0.38	Attention deficit hyperactivity disorder;	chr3:39483682	chr8:80558870~80559757:+
THCA	trans	rs1816752	0.633	rs9578729	ENSG00000224976.2	PARP4P2	-8.89	1.32e-17	3.5e-11	-0.45	-0.38	Obesity-related traits;	chr13:24425106	chr13:19349137~19407962:+
THCA	trans	rs1816752	0.87	rs9581029	ENSG00000224976.2	PARP4P2	-8.89	1.32e-17	3.5e-11	-0.45	-0.38	Obesity-related traits;	chr13:24425147	chr13:19349137~19407962:+
THCA	trans	rs3806843	0.766	rs6848	ENSG00000231043.3	AC007238.1	8.89	1.32e-17	3.5e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140706477	chr2:58460292~58462032:-
THCA	trans	rs11098499	0.955	rs13129661	ENSG00000275858.1	RP11-291L22.8	8.89	1.32e-17	3.51e-11	0.5	0.38	Corneal astigmatism;	chr4:119231754	chr10:38450738~38451069:-
THCA	trans	rs7647973	1	rs10155014	ENSG00000197582.5	GPX1P1	8.89	1.33e-17	3.52e-11	0.59	0.38	Menarche (age at onset);	chr3:49394888	chrX:13378735~13379340:-
THCA	trans	rs1816752	0.774	rs2862895	ENSG00000224976.2	PARP4P2	-8.89	1.34e-17	3.56e-11	-0.45	-0.38	Obesity-related traits;	chr13:24410328	chr13:19349137~19407962:+
THCA	trans	rs3806843	0.868	rs2563281	ENSG00000231043.3	AC007238.1	8.88	1.37e-17	3.63e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140751634	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.9	rs2563280	ENSG00000231043.3	AC007238.1	8.88	1.37e-17	3.63e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140751945	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.838	rs2262567	ENSG00000231043.3	AC007238.1	8.88	1.37e-17	3.63e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140752549	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.838	rs2337514	ENSG00000231043.3	AC007238.1	8.88	1.37e-17	3.63e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140753147	chr2:58460292~58462032:-
THCA	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-8.88	1.37e-17	3.64e-11	-0.48	-0.38	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
THCA	trans	rs3806843	0.9	rs2531341	ENSG00000231043.3	AC007238.1	8.88	1.4e-17	3.71e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140751309	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.9	rs2531340	ENSG00000231043.3	AC007238.1	8.88	1.4e-17	3.71e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140751461	chr2:58460292~58462032:-
THCA	trans	rs2665103	0.715	rs16973457	ENSG00000235370.6	DNM1P51	-8.88	1.4e-17	3.73e-11	-0.47	-0.38	Intelligence (multi-trait analysis);	chr15:82271650	chr15:84398316~84411701:-
THCA	trans	rs10037055	0.853	rs9313749	ENSG00000228305.2	AC016734.2	-8.88	1.41e-17	3.75e-11	-0.41	-0.38	Migraine without aura;	chr5:177170693	chr2:63622178~63622831:-
THCA	trans	rs9650657	0.537	rs11250092	ENSG00000253893.2	FAM85B	-8.88	1.44e-17	3.82e-11	-0.49	-0.38	Neuroticism;	chr8:10929033	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.792	rs11646756	ENSG00000230849.2	GOT2P2	8.88	1.45e-17	3.85e-11	0.47	0.38	Blood metabolite ratios;	chr16:58773598	chr1:173141100~173142350:-
THCA	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	8.88	1.46e-17	3.86e-11	0.6	0.38	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	8.88	1.46e-17	3.86e-11	0.6	0.38	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
THCA	trans	rs7819412	0.654	rs6987059	ENSG00000253893.2	FAM85B	8.88	1.46e-17	3.88e-11	0.52	0.38	Triglycerides;	chr8:11213548	chr8:8167819~8226614:-
THCA	trans	rs1039766	1	rs1039766	ENSG00000224334.1	AP000357.4	-8.87	1.5e-17	3.96e-11	-0.58	-0.38	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr22:24686923~24688087:+
THCA	trans	rs9329221	0.905	rs28507213	ENSG00000253893.2	FAM85B	8.87	1.5e-17	3.97e-11	0.49	0.38	Neuroticism;	chr8:10393339	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.905	rs28712068	ENSG00000253893.2	FAM85B	8.87	1.5e-17	3.97e-11	0.49	0.38	Neuroticism;	chr8:10393635	chr8:8167819~8226614:-
THCA	trans	rs2665103	0.715	rs11639440	ENSG00000235370.6	DNM1P51	-8.87	1.53e-17	4.05e-11	-0.47	-0.38	Intelligence (multi-trait analysis);	chr15:82278705	chr15:84398316~84411701:-
THCA	trans	rs7937890	0.505	rs4403769	ENSG00000236360.2	RP11-334A14.2	8.87	1.53e-17	4.05e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14428630	chr1:52993201~52993702:-
THCA	trans	rs7819412	0.765	rs7000132	ENSG00000253893.2	FAM85B	8.87	1.53e-17	4.05e-11	0.52	0.38	Triglycerides;	chr8:11173426	chr8:8167819~8226614:-
THCA	trans	rs864643	0.524	rs17038918	ENSG00000188856.6	RPSAP47	8.87	1.56e-17	4.12e-11	0.71	0.38	Attention deficit hyperactivity disorder;	chr3:39480975	chr8:80558870~80559757:+
THCA	trans	rs3806843	0.9	rs2261651	ENSG00000231043.3	AC007238.1	8.86	1.6e-17	4.23e-11	0.43	0.38	Depressive symptoms (multi-trait analysis);	chr5:140757219	chr2:58460292~58462032:-
THCA	trans	rs7647973	1	rs974495	ENSG00000197582.5	GPX1P1	8.86	1.6e-17	4.24e-11	0.59	0.38	Menarche (age at onset);	chr3:49363049	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs11719762	ENSG00000197582.5	GPX1P1	8.86	1.6e-17	4.24e-11	0.59	0.38	Menarche (age at onset);	chr3:49371569	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs940045	ENSG00000197582.5	GPX1P1	8.86	1.6e-17	4.24e-11	0.59	0.38	Menarche (age at onset);	chr3:49412205	chrX:13378735~13379340:-
THCA	trans	rs7662987	0.938	rs28730605	ENSG00000233859.2	ADH5P4	8.86	1.63e-17	4.3e-11	0.78	0.38	Smoking initiation;	chr4:99080389	chr6:65836930~65838039:-
THCA	trans	rs9858542	0.903	rs17080528	ENSG00000197582.5	GPX1P1	-8.86	1.63e-17	4.3e-11	-0.58	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49352409	chrX:13378735~13379340:-
THCA	trans	rs13090388	1	rs13090388	ENSG00000197582.5	GPX1P1	-8.86	1.63e-17	4.3e-11	-0.58	-0.38	Educational attainment (years of education);Intelligence (multi-trait analysis);	chr3:49353649	chrX:13378735~13379340:-
THCA	trans	rs7937890	0.559	rs2575853	ENSG00000236360.2	RP11-334A14.2	8.86	1.64e-17	4.33e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14512417	chr1:52993201~52993702:-
THCA	trans	rs3806843	0.568	rs2530232	ENSG00000231043.3	AC007238.1	8.86	1.65e-17	4.35e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr2:58460292~58462032:-
THCA	trans	rs1023500	1	rs3752591	ENSG00000268568.1	AC007228.9	-8.86	1.65e-17	4.35e-11	-0.52	-0.38	Schizophrenia;	chr22:41943512	chr19:56672574~56673901:-
THCA	trans	rs3806843	0.868	rs2531349	ENSG00000231043.3	AC007238.1	8.86	1.65e-17	4.37e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140741368	chr2:58460292~58462032:-
THCA	trans	rs11023332	0.641	rs4281505	ENSG00000236360.2	RP11-334A14.2	8.86	1.66e-17	4.38e-11	0.48	0.38	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr1:52993201~52993702:-
THCA	trans	rs11023332	0.65	rs2122942	ENSG00000236360.2	RP11-334A14.2	8.86	1.66e-17	4.38e-11	0.48	0.38	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr1:52993201~52993702:-
THCA	trans	rs2060793	0.55	rs1037378	ENSG00000236360.2	RP11-334A14.2	8.86	1.66e-17	4.39e-11	0.5	0.38	Vitamin D levels;	chr11:14830944	chr1:52993201~52993702:-
THCA	trans	rs877636	1	rs4759229	ENSG00000212829.8	RPS26P3	-8.86	1.69e-17	4.45e-11	-0.48	-0.38	Cognitive function;	chr12:56080696	chr9:9090898~9091245:+
THCA	trans	rs12145833	0.748	rs11807162	ENSG00000154608.12	CEP170P1	-8.86	1.71e-17	4.51e-11	-0.5	-0.38	Obesity (early onset extreme);	chr1:243291378	chr4:118467590~118554204:+
THCA	trans	rs10037055	0.898	rs4976636	ENSG00000228305.2	AC016734.2	-8.85	1.72e-17	4.55e-11	-0.41	-0.38	Migraine without aura;	chr5:177118091	chr2:63622178~63622831:-
THCA	trans	rs10037055	0.898	rs4976637	ENSG00000228305.2	AC016734.2	-8.85	1.72e-17	4.55e-11	-0.41	-0.38	Migraine without aura;	chr5:177118141	chr2:63622178~63622831:-
THCA	trans	rs116095464	1	rs2015774	ENSG00000185986.11	SDHAP3	8.85	1.74e-17	4.59e-11	0.56	0.38	Breast cancer;	chr5:312843	chr5:1572222~1594620:-
THCA	trans	rs11868206	1	rs11868206	ENSG00000234130.2	RP13-88F20.1	8.85	1.75e-17	4.61e-11	0.49	0.38	Mean platelet volume;	chr17:35632228	chrX:93222220~93225015:-
THCA	trans	rs804280	0.509	rs35626932	ENSG00000253893.2	FAM85B	-8.85	1.75e-17	4.61e-11	-0.52	-0.38	Myopia (pathological);	chr8:11929423	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.953	rs11715915	ENSG00000197582.5	GPX1P1	8.85	1.76e-17	4.63e-11	0.58	0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49417897	chrX:13378735~13379340:-
THCA	trans	rs7819412	0.806	rs10113808	ENSG00000253893.2	FAM85B	8.85	1.76e-17	4.64e-11	0.5	0.38	Triglycerides;	chr8:11069382	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.566	rs7664440	ENSG00000275858.1	RP11-291L22.8	8.85	1.77e-17	4.67e-11	0.51	0.38	Corneal astigmatism;	chr4:119657385	chr10:38450738~38451069:-
THCA	trans	rs7819412	0.775	rs2001329	ENSG00000253893.2	FAM85B	8.85	1.79e-17	4.71e-11	0.5	0.38	Triglycerides;	chr8:11129349	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.792	rs12325054	ENSG00000230849.2	GOT2P2	8.85	1.81e-17	4.76e-11	0.47	0.38	Blood metabolite ratios;	chr16:58749804	chr1:173141100~173142350:-
THCA	trans	rs453301	0.571	rs330057	ENSG00000253893.2	FAM85B	8.85	1.81e-17	4.77e-11	0.48	0.38	Joint mobility (Beighton score);	chr8:9232283	chr8:8167819~8226614:-
THCA	trans	rs453301	0.624	rs330060	ENSG00000253893.2	FAM85B	8.85	1.85e-17	4.86e-11	0.48	0.38	Joint mobility (Beighton score);	chr8:9233392	chr8:8167819~8226614:-
THCA	trans	rs3806843	1	rs12717860	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140791857	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs6870764	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140792205	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs6891995	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140792423	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs13184940	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140793333	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs1476768	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140794012	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs9686540	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140795037	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs3756339	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140800952	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs3733708	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140802149	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs2240694	ENSG00000231043.3	AC007238.1	-8.84	1.86e-17	4.9e-11	-0.43	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140803473	chr2:58460292~58462032:-
THCA	trans	rs116095464	1	rs56235400	ENSG00000185986.11	SDHAP3	8.84	1.87e-17	4.93e-11	0.56	0.38	Breast cancer;	chr5:312510	chr5:1572222~1594620:-
THCA	trans	rs2060793	0.526	rs10766194	ENSG00000236360.2	RP11-334A14.2	8.84	1.89e-17	4.96e-11	0.5	0.38	Vitamin D levels;	chr11:14842668	chr1:52993201~52993702:-
THCA	trans	rs9650657	0.53	rs6982381	ENSG00000253893.2	FAM85B	8.84	1.89e-17	4.96e-11	0.51	0.38	Neuroticism;	chr8:11094990	chr8:8167819~8226614:-
THCA	trans	rs2665103	0.715	rs7403041	ENSG00000235370.6	DNM1P51	8.84	1.89e-17	4.97e-11	0.47	0.38	Intelligence (multi-trait analysis);	chr15:82287841	chr15:84398316~84411701:-
THCA	trans	rs11023332	0.617	rs1451678	ENSG00000236360.2	RP11-334A14.2	8.84	1.9e-17	5e-11	0.48	0.38	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr1:52993201~52993702:-
THCA	trans	rs1816752	0.719	rs11841989	ENSG00000224976.2	PARP4P2	-8.84	1.91e-17	5.03e-11	-0.45	-0.38	Obesity-related traits;	chr13:24423560	chr13:19349137~19407962:+
THCA	trans	rs12709013	0.792	rs62064901	ENSG00000230849.2	GOT2P2	8.84	1.92e-17	5.04e-11	0.46	0.38	Blood metabolite ratios;	chr16:58776758	chr1:173141100~173142350:-
THCA	trans	rs864643	0.524	rs72869124	ENSG00000188856.6	RPSAP47	8.84	1.92e-17	5.04e-11	0.7	0.38	Attention deficit hyperactivity disorder;	chr3:39469788	chr8:80558870~80559757:+
THCA	trans	rs877636	1	rs4759229	ENSG00000234354.3	RPS26P47	-8.84	1.93e-17	5.06e-11	-0.5	-0.38	Cognitive function;	chr12:56080696	chr13:100539901~100540248:-
THCA	trans	rs7113874	0.578	rs34059271	ENSG00000266891.1	RP11-692N5.2	8.84	1.95e-17	5.12e-11	0.57	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8546311	chr18:9734882~9735602:-
THCA	trans	rs3806843	0.733	rs801181	ENSG00000231043.3	AC007238.1	8.84	1.96e-17	5.15e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140713229	chr2:58460292~58462032:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000196933.5	RPS26P11	-8.84	1.97e-17	5.17e-11	-0.49	-0.38	Cognitive function;	chr12:55996852	chrX:72044545~72044892:+
THCA	trans	rs453301	0.624	rs330056	ENSG00000253893.2	FAM85B	8.84	2e-17	5.25e-11	0.48	0.38	Joint mobility (Beighton score);	chr8:9232185	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.623	rs7833435	ENSG00000253893.2	FAM85B	8.83	2.02e-17	5.3e-11	0.49	0.38	Triglycerides;	chr8:10943627	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.961	rs4955430	ENSG00000197582.5	GPX1P1	8.83	2.03e-17	5.32e-11	0.6	0.38	Menarche (age at onset);	chr3:49340655	chrX:13378735~13379340:-
THCA	trans	rs7819412	0.749	rs11991118	ENSG00000253893.2	FAM85B	-8.83	2.03e-17	5.32e-11	-0.48	-0.38	Triglycerides;	chr8:11081763	chr8:8167819~8226614:-
THCA	trans	rs864643	0.524	rs12106854	ENSG00000188856.6	RPSAP47	8.83	2.03e-17	5.33e-11	0.71	0.38	Attention deficit hyperactivity disorder;	chr3:39487321	chr8:80558870~80559757:+
THCA	trans	rs864643	0.524	rs17038967	ENSG00000188856.6	RPSAP47	8.83	2.03e-17	5.33e-11	0.71	0.38	Attention deficit hyperactivity disorder;	chr3:39489530	chr8:80558870~80559757:+
THCA	trans	rs7937890	0.559	rs4369365	ENSG00000236360.2	RP11-334A14.2	8.83	2.05e-17	5.38e-11	0.52	0.38	Mitochondrial DNA levels;	chr11:14422969	chr1:52993201~52993702:-
THCA	trans	rs7647973	1	rs62261249	ENSG00000197582.5	GPX1P1	-8.83	2.05e-17	5.38e-11	-0.6	-0.38	Menarche (age at onset);	chr3:49556627	chrX:13378735~13379340:-
THCA	trans	rs916888	0.61	rs199446	ENSG00000204650.12	CRHR1-IT1	-8.83	2.07e-17	5.42e-11	-0.38	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45620328~45648216:+
THCA	trans	rs877636	1	rs877636	ENSG00000204652.6	RPS26P8	-8.83	2.07e-17	5.43e-11	-0.5	-0.38	Cognitive function;	chr12:56086799	chr17:45608571~45608918:+
THCA	trans	rs3806843	0.9	rs2337984	ENSG00000231043.3	AC007238.1	8.83	2.1e-17	5.49e-11	0.43	0.38	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr2:58460292~58462032:-
THCA	trans	rs1816752	0.719	rs11843470	ENSG00000224976.2	PARP4P2	-8.83	2.11e-17	5.53e-11	-0.45	-0.38	Obesity-related traits;	chr13:24423561	chr13:19349137~19407962:+
THCA	trans	rs116095464	1	rs6873902	ENSG00000185986.11	SDHAP3	8.83	2.12e-17	5.56e-11	0.56	0.38	Breast cancer;	chr5:313222	chr5:1572222~1594620:-
THCA	trans	rs116095464	1	rs7736	ENSG00000185986.11	SDHAP3	8.83	2.12e-17	5.56e-11	0.56	0.38	Breast cancer;	chr5:314820	chr5:1572222~1594620:-
THCA	trans	rs12709013	0.792	rs1646276	ENSG00000230849.2	GOT2P2	8.83	2.15e-17	5.62e-11	0.46	0.38	Blood metabolite ratios;	chr16:58749654	chr1:173141100~173142350:-
THCA	trans	rs7819412	0.659	rs4073948	ENSG00000253893.2	FAM85B	8.83	2.15e-17	5.63e-11	0.46	0.38	Triglycerides;	chr8:10915134	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.504	rs2575847	ENSG00000236360.2	RP11-334A14.2	8.83	2.16e-17	5.64e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14449626	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2575825	ENSG00000236360.2	RP11-334A14.2	8.83	2.16e-17	5.64e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14450550	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.532	rs2575827	ENSG00000236360.2	RP11-334A14.2	8.83	2.16e-17	5.64e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14453969	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2597206	ENSG00000236360.2	RP11-334A14.2	8.83	2.16e-17	5.64e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14455992	chr1:52993201~52993702:-
THCA	trans	rs3806843	0.766	rs2251860	ENSG00000231043.3	AC007238.1	8.82	2.19e-17	5.72e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140668624	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.766	rs702397	ENSG00000231043.3	AC007238.1	8.82	2.19e-17	5.72e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140670680	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.766	rs2530239	ENSG00000231043.3	AC007238.1	8.82	2.19e-17	5.72e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140682962	chr2:58460292~58462032:-
THCA	trans	rs2929278	0.589	rs11638972	ENSG00000180867.10	PDIA3P1	8.82	2.19e-17	5.73e-11	0.33	0.38	Schizophrenia;	chr15:43782493	chr1:147178113~147179622:+
THCA	trans	rs7937890	0.559	rs2597188	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14495360	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2597187	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14495473	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.504	rs2575822	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14498305	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2575823	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14499808	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2597221	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14505529	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs6486197	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14508328	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2597219	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14509320	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2575852	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14511822	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.531	rs2597216	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14512370	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs1548074	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14513279	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.561	rs2575849	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14518093	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.507	rs4463820	ENSG00000236360.2	RP11-334A14.2	8.82	2.2e-17	5.76e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14534796	chr1:52993201~52993702:-
THCA	trans	rs9899728	0.614	rs12949451	ENSG00000234925.2	ATP5HP4	-8.82	2.23e-17	5.83e-11	-0.8	-0.38	Alzheimer's disease or small vessel stroke;	chr17:75036224	chr12:68642519~68642993:-
THCA	trans	rs9650657	0.571	rs11783247	ENSG00000253893.2	FAM85B	8.82	2.27e-17	5.92e-11	0.48	0.38	Neuroticism;	chr8:10931365	chr8:8167819~8226614:-
THCA	trans	rs7647973	1	rs6446268	ENSG00000197582.5	GPX1P1	-8.82	2.29e-17	5.99e-11	-0.59	-0.38	Menarche (age at onset);	chr3:49408262	chrX:13378735~13379340:-
THCA	trans	rs2243480	0.901	rs3813708	ENSG00000273142.1	RP11-458F8.4	-8.82	2.31e-17	6.04e-11	-0.48	-0.38	Diabetic kidney disease;	chr7:65840645	chr7:66902857~66906297:+
THCA	trans	rs7647973	1	rs13088309	ENSG00000197582.5	GPX1P1	8.82	2.33e-17	6.08e-11	0.6	0.38	Menarche (age at onset);	chr3:49330884	chrX:13378735~13379340:-
THCA	trans	rs393155	0.517	rs330050	ENSG00000253893.2	FAM85B	8.81	2.34e-17	6.1e-11	0.47	0.38	Neuroticism;	chr8:9230169	chr8:8167819~8226614:-
THCA	trans	rs453301	0.571	rs330054	ENSG00000253893.2	FAM85B	8.81	2.34e-17	6.1e-11	0.47	0.38	Joint mobility (Beighton score);	chr8:9230781	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.792	rs1657165	ENSG00000230849.2	GOT2P2	8.81	2.35e-17	6.13e-11	0.46	0.38	Blood metabolite ratios;	chr16:58747980	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.818	rs1646273	ENSG00000230849.2	GOT2P2	8.81	2.35e-17	6.13e-11	0.46	0.38	Blood metabolite ratios;	chr16:58748318	chr1:173141100~173142350:-
THCA	trans	rs3806843	0.9	rs2262576	ENSG00000231043.3	AC007238.1	8.81	2.37e-17	6.18e-11	0.43	0.38	Depressive symptoms (multi-trait analysis);	chr5:140755951	chr2:58460292~58462032:-
THCA	trans	rs28647808	0.867	rs34399743	ENSG00000234981.1	RP11-534L20.4	8.81	2.38e-17	6.21e-11	0.74	0.38	Blood protein levels;	chr9:133385574	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs28617580	ENSG00000234981.1	RP11-534L20.4	8.81	2.38e-17	6.21e-11	0.74	0.38	Blood protein levels;	chr9:133387168	chr1:206528915~206529706:+
THCA	trans	rs877636	0.74	rs705698	ENSG00000242970.2	AC068522.4	8.81	2.4e-17	6.26e-11	0.53	0.38	Cognitive function;	chr12:55990903	chr8:58588420~58588764:-
THCA	trans	rs2470135	1	rs2470135	ENSG00000180867.10	PDIA3P1	-8.81	2.44e-17	6.37e-11	-0.33	-0.38	Diastolic blood pressure;	chr15:43703591	chr1:147178113~147179622:+
THCA	trans	rs9650657	0.504	rs7813802	ENSG00000253893.2	FAM85B	-8.81	2.46e-17	6.41e-11	-0.5	-0.38	Neuroticism;	chr8:11176467	chr8:8167819~8226614:-
THCA	trans	rs453301	0.624	rs330058	ENSG00000253893.2	FAM85B	8.81	2.48e-17	6.46e-11	0.48	0.38	Joint mobility (Beighton score);	chr8:9232299	chr8:8167819~8226614:-
THCA	trans	rs7554547	0.6	rs2180180	ENSG00000261819.1	RP11-680G24.4	-8.81	2.48e-17	6.47e-11	-0.51	-0.38	Nonsyndromic cleft lip with cleft palate;	chr1:11959312	chr16:14988259~14990160:-
THCA	trans	rs13014235	0.905	rs6435082	ENSG00000235105.1	RP11-329A14.1	8.81	2.49e-17	6.5e-11	0.43	0.38	Basal cell carcinoma;	chr2:201372558	chr1:48435967~48437223:+
THCA	trans	rs2929278	0.561	rs62018952	ENSG00000180867.10	PDIA3P1	8.81	2.5e-17	6.5e-11	0.34	0.38	Schizophrenia;	chr15:43788539	chr1:147178113~147179622:+
THCA	trans	rs9650657	0.537	rs7016385	ENSG00000253893.2	FAM85B	-8.8	2.53e-17	6.57e-11	-0.47	-0.38	Neuroticism;	chr8:10921962	chr8:8167819~8226614:-
THCA	trans	rs6424115	0.8	rs2229581	ENSG00000228217.1	AL390877.1	-8.8	2.53e-17	6.58e-11	-0.5	-0.38	Immature fraction of reticulocytes;	chr1:23874604	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.743	rs2229580	ENSG00000228217.1	AL390877.1	-8.8	2.53e-17	6.58e-11	-0.5	-0.38	Immature fraction of reticulocytes;	chr1:23874619	chr1:117778087~117778506:-
THCA	trans	rs11098499	0.604	rs12642411	ENSG00000275858.1	RP11-291L22.8	8.8	2.62e-17	6.81e-11	0.52	0.38	Corneal astigmatism;	chr4:119659370	chr10:38450738~38451069:-
THCA	trans	rs6087990	0.568	rs853854	ENSG00000253915.1	MAPRE1P1	8.8	2.63e-17	6.84e-11	0.48	0.38	Ulcerative colitis;	chr20:32832951	chr8:135625185~135625981:-
THCA	trans	rs2657294	0.734	rs10740449	ENSG00000172974.11	AC007318.5	8.8	2.65e-17	6.88e-11	0.45	0.38	Pneumonia;	chr10:75086620	chr2:65205108~65205988:+
THCA	trans	rs12138950	0.681	rs28630511	ENSG00000224237.1	MINOS1P3	8.8	2.67e-17	6.95e-11	0.51	0.38	Hypothyroidism;Thyroid volume;	chr1:19516538	chr3:27214816~27215018:-
THCA	trans	rs10037055	0.853	rs10077929	ENSG00000217325.2	PRELID1P1	8.79	2.75e-17	7.15e-11	0.39	0.38	Migraine without aura;	chr5:177270843	chr6:126643488~126644390:+
THCA	trans	rs3806843	0.868	rs2531352	ENSG00000231043.3	AC007238.1	8.79	2.75e-17	7.15e-11	0.43	0.38	Depressive symptoms (multi-trait analysis);	chr5:140739949	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.778	rs2531346	ENSG00000231043.3	AC007238.1	8.79	2.77e-17	7.19e-11	0.43	0.38	Depressive symptoms (multi-trait analysis);	chr5:140746554	chr2:58460292~58462032:-
THCA	trans	rs6743068	0.541	rs10206231	ENSG00000235105.1	RP11-329A14.1	8.79	2.83e-17	7.35e-11	0.42	0.38	Lymphocyte percentage of white cells;	chr2:201364502	chr1:48435967~48437223:+
THCA	trans	rs3806843	0.808	rs6893708	ENSG00000231043.3	AC007238.1	8.79	2.86e-17	7.42e-11	0.43	0.38	Depressive symptoms (multi-trait analysis);	chr5:140746337	chr2:58460292~58462032:-
THCA	trans	rs7662987	1	rs28730595	ENSG00000233859.2	ADH5P4	8.79	2.87e-17	7.45e-11	0.78	0.38	Smoking initiation;	chr4:99082182	chr6:65836930~65838039:-
THCA	trans	rs7662987	0.938	rs28730592	ENSG00000233859.2	ADH5P4	8.79	2.87e-17	7.45e-11	0.78	0.38	Smoking initiation;	chr4:99082592	chr6:65836930~65838039:-
THCA	trans	rs7662987	1	rs28730591	ENSG00000233859.2	ADH5P4	8.79	2.87e-17	7.45e-11	0.78	0.38	Smoking initiation;	chr4:99082596	chr6:65836930~65838039:-
THCA	trans	rs11098499	0.691	rs12502524	ENSG00000275858.1	RP11-291L22.8	8.79	2.88e-17	7.46e-11	0.48	0.38	Corneal astigmatism;	chr4:119350259	chr10:38450738~38451069:-
THCA	trans	rs916888	0.61	rs199536	ENSG00000204650.12	CRHR1-IT1	-8.79	2.89e-17	7.5e-11	-0.37	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45620328~45648216:+
THCA	trans	rs58106596	0.848	rs2241742	ENSG00000259020.3	RP11-529H20.3	8.79	2.89e-17	7.5e-11	0.63	0.38	Lymphocyte counts;White blood cell count;	chr2:231710097	chr14:92026566~92026887:+
THCA	trans	rs9329221	0.772	rs7824675	ENSG00000253893.2	FAM85B	8.79	2.89e-17	7.5e-11	0.48	0.38	Neuroticism;	chr8:10385908	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.559	rs2597201	ENSG00000236360.2	RP11-334A14.2	8.79	2.9e-17	7.52e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14463858	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2575831	ENSG00000236360.2	RP11-334A14.2	8.79	2.9e-17	7.52e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14464648	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.532	rs2575832	ENSG00000236360.2	RP11-334A14.2	8.79	2.9e-17	7.52e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14467264	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.559	rs2597197	ENSG00000236360.2	RP11-334A14.2	8.79	2.9e-17	7.52e-11	0.51	0.38	Mitochondrial DNA levels;	chr11:14468286	chr1:52993201~52993702:-
THCA	trans	rs2898290	0.622	rs1382567	ENSG00000253893.2	FAM85B	8.79	2.91e-17	7.55e-11	0.5	0.38	Systolic blood pressure;	chr8:11493390	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.578	rs12787407	ENSG00000266891.1	RP11-692N5.2	8.79	2.94e-17	7.61e-11	0.57	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8532605	chr18:9734882~9735602:-
THCA	trans	rs1023500	1	rs6002552	ENSG00000268568.1	AC007228.9	-8.78	2.94e-17	7.63e-11	-0.52	-0.38	Schizophrenia;	chr22:41942347	chr19:56672574~56673901:-
THCA	trans	rs2898290	0.622	rs4840567	ENSG00000253893.2	FAM85B	8.78	2.96e-17	7.68e-11	0.51	0.38	Systolic blood pressure;	chr8:11490116	chr8:8167819~8226614:-
THCA	trans	rs864643	0.524	rs78956370	ENSG00000188856.6	RPSAP47	8.78	2.98e-17	7.73e-11	0.7	0.38	Attention deficit hyperactivity disorder;	chr3:39463883	chr8:80558870~80559757:+
THCA	trans	rs6790105	1	rs6790105	ENSG00000197582.5	GPX1P1	8.78	2.99e-17	7.73e-11	0.59	0.38	Childhood ear infection;	chr3:49355976	chrX:13378735~13379340:-
THCA	trans	rs10816533	1	rs11562317	ENSG00000232063.1	RP11-307E17.8	-8.78	3.04e-17	7.85e-11	-0.89	-0.38	Height;	chr9:96806453	chr9:94332476~94360948:+
THCA	trans	rs877636	0.702	rs773112	ENSG00000196933.5	RPS26P11	8.78	3.04e-17	7.87e-11	0.49	0.38	Cognitive function;	chr12:55982097	chrX:72044545~72044892:+
THCA	trans	rs12497850	0.966	rs6792510	ENSG00000197582.5	GPX1P1	8.78	3.07e-17	7.92e-11	0.55	0.38	Parkinson's disease;	chr3:48685869	chrX:13378735~13379340:-
THCA	trans	rs8010715	0.636	rs3825584	ENSG00000238000.1	RP11-274E7.2	8.78	3.08e-17	7.96e-11	0.42	0.38	IgG glycosylation;	chr14:24118430	chr5:98213402~98214121:+
THCA	trans	rs3806843	0.868	rs2531345	ENSG00000231043.3	AC007238.1	8.78	3.1e-17	8e-11	0.43	0.38	Depressive symptoms (multi-trait analysis);	chr5:140747196	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.864	rs2531343	ENSG00000231043.3	AC007238.1	8.78	3.1e-17	8e-11	0.43	0.38	Depressive symptoms (multi-trait analysis);	chr5:140749761	chr2:58460292~58462032:-
THCA	trans	rs7819412	0.715	rs35223712	ENSG00000253893.2	FAM85B	8.78	3.11e-17	8.04e-11	0.5	0.38	Triglycerides;	chr8:11186417	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000196933.5	RPS26P11	8.78	3.13e-17	8.08e-11	0.49	0.38	Cognitive function;	chr12:55981353	chrX:72044545~72044892:+
THCA	trans	rs877636	0.702	rs773111	ENSG00000196933.5	RPS26P11	8.78	3.13e-17	8.08e-11	0.49	0.38	Cognitive function;	chr12:55981956	chrX:72044545~72044892:+
THCA	trans	rs6424115	0.8	rs6665733	ENSG00000228217.1	AL390877.1	-8.78	3.14e-17	8.1e-11	-0.49	-0.38	Immature fraction of reticulocytes;	chr1:23873668	chr1:117778087~117778506:-
THCA	trans	rs1816752	0.603	rs9551099	ENSG00000224976.2	PARP4P2	8.78	3.14e-17	8.11e-11	0.45	0.38	Obesity-related traits;	chr13:24410978	chr13:19349137~19407962:+
THCA	trans	rs9858542	0.953	rs4625	ENSG00000197582.5	GPX1P1	-8.78	3.16e-17	8.15e-11	-0.57	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49534707	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.712	rs2530244	ENSG00000231043.3	AC007238.1	8.78	3.16e-17	8.16e-11	0.44	0.38	Depressive symptoms (multi-trait analysis);	chr5:140729570	chr2:58460292~58462032:-
THCA	trans	rs959695	0.834	rs6468693	ENSG00000260318.1	COX6CP1	-8.77	3.19e-17	8.24e-11	-0.51	-0.38	Hippocampal atrophy;	chr8:99839040	chr16:11903923~11904137:-
THCA	trans	rs13014235	0.905	rs6730666	ENSG00000235105.1	RP11-329A14.1	8.77	3.21e-17	8.27e-11	0.42	0.38	Basal cell carcinoma;	chr2:201374076	chr1:48435967~48437223:+
THCA	trans	rs864643	0.524	rs6810264	ENSG00000188856.6	RPSAP47	8.77	3.23e-17	8.32e-11	0.7	0.38	Attention deficit hyperactivity disorder;	chr3:39471605	chr8:80558870~80559757:+
THCA	trans	rs864643	0.524	rs11706953	ENSG00000188856.6	RPSAP47	8.77	3.23e-17	8.32e-11	0.7	0.38	Attention deficit hyperactivity disorder;	chr3:39472119	chr8:80558870~80559757:+
THCA	trans	rs864643	0.524	rs72869131	ENSG00000188856.6	RPSAP47	8.77	3.23e-17	8.32e-11	0.7	0.38	Attention deficit hyperactivity disorder;	chr3:39472959	chr8:80558870~80559757:+
THCA	trans	rs11023332	0.706	rs11023380	ENSG00000236360.2	RP11-334A14.2	8.77	3.3e-17	8.52e-11	0.49	0.38	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr1:52993201~52993702:-
THCA	trans	rs11023332	0.8	rs12271890	ENSG00000236360.2	RP11-334A14.2	8.77	3.3e-17	8.52e-11	0.49	0.38	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr1:52993201~52993702:-
THCA	trans	rs11098499	0.661	rs10015965	ENSG00000275858.1	RP11-291L22.8	8.77	3.32e-17	8.56e-11	0.48	0.37	Corneal astigmatism;	chr4:119347082	chr10:38450738~38451069:-
THCA	trans	rs10028773	0.6	rs4001390	ENSG00000275858.1	RP11-291L22.8	8.77	3.33e-17	8.57e-11	0.48	0.37	Educational attainment;	chr4:119344628	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.691	rs2136911	ENSG00000275858.1	RP11-291L22.8	8.77	3.33e-17	8.57e-11	0.48	0.37	Corneal astigmatism;	chr4:119344704	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.779	rs6815934	ENSG00000275858.1	RP11-291L22.8	8.77	3.33e-17	8.57e-11	0.48	0.37	Corneal astigmatism;	chr4:119346155	chr10:38450738~38451069:-
THCA	trans	rs10028773	0.568	rs6838457	ENSG00000275858.1	RP11-291L22.8	8.77	3.33e-17	8.57e-11	0.48	0.37	Educational attainment;	chr4:119346212	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.535	rs10005542	ENSG00000275858.1	RP11-291L22.8	8.77	3.33e-17	8.57e-11	0.48	0.37	Corneal astigmatism;	chr4:119347147	chr10:38450738~38451069:-
THCA	trans	rs7937890	0.559	rs2597196	ENSG00000236360.2	RP11-334A14.2	-8.77	3.33e-17	8.58e-11	-0.51	-0.37	Mitochondrial DNA levels;	chr11:14470055	chr1:52993201~52993702:-
THCA	trans	rs11098499	0.604	rs2389886	ENSG00000275858.1	RP11-291L22.8	8.77	3.34e-17	8.59e-11	0.51	0.37	Corneal astigmatism;	chr4:119649267	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.604	rs2389887	ENSG00000275858.1	RP11-291L22.8	8.77	3.34e-17	8.59e-11	0.51	0.37	Corneal astigmatism;	chr4:119649489	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.604	rs34278750	ENSG00000275858.1	RP11-291L22.8	8.77	3.34e-17	8.59e-11	0.51	0.37	Corneal astigmatism;	chr4:119649981	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.604	rs10022185	ENSG00000275858.1	RP11-291L22.8	8.77	3.34e-17	8.59e-11	0.51	0.37	Corneal astigmatism;	chr4:119650610	chr10:38450738~38451069:-
THCA	trans	rs8010715	0.636	rs2277482	ENSG00000238000.1	RP11-274E7.2	8.77	3.35e-17	8.62e-11	0.42	0.37	IgG glycosylation;	chr14:24118586	chr5:98213402~98214121:+
THCA	trans	rs7819412	0.745	rs2898260	ENSG00000253893.2	FAM85B	8.77	3.37e-17	8.67e-11	0.49	0.37	Triglycerides;	chr8:11081980	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.622	rs13272061	ENSG00000253893.2	FAM85B	8.77	3.37e-17	8.67e-11	0.51	0.37	Systolic blood pressure;	chr8:11494752	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.792	rs1657170	ENSG00000230849.2	GOT2P2	8.76	3.46e-17	8.9e-11	0.46	0.37	Blood metabolite ratios;	chr16:58752082	chr1:173141100~173142350:-
THCA	trans	rs11023332	0.706	rs11023379	ENSG00000236360.2	RP11-334A14.2	8.76	3.5e-17	9e-11	0.49	0.37	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr1:52993201~52993702:-
THCA	trans	rs3806843	0.9	rs3756334	ENSG00000231043.3	AC007238.1	-8.76	3.5e-17	9e-11	-0.44	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140834211	chr2:58460292~58462032:-
THCA	trans	rs877636	0.859	rs3741499	ENSG00000234354.3	RPS26P47	-8.76	3.51e-17	9.02e-11	-0.5	-0.37	Cognitive function;	chr12:56080595	chr13:100539901~100540248:-
THCA	trans	rs3806843	0.9	rs2563279	ENSG00000231043.3	AC007238.1	8.76	3.51e-17	9.03e-11	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140751950	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs2563265	ENSG00000231043.3	AC007238.1	8.76	3.52e-17	9.04e-11	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr2:58460292~58462032:-
THCA	trans	rs2288327	0.673	rs6723399	ENSG00000269800.1	PLEKHA3P1	8.76	3.52e-17	9.05e-11	0.48	0.37	Atrial fibrillation;	chr2:178516988	chr19:41521043~41521989:-
THCA	trans	rs7554547	0.6	rs2273290	ENSG00000261819.1	RP11-680G24.4	8.76	3.52e-17	9.06e-11	0.52	0.37	Nonsyndromic cleft lip with cleft palate;	chr1:11958321	chr16:14988259~14990160:-
THCA	trans	rs12709013	0.766	rs11648511	ENSG00000230849.2	GOT2P2	8.76	3.53e-17	9.06e-11	0.46	0.37	Blood metabolite ratios;	chr16:58798171	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.716	rs11647582	ENSG00000230849.2	GOT2P2	8.76	3.53e-17	9.06e-11	0.46	0.37	Blood metabolite ratios;	chr16:58801474	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs35684307	ENSG00000230849.2	GOT2P2	8.76	3.53e-17	9.06e-11	0.46	0.37	Blood metabolite ratios;	chr16:58801651	chr1:173141100~173142350:-
THCA	trans	rs12497850	0.931	rs1134591	ENSG00000197582.5	GPX1P1	8.76	3.55e-17	9.12e-11	0.56	0.37	Parkinson's disease;	chr3:48935459	chrX:13378735~13379340:-
THCA	trans	rs7937890	0.559	rs2575836	ENSG00000236360.2	RP11-334A14.2	8.76	3.56e-17	9.14e-11	0.51	0.37	Mitochondrial DNA levels;	chr11:14476318	chr1:52993201~52993702:-
THCA	trans	rs7937890	0.531	rs2575859	ENSG00000236360.2	RP11-334A14.2	8.76	3.56e-17	9.14e-11	0.51	0.37	Mitochondrial DNA levels;	chr11:14489190	chr1:52993201~52993702:-
THCA	trans	rs3806843	0.868	rs2531342	ENSG00000231043.3	AC007238.1	8.76	3.59e-17	9.22e-11	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140751027	chr2:58460292~58462032:-
THCA	trans	rs10037055	0.947	rs10063803	ENSG00000228305.2	AC016734.2	8.76	3.59e-17	9.23e-11	0.41	0.37	Migraine without aura;	chr5:177240326	chr2:63622178~63622831:-
THCA	trans	rs4295623	0.816	rs35558975	ENSG00000253893.2	FAM85B	8.76	3.64e-17	9.35e-11	0.51	0.37	Morning vs. evening chronotype;	chr8:11726967	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.905	rs17709397	ENSG00000253893.2	FAM85B	8.76	3.66e-17	9.39e-11	0.49	0.37	Neuroticism;	chr8:10392351	chr8:8167819~8226614:-
THCA	trans	rs7833986	0.501	rs72651502	ENSG00000244245.1	RP11-120B7.1	8.76	3.67e-17	9.41e-11	0.51	0.37	Height;	chr8:55962974	chr5:108593609~108593967:+
THCA	trans	rs916888	0.779	rs199526	ENSG00000204650.12	CRHR1-IT1	-8.75	3.7e-17	9.5e-11	-0.38	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45620328~45648216:+
THCA	trans	rs2929278	0.617	rs11070410	ENSG00000180867.10	PDIA3P1	8.75	3.71e-17	9.51e-11	0.33	0.37	Schizophrenia;	chr15:43764847	chr1:147178113~147179622:+
THCA	trans	rs7937890	0.532	rs2575833	ENSG00000236360.2	RP11-334A14.2	8.75	3.71e-17	9.52e-11	0.51	0.37	Mitochondrial DNA levels;	chr11:14470959	chr1:52993201~52993702:-
THCA	trans	rs12709013	0.792	rs1646270	ENSG00000230849.2	GOT2P2	8.75	3.73e-17	9.57e-11	0.46	0.37	Blood metabolite ratios;	chr16:58745823	chr1:173141100~173142350:-
THCA	trans	rs9611519	0.58	rs7286603	ENSG00000268568.1	AC007228.9	-8.75	3.73e-17	9.57e-11	-0.42	-0.37	Neuroticism;	chr22:41044057	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.558	rs8137906	ENSG00000268568.1	AC007228.9	-8.75	3.73e-17	9.57e-11	-0.42	-0.37	Neuroticism;	chr22:41046562	chr19:56672574~56673901:-
THCA	trans	rs9650657	0.529	rs10108618	ENSG00000253893.2	FAM85B	8.75	3.76e-17	9.65e-11	0.5	0.37	Neuroticism;	chr8:11095582	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.506	rs7823296	ENSG00000253893.2	FAM85B	8.75	3.77e-17	9.67e-11	0.47	0.37	Neuroticism;	chr8:10921036	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.792	rs12935488	ENSG00000230849.2	GOT2P2	8.75	3.79e-17	9.73e-11	0.46	0.37	Blood metabolite ratios;	chr16:58766320	chr1:173141100~173142350:-
THCA	trans	rs6424115	0.83	rs1130321	ENSG00000228217.1	AL390877.1	-8.75	3.82e-17	9.8e-11	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23874034	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs1130320	ENSG00000228217.1	AL390877.1	-8.75	3.82e-17	9.8e-11	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23874116	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs1106	ENSG00000228217.1	AL390877.1	-8.75	3.82e-17	9.8e-11	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23874282	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs1105	ENSG00000228217.1	AL390877.1	-8.75	3.88e-17	9.94e-11	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23874310	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs2229585	ENSG00000228217.1	AL390877.1	-8.75	3.88e-17	9.94e-11	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23874431	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs2229584	ENSG00000228217.1	AL390877.1	-8.75	3.88e-17	9.94e-11	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23874479	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.8	rs2229583	ENSG00000228217.1	AL390877.1	-8.75	3.88e-17	9.94e-11	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23874493	chr1:117778087~117778506:-
THCA	trans	rs12709013	0.755	rs1628029	ENSG00000230849.2	GOT2P2	8.75	3.9e-17	9.99e-11	0.46	0.37	Blood metabolite ratios;	chr16:58763846	chr1:173141100~173142350:-
THCA	trans	rs2929278	0.562	rs8033846	ENSG00000180867.10	PDIA3P1	8.75	3.99e-17	1.02e-10	0.33	0.37	Schizophrenia;	chr15:43743165	chr1:147178113~147179622:+
THCA	trans	rs9858542	0.953	rs3811699	ENSG00000197582.5	GPX1P1	-8.74	3.99e-17	1.02e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chrX:13378735~13379340:-
THCA	trans	rs3806843	1	rs991918	ENSG00000231043.3	AC007238.1	-8.74	4e-17	1.02e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140815273	chr2:58460292~58462032:-
THCA	trans	rs7937890	0.559	rs2597208	ENSG00000236360.2	RP11-334A14.2	8.74	4.02e-17	1.03e-10	0.52	0.37	Mitochondrial DNA levels;	chr11:14450783	chr1:52993201~52993702:-
THCA	trans	rs11098499	0.554	rs2175381	ENSG00000275858.1	RP11-291L22.8	8.74	4.08e-17	1.04e-10	0.48	0.37	Corneal astigmatism;	chr4:119344812	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.599	rs3864142	ENSG00000275858.1	RP11-291L22.8	8.74	4.08e-17	1.04e-10	0.48	0.37	Corneal astigmatism;	chr4:119345036	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.605	rs6833140	ENSG00000275858.1	RP11-291L22.8	8.74	4.08e-17	1.04e-10	0.48	0.37	Corneal astigmatism;	chr4:119345667	chr10:38450738~38451069:-
THCA	trans	rs877636	1	rs877636	ENSG00000243538.1	CTB-55B8.1	-8.74	4.14e-17	1.06e-10	-0.46	-0.37	Cognitive function;	chr12:56086799	chr5:16902294~16902641:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000196933.5	RPS26P11	8.74	4.14e-17	1.06e-10	0.49	0.37	Cognitive function;	chr12:55996580	chrX:72044545~72044892:+
THCA	trans	rs6743068	0.521	rs2349078	ENSG00000235105.1	RP11-329A14.1	8.74	4.16e-17	1.06e-10	0.42	0.37	Lymphocyte percentage of white cells;	chr2:201369342	chr1:48435967~48437223:+
THCA	trans	rs55894533	0.597	rs2645408	ENSG00000256560.1	LINC01486	8.74	4.24e-17	1.08e-10	0.46	0.37	Leprosy;	chr8:11888849	chr12:109354083~109359488:-
THCA	trans	rs4512344	0.509	rs2409784	ENSG00000253893.2	FAM85B	8.74	4.25e-17	1.09e-10	0.49	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.629	rs28369518	ENSG00000275858.1	RP11-291L22.8	8.74	4.27e-17	1.09e-10	0.48	0.37	Corneal astigmatism;	chr4:119350475	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.722	rs10025925	ENSG00000275858.1	RP11-291L22.8	8.74	4.27e-17	1.09e-10	0.48	0.37	Corneal astigmatism;	chr4:119350589	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.731	rs10015579	ENSG00000275858.1	RP11-291L22.8	8.74	4.27e-17	1.09e-10	0.48	0.37	Corneal astigmatism;	chr4:119350647	chr10:38450738~38451069:-
THCA	trans	rs148734725	1	rs148734725	ENSG00000197582.5	GPX1P1	-8.74	4.27e-17	1.09e-10	-0.56	-0.37	Educational attainment (college completion);	chr3:49369275	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs34588335	ENSG00000197582.5	GPX1P1	-8.74	4.27e-17	1.09e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49370227	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs6809216	ENSG00000197582.5	GPX1P1	-8.74	4.27e-17	1.09e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49375126	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs7623659	ENSG00000197582.5	GPX1P1	-8.74	4.27e-17	1.09e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49377358	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs35169793	ENSG00000197582.5	GPX1P1	-8.74	4.27e-17	1.09e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49385841	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs9878943	ENSG00000197582.5	GPX1P1	-8.74	4.27e-17	1.09e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs6779524	ENSG00000197582.5	GPX1P1	-8.74	4.27e-17	1.09e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.868	rs2262574	ENSG00000231043.3	AC007238.1	8.74	4.3e-17	1.1e-10	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr2:58460292~58462032:-
THCA	trans	rs9858542	0.953	rs7648841	ENSG00000197582.5	GPX1P1	-8.73	4.37e-17	1.12e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379392	chrX:13378735~13379340:-
THCA	trans	rs2929278	0.617	rs4617832	ENSG00000180867.10	PDIA3P1	8.73	4.37e-17	1.12e-10	0.33	0.37	Schizophrenia;	chr15:43738381	chr1:147178113~147179622:+
THCA	trans	rs11098499	0.691	rs28396837	ENSG00000275858.1	RP11-291L22.8	8.73	4.4e-17	1.12e-10	0.48	0.37	Corneal astigmatism;	chr4:119350386	chr10:38450738~38451069:-
THCA	trans	rs9858542	0.953	rs7633271	ENSG00000197582.5	GPX1P1	-8.73	4.42e-17	1.13e-10	-0.57	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49518530	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.801	rs801171	ENSG00000231043.3	AC007238.1	8.73	4.44e-17	1.13e-10	0.44	0.37	Depressive symptoms (multi-trait analysis);	chr5:140735718	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.9	rs2563286	ENSG00000231043.3	AC007238.1	8.73	4.45e-17	1.14e-10	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140745614	chr2:58460292~58462032:-
THCA	trans	rs12709013	0.792	rs1615326	ENSG00000230849.2	GOT2P2	8.73	4.45e-17	1.14e-10	0.46	0.37	Blood metabolite ratios;	chr16:58747148	chr1:173141100~173142350:-
THCA	trans	rs3806843	0.966	rs10060640	ENSG00000231043.3	AC007238.1	-8.73	4.57e-17	1.17e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140831641	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.676	rs2245643	ENSG00000231043.3	AC007238.1	8.73	4.59e-17	1.17e-10	0.44	0.37	Depressive symptoms (multi-trait analysis);	chr5:140650195	chr2:58460292~58462032:-
THCA	trans	rs11098499	0.691	rs12510133	ENSG00000275858.1	RP11-291L22.8	8.73	4.64e-17	1.18e-10	0.48	0.37	Corneal astigmatism;	chr4:119350189	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.754	rs12506487	ENSG00000275858.1	RP11-291L22.8	8.73	4.64e-17	1.18e-10	0.48	0.37	Corneal astigmatism;	chr4:119350206	chr10:38450738~38451069:-
THCA	trans	rs2657294	0.734	rs2894244	ENSG00000172974.11	AC007318.5	8.72	4.66e-17	1.19e-10	0.45	0.37	Pneumonia;	chr10:75087112	chr2:65205108~65205988:+
THCA	trans	rs1908814	0.503	rs34657250	ENSG00000253893.2	FAM85B	8.72	4.66e-17	1.19e-10	0.52	0.37	Neuroticism;	chr8:11937864	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.722	rs17595727	ENSG00000275858.1	RP11-291L22.8	-8.72	4.7e-17	1.2e-10	-0.48	-0.37	Corneal astigmatism;	chr4:119340919	chr10:38450738~38451069:-
THCA	trans	rs748404	0.518	rs2927085	ENSG00000180867.10	PDIA3P1	-8.72	4.74e-17	1.21e-10	-0.33	-0.37	Lung cancer;	chr15:43697332	chr1:147178113~147179622:+
THCA	trans	rs7819412	0.806	rs2898256	ENSG00000253893.2	FAM85B	8.72	4.78e-17	1.22e-10	0.49	0.37	Triglycerides;	chr8:11075185	chr8:8167819~8226614:-
THCA	trans	rs3806843	0.868	rs2262573	ENSG00000231043.3	AC007238.1	8.72	4.82e-17	1.23e-10	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr2:58460292~58462032:-
THCA	trans	rs9858542	0.953	rs6997	ENSG00000197582.5	GPX1P1	-8.72	4.86e-17	1.24e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416401	chrX:13378735~13379340:-
THCA	trans	rs2657294	0.674	rs10824268	ENSG00000172974.11	AC007318.5	8.72	4.87e-17	1.24e-10	0.44	0.37	Pneumonia;	chr10:75085937	chr2:65205108~65205988:+
THCA	trans	rs11098499	0.691	rs10028773	ENSG00000275858.1	RP11-291L22.8	-8.72	4.88e-17	1.24e-10	-0.48	-0.37	Corneal astigmatism;	chr4:119344104	chr10:38450738~38451069:-
THCA	trans	rs7113874	0.534	rs2311392	ENSG00000266891.1	RP11-692N5.2	8.72	4.91e-17	1.25e-10	0.57	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8468889	chr18:9734882~9735602:-
THCA	trans	rs2929278	0.589	rs7174732	ENSG00000180867.10	PDIA3P1	8.72	4.92e-17	1.25e-10	0.33	0.37	Schizophrenia;	chr15:43746265	chr1:147178113~147179622:+
THCA	trans	rs10917477	0.655	rs2745212	ENSG00000224237.1	MINOS1P3	-8.72	4.95e-17	1.26e-10	-0.49	-0.37	Thyroid function;	chr1:19572856	chr3:27214816~27215018:-
THCA	trans	rs12145833	1	rs2802727	ENSG00000154608.12	CEP170P1	8.72	4.99e-17	1.27e-10	0.47	0.37	Obesity (early onset extreme);	chr1:243320024	chr4:118467590~118554204:+
THCA	trans	rs11098499	0.691	rs17009144	ENSG00000275858.1	RP11-291L22.8	-8.71	5.03e-17	1.28e-10	-0.48	-0.37	Corneal astigmatism;	chr4:119349640	chr10:38450738~38451069:-
THCA	trans	rs7647973	0.961	rs6778080	ENSG00000197582.5	GPX1P1	-8.71	5.08e-17	1.29e-10	-0.58	-0.37	Menarche (age at onset);	chr3:49279905	chrX:13378735~13379340:-
THCA	trans	rs3806843	1	rs4404730	ENSG00000231043.3	AC007238.1	-8.71	5.09e-17	1.29e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140783025	chr2:58460292~58462032:-
THCA	trans	rs2929278	0.617	rs663214	ENSG00000180867.10	PDIA3P1	8.71	5.22e-17	1.32e-10	0.33	0.37	Schizophrenia;	chr15:43821584	chr1:147178113~147179622:+
THCA	trans	rs10870270	0.957	rs10870307	ENSG00000197358.9	BNIP3P1	8.71	5.23e-17	1.33e-10	0.5	0.37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131967106	chr14:28264390~28265974:+
THCA	trans	rs3806843	0.966	rs6891559	ENSG00000231043.3	AC007238.1	-8.71	5.23e-17	1.33e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs11741994	ENSG00000231043.3	AC007238.1	-8.71	5.23e-17	1.33e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr2:58460292~58462032:-
THCA	trans	rs11250097	0.528	rs36043848	ENSG00000253893.2	FAM85B	8.71	5.24e-17	1.33e-10	0.5	0.37	Neuroticism;	chr8:11452024	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.729	rs34324769	ENSG00000233719.3	GOT2P3	8.71	5.25e-17	1.33e-10	0.46	0.37	Blood metabolite ratios;	chr16:58778131	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.792	rs11649387	ENSG00000230849.2	GOT2P2	8.71	5.32e-17	1.35e-10	0.46	0.37	Blood metabolite ratios;	chr16:58803176	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs11649133	ENSG00000230849.2	GOT2P2	8.71	5.32e-17	1.35e-10	0.46	0.37	Blood metabolite ratios;	chr16:58803275	chr1:173141100~173142350:-
THCA	trans	rs2665103	0.687	rs11633000	ENSG00000235370.6	DNM1P51	-8.71	5.32e-17	1.35e-10	-0.47	-0.37	Intelligence (multi-trait analysis);	chr15:82269320	chr15:84398316~84411701:-
THCA	trans	rs7662987	0.793	rs78790289	ENSG00000233859.2	ADH5P4	8.7	5.43e-17	1.38e-10	0.69	0.37	Smoking initiation;	chr4:99066736	chr6:65836930~65838039:-
THCA	trans	rs116095464	1	rs6555159	ENSG00000185986.11	SDHAP3	8.7	5.43e-17	1.38e-10	0.55	0.37	Breast cancer;	chr5:311447	chr5:1572222~1594620:-
THCA	trans	rs3806843	0.9	rs2563287	ENSG00000231043.3	AC007238.1	-8.7	5.49e-17	1.39e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140745201	chr2:58460292~58462032:-
THCA	trans	rs1614887	1	rs1614887	ENSG00000242375.1	RP11-498P14.3	8.7	5.52e-17	1.4e-10	0.52	0.37	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr9:97195351~97197687:-
THCA	trans	rs2657294	0.704	rs10824266	ENSG00000172974.11	AC007318.5	8.7	5.57e-17	1.41e-10	0.45	0.37	Pneumonia;	chr10:75083476	chr2:65205108~65205988:+
THCA	trans	rs3806843	1	rs3806845	ENSG00000231043.3	AC007238.1	-8.7	5.58e-17	1.41e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140801152	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs3733707	ENSG00000231043.3	AC007238.1	-8.7	5.58e-17	1.41e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140802307	chr2:58460292~58462032:-
THCA	trans	rs8076336	1	rs8076336	ENSG00000263946.1	RP11-434D2.11	-8.7	5.59e-17	1.42e-10	-0.44	-0.37	Parental longevity (combined parental age at death);	chr17:18309300	chr17:20554971~20559410:-
THCA	trans	rs11250097	0.507	rs2409779	ENSG00000253893.2	FAM85B	8.7	5.68e-17	1.44e-10	0.5	0.37	Neuroticism;	chr8:11453831	chr8:8167819~8226614:-
THCA	trans	rs61990749	1	rs61990749	ENSG00000235400.1	RP4-641G12.4	-8.7	5.73e-17	1.45e-10	-0.79	-0.37	Fibroblast growth factor basic levels;	chr14:77906158	chr1:78749073~78750659:+
THCA	trans	rs11098499	0.615	rs28551750	ENSG00000275858.1	RP11-291L22.8	8.7	5.75e-17	1.45e-10	0.48	0.37	Corneal astigmatism;	chr4:119343746	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.691	rs9995716	ENSG00000275858.1	RP11-291L22.8	8.7	5.75e-17	1.45e-10	0.48	0.37	Corneal astigmatism;	chr4:119343841	chr10:38450738~38451069:-
THCA	trans	rs9858542	0.953	rs1801143	ENSG00000197582.5	GPX1P1	-8.7	5.77e-17	1.46e-10	-0.57	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49532767	chrX:13378735~13379340:-
THCA	trans	rs2243480	0.901	rs2900904	ENSG00000273142.1	RP11-458F8.4	-8.7	5.79e-17	1.47e-10	-0.47	-0.37	Diabetic kidney disease;	chr7:65739282	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs6460260	ENSG00000273142.1	RP11-458F8.4	8.7	5.79e-17	1.47e-10	0.47	0.37	Diabetic kidney disease;	chr7:65750468	chr7:66902857~66906297:+
THCA	trans	rs2243480	1	rs6460261	ENSG00000273142.1	RP11-458F8.4	8.7	5.79e-17	1.47e-10	0.47	0.37	Diabetic kidney disease;	chr7:65750593	chr7:66902857~66906297:+
THCA	trans	rs3806843	0.676	rs2245640	ENSG00000231043.3	AC007238.1	8.7	5.81e-17	1.47e-10	0.44	0.37	Depressive symptoms (multi-trait analysis);	chr5:140650373	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs11167600	ENSG00000231043.3	AC007238.1	-8.69	5.84e-17	1.48e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140795280	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs3756340	ENSG00000231043.3	AC007238.1	-8.69	5.84e-17	1.48e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140800866	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs3756338	ENSG00000231043.3	AC007238.1	-8.69	5.84e-17	1.48e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140800976	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs7701755	ENSG00000231043.3	AC007238.1	-8.69	5.84e-17	1.48e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140802516	chr2:58460292~58462032:-
THCA	trans	rs1039766	0.778	rs13399786	ENSG00000224334.1	AP000357.4	-8.69	5.89e-17	1.49e-10	-0.61	-0.37	Lung adenocarcinoma;Lung cancer;	chr2:65283571	chr22:24686923~24688087:+
THCA	trans	rs12709013	0.792	rs12598527	ENSG00000230849.2	GOT2P2	8.69	5.92e-17	1.5e-10	0.45	0.37	Blood metabolite ratios;	chr16:58772987	chr1:173141100~173142350:-
THCA	trans	rs8010715	0.636	rs2277480	ENSG00000238000.1	RP11-274E7.2	8.69	5.93e-17	1.5e-10	0.42	0.37	IgG glycosylation;	chr14:24118306	chr5:98213402~98214121:+
THCA	trans	rs9858542	0.953	rs6446264	ENSG00000197582.5	GPX1P1	-8.69	5.95e-17	1.5e-10	-0.56	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chrX:13378735~13379340:-
THCA	trans	rs7260598	0.535	rs13343732	ENSG00000261770.1	CTC-459F4.1	8.69	5.97e-17	1.51e-10	0.53	0.37	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:27757184~27760849:-
THCA	trans	rs9611519	0.579	rs8136274	ENSG00000268568.1	AC007228.9	-8.69	6.03e-17	1.52e-10	-0.43	-0.37	Neuroticism;	chr22:41019307	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.59	rs4821980	ENSG00000268568.1	AC007228.9	-8.69	6.03e-17	1.52e-10	-0.43	-0.37	Neuroticism;	chr22:41019475	chr19:56672574~56673901:-
THCA	trans	rs3806843	0.832	rs2531360	ENSG00000231043.3	AC007238.1	8.69	6.06e-17	1.53e-10	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140737079	chr2:58460292~58462032:-
THCA	trans	rs453301	0.571	rs330048	ENSG00000253893.2	FAM85B	8.69	6.07e-17	1.53e-10	0.47	0.37	Joint mobility (Beighton score);	chr8:9229768	chr8:8167819~8226614:-
THCA	trans	rs6424115	0.83	rs6663474	ENSG00000228217.1	AL390877.1	-8.69	6.14e-17	1.55e-10	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23873152	chr1:117778087~117778506:-
THCA	trans	rs3003334	1	rs3003334	ENSG00000228217.1	AL390877.1	-8.69	6.14e-17	1.55e-10	-0.49	-0.37	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr1:23873379	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs3003335	ENSG00000228217.1	AL390877.1	-8.69	6.14e-17	1.55e-10	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23873562	chr1:117778087~117778506:-
THCA	trans	rs1908814	0.509	rs13282439	ENSG00000253893.2	FAM85B	-8.69	6.23e-17	1.57e-10	-0.51	-0.37	Neuroticism;	chr8:11937392	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.961	rs7619016	ENSG00000197582.5	GPX1P1	8.69	6.24e-17	1.58e-10	0.59	0.37	Menarche (age at onset);	chr3:49235156	chrX:13378735~13379340:-
THCA	trans	rs877636	1	rs705696	ENSG00000212829.8	RPS26P3	8.69	6.27e-17	1.58e-10	0.49	0.37	Cognitive function;	chr12:56086864	chr9:9090898~9091245:+
THCA	trans	rs864643	0.577	rs76395532	ENSG00000188856.6	RPSAP47	8.68	6.37e-17	1.61e-10	0.7	0.37	Attention deficit hyperactivity disorder;	chr3:39490370	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.569	rs10023641	ENSG00000275858.1	RP11-291L22.8	8.68	6.4e-17	1.61e-10	0.48	0.37	Corneal astigmatism;	chr4:119337255	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.644	rs3986377	ENSG00000275858.1	RP11-291L22.8	8.68	6.4e-17	1.61e-10	0.48	0.37	Corneal astigmatism;	chr4:119339115	chr10:38450738~38451069:-
THCA	trans	rs10028773	0.556	rs4473640	ENSG00000275858.1	RP11-291L22.8	8.68	6.4e-17	1.61e-10	0.48	0.37	Educational attainment;	chr4:119339282	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.691	rs10010355	ENSG00000275858.1	RP11-291L22.8	8.68	6.4e-17	1.61e-10	0.48	0.37	Corneal astigmatism;	chr4:119339888	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.691	rs9307471	ENSG00000275858.1	RP11-291L22.8	8.68	6.4e-17	1.61e-10	0.48	0.37	Corneal astigmatism;	chr4:119340107	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.644	rs17517414	ENSG00000275858.1	RP11-291L22.8	8.68	6.4e-17	1.61e-10	0.48	0.37	Corneal astigmatism;	chr4:119340946	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.722	rs10006192	ENSG00000275858.1	RP11-291L22.8	8.68	6.4e-17	1.61e-10	0.48	0.37	Corneal astigmatism;	chr4:119341867	chr10:38450738~38451069:-
THCA	trans	rs12497850	1	rs12493578	ENSG00000197582.5	GPX1P1	-8.68	6.42e-17	1.62e-10	-0.55	-0.37	Parkinson's disease;	chr3:48692683	chrX:13378735~13379340:-
THCA	trans	rs864643	0.524	rs77309543	ENSG00000188856.6	RPSAP47	8.68	6.48e-17	1.63e-10	0.7	0.37	Attention deficit hyperactivity disorder;	chr3:39489578	chr8:80558870~80559757:+
THCA	trans	rs7647973	0.826	rs9834535	ENSG00000197582.5	GPX1P1	8.68	6.51e-17	1.64e-10	0.6	0.37	Menarche (age at onset);	chr3:49341364	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.801	rs801170	ENSG00000231043.3	AC007238.1	8.68	6.52e-17	1.64e-10	0.44	0.37	Depressive symptoms (multi-trait analysis);	chr5:140735758	chr2:58460292~58462032:-
THCA	trans	rs2657294	0.646	rs10762656	ENSG00000172974.11	AC007318.5	8.68	6.53e-17	1.65e-10	0.44	0.37	Pneumonia;	chr10:75085706	chr2:65205108~65205988:+
THCA	trans	rs7824557	0.518	rs11250094	ENSG00000253893.2	FAM85B	8.68	6.58e-17	1.66e-10	0.49	0.37	Retinal vascular caliber;	chr8:10944491	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.518	rs12546366	ENSG00000253893.2	FAM85B	8.68	6.58e-17	1.66e-10	0.49	0.37	Retinal vascular caliber;	chr8:10944636	chr8:8167819~8226614:-
THCA	trans	rs4295623	0.789	rs12541318	ENSG00000253893.2	FAM85B	8.68	6.64e-17	1.67e-10	0.5	0.37	Morning vs. evening chronotype;	chr8:11737461	chr8:8167819~8226614:-
THCA	trans	rs7937890	0.559	rs1116739	ENSG00000236360.2	RP11-334A14.2	8.68	6.79e-17	1.71e-10	0.51	0.37	Mitochondrial DNA levels;	chr11:14467636	chr1:52993201~52993702:-
THCA	trans	rs6424115	0.83	rs2501423	ENSG00000228217.1	AL390877.1	-8.67	6.84e-17	1.72e-10	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23872536	chr1:117778087~117778506:-
THCA	trans	rs3806843	0.966	rs2563261	ENSG00000231043.3	AC007238.1	8.67	6.91e-17	1.74e-10	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140758128	chr2:58460292~58462032:-
THCA	trans	rs9611519	0.531	rs1967708	ENSG00000268568.1	AC007228.9	-8.67	6.94e-17	1.74e-10	-0.42	-0.37	Neuroticism;	chr22:41048440	chr19:56672574~56673901:-
THCA	trans	rs11951515	0.508	rs7706431	ENSG00000174977.8	AC026271.5	-8.67	6.96e-17	1.75e-10	-0.41	-0.37	Metabolite levels  (X-11787);	chr5:43582321	chr17:18650195~18651542:+
THCA	trans	rs11951515	0.508	rs6898866	ENSG00000174977.8	AC026271.5	-8.67	6.96e-17	1.75e-10	-0.41	-0.37	Metabolite levels  (X-11787);	chr5:43586273	chr17:18650195~18651542:+
THCA	trans	rs7824557	0.518	rs11777007	ENSG00000253893.2	FAM85B	8.67	6.99e-17	1.76e-10	0.49	0.37	Retinal vascular caliber;	chr8:10944347	chr8:8167819~8226614:-
THCA	trans	rs6424115	0.83	rs6672157	ENSG00000228217.1	AL390877.1	-8.67	7.01e-17	1.76e-10	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23872350	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.733	rs2502996	ENSG00000228217.1	AL390877.1	-8.67	7.01e-17	1.76e-10	-0.49	-0.37	Immature fraction of reticulocytes;	chr1:23872551	chr1:117778087~117778506:-
THCA	trans	rs877636	1	rs705696	ENSG00000234354.3	RPS26P47	8.67	7.05e-17	1.77e-10	0.51	0.37	Cognitive function;	chr12:56086864	chr13:100539901~100540248:-
THCA	trans	rs6743068	0.541	rs10178982	ENSG00000235105.1	RP11-329A14.1	8.67	7.11e-17	1.79e-10	0.41	0.37	Lymphocyte percentage of white cells;	chr2:201362917	chr1:48435967~48437223:+
THCA	trans	rs3806843	1	rs7710794	ENSG00000231043.3	AC007238.1	-8.67	7.12e-17	1.79e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140829882	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs10038174	ENSG00000231043.3	AC007238.1	-8.67	7.12e-17	1.79e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140831031	chr2:58460292~58462032:-
THCA	trans	rs1079467	0.786	rs2136907	ENSG00000233426.3	EIF3FP3	-8.67	7.26e-17	1.82e-10	-0.62	-0.37	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7951686	chr2:58251440~58252525:+
THCA	trans	rs9611519	0.603	rs9607764	ENSG00000268568.1	AC007228.9	-8.67	7.27e-17	1.83e-10	-0.43	-0.37	Neuroticism;	chr22:41015800	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.589	rs8138917	ENSG00000268568.1	AC007228.9	-8.67	7.27e-17	1.83e-10	-0.43	-0.37	Neuroticism;	chr22:41016421	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.58	rs8138349	ENSG00000268568.1	AC007228.9	-8.67	7.27e-17	1.83e-10	-0.43	-0.37	Neuroticism;	chr22:41016719	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.602	rs8138520	ENSG00000268568.1	AC007228.9	-8.67	7.27e-17	1.83e-10	-0.43	-0.37	Neuroticism;	chr22:41016924	chr19:56672574~56673901:-
THCA	trans	rs3806843	1	rs4151682	ENSG00000231043.3	AC007238.1	-8.67	7.3e-17	1.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140821679	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs11958868	ENSG00000231043.3	AC007238.1	-8.67	7.3e-17	1.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140821835	chr2:58460292~58462032:-
THCA	trans	rs730566	1	rs4858819	ENSG00000235912.1	RP1-159A19.3	8.66	7.38e-17	1.85e-10	0.48	0.37	Prion diseases;	chr3:48436678	chr1:27649419~27649610:+
THCA	trans	rs7113874	0.511	rs35091649	ENSG00000266891.1	RP11-692N5.2	8.66	7.4e-17	1.86e-10	0.56	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8526636	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.578	rs35807094	ENSG00000266891.1	RP11-692N5.2	8.66	7.4e-17	1.86e-10	0.56	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8528798	chr18:9734882~9735602:-
THCA	trans	rs4929947	0.515	rs67191473	ENSG00000266891.1	RP11-692N5.2	8.66	7.4e-17	1.86e-10	0.56	0.37	Menarche (age at onset);	chr11:8530643	chr18:9734882~9735602:-
THCA	trans	rs3806843	0.966	rs3756341	ENSG00000231043.3	AC007238.1	-8.66	7.42e-17	1.86e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140791609	chr2:58460292~58462032:-
THCA	trans	rs5022636	0.927	rs4971030	ENSG00000180764.13	PIPSL	-8.66	7.5e-17	1.88e-10	-0.42	-0.37	Gut microbiota (functional units);	chr1:151308519	chr10:93958191~93961540:-
THCA	trans	rs3806843	1	rs2879089	ENSG00000231043.3	AC007238.1	-8.66	7.65e-17	1.92e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140812308	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs11167609	ENSG00000231043.3	AC007238.1	-8.66	7.65e-17	1.92e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140820841	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs6885319	ENSG00000231043.3	AC007238.1	-8.66	7.65e-17	1.92e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140821026	chr2:58460292~58462032:-
THCA	trans	rs7647973	1	rs7613491	ENSG00000197582.5	GPX1P1	-8.66	7.68e-17	1.92e-10	-0.58	-0.37	Menarche (age at onset);	chr3:49471543	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs7647973	ENSG00000197582.5	GPX1P1	-8.66	7.68e-17	1.92e-10	-0.58	-0.37	Menarche (age at onset);	chr3:49473498	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs6783003	ENSG00000197582.5	GPX1P1	-8.66	7.68e-17	1.92e-10	-0.58	-0.37	Menarche (age at onset);	chr3:49487345	chrX:13378735~13379340:-
THCA	trans	rs5022636	0.929	rs7552906	ENSG00000180764.13	PIPSL	8.66	7.7e-17	1.93e-10	0.43	0.37	Gut microbiota (functional units);	chr1:151341298	chr10:93958191~93961540:-
THCA	trans	rs7113874	0.545	rs12791925	ENSG00000266891.1	RP11-692N5.2	8.66	7.71e-17	1.93e-10	0.56	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8530038	chr18:9734882~9735602:-
THCA	trans	rs3806843	0.676	rs778593	ENSG00000231043.3	AC007238.1	8.66	7.73e-17	1.94e-10	0.44	0.37	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.676	rs778594	ENSG00000231043.3	AC007238.1	8.66	7.73e-17	1.94e-10	0.44	0.37	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr2:58460292~58462032:-
THCA	trans	rs7819412	0.654	rs34741518	ENSG00000253893.2	FAM85B	8.66	7.84e-17	1.96e-10	0.46	0.37	Triglycerides;	chr8:10919350	chr8:8167819~8226614:-
THCA	trans	rs9467773	0.511	rs11755443	ENSG00000242375.1	RP11-498P14.3	8.66	7.86e-17	1.97e-10	0.52	0.37	Intelligence (multi-trait analysis);	chr6:26923824	chr9:97195351~97197687:-
THCA	trans	rs3806843	0.966	rs4141841	ENSG00000231043.3	AC007238.1	-8.65	7.96e-17	1.99e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140823847	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs10050455	ENSG00000231043.3	AC007238.1	-8.65	7.96e-17	1.99e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140825065	chr2:58460292~58462032:-
THCA	trans	rs11098499	0.698	rs4422403	ENSG00000275858.1	RP11-291L22.8	8.65	8e-17	2e-10	0.48	0.37	Corneal astigmatism;	chr4:119337039	chr10:38450738~38451069:-
THCA	trans	rs58106596	0.605	rs58212470	ENSG00000259020.3	RP11-529H20.3	8.65	8.03e-17	2.01e-10	0.58	0.37	Lymphocyte counts;White blood cell count;	chr2:231696869	chr14:92026566~92026887:+
THCA	trans	rs3806843	0.966	rs3806842	ENSG00000231043.3	AC007238.1	-8.65	8.07e-17	2.02e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140833091	chr2:58460292~58462032:-
THCA	trans	rs10242455	1	rs17161692	ENSG00000228834.1	RP11-249L21.4	-8.65	8.08e-17	2.02e-10	-0.77	-0.37	Blood metabolite levels;	chr7:99356240	chr6:108907615~108907873:-
THCA	trans	rs864643	0.524	rs77060785	ENSG00000188856.6	RPSAP47	8.65	8.09e-17	2.02e-10	0.7	0.37	Attention deficit hyperactivity disorder;	chr3:39491177	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1768244	ENSG00000188856.6	RPSAP47	8.65	8.15e-17	2.04e-10	0.54	0.37	Attention deficit hyperactivity disorder;	chr3:39500688	chr8:80558870~80559757:+
THCA	trans	rs7819412	0.715	rs2409727	ENSG00000253893.2	FAM85B	8.65	8.16e-17	2.04e-10	0.49	0.37	Triglycerides;	chr8:11185727	chr8:8167819~8226614:-
THCA	trans	rs11250098	0.503	rs7821826	ENSG00000253893.2	FAM85B	8.65	8.21e-17	2.05e-10	0.46	0.37	Morning vs. evening chronotype;	chr8:10911929	chr8:8167819~8226614:-
THCA	trans	rs740160	0.51	rs6973408	ENSG00000228834.1	RP11-249L21.4	8.65	8.21e-17	2.06e-10	0.74	0.37	Dehydroepiandrosterone sulphate levels;	chr7:99303230	chr6:108907615~108907873:-
THCA	trans	rs9858542	0.953	rs11922013	ENSG00000197582.5	GPX1P1	-8.65	8.25e-17	2.06e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49420922	chrX:13378735~13379340:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000196933.5	RPS26P11	8.65	8.34e-17	2.08e-10	0.49	0.37	Cognitive function;	chr12:55988132	chrX:72044545~72044892:+
THCA	trans	rs7819412	0.668	rs920047	ENSG00000253893.2	FAM85B	8.64	8.54e-17	2.13e-10	0.5	0.37	Triglycerides;	chr8:11229966	chr8:8167819~8226614:-
THCA	trans	rs3806843	1	rs10037757	ENSG00000231043.3	AC007238.1	-8.64	8.56e-17	2.14e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140817637	chr2:58460292~58462032:-
THCA	trans	rs2898290	0.622	rs7829381	ENSG00000253893.2	FAM85B	8.64	8.6e-17	2.15e-10	0.5	0.37	Systolic blood pressure;	chr8:11487064	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.622	rs11250140	ENSG00000253893.2	FAM85B	8.64	8.6e-17	2.15e-10	0.5	0.37	Systolic blood pressure;	chr8:11489083	chr8:8167819~8226614:-
THCA	trans	rs11250098	0.574	rs4554431	ENSG00000253893.2	FAM85B	8.64	8.62e-17	2.15e-10	0.45	0.37	Morning vs. evening chronotype;	chr8:10914128	chr8:8167819~8226614:-
THCA	trans	rs864643	0.524	rs11715885	ENSG00000188856.6	RPSAP47	8.64	8.66e-17	2.16e-10	0.69	0.37	Attention deficit hyperactivity disorder;	chr3:39475107	chr8:80558870~80559757:+
THCA	trans	rs10242455	1	rs6948775	ENSG00000228834.1	RP11-249L21.4	8.64	8.76e-17	2.19e-10	0.78	0.37	Blood metabolite levels;	chr7:99347857	chr6:108907615~108907873:-
THCA	trans	rs3806843	1	rs10053586	ENSG00000231043.3	AC007238.1	-8.64	8.81e-17	2.2e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140831175	chr2:58460292~58462032:-
THCA	trans	rs7647973	1	rs6446262	ENSG00000197582.5	GPX1P1	8.64	8.82e-17	2.2e-10	0.59	0.37	Menarche (age at onset);	chr3:49363720	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs62259947	ENSG00000197582.5	GPX1P1	-8.64	8.82e-17	2.2e-10	-0.59	-0.37	Menarche (age at onset);	chr3:49402491	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs73088137	ENSG00000197582.5	GPX1P1	-8.64	8.82e-17	2.2e-10	-0.59	-0.37	Menarche (age at onset);	chr3:49410990	chrX:13378735~13379340:-
THCA	trans	rs10435719	0.746	rs58007588	ENSG00000253893.2	FAM85B	-8.64	8.85e-17	2.21e-10	-0.51	-0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:8167819~8226614:-
THCA	trans	rs1079467	0.679	rs12286813	ENSG00000233426.3	EIF3FP3	-8.64	9.03e-17	2.25e-10	-0.62	-0.37	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7949826	chr2:58251440~58252525:+
THCA	trans	rs740160	0.51	rs11771702	ENSG00000228834.1	RP11-249L21.4	8.64	9.1e-17	2.27e-10	0.73	0.37	Dehydroepiandrosterone sulphate levels;	chr7:99306677	chr6:108907615~108907873:-
THCA	trans	rs3806843	0.966	rs3806844	ENSG00000231043.3	AC007238.1	-8.63	9.21e-17	2.29e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140826678	chr2:58460292~58462032:-
THCA	trans	rs7819412	0.806	rs2409689	ENSG00000253893.2	FAM85B	8.63	9.32e-17	2.32e-10	0.48	0.37	Triglycerides;	chr8:11075358	chr8:8167819~8226614:-
THCA	trans	rs6743068	0.541	rs6435081	ENSG00000235105.1	RP11-329A14.1	8.63	9.39e-17	2.34e-10	0.41	0.37	Lymphocyte percentage of white cells;	chr2:201355900	chr1:48435967~48437223:+
THCA	trans	rs6743068	0.541	rs6737085	ENSG00000235105.1	RP11-329A14.1	8.63	9.39e-17	2.34e-10	0.41	0.37	Lymphocyte percentage of white cells;	chr2:201356718	chr1:48435967~48437223:+
THCA	trans	rs3806843	1	rs2098058	ENSG00000231043.3	AC007238.1	8.63	9.41e-17	2.34e-10	0.42	0.37	Depressive symptoms (multi-trait analysis);	chr5:140777842	chr2:58460292~58462032:-
THCA	trans	rs72615157	0.634	rs74774557	ENSG00000228546.2	CTA-313A17.3	8.63	9.47e-17	2.36e-10	0.58	0.37	Lung function (FEV1/FVC);	chr7:100212802	chr7:102337316~102339115:+
THCA	trans	rs3806843	1	rs7732179	ENSG00000231043.3	AC007238.1	-8.63	9.51e-17	2.37e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140819454	chr2:58460292~58462032:-
THCA	trans	rs13016963	0.526	rs6726823	ENSG00000235105.1	RP11-329A14.1	8.63	9.54e-17	2.37e-10	0.4	0.37	Esophageal squamous cell carcinoma;Melanoma;	chr2:201352193	chr1:48435967~48437223:+
THCA	trans	rs10028773	0.666	rs12498657	ENSG00000275858.1	RP11-291L22.8	8.63	9.77e-17	2.43e-10	0.48	0.37	Educational attainment;	chr4:119341711	chr10:38450738~38451069:-
THCA	trans	rs7662987	0.793	rs12697	ENSG00000233859.2	ADH5P4	-8.62	1.01e-16	2.51e-10	-0.68	-0.37	Smoking initiation;	chr4:99072225	chr6:65836930~65838039:-
THCA	trans	rs7032940	0.533	rs7868072	ENSG00000262519.1	TXNP4	8.62	1.03e-16	2.55e-10	0.46	0.37	Height;	chr9:110205824	chr17:4572206~4572515:+
THCA	trans	rs3806843	0.676	rs2569159	ENSG00000231043.3	AC007238.1	8.62	1.03e-16	2.55e-10	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140651125	chr2:58460292~58462032:-
THCA	trans	rs10870270	1	rs10781564	ENSG00000197358.9	BNIP3P1	8.62	1.06e-16	2.64e-10	0.5	0.37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131944418	chr14:28264390~28265974:+
THCA	trans	rs7113874	0.592	rs10840057	ENSG00000266891.1	RP11-692N5.2	8.62	1.07e-16	2.65e-10	0.56	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8476681	chr18:9734882~9735602:-
THCA	trans	rs7819412	0.645	rs10156356	ENSG00000253893.2	FAM85B	8.61	1.08e-16	2.68e-10	0.5	0.37	Triglycerides;	chr8:11188700	chr8:8167819~8226614:-
THCA	trans	rs3806843	0.966	rs10053945	ENSG00000231043.3	AC007238.1	-8.61	1.11e-16	2.74e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140780542	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs1548700	ENSG00000231043.3	AC007238.1	-8.61	1.11e-16	2.74e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140785304	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs1548699	ENSG00000231043.3	AC007238.1	-8.61	1.11e-16	2.74e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140785333	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs12055222	ENSG00000231043.3	AC007238.1	-8.61	1.11e-16	2.74e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140785983	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs6898939	ENSG00000231043.3	AC007238.1	-8.61	1.11e-16	2.74e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140789770	chr2:58460292~58462032:-
THCA	trans	rs6424115	0.83	rs6680132	ENSG00000228217.1	AL390877.1	-8.61	1.11e-16	2.75e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23872314	chr1:117778087~117778506:-
THCA	trans	rs1023500	1	rs10154646	ENSG00000268568.1	AC007228.9	-8.61	1.12e-16	2.78e-10	-0.51	-0.37	Schizophrenia;	chr22:41935405	chr19:56672574~56673901:-
THCA	trans	rs7937890	0.706	rs7115393	ENSG00000236360.2	RP11-334A14.2	-8.61	1.12e-16	2.78e-10	-0.51	-0.37	Mitochondrial DNA levels;	chr11:14246832	chr1:52993201~52993702:-
THCA	trans	rs13014235	0.846	rs10454127	ENSG00000235105.1	RP11-329A14.1	8.61	1.13e-16	2.79e-10	0.41	0.37	Basal cell carcinoma;	chr2:201347651	chr1:48435967~48437223:+
THCA	trans	rs11098499	0.604	rs2389882	ENSG00000275858.1	RP11-291L22.8	8.61	1.14e-16	2.82e-10	0.51	0.37	Corneal astigmatism;	chr4:119645578	chr10:38450738~38451069:-
THCA	trans	rs3806843	0.966	rs2240693	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140803740	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs2240692	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140804000	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs6579987	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140804074	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs1030163	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140805547	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs1030164	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140805687	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs1030165	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140805863	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs1030166	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140805888	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs4151680	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140807072	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs3822346	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140807737	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.933	rs2337987	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140808798	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.933	rs2879087	ENSG00000231043.3	AC007238.1	-8.61	1.14e-16	2.83e-10	-0.43	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140808990	chr2:58460292~58462032:-
THCA	trans	rs7937890	0.559	rs10766184	ENSG00000236360.2	RP11-334A14.2	8.61	1.15e-16	2.85e-10	0.51	0.37	Mitochondrial DNA levels;	chr11:14521031	chr1:52993201~52993702:-
THCA	trans	rs7121616	0.531	rs11218941	ENSG00000229091.2	HSPA8P8	8.6	1.16e-16	2.87e-10	0.52	0.37	Breast cancer;	chr11:123061701	chr7:10451311~10452526:+
THCA	trans	rs12138950	0.596	rs10917471	ENSG00000224237.1	MINOS1P3	8.6	1.18e-16	2.91e-10	0.5	0.37	Hypothyroidism;Thyroid volume;	chr1:19521118	chr3:27214816~27215018:-
THCA	trans	rs877636	1	rs877636	ENSG00000196933.5	RPS26P11	-8.6	1.21e-16	3e-10	-0.48	-0.37	Cognitive function;	chr12:56086799	chrX:72044545~72044892:+
THCA	trans	rs9611519	0.566	rs4821981	ENSG00000268568.1	AC007228.9	8.6	1.21e-16	3e-10	0.42	0.37	Neuroticism;	chr22:41019640	chr19:56672574~56673901:-
THCA	trans	rs3806843	1	rs13157397	ENSG00000231043.3	AC007238.1	-8.6	1.22e-16	3.02e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140804857	chr2:58460292~58462032:-
THCA	trans	rs12497850	0.644	rs11928552	ENSG00000197582.5	GPX1P1	8.6	1.22e-16	3.03e-10	0.55	0.37	Parkinson's disease;	chr3:48702450	chrX:13378735~13379340:-
THCA	trans	rs7647973	1	rs9862534	ENSG00000197582.5	GPX1P1	8.6	1.24e-16	3.07e-10	0.58	0.37	Menarche (age at onset);	chr3:49560631	chrX:13378735~13379340:-
THCA	trans	rs7113874	0.512	rs7952429	ENSG00000266891.1	RP11-692N5.2	8.59	1.26e-16	3.12e-10	0.56	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516370	chr18:9734882~9735602:-
THCA	trans	rs2898290	0.622	rs1600250	ENSG00000253893.2	FAM85B	8.59	1.28e-16	3.15e-10	0.5	0.37	Systolic blood pressure;	chr8:11487916	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.593	rs1600252	ENSG00000253893.2	FAM85B	8.59	1.28e-16	3.15e-10	0.5	0.37	Systolic blood pressure;	chr8:11488135	chr8:8167819~8226614:-
THCA	trans	rs7647973	1	rs1464569	ENSG00000197582.5	GPX1P1	8.59	1.29e-16	3.18e-10	0.57	0.37	Menarche (age at onset);	chr3:49422917	chrX:13378735~13379340:-
THCA	trans	rs10242455	1	rs7808022	ENSG00000228834.1	RP11-249L21.4	8.59	1.29e-16	3.19e-10	0.69	0.37	Blood metabolite levels;	chr7:99622460	chr6:108907615~108907873:-
THCA	trans	rs13016963	0.546	rs10186527	ENSG00000235105.1	RP11-329A14.1	8.59	1.33e-16	3.28e-10	0.4	0.37	Esophageal squamous cell carcinoma;Melanoma;	chr2:201335852	chr1:48435967~48437223:+
THCA	trans	rs12709013	0.792	rs12596434	ENSG00000230849.2	GOT2P2	8.58	1.34e-16	3.31e-10	0.45	0.37	Blood metabolite ratios;	chr16:58792309	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs62064940	ENSG00000230849.2	GOT2P2	8.58	1.34e-16	3.31e-10	0.45	0.37	Blood metabolite ratios;	chr16:58796560	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs11644344	ENSG00000230849.2	GOT2P2	8.58	1.34e-16	3.31e-10	0.45	0.37	Blood metabolite ratios;	chr16:58803080	chr1:173141100~173142350:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000196933.5	RPS26P11	8.58	1.35e-16	3.33e-10	0.49	0.37	Cognitive function;	chr12:55980911	chrX:72044545~72044892:+
THCA	trans	rs3806843	0.966	rs2337516	ENSG00000231043.3	AC007238.1	8.58	1.35e-16	3.33e-10	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140761268	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.931	rs13168670	ENSG00000231043.3	AC007238.1	-8.58	1.36e-16	3.36e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140767314	chr2:58460292~58462032:-
THCA	trans	rs7819412	0.807	rs10105315	ENSG00000253893.2	FAM85B	8.58	1.39e-16	3.42e-10	0.49	0.37	Triglycerides;	chr8:11074693	chr8:8167819~8226614:-
THCA	trans	rs7121616	0.531	rs10892958	ENSG00000229091.2	HSPA8P8	8.58	1.42e-16	3.5e-10	0.52	0.37	Breast cancer;	chr11:123061415	chr7:10451311~10452526:+
THCA	trans	rs9858542	0.953	rs6446272	ENSG00000197582.5	GPX1P1	-8.58	1.42e-16	3.5e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49425854	chrX:13378735~13379340:-
THCA	trans	rs3806843	0.966	rs10036519	ENSG00000231043.3	AC007238.1	8.58	1.42e-16	3.51e-10	0.42	0.37	Depressive symptoms (multi-trait analysis);	chr5:140772116	chr2:58460292~58462032:-
THCA	trans	rs6743068	0.541	rs6714736	ENSG00000235105.1	RP11-329A14.1	-8.57	1.45e-16	3.57e-10	-0.41	-0.37	Lymphocyte percentage of white cells;	chr2:201349425	chr1:48435967~48437223:+
THCA	trans	rs9858542	0.953	rs9859556	ENSG00000197582.5	GPX1P1	-8.57	1.45e-16	3.58e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chrX:13378735~13379340:-
THCA	trans	rs7819412	0.745	rs7017567	ENSG00000253893.2	FAM85B	8.57	1.48e-16	3.64e-10	0.48	0.37	Triglycerides;	chr8:11076189	chr8:8167819~8226614:-
THCA	trans	rs7503168	0.908	rs9897552	ENSG00000234130.2	RP13-88F20.1	8.57	1.49e-16	3.66e-10	0.48	0.37	Plateletcrit;	chr17:35647462	chrX:93222220~93225015:-
THCA	trans	rs11951515	0.508	rs10065689	ENSG00000174977.8	AC026271.5	-8.57	1.54e-16	3.78e-10	-0.41	-0.37	Metabolite levels  (X-11787);	chr5:43604156	chr17:18650195~18651542:+
THCA	trans	rs3806843	1	rs10057161	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140777246	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs2337985	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140778276	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs2337986	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140781037	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs1548701	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140784972	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs10073974	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140785646	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs3756342	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140786039	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.933	rs2240696	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140788485	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs2240695	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140788566	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs6579965	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140789226	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs6898906	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140789714	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs10477034	ENSG00000231043.3	AC007238.1	-8.57	1.55e-16	3.82e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140790145	chr2:58460292~58462032:-
THCA	trans	rs9329221	0.935	rs3750310	ENSG00000253893.2	FAM85B	8.56	1.57e-16	3.86e-10	0.49	0.37	Neuroticism;	chr8:10425916	chr8:8167819~8226614:-
THCA	trans	rs867371	0.929	rs7176075	ENSG00000235370.6	DNM1P51	-8.56	1.57e-16	3.86e-10	-0.45	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:84398316~84411701:-
THCA	trans	rs6945071	1	rs73281586	ENSG00000217241.1	CBX3P9	8.56	1.58e-16	3.88e-10	0.94	0.37	Superior frontal gyrus grey matter volume;	chr7:26233023	chr6:116453014~116453565:-
THCA	trans	rs9858542	0.951	rs1800668	ENSG00000197582.5	GPX1P1	-8.56	1.62e-16	3.98e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358324	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs1987628	ENSG00000197582.5	GPX1P1	-8.56	1.62e-16	3.98e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49361826	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs11706370	ENSG00000197582.5	GPX1P1	-8.56	1.62e-16	3.98e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chrX:13378735~13379340:-
THCA	trans	rs9329221	0.935	rs6601450	ENSG00000253893.2	FAM85B	-8.56	1.63e-16	3.99e-10	-0.46	-0.37	Neuroticism;	chr8:10385591	chr8:8167819~8226614:-
THCA	trans	rs867371	1	rs8041868	ENSG00000235370.6	DNM1P51	-8.56	1.64e-16	4.02e-10	-0.45	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:84398316~84411701:-
THCA	trans	rs9858542	0.953	rs9814873	ENSG00000197582.5	GPX1P1	-8.56	1.65e-16	4.05e-10	-0.55	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chrX:13378735~13379340:-
THCA	trans	rs12709013	0.792	rs12928733	ENSG00000230849.2	GOT2P2	8.56	1.66e-16	4.06e-10	0.45	0.37	Blood metabolite ratios;	chr16:58807216	chr1:173141100~173142350:-
THCA	trans	rs1023500	1	rs1047997	ENSG00000268568.1	AC007228.9	-8.56	1.66e-16	4.08e-10	-0.5	-0.37	Schizophrenia;	chr22:41938949	chr19:56672574~56673901:-
THCA	trans	rs116095464	0.85	rs73023433	ENSG00000185986.11	SDHAP3	8.55	1.68e-16	4.13e-10	0.54	0.37	Breast cancer;	chr5:317555	chr5:1572222~1594620:-
THCA	trans	rs12709013	0.792	rs62066381	ENSG00000230849.2	GOT2P2	8.55	1.69e-16	4.15e-10	0.45	0.37	Blood metabolite ratios;	chr16:58807981	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.792	rs36098613	ENSG00000230849.2	GOT2P2	8.55	1.69e-16	4.15e-10	0.45	0.37	Blood metabolite ratios;	chr16:58810562	chr1:173141100~173142350:-
THCA	trans	rs7399018	1	rs7399018	ENSG00000223825.5	DAZAP2P1	-8.55	1.7e-16	4.17e-10	-0.49	-0.37	Cisplatin-induced ototoxicity;	chr12:51216581	chr2:202201384~202201886:-
THCA	trans	rs11951515	0.508	rs67261887	ENSG00000174977.8	AC026271.5	-8.55	1.72e-16	4.21e-10	-0.41	-0.37	Metabolite levels  (X-11787);	chr5:43612339	chr17:18650195~18651542:+
THCA	trans	rs10435719	0.867	rs35778860	ENSG00000256560.1	LINC01486	8.55	1.73e-16	4.23e-10	0.47	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr12:109354083~109359488:-
THCA	trans	rs2898290	0.622	rs978803	ENSG00000253893.2	FAM85B	-8.55	1.75e-16	4.29e-10	-0.5	-0.37	Systolic blood pressure;	chr8:11485966	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.961	rs62259943	ENSG00000197582.5	GPX1P1	-8.55	1.76e-16	4.32e-10	-0.58	-0.37	Menarche (age at onset);	chr3:49387734	chrX:13378735~13379340:-
THCA	trans	rs1079467	0.73	rs4259814	ENSG00000233426.3	EIF3FP3	-8.55	1.77e-16	4.32e-10	-0.61	-0.37	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950941	chr2:58251440~58252525:+
THCA	trans	rs3806843	1	rs10066278	ENSG00000231043.3	AC007238.1	-8.55	1.77e-16	4.34e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140776733	chr2:58460292~58462032:-
THCA	trans	rs3806843	1	rs10223116	ENSG00000231043.3	AC007238.1	-8.55	1.78e-16	4.37e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140813058	chr2:58460292~58462032:-
THCA	trans	rs9611519	0.507	rs12484525	ENSG00000268568.1	AC007228.9	-8.55	1.79e-16	4.39e-10	-0.41	-0.37	Neuroticism;	chr22:41047873	chr19:56672574~56673901:-
THCA	trans	rs12709013	0.766	rs12599331	ENSG00000230849.2	GOT2P2	8.55	1.8e-16	4.4e-10	0.45	0.37	Blood metabolite ratios;	chr16:58805307	chr1:173141100~173142350:-
THCA	trans	rs7647973	0.925	rs4384984	ENSG00000197582.5	GPX1P1	8.55	1.81e-16	4.42e-10	0.58	0.37	Menarche (age at onset);	chr3:49252445	chrX:13378735~13379340:-
THCA	trans	rs10865397	0.539	rs13414338	ENSG00000236165.1	PRADC1P1	8.54	1.88e-16	4.59e-10	0.49	0.37	Intelligence (multi-trait analysis);	chr2:73156247	chr3:36976316~36976840:+
THCA	trans	rs10435719	0.902	rs4840599	ENSG00000256560.1	LINC01486	-8.54	1.92e-16	4.68e-10	-0.46	-0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr12:109354083~109359488:-
THCA	trans	rs1816752	0.819	rs7400583	ENSG00000224976.2	PARP4P2	-8.54	1.92e-16	4.69e-10	-0.43	-0.37	Obesity-related traits;	chr13:24415916	chr13:19349137~19407962:+
THCA	trans	rs1908814	0.516	rs7825529	ENSG00000256560.1	LINC01486	8.54	1.93e-16	4.71e-10	0.46	0.37	Neuroticism;	chr8:11936935	chr12:109354083~109359488:-
THCA	trans	rs6424115	0.8	rs4649123	ENSG00000228217.1	AL390877.1	-8.54	1.93e-16	4.72e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23871206	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs2503000	ENSG00000228217.1	AL390877.1	-8.54	1.93e-16	4.72e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23871408	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs2502999	ENSG00000228217.1	AL390877.1	-8.54	1.93e-16	4.72e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23871831	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.793	rs2502998	ENSG00000228217.1	AL390877.1	-8.54	1.93e-16	4.72e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23871837	chr1:117778087~117778506:-
THCA	trans	rs10870270	0.913	rs4550	ENSG00000197358.9	BNIP3P1	8.54	1.94e-16	4.74e-10	0.5	0.37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131968294	chr14:28264390~28265974:+
THCA	trans	rs7733403	1	rs7733403	ENSG00000231043.3	AC007238.1	-8.53	1.97e-16	4.81e-10	-0.42	-0.37	Schizophrenia;	chr5:140774630	chr2:58460292~58462032:-
THCA	trans	rs61990749	1	rs6574411	ENSG00000235400.1	RP4-641G12.4	-8.53	1.97e-16	4.81e-10	-0.76	-0.37	Fibroblast growth factor basic levels;	chr14:77907984	chr1:78749073~78750659:+
THCA	trans	rs3806843	1	rs3733710	ENSG00000231043.3	AC007238.1	-8.53	1.98e-16	4.84e-10	-0.42	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140787878	chr2:58460292~58462032:-
THCA	trans	rs6424115	0.83	rs2502995	ENSG00000228217.1	AL390877.1	-8.53	2e-16	4.89e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23872800	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs2501425	ENSG00000228217.1	AL390877.1	-8.53	2e-16	4.89e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23872849	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs2502994	ENSG00000228217.1	AL390877.1	-8.53	2e-16	4.89e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23872873	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.83	rs2501426	ENSG00000228217.1	AL390877.1	-8.53	2e-16	4.89e-10	-0.48	-0.37	Immature fraction of reticulocytes;	chr1:23872874	chr1:117778087~117778506:-
THCA	trans	rs10870270	0.956	rs6557	ENSG00000197358.9	BNIP3P1	8.53	2e-16	4.89e-10	0.5	0.37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131967945	chr14:28264390~28265974:+
THCA	trans	rs7819412	0.654	rs4840550	ENSG00000253893.2	FAM85B	8.53	2e-16	4.89e-10	0.49	0.37	Triglycerides;	chr8:11171520	chr8:8167819~8226614:-
THCA	trans	rs10242455	1	rs73395557	ENSG00000228834.1	RP11-249L21.4	8.53	2.02e-16	4.92e-10	0.78	0.37	Blood metabolite levels;	chr7:99336801	chr6:108907615~108907873:-
THCA	trans	rs3806843	0.619	rs2569160	ENSG00000231043.3	AC007238.1	8.53	2.02e-16	4.93e-10	0.43	0.37	Depressive symptoms (multi-trait analysis);	chr5:140649189	chr2:58460292~58462032:-
THCA	trans	rs2277458	0.623	rs1998194	ENSG00000214249.3	CTAGE11P	-8.53	2.07e-16	5.04e-10	-0.53	-0.37	Vitamin D levels;	chr14:39221650	chr13:75237944~75240296:-
THCA	trans	rs1023500	1	rs6002548	ENSG00000268568.1	AC007228.9	-8.53	2.08e-16	5.08e-10	-0.5	-0.37	Schizophrenia;	chr22:41941036	chr19:56672574~56673901:-
THCA	trans	rs9329221	0.935	rs3750311	ENSG00000253893.2	FAM85B	8.53	2.09e-16	5.09e-10	0.48	0.37	Neuroticism;	chr8:10426092	chr8:8167819~8226614:-
THCA	trans	rs1023500	1	rs9620001	ENSG00000268568.1	AC007228.9	-8.52	2.11e-16	5.14e-10	-0.5	-0.37	Schizophrenia;	chr22:41934225	chr19:56672574~56673901:-
THCA	trans	rs877636	1	rs2292239	ENSG00000234354.3	RPS26P47	8.52	2.13e-16	5.19e-10	0.49	0.37	Cognitive function;	chr12:56088396	chr13:100539901~100540248:-
THCA	trans	rs1908814	0.503	rs34657250	ENSG00000256560.1	LINC01486	-8.52	2.13e-16	5.2e-10	-0.47	-0.37	Neuroticism;	chr8:11937864	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.902	rs7459545	ENSG00000256560.1	LINC01486	8.52	2.17e-16	5.27e-10	0.47	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr12:109354083~109359488:-
THCA	trans	rs2288327	1	rs2288327	ENSG00000269800.1	PLEKHA3P1	8.52	2.19e-16	5.32e-10	0.49	0.37	Atrial fibrillation;	chr2:178546938	chr19:41521043~41521989:-
THCA	trans	rs11638815	0.52	rs4779032	ENSG00000235370.6	DNM1P51	-8.52	2.21e-16	5.38e-10	-0.46	-0.37	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82576576	chr15:84398316~84411701:-
THCA	trans	rs11250098	0.574	rs4240672	ENSG00000253893.2	FAM85B	8.52	2.23e-16	5.43e-10	0.45	0.37	Morning vs. evening chronotype;	chr8:10910407	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.811	rs2409691	ENSG00000253893.2	FAM85B	8.52	2.26e-16	5.49e-10	0.47	0.37	Triglycerides;	chr8:11085766	chr8:8167819~8226614:-
THCA	trans	rs10242455	1	rs73395547	ENSG00000228834.1	RP11-249L21.4	8.51	2.27e-16	5.52e-10	0.78	0.37	Blood metabolite levels;	chr7:99325123	chr6:108907615~108907873:-
THCA	trans	rs73108077	0.736	rs6060436	ENSG00000279352.1	RP11-411B10.7	8.51	2.27e-16	5.52e-10	0.66	0.37	Red blood cell density in sickle cell anemia;	chr20:31258500	chr18:14010054~14010917:+
THCA	trans	rs10435719	0.902	rs7006538	ENSG00000256560.1	LINC01486	8.51	2.29e-16	5.58e-10	0.46	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr12:109354083~109359488:-
THCA	trans	rs4879656	0.564	rs20583	ENSG00000215007.3	DNAJA1P3	8.51	2.33e-16	5.67e-10	0.43	0.37	Menopause (age at onset);	chr9:33026574	chrX:107351650~107352843:-
THCA	trans	rs3808502	0.509	rs2729940	ENSG00000253893.2	FAM85B	-8.51	2.39e-16	5.82e-10	-0.48	-0.37	Neuroticism;	chr8:11524858	chr8:8167819~8226614:-
THCA	trans	rs10870270	0.83	rs11146269	ENSG00000197358.9	BNIP3P1	8.51	2.42e-16	5.87e-10	0.49	0.37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131948316	chr14:28264390~28265974:+
THCA	trans	rs6424115	0.83	rs3123554	ENSG00000228217.1	AL390877.1	8.51	2.44e-16	5.92e-10	0.48	0.37	Immature fraction of reticulocytes;	chr1:23869911	chr1:117778087~117778506:-
THCA	trans	rs7113874	0.578	rs67067089	ENSG00000266891.1	RP11-692N5.2	8.5	2.48e-16	6.02e-10	0.55	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508480	chr18:9734882~9735602:-
THCA	trans	rs13190036	0.681	rs28461408	ENSG00000228305.2	AC016734.2	8.5	2.52e-16	6.11e-10	0.48	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr2:63622178~63622831:-
THCA	trans	rs2645424	0.93	rs1293315	ENSG00000229857.1	RP11-159H20.3	8.5	2.52e-16	6.11e-10	0.45	0.37	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11832913	chr9:76992099~76993108:+
THCA	trans	rs453301	0.507	rs2929306	ENSG00000253893.2	FAM85B	8.5	2.52e-16	6.12e-10	0.46	0.37	Joint mobility (Beighton score);	chr8:9227399	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.583	rs2263511	ENSG00000253893.2	FAM85B	8.5	2.53e-16	6.14e-10	0.48	0.37	Retinal vascular caliber;	chr8:11375809	chr8:8167819~8226614:-
THCA	trans	rs867371	1	rs6495643	ENSG00000235370.6	DNM1P51	-8.5	2.53e-16	6.15e-10	-0.45	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:84398316~84411701:-
THCA	trans	rs1816752	1	rs9507341	ENSG00000224976.2	PARP4P2	8.5	2.56e-16	6.23e-10	0.43	0.36	Obesity-related traits;	chr13:24432440	chr13:19349137~19407962:+
THCA	trans	rs1023500	0.956	rs1894713	ENSG00000268568.1	AC007228.9	-8.5	2.57e-16	6.24e-10	-0.5	-0.36	Schizophrenia;	chr22:41939617	chr19:56672574~56673901:-
THCA	trans	rs877636	1	rs705696	ENSG00000243538.1	CTB-55B8.1	8.5	2.58e-16	6.26e-10	0.47	0.36	Cognitive function;	chr12:56086864	chr5:16902294~16902641:-
THCA	trans	rs2898290	0.622	rs978804	ENSG00000253893.2	FAM85B	8.5	2.58e-16	6.26e-10	0.49	0.36	Systolic blood pressure;	chr8:11486164	chr8:8167819~8226614:-
THCA	trans	rs13086611	1	rs13086611	ENSG00000197582.5	GPX1P1	-8.5	2.6e-16	6.3e-10	-0.56	-0.36	Educational attainment;	chr3:49347984	chrX:13378735~13379340:-
THCA	trans	rs1908814	0.516	rs13275143	ENSG00000256560.1	LINC01486	8.5	2.6e-16	6.3e-10	0.47	0.36	Neuroticism;	chr8:11939481	chr12:109354083~109359488:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000234354.3	RPS26P47	-8.5	2.6e-16	6.32e-10	-0.49	-0.36	Cognitive function;	chr12:55996852	chr13:100539901~100540248:-
THCA	trans	rs3806843	0.966	rs2563255	ENSG00000231043.3	AC007238.1	8.5	2.61e-16	6.32e-10	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140762962	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.9	rs2563254	ENSG00000231043.3	AC007238.1	8.5	2.61e-16	6.32e-10	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140763116	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs7737424	ENSG00000231043.3	AC007238.1	-8.5	2.61e-16	6.32e-10	-0.42	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140766760	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.966	rs12659129	ENSG00000231043.3	AC007238.1	-8.5	2.61e-16	6.32e-10	-0.42	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140767663	chr2:58460292~58462032:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000234354.3	RPS26P47	8.49	2.68e-16	6.48e-10	0.49	0.36	Cognitive function;	chr12:55996580	chr13:100539901~100540248:-
THCA	trans	rs10435719	0.867	rs34465618	ENSG00000256560.1	LINC01486	8.49	2.68e-16	6.49e-10	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.867	rs34583868	ENSG00000256560.1	LINC01486	8.49	2.68e-16	6.49e-10	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs4919740	ENSG00000224520.2	KRT8P45	-8.49	2.68e-16	6.49e-10	-0.7	-0.36	Prostate cancer;	chr12:52877187	chr1:157073257~157074703:+
THCA	trans	rs3806843	0.897	rs2531338	ENSG00000231043.3	AC007238.1	8.49	2.68e-16	6.5e-10	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140757372	chr2:58460292~58462032:-
THCA	trans	rs1023500	1	rs1023498	ENSG00000268568.1	AC007228.9	-8.49	2.69e-16	6.51e-10	-0.5	-0.36	Schizophrenia;	chr22:41944565	chr19:56672574~56673901:-
THCA	trans	rs877636	1	rs877636	ENSG00000244604.1	RP11-713H12.1	-8.49	2.72e-16	6.58e-10	-0.47	-0.36	Cognitive function;	chr12:56086799	chr17:8561230~8561576:+
THCA	trans	rs1023500	1	rs6002554	ENSG00000268568.1	AC007228.9	-8.49	2.75e-16	6.65e-10	-0.5	-0.36	Schizophrenia;	chr22:41943091	chr19:56672574~56673901:-
THCA	trans	rs72615157	0.716	rs75779608	ENSG00000228546.2	CTA-313A17.3	8.49	2.75e-16	6.66e-10	0.61	0.36	Lung function (FEV1/FVC);	chr7:100171334	chr7:102337316~102339115:+
THCA	trans	rs3806843	0.966	rs2563264	ENSG00000231043.3	AC007238.1	8.49	2.75e-16	6.67e-10	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140757918	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.932	rs2563257	ENSG00000231043.3	AC007238.1	8.49	2.75e-16	6.67e-10	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140760944	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.932	rs2563256	ENSG00000231043.3	AC007238.1	8.49	2.75e-16	6.67e-10	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140762194	chr2:58460292~58462032:-
THCA	trans	rs7824557	0.583	rs2263512	ENSG00000253893.2	FAM85B	8.49	2.77e-16	6.69e-10	0.48	0.36	Retinal vascular caliber;	chr8:11375910	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.583	rs6601585	ENSG00000253893.2	FAM85B	8.49	2.77e-16	6.69e-10	0.48	0.36	Retinal vascular caliber;	chr8:11376150	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.953	rs10640	ENSG00000197582.5	GPX1P1	-8.49	2.77e-16	6.71e-10	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chrX:13378735~13379340:-
THCA	trans	rs902774	0.818	rs73110432	ENSG00000224520.2	KRT8P45	-8.49	2.8e-16	6.76e-10	-0.72	-0.36	Prostate cancer;	chr12:52894051	chr1:157073257~157074703:+
THCA	trans	rs11250097	0.549	rs11778177	ENSG00000253893.2	FAM85B	8.49	2.8e-16	6.78e-10	0.49	0.36	Neuroticism;	chr8:11452853	chr8:8167819~8226614:-
THCA	trans	rs11250097	0.549	rs11784897	ENSG00000253893.2	FAM85B	8.49	2.8e-16	6.78e-10	0.49	0.36	Neuroticism;	chr8:11452933	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.899	rs11250177	ENSG00000256560.1	LINC01486	8.49	2.81e-16	6.79e-10	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr12:109354083~109359488:-
THCA	trans	rs867371	0.964	rs7169961	ENSG00000235370.6	DNM1P51	-8.48	2.84e-16	6.86e-10	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:84398316~84411701:-
THCA	trans	rs3806843	0.966	rs2563263	ENSG00000231043.3	AC007238.1	-8.48	2.91e-16	7.02e-10	-0.42	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140758059	chr2:58460292~58462032:-
THCA	trans	rs867371	1	rs1501372	ENSG00000235370.6	DNM1P51	-8.48	2.95e-16	7.12e-10	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:84398316~84411701:-
THCA	trans	rs867371	1	rs1846911	ENSG00000235370.6	DNM1P51	-8.48	2.95e-16	7.12e-10	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:84398316~84411701:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000227586.5	RP11-162A23.5	-8.48	2.96e-16	7.16e-10	-0.44	-0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:123171535~123171875:-
THCA	trans	rs877636	1	rs705696	ENSG00000196933.5	RPS26P11	8.48	3.05e-16	7.36e-10	0.49	0.36	Cognitive function;	chr12:56086864	chrX:72044545~72044892:+
THCA	trans	rs61041336	1	rs61041336	ENSG00000230849.2	GOT2P2	-8.48	3.05e-16	7.36e-10	-0.57	-0.36	Neuritic plaque;	chr16:58699258	chr1:173141100~173142350:-
THCA	trans	rs2929278	0.617	rs575082	ENSG00000180867.10	PDIA3P1	8.48	3.05e-16	7.36e-10	0.32	0.36	Schizophrenia;	chr15:43817944	chr1:147178113~147179622:+
THCA	trans	rs10242455	1	rs2301889	ENSG00000228834.1	RP11-249L21.4	8.47	3.09e-16	7.46e-10	0.77	0.36	Blood metabolite levels;	chr7:99333482	chr6:108907615~108907873:-
THCA	trans	rs13016963	0.526	rs2110684	ENSG00000235105.1	RP11-329A14.1	8.47	3.18e-16	7.68e-10	0.39	0.36	Esophageal squamous cell carcinoma;Melanoma;	chr2:201357198	chr1:48435967~48437223:+
THCA	trans	rs7824557	0.564	rs2572399	ENSG00000253893.2	FAM85B	8.47	3.22e-16	7.78e-10	0.48	0.36	Retinal vascular caliber;	chr8:11377011	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs11996277	ENSG00000256560.1	LINC01486	8.47	3.25e-16	7.83e-10	0.46	0.36	Neuroticism;	chr8:11942522	chr12:109354083~109359488:-
THCA	trans	rs11250098	0.503	rs13270870	ENSG00000253893.2	FAM85B	8.47	3.25e-16	7.84e-10	0.45	0.36	Morning vs. evening chronotype;	chr8:10913272	chr8:8167819~8226614:-
THCA	trans	rs804280	0.542	rs36100659	ENSG00000256560.1	LINC01486	8.47	3.25e-16	7.85e-10	0.46	0.36	Myopia (pathological);	chr8:11934144	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs4841641	ENSG00000256560.1	LINC01486	8.47	3.26e-16	7.87e-10	0.46	0.36	Neuroticism;	chr8:11940718	chr12:109354083~109359488:-
THCA	trans	rs3806843	0.966	rs11953833	ENSG00000231043.3	AC007238.1	-8.47	3.27e-16	7.89e-10	-0.42	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140775538	chr2:58460292~58462032:-
THCA	trans	rs3806843	0.676	rs1583005	ENSG00000231043.3	AC007238.1	8.47	3.29e-16	7.93e-10	0.43	0.36	Depressive symptoms (multi-trait analysis);	chr5:140651952	chr2:58460292~58462032:-
THCA	trans	rs13016963	0.526	rs11681616	ENSG00000235105.1	RP11-329A14.1	8.46	3.33e-16	8.02e-10	0.39	0.36	Esophageal squamous cell carcinoma;Melanoma;	chr2:201360013	chr1:48435967~48437223:+
THCA	trans	rs7662987	1	rs7683704	ENSG00000233859.2	ADH5P4	8.46	3.35e-16	8.07e-10	0.73	0.36	Smoking initiation;	chr4:99083075	chr6:65836930~65838039:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000196933.5	RPS26P11	8.46	3.35e-16	8.08e-10	0.48	0.36	Cognitive function;	chr12:55990903	chrX:72044545~72044892:+
THCA	trans	rs877636	0.702	rs773110	ENSG00000234354.3	RPS26P47	8.46	3.37e-16	8.13e-10	0.49	0.36	Cognitive function;	chr12:55981353	chr13:100539901~100540248:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000234354.3	RPS26P47	8.46	3.37e-16	8.13e-10	0.49	0.36	Cognitive function;	chr12:55981956	chr13:100539901~100540248:-
THCA	trans	rs7647973	0.925	rs6446256	ENSG00000197582.5	GPX1P1	8.46	3.49e-16	8.4e-10	0.57	0.36	Menarche (age at onset);	chr3:49186777	chrX:13378735~13379340:-
THCA	trans	rs10435719	0.902	rs7459983	ENSG00000256560.1	LINC01486	8.46	3.5e-16	8.42e-10	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr12:109354083~109359488:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000234354.3	RPS26P47	8.45	3.55e-16	8.54e-10	0.49	0.36	Cognitive function;	chr12:55982097	chr13:100539901~100540248:-
THCA	trans	rs7113874	0.802	rs10128597	ENSG00000266891.1	RP11-692N5.2	8.45	3.57e-16	8.58e-10	0.48	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8673283	chr18:9734882~9735602:-
THCA	trans	rs3806843	0.966	rs2563262	ENSG00000231043.3	AC007238.1	8.45	3.57e-16	8.58e-10	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140758127	chr2:58460292~58462032:-
THCA	trans	rs7819412	0.74	rs11250119	ENSG00000253893.2	FAM85B	8.45	3.58e-16	8.6e-10	0.48	0.36	Triglycerides;	chr8:11179525	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs35391955	ENSG00000256560.1	LINC01486	8.45	3.59e-16	8.62e-10	0.46	0.36	Neuroticism;	chr8:11939219	chr12:109354083~109359488:-
THCA	trans	rs804280	0.509	rs10109241	ENSG00000256560.1	LINC01486	8.45	3.61e-16	8.66e-10	0.46	0.36	Myopia (pathological);	chr8:11927476	chr12:109354083~109359488:-
THCA	trans	rs3806843	1	rs10477033	ENSG00000231043.3	AC007238.1	-8.45	3.63e-16	8.73e-10	-0.42	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140790018	chr2:58460292~58462032:-
THCA	trans	rs7824557	0.527	rs2572449	ENSG00000253893.2	FAM85B	-8.45	3.67e-16	8.8e-10	-0.47	-0.36	Retinal vascular caliber;	chr8:11381628	chr8:8167819~8226614:-
THCA	trans	rs804280	1	rs804280	ENSG00000253893.2	FAM85B	-8.45	3.69e-16	8.86e-10	-0.49	-0.36	Myopia (pathological);	chr8:11755189	chr8:8167819~8226614:-
THCA	trans	rs2288327	0.673	rs35504893	ENSG00000269800.1	PLEKHA3P1	8.45	3.69e-16	8.87e-10	0.46	0.36	Atrial fibrillation;	chr2:178556567	chr19:41521043~41521989:-
THCA	trans	rs7824557	0.564	rs2043508	ENSG00000253893.2	FAM85B	8.45	3.7e-16	8.87e-10	0.48	0.36	Retinal vascular caliber;	chr8:11369897	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.622	rs978802	ENSG00000253893.2	FAM85B	8.45	3.72e-16	8.91e-10	0.49	0.36	Systolic blood pressure;	chr8:11485769	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.953	rs9858280	ENSG00000197582.5	GPX1P1	-8.45	3.72e-16	8.92e-10	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49560304	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs9827021	ENSG00000197582.5	GPX1P1	-8.45	3.72e-16	8.93e-10	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49477331	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs9818590	ENSG00000197582.5	GPX1P1	-8.45	3.72e-16	8.93e-10	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49487663	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs35261698	ENSG00000197582.5	GPX1P1	-8.45	3.72e-16	8.93e-10	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500406	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs6766131	ENSG00000197582.5	GPX1P1	-8.45	3.72e-16	8.93e-10	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501499	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs9821311	ENSG00000197582.5	GPX1P1	-8.45	3.72e-16	8.93e-10	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49506223	chrX:13378735~13379340:-
THCA	trans	rs72615157	0.634	rs7789890	ENSG00000228546.2	CTA-313A17.3	8.45	3.77e-16	9.03e-10	0.58	0.36	Lung function (FEV1/FVC);	chr7:100202936	chr7:102337316~102339115:+
THCA	trans	rs72615157	0.634	rs79986079	ENSG00000228546.2	CTA-313A17.3	8.45	3.77e-16	9.03e-10	0.58	0.36	Lung function (FEV1/FVC);	chr7:100204421	chr7:102337316~102339115:+
THCA	trans	rs7824557	0.527	rs2409756	ENSG00000253893.2	FAM85B	8.45	3.79e-16	9.09e-10	0.49	0.36	Retinal vascular caliber;	chr8:11384516	chr8:8167819~8226614:-
THCA	trans	rs7647973	1	rs62259944	ENSG00000197582.5	GPX1P1	-8.45	3.8e-16	9.11e-10	-0.59	-0.36	Menarche (age at onset);	chr3:49393450	chrX:13378735~13379340:-
THCA	trans	rs2929278	0.617	rs2955969	ENSG00000180867.10	PDIA3P1	8.44	3.85e-16	9.22e-10	0.32	0.36	Schizophrenia;	chr15:43822329	chr1:147178113~147179622:+
THCA	trans	rs7824557	0.679	rs10110008	ENSG00000253893.2	FAM85B	8.44	3.88e-16	9.29e-10	0.48	0.36	Retinal vascular caliber;	chr8:11276227	chr8:8167819~8226614:-
THCA	trans	rs6424115	0.867	rs34902309	ENSG00000228217.1	AL390877.1	8.44	3.88e-16	9.29e-10	0.48	0.36	Immature fraction of reticulocytes;	chr1:23865710	chr1:117778087~117778506:-
THCA	trans	rs1908814	0.516	rs4840597	ENSG00000256560.1	LINC01486	8.44	3.92e-16	9.38e-10	0.46	0.36	Neuroticism;	chr8:11938559	chr12:109354083~109359488:-
THCA	trans	rs804280	0.509	rs4841639	ENSG00000256560.1	LINC01486	8.44	3.92e-16	9.38e-10	0.46	0.36	Myopia (pathological);	chr8:11938584	chr12:109354083~109359488:-
THCA	trans	rs6732160	0.51	rs57825971	ENSG00000236165.1	PRADC1P1	8.44	3.94e-16	9.42e-10	0.48	0.36	Intelligence (multi-trait analysis);	chr2:73157668	chr3:36976316~36976840:+
THCA	trans	rs10865397	0.506	rs60764301	ENSG00000236165.1	PRADC1P1	8.44	3.94e-16	9.42e-10	0.48	0.36	Intelligence (multi-trait analysis);	chr2:73157722	chr3:36976316~36976840:+
THCA	trans	rs867371	1	rs1392976	ENSG00000235370.6	DNM1P51	8.44	3.94e-16	9.43e-10	0.45	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:84398316~84411701:-
THCA	trans	rs2898290	0.694	rs2248909	ENSG00000253893.2	FAM85B	8.44	3.96e-16	9.46e-10	0.47	0.36	Systolic blood pressure;	chr8:11534584	chr8:8167819~8226614:-
THCA	trans	rs453301	0.624	rs330049	ENSG00000253893.2	FAM85B	-8.44	3.97e-16	9.47e-10	-0.46	-0.36	Joint mobility (Beighton score);	chr8:9229789	chr8:8167819~8226614:-
THCA	trans	rs3806843	0.676	rs778591	ENSG00000231043.3	AC007238.1	8.44	4.03e-16	9.62e-10	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140645899	chr2:58460292~58462032:-
THCA	trans	rs4879656	0.564	rs1197774	ENSG00000215007.3	DNAJA1P3	8.44	4.03e-16	9.63e-10	0.42	0.36	Menopause (age at onset);	chr9:33001451	chrX:107351650~107352843:-
THCA	trans	rs616147	1	rs1768208	ENSG00000214263.2	RPSAP53	-8.44	4.06e-16	9.68e-10	-0.49	-0.36	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr13:67266845~67267706:-
THCA	trans	rs7647973	0.961	rs11130187	ENSG00000197582.5	GPX1P1	8.44	4.1e-16	9.78e-10	0.57	0.36	Menarche (age at onset);	chr3:49270439	chrX:13378735~13379340:-
THCA	trans	rs804280	0.543	rs13261205	ENSG00000256560.1	LINC01486	8.44	4.1e-16	9.79e-10	0.46	0.36	Myopia (pathological);	chr8:11933707	chr12:109354083~109359488:-
THCA	trans	rs804280	0.518	rs34266352	ENSG00000256560.1	LINC01486	8.44	4.1e-16	9.79e-10	0.46	0.36	Myopia (pathological);	chr8:11933953	chr12:109354083~109359488:-
THCA	trans	rs804280	0.542	rs34117651	ENSG00000256560.1	LINC01486	8.44	4.1e-16	9.79e-10	0.46	0.36	Myopia (pathological);	chr8:11934108	chr12:109354083~109359488:-
THCA	trans	rs740160	0.51	rs12112936	ENSG00000228834.1	RP11-249L21.4	8.43	4.14e-16	9.88e-10	0.72	0.36	Dehydroepiandrosterone sulphate levels;	chr7:99301877	chr6:108907615~108907873:-
THCA	trans	rs7647973	0.961	rs11130186	ENSG00000197582.5	GPX1P1	8.43	4.18e-16	9.96e-10	0.57	0.36	Menarche (age at onset);	chr3:49238395	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.961	rs10154992	ENSG00000197582.5	GPX1P1	8.43	4.18e-16	9.96e-10	0.57	0.36	Menarche (age at onset);	chr3:49238644	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.961	rs4955443	ENSG00000197582.5	GPX1P1	8.43	4.18e-16	9.96e-10	0.57	0.36	Menarche (age at onset);	chr3:49249185	chrX:13378735~13379340:-
THCA	trans	rs11250098	0.548	rs7837038	ENSG00000253893.2	FAM85B	8.43	4.18e-16	9.96e-10	0.45	0.36	Morning vs. evening chronotype;	chr8:10925564	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.868	rs7831557	ENSG00000253893.2	FAM85B	8.43	4.18e-16	9.97e-10	0.49	0.36	Neuroticism;	chr8:10422718	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000234354.3	RPS26P47	8.43	4.2e-16	1e-09	0.49	0.36	Cognitive function;	chr12:55988132	chr13:100539901~100540248:-
THCA	trans	rs3806843	0.933	rs10069930	ENSG00000231043.3	AC007238.1	-8.43	4.21e-16	1e-09	-0.42	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140783743	chr2:58460292~58462032:-
THCA	trans	rs1908814	0.516	rs13281077	ENSG00000256560.1	LINC01486	8.43	4.22e-16	1.01e-09	0.46	0.36	Neuroticism;	chr8:11937305	chr12:109354083~109359488:-
THCA	trans	rs12709013	0.792	rs8049572	ENSG00000230849.2	GOT2P2	8.43	4.25e-16	1.01e-09	0.45	0.36	Blood metabolite ratios;	chr16:58809672	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.766	rs34438483	ENSG00000230849.2	GOT2P2	8.43	4.25e-16	1.01e-09	0.45	0.36	Blood metabolite ratios;	chr16:58810530	chr1:173141100~173142350:-
THCA	trans	rs7662987	1	rs1803037	ENSG00000233859.2	ADH5P4	8.43	4.25e-16	1.01e-09	0.74	0.36	Smoking initiation;	chr4:99072000	chr6:65836930~65838039:-
THCA	trans	rs864643	0.836	rs1708009	ENSG00000188856.6	RPSAP47	8.43	4.25e-16	1.01e-09	0.52	0.36	Attention deficit hyperactivity disorder;	chr3:39496851	chr8:80558870~80559757:+
THCA	trans	rs7647973	0.771	rs9865051	ENSG00000197582.5	GPX1P1	8.43	4.29e-16	1.02e-09	0.61	0.36	Menarche (age at onset);	chr3:49128636	chrX:13378735~13379340:-
THCA	trans	rs12497850	0.931	rs6442130	ENSG00000197582.5	GPX1P1	8.43	4.32e-16	1.03e-09	0.54	0.36	Parkinson's disease;	chr3:48740594	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs9837027	ENSG00000197582.5	GPX1P1	-8.43	4.35e-16	1.03e-09	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559580	chrX:13378735~13379340:-
THCA	trans	rs11992162	0.967	rs10112888	ENSG00000253893.2	FAM85B	-8.43	4.36e-16	1.04e-09	-0.48	-0.36	Monocyte count;	chr8:11972699	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.589	rs6985109	ENSG00000253893.2	FAM85B	-8.43	4.42e-16	1.05e-09	-0.46	-0.36	Neuroticism;	chr8:10904075	chr8:8167819~8226614:-
THCA	trans	rs2412819	0.599	rs2470120	ENSG00000180867.10	PDIA3P1	-8.42	4.43e-16	1.05e-09	-0.32	-0.36	Lung cancer;	chr15:43636872	chr1:147178113~147179622:+
THCA	trans	rs6424115	0.83	rs2503002	ENSG00000228217.1	AL390877.1	-8.42	4.44e-16	1.06e-09	-0.47	-0.36	Immature fraction of reticulocytes;	chr1:23870467	chr1:117778087~117778506:-
THCA	trans	rs867371	1	rs8037224	ENSG00000235370.6	DNM1P51	-8.42	4.46e-16	1.06e-09	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:84398316~84411701:-
THCA	trans	rs12709013	0.792	rs7185513	ENSG00000230849.2	GOT2P2	8.42	4.52e-16	1.07e-09	0.44	0.36	Blood metabolite ratios;	chr16:58794889	chr1:173141100~173142350:-
THCA	trans	rs1908814	0.541	rs7824267	ENSG00000256560.1	LINC01486	8.42	4.56e-16	1.08e-09	0.46	0.36	Neuroticism;	chr8:11936770	chr12:109354083~109359488:-
THCA	trans	rs748404	0.66	rs690367	ENSG00000180867.10	PDIA3P1	8.42	4.56e-16	1.08e-09	0.31	0.36	Lung cancer;	chr15:43456106	chr1:147178113~147179622:+
THCA	trans	rs66887589	0.66	rs4833613	ENSG00000275858.1	RP11-291L22.8	-8.42	4.62e-16	1.1e-09	-0.43	-0.36	Diastolic blood pressure;	chr4:119229001	chr10:38450738~38451069:-
THCA	trans	rs2929278	0.546	rs686666	ENSG00000180867.10	PDIA3P1	-8.42	4.64e-16	1.1e-09	-0.32	-0.36	Schizophrenia;	chr15:43869352	chr1:147178113~147179622:+
THCA	trans	rs10865397	0.506	rs13414160	ENSG00000236165.1	PRADC1P1	8.42	4.69e-16	1.11e-09	0.48	0.36	Intelligence (multi-trait analysis);	chr2:73156133	chr3:36976316~36976840:+
THCA	trans	rs867371	1	rs8041924	ENSG00000235370.6	DNM1P51	-8.42	4.71e-16	1.12e-09	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:84398316~84411701:-
THCA	trans	rs867371	1	rs2088858	ENSG00000235370.6	DNM1P51	-8.42	4.71e-16	1.12e-09	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:84398316~84411701:-
THCA	trans	rs867371	1	rs4778982	ENSG00000235370.6	DNM1P51	-8.42	4.71e-16	1.12e-09	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:84398316~84411701:-
THCA	trans	rs867371	1	rs2867579	ENSG00000235370.6	DNM1P51	-8.42	4.71e-16	1.12e-09	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:84398316~84411701:-
THCA	trans	rs867371	1	rs881308	ENSG00000235370.6	DNM1P51	-8.42	4.71e-16	1.12e-09	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:84398316~84411701:-
THCA	trans	rs864643	0.729	rs7616236	ENSG00000188856.6	RPSAP47	8.42	4.74e-16	1.12e-09	0.7	0.36	Attention deficit hyperactivity disorder;	chr3:39500645	chr8:80558870~80559757:+
THCA	trans	rs10870270	1	rs11146324	ENSG00000197358.9	BNIP3P1	8.41	4.81e-16	1.14e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131953941	chr14:28264390~28265974:+
THCA	trans	rs7113874	0.802	rs7118611	ENSG00000266891.1	RP11-692N5.2	8.41	4.81e-16	1.14e-09	0.47	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8664138	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.802	rs11042030	ENSG00000266891.1	RP11-692N5.2	8.41	4.81e-16	1.14e-09	0.47	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8669171	chr18:9734882~9735602:-
THCA	trans	rs748404	0.518	rs480108	ENSG00000180867.10	PDIA3P1	-8.41	4.87e-16	1.16e-09	-0.32	-0.36	Lung cancer;	chr15:43525208	chr1:147178113~147179622:+
THCA	trans	rs748404	0.56	rs572837	ENSG00000180867.10	PDIA3P1	-8.41	4.87e-16	1.16e-09	-0.32	-0.36	Lung cancer;	chr15:43531615	chr1:147178113~147179622:+
THCA	trans	rs11992162	0.967	rs10088415	ENSG00000253893.2	FAM85B	8.41	4.95e-16	1.17e-09	0.48	0.36	Monocyte count;	chr8:11973316	chr8:8167819~8226614:-
THCA	trans	rs6732160	0.518	rs6731057	ENSG00000236165.1	PRADC1P1	8.41	4.96e-16	1.17e-09	0.5	0.36	Intelligence (multi-trait analysis);	chr2:73172295	chr3:36976316~36976840:+
THCA	trans	rs7824557	0.679	rs7004362	ENSG00000253893.2	FAM85B	8.41	4.97e-16	1.18e-09	0.48	0.36	Retinal vascular caliber;	chr8:11278465	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.953	rs7646366	ENSG00000197582.5	GPX1P1	-8.41	4.98e-16	1.18e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs67216675	ENSG00000197582.5	GPX1P1	-8.41	4.98e-16	1.18e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chrX:13378735~13379340:-
THCA	trans	rs10435719	0.867	rs6999030	ENSG00000256560.1	LINC01486	8.41	5.07e-16	1.2e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.834	rs6985792	ENSG00000256560.1	LINC01486	8.41	5.07e-16	1.2e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs2736288	ENSG00000253893.2	FAM85B	8.41	5.1e-16	1.21e-09	0.47	0.36	Retinal vascular caliber;	chr8:11370591	chr8:8167819~8226614:-
THCA	trans	rs864643	0.678	rs1707953	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39483918	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs683089	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39484334	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs590805	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39485463	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs606973	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39485876	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs521226	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39486099	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs521139	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39486128	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs519385	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39486304	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs604831	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39486327	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs517376	ENSG00000188856.6	RPSAP47	8.41	5.11e-16	1.21e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39486571	chr8:80558870~80559757:+
THCA	trans	rs7819412	0.668	rs2409721	ENSG00000253893.2	FAM85B	8.4	5.16e-16	1.22e-09	0.48	0.36	Triglycerides;	chr8:11180735	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.509	rs13248956	ENSG00000256560.1	LINC01486	8.4	5.18e-16	1.22e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932259	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.528	rs13250020	ENSG00000256560.1	LINC01486	8.4	5.18e-16	1.22e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932260	chr12:109354083~109359488:-
THCA	trans	rs9858542	0.953	rs9853683	ENSG00000197582.5	GPX1P1	-8.4	5.18e-16	1.22e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49475155	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs12330269	ENSG00000197582.5	GPX1P1	-8.4	5.18e-16	1.22e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49476477	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs11719996	ENSG00000197582.5	GPX1P1	-8.4	5.18e-16	1.22e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49488525	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs34363169	ENSG00000197582.5	GPX1P1	-8.4	5.18e-16	1.22e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500279	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs6766581	ENSG00000197582.5	GPX1P1	-8.4	5.18e-16	1.22e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501968	chrX:13378735~13379340:-
THCA	trans	rs7824557	0.564	rs2736293	ENSG00000253893.2	FAM85B	8.4	5.21e-16	1.23e-09	0.48	0.36	Retinal vascular caliber;	chr8:11377104	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2736294	ENSG00000253893.2	FAM85B	8.4	5.21e-16	1.23e-09	0.48	0.36	Retinal vascular caliber;	chr8:11377117	chr8:8167819~8226614:-
THCA	trans	rs2929278	0.617	rs693919	ENSG00000180867.10	PDIA3P1	8.4	5.21e-16	1.23e-09	0.32	0.36	Schizophrenia;	chr15:43810130	chr1:147178113~147179622:+
THCA	trans	rs9611519	0.542	rs8139770	ENSG00000268568.1	AC007228.9	-8.4	5.22e-16	1.23e-09	-0.41	-0.36	Neuroticism;	chr22:41020177	chr19:56672574~56673901:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000235459.5	RPS26P31	-8.4	5.22e-16	1.23e-09	-0.52	-0.36	Asthma;	chr12:55970537	chr7:122681315~122681662:+
THCA	trans	rs7824557	0.564	rs13260727	ENSG00000253893.2	FAM85B	-8.4	5.25e-16	1.24e-09	-0.47	-0.36	Retinal vascular caliber;	chr8:11375351	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.902	rs6601633	ENSG00000256560.1	LINC01486	-8.4	5.29e-16	1.25e-09	-0.46	-0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.773	rs7842810	ENSG00000256560.1	LINC01486	8.4	5.29e-16	1.25e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr12:109354083~109359488:-
THCA	trans	rs13190036	0.551	rs4976639	ENSG00000228305.2	AC016734.2	8.4	5.31e-16	1.25e-09	0.42	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr2:63622178~63622831:-
THCA	trans	rs7824557	0.564	rs2572400	ENSG00000253893.2	FAM85B	8.4	5.35e-16	1.26e-09	0.48	0.36	Retinal vascular caliber;	chr8:11376858	chr8:8167819~8226614:-
THCA	trans	rs10870270	0.956	rs4131689	ENSG00000197358.9	BNIP3P1	-8.4	5.41e-16	1.28e-09	-0.49	-0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131930824	chr14:28264390~28265974:+
THCA	trans	rs74781061	0.585	rs4646903	ENSG00000227288.3	RP5-837I24.1	8.4	5.41e-16	1.28e-09	0.52	0.36	Endometriosis;	chr15:74719300	chr1:81501794~81503468:+
THCA	trans	rs3806843	1	rs10072015	ENSG00000231043.3	AC007238.1	8.4	5.52e-16	1.3e-09	0.41	0.36	Depressive symptoms (multi-trait analysis);	chr5:140791070	chr2:58460292~58462032:-
THCA	trans	rs1908814	0.516	rs7812563	ENSG00000256560.1	LINC01486	8.39	5.58e-16	1.32e-09	0.45	0.36	Neuroticism;	chr8:11936979	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs2736290	ENSG00000253893.2	FAM85B	8.39	5.6e-16	1.32e-09	0.48	0.36	Retinal vascular caliber;	chr8:11376789	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000234354.3	RPS26P47	8.39	5.61e-16	1.32e-09	0.49	0.36	Cognitive function;	chr12:55980911	chr13:100539901~100540248:-
THCA	trans	rs13016963	0.526	rs7577057	ENSG00000235105.1	RP11-329A14.1	8.39	5.61e-16	1.32e-09	0.39	0.36	Esophageal squamous cell carcinoma;Melanoma;	chr2:201343270	chr1:48435967~48437223:+
THCA	trans	rs10870270	0.956	rs11146325	ENSG00000197358.9	BNIP3P1	8.39	5.65e-16	1.33e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131954025	chr14:28264390~28265974:+
THCA	trans	rs11250098	0.583	rs66724331	ENSG00000253893.2	FAM85B	8.39	5.69e-16	1.34e-09	0.45	0.36	Morning vs. evening chronotype;	chr8:10931835	chr8:8167819~8226614:-
THCA	trans	rs916888	0.61	rs199530	ENSG00000204650.12	CRHR1-IT1	-8.39	5.72e-16	1.35e-09	-0.36	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45620328~45648216:+
THCA	trans	rs34421088	0.559	rs12386974	ENSG00000253893.2	FAM85B	-8.39	5.73e-16	1.35e-09	-0.48	-0.36	Neuroticism;	chr8:11543119	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs4634600	ENSG00000253893.2	FAM85B	8.39	5.74e-16	1.35e-09	0.47	0.36	Retinal vascular caliber;	chr8:11381508	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs4631425	ENSG00000253893.2	FAM85B	8.39	5.74e-16	1.35e-09	0.47	0.36	Retinal vascular caliber;	chr8:11381545	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.585	rs4549730	ENSG00000253893.2	FAM85B	8.39	5.74e-16	1.35e-09	0.47	0.36	Neuroticism;	chr8:11381569	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.744	rs11250175	ENSG00000256560.1	LINC01486	8.39	5.75e-16	1.35e-09	0.45	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs13252853	ENSG00000256560.1	LINC01486	8.39	5.75e-16	1.35e-09	0.45	0.36	Neuroticism;	chr8:11935465	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs13252854	ENSG00000256560.1	LINC01486	8.39	5.75e-16	1.35e-09	0.45	0.36	Neuroticism;	chr8:11935469	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs13279577	ENSG00000256560.1	LINC01486	8.39	5.75e-16	1.35e-09	0.45	0.36	Neuroticism;	chr8:11935587	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs10112958	ENSG00000256560.1	LINC01486	8.39	5.75e-16	1.35e-09	0.45	0.36	Neuroticism;	chr8:11935631	chr12:109354083~109359488:-
THCA	trans	rs804280	0.56	rs10503426	ENSG00000253893.2	FAM85B	-8.39	5.77e-16	1.36e-09	-0.48	-0.36	Myopia (pathological);	chr8:11731874	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.899	rs7815595	ENSG00000256560.1	LINC01486	8.39	5.8e-16	1.37e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.834	rs11250176	ENSG00000256560.1	LINC01486	8.39	5.8e-16	1.37e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs4367597	ENSG00000256560.1	LINC01486	8.39	5.8e-16	1.37e-09	0.46	0.36	Neuroticism;	chr8:11936020	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.899	rs9329251	ENSG00000256560.1	LINC01486	8.39	5.8e-16	1.37e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr12:109354083~109359488:-
THCA	trans	rs12138950	0.681	rs10917468	ENSG00000224237.1	MINOS1P3	-8.39	5.93e-16	1.39e-09	-0.49	-0.36	Hypothyroidism;Thyroid volume;	chr1:19516860	chr3:27214816~27215018:-
THCA	trans	rs6132905	0.52	rs2422823	ENSG00000235559.1	NOP56P1	-8.39	5.94e-16	1.4e-09	-0.46	-0.36	Mumps;	chr20:2665687	chr6:28783633~28784004:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000196933.5	RPS26P11	8.39	5.95e-16	1.4e-09	0.49	0.36	Cognitive function;	chr12:55976127	chrX:72044545~72044892:+
THCA	trans	rs748404	0.56	rs1060939	ENSG00000180867.10	PDIA3P1	-8.39	5.95e-16	1.4e-09	-0.32	-0.36	Lung cancer;	chr15:43524719	chr1:147178113~147179622:+
THCA	trans	rs3806843	0.766	rs801399	ENSG00000231043.3	AC007238.1	8.38	6.05e-16	1.42e-09	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr2:58460292~58462032:-
THCA	trans	rs11250098	0.574	rs7015168	ENSG00000253893.2	FAM85B	8.38	6.09e-16	1.43e-09	0.45	0.36	Morning vs. evening chronotype;	chr8:10914700	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs13281315	ENSG00000256560.1	LINC01486	8.38	6.11e-16	1.43e-09	0.45	0.36	Neuroticism;	chr8:11937346	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	8.38	6.12e-16	1.44e-09	0.46	0.36	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
THCA	trans	rs877636	1	rs705696	ENSG00000204652.6	RPS26P8	8.38	6.18e-16	1.45e-09	0.49	0.36	Cognitive function;	chr12:56086864	chr17:45608571~45608918:+
THCA	trans	rs10435719	0.647	rs10092605	ENSG00000256560.1	LINC01486	8.38	6.26e-16	1.47e-09	0.45	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs58869268	ENSG00000256560.1	LINC01486	8.38	6.38e-16	1.5e-09	0.46	0.36	Neuroticism;	chr8:11939586	chr12:109354083~109359488:-
THCA	trans	rs867371	1	rs13380319	ENSG00000235370.6	DNM1P51	-8.37	6.48e-16	1.52e-09	-0.45	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:84398316~84411701:-
THCA	trans	rs9650657	0.562	rs10090444	ENSG00000253893.2	FAM85B	-8.37	6.5e-16	1.52e-09	-0.46	-0.36	Neuroticism;	chr8:10887959	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.961	rs4955417	ENSG00000197582.5	GPX1P1	8.37	6.59e-16	1.54e-09	0.56	0.36	Menarche (age at onset);	chr3:49260772	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.925	rs4955439	ENSG00000197582.5	GPX1P1	-8.37	6.6e-16	1.55e-09	-0.57	-0.36	Menarche (age at onset);	chr3:49208212	chrX:13378735~13379340:-
THCA	trans	rs877636	0.859	rs3741499	ENSG00000243538.1	CTB-55B8.1	-8.37	6.79e-16	1.59e-09	-0.45	-0.36	Cognitive function;	chr12:56080595	chr5:16902294~16902641:-
THCA	trans	rs7937890	0.668	rs12361851	ENSG00000236360.2	RP11-334A14.2	-8.37	6.81e-16	1.6e-09	-0.49	-0.36	Mitochondrial DNA levels;	chr11:14246122	chr1:52993201~52993702:-
THCA	trans	rs7824557	0.545	rs34482136	ENSG00000253893.2	FAM85B	8.36	6.94e-16	1.62e-09	0.48	0.36	Retinal vascular caliber;	chr8:11370376	chr8:8167819~8226614:-
THCA	trans	rs864643	0.678	rs656071	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39488646	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs656454	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39488711	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs1708112	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39489034	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1708111	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39489098	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1768219	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39489162	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1398675	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39489772	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1708109	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39490085	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs1768220	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39490545	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1768221	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39490789	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1768222	ENSG00000188856.6	RPSAP47	8.36	6.99e-16	1.64e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39490852	chr8:80558870~80559757:+
THCA	trans	rs9467773	0.511	rs17278688	ENSG00000242375.1	RP11-498P14.3	8.36	6.99e-16	1.64e-09	0.51	0.36	Intelligence (multi-trait analysis);	chr6:26922357	chr9:97195351~97197687:-
THCA	trans	rs9858542	0.953	rs3811697	ENSG00000197582.5	GPX1P1	-8.36	7.03e-16	1.64e-09	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49553337	chrX:13378735~13379340:-
THCA	trans	rs7113874	0.613	rs35225809	ENSG00000266891.1	RP11-692N5.2	8.36	7.04e-16	1.65e-09	0.54	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8512038	chr18:9734882~9735602:-
THCA	trans	rs1908814	0.516	rs10113042	ENSG00000256560.1	LINC01486	8.36	7.06e-16	1.65e-09	0.45	0.36	Neuroticism;	chr8:11935669	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs35009431	ENSG00000253893.2	FAM85B	8.36	7.07e-16	1.65e-09	0.48	0.36	Retinal vascular caliber;	chr8:11375279	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.603	rs2249804	ENSG00000253893.2	FAM85B	-8.36	7.07e-16	1.65e-09	-0.49	-0.36	Retinal vascular caliber;	chr8:11358108	chr8:8167819~8226614:-
THCA	trans	rs3806843	0.648	rs702399	ENSG00000231043.3	AC007238.1	8.36	7.09e-16	1.66e-09	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140644847	chr2:58460292~58462032:-
THCA	trans	rs1908814	0.516	rs10113062	ENSG00000256560.1	LINC01486	8.36	7.13e-16	1.67e-09	0.45	0.36	Neuroticism;	chr8:11935740	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs10113145	ENSG00000256560.1	LINC01486	8.36	7.13e-16	1.67e-09	0.45	0.36	Neuroticism;	chr8:11935786	chr12:109354083~109359488:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000212994.5	RPS26P6	-8.36	7.13e-16	1.67e-09	-0.52	-0.36	Asthma;	chr12:55970537	chr8:100895771~100896118:+
THCA	trans	rs2929278	0.588	rs1975364	ENSG00000180867.10	PDIA3P1	-8.36	7.15e-16	1.67e-09	-0.32	-0.36	Schizophrenia;	chr15:43857991	chr1:147178113~147179622:+
THCA	trans	rs13190036	0.591	rs78523677	ENSG00000228305.2	AC016734.2	-8.36	7.17e-16	1.68e-09	-0.42	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr2:63622178~63622831:-
THCA	trans	rs9858542	0.953	rs11711485	ENSG00000197582.5	GPX1P1	-8.36	7.21e-16	1.68e-09	-0.56	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49454550	chrX:13378735~13379340:-
THCA	trans	rs9650657	0.645	rs56057779	ENSG00000253893.2	FAM85B	8.36	7.25e-16	1.69e-09	0.44	0.36	Neuroticism;	chr8:10659370	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.903	rs9875617	ENSG00000197582.5	GPX1P1	-8.36	7.3e-16	1.71e-09	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49597263	chrX:13378735~13379340:-
THCA	trans	rs453301	0.571	rs2929453	ENSG00000253893.2	FAM85B	8.36	7.32e-16	1.71e-09	0.45	0.36	Joint mobility (Beighton score);	chr8:9226831	chr8:8167819~8226614:-
THCA	trans	rs7113874	1	rs10769939	ENSG00000266891.1	RP11-692N5.2	8.36	7.33e-16	1.71e-09	0.47	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8662092	chr18:9734882~9735602:-
THCA	trans	rs9858542	0.953	rs35115732	ENSG00000197582.5	GPX1P1	-8.36	7.35e-16	1.72e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chrX:13378735~13379340:-
THCA	trans	rs73108077	0.607	rs6057566	ENSG00000279352.1	RP11-411B10.7	8.36	7.36e-16	1.72e-09	0.67	0.36	Red blood cell density in sickle cell anemia;	chr20:31227621	chr18:14010054~14010917:+
THCA	trans	rs10870270	0.956	rs7894	ENSG00000197358.9	BNIP3P1	8.36	7.39e-16	1.72e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131955978	chr14:28264390~28265974:+
THCA	trans	rs6424115	0.771	rs2229586	ENSG00000228217.1	AL390877.1	-8.35	7.43e-16	1.73e-09	-0.47	-0.36	Immature fraction of reticulocytes;	chr1:23874413	chr1:117778087~117778506:-
THCA	trans	rs13016963	0.526	rs11687854	ENSG00000235105.1	RP11-329A14.1	8.35	7.56e-16	1.76e-09	0.39	0.36	Esophageal squamous cell carcinoma;Melanoma;	chr2:201363879	chr1:48435967~48437223:+
THCA	trans	rs2060793	1	rs2060793	ENSG00000236360.2	RP11-334A14.2	8.35	7.57e-16	1.76e-09	0.48	0.36	Vitamin D levels;	chr11:14893764	chr1:52993201~52993702:-
THCA	trans	rs2250402	0.51	rs8031319	ENSG00000234106.3	RP11-288E14.2	8.35	7.65e-16	1.78e-09	0.67	0.36	Corneal curvature;	chr15:40031491	chr11:93535468~93535816:+
THCA	trans	rs13190036	0.901	rs4631	ENSG00000228305.2	AC016734.2	8.35	7.67e-16	1.79e-09	0.46	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr2:63622178~63622831:-
THCA	trans	rs453301	0.571	rs2929452	ENSG00000253893.2	FAM85B	8.35	7.67e-16	1.79e-09	0.45	0.36	Joint mobility (Beighton score);	chr8:9226955	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.716	rs6416775	ENSG00000230849.2	GOT2P2	8.35	7.73e-16	1.8e-09	0.44	0.36	Blood metabolite ratios;	chr16:58830410	chr1:173141100~173142350:-
THCA	trans	rs9858542	0.953	rs9841110	ENSG00000197582.5	GPX1P1	-8.35	7.76e-16	1.81e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455048	chrX:13378735~13379340:-
THCA	trans	rs7824557	0.525	rs12682349	ENSG00000253893.2	FAM85B	-8.35	7.78e-16	1.81e-09	-0.48	-0.36	Retinal vascular caliber;	chr8:11387794	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.583	rs2736292	ENSG00000253893.2	FAM85B	-8.35	7.84e-16	1.83e-09	-0.47	-0.36	Retinal vascular caliber;	chr8:11376991	chr8:8167819~8226614:-
THCA	trans	rs877636	1	rs4759229	ENSG00000243538.1	CTB-55B8.1	-8.35	7.91e-16	1.84e-09	-0.44	-0.36	Cognitive function;	chr12:56080696	chr5:16902294~16902641:-
THCA	trans	rs66887589	0.777	rs4643791	ENSG00000275858.1	RP11-291L22.8	-8.35	7.95e-16	1.85e-09	-0.44	-0.36	Diastolic blood pressure;	chr4:119344464	chr10:38450738~38451069:-
THCA	trans	rs10870270	0.956	rs67378218	ENSG00000197358.9	BNIP3P1	8.35	7.98e-16	1.86e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131938916	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs10870270	ENSG00000197358.9	BNIP3P1	8.35	7.98e-16	1.86e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131940830	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs3935905	ENSG00000197358.9	BNIP3P1	8.35	7.98e-16	1.86e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131944758	chr14:28264390~28265974:+
THCA	trans	rs10435719	0.902	rs11250179	ENSG00000256560.1	LINC01486	8.35	8e-16	1.86e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr12:109354083~109359488:-
THCA	trans	rs80033912	0.626	rs71324982	ENSG00000197582.5	GPX1P1	8.34	8.01e-16	1.86e-09	0.57	0.36	Intelligence (multi-trait analysis);	chr3:49632515	chrX:13378735~13379340:-
THCA	trans	rs11992162	0.967	rs7836456	ENSG00000253893.2	FAM85B	-8.34	8.18e-16	1.9e-09	-0.48	-0.36	Monocyte count;	chr8:11971666	chr8:8167819~8226614:-
THCA	trans	rs804280	0.509	rs13276433	ENSG00000256560.1	LINC01486	8.34	8.21e-16	1.91e-09	0.45	0.36	Myopia (pathological);	chr8:11925527	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs2572448	ENSG00000253893.2	FAM85B	8.34	8.24e-16	1.92e-09	0.47	0.36	Retinal vascular caliber;	chr8:11381843	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs2572447	ENSG00000253893.2	FAM85B	8.34	8.24e-16	1.92e-09	0.47	0.36	Retinal vascular caliber;	chr8:11382001	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs2572446	ENSG00000253893.2	FAM85B	8.34	8.24e-16	1.92e-09	0.47	0.36	Retinal vascular caliber;	chr8:11382056	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs10109537	ENSG00000253893.2	FAM85B	8.34	8.24e-16	1.92e-09	0.47	0.36	Retinal vascular caliber;	chr8:11382131	chr8:8167819~8226614:-
THCA	trans	rs9425766	0.85	rs9425755	ENSG00000213331.4	RP11-713C19.2	8.34	8.29e-16	1.93e-09	0.46	0.36	Life satisfaction;	chr1:173843501	chr4:187970273~187971284:+
THCA	trans	rs9425766	0.85	rs1322770	ENSG00000213331.4	RP11-713C19.2	8.34	8.29e-16	1.93e-09	0.46	0.36	Life satisfaction;	chr1:173863198	chr4:187970273~187971284:+
THCA	trans	rs7113874	0.659	rs67320655	ENSG00000266891.1	RP11-692N5.2	8.34	8.39e-16	1.95e-09	0.54	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8497662	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.625	rs35760680	ENSG00000266891.1	RP11-692N5.2	8.34	8.39e-16	1.95e-09	0.54	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500525	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.659	rs2121313	ENSG00000266891.1	RP11-692N5.2	8.34	8.39e-16	1.95e-09	0.54	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501495	chr18:9734882~9735602:-
THCA	trans	rs1908814	0.516	rs60176945	ENSG00000256560.1	LINC01486	8.34	8.41e-16	1.95e-09	0.46	0.36	Neuroticism;	chr8:11939165	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs56102998	ENSG00000256560.1	LINC01486	8.34	8.41e-16	1.95e-09	0.46	0.36	Neuroticism;	chr8:11939166	chr12:109354083~109359488:-
THCA	trans	rs7937890	0.505	rs1403248	ENSG00000236360.2	RP11-334A14.2	8.34	8.42e-16	1.96e-09	0.48	0.36	Mitochondrial DNA levels;	chr11:14657471	chr1:52993201~52993702:-
THCA	trans	rs11951515	0.508	rs7705166	ENSG00000174977.8	AC026271.5	-8.34	8.43e-16	1.96e-09	-0.4	-0.36	Metabolite levels  (X-11787);	chr5:43587346	chr17:18650195~18651542:+
THCA	trans	rs804280	0.542	rs35647515	ENSG00000256560.1	LINC01486	8.34	8.5e-16	1.97e-09	0.46	0.36	Myopia (pathological);	chr8:11934120	chr12:109354083~109359488:-
THCA	trans	rs7113874	0.802	rs35319120	ENSG00000266891.1	RP11-692N5.2	8.34	8.56e-16	1.99e-09	0.47	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8648147	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.802	rs10840102	ENSG00000266891.1	RP11-692N5.2	8.34	8.56e-16	1.99e-09	0.47	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8654691	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.802	rs7941510	ENSG00000266891.1	RP11-692N5.2	8.34	8.56e-16	1.99e-09	0.47	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8655516	chr18:9734882~9735602:-
THCA	trans	rs864643	0.898	rs1473864	ENSG00000188856.6	RPSAP47	8.34	8.58e-16	1.99e-09	0.52	0.36	Attention deficit hyperactivity disorder;	chr3:39499703	chr8:80558870~80559757:+
THCA	trans	rs10870270	0.956	rs10870281	ENSG00000197358.9	BNIP3P1	8.33	8.68e-16	2.01e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131949138	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs4880246	ENSG00000197358.9	BNIP3P1	8.33	8.68e-16	2.01e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131950560	chr14:28264390~28265974:+
THCA	trans	rs10435719	0.902	rs12681142	ENSG00000256560.1	LINC01486	8.33	8.74e-16	2.03e-09	0.46	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr12:109354083~109359488:-
THCA	trans	rs13177918	0.911	rs12186451	ENSG00000226396.1	RP5-1056L3.3	8.33	8.76e-16	2.03e-09	0.39	0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150432625	chr1:19608114~19608568:+
THCA	trans	rs7824557	0.603	rs2250028	ENSG00000253893.2	FAM85B	-8.33	8.81e-16	2.05e-09	-0.48	-0.36	Retinal vascular caliber;	chr8:11356080	chr8:8167819~8226614:-
THCA	trans	rs7662987	0.793	rs28730602	ENSG00000233859.2	ADH5P4	8.33	8.85e-16	2.05e-09	0.64	0.36	Smoking initiation;	chr4:99080531	chr6:65836930~65838039:-
THCA	trans	rs2060793	0.712	rs10832290	ENSG00000236360.2	RP11-334A14.2	8.33	8.86e-16	2.05e-09	0.48	0.36	Vitamin D levels;	chr11:14650684	chr1:52993201~52993702:-
THCA	trans	rs2060793	0.774	rs1403249	ENSG00000236360.2	RP11-334A14.2	8.33	8.86e-16	2.05e-09	0.48	0.36	Vitamin D levels;	chr11:14651438	chr1:52993201~52993702:-
THCA	trans	rs2929278	0.588	rs688009	ENSG00000180867.10	PDIA3P1	-8.33	8.98e-16	2.08e-09	-0.32	-0.36	Schizophrenia;	chr15:43864104	chr1:147178113~147179622:+
THCA	trans	rs7819412	0.642	rs11250117	ENSG00000253893.2	FAM85B	8.33	9e-16	2.09e-09	0.49	0.36	Triglycerides;	chr8:11115230	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.583	rs2736306	ENSG00000253893.2	FAM85B	-8.33	9.06e-16	2.1e-09	-0.48	-0.36	Retinal vascular caliber;	chr8:11382253	chr8:8167819~8226614:-
THCA	trans	rs10870270	1	rs7077744	ENSG00000197358.9	BNIP3P1	8.33	9.14e-16	2.12e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131956697	chr14:28264390~28265974:+
THCA	trans	rs10037055	1	rs6886255	ENSG00000228305.2	AC016734.2	8.33	9.15e-16	2.12e-09	0.39	0.36	Migraine without aura;	chr5:177291360	chr2:63622178~63622831:-
THCA	trans	rs13014235	0.652	rs6435080	ENSG00000235105.1	RP11-329A14.1	8.33	9.21e-16	2.13e-09	0.39	0.36	Basal cell carcinoma;	chr2:201341597	chr1:48435967~48437223:+
THCA	trans	rs9858542	0.953	rs11713474	ENSG00000197582.5	GPX1P1	-8.33	9.21e-16	2.14e-09	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49574024	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs9811982	ENSG00000197582.5	GPX1P1	-8.33	9.21e-16	2.14e-09	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49586944	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.903	rs35999162	ENSG00000197582.5	GPX1P1	-8.33	9.23e-16	2.14e-09	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559797	chrX:13378735~13379340:-
THCA	trans	rs10242455	0.85	rs3779354	ENSG00000228834.1	RP11-249L21.4	8.33	9.23e-16	2.14e-09	0.71	0.36	Blood metabolite levels;	chr7:99454805	chr6:108907615~108907873:-
THCA	trans	rs7824557	0.564	rs2572389	ENSG00000253893.2	FAM85B	8.33	9.26e-16	2.14e-09	0.47	0.36	Retinal vascular caliber;	chr8:11378883	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2736301	ENSG00000253893.2	FAM85B	8.33	9.26e-16	2.14e-09	0.47	0.36	Retinal vascular caliber;	chr8:11378904	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2736302	ENSG00000253893.2	FAM85B	8.33	9.26e-16	2.14e-09	0.47	0.36	Retinal vascular caliber;	chr8:11378910	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.647	rs7821302	ENSG00000253893.2	FAM85B	8.33	9.26e-16	2.14e-09	0.47	0.36	Neuroticism;	chr8:11379063	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs7821459	ENSG00000253893.2	FAM85B	8.33	9.26e-16	2.14e-09	0.47	0.36	Retinal vascular caliber;	chr8:11379172	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs7834572	ENSG00000253893.2	FAM85B	8.33	9.26e-16	2.14e-09	0.47	0.36	Retinal vascular caliber;	chr8:11379176	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs4631424	ENSG00000253893.2	FAM85B	8.33	9.26e-16	2.14e-09	0.47	0.36	Retinal vascular caliber;	chr8:11379300	chr8:8167819~8226614:-
THCA	trans	rs748404	0.516	rs523156	ENSG00000180867.10	PDIA3P1	8.32	9.37e-16	2.17e-09	0.31	0.36	Lung cancer;	chr15:43519645	chr1:147178113~147179622:+
THCA	trans	rs7824557	0.527	rs2736296	ENSG00000253893.2	FAM85B	8.32	9.38e-16	2.17e-09	0.47	0.36	Retinal vascular caliber;	chr8:11377335	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.51	rs2736297	ENSG00000253893.2	FAM85B	8.32	9.38e-16	2.17e-09	0.47	0.36	Retinal vascular caliber;	chr8:11377376	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs2736298	ENSG00000253893.2	FAM85B	8.32	9.38e-16	2.17e-09	0.47	0.36	Retinal vascular caliber;	chr8:11377627	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs57629785	ENSG00000253893.2	FAM85B	8.32	9.38e-16	2.17e-09	0.47	0.36	Retinal vascular caliber;	chr8:11377641	chr8:8167819~8226614:-
THCA	trans	rs6743068	0.541	rs2349075	ENSG00000235105.1	RP11-329A14.1	8.32	9.53e-16	2.21e-09	0.4	0.36	Lymphocyte percentage of white cells;	chr2:201358843	chr1:48435967~48437223:+
THCA	trans	rs2645424	0.635	rs6980952	ENSG00000229857.1	RP11-159H20.3	8.32	9.62e-16	2.23e-09	0.45	0.36	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11858964	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.564	rs2572379	ENSG00000253893.2	FAM85B	8.32	9.7e-16	2.24e-09	0.47	0.36	Retinal vascular caliber;	chr8:11379971	chr8:8167819~8226614:-
THCA	trans	rs10865397	0.506	rs6546807	ENSG00000236165.1	PRADC1P1	8.32	9.71e-16	2.25e-09	0.47	0.36	Intelligence (multi-trait analysis);	chr2:73159084	chr3:36976316~36976840:+
THCA	trans	rs13177918	0.906	rs12652032	ENSG00000226396.1	RP5-1056L3.3	8.32	9.79e-16	2.26e-09	0.39	0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:19608114~19608568:+
THCA	trans	rs453301	0.571	rs2929305	ENSG00000253893.2	FAM85B	8.32	9.8e-16	2.27e-09	0.45	0.36	Joint mobility (Beighton score);	chr8:9227707	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs12550129	ENSG00000253893.2	FAM85B	8.32	9.86e-16	2.28e-09	0.47	0.36	Retinal vascular caliber;	chr8:11376408	chr8:8167819~8226614:-
THCA	trans	rs9581094	0.505	rs6490945	ENSG00000224976.2	PARP4P2	-8.32	9.88e-16	2.28e-09	-0.46	-0.36	Sudden cardiac arrest;	chr13:24514056	chr13:19349137~19407962:+
THCA	trans	rs864643	0.678	rs3856566	ENSG00000188856.6	RPSAP47	8.32	9.89e-16	2.29e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39491097	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1609647	ENSG00000188856.6	RPSAP47	8.32	9.89e-16	2.29e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39491580	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1768224	ENSG00000188856.6	RPSAP47	8.32	9.89e-16	2.29e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39491843	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs7627794	ENSG00000188856.6	RPSAP47	8.32	9.89e-16	2.29e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39492039	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs7639473	ENSG00000188856.6	RPSAP47	8.32	9.89e-16	2.29e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39492324	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs10510702	ENSG00000188856.6	RPSAP47	8.32	9.89e-16	2.29e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39492461	chr8:80558870~80559757:+
THCA	trans	rs1908814	0.51	rs57655799	ENSG00000256560.1	LINC01486	8.31	1e-15	2.32e-09	0.45	0.36	Neuroticism;	chr8:11924908	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.505	rs2572440	ENSG00000253893.2	FAM85B	-8.31	1.01e-15	2.33e-09	-0.47	-0.36	Retinal vascular caliber;	chr8:11391501	chr8:8167819~8226614:-
THCA	trans	rs2288327	1	rs890578	ENSG00000269800.1	PLEKHA3P1	8.31	1.01e-15	2.34e-09	0.47	0.36	Atrial fibrillation;	chr2:178549906	chr19:41521043~41521989:-
THCA	trans	rs10242455	1	rs28468623	ENSG00000228834.1	RP11-249L21.4	8.31	1.03e-15	2.37e-09	0.74	0.36	Blood metabolite levels;	chr7:99325189	chr6:108907615~108907873:-
THCA	trans	rs2657294	0.632	rs1259503	ENSG00000172974.11	AC007318.5	8.31	1.03e-15	2.37e-09	0.45	0.36	Pneumonia;	chr10:75232686	chr2:65205108~65205988:+
THCA	trans	rs864643	0.625	rs602408	ENSG00000188856.6	RPSAP47	8.31	1.04e-15	2.39e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39493754	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs601925	ENSG00000188856.6	RPSAP47	8.31	1.04e-15	2.39e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39493871	chr8:80558870~80559757:+
THCA	trans	rs9425766	0.927	rs9425757	ENSG00000213331.4	RP11-713C19.2	8.31	1.04e-15	2.4e-09	0.46	0.36	Life satisfaction;	chr1:173855675	chr4:187970273~187971284:+
THCA	trans	rs7824557	0.564	rs2572394	ENSG00000253893.2	FAM85B	8.31	1.04e-15	2.41e-09	0.47	0.36	Retinal vascular caliber;	chr8:11377884	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2437152	ENSG00000253893.2	FAM85B	8.31	1.04e-15	2.41e-09	0.47	0.36	Retinal vascular caliber;	chr8:11377988	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2736300	ENSG00000253893.2	FAM85B	8.31	1.04e-15	2.41e-09	0.47	0.36	Retinal vascular caliber;	chr8:11378070	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2572392	ENSG00000253893.2	FAM85B	8.31	1.04e-15	2.41e-09	0.47	0.36	Retinal vascular caliber;	chr8:11378096	chr8:8167819~8226614:-
THCA	trans	rs72615157	0.634	rs11762932	ENSG00000228546.2	CTA-313A17.3	-8.31	1.05e-15	2.42e-09	-0.57	-0.36	Lung function (FEV1/FVC);	chr7:100195043	chr7:102337316~102339115:+
THCA	trans	rs9425766	0.924	rs9286895	ENSG00000213331.4	RP11-713C19.2	8.31	1.05e-15	2.42e-09	0.46	0.36	Life satisfaction;	chr1:173873329	chr4:187970273~187971284:+
THCA	trans	rs2657294	0.659	rs1259500	ENSG00000172974.11	AC007318.5	8.31	1.05e-15	2.43e-09	0.45	0.36	Pneumonia;	chr10:75230355	chr2:65205108~65205988:+
THCA	trans	rs10870270	1	rs7199	ENSG00000197358.9	BNIP3P1	8.3	1.07e-15	2.48e-09	0.48	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131956344	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs11146338	ENSG00000197358.9	BNIP3P1	8.3	1.07e-15	2.48e-09	0.48	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131956787	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs7078692	ENSG00000197358.9	BNIP3P1	8.3	1.07e-15	2.48e-09	0.48	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131961866	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs7898755	ENSG00000197358.9	BNIP3P1	8.3	1.07e-15	2.48e-09	0.48	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131963618	chr14:28264390~28265974:+
THCA	trans	rs7824557	0.564	rs13274106	ENSG00000253893.2	FAM85B	8.3	1.08e-15	2.49e-09	0.47	0.36	Retinal vascular caliber;	chr8:11376449	chr8:8167819~8226614:-
THCA	trans	rs864643	0.574	rs1768213	ENSG00000188856.6	RPSAP47	8.3	1.08e-15	2.49e-09	0.53	0.36	Attention deficit hyperactivity disorder;	chr3:39486790	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs493794	ENSG00000188856.6	RPSAP47	8.3	1.08e-15	2.49e-09	0.53	0.36	Attention deficit hyperactivity disorder;	chr3:39486804	chr8:80558870~80559757:+
THCA	trans	rs7819412	0.74	rs7844536	ENSG00000253893.2	FAM85B	8.3	1.08e-15	2.49e-09	0.48	0.36	Triglycerides;	chr8:11176519	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.874	rs28452522	ENSG00000275858.1	RP11-291L22.8	8.3	1.08e-15	2.49e-09	0.48	0.36	Corneal astigmatism;	chr4:119189629	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.777	rs10015883	ENSG00000275858.1	RP11-291L22.8	8.3	1.1e-15	2.54e-09	0.43	0.36	Diastolic blood pressure;	chr4:119346991	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.874	rs13123591	ENSG00000275858.1	RP11-291L22.8	8.3	1.14e-15	2.61e-09	0.47	0.36	Corneal astigmatism;	chr4:119184835	chr10:38450738~38451069:-
THCA	trans	rs7647973	0.925	rs7429661	ENSG00000197582.5	GPX1P1	8.3	1.14e-15	2.62e-09	0.57	0.36	Menarche (age at onset);	chr3:49191367	chrX:13378735~13379340:-
THCA	trans	rs2237234	0.542	rs7755997	ENSG00000242375.1	RP11-498P14.3	8.3	1.14e-15	2.63e-09	0.53	0.36	Autism spectrum disorder or schizophrenia;	chr6:26482820	chr9:97195351~97197687:-
THCA	trans	rs877636	1	rs705696	ENSG00000244604.1	RP11-713H12.1	8.29	1.16e-15	2.66e-09	0.48	0.36	Cognitive function;	chr12:56086864	chr17:8561230~8561576:+
THCA	trans	rs116095464	1	rs56075848	ENSG00000185986.11	SDHAP3	8.29	1.16e-15	2.67e-09	0.53	0.36	Breast cancer;	chr5:308237	chr5:1572222~1594620:-
THCA	trans	rs10870270	1	rs6560694	ENSG00000197358.9	BNIP3P1	8.29	1.16e-15	2.67e-09	0.48	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131959944	chr14:28264390~28265974:+
THCA	trans	rs867371	1	rs1174543	ENSG00000235370.6	DNM1P51	8.29	1.16e-15	2.67e-09	0.44	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:84398316~84411701:-
THCA	trans	rs11250098	0.6	rs4240671	ENSG00000253893.2	FAM85B	-8.29	1.16e-15	2.68e-09	-0.44	-0.36	Morning vs. evening chronotype;	chr8:10910238	chr8:8167819~8226614:-
THCA	trans	rs10816533	1	rs10116439	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.68e-09	0.87	0.36	Height;	chr9:96789823	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs12237908	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.68e-09	0.87	0.36	Height;	chr9:96821112	chr9:94332476~94360948:+
THCA	trans	rs7824557	0.545	rs2572380	ENSG00000253893.2	FAM85B	8.29	1.17e-15	2.69e-09	0.47	0.36	Retinal vascular caliber;	chr8:11379968	chr8:8167819~8226614:-
THCA	trans	rs10816533	1	rs7850707	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96782463	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs7847673	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96782539	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs7848081	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96782838	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10978963	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96783799	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10978968	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96784167	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10978970	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96784176	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10978971	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96784203	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10978973	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96784304	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10120515	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96784883	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs28678226	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96785864	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10115492	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96788455	chr9:94332476~94360948:+
THCA	trans	rs10816533	0.661	rs10121639	ENSG00000232063.1	RP11-307E17.8	8.29	1.17e-15	2.69e-09	0.87	0.36	Height;	chr9:96789167	chr9:94332476~94360948:+
THCA	trans	rs864643	0.678	rs1609646	ENSG00000188856.6	RPSAP47	8.29	1.17e-15	2.69e-09	0.54	0.36	Attention deficit hyperactivity disorder;	chr3:39491415	chr8:80558870~80559757:+
THCA	trans	rs867371	0.929	rs7173852	ENSG00000235370.6	DNM1P51	-8.29	1.17e-15	2.69e-09	-0.44	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:84398316~84411701:-
THCA	trans	rs7113874	1	rs10840099	ENSG00000266891.1	RP11-692N5.2	-8.29	1.18e-15	2.71e-09	-0.46	-0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8646133	chr18:9734882~9735602:-
THCA	trans	rs916888	0.647	rs199524	ENSG00000204650.12	CRHR1-IT1	-8.29	1.18e-15	2.71e-09	-0.35	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45620328~45648216:+
THCA	trans	rs7824557	0.564	rs2572395	ENSG00000253893.2	FAM85B	8.29	1.19e-15	2.72e-09	0.47	0.36	Retinal vascular caliber;	chr8:11377851	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.953	rs71324979	ENSG00000197582.5	GPX1P1	-8.29	1.2e-15	2.75e-09	-0.55	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49582218	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	8.29	1.2e-15	2.76e-09	0.47	0.36	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
THCA	trans	rs804280	0.517	rs7815179	ENSG00000256560.1	LINC01486	8.29	1.2e-15	2.76e-09	0.45	0.36	Myopia (pathological);	chr8:11934539	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.871	rs7815186	ENSG00000256560.1	LINC01486	8.29	1.2e-15	2.76e-09	0.45	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.516	rs7833079	ENSG00000256560.1	LINC01486	8.29	1.2e-15	2.76e-09	0.45	0.36	Neuroticism;	chr8:11934620	chr12:109354083~109359488:-
THCA	trans	rs7647973	0.925	rs9834003	ENSG00000197582.5	GPX1P1	8.29	1.21e-15	2.78e-09	0.56	0.36	Menarche (age at onset);	chr3:49179039	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.925	rs4955421	ENSG00000197582.5	GPX1P1	8.29	1.21e-15	2.78e-09	0.56	0.36	Menarche (age at onset);	chr3:49181455	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.925	rs4955423	ENSG00000197582.5	GPX1P1	8.29	1.21e-15	2.78e-09	0.56	0.36	Menarche (age at onset);	chr3:49183015	chrX:13378735~13379340:-
THCA	trans	rs10870270	0.956	rs10870293	ENSG00000197358.9	BNIP3P1	8.29	1.23e-15	2.81e-09	0.48	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131957909	chr14:28264390~28265974:+
THCA	trans	rs7503168	1	rs10512472	ENSG00000234130.2	RP13-88F20.1	8.28	1.25e-15	2.86e-09	0.46	0.36	Plateletcrit;	chr17:35557785	chrX:93222220~93225015:-
THCA	trans	rs10870270	1	rs4880250	ENSG00000197358.9	BNIP3P1	8.28	1.26e-15	2.89e-09	0.48	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131960415	chr14:28264390~28265974:+
THCA	trans	rs1023500	1	rs1023499	ENSG00000268568.1	AC007228.9	-8.28	1.27e-15	2.9e-09	-0.49	-0.36	Schizophrenia;	chr22:41944578	chr19:56672574~56673901:-
THCA	trans	rs7824557	0.564	rs2572386	ENSG00000253893.2	FAM85B	8.28	1.28e-15	2.92e-09	0.47	0.36	Retinal vascular caliber;	chr8:11379466	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.716	rs4784987	ENSG00000230849.2	GOT2P2	8.28	1.28e-15	2.93e-09	0.44	0.36	Blood metabolite ratios;	chr16:58824135	chr1:173141100~173142350:-
THCA	trans	rs1023500	1	rs1023497	ENSG00000268568.1	AC007228.9	-8.28	1.29e-15	2.96e-09	-0.48	-0.36	Schizophrenia;	chr22:41944504	chr19:56672574~56673901:-
THCA	trans	rs916888	0.647	rs199523	ENSG00000204650.12	CRHR1-IT1	-8.28	1.29e-15	2.96e-09	-0.35	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45620328~45648216:+
THCA	trans	rs9292918	1	rs13179496	ENSG00000231752.4	EMBP1	8.28	1.31e-15	3e-09	0.53	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45392440	chr1:121519112~121571892:+
THCA	trans	rs10435719	0.867	rs62493601	ENSG00000256560.1	LINC01486	8.28	1.31e-15	3e-09	0.45	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr12:109354083~109359488:-
THCA	trans	rs867371	1	rs7166570	ENSG00000235370.6	DNM1P51	-8.28	1.32e-15	3.02e-09	-0.44	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:84398316~84411701:-
THCA	trans	rs804280	0.509	rs13268030	ENSG00000256560.1	LINC01486	8.28	1.33e-15	3.03e-09	0.44	0.36	Myopia (pathological);	chr8:11925564	chr12:109354083~109359488:-
THCA	trans	rs867371	1	rs13380317	ENSG00000235370.6	DNM1P51	8.27	1.35e-15	3.07e-09	0.44	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:84398316~84411701:-
THCA	trans	rs7824557	0.527	rs2572369	ENSG00000253893.2	FAM85B	8.27	1.35e-15	3.08e-09	0.47	0.36	Retinal vascular caliber;	chr8:11381088	chr8:8167819~8226614:-
THCA	trans	rs11250098	0.548	rs7843470	ENSG00000253893.2	FAM85B	8.27	1.35e-15	3.09e-09	0.45	0.36	Morning vs. evening chronotype;	chr8:10926982	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs11785394	ENSG00000253893.2	FAM85B	8.27	1.36e-15	3.1e-09	0.47	0.36	Retinal vascular caliber;	chr8:11380520	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.953	rs7622302	ENSG00000197582.5	GPX1P1	-8.27	1.37e-15	3.12e-09	-0.54	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49510128	chrX:13378735~13379340:-
THCA	trans	rs7824557	0.51	rs1435274	ENSG00000253893.2	FAM85B	8.27	1.37e-15	3.13e-09	0.47	0.36	Retinal vascular caliber;	chr8:11378401	chr8:8167819~8226614:-
THCA	trans	rs10870270	1	rs11146354	ENSG00000197358.9	BNIP3P1	8.27	1.38e-15	3.15e-09	0.48	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131961253	chr14:28264390~28265974:+
THCA	trans	rs9292918	0.95	rs7717890	ENSG00000231752.4	EMBP1	8.27	1.38e-15	3.16e-09	0.53	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45309375	chr1:121519112~121571892:+
THCA	trans	rs9292918	1	rs6895055	ENSG00000231752.4	EMBP1	8.27	1.38e-15	3.16e-09	0.53	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45321306	chr1:121519112~121571892:+
THCA	trans	rs9292918	1	rs6888352	ENSG00000231752.4	EMBP1	8.27	1.38e-15	3.16e-09	0.53	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45325813	chr1:121519112~121571892:+
THCA	trans	rs9292918	1	rs1501361	ENSG00000231752.4	EMBP1	8.27	1.38e-15	3.16e-09	0.53	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45326671	chr1:121519112~121571892:+
THCA	trans	rs9292918	1	rs13168931	ENSG00000231752.4	EMBP1	8.27	1.38e-15	3.16e-09	0.53	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45332722	chr1:121519112~121571892:+
THCA	trans	rs28647808	0.748	rs114667516	ENSG00000234981.1	RP11-534L20.4	8.27	1.42e-15	3.25e-09	0.66	0.36	Blood protein levels;	chr9:133393414	chr1:206528915~206529706:+
THCA	trans	rs10870270	1	rs4880263	ENSG00000197358.9	BNIP3P1	8.26	1.46e-15	3.32e-09	0.49	0.36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131974125	chr14:28264390~28265974:+
THCA	trans	rs6424115	0.83	rs2501424	ENSG00000228217.1	AL390877.1	-8.26	1.46e-15	3.32e-09	-0.46	-0.36	Immature fraction of reticulocytes;	chr1:23872692	chr1:117778087~117778506:-
THCA	trans	rs864643	0.513	rs1768149	ENSG00000183298.5	RP11-556K13.1	8.26	1.46e-15	3.33e-09	0.58	0.36	Attention deficit hyperactivity disorder;	chr3:39466089	chr1:101786340~101787219:-
THCA	trans	rs11951515	0.508	rs1366410	ENSG00000174977.8	AC026271.5	-8.26	1.46e-15	3.33e-09	-0.4	-0.36	Metabolite levels  (X-11787);	chr5:43601508	chr17:18650195~18651542:+
THCA	trans	rs877636	1	rs877636	ENSG00000224553.1	AC008065.1	-8.26	1.49e-15	3.39e-09	-0.44	-0.36	Cognitive function;	chr12:56086799	chr2:171374931~171375278:-
THCA	trans	rs11250098	0.642	rs4841460	ENSG00000253893.2	FAM85B	8.26	1.53e-15	3.47e-09	0.45	0.36	Morning vs. evening chronotype;	chr8:10931983	chr8:8167819~8226614:-
THCA	trans	rs2929278	0.561	rs2927071	ENSG00000180867.10	PDIA3P1	-8.26	1.53e-15	3.49e-09	-0.32	-0.36	Schizophrenia;	chr15:43626883	chr1:147178113~147179622:+
THCA	trans	rs7647973	0.925	rs11130183	ENSG00000197582.5	GPX1P1	8.26	1.53e-15	3.49e-09	0.56	0.36	Menarche (age at onset);	chr3:49191513	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.925	rs6808036	ENSG00000197582.5	GPX1P1	8.26	1.53e-15	3.49e-09	0.56	0.36	Menarche (age at onset);	chr3:49199006	chrX:13378735~13379340:-
THCA	trans	rs740160	0.558	rs12538893	ENSG00000228834.1	RP11-249L21.4	8.26	1.55e-15	3.52e-09	0.72	0.36	Dehydroepiandrosterone sulphate levels;	chr7:99310874	chr6:108907615~108907873:-
THCA	trans	rs3806843	0.735	rs2563333	ENSG00000231043.3	AC007238.1	8.25	1.58e-15	3.59e-09	0.42	0.36	Depressive symptoms (multi-trait analysis);	chr5:140672686	chr2:58460292~58462032:-
THCA	trans	rs28647808	0.748	rs28502181	ENSG00000234981.1	RP11-534L20.4	8.25	1.59e-15	3.6e-09	0.66	0.36	Blood protein levels;	chr9:133392016	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs4962047	ENSG00000234981.1	RP11-534L20.4	8.25	1.6e-15	3.63e-09	0.66	0.36	Blood protein levels;	chr9:133397789	chr1:206528915~206529706:+
THCA	trans	rs351855	0.642	rs2546095	ENSG00000217325.2	PRELID1P1	8.25	1.6e-15	3.64e-09	0.39	0.36	Waist-to-hip ratio adjusted for body mass index;	chr5:177082583	chr6:126643488~126644390:+
THCA	trans	rs1023500	1	rs7293091	ENSG00000268568.1	AC007228.9	-8.25	1.61e-15	3.66e-09	-0.48	-0.36	Schizophrenia;	chr22:41945304	chr19:56672574~56673901:-
THCA	trans	rs7819412	0.745	rs7017567	ENSG00000229857.1	RP11-159H20.3	8.25	1.62e-15	3.69e-09	0.45	0.36	Triglycerides;	chr8:11076189	chr9:76992099~76993108:+
THCA	trans	rs3806843	0.762	rs3756337	ENSG00000231043.3	AC007238.1	-8.25	1.63e-15	3.71e-09	-0.43	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140806853	chr2:58460292~58462032:-
THCA	trans	rs10435719	0.805	rs13269417	ENSG00000256560.1	LINC01486	8.25	1.63e-15	3.71e-09	0.45	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.604	rs17051352	ENSG00000275858.1	RP11-291L22.8	8.25	1.64e-15	3.73e-09	0.5	0.36	Corneal astigmatism;	chr4:119660272	chr10:38450738~38451069:-
THCA	trans	rs12709013	0.716	rs4784987	ENSG00000233719.3	GOT2P3	8.25	1.65e-15	3.75e-09	0.43	0.36	Blood metabolite ratios;	chr16:58824135	chr12:9641802~9643007:+
THCA	trans	rs11992162	0.967	rs4840601	ENSG00000253893.2	FAM85B	-8.25	1.66e-15	3.76e-09	-0.48	-0.36	Monocyte count;	chr8:11971221	chr8:8167819~8226614:-
THCA	trans	rs72615157	0.634	rs2272343	ENSG00000228546.2	CTA-313A17.3	8.25	1.66e-15	3.77e-09	0.56	0.36	Lung function (FEV1/FVC);	chr7:100180662	chr7:102337316~102339115:+
THCA	trans	rs72615157	0.634	rs74742883	ENSG00000228546.2	CTA-313A17.3	8.25	1.66e-15	3.77e-09	0.56	0.36	Lung function (FEV1/FVC);	chr7:100188142	chr7:102337316~102339115:+
THCA	trans	rs10865397	0.506	rs6546810	ENSG00000236165.1	PRADC1P1	8.24	1.67e-15	3.79e-09	0.48	0.36	Intelligence (multi-trait analysis);	chr2:73162588	chr3:36976316~36976840:+
THCA	trans	rs740160	0.558	rs17161669	ENSG00000228834.1	RP11-249L21.4	8.24	1.68e-15	3.82e-09	0.73	0.36	Dehydroepiandrosterone sulphate levels;	chr7:99311040	chr6:108907615~108907873:-
THCA	trans	rs7824557	0.527	rs2572376	ENSG00000253893.2	FAM85B	8.24	1.69e-15	3.84e-09	0.46	0.36	Retinal vascular caliber;	chr8:11380247	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs2736305	ENSG00000253893.2	FAM85B	8.24	1.69e-15	3.84e-09	0.46	0.36	Retinal vascular caliber;	chr8:11380264	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.925	rs6769821	ENSG00000197582.5	GPX1P1	8.24	1.72e-15	3.91e-09	0.58	0.36	Menarche (age at onset);	chr3:49207224	chrX:13378735~13379340:-
THCA	trans	rs3849046	0.817	rs13160755	ENSG00000226666.1	HSPA9P1	8.24	1.73e-15	3.92e-09	0.37	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138549942	chr2:221961737~221963765:+
THCA	trans	rs13177918	1	rs13161334	ENSG00000226396.1	RP5-1056L3.3	8.24	1.73e-15	3.92e-09	0.38	0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:19608114~19608568:+
THCA	trans	rs13177918	1	rs35007082	ENSG00000226396.1	RP5-1056L3.3	8.24	1.73e-15	3.92e-09	0.38	0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:19608114~19608568:+
THCA	trans	rs13177918	1	rs13177918	ENSG00000226396.1	RP5-1056L3.3	8.24	1.73e-15	3.92e-09	0.38	0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:19608114~19608568:+
THCA	trans	rs2645424	1	rs962366	ENSG00000229857.1	RP11-159H20.3	-8.24	1.74e-15	3.94e-09	-0.44	-0.36	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826894	chr9:76992099~76993108:+
THCA	trans	rs3849046	0.817	rs6596438	ENSG00000226666.1	HSPA9P1	8.24	1.76e-15	3.98e-09	0.37	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138569759	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.817	rs6874487	ENSG00000226666.1	HSPA9P1	8.24	1.76e-15	3.98e-09	0.37	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138571317	chr2:221961737~221963765:+
THCA	trans	rs9329221	0.651	rs2975648	ENSG00000253893.2	FAM85B	8.24	1.77e-15	4.01e-09	0.44	0.36	Neuroticism;	chr8:10278466	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.817	rs11959184	ENSG00000226666.1	HSPA9P1	8.24	1.78e-15	4.03e-09	0.37	0.36	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138596189	chr2:221961737~221963765:+
THCA	trans	rs877636	0.702	rs61937249	ENSG00000243538.1	CTB-55B8.1	8.24	1.79e-15	4.05e-09	0.45	0.36	Cognitive function;	chr12:55988132	chr5:16902294~16902641:-
THCA	trans	rs804280	0.509	rs9886639	ENSG00000256560.1	LINC01486	8.24	1.79e-15	4.05e-09	0.45	0.36	Myopia (pathological);	chr8:11927020	chr12:109354083~109359488:-
THCA	trans	rs6424115	0.79	rs72874118	ENSG00000228217.1	AL390877.1	8.23	1.79e-15	4.06e-09	0.47	0.36	Immature fraction of reticulocytes;	chr1:23851310	chr1:117778087~117778506:-
THCA	trans	rs7113874	0.959	rs11042023	ENSG00000266891.1	RP11-692N5.2	-8.23	1.81e-15	4.09e-09	-0.46	-0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8640969	chr18:9734882~9735602:-
THCA	trans	rs28647808	0.881	rs7852803	ENSG00000234981.1	RP11-534L20.4	8.23	1.81e-15	4.09e-09	0.66	0.36	Blood protein levels;	chr9:133379032	chr1:206528915~206529706:+
THCA	trans	rs11951515	0.508	rs6860493	ENSG00000174977.8	AC026271.5	-8.23	1.81e-15	4.1e-09	-0.4	-0.36	Metabolite levels  (X-11787);	chr5:43602611	chr17:18650195~18651542:+
THCA	trans	rs7824557	0.603	rs2246606	ENSG00000253893.2	FAM85B	-8.23	1.83e-15	4.13e-09	-0.48	-0.35	Retinal vascular caliber;	chr8:11361825	chr8:8167819~8226614:-
THCA	trans	rs2657294	0.606	rs10824290	ENSG00000172974.11	AC007318.5	8.23	1.85e-15	4.18e-09	0.44	0.35	Pneumonia;	chr10:75204210	chr2:65205108~65205988:+
THCA	trans	rs2657294	0.632	rs2657289	ENSG00000172974.11	AC007318.5	8.23	1.85e-15	4.18e-09	0.44	0.35	Pneumonia;	chr10:75206705	chr2:65205108~65205988:+
THCA	trans	rs7113874	0.802	rs11042025	ENSG00000266891.1	RP11-692N5.2	-8.23	1.85e-15	4.18e-09	-0.46	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8653928	chr18:9734882~9735602:-
THCA	trans	rs10870270	1	rs9971066	ENSG00000197358.9	BNIP3P1	8.23	1.86e-15	4.19e-09	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131974729	chr14:28264390~28265974:+
THCA	trans	rs13190036	0.551	rs28932178	ENSG00000228305.2	AC016734.2	-8.23	1.86e-15	4.2e-09	-0.42	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr2:63622178~63622831:-
THCA	trans	rs9292918	1	rs3923055	ENSG00000231752.4	EMBP1	8.23	1.87e-15	4.22e-09	0.53	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45391821	chr1:121519112~121571892:+
THCA	trans	rs7662987	0.818	rs35123946	ENSG00000233859.2	ADH5P4	8.23	1.87e-15	4.23e-09	0.87	0.35	Smoking initiation;	chr4:99079760	chr6:65836930~65838039:-
THCA	trans	rs11098499	0.913	rs56122576	ENSG00000275858.1	RP11-291L22.8	8.23	1.87e-15	4.23e-09	0.47	0.35	Corneal astigmatism;	chr4:119208181	chr10:38450738~38451069:-
THCA	trans	rs10816533	1	rs10117921	ENSG00000232063.1	RP11-307E17.8	8.23	1.92e-15	4.33e-09	0.86	0.35	Height;	chr9:96788152	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10117923	ENSG00000232063.1	RP11-307E17.8	8.23	1.92e-15	4.33e-09	0.86	0.35	Height;	chr9:96788165	chr9:94332476~94360948:+
THCA	trans	rs9329221	0.617	rs615632	ENSG00000253893.2	FAM85B	8.22	1.93e-15	4.36e-09	0.47	0.35	Neuroticism;	chr8:9938811	chr8:8167819~8226614:-
THCA	trans	rs73108077	0.736	rs6058479	ENSG00000279352.1	RP11-411B10.7	8.22	1.95e-15	4.41e-09	0.64	0.35	Red blood cell density in sickle cell anemia;	chr20:31282419	chr18:14010054~14010917:+
THCA	trans	rs877636	1	rs4759229	ENSG00000224553.1	AC008065.1	-8.22	1.96e-15	4.43e-09	-0.44	-0.35	Cognitive function;	chr12:56080696	chr2:171374931~171375278:-
THCA	trans	rs13190036	0.551	rs1052432	ENSG00000228305.2	AC016734.2	-8.22	1.97e-15	4.44e-09	-0.41	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr2:63622178~63622831:-
THCA	trans	rs6743068	0.541	rs13014235	ENSG00000235105.1	RP11-329A14.1	8.22	2e-15	4.52e-09	0.39	0.35	Lymphocyte percentage of white cells;	chr2:201350769	chr1:48435967~48437223:+
THCA	trans	rs10435719	0.718	rs7813935	ENSG00000256560.1	LINC01486	8.22	2.01e-15	4.52e-09	0.45	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr12:109354083~109359488:-
THCA	trans	rs1908814	0.504	rs7830734	ENSG00000256560.1	LINC01486	8.22	2.01e-15	4.52e-09	0.45	0.35	Neuroticism;	chr8:11938130	chr12:109354083~109359488:-
THCA	trans	rs330048	0.561	rs4840401	ENSG00000253893.2	FAM85B	8.22	2.03e-15	4.58e-09	0.48	0.35	Systemic lupus erythematosus;	chr8:9290615	chr8:8167819~8226614:-
THCA	trans	rs9292918	1	rs994092	ENSG00000231752.4	EMBP1	8.22	2.06e-15	4.63e-09	0.52	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45335657	chr1:121519112~121571892:+
THCA	trans	rs7647973	0.925	rs9881860	ENSG00000197582.5	GPX1P1	8.21	2.08e-15	4.68e-09	0.57	0.35	Menarche (age at onset);	chr3:49315089	chrX:13378735~13379340:-
THCA	trans	rs7113874	0.802	rs4291677	ENSG00000266891.1	RP11-692N5.2	8.21	2.1e-15	4.72e-09	0.46	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8659344	chr18:9734882~9735602:-
THCA	trans	rs13016963	0.506	rs11684505	ENSG00000235105.1	RP11-329A14.1	8.21	2.12e-15	4.77e-09	0.39	0.35	Esophageal squamous cell carcinoma;Melanoma;	chr2:201376440	chr1:48435967~48437223:+
THCA	trans	rs9425766	0.962	rs1322780	ENSG00000213331.4	RP11-713C19.2	8.21	2.13e-15	4.8e-09	0.45	0.35	Life satisfaction;	chr1:173896448	chr4:187970273~187971284:+
THCA	trans	rs9425766	0.962	rs9425435	ENSG00000213331.4	RP11-713C19.2	8.21	2.13e-15	4.8e-09	0.45	0.35	Life satisfaction;	chr1:173896936	chr4:187970273~187971284:+
THCA	trans	rs9650657	0.617	rs28680211	ENSG00000253893.2	FAM85B	8.21	2.14e-15	4.81e-09	0.44	0.35	Neuroticism;	chr8:10661935	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.561	rs2001328	ENSG00000253893.2	FAM85B	8.21	2.14e-15	4.81e-09	0.48	0.35	Triglycerides;	chr8:11129689	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.913	rs10006304	ENSG00000275858.1	RP11-291L22.8	8.21	2.14e-15	4.81e-09	0.46	0.35	Corneal astigmatism;	chr4:119203150	chr10:38450738~38451069:-
THCA	trans	rs9425766	0.886	rs9661233	ENSG00000213331.4	RP11-713C19.2	8.21	2.15e-15	4.84e-09	0.45	0.35	Life satisfaction;	chr1:173874913	chr4:187970273~187971284:+
THCA	trans	rs9292918	1	rs10473384	ENSG00000231752.4	EMBP1	-8.21	2.17e-15	4.87e-09	-0.53	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45343708	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.595	rs10503416	ENSG00000253893.2	FAM85B	-8.21	2.17e-15	4.88e-09	-0.48	-0.35	Triglycerides;	chr8:11130043	chr8:8167819~8226614:-
THCA	trans	rs4879656	0.564	rs1888869	ENSG00000215007.3	DNAJA1P3	-8.21	2.22e-15	4.98e-09	-0.41	-0.35	Menopause (age at onset);	chr9:32998239	chrX:107351650~107352843:-
THCA	trans	rs11098499	0.913	rs13126596	ENSG00000275858.1	RP11-291L22.8	8.21	2.23e-15	5e-09	0.46	0.35	Corneal astigmatism;	chr4:119219574	chr10:38450738~38451069:-
THCA	trans	rs9292918	1	rs10045420	ENSG00000231752.4	EMBP1	8.21	2.23e-15	5e-09	0.53	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45393652	chr1:121519112~121571892:+
THCA	trans	rs877636	0.74	rs705702	ENSG00000204652.6	RPS26P8	-8.2	2.23e-15	5.01e-09	-0.47	-0.35	Cognitive function;	chr12:55996852	chr17:45608571~45608918:+
THCA	trans	rs2250402	0.51	rs6492926	ENSG00000234106.3	RP11-288E14.2	8.2	2.26e-15	5.07e-09	0.66	0.35	Corneal curvature;	chr15:40033628	chr11:93535468~93535816:+
THCA	trans	rs6424115	0.83	rs3003333	ENSG00000228217.1	AL390877.1	8.2	2.27e-15	5.1e-09	0.46	0.35	Immature fraction of reticulocytes;	chr1:23867524	chr1:117778087~117778506:-
THCA	trans	rs28647808	0.786	rs28458971	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133389952	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.786	rs28590601	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133390448	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.786	rs4962134	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133390850	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.786	rs4962135	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133390854	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.786	rs4962136	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133391018	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.786	rs4962137	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133391050	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.786	rs28649804	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133391933	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs71483208	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133393697	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs41316984	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133394104	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28591209	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133394541	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs41297211	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133395594	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs57394597	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133395903	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs28461467	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133396161	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs7040821	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133398457	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs7029256	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133398528	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs7029386	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133398609	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs28625799	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133399428	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs4246171	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133399602	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs4549850	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133400111	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs28494844	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133401060	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs7042326	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133401507	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.618	rs7025970	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133402044	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.748	rs28721280	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133402189	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs28622217	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133402194	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs28602295	ENSG00000234981.1	RP11-534L20.4	8.2	2.28e-15	5.12e-09	0.65	0.35	Blood protein levels;	chr9:133402342	chr1:206528915~206529706:+
THCA	trans	rs6424115	1	rs2179395	ENSG00000228217.1	AL390877.1	-8.2	2.28e-15	5.12e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23821875	chr1:117778087~117778506:-
THCA	trans	rs6424115	1	rs6424115	ENSG00000228217.1	AL390877.1	8.2	2.28e-15	5.12e-09	0.46	0.35	Immature fraction of reticulocytes;	chr1:23826741	chr1:117778087~117778506:-
THCA	trans	rs9292918	1	rs10044408	ENSG00000231752.4	EMBP1	8.2	2.3e-15	5.16e-09	0.52	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45388687	chr1:121519112~121571892:+
THCA	trans	rs1908814	0.516	rs11250178	ENSG00000256560.1	LINC01486	8.2	2.3e-15	5.16e-09	0.45	0.35	Neuroticism;	chr8:11942725	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.713	rs6601575	ENSG00000253893.2	FAM85B	-8.2	2.35e-15	5.25e-09	-0.45	-0.35	Retinal vascular caliber;	chr8:11240295	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.764	rs10103485	ENSG00000256560.1	LINC01486	8.2	2.35e-15	5.27e-09	0.44	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.874	rs9995277	ENSG00000275858.1	RP11-291L22.8	8.2	2.36e-15	5.28e-09	0.46	0.35	Corneal astigmatism;	chr4:119187448	chr10:38450738~38451069:-
THCA	trans	rs35851103	0.627	rs58602899	ENSG00000256560.1	LINC01486	8.2	2.37e-15	5.31e-09	0.43	0.35	Neuroticism;	chr8:11991324	chr12:109354083~109359488:-
THCA	trans	rs3806843	0.966	rs7710380	ENSG00000231043.3	AC007238.1	-8.2	2.39e-15	5.34e-09	-0.4	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140776679	chr2:58460292~58462032:-
THCA	trans	rs4276421	0.577	rs10054424	ENSG00000231752.4	EMBP1	8.19	2.4e-15	5.37e-09	0.75	0.35	P wave duration;	chr5:45748769	chr1:121519112~121571892:+
THCA	trans	rs7113874	0.959	rs11042017	ENSG00000266891.1	RP11-692N5.2	-8.19	2.48e-15	5.55e-09	-0.46	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8628144	chr18:9734882~9735602:-
THCA	trans	rs7113874	1	rs11042018	ENSG00000266891.1	RP11-692N5.2	-8.19	2.48e-15	5.55e-09	-0.46	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8628160	chr18:9734882~9735602:-
THCA	trans	rs74781061	0.722	rs77102700	ENSG00000227288.3	RP5-837I24.1	8.19	2.49e-15	5.56e-09	0.53	0.35	Endometriosis;	chr15:74604600	chr1:81501794~81503468:+
THCA	trans	rs7647973	0.961	rs7626076	ENSG00000197582.5	GPX1P1	8.19	2.5e-15	5.59e-09	0.56	0.35	Menarche (age at onset);	chr3:49260706	chrX:13378735~13379340:-
THCA	trans	rs66887589	0.777	rs2017058	ENSG00000275858.1	RP11-291L22.8	8.19	2.5e-15	5.59e-09	0.43	0.35	Diastolic blood pressure;	chr4:119336584	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.777	rs1814815	ENSG00000275858.1	RP11-291L22.8	8.19	2.5e-15	5.59e-09	0.43	0.35	Diastolic blood pressure;	chr4:119336936	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.748	rs28439855	ENSG00000275858.1	RP11-291L22.8	8.19	2.5e-15	5.59e-09	0.43	0.35	Diastolic blood pressure;	chr4:119341101	chr10:38450738~38451069:-
THCA	trans	rs7113874	0.802	rs885114	ENSG00000266891.1	RP11-692N5.2	8.19	2.51e-15	5.61e-09	0.46	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8657209	chr18:9734882~9735602:-
THCA	trans	rs35851103	0.6	rs4841662	ENSG00000256560.1	LINC01486	-8.19	2.54e-15	5.67e-09	-0.43	-0.35	Neuroticism;	chr8:11986249	chr12:109354083~109359488:-
THCA	trans	rs4879656	0.564	rs4879657	ENSG00000215007.3	DNAJA1P3	8.19	2.54e-15	5.67e-09	0.41	0.35	Menopause (age at onset);	chr9:33012467	chrX:107351650~107352843:-
THCA	trans	rs4879656	0.525	rs7852206	ENSG00000215007.3	DNAJA1P3	8.19	2.54e-15	5.67e-09	0.41	0.35	Menopause (age at onset);	chr9:33017383	chrX:107351650~107352843:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000243538.1	CTB-55B8.1	8.19	2.54e-15	5.67e-09	0.44	0.35	Cognitive function;	chr12:55981353	chr5:16902294~16902641:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000243538.1	CTB-55B8.1	8.19	2.54e-15	5.67e-09	0.44	0.35	Cognitive function;	chr12:55981956	chr5:16902294~16902641:-
THCA	trans	rs11098499	0.874	rs17839089	ENSG00000275858.1	RP11-291L22.8	8.18	2.59e-15	5.78e-09	0.46	0.35	Corneal astigmatism;	chr4:119189914	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.874	rs6826823	ENSG00000275858.1	RP11-291L22.8	8.18	2.59e-15	5.78e-09	0.46	0.35	Corneal astigmatism;	chr4:119190943	chr10:38450738~38451069:-
THCA	trans	rs867371	1	rs9944197	ENSG00000235370.6	DNM1P51	-8.18	2.61e-15	5.81e-09	-0.43	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:84398316~84411701:-
THCA	trans	rs2929278	0.561	rs3099045	ENSG00000180867.10	PDIA3P1	-8.18	2.61e-15	5.81e-09	-0.31	-0.35	Schizophrenia;	chr15:43631757	chr1:147178113~147179622:+
THCA	trans	rs864643	0.891	rs74417330	ENSG00000188856.6	RPSAP47	8.18	2.62e-15	5.84e-09	0.68	0.35	Attention deficit hyperactivity disorder;	chr3:39540212	chr8:80558870~80559757:+
THCA	trans	rs7113874	0.959	rs12803166	ENSG00000266891.1	RP11-692N5.2	-8.18	2.73e-15	6.09e-09	-0.46	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8624690	chr18:9734882~9735602:-
THCA	trans	rs3849046	0.846	rs256007	ENSG00000226666.1	HSPA9P1	8.18	2.76e-15	6.15e-09	0.38	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561900	chr2:221961737~221963765:+
THCA	trans	rs11951515	0.508	rs10059993	ENSG00000174977.8	AC026271.5	-8.18	2.77e-15	6.16e-09	-0.4	-0.35	Metabolite levels  (X-11787);	chr5:43598250	chr17:18650195~18651542:+
THCA	trans	rs7258465	0.563	rs10854166	ENSG00000267533.1	RP11-815J4.7	-8.17	2.79e-15	6.21e-09	-0.47	-0.35	Breast cancer;	chr19:18542034	chr18:12067173~12068417:-
THCA	trans	rs916888	0.779	rs199498	ENSG00000204650.12	CRHR1-IT1	8.17	2.82e-15	6.27e-09	0.36	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45620328~45648216:+
THCA	trans	rs7113874	1	rs4929926	ENSG00000266891.1	RP11-692N5.2	-8.17	2.82e-15	6.28e-09	-0.46	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8636829	chr18:9734882~9735602:-
THCA	trans	rs7113874	1	rs4929927	ENSG00000266891.1	RP11-692N5.2	-8.17	2.82e-15	6.28e-09	-0.46	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8636938	chr18:9734882~9735602:-
THCA	trans	rs3806843	1	rs4451093	ENSG00000231043.3	AC007238.1	8.17	2.83e-15	6.29e-09	0.4	0.35	Depressive symptoms (multi-trait analysis);	chr5:140778957	chr2:58460292~58462032:-
THCA	trans	rs867371	1	rs7173339	ENSG00000235370.6	DNM1P51	-8.17	2.83e-15	6.3e-09	-0.44	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:84398316~84411701:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000204652.6	RPS26P8	8.17	2.84e-15	6.31e-09	0.47	0.35	Cognitive function;	chr12:55996580	chr17:45608571~45608918:+
THCA	trans	rs867371	1	rs11855089	ENSG00000235370.6	DNM1P51	-8.17	2.86e-15	6.35e-09	-0.44	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:84398316~84411701:-
THCA	trans	rs10870270	1	rs6560695	ENSG00000197358.9	BNIP3P1	8.17	2.87e-15	6.38e-09	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131961482	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs7098014	ENSG00000197358.9	BNIP3P1	8.17	2.87e-15	6.38e-09	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131961525	chr14:28264390~28265974:+
THCA	trans	rs28647808	0.881	rs71483207	ENSG00000234981.1	RP11-534L20.4	8.17	2.89e-15	6.42e-09	0.65	0.35	Blood protein levels;	chr9:133393575	chr1:206528915~206529706:+
THCA	trans	rs282544	1	rs7717033	ENSG00000231752.4	EMBP1	-8.17	2.9e-15	6.45e-09	-0.49	-0.35	Myopia (pathological);	chr5:50686892	chr1:121519112~121571892:+
THCA	trans	rs10870270	0.913	rs115236491	ENSG00000197358.9	BNIP3P1	8.17	2.91e-15	6.47e-09	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131953351	chr14:28264390~28265974:+
THCA	trans	rs877636	1	rs4759229	ENSG00000204652.6	RPS26P8	-8.17	2.95e-15	6.55e-09	-0.47	-0.35	Cognitive function;	chr12:56080696	chr17:45608571~45608918:+
THCA	trans	rs7647973	1	rs13096474	ENSG00000197582.5	GPX1P1	-8.17	2.96e-15	6.57e-09	-0.55	-0.35	Menarche (age at onset);	chr3:49405648	chrX:13378735~13379340:-
THCA	trans	rs282544	1	rs10471414	ENSG00000231752.4	EMBP1	-8.17	2.98e-15	6.62e-09	-0.5	-0.35	Myopia (pathological);	chr5:50664839	chr1:121519112~121571892:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000204652.6	RPS26P8	-8.16	2.99e-15	6.64e-09	-0.47	-0.35	Cognitive function;	chr12:56080595	chr17:45608571~45608918:+
THCA	trans	rs11098499	0.874	rs12509054	ENSG00000275858.1	RP11-291L22.8	8.16	3e-15	6.66e-09	0.46	0.35	Corneal astigmatism;	chr4:119193920	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.874	rs10022508	ENSG00000275858.1	RP11-291L22.8	8.16	3e-15	6.66e-09	0.46	0.35	Corneal astigmatism;	chr4:119194073	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.874	rs12502503	ENSG00000275858.1	RP11-291L22.8	8.16	3e-15	6.66e-09	0.46	0.35	Corneal astigmatism;	chr4:119195100	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.874	rs6832670	ENSG00000275858.1	RP11-291L22.8	8.16	3e-15	6.66e-09	0.46	0.35	Corneal astigmatism;	chr4:119197637	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.874	rs6822498	ENSG00000275858.1	RP11-291L22.8	8.16	3e-15	6.66e-09	0.46	0.35	Corneal astigmatism;	chr4:119199028	chr10:38450738~38451069:-
THCA	trans	rs10870270	1	rs10870271	ENSG00000197358.9	BNIP3P1	-8.16	3.02e-15	6.7e-09	-0.48	-0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131941303	chr14:28264390~28265974:+
THCA	trans	rs9292918	1	rs12332696	ENSG00000231752.4	EMBP1	8.16	3.05e-15	6.76e-09	0.53	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45392583	chr1:121519112~121571892:+
THCA	trans	rs877636	0.702	rs773112	ENSG00000243538.1	CTB-55B8.1	8.16	3.06e-15	6.78e-09	0.44	0.35	Cognitive function;	chr12:55982097	chr5:16902294~16902641:-
THCA	trans	rs3849046	0.846	rs10117	ENSG00000226666.1	HSPA9P1	8.16	3.07e-15	6.8e-09	0.38	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138556481	chr2:221961737~221963765:+
THCA	trans	rs3808502	0.503	rs2061830	ENSG00000253893.2	FAM85B	-8.16	3.09e-15	6.85e-09	-0.47	-0.35	Neuroticism;	chr8:11539948	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.874	rs7661020	ENSG00000275858.1	RP11-291L22.8	8.16	3.11e-15	6.89e-09	0.46	0.35	Corneal astigmatism;	chr4:119185827	chr10:38450738~38451069:-
THCA	trans	rs3849046	0.846	rs2043273	ENSG00000226666.1	HSPA9P1	-8.16	3.12e-15	6.92e-09	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138595402	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.79	rs17207604	ENSG00000226666.1	HSPA9P1	-8.16	3.12e-15	6.92e-09	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138595901	chr2:221961737~221963765:+
THCA	trans	rs4879656	0.564	rs7864363	ENSG00000215007.3	DNAJA1P3	-8.16	3.17e-15	7.03e-09	-0.41	-0.35	Menopause (age at onset);	chr9:33022002	chrX:107351650~107352843:-
THCA	trans	rs7113874	0.797	rs4503528	ENSG00000266891.1	RP11-692N5.2	-8.16	3.19e-15	7.06e-09	-0.45	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8642907	chr18:9734882~9735602:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000243538.1	CTB-55B8.1	8.16	3.2e-15	7.08e-09	0.44	0.35	Cognitive function;	chr12:55996580	chr5:16902294~16902641:-
THCA	trans	rs7824557	0.564	rs1435275	ENSG00000253893.2	FAM85B	8.16	3.2e-15	7.09e-09	0.47	0.35	Retinal vascular caliber;	chr8:11378226	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.846	rs256006	ENSG00000226666.1	HSPA9P1	8.15	3.21e-15	7.11e-09	0.38	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561405	chr2:221961737~221963765:+
THCA	trans	rs9292918	1	rs6451796	ENSG00000231752.4	EMBP1	8.15	3.26e-15	7.21e-09	0.52	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45356532	chr1:121519112~121571892:+
THCA	trans	rs9292918	0.901	rs1501357	ENSG00000231752.4	EMBP1	8.15	3.26e-15	7.21e-09	0.52	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45364773	chr1:121519112~121571892:+
THCA	trans	rs9292918	1	rs7721486	ENSG00000231752.4	EMBP1	8.15	3.26e-15	7.21e-09	0.52	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45389472	chr1:121519112~121571892:+
THCA	trans	rs3779195	0.584	rs1688605	ENSG00000225169.1	BRI3P1	-8.15	3.3e-15	7.29e-09	-0.59	-0.35	Sex hormone-binding globulin levels;	chr7:98410534	chr1:100213293~100213670:+
THCA	trans	rs10435719	0.78	rs9692662	ENSG00000256560.1	LINC01486	8.15	3.32e-15	7.33e-09	0.45	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.899	rs9693925	ENSG00000256560.1	LINC01486	8.15	3.32e-15	7.33e-09	0.45	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr12:109354083~109359488:-
THCA	trans	rs61990749	1	rs17106604	ENSG00000235400.1	RP4-641G12.4	8.15	3.34e-15	7.38e-09	0.71	0.35	Fibroblast growth factor basic levels;	chr14:77912813	chr1:78749073~78750659:+
THCA	trans	rs9425766	0.962	rs2065171	ENSG00000213331.4	RP11-713C19.2	8.15	3.35e-15	7.4e-09	0.45	0.35	Life satisfaction;	chr1:173876972	chr4:187970273~187971284:+
THCA	trans	rs9425766	0.962	rs4652229	ENSG00000213331.4	RP11-713C19.2	8.15	3.35e-15	7.4e-09	0.45	0.35	Life satisfaction;	chr1:173877452	chr4:187970273~187971284:+
THCA	trans	rs9425766	0.927	rs9425765	ENSG00000213331.4	RP11-713C19.2	8.15	3.35e-15	7.4e-09	0.45	0.35	Life satisfaction;	chr1:173878871	chr4:187970273~187971284:+
THCA	trans	rs11098499	0.874	rs6851169	ENSG00000275858.1	RP11-291L22.8	8.15	3.37e-15	7.44e-09	0.46	0.35	Corneal astigmatism;	chr4:119196355	chr10:38450738~38451069:-
THCA	trans	rs7824557	0.564	rs2736304	ENSG00000253893.2	FAM85B	8.15	3.39e-15	7.48e-09	0.46	0.35	Retinal vascular caliber;	chr8:11379455	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.512	rs12546887	ENSG00000253893.2	FAM85B	-8.15	3.4e-15	7.5e-09	-0.45	-0.35	Neuroticism;	chr8:10435366	chr8:8167819~8226614:-
THCA	trans	rs7647973	1	rs6805609	ENSG00000197582.5	GPX1P1	-8.14	3.5e-15	7.73e-09	-0.53	-0.35	Menarche (age at onset);	chr3:49434089	chrX:13378735~13379340:-
THCA	trans	rs9648716	1	rs10281173	ENSG00000224775.2	BRAFP1	-8.14	3.51e-15	7.73e-09	-0.61	-0.35	Type 2 diabetes;	chr7:140880076	chrX:75582676~75585506:+
THCA	trans	rs2250402	0.51	rs2291619	ENSG00000234106.3	RP11-288E14.2	-8.14	3.51e-15	7.75e-09	-0.66	-0.35	Corneal curvature;	chr15:40036832	chr11:93535468~93535816:+
THCA	trans	rs3849046	0.817	rs4835687	ENSG00000226666.1	HSPA9P1	-8.14	3.53e-15	7.78e-09	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138536367	chr2:221961737~221963765:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000224553.1	AC008065.1	-8.14	3.56e-15	7.85e-09	-0.43	-0.35	Cognitive function;	chr12:56080595	chr2:171374931~171375278:-
THCA	trans	rs7809615	0.551	rs952319	ENSG00000228834.1	RP11-249L21.4	8.14	3.57e-15	7.87e-09	0.63	0.35	Blood metabolite ratios;	chr7:99573826	chr6:108907615~108907873:-
THCA	trans	rs9425766	0.886	rs1322775	ENSG00000213331.4	RP11-713C19.2	8.14	3.61e-15	7.95e-09	0.45	0.35	Life satisfaction;	chr1:173886160	chr4:187970273~187971284:+
THCA	trans	rs864643	0.735	rs76417541	ENSG00000188856.6	RPSAP47	8.14	3.61e-15	7.95e-09	0.68	0.35	Attention deficit hyperactivity disorder;	chr3:39519802	chr8:80558870~80559757:+
THCA	trans	rs282544	1	rs4548483	ENSG00000231752.4	EMBP1	-8.14	3.66e-15	8.06e-09	-0.49	-0.35	Myopia (pathological);	chr5:50703291	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.913	rs68128210	ENSG00000275858.1	RP11-291L22.8	8.14	3.67e-15	8.08e-09	0.46	0.35	Corneal astigmatism;	chr4:119216664	chr10:38450738~38451069:-
THCA	trans	rs864643	0.513	rs1398666	ENSG00000183298.5	RP11-556K13.1	8.14	3.67e-15	8.08e-09	0.57	0.35	Attention deficit hyperactivity disorder;	chr3:39475540	chr1:101786340~101787219:-
THCA	trans	rs864643	0.513	rs1768202	ENSG00000183298.5	RP11-556K13.1	8.14	3.67e-15	8.08e-09	0.57	0.35	Attention deficit hyperactivity disorder;	chr3:39476053	chr1:101786340~101787219:-
THCA	trans	rs11098499	0.863	rs12508173	ENSG00000253326.2	RP11-261C10.7	8.14	3.68e-15	8.1e-09	0.5	0.35	Corneal astigmatism;	chr4:119397371	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.908	rs12504149	ENSG00000253326.2	RP11-261C10.7	8.14	3.68e-15	8.1e-09	0.5	0.35	Corneal astigmatism;	chr4:119397422	chr1:243054861~243056394:-
THCA	trans	rs12145833	0.92	rs12354170	ENSG00000154608.12	CEP170P1	-8.13	3.71e-15	8.18e-09	-0.46	-0.35	Obesity (early onset extreme);	chr1:243294474	chr4:118467590~118554204:+
THCA	trans	rs7824557	0.51	rs4841524	ENSG00000253893.2	FAM85B	8.13	3.73e-15	8.22e-09	0.47	0.35	Retinal vascular caliber;	chr8:11385617	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000204652.6	RPS26P8	8.13	3.82e-15	8.4e-09	0.48	0.35	Cognitive function;	chr12:55980911	chr17:45608571~45608918:+
THCA	trans	rs9292918	0.853	rs1392973	ENSG00000231752.4	EMBP1	8.13	3.82e-15	8.41e-09	0.52	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45307131	chr1:121519112~121571892:+
THCA	trans	rs74781061	0.86	rs4887149	ENSG00000227288.3	RP5-837I24.1	8.13	3.83e-15	8.42e-09	0.5	0.35	Endometriosis;	chr15:74444108	chr1:81501794~81503468:+
THCA	trans	rs282544	1	rs11746825	ENSG00000231752.4	EMBP1	-8.13	3.86e-15	8.49e-09	-0.48	-0.35	Myopia (pathological);	chr5:50616675	chr1:121519112~121571892:+
THCA	trans	rs877636	0.702	rs773112	ENSG00000204652.6	RPS26P8	8.13	3.88e-15	8.54e-09	0.47	0.35	Cognitive function;	chr12:55982097	chr17:45608571~45608918:+
THCA	trans	rs9648716	1	rs6950946	ENSG00000224775.2	BRAFP1	8.13	3.9e-15	8.57e-09	0.61	0.35	Type 2 diabetes;	chr7:140872745	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs62484301	ENSG00000224775.2	BRAFP1	8.13	3.9e-15	8.57e-09	0.61	0.35	Type 2 diabetes;	chr7:140873582	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs56797136	ENSG00000224775.2	BRAFP1	8.13	3.9e-15	8.57e-09	0.61	0.35	Type 2 diabetes;	chr7:140873685	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs57248447	ENSG00000224775.2	BRAFP1	8.13	3.9e-15	8.57e-09	0.61	0.35	Type 2 diabetes;	chr7:140873695	chrX:75582676~75585506:+
THCA	trans	rs282544	0.93	rs6864477	ENSG00000231752.4	EMBP1	-8.13	3.93e-15	8.63e-09	-0.49	-0.35	Myopia (pathological);	chr5:50630366	chr1:121519112~121571892:+
THCA	trans	rs3849046	0.846	rs462783	ENSG00000226666.1	HSPA9P1	-8.13	3.97e-15	8.72e-09	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138536427	chr2:221961737~221963765:+
THCA	trans	rs7113874	0.959	rs4929948	ENSG00000266891.1	RP11-692N5.2	-8.12	3.99e-15	8.75e-09	-0.45	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8622983	chr18:9734882~9735602:-
THCA	trans	rs282544	0.965	rs55849844	ENSG00000231752.4	EMBP1	-8.12	4.01e-15	8.8e-09	-0.49	-0.35	Myopia (pathological);	chr5:50628250	chr1:121519112~121571892:+
THCA	trans	rs748404	0.588	rs2255410	ENSG00000180867.10	PDIA3P1	-8.12	4.05e-15	8.89e-09	-0.31	-0.35	Lung cancer;	chr15:43538899	chr1:147178113~147179622:+
THCA	trans	rs7113874	1	rs4256980	ENSG00000266891.1	RP11-692N5.2	-8.12	4.06e-15	8.92e-09	-0.46	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8652392	chr18:9734882~9735602:-
THCA	trans	rs7819412	0.594	rs60921132	ENSG00000253893.2	FAM85B	8.12	4.07e-15	8.93e-09	0.48	0.35	Triglycerides;	chr8:11107459	chr8:8167819~8226614:-
THCA	trans	rs282544	1	rs66912405	ENSG00000231752.4	EMBP1	-8.12	4.16e-15	9.11e-09	-0.5	-0.35	Myopia (pathological);	chr5:50666332	chr1:121519112~121571892:+
THCA	trans	rs282544	1	rs12153387	ENSG00000231752.4	EMBP1	-8.12	4.16e-15	9.12e-09	-0.49	-0.35	Myopia (pathological);	chr5:50662771	chr1:121519112~121571892:+
THCA	trans	rs73108077	0.736	rs6061028	ENSG00000279352.1	RP11-411B10.7	8.12	4.17e-15	9.14e-09	0.63	0.35	Red blood cell density in sickle cell anemia;	chr20:31285774	chr18:14010054~14010917:+
THCA	trans	rs74781061	0.722	rs4073149	ENSG00000227288.3	RP5-837I24.1	-8.12	4.17e-15	9.15e-09	-0.53	-0.35	Endometriosis;	chr15:74606078	chr1:81501794~81503468:+
THCA	trans	rs9858542	0.953	rs11926781	ENSG00000197582.5	GPX1P1	-8.12	4.18e-15	9.15e-09	-0.54	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49565856	chrX:13378735~13379340:-
THCA	trans	rs12145833	1	rs61833916	ENSG00000154608.12	CEP170P1	-8.11	4.3e-15	9.41e-09	-0.46	-0.35	Obesity (early onset extreme);	chr1:243306644	chr4:118467590~118554204:+
THCA	trans	rs11098499	0.58	rs12509234	ENSG00000253326.2	RP11-261C10.7	8.11	4.3e-15	9.42e-09	0.5	0.35	Corneal astigmatism;	chr4:119398279	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs10014719	ENSG00000253326.2	RP11-261C10.7	8.11	4.3e-15	9.42e-09	0.5	0.35	Corneal astigmatism;	chr4:119399560	chr1:243054861~243056394:-
THCA	trans	rs7113874	0.625	rs16938253	ENSG00000266891.1	RP11-692N5.2	8.11	4.34e-15	9.51e-09	0.53	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8478833	chr18:9734882~9735602:-
THCA	trans	rs282544	1	rs55932149	ENSG00000231752.4	EMBP1	-8.11	4.36e-15	9.54e-09	-0.49	-0.35	Myopia (pathological);	chr5:50687303	chr1:121519112~121571892:+
THCA	trans	rs282544	1	rs11954386	ENSG00000231752.4	EMBP1	-8.11	4.36e-15	9.54e-09	-0.49	-0.35	Myopia (pathological);	chr5:50689818	chr1:121519112~121571892:+
THCA	trans	rs2060793	0.741	rs10741656	ENSG00000236360.2	RP11-334A14.2	8.11	4.4e-15	9.62e-09	0.47	0.35	Vitamin D levels;	chr11:14803699	chr1:52993201~52993702:-
THCA	trans	rs4879656	0.564	rs1537253	ENSG00000215007.3	DNAJA1P3	-8.11	4.41e-15	9.66e-09	-0.41	-0.35	Menopause (age at onset);	chr9:32983373	chrX:107351650~107352843:-
THCA	trans	rs7113874	1	rs6486253	ENSG00000266891.1	RP11-692N5.2	-8.11	4.43e-15	9.69e-09	-0.45	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8646803	chr18:9734882~9735602:-
THCA	trans	rs7113874	1	rs10840100	ENSG00000266891.1	RP11-692N5.2	8.11	4.44e-15	9.71e-09	0.45	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8647890	chr18:9734882~9735602:-
THCA	trans	rs12145833	1	rs76473275	ENSG00000154608.12	CEP170P1	-8.11	4.55e-15	9.94e-09	-0.46	-0.35	Obesity (early onset extreme);	chr1:243297253	chr4:118467590~118554204:+
THCA	trans	rs3849046	0.846	rs154076	ENSG00000226666.1	HSPA9P1	-8.11	4.58e-15	1e-08	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138527445	chr2:221961737~221963765:+
THCA	trans	rs7824557	0.564	rs12547100	ENSG00000253893.2	FAM85B	8.11	4.59e-15	1e-08	0.47	0.35	Retinal vascular caliber;	chr8:11385123	chr8:8167819~8226614:-
THCA	trans	rs740160	0.51	rs6958704	ENSG00000228834.1	RP11-249L21.4	8.11	4.6e-15	1e-08	0.68	0.35	Dehydroepiandrosterone sulphate levels;	chr7:99300735	chr6:108907615~108907873:-
THCA	trans	rs3849046	0.79	rs188731	ENSG00000226666.1	HSPA9P1	8.1	4.6e-15	1e-08	0.37	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138545415	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.619	rs181919	ENSG00000226666.1	HSPA9P1	8.1	4.6e-15	1e-08	0.37	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138546923	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.875	rs255999	ENSG00000226666.1	HSPA9P1	8.1	4.6e-15	1e-08	0.37	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138554110	chr2:221961737~221963765:+
THCA	trans	rs11098499	0.908	rs7695996	ENSG00000253326.2	RP11-261C10.7	8.1	4.64e-15	1.01e-08	0.5	0.35	Corneal astigmatism;	chr4:119400878	chr1:243054861~243056394:-
THCA	trans	rs7113874	0.802	rs10769938	ENSG00000266891.1	RP11-692N5.2	8.1	4.65e-15	1.01e-08	0.46	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8650000	chr18:9734882~9735602:-
THCA	trans	rs12145833	1	rs10926984	ENSG00000154608.12	CEP170P1	-8.1	4.65e-15	1.01e-08	-0.46	-0.35	Obesity (early onset extreme);	chr1:243298851	chr4:118467590~118554204:+
THCA	trans	rs7937890	0.506	rs10741655	ENSG00000236360.2	RP11-334A14.2	8.1	4.66e-15	1.02e-08	0.47	0.35	Mitochondrial DNA levels;	chr11:14746838	chr1:52993201~52993702:-
THCA	trans	rs9425766	1	rs9425766	ENSG00000213331.4	RP11-713C19.2	8.1	4.66e-15	1.02e-08	0.45	0.35	Life satisfaction;	chr1:173883989	chr4:187970273~187971284:+
THCA	trans	rs7647973	1	rs6774724	ENSG00000197582.5	GPX1P1	8.1	4.72e-15	1.03e-08	0.56	0.35	Menarche (age at onset);	chr3:49344478	chrX:13378735~13379340:-
THCA	trans	rs9648716	1	rs10263448	ENSG00000224775.2	BRAFP1	8.1	4.73e-15	1.03e-08	0.6	0.35	Type 2 diabetes;	chr7:140918213	chrX:75582676~75585506:+
THCA	trans	rs7113874	0.802	rs4272783	ENSG00000266891.1	RP11-692N5.2	8.1	4.75e-15	1.04e-08	0.46	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8663846	chr18:9734882~9735602:-
THCA	trans	rs9292918	1	rs9292918	ENSG00000231752.4	EMBP1	8.1	4.77e-15	1.04e-08	0.52	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45300933	chr1:121519112~121571892:+
THCA	trans	rs10435719	0.753	rs9694940	ENSG00000256560.1	LINC01486	8.1	4.82e-15	1.05e-08	0.44	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr12:109354083~109359488:-
THCA	trans	rs3849046	0.781	rs11745065	ENSG00000226666.1	HSPA9P1	-8.1	4.85e-15	1.06e-08	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138603481	chr2:221961737~221963765:+
THCA	trans	rs9425766	0.85	rs7349095	ENSG00000213331.4	RP11-713C19.2	8.1	4.88e-15	1.06e-08	0.45	0.35	Life satisfaction;	chr1:173887899	chr4:187970273~187971284:+
THCA	trans	rs6424115	1	rs4237	ENSG00000228217.1	AL390877.1	-8.09	4.97e-15	1.08e-08	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23787639	chr1:117778087~117778506:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000204652.6	RPS26P8	8.09	4.98e-15	1.08e-08	0.47	0.35	Cognitive function;	chr12:55981353	chr17:45608571~45608918:+
THCA	trans	rs877636	0.702	rs773111	ENSG00000204652.6	RPS26P8	8.09	4.98e-15	1.08e-08	0.47	0.35	Cognitive function;	chr12:55981956	chr17:45608571~45608918:+
THCA	trans	rs61990749	1	rs4533193	ENSG00000235400.1	RP4-641G12.4	-8.09	5.07e-15	1.1e-08	-0.71	-0.35	Fibroblast growth factor basic levels;	chr14:77913825	chr1:78749073~78750659:+
THCA	trans	rs11098499	0.954	rs10008392	ENSG00000253326.2	RP11-261C10.7	8.09	5.11e-15	1.11e-08	0.5	0.35	Corneal astigmatism;	chr4:119397684	chr1:243054861~243056394:-
THCA	trans	rs9648716	0.935	rs7791924	ENSG00000224775.2	BRAFP1	8.09	5.14e-15	1.12e-08	0.6	0.35	Type 2 diabetes;	chr7:140878270	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs10244133	ENSG00000224775.2	BRAFP1	8.09	5.14e-15	1.12e-08	0.6	0.35	Type 2 diabetes;	chr7:140903529	chrX:75582676~75585506:+
THCA	trans	rs2898290	0.593	rs2199690	ENSG00000253893.2	FAM85B	8.09	5.16e-15	1.12e-08	0.47	0.35	Systolic blood pressure;	chr8:11482107	chr8:8167819~8226614:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000243538.1	CTB-55B8.1	-8.09	5.16e-15	1.12e-08	-0.44	-0.35	Cognitive function;	chr12:55996852	chr5:16902294~16902641:-
THCA	trans	rs9650657	0.617	rs7814795	ENSG00000253893.2	FAM85B	8.09	5.18e-15	1.13e-08	0.43	0.35	Neuroticism;	chr8:10661775	chr8:8167819~8226614:-
THCA	trans	rs867371	0.826	rs2047678	ENSG00000235370.6	DNM1P51	-8.09	5.27e-15	1.14e-08	-0.43	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:84398316~84411701:-
THCA	trans	rs10870270	1	rs10870292	ENSG00000197358.9	BNIP3P1	8.09	5.3e-15	1.15e-08	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131957278	chr14:28264390~28265974:+
THCA	trans	rs7937890	0.505	rs9971395	ENSG00000236360.2	RP11-334A14.2	8.08	5.35e-15	1.16e-08	0.47	0.35	Mitochondrial DNA levels;	chr11:14745580	chr1:52993201~52993702:-
THCA	trans	rs7819412	0.608	rs17780806	ENSG00000253893.2	FAM85B	8.08	5.37e-15	1.17e-08	0.48	0.35	Triglycerides;	chr8:11118119	chr8:8167819~8226614:-
THCA	trans	rs1023500	1	rs1023500	ENSG00000268568.1	AC007228.9	8.08	5.4e-15	1.17e-08	0.47	0.35	Schizophrenia;	chr22:41944840	chr19:56672574~56673901:-
THCA	trans	rs10870270	1	rs72636963	ENSG00000197358.9	BNIP3P1	8.08	5.41e-15	1.17e-08	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131957767	chr14:28264390~28265974:+
THCA	trans	rs867371	0.82	rs7164362	ENSG00000235370.6	DNM1P51	-8.08	5.42e-15	1.18e-08	-0.43	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:84398316~84411701:-
THCA	trans	rs7121616	0.576	rs4936767	ENSG00000229091.2	HSPA8P8	8.08	5.48e-15	1.19e-08	0.44	0.35	Breast cancer;	chr11:123047451	chr7:10451311~10452526:+
THCA	trans	rs9648716	1	rs1267612	ENSG00000224775.2	BRAFP1	8.08	5.52e-15	1.2e-08	0.6	0.35	Type 2 diabetes;	chr7:140811960	chrX:75582676~75585506:+
THCA	trans	rs2060793	0.741	rs2060794	ENSG00000236360.2	RP11-334A14.2	8.08	5.52e-15	1.2e-08	0.47	0.35	Vitamin D levels;	chr11:14791437	chr1:52993201~52993702:-
THCA	trans	rs2060793	0.741	rs3740823	ENSG00000236360.2	RP11-334A14.2	8.08	5.52e-15	1.2e-08	0.47	0.35	Vitamin D levels;	chr11:14804158	chr1:52993201~52993702:-
THCA	trans	rs73108077	0.736	rs6057603	ENSG00000279352.1	RP11-411B10.7	-8.08	5.53e-15	1.2e-08	-0.6	-0.35	Red blood cell density in sickle cell anemia;	chr20:31354892	chr18:14010054~14010917:+
THCA	trans	rs11098499	0.866	rs72676074	ENSG00000253326.2	RP11-261C10.7	8.08	5.55e-15	1.2e-08	0.49	0.35	Corneal astigmatism;	chr4:119438686	chr1:243054861~243056394:-
THCA	trans	rs864643	0.678	rs500507	ENSG00000188856.6	RPSAP47	8.08	5.57e-15	1.21e-08	0.52	0.35	Attention deficit hyperactivity disorder;	chr3:39492886	chr8:80558870~80559757:+
THCA	trans	rs10870270	0.957	rs3753008	ENSG00000197358.9	BNIP3P1	8.08	5.59e-15	1.21e-08	0.47	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131971625	chr14:28264390~28265974:+
THCA	trans	rs9425766	0.962	rs1322777	ENSG00000213331.4	RP11-713C19.2	8.08	5.6e-15	1.21e-08	0.45	0.35	Life satisfaction;	chr1:173889962	chr4:187970273~187971284:+
THCA	trans	rs864643	0.678	rs1768206	ENSG00000183298.5	RP11-556K13.1	8.08	5.61e-15	1.22e-08	0.6	0.35	Attention deficit hyperactivity disorder;	chr3:39480342	chr1:101786340~101787219:-
THCA	trans	rs748404	0.56	rs689797	ENSG00000180867.10	PDIA3P1	-8.08	5.65e-15	1.23e-08	-0.3	-0.35	Lung cancer;	chr15:43534359	chr1:147178113~147179622:+
THCA	trans	rs748404	0.56	rs2255663	ENSG00000180867.10	PDIA3P1	8.08	5.65e-15	1.23e-08	0.3	0.35	Lung cancer;	chr15:43536810	chr1:147178113~147179622:+
THCA	trans	rs7113874	0.959	rs4929928	ENSG00000266891.1	RP11-692N5.2	-8.08	5.66e-15	1.23e-08	-0.45	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8653539	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.921	rs34867877	ENSG00000266891.1	RP11-692N5.2	-8.08	5.66e-15	1.23e-08	-0.45	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8655654	chr18:9734882~9735602:-
THCA	trans	rs12709013	0.729	rs34324769	ENSG00000230849.2	GOT2P2	8.08	5.68e-15	1.23e-08	0.44	0.35	Blood metabolite ratios;	chr16:58778131	chr1:173141100~173142350:-
THCA	trans	rs7824557	0.545	rs2572450	ENSG00000253893.2	FAM85B	8.07	5.75e-15	1.25e-08	0.47	0.35	Retinal vascular caliber;	chr8:11372129	chr8:8167819~8226614:-
THCA	trans	rs11250098	0.51	rs4840525	ENSG00000253893.2	FAM85B	8.07	5.78e-15	1.25e-08	0.43	0.35	Morning vs. evening chronotype;	chr8:10908125	chr8:8167819~8226614:-
THCA	trans	rs73108077	0.736	rs732860	ENSG00000279352.1	RP11-411B10.7	8.07	5.82e-15	1.26e-08	0.63	0.35	Red blood cell density in sickle cell anemia;	chr20:31269641	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs6121224	ENSG00000279352.1	RP11-411B10.7	8.07	5.82e-15	1.26e-08	0.63	0.35	Red blood cell density in sickle cell anemia;	chr20:31272881	chr18:14010054~14010917:+
THCA	trans	rs864643	0.513	rs481523	ENSG00000183298.5	RP11-556K13.1	8.07	5.83e-15	1.26e-08	0.57	0.35	Attention deficit hyperactivity disorder;	chr3:39477849	chr1:101786340~101787219:-
THCA	trans	rs282544	1	rs12055210	ENSG00000231752.4	EMBP1	-8.07	5.86e-15	1.27e-08	-0.49	-0.35	Myopia (pathological);	chr5:50693867	chr1:121519112~121571892:+
THCA	trans	rs282544	1	rs12186752	ENSG00000231752.4	EMBP1	-8.07	5.86e-15	1.27e-08	-0.49	-0.35	Myopia (pathological);	chr5:50697648	chr1:121519112~121571892:+
THCA	trans	rs2243480	0.706	rs6460257	ENSG00000273142.1	RP11-458F8.4	-8.07	5.87e-15	1.27e-08	-0.4	-0.35	Diabetic kidney disease;	chr7:65731813	chr7:66902857~66906297:+
THCA	trans	rs7113874	1	rs4929925	ENSG00000266891.1	RP11-692N5.2	-8.07	6.01e-15	1.3e-08	-0.45	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8633640	chr18:9734882~9735602:-
THCA	trans	rs6424115	0.931	rs2473377	ENSG00000228217.1	AL390877.1	-8.07	6.05e-15	1.31e-08	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23821770	chr1:117778087~117778506:-
THCA	trans	rs9650657	0.707	rs11250076	ENSG00000253893.2	FAM85B	8.07	6.06e-15	1.31e-08	0.44	0.35	Neuroticism;	chr8:10790313	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000234354.3	RPS26P47	8.07	6.07e-15	1.31e-08	0.49	0.35	Cognitive function;	chr12:55976127	chr13:100539901~100540248:-
THCA	trans	rs7113874	0.625	rs10743073	ENSG00000266891.1	RP11-692N5.2	-8.07	6.11e-15	1.32e-08	-0.49	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483072	chr18:9734882~9735602:-
THCA	trans	rs10870270	0.83	rs10781571	ENSG00000197358.9	BNIP3P1	8.06	6.18e-15	1.34e-08	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131960812	chr14:28264390~28265974:+
THCA	trans	rs28647808	0.881	rs41316982	ENSG00000234981.1	RP11-534L20.4	8.06	6.29e-15	1.36e-08	0.64	0.35	Blood protein levels;	chr9:133393990	chr1:206528915~206529706:+
THCA	trans	rs7824557	0.564	rs13268126	ENSG00000253893.2	FAM85B	8.06	6.32e-15	1.37e-08	0.46	0.35	Retinal vascular caliber;	chr8:11373065	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs4919740	ENSG00000248568.1	KRT8P48	-8.06	6.35e-15	1.37e-08	-0.67	-0.35	Prostate cancer;	chr12:52877187	chr5:146706381~146707600:-
THCA	trans	rs7824557	0.564	rs55758514	ENSG00000253893.2	FAM85B	8.06	6.35e-15	1.37e-08	0.46	0.35	Retinal vascular caliber;	chr8:11372750	chr8:8167819~8226614:-
THCA	trans	rs282544	0.965	rs2354533	ENSG00000231752.4	EMBP1	-8.06	6.46e-15	1.39e-08	-0.49	-0.35	Myopia (pathological);	chr5:50676103	chr1:121519112~121571892:+
THCA	trans	rs35851103	0.627	rs6601644	ENSG00000256560.1	LINC01486	8.06	6.52e-15	1.41e-08	0.42	0.35	Neuroticism;	chr8:11989569	chr12:109354083~109359488:-
THCA	trans	rs2060793	0.712	rs10741654	ENSG00000236360.2	RP11-334A14.2	8.05	6.6e-15	1.42e-08	0.47	0.35	Vitamin D levels;	chr11:14726506	chr1:52993201~52993702:-
THCA	trans	rs3849046	0.746	rs1811371	ENSG00000226666.1	HSPA9P1	-8.05	6.63e-15	1.43e-08	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138601216	chr2:221961737~221963765:+
THCA	trans	rs902774	0.818	rs55958994	ENSG00000224520.2	KRT8P45	-8.05	6.67e-15	1.44e-08	-0.72	-0.35	Prostate cancer;	chr12:52907235	chr1:157073257~157074703:+
THCA	trans	rs9648716	1	rs10261732	ENSG00000224775.2	BRAFP1	8.05	6.69e-15	1.44e-08	0.6	0.35	Type 2 diabetes;	chr7:140870345	chrX:75582676~75585506:+
THCA	trans	rs877636	0.702	rs773108	ENSG00000204652.6	RPS26P8	8.05	6.7e-15	1.44e-08	0.48	0.35	Cognitive function;	chr12:55976127	chr17:45608571~45608918:+
THCA	trans	rs10816533	1	rs10119556	ENSG00000232063.1	RP11-307E17.8	8.05	6.7e-15	1.45e-08	0.83	0.35	Height;	chr9:96789704	chr9:94332476~94360948:+
THCA	trans	rs804280	0.509	rs7461273	ENSG00000256560.1	LINC01486	8.05	6.75e-15	1.45e-08	0.44	0.35	Myopia (pathological);	chr8:11920468	chr12:109354083~109359488:-
THCA	trans	rs58106596	0.8	rs11693819	ENSG00000259020.3	RP11-529H20.3	8.05	6.75e-15	1.46e-08	0.58	0.35	Lymphocyte counts;White blood cell count;	chr2:231701496	chr14:92026566~92026887:+
THCA	trans	rs10242455	0.867	rs2037499	ENSG00000228834.1	RP11-249L21.4	-8.05	6.76e-15	1.46e-08	-0.64	-0.35	Blood metabolite levels;	chr7:99715030	chr6:108907615~108907873:-
THCA	trans	rs7113874	0.921	rs10769931	ENSG00000266891.1	RP11-692N5.2	-8.05	6.77e-15	1.46e-08	-0.45	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8614558	chr18:9734882~9735602:-
THCA	trans	rs10870270	1	rs10159943	ENSG00000197358.9	BNIP3P1	8.05	6.77e-15	1.46e-08	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131931240	chr14:28264390~28265974:+
THCA	trans	rs9648716	1	rs10255711	ENSG00000224775.2	BRAFP1	8.05	6.79e-15	1.46e-08	0.6	0.35	Type 2 diabetes;	chr7:140908676	chrX:75582676~75585506:+
THCA	trans	rs10435719	0.809	rs77601743	ENSG00000256560.1	LINC01486	8.05	6.8e-15	1.46e-08	0.45	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933060	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.678	rs74724594	ENSG00000256560.1	LINC01486	8.05	6.8e-15	1.46e-08	0.45	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933067	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.702	rs77055881	ENSG00000256560.1	LINC01486	8.05	6.8e-15	1.46e-08	0.45	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933072	chr12:109354083~109359488:-
THCA	trans	rs282544	1	rs3864235	ENSG00000231752.4	EMBP1	-8.05	6.82e-15	1.47e-08	-0.49	-0.35	Myopia (pathological);	chr5:50649640	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.569	rs2409718	ENSG00000229857.1	RP11-159H20.3	8.05	6.83e-15	1.47e-08	0.44	0.35	Retinal vascular caliber;	chr8:11155467	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.564	rs34964435	ENSG00000253893.2	FAM85B	8.05	6.84e-15	1.47e-08	0.46	0.35	Retinal vascular caliber;	chr8:11372697	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.885	rs11042016	ENSG00000266891.1	RP11-692N5.2	-8.05	6.96e-15	1.5e-08	-0.45	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625577	chr18:9734882~9735602:-
THCA	trans	rs14057	0.929	rs12145525	ENSG00000215869.3	RP11-364B6.1	8.05	7.02e-15	1.51e-08	0.49	0.35	Systolic blood pressure;	chr1:6651086	chr1:104073023~104077087:+
THCA	trans	rs72615157	0.697	rs2056726	ENSG00000228546.2	CTA-313A17.3	8.05	7.03e-15	1.51e-08	0.55	0.35	Lung function (FEV1/FVC);	chr7:100182660	chr7:102337316~102339115:+
THCA	trans	rs9292918	0.901	rs6874677	ENSG00000231752.4	EMBP1	8.05	7.03e-15	1.51e-08	0.53	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45393450	chr1:121519112~121571892:+
THCA	trans	rs867371	0.929	rs1501371	ENSG00000235370.6	DNM1P51	-8.05	7.03e-15	1.51e-08	-0.44	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:84398316~84411701:-
THCA	trans	rs9648716	1	rs17161762	ENSG00000224775.2	BRAFP1	8.05	7.09e-15	1.52e-08	0.6	0.35	Type 2 diabetes;	chr7:140889408	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs17161763	ENSG00000224775.2	BRAFP1	8.05	7.09e-15	1.52e-08	0.6	0.35	Type 2 diabetes;	chr7:140889439	chrX:75582676~75585506:+
THCA	trans	rs7824557	0.544	rs1865521	ENSG00000253893.2	FAM85B	-8.04	7.12e-15	1.53e-08	-0.46	-0.35	Retinal vascular caliber;	chr8:11373740	chr8:8167819~8226614:-
THCA	trans	rs7113874	1	rs36092927	ENSG00000266891.1	RP11-692N5.2	8.04	7.12e-15	1.53e-08	0.45	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8670792	chr18:9734882~9735602:-
THCA	trans	rs4929949	0.565	rs11517718	ENSG00000266891.1	RP11-692N5.2	8.04	7.12e-15	1.53e-08	0.45	0.35	Body mass index;	chr11:8671858	chr18:9734882~9735602:-
THCA	trans	rs9648716	0.81	rs6944039	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140884217	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6948703	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140884638	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6954652	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140886071	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs10251380	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140887095	chrX:75582676~75585506:+
THCA	trans	rs9648716	0.873	rs10251793	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140887369	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs10255130	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140887833	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs62485365	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140888415	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6966197	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140897429	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6965532	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140897716	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs7800472	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140900334	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs7796827	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140902043	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs7798031	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140902799	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs7793758	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140904196	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs59055264	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140905073	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs7776491	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140905267	chrX:75582676~75585506:+
THCA	trans	rs9648716	0.872	rs6964937	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140909890	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs9648715	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140912045	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs9648716	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140912363	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6962239	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140914119	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6961127	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140914152	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6944385	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140914587	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs28529157	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140915030	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs10232600	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140919517	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs7785306	ENSG00000224775.2	BRAFP1	8.04	7.17e-15	1.54e-08	0.6	0.35	Type 2 diabetes;	chr7:140919688	chrX:75582676~75585506:+
THCA	trans	rs902774	0.818	rs17120257	ENSG00000224520.2	KRT8P45	-8.04	7.18e-15	1.54e-08	-0.72	-0.35	Prostate cancer;	chr12:52909547	chr1:157073257~157074703:+
THCA	trans	rs8067354	0.54	rs7221472	ENSG00000187870.7	RNFT1P3	8.04	7.26e-15	1.56e-08	0.57	0.35	Hemoglobin concentration;	chr17:59959376	chr17:20743333~20754501:-
THCA	trans	rs2060793	0.741	rs4344519	ENSG00000236360.2	RP11-334A14.2	8.04	7.36e-15	1.58e-08	0.47	0.35	Vitamin D levels;	chr11:14701347	chr1:52993201~52993702:-
THCA	trans	rs2645424	0.866	rs2645426	ENSG00000256560.1	LINC01486	-8.04	7.39e-15	1.58e-08	-0.43	-0.35	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11825262	chr12:109354083~109359488:-
THCA	trans	rs7113874	1	rs2316901	ENSG00000266891.1	RP11-692N5.2	8.03	7.64e-15	1.64e-08	0.45	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8657469	chr18:9734882~9735602:-
THCA	trans	rs7113874	1	rs7113874	ENSG00000266891.1	RP11-692N5.2	8.03	7.64e-15	1.64e-08	0.45	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8666469	chr18:9734882~9735602:-
THCA	trans	rs7113874	1	rs7126235	ENSG00000266891.1	RP11-692N5.2	8.03	7.64e-15	1.64e-08	0.45	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8667789	chr18:9734882~9735602:-
THCA	trans	rs3849046	0.817	rs409273	ENSG00000226666.1	HSPA9P1	-8.03	7.69e-15	1.65e-08	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138578193	chr2:221961737~221963765:+
THCA	trans	rs877636	0.702	rs773109	ENSG00000243538.1	CTB-55B8.1	8.03	7.76e-15	1.66e-08	0.44	0.35	Cognitive function;	chr12:55980911	chr5:16902294~16902641:-
THCA	trans	rs3849046	0.846	rs256002	ENSG00000226666.1	HSPA9P1	8.03	7.78e-15	1.67e-08	0.37	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138559529	chr2:221961737~221963765:+
THCA	trans	rs73108077	0.688	rs6058752	ENSG00000279352.1	RP11-411B10.7	8.03	7.81e-15	1.67e-08	0.6	0.35	Red blood cell density in sickle cell anemia;	chr20:31353900	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.688	rs60840652	ENSG00000279352.1	RP11-411B10.7	8.03	7.81e-15	1.67e-08	0.6	0.35	Red blood cell density in sickle cell anemia;	chr20:31354399	chr18:14010054~14010917:+
THCA	trans	rs864643	0.513	rs1707956	ENSG00000183298.5	RP11-556K13.1	-8.03	7.94e-15	1.7e-08	-0.56	-0.35	Attention deficit hyperactivity disorder;	chr3:39482025	chr1:101786340~101787219:-
THCA	trans	rs864643	0.588	rs604869	ENSG00000183298.5	RP11-556K13.1	8.03	7.94e-15	1.7e-08	0.56	0.35	Attention deficit hyperactivity disorder;	chr3:39486307	chr1:101786340~101787219:-
THCA	trans	rs9425766	0.962	rs6663875	ENSG00000213331.4	RP11-713C19.2	8.03	7.95e-15	1.7e-08	0.44	0.35	Life satisfaction;	chr1:173894071	chr4:187970273~187971284:+
THCA	trans	rs6424115	0.931	rs2982390	ENSG00000228217.1	AL390877.1	-8.03	7.95e-15	1.7e-08	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23821340	chr1:117778087~117778506:-
THCA	trans	rs7824557	0.583	rs4448232	ENSG00000253893.2	FAM85B	-8.03	7.97e-15	1.71e-08	-0.46	-0.35	Retinal vascular caliber;	chr8:11373845	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.592	rs12808779	ENSG00000266891.1	RP11-692N5.2	8.03	7.97e-15	1.71e-08	0.52	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8416280	chr18:9734882~9735602:-
THCA	trans	rs941207	0.724	rs4788	ENSG00000257210.1	NACAP3	8.03	7.99e-15	1.71e-08	0.46	0.35	Platelet count;	chr12:56712876	chr12:93124063~93124543:-
THCA	trans	rs9650657	0.74	rs34653170	ENSG00000253893.2	FAM85B	8.03	8.02e-15	1.72e-08	0.45	0.35	Neuroticism;	chr8:10819032	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.954	rs10017543	ENSG00000253326.2	RP11-261C10.7	8.03	8.05e-15	1.72e-08	0.49	0.35	Corneal astigmatism;	chr4:119400265	chr1:243054861~243056394:-
THCA	trans	rs2645424	0.604	rs9644756	ENSG00000229857.1	RP11-159H20.3	-8.03	8.1e-15	1.73e-08	-0.44	-0.35	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11857591	chr9:76992099~76993108:+
THCA	trans	rs877636	0.702	rs61937249	ENSG00000204652.6	RPS26P8	8.03	8.13e-15	1.74e-08	0.47	0.35	Cognitive function;	chr12:55988132	chr17:45608571~45608918:+
THCA	trans	rs9648716	0.938	rs11981790	ENSG00000224775.2	BRAFP1	8.03	8.14e-15	1.74e-08	0.6	0.35	Type 2 diabetes;	chr7:140888584	chrX:75582676~75585506:+
THCA	trans	rs10870270	0.913	rs4880326	ENSG00000197358.9	BNIP3P1	8.03	8.14e-15	1.74e-08	0.47	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131932043	chr14:28264390~28265974:+
THCA	trans	rs10870270	0.956	rs10781555	ENSG00000197358.9	BNIP3P1	8.03	8.14e-15	1.74e-08	0.47	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131932216	chr14:28264390~28265974:+
THCA	trans	rs7824557	0.564	rs11781637	ENSG00000253893.2	FAM85B	8.03	8.18e-15	1.75e-08	0.45	0.35	Retinal vascular caliber;	chr8:11357463	chr8:8167819~8226614:-
THCA	trans	rs864643	0.838	rs58141864	ENSG00000188856.6	RPSAP47	8.02	8.19e-15	1.75e-08	0.67	0.35	Attention deficit hyperactivity disorder;	chr3:39505344	chr8:80558870~80559757:+
THCA	trans	rs2134046	0.587	rs11854289	ENSG00000235370.6	DNM1P51	8.02	8.27e-15	1.77e-08	0.45	0.35	Cognitive ability;	chr15:82266461	chr15:84398316~84411701:-
THCA	trans	rs7937890	0.695	rs17557844	ENSG00000236360.2	RP11-334A14.2	-8.02	8.42e-15	1.8e-08	-0.49	-0.35	Mitochondrial DNA levels;	chr11:14241013	chr1:52993201~52993702:-
THCA	trans	rs3849046	0.817	rs68128065	ENSG00000226666.1	HSPA9P1	-8.02	8.42e-15	1.8e-08	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138590778	chr2:221961737~221963765:+
THCA	trans	rs2645424	1	rs2645424	ENSG00000229857.1	RP11-159H20.3	8.02	8.42e-15	1.8e-08	0.43	0.35	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826954	chr9:76992099~76993108:+
THCA	trans	rs2060793	0.712	rs11023310	ENSG00000236360.2	RP11-334A14.2	8.02	8.43e-15	1.8e-08	0.46	0.35	Vitamin D levels;	chr11:14703717	chr1:52993201~52993702:-
THCA	trans	rs877636	1	rs2292239	ENSG00000204652.6	RPS26P8	8.02	8.5e-15	1.81e-08	0.46	0.35	Cognitive function;	chr12:56088396	chr17:45608571~45608918:+
THCA	trans	rs7819412	0.745	rs4841498	ENSG00000229857.1	RP11-159H20.3	8.02	8.5e-15	1.81e-08	0.44	0.35	Triglycerides;	chr8:11127922	chr9:76992099~76993108:+
THCA	trans	rs2060793	0.506	rs10741658	ENSG00000236360.2	RP11-334A14.2	8.02	8.57e-15	1.83e-08	0.45	0.35	Vitamin D levels;	chr11:14903190	chr1:52993201~52993702:-
THCA	trans	rs8067354	0.574	rs2531898	ENSG00000187870.7	RNFT1P3	8.02	8.57e-15	1.83e-08	0.57	0.35	Hemoglobin concentration;	chr17:59934990	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.574	rs9789060	ENSG00000187870.7	RNFT1P3	8.02	8.57e-15	1.83e-08	0.57	0.35	Hemoglobin concentration;	chr17:59941209	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.574	rs7219089	ENSG00000187870.7	RNFT1P3	8.02	8.57e-15	1.83e-08	0.57	0.35	Hemoglobin concentration;	chr17:59955504	chr17:20743333~20754501:-
THCA	trans	rs9329221	0.543	rs2952205	ENSG00000253893.2	FAM85B	-8.02	8.62e-15	1.84e-08	-0.43	-0.35	Neuroticism;	chr8:10282355	chr8:8167819~8226614:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000227887.1	RPS26P13	-8.02	8.62e-15	1.84e-08	-0.5	-0.35	Asthma;	chr12:55970537	chr1:208697369~208697698:-
THCA	trans	rs2060793	0.741	rs7119073	ENSG00000236360.2	RP11-334A14.2	8.02	8.64e-15	1.84e-08	0.46	0.35	Vitamin D levels;	chr11:14669416	chr1:52993201~52993702:-
THCA	trans	rs2060793	0.741	rs10741653	ENSG00000236360.2	RP11-334A14.2	8.02	8.64e-15	1.84e-08	0.46	0.35	Vitamin D levels;	chr11:14683294	chr1:52993201~52993702:-
THCA	trans	rs9650657	0.707	rs10098699	ENSG00000253893.2	FAM85B	8.02	8.71e-15	1.86e-08	0.45	0.35	Neuroticism;	chr8:10819246	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs34389419	ENSG00000253893.2	FAM85B	8.02	8.79e-15	1.87e-08	0.47	0.35	Retinal vascular caliber;	chr8:11371810	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.846	rs256014	ENSG00000226666.1	HSPA9P1	8.01	8.87e-15	1.89e-08	0.37	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138567395	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.81	rs11957778	ENSG00000226666.1	HSPA9P1	-8.01	8.87e-15	1.89e-08	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138582137	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.846	rs11738995	ENSG00000226666.1	HSPA9P1	-8.01	8.87e-15	1.89e-08	-0.37	-0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138591930	chr2:221961737~221963765:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000233278.1	RPS26P2	8.01	8.87e-15	1.89e-08	0.4	0.35	Cognitive function;	chr12:56076841	chr9:30831878~30832225:-
THCA	trans	rs7113874	0.659	rs1867810	ENSG00000266891.1	RP11-692N5.2	8.01	8.93e-15	1.9e-08	0.48	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483981	chr18:9734882~9735602:-
THCA	trans	rs9648716	0.808	rs6953658	ENSG00000224775.2	BRAFP1	8.01	8.95e-15	1.91e-08	0.59	0.35	Type 2 diabetes;	chr7:140767295	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267637	ENSG00000224775.2	BRAFP1	8.01	8.95e-15	1.91e-08	0.59	0.35	Type 2 diabetes;	chr7:140773538	chrX:75582676~75585506:+
THCA	trans	rs804280	0.509	rs35626932	ENSG00000256560.1	LINC01486	8.01	9e-15	1.92e-08	0.44	0.35	Myopia (pathological);	chr8:11929423	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.954	rs28572238	ENSG00000253326.2	RP11-261C10.7	8.01	9.09e-15	1.93e-08	0.49	0.35	Corneal astigmatism;	chr4:119395531	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs28714195	ENSG00000253326.2	RP11-261C10.7	8.01	9.09e-15	1.93e-08	0.49	0.35	Corneal astigmatism;	chr4:119395795	chr1:243054861~243056394:-
THCA	trans	rs941207	0.724	rs1979325	ENSG00000257210.1	NACAP3	8.01	9.1e-15	1.94e-08	0.46	0.35	Platelet count;	chr12:56728152	chr12:93124063~93124543:-
THCA	trans	rs13016963	0.564	rs2110690	ENSG00000235105.1	RP11-329A14.1	8.01	9.22e-15	1.96e-08	0.37	0.35	Esophageal squamous cell carcinoma;Melanoma;	chr2:201320409	chr1:48435967~48437223:+
THCA	trans	rs6424115	1	rs58035855	ENSG00000228217.1	AL390877.1	8.01	9.24e-15	1.97e-08	0.46	0.35	Immature fraction of reticulocytes;	chr1:23838758	chr1:117778087~117778506:-
THCA	trans	rs282544	0.93	rs62366908	ENSG00000231752.4	EMBP1	-8.01	9.28e-15	1.97e-08	-0.49	-0.35	Myopia (pathological);	chr5:50648089	chr1:121519112~121571892:+
THCA	trans	rs73108077	0.736	rs6058492	ENSG00000279352.1	RP11-411B10.7	8.01	9.33e-15	1.98e-08	0.62	0.35	Red blood cell density in sickle cell anemia;	chr20:31286965	chr18:14010054~14010917:+
THCA	trans	rs748404	0.56	rs570933	ENSG00000180867.10	PDIA3P1	-8.01	9.37e-15	1.99e-08	-0.3	-0.35	Lung cancer;	chr15:43531832	chr1:147178113~147179622:+
THCA	trans	rs11098499	0.909	rs71614422	ENSG00000253326.2	RP11-261C10.7	8	9.69e-15	2.06e-08	0.49	0.35	Corneal astigmatism;	chr4:119438185	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.738	rs34566984	ENSG00000253326.2	RP11-261C10.7	8	9.69e-15	2.06e-08	0.49	0.35	Corneal astigmatism;	chr4:119440115	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs17009122	ENSG00000253326.2	RP11-261C10.7	8	9.69e-15	2.06e-08	0.49	0.35	Corneal astigmatism;	chr4:119441248	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.505	rs75122014	ENSG00000253326.2	RP11-261C10.7	8	9.69e-15	2.06e-08	0.49	0.35	Corneal astigmatism;	chr4:119441271	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs9685777	ENSG00000253326.2	RP11-261C10.7	8	9.69e-15	2.06e-08	0.49	0.35	Corneal astigmatism;	chr4:119444810	chr1:243054861~243056394:-
THCA	trans	rs10870270	0.956	rs4880405	ENSG00000197358.9	BNIP3P1	8	9.72e-15	2.06e-08	0.48	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131973517	chr14:28264390~28265974:+
THCA	trans	rs7819412	0.608	rs28417109	ENSG00000253893.2	FAM85B	8	9.86e-15	2.09e-08	0.47	0.35	Triglycerides;	chr8:11117571	chr8:8167819~8226614:-
THCA	trans	rs864643	0.678	rs617068	ENSG00000188856.6	RPSAP47	-8	9.92e-15	2.1e-08	-0.52	-0.35	Attention deficit hyperactivity disorder;	chr3:39492781	chr8:80558870~80559757:+
THCA	trans	rs282544	1	rs1375128	ENSG00000231752.4	EMBP1	-8	1e-14	2.12e-08	-0.48	-0.35	Myopia (pathological);	chr5:50718840	chr1:121519112~121571892:+
THCA	trans	rs282544	1	rs10737958	ENSG00000231752.4	EMBP1	-8	1e-14	2.12e-08	-0.48	-0.35	Myopia (pathological);	chr5:50727540	chr1:121519112~121571892:+
THCA	trans	rs282544	1	rs2594708	ENSG00000231752.4	EMBP1	-8	1e-14	2.12e-08	-0.48	-0.35	Myopia (pathological);	chr5:50728834	chr1:121519112~121571892:+
THCA	trans	rs282544	1	rs2463796	ENSG00000231752.4	EMBP1	-8	1e-14	2.12e-08	-0.48	-0.35	Myopia (pathological);	chr5:50729856	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.645	rs9969657	ENSG00000253893.2	FAM85B	-8	1e-14	2.12e-08	-0.42	-0.35	Neuroticism;	chr8:10657768	chr8:8167819~8226614:-
THCA	trans	rs864643	0.574	rs1768213	ENSG00000183298.5	RP11-556K13.1	8	1.01e-14	2.13e-08	0.56	0.35	Attention deficit hyperactivity disorder;	chr3:39486790	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs493794	ENSG00000183298.5	RP11-556K13.1	8	1.01e-14	2.13e-08	0.56	0.35	Attention deficit hyperactivity disorder;	chr3:39486804	chr1:101786340~101787219:-
THCA	trans	rs28647808	0.881	rs4962139	ENSG00000234981.1	RP11-534L20.4	-8	1.01e-14	2.13e-08	-0.62	-0.35	Blood protein levels;	chr9:133402740	chr1:206528915~206529706:+
THCA	trans	rs867371	0.892	rs4344697	ENSG00000235370.6	DNM1P51	-7.99	1.03e-14	2.17e-08	-0.43	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:84398316~84411701:-
THCA	trans	rs7819412	0.538	rs4523214	ENSG00000229857.1	RP11-159H20.3	7.99	1.03e-14	2.19e-08	0.44	0.35	Triglycerides;	chr8:11113263	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.954	rs17005535	ENSG00000253326.2	RP11-261C10.7	7.99	1.04e-14	2.19e-08	0.49	0.35	Corneal astigmatism;	chr4:119490407	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.603	rs11250130	ENSG00000253893.2	FAM85B	7.99	1.04e-14	2.2e-08	0.45	0.35	Retinal vascular caliber;	chr8:11356946	chr8:8167819~8226614:-
THCA	trans	rs13016963	0.526	rs1406121	ENSG00000235105.1	RP11-329A14.1	7.99	1.05e-14	2.22e-08	0.39	0.35	Esophageal squamous cell carcinoma;Melanoma;	chr2:201330307	chr1:48435967~48437223:+
THCA	trans	rs9650657	0.645	rs4841408	ENSG00000253893.2	FAM85B	7.99	1.05e-14	2.22e-08	0.43	0.35	Neuroticism;	chr8:10658826	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.545	rs2084187	ENSG00000266891.1	RP11-692N5.2	7.99	1.06e-14	2.23e-08	0.49	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515394	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.613	rs2100067	ENSG00000266891.1	RP11-692N5.2	7.99	1.06e-14	2.23e-08	0.49	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515503	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.578	rs7924477	ENSG00000266891.1	RP11-692N5.2	7.99	1.06e-14	2.23e-08	0.49	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516700	chr18:9734882~9735602:-
THCA	trans	rs11992162	0.967	rs10108320	ENSG00000253893.2	FAM85B	7.99	1.06e-14	2.24e-08	0.46	0.35	Monocyte count;	chr8:11974754	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.908	rs71614449	ENSG00000253326.2	RP11-261C10.7	7.99	1.06e-14	2.24e-08	0.49	0.35	Corneal astigmatism;	chr4:119465900	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs35063680	ENSG00000253326.2	RP11-261C10.7	7.99	1.06e-14	2.24e-08	0.49	0.35	Corneal astigmatism;	chr4:119465947	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs34858317	ENSG00000253326.2	RP11-261C10.7	7.99	1.06e-14	2.24e-08	0.49	0.35	Corneal astigmatism;	chr4:119465955	chr1:243054861~243056394:-
THCA	trans	rs9648716	1	rs1267645	ENSG00000224775.2	BRAFP1	7.99	1.07e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140785535	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267646	ENSG00000224775.2	BRAFP1	7.99	1.07e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140785890	chrX:75582676~75585506:+
THCA	trans	rs9648716	0.935	rs1267647	ENSG00000224775.2	BRAFP1	7.99	1.07e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140786488	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267632	ENSG00000224775.2	BRAFP1	7.99	1.07e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140787402	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267634	ENSG00000224775.2	BRAFP1	7.99	1.07e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140790582	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs986050	ENSG00000224775.2	BRAFP1	7.99	1.07e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140791128	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267635	ENSG00000224775.2	BRAFP1	7.99	1.07e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140791878	chrX:75582676~75585506:+
THCA	trans	rs740160	0.558	rs73395508	ENSG00000228834.1	RP11-249L21.4	7.99	1.08e-14	2.27e-08	0.73	0.35	Dehydroepiandrosterone sulphate levels;	chr7:99304271	chr6:108907615~108907873:-
THCA	trans	rs740160	0.558	rs68164591	ENSG00000228834.1	RP11-249L21.4	7.99	1.08e-14	2.27e-08	0.73	0.35	Dehydroepiandrosterone sulphate levels;	chr7:99306817	chr6:108907615~108907873:-
THCA	trans	rs9648716	1	rs4140846	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140809916	chrX:75582676~75585506:+
THCA	trans	rs9648716	0.935	rs1267615	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140813850	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267616	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140814331	chrX:75582676~75585506:+
THCA	trans	rs9648716	0.81	rs2706775	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140819168	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs10234502	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140822753	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267623	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140834467	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267624	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140835964	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267625	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140836939	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs2535946	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140838208	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs2706774	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140838327	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6947950	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140839865	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267602	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140844604	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267603	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140844647	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs1267618	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140860218	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs10281508	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140865418	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs7792984	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140866443	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs10272940	ENSG00000224775.2	BRAFP1	7.99	1.08e-14	2.27e-08	0.59	0.35	Type 2 diabetes;	chr7:140869352	chrX:75582676~75585506:+
THCA	trans	rs11098499	0.954	rs9993199	ENSG00000253326.2	RP11-261C10.7	-7.98	1.09e-14	2.3e-08	-0.49	-0.35	Corneal astigmatism;	chr4:119471718	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.779	rs28495013	ENSG00000253326.2	RP11-261C10.7	7.98	1.11e-14	2.34e-08	0.49	0.35	Corneal astigmatism;	chr4:119454676	chr1:243054861~243056394:-
THCA	trans	rs9648716	1	rs9648696	ENSG00000224775.2	BRAFP1	7.98	1.11e-14	2.34e-08	0.59	0.35	Type 2 diabetes;	chr7:140749350	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs10282499	ENSG00000224775.2	BRAFP1	7.98	1.11e-14	2.34e-08	0.59	0.35	Type 2 diabetes;	chr7:140750034	chrX:75582676~75585506:+
THCA	trans	rs9292918	0.95	rs7735655	ENSG00000231752.4	EMBP1	7.98	1.12e-14	2.35e-08	0.51	0.35	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45309411	chr1:121519112~121571892:+
THCA	trans	rs864643	0.513	rs614823	ENSG00000183298.5	RP11-556K13.1	7.98	1.12e-14	2.35e-08	0.56	0.35	Attention deficit hyperactivity disorder;	chr3:39493267	chr1:101786340~101787219:-
THCA	trans	rs11098499	0.954	rs13133522	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119403269	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs35091806	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119404374	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs6846442	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119405168	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.738	rs34965784	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119440431	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs71614438	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119450097	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs66506550	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119450290	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs7659501	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119450397	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.657	rs71614442	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119458191	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs2892848	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119460186	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.697	rs11941899	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119461603	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs7681978	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119462620	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.821	rs28665282	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119463031	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.738	rs10026493	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119463039	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs7681214	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119464165	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.908	rs28559989	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119465472	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs28632018	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119465575	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs17046116	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119466104	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs17046118	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119466341	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs7654587	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119467251	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs11098525	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119468997	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs6838814	ENSG00000253326.2	RP11-261C10.7	7.98	1.12e-14	2.36e-08	0.49	0.35	Corneal astigmatism;	chr4:119471288	chr1:243054861~243056394:-
THCA	trans	rs7113874	0.527	rs12790154	ENSG00000266891.1	RP11-692N5.2	7.98	1.13e-14	2.37e-08	0.52	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8383601	chr18:9734882~9735602:-
THCA	trans	rs8067354	0.507	rs2645478	ENSG00000187870.7	RNFT1P3	7.98	1.13e-14	2.37e-08	0.56	0.35	Hemoglobin concentration;	chr17:59937351	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.54	rs72840315	ENSG00000187870.7	RNFT1P3	7.98	1.13e-14	2.37e-08	0.56	0.35	Hemoglobin concentration;	chr17:59940781	chr17:20743333~20754501:-
THCA	trans	rs12709013	0.716	rs6416775	ENSG00000233719.3	GOT2P3	7.98	1.14e-14	2.4e-08	0.41	0.35	Blood metabolite ratios;	chr16:58830410	chr12:9641802~9643007:+
THCA	trans	rs7824557	0.603	rs2736278	ENSG00000253893.2	FAM85B	-7.98	1.15e-14	2.42e-08	-0.47	-0.35	Retinal vascular caliber;	chr8:11362272	chr8:8167819~8226614:-
THCA	trans	rs8067354	0.574	rs1296279	ENSG00000187870.7	RNFT1P3	7.98	1.16e-14	2.43e-08	0.56	0.35	Hemoglobin concentration;	chr17:59888370	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.527	rs1292039	ENSG00000187870.7	RNFT1P3	7.98	1.16e-14	2.43e-08	0.56	0.35	Hemoglobin concentration;	chr17:59897552	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.574	rs2526353	ENSG00000187870.7	RNFT1P3	7.98	1.16e-14	2.43e-08	0.56	0.35	Hemoglobin concentration;	chr17:59911246	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.574	rs1292035	ENSG00000187870.7	RNFT1P3	7.98	1.16e-14	2.43e-08	0.56	0.35	Hemoglobin concentration;	chr17:59912196	chr17:20743333~20754501:-
THCA	trans	rs9648716	1	rs6950312	ENSG00000224775.2	BRAFP1	7.98	1.16e-14	2.44e-08	0.59	0.35	Type 2 diabetes;	chr7:140872383	chrX:75582676~75585506:+
THCA	trans	rs7647973	0.922	rs6809851	ENSG00000197582.5	GPX1P1	7.97	1.17e-14	2.46e-08	0.54	0.35	Menarche (age at onset);	chr3:49272354	chrX:13378735~13379340:-
THCA	trans	rs748404	0.66	rs2467738	ENSG00000180867.10	PDIA3P1	-7.97	1.19e-14	2.49e-08	-0.3	-0.35	Lung cancer;	chr15:43447738	chr1:147178113~147179622:+
THCA	trans	rs7819412	0.775	rs6601564	ENSG00000229857.1	RP11-159H20.3	7.97	1.19e-14	2.49e-08	0.45	0.35	Triglycerides;	chr8:11124541	chr9:76992099~76993108:+
THCA	trans	rs6424115	1	rs12116511	ENSG00000228217.1	AL390877.1	7.97	1.19e-14	2.5e-08	0.45	0.35	Immature fraction of reticulocytes;	chr1:23836172	chr1:117778087~117778506:-
THCA	trans	rs11098499	0.821	rs10032151	ENSG00000253326.2	RP11-261C10.7	7.97	1.2e-14	2.51e-08	0.49	0.35	Corneal astigmatism;	chr4:119470473	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs10032158	ENSG00000253326.2	RP11-261C10.7	7.97	1.2e-14	2.51e-08	0.49	0.35	Corneal astigmatism;	chr4:119470477	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs7436506	ENSG00000253326.2	RP11-261C10.7	7.97	1.2e-14	2.51e-08	0.49	0.35	Corneal astigmatism;	chr4:119472614	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10008459	ENSG00000253326.2	RP11-261C10.7	7.97	1.2e-14	2.51e-08	0.49	0.35	Corneal astigmatism;	chr4:119473076	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs2127821	ENSG00000253326.2	RP11-261C10.7	7.97	1.2e-14	2.51e-08	0.49	0.35	Corneal astigmatism;	chr4:119473380	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10006525	ENSG00000253326.2	RP11-261C10.7	7.97	1.2e-14	2.51e-08	0.49	0.35	Corneal astigmatism;	chr4:119487776	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs12508504	ENSG00000253326.2	RP11-261C10.7	7.97	1.2e-14	2.51e-08	0.49	0.35	Corneal astigmatism;	chr4:119489452	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.779	rs80242894	ENSG00000253326.2	RP11-261C10.7	7.97	1.2e-14	2.52e-08	0.49	0.35	Corneal astigmatism;	chr4:119454597	chr1:243054861~243056394:-
THCA	trans	rs66887589	0.807	rs9799664	ENSG00000275858.1	RP11-291L22.8	7.97	1.2e-14	2.52e-08	0.41	0.35	Diastolic blood pressure;	chr4:119405523	chr10:38450738~38451069:-
THCA	trans	rs864643	0.513	rs6599028	ENSG00000183298.5	RP11-556K13.1	7.97	1.22e-14	2.55e-08	0.56	0.35	Attention deficit hyperactivity disorder;	chr3:39492344	chr1:101786340~101787219:-
THCA	trans	rs10870270	1	rs10430617	ENSG00000197358.9	BNIP3P1	7.97	1.22e-14	2.55e-08	0.47	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131935385	chr14:28264390~28265974:+
THCA	trans	rs10870270	0.956	rs10430618	ENSG00000197358.9	BNIP3P1	7.97	1.22e-14	2.55e-08	0.47	0.35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131935492	chr14:28264390~28265974:+
THCA	trans	rs3849046	0.781	rs11745933	ENSG00000226666.1	HSPA9P1	-7.97	1.23e-14	2.58e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138604476	chr2:221961737~221963765:+
THCA	trans	rs2898290	0.622	rs17799486	ENSG00000253893.2	FAM85B	7.97	1.23e-14	2.58e-08	0.47	0.34	Systolic blood pressure;	chr8:11482985	chr8:8167819~8226614:-
THCA	trans	rs7819412	1	rs7819412	ENSG00000229857.1	RP11-159H20.3	-7.97	1.24e-14	2.59e-08	-0.44	-0.34	Triglycerides;	chr8:11187652	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.569	rs10106207	ENSG00000229857.1	RP11-159H20.3	7.97	1.24e-14	2.6e-08	0.44	0.34	Retinal vascular caliber;	chr8:11157828	chr9:76992099~76993108:+
THCA	trans	rs73108077	0.736	rs6058637	ENSG00000279352.1	RP11-411B10.7	7.97	1.24e-14	2.6e-08	0.62	0.34	Red blood cell density in sickle cell anemia;	chr20:31325430	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs6057561	ENSG00000279352.1	RP11-411B10.7	7.97	1.24e-14	2.6e-08	0.62	0.34	Red blood cell density in sickle cell anemia;	chr20:31327238	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs6119830	ENSG00000279352.1	RP11-411B10.7	7.97	1.24e-14	2.6e-08	0.62	0.34	Red blood cell density in sickle cell anemia;	chr20:31327636	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs6119831	ENSG00000279352.1	RP11-411B10.7	7.97	1.24e-14	2.6e-08	0.62	0.34	Red blood cell density in sickle cell anemia;	chr20:31328473	chr18:14010054~14010917:+
THCA	trans	rs10242455	0.867	rs2687136	ENSG00000228834.1	RP11-249L21.4	-7.96	1.26e-14	2.64e-08	-0.63	-0.34	Blood metabolite levels;	chr7:99728259	chr6:108907615~108907873:-
THCA	trans	rs14057	0.929	rs11122114	ENSG00000215869.3	RP11-364B6.1	7.96	1.27e-14	2.65e-08	0.49	0.34	Systolic blood pressure;	chr1:6654626	chr1:104073023~104077087:+
THCA	trans	rs748404	0.56	rs529611	ENSG00000180867.10	PDIA3P1	-7.96	1.27e-14	2.65e-08	-0.3	-0.34	Lung cancer;	chr15:43513790	chr1:147178113~147179622:+
THCA	trans	rs7819412	0.617	rs10087081	ENSG00000253893.2	FAM85B	7.96	1.27e-14	2.66e-08	0.47	0.34	Triglycerides;	chr8:11117407	chr8:8167819~8226614:-
THCA	trans	rs2060793	1	rs10741657	ENSG00000236360.2	RP11-334A14.2	7.96	1.28e-14	2.67e-08	0.46	0.34	Vitamin D levels;	chr11:14893332	chr1:52993201~52993702:-
THCA	trans	rs9648716	1	rs6964724	ENSG00000224775.2	BRAFP1	7.96	1.28e-14	2.68e-08	0.59	0.34	Type 2 diabetes;	chr7:140802136	chrX:75582676~75585506:+
THCA	trans	rs9650657	0.53	rs6982381	ENSG00000229857.1	RP11-159H20.3	7.96	1.29e-14	2.69e-08	0.45	0.34	Neuroticism;	chr8:11094990	chr9:76992099~76993108:+
THCA	trans	rs9292918	0.951	rs35804423	ENSG00000231752.4	EMBP1	7.96	1.29e-14	2.69e-08	0.51	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45354697	chr1:121519112~121571892:+
THCA	trans	rs66887589	0.807	rs13134517	ENSG00000275858.1	RP11-291L22.8	7.96	1.29e-14	2.69e-08	0.41	0.34	Diastolic blood pressure;	chr4:119484107	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.837	rs6534135	ENSG00000275858.1	RP11-291L22.8	7.96	1.29e-14	2.69e-08	0.41	0.34	Diastolic blood pressure;	chr4:119485147	chr10:38450738~38451069:-
THCA	trans	rs9425766	0.962	rs9425430	ENSG00000213331.4	RP11-713C19.2	7.96	1.29e-14	2.69e-08	0.44	0.34	Life satisfaction;	chr1:173888145	chr4:187970273~187971284:+
THCA	trans	rs11098499	0.954	rs10518331	ENSG00000253326.2	RP11-261C10.7	7.96	1.29e-14	2.69e-08	0.49	0.34	Corneal astigmatism;	chr4:119402440	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs2389802	ENSG00000253326.2	RP11-261C10.7	7.96	1.29e-14	2.7e-08	0.49	0.34	Corneal astigmatism;	chr4:119404577	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.575	rs9996586	ENSG00000275858.1	RP11-291L22.8	7.96	1.29e-14	2.7e-08	0.41	0.34	Corneal astigmatism;	chr4:119405787	chr10:38450738~38451069:-
THCA	trans	rs9648716	1	rs10232557	ENSG00000224775.2	BRAFP1	7.96	1.31e-14	2.73e-08	0.59	0.34	Type 2 diabetes;	chr7:140752563	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs7801086	ENSG00000224775.2	BRAFP1	7.96	1.31e-14	2.73e-08	0.59	0.34	Type 2 diabetes;	chr7:140755173	chrX:75582676~75585506:+
THCA	trans	rs66887589	0.837	rs7661498	ENSG00000275858.1	RP11-291L22.8	7.96	1.32e-14	2.75e-08	0.41	0.34	Diastolic blood pressure;	chr4:119486953	chr10:38450738~38451069:-
THCA	trans	rs748404	0.646	rs2253268	ENSG00000180867.10	PDIA3P1	-7.96	1.32e-14	2.76e-08	-0.3	-0.34	Lung cancer;	chr15:43508770	chr1:147178113~147179622:+
THCA	trans	rs4879656	0.564	rs2183870	ENSG00000215007.3	DNAJA1P3	-7.96	1.33e-14	2.78e-08	-0.4	-0.34	Menopause (age at onset);	chr9:32994502	chrX:107351650~107352843:-
THCA	trans	rs14057	0.894	rs2076365	ENSG00000215869.3	RP11-364B6.1	7.96	1.33e-14	2.78e-08	0.49	0.34	Systolic blood pressure;	chr1:6645511	chr1:104073023~104077087:+
THCA	trans	rs6743068	0.522	rs7597617	ENSG00000235105.1	RP11-329A14.1	7.95	1.36e-14	2.82e-08	0.38	0.34	Lymphocyte percentage of white cells;	chr2:201338512	chr1:48435967~48437223:+
THCA	trans	rs12145833	1	rs12145004	ENSG00000154608.12	CEP170P1	-7.95	1.36e-14	2.83e-08	-0.47	-0.34	Obesity (early onset extreme);	chr1:243320063	chr4:118467590~118554204:+
THCA	trans	rs867371	1	rs7181655	ENSG00000235370.6	DNM1P51	-7.95	1.36e-14	2.84e-08	-0.43	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:84398316~84411701:-
THCA	trans	rs867371	1	rs7180584	ENSG00000235370.6	DNM1P51	-7.95	1.36e-14	2.84e-08	-0.43	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:84398316~84411701:-
THCA	trans	rs748404	0.66	rs690012	ENSG00000180867.10	PDIA3P1	-7.95	1.37e-14	2.85e-08	-0.3	-0.34	Lung cancer;	chr15:43427557	chr1:147178113~147179622:+
THCA	trans	rs66887589	0.774	rs9307477	ENSG00000275858.1	RP11-291L22.8	7.95	1.38e-14	2.87e-08	0.41	0.34	Diastolic blood pressure;	chr4:119500654	chr10:38450738~38451069:-
THCA	trans	rs7032940	0.626	rs4314718	ENSG00000262519.1	TXNP4	7.95	1.38e-14	2.87e-08	0.43	0.34	Height;	chr9:110211368	chr17:4572206~4572515:+
THCA	trans	rs73108077	0.736	rs6058546	ENSG00000279352.1	RP11-411B10.7	7.95	1.38e-14	2.87e-08	0.62	0.34	Red blood cell density in sickle cell anemia;	chr20:31314582	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs1997741	ENSG00000279352.1	RP11-411B10.7	7.95	1.38e-14	2.87e-08	0.62	0.34	Red blood cell density in sickle cell anemia;	chr20:31323198	chr18:14010054~14010917:+
THCA	trans	rs864643	0.579	rs694365	ENSG00000188856.6	RPSAP47	7.95	1.4e-14	2.91e-08	0.53	0.34	Attention deficit hyperactivity disorder;	chr3:39494422	chr8:80558870~80559757:+
THCA	trans	rs77688320	1	rs2714486	ENSG00000235105.1	RP11-329A14.1	-7.95	1.4e-14	2.92e-08	-0.46	-0.34	Breast cancer;	chr2:201384985	chr1:48435967~48437223:+
THCA	trans	rs941207	0.756	rs2958149	ENSG00000257210.1	NACAP3	7.95	1.41e-14	2.94e-08	0.45	0.34	Platelet count;	chr12:56716008	chr12:93124063~93124543:-
THCA	trans	rs7647973	0.731	rs13084037	ENSG00000197582.5	GPX1P1	7.95	1.42e-14	2.94e-08	0.57	0.34	Menarche (age at onset);	chr3:49176633	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.865	rs11098513	ENSG00000253326.2	RP11-261C10.7	7.95	1.42e-14	2.94e-08	0.48	0.34	Corneal astigmatism;	chr4:119394920	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.738	rs72918577	ENSG00000253326.2	RP11-261C10.7	7.94	1.45e-14	3.01e-08	0.49	0.34	Corneal astigmatism;	chr4:119405546	chr1:243054861~243056394:-
THCA	trans	rs9648716	1	rs3789806	ENSG00000224775.2	BRAFP1	7.94	1.47e-14	3.05e-08	0.59	0.34	Type 2 diabetes;	chr7:140749271	chrX:75582676~75585506:+
THCA	trans	rs3806843	0.676	rs753280	ENSG00000231043.3	AC007238.1	-7.94	1.49e-14	3.09e-08	-0.39	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140644457	chr2:58460292~58462032:-
THCA	trans	rs864643	0.685	rs112164405	ENSG00000188856.6	RPSAP47	7.94	1.5e-14	3.12e-08	0.65	0.34	Attention deficit hyperactivity disorder;	chr3:39551043	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.865	rs28634456	ENSG00000253326.2	RP11-261C10.7	7.94	1.51e-14	3.13e-08	0.49	0.34	Corneal astigmatism;	chr4:119454623	chr1:243054861~243056394:-
THCA	trans	rs2645424	0.671	rs2294138	ENSG00000260438.1	RP11-405F3.2	7.94	1.51e-14	3.13e-08	0.49	0.34	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847630	chr16:57713782~57714957:+
THCA	trans	rs8067354	0.574	rs2531899	ENSG00000187870.7	RNFT1P3	-7.94	1.51e-14	3.14e-08	-0.56	-0.34	Hemoglobin concentration;	chr17:59929832	chr17:20743333~20754501:-
THCA	trans	rs2134046	0.555	rs11854483	ENSG00000235370.6	DNM1P51	-7.94	1.53e-14	3.18e-08	-0.44	-0.34	Cognitive ability;	chr15:82267217	chr15:84398316~84411701:-
THCA	trans	rs11098499	0.588	rs6534149	ENSG00000275858.1	RP11-291L22.8	-7.94	1.54e-14	3.19e-08	-0.43	-0.34	Corneal astigmatism;	chr4:119638137	chr10:38450738~38451069:-
THCA	trans	rs902774	0.818	rs4919740	ENSG00000255815.3	KRT8P11	-7.94	1.55e-14	3.22e-08	-0.67	-0.34	Prostate cancer;	chr12:52877187	chr9:99305176~99306611:+
THCA	trans	rs7647973	0.848	rs4955411	ENSG00000197582.5	GPX1P1	7.94	1.55e-14	3.22e-08	0.58	0.34	Menarche (age at onset);	chr3:49107871	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.848	rs4292260	ENSG00000197582.5	GPX1P1	7.94	1.55e-14	3.22e-08	0.58	0.34	Menarche (age at onset);	chr3:49111457	chrX:13378735~13379340:-
THCA	trans	rs6424115	1	rs6697805	ENSG00000228217.1	AL390877.1	7.94	1.55e-14	3.22e-08	0.45	0.34	Immature fraction of reticulocytes;	chr1:23825506	chr1:117778087~117778506:-
THCA	trans	rs7121616	0.563	rs1461494	ENSG00000229091.2	HSPA8P8	7.93	1.56e-14	3.23e-08	0.43	0.34	Breast cancer;	chr11:123055777	chr7:10451311~10452526:+
THCA	trans	rs877636	1	rs2292239	ENSG00000212829.8	RPS26P3	7.93	1.56e-14	3.23e-08	0.44	0.34	Cognitive function;	chr12:56088396	chr9:9090898~9091245:+
THCA	trans	rs11992162	0.933	rs10108075	ENSG00000253893.2	FAM85B	-7.93	1.56e-14	3.23e-08	-0.46	-0.34	Monocyte count;	chr8:11974570	chr8:8167819~8226614:-
THCA	trans	rs9648716	1	rs7803738	ENSG00000224775.2	BRAFP1	7.93	1.58e-14	3.27e-08	0.59	0.34	Type 2 diabetes;	chr7:140743019	chrX:75582676~75585506:+
THCA	trans	rs9648716	0.935	rs6957490	ENSG00000224775.2	BRAFP1	7.93	1.6e-14	3.32e-08	0.59	0.34	Type 2 diabetes;	chr7:140860507	chrX:75582676~75585506:+
THCA	trans	rs7647973	0.925	rs6446257	ENSG00000197582.5	GPX1P1	-7.93	1.61e-14	3.33e-08	-0.53	-0.34	Menarche (age at onset);	chr3:49216059	chrX:13378735~13379340:-
THCA	trans	rs3740713	0.669	rs2896526	ENSG00000214110.3	LDHAP4	7.93	1.61e-14	3.34e-08	0.56	0.34	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr9:14921337~14922334:-
THCA	trans	rs3849046	0.596	rs28377921	ENSG00000226666.1	HSPA9P1	7.93	1.62e-14	3.36e-08	0.36	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138607633	chr2:221961737~221963765:+
THCA	trans	rs282544	1	rs32396	ENSG00000231752.4	EMBP1	7.93	1.62e-14	3.36e-08	0.47	0.34	Myopia (pathological);	chr5:50810605	chr1:121519112~121571892:+
THCA	trans	rs1908814	0.509	rs13282439	ENSG00000256560.1	LINC01486	7.93	1.63e-14	3.37e-08	0.44	0.34	Neuroticism;	chr8:11937392	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.738	rs28408407	ENSG00000253326.2	RP11-261C10.7	7.93	1.63e-14	3.38e-08	0.48	0.34	Corneal astigmatism;	chr4:119454875	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs1809406	ENSG00000253326.2	RP11-261C10.7	7.93	1.63e-14	3.38e-08	0.48	0.34	Corneal astigmatism;	chr4:119455967	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs2389809	ENSG00000253326.2	RP11-261C10.7	7.93	1.63e-14	3.38e-08	0.48	0.34	Corneal astigmatism;	chr4:119456244	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs9994810	ENSG00000253326.2	RP11-261C10.7	7.93	1.63e-14	3.38e-08	0.48	0.34	Corneal astigmatism;	chr4:119460435	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.697	rs10020027	ENSG00000253326.2	RP11-261C10.7	7.93	1.63e-14	3.38e-08	0.48	0.34	Corneal astigmatism;	chr4:119460724	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.779	rs7356491	ENSG00000253326.2	RP11-261C10.7	7.93	1.63e-14	3.38e-08	0.48	0.34	Corneal astigmatism;	chr4:119460819	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.908	rs28499576	ENSG00000253326.2	RP11-261C10.7	7.93	1.63e-14	3.38e-08	0.48	0.34	Corneal astigmatism;	chr4:119465522	chr1:243054861~243056394:-
THCA	trans	rs941207	0.756	rs2926743	ENSG00000257210.1	NACAP3	7.93	1.63e-14	3.38e-08	0.45	0.34	Platelet count;	chr12:56720316	chr12:93124063~93124543:-
THCA	trans	rs7819412	0.806	rs17723229	ENSG00000229857.1	RP11-159H20.3	7.93	1.63e-14	3.38e-08	0.44	0.34	Triglycerides;	chr8:11072559	chr9:76992099~76993108:+
THCA	trans	rs6915893	1	rs9477630	ENSG00000267156.1	TPMTP1	7.93	1.64e-14	3.38e-08	0.37	0.34	Intrinsic epigenetic age acceleration;	chr6:18117867	chr18:47630112~47630848:+
THCA	trans	rs3808502	0.527	rs2736389	ENSG00000253893.2	FAM85B	-7.93	1.64e-14	3.38e-08	-0.48	-0.34	Neuroticism;	chr8:11303801	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.584	rs6058897	ENSG00000253915.1	MAPRE1P1	-7.93	1.64e-14	3.4e-08	-0.44	-0.34	Ulcerative colitis;	chr20:32810299	chr8:135625185~135625981:-
THCA	trans	rs14057	0.929	rs12755051	ENSG00000215869.3	RP11-364B6.1	7.93	1.66e-14	3.43e-08	0.48	0.34	Systolic blood pressure;	chr1:6658318	chr1:104073023~104077087:+
THCA	trans	rs877636	1	rs2292239	ENSG00000243538.1	CTB-55B8.1	7.93	1.67e-14	3.44e-08	0.42	0.34	Cognitive function;	chr12:56088396	chr5:16902294~16902641:-
THCA	trans	rs7113874	0.921	rs4929923	ENSG00000266891.1	RP11-692N5.2	-7.93	1.67e-14	3.45e-08	-0.44	-0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8617653	chr18:9734882~9735602:-
THCA	trans	rs3740713	0.748	rs35292478	ENSG00000214110.3	LDHAP4	7.92	1.68e-14	3.46e-08	0.56	0.34	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr9:14921337~14922334:-
THCA	trans	rs11098499	0.865	rs4001305	ENSG00000253326.2	RP11-261C10.7	7.92	1.68e-14	3.47e-08	0.48	0.34	Corneal astigmatism;	chr4:119438081	chr1:243054861~243056394:-
THCA	trans	rs11992162	0.967	rs7461062	ENSG00000253893.2	FAM85B	-7.92	1.69e-14	3.49e-08	-0.46	-0.34	Monocyte count;	chr8:11974439	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.913	rs12186259	ENSG00000275858.1	RP11-291L22.8	7.92	1.69e-14	3.5e-08	0.46	0.34	Corneal astigmatism;	chr4:119230884	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs35165976	ENSG00000253326.2	RP11-261C10.7	7.92	1.7e-14	3.51e-08	0.49	0.34	Corneal astigmatism;	chr4:119404475	chr1:243054861~243056394:-
THCA	trans	rs8067354	0.54	rs12600680	ENSG00000187870.7	RNFT1P3	7.92	1.71e-14	3.52e-08	0.56	0.34	Hemoglobin concentration;	chr17:59960013	chr17:20743333~20754501:-
THCA	trans	rs9648716	0.832	rs10258390	ENSG00000224775.2	BRAFP1	7.92	1.71e-14	3.53e-08	0.59	0.34	Type 2 diabetes;	chr7:140885326	chrX:75582676~75585506:+
THCA	trans	rs864643	0.947	rs1473865	ENSG00000188856.6	RPSAP47	7.92	1.71e-14	3.54e-08	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39501313	chr8:80558870~80559757:+
THCA	trans	rs10028773	0.515	rs9994651	ENSG00000275858.1	RP11-291L22.8	7.92	1.72e-14	3.55e-08	0.44	0.34	Educational attainment;	chr4:119666648	chr10:38450738~38451069:-
THCA	trans	rs7647973	0.731	rs7617480	ENSG00000197582.5	GPX1P1	-7.92	1.74e-14	3.59e-08	-0.57	-0.34	Menarche (age at onset);	chr3:49173299	chrX:13378735~13379340:-
THCA	trans	rs73108077	0.736	rs6119276	ENSG00000279352.1	RP11-411B10.7	7.92	1.74e-14	3.59e-08	0.63	0.34	Red blood cell density in sickle cell anemia;	chr20:31363733	chr18:14010054~14010917:+
THCA	trans	rs2288327	1	rs3731746	ENSG00000269800.1	PLEKHA3P1	7.92	1.74e-14	3.6e-08	0.46	0.34	Atrial fibrillation;	chr2:178566270	chr19:41521043~41521989:-
THCA	trans	rs11098499	0.954	rs13107475	ENSG00000253326.2	RP11-261C10.7	7.92	1.74e-14	3.6e-08	0.48	0.34	Corneal astigmatism;	chr4:119471856	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs6849171	ENSG00000253326.2	RP11-261C10.7	7.92	1.74e-14	3.6e-08	0.48	0.34	Corneal astigmatism;	chr4:119488394	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs1480931	ENSG00000253326.2	RP11-261C10.7	7.92	1.75e-14	3.62e-08	0.48	0.34	Corneal astigmatism;	chr4:119474654	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs11098524	ENSG00000253326.2	RP11-261C10.7	7.92	1.76e-14	3.62e-08	0.46	0.34	Corneal astigmatism;	chr4:119468877	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.562	rs58583086	ENSG00000275858.1	RP11-291L22.8	-7.92	1.78e-14	3.67e-08	-0.43	-0.34	Corneal astigmatism;	chr4:119635207	chr10:38450738~38451069:-
THCA	trans	rs8067354	0.574	rs1295923	ENSG00000187870.7	RNFT1P3	7.91	1.79e-14	3.7e-08	0.56	0.34	Hemoglobin concentration;	chr17:59883075	chr17:20743333~20754501:-
THCA	trans	rs11098499	0.697	rs28655325	ENSG00000253326.2	RP11-261C10.7	7.91	1.81e-14	3.73e-08	0.49	0.34	Corneal astigmatism;	chr4:119451844	chr1:243054861~243056394:-
THCA	trans	rs864643	0.729	rs9811533	ENSG00000188856.6	RPSAP47	7.91	1.81e-14	3.74e-08	0.61	0.34	Attention deficit hyperactivity disorder;	chr3:39498420	chr8:80558870~80559757:+
THCA	trans	rs864643	0.729	rs9849520	ENSG00000188856.6	RPSAP47	7.91	1.81e-14	3.74e-08	0.61	0.34	Attention deficit hyperactivity disorder;	chr3:39498425	chr8:80558870~80559757:+
THCA	trans	rs864643	0.513	rs1707944	ENSG00000183298.5	RP11-556K13.1	7.91	1.82e-14	3.75e-08	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39487141	chr1:101786340~101787219:-
THCA	trans	rs7662987	1	rs11547772	ENSG00000228407.2	RP4-800M22.1	7.91	1.82e-14	3.76e-08	0.73	0.34	Smoking initiation;	chr4:99071642	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs28730640	ENSG00000228407.2	RP4-800M22.1	7.91	1.82e-14	3.76e-08	0.73	0.34	Smoking initiation;	chr4:99072902	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs7658118	ENSG00000228407.2	RP4-800M22.1	7.91	1.82e-14	3.76e-08	0.73	0.34	Smoking initiation;	chr4:99073457	chr1:52160261~52160600:-
THCA	trans	rs9611519	0.639	rs7290458	ENSG00000268568.1	AC007228.9	7.91	1.84e-14	3.79e-08	0.38	0.34	Neuroticism;	chr22:41080333	chr19:56672574~56673901:-
THCA	trans	rs11098499	0.954	rs28685688	ENSG00000253326.2	RP11-261C10.7	7.91	1.84e-14	3.79e-08	0.49	0.34	Corneal astigmatism;	chr4:119499179	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs7687843	ENSG00000253326.2	RP11-261C10.7	7.91	1.84e-14	3.79e-08	0.49	0.34	Corneal astigmatism;	chr4:119500056	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs2306455	ENSG00000253326.2	RP11-261C10.7	7.91	1.84e-14	3.79e-08	0.49	0.34	Corneal astigmatism;	chr4:119500814	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10031483	ENSG00000253326.2	RP11-261C10.7	7.91	1.84e-14	3.79e-08	0.49	0.34	Corneal astigmatism;	chr4:119501481	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10031665	ENSG00000253326.2	RP11-261C10.7	7.91	1.84e-14	3.79e-08	0.49	0.34	Corneal astigmatism;	chr4:119501697	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs3733523	ENSG00000253326.2	RP11-261C10.7	7.91	1.84e-14	3.79e-08	0.49	0.34	Corneal astigmatism;	chr4:119502564	chr1:243054861~243056394:-
THCA	trans	rs8067354	0.54	rs1051424	ENSG00000187870.7	RNFT1P3	7.91	1.86e-14	3.82e-08	0.57	0.34	Hemoglobin concentration;	chr17:59946963	chr17:20743333~20754501:-
THCA	trans	rs11098499	0.954	rs10034623	ENSG00000253326.2	RP11-261C10.7	7.91	1.89e-14	3.88e-08	0.48	0.34	Corneal astigmatism;	chr4:119476674	chr1:243054861~243056394:-
THCA	trans	rs9611519	0.639	rs7289989	ENSG00000268568.1	AC007228.9	-7.91	1.9e-14	3.9e-08	-0.38	-0.34	Neuroticism;	chr22:41080795	chr19:56672574~56673901:-
THCA	trans	rs11992162	0.967	rs4841661	ENSG00000253893.2	FAM85B	-7.91	1.9e-14	3.9e-08	-0.46	-0.34	Monocyte count;	chr8:11975260	chr8:8167819~8226614:-
THCA	trans	rs11992162	1	rs11994417	ENSG00000253893.2	FAM85B	-7.91	1.9e-14	3.9e-08	-0.46	-0.34	Monocyte count;	chr8:11975753	chr8:8167819~8226614:-
THCA	trans	rs282544	1	rs204915	ENSG00000231752.4	EMBP1	-7.9	1.93e-14	3.97e-08	-0.47	-0.34	Myopia (pathological);	chr5:50731094	chr1:121519112~121571892:+
THCA	trans	rs748404	0.56	rs1869258	ENSG00000180867.10	PDIA3P1	-7.9	1.93e-14	3.97e-08	-0.3	-0.34	Lung cancer;	chr15:43511423	chr1:147178113~147179622:+
THCA	trans	rs66887589	0.967	rs13104219	ENSG00000275858.1	RP11-291L22.8	7.9	1.93e-14	3.98e-08	0.41	0.34	Diastolic blood pressure;	chr4:119517019	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.954	rs7681544	ENSG00000253326.2	RP11-261C10.7	7.9	1.94e-14	3.98e-08	0.48	0.34	Corneal astigmatism;	chr4:119490100	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs11940028	ENSG00000253326.2	RP11-261C10.7	7.9	1.94e-14	3.98e-08	0.48	0.34	Corneal astigmatism;	chr4:119490752	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs11935596	ENSG00000253326.2	RP11-261C10.7	7.9	1.94e-14	3.98e-08	0.48	0.34	Corneal astigmatism;	chr4:119491302	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs12507964	ENSG00000253326.2	RP11-261C10.7	7.9	1.94e-14	3.98e-08	0.48	0.34	Corneal astigmatism;	chr4:119491906	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs11098530	ENSG00000253326.2	RP11-261C10.7	7.9	1.94e-14	3.98e-08	0.48	0.34	Corneal astigmatism;	chr4:119491999	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs6834796	ENSG00000253326.2	RP11-261C10.7	7.9	1.94e-14	3.98e-08	0.48	0.34	Corneal astigmatism;	chr4:119493538	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs11734241	ENSG00000253326.2	RP11-261C10.7	7.9	1.94e-14	3.98e-08	0.48	0.34	Corneal astigmatism;	chr4:119495717	chr1:243054861~243056394:-
THCA	trans	rs748404	0.66	rs493377	ENSG00000180867.10	PDIA3P1	-7.9	1.95e-14	3.99e-08	-0.3	-0.34	Lung cancer;	chr15:43481269	chr1:147178113~147179622:+
THCA	trans	rs748404	0.631	rs7163288	ENSG00000180867.10	PDIA3P1	-7.9	1.97e-14	4.04e-08	-0.3	-0.34	Lung cancer;	chr15:43379157	chr1:147178113~147179622:+
THCA	trans	rs7113874	0.559	rs34378489	ENSG00000266891.1	RP11-692N5.2	7.9	1.97e-14	4.05e-08	0.51	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8407803	chr18:9734882~9735602:-
THCA	trans	rs10435719	0.746	rs58007588	ENSG00000256560.1	LINC01486	7.9	1.98e-14	4.05e-08	0.44	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr12:109354083~109359488:-
THCA	trans	rs282544	1	rs27934	ENSG00000231752.4	EMBP1	7.9	1.99e-14	4.08e-08	0.47	0.34	Myopia (pathological);	chr5:50823125	chr1:121519112~121571892:+
THCA	trans	rs7113874	1	rs12575252	ENSG00000266891.1	RP11-692N5.2	7.9	2.02e-14	4.13e-08	0.44	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8672526	chr18:9734882~9735602:-
THCA	trans	rs10870270	0.957	rs9971084	ENSG00000197358.9	BNIP3P1	7.9	2.02e-14	4.14e-08	0.46	0.34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131975243	chr14:28264390~28265974:+
THCA	trans	rs11098499	0.954	rs67265404	ENSG00000253326.2	RP11-261C10.7	7.9	2.03e-14	4.15e-08	0.49	0.34	Corneal astigmatism;	chr4:119438115	chr1:243054861~243056394:-
THCA	trans	rs748404	0.66	rs518288	ENSG00000180867.10	PDIA3P1	-7.9	2.03e-14	4.16e-08	-0.29	-0.34	Lung cancer;	chr15:43471801	chr1:147178113~147179622:+
THCA	trans	rs10242455	0.867	rs73410654	ENSG00000228834.1	RP11-249L21.4	7.9	2.04e-14	4.17e-08	0.65	0.34	Blood metabolite levels;	chr7:99729040	chr6:108907615~108907873:-
THCA	trans	rs10435719	0.61	rs76311455	ENSG00000256560.1	LINC01486	7.9	2.04e-14	4.19e-08	0.44	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933017	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.61	rs80269926	ENSG00000256560.1	LINC01486	7.9	2.04e-14	4.19e-08	0.44	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933018	chr12:109354083~109359488:-
THCA	trans	rs11638815	0.626	rs11635624	ENSG00000235370.6	DNM1P51	-7.9	2.05e-14	4.2e-08	-0.45	-0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:84398316~84411701:-
THCA	trans	rs748404	0.69	rs2467737	ENSG00000180867.10	PDIA3P1	-7.9	2.05e-14	4.21e-08	-0.3	-0.34	Lung cancer;	chr15:43444990	chr1:147178113~147179622:+
THCA	trans	rs6424115	0.965	rs2502979	ENSG00000228217.1	AL390877.1	-7.9	2.06e-14	4.22e-08	-0.45	-0.34	Immature fraction of reticulocytes;	chr1:23822825	chr1:117778087~117778506:-
THCA	trans	rs2840044	0.711	rs225301	ENSG00000234130.2	RP13-88F20.1	-7.9	2.06e-14	4.22e-08	-0.43	-0.34	Response to radiotherapy in cancer (late toxicity);	chr17:35595392	chrX:93222220~93225015:-
THCA	trans	rs748404	0.66	rs690472	ENSG00000180867.10	PDIA3P1	-7.89	2.07e-14	4.23e-08	-0.3	-0.34	Lung cancer;	chr15:43472170	chr1:147178113~147179622:+
THCA	trans	rs748404	0.69	rs1079309	ENSG00000180867.10	PDIA3P1	-7.89	2.07e-14	4.23e-08	-0.3	-0.34	Lung cancer;	chr15:43490966	chr1:147178113~147179622:+
THCA	trans	rs12709013	0.804	rs8051459	ENSG00000230849.2	GOT2P2	7.89	2.07e-14	4.24e-08	0.42	0.34	Blood metabolite ratios;	chr16:58783436	chr1:173141100~173142350:-
THCA	trans	rs9648716	1	rs964942	ENSG00000224775.2	BRAFP1	7.89	2.07e-14	4.24e-08	0.59	0.34	Type 2 diabetes;	chr7:140922555	chrX:75582676~75585506:+
THCA	trans	rs7824557	0.67	rs2736381	ENSG00000253893.2	FAM85B	7.89	2.07e-14	4.24e-08	0.45	0.34	Retinal vascular caliber;	chr8:11275257	chr8:8167819~8226614:-
THCA	trans	rs867371	0.896	rs6495647	ENSG00000235370.6	DNM1P51	-7.89	2.07e-14	4.24e-08	-0.42	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:84398316~84411701:-
THCA	trans	rs12709013	0.967	rs11643969	ENSG00000233719.3	GOT2P3	7.89	2.08e-14	4.25e-08	0.42	0.34	Blood metabolite ratios;	chr16:58785354	chr12:9641802~9643007:+
THCA	trans	rs2060793	0.684	rs1597689	ENSG00000236360.2	RP11-334A14.2	7.89	2.08e-14	4.25e-08	0.46	0.34	Vitamin D levels;	chr11:14824638	chr1:52993201~52993702:-
THCA	trans	rs748404	0.66	rs690446	ENSG00000180867.10	PDIA3P1	-7.89	2.1e-14	4.29e-08	-0.3	-0.34	Lung cancer;	chr15:43469066	chr1:147178113~147179622:+
THCA	trans	rs748404	0.631	rs560191	ENSG00000180867.10	PDIA3P1	-7.89	2.1e-14	4.29e-08	-0.3	-0.34	Lung cancer;	chr15:43475576	chr1:147178113~147179622:+
THCA	trans	rs748404	0.69	rs2924369	ENSG00000180867.10	PDIA3P1	7.89	2.1e-14	4.29e-08	0.3	0.34	Lung cancer;	chr15:43485787	chr1:147178113~147179622:+
THCA	trans	rs748404	0.66	rs2444251	ENSG00000180867.10	PDIA3P1	-7.89	2.1e-14	4.29e-08	-0.3	-0.34	Lung cancer;	chr15:43496397	chr1:147178113~147179622:+
THCA	trans	rs748404	0.66	rs548704	ENSG00000180867.10	PDIA3P1	-7.89	2.1e-14	4.29e-08	-0.3	-0.34	Lung cancer;	chr15:43499508	chr1:147178113~147179622:+
THCA	trans	rs8067354	0.574	rs1292033	ENSG00000187870.7	RNFT1P3	7.89	2.11e-14	4.32e-08	0.55	0.34	Hemoglobin concentration;	chr17:59913236	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.574	rs1291947	ENSG00000187870.7	RNFT1P3	7.89	2.11e-14	4.32e-08	0.55	0.34	Hemoglobin concentration;	chr17:59918975	chr17:20743333~20754501:-
THCA	trans	rs3849046	0.68	rs34858014	ENSG00000226666.1	HSPA9P1	-7.89	2.11e-14	4.32e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138608317	chr2:221961737~221963765:+
THCA	trans	rs748404	0.66	rs509306	ENSG00000180867.10	PDIA3P1	-7.89	2.12e-14	4.33e-08	-0.3	-0.34	Lung cancer;	chr15:43422973	chr1:147178113~147179622:+
THCA	trans	rs864643	0.678	rs1768201	ENSG00000183298.5	RP11-556K13.1	7.89	2.13e-14	4.36e-08	0.57	0.34	Attention deficit hyperactivity disorder;	chr3:39476050	chr1:101786340~101787219:-
THCA	trans	rs11098499	0.909	rs28571712	ENSG00000253326.2	RP11-261C10.7	7.89	2.15e-14	4.39e-08	0.48	0.34	Corneal astigmatism;	chr4:119454825	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs9994730	ENSG00000253326.2	RP11-261C10.7	7.89	2.15e-14	4.39e-08	0.48	0.34	Corneal astigmatism;	chr4:119460409	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs11098526	ENSG00000253326.2	RP11-261C10.7	7.89	2.15e-14	4.39e-08	0.48	0.34	Corneal astigmatism;	chr4:119469204	chr1:243054861~243056394:-
THCA	trans	rs10870270	0.957	rs7074604	ENSG00000197358.9	BNIP3P1	7.89	2.18e-14	4.45e-08	0.46	0.34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131926869	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs10159746	ENSG00000197358.9	BNIP3P1	7.89	2.18e-14	4.45e-08	0.46	0.34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131929173	chr14:28264390~28265974:+
THCA	trans	rs11098499	0.908	rs9995234	ENSG00000253326.2	RP11-261C10.7	7.89	2.18e-14	4.45e-08	0.49	0.34	Corneal astigmatism;	chr4:119400672	chr1:243054861~243056394:-
THCA	trans	rs66887589	0.967	rs6844263	ENSG00000275858.1	RP11-291L22.8	7.89	2.18e-14	4.46e-08	0.41	0.34	Diastolic blood pressure;	chr4:119512652	chr10:38450738~38451069:-
THCA	trans	rs9329221	1	rs9329221	ENSG00000253893.2	FAM85B	-7.89	2.19e-14	4.47e-08	-0.42	-0.34	Neuroticism;	chr8:10382692	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.713	rs13159624	ENSG00000226666.1	HSPA9P1	-7.89	2.19e-14	4.47e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138609348	chr2:221961737~221963765:+
THCA	trans	rs11098499	0.954	rs11729521	ENSG00000253326.2	RP11-261C10.7	7.89	2.2e-14	4.49e-08	0.48	0.34	Corneal astigmatism;	chr4:119495633	chr1:243054861~243056394:-
THCA	trans	rs7113874	0.885	rs7950166	ENSG00000266891.1	RP11-692N5.2	-7.89	2.2e-14	4.49e-08	-0.44	-0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8620671	chr18:9734882~9735602:-
THCA	trans	rs11098499	0.954	rs17006190	ENSG00000253326.2	RP11-261C10.7	7.89	2.21e-14	4.51e-08	0.48	0.34	Corneal astigmatism;	chr4:119497683	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs3733519	ENSG00000253326.2	RP11-261C10.7	7.89	2.21e-14	4.51e-08	0.48	0.34	Corneal astigmatism;	chr4:119502293	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs3733520	ENSG00000253326.2	RP11-261C10.7	7.88	2.23e-14	4.55e-08	0.48	0.34	Corneal astigmatism;	chr4:119502325	chr1:243054861~243056394:-
THCA	trans	rs3849046	0.817	rs2304057	ENSG00000226666.1	HSPA9P1	7.88	2.24e-14	4.56e-08	0.36	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561485	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.623	rs10041640	ENSG00000226666.1	HSPA9P1	7.88	2.24e-14	4.57e-08	0.35	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138609446	chr2:221961737~221963765:+
THCA	trans	rs864643	0.678	rs1768201	ENSG00000188856.6	RPSAP47	7.88	2.24e-14	4.58e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39476050	chr8:80558870~80559757:+
THCA	trans	rs867371	1	rs867370	ENSG00000235370.6	DNM1P51	7.88	2.25e-14	4.59e-08	0.43	0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:84398316~84411701:-
THCA	trans	rs867371	1	rs867371	ENSG00000235370.6	DNM1P51	7.88	2.25e-14	4.59e-08	0.43	0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:84398316~84411701:-
THCA	trans	rs7819412	0.775	rs2001329	ENSG00000229857.1	RP11-159H20.3	7.88	2.26e-14	4.61e-08	0.43	0.34	Triglycerides;	chr8:11129349	chr9:76992099~76993108:+
THCA	trans	rs864643	0.625	rs1708083	ENSG00000188856.6	RPSAP47	7.88	2.27e-14	4.62e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39464295	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs1768182	ENSG00000188856.6	RPSAP47	7.88	2.27e-14	4.62e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39464531	chr8:80558870~80559757:+
THCA	trans	rs748404	0.631	rs3809482	ENSG00000180867.10	PDIA3P1	-7.88	2.27e-14	4.62e-08	-0.3	-0.34	Lung cancer;	chr15:43369604	chr1:147178113~147179622:+
THCA	trans	rs7113874	0.613	rs10840066	ENSG00000266891.1	RP11-692N5.2	7.88	2.27e-14	4.63e-08	0.49	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8510456	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.921	rs4929947	ENSG00000266891.1	RP11-692N5.2	7.88	2.29e-14	4.67e-08	0.44	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8618447	chr18:9734882~9735602:-
THCA	trans	rs7819412	0.593	rs11778398	ENSG00000253893.2	FAM85B	7.88	2.29e-14	4.67e-08	0.48	0.34	Triglycerides;	chr8:11116733	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.954	rs3890049	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119405128	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs71629403	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119451412	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs12499324	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119472631	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs9998585	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119475647	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs6842762	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119477081	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.908	rs11098527	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119478751	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10518328	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119480624	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs6848389	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119481467	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs6822679	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119481547	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs4577559	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119482888	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs7656252	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119483113	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs28845498	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119484031	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs28753180	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119484212	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs56270433	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119484875	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10006706	ENSG00000253326.2	RP11-261C10.7	7.88	2.3e-14	4.68e-08	0.48	0.34	Corneal astigmatism;	chr4:119487997	chr1:243054861~243056394:-
THCA	trans	rs7113874	0.802	rs1502317	ENSG00000266891.1	RP11-692N5.2	7.88	2.3e-14	4.68e-08	0.45	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8660471	chr18:9734882~9735602:-
THCA	trans	rs9467773	0.804	rs2073526	ENSG00000242375.1	RP11-498P14.3	-7.88	2.3e-14	4.69e-08	-0.45	-0.34	Intelligence (multi-trait analysis);	chr6:26374430	chr9:97195351~97197687:-
THCA	trans	rs6424115	0.546	rs35993651	ENSG00000228217.1	AL390877.1	7.88	2.31e-14	4.7e-08	0.45	0.34	Immature fraction of reticulocytes;	chr1:23854123	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.557	rs35904775	ENSG00000228217.1	AL390877.1	7.88	2.31e-14	4.7e-08	0.45	0.34	Immature fraction of reticulocytes;	chr1:23854133	chr1:117778087~117778506:-
THCA	trans	rs7824557	0.564	rs6601584	ENSG00000253893.2	FAM85B	7.88	2.31e-14	4.7e-08	0.45	0.34	Retinal vascular caliber;	chr8:11374834	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.71	rs4835692	ENSG00000226666.1	HSPA9P1	-7.88	2.32e-14	4.71e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610062	chr2:221961737~221963765:+
THCA	trans	rs11098499	0.909	rs78332141	ENSG00000253326.2	RP11-261C10.7	7.88	2.35e-14	4.77e-08	0.49	0.34	Corneal astigmatism;	chr4:119454627	chr1:243054861~243056394:-
THCA	trans	rs6424115	0.964	rs2473375	ENSG00000228217.1	AL390877.1	-7.88	2.36e-14	4.79e-08	-0.45	-0.34	Immature fraction of reticulocytes;	chr1:23810055	chr1:117778087~117778506:-
THCA	trans	rs748404	0.587	rs690276	ENSG00000180867.10	PDIA3P1	-7.88	2.36e-14	4.8e-08	-0.3	-0.34	Lung cancer;	chr15:43412360	chr1:147178113~147179622:+
THCA	trans	rs9648716	1	rs6464037	ENSG00000224775.2	BRAFP1	-7.87	2.4e-14	4.87e-08	-0.58	-0.34	Type 2 diabetes;	chr7:140756264	chrX:75582676~75585506:+
THCA	trans	rs7113874	0.802	rs11042029	ENSG00000266891.1	RP11-692N5.2	7.87	2.4e-14	4.89e-08	0.45	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8666578	chr18:9734882~9735602:-
THCA	trans	rs7121616	0.563	rs4936770	ENSG00000229091.2	HSPA8P8	7.87	2.42e-14	4.92e-08	0.43	0.34	Breast cancer;	chr11:123058167	chr7:10451311~10452526:+
THCA	trans	rs748404	0.66	rs2467742	ENSG00000180867.10	PDIA3P1	-7.87	2.45e-14	4.98e-08	-0.29	-0.34	Lung cancer;	chr15:43458039	chr1:147178113~147179622:+
THCA	trans	rs748404	0.69	rs2244981	ENSG00000180867.10	PDIA3P1	-7.87	2.45e-14	4.98e-08	-0.29	-0.34	Lung cancer;	chr15:43460553	chr1:147178113~147179622:+
THCA	trans	rs7647973	0.731	rs9831648	ENSG00000197582.5	GPX1P1	7.87	2.47e-14	5.02e-08	0.56	0.34	Menarche (age at onset);	chr3:49176870	chrX:13378735~13379340:-
THCA	trans	rs4879656	0.525	rs10122739	ENSG00000215007.3	DNAJA1P3	7.87	2.47e-14	5.03e-08	0.4	0.34	Menopause (age at onset);	chr9:33085601	chrX:107351650~107352843:-
THCA	trans	rs2060793	1	rs1993116	ENSG00000236360.2	RP11-334A14.2	7.87	2.48e-14	5.03e-08	0.45	0.34	Vitamin D levels;	chr11:14888688	chr1:52993201~52993702:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000243538.1	CTB-55B8.1	7.87	2.48e-14	5.03e-08	0.43	0.34	Cognitive function;	chr12:55990903	chr5:16902294~16902641:-
THCA	trans	rs2645424	0.635	rs62495697	ENSG00000229857.1	RP11-159H20.3	-7.87	2.5e-14	5.08e-08	-0.44	-0.34	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851498	chr9:76992099~76993108:+
THCA	trans	rs11671005	0.61	rs11669345	ENSG00000279267.1	RP11-395L14.18	7.87	2.51e-14	5.09e-08	0.49	0.34	Mean platelet volume;	chr19:58550892	chr2:113605867~113607908:-
THCA	trans	rs1707322	0.686	rs2230659	ENSG00000255397.1	AC022182.2	7.87	2.52e-14	5.12e-08	0.48	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.615	rs59867181	ENSG00000275858.1	RP11-291L22.8	-7.87	2.53e-14	5.14e-08	-0.43	-0.34	Corneal astigmatism;	chr4:119635312	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.562	rs2389879	ENSG00000275858.1	RP11-291L22.8	-7.87	2.53e-14	5.14e-08	-0.43	-0.34	Corneal astigmatism;	chr4:119636529	chr10:38450738~38451069:-
THCA	trans	rs7121616	0.576	rs4802	ENSG00000229091.2	HSPA8P8	7.87	2.54e-14	5.15e-08	0.43	0.34	Breast cancer;	chr11:123057914	chr7:10451311~10452526:+
THCA	trans	rs6915893	0.967	rs9477631	ENSG00000267156.1	TPMTP1	7.87	2.54e-14	5.15e-08	0.36	0.34	Intrinsic epigenetic age acceleration;	chr6:18123541	chr18:47630112~47630848:+
THCA	trans	rs9329221	0.527	rs10903328	ENSG00000253893.2	FAM85B	-7.87	2.54e-14	5.15e-08	-0.46	-0.34	Neuroticism;	chr8:10474657	chr8:8167819~8226614:-
THCA	trans	rs6132905	0.52	rs2422823	ENSG00000257956.1	NOP56P3	-7.87	2.55e-14	5.16e-08	-0.47	-0.34	Mumps;	chr20:2665687	chr12:79558782~79559166:+
THCA	trans	rs7819412	0.595	rs10106914	ENSG00000253893.2	FAM85B	7.86	2.55e-14	5.18e-08	0.45	0.34	Triglycerides;	chr8:11130141	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.806	rs2898256	ENSG00000229857.1	RP11-159H20.3	7.86	2.56e-14	5.19e-08	0.44	0.34	Triglycerides;	chr8:11075185	chr9:76992099~76993108:+
THCA	trans	rs9611519	0.603	rs8142276	ENSG00000268568.1	AC007228.9	-7.86	2.57e-14	5.21e-08	-0.38	-0.34	Neuroticism;	chr22:41075443	chr19:56672574~56673901:-
THCA	trans	rs9611519	0.567	rs8141730	ENSG00000268568.1	AC007228.9	-7.86	2.57e-14	5.21e-08	-0.38	-0.34	Neuroticism;	chr22:41077057	chr19:56672574~56673901:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000212829.8	RPS26P3	-7.86	2.57e-14	5.22e-08	-0.44	-0.34	Cognitive function;	chr12:55996852	chr9:9090898~9091245:+
THCA	trans	rs902774	0.818	rs73110432	ENSG00000248568.1	KRT8P48	-7.86	2.58e-14	5.23e-08	-0.68	-0.34	Prostate cancer;	chr12:52894051	chr5:146706381~146707600:-
THCA	trans	rs66887589	0.627	rs3872807	ENSG00000275858.1	RP11-291L22.8	7.86	2.59e-14	5.25e-08	0.41	0.34	Diastolic blood pressure;	chr4:119439096	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.56	rs9684327	ENSG00000275858.1	RP11-291L22.8	7.86	2.59e-14	5.25e-08	0.41	0.34	Diastolic blood pressure;	chr4:119444286	chr10:38450738~38451069:-
THCA	trans	rs7824557	0.524	rs7835318	ENSG00000229857.1	RP11-159H20.3	7.86	2.6e-14	5.27e-08	0.44	0.34	Retinal vascular caliber;	chr8:11096364	chr9:76992099~76993108:+
THCA	trans	rs66887589	0.775	rs6843229	ENSG00000275858.1	RP11-291L22.8	7.86	2.6e-14	5.27e-08	0.41	0.34	Diastolic blood pressure;	chr4:119502932	chr10:38450738~38451069:-
THCA	trans	rs16937956	0.688	rs10500704	ENSG00000266891.1	RP11-692N5.2	7.86	2.61e-14	5.28e-08	0.46	0.34	Body mass index;	chr11:8429677	chr18:9734882~9735602:-
THCA	trans	rs7819412	0.527	rs7821914	ENSG00000253893.2	FAM85B	7.86	2.62e-14	5.3e-08	0.44	0.34	Triglycerides;	chr8:10947505	chr8:8167819~8226614:-
THCA	trans	rs877636	0.74	rs772920	ENSG00000212829.8	RPS26P3	7.86	2.65e-14	5.38e-08	0.44	0.34	Cognitive function;	chr12:55996580	chr9:9090898~9091245:+
THCA	trans	rs2060793	0.867	rs2122941	ENSG00000236360.2	RP11-334A14.2	7.86	2.66e-14	5.38e-08	0.47	0.34	Vitamin D levels;	chr11:14834821	chr1:52993201~52993702:-
THCA	trans	rs11671005	0.652	rs11670864	ENSG00000279267.1	RP11-395L14.18	7.85	2.76e-14	5.58e-08	0.5	0.34	Mean platelet volume;	chr19:58519213	chr2:113605867~113607908:-
THCA	trans	rs902774	0.818	rs73110432	ENSG00000255815.3	KRT8P11	-7.85	2.77e-14	5.6e-08	-0.68	-0.34	Prostate cancer;	chr12:52894051	chr9:99305176~99306611:+
THCA	trans	rs11638815	0.626	rs11633829	ENSG00000235370.6	DNM1P51	7.85	2.8e-14	5.67e-08	0.44	0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:84398316~84411701:-
THCA	trans	rs877636	1	rs2292239	ENSG00000196933.5	RPS26P11	7.85	2.81e-14	5.69e-08	0.44	0.34	Cognitive function;	chr12:56088396	chrX:72044545~72044892:+
THCA	trans	rs864643	0.678	rs1768191	ENSG00000188856.6	RPSAP47	7.85	2.83e-14	5.73e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39469772	chr8:80558870~80559757:+
THCA	trans	rs804280	0.564	rs4639	ENSG00000256560.1	LINC01486	7.85	2.83e-14	5.73e-08	0.38	0.34	Myopia (pathological);	chr8:11787242	chr12:109354083~109359488:-
THCA	trans	rs77688320	1	rs2540334	ENSG00000235105.1	RP11-329A14.1	-7.85	2.84e-14	5.74e-08	-0.46	-0.34	Breast cancer;	chr2:201406624	chr1:48435967~48437223:+
THCA	trans	rs282544	1	rs27964	ENSG00000231752.4	EMBP1	7.85	2.84e-14	5.75e-08	0.47	0.34	Myopia (pathological);	chr5:50856633	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.524	rs2163379	ENSG00000253893.2	FAM85B	-7.85	2.87e-14	5.79e-08	-0.44	-0.34	Neuroticism;	chr8:10874540	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.515	rs7820860	ENSG00000229857.1	RP11-159H20.3	7.85	2.89e-14	5.84e-08	0.44	0.34	Neuroticism;	chr8:11092886	chr9:76992099~76993108:+
THCA	trans	rs66887589	0.967	rs3775842	ENSG00000275858.1	RP11-291L22.8	7.85	2.91e-14	5.88e-08	0.41	0.34	Diastolic blood pressure;	chr4:119506577	chr10:38450738~38451069:-
THCA	trans	rs73108077	0.736	rs2376545	ENSG00000279352.1	RP11-411B10.7	7.85	2.91e-14	5.88e-08	0.61	0.34	Red blood cell density in sickle cell anemia;	chr20:31293314	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs13433373	ENSG00000279352.1	RP11-411B10.7	7.85	2.91e-14	5.88e-08	0.61	0.34	Red blood cell density in sickle cell anemia;	chr20:31296736	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.688	rs6061150	ENSG00000279352.1	RP11-411B10.7	7.85	2.91e-14	5.88e-08	0.61	0.34	Red blood cell density in sickle cell anemia;	chr20:31301527	chr18:14010054~14010917:+
THCA	trans	rs7824557	0.564	rs7828263	ENSG00000253893.2	FAM85B	7.84	2.97e-14	5.99e-08	0.46	0.34	Retinal vascular caliber;	chr8:11374377	chr8:8167819~8226614:-
THCA	trans	rs9648716	1	rs6976462	ENSG00000224775.2	BRAFP1	7.84	2.98e-14	6.01e-08	0.59	0.34	Type 2 diabetes;	chr7:140937122	chrX:75582676~75585506:+
THCA	trans	rs2250402	0.51	rs2291621	ENSG00000234106.3	RP11-288E14.2	7.84	2.99e-14	6.03e-08	0.62	0.34	Corneal curvature;	chr15:40032636	chr11:93535468~93535816:+
THCA	trans	rs7819412	0.745	rs2898260	ENSG00000229857.1	RP11-159H20.3	7.84	2.99e-14	6.04e-08	0.43	0.34	Triglycerides;	chr8:11081980	chr9:76992099~76993108:+
THCA	trans	rs73108077	0.688	rs6119825	ENSG00000279352.1	RP11-411B10.7	7.84	3e-14	6.05e-08	0.59	0.34	Red blood cell density in sickle cell anemia;	chr20:31326768	chr18:14010054~14010917:+
THCA	trans	rs6424115	1	rs4649115	ENSG00000228217.1	AL390877.1	7.84	3.01e-14	6.08e-08	0.45	0.34	Immature fraction of reticulocytes;	chr1:23829241	chr1:117778087~117778506:-
THCA	trans	rs8067354	0.574	rs1292043	ENSG00000187870.7	RNFT1P3	7.84	3.02e-14	6.09e-08	0.55	0.34	Hemoglobin concentration;	chr17:59856808	chr17:20743333~20754501:-
THCA	trans	rs2060793	0.659	rs1839834	ENSG00000236360.2	RP11-334A14.2	7.84	3.02e-14	6.1e-08	0.45	0.34	Vitamin D levels;	chr11:14807914	chr1:52993201~52993702:-
THCA	trans	rs12145833	1	rs10926986	ENSG00000154608.12	CEP170P1	7.84	3.06e-14	6.16e-08	0.44	0.34	Obesity (early onset extreme);	chr1:243304309	chr4:118467590~118554204:+
THCA	trans	rs9650657	0.801	rs2409663	ENSG00000253893.2	FAM85B	7.84	3.07e-14	6.18e-08	0.43	0.34	Neuroticism;	chr8:10785723	chr8:8167819~8226614:-
THCA	trans	rs11992162	1	rs12334769	ENSG00000253893.2	FAM85B	-7.84	3.07e-14	6.2e-08	-0.46	-0.34	Monocyte count;	chr8:11975652	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.967	rs11250185	ENSG00000253893.2	FAM85B	-7.84	3.09e-14	6.24e-08	-0.46	-0.34	Monocyte count;	chr8:11975614	chr8:8167819~8226614:-
THCA	trans	rs282544	1	rs27255	ENSG00000231752.4	EMBP1	7.84	3.13e-14	6.3e-08	0.47	0.34	Myopia (pathological);	chr5:50825789	chr1:121519112~121571892:+
THCA	trans	rs8067354	0.574	rs1292050	ENSG00000187870.7	RNFT1P3	7.84	3.13e-14	6.3e-08	0.55	0.34	Hemoglobin concentration;	chr17:59887808	chr17:20743333~20754501:-
THCA	trans	rs7819412	0.838	rs3021494	ENSG00000229857.1	RP11-159H20.3	7.84	3.13e-14	6.31e-08	0.44	0.34	Triglycerides;	chr8:11126024	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.566	rs17051356	ENSG00000275858.1	RP11-291L22.8	7.84	3.14e-14	6.32e-08	0.46	0.34	Corneal astigmatism;	chr4:119664153	chr10:38450738~38451069:-
THCA	trans	rs10242455	1	rs1859690	ENSG00000228834.1	RP11-249L21.4	7.84	3.15e-14	6.35e-08	0.63	0.34	Blood metabolite levels;	chr7:99629549	chr6:108907615~108907873:-
THCA	trans	rs9611519	0.603	rs4821999	ENSG00000268568.1	AC007228.9	-7.83	3.17e-14	6.39e-08	-0.38	-0.34	Neuroticism;	chr22:41073997	chr19:56672574~56673901:-
THCA	trans	rs867371	1	rs6495642	ENSG00000235370.6	DNM1P51	-7.83	3.18e-14	6.4e-08	-0.43	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:84398316~84411701:-
THCA	trans	rs1563304	1	rs1563304	ENSG00000214425.5	LRRC37A4P	-7.83	3.19e-14	6.41e-08	-0.6	-0.34	Neuroticism;	chr17:46797087	chr17:45506741~45550335:-
THCA	trans	rs864643	0.678	rs1768158	ENSG00000188856.6	RPSAP47	-7.83	3.2e-14	6.43e-08	-0.52	-0.34	Attention deficit hyperactivity disorder;	chr3:39465870	chr8:80558870~80559757:+
THCA	trans	rs864643	0.677	rs1708087	ENSG00000188856.6	RPSAP47	7.83	3.2e-14	6.43e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39468197	chr8:80558870~80559757:+
THCA	trans	rs877636	1	rs2292239	ENSG00000244604.1	RP11-713H12.1	7.83	3.22e-14	6.48e-08	0.44	0.34	Cognitive function;	chr12:56088396	chr17:8561230~8561576:+
THCA	trans	rs9650657	0.74	rs6980805	ENSG00000253893.2	FAM85B	7.83	3.27e-14	6.58e-08	0.44	0.34	Neuroticism;	chr8:10822332	chr8:8167819~8226614:-
THCA	trans	rs10037055	0.853	rs10077929	ENSG00000226986.4	RP11-543B16.2	7.83	3.31e-14	6.66e-08	0.36	0.34	Migraine without aura;	chr5:177270843	chr1:211207239~211207897:+
THCA	trans	rs2060793	0.769	rs7125781	ENSG00000236360.2	RP11-334A14.2	7.83	3.33e-14	6.69e-08	0.47	0.34	Vitamin D levels;	chr11:14856401	chr1:52993201~52993702:-
THCA	trans	rs2060793	0.87	rs6486205	ENSG00000236360.2	RP11-334A14.2	7.83	3.33e-14	6.69e-08	0.47	0.34	Vitamin D levels;	chr11:14859710	chr1:52993201~52993702:-
THCA	trans	rs2060793	0.87	rs7116978	ENSG00000236360.2	RP11-334A14.2	7.83	3.33e-14	6.69e-08	0.47	0.34	Vitamin D levels;	chr11:14860225	chr1:52993201~52993702:-
THCA	trans	rs2060793	0.87	rs1868997	ENSG00000236360.2	RP11-334A14.2	7.83	3.33e-14	6.69e-08	0.47	0.34	Vitamin D levels;	chr11:14872674	chr1:52993201~52993702:-
THCA	trans	rs864643	0.625	rs694380	ENSG00000188856.6	RPSAP47	7.83	3.35e-14	6.73e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39494399	chr8:80558870~80559757:+
THCA	trans	rs12709013	0.967	rs8054482	ENSG00000233719.3	GOT2P3	7.83	3.37e-14	6.77e-08	0.41	0.34	Blood metabolite ratios;	chr16:58810532	chr12:9641802~9643007:+
THCA	trans	rs9858542	0.903	rs11921590	ENSG00000197582.5	GPX1P1	-7.83	3.38e-14	6.78e-08	-0.53	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606760	chrX:13378735~13379340:-
THCA	trans	rs2250402	0.51	rs2898984	ENSG00000234106.3	RP11-288E14.2	7.83	3.38e-14	6.79e-08	0.62	0.34	Corneal curvature;	chr15:40031874	chr11:93535468~93535816:+
THCA	trans	rs11671005	0.651	rs55716128	ENSG00000279267.1	RP11-395L14.18	7.82	3.4e-14	6.82e-08	0.49	0.34	Mean platelet volume;	chr19:58537387	chr2:113605867~113607908:-
THCA	trans	rs11098499	0.588	rs2389874	ENSG00000275858.1	RP11-291L22.8	-7.82	3.42e-14	6.86e-08	-0.42	-0.34	Corneal astigmatism;	chr4:119633836	chr10:38450738~38451069:-
THCA	trans	rs9650657	0.871	rs7814142	ENSG00000253893.2	FAM85B	7.82	3.42e-14	6.86e-08	0.43	0.34	Neuroticism;	chr8:10780042	chr8:8167819~8226614:-
THCA	trans	rs748404	0.66	rs693510	ENSG00000180867.10	PDIA3P1	-7.82	3.43e-14	6.87e-08	-0.29	-0.34	Lung cancer;	chr15:43422427	chr1:147178113~147179622:+
THCA	trans	rs748404	0.66	rs690512	ENSG00000180867.10	PDIA3P1	-7.82	3.43e-14	6.87e-08	-0.29	-0.34	Lung cancer;	chr15:43425480	chr1:147178113~147179622:+
THCA	trans	rs748404	0.66	rs542898	ENSG00000180867.10	PDIA3P1	-7.82	3.43e-14	6.87e-08	-0.29	-0.34	Lung cancer;	chr15:43427194	chr1:147178113~147179622:+
THCA	trans	rs748404	0.66	rs2249952	ENSG00000180867.10	PDIA3P1	-7.82	3.43e-14	6.87e-08	-0.29	-0.34	Lung cancer;	chr15:43428335	chr1:147178113~147179622:+
THCA	trans	rs748404	0.66	rs689767	ENSG00000180867.10	PDIA3P1	-7.82	3.43e-14	6.87e-08	-0.29	-0.34	Lung cancer;	chr15:43429879	chr1:147178113~147179622:+
THCA	trans	rs748404	0.66	rs2439845	ENSG00000180867.10	PDIA3P1	-7.82	3.43e-14	6.87e-08	-0.29	-0.34	Lung cancer;	chr15:43430412	chr1:147178113~147179622:+
THCA	trans	rs748404	0.631	rs2467745	ENSG00000180867.10	PDIA3P1	-7.82	3.43e-14	6.87e-08	-0.29	-0.34	Lung cancer;	chr15:43430544	chr1:147178113~147179622:+
THCA	trans	rs877636	1	rs4759229	ENSG00000244604.1	RP11-713H12.1	-7.82	3.43e-14	6.89e-08	-0.44	-0.34	Cognitive function;	chr12:56080696	chr17:8561230~8561576:+
THCA	trans	rs10028773	0.546	rs13117947	ENSG00000275858.1	RP11-291L22.8	7.82	3.46e-14	6.94e-08	0.42	0.34	Educational attainment;	chr4:119335905	chr10:38450738~38451069:-
THCA	trans	rs7819412	0.807	rs10105315	ENSG00000229857.1	RP11-159H20.3	7.82	3.47e-14	6.97e-08	0.43	0.34	Triglycerides;	chr8:11074693	chr9:76992099~76993108:+
THCA	trans	rs877636	1	rs2292239	ENSG00000224553.1	AC008065.1	7.82	3.49e-14	7e-08	0.41	0.34	Cognitive function;	chr12:56088396	chr2:171374931~171375278:-
THCA	trans	rs864643	0.812	rs6809442	ENSG00000188856.6	RPSAP47	-7.82	3.49e-14	7e-08	-0.48	-0.34	Attention deficit hyperactivity disorder;	chr3:39517666	chr8:80558870~80559757:+
THCA	trans	rs6732160	0.932	rs13417029	ENSG00000236165.1	PRADC1P1	7.82	3.5e-14	7.01e-08	0.46	0.34	Intelligence (multi-trait analysis);	chr2:73153295	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.932	rs6546803	ENSG00000236165.1	PRADC1P1	7.82	3.5e-14	7.01e-08	0.46	0.34	Intelligence (multi-trait analysis);	chr2:73154187	chr3:36976316~36976840:+
THCA	trans	rs748404	0.586	rs2584700	ENSG00000180867.10	PDIA3P1	-7.82	3.5e-14	7.01e-08	-0.3	-0.34	Lung cancer;	chr15:43393134	chr1:147178113~147179622:+
THCA	trans	rs9650657	0.515	rs6601560	ENSG00000229857.1	RP11-159H20.3	7.82	3.51e-14	7.03e-08	0.44	0.34	Neuroticism;	chr8:11093356	chr9:76992099~76993108:+
THCA	trans	rs73108077	0.736	rs1997742	ENSG00000279352.1	RP11-411B10.7	7.82	3.52e-14	7.05e-08	0.59	0.34	Red blood cell density in sickle cell anemia;	chr20:31347432	chr18:14010054~14010917:+
THCA	trans	rs34421088	0.56	rs1478898	ENSG00000253893.2	FAM85B	7.82	3.56e-14	7.13e-08	0.45	0.34	Neuroticism;	chr8:11537570	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.825	rs62367471	ENSG00000231752.4	EMBP1	7.82	3.57e-14	7.15e-08	0.54	0.34	Age at first birth;	chr5:45197217	chr1:121519112~121571892:+
THCA	trans	rs1991651	0.507	rs17778581	ENSG00000253893.2	FAM85B	7.82	3.58e-14	7.16e-08	0.42	0.34	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10885911	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.908	rs7696649	ENSG00000253326.2	RP11-261C10.7	7.82	3.59e-14	7.18e-08	0.48	0.34	Corneal astigmatism;	chr4:119401022	chr1:243054861~243056394:-
THCA	trans	rs748404	0.631	rs6493083	ENSG00000180867.10	PDIA3P1	-7.82	3.61e-14	7.23e-08	-0.3	-0.34	Lung cancer;	chr15:43345787	chr1:147178113~147179622:+
THCA	trans	rs864643	0.812	rs7620264	ENSG00000188856.6	RPSAP47	-7.82	3.62e-14	7.24e-08	-0.48	-0.34	Attention deficit hyperactivity disorder;	chr3:39537539	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.562	rs13101722	ENSG00000275858.1	RP11-291L22.8	-7.81	3.66e-14	7.31e-08	-0.42	-0.34	Corneal astigmatism;	chr4:119634820	chr10:38450738~38451069:-
THCA	trans	rs748404	0.66	rs2602141	ENSG00000180867.10	PDIA3P1	-7.81	3.67e-14	7.34e-08	-0.29	-0.34	Lung cancer;	chr15:43432448	chr1:147178113~147179622:+
THCA	trans	rs864643	0.773	rs2280082	ENSG00000188856.6	RPSAP47	-7.81	3.69e-14	7.37e-08	-0.47	-0.34	Attention deficit hyperactivity disorder;	chr3:39528519	chr8:80558870~80559757:+
THCA	trans	rs6743068	0.522	rs6757783	ENSG00000235105.1	RP11-329A14.1	7.81	3.69e-14	7.38e-08	0.37	0.34	Lymphocyte percentage of white cells;	chr2:201335101	chr1:48435967~48437223:+
THCA	trans	rs6743068	0.541	rs12052257	ENSG00000235105.1	RP11-329A14.1	-7.81	3.73e-14	7.45e-08	-0.37	-0.34	Lymphocyte percentage of white cells;	chr2:201376871	chr1:48435967~48437223:+
THCA	trans	rs11992162	1	rs11784499	ENSG00000253893.2	FAM85B	-7.81	3.73e-14	7.46e-08	-0.46	-0.34	Monocyte count;	chr8:11977030	chr8:8167819~8226614:-
THCA	trans	rs14057	0.864	rs3827729	ENSG00000215869.3	RP11-364B6.1	7.81	3.77e-14	7.53e-08	0.49	0.34	Systolic blood pressure;	chr1:6696374	chr1:104073023~104077087:+
THCA	trans	rs10242455	0.867	rs10282706	ENSG00000228834.1	RP11-249L21.4	7.81	3.78e-14	7.55e-08	0.64	0.34	Blood metabolite levels;	chr7:99619801	chr6:108907615~108907873:-
THCA	trans	rs12709013	1	rs6499983	ENSG00000233719.3	GOT2P3	7.81	3.78e-14	7.55e-08	0.41	0.34	Blood metabolite ratios;	chr16:58810005	chr12:9641802~9643007:+
THCA	trans	rs10242455	0.867	rs2687144	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99721185	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2740562	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99721534	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687143	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99722846	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687142	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99722947	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.764	rs2740561	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99723818	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687141	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99723856	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2404770	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99723989	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2404769	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99724093	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687139	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99725451	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.681	rs2740559	ENSG00000228834.1	RP11-249L21.4	-7.81	3.79e-14	7.56e-08	-0.62	-0.34	Blood metabolite levels;	chr7:99726892	chr6:108907615~108907873:-
THCA	trans	rs867371	0.929	rs1045508	ENSG00000235370.6	DNM1P51	7.81	3.82e-14	7.63e-08	0.42	0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:84398316~84411701:-
THCA	trans	rs7113874	0.659	rs12295855	ENSG00000266891.1	RP11-692N5.2	7.81	3.84e-14	7.65e-08	0.48	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8505871	chr18:9734882~9735602:-
THCA	trans	rs14057	0.965	rs2294526	ENSG00000215869.3	RP11-364B6.1	7.81	3.84e-14	7.66e-08	0.48	0.34	Systolic blood pressure;	chr1:6675642	chr1:104073023~104077087:+
THCA	trans	rs11098499	0.909	rs11723839	ENSG00000253326.2	RP11-261C10.7	7.81	3.87e-14	7.71e-08	0.48	0.34	Corneal astigmatism;	chr4:119378518	chr1:243054861~243056394:-
THCA	trans	rs10242455	0.867	rs13362853	ENSG00000228834.1	RP11-249L21.4	7.8	3.94e-14	7.86e-08	0.63	0.34	Blood metabolite levels;	chr7:99625524	chr6:108907615~108907873:-
THCA	trans	rs748404	0.578	rs507178	ENSG00000180867.10	PDIA3P1	-7.8	3.95e-14	7.87e-08	-0.29	-0.34	Lung cancer;	chr15:43317937	chr1:147178113~147179622:+
THCA	trans	rs7032940	0.677	rs4279674	ENSG00000262519.1	TXNP4	7.8	3.95e-14	7.88e-08	0.43	0.34	Height;	chr9:110179726	chr17:4572206~4572515:+
THCA	trans	rs748404	0.631	rs7167882	ENSG00000180867.10	PDIA3P1	-7.8	3.99e-14	7.95e-08	-0.3	-0.34	Lung cancer;	chr15:43386465	chr1:147178113~147179622:+
THCA	trans	rs941207	0.756	rs7978685	ENSG00000257210.1	NACAP3	7.8	4e-14	7.96e-08	0.45	0.34	Platelet count;	chr12:56709370	chr12:93124063~93124543:-
THCA	trans	rs7824557	0.564	rs11782430	ENSG00000253893.2	FAM85B	7.8	4e-14	7.97e-08	0.45	0.34	Retinal vascular caliber;	chr8:11368562	chr8:8167819~8226614:-
THCA	trans	rs864643	0.812	rs3821372	ENSG00000188856.6	RPSAP47	-7.8	4.01e-14	7.99e-08	-0.48	-0.34	Attention deficit hyperactivity disorder;	chr3:39506880	chr8:80558870~80559757:+
THCA	trans	rs12709013	1	rs11648514	ENSG00000233719.3	GOT2P3	7.8	4.02e-14	8.01e-08	0.41	0.34	Blood metabolite ratios;	chr16:58798176	chr12:9641802~9643007:+
THCA	trans	rs12709013	1	rs8057892	ENSG00000233719.3	GOT2P3	7.8	4.02e-14	8.01e-08	0.41	0.34	Blood metabolite ratios;	chr16:58798855	chr12:9641802~9643007:+
THCA	trans	rs12709013	1	rs11644891	ENSG00000233719.3	GOT2P3	7.8	4.02e-14	8.01e-08	0.41	0.34	Blood metabolite ratios;	chr16:58799921	chr12:9641802~9643007:+
THCA	trans	rs12709013	1	rs11641566	ENSG00000233719.3	GOT2P3	7.8	4.02e-14	8.01e-08	0.41	0.34	Blood metabolite ratios;	chr16:58801276	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.967	rs56107162	ENSG00000233719.3	GOT2P3	7.8	4.03e-14	8.03e-08	0.41	0.34	Blood metabolite ratios;	chr16:58804358	chr12:9641802~9643007:+
THCA	trans	rs1707322	0.717	rs2275086	ENSG00000255397.1	AC022182.2	7.8	4.05e-14	8.07e-08	0.48	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr8:60937705~60939871:-
THCA	trans	rs7819412	0.595	rs4841500	ENSG00000253893.2	FAM85B	7.8	4.06e-14	8.08e-08	0.45	0.34	Triglycerides;	chr8:11130765	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.909	rs9759478	ENSG00000253326.2	RP11-261C10.7	7.8	4.06e-14	8.08e-08	0.48	0.34	Corneal astigmatism;	chr4:119446843	chr1:243054861~243056394:-
THCA	trans	rs748404	0.631	rs2412781	ENSG00000180867.10	PDIA3P1	7.8	4.08e-14	8.13e-08	0.3	0.34	Lung cancer;	chr15:43375702	chr1:147178113~147179622:+
THCA	trans	rs10816533	1	rs10117162	ENSG00000232063.1	RP11-307E17.8	7.8	4.09e-14	8.14e-08	0.84	0.34	Height;	chr9:96841714	chr9:94332476~94360948:+
THCA	trans	rs282544	1	rs26072	ENSG00000231752.4	EMBP1	7.8	4.12e-14	8.19e-08	0.47	0.34	Myopia (pathological);	chr5:50807784	chr1:121519112~121571892:+
THCA	trans	rs11250098	0.567	rs4326350	ENSG00000253893.2	FAM85B	-7.8	4.16e-14	8.28e-08	-0.42	-0.34	Morning vs. evening chronotype;	chr8:10906145	chr8:8167819~8226614:-
THCA	trans	rs79149102	0.522	rs74925675	ENSG00000227288.3	RP5-837I24.1	7.8	4.18e-14	8.3e-08	0.53	0.34	Lung cancer;	chr15:74613415	chr1:81501794~81503468:+
THCA	trans	rs864643	0.678	rs1398668	ENSG00000183298.5	RP11-556K13.1	7.79	4.26e-14	8.46e-08	0.57	0.34	Attention deficit hyperactivity disorder;	chr3:39475753	chr1:101786340~101787219:-
THCA	trans	rs11250098	0.547	rs2409764	ENSG00000253893.2	FAM85B	-7.79	4.26e-14	8.47e-08	-0.44	-0.34	Morning vs. evening chronotype;	chr8:11423764	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.613	rs4326784	ENSG00000266891.1	RP11-692N5.2	7.79	4.26e-14	8.47e-08	0.48	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8511602	chr18:9734882~9735602:-
THCA	trans	rs282544	1	rs282544	ENSG00000231752.4	EMBP1	-7.79	4.29e-14	8.52e-08	-0.47	-0.34	Myopia (pathological);	chr5:50730631	chr1:121519112~121571892:+
THCA	trans	rs864643	0.678	rs512923	ENSG00000188856.6	RPSAP47	7.79	4.31e-14	8.57e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39480472	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs621842	ENSG00000188856.6	RPSAP47	7.79	4.31e-14	8.57e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39480785	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs610006	ENSG00000188856.6	RPSAP47	7.79	4.31e-14	8.57e-08	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39481104	chr8:80558870~80559757:+
THCA	trans	rs11671005	0.61	rs2305122	ENSG00000279267.1	RP11-395L14.18	7.79	4.33e-14	8.6e-08	0.49	0.34	Mean platelet volume;	chr19:58545385	chr2:113605867~113607908:-
THCA	trans	rs13091206	1	rs13091206	ENSG00000197582.5	GPX1P1	7.79	4.35e-14	8.64e-08	0.6	0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr3:49201285	chrX:13378735~13379340:-
THCA	trans	rs9648716	1	rs7798324	ENSG00000224775.2	BRAFP1	7.79	4.38e-14	8.69e-08	0.58	0.34	Type 2 diabetes;	chr7:140867652	chrX:75582676~75585506:+
THCA	trans	rs740160	0.51	rs733991	ENSG00000228834.1	RP11-249L21.4	7.79	4.43e-14	8.79e-08	0.67	0.34	Dehydroepiandrosterone sulphate levels;	chr7:99297627	chr6:108907615~108907873:-
THCA	trans	rs864643	0.686	rs7649257	ENSG00000188856.6	RPSAP47	7.78	4.48e-14	8.89e-08	0.65	0.34	Attention deficit hyperactivity disorder;	chr3:39557052	chr8:80558870~80559757:+
THCA	trans	rs14057	0.93	rs3789573	ENSG00000215869.3	RP11-364B6.1	7.78	4.49e-14	8.91e-08	0.48	0.34	Systolic blood pressure;	chr1:6670845	chr1:104073023~104077087:+
THCA	trans	rs14057	0.965	rs2294528	ENSG00000215869.3	RP11-364B6.1	7.78	4.54e-14	9e-08	0.48	0.34	Systolic blood pressure;	chr1:6669689	chr1:104073023~104077087:+
THCA	trans	rs7819412	0.525	rs10086521	ENSG00000253893.2	FAM85B	7.78	4.55e-14	9.02e-08	0.44	0.34	Triglycerides;	chr8:10926259	chr8:8167819~8226614:-
THCA	trans	rs2060793	0.712	rs6486202	ENSG00000236360.2	RP11-334A14.2	7.78	4.56e-14	9.04e-08	0.45	0.34	Vitamin D levels;	chr11:14777260	chr1:52993201~52993702:-
THCA	trans	rs864643	0.812	rs2039843	ENSG00000188856.6	RPSAP47	-7.78	4.62e-14	9.15e-08	-0.48	-0.34	Attention deficit hyperactivity disorder;	chr3:39515347	chr8:80558870~80559757:+
THCA	trans	rs864643	0.812	rs12490768	ENSG00000188856.6	RPSAP47	-7.78	4.64e-14	9.18e-08	-0.47	-0.34	Attention deficit hyperactivity disorder;	chr3:39521874	chr8:80558870~80559757:+
THCA	trans	rs6424115	1	rs7521961	ENSG00000228217.1	AL390877.1	7.78	4.7e-14	9.29e-08	0.44	0.34	Immature fraction of reticulocytes;	chr1:23831144	chr1:117778087~117778506:-
THCA	trans	rs6424115	1	rs7515969	ENSG00000228217.1	AL390877.1	7.78	4.7e-14	9.29e-08	0.44	0.34	Immature fraction of reticulocytes;	chr1:23831908	chr1:117778087~117778506:-
THCA	trans	rs7819412	0.807	rs4840542	ENSG00000229857.1	RP11-159H20.3	7.78	4.7e-14	9.3e-08	0.43	0.34	Triglycerides;	chr8:11087299	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.954	rs12506546	ENSG00000253326.2	RP11-261C10.7	7.78	4.72e-14	9.34e-08	0.48	0.34	Corneal astigmatism;	chr4:119380463	chr1:243054861~243056394:-
THCA	trans	rs73108077	0.736	rs56047717	ENSG00000279352.1	RP11-411B10.7	7.78	4.8e-14	9.51e-08	0.62	0.34	Red blood cell density in sickle cell anemia;	chr20:31279756	chr18:14010054~14010917:+
THCA	trans	rs9650657	0.707	rs7814757	ENSG00000253893.2	FAM85B	7.77	4.82e-14	9.54e-08	0.43	0.34	Neuroticism;	chr8:10817678	chr8:8167819~8226614:-
THCA	trans	rs9292918	0.951	rs6874127	ENSG00000231752.4	EMBP1	7.77	4.84e-14	9.57e-08	0.49	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45305513	chr1:121519112~121571892:+
THCA	trans	rs12709013	0.967	rs2118019	ENSG00000233719.3	GOT2P3	-7.77	4.87e-14	9.63e-08	-0.41	-0.34	Blood metabolite ratios;	chr16:58797825	chr12:9641802~9643007:+
THCA	trans	rs7312770	0.637	rs705700	ENSG00000233278.1	RPS26P2	7.77	4.88e-14	9.65e-08	0.39	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr9:30831878~30832225:-
THCA	trans	rs11098499	0.697	rs4560394	ENSG00000253326.2	RP11-261C10.7	7.77	4.9e-14	9.69e-08	0.48	0.34	Corneal astigmatism;	chr4:119392280	chr1:243054861~243056394:-
THCA	trans	rs864643	0.947	rs111513993	ENSG00000188856.6	RPSAP47	7.77	4.93e-14	9.71e-08	0.65	0.34	Attention deficit hyperactivity disorder;	chr3:39552381	chr8:80558870~80559757:+
THCA	trans	rs867371	0.82	rs12443224	ENSG00000235370.6	DNM1P51	-7.77	4.93e-14	9.73e-08	-0.42	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:84398316~84411701:-
THCA	trans	rs7121616	0.562	rs7131452	ENSG00000229091.2	HSPA8P8	7.77	4.98e-14	9.82e-08	0.44	0.34	Breast cancer;	chr11:123065314	chr7:10451311~10452526:+
THCA	trans	rs11098499	0.954	rs12502423	ENSG00000253326.2	RP11-261C10.7	7.77	5.01e-14	9.88e-08	0.48	0.34	Corneal astigmatism;	chr4:119503017	chr1:243054861~243056394:-
THCA	trans	rs282544	0.686	rs282547	ENSG00000231752.4	EMBP1	-7.77	5.05e-14	9.95e-08	-0.47	-0.34	Myopia (pathological);	chr5:50761895	chr1:121519112~121571892:+
THCA	trans	rs11671005	0.61	rs3794966	ENSG00000279267.1	RP11-395L14.18	7.77	5.08e-14	1e-07	0.48	0.34	Mean platelet volume;	chr19:58557629	chr2:113605867~113607908:-
THCA	trans	rs10242455	0.867	rs2037498	ENSG00000228834.1	RP11-249L21.4	-7.77	5.08e-14	1e-07	-0.61	-0.34	Blood metabolite levels;	chr7:99713927	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687075	ENSG00000228834.1	RP11-249L21.4	-7.77	5.08e-14	1e-07	-0.61	-0.34	Blood metabolite levels;	chr7:99717363	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.614	rs2687072	ENSG00000228834.1	RP11-249L21.4	-7.77	5.08e-14	1e-07	-0.61	-0.34	Blood metabolite levels;	chr7:99719303	chr6:108907615~108907873:-
THCA	trans	rs6424115	1	rs34477640	ENSG00000228217.1	AL390877.1	7.77	5.12e-14	1.01e-07	0.44	0.34	Immature fraction of reticulocytes;	chr1:23827577	chr1:117778087~117778506:-
THCA	trans	rs6424115	1	rs7519554	ENSG00000228217.1	AL390877.1	7.77	5.12e-14	1.01e-07	0.44	0.34	Immature fraction of reticulocytes;	chr1:23828076	chr1:117778087~117778506:-
THCA	trans	rs2060793	0.741	rs10734227	ENSG00000236360.2	RP11-334A14.2	7.77	5.14e-14	1.01e-07	0.45	0.34	Vitamin D levels;	chr11:14767471	chr1:52993201~52993702:-
THCA	trans	rs9648716	1	rs765373	ENSG00000224775.2	BRAFP1	7.77	5.15e-14	1.01e-07	0.58	0.34	Type 2 diabetes;	chr7:140927176	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6464157	ENSG00000224775.2	BRAFP1	7.77	5.15e-14	1.01e-07	0.58	0.34	Type 2 diabetes;	chr7:140929608	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs6464159	ENSG00000224775.2	BRAFP1	7.77	5.15e-14	1.01e-07	0.58	0.34	Type 2 diabetes;	chr7:140930466	chrX:75582676~75585506:+
THCA	trans	rs9648716	0.935	rs28605757	ENSG00000224775.2	BRAFP1	7.77	5.15e-14	1.01e-07	0.58	0.34	Type 2 diabetes;	chr7:140931895	chrX:75582676~75585506:+
THCA	trans	rs748404	0.66	rs2439846	ENSG00000180867.10	PDIA3P1	-7.76	5.18e-14	1.02e-07	-0.29	-0.34	Lung cancer;	chr15:43448772	chr1:147178113~147179622:+
THCA	trans	rs748404	0.66	rs2467741	ENSG00000180867.10	PDIA3P1	-7.76	5.18e-14	1.02e-07	-0.29	-0.34	Lung cancer;	chr15:43450428	chr1:147178113~147179622:+
THCA	trans	rs10242455	1	rs10229552	ENSG00000228834.1	RP11-249L21.4	7.76	5.19e-14	1.02e-07	0.63	0.34	Blood metabolite levels;	chr7:99637276	chr6:108907615~108907873:-
THCA	trans	rs864643	0.773	rs3821373	ENSG00000188856.6	RPSAP47	-7.76	5.19e-14	1.02e-07	-0.47	-0.34	Attention deficit hyperactivity disorder;	chr3:39512285	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs563767	ENSG00000188856.6	RPSAP47	7.76	5.19e-14	1.02e-07	0.5	0.34	Attention deficit hyperactivity disorder;	chr3:39498075	chr8:80558870~80559757:+
THCA	trans	rs11638815	0.603	rs2678448	ENSG00000235370.6	DNM1P51	-7.76	5.2e-14	1.02e-07	-0.43	-0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82594655	chr15:84398316~84411701:-
THCA	trans	rs864643	0.678	rs1768206	ENSG00000188856.6	RPSAP47	7.76	5.21e-14	1.02e-07	0.53	0.34	Attention deficit hyperactivity disorder;	chr3:39480342	chr8:80558870~80559757:+
THCA	trans	rs748404	0.578	rs510108	ENSG00000180867.10	PDIA3P1	-7.76	5.21e-14	1.02e-07	-0.29	-0.34	Lung cancer;	chr15:43313241	chr1:147178113~147179622:+
THCA	trans	rs748404	0.578	rs4547312	ENSG00000180867.10	PDIA3P1	-7.76	5.25e-14	1.03e-07	-0.29	-0.34	Lung cancer;	chr15:43339940	chr1:147178113~147179622:+
THCA	trans	rs6424115	1	rs12031592	ENSG00000228217.1	AL390877.1	-7.76	5.27e-14	1.03e-07	-0.44	-0.34	Immature fraction of reticulocytes;	chr1:23801374	chr1:117778087~117778506:-
THCA	trans	rs7032940	0.677	rs1331310	ENSG00000262519.1	TXNP4	7.76	5.29e-14	1.04e-07	0.43	0.34	Height;	chr9:110179601	chr17:4572206~4572515:+
THCA	trans	rs11098499	0.954	rs59394118	ENSG00000253326.2	RP11-261C10.7	7.76	5.34e-14	1.05e-07	0.47	0.34	Corneal astigmatism;	chr4:119374396	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs9996417	ENSG00000253326.2	RP11-261C10.7	7.76	5.34e-14	1.05e-07	0.47	0.34	Corneal astigmatism;	chr4:119374707	chr1:243054861~243056394:-
THCA	trans	rs10242455	0.867	rs45624139	ENSG00000228834.1	RP11-249L21.4	7.76	5.34e-14	1.05e-07	0.63	0.34	Blood metabolite levels;	chr7:99721872	chr6:108907615~108907873:-
THCA	trans	rs748404	0.578	rs576557	ENSG00000180867.10	PDIA3P1	-7.76	5.36e-14	1.05e-07	-0.29	-0.34	Lung cancer;	chr15:43305539	chr1:147178113~147179622:+
THCA	trans	rs13190036	0.748	rs28395268	ENSG00000228305.2	AC016734.2	7.76	5.36e-14	1.05e-07	0.38	0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr2:63622178~63622831:-
THCA	trans	rs3849046	0.817	rs154069	ENSG00000226666.1	HSPA9P1	7.76	5.39e-14	1.06e-07	0.36	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138541231	chr2:221961737~221963765:+
THCA	trans	rs6743068	0.541	rs6435079	ENSG00000235105.1	RP11-329A14.1	7.76	5.41e-14	1.06e-07	0.37	0.34	Lymphocyte percentage of white cells;	chr2:201335608	chr1:48435967~48437223:+
THCA	trans	rs11098499	0.954	rs3733524	ENSG00000253326.2	RP11-261C10.7	7.76	5.43e-14	1.06e-07	0.48	0.34	Corneal astigmatism;	chr4:119502574	chr1:243054861~243056394:-
THCA	trans	rs12709013	1	rs12926993	ENSG00000233719.3	GOT2P3	7.76	5.45e-14	1.07e-07	0.41	0.34	Blood metabolite ratios;	chr16:58789218	chr12:9641802~9643007:+
THCA	trans	rs864643	0.678	rs1398668	ENSG00000188856.6	RPSAP47	7.76	5.46e-14	1.07e-07	0.52	0.34	Attention deficit hyperactivity disorder;	chr3:39475753	chr8:80558870~80559757:+
THCA	trans	rs9650657	0.812	rs7834466	ENSG00000253893.2	FAM85B	7.76	5.49e-14	1.08e-07	0.43	0.34	Neuroticism;	chr8:10777295	chr8:8167819~8226614:-
THCA	trans	rs864643	0.678	rs1768198	ENSG00000183298.5	RP11-556K13.1	7.76	5.5e-14	1.08e-07	0.57	0.34	Attention deficit hyperactivity disorder;	chr3:39474994	chr1:101786340~101787219:-
THCA	trans	rs748404	0.578	rs478028	ENSG00000180867.10	PDIA3P1	-7.75	5.56e-14	1.09e-07	-0.29	-0.34	Lung cancer;	chr15:43318574	chr1:147178113~147179622:+
THCA	trans	rs748404	0.578	rs552701	ENSG00000180867.10	PDIA3P1	-7.75	5.56e-14	1.09e-07	-0.29	-0.34	Lung cancer;	chr15:43321612	chr1:147178113~147179622:+
THCA	trans	rs748404	0.578	rs573615	ENSG00000180867.10	PDIA3P1	-7.75	5.56e-14	1.09e-07	-0.29	-0.34	Lung cancer;	chr15:43322083	chr1:147178113~147179622:+
THCA	trans	rs10783779	0.647	rs705708	ENSG00000212994.5	RPS26P6	7.75	5.6e-14	1.1e-07	0.42	0.34	Educational attainment;	chr12:56095129	chr8:100895771~100896118:+
THCA	trans	rs2060793	0.87	rs10732460	ENSG00000236360.2	RP11-334A14.2	7.75	5.64e-14	1.1e-07	0.46	0.34	Vitamin D levels;	chr11:14854025	chr1:52993201~52993702:-
THCA	trans	rs1821002	1	rs1821002	ENSG00000253893.2	FAM85B	7.75	5.73e-14	1.12e-07	0.43	0.34	Systolic blood pressure;	chr8:10782555	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.903	rs11917431	ENSG00000197582.5	GPX1P1	-7.75	5.74e-14	1.12e-07	-0.53	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606579	chrX:13378735~13379340:-
THCA	trans	rs6915893	0.967	rs10949483	ENSG00000267156.1	TPMTP1	7.75	5.77e-14	1.13e-07	0.36	0.34	Intrinsic epigenetic age acceleration;	chr6:18122275	chr18:47630112~47630848:+
THCA	trans	rs1707322	0.686	rs2230658	ENSG00000255397.1	AC022182.2	7.75	5.77e-14	1.13e-07	0.48	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.686	rs2991986	ENSG00000255397.1	AC022182.2	7.75	5.77e-14	1.13e-07	0.48	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.686	rs2991987	ENSG00000255397.1	AC022182.2	7.75	5.77e-14	1.13e-07	0.48	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr8:60937705~60939871:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000204652.6	RPS26P8	7.75	5.82e-14	1.14e-07	0.46	0.34	Cognitive function;	chr12:55990903	chr17:45608571~45608918:+
THCA	trans	rs6424115	1	rs1018396	ENSG00000228217.1	AL390877.1	-7.75	5.87e-14	1.15e-07	-0.44	-0.34	Immature fraction of reticulocytes;	chr1:23807122	chr1:117778087~117778506:-
THCA	trans	rs6424115	1	rs35385477	ENSG00000228217.1	AL390877.1	-7.75	5.91e-14	1.15e-07	-0.44	-0.34	Immature fraction of reticulocytes;	chr1:23829434	chr1:117778087~117778506:-
THCA	trans	rs748404	0.66	rs694725	ENSG00000180867.10	PDIA3P1	-7.74	5.95e-14	1.16e-07	-0.29	-0.34	Lung cancer;	chr15:43464012	chr1:147178113~147179622:+
THCA	trans	rs11098499	0.954	rs59866101	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119375436	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.618	rs6858383	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119375617	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.697	rs6832410	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119375645	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs1112817	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119376645	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.779	rs10016060	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119377257	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10005644	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119377322	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.697	rs10016448	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119377690	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.657	rs9996569	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119377849	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.908	rs11729050	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119378911	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs28429722	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119378938	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10014845	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119379922	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.779	rs7674500	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119382438	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs28884220	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119386056	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs28793658	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119386059	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs4507344	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119386330	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.697	rs4373140	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119386543	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs13113483	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119387884	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.542	rs10440343	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119388632	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs28668716	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119388720	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.542	rs7677836	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119389483	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs10002083	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119389997	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10024844	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119390373	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs7437420	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119391748	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs4345162	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119391804	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.657	rs4463052	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119392103	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs13151285	ENSG00000253326.2	RP11-261C10.7	7.74	5.96e-14	1.16e-07	0.47	0.34	Corneal astigmatism;	chr4:119393586	chr1:243054861~243056394:-
THCA	trans	rs66887589	0.967	rs1155577	ENSG00000275858.1	RP11-291L22.8	-7.74	5.97e-14	1.16e-07	-0.4	-0.34	Diastolic blood pressure;	chr4:119528655	chr10:38450738~38451069:-
THCA	trans	rs7113874	0.659	rs7931834	ENSG00000266891.1	RP11-692N5.2	7.74	6.06e-14	1.18e-07	0.47	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8503746	chr18:9734882~9735602:-
THCA	trans	rs864643	0.678	rs1707959	ENSG00000188856.6	RPSAP47	7.74	6.07e-14	1.18e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39481807	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1707957	ENSG00000188856.6	RPSAP47	7.74	6.07e-14	1.18e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39482000	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1707960	ENSG00000188856.6	RPSAP47	-7.74	6.07e-14	1.18e-07	-0.51	-0.34	Attention deficit hyperactivity disorder;	chr3:39481761	chr8:80558870~80559757:+
THCA	trans	rs35851103	0.506	rs4841659	ENSG00000256560.1	LINC01486	7.74	6.09e-14	1.19e-07	0.41	0.34	Neuroticism;	chr8:11970691	chr12:109354083~109359488:-
THCA	trans	rs10242455	0.764	rs2037497	ENSG00000228834.1	RP11-249L21.4	-7.74	6.13e-14	1.19e-07	-0.61	-0.34	Blood metabolite levels;	chr7:99718281	chr6:108907615~108907873:-
THCA	trans	rs877636	0.859	rs3741499	ENSG00000244604.1	RP11-713H12.1	-7.74	6.17e-14	1.2e-07	-0.44	-0.34	Cognitive function;	chr12:56080595	chr17:8561230~8561576:+
THCA	trans	rs6981523	0.5	rs4412337	ENSG00000253893.2	FAM85B	-7.74	6.2e-14	1.21e-07	-0.47	-0.34	Neuroticism;	chr8:11214511	chr8:8167819~8226614:-
THCA	trans	rs864643	0.574	rs1768192	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39470669	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs568085	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39472661	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs628725	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39472887	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs570136	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39472922	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs7615732	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39473732	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1768203	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39476377	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs1708100	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39476400	chr8:80558870~80559757:+
THCA	trans	rs864643	0.625	rs7613883	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39476825	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs6779639	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39477191	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs6782255	ENSG00000188856.6	RPSAP47	7.74	6.21e-14	1.21e-07	0.51	0.34	Attention deficit hyperactivity disorder;	chr3:39477236	chr8:80558870~80559757:+
THCA	trans	rs10242455	0.867	rs2687078	ENSG00000228834.1	RP11-249L21.4	-7.74	6.26e-14	1.22e-07	-0.61	-0.34	Blood metabolite levels;	chr7:99707089	chr6:108907615~108907873:-
THCA	trans	rs2060793	0.741	rs1542291	ENSG00000236360.2	RP11-334A14.2	7.74	6.3e-14	1.22e-07	0.45	0.34	Vitamin D levels;	chr11:14784720	chr1:52993201~52993702:-
THCA	trans	rs11098499	0.779	rs7699346	ENSG00000253326.2	RP11-261C10.7	7.74	6.3e-14	1.23e-07	0.48	0.34	Corneal astigmatism;	chr4:119389387	chr1:243054861~243056394:-
THCA	trans	rs12709013	0.935	rs34657766	ENSG00000233719.3	GOT2P3	7.74	6.32e-14	1.23e-07	0.4	0.34	Blood metabolite ratios;	chr16:58779468	chr12:9641802~9643007:+
THCA	trans	rs12709013	0.729	rs71400031	ENSG00000233719.3	GOT2P3	7.74	6.32e-14	1.23e-07	0.4	0.34	Blood metabolite ratios;	chr16:58779554	chr12:9641802~9643007:+
THCA	trans	rs9648716	1	rs1267648	ENSG00000224775.2	BRAFP1	7.74	6.34e-14	1.23e-07	0.58	0.34	Type 2 diabetes;	chr7:140805300	chrX:75582676~75585506:+
THCA	trans	rs7824557	0.547	rs2409749	ENSG00000229857.1	RP11-159H20.3	7.73	6.38e-14	1.24e-07	0.44	0.34	Retinal vascular caliber;	chr8:11221440	chr9:76992099~76993108:+
THCA	trans	rs8067354	0.574	rs2250526	ENSG00000187870.7	RNFT1P3	7.73	6.4e-14	1.24e-07	0.54	0.34	Hemoglobin concentration;	chr17:59874612	chr17:20743333~20754501:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000233278.1	RPS26P2	7.73	6.43e-14	1.25e-07	0.39	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:30831878~30832225:-
THCA	trans	rs282544	1	rs6450391	ENSG00000231752.4	EMBP1	7.73	6.44e-14	1.25e-07	0.46	0.34	Myopia (pathological);	chr5:50768553	chr1:121519112~121571892:+
THCA	trans	rs74781061	0.929	rs8029116	ENSG00000227288.3	RP5-837I24.1	7.73	6.48e-14	1.26e-07	0.46	0.34	Endometriosis;	chr15:74530753	chr1:81501794~81503468:+
THCA	trans	rs28647808	1	rs8181069	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133387172	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs33919837	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133403828	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs17150557	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133405671	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs4962144	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133410021	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs2285485	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133412261	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs2285487	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133412362	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28513445	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133412544	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28660681	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133413590	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs71503189	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133413692	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs71503190	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133413712	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28675874	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133413996	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs3780805	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133414075	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs3780807	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133414312	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs4962048	ENSG00000234981.1	RP11-534L20.4	7.73	6.5e-14	1.26e-07	0.75	0.34	Blood protein levels;	chr9:133415918	chr1:206528915~206529706:+
THCA	trans	rs3849046	0.817	rs4835690	ENSG00000226666.1	HSPA9P1	7.73	6.51e-14	1.26e-07	0.35	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138594081	chr2:221961737~221963765:+
THCA	trans	rs11098499	0.954	rs6849561	ENSG00000253326.2	RP11-261C10.7	-7.73	6.62e-14	1.28e-07	-0.48	-0.34	Corneal astigmatism;	chr4:119488539	chr1:243054861~243056394:-
THCA	trans	rs902774	0.818	rs73110471	ENSG00000224520.2	KRT8P45	-7.73	6.63e-14	1.29e-07	-0.69	-0.34	Prostate cancer;	chr12:52923037	chr1:157073257~157074703:+
THCA	trans	rs10242455	0.867	rs1403196	ENSG00000228834.1	RP11-249L21.4	-7.73	6.7e-14	1.3e-07	-0.61	-0.34	Blood metabolite levels;	chr7:99708698	chr6:108907615~108907873:-
THCA	trans	rs804280	0.527	rs2686187	ENSG00000256560.1	LINC01486	7.73	6.74e-14	1.31e-07	0.37	0.34	Myopia (pathological);	chr8:11797287	chr12:109354083~109359488:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000233278.1	RPS26P2	-7.73	6.75e-14	1.31e-07	-0.4	-0.34	Cognitive function;	chr12:56083910	chr9:30831878~30832225:-
THCA	trans	rs864643	0.678	rs1707953	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39483918	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs683089	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39484334	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs590805	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39485463	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs606973	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39485876	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs521226	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39486099	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs521139	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39486128	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs519385	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39486304	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs604831	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39486327	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs517376	ENSG00000183298.5	RP11-556K13.1	7.73	6.77e-14	1.31e-07	0.55	0.34	Attention deficit hyperactivity disorder;	chr3:39486571	chr1:101786340~101787219:-
THCA	trans	rs9650657	0.529	rs10108618	ENSG00000229857.1	RP11-159H20.3	7.73	6.79e-14	1.31e-07	0.44	0.34	Neuroticism;	chr8:11095582	chr9:76992099~76993108:+
THCA	trans	rs7113874	0.659	rs12574009	ENSG00000266891.1	RP11-692N5.2	7.73	6.79e-14	1.32e-07	0.47	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498406	chr18:9734882~9735602:-
THCA	trans	rs11098499	0.779	rs10011097	ENSG00000253326.2	RP11-261C10.7	7.72	6.83e-14	1.32e-07	0.47	0.34	Corneal astigmatism;	chr4:119389204	chr1:243054861~243056394:-
THCA	trans	rs282544	0.965	rs27243	ENSG00000231752.4	EMBP1	-7.72	6.85e-14	1.32e-07	-0.46	-0.34	Myopia (pathological);	chr5:50843524	chr1:121519112~121571892:+
THCA	trans	rs7113874	0.921	rs4929924	ENSG00000266891.1	RP11-692N5.2	-7.72	6.85e-14	1.33e-07	-0.43	-0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8617778	chr18:9734882~9735602:-
THCA	trans	rs6424115	1	rs12121387	ENSG00000228217.1	AL390877.1	7.72	6.9e-14	1.34e-07	0.44	0.34	Immature fraction of reticulocytes;	chr1:23840046	chr1:117778087~117778506:-
THCA	trans	rs10242455	0.867	rs2687135	ENSG00000228834.1	RP11-249L21.4	-7.72	6.95e-14	1.34e-07	-0.61	-0.34	Blood metabolite levels;	chr7:99728686	chr6:108907615~108907873:-
THCA	trans	rs10028773	0.515	rs9994488	ENSG00000275858.1	RP11-291L22.8	7.72	6.96e-14	1.35e-07	0.43	0.34	Educational attainment;	chr4:119666626	chr10:38450738~38451069:-
THCA	trans	rs7647973	0.559	rs9586	ENSG00000197582.5	GPX1P1	7.72	6.98e-14	1.35e-07	0.56	0.34	Menarche (age at onset);	chr3:49176204	chrX:13378735~13379340:-
THCA	trans	rs6732160	0.932	rs768851	ENSG00000236165.1	PRADC1P1	7.72	7.06e-14	1.36e-07	0.46	0.34	Intelligence (multi-trait analysis);	chr2:73151113	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.934	rs2421390	ENSG00000236165.1	PRADC1P1	7.72	7.06e-14	1.36e-07	0.46	0.34	Intelligence (multi-trait analysis);	chr2:73151975	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.932	rs6546802	ENSG00000236165.1	PRADC1P1	7.72	7.06e-14	1.36e-07	0.46	0.34	Intelligence (multi-trait analysis);	chr2:73152436	chr3:36976316~36976840:+
THCA	trans	rs3849046	0.817	rs11953219	ENSG00000226666.1	HSPA9P1	7.72	7.13e-14	1.38e-07	0.35	0.34	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138592481	chr2:221961737~221963765:+
THCA	trans	rs864643	0.812	rs1398669	ENSG00000188856.6	RPSAP47	-7.72	7.14e-14	1.38e-07	-0.47	-0.34	Attention deficit hyperactivity disorder;	chr3:39504500	chr8:80558870~80559757:+
THCA	trans	rs7113874	0.592	rs75600349	ENSG00000266891.1	RP11-692N5.2	7.72	7.16e-14	1.38e-07	0.53	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8426545	chr18:9734882~9735602:-
THCA	trans	rs1707322	0.627	rs3014213	ENSG00000255397.1	AC022182.2	7.72	7.24e-14	1.4e-07	0.47	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.686	rs2152078	ENSG00000255397.1	AC022182.2	7.72	7.24e-14	1.4e-07	0.47	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.686	rs2991979	ENSG00000255397.1	AC022182.2	7.72	7.24e-14	1.4e-07	0.47	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr8:60937705~60939871:-
THCA	trans	rs864643	0.678	rs625898	ENSG00000183298.5	RP11-556K13.1	-7.72	7.24e-14	1.4e-07	-0.56	-0.34	Attention deficit hyperactivity disorder;	chr3:39471624	chr1:101786340~101787219:-
THCA	trans	rs1707322	0.506	rs2991983	ENSG00000255397.1	AC022182.2	7.72	7.3e-14	1.41e-07	0.48	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.717	rs3014249	ENSG00000255397.1	AC022182.2	7.72	7.3e-14	1.41e-07	0.48	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr8:60937705~60939871:-
THCA	trans	rs864643	0.678	rs7631217	ENSG00000188856.6	RPSAP47	-7.71	7.4e-14	1.43e-07	-0.51	-0.34	Attention deficit hyperactivity disorder;	chr3:39478568	chr8:80558870~80559757:+
THCA	trans	rs9329221	0.527	rs4452832	ENSG00000253893.2	FAM85B	7.71	7.43e-14	1.43e-07	0.45	0.34	Neuroticism;	chr8:10463044	chr8:8167819~8226614:-
THCA	trans	rs66887589	0.967	rs59516282	ENSG00000275858.1	RP11-291L22.8	-7.71	7.46e-14	1.44e-07	-0.4	-0.34	Diastolic blood pressure;	chr4:119580861	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.934	rs12648182	ENSG00000275858.1	RP11-291L22.8	-7.71	7.46e-14	1.44e-07	-0.4	-0.34	Diastolic blood pressure;	chr4:119582736	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.909	rs10026736	ENSG00000253326.2	RP11-261C10.7	7.71	7.48e-14	1.44e-07	0.48	0.34	Corneal astigmatism;	chr4:119463167	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs4309825	ENSG00000253326.2	RP11-261C10.7	-7.71	7.51e-14	1.45e-07	-0.47	-0.34	Corneal astigmatism;	chr4:119393726	chr1:243054861~243056394:-
THCA	trans	rs864643	0.574	rs1768192	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39470669	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs568085	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39472661	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs628725	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39472887	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs570136	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39472922	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs7615732	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39473732	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1768203	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39476377	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1708100	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39476400	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs7613883	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39476825	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs6779639	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39477191	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs6782255	ENSG00000183298.5	RP11-556K13.1	7.71	7.53e-14	1.45e-07	0.56	0.34	Attention deficit hyperactivity disorder;	chr3:39477236	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs625898	ENSG00000188856.6	RPSAP47	-7.71	7.7e-14	1.48e-07	-0.51	-0.33	Attention deficit hyperactivity disorder;	chr3:39471624	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.909	rs73842633	ENSG00000253326.2	RP11-261C10.7	7.71	7.75e-14	1.49e-07	0.48	0.33	Corneal astigmatism;	chr4:119454309	chr1:243054861~243056394:-
THCA	trans	rs282544	0.965	rs282548	ENSG00000231752.4	EMBP1	-7.71	7.76e-14	1.49e-07	-0.46	-0.33	Myopia (pathological);	chr5:50760601	chr1:121519112~121571892:+
THCA	trans	rs864643	0.738	rs1398664	ENSG00000188856.6	RPSAP47	-7.71	7.78e-14	1.5e-07	-0.47	-0.33	Attention deficit hyperactivity disorder;	chr3:39534259	chr8:80558870~80559757:+
THCA	trans	rs11638815	0.581	rs2870965	ENSG00000235370.6	DNM1P51	-7.71	7.79e-14	1.5e-07	-0.43	-0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82632278	chr15:84398316~84411701:-
THCA	trans	rs6743068	0.521	rs9288318	ENSG00000235105.1	RP11-329A14.1	7.7	7.85e-14	1.51e-07	0.37	0.33	Lymphocyte percentage of white cells;	chr2:201331340	chr1:48435967~48437223:+
THCA	trans	rs877636	0.692	rs10876870	ENSG00000233278.1	RPS26P2	-7.7	7.95e-14	1.53e-07	-0.4	-0.33	Cognitive function;	chr12:56084218	chr9:30831878~30832225:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000233278.1	RPS26P2	-7.7	7.95e-14	1.53e-07	-0.4	-0.33	Cognitive function;	chr12:56084874	chr9:30831878~30832225:-
THCA	trans	rs1707322	0.717	rs1972410	ENSG00000255397.1	AC022182.2	-7.7	7.97e-14	1.53e-07	-0.47	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr8:60937705~60939871:-
THCA	trans	rs9329221	0.527	rs6989657	ENSG00000253893.2	FAM85B	-7.7	7.97e-14	1.53e-07	-0.46	-0.33	Neuroticism;	chr8:10473363	chr8:8167819~8226614:-
THCA	trans	rs10870270	0.956	rs11146425	ENSG00000197358.9	BNIP3P1	7.7	8e-14	1.54e-07	0.46	0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131920757	chr14:28264390~28265974:+
THCA	trans	rs10870270	0.956	rs7904594	ENSG00000197358.9	BNIP3P1	7.7	8e-14	1.54e-07	0.46	0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131921167	chr14:28264390~28265974:+
THCA	trans	rs10870270	0.912	rs7079991	ENSG00000197358.9	BNIP3P1	7.7	8e-14	1.54e-07	0.46	0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131922626	chr14:28264390~28265974:+
THCA	trans	rs10870270	1	rs10870232	ENSG00000197358.9	BNIP3P1	7.7	8e-14	1.54e-07	0.46	0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131925033	chr14:28264390~28265974:+
THCA	trans	rs1707322	0.686	rs3014251	ENSG00000255397.1	AC022182.2	7.7	8.01e-14	1.54e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr8:60937705~60939871:-
THCA	trans	rs9648716	1	rs2109742	ENSG00000224775.2	BRAFP1	7.7	8.03e-14	1.54e-07	0.57	0.33	Type 2 diabetes;	chr7:140821719	chrX:75582676~75585506:+
THCA	trans	rs9648716	1	rs2109743	ENSG00000224775.2	BRAFP1	7.7	8.03e-14	1.54e-07	0.57	0.33	Type 2 diabetes;	chr7:140821741	chrX:75582676~75585506:+
THCA	trans	rs11098499	0.909	rs11723757	ENSG00000253326.2	RP11-261C10.7	7.7	8.03e-14	1.54e-07	0.47	0.33	Corneal astigmatism;	chr4:119378514	chr1:243054861~243056394:-
THCA	trans	rs9650657	0.644	rs4395858	ENSG00000253893.2	FAM85B	-7.7	8.04e-14	1.55e-07	-0.43	-0.33	Neuroticism;	chr8:10663511	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.612	rs11517715	ENSG00000266891.1	RP11-692N5.2	7.7	8.04e-14	1.55e-07	0.47	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8490341	chr18:9734882~9735602:-
THCA	trans	rs748404	0.587	rs9920879	ENSG00000180867.10	PDIA3P1	-7.7	8.1e-14	1.56e-07	-0.29	-0.33	Lung cancer;	chr15:43347572	chr1:147178113~147179622:+
THCA	trans	rs748404	0.631	rs7166812	ENSG00000180867.10	PDIA3P1	-7.7	8.1e-14	1.56e-07	-0.29	-0.33	Lung cancer;	chr15:43352562	chr1:147178113~147179622:+
THCA	trans	rs864643	0.678	rs656071	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39488646	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs656454	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39488711	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs1708112	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39489034	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1708111	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39489098	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1768219	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39489162	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1398675	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39489772	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1708109	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39490085	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs1768220	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39490545	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1768221	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39490789	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1768222	ENSG00000183298.5	RP11-556K13.1	7.7	8.22e-14	1.58e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39490852	chr1:101786340~101787219:-
THCA	trans	rs7819412	0.594	rs7460507	ENSG00000253893.2	FAM85B	7.7	8.28e-14	1.59e-07	0.45	0.33	Triglycerides;	chr8:11111565	chr8:8167819~8226614:-
THCA	trans	rs6424115	0.965	rs2502986	ENSG00000228217.1	AL390877.1	-7.7	8.38e-14	1.61e-07	-0.43	-0.33	Immature fraction of reticulocytes;	chr1:23808802	chr1:117778087~117778506:-
THCA	trans	rs877636	1	rs705696	ENSG00000224553.1	AC008065.1	7.7	8.39e-14	1.61e-07	0.43	0.33	Cognitive function;	chr12:56086864	chr2:171374931~171375278:-
THCA	trans	rs8067354	0.574	rs2526358	ENSG00000187870.7	RNFT1P3	7.69	8.4e-14	1.61e-07	0.54	0.33	Hemoglobin concentration;	chr17:59865224	chr17:20743333~20754501:-
THCA	trans	rs1707322	0.686	rs2275085	ENSG00000255397.1	AC022182.2	7.69	8.47e-14	1.63e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr8:60937705~60939871:-
THCA	trans	rs9876781	0.539	rs9809695	ENSG00000225528.1	RP3-370M22.8	7.69	8.5e-14	1.63e-07	0.41	0.33	Longevity;	chr3:48364654	chr22:39960397~39964683:+
THCA	trans	rs6424115	0.867	rs11588187	ENSG00000228217.1	AL390877.1	-7.69	8.63e-14	1.66e-07	-0.44	-0.33	Immature fraction of reticulocytes;	chr1:23818557	chr1:117778087~117778506:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000223416.3	RPS26P15	-7.69	8.71e-14	1.67e-07	-0.47	-0.33	Asthma;	chr12:55970537	chr1:58056133~58056480:-
THCA	trans	rs804280	0.544	rs804276	ENSG00000256560.1	LINC01486	7.69	8.72e-14	1.67e-07	0.39	0.33	Myopia (pathological);	chr8:11767499	chr12:109354083~109359488:-
THCA	trans	rs73108077	0.605	rs2143192	ENSG00000279352.1	RP11-411B10.7	7.69	8.72e-14	1.67e-07	0.58	0.33	Red blood cell density in sickle cell anemia;	chr20:31364639	chr18:14010054~14010917:+
THCA	trans	rs7121616	0.842	rs10892966	ENSG00000234176.1	HSPA8P1	7.69	8.86e-14	1.7e-07	0.48	0.33	Breast cancer;	chr11:123126824	chrX:121203182~121205014:-
THCA	trans	rs6743068	0.541	rs1966423	ENSG00000235105.1	RP11-329A14.1	7.69	8.87e-14	1.7e-07	0.36	0.33	Lymphocyte percentage of white cells;	chr2:201351938	chr1:48435967~48437223:+
THCA	trans	rs7819412	0.805	rs2409710	ENSG00000229857.1	RP11-159H20.3	7.69	8.91e-14	1.71e-07	0.43	0.33	Triglycerides;	chr8:11122311	chr9:76992099~76993108:+
THCA	trans	rs12709013	0.935	rs11648634	ENSG00000233719.3	GOT2P3	7.69	8.95e-14	1.71e-07	0.4	0.33	Blood metabolite ratios;	chr16:58785256	chr12:9641802~9643007:+
THCA	trans	rs12709013	1	rs34319345	ENSG00000233719.3	GOT2P3	7.69	8.95e-14	1.71e-07	0.4	0.33	Blood metabolite ratios;	chr16:58786688	chr12:9641802~9643007:+
THCA	trans	rs748404	0.578	rs2278856	ENSG00000180867.10	PDIA3P1	-7.68	9.11e-14	1.75e-07	-0.29	-0.33	Lung cancer;	chr15:43339158	chr1:147178113~147179622:+
THCA	trans	rs11098499	0.618	rs28491261	ENSG00000253326.2	RP11-261C10.7	7.68	9.19e-14	1.76e-07	0.47	0.33	Corneal astigmatism;	chr4:119373745	chr1:243054861~243056394:-
THCA	trans	rs9876781	0.56	rs4558783	ENSG00000225528.1	RP3-370M22.8	7.68	9.21e-14	1.76e-07	0.41	0.33	Longevity;	chr3:48365972	chr22:39960397~39964683:+
THCA	trans	rs11295209	1	rs11295209	ENSG00000275858.1	RP11-291L22.8	-7.68	9.21e-14	1.76e-07	-0.4	-0.33	Plateletcrit;	chr4:119559079	chr10:38450738~38451069:-
THCA	trans	rs12709013	0.967	rs62064905	ENSG00000233719.3	GOT2P3	7.68	9.22e-14	1.77e-07	0.4	0.33	Blood metabolite ratios;	chr16:58778839	chr12:9641802~9643007:+
THCA	trans	rs34421088	0.56	rs11780851	ENSG00000253893.2	FAM85B	7.68	9.24e-14	1.77e-07	0.45	0.33	Neuroticism;	chr8:11543607	chr8:8167819~8226614:-
THCA	trans	rs6424115	1	rs2256179	ENSG00000228217.1	AL390877.1	7.68	9.27e-14	1.77e-07	0.43	0.33	Immature fraction of reticulocytes;	chr1:23805815	chr1:117778087~117778506:-
THCA	trans	rs902774	0.759	rs4919707	ENSG00000224520.2	KRT8P45	-7.68	9.27e-14	1.77e-07	-0.7	-0.33	Prostate cancer;	chr12:52895864	chr1:157073257~157074703:+
THCA	trans	rs902774	0.818	rs56095813	ENSG00000224520.2	KRT8P45	-7.68	9.27e-14	1.77e-07	-0.7	-0.33	Prostate cancer;	chr12:52900963	chr1:157073257~157074703:+
THCA	trans	rs11671005	0.61	rs8103813	ENSG00000279267.1	RP11-395L14.18	7.68	9.41e-14	1.8e-07	0.48	0.33	Mean platelet volume;	chr19:58561317	chr2:113605867~113607908:-
THCA	trans	rs282544	1	rs6450384	ENSG00000231752.4	EMBP1	7.68	9.47e-14	1.81e-07	0.46	0.33	Myopia (pathological);	chr5:50762850	chr1:121519112~121571892:+
THCA	trans	rs941207	0.756	rs7313074	ENSG00000257210.1	NACAP3	-7.68	9.48e-14	1.81e-07	-0.45	-0.33	Platelet count;	chr12:56760705	chr12:93124063~93124543:-
THCA	trans	rs2645424	1	rs7009302	ENSG00000229857.1	RP11-159H20.3	-7.68	9.49e-14	1.81e-07	-0.41	-0.33	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11828472	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.501	rs3021500	ENSG00000229857.1	RP11-159H20.3	7.68	9.5e-14	1.82e-07	0.43	0.33	Neuroticism;	chr8:11166488	chr9:76992099~76993108:+
THCA	trans	rs902774	0.818	rs4919763	ENSG00000224520.2	KRT8P45	-7.68	9.55e-14	1.83e-07	-0.7	-0.33	Prostate cancer;	chr12:52885839	chr1:157073257~157074703:+
THCA	trans	rs902774	0.818	rs55914512	ENSG00000224520.2	KRT8P45	-7.68	9.55e-14	1.83e-07	-0.7	-0.33	Prostate cancer;	chr12:52888490	chr1:157073257~157074703:+
THCA	trans	rs902774	0.818	rs73108466	ENSG00000224520.2	KRT8P45	-7.68	9.55e-14	1.83e-07	-0.7	-0.33	Prostate cancer;	chr12:52889857	chr1:157073257~157074703:+
THCA	trans	rs902774	0.818	rs55999178	ENSG00000224520.2	KRT8P45	-7.68	9.55e-14	1.83e-07	-0.7	-0.33	Prostate cancer;	chr12:52890576	chr1:157073257~157074703:+
THCA	trans	rs864643	0.947	rs704962	ENSG00000188856.6	RPSAP47	-7.68	9.56e-14	1.83e-07	-0.5	-0.33	Attention deficit hyperactivity disorder;	chr3:39515629	chr8:80558870~80559757:+
THCA	trans	rs864643	0.812	rs7618019	ENSG00000188856.6	RPSAP47	-7.68	9.64e-14	1.84e-07	-0.48	-0.33	Attention deficit hyperactivity disorder;	chr3:39538620	chr8:80558870~80559757:+
THCA	trans	rs3849046	0.781	rs10070909	ENSG00000226666.1	HSPA9P1	7.67	9.65e-14	1.84e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138581104	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.817	rs9968657	ENSG00000226666.1	HSPA9P1	7.67	9.65e-14	1.84e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138584741	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.738	rs57958956	ENSG00000226666.1	HSPA9P1	7.67	9.65e-14	1.84e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138590952	chr2:221961737~221963765:+
THCA	trans	rs11098499	0.618	rs35265692	ENSG00000253326.2	RP11-261C10.7	7.67	9.66e-14	1.85e-07	0.47	0.33	Corneal astigmatism;	chr4:119403980	chr1:243054861~243056394:-
THCA	trans	rs864643	0.678	rs512923	ENSG00000183298.5	RP11-556K13.1	7.67	9.71e-14	1.85e-07	0.56	0.33	Attention deficit hyperactivity disorder;	chr3:39480472	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs621842	ENSG00000183298.5	RP11-556K13.1	7.67	9.71e-14	1.85e-07	0.56	0.33	Attention deficit hyperactivity disorder;	chr3:39480785	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs610006	ENSG00000183298.5	RP11-556K13.1	7.67	9.71e-14	1.85e-07	0.56	0.33	Attention deficit hyperactivity disorder;	chr3:39481104	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs602408	ENSG00000183298.5	RP11-556K13.1	7.67	9.75e-14	1.86e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39493754	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs601925	ENSG00000183298.5	RP11-556K13.1	7.67	9.75e-14	1.86e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39493871	chr1:101786340~101787219:-
THCA	trans	rs7617480	0.648	rs10865953	ENSG00000197582.5	GPX1P1	7.67	9.79e-14	1.87e-07	0.57	0.33	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48722129	chrX:13378735~13379340:-
THCA	trans	rs10870270	0.957	rs3829156	ENSG00000197358.9	BNIP3P1	7.67	9.97e-14	1.9e-07	0.45	0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131975882	chr14:28264390~28265974:+
THCA	trans	rs79149102	0.649	rs9788672	ENSG00000227288.3	RP5-837I24.1	7.67	1e-13	1.91e-07	0.51	0.33	Lung cancer;	chr15:74584012	chr1:81501794~81503468:+
THCA	trans	rs2237234	0.58	rs7763910	ENSG00000242375.1	RP11-498P14.3	-7.67	1e-13	1.91e-07	-0.5	-0.33	Autism spectrum disorder or schizophrenia;	chr6:26472427	chr9:97195351~97197687:-
THCA	trans	rs6885307	0.556	rs12516537	ENSG00000231752.4	EMBP1	7.67	1.01e-13	1.92e-07	0.54	0.33	Age at first birth;	chr5:45233522	chr1:121519112~121571892:+
THCA	trans	rs1707322	0.686	rs2991977	ENSG00000255397.1	AC022182.2	7.67	1.01e-13	1.92e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.656	rs2991981	ENSG00000255397.1	AC022182.2	7.67	1.01e-13	1.92e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.656	rs3014210	ENSG00000255397.1	AC022182.2	7.67	1.01e-13	1.92e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr8:60937705~60939871:-
THCA	trans	rs864643	0.678	rs1707960	ENSG00000183298.5	RP11-556K13.1	-7.67	1.01e-13	1.92e-07	-0.56	-0.33	Attention deficit hyperactivity disorder;	chr3:39481761	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1707959	ENSG00000183298.5	RP11-556K13.1	7.67	1.01e-13	1.92e-07	0.56	0.33	Attention deficit hyperactivity disorder;	chr3:39481807	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1707957	ENSG00000183298.5	RP11-556K13.1	7.67	1.01e-13	1.92e-07	0.56	0.33	Attention deficit hyperactivity disorder;	chr3:39482000	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs1473863	ENSG00000188856.6	RPSAP47	7.67	1.01e-13	1.93e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39499544	chr8:80558870~80559757:+
THCA	trans	rs10870270	0.917	rs9971362	ENSG00000197358.9	BNIP3P1	7.67	1.01e-13	1.93e-07	0.46	0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131976646	chr14:28264390~28265974:+
THCA	trans	rs3740713	1	rs73438604	ENSG00000214110.3	LDHAP4	7.67	1.02e-13	1.94e-07	0.59	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr9:14921337~14922334:-
THCA	trans	rs79149102	0.522	rs950323	ENSG00000227288.3	RP5-837I24.1	7.67	1.02e-13	1.94e-07	0.51	0.33	Lung cancer;	chr15:74674188	chr1:81501794~81503468:+
THCA	trans	rs79149102	0.522	rs7170734	ENSG00000227288.3	RP5-837I24.1	7.67	1.02e-13	1.94e-07	0.51	0.33	Lung cancer;	chr15:74697065	chr1:81501794~81503468:+
THCA	trans	rs10242455	1	rs776746	ENSG00000228834.1	RP11-249L21.4	-7.67	1.02e-13	1.95e-07	-0.63	-0.33	Blood metabolite levels;	chr7:99672916	chr6:108907615~108907873:-
THCA	trans	rs7819412	0.806	rs6980856	ENSG00000229857.1	RP11-159H20.3	-7.67	1.03e-13	1.95e-07	-0.42	-0.33	Triglycerides;	chr8:11080750	chr9:76992099~76993108:+
THCA	trans	rs748404	0.534	rs489509	ENSG00000180867.10	PDIA3P1	-7.67	1.03e-13	1.96e-07	-0.29	-0.33	Lung cancer;	chr15:43294709	chr1:147178113~147179622:+
THCA	trans	rs3849046	0.817	rs7711958	ENSG00000226666.1	HSPA9P1	7.67	1.03e-13	1.96e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138565812	chr2:221961737~221963765:+
THCA	trans	rs79149102	0.522	rs8028893	ENSG00000227288.3	RP5-837I24.1	7.66	1.04e-13	1.98e-07	0.52	0.33	Lung cancer;	chr15:74553582	chr1:81501794~81503468:+
THCA	trans	rs79149102	0.522	rs4887158	ENSG00000227288.3	RP5-837I24.1	7.66	1.04e-13	1.98e-07	0.52	0.33	Lung cancer;	chr15:74555473	chr1:81501794~81503468:+
THCA	trans	rs79149102	0.522	rs59665282	ENSG00000227288.3	RP5-837I24.1	7.66	1.04e-13	1.98e-07	0.52	0.33	Lung cancer;	chr15:74572227	chr1:81501794~81503468:+
THCA	trans	rs3849046	0.817	rs4835689	ENSG00000226666.1	HSPA9P1	7.66	1.04e-13	1.98e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138580078	chr2:221961737~221963765:+
THCA	trans	rs864643	0.678	rs3856566	ENSG00000183298.5	RP11-556K13.1	7.66	1.04e-13	1.98e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39491097	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1609647	ENSG00000183298.5	RP11-556K13.1	7.66	1.04e-13	1.98e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39491580	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1768224	ENSG00000183298.5	RP11-556K13.1	7.66	1.04e-13	1.98e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39491843	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs7627794	ENSG00000183298.5	RP11-556K13.1	7.66	1.04e-13	1.98e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39492039	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs7639473	ENSG00000183298.5	RP11-556K13.1	7.66	1.04e-13	1.98e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39492324	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs10510702	ENSG00000183298.5	RP11-556K13.1	7.66	1.04e-13	1.98e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39492461	chr1:101786340~101787219:-
THCA	trans	rs3849046	0.817	rs34629616	ENSG00000226666.1	HSPA9P1	7.66	1.04e-13	1.98e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138532917	chr2:221961737~221963765:+
THCA	trans	rs9650657	0.535	rs7011756	ENSG00000229857.1	RP11-159H20.3	7.66	1.04e-13	1.99e-07	0.42	0.33	Neuroticism;	chr8:11162068	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.521	rs17693945	ENSG00000253893.2	FAM85B	7.66	1.06e-13	2.01e-07	0.45	0.33	Neuroticism;	chr8:10248500	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.636	rs4841644	ENSG00000253893.2	FAM85B	-7.66	1.06e-13	2.01e-07	-0.45	-0.33	Monocyte count;	chr8:11940924	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.812	rs11250072	ENSG00000253893.2	FAM85B	7.66	1.06e-13	2.01e-07	0.42	0.33	Neuroticism;	chr8:10774611	chr8:8167819~8226614:-
THCA	trans	rs804280	1	rs804281	ENSG00000253893.2	FAM85B	-7.66	1.06e-13	2.01e-07	-0.46	-0.33	Myopia (pathological);	chr8:11754356	chr8:8167819~8226614:-
THCA	trans	rs10870270	0.917	rs11146417	ENSG00000197358.9	BNIP3P1	7.66	1.06e-13	2.02e-07	0.45	0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131977530	chr14:28264390~28265974:+
THCA	trans	rs9650657	0.737	rs2116095	ENSG00000253893.2	FAM85B	7.66	1.07e-13	2.03e-07	0.42	0.33	Neuroticism;	chr8:10777787	chr8:8167819~8226614:-
THCA	trans	rs6424115	1	rs974698	ENSG00000228217.1	AL390877.1	-7.66	1.07e-13	2.03e-07	-0.43	-0.33	Immature fraction of reticulocytes;	chr1:23806295	chr1:117778087~117778506:-
THCA	trans	rs7113874	0.659	rs12577287	ENSG00000266891.1	RP11-692N5.2	7.66	1.07e-13	2.03e-07	0.47	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498370	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.659	rs12274454	ENSG00000266891.1	RP11-692N5.2	7.66	1.07e-13	2.03e-07	0.47	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500419	chr18:9734882~9735602:-
THCA	trans	rs13217239	0.572	rs9379958	ENSG00000242375.1	RP11-498P14.3	-7.66	1.07e-13	2.04e-07	-0.47	-0.33	Schizophrenia;	chr6:27098384	chr9:97195351~97197687:-
THCA	trans	rs864643	0.678	rs1768158	ENSG00000183298.5	RP11-556K13.1	-7.66	1.07e-13	2.04e-07	-0.55	-0.33	Attention deficit hyperactivity disorder;	chr3:39465870	chr1:101786340~101787219:-
THCA	trans	rs864643	0.677	rs1708087	ENSG00000183298.5	RP11-556K13.1	7.66	1.07e-13	2.04e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39468197	chr1:101786340~101787219:-
THCA	trans	rs7819412	0.539	rs11250131	ENSG00000253893.2	FAM85B	7.66	1.08e-13	2.05e-07	0.43	0.33	Triglycerides;	chr8:11393666	chr8:8167819~8226614:-
THCA	trans	rs10816533	1	rs35334289	ENSG00000232063.1	RP11-307E17.8	-7.66	1.09e-13	2.06e-07	-0.79	-0.33	Height;	chr9:96778009	chr9:94332476~94360948:+
THCA	trans	rs1707322	0.717	rs2253862	ENSG00000255397.1	AC022182.2	7.66	1.09e-13	2.07e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.717	rs2991988	ENSG00000255397.1	AC022182.2	7.66	1.09e-13	2.07e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.717	rs2991989	ENSG00000255397.1	AC022182.2	7.66	1.09e-13	2.07e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr8:60937705~60939871:-
THCA	trans	rs748404	0.631	rs1133395	ENSG00000180867.10	PDIA3P1	-7.66	1.1e-13	2.09e-07	-0.29	-0.33	Lung cancer;	chr15:43358186	chr1:147178113~147179622:+
THCA	trans	rs902774	0.818	rs73108469	ENSG00000224520.2	KRT8P45	-7.66	1.1e-13	2.09e-07	-0.7	-0.33	Prostate cancer;	chr12:52891065	chr1:157073257~157074703:+
THCA	trans	rs11098499	0.954	rs2389803	ENSG00000253326.2	RP11-261C10.7	-7.66	1.1e-13	2.09e-07	-0.48	-0.33	Corneal astigmatism;	chr4:119472356	chr1:243054861~243056394:-
THCA	trans	rs14057	0.864	rs34559878	ENSG00000215869.3	RP11-364B6.1	7.66	1.1e-13	2.09e-07	0.48	0.33	Systolic blood pressure;	chr1:6699035	chr1:104073023~104077087:+
THCA	trans	rs14057	0.832	rs12567649	ENSG00000215869.3	RP11-364B6.1	7.66	1.1e-13	2.09e-07	0.48	0.33	Systolic blood pressure;	chr1:6700137	chr1:104073023~104077087:+
THCA	trans	rs14057	0.864	rs3761925	ENSG00000215869.3	RP11-364B6.1	7.66	1.1e-13	2.09e-07	0.48	0.33	Systolic blood pressure;	chr1:6701642	chr1:104073023~104077087:+
THCA	trans	rs13217239	0.646	rs9393789	ENSG00000242375.1	RP11-498P14.3	-7.66	1.11e-13	2.1e-07	-0.47	-0.33	Schizophrenia;	chr6:27099249	chr9:97195351~97197687:-
THCA	trans	rs748404	0.588	rs506120	ENSG00000180867.10	PDIA3P1	-7.65	1.12e-13	2.12e-07	-0.29	-0.33	Lung cancer;	chr15:43509826	chr1:147178113~147179622:+
THCA	trans	rs10242455	0.867	rs1357319	ENSG00000228834.1	RP11-249L21.4	7.65	1.12e-13	2.12e-07	0.61	0.33	Blood metabolite levels;	chr7:99712558	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687145	ENSG00000228834.1	RP11-249L21.4	7.65	1.12e-13	2.12e-07	0.61	0.33	Blood metabolite levels;	chr7:99721021	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687077	ENSG00000228834.1	RP11-249L21.4	-7.65	1.12e-13	2.12e-07	-0.61	-0.33	Blood metabolite levels;	chr7:99708943	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2257401	ENSG00000228834.1	RP11-249L21.4	-7.65	1.12e-13	2.12e-07	-0.61	-0.33	Blood metabolite levels;	chr7:99709062	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687076	ENSG00000228834.1	RP11-249L21.4	-7.65	1.12e-13	2.12e-07	-0.61	-0.33	Blood metabolite levels;	chr7:99709645	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2222411	ENSG00000228834.1	RP11-249L21.4	-7.65	1.12e-13	2.12e-07	-0.61	-0.33	Blood metabolite levels;	chr7:99712708	chr6:108907615~108907873:-
THCA	trans	rs3002142	0.658	rs1053316	ENSG00000219201.4	RP11-181C21.4	7.65	1.13e-13	2.13e-07	0.47	0.33	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:77810861~77811781:-
THCA	trans	rs1707322	0.686	rs1547924	ENSG00000255397.1	AC022182.2	-7.65	1.13e-13	2.14e-07	-0.47	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.686	rs3014236	ENSG00000255397.1	AC022182.2	7.65	1.13e-13	2.14e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr8:60937705~60939871:-
THCA	trans	rs7937890	0.559	rs6486193	ENSG00000236360.2	RP11-334A14.2	7.65	1.13e-13	2.14e-07	0.42	0.33	Mitochondrial DNA levels;	chr11:14416061	chr1:52993201~52993702:-
THCA	trans	rs7032940	0.533	rs7868072	ENSG00000228236.2	TXNP5	7.65	1.13e-13	2.14e-07	0.39	0.33	Height;	chr9:110205824	chr2:149068596~149068910:-
THCA	trans	rs9650657	0.801	rs718741	ENSG00000253893.2	FAM85B	7.65	1.15e-13	2.17e-07	0.42	0.33	Neuroticism;	chr8:10756874	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.812	rs11250073	ENSG00000253893.2	FAM85B	7.65	1.15e-13	2.17e-07	0.42	0.33	Neuroticism;	chr8:10774726	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.811	rs2409691	ENSG00000229857.1	RP11-159H20.3	7.65	1.17e-13	2.21e-07	0.41	0.33	Triglycerides;	chr8:11085766	chr9:76992099~76993108:+
THCA	trans	rs7113874	0.659	rs57757082	ENSG00000266891.1	RP11-692N5.2	7.65	1.17e-13	2.21e-07	0.47	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8507106	chr18:9734882~9735602:-
THCA	trans	rs864643	0.947	rs1708040	ENSG00000188856.6	RPSAP47	7.65	1.17e-13	2.21e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39523258	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs505176	ENSG00000188856.6	RPSAP47	7.65	1.17e-13	2.21e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39524857	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs1708000	ENSG00000188856.6	RPSAP47	7.65	1.17e-13	2.21e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39525645	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs1708001	ENSG00000188856.6	RPSAP47	7.65	1.17e-13	2.21e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39525714	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs816519	ENSG00000188856.6	RPSAP47	7.65	1.17e-13	2.21e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39527786	chr8:80558870~80559757:+
THCA	trans	rs864643	0.731	rs1417148	ENSG00000188856.6	RPSAP47	7.65	1.17e-13	2.21e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39534217	chr8:80558870~80559757:+
THCA	trans	rs11992162	0.507	rs60902764	ENSG00000256560.1	LINC01486	-7.65	1.18e-13	2.24e-07	-0.42	-0.33	Monocyte count;	chr8:11927482	chr12:109354083~109359488:-
THCA	trans	rs864643	0.659	rs1398663	ENSG00000188856.6	RPSAP47	-7.65	1.18e-13	2.24e-07	-0.46	-0.33	Attention deficit hyperactivity disorder;	chr3:39534874	chr8:80558870~80559757:+
THCA	trans	rs1707322	0.686	rs1084086	ENSG00000255397.1	AC022182.2	7.64	1.19e-13	2.25e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr8:60937705~60939871:-
THCA	trans	rs61826828	1	rs61826828	ENSG00000213331.4	RP11-713C19.2	7.64	1.19e-13	2.26e-07	0.49	0.33	Schizophrenia;	chr1:174046123	chr4:187970273~187971284:+
THCA	trans	rs11671005	0.569	rs73068335	ENSG00000279267.1	RP11-395L14.18	7.64	1.2e-13	2.26e-07	0.48	0.33	Mean platelet volume;	chr19:58577941	chr2:113605867~113607908:-
THCA	trans	rs11098499	0.954	rs12510138	ENSG00000253326.2	RP11-261C10.7	7.64	1.2e-13	2.26e-07	0.47	0.33	Corneal astigmatism;	chr4:119502780	chr1:243054861~243056394:-
THCA	trans	rs79149102	0.522	rs10459601	ENSG00000227288.3	RP5-837I24.1	7.64	1.2e-13	2.26e-07	0.51	0.33	Lung cancer;	chr15:74573068	chr1:81501794~81503468:+
THCA	trans	rs79149102	0.522	rs79811537	ENSG00000227288.3	RP5-837I24.1	7.64	1.2e-13	2.26e-07	0.51	0.33	Lung cancer;	chr15:74579474	chr1:81501794~81503468:+
THCA	trans	rs10242455	0.867	rs868564	ENSG00000228834.1	RP11-249L21.4	7.64	1.2e-13	2.27e-07	0.63	0.33	Blood metabolite levels;	chr7:99604750	chr6:108907615~108907873:-
THCA	trans	rs9329221	0.741	rs534523	ENSG00000253893.2	FAM85B	7.64	1.21e-13	2.28e-07	0.42	0.33	Neuroticism;	chr8:10027489	chr8:8167819~8226614:-
THCA	trans	rs7662987	1	rs7683802	ENSG00000228407.2	RP4-800M22.1	7.64	1.21e-13	2.28e-07	0.71	0.33	Smoking initiation;	chr4:99073987	chr1:52160261~52160600:-
THCA	trans	rs7662987	0.818	rs4699701	ENSG00000228407.2	RP4-800M22.1	7.64	1.21e-13	2.28e-07	0.71	0.33	Smoking initiation;	chr4:99077296	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs13146416	ENSG00000228407.2	RP4-800M22.1	7.64	1.21e-13	2.28e-07	0.71	0.33	Smoking initiation;	chr4:99078009	chr1:52160261~52160600:-
THCA	trans	rs9650657	0.77	rs9969626	ENSG00000253893.2	FAM85B	7.64	1.21e-13	2.28e-07	0.43	0.33	Neuroticism;	chr8:10813291	chr8:8167819~8226614:-
THCA	trans	rs11671005	0.568	rs73068329	ENSG00000279267.1	RP11-395L14.18	7.64	1.24e-13	2.34e-07	0.48	0.33	Mean platelet volume;	chr19:58568958	chr2:113605867~113607908:-
THCA	trans	rs13217239	0.646	rs6456767	ENSG00000242375.1	RP11-498P14.3	-7.64	1.24e-13	2.35e-07	-0.47	-0.33	Schizophrenia;	chr6:27102764	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs7768407	ENSG00000242375.1	RP11-498P14.3	7.64	1.25e-13	2.36e-07	0.47	0.33	Schizophrenia;	chr6:27049016	chr9:97195351~97197687:-
THCA	trans	rs3740713	1	rs73436638	ENSG00000214110.3	LDHAP4	7.64	1.25e-13	2.36e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73436642	ENSG00000214110.3	LDHAP4	7.64	1.25e-13	2.36e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73436666	ENSG00000214110.3	LDHAP4	7.64	1.25e-13	2.36e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438611	ENSG00000214110.3	LDHAP4	7.64	1.25e-13	2.36e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs2643872	ENSG00000214110.3	LDHAP4	7.64	1.25e-13	2.36e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs75381502	ENSG00000214110.3	LDHAP4	7.64	1.25e-13	2.36e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr9:14921337~14922334:-
THCA	trans	rs1707322	0.717	rs3014246	ENSG00000255397.1	AC022182.2	7.64	1.26e-13	2.37e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr8:60937705~60939871:-
THCA	trans	rs6743068	0.521	rs6710974	ENSG00000235105.1	RP11-329A14.1	7.64	1.27e-13	2.4e-07	0.36	0.33	Lymphocyte percentage of white cells;	chr2:201348659	chr1:48435967~48437223:+
THCA	trans	rs3740713	0.592	rs73434674	ENSG00000214110.3	LDHAP4	7.64	1.27e-13	2.4e-07	0.54	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438686	ENSG00000214110.3	LDHAP4	7.63	1.28e-13	2.41e-07	0.6	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr9:14921337~14922334:-
THCA	trans	rs10870270	0.956	rs7915388	ENSG00000197358.9	BNIP3P1	7.63	1.28e-13	2.42e-07	0.45	0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131921468	chr14:28264390~28265974:+
THCA	trans	rs7647973	0.848	rs4955426	ENSG00000197582.5	GPX1P1	7.63	1.29e-13	2.43e-07	0.59	0.33	Menarche (age at onset);	chr3:49106005	chrX:13378735~13379340:-
THCA	trans	rs79149102	0.522	rs4887156	ENSG00000227288.3	RP5-837I24.1	7.63	1.3e-13	2.45e-07	0.52	0.33	Lung cancer;	chr15:74538844	chr1:81501794~81503468:+
THCA	trans	rs9292918	0.906	rs7709262	ENSG00000231752.4	EMBP1	7.63	1.3e-13	2.45e-07	0.48	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45341942	chr1:121519112~121571892:+
THCA	trans	rs9292918	0.901	rs1501362	ENSG00000231752.4	EMBP1	7.63	1.3e-13	2.45e-07	0.48	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45378105	chr1:121519112~121571892:+
THCA	trans	rs9292918	0.951	rs6451798	ENSG00000231752.4	EMBP1	7.63	1.3e-13	2.45e-07	0.48	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45387752	chr1:121519112~121571892:+
THCA	trans	rs7662987	0.762	rs13109048	ENSG00000233859.2	ADH5P4	7.63	1.3e-13	2.45e-07	0.79	0.33	Smoking initiation;	chr4:99086315	chr6:65836930~65838039:-
THCA	trans	rs9329221	0.617	rs483916	ENSG00000253893.2	FAM85B	7.63	1.31e-13	2.47e-07	0.44	0.33	Neuroticism;	chr8:9936091	chr8:8167819~8226614:-
THCA	trans	rs864643	0.678	rs7631217	ENSG00000183298.5	RP11-556K13.1	-7.63	1.32e-13	2.49e-07	-0.55	-0.33	Attention deficit hyperactivity disorder;	chr3:39478568	chr1:101786340~101787219:-
THCA	trans	rs3740713	0.719	rs78515595	ENSG00000214110.3	LDHAP4	7.63	1.32e-13	2.49e-07	0.55	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18409830	chr9:14921337~14922334:-
THCA	trans	rs12709013	1	rs12709013	ENSG00000233719.3	GOT2P3	-7.63	1.33e-13	2.5e-07	-0.4	-0.33	Blood metabolite ratios;	chr16:58795886	chr12:9641802~9643007:+
THCA	trans	rs902774	0.818	rs4919737	ENSG00000224520.2	KRT8P45	-7.63	1.33e-13	2.5e-07	-0.69	-0.33	Prostate cancer;	chr12:52877011	chr1:157073257~157074703:+
THCA	trans	rs902774	0.818	rs73108429	ENSG00000224520.2	KRT8P45	-7.63	1.33e-13	2.5e-07	-0.69	-0.33	Prostate cancer;	chr12:52877887	chr1:157073257~157074703:+
THCA	trans	rs9650657	0.737	rs2409669	ENSG00000253893.2	FAM85B	7.63	1.35e-13	2.53e-07	0.42	0.33	Neuroticism;	chr8:10766459	chr8:8167819~8226614:-
THCA	trans	rs864643	1	rs1708002	ENSG00000188856.6	RPSAP47	7.63	1.35e-13	2.54e-07	0.5	0.33	Attention deficit hyperactivity disorder;	chr3:39511185	chr8:80558870~80559757:+
THCA	trans	rs748404	0.631	rs6493086	ENSG00000180867.10	PDIA3P1	-7.62	1.37e-13	2.57e-07	-0.29	-0.33	Lung cancer;	chr15:43363196	chr1:147178113~147179622:+
THCA	trans	rs11992162	0.905	rs7836953	ENSG00000253893.2	FAM85B	-7.62	1.37e-13	2.57e-07	-0.42	-0.33	Monocyte count;	chr8:11978203	chr8:8167819~8226614:-
THCA	trans	rs867371	0.896	rs8033831	ENSG00000235370.6	DNM1P51	-7.62	1.37e-13	2.57e-07	-0.41	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:84398316~84411701:-
THCA	trans	rs2896526	0.736	rs78950598	ENSG00000214110.3	LDHAP4	7.62	1.37e-13	2.58e-07	0.56	0.33	Amyloid A serum levels;	chr11:18375599	chr9:14921337~14922334:-
THCA	trans	rs7819412	0.618	rs10105377	ENSG00000253893.2	FAM85B	7.62	1.38e-13	2.58e-07	0.45	0.33	Triglycerides;	chr8:11118223	chr8:8167819~8226614:-
THCA	trans	rs7833986	0.501	rs72653981	ENSG00000236862.1	RPS20P24	7.62	1.39e-13	2.62e-07	0.49	0.33	Height;	chr8:56115255	chr9:72655832~72656192:-
THCA	trans	rs9650657	0.769	rs1968400	ENSG00000253893.2	FAM85B	7.62	1.39e-13	2.62e-07	0.42	0.33	Neuroticism;	chr8:10757921	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.717	rs1135850	ENSG00000255397.1	AC022182.2	-7.62	1.41e-13	2.65e-07	-0.47	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.655	rs3014240	ENSG00000255397.1	AC022182.2	7.62	1.41e-13	2.65e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.686	rs3014235	ENSG00000255397.1	AC022182.2	7.62	1.41e-13	2.65e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr8:60937705~60939871:-
THCA	trans	rs9858542	0.953	rs9824092	ENSG00000197582.5	GPX1P1	-7.62	1.41e-13	2.65e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49636714	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs9862080	ENSG00000197582.5	GPX1P1	-7.62	1.41e-13	2.65e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637025	chrX:13378735~13379340:-
THCA	trans	rs11671005	0.568	rs55987239	ENSG00000279267.1	RP11-395L14.18	7.62	1.41e-13	2.65e-07	0.47	0.33	Mean platelet volume;	chr19:58573678	chr2:113605867~113607908:-
THCA	trans	rs10242455	0.867	rs2687079	ENSG00000228834.1	RP11-249L21.4	7.62	1.42e-13	2.67e-07	0.6	0.33	Blood metabolite levels;	chr7:99706995	chr6:108907615~108907873:-
THCA	trans	rs7647973	0.961	rs56324858	ENSG00000197582.5	GPX1P1	-7.62	1.43e-13	2.68e-07	-0.59	-0.33	Menarche (age at onset);	chr3:49506796	chrX:13378735~13379340:-
THCA	trans	rs9650657	0.769	rs6601527	ENSG00000253893.2	FAM85B	7.62	1.43e-13	2.69e-07	0.42	0.33	Neuroticism;	chr8:10807934	chr8:8167819~8226614:-
THCA	trans	rs864643	1	rs816491	ENSG00000188856.6	RPSAP47	-7.62	1.43e-13	2.69e-07	-0.5	-0.33	Attention deficit hyperactivity disorder;	chr3:39514006	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs864643	ENSG00000188856.6	RPSAP47	7.62	1.43e-13	2.69e-07	0.5	0.33	Attention deficit hyperactivity disorder;	chr3:39514089	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs816492	ENSG00000188856.6	RPSAP47	7.62	1.43e-13	2.69e-07	0.5	0.33	Attention deficit hyperactivity disorder;	chr3:39514664	chr8:80558870~80559757:+
THCA	trans	rs16937956	0.597	rs4584570	ENSG00000266891.1	RP11-692N5.2	7.62	1.43e-13	2.69e-07	0.45	0.33	Body mass index;	chr11:8384489	chr18:9734882~9735602:-
THCA	trans	rs11992162	0.573	rs61468577	ENSG00000256560.1	LINC01486	-7.62	1.44e-13	2.7e-07	-0.42	-0.33	Monocyte count;	chr8:11927416	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.665	rs62367520	ENSG00000231752.4	EMBP1	7.62	1.44e-13	2.7e-07	0.54	0.33	Age at first birth;	chr5:45279756	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.665	rs62367522	ENSG00000231752.4	EMBP1	7.62	1.44e-13	2.7e-07	0.54	0.33	Age at first birth;	chr5:45280110	chr1:121519112~121571892:+
THCA	trans	rs6743068	0.521	rs6705845	ENSG00000235105.1	RP11-329A14.1	7.62	1.44e-13	2.71e-07	0.36	0.33	Lymphocyte percentage of white cells;	chr2:201354316	chr1:48435967~48437223:+
THCA	trans	rs11992162	0.636	rs4841645	ENSG00000253893.2	FAM85B	7.62	1.44e-13	2.71e-07	0.45	0.33	Monocyte count;	chr8:11941175	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.812	rs10089615	ENSG00000253893.2	FAM85B	7.62	1.44e-13	2.71e-07	0.42	0.33	Neuroticism;	chr8:10776622	chr8:8167819~8226614:-
THCA	trans	rs10242455	0.764	rs4646465	ENSG00000228834.1	RP11-249L21.4	-7.62	1.45e-13	2.72e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99706901	chr6:108907615~108907873:-
THCA	trans	rs1707322	0.686	rs3014239	ENSG00000255397.1	AC022182.2	7.61	1.47e-13	2.76e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.547	rs6601570	ENSG00000229857.1	RP11-159H20.3	7.61	1.47e-13	2.76e-07	0.43	0.33	Retinal vascular caliber;	chr8:11221858	chr9:76992099~76993108:+
THCA	trans	rs79149102	0.522	rs6495119	ENSG00000227288.3	RP5-837I24.1	7.61	1.48e-13	2.76e-07	0.51	0.33	Lung cancer;	chr15:74642099	chr1:81501794~81503468:+
THCA	trans	rs66887589	0.807	rs7694483	ENSG00000275858.1	RP11-291L22.8	7.61	1.49e-13	2.78e-07	0.39	0.33	Diastolic blood pressure;	chr4:119484774	chr10:38450738~38451069:-
THCA	trans	rs79149102	0.522	rs6495112	ENSG00000227288.3	RP5-837I24.1	7.61	1.5e-13	2.8e-07	0.51	0.33	Lung cancer;	chr15:74540457	chr1:81501794~81503468:+
THCA	trans	rs79149102	0.522	rs7175512	ENSG00000227288.3	RP5-837I24.1	7.61	1.5e-13	2.8e-07	0.51	0.33	Lung cancer;	chr15:74540640	chr1:81501794~81503468:+
THCA	trans	rs2645424	0.525	rs17814426	ENSG00000260438.1	RP11-405F3.2	7.61	1.53e-13	2.87e-07	0.44	0.33	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856796	chr16:57713782~57714957:+
THCA	trans	rs9650657	0.812	rs6601522	ENSG00000253893.2	FAM85B	7.61	1.53e-13	2.87e-07	0.42	0.33	Neuroticism;	chr8:10771551	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.585	rs2572385	ENSG00000253893.2	FAM85B	-7.61	1.54e-13	2.88e-07	-0.45	-0.33	Retinal vascular caliber;	chr8:11351394	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.682	rs12037459	ENSG00000255397.1	AC022182.2	-7.61	1.54e-13	2.89e-07	-0.47	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.707	rs6984744	ENSG00000253893.2	FAM85B	7.61	1.55e-13	2.91e-07	0.41	0.33	Neuroticism;	chr8:10758755	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs73110464	ENSG00000224520.2	KRT8P45	-7.61	1.56e-13	2.92e-07	-0.66	-0.33	Prostate cancer;	chr12:52918828	chr1:157073257~157074703:+
THCA	trans	rs7824557	0.547	rs4512344	ENSG00000229857.1	RP11-159H20.3	7.6	1.57e-13	2.94e-07	0.43	0.33	Retinal vascular caliber;	chr8:11221272	chr9:76992099~76993108:+
THCA	trans	rs14057	0.864	rs11122118	ENSG00000215869.3	RP11-364B6.1	7.6	1.57e-13	2.95e-07	0.48	0.33	Systolic blood pressure;	chr1:6704747	chr1:104073023~104077087:+
THCA	trans	rs2060793	0.741	rs4757268	ENSG00000236360.2	RP11-334A14.2	7.6	1.58e-13	2.95e-07	0.44	0.33	Vitamin D levels;	chr11:14789216	chr1:52993201~52993702:-
THCA	trans	rs7833986	0.501	rs72653978	ENSG00000236862.1	RPS20P24	7.6	1.59e-13	2.97e-07	0.49	0.33	Height;	chr8:56105834	chr9:72655832~72656192:-
THCA	trans	rs748404	0.631	rs8042688	ENSG00000180867.10	PDIA3P1	-7.6	1.59e-13	2.97e-07	-0.29	-0.33	Lung cancer;	chr15:43346327	chr1:147178113~147179622:+
THCA	trans	rs748404	0.631	rs4296223	ENSG00000180867.10	PDIA3P1	-7.6	1.59e-13	2.97e-07	-0.29	-0.33	Lung cancer;	chr15:43353048	chr1:147178113~147179622:+
THCA	trans	rs10870270	0.784	rs10430614	ENSG00000197358.9	BNIP3P1	-7.6	1.6e-13	2.99e-07	-0.44	-0.33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131935136	chr14:28264390~28265974:+
THCA	trans	rs1707322	0.686	rs2050376	ENSG00000255397.1	AC022182.2	-7.6	1.61e-13	3e-07	-0.47	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr8:60937705~60939871:-
THCA	trans	rs6885307	0.882	rs7711444	ENSG00000231752.4	EMBP1	7.6	1.61e-13	3.01e-07	0.51	0.33	Age at first birth;	chr5:45211854	chr1:121519112~121571892:+
THCA	trans	rs3849046	0.68	rs13165665	ENSG00000226666.1	HSPA9P1	-7.6	1.62e-13	3.03e-07	-0.35	-0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610811	chr2:221961737~221963765:+
THCA	trans	rs9650657	0.74	rs2277130	ENSG00000253893.2	FAM85B	7.6	1.62e-13	3.03e-07	0.42	0.33	Neuroticism;	chr8:10820091	chr8:8167819~8226614:-
THCA	trans	rs941207	1	rs941207	ENSG00000257210.1	NACAP3	-7.6	1.63e-13	3.05e-07	-0.45	-0.33	Platelet count;	chr12:56629500	chr12:93124063~93124543:-
THCA	trans	rs73108077	0.736	rs6060993	ENSG00000279352.1	RP11-411B10.7	7.6	1.64e-13	3.05e-07	0.6	0.33	Red blood cell density in sickle cell anemia;	chr20:31278917	chr18:14010054~14010917:+
THCA	trans	rs11671005	0.61	rs3816329	ENSG00000279267.1	RP11-395L14.18	7.6	1.64e-13	3.05e-07	0.48	0.33	Mean platelet volume;	chr19:58547326	chr2:113605867~113607908:-
THCA	trans	rs66887589	0.934	rs56843000	ENSG00000275858.1	RP11-291L22.8	-7.6	1.65e-13	3.07e-07	-0.39	-0.33	Diastolic blood pressure;	chr4:119595442	chr10:38450738~38451069:-
THCA	trans	rs13177918	0.626	rs3819332	ENSG00000226396.1	RP5-1056L3.3	7.6	1.67e-13	3.12e-07	0.31	0.33	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:19608114~19608568:+
THCA	trans	rs2250402	0.51	rs7535	ENSG00000234106.3	RP11-288E14.2	7.6	1.67e-13	3.12e-07	0.6	0.33	Corneal curvature;	chr15:40036374	chr11:93535468~93535816:+
THCA	trans	rs9329221	0.657	rs17694485	ENSG00000253893.2	FAM85B	-7.6	1.67e-13	3.12e-07	-0.46	-0.33	Neuroticism;	chr8:10256948	chr8:8167819~8226614:-
THCA	trans	rs7833986	0.501	rs2976038	ENSG00000236862.1	RPS20P24	7.59	1.69e-13	3.16e-07	0.49	0.33	Height;	chr8:56116305	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2976036	ENSG00000236862.1	RPS20P24	7.59	1.69e-13	3.16e-07	0.49	0.33	Height;	chr8:56119162	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.534	rs17759244	ENSG00000236862.1	RPS20P24	7.59	1.69e-13	3.16e-07	0.49	0.33	Height;	chr8:56121209	chr9:72655832~72656192:-
THCA	trans	rs864643	0.678	rs1609646	ENSG00000183298.5	RP11-556K13.1	7.59	1.7e-13	3.16e-07	0.54	0.33	Attention deficit hyperactivity disorder;	chr3:39491415	chr1:101786340~101787219:-
THCA	trans	rs748404	0.631	rs28702649	ENSG00000180867.10	PDIA3P1	-7.59	1.7e-13	3.17e-07	-0.29	-0.33	Lung cancer;	chr15:43356431	chr1:147178113~147179622:+
THCA	trans	rs3808502	0.527	rs4410870	ENSG00000253893.2	FAM85B	7.59	1.7e-13	3.18e-07	0.47	0.33	Neuroticism;	chr8:11298611	chr8:8167819~8226614:-
THCA	trans	rs66887589	0.967	rs2892869	ENSG00000275858.1	RP11-291L22.8	-7.59	1.7e-13	3.18e-07	-0.39	-0.33	Diastolic blood pressure;	chr4:119600142	chr10:38450738~38451069:-
THCA	trans	rs1707322	0.686	rs3014242	ENSG00000255397.1	AC022182.2	7.59	1.71e-13	3.19e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr8:60937705~60939871:-
THCA	trans	rs74781061	0.585	rs7161990	ENSG00000227288.3	RP5-837I24.1	7.59	1.71e-13	3.19e-07	0.5	0.33	Endometriosis;	chr15:74443323	chr1:81501794~81503468:+
THCA	trans	rs902774	0.818	rs4919742	ENSG00000224520.2	KRT8P45	-7.59	1.73e-13	3.23e-07	-0.68	-0.33	Prostate cancer;	chr12:52879180	chr1:157073257~157074703:+
THCA	trans	rs34421088	0.56	rs2245250	ENSG00000253893.2	FAM85B	7.59	1.74e-13	3.24e-07	0.44	0.33	Neuroticism;	chr8:11543171	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.55	rs61426048	ENSG00000256560.1	LINC01486	-7.59	1.74e-13	3.24e-07	-0.41	-0.33	Monocyte count;	chr8:11927447	chr12:109354083~109359488:-
THCA	trans	rs72615157	0.629	rs55839153	ENSG00000228546.2	CTA-313A17.3	7.59	1.76e-13	3.28e-07	0.57	0.33	Lung function (FEV1/FVC);	chr7:100154943	chr7:102337316~102339115:+
THCA	trans	rs748404	0.604	rs2278857	ENSG00000180867.10	PDIA3P1	-7.59	1.77e-13	3.29e-07	-0.28	-0.33	Lung cancer;	chr15:43340351	chr1:147178113~147179622:+
THCA	trans	rs3808502	0.527	rs2736374	ENSG00000253893.2	FAM85B	7.59	1.77e-13	3.3e-07	0.45	0.33	Neuroticism;	chr8:11256319	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.721	rs10430124	ENSG00000255397.1	AC022182.2	-7.59	1.79e-13	3.33e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr8:60937705~60939871:-
THCA	trans	rs941207	0.756	rs7315472	ENSG00000257210.1	NACAP3	-7.58	1.81e-13	3.36e-07	-0.44	-0.33	Platelet count;	chr12:56648276	chr12:93124063~93124543:-
THCA	trans	rs9858542	0.953	rs6803222	ENSG00000197582.5	GPX1P1	-7.58	1.81e-13	3.38e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49628543	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.953	rs11710037	ENSG00000197582.5	GPX1P1	-7.58	1.81e-13	3.38e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637901	chrX:13378735~13379340:-
THCA	trans	rs7824557	0.564	rs2736295	ENSG00000253893.2	FAM85B	-7.58	1.82e-13	3.38e-07	-0.44	-0.33	Retinal vascular caliber;	chr8:11377271	chr8:8167819~8226614:-
THCA	trans	rs2060793	0.835	rs1037379	ENSG00000236360.2	RP11-334A14.2	7.58	1.83e-13	3.4e-07	0.45	0.33	Vitamin D levels;	chr11:14831238	chr1:52993201~52993702:-
THCA	trans	rs7819412	0.744	rs4841503	ENSG00000229857.1	RP11-159H20.3	7.58	1.83e-13	3.41e-07	0.42	0.33	Triglycerides;	chr8:11166817	chr9:76992099~76993108:+
THCA	trans	rs6732160	0.967	rs6760964	ENSG00000236165.1	PRADC1P1	7.58	1.89e-13	3.5e-07	0.45	0.33	Intelligence (multi-trait analysis);	chr2:73160258	chr3:36976316~36976840:+
THCA	trans	rs941207	0.756	rs2950394	ENSG00000257210.1	NACAP3	-7.58	1.9e-13	3.53e-07	-0.44	-0.33	Platelet count;	chr12:56644548	chr12:93124063~93124543:-
THCA	trans	rs66887589	0.967	rs1480933	ENSG00000275858.1	RP11-291L22.8	7.58	1.91e-13	3.55e-07	0.4	0.33	Diastolic blood pressure;	chr4:119512093	chr10:38450738~38451069:-
THCA	trans	rs34421088	0.702	rs7838131	ENSG00000253893.2	FAM85B	7.58	1.91e-13	3.56e-07	0.42	0.33	Neuroticism;	chr8:11738654	chr8:8167819~8226614:-
THCA	trans	rs16937956	0.597	rs2311434	ENSG00000266891.1	RP11-692N5.2	7.58	1.91e-13	3.56e-07	0.45	0.33	Body mass index;	chr11:8384502	chr18:9734882~9735602:-
THCA	trans	rs9858542	0.953	rs9827708	ENSG00000197582.5	GPX1P1	-7.57	1.93e-13	3.58e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49612556	chrX:13378735~13379340:-
THCA	trans	rs3849046	0.79	rs13187637	ENSG00000226666.1	HSPA9P1	7.57	1.94e-13	3.6e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138540962	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.817	rs2268439	ENSG00000226666.1	HSPA9P1	7.57	1.94e-13	3.6e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138545103	chr2:221961737~221963765:+
THCA	trans	rs10242455	0.717	rs776745	ENSG00000228834.1	RP11-249L21.4	7.57	1.95e-13	3.61e-07	0.6	0.33	Blood metabolite levels;	chr7:99693714	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs776742	ENSG00000228834.1	RP11-249L21.4	7.57	1.95e-13	3.61e-07	0.6	0.33	Blood metabolite levels;	chr7:99695132	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687087	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99696849	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs1879859	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99697139	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687086	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99697827	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.764	rs2740564	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99698070	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs1818797	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99698572	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.681	rs1851425	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99702608	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs2687081	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99703135	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.867	rs10211	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99705371	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.764	rs12360	ENSG00000228834.1	RP11-249L21.4	-7.57	1.95e-13	3.61e-07	-0.6	-0.33	Blood metabolite levels;	chr7:99705471	chr6:108907615~108907873:-
THCA	trans	rs73108077	0.736	rs77855283	ENSG00000279352.1	RP11-411B10.7	7.57	1.95e-13	3.62e-07	0.6	0.33	Red blood cell density in sickle cell anemia;	chr20:31262576	chr18:14010054~14010917:+
THCA	trans	rs6945071	1	rs11976883	ENSG00000217241.1	CBX3P9	7.57	1.95e-13	3.62e-07	0.87	0.33	Superior frontal gyrus grey matter volume;	chr7:26239264	chr6:116453014~116453565:-
THCA	trans	rs14057	0.827	rs61780562	ENSG00000215869.3	RP11-364B6.1	7.57	1.96e-13	3.63e-07	0.47	0.33	Systolic blood pressure;	chr1:6698080	chr1:104073023~104077087:+
THCA	trans	rs11638815	0.581	rs783537	ENSG00000235370.6	DNM1P51	-7.57	1.96e-13	3.63e-07	-0.43	-0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:84398316~84411701:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000212829.8	RPS26P3	7.57	1.97e-13	3.65e-07	0.43	0.33	Cognitive function;	chr12:55981353	chr9:9090898~9091245:+
THCA	trans	rs877636	0.702	rs773111	ENSG00000212829.8	RPS26P3	7.57	1.97e-13	3.65e-07	0.43	0.33	Cognitive function;	chr12:55981956	chr9:9090898~9091245:+
THCA	trans	rs7824557	0.505	rs2736313	ENSG00000229857.1	RP11-159H20.3	-7.57	1.99e-13	3.68e-07	-0.42	-0.33	Retinal vascular caliber;	chr8:11229433	chr9:76992099~76993108:+
THCA	trans	rs14057	0.965	rs3789572	ENSG00000215869.3	RP11-364B6.1	7.57	1.99e-13	3.68e-07	0.47	0.33	Systolic blood pressure;	chr1:6672508	chr1:104073023~104077087:+
THCA	trans	rs7819412	0.522	rs4841497	ENSG00000253893.2	FAM85B	7.57	2e-13	3.7e-07	0.46	0.33	Triglycerides;	chr8:11127630	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.837	rs17724467	ENSG00000229857.1	RP11-159H20.3	7.57	2e-13	3.71e-07	0.43	0.33	Triglycerides;	chr8:11118172	chr9:76992099~76993108:+
THCA	trans	rs66887589	0.934	rs41464847	ENSG00000275858.1	RP11-291L22.8	-7.57	2.01e-13	3.73e-07	-0.39	-0.33	Diastolic blood pressure;	chr4:119611246	chr10:38450738~38451069:-
THCA	trans	rs11992162	0.56	rs7846248	ENSG00000253893.2	FAM85B	-7.57	2.02e-13	3.73e-07	-0.45	-0.33	Monocyte count;	chr8:11936540	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.717	rs3014245	ENSG00000255397.1	AC022182.2	7.57	2.02e-13	3.74e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr8:60937705~60939871:-
THCA	trans	rs6132905	0.52	rs2422824	ENSG00000235559.1	NOP56P1	7.57	2.03e-13	3.75e-07	0.41	0.33	Mumps;	chr20:2666724	chr6:28783633~28784004:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000212829.8	RPS26P3	7.57	2.03e-13	3.75e-07	0.43	0.33	Cognitive function;	chr12:55988132	chr9:9090898~9091245:+
THCA	trans	rs13177918	0.626	rs13170300	ENSG00000226396.1	RP5-1056L3.3	7.57	2.03e-13	3.76e-07	0.31	0.33	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:19608114~19608568:+
THCA	trans	rs6885307	0.825	rs62367470	ENSG00000231752.4	EMBP1	7.57	2.03e-13	3.76e-07	0.53	0.33	Age at first birth;	chr5:45192174	chr1:121519112~121571892:+
THCA	trans	rs7192380	0.756	rs12596945	ENSG00000257513.6	NPIPB1P	-7.57	2.03e-13	3.76e-07	-0.39	-0.33	Sjögren's syndrome;	chr16:69746916	chr18:11619509~11639699:-
THCA	trans	rs6732160	1	rs6732160	ENSG00000236165.1	PRADC1P1	7.57	2.04e-13	3.77e-07	0.44	0.33	Intelligence (multi-trait analysis);	chr2:73160100	chr3:36976316~36976840:+
THCA	trans	rs79149102	0.522	rs12441794	ENSG00000227288.3	RP5-837I24.1	7.56	2.06e-13	3.82e-07	0.5	0.33	Lung cancer;	chr15:74471808	chr1:81501794~81503468:+
THCA	trans	rs6915893	0.933	rs4588678	ENSG00000267156.1	TPMTP1	7.56	2.07e-13	3.82e-07	0.36	0.33	Intrinsic epigenetic age acceleration;	chr6:18119246	chr18:47630112~47630848:+
THCA	trans	rs34421088	0.56	rs2245357	ENSG00000253893.2	FAM85B	7.56	2.07e-13	3.83e-07	0.44	0.33	Neuroticism;	chr8:11541975	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs79199586	ENSG00000214110.3	LDHAP4	7.56	2.08e-13	3.84e-07	0.6	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr9:14921337~14922334:-
THCA	trans	rs16937956	0.597	rs12788149	ENSG00000266891.1	RP11-692N5.2	7.56	2.08e-13	3.84e-07	0.44	0.33	Body mass index;	chr11:8385383	chr18:9734882~9735602:-
THCA	trans	rs10242455	0.614	rs77340964	ENSG00000228834.1	RP11-249L21.4	7.56	2.08e-13	3.85e-07	0.65	0.33	Blood metabolite levels;	chr7:99446620	chr6:108907615~108907873:-
THCA	trans	rs7833986	0.501	rs72653959	ENSG00000236862.1	RPS20P24	7.56	2.09e-13	3.86e-07	0.48	0.33	Height;	chr8:56083957	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs72653962	ENSG00000236862.1	RPS20P24	7.56	2.09e-13	3.86e-07	0.48	0.33	Height;	chr8:56084946	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs72653967	ENSG00000236862.1	RPS20P24	7.56	2.09e-13	3.86e-07	0.48	0.33	Height;	chr8:56086873	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.534	rs10504198	ENSG00000236862.1	RPS20P24	7.56	2.09e-13	3.86e-07	0.48	0.33	Height;	chr8:56093695	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.534	rs2976022	ENSG00000236862.1	RPS20P24	7.56	2.09e-13	3.86e-07	0.48	0.33	Height;	chr8:56095284	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2976018	ENSG00000236862.1	RPS20P24	7.56	2.09e-13	3.86e-07	0.48	0.33	Height;	chr8:56102193	chr9:72655832~72656192:-
THCA	trans	rs73110464	0.505	rs2682296	ENSG00000259470.2	KRT8P9	-7.56	2.09e-13	3.87e-07	-0.44	-0.33	Cancer (pleiotropy);	chr12:52914481	chr15:70858714~70860162:+
THCA	trans	rs7824557	0.767	rs4559208	ENSG00000253893.2	FAM85B	-7.56	2.11e-13	3.9e-07	-0.43	-0.33	Retinal vascular caliber;	chr8:11296416	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.527	rs7833781	ENSG00000253893.2	FAM85B	-7.56	2.11e-13	3.9e-07	-0.45	-0.33	Neuroticism;	chr8:10475967	chr8:8167819~8226614:-
THCA	trans	rs10816533	1	rs10816533	ENSG00000232063.1	RP11-307E17.8	-7.56	2.11e-13	3.91e-07	-0.79	-0.33	Height;	chr9:96776856	chr9:94332476~94360948:+
THCA	trans	rs1190596	0.83	rs4947	ENSG00000181359.5	HSP90AA6P	7.56	2.12e-13	3.92e-07	0.49	0.33	Behavioural disinhibition (generation interaction);	chr14:102084466	chr4:170581470~170605450:-
THCA	trans	rs1190596	0.83	rs61992489	ENSG00000181359.5	HSP90AA6P	7.56	2.12e-13	3.92e-07	0.49	0.33	Behavioural disinhibition (generation interaction);	chr14:102086830	chr4:170581470~170605450:-
THCA	trans	rs66887589	0.967	rs56173225	ENSG00000275858.1	RP11-291L22.8	-7.56	2.13e-13	3.93e-07	-0.39	-0.33	Diastolic blood pressure;	chr4:119588817	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.967	rs7678973	ENSG00000275858.1	RP11-291L22.8	-7.56	2.13e-13	3.93e-07	-0.39	-0.33	Diastolic blood pressure;	chr4:119590662	chr10:38450738~38451069:-
THCA	trans	rs748404	0.631	rs6493084	ENSG00000180867.10	PDIA3P1	-7.56	2.13e-13	3.94e-07	-0.29	-0.33	Lung cancer;	chr15:43355429	chr1:147178113~147179622:+
THCA	trans	rs748404	0.631	rs12905772	ENSG00000180867.10	PDIA3P1	-7.56	2.13e-13	3.94e-07	-0.29	-0.33	Lung cancer;	chr15:43356246	chr1:147178113~147179622:+
THCA	trans	rs748404	0.676	rs4401024	ENSG00000180867.10	PDIA3P1	-7.56	2.13e-13	3.94e-07	-0.29	-0.33	Lung cancer;	chr15:43358137	chr1:147178113~147179622:+
THCA	trans	rs7113874	0.659	rs2166470	ENSG00000266891.1	RP11-692N5.2	-7.56	2.16e-13	3.98e-07	-0.46	-0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501625	chr18:9734882~9735602:-
THCA	trans	rs3740713	0.669	rs113003553	ENSG00000214110.3	LDHAP4	7.56	2.17e-13	4e-07	0.54	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr9:14921337~14922334:-
THCA	trans	rs1190596	0.83	rs2298877	ENSG00000181359.5	HSP90AA6P	7.56	2.19e-13	4.04e-07	0.5	0.33	Behavioural disinhibition (generation interaction);	chr14:102081887	chr4:170581470~170605450:-
THCA	trans	rs3740713	1	rs12289603	ENSG00000214110.3	LDHAP4	7.55	2.21e-13	4.08e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr9:14921337~14922334:-
THCA	trans	rs7662987	1	rs7683704	ENSG00000228407.2	RP4-800M22.1	7.55	2.21e-13	4.08e-07	0.68	0.33	Smoking initiation;	chr4:99083075	chr1:52160261~52160600:-
THCA	trans	rs9650657	0.769	rs2116093	ENSG00000253893.2	FAM85B	7.55	2.23e-13	4.12e-07	0.42	0.33	Neuroticism;	chr8:10755789	chr8:8167819~8226614:-
THCA	trans	rs11638815	0.603	rs10162807	ENSG00000235370.6	DNM1P51	-7.55	2.24e-13	4.13e-07	-0.42	-0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:84398316~84411701:-
THCA	trans	rs6424115	0.931	rs11800561	ENSG00000228217.1	AL390877.1	-7.55	2.25e-13	4.14e-07	-0.43	-0.33	Immature fraction of reticulocytes;	chr1:23837908	chr1:117778087~117778506:-
THCA	trans	rs11098499	0.874	rs13139045	ENSG00000275858.1	RP11-291L22.8	7.55	2.25e-13	4.15e-07	0.41	0.33	Corneal astigmatism;	chr4:119247433	chr10:38450738~38451069:-
THCA	trans	rs864643	0.678	rs1629282	ENSG00000188856.6	RPSAP47	-7.55	2.26e-13	4.17e-07	-0.5	-0.33	Attention deficit hyperactivity disorder;	chr3:39491770	chr8:80558870~80559757:+
THCA	trans	rs7824557	0.585	rs2572382	ENSG00000253893.2	FAM85B	-7.55	2.26e-13	4.17e-07	-0.45	-0.33	Retinal vascular caliber;	chr8:11353793	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.817	rs9327813	ENSG00000226666.1	HSPA9P1	7.55	2.29e-13	4.22e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138528732	chr2:221961737~221963765:+
THCA	trans	rs11671005	0.568	rs73068325	ENSG00000279267.1	RP11-395L14.18	7.55	2.3e-13	4.24e-07	0.47	0.33	Mean platelet volume;	chr19:58567729	chr2:113605867~113607908:-
THCA	trans	rs9329221	0.619	rs591346	ENSG00000253893.2	FAM85B	7.55	2.3e-13	4.24e-07	0.44	0.33	Neuroticism;	chr8:9960555	chr8:8167819~8226614:-
THCA	trans	rs11992162	1	rs7460395	ENSG00000253893.2	FAM85B	-7.55	2.32e-13	4.27e-07	-0.44	-0.33	Monocyte count;	chr8:11977866	chr8:8167819~8226614:-
THCA	trans	rs864643	0.678	rs1768191	ENSG00000183298.5	RP11-556K13.1	7.55	2.32e-13	4.27e-07	0.55	0.33	Attention deficit hyperactivity disorder;	chr3:39469772	chr1:101786340~101787219:-
THCA	trans	rs7662987	0.527	rs13106879	ENSG00000233859.2	ADH5P4	7.55	2.33e-13	4.29e-07	0.77	0.33	Smoking initiation;	chr4:99128867	chr6:65836930~65838039:-
THCA	trans	rs11992162	0.551	rs35010200	ENSG00000256560.1	LINC01486	-7.55	2.33e-13	4.3e-07	-0.41	-0.33	Monocyte count;	chr8:11928146	chr12:109354083~109359488:-
THCA	trans	rs3849046	0.817	rs12654060	ENSG00000226666.1	HSPA9P1	7.55	2.35e-13	4.32e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138600025	chr2:221961737~221963765:+
THCA	trans	rs748404	0.631	rs11070399	ENSG00000180867.10	PDIA3P1	-7.55	2.35e-13	4.33e-07	-0.29	-0.33	Lung cancer;	chr15:43354149	chr1:147178113~147179622:+
THCA	trans	rs13217239	0.646	rs10946897	ENSG00000242375.1	RP11-498P14.3	7.55	2.36e-13	4.35e-07	0.46	0.33	Schizophrenia;	chr6:27027472	chr9:97195351~97197687:-
THCA	trans	rs6885307	0.825	rs12515820	ENSG00000231752.4	EMBP1	7.54	2.36e-13	4.35e-07	0.54	0.33	Age at first birth;	chr5:45193367	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.714	rs12523359	ENSG00000231752.4	EMBP1	7.54	2.36e-13	4.35e-07	0.54	0.33	Age at first birth;	chr5:45193448	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs10941694	ENSG00000231752.4	EMBP1	7.54	2.36e-13	4.35e-07	0.54	0.33	Age at first birth;	chr5:45197677	chr1:121519112~121571892:+
THCA	trans	rs2645424	0.525	rs17814426	ENSG00000256560.1	LINC01486	7.54	2.37e-13	4.36e-07	0.38	0.33	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856796	chr12:109354083~109359488:-
THCA	trans	rs76228276	0.737	rs79506327	ENSG00000260318.1	COX6CP1	7.54	2.38e-13	4.37e-07	0.98	0.33	Childhood ear infection;	chr8:99148110	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11995021	ENSG00000260318.1	COX6CP1	7.54	2.38e-13	4.37e-07	0.98	0.33	Childhood ear infection;	chr8:99154100	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs78457441	ENSG00000260318.1	COX6CP1	7.54	2.38e-13	4.37e-07	0.98	0.33	Childhood ear infection;	chr8:99155137	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11997104	ENSG00000260318.1	COX6CP1	7.54	2.38e-13	4.37e-07	0.98	0.33	Childhood ear infection;	chr8:99156144	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs76017701	ENSG00000260318.1	COX6CP1	7.54	2.38e-13	4.37e-07	0.98	0.33	Childhood ear infection;	chr8:99282542	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs78913683	ENSG00000260318.1	COX6CP1	7.54	2.38e-13	4.37e-07	0.98	0.33	Childhood ear infection;	chr8:99283052	chr16:11903923~11904137:-
THCA	trans	rs11992162	0.56	rs13276386	ENSG00000253893.2	FAM85B	-7.54	2.38e-13	4.38e-07	-0.45	-0.33	Monocyte count;	chr8:11939912	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.621	rs13268810	ENSG00000253893.2	FAM85B	-7.54	2.38e-13	4.38e-07	-0.45	-0.33	Monocyte count;	chr8:11939921	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.636	rs13265816	ENSG00000253893.2	FAM85B	-7.54	2.38e-13	4.38e-07	-0.45	-0.33	Monocyte count;	chr8:11939976	chr8:8167819~8226614:-
THCA	trans	rs13217239	0.646	rs9379956	ENSG00000242375.1	RP11-498P14.3	-7.54	2.39e-13	4.39e-07	-0.46	-0.33	Schizophrenia;	chr6:27065956	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs7747454	ENSG00000242375.1	RP11-498P14.3	-7.54	2.39e-13	4.39e-07	-0.46	-0.33	Schizophrenia;	chr6:27066474	chr9:97195351~97197687:-
THCA	trans	rs79149102	0.522	rs28854237	ENSG00000227288.3	RP5-837I24.1	7.54	2.42e-13	4.45e-07	0.51	0.33	Lung cancer;	chr15:74511279	chr1:81501794~81503468:+
THCA	trans	rs79149102	0.522	rs11857192	ENSG00000227288.3	RP5-837I24.1	7.54	2.42e-13	4.45e-07	0.51	0.33	Lung cancer;	chr15:74530103	chr1:81501794~81503468:+
THCA	trans	rs74781061	0.79	rs74788606	ENSG00000227288.3	RP5-837I24.1	7.54	2.42e-13	4.45e-07	0.51	0.33	Endometriosis;	chr15:74532649	chr1:81501794~81503468:+
THCA	trans	rs7819412	0.522	rs3021495	ENSG00000253893.2	FAM85B	7.54	2.43e-13	4.46e-07	0.46	0.33	Triglycerides;	chr8:11137233	chr8:8167819~8226614:-
THCA	trans	rs9858542	0.953	rs1873625	ENSG00000197582.5	GPX1P1	-7.54	2.44e-13	4.48e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49629531	chrX:13378735~13379340:-
THCA	trans	rs73108077	0.736	rs6060596	ENSG00000279352.1	RP11-411B10.7	7.54	2.45e-13	4.5e-07	0.6	0.33	Red blood cell density in sickle cell anemia;	chr20:31261457	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs6060617	ENSG00000279352.1	RP11-411B10.7	7.54	2.45e-13	4.5e-07	0.6	0.33	Red blood cell density in sickle cell anemia;	chr20:31261849	chr18:14010054~14010917:+
THCA	trans	rs7819412	0.807	rs9657519	ENSG00000229857.1	RP11-159H20.3	7.54	2.46e-13	4.52e-07	0.42	0.33	Triglycerides;	chr8:11087929	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs4840551	ENSG00000229857.1	RP11-159H20.3	7.54	2.49e-13	4.57e-07	0.43	0.33	Triglycerides;	chr8:11171530	chr9:76992099~76993108:+
THCA	trans	rs2069408	1	rs2069408	ENSG00000196656.7	AC004057.1	-7.54	2.49e-13	4.58e-07	-0.46	-0.33	Asthma;	chr12:55970537	chr4:113214046~113217170:-
THCA	trans	rs7113874	0.592	rs10500703	ENSG00000266891.1	RP11-692N5.2	7.54	2.5e-13	4.59e-07	0.49	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8412317	chr18:9734882~9735602:-
THCA	trans	rs1707322	0.686	rs1250	ENSG00000255397.1	AC022182.2	-7.54	2.51e-13	4.6e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr8:60937705~60939871:-
THCA	trans	rs74781061	0.585	rs1866114	ENSG00000227288.3	RP5-837I24.1	7.54	2.51e-13	4.61e-07	0.5	0.33	Endometriosis;	chr15:74441465	chr1:81501794~81503468:+
THCA	trans	rs6885307	0.723	rs6451793	ENSG00000231752.4	EMBP1	-7.53	2.53e-13	4.65e-07	-0.5	-0.33	Age at first birth;	chr5:45277010	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.954	rs13145352	ENSG00000253326.2	RP11-261C10.7	-7.53	2.54e-13	4.65e-07	-0.47	-0.33	Corneal astigmatism;	chr4:119488808	chr1:243054861~243056394:-
THCA	trans	rs941207	0.756	rs67046307	ENSG00000257210.1	NACAP3	-7.53	2.54e-13	4.66e-07	-0.44	-0.33	Platelet count;	chr12:56651152	chr12:93124063~93124543:-
THCA	trans	rs941207	0.756	rs10876915	ENSG00000257210.1	NACAP3	-7.53	2.54e-13	4.66e-07	-0.44	-0.33	Platelet count;	chr12:56655280	chr12:93124063~93124543:-
THCA	trans	rs10816533	1	rs10118617	ENSG00000232063.1	RP11-307E17.8	7.53	2.56e-13	4.7e-07	0.76	0.33	Height;	chr9:96788187	chr9:94332476~94360948:+
THCA	trans	rs864643	1	rs634338	ENSG00000188856.6	RPSAP47	7.53	2.57e-13	4.71e-07	0.48	0.33	Attention deficit hyperactivity disorder;	chr3:39522752	chr8:80558870~80559757:+
THCA	trans	rs3849046	0.781	rs11242436	ENSG00000226666.1	HSPA9P1	7.53	2.59e-13	4.75e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138601629	chr2:221961737~221963765:+
THCA	trans	rs58106596	0.747	rs72994902	ENSG00000259020.3	RP11-529H20.3	7.53	2.6e-13	4.76e-07	0.54	0.33	Lymphocyte counts;White blood cell count;	chr2:231720407	chr14:92026566~92026887:+
THCA	trans	rs616147	0.627	rs9871799	ENSG00000243904.1	RP11-600F24.1	7.53	2.61e-13	4.78e-07	0.39	0.33	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr14:103374033~103374916:-
THCA	trans	rs34421088	0.56	rs2248699	ENSG00000253893.2	FAM85B	7.53	2.61e-13	4.78e-07	0.44	0.33	Neuroticism;	chr8:11536255	chr8:8167819~8226614:-
THCA	trans	rs941207	0.756	rs9634246	ENSG00000257210.1	NACAP3	-7.53	2.61e-13	4.79e-07	-0.44	-0.33	Platelet count;	chr12:56640604	chr12:93124063~93124543:-
THCA	trans	rs7819412	0.668	rs920047	ENSG00000229857.1	RP11-159H20.3	7.53	2.62e-13	4.8e-07	0.42	0.33	Triglycerides;	chr8:11229966	chr9:76992099~76993108:+
THCA	trans	rs877636	0.702	rs773108	ENSG00000243538.1	CTB-55B8.1	7.53	2.63e-13	4.81e-07	0.42	0.33	Cognitive function;	chr12:55976127	chr5:16902294~16902641:-
THCA	trans	rs6743068	0.521	rs2349074	ENSG00000235105.1	RP11-329A14.1	7.53	2.65e-13	4.85e-07	0.35	0.33	Lymphocyte percentage of white cells;	chr2:201357784	chr1:48435967~48437223:+
THCA	trans	rs7113874	0.921	rs10769932	ENSG00000266891.1	RP11-692N5.2	-7.53	2.65e-13	4.85e-07	-0.42	-0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8614792	chr18:9734882~9735602:-
THCA	trans	rs1707322	0.686	rs1541131	ENSG00000255397.1	AC022182.2	7.53	2.65e-13	4.85e-07	0.46	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr8:60937705~60939871:-
THCA	trans	rs13217239	0.608	rs6930508	ENSG00000242375.1	RP11-498P14.3	-7.53	2.65e-13	4.85e-07	-0.46	-0.33	Schizophrenia;	chr6:27085363	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs2142685	ENSG00000242375.1	RP11-498P14.3	-7.53	2.65e-13	4.85e-07	-0.46	-0.33	Schizophrenia;	chr6:27086718	chr9:97195351~97197687:-
THCA	trans	rs9858542	1	rs4283605	ENSG00000197582.5	GPX1P1	-7.53	2.66e-13	4.87e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49641218	chrX:13378735~13379340:-
THCA	trans	rs9858542	1	rs9812791	ENSG00000197582.5	GPX1P1	-7.53	2.66e-13	4.87e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49644878	chrX:13378735~13379340:-
THCA	trans	rs3849046	0.718	rs28587037	ENSG00000226666.1	HSPA9P1	7.53	2.7e-13	4.94e-07	0.34	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138599355	chr2:221961737~221963765:+
THCA	trans	rs6915893	0.903	rs6921836	ENSG00000267156.1	TPMTP1	7.52	2.72e-13	4.97e-07	0.35	0.33	Intrinsic epigenetic age acceleration;	chr6:18104045	chr18:47630112~47630848:+
THCA	trans	rs2060793	0.601	rs35321904	ENSG00000236360.2	RP11-334A14.2	7.52	2.73e-13	5e-07	0.45	0.33	Vitamin D levels;	chr11:14854914	chr1:52993201~52993702:-
THCA	trans	rs79149102	0.522	rs117774781	ENSG00000227288.3	RP5-837I24.1	7.52	2.74e-13	5.01e-07	0.5	0.33	Lung cancer;	chr15:74480109	chr1:81501794~81503468:+
THCA	trans	rs79149102	0.522	rs8023786	ENSG00000227288.3	RP5-837I24.1	7.52	2.74e-13	5.01e-07	0.5	0.33	Lung cancer;	chr15:74530155	chr1:81501794~81503468:+
THCA	trans	rs902774	0.818	rs56207534	ENSG00000224520.2	KRT8P45	-7.52	2.75e-13	5.03e-07	-0.67	-0.33	Prostate cancer;	chr12:52873525	chr1:157073257~157074703:+
THCA	trans	rs14057	0.827	rs2019784	ENSG00000215869.3	RP11-364B6.1	7.52	2.76e-13	5.04e-07	0.48	0.33	Systolic blood pressure;	chr1:6699756	chr1:104073023~104077087:+
THCA	trans	rs11992162	0.613	rs6998690	ENSG00000253893.2	FAM85B	-7.52	2.77e-13	5.06e-07	-0.44	-0.33	Monocyte count;	chr8:11941287	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.665	rs16902083	ENSG00000231752.4	EMBP1	7.52	2.78e-13	5.08e-07	0.53	0.33	Age at first birth;	chr5:45282706	chr1:121519112~121571892:+
THCA	trans	rs9876781	0.507	rs1824362	ENSG00000225528.1	RP3-370M22.8	7.52	2.79e-13	5.09e-07	0.4	0.33	Longevity;	chr3:48360459	chr22:39960397~39964683:+
THCA	trans	rs9329221	0.527	rs34259385	ENSG00000253893.2	FAM85B	7.52	2.79e-13	5.09e-07	0.44	0.33	Neuroticism;	chr8:10467946	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.74	rs11250077	ENSG00000253893.2	FAM85B	7.52	2.8e-13	5.1e-07	0.42	0.33	Neuroticism;	chr8:10798927	chr8:8167819~8226614:-
THCA	trans	rs941207	0.756	rs1465081	ENSG00000257210.1	NACAP3	-7.52	2.8e-13	5.11e-07	-0.44	-0.33	Platelet count;	chr12:56656390	chr12:93124063~93124543:-
THCA	trans	rs6885307	0.882	rs4533895	ENSG00000231752.4	EMBP1	7.52	2.8e-13	5.11e-07	0.5	0.33	Age at first birth;	chr5:45186842	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.882	rs4308490	ENSG00000231752.4	EMBP1	7.52	2.8e-13	5.11e-07	0.5	0.33	Age at first birth;	chr5:45186929	chr1:121519112~121571892:+
THCA	trans	rs282544	1	rs282556	ENSG00000231752.4	EMBP1	-7.52	2.81e-13	5.13e-07	-0.45	-0.33	Myopia (pathological);	chr5:50736451	chr1:121519112~121571892:+
THCA	trans	rs13217239	0.646	rs4269366	ENSG00000242375.1	RP11-498P14.3	7.52	2.84e-13	5.18e-07	0.46	0.33	Schizophrenia;	chr6:27048634	chr9:97195351~97197687:-
THCA	trans	rs6885307	0.825	rs1472584	ENSG00000231752.4	EMBP1	7.52	2.85e-13	5.19e-07	0.53	0.33	Age at first birth;	chr5:45210180	chr1:121519112~121571892:+
THCA	trans	rs14057	0.864	rs12126058	ENSG00000215869.3	RP11-364B6.1	7.52	2.86e-13	5.22e-07	0.47	0.33	Systolic blood pressure;	chr1:6684649	chr1:104073023~104077087:+
THCA	trans	rs9329221	0.506	rs6993610	ENSG00000253893.2	FAM85B	7.52	2.88e-13	5.25e-07	0.44	0.33	Neuroticism;	chr8:10473484	chr8:8167819~8226614:-
THCA	trans	rs16937956	0.597	rs72852616	ENSG00000266891.1	RP11-692N5.2	7.52	2.89e-13	5.27e-07	0.44	0.33	Body mass index;	chr11:8385339	chr18:9734882~9735602:-
THCA	trans	rs941207	0.756	rs2950388	ENSG00000257210.1	NACAP3	-7.51	2.9e-13	5.29e-07	-0.44	-0.33	Platelet count;	chr12:56639569	chr12:93124063~93124543:-
THCA	trans	rs7824557	0.778	rs3808502	ENSG00000253893.2	FAM85B	-7.51	2.91e-13	5.3e-07	-0.43	-0.33	Retinal vascular caliber;	chr8:11321949	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs78549183	ENSG00000214110.3	LDHAP4	7.51	2.92e-13	5.32e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr9:14921337~14922334:-
THCA	trans	rs7819412	0.818	rs11989439	ENSG00000229857.1	RP11-159H20.3	7.51	2.92e-13	5.33e-07	0.42	0.33	Triglycerides;	chr8:11198088	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.636	rs4841642	ENSG00000253893.2	FAM85B	-7.51	2.93e-13	5.34e-07	-0.44	-0.33	Monocyte count;	chr8:11940825	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.636	rs4841646	ENSG00000253893.2	FAM85B	-7.51	2.93e-13	5.34e-07	-0.44	-0.33	Monocyte count;	chr8:11941198	chr8:8167819~8226614:-
THCA	trans	rs7192380	0.639	rs7186296	ENSG00000257513.6	NPIPB1P	-7.51	2.95e-13	5.37e-07	-0.38	-0.33	Sjögren's syndrome;	chr16:69775095	chr18:11619509~11639699:-
THCA	trans	rs13217239	0.646	rs10946898	ENSG00000242375.1	RP11-498P14.3	7.51	2.97e-13	5.41e-07	0.46	0.33	Schizophrenia;	chr6:27036105	chr9:97195351~97197687:-
THCA	trans	rs6885307	0.825	rs62367469	ENSG00000231752.4	EMBP1	7.51	2.97e-13	5.41e-07	0.53	0.33	Age at first birth;	chr5:45186952	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs4566805	ENSG00000231752.4	EMBP1	7.51	2.97e-13	5.41e-07	0.53	0.33	Age at first birth;	chr5:45187816	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.875	rs11250121	ENSG00000229857.1	RP11-159H20.3	7.51	2.99e-13	5.44e-07	0.42	0.33	Triglycerides;	chr8:11202802	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.521	rs10100660	ENSG00000253893.2	FAM85B	7.51	3e-13	5.46e-07	0.46	0.33	Triglycerides;	chr8:11181376	chr8:8167819~8226614:-
THCA	trans	rs9858542	1	rs13316695	ENSG00000197582.5	GPX1P1	-7.51	3.01e-13	5.48e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49647484	chrX:13378735~13379340:-
THCA	trans	rs9858542	1	rs6770670	ENSG00000197582.5	GPX1P1	-7.51	3.01e-13	5.48e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49649249	chrX:13378735~13379340:-
THCA	trans	rs9858542	1	rs34762726	ENSG00000197582.5	GPX1P1	-7.51	3.01e-13	5.48e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49651777	chrX:13378735~13379340:-
THCA	trans	rs1707322	0.721	rs11211163	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs12037803	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs10789470	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs61784796	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs10749856	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs10890344	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs4564187	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs28438704	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs28442079	ENSG00000255397.1	AC022182.2	-7.51	3.02e-13	5.5e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr8:60937705~60939871:-
THCA	trans	rs3849046	0.79	rs10793825	ENSG00000226666.1	HSPA9P1	7.51	3.04e-13	5.53e-07	0.35	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138598882	chr2:221961737~221963765:+
THCA	trans	rs7121616	0.595	rs7949414	ENSG00000229091.2	HSPA8P8	7.51	3.04e-13	5.54e-07	0.42	0.33	Breast cancer;	chr11:123072787	chr7:10451311~10452526:+
THCA	trans	rs2736345	0.788	rs998683	ENSG00000253893.2	FAM85B	7.51	3.05e-13	5.55e-07	0.46	0.33	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:8167819~8226614:-
THCA	trans	rs1580019	0.563	rs764483	ENSG00000176826.14	FKBP9P1	-7.51	3.07e-13	5.58e-07	-0.43	-0.33	Cognitive ability;	chr7:32538538	chr7:55681074~55713252:-
THCA	trans	rs14057	0.759	rs11122119	ENSG00000215869.3	RP11-364B6.1	7.5	3.13e-13	5.68e-07	0.45	0.33	Systolic blood pressure;	chr1:6708796	chr1:104073023~104077087:+
THCA	trans	rs864643	0.678	rs500507	ENSG00000183298.5	RP11-556K13.1	7.5	3.15e-13	5.72e-07	0.53	0.33	Attention deficit hyperactivity disorder;	chr3:39492886	chr1:101786340~101787219:-
THCA	trans	rs7824557	0.606	rs1435277	ENSG00000253893.2	FAM85B	-7.5	3.16e-13	5.74e-07	-0.44	-0.33	Retinal vascular caliber;	chr8:11339461	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.606	rs2736273	ENSG00000253893.2	FAM85B	-7.5	3.16e-13	5.74e-07	-0.44	-0.33	Retinal vascular caliber;	chr8:11342429	chr8:8167819~8226614:-
THCA	trans	rs10420951	0.617	rs8101992	ENSG00000267533.1	RP11-815J4.7	7.5	3.16e-13	5.75e-07	0.62	0.33	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18503613	chr18:12067173~12068417:-
THCA	trans	rs10435719	0.58	rs13260712	ENSG00000256560.1	LINC01486	-7.5	3.2e-13	5.81e-07	-0.41	-0.33	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.551	rs13268217	ENSG00000256560.1	LINC01486	-7.5	3.2e-13	5.81e-07	-0.41	-0.33	Monocyte count;	chr8:11925100	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.573	rs13264994	ENSG00000256560.1	LINC01486	-7.5	3.2e-13	5.81e-07	-0.41	-0.33	Monocyte count;	chr8:11925250	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.573	rs13275808	ENSG00000256560.1	LINC01486	-7.5	3.2e-13	5.81e-07	-0.41	-0.33	Monocyte count;	chr8:11925306	chr12:109354083~109359488:-
THCA	trans	rs9425766	0.924	rs5877	ENSG00000213331.4	RP11-713C19.2	7.5	3.25e-13	5.9e-07	0.42	0.33	Life satisfaction;	chr1:173909724	chr4:187970273~187971284:+
THCA	trans	rs7824557	0.606	rs2736270	ENSG00000253893.2	FAM85B	-7.5	3.26e-13	5.91e-07	-0.44	-0.33	Retinal vascular caliber;	chr8:11335084	chr8:8167819~8226614:-
THCA	trans	rs16937956	0.597	rs16937958	ENSG00000266891.1	RP11-692N5.2	7.5	3.27e-13	5.94e-07	0.45	0.33	Body mass index;	chr11:8382988	chr18:9734882~9735602:-
THCA	trans	rs282544	1	rs166863	ENSG00000231752.4	EMBP1	-7.5	3.29e-13	5.98e-07	-0.45	-0.33	Myopia (pathological);	chr5:50741617	chr1:121519112~121571892:+
THCA	trans	rs10816533	1	rs3824482	ENSG00000232063.1	RP11-307E17.8	7.5	3.32e-13	6.02e-07	0.79	0.33	Height;	chr9:96777167	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs3780551	ENSG00000232063.1	RP11-307E17.8	7.5	3.32e-13	6.02e-07	0.79	0.33	Height;	chr9:96777457	chr9:94332476~94360948:+
THCA	trans	rs9858542	1	rs9882740	ENSG00000197582.5	GPX1P1	-7.5	3.32e-13	6.03e-07	-0.51	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49665051	chrX:13378735~13379340:-
THCA	trans	rs13217239	0.646	rs7451149	ENSG00000242375.1	RP11-498P14.3	-7.49	3.33e-13	6.05e-07	-0.46	-0.33	Schizophrenia;	chr6:27089739	chr9:97195351~97197687:-
THCA	trans	rs6915893	0.967	rs12199316	ENSG00000267156.1	TPMTP1	7.49	3.36e-13	6.1e-07	0.35	0.33	Intrinsic epigenetic age acceleration;	chr6:18123271	chr18:47630112~47630848:+
THCA	trans	rs864643	1	rs1768127	ENSG00000188856.6	RPSAP47	7.49	3.37e-13	6.11e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39523790	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs2542	ENSG00000188856.6	RPSAP47	7.49	3.37e-13	6.11e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39525858	chr8:80558870~80559757:+
THCA	trans	rs864643	0.891	rs816518	ENSG00000188856.6	RPSAP47	7.49	3.37e-13	6.11e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39527559	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1615844	ENSG00000188856.6	RPSAP47	7.49	3.37e-13	6.11e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39532375	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1513216	ENSG00000188856.6	RPSAP47	7.49	3.37e-13	6.11e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39532651	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1768134	ENSG00000188856.6	RPSAP47	7.49	3.37e-13	6.11e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39533080	chr8:80558870~80559757:+
THCA	trans	rs864643	0.891	rs1624647	ENSG00000188856.6	RPSAP47	7.49	3.37e-13	6.11e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39533558	chr8:80558870~80559757:+
THCA	trans	rs453301	0.653	rs1045529	ENSG00000229857.1	RP11-159H20.3	7.49	3.39e-13	6.15e-07	0.39	0.33	Joint mobility (Beighton score);	chr8:9032588	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.872	rs2572417	ENSG00000253893.2	FAM85B	7.49	3.42e-13	6.21e-07	0.41	0.33	Retinal vascular caliber;	chr8:11253953	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs73440615	ENSG00000214110.3	LDHAP4	7.49	3.42e-13	6.21e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr9:14921337~14922334:-
THCA	trans	rs11992162	0.508	rs7003792	ENSG00000256560.1	LINC01486	-7.49	3.43e-13	6.22e-07	-0.41	-0.33	Monocyte count;	chr8:11923955	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.805	rs4333549	ENSG00000229857.1	RP11-159H20.3	7.49	3.44e-13	6.23e-07	0.42	0.33	Triglycerides;	chr8:11122051	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.623	rs10087493	ENSG00000256560.1	LINC01486	-7.49	3.44e-13	6.24e-07	-0.4	-0.33	Mood instability;	chr8:8516047	chr12:109354083~109359488:-
THCA	trans	rs3740713	0.669	rs34740438	ENSG00000214110.3	LDHAP4	7.49	3.46e-13	6.26e-07	0.54	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr9:14921337~14922334:-
THCA	trans	rs7819412	0.522	rs10088853	ENSG00000253893.2	FAM85B	7.49	3.46e-13	6.27e-07	0.45	0.33	Triglycerides;	chr8:11130457	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs7839307	ENSG00000253893.2	FAM85B	-7.49	3.48e-13	6.3e-07	-0.43	-0.33	Retinal vascular caliber;	chr8:11341283	chr8:8167819~8226614:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000234354.3	RPS26P47	7.49	3.49e-13	6.32e-07	0.45	0.33	Cognitive function;	chr12:55990903	chr13:100539901~100540248:-
THCA	trans	rs9650657	0.783	rs28570522	ENSG00000253893.2	FAM85B	7.49	3.5e-13	6.34e-07	0.42	0.33	Neuroticism;	chr8:10773058	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.669	rs28630509	ENSG00000253893.2	FAM85B	7.49	3.53e-13	6.38e-07	0.45	0.33	Triglycerides;	chr8:11139529	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.502	rs4841499	ENSG00000253893.2	FAM85B	7.49	3.55e-13	6.41e-07	0.46	0.33	Triglycerides;	chr8:11130628	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs73438631	ENSG00000214110.3	LDHAP4	7.49	3.55e-13	6.43e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr9:14921337~14922334:-
THCA	trans	rs864643	0.625	rs1708083	ENSG00000183298.5	RP11-556K13.1	7.49	3.55e-13	6.43e-07	0.54	0.33	Attention deficit hyperactivity disorder;	chr3:39464295	chr1:101786340~101787219:-
THCA	trans	rs864643	0.625	rs1768182	ENSG00000183298.5	RP11-556K13.1	7.49	3.55e-13	6.43e-07	0.54	0.33	Attention deficit hyperactivity disorder;	chr3:39464531	chr1:101786340~101787219:-
THCA	trans	rs1707322	0.656	rs9429172	ENSG00000255397.1	AC022182.2	7.48	3.57e-13	6.46e-07	0.47	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr8:60937705~60939871:-
THCA	trans	rs6915893	1	rs12189658	ENSG00000267156.1	TPMTP1	7.48	3.6e-13	6.51e-07	0.35	0.33	Intrinsic epigenetic age acceleration;	chr6:18103106	chr18:47630112~47630848:+
THCA	trans	rs6885307	0.882	rs4493682	ENSG00000231752.4	EMBP1	7.48	3.61e-13	6.52e-07	0.5	0.33	Age at first birth;	chr5:45187922	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.594	rs17724226	ENSG00000253893.2	FAM85B	7.48	3.61e-13	6.53e-07	0.44	0.33	Triglycerides;	chr8:11111416	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.505	rs17726209	ENSG00000253893.2	FAM85B	-7.48	3.62e-13	6.55e-07	-0.46	-0.33	Triglycerides;	chr8:11164675	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.863	rs13134665	ENSG00000253326.2	RP11-261C10.7	7.48	3.65e-13	6.59e-07	0.46	0.33	Corneal astigmatism;	chr4:119505275	chr1:243054861~243056394:-
THCA	trans	rs864643	1	rs1340225	ENSG00000188856.6	RPSAP47	7.48	3.67e-13	6.63e-07	0.49	0.33	Attention deficit hyperactivity disorder;	chr3:39533951	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.909	rs10017335	ENSG00000253326.2	RP11-261C10.7	-7.48	3.68e-13	6.64e-07	-0.46	-0.33	Corneal astigmatism;	chr4:119460368	chr1:243054861~243056394:-
THCA	trans	rs1707322	0.716	rs10890342	ENSG00000255397.1	AC022182.2	-7.48	3.74e-13	6.74e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs6658700	ENSG00000255397.1	AC022182.2	-7.48	3.74e-13	6.74e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs12047629	ENSG00000255397.1	AC022182.2	-7.48	3.74e-13	6.74e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs11211169	ENSG00000255397.1	AC022182.2	-7.48	3.74e-13	6.74e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs11211171	ENSG00000255397.1	AC022182.2	-7.48	3.74e-13	6.74e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs28623463	ENSG00000255397.1	AC022182.2	-7.48	3.74e-13	6.74e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.716	rs28370457	ENSG00000255397.1	AC022182.2	-7.48	3.74e-13	6.74e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr8:60937705~60939871:-
THCA	trans	rs13217239	0.646	rs12527111	ENSG00000242375.1	RP11-498P14.3	7.48	3.74e-13	6.76e-07	0.46	0.33	Schizophrenia;	chr6:27038696	chr9:97195351~97197687:-
THCA	trans	rs2645424	0.55	rs12338	ENSG00000229857.1	RP11-159H20.3	-7.48	3.76e-13	6.78e-07	-0.4	-0.33	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853379	chr9:76992099~76993108:+
THCA	trans	rs9650657	1	rs9650657	ENSG00000253893.2	FAM85B	7.48	3.77e-13	6.8e-07	0.4	0.33	Neuroticism;	chr8:10749890	chr8:8167819~8226614:-
THCA	trans	rs13217239	0.646	rs6937880	ENSG00000242375.1	RP11-498P14.3	7.48	3.77e-13	6.8e-07	0.46	0.33	Schizophrenia;	chr6:27032457	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.621	rs12527231	ENSG00000242375.1	RP11-498P14.3	7.48	3.77e-13	6.8e-07	0.46	0.33	Schizophrenia;	chr6:27033509	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs12523820	ENSG00000242375.1	RP11-498P14.3	7.48	3.77e-13	6.8e-07	0.46	0.33	Schizophrenia;	chr6:27033723	chr9:97195351~97197687:-
THCA	trans	rs11992162	0.56	rs13256329	ENSG00000256560.1	LINC01486	-7.48	3.79e-13	6.84e-07	-0.4	-0.33	Monocyte count;	chr8:11924705	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.638	rs67146188	ENSG00000256560.1	LINC01486	-7.48	3.79e-13	6.84e-07	-0.4	-0.33	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr12:109354083~109359488:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000212829.8	RPS26P3	7.47	3.82e-13	6.89e-07	0.42	0.33	Cognitive function;	chr12:55982097	chr9:9090898~9091245:+
THCA	trans	rs2645424	0.55	rs28577034	ENSG00000229857.1	RP11-159H20.3	-7.47	3.82e-13	6.89e-07	-0.41	-0.33	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851206	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.505	rs17782554	ENSG00000253893.2	FAM85B	7.47	3.83e-13	6.9e-07	0.45	0.33	Triglycerides;	chr8:11164596	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.769	rs11130181	ENSG00000197582.5	GPX1P1	7.47	3.86e-13	6.96e-07	0.54	0.33	Menarche (age at onset);	chr3:49072486	chrX:13378735~13379340:-
THCA	trans	rs7819412	0.875	rs6981523	ENSG00000229857.1	RP11-159H20.3	7.47	3.88e-13	6.99e-07	0.42	0.33	Triglycerides;	chr8:11204283	chr9:76992099~76993108:+
THCA	trans	rs864643	0.812	rs1606473	ENSG00000188856.6	RPSAP47	-7.47	3.91e-13	7.04e-07	-0.47	-0.33	Attention deficit hyperactivity disorder;	chr3:39541433	chr8:80558870~80559757:+
THCA	trans	rs3740713	1	rs73436645	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr9:14921337~14922334:-
THCA	trans	rs3740713	0.925	rs73436650	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73436655	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr9:14921337~14922334:-
THCA	trans	rs3740713	0.92	rs80254575	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73436662	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs113725670	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73436682	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73436685	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs2056781	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73436701	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438607	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs75010364	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438627	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438634	ENSG00000214110.3	LDHAP4	7.47	3.95e-13	7.11e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr9:14921337~14922334:-
THCA	trans	rs11992162	0.551	rs59191504	ENSG00000253893.2	FAM85B	7.47	3.96e-13	7.13e-07	0.43	0.33	Monocyte count;	chr8:11927572	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.812	rs4240669	ENSG00000253893.2	FAM85B	7.47	3.97e-13	7.15e-07	0.41	0.33	Neuroticism;	chr8:10772477	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.721	rs11211165	ENSG00000255397.1	AC022182.2	-7.47	3.97e-13	7.15e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs11211166	ENSG00000255397.1	AC022182.2	-7.47	3.97e-13	7.15e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr8:60937705~60939871:-
THCA	trans	rs66887589	0.934	rs7681980	ENSG00000275858.1	RP11-291L22.8	-7.47	4.01e-13	7.21e-07	-0.38	-0.33	Diastolic blood pressure;	chr4:119612068	chr10:38450738~38451069:-
THCA	trans	rs867371	0.656	rs2665103	ENSG00000235370.6	DNM1P51	7.47	4.01e-13	7.21e-07	0.39	0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:84398316~84411701:-
THCA	trans	rs1707322	0.721	rs10890333	ENSG00000255397.1	AC022182.2	-7.47	4.01e-13	7.22e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs12043945	ENSG00000255397.1	AC022182.2	-7.47	4.01e-13	7.22e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs12091503	ENSG00000255397.1	AC022182.2	-7.47	4.01e-13	7.22e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs10890336	ENSG00000255397.1	AC022182.2	-7.47	4.01e-13	7.22e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr8:60937705~60939871:-
THCA	trans	rs34421088	0.56	rs2618434	ENSG00000253893.2	FAM85B	7.47	4.02e-13	7.23e-07	0.43	0.33	Neuroticism;	chr8:11541356	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.721	rs10430123	ENSG00000255397.1	AC022182.2	-7.47	4.03e-13	7.25e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr8:60937705~60939871:-
THCA	trans	rs13217239	0.646	rs10946888	ENSG00000242375.1	RP11-498P14.3	7.47	4.07e-13	7.33e-07	0.46	0.33	Schizophrenia;	chr6:26983899	chr9:97195351~97197687:-
THCA	trans	rs2929278	0.736	rs2412823	ENSG00000180867.10	PDIA3P1	7.46	4.08e-13	7.33e-07	0.28	0.33	Schizophrenia;	chr15:43935072	chr1:147178113~147179622:+
THCA	trans	rs13177918	0.578	rs35919198	ENSG00000226396.1	RP5-1056L3.3	7.46	4.09e-13	7.35e-07	0.31	0.33	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:19608114~19608568:+
THCA	trans	rs3740713	1	rs3740713	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.39e-07	0.6	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr9:14921337~14922334:-
THCA	trans	rs13217239	0.646	rs11756275	ENSG00000242375.1	RP11-498P14.3	-7.46	4.11e-13	7.39e-07	-0.46	-0.33	Schizophrenia;	chr6:27039334	chr9:97195351~97197687:-
THCA	trans	rs3740713	1	rs57311859	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr9:14921337~14922334:-
THCA	trans	rs3740713	0.92	rs112973292	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr9:14921337~14922334:-
THCA	trans	rs3740713	0.92	rs73438656	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr9:14921337~14922334:-
THCA	trans	rs3740713	0.92	rs73438659	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438666	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs16935424	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438674	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438690	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438695	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73440606	ENSG00000214110.3	LDHAP4	7.46	4.11e-13	7.4e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr9:14921337~14922334:-
THCA	trans	rs7032940	0.651	rs7873398	ENSG00000262519.1	TXNP4	7.46	4.12e-13	7.41e-07	0.41	0.33	Height;	chr9:110194413	chr17:4572206~4572515:+
THCA	trans	rs13217239	0.646	rs35691005	ENSG00000242375.1	RP11-498P14.3	7.46	4.14e-13	7.44e-07	0.46	0.33	Schizophrenia;	chr6:27004291	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs10946891	ENSG00000242375.1	RP11-498P14.3	7.46	4.14e-13	7.44e-07	0.46	0.33	Schizophrenia;	chr6:27005436	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs12201393	ENSG00000242375.1	RP11-498P14.3	7.46	4.14e-13	7.44e-07	0.46	0.33	Schizophrenia;	chr6:27007911	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs12209886	ENSG00000242375.1	RP11-498P14.3	7.46	4.14e-13	7.44e-07	0.46	0.33	Schizophrenia;	chr6:27016978	chr9:97195351~97197687:-
THCA	trans	rs6940638	0.531	rs12211984	ENSG00000242375.1	RP11-498P14.3	7.46	4.14e-13	7.44e-07	0.46	0.33	Intelligence (multi-trait analysis);	chr6:27018275	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs10456351	ENSG00000242375.1	RP11-498P14.3	7.46	4.14e-13	7.44e-07	0.46	0.33	Schizophrenia;	chr6:27019013	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs10456352	ENSG00000242375.1	RP11-498P14.3	7.46	4.14e-13	7.44e-07	0.46	0.33	Schizophrenia;	chr6:27022579	chr9:97195351~97197687:-
THCA	trans	rs13217239	0.646	rs4583981	ENSG00000242375.1	RP11-498P14.3	7.46	4.14e-13	7.44e-07	0.46	0.33	Schizophrenia;	chr6:27024244	chr9:97195351~97197687:-
THCA	trans	rs1991651	0.578	rs13259086	ENSG00000253893.2	FAM85B	-7.46	4.17e-13	7.48e-07	-0.42	-0.33	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632708	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.836	rs1073913	ENSG00000253893.2	FAM85B	7.46	4.19e-13	7.52e-07	0.41	0.33	Neuroticism;	chr8:10754198	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.504	rs6986032	ENSG00000229857.1	RP11-159H20.3	7.46	4.2e-13	7.54e-07	0.42	0.33	Neuroticism;	chr8:11174731	chr9:76992099~76993108:+
THCA	trans	rs1580019	0.563	rs34201720	ENSG00000176826.14	FKBP9P1	-7.46	4.22e-13	7.58e-07	-0.43	-0.33	Cognitive ability;	chr7:32529323	chr7:55681074~55713252:-
THCA	trans	rs12709013	0.967	rs11643969	ENSG00000230849.2	GOT2P2	7.46	4.22e-13	7.58e-07	0.4	0.33	Blood metabolite ratios;	chr16:58785354	chr1:173141100~173142350:-
THCA	trans	rs1190596	0.83	rs3736807	ENSG00000181359.5	HSP90AA6P	7.46	4.24e-13	7.61e-07	0.49	0.33	Behavioural disinhibition (generation interaction);	chr14:102086438	chr4:170581470~170605450:-
THCA	trans	rs9858542	0.953	rs9837341	ENSG00000197582.5	GPX1P1	-7.46	4.25e-13	7.63e-07	-0.5	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49627334	chrX:13378735~13379340:-
THCA	trans	rs3740713	1	rs76586692	ENSG00000214110.3	LDHAP4	7.46	4.27e-13	7.66e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs76062966	ENSG00000214110.3	LDHAP4	7.46	4.27e-13	7.66e-07	0.58	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr9:14921337~14922334:-
THCA	trans	rs6885307	0.882	rs12523157	ENSG00000231752.4	EMBP1	7.46	4.28e-13	7.68e-07	0.5	0.33	Age at first birth;	chr5:45175716	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.769	rs1115866	ENSG00000253893.2	FAM85B	7.46	4.28e-13	7.69e-07	0.41	0.33	Neuroticism;	chr8:10780823	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.502	rs4840548	ENSG00000253893.2	FAM85B	7.46	4.29e-13	7.7e-07	0.46	0.33	Triglycerides;	chr8:11135373	chr8:8167819~8226614:-
THCA	trans	rs12210905	0.748	rs6901225	ENSG00000242375.1	RP11-498P14.3	-7.46	4.3e-13	7.72e-07	-0.75	-0.33	Hip circumference adjusted for BMI;	chr6:26670263	chr9:97195351~97197687:-
THCA	trans	rs1707322	0.65	rs4553239	ENSG00000255397.1	AC022182.2	-7.46	4.3e-13	7.72e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr8:60937705~60939871:-
THCA	trans	rs3740713	1	rs73440636	ENSG00000214110.3	LDHAP4	7.46	4.32e-13	7.75e-07	0.57	0.33	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr9:14921337~14922334:-
THCA	trans	rs66887589	0.934	rs2389873	ENSG00000275858.1	RP11-291L22.8	-7.45	4.38e-13	7.85e-07	-0.38	-0.33	Diastolic blood pressure;	chr4:119633559	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.934	rs4834792	ENSG00000275858.1	RP11-291L22.8	-7.45	4.38e-13	7.85e-07	-0.38	-0.33	Diastolic blood pressure;	chr4:119634541	chr10:38450738~38451069:-
THCA	trans	rs9650657	0.504	rs10093053	ENSG00000229857.1	RP11-159H20.3	7.45	4.43e-13	7.95e-07	0.42	0.33	Neuroticism;	chr8:11179678	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.909	rs10020034	ENSG00000253326.2	RP11-261C10.7	7.45	4.46e-13	7.98e-07	0.46	0.33	Corneal astigmatism;	chr4:119373176	chr1:243054861~243056394:-
THCA	trans	rs13177918	0.603	rs13175992	ENSG00000226396.1	RP5-1056L3.3	7.45	4.5e-13	8.06e-07	0.3	0.33	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:19608114~19608568:+
THCA	trans	rs9858542	1	rs2172252	ENSG00000197582.5	GPX1P1	-7.45	4.54e-13	8.13e-07	-0.51	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49640874	chrX:13378735~13379340:-
THCA	trans	rs282544	1	rs154136	ENSG00000231752.4	EMBP1	7.45	4.64e-13	8.31e-07	0.44	0.32	Myopia (pathological);	chr5:50775731	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.882	rs12514414	ENSG00000231752.4	EMBP1	7.44	4.67e-13	8.36e-07	0.5	0.32	Age at first birth;	chr5:45194899	chr1:121519112~121571892:+
THCA	trans	rs1580019	0.563	rs13225132	ENSG00000176826.14	FKBP9P1	-7.44	4.68e-13	8.38e-07	-0.43	-0.32	Cognitive ability;	chr7:32761363	chr7:55681074~55713252:-
THCA	trans	rs6915893	1	rs4294009	ENSG00000267156.1	TPMTP1	7.44	4.69e-13	8.39e-07	0.35	0.32	Intrinsic epigenetic age acceleration;	chr6:18105845	chr18:47630112~47630848:+
THCA	trans	rs9650657	0.504	rs2409724	ENSG00000229857.1	RP11-159H20.3	7.44	4.71e-13	8.42e-07	0.41	0.32	Neuroticism;	chr8:11184133	chr9:76992099~76993108:+
THCA	trans	rs13177918	0.626	rs13175436	ENSG00000226396.1	RP5-1056L3.3	7.44	4.75e-13	8.5e-07	0.3	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:19608114~19608568:+
THCA	trans	rs6885307	0.825	rs75856200	ENSG00000231752.4	EMBP1	7.44	4.76e-13	8.51e-07	0.53	0.32	Age at first birth;	chr5:45188128	chr1:121519112~121571892:+
THCA	trans	rs7833986	0.501	rs2953911	ENSG00000236862.1	RPS20P24	7.44	4.77e-13	8.53e-07	0.48	0.32	Height;	chr8:56035450	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2667999	ENSG00000236862.1	RPS20P24	7.44	4.77e-13	8.53e-07	0.48	0.32	Height;	chr8:56037915	chr9:72655832~72656192:-
THCA	trans	rs9650657	0.707	rs4593498	ENSG00000253893.2	FAM85B	7.44	4.79e-13	8.57e-07	0.41	0.32	Neuroticism;	chr8:10797960	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.737	rs4504595	ENSG00000253893.2	FAM85B	7.44	4.79e-13	8.57e-07	0.41	0.32	Neuroticism;	chr8:10797995	chr8:8167819~8226614:-
THCA	trans	rs10242455	0.764	rs2687084	ENSG00000228834.1	RP11-249L21.4	-7.44	4.8e-13	8.58e-07	-0.59	-0.32	Blood metabolite levels;	chr7:99700509	chr6:108907615~108907873:-
THCA	trans	rs9650657	0.836	rs891556	ENSG00000253893.2	FAM85B	7.44	4.83e-13	8.63e-07	0.41	0.32	Neuroticism;	chr8:10766123	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.774	rs34208825	ENSG00000229857.1	RP11-159H20.3	7.44	4.86e-13	8.69e-07	0.41	0.32	Triglycerides;	chr8:11157106	chr9:76992099~76993108:+
THCA	trans	rs10420951	0.542	rs2303693	ENSG00000267533.1	RP11-815J4.7	-7.44	4.86e-13	8.69e-07	-0.62	-0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18446863	chr18:12067173~12068417:-
THCA	trans	rs13217239	0.646	rs62401067	ENSG00000242375.1	RP11-498P14.3	7.44	4.87e-13	8.69e-07	0.46	0.32	Schizophrenia;	chr6:27050322	chr9:97195351~97197687:-
THCA	trans	rs34421088	0.576	rs2572432	ENSG00000253893.2	FAM85B	7.44	4.87e-13	8.69e-07	0.47	0.32	Neuroticism;	chr8:11244214	chr8:8167819~8226614:-
THCA	trans	rs13177918	0.626	rs67026795	ENSG00000226396.1	RP5-1056L3.3	7.44	4.88e-13	8.72e-07	0.3	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.603	rs10447222	ENSG00000226396.1	RP5-1056L3.3	7.44	4.88e-13	8.72e-07	0.3	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:19608114~19608568:+
THCA	trans	rs2288327	0.841	rs16866418	ENSG00000269800.1	PLEKHA3P1	7.44	4.92e-13	8.79e-07	0.43	0.32	Atrial fibrillation;	chr2:178626227	chr19:41521043~41521989:-
THCA	trans	rs1707322	0.682	rs10890335	ENSG00000255397.1	AC022182.2	-7.44	4.97e-13	8.88e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr8:60937705~60939871:-
THCA	trans	rs73108077	0.736	rs2206384	ENSG00000279352.1	RP11-411B10.7	7.44	4.99e-13	8.91e-07	0.57	0.32	Red blood cell density in sickle cell anemia;	chr20:31339363	chr18:14010054~14010917:+
THCA	trans	rs1707322	0.682	rs10890334	ENSG00000255397.1	AC022182.2	-7.44	4.99e-13	8.91e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.716	rs6694889	ENSG00000255397.1	AC022182.2	-7.44	4.99e-13	8.91e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.682	rs12041197	ENSG00000255397.1	AC022182.2	-7.44	4.99e-13	8.91e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs11211145	ENSG00000255397.1	AC022182.2	-7.44	4.99e-13	8.91e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs11211146	ENSG00000255397.1	AC022182.2	-7.44	4.99e-13	8.91e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs11211147	ENSG00000255397.1	AC022182.2	-7.44	4.99e-13	8.91e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr8:60937705~60939871:-
THCA	trans	rs12709013	0.935	rs8046667	ENSG00000233719.3	GOT2P3	7.43	5.01e-13	8.94e-07	0.39	0.32	Blood metabolite ratios;	chr16:58790935	chr12:9641802~9643007:+
THCA	trans	rs12709013	1	rs8046998	ENSG00000233719.3	GOT2P3	7.43	5.01e-13	8.94e-07	0.39	0.32	Blood metabolite ratios;	chr16:58791109	chr12:9641802~9643007:+
THCA	trans	rs66887589	0.87	rs2389875	ENSG00000275858.1	RP11-291L22.8	-7.43	5.02e-13	8.96e-07	-0.39	-0.32	Diastolic blood pressure;	chr4:119635859	chr10:38450738~38451069:-
THCA	trans	rs12709013	0.875	rs9924389	ENSG00000233719.3	GOT2P3	7.43	5.03e-13	8.98e-07	0.39	0.32	Blood metabolite ratios;	chr16:58779849	chr12:9641802~9643007:+
THCA	trans	rs1707322	0.682	rs3014241	ENSG00000255397.1	AC022182.2	7.43	5.05e-13	9.01e-07	0.46	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.909	rs79026312	ENSG00000253326.2	RP11-261C10.7	7.43	5.12e-13	9.13e-07	0.46	0.32	Corneal astigmatism;	chr4:119519522	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs35111518	ENSG00000253326.2	RP11-261C10.7	7.43	5.12e-13	9.13e-07	0.46	0.32	Corneal astigmatism;	chr4:119519527	chr1:243054861~243056394:-
THCA	trans	rs9858542	1	rs11718165	ENSG00000197582.5	GPX1P1	-7.43	5.14e-13	9.17e-07	-0.51	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49659364	chrX:13378735~13379340:-
THCA	trans	rs9858542	1	rs9823546	ENSG00000197582.5	GPX1P1	-7.43	5.14e-13	9.17e-07	-0.51	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49668079	chrX:13378735~13379340:-
THCA	trans	rs34421088	0.678	rs35928010	ENSG00000253893.2	FAM85B	7.43	5.15e-13	9.19e-07	0.41	0.32	Neuroticism;	chr8:11734367	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.954	rs10017371	ENSG00000253326.2	RP11-261C10.7	7.43	5.23e-13	9.31e-07	0.46	0.32	Corneal astigmatism;	chr4:119372621	chr1:243054861~243056394:-
THCA	trans	rs7121616	0.842	rs11825379	ENSG00000234176.1	HSPA8P1	7.43	5.26e-13	9.38e-07	0.48	0.32	Breast cancer;	chr11:123126599	chrX:121203182~121205014:-
THCA	trans	rs6885307	0.825	rs62367462	ENSG00000231752.4	EMBP1	7.43	5.28e-13	9.4e-07	0.53	0.32	Age at first birth;	chr5:45157372	chr1:121519112~121571892:+
THCA	trans	rs11992162	0.597	rs6996342	ENSG00000256560.1	LINC01486	-7.43	5.31e-13	9.47e-07	-0.41	-0.32	Monocyte count;	chr8:11927032	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs79377635	ENSG00000224520.2	KRT8P45	-7.43	5.32e-13	9.48e-07	-0.67	-0.32	Prostate cancer;	chr12:52883148	chr1:157073257~157074703:+
THCA	trans	rs1580019	0.539	rs11769109	ENSG00000176826.14	FKBP9P1	-7.43	5.33e-13	9.5e-07	-0.43	-0.32	Cognitive ability;	chr7:32531740	chr7:55681074~55713252:-
THCA	trans	rs7824557	0.569	rs35418978	ENSG00000253893.2	FAM85B	-7.43	5.34e-13	9.51e-07	-0.43	-0.32	Retinal vascular caliber;	chr8:11328944	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.606	rs2736264	ENSG00000253893.2	FAM85B	-7.43	5.34e-13	9.51e-07	-0.43	-0.32	Retinal vascular caliber;	chr8:11329130	chr8:8167819~8226614:-
THCA	trans	rs748404	0.578	rs512628	ENSG00000180867.10	PDIA3P1	-7.42	5.34e-13	9.52e-07	-0.28	-0.32	Lung cancer;	chr15:43326536	chr1:147178113~147179622:+
THCA	trans	rs9329221	0.618	rs73197281	ENSG00000253893.2	FAM85B	7.42	5.38e-13	9.58e-07	0.41	0.32	Neuroticism;	chr8:10405772	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.745	rs6601569	ENSG00000229857.1	RP11-159H20.3	7.42	5.38e-13	9.59e-07	0.41	0.32	Triglycerides;	chr8:11216069	chr9:76992099~76993108:+
THCA	trans	rs1707322	0.717	rs11211161	ENSG00000255397.1	AC022182.2	-7.42	5.39e-13	9.59e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs61784793	ENSG00000255397.1	AC022182.2	-7.42	5.39e-13	9.59e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs4586014	ENSG00000255397.1	AC022182.2	-7.42	5.39e-13	9.59e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.648	rs4439382	ENSG00000255397.1	AC022182.2	-7.42	5.39e-13	9.59e-07	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.769	rs2116094	ENSG00000253893.2	FAM85B	7.42	5.41e-13	9.64e-07	0.41	0.32	Neuroticism;	chr8:10741312	chr8:8167819~8226614:-
THCA	trans	rs6915893	1	rs4074444	ENSG00000267156.1	TPMTP1	7.42	5.48e-13	9.75e-07	0.35	0.32	Intrinsic epigenetic age acceleration;	chr6:18106258	chr18:47630112~47630848:+
THCA	trans	rs6885307	0.882	rs62367464	ENSG00000231752.4	EMBP1	7.42	5.49e-13	9.77e-07	0.5	0.32	Age at first birth;	chr5:45168602	chr1:121519112~121571892:+
THCA	trans	rs6981523	0.553	rs11783890	ENSG00000253893.2	FAM85B	7.42	5.49e-13	9.77e-07	0.45	0.32	Neuroticism;	chr8:11198879	chr8:8167819~8226614:-
THCA	trans	rs864643	0.891	rs1708032	ENSG00000188856.6	RPSAP47	7.42	5.5e-13	9.79e-07	0.47	0.32	Attention deficit hyperactivity disorder;	chr3:39497642	chr8:80558870~80559757:+
THCA	trans	rs7833986	0.501	rs72653986	ENSG00000236862.1	RPS20P24	7.42	5.54e-13	9.86e-07	0.48	0.32	Height;	chr8:56122489	chr9:72655832~72656192:-
THCA	trans	rs10420951	0.617	rs77571703	ENSG00000267533.1	RP11-815J4.7	7.42	5.54e-13	9.86e-07	0.62	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18468174	chr18:12067173~12068417:-
THCA	trans	rs7819412	0.522	rs4642600	ENSG00000253893.2	FAM85B	7.42	5.54e-13	9.86e-07	0.46	0.32	Triglycerides;	chr8:11155515	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.707	rs4841452	ENSG00000253893.2	FAM85B	7.42	5.61e-13	9.97e-07	0.41	0.32	Neuroticism;	chr8:10829611	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.678	rs35726503	ENSG00000253893.2	FAM85B	7.42	5.62e-13	9.99e-07	0.41	0.32	Neuroticism;	chr8:11734407	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.882	rs12519474	ENSG00000231752.4	EMBP1	7.42	5.64e-13	1e-06	0.5	0.32	Age at first birth;	chr5:45170277	chr1:121519112~121571892:+
THCA	trans	rs11992162	0.529	rs6995037	ENSG00000256560.1	LINC01486	-7.42	5.67e-13	1.01e-06	-0.41	-0.32	Monocyte count;	chr8:11923378	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.882	rs6864149	ENSG00000231752.4	EMBP1	7.42	5.68e-13	1.01e-06	0.5	0.32	Age at first birth;	chr5:45263333	chr1:121519112~121571892:+
THCA	trans	rs1707322	0.721	rs11211151	ENSG00000255397.1	AC022182.2	-7.42	5.69e-13	1.01e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs12045096	ENSG00000255397.1	AC022182.2	-7.42	5.69e-13	1.01e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs4609469	ENSG00000255397.1	AC022182.2	-7.42	5.69e-13	1.01e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs12049027	ENSG00000255397.1	AC022182.2	-7.42	5.69e-13	1.01e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs10789467	ENSG00000255397.1	AC022182.2	-7.42	5.69e-13	1.01e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs10890337	ENSG00000255397.1	AC022182.2	-7.42	5.69e-13	1.01e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs3811435	ENSG00000255397.1	AC022182.2	-7.42	5.69e-13	1.01e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr8:60937705~60939871:-
THCA	trans	rs3947	0.653	rs1293296	ENSG00000253893.2	FAM85B	7.42	5.69e-13	1.01e-06	0.49	0.32	Blood protein levels;	chr8:11853648	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.531	rs2245232	ENSG00000253893.2	FAM85B	7.42	5.7e-13	1.01e-06	0.44	0.32	Neuroticism;	chr8:11543435	chr8:8167819~8226614:-
THCA	trans	rs2288327	0.915	rs2303838	ENSG00000269800.1	PLEKHA3P1	7.42	5.72e-13	1.02e-06	0.42	0.32	Atrial fibrillation;	chr2:178580212	chr19:41521043~41521989:-
THCA	trans	rs6885307	0.882	rs62367475	ENSG00000231752.4	EMBP1	7.41	5.75e-13	1.02e-06	0.5	0.32	Age at first birth;	chr5:45234160	chr1:121519112~121571892:+
THCA	trans	rs9329221	0.527	rs34308302	ENSG00000253893.2	FAM85B	7.41	5.81e-13	1.03e-06	0.44	0.32	Neuroticism;	chr8:10474512	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.723	rs58713827	ENSG00000231752.4	EMBP1	7.41	5.84e-13	1.04e-06	0.49	0.32	Age at first birth;	chr5:45281525	chr1:121519112~121571892:+
THCA	trans	rs10420951	0.617	rs74497531	ENSG00000267533.1	RP11-815J4.7	7.41	5.89e-13	1.05e-06	0.62	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18467368	chr18:12067173~12068417:-
THCA	trans	rs2060793	0.741	rs7928396	ENSG00000236360.2	RP11-334A14.2	7.41	5.92e-13	1.05e-06	0.43	0.32	Vitamin D levels;	chr11:14822583	chr1:52993201~52993702:-
THCA	trans	rs9650657	0.655	rs1991651	ENSG00000253893.2	FAM85B	-7.41	5.93e-13	1.05e-06	-0.42	-0.32	Neuroticism;	chr8:10848901	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.825	rs1392970	ENSG00000231752.4	EMBP1	7.41	5.96e-13	1.06e-06	0.52	0.32	Age at first birth;	chr5:45229571	chr1:121519112~121571892:+
THCA	trans	rs1292059	1	rs1292059	ENSG00000187870.7	RNFT1P3	7.41	6.01e-13	1.07e-06	0.52	0.32	Eosinophil percentage of granulocytes;	chr17:59880527	chr17:20743333~20754501:-
THCA	trans	rs7824557	0.652	rs12677504	ENSG00000253893.2	FAM85B	7.41	6.01e-13	1.07e-06	0.43	0.32	Retinal vascular caliber;	chr8:11275666	chr8:8167819~8226614:-
THCA	trans	rs7032940	0.677	rs10816931	ENSG00000262519.1	TXNP4	7.41	6.03e-13	1.07e-06	0.42	0.32	Height;	chr9:110177912	chr17:4572206~4572515:+
THCA	trans	rs7833986	0.501	rs17814658	ENSG00000236862.1	RPS20P24	7.41	6.07e-13	1.08e-06	0.48	0.32	Height;	chr8:56076571	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs72653957	ENSG00000236862.1	RPS20P24	7.41	6.07e-13	1.08e-06	0.48	0.32	Height;	chr8:56077489	chr9:72655832~72656192:-
THCA	trans	rs2736345	0.502	rs12680762	ENSG00000253893.2	FAM85B	7.41	6.08e-13	1.08e-06	0.45	0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11474517	chr8:8167819~8226614:-
THCA	trans	rs9858542	1	rs9858542	ENSG00000197582.5	GPX1P1	7.41	6.08e-13	1.08e-06	0.5	0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49664550	chrX:13378735~13379340:-
THCA	trans	rs74781061	0.585	rs2899826	ENSG00000227288.3	RP5-837I24.1	7.4	6.19e-13	1.1e-06	0.49	0.32	Endometriosis;	chr15:74442159	chr1:81501794~81503468:+
THCA	trans	rs7833986	0.501	rs72653953	ENSG00000236862.1	RPS20P24	7.4	6.21e-13	1.1e-06	0.48	0.32	Height;	chr8:56058236	chr9:72655832~72656192:-
THCA	trans	rs66887589	0.87	rs59590064	ENSG00000275858.1	RP11-291L22.8	-7.4	6.22e-13	1.1e-06	-0.38	-0.32	Diastolic blood pressure;	chr4:119618598	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.934	rs6817317	ENSG00000275858.1	RP11-291L22.8	-7.4	6.22e-13	1.1e-06	-0.38	-0.32	Diastolic blood pressure;	chr4:119621672	chr10:38450738~38451069:-
THCA	trans	rs66887589	0.934	rs7672519	ENSG00000275858.1	RP11-291L22.8	-7.4	6.22e-13	1.1e-06	-0.38	-0.32	Diastolic blood pressure;	chr4:119622957	chr10:38450738~38451069:-
THCA	trans	rs12709013	1	rs11641836	ENSG00000233719.3	GOT2P3	7.4	6.28e-13	1.11e-06	0.39	0.32	Blood metabolite ratios;	chr16:58798143	chr12:9641802~9643007:+
THCA	trans	rs864643	0.678	rs1768198	ENSG00000188856.6	RPSAP47	7.4	6.28e-13	1.11e-06	0.5	0.32	Attention deficit hyperactivity disorder;	chr3:39474994	chr8:80558870~80559757:+
THCA	trans	rs748404	0.697	rs473016	ENSG00000180867.10	PDIA3P1	-7.4	6.32e-13	1.12e-06	-0.28	-0.32	Lung cancer;	chr15:43266625	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs471122	ENSG00000180867.10	PDIA3P1	7.4	6.32e-13	1.12e-06	0.28	0.32	Lung cancer;	chr15:43266376	chr1:147178113~147179622:+
THCA	trans	rs7113874	0.545	rs7122890	ENSG00000266891.1	RP11-692N5.2	7.4	6.38e-13	1.13e-06	0.41	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8382059	chr18:9734882~9735602:-
THCA	trans	rs11098499	0.863	rs3736115	ENSG00000253326.2	RP11-261C10.7	-7.4	6.44e-13	1.14e-06	-0.46	-0.32	Corneal astigmatism;	chr4:119567548	chr1:243054861~243056394:-
THCA	trans	rs6915893	1	rs6915893	ENSG00000267156.1	TPMTP1	7.4	6.45e-13	1.14e-06	0.34	0.32	Intrinsic epigenetic age acceleration;	chr6:18110325	chr18:47630112~47630848:+
THCA	trans	rs9650657	0.707	rs1115867	ENSG00000253893.2	FAM85B	7.4	6.51e-13	1.15e-06	0.41	0.32	Neuroticism;	chr8:10781240	chr8:8167819~8226614:-
THCA	trans	rs9858542	1	rs9822268	ENSG00000197582.5	GPX1P1	-7.4	6.53e-13	1.15e-06	-0.5	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49682296	chrX:13378735~13379340:-
THCA	trans	rs9858542	1	rs13085791	ENSG00000197582.5	GPX1P1	-7.4	6.53e-13	1.15e-06	-0.5	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684365	chrX:13378735~13379340:-
THCA	trans	rs6885307	0.825	rs4357042	ENSG00000231752.4	EMBP1	7.4	6.53e-13	1.15e-06	0.53	0.32	Age at first birth;	chr5:45183067	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs62367468	ENSG00000231752.4	EMBP1	7.4	6.53e-13	1.15e-06	0.53	0.32	Age at first birth;	chr5:45183643	chr1:121519112~121571892:+
THCA	trans	rs748404	0.723	rs573169	ENSG00000180867.10	PDIA3P1	-7.39	6.67e-13	1.18e-06	-0.28	-0.32	Lung cancer;	chr15:43258383	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs524547	ENSG00000180867.10	PDIA3P1	-7.39	6.67e-13	1.18e-06	-0.28	-0.32	Lung cancer;	chr15:43258825	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs564946	ENSG00000180867.10	PDIA3P1	-7.39	6.67e-13	1.18e-06	-0.28	-0.32	Lung cancer;	chr15:43264074	chr1:147178113~147179622:+
THCA	trans	rs748404	0.723	rs565658	ENSG00000180867.10	PDIA3P1	-7.39	6.67e-13	1.18e-06	-0.28	-0.32	Lung cancer;	chr15:43264109	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs579651	ENSG00000180867.10	PDIA3P1	-7.39	6.67e-13	1.18e-06	-0.28	-0.32	Lung cancer;	chr15:43266178	chr1:147178113~147179622:+
THCA	trans	rs7833986	0.501	rs2953909	ENSG00000236862.1	RPS20P24	7.39	6.68e-13	1.18e-06	0.48	0.32	Height;	chr8:56055641	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2953910	ENSG00000236862.1	RPS20P24	7.39	6.68e-13	1.18e-06	0.48	0.32	Height;	chr8:56056202	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2976012	ENSG00000236862.1	RPS20P24	7.39	6.68e-13	1.18e-06	0.48	0.32	Height;	chr8:56061784	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2953922	ENSG00000236862.1	RPS20P24	7.39	6.68e-13	1.18e-06	0.48	0.32	Height;	chr8:56064926	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2953897	ENSG00000236862.1	RPS20P24	7.39	6.68e-13	1.18e-06	0.48	0.32	Height;	chr8:56068010	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2953898	ENSG00000236862.1	RPS20P24	7.39	6.68e-13	1.18e-06	0.48	0.32	Height;	chr8:56068244	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2953901	ENSG00000236862.1	RPS20P24	7.39	6.68e-13	1.18e-06	0.48	0.32	Height;	chr8:56069265	chr9:72655832~72656192:-
THCA	trans	rs17711722	0.523	rs313812	ENSG00000213640.3	EEF1DP4	7.39	6.7e-13	1.18e-06	0.38	0.32	Calcium levels;	chr7:66040056	chr7:64862999~64864370:+
THCA	trans	rs6424115	1	rs7514394	ENSG00000228217.1	AL390877.1	7.39	6.7e-13	1.18e-06	0.42	0.32	Immature fraction of reticulocytes;	chr1:23773733	chr1:117778087~117778506:-
THCA	trans	rs11992162	0.591	rs35657308	ENSG00000253893.2	FAM85B	7.39	6.74e-13	1.19e-06	0.43	0.32	Monocyte count;	chr8:11946893	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.804	rs8051459	ENSG00000233719.3	GOT2P3	7.39	6.75e-13	1.19e-06	0.39	0.32	Blood metabolite ratios;	chr16:58783436	chr12:9641802~9643007:+
THCA	trans	rs9650657	0.77	rs6601529	ENSG00000253893.2	FAM85B	7.39	6.79e-13	1.2e-06	0.41	0.32	Neuroticism;	chr8:10813040	chr8:8167819~8226614:-
THCA	trans	rs79149102	0.522	rs1030888	ENSG00000227288.3	RP5-837I24.1	7.39	6.86e-13	1.21e-06	0.51	0.32	Lung cancer;	chr15:74550982	chr1:81501794~81503468:+
THCA	trans	rs748404	0.697	rs572959	ENSG00000180867.10	PDIA3P1	-7.39	6.87e-13	1.21e-06	-0.28	-0.32	Lung cancer;	chr15:43258304	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs554001	ENSG00000180867.10	PDIA3P1	-7.39	6.87e-13	1.21e-06	-0.28	-0.32	Lung cancer;	chr15:43259721	chr1:147178113~147179622:+
THCA	trans	rs11098499	0.863	rs7664986	ENSG00000253326.2	RP11-261C10.7	7.39	6.89e-13	1.21e-06	0.46	0.32	Corneal astigmatism;	chr4:119508797	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.818	rs10008791	ENSG00000253326.2	RP11-261C10.7	7.39	6.89e-13	1.21e-06	0.46	0.32	Corneal astigmatism;	chr4:119510314	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs11736416	ENSG00000253326.2	RP11-261C10.7	7.39	6.89e-13	1.21e-06	0.46	0.32	Corneal astigmatism;	chr4:119510506	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3775845	ENSG00000253326.2	RP11-261C10.7	7.39	6.89e-13	1.21e-06	0.46	0.32	Corneal astigmatism;	chr4:119511292	chr1:243054861~243056394:-
THCA	trans	rs1580019	0.563	rs896137	ENSG00000176826.14	FKBP9P1	-7.39	6.9e-13	1.21e-06	-0.42	-0.32	Cognitive ability;	chr7:32539733	chr7:55681074~55713252:-
THCA	trans	rs1580019	0.523	rs9791770	ENSG00000176826.14	FKBP9P1	-7.39	6.9e-13	1.21e-06	-0.42	-0.32	Cognitive ability;	chr7:32542640	chr7:55681074~55713252:-
THCA	trans	rs902774	0.818	rs11831919	ENSG00000224520.2	KRT8P45	-7.39	6.9e-13	1.21e-06	-0.66	-0.32	Prostate cancer;	chr12:52878231	chr1:157073257~157074703:+
THCA	trans	rs748404	0.697	rs513970	ENSG00000180867.10	PDIA3P1	-7.39	6.92e-13	1.22e-06	-0.28	-0.32	Lung cancer;	chr15:43287368	chr1:147178113~147179622:+
THCA	trans	rs7833986	0.501	rs2719255	ENSG00000236862.1	RPS20P24	7.39	6.94e-13	1.22e-06	0.48	0.32	Height;	chr8:56124099	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs72653990	ENSG00000236862.1	RPS20P24	7.39	6.94e-13	1.22e-06	0.48	0.32	Height;	chr8:56124556	chr9:72655832~72656192:-
THCA	trans	rs6743068	0.521	rs12472273	ENSG00000235105.1	RP11-329A14.1	7.39	6.98e-13	1.23e-06	0.35	0.32	Lymphocyte percentage of white cells;	chr2:201346972	chr1:48435967~48437223:+
THCA	trans	rs1190596	0.732	rs7156564	ENSG00000181359.5	HSP90AA6P	7.39	6.99e-13	1.23e-06	0.48	0.32	Behavioural disinhibition (generation interaction);	chr14:102092251	chr4:170581470~170605450:-
THCA	trans	rs11992162	0.597	rs7011924	ENSG00000256560.1	LINC01486	-7.38	7.06e-13	1.24e-06	-0.41	-0.32	Monocyte count;	chr8:11923084	chr12:109354083~109359488:-
THCA	trans	rs6915893	0.548	rs6899431	ENSG00000267156.1	TPMTP1	7.38	7.07e-13	1.24e-06	0.34	0.32	Intrinsic epigenetic age acceleration;	chr6:18110212	chr18:47630112~47630848:+
THCA	trans	rs1707322	0.752	rs4660313	ENSG00000255397.1	AC022182.2	7.38	7.07e-13	1.24e-06	0.45	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr8:60937705~60939871:-
THCA	trans	rs34421088	0.56	rs2248325	ENSG00000253893.2	FAM85B	7.38	7.08e-13	1.24e-06	0.43	0.32	Neuroticism;	chr8:11539365	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.56	rs2248316	ENSG00000253893.2	FAM85B	7.38	7.08e-13	1.24e-06	0.43	0.32	Neuroticism;	chr8:11539564	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.56	rs2248315	ENSG00000253893.2	FAM85B	7.38	7.08e-13	1.24e-06	0.43	0.32	Neuroticism;	chr8:11539577	chr8:8167819~8226614:-
THCA	trans	rs2645424	0.666	rs2272767	ENSG00000229857.1	RP11-159H20.3	-7.38	7.08e-13	1.24e-06	-0.41	-0.32	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853550	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.806	rs2409689	ENSG00000229857.1	RP11-159H20.3	7.38	7.08e-13	1.24e-06	0.4	0.32	Triglycerides;	chr8:11075358	chr9:76992099~76993108:+
THCA	trans	rs9858542	1	rs11130213	ENSG00000197582.5	GPX1P1	-7.38	7.12e-13	1.25e-06	-0.5	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49674864	chrX:13378735~13379340:-
THCA	trans	rs9858542	1	rs1131095	ENSG00000197582.5	GPX1P1	-7.38	7.12e-13	1.25e-06	-0.5	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49676792	chrX:13378735~13379340:-
THCA	trans	rs1707322	0.752	rs11211152	ENSG00000255397.1	AC022182.2	-7.38	7.16e-13	1.26e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs4607935	ENSG00000255397.1	AC022182.2	-7.38	7.16e-13	1.26e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.681	rs12048866	ENSG00000255397.1	AC022182.2	-7.38	7.16e-13	1.26e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs3811436	ENSG00000255397.1	AC022182.2	-7.38	7.16e-13	1.26e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr8:60937705~60939871:-
THCA	trans	rs864643	0.579	rs694365	ENSG00000183298.5	RP11-556K13.1	7.38	7.17e-13	1.26e-06	0.54	0.32	Attention deficit hyperactivity disorder;	chr3:39494422	chr1:101786340~101787219:-
THCA	trans	rs34421088	0.576	rs2572437	ENSG00000253893.2	FAM85B	7.38	7.21e-13	1.27e-06	0.47	0.32	Neuroticism;	chr8:11240932	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.899	rs9650656	ENSG00000253893.2	FAM85B	7.38	7.24e-13	1.27e-06	0.4	0.32	Neuroticism;	chr8:10749744	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.576	rs2736369	ENSG00000253893.2	FAM85B	7.38	7.24e-13	1.27e-06	0.46	0.32	Neuroticism;	chr8:11243889	chr8:8167819~8226614:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000234192.1	RP11-57C13.5	7.38	7.29e-13	1.28e-06	0.38	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr10:87642607~87642954:+
THCA	trans	rs7662987	0.938	rs28730605	ENSG00000228407.2	RP4-800M22.1	7.38	7.29e-13	1.28e-06	0.69	0.32	Smoking initiation;	chr4:99080389	chr1:52160261~52160600:-
THCA	trans	rs3740713	1	rs73440634	ENSG00000214110.3	LDHAP4	7.38	7.34e-13	1.29e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18451999	chr9:14921337~14922334:-
THCA	trans	rs7121616	0.576	rs11218967	ENSG00000229091.2	HSPA8P8	7.38	7.35e-13	1.29e-06	0.42	0.32	Breast cancer;	chr11:123087551	chr7:10451311~10452526:+
THCA	trans	rs66887589	1	rs66887589	ENSG00000275858.1	RP11-291L22.8	-7.38	7.37e-13	1.29e-06	-0.39	-0.32	Diastolic blood pressure;	chr4:119588124	chr10:38450738~38451069:-
THCA	trans	rs58106596	0.747	rs10166046	ENSG00000259020.3	RP11-529H20.3	-7.38	7.44e-13	1.31e-06	-0.48	-0.32	Lymphocyte counts;White blood cell count;	chr2:231696274	chr14:92026566~92026887:+
THCA	trans	rs7819412	0.806	rs10113808	ENSG00000229857.1	RP11-159H20.3	7.38	7.44e-13	1.31e-06	0.41	0.32	Triglycerides;	chr8:11069382	chr9:76992099~76993108:+
THCA	trans	rs748404	0.697	rs501884	ENSG00000180867.10	PDIA3P1	-7.38	7.48e-13	1.31e-06	-0.28	-0.32	Lung cancer;	chr15:43261784	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs504417	ENSG00000180867.10	PDIA3P1	-7.38	7.48e-13	1.31e-06	-0.28	-0.32	Lung cancer;	chr15:43262028	chr1:147178113~147179622:+
THCA	trans	rs748404	0.723	rs560134	ENSG00000180867.10	PDIA3P1	-7.38	7.48e-13	1.31e-06	-0.28	-0.32	Lung cancer;	chr15:43263501	chr1:147178113~147179622:+
THCA	trans	rs11098499	0.82	rs6829903	ENSG00000253326.2	RP11-261C10.7	7.37	7.49e-13	1.31e-06	0.46	0.32	Corneal astigmatism;	chr4:119585729	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs7669520	ENSG00000253326.2	RP11-261C10.7	7.37	7.49e-13	1.31e-06	0.46	0.32	Corneal astigmatism;	chr4:119594123	chr1:243054861~243056394:-
THCA	trans	rs6885307	0.825	rs12522305	ENSG00000231752.4	EMBP1	7.37	7.56e-13	1.33e-06	0.52	0.32	Age at first birth;	chr5:45146259	chr1:121519112~121571892:+
THCA	trans	rs7833986	0.501	rs17815934	ENSG00000236862.1	RPS20P24	7.37	7.59e-13	1.33e-06	0.48	0.32	Height;	chr8:56125836	chr9:72655832~72656192:-
THCA	trans	rs1707322	0.717	rs1547925	ENSG00000255397.1	AC022182.2	7.37	7.65e-13	1.34e-06	0.46	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr8:60937705~60939871:-
THCA	trans	rs7833986	0.501	rs2719257	ENSG00000236862.1	RPS20P24	7.37	7.68e-13	1.35e-06	0.47	0.32	Height;	chr8:56027614	chr9:72655832~72656192:-
THCA	trans	rs1580019	0.563	rs4723169	ENSG00000176826.14	FKBP9P1	-7.37	7.74e-13	1.36e-06	-0.43	-0.32	Cognitive ability;	chr7:32527965	chr7:55681074~55713252:-
THCA	trans	rs7819412	1	rs2409722	ENSG00000229857.1	RP11-159H20.3	7.37	7.75e-13	1.36e-06	0.41	0.32	Triglycerides;	chr8:11182307	chr9:76992099~76993108:+
THCA	trans	rs13217239	0.646	rs4403259	ENSG00000242375.1	RP11-498P14.3	7.37	7.76e-13	1.36e-06	0.45	0.32	Schizophrenia;	chr6:27029838	chr9:97195351~97197687:-
THCA	trans	rs9650657	0.836	rs4841438	ENSG00000253893.2	FAM85B	7.37	7.78e-13	1.36e-06	0.41	0.32	Neuroticism;	chr8:10749246	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.836	rs11250067	ENSG00000253893.2	FAM85B	7.37	7.78e-13	1.36e-06	0.41	0.32	Neuroticism;	chr8:10749444	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.613	rs6601634	ENSG00000253893.2	FAM85B	7.37	7.79e-13	1.36e-06	0.44	0.32	Monocyte count;	chr8:11948947	chr8:8167819~8226614:-
THCA	trans	rs748404	0.578	rs2584701	ENSG00000180867.10	PDIA3P1	-7.37	7.86e-13	1.38e-06	-0.28	-0.32	Lung cancer;	chr15:43392741	chr1:147178113~147179622:+
THCA	trans	rs11992162	0.548	rs4841631	ENSG00000256560.1	LINC01486	-7.37	7.9e-13	1.38e-06	-0.4	-0.32	Monocyte count;	chr8:11924159	chr12:109354083~109359488:-
THCA	trans	rs73110464	0.505	rs2638503	ENSG00000259470.2	KRT8P9	-7.37	7.91e-13	1.39e-06	-0.43	-0.32	Cancer (pleiotropy);	chr12:52913585	chr15:70858714~70860162:+
THCA	trans	rs16937956	0.597	rs34617462	ENSG00000266891.1	RP11-692N5.2	7.37	7.94e-13	1.39e-06	0.43	0.32	Body mass index;	chr11:8403484	chr18:9734882~9735602:-
THCA	trans	rs7824557	0.767	rs2164272	ENSG00000253893.2	FAM85B	-7.37	7.95e-13	1.39e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11304987	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.701	rs2060465	ENSG00000253893.2	FAM85B	-7.37	7.95e-13	1.39e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11305100	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.68	rs11746692	ENSG00000226666.1	HSPA9P1	-7.37	7.95e-13	1.39e-06	-0.34	-0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610666	chr2:221961737~221963765:+
THCA	trans	rs6087990	0.765	rs6058900	ENSG00000253915.1	MAPRE1P1	7.37	7.96e-13	1.39e-06	0.41	0.32	Ulcerative colitis;	chr20:32812867	chr8:135625185~135625981:-
THCA	trans	rs1347297	0.59	rs9288019	ENSG00000269800.1	PLEKHA3P1	7.36	8.04e-13	1.41e-06	0.34	0.32	Alzheimer disease and age of onset;	chr2:178412167	chr19:41521043~41521989:-
THCA	trans	rs3740713	1	rs75740864	ENSG00000214110.3	LDHAP4	7.36	8.04e-13	1.41e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr9:14921337~14922334:-
THCA	trans	rs864643	0.945	rs1707972	ENSG00000188856.6	RPSAP47	7.36	8.05e-13	1.41e-06	0.49	0.32	Attention deficit hyperactivity disorder;	chr3:39507243	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.863	rs3822192	ENSG00000253326.2	RP11-261C10.7	7.36	8.07e-13	1.41e-06	0.46	0.32	Corneal astigmatism;	chr4:119524565	chr1:243054861~243056394:-
THCA	trans	rs9650657	0.801	rs7018334	ENSG00000253893.2	FAM85B	7.36	8.09e-13	1.42e-06	0.41	0.32	Neuroticism;	chr8:10754565	chr8:8167819~8226614:-
THCA	trans	rs864643	0.678	rs1708089	ENSG00000183298.5	RP11-556K13.1	7.36	8.11e-13	1.42e-06	0.55	0.32	Attention deficit hyperactivity disorder;	chr3:39470371	chr1:101786340~101787219:-
THCA	trans	rs1580019	0.563	rs10486509	ENSG00000176826.14	FKBP9P1	7.36	8.13e-13	1.42e-06	0.42	0.32	Cognitive ability;	chr7:32545831	chr7:55681074~55713252:-
THCA	trans	rs902774	0.818	rs4919743	ENSG00000224520.2	KRT8P45	-7.36	8.14e-13	1.42e-06	-0.61	-0.32	Prostate cancer;	chr12:52915800	chr1:157073257~157074703:+
THCA	trans	rs3740713	0.669	rs78098319	ENSG00000214110.3	LDHAP4	7.36	8.15e-13	1.43e-06	0.53	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr9:14921337~14922334:-
THCA	trans	rs11098499	0.863	rs1155576	ENSG00000253326.2	RP11-261C10.7	7.36	8.18e-13	1.43e-06	0.45	0.32	Corneal astigmatism;	chr4:119529004	chr1:243054861~243056394:-
THCA	trans	rs10420951	0.617	rs7246328	ENSG00000267533.1	RP11-815J4.7	7.36	8.26e-13	1.44e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18508247	chr18:12067173~12068417:-
THCA	trans	rs7824557	0.767	rs17797443	ENSG00000253893.2	FAM85B	-7.36	8.27e-13	1.44e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11306503	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.882	rs62367474	ENSG00000231752.4	EMBP1	7.36	8.31e-13	1.45e-06	0.52	0.32	Age at first birth;	chr5:45221091	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.836	rs2898252	ENSG00000253893.2	FAM85B	7.36	8.36e-13	1.46e-06	0.41	0.32	Neuroticism;	chr8:10746654	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.606	rs1047950	ENSG00000253893.2	FAM85B	-7.36	8.44e-13	1.48e-06	-0.43	-0.32	Retinal vascular caliber;	chr8:11327587	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.936	rs7814499	ENSG00000229857.1	RP11-159H20.3	7.36	8.47e-13	1.48e-06	0.41	0.32	Triglycerides;	chr8:11183138	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.521	rs4451268	ENSG00000253893.2	FAM85B	7.36	8.48e-13	1.48e-06	0.44	0.32	Triglycerides;	chr8:11177350	chr8:8167819~8226614:-
THCA	trans	rs12709013	1	rs12599931	ENSG00000233719.3	GOT2P3	7.36	8.49e-13	1.48e-06	0.39	0.32	Blood metabolite ratios;	chr16:58792627	chr12:9641802~9643007:+
THCA	trans	rs864643	0.782	rs561543	ENSG00000183298.5	RP11-556K13.1	7.36	8.53e-13	1.49e-06	0.54	0.32	Attention deficit hyperactivity disorder;	chr3:39494916	chr1:101786340~101787219:-
THCA	trans	rs2645424	0.639	rs35581201	ENSG00000229857.1	RP11-159H20.3	-7.35	8.58e-13	1.5e-06	-0.41	-0.32	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11849325	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.863	rs1383533	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119513421	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs2291185	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119513678	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs10030660	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119515549	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs13149407	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119516670	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs34868248	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119521275	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3733525	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119525893	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3775847	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119526487	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3775848	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119526569	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs10013305	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119529269	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3775849	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119529753	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.818	rs7688802	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119530513	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs7695620	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119531621	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs12502389	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119533036	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.821	rs3775852	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119533401	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.82	rs6534140	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119534156	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs7657849	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119534339	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs10034450	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119534494	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs1480939	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119535772	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs1480940	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119536527	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs58452170	ENSG00000253326.2	RP11-261C10.7	7.35	8.59e-13	1.5e-06	0.46	0.32	Corneal astigmatism;	chr4:119538519	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs1383532	ENSG00000253326.2	RP11-261C10.7	-7.35	8.59e-13	1.5e-06	-0.46	-0.32	Corneal astigmatism;	chr4:119513249	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.82	rs13128602	ENSG00000253326.2	RP11-261C10.7	-7.35	8.59e-13	1.5e-06	-0.46	-0.32	Corneal astigmatism;	chr4:119538211	chr1:243054861~243056394:-
THCA	trans	rs804280	0.565	rs2645453	ENSG00000256560.1	LINC01486	7.35	8.66e-13	1.51e-06	0.38	0.32	Myopia (pathological);	chr8:11764492	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.882	rs12522803	ENSG00000231752.4	EMBP1	7.35	8.71e-13	1.52e-06	0.5	0.32	Age at first birth;	chr5:45143267	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.882	rs6893494	ENSG00000231752.4	EMBP1	7.35	8.71e-13	1.52e-06	0.5	0.32	Age at first birth;	chr5:45143600	chr1:121519112~121571892:+
THCA	trans	rs10917477	0.624	rs2745217	ENSG00000224237.1	MINOS1P3	-7.35	8.82e-13	1.54e-06	-0.41	-0.32	Thyroid function;	chr1:19595253	chr3:27214816~27215018:-
THCA	trans	rs10783779	0.647	rs705708	ENSG00000243403.1	RP11-330L19.1	7.35	8.83e-13	1.54e-06	0.38	0.32	Educational attainment;	chr12:56095129	chr15:64592979~64593326:+
THCA	trans	rs11098499	0.863	rs10018280	ENSG00000253326.2	RP11-261C10.7	7.35	8.93e-13	1.56e-06	0.45	0.32	Corneal astigmatism;	chr4:119556984	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs6534141	ENSG00000253326.2	RP11-261C10.7	7.35	8.93e-13	1.56e-06	0.45	0.32	Corneal astigmatism;	chr4:119564068	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs2127823	ENSG00000253326.2	RP11-261C10.7	7.35	8.93e-13	1.56e-06	0.45	0.32	Corneal astigmatism;	chr4:119564515	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3775858	ENSG00000253326.2	RP11-261C10.7	7.35	8.93e-13	1.56e-06	0.45	0.32	Corneal astigmatism;	chr4:119564873	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.843	rs2572418	ENSG00000253893.2	FAM85B	7.35	8.98e-13	1.56e-06	0.41	0.32	Retinal vascular caliber;	chr8:11255580	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.691	rs11211174	ENSG00000255397.1	AC022182.2	-7.35	9.03e-13	1.57e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.647	rs6686944	ENSG00000255397.1	AC022182.2	-7.35	9.04e-13	1.57e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr8:60937705~60939871:-
THCA	trans	rs2645424	0.639	rs35581201	ENSG00000260438.1	RP11-405F3.2	7.35	9.04e-13	1.57e-06	0.44	0.32	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11849325	chr16:57713782~57714957:+
THCA	trans	rs2645424	0.686	rs2294140	ENSG00000260438.1	RP11-405F3.2	-7.35	9.07e-13	1.58e-06	-0.44	-0.32	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr16:57713782~57714957:+
THCA	trans	rs7819412	0.521	rs9329238	ENSG00000253893.2	FAM85B	7.35	9.07e-13	1.58e-06	0.44	0.32	Triglycerides;	chr8:11176228	chr8:8167819~8226614:-
THCA	trans	rs877636	0.692	rs11171739	ENSG00000242206.2	RPS26P35	7.35	9.09e-13	1.58e-06	0.37	0.32	Cognitive function;	chr12:56076841	chr8:118761856~118762201:-
THCA	trans	rs1580019	0.523	rs13236410	ENSG00000176826.14	FKBP9P1	-7.35	9.12e-13	1.59e-06	-0.43	-0.32	Cognitive ability;	chr7:32651051	chr7:55681074~55713252:-
THCA	trans	rs79149102	0.522	rs6495104	ENSG00000227288.3	RP5-837I24.1	7.35	9.15e-13	1.59e-06	0.49	0.32	Lung cancer;	chr15:74475760	chr1:81501794~81503468:+
THCA	trans	rs7819412	0.505	rs17782536	ENSG00000253893.2	FAM85B	7.34	9.19e-13	1.6e-06	0.45	0.32	Triglycerides;	chr8:11164172	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.781	rs4835691	ENSG00000226666.1	HSPA9P1	-7.34	9.24e-13	1.61e-06	-0.34	-0.32	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138602884	chr2:221961737~221963765:+
THCA	trans	rs11992162	0.597	rs7016320	ENSG00000256560.1	LINC01486	-7.34	9.27e-13	1.61e-06	-0.41	-0.32	Monocyte count;	chr8:11923543	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.707	rs2005309	ENSG00000253893.2	FAM85B	7.34	9.28e-13	1.61e-06	0.41	0.32	Neuroticism;	chr8:10794660	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.863	rs6858592	ENSG00000253326.2	RP11-261C10.7	7.34	9.34e-13	1.62e-06	0.45	0.32	Corneal astigmatism;	chr4:119537537	chr1:243054861~243056394:-
THCA	trans	rs6885307	0.505	rs62367466	ENSG00000231752.4	EMBP1	7.34	9.35e-13	1.63e-06	0.5	0.32	Age at first birth;	chr5:45169244	chr1:121519112~121571892:+
THCA	trans	rs1707322	0.717	rs3014237	ENSG00000255397.1	AC022182.2	7.34	9.36e-13	1.63e-06	0.46	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr8:60937705~60939871:-
THCA	trans	rs116095464	1	rs7723693	ENSG00000185986.11	SDHAP3	7.34	9.4e-13	1.63e-06	0.49	0.32	Breast cancer;	chr5:305917	chr5:1572222~1594620:-
THCA	trans	rs79149102	0.522	rs11072499	ENSG00000227288.3	RP5-837I24.1	7.34	9.4e-13	1.63e-06	0.5	0.32	Lung cancer;	chr15:74676532	chr1:81501794~81503468:+
THCA	trans	rs1707322	0.721	rs28817701	ENSG00000255397.1	AC022182.2	-7.34	9.46e-13	1.64e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.691	rs28495425	ENSG00000255397.1	AC022182.2	-7.34	9.46e-13	1.64e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.691	rs61784803	ENSG00000255397.1	AC022182.2	7.34	9.46e-13	1.64e-06	0.45	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.663	rs3935296	ENSG00000255397.1	AC022182.2	7.34	9.46e-13	1.64e-06	0.45	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr8:60937705~60939871:-
THCA	trans	rs864643	1	rs1340223	ENSG00000188856.6	RPSAP47	7.34	9.47e-13	1.65e-06	0.49	0.32	Attention deficit hyperactivity disorder;	chr3:39508208	chr8:80558870~80559757:+
THCA	trans	rs9650657	0.707	rs10097283	ENSG00000253893.2	FAM85B	7.34	9.5e-13	1.65e-06	0.41	0.32	Neuroticism;	chr8:10801896	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.685	rs28617418	ENSG00000255397.1	AC022182.2	-7.34	9.53e-13	1.65e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.682	rs28490344	ENSG00000255397.1	AC022182.2	-7.34	9.53e-13	1.65e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs28641748	ENSG00000255397.1	AC022182.2	-7.34	9.53e-13	1.65e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs6697821	ENSG00000255397.1	AC022182.2	-7.34	9.53e-13	1.65e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs4330955	ENSG00000255397.1	AC022182.2	-7.34	9.53e-13	1.65e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.691	rs12031182	ENSG00000255397.1	AC022182.2	-7.34	9.53e-13	1.65e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr8:60937705~60939871:-
THCA	trans	rs3956705	0.762	rs13437980	ENSG00000176826.14	FKBP9P1	-7.34	9.54e-13	1.66e-06	-0.42	-0.32	Red cell distribution width;	chr7:32958137	chr7:55681074~55713252:-
THCA	trans	rs7819412	0.54	rs11777355	ENSG00000253893.2	FAM85B	7.34	9.55e-13	1.66e-06	0.44	0.32	Triglycerides;	chr8:11187180	chr8:8167819~8226614:-
THCA	trans	rs16937956	0.626	rs34922792	ENSG00000266891.1	RP11-692N5.2	7.34	9.61e-13	1.67e-06	0.43	0.32	Body mass index;	chr11:8394952	chr18:9734882~9735602:-
THCA	trans	rs6885307	0.825	rs62371361	ENSG00000231752.4	EMBP1	7.34	9.62e-13	1.67e-06	0.52	0.32	Age at first birth;	chr5:45153407	chr1:121519112~121571892:+
THCA	trans	rs12709013	1	rs12709013	ENSG00000230849.2	GOT2P2	-7.34	9.63e-13	1.67e-06	-0.39	-0.32	Blood metabolite ratios;	chr16:58795886	chr1:173141100~173142350:-
THCA	trans	rs9876781	0.56	rs2362451	ENSG00000225528.1	RP3-370M22.8	7.34	9.64e-13	1.67e-06	0.39	0.32	Longevity;	chr3:48358338	chr22:39960397~39964683:+
THCA	trans	rs748404	0.697	rs530188	ENSG00000180867.10	PDIA3P1	-7.34	9.67e-13	1.68e-06	-0.28	-0.32	Lung cancer;	chr15:43253116	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs475227	ENSG00000180867.10	PDIA3P1	-7.34	9.67e-13	1.68e-06	-0.28	-0.32	Lung cancer;	chr15:43254248	chr1:147178113~147179622:+
THCA	trans	rs1707322	0.752	rs11211168	ENSG00000255397.1	AC022182.2	-7.34	9.75e-13	1.69e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.739	rs4833612	ENSG00000275858.1	RP11-291L22.8	-7.34	9.78e-13	1.7e-06	-0.4	-0.32	Corneal astigmatism;	chr4:119226441	chr10:38450738~38451069:-
THCA	trans	rs11098499	0.739	rs10013032	ENSG00000275858.1	RP11-291L22.8	-7.34	9.78e-13	1.7e-06	-0.4	-0.32	Corneal astigmatism;	chr4:119228264	chr10:38450738~38451069:-
THCA	trans	rs72615157	0.606	rs941288	ENSG00000228546.2	CTA-313A17.3	7.33	9.79e-13	1.7e-06	0.51	0.32	Lung function (FEV1/FVC);	chr7:100179185	chr7:102337316~102339115:+
THCA	trans	rs748404	0.697	rs555001	ENSG00000180867.10	PDIA3P1	-7.33	9.81e-13	1.7e-06	-0.27	-0.32	Lung cancer;	chr15:43253530	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs475261	ENSG00000180867.10	PDIA3P1	-7.33	9.81e-13	1.7e-06	-0.27	-0.32	Lung cancer;	chr15:43254258	chr1:147178113~147179622:+
THCA	trans	rs9650657	0.805	rs6982210	ENSG00000253893.2	FAM85B	7.33	9.84e-13	1.71e-06	0.41	0.32	Neuroticism;	chr8:10742484	chr8:8167819~8226614:-
THCA	trans	rs1580019	0.522	rs10951340	ENSG00000176826.14	FKBP9P1	-7.33	9.84e-13	1.71e-06	-0.42	-0.32	Cognitive ability;	chr7:32522796	chr7:55681074~55713252:-
THCA	trans	rs1045902	0.537	rs1018342	ENSG00000236165.1	PRADC1P1	7.33	9.91e-13	1.72e-06	0.45	0.32	Intelligence (multi-trait analysis);	chr2:73244525	chr3:36976316~36976840:+
THCA	trans	rs282544	1	rs2404958	ENSG00000231752.4	EMBP1	7.33	9.94e-13	1.72e-06	0.44	0.32	Myopia (pathological);	chr5:50767201	chr1:121519112~121571892:+
THCA	trans	rs748404	0.65	rs556851	ENSG00000180867.10	PDIA3P1	-7.33	9.98e-13	1.73e-06	-0.28	-0.32	Lung cancer;	chr15:43279021	chr1:147178113~147179622:+
THCA	trans	rs9329221	0.527	rs4841351	ENSG00000253893.2	FAM85B	7.33	1e-12	1.74e-06	0.44	0.32	Neuroticism;	chr8:10469857	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.56	rs13265553	ENSG00000253893.2	FAM85B	7.33	1e-12	1.74e-06	0.45	0.32	Triglycerides;	chr8:11131547	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.82	rs11737395	ENSG00000253326.2	RP11-261C10.7	7.33	1.01e-12	1.76e-06	0.46	0.32	Corneal astigmatism;	chr4:119599549	chr1:243054861~243056394:-
THCA	trans	rs748404	0.697	rs493177	ENSG00000180867.10	PDIA3P1	-7.33	1.02e-12	1.76e-06	-0.28	-0.32	Lung cancer;	chr15:43251060	chr1:147178113~147179622:+
THCA	trans	rs34421088	0.576	rs2572436	ENSG00000253893.2	FAM85B	7.33	1.02e-12	1.77e-06	0.47	0.32	Neuroticism;	chr8:11241700	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.825	rs62367467	ENSG00000231752.4	EMBP1	7.33	1.02e-12	1.77e-06	0.52	0.32	Age at first birth;	chr5:45173155	chr1:121519112~121571892:+
THCA	trans	rs10242455	0.867	rs15524	ENSG00000228834.1	RP11-249L21.4	7.33	1.03e-12	1.79e-06	0.59	0.32	Blood metabolite levels;	chr7:99648291	chr6:108907615~108907873:-
THCA	trans	rs864643	0.947	rs1417147	ENSG00000188856.6	RPSAP47	7.33	1.03e-12	1.79e-06	0.47	0.32	Attention deficit hyperactivity disorder;	chr3:39499236	chr8:80558870~80559757:+
THCA	trans	rs11992162	0.597	rs7824564	ENSG00000253893.2	FAM85B	7.33	1.04e-12	1.8e-06	0.44	0.32	Monocyte count;	chr8:11922671	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.74	rs12927495	ENSG00000233719.3	GOT2P3	7.33	1.04e-12	1.81e-06	0.38	0.32	Blood metabolite ratios;	chr16:58821934	chr12:9641802~9643007:+
THCA	trans	rs1580019	0.563	rs2392071	ENSG00000176826.14	FKBP9P1	-7.33	1.04e-12	1.81e-06	-0.42	-0.32	Cognitive ability;	chr7:32532924	chr7:55681074~55713252:-
THCA	trans	rs74781061	0.585	rs750608	ENSG00000227288.3	RP5-837I24.1	7.33	1.04e-12	1.81e-06	0.49	0.32	Endometriosis;	chr15:74442274	chr1:81501794~81503468:+
THCA	trans	rs864643	1	rs1612165	ENSG00000188856.6	RPSAP47	7.32	1.05e-12	1.81e-06	0.51	0.32	Attention deficit hyperactivity disorder;	chr3:39501996	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.863	rs3775841	ENSG00000253326.2	RP11-261C10.7	7.32	1.05e-12	1.82e-06	0.45	0.32	Corneal astigmatism;	chr4:119504622	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs1010740	ENSG00000253326.2	RP11-261C10.7	-7.32	1.07e-12	1.84e-06	-0.46	-0.32	Corneal astigmatism;	chr4:119542254	chr1:243054861~243056394:-
THCA	trans	rs1707322	0.721	rs28501477	ENSG00000255397.1	AC022182.2	-7.32	1.07e-12	1.85e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr8:60937705~60939871:-
THCA	trans	rs7819412	0.521	rs10110684	ENSG00000253893.2	FAM85B	7.32	1.07e-12	1.85e-06	0.44	0.32	Triglycerides;	chr8:11181650	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.771	rs6601513	ENSG00000253893.2	FAM85B	7.32	1.07e-12	1.86e-06	0.4	0.32	Neuroticism;	chr8:10737333	chr8:8167819~8226614:-
THCA	trans	rs2929278	0.617	rs533143	ENSG00000180867.10	PDIA3P1	-7.32	1.08e-12	1.87e-06	-0.28	-0.32	Schizophrenia;	chr15:43896656	chr1:147178113~147179622:+
THCA	trans	rs9329221	0.592	rs7832708	ENSG00000229857.1	RP11-159H20.3	-7.32	1.08e-12	1.87e-06	-0.4	-0.32	Neuroticism;	chr8:10332530	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.741	rs9650622	ENSG00000253893.2	FAM85B	7.32	1.08e-12	1.87e-06	0.42	0.32	Neuroticism;	chr8:9946782	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.623	rs7010753	ENSG00000256560.1	LINC01486	7.32	1.08e-12	1.87e-06	0.38	0.32	Mood instability;	chr8:8516446	chr12:109354083~109359488:-
THCA	trans	rs9425766	0.962	rs941989	ENSG00000213331.4	RP11-713C19.2	-7.32	1.08e-12	1.87e-06	-0.42	-0.32	Life satisfaction;	chr1:173912733	chr4:187970273~187971284:+
THCA	trans	rs2929278	0.617	rs524908	ENSG00000180867.10	PDIA3P1	7.32	1.09e-12	1.88e-06	0.29	0.32	Schizophrenia;	chr15:43895793	chr1:147178113~147179622:+
THCA	trans	rs11098499	0.739	rs9884728	ENSG00000275858.1	RP11-291L22.8	-7.32	1.09e-12	1.89e-06	-0.4	-0.32	Corneal astigmatism;	chr4:119205924	chr10:38450738~38451069:-
THCA	trans	rs10420951	0.617	rs2303694	ENSG00000267533.1	RP11-815J4.7	7.32	1.09e-12	1.89e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18451628	chr18:12067173~12068417:-
THCA	trans	rs10420951	0.617	rs79257623	ENSG00000267533.1	RP11-815J4.7	7.32	1.09e-12	1.89e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18452904	chr18:12067173~12068417:-
THCA	trans	rs10420951	0.617	rs8103520	ENSG00000267533.1	RP11-815J4.7	7.32	1.09e-12	1.89e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18453160	chr18:12067173~12068417:-
THCA	trans	rs10420951	0.617	rs3746176	ENSG00000267533.1	RP11-815J4.7	7.32	1.09e-12	1.89e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18458141	chr18:12067173~12068417:-
THCA	trans	rs10420951	0.617	rs79888481	ENSG00000267533.1	RP11-815J4.7	7.32	1.09e-12	1.89e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18459147	chr18:12067173~12068417:-
THCA	trans	rs10420951	0.579	rs75445489	ENSG00000267533.1	RP11-815J4.7	7.32	1.09e-12	1.89e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18460340	chr18:12067173~12068417:-
THCA	trans	rs9650657	0.836	rs3905581	ENSG00000253893.2	FAM85B	7.32	1.09e-12	1.89e-06	0.41	0.32	Neuroticism;	chr8:10746195	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.739	rs951570	ENSG00000275858.1	RP11-291L22.8	-7.32	1.1e-12	1.89e-06	-0.4	-0.32	Corneal astigmatism;	chr4:119229312	chr10:38450738~38451069:-
THCA	trans	rs6424115	0.729	rs586173	ENSG00000228217.1	AL390877.1	7.32	1.1e-12	1.9e-06	0.42	0.32	Immature fraction of reticulocytes;	chr1:23729228	chr1:117778087~117778506:-
THCA	trans	rs6981523	0.517	rs13251510	ENSG00000253893.2	FAM85B	7.32	1.1e-12	1.9e-06	0.42	0.32	Neuroticism;	chr8:11059464	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.863	rs9884402	ENSG00000253326.2	RP11-261C10.7	7.32	1.11e-12	1.91e-06	0.45	0.32	Corneal astigmatism;	chr4:119568827	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.731	rs9995026	ENSG00000253326.2	RP11-261C10.7	7.32	1.11e-12	1.91e-06	0.45	0.32	Corneal astigmatism;	chr4:119569344	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs11098532	ENSG00000253326.2	RP11-261C10.7	7.32	1.11e-12	1.91e-06	0.45	0.32	Corneal astigmatism;	chr4:119569571	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs13140391	ENSG00000253326.2	RP11-261C10.7	7.32	1.11e-12	1.91e-06	0.45	0.32	Corneal astigmatism;	chr4:119582282	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs13140409	ENSG00000253326.2	RP11-261C10.7	7.32	1.11e-12	1.91e-06	0.45	0.32	Corneal astigmatism;	chr4:119582305	chr1:243054861~243056394:-
THCA	trans	rs10420951	0.573	rs76184771	ENSG00000267533.1	RP11-815J4.7	7.32	1.11e-12	1.92e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18456379	chr18:12067173~12068417:-
THCA	trans	rs6885307	0.825	rs12513513	ENSG00000231752.4	EMBP1	7.32	1.12e-12	1.92e-06	0.52	0.32	Age at first birth;	chr5:45228981	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs1909937	ENSG00000231752.4	EMBP1	7.32	1.12e-12	1.92e-06	0.52	0.32	Age at first birth;	chr5:45235985	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs62367461	ENSG00000231752.4	EMBP1	7.32	1.12e-12	1.93e-06	0.52	0.32	Age at first birth;	chr5:45153743	chr1:121519112~121571892:+
THCA	trans	rs7662987	1	rs6852848	ENSG00000228407.2	RP4-800M22.1	-7.32	1.12e-12	1.93e-06	-0.69	-0.32	Smoking initiation;	chr4:99080781	chr1:52160261~52160600:-
THCA	trans	rs11098499	0.863	rs3775843	ENSG00000253326.2	RP11-261C10.7	7.32	1.12e-12	1.93e-06	0.45	0.32	Corneal astigmatism;	chr4:119506689	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3775844	ENSG00000253326.2	RP11-261C10.7	7.32	1.12e-12	1.93e-06	0.45	0.32	Corneal astigmatism;	chr4:119506878	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs7678400	ENSG00000253326.2	RP11-261C10.7	7.32	1.12e-12	1.93e-06	0.45	0.32	Corneal astigmatism;	chr4:119540802	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs1480936	ENSG00000253326.2	RP11-261C10.7	7.32	1.12e-12	1.93e-06	0.45	0.32	Corneal astigmatism;	chr4:119541706	chr1:243054861~243056394:-
THCA	trans	rs1580019	0.563	rs34319173	ENSG00000176826.14	FKBP9P1	-7.31	1.13e-12	1.94e-06	-0.42	-0.32	Cognitive ability;	chr7:32546292	chr7:55681074~55713252:-
THCA	trans	rs916888	0.779	rs199498	ENSG00000280022.1	RP11-707O23.1	-7.31	1.13e-12	1.95e-06	-0.35	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45592621~45593369:+
THCA	trans	rs11098499	0.909	rs1546502	ENSG00000253326.2	RP11-261C10.7	7.31	1.13e-12	1.95e-06	0.45	0.32	Corneal astigmatism;	chr4:119314743	chr1:243054861~243056394:-
THCA	trans	rs6885307	0.825	rs62371360	ENSG00000231752.4	EMBP1	7.31	1.13e-12	1.95e-06	0.52	0.32	Age at first birth;	chr5:45151368	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.739	rs2203039	ENSG00000275858.1	RP11-291L22.8	-7.31	1.13e-12	1.95e-06	-0.4	-0.32	Corneal astigmatism;	chr4:119211192	chr10:38450738~38451069:-
THCA	trans	rs1045902	0.516	rs7851	ENSG00000236165.1	PRADC1P1	7.31	1.14e-12	1.96e-06	0.45	0.32	Intelligence (multi-trait analysis);	chr2:73251333	chr3:36976316~36976840:+
THCA	trans	rs11992162	0.56	rs13276386	ENSG00000256560.1	LINC01486	7.31	1.14e-12	1.96e-06	0.4	0.32	Monocyte count;	chr8:11939912	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.621	rs13268810	ENSG00000256560.1	LINC01486	7.31	1.14e-12	1.96e-06	0.4	0.32	Monocyte count;	chr8:11939921	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.636	rs13265816	ENSG00000256560.1	LINC01486	7.31	1.14e-12	1.96e-06	0.4	0.32	Monocyte count;	chr8:11939976	chr12:109354083~109359488:-
THCA	trans	rs9329221	0.741	rs13264066	ENSG00000253893.2	FAM85B	7.31	1.14e-12	1.96e-06	0.42	0.32	Neuroticism;	chr8:9946565	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.825	rs62367473	ENSG00000231752.4	EMBP1	7.31	1.14e-12	1.97e-06	0.52	0.32	Age at first birth;	chr5:45216147	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs2877195	ENSG00000231752.4	EMBP1	7.31	1.14e-12	1.97e-06	0.52	0.32	Age at first birth;	chr5:45218497	chr1:121519112~121571892:+
THCA	trans	rs1707322	0.685	rs11211177	ENSG00000255397.1	AC022182.2	-7.31	1.15e-12	1.98e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.863	rs6835635	ENSG00000253326.2	RP11-261C10.7	7.31	1.16e-12	1.99e-06	0.46	0.32	Corneal astigmatism;	chr4:119537712	chr1:243054861~243056394:-
THCA	trans	rs9329221	0.623	rs7825778	ENSG00000253893.2	FAM85B	7.31	1.16e-12	1.99e-06	0.4	0.32	Neuroticism;	chr8:10403500	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.669	rs7823349	ENSG00000253893.2	FAM85B	7.31	1.16e-12	1.99e-06	0.44	0.32	Triglycerides;	chr8:11141120	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.669	rs4840549	ENSG00000253893.2	FAM85B	7.31	1.16e-12	1.99e-06	0.44	0.32	Triglycerides;	chr8:11141445	chr8:8167819~8226614:-
THCA	trans	rs3956705	0.762	rs13311608	ENSG00000176826.14	FKBP9P1	7.31	1.16e-12	2e-06	0.41	0.32	Red cell distribution width;	chr7:32959989	chr7:55681074~55713252:-
THCA	trans	rs2736345	0.788	rs2618476	ENSG00000253893.2	FAM85B	-7.31	1.16e-12	2e-06	-0.45	-0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:8167819~8226614:-
THCA	trans	rs10917477	0.594	rs2792043	ENSG00000224237.1	MINOS1P3	7.31	1.17e-12	2.01e-06	0.4	0.32	Thyroid function;	chr1:19598168	chr3:27214816~27215018:-
THCA	trans	rs1707322	0.752	rs28890893	ENSG00000255397.1	AC022182.2	-7.31	1.17e-12	2.01e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.675	rs2409658	ENSG00000253893.2	FAM85B	7.31	1.17e-12	2.01e-06	0.4	0.32	Neuroticism;	chr8:10811455	chr8:8167819~8226614:-
THCA	trans	rs748404	0.697	rs546722	ENSG00000180867.10	PDIA3P1	-7.31	1.17e-12	2.02e-06	-0.28	-0.32	Lung cancer;	chr15:43288621	chr1:147178113~147179622:+
THCA	trans	rs1707322	0.752	rs28550303	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.716	rs28375469	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs28545085	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs28719889	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs28812624	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs28507722	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs28568986	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.717	rs28396194	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.717	rs28752166	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.717	rs10890345	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs10789471	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs11211173	ENSG00000255397.1	AC022182.2	-7.31	1.18e-12	2.02e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr8:60937705~60939871:-
THCA	trans	rs7192380	0.639	rs12448486	ENSG00000257513.6	NPIPB1P	-7.31	1.18e-12	2.03e-06	-0.37	-0.32	Sjögren's syndrome;	chr16:69768975	chr18:11619509~11639699:-
THCA	trans	rs11992162	0.597	rs7824564	ENSG00000256560.1	LINC01486	-7.31	1.18e-12	2.03e-06	-0.41	-0.32	Monocyte count;	chr8:11922671	chr12:109354083~109359488:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000233778.3	RP11-777J24.1	-7.31	1.18e-12	2.04e-06	-0.44	-0.32	Asthma;	chr12:55970537	chr8:92144088~92144435:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000234192.1	RP11-57C13.5	7.31	1.18e-12	2.04e-06	0.38	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:87642607~87642954:+
THCA	trans	rs17783634	0.509	rs11775489	ENSG00000253893.2	FAM85B	7.31	1.19e-12	2.04e-06	0.44	0.32	Subjective well-being;	chr8:11179334	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.736	rs10107010	ENSG00000253893.2	FAM85B	7.31	1.19e-12	2.04e-06	0.42	0.32	Retinal vascular caliber;	chr8:11275203	chr8:8167819~8226614:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000242206.2	RPS26P35	-7.3	1.22e-12	2.1e-06	-0.37	-0.32	Cognitive function;	chr12:56084218	chr8:118761856~118762201:-
THCA	trans	rs877636	0.692	rs7971751	ENSG00000242206.2	RPS26P35	-7.3	1.22e-12	2.1e-06	-0.37	-0.32	Cognitive function;	chr12:56084874	chr8:118761856~118762201:-
THCA	trans	rs11992162	0.591	rs34123222	ENSG00000256560.1	LINC01486	-7.3	1.22e-12	2.1e-06	-0.41	-0.32	Monocyte count;	chr8:11937840	chr12:109354083~109359488:-
THCA	trans	rs1707322	0.717	rs12023439	ENSG00000255397.1	AC022182.2	-7.3	1.23e-12	2.11e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr8:60937705~60939871:-
THCA	trans	rs864643	0.625	rs694380	ENSG00000183298.5	RP11-556K13.1	7.3	1.23e-12	2.11e-06	0.53	0.32	Attention deficit hyperactivity disorder;	chr3:39494399	chr1:101786340~101787219:-
THCA	trans	rs902774	0.818	rs55958994	ENSG00000255815.3	KRT8P11	-7.3	1.25e-12	2.15e-06	-0.67	-0.32	Prostate cancer;	chr12:52907235	chr9:99305176~99306611:+
THCA	trans	rs10420951	0.617	rs78855479	ENSG00000267533.1	RP11-815J4.7	7.3	1.25e-12	2.15e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18471106	chr18:12067173~12068417:-
THCA	trans	rs1707322	0.721	rs9793568	ENSG00000255397.1	AC022182.2	-7.3	1.25e-12	2.15e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs11211157	ENSG00000255397.1	AC022182.2	-7.3	1.25e-12	2.15e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs11211158	ENSG00000255397.1	AC022182.2	-7.3	1.25e-12	2.15e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs6429575	ENSG00000255397.1	AC022182.2	-7.3	1.25e-12	2.15e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.685	rs6690926	ENSG00000255397.1	AC022182.2	-7.3	1.25e-12	2.15e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs8179402	ENSG00000255397.1	AC022182.2	-7.3	1.25e-12	2.15e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs8179296	ENSG00000255397.1	AC022182.2	-7.3	1.25e-12	2.15e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr8:60937705~60939871:-
THCA	trans	rs10420951	0.579	rs79341622	ENSG00000267533.1	RP11-815J4.7	7.3	1.26e-12	2.16e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18487403	chr18:12067173~12068417:-
THCA	trans	rs6132905	0.52	rs2422824	ENSG00000257956.1	NOP56P3	7.3	1.26e-12	2.16e-06	0.43	0.32	Mumps;	chr20:2666724	chr12:79558782~79559166:+
THCA	trans	rs10420951	0.617	rs7251067	ENSG00000267533.1	RP11-815J4.7	7.3	1.26e-12	2.17e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18489246	chr18:12067173~12068417:-
THCA	trans	rs6732160	0.624	rs10865397	ENSG00000236165.1	PRADC1P1	7.3	1.27e-12	2.18e-06	0.42	0.32	Intelligence (multi-trait analysis);	chr2:73131164	chr3:36976316~36976840:+
THCA	trans	rs3740713	1	rs61081934	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr9:14921337~14922334:-
THCA	trans	rs3740713	0.92	rs112818034	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs76708296	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438668	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs75647856	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438687	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs74663287	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438699	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73440604	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73440610	ENSG00000214110.3	LDHAP4	7.29	1.29e-12	2.21e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr9:14921337~14922334:-
THCA	trans	rs7824557	0.736	rs35392635	ENSG00000253893.2	FAM85B	-7.29	1.3e-12	2.22e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11306840	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.767	rs11775635	ENSG00000253893.2	FAM85B	-7.29	1.3e-12	2.22e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11307356	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.767	rs28507159	ENSG00000253893.2	FAM85B	-7.29	1.3e-12	2.22e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11308567	chr8:8167819~8226614:-
THCA	trans	rs864643	0.947	rs1708064	ENSG00000188856.6	RPSAP47	7.29	1.3e-12	2.23e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39500679	chr8:80558870~80559757:+
THCA	trans	rs7829975	0.517	rs12542733	ENSG00000229857.1	RP11-159H20.3	7.29	1.33e-12	2.27e-06	0.38	0.32	Mood instability;	chr8:8967348	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.504	rs10108347	ENSG00000229857.1	RP11-159H20.3	7.29	1.33e-12	2.27e-06	0.41	0.32	Neuroticism;	chr8:11176008	chr9:76992099~76993108:+
THCA	trans	rs10420951	0.617	rs75245298	ENSG00000267533.1	RP11-815J4.7	7.29	1.33e-12	2.28e-06	0.61	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18470417	chr18:12067173~12068417:-
THCA	trans	rs867371	1	rs8042464	ENSG00000235370.6	DNM1P51	-7.29	1.33e-12	2.28e-06	-0.4	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:84398316~84411701:-
THCA	trans	rs3740713	1	rs113497813	ENSG00000214110.3	LDHAP4	7.29	1.34e-12	2.29e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs73438697	ENSG00000214110.3	LDHAP4	7.29	1.34e-12	2.29e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs114330751	ENSG00000214110.3	LDHAP4	7.29	1.34e-12	2.29e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr9:14921337~14922334:-
THCA	trans	rs11098499	0.863	rs59732491	ENSG00000253326.2	RP11-261C10.7	7.29	1.34e-12	2.29e-06	0.45	0.32	Corneal astigmatism;	chr4:119568433	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs11723090	ENSG00000253326.2	RP11-261C10.7	7.29	1.34e-12	2.29e-06	0.45	0.32	Corneal astigmatism;	chr4:119569437	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs6833334	ENSG00000253326.2	RP11-261C10.7	7.29	1.34e-12	2.29e-06	0.45	0.32	Corneal astigmatism;	chr4:119583072	chr1:243054861~243056394:-
THCA	trans	rs10420951	0.617	rs75681761	ENSG00000267533.1	RP11-815J4.7	7.29	1.35e-12	2.3e-06	0.65	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18474519	chr18:12067173~12068417:-
THCA	trans	rs16937956	0.597	rs35022013	ENSG00000266891.1	RP11-692N5.2	7.29	1.35e-12	2.31e-06	0.42	0.32	Body mass index;	chr11:8395956	chr18:9734882~9735602:-
THCA	trans	rs1190596	1	rs1190596	ENSG00000181359.5	HSP90AA6P	7.29	1.35e-12	2.31e-06	0.5	0.32	Behavioural disinhibition (generation interaction);	chr14:102129288	chr4:170581470~170605450:-
THCA	trans	rs10420951	0.579	rs78036311	ENSG00000267533.1	RP11-815J4.7	7.29	1.35e-12	2.32e-06	0.65	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18495559	chr18:12067173~12068417:-
THCA	trans	rs7829975	0.806	rs2428	ENSG00000256560.1	LINC01486	7.29	1.37e-12	2.33e-06	0.36	0.32	Mood instability;	chr8:8783635	chr12:109354083~109359488:-
THCA	trans	rs9329221	0.655	rs656319	ENSG00000253893.2	FAM85B	7.28	1.37e-12	2.34e-06	0.42	0.32	Neuroticism;	chr8:9956901	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.623	rs10092965	ENSG00000256560.1	LINC01486	7.28	1.37e-12	2.34e-06	0.38	0.32	Mood instability;	chr8:8515975	chr12:109354083~109359488:-
THCA	trans	rs7662987	1	rs7662987	ENSG00000228407.2	RP4-800M22.1	7.28	1.38e-12	2.35e-06	0.69	0.32	Smoking initiation;	chr4:99070491	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs7658127	ENSG00000228407.2	RP4-800M22.1	7.28	1.38e-12	2.35e-06	0.69	0.32	Smoking initiation;	chr4:99073471	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs4699699	ENSG00000228407.2	RP4-800M22.1	7.28	1.38e-12	2.35e-06	0.69	0.32	Smoking initiation;	chr4:99076028	chr1:52160261~52160600:-
THCA	trans	rs7662987	0.938	rs13118409	ENSG00000228407.2	RP4-800M22.1	7.28	1.38e-12	2.35e-06	0.69	0.32	Smoking initiation;	chr4:99077585	chr1:52160261~52160600:-
THCA	trans	rs11098499	0.954	rs1022145	ENSG00000253326.2	RP11-261C10.7	7.28	1.38e-12	2.36e-06	0.45	0.32	Corneal astigmatism;	chr4:119309824	chr1:243054861~243056394:-
THCA	trans	rs902774	0.818	rs17120257	ENSG00000255815.3	KRT8P11	-7.28	1.38e-12	2.36e-06	-0.67	-0.32	Prostate cancer;	chr12:52909547	chr9:99305176~99306611:+
THCA	trans	rs6885307	0.882	rs12520430	ENSG00000231752.4	EMBP1	7.28	1.4e-12	2.4e-06	0.52	0.32	Age at first birth;	chr5:45166466	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.818	rs55825515	ENSG00000253326.2	RP11-261C10.7	7.28	1.41e-12	2.4e-06	0.46	0.32	Corneal astigmatism;	chr4:119565247	chr1:243054861~243056394:-
THCA	trans	rs7819412	0.54	rs2409725	ENSG00000253893.2	FAM85B	7.28	1.41e-12	2.4e-06	0.44	0.32	Triglycerides;	chr8:11184152	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.54	rs2409726	ENSG00000253893.2	FAM85B	7.28	1.41e-12	2.4e-06	0.44	0.32	Triglycerides;	chr8:11185629	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.767	rs2164273	ENSG00000253893.2	FAM85B	-7.28	1.41e-12	2.41e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11310990	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.739	rs7441137	ENSG00000275858.1	RP11-291L22.8	-7.28	1.41e-12	2.41e-06	-0.4	-0.32	Corneal astigmatism;	chr4:119212066	chr10:38450738~38451069:-
THCA	trans	rs6885307	0.882	rs7703487	ENSG00000231752.4	EMBP1	7.28	1.41e-12	2.41e-06	0.49	0.32	Age at first birth;	chr5:45245580	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.71	rs6851130	ENSG00000275858.1	RP11-291L22.8	-7.28	1.42e-12	2.43e-06	-0.4	-0.32	Corneal astigmatism;	chr4:119212557	chr10:38450738~38451069:-
THCA	trans	rs74781061	0.585	rs8041068	ENSG00000227288.3	RP5-837I24.1	7.28	1.42e-12	2.43e-06	0.49	0.32	Endometriosis;	chr15:74437865	chr1:81501794~81503468:+
THCA	trans	rs2736345	0.747	rs1478901	ENSG00000253893.2	FAM85B	-7.28	1.45e-12	2.47e-06	-0.46	-0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11490324	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.643	rs7829396	ENSG00000253893.2	FAM85B	7.28	1.45e-12	2.47e-06	0.44	0.32	Triglycerides;	chr8:11142073	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs73436668	ENSG00000214110.3	LDHAP4	7.28	1.45e-12	2.48e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr9:14921337~14922334:-
THCA	trans	rs10917477	0.653	rs1770480	ENSG00000224237.1	MINOS1P3	7.28	1.46e-12	2.49e-06	0.4	0.32	Thyroid function;	chr1:19590290	chr3:27214816~27215018:-
THCA	trans	rs11992162	0.613	rs6998690	ENSG00000256560.1	LINC01486	7.28	1.46e-12	2.49e-06	0.4	0.32	Monocyte count;	chr8:11941287	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.636	rs4841642	ENSG00000256560.1	LINC01486	7.27	1.46e-12	2.49e-06	0.4	0.32	Monocyte count;	chr8:11940825	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.636	rs4841646	ENSG00000256560.1	LINC01486	7.27	1.46e-12	2.49e-06	0.4	0.32	Monocyte count;	chr8:11941198	chr12:109354083~109359488:-
THCA	trans	rs3740713	1	rs113036885	ENSG00000214110.3	LDHAP4	7.27	1.47e-12	2.5e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs112410494	ENSG00000214110.3	LDHAP4	7.27	1.47e-12	2.5e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs74741949	ENSG00000214110.3	LDHAP4	7.27	1.47e-12	2.5e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr9:14921337~14922334:-
THCA	trans	rs3740713	0.925	rs55727925	ENSG00000214110.3	LDHAP4	7.27	1.47e-12	2.5e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr9:14921337~14922334:-
THCA	trans	rs748404	0.697	rs493444	ENSG00000180867.10	PDIA3P1	-7.27	1.49e-12	2.54e-06	-0.28	-0.32	Lung cancer;	chr15:43274272	chr1:147178113~147179622:+
THCA	trans	rs2288327	0.73	rs16866358	ENSG00000269800.1	PLEKHA3P1	7.27	1.5e-12	2.55e-06	0.45	0.32	Atrial fibrillation;	chr2:178515369	chr19:41521043~41521989:-
THCA	trans	rs2288327	0.818	rs13029629	ENSG00000269800.1	PLEKHA3P1	7.27	1.5e-12	2.55e-06	0.45	0.32	Atrial fibrillation;	chr2:178515438	chr19:41521043~41521989:-
THCA	trans	rs11992162	0.636	rs4841645	ENSG00000256560.1	LINC01486	-7.27	1.5e-12	2.56e-06	-0.4	-0.32	Monocyte count;	chr8:11941175	chr12:109354083~109359488:-
THCA	trans	rs1816752	0.819	rs4769349	ENSG00000224976.2	PARP4P2	7.27	1.51e-12	2.56e-06	0.36	0.32	Obesity-related traits;	chr13:24408694	chr13:19349137~19407962:+
THCA	trans	rs11992162	0.636	rs11250182	ENSG00000253893.2	FAM85B	7.27	1.51e-12	2.57e-06	0.42	0.32	Monocyte count;	chr8:11950067	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.767	rs3808509	ENSG00000253893.2	FAM85B	-7.27	1.51e-12	2.58e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11305747	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.825	rs12521953	ENSG00000231752.4	EMBP1	7.27	1.52e-12	2.58e-06	0.52	0.32	Age at first birth;	chr5:45249411	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs62367515	ENSG00000231752.4	EMBP1	7.27	1.52e-12	2.58e-06	0.52	0.32	Age at first birth;	chr5:45249772	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs12514615	ENSG00000231752.4	EMBP1	7.27	1.52e-12	2.58e-06	0.52	0.32	Age at first birth;	chr5:45253557	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs16902068	ENSG00000231752.4	EMBP1	7.27	1.52e-12	2.58e-06	0.52	0.32	Age at first birth;	chr5:45255376	chr1:121519112~121571892:+
THCA	trans	rs16937956	0.597	rs12793878	ENSG00000266891.1	RP11-692N5.2	7.27	1.52e-12	2.58e-06	0.44	0.32	Body mass index;	chr11:8380662	chr18:9734882~9735602:-
THCA	trans	rs16937956	0.597	rs11822608	ENSG00000266891.1	RP11-692N5.2	7.27	1.52e-12	2.59e-06	0.44	0.32	Body mass index;	chr11:8380117	chr18:9734882~9735602:-
THCA	trans	rs9648716	1	rs1267621	ENSG00000224775.2	BRAFP1	7.27	1.53e-12	2.61e-06	0.55	0.32	Type 2 diabetes;	chr7:140856367	chrX:75582676~75585506:+
THCA	trans	rs7258465	0.511	rs11668719	ENSG00000267533.1	RP11-815J4.7	7.27	1.53e-12	2.61e-06	0.43	0.32	Breast cancer;	chr19:18404931	chr18:12067173~12068417:-
THCA	trans	rs6885307	0.825	rs12515179	ENSG00000231752.4	EMBP1	7.27	1.53e-12	2.61e-06	0.48	0.32	Age at first birth;	chr5:45246993	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.504	rs10109167	ENSG00000229857.1	RP11-159H20.3	7.27	1.53e-12	2.61e-06	0.41	0.32	Neuroticism;	chr8:11176016	chr9:76992099~76993108:+
THCA	trans	rs79149102	0.522	rs7497036	ENSG00000227288.3	RP5-837I24.1	-7.27	1.53e-12	2.61e-06	-0.5	-0.32	Lung cancer;	chr15:74581338	chr1:81501794~81503468:+
THCA	trans	rs58106596	0.8	rs28883318	ENSG00000259020.3	RP11-529H20.3	7.27	1.54e-12	2.62e-06	0.49	0.32	Lymphocyte counts;White blood cell count;	chr2:231698225	chr14:92026566~92026887:+
THCA	trans	rs11098499	0.954	rs6847248	ENSG00000253326.2	RP11-261C10.7	7.27	1.54e-12	2.62e-06	0.45	0.32	Corneal astigmatism;	chr4:119304800	chr1:243054861~243056394:-
THCA	trans	rs7819412	0.775	rs4841490	ENSG00000229857.1	RP11-159H20.3	7.27	1.54e-12	2.62e-06	0.4	0.32	Triglycerides;	chr8:11079381	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.739	rs6534130	ENSG00000275858.1	RP11-291L22.8	-7.27	1.55e-12	2.64e-06	-0.4	-0.32	Corneal astigmatism;	chr4:119210184	chr10:38450738~38451069:-
THCA	trans	rs5022636	0.896	rs744536	ENSG00000180764.13	PIPSL	7.27	1.56e-12	2.65e-06	0.35	0.32	Gut microbiota (functional units);	chr1:151356318	chr10:93958191~93961540:-
THCA	trans	rs9650657	0.645	rs4841409	ENSG00000253893.2	FAM85B	-7.27	1.56e-12	2.65e-06	-0.4	-0.32	Neuroticism;	chr8:10658864	chr8:8167819~8226614:-
THCA	trans	rs6743068	0.521	rs7578970	ENSG00000235105.1	RP11-329A14.1	7.26	1.56e-12	2.66e-06	0.35	0.32	Lymphocyte percentage of white cells;	chr2:201365061	chr1:48435967~48437223:+
THCA	trans	rs7824557	0.767	rs7003241	ENSG00000253893.2	FAM85B	-7.26	1.56e-12	2.66e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11311566	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.721	rs10890341	ENSG00000255397.1	AC022182.2	-7.26	1.57e-12	2.67e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs12024590	ENSG00000255397.1	AC022182.2	-7.26	1.58e-12	2.68e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs12027622	ENSG00000255397.1	AC022182.2	-7.26	1.58e-12	2.68e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs4415615	ENSG00000255397.1	AC022182.2	-7.26	1.58e-12	2.68e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs7529699	ENSG00000255397.1	AC022182.2	-7.26	1.58e-12	2.68e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.716	rs6699444	ENSG00000255397.1	AC022182.2	-7.26	1.58e-12	2.68e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs10430105	ENSG00000255397.1	AC022182.2	-7.26	1.58e-12	2.68e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.863	rs10019674	ENSG00000253326.2	RP11-261C10.7	-7.26	1.58e-12	2.69e-06	-0.45	-0.32	Corneal astigmatism;	chr4:119522334	chr1:243054861~243056394:-
THCA	trans	rs2645424	0.519	rs17154027	ENSG00000229857.1	RP11-159H20.3	7.26	1.59e-12	2.69e-06	0.41	0.32	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856343	chr9:76992099~76993108:+
THCA	trans	rs7260598	0.792	rs17620072	ENSG00000261770.1	CTC-459F4.1	7.26	1.59e-12	2.7e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24177850	chr19:27757184~27760849:-
THCA	trans	rs7662987	1	rs13119035	ENSG00000228407.2	RP4-800M22.1	7.26	1.59e-12	2.71e-06	0.69	0.32	Smoking initiation;	chr4:99077979	chr1:52160261~52160600:-
THCA	trans	rs3740713	1	rs73440625	ENSG00000214110.3	LDHAP4	7.26	1.6e-12	2.71e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr9:14921337~14922334:-
THCA	trans	rs17711722	0.523	rs365896	ENSG00000213640.3	EEF1DP4	7.26	1.6e-12	2.72e-06	0.37	0.32	Calcium levels;	chr7:66045710	chr7:64862999~64864370:+
THCA	trans	rs453301	0.624	rs2979265	ENSG00000229857.1	RP11-159H20.3	-7.26	1.6e-12	2.72e-06	-0.38	-0.32	Joint mobility (Beighton score);	chr8:9001207	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.595	rs2409712	ENSG00000253893.2	FAM85B	7.26	1.62e-12	2.75e-06	0.41	0.32	Triglycerides;	chr8:11129327	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.504	rs6601565	ENSG00000229857.1	RP11-159H20.3	7.26	1.63e-12	2.77e-06	0.41	0.32	Neuroticism;	chr8:11174719	chr9:76992099~76993108:+
THCA	trans	rs7833986	0.534	rs17814089	ENSG00000236862.1	RPS20P24	-7.26	1.65e-12	2.8e-06	-0.47	-0.32	Height;	chr8:56053004	chr9:72655832~72656192:-
THCA	trans	rs9329221	0.712	rs1962073	ENSG00000253893.2	FAM85B	7.26	1.65e-12	2.8e-06	0.4	0.32	Neuroticism;	chr8:10403043	chr8:8167819~8226614:-
THCA	trans	rs16937956	0.657	rs3751095	ENSG00000266891.1	RP11-692N5.2	7.26	1.65e-12	2.8e-06	0.42	0.32	Body mass index;	chr11:8413530	chr18:9734882~9735602:-
THCA	trans	rs16937956	0.657	rs3751096	ENSG00000266891.1	RP11-692N5.2	7.26	1.65e-12	2.8e-06	0.42	0.32	Body mass index;	chr11:8413531	chr18:9734882~9735602:-
THCA	trans	rs11098499	0.863	rs11098531	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119543846	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs28718422	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119545149	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs12498539	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119547215	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.818	rs12498599	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119547348	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs10009626	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119548850	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3822194	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119550493	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3822195	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119550505	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3775854	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119550816	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs2306456	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119551267	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs11947234	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119553704	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs6853998	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119554705	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs6858777	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119554811	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs11933966	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119555560	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs36040693	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119556461	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs11731756	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119557541	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs34308924	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119560276	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs2170276	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119564669	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs1552092	ENSG00000253326.2	RP11-261C10.7	7.26	1.65e-12	2.8e-06	0.45	0.32	Corneal astigmatism;	chr4:119567341	chr1:243054861~243056394:-
THCA	trans	rs1707322	0.686	rs61784833	ENSG00000255397.1	AC022182.2	-7.26	1.66e-12	2.81e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr8:60937705~60939871:-
THCA	trans	rs1045902	0.574	rs1053329	ENSG00000236165.1	PRADC1P1	7.26	1.66e-12	2.82e-06	0.45	0.32	Intelligence (multi-trait analysis);	chr2:73234355	chr3:36976316~36976840:+
THCA	trans	rs6885307	0.825	rs62369918	ENSG00000231752.4	EMBP1	7.26	1.67e-12	2.82e-06	0.51	0.32	Age at first birth;	chr5:45137932	chr1:121519112~121571892:+
THCA	trans	rs11250098	0.583	rs7000276	ENSG00000253893.2	FAM85B	7.26	1.67e-12	2.83e-06	0.42	0.32	Morning vs. evening chronotype;	chr8:10947333	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.662	rs11211160	ENSG00000255397.1	AC022182.2	-7.25	1.67e-12	2.83e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr8:60937705~60939871:-
THCA	trans	rs12709013	0.967	rs62064905	ENSG00000230849.2	GOT2P2	7.25	1.67e-12	2.84e-06	0.39	0.32	Blood metabolite ratios;	chr16:58778839	chr1:173141100~173142350:-
THCA	trans	rs7819412	0.74	rs11250119	ENSG00000229857.1	RP11-159H20.3	7.25	1.68e-12	2.84e-06	0.4	0.32	Triglycerides;	chr8:11179525	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.703	rs2409713	ENSG00000253893.2	FAM85B	7.25	1.68e-12	2.84e-06	0.43	0.32	Triglycerides;	chr8:11152287	chr8:8167819~8226614:-
THCA	trans	rs28647808	1	rs28496755	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133348694	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs7700	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133350027	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28693986	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133351103	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28483151	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133353473	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs34847665	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133353536	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs71503186	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133357957	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs35763556	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133358017	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28627547	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133358539	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28548424	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133358600	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs34104559	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133358763	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.881	rs35811795	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133359654	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs34939258	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133361130	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs11543366	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133363074	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28693733	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133365870	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28659967	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133366892	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28688336	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133368982	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs28406995	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133369746	chr1:206528915~206529706:+
THCA	trans	rs28647808	1	rs3739892	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133372043	chr1:206528915~206529706:+
THCA	trans	rs28647808	0.867	rs28578742	ENSG00000234981.1	RP11-534L20.4	7.25	1.68e-12	2.85e-06	0.74	0.32	Blood protein levels;	chr9:133374726	chr1:206528915~206529706:+
THCA	trans	rs864643	0.947	rs1768243	ENSG00000188856.6	RPSAP47	7.25	1.69e-12	2.86e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39500306	chr8:80558870~80559757:+
THCA	trans	rs2288327	0.818	rs12618265	ENSG00000269800.1	PLEKHA3P1	7.25	1.69e-12	2.86e-06	0.45	0.32	Atrial fibrillation;	chr2:178518082	chr19:41521043~41521989:-
THCA	trans	rs9329221	0.572	rs4841295	ENSG00000253893.2	FAM85B	-7.25	1.69e-12	2.86e-06	-0.42	-0.32	Neuroticism;	chr8:10247605	chr8:8167819~8226614:-
THCA	trans	rs6915893	0.669	rs10456213	ENSG00000267156.1	TPMTP1	7.25	1.7e-12	2.87e-06	0.33	0.32	Intrinsic epigenetic age acceleration;	chr6:18118881	chr18:47630112~47630848:+
THCA	trans	rs748404	0.697	rs574065	ENSG00000180867.10	PDIA3P1	7.25	1.7e-12	2.88e-06	0.27	0.32	Lung cancer;	chr15:43258457	chr1:147178113~147179622:+
THCA	trans	rs9650657	0.836	rs6601523	ENSG00000253893.2	FAM85B	7.25	1.71e-12	2.89e-06	0.4	0.32	Neuroticism;	chr8:10777631	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.522	rs11776603	ENSG00000253893.2	FAM85B	7.25	1.71e-12	2.9e-06	0.45	0.32	Triglycerides;	chr8:11162803	chr8:8167819~8226614:-
THCA	trans	rs11250098	0.583	rs7001456	ENSG00000253893.2	FAM85B	7.25	1.72e-12	2.91e-06	0.42	0.32	Morning vs. evening chronotype;	chr8:10947355	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.682	rs6989160	ENSG00000253893.2	FAM85B	7.25	1.73e-12	2.92e-06	0.41	0.32	Neuroticism;	chr8:10847850	chr8:8167819~8226614:-
THCA	trans	rs6915893	0.74	rs6910353	ENSG00000267156.1	TPMTP1	-7.25	1.73e-12	2.93e-06	-0.33	-0.32	Intrinsic epigenetic age acceleration;	chr6:18102327	chr18:47630112~47630848:+
THCA	trans	rs7824557	0.767	rs1897951	ENSG00000253893.2	FAM85B	-7.25	1.74e-12	2.94e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11312345	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.767	rs11250127	ENSG00000253893.2	FAM85B	-7.25	1.74e-12	2.94e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11312700	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.613	rs56094399	ENSG00000256560.1	LINC01486	-7.25	1.74e-12	2.94e-06	-0.41	-0.32	Monocyte count;	chr8:11939961	chr12:109354083~109359488:-
THCA	trans	rs804280	0.565	rs1466785	ENSG00000256560.1	LINC01486	7.25	1.74e-12	2.95e-06	0.37	0.32	Myopia (pathological);	chr8:11765947	chr12:109354083~109359488:-
THCA	trans	rs7260598	0.792	rs11670331	ENSG00000261770.1	CTC-459F4.1	7.25	1.76e-12	2.97e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24155040	chr19:27757184~27760849:-
THCA	trans	rs1580019	0.587	rs7804457	ENSG00000176826.14	FKBP9P1	-7.25	1.76e-12	2.98e-06	-0.42	-0.32	Cognitive ability;	chr7:32518369	chr7:55681074~55713252:-
THCA	trans	rs1707322	0.721	rs11211149	ENSG00000255397.1	AC022182.2	-7.25	1.77e-12	2.98e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr8:60937705~60939871:-
THCA	trans	rs6424115	0.692	rs573361	ENSG00000228217.1	AL390877.1	-7.25	1.78e-12	3e-06	-0.42	-0.32	Immature fraction of reticulocytes;	chr1:23727184	chr1:117778087~117778506:-
THCA	trans	rs11098499	0.863	rs9997631	ENSG00000253326.2	RP11-261C10.7	7.25	1.78e-12	3e-06	0.44	0.32	Corneal astigmatism;	chr4:119548840	chr1:243054861~243056394:-
THCA	trans	rs1580019	0.537	rs7804609	ENSG00000176826.14	FKBP9P1	-7.24	1.79e-12	3.02e-06	-0.42	-0.32	Cognitive ability;	chr7:32518482	chr7:55681074~55713252:-
THCA	trans	rs804280	0.504	rs2645457	ENSG00000253893.2	FAM85B	7.24	1.79e-12	3.02e-06	0.44	0.32	Myopia (pathological);	chr8:11756603	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.825	rs12520698	ENSG00000231752.4	EMBP1	7.24	1.79e-12	3.02e-06	0.52	0.32	Age at first birth;	chr5:45140360	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs12522822	ENSG00000231752.4	EMBP1	7.24	1.79e-12	3.02e-06	0.52	0.32	Age at first birth;	chr5:45143363	chr1:121519112~121571892:+
THCA	trans	rs7662987	1	rs28730595	ENSG00000228407.2	RP4-800M22.1	7.24	1.79e-12	3.02e-06	0.69	0.32	Smoking initiation;	chr4:99082182	chr1:52160261~52160600:-
THCA	trans	rs7662987	0.938	rs28730592	ENSG00000228407.2	RP4-800M22.1	7.24	1.79e-12	3.02e-06	0.69	0.32	Smoking initiation;	chr4:99082592	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs28730591	ENSG00000228407.2	RP4-800M22.1	7.24	1.79e-12	3.02e-06	0.69	0.32	Smoking initiation;	chr4:99082596	chr1:52160261~52160600:-
THCA	trans	rs1707322	0.752	rs4660880	ENSG00000255397.1	AC022182.2	-7.24	1.79e-12	3.03e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr8:60937705~60939871:-
THCA	trans	rs7260598	0.792	rs73031010	ENSG00000261770.1	CTC-459F4.1	7.24	1.81e-12	3.05e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24178160	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs7260592	ENSG00000261770.1	CTC-459F4.1	7.24	1.81e-12	3.05e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24178786	chr19:27757184~27760849:-
THCA	trans	rs1707322	0.721	rs10890343	ENSG00000255397.1	AC022182.2	-7.24	1.83e-12	3.08e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.739	rs9996382	ENSG00000275858.1	RP11-291L22.8	7.24	1.83e-12	3.09e-06	0.4	0.32	Corneal astigmatism;	chr4:119229857	chr10:38450738~38451069:-
THCA	trans	rs7824557	0.767	rs3808513	ENSG00000253893.2	FAM85B	7.24	1.83e-12	3.09e-06	0.42	0.32	Retinal vascular caliber;	chr8:11299951	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773109	ENSG00000212829.8	RPS26P3	7.24	1.84e-12	3.1e-06	0.41	0.32	Cognitive function;	chr12:55980911	chr9:9090898~9091245:+
THCA	trans	rs864643	0.947	rs1708073	ENSG00000188856.6	RPSAP47	7.24	1.85e-12	3.11e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39501530	chr8:80558870~80559757:+
THCA	trans	rs7824557	0.767	rs2060463	ENSG00000253893.2	FAM85B	-7.24	1.85e-12	3.12e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11304101	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000224553.1	AC008065.1	7.24	1.86e-12	3.13e-06	0.39	0.32	Cognitive function;	chr12:55981353	chr2:171374931~171375278:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000224553.1	AC008065.1	7.24	1.86e-12	3.13e-06	0.39	0.32	Cognitive function;	chr12:55981956	chr2:171374931~171375278:-
THCA	trans	rs11098499	0.954	rs11722872	ENSG00000253326.2	RP11-261C10.7	7.24	1.86e-12	3.13e-06	0.44	0.32	Corneal astigmatism;	chr4:119311875	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.701	rs4568582	ENSG00000253893.2	FAM85B	-7.24	1.87e-12	3.14e-06	-0.42	-0.32	Retinal vascular caliber;	chr8:11302986	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.5	rs11998678	ENSG00000256560.1	LINC01486	-7.24	1.87e-12	3.14e-06	-0.39	-0.32	Systolic blood pressure;	chr8:11972641	chr12:109354083~109359488:-
THCA	trans	rs3740713	1	rs1848048	ENSG00000214110.3	LDHAP4	7.24	1.87e-12	3.14e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs16935432	ENSG00000214110.3	LDHAP4	7.24	1.87e-12	3.14e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr9:14921337~14922334:-
THCA	trans	rs3740713	1	rs76599129	ENSG00000214110.3	LDHAP4	7.24	1.87e-12	3.14e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr9:14921337~14922334:-
THCA	trans	rs11992162	0.636	rs4841644	ENSG00000256560.1	LINC01486	7.24	1.88e-12	3.16e-06	0.4	0.32	Monocyte count;	chr8:11940924	chr12:109354083~109359488:-
THCA	trans	rs1580019	0.587	rs10951338	ENSG00000176826.14	FKBP9P1	-7.24	1.88e-12	3.16e-06	-0.42	-0.32	Cognitive ability;	chr7:32520477	chr7:55681074~55713252:-
THCA	trans	rs7647973	0.696	rs3087866	ENSG00000197582.5	GPX1P1	7.24	1.88e-12	3.16e-06	0.54	0.32	Menarche (age at onset);	chr3:49017259	chrX:13378735~13379340:-
THCA	trans	rs1707322	0.717	rs1135812	ENSG00000255397.1	AC022182.2	-7.24	1.89e-12	3.17e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.752	rs6703748	ENSG00000255397.1	AC022182.2	-7.24	1.89e-12	3.17e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr8:60937705~60939871:-
THCA	trans	rs7833986	0.501	rs2976044	ENSG00000236862.1	RPS20P24	7.24	1.89e-12	3.18e-06	0.44	0.32	Height;	chr8:56074178	chr9:72655832~72656192:-
THCA	trans	rs6885307	0.825	rs62367465	ENSG00000231752.4	EMBP1	7.23	1.91e-12	3.21e-06	0.52	0.32	Age at first birth;	chr5:45168826	chr1:121519112~121571892:+
THCA	trans	rs877636	0.702	rs61937249	ENSG00000224553.1	AC008065.1	7.23	1.91e-12	3.21e-06	0.39	0.32	Cognitive function;	chr12:55988132	chr2:171374931~171375278:-
THCA	trans	rs12709013	0.875	rs9924389	ENSG00000230849.2	GOT2P2	7.23	1.91e-12	3.22e-06	0.38	0.32	Blood metabolite ratios;	chr16:58779849	chr1:173141100~173142350:-
THCA	trans	rs11098499	0.865	rs11722183	ENSG00000253326.2	RP11-261C10.7	7.23	1.92e-12	3.23e-06	0.44	0.32	Corneal astigmatism;	chr4:119359442	chr1:243054861~243056394:-
THCA	trans	rs9858542	1	rs9836291	ENSG00000197582.5	GPX1P1	-7.23	1.93e-12	3.25e-06	-0.49	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49660026	chrX:13378735~13379340:-
THCA	trans	rs748404	0.697	rs505249	ENSG00000180867.10	PDIA3P1	-7.23	1.93e-12	3.25e-06	-0.27	-0.32	Lung cancer;	chr15:43267762	chr1:147178113~147179622:+
THCA	trans	rs7260598	0.792	rs11671489	ENSG00000261770.1	CTC-459F4.1	7.23	1.94e-12	3.26e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24156070	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs60773823	ENSG00000261770.1	CTC-459F4.1	7.23	1.94e-12	3.26e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24156730	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs11669171	ENSG00000261770.1	CTC-459F4.1	7.23	1.94e-12	3.27e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24153957	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs11669295	ENSG00000261770.1	CTC-459F4.1	7.23	1.94e-12	3.27e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24154184	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs11670299	ENSG00000261770.1	CTC-459F4.1	7.23	1.94e-12	3.27e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24154959	chr19:27757184~27760849:-
THCA	trans	rs3806843	0.569	rs753279	ENSG00000231043.3	AC007238.1	7.23	1.95e-12	3.28e-06	0.36	0.32	Depressive symptoms (multi-trait analysis);	chr5:140644233	chr2:58460292~58462032:-
THCA	trans	rs9858542	1	rs3197999	ENSG00000197582.5	GPX1P1	-7.23	1.96e-12	3.29e-06	-0.51	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684099	chrX:13378735~13379340:-
THCA	trans	rs7260598	0.792	rs11669251	ENSG00000261770.1	CTC-459F4.1	7.23	2e-12	3.36e-06	0.53	0.32	Response to taxane treatment (placlitaxel);	chr19:24154192	chr19:27757184~27760849:-
THCA	trans	rs9329221	0.597	rs17751178	ENSG00000253893.2	FAM85B	-7.23	2e-12	3.36e-06	-0.43	-0.32	Neuroticism;	chr8:10259220	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.721	rs4559551	ENSG00000255397.1	AC022182.2	-7.23	2.01e-12	3.37e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.812	rs10107289	ENSG00000253893.2	FAM85B	7.23	2.01e-12	3.37e-06	0.4	0.32	Neuroticism;	chr8:10776738	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs6677777	ENSG00000255397.1	AC022182.2	-7.23	2.01e-12	3.38e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.927	rs6690386	ENSG00000255397.1	AC022182.2	-7.23	2.01e-12	3.38e-06	-0.45	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.74	rs7002282	ENSG00000253893.2	FAM85B	7.23	2.02e-12	3.39e-06	0.41	0.32	Neuroticism;	chr8:10809483	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.737	rs4841436	ENSG00000253893.2	FAM85B	-7.23	2.03e-12	3.4e-06	-0.39	-0.32	Neuroticism;	chr8:10736964	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.713	rs62369916	ENSG00000231752.4	EMBP1	7.23	2.03e-12	3.4e-06	0.52	0.32	Age at first birth;	chr5:45125570	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs10941693	ENSG00000231752.4	EMBP1	7.23	2.03e-12	3.4e-06	0.52	0.32	Age at first birth;	chr5:45125981	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.767	rs1897950	ENSG00000253893.2	FAM85B	-7.23	2.03e-12	3.4e-06	-0.41	-0.32	Retinal vascular caliber;	chr8:11312042	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.711	rs4481596	ENSG00000256560.1	LINC01486	7.23	2.03e-12	3.4e-06	0.38	0.32	Mood instability;	chr8:8846820	chr12:109354083~109359488:-
THCA	trans	rs73108077	0.92	rs6057657	ENSG00000279352.1	RP11-411B10.7	-7.23	2.03e-12	3.41e-06	-0.59	-0.32	Red blood cell density in sickle cell anemia;	chr20:31376027	chr18:14010054~14010917:+
THCA	trans	rs7824557	0.815	rs2572430	ENSG00000253893.2	FAM85B	-7.22	2.05e-12	3.44e-06	-0.38	-0.32	Retinal vascular caliber;	chr8:11247795	chr8:8167819~8226614:-
THCA	trans	rs10917477	0.624	rs1320978	ENSG00000224237.1	MINOS1P3	7.22	2.05e-12	3.44e-06	0.4	0.32	Thyroid function;	chr1:19621479	chr3:27214816~27215018:-
THCA	trans	rs11098499	0.863	rs10004484	ENSG00000253326.2	RP11-261C10.7	7.22	2.06e-12	3.45e-06	0.44	0.32	Corneal astigmatism;	chr4:119521273	chr1:243054861~243056394:-
THCA	trans	rs9858213	1	rs9858213	ENSG00000197582.5	GPX1P1	-7.22	2.06e-12	3.45e-06	-0.5	-0.32	Educational attainment;	chr3:49694428	chrX:13378735~13379340:-
THCA	trans	rs941207	0.789	rs2958145	ENSG00000257210.1	NACAP3	-7.22	2.08e-12	3.49e-06	-0.42	-0.32	Platelet count;	chr12:56662290	chr12:93124063~93124543:-
THCA	trans	rs6981523	0.553	rs11783045	ENSG00000253893.2	FAM85B	7.22	2.09e-12	3.5e-06	0.43	0.32	Neuroticism;	chr8:11198666	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.617	rs10087081	ENSG00000229857.1	RP11-159H20.3	7.22	2.12e-12	3.56e-06	0.42	0.32	Triglycerides;	chr8:11117407	chr9:76992099~76993108:+
THCA	trans	rs7113874	0.518	rs7112091	ENSG00000266891.1	RP11-692N5.2	7.22	2.15e-12	3.6e-06	0.4	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8381845	chr18:9734882~9735602:-
THCA	trans	rs7819412	0.645	rs4841508	ENSG00000229857.1	RP11-159H20.3	7.22	2.16e-12	3.62e-06	0.41	0.32	Triglycerides;	chr8:11207494	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.669	rs35499486	ENSG00000229857.1	RP11-159H20.3	7.22	2.17e-12	3.63e-06	0.42	0.32	Triglycerides;	chr8:11216527	chr9:76992099~76993108:+
THCA	trans	rs6993244	1	rs6993244	ENSG00000229857.1	RP11-159H20.3	-7.21	2.21e-12	3.69e-06	-0.38	-0.32	Mean corpuscular hemoglobin;	chr8:9005549	chr9:76992099~76993108:+
THCA	trans	rs6885307	0.882	rs6898476	ENSG00000231752.4	EMBP1	7.21	2.21e-12	3.7e-06	0.49	0.32	Age at first birth;	chr5:45165244	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.746	rs4841441	ENSG00000253893.2	FAM85B	7.21	2.22e-12	3.71e-06	0.4	0.32	Neuroticism;	chr8:10773388	chr8:8167819~8226614:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000233278.1	RPS26P2	7.21	2.22e-12	3.71e-06	0.36	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:30831878~30832225:-
THCA	trans	rs12709013	0.935	rs34657766	ENSG00000230849.2	GOT2P2	7.21	2.23e-12	3.72e-06	0.38	0.32	Blood metabolite ratios;	chr16:58779468	chr1:173141100~173142350:-
THCA	trans	rs12709013	0.729	rs71400031	ENSG00000230849.2	GOT2P2	7.21	2.23e-12	3.72e-06	0.38	0.32	Blood metabolite ratios;	chr16:58779554	chr1:173141100~173142350:-
THCA	trans	rs1707322	0.721	rs10890346	ENSG00000255397.1	AC022182.2	7.21	2.23e-12	3.73e-06	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.685	rs56177313	ENSG00000255397.1	AC022182.2	-7.21	2.23e-12	3.73e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs11211178	ENSG00000255397.1	AC022182.2	-7.21	2.23e-12	3.73e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs4660314	ENSG00000255397.1	AC022182.2	-7.21	2.23e-12	3.73e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr8:60937705~60939871:-
THCA	trans	rs7647973	0.769	rs4974081	ENSG00000197582.5	GPX1P1	-7.21	2.26e-12	3.77e-06	-0.54	-0.32	Menarche (age at onset);	chr3:49033066	chrX:13378735~13379340:-
THCA	trans	rs7662987	1	rs7684986	ENSG00000228407.2	RP4-800M22.1	7.21	2.27e-12	3.79e-06	0.69	0.32	Smoking initiation;	chr4:99070525	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs1061187	ENSG00000228407.2	RP4-800M22.1	7.21	2.27e-12	3.79e-06	0.69	0.32	Smoking initiation;	chr4:99071702	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs13145727	ENSG00000228407.2	RP4-800M22.1	7.21	2.27e-12	3.79e-06	0.69	0.32	Smoking initiation;	chr4:99077715	chr1:52160261~52160600:-
THCA	trans	rs7662987	1	rs13125919	ENSG00000228407.2	RP4-800M22.1	7.21	2.27e-12	3.79e-06	0.69	0.32	Smoking initiation;	chr4:99078697	chr1:52160261~52160600:-
THCA	trans	rs864643	1	rs1768252	ENSG00000188856.6	RPSAP47	7.21	2.28e-12	3.8e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39506768	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1340224	ENSG00000188856.6	RPSAP47	7.21	2.32e-12	3.87e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39508072	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1340222	ENSG00000188856.6	RPSAP47	7.21	2.32e-12	3.87e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39508312	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs536454	ENSG00000188856.6	RPSAP47	7.21	2.32e-12	3.87e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39508827	chr8:80558870~80559757:+
THCA	trans	rs864643	0.945	rs583083	ENSG00000188856.6	RPSAP47	7.21	2.32e-12	3.87e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39508954	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs581691	ENSG00000188856.6	RPSAP47	7.21	2.32e-12	3.87e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39509244	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs689352	ENSG00000188856.6	RPSAP47	7.21	2.32e-12	3.87e-06	0.48	0.32	Attention deficit hyperactivity disorder;	chr3:39509275	chr8:80558870~80559757:+
THCA	trans	rs7819412	0.765	rs17783634	ENSG00000229857.1	RP11-159H20.3	7.21	2.32e-12	3.88e-06	0.41	0.32	Triglycerides;	chr8:11196588	chr9:76992099~76993108:+
THCA	trans	rs748404	0.697	rs1095389	ENSG00000180867.10	PDIA3P1	-7.2	2.33e-12	3.89e-06	-0.27	-0.32	Lung cancer;	chr15:43274473	chr1:147178113~147179622:+
THCA	trans	rs6601450	0.547	rs10105843	ENSG00000253893.2	FAM85B	-7.2	2.34e-12	3.9e-06	-0.39	-0.32	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10340353	chr8:8167819~8226614:-
THCA	trans	rs7617480	0.648	rs7653408	ENSG00000197582.5	GPX1P1	7.2	2.36e-12	3.93e-06	0.53	0.32	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48934918	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.696	rs7100	ENSG00000197582.5	GPX1P1	7.2	2.37e-12	3.95e-06	0.54	0.32	Menarche (age at onset);	chr3:49015786	chrX:13378735~13379340:-
THCA	trans	rs9329221	0.527	rs4841352	ENSG00000253893.2	FAM85B	-7.2	2.37e-12	3.95e-06	-0.43	-0.32	Neuroticism;	chr8:10470080	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.56	rs7846248	ENSG00000256560.1	LINC01486	7.2	2.37e-12	3.95e-06	0.4	0.32	Monocyte count;	chr8:11936540	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.739	rs10031033	ENSG00000275858.1	RP11-291L22.8	7.2	2.38e-12	3.97e-06	0.4	0.32	Corneal astigmatism;	chr4:119230297	chr10:38450738~38451069:-
THCA	trans	rs2645424	0.866	rs2645426	ENSG00000229857.1	RP11-159H20.3	7.2	2.39e-12	3.98e-06	0.4	0.32	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11825262	chr9:76992099~76993108:+
THCA	trans	rs11671005	0.656	rs11671092	ENSG00000279267.1	RP11-395L14.18	7.2	2.4e-12	4.01e-06	0.49	0.32	Mean platelet volume;	chr19:58497742	chr2:113605867~113607908:-
THCA	trans	rs11671005	0.656	rs55928441	ENSG00000279267.1	RP11-395L14.18	7.2	2.4e-12	4.01e-06	0.49	0.32	Mean platelet volume;	chr19:58498307	chr2:113605867~113607908:-
THCA	trans	rs7617480	0.648	rs4858800	ENSG00000197582.5	GPX1P1	7.2	2.43e-12	4.05e-06	0.53	0.32	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48718387	chrX:13378735~13379340:-
THCA	trans	rs864643	0.678	rs1708089	ENSG00000188856.6	RPSAP47	7.2	2.43e-12	4.05e-06	0.5	0.32	Attention deficit hyperactivity disorder;	chr3:39470371	chr8:80558870~80559757:+
THCA	trans	rs6885307	0.825	rs12055286	ENSG00000231752.4	EMBP1	7.2	2.46e-12	4.09e-06	0.52	0.32	Age at first birth;	chr5:45117928	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.767	rs7837036	ENSG00000253893.2	FAM85B	-7.2	2.46e-12	4.1e-06	-0.41	-0.32	Retinal vascular caliber;	chr8:11317980	chr8:8167819~8226614:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000212829.8	RPS26P3	7.2	2.47e-12	4.12e-06	0.42	0.32	Cognitive function;	chr12:55976127	chr9:9090898~9091245:+
THCA	trans	rs76228276	0.737	rs7832595	ENSG00000260318.1	COX6CP1	7.2	2.48e-12	4.13e-06	0.92	0.31	Childhood ear infection;	chr8:99190742	chr16:11903923~11904137:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000224553.1	AC008065.1	7.19	2.5e-12	4.16e-06	0.39	0.31	Cognitive function;	chr12:55982097	chr2:171374931~171375278:-
THCA	trans	rs9650657	0.738	rs11250078	ENSG00000253893.2	FAM85B	7.19	2.51e-12	4.18e-06	0.4	0.31	Neuroticism;	chr8:10809071	chr8:8167819~8226614:-
THCA	trans	rs6601450	0.522	rs7837979	ENSG00000253893.2	FAM85B	-7.19	2.54e-12	4.22e-06	-0.38	-0.31	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10341024	chr8:8167819~8226614:-
THCA	trans	rs1580019	0.562	rs4720064	ENSG00000176826.14	FKBP9P1	-7.19	2.54e-12	4.23e-06	-0.42	-0.31	Cognitive ability;	chr7:32520026	chr7:55681074~55713252:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000212829.8	RPS26P3	7.19	2.56e-12	4.26e-06	0.41	0.31	Cognitive function;	chr12:55990903	chr9:9090898~9091245:+
THCA	trans	rs748404	0.697	rs531910	ENSG00000180867.10	PDIA3P1	-7.19	2.58e-12	4.28e-06	-0.27	-0.31	Lung cancer;	chr15:43268409	chr1:147178113~147179622:+
THCA	trans	rs748404	0.697	rs492743	ENSG00000180867.10	PDIA3P1	-7.19	2.58e-12	4.28e-06	-0.27	-0.31	Lung cancer;	chr15:43268747	chr1:147178113~147179622:+
THCA	trans	rs61041336	1	rs61041336	ENSG00000233719.3	GOT2P3	-7.19	2.58e-12	4.29e-06	-0.49	-0.31	Neuritic plaque;	chr16:58699258	chr12:9641802~9643007:+
THCA	trans	rs1580019	0.587	rs7806113	ENSG00000176826.14	FKBP9P1	-7.19	2.59e-12	4.3e-06	-0.42	-0.31	Cognitive ability;	chr7:32513472	chr7:55681074~55713252:-
THCA	trans	rs76228276	0.737	rs1011534	ENSG00000260318.1	COX6CP1	7.19	2.59e-12	4.31e-06	0.9	0.31	Childhood ear infection;	chr8:99330013	chr16:11903923~11904137:-
THCA	trans	rs7260598	0.792	rs17620048	ENSG00000261770.1	CTC-459F4.1	7.19	2.61e-12	4.34e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24174677	chr19:27757184~27760849:-
THCA	trans	rs1580019	0.587	rs9638880	ENSG00000176826.14	FKBP9P1	-7.19	2.62e-12	4.35e-06	-0.42	-0.31	Cognitive ability;	chr7:32512789	chr7:55681074~55713252:-
THCA	trans	rs11671005	0.656	rs11672609	ENSG00000279267.1	RP11-395L14.18	7.19	2.62e-12	4.36e-06	0.49	0.31	Mean platelet volume;	chr19:58495557	chr2:113605867~113607908:-
THCA	trans	rs9329221	0.521	rs4841294	ENSG00000253893.2	FAM85B	7.19	2.62e-12	4.36e-06	0.42	0.31	Neuroticism;	chr8:10247558	chr8:8167819~8226614:-
THCA	trans	rs8067354	0.574	rs1292042	ENSG00000187870.7	RNFT1P3	7.19	2.63e-12	4.37e-06	0.51	0.31	Hemoglobin concentration;	chr17:59857634	chr17:20743333~20754501:-
THCA	trans	rs9329221	0.683	rs658385	ENSG00000253893.2	FAM85B	7.19	2.63e-12	4.37e-06	0.4	0.31	Neuroticism;	chr8:10034667	chr8:8167819~8226614:-
THCA	trans	rs282544	0.932	rs27598	ENSG00000231752.4	EMBP1	-7.19	2.64e-12	4.38e-06	-0.43	-0.31	Myopia (pathological);	chr5:50862465	chr1:121519112~121571892:+
THCA	trans	rs877636	0.74	rs772920	ENSG00000224553.1	AC008065.1	7.19	2.65e-12	4.4e-06	0.39	0.31	Cognitive function;	chr12:55996580	chr2:171374931~171375278:-
THCA	trans	rs7819412	0.502	rs11777918	ENSG00000253893.2	FAM85B	-7.18	2.66e-12	4.41e-06	-0.44	-0.31	Triglycerides;	chr8:11179410	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs17120257	ENSG00000248568.1	KRT8P48	-7.18	2.68e-12	4.46e-06	-0.66	-0.31	Prostate cancer;	chr12:52909547	chr5:146706381~146707600:-
THCA	trans	rs864643	1	rs1513213	ENSG00000188856.6	RPSAP47	7.18	2.69e-12	4.46e-06	0.48	0.31	Attention deficit hyperactivity disorder;	chr3:39509406	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1768261	ENSG00000188856.6	RPSAP47	7.18	2.69e-12	4.46e-06	0.48	0.31	Attention deficit hyperactivity disorder;	chr3:39510494	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1768262	ENSG00000188856.6	RPSAP47	7.18	2.69e-12	4.46e-06	0.48	0.31	Attention deficit hyperactivity disorder;	chr3:39511785	chr8:80558870~80559757:+
THCA	trans	rs9648716	1	rs1267641	ENSG00000224775.2	BRAFP1	7.18	2.69e-12	4.47e-06	0.55	0.31	Type 2 diabetes;	chr7:140780263	chrX:75582676~75585506:+
THCA	trans	rs877636	0.692	rs11171739	ENSG00000234192.1	RP11-57C13.5	7.18	2.69e-12	4.47e-06	0.37	0.31	Cognitive function;	chr12:56076841	chr10:87642607~87642954:+
THCA	trans	rs7192380	0.63	rs2965749	ENSG00000257513.6	NPIPB1P	-7.18	2.7e-12	4.48e-06	-0.37	-0.31	Sjögren's syndrome;	chr16:69738011	chr18:11619509~11639699:-
THCA	trans	rs2736345	0.788	rs9693589	ENSG00000253893.2	FAM85B	-7.18	2.7e-12	4.48e-06	-0.46	-0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491452	chr8:8167819~8226614:-
THCA	trans	rs2736345	0.788	rs13277113	ENSG00000253893.2	FAM85B	-7.18	2.7e-12	4.48e-06	-0.46	-0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491677	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs55958994	ENSG00000248568.1	KRT8P48	-7.18	2.7e-12	4.48e-06	-0.65	-0.31	Prostate cancer;	chr12:52907235	chr5:146706381~146707600:-
THCA	trans	rs7662987	1	rs28730587	ENSG00000228407.2	RP4-800M22.1	7.18	2.7e-12	4.48e-06	0.69	0.31	Smoking initiation;	chr4:99083190	chr1:52160261~52160600:-
THCA	trans	rs6743068	0.521	rs1406122	ENSG00000235105.1	RP11-329A14.1	-7.18	2.71e-12	4.49e-06	-0.35	-0.31	Lymphocyte percentage of white cells;	chr2:201346720	chr1:48435967~48437223:+
THCA	trans	rs10242455	0.571	rs12334072	ENSG00000228834.1	RP11-249L21.4	7.18	2.71e-12	4.49e-06	0.59	0.31	Blood metabolite levels;	chr7:99654084	chr6:108907615~108907873:-
THCA	trans	rs1707322	0.785	rs10890348	ENSG00000255397.1	AC022182.2	-7.18	2.71e-12	4.5e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr8:60937705~60939871:-
THCA	trans	rs7260598	0.792	rs11672981	ENSG00000261770.1	CTC-459F4.1	7.18	2.72e-12	4.51e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24144735	chr19:27757184~27760849:-
THCA	trans	rs864643	0.945	rs1707972	ENSG00000183298.5	RP11-556K13.1	7.18	2.73e-12	4.53e-06	0.52	0.31	Attention deficit hyperactivity disorder;	chr3:39507243	chr1:101786340~101787219:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000233278.1	RPS26P2	-7.18	2.74e-12	4.54e-06	-0.36	-0.31	Cognitive function;	chr12:56080024	chr9:30831878~30832225:-
THCA	trans	rs13217239	0.574	rs9366680	ENSG00000242375.1	RP11-498P14.3	7.18	2.74e-12	4.55e-06	0.44	0.31	Schizophrenia;	chr6:27038344	chr9:97195351~97197687:-
THCA	trans	rs11098499	0.908	rs1002152	ENSG00000253326.2	RP11-261C10.7	7.18	2.74e-12	4.55e-06	0.44	0.31	Corneal astigmatism;	chr4:119352232	chr1:243054861~243056394:-
THCA	trans	rs11992162	0.551	rs59191504	ENSG00000256560.1	LINC01486	-7.18	2.75e-12	4.56e-06	-0.39	-0.31	Monocyte count;	chr8:11927572	chr12:109354083~109359488:-
THCA	trans	rs1580019	0.587	rs7806941	ENSG00000176826.14	FKBP9P1	-7.18	2.76e-12	4.57e-06	-0.42	-0.31	Cognitive ability;	chr7:32513707	chr7:55681074~55713252:-
THCA	trans	rs7833986	0.877	rs35399547	ENSG00000244245.1	RP11-120B7.1	7.18	2.76e-12	4.58e-06	0.5	0.31	Height;	chr8:56162914	chr5:108593609~108593967:+
THCA	trans	rs1707322	0.752	rs6678444	ENSG00000255397.1	AC022182.2	-7.18	2.78e-12	4.6e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr8:60937705~60939871:-
THCA	trans	rs66887589	0.776	rs10518337	ENSG00000275858.1	RP11-291L22.8	-7.18	2.8e-12	4.63e-06	-0.37	-0.31	Diastolic blood pressure;	chr4:119653719	chr10:38450738~38451069:-
THCA	trans	rs16937956	0.657	rs35976355	ENSG00000266891.1	RP11-692N5.2	7.18	2.8e-12	4.63e-06	0.42	0.31	Body mass index;	chr11:8407110	chr18:9734882~9735602:-
THCA	trans	rs58106596	0.8	rs11686900	ENSG00000259020.3	RP11-529H20.3	7.18	2.82e-12	4.66e-06	0.5	0.31	Lymphocyte counts;White blood cell count;	chr2:231703982	chr14:92026566~92026887:+
THCA	trans	rs941207	0.756	rs2958153	ENSG00000257210.1	NACAP3	7.18	2.82e-12	4.68e-06	0.42	0.31	Platelet count;	chr12:56687733	chr12:93124063~93124543:-
THCA	trans	rs9650657	0.812	rs11250074	ENSG00000253893.2	FAM85B	7.18	2.83e-12	4.68e-06	0.4	0.31	Neuroticism;	chr8:10774749	chr8:8167819~8226614:-
THCA	trans	rs864643	0.625	rs1707958	ENSG00000188856.6	RPSAP47	7.18	2.83e-12	4.69e-06	0.48	0.31	Attention deficit hyperactivity disorder;	chr3:39481931	chr8:80558870~80559757:+
THCA	trans	rs6424115	0.729	rs561733	ENSG00000228217.1	AL390877.1	-7.17	2.86e-12	4.73e-06	-0.41	-0.31	Immature fraction of reticulocytes;	chr1:23723105	chr1:117778087~117778506:-
THCA	trans	rs6424115	0.76	rs2999566	ENSG00000228217.1	AL390877.1	-7.17	2.86e-12	4.73e-06	-0.41	-0.31	Immature fraction of reticulocytes;	chr1:23724634	chr1:117778087~117778506:-
THCA	trans	rs7260598	0.792	rs17620029	ENSG00000261770.1	CTC-459F4.1	7.17	2.86e-12	4.74e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24171510	chr19:27757184~27760849:-
THCA	trans	rs11098499	0.954	rs878373	ENSG00000253326.2	RP11-261C10.7	7.17	2.87e-12	4.76e-06	0.44	0.31	Corneal astigmatism;	chr4:119316329	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.954	rs10006877	ENSG00000253326.2	RP11-261C10.7	7.17	2.87e-12	4.76e-06	0.44	0.31	Corneal astigmatism;	chr4:119321638	chr1:243054861~243056394:-
THCA	trans	rs9650657	0.613	rs877116	ENSG00000253893.2	FAM85B	7.17	2.89e-12	4.78e-06	0.4	0.31	Neuroticism;	chr8:10855435	chr8:8167819~8226614:-
THCA	trans	rs748404	0.697	rs491804	ENSG00000180867.10	PDIA3P1	-7.17	2.9e-12	4.81e-06	-0.27	-0.31	Lung cancer;	chr15:43268627	chr1:147178113~147179622:+
THCA	trans	rs1707322	0.691	rs61784799	ENSG00000255397.1	AC022182.2	7.17	2.91e-12	4.82e-06	0.44	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr8:60937705~60939871:-
THCA	trans	rs1045902	0.574	rs1474298	ENSG00000236165.1	PRADC1P1	7.17	2.92e-12	4.83e-06	0.44	0.31	Intelligence (multi-trait analysis);	chr2:73239464	chr3:36976316~36976840:+
THCA	trans	rs748404	0.697	rs498227	ENSG00000180867.10	PDIA3P1	-7.17	2.93e-12	4.85e-06	-0.27	-0.31	Lung cancer;	chr15:43280854	chr1:147178113~147179622:+
THCA	trans	rs8073060	0.518	rs225285	ENSG00000234130.2	RP13-88F20.1	-7.17	3e-12	4.96e-06	-0.38	-0.31	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35604065	chrX:93222220~93225015:-
THCA	trans	rs1391708	0.518	rs77947411	ENSG00000121089.4	NACA3P	-7.17	3.01e-12	4.97e-06	-0.74	-0.31	Airway wall thickness;	chr12:56929095	chr4:164943290~164943937:+
THCA	trans	rs7260598	0.792	rs10500223	ENSG00000261770.1	CTC-459F4.1	7.16	3.04e-12	5.02e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24163222	chr19:27757184~27760849:-
THCA	trans	rs282544	0.9	rs10940417	ENSG00000231752.4	EMBP1	-7.16	3.06e-12	5.05e-06	-0.43	-0.31	Myopia (pathological);	chr5:50595417	chr1:121519112~121571892:+
THCA	trans	rs7617480	0.648	rs4858830	ENSG00000197582.5	GPX1P1	7.16	3.06e-12	5.05e-06	0.53	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48696569	chrX:13378735~13379340:-
THCA	trans	rs7617480	0.544	rs6442129	ENSG00000197582.5	GPX1P1	7.16	3.06e-12	5.05e-06	0.53	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48697823	chrX:13378735~13379340:-
THCA	trans	rs7824557	0.767	rs6985146	ENSG00000253893.2	FAM85B	-7.16	3.08e-12	5.08e-06	-0.4	-0.31	Retinal vascular caliber;	chr8:11313212	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.74	rs12676417	ENSG00000253893.2	FAM85B	-7.16	3.08e-12	5.08e-06	-0.4	-0.31	Neuroticism;	chr8:10811124	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.827	rs6694302	ENSG00000255397.1	AC022182.2	-7.16	3.09e-12	5.09e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr8:60937705~60939871:-
THCA	trans	rs3956705	1	rs3956705	ENSG00000176826.14	FKBP9P1	-7.16	3.11e-12	5.12e-06	-0.42	-0.31	Red cell distribution width;	chr7:32913683	chr7:55681074~55713252:-
THCA	trans	rs116095464	1	rs62331562	ENSG00000185986.11	SDHAP3	7.16	3.11e-12	5.13e-06	0.57	0.31	Breast cancer;	chr5:349183	chr5:1572222~1594620:-
THCA	trans	rs11098499	0.954	rs6820115	ENSG00000253326.2	RP11-261C10.7	7.16	3.12e-12	5.14e-06	0.41	0.31	Corneal astigmatism;	chr4:119477027	chr1:243054861~243056394:-
THCA	trans	rs6885307	0.825	rs12522524	ENSG00000231752.4	EMBP1	7.16	3.12e-12	5.14e-06	0.52	0.31	Age at first birth;	chr5:45256984	chr1:121519112~121571892:+
THCA	trans	rs9693857	1	rs9693857	ENSG00000253893.2	FAM85B	7.16	3.12e-12	5.15e-06	0.41	0.31	Systolic blood pressure;	chr8:9409607	chr8:8167819~8226614:-
THCA	trans	rs1039766	0.706	rs72822420	ENSG00000224334.1	AP000357.4	-7.16	3.13e-12	5.16e-06	-0.64	-0.31	Lung adenocarcinoma;Lung cancer;	chr2:65286633	chr22:24686923~24688087:+
THCA	trans	rs748404	0.723	rs512431	ENSG00000180867.10	PDIA3P1	7.16	3.14e-12	5.18e-06	0.27	0.31	Lung cancer;	chr15:43249741	chr1:147178113~147179622:+
THCA	trans	rs10420951	0.617	rs77852139	ENSG00000267533.1	RP11-815J4.7	7.16	3.15e-12	5.19e-06	0.62	0.31	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18495716	chr18:12067173~12068417:-
THCA	trans	rs11098499	0.863	rs1552095	ENSG00000253326.2	RP11-261C10.7	7.16	3.18e-12	5.24e-06	0.45	0.31	Corneal astigmatism;	chr4:119539151	chr1:243054861~243056394:-
THCA	trans	rs9292918	0.806	rs9790873	ENSG00000231752.4	EMBP1	7.16	3.18e-12	5.24e-06	0.52	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45291412	chr1:121519112~121571892:+
THCA	trans	rs748404	0.697	rs1814323	ENSG00000180867.10	PDIA3P1	7.16	3.18e-12	5.25e-06	0.27	0.31	Lung cancer;	chr15:43271039	chr1:147178113~147179622:+
THCA	trans	rs14057	0.86	rs731024	ENSG00000215869.3	RP11-364B6.1	-7.16	3.19e-12	5.26e-06	-0.45	-0.31	Systolic blood pressure;	chr1:6584663	chr1:104073023~104077087:+
THCA	trans	rs7819412	0.669	rs2409743	ENSG00000229857.1	RP11-159H20.3	7.16	3.2e-12	5.27e-06	0.41	0.31	Triglycerides;	chr8:11212851	chr9:76992099~76993108:+
THCA	trans	rs13177918	0.798	rs12516161	ENSG00000226396.1	RP5-1056L3.3	7.16	3.2e-12	5.27e-06	0.32	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:19608114~19608568:+
THCA	trans	rs7973618	1	rs7973618	ENSG00000228224.3	NACAP1	-7.16	3.22e-12	5.31e-06	-0.33	-0.31	Mean platelet volume;	chr12:56625659	chr8:101361794~101372707:+
THCA	trans	rs9650657	0.803	rs13276026	ENSG00000253893.2	FAM85B	7.16	3.23e-12	5.31e-06	0.39	0.31	Neuroticism;	chr8:10752445	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.963	rs4630155	ENSG00000255397.1	AC022182.2	-7.15	3.24e-12	5.33e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs4508055	ENSG00000255397.1	AC022182.2	-7.15	3.24e-12	5.33e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs12076580	ENSG00000255397.1	AC022182.2	-7.15	3.24e-12	5.33e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr8:60937705~60939871:-
THCA	trans	rs864643	0.812	rs12490768	ENSG00000183298.5	RP11-556K13.1	-7.15	3.24e-12	5.34e-06	-0.48	-0.31	Attention deficit hyperactivity disorder;	chr3:39521874	chr1:101786340~101787219:-
THCA	trans	rs1580019	0.587	rs1597555	ENSG00000176826.14	FKBP9P1	-7.15	3.27e-12	5.37e-06	-0.42	-0.31	Cognitive ability;	chr7:32506506	chr7:55681074~55713252:-
THCA	trans	rs2950393	0.509	rs10459247	ENSG00000257210.1	NACAP3	-7.15	3.27e-12	5.38e-06	-0.42	-0.31	Platelet distribution width;	chr12:56777732	chr12:93124063~93124543:-
THCA	trans	rs7617480	0.648	rs6806356	ENSG00000197582.5	GPX1P1	7.15	3.27e-12	5.38e-06	0.53	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48690203	chrX:13378735~13379340:-
THCA	trans	rs6424115	0.729	rs1737362	ENSG00000228217.1	AL390877.1	-7.15	3.29e-12	5.4e-06	-0.41	-0.31	Immature fraction of reticulocytes;	chr1:23728310	chr1:117778087~117778506:-
THCA	trans	rs12709013	1	rs11648514	ENSG00000230849.2	GOT2P2	7.15	3.31e-12	5.44e-06	0.38	0.31	Blood metabolite ratios;	chr16:58798176	chr1:173141100~173142350:-
THCA	trans	rs12709013	1	rs8057892	ENSG00000230849.2	GOT2P2	7.15	3.31e-12	5.44e-06	0.38	0.31	Blood metabolite ratios;	chr16:58798855	chr1:173141100~173142350:-
THCA	trans	rs12709013	1	rs11644891	ENSG00000230849.2	GOT2P2	7.15	3.31e-12	5.44e-06	0.38	0.31	Blood metabolite ratios;	chr16:58799921	chr1:173141100~173142350:-
THCA	trans	rs12709013	1	rs11641566	ENSG00000230849.2	GOT2P2	7.15	3.31e-12	5.44e-06	0.38	0.31	Blood metabolite ratios;	chr16:58801276	chr1:173141100~173142350:-
THCA	trans	rs7260598	0.685	rs73524177	ENSG00000261770.1	CTC-459F4.1	7.15	3.32e-12	5.46e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24156376	chr19:27757184~27760849:-
THCA	trans	rs12709013	0.967	rs56107162	ENSG00000230849.2	GOT2P2	7.15	3.33e-12	5.47e-06	0.38	0.31	Blood metabolite ratios;	chr16:58804358	chr1:173141100~173142350:-
THCA	trans	rs1347297	0.614	rs4894017	ENSG00000269800.1	PLEKHA3P1	7.15	3.33e-12	5.48e-06	0.33	0.31	Alzheimer disease and age of onset;	chr2:178416335	chr19:41521043~41521989:-
THCA	trans	rs76228276	0.737	rs4734436	ENSG00000260318.1	COX6CP1	7.15	3.35e-12	5.5e-06	0.95	0.31	Childhood ear infection;	chr8:99729139	chr16:11903923~11904137:-
THCA	trans	rs1347297	0.774	rs9973732	ENSG00000269800.1	PLEKHA3P1	7.15	3.39e-12	5.58e-06	0.34	0.31	Alzheimer disease and age of onset;	chr2:178416708	chr19:41521043~41521989:-
THCA	trans	rs7819412	0.74	rs28633434	ENSG00000229857.1	RP11-159H20.3	7.15	3.4e-12	5.59e-06	0.4	0.31	Triglycerides;	chr8:11196413	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.618	rs10105377	ENSG00000229857.1	RP11-159H20.3	7.15	3.41e-12	5.6e-06	0.41	0.31	Triglycerides;	chr8:11118223	chr9:76992099~76993108:+
THCA	trans	rs7833986	0.501	rs72653941	ENSG00000236862.1	RPS20P24	7.15	3.42e-12	5.62e-06	0.45	0.31	Height;	chr8:56029688	chr9:72655832~72656192:-
THCA	trans	rs902774	0.759	rs4919707	ENSG00000255815.3	KRT8P11	-7.15	3.42e-12	5.62e-06	-0.67	-0.31	Prostate cancer;	chr12:52895864	chr9:99305176~99306611:+
THCA	trans	rs902774	0.818	rs56095813	ENSG00000255815.3	KRT8P11	-7.15	3.42e-12	5.62e-06	-0.67	-0.31	Prostate cancer;	chr12:52900963	chr9:99305176~99306611:+
THCA	trans	rs1707322	0.826	rs10890349	ENSG00000255397.1	AC022182.2	-7.15	3.44e-12	5.64e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.758	rs10789474	ENSG00000255397.1	AC022182.2	-7.15	3.44e-12	5.64e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.908	rs2017057	ENSG00000253326.2	RP11-261C10.7	7.15	3.44e-12	5.65e-06	0.44	0.31	Corneal astigmatism;	chr4:119336556	chr1:243054861~243056394:-
THCA	trans	rs9650657	0.74	rs10481451	ENSG00000253893.2	FAM85B	7.15	3.44e-12	5.65e-06	0.4	0.31	Neuroticism;	chr8:10791818	chr8:8167819~8226614:-
THCA	trans	rs7617480	0.617	rs7610519	ENSG00000197582.5	GPX1P1	7.15	3.45e-12	5.66e-06	0.54	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48708994	chrX:13378735~13379340:-
THCA	trans	rs864643	0.773	rs2280082	ENSG00000183298.5	RP11-556K13.1	-7.14	3.49e-12	5.73e-06	-0.48	-0.31	Attention deficit hyperactivity disorder;	chr3:39528519	chr1:101786340~101787219:-
THCA	trans	rs7260598	0.792	rs73021461	ENSG00000261770.1	CTC-459F4.1	7.14	3.5e-12	5.75e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24140154	chr19:27757184~27760849:-
THCA	trans	rs11098499	0.954	rs12505469	ENSG00000253326.2	RP11-261C10.7	7.14	3.53e-12	5.8e-06	0.44	0.31	Corneal astigmatism;	chr4:119328430	chr1:243054861~243056394:-
THCA	trans	rs7260598	0.792	rs73029291	ENSG00000261770.1	CTC-459F4.1	7.14	3.54e-12	5.8e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24171866	chr19:27757184~27760849:-
THCA	trans	rs11098499	0.863	rs17050695	ENSG00000253326.2	RP11-261C10.7	7.14	3.55e-12	5.83e-06	0.43	0.31	Corneal astigmatism;	chr4:119568372	chr1:243054861~243056394:-
THCA	trans	rs6600671	1	rs12047116	ENSG00000270392.2	PFN1P2	7.14	3.56e-12	5.84e-06	0.3	0.31	Hip geometry;	chr1:121443912	chr1:120432204~120434052:-
THCA	trans	rs6600671	0.967	rs11249347	ENSG00000270392.2	PFN1P2	7.14	3.56e-12	5.84e-06	0.3	0.31	Hip geometry;	chr1:121446489	chr1:120432204~120434052:-
THCA	trans	rs6885307	0.825	rs62369913	ENSG00000231752.4	EMBP1	7.14	3.61e-12	5.92e-06	0.51	0.31	Age at first birth;	chr5:45112251	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs73106451	ENSG00000224520.2	KRT8P45	-7.14	3.62e-12	5.94e-06	-0.63	-0.31	Prostate cancer;	chr12:52872955	chr1:157073257~157074703:+
THCA	trans	rs748404	0.697	rs567357	ENSG00000180867.10	PDIA3P1	-7.14	3.62e-12	5.94e-06	-0.27	-0.31	Lung cancer;	chr15:43279192	chr1:147178113~147179622:+
THCA	trans	rs2645424	1	rs962366	ENSG00000256560.1	LINC01486	7.14	3.62e-12	5.94e-06	0.38	0.31	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826894	chr12:109354083~109359488:-
THCA	trans	rs3740713	1	rs75487138	ENSG00000214110.3	LDHAP4	7.14	3.64e-12	5.96e-06	0.56	0.31	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr9:14921337~14922334:-
THCA	trans	rs941207	0.526	rs2950387	ENSG00000228224.3	NACAP1	-7.14	3.65e-12	5.99e-06	-0.33	-0.31	Platelet count;	chr12:56627222	chr8:101361794~101372707:+
THCA	trans	rs902774	0.818	rs4919737	ENSG00000255815.3	KRT8P11	-7.14	3.66e-12	6e-06	-0.66	-0.31	Prostate cancer;	chr12:52877011	chr9:99305176~99306611:+
THCA	trans	rs902774	0.818	rs73108429	ENSG00000255815.3	KRT8P11	-7.14	3.66e-12	6e-06	-0.66	-0.31	Prostate cancer;	chr12:52877887	chr9:99305176~99306611:+
THCA	trans	rs748404	0.697	rs530683	ENSG00000180867.10	PDIA3P1	7.14	3.67e-12	6.01e-06	0.27	0.31	Lung cancer;	chr15:43276801	chr1:147178113~147179622:+
THCA	trans	rs11992162	0.529	rs6995037	ENSG00000253893.2	FAM85B	7.14	3.67e-12	6.02e-06	0.43	0.31	Monocyte count;	chr8:11923378	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.721	rs6699418	ENSG00000255397.1	AC022182.2	-7.13	3.69e-12	6.05e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs4431884	ENSG00000255397.1	AC022182.2	-7.13	3.69e-12	6.05e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.65	rs4660879	ENSG00000255397.1	AC022182.2	-7.13	3.69e-12	6.05e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs10789468	ENSG00000255397.1	AC022182.2	-7.13	3.69e-12	6.05e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs6429574	ENSG00000255397.1	AC022182.2	-7.13	3.69e-12	6.05e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr8:60937705~60939871:-
THCA	trans	rs11638815	0.626	rs1313492	ENSG00000235370.6	DNM1P51	-7.13	3.7e-12	6.07e-06	-0.4	-0.31	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82604206	chr15:84398316~84411701:-
THCA	trans	rs7819412	0.669	rs2409743	ENSG00000256560.1	LINC01486	-7.13	3.7e-12	6.07e-06	-0.39	-0.31	Triglycerides;	chr8:11212851	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.825	rs12522910	ENSG00000231752.4	EMBP1	7.13	3.73e-12	6.11e-06	0.51	0.31	Age at first birth;	chr5:45259261	chr1:121519112~121571892:+
THCA	trans	rs58106596	0.8	rs11675826	ENSG00000259020.3	RP11-529H20.3	7.13	3.82e-12	6.25e-06	0.48	0.31	Lymphocyte counts;White blood cell count;	chr2:231700797	chr14:92026566~92026887:+
THCA	trans	rs7833986	0.501	rs2719261	ENSG00000236862.1	RPS20P24	7.13	3.83e-12	6.27e-06	0.45	0.31	Height;	chr8:56029423	chr9:72655832~72656192:-
THCA	trans	rs9650657	0.775	rs10100265	ENSG00000253893.2	FAM85B	7.13	3.86e-12	6.32e-06	0.4	0.31	Neuroticism;	chr8:10775649	chr8:8167819~8226614:-
THCA	trans	rs7260598	0.685	rs73021420	ENSG00000261770.1	CTC-459F4.1	7.13	3.86e-12	6.32e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24082833	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs11671960	ENSG00000261770.1	CTC-459F4.1	7.13	3.87e-12	6.33e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24135019	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs59756985	ENSG00000261770.1	CTC-459F4.1	7.13	3.87e-12	6.33e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24141664	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs73021467	ENSG00000261770.1	CTC-459F4.1	7.13	3.87e-12	6.33e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24142863	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs4019979	ENSG00000261770.1	CTC-459F4.1	7.13	3.87e-12	6.33e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24143881	chr19:27757184~27760849:-
THCA	trans	rs561341	0.689	rs578635	ENSG00000263531.1	RP13-753N3.1	7.13	3.88e-12	6.34e-06	0.47	0.31	Hip circumference adjusted for BMI;	chr17:31962878	chr17:30863921~30864940:-
THCA	trans	rs748404	0.697	rs473554	ENSG00000180867.10	PDIA3P1	-7.13	3.89e-12	6.35e-06	-0.27	-0.31	Lung cancer;	chr15:43276009	chr1:147178113~147179622:+
THCA	trans	rs7819412	0.635	rs4841501	ENSG00000253893.2	FAM85B	7.13	3.9e-12	6.38e-06	0.43	0.31	Triglycerides;	chr8:11143466	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.825	rs12153053	ENSG00000231752.4	EMBP1	7.13	3.93e-12	6.42e-06	0.52	0.31	Age at first birth;	chr5:45108386	chr1:121519112~121571892:+
THCA	trans	rs1707322	0.721	rs7519900	ENSG00000255397.1	AC022182.2	-7.13	3.93e-12	6.43e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr8:60937705~60939871:-
THCA	trans	rs7647973	0.577	rs6446247	ENSG00000197582.5	GPX1P1	7.13	3.93e-12	6.43e-06	0.52	0.31	Menarche (age at onset);	chr3:49064568	chrX:13378735~13379340:-
THCA	trans	rs6915893	0.74	rs9477622	ENSG00000267156.1	TPMTP1	-7.12	3.95e-12	6.45e-06	-0.32	-0.31	Intrinsic epigenetic age acceleration;	chr6:18103430	chr18:47630112~47630848:+
THCA	trans	rs7819412	0.775	rs34094119	ENSG00000229857.1	RP11-159H20.3	7.12	3.96e-12	6.48e-06	0.39	0.31	Triglycerides;	chr8:11078388	chr9:76992099~76993108:+
THCA	trans	rs11638815	0.626	rs4779039	ENSG00000235370.6	DNM1P51	7.12	3.98e-12	6.5e-06	0.4	0.31	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82649016	chr15:84398316~84411701:-
THCA	trans	rs748404	0.697	rs546170	ENSG00000180867.10	PDIA3P1	-7.12	3.99e-12	6.52e-06	-0.27	-0.31	Lung cancer;	chr15:43272651	chr1:147178113~147179622:+
THCA	trans	rs12709013	1	rs11641836	ENSG00000230849.2	GOT2P2	7.12	4e-12	6.54e-06	0.38	0.31	Blood metabolite ratios;	chr16:58798143	chr1:173141100~173142350:-
THCA	trans	rs2898290	0.622	rs1478890	ENSG00000256560.1	LINC01486	-7.12	4.02e-12	6.56e-06	-0.39	-0.31	Systolic blood pressure;	chr8:11498093	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.737	rs4551304	ENSG00000253893.2	FAM85B	7.12	4.02e-12	6.57e-06	0.4	0.31	Neuroticism;	chr8:10807559	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.771	rs4240670	ENSG00000253893.2	FAM85B	7.12	4.02e-12	6.57e-06	0.4	0.31	Neuroticism;	chr8:10808338	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.683	rs555200	ENSG00000253893.2	FAM85B	7.12	4.04e-12	6.59e-06	0.4	0.31	Neuroticism;	chr8:10031219	chr8:8167819~8226614:-
THCA	trans	rs616147	0.548	rs2370965	ENSG00000243904.1	RP11-600F24.1	-7.12	4.09e-12	6.68e-06	-0.38	-0.31	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr14:103374033~103374916:-
THCA	trans	rs864643	0.947	rs6762335	ENSG00000188856.6	RPSAP47	7.12	4.1e-12	6.69e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39496043	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.863	rs3822190	ENSG00000253326.2	RP11-261C10.7	7.12	4.11e-12	6.7e-06	0.45	0.31	Corneal astigmatism;	chr4:119506943	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.863	rs3822191	ENSG00000253326.2	RP11-261C10.7	7.12	4.11e-12	6.7e-06	0.45	0.31	Corneal astigmatism;	chr4:119506946	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.707	rs3808519	ENSG00000253893.2	FAM85B	-7.12	4.12e-12	6.72e-06	-0.4	-0.31	Retinal vascular caliber;	chr8:11285461	chr8:8167819~8226614:-
THCA	trans	rs12709013	0.935	rs8046667	ENSG00000230849.2	GOT2P2	7.12	4.16e-12	6.78e-06	0.38	0.31	Blood metabolite ratios;	chr16:58790935	chr1:173141100~173142350:-
THCA	trans	rs12709013	1	rs8046998	ENSG00000230849.2	GOT2P2	7.12	4.16e-12	6.78e-06	0.38	0.31	Blood metabolite ratios;	chr16:58791109	chr1:173141100~173142350:-
THCA	trans	rs7647973	0.566	rs57630346	ENSG00000197582.5	GPX1P1	7.11	4.21e-12	6.86e-06	0.52	0.31	Menarche (age at onset);	chr3:49048782	chrX:13378735~13379340:-
THCA	trans	rs6940638	0.513	rs4424065	ENSG00000242375.1	RP11-498P14.3	-7.11	4.22e-12	6.89e-06	-0.44	-0.31	Intelligence (multi-trait analysis);	chr6:27068677	chr9:97195351~97197687:-
THCA	trans	rs1991651	0.578	rs11778453	ENSG00000253893.2	FAM85B	7.11	4.24e-12	6.91e-06	0.39	0.31	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632326	chr8:8167819~8226614:-
THCA	trans	rs1580019	0.587	rs7805311	ENSG00000176826.14	FKBP9P1	7.11	4.24e-12	6.92e-06	0.41	0.31	Cognitive ability;	chr7:32518690	chr7:55681074~55713252:-
THCA	trans	rs3740713	1	rs73440614	ENSG00000214110.3	LDHAP4	7.11	4.25e-12	6.93e-06	0.56	0.31	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr9:14921337~14922334:-
THCA	trans	rs7829975	0.606	rs10112585	ENSG00000229857.1	RP11-159H20.3	7.11	4.26e-12	6.94e-06	0.38	0.31	Mood instability;	chr8:8937520	chr9:76992099~76993108:+
THCA	trans	rs864643	0.738	rs1398664	ENSG00000183298.5	RP11-556K13.1	-7.11	4.26e-12	6.94e-06	-0.48	-0.31	Attention deficit hyperactivity disorder;	chr3:39534259	chr1:101786340~101787219:-
THCA	trans	rs7260598	0.792	rs73021416	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24081849	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.685	rs73021422	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24082919	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.685	rs73021424	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24090897	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.685	rs11667970	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24094893	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.581	rs73021432	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24101827	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.685	rs11671000	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24110025	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs11672468	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24119770	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs73021445	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24121306	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs7252836	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24122787	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs61737180	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24127230	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.792	rs73021454	ENSG00000261770.1	CTC-459F4.1	7.11	4.26e-12	6.95e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24133074	chr19:27757184~27760849:-
THCA	trans	rs1707322	1	rs6672115	ENSG00000255397.1	AC022182.2	-7.11	4.28e-12	6.98e-06	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr8:60937705~60939871:-
THCA	trans	rs877636	0.669	rs7297175	ENSG00000242206.2	RPS26P35	-7.11	4.29e-12	6.99e-06	-0.35	-0.31	Cognitive function;	chr12:56080024	chr8:118761856~118762201:-
THCA	trans	rs9292918	0.806	rs10060015	ENSG00000231752.4	EMBP1	-7.11	4.32e-12	7.03e-06	-0.51	-0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45339141	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs73108469	ENSG00000248568.1	KRT8P48	-7.11	4.32e-12	7.03e-06	-0.65	-0.31	Prostate cancer;	chr12:52891065	chr5:146706381~146707600:-
THCA	trans	rs902774	0.818	rs4919763	ENSG00000255815.3	KRT8P11	-7.11	4.33e-12	7.05e-06	-0.66	-0.31	Prostate cancer;	chr12:52885839	chr9:99305176~99306611:+
THCA	trans	rs902774	0.818	rs55914512	ENSG00000255815.3	KRT8P11	-7.11	4.33e-12	7.05e-06	-0.66	-0.31	Prostate cancer;	chr12:52888490	chr9:99305176~99306611:+
THCA	trans	rs902774	0.818	rs73108466	ENSG00000255815.3	KRT8P11	-7.11	4.33e-12	7.05e-06	-0.66	-0.31	Prostate cancer;	chr12:52889857	chr9:99305176~99306611:+
THCA	trans	rs902774	0.818	rs55999178	ENSG00000255815.3	KRT8P11	-7.11	4.33e-12	7.05e-06	-0.66	-0.31	Prostate cancer;	chr12:52890576	chr9:99305176~99306611:+
THCA	trans	rs3806843	0.518	rs2569191	ENSG00000231043.3	AC007238.1	7.11	4.33e-12	7.05e-06	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140634318	chr2:58460292~58462032:-
THCA	trans	rs11992162	0.597	rs7011924	ENSG00000253893.2	FAM85B	7.11	4.35e-12	7.08e-06	0.42	0.31	Monocyte count;	chr8:11923084	chr8:8167819~8226614:-
THCA	trans	rs864643	0.947	rs587054	ENSG00000188856.6	RPSAP47	7.11	4.35e-12	7.08e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39524496	chr8:80558870~80559757:+
THCA	trans	rs12709013	0.935	rs11648634	ENSG00000230849.2	GOT2P2	7.11	4.36e-12	7.1e-06	0.38	0.31	Blood metabolite ratios;	chr16:58785256	chr1:173141100~173142350:-
THCA	trans	rs12709013	1	rs34319345	ENSG00000230849.2	GOT2P2	7.11	4.36e-12	7.1e-06	0.38	0.31	Blood metabolite ratios;	chr16:58786688	chr1:173141100~173142350:-
THCA	trans	rs3740713	1	rs60376560	ENSG00000214110.3	LDHAP4	7.11	4.39e-12	7.14e-06	0.56	0.31	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr9:14921337~14922334:-
THCA	trans	rs7819412	0.668	rs2409715	ENSG00000253893.2	FAM85B	7.11	4.39e-12	7.14e-06	0.42	0.31	Triglycerides;	chr8:11152626	chr8:8167819~8226614:-
THCA	trans	rs2645424	0.519	rs17154027	ENSG00000260438.1	RP11-405F3.2	-7.11	4.4e-12	7.16e-06	-0.44	-0.31	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856343	chr16:57713782~57714957:+
THCA	trans	rs902774	0.818	rs4919740	ENSG00000230716.3	KRT8P7	-7.11	4.43e-12	7.21e-06	-0.6	-0.31	Prostate cancer;	chr12:52877187	chr11:119602875~119604306:-
THCA	trans	rs7617480	0.648	rs9848268	ENSG00000197582.5	GPX1P1	7.11	4.44e-12	7.23e-06	0.56	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48724838	chrX:13378735~13379340:-
THCA	trans	rs864643	0.836	rs1708009	ENSG00000183298.5	RP11-556K13.1	7.11	4.47e-12	7.26e-06	0.49	0.31	Attention deficit hyperactivity disorder;	chr3:39496851	chr1:101786340~101787219:-
THCA	trans	rs10242455	1	rs4646457	ENSG00000228834.1	RP11-249L21.4	7.11	4.48e-12	7.29e-06	0.58	0.31	Blood metabolite levels;	chr7:99647457	chr6:108907615~108907873:-
THCA	trans	rs7824557	0.707	rs3808518	ENSG00000253893.2	FAM85B	7.1	4.51e-12	7.33e-06	0.4	0.31	Retinal vascular caliber;	chr8:11285763	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.521	rs11777887	ENSG00000253893.2	FAM85B	-7.1	4.51e-12	7.33e-06	-0.43	-0.31	Triglycerides;	chr8:11179290	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs73440637	ENSG00000214110.3	LDHAP4	7.1	4.53e-12	7.36e-06	0.56	0.31	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr9:14921337~14922334:-
THCA	trans	rs7819412	0.56	rs3021497	ENSG00000253893.2	FAM85B	7.1	4.54e-12	7.37e-06	0.44	0.31	Triglycerides;	chr8:11138579	chr8:8167819~8226614:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000244604.1	RP11-713H12.1	-7.1	4.54e-12	7.38e-06	-0.41	-0.31	Cognitive function;	chr12:55996852	chr17:8561230~8561576:+
THCA	trans	rs1347297	0.789	rs7589565	ENSG00000269800.1	PLEKHA3P1	7.1	4.55e-12	7.4e-06	0.33	0.31	Alzheimer disease and age of onset;	chr2:178417610	chr19:41521043~41521989:-
THCA	trans	rs6964833	1	rs17515241	ENSG00000214544.6	GTF2IRD2P1	7.1	4.57e-12	7.42e-06	0.45	0.31	Menarche (age at onset);	chr7:74717695	chr7:73242751~73280119:-
THCA	trans	rs11098499	0.909	rs1546504	ENSG00000253326.2	RP11-261C10.7	7.1	4.58e-12	7.44e-06	0.44	0.31	Corneal astigmatism;	chr4:119320024	chr1:243054861~243056394:-
THCA	trans	rs7819412	0.765	rs7000132	ENSG00000229857.1	RP11-159H20.3	7.1	4.58e-12	7.45e-06	0.41	0.31	Triglycerides;	chr8:11173426	chr9:76992099~76993108:+
THCA	trans	rs6885307	0.825	rs62369912	ENSG00000231752.4	EMBP1	7.1	4.6e-12	7.47e-06	0.51	0.31	Age at first birth;	chr5:45112091	chr1:121519112~121571892:+
THCA	trans	rs1707322	0.827	rs12125508	ENSG00000255397.1	AC022182.2	-7.1	4.6e-12	7.48e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr8:60937705~60939871:-
THCA	trans	rs453301	0.598	rs1025395	ENSG00000229857.1	RP11-159H20.3	-7.1	4.61e-12	7.48e-06	-0.37	-0.31	Joint mobility (Beighton score);	chr8:8979093	chr9:76992099~76993108:+
THCA	trans	rs1707322	0.721	rs12069121	ENSG00000255397.1	AC022182.2	-7.1	4.61e-12	7.49e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr8:60937705~60939871:-
THCA	trans	rs864643	0.812	rs1513218	ENSG00000188856.6	RPSAP47	7.1	4.63e-12	7.52e-06	0.44	0.31	Attention deficit hyperactivity disorder;	chr3:39504097	chr8:80558870~80559757:+
THCA	trans	rs2950393	0.777	rs7966391	ENSG00000228224.3	NACAP1	7.1	4.63e-12	7.53e-06	0.31	0.31	Platelet distribution width;	chr12:56745272	chr8:101361794~101372707:+
THCA	trans	rs10420951	0.617	rs113465793	ENSG00000267533.1	RP11-815J4.7	7.1	4.65e-12	7.55e-06	0.6	0.31	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18445607	chr18:12067173~12068417:-
THCA	trans	rs7833986	0.501	rs72653951	ENSG00000236862.1	RPS20P24	7.1	4.65e-12	7.55e-06	0.45	0.31	Height;	chr8:56049278	chr9:72655832~72656192:-
THCA	trans	rs7032940	0.626	rs4314718	ENSG00000228236.2	TXNP5	7.1	4.66e-12	7.56e-06	0.37	0.31	Height;	chr9:110211368	chr2:149068596~149068910:-
THCA	trans	rs76228276	0.737	rs4734437	ENSG00000260318.1	COX6CP1	7.1	4.7e-12	7.63e-06	0.94	0.31	Childhood ear infection;	chr8:99735195	chr16:11903923~11904137:-
THCA	trans	rs1707322	0.752	rs7541962	ENSG00000255397.1	AC022182.2	-7.1	4.71e-12	7.65e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr8:60937705~60939871:-
THCA	trans	rs6915893	0.74	rs12189652	ENSG00000267156.1	TPMTP1	7.1	4.73e-12	7.68e-06	0.32	0.31	Intrinsic epigenetic age acceleration;	chr6:18103080	chr18:47630112~47630848:+
THCA	trans	rs864643	1	rs602527	ENSG00000188856.6	RPSAP47	7.1	4.73e-12	7.68e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39527293	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs816520	ENSG00000188856.6	RPSAP47	7.1	4.73e-12	7.68e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39528222	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs866537	ENSG00000188856.6	RPSAP47	7.1	4.73e-12	7.68e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39530125	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.863	rs2306457	ENSG00000253326.2	RP11-261C10.7	7.1	4.74e-12	7.69e-06	0.45	0.31	Corneal astigmatism;	chr4:119551684	chr1:243054861~243056394:-
THCA	trans	rs116095464	1	rs6555160	ENSG00000185986.11	SDHAP3	-7.1	4.75e-12	7.71e-06	-0.44	-0.31	Breast cancer;	chr5:311554	chr5:1572222~1594620:-
THCA	trans	rs1580019	0.587	rs2392069	ENSG00000176826.14	FKBP9P1	-7.1	4.76e-12	7.72e-06	-0.41	-0.31	Cognitive ability;	chr7:32507542	chr7:55681074~55713252:-
THCA	trans	rs1580019	0.587	rs34488151	ENSG00000176826.14	FKBP9P1	-7.1	4.76e-12	7.72e-06	-0.41	-0.31	Cognitive ability;	chr7:32508534	chr7:55681074~55713252:-
THCA	trans	rs7833986	0.501	rs72653948	ENSG00000236862.1	RPS20P24	7.1	4.78e-12	7.75e-06	0.45	0.31	Height;	chr8:56043130	chr9:72655832~72656192:-
THCA	trans	rs804280	0.703	rs745379	ENSG00000256560.1	LINC01486	-7.09	4.83e-12	7.83e-06	-0.38	-0.31	Myopia (pathological);	chr8:11758186	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.669	rs6601568	ENSG00000229857.1	RP11-159H20.3	7.09	4.84e-12	7.85e-06	0.41	0.31	Triglycerides;	chr8:11215893	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.634	rs4841485	ENSG00000229857.1	RP11-159H20.3	-7.09	4.85e-12	7.86e-06	-0.39	-0.31	Triglycerides;	chr8:11052426	chr9:76992099~76993108:+
THCA	trans	rs877636	0.702	rs773109	ENSG00000224553.1	AC008065.1	7.09	4.85e-12	7.86e-06	0.39	0.31	Cognitive function;	chr12:55980911	chr2:171374931~171375278:-
THCA	trans	rs902774	0.759	rs4919707	ENSG00000248568.1	KRT8P48	-7.09	4.87e-12	7.9e-06	-0.66	-0.31	Prostate cancer;	chr12:52895864	chr5:146706381~146707600:-
THCA	trans	rs902774	0.818	rs56095813	ENSG00000248568.1	KRT8P48	-7.09	4.87e-12	7.9e-06	-0.66	-0.31	Prostate cancer;	chr12:52900963	chr5:146706381~146707600:-
THCA	trans	rs4720118	0.875	rs3779239	ENSG00000213492.2	NT5C3AP1	7.09	4.88e-12	7.92e-06	0.39	0.31	Leprosy;	chr7:33390659	chr4:117574512~117576174:-
THCA	trans	rs2645424	0.55	rs12338	ENSG00000260438.1	RP11-405F3.2	7.09	4.91e-12	7.96e-06	0.42	0.31	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853379	chr16:57713782~57714957:+
THCA	trans	rs616147	0.627	rs816510	ENSG00000243904.1	RP11-600F24.1	-7.09	4.92e-12	7.98e-06	-0.37	-0.31	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr14:103374033~103374916:-
THCA	trans	rs7647973	0.807	rs4955416	ENSG00000197582.5	GPX1P1	7.09	4.94e-12	8.01e-06	0.52	0.31	Menarche (age at onset);	chr3:49070995	chrX:13378735~13379340:-
THCA	trans	rs864643	0.947	rs1708015	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39496891	chr8:80558870~80559757:+
THCA	trans	rs864643	0.891	rs1708018	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39496978	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs535220	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39497234	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs538214	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39497603	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs614359	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39498035	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs1768237	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39498712	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs482495	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39498924	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs645403	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39498968	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs645457	ENSG00000188856.6	RPSAP47	7.09	4.96e-12	8.04e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39499006	chr8:80558870~80559757:+
THCA	trans	rs864643	0.678	rs617068	ENSG00000183298.5	RP11-556K13.1	-7.09	4.98e-12	8.07e-06	-0.51	-0.31	Attention deficit hyperactivity disorder;	chr3:39492781	chr1:101786340~101787219:-
THCA	trans	rs864643	0.773	rs13064980	ENSG00000188856.6	RPSAP47	-7.09	4.99e-12	8.08e-06	-0.44	-0.31	Attention deficit hyperactivity disorder;	chr3:39503973	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.866	rs7665125	ENSG00000253326.2	RP11-261C10.7	7.09	4.99e-12	8.09e-06	0.41	0.31	Corneal astigmatism;	chr4:119480924	chr1:243054861~243056394:-
THCA	trans	rs3808502	0.503	rs2061830	ENSG00000229857.1	RP11-159H20.3	-7.09	5.01e-12	8.11e-06	-0.4	-0.31	Neuroticism;	chr8:11539948	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.711	rs35091929	ENSG00000253893.2	FAM85B	7.09	5.02e-12	8.14e-06	0.4	0.31	Neuroticism;	chr8:10835982	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.789	rs10789473	ENSG00000255397.1	AC022182.2	-7.09	5.03e-12	8.15e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr8:60937705~60939871:-
THCA	trans	rs864643	0.659	rs1398663	ENSG00000183298.5	RP11-556K13.1	-7.09	5.05e-12	8.18e-06	-0.47	-0.31	Attention deficit hyperactivity disorder;	chr3:39534874	chr1:101786340~101787219:-
THCA	trans	rs6885307	0.882	rs12516998	ENSG00000231752.4	EMBP1	7.09	5.06e-12	8.19e-06	0.49	0.31	Age at first birth;	chr5:45169909	chr1:121519112~121571892:+
THCA	trans	rs6087990	0.899	rs6087999	ENSG00000253915.1	MAPRE1P1	7.09	5.07e-12	8.21e-06	0.4	0.31	Ulcerative colitis;	chr20:32775968	chr8:135625185~135625981:-
THCA	trans	rs7833986	0.501	rs2719258	ENSG00000236862.1	RPS20P24	7.09	5.08e-12	8.23e-06	0.44	0.31	Height;	chr8:56028830	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2719259	ENSG00000236862.1	RPS20P24	7.09	5.08e-12	8.23e-06	0.44	0.31	Height;	chr8:56029071	chr9:72655832~72656192:-
THCA	trans	rs7819412	0.775	rs4841489	ENSG00000229857.1	RP11-159H20.3	7.09	5.09e-12	8.25e-06	0.39	0.31	Triglycerides;	chr8:11079301	chr9:76992099~76993108:+
THCA	trans	rs864643	0.524	rs9822783	ENSG00000183298.5	RP11-556K13.1	7.08	5.13e-12	8.3e-06	0.62	0.31	Attention deficit hyperactivity disorder;	chr3:39463311	chr1:101786340~101787219:-
THCA	trans	rs6885307	0.825	rs12153189	ENSG00000231752.4	EMBP1	7.08	5.15e-12	8.34e-06	0.51	0.31	Age at first birth;	chr5:45109859	chr1:121519112~121571892:+
THCA	trans	rs4263408	0.934	rs4975036	ENSG00000237550.5	UBE2Q2P6	7.08	5.15e-12	8.34e-06	0.37	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39713470	chr15:82372196~82372912:-
THCA	trans	rs116095464	1	rs3777237	ENSG00000185986.11	SDHAP3	7.08	5.16e-12	8.35e-06	0.57	0.31	Breast cancer;	chr5:307526	chr5:1572222~1594620:-
THCA	trans	rs7824557	0.734	rs2293856	ENSG00000253893.2	FAM85B	-7.08	5.19e-12	8.4e-06	-0.41	-0.31	Retinal vascular caliber;	chr8:11319938	chr8:8167819~8226614:-
THCA	trans	rs7617480	0.558	rs12715430	ENSG00000197582.5	GPX1P1	7.08	5.19e-12	8.4e-06	0.52	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48905422	chrX:13378735~13379340:-
THCA	trans	rs76228276	0.737	rs11996944	ENSG00000260318.1	COX6CP1	7.08	5.2e-12	8.41e-06	0.91	0.31	Childhood ear infection;	chr8:99155787	chr16:11903923~11904137:-
THCA	trans	rs2950393	0.804	rs1131514	ENSG00000228224.3	NACAP1	-7.08	5.21e-12	8.43e-06	-0.32	-0.31	Platelet distribution width;	chr12:56739356	chr8:101361794~101372707:+
THCA	trans	rs2645424	0.55	rs28577034	ENSG00000260438.1	RP11-405F3.2	7.08	5.22e-12	8.43e-06	0.43	0.31	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851206	chr16:57713782~57714957:+
THCA	trans	rs9650657	0.801	rs4841437	ENSG00000253893.2	FAM85B	7.08	5.24e-12	8.47e-06	0.39	0.31	Neuroticism;	chr8:10739285	chr8:8167819~8226614:-
THCA	trans	rs7662987	1	rs17595424	ENSG00000228407.2	RP4-800M22.1	7.08	5.27e-12	8.52e-06	0.67	0.31	Smoking initiation;	chr4:99072718	chr1:52160261~52160600:-
THCA	trans	rs12614435	0.512	rs36113194	ENSG00000269800.1	PLEKHA3P1	7.08	5.28e-12	8.54e-06	0.37	0.31	Atrial fibrillation;	chr2:178626058	chr19:41521043~41521989:-
THCA	trans	rs13014235	0.934	rs10202963	ENSG00000235105.1	RP11-329A14.1	7.08	5.29e-12	8.55e-06	0.35	0.31	Basal cell carcinoma;	chr2:201377184	chr1:48435967~48437223:+
THCA	trans	rs864643	0.891	rs55780606	ENSG00000188856.6	RPSAP47	7.08	5.29e-12	8.55e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39496599	chr8:80558870~80559757:+
THCA	trans	rs76228276	0.737	rs7841162	ENSG00000260318.1	COX6CP1	7.08	5.31e-12	8.58e-06	0.92	0.31	Childhood ear infection;	chr8:99895567	chr16:11903923~11904137:-
THCA	trans	rs7829975	0.688	rs13270194	ENSG00000256560.1	LINC01486	7.08	5.31e-12	8.58e-06	0.37	0.31	Mood instability;	chr8:8520592	chr12:109354083~109359488:-
THCA	trans	rs740160	0.558	rs17161662	ENSG00000228834.1	RP11-249L21.4	7.08	5.32e-12	8.59e-06	0.66	0.31	Dehydroepiandrosterone sulphate levels;	chr7:99309773	chr6:108907615~108907873:-
THCA	trans	rs11992162	0.636	rs11250182	ENSG00000256560.1	LINC01486	-7.08	5.33e-12	8.61e-06	-0.39	-0.31	Monocyte count;	chr8:11950067	chr12:109354083~109359488:-
THCA	trans	rs864643	1	rs1708056	ENSG00000188856.6	RPSAP47	7.08	5.36e-12	8.65e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39531662	chr8:80558870~80559757:+
THCA	trans	rs9581094	0.591	rs9553318	ENSG00000224976.2	PARP4P2	7.08	5.36e-12	8.65e-06	0.46	0.31	Sudden cardiac arrest;	chr13:24477107	chr13:19349137~19407962:+
THCA	trans	rs76228276	0.737	rs7818738	ENSG00000260318.1	COX6CP1	7.08	5.37e-12	8.68e-06	0.9	0.31	Childhood ear infection;	chr8:99186249	chr16:11903923~11904137:-
THCA	trans	rs4263408	1	rs7656037	ENSG00000237550.5	UBE2Q2P6	7.08	5.38e-12	8.69e-06	0.37	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39716345	chr15:82372196~82372912:-
THCA	trans	rs4263408	1	rs7661070	ENSG00000237550.5	UBE2Q2P6	7.08	5.4e-12	8.72e-06	0.37	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39722745	chr15:82372196~82372912:-
THCA	trans	rs7824557	0.591	rs2572452	ENSG00000253893.2	FAM85B	7.08	5.45e-12	8.8e-06	0.41	0.31	Retinal vascular caliber;	chr8:11370745	chr8:8167819~8226614:-
THCA	trans	rs6600671	1	rs4844381	ENSG00000270392.2	PFN1P2	7.07	5.46e-12	8.81e-06	0.3	0.31	Hip geometry;	chr1:121443040	chr1:120432204~120434052:-
THCA	trans	rs1580019	0.587	rs6951955	ENSG00000176826.14	FKBP9P1	-7.07	5.47e-12	8.83e-06	-0.41	-0.31	Cognitive ability;	chr7:32509149	chr7:55681074~55713252:-
THCA	trans	rs1580019	0.587	rs6972365	ENSG00000176826.14	FKBP9P1	-7.07	5.47e-12	8.83e-06	-0.41	-0.31	Cognitive ability;	chr7:32509319	chr7:55681074~55713252:-
THCA	trans	rs864643	1	rs1513214	ENSG00000188856.6	RPSAP47	7.07	5.51e-12	8.89e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39518774	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1768267	ENSG00000188856.6	RPSAP47	7.07	5.51e-12	8.89e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39518945	chr8:80558870~80559757:+
THCA	trans	rs4263408	0.967	rs11947966	ENSG00000237550.5	UBE2Q2P6	7.07	5.51e-12	8.89e-06	0.36	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39765721	chr15:82372196~82372912:-
THCA	trans	rs9329221	0.513	rs4841296	ENSG00000253893.2	FAM85B	7.07	5.53e-12	8.91e-06	0.41	0.31	Neuroticism;	chr8:10247937	chr8:8167819~8226614:-
THCA	trans	rs864643	0.947	rs6762416	ENSG00000188856.6	RPSAP47	7.07	5.53e-12	8.92e-06	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39496111	chr8:80558870~80559757:+
THCA	trans	rs8067354	0.609	rs1292066	ENSG00000187870.7	RNFT1P3	7.07	5.54e-12	8.93e-06	0.48	0.31	Hemoglobin concentration;	chr17:59854953	chr17:20743333~20754501:-
THCA	trans	rs864643	0.625	rs1707958	ENSG00000183298.5	RP11-556K13.1	7.07	5.56e-12	8.96e-06	0.52	0.31	Attention deficit hyperactivity disorder;	chr3:39481931	chr1:101786340~101787219:-
THCA	trans	rs7829975	0.774	rs35431455	ENSG00000256560.1	LINC01486	7.07	5.56e-12	8.97e-06	0.37	0.31	Mood instability;	chr8:8816226	chr12:109354083~109359488:-
THCA	trans	rs9581094	0.591	rs9553318	ENSG00000237917.1	PARP4P1	-7.07	5.59e-12	9.02e-06	-0.48	-0.31	Sudden cardiac arrest;	chr13:24477107	chrY:26594851~26634652:-
THCA	trans	rs7260598	0.792	rs73021412	ENSG00000261770.1	CTC-459F4.1	7.07	5.62e-12	9.06e-06	0.52	0.31	Response to taxane treatment (placlitaxel);	chr19:24070755	chr19:27757184~27760849:-
THCA	trans	rs6915893	0.844	rs6910196	ENSG00000267156.1	TPMTP1	-7.07	5.64e-12	9.09e-06	-0.35	-0.31	Intrinsic epigenetic age acceleration;	chr6:18102276	chr18:47630112~47630848:+
THCA	trans	rs11098499	0.954	rs1546505	ENSG00000253326.2	RP11-261C10.7	7.07	5.66e-12	9.12e-06	0.44	0.31	Corneal astigmatism;	chr4:119320069	chr1:243054861~243056394:-
THCA	trans	rs902774	0.818	rs4919742	ENSG00000255815.3	KRT8P11	-7.07	5.68e-12	9.16e-06	-0.65	-0.31	Prostate cancer;	chr12:52879180	chr9:99305176~99306611:+
THCA	trans	rs864643	0.947	rs1708040	ENSG00000183298.5	RP11-556K13.1	7.07	5.69e-12	9.16e-06	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39523258	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs505176	ENSG00000183298.5	RP11-556K13.1	7.07	5.69e-12	9.16e-06	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39524857	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs1708000	ENSG00000183298.5	RP11-556K13.1	7.07	5.69e-12	9.16e-06	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39525645	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs1708001	ENSG00000183298.5	RP11-556K13.1	7.07	5.69e-12	9.16e-06	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39525714	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs816519	ENSG00000183298.5	RP11-556K13.1	7.07	5.69e-12	9.16e-06	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39527786	chr1:101786340~101787219:-
THCA	trans	rs864643	0.731	rs1417148	ENSG00000183298.5	RP11-556K13.1	7.07	5.69e-12	9.16e-06	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39534217	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs6762416	ENSG00000183298.5	RP11-556K13.1	7.07	5.69e-12	9.17e-06	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39496111	chr1:101786340~101787219:-
THCA	trans	rs877636	0.74	rs705702	ENSG00000224553.1	AC008065.1	-7.07	5.72e-12	9.22e-06	-0.38	-0.31	Cognitive function;	chr12:55996852	chr2:171374931~171375278:-
THCA	trans	rs7819412	0.634	rs6987767	ENSG00000229857.1	RP11-159H20.3	-7.07	5.75e-12	9.26e-06	-0.39	-0.31	Triglycerides;	chr8:11052556	chr9:76992099~76993108:+
THCA	trans	rs1580019	0.51	rs4723162	ENSG00000176826.14	FKBP9P1	-7.07	5.75e-12	9.26e-06	-0.41	-0.31	Cognitive ability;	chr7:32504192	chr7:55681074~55713252:-
THCA	trans	rs902774	0.818	rs4919763	ENSG00000248568.1	KRT8P48	-7.07	5.76e-12	9.27e-06	-0.66	-0.31	Prostate cancer;	chr12:52885839	chr5:146706381~146707600:-
THCA	trans	rs902774	0.818	rs55914512	ENSG00000248568.1	KRT8P48	-7.07	5.76e-12	9.27e-06	-0.66	-0.31	Prostate cancer;	chr12:52888490	chr5:146706381~146707600:-
THCA	trans	rs902774	0.818	rs73108466	ENSG00000248568.1	KRT8P48	-7.07	5.76e-12	9.27e-06	-0.66	-0.31	Prostate cancer;	chr12:52889857	chr5:146706381~146707600:-
THCA	trans	rs902774	0.818	rs55999178	ENSG00000248568.1	KRT8P48	-7.07	5.76e-12	9.27e-06	-0.66	-0.31	Prostate cancer;	chr12:52890576	chr5:146706381~146707600:-
THCA	trans	rs453301	0.624	rs2288673	ENSG00000229857.1	RP11-159H20.3	-7.07	5.77e-12	9.28e-06	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9002766	chr9:76992099~76993108:+
THCA	trans	rs13177918	0.834	rs13163277	ENSG00000226396.1	RP5-1056L3.3	7.07	5.79e-12	9.32e-06	0.32	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr1:19608114~19608568:+
THCA	trans	rs73108077	0.736	rs7273790	ENSG00000279352.1	RP11-411B10.7	-7.07	5.79e-12	9.32e-06	-0.67	-0.31	Red blood cell density in sickle cell anemia;	chr20:31312478	chr18:14010054~14010917:+
THCA	trans	rs11098499	0.71	rs4145952	ENSG00000275858.1	RP11-291L22.8	7.07	5.8e-12	9.34e-06	0.38	0.31	Corneal astigmatism;	chr4:119234651	chr10:38450738~38451069:-
THCA	trans	rs58106596	0.747	rs6731997	ENSG00000259020.3	RP11-529H20.3	7.06	5.84e-12	9.4e-06	0.47	0.31	Lymphocyte counts;White blood cell count;	chr2:231695701	chr14:92026566~92026887:+
THCA	trans	rs6600671	1	rs6600669	ENSG00000270392.2	PFN1P2	7.06	5.85e-12	9.42e-06	0.31	0.31	Hip geometry;	chr1:121471785	chr1:120432204~120434052:-
THCA	trans	rs7819412	0.582	rs2409685	ENSG00000229857.1	RP11-159H20.3	7.06	5.86e-12	9.42e-06	0.39	0.31	Triglycerides;	chr8:11051683	chr9:76992099~76993108:+
THCA	trans	rs10420951	0.617	rs74389203	ENSG00000267533.1	RP11-815J4.7	7.06	5.89e-12	9.48e-06	0.61	0.31	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18495846	chr18:12067173~12068417:-
THCA	trans	rs6981523	0.553	rs11989369	ENSG00000253893.2	FAM85B	-7.06	5.91e-12	9.51e-06	-0.44	-0.31	Neuroticism;	chr8:11197876	chr8:8167819~8226614:-
THCA	trans	rs453301	0.624	rs6987558	ENSG00000229857.1	RP11-159H20.3	-7.06	5.95e-12	9.57e-06	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9005011	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs11773990	ENSG00000229857.1	RP11-159H20.3	7.06	5.98e-12	9.62e-06	0.39	0.31	Triglycerides;	chr8:11077572	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs4545055	ENSG00000229857.1	RP11-159H20.3	7.06	5.98e-12	9.62e-06	0.39	0.31	Triglycerides;	chr8:11077856	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs2898257	ENSG00000229857.1	RP11-159H20.3	7.06	5.98e-12	9.62e-06	0.39	0.31	Triglycerides;	chr8:11077858	chr9:76992099~76993108:+
THCA	trans	rs12145833	1	rs12145833	ENSG00000154608.12	CEP170P1	7.06	6e-12	9.65e-06	0.36	0.31	Obesity (early onset extreme);	chr1:243320452	chr4:118467590~118554204:+
THCA	trans	rs2950393	0.804	rs2958130	ENSG00000228224.3	NACAP1	7.06	6.01e-12	9.66e-06	0.31	0.31	Platelet distribution width;	chr12:56746722	chr8:101361794~101372707:+
THCA	trans	rs5022636	0.865	rs12069445	ENSG00000180764.13	PIPSL	7.06	6.03e-12	9.68e-06	0.35	0.31	Gut microbiota (functional units);	chr1:151362964	chr10:93958191~93961540:-
THCA	trans	rs7617480	0.648	rs9864243	ENSG00000197582.5	GPX1P1	7.06	6.08e-12	9.76e-06	0.52	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48945299	chrX:13378735~13379340:-
THCA	trans	rs1707322	0.821	rs10749857	ENSG00000255397.1	AC022182.2	-7.06	6.12e-12	9.82e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr8:60937705~60939871:-
THCA	trans	rs864643	0.947	rs538972	ENSG00000183298.5	RP11-556K13.1	7.06	6.12e-12	9.82e-06	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39497652	chr1:101786340~101787219:-
THCA	trans	rs61041336	0.583	rs11647748	ENSG00000230849.2	GOT2P2	-7.06	6.13e-12	9.84e-06	-0.53	-0.31	Neuritic plaque;	chr16:58697980	chr1:173141100~173142350:-
THCA	trans	rs7833986	0.501	rs2719226	ENSG00000236862.1	RPS20P24	7.06	6.13e-12	9.84e-06	0.46	0.31	Height;	chr8:56131507	chr9:72655832~72656192:-
THCA	trans	rs2950393	0.804	rs2926752	ENSG00000228224.3	NACAP1	7.06	6.16e-12	9.88e-06	0.31	0.31	Platelet distribution width;	chr12:56710144	chr8:101361794~101372707:+
THCA	trans	rs2950393	0.777	rs2958148	ENSG00000228224.3	NACAP1	7.06	6.16e-12	9.88e-06	0.31	0.31	Platelet distribution width;	chr12:56710153	chr8:101361794~101372707:+
THCA	trans	rs864643	0.891	rs661366	ENSG00000188856.6	RPSAP47	7.06	6.17e-12	9.9e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39519857	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs572971	ENSG00000188856.6	RPSAP47	7.06	6.17e-12	9.9e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39519936	chr8:80558870~80559757:+
THCA	trans	rs864643	0.945	rs1355733	ENSG00000188856.6	RPSAP47	7.06	6.17e-12	9.9e-06	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39521165	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.866	rs3756156	ENSG00000253326.2	RP11-261C10.7	7.05	6.24e-12	1e-05	0.44	0.31	Corneal astigmatism;	chr4:119603686	chr1:243054861~243056394:-
THCA	trans	rs2572431	0.505	rs13269118	ENSG00000253893.2	FAM85B	-7.05	6.28e-12	1.01e-05	-0.42	-0.31	Neuroticism;	chr8:11390305	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.742	rs7832968	ENSG00000256560.1	LINC01486	7.05	6.29e-12	1.01e-05	0.36	0.31	Mood instability;	chr8:8795379	chr12:109354083~109359488:-
THCA	trans	rs12145833	0.85	rs2490392	ENSG00000154608.12	CEP170P1	7.05	6.35e-12	1.02e-05	0.36	0.31	Obesity (early onset extreme);	chr1:243299221	chr4:118467590~118554204:+
THCA	trans	rs7192380	0.639	rs2917666	ENSG00000257513.6	NPIPB1P	-7.05	6.37e-12	1.02e-05	-0.36	-0.31	Sjögren's syndrome;	chr16:69730057	chr18:11619509~11639699:-
THCA	trans	rs7824557	0.767	rs6991606	ENSG00000253893.2	FAM85B	-7.05	6.4e-12	1.03e-05	-0.41	-0.31	Retinal vascular caliber;	chr8:11318650	chr8:8167819~8226614:-
THCA	trans	rs12614435	0.512	rs16866420	ENSG00000269800.1	PLEKHA3P1	7.05	6.44e-12	1.03e-05	0.37	0.31	Atrial fibrillation;	chr2:178626508	chr19:41521043~41521989:-
THCA	trans	rs7833986	0.534	rs17813240	ENSG00000236862.1	RPS20P24	7.05	6.44e-12	1.03e-05	0.46	0.31	Height;	chr8:56013232	chr9:72655832~72656192:-
THCA	trans	rs73108077	0.764	rs75475053	ENSG00000279352.1	RP11-411B10.7	7.05	6.47e-12	1.04e-05	0.69	0.31	Red blood cell density in sickle cell anemia;	chr20:31217143	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.621	rs7261582	ENSG00000279352.1	RP11-411B10.7	7.05	6.47e-12	1.04e-05	0.69	0.31	Red blood cell density in sickle cell anemia;	chr20:31226977	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.57	rs73119526	ENSG00000279352.1	RP11-411B10.7	7.05	6.47e-12	1.04e-05	0.69	0.31	Red blood cell density in sickle cell anemia;	chr20:31252117	chr18:14010054~14010917:+
THCA	trans	rs877636	0.74	rs772920	ENSG00000227586.5	RP11-162A23.5	7.05	6.47e-12	1.04e-05	0.4	0.31	Cognitive function;	chr12:55996580	chr10:123171535~123171875:-
THCA	trans	rs7819412	0.715	rs2409727	ENSG00000229857.1	RP11-159H20.3	7.05	6.51e-12	1.04e-05	0.4	0.31	Triglycerides;	chr8:11185727	chr9:76992099~76993108:+
THCA	trans	rs5022636	0.896	rs10788804	ENSG00000180764.13	PIPSL	7.05	6.57e-12	1.05e-05	0.35	0.31	Gut microbiota (functional units);	chr1:151365312	chr10:93958191~93961540:-
THCA	trans	rs6915893	0.692	rs4074443	ENSG00000267156.1	TPMTP1	7.04	6.67e-12	1.07e-05	0.32	0.31	Intrinsic epigenetic age acceleration;	chr6:18106371	chr18:47630112~47630848:+
THCA	trans	rs902774	0.818	rs73108469	ENSG00000255815.3	KRT8P11	-7.04	6.69e-12	1.07e-05	-0.65	-0.31	Prostate cancer;	chr12:52891065	chr9:99305176~99306611:+
THCA	trans	rs11638815	0.626	rs4779041	ENSG00000235370.6	DNM1P51	7.04	6.71e-12	1.07e-05	0.39	0.31	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82668307	chr15:84398316~84411701:-
THCA	trans	rs7824557	0.507	rs7010590	ENSG00000229857.1	RP11-159H20.3	-7.04	6.72e-12	1.08e-05	-0.39	-0.31	Retinal vascular caliber;	chr8:11205373	chr9:76992099~76993108:+
THCA	trans	rs1707322	0.752	rs11488313	ENSG00000255397.1	AC022182.2	-7.04	6.78e-12	1.08e-05	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.821	rs11211182	ENSG00000255397.1	AC022182.2	-7.04	6.82e-12	1.09e-05	-0.44	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr8:60937705~60939871:-
THCA	trans	rs864643	1	rs704963	ENSG00000183298.5	RP11-556K13.1	-7.04	6.82e-12	1.09e-05	-0.51	-0.31	Attention deficit hyperactivity disorder;	chr3:39515747	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs6762335	ENSG00000183298.5	RP11-556K13.1	7.04	6.85e-12	1.1e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39496043	chr1:101786340~101787219:-
THCA	trans	rs12709013	1	rs12926993	ENSG00000230849.2	GOT2P2	7.04	6.87e-12	1.1e-05	0.38	0.31	Blood metabolite ratios;	chr16:58789218	chr1:173141100~173142350:-
THCA	trans	rs9914988	0.565	rs34039488	ENSG00000267449.1	RP11-264B14.2	7.04	6.9e-12	1.1e-05	0.48	0.31	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28993214	chr17:61069856~61070356:-
THCA	trans	rs9914988	0.619	rs35477460	ENSG00000267449.1	RP11-264B14.2	7.04	6.9e-12	1.1e-05	0.48	0.31	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28993258	chr17:61069856~61070356:-
THCA	trans	rs76228276	0.737	rs73271394	ENSG00000260318.1	COX6CP1	7.04	6.91e-12	1.1e-05	0.93	0.31	Childhood ear infection;	chr8:99841632	chr16:11903923~11904137:-
THCA	trans	rs9650657	0.648	rs7833945	ENSG00000253893.2	FAM85B	7.04	6.96e-12	1.11e-05	0.4	0.31	Neuroticism;	chr8:10842756	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.825	rs12520151	ENSG00000231752.4	EMBP1	-7.04	6.96e-12	1.11e-05	-0.5	-0.31	Age at first birth;	chr5:45143202	chr1:121519112~121571892:+
THCA	trans	rs11992162	0.548	rs4841631	ENSG00000253893.2	FAM85B	7.04	6.98e-12	1.11e-05	0.41	0.31	Monocyte count;	chr8:11924159	chr8:8167819~8226614:-
THCA	trans	rs61041336	0.534	rs11641633	ENSG00000230849.2	GOT2P2	7.04	6.99e-12	1.12e-05	0.54	0.31	Neuritic plaque;	chr16:58679717	chr1:173141100~173142350:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000227586.5	RP11-162A23.5	7.04	6.99e-12	1.12e-05	0.4	0.31	Cognitive function;	chr12:55988132	chr10:123171535~123171875:-
THCA	trans	rs453301	0.653	rs7853	ENSG00000229857.1	RP11-159H20.3	-7.04	7.01e-12	1.12e-05	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9033304	chr9:76992099~76993108:+
THCA	trans	rs9292918	0.806	rs1501358	ENSG00000231752.4	EMBP1	7.04	7.03e-12	1.12e-05	0.51	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45338114	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.812	rs6993841	ENSG00000253893.2	FAM85B	7.03	7.1e-12	1.13e-05	0.39	0.31	Neuroticism;	chr8:10775174	chr8:8167819~8226614:-
THCA	trans	rs3002142	0.658	rs3008634	ENSG00000219201.4	RP11-181C21.4	7.03	7.1e-12	1.13e-05	0.44	0.31	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:77810861~77811781:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000227586.5	RP11-162A23.5	7.03	7.12e-12	1.14e-05	0.4	0.31	Cognitive function;	chr12:55981353	chr10:123171535~123171875:-
THCA	trans	rs877636	0.702	rs773111	ENSG00000227586.5	RP11-162A23.5	7.03	7.12e-12	1.14e-05	0.4	0.31	Cognitive function;	chr12:55981956	chr10:123171535~123171875:-
THCA	trans	rs12709013	0.967	rs2118019	ENSG00000230849.2	GOT2P2	-7.03	7.12e-12	1.14e-05	-0.38	-0.31	Blood metabolite ratios;	chr16:58797825	chr1:173141100~173142350:-
THCA	trans	rs7824557	0.547	rs2736287	ENSG00000253893.2	FAM85B	7.03	7.14e-12	1.14e-05	0.41	0.31	Retinal vascular caliber;	chr8:11370497	chr8:8167819~8226614:-
THCA	trans	rs6732160	0.834	rs57456443	ENSG00000236165.1	PRADC1P1	7.03	7.15e-12	1.14e-05	0.43	0.31	Intelligence (multi-trait analysis);	chr2:73139313	chr3:36976316~36976840:+
THCA	trans	rs1347297	0.614	rs7589679	ENSG00000269800.1	PLEKHA3P1	7.03	7.17e-12	1.14e-05	0.33	0.31	Alzheimer disease and age of onset;	chr2:178417710	chr19:41521043~41521989:-
THCA	trans	rs6885307	0.825	rs62369907	ENSG00000231752.4	EMBP1	7.03	7.18e-12	1.15e-05	0.51	0.31	Age at first birth;	chr5:45104023	chr1:121519112~121571892:+
THCA	trans	rs453301	0.653	rs1045529	ENSG00000256560.1	LINC01486	-7.03	7.19e-12	1.15e-05	-0.35	-0.31	Joint mobility (Beighton score);	chr8:9032588	chr12:109354083~109359488:-
THCA	trans	rs853679	0.546	rs34676049	ENSG00000253570.1	RNF5P1	7.03	7.21e-12	1.15e-05	0.9	0.31	Depression;	chr6:28485841	chr8:38600661~38601200:-
THCA	trans	rs7819412	0.668	rs2409721	ENSG00000229857.1	RP11-159H20.3	7.03	7.23e-12	1.15e-05	0.4	0.31	Triglycerides;	chr8:11180735	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.56	rs2467520	ENSG00000253893.2	FAM85B	7.03	7.25e-12	1.16e-05	0.41	0.31	Neuroticism;	chr8:11541444	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.872	rs2572431	ENSG00000253893.2	FAM85B	7.03	7.25e-12	1.16e-05	0.38	0.31	Retinal vascular caliber;	chr8:11247568	chr8:8167819~8226614:-
THCA	trans	rs6600671	0.934	rs11249348	ENSG00000270392.2	PFN1P2	7.03	7.25e-12	1.16e-05	0.3	0.31	Hip geometry;	chr1:121446444	chr1:120432204~120434052:-
THCA	trans	rs864643	0.891	rs1068953	ENSG00000183298.5	RP11-556K13.1	7.03	7.3e-12	1.16e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39515070	chr1:101786340~101787219:-
THCA	trans	rs864643	0.678	rs1768244	ENSG00000183298.5	RP11-556K13.1	7.03	7.33e-12	1.17e-05	0.49	0.31	Attention deficit hyperactivity disorder;	chr3:39500688	chr1:101786340~101787219:-
THCA	trans	rs2950393	0.804	rs1026565	ENSG00000228224.3	NACAP1	7.03	7.36e-12	1.17e-05	0.31	0.31	Platelet distribution width;	chr12:56744044	chr8:101361794~101372707:+
THCA	trans	rs11992162	0.591	rs35657308	ENSG00000256560.1	LINC01486	-7.03	7.36e-12	1.17e-05	-0.38	-0.31	Monocyte count;	chr8:11946893	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs7539800	ENSG00000255397.1	AC022182.2	7.03	7.4e-12	1.18e-05	0.43	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr8:60937705~60939871:-
THCA	trans	rs6087990	0.806	rs4911254	ENSG00000253915.1	MAPRE1P1	7.03	7.41e-12	1.18e-05	0.4	0.31	Ulcerative colitis;	chr20:32769773	chr8:135625185~135625981:-
THCA	trans	rs6087990	0.748	rs4911255	ENSG00000253915.1	MAPRE1P1	7.03	7.41e-12	1.18e-05	0.4	0.31	Ulcerative colitis;	chr20:32769774	chr8:135625185~135625981:-
THCA	trans	rs6981523	0.517	rs13251510	ENSG00000229857.1	RP11-159H20.3	7.03	7.41e-12	1.18e-05	0.39	0.31	Neuroticism;	chr8:11059464	chr9:76992099~76993108:+
THCA	trans	rs864643	0.947	rs538972	ENSG00000188856.6	RPSAP47	7.03	7.42e-12	1.18e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39497652	chr8:80558870~80559757:+
THCA	trans	rs10816533	1	rs12340602	ENSG00000232063.1	RP11-307E17.8	7.03	7.43e-12	1.18e-05	0.82	0.31	Height;	chr9:96778427	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs28489285	ENSG00000232063.1	RP11-307E17.8	7.03	7.43e-12	1.18e-05	0.82	0.31	Height;	chr9:96780947	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs7847117	ENSG00000232063.1	RP11-307E17.8	7.03	7.43e-12	1.18e-05	0.82	0.31	Height;	chr9:96781905	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs10122464	ENSG00000232063.1	RP11-307E17.8	7.03	7.43e-12	1.18e-05	0.82	0.31	Height;	chr9:96790039	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs7874781	ENSG00000232063.1	RP11-307E17.8	7.03	7.43e-12	1.18e-05	0.82	0.31	Height;	chr9:96810783	chr9:94332476~94360948:+
THCA	trans	rs864643	0.891	rs55780606	ENSG00000183298.5	RP11-556K13.1	7.03	7.44e-12	1.19e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39496599	chr1:101786340~101787219:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000242206.2	RPS26P35	-7.03	7.44e-12	1.19e-05	-0.36	-0.31	Cognitive function;	chr12:56083910	chr8:118761856~118762201:-
THCA	trans	rs9858542	1	rs11709525	ENSG00000197582.5	GPX1P1	-7.03	7.46e-12	1.19e-05	-0.48	-0.31	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49653063	chrX:13378735~13379340:-
THCA	trans	rs864643	0.947	rs645488	ENSG00000188856.6	RPSAP47	7.03	7.47e-12	1.19e-05	0.45	0.31	Attention deficit hyperactivity disorder;	chr3:39499028	chr8:80558870~80559757:+
THCA	trans	rs7819412	0.521	rs2409720	ENSG00000253893.2	FAM85B	7.03	7.48e-12	1.19e-05	0.43	0.31	Triglycerides;	chr8:11180394	chr8:8167819~8226614:-
THCA	trans	rs10816533	1	rs60072763	ENSG00000232063.1	RP11-307E17.8	7.03	7.49e-12	1.19e-05	0.82	0.31	Height;	chr9:96785698	chr9:94332476~94360948:+
THCA	trans	rs9329221	0.736	rs34381075	ENSG00000253893.2	FAM85B	-7.03	7.49e-12	1.19e-05	-0.41	-0.31	Neuroticism;	chr8:10386275	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.585	rs4841401	ENSG00000253893.2	FAM85B	7.02	7.56e-12	1.2e-05	0.4	0.31	Neuroticism;	chr8:10632082	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.572	rs7005000	ENSG00000229857.1	RP11-159H20.3	7.02	7.64e-12	1.22e-05	0.38	0.31	Mood instability;	chr8:8939092	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.777	rs560544	ENSG00000256560.1	LINC01486	-7.02	7.69e-12	1.22e-05	-0.36	-0.31	Mood instability;	chr8:8779919	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs56207534	ENSG00000255815.3	KRT8P11	-7.02	7.77e-12	1.24e-05	-0.64	-0.31	Prostate cancer;	chr12:52873525	chr9:99305176~99306611:+
THCA	trans	rs2645424	0.686	rs2294140	ENSG00000229857.1	RP11-159H20.3	7.02	7.78e-12	1.24e-05	0.39	0.31	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr9:76992099~76993108:+
THCA	trans	rs2736345	0.89	rs4840565	ENSG00000253893.2	FAM85B	-7.02	7.86e-12	1.25e-05	-0.42	-0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11488036	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.863	rs7699064	ENSG00000253326.2	RP11-261C10.7	-7.02	7.86e-12	1.25e-05	-0.44	-0.31	Corneal astigmatism;	chr4:119507154	chr1:243054861~243056394:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000227586.5	RP11-162A23.5	7.02	7.88e-12	1.25e-05	0.4	0.31	Cognitive function;	chr12:55982097	chr10:123171535~123171875:-
THCA	trans	rs76228276	0.737	rs7003135	ENSG00000260318.1	COX6CP1	7.02	7.93e-12	1.26e-05	0.93	0.31	Childhood ear infection;	chr8:99844405	chr16:11903923~11904137:-
THCA	trans	rs4263408	0.934	rs2381428	ENSG00000237550.5	UBE2Q2P6	7.02	7.94e-12	1.26e-05	0.36	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39761846	chr15:82372196~82372912:-
THCA	trans	rs1707322	0.963	rs6429581	ENSG00000255397.1	AC022182.2	-7.02	7.98e-12	1.27e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr8:60937705~60939871:-
THCA	trans	rs748404	0.65	rs518234	ENSG00000180867.10	PDIA3P1	-7.02	7.99e-12	1.27e-05	-0.27	-0.31	Lung cancer;	chr15:43281223	chr1:147178113~147179622:+
THCA	trans	rs748404	0.65	rs518261	ENSG00000180867.10	PDIA3P1	-7.02	7.99e-12	1.27e-05	-0.27	-0.31	Lung cancer;	chr15:43281231	chr1:147178113~147179622:+
THCA	trans	rs116095464	1	rs10069360	ENSG00000185986.11	SDHAP3	7.02	8.03e-12	1.28e-05	0.54	0.31	Breast cancer;	chr5:351500	chr5:1572222~1594620:-
THCA	trans	rs6424115	0.657	rs519202	ENSG00000228217.1	AL390877.1	-7.02	8.04e-12	1.28e-05	-0.4	-0.31	Immature fraction of reticulocytes;	chr1:23719330	chr1:117778087~117778506:-
THCA	trans	rs11098499	0.69	rs34818745	ENSG00000253326.2	RP11-261C10.7	7.01	8.07e-12	1.28e-05	0.44	0.31	Corneal astigmatism;	chr4:119335900	chr1:243054861~243056394:-
THCA	trans	rs3956705	0.933	rs13311772	ENSG00000176826.14	FKBP9P1	-7.01	8.08e-12	1.28e-05	-0.41	-0.31	Red cell distribution width;	chr7:32960198	chr7:55681074~55713252:-
THCA	trans	rs902774	0.818	rs4919737	ENSG00000248568.1	KRT8P48	-7.01	8.09e-12	1.29e-05	-0.64	-0.31	Prostate cancer;	chr12:52877011	chr5:146706381~146707600:-
THCA	trans	rs902774	0.818	rs73108429	ENSG00000248568.1	KRT8P48	-7.01	8.09e-12	1.29e-05	-0.64	-0.31	Prostate cancer;	chr12:52877887	chr5:146706381~146707600:-
THCA	trans	rs3808502	0.527	rs56177149	ENSG00000253893.2	FAM85B	-7.01	8.12e-12	1.29e-05	-0.42	-0.31	Neuroticism;	chr8:11389789	chr8:8167819~8226614:-
THCA	trans	rs864643	0.947	rs704962	ENSG00000183298.5	RP11-556K13.1	-7.01	8.12e-12	1.29e-05	-0.5	-0.31	Attention deficit hyperactivity disorder;	chr3:39515629	chr1:101786340~101787219:-
THCA	trans	rs2645424	0.93	rs1293315	ENSG00000256560.1	LINC01486	-7.01	8.13e-12	1.29e-05	-0.37	-0.31	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11832913	chr12:109354083~109359488:-
THCA	trans	rs3740713	1	rs35593189	ENSG00000214110.3	LDHAP4	7.01	8.17e-12	1.3e-05	0.55	0.31	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr9:14921337~14922334:-
THCA	trans	rs7819412	0.66	rs7462931	ENSG00000229857.1	RP11-159H20.3	7.01	8.2e-12	1.3e-05	0.39	0.31	Triglycerides;	chr8:11052833	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.606	rs6422352	ENSG00000229857.1	RP11-159H20.3	7.01	8.23e-12	1.31e-05	0.38	0.31	Mood instability;	chr8:8936683	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.606	rs891570	ENSG00000229857.1	RP11-159H20.3	7.01	8.23e-12	1.31e-05	0.38	0.31	Mood instability;	chr8:8936944	chr9:76992099~76993108:+
THCA	trans	rs864643	0.812	rs2039843	ENSG00000183298.5	RP11-556K13.1	-7.01	8.3e-12	1.32e-05	-0.47	-0.31	Attention deficit hyperactivity disorder;	chr3:39515347	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1707973	ENSG00000183298.5	RP11-556K13.1	7.01	8.31e-12	1.32e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39507275	chr1:101786340~101787219:-
THCA	trans	rs864643	0.812	rs6809442	ENSG00000183298.5	RP11-556K13.1	-7.01	8.33e-12	1.32e-05	-0.47	-0.31	Attention deficit hyperactivity disorder;	chr3:39517666	chr1:101786340~101787219:-
THCA	trans	rs804280	1	rs804281	ENSG00000256560.1	LINC01486	7.01	8.35e-12	1.33e-05	0.39	0.31	Myopia (pathological);	chr8:11754356	chr12:109354083~109359488:-
THCA	trans	rs12709013	1	rs12599931	ENSG00000230849.2	GOT2P2	7.01	8.36e-12	1.33e-05	0.37	0.31	Blood metabolite ratios;	chr16:58792627	chr1:173141100~173142350:-
THCA	trans	rs2950393	0.804	rs2290894	ENSG00000228224.3	NACAP1	7.01	8.41e-12	1.34e-05	0.31	0.31	Platelet distribution width;	chr12:56714911	chr8:101361794~101372707:+
THCA	trans	rs11098499	0.866	rs10518329	ENSG00000253326.2	RP11-261C10.7	7.01	8.49e-12	1.35e-05	0.4	0.31	Corneal astigmatism;	chr4:119480680	chr1:243054861~243056394:-
THCA	trans	rs864643	0.947	rs1708015	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39496891	chr1:101786340~101787219:-
THCA	trans	rs864643	0.891	rs1708018	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39496978	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs535220	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39497234	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs538214	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39497603	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs614359	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39498035	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs1768237	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39498712	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs482495	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39498924	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs645403	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39498968	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs645457	ENSG00000183298.5	RP11-556K13.1	7.01	8.51e-12	1.35e-05	0.5	0.31	Attention deficit hyperactivity disorder;	chr3:39499006	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs704963	ENSG00000188856.6	RPSAP47	-7.01	8.55e-12	1.36e-05	-0.46	-0.31	Attention deficit hyperactivity disorder;	chr3:39515747	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs816494	ENSG00000183298.5	RP11-556K13.1	7.01	8.58e-12	1.36e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39515354	chr1:101786340~101787219:-
THCA	trans	rs34421088	0.559	rs12386974	ENSG00000256560.1	LINC01486	7.01	8.59e-12	1.36e-05	0.38	0.31	Neuroticism;	chr8:11543119	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.824	rs7711528	ENSG00000231752.4	EMBP1	7	8.61e-12	1.37e-05	0.48	0.31	Age at first birth;	chr5:45182029	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.537	rs2127127	ENSG00000229857.1	RP11-159H20.3	7	8.62e-12	1.37e-05	0.39	0.31	Triglycerides;	chr8:11577283	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.51	rs332037	ENSG00000256560.1	LINC01486	7	8.71e-12	1.38e-05	0.38	0.31	Mood instability;	chr8:8865165	chr12:109354083~109359488:-
THCA	trans	rs3740713	0.669	rs2896526	ENSG00000236090.2	LDHAP3	7	8.72e-12	1.38e-05	0.52	0.31	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:41819747~41820754:+
THCA	trans	rs4263408	1	rs7687557	ENSG00000237550.5	UBE2Q2P6	7	8.75e-12	1.39e-05	0.36	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39767640	chr15:82372196~82372912:-
THCA	trans	rs6600671	1	rs1986111	ENSG00000270392.2	PFN1P2	7	8.75e-12	1.39e-05	0.3	0.31	Hip geometry;	chr1:121462934	chr1:120432204~120434052:-
THCA	trans	rs453301	0.592	rs4841084	ENSG00000229857.1	RP11-159H20.3	-7	8.76e-12	1.39e-05	-0.36	-0.31	Joint mobility (Beighton score);	chr8:9026395	chr9:76992099~76993108:+
THCA	trans	rs453301	0.653	rs2956244	ENSG00000229857.1	RP11-159H20.3	-7	8.76e-12	1.39e-05	-0.36	-0.31	Joint mobility (Beighton score);	chr8:9027656	chr9:76992099~76993108:+
THCA	trans	rs116095464	1	rs6863730	ENSG00000185986.11	SDHAP3	7	8.84e-12	1.4e-05	0.47	0.31	Breast cancer;	chr5:324888	chr5:1572222~1594620:-
THCA	trans	rs330071	0.622	rs898797	ENSG00000253893.2	FAM85B	-7	8.92e-12	1.41e-05	-0.42	-0.31	Acne (severe);	chr8:9372179	chr8:8167819~8226614:-
THCA	trans	rs1580019	0.534	rs13237495	ENSG00000176826.14	FKBP9P1	-7	8.93e-12	1.41e-05	-0.41	-0.31	Cognitive ability;	chr7:32521075	chr7:55681074~55713252:-
THCA	trans	rs7829975	0.606	rs11776838	ENSG00000229857.1	RP11-159H20.3	7	9.04e-12	1.43e-05	0.38	0.31	Mood instability;	chr8:8937291	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.585	rs7830317	ENSG00000253893.2	FAM85B	7	9.08e-12	1.44e-05	0.4	0.31	Neuroticism;	chr8:10842744	chr8:8167819~8226614:-
THCA	trans	rs853679	0.607	rs34243448	ENSG00000253570.1	RNF5P1	7	9.1e-12	1.44e-05	0.85	0.31	Depression;	chr6:28225324	chr8:38600661~38601200:-
THCA	trans	rs3806843	0.518	rs2563310	ENSG00000231043.3	AC007238.1	7	9.11e-12	1.44e-05	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140636156	chr2:58460292~58462032:-
THCA	trans	rs864643	0.947	rs1708053	ENSG00000188856.6	RPSAP47	7	9.15e-12	1.45e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39499706	chr8:80558870~80559757:+
THCA	trans	rs864643	0.891	rs1708057	ENSG00000188856.6	RPSAP47	7	9.15e-12	1.45e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39499895	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs1768241	ENSG00000188856.6	RPSAP47	7	9.15e-12	1.45e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39499987	chr8:80558870~80559757:+
THCA	trans	rs864643	0.891	rs1708059	ENSG00000188856.6	RPSAP47	7	9.15e-12	1.45e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39500059	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs1768242	ENSG00000188856.6	RPSAP47	7	9.15e-12	1.45e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39500222	chr8:80558870~80559757:+
THCA	trans	rs6732160	0.564	rs60796597	ENSG00000236165.1	PRADC1P1	6.99	9.19e-12	1.45e-05	0.44	0.31	Intelligence (multi-trait analysis);	chr2:73155786	chr3:36976316~36976840:+
THCA	trans	rs13177918	0.822	rs62382255	ENSG00000226396.1	RP5-1056L3.3	6.99	9.21e-12	1.46e-05	0.31	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459154	chr1:19608114~19608568:+
THCA	trans	rs864643	0.773	rs3821373	ENSG00000183298.5	RP11-556K13.1	-6.99	9.24e-12	1.46e-05	-0.47	-0.31	Attention deficit hyperactivity disorder;	chr3:39512285	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1707968	ENSG00000183298.5	RP11-556K13.1	6.99	9.3e-12	1.47e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39506914	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1707969	ENSG00000183298.5	RP11-556K13.1	6.99	9.3e-12	1.47e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39506998	chr1:101786340~101787219:-
THCA	trans	rs116095464	1	rs2721025	ENSG00000185986.11	SDHAP3	6.99	9.36e-12	1.48e-05	0.52	0.31	Breast cancer;	chr5:347329	chr5:1572222~1594620:-
THCA	trans	rs902774	0.818	rs4919742	ENSG00000248568.1	KRT8P48	-6.99	9.38e-12	1.48e-05	-0.64	-0.31	Prostate cancer;	chr12:52879180	chr5:146706381~146707600:-
THCA	trans	rs7819412	0.594	rs7460507	ENSG00000229857.1	RP11-159H20.3	6.99	9.44e-12	1.49e-05	0.4	0.31	Triglycerides;	chr8:11111565	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.65	rs657913	ENSG00000253893.2	FAM85B	6.99	9.45e-12	1.49e-05	0.39	0.31	Neuroticism;	chr8:10025065	chr8:8167819~8226614:-
THCA	trans	rs864643	1	rs574074	ENSG00000188856.6	RPSAP47	6.99	9.53e-12	1.51e-05	0.48	0.31	Attention deficit hyperactivity disorder;	chr3:39520090	chr8:80558870~80559757:+
THCA	trans	rs12145833	0.619	rs12035042	ENSG00000154608.12	CEP170P1	-6.99	9.56e-12	1.51e-05	-0.4	-0.31	Obesity (early onset extreme);	chr1:243420597	chr4:118467590~118554204:+
THCA	trans	rs877636	0.74	rs772920	ENSG00000244604.1	RP11-713H12.1	6.99	9.6e-12	1.52e-05	0.4	0.31	Cognitive function;	chr12:55996580	chr17:8561230~8561576:+
THCA	trans	rs864643	1	rs816491	ENSG00000183298.5	RP11-556K13.1	-6.99	9.75e-12	1.54e-05	-0.51	-0.31	Attention deficit hyperactivity disorder;	chr3:39514006	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs864643	ENSG00000183298.5	RP11-556K13.1	6.99	9.75e-12	1.54e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39514089	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs816492	ENSG00000183298.5	RP11-556K13.1	6.99	9.75e-12	1.54e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39514664	chr1:101786340~101787219:-
THCA	trans	rs7819412	0.608	rs28417109	ENSG00000229857.1	RP11-159H20.3	6.98	9.91e-12	1.56e-05	0.4	0.31	Triglycerides;	chr8:11117571	chr9:76992099~76993108:+
THCA	trans	rs6964833	1	rs4717907	ENSG00000214544.6	GTF2IRD2P1	-6.98	9.97e-12	1.57e-05	-0.43	-0.31	Menarche (age at onset);	chr7:74672169	chr7:73242751~73280119:-
THCA	trans	rs7819412	0.715	rs2409727	ENSG00000256560.1	LINC01486	-6.98	1e-11	1.58e-05	-0.38	-0.31	Triglycerides;	chr8:11185727	chr12:109354083~109359488:-
THCA	trans	rs864643	0.812	rs1398669	ENSG00000183298.5	RP11-556K13.1	-6.98	1.02e-11	1.6e-05	-0.47	-0.31	Attention deficit hyperactivity disorder;	chr3:39504500	chr1:101786340~101787219:-
THCA	trans	rs2950393	0.857	rs1563896	ENSG00000257210.1	NACAP3	6.98	1.02e-11	1.61e-05	0.38	0.31	Platelet distribution width;	chr12:56699312	chr12:93124063~93124543:-
THCA	trans	rs941207	0.526	rs11171916	ENSG00000257210.1	NACAP3	-6.98	1.02e-11	1.61e-05	-0.38	-0.31	Platelet count;	chr12:56653236	chr12:93124063~93124543:-
THCA	trans	rs2950393	0.777	rs2926747	ENSG00000228224.3	NACAP1	6.98	1.02e-11	1.61e-05	0.31	0.31	Platelet distribution width;	chr12:56716147	chr8:101361794~101372707:+
THCA	trans	rs7824557	0.843	rs2736375	ENSG00000253893.2	FAM85B	6.98	1.03e-11	1.62e-05	0.38	0.31	Retinal vascular caliber;	chr8:11258240	chr8:8167819~8226614:-
THCA	trans	rs2985684	0.895	rs4900940	ENSG00000240785.1	RPL36AP21	6.98	1.03e-11	1.62e-05	0.4	0.31	Carotid intima media thickness;	chr14:49608592	chr5:18049550~18049872:+
THCA	trans	rs34421088	0.623	rs2572433	ENSG00000253893.2	FAM85B	-6.98	1.03e-11	1.62e-05	-0.43	-0.31	Neuroticism;	chr8:11243532	chr8:8167819~8226614:-
THCA	trans	rs864643	0.812	rs1513218	ENSG00000183298.5	RP11-556K13.1	6.98	1.03e-11	1.63e-05	0.48	0.31	Attention deficit hyperactivity disorder;	chr3:39504097	chr1:101786340~101787219:-
THCA	trans	rs1707322	1	rs785507	ENSG00000255397.1	AC022182.2	6.98	1.04e-11	1.63e-05	0.44	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr8:60937705~60939871:-
THCA	trans	rs6087990	0.899	rs1003521	ENSG00000253915.1	MAPRE1P1	6.98	1.04e-11	1.64e-05	0.39	0.31	Ulcerative colitis;	chr20:32778792	chr8:135625185~135625981:-
THCA	trans	rs9292918	0.806	rs6451795	ENSG00000231752.4	EMBP1	6.98	1.04e-11	1.64e-05	0.5	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45341699	chr1:121519112~121571892:+
THCA	trans	rs1707322	0.964	rs6675259	ENSG00000255397.1	AC022182.2	6.98	1.04e-11	1.64e-05	0.43	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr8:60937705~60939871:-
THCA	trans	rs864643	1	rs816490	ENSG00000183298.5	RP11-556K13.1	6.97	1.04e-11	1.64e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39512993	chr1:101786340~101787219:-
THCA	trans	rs16937956	0.597	rs12793685	ENSG00000266891.1	RP11-692N5.2	6.97	1.05e-11	1.65e-05	0.43	0.31	Body mass index;	chr11:8380583	chr18:9734882~9735602:-
THCA	trans	rs9292918	0.806	rs9885523	ENSG00000231752.4	EMBP1	6.97	1.05e-11	1.66e-05	0.5	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45322454	chr1:121519112~121571892:+
THCA	trans	rs7617480	0.648	rs6766238	ENSG00000197582.5	GPX1P1	6.97	1.05e-11	1.66e-05	0.52	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48764496	chrX:13378735~13379340:-
THCA	trans	rs17807624	0.702	rs7815172	ENSG00000253893.2	FAM85B	-6.97	1.06e-11	1.66e-05	-0.39	-0.31	Systemic lupus erythematosus;	chr8:11596162	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.899	rs1883729	ENSG00000253915.1	MAPRE1P1	6.97	1.06e-11	1.68e-05	0.39	0.31	Ulcerative colitis;	chr20:32775387	chr8:135625185~135625981:-
THCA	trans	rs864643	0.898	rs1473864	ENSG00000183298.5	RP11-556K13.1	6.97	1.07e-11	1.68e-05	0.48	0.31	Attention deficit hyperactivity disorder;	chr3:39499703	chr1:101786340~101787219:-
THCA	trans	rs34421088	0.532	rs2736258	ENSG00000253893.2	FAM85B	-6.97	1.07e-11	1.68e-05	-0.4	-0.31	Neuroticism;	chr8:11312940	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.882	rs12523231	ENSG00000231752.4	EMBP1	-6.97	1.07e-11	1.69e-05	-0.47	-0.31	Age at first birth;	chr5:45228734	chr1:121519112~121571892:+
THCA	trans	rs1707322	1	rs12097761	ENSG00000255397.1	AC022182.2	-6.97	1.08e-11	1.7e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs10789478	ENSG00000255397.1	AC022182.2	-6.97	1.08e-11	1.7e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs10789479	ENSG00000255397.1	AC022182.2	-6.97	1.08e-11	1.7e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.964	rs7512395	ENSG00000255397.1	AC022182.2	-6.97	1.08e-11	1.7e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.737	rs2293855	ENSG00000253893.2	FAM85B	-6.97	1.08e-11	1.7e-05	-0.4	-0.31	Retinal vascular caliber;	chr8:11319901	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.744	rs4841503	ENSG00000256560.1	LINC01486	-6.97	1.09e-11	1.72e-05	-0.38	-0.31	Triglycerides;	chr8:11166817	chr12:109354083~109359488:-
THCA	trans	rs12709013	1	rs6499983	ENSG00000230849.2	GOT2P2	6.97	1.09e-11	1.72e-05	0.38	0.31	Blood metabolite ratios;	chr16:58810005	chr1:173141100~173142350:-
THCA	trans	rs1707322	1	rs10890382	ENSG00000255397.1	AC022182.2	-6.97	1.09e-11	1.72e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4660335	ENSG00000255397.1	AC022182.2	-6.97	1.09e-11	1.72e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr8:60937705~60939871:-
THCA	trans	rs11250098	0.562	rs6987134	ENSG00000253893.2	FAM85B	6.97	1.1e-11	1.72e-05	0.4	0.31	Morning vs. evening chronotype;	chr8:10947396	chr8:8167819~8226614:-
THCA	trans	rs864643	1	rs1708002	ENSG00000183298.5	RP11-556K13.1	6.97	1.1e-11	1.73e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39511185	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs4113192	ENSG00000188856.6	RPSAP47	6.97	1.1e-11	1.74e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39495699	chr8:80558870~80559757:+
THCA	trans	rs864643	0.947	rs4113193	ENSG00000188856.6	RPSAP47	6.97	1.1e-11	1.74e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39495779	chr8:80558870~80559757:+
THCA	trans	rs73108077	1	rs73105971	ENSG00000279352.1	RP11-411B10.7	6.97	1.11e-11	1.74e-05	0.57	0.31	Red blood cell density in sickle cell anemia;	chr20:31369934	chr18:14010054~14010917:+
THCA	trans	rs9650657	0.683	rs7005905	ENSG00000253893.2	FAM85B	-6.96	1.11e-11	1.75e-05	-0.37	-0.31	Neuroticism;	chr8:10727634	chr8:8167819~8226614:-
THCA	trans	rs864643	0.812	rs7620264	ENSG00000183298.5	RP11-556K13.1	-6.96	1.12e-11	1.76e-05	-0.48	-0.31	Attention deficit hyperactivity disorder;	chr3:39537539	chr1:101786340~101787219:-
THCA	trans	rs1707322	0.752	rs12062535	ENSG00000255397.1	AC022182.2	-6.96	1.12e-11	1.76e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr8:60937705~60939871:-
THCA	trans	rs864643	0.812	rs3821372	ENSG00000183298.5	RP11-556K13.1	-6.96	1.12e-11	1.76e-05	-0.47	-0.31	Attention deficit hyperactivity disorder;	chr3:39506880	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs4113192	ENSG00000183298.5	RP11-556K13.1	6.96	1.13e-11	1.77e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39495699	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs4113193	ENSG00000183298.5	RP11-556K13.1	6.96	1.13e-11	1.77e-05	0.51	0.31	Attention deficit hyperactivity disorder;	chr3:39495779	chr1:101786340~101787219:-
THCA	trans	rs7819412	0.594	rs60921132	ENSG00000229857.1	RP11-159H20.3	6.96	1.13e-11	1.78e-05	0.41	0.31	Triglycerides;	chr8:11107459	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.711	rs12682352	ENSG00000256560.1	LINC01486	6.96	1.15e-11	1.8e-05	0.36	0.31	Mood instability;	chr8:8788736	chr12:109354083~109359488:-
THCA	trans	rs2896526	0.736	rs78950598	ENSG00000236090.2	LDHAP3	6.96	1.15e-11	1.81e-05	0.53	0.31	Amyloid A serum levels;	chr11:18375599	chr2:41819747~41820754:+
THCA	trans	rs864643	0.773	rs13064980	ENSG00000183298.5	RP11-556K13.1	-6.96	1.15e-11	1.81e-05	-0.47	-0.31	Attention deficit hyperactivity disorder;	chr3:39503973	chr1:101786340~101787219:-
THCA	trans	rs4263408	0.654	rs305827	ENSG00000237550.5	UBE2Q2P6	6.96	1.15e-11	1.81e-05	0.37	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39758369	chr15:82372196~82372912:-
THCA	trans	rs2950393	0.804	rs2958127	ENSG00000228224.3	NACAP1	6.96	1.16e-11	1.82e-05	0.31	0.31	Platelet distribution width;	chr12:56720523	chr8:101361794~101372707:+
THCA	trans	rs2645424	1	rs2645424	ENSG00000256560.1	LINC01486	-6.96	1.18e-11	1.86e-05	-0.37	-0.31	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826954	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.882	rs7711446	ENSG00000231752.4	EMBP1	6.96	1.19e-11	1.86e-05	0.47	0.31	Age at first birth;	chr5:45181775	chr1:121519112~121571892:+
THCA	trans	rs2736345	0.755	rs2736340	ENSG00000253893.2	FAM85B	-6.95	1.19e-11	1.86e-05	-0.45	-0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:8167819~8226614:-
THCA	trans	rs4295623	0.556	rs10903343	ENSG00000260438.1	RP11-405F3.2	-6.95	1.19e-11	1.86e-05	-0.42	-0.31	Morning vs. evening chronotype;	chr8:11838363	chr16:57713782~57714957:+
THCA	trans	rs9329221	0.538	rs9650651	ENSG00000253893.2	FAM85B	-6.95	1.19e-11	1.87e-05	-0.39	-0.31	Neuroticism;	chr8:10410030	chr8:8167819~8226614:-
THCA	trans	rs3740713	0.592	rs73434674	ENSG00000236090.2	LDHAP3	6.95	1.19e-11	1.87e-05	0.51	0.31	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:41819747~41820754:+
THCA	trans	rs902774	0.818	rs4919740	ENSG00000223940.1	KRT8P8	-6.95	1.19e-11	1.87e-05	-0.59	-0.31	Prostate cancer;	chr12:52877187	chrX:152479577~152481024:+
THCA	trans	rs9329221	0.648	rs4512422	ENSG00000253893.2	FAM85B	6.95	1.2e-11	1.88e-05	0.39	0.31	Neuroticism;	chr8:10401379	chr8:8167819~8226614:-
THCA	trans	rs6981523	0.532	rs1987190	ENSG00000253893.2	FAM85B	6.95	1.2e-11	1.88e-05	0.43	0.31	Neuroticism;	chr8:11196005	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.654	rs4840550	ENSG00000229857.1	RP11-159H20.3	6.95	1.2e-11	1.88e-05	0.4	0.31	Triglycerides;	chr8:11171520	chr9:76992099~76993108:+
THCA	trans	rs17711722	0.565	rs73372653	ENSG00000213640.3	EEF1DP4	-6.95	1.21e-11	1.9e-05	-0.37	-0.31	Calcium levels;	chr7:65977808	chr7:64862999~64864370:+
THCA	trans	rs6600671	1	rs11249350	ENSG00000270392.2	PFN1P2	6.95	1.21e-11	1.9e-05	0.3	0.31	Hip geometry;	chr1:121436587	chr1:120432204~120434052:-
THCA	trans	rs7829975	0.688	rs6995407	ENSG00000229857.1	RP11-159H20.3	-6.95	1.23e-11	1.93e-05	-0.39	-0.31	Mood instability;	chr8:8527137	chr9:76992099~76993108:+
THCA	trans	rs9876781	0.559	rs1903144	ENSG00000225528.1	RP3-370M22.8	-6.95	1.23e-11	1.93e-05	-0.38	-0.31	Longevity;	chr3:48364907	chr22:39960397~39964683:+
THCA	trans	rs902774	0.818	rs56207534	ENSG00000248568.1	KRT8P48	-6.95	1.24e-11	1.94e-05	-0.63	-0.31	Prostate cancer;	chr12:52873525	chr5:146706381~146707600:-
THCA	trans	rs11992162	0.591	rs4240678	ENSG00000256560.1	LINC01486	-6.95	1.25e-11	1.95e-05	-0.38	-0.31	Monocyte count;	chr8:11944917	chr12:109354083~109359488:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000224553.1	AC008065.1	6.95	1.25e-11	1.96e-05	0.38	0.31	Cognitive function;	chr12:55990903	chr2:171374931~171375278:-
THCA	trans	rs864643	1	rs816490	ENSG00000188856.6	RPSAP47	6.95	1.25e-11	1.96e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39512993	chr8:80558870~80559757:+
THCA	trans	rs7617480	0.648	rs6801211	ENSG00000197582.5	GPX1P1	6.95	1.25e-11	1.96e-05	0.51	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48736987	chrX:13378735~13379340:-
THCA	trans	rs2950393	0.927	rs11171914	ENSG00000257210.1	NACAP3	-6.95	1.25e-11	1.96e-05	-0.37	-0.31	Platelet distribution width;	chr12:56649462	chr12:93124063~93124543:-
THCA	trans	rs864643	0.945	rs529839	ENSG00000188856.6	RPSAP47	6.95	1.26e-11	1.97e-05	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39525267	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs546031	ENSG00000188856.6	RPSAP47	6.95	1.26e-11	1.97e-05	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39529886	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs569888	ENSG00000188856.6	RPSAP47	6.95	1.26e-11	1.97e-05	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39530165	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs946409	ENSG00000188856.6	RPSAP47	6.95	1.26e-11	1.97e-05	0.47	0.31	Attention deficit hyperactivity disorder;	chr3:39531549	chr8:80558870~80559757:+
THCA	trans	rs17711722	0.503	rs453835	ENSG00000213640.3	EEF1DP4	6.94	1.27e-11	1.98e-05	0.37	0.31	Calcium levels;	chr7:66046172	chr7:64862999~64864370:+
THCA	trans	rs1707322	1	rs4606257	ENSG00000255397.1	AC022182.2	-6.94	1.27e-11	1.99e-05	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr8:60937705~60939871:-
THCA	trans	rs864643	0.898	rs1768144	ENSG00000188856.6	RPSAP47	6.94	1.27e-11	1.99e-05	0.45	0.31	Attention deficit hyperactivity disorder;	chr3:39550569	chr8:80558870~80559757:+
THCA	trans	rs1190596	0.526	rs1190572	ENSG00000181359.5	HSP90AA6P	6.94	1.27e-11	1.99e-05	0.43	0.31	Behavioural disinhibition (generation interaction);	chr14:102168252	chr4:170581470~170605450:-
THCA	trans	rs864643	0.891	rs1068953	ENSG00000188856.6	RPSAP47	6.94	1.27e-11	1.99e-05	0.46	0.31	Attention deficit hyperactivity disorder;	chr3:39515070	chr8:80558870~80559757:+
THCA	trans	rs8177876	0.642	rs12445303	ENSG00000224837.1	GCSHP5	-6.94	1.28e-11	2e-05	-0.45	-0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr1:168055901~168056422:-
THCA	trans	rs853679	0.607	rs35749575	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28147040	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs72846780	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28151277	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13205911	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28156336	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13197176	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28161454	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13201308	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28162311	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34765154	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28162672	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34505829	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28165461	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs35098436	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28166443	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs72846794	ENSG00000253570.1	RNF5P1	6.94	1.28e-11	2e-05	0.86	0.31	Depression;	chr6:28169721	chr8:38600661~38601200:-
THCA	trans	rs9329221	0.683	rs3105738	ENSG00000253893.2	FAM85B	6.94	1.28e-11	2.01e-05	0.39	0.3	Neuroticism;	chr8:10032404	chr8:8167819~8226614:-
THCA	trans	rs7312770	1	rs7312770	ENSG00000233278.1	RPS26P2	-6.94	1.29e-11	2.02e-05	-0.34	-0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:30831878~30832225:-
THCA	trans	rs11992162	0.508	rs7003792	ENSG00000253893.2	FAM85B	6.94	1.3e-11	2.03e-05	0.41	0.3	Monocyte count;	chr8:11923955	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.715	rs35223712	ENSG00000229857.1	RP11-159H20.3	6.94	1.3e-11	2.04e-05	0.39	0.3	Triglycerides;	chr8:11186417	chr9:76992099~76993108:+
THCA	trans	rs864643	1	rs816494	ENSG00000188856.6	RPSAP47	6.94	1.31e-11	2.05e-05	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39515354	chr8:80558870~80559757:+
THCA	trans	rs7824557	0.713	rs9286062	ENSG00000253893.2	FAM85B	6.94	1.31e-11	2.05e-05	0.38	0.3	Retinal vascular caliber;	chr8:11261018	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.777	rs486781	ENSG00000256560.1	LINC01486	-6.94	1.32e-11	2.06e-05	-0.36	-0.3	Mood instability;	chr8:8782230	chr12:109354083~109359488:-
THCA	trans	rs2945232	1	rs2945232	ENSG00000229857.1	RP11-159H20.3	-6.94	1.32e-11	2.07e-05	-0.36	-0.3	Schizophrenia;	chr8:8240516	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.82	rs28394116	ENSG00000253326.2	RP11-261C10.7	6.94	1.32e-11	2.07e-05	0.43	0.3	Corneal astigmatism;	chr4:119603128	chr1:243054861~243056394:-
THCA	trans	rs7829975	0.582	rs448231	ENSG00000229857.1	RP11-159H20.3	6.94	1.32e-11	2.07e-05	0.38	0.3	Mood instability;	chr8:8932549	chr9:76992099~76993108:+
THCA	trans	rs1051424	0.642	rs115869798	ENSG00000187870.7	RNFT1P3	6.94	1.33e-11	2.08e-05	0.47	0.3	Obesity-related traits;	chr17:59815468	chr17:20743333~20754501:-
THCA	trans	rs11638815	0.581	rs783535	ENSG00000235370.6	DNM1P51	-6.94	1.33e-11	2.08e-05	-0.39	-0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82581676	chr15:84398316~84411701:-
THCA	trans	rs116095464	0.867	rs62330032	ENSG00000185986.11	SDHAP3	6.94	1.33e-11	2.08e-05	0.54	0.3	Breast cancer;	chr5:330442	chr5:1572222~1594620:-
THCA	trans	rs453301	0.624	rs2288671	ENSG00000229857.1	RP11-159H20.3	-6.94	1.33e-11	2.08e-05	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9003384	chr9:76992099~76993108:+
THCA	trans	rs2288327	0.818	rs2303539	ENSG00000269800.1	PLEKHA3P1	6.94	1.33e-11	2.09e-05	0.44	0.3	Atrial fibrillation;	chr2:178538866	chr19:41521043~41521989:-
THCA	trans	rs282544	1	rs2463797	ENSG00000231752.4	EMBP1	-6.94	1.33e-11	2.09e-05	-0.43	-0.3	Myopia (pathological);	chr5:50748788	chr1:121519112~121571892:+
THCA	trans	rs7617480	0.585	rs7373072	ENSG00000197582.5	GPX1P1	6.94	1.34e-11	2.1e-05	0.51	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48922584	chrX:13378735~13379340:-
THCA	trans	rs5022636	0.896	rs7531495	ENSG00000180764.13	PIPSL	6.94	1.34e-11	2.1e-05	0.34	0.3	Gut microbiota (functional units);	chr1:151352996	chr10:93958191~93961540:-
THCA	trans	rs864643	1	rs1707968	ENSG00000188856.6	RPSAP47	6.93	1.35e-11	2.11e-05	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39506914	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1707969	ENSG00000188856.6	RPSAP47	6.93	1.35e-11	2.11e-05	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39506998	chr8:80558870~80559757:+
THCA	trans	rs58106596	0.8	rs6737601	ENSG00000259020.3	RP11-529H20.3	6.93	1.37e-11	2.14e-05	0.48	0.3	Lymphocyte counts;White blood cell count;	chr2:231707671	chr14:92026566~92026887:+
THCA	trans	rs7617480	0.648	rs6796790	ENSG00000197582.5	GPX1P1	6.93	1.37e-11	2.14e-05	0.51	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48742884	chrX:13378735~13379340:-
THCA	trans	rs864643	0.947	rs645488	ENSG00000183298.5	RP11-556K13.1	6.93	1.37e-11	2.14e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39499028	chr1:101786340~101787219:-
THCA	trans	rs864643	0.891	rs1708032	ENSG00000183298.5	RP11-556K13.1	6.93	1.37e-11	2.15e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39497642	chr1:101786340~101787219:-
THCA	trans	rs656319	0.702	rs477860	ENSG00000253893.2	FAM85B	6.93	1.38e-11	2.16e-05	0.43	0.3	Myopia (pathological);	chr8:9954255	chr8:8167819~8226614:-
THCA	trans	rs6732160	0.588	rs28626211	ENSG00000236165.1	PRADC1P1	6.93	1.38e-11	2.16e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73151394	chr3:36976316~36976840:+
THCA	trans	rs864643	1	rs1708055	ENSG00000188856.6	RPSAP47	6.93	1.38e-11	2.16e-05	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39531672	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1615046	ENSG00000188856.6	RPSAP47	6.93	1.38e-11	2.16e-05	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39532309	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1615994	ENSG00000188856.6	RPSAP47	6.93	1.38e-11	2.16e-05	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39532428	chr8:80558870~80559757:+
THCA	trans	rs9329221	0.967	rs7005363	ENSG00000253893.2	FAM85B	6.93	1.39e-11	2.17e-05	0.39	0.3	Neuroticism;	chr8:10426238	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.882	rs6890289	ENSG00000231752.4	EMBP1	-6.93	1.39e-11	2.17e-05	-0.47	-0.3	Age at first birth;	chr5:45196045	chr1:121519112~121571892:+
THCA	trans	rs864643	0.812	rs7618019	ENSG00000183298.5	RP11-556K13.1	-6.93	1.42e-11	2.22e-05	-0.48	-0.3	Attention deficit hyperactivity disorder;	chr3:39538620	chr1:101786340~101787219:-
THCA	trans	rs2950393	0.804	rs1466382	ENSG00000228224.3	NACAP1	-6.93	1.42e-11	2.22e-05	-0.3	-0.3	Platelet distribution width;	chr12:56723050	chr8:101361794~101372707:+
THCA	trans	rs1580019	0.587	rs6968990	ENSG00000176826.14	FKBP9P1	6.93	1.44e-11	2.24e-05	0.41	0.3	Cognitive ability;	chr7:32512547	chr7:55681074~55713252:-
THCA	trans	rs16937956	0.597	rs12788830	ENSG00000266891.1	RP11-692N5.2	6.93	1.44e-11	2.24e-05	0.42	0.3	Body mass index;	chr11:8380429	chr18:9734882~9735602:-
THCA	trans	rs11638815	0.581	rs28808991	ENSG00000235370.6	DNM1P51	-6.92	1.44e-11	2.25e-05	-0.38	-0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82592229	chr15:84398316~84411701:-
THCA	trans	rs864643	1	rs1707973	ENSG00000188856.6	RPSAP47	6.92	1.45e-11	2.26e-05	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39507275	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.954	rs6857105	ENSG00000253326.2	RP11-261C10.7	6.92	1.45e-11	2.27e-05	0.43	0.3	Corneal astigmatism;	chr4:119301143	chr1:243054861~243056394:-
THCA	trans	rs6600671	1	rs12145080	ENSG00000270392.2	PFN1P2	-6.92	1.45e-11	2.27e-05	-0.3	-0.3	Hip geometry;	chr1:121443673	chr1:120432204~120434052:-
THCA	trans	rs7617480	0.549	rs9879978	ENSG00000197582.5	GPX1P1	6.92	1.47e-11	2.29e-05	0.51	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48809167	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.769	rs6772452	ENSG00000197582.5	GPX1P1	6.92	1.47e-11	2.3e-05	0.51	0.3	Menarche (age at onset);	chr3:49003029	chrX:13378735~13379340:-
THCA	trans	rs2950393	0.804	rs898609	ENSG00000228224.3	NACAP1	6.92	1.48e-11	2.3e-05	0.31	0.3	Platelet distribution width;	chr12:56713026	chr8:101361794~101372707:+
THCA	trans	rs2950393	0.804	rs4902	ENSG00000228224.3	NACAP1	6.92	1.48e-11	2.3e-05	0.31	0.3	Platelet distribution width;	chr12:56714419	chr8:101361794~101372707:+
THCA	trans	rs2950393	0.804	rs2926748	ENSG00000228224.3	NACAP1	6.92	1.48e-11	2.3e-05	0.31	0.3	Platelet distribution width;	chr12:56715628	chr8:101361794~101372707:+
THCA	trans	rs7829975	0.624	rs7823056	ENSG00000229857.1	RP11-159H20.3	-6.92	1.48e-11	2.3e-05	-0.38	-0.3	Mood instability;	chr8:8525195	chr9:76992099~76993108:+
THCA	trans	rs2069408	1	rs2069408	ENSG00000196933.5	RPS26P11	-6.92	1.48e-11	2.31e-05	-0.44	-0.3	Asthma;	chr12:55970537	chrX:72044545~72044892:+
THCA	trans	rs864643	1	rs1708055	ENSG00000183298.5	RP11-556K13.1	6.92	1.48e-11	2.31e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39531672	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1615046	ENSG00000183298.5	RP11-556K13.1	6.92	1.48e-11	2.31e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39532309	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1615994	ENSG00000183298.5	RP11-556K13.1	6.92	1.48e-11	2.31e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39532428	chr1:101786340~101787219:-
THCA	trans	rs7829975	0.688	rs7817376	ENSG00000256560.1	LINC01486	-6.92	1.49e-11	2.32e-05	-0.37	-0.3	Mood instability;	chr8:8523020	chr12:109354083~109359488:-
THCA	trans	rs864643	0.891	rs4129648	ENSG00000188856.6	RPSAP47	6.92	1.49e-11	2.32e-05	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39519319	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs673426	ENSG00000188856.6	RPSAP47	6.92	1.49e-11	2.32e-05	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39520286	chr8:80558870~80559757:+
THCA	trans	rs2288327	0.818	rs2288325	ENSG00000269800.1	PLEKHA3P1	6.92	1.49e-11	2.32e-05	0.43	0.3	Atrial fibrillation;	chr2:178540059	chr19:41521043~41521989:-
THCA	trans	rs1347297	0.789	rs11688081	ENSG00000269800.1	PLEKHA3P1	6.92	1.49e-11	2.33e-05	0.33	0.3	Alzheimer disease and age of onset;	chr2:178416072	chr19:41521043~41521989:-
THCA	trans	rs7819412	0.522	rs13276708	ENSG00000253893.2	FAM85B	6.92	1.49e-11	2.33e-05	0.42	0.3	Triglycerides;	chr8:11131696	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.522	rs13266785	ENSG00000253893.2	FAM85B	6.92	1.49e-11	2.33e-05	0.42	0.3	Triglycerides;	chr8:11132011	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.522	rs4291231	ENSG00000253893.2	FAM85B	6.92	1.49e-11	2.33e-05	0.42	0.3	Triglycerides;	chr8:11132654	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.522	rs10101329	ENSG00000253893.2	FAM85B	6.92	1.49e-11	2.33e-05	0.42	0.3	Triglycerides;	chr8:11133162	chr8:8167819~8226614:-
THCA	trans	rs10242455	0.867	rs1003009	ENSG00000228834.1	RP11-249L21.4	6.92	1.51e-11	2.35e-05	0.56	0.3	Blood metabolite levels;	chr7:99626336	chr6:108907615~108907873:-
THCA	trans	rs7829975	0.617	rs4841072	ENSG00000229857.1	RP11-159H20.3	6.92	1.52e-11	2.37e-05	0.38	0.3	Mood instability;	chr8:8933743	chr9:76992099~76993108:+
THCA	trans	rs12145833	0.79	rs74666281	ENSG00000154608.12	CEP170P1	-6.91	1.54e-11	2.39e-05	-0.4	-0.3	Obesity (early onset extreme);	chr1:243352678	chr4:118467590~118554204:+
THCA	trans	rs6087990	0.836	rs2424909	ENSG00000253915.1	MAPRE1P1	6.91	1.54e-11	2.39e-05	0.39	0.3	Ulcerative colitis;	chr20:32774055	chr8:135625185~135625981:-
THCA	trans	rs11992162	0.591	rs34123222	ENSG00000253893.2	FAM85B	6.91	1.54e-11	2.39e-05	0.42	0.3	Monocyte count;	chr8:11937840	chr8:8167819~8226614:-
THCA	trans	rs6600671	1	rs10903159	ENSG00000270392.2	PFN1P2	6.91	1.54e-11	2.4e-05	0.3	0.3	Hip geometry;	chr1:121440138	chr1:120432204~120434052:-
THCA	trans	rs1707322	1	rs1622208	ENSG00000255397.1	AC022182.2	6.91	1.55e-11	2.41e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr8:60937705~60939871:-
THCA	trans	rs7819412	0.668	rs2409714	ENSG00000253893.2	FAM85B	6.91	1.55e-11	2.42e-05	0.41	0.3	Triglycerides;	chr8:11152608	chr8:8167819~8226614:-
THCA	trans	rs9616064	0.506	rs2073275	ENSG00000258384.1	AC068831.6	6.91	1.56e-11	2.43e-05	0.37	0.3	Urate levels in obese individuals;	chr22:46674535	chr15:90952239~90955225:-
THCA	trans	rs9329221	0.662	rs9650650	ENSG00000253893.2	FAM85B	-6.91	1.57e-11	2.44e-05	-0.41	-0.3	Neuroticism;	chr8:10390466	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.622	rs1382567	ENSG00000256560.1	LINC01486	-6.91	1.58e-11	2.46e-05	-0.38	-0.3	Systolic blood pressure;	chr8:11493390	chr12:109354083~109359488:-
THCA	trans	rs864643	0.947	rs1708064	ENSG00000183298.5	RP11-556K13.1	6.91	1.58e-11	2.46e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39500679	chr1:101786340~101787219:-
THCA	trans	rs1707322	1	rs785490	ENSG00000255397.1	AC022182.2	6.91	1.59e-11	2.47e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs785493	ENSG00000255397.1	AC022182.2	6.91	1.59e-11	2.47e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.964	rs785496	ENSG00000255397.1	AC022182.2	6.91	1.59e-11	2.47e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs785497	ENSG00000255397.1	AC022182.2	6.91	1.59e-11	2.47e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.964	rs785499	ENSG00000255397.1	AC022182.2	6.91	1.59e-11	2.47e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr8:60937705~60939871:-
THCA	trans	rs7617480	0.648	rs9284885	ENSG00000197582.5	GPX1P1	6.91	1.6e-11	2.48e-05	0.51	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48845667	chrX:13378735~13379340:-
THCA	trans	rs864643	1	rs1612165	ENSG00000183298.5	RP11-556K13.1	6.91	1.62e-11	2.51e-05	0.53	0.3	Attention deficit hyperactivity disorder;	chr3:39501996	chr1:101786340~101787219:-
THCA	trans	rs10242455	0.867	rs2740560	ENSG00000228834.1	RP11-249L21.4	-6.91	1.62e-11	2.51e-05	-0.56	-0.3	Blood metabolite levels;	chr7:99724697	chr6:108907615~108907873:-
THCA	trans	rs10242455	0.681	rs2687140	ENSG00000228834.1	RP11-249L21.4	-6.91	1.62e-11	2.51e-05	-0.56	-0.3	Blood metabolite levels;	chr7:99724719	chr6:108907615~108907873:-
THCA	trans	rs2950393	0.804	rs2035081	ENSG00000228224.3	NACAP1	6.91	1.62e-11	2.51e-05	0.31	0.3	Platelet distribution width;	chr12:56732095	chr8:101361794~101372707:+
THCA	trans	rs2950393	0.804	rs10783796	ENSG00000228224.3	NACAP1	6.91	1.62e-11	2.51e-05	0.31	0.3	Platelet distribution width;	chr12:56733387	chr8:101361794~101372707:+
THCA	trans	rs1707322	1	rs785467	ENSG00000255397.1	AC022182.2	6.91	1.62e-11	2.51e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.683	rs7830431	ENSG00000253893.2	FAM85B	6.91	1.62e-11	2.52e-05	0.39	0.3	Neuroticism;	chr8:10842807	chr8:8167819~8226614:-
THCA	trans	rs864643	0.853	rs7645925	ENSG00000188856.6	RPSAP47	-6.91	1.63e-11	2.52e-05	-0.43	-0.3	Attention deficit hyperactivity disorder;	chr3:39538192	chr8:80558870~80559757:+
THCA	trans	rs11992162	0.613	rs56094399	ENSG00000253893.2	FAM85B	6.91	1.63e-11	2.53e-05	0.42	0.3	Monocyte count;	chr8:11939961	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.614	rs2736277	ENSG00000253893.2	FAM85B	6.9	1.64e-11	2.54e-05	0.4	0.3	Retinal vascular caliber;	chr8:11361384	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs73110471	ENSG00000255815.3	KRT8P11	-6.9	1.65e-11	2.56e-05	-0.63	-0.3	Prostate cancer;	chr12:52923037	chr9:99305176~99306611:+
THCA	trans	rs61041336	0.534	rs2280398	ENSG00000230849.2	GOT2P2	-6.9	1.66e-11	2.58e-05	-0.53	-0.3	Neuritic plaque;	chr16:58678226	chr1:173141100~173142350:-
THCA	trans	rs9329221	0.638	rs7460436	ENSG00000253893.2	FAM85B	-6.9	1.66e-11	2.58e-05	-0.41	-0.3	Neuroticism;	chr8:10396812	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.659	rs4073948	ENSG00000229857.1	RP11-159H20.3	6.9	1.67e-11	2.59e-05	0.36	0.3	Triglycerides;	chr8:10915134	chr9:76992099~76993108:+
THCA	trans	rs877636	0.702	rs773109	ENSG00000227586.5	RP11-162A23.5	6.9	1.67e-11	2.59e-05	0.4	0.3	Cognitive function;	chr12:55980911	chr10:123171535~123171875:-
THCA	trans	rs1707322	0.827	rs6683274	ENSG00000255397.1	AC022182.2	-6.9	1.67e-11	2.6e-05	-0.43	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr8:60937705~60939871:-
THCA	trans	rs2288327	0.818	rs16866397	ENSG00000269800.1	PLEKHA3P1	-6.9	1.7e-11	2.64e-05	-0.43	-0.3	Atrial fibrillation;	chr2:178556743	chr19:41521043~41521989:-
THCA	trans	rs9329221	0.683	rs688491	ENSG00000253893.2	FAM85B	6.9	1.71e-11	2.64e-05	0.39	0.3	Neuroticism;	chr8:10027313	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.863	rs13136462	ENSG00000253326.2	RP11-261C10.7	6.9	1.72e-11	2.67e-05	0.42	0.3	Corneal astigmatism;	chr4:119622018	chr1:243054861~243056394:-
THCA	trans	rs941207	0.526	rs2950393	ENSG00000257210.1	NACAP3	-6.9	1.73e-11	2.68e-05	-0.37	-0.3	Platelet count;	chr12:56642239	chr12:93124063~93124543:-
THCA	trans	rs7819412	0.715	rs35223712	ENSG00000256560.1	LINC01486	-6.9	1.73e-11	2.69e-05	-0.38	-0.3	Triglycerides;	chr8:11186417	chr12:109354083~109359488:-
THCA	trans	rs66823261	0.741	rs7841786	ENSG00000262094.1	AC139099.5	-6.89	1.74e-11	2.7e-05	-0.45	-0.3	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr17:83220527~83227721:-
THCA	trans	rs7829975	0.572	rs28730413	ENSG00000229857.1	RP11-159H20.3	6.89	1.75e-11	2.71e-05	0.38	0.3	Mood instability;	chr8:8937937	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.597	rs7016320	ENSG00000253893.2	FAM85B	6.89	1.76e-11	2.73e-05	0.41	0.3	Monocyte count;	chr8:11923543	chr8:8167819~8226614:-
THCA	trans	rs8067354	0.645	rs56236317	ENSG00000187870.7	RNFT1P3	6.89	1.78e-11	2.75e-05	0.46	0.3	Hemoglobin concentration;	chr17:59744764	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs7215180	ENSG00000187870.7	RNFT1P3	6.89	1.78e-11	2.75e-05	0.46	0.3	Hemoglobin concentration;	chr17:59744993	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.681	rs9907923	ENSG00000187870.7	RNFT1P3	6.89	1.78e-11	2.75e-05	0.46	0.3	Hemoglobin concentration;	chr17:59747566	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs72840522	ENSG00000187870.7	RNFT1P3	6.89	1.78e-11	2.75e-05	0.46	0.3	Hemoglobin concentration;	chr17:59752631	chr17:20743333~20754501:-
THCA	trans	rs7819412	0.74	rs7844536	ENSG00000229857.1	RP11-159H20.3	6.89	1.78e-11	2.76e-05	0.39	0.3	Triglycerides;	chr8:11176519	chr9:76992099~76993108:+
THCA	trans	rs7662987	1	rs1803037	ENSG00000228407.2	RP4-800M22.1	6.89	1.78e-11	2.76e-05	0.64	0.3	Smoking initiation;	chr4:99072000	chr1:52160261~52160600:-
THCA	trans	rs2898290	0.694	rs2248909	ENSG00000256560.1	LINC01486	-6.89	1.8e-11	2.78e-05	-0.37	-0.3	Systolic blood pressure;	chr8:11534584	chr12:109354083~109359488:-
THCA	trans	rs1051424	0.651	rs1292063	ENSG00000187870.7	RNFT1P3	-6.89	1.81e-11	2.79e-05	-0.46	-0.3	Obesity-related traits;	chr17:59830407	chr17:20743333~20754501:-
THCA	trans	rs1707322	0.964	rs785516	ENSG00000255397.1	AC022182.2	6.89	1.81e-11	2.81e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs785517	ENSG00000255397.1	AC022182.2	6.89	1.81e-11	2.81e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr8:60937705~60939871:-
THCA	trans	rs8067354	0.645	rs2102507	ENSG00000187870.7	RNFT1P3	6.89	1.82e-11	2.81e-05	0.46	0.3	Hemoglobin concentration;	chr17:59798546	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs2645491	ENSG00000187870.7	RNFT1P3	6.89	1.82e-11	2.81e-05	0.46	0.3	Hemoglobin concentration;	chr17:59799688	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs2665400	ENSG00000187870.7	RNFT1P3	6.89	1.82e-11	2.81e-05	0.46	0.3	Hemoglobin concentration;	chr17:59802840	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs2645489	ENSG00000187870.7	RNFT1P3	6.89	1.82e-11	2.81e-05	0.46	0.3	Hemoglobin concentration;	chr17:59806010	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs2645486	ENSG00000187870.7	RNFT1P3	6.89	1.82e-11	2.81e-05	0.46	0.3	Hemoglobin concentration;	chr17:59808540	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs2645487	ENSG00000187870.7	RNFT1P3	6.89	1.82e-11	2.81e-05	0.46	0.3	Hemoglobin concentration;	chr17:59808764	chr17:20743333~20754501:-
THCA	trans	rs1707322	0.963	rs12145287	ENSG00000255397.1	AC022182.2	-6.89	1.82e-11	2.82e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr8:60937705~60939871:-
THCA	trans	rs9329221	0.683	rs4598253	ENSG00000253893.2	FAM85B	6.89	1.82e-11	2.82e-05	0.38	0.3	Neuroticism;	chr8:10032794	chr8:8167819~8226614:-
THCA	trans	rs889398	0.641	rs7200258	ENSG00000257513.6	NPIPB1P	6.89	1.84e-11	2.84e-05	0.33	0.3	Body mass index;	chr16:69863566	chr18:11619509~11639699:-
THCA	trans	rs853679	0.546	rs13195291	ENSG00000253570.1	RNF5P1	6.89	1.84e-11	2.85e-05	0.84	0.3	Depression;	chr6:28201463	chr8:38600661~38601200:-
THCA	trans	rs853679	0.556	rs13197633	ENSG00000253570.1	RNF5P1	6.89	1.84e-11	2.85e-05	0.84	0.3	Depression;	chr6:28206979	chr8:38600661~38601200:-
THCA	trans	rs7617480	0.648	rs9882443	ENSG00000197582.5	GPX1P1	6.89	1.84e-11	2.85e-05	0.53	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48711631	chrX:13378735~13379340:-
THCA	trans	rs7833986	0.501	rs17812659	ENSG00000236862.1	RPS20P24	6.89	1.85e-11	2.85e-05	0.47	0.3	Height;	chr8:55977303	chr9:72655832~72656192:-
THCA	trans	rs864643	0.891	rs1626197	ENSG00000188856.6	RPSAP47	6.89	1.86e-11	2.87e-05	0.48	0.3	Attention deficit hyperactivity disorder;	chr3:39539974	chr8:80558870~80559757:+
THCA	trans	rs7829975	0.714	rs4840362	ENSG00000256560.1	LINC01486	-6.88	1.86e-11	2.88e-05	-0.36	-0.3	Mood instability;	chr8:8812572	chr12:109354083~109359488:-
THCA	trans	rs3956705	0.866	rs71532543	ENSG00000176826.14	FKBP9P1	-6.88	1.87e-11	2.88e-05	-0.4	-0.3	Red cell distribution width;	chr7:32959298	chr7:55681074~55713252:-
THCA	trans	rs9650657	0.501	rs3021500	ENSG00000256560.1	LINC01486	-6.88	1.87e-11	2.88e-05	-0.37	-0.3	Neuroticism;	chr8:11166488	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs11211232	ENSG00000255397.1	AC022182.2	-6.88	1.89e-11	2.91e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.564	rs1435275	ENSG00000254153.1	CTA-398F10.2	6.88	1.89e-11	2.92e-05	0.34	0.3	Retinal vascular caliber;	chr8:11378226	chr8:8456909~8461337:-
THCA	trans	rs853679	0.607	rs35902873	ENSG00000253570.1	RNF5P1	6.88	1.89e-11	2.92e-05	0.84	0.3	Depression;	chr6:28091171	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13197574	ENSG00000253570.1	RNF5P1	6.88	1.89e-11	2.92e-05	0.84	0.3	Depression;	chr6:28092461	chr8:38600661~38601200:-
THCA	trans	rs7824557	0.591	rs2736283	ENSG00000253893.2	FAM85B	6.88	1.89e-11	2.93e-05	0.4	0.3	Retinal vascular caliber;	chr8:11368401	chr8:8167819~8226614:-
THCA	trans	rs853679	0.607	rs13204012	ENSG00000253570.1	RNF5P1	6.88	1.9e-11	2.93e-05	0.84	0.3	Depression;	chr6:28233753	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13205211	ENSG00000253570.1	RNF5P1	6.88	1.9e-11	2.93e-05	0.84	0.3	Depression;	chr6:28235278	chr8:38600661~38601200:-
THCA	trans	rs7819412	0.668	rs2409721	ENSG00000256560.1	LINC01486	-6.88	1.9e-11	2.93e-05	-0.38	-0.3	Triglycerides;	chr8:11180735	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs11831919	ENSG00000255815.3	KRT8P11	-6.88	1.9e-11	2.93e-05	-0.63	-0.3	Prostate cancer;	chr12:52878231	chr9:99305176~99306611:+
THCA	trans	rs9329221	0.683	rs525726	ENSG00000253893.2	FAM85B	6.88	1.9e-11	2.94e-05	0.39	0.3	Neuroticism;	chr8:10030287	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.774	rs1039915	ENSG00000256560.1	LINC01486	6.88	1.92e-11	2.96e-05	0.36	0.3	Mood instability;	chr8:8822104	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.774	rs57312668	ENSG00000256560.1	LINC01486	6.88	1.93e-11	2.97e-05	0.36	0.3	Mood instability;	chr8:8822967	chr12:109354083~109359488:-
THCA	trans	rs853679	0.607	rs35001169	ENSG00000253570.1	RNF5P1	6.88	1.93e-11	2.98e-05	0.84	0.3	Depression;	chr6:28219854	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs35656932	ENSG00000253570.1	RNF5P1	6.88	1.93e-11	2.98e-05	0.84	0.3	Depression;	chr6:28223510	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13208096	ENSG00000253570.1	RNF5P1	6.88	1.93e-11	2.98e-05	0.84	0.3	Depression;	chr6:28257533	chr8:38600661~38601200:-
THCA	trans	rs9467773	0.587	rs3208733	ENSG00000242375.1	RP11-498P14.3	-6.88	1.93e-11	2.98e-05	-0.43	-0.3	Intelligence (multi-trait analysis);	chr6:26414197	chr9:97195351~97197687:-
THCA	trans	rs3806843	0.518	rs2569188	ENSG00000231043.3	AC007238.1	6.88	1.93e-11	2.98e-05	0.35	0.3	Depressive symptoms (multi-trait analysis);	chr5:140628834	chr2:58460292~58462032:-
THCA	trans	rs7819412	0.593	rs11778398	ENSG00000229857.1	RP11-159H20.3	6.88	1.94e-11	3e-05	0.41	0.3	Triglycerides;	chr8:11116733	chr9:76992099~76993108:+
THCA	trans	rs877636	0.74	rs705702	ENSG00000227586.5	RP11-162A23.5	-6.88	1.96e-11	3.02e-05	-0.39	-0.3	Cognitive function;	chr12:55996852	chr10:123171535~123171875:-
THCA	trans	rs902774	0.818	rs73110471	ENSG00000254285.3	KRT8P3	-6.88	1.96e-11	3.02e-05	-0.62	-0.3	Prostate cancer;	chr12:52923037	chr8:61578220~61579668:+
THCA	trans	rs1432133	0.844	rs12899579	ENSG00000256393.1	RPL41P5	-6.88	1.96e-11	3.02e-05	-0.42	-0.3	Hepatitis;	chr15:26979174	chr12:93083598~93083675:-
THCA	trans	rs853679	0.607	rs34788973	ENSG00000253570.1	RNF5P1	6.88	1.98e-11	3.05e-05	0.84	0.3	Depression;	chr6:27911422	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs61742093	ENSG00000253570.1	RNF5P1	6.88	1.98e-11	3.05e-05	0.84	0.3	Depression;	chr6:27912204	chr8:38600661~38601200:-
THCA	trans	rs34421088	0.548	rs2618443	ENSG00000253893.2	FAM85B	6.88	1.98e-11	3.05e-05	0.4	0.3	Neuroticism;	chr8:11527047	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.688	rs6601703	ENSG00000256560.1	LINC01486	6.87	1.98e-11	3.06e-05	0.37	0.3	Mood instability;	chr8:8522714	chr12:109354083~109359488:-
THCA	trans	rs9876781	0.53	rs35516531	ENSG00000225528.1	RP3-370M22.8	-6.87	1.99e-11	3.07e-05	-0.37	-0.3	Longevity;	chr3:48364275	chr22:39960397~39964683:+
THCA	trans	rs8067354	0.645	rs9910518	ENSG00000187870.7	RNFT1P3	6.87	1.99e-11	3.07e-05	0.46	0.3	Hemoglobin concentration;	chr17:59734706	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs28516945	ENSG00000187870.7	RNFT1P3	6.87	1.99e-11	3.07e-05	0.46	0.3	Hemoglobin concentration;	chr17:59739217	chr17:20743333~20754501:-
THCA	trans	rs11992162	0.56	rs13256329	ENSG00000253893.2	FAM85B	6.87	2e-11	3.08e-05	0.4	0.3	Monocyte count;	chr8:11924705	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.638	rs67146188	ENSG00000253893.2	FAM85B	6.87	2e-11	3.08e-05	0.4	0.3	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.863	rs6534139	ENSG00000253326.2	RP11-261C10.7	-6.87	2e-11	3.08e-05	-0.43	-0.3	Corneal astigmatism;	chr4:119528301	chr1:243054861~243056394:-
THCA	trans	rs1707322	0.721	rs6665808	ENSG00000255397.1	AC022182.2	-6.87	2e-11	3.09e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr8:60937705~60939871:-
THCA	trans	rs7819412	0.749	rs11991118	ENSG00000229857.1	RP11-159H20.3	-6.87	2.01e-11	3.1e-05	-0.37	-0.3	Triglycerides;	chr8:11081763	chr9:76992099~76993108:+
THCA	trans	rs8067354	0.645	rs2645467	ENSG00000187870.7	RNFT1P3	6.87	2.02e-11	3.11e-05	0.46	0.3	Hemoglobin concentration;	chr17:59777422	chr17:20743333~20754501:-
THCA	trans	rs864643	1	rs1340223	ENSG00000183298.5	RP11-556K13.1	6.87	2.02e-11	3.11e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39508208	chr1:101786340~101787219:-
THCA	trans	rs11098499	0.73	rs12505735	ENSG00000253326.2	RP11-261C10.7	6.87	2.03e-11	3.12e-05	0.42	0.3	Corneal astigmatism;	chr4:119611801	chr1:243054861~243056394:-
THCA	trans	rs7819412	0.669	rs6601568	ENSG00000256560.1	LINC01486	-6.87	2.03e-11	3.12e-05	-0.38	-0.3	Triglycerides;	chr8:11215893	chr12:109354083~109359488:-
THCA	trans	rs6732160	0.613	rs10179063	ENSG00000236165.1	PRADC1P1	6.87	2.05e-11	3.15e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73157983	chr3:36976316~36976840:+
THCA	trans	rs9329221	0.678	rs560638	ENSG00000253893.2	FAM85B	6.87	2.05e-11	3.16e-05	0.39	0.3	Neuroticism;	chr8:10025257	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.58	rs13260712	ENSG00000253893.2	FAM85B	6.87	2.05e-11	3.16e-05	0.4	0.3	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.551	rs13268217	ENSG00000253893.2	FAM85B	6.87	2.05e-11	3.16e-05	0.4	0.3	Monocyte count;	chr8:11925100	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.573	rs13264994	ENSG00000253893.2	FAM85B	6.87	2.05e-11	3.16e-05	0.4	0.3	Monocyte count;	chr8:11925250	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.573	rs13275808	ENSG00000253893.2	FAM85B	6.87	2.05e-11	3.16e-05	0.4	0.3	Monocyte count;	chr8:11925306	chr8:8167819~8226614:-
THCA	trans	rs7260598	0.792	rs73031013	ENSG00000261770.1	CTC-459F4.1	6.87	2.06e-11	3.17e-05	0.51	0.3	Response to taxane treatment (placlitaxel);	chr19:24182049	chr19:27757184~27760849:-
THCA	trans	rs864643	0.947	rs1708053	ENSG00000183298.5	RP11-556K13.1	6.87	2.07e-11	3.18e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39499706	chr1:101786340~101787219:-
THCA	trans	rs864643	0.891	rs1708057	ENSG00000183298.5	RP11-556K13.1	6.87	2.07e-11	3.18e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39499895	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs1768241	ENSG00000183298.5	RP11-556K13.1	6.87	2.07e-11	3.18e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39499987	chr1:101786340~101787219:-
THCA	trans	rs864643	0.891	rs1708059	ENSG00000183298.5	RP11-556K13.1	6.87	2.07e-11	3.18e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39500059	chr1:101786340~101787219:-
THCA	trans	rs864643	0.947	rs1768242	ENSG00000183298.5	RP11-556K13.1	6.87	2.07e-11	3.18e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39500222	chr1:101786340~101787219:-
THCA	trans	rs453301	0.507	rs2929306	ENSG00000229857.1	RP11-159H20.3	6.87	2.08e-11	3.19e-05	0.37	0.3	Joint mobility (Beighton score);	chr8:9227399	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.591	rs4240678	ENSG00000253893.2	FAM85B	6.87	2.09e-11	3.21e-05	0.4	0.3	Monocyte count;	chr8:11944917	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.771	rs4840516	ENSG00000253893.2	FAM85B	-6.87	2.09e-11	3.21e-05	-0.36	-0.3	Neuroticism;	chr8:10809825	chr8:8167819~8226614:-
THCA	trans	rs10783779	0.647	rs705708	ENSG00000234513.1	AC073072.7	6.87	2.09e-11	3.22e-05	0.37	0.3	Educational attainment;	chr12:56095129	chr7:22773646~22773993:-
THCA	trans	rs864643	1	rs1768127	ENSG00000183298.5	RP11-556K13.1	6.87	2.11e-11	3.24e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39523790	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs2542	ENSG00000183298.5	RP11-556K13.1	6.87	2.11e-11	3.24e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39525858	chr1:101786340~101787219:-
THCA	trans	rs864643	0.891	rs816518	ENSG00000183298.5	RP11-556K13.1	6.87	2.11e-11	3.24e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39527559	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1615844	ENSG00000183298.5	RP11-556K13.1	6.87	2.11e-11	3.24e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39532375	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1513216	ENSG00000183298.5	RP11-556K13.1	6.87	2.11e-11	3.24e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39532651	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1768134	ENSG00000183298.5	RP11-556K13.1	6.87	2.11e-11	3.24e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39533080	chr1:101786340~101787219:-
THCA	trans	rs864643	0.891	rs1624647	ENSG00000183298.5	RP11-556K13.1	6.87	2.11e-11	3.24e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39533558	chr1:101786340~101787219:-
THCA	trans	rs34421088	0.532	rs4515509	ENSG00000253893.2	FAM85B	-6.87	2.11e-11	3.24e-05	-0.4	-0.3	Neuroticism;	chr8:11314614	chr8:8167819~8226614:-
THCA	trans	rs2288327	0.818	rs16866365	ENSG00000269800.1	PLEKHA3P1	6.87	2.11e-11	3.24e-05	0.43	0.3	Atrial fibrillation;	chr2:178521125	chr19:41521043~41521989:-
THCA	trans	rs2288327	0.818	rs13034990	ENSG00000269800.1	PLEKHA3P1	6.87	2.11e-11	3.24e-05	0.43	0.3	Atrial fibrillation;	chr2:178521513	chr19:41521043~41521989:-
THCA	trans	rs7829975	0.774	rs13259216	ENSG00000256560.1	LINC01486	6.87	2.11e-11	3.24e-05	0.36	0.3	Mood instability;	chr8:8816091	chr12:109354083~109359488:-
THCA	trans	rs3740713	0.669	rs113003553	ENSG00000236090.2	LDHAP3	6.87	2.11e-11	3.24e-05	0.5	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr2:41819747~41820754:+
THCA	trans	rs7824557	0.564	rs2572389	ENSG00000254153.1	CTA-398F10.2	6.86	2.12e-11	3.26e-05	0.34	0.3	Retinal vascular caliber;	chr8:11378883	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs2736301	ENSG00000254153.1	CTA-398F10.2	6.86	2.12e-11	3.26e-05	0.34	0.3	Retinal vascular caliber;	chr8:11378904	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs2736302	ENSG00000254153.1	CTA-398F10.2	6.86	2.12e-11	3.26e-05	0.34	0.3	Retinal vascular caliber;	chr8:11378910	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.647	rs7821302	ENSG00000254153.1	CTA-398F10.2	6.86	2.12e-11	3.26e-05	0.34	0.3	Neuroticism;	chr8:11379063	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs7821459	ENSG00000254153.1	CTA-398F10.2	6.86	2.12e-11	3.26e-05	0.34	0.3	Retinal vascular caliber;	chr8:11379172	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs7834572	ENSG00000254153.1	CTA-398F10.2	6.86	2.12e-11	3.26e-05	0.34	0.3	Retinal vascular caliber;	chr8:11379176	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs4631424	ENSG00000254153.1	CTA-398F10.2	6.86	2.12e-11	3.26e-05	0.34	0.3	Retinal vascular caliber;	chr8:11379300	chr8:8456909~8461337:-
THCA	trans	rs11638815	0.626	rs1367841	ENSG00000235370.6	DNM1P51	6.86	2.12e-11	3.26e-05	0.38	0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82641874	chr15:84398316~84411701:-
THCA	trans	rs17040773	1	rs17040773	ENSG00000204745.3	AC083899.3	6.86	2.13e-11	3.27e-05	0.46	0.3	Bone mineral density;	chr2:111742458	chr2:87125390~87196647:+
THCA	trans	rs4512344	0.509	rs2409784	ENSG00000229857.1	RP11-159H20.3	6.86	2.15e-11	3.3e-05	0.38	0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr9:76992099~76993108:+
THCA	trans	rs6600671	1	rs10903161	ENSG00000270392.2	PFN1P2	6.86	2.15e-11	3.3e-05	0.3	0.3	Hip geometry;	chr1:121436882	chr1:120432204~120434052:-
THCA	trans	rs11638815	0.603	rs783520	ENSG00000235370.6	DNM1P51	-6.86	2.19e-11	3.36e-05	-0.38	-0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82610755	chr15:84398316~84411701:-
THCA	trans	rs9329221	0.662	rs4240645	ENSG00000253893.2	FAM85B	6.86	2.19e-11	3.36e-05	0.4	0.3	Neuroticism;	chr8:10396953	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.659	rs4382480	ENSG00000256560.1	LINC01486	6.86	2.19e-11	3.36e-05	0.37	0.3	Mood instability;	chr8:8863963	chr12:109354083~109359488:-
THCA	trans	rs7113874	0.591	rs2311436	ENSG00000266891.1	RP11-692N5.2	6.86	2.2e-11	3.37e-05	0.38	0.3	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8385174	chr18:9734882~9735602:-
THCA	trans	rs73108077	0.736	rs73119530	ENSG00000279352.1	RP11-411B10.7	6.86	2.21e-11	3.39e-05	0.65	0.3	Red blood cell density in sickle cell anemia;	chr20:31258810	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs73104095	ENSG00000279352.1	RP11-411B10.7	6.86	2.22e-11	3.4e-05	0.65	0.3	Red blood cell density in sickle cell anemia;	chr20:31312074	chr18:14010054~14010917:+
THCA	trans	rs7829975	0.688	rs7837587	ENSG00000256560.1	LINC01486	6.86	2.23e-11	3.42e-05	0.37	0.3	Mood instability;	chr8:8521482	chr12:109354083~109359488:-
THCA	trans	rs7647973	0.769	rs7434187	ENSG00000197582.5	GPX1P1	6.86	2.23e-11	3.43e-05	0.52	0.3	Menarche (age at onset);	chr3:48995534	chrX:13378735~13379340:-
THCA	trans	rs804280	0.662	rs11784693	ENSG00000253893.2	FAM85B	6.86	2.24e-11	3.43e-05	0.44	0.3	Myopia (pathological);	chr8:11753165	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs79377635	ENSG00000255815.3	KRT8P11	-6.86	2.25e-11	3.45e-05	-0.63	-0.3	Prostate cancer;	chr12:52883148	chr9:99305176~99306611:+
THCA	trans	rs816535	1	rs816535	ENSG00000279352.1	RP11-411B10.7	6.85	2.25e-11	3.45e-05	0.45	0.3	Parkinson disease and lewy body pathology;	chr20:26275360	chr18:14010054~14010917:+
THCA	trans	rs616147	0.671	rs674192	ENSG00000243904.1	RP11-600F24.1	-6.85	2.27e-11	3.48e-05	-0.37	-0.3	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr14:103374033~103374916:-
THCA	trans	rs7824557	0.767	rs10104728	ENSG00000253893.2	FAM85B	-6.85	2.27e-11	3.48e-05	-0.39	-0.3	Retinal vascular caliber;	chr8:11313791	chr8:8167819~8226614:-
THCA	trans	rs453301	0.571	rs2929453	ENSG00000229857.1	RP11-159H20.3	6.85	2.28e-11	3.5e-05	0.37	0.3	Joint mobility (Beighton score);	chr8:9226831	chr9:76992099~76993108:+
THCA	trans	rs889398	0.617	rs4985447	ENSG00000257513.6	NPIPB1P	6.85	2.29e-11	3.51e-05	0.33	0.3	Body mass index;	chr16:69851263	chr18:11619509~11639699:-
THCA	trans	rs116095464	1	rs3936676	ENSG00000185986.11	SDHAP3	6.85	2.29e-11	3.51e-05	0.53	0.3	Breast cancer;	chr5:353562	chr5:1572222~1594620:-
THCA	trans	rs6885307	0.882	rs56699889	ENSG00000231752.4	EMBP1	6.85	2.29e-11	3.51e-05	0.48	0.3	Age at first birth;	chr5:45125516	chr1:121519112~121571892:+
THCA	trans	rs34421088	0.506	rs2572426	ENSG00000253893.2	FAM85B	-6.85	2.3e-11	3.52e-05	-0.4	-0.3	Neuroticism;	chr8:11289614	chr8:8167819~8226614:-
THCA	trans	rs941207	0.526	rs12229457	ENSG00000257210.1	NACAP3	-6.85	2.32e-11	3.55e-05	-0.37	-0.3	Platelet count;	chr12:56639896	chr12:93124063~93124543:-
THCA	trans	rs6964833	1	rs34324835	ENSG00000214544.6	GTF2IRD2P1	-6.85	2.32e-11	3.56e-05	-0.45	-0.3	Menarche (age at onset);	chr7:74717986	chr7:73242751~73280119:-
THCA	trans	rs2736345	0.516	rs9657551	ENSG00000253893.2	FAM85B	-6.85	2.33e-11	3.56e-05	-0.4	-0.3	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11540674	chr8:8167819~8226614:-
THCA	trans	rs8067354	0.645	rs9899611	ENSG00000187870.7	RNFT1P3	6.85	2.33e-11	3.57e-05	0.46	0.3	Hemoglobin concentration;	chr17:59754829	chr17:20743333~20754501:-
THCA	trans	rs7819412	0.502	rs10095003	ENSG00000253893.2	FAM85B	6.85	2.36e-11	3.62e-05	0.45	0.3	Triglycerides;	chr8:11184940	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs73438686	ENSG00000236090.2	LDHAP3	6.85	2.37e-11	3.63e-05	0.56	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr2:41819747~41820754:+
THCA	trans	rs13177918	0.871	rs11745133	ENSG00000226396.1	RP5-1056L3.3	6.85	2.38e-11	3.63e-05	0.31	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.871	rs11745194	ENSG00000226396.1	RP5-1056L3.3	6.85	2.38e-11	3.63e-05	0.31	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr1:19608114~19608568:+
THCA	trans	rs58106596	0.8	rs67402940	ENSG00000259020.3	RP11-529H20.3	6.85	2.38e-11	3.64e-05	0.48	0.3	Lymphocyte counts;White blood cell count;	chr2:231701789	chr14:92026566~92026887:+
THCA	trans	rs3764796	0.609	rs17502404	ENSG00000250030.2	RP11-584P21.4	6.85	2.38e-11	3.64e-05	0.58	0.3	Calcium levels;	chr8:17214113	chr4:67446267~67446574:+
THCA	trans	rs7833986	0.501	rs72653917	ENSG00000236862.1	RPS20P24	6.85	2.38e-11	3.65e-05	0.46	0.3	Height;	chr8:55980285	chr9:72655832~72656192:-
THCA	trans	rs2980439	0.556	rs2921059	ENSG00000256560.1	LINC01486	6.85	2.39e-11	3.65e-05	0.36	0.3	Neuroticism;	chr8:8460377	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.648	rs6601512	ENSG00000253893.2	FAM85B	6.85	2.4e-11	3.66e-05	0.37	0.3	Neuroticism;	chr8:10728086	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.547	rs2409745	ENSG00000229857.1	RP11-159H20.3	-6.84	2.4e-11	3.67e-05	-0.39	-0.3	Retinal vascular caliber;	chr8:11219126	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.559	rs12386974	ENSG00000229857.1	RP11-159H20.3	-6.84	2.41e-11	3.68e-05	-0.39	-0.3	Neuroticism;	chr8:11543119	chr9:76992099~76993108:+
THCA	trans	rs7617480	0.648	rs4974083	ENSG00000197582.5	GPX1P1	6.84	2.42e-11	3.7e-05	0.52	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48963193	chrX:13378735~13379340:-
THCA	trans	rs8067354	0.645	rs9901606	ENSG00000187870.7	RNFT1P3	6.84	2.43e-11	3.71e-05	0.46	0.3	Hemoglobin concentration;	chr17:59734046	chr17:20743333~20754501:-
THCA	trans	rs2898290	0.622	rs7822109	ENSG00000256560.1	LINC01486	-6.84	2.43e-11	3.71e-05	-0.38	-0.3	Systolic blood pressure;	chr8:11491638	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.742	rs882462	ENSG00000256560.1	LINC01486	6.84	2.43e-11	3.72e-05	0.36	0.3	Mood instability;	chr8:8821020	chr12:109354083~109359488:-
THCA	trans	rs10870270	0.5	rs9419217	ENSG00000197358.9	BNIP3P1	6.84	2.44e-11	3.72e-05	0.37	0.3	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr10:131944875	chr14:28264390~28265974:+
THCA	trans	rs330048	0.545	rs719409	ENSG00000253893.2	FAM85B	-6.84	2.44e-11	3.72e-05	-0.38	-0.3	Systemic lupus erythematosus;	chr8:9293716	chr8:8167819~8226614:-
THCA	trans	rs889398	0.617	rs4985450	ENSG00000257513.6	NPIPB1P	-6.84	2.45e-11	3.74e-05	-0.33	-0.3	Body mass index;	chr16:69867203	chr18:11619509~11639699:-
THCA	trans	rs6732160	0.588	rs3891890	ENSG00000236165.1	PRADC1P1	6.84	2.45e-11	3.75e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73150921	chr3:36976316~36976840:+
THCA	trans	rs34421088	0.532	rs2736388	ENSG00000253893.2	FAM85B	-6.84	2.46e-11	3.76e-05	-0.4	-0.3	Neuroticism;	chr8:11302079	chr8:8167819~8226614:-
THCA	trans	rs847577	0.646	rs10270222	ENSG00000225169.1	BRI3P1	-6.84	2.47e-11	3.77e-05	-0.39	-0.3	Breast cancer;	chr7:98152487	chr1:100213293~100213670:+
THCA	trans	rs2060793	0.519	rs7931378	ENSG00000236360.2	RP11-334A14.2	6.84	2.47e-11	3.77e-05	0.4	0.3	Vitamin D levels;	chr11:14592869	chr1:52993201~52993702:-
THCA	trans	rs1707322	0.827	rs10890347	ENSG00000255397.1	AC022182.2	6.84	2.48e-11	3.78e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.771	rs12542888	ENSG00000253893.2	FAM85B	6.84	2.48e-11	3.78e-05	0.38	0.3	Neuroticism;	chr8:10805045	chr8:8167819~8226614:-
THCA	trans	rs853679	0.546	rs71537572	ENSG00000253570.1	RNF5P1	6.84	2.48e-11	3.78e-05	0.84	0.3	Depression;	chr6:28002937	chr8:38600661~38601200:-
THCA	trans	rs4911259	0.533	rs6058931	ENSG00000253915.1	MAPRE1P1	-6.84	2.48e-11	3.79e-05	-0.39	-0.3	Inflammatory bowel disease;	chr20:32883206	chr8:135625185~135625981:-
THCA	trans	rs11992162	0.569	rs11786149	ENSG00000256560.1	LINC01486	-6.84	2.49e-11	3.8e-05	-0.39	-0.3	Monocyte count;	chr8:11943309	chr12:109354083~109359488:-
THCA	trans	rs853679	0.546	rs35017208	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28377505	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs13213152	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28381921	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs36092177	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28390030	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs13213986	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28390232	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs2232429	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28391855	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs2232426	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28392882	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs34546986	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28394532	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs34871267	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28396455	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs2232423	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28398374	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs35883476	ENSG00000228022.4	HCG20	-6.84	2.5e-11	3.82e-05	-0.76	-0.3	Depression;	chr6:28400731	chr6:30766825~30792250:+
THCA	trans	rs2060793	0.519	rs2597212	ENSG00000236360.2	RP11-334A14.2	-6.84	2.5e-11	3.82e-05	-0.4	-0.3	Vitamin D levels;	chr11:14560216	chr1:52993201~52993702:-
THCA	trans	rs76228276	0.737	rs11990888	ENSG00000260318.1	COX6CP1	6.84	2.52e-11	3.84e-05	0.91	0.3	Childhood ear infection;	chr8:99190449	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11986652	ENSG00000260318.1	COX6CP1	6.84	2.52e-11	3.84e-05	0.91	0.3	Childhood ear infection;	chr8:99271882	chr16:11903923~11904137:-
THCA	trans	rs6885307	0.825	rs62369905	ENSG00000231752.4	EMBP1	6.84	2.52e-11	3.84e-05	0.45	0.3	Age at first birth;	chr5:45094898	chr1:121519112~121571892:+
THCA	trans	rs656319	0.607	rs12156030	ENSG00000253893.2	FAM85B	6.84	2.52e-11	3.85e-05	0.42	0.3	Myopia (pathological);	chr8:10240012	chr8:8167819~8226614:-
THCA	trans	rs616147	0.627	rs816487	ENSG00000243904.1	RP11-600F24.1	-6.84	2.52e-11	3.85e-05	-0.36	-0.3	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr14:103374033~103374916:-
THCA	trans	rs2288327	0.818	rs744426	ENSG00000269800.1	PLEKHA3P1	6.84	2.53e-11	3.86e-05	0.44	0.3	Atrial fibrillation;	chr2:178571293	chr19:41521043~41521989:-
THCA	trans	rs7829975	0.591	rs12677543	ENSG00000256560.1	LINC01486	6.84	2.53e-11	3.86e-05	0.36	0.3	Mood instability;	chr8:8786764	chr12:109354083~109359488:-
THCA	trans	rs453301	0.571	rs2929452	ENSG00000229857.1	RP11-159H20.3	6.84	2.53e-11	3.86e-05	0.36	0.3	Joint mobility (Beighton score);	chr8:9226955	chr9:76992099~76993108:+
THCA	trans	rs7826238	0.564	rs2921053	ENSG00000256560.1	LINC01486	6.84	2.54e-11	3.87e-05	0.36	0.3	Systolic blood pressure;	chr8:8462453	chr12:109354083~109359488:-
THCA	trans	rs453301	0.624	rs330060	ENSG00000229857.1	RP11-159H20.3	6.84	2.55e-11	3.89e-05	0.37	0.3	Joint mobility (Beighton score);	chr8:9233392	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.597	rs6996342	ENSG00000253893.2	FAM85B	6.83	2.56e-11	3.9e-05	0.41	0.3	Monocyte count;	chr8:11927032	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.882	rs11954598	ENSG00000231752.4	EMBP1	6.83	2.58e-11	3.94e-05	0.46	0.3	Age at first birth;	chr5:45236309	chr1:121519112~121571892:+
THCA	trans	rs453301	0.571	rs330057	ENSG00000229857.1	RP11-159H20.3	6.83	2.61e-11	3.98e-05	0.37	0.3	Joint mobility (Beighton score);	chr8:9232283	chr9:76992099~76993108:+
THCA	trans	rs2336384	1	rs2103876	ENSG00000261819.1	RP11-680G24.4	6.83	2.63e-11	4.01e-05	0.39	0.3	Platelet count;	chr1:11993043	chr16:14988259~14990160:-
THCA	trans	rs9650657	0.683	rs7836366	ENSG00000253893.2	FAM85B	6.83	2.64e-11	4.02e-05	0.37	0.3	Neuroticism;	chr8:10728173	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.815	rs958648	ENSG00000253893.2	FAM85B	6.83	2.64e-11	4.02e-05	0.37	0.3	Retinal vascular caliber;	chr8:11246386	chr8:8167819~8226614:-
THCA	trans	rs67340775	0.834	rs13218875	ENSG00000228022.4	HCG20	-6.83	2.64e-11	4.03e-05	-0.76	-0.3	Lung cancer in ever smokers;	chr6:27916234	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs67040724	ENSG00000228022.4	HCG20	-6.83	2.64e-11	4.03e-05	-0.76	-0.3	Depression;	chr6:27937731	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs67662114	ENSG00000228022.4	HCG20	-6.83	2.64e-11	4.03e-05	-0.76	-0.3	Depression;	chr6:27964523	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13216117	ENSG00000228022.4	HCG20	-6.83	2.64e-11	4.03e-05	-0.76	-0.3	Depression;	chr6:27970706	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs36101351	ENSG00000228022.4	HCG20	-6.83	2.64e-11	4.03e-05	-0.76	-0.3	Depression;	chr6:27975591	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs28360499	ENSG00000228022.4	HCG20	-6.83	2.64e-11	4.03e-05	-0.76	-0.3	Depression;	chr6:27977618	chr6:30766825~30792250:+
THCA	trans	rs864643	0.947	rs563767	ENSG00000183298.5	RP11-556K13.1	6.83	2.66e-11	4.05e-05	0.48	0.3	Attention deficit hyperactivity disorder;	chr3:39498075	chr1:101786340~101787219:-
THCA	trans	rs12145833	0.679	rs6429425	ENSG00000154608.12	CEP170P1	-6.83	2.67e-11	4.06e-05	-0.4	-0.3	Obesity (early onset extreme);	chr1:243427688	chr4:118467590~118554204:+
THCA	trans	rs864643	0.945	rs614453	ENSG00000188856.6	RPSAP47	6.83	2.67e-11	4.06e-05	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39541076	chr8:80558870~80559757:+
THCA	trans	rs7824557	0.569	rs2409718	ENSG00000256560.1	LINC01486	-6.83	2.68e-11	4.08e-05	-0.37	-0.3	Retinal vascular caliber;	chr8:11155467	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs1612419	ENSG00000255397.1	AC022182.2	6.83	2.69e-11	4.1e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr8:60937705~60939871:-
THCA	trans	rs9329221	0.683	rs814359	ENSG00000253893.2	FAM85B	6.83	2.69e-11	4.1e-05	0.38	0.3	Neuroticism;	chr8:10025622	chr8:8167819~8226614:-
THCA	trans	rs1391708	0.504	rs11832720	ENSG00000121089.4	NACA3P	-6.83	2.69e-11	4.1e-05	-0.55	-0.3	Airway wall thickness;	chr12:56863460	chr4:164943290~164943937:+
THCA	trans	rs6732160	0.588	rs2043101	ENSG00000236165.1	PRADC1P1	6.83	2.71e-11	4.12e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73146922	chr3:36976316~36976840:+
THCA	trans	rs9393777	0.841	rs67092078	ENSG00000253570.1	RNF5P1	6.83	2.71e-11	4.12e-05	0.85	0.3	Intelligence (multi-trait analysis);	chr6:27086993	chr8:38600661~38601200:-
THCA	trans	rs116095464	1	rs61079948	ENSG00000185986.11	SDHAP3	6.83	2.71e-11	4.12e-05	0.53	0.3	Breast cancer;	chr5:325388	chr5:1572222~1594620:-
THCA	trans	rs2950393	0.777	rs12828563	ENSG00000228224.3	NACAP1	6.83	2.71e-11	4.13e-05	0.31	0.3	Platelet distribution width;	chr12:56709378	chr8:101361794~101372707:+
THCA	trans	rs1707322	1	rs10890381	ENSG00000255397.1	AC022182.2	-6.83	2.71e-11	4.13e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr8:60937705~60939871:-
THCA	trans	rs847577	0.677	rs10242903	ENSG00000225169.1	BRI3P1	-6.83	2.72e-11	4.13e-05	-0.39	-0.3	Breast cancer;	chr7:98112483	chr1:100213293~100213670:+
THCA	trans	rs9329221	0.618	rs4314693	ENSG00000253893.2	FAM85B	6.83	2.72e-11	4.13e-05	0.38	0.3	Neuroticism;	chr8:10401422	chr8:8167819~8226614:-
THCA	trans	rs2288327	0.818	rs3731749	ENSG00000269800.1	PLEKHA3P1	6.82	2.74e-11	4.16e-05	0.43	0.3	Atrial fibrillation;	chr2:178541464	chr19:41521043~41521989:-
THCA	trans	rs4263408	1	rs13122400	ENSG00000237550.5	UBE2Q2P6	6.82	2.76e-11	4.19e-05	0.36	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39712123	chr15:82372196~82372912:-
THCA	trans	rs8067354	0.645	rs72838857	ENSG00000187870.7	RNFT1P3	6.82	2.76e-11	4.2e-05	0.48	0.3	Hemoglobin concentration;	chr17:59759406	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs16943838	ENSG00000187870.7	RNFT1P3	6.82	2.76e-11	4.2e-05	0.48	0.3	Hemoglobin concentration;	chr17:59762243	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs1874548	ENSG00000187870.7	RNFT1P3	6.82	2.76e-11	4.2e-05	0.48	0.3	Hemoglobin concentration;	chr17:59763996	chr17:20743333~20754501:-
THCA	trans	rs116095464	1	rs6879758	ENSG00000185986.11	SDHAP3	6.82	2.78e-11	4.22e-05	0.53	0.3	Breast cancer;	chr5:350162	chr5:1572222~1594620:-
THCA	trans	rs864643	1	rs1340224	ENSG00000183298.5	RP11-556K13.1	6.82	2.78e-11	4.22e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39508072	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1340222	ENSG00000183298.5	RP11-556K13.1	6.82	2.78e-11	4.22e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39508312	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs536454	ENSG00000183298.5	RP11-556K13.1	6.82	2.78e-11	4.22e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39508827	chr1:101786340~101787219:-
THCA	trans	rs864643	0.945	rs583083	ENSG00000183298.5	RP11-556K13.1	6.82	2.78e-11	4.22e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39508954	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs581691	ENSG00000183298.5	RP11-556K13.1	6.82	2.78e-11	4.22e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39509244	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs689352	ENSG00000183298.5	RP11-556K13.1	6.82	2.78e-11	4.22e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39509275	chr1:101786340~101787219:-
THCA	trans	rs3849046	0.934	rs7714751	ENSG00000226666.1	HSPA9P1	-6.82	2.78e-11	4.23e-05	-0.31	-0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138513377	chr2:221961737~221963765:+
THCA	trans	rs6732160	0.588	rs1430344	ENSG00000236165.1	PRADC1P1	6.82	2.78e-11	4.23e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73146216	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.588	rs2043100	ENSG00000236165.1	PRADC1P1	6.82	2.78e-11	4.23e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73146968	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.588	rs2043099	ENSG00000236165.1	PRADC1P1	6.82	2.78e-11	4.23e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73147028	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.588	rs11126392	ENSG00000236165.1	PRADC1P1	6.82	2.78e-11	4.23e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73147326	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.588	rs7578991	ENSG00000236165.1	PRADC1P1	6.82	2.78e-11	4.23e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73149043	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.564	rs7605716	ENSG00000236165.1	PRADC1P1	6.82	2.78e-11	4.23e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73149122	chr3:36976316~36976840:+
THCA	trans	rs7824557	1	rs7824557	ENSG00000253893.2	FAM85B	6.82	2.79e-11	4.23e-05	0.38	0.3	Retinal vascular caliber;	chr8:11246602	chr8:8167819~8226614:-
THCA	trans	rs2336384	1	rs6668386	ENSG00000261819.1	RP11-680G24.4	6.82	2.79e-11	4.24e-05	0.39	0.3	Platelet count;	chr1:11987176	chr16:14988259~14990160:-
THCA	trans	rs6087990	0.735	rs1855350	ENSG00000253915.1	MAPRE1P1	6.82	2.81e-11	4.27e-05	0.39	0.3	Ulcerative colitis;	chr20:32799719	chr8:135625185~135625981:-
THCA	trans	rs864643	0.524	rs80322842	ENSG00000183298.5	RP11-556K13.1	6.82	2.81e-11	4.27e-05	0.62	0.3	Attention deficit hyperactivity disorder;	chr3:39483682	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1340225	ENSG00000183298.5	RP11-556K13.1	6.82	2.82e-11	4.28e-05	0.5	0.3	Attention deficit hyperactivity disorder;	chr3:39533951	chr1:101786340~101787219:-
THCA	trans	rs116095464	1	rs62331560	ENSG00000185986.11	SDHAP3	6.82	2.82e-11	4.28e-05	0.51	0.3	Breast cancer;	chr5:346670	chr5:1572222~1594620:-
THCA	trans	rs864643	0.524	rs17038918	ENSG00000183298.5	RP11-556K13.1	6.82	2.82e-11	4.28e-05	0.61	0.3	Attention deficit hyperactivity disorder;	chr3:39480975	chr1:101786340~101787219:-
THCA	trans	rs10242455	0.867	rs3735453	ENSG00000228834.1	RP11-249L21.4	-6.82	2.82e-11	4.28e-05	-0.55	-0.3	Blood metabolite levels;	chr7:99631812	chr6:108907615~108907873:-
THCA	trans	rs877636	1	rs877636	ENSG00000227586.5	RP11-162A23.5	-6.82	2.82e-11	4.29e-05	-0.38	-0.3	Cognitive function;	chr12:56086799	chr10:123171535~123171875:-
THCA	trans	rs7824557	0.872	rs1347410	ENSG00000253893.2	FAM85B	6.82	2.84e-11	4.32e-05	0.37	0.3	Retinal vascular caliber;	chr8:11253733	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.628	rs7820301	ENSG00000253893.2	FAM85B	-6.82	2.84e-11	4.32e-05	-0.4	-0.3	Retinal vascular caliber;	chr8:11371163	chr8:8167819~8226614:-
THCA	trans	rs3849046	1	rs13155345	ENSG00000226666.1	HSPA9P1	-6.82	2.86e-11	4.33e-05	-0.31	-0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138519235	chr2:221961737~221963765:+
THCA	trans	rs7647973	0.769	rs6446204	ENSG00000197582.5	GPX1P1	6.82	2.86e-11	4.34e-05	0.52	0.3	Menarche (age at onset);	chr3:48997446	chrX:13378735~13379340:-
THCA	trans	rs453301	0.624	rs330056	ENSG00000229857.1	RP11-159H20.3	6.82	2.87e-11	4.35e-05	0.37	0.3	Joint mobility (Beighton score);	chr8:9232185	chr9:76992099~76993108:+
THCA	trans	rs11250098	0.583	rs36030755	ENSG00000253893.2	FAM85B	6.82	2.88e-11	4.37e-05	0.39	0.3	Morning vs. evening chronotype;	chr8:10959261	chr8:8167819~8226614:-
THCA	trans	rs116095464	1	rs56700778	ENSG00000185986.11	SDHAP3	6.81	2.91e-11	4.42e-05	0.53	0.3	Breast cancer;	chr5:313071	chr5:1572222~1594620:-
THCA	trans	rs6732160	0.588	rs62151795	ENSG00000236165.1	PRADC1P1	6.81	2.91e-11	4.42e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:73149712	chr3:36976316~36976840:+
THCA	trans	rs7829975	0.744	rs2409092	ENSG00000256560.1	LINC01486	6.81	2.91e-11	4.42e-05	0.36	0.3	Mood instability;	chr8:8824682	chr12:109354083~109359488:-
THCA	trans	rs7662987	0.877	rs13120000	ENSG00000228407.2	RP4-800M22.1	6.81	2.93e-11	4.45e-05	0.67	0.3	Smoking initiation;	chr4:99065196	chr1:52160261~52160600:-
THCA	trans	rs2929278	0.638	rs2016840	ENSG00000180867.10	PDIA3P1	6.81	2.94e-11	4.45e-05	0.26	0.3	Schizophrenia;	chr15:43919670	chr1:147178113~147179622:+
THCA	trans	rs9650657	0.655	rs4841434	ENSG00000253893.2	FAM85B	6.81	2.94e-11	4.46e-05	0.37	0.3	Neuroticism;	chr8:10728613	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.963	rs10890373	ENSG00000255397.1	AC022182.2	-6.81	2.95e-11	4.47e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr8:60937705~60939871:-
THCA	trans	rs3740713	1	rs73438604	ENSG00000236090.2	LDHAP3	6.81	2.95e-11	4.48e-05	0.54	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr2:41819747~41820754:+
THCA	trans	rs6087990	0.735	rs2424928	ENSG00000253915.1	MAPRE1P1	6.81	2.96e-11	4.48e-05	0.39	0.3	Ulcerative colitis;	chr20:32800830	chr8:135625185~135625981:-
THCA	trans	rs6087990	0.735	rs2065576	ENSG00000253915.1	MAPRE1P1	6.81	2.96e-11	4.48e-05	0.39	0.3	Ulcerative colitis;	chr20:32801203	chr8:135625185~135625981:-
THCA	trans	rs62344088	0.59	rs60845955	ENSG00000185986.11	SDHAP3	6.81	2.96e-11	4.48e-05	0.47	0.3	Asthma (childhood onset);	chr5:184979	chr5:1572222~1594620:-
THCA	trans	rs853679	0.556	rs13200214	ENSG00000253570.1	RNF5P1	6.81	2.97e-11	4.5e-05	0.83	0.3	Depression;	chr6:28049472	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs71559070	ENSG00000253570.1	RNF5P1	6.81	2.97e-11	4.5e-05	0.83	0.3	Depression;	chr6:28071151	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34166054	ENSG00000253570.1	RNF5P1	6.81	2.97e-11	4.5e-05	0.83	0.3	Depression;	chr6:28098023	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34662244	ENSG00000253570.1	RNF5P1	6.81	2.97e-11	4.5e-05	0.83	0.3	Depression;	chr6:28106103	chr8:38600661~38601200:-
THCA	trans	rs35952432	1	rs35952432	ENSG00000253570.1	RNF5P1	6.81	2.97e-11	4.5e-05	0.83	0.3	Lung cancer;	chr6:28107123	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13203816	ENSG00000253570.1	RNF5P1	6.81	2.97e-11	4.5e-05	0.83	0.3	Depression;	chr6:28111820	chr8:38600661~38601200:-
THCA	trans	rs853679	0.556	rs34588114	ENSG00000253570.1	RNF5P1	6.81	2.97e-11	4.5e-05	0.83	0.3	Depression;	chr6:28112850	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs34371502	ENSG00000253570.1	RNF5P1	6.81	2.97e-11	4.5e-05	0.83	0.3	Depression;	chr6:28113980	chr8:38600661~38601200:-
THCA	trans	rs877636	0.702	rs61937249	ENSG00000244604.1	RP11-713H12.1	6.81	2.97e-11	4.51e-05	0.4	0.3	Cognitive function;	chr12:55988132	chr17:8561230~8561576:+
THCA	trans	rs9329221	0.686	rs35840352	ENSG00000253893.2	FAM85B	-6.81	2.98e-11	4.52e-05	-0.41	-0.3	Neuroticism;	chr8:10382297	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.863	rs1569686	ENSG00000253915.1	MAPRE1P1	6.81	3e-11	4.55e-05	0.39	0.3	Ulcerative colitis;	chr20:32779273	chr8:135625185~135625981:-
THCA	trans	rs73108077	0.79	rs8122544	ENSG00000279352.1	RP11-411B10.7	6.81	3.01e-11	4.57e-05	0.65	0.3	Red blood cell density in sickle cell anemia;	chr20:31346428	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs73105954	ENSG00000279352.1	RP11-411B10.7	6.81	3.01e-11	4.57e-05	0.65	0.3	Red blood cell density in sickle cell anemia;	chr20:31355903	chr18:14010054~14010917:+
THCA	trans	rs6732160	0.613	rs59979991	ENSG00000236165.1	PRADC1P1	6.81	3.02e-11	4.58e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:73157294	chr3:36976316~36976840:+
THCA	trans	rs9467711	0.79	rs35400317	ENSG00000280107.1	AL022393.9	-6.81	3.02e-11	4.58e-05	-0.61	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.79	rs67777156	ENSG00000280107.1	AL022393.9	-6.81	3.02e-11	4.58e-05	-0.61	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.722	rs13201782	ENSG00000280107.1	AL022393.9	-6.81	3.02e-11	4.58e-05	-0.61	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr6:28170845~28172521:+
THCA	trans	rs2288327	0.915	rs12614435	ENSG00000269800.1	PLEKHA3P1	6.81	3.03e-11	4.59e-05	0.4	0.3	Atrial fibrillation;	chr2:178624999	chr19:41521043~41521989:-
THCA	trans	rs9650657	0.504	rs6986032	ENSG00000256560.1	LINC01486	-6.81	3.03e-11	4.59e-05	-0.37	-0.3	Neuroticism;	chr8:11174731	chr12:109354083~109359488:-
THCA	trans	rs1391708	0.504	rs75465620	ENSG00000121089.4	NACA3P	-6.81	3.03e-11	4.6e-05	-0.54	-0.3	Airway wall thickness;	chr12:56865907	chr4:164943290~164943937:+
THCA	trans	rs7824557	0.564	rs2572394	ENSG00000254153.1	CTA-398F10.2	6.81	3.06e-11	4.64e-05	0.33	0.3	Retinal vascular caliber;	chr8:11377884	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs2437152	ENSG00000254153.1	CTA-398F10.2	6.81	3.06e-11	4.64e-05	0.33	0.3	Retinal vascular caliber;	chr8:11377988	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs2736300	ENSG00000254153.1	CTA-398F10.2	6.81	3.06e-11	4.64e-05	0.33	0.3	Retinal vascular caliber;	chr8:11378070	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs2572392	ENSG00000254153.1	CTA-398F10.2	6.81	3.06e-11	4.64e-05	0.33	0.3	Retinal vascular caliber;	chr8:11378096	chr8:8456909~8461337:-
THCA	trans	rs11098499	0.82	rs28535956	ENSG00000253326.2	RP11-261C10.7	-6.81	3.06e-11	4.64e-05	-0.42	-0.3	Corneal astigmatism;	chr4:119615703	chr1:243054861~243056394:-
THCA	trans	rs8067354	0.645	rs2132715	ENSG00000187870.7	RNFT1P3	6.81	3.08e-11	4.67e-05	0.47	0.3	Hemoglobin concentration;	chr17:59781013	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs2173119	ENSG00000187870.7	RNFT1P3	6.81	3.08e-11	4.67e-05	0.47	0.3	Hemoglobin concentration;	chr17:59782344	chr17:20743333~20754501:-
THCA	trans	rs2336384	1	rs1810563	ENSG00000261819.1	RP11-680G24.4	-6.81	3.09e-11	4.67e-05	-0.39	-0.3	Platelet count;	chr1:11993973	chr16:14988259~14990160:-
THCA	trans	rs453301	0.571	rs2929454	ENSG00000229857.1	RP11-159H20.3	6.8	3.09e-11	4.68e-05	0.36	0.3	Joint mobility (Beighton score);	chr8:9226344	chr9:76992099~76993108:+
THCA	trans	rs11638815	0.603	rs7171180	ENSG00000235370.6	DNM1P51	6.8	3.09e-11	4.68e-05	0.38	0.3	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82640357	chr15:84398316~84411701:-
THCA	trans	rs3740713	0.748	rs35292478	ENSG00000236090.2	LDHAP3	6.8	3.1e-11	4.69e-05	0.5	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:41819747~41820754:+
THCA	trans	rs3740713	0.669	rs34740438	ENSG00000236090.2	LDHAP3	6.8	3.11e-11	4.71e-05	0.51	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr2:41819747~41820754:+
THCA	trans	rs13191038	1	rs13191038	ENSG00000253570.1	RNF5P1	6.8	3.11e-11	4.71e-05	0.84	0.3	Urinary tract infection frequency;	chr6:28515140	chr8:38600661~38601200:-
THCA	trans	rs1580019	0.563	rs13244332	ENSG00000176826.14	FKBP9P1	-6.8	3.12e-11	4.72e-05	-0.4	-0.3	Cognitive ability;	chr7:32498067	chr7:55681074~55713252:-
THCA	trans	rs6087990	0.899	rs4911107	ENSG00000253915.1	MAPRE1P1	6.8	3.13e-11	4.73e-05	0.38	0.3	Ulcerative colitis;	chr20:32787185	chr8:135625185~135625981:-
THCA	trans	rs7819412	0.608	rs17780806	ENSG00000229857.1	RP11-159H20.3	6.8	3.13e-11	4.74e-05	0.39	0.3	Triglycerides;	chr8:11118119	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.532	rs1369368	ENSG00000253893.2	FAM85B	-6.8	3.15e-11	4.76e-05	-0.4	-0.3	Neuroticism;	chr8:11292704	chr8:8167819~8226614:-
THCA	trans	rs10816533	1	rs12349952	ENSG00000232063.1	RP11-307E17.8	6.8	3.15e-11	4.76e-05	0.79	0.3	Height;	chr9:96778237	chr9:94332476~94360948:+
THCA	trans	rs1707322	0.721	rs4660883	ENSG00000255397.1	AC022182.2	-6.8	3.15e-11	4.77e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr8:60937705~60939871:-
THCA	trans	rs2980439	0.729	rs2955585	ENSG00000256560.1	LINC01486	6.8	3.16e-11	4.77e-05	0.34	0.3	Neuroticism;	chr8:8235989	chr12:109354083~109359488:-
THCA	trans	rs7833986	0.501	rs2719233	ENSG00000236862.1	RPS20P24	6.8	3.17e-11	4.79e-05	0.46	0.3	Height;	chr8:55973597	chr9:72655832~72656192:-
THCA	trans	rs7824557	0.614	rs2736286	ENSG00000253893.2	FAM85B	6.8	3.17e-11	4.79e-05	0.39	0.3	Retinal vascular caliber;	chr8:11369595	chr8:8167819~8226614:-
THCA	trans	rs9467773	0.595	rs3846845	ENSG00000242375.1	RP11-498P14.3	-6.8	3.18e-11	4.8e-05	-0.42	-0.3	Intelligence (multi-trait analysis);	chr6:26444687	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.572	rs3846846	ENSG00000242375.1	RP11-498P14.3	-6.8	3.18e-11	4.8e-05	-0.42	-0.3	Intelligence (multi-trait analysis);	chr6:26444811	chr9:97195351~97197687:-
THCA	trans	rs1707322	1	rs12124847	ENSG00000255397.1	AC022182.2	-6.8	3.18e-11	4.81e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr8:60937705~60939871:-
THCA	trans	rs864643	0.898	rs1631776	ENSG00000188856.6	RPSAP47	6.8	3.19e-11	4.82e-05	0.44	0.3	Attention deficit hyperactivity disorder;	chr3:39548704	chr8:80558870~80559757:+
THCA	trans	rs864643	1	rs1513213	ENSG00000183298.5	RP11-556K13.1	6.8	3.21e-11	4.85e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39509406	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1768261	ENSG00000183298.5	RP11-556K13.1	6.8	3.21e-11	4.85e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39510494	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1768262	ENSG00000183298.5	RP11-556K13.1	6.8	3.21e-11	4.85e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39511785	chr1:101786340~101787219:-
THCA	trans	rs7824557	0.564	rs2572395	ENSG00000254153.1	CTA-398F10.2	6.8	3.21e-11	4.85e-05	0.33	0.3	Retinal vascular caliber;	chr8:11377851	chr8:8456909~8461337:-
THCA	trans	rs864643	0.947	rs1417147	ENSG00000183298.5	RP11-556K13.1	6.8	3.25e-11	4.92e-05	0.48	0.3	Attention deficit hyperactivity disorder;	chr3:39499236	chr1:101786340~101787219:-
THCA	trans	rs12709013	0.967	rs8054482	ENSG00000230849.2	GOT2P2	6.8	3.26e-11	4.93e-05	0.37	0.3	Blood metabolite ratios;	chr16:58810532	chr1:173141100~173142350:-
THCA	trans	rs1707322	1	rs4660332	ENSG00000255397.1	AC022182.2	-6.8	3.27e-11	4.95e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr8:60937705~60939871:-
THCA	trans	rs2645424	0.762	rs2294139	ENSG00000260438.1	RP11-405F3.2	6.79	3.3e-11	4.99e-05	0.43	0.3	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847933	chr16:57713782~57714957:+
THCA	trans	rs7819412	0.669	rs35499486	ENSG00000256560.1	LINC01486	-6.79	3.31e-11	5e-05	-0.38	-0.3	Triglycerides;	chr8:11216527	chr12:109354083~109359488:-
THCA	trans	rs116095464	0.718	rs62331563	ENSG00000185986.11	SDHAP3	6.79	3.32e-11	5.01e-05	0.51	0.3	Breast cancer;	chr5:355171	chr5:1572222~1594620:-
THCA	trans	rs7829975	0.593	rs2921051	ENSG00000229857.1	RP11-159H20.3	-6.79	3.33e-11	5.02e-05	-0.37	-0.3	Mood instability;	chr8:8462594	chr9:76992099~76993108:+
THCA	trans	rs853679	0.546	rs71537572	ENSG00000228022.4	HCG20	-6.79	3.33e-11	5.03e-05	-0.76	-0.3	Depression;	chr6:28002937	chr6:30766825~30792250:+
THCA	trans	rs11992162	0.573	rs61468577	ENSG00000253893.2	FAM85B	6.79	3.33e-11	5.03e-05	0.4	0.3	Monocyte count;	chr8:11927416	chr8:8167819~8226614:-
THCA	trans	rs731945	1	rs731945	ENSG00000267533.1	RP11-815J4.7	-6.79	3.36e-11	5.07e-05	-0.43	-0.3	Self-reported allergy;	chr19:18456229	chr18:12067173~12068417:-
THCA	trans	rs7617480	0.648	rs14018	ENSG00000197582.5	GPX1P1	6.79	3.37e-11	5.08e-05	0.53	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48746837	chrX:13378735~13379340:-
THCA	trans	rs74781061	0.929	rs12441932	ENSG00000227288.3	RP5-837I24.1	6.79	3.37e-11	5.09e-05	0.44	0.3	Endometriosis;	chr15:74617658	chr1:81501794~81503468:+
THCA	trans	rs2950393	0.804	rs3214051	ENSG00000228224.3	NACAP1	6.79	3.38e-11	5.1e-05	0.3	0.3	Platelet distribution width;	chr12:56725452	chr8:101361794~101372707:+
THCA	trans	rs9329221	0.621	rs12156350	ENSG00000253893.2	FAM85B	6.79	3.38e-11	5.1e-05	0.38	0.3	Neuroticism;	chr8:10411006	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.567	rs6601273	ENSG00000229857.1	RP11-159H20.3	6.79	3.38e-11	5.1e-05	0.37	0.3	Mood instability;	chr8:8939009	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.621	rs522483	ENSG00000253893.2	FAM85B	6.79	3.39e-11	5.11e-05	0.39	0.3	Neuroticism;	chr8:9955459	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2572379	ENSG00000254153.1	CTA-398F10.2	6.79	3.4e-11	5.13e-05	0.33	0.3	Retinal vascular caliber;	chr8:11379971	chr8:8456909~8461337:-
THCA	trans	rs2288327	0.818	rs3731751	ENSG00000269800.1	PLEKHA3P1	6.79	3.41e-11	5.15e-05	0.43	0.3	Atrial fibrillation;	chr2:178541158	chr19:41521043~41521989:-
THCA	trans	rs11098499	0.863	rs1010739	ENSG00000253326.2	RP11-261C10.7	6.79	3.42e-11	5.16e-05	0.43	0.3	Corneal astigmatism;	chr4:119542316	chr1:243054861~243056394:-
THCA	trans	rs7829975	0.509	rs7838674	ENSG00000229857.1	RP11-159H20.3	6.79	3.45e-11	5.2e-05	0.37	0.3	Mood instability;	chr8:8939563	chr9:76992099~76993108:+
THCA	trans	rs6087990	0.899	rs998382	ENSG00000253915.1	MAPRE1P1	-6.79	3.45e-11	5.2e-05	-0.38	-0.3	Ulcerative colitis;	chr20:32796330	chr8:135625185~135625981:-
THCA	trans	rs864643	0.841	rs1708042	ENSG00000188856.6	RPSAP47	6.79	3.46e-11	5.22e-05	0.45	0.3	Attention deficit hyperactivity disorder;	chr3:39546246	chr8:80558870~80559757:+
THCA	trans	rs7833986	1	rs13281873	ENSG00000244245.1	RP11-120B7.1	6.79	3.49e-11	5.26e-05	0.39	0.3	Height;	chr8:56189240	chr5:108593609~108593967:+
THCA	trans	rs7617480	0.616	rs9873227	ENSG00000197582.5	GPX1P1	6.79	3.49e-11	5.26e-05	0.53	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48735675	chrX:13378735~13379340:-
THCA	trans	rs847577	0.677	rs951988	ENSG00000225169.1	BRI3P1	-6.78	3.51e-11	5.28e-05	-0.39	-0.3	Breast cancer;	chr7:98133162	chr1:100213293~100213670:+
THCA	trans	rs864643	0.524	rs12106854	ENSG00000183298.5	RP11-556K13.1	6.78	3.52e-11	5.3e-05	0.61	0.3	Attention deficit hyperactivity disorder;	chr3:39487321	chr1:101786340~101787219:-
THCA	trans	rs864643	0.524	rs17038967	ENSG00000183298.5	RP11-556K13.1	6.78	3.52e-11	5.3e-05	0.61	0.3	Attention deficit hyperactivity disorder;	chr3:39489530	chr1:101786340~101787219:-
THCA	trans	rs4784054	0.667	rs11864685	ENSG00000230849.2	GOT2P2	-6.78	3.52e-11	5.3e-05	-0.49	-0.3	Blood metabolite levels;	chr16:58771226	chr1:173141100~173142350:-
THCA	trans	rs7829975	0.536	rs2980439	ENSG00000229857.1	RP11-159H20.3	-6.78	3.53e-11	5.32e-05	-0.35	-0.3	Mood instability;	chr8:8237348	chr9:76992099~76993108:+
THCA	trans	rs1707322	1	rs785484	ENSG00000255397.1	AC022182.2	6.78	3.54e-11	5.33e-05	0.43	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr8:60937705~60939871:-
THCA	trans	rs13217239	0.511	rs3800314	ENSG00000242375.1	RP11-498P14.3	-6.78	3.55e-11	5.34e-05	-0.43	-0.3	Schizophrenia;	chr6:27268269	chr9:97195351~97197687:-
THCA	trans	rs453301	0.571	rs2929456	ENSG00000229857.1	RP11-159H20.3	6.78	3.55e-11	5.34e-05	0.36	0.3	Joint mobility (Beighton score);	chr8:9225906	chr9:76992099~76993108:+
THCA	trans	rs73108077	0.79	rs73105930	ENSG00000279352.1	RP11-411B10.7	6.78	3.58e-11	5.39e-05	0.65	0.3	Red blood cell density in sickle cell anemia;	chr20:31327265	chr18:14010054~14010917:+
THCA	trans	rs902774	0.818	rs73110471	ENSG00000248568.1	KRT8P48	-6.78	3.6e-11	5.41e-05	-0.62	-0.3	Prostate cancer;	chr12:52923037	chr5:146706381~146707600:-
THCA	trans	rs2898290	0.593	rs2199690	ENSG00000229857.1	RP11-159H20.3	6.78	3.61e-11	5.43e-05	0.39	0.3	Systolic blood pressure;	chr8:11482107	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.613	rs6601634	ENSG00000256560.1	LINC01486	-6.78	3.62e-11	5.45e-05	-0.38	-0.3	Monocyte count;	chr8:11948947	chr12:109354083~109359488:-
THCA	trans	rs853679	0.556	rs13200214	ENSG00000228022.4	HCG20	-6.78	3.66e-11	5.51e-05	-0.75	-0.3	Depression;	chr6:28049472	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs71559070	ENSG00000228022.4	HCG20	-6.78	3.66e-11	5.51e-05	-0.75	-0.3	Depression;	chr6:28071151	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34166054	ENSG00000228022.4	HCG20	-6.78	3.66e-11	5.51e-05	-0.75	-0.3	Depression;	chr6:28098023	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34662244	ENSG00000228022.4	HCG20	-6.78	3.66e-11	5.51e-05	-0.75	-0.3	Depression;	chr6:28106103	chr6:30766825~30792250:+
THCA	trans	rs35952432	1	rs35952432	ENSG00000228022.4	HCG20	-6.78	3.66e-11	5.51e-05	-0.75	-0.3	Lung cancer;	chr6:28107123	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13203816	ENSG00000228022.4	HCG20	-6.78	3.66e-11	5.51e-05	-0.75	-0.3	Depression;	chr6:28111820	chr6:30766825~30792250:+
THCA	trans	rs853679	0.556	rs34588114	ENSG00000228022.4	HCG20	-6.78	3.66e-11	5.51e-05	-0.75	-0.3	Depression;	chr6:28112850	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs34371502	ENSG00000228022.4	HCG20	-6.78	3.66e-11	5.51e-05	-0.75	-0.3	Depression;	chr6:28113980	chr6:30766825~30792250:+
THCA	trans	rs34119086	1	rs34119086	ENSG00000253570.1	RNF5P1	6.78	3.66e-11	5.51e-05	0.84	0.3	Breast cancer;	chr6:28594471	chr8:38600661~38601200:-
THCA	trans	rs7824557	0.815	rs2736372	ENSG00000253893.2	FAM85B	6.78	3.67e-11	5.52e-05	0.37	0.3	Retinal vascular caliber;	chr8:11248532	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.838	rs3021494	ENSG00000256560.1	LINC01486	-6.78	3.72e-11	5.6e-05	-0.37	-0.3	Triglycerides;	chr8:11126024	chr12:109354083~109359488:-
THCA	trans	rs3812762	1	rs3812762	ENSG00000266891.1	RP11-692N5.2	6.78	3.72e-11	5.6e-05	0.4	0.3	Hypospadias;	chr11:8730093	chr18:9734882~9735602:-
THCA	trans	rs4512344	0.509	rs2409784	ENSG00000256560.1	LINC01486	-6.77	3.73e-11	5.61e-05	-0.36	-0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr12:109354083~109359488:-
THCA	trans	rs864643	0.898	rs635235	ENSG00000188856.6	RPSAP47	6.77	3.74e-11	5.61e-05	0.45	0.3	Attention deficit hyperactivity disorder;	chr3:39549614	chr8:80558870~80559757:+
THCA	trans	rs34421088	0.506	rs2572428	ENSG00000253893.2	FAM85B	-6.77	3.74e-11	5.62e-05	-0.39	-0.3	Neuroticism;	chr8:11289163	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.627	rs876954	ENSG00000256560.1	LINC01486	6.77	3.75e-11	5.64e-05	0.36	0.3	Mood instability;	chr8:8453413	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.504	rs7813802	ENSG00000256560.1	LINC01486	6.77	3.77e-11	5.66e-05	0.37	0.3	Neuroticism;	chr8:11176467	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs4074225	ENSG00000255397.1	AC022182.2	-6.77	3.77e-11	5.66e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4134387	ENSG00000255397.1	AC022182.2	-6.77	3.77e-11	5.66e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs10890376	ENSG00000255397.1	AC022182.2	-6.77	3.77e-11	5.66e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs10789485	ENSG00000255397.1	AC022182.2	-6.77	3.77e-11	5.66e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr8:60937705~60939871:-
THCA	trans	rs61041336	0.534	rs2280399	ENSG00000230849.2	GOT2P2	-6.77	3.77e-11	5.67e-05	-0.52	-0.3	Neuritic plaque;	chr16:58677628	chr1:173141100~173142350:-
THCA	trans	rs1563304	1	rs1563304	ENSG00000204650.12	CRHR1-IT1	6.77	3.78e-11	5.67e-05	0.42	0.3	Neuroticism;	chr17:46797087	chr17:45620328~45648216:+
THCA	trans	rs6601327	0.634	rs12679956	ENSG00000253893.2	FAM85B	6.77	3.78e-11	5.68e-05	0.37	0.3	Multiple myeloma (hyperdiploidy);	chr8:9727339	chr8:8167819~8226614:-
THCA	trans	rs74781061	0.929	rs10459648	ENSG00000227288.3	RP5-837I24.1	-6.77	3.78e-11	5.68e-05	-0.42	-0.3	Endometriosis;	chr15:74573099	chr1:81501794~81503468:+
THCA	trans	rs330071	0.686	rs10087406	ENSG00000253893.2	FAM85B	6.77	3.78e-11	5.68e-05	0.38	0.3	Acne (severe);	chr8:9389088	chr8:8167819~8226614:-
THCA	trans	rs853679	0.607	rs67998226	ENSG00000253570.1	RNF5P1	6.77	3.8e-11	5.71e-05	0.83	0.3	Depression;	chr6:28270281	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34878803	ENSG00000253570.1	RNF5P1	6.77	3.8e-11	5.71e-05	0.83	0.3	Depression;	chr6:28282402	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34396849	ENSG00000253570.1	RNF5P1	6.77	3.8e-11	5.71e-05	0.83	0.3	Depression;	chr6:28283178	chr8:38600661~38601200:-
THCA	trans	rs61041336	0.534	rs59234479	ENSG00000230849.2	GOT2P2	-6.77	3.81e-11	5.72e-05	-0.53	-0.3	Neuritic plaque;	chr16:58673724	chr1:173141100~173142350:-
THCA	trans	rs1391708	0.504	rs74995587	ENSG00000121089.4	NACA3P	-6.77	3.82e-11	5.73e-05	-0.55	-0.3	Airway wall thickness;	chr12:56870642	chr4:164943290~164943937:+
THCA	trans	rs6601450	0.519	rs34906836	ENSG00000253893.2	FAM85B	-6.77	3.84e-11	5.76e-05	-0.37	-0.3	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10431482	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.507	rs60902764	ENSG00000253893.2	FAM85B	6.77	3.84e-11	5.77e-05	0.4	0.3	Monocyte count;	chr8:11927482	chr8:8167819~8226614:-
THCA	trans	rs12145833	0.538	rs12042959	ENSG00000154608.12	CEP170P1	-6.77	3.85e-11	5.78e-05	-0.4	-0.3	Obesity (early onset extreme);	chr1:243369971	chr4:118467590~118554204:+
THCA	trans	rs9914988	0.943	rs4795467	ENSG00000267449.1	RP11-264B14.2	6.77	3.86e-11	5.8e-05	0.47	0.3	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28853766	chr17:61069856~61070356:-
THCA	trans	rs853679	0.607	rs35902873	ENSG00000228022.4	HCG20	-6.77	3.87e-11	5.81e-05	-0.75	-0.3	Depression;	chr6:28091171	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13197574	ENSG00000228022.4	HCG20	-6.77	3.87e-11	5.81e-05	-0.75	-0.3	Depression;	chr6:28092461	chr6:30766825~30792250:+
THCA	trans	rs8067354	0.645	rs11079389	ENSG00000187870.7	RNFT1P3	6.77	3.88e-11	5.82e-05	0.47	0.3	Hemoglobin concentration;	chr17:59810591	chr17:20743333~20754501:-
THCA	trans	rs8067354	0.645	rs2665403	ENSG00000187870.7	RNFT1P3	6.77	3.88e-11	5.82e-05	0.47	0.3	Hemoglobin concentration;	chr17:59812624	chr17:20743333~20754501:-
THCA	trans	rs34546498	1	rs34546498	ENSG00000280107.1	AL022393.9	-6.77	3.9e-11	5.84e-05	-0.61	-0.3	Breast cancer;	chr6:26993501	chr6:28170845~28172521:+
THCA	trans	rs616147	0.671	rs675595	ENSG00000243904.1	RP11-600F24.1	-6.77	3.9e-11	5.86e-05	-0.37	-0.3	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr14:103374033~103374916:-
THCA	trans	rs9650657	0.504	rs10093053	ENSG00000256560.1	LINC01486	-6.77	3.91e-11	5.86e-05	-0.37	-0.3	Neuroticism;	chr8:11179678	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.714	rs59046059	ENSG00000256560.1	LINC01486	6.77	3.91e-11	5.87e-05	0.35	0.3	Mood instability;	chr8:8813226	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.82	rs2389885	ENSG00000253326.2	RP11-261C10.7	6.77	3.92e-11	5.88e-05	0.42	0.3	Corneal astigmatism;	chr4:119612776	chr1:243054861~243056394:-
THCA	trans	rs2288327	0.818	rs3829748	ENSG00000269800.1	PLEKHA3P1	6.77	3.93e-11	5.89e-05	0.42	0.3	Atrial fibrillation;	chr2:178531627	chr19:41521043~41521989:-
THCA	trans	rs2288327	0.818	rs2857265	ENSG00000269800.1	PLEKHA3P1	6.77	3.93e-11	5.89e-05	0.42	0.3	Atrial fibrillation;	chr2:178534096	chr19:41521043~41521989:-
THCA	trans	rs76228276	0.737	rs4734427	ENSG00000260318.1	COX6CP1	6.77	3.95e-11	5.92e-05	0.85	0.3	Childhood ear infection;	chr8:99200353	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs4734428	ENSG00000260318.1	COX6CP1	6.77	3.95e-11	5.92e-05	0.85	0.3	Childhood ear infection;	chr8:99200371	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs77825749	ENSG00000260318.1	COX6CP1	6.77	3.95e-11	5.92e-05	0.85	0.3	Childhood ear infection;	chr8:99212343	chr16:11903923~11904137:-
THCA	trans	rs6600671	0.934	rs12131379	ENSG00000270392.2	PFN1P2	6.77	3.96e-11	5.94e-05	0.29	0.3	Hip geometry;	chr1:121551639	chr1:120432204~120434052:-
THCA	trans	rs941207	0.542	rs7315786	ENSG00000257210.1	NACAP3	-6.77	3.97e-11	5.95e-05	-0.38	-0.3	Platelet count;	chr12:56801595	chr12:93124063~93124543:-
THCA	trans	rs12145833	0.619	rs10927006	ENSG00000154608.12	CEP170P1	-6.76	3.99e-11	5.99e-05	-0.4	-0.3	Obesity (early onset extreme);	chr1:243394357	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.679	rs12029086	ENSG00000154608.12	CEP170P1	-6.76	3.99e-11	5.99e-05	-0.4	-0.3	Obesity (early onset extreme);	chr1:243401420	chr4:118467590~118554204:+
THCA	trans	rs2645424	0.53	rs1293303	ENSG00000256560.1	LINC01486	-6.76	4.02e-11	6.03e-05	-0.36	-0.3	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11862718	chr12:109354083~109359488:-
THCA	trans	rs7833986	1	rs13273123	ENSG00000244245.1	RP11-120B7.1	-6.76	4.06e-11	6.08e-05	-0.39	-0.3	Height;	chr8:56188232	chr5:108593609~108593967:+
THCA	trans	rs2060793	0.519	rs10766187	ENSG00000236360.2	RP11-334A14.2	6.76	4.07e-11	6.09e-05	0.39	0.3	Vitamin D levels;	chr11:14603836	chr1:52993201~52993702:-
THCA	trans	rs853679	0.607	rs66886492	ENSG00000253570.1	RNF5P1	6.76	4.08e-11	6.11e-05	0.85	0.3	Depression;	chr6:28121953	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs35345226	ENSG00000253570.1	RNF5P1	6.76	4.08e-11	6.11e-05	0.85	0.3	Depression;	chr6:28123802	chr8:38600661~38601200:-
THCA	trans	rs9650657	0.589	rs12542037	ENSG00000229857.1	RP11-159H20.3	-6.76	4.09e-11	6.12e-05	-0.36	-0.3	Neuroticism;	chr8:10900986	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.686	rs35406700	ENSG00000253893.2	FAM85B	-6.76	4.1e-11	6.14e-05	-0.39	-0.3	Neuroticism;	chr8:10387083	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.74	rs11250119	ENSG00000256560.1	LINC01486	-6.76	4.1e-11	6.15e-05	-0.37	-0.3	Triglycerides;	chr8:11179525	chr12:109354083~109359488:-
THCA	trans	rs2980436	1	rs2980436	ENSG00000256560.1	LINC01486	-6.76	4.1e-11	6.15e-05	-0.34	-0.3	Schizophrenia;	chr8:8234503	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.714	rs11784052	ENSG00000256560.1	LINC01486	6.76	4.13e-11	6.18e-05	0.35	0.3	Mood instability;	chr8:8814452	chr12:109354083~109359488:-
THCA	trans	rs864643	0.853	rs4676643	ENSG00000188856.6	RPSAP47	-6.76	4.13e-11	6.19e-05	-0.43	-0.3	Attention deficit hyperactivity disorder;	chr3:39537413	chr8:80558870~80559757:+
THCA	trans	rs2985684	1	rs8014170	ENSG00000240785.1	RPL36AP21	6.76	4.14e-11	6.2e-05	0.38	0.3	Carotid intima media thickness;	chr14:49604976	chr5:18049550~18049872:+
THCA	trans	rs2950393	0.794	rs1563897	ENSG00000228224.3	NACAP1	6.76	4.15e-11	6.21e-05	0.31	0.3	Platelet distribution width;	chr12:56699316	chr8:101361794~101372707:+
THCA	trans	rs67340775	0.834	rs13218875	ENSG00000253570.1	RNF5P1	6.76	4.16e-11	6.23e-05	0.83	0.3	Lung cancer in ever smokers;	chr6:27916234	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs67040724	ENSG00000253570.1	RNF5P1	6.76	4.16e-11	6.23e-05	0.83	0.3	Depression;	chr6:27937731	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs67662114	ENSG00000253570.1	RNF5P1	6.76	4.16e-11	6.23e-05	0.83	0.3	Depression;	chr6:27964523	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13216117	ENSG00000253570.1	RNF5P1	6.76	4.16e-11	6.23e-05	0.83	0.3	Depression;	chr6:27970706	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs36101351	ENSG00000253570.1	RNF5P1	6.76	4.16e-11	6.23e-05	0.83	0.3	Depression;	chr6:27975591	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs28360499	ENSG00000253570.1	RNF5P1	6.76	4.16e-11	6.23e-05	0.83	0.3	Depression;	chr6:27977618	chr8:38600661~38601200:-
THCA	trans	rs1478897	0.804	rs9329246	ENSG00000253893.2	FAM85B	-6.76	4.16e-11	6.23e-05	-0.37	-0.3	Systemic lupus erythematosus;	chr8:11535371	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.805	rs2409710	ENSG00000256560.1	LINC01486	-6.76	4.18e-11	6.25e-05	-0.37	-0.3	Triglycerides;	chr8:11122311	chr12:109354083~109359488:-
THCA	trans	rs453301	0.653	rs7853	ENSG00000256560.1	LINC01486	6.76	4.18e-11	6.26e-05	0.34	0.3	Joint mobility (Beighton score);	chr8:9033304	chr12:109354083~109359488:-
THCA	trans	rs4263408	0.935	rs62310129	ENSG00000237550.5	UBE2Q2P6	6.76	4.21e-11	6.29e-05	0.35	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39772802	chr15:82372196~82372912:-
THCA	trans	rs6964833	0.935	rs13238996	ENSG00000214544.6	GTF2IRD2P1	-6.76	4.23e-11	6.33e-05	-0.46	-0.3	Menarche (age at onset);	chr7:74655318	chr7:73242751~73280119:-
THCA	trans	rs13016963	0.604	rs12986657	ENSG00000235105.1	RP11-329A14.1	6.75	4.26e-11	6.37e-05	0.33	0.3	Esophageal squamous cell carcinoma;Melanoma;	chr2:201313366	chr1:48435967~48437223:+
THCA	trans	rs34421088	0.532	rs1545073	ENSG00000253893.2	FAM85B	-6.75	4.27e-11	6.39e-05	-0.39	-0.3	Neuroticism;	chr8:11310191	chr8:8167819~8226614:-
THCA	trans	rs12367822	0.956	rs9706160	ENSG00000257210.1	NACAP3	-6.75	4.28e-11	6.39e-05	-0.38	-0.3	Platelet aggregation;	chr12:56791119	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs2888095	ENSG00000257210.1	NACAP3	-6.75	4.28e-11	6.39e-05	-0.38	-0.3	Platelet count;	chr12:56793689	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs2888096	ENSG00000257210.1	NACAP3	-6.75	4.28e-11	6.39e-05	-0.38	-0.3	Platelet count;	chr12:56793851	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs6581106	ENSG00000257210.1	NACAP3	-6.75	4.28e-11	6.39e-05	-0.38	-0.3	Platelet count;	chr12:56796759	chr12:93124063~93124543:-
THCA	trans	rs6601327	0.575	rs6994574	ENSG00000253893.2	FAM85B	6.75	4.28e-11	6.39e-05	0.37	0.3	Multiple myeloma (hyperdiploidy);	chr8:9720745	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.71	rs11779205	ENSG00000253893.2	FAM85B	-6.75	4.28e-11	6.4e-05	-0.4	-0.3	Neuroticism;	chr8:10402590	chr8:8167819~8226614:-
THCA	trans	rs453301	0.682	rs2929451	ENSG00000229857.1	RP11-159H20.3	-6.75	4.3e-11	6.43e-05	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9227785	chr9:76992099~76993108:+
THCA	trans	rs6600671	0.899	rs11249432	ENSG00000270392.2	PFN1P2	6.75	4.32e-11	6.45e-05	0.29	0.3	Hip geometry;	chr1:121541678	chr1:120432204~120434052:-
THCA	trans	rs453301	0.624	rs4841083	ENSG00000229857.1	RP11-159H20.3	-6.75	4.32e-11	6.45e-05	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9012918	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.633	rs2979181	ENSG00000256560.1	LINC01486	6.75	4.33e-11	6.47e-05	0.36	0.3	Mood instability;	chr8:8465578	chr12:109354083~109359488:-
THCA	trans	rs2736345	1	rs2736345	ENSG00000253893.2	FAM85B	-6.75	4.35e-11	6.5e-05	-0.4	-0.3	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11494976	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.56	rs2245250	ENSG00000256560.1	LINC01486	-6.75	4.38e-11	6.54e-05	-0.37	-0.3	Neuroticism;	chr8:11543171	chr12:109354083~109359488:-
THCA	trans	rs76228276	0.609	rs78437785	ENSG00000260318.1	COX6CP1	6.75	4.41e-11	6.58e-05	0.87	0.3	Childhood ear infection;	chr8:99790937	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs16897726	ENSG00000260318.1	COX6CP1	6.75	4.41e-11	6.58e-05	0.87	0.3	Childhood ear infection;	chr8:99808566	chr16:11903923~11904137:-
THCA	trans	rs864643	0.947	rs1768243	ENSG00000183298.5	RP11-556K13.1	6.75	4.42e-11	6.6e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39500306	chr1:101786340~101787219:-
THCA	trans	rs9467773	0.595	rs4320356	ENSG00000242375.1	RP11-498P14.3	-6.75	4.42e-11	6.6e-05	-0.42	-0.3	Intelligence (multi-trait analysis);	chr6:26423332	chr9:97195351~97197687:-
THCA	trans	rs9329221	0.662	rs11249996	ENSG00000253893.2	FAM85B	6.75	4.46e-11	6.65e-05	0.39	0.3	Neuroticism;	chr8:10387953	chr8:8167819~8226614:-
THCA	trans	rs13191038	1	rs13191038	ENSG00000228022.4	HCG20	-6.75	4.47e-11	6.67e-05	-0.75	-0.3	Urinary tract infection frequency;	chr6:28515140	chr6:30766825~30792250:+
THCA	trans	rs453301	0.682	rs2929308	ENSG00000229857.1	RP11-159H20.3	6.75	4.47e-11	6.67e-05	0.36	0.3	Joint mobility (Beighton score);	chr8:9226611	chr9:76992099~76993108:+
THCA	trans	rs941207	0.542	rs11171979	ENSG00000257210.1	NACAP3	-6.75	4.47e-11	6.67e-05	-0.38	-0.3	Platelet count;	chr12:56802199	chr12:93124063~93124543:-
THCA	trans	rs7824557	0.569	rs10106207	ENSG00000256560.1	LINC01486	-6.75	4.5e-11	6.72e-05	-0.36	-0.3	Retinal vascular caliber;	chr8:11157828	chr12:109354083~109359488:-
THCA	trans	rs7121616	0.595	rs7941144	ENSG00000229091.2	HSPA8P8	6.75	4.5e-11	6.72e-05	0.39	0.3	Breast cancer;	chr11:123079805	chr7:10451311~10452526:+
THCA	trans	rs864643	0.524	rs72869124	ENSG00000183298.5	RP11-556K13.1	6.74	4.54e-11	6.77e-05	0.6	0.3	Attention deficit hyperactivity disorder;	chr3:39469788	chr1:101786340~101787219:-
THCA	trans	rs9467773	0.595	rs9366657	ENSG00000242375.1	RP11-498P14.3	6.74	4.56e-11	6.81e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr6:26434686	chr9:97195351~97197687:-
THCA	trans	rs6964833	1	rs36044436	ENSG00000214544.6	GTF2IRD2P1	-6.74	4.59e-11	6.84e-05	-0.44	-0.3	Menarche (age at onset);	chr7:74675495	chr7:73242751~73280119:-
THCA	trans	rs9467773	0.595	rs6907924	ENSG00000242375.1	RP11-498P14.3	-6.74	4.6e-11	6.86e-05	-0.42	-0.3	Intelligence (multi-trait analysis);	chr6:26438589	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.55	rs9379874	ENSG00000242375.1	RP11-498P14.3	-6.74	4.6e-11	6.86e-05	-0.42	-0.3	Intelligence (multi-trait analysis);	chr6:26440201	chr9:97195351~97197687:-
THCA	trans	rs6600671	0.899	rs6674392	ENSG00000270392.2	PFN1P2	6.74	4.63e-11	6.9e-05	0.29	0.3	Hip geometry;	chr1:121518864	chr1:120432204~120434052:-
THCA	trans	rs2060793	0.552	rs939968	ENSG00000236360.2	RP11-334A14.2	6.74	4.64e-11	6.91e-05	0.39	0.3	Vitamin D levels;	chr11:14608134	chr1:52993201~52993702:-
THCA	trans	rs2980439	0.558	rs2955584	ENSG00000256560.1	LINC01486	6.74	4.65e-11	6.93e-05	0.35	0.3	Neuroticism;	chr8:8234652	chr12:109354083~109359488:-
THCA	trans	rs1707322	0.964	rs12067716	ENSG00000255397.1	AC022182.2	-6.74	4.66e-11	6.94e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr8:60937705~60939871:-
THCA	trans	rs2975734	0.68	rs1052453	ENSG00000253893.2	FAM85B	6.74	4.66e-11	6.95e-05	0.42	0.3	Chronotype;Morning vs. evening chronotype;	chr8:10250815	chr8:8167819~8226614:-
THCA	trans	rs864643	0.947	rs1708073	ENSG00000183298.5	RP11-556K13.1	6.74	4.68e-11	6.97e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39501530	chr1:101786340~101787219:-
THCA	trans	rs7829975	0.688	rs7827182	ENSG00000256560.1	LINC01486	6.74	4.7e-11	7e-05	0.36	0.3	Mood instability;	chr8:8522961	chr12:109354083~109359488:-
THCA	trans	rs941207	0.542	rs7311381	ENSG00000257210.1	NACAP3	-6.74	4.73e-11	7.05e-05	-0.38	-0.3	Platelet count;	chr12:56800286	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs6581107	ENSG00000257210.1	NACAP3	-6.74	4.73e-11	7.05e-05	-0.38	-0.3	Platelet count;	chr12:56801197	chr12:93124063~93124543:-
THCA	trans	rs7829975	0.572	rs28446104	ENSG00000229857.1	RP11-159H20.3	6.74	4.74e-11	7.06e-05	0.38	0.3	Mood instability;	chr8:8938391	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.564	rs2921060	ENSG00000229857.1	RP11-159H20.3	6.74	4.77e-11	7.1e-05	0.36	0.3	Mood instability;	chr8:8460307	chr9:76992099~76993108:+
THCA	trans	rs3808502	0.503	rs2061830	ENSG00000256560.1	LINC01486	6.74	4.77e-11	7.11e-05	0.37	0.3	Neuroticism;	chr8:11539948	chr12:109354083~109359488:-
THCA	trans	rs17807624	0.78	rs11250152	ENSG00000253893.2	FAM85B	6.74	4.77e-11	7.11e-05	0.38	0.3	Systemic lupus erythematosus;	chr8:11596691	chr8:8167819~8226614:-
THCA	trans	rs9876781	0.559	rs11130167	ENSG00000225528.1	RP3-370M22.8	-6.74	4.78e-11	7.12e-05	-0.37	-0.3	Longevity;	chr3:48358570	chr22:39960397~39964683:+
THCA	trans	rs9876781	0.559	rs13073692	ENSG00000225528.1	RP3-370M22.8	-6.74	4.78e-11	7.12e-05	-0.37	-0.3	Longevity;	chr3:48361812	chr22:39960397~39964683:+
THCA	trans	rs9876781	0.559	rs7611415	ENSG00000225528.1	RP3-370M22.8	-6.74	4.78e-11	7.12e-05	-0.37	-0.3	Longevity;	chr3:48363659	chr22:39960397~39964683:+
THCA	trans	rs1707322	1	rs1707317	ENSG00000255397.1	AC022182.2	6.74	4.8e-11	7.14e-05	0.42	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr8:60937705~60939871:-
THCA	trans	rs7833986	0.501	rs2719227	ENSG00000236862.1	RPS20P24	-6.73	4.81e-11	7.15e-05	-0.43	-0.3	Height;	chr8:56131235	chr9:72655832~72656192:-
THCA	trans	rs34421088	0.56	rs1478898	ENSG00000256560.1	LINC01486	-6.73	4.81e-11	7.16e-05	-0.37	-0.3	Neuroticism;	chr8:11537570	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.82	rs28578366	ENSG00000253326.2	RP11-261C10.7	-6.73	4.82e-11	7.18e-05	-0.42	-0.3	Corneal astigmatism;	chr4:119615750	chr1:243054861~243056394:-
THCA	trans	rs6732160	0.588	rs72841902	ENSG00000236165.1	PRADC1P1	6.73	4.84e-11	7.2e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:73145084	chr3:36976316~36976840:+
THCA	trans	rs2645424	1	rs7009302	ENSG00000256560.1	LINC01486	6.73	4.84e-11	7.21e-05	0.36	0.3	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11828472	chr12:109354083~109359488:-
THCA	trans	rs7833986	1	rs36103212	ENSG00000244245.1	RP11-120B7.1	6.73	4.84e-11	7.21e-05	0.39	0.3	Height;	chr8:56188916	chr5:108593609~108593967:+
THCA	trans	rs7829975	0.564	rs2921057	ENSG00000229857.1	RP11-159H20.3	-6.73	4.85e-11	7.21e-05	-0.37	-0.3	Mood instability;	chr8:8461157	chr9:76992099~76993108:+
THCA	trans	rs7121616	0.562	rs2061602	ENSG00000229091.2	HSPA8P8	6.73	4.85e-11	7.22e-05	0.39	0.3	Breast cancer;	chr11:123065079	chr7:10451311~10452526:+
THCA	trans	rs864643	0.524	rs78956370	ENSG00000183298.5	RP11-556K13.1	6.73	4.87e-11	7.24e-05	0.61	0.3	Attention deficit hyperactivity disorder;	chr3:39463883	chr1:101786340~101787219:-
THCA	trans	rs2898290	0.622	rs13272061	ENSG00000256560.1	LINC01486	-6.73	4.88e-11	7.26e-05	-0.37	-0.3	Systolic blood pressure;	chr8:11494752	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.593	rs2921051	ENSG00000256560.1	LINC01486	6.73	4.9e-11	7.29e-05	0.35	0.3	Mood instability;	chr8:8462594	chr12:109354083~109359488:-
THCA	trans	rs4295623	0.585	rs34421088	ENSG00000229857.1	RP11-159H20.3	6.73	4.94e-11	7.34e-05	0.37	0.3	Morning vs. evening chronotype;	chr8:11731533	chr9:76992099~76993108:+
THCA	trans	rs889398	0.594	rs1466863	ENSG00000257513.6	NPIPB1P	-6.73	4.95e-11	7.36e-05	-0.32	-0.3	Body mass index;	chr16:69870235	chr18:11619509~11639699:-
THCA	trans	rs864643	0.898	rs614494	ENSG00000188856.6	RPSAP47	6.73	4.96e-11	7.37e-05	0.44	0.3	Attention deficit hyperactivity disorder;	chr3:39547136	chr8:80558870~80559757:+
THCA	trans	rs6885307	1	rs4634357	ENSG00000231752.4	EMBP1	6.73	4.96e-11	7.37e-05	0.45	0.3	Age at first birth;	chr5:45089824	chr1:121519112~121571892:+
THCA	trans	rs453301	0.624	rs2979256	ENSG00000229857.1	RP11-159H20.3	-6.73	4.97e-11	7.39e-05	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9014200	chr9:76992099~76993108:+
THCA	trans	rs941207	0.542	rs2126068	ENSG00000257210.1	NACAP3	-6.73	4.98e-11	7.4e-05	-0.38	-0.3	Platelet count;	chr12:56804716	chr12:93124063~93124543:-
THCA	trans	rs7824557	1	rs2736371	ENSG00000253893.2	FAM85B	6.73	5.01e-11	7.44e-05	0.38	0.3	Retinal vascular caliber;	chr8:11248020	chr8:8167819~8226614:-
THCA	trans	rs7617480	0.648	rs9859473	ENSG00000197582.5	GPX1P1	6.73	5.02e-11	7.46e-05	0.49	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48799749	chrX:13378735~13379340:-
THCA	trans	rs6601327	0.54	rs6982148	ENSG00000253893.2	FAM85B	6.73	5.02e-11	7.46e-05	0.37	0.3	Multiple myeloma (hyperdiploidy);	chr8:9723560	chr8:8167819~8226614:-
THCA	trans	rs804280	0.525	rs1004712	ENSG00000256560.1	LINC01486	6.73	5.03e-11	7.47e-05	0.35	0.3	Myopia (pathological);	chr8:11764784	chr12:109354083~109359488:-
THCA	trans	rs2336384	1	rs2878677	ENSG00000261819.1	RP11-680G24.4	-6.73	5.05e-11	7.51e-05	-0.38	-0.3	Platelet count;	chr1:11993207	chr16:14988259~14990160:-
THCA	trans	rs1707322	0.752	rs6662164	ENSG00000255397.1	AC022182.2	-6.73	5.05e-11	7.51e-05	-0.42	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr8:60937705~60939871:-
THCA	trans	rs2898290	0.622	rs7829381	ENSG00000229857.1	RP11-159H20.3	6.73	5.06e-11	7.52e-05	0.39	0.3	Systolic blood pressure;	chr8:11487064	chr9:76992099~76993108:+
THCA	trans	rs2898290	0.622	rs11250140	ENSG00000229857.1	RP11-159H20.3	6.73	5.06e-11	7.52e-05	0.39	0.3	Systolic blood pressure;	chr8:11489083	chr9:76992099~76993108:+
THCA	trans	rs330048	0.561	rs330088	ENSG00000229857.1	RP11-159H20.3	-6.73	5.07e-11	7.52e-05	-0.37	-0.3	Systemic lupus erythematosus;	chr8:9292236	chr9:76992099~76993108:+
THCA	trans	rs11172055	0.846	rs7303219	ENSG00000121089.4	NACA3P	-6.73	5.07e-11	7.53e-05	-0.34	-0.3	Migraine;	chr12:56858748	chr4:164943290~164943937:+
THCA	trans	rs11992162	0.55	rs61426048	ENSG00000253893.2	FAM85B	6.73	5.1e-11	7.57e-05	0.4	0.3	Monocyte count;	chr8:11927447	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2572386	ENSG00000254153.1	CTA-398F10.2	6.72	5.12e-11	7.6e-05	0.33	0.3	Retinal vascular caliber;	chr8:11379466	chr8:8456909~8461337:-
THCA	trans	rs1347297	0.756	rs10173183	ENSG00000269800.1	PLEKHA3P1	6.72	5.13e-11	7.61e-05	0.32	0.3	Alzheimer disease and age of onset;	chr2:178411700	chr19:41521043~41521989:-
THCA	trans	rs941207	0.542	rs1813109	ENSG00000257210.1	NACAP3	-6.72	5.14e-11	7.62e-05	-0.38	-0.3	Platelet count;	chr12:56798079	chr12:93124063~93124543:-
THCA	trans	rs7824557	0.767	rs6985460	ENSG00000253893.2	FAM85B	-6.72	5.16e-11	7.66e-05	-0.39	-0.3	Retinal vascular caliber;	chr8:11313578	chr8:8167819~8226614:-
THCA	trans	rs2985684	0.948	rs6572592	ENSG00000240785.1	RPL36AP21	6.72	5.16e-11	7.66e-05	0.38	0.3	Carotid intima media thickness;	chr14:49614153	chr5:18049550~18049872:+
THCA	trans	rs2985684	0.948	rs12886130	ENSG00000240785.1	RPL36AP21	6.72	5.16e-11	7.66e-05	0.38	0.3	Carotid intima media thickness;	chr14:49616035	chr5:18049550~18049872:+
THCA	trans	rs7824557	0.591	rs2043510	ENSG00000253893.2	FAM85B	6.72	5.2e-11	7.71e-05	0.39	0.3	Retinal vascular caliber;	chr8:11367659	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.504	rs6601565	ENSG00000256560.1	LINC01486	-6.72	5.21e-11	7.73e-05	-0.37	-0.3	Neuroticism;	chr8:11174719	chr12:109354083~109359488:-
THCA	trans	rs12145833	0.679	rs12048498	ENSG00000154608.12	CEP170P1	-6.72	5.22e-11	7.74e-05	-0.4	-0.3	Obesity (early onset extreme);	chr1:243387345	chr4:118467590~118554204:+
THCA	trans	rs14057	0.896	rs12124126	ENSG00000215869.3	RP11-364B6.1	6.72	5.23e-11	7.75e-05	0.43	0.3	Systolic blood pressure;	chr1:6600289	chr1:104073023~104077087:+
THCA	trans	rs6601327	0.606	rs13268319	ENSG00000253893.2	FAM85B	6.72	5.23e-11	7.76e-05	0.37	0.3	Multiple myeloma (hyperdiploidy);	chr8:9721739	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs73110464	ENSG00000248568.1	KRT8P48	-6.72	5.24e-11	7.78e-05	-0.6	-0.3	Prostate cancer;	chr12:52918828	chr5:146706381~146707600:-
THCA	trans	rs11098499	0.955	rs56386062	ENSG00000253326.2	RP11-261C10.7	6.72	5.25e-11	7.78e-05	0.4	0.3	Corneal astigmatism;	chr4:119233980	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs4145951	ENSG00000253326.2	RP11-261C10.7	6.72	5.25e-11	7.78e-05	0.4	0.3	Corneal astigmatism;	chr4:119234662	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs35916640	ENSG00000253326.2	RP11-261C10.7	6.72	5.25e-11	7.78e-05	0.4	0.3	Corneal astigmatism;	chr4:119234697	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs13114751	ENSG00000253326.2	RP11-261C10.7	6.72	5.25e-11	7.78e-05	0.4	0.3	Corneal astigmatism;	chr4:119235462	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.913	rs35271032	ENSG00000253326.2	RP11-261C10.7	6.72	5.25e-11	7.78e-05	0.4	0.3	Corneal astigmatism;	chr4:119235504	chr1:243054861~243056394:-
THCA	trans	rs7829975	0.714	rs4841040	ENSG00000256560.1	LINC01486	6.72	5.27e-11	7.81e-05	0.35	0.3	Mood instability;	chr8:8797017	chr12:109354083~109359488:-
THCA	trans	rs73108077	0.736	rs17325435	ENSG00000279352.1	RP11-411B10.7	6.72	5.28e-11	7.82e-05	0.64	0.3	Red blood cell density in sickle cell anemia;	chr20:31259887	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.736	rs73119535	ENSG00000279352.1	RP11-411B10.7	6.72	5.28e-11	7.82e-05	0.64	0.3	Red blood cell density in sickle cell anemia;	chr20:31260483	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.79	rs73104050	ENSG00000279352.1	RP11-411B10.7	6.72	5.28e-11	7.82e-05	0.64	0.3	Red blood cell density in sickle cell anemia;	chr20:31289961	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.79	rs73104055	ENSG00000279352.1	RP11-411B10.7	6.72	5.28e-11	7.82e-05	0.64	0.3	Red blood cell density in sickle cell anemia;	chr20:31293082	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.79	rs73104064	ENSG00000279352.1	RP11-411B10.7	6.72	5.28e-11	7.82e-05	0.64	0.3	Red blood cell density in sickle cell anemia;	chr20:31297920	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.79	rs73104067	ENSG00000279352.1	RP11-411B10.7	6.72	5.28e-11	7.82e-05	0.64	0.3	Red blood cell density in sickle cell anemia;	chr20:31298693	chr18:14010054~14010917:+
THCA	trans	rs902774	0.818	rs17120257	ENSG00000254285.3	KRT8P3	-6.72	5.28e-11	7.83e-05	-0.62	-0.3	Prostate cancer;	chr12:52909547	chr8:61578220~61579668:+
THCA	trans	rs864643	0.898	rs66860744	ENSG00000188856.6	RPSAP47	6.72	5.29e-11	7.84e-05	0.44	0.3	Attention deficit hyperactivity disorder;	chr3:39548245	chr8:80558870~80559757:+
THCA	trans	rs330048	0.545	rs10503387	ENSG00000253893.2	FAM85B	-6.72	5.3e-11	7.85e-05	-0.37	-0.3	Systemic lupus erythematosus;	chr8:9293015	chr8:8167819~8226614:-
THCA	trans	rs864643	1	rs1768252	ENSG00000183298.5	RP11-556K13.1	6.72	5.3e-11	7.85e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39506768	chr1:101786340~101787219:-
THCA	trans	rs6601327	0.518	rs13264850	ENSG00000253893.2	FAM85B	6.72	5.35e-11	7.92e-05	0.37	0.3	Multiple myeloma (hyperdiploidy);	chr8:9717821	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.505	rs2736313	ENSG00000256560.1	LINC01486	6.72	5.35e-11	7.92e-05	0.37	0.3	Retinal vascular caliber;	chr8:11229433	chr12:109354083~109359488:-
THCA	trans	rs3740713	1	rs73436638	ENSG00000236090.2	LDHAP3	6.72	5.35e-11	7.93e-05	0.53	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73436642	ENSG00000236090.2	LDHAP3	6.72	5.35e-11	7.93e-05	0.53	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73436666	ENSG00000236090.2	LDHAP3	6.72	5.35e-11	7.93e-05	0.53	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438611	ENSG00000236090.2	LDHAP3	6.72	5.35e-11	7.93e-05	0.53	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs2643872	ENSG00000236090.2	LDHAP3	6.72	5.35e-11	7.93e-05	0.53	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs75381502	ENSG00000236090.2	LDHAP3	6.72	5.35e-11	7.93e-05	0.53	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr2:41819747~41820754:+
THCA	trans	rs6732160	0.588	rs13403748	ENSG00000236165.1	PRADC1P1	6.72	5.36e-11	7.94e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:73144347	chr3:36976316~36976840:+
THCA	trans	rs6732160	0.588	rs13390460	ENSG00000236165.1	PRADC1P1	6.72	5.36e-11	7.94e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:73144348	chr3:36976316~36976840:+
THCA	trans	rs3764796	0.618	rs17586836	ENSG00000250030.2	RP11-584P21.4	6.72	5.37e-11	7.95e-05	0.58	0.3	Calcium levels;	chr8:17208715	chr4:67446267~67446574:+
THCA	trans	rs7819412	1	rs7819412	ENSG00000256560.1	LINC01486	6.72	5.37e-11	7.95e-05	0.37	0.3	Triglycerides;	chr8:11187652	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.714	rs7823757	ENSG00000256560.1	LINC01486	6.72	5.38e-11	7.96e-05	0.35	0.3	Mood instability;	chr8:8812667	chr12:109354083~109359488:-
THCA	trans	rs7833986	0.534	rs72653928	ENSG00000236862.1	RPS20P24	6.72	5.39e-11	7.98e-05	0.46	0.3	Height;	chr8:55995176	chr9:72655832~72656192:-
THCA	trans	rs6087990	1	rs1007124	ENSG00000253915.1	MAPRE1P1	6.72	5.39e-11	7.99e-05	0.38	0.3	Ulcerative colitis;	chr20:32757946	chr8:135625185~135625981:-
THCA	trans	rs7829975	0.617	rs4841071	ENSG00000229857.1	RP11-159H20.3	-6.72	5.42e-11	8.02e-05	-0.37	-0.3	Mood instability;	chr8:8933634	chr9:76992099~76993108:+
THCA	trans	rs864643	0.853	rs7645925	ENSG00000183298.5	RP11-556K13.1	-6.72	5.42e-11	8.02e-05	-0.46	-0.3	Attention deficit hyperactivity disorder;	chr3:39538192	chr1:101786340~101787219:-
THCA	trans	rs1406428	0.748	rs1919427	ENSG00000256393.1	RPL41P5	6.71	5.44e-11	8.05e-05	0.45	0.3	Response to tocilizumab in rheumatoid arthritis;	chr2:51508356	chr12:93083598~93083675:-
THCA	trans	rs11098499	0.82	rs13122709	ENSG00000253326.2	RP11-261C10.7	6.71	5.44e-11	8.06e-05	0.42	0.3	Corneal astigmatism;	chr4:119634201	chr1:243054861~243056394:-
THCA	trans	rs889398	0.617	rs1566456	ENSG00000257513.6	NPIPB1P	6.71	5.45e-11	8.06e-05	0.32	0.3	Body mass index;	chr16:69866323	chr18:11619509~11639699:-
THCA	trans	rs864643	0.891	rs661366	ENSG00000183298.5	RP11-556K13.1	6.71	5.46e-11	8.08e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39519857	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs572971	ENSG00000183298.5	RP11-556K13.1	6.71	5.46e-11	8.08e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39519936	chr1:101786340~101787219:-
THCA	trans	rs864643	0.945	rs1355733	ENSG00000183298.5	RP11-556K13.1	6.71	5.46e-11	8.08e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39521165	chr1:101786340~101787219:-
THCA	trans	rs6087990	0.735	rs6058891	ENSG00000253915.1	MAPRE1P1	6.71	5.47e-11	8.09e-05	0.39	0.3	Ulcerative colitis;	chr20:32798541	chr8:135625185~135625981:-
THCA	trans	rs6087990	0.735	rs2424922	ENSG00000253915.1	MAPRE1P1	6.71	5.47e-11	8.09e-05	0.39	0.3	Ulcerative colitis;	chr20:32798643	chr8:135625185~135625981:-
THCA	trans	rs11172055	0.846	rs7306442	ENSG00000121089.4	NACA3P	-6.71	5.48e-11	8.1e-05	-0.34	-0.3	Migraine;	chr12:56859089	chr4:164943290~164943937:+
THCA	trans	rs889398	0.617	rs3790082	ENSG00000257513.6	NPIPB1P	6.71	5.48e-11	8.11e-05	0.32	0.3	Body mass index;	chr16:69862851	chr18:11619509~11639699:-
THCA	trans	rs76228276	0.737	rs72672378	ENSG00000260318.1	COX6CP1	6.71	5.5e-11	8.14e-05	0.9	0.3	Childhood ear infection;	chr8:99350758	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11985286	ENSG00000260318.1	COX6CP1	6.71	5.5e-11	8.14e-05	0.9	0.3	Childhood ear infection;	chr8:99379894	chr16:11903923~11904137:-
THCA	trans	rs6732160	0.517	rs10189791	ENSG00000236165.1	PRADC1P1	6.71	5.5e-11	8.14e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:73170571	chr3:36976316~36976840:+
THCA	trans	rs877636	0.702	rs773108	ENSG00000224553.1	AC008065.1	6.71	5.51e-11	8.15e-05	0.38	0.3	Cognitive function;	chr12:55976127	chr2:171374931~171375278:-
THCA	trans	rs864643	1	rs1513214	ENSG00000183298.5	RP11-556K13.1	6.71	5.52e-11	8.16e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39518774	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs1768267	ENSG00000183298.5	RP11-556K13.1	6.71	5.52e-11	8.16e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39518945	chr1:101786340~101787219:-
THCA	trans	rs7824557	0.545	rs2572380	ENSG00000254153.1	CTA-398F10.2	6.71	5.52e-11	8.16e-05	0.33	0.3	Retinal vascular caliber;	chr8:11379968	chr8:8456909~8461337:-
THCA	trans	rs3740713	1	rs79199586	ENSG00000236090.2	LDHAP3	6.71	5.54e-11	8.19e-05	0.55	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr2:41819747~41820754:+
THCA	trans	rs3002142	0.658	rs2291833	ENSG00000219201.4	RP11-181C21.4	-6.71	5.56e-11	8.21e-05	-0.42	-0.3	LDL peak particle diameter (total fat intake interaction);	chr1:222653505	chr1:77810861~77811781:-
THCA	trans	rs4263408	0.967	rs4974948	ENSG00000237550.5	UBE2Q2P6	6.71	5.58e-11	8.24e-05	0.35	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39751016	chr15:82372196~82372912:-
THCA	trans	rs902774	0.818	rs79377635	ENSG00000248568.1	KRT8P48	-6.71	5.59e-11	8.27e-05	-0.62	-0.3	Prostate cancer;	chr12:52883148	chr5:146706381~146707600:-
THCA	trans	rs7829975	0.774	rs11775523	ENSG00000256560.1	LINC01486	6.71	5.61e-11	8.29e-05	0.35	0.3	Mood instability;	chr8:8821666	chr12:109354083~109359488:-
THCA	trans	rs9876781	0.559	rs7630053	ENSG00000225528.1	RP3-370M22.8	-6.71	5.62e-11	8.3e-05	-0.37	-0.3	Longevity;	chr3:48357096	chr22:39960397~39964683:+
THCA	trans	rs6087990	0.735	rs2424921	ENSG00000253915.1	MAPRE1P1	6.71	5.65e-11	8.35e-05	0.39	0.3	Ulcerative colitis;	chr20:32798008	chr8:135625185~135625981:-
THCA	trans	rs453301	0.598	rs2921383	ENSG00000229857.1	RP11-159H20.3	-6.71	5.68e-11	8.39e-05	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9034711	chr9:76992099~76993108:+
THCA	trans	rs853679	0.607	rs67340775	ENSG00000253570.1	RNF5P1	6.71	5.72e-11	8.45e-05	0.81	0.3	Depression;	chr6:28336607	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs35030260	ENSG00000253570.1	RNF5P1	6.71	5.72e-11	8.45e-05	0.81	0.3	Depression;	chr6:28337731	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13217619	ENSG00000253570.1	RNF5P1	6.71	5.72e-11	8.45e-05	0.81	0.3	Depression;	chr6:28338894	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs35016036	ENSG00000253570.1	RNF5P1	6.71	5.72e-11	8.45e-05	0.81	0.3	Depression;	chr6:28347103	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs35744819	ENSG00000253570.1	RNF5P1	6.71	5.72e-11	8.45e-05	0.81	0.3	Depression;	chr6:28350554	chr8:38600661~38601200:-
THCA	trans	rs4263408	0.935	rs62310123	ENSG00000237550.5	UBE2Q2P6	6.71	5.72e-11	8.45e-05	0.35	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39744462	chr15:82372196~82372912:-
THCA	trans	rs76228276	0.737	rs72672353	ENSG00000260318.1	COX6CP1	6.71	5.76e-11	8.51e-05	0.84	0.3	Childhood ear infection;	chr8:99298831	chr16:11903923~11904137:-
THCA	trans	rs3849046	1	rs13164092	ENSG00000226666.1	HSPA9P1	-6.71	5.77e-11	8.52e-05	-0.31	-0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138505171	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.967	rs55985421	ENSG00000226666.1	HSPA9P1	-6.71	5.77e-11	8.52e-05	-0.31	-0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138505574	chr2:221961737~221963765:+
THCA	trans	rs1391708	1	rs34285886	ENSG00000121089.4	NACA3P	-6.71	5.78e-11	8.54e-05	-0.49	-0.3	Airway wall thickness;	chr12:56908736	chr4:164943290~164943937:+
THCA	trans	rs902774	0.818	rs73110464	ENSG00000255815.3	KRT8P11	-6.71	5.79e-11	8.55e-05	-0.6	-0.3	Prostate cancer;	chr12:52918828	chr9:99305176~99306611:+
THCA	trans	rs7617480	0.587	rs9311431	ENSG00000197582.5	GPX1P1	6.7	5.8e-11	8.56e-05	0.51	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48811354	chrX:13378735~13379340:-
THCA	trans	rs7617480	0.648	rs4974088	ENSG00000197582.5	GPX1P1	6.7	5.8e-11	8.56e-05	0.51	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48861316	chrX:13378735~13379340:-
THCA	trans	rs864643	0.524	rs6810264	ENSG00000183298.5	RP11-556K13.1	6.7	5.8e-11	8.57e-05	0.6	0.3	Attention deficit hyperactivity disorder;	chr3:39471605	chr1:101786340~101787219:-
THCA	trans	rs864643	0.524	rs11706953	ENSG00000183298.5	RP11-556K13.1	6.7	5.8e-11	8.57e-05	0.6	0.3	Attention deficit hyperactivity disorder;	chr3:39472119	chr1:101786340~101787219:-
THCA	trans	rs864643	0.524	rs72869131	ENSG00000183298.5	RP11-556K13.1	6.7	5.8e-11	8.57e-05	0.6	0.3	Attention deficit hyperactivity disorder;	chr3:39472959	chr1:101786340~101787219:-
THCA	trans	rs9467773	0.595	rs3799379	ENSG00000242375.1	RP11-498P14.3	-6.7	5.82e-11	8.58e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr6:26404466	chr9:97195351~97197687:-
THCA	trans	rs9650657	0.572	rs4841465	ENSG00000229857.1	RP11-159H20.3	6.7	5.82e-11	8.59e-05	0.37	0.3	Neuroticism;	chr8:10962344	chr9:76992099~76993108:+
THCA	trans	rs1391708	1	rs7957145	ENSG00000121089.4	NACA3P	-6.7	5.83e-11	8.61e-05	-0.5	-0.3	Airway wall thickness;	chr12:56908336	chr4:164943290~164943937:+
THCA	trans	rs3740713	1	rs3740713	ENSG00000236090.2	LDHAP3	6.7	5.83e-11	8.61e-05	0.56	0.3	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr2:41819747~41820754:+
THCA	trans	rs7829975	0.688	rs7826654	ENSG00000256560.1	LINC01486	6.7	5.85e-11	8.63e-05	0.36	0.3	Mood instability;	chr8:8521596	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.688	rs7826660	ENSG00000256560.1	LINC01486	6.7	5.85e-11	8.63e-05	0.36	0.3	Mood instability;	chr8:8521597	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.669	rs2424929	ENSG00000253915.1	MAPRE1P1	6.7	5.87e-11	8.66e-05	0.38	0.3	Ulcerative colitis;	chr20:32801712	chr8:135625185~135625981:-
THCA	trans	rs7819412	0.522	rs4841497	ENSG00000229857.1	RP11-159H20.3	6.7	5.91e-11	8.71e-05	0.4	0.3	Triglycerides;	chr8:11127630	chr9:76992099~76993108:+
THCA	trans	rs13016963	0.604	rs11674814	ENSG00000235105.1	RP11-329A14.1	-6.7	5.93e-11	8.74e-05	-0.32	-0.3	Esophageal squamous cell carcinoma;Melanoma;	chr2:201289123	chr1:48435967~48437223:+
THCA	trans	rs6600671	0.692	rs11249430	ENSG00000270392.2	PFN1P2	6.7	5.93e-11	8.75e-05	0.3	0.3	Hip geometry;	chr1:121547115	chr1:120432204~120434052:-
THCA	trans	rs1707322	0.789	rs7540578	ENSG00000255397.1	AC022182.2	-6.7	5.95e-11	8.78e-05	-0.41	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr8:60937705~60939871:-
THCA	trans	rs8067354	0.645	rs2271304	ENSG00000187870.7	RNFT1P3	6.7	5.95e-11	8.78e-05	0.47	0.3	Hemoglobin concentration;	chr17:59737280	chr17:20743333~20754501:-
THCA	trans	rs6087990	0.965	rs742630	ENSG00000253915.1	MAPRE1P1	6.7	5.97e-11	8.8e-05	0.38	0.3	Ulcerative colitis;	chr20:32762858	chr8:135625185~135625981:-
THCA	trans	rs853679	0.607	rs13211507	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28289600	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34691223	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28290431	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13207345	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28297795	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs72854513	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28298177	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs56189111	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28304196	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34950484	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28310911	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs35072899	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28313764	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34661125	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28314117	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13190888	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28318208	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs56075693	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28322551	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs34218844	ENSG00000253570.1	RNF5P1	6.7	5.97e-11	8.8e-05	0.81	0.3	Depression;	chr6:28322870	chr8:38600661~38601200:-
THCA	trans	rs76228276	0.737	rs72672374	ENSG00000260318.1	COX6CP1	6.7	5.99e-11	8.83e-05	0.88	0.3	Childhood ear infection;	chr8:99344162	chr16:11903923~11904137:-
THCA	trans	rs6921919	0.562	rs13198809	ENSG00000253570.1	RNF5P1	6.7	6.01e-11	8.86e-05	0.81	0.3	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs35353359	ENSG00000253570.1	RNF5P1	6.7	6.01e-11	8.86e-05	0.81	0.3	Depression;	chr6:28356601	chr8:38600661~38601200:-
THCA	trans	rs1707322	0.721	rs61784800	ENSG00000255397.1	AC022182.2	6.7	6.03e-11	8.89e-05	0.41	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.682	rs28508523	ENSG00000255397.1	AC022182.2	-6.7	6.07e-11	8.95e-05	-0.41	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.691	rs11211175	ENSG00000255397.1	AC022182.2	-6.7	6.07e-11	8.95e-05	-0.41	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr8:60937705~60939871:-
THCA	trans	rs864643	0.812	rs1606473	ENSG00000183298.5	RP11-556K13.1	-6.7	6.08e-11	8.95e-05	-0.46	-0.3	Attention deficit hyperactivity disorder;	chr3:39541433	chr1:101786340~101787219:-
THCA	trans	rs7829975	0.606	rs7819827	ENSG00000229857.1	RP11-159H20.3	6.7	6.08e-11	8.96e-05	0.37	0.3	Mood instability;	chr8:8939545	chr9:76992099~76993108:+
THCA	trans	rs116095464	1	rs10475185	ENSG00000185986.11	SDHAP3	6.7	6.11e-11	8.99e-05	0.53	0.3	Breast cancer;	chr5:306866	chr5:1572222~1594620:-
THCA	trans	rs116095464	1	rs56095714	ENSG00000185986.11	SDHAP3	6.7	6.11e-11	8.99e-05	0.53	0.3	Breast cancer;	chr5:311141	chr5:1572222~1594620:-
THCA	trans	rs1045902	0.532	rs2288631	ENSG00000236165.1	PRADC1P1	6.7	6.11e-11	9e-05	0.41	0.3	Intelligence (multi-trait analysis);	chr2:73228619	chr3:36976316~36976840:+
THCA	trans	rs1045902	0.532	rs10185579	ENSG00000236165.1	PRADC1P1	6.7	6.11e-11	9e-05	0.41	0.3	Intelligence (multi-trait analysis);	chr2:73229214	chr3:36976316~36976840:+
THCA	trans	rs2980439	0.557	rs2976876	ENSG00000256560.1	LINC01486	6.7	6.11e-11	9e-05	0.35	0.3	Neuroticism;	chr8:8461340	chr12:109354083~109359488:-
THCA	trans	rs941207	0.542	rs1903370	ENSG00000257210.1	NACAP3	-6.7	6.12e-11	9.01e-05	-0.38	-0.3	Platelet count;	chr12:56812900	chr12:93124063~93124543:-
THCA	trans	rs9393777	0.764	rs35565446	ENSG00000253570.1	RNF5P1	6.7	6.13e-11	9.02e-05	0.83	0.3	Intelligence (multi-trait analysis);	chr6:27177562	chr8:38600661~38601200:-
THCA	trans	rs7824557	0.527	rs2572449	ENSG00000254153.1	CTA-398F10.2	-6.7	6.13e-11	9.03e-05	-0.32	-0.3	Retinal vascular caliber;	chr8:11381628	chr8:8456909~8461337:-
THCA	trans	rs1391708	1	rs1391708	ENSG00000121089.4	NACA3P	-6.7	6.14e-11	9.03e-05	-0.49	-0.3	Airway wall thickness;	chr12:56911796	chr4:164943290~164943937:+
THCA	trans	rs853679	0.546	rs34676049	ENSG00000228022.4	HCG20	-6.7	6.14e-11	9.04e-05	-0.78	-0.3	Depression;	chr6:28485841	chr6:30766825~30792250:+
THCA	trans	rs864643	1	rs602527	ENSG00000183298.5	RP11-556K13.1	6.7	6.15e-11	9.05e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39527293	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs816520	ENSG00000183298.5	RP11-556K13.1	6.7	6.15e-11	9.05e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39528222	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs866537	ENSG00000183298.5	RP11-556K13.1	6.7	6.15e-11	9.05e-05	0.49	0.3	Attention deficit hyperactivity disorder;	chr3:39530125	chr1:101786340~101787219:-
THCA	trans	rs453301	0.653	rs7016139	ENSG00000229857.1	RP11-159H20.3	6.7	6.15e-11	9.05e-05	0.35	0.3	Joint mobility (Beighton score);	chr8:9037960	chr9:76992099~76993108:+
THCA	trans	rs7833986	0.534	rs2667980	ENSG00000236862.1	RPS20P24	6.7	6.15e-11	9.06e-05	0.46	0.3	Height;	chr8:55983982	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs72653921	ENSG00000236862.1	RPS20P24	6.7	6.15e-11	9.06e-05	0.46	0.3	Height;	chr8:55984598	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.534	rs2458083	ENSG00000236862.1	RPS20P24	6.7	6.15e-11	9.06e-05	0.46	0.3	Height;	chr8:55986226	chr9:72655832~72656192:-
THCA	trans	rs877636	0.702	rs773112	ENSG00000244604.1	RP11-713H12.1	6.7	6.16e-11	9.06e-05	0.39	0.3	Cognitive function;	chr12:55982097	chr17:8561230~8561576:+
THCA	trans	rs889398	0.594	rs2133799	ENSG00000257513.6	NPIPB1P	6.7	6.16e-11	9.07e-05	0.32	0.3	Body mass index;	chr16:69879123	chr18:11619509~11639699:-
THCA	trans	rs9329221	0.736	rs11249999	ENSG00000253893.2	FAM85B	6.69	6.17e-11	9.08e-05	0.39	0.3	Neuroticism;	chr8:10393755	chr8:8167819~8226614:-
THCA	trans	rs941207	0.542	rs6581102	ENSG00000257210.1	NACAP3	-6.69	6.22e-11	9.15e-05	-0.38	-0.3	Platelet count;	chr12:56790632	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs6581103	ENSG00000257210.1	NACAP3	-6.69	6.22e-11	9.15e-05	-0.38	-0.3	Platelet count;	chr12:56790641	chr12:93124063~93124543:-
THCA	trans	rs2950393	0.929	rs10876916	ENSG00000228224.3	NACAP1	6.69	6.22e-11	9.16e-05	0.3	0.3	Platelet distribution width;	chr12:56692728	chr8:101361794~101372707:+
THCA	trans	rs941207	0.547	rs56183434	ENSG00000257210.1	NACAP3	6.69	6.23e-11	9.16e-05	0.36	0.3	Platelet count;	chr12:56676145	chr12:93124063~93124543:-
THCA	trans	rs7829975	0.627	rs876954	ENSG00000229857.1	RP11-159H20.3	-6.69	6.24e-11	9.18e-05	-0.37	-0.29	Mood instability;	chr8:8453413	chr9:76992099~76993108:+
THCA	trans	rs902774	0.818	rs73110432	ENSG00000230716.3	KRT8P7	-6.69	6.25e-11	9.19e-05	-0.58	-0.29	Prostate cancer;	chr12:52894051	chr11:119602875~119604306:-
THCA	trans	rs34421088	0.532	rs2409754	ENSG00000253893.2	FAM85B	-6.69	6.25e-11	9.19e-05	-0.39	-0.29	Neuroticism;	chr8:11298104	chr8:8167819~8226614:-
THCA	trans	rs864643	0.947	rs1473863	ENSG00000183298.5	RP11-556K13.1	6.69	6.26e-11	9.21e-05	0.48	0.29	Attention deficit hyperactivity disorder;	chr3:39499544	chr1:101786340~101787219:-
THCA	trans	rs3956705	1	rs12701265	ENSG00000176826.14	FKBP9P1	-6.69	6.28e-11	9.23e-05	-0.4	-0.29	Red cell distribution width;	chr7:32931624	chr7:55681074~55713252:-
THCA	trans	rs3956705	1	rs35500246	ENSG00000176826.14	FKBP9P1	-6.69	6.28e-11	9.23e-05	-0.4	-0.29	Red cell distribution width;	chr7:32932161	chr7:55681074~55713252:-
THCA	trans	rs7617480	0.616	rs7429596	ENSG00000197582.5	GPX1P1	6.69	6.3e-11	9.26e-05	0.52	0.29	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48771098	chrX:13378735~13379340:-
THCA	trans	rs3740713	1	rs57311859	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr2:41819747~41820754:+
THCA	trans	rs3740713	0.92	rs112973292	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr2:41819747~41820754:+
THCA	trans	rs3740713	0.92	rs73438656	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr2:41819747~41820754:+
THCA	trans	rs3740713	0.92	rs73438659	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438666	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs16935424	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438674	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438690	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438695	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73440606	ENSG00000236090.2	LDHAP3	6.69	6.3e-11	9.27e-05	0.54	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr2:41819747~41820754:+
THCA	trans	rs73108077	0.79	rs73102048	ENSG00000279352.1	RP11-411B10.7	6.69	6.31e-11	9.28e-05	0.64	0.29	Red blood cell density in sickle cell anemia;	chr20:31277508	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.704	rs7273922	ENSG00000279352.1	RP11-411B10.7	6.69	6.31e-11	9.28e-05	0.64	0.29	Red blood cell density in sickle cell anemia;	chr20:31282601	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.79	rs73102082	ENSG00000279352.1	RP11-411B10.7	6.69	6.31e-11	9.28e-05	0.64	0.29	Red blood cell density in sickle cell anemia;	chr20:31288687	chr18:14010054~14010917:+
THCA	trans	rs73108077	0.704	rs73119542	ENSG00000279352.1	RP11-411B10.7	6.69	6.34e-11	9.31e-05	0.64	0.29	Red blood cell density in sickle cell anemia;	chr20:31268950	chr18:14010054~14010917:+
THCA	trans	rs941207	0.542	rs1870674	ENSG00000257210.1	NACAP3	-6.69	6.35e-11	9.33e-05	-0.38	-0.29	Platelet count;	chr12:56805721	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs11171980	ENSG00000257210.1	NACAP3	-6.69	6.35e-11	9.33e-05	-0.38	-0.29	Platelet count;	chr12:56806397	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs12366897	ENSG00000257210.1	NACAP3	-6.69	6.35e-11	9.33e-05	-0.38	-0.29	Platelet count;	chr12:56808329	chr12:93124063~93124543:-
THCA	trans	rs9329221	0.686	rs13264580	ENSG00000253893.2	FAM85B	-6.69	6.37e-11	9.36e-05	-0.39	-0.29	Neuroticism;	chr8:10393189	chr8:8167819~8226614:-
THCA	trans	rs2980439	0.557	rs2921056	ENSG00000256560.1	LINC01486	6.69	6.41e-11	9.42e-05	0.35	0.29	Neuroticism;	chr8:8461672	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.551	rs35010200	ENSG00000253893.2	FAM85B	6.69	6.42e-11	9.43e-05	0.4	0.29	Monocyte count;	chr8:11928146	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.591	rs2736282	ENSG00000253893.2	FAM85B	-6.69	6.42e-11	9.43e-05	-0.39	-0.29	Retinal vascular caliber;	chr8:11367971	chr8:8167819~8226614:-
THCA	trans	rs4911259	0.513	rs4287835	ENSG00000253915.1	MAPRE1P1	-6.69	6.44e-11	9.46e-05	-0.38	-0.29	Inflammatory bowel disease;	chr20:32869531	chr8:135625185~135625981:-
THCA	trans	rs6885307	0.607	rs79174895	ENSG00000231752.4	EMBP1	6.69	6.45e-11	9.48e-05	0.46	0.29	Age at first birth;	chr5:45266705	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.655	rs10093774	ENSG00000253893.2	FAM85B	-6.69	6.46e-11	9.49e-05	-0.38	-0.29	Neuroticism;	chr8:10845783	chr8:8167819~8226614:-
THCA	trans	rs941207	0.542	rs4277148	ENSG00000257210.1	NACAP3	-6.69	6.51e-11	9.56e-05	-0.38	-0.29	Platelet count;	chr12:56787071	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs12370142	ENSG00000257210.1	NACAP3	-6.69	6.51e-11	9.56e-05	-0.38	-0.29	Platelet count;	chr12:56790801	chr12:93124063~93124543:-
THCA	trans	rs7824557	0.737	rs10481445	ENSG00000229857.1	RP11-159H20.3	6.69	6.52e-11	9.58e-05	0.37	0.29	Retinal vascular caliber;	chr8:11251760	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.56	rs2248325	ENSG00000229857.1	RP11-159H20.3	6.69	6.53e-11	9.58e-05	0.38	0.29	Neuroticism;	chr8:11539365	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.56	rs2248316	ENSG00000229857.1	RP11-159H20.3	6.69	6.53e-11	9.58e-05	0.38	0.29	Neuroticism;	chr8:11539564	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.56	rs2248315	ENSG00000229857.1	RP11-159H20.3	6.69	6.53e-11	9.58e-05	0.38	0.29	Neuroticism;	chr8:11539577	chr9:76992099~76993108:+
THCA	trans	rs9425766	0.888	rs1799876	ENSG00000213331.4	RP11-713C19.2	6.69	6.55e-11	9.61e-05	0.38	0.29	Life satisfaction;	chr1:173909333	chr4:187970273~187971284:+
THCA	trans	rs16937956	0.536	rs12362113	ENSG00000266891.1	RP11-692N5.2	-6.69	6.55e-11	9.62e-05	-0.38	-0.29	Body mass index;	chr11:8379019	chr18:9734882~9735602:-
THCA	trans	rs6087990	0.965	rs6058869	ENSG00000253915.1	MAPRE1P1	6.68	6.56e-11	9.63e-05	0.38	0.29	Ulcerative colitis;	chr20:32760944	chr8:135625185~135625981:-
THCA	trans	rs34421088	0.506	rs2117616	ENSG00000253893.2	FAM85B	6.68	6.57e-11	9.64e-05	0.4	0.29	Neuroticism;	chr8:11288402	chr8:8167819~8226614:-
THCA	trans	rs453301	0.624	rs330058	ENSG00000229857.1	RP11-159H20.3	6.68	6.58e-11	9.66e-05	0.36	0.29	Joint mobility (Beighton score);	chr8:9232299	chr9:76992099~76993108:+
THCA	trans	rs864643	0.947	rs587054	ENSG00000183298.5	RP11-556K13.1	6.68	6.63e-11	9.73e-05	0.49	0.29	Attention deficit hyperactivity disorder;	chr3:39524496	chr1:101786340~101787219:-
THCA	trans	rs4378355	1	rs4378355	ENSG00000225531.1	RP11-196I18.3	6.68	6.65e-11	9.76e-05	0.38	0.29	Prostate-specific antigen levels;	chr11:34761870	chr9:107116829~107117557:+
THCA	trans	rs9649213	0.593	rs6947340	ENSG00000225169.1	BRI3P1	-6.68	6.66e-11	9.76e-05	-0.38	-0.29	Prostate cancer (SNP x SNP interaction);	chr7:98282929	chr1:100213293~100213670:+
THCA	trans	rs6601327	0.54	rs12542912	ENSG00000253893.2	FAM85B	6.68	6.66e-11	9.77e-05	0.37	0.29	Multiple myeloma (hyperdiploidy);	chr8:9727686	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.622	rs17799486	ENSG00000229857.1	RP11-159H20.3	6.68	6.69e-11	9.81e-05	0.38	0.29	Systolic blood pressure;	chr8:11482985	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs6601564	ENSG00000256560.1	LINC01486	-6.68	6.73e-11	9.87e-05	-0.37	-0.29	Triglycerides;	chr8:11124541	chr12:109354083~109359488:-
THCA	trans	rs877636	0.702	rs773110	ENSG00000244604.1	RP11-713H12.1	6.68	6.74e-11	9.88e-05	0.39	0.29	Cognitive function;	chr12:55981353	chr17:8561230~8561576:+
THCA	trans	rs877636	0.702	rs773111	ENSG00000244604.1	RP11-713H12.1	6.68	6.74e-11	9.88e-05	0.39	0.29	Cognitive function;	chr12:55981956	chr17:8561230~8561576:+
THCA	trans	rs76228276	0.737	rs11987013	ENSG00000260318.1	COX6CP1	-6.68	6.75e-11	9.89e-05	-0.88	-0.29	Childhood ear infection;	chr8:99569804	chr16:11903923~11904137:-
THCA	trans	rs6981523	0.553	rs2409730	ENSG00000253893.2	FAM85B	6.68	6.81e-11	9.98e-05	0.4	0.29	Neuroticism;	chr8:11203129	chr8:8167819~8226614:-
THCA	trans	rs656319	0.607	rs55836143	ENSG00000253893.2	FAM85B	6.68	6.84e-11	1e-04	0.4	0.29	Myopia (pathological);	chr8:10242560	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.735	rs2424920	ENSG00000253915.1	MAPRE1P1	6.68	6.86e-11	0.000101	0.38	0.29	Ulcerative colitis;	chr20:32797646	chr8:135625185~135625981:-
THCA	trans	rs453301	0.571	rs2929305	ENSG00000229857.1	RP11-159H20.3	6.68	6.87e-11	0.000101	0.36	0.29	Joint mobility (Beighton score);	chr8:9227707	chr9:76992099~76993108:+
THCA	trans	rs3740713	1	rs73440615	ENSG00000236090.2	LDHAP3	6.68	6.87e-11	0.000101	0.53	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr2:41819747~41820754:+
THCA	trans	rs2336384	1	rs6672267	ENSG00000261819.1	RP11-680G24.4	6.68	6.88e-11	0.000101	0.39	0.29	Platelet count;	chr1:11994854	chr16:14988259~14990160:-
THCA	trans	rs14057	0.896	rs12028517	ENSG00000215869.3	RP11-364B6.1	6.68	6.89e-11	0.000101	0.42	0.29	Systolic blood pressure;	chr1:6601672	chr1:104073023~104077087:+
THCA	trans	rs9329221	0.662	rs35472251	ENSG00000253893.2	FAM85B	-6.68	6.93e-11	0.000101	-0.39	-0.29	Neuroticism;	chr8:10389159	chr8:8167819~8226614:-
THCA	trans	rs453301	0.653	rs7005133	ENSG00000229857.1	RP11-159H20.3	-6.68	6.94e-11	0.000102	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9043712	chr9:76992099~76993108:+
THCA	trans	rs864643	1	rs1708056	ENSG00000183298.5	RP11-556K13.1	6.68	6.94e-11	0.000102	0.49	0.29	Attention deficit hyperactivity disorder;	chr3:39531662	chr1:101786340~101787219:-
THCA	trans	rs9329221	0.502	rs11777364	ENSG00000253893.2	FAM85B	-6.68	6.96e-11	0.000102	-0.38	-0.29	Neuroticism;	chr8:10431036	chr8:8167819~8226614:-
THCA	trans	rs2950393	0.895	rs2958154	ENSG00000257210.1	NACAP3	-6.68	6.97e-11	0.000102	-0.36	-0.29	Platelet distribution width;	chr12:56671929	chr12:93124063~93124543:-
THCA	trans	rs11671005	0.571	rs56243535	ENSG00000279267.1	RP11-395L14.18	6.68	6.98e-11	0.000102	0.44	0.29	Mean platelet volume;	chr19:58494783	chr2:113605867~113607908:-
THCA	trans	rs902774	0.818	rs4919743	ENSG00000250539.1	KRT8P33	-6.67	7.01e-11	0.000103	-0.51	-0.29	Prostate cancer;	chr12:52915800	chr5:123400922~123402344:-
THCA	trans	rs4911259	0.552	rs62208880	ENSG00000253915.1	MAPRE1P1	-6.67	7.01e-11	0.000103	-0.38	-0.29	Inflammatory bowel disease;	chr20:32875478	chr8:135625185~135625981:-
THCA	trans	rs9329221	0.71	rs11785061	ENSG00000253893.2	FAM85B	-6.67	7.05e-11	0.000103	-0.4	-0.29	Neuroticism;	chr8:10402018	chr8:8167819~8226614:-
THCA	trans	rs10783779	0.647	rs705708	ENSG00000235459.5	RPS26P31	6.67	7.06e-11	0.000103	0.37	0.29	Educational attainment;	chr12:56095129	chr7:122681315~122681662:+
THCA	trans	rs4263408	1	rs4263408	ENSG00000237550.5	UBE2Q2P6	6.67	7.1e-11	0.000104	0.34	0.29	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39783656	chr15:82372196~82372912:-
THCA	trans	rs4929949	0.546	rs2121312	ENSG00000266891.1	RP11-692N5.2	6.67	7.1e-11	0.000104	0.39	0.29	Body mass index;	chr11:8432047	chr18:9734882~9735602:-
THCA	trans	rs1391708	0.504	rs117991841	ENSG00000121089.4	NACA3P	-6.67	7.1e-11	0.000104	-0.54	-0.29	Airway wall thickness;	chr12:56869833	chr4:164943290~164943937:+
THCA	trans	rs3740713	1	rs78549183	ENSG00000236090.2	LDHAP3	6.67	7.11e-11	0.000104	0.53	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr2:41819747~41820754:+
THCA	trans	rs7819412	0.774	rs34208825	ENSG00000254153.1	CTA-398F10.2	6.67	7.11e-11	0.000104	0.33	0.29	Triglycerides;	chr8:11157106	chr8:8456909~8461337:-
THCA	trans	rs9329221	0.736	rs11250002	ENSG00000253893.2	FAM85B	-6.67	7.14e-11	0.000104	-0.39	-0.29	Neuroticism;	chr8:10399531	chr8:8167819~8226614:-
THCA	trans	rs2288327	0.818	rs3829747	ENSG00000269800.1	PLEKHA3P1	6.67	7.14e-11	0.000104	0.42	0.29	Atrial fibrillation;	chr2:178532834	chr19:41521043~41521989:-
THCA	trans	rs3740713	1	rs76586692	ENSG00000236090.2	LDHAP3	6.67	7.2e-11	0.000105	0.53	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs76062966	ENSG00000236090.2	LDHAP3	6.67	7.2e-11	0.000105	0.53	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr2:41819747~41820754:+
THCA	trans	rs902774	0.818	rs73110432	ENSG00000223940.1	KRT8P8	-6.67	7.2e-11	0.000105	-0.59	-0.29	Prostate cancer;	chr12:52894051	chrX:152479577~152481024:+
THCA	trans	rs7833986	0.941	rs13278255	ENSG00000244245.1	RP11-120B7.1	6.67	7.22e-11	0.000106	0.39	0.29	Height;	chr8:56155416	chr5:108593609~108593967:+
THCA	trans	rs902774	0.818	rs11831919	ENSG00000248568.1	KRT8P48	-6.67	7.24e-11	0.000106	-0.6	-0.29	Prostate cancer;	chr12:52878231	chr5:146706381~146707600:-
THCA	trans	rs6087990	0.735	rs1040554	ENSG00000253915.1	MAPRE1P1	6.67	7.26e-11	0.000106	0.38	0.29	Ulcerative colitis;	chr20:32792267	chr8:135625185~135625981:-
THCA	trans	rs6885307	0.882	rs6881773	ENSG00000231752.4	EMBP1	6.67	7.27e-11	0.000106	0.45	0.29	Age at first birth;	chr5:45227398	chr1:121519112~121571892:+
THCA	trans	rs2898290	0.622	rs4840567	ENSG00000256560.1	LINC01486	-6.67	7.28e-11	0.000106	-0.37	-0.29	Systolic blood pressure;	chr8:11490116	chr12:109354083~109359488:-
THCA	trans	rs34421088	0.548	rs2618443	ENSG00000229857.1	RP11-159H20.3	6.67	7.28e-11	0.000106	0.38	0.29	Neuroticism;	chr8:11527047	chr9:76992099~76993108:+
THCA	trans	rs9467711	0.659	rs3823158	ENSG00000280107.1	AL022393.9	-6.67	7.29e-11	0.000107	-0.57	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr6:28170845~28172521:+
THCA	trans	rs9899728	0.656	rs9904728	ENSG00000234925.2	ATP5HP4	6.67	7.3e-11	0.000107	0.56	0.29	Alzheimer's disease or small vessel stroke;	chr17:75034540	chr12:68642519~68642993:-
THCA	trans	rs6600671	1	rs1591882	ENSG00000270392.2	PFN1P2	6.67	7.33e-11	0.000107	0.29	0.29	Hip geometry;	chr1:121441455	chr1:120432204~120434052:-
THCA	trans	rs2898290	0.506	rs2736311	ENSG00000253893.2	FAM85B	6.67	7.35e-11	0.000107	0.39	0.29	Systolic blood pressure;	chr8:11394661	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.56	rs2245357	ENSG00000229857.1	RP11-159H20.3	6.67	7.36e-11	0.000108	0.38	0.29	Neuroticism;	chr8:11541975	chr9:76992099~76993108:+
THCA	trans	rs6601327	0.551	rs13272424	ENSG00000253893.2	FAM85B	6.67	7.38e-11	0.000108	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9717809	chr8:8167819~8226614:-
THCA	trans	rs453301	0.624	rs2979265	ENSG00000256560.1	LINC01486	6.67	7.38e-11	0.000108	0.34	0.29	Joint mobility (Beighton score);	chr8:9001207	chr12:109354083~109359488:-
THCA	trans	rs34421088	0.506	rs4841519	ENSG00000253893.2	FAM85B	-6.67	7.41e-11	0.000108	-0.39	-0.29	Neuroticism;	chr8:11288719	chr8:8167819~8226614:-
THCA	trans	rs3764796	0.737	rs117747577	ENSG00000250030.2	RP11-584P21.4	6.67	7.42e-11	0.000108	0.59	0.29	Calcium levels;	chr8:17289670	chr4:67446267~67446574:+
THCA	trans	rs16937956	0.639	rs11041897	ENSG00000266891.1	RP11-692N5.2	6.67	7.43e-11	0.000109	0.37	0.29	Body mass index;	chr11:8382601	chr18:9734882~9735602:-
THCA	trans	rs4720118	0.508	rs6944723	ENSG00000213492.2	NT5C3AP1	6.66	7.44e-11	0.000109	0.39	0.29	Leprosy;	chr7:33384348	chr4:117574512~117576174:-
THCA	trans	rs941207	0.542	rs67808059	ENSG00000257210.1	NACAP3	-6.66	7.44e-11	0.000109	-0.38	-0.29	Platelet count;	chr12:56805228	chr12:93124063~93124543:-
THCA	trans	rs615632	0.57	rs17734541	ENSG00000253893.2	FAM85B	-6.66	7.45e-11	0.000109	-0.4	-0.29	Neuroticism;	chr8:9850923	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.622	rs7829381	ENSG00000256560.1	LINC01486	-6.66	7.47e-11	0.000109	-0.37	-0.29	Systolic blood pressure;	chr8:11487064	chr12:109354083~109359488:-
THCA	trans	rs2898290	0.622	rs11250140	ENSG00000256560.1	LINC01486	-6.66	7.47e-11	0.000109	-0.37	-0.29	Systolic blood pressure;	chr8:11489083	chr12:109354083~109359488:-
THCA	trans	rs847577	0.575	rs41278842	ENSG00000225169.1	BRI3P1	-6.66	7.49e-11	0.000109	-0.38	-0.29	Breast cancer;	chr7:98186687	chr1:100213293~100213670:+
THCA	trans	rs7829975	0.688	rs6601703	ENSG00000229857.1	RP11-159H20.3	-6.66	7.5e-11	0.00011	-0.37	-0.29	Mood instability;	chr8:8522714	chr9:76992099~76993108:+
THCA	trans	rs9393777	0.92	rs66462181	ENSG00000280107.1	AL022393.9	-6.66	7.5e-11	0.00011	-0.6	-0.29	Intelligence (multi-trait analysis);	chr6:27123882	chr6:28170845~28172521:+
THCA	trans	rs13016963	0.625	rs13015294	ENSG00000235105.1	RP11-329A14.1	6.66	7.51e-11	0.00011	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201310267	chr1:48435967~48437223:+
THCA	trans	rs9467711	0.79	rs13195401	ENSG00000280107.1	AL022393.9	-6.66	7.52e-11	0.00011	-0.59	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.79	rs13195402	ENSG00000280107.1	AL022393.9	-6.66	7.52e-11	0.00011	-0.59	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr6:28170845~28172521:+
THCA	trans	rs34421088	0.56	rs2618434	ENSG00000229857.1	RP11-159H20.3	6.66	7.56e-11	0.00011	0.38	0.29	Neuroticism;	chr8:11541356	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.736	rs2001338	ENSG00000253893.2	FAM85B	-6.66	7.57e-11	0.000111	-0.39	-0.29	Neuroticism;	chr8:10393707	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.624	rs7823056	ENSG00000256560.1	LINC01486	6.66	7.6e-11	0.000111	0.36	0.29	Mood instability;	chr8:8525195	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.899	rs4911262	ENSG00000253915.1	MAPRE1P1	6.66	7.67e-11	0.000112	0.37	0.29	Ulcerative colitis;	chr20:32805546	chr8:135625185~135625981:-
THCA	trans	rs3764796	0.737	rs13275944	ENSG00000250030.2	RP11-584P21.4	6.66	7.68e-11	0.000112	0.58	0.29	Calcium levels;	chr8:17228271	chr4:67446267~67446574:+
THCA	trans	rs9876781	0.559	rs7610524	ENSG00000225528.1	RP3-370M22.8	-6.66	7.72e-11	0.000113	-0.37	-0.29	Longevity;	chr3:48353882	chr22:39960397~39964683:+
THCA	trans	rs2898290	0.622	rs1600250	ENSG00000256560.1	LINC01486	-6.66	7.73e-11	0.000113	-0.37	-0.29	Systolic blood pressure;	chr8:11487916	chr12:109354083~109359488:-
THCA	trans	rs2898290	0.593	rs1600252	ENSG00000256560.1	LINC01486	-6.66	7.73e-11	0.000113	-0.37	-0.29	Systolic blood pressure;	chr8:11488135	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.564	rs2921060	ENSG00000256560.1	LINC01486	-6.66	7.74e-11	0.000113	-0.35	-0.29	Mood instability;	chr8:8460307	chr12:109354083~109359488:-
THCA	trans	rs2898290	0.592	rs2736342	ENSG00000256560.1	LINC01486	-6.66	7.79e-11	0.000114	-0.36	-0.29	Systolic blood pressure;	chr8:11489780	chr12:109354083~109359488:-
THCA	trans	rs2898290	0.622	rs1478890	ENSG00000229857.1	RP11-159H20.3	6.66	7.79e-11	0.000114	0.38	0.29	Systolic blood pressure;	chr8:11498093	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.681	rs2271342	ENSG00000256560.1	LINC01486	6.66	7.81e-11	0.000114	0.35	0.29	Mood instability;	chr8:8786428	chr12:109354083~109359488:-
THCA	trans	rs4415084	0.804	rs4866922	ENSG00000231752.4	EMBP1	-6.66	7.83e-11	0.000114	-0.4	-0.29	Breast cancer;	chr5:44932403	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs4919740	ENSG00000254285.3	KRT8P3	-6.66	7.87e-11	0.000115	-0.56	-0.29	Prostate cancer;	chr12:52877187	chr8:61578220~61579668:+
THCA	trans	rs656319	0.591	rs17734690	ENSG00000253893.2	FAM85B	6.66	7.88e-11	0.000115	0.4	0.29	Myopia (pathological);	chr8:9855686	chr8:8167819~8226614:-
THCA	trans	rs8177876	0.822	rs8177959	ENSG00000224837.1	GCSHP5	6.66	7.89e-11	0.000115	0.45	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr1:168055901~168056422:-
THCA	trans	rs6732160	0.613	rs6546804	ENSG00000236165.1	PRADC1P1	6.66	7.9e-11	0.000115	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73158791	chr3:36976316~36976840:+
THCA	trans	rs11098499	1	rs3749591	ENSG00000253326.2	RP11-261C10.7	6.65	7.96e-11	0.000116	0.4	0.29	Corneal astigmatism;	chr4:119292875	chr1:243054861~243056394:-
THCA	trans	rs9329221	0.682	rs11786677	ENSG00000253893.2	FAM85B	-6.65	7.97e-11	0.000116	-0.37	-0.29	Neuroticism;	chr8:10406750	chr8:8167819~8226614:-
THCA	trans	rs1580019	0.52	rs13228793	ENSG00000176826.14	FKBP9P1	-6.65	7.99e-11	0.000116	-0.41	-0.29	Cognitive ability;	chr7:32671853	chr7:55681074~55713252:-
THCA	trans	rs13016963	0.604	rs2110691	ENSG00000235105.1	RP11-329A14.1	6.65	8.01e-11	0.000117	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201320439	chr1:48435967~48437223:+
THCA	trans	rs2898290	0.622	rs4840567	ENSG00000229857.1	RP11-159H20.3	6.65	8.02e-11	0.000117	0.38	0.29	Systolic blood pressure;	chr8:11490116	chr9:76992099~76993108:+
THCA	trans	rs6087990	0.735	rs2064350	ENSG00000253915.1	MAPRE1P1	6.65	8.07e-11	0.000118	0.38	0.29	Ulcerative colitis;	chr20:32802727	chr8:135625185~135625981:-
THCA	trans	rs6087990	0.735	rs4911261	ENSG00000253915.1	MAPRE1P1	6.65	8.07e-11	0.000118	0.38	0.29	Ulcerative colitis;	chr20:32803554	chr8:135625185~135625981:-
THCA	trans	rs77686669	1	rs77686669	ENSG00000228546.2	CTA-313A17.3	6.65	8.07e-11	0.000118	0.43	0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:102337316~102339115:+
THCA	trans	rs9914988	0.576	rs67777803	ENSG00000267449.1	RP11-264B14.2	6.65	8.13e-11	0.000118	0.45	0.29	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28996304	chr17:61069856~61070356:-
THCA	trans	rs3740713	0.669	rs78098319	ENSG00000236090.2	LDHAP3	6.65	8.13e-11	0.000118	0.49	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr2:41819747~41820754:+
THCA	trans	rs80033912	0.64	rs6785832	ENSG00000197582.5	GPX1P1	6.65	8.15e-11	0.000119	0.41	0.29	Intelligence (multi-trait analysis);	chr3:49186883	chrX:13378735~13379340:-
THCA	trans	rs13016963	0.604	rs2080302	ENSG00000235105.1	RP11-329A14.1	6.65	8.17e-11	0.000119	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201300358	chr1:48435967~48437223:+
THCA	trans	rs1707322	1	rs785510	ENSG00000255397.1	AC022182.2	6.65	8.18e-11	0.000119	0.42	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr8:60937705~60939871:-
THCA	trans	rs11992162	1	rs7460395	ENSG00000256560.1	LINC01486	6.65	8.19e-11	0.000119	0.37	0.29	Monocyte count;	chr8:11977866	chr12:109354083~109359488:-
THCA	trans	rs1580019	0.547	rs56981934	ENSG00000176826.14	FKBP9P1	-6.65	8.19e-11	0.000119	-0.39	-0.29	Cognitive ability;	chr7:32495590	chr7:55681074~55713252:-
THCA	trans	rs76228276	0.737	rs76397965	ENSG00000260318.1	COX6CP1	6.65	8.2e-11	0.000119	0.86	0.29	Childhood ear infection;	chr8:99811418	chr16:11903923~11904137:-
THCA	trans	rs4646450	0.735	rs2404323	ENSG00000228834.1	RP11-249L21.4	6.65	8.22e-11	0.00012	0.51	0.29	Blood metabolite levels;	chr7:99387773	chr6:108907615~108907873:-
THCA	trans	rs941207	0.526	rs2255074	ENSG00000228224.3	NACAP1	-6.65	8.23e-11	0.00012	-0.31	-0.29	Platelet count;	chr12:56636242	chr8:101361794~101372707:+
THCA	trans	rs13016963	0.604	rs13009885	ENSG00000235105.1	RP11-329A14.1	6.65	8.27e-11	0.00012	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201296913	chr1:48435967~48437223:+
THCA	trans	rs13016963	0.604	rs11679181	ENSG00000235105.1	RP11-329A14.1	6.65	8.27e-11	0.00012	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201297615	chr1:48435967~48437223:+
THCA	trans	rs11250097	0.501	rs2409665	ENSG00000253893.2	FAM85B	6.65	8.27e-11	0.00012	0.39	0.29	Neuroticism;	chr8:10878723	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.941	rs7709661	ENSG00000231752.4	EMBP1	6.65	8.28e-11	0.000121	0.45	0.29	Age at first birth;	chr5:45003987	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.941	rs12517629	ENSG00000231752.4	EMBP1	6.65	8.28e-11	0.000121	0.45	0.29	Age at first birth;	chr5:45004083	chr1:121519112~121571892:+
THCA	trans	rs6885307	1	rs62369866	ENSG00000231752.4	EMBP1	6.65	8.28e-11	0.000121	0.45	0.29	Age at first birth;	chr5:45004439	chr1:121519112~121571892:+
THCA	trans	rs7829975	0.573	rs7842359	ENSG00000229857.1	RP11-159H20.3	6.65	8.29e-11	0.000121	0.36	0.29	Mood instability;	chr8:8939568	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs4840551	ENSG00000256560.1	LINC01486	-6.65	8.32e-11	0.000121	-0.37	-0.29	Triglycerides;	chr8:11171530	chr12:109354083~109359488:-
THCA	trans	rs2898290	0.622	rs978804	ENSG00000229857.1	RP11-159H20.3	6.65	8.33e-11	0.000121	0.38	0.29	Systolic blood pressure;	chr8:11486164	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.532	rs2736385	ENSG00000253893.2	FAM85B	-6.65	8.37e-11	0.000122	-0.39	-0.29	Neuroticism;	chr8:11291104	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.899	rs6058893	ENSG00000253915.1	MAPRE1P1	6.65	8.4e-11	0.000122	0.37	0.29	Ulcerative colitis;	chr20:32804971	chr8:135625185~135625981:-
THCA	trans	rs889398	0.617	rs11648348	ENSG00000257513.6	NPIPB1P	6.64	8.42e-11	0.000122	0.32	0.29	Body mass index;	chr16:69856819	chr18:11619509~11639699:-
THCA	trans	rs13016963	0.604	rs12622439	ENSG00000235105.1	RP11-329A14.1	6.64	8.47e-11	0.000123	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201311179	chr1:48435967~48437223:+
THCA	trans	rs13016963	0.604	rs7609223	ENSG00000235105.1	RP11-329A14.1	6.64	8.47e-11	0.000123	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201311672	chr1:48435967~48437223:+
THCA	trans	rs9329221	0.662	rs34155841	ENSG00000253893.2	FAM85B	-6.64	8.49e-11	0.000123	-0.4	-0.29	Neuroticism;	chr8:10390019	chr8:8167819~8226614:-
THCA	trans	rs11098499	1	rs13435802	ENSG00000253326.2	RP11-261C10.7	-6.64	8.49e-11	0.000123	-0.39	-0.29	Corneal astigmatism;	chr4:119256805	chr1:243054861~243056394:-
THCA	trans	rs2645424	0.671	rs2294138	ENSG00000281304.1	Metazoa_SRP	6.64	8.51e-11	0.000124	0.41	0.29	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847630	chr6:35911481~35911729:-
THCA	trans	rs76228276	0.737	rs72674626	ENSG00000260318.1	COX6CP1	6.64	8.54e-11	0.000124	0.85	0.29	Childhood ear infection;	chr8:99455996	chr16:11903923~11904137:-
THCA	trans	rs12614435	0.512	rs12693162	ENSG00000269800.1	PLEKHA3P1	6.64	8.55e-11	0.000124	0.36	0.29	Atrial fibrillation;	chr2:178623467	chr19:41521043~41521989:-
THCA	trans	rs941207	0.526	rs11171916	ENSG00000228224.3	NACAP1	-6.64	8.57e-11	0.000124	-0.31	-0.29	Platelet count;	chr12:56653236	chr8:101361794~101372707:+
THCA	trans	rs889398	0.617	rs3790083	ENSG00000257513.6	NPIPB1P	-6.64	8.57e-11	0.000124	-0.32	-0.29	Body mass index;	chr16:69861383	chr18:11619509~11639699:-
THCA	trans	rs2929451	0.566	rs17658270	ENSG00000253893.2	FAM85B	-6.64	8.59e-11	0.000125	-0.39	-0.29	Nose size;	chr8:9296109	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.742	rs12547493	ENSG00000256560.1	LINC01486	-6.64	8.63e-11	0.000125	-0.35	-0.29	Mood instability;	chr8:8804024	chr12:109354083~109359488:-
THCA	trans	rs7113874	0.744	rs16937956	ENSG00000266891.1	RP11-692N5.2	6.64	8.65e-11	0.000126	0.37	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8382954	chr18:9734882~9735602:-
THCA	trans	rs2980439	0.729	rs2955586	ENSG00000256560.1	LINC01486	6.64	8.66e-11	0.000126	0.34	0.29	Neuroticism;	chr8:8236445	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.806	rs992472	ENSG00000253915.1	MAPRE1P1	6.64	8.73e-11	0.000127	0.37	0.29	Ulcerative colitis;	chr20:32797463	chr8:135625185~135625981:-
THCA	trans	rs853679	0.607	rs67340775	ENSG00000228022.4	HCG20	-6.64	8.73e-11	0.000127	-0.73	-0.29	Depression;	chr6:28336607	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs35030260	ENSG00000228022.4	HCG20	-6.64	8.73e-11	0.000127	-0.73	-0.29	Depression;	chr6:28337731	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13217619	ENSG00000228022.4	HCG20	-6.64	8.73e-11	0.000127	-0.73	-0.29	Depression;	chr6:28338894	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs35016036	ENSG00000228022.4	HCG20	-6.64	8.73e-11	0.000127	-0.73	-0.29	Depression;	chr6:28347103	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs35744819	ENSG00000228022.4	HCG20	-6.64	8.73e-11	0.000127	-0.73	-0.29	Depression;	chr6:28350554	chr6:30766825~30792250:+
THCA	trans	rs7829975	0.593	rs2921061	ENSG00000256560.1	LINC01486	6.64	8.75e-11	0.000127	0.36	0.29	Mood instability;	chr8:8460105	chr12:109354083~109359488:-
THCA	trans	rs853679	0.546	rs35017208	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28377505	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs13213152	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28381921	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs36092177	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28390030	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs13213986	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28390232	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs2232429	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28391855	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs2232426	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28392882	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs34546986	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28394532	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs34871267	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28396455	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs2232423	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28398374	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs35883476	ENSG00000253570.1	RNF5P1	6.64	8.76e-11	0.000127	0.82	0.29	Depression;	chr6:28400731	chr8:38600661~38601200:-
THCA	trans	rs16937956	0.639	rs2123990	ENSG00000266891.1	RP11-692N5.2	6.64	8.78e-11	0.000127	0.38	0.29	Body mass index;	chr11:8378959	chr18:9734882~9735602:-
THCA	trans	rs13016963	0.604	rs10931940	ENSG00000235105.1	RP11-329A14.1	6.64	8.79e-11	0.000128	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201313949	chr1:48435967~48437223:+
THCA	trans	rs9329221	0.736	rs2001337	ENSG00000253893.2	FAM85B	-6.64	8.89e-11	0.000129	-0.39	-0.29	Neuroticism;	chr8:10393644	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.642	rs11250117	ENSG00000229857.1	RP11-159H20.3	6.64	8.93e-11	0.000129	0.38	0.29	Triglycerides;	chr8:11115230	chr9:76992099~76993108:+
THCA	trans	rs6499244	0.508	rs11642008	ENSG00000257513.6	NPIPB1P	6.64	8.93e-11	0.00013	0.32	0.29	Menarche (age at onset);	chr16:69894736	chr18:11619509~11639699:-
THCA	trans	rs7824557	0.564	rs2736304	ENSG00000254153.1	CTA-398F10.2	6.64	8.94e-11	0.00013	0.33	0.29	Retinal vascular caliber;	chr8:11379455	chr8:8456909~8461337:-
THCA	trans	rs13016963	0.604	rs7596930	ENSG00000235105.1	RP11-329A14.1	6.63	8.95e-11	0.00013	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201315319	chr1:48435967~48437223:+
THCA	trans	rs889398	0.617	rs11075742	ENSG00000257513.6	NPIPB1P	6.63	8.97e-11	0.00013	0.32	0.29	Body mass index;	chr16:69865031	chr18:11619509~11639699:-
THCA	trans	rs6601327	0.641	rs4129360	ENSG00000253893.2	FAM85B	6.63	8.97e-11	0.00013	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9715774	chr8:8167819~8226614:-
THCA	trans	rs853679	0.607	rs13211507	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28289600	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34691223	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28290431	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13207345	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28297795	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs72854513	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28298177	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs56189111	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28304196	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34950484	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28310911	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs35072899	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28313764	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34661125	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28314117	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13190888	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28318208	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs56075693	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28322551	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34218844	ENSG00000228022.4	HCG20	-6.63	8.99e-11	0.00013	-0.73	-0.29	Depression;	chr6:28322870	chr6:30766825~30792250:+
THCA	trans	rs889398	0.617	rs6499265	ENSG00000257513.6	NPIPB1P	6.63	8.99e-11	0.00013	0.32	0.29	Body mass index;	chr16:69864095	chr18:11619509~11639699:-
THCA	trans	rs941207	0.542	rs12367312	ENSG00000257210.1	NACAP3	-6.63	9e-11	0.00013	-0.37	-0.29	Platelet count;	chr12:56809369	chr12:93124063~93124543:-
THCA	trans	rs941207	0.542	rs12367339	ENSG00000257210.1	NACAP3	-6.63	9e-11	0.00013	-0.37	-0.29	Platelet count;	chr12:56809521	chr12:93124063~93124543:-
THCA	trans	rs14057	0.792	rs78728410	ENSG00000215869.3	RP11-364B6.1	6.63	9.01e-11	0.000131	0.42	0.29	Systolic blood pressure;	chr1:6602971	chr1:104073023~104077087:+
THCA	trans	rs2975734	0.709	rs6988826	ENSG00000253893.2	FAM85B	6.63	9.01e-11	0.000131	0.41	0.29	Chronotype;Morning vs. evening chronotype;	chr8:10252115	chr8:8167819~8226614:-
THCA	trans	rs3096299	0.504	rs4785574	ENSG00000215030.5	RPL13P12	-6.63	9.04e-11	0.000131	-0.3	-0.29	Multiple myeloma (IgH translocation);	chr16:89502467	chr17:17383377~17384012:-
THCA	trans	rs7824557	0.651	rs6601582	ENSG00000253893.2	FAM85B	-6.63	9.06e-11	0.000131	-0.39	-0.29	Retinal vascular caliber;	chr8:11349858	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.688	rs7827182	ENSG00000229857.1	RP11-159H20.3	-6.63	9.12e-11	0.000132	-0.37	-0.29	Mood instability;	chr8:8522961	chr9:76992099~76993108:+
THCA	trans	rs7032940	0.651	rs7873398	ENSG00000228236.2	TXNP5	6.63	9.14e-11	0.000132	0.35	0.29	Height;	chr9:110194413	chr2:149068596~149068910:-
THCA	trans	rs7829975	0.564	rs2921057	ENSG00000256560.1	LINC01486	6.63	9.21e-11	0.000133	0.35	0.29	Mood instability;	chr8:8461157	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.582	rs6983150	ENSG00000229857.1	RP11-159H20.3	6.63	9.24e-11	0.000134	0.37	0.29	Mood instability;	chr8:8934916	chr9:76992099~76993108:+
THCA	trans	rs941207	0.542	rs11171983	ENSG00000257210.1	NACAP3	-6.63	9.28e-11	0.000134	-0.37	-0.29	Platelet count;	chr12:56814461	chr12:93124063~93124543:-
THCA	trans	rs76228276	0.737	rs4735642	ENSG00000260318.1	COX6CP1	6.63	9.33e-11	0.000135	0.86	0.29	Childhood ear infection;	chr8:99746260	chr16:11903923~11904137:-
THCA	trans	rs3105169	0.733	rs1667633	ENSG00000260318.1	COX6CP1	6.63	9.33e-11	0.000135	0.86	0.29	Smoking initiation;	chr8:99777587	chr16:11903923~11904137:-
THCA	trans	rs11671005	0.611	rs56026876	ENSG00000279267.1	RP11-395L14.18	6.63	9.35e-11	0.000135	0.43	0.29	Mean platelet volume;	chr19:58494790	chr2:113605867~113607908:-
THCA	trans	rs11098499	0.78	rs12504773	ENSG00000253326.2	RP11-261C10.7	6.63	9.36e-11	0.000135	0.41	0.29	Corneal astigmatism;	chr4:119640994	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.78	rs7680914	ENSG00000253326.2	RP11-261C10.7	6.63	9.36e-11	0.000135	0.41	0.29	Corneal astigmatism;	chr4:119641898	chr1:243054861~243056394:-
THCA	trans	rs3764796	0.737	rs117531853	ENSG00000250030.2	RP11-584P21.4	6.63	9.38e-11	0.000136	0.59	0.29	Calcium levels;	chr8:17294472	chr4:67446267~67446574:+
THCA	trans	rs9329221	0.662	rs12541491	ENSG00000253893.2	FAM85B	-6.63	9.41e-11	0.000136	-0.39	-0.29	Neuroticism;	chr8:10392538	chr8:8167819~8226614:-
THCA	trans	rs10420951	0.535	rs78061871	ENSG00000267533.1	RP11-815J4.7	6.63	9.42e-11	0.000136	0.55	0.29	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18455827	chr18:12067173~12068417:-
THCA	trans	rs11098499	0.955	rs13129661	ENSG00000253326.2	RP11-261C10.7	6.63	9.47e-11	0.000137	0.4	0.29	Corneal astigmatism;	chr4:119231754	chr1:243054861~243056394:-
THCA	trans	rs7826238	0.524	rs2921055	ENSG00000256560.1	LINC01486	6.62	9.54e-11	0.000138	0.35	0.29	Systolic blood pressure;	chr8:8461832	chr12:109354083~109359488:-
THCA	trans	rs941207	0.526	rs2950390	ENSG00000257210.1	NACAP3	6.62	9.6e-11	0.000139	0.36	0.29	Platelet count;	chr12:56661507	chr12:93124063~93124543:-
THCA	trans	rs6600671	1	rs4844380	ENSG00000270392.2	PFN1P2	6.62	9.63e-11	0.000139	0.29	0.29	Hip geometry;	chr1:121451764	chr1:120432204~120434052:-
THCA	trans	rs9649213	0.555	rs6948346	ENSG00000225169.1	BRI3P1	6.62	9.63e-11	0.000139	0.38	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr1:100213293~100213670:+
THCA	trans	rs889398	0.617	rs55887947	ENSG00000257513.6	NPIPB1P	6.62	9.64e-11	0.000139	0.32	0.29	Body mass index;	chr16:69859440	chr18:11619509~11639699:-
THCA	trans	rs7824557	0.564	rs35009431	ENSG00000254153.1	CTA-398F10.2	6.62	9.64e-11	0.000139	0.33	0.29	Retinal vascular caliber;	chr8:11375279	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.688	rs7826654	ENSG00000229857.1	RP11-159H20.3	-6.62	9.64e-11	0.000139	-0.37	-0.29	Mood instability;	chr8:8521596	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.688	rs7826660	ENSG00000229857.1	RP11-159H20.3	-6.62	9.64e-11	0.000139	-0.37	-0.29	Mood instability;	chr8:8521597	chr9:76992099~76993108:+
THCA	trans	rs2945232	1	rs2945232	ENSG00000256560.1	LINC01486	6.62	9.66e-11	0.00014	0.34	0.29	Schizophrenia;	chr8:8240516	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.556	rs78050275	ENSG00000231752.4	EMBP1	6.62	9.67e-11	0.00014	0.57	0.29	Age at first birth;	chr5:45244827	chr1:121519112~121571892:+
THCA	trans	rs6885307	1	rs4533894	ENSG00000231752.4	EMBP1	6.62	9.69e-11	0.00014	0.44	0.29	Age at first birth;	chr5:45024967	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.943	rs4371761	ENSG00000231752.4	EMBP1	6.62	9.69e-11	0.00014	0.44	0.29	Age at first birth;	chr5:45026118	chr1:121519112~121571892:+
THCA	trans	rs6885307	1	rs7731099	ENSG00000231752.4	EMBP1	6.62	9.69e-11	0.00014	0.44	0.29	Age at first birth;	chr5:45037924	chr1:121519112~121571892:+
THCA	trans	rs941207	0.542	rs12367822	ENSG00000257210.1	NACAP3	-6.62	9.7e-11	0.00014	-0.37	-0.29	Platelet count;	chr12:56810376	chr12:93124063~93124543:-
THCA	trans	rs11098499	0.826	rs4472123	ENSG00000253326.2	RP11-261C10.7	6.62	9.7e-11	0.00014	0.4	0.29	Corneal astigmatism;	chr4:119315475	chr1:243054861~243056394:-
THCA	trans	rs853679	0.607	rs13217984	ENSG00000253570.1	RNF5P1	6.62	9.77e-11	0.000141	0.84	0.29	Depression;	chr6:28171932	chr8:38600661~38601200:-
THCA	trans	rs853679	0.556	rs67297533	ENSG00000253570.1	RNF5P1	6.62	9.77e-11	0.000141	0.84	0.29	Depression;	chr6:28173475	chr8:38600661~38601200:-
THCA	trans	rs853679	0.505	rs35781323	ENSG00000253570.1	RNF5P1	6.62	9.77e-11	0.000141	0.84	0.29	Depression;	chr6:28177054	chr8:38600661~38601200:-
THCA	trans	rs6601327	0.641	rs12155819	ENSG00000253893.2	FAM85B	6.62	9.81e-11	0.000142	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9715169	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.7	rs12114661	ENSG00000253893.2	FAM85B	6.62	9.81e-11	0.000142	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9715644	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.578	rs4075359	ENSG00000253893.2	FAM85B	6.62	9.81e-11	0.000142	0.37	0.29	Multiple myeloma (hyperdiploidy);	chr8:9630303	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.56	rs11780851	ENSG00000256560.1	LINC01486	-6.62	9.82e-11	0.000142	-0.37	-0.29	Neuroticism;	chr8:11543607	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs55958994	ENSG00000254285.3	KRT8P3	-6.62	9.84e-11	0.000142	-0.61	-0.29	Prostate cancer;	chr12:52907235	chr8:61578220~61579668:+
THCA	trans	rs941207	0.542	rs11171978	ENSG00000257210.1	NACAP3	6.62	9.85e-11	0.000142	0.37	0.29	Platelet count;	chr12:56800015	chr12:93124063~93124543:-
THCA	trans	rs2645424	0.635	rs62495697	ENSG00000269898.1	RP11-568J23.4	-6.62	9.92e-11	0.000143	-0.36	-0.29	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851498	chr16:85743287~85744225:+
THCA	trans	rs7826238	0.535	rs2979179	ENSG00000256560.1	LINC01486	6.62	9.95e-11	0.000144	0.34	0.29	Systolic blood pressure;	chr8:8462519	chr12:109354083~109359488:-
THCA	trans	rs7200543	1	rs16966953	ENSG00000250569.1	NTAN1P2	6.62	9.97e-11	0.000144	0.3	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr8:86481754~86483002:-
THCA	trans	rs2950393	0.804	rs2958132	ENSG00000228224.3	NACAP1	6.62	9.97e-11	0.000144	0.29	0.29	Platelet distribution width;	chr12:56750749	chr8:101361794~101372707:+
THCA	trans	rs7701967	0.697	rs11948761	ENSG00000224431.1	AC063976.7	-6.62	9.98e-11	0.000144	-0.28	-0.29	Itch intensity from mosquito bite;Mosquito bite size;Itch intensity from mosquito bite adjusted by bite size;	chr5:131035277	chr5:132199456~132203487:+
THCA	trans	rs3740713	1	rs75740864	ENSG00000236090.2	LDHAP3	6.62	1e-10	0.000144	0.53	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr2:41819747~41820754:+
THCA	trans	rs4784054	0.803	rs73553511	ENSG00000230849.2	GOT2P2	6.62	1e-10	0.000145	0.47	0.29	Blood metabolite levels;	chr16:58758077	chr1:173141100~173142350:-
THCA	trans	rs6921919	0.562	rs13198809	ENSG00000228022.4	HCG20	-6.62	1e-10	0.000145	-0.72	-0.29	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs35353359	ENSG00000228022.4	HCG20	-6.62	1e-10	0.000145	-0.72	-0.29	Depression;	chr6:28356601	chr6:30766825~30792250:+
THCA	trans	rs34421088	0.585	rs10101661	ENSG00000253893.2	FAM85B	6.62	1.01e-10	0.000145	0.38	0.29	Neuroticism;	chr8:11735995	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs1707303	ENSG00000255397.1	AC022182.2	6.62	1.01e-10	0.000145	0.42	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr8:60937705~60939871:-
THCA	trans	rs7833986	1	rs34230678	ENSG00000244245.1	RP11-120B7.1	6.62	1.01e-10	0.000146	0.38	0.29	Height;	chr8:56170558	chr5:108593609~108593967:+
THCA	trans	rs2898290	0.622	rs978803	ENSG00000256560.1	LINC01486	6.61	1.02e-10	0.000146	0.37	0.29	Systolic blood pressure;	chr8:11485966	chr12:109354083~109359488:-
THCA	trans	rs14057	0.8	rs6674407	ENSG00000215869.3	RP11-364B6.1	6.61	1.02e-10	0.000147	0.42	0.29	Systolic blood pressure;	chr1:6602853	chr1:104073023~104077087:+
THCA	trans	rs889398	0.594	rs7202233	ENSG00000257513.6	NPIPB1P	6.61	1.02e-10	0.000147	0.32	0.29	Body mass index;	chr16:69860529	chr18:11619509~11639699:-
THCA	trans	rs453301	0.592	rs4841084	ENSG00000256560.1	LINC01486	6.61	1.02e-10	0.000147	0.33	0.29	Joint mobility (Beighton score);	chr8:9026395	chr12:109354083~109359488:-
THCA	trans	rs453301	0.653	rs2956244	ENSG00000256560.1	LINC01486	6.61	1.02e-10	0.000147	0.33	0.29	Joint mobility (Beighton score);	chr8:9027656	chr12:109354083~109359488:-
THCA	trans	rs34421088	0.532	rs3808515	ENSG00000253893.2	FAM85B	-6.61	1.03e-10	0.000149	-0.39	-0.29	Neuroticism;	chr8:11298532	chr8:8167819~8226614:-
THCA	trans	rs4911259	0.552	rs6057663	ENSG00000253915.1	MAPRE1P1	-6.61	1.04e-10	0.000149	-0.37	-0.29	Inflammatory bowel disease;	chr20:32875265	chr8:135625185~135625981:-
THCA	trans	rs4911259	0.513	rs6057665	ENSG00000253915.1	MAPRE1P1	-6.61	1.04e-10	0.000149	-0.37	-0.29	Inflammatory bowel disease;	chr20:32875654	chr8:135625185~135625981:-
THCA	trans	rs4911259	0.593	rs6058924	ENSG00000253915.1	MAPRE1P1	-6.61	1.04e-10	0.000149	-0.37	-0.29	Inflammatory bowel disease;	chr20:32876661	chr8:135625185~135625981:-
THCA	trans	rs4911259	0.552	rs6058925	ENSG00000253915.1	MAPRE1P1	-6.61	1.04e-10	0.000149	-0.37	-0.29	Inflammatory bowel disease;	chr20:32877568	chr8:135625185~135625981:-
THCA	trans	rs4911259	0.552	rs6058926	ENSG00000253915.1	MAPRE1P1	-6.61	1.04e-10	0.000149	-0.37	-0.29	Inflammatory bowel disease;	chr20:32877644	chr8:135625185~135625981:-
THCA	trans	rs3740713	0.719	rs78515595	ENSG00000236090.2	LDHAP3	6.61	1.04e-10	0.000149	0.5	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18409830	chr2:41819747~41820754:+
THCA	trans	rs2950393	0.857	rs1563896	ENSG00000228224.3	NACAP1	6.61	1.04e-10	0.00015	0.31	0.29	Platelet distribution width;	chr12:56699312	chr8:101361794~101372707:+
THCA	trans	rs7833986	0.501	rs9650314	ENSG00000236862.1	RPS20P24	6.61	1.04e-10	0.00015	0.45	0.29	Height;	chr8:55991051	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.534	rs72653924	ENSG00000236862.1	RPS20P24	6.61	1.04e-10	0.00015	0.45	0.29	Height;	chr8:55993529	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.534	rs2667972	ENSG00000236862.1	RPS20P24	6.61	1.04e-10	0.00015	0.45	0.29	Height;	chr8:55994102	chr9:72655832~72656192:-
THCA	trans	rs2288327	0.818	rs3731748	ENSG00000269800.1	PLEKHA3P1	6.61	1.04e-10	0.00015	0.42	0.29	Atrial fibrillation;	chr2:178548383	chr19:41521043~41521989:-
THCA	trans	rs10716881	1	rs10716881	ENSG00000228224.3	NACAP1	-6.61	1.05e-10	0.00015	-0.3	-0.29	High light scatter reticulocyte count;	chr12:56644387	chr8:101361794~101372707:+
THCA	trans	rs2985684	0.948	rs11623263	ENSG00000240785.1	RPL36AP21	6.61	1.05e-10	0.00015	0.38	0.29	Carotid intima media thickness;	chr14:49616577	chr5:18049550~18049872:+
THCA	trans	rs7819412	0.654	rs4840550	ENSG00000254153.1	CTA-398F10.2	6.61	1.05e-10	0.00015	0.33	0.29	Triglycerides;	chr8:11171520	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.711	rs1039916	ENSG00000256560.1	LINC01486	6.61	1.05e-10	0.000151	0.35	0.29	Mood instability;	chr8:8828344	chr12:109354083~109359488:-
THCA	trans	rs4911259	0.552	rs13037833	ENSG00000253915.1	MAPRE1P1	-6.61	1.05e-10	0.000151	-0.37	-0.29	Inflammatory bowel disease;	chr20:32871756	chr8:135625185~135625981:-
THCA	trans	rs4911259	0.552	rs11697394	ENSG00000253915.1	MAPRE1P1	-6.61	1.05e-10	0.000151	-0.37	-0.29	Inflammatory bowel disease;	chr20:32872270	chr8:135625185~135625981:-
THCA	trans	rs4911259	0.552	rs11700082	ENSG00000253915.1	MAPRE1P1	-6.61	1.05e-10	0.000151	-0.37	-0.29	Inflammatory bowel disease;	chr20:32872438	chr8:135625185~135625981:-
THCA	trans	rs804280	1	rs804280	ENSG00000256560.1	LINC01486	6.61	1.05e-10	0.000151	0.37	0.29	Myopia (pathological);	chr8:11755189	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.899	rs4911110	ENSG00000253915.1	MAPRE1P1	-6.61	1.06e-10	0.000152	-0.38	-0.29	Ulcerative colitis;	chr20:32804560	chr8:135625185~135625981:-
THCA	trans	rs2048656	0.637	rs10107396	ENSG00000253893.2	FAM85B	6.61	1.07e-10	0.000153	0.39	0.29	Schizophrenia;	chr8:9815642	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.905	rs7836953	ENSG00000256560.1	LINC01486	6.61	1.07e-10	0.000154	0.35	0.29	Monocyte count;	chr8:11978203	chr12:109354083~109359488:-
THCA	trans	rs853679	0.607	rs68188794	ENSG00000253570.1	RNF5P1	6.6	1.08e-10	0.000155	0.81	0.29	Depression;	chr6:28112999	chr8:38600661~38601200:-
THCA	trans	rs6087990	0.966	rs2377667	ENSG00000253915.1	MAPRE1P1	6.6	1.08e-10	0.000155	0.38	0.29	Ulcerative colitis;	chr20:32759119	chr8:135625185~135625981:-
THCA	trans	rs6885307	0.607	rs79021811	ENSG00000231752.4	EMBP1	6.6	1.08e-10	0.000155	0.58	0.29	Age at first birth;	chr5:45108898	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.592	rs2572371	ENSG00000253893.2	FAM85B	-6.6	1.09e-10	0.000156	-0.39	-0.29	Retinal vascular caliber;	chr8:11366284	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs12289603	ENSG00000236090.2	LDHAP3	6.6	1.09e-10	0.000156	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr2:41819747~41820754:+
THCA	trans	rs2898290	0.622	rs1382567	ENSG00000229857.1	RP11-159H20.3	6.6	1.09e-10	0.000157	0.38	0.29	Systolic blood pressure;	chr8:11493390	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.716	rs10057341	ENSG00000231752.4	EMBP1	-6.6	1.1e-10	0.000158	-0.41	-0.29	Breast cancer;	chr5:44931738	chr1:121519112~121571892:+
THCA	trans	rs6087990	0.735	rs910083	ENSG00000253915.1	MAPRE1P1	6.6	1.1e-10	0.000158	0.38	0.29	Ulcerative colitis;	chr20:32790884	chr8:135625185~135625981:-
THCA	trans	rs12709013	0.74	rs12927495	ENSG00000230849.2	GOT2P2	6.6	1.1e-10	0.000159	0.35	0.29	Blood metabolite ratios;	chr16:58821934	chr1:173141100~173142350:-
THCA	trans	rs2898290	0.622	rs978803	ENSG00000229857.1	RP11-159H20.3	-6.6	1.11e-10	0.00016	-0.38	-0.29	Systolic blood pressure;	chr8:11485966	chr9:76992099~76993108:+
THCA	trans	rs2950393	0.895	rs2926740	ENSG00000257210.1	NACAP3	6.6	1.11e-10	0.00016	0.36	0.29	Platelet distribution width;	chr12:56666751	chr12:93124063~93124543:-
THCA	trans	rs7829975	0.714	rs60315134	ENSG00000256560.1	LINC01486	6.6	1.11e-10	0.00016	0.34	0.29	Mood instability;	chr8:8813089	chr12:109354083~109359488:-
THCA	trans	rs34421088	0.56	rs2245357	ENSG00000256560.1	LINC01486	-6.6	1.12e-10	0.00016	-0.36	-0.29	Neuroticism;	chr8:11541975	chr12:109354083~109359488:-
THCA	trans	rs6601327	0.607	rs13276086	ENSG00000253893.2	FAM85B	6.6	1.12e-10	0.00016	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9721472	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.606	rs4841203	ENSG00000253893.2	FAM85B	6.6	1.12e-10	0.00016	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9725220	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.593	rs2921061	ENSG00000229857.1	RP11-159H20.3	-6.6	1.12e-10	0.000161	-0.37	-0.29	Mood instability;	chr8:8460105	chr9:76992099~76993108:+
THCA	trans	rs6087990	1	rs2424900	ENSG00000253915.1	MAPRE1P1	6.6	1.12e-10	0.000161	0.38	0.29	Ulcerative colitis;	chr20:32756536	chr8:135625185~135625981:-
THCA	trans	rs6087990	1	rs2424901	ENSG00000253915.1	MAPRE1P1	6.6	1.12e-10	0.000161	0.38	0.29	Ulcerative colitis;	chr20:32756706	chr8:135625185~135625981:-
THCA	trans	rs7829975	0.688	rs7837587	ENSG00000229857.1	RP11-159H20.3	-6.6	1.13e-10	0.000162	-0.37	-0.29	Mood instability;	chr8:8521482	chr9:76992099~76993108:+
THCA	trans	rs76228276	0.609	rs16897410	ENSG00000260318.1	COX6CP1	6.6	1.13e-10	0.000162	0.86	0.29	Childhood ear infection;	chr8:99511814	chr16:11903923~11904137:-
THCA	trans	rs9467773	0.595	rs2237236	ENSG00000242375.1	RP11-498P14.3	-6.6	1.14e-10	0.000163	-0.41	-0.29	Intelligence (multi-trait analysis);	chr6:26451325	chr9:97195351~97197687:-
THCA	trans	rs4646450	0.735	rs2286162	ENSG00000228834.1	RP11-249L21.4	6.6	1.14e-10	0.000164	0.51	0.29	Blood metabolite levels;	chr7:99358181	chr6:108907615~108907873:-
THCA	trans	rs889398	0.641	rs9936589	ENSG00000257513.6	NPIPB1P	6.6	1.14e-10	0.000164	0.32	0.29	Body mass index;	chr16:69850914	chr18:11619509~11639699:-
THCA	trans	rs6601327	0.641	rs10102170	ENSG00000253893.2	FAM85B	-6.6	1.14e-10	0.000164	-0.37	-0.29	Multiple myeloma (hyperdiploidy);	chr8:9753960	chr8:8167819~8226614:-
THCA	trans	rs8067354	0.681	rs76856339	ENSG00000187870.7	RNFT1P3	6.6	1.15e-10	0.000164	0.47	0.29	Hemoglobin concentration;	chr17:59723605	chr17:20743333~20754501:-
THCA	trans	rs6601327	0.613	rs10094989	ENSG00000253893.2	FAM85B	-6.59	1.15e-10	0.000165	-0.37	-0.29	Multiple myeloma (hyperdiploidy);	chr8:9754499	chr8:8167819~8226614:-
THCA	trans	rs4879656	0.835	rs7036559	ENSG00000215007.3	DNAJA1P3	6.59	1.15e-10	0.000165	0.33	0.29	Menopause (age at onset);	chr9:33064929	chrX:107351650~107352843:-
THCA	trans	rs393155	0.517	rs330050	ENSG00000229857.1	RP11-159H20.3	6.59	1.15e-10	0.000165	0.35	0.29	Neuroticism;	chr8:9230169	chr9:76992099~76993108:+
THCA	trans	rs453301	0.571	rs330054	ENSG00000229857.1	RP11-159H20.3	6.59	1.15e-10	0.000165	0.35	0.29	Joint mobility (Beighton score);	chr8:9230781	chr9:76992099~76993108:+
THCA	trans	rs9649213	0.593	rs13232181	ENSG00000225169.1	BRI3P1	6.59	1.15e-10	0.000165	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr1:100213293~100213670:+
THCA	trans	rs4911259	0.552	rs13041458	ENSG00000253915.1	MAPRE1P1	-6.59	1.15e-10	0.000165	-0.37	-0.29	Inflammatory bowel disease;	chr20:32879570	chr8:135625185~135625981:-
THCA	trans	rs4911259	0.552	rs13042651	ENSG00000253915.1	MAPRE1P1	-6.59	1.15e-10	0.000165	-0.37	-0.29	Inflammatory bowel disease;	chr20:32879617	chr8:135625185~135625981:-
THCA	trans	rs4911259	0.552	rs13038017	ENSG00000253915.1	MAPRE1P1	-6.59	1.15e-10	0.000165	-0.37	-0.29	Inflammatory bowel disease;	chr20:32879745	chr8:135625185~135625981:-
THCA	trans	rs7829975	0.633	rs2979181	ENSG00000229857.1	RP11-159H20.3	-6.59	1.15e-10	0.000165	-0.37	-0.29	Mood instability;	chr8:8465578	chr9:76992099~76993108:+
THCA	trans	rs2950393	0.804	rs7967600	ENSG00000228224.3	NACAP1	6.59	1.15e-10	0.000165	0.29	0.29	Platelet distribution width;	chr12:56768208	chr8:101361794~101372707:+
THCA	trans	rs6601327	0.607	rs6992666	ENSG00000253893.2	FAM85B	6.59	1.15e-10	0.000165	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9729194	chr8:8167819~8226614:-
THCA	trans	rs8067354	0.645	rs2173120	ENSG00000187870.7	RNFT1P3	6.59	1.16e-10	0.000166	0.46	0.29	Hemoglobin concentration;	chr17:59815279	chr17:20743333~20754501:-
THCA	trans	rs6600671	0.693	rs1853731	ENSG00000270392.2	PFN1P2	6.59	1.16e-10	0.000166	0.3	0.29	Hip geometry;	chr1:121510262	chr1:120432204~120434052:-
THCA	trans	rs2980439	0.818	rs2948294	ENSG00000256560.1	LINC01486	6.59	1.17e-10	0.000167	0.33	0.29	Neuroticism;	chr8:8237439	chr12:109354083~109359488:-
THCA	trans	rs1964356	0.967	rs2953802	ENSG00000229857.1	RP11-159H20.3	-6.59	1.17e-10	0.000167	-0.35	-0.29	Mean corpuscular volume;	chr8:8994371	chr9:76992099~76993108:+
THCA	trans	rs6087990	0.735	rs6058883	ENSG00000253915.1	MAPRE1P1	-6.59	1.17e-10	0.000168	-0.38	-0.29	Ulcerative colitis;	chr20:32777913	chr8:135625185~135625981:-
THCA	trans	rs2572431	0.543	rs2256016	ENSG00000253893.2	FAM85B	-6.59	1.17e-10	0.000168	-0.38	-0.29	Neuroticism;	chr8:11305093	chr8:8167819~8226614:-
THCA	trans	rs8067354	0.507	rs72840511	ENSG00000187870.7	RNFT1P3	6.59	1.18e-10	0.000168	0.46	0.29	Hemoglobin concentration;	chr17:59728650	chr17:20743333~20754501:-
THCA	trans	rs9292918	0.806	rs12655983	ENSG00000231752.4	EMBP1	6.59	1.18e-10	0.000169	0.5	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45307824	chr1:121519112~121571892:+
THCA	trans	rs1707322	1	rs11211190	ENSG00000255397.1	AC022182.2	-6.59	1.18e-10	0.000169	-0.41	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs6429580	ENSG00000255397.1	AC022182.2	-6.59	1.18e-10	0.000169	-0.41	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr8:60937705~60939871:-
THCA	trans	rs330048	0.545	rs11249913	ENSG00000253893.2	FAM85B	6.59	1.19e-10	0.000171	0.37	0.29	Systemic lupus erythematosus;	chr8:9286011	chr8:8167819~8226614:-
THCA	trans	rs11098499	1	rs11098500	ENSG00000253326.2	RP11-261C10.7	6.59	1.19e-10	0.000171	0.4	0.29	Corneal astigmatism;	chr4:119298084	chr1:243054861~243056394:-
THCA	trans	rs3956705	1	rs2392158	ENSG00000176826.14	FKBP9P1	-6.59	1.2e-10	0.000171	-0.39	-0.29	Red cell distribution width;	chr7:32940591	chr7:55681074~55713252:-
THCA	trans	rs3956705	0.966	rs1037324	ENSG00000176826.14	FKBP9P1	-6.59	1.2e-10	0.000171	-0.39	-0.29	Red cell distribution width;	chr7:32941549	chr7:55681074~55713252:-
THCA	trans	rs7819412	0.537	rs2127127	ENSG00000256560.1	LINC01486	-6.59	1.2e-10	0.000172	-0.36	-0.29	Triglycerides;	chr8:11577283	chr12:109354083~109359488:-
THCA	trans	rs864643	1	rs574074	ENSG00000183298.5	RP11-556K13.1	6.59	1.2e-10	0.000172	0.49	0.29	Attention deficit hyperactivity disorder;	chr3:39520090	chr1:101786340~101787219:-
THCA	trans	rs853679	0.599	rs13193295	ENSG00000253570.1	RNF5P1	6.59	1.21e-10	0.000173	0.8	0.29	Depression;	chr6:28035450	chr8:38600661~38601200:-
THCA	trans	rs453301	0.653	rs1562211	ENSG00000229857.1	RP11-159H20.3	6.59	1.21e-10	0.000173	0.34	0.29	Joint mobility (Beighton score);	chr8:9044914	chr9:76992099~76993108:+
THCA	trans	rs7647973	0.71	rs1532204	ENSG00000197582.5	GPX1P1	6.59	1.21e-10	0.000173	0.53	0.29	Menarche (age at onset);	chr3:49572044	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.71	rs6797299	ENSG00000197582.5	GPX1P1	6.59	1.21e-10	0.000173	0.53	0.29	Menarche (age at onset);	chr3:49572361	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.71	rs11130207	ENSG00000197582.5	GPX1P1	6.59	1.21e-10	0.000173	0.53	0.29	Menarche (age at onset);	chr3:49574233	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.71	rs11130208	ENSG00000197582.5	GPX1P1	6.59	1.21e-10	0.000173	0.53	0.29	Menarche (age at onset);	chr3:49578191	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.71	rs6446284	ENSG00000197582.5	GPX1P1	6.59	1.21e-10	0.000173	0.53	0.29	Menarche (age at onset);	chr3:49579564	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.71	rs9869120	ENSG00000197582.5	GPX1P1	6.59	1.21e-10	0.000173	0.53	0.29	Menarche (age at onset);	chr3:49586632	chrX:13378735~13379340:-
THCA	trans	rs9649213	0.555	rs6968193	ENSG00000225169.1	BRI3P1	6.59	1.21e-10	0.000173	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr1:100213293~100213670:+
THCA	trans	rs3808502	0.534	rs1529858	ENSG00000253893.2	FAM85B	-6.59	1.21e-10	0.000173	-0.38	-0.29	Neuroticism;	chr8:11288153	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.619	rs7012218	ENSG00000253893.2	FAM85B	-6.59	1.21e-10	0.000173	-0.38	-0.29	Retinal vascular caliber;	chr8:11288167	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.501	rs7012219	ENSG00000253893.2	FAM85B	-6.59	1.21e-10	0.000173	-0.38	-0.29	Neuroticism;	chr8:11288170	chr8:8167819~8226614:-
THCA	trans	rs941207	0.507	rs1107479	ENSG00000257210.1	NACAP3	-6.59	1.22e-10	0.000174	-0.35	-0.29	Platelet count;	chr12:56636902	chr12:93124063~93124543:-
THCA	trans	rs941207	0.514	rs6581105	ENSG00000257210.1	NACAP3	-6.58	1.22e-10	0.000175	-0.37	-0.29	Platelet count;	chr12:56792184	chr12:93124063~93124543:-
THCA	trans	rs11098499	0.955	rs6815725	ENSG00000253326.2	RP11-261C10.7	6.58	1.23e-10	0.000176	0.39	0.29	Corneal astigmatism;	chr4:119237255	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs1551	ENSG00000253326.2	RP11-261C10.7	6.58	1.23e-10	0.000176	0.39	0.29	Corneal astigmatism;	chr4:119237345	chr1:243054861~243056394:-
THCA	trans	rs9649213	0.593	rs11760930	ENSG00000225169.1	BRI3P1	6.58	1.23e-10	0.000176	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr1:100213293~100213670:+
THCA	trans	rs864643	0.524	rs77309543	ENSG00000183298.5	RP11-556K13.1	6.58	1.23e-10	0.000176	0.6	0.29	Attention deficit hyperactivity disorder;	chr3:39489578	chr1:101786340~101787219:-
THCA	trans	rs2950393	0.804	rs7980317	ENSG00000228224.3	NACAP1	6.58	1.24e-10	0.000177	0.29	0.29	Platelet distribution width;	chr12:56764399	chr8:101361794~101372707:+
THCA	trans	rs6601327	0.606	rs4841204	ENSG00000253893.2	FAM85B	6.58	1.24e-10	0.000178	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9725897	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.735	rs1040555	ENSG00000253915.1	MAPRE1P1	-6.58	1.25e-10	0.000178	-0.37	-0.29	Ulcerative colitis;	chr20:32792395	chr8:135625185~135625981:-
THCA	trans	rs3740713	1	rs73436645	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr2:41819747~41820754:+
THCA	trans	rs3740713	0.925	rs73436650	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73436655	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr2:41819747~41820754:+
THCA	trans	rs3740713	0.92	rs80254575	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73436662	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs113725670	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73436682	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73436685	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs2056781	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73436701	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438607	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs75010364	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438627	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438634	ENSG00000236090.2	LDHAP3	6.58	1.25e-10	0.000178	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr2:41819747~41820754:+
THCA	trans	rs9649213	0.593	rs13246725	ENSG00000225169.1	BRI3P1	6.58	1.25e-10	0.000179	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs11766808	ENSG00000225169.1	BRI3P1	6.58	1.25e-10	0.000179	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs35941058	ENSG00000225169.1	BRI3P1	6.58	1.25e-10	0.000179	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr1:100213293~100213670:+
THCA	trans	rs7829975	0.501	rs2980769	ENSG00000256560.1	LINC01486	6.58	1.25e-10	0.000179	0.34	0.29	Mood instability;	chr8:8462781	chr12:109354083~109359488:-
THCA	trans	rs9649213	0.593	rs6969731	ENSG00000225169.1	BRI3P1	6.58	1.26e-10	0.000179	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr1:100213293~100213670:+
THCA	trans	rs13016963	0.604	rs7570324	ENSG00000235105.1	RP11-329A14.1	-6.58	1.26e-10	0.000179	-0.32	-0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201320881	chr1:48435967~48437223:+
THCA	trans	rs6087990	0.965	rs2424903	ENSG00000253915.1	MAPRE1P1	6.58	1.26e-10	0.00018	0.38	0.29	Ulcerative colitis;	chr20:32761509	chr8:135625185~135625981:-
THCA	trans	rs6087990	1	rs6087990	ENSG00000253915.1	MAPRE1P1	6.58	1.26e-10	0.00018	0.38	0.29	Ulcerative colitis;	chr20:32762102	chr8:135625185~135625981:-
THCA	trans	rs616147	0.72	rs2965067	ENSG00000243904.1	RP11-600F24.1	-6.58	1.26e-10	0.00018	-0.36	-0.29	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr14:103374033~103374916:-
THCA	trans	rs6732160	0.588	rs10192654	ENSG00000236165.1	PRADC1P1	-6.58	1.27e-10	0.000181	-0.41	-0.29	Intelligence (multi-trait analysis);	chr2:73143754	chr3:36976316~36976840:+
THCA	trans	rs13177918	0.559	rs12109637	ENSG00000226396.1	RP5-1056L3.3	6.58	1.27e-10	0.000181	0.26	0.29	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:19608114~19608568:+
THCA	trans	rs864643	0.577	rs76395532	ENSG00000183298.5	RP11-556K13.1	6.58	1.27e-10	0.000181	0.6	0.29	Attention deficit hyperactivity disorder;	chr3:39490370	chr1:101786340~101787219:-
THCA	trans	rs11098499	0.955	rs7685268	ENSG00000253326.2	RP11-261C10.7	6.58	1.27e-10	0.000182	0.39	0.29	Corneal astigmatism;	chr4:119241033	chr1:243054861~243056394:-
THCA	trans	rs3740713	0.925	rs55727925	ENSG00000236090.2	LDHAP3	6.58	1.28e-10	0.000183	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr2:41819747~41820754:+
THCA	trans	rs7833986	0.501	rs2667983	ENSG00000236862.1	RPS20P24	6.58	1.28e-10	0.000183	0.45	0.29	Height;	chr8:55981528	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2667981	ENSG00000236862.1	RPS20P24	6.58	1.28e-10	0.000183	0.45	0.29	Height;	chr8:55981744	chr9:72655832~72656192:-
THCA	trans	rs7833986	0.501	rs2719245	ENSG00000236862.1	RPS20P24	6.58	1.28e-10	0.000183	0.45	0.29	Height;	chr8:55981800	chr9:72655832~72656192:-
THCA	trans	rs853679	0.607	rs33932084	ENSG00000228022.4	HCG20	-6.58	1.28e-10	0.000183	-0.69	-0.29	Depression;	chr6:28301047	chr6:30766825~30792250:+
THCA	trans	rs877636	0.702	rs773108	ENSG00000244604.1	RP11-713H12.1	6.58	1.29e-10	0.000184	0.39	0.29	Cognitive function;	chr12:55976127	chr17:8561230~8561576:+
THCA	trans	rs9467711	0.659	rs13195509	ENSG00000280107.1	AL022393.9	-6.58	1.29e-10	0.000184	-0.56	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr6:28170845~28172521:+
THCA	trans	rs9649213	0.593	rs6970801	ENSG00000225169.1	BRI3P1	6.58	1.29e-10	0.000184	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs12704982	ENSG00000225169.1	BRI3P1	6.58	1.29e-10	0.000184	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs34129434	ENSG00000225169.1	BRI3P1	6.58	1.29e-10	0.000184	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs12704983	ENSG00000225169.1	BRI3P1	6.58	1.29e-10	0.000184	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs7781916	ENSG00000225169.1	BRI3P1	6.58	1.29e-10	0.000184	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs736753	ENSG00000225169.1	BRI3P1	6.58	1.29e-10	0.000184	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs736754	ENSG00000225169.1	BRI3P1	6.58	1.29e-10	0.000184	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr1:100213293~100213670:+
THCA	trans	rs902774	0.818	rs73106451	ENSG00000255815.3	KRT8P11	-6.58	1.29e-10	0.000184	-0.59	-0.29	Prostate cancer;	chr12:52872955	chr9:99305176~99306611:+
THCA	trans	rs1580019	0.52	rs6945238	ENSG00000176826.14	FKBP9P1	6.58	1.29e-10	0.000184	0.4	0.29	Cognitive ability;	chr7:32606484	chr7:55681074~55713252:-
THCA	trans	rs889398	0.641	rs9936723	ENSG00000257513.6	NPIPB1P	6.57	1.3e-10	0.000185	0.31	0.29	Body mass index;	chr16:69850951	chr18:11619509~11639699:-
THCA	trans	rs4879656	0.872	rs1537040	ENSG00000215007.3	DNAJA1P3	6.57	1.3e-10	0.000185	0.33	0.29	Menopause (age at onset);	chr9:33061442	chrX:107351650~107352843:-
THCA	trans	rs6601327	0.641	rs6601350	ENSG00000253893.2	FAM85B	6.57	1.3e-10	0.000186	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9716446	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.582	rs6982832	ENSG00000229857.1	RP11-159H20.3	6.57	1.3e-10	0.000186	0.36	0.29	Mood instability;	chr8:8934707	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.955	rs1397608	ENSG00000253326.2	RP11-261C10.7	6.57	1.31e-10	0.000186	0.39	0.29	Corneal astigmatism;	chr4:119240589	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs7684942	ENSG00000253326.2	RP11-261C10.7	6.57	1.31e-10	0.000186	0.39	0.29	Corneal astigmatism;	chr4:119241046	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.913	rs10010696	ENSG00000253326.2	RP11-261C10.7	6.57	1.31e-10	0.000186	0.39	0.29	Corneal astigmatism;	chr4:119243148	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.913	rs11098496	ENSG00000253326.2	RP11-261C10.7	6.57	1.31e-10	0.000186	0.39	0.29	Corneal astigmatism;	chr4:119246311	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs35197422	ENSG00000253326.2	RP11-261C10.7	6.57	1.31e-10	0.000186	0.39	0.29	Corneal astigmatism;	chr4:119248159	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs1511015	ENSG00000253326.2	RP11-261C10.7	6.57	1.31e-10	0.000186	0.39	0.29	Corneal astigmatism;	chr4:119249318	chr1:243054861~243056394:-
THCA	trans	rs11098499	1	rs28374891	ENSG00000253326.2	RP11-261C10.7	6.57	1.31e-10	0.000186	0.39	0.29	Corneal astigmatism;	chr4:119262395	chr1:243054861~243056394:-
THCA	trans	rs2950393	0.804	rs11171951	ENSG00000228224.3	NACAP1	6.57	1.31e-10	0.000186	0.3	0.29	Platelet distribution width;	chr12:56718853	chr8:101361794~101372707:+
THCA	trans	rs76228276	0.737	rs72674607	ENSG00000260318.1	COX6CP1	6.57	1.31e-10	0.000186	0.88	0.29	Childhood ear infection;	chr8:99401101	chr16:11903923~11904137:-
THCA	trans	rs853679	0.546	rs13195291	ENSG00000228022.4	HCG20	-6.57	1.31e-10	0.000187	-0.73	-0.29	Depression;	chr6:28201463	chr6:30766825~30792250:+
THCA	trans	rs853679	0.556	rs13197633	ENSG00000228022.4	HCG20	-6.57	1.31e-10	0.000187	-0.73	-0.29	Depression;	chr6:28206979	chr6:30766825~30792250:+
THCA	trans	rs864643	0.891	rs816493	ENSG00000188856.6	RPSAP47	6.57	1.31e-10	0.000187	0.44	0.29	Attention deficit hyperactivity disorder;	chr3:39514702	chr8:80558870~80559757:+
THCA	trans	rs2975734	0.736	rs4841300	ENSG00000253893.2	FAM85B	6.57	1.32e-10	0.000188	0.41	0.29	Chronotype;Morning vs. evening chronotype;	chr8:10255085	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.654	rs4840550	ENSG00000256560.1	LINC01486	-6.57	1.32e-10	0.000188	-0.36	-0.29	Triglycerides;	chr8:11171520	chr12:109354083~109359488:-
THCA	trans	rs14057	0.896	rs2232460	ENSG00000215869.3	RP11-364B6.1	6.57	1.33e-10	0.000189	0.42	0.29	Systolic blood pressure;	chr1:6599445	chr1:104073023~104077087:+
THCA	trans	rs2975734	0.676	rs4841299	ENSG00000253893.2	FAM85B	6.57	1.33e-10	0.000189	0.41	0.29	Chronotype;Morning vs. evening chronotype;	chr8:10255083	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.901	rs11956240	ENSG00000226666.1	HSPA9P1	6.57	1.33e-10	0.000189	0.3	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138504604	chr2:221961737~221963765:+
THCA	trans	rs11098499	1	rs10029750	ENSG00000253326.2	RP11-261C10.7	6.57	1.34e-10	0.00019	0.39	0.29	Corneal astigmatism;	chr4:119251388	chr1:243054861~243056394:-
THCA	trans	rs14057	0.896	rs2235566	ENSG00000215869.3	RP11-364B6.1	6.57	1.34e-10	0.000191	0.42	0.29	Systolic blood pressure;	chr1:6594993	chr1:104073023~104077087:+
THCA	trans	rs902774	0.818	rs73106451	ENSG00000254285.3	KRT8P3	-6.57	1.34e-10	0.000191	-0.59	-0.29	Prostate cancer;	chr12:52872955	chr8:61578220~61579668:+
THCA	trans	rs3740713	1	rs73438631	ENSG00000236090.2	LDHAP3	6.57	1.35e-10	0.000192	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr2:41819747~41820754:+
THCA	trans	rs9329221	0.71	rs11249995	ENSG00000253893.2	FAM85B	-6.57	1.36e-10	0.000193	-0.39	-0.29	Neuroticism;	chr8:10381412	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.965	rs2424904	ENSG00000253915.1	MAPRE1P1	6.57	1.36e-10	0.000193	0.38	0.29	Ulcerative colitis;	chr20:32764510	chr8:135625185~135625981:-
THCA	trans	rs6601327	0.607	rs35316422	ENSG00000253893.2	FAM85B	6.57	1.36e-10	0.000193	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9717619	chr8:8167819~8226614:-
THCA	trans	rs7260598	0.636	rs62114769	ENSG00000261770.1	CTC-459F4.1	6.57	1.36e-10	0.000193	0.43	0.29	Response to taxane treatment (placlitaxel);	chr19:24052658	chr19:27757184~27760849:-
THCA	trans	rs7819412	0.668	rs920047	ENSG00000256560.1	LINC01486	-6.57	1.36e-10	0.000193	-0.36	-0.29	Triglycerides;	chr8:11229966	chr12:109354083~109359488:-
THCA	trans	rs9467711	0.79	rs13220495	ENSG00000280107.1	AL022393.9	-6.57	1.36e-10	0.000194	-0.6	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr6:28170845~28172521:+
THCA	trans	rs2898290	0.622	rs978802	ENSG00000229857.1	RP11-159H20.3	6.57	1.36e-10	0.000194	0.38	0.29	Systolic blood pressure;	chr8:11485769	chr9:76992099~76993108:+
THCA	trans	rs877636	0.702	rs773109	ENSG00000244604.1	RP11-713H12.1	6.57	1.36e-10	0.000194	0.39	0.29	Cognitive function;	chr12:55980911	chr17:8561230~8561576:+
THCA	trans	rs864643	1	rs552724	ENSG00000188856.6	RPSAP47	-6.57	1.37e-10	0.000194	-0.44	-0.29	Attention deficit hyperactivity disorder;	chr3:39513455	chr8:80558870~80559757:+
THCA	trans	rs76228276	0.737	rs77086359	ENSG00000260318.1	COX6CP1	6.57	1.38e-10	0.000196	0.86	0.29	Childhood ear infection;	chr8:99396845	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs72674611	ENSG00000260318.1	COX6CP1	6.57	1.38e-10	0.000196	0.86	0.29	Childhood ear infection;	chr8:99405854	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs72674612	ENSG00000260318.1	COX6CP1	6.57	1.38e-10	0.000196	0.86	0.29	Childhood ear infection;	chr8:99406273	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.618	rs11996968	ENSG00000260318.1	COX6CP1	6.56	1.39e-10	0.000197	0.86	0.29	Childhood ear infection;	chr8:99423437	chr16:11903923~11904137:-
THCA	trans	rs6600671	1	rs2185281	ENSG00000270392.2	PFN1P2	6.56	1.39e-10	0.000197	0.28	0.29	Hip geometry;	chr1:121438132	chr1:120432204~120434052:-
THCA	trans	rs1190596	0.525	rs6575897	ENSG00000181359.5	HSP90AA6P	-6.56	1.39e-10	0.000197	-0.41	-0.29	Behavioural disinhibition (generation interaction);	chr14:102180788	chr4:170581470~170605450:-
THCA	trans	rs941207	0.526	rs7303216	ENSG00000257210.1	NACAP3	6.56	1.39e-10	0.000198	0.35	0.29	Platelet count;	chr12:56680909	chr12:93124063~93124543:-
THCA	trans	rs941207	0.507	rs7297289	ENSG00000257210.1	NACAP3	6.56	1.39e-10	0.000198	0.35	0.29	Platelet count;	chr12:56682703	chr12:93124063~93124543:-
THCA	trans	rs941207	0.526	rs4759028	ENSG00000257210.1	NACAP3	6.56	1.39e-10	0.000198	0.35	0.29	Platelet count;	chr12:56686399	chr12:93124063~93124543:-
THCA	trans	rs34421088	0.506	rs2409755	ENSG00000253893.2	FAM85B	-6.56	1.39e-10	0.000198	-0.38	-0.29	Neuroticism;	chr8:11312474	chr8:8167819~8226614:-
THCA	trans	rs9649213	0.574	rs6961790	ENSG00000225169.1	BRI3P1	6.56	1.4e-10	0.000198	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr1:100213293~100213670:+
THCA	trans	rs6601327	0.641	rs7014663	ENSG00000253893.2	FAM85B	6.56	1.4e-10	0.000198	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9729765	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.641	rs11778555	ENSG00000253893.2	FAM85B	6.56	1.4e-10	0.000198	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9730064	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.641	rs11785923	ENSG00000253893.2	FAM85B	6.56	1.4e-10	0.000198	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9730164	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.641	rs11782886	ENSG00000253893.2	FAM85B	6.56	1.4e-10	0.000198	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9730381	chr8:8167819~8226614:-
THCA	trans	rs864643	0.947	rs1473865	ENSG00000183298.5	RP11-556K13.1	6.56	1.4e-10	0.000198	0.47	0.29	Attention deficit hyperactivity disorder;	chr3:39501313	chr1:101786340~101787219:-
THCA	trans	rs7829975	0.593	rs2921077	ENSG00000256560.1	LINC01486	6.56	1.4e-10	0.000199	0.34	0.29	Mood instability;	chr8:8446992	chr12:109354083~109359488:-
THCA	trans	rs853679	0.607	rs35001169	ENSG00000228022.4	HCG20	-6.56	1.4e-10	0.000199	-0.73	-0.29	Depression;	chr6:28219854	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs35656932	ENSG00000228022.4	HCG20	-6.56	1.4e-10	0.000199	-0.73	-0.29	Depression;	chr6:28223510	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13208096	ENSG00000228022.4	HCG20	-6.56	1.4e-10	0.000199	-0.73	-0.29	Depression;	chr6:28257533	chr6:30766825~30792250:+
THCA	trans	rs4646450	0.735	rs28495024	ENSG00000228834.1	RP11-249L21.4	6.56	1.41e-10	2e-04	0.49	0.29	Blood metabolite levels;	chr7:99419060	chr6:108907615~108907873:-
THCA	trans	rs12200782	1	rs12195971	ENSG00000242375.1	RP11-498P14.3	-6.56	1.42e-10	0.000201	-0.75	-0.29	Small cell lung carcinoma;	chr6:26460196	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs12211201	ENSG00000242375.1	RP11-498P14.3	-6.56	1.42e-10	0.000201	-0.75	-0.29	Small cell lung carcinoma;	chr6:26461233	chr9:97195351~97197687:-
THCA	trans	rs6087990	0.965	rs2424899	ENSG00000253915.1	MAPRE1P1	6.56	1.42e-10	0.000202	0.37	0.29	Ulcerative colitis;	chr20:32755737	chr8:135625185~135625981:-
THCA	trans	rs4646450	0.735	rs10155966	ENSG00000228834.1	RP11-249L21.4	6.56	1.42e-10	0.000202	0.5	0.29	Blood metabolite levels;	chr7:99383610	chr6:108907615~108907873:-
THCA	trans	rs4911259	0.552	rs13038881	ENSG00000253915.1	MAPRE1P1	-6.56	1.43e-10	0.000203	-0.37	-0.29	Inflammatory bowel disease;	chr20:32880307	chr8:135625185~135625981:-
THCA	trans	rs864643	0.945	rs1768254	ENSG00000188856.6	RPSAP47	6.56	1.44e-10	0.000204	0.44	0.29	Attention deficit hyperactivity disorder;	chr3:39506929	chr8:80558870~80559757:+
THCA	trans	rs7824557	0.507	rs7010590	ENSG00000256560.1	LINC01486	6.56	1.44e-10	0.000204	0.36	0.29	Retinal vascular caliber;	chr8:11205373	chr12:109354083~109359488:-
THCA	trans	rs138024639	1	rs138024639	ENSG00000228022.4	HCG20	-6.56	1.44e-10	0.000204	-0.72	-0.29	Breast cancer;	chr6:28468244	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs55690788	ENSG00000228022.4	HCG20	-6.56	1.44e-10	0.000204	-0.72	-0.29	Depression;	chr6:28468368	chr6:30766825~30792250:+
THCA	trans	rs864643	0.524	rs77060785	ENSG00000183298.5	RP11-556K13.1	6.56	1.44e-10	0.000205	0.6	0.29	Attention deficit hyperactivity disorder;	chr3:39491177	chr1:101786340~101787219:-
THCA	trans	rs9649213	0.593	rs10953255	ENSG00000225169.1	BRI3P1	6.56	1.45e-10	0.000205	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr1:100213293~100213670:+
THCA	trans	rs7833986	1	rs36088882	ENSG00000244245.1	RP11-120B7.1	6.56	1.45e-10	0.000206	0.38	0.29	Height;	chr8:56180355	chr5:108593609~108593967:+
THCA	trans	rs6921919	0.673	rs13201681	ENSG00000228022.4	HCG20	-6.56	1.46e-10	0.000206	-0.72	-0.29	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:30766825~30792250:+
THCA	trans	rs6921919	0.778	rs67381177	ENSG00000228022.4	HCG20	-6.56	1.46e-10	0.000206	-0.72	-0.29	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:30766825~30792250:+
THCA	trans	rs34421088	0.56	rs2467520	ENSG00000229857.1	RP11-159H20.3	6.56	1.46e-10	0.000206	0.37	0.29	Neuroticism;	chr8:11541444	chr9:76992099~76993108:+
THCA	trans	rs10816533	1	rs4344199	ENSG00000232063.1	RP11-307E17.8	6.56	1.46e-10	0.000206	0.74	0.29	Height;	chr9:96787167	chr9:94332476~94360948:+
THCA	trans	rs2898290	0.622	rs7822109	ENSG00000229857.1	RP11-159H20.3	6.56	1.46e-10	0.000206	0.38	0.29	Systolic blood pressure;	chr8:11491638	chr9:76992099~76993108:+
THCA	trans	rs9292918	0.76	rs10064595	ENSG00000231752.4	EMBP1	6.56	1.46e-10	0.000207	0.49	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45332510	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.51	rs1435274	ENSG00000254153.1	CTA-398F10.2	6.56	1.46e-10	0.000207	0.32	0.29	Retinal vascular caliber;	chr8:11378401	chr8:8456909~8461337:-
THCA	trans	rs11671005	0.572	rs11669127	ENSG00000279267.1	RP11-395L14.18	-6.56	1.47e-10	0.000207	-0.43	-0.29	Mean platelet volume;	chr19:58492463	chr2:113605867~113607908:-
THCA	trans	rs7824557	0.527	rs4634600	ENSG00000254153.1	CTA-398F10.2	6.55	1.47e-10	0.000208	0.32	0.29	Retinal vascular caliber;	chr8:11381508	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.527	rs4631425	ENSG00000254153.1	CTA-398F10.2	6.55	1.47e-10	0.000208	0.32	0.29	Retinal vascular caliber;	chr8:11381545	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.585	rs4549730	ENSG00000254153.1	CTA-398F10.2	6.55	1.47e-10	0.000208	0.32	0.29	Neuroticism;	chr8:11381569	chr8:8456909~8461337:-
THCA	trans	rs76228276	0.737	rs1349244	ENSG00000260318.1	COX6CP1	6.55	1.48e-10	0.000209	0.83	0.29	Childhood ear infection;	chr8:99745774	chr16:11903923~11904137:-
THCA	trans	rs34421088	0.531	rs2245232	ENSG00000256560.1	LINC01486	-6.55	1.48e-10	0.00021	-0.37	-0.29	Neuroticism;	chr8:11543435	chr12:109354083~109359488:-
THCA	trans	rs2975734	0.68	rs10503406	ENSG00000253893.2	FAM85B	6.55	1.49e-10	0.00021	0.4	0.29	Chronotype;Morning vs. evening chronotype;	chr8:10251462	chr8:8167819~8226614:-
THCA	trans	rs11992162	1	rs11784499	ENSG00000256560.1	LINC01486	6.55	1.49e-10	0.000211	0.36	0.29	Monocyte count;	chr8:11977030	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.905	rs7836953	ENSG00000254153.1	CTA-398F10.2	-6.55	1.49e-10	0.000211	-0.31	-0.29	Monocyte count;	chr8:11978203	chr8:8456909~8461337:-
THCA	trans	rs3740713	1	rs61081934	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr2:41819747~41820754:+
THCA	trans	rs3740713	0.92	rs112818034	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs76708296	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438668	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs75647856	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438687	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs74663287	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438699	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73440604	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73440610	ENSG00000236090.2	LDHAP3	6.55	1.49e-10	0.000211	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr2:41819747~41820754:+
THCA	trans	rs12472274	0.941	rs36066920	ENSG00000224699.7	LAMTOR5-AS1	-6.55	1.5e-10	0.000212	-0.25	-0.29	Phospholipid levels (plasma);	chr2:238165839	chr1:110347116~110443817:+
THCA	trans	rs7829975	0.774	rs1703982	ENSG00000256560.1	LINC01486	-6.55	1.5e-10	0.000212	-0.34	-0.29	Mood instability;	chr8:8740878	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.592	rs920044	ENSG00000253893.2	FAM85B	-6.55	1.51e-10	0.000213	-0.39	-0.29	Retinal vascular caliber;	chr8:11366804	chr8:8167819~8226614:-
THCA	trans	rs1190596	0.525	rs4601978	ENSG00000181359.5	HSP90AA6P	-6.55	1.51e-10	0.000214	-0.41	-0.29	Behavioural disinhibition (generation interaction);	chr14:102284740	chr4:170581470~170605450:-
THCA	trans	rs11098499	1	rs13116504	ENSG00000253326.2	RP11-261C10.7	6.55	1.52e-10	0.000214	0.39	0.29	Corneal astigmatism;	chr4:119288257	chr1:243054861~243056394:-
THCA	trans	rs34421088	0.56	rs2618434	ENSG00000256560.1	LINC01486	-6.55	1.52e-10	0.000214	-0.36	-0.29	Neuroticism;	chr8:11541356	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.538	rs10111950	ENSG00000229857.1	RP11-159H20.3	6.55	1.52e-10	0.000214	0.36	0.29	Neuroticism;	chr8:10958244	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.846	rs1879957	ENSG00000229857.1	RP11-159H20.3	6.55	1.52e-10	0.000214	0.35	0.29	Mood instability;	chr8:8687298	chr9:76992099~76993108:+
THCA	trans	rs864643	0.678	rs1629282	ENSG00000183298.5	RP11-556K13.1	-6.55	1.52e-10	0.000215	-0.48	-0.29	Attention deficit hyperactivity disorder;	chr3:39491770	chr1:101786340~101787219:-
THCA	trans	rs1707322	0.686	rs11211179	ENSG00000255397.1	AC022182.2	-6.55	1.52e-10	0.000215	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.721	rs10157795	ENSG00000255397.1	AC022182.2	-6.55	1.52e-10	0.000215	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr8:60937705~60939871:-
THCA	trans	rs1190596	0.526	rs8003556	ENSG00000181359.5	HSP90AA6P	-6.55	1.53e-10	0.000216	-0.41	-0.29	Behavioural disinhibition (generation interaction);	chr14:102193330	chr4:170581470~170605450:-
THCA	trans	rs34421088	0.532	rs2736390	ENSG00000253893.2	FAM85B	-6.55	1.53e-10	0.000216	-0.39	-0.29	Neuroticism;	chr8:11304287	chr8:8167819~8226614:-
THCA	trans	rs3740713	1	rs113036885	ENSG00000236090.2	LDHAP3	6.55	1.53e-10	0.000216	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs112410494	ENSG00000236090.2	LDHAP3	6.55	1.53e-10	0.000216	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs74741949	ENSG00000236090.2	LDHAP3	6.55	1.53e-10	0.000216	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr2:41819747~41820754:+
THCA	trans	rs7819412	0.805	rs4333549	ENSG00000256560.1	LINC01486	-6.55	1.54e-10	0.000218	-0.36	-0.29	Triglycerides;	chr8:11122051	chr12:109354083~109359488:-
THCA	trans	rs877636	0.692	rs2271194	ENSG00000234192.1	RP11-57C13.5	-6.55	1.55e-10	0.000218	-0.35	-0.29	Cognitive function;	chr12:56083910	chr10:87642607~87642954:+
THCA	trans	rs6921919	0.673	rs13201681	ENSG00000253570.1	RNF5P1	6.55	1.55e-10	0.000219	0.8	0.29	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr8:38600661~38601200:-
THCA	trans	rs6921919	0.778	rs67381177	ENSG00000253570.1	RNF5P1	6.55	1.55e-10	0.000219	0.8	0.29	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr8:38600661~38601200:-
THCA	trans	rs4925166	1	rs4925166	ENSG00000188933.13	USP32P1	6.55	1.55e-10	0.000219	0.39	0.29	Multiple sclerosis;	chr17:18307496	chr17:16786489~16804455:+
THCA	trans	rs1600249	0.562	rs17153419	ENSG00000253893.2	FAM85B	6.55	1.55e-10	0.000219	0.4	0.29	Rheumatoid arthritis;	chr8:11536724	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.614	rs10503421	ENSG00000253893.2	FAM85B	-6.55	1.56e-10	0.00022	-0.4	-0.29	Retinal vascular caliber;	chr8:11363804	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.955	rs13113112	ENSG00000253326.2	RP11-261C10.7	6.54	1.56e-10	0.00022	0.39	0.29	Corneal astigmatism;	chr4:119234885	chr1:243054861~243056394:-
THCA	trans	rs13016963	0.604	rs11688692	ENSG00000235105.1	RP11-329A14.1	6.54	1.56e-10	0.000221	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201324728	chr1:48435967~48437223:+
THCA	trans	rs889398	0.594	rs8047194	ENSG00000257513.6	NPIPB1P	6.54	1.56e-10	0.000221	0.32	0.29	Body mass index;	chr16:69857607	chr18:11619509~11639699:-
THCA	trans	rs9393777	0.92	rs66462181	ENSG00000253570.1	RNF5P1	6.54	1.57e-10	0.000221	0.82	0.29	Intelligence (multi-trait analysis);	chr6:27123882	chr8:38600661~38601200:-
THCA	trans	rs4415084	0.774	rs11958808	ENSG00000231752.4	EMBP1	6.54	1.57e-10	0.000221	0.4	0.29	Breast cancer;	chr5:44944988	chr1:121519112~121571892:+
THCA	trans	rs34421088	0.506	rs4841518	ENSG00000253893.2	FAM85B	-6.54	1.57e-10	0.000221	-0.38	-0.29	Neuroticism;	chr8:11288454	chr8:8167819~8226614:-
THCA	trans	rs9467711	1	rs9467704	ENSG00000176998.4	HCG4	6.54	1.58e-10	0.000223	0.52	0.29	Autism spectrum disorder or schizophrenia;	chr6:26319258	chr6:29791753~29792750:-
THCA	trans	rs1707322	0.721	rs56255771	ENSG00000255397.1	AC022182.2	-6.54	1.59e-10	0.000225	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr8:60937705~60939871:-
THCA	trans	rs853679	0.607	rs68188794	ENSG00000228022.4	HCG20	-6.54	1.6e-10	0.000226	-0.73	-0.29	Depression;	chr6:28112999	chr6:30766825~30792250:+
THCA	trans	rs9876781	0.559	rs1841178	ENSG00000225528.1	RP3-370M22.8	-6.54	1.6e-10	0.000226	-0.36	-0.29	Longevity;	chr3:48355556	chr22:39960397~39964683:+
THCA	trans	rs9876781	0.53	rs11708617	ENSG00000225528.1	RP3-370M22.8	-6.54	1.6e-10	0.000226	-0.36	-0.29	Longevity;	chr3:48354819	chr22:39960397~39964683:+
THCA	trans	rs8177876	0.822	rs9923732	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs9933184	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs9926174	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.642	rs8052490	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs8056972	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs74437879	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs76948085	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs80315956	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.642	rs16954572	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs9929586	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs9938965	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs7204040	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.731	rs7188508	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.642	rs10514513	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs28672349	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs4306521	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs4324142	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.642	rs4324143	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.818	rs59177227	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs59685942	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs10514514	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs10514515	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs1410	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs1412	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs1414	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs8177950	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.731	rs8177948	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs8177940	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.73	rs76656387	ENSG00000224837.1	GCSHP5	6.54	1.61e-10	0.000227	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr1:168055901~168056422:-
THCA	trans	rs138024639	1	rs138024639	ENSG00000253570.1	RNF5P1	6.54	1.61e-10	0.000227	0.8	0.29	Breast cancer;	chr6:28468244	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs55690788	ENSG00000253570.1	RNF5P1	6.54	1.61e-10	0.000227	0.8	0.29	Depression;	chr6:28468368	chr8:38600661~38601200:-
THCA	trans	rs4646450	0.735	rs10243678	ENSG00000228834.1	RP11-249L21.4	6.54	1.62e-10	0.000228	0.5	0.29	Blood metabolite levels;	chr7:99394321	chr6:108907615~108907873:-
THCA	trans	rs2898290	0.622	rs1600250	ENSG00000229857.1	RP11-159H20.3	6.54	1.62e-10	0.000228	0.38	0.29	Systolic blood pressure;	chr8:11487916	chr9:76992099~76993108:+
THCA	trans	rs2898290	0.593	rs1600252	ENSG00000229857.1	RP11-159H20.3	6.54	1.62e-10	0.000228	0.38	0.29	Systolic blood pressure;	chr8:11488135	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.614	rs2293860	ENSG00000253893.2	FAM85B	-6.54	1.62e-10	0.000228	-0.38	-0.29	Retinal vascular caliber;	chr8:11361877	chr8:8167819~8226614:-
THCA	trans	rs9467711	0.79	rs72843784	ENSG00000228022.4	HCG20	-6.54	1.62e-10	0.000229	-0.81	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26498530	chr6:30766825~30792250:+
THCA	trans	rs9467711	0.79	rs45527431	ENSG00000228022.4	HCG20	-6.54	1.62e-10	0.000229	-0.81	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26599281	chr6:30766825~30792250:+
THCA	trans	rs9467711	0.79	rs66488313	ENSG00000228022.4	HCG20	-6.54	1.62e-10	0.000229	-0.81	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26631340	chr6:30766825~30792250:+
THCA	trans	rs864643	0.524	rs11715885	ENSG00000183298.5	RP11-556K13.1	6.54	1.63e-10	0.000229	0.59	0.29	Attention deficit hyperactivity disorder;	chr3:39475107	chr1:101786340~101787219:-
THCA	trans	rs453301	0.624	rs2288673	ENSG00000256560.1	LINC01486	6.54	1.63e-10	0.00023	0.34	0.29	Joint mobility (Beighton score);	chr8:9002766	chr12:109354083~109359488:-
THCA	trans	rs2164273	0.528	rs3824212	ENSG00000253893.2	FAM85B	-6.54	1.64e-10	0.000231	-0.38	-0.29	Extraversion;	chr8:11285409	chr8:8167819~8226614:-
THCA	trans	rs335206	1	rs335205	ENSG00000256427.1	RP11-118B22.4	-6.54	1.64e-10	0.000231	-0.31	-0.29	QRS duration;	chr5:123168988	chr12:9246497~9257960:+
THCA	trans	rs9292918	0.806	rs28856284	ENSG00000231752.4	EMBP1	6.54	1.65e-10	0.000233	0.49	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45341850	chr1:121519112~121571892:+
THCA	trans	rs9292918	0.707	rs2330704	ENSG00000231752.4	EMBP1	6.54	1.65e-10	0.000233	0.49	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45344196	chr1:121519112~121571892:+
THCA	trans	rs9292918	0.806	rs34835217	ENSG00000231752.4	EMBP1	6.54	1.65e-10	0.000233	0.49	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45346087	chr1:121519112~121571892:+
THCA	trans	rs941207	0.526	rs12229457	ENSG00000228224.3	NACAP1	-6.53	1.66e-10	0.000234	-0.31	-0.29	Platelet count;	chr12:56639896	chr8:101361794~101372707:+
THCA	trans	rs853679	0.607	rs34788973	ENSG00000228022.4	HCG20	-6.53	1.67e-10	0.000235	-0.72	-0.29	Depression;	chr6:27911422	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs61742093	ENSG00000228022.4	HCG20	-6.53	1.67e-10	0.000235	-0.72	-0.29	Depression;	chr6:27912204	chr6:30766825~30792250:+
THCA	trans	rs877636	0.859	rs3741499	ENSG00000227586.5	RP11-162A23.5	-6.53	1.67e-10	0.000235	-0.37	-0.29	Cognitive function;	chr12:56080595	chr10:123171535~123171875:-
THCA	trans	rs7769051	1	rs6934161	ENSG00000227615.1	RP11-864N7.2	-6.53	1.67e-10	0.000235	-0.46	-0.29	Type 2 diabetes nephropathy;	chr6:132802938	chr11:74745716~74746114:-
THCA	trans	rs7829975	0.688	rs7817376	ENSG00000229857.1	RP11-159H20.3	6.53	1.68e-10	0.000236	0.36	0.29	Mood instability;	chr8:8523020	chr9:76992099~76993108:+
THCA	trans	rs7200543	0.961	rs3803573	ENSG00000250569.1	NTAN1P2	6.53	1.68e-10	0.000237	0.29	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr8:86481754~86483002:-
THCA	trans	rs616147	0.72	rs1768209	ENSG00000243904.1	RP11-600F24.1	-6.53	1.68e-10	0.000237	-0.36	-0.29	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr14:103374033~103374916:-
THCA	trans	rs6885307	1	rs6885307	ENSG00000231752.4	EMBP1	-6.53	1.69e-10	0.000237	-0.43	-0.29	Age at first birth;	chr5:45094401	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.572	rs11250098	ENSG00000229857.1	RP11-159H20.3	6.53	1.69e-10	0.000238	0.36	0.29	Neuroticism;	chr8:10961097	chr9:76992099~76993108:+
THCA	trans	rs4720118	0.508	rs2392232	ENSG00000213492.2	NT5C3AP1	6.53	1.69e-10	0.000238	0.38	0.29	Leprosy;	chr7:33397224	chr4:117574512~117576174:-
THCA	trans	rs9649213	0.593	rs7778015	ENSG00000225169.1	BRI3P1	6.53	1.7e-10	0.000239	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs1132971	ENSG00000225169.1	BRI3P1	6.53	1.7e-10	0.000239	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs6465664	ENSG00000225169.1	BRI3P1	6.53	1.7e-10	0.000239	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr1:100213293~100213670:+
THCA	trans	rs11077773	1	rs11077773	ENSG00000234925.2	ATP5HP4	-6.53	1.7e-10	0.000239	-0.5	-0.29	Information processing speed;	chr17:75063978	chr12:68642519~68642993:-
THCA	trans	rs12200782	0.932	rs12202419	ENSG00000242375.1	RP11-498P14.3	6.53	1.7e-10	0.000239	0.78	0.29	Small cell lung carcinoma;	chr6:26465156	chr9:97195351~97197687:-
THCA	trans	rs3740713	1	rs113497813	ENSG00000236090.2	LDHAP3	6.53	1.7e-10	0.000239	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs73438697	ENSG00000236090.2	LDHAP3	6.53	1.7e-10	0.000239	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs114330751	ENSG00000236090.2	LDHAP3	6.53	1.7e-10	0.000239	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr2:41819747~41820754:+
THCA	trans	rs16937956	0.657	rs16938063	ENSG00000266891.1	RP11-692N5.2	-6.53	1.7e-10	0.000239	-0.38	-0.29	Body mass index;	chr11:8410110	chr18:9734882~9735602:-
THCA	trans	rs11992162	0.967	rs7836456	ENSG00000256560.1	LINC01486	6.53	1.7e-10	0.000239	0.36	0.29	Monocyte count;	chr8:11971666	chr12:109354083~109359488:-
THCA	trans	rs6732160	0.613	rs62151837	ENSG00000236165.1	PRADC1P1	6.53	1.71e-10	0.00024	0.4	0.29	Intelligence (multi-trait analysis);	chr2:73163268	chr3:36976316~36976840:+
THCA	trans	rs6087990	0.735	rs6057647	ENSG00000253915.1	MAPRE1P1	6.53	1.71e-10	0.00024	0.38	0.29	Ulcerative colitis;	chr20:32793884	chr8:135625185~135625981:-
THCA	trans	rs7929679	0.521	rs10836304	ENSG00000225531.1	RP11-196I18.3	-6.53	1.71e-10	0.000241	-0.36	-0.29	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34772477	chr9:107116829~107117557:+
THCA	trans	rs7929679	0.551	rs10466455	ENSG00000225531.1	RP11-196I18.3	-6.53	1.71e-10	0.000241	-0.36	-0.29	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34759389	chr9:107116829~107117557:+
THCA	trans	rs3740713	1	rs73440636	ENSG00000236090.2	LDHAP3	6.53	1.71e-10	0.000241	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr2:41819747~41820754:+
THCA	trans	rs9329221	0.62	rs6601427	ENSG00000229857.1	RP11-159H20.3	6.53	1.72e-10	0.000241	0.37	0.29	Neuroticism;	chr8:10298515	chr9:76992099~76993108:+
THCA	trans	rs58106596	0.95	rs11695646	ENSG00000259020.3	RP11-529H20.3	-6.53	1.72e-10	0.000242	-0.41	-0.29	Lymphocyte counts;White blood cell count;	chr2:231720097	chr14:92026566~92026887:+
THCA	trans	rs4879656	0.797	rs7872744	ENSG00000215007.3	DNAJA1P3	6.53	1.72e-10	0.000242	0.33	0.29	Menopause (age at onset);	chr9:33054164	chrX:107351650~107352843:-
THCA	trans	rs7833986	1	rs66796428	ENSG00000244245.1	RP11-120B7.1	6.53	1.73e-10	0.000243	0.38	0.29	Height;	chr8:56182238	chr5:108593609~108593967:+
THCA	trans	rs7833986	1	rs34516759	ENSG00000244245.1	RP11-120B7.1	6.53	1.73e-10	0.000243	0.38	0.29	Height;	chr8:56184579	chr5:108593609~108593967:+
THCA	trans	rs7833986	1	rs34952804	ENSG00000244245.1	RP11-120B7.1	6.53	1.73e-10	0.000243	0.38	0.29	Height;	chr8:56184840	chr5:108593609~108593967:+
THCA	trans	rs7824557	0.836	rs765731	ENSG00000253893.2	FAM85B	6.53	1.73e-10	0.000244	0.37	0.29	Retinal vascular caliber;	chr8:11263989	chr8:8167819~8226614:-
THCA	trans	rs853679	0.607	rs13204012	ENSG00000228022.4	HCG20	-6.53	1.76e-10	0.000247	-0.73	-0.29	Depression;	chr6:28233753	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13205211	ENSG00000228022.4	HCG20	-6.53	1.76e-10	0.000247	-0.73	-0.29	Depression;	chr6:28235278	chr6:30766825~30792250:+
THCA	trans	rs4720118	0.508	rs3823763	ENSG00000213492.2	NT5C3AP1	6.53	1.76e-10	0.000247	0.38	0.29	Leprosy;	chr7:33368282	chr4:117574512~117576174:-
THCA	trans	rs8177876	0.822	rs9925940	ENSG00000224837.1	GCSHP5	6.52	1.77e-10	0.000248	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs9925943	ENSG00000224837.1	GCSHP5	6.52	1.77e-10	0.000248	0.43	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr1:168055901~168056422:-
THCA	trans	rs9649213	0.593	rs6465662	ENSG00000225169.1	BRI3P1	6.52	1.77e-10	0.000248	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr1:100213293~100213670:+
THCA	trans	rs6087990	0.735	rs2424914	ENSG00000253915.1	MAPRE1P1	6.52	1.77e-10	0.000248	0.38	0.29	Ulcerative colitis;	chr20:32786714	chr8:135625185~135625981:-
THCA	trans	rs930395	0.514	rs34325259	ENSG00000231752.4	EMBP1	6.52	1.77e-10	0.000249	0.41	0.29	Breast cancer;	chr5:44936758	chr1:121519112~121571892:+
THCA	trans	rs1707322	0.929	rs785513	ENSG00000255397.1	AC022182.2	6.52	1.78e-10	0.00025	0.4	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr8:60937705~60939871:-
THCA	trans	rs13016963	0.604	rs7569952	ENSG00000235105.1	RP11-329A14.1	6.52	1.78e-10	0.00025	0.32	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201320709	chr1:48435967~48437223:+
THCA	trans	rs10242455	0.681	rs59836234	ENSG00000228834.1	RP11-249L21.4	6.52	1.78e-10	0.00025	0.53	0.29	Blood metabolite levels;	chr7:99755926	chr6:108907615~108907873:-
THCA	trans	rs2060793	0.519	rs1403247	ENSG00000236360.2	RP11-334A14.2	-6.52	1.78e-10	0.00025	-0.39	-0.29	Vitamin D levels;	chr11:14611024	chr1:52993201~52993702:-
THCA	trans	rs9616064	0.557	rs9616085	ENSG00000258384.1	AC068831.6	6.52	1.8e-10	0.000253	0.35	0.29	Urate levels in obese individuals;	chr22:46649659	chr15:90952239~90955225:-
THCA	trans	rs1707322	1	rs1707322	ENSG00000255397.1	AC022182.2	-6.52	1.8e-10	0.000253	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr8:60937705~60939871:-
THCA	trans	rs3812762	0.912	rs4929936	ENSG00000266891.1	RP11-692N5.2	6.52	1.8e-10	0.000253	0.39	0.29	Hypospadias;	chr11:8771075	chr18:9734882~9735602:-
THCA	trans	rs804280	0.565	rs1466785	ENSG00000253893.2	FAM85B	-6.52	1.81e-10	0.000254	-0.36	-0.29	Myopia (pathological);	chr8:11765947	chr8:8167819~8226614:-
THCA	trans	rs11098499	1	rs12506395	ENSG00000253326.2	RP11-261C10.7	6.52	1.81e-10	0.000254	0.39	0.29	Corneal astigmatism;	chr4:119263939	chr1:243054861~243056394:-
THCA	trans	rs9649213	0.593	rs6975156	ENSG00000225169.1	BRI3P1	6.52	1.82e-10	0.000255	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr1:100213293~100213670:+
THCA	trans	rs2898290	0.622	rs978804	ENSG00000256560.1	LINC01486	-6.52	1.82e-10	0.000255	-0.36	-0.29	Systolic blood pressure;	chr8:11486164	chr12:109354083~109359488:-
THCA	trans	rs7200543	1	rs14347	ENSG00000250569.1	NTAN1P2	6.52	1.83e-10	0.000257	0.29	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr8:86481754~86483002:-
THCA	trans	rs4295623	0.789	rs12541318	ENSG00000229857.1	RP11-159H20.3	6.52	1.83e-10	0.000257	0.37	0.29	Morning vs. evening chronotype;	chr8:11737461	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.527	rs2572376	ENSG00000254153.1	CTA-398F10.2	6.52	1.83e-10	0.000257	0.32	0.29	Retinal vascular caliber;	chr8:11380247	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.527	rs2736305	ENSG00000254153.1	CTA-398F10.2	6.52	1.83e-10	0.000257	0.32	0.29	Retinal vascular caliber;	chr8:11380264	chr8:8456909~8461337:-
THCA	trans	rs2898290	0.5	rs11998678	ENSG00000229857.1	RP11-159H20.3	6.52	1.84e-10	0.000257	0.37	0.29	Systolic blood pressure;	chr8:11972641	chr9:76992099~76993108:+
THCA	trans	rs902774	0.818	rs4919737	ENSG00000254285.3	KRT8P3	-6.52	1.84e-10	0.000258	-0.6	-0.29	Prostate cancer;	chr12:52877011	chr8:61578220~61579668:+
THCA	trans	rs902774	0.818	rs73108429	ENSG00000254285.3	KRT8P3	-6.52	1.84e-10	0.000258	-0.6	-0.29	Prostate cancer;	chr12:52877887	chr8:61578220~61579668:+
THCA	trans	rs1964356	0.967	rs17701675	ENSG00000229857.1	RP11-159H20.3	6.52	1.84e-10	0.000258	0.35	0.29	Mean corpuscular volume;	chr8:8993123	chr9:76992099~76993108:+
THCA	trans	rs2980436	1	rs2980436	ENSG00000229857.1	RP11-159H20.3	6.52	1.84e-10	0.000258	0.34	0.29	Schizophrenia;	chr8:8234503	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.624	rs13278982	ENSG00000253893.2	FAM85B	-6.52	1.84e-10	0.000258	-0.39	-0.29	Neuroticism;	chr8:11731524	chr8:8167819~8226614:-
THCA	trans	rs864643	0.891	rs4129648	ENSG00000183298.5	RP11-556K13.1	6.52	1.86e-10	0.00026	0.49	0.29	Attention deficit hyperactivity disorder;	chr3:39519319	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs673426	ENSG00000183298.5	RP11-556K13.1	6.52	1.86e-10	0.00026	0.49	0.29	Attention deficit hyperactivity disorder;	chr3:39520286	chr1:101786340~101787219:-
THCA	trans	rs2950393	0.929	rs2290893	ENSG00000228224.3	NACAP1	6.52	1.86e-10	0.000261	0.3	0.29	Platelet distribution width;	chr12:56684836	chr8:101361794~101372707:+
THCA	trans	rs6087990	0.806	rs2424918	ENSG00000253915.1	MAPRE1P1	6.52	1.87e-10	0.000261	0.37	0.29	Ulcerative colitis;	chr20:32794964	chr8:135625185~135625981:-
THCA	trans	rs6087990	0.806	rs910085	ENSG00000253915.1	MAPRE1P1	6.52	1.87e-10	0.000261	0.37	0.29	Ulcerative colitis;	chr20:32795547	chr8:135625185~135625981:-
THCA	trans	rs6732160	0.588	rs13407363	ENSG00000236165.1	PRADC1P1	6.52	1.87e-10	0.000261	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73145430	chr3:36976316~36976840:+
THCA	trans	rs3808502	0.526	rs7822958	ENSG00000229857.1	RP11-159H20.3	6.52	1.87e-10	0.000261	0.37	0.29	Neuroticism;	chr8:11564933	chr9:76992099~76993108:+
THCA	trans	rs616147	0.616	rs1768234	ENSG00000243904.1	RP11-600F24.1	-6.52	1.87e-10	0.000262	-0.36	-0.29	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr14:103374033~103374916:-
THCA	trans	rs616147	0.655	rs1707981	ENSG00000243904.1	RP11-600F24.1	-6.52	1.87e-10	0.000262	-0.36	-0.29	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr14:103374033~103374916:-
THCA	trans	rs4295623	0.556	rs10903343	ENSG00000256560.1	LINC01486	6.52	1.87e-10	0.000262	0.35	0.29	Morning vs. evening chronotype;	chr8:11838363	chr12:109354083~109359488:-
THCA	trans	rs864643	0.773	rs11129838	ENSG00000183298.5	RP11-556K13.1	6.51	1.88e-10	0.000263	0.44	0.29	Attention deficit hyperactivity disorder;	chr3:39557696	chr1:101786340~101787219:-
THCA	trans	rs11098499	0.955	rs11931312	ENSG00000253326.2	RP11-261C10.7	6.51	1.88e-10	0.000263	0.39	0.29	Corneal astigmatism;	chr4:119237868	chr1:243054861~243056394:-
THCA	trans	rs930395	0.514	rs10073945	ENSG00000231752.4	EMBP1	-6.51	1.88e-10	0.000263	-0.4	-0.29	Breast cancer;	chr5:44932032	chr1:121519112~121571892:+
THCA	trans	rs2980439	0.818	rs2945249	ENSG00000256560.1	LINC01486	6.51	1.88e-10	0.000263	0.33	0.29	Neuroticism;	chr8:8237204	chr12:109354083~109359488:-
THCA	trans	rs453301	0.653	rs11784393	ENSG00000229857.1	RP11-159H20.3	-6.51	1.88e-10	0.000264	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9045624	chr9:76992099~76993108:+
THCA	trans	rs9649213	0.574	rs7790229	ENSG00000225169.1	BRI3P1	6.51	1.89e-10	0.000264	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr1:100213293~100213670:+
THCA	trans	rs7200543	1	rs3803575	ENSG00000250569.1	NTAN1P2	6.51	1.9e-10	0.000266	0.29	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr8:86481754~86483002:-
THCA	trans	rs1962073	0.507	rs7460226	ENSG00000253893.2	FAM85B	-6.51	1.9e-10	0.000266	-0.38	-0.29	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10340208	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.941	rs10805692	ENSG00000231752.4	EMBP1	-6.51	1.9e-10	0.000266	-0.45	-0.29	Age at first birth;	chr5:45099356	chr1:121519112~121571892:+
THCA	trans	rs7769051	1	rs9493454	ENSG00000227615.1	RP11-864N7.2	-6.51	1.9e-10	0.000266	-0.46	-0.29	Type 2 diabetes nephropathy;	chr6:132823490	chr11:74745716~74746114:-
THCA	trans	rs2950393	0.929	rs2958155	ENSG00000228224.3	NACAP1	6.51	1.9e-10	0.000266	0.29	0.29	Platelet distribution width;	chr12:56670761	chr8:101361794~101372707:+
THCA	trans	rs1707322	1	rs10890370	ENSG00000255397.1	AC022182.2	-6.51	1.9e-10	0.000266	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr8:60937705~60939871:-
THCA	trans	rs941207	0.507	rs1107479	ENSG00000228224.3	NACAP1	-6.51	1.91e-10	0.000267	-0.3	-0.29	Platelet count;	chr12:56636902	chr8:101361794~101372707:+
THCA	trans	rs6732160	0.613	rs58317144	ENSG00000236165.1	PRADC1P1	6.51	1.91e-10	0.000268	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73161025	chr3:36976316~36976840:+
THCA	trans	rs34119086	1	rs34119086	ENSG00000228022.4	HCG20	-6.51	1.92e-10	0.000269	-0.73	-0.29	Breast cancer;	chr6:28594471	chr6:30766825~30792250:+
THCA	trans	rs3764796	0.867	rs73208582	ENSG00000250030.2	RP11-584P21.4	6.51	1.92e-10	0.000269	0.58	0.29	Calcium levels;	chr8:17283972	chr4:67446267~67446574:+
THCA	trans	rs864643	1	rs559349	ENSG00000188856.6	RPSAP47	6.51	1.93e-10	0.000269	0.44	0.29	Attention deficit hyperactivity disorder;	chr3:39505562	chr8:80558870~80559757:+
THCA	trans	rs9425766	0.927	rs5878	ENSG00000213331.4	RP11-713C19.2	6.51	1.93e-10	0.00027	0.35	0.29	Life satisfaction;	chr1:173909694	chr4:187970273~187971284:+
THCA	trans	rs6601327	0.641	rs11780399	ENSG00000253893.2	FAM85B	6.51	1.94e-10	0.000272	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9731657	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.909	rs28555550	ENSG00000253326.2	RP11-261C10.7	6.51	1.95e-10	0.000272	0.39	0.29	Corneal astigmatism;	chr4:119289885	chr1:243054861~243056394:-
THCA	trans	rs11098499	1	rs28419773	ENSG00000253326.2	RP11-261C10.7	6.51	1.95e-10	0.000272	0.39	0.29	Corneal astigmatism;	chr4:119289906	chr1:243054861~243056394:-
THCA	trans	rs11098499	1	rs11726229	ENSG00000253326.2	RP11-261C10.7	6.51	1.95e-10	0.000272	0.39	0.29	Corneal astigmatism;	chr4:119290425	chr1:243054861~243056394:-
THCA	trans	rs1707322	0.964	rs785508	ENSG00000255397.1	AC022182.2	6.51	1.96e-10	0.000274	0.4	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.964	rs785509	ENSG00000255397.1	AC022182.2	6.51	1.96e-10	0.000274	0.4	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr8:60937705~60939871:-
THCA	trans	rs3808502	0.526	rs7823100	ENSG00000229857.1	RP11-159H20.3	6.51	1.97e-10	0.000275	0.37	0.29	Neuroticism;	chr8:11564982	chr9:76992099~76993108:+
THCA	trans	rs3808502	0.526	rs7823101	ENSG00000229857.1	RP11-159H20.3	6.51	1.97e-10	0.000275	0.37	0.29	Neuroticism;	chr8:11564983	chr9:76992099~76993108:+
THCA	trans	rs3808502	0.526	rs11985709	ENSG00000229857.1	RP11-159H20.3	6.51	1.97e-10	0.000275	0.37	0.29	Neuroticism;	chr8:11565574	chr9:76992099~76993108:+
THCA	trans	rs1707322	0.964	rs10890358	ENSG00000255397.1	AC022182.2	-6.51	1.98e-10	0.000277	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr8:60937705~60939871:-
THCA	trans	rs12472274	0.941	rs12616232	ENSG00000224699.7	LAMTOR5-AS1	-6.51	1.98e-10	0.000277	-0.25	-0.29	Phospholipid levels (plasma);	chr2:238171452	chr1:110347116~110443817:+
THCA	trans	rs853679	0.567	rs13196606	ENSG00000228078.1	HLA-U	-6.51	1.98e-10	0.000277	-0.39	-0.29	Depression;	chr6:28402301	chr6:29934101~29934286:+
THCA	trans	rs7112043	1	rs7112043	ENSG00000225531.1	RP11-196I18.3	6.5	1.99e-10	0.000279	0.36	0.29	Lung disease severity in cystic fibrosis;	chr11:34767839	chr9:107116829~107117557:+
THCA	trans	rs4784054	0.803	rs34295929	ENSG00000230849.2	GOT2P2	6.5	2e-10	0.00028	0.46	0.29	Blood metabolite levels;	chr16:58748936	chr1:173141100~173142350:-
THCA	trans	rs7824557	0.815	rs958648	ENSG00000229857.1	RP11-159H20.3	6.5	2.01e-10	0.00028	0.34	0.29	Retinal vascular caliber;	chr8:11246386	chr9:76992099~76993108:+
THCA	trans	rs10816533	1	rs28786462	ENSG00000232063.1	RP11-307E17.8	6.5	2.01e-10	0.000281	0.79	0.29	Height;	chr9:96830709	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs12339579	ENSG00000232063.1	RP11-307E17.8	6.5	2.01e-10	0.000281	0.79	0.29	Height;	chr9:96832329	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs28844439	ENSG00000232063.1	RP11-307E17.8	6.5	2.01e-10	0.000281	0.79	0.29	Height;	chr9:96835103	chr9:94332476~94360948:+
THCA	trans	rs10816533	1	rs7856667	ENSG00000232063.1	RP11-307E17.8	6.5	2.01e-10	0.000281	0.79	0.29	Height;	chr9:96842897	chr9:94332476~94360948:+
THCA	trans	rs4879656	0.872	rs10758180	ENSG00000215007.3	DNAJA1P3	-6.5	2.02e-10	0.000282	-0.33	-0.29	Menopause (age at onset);	chr9:33045149	chrX:107351650~107352843:-
THCA	trans	rs11098499	1	rs6849889	ENSG00000253326.2	RP11-261C10.7	6.5	2.02e-10	0.000282	0.39	0.29	Corneal astigmatism;	chr4:119265193	chr1:243054861~243056394:-
THCA	trans	rs9649213	0.593	rs35983874	ENSG00000225169.1	BRI3P1	6.5	2.03e-10	0.000284	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr1:100213293~100213670:+
THCA	trans	rs7819412	0.527	rs7821914	ENSG00000229857.1	RP11-159H20.3	6.5	2.03e-10	0.000284	0.35	0.29	Triglycerides;	chr8:10947505	chr9:76992099~76993108:+
THCA	trans	rs847577	0.677	rs1495525	ENSG00000225169.1	BRI3P1	-6.5	2.03e-10	0.000284	-0.38	-0.29	Breast cancer;	chr7:98196920	chr1:100213293~100213670:+
THCA	trans	rs3096299	0.503	rs4785677	ENSG00000215030.5	RPL13P12	-6.5	2.04e-10	0.000284	-0.3	-0.29	Multiple myeloma (IgH translocation);	chr16:89488693	chr17:17383377~17384012:-
THCA	trans	rs7520050	0.751	rs592214	ENSG00000255397.1	AC022182.2	6.5	2.04e-10	0.000285	0.38	0.29	Reticulocyte count;Red blood cell count;	chr1:45558833	chr8:60937705~60939871:-
THCA	trans	rs11098499	1	rs35643470	ENSG00000253326.2	RP11-261C10.7	6.5	2.04e-10	0.000285	0.39	0.29	Corneal astigmatism;	chr4:119263793	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.564	rs2736293	ENSG00000254153.1	CTA-398F10.2	6.5	2.04e-10	0.000285	0.32	0.29	Retinal vascular caliber;	chr8:11377104	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs2736294	ENSG00000254153.1	CTA-398F10.2	6.5	2.04e-10	0.000285	0.32	0.29	Retinal vascular caliber;	chr8:11377117	chr8:8456909~8461337:-
THCA	trans	rs3956705	0.798	rs1045477	ENSG00000176826.14	FKBP9P1	-6.5	2.05e-10	0.000286	-0.38	-0.29	Red cell distribution width;	chr7:32869092	chr7:55681074~55713252:-
THCA	trans	rs11098499	0.955	rs11944880	ENSG00000253326.2	RP11-261C10.7	-6.5	2.06e-10	0.000287	-0.39	-0.29	Corneal astigmatism;	chr4:119238179	chr1:243054861~243056394:-
THCA	trans	rs11992162	0.569	rs11786149	ENSG00000253893.2	FAM85B	6.5	2.06e-10	0.000287	0.4	0.29	Monocyte count;	chr8:11943309	chr8:8167819~8226614:-
THCA	trans	rs2898290	0.592	rs2736342	ENSG00000229857.1	RP11-159H20.3	6.5	2.07e-10	0.000289	0.37	0.29	Systolic blood pressure;	chr8:11489780	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.662	rs13254942	ENSG00000253893.2	FAM85B	6.5	2.08e-10	0.00029	0.39	0.29	Neuroticism;	chr8:10400168	chr8:8167819~8226614:-
THCA	trans	rs864643	0.945	rs529839	ENSG00000183298.5	RP11-556K13.1	6.5	2.08e-10	0.00029	0.48	0.29	Attention deficit hyperactivity disorder;	chr3:39525267	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs546031	ENSG00000183298.5	RP11-556K13.1	6.5	2.08e-10	0.00029	0.48	0.29	Attention deficit hyperactivity disorder;	chr3:39529886	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs569888	ENSG00000183298.5	RP11-556K13.1	6.5	2.08e-10	0.00029	0.48	0.29	Attention deficit hyperactivity disorder;	chr3:39530165	chr1:101786340~101787219:-
THCA	trans	rs864643	1	rs946409	ENSG00000183298.5	RP11-556K13.1	6.5	2.08e-10	0.00029	0.48	0.29	Attention deficit hyperactivity disorder;	chr3:39531549	chr1:101786340~101787219:-
THCA	trans	rs7819412	0.522	rs4642600	ENSG00000229857.1	RP11-159H20.3	6.5	2.08e-10	0.000291	0.39	0.29	Triglycerides;	chr8:11155515	chr9:76992099~76993108:+
THCA	trans	rs2898290	0.622	rs978802	ENSG00000256560.1	LINC01486	-6.5	2.08e-10	0.000291	-0.36	-0.29	Systolic blood pressure;	chr8:11485769	chr12:109354083~109359488:-
THCA	trans	rs7746199	0.736	rs35037868	ENSG00000253570.1	RNF5P1	6.5	2.08e-10	0.000291	0.82	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr8:38600661~38601200:-
THCA	trans	rs8067354	0.645	rs2645492	ENSG00000187870.7	RNFT1P3	-6.5	2.09e-10	0.000292	-0.45	-0.29	Hemoglobin concentration;	chr17:59798193	chr17:20743333~20754501:-
THCA	trans	rs6600671	1	rs1832558	ENSG00000270392.2	PFN1P2	6.5	2.1e-10	0.000293	0.28	0.29	Hip geometry;	chr1:121435521	chr1:120432204~120434052:-
THCA	trans	rs9649213	0.574	rs12873	ENSG00000225169.1	BRI3P1	6.5	2.11e-10	0.000294	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr1:100213293~100213670:+
THCA	trans	rs6600671	0.967	rs11249349	ENSG00000270392.2	PFN1P2	6.5	2.11e-10	0.000294	0.28	0.29	Hip geometry;	chr1:121437310	chr1:120432204~120434052:-
THCA	trans	rs7829975	0.742	rs7832968	ENSG00000229857.1	RP11-159H20.3	-6.5	2.12e-10	0.000295	-0.35	-0.29	Mood instability;	chr8:8795379	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.774	rs35039922	ENSG00000256560.1	LINC01486	6.49	2.12e-10	0.000296	0.34	0.29	Mood instability;	chr8:8817815	chr12:109354083~109359488:-
THCA	trans	rs1190596	0.525	rs7153005	ENSG00000181359.5	HSP90AA6P	6.49	2.13e-10	0.000297	0.41	0.29	Behavioural disinhibition (generation interaction);	chr14:102232262	chr4:170581470~170605450:-
THCA	trans	rs6964833	1	rs6964833	ENSG00000214544.6	GTF2IRD2P1	-6.49	2.13e-10	0.000297	-0.42	-0.29	Menarche (age at onset);	chr7:74687575	chr7:73242751~73280119:-
THCA	trans	rs902774	0.818	rs56207534	ENSG00000254285.3	KRT8P3	-6.49	2.13e-10	0.000297	-0.59	-0.29	Prostate cancer;	chr12:52873525	chr8:61578220~61579668:+
THCA	trans	rs9616064	0.531	rs66909472	ENSG00000258384.1	AC068831.6	6.49	2.14e-10	0.000298	0.35	0.29	Urate levels in obese individuals;	chr22:46654313	chr15:90952239~90955225:-
THCA	trans	rs9616064	0.531	rs17821649	ENSG00000258384.1	AC068831.6	6.49	2.14e-10	0.000298	0.35	0.29	Urate levels in obese individuals;	chr22:46654490	chr15:90952239~90955225:-
THCA	trans	rs9616064	0.531	rs9616086	ENSG00000258384.1	AC068831.6	6.49	2.14e-10	0.000298	0.35	0.29	Urate levels in obese individuals;	chr22:46654847	chr15:90952239~90955225:-
THCA	trans	rs6601327	0.606	rs9644707	ENSG00000253893.2	FAM85B	6.49	2.14e-10	0.000298	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9732606	chr8:8167819~8226614:-
THCA	trans	rs853679	0.599	rs13193295	ENSG00000228022.4	HCG20	-6.49	2.15e-10	0.000299	-0.72	-0.29	Depression;	chr6:28035450	chr6:30766825~30792250:+
THCA	trans	rs9914988	0.619	rs9898529	ENSG00000267449.1	RP11-264B14.2	6.49	2.15e-10	0.000299	0.44	0.29	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28991843	chr17:61069856~61070356:-
THCA	trans	rs9650657	0.504	rs10093053	ENSG00000254153.1	CTA-398F10.2	6.49	2.15e-10	0.000299	0.32	0.29	Neuroticism;	chr8:11179678	chr8:8456909~8461337:-
THCA	trans	rs9649213	0.593	rs3801264	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs1468338	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs2158553	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs10808107	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.613	rs10953256	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.613	rs2286074	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs7789380	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs6948540	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.574	rs6979373	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.574	rs34717219	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs62478177	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs3801263	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.555	rs12667634	ENSG00000225169.1	BRI3P1	6.49	2.15e-10	3e-04	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr1:100213293~100213670:+
THCA	trans	rs9393777	0.777	rs56114371	ENSG00000253570.1	RNF5P1	6.49	2.16e-10	3e-04	0.8	0.29	Intelligence (multi-trait analysis);	chr6:27307055	chr8:38600661~38601200:-
THCA	trans	rs7647973	0.71	rs1491983	ENSG00000197582.5	GPX1P1	6.49	2.16e-10	0.000301	0.53	0.29	Menarche (age at onset);	chr3:49602370	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.677	rs11130211	ENSG00000197582.5	GPX1P1	6.49	2.16e-10	0.000301	0.53	0.29	Menarche (age at onset);	chr3:49607776	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.667	rs11721148	ENSG00000197582.5	GPX1P1	6.49	2.16e-10	0.000301	0.53	0.29	Menarche (age at onset);	chr3:49609236	chrX:13378735~13379340:-
THCA	trans	rs7929679	0.521	rs7122506	ENSG00000225531.1	RP11-196I18.3	6.49	2.16e-10	0.000301	0.36	0.29	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34765306	chr9:107116829~107117557:+
THCA	trans	rs9649213	0.593	rs7796611	ENSG00000225169.1	BRI3P1	6.49	2.16e-10	0.000301	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.574	rs13238610	ENSG00000225169.1	BRI3P1	6.49	2.16e-10	0.000301	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr1:100213293~100213670:+
THCA	trans	rs902774	0.818	rs4919763	ENSG00000254285.3	KRT8P3	-6.49	2.17e-10	0.000301	-0.61	-0.29	Prostate cancer;	chr12:52885839	chr8:61578220~61579668:+
THCA	trans	rs902774	0.818	rs55914512	ENSG00000254285.3	KRT8P3	-6.49	2.17e-10	0.000301	-0.61	-0.29	Prostate cancer;	chr12:52888490	chr8:61578220~61579668:+
THCA	trans	rs902774	0.818	rs73108466	ENSG00000254285.3	KRT8P3	-6.49	2.17e-10	0.000301	-0.61	-0.29	Prostate cancer;	chr12:52889857	chr8:61578220~61579668:+
THCA	trans	rs902774	0.818	rs55999178	ENSG00000254285.3	KRT8P3	-6.49	2.17e-10	0.000301	-0.61	-0.29	Prostate cancer;	chr12:52890576	chr8:61578220~61579668:+
THCA	trans	rs902774	0.818	rs4919743	ENSG00000248568.1	KRT8P48	-6.49	2.17e-10	0.000301	-0.55	-0.29	Prostate cancer;	chr12:52915800	chr5:146706381~146707600:-
THCA	trans	rs7824557	0.564	rs7828263	ENSG00000254153.1	CTA-398F10.2	6.49	2.17e-10	0.000301	0.33	0.29	Retinal vascular caliber;	chr8:11374377	chr8:8456909~8461337:-
THCA	trans	rs9649213	0.593	rs6963210	ENSG00000225169.1	BRI3P1	6.49	2.17e-10	0.000302	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.574	rs9648908	ENSG00000225169.1	BRI3P1	6.49	2.17e-10	0.000302	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs7797943	ENSG00000225169.1	BRI3P1	6.49	2.17e-10	0.000302	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr1:100213293~100213670:+
THCA	trans	rs2975734	0.709	rs4841298	ENSG00000253893.2	FAM85B	6.49	2.18e-10	0.000303	0.41	0.29	Chronotype;Morning vs. evening chronotype;	chr8:10254127	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.777	rs560544	ENSG00000229857.1	RP11-159H20.3	6.49	2.18e-10	0.000303	0.35	0.29	Mood instability;	chr8:8779919	chr9:76992099~76993108:+
THCA	trans	rs864643	0.773	rs11915323	ENSG00000183298.5	RP11-556K13.1	-6.49	2.2e-10	0.000305	-0.44	-0.29	Attention deficit hyperactivity disorder;	chr3:39551612	chr1:101786340~101787219:-
THCA	trans	rs7824557	0.547	rs4512344	ENSG00000256560.1	LINC01486	-6.49	2.2e-10	0.000306	-0.36	-0.29	Retinal vascular caliber;	chr8:11221272	chr12:109354083~109359488:-
THCA	trans	rs9649213	0.593	rs2107716	ENSG00000225169.1	BRI3P1	6.49	2.2e-10	0.000306	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr1:100213293~100213670:+
THCA	trans	rs2736337	0.53	rs2003422	ENSG00000253893.2	FAM85B	-6.49	2.2e-10	0.000307	-0.37	-0.29	Rheumatoid arthritis;	chr8:11445628	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2736295	ENSG00000254153.1	CTA-398F10.2	-6.49	2.21e-10	0.000307	-0.32	-0.29	Retinal vascular caliber;	chr8:11377271	chr8:8456909~8461337:-
THCA	trans	rs3740713	1	rs73440625	ENSG00000236090.2	LDHAP3	6.49	2.21e-10	0.000307	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr2:41819747~41820754:+
THCA	trans	rs3764796	0.609	rs73208598	ENSG00000250030.2	RP11-584P21.4	6.49	2.21e-10	0.000307	0.58	0.29	Calcium levels;	chr8:17296783	chr4:67446267~67446574:+
THCA	trans	rs853679	0.607	rs13199649	ENSG00000228022.4	HCG20	-6.49	2.21e-10	0.000307	-0.73	-0.29	Depression;	chr6:27901014	chr6:30766825~30792250:+
THCA	trans	rs6601327	0.641	rs7462070	ENSG00000253893.2	FAM85B	6.49	2.22e-10	0.000308	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9713854	chr8:8167819~8226614:-
THCA	trans	rs804280	0.56	rs10503426	ENSG00000256560.1	LINC01486	6.49	2.22e-10	0.000308	0.35	0.29	Myopia (pathological);	chr8:11731874	chr12:109354083~109359488:-
THCA	trans	rs453301	0.522	rs1964356	ENSG00000229857.1	RP11-159H20.3	-6.49	2.23e-10	0.00031	-0.35	-0.29	Joint mobility (Beighton score);	chr8:8995760	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.875	rs6981523	ENSG00000256560.1	LINC01486	-6.49	2.24e-10	0.000311	-0.35	-0.29	Triglycerides;	chr8:11204283	chr12:109354083~109359488:-
THCA	trans	rs2950393	0.929	rs7980835	ENSG00000228224.3	NACAP1	6.49	2.24e-10	0.000312	0.29	0.29	Platelet distribution width;	chr12:56676847	chr8:101361794~101372707:+
THCA	trans	rs2950393	0.929	rs10747769	ENSG00000228224.3	NACAP1	6.49	2.24e-10	0.000312	0.29	0.29	Platelet distribution width;	chr12:56677056	chr8:101361794~101372707:+
THCA	trans	rs6087990	0.735	rs6087420	ENSG00000253915.1	MAPRE1P1	6.49	2.24e-10	0.000312	0.37	0.29	Ulcerative colitis;	chr20:32771585	chr8:135625185~135625981:-
THCA	trans	rs3956705	0.798	rs6462427	ENSG00000176826.14	FKBP9P1	-6.48	2.26e-10	0.000314	-0.38	-0.29	Red cell distribution width;	chr7:32867732	chr7:55681074~55713252:-
THCA	trans	rs902774	0.818	rs4919742	ENSG00000254285.3	KRT8P3	-6.48	2.27e-10	0.000315	-0.6	-0.29	Prostate cancer;	chr12:52879180	chr8:61578220~61579668:+
THCA	trans	rs2975734	0.674	rs6983870	ENSG00000253893.2	FAM85B	6.48	2.27e-10	0.000315	0.4	0.29	Chronotype;Morning vs. evening chronotype;	chr8:10253784	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.905	rs7836953	ENSG00000229857.1	RP11-159H20.3	-6.48	2.27e-10	0.000315	-0.35	-0.29	Monocyte count;	chr8:11978203	chr9:76992099~76993108:+
THCA	trans	rs2736345	1	rs922483	ENSG00000253893.2	FAM85B	-6.48	2.27e-10	0.000315	-0.39	-0.29	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11494403	chr8:8167819~8226614:-
THCA	trans	rs7200543	1	rs6498541	ENSG00000250569.1	NTAN1P2	6.48	2.27e-10	0.000315	0.29	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr8:86481754~86483002:-
THCA	trans	rs7824557	0.527	rs2572369	ENSG00000254153.1	CTA-398F10.2	6.48	2.27e-10	0.000316	0.32	0.29	Retinal vascular caliber;	chr8:11381088	chr8:8456909~8461337:-
THCA	trans	rs12472274	0.941	rs2880131	ENSG00000224699.7	LAMTOR5-AS1	-6.48	2.28e-10	0.000317	-0.25	-0.29	Phospholipid levels (plasma);	chr2:238180510	chr1:110347116~110443817:+
THCA	trans	rs9292918	1	rs6864928	ENSG00000231752.4	EMBP1	-6.48	2.29e-10	0.000318	-0.42	-0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45298509	chr1:121519112~121571892:+
THCA	trans	rs2980439	0.517	rs17594065	ENSG00000229857.1	RP11-159H20.3	6.48	2.3e-10	0.000319	0.36	0.29	Neuroticism;	chr8:8247883	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.714	rs11777085	ENSG00000256560.1	LINC01486	6.48	2.31e-10	0.00032	0.34	0.29	Mood instability;	chr8:8814919	chr12:109354083~109359488:-
THCA	trans	rs4879656	0.872	rs2274767	ENSG00000215007.3	DNAJA1P3	6.48	2.31e-10	0.000321	0.33	0.29	Menopause (age at onset);	chr9:33047400	chrX:107351650~107352843:-
THCA	trans	rs7662987	0.534	rs34600299	ENSG00000233859.2	ADH5P4	6.48	2.31e-10	0.000321	0.65	0.29	Smoking initiation;	chr4:99242390	chr6:65836930~65838039:-
THCA	trans	rs902774	0.759	rs4919707	ENSG00000254285.3	KRT8P3	-6.48	2.32e-10	0.000322	-0.61	-0.29	Prostate cancer;	chr12:52895864	chr8:61578220~61579668:+
THCA	trans	rs902774	0.818	rs56095813	ENSG00000254285.3	KRT8P3	-6.48	2.32e-10	0.000322	-0.61	-0.29	Prostate cancer;	chr12:52900963	chr8:61578220~61579668:+
THCA	trans	rs1707322	1	rs2458400	ENSG00000255397.1	AC022182.2	6.48	2.32e-10	0.000322	0.4	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.547	rs6601570	ENSG00000256560.1	LINC01486	-6.48	2.32e-10	0.000322	-0.36	-0.29	Retinal vascular caliber;	chr8:11221858	chr12:109354083~109359488:-
THCA	trans	rs66823261	0.778	rs2906332	ENSG00000262094.1	AC139099.5	-6.48	2.33e-10	0.000323	-0.44	-0.29	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr17:83220527~83227721:-
THCA	trans	rs6885307	1	rs62369898	ENSG00000231752.4	EMBP1	6.48	2.33e-10	0.000323	0.43	0.29	Age at first birth;	chr5:45073687	chr1:121519112~121571892:+
THCA	trans	rs3808502	0.526	rs1042701	ENSG00000229857.1	RP11-159H20.3	6.48	2.33e-10	0.000323	0.37	0.29	Neuroticism;	chr8:11564536	chr9:76992099~76993108:+
THCA	trans	rs3808502	0.526	rs7843987	ENSG00000229857.1	RP11-159H20.3	6.48	2.33e-10	0.000323	0.37	0.29	Neuroticism;	chr8:11564621	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.513	rs4314618	ENSG00000229857.1	RP11-159H20.3	6.48	2.35e-10	0.000326	0.36	0.29	Neuroticism;	chr8:10959262	chr9:76992099~76993108:+
THCA	trans	rs6087990	0.735	rs6058892	ENSG00000253915.1	MAPRE1P1	6.48	2.36e-10	0.000327	0.37	0.29	Ulcerative colitis;	chr20:32800655	chr8:135625185~135625981:-
THCA	trans	rs3740713	1	rs75487138	ENSG00000236090.2	LDHAP3	6.48	2.36e-10	0.000328	0.52	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr2:41819747~41820754:+
THCA	trans	rs34421088	0.56	rs2248325	ENSG00000256560.1	LINC01486	-6.48	2.37e-10	0.000328	-0.36	-0.29	Neuroticism;	chr8:11539365	chr12:109354083~109359488:-
THCA	trans	rs34421088	0.56	rs2248316	ENSG00000256560.1	LINC01486	-6.48	2.37e-10	0.000328	-0.36	-0.29	Neuroticism;	chr8:11539564	chr12:109354083~109359488:-
THCA	trans	rs34421088	0.56	rs2248315	ENSG00000256560.1	LINC01486	-6.48	2.37e-10	0.000328	-0.36	-0.29	Neuroticism;	chr8:11539577	chr12:109354083~109359488:-
THCA	trans	rs7647973	0.667	rs4241405	ENSG00000197582.5	GPX1P1	6.48	2.37e-10	0.000329	0.52	0.29	Menarche (age at onset);	chr3:49604594	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.71	rs12637313	ENSG00000197582.5	GPX1P1	6.48	2.37e-10	0.000329	0.52	0.29	Menarche (age at onset);	chr3:49608025	chrX:13378735~13379340:-
THCA	trans	rs335206	0.967	rs335211	ENSG00000256427.1	RP11-118B22.4	-6.48	2.37e-10	0.000329	-0.31	-0.29	QRS duration;	chr5:123166081	chr12:9246497~9257960:+
THCA	trans	rs7819412	0.521	rs13256092	ENSG00000253893.2	FAM85B	6.48	2.38e-10	0.00033	0.4	0.29	Triglycerides;	chr8:11142867	chr8:8167819~8226614:-
THCA	trans	rs9649213	0.593	rs34534766	ENSG00000225169.1	BRI3P1	6.48	2.39e-10	0.000331	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr1:100213293~100213670:+
THCA	trans	rs864643	0.738	rs13063581	ENSG00000183298.5	RP11-556K13.1	-6.48	2.39e-10	0.000331	-0.44	-0.29	Attention deficit hyperactivity disorder;	chr3:39551168	chr1:101786340~101787219:-
THCA	trans	rs7833986	0.818	rs79824205	ENSG00000244245.1	RP11-120B7.1	6.47	2.39e-10	0.000331	0.38	0.29	Height;	chr8:56180674	chr5:108593609~108593967:+
THCA	trans	rs7833986	1	rs72654002	ENSG00000244245.1	RP11-120B7.1	6.47	2.41e-10	0.000334	0.38	0.29	Height;	chr8:56183380	chr5:108593609~108593967:+
THCA	trans	rs7833986	1	rs66553445	ENSG00000244245.1	RP11-120B7.1	6.47	2.41e-10	0.000334	0.38	0.29	Height;	chr8:56184222	chr5:108593609~108593967:+
THCA	trans	rs7833986	1	rs34608229	ENSG00000244245.1	RP11-120B7.1	6.47	2.41e-10	0.000334	0.38	0.29	Height;	chr8:56184458	chr5:108593609~108593967:+
THCA	trans	rs7833986	1	rs34404111	ENSG00000244245.1	RP11-120B7.1	6.47	2.41e-10	0.000334	0.38	0.29	Height;	chr8:56186631	chr5:108593609~108593967:+
THCA	trans	rs7833986	1	rs4263734	ENSG00000244245.1	RP11-120B7.1	6.47	2.41e-10	0.000334	0.38	0.29	Height;	chr8:56187372	chr5:108593609~108593967:+
THCA	trans	rs748404	0.723	rs11853991	ENSG00000180867.10	PDIA3P1	-6.47	2.44e-10	0.000337	-0.24	-0.29	Lung cancer;	chr15:43265351	chr1:147178113~147179622:+
THCA	trans	rs9649213	0.593	rs10953257	ENSG00000225169.1	BRI3P1	-6.47	2.44e-10	0.000338	-0.36	-0.29	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr1:100213293~100213670:+
THCA	trans	rs453301	0.571	rs330048	ENSG00000229857.1	RP11-159H20.3	6.47	2.44e-10	0.000338	0.35	0.29	Joint mobility (Beighton score);	chr8:9229768	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.538	rs2272597	ENSG00000253893.2	FAM85B	6.47	2.45e-10	0.000339	0.38	0.29	Neuroticism;	chr8:10243014	chr8:8167819~8226614:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000227586.5	RP11-162A23.5	6.47	2.45e-10	0.00034	0.38	0.29	Cognitive function;	chr12:55990903	chr10:123171535~123171875:-
THCA	trans	rs7829975	0.536	rs2980439	ENSG00000256560.1	LINC01486	6.47	2.46e-10	0.00034	0.32	0.29	Mood instability;	chr8:8237348	chr12:109354083~109359488:-
THCA	trans	rs2645424	0.671	rs2294138	ENSG00000229857.1	RP11-159H20.3	-6.47	2.47e-10	0.000342	-0.37	-0.29	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847630	chr9:76992099~76993108:+
THCA	trans	rs335206	1	rs335206	ENSG00000256427.1	RP11-118B22.4	-6.47	2.47e-10	0.000342	-0.31	-0.29	QRS duration;	chr5:123168872	chr12:9246497~9257960:+
THCA	trans	rs2950393	0.895	rs2958123	ENSG00000228224.3	NACAP1	6.47	2.47e-10	0.000342	0.29	0.29	Platelet distribution width;	chr12:56668441	chr8:101361794~101372707:+
THCA	trans	rs9649213	0.537	rs6971825	ENSG00000225169.1	BRI3P1	6.47	2.47e-10	0.000342	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr1:100213293~100213670:+
THCA	trans	rs11098499	0.955	rs1511018	ENSG00000253326.2	RP11-261C10.7	6.47	2.49e-10	0.000344	0.39	0.29	Corneal astigmatism;	chr4:119240425	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs1511019	ENSG00000253326.2	RP11-261C10.7	6.47	2.49e-10	0.000344	0.39	0.29	Corneal astigmatism;	chr4:119244852	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.955	rs35434465	ENSG00000253326.2	RP11-261C10.7	6.47	2.49e-10	0.000344	0.39	0.29	Corneal astigmatism;	chr4:119248223	chr1:243054861~243056394:-
THCA	trans	rs11098499	1	rs6837898	ENSG00000253326.2	RP11-261C10.7	6.47	2.49e-10	0.000344	0.39	0.29	Corneal astigmatism;	chr4:119257999	chr1:243054861~243056394:-
THCA	trans	rs1707322	0.721	rs7520123	ENSG00000255397.1	AC022182.2	-6.47	2.49e-10	0.000345	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.535	rs7011756	ENSG00000256560.1	LINC01486	-6.47	2.5e-10	0.000345	-0.35	-0.29	Neuroticism;	chr8:11162068	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.735	rs2424907	ENSG00000253915.1	MAPRE1P1	6.47	2.53e-10	0.000349	0.37	0.29	Ulcerative colitis;	chr20:32772013	chr8:135625185~135625981:-
THCA	trans	rs902774	0.818	rs4919740	ENSG00000220378.3	KRT8P42	-6.47	2.53e-10	0.000349	-0.57	-0.29	Prostate cancer;	chr12:52877187	chr6:134296997~134298695:-
THCA	trans	rs7829975	0.811	rs7011229	ENSG00000229857.1	RP11-159H20.3	6.47	2.53e-10	0.00035	0.34	0.29	Mood instability;	chr8:8685814	chr9:76992099~76993108:+
THCA	trans	rs2288327	0.818	rs13009158	ENSG00000269800.1	PLEKHA3P1	6.46	2.54e-10	0.000351	0.41	0.29	Atrial fibrillation;	chr2:178600227	chr19:41521043~41521989:-
THCA	trans	rs2950393	0.929	rs7973157	ENSG00000228224.3	NACAP1	-6.46	2.55e-10	0.000352	-0.3	-0.29	Platelet distribution width;	chr12:56655409	chr8:101361794~101372707:+
THCA	trans	rs902774	0.818	rs73106451	ENSG00000248568.1	KRT8P48	-6.46	2.55e-10	0.000353	-0.58	-0.29	Prostate cancer;	chr12:52872955	chr5:146706381~146707600:-
THCA	trans	rs9649213	0.593	rs6947208	ENSG00000225169.1	BRI3P1	6.46	2.55e-10	0.000353	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr1:100213293~100213670:+
THCA	trans	rs7032940	0.677	rs1331310	ENSG00000228236.2	TXNP5	6.46	2.56e-10	0.000354	0.34	0.29	Height;	chr9:110179601	chr2:149068596~149068910:-
THCA	trans	rs6087990	0.871	rs2424905	ENSG00000253915.1	MAPRE1P1	6.46	2.56e-10	0.000354	0.37	0.29	Ulcerative colitis;	chr20:32765121	chr8:135625185~135625981:-
THCA	trans	rs3002142	0.731	rs3008620	ENSG00000219201.4	RP11-181C21.4	-6.46	2.56e-10	0.000354	-0.41	-0.29	LDL peak particle diameter (total fat intake interaction);	chr1:222629584	chr1:77810861~77811781:-
THCA	trans	rs9650657	0.504	rs6601566	ENSG00000229857.1	RP11-159H20.3	6.46	2.58e-10	0.000357	0.37	0.29	Neuroticism;	chr8:11185465	chr9:76992099~76993108:+
THCA	trans	rs453301	0.653	rs11784393	ENSG00000256560.1	LINC01486	6.46	2.6e-10	0.000359	0.32	0.29	Joint mobility (Beighton score);	chr8:9045624	chr12:109354083~109359488:-
THCA	trans	rs3956705	0.798	rs35443929	ENSG00000176826.14	FKBP9P1	-6.46	2.6e-10	0.000359	-0.37	-0.29	Red cell distribution width;	chr7:32895822	chr7:55681074~55713252:-
THCA	trans	rs6601327	0.613	rs11785458	ENSG00000253893.2	FAM85B	6.46	2.61e-10	0.00036	0.36	0.29	Multiple myeloma (hyperdiploidy);	chr8:9649300	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.638	rs1416706	ENSG00000255397.1	AC022182.2	6.46	2.61e-10	0.00036	0.41	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr8:60937705~60939871:-
THCA	trans	rs6087990	1	rs2018002	ENSG00000253915.1	MAPRE1P1	6.46	2.61e-10	0.00036	0.37	0.29	Ulcerative colitis;	chr20:32763817	chr8:135625185~135625981:-
THCA	trans	rs2950393	0.927	rs11171914	ENSG00000228224.3	NACAP1	-6.46	2.61e-10	0.00036	-0.3	-0.29	Platelet distribution width;	chr12:56649462	chr8:101361794~101372707:+
THCA	trans	rs9467773	0.55	rs4712987	ENSG00000242375.1	RP11-498P14.3	-6.46	2.61e-10	0.000361	-0.4	-0.29	Intelligence (multi-trait analysis);	chr6:26399387	chr9:97195351~97197687:-
THCA	trans	rs9329221	0.686	rs60755617	ENSG00000253893.2	FAM85B	-6.46	2.62e-10	0.000362	-0.38	-0.29	Neuroticism;	chr8:10385817	chr8:8167819~8226614:-
THCA	trans	rs6087990	1	rs1007123	ENSG00000253915.1	MAPRE1P1	6.46	2.63e-10	0.000362	0.37	0.29	Ulcerative colitis;	chr20:32758034	chr8:135625185~135625981:-
THCA	trans	rs1391708	0.834	rs4612852	ENSG00000121089.4	NACA3P	-6.46	2.63e-10	0.000363	-0.47	-0.29	Airway wall thickness;	chr12:56902257	chr4:164943290~164943937:+
THCA	trans	rs7824557	0.527	rs2736296	ENSG00000254153.1	CTA-398F10.2	6.46	2.63e-10	0.000363	0.32	0.29	Retinal vascular caliber;	chr8:11377335	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.51	rs2736297	ENSG00000254153.1	CTA-398F10.2	6.46	2.63e-10	0.000363	0.32	0.29	Retinal vascular caliber;	chr8:11377376	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.527	rs2736298	ENSG00000254153.1	CTA-398F10.2	6.46	2.63e-10	0.000363	0.32	0.29	Retinal vascular caliber;	chr8:11377627	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.527	rs57629785	ENSG00000254153.1	CTA-398F10.2	6.46	2.63e-10	0.000363	0.32	0.29	Retinal vascular caliber;	chr8:11377641	chr8:8456909~8461337:-
THCA	trans	rs3740713	1	rs73440634	ENSG00000236090.2	LDHAP3	6.46	2.63e-10	0.000363	0.51	0.29	Amyotrophic lateral sclerosis (sporadic);	chr11:18451999	chr2:41819747~41820754:+
THCA	trans	rs4646450	0.735	rs10953287	ENSG00000228834.1	RP11-249L21.4	6.46	2.64e-10	0.000364	0.49	0.29	Blood metabolite levels;	chr7:99324799	chr6:108907615~108907873:-
THCA	trans	rs1707322	1	rs785504	ENSG00000255397.1	AC022182.2	6.46	2.64e-10	0.000365	0.4	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr8:60937705~60939871:-
THCA	trans	rs76228276	0.737	rs72672355	ENSG00000260318.1	COX6CP1	6.46	2.65e-10	0.000365	0.85	0.29	Childhood ear infection;	chr8:99303139	chr16:11903923~11904137:-
THCA	trans	rs1707322	0.928	rs7527244	ENSG00000255397.1	AC022182.2	-6.46	2.66e-10	0.000367	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr8:60937705~60939871:-
THCA	trans	rs335206	1	rs335204	ENSG00000256427.1	RP11-118B22.4	-6.46	2.67e-10	0.000368	-0.31	-0.29	QRS duration;	chr5:123170566	chr12:9246497~9257960:+
THCA	trans	rs864643	0.782	rs561543	ENSG00000188856.6	RPSAP47	6.46	2.67e-10	0.000369	0.44	0.29	Attention deficit hyperactivity disorder;	chr3:39494916	chr8:80558870~80559757:+
THCA	trans	rs6601327	0.613	rs4612345	ENSG00000253893.2	FAM85B	6.46	2.67e-10	0.000369	0.35	0.29	Multiple myeloma (hyperdiploidy);	chr8:9722491	chr8:8167819~8226614:-
THCA	trans	rs6600671	0.934	rs67718113	ENSG00000270392.2	PFN1P2	-6.46	2.68e-10	0.000369	-0.29	-0.29	Hip geometry;	chr1:121497112	chr1:120432204~120434052:-
THCA	trans	rs7829975	0.688	rs6995407	ENSG00000256560.1	LINC01486	6.46	2.68e-10	0.00037	0.35	0.29	Mood instability;	chr8:8527137	chr12:109354083~109359488:-
THCA	trans	rs9649213	0.593	rs7458551	ENSG00000225169.1	BRI3P1	6.45	2.72e-10	0.000374	0.36	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr1:100213293~100213670:+
THCA	trans	rs9616064	0.557	rs5767318	ENSG00000258384.1	AC068831.6	6.45	2.74e-10	0.000377	0.35	0.29	Urate levels in obese individuals;	chr22:46652895	chr15:90952239~90955225:-
THCA	trans	rs7200543	1	rs4985154	ENSG00000250569.1	NTAN1P2	6.45	2.75e-10	0.000379	0.29	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr8:86481754~86483002:-
THCA	trans	rs7200543	1	rs34614532	ENSG00000250569.1	NTAN1P2	6.45	2.75e-10	0.000379	0.29	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr8:86481754~86483002:-
THCA	trans	rs6600671	1	rs6600671	ENSG00000270392.2	PFN1P2	-6.45	2.76e-10	0.00038	-0.29	-0.29	Hip geometry;	chr1:121458637	chr1:120432204~120434052:-
THCA	trans	rs11098499	0.731	rs6846966	ENSG00000253326.2	RP11-261C10.7	6.45	2.76e-10	0.00038	0.38	0.29	Corneal astigmatism;	chr4:119372053	chr1:243054861~243056394:-
THCA	trans	rs6600671	1	rs4844607	ENSG00000270392.2	PFN1P2	-6.45	2.77e-10	0.000381	-0.27	-0.29	Hip geometry;	chr1:121442201	chr1:120432204~120434052:-
THCA	trans	rs9649213	0.593	rs7787858	ENSG00000225169.1	BRI3P1	6.45	2.77e-10	0.000382	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs3801254	ENSG00000225169.1	BRI3P1	6.45	2.77e-10	0.000382	0.37	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr1:100213293~100213670:+
THCA	trans	rs6601327	0.767	rs10109026	ENSG00000253893.2	FAM85B	-6.45	2.77e-10	0.000382	-0.37	-0.29	Multiple myeloma (hyperdiploidy);	chr8:9554476	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.56	rs1478898	ENSG00000229857.1	RP11-159H20.3	6.45	2.78e-10	0.000383	0.36	0.29	Neuroticism;	chr8:11537570	chr9:76992099~76993108:+
THCA	trans	rs12145833	0.679	rs12037698	ENSG00000154608.12	CEP170P1	-6.45	2.78e-10	0.000383	-0.38	-0.29	Obesity (early onset extreme);	chr1:243421043	chr4:118467590~118554204:+
THCA	trans	rs7929679	0.551	rs11032840	ENSG00000225531.1	RP11-196I18.3	6.45	2.79e-10	0.000384	0.36	0.29	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34757917	chr9:107116829~107117557:+
THCA	trans	rs76228276	0.737	rs74864785	ENSG00000260318.1	COX6CP1	6.45	2.79e-10	0.000384	0.85	0.29	Childhood ear infection;	chr8:99197751	chr16:11903923~11904137:-
THCA	trans	rs6601327	0.641	rs7461939	ENSG00000253893.2	FAM85B	6.45	2.79e-10	0.000384	0.35	0.29	Multiple myeloma (hyperdiploidy);	chr8:9714111	chr8:8167819~8226614:-
THCA	trans	rs12145833	0.596	rs10927016	ENSG00000154608.12	CEP170P1	-6.45	2.79e-10	0.000385	-0.39	-0.29	Obesity (early onset extreme);	chr1:243431834	chr4:118467590~118554204:+
THCA	trans	rs2060793	0.519	rs10832285	ENSG00000236360.2	RP11-334A14.2	6.45	2.8e-10	0.000385	0.38	0.29	Vitamin D levels;	chr11:14628031	chr1:52993201~52993702:-
THCA	trans	rs9329221	0.905	rs4841329	ENSG00000229857.1	RP11-159H20.3	6.45	2.8e-10	0.000386	0.35	0.29	Neuroticism;	chr8:10395588	chr9:76992099~76993108:+
THCA	trans	rs76228276	0.529	rs11990603	ENSG00000260318.1	COX6CP1	6.45	2.8e-10	0.000386	0.85	0.29	Childhood ear infection;	chr8:99210604	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.609	rs113176745	ENSG00000260318.1	COX6CP1	6.45	2.8e-10	0.000386	0.85	0.29	Childhood ear infection;	chr8:99232853	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs79477531	ENSG00000260318.1	COX6CP1	6.45	2.8e-10	0.000386	0.85	0.29	Childhood ear infection;	chr8:99251537	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs75904832	ENSG00000260318.1	COX6CP1	6.45	2.8e-10	0.000386	0.85	0.29	Childhood ear infection;	chr8:99261094	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11995289	ENSG00000260318.1	COX6CP1	6.45	2.8e-10	0.000386	0.85	0.29	Childhood ear infection;	chr8:99270430	chr16:11903923~11904137:-
THCA	trans	rs2645424	0.666	rs2272767	ENSG00000269898.1	RP11-568J23.4	-6.45	2.81e-10	0.000387	-0.34	-0.29	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853550	chr16:85743287~85744225:+
THCA	trans	rs2645424	0.762	rs2294139	ENSG00000229857.1	RP11-159H20.3	-6.45	2.82e-10	0.000388	-0.37	-0.29	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847933	chr9:76992099~76993108:+
THCA	trans	rs7647973	0.71	rs2029591	ENSG00000197582.5	GPX1P1	-6.45	2.82e-10	0.000388	-0.52	-0.29	Menarche (age at onset);	chr3:49609548	chrX:13378735~13379340:-
THCA	trans	rs2336384	1	rs2336384	ENSG00000261819.1	RP11-680G24.4	-6.45	2.83e-10	0.000389	-0.37	-0.29	Platelet count;	chr1:11986006	chr16:14988259~14990160:-
THCA	trans	rs9649213	0.502	rs6465680	ENSG00000225169.1	BRI3P1	6.45	2.83e-10	0.000389	0.36	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr1:100213293~100213670:+
THCA	trans	rs6885307	0.941	rs62369906	ENSG00000231752.4	EMBP1	6.45	2.83e-10	0.000389	0.44	0.29	Age at first birth;	chr5:45100027	chr1:121519112~121571892:+
THCA	trans	rs941207	0.526	rs2950390	ENSG00000228224.3	NACAP1	6.45	2.83e-10	0.00039	0.3	0.29	Platelet count;	chr12:56661507	chr8:101361794~101372707:+
THCA	trans	rs864643	0.898	rs636476	ENSG00000188856.6	RPSAP47	6.45	2.83e-10	0.00039	0.44	0.29	Attention deficit hyperactivity disorder;	chr3:39549841	chr8:80558870~80559757:+
THCA	trans	rs1190596	0.525	rs28565231	ENSG00000181359.5	HSP90AA6P	-6.45	2.83e-10	0.00039	-0.41	-0.29	Behavioural disinhibition (generation interaction);	chr14:102196911	chr4:170581470~170605450:-
THCA	trans	rs877636	1	rs4759229	ENSG00000227586.5	RP11-162A23.5	-6.45	2.84e-10	0.000391	-0.37	-0.29	Cognitive function;	chr12:56080696	chr10:123171535~123171875:-
THCA	trans	rs11098499	1	rs7659194	ENSG00000253326.2	RP11-261C10.7	6.45	2.85e-10	0.000392	0.39	0.29	Corneal astigmatism;	chr4:119285992	chr1:243054861~243056394:-
THCA	trans	rs7809615	0.515	rs10257273	ENSG00000228834.1	RP11-249L21.4	6.45	2.85e-10	0.000393	0.45	0.28	Blood metabolite ratios;	chr7:99590966	chr6:108907615~108907873:-
THCA	trans	rs76228276	0.737	rs76126670	ENSG00000260318.1	COX6CP1	6.45	2.86e-10	0.000393	0.84	0.28	Childhood ear infection;	chr8:99690249	chr16:11903923~11904137:-
THCA	trans	rs7829975	0.846	rs6601724	ENSG00000229857.1	RP11-159H20.3	6.45	2.87e-10	0.000394	0.34	0.28	Mood instability;	chr8:8687362	chr9:76992099~76993108:+
THCA	trans	rs4646450	0.735	rs6972337	ENSG00000228834.1	RP11-249L21.4	6.44	2.87e-10	0.000395	0.49	0.28	Blood metabolite levels;	chr7:99345684	chr6:108907615~108907873:-
THCA	trans	rs9649213	0.593	rs6961438	ENSG00000225169.1	BRI3P1	6.44	2.88e-10	0.000396	0.37	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr1:100213293~100213670:+
THCA	trans	rs4784054	0.568	rs35512562	ENSG00000230849.2	GOT2P2	6.44	2.88e-10	0.000396	0.44	0.28	Blood metabolite levels;	chr16:58805641	chr1:173141100~173142350:-
THCA	trans	rs864643	1	rs559349	ENSG00000183298.5	RP11-556K13.1	6.44	2.89e-10	0.000397	0.47	0.28	Attention deficit hyperactivity disorder;	chr3:39505562	chr1:101786340~101787219:-
THCA	trans	rs34421088	0.506	rs7813424	ENSG00000253893.2	FAM85B	-6.44	2.89e-10	0.000397	-0.38	-0.28	Neuroticism;	chr8:11287008	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.967	rs11250185	ENSG00000256560.1	LINC01486	6.44	2.89e-10	0.000397	0.36	0.28	Monocyte count;	chr8:11975614	chr12:109354083~109359488:-
THCA	trans	rs2288327	0.818	rs16866373	ENSG00000269800.1	PLEKHA3P1	6.44	2.89e-10	0.000398	0.41	0.28	Atrial fibrillation;	chr2:178527353	chr19:41521043~41521989:-
THCA	trans	rs11992162	0.967	rs4841661	ENSG00000256560.1	LINC01486	6.44	2.9e-10	0.000398	0.35	0.28	Monocyte count;	chr8:11975260	chr12:109354083~109359488:-
THCA	trans	rs11992162	1	rs11994417	ENSG00000256560.1	LINC01486	6.44	2.9e-10	0.000398	0.35	0.28	Monocyte count;	chr8:11975753	chr12:109354083~109359488:-
THCA	trans	rs335206	1	rs335201	ENSG00000256427.1	RP11-118B22.4	-6.44	2.9e-10	0.000398	-0.31	-0.28	QRS duration;	chr5:123173955	chr12:9246497~9257960:+
THCA	trans	rs902774	0.818	rs4919743	ENSG00000255815.3	KRT8P11	-6.44	2.9e-10	0.000398	-0.55	-0.28	Prostate cancer;	chr12:52915800	chr9:99305176~99306611:+
THCA	trans	rs76228276	0.737	rs2084554	ENSG00000260318.1	COX6CP1	6.44	2.91e-10	4e-04	0.84	0.28	Childhood ear infection;	chr8:99685142	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs2100220	ENSG00000260318.1	COX6CP1	6.44	2.91e-10	4e-04	0.84	0.28	Childhood ear infection;	chr8:99685234	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs4735632	ENSG00000260318.1	COX6CP1	6.44	2.91e-10	4e-04	0.84	0.28	Childhood ear infection;	chr8:99686271	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs76599759	ENSG00000260318.1	COX6CP1	6.44	2.91e-10	4e-04	0.84	0.28	Childhood ear infection;	chr8:99687826	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs80337710	ENSG00000260318.1	COX6CP1	6.44	2.91e-10	4e-04	0.84	0.28	Childhood ear infection;	chr8:99690946	chr16:11903923~11904137:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000242970.2	AC068522.4	-6.44	2.91e-10	4e-04	-0.43	-0.28	Asthma;	chr12:55970537	chr8:58588420~58588764:-
THCA	trans	rs941207	0.542	rs10876928	ENSG00000257210.1	NACAP3	-6.44	2.91e-10	4e-04	-0.36	-0.28	Platelet count;	chr12:56813646	chr12:93124063~93124543:-
THCA	trans	rs864643	1	rs634338	ENSG00000183298.5	RP11-556K13.1	6.44	2.91e-10	4e-04	0.46	0.28	Attention deficit hyperactivity disorder;	chr3:39522752	chr1:101786340~101787219:-
THCA	trans	rs453301	0.598	rs2921383	ENSG00000256560.1	LINC01486	6.44	2.91e-10	4e-04	0.32	0.28	Joint mobility (Beighton score);	chr8:9034711	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs4660906	ENSG00000255397.1	AC022182.2	-6.44	2.92e-10	0.000402	-0.4	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr8:60937705~60939871:-
THCA	trans	rs13016963	0.584	rs1918881	ENSG00000235105.1	RP11-329A14.1	6.44	2.93e-10	0.000403	0.31	0.28	Esophageal squamous cell carcinoma;Melanoma;	chr2:201325945	chr1:48435967~48437223:+
THCA	trans	rs3808502	0.563	rs12541800	ENSG00000256560.1	LINC01486	6.44	2.93e-10	0.000403	0.35	0.28	Neuroticism;	chr8:11565563	chr12:109354083~109359488:-
THCA	trans	rs9649213	0.574	rs3801257	ENSG00000225169.1	BRI3P1	6.44	2.94e-10	0.000404	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs7803372	ENSG00000225169.1	BRI3P1	6.44	2.94e-10	0.000404	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr1:100213293~100213670:+
THCA	trans	rs6087990	0.871	rs1007122	ENSG00000253915.1	MAPRE1P1	6.44	2.95e-10	0.000405	0.38	0.28	Ulcerative colitis;	chr20:32758195	chr8:135625185~135625981:-
THCA	trans	rs7819412	0.875	rs11250121	ENSG00000256560.1	LINC01486	-6.44	2.95e-10	0.000406	-0.35	-0.28	Triglycerides;	chr8:11202802	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.742	rs1533058	ENSG00000256560.1	LINC01486	6.44	2.96e-10	0.000407	0.34	0.28	Mood instability;	chr8:8827680	chr12:109354083~109359488:-
THCA	trans	rs864643	0.773	rs13077475	ENSG00000188856.6	RPSAP47	-6.44	2.97e-10	0.000408	-0.4	-0.28	Attention deficit hyperactivity disorder;	chr3:39546814	chr8:80558870~80559757:+
THCA	trans	rs7824557	0.872	rs2572417	ENSG00000254153.1	CTA-398F10.2	6.44	2.99e-10	0.00041	0.3	0.28	Retinal vascular caliber;	chr8:11253953	chr8:8456909~8461337:-
THCA	trans	rs4646450	0.636	rs6953476	ENSG00000228834.1	RP11-249L21.4	6.44	3.03e-10	0.000415	0.49	0.28	Blood metabolite levels;	chr7:99323977	chr6:108907615~108907873:-
THCA	trans	rs902774	0.818	rs55958994	ENSG00000250539.1	KRT8P33	-6.44	3.03e-10	0.000415	-0.53	-0.28	Prostate cancer;	chr12:52907235	chr5:123400922~123402344:-
THCA	trans	rs9467711	0.72	rs75782365	ENSG00000280107.1	AL022393.9	-6.44	3.03e-10	0.000416	-0.6	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26408323	chr6:28170845~28172521:+
THCA	trans	rs853679	0.607	rs13199649	ENSG00000253570.1	RNF5P1	6.44	3.04e-10	0.000417	0.81	0.28	Depression;	chr6:27901014	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.659	rs13195509	ENSG00000219392.1	RP1-265C24.5	-6.44	3.05e-10	0.000418	-0.62	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr6:28115628~28116551:+
THCA	trans	rs1707322	0.964	rs6697830	ENSG00000255397.1	AC022182.2	-6.43	3.05e-10	0.000419	-0.4	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs12060274	ENSG00000255397.1	AC022182.2	-6.43	3.05e-10	0.000419	-0.4	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr8:60937705~60939871:-
THCA	trans	rs6600671	0.899	rs2319971	ENSG00000270392.2	PFN1P2	6.43	3.05e-10	0.000419	0.29	0.28	Hip geometry;	chr1:121485184	chr1:120432204~120434052:-
THCA	trans	rs7769051	1	rs9399041	ENSG00000227615.1	RP11-864N7.2	6.43	3.06e-10	0.000419	0.49	0.28	Type 2 diabetes nephropathy;	chr6:132775094	chr11:74745716~74746114:-
THCA	trans	rs7769051	1	rs9493438	ENSG00000227615.1	RP11-864N7.2	6.43	3.06e-10	0.000419	0.49	0.28	Type 2 diabetes nephropathy;	chr6:132777210	chr11:74745716~74746114:-
THCA	trans	rs864643	0.945	rs1768254	ENSG00000183298.5	RP11-556K13.1	6.43	3.06e-10	0.00042	0.47	0.28	Attention deficit hyperactivity disorder;	chr3:39506929	chr1:101786340~101787219:-
THCA	trans	rs9650657	0.572	rs11250098	ENSG00000256560.1	LINC01486	-6.43	3.07e-10	0.000421	-0.34	-0.28	Neuroticism;	chr8:10961097	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs2409756	ENSG00000254153.1	CTA-398F10.2	6.43	3.07e-10	0.000421	0.32	0.28	Retinal vascular caliber;	chr8:11384516	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.765	rs7000132	ENSG00000256560.1	LINC01486	-6.43	3.08e-10	0.000422	-0.36	-0.28	Triglycerides;	chr8:11173426	chr12:109354083~109359488:-
THCA	trans	rs9329221	0.716	rs11989640	ENSG00000253893.2	FAM85B	6.43	3.08e-10	0.000422	0.38	0.28	Neuroticism;	chr8:10398544	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.585	rs1394	ENSG00000253893.2	FAM85B	6.43	3.09e-10	0.000424	0.35	0.28	Multiple myeloma (hyperdiploidy);	chr8:9654144	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2736290	ENSG00000254153.1	CTA-398F10.2	6.43	3.1e-10	0.000424	0.32	0.28	Retinal vascular caliber;	chr8:11376789	chr8:8456909~8461337:-
THCA	trans	rs11098499	0.78	rs7692994	ENSG00000253326.2	RP11-261C10.7	6.43	3.1e-10	0.000425	0.37	0.28	Corneal astigmatism;	chr4:119506334	chr1:243054861~243056394:-
THCA	trans	rs7819412	0.645	rs4841508	ENSG00000256560.1	LINC01486	-6.43	3.1e-10	0.000425	-0.36	-0.28	Triglycerides;	chr8:11207494	chr12:109354083~109359488:-
THCA	trans	rs2950393	0.804	rs2958132	ENSG00000257210.1	NACAP3	6.43	3.1e-10	0.000425	0.33	0.28	Platelet distribution width;	chr12:56750749	chr12:93124063~93124543:-
THCA	trans	rs804280	0.525	rs1004712	ENSG00000253893.2	FAM85B	-6.43	3.1e-10	0.000425	-0.36	-0.28	Myopia (pathological);	chr8:11764784	chr8:8167819~8226614:-
THCA	trans	rs7200543	0.961	rs3803573	ENSG00000255185.4	PDXDC2P	6.43	3.1e-10	0.000425	0.4	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:70010751~70065945:-
THCA	trans	rs9649213	0.593	rs6949718	ENSG00000225169.1	BRI3P1	6.43	3.12e-10	0.000427	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr1:100213293~100213670:+
THCA	trans	rs853679	0.607	rs67998226	ENSG00000228022.4	HCG20	-6.43	3.13e-10	0.000428	-0.71	-0.28	Depression;	chr6:28270281	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34878803	ENSG00000228022.4	HCG20	-6.43	3.13e-10	0.000428	-0.71	-0.28	Depression;	chr6:28282402	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34396849	ENSG00000228022.4	HCG20	-6.43	3.13e-10	0.000428	-0.71	-0.28	Depression;	chr6:28283178	chr6:30766825~30792250:+
THCA	trans	rs9649213	0.574	rs60077733	ENSG00000225169.1	BRI3P1	6.43	3.13e-10	0.000429	0.37	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr1:100213293~100213670:+
THCA	trans	rs7746199	0.736	rs13202295	ENSG00000253570.1	RNF5P1	6.43	3.13e-10	0.000429	0.81	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr8:38600661~38601200:-
THCA	trans	rs76228276	0.737	rs72672329	ENSG00000260318.1	COX6CP1	6.43	3.13e-10	0.000429	0.79	0.28	Childhood ear infection;	chr8:99230997	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs72672337	ENSG00000260318.1	COX6CP1	6.43	3.13e-10	0.000429	0.79	0.28	Childhood ear infection;	chr8:99256175	chr16:11903923~11904137:-
THCA	trans	rs13177918	0.798	rs13182116	ENSG00000226396.1	RP5-1056L3.3	-6.43	3.14e-10	0.00043	-0.28	-0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:19608114~19608568:+
THCA	trans	rs1190596	0.525	rs8010950	ENSG00000181359.5	HSP90AA6P	-6.43	3.15e-10	0.000431	-0.41	-0.28	Behavioural disinhibition (generation interaction);	chr14:102291520	chr4:170581470~170605450:-
THCA	trans	rs9649213	0.593	rs6955647	ENSG00000225169.1	BRI3P1	6.43	3.15e-10	0.000431	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr1:100213293~100213670:+
THCA	trans	rs7824557	0.527	rs2572448	ENSG00000254153.1	CTA-398F10.2	6.43	3.15e-10	0.000431	0.32	0.28	Retinal vascular caliber;	chr8:11381843	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.527	rs2572447	ENSG00000254153.1	CTA-398F10.2	6.43	3.15e-10	0.000431	0.32	0.28	Retinal vascular caliber;	chr8:11382001	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.527	rs2572446	ENSG00000254153.1	CTA-398F10.2	6.43	3.15e-10	0.000431	0.32	0.28	Retinal vascular caliber;	chr8:11382056	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.527	rs10109537	ENSG00000254153.1	CTA-398F10.2	6.43	3.15e-10	0.000431	0.32	0.28	Retinal vascular caliber;	chr8:11382131	chr8:8456909~8461337:-
THCA	trans	rs9650657	0.524	rs10088408	ENSG00000229857.1	RP11-159H20.3	6.43	3.16e-10	0.000432	0.35	0.28	Neuroticism;	chr8:10959687	chr9:76992099~76993108:+
THCA	trans	rs656319	0.585	rs13272731	ENSG00000253893.2	FAM85B	6.43	3.16e-10	0.000433	0.4	0.28	Myopia (pathological);	chr8:10049424	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.527	rs11785394	ENSG00000254153.1	CTA-398F10.2	6.43	3.17e-10	0.000433	0.32	0.28	Retinal vascular caliber;	chr8:11380520	chr8:8456909~8461337:-
THCA	trans	rs35851103	0.507	rs6601649	ENSG00000256560.1	LINC01486	-6.43	3.18e-10	0.000435	-0.36	-0.28	Neuroticism;	chr8:11999808	chr12:109354083~109359488:-
THCA	trans	rs9649213	0.593	rs6465677	ENSG00000225169.1	BRI3P1	6.43	3.18e-10	0.000435	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs6465678	ENSG00000225169.1	BRI3P1	6.43	3.18e-10	0.000435	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr1:100213293~100213670:+
THCA	trans	rs335206	1	rs335214	ENSG00000256427.1	RP11-118B22.4	-6.43	3.19e-10	0.000436	-0.31	-0.28	QRS duration;	chr5:123164273	chr12:9246497~9257960:+
THCA	trans	rs643955	0.583	rs13250399	ENSG00000253893.2	FAM85B	6.43	3.19e-10	0.000436	0.39	0.28	Systemic lupus erythematosus;	chr8:10015300	chr8:8167819~8226614:-
THCA	trans	rs864643	0.738	rs13063581	ENSG00000188856.6	RPSAP47	-6.43	3.2e-10	0.000438	-0.4	-0.28	Attention deficit hyperactivity disorder;	chr3:39551168	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.754	rs878376	ENSG00000253326.2	RP11-261C10.7	6.43	3.21e-10	0.000439	0.39	0.28	Corneal astigmatism;	chr4:119316547	chr1:243054861~243056394:-
THCA	trans	rs1707322	1	rs785498	ENSG00000255397.1	AC022182.2	6.43	3.21e-10	0.000439	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr8:60937705~60939871:-
THCA	trans	rs853679	0.607	rs66868086	ENSG00000228022.4	HCG20	-6.43	3.22e-10	0.00044	-0.73	-0.28	Depression;	chr6:27898124	chr6:30766825~30792250:+
THCA	trans	rs1707322	1	rs4298677	ENSG00000255397.1	AC022182.2	-6.43	3.22e-10	0.000441	-0.4	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.789	rs10212719	ENSG00000253326.2	RP11-261C10.7	6.43	3.23e-10	0.000442	0.39	0.28	Corneal astigmatism;	chr4:119333282	chr1:243054861~243056394:-
THCA	trans	rs34421088	0.532	rs11782742	ENSG00000253893.2	FAM85B	-6.43	3.23e-10	0.000442	-0.37	-0.28	Neuroticism;	chr8:11307500	chr8:8167819~8226614:-
THCA	trans	rs453301	0.653	rs7016139	ENSG00000256560.1	LINC01486	-6.43	3.23e-10	0.000442	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9037960	chr12:109354083~109359488:-
THCA	trans	rs853679	0.567	rs3799499	ENSG00000228078.1	HLA-U	-6.43	3.24e-10	0.000443	-0.39	-0.28	Depression;	chr6:28386473	chr6:29934101~29934286:+
THCA	trans	rs853679	0.567	rs2232427	ENSG00000228078.1	HLA-U	-6.43	3.24e-10	0.000443	-0.39	-0.28	Depression;	chr6:28391932	chr6:29934101~29934286:+
THCA	trans	rs7819412	0.775	rs2001329	ENSG00000256560.1	LINC01486	-6.42	3.25e-10	0.000444	-0.35	-0.28	Triglycerides;	chr8:11129349	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs785486	ENSG00000255397.1	AC022182.2	6.42	3.25e-10	0.000444	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.865	rs785501	ENSG00000255397.1	AC022182.2	6.42	3.25e-10	0.000444	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.929	rs785500	ENSG00000255397.1	AC022182.2	6.42	3.25e-10	0.000444	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.564	rs2572400	ENSG00000254153.1	CTA-398F10.2	6.42	3.25e-10	0.000444	0.32	0.28	Retinal vascular caliber;	chr8:11376858	chr8:8456909~8461337:-
THCA	trans	rs941207	0.507	rs73337030	ENSG00000228224.3	NACAP1	-6.42	3.25e-10	0.000445	-0.29	-0.28	Platelet count;	chr12:56652410	chr8:101361794~101372707:+
THCA	trans	rs2898290	0.622	rs13272061	ENSG00000229857.1	RP11-159H20.3	6.42	3.26e-10	0.000446	0.37	0.28	Systolic blood pressure;	chr8:11494752	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.56	rs2245250	ENSG00000229857.1	RP11-159H20.3	6.42	3.29e-10	0.000449	0.37	0.28	Neuroticism;	chr8:11543171	chr9:76992099~76993108:+
THCA	trans	rs4646450	0.735	rs10272998	ENSG00000228834.1	RP11-249L21.4	6.42	3.29e-10	0.000449	0.49	0.28	Blood metabolite levels;	chr7:99336295	chr6:108907615~108907873:-
THCA	trans	rs6087990	0.701	rs1997797	ENSG00000253915.1	MAPRE1P1	6.42	3.29e-10	0.00045	0.37	0.28	Ulcerative colitis;	chr20:32800148	chr8:135625185~135625981:-
THCA	trans	rs13016963	0.625	rs11681399	ENSG00000235105.1	RP11-329A14.1	6.42	3.31e-10	0.000452	0.31	0.28	Esophageal squamous cell carcinoma;Melanoma;	chr2:201280883	chr1:48435967~48437223:+
THCA	trans	rs3808502	0.549	rs7831039	ENSG00000229857.1	RP11-159H20.3	6.42	3.32e-10	0.000453	0.36	0.28	Neuroticism;	chr8:11570128	chr9:76992099~76993108:+
THCA	trans	rs9393777	0.92	rs35768595	ENSG00000253570.1	RNF5P1	6.42	3.33e-10	0.000454	0.81	0.28	Intelligence (multi-trait analysis);	chr6:27174125	chr8:38600661~38601200:-
THCA	trans	rs9329221	0.638	rs12543645	ENSG00000253893.2	FAM85B	6.42	3.33e-10	0.000455	0.38	0.28	Neuroticism;	chr8:10388815	chr8:8167819~8226614:-
THCA	trans	rs2645424	0.686	rs2294140	ENSG00000281304.1	Metazoa_SRP	-6.42	3.34e-10	0.000456	-0.38	-0.28	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr6:35911481~35911729:-
THCA	trans	rs853679	0.556	rs45509595	ENSG00000228022.4	HCG20	-6.42	3.36e-10	0.000458	-0.73	-0.28	Depression;	chr6:27873148	chr6:30766825~30792250:+
THCA	trans	rs11992162	0.967	rs4840601	ENSG00000256560.1	LINC01486	6.42	3.36e-10	0.000458	0.35	0.28	Monocyte count;	chr8:11971221	chr12:109354083~109359488:-
THCA	trans	rs3740713	1	rs73436668	ENSG00000236090.2	LDHAP3	6.42	3.36e-10	0.000458	0.51	0.28	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr2:41819747~41820754:+
THCA	trans	rs6600671	0.934	rs12060031	ENSG00000270392.2	PFN1P2	-6.42	3.36e-10	0.000459	-0.29	-0.28	Hip geometry;	chr1:121501652	chr1:120432204~120434052:-
THCA	trans	rs6600671	0.934	rs7528274	ENSG00000270392.2	PFN1P2	6.42	3.37e-10	0.00046	0.28	0.28	Hip geometry;	chr1:121545103	chr1:120432204~120434052:-
THCA	trans	rs76228276	0.737	rs77547719	ENSG00000260318.1	COX6CP1	6.42	3.37e-10	0.00046	0.83	0.28	Childhood ear infection;	chr8:99583331	chr16:11903923~11904137:-
THCA	trans	rs2950393	0.895	rs2926740	ENSG00000228224.3	NACAP1	6.42	3.37e-10	0.00046	0.3	0.28	Platelet distribution width;	chr12:56666751	chr8:101361794~101372707:+
THCA	trans	rs4784054	0.667	rs12925419	ENSG00000230849.2	GOT2P2	6.42	3.38e-10	0.00046	0.46	0.28	Blood metabolite levels;	chr16:58750078	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.667	rs8044439	ENSG00000230849.2	GOT2P2	6.42	3.38e-10	0.00046	0.46	0.28	Blood metabolite levels;	chr16:58757121	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.667	rs7206052	ENSG00000230849.2	GOT2P2	6.42	3.38e-10	0.00046	0.46	0.28	Blood metabolite levels;	chr16:58769607	chr1:173141100~173142350:-
THCA	trans	rs9649213	0.537	rs6465663	ENSG00000225169.1	BRI3P1	6.42	3.38e-10	0.00046	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr1:100213293~100213670:+
THCA	trans	rs34421088	0.56	rs2467520	ENSG00000256560.1	LINC01486	-6.42	3.39e-10	0.000463	-0.36	-0.28	Neuroticism;	chr8:11541444	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.789	rs9991166	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119316696	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.708	rs10005237	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119316742	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs878372	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119317625	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs10213267	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119317919	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs10212775	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119318089	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs11732087	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119318676	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs2964	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119318976	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs1511025	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119319083	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs12510269	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119320491	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs12506610	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119320504	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.743	rs10003567	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119320519	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs10006259	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119320990	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs28652763	ENSG00000253326.2	RP11-261C10.7	6.42	3.39e-10	0.000463	0.39	0.28	Corneal astigmatism;	chr4:119321157	chr1:243054861~243056394:-
THCA	trans	rs3956705	0.798	rs1045530	ENSG00000176826.14	FKBP9P1	-6.42	3.4e-10	0.000463	-0.37	-0.28	Red cell distribution width;	chr7:32868523	chr7:55681074~55713252:-
THCA	trans	rs11098499	0.575	rs907204	ENSG00000253326.2	RP11-261C10.7	6.42	3.41e-10	0.000465	0.39	0.28	Corneal astigmatism;	chr4:119317499	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.575	rs907205	ENSG00000253326.2	RP11-261C10.7	6.42	3.41e-10	0.000465	0.39	0.28	Corneal astigmatism;	chr4:119317509	chr1:243054861~243056394:-
THCA	trans	rs4784054	0.667	rs12925537	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58750094	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.667	rs2013333	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58750920	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.803	rs11859128	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58752257	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.667	rs8052646	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58754064	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.667	rs11643711	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58754648	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.667	rs12931903	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58755140	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.614	rs8054775	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58759666	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.614	rs8046937	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58762282	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.803	rs4784980	ENSG00000230849.2	GOT2P2	6.42	3.41e-10	0.000465	0.46	0.28	Blood metabolite levels;	chr16:58763722	chr1:173141100~173142350:-
THCA	trans	rs6600671	0.934	rs11249431	ENSG00000270392.2	PFN1P2	-6.42	3.42e-10	0.000466	-0.29	-0.28	Hip geometry;	chr1:121544405	chr1:120432204~120434052:-
THCA	trans	rs2980439	0.846	rs2980437	ENSG00000256560.1	LINC01486	-6.42	3.42e-10	0.000466	-0.32	-0.28	Neuroticism;	chr8:8237241	chr12:109354083~109359488:-
THCA	trans	rs7200543	1	rs1135999	ENSG00000250569.1	NTAN1P2	6.42	3.42e-10	0.000466	0.29	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr8:86481754~86483002:-
THCA	trans	rs7200543	1	rs1136001	ENSG00000250569.1	NTAN1P2	6.42	3.42e-10	0.000466	0.29	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr8:86481754~86483002:-
THCA	trans	rs7200543	1	rs2740	ENSG00000250569.1	NTAN1P2	6.42	3.42e-10	0.000466	0.29	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr8:86481754~86483002:-
THCA	trans	rs9329221	0.905	rs13252982	ENSG00000229857.1	RP11-159H20.3	6.42	3.43e-10	0.000467	0.35	0.28	Neuroticism;	chr8:10397595	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.87	rs11777976	ENSG00000229857.1	RP11-159H20.3	6.42	3.43e-10	0.000467	0.35	0.28	Neuroticism;	chr8:10397892	chr9:76992099~76993108:+
THCA	trans	rs853679	0.567	rs13209596	ENSG00000228078.1	HLA-U	-6.42	3.44e-10	0.000468	-0.39	-0.28	Depression;	chr6:28428413	chr6:29934101~29934286:+
THCA	trans	rs853679	0.567	rs9969098	ENSG00000228078.1	HLA-U	-6.42	3.44e-10	0.000468	-0.39	-0.28	Depression;	chr6:28430971	chr6:29934101~29934286:+
THCA	trans	rs853679	0.567	rs7740429	ENSG00000228078.1	HLA-U	-6.42	3.44e-10	0.000468	-0.39	-0.28	Depression;	chr6:28431469	chr6:29934101~29934286:+
THCA	trans	rs853679	0.567	rs16894106	ENSG00000228078.1	HLA-U	-6.42	3.44e-10	0.000468	-0.39	-0.28	Depression;	chr6:28432562	chr6:29934101~29934286:+
THCA	trans	rs1580019	0.665	rs34147895	ENSG00000176826.14	FKBP9P1	-6.42	3.44e-10	0.000468	-0.39	-0.28	Cognitive ability;	chr7:32492184	chr7:55681074~55713252:-
THCA	trans	rs3740713	1	rs1848048	ENSG00000236090.2	LDHAP3	6.41	3.44e-10	0.000469	0.52	0.28	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs16935432	ENSG00000236090.2	LDHAP3	6.41	3.44e-10	0.000469	0.52	0.28	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr2:41819747~41820754:+
THCA	trans	rs3740713	1	rs76599129	ENSG00000236090.2	LDHAP3	6.41	3.44e-10	0.000469	0.52	0.28	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr2:41819747~41820754:+
THCA	trans	rs9467711	0.79	rs13220495	ENSG00000253570.1	RNF5P1	6.41	3.44e-10	0.000469	0.82	0.28	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr8:38600661~38601200:-
THCA	trans	rs7929679	0.551	rs11032849	ENSG00000225531.1	RP11-196I18.3	6.41	3.46e-10	0.000471	0.36	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34764193	chr9:107116829~107117557:+
THCA	trans	rs7929679	0.521	rs11032852	ENSG00000225531.1	RP11-196I18.3	6.41	3.46e-10	0.000471	0.36	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34766761	chr9:107116829~107117557:+
THCA	trans	rs7929679	0.521	rs11499809	ENSG00000225531.1	RP11-196I18.3	6.41	3.46e-10	0.000471	0.36	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34769196	chr9:107116829~107117557:+
THCA	trans	rs7929679	0.521	rs1509667	ENSG00000225531.1	RP11-196I18.3	6.41	3.46e-10	0.000471	0.36	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34769756	chr9:107116829~107117557:+
THCA	trans	rs7929679	0.551	rs10836302	ENSG00000225531.1	RP11-196I18.3	6.41	3.46e-10	0.000471	0.36	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34770350	chr9:107116829~107117557:+
THCA	trans	rs7929679	0.521	rs10768094	ENSG00000225531.1	RP11-196I18.3	6.41	3.46e-10	0.000471	0.36	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34770642	chr9:107116829~107117557:+
THCA	trans	rs7929679	0.551	rs10836303	ENSG00000225531.1	RP11-196I18.3	6.41	3.46e-10	0.000471	0.36	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34771155	chr9:107116829~107117557:+
THCA	trans	rs7929679	0.521	rs10768097	ENSG00000225531.1	RP11-196I18.3	6.41	3.46e-10	0.000471	0.36	0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34771355	chr9:107116829~107117557:+
THCA	trans	rs7824557	0.592	rs2736280	ENSG00000253893.2	FAM85B	-6.41	3.47e-10	0.000472	-0.38	-0.28	Retinal vascular caliber;	chr8:11365513	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.775	rs12156017	ENSG00000253893.2	FAM85B	6.41	3.47e-10	0.000473	0.36	0.28	Multiple myeloma (hyperdiploidy);	chr8:9549327	chr8:8167819~8226614:-
THCA	trans	rs11172055	0.902	rs10783807	ENSG00000121089.4	NACA3P	-6.41	3.47e-10	0.000473	-0.32	-0.28	Migraine;	chr12:56872529	chr4:164943290~164943937:+
THCA	trans	rs4784054	0.803	rs73553527	ENSG00000230849.2	GOT2P2	6.41	3.48e-10	0.000474	0.46	0.28	Blood metabolite levels;	chr16:58762002	chr1:173141100~173142350:-
THCA	trans	rs4784054	0.667	rs8052824	ENSG00000230849.2	GOT2P2	6.41	3.48e-10	0.000474	0.46	0.28	Blood metabolite levels;	chr16:58762045	chr1:173141100~173142350:-
THCA	trans	rs9649213	0.593	rs13246942	ENSG00000225169.1	BRI3P1	6.41	3.5e-10	0.000476	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs6968144	ENSG00000225169.1	BRI3P1	6.41	3.5e-10	0.000476	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.574	rs62479853	ENSG00000225169.1	BRI3P1	6.41	3.5e-10	0.000476	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr1:100213293~100213670:+
THCA	trans	rs1707322	1	rs10890353	ENSG00000255397.1	AC022182.2	-6.41	3.51e-10	0.000478	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr8:60937705~60939871:-
THCA	trans	rs9368481	0.594	rs2636425	ENSG00000242375.1	RP11-498P14.3	6.41	3.52e-10	0.000479	0.41	0.28	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr9:97195351~97197687:-
THCA	trans	rs7819412	0.595	rs2409712	ENSG00000229857.1	RP11-159H20.3	6.41	3.53e-10	0.00048	0.36	0.28	Triglycerides;	chr8:11129327	chr9:76992099~76993108:+
THCA	trans	rs864643	0.891	rs816493	ENSG00000183298.5	RP11-556K13.1	6.41	3.54e-10	0.000481	0.47	0.28	Attention deficit hyperactivity disorder;	chr3:39514702	chr1:101786340~101787219:-
THCA	trans	rs7819412	0.936	rs7814499	ENSG00000256560.1	LINC01486	-6.41	3.55e-10	0.000482	-0.35	-0.28	Triglycerides;	chr8:11183138	chr12:109354083~109359488:-
THCA	trans	rs9649213	0.613	rs7777415	ENSG00000225169.1	BRI3P1	6.41	3.56e-10	0.000483	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98329902	chr1:100213293~100213670:+
THCA	trans	rs11098499	0.78	rs10013652	ENSG00000253326.2	RP11-261C10.7	6.41	3.56e-10	0.000483	0.38	0.28	Corneal astigmatism;	chr4:119371101	chr1:243054861~243056394:-
THCA	trans	rs864643	0.773	rs11129838	ENSG00000188856.6	RPSAP47	6.41	3.57e-10	0.000485	0.39	0.28	Attention deficit hyperactivity disorder;	chr3:39557696	chr8:80558870~80559757:+
THCA	trans	rs6732160	0.613	rs57208378	ENSG00000236165.1	PRADC1P1	6.41	3.58e-10	0.000486	0.4	0.28	Intelligence (multi-trait analysis);	chr2:73162871	chr3:36976316~36976840:+
THCA	trans	rs9649213	0.593	rs6970990	ENSG00000225169.1	BRI3P1	6.41	3.58e-10	0.000486	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.555	rs34695842	ENSG00000225169.1	BRI3P1	6.41	3.58e-10	0.000486	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr1:100213293~100213670:+
THCA	trans	rs804280	0.544	rs804276	ENSG00000253893.2	FAM85B	-6.41	3.59e-10	0.000488	-0.36	-0.28	Myopia (pathological);	chr8:11767499	chr8:8167819~8226614:-
THCA	trans	rs330048	0.545	rs11781008	ENSG00000253893.2	FAM85B	-6.41	3.61e-10	0.00049	-0.37	-0.28	Systemic lupus erythematosus;	chr8:9295729	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.678	rs10106040	ENSG00000253893.2	FAM85B	-6.41	3.61e-10	0.00049	-0.36	-0.28	Multiple myeloma (hyperdiploidy);	chr8:9754903	chr8:8167819~8226614:-
THCA	trans	rs453301	0.624	rs4841083	ENSG00000256560.1	LINC01486	6.41	3.61e-10	0.00049	0.33	0.28	Joint mobility (Beighton score);	chr8:9012918	chr12:109354083~109359488:-
THCA	trans	rs12145833	0.538	rs10927014	ENSG00000154608.12	CEP170P1	-6.41	3.62e-10	0.000491	-0.38	-0.28	Obesity (early onset extreme);	chr1:243429374	chr4:118467590~118554204:+
THCA	trans	rs941207	1	rs941207	ENSG00000228224.3	NACAP1	-6.41	3.63e-10	0.000492	-0.33	-0.28	Platelet count;	chr12:56629500	chr8:101361794~101372707:+
THCA	trans	rs13177918	0.798	rs12514700	ENSG00000226396.1	RP5-1056L3.3	6.41	3.64e-10	0.000493	0.28	0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:19608114~19608568:+
THCA	trans	rs7824557	0.564	rs2043508	ENSG00000254153.1	CTA-398F10.2	6.41	3.64e-10	0.000494	0.31	0.28	Retinal vascular caliber;	chr8:11369897	chr8:8456909~8461337:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000227586.5	RP11-162A23.5	6.41	3.65e-10	0.000495	0.38	0.28	Cognitive function;	chr12:55976127	chr10:123171535~123171875:-
THCA	trans	rs1707322	0.896	rs809774	ENSG00000255397.1	AC022182.2	6.4	3.66e-10	0.000496	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr8:60937705~60939871:-
THCA	trans	rs4784054	0.568	rs13333259	ENSG00000230849.2	GOT2P2	6.4	3.67e-10	0.000498	0.43	0.28	Blood metabolite levels;	chr16:58789172	chr1:173141100~173142350:-
THCA	trans	rs7113874	0.802	rs10769936	ENSG00000266891.1	RP11-692N5.2	6.4	3.68e-10	0.000499	0.36	0.28	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8632981	chr18:9734882~9735602:-
THCA	trans	rs1707322	0.613	rs1473840	ENSG00000255397.1	AC022182.2	6.4	3.69e-10	0.000499	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.964	rs785483	ENSG00000255397.1	AC022182.2	6.4	3.7e-10	0.000501	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.964	rs796773	ENSG00000255397.1	AC022182.2	6.4	3.7e-10	0.000501	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.896	rs785518	ENSG00000255397.1	AC022182.2	6.4	3.7e-10	0.000501	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs785519	ENSG00000255397.1	AC022182.2	6.4	3.7e-10	0.000501	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr8:60937705~60939871:-
THCA	trans	rs3740713	1	rs73440614	ENSG00000236090.2	LDHAP3	6.4	3.7e-10	0.000502	0.52	0.28	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr2:41819747~41820754:+
THCA	trans	rs902774	0.818	rs17120257	ENSG00000250539.1	KRT8P33	-6.4	3.71e-10	0.000502	-0.53	-0.28	Prostate cancer;	chr12:52909547	chr5:123400922~123402344:-
THCA	trans	rs4911259	0.552	rs2014837	ENSG00000253915.1	MAPRE1P1	6.4	3.72e-10	0.000503	0.37	0.28	Inflammatory bowel disease;	chr20:32873276	chr8:135625185~135625981:-
THCA	trans	rs2898290	0.617	rs13278965	ENSG00000229857.1	RP11-159H20.3	-6.4	3.72e-10	0.000503	-0.36	-0.28	Systolic blood pressure;	chr8:11609236	chr9:76992099~76993108:+
THCA	trans	rs656319	0.565	rs73189192	ENSG00000253893.2	FAM85B	6.4	3.72e-10	0.000504	0.4	0.28	Myopia (pathological);	chr8:10053129	chr8:8167819~8226614:-
THCA	trans	rs7769051	1	rs7761365	ENSG00000227615.1	RP11-864N7.2	6.4	3.73e-10	0.000505	0.48	0.28	Type 2 diabetes nephropathy;	chr6:132780422	chr11:74745716~74746114:-
THCA	trans	rs7769051	1	rs7765224	ENSG00000227615.1	RP11-864N7.2	6.4	3.73e-10	0.000505	0.48	0.28	Type 2 diabetes nephropathy;	chr6:132780485	chr11:74745716~74746114:-
THCA	trans	rs7769051	0.614	rs6912936	ENSG00000227615.1	RP11-864N7.2	6.4	3.73e-10	0.000505	0.48	0.28	Type 2 diabetes nephropathy;	chr6:132781525	chr11:74745716~74746114:-
THCA	trans	rs656319	0.629	rs10111315	ENSG00000253893.2	FAM85B	6.4	3.73e-10	0.000505	0.38	0.28	Myopia (pathological);	chr8:10008078	chr8:8167819~8226614:-
THCA	trans	rs9467773	0.587	rs10946812	ENSG00000242375.1	RP11-498P14.3	-6.4	3.74e-10	0.000506	-0.41	-0.28	Intelligence (multi-trait analysis);	chr6:26344747	chr9:97195351~97197687:-
THCA	trans	rs6831352	0.819	rs13832	ENSG00000228407.2	RP4-800M22.1	-6.4	3.77e-10	0.00051	-0.38	-0.28	Alcohol dependence;	chr4:99071924	chr1:52160261~52160600:-
THCA	trans	rs2950393	0.804	rs2958130	ENSG00000257210.1	NACAP3	6.4	3.79e-10	0.000513	0.33	0.28	Platelet distribution width;	chr12:56746722	chr12:93124063~93124543:-
THCA	trans	rs11992162	1	rs11784499	ENSG00000229857.1	RP11-159H20.3	-6.4	3.79e-10	0.000513	-0.37	-0.28	Monocyte count;	chr8:11977030	chr9:76992099~76993108:+
THCA	trans	rs7833986	1	rs34037954	ENSG00000244245.1	RP11-120B7.1	6.4	3.81e-10	0.000516	0.37	0.28	Height;	chr8:56184282	chr5:108593609~108593967:+
THCA	trans	rs9467711	0.659	rs34605993	ENSG00000280107.1	AL022393.9	-6.4	3.82e-10	0.000517	-0.58	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs66757203	ENSG00000280107.1	AL022393.9	-6.4	3.82e-10	0.000517	-0.58	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26454728	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs35680819	ENSG00000280107.1	AL022393.9	-6.4	3.82e-10	0.000517	-0.58	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs36033628	ENSG00000280107.1	AL022393.9	-6.4	3.82e-10	0.000517	-0.58	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26455846	chr6:28170845~28172521:+
THCA	trans	rs9329221	0.905	rs13254263	ENSG00000229857.1	RP11-159H20.3	6.4	3.82e-10	0.000517	0.35	0.28	Neuroticism;	chr8:10397671	chr9:76992099~76993108:+
THCA	trans	rs9649213	0.593	rs6465683	ENSG00000225169.1	BRI3P1	6.4	3.83e-10	0.000518	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98396780	chr1:100213293~100213670:+
THCA	trans	rs6087990	0.806	rs875041	ENSG00000253915.1	MAPRE1P1	6.4	3.83e-10	0.000519	0.36	0.28	Ulcerative colitis;	chr20:32795724	chr8:135625185~135625981:-
THCA	trans	rs11098499	1	rs58601355	ENSG00000253326.2	RP11-261C10.7	6.4	3.84e-10	0.000519	0.39	0.28	Corneal astigmatism;	chr4:119265212	chr1:243054861~243056394:-
THCA	trans	rs9650657	0.504	rs6986032	ENSG00000254153.1	CTA-398F10.2	6.4	3.86e-10	0.000521	0.32	0.28	Neuroticism;	chr8:11174731	chr8:8456909~8461337:-
THCA	trans	rs2645424	0.53	rs1293303	ENSG00000260438.1	RP11-405F3.2	-6.4	3.86e-10	0.000522	-0.39	-0.28	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11862718	chr16:57713782~57714957:+
THCA	trans	rs7200543	1	rs16966952	ENSG00000250569.1	NTAN1P2	6.4	3.87e-10	0.000524	0.29	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr8:86481754~86483002:-
THCA	trans	rs34421088	0.585	rs1390950	ENSG00000253893.2	FAM85B	6.4	3.88e-10	0.000524	0.37	0.28	Neuroticism;	chr8:11738320	chr8:8167819~8226614:-
THCA	trans	rs853679	0.607	rs66868086	ENSG00000253570.1	RNF5P1	6.39	3.91e-10	0.000527	0.8	0.28	Depression;	chr6:27898124	chr8:38600661~38601200:-
THCA	trans	rs453301	0.653	rs1562211	ENSG00000256560.1	LINC01486	-6.39	3.93e-10	0.000531	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9044914	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.754	rs1849457	ENSG00000253326.2	RP11-261C10.7	6.39	3.94e-10	0.000532	0.39	0.28	Corneal astigmatism;	chr4:119333200	chr1:243054861~243056394:-
THCA	trans	rs9649213	0.593	rs3779194	ENSG00000225169.1	BRI3P1	6.39	3.95e-10	0.000534	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr1:100213293~100213670:+
THCA	trans	rs13177918	0.559	rs10447224	ENSG00000226396.1	RP5-1056L3.3	6.39	3.96e-10	0.000535	0.25	0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:19608114~19608568:+
THCA	trans	rs13177918	0.559	rs10447225	ENSG00000226396.1	RP5-1056L3.3	6.39	3.96e-10	0.000535	0.25	0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:19608114~19608568:+
THCA	trans	rs847577	0.715	rs12665986	ENSG00000225169.1	BRI3P1	-6.39	3.97e-10	0.000535	-0.37	-0.28	Breast cancer;	chr7:98090364	chr1:100213293~100213670:+
THCA	trans	rs12145833	0.62	rs12138272	ENSG00000154608.12	CEP170P1	-6.39	3.97e-10	0.000536	-0.36	-0.28	Obesity (early onset extreme);	chr1:243430900	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.62	rs10927017	ENSG00000154608.12	CEP170P1	-6.39	3.97e-10	0.000536	-0.36	-0.28	Obesity (early onset extreme);	chr1:243432511	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.62	rs12140393	ENSG00000154608.12	CEP170P1	-6.39	3.97e-10	0.000536	-0.36	-0.28	Obesity (early onset extreme);	chr1:243432929	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.62	rs12140431	ENSG00000154608.12	CEP170P1	-6.39	3.97e-10	0.000536	-0.36	-0.28	Obesity (early onset extreme);	chr1:243432982	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.62	rs12118439	ENSG00000154608.12	CEP170P1	-6.39	3.97e-10	0.000536	-0.36	-0.28	Obesity (early onset extreme);	chr1:243433069	chr4:118467590~118554204:+
THCA	trans	rs12145833	0.62	rs12039979	ENSG00000154608.12	CEP170P1	-6.39	3.97e-10	0.000536	-0.36	-0.28	Obesity (early onset extreme);	chr1:243433926	chr4:118467590~118554204:+
THCA	trans	rs7819412	0.645	rs4841508	ENSG00000254153.1	CTA-398F10.2	6.39	3.98e-10	0.000537	0.32	0.28	Triglycerides;	chr8:11207494	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.593	rs2979241	ENSG00000256560.1	LINC01486	6.39	3.98e-10	0.000538	0.33	0.28	Mood instability;	chr8:8445843	chr12:109354083~109359488:-
THCA	trans	rs34421088	0.586	rs2272594	ENSG00000253893.2	FAM85B	-6.39	3.99e-10	0.000539	-0.38	-0.28	Neuroticism;	chr8:11285116	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.967	rs4841661	ENSG00000229857.1	RP11-159H20.3	-6.39	4e-10	0.00054	-0.36	-0.28	Monocyte count;	chr8:11975260	chr9:76992099~76993108:+
THCA	trans	rs11992162	1	rs11994417	ENSG00000229857.1	RP11-159H20.3	-6.39	4e-10	0.00054	-0.36	-0.28	Monocyte count;	chr8:11975753	chr9:76992099~76993108:+
THCA	trans	rs6921919	0.945	rs7765989	ENSG00000228078.1	HLA-U	-6.39	4.01e-10	0.000541	-0.42	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:29934101~29934286:+
THCA	trans	rs941207	0.526	rs2950393	ENSG00000228224.3	NACAP1	-6.39	4.02e-10	0.000542	-0.3	-0.28	Platelet count;	chr12:56642239	chr8:101361794~101372707:+
THCA	trans	rs6921919	0.945	rs16901847	ENSG00000228078.1	HLA-U	-6.39	4.03e-10	0.000544	-0.42	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:29934101~29934286:+
THCA	trans	rs9467711	0.79	rs35400317	ENSG00000253570.1	RNF5P1	6.39	4.05e-10	0.000546	0.8	0.28	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.79	rs67777156	ENSG00000253570.1	RNF5P1	6.39	4.05e-10	0.000546	0.8	0.28	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.722	rs13201782	ENSG00000253570.1	RNF5P1	6.39	4.05e-10	0.000546	0.8	0.28	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr8:38600661~38601200:-
THCA	trans	rs12145833	0.619	rs12132986	ENSG00000154608.12	CEP170P1	-6.39	4.06e-10	0.000547	-0.38	-0.28	Obesity (early onset extreme);	chr1:243429295	chr4:118467590~118554204:+
THCA	trans	rs11098499	0.738	rs28687057	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119359657	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.775	rs67281037	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119360002	chr1:243054861~243056394:-
THCA	trans	rs10028773	0.506	rs12374346	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Educational attainment;	chr4:119360550	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs12374244	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119360817	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs12374352	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119360822	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.775	rs10021601	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119361408	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs6857892	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119361541	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.909	rs28581362	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119362393	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.82	rs12503082	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119363162	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs12499602	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119363232	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.774	rs11098505	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119363472	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs13105020	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119364533	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs6824111	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119364813	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.775	rs10029303	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119365600	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs9995136	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119365690	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs13125526	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119366864	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs12513310	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119366884	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs12510451	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119367988	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.774	rs73842616	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119369528	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.645	rs72676059	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119369673	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.569	rs55845118	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119369758	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs7677068	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119370549	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.866	rs9991221	ENSG00000253326.2	RP11-261C10.7	6.39	4.06e-10	0.000547	0.37	0.28	Corneal astigmatism;	chr4:119370952	chr1:243054861~243056394:-
THCA	trans	rs2074193	0.585	rs11183915	ENSG00000275964.1	RP11-61K9.3	-6.39	4.07e-10	0.000549	-0.3	-0.28	Migraine with aura;	chr12:47377201	chr13:19863858~19865048:+
THCA	trans	rs6921919	0.945	rs61289879	ENSG00000228078.1	HLA-U	-6.39	4.08e-10	0.000549	-0.43	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:29934101~29934286:+
THCA	trans	rs76228276	0.737	rs61753724	ENSG00000260318.1	COX6CP1	6.39	4.11e-10	0.000554	0.83	0.28	Childhood ear infection;	chr8:99720960	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs76975870	ENSG00000260318.1	COX6CP1	6.39	4.11e-10	0.000554	0.83	0.28	Childhood ear infection;	chr8:99724094	chr16:11903923~11904137:-
THCA	trans	rs453301	0.624	rs2979256	ENSG00000256560.1	LINC01486	6.38	4.14e-10	0.000557	0.33	0.28	Joint mobility (Beighton score);	chr8:9014200	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.513	rs7005884	ENSG00000229857.1	RP11-159H20.3	6.38	4.14e-10	0.000557	0.35	0.28	Neuroticism;	chr8:10938962	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.779	rs10857066	ENSG00000253326.2	RP11-261C10.7	6.38	4.15e-10	0.000558	0.37	0.28	Corneal astigmatism;	chr4:119365441	chr1:243054861~243056394:-
THCA	trans	rs6885307	0.505	rs115825538	ENSG00000231752.4	EMBP1	6.38	4.15e-10	0.000559	0.58	0.28	Age at first birth;	chr5:45214597	chr1:121519112~121571892:+
THCA	trans	rs9649213	0.593	rs3823740	ENSG00000225169.1	BRI3P1	6.38	4.16e-10	0.00056	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs35535338	ENSG00000225169.1	BRI3P1	6.38	4.16e-10	0.00056	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs36017146	ENSG00000225169.1	BRI3P1	6.38	4.16e-10	0.00056	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr1:100213293~100213670:+
THCA	trans	rs4295623	0.585	rs13259242	ENSG00000229857.1	RP11-159H20.3	6.38	4.16e-10	0.00056	0.36	0.28	Morning vs. evening chronotype;	chr8:11735524	chr9:76992099~76993108:+
THCA	trans	rs1707322	1	rs7531911	ENSG00000255397.1	AC022182.2	-6.38	4.16e-10	0.000561	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr8:60937705~60939871:-
THCA	trans	rs335206	1	rs162953	ENSG00000256427.1	RP11-118B22.4	-6.38	4.17e-10	0.000561	-0.31	-0.28	QRS duration;	chr5:123163954	chr12:9246497~9257960:+
THCA	trans	rs853679	0.567	rs1005126	ENSG00000228078.1	HLA-U	-6.38	4.18e-10	0.000562	-0.38	-0.28	Depression;	chr6:28399846	chr6:29934101~29934286:+
THCA	trans	rs3740713	1	rs60376560	ENSG00000236090.2	LDHAP3	6.38	4.18e-10	0.000563	0.52	0.28	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr2:41819747~41820754:+
THCA	trans	rs6600671	0.691	rs6600662	ENSG00000270392.2	PFN1P2	6.38	4.19e-10	0.000564	0.29	0.28	Hip geometry;	chr1:121488992	chr1:120432204~120434052:-
THCA	trans	rs2048656	0.54	rs55868514	ENSG00000253893.2	FAM85B	6.38	4.21e-10	0.000567	0.37	0.28	Schizophrenia;	chr8:9822890	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2572399	ENSG00000254153.1	CTA-398F10.2	6.38	4.22e-10	0.000567	0.31	0.28	Retinal vascular caliber;	chr8:11377011	chr8:8456909~8461337:-
THCA	trans	rs9649213	0.593	rs7807555	ENSG00000225169.1	BRI3P1	6.38	4.22e-10	0.000567	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs7807455	ENSG00000225169.1	BRI3P1	6.38	4.22e-10	0.000567	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs6465667	ENSG00000225169.1	BRI3P1	6.38	4.22e-10	0.000567	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs6949214	ENSG00000225169.1	BRI3P1	6.38	4.22e-10	0.000567	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.537	rs35997266	ENSG00000225169.1	BRI3P1	6.38	4.22e-10	0.000567	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs6945554	ENSG00000225169.1	BRI3P1	6.38	4.22e-10	0.000567	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr1:100213293~100213670:+
THCA	trans	rs11992162	1	rs12334769	ENSG00000256560.1	LINC01486	6.38	4.24e-10	0.00057	0.35	0.28	Monocyte count;	chr8:11975652	chr12:109354083~109359488:-
THCA	trans	rs9649213	0.593	rs6465672	ENSG00000225169.1	BRI3P1	-6.38	4.24e-10	0.00057	-0.36	-0.28	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr1:100213293~100213670:+
THCA	trans	rs7824557	0.815	rs2572430	ENSG00000229857.1	RP11-159H20.3	-6.38	4.24e-10	0.000571	-0.33	-0.28	Retinal vascular caliber;	chr8:11247795	chr9:76992099~76993108:+
THCA	trans	rs853679	0.567	rs7774981	ENSG00000228078.1	HLA-U	-6.38	4.25e-10	0.000571	-0.39	-0.28	Depression;	chr6:28379133	chr6:29934101~29934286:+
THCA	trans	rs853679	0.567	rs7754960	ENSG00000228078.1	HLA-U	-6.38	4.25e-10	0.000571	-0.39	-0.28	Depression;	chr6:28379168	chr6:29934101~29934286:+
THCA	trans	rs11098499	0.691	rs9996644	ENSG00000253326.2	RP11-261C10.7	6.38	4.25e-10	0.000572	0.39	0.28	Corneal astigmatism;	chr4:119317722	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.691	rs9996494	ENSG00000253326.2	RP11-261C10.7	6.38	4.25e-10	0.000572	0.39	0.28	Corneal astigmatism;	chr4:119317725	chr1:243054861~243056394:-
THCA	trans	rs4415084	0.804	rs4412123	ENSG00000231752.4	EMBP1	-6.38	4.26e-10	0.000572	-0.38	-0.28	Breast cancer;	chr5:44876186	chr1:121519112~121571892:+
THCA	trans	rs9649213	0.574	rs7791321	ENSG00000225169.1	BRI3P1	6.38	4.26e-10	0.000573	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr1:100213293~100213670:+
THCA	trans	rs13016963	0.526	rs13027605	ENSG00000235105.1	RP11-329A14.1	6.38	4.26e-10	0.000573	0.31	0.28	Esophageal squamous cell carcinoma;Melanoma;	chr2:201278534	chr1:48435967~48437223:+
THCA	trans	rs13016963	0.604	rs13113	ENSG00000235105.1	RP11-329A14.1	6.38	4.27e-10	0.000574	0.31	0.28	Esophageal squamous cell carcinoma;Melanoma;	chr2:201287439	chr1:48435967~48437223:+
THCA	trans	rs9899728	0.706	rs7224300	ENSG00000234925.2	ATP5HP4	6.38	4.29e-10	0.000577	0.59	0.28	Alzheimer's disease or small vessel stroke;	chr17:75033161	chr12:68642519~68642993:-
THCA	trans	rs941207	0.526	rs2950387	ENSG00000257210.1	NACAP3	-6.38	4.31e-10	0.00058	-0.34	-0.28	Platelet count;	chr12:56627222	chr12:93124063~93124543:-
THCA	trans	rs7824557	0.547	rs2409749	ENSG00000256560.1	LINC01486	-6.38	4.31e-10	0.00058	-0.36	-0.28	Retinal vascular caliber;	chr8:11221440	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.806	rs2428	ENSG00000229857.1	RP11-159H20.3	-6.38	4.32e-10	0.00058	-0.33	-0.28	Mood instability;	chr8:8783635	chr9:76992099~76993108:+
THCA	trans	rs941207	0.762	rs10450	ENSG00000257210.1	NACAP3	6.38	4.33e-10	0.000581	0.36	0.28	Platelet count;	chr12:56590822	chr12:93124063~93124543:-
THCA	trans	rs7200543	1	rs14347	ENSG00000255185.4	PDXDC2P	6.38	4.33e-10	0.000582	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:70010751~70065945:-
THCA	trans	rs9649213	0.593	rs55825602	ENSG00000225169.1	BRI3P1	6.38	4.33e-10	0.000582	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr1:100213293~100213670:+
THCA	trans	rs656319	0.605	rs13252276	ENSG00000253893.2	FAM85B	6.38	4.34e-10	0.000583	0.39	0.28	Myopia (pathological);	chr8:10047203	chr8:8167819~8226614:-
THCA	trans	rs9649213	0.593	rs1468341	ENSG00000225169.1	BRI3P1	6.38	4.35e-10	0.000584	0.37	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr1:100213293~100213670:+
THCA	trans	rs8177876	0.822	rs16954582	ENSG00000224837.1	GCSHP5	6.38	4.35e-10	0.000585	0.4	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr1:168055901~168056422:-
THCA	trans	rs941207	0.547	rs56183434	ENSG00000228224.3	NACAP1	6.38	4.36e-10	0.000585	0.3	0.28	Platelet count;	chr12:56676145	chr8:101361794~101372707:+
THCA	trans	rs950169	0.922	rs6603022	ENSG00000259295.5	CSPG4P12	-6.38	4.37e-10	0.000586	-0.43	-0.28	Schizophrenia;	chr15:84161418	chr15:85191438~85213905:+
THCA	trans	rs7647973	0.626	rs1463728	ENSG00000197582.5	GPX1P1	6.37	4.39e-10	0.000589	0.52	0.28	Menarche (age at onset);	chr3:49609971	chrX:13378735~13379340:-
THCA	trans	rs9467711	0.659	rs3823158	ENSG00000219392.1	RP1-265C24.5	-6.37	4.41e-10	0.000592	-0.62	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr6:28115628~28116551:+
THCA	trans	rs9393777	0.92	rs55834529	ENSG00000253570.1	RNF5P1	6.37	4.41e-10	0.000592	0.84	0.28	Intelligence (multi-trait analysis);	chr6:27104763	chr8:38600661~38601200:-
THCA	trans	rs34421088	0.564	rs6983129	ENSG00000256560.1	LINC01486	6.37	4.41e-10	0.000593	0.33	0.28	Neuroticism;	chr8:11733627	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.866	rs6847778	ENSG00000253326.2	RP11-261C10.7	6.37	4.44e-10	0.000596	0.37	0.28	Corneal astigmatism;	chr4:119372427	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.547	rs2409745	ENSG00000256560.1	LINC01486	6.37	4.44e-10	0.000596	0.35	0.28	Retinal vascular caliber;	chr8:11219126	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.663	rs9996501	ENSG00000253326.2	RP11-261C10.7	6.37	4.45e-10	0.000598	0.39	0.28	Corneal astigmatism;	chr4:119317763	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.697	rs28458294	ENSG00000253326.2	RP11-261C10.7	6.37	4.45e-10	0.000598	0.39	0.28	Corneal astigmatism;	chr4:119317769	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.663	rs28369503	ENSG00000253326.2	RP11-261C10.7	6.37	4.45e-10	0.000598	0.39	0.28	Corneal astigmatism;	chr4:119317770	chr1:243054861~243056394:-
THCA	trans	rs3808502	0.549	rs11991139	ENSG00000256560.1	LINC01486	-6.37	4.46e-10	0.000598	-0.35	-0.28	Neuroticism;	chr8:11570886	chr12:109354083~109359488:-
THCA	trans	rs8177876	0.822	rs4324141	ENSG00000224837.1	GCSHP5	-6.37	4.52e-10	0.000606	-0.43	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr1:168055901~168056422:-
THCA	trans	rs9649213	0.593	rs56286037	ENSG00000225169.1	BRI3P1	6.37	4.53e-10	0.000607	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98390210	chr1:100213293~100213670:+
THCA	trans	rs6964833	0.786	rs35633336	ENSG00000214544.6	GTF2IRD2P1	-6.37	4.54e-10	0.000608	-0.42	-0.28	Menarche (age at onset);	chr7:74643961	chr7:73242751~73280119:-
THCA	trans	rs6964833	0.935	rs35735900	ENSG00000214544.6	GTF2IRD2P1	-6.37	4.54e-10	0.000608	-0.42	-0.28	Menarche (age at onset);	chr7:74651887	chr7:73242751~73280119:-
THCA	trans	rs864643	0.704	rs4441592	ENSG00000183298.5	RP11-556K13.1	-6.37	4.54e-10	0.000609	-0.43	-0.28	Attention deficit hyperactivity disorder;	chr3:39550772	chr1:101786340~101787219:-
THCA	trans	rs864643	0.738	rs34922979	ENSG00000183298.5	RP11-556K13.1	-6.37	4.54e-10	0.000609	-0.43	-0.28	Attention deficit hyperactivity disorder;	chr3:39550934	chr1:101786340~101787219:-
THCA	trans	rs6964833	1	rs13227433	ENSG00000214544.6	GTF2IRD2P1	-6.37	4.54e-10	0.000609	-0.41	-0.28	Menarche (age at onset);	chr7:74680386	chr7:73242751~73280119:-
THCA	trans	rs6921919	0.887	rs16894116	ENSG00000228078.1	HLA-U	-6.37	4.56e-10	0.000611	-0.42	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:29934101~29934286:+
THCA	trans	rs7903456	0.512	rs7083075	ENSG00000232706.3	NUTM2HP	6.37	4.57e-10	0.000613	0.41	0.28	Gout;Renal underexcretion gout;	chr10:87056203	chr10:50676743~50686326:+
THCA	trans	rs615632	0.53	rs10092464	ENSG00000253893.2	FAM85B	6.37	4.58e-10	0.000613	0.38	0.28	Neuroticism;	chr8:9946675	chr8:8167819~8226614:-
THCA	trans	rs9467773	0.587	rs12214031	ENSG00000242375.1	RP11-498P14.3	-6.37	4.59e-10	0.000615	-0.41	-0.28	Intelligence (multi-trait analysis);	chr6:26376400	chr9:97195351~97197687:-
THCA	trans	rs902774	0.818	rs11831919	ENSG00000254285.3	KRT8P3	-6.37	4.61e-10	0.000618	-0.58	-0.28	Prostate cancer;	chr12:52878231	chr8:61578220~61579668:+
THCA	trans	rs9650657	0.571	rs11783247	ENSG00000229857.1	RP11-159H20.3	6.37	4.62e-10	0.000619	0.35	0.28	Neuroticism;	chr8:10931365	chr9:76992099~76993108:+
THCA	trans	rs4150642	1	rs4150642	ENSG00000235847.2	LDHAP7	-6.37	4.63e-10	0.00062	-0.47	-0.28	Amyloid A serum levels;	chr11:18349351	chr2:84777259~84778223:-
THCA	trans	rs853679	0.607	rs33932084	ENSG00000253570.1	RNF5P1	6.37	4.63e-10	0.00062	0.75	0.28	Depression;	chr6:28301047	chr8:38600661~38601200:-
THCA	trans	rs12682352	0.605	rs60707155	ENSG00000256560.1	LINC01486	6.37	4.63e-10	0.00062	0.34	0.28	Neuroticism;	chr8:8866905	chr12:109354083~109359488:-
THCA	trans	rs4784054	0.803	rs11644269	ENSG00000230849.2	GOT2P2	6.37	4.64e-10	0.000621	0.48	0.28	Blood metabolite levels;	chr16:58741398	chr1:173141100~173142350:-
THCA	trans	rs4784054	1	rs4784054	ENSG00000230849.2	GOT2P2	-6.37	4.64e-10	0.000621	-0.48	-0.28	Blood metabolite levels;	chr16:58742410	chr1:173141100~173142350:-
THCA	trans	rs8177876	0.731	rs74882687	ENSG00000224837.1	GCSHP5	6.36	4.65e-10	0.000623	0.43	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.642	rs76909932	ENSG00000224837.1	GCSHP5	6.36	4.65e-10	0.000623	0.43	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.822	rs8177939	ENSG00000224837.1	GCSHP5	6.36	4.65e-10	0.000623	0.43	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr1:168055901~168056422:-
THCA	trans	rs11250097	0.549	rs11778177	ENSG00000229857.1	RP11-159H20.3	6.36	4.66e-10	0.000624	0.36	0.28	Neuroticism;	chr8:11452853	chr9:76992099~76993108:+
THCA	trans	rs11250097	0.549	rs11784897	ENSG00000229857.1	RP11-159H20.3	6.36	4.66e-10	0.000624	0.36	0.28	Neuroticism;	chr8:11452933	chr9:76992099~76993108:+
THCA	trans	rs3740713	1	rs73440637	ENSG00000236090.2	LDHAP3	6.36	4.69e-10	0.000628	0.52	0.28	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr2:41819747~41820754:+
THCA	trans	rs864643	0.773	rs11915323	ENSG00000188856.6	RPSAP47	-6.36	4.69e-10	0.000628	-0.39	-0.28	Attention deficit hyperactivity disorder;	chr3:39551612	chr8:80558870~80559757:+
THCA	trans	rs9649213	0.593	rs12728	ENSG00000225169.1	BRI3P1	6.36	4.69e-10	0.000628	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr1:100213293~100213670:+
THCA	trans	rs3812762	0.912	rs11042058	ENSG00000266891.1	RP11-692N5.2	6.36	4.7e-10	0.000629	0.38	0.28	Hypospadias;	chr11:8742268	chr18:9734882~9735602:-
THCA	trans	rs11098499	0.754	rs12711071	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119319779	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs1546503	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119320012	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.708	rs1546506	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119320085	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs28643450	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119324087	chr1:243054861~243056394:-
THCA	trans	rs10028773	0.7	rs7671797	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Educational attainment;	chr4:119327002	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs7672372	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119327251	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs7672594	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119327388	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs7672778	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119327430	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs2036860	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119327779	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs2036857	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119328085	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs2036856	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119328133	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs4443261	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119328146	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs12513083	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119328457	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs12509621	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119328505	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs1511017	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119329650	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.789	rs12498994	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119329663	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs12507565	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119329966	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.826	rs12511640	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119330093	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs1980026	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119330488	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.722	rs28713555	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119330840	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.743	rs11098501	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119330862	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs11098502	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119330908	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.708	rs11732686	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119331175	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs11724409	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119331206	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.789	rs1980024	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119331892	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs34425882	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119332022	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs4107728	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119332755	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs17049949	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119334135	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs7689729	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119335037	chr1:243054861~243056394:-
THCA	trans	rs10028773	0.7	rs7690338	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Educational attainment;	chr4:119335313	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.865	rs3956464	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119335609	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.619	rs28502463	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119335868	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.648	rs2002047	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119336073	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.775	rs2002049	ENSG00000253326.2	RP11-261C10.7	6.36	4.72e-10	0.000631	0.39	0.28	Corneal astigmatism;	chr4:119336262	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs9991959	ENSG00000253326.2	RP11-261C10.7	-6.36	4.72e-10	0.000631	-0.39	-0.28	Corneal astigmatism;	chr4:119332618	chr1:243054861~243056394:-
THCA	trans	rs2985684	0.748	rs2985686	ENSG00000240785.1	RPL36AP21	6.36	4.72e-10	0.000631	0.37	0.28	Carotid intima media thickness;	chr14:49633965	chr5:18049550~18049872:+
THCA	trans	rs6964833	1	rs35203738	ENSG00000214544.6	GTF2IRD2P1	-6.36	4.73e-10	0.000632	-0.41	-0.28	Menarche (age at onset);	chr7:74690864	chr7:73242751~73280119:-
THCA	trans	rs7829975	0.774	rs11249893	ENSG00000256560.1	LINC01486	6.36	4.73e-10	0.000632	0.34	0.28	Mood instability;	chr8:8843341	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.591	rs2293859	ENSG00000253893.2	FAM85B	-6.36	4.74e-10	0.000633	-0.38	-0.28	Retinal vascular caliber;	chr8:11359252	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.56	rs2248699	ENSG00000256560.1	LINC01486	-6.36	4.75e-10	0.000635	-0.35	-0.28	Neuroticism;	chr8:11536255	chr12:109354083~109359488:-
THCA	trans	rs941207	0.756	rs7315472	ENSG00000228224.3	NACAP1	-6.36	4.75e-10	0.000635	-0.33	-0.28	Platelet count;	chr12:56648276	chr8:101361794~101372707:+
THCA	trans	rs6600671	0.902	rs2222371	ENSG00000270392.2	PFN1P2	-6.36	4.76e-10	0.000636	-0.29	-0.28	Hip geometry;	chr1:121547320	chr1:120432204~120434052:-
THCA	trans	rs76228276	0.737	rs11995956	ENSG00000260318.1	COX6CP1	6.36	4.77e-10	0.000637	0.83	0.28	Childhood ear infection;	chr8:99337855	chr16:11903923~11904137:-
THCA	trans	rs1707322	1	rs10890359	ENSG00000255397.1	AC022182.2	-6.36	4.77e-10	0.000637	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr8:60937705~60939871:-
THCA	trans	rs3956705	0.83	rs7811609	ENSG00000176826.14	FKBP9P1	6.36	4.78e-10	0.000638	0.37	0.28	Red cell distribution width;	chr7:32890985	chr7:55681074~55713252:-
THCA	trans	rs9329221	0.538	rs17750324	ENSG00000253893.2	FAM85B	6.36	4.78e-10	0.000638	0.38	0.28	Neuroticism;	chr8:10243402	chr8:8167819~8226614:-
THCA	trans	rs335206	0.935	rs463106	ENSG00000256427.1	RP11-118B22.4	-6.36	4.78e-10	0.000638	-0.3	-0.28	QRS duration;	chr5:123166873	chr12:9246497~9257960:+
THCA	trans	rs941207	0.526	rs7303216	ENSG00000228224.3	NACAP1	6.36	4.8e-10	0.000641	0.3	0.28	Platelet count;	chr12:56680909	chr8:101361794~101372707:+
THCA	trans	rs941207	0.507	rs7297289	ENSG00000228224.3	NACAP1	6.36	4.8e-10	0.000641	0.3	0.28	Platelet count;	chr12:56682703	chr8:101361794~101372707:+
THCA	trans	rs941207	0.526	rs4759028	ENSG00000228224.3	NACAP1	6.36	4.8e-10	0.000641	0.3	0.28	Platelet count;	chr12:56686399	chr8:101361794~101372707:+
THCA	trans	rs902774	0.818	rs73110464	ENSG00000254285.3	KRT8P3	-6.36	4.84e-10	0.000646	-0.57	-0.28	Prostate cancer;	chr12:52918828	chr8:61578220~61579668:+
THCA	trans	rs1707322	1	rs785465	ENSG00000255397.1	AC022182.2	-6.36	4.84e-10	0.000646	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr8:60937705~60939871:-
THCA	trans	rs11992162	0.967	rs10112888	ENSG00000256560.1	LINC01486	6.36	4.87e-10	0.00065	0.35	0.28	Monocyte count;	chr8:11972699	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs785469	ENSG00000255397.1	AC022182.2	6.36	4.87e-10	0.00065	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs785468	ENSG00000255397.1	AC022182.2	6.36	4.87e-10	0.00065	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr8:60937705~60939871:-
THCA	trans	rs941207	0.756	rs67046307	ENSG00000228224.3	NACAP1	-6.36	4.88e-10	0.000651	-0.33	-0.28	Platelet count;	chr12:56651152	chr8:101361794~101372707:+
THCA	trans	rs941207	0.756	rs10876915	ENSG00000228224.3	NACAP1	-6.36	4.88e-10	0.000651	-0.33	-0.28	Platelet count;	chr12:56655280	chr8:101361794~101372707:+
THCA	trans	rs1707322	1	rs3922887	ENSG00000255397.1	AC022182.2	-6.36	4.88e-10	0.000652	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs3922886	ENSG00000255397.1	AC022182.2	-6.36	4.88e-10	0.000652	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr8:60937705~60939871:-
THCA	trans	rs4646450	0.735	rs3801288	ENSG00000228834.1	RP11-249L21.4	6.36	4.89e-10	0.000653	0.49	0.28	Blood metabolite levels;	chr7:99348285	chr6:108907615~108907873:-
THCA	trans	rs2985684	1	rs3007030	ENSG00000240785.1	RPL36AP21	6.36	4.9e-10	0.000654	0.37	0.28	Carotid intima media thickness;	chr14:49619845	chr5:18049550~18049872:+
THCA	trans	rs1707322	1	rs34694458	ENSG00000255397.1	AC022182.2	-6.36	4.9e-10	0.000654	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr8:60937705~60939871:-
THCA	trans	rs853679	0.556	rs45509595	ENSG00000253570.1	RNF5P1	6.36	4.92e-10	0.000656	0.8	0.28	Depression;	chr6:27873148	chr8:38600661~38601200:-
THCA	trans	rs8177876	0.822	rs1563077	ENSG00000224837.1	GCSHP5	6.35	4.95e-10	0.000661	0.42	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr1:168055901~168056422:-
THCA	trans	rs11098499	0.722	rs1814814	ENSG00000253326.2	RP11-261C10.7	6.35	4.96e-10	0.000661	0.37	0.28	Corneal astigmatism;	chr4:119336969	chr1:243054861~243056394:-
THCA	trans	rs877636	0.692	rs10876870	ENSG00000234192.1	RP11-57C13.5	-6.35	4.97e-10	0.000663	-0.34	-0.28	Cognitive function;	chr12:56084218	chr10:87642607~87642954:+
THCA	trans	rs877636	0.692	rs7971751	ENSG00000234192.1	RP11-57C13.5	-6.35	4.97e-10	0.000663	-0.34	-0.28	Cognitive function;	chr12:56084874	chr10:87642607~87642954:+
THCA	trans	rs2950393	0.804	rs7980317	ENSG00000257210.1	NACAP3	6.35	4.97e-10	0.000663	0.33	0.28	Platelet distribution width;	chr12:56764399	chr12:93124063~93124543:-
THCA	trans	rs2736345	0.516	rs7844858	ENSG00000253893.2	FAM85B	-6.35	4.97e-10	0.000663	-0.37	-0.28	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11535150	chr8:8167819~8226614:-
THCA	trans	rs6458375	0.953	rs11962761	ENSG00000205940.8	HSP90AB2P	6.35	4.98e-10	0.000664	0.39	0.28	Interleukin-10 levels;	chr6:44236327	chr4:13333414~13338657:+
THCA	trans	rs12145833	0.679	rs7537757	ENSG00000154608.12	CEP170P1	-6.35	4.98e-10	0.000664	-0.36	-0.28	Obesity (early onset extreme);	chr1:243431362	chr4:118467590~118554204:+
THCA	trans	rs7824557	0.815	rs2736372	ENSG00000229857.1	RP11-159H20.3	6.35	4.98e-10	0.000664	0.33	0.28	Retinal vascular caliber;	chr8:11248532	chr9:76992099~76993108:+
THCA	trans	rs902774	0.818	rs73110432	ENSG00000254285.3	KRT8P3	-6.35	4.99e-10	0.000665	-0.56	-0.28	Prostate cancer;	chr12:52894051	chr8:61578220~61579668:+
THCA	trans	rs2336384	1	rs61776516	ENSG00000261819.1	RP11-680G24.4	6.35	4.99e-10	0.000665	0.37	0.28	Platelet count;	chr1:11986971	chr16:14988259~14990160:-
THCA	trans	rs2336384	1	rs7551874	ENSG00000261819.1	RP11-680G24.4	6.35	4.99e-10	0.000665	0.37	0.28	Platelet count;	chr1:11988073	chr16:14988259~14990160:-
THCA	trans	rs2336384	1	rs4846085	ENSG00000261819.1	RP11-680G24.4	6.35	4.99e-10	0.000665	0.37	0.28	Platelet count;	chr1:11990577	chr16:14988259~14990160:-
THCA	trans	rs453301	0.522	rs2929455	ENSG00000229857.1	RP11-159H20.3	6.35	4.99e-10	0.000665	0.34	0.28	Joint mobility (Beighton score);	chr8:9225923	chr9:76992099~76993108:+
THCA	trans	rs7826238	0.72	rs12546760	ENSG00000256560.1	LINC01486	-6.35	5.01e-10	0.000668	-0.34	-0.28	Systolic blood pressure;	chr8:8517326	chr12:109354083~109359488:-
THCA	trans	rs7192380	0.756	rs12596945	ENSG00000196796.5	CTB-134H23.2	-6.35	5.01e-10	0.000668	-0.34	-0.28	Sjögren's syndrome;	chr16:69746916	chr16:29038655~29052726:+
THCA	trans	rs11098499	1	rs11098499	ENSG00000253326.2	RP11-261C10.7	6.35	5.01e-10	0.000668	0.39	0.28	Corneal astigmatism;	chr4:119266456	chr1:243054861~243056394:-
THCA	trans	rs2950393	0.804	rs898609	ENSG00000257210.1	NACAP3	6.35	5.02e-10	0.000669	0.33	0.28	Platelet distribution width;	chr12:56713026	chr12:93124063~93124543:-
THCA	trans	rs2950393	0.804	rs4902	ENSG00000257210.1	NACAP3	6.35	5.02e-10	0.000669	0.33	0.28	Platelet distribution width;	chr12:56714419	chr12:93124063~93124543:-
THCA	trans	rs2950393	0.804	rs2926748	ENSG00000257210.1	NACAP3	6.35	5.02e-10	0.000669	0.33	0.28	Platelet distribution width;	chr12:56715628	chr12:93124063~93124543:-
THCA	trans	rs6600671	0.934	rs11249429	ENSG00000270392.2	PFN1P2	-6.35	5.03e-10	0.000671	-0.28	-0.28	Hip geometry;	chr1:121549282	chr1:120432204~120434052:-
THCA	trans	rs7212590	0.881	rs7214032	ENSG00000187870.7	RNFT1P3	6.35	5.03e-10	0.000671	0.56	0.28	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808467	chr17:20743333~20754501:-
THCA	trans	rs7824557	0.836	rs1435278	ENSG00000253893.2	FAM85B	6.35	5.03e-10	0.000671	0.36	0.28	Retinal vascular caliber;	chr8:11265520	chr8:8167819~8226614:-
THCA	trans	rs2336384	1	rs4846083	ENSG00000261819.1	RP11-680G24.4	6.35	5.04e-10	0.000671	0.37	0.28	Platelet count;	chr1:11985498	chr16:14988259~14990160:-
THCA	trans	rs7829975	0.659	rs4382480	ENSG00000229857.1	RP11-159H20.3	-6.35	5.04e-10	0.000672	-0.36	-0.28	Mood instability;	chr8:8863963	chr9:76992099~76993108:+
THCA	trans	rs10716881	1	rs10716881	ENSG00000257210.1	NACAP3	-6.35	5.05e-10	0.000673	-0.34	-0.28	High light scatter reticulocyte count;	chr12:56644387	chr12:93124063~93124543:-
THCA	trans	rs864643	0.898	rs1768144	ENSG00000183298.5	RP11-556K13.1	6.35	5.08e-10	0.000677	0.45	0.28	Attention deficit hyperactivity disorder;	chr3:39550569	chr1:101786340~101787219:-
THCA	trans	rs7973618	1	rs7973618	ENSG00000257210.1	NACAP3	-6.35	5.08e-10	0.000677	-0.34	-0.28	Mean platelet volume;	chr12:56625659	chr12:93124063~93124543:-
THCA	trans	rs889398	0.617	rs4985447	ENSG00000196796.5	CTB-134H23.2	6.35	5.08e-10	0.000677	0.31	0.28	Body mass index;	chr16:69851263	chr16:29038655~29052726:+
THCA	trans	rs453301	0.522	rs2929309	ENSG00000229857.1	RP11-159H20.3	6.35	5.09e-10	0.000677	0.34	0.28	Joint mobility (Beighton score);	chr8:9226261	chr9:76992099~76993108:+
THCA	trans	rs656319	0.607	rs35437983	ENSG00000253893.2	FAM85B	6.35	5.09e-10	0.000678	0.38	0.28	Myopia (pathological);	chr8:10147543	chr8:8167819~8226614:-
THCA	trans	rs9467773	0.626	rs6936006	ENSG00000242375.1	RP11-498P14.3	-6.35	5.09e-10	0.000678	-0.41	-0.28	Intelligence (multi-trait analysis);	chr6:26350337	chr9:97195351~97197687:-
THCA	trans	rs656319	0.629	rs11774276	ENSG00000253893.2	FAM85B	6.35	5.11e-10	0.00068	0.42	0.28	Myopia (pathological);	chr8:10212799	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.503	rs34190028	ENSG00000229857.1	RP11-159H20.3	6.35	5.11e-10	0.000681	0.36	0.28	Neuroticism;	chr8:11559641	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.668	rs920047	ENSG00000254153.1	CTA-398F10.2	6.35	5.13e-10	0.000682	0.32	0.28	Triglycerides;	chr8:11229966	chr8:8456909~8461337:-
THCA	trans	rs1707322	1	rs7532204	ENSG00000255397.1	AC022182.2	6.35	5.14e-10	0.000684	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.835	rs946525	ENSG00000255397.1	AC022182.2	6.35	5.14e-10	0.000684	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs946524	ENSG00000255397.1	AC022182.2	6.35	5.14e-10	0.000684	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4660336	ENSG00000255397.1	AC022182.2	6.35	5.14e-10	0.000684	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211248	ENSG00000255397.1	AC022182.2	-6.35	5.14e-10	0.000684	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr8:60937705~60939871:-
THCA	trans	rs3808502	0.549	rs4841564	ENSG00000229857.1	RP11-159H20.3	6.35	5.14e-10	0.000684	0.36	0.28	Neuroticism;	chr8:11568300	chr9:76992099~76993108:+
THCA	trans	rs4295623	0.559	rs2409836	ENSG00000256560.1	LINC01486	6.35	5.14e-10	0.000685	0.35	0.28	Morning vs. evening chronotype;	chr8:11831719	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.842	rs4911253	ENSG00000253915.1	MAPRE1P1	6.35	5.16e-10	0.000687	0.37	0.28	Ulcerative colitis;	chr20:32764779	chr8:135625185~135625981:-
THCA	trans	rs11098499	0.754	rs938056	ENSG00000253326.2	RP11-261C10.7	6.35	5.17e-10	0.000688	0.39	0.28	Corneal astigmatism;	chr4:119316298	chr1:243054861~243056394:-
THCA	trans	rs902774	0.818	rs79377635	ENSG00000254285.3	KRT8P3	-6.35	5.17e-10	0.000688	-0.58	-0.28	Prostate cancer;	chr12:52883148	chr8:61578220~61579668:+
THCA	trans	rs7200543	1	rs4985154	ENSG00000255185.4	PDXDC2P	6.35	5.18e-10	0.000689	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:70010751~70065945:-
THCA	trans	rs7200543	1	rs34614532	ENSG00000255185.4	PDXDC2P	6.35	5.18e-10	0.000689	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:70010751~70065945:-
THCA	trans	rs2950393	0.804	rs2958127	ENSG00000257210.1	NACAP3	6.35	5.18e-10	0.000689	0.33	0.28	Platelet distribution width;	chr12:56720523	chr12:93124063~93124543:-
THCA	trans	rs877636	1	rs705696	ENSG00000227586.5	RP11-162A23.5	6.35	5.18e-10	0.00069	0.37	0.28	Cognitive function;	chr12:56086864	chr10:123171535~123171875:-
THCA	trans	rs1707322	1	rs9429186	ENSG00000255397.1	AC022182.2	6.35	5.19e-10	0.000691	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs785506	ENSG00000255397.1	AC022182.2	6.35	5.19e-10	0.000691	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr8:60937705~60939871:-
THCA	trans	rs864643	0.898	rs530080	ENSG00000188856.6	RPSAP47	6.35	5.2e-10	0.000691	0.44	0.28	Attention deficit hyperactivity disorder;	chr3:39547507	chr8:80558870~80559757:+
THCA	trans	rs11098499	0.866	rs11098506	ENSG00000253326.2	RP11-261C10.7	6.35	5.21e-10	0.000693	0.38	0.28	Corneal astigmatism;	chr4:119363816	chr1:243054861~243056394:-
THCA	trans	rs1707322	1	rs7538978	ENSG00000255397.1	AC022182.2	6.35	5.22e-10	0.000694	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr8:60937705~60939871:-
THCA	trans	rs902774	0.818	rs73110432	ENSG00000220378.3	KRT8P42	-6.35	5.22e-10	0.000694	-0.58	-0.28	Prostate cancer;	chr12:52894051	chr6:134296997~134298695:-
THCA	trans	rs9650657	0.711	rs7007318	ENSG00000253893.2	FAM85B	6.35	5.22e-10	0.000694	0.36	0.28	Neuroticism;	chr8:10734768	chr8:8167819~8226614:-
THCA	trans	rs2288327	0.818	rs7597154	ENSG00000269800.1	PLEKHA3P1	6.35	5.22e-10	0.000695	0.4	0.28	Atrial fibrillation;	chr2:178523763	chr19:41521043~41521989:-
THCA	trans	rs2288327	0.818	rs13005601	ENSG00000269800.1	PLEKHA3P1	6.35	5.22e-10	0.000695	0.4	0.28	Atrial fibrillation;	chr2:178523930	chr19:41521043~41521989:-
THCA	trans	rs2288327	0.818	rs16866369	ENSG00000269800.1	PLEKHA3P1	6.35	5.22e-10	0.000695	0.4	0.28	Atrial fibrillation;	chr2:178524267	chr19:41521043~41521989:-
THCA	trans	rs1707322	1	rs4073847	ENSG00000255397.1	AC022182.2	6.34	5.25e-10	0.000698	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr8:60937705~60939871:-
THCA	trans	rs453301	0.624	rs7014430	ENSG00000229857.1	RP11-159H20.3	-6.34	5.25e-10	0.000698	-0.34	-0.28	Joint mobility (Beighton score);	chr8:8970227	chr9:76992099~76993108:+
THCA	trans	rs853679	0.607	rs13194781	ENSG00000228022.4	HCG20	-6.34	5.25e-10	0.000698	-0.71	-0.28	Depression;	chr6:27847861	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs36116761	ENSG00000228022.4	HCG20	-6.34	5.25e-10	0.000698	-0.71	-0.28	Depression;	chr6:27850704	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs34194357	ENSG00000228022.4	HCG20	-6.34	5.25e-10	0.000698	-0.71	-0.28	Depression;	chr6:27850757	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13199772	ENSG00000228022.4	HCG20	-6.34	5.25e-10	0.000698	-0.71	-0.28	Depression;	chr6:27866307	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13199906	ENSG00000228022.4	HCG20	-6.34	5.25e-10	0.000698	-0.71	-0.28	Depression;	chr6:27866361	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs17763089	ENSG00000228022.4	HCG20	-6.34	5.25e-10	0.000698	-0.71	-0.28	Depression;	chr6:27867440	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs17695758	ENSG00000228022.4	HCG20	-6.34	5.25e-10	0.000698	-0.71	-0.28	Depression;	chr6:27869405	chr6:30766825~30792250:+
THCA	trans	rs9650657	0.556	rs6601530	ENSG00000253893.2	FAM85B	6.34	5.26e-10	7e-04	0.36	0.28	Neuroticism;	chr8:10813762	chr8:8167819~8226614:-
THCA	trans	rs864643	0.853	rs4676643	ENSG00000183298.5	RP11-556K13.1	-6.34	5.28e-10	0.000702	-0.44	-0.28	Attention deficit hyperactivity disorder;	chr3:39537413	chr1:101786340~101787219:-
THCA	trans	rs7819412	0.806	rs2409689	ENSG00000256560.1	LINC01486	-6.34	5.29e-10	0.000704	-0.34	-0.28	Triglycerides;	chr8:11075358	chr12:109354083~109359488:-
THCA	trans	rs2980439	0.517	rs793753	ENSG00000229857.1	RP11-159H20.3	6.34	5.31e-10	0.000705	0.35	0.28	Neuroticism;	chr8:8247837	chr9:76992099~76993108:+
THCA	trans	rs941207	0.724	rs4788	ENSG00000228224.3	NACAP1	6.34	5.31e-10	0.000706	0.32	0.28	Platelet count;	chr12:56712876	chr8:101361794~101372707:+
THCA	trans	rs34421088	0.506	rs10091637	ENSG00000253893.2	FAM85B	-6.34	5.31e-10	0.000706	-0.37	-0.28	Neuroticism;	chr8:11286805	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2736288	ENSG00000254153.1	CTA-398F10.2	6.34	5.32e-10	0.000707	0.31	0.28	Retinal vascular caliber;	chr8:11370591	chr8:8456909~8461337:-
THCA	trans	rs2243480	1	rs7456042	ENSG00000232546.1	RP11-458F8.1	-6.34	5.35e-10	0.000711	-0.36	-0.28	Diabetic kidney disease;	chr7:65834791	chr7:66848496~66858136:+
THCA	trans	rs2243480	1	rs73142121	ENSG00000232546.1	RP11-458F8.1	-6.34	5.35e-10	0.000711	-0.36	-0.28	Diabetic kidney disease;	chr7:65846219	chr7:66848496~66858136:+
THCA	trans	rs8177876	0.822	rs56119129	ENSG00000224837.1	GCSHP5	6.34	5.36e-10	0.000712	0.42	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.731	rs77145371	ENSG00000224837.1	GCSHP5	6.34	5.36e-10	0.000712	0.42	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr1:168055901~168056422:-
THCA	trans	rs8177876	0.908	rs80187824	ENSG00000224837.1	GCSHP5	6.34	5.36e-10	0.000712	0.42	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr1:168055901~168056422:-
THCA	trans	rs9649213	0.593	rs6944262	ENSG00000225169.1	BRI3P1	6.34	5.36e-10	0.000712	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr1:100213293~100213670:+
THCA	trans	rs6885307	0.941	rs62369867	ENSG00000231752.4	EMBP1	6.34	5.36e-10	0.000712	0.43	0.28	Age at first birth;	chr5:45014940	chr1:121519112~121571892:+
THCA	trans	rs9914988	0.619	rs34580233	ENSG00000267449.1	RP11-264B14.2	6.34	5.37e-10	0.000714	0.43	0.28	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28990917	chr17:61069856~61070356:-
THCA	trans	rs7617480	0.756	rs990211	ENSG00000197582.5	GPX1P1	6.34	5.39e-10	0.000716	0.5	0.28	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48683607	chrX:13378735~13379340:-
THCA	trans	rs11098499	0.564	rs11098507	ENSG00000253326.2	RP11-261C10.7	6.34	5.41e-10	0.000719	0.37	0.28	Corneal astigmatism;	chr4:119367131	chr1:243054861~243056394:-
THCA	trans	rs8177876	0.642	rs56032321	ENSG00000224837.1	GCSHP5	6.34	5.42e-10	0.000719	0.42	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr1:168055901~168056422:-
THCA	trans	rs6087990	0.735	rs1003522	ENSG00000253915.1	MAPRE1P1	6.34	5.46e-10	0.000725	0.37	0.28	Ulcerative colitis;	chr20:32780754	chr8:135625185~135625981:-
THCA	trans	rs7824557	0.51	rs4841524	ENSG00000254153.1	CTA-398F10.2	6.34	5.46e-10	0.000725	0.32	0.28	Retinal vascular caliber;	chr8:11385617	chr8:8456909~8461337:-
THCA	trans	rs12682352	0.579	rs7006589	ENSG00000256560.1	LINC01486	6.34	5.48e-10	0.000728	0.34	0.28	Neuroticism;	chr8:8810976	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.967	rs11250185	ENSG00000229857.1	RP11-159H20.3	-6.34	5.48e-10	0.000728	-0.36	-0.28	Monocyte count;	chr8:11975614	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.501	rs2980769	ENSG00000229857.1	RP11-159H20.3	-6.34	5.49e-10	0.000728	-0.34	-0.28	Mood instability;	chr8:8462781	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.626	rs907183	ENSG00000229857.1	RP11-159H20.3	6.34	5.51e-10	0.000731	0.35	0.28	Mood instability;	chr8:8872251	chr9:76992099~76993108:+
THCA	trans	rs656319	0.513	rs688541	ENSG00000253893.2	FAM85B	6.34	5.51e-10	0.000731	0.4	0.28	Myopia (pathological);	chr8:9960490	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.765	rs17783634	ENSG00000256560.1	LINC01486	-6.34	5.51e-10	0.000732	-0.35	-0.28	Triglycerides;	chr8:11196588	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.754	rs10212714	ENSG00000253326.2	RP11-261C10.7	6.34	5.55e-10	0.000736	0.39	0.28	Corneal astigmatism;	chr4:119333147	chr1:243054861~243056394:-
THCA	trans	rs7200543	1	rs35574015	ENSG00000255185.4	PDXDC2P	6.34	5.55e-10	0.000736	0.4	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:70010751~70065945:-
THCA	trans	rs2950393	0.895	rs2958154	ENSG00000228224.3	NACAP1	-6.33	5.56e-10	0.000738	-0.3	-0.28	Platelet distribution width;	chr12:56671929	chr8:101361794~101372707:+
THCA	trans	rs2950393	0.804	rs2290894	ENSG00000257210.1	NACAP3	6.33	5.58e-10	0.00074	0.32	0.28	Platelet distribution width;	chr12:56714911	chr12:93124063~93124543:-
THCA	trans	rs6424115	0.594	rs10799802	ENSG00000228217.1	AL390877.1	-6.33	5.59e-10	0.000741	-0.36	-0.28	Immature fraction of reticulocytes;	chr1:23683054	chr1:117778087~117778506:-
THCA	trans	rs3812762	0.783	rs34524863	ENSG00000266891.1	RP11-692N5.2	6.33	5.6e-10	0.000742	0.38	0.28	Hypospadias;	chr11:8755861	chr18:9734882~9735602:-
THCA	trans	rs9649213	0.593	rs2240349	ENSG00000225169.1	BRI3P1	6.33	5.63e-10	0.000746	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs13307593	ENSG00000225169.1	BRI3P1	6.33	5.63e-10	0.000746	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr1:100213293~100213670:+
THCA	trans	rs6601327	0.55	rs4422774	ENSG00000253893.2	FAM85B	6.33	5.66e-10	0.00075	0.35	0.28	Multiple myeloma (hyperdiploidy);	chr8:9664501	chr8:8167819~8226614:-
THCA	trans	rs6885307	0.943	rs62369904	ENSG00000231752.4	EMBP1	6.33	5.66e-10	0.000751	0.45	0.28	Age at first birth;	chr5:45092831	chr1:121519112~121571892:+
THCA	trans	rs1190596	0.525	rs72698572	ENSG00000181359.5	HSP90AA6P	-6.33	5.68e-10	0.000752	-0.4	-0.28	Behavioural disinhibition (generation interaction);	chr14:102289870	chr4:170581470~170605450:-
THCA	trans	rs9467711	0.606	rs13190739	ENSG00000280107.1	AL022393.9	-6.33	5.68e-10	0.000753	-0.53	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.606	rs34781270	ENSG00000280107.1	AL022393.9	-6.33	5.68e-10	0.000753	-0.53	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.606	rs35076545	ENSG00000280107.1	AL022393.9	-6.33	5.68e-10	0.000753	-0.53	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.606	rs13212985	ENSG00000280107.1	AL022393.9	-6.33	5.68e-10	0.000753	-0.53	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr6:28170845~28172521:+
THCA	trans	rs7200543	1	rs1135999	ENSG00000255185.4	PDXDC2P	6.33	5.72e-10	0.000758	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:70010751~70065945:-
THCA	trans	rs7200543	1	rs1136001	ENSG00000255185.4	PDXDC2P	6.33	5.72e-10	0.000758	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:70010751~70065945:-
THCA	trans	rs7200543	1	rs2740	ENSG00000255185.4	PDXDC2P	6.33	5.72e-10	0.000758	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:70010751~70065945:-
THCA	trans	rs656319	0.625	rs4526366	ENSG00000253893.2	FAM85B	6.33	5.73e-10	0.000759	0.39	0.28	Myopia (pathological);	chr8:10032669	chr8:8167819~8226614:-
THCA	trans	rs9649213	0.593	rs6969234	ENSG00000225169.1	BRI3P1	6.33	5.73e-10	0.000759	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs3801256	ENSG00000225169.1	BRI3P1	6.33	5.73e-10	0.000759	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs1468340	ENSG00000225169.1	BRI3P1	6.33	5.73e-10	0.000759	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.555	rs6956686	ENSG00000225169.1	BRI3P1	6.33	5.73e-10	0.000759	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs13246843	ENSG00000225169.1	BRI3P1	6.33	5.73e-10	0.000759	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr1:100213293~100213670:+
THCA	trans	rs4415084	0.834	rs10043344	ENSG00000231752.4	EMBP1	-6.33	5.73e-10	0.000759	-0.38	-0.28	Breast cancer;	chr5:44926416	chr1:121519112~121571892:+
THCA	trans	rs2950393	0.777	rs7966391	ENSG00000257210.1	NACAP3	6.33	5.74e-10	0.00076	0.33	0.28	Platelet distribution width;	chr12:56745272	chr12:93124063~93124543:-
THCA	trans	rs76228276	0.737	rs16897302	ENSG00000260318.1	COX6CP1	6.33	5.74e-10	0.000761	0.83	0.28	Childhood ear infection;	chr8:99351561	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11991039	ENSG00000260318.1	COX6CP1	6.33	5.74e-10	0.000761	0.83	0.28	Childhood ear infection;	chr8:99363319	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs16897325	ENSG00000260318.1	COX6CP1	6.33	5.74e-10	0.000761	0.83	0.28	Childhood ear infection;	chr8:99388063	chr16:11903923~11904137:-
THCA	trans	rs7200543	1	rs4500751	ENSG00000250569.1	NTAN1P2	6.33	5.75e-10	0.000761	0.28	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr8:86481754~86483002:-
THCA	trans	rs7824557	0.843	rs2572418	ENSG00000254153.1	CTA-398F10.2	6.33	5.75e-10	0.000761	0.3	0.28	Retinal vascular caliber;	chr8:11255580	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.563	rs12549144	ENSG00000256560.1	LINC01486	6.33	5.75e-10	0.000761	0.35	0.28	Neuroticism;	chr8:11565352	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.872	rs1347410	ENSG00000254153.1	CTA-398F10.2	6.33	5.76e-10	0.000762	0.3	0.28	Retinal vascular caliber;	chr8:11253733	chr8:8456909~8461337:-
THCA	trans	rs2980439	0.783	rs2955587	ENSG00000256560.1	LINC01486	6.33	5.76e-10	0.000762	0.33	0.28	Neuroticism;	chr8:8240557	chr12:109354083~109359488:-
THCA	trans	rs2243480	1	rs3885839	ENSG00000232546.1	RP11-458F8.1	-6.33	5.79e-10	0.000766	-0.37	-0.28	Diabetic kidney disease;	chr7:65825416	chr7:66848496~66858136:+
THCA	trans	rs2243480	1	rs73142122	ENSG00000232546.1	RP11-458F8.1	-6.33	5.79e-10	0.000766	-0.37	-0.28	Diabetic kidney disease;	chr7:65846311	chr7:66848496~66858136:+
THCA	trans	rs853679	0.567	rs6905380	ENSG00000228078.1	HLA-U	-6.33	5.79e-10	0.000766	-0.38	-0.28	Depression;	chr6:28407125	chr6:29934101~29934286:+
THCA	trans	rs4879656	0.797	rs2297218	ENSG00000215007.3	DNAJA1P3	6.33	5.79e-10	0.000767	0.32	0.28	Menopause (age at onset);	chr9:33025253	chrX:107351650~107352843:-
THCA	trans	rs1962073	0.623	rs7459532	ENSG00000253893.2	FAM85B	6.33	5.8e-10	0.000768	0.34	0.28	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10403558	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.505	rs2736313	ENSG00000254153.1	CTA-398F10.2	-6.33	5.81e-10	0.000769	-0.31	-0.28	Retinal vascular caliber;	chr8:11229433	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.614	rs2060456	ENSG00000253893.2	FAM85B	-6.33	5.81e-10	0.000769	-0.37	-0.28	Retinal vascular caliber;	chr8:11355854	chr8:8167819~8226614:-
THCA	trans	rs9467711	0.79	rs13198716	ENSG00000280107.1	AL022393.9	6.33	5.81e-10	0.000769	0.55	0.28	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:28170845~28172521:+
THCA	trans	rs941207	0.507	rs2958124	ENSG00000228224.3	NACAP1	-6.33	5.82e-10	0.00077	-0.29	-0.28	Platelet count;	chr12:56633837	chr8:101361794~101372707:+
THCA	trans	rs2336384	1	rs873457	ENSG00000261819.1	RP11-680G24.4	6.33	5.87e-10	0.000776	0.36	0.28	Platelet count;	chr1:11986277	chr16:14988259~14990160:-
THCA	trans	rs11992162	0.569	rs35283519	ENSG00000253893.2	FAM85B	6.33	5.89e-10	0.000779	0.43	0.28	Monocyte count;	chr8:11974152	chr8:8167819~8226614:-
THCA	trans	rs4140564	0.73	rs1980454	ENSG00000227939.1	RPL3P2	6.33	5.9e-10	0.000779	0.34	0.28	Knee osteoarthritis;	chr1:186800368	chr6:31280317~31281519:+
THCA	trans	rs11098499	0.754	rs9999724	ENSG00000253326.2	RP11-261C10.7	6.33	5.9e-10	0.00078	0.38	0.28	Corneal astigmatism;	chr4:119318789	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs714899	ENSG00000253326.2	RP11-261C10.7	6.33	5.9e-10	0.00078	0.38	0.28	Corneal astigmatism;	chr4:119321880	chr1:243054861~243056394:-
THCA	trans	rs4295623	0.816	rs35558975	ENSG00000229857.1	RP11-159H20.3	6.33	5.9e-10	0.00078	0.36	0.28	Morning vs. evening chronotype;	chr8:11726967	chr9:76992099~76993108:+
THCA	trans	rs12200782	1	rs3800304	ENSG00000242375.1	RP11-498P14.3	-6.32	5.9e-10	0.000781	-0.74	-0.28	Small cell lung carcinoma;	chr6:26598570	chr9:97195351~97197687:-
THCA	trans	rs9649213	0.593	rs6967457	ENSG00000225169.1	BRI3P1	6.32	5.91e-10	0.000782	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr1:100213293~100213670:+
THCA	trans	rs12472274	0.817	rs34791859	ENSG00000224699.7	LAMTOR5-AS1	-6.32	5.94e-10	0.000786	-0.25	-0.28	Phospholipid levels (plasma);	chr2:238162278	chr1:110347116~110443817:+
THCA	trans	rs11992162	1	rs12334769	ENSG00000229857.1	RP11-159H20.3	-6.32	5.94e-10	0.000786	-0.36	-0.28	Monocyte count;	chr8:11975652	chr9:76992099~76993108:+
THCA	trans	rs9649213	0.593	rs3801255	ENSG00000225169.1	BRI3P1	6.32	5.94e-10	0.000786	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr1:100213293~100213670:+
THCA	trans	rs7824557	0.836	rs2736378	ENSG00000253893.2	FAM85B	6.32	5.96e-10	0.000787	0.35	0.28	Retinal vascular caliber;	chr8:11262251	chr8:8167819~8226614:-
THCA	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	6.32	5.96e-10	0.000788	0.41	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
THCA	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	6.32	5.96e-10	0.000788	0.41	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
THCA	trans	rs453301	0.652	rs2043129	ENSG00000229857.1	RP11-159H20.3	-6.32	5.97e-10	0.000788	-0.34	-0.28	Joint mobility (Beighton score);	chr8:8967994	chr9:76992099~76993108:+
THCA	trans	rs9649213	0.593	rs6465675	ENSG00000225169.1	BRI3P1	-6.32	5.97e-10	0.000789	-0.36	-0.28	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs7795176	ENSG00000225169.1	BRI3P1	6.32	5.97e-10	0.000789	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs62478200	ENSG00000225169.1	BRI3P1	6.32	5.97e-10	0.000789	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr1:100213293~100213670:+
THCA	trans	rs853679	0.538	rs13199081	ENSG00000228078.1	HLA-U	-6.32	5.98e-10	0.00079	-0.39	-0.28	Depression;	chr6:28364057	chr6:29934101~29934286:+
THCA	trans	rs3812762	0.912	rs10769953	ENSG00000266891.1	RP11-692N5.2	-6.32	5.99e-10	0.000792	-0.37	-0.28	Hypospadias;	chr11:8756805	chr18:9734882~9735602:-
THCA	trans	rs12200782	1	rs12213722	ENSG00000242375.1	RP11-498P14.3	-6.32	6.01e-10	0.000793	-0.73	-0.28	Small cell lung carcinoma;	chr6:26472855	chr9:97195351~97197687:-
THCA	trans	rs34421088	0.585	rs6992190	ENSG00000253893.2	FAM85B	6.32	6.02e-10	0.000795	0.38	0.28	Neuroticism;	chr8:11739040	chr8:8167819~8226614:-
THCA	trans	rs453301	0.686	rs13252797	ENSG00000229857.1	RP11-159H20.3	-6.32	6.02e-10	0.000796	-0.34	-0.28	Joint mobility (Beighton score);	chr8:9003920	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.777	rs486781	ENSG00000229857.1	RP11-159H20.3	6.32	6.03e-10	0.000797	0.34	0.28	Mood instability;	chr8:8782230	chr9:76992099~76993108:+
THCA	trans	rs4646450	0.735	rs10270459	ENSG00000228834.1	RP11-249L21.4	6.32	6.06e-10	8e-04	0.48	0.28	Blood metabolite levels;	chr7:99381337	chr6:108907615~108907873:-
THCA	trans	rs877636	0.74	rs705698	ENSG00000244604.1	RP11-713H12.1	6.32	6.08e-10	0.000802	0.37	0.28	Cognitive function;	chr12:55990903	chr17:8561230~8561576:+
THCA	trans	rs950169	0.922	rs8037078	ENSG00000259295.5	CSPG4P12	-6.32	6.08e-10	0.000803	-0.43	-0.28	Schizophrenia;	chr15:84150119	chr15:85191438~85213905:+
THCA	trans	rs7819412	0.594	rs17724226	ENSG00000229857.1	RP11-159H20.3	6.32	6.09e-10	0.000804	0.37	0.28	Triglycerides;	chr8:11111416	chr9:76992099~76993108:+
THCA	trans	rs1190596	0.614	rs4322602	ENSG00000181359.5	HSP90AA6P	6.32	6.1e-10	0.000805	0.47	0.28	Behavioural disinhibition (generation interaction);	chr14:102299146	chr4:170581470~170605450:-
THCA	trans	rs3812762	0.912	rs10769954	ENSG00000266891.1	RP11-692N5.2	-6.32	6.1e-10	0.000805	-0.37	-0.28	Hypospadias;	chr11:8762166	chr18:9734882~9735602:-
THCA	trans	rs889398	0.641	rs9936589	ENSG00000196796.5	CTB-134H23.2	6.32	6.11e-10	0.000807	0.31	0.28	Body mass index;	chr16:69850914	chr16:29038655~29052726:+
THCA	trans	rs330071	0.686	rs4841139	ENSG00000253893.2	FAM85B	-6.32	6.12e-10	0.000808	-0.35	-0.28	Acne (severe);	chr8:9391700	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.547	rs11250099	ENSG00000229857.1	RP11-159H20.3	-6.32	6.12e-10	0.000808	-0.34	-0.28	Neuroticism;	chr8:10961147	chr9:76992099~76993108:+
THCA	trans	rs6885307	0.943	rs10941691	ENSG00000231752.4	EMBP1	6.32	6.14e-10	0.00081	0.44	0.28	Age at first birth;	chr5:45087688	chr1:121519112~121571892:+
THCA	trans	rs7769051	1	rs12203977	ENSG00000227615.1	RP11-864N7.2	6.32	6.15e-10	0.000811	0.45	0.28	Type 2 diabetes nephropathy;	chr6:132801621	chr11:74745716~74746114:-
THCA	trans	rs7769051	1	rs9493445	ENSG00000227615.1	RP11-864N7.2	6.32	6.15e-10	0.000811	0.45	0.28	Type 2 diabetes nephropathy;	chr6:132804270	chr11:74745716~74746114:-
THCA	trans	rs7769051	1	rs9493446	ENSG00000227615.1	RP11-864N7.2	6.32	6.15e-10	0.000811	0.45	0.28	Type 2 diabetes nephropathy;	chr6:132804504	chr11:74745716~74746114:-
THCA	trans	rs7769051	1	rs5006218	ENSG00000227615.1	RP11-864N7.2	6.32	6.15e-10	0.000811	0.45	0.28	Type 2 diabetes nephropathy;	chr6:132805081	chr11:74745716~74746114:-
THCA	trans	rs9467773	0.626	rs6935803	ENSG00000242375.1	RP11-498P14.3	-6.32	6.15e-10	0.000811	-0.4	-0.28	Intelligence (multi-trait analysis);	chr6:26350267	chr9:97195351~97197687:-
THCA	trans	rs3808502	0.605	rs11784572	ENSG00000253893.2	FAM85B	6.32	6.15e-10	0.000811	0.38	0.28	Neuroticism;	chr8:11316975	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs4390216	ENSG00000255397.1	AC022182.2	-6.32	6.16e-10	0.000813	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.964	rs10437063	ENSG00000255397.1	AC022182.2	-6.32	6.16e-10	0.000813	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs6676982	ENSG00000255397.1	AC022182.2	-6.32	6.16e-10	0.000813	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.927	rs11211194	ENSG00000255397.1	AC022182.2	-6.32	6.16e-10	0.000813	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr8:60937705~60939871:-
THCA	trans	rs6458375	1	rs6916554	ENSG00000205940.8	HSP90AB2P	6.32	6.18e-10	0.000815	0.39	0.28	Interleukin-10 levels;	chr6:44236999	chr4:13333414~13338657:+
THCA	trans	rs7824557	0.591	rs2060457	ENSG00000253893.2	FAM85B	-6.32	6.18e-10	0.000815	-0.37	-0.28	Retinal vascular caliber;	chr8:11355741	chr8:8167819~8226614:-
THCA	trans	rs1432133	0.844	rs12899579	ENSG00000241431.1	RPL37P6	-6.32	6.18e-10	0.000816	-0.31	-0.28	Hepatitis;	chr15:26979174	chr8:56588385~56588787:+
THCA	trans	rs7819412	0.74	rs28633434	ENSG00000256560.1	LINC01486	-6.32	6.19e-10	0.000816	-0.35	-0.28	Triglycerides;	chr8:11196413	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.537	rs4841457	ENSG00000229857.1	RP11-159H20.3	6.32	6.19e-10	0.000817	0.34	0.28	Neuroticism;	chr8:10916001	chr9:76992099~76993108:+
THCA	trans	rs6964833	1	rs4717906	ENSG00000214544.6	GTF2IRD2P1	-6.32	6.2e-10	0.000817	-0.41	-0.28	Menarche (age at onset);	chr7:74671923	chr7:73242751~73280119:-
THCA	trans	rs7829975	0.508	rs1594437	ENSG00000229857.1	RP11-159H20.3	-6.32	6.21e-10	0.000819	-0.34	-0.28	Mood instability;	chr8:8968365	chr9:76992099~76993108:+
THCA	trans	rs2288327	0.841	rs12998857	ENSG00000269800.1	PLEKHA3P1	6.32	6.23e-10	0.000821	0.38	0.28	Atrial fibrillation;	chr2:178668882	chr19:41521043~41521989:-
THCA	trans	rs902774	0.818	rs55958994	ENSG00000230716.3	KRT8P7	-6.32	6.23e-10	0.000821	-0.58	-0.28	Prostate cancer;	chr12:52907235	chr11:119602875~119604306:-
THCA	trans	rs7819412	0.703	rs2409713	ENSG00000256560.1	LINC01486	-6.32	6.24e-10	0.000823	-0.35	-0.28	Triglycerides;	chr8:11152287	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.735	rs2424906	ENSG00000253915.1	MAPRE1P1	6.32	6.24e-10	0.000823	0.36	0.28	Ulcerative colitis;	chr20:32771303	chr8:135625185~135625981:-
THCA	trans	rs9650657	0.504	rs7813802	ENSG00000229857.1	RP11-159H20.3	-6.32	6.25e-10	0.000824	-0.36	-0.28	Neuroticism;	chr8:11176467	chr9:76992099~76993108:+
THCA	trans	rs7260598	0.581	rs17311328	ENSG00000261770.1	CTC-459F4.1	6.31	6.28e-10	0.000827	0.49	0.28	Response to taxane treatment (placlitaxel);	chr19:24186640	chr19:27757184~27760849:-
THCA	trans	rs6732160	0.588	rs1430345	ENSG00000236165.1	PRADC1P1	6.31	6.29e-10	0.000829	0.4	0.28	Intelligence (multi-trait analysis);	chr2:73143554	chr3:36976316~36976840:+
THCA	trans	rs3808502	0.525	rs9650661	ENSG00000229857.1	RP11-159H20.3	6.31	6.31e-10	0.000831	0.35	0.28	Neuroticism;	chr8:11569624	chr9:76992099~76993108:+
THCA	trans	rs12682352	0.602	rs4841044	ENSG00000256560.1	LINC01486	-6.31	6.31e-10	0.000832	-0.34	-0.28	Neuroticism;	chr8:8807430	chr12:109354083~109359488:-
THCA	trans	rs12200782	1	rs72844495	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26610412	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs72844496	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26611380	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs6456741	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26616830	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs6456742	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26616847	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs4292511	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26622062	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs4515370	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26625091	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs12205909	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26630771	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs72845509	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26639637	chr9:97195351~97197687:-
THCA	trans	rs12200782	0.932	rs12212145	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26646190	chr9:97195351~97197687:-
THCA	trans	rs12200782	0.799	rs72845515	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Small cell lung carcinoma;	chr6:26646643	chr9:97195351~97197687:-
THCA	trans	rs12210905	0.8	rs12209651	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Hip circumference adjusted for BMI;	chr6:26660697	chr9:97195351~97197687:-
THCA	trans	rs12210905	0.8	rs12201890	ENSG00000242375.1	RP11-498P14.3	-6.31	6.32e-10	0.000832	-0.74	-0.28	Hip circumference adjusted for BMI;	chr6:26662398	chr9:97195351~97197687:-
THCA	trans	rs1707322	0.896	rs785512	ENSG00000255397.1	AC022182.2	6.31	6.33e-10	0.000833	0.4	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr8:60937705~60939871:-
THCA	trans	rs58106596	0.627	rs1058315	ENSG00000259020.3	RP11-529H20.3	6.31	6.34e-10	0.000835	0.42	0.28	Lymphocyte counts;White blood cell count;	chr2:231709234	chr14:92026566~92026887:+
THCA	trans	rs7200543	1	rs1121	ENSG00000250569.1	NTAN1P2	6.31	6.34e-10	0.000835	0.28	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr8:86481754~86483002:-
THCA	trans	rs12200782	0.932	rs72844476	ENSG00000242375.1	RP11-498P14.3	-6.31	6.34e-10	0.000836	-0.74	-0.28	Small cell lung carcinoma;	chr6:26573922	chr9:97195351~97197687:-
THCA	trans	rs7829975	0.509	rs2945269	ENSG00000229857.1	RP11-159H20.3	-6.31	6.37e-10	0.000839	-0.34	-0.28	Mood instability;	chr8:8258056	chr9:76992099~76993108:+
THCA	trans	rs9649213	0.555	rs67132564	ENSG00000225169.1	BRI3P1	6.31	6.37e-10	0.000839	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98385588	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs6465682	ENSG00000225169.1	BRI3P1	6.31	6.37e-10	0.000839	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98387105	chr1:100213293~100213670:+
THCA	trans	rs7819412	0.669	rs7823349	ENSG00000256560.1	LINC01486	-6.31	6.37e-10	0.000839	-0.36	-0.28	Triglycerides;	chr8:11141120	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.669	rs4840549	ENSG00000256560.1	LINC01486	-6.31	6.37e-10	0.000839	-0.36	-0.28	Triglycerides;	chr8:11141445	chr12:109354083~109359488:-
THCA	trans	rs864643	0.891	rs1626197	ENSG00000183298.5	RP11-556K13.1	6.31	6.39e-10	0.000841	0.48	0.28	Attention deficit hyperactivity disorder;	chr3:39539974	chr1:101786340~101787219:-
THCA	trans	rs9649213	0.593	rs62478233	ENSG00000225169.1	BRI3P1	6.31	6.4e-10	0.000842	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98393780	chr1:100213293~100213670:+
THCA	trans	rs7829975	0.711	rs4841051	ENSG00000256560.1	LINC01486	-6.31	6.41e-10	0.000843	-0.33	-0.28	Mood instability;	chr8:8828136	chr12:109354083~109359488:-
THCA	trans	rs9467773	0.529	rs7356988	ENSG00000242375.1	RP11-498P14.3	-6.31	6.41e-10	0.000844	-0.4	-0.28	Intelligence (multi-trait analysis);	chr6:26396499	chr9:97195351~97197687:-
THCA	trans	rs11638815	0.639	rs6603030	ENSG00000235370.6	DNM1P51	-6.31	6.42e-10	0.000845	-0.44	-0.28	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82561353	chr15:84398316~84411701:-
THCA	trans	rs7824557	0.545	rs34482136	ENSG00000254153.1	CTA-398F10.2	6.31	6.44e-10	0.000847	0.32	0.28	Retinal vascular caliber;	chr8:11370376	chr8:8456909~8461337:-
THCA	trans	rs941207	0.724	rs1979325	ENSG00000228224.3	NACAP1	6.31	6.45e-10	0.000849	0.32	0.28	Platelet count;	chr12:56728152	chr8:101361794~101372707:+
THCA	trans	rs6601327	0.965	rs7016732	ENSG00000253893.2	FAM85B	6.31	6.46e-10	0.00085	0.35	0.28	Multiple myeloma (hyperdiploidy);	chr8:9539717	chr8:8167819~8226614:-
THCA	trans	rs453301	0.506	rs476845	ENSG00000256560.1	LINC01486	-6.31	6.46e-10	0.00085	-0.32	-0.28	Joint mobility (Beighton score);	chr8:8765367	chr12:109354083~109359488:-
THCA	trans	rs2898290	0.593	rs2199690	ENSG00000256560.1	LINC01486	-6.31	6.47e-10	0.000851	-0.35	-0.28	Systolic blood pressure;	chr8:11482107	chr12:109354083~109359488:-
THCA	trans	rs7200543	1	rs7200543	ENSG00000250569.1	NTAN1P2	-6.31	6.49e-10	0.000854	-0.28	-0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr8:86481754~86483002:-
THCA	trans	rs7824557	0.614	rs2293858	ENSG00000253893.2	FAM85B	-6.31	6.49e-10	0.000854	-0.37	-0.28	Retinal vascular caliber;	chr8:11356372	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.966	rs1883730	ENSG00000253915.1	MAPRE1P1	6.31	6.49e-10	0.000854	0.36	0.28	Ulcerative colitis;	chr20:32749681	chr8:135625185~135625981:-
THCA	trans	rs12682352	0.602	rs11783966	ENSG00000256560.1	LINC01486	-6.31	6.5e-10	0.000855	-0.34	-0.28	Neuroticism;	chr8:8807637	chr12:109354083~109359488:-
THCA	trans	rs9649213	0.593	rs6465666	ENSG00000225169.1	BRI3P1	-6.31	6.52e-10	0.000858	-0.36	-0.28	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr1:100213293~100213670:+
THCA	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	6.31	6.52e-10	0.000858	0.41	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
THCA	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	6.31	6.52e-10	0.000858	0.41	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
THCA	trans	rs6458375	1	rs62401156	ENSG00000205940.8	HSP90AB2P	6.31	6.52e-10	0.000858	0.39	0.28	Interleukin-10 levels;	chr6:44235623	chr4:13333414~13338657:+
THCA	trans	rs6424115	0.708	rs12748109	ENSG00000228217.1	AL390877.1	6.31	6.53e-10	0.000859	0.39	0.28	Immature fraction of reticulocytes;	chr1:23854687	chr1:117778087~117778506:-
THCA	trans	rs7769051	0.708	rs9483514	ENSG00000227615.1	RP11-864N7.2	6.31	6.54e-10	0.00086	0.46	0.28	Type 2 diabetes nephropathy;	chr6:132907577	chr11:74745716~74746114:-
THCA	trans	rs3808502	0.549	rs7831039	ENSG00000256560.1	LINC01486	-6.31	6.55e-10	0.000861	-0.34	-0.28	Neuroticism;	chr8:11570128	chr12:109354083~109359488:-
THCA	trans	rs73108077	1	rs73105976	ENSG00000279352.1	RP11-411B10.7	6.31	6.55e-10	0.000862	0.62	0.28	Red blood cell density in sickle cell anemia;	chr20:31378130	chr18:14010054~14010917:+
THCA	trans	rs7824557	0.534	rs10092549	ENSG00000253893.2	FAM85B	6.31	6.57e-10	0.000863	0.35	0.28	Retinal vascular caliber;	chr8:11231570	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.905	rs4433149	ENSG00000229857.1	RP11-159H20.3	6.31	6.59e-10	0.000866	0.35	0.28	Neuroticism;	chr8:10391758	chr9:76992099~76993108:+
THCA	trans	rs2980439	0.517	rs712253	ENSG00000229857.1	RP11-159H20.3	6.31	6.6e-10	0.000868	0.35	0.28	Neuroticism;	chr8:8246260	chr9:76992099~76993108:+
THCA	trans	rs3812762	0.833	rs35670750	ENSG00000266891.1	RP11-692N5.2	6.31	6.6e-10	0.000868	0.37	0.28	Hypospadias;	chr11:8760897	chr18:9734882~9735602:-
THCA	trans	rs7212590	0.618	rs56142307	ENSG00000187870.7	RNFT1P3	6.31	6.61e-10	0.000869	0.56	0.28	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59800788	chr17:20743333~20754501:-
THCA	trans	rs6087990	0.806	rs4911108	ENSG00000253915.1	MAPRE1P1	6.3	6.67e-10	0.000876	0.35	0.28	Ulcerative colitis;	chr20:32787505	chr8:135625185~135625981:-
THCA	trans	rs7829975	0.688	rs13270194	ENSG00000229857.1	RP11-159H20.3	-6.3	6.68e-10	0.000878	-0.35	-0.28	Mood instability;	chr8:8520592	chr9:76992099~76993108:+
THCA	trans	rs6601327	1	rs6601327	ENSG00000253893.2	FAM85B	6.3	6.69e-10	0.000879	0.35	0.28	Multiple myeloma (hyperdiploidy);	chr8:9538022	chr8:8167819~8226614:-
THCA	trans	rs35851103	0.6	rs4841662	ENSG00000229857.1	RP11-159H20.3	6.3	6.7e-10	0.00088	0.35	0.28	Neuroticism;	chr8:11986249	chr9:76992099~76993108:+
THCA	trans	rs902774	0.818	rs17120257	ENSG00000230716.3	KRT8P7	-6.3	6.71e-10	0.000881	-0.58	-0.28	Prostate cancer;	chr12:52909547	chr11:119602875~119604306:-
THCA	trans	rs1707322	1	rs1707337	ENSG00000255397.1	AC022182.2	6.3	6.73e-10	0.000884	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs1768807	ENSG00000255397.1	AC022182.2	6.3	6.73e-10	0.000884	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr8:60937705~60939871:-
THCA	trans	rs2243480	0.706	rs6460257	ENSG00000232546.1	RP11-458F8.1	-6.3	6.73e-10	0.000884	-0.32	-0.28	Diabetic kidney disease;	chr7:65731813	chr7:66848496~66858136:+
THCA	trans	rs11098499	0.754	rs10518300	ENSG00000253326.2	RP11-261C10.7	-6.3	6.73e-10	0.000884	-0.39	-0.28	Corneal astigmatism;	chr4:119328344	chr1:243054861~243056394:-
THCA	trans	rs7819412	0.745	rs4841498	ENSG00000256560.1	LINC01486	-6.3	6.74e-10	0.000885	-0.35	-0.28	Triglycerides;	chr8:11127922	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs11211205	ENSG00000255397.1	AC022182.2	-6.3	6.75e-10	0.000886	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.662	rs13108589	ENSG00000253326.2	RP11-261C10.7	6.3	6.76e-10	0.000888	0.38	0.28	Corneal astigmatism;	chr4:119346947	chr1:243054861~243056394:-
THCA	trans	rs9467773	0.609	rs12663780	ENSG00000242375.1	RP11-498P14.3	-6.3	6.76e-10	0.000888	-0.4	-0.28	Intelligence (multi-trait analysis);	chr6:26397345	chr9:97195351~97197687:-
THCA	trans	rs73108077	1	rs73108009	ENSG00000279352.1	RP11-411B10.7	6.3	6.77e-10	0.000889	0.62	0.28	Red blood cell density in sickle cell anemia;	chr20:31390409	chr18:14010054~14010917:+
THCA	trans	rs853679	0.607	rs35749575	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28147040	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs72846780	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28151277	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13205911	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28156336	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13197176	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28161454	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13201308	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28162311	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34765154	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28162672	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34505829	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28165461	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs35098436	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28166443	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs72846794	ENSG00000204338.7	CYP21A1P	-6.3	6.78e-10	0.000891	-0.63	-0.28	Depression;	chr6:28169721	chr6:32005636~32008451:+
THCA	trans	rs6601327	0.613	rs12677507	ENSG00000253893.2	FAM85B	6.3	6.8e-10	0.000893	0.35	0.28	Multiple myeloma (hyperdiploidy);	chr8:9624177	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.964	rs1768802	ENSG00000255397.1	AC022182.2	6.3	6.82e-10	0.000895	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs1588663	ENSG00000255397.1	AC022182.2	6.3	6.82e-10	0.000895	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs1768801	ENSG00000255397.1	AC022182.2	6.3	6.82e-10	0.000895	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs1768800	ENSG00000255397.1	AC022182.2	6.3	6.82e-10	0.000895	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr8:60937705~60939871:-
THCA	trans	rs7709909	0.72	rs408626	ENSG00000188985.6	DHFRP1	6.3	6.82e-10	0.000896	0.33	0.28	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80655314	chr18:26170726~26171284:-
THCA	trans	rs11098499	0.687	rs71610270	ENSG00000253326.2	RP11-261C10.7	6.3	6.85e-10	0.000899	0.37	0.28	Corneal astigmatism;	chr4:119366281	chr1:243054861~243056394:-
THCA	trans	rs1190596	0.581	rs1190571	ENSG00000181359.5	HSP90AA6P	6.3	6.86e-10	9e-04	0.39	0.28	Behavioural disinhibition (generation interaction);	chr14:102168564	chr4:170581470~170605450:-
THCA	trans	rs7769051	1	rs58832890	ENSG00000227615.1	RP11-864N7.2	6.3	6.86e-10	9e-04	0.46	0.28	Type 2 diabetes nephropathy;	chr6:132806000	chr11:74745716~74746114:-
THCA	trans	rs6600671	0.966	rs6600664	ENSG00000270392.2	PFN1P2	6.3	6.86e-10	9e-04	0.28	0.28	Hip geometry;	chr1:121480638	chr1:120432204~120434052:-
THCA	trans	rs6600671	0.932	rs6600663	ENSG00000270392.2	PFN1P2	6.3	6.86e-10	9e-04	0.28	0.28	Hip geometry;	chr1:121480639	chr1:120432204~120434052:-
THCA	trans	rs4646450	0.735	rs10255399	ENSG00000228834.1	RP11-249L21.4	6.3	6.91e-10	0.000906	0.48	0.28	Blood metabolite levels;	chr7:99372501	chr6:108907615~108907873:-
THCA	trans	rs4646450	0.735	rs10270917	ENSG00000228834.1	RP11-249L21.4	6.3	6.91e-10	0.000906	0.48	0.28	Blood metabolite levels;	chr7:99372591	chr6:108907615~108907873:-
THCA	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	6.3	6.92e-10	0.000907	0.4	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
THCA	trans	rs6921919	1	rs35875412	ENSG00000228078.1	HLA-U	-6.3	6.94e-10	0.00091	-0.42	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:29934101~29934286:+
THCA	trans	rs9329221	0.905	rs4610752	ENSG00000254153.1	CTA-398F10.2	6.3	6.96e-10	0.000912	0.3	0.28	Neuroticism;	chr8:10391452	chr8:8456909~8461337:-
THCA	trans	rs9329221	0.725	rs11250001	ENSG00000253893.2	FAM85B	6.3	6.96e-10	0.000912	0.37	0.28	Neuroticism;	chr8:10398391	chr8:8167819~8226614:-
THCA	trans	rs11951515	0.933	rs7701642	ENSG00000174977.8	AC026271.5	-6.3	6.98e-10	0.000915	-0.33	-0.28	Metabolite levels  (X-11787);	chr5:43394676	chr17:18650195~18651542:+
THCA	trans	rs9616064	0.531	rs867212	ENSG00000258384.1	AC068831.6	-6.3	6.99e-10	0.000916	-0.34	-0.28	Urate levels in obese individuals;	chr22:46667433	chr15:90952239~90955225:-
THCA	trans	rs9292918	0.715	rs6861150	ENSG00000231752.4	EMBP1	6.3	7.01e-10	0.000919	0.53	0.28	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45336687	chr1:121519112~121571892:+
THCA	trans	rs9467711	0.72	rs35627490	ENSG00000280107.1	AL022393.9	-6.3	7.02e-10	0.00092	-0.56	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26461876	chr6:28170845~28172521:+
THCA	trans	rs2950393	0.777	rs2926747	ENSG00000257210.1	NACAP3	6.3	7.04e-10	0.000922	0.32	0.28	Platelet distribution width;	chr12:56716147	chr12:93124063~93124543:-
THCA	trans	rs7824557	0.614	rs5029571	ENSG00000253893.2	FAM85B	-6.3	7.05e-10	0.000924	-0.37	-0.28	Retinal vascular caliber;	chr8:11355880	chr8:8167819~8226614:-
THCA	trans	rs2950393	0.777	rs12828563	ENSG00000257210.1	NACAP3	6.29	7.08e-10	0.000927	0.33	0.28	Platelet distribution width;	chr12:56709378	chr12:93124063~93124543:-
THCA	trans	rs7829975	0.714	rs6994038	ENSG00000256560.1	LINC01486	6.29	7.1e-10	0.00093	0.33	0.28	Mood instability;	chr8:8803028	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs11211223	ENSG00000255397.1	AC022182.2	-6.29	7.12e-10	0.000933	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.564	rs13274106	ENSG00000254153.1	CTA-398F10.2	6.29	7.15e-10	0.000936	0.31	0.28	Retinal vascular caliber;	chr8:11376449	chr8:8456909~8461337:-
THCA	trans	rs804280	0.504	rs2645457	ENSG00000229857.1	RP11-159H20.3	6.29	7.15e-10	0.000936	0.37	0.28	Myopia (pathological);	chr8:11756603	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.535	rs7671759	ENSG00000253326.2	RP11-261C10.7	6.29	7.16e-10	0.000938	0.39	0.28	Corneal astigmatism;	chr4:119326939	chr1:243054861~243056394:-
THCA	trans	rs9393777	0.841	rs67092078	ENSG00000280107.1	AL022393.9	-6.29	7.18e-10	0.00094	-0.57	-0.28	Intelligence (multi-trait analysis);	chr6:27086993	chr6:28170845~28172521:+
THCA	trans	rs9650657	0.589	rs6985109	ENSG00000256560.1	LINC01486	6.29	7.2e-10	0.000943	0.33	0.28	Neuroticism;	chr8:10904075	chr12:109354083~109359488:-
THCA	trans	rs9467711	1	rs1883215	ENSG00000176998.4	HCG4	-6.29	7.22e-10	0.000946	-0.5	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26314005	chr6:29791753~29792750:-
THCA	trans	rs941207	0.507	rs2958124	ENSG00000257210.1	NACAP3	-6.29	7.24e-10	0.000948	-0.34	-0.28	Platelet count;	chr12:56633837	chr12:93124063~93124543:-
THCA	trans	rs7829975	0.846	rs7005216	ENSG00000229857.1	RP11-159H20.3	6.29	7.27e-10	0.000952	0.33	0.28	Mood instability;	chr8:8689600	chr9:76992099~76993108:+
THCA	trans	rs4646450	0.735	rs6943920	ENSG00000228834.1	RP11-249L21.4	6.29	7.31e-10	0.000957	0.46	0.28	Blood metabolite levels;	chr7:99410792	chr6:108907615~108907873:-
THCA	trans	rs7824557	0.507	rs7010590	ENSG00000254153.1	CTA-398F10.2	-6.29	7.33e-10	0.000959	-0.31	-0.28	Retinal vascular caliber;	chr8:11205373	chr8:8456909~8461337:-
THCA	trans	rs2277458	0.858	rs2144529	ENSG00000214249.3	CTAGE11P	6.29	7.34e-10	0.00096	0.44	0.28	Vitamin D levels;	chr14:39093525	chr13:75237944~75240296:-
THCA	trans	rs2277458	0.925	rs2180216	ENSG00000214249.3	CTAGE11P	6.29	7.34e-10	0.00096	0.44	0.28	Vitamin D levels;	chr14:39094098	chr13:75237944~75240296:-
THCA	trans	rs7829975	0.742	rs12547493	ENSG00000229857.1	RP11-159H20.3	6.29	7.35e-10	0.000962	0.35	0.28	Mood instability;	chr8:8804024	chr9:76992099~76993108:+
THCA	trans	rs2243480	1	rs34703416	ENSG00000232546.1	RP11-458F8.1	-6.29	7.38e-10	0.000965	-0.36	-0.28	Diabetic kidney disease;	chr7:65835655	chr7:66848496~66858136:+
THCA	trans	rs1707322	0.89	rs2297883	ENSG00000255397.1	AC022182.2	6.29	7.39e-10	0.000967	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs1707338	ENSG00000255397.1	AC022182.2	6.29	7.39e-10	0.000967	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.964	rs1707339	ENSG00000255397.1	AC022182.2	6.29	7.39e-10	0.000967	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs1768818	ENSG00000255397.1	AC022182.2	6.29	7.39e-10	0.000967	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs1768817	ENSG00000255397.1	AC022182.2	6.29	7.39e-10	0.000967	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs785470	ENSG00000255397.1	AC022182.2	6.29	7.39e-10	0.000967	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr8:60937705~60939871:-
THCA	trans	rs11671005	0.696	rs73066211	ENSG00000279267.1	RP11-395L14.18	6.29	7.4e-10	0.000968	0.42	0.28	Mean platelet volume;	chr19:58485712	chr2:113605867~113607908:-
THCA	trans	rs3808502	0.527	rs2736374	ENSG00000256560.1	LINC01486	-6.29	7.41e-10	0.000969	-0.35	-0.28	Neuroticism;	chr8:11256319	chr12:109354083~109359488:-
THCA	trans	rs543686	0.77	rs4923765	ENSG00000198618.5	PPIAP22	-6.29	7.49e-10	0.000979	-0.37	-0.28	Prostate cancer (SNP x SNP interaction);	chr15:34760204	chr21:18857779~18858276:+
THCA	trans	rs941207	0.526	rs2255074	ENSG00000257210.1	NACAP3	-6.29	7.49e-10	0.000979	-0.34	-0.28	Platelet count;	chr12:56636242	chr12:93124063~93124543:-
THCA	trans	rs7819412	0.669	rs28630509	ENSG00000256560.1	LINC01486	-6.28	7.5e-10	0.00098	-0.36	-0.28	Triglycerides;	chr8:11139529	chr12:109354083~109359488:-
THCA	trans	rs7826238	0.524	rs2921055	ENSG00000229857.1	RP11-159H20.3	-6.28	7.5e-10	0.00098	-0.34	-0.28	Systolic blood pressure;	chr8:8461832	chr9:76992099~76993108:+
THCA	trans	rs616147	0.962	rs545397	ENSG00000243904.1	RP11-600F24.1	6.28	7.51e-10	0.000982	0.35	0.28	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr14:103374033~103374916:-
THCA	trans	rs3808502	0.549	rs11991139	ENSG00000229857.1	RP11-159H20.3	6.28	7.53e-10	0.000985	0.36	0.28	Neuroticism;	chr8:11570886	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.905	rs4433149	ENSG00000254153.1	CTA-398F10.2	6.28	7.56e-10	0.000988	0.3	0.28	Neuroticism;	chr8:10391758	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.668	rs2409715	ENSG00000256560.1	LINC01486	-6.28	7.56e-10	0.000989	-0.35	-0.28	Triglycerides;	chr8:11152626	chr12:109354083~109359488:-
THCA	trans	rs2736345	0.742	rs4840568	ENSG00000253893.2	FAM85B	-6.28	7.58e-10	0.00099	-0.39	-0.28	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11493510	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.569	rs2409718	ENSG00000254153.1	CTA-398F10.2	6.28	7.61e-10	0.000995	0.31	0.28	Retinal vascular caliber;	chr8:11155467	chr8:8456909~8461337:-
THCA	trans	rs3812762	0.833	rs10500705	ENSG00000266891.1	RP11-692N5.2	6.28	7.63e-10	0.000996	0.38	0.28	Hypospadias;	chr11:8783714	chr18:9734882~9735602:-
THCA	trans	rs12682352	0.652	rs3789843	ENSG00000256560.1	LINC01486	6.28	7.63e-10	0.000996	0.35	0.28	Neuroticism;	chr8:8866747	chr12:109354083~109359488:-
THCA	trans	rs12682352	0.652	rs3827806	ENSG00000256560.1	LINC01486	6.28	7.63e-10	0.000996	0.35	0.28	Neuroticism;	chr8:8866766	chr12:109354083~109359488:-
THCA	trans	rs6732160	0.564	rs2043096	ENSG00000236165.1	PRADC1P1	6.28	7.65e-10	0.000999	0.4	0.28	Intelligence (multi-trait analysis);	chr2:73148595	chr3:36976316~36976840:+
THCA	trans	rs3764796	0.737	rs73208577	ENSG00000250030.2	RP11-584P21.4	6.28	7.65e-10	0.000999	0.56	0.28	Calcium levels;	chr8:17282126	chr4:67446267~67446574:+
THCA	trans	rs1347297	0.666	rs4019558	ENSG00000269800.1	PLEKHA3P1	6.28	7.67e-10	0.001	0.3	0.28	Alzheimer disease and age of onset;	chr2:178406156	chr19:41521043~41521989:-
THCA	trans	rs7824557	0.564	rs12550129	ENSG00000254153.1	CTA-398F10.2	6.28	7.67e-10	0.001	0.31	0.28	Retinal vascular caliber;	chr8:11376408	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.526	rs36048422	ENSG00000229857.1	RP11-159H20.3	6.28	7.71e-10	0.00101	0.35	0.28	Neuroticism;	chr8:11559635	chr9:76992099~76993108:+
THCA	trans	rs3808502	0.526	rs11783065	ENSG00000229857.1	RP11-159H20.3	6.28	7.71e-10	0.00101	0.35	0.28	Neuroticism;	chr8:11559748	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.561	rs2001328	ENSG00000229857.1	RP11-159H20.3	6.28	7.73e-10	0.00101	0.36	0.28	Triglycerides;	chr8:11129689	chr9:76992099~76993108:+
THCA	trans	rs6424115	0.708	rs12755062	ENSG00000228217.1	AL390877.1	6.28	7.75e-10	0.00101	0.39	0.28	Immature fraction of reticulocytes;	chr1:23858535	chr1:117778087~117778506:-
THCA	trans	rs12210905	1	rs7759955	ENSG00000242375.1	RP11-498P14.3	-6.28	7.8e-10	0.00102	-0.74	-0.28	Hip circumference adjusted for BMI;	chr6:26792463	chr9:97195351~97197687:-
THCA	trans	rs6885307	0.825	rs80017032	ENSG00000231752.4	EMBP1	6.28	7.82e-10	0.00102	0.47	0.28	Age at first birth;	chr5:45231233	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.825	rs75089238	ENSG00000231752.4	EMBP1	6.28	7.82e-10	0.00102	0.47	0.28	Age at first birth;	chr5:45231407	chr1:121519112~121571892:+
THCA	trans	rs6601327	0.585	rs11249934	ENSG00000253893.2	FAM85B	-6.28	7.86e-10	0.00103	-0.34	-0.28	Multiple myeloma (hyperdiploidy);	chr8:9653320	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.754	rs17595608	ENSG00000253326.2	RP11-261C10.7	6.28	7.87e-10	0.00103	0.38	0.28	Corneal astigmatism;	chr4:119329351	chr1:243054861~243056394:-
THCA	trans	rs7032940	0.677	rs10816931	ENSG00000228236.2	TXNP5	6.28	7.93e-10	0.00103	0.34	0.28	Height;	chr9:110177912	chr2:149068596~149068910:-
THCA	trans	rs9649213	0.593	rs6465673	ENSG00000225169.1	BRI3P1	6.28	7.95e-10	0.00104	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr1:100213293~100213670:+
THCA	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-6.27	7.95e-10	0.00104	-0.39	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
THCA	trans	rs9649213	0.593	rs1859482	ENSG00000225169.1	BRI3P1	6.27	7.95e-10	0.00104	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs13246868	ENSG00000225169.1	BRI3P1	6.27	7.95e-10	0.00104	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs12672092	ENSG00000225169.1	BRI3P1	6.27	7.95e-10	0.00104	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr1:100213293~100213670:+
THCA	trans	rs2950393	0.572	rs10783794	ENSG00000228224.3	NACAP1	-6.27	7.96e-10	0.00104	-0.28	-0.28	Platelet distribution width;	chr12:56593395	chr8:101361794~101372707:+
THCA	trans	rs330048	0.545	rs11774353	ENSG00000253893.2	FAM85B	-6.27	7.97e-10	0.00104	-0.35	-0.28	Systemic lupus erythematosus;	chr8:9295617	chr8:8167819~8226614:-
THCA	trans	rs3808502	0.574	rs4841559	ENSG00000229857.1	RP11-159H20.3	6.27	8e-10	0.00104	0.35	0.28	Neuroticism;	chr8:11559376	chr9:76992099~76993108:+
THCA	trans	rs6601327	0.603	rs10095171	ENSG00000253893.2	FAM85B	6.27	8.01e-10	0.00104	0.37	0.28	Multiple myeloma (hyperdiploidy);	chr8:9812375	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.644	rs10050092	ENSG00000253326.2	RP11-261C10.7	6.27	8.02e-10	0.00105	0.38	0.28	Corneal astigmatism;	chr4:119610930	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.602	rs7820895	ENSG00000253893.2	FAM85B	-6.27	8.04e-10	0.00105	-0.37	-0.28	Retinal vascular caliber;	chr8:11348753	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.735	rs4911260	ENSG00000253915.1	MAPRE1P1	6.27	8.05e-10	0.00105	0.36	0.28	Ulcerative colitis;	chr20:32788684	chr8:135625185~135625981:-
THCA	trans	rs7032940	0.677	rs4279674	ENSG00000228236.2	TXNP5	6.27	8.06e-10	0.00105	0.33	0.28	Height;	chr9:110179726	chr2:149068596~149068910:-
THCA	trans	rs9649213	0.593	rs7776638	ENSG00000225169.1	BRI3P1	6.27	8.08e-10	0.00105	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.574	rs36099592	ENSG00000225169.1	BRI3P1	6.27	8.08e-10	0.00105	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr1:100213293~100213670:+
THCA	trans	rs76228276	0.737	rs16897662	ENSG00000260318.1	COX6CP1	6.27	8.09e-10	0.00105	0.77	0.28	Childhood ear infection;	chr8:99754292	chr16:11903923~11904137:-
THCA	trans	rs6732160	0.588	rs13394018	ENSG00000236165.1	PRADC1P1	6.27	8.12e-10	0.00106	0.4	0.28	Intelligence (multi-trait analysis);	chr2:73145477	chr3:36976316~36976840:+
THCA	trans	rs853679	0.607	rs34243448	ENSG00000228022.4	HCG20	-6.27	8.12e-10	0.00106	-0.7	-0.28	Depression;	chr6:28225324	chr6:30766825~30792250:+
THCA	trans	rs1707322	1	rs6687301	ENSG00000255397.1	AC022182.2	-6.27	8.12e-10	0.00106	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr8:60937705~60939871:-
THCA	trans	rs2288327	0.822	rs1429094	ENSG00000269800.1	PLEKHA3P1	6.27	8.13e-10	0.00106	0.38	0.28	Atrial fibrillation;	chr2:178651047	chr19:41521043~41521989:-
THCA	trans	rs2985684	0.901	rs7146248	ENSG00000240785.1	RPL36AP21	6.27	8.16e-10	0.00106	0.36	0.28	Carotid intima media thickness;	chr14:49645349	chr5:18049550~18049872:+
THCA	trans	rs9650657	0.571	rs4240673	ENSG00000229857.1	RP11-159H20.3	6.27	8.17e-10	0.00106	0.34	0.28	Neuroticism;	chr8:10930102	chr9:76992099~76993108:+
THCA	trans	rs1707322	1	rs10890365	ENSG00000255397.1	AC022182.2	-6.27	8.17e-10	0.00106	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr8:60937705~60939871:-
THCA	trans	rs9329221	0.682	rs6982308	ENSG00000229857.1	RP11-159H20.3	6.27	8.2e-10	0.00107	0.34	0.28	Neuroticism;	chr8:10336262	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.754	rs66900435	ENSG00000253326.2	RP11-261C10.7	6.27	8.21e-10	0.00107	0.38	0.28	Corneal astigmatism;	chr4:119328270	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs1980027	ENSG00000253326.2	RP11-261C10.7	6.27	8.21e-10	0.00107	0.38	0.28	Corneal astigmatism;	chr4:119330422	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs10213554	ENSG00000253326.2	RP11-261C10.7	-6.27	8.21e-10	0.00107	-0.38	-0.28	Corneal astigmatism;	chr4:119339630	chr1:243054861~243056394:-
THCA	trans	rs7819412	0.502	rs4840548	ENSG00000254153.1	CTA-398F10.2	6.27	8.23e-10	0.00107	0.33	0.28	Triglycerides;	chr8:11135373	chr8:8456909~8461337:-
THCA	trans	rs6885307	0.941	rs62369897	ENSG00000231752.4	EMBP1	6.27	8.23e-10	0.00107	0.44	0.28	Age at first birth;	chr5:45068194	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	6.27	8.24e-10	0.00107	0.4	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
THCA	trans	rs4512344	0.514	rs13255193	ENSG00000229857.1	RP11-159H20.3	6.27	8.25e-10	0.00107	0.35	0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11451683	chr9:76992099~76993108:+
THCA	trans	rs3764796	0.737	rs3750251	ENSG00000250030.2	RP11-584P21.4	6.27	8.25e-10	0.00107	0.56	0.28	Calcium levels;	chr8:17276218	chr4:67446267~67446574:+
THCA	trans	rs9650657	0.538	rs10111950	ENSG00000256560.1	LINC01486	-6.27	8.26e-10	0.00108	-0.34	-0.28	Neuroticism;	chr8:10958244	chr12:109354083~109359488:-
THCA	trans	rs1707322	1	rs12403666	ENSG00000255397.1	AC022182.2	-6.27	8.3e-10	0.00108	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr8:60937705~60939871:-
THCA	trans	rs6424115	0.708	rs13551	ENSG00000228217.1	AL390877.1	6.27	8.31e-10	0.00108	0.39	0.28	Immature fraction of reticulocytes;	chr1:23854472	chr1:117778087~117778506:-
THCA	trans	rs7824557	0.751	rs2099456	ENSG00000253893.2	FAM85B	-6.27	8.32e-10	0.00108	-0.35	-0.28	Retinal vascular caliber;	chr8:11269492	chr8:8167819~8226614:-
THCA	trans	rs11098499	1	rs1011054	ENSG00000253326.2	RP11-261C10.7	-6.27	8.32e-10	0.00108	-0.38	-0.28	Corneal astigmatism;	chr4:119281232	chr1:243054861~243056394:-
THCA	trans	rs2950393	0.857	rs9989034	ENSG00000228224.3	NACAP1	6.27	8.32e-10	0.00108	0.29	0.28	Platelet distribution width;	chr12:56674508	chr8:101361794~101372707:+
THCA	trans	rs11671005	0.737	rs11673101	ENSG00000279267.1	RP11-395L14.18	6.27	8.36e-10	0.00109	0.43	0.28	Mean platelet volume;	chr19:58483686	chr2:113605867~113607908:-
THCA	trans	rs950169	0.922	rs11639244	ENSG00000259295.5	CSPG4P12	6.27	8.36e-10	0.00109	0.43	0.28	Schizophrenia;	chr15:84163898	chr15:85191438~85213905:+
THCA	trans	rs11098499	0.644	rs7693919	ENSG00000253326.2	RP11-261C10.7	6.27	8.37e-10	0.00109	0.38	0.28	Corneal astigmatism;	chr4:119619416	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.57	rs6832740	ENSG00000253326.2	RP11-261C10.7	6.27	8.37e-10	0.00109	0.38	0.28	Corneal astigmatism;	chr4:119624981	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.644	rs6855918	ENSG00000253326.2	RP11-261C10.7	6.27	8.37e-10	0.00109	0.38	0.28	Corneal astigmatism;	chr4:119625144	chr1:243054861~243056394:-
THCA	trans	rs4930561	0.765	rs7931502	ENSG00000155070.8	UNC93B2	6.27	8.43e-10	0.0011	0.32	0.28	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68192140	chr7:6855485~6859830:-
THCA	trans	rs9650657	0.572	rs4841465	ENSG00000256560.1	LINC01486	-6.26	8.48e-10	0.0011	-0.33	-0.28	Neuroticism;	chr8:10962344	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.504	rs6601565	ENSG00000254153.1	CTA-398F10.2	6.26	8.48e-10	0.0011	0.31	0.28	Neuroticism;	chr8:11174719	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.549	rs1382563	ENSG00000229857.1	RP11-159H20.3	-6.26	8.48e-10	0.0011	-0.35	-0.28	Neuroticism;	chr8:11569281	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.967	rs10088415	ENSG00000256560.1	LINC01486	-6.26	8.49e-10	0.0011	-0.34	-0.28	Monocyte count;	chr8:11973316	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.941	rs73752426	ENSG00000231752.4	EMBP1	6.26	8.51e-10	0.00111	0.42	0.28	Age at first birth;	chr5:45053194	chr1:121519112~121571892:+
THCA	trans	rs6885307	1	rs12054976	ENSG00000231752.4	EMBP1	6.26	8.51e-10	0.00111	0.42	0.28	Age at first birth;	chr5:45057218	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.504	rs2409724	ENSG00000256560.1	LINC01486	-6.26	8.53e-10	0.00111	-0.34	-0.28	Neuroticism;	chr8:11184133	chr12:109354083~109359488:-
THCA	trans	rs864643	0.841	rs1708042	ENSG00000183298.5	RP11-556K13.1	6.26	8.54e-10	0.00111	0.45	0.28	Attention deficit hyperactivity disorder;	chr3:39546246	chr1:101786340~101787219:-
THCA	trans	rs7200543	0.961	rs1741	ENSG00000255185.4	PDXDC2P	6.26	8.54e-10	0.00111	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:70010751~70065945:-
THCA	trans	rs2243480	1	rs34815098	ENSG00000232546.1	RP11-458F8.1	-6.26	8.54e-10	0.00111	-0.36	-0.28	Diabetic kidney disease;	chr7:65827267	chr7:66848496~66858136:+
THCA	trans	rs2243480	1	rs35735127	ENSG00000232546.1	RP11-458F8.1	-6.26	8.54e-10	0.00111	-0.36	-0.28	Diabetic kidney disease;	chr7:65835436	chr7:66848496~66858136:+
THCA	trans	rs2243480	0.901	rs35256305	ENSG00000232546.1	RP11-458F8.1	-6.26	8.54e-10	0.00111	-0.36	-0.28	Diabetic kidney disease;	chr7:65841418	chr7:66848496~66858136:+
THCA	trans	rs2243480	0.803	rs34004500	ENSG00000232546.1	RP11-458F8.1	-6.26	8.54e-10	0.00111	-0.36	-0.28	Diabetic kidney disease;	chr7:65847191	chr7:66848496~66858136:+
THCA	trans	rs7200543	1	rs16966953	ENSG00000255185.4	PDXDC2P	6.26	8.55e-10	0.00111	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:70010751~70065945:-
THCA	trans	rs930395	0.514	rs7707315	ENSG00000231752.4	EMBP1	-6.26	8.55e-10	0.00111	-0.38	-0.28	Breast cancer;	chr5:44918703	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs4298259	ENSG00000231752.4	EMBP1	-6.26	8.55e-10	0.00111	-0.38	-0.28	Breast cancer;	chr5:44920609	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs7728431	ENSG00000231752.4	EMBP1	-6.26	8.55e-10	0.00111	-0.38	-0.28	Breast cancer;	chr5:44922577	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs10038554	ENSG00000231752.4	EMBP1	-6.26	8.55e-10	0.00111	-0.38	-0.28	Breast cancer;	chr5:44927005	chr1:121519112~121571892:+
THCA	trans	rs7903456	0.648	rs2146720	ENSG00000232706.3	NUTM2HP	6.26	8.64e-10	0.00112	0.41	0.28	Gout;Renal underexcretion gout;	chr10:87074325	chr10:50676743~50686326:+
THCA	trans	rs7200543	1	rs6498540	ENSG00000255185.4	PDXDC2P	6.26	8.64e-10	0.00112	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:70010751~70065945:-
THCA	trans	rs9649213	0.593	rs6973775	ENSG00000225169.1	BRI3P1	6.26	8.69e-10	0.00113	0.36	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr1:100213293~100213670:+
THCA	trans	rs11098499	0.657	rs10434028	ENSG00000253326.2	RP11-261C10.7	6.26	8.72e-10	0.00113	0.37	0.28	Corneal astigmatism;	chr4:119373309	chr1:243054861~243056394:-
THCA	trans	rs4295623	0.553	rs34962960	ENSG00000229857.1	RP11-159H20.3	6.26	8.75e-10	0.00114	0.35	0.28	Morning vs. evening chronotype;	chr8:11737088	chr9:76992099~76993108:+
THCA	trans	rs141670911	1	rs141670911	ENSG00000242375.1	RP11-498P14.3	-6.26	8.78e-10	0.00114	-0.75	-0.28	Small cell lung carcinoma;	chr6:26581030	chr9:97195351~97197687:-
THCA	trans	rs1707322	1	rs10789486	ENSG00000255397.1	AC022182.2	-6.26	8.79e-10	0.00114	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr8:60937705~60939871:-
THCA	trans	rs12145833	0.569	rs12136239	ENSG00000154608.12	CEP170P1	-6.26	8.79e-10	0.00114	-0.35	-0.28	Obesity (early onset extreme);	chr1:243429078	chr4:118467590~118554204:+
THCA	trans	rs864643	0.945	rs614453	ENSG00000183298.5	RP11-556K13.1	6.26	8.82e-10	0.00114	0.48	0.28	Attention deficit hyperactivity disorder;	chr3:39541076	chr1:101786340~101787219:-
THCA	trans	rs4646450	0.685	rs10258757	ENSG00000228834.1	RP11-249L21.4	6.26	8.82e-10	0.00114	0.48	0.28	Blood metabolite levels;	chr7:99373052	chr6:108907615~108907873:-
THCA	trans	rs9329221	0.905	rs17765901	ENSG00000254153.1	CTA-398F10.2	6.26	8.83e-10	0.00115	0.3	0.28	Neuroticism;	chr8:10391970	chr8:8456909~8461337:-
THCA	trans	rs2950393	0.804	rs2035081	ENSG00000257210.1	NACAP3	6.26	8.84e-10	0.00115	0.33	0.28	Platelet distribution width;	chr12:56732095	chr12:93124063~93124543:-
THCA	trans	rs2950393	0.804	rs10783796	ENSG00000257210.1	NACAP3	6.26	8.84e-10	0.00115	0.33	0.28	Platelet distribution width;	chr12:56733387	chr12:93124063~93124543:-
THCA	trans	rs1707322	1	rs10890350	ENSG00000255397.1	AC022182.2	-6.26	8.86e-10	0.00115	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr8:60937705~60939871:-
THCA	trans	rs7746199	0.736	rs13202295	ENSG00000228022.4	HCG20	-6.26	8.87e-10	0.00115	-0.72	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs35037868	ENSG00000228022.4	HCG20	-6.26	8.9e-10	0.00115	-0.71	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:30766825~30792250:+
THCA	trans	rs2980439	0.87	rs2945230	ENSG00000229857.1	RP11-159H20.3	-6.26	8.9e-10	0.00115	-0.34	-0.28	Neuroticism;	chr8:8252414	chr9:76992099~76993108:+
THCA	trans	rs12200782	1	rs72843802	ENSG00000242375.1	RP11-498P14.3	-6.26	8.9e-10	0.00115	-0.72	-0.28	Small cell lung carcinoma;	chr6:26517287	chr9:97195351~97197687:-
THCA	trans	rs12200782	0.674	rs12207224	ENSG00000242375.1	RP11-498P14.3	-6.26	8.9e-10	0.00115	-0.72	-0.28	Small cell lung carcinoma;	chr6:26519052	chr9:97195351~97197687:-
THCA	trans	rs12200782	0.932	rs12189841	ENSG00000242375.1	RP11-498P14.3	-6.26	8.9e-10	0.00115	-0.72	-0.28	Small cell lung carcinoma;	chr6:26544570	chr9:97195351~97197687:-
THCA	trans	rs7833986	0.501	rs72651502	ENSG00000236862.1	RPS20P24	6.26	8.92e-10	0.00116	0.43	0.28	Height;	chr8:55962974	chr9:72655832~72656192:-
THCA	trans	rs1391708	0.834	rs4403833	ENSG00000121089.4	NACA3P	-6.25	8.95e-10	0.00116	-0.46	-0.28	Airway wall thickness;	chr12:56872137	chr4:164943290~164943937:+
THCA	trans	rs9467773	0.587	rs10946813	ENSG00000242375.1	RP11-498P14.3	6.25	8.96e-10	0.00116	0.39	0.28	Intelligence (multi-trait analysis);	chr6:26344913	chr9:97195351~97197687:-
THCA	trans	rs4415084	0.834	rs1438821	ENSG00000231752.4	EMBP1	-6.25	8.98e-10	0.00116	-0.37	-0.28	Breast cancer;	chr5:44858349	chr1:121519112~121571892:+
THCA	trans	rs2060793	0.519	rs1357332	ENSG00000236360.2	RP11-334A14.2	6.25	9.08e-10	0.00118	0.37	0.28	Vitamin D levels;	chr11:14618570	chr1:52993201~52993702:-
THCA	trans	rs2980439	0.807	rs2980438	ENSG00000229857.1	RP11-159H20.3	-6.25	9.1e-10	0.00118	-0.33	-0.28	Neuroticism;	chr8:8237303	chr9:76992099~76993108:+
THCA	trans	rs7520050	0.751	rs2230657	ENSG00000255397.1	AC022182.2	6.25	9.11e-10	0.00118	0.36	0.28	Reticulocyte count;Red blood cell count;	chr1:45607817	chr8:60937705~60939871:-
THCA	trans	rs35851103	0.506	rs4841659	ENSG00000229857.1	RP11-159H20.3	-6.25	9.12e-10	0.00118	-0.35	-0.28	Neuroticism;	chr8:11970691	chr9:76992099~76993108:+
THCA	trans	rs941207	0.756	rs1465081	ENSG00000228224.3	NACAP1	-6.25	9.13e-10	0.00118	-0.32	-0.28	Platelet count;	chr12:56656390	chr8:101361794~101372707:+
THCA	trans	rs2898290	0.622	rs17799486	ENSG00000256560.1	LINC01486	-6.25	9.15e-10	0.00119	-0.35	-0.28	Systolic blood pressure;	chr8:11482985	chr12:109354083~109359488:-
THCA	trans	rs7929679	0.551	rs906902	ENSG00000225531.1	RP11-196I18.3	-6.25	9.19e-10	0.00119	-0.35	-0.28	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34758731	chr9:107116829~107117557:+
THCA	trans	rs7200543	1	rs1121	ENSG00000255185.4	PDXDC2P	6.25	9.2e-10	0.00119	0.39	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:70010751~70065945:-
THCA	trans	rs3808502	0.549	rs1382563	ENSG00000256560.1	LINC01486	6.25	9.22e-10	0.00119	0.34	0.28	Neuroticism;	chr8:11569281	chr12:109354083~109359488:-
THCA	trans	rs2950393	0.804	rs1466382	ENSG00000257210.1	NACAP3	-6.25	9.23e-10	0.0012	-0.32	-0.28	Platelet distribution width;	chr12:56723050	chr12:93124063~93124543:-
THCA	trans	rs6964833	0.935	rs34630792	ENSG00000214544.6	GTF2IRD2P1	-6.25	9.24e-10	0.0012	-0.41	-0.28	Menarche (age at onset);	chr7:74646869	chr7:73242751~73280119:-
THCA	trans	rs7829975	0.681	rs2271342	ENSG00000229857.1	RP11-159H20.3	-6.25	9.34e-10	0.00121	-0.34	-0.28	Mood instability;	chr8:8786428	chr9:76992099~76993108:+
THCA	trans	rs7903456	0.512	rs7076542	ENSG00000232706.3	NUTM2HP	6.25	9.35e-10	0.00121	0.4	0.28	Gout;Renal underexcretion gout;	chr10:87067342	chr10:50676743~50686326:+
THCA	trans	rs2243480	1	rs1404147	ENSG00000232546.1	RP11-458F8.1	-6.25	9.36e-10	0.00121	-0.34	-0.28	Diabetic kidney disease;	chr7:65799537	chr7:66848496~66858136:+
THCA	trans	rs1478897	0.898	rs2248700	ENSG00000253893.2	FAM85B	6.25	9.37e-10	0.00121	0.37	0.28	Systemic lupus erythematosus;	chr8:11536236	chr8:8167819~8226614:-
THCA	trans	rs7200543	0.848	rs62039480	ENSG00000250569.1	NTAN1P2	6.25	9.39e-10	0.00122	0.27	0.28	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr8:86481754~86483002:-
THCA	trans	rs7819412	1	rs7819412	ENSG00000254153.1	CTA-398F10.2	-6.25	9.4e-10	0.00122	-0.31	-0.28	Triglycerides;	chr8:11187652	chr8:8456909~8461337:-
THCA	trans	rs3740713	1	rs35593189	ENSG00000236090.2	LDHAP3	6.25	9.43e-10	0.00122	0.5	0.28	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr2:41819747~41820754:+
THCA	trans	rs7829975	0.593	rs2921077	ENSG00000229857.1	RP11-159H20.3	-6.25	9.44e-10	0.00122	-0.33	-0.28	Mood instability;	chr8:8446992	chr9:76992099~76993108:+
THCA	trans	rs1707322	1	rs6657720	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs7519181	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs10890372	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.928	rs6681068	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211228	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs9803784	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs12022335	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs10890375	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs10890377	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs10789484	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs7527079	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs34446427	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs4660900	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4454479	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs7517560	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs12077546	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs12124291	ENSG00000255397.1	AC022182.2	-6.25	9.45e-10	0.00122	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs10890378	ENSG00000255397.1	AC022182.2	6.25	9.45e-10	0.00122	0.38	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs785478	ENSG00000255397.1	AC022182.2	6.25	9.45e-10	0.00122	0.38	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr8:60937705~60939871:-
THCA	trans	rs4415084	0.68	rs4495192	ENSG00000231752.4	EMBP1	-6.25	9.47e-10	0.00122	-0.39	-0.28	Breast cancer;	chr5:44929075	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs4919743	ENSG00000254285.3	KRT8P3	-6.25	9.49e-10	0.00123	-0.53	-0.28	Prostate cancer;	chr12:52915800	chr8:61578220~61579668:+
THCA	trans	rs7647973	0.71	rs34890793	ENSG00000197582.5	GPX1P1	6.25	9.49e-10	0.00123	0.5	0.28	Menarche (age at onset);	chr3:49582060	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.71	rs7629322	ENSG00000197582.5	GPX1P1	6.25	9.49e-10	0.00123	0.5	0.28	Menarche (age at onset);	chr3:49584561	chrX:13378735~13379340:-
THCA	trans	rs941207	0.756	rs7978685	ENSG00000228224.3	NACAP1	6.24	9.51e-10	0.00123	0.32	0.28	Platelet count;	chr12:56709370	chr8:101361794~101372707:+
THCA	trans	rs11638815	0.639	rs783542	ENSG00000235370.6	DNM1P51	-6.24	9.51e-10	0.00123	-0.44	-0.28	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82567264	chr15:84398316~84411701:-
THCA	trans	rs58106596	0.66	rs13398149	ENSG00000259020.3	RP11-529H20.3	6.24	9.54e-10	0.00123	0.45	0.28	Lymphocyte counts;White blood cell count;	chr2:231700171	chr14:92026566~92026887:+
THCA	trans	rs6885307	0.825	rs73752432	ENSG00000231752.4	EMBP1	6.24	9.55e-10	0.00123	0.42	0.28	Age at first birth;	chr5:45064097	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.941	rs12521639	ENSG00000231752.4	EMBP1	6.24	9.55e-10	0.00123	0.42	0.28	Age at first birth;	chr5:45078379	chr1:121519112~121571892:+
THCA	trans	rs11992162	0.967	rs10108320	ENSG00000256560.1	LINC01486	-6.24	9.56e-10	0.00124	-0.34	-0.28	Monocyte count;	chr8:11974754	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.875	rs6981523	ENSG00000254153.1	CTA-398F10.2	6.24	9.56e-10	0.00124	0.31	0.28	Triglycerides;	chr8:11204283	chr8:8456909~8461337:-
THCA	trans	rs9467773	0.572	rs9467737	ENSG00000242375.1	RP11-498P14.3	-6.24	9.56e-10	0.00124	-0.4	-0.28	Intelligence (multi-trait analysis);	chr6:26381402	chr9:97195351~97197687:-
THCA	trans	rs12682352	0.65	rs13265731	ENSG00000256560.1	LINC01486	6.24	9.57e-10	0.00124	0.34	0.28	Neuroticism;	chr8:8815810	chr12:109354083~109359488:-
THCA	trans	rs11172055	0.807	rs7314567	ENSG00000121089.4	NACA3P	6.24	9.59e-10	0.00124	0.3	0.28	Migraine;	chr12:56864231	chr4:164943290~164943937:+
THCA	trans	rs11992162	0.967	rs7461062	ENSG00000229857.1	RP11-159H20.3	-6.24	9.59e-10	0.00124	-0.36	-0.28	Monocyte count;	chr8:11974439	chr9:76992099~76993108:+
THCA	trans	rs34421088	0.531	rs2245232	ENSG00000229857.1	RP11-159H20.3	6.24	9.6e-10	0.00124	0.36	0.28	Neuroticism;	chr8:11543435	chr9:76992099~76993108:+
THCA	trans	rs9649213	0.613	rs6961129	ENSG00000225169.1	BRI3P1	6.24	9.61e-10	0.00124	0.35	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr1:100213293~100213670:+
THCA	trans	rs12200782	1	rs12204145	ENSG00000242375.1	RP11-498P14.3	-6.24	9.61e-10	0.00124	-0.72	-0.28	Small cell lung carcinoma;	chr6:26599928	chr9:97195351~97197687:-
THCA	trans	rs7829975	1	rs7829975	ENSG00000256560.1	LINC01486	-6.24	9.62e-10	0.00124	-0.33	-0.28	Mood instability;	chr8:8690607	chr12:109354083~109359488:-
THCA	trans	rs2277458	1	rs2277458	ENSG00000214249.3	CTAGE11P	6.24	9.63e-10	0.00124	0.44	0.28	Vitamin D levels;	chr14:39114277	chr13:75237944~75240296:-
THCA	trans	rs6964833	0.873	rs4717905	ENSG00000214544.6	GTF2IRD2P1	-6.24	9.63e-10	0.00124	-0.4	-0.28	Menarche (age at onset);	chr7:74668903	chr7:73242751~73280119:-
THCA	trans	rs7824557	0.675	rs2736265	ENSG00000253893.2	FAM85B	-6.24	9.65e-10	0.00125	-0.36	-0.28	Retinal vascular caliber;	chr8:11329165	chr8:8167819~8226614:-
THCA	trans	rs4929949	0.618	rs7129564	ENSG00000266891.1	RP11-692N5.2	6.24	9.66e-10	0.00125	0.37	0.28	Body mass index;	chr11:8428702	chr18:9734882~9735602:-
THCA	trans	rs4929949	0.688	rs7118189	ENSG00000266891.1	RP11-692N5.2	6.24	9.66e-10	0.00125	0.37	0.28	Body mass index;	chr11:8428712	chr18:9734882~9735602:-
THCA	trans	rs11098499	0.754	rs1980025	ENSG00000253326.2	RP11-261C10.7	-6.24	9.68e-10	0.00125	-0.38	-0.28	Corneal astigmatism;	chr4:119331651	chr1:243054861~243056394:-
THCA	trans	rs902774	1	rs11831942	ENSG00000224520.2	KRT8P45	-6.24	9.69e-10	0.00125	-0.49	-0.28	Prostate cancer;	chr12:52878329	chr1:157073257~157074703:+
THCA	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	6.24	9.7e-10	0.00125	0.4	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
THCA	trans	rs11250098	0.547	rs2409764	ENSG00000229857.1	RP11-159H20.3	-6.24	9.71e-10	0.00125	-0.34	-0.28	Morning vs. evening chronotype;	chr8:11423764	chr9:76992099~76993108:+
THCA	trans	rs889398	0.641	rs9936723	ENSG00000196796.5	CTB-134H23.2	6.24	9.72e-10	0.00126	0.31	0.28	Body mass index;	chr16:69850951	chr16:29038655~29052726:+
THCA	trans	rs9329221	0.905	rs13252982	ENSG00000254153.1	CTA-398F10.2	6.24	9.76e-10	0.00126	0.3	0.28	Neuroticism;	chr8:10397595	chr8:8456909~8461337:-
THCA	trans	rs9329221	0.87	rs11777976	ENSG00000254153.1	CTA-398F10.2	6.24	9.76e-10	0.00126	0.3	0.28	Neuroticism;	chr8:10397892	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.745	rs7017567	ENSG00000256560.1	LINC01486	-6.24	9.76e-10	0.00126	-0.34	-0.28	Triglycerides;	chr8:11076189	chr12:109354083~109359488:-
THCA	trans	rs2243480	0.908	rs4718273	ENSG00000232546.1	RP11-458F8.1	6.24	9.77e-10	0.00126	0.36	0.28	Diabetic kidney disease;	chr7:65751112	chr7:66848496~66858136:+
THCA	trans	rs6424115	0.708	rs34570472	ENSG00000228217.1	AL390877.1	6.24	9.78e-10	0.00126	0.39	0.28	Immature fraction of reticulocytes;	chr1:23865230	chr1:117778087~117778506:-
THCA	trans	rs11250097	0.507	rs2409779	ENSG00000229857.1	RP11-159H20.3	6.24	9.79e-10	0.00126	0.36	0.28	Neuroticism;	chr8:11453831	chr9:76992099~76993108:+
THCA	trans	rs3764796	0.737	rs73208569	ENSG00000250030.2	RP11-584P21.4	6.24	9.8e-10	0.00127	0.56	0.28	Calcium levels;	chr8:17277099	chr4:67446267~67446574:+
THCA	trans	rs3764796	0.737	rs73208572	ENSG00000250030.2	RP11-584P21.4	6.24	9.8e-10	0.00127	0.56	0.28	Calcium levels;	chr8:17278133	chr4:67446267~67446574:+
THCA	trans	rs7429990	0.833	rs869508	ENSG00000235912.1	RP1-159A19.3	-6.24	9.82e-10	0.00127	-0.35	-0.28	Educational attainment (years of education);	chr3:47571812	chr1:27649419~27649610:+
THCA	trans	rs2985684	0.947	rs1952013	ENSG00000240785.1	RPL36AP21	6.24	9.84e-10	0.00127	0.37	0.28	Carotid intima media thickness;	chr14:49620639	chr5:18049550~18049872:+
THCA	trans	rs11992162	0.967	rs10088415	ENSG00000254153.1	CTA-398F10.2	6.24	9.84e-10	0.00127	0.31	0.28	Monocyte count;	chr8:11973316	chr8:8456909~8461337:-
THCA	trans	rs4415084	0.804	rs10077814	ENSG00000231752.4	EMBP1	-6.24	9.84e-10	0.00127	-0.37	-0.28	Breast cancer;	chr5:44916687	chr1:121519112~121571892:+
THCA	trans	rs1707322	1	rs7547189	ENSG00000255397.1	AC022182.2	-6.24	9.85e-10	0.00127	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs7547284	ENSG00000255397.1	AC022182.2	-6.24	9.85e-10	0.00127	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr8:60937705~60939871:-
THCA	trans	rs3849046	0.967	rs154073	ENSG00000226666.1	HSPA9P1	6.24	9.87e-10	0.00127	0.28	0.28	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138522378	chr2:221961737~221963765:+
THCA	trans	rs1707322	1	rs785480	ENSG00000255397.1	AC022182.2	-6.24	9.88e-10	0.00127	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr8:60937705~60939871:-
THCA	trans	rs76228276	0.737	rs16897656	ENSG00000260318.1	COX6CP1	6.24	9.89e-10	0.00128	0.76	0.28	Childhood ear infection;	chr8:99748682	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs16897666	ENSG00000260318.1	COX6CP1	6.24	9.89e-10	0.00128	0.76	0.28	Childhood ear infection;	chr8:99759318	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs77609205	ENSG00000260318.1	COX6CP1	6.24	9.89e-10	0.00128	0.76	0.28	Childhood ear infection;	chr8:99761134	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.618	rs57753543	ENSG00000260318.1	COX6CP1	6.24	9.89e-10	0.00128	0.76	0.28	Childhood ear infection;	chr8:99764693	chr16:11903923~11904137:-
THCA	trans	rs4512344	0.514	rs13255193	ENSG00000256560.1	LINC01486	-6.24	9.9e-10	0.00128	-0.34	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11451683	chr12:109354083~109359488:-
THCA	trans	rs9329221	0.905	rs6601451	ENSG00000229857.1	RP11-159H20.3	6.24	9.9e-10	0.00128	0.34	0.28	Neuroticism;	chr8:10386171	chr9:76992099~76993108:+
THCA	trans	rs4150642	1	rs7103375	ENSG00000235847.2	LDHAP7	-6.24	9.93e-10	0.00128	-0.47	-0.28	Amyloid A serum levels;	chr11:18353986	chr2:84777259~84778223:-
THCA	trans	rs2980439	0.557	rs2921056	ENSG00000229857.1	RP11-159H20.3	-6.24	9.95e-10	0.00128	-0.34	-0.28	Neuroticism;	chr8:8461672	chr9:76992099~76993108:+
THCA	trans	rs2277458	0.687	rs8022510	ENSG00000214249.3	CTAGE11P	6.24	9.99e-10	0.00129	0.43	0.28	Vitamin D levels;	chr14:39062788	chr13:75237944~75240296:-
THCA	trans	rs7903456	0.512	rs7076857	ENSG00000232706.3	NUTM2HP	6.23	1.01e-09	0.0013	0.4	0.28	Gout;Renal underexcretion gout;	chr10:87067496	chr10:50676743~50686326:+
THCA	trans	rs453301	0.506	rs686189	ENSG00000256560.1	LINC01486	-6.23	1.01e-09	0.0013	-0.32	-0.28	Joint mobility (Beighton score);	chr8:8766127	chr12:109354083~109359488:-
THCA	trans	rs7212590	0.748	rs7220187	ENSG00000187870.7	RNFT1P3	6.23	1.01e-09	0.0013	0.56	0.28	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59820248	chr17:20743333~20754501:-
THCA	trans	rs9425766	0.64	rs9425756	ENSG00000213331.4	RP11-713C19.2	6.23	1.01e-09	0.0013	0.38	0.28	Life satisfaction;	chr1:173847448	chr4:187970273~187971284:+
THCA	trans	rs9425766	0.546	rs6691001	ENSG00000213331.4	RP11-713C19.2	6.23	1.01e-09	0.0013	0.38	0.28	Life satisfaction;	chr1:173849938	chr4:187970273~187971284:+
THCA	trans	rs930395	0.514	rs7703618	ENSG00000231752.4	EMBP1	-6.23	1.01e-09	0.0013	-0.39	-0.28	Breast cancer;	chr5:44914477	chr1:121519112~121571892:+
THCA	trans	rs3849046	0.967	rs154072	ENSG00000226666.1	HSPA9P1	6.23	1.01e-09	0.0013	0.28	0.28	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138520684	chr2:221961737~221963765:+
THCA	trans	rs2980439	0.557	rs2976876	ENSG00000229857.1	RP11-159H20.3	-6.23	1.01e-09	0.0013	-0.34	-0.28	Neuroticism;	chr8:8461340	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.821	rs56155624	ENSG00000253326.2	RP11-261C10.7	6.23	1.01e-09	0.0013	0.37	0.28	Corneal astigmatism;	chr4:119369871	chr1:243054861~243056394:-
THCA	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-6.23	1.01e-09	0.00131	-0.39	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
THCA	trans	rs12682352	0.652	rs1567398	ENSG00000229857.1	RP11-159H20.3	6.23	1.01e-09	0.00131	0.36	0.28	Neuroticism;	chr8:8869294	chr9:76992099~76993108:+
THCA	trans	rs1391708	0.834	rs58911887	ENSG00000121089.4	NACA3P	-6.23	1.01e-09	0.00131	-0.45	-0.28	Airway wall thickness;	chr12:56884858	chr4:164943290~164943937:+
THCA	trans	rs1391708	0.834	rs34465459	ENSG00000121089.4	NACA3P	-6.23	1.01e-09	0.00131	-0.45	-0.28	Airway wall thickness;	chr12:56885552	chr4:164943290~164943937:+
THCA	trans	rs12682352	0.602	rs1473029	ENSG00000256560.1	LINC01486	6.23	1.02e-09	0.00131	0.34	0.28	Neuroticism;	chr8:8811407	chr12:109354083~109359488:-
THCA	trans	rs9616064	0.557	rs9615397	ENSG00000258384.1	AC068831.6	6.23	1.02e-09	0.00132	0.34	0.28	Urate levels in obese individuals;	chr22:46653189	chr15:90952239~90955225:-
THCA	trans	rs804280	0.662	rs11250164	ENSG00000253893.2	FAM85B	6.23	1.02e-09	0.00132	0.4	0.28	Myopia (pathological);	chr8:11753177	chr8:8167819~8226614:-
THCA	trans	rs2288327	0.915	rs35112591	ENSG00000269800.1	PLEKHA3P1	6.23	1.02e-09	0.00132	0.38	0.28	Atrial fibrillation;	chr2:178678490	chr19:41521043~41521989:-
THCA	trans	rs12472274	0.941	rs11677230	ENSG00000224699.7	LAMTOR5-AS1	-6.23	1.02e-09	0.00132	-0.24	-0.28	Phospholipid levels (plasma);	chr2:238183413	chr1:110347116~110443817:+
THCA	trans	rs3808502	0.525	rs9650661	ENSG00000256560.1	LINC01486	-6.23	1.02e-09	0.00132	-0.34	-0.28	Neuroticism;	chr8:11569624	chr12:109354083~109359488:-
THCA	trans	rs9393777	0.92	rs67859638	ENSG00000204338.7	CYP21A1P	-6.23	1.02e-09	0.00132	-0.63	-0.28	Intelligence (multi-trait analysis);	chr6:27390199	chr6:32005636~32008451:+
THCA	trans	rs7824557	0.614	rs2060459	ENSG00000253893.2	FAM85B	-6.23	1.03e-09	0.00133	-0.37	-0.28	Retinal vascular caliber;	chr8:11355090	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.614	rs4394351	ENSG00000253893.2	FAM85B	-6.23	1.03e-09	0.00133	-0.37	-0.28	Retinal vascular caliber;	chr8:11355366	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.806	rs10503418	ENSG00000253893.2	FAM85B	6.23	1.03e-09	0.00133	0.34	0.28	Retinal vascular caliber;	chr8:11261474	chr8:8167819~8226614:-
THCA	trans	rs9649213	0.574	rs7802560	ENSG00000225169.1	BRI3P1	-6.23	1.04e-09	0.00134	-0.35	-0.28	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr1:100213293~100213670:+
THCA	trans	rs3808502	0.549	rs4841564	ENSG00000256560.1	LINC01486	-6.23	1.04e-09	0.00134	-0.34	-0.28	Neuroticism;	chr8:11568300	chr12:109354083~109359488:-
THCA	trans	rs7769051	1	rs12204027	ENSG00000227615.1	RP11-864N7.2	6.23	1.04e-09	0.00134	0.45	0.28	Type 2 diabetes nephropathy;	chr6:132801692	chr11:74745716~74746114:-
THCA	trans	rs7769051	1	rs9493444	ENSG00000227615.1	RP11-864N7.2	6.23	1.04e-09	0.00134	0.45	0.28	Type 2 diabetes nephropathy;	chr6:132804181	chr11:74745716~74746114:-
THCA	trans	rs7769051	1	rs7769051	ENSG00000227615.1	RP11-864N7.2	6.23	1.04e-09	0.00134	0.46	0.28	Type 2 diabetes nephropathy;	chr6:132825657	chr11:74745716~74746114:-
THCA	trans	rs12210905	0.925	rs12214640	ENSG00000242375.1	RP11-498P14.3	-6.23	1.04e-09	0.00134	-0.73	-0.28	Hip circumference adjusted for BMI;	chr6:26739806	chr9:97195351~97197687:-
THCA	trans	rs12682352	0.715	rs332039	ENSG00000229857.1	RP11-159H20.3	-6.23	1.04e-09	0.00134	-0.35	-0.28	Neuroticism;	chr8:8866141	chr9:76992099~76993108:+
THCA	trans	rs6993244	1	rs6993244	ENSG00000256560.1	LINC01486	6.23	1.04e-09	0.00134	0.32	0.28	Mean corpuscular hemoglobin;	chr8:9005549	chr12:109354083~109359488:-
THCA	trans	rs9467711	0.606	rs9379875	ENSG00000253570.1	RNF5P1	6.23	1.05e-09	0.00135	0.66	0.28	Autism spectrum disorder or schizophrenia;	chr6:26444504	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.538	rs35942482	ENSG00000253570.1	RNF5P1	6.23	1.05e-09	0.00135	0.66	0.28	Autism spectrum disorder or schizophrenia;	chr6:26444710	chr8:38600661~38601200:-
THCA	trans	rs616147	0.962	rs1513219	ENSG00000243904.1	RP11-600F24.1	6.23	1.05e-09	0.00135	0.35	0.28	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr14:103374033~103374916:-
THCA	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-6.23	1.05e-09	0.00136	-0.39	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
THCA	trans	rs950169	0.922	rs4842940	ENSG00000259295.5	CSPG4P12	-6.23	1.05e-09	0.00136	-0.42	-0.28	Schizophrenia;	chr15:84162473	chr15:85191438~85213905:+
THCA	trans	rs950169	0.922	rs4842941	ENSG00000259295.5	CSPG4P12	-6.23	1.05e-09	0.00136	-0.42	-0.28	Schizophrenia;	chr15:84162560	chr15:85191438~85213905:+
THCA	trans	rs950169	0.922	rs12911223	ENSG00000259295.5	CSPG4P12	-6.23	1.05e-09	0.00136	-0.42	-0.28	Schizophrenia;	chr15:84162919	chr15:85191438~85213905:+
THCA	trans	rs7819412	0.538	rs4523214	ENSG00000256560.1	LINC01486	-6.23	1.06e-09	0.00136	-0.34	-0.28	Triglycerides;	chr8:11113263	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.504	rs10108347	ENSG00000254153.1	CTA-398F10.2	6.23	1.06e-09	0.00136	0.31	0.28	Neuroticism;	chr8:11176008	chr8:8456909~8461337:-
THCA	trans	rs2243480	1	rs4718269	ENSG00000232546.1	RP11-458F8.1	6.23	1.06e-09	0.00136	0.36	0.28	Diabetic kidney disease;	chr7:65735810	chr7:66848496~66858136:+
THCA	trans	rs2243480	1	rs4718270	ENSG00000232546.1	RP11-458F8.1	-6.23	1.06e-09	0.00136	-0.36	-0.28	Diabetic kidney disease;	chr7:65737415	chr7:66848496~66858136:+
THCA	trans	rs7192380	0.893	rs12921782	ENSG00000257513.6	NPIPB1P	-6.23	1.06e-09	0.00136	-0.3	-0.28	Sjögren's syndrome;	chr16:69746119	chr18:11619509~11639699:-
THCA	trans	rs7824557	0.564	rs34389419	ENSG00000254153.1	CTA-398F10.2	6.23	1.06e-09	0.00137	0.31	0.28	Retinal vascular caliber;	chr8:11371810	chr8:8456909~8461337:-
THCA	trans	rs656319	0.605	rs4840467	ENSG00000253893.2	FAM85B	-6.23	1.06e-09	0.00137	-0.4	-0.28	Myopia (pathological);	chr8:10222127	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs6661500	ENSG00000255397.1	AC022182.2	-6.23	1.06e-09	0.00137	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr8:60937705~60939871:-
THCA	trans	rs4646450	0.891	rs34777615	ENSG00000228834.1	RP11-249L21.4	6.23	1.06e-09	0.00137	0.44	0.28	Blood metabolite levels;	chr7:99595834	chr6:108907615~108907873:-
THCA	trans	rs4415084	0.804	rs10044096	ENSG00000231752.4	EMBP1	-6.23	1.06e-09	0.00137	-0.37	-0.28	Breast cancer;	chr5:44927263	chr1:121519112~121571892:+
THCA	trans	rs76228276	0.737	rs1979117	ENSG00000260318.1	COX6CP1	-6.23	1.07e-09	0.00137	-0.74	-0.28	Childhood ear infection;	chr8:99807661	chr16:11903923~11904137:-
THCA	trans	rs1707322	0.963	rs1768815	ENSG00000255397.1	AC022182.2	6.23	1.07e-09	0.00137	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr8:60937705~60939871:-
THCA	trans	rs11992162	0.967	rs7461062	ENSG00000256560.1	LINC01486	6.22	1.07e-09	0.00137	0.34	0.28	Monocyte count;	chr8:11974439	chr12:109354083~109359488:-
THCA	trans	rs4929949	0.688	rs7108993	ENSG00000266891.1	RP11-692N5.2	6.22	1.07e-09	0.00137	0.36	0.28	Body mass index;	chr11:8425646	chr18:9734882~9735602:-
THCA	trans	rs7769051	1	rs9493443	ENSG00000227615.1	RP11-864N7.2	6.22	1.07e-09	0.00137	0.45	0.28	Type 2 diabetes nephropathy;	chr6:132800210	chr11:74745716~74746114:-
THCA	trans	rs11098499	0.866	rs12501602	ENSG00000253326.2	RP11-261C10.7	6.22	1.07e-09	0.00137	0.37	0.28	Corneal astigmatism;	chr4:119366780	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.628	rs11777746	ENSG00000253893.2	FAM85B	-6.22	1.08e-09	0.00138	-0.37	-0.28	Retinal vascular caliber;	chr8:11347246	chr8:8167819~8226614:-
THCA	trans	rs1190596	0.562	rs1307671	ENSG00000181359.5	HSP90AA6P	6.22	1.08e-09	0.00138	0.46	0.28	Behavioural disinhibition (generation interaction);	chr14:102176116	chr4:170581470~170605450:-
THCA	trans	rs7829975	0.66	rs10093926	ENSG00000229857.1	RP11-159H20.3	6.22	1.08e-09	0.00139	0.34	0.28	Mood instability;	chr8:8691510	chr9:76992099~76993108:+
THCA	trans	rs864643	0.704	rs4441592	ENSG00000188856.6	RPSAP47	-6.22	1.08e-09	0.00139	-0.38	-0.28	Attention deficit hyperactivity disorder;	chr3:39550772	chr8:80558870~80559757:+
THCA	trans	rs864643	0.738	rs34922979	ENSG00000188856.6	RPSAP47	-6.22	1.08e-09	0.00139	-0.38	-0.28	Attention deficit hyperactivity disorder;	chr3:39550934	chr8:80558870~80559757:+
THCA	trans	rs6885307	0.941	rs12522398	ENSG00000231752.4	EMBP1	6.22	1.09e-09	0.00139	0.44	0.28	Age at first birth;	chr5:45049371	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.941	rs62369894	ENSG00000231752.4	EMBP1	6.22	1.09e-09	0.00139	0.44	0.28	Age at first birth;	chr5:45055412	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.941	rs62369895	ENSG00000231752.4	EMBP1	6.22	1.09e-09	0.00139	0.44	0.28	Age at first birth;	chr5:45058905	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.941	rs62369896	ENSG00000231752.4	EMBP1	6.22	1.09e-09	0.00139	0.44	0.28	Age at first birth;	chr5:45062241	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.882	rs4485937	ENSG00000231752.4	EMBP1	6.22	1.09e-09	0.00139	0.44	0.28	Age at first birth;	chr5:45065541	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.882	rs62369900	ENSG00000231752.4	EMBP1	6.22	1.09e-09	0.00139	0.44	0.28	Age at first birth;	chr5:45078221	chr1:121519112~121571892:+
THCA	trans	rs9329221	0.585	rs12550717	ENSG00000253893.2	FAM85B	-6.22	1.09e-09	0.0014	-0.36	-0.28	Neuroticism;	chr8:10409196	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.641	rs9644704	ENSG00000253893.2	FAM85B	6.22	1.09e-09	0.0014	0.34	0.28	Multiple myeloma (hyperdiploidy);	chr8:9702659	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.737	rs10481445	ENSG00000256560.1	LINC01486	-6.22	1.09e-09	0.0014	-0.34	-0.28	Retinal vascular caliber;	chr8:11251760	chr12:109354083~109359488:-
THCA	trans	rs9329221	0.698	rs35388602	ENSG00000253893.2	FAM85B	-6.22	1.1e-09	0.00141	-0.37	-0.28	Neuroticism;	chr8:10401678	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.614	rs17741537	ENSG00000253893.2	FAM85B	-6.22	1.1e-09	0.00142	-0.37	-0.28	Retinal vascular caliber;	chr8:11355583	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.967	rs10077407	ENSG00000226666.1	HSPA9P1	6.22	1.1e-09	0.00142	0.28	0.28	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138513837	chr2:221961737~221963765:+
THCA	trans	rs3849046	0.967	rs154067	ENSG00000226666.1	HSPA9P1	6.22	1.1e-09	0.00142	0.28	0.28	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138514370	chr2:221961737~221963765:+
THCA	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-6.22	1.11e-09	0.00142	-0.39	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
THCA	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-6.22	1.11e-09	0.00142	-0.39	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
THCA	trans	rs9329221	0.592	rs7832708	ENSG00000256560.1	LINC01486	6.22	1.11e-09	0.00142	0.34	0.28	Neuroticism;	chr8:10332530	chr12:109354083~109359488:-
THCA	trans	rs2243480	1	rs4548056	ENSG00000232546.1	RP11-458F8.1	-6.22	1.11e-09	0.00143	-0.36	-0.28	Diabetic kidney disease;	chr7:65833886	chr7:66848496~66858136:+
THCA	trans	rs3808502	0.503	rs34190028	ENSG00000256560.1	LINC01486	-6.22	1.11e-09	0.00143	-0.34	-0.28	Neuroticism;	chr8:11559641	chr12:109354083~109359488:-
THCA	trans	rs864643	0.898	rs614494	ENSG00000183298.5	RP11-556K13.1	6.22	1.11e-09	0.00143	0.45	0.28	Attention deficit hyperactivity disorder;	chr3:39547136	chr1:101786340~101787219:-
THCA	trans	rs12145833	0.679	rs12140432	ENSG00000154608.12	CEP170P1	-6.22	1.12e-09	0.00143	-0.37	-0.28	Obesity (early onset extreme);	chr1:243432985	chr4:118467590~118554204:+
THCA	trans	rs7833986	1	rs34480844	ENSG00000244245.1	RP11-120B7.1	6.22	1.12e-09	0.00144	0.34	0.28	Height;	chr8:56180414	chr5:108593609~108593967:+
THCA	trans	rs2288327	0.591	rs2562845	ENSG00000269800.1	PLEKHA3P1	6.22	1.13e-09	0.00144	0.35	0.28	Atrial fibrillation;	chr2:178649706	chr19:41521043~41521989:-
THCA	trans	rs4415084	0.804	rs4518409	ENSG00000231752.4	EMBP1	-6.21	1.14e-09	0.00146	-0.37	-0.28	Breast cancer;	chr5:44870750	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.838	rs3021494	ENSG00000254153.1	CTA-398F10.2	6.21	1.15e-09	0.00147	0.31	0.28	Triglycerides;	chr8:11126024	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.564	rs12547100	ENSG00000254153.1	CTA-398F10.2	6.21	1.15e-09	0.00148	0.31	0.28	Retinal vascular caliber;	chr8:11385123	chr8:8456909~8461337:-
THCA	trans	rs6087990	0.735	rs2424913	ENSG00000253915.1	MAPRE1P1	6.21	1.15e-09	0.00148	0.36	0.28	Ulcerative colitis;	chr20:32786453	chr8:135625185~135625981:-
THCA	trans	rs4929949	0.688	rs7128727	ENSG00000266891.1	RP11-692N5.2	6.21	1.16e-09	0.00148	0.36	0.28	Body mass index;	chr11:8428746	chr18:9734882~9735602:-
THCA	trans	rs13217239	0.534	rs9379968	ENSG00000242375.1	RP11-498P14.3	-6.21	1.16e-09	0.00148	-0.39	-0.28	Schizophrenia;	chr6:27276811	chr9:97195351~97197687:-
THCA	trans	rs4784054	0.568	rs7193640	ENSG00000230849.2	GOT2P2	6.21	1.16e-09	0.00149	0.42	0.28	Blood metabolite levels;	chr16:58785816	chr1:173141100~173142350:-
THCA	trans	rs7260598	0.535	rs13343732	ENSG00000281468.1	CTC-459F4.9	-6.21	1.16e-09	0.00149	-0.35	-0.28	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:27802838~27803472:+
THCA	trans	rs6424115	0.708	rs11803575	ENSG00000228217.1	AL390877.1	6.21	1.16e-09	0.00149	0.38	0.28	Immature fraction of reticulocytes;	chr1:23855858	chr1:117778087~117778506:-
THCA	trans	rs7260598	0.892	rs2116956	ENSG00000261770.1	CTC-459F4.1	6.21	1.17e-09	0.00149	0.47	0.28	Response to taxane treatment (placlitaxel);	chr19:24005987	chr19:27757184~27760849:-
THCA	trans	rs11172055	0.967	rs10876953	ENSG00000121089.4	NACA3P	6.21	1.17e-09	0.00149	0.31	0.28	Migraine;	chr12:56916418	chr4:164943290~164943937:+
THCA	trans	rs9650657	0.538	rs6984496	ENSG00000229857.1	RP11-159H20.3	6.21	1.17e-09	0.0015	0.34	0.28	Neuroticism;	chr8:10938583	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.668	rs2409714	ENSG00000256560.1	LINC01486	-6.21	1.17e-09	0.0015	-0.34	-0.28	Triglycerides;	chr8:11152608	chr12:109354083~109359488:-
THCA	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	6.21	1.17e-09	0.0015	0.4	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
THCA	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	6.21	1.17e-09	0.0015	0.4	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
THCA	trans	rs804280	0.662	rs11784764	ENSG00000253893.2	FAM85B	6.21	1.18e-09	0.00151	0.41	0.28	Myopia (pathological);	chr8:11753365	chr8:8167819~8226614:-
THCA	trans	rs3764796	0.737	rs73200931	ENSG00000250030.2	RP11-584P21.4	6.21	1.18e-09	0.00151	0.55	0.28	Calcium levels;	chr8:17262515	chr4:67446267~67446574:+
THCA	trans	rs11992162	0.933	rs10108075	ENSG00000229857.1	RP11-159H20.3	-6.21	1.18e-09	0.00151	-0.35	-0.28	Monocyte count;	chr8:11974570	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.804	rs7705343	ENSG00000231752.4	EMBP1	6.21	1.18e-09	0.00151	0.37	0.28	Breast cancer;	chr5:44879475	chr1:121519112~121571892:+
THCA	trans	rs3808502	0.525	rs13280813	ENSG00000256560.1	LINC01486	-6.21	1.18e-09	0.00152	-0.34	-0.28	Neuroticism;	chr8:11567596	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.933	rs10108075	ENSG00000256560.1	LINC01486	6.21	1.18e-09	0.00152	0.34	0.28	Monocyte count;	chr8:11974570	chr12:109354083~109359488:-
THCA	trans	rs3764796	0.737	rs73200948	ENSG00000250030.2	RP11-584P21.4	6.21	1.18e-09	0.00152	0.55	0.28	Calcium levels;	chr8:17268448	chr4:67446267~67446574:+
THCA	trans	rs7829975	0.846	rs11779061	ENSG00000229857.1	RP11-159H20.3	6.21	1.19e-09	0.00152	0.34	0.28	Mood instability;	chr8:8691922	chr9:76992099~76993108:+
THCA	trans	rs12682352	0.602	rs6988939	ENSG00000256560.1	LINC01486	6.21	1.19e-09	0.00152	0.33	0.28	Neuroticism;	chr8:8809406	chr12:109354083~109359488:-
THCA	trans	rs1475911	0.708	rs8129075	ENSG00000229759.1	MRPS18AP1	-6.21	1.19e-09	0.00152	-0.36	-0.28	IgG glycosylation;	chr21:42103320	chr3:48256350~48256938:-
THCA	trans	rs7903456	0.512	rs9420425	ENSG00000232706.3	NUTM2HP	6.21	1.19e-09	0.00152	0.4	0.28	Gout;Renal underexcretion gout;	chr10:87046682	chr10:50676743~50686326:+
THCA	trans	rs4646450	0.735	rs2072181	ENSG00000228834.1	RP11-249L21.4	-6.21	1.19e-09	0.00152	-0.46	-0.28	Blood metabolite levels;	chr7:99400848	chr6:108907615~108907873:-
THCA	trans	rs7364180	1	rs7364180	ENSG00000268568.1	AC007228.9	-6.21	1.19e-09	0.00153	-0.34	-0.28	Alzheimer's disease biomarkers;	chr22:41822852	chr19:56672574~56673901:-
THCA	trans	rs12200782	0.872	rs10484440	ENSG00000242375.1	RP11-498P14.3	6.21	1.19e-09	0.00153	0.57	0.28	Small cell lung carcinoma;	chr6:26453514	chr9:97195351~97197687:-
THCA	trans	rs6885307	0.941	rs78273393	ENSG00000231752.4	EMBP1	6.21	1.19e-09	0.00153	0.44	0.28	Age at first birth;	chr5:45045988	chr1:121519112~121571892:+
THCA	trans	rs7520050	0.778	rs2088102	ENSG00000255397.1	AC022182.2	6.21	1.2e-09	0.00153	0.36	0.28	Reticulocyte count;Red blood cell count;	chr1:45567302	chr8:60937705~60939871:-
THCA	trans	rs9368481	0.743	rs9368480	ENSG00000242375.1	RP11-498P14.3	6.21	1.2e-09	0.00153	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr9:97195351~97197687:-
THCA	trans	rs930395	0.514	rs4323241	ENSG00000231752.4	EMBP1	-6.21	1.2e-09	0.00153	-0.39	-0.28	Breast cancer;	chr5:44929054	chr1:121519112~121571892:+
THCA	trans	rs2069408	1	rs2069408	ENSG00000224553.1	AC008065.1	-6.2	1.2e-09	0.00154	-0.38	-0.28	Asthma;	chr12:55970537	chr2:171374931~171375278:-
THCA	trans	rs7833986	1	rs35883156	ENSG00000244245.1	RP11-120B7.1	6.2	1.2e-09	0.00154	0.37	0.28	Height;	chr8:56166374	chr5:108593609~108593967:+
THCA	trans	rs4295623	0.559	rs4841600	ENSG00000256560.1	LINC01486	6.2	1.2e-09	0.00154	0.34	0.28	Morning vs. evening chronotype;	chr8:11830639	chr12:109354083~109359488:-
THCA	trans	rs2950393	0.804	rs2926752	ENSG00000257210.1	NACAP3	6.2	1.21e-09	0.00154	0.32	0.28	Platelet distribution width;	chr12:56710144	chr12:93124063~93124543:-
THCA	trans	rs2950393	0.777	rs2958148	ENSG00000257210.1	NACAP3	6.2	1.21e-09	0.00154	0.32	0.28	Platelet distribution width;	chr12:56710153	chr12:93124063~93124543:-
THCA	trans	rs804280	0.542	rs35647515	ENSG00000254153.1	CTA-398F10.2	-6.2	1.21e-09	0.00154	-0.32	-0.28	Myopia (pathological);	chr8:11934120	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.628	rs17797894	ENSG00000253893.2	FAM85B	-6.2	1.21e-09	0.00155	-0.36	-0.28	Retinal vascular caliber;	chr8:11354572	chr8:8167819~8226614:-
THCA	trans	rs6600671	0.719	rs9728991	ENSG00000270392.2	PFN1P2	6.2	1.21e-09	0.00155	0.28	0.28	Hip geometry;	chr1:121522281	chr1:120432204~120434052:-
THCA	trans	rs902774	0.818	rs4919737	ENSG00000230716.3	KRT8P7	-6.2	1.21e-09	0.00155	-0.57	-0.28	Prostate cancer;	chr12:52877011	chr11:119602875~119604306:-
THCA	trans	rs902774	0.818	rs73108429	ENSG00000230716.3	KRT8P7	-6.2	1.21e-09	0.00155	-0.57	-0.28	Prostate cancer;	chr12:52877887	chr11:119602875~119604306:-
THCA	trans	rs1707322	1	rs6671754	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs6666763	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4489497	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211235	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.893	rs9919275	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211236	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4660328	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.928	rs61785614	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs9793167	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211237	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs11211238	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4460583	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs4459051	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211239	ENSG00000255397.1	AC022182.2	-6.2	1.21e-09	0.00155	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr8:60937705~60939871:-
THCA	trans	rs853679	0.556	rs13200214	ENSG00000204338.7	CYP21A1P	-6.2	1.21e-09	0.00155	-0.61	-0.28	Depression;	chr6:28049472	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs71559070	ENSG00000204338.7	CYP21A1P	-6.2	1.21e-09	0.00155	-0.61	-0.28	Depression;	chr6:28071151	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34166054	ENSG00000204338.7	CYP21A1P	-6.2	1.21e-09	0.00155	-0.61	-0.28	Depression;	chr6:28098023	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34662244	ENSG00000204338.7	CYP21A1P	-6.2	1.21e-09	0.00155	-0.61	-0.28	Depression;	chr6:28106103	chr6:32005636~32008451:+
THCA	trans	rs35952432	1	rs35952432	ENSG00000204338.7	CYP21A1P	-6.2	1.21e-09	0.00155	-0.61	-0.28	Lung cancer;	chr6:28107123	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13203816	ENSG00000204338.7	CYP21A1P	-6.2	1.21e-09	0.00155	-0.61	-0.28	Depression;	chr6:28111820	chr6:32005636~32008451:+
THCA	trans	rs853679	0.556	rs34588114	ENSG00000204338.7	CYP21A1P	-6.2	1.21e-09	0.00155	-0.61	-0.28	Depression;	chr6:28112850	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs34371502	ENSG00000204338.7	CYP21A1P	-6.2	1.21e-09	0.00155	-0.61	-0.28	Depression;	chr6:28113980	chr6:32005636~32008451:+
THCA	trans	rs9650657	0.504	rs10109167	ENSG00000254153.1	CTA-398F10.2	6.2	1.21e-09	0.00155	0.31	0.28	Neuroticism;	chr8:11176016	chr8:8456909~8461337:-
THCA	trans	rs2524276	1	rs2524276	ENSG00000230521.1	HCG4P7	6.2	1.21e-09	0.00155	0.66	0.28	Capecitabine sensitivity;	chr6:31440488	chr6:29887294~29888268:-
THCA	trans	rs12145833	0.62	rs7513566	ENSG00000154608.12	CEP170P1	-6.2	1.22e-09	0.00155	-0.35	-0.28	Obesity (early onset extreme);	chr1:243425299	chr4:118467590~118554204:+
THCA	trans	rs1707322	1	rs946527	ENSG00000255397.1	AC022182.2	-6.2	1.22e-09	0.00156	-0.39	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr8:60937705~60939871:-
THCA	trans	rs9393777	0.92	rs72839445	ENSG00000253570.1	RNF5P1	6.2	1.22e-09	0.00156	0.79	0.28	Intelligence (multi-trait analysis);	chr6:27281907	chr8:38600661~38601200:-
THCA	trans	rs1707322	1	rs4660331	ENSG00000255397.1	AC022182.2	-6.2	1.22e-09	0.00156	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs34444543	ENSG00000255397.1	AC022182.2	-6.2	1.23e-09	0.00157	-0.38	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr8:60937705~60939871:-
THCA	trans	rs3812762	0.868	rs7934519	ENSG00000266891.1	RP11-692N5.2	-6.2	1.23e-09	0.00157	-0.36	-0.28	Hypospadias;	chr11:8770434	chr18:9734882~9735602:-
THCA	trans	rs902774	0.759	rs4919707	ENSG00000230716.3	KRT8P7	-6.2	1.23e-09	0.00157	-0.58	-0.28	Prostate cancer;	chr12:52895864	chr11:119602875~119604306:-
THCA	trans	rs902774	0.818	rs56095813	ENSG00000230716.3	KRT8P7	-6.2	1.23e-09	0.00157	-0.58	-0.28	Prostate cancer;	chr12:52900963	chr11:119602875~119604306:-
THCA	trans	rs7819412	0.74	rs11250119	ENSG00000254153.1	CTA-398F10.2	6.2	1.23e-09	0.00157	0.31	0.28	Triglycerides;	chr8:11179525	chr8:8456909~8461337:-
THCA	trans	rs76228276	0.737	rs72674605	ENSG00000260318.1	COX6CP1	6.2	1.23e-09	0.00158	0.81	0.27	Childhood ear infection;	chr8:99396268	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs72674616	ENSG00000260318.1	COX6CP1	6.2	1.23e-09	0.00158	0.81	0.27	Childhood ear infection;	chr8:99420451	chr16:11903923~11904137:-
THCA	trans	rs1190596	0.666	rs12892927	ENSG00000181359.5	HSP90AA6P	-6.2	1.24e-09	0.00158	-0.46	-0.27	Behavioural disinhibition (generation interaction);	chr14:102297705	chr4:170581470~170605450:-
THCA	trans	rs941207	0.756	rs2958149	ENSG00000228224.3	NACAP1	6.2	1.24e-09	0.00158	0.31	0.27	Platelet count;	chr12:56716008	chr8:101361794~101372707:+
THCA	trans	rs1707322	1	rs6429588	ENSG00000255397.1	AC022182.2	-6.2	1.24e-09	0.00158	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs12097799	ENSG00000255397.1	AC022182.2	-6.2	1.24e-09	0.00158	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr8:60937705~60939871:-
THCA	trans	rs7819412	0.522	rs4642600	ENSG00000254153.1	CTA-398F10.2	6.2	1.24e-09	0.00158	0.33	0.27	Triglycerides;	chr8:11155515	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.502	rs4841499	ENSG00000229857.1	RP11-159H20.3	6.2	1.25e-09	0.0016	0.37	0.27	Triglycerides;	chr8:11130628	chr9:76992099~76993108:+
THCA	trans	rs7200543	1	rs4985124	ENSG00000250569.1	NTAN1P2	6.2	1.25e-09	0.0016	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr8:86481754~86483002:-
THCA	trans	rs4415084	0.834	rs11957920	ENSG00000231752.4	EMBP1	-6.2	1.25e-09	0.0016	-0.37	-0.27	Breast cancer;	chr5:44904984	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.804	rs10070339	ENSG00000231752.4	EMBP1	-6.2	1.25e-09	0.0016	-0.37	-0.27	Breast cancer;	chr5:44907780	chr1:121519112~121571892:+
THCA	trans	rs2985684	1	rs2985696	ENSG00000240785.1	RPL36AP21	6.2	1.25e-09	0.0016	0.36	0.27	Carotid intima media thickness;	chr14:49628195	chr5:18049550~18049872:+
THCA	trans	rs2060793	0.539	rs962025	ENSG00000236360.2	RP11-334A14.2	6.2	1.26e-09	0.0016	0.36	0.27	Vitamin D levels;	chr11:14618744	chr1:52993201~52993702:-
THCA	trans	rs7769051	1	rs73554431	ENSG00000227615.1	RP11-864N7.2	6.2	1.26e-09	0.0016	0.44	0.27	Type 2 diabetes nephropathy;	chr6:132808783	chr11:74745716~74746114:-
THCA	trans	rs9393777	0.92	rs67859638	ENSG00000253570.1	RNF5P1	6.2	1.26e-09	0.00161	0.79	0.27	Intelligence (multi-trait analysis);	chr6:27390199	chr8:38600661~38601200:-
THCA	trans	rs12682352	0.602	rs13260419	ENSG00000256560.1	LINC01486	6.2	1.26e-09	0.00161	0.33	0.27	Neuroticism;	chr8:8817666	chr12:109354083~109359488:-
THCA	trans	rs4415084	0.834	rs13362132	ENSG00000231752.4	EMBP1	6.2	1.27e-09	0.00162	0.37	0.27	Breast cancer;	chr5:44858158	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.697	rs35280960	ENSG00000253326.2	RP11-261C10.7	6.2	1.27e-09	0.00162	0.39	0.27	Corneal astigmatism;	chr4:119335904	chr1:243054861~243056394:-
THCA	trans	rs7819412	0.765	rs7000132	ENSG00000254153.1	CTA-398F10.2	6.19	1.28e-09	0.00163	0.32	0.27	Triglycerides;	chr8:11173426	chr8:8456909~8461337:-
THCA	trans	rs2950393	0.804	rs7967600	ENSG00000257210.1	NACAP3	6.19	1.28e-09	0.00163	0.32	0.27	Platelet distribution width;	chr12:56768208	chr12:93124063~93124543:-
THCA	trans	rs8177876	0.822	rs4889231	ENSG00000224837.1	GCSHP5	-6.19	1.28e-09	0.00163	-0.41	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr1:168055901~168056422:-
THCA	trans	rs616147	0.962	rs1708104	ENSG00000243904.1	RP11-600F24.1	-6.19	1.28e-09	0.00163	-0.34	-0.27	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr14:103374033~103374916:-
THCA	trans	rs1707322	1	rs10890380	ENSG00000255397.1	AC022182.2	-6.19	1.28e-09	0.00164	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr8:60937705~60939871:-
THCA	trans	rs45509595	0.841	rs17751184	ENSG00000228022.4	HCG20	-6.19	1.29e-09	0.00164	-0.7	-0.27	Breast cancer;	chr6:27807250	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs67101035	ENSG00000228022.4	HCG20	-6.19	1.29e-09	0.00164	-0.7	-0.27	Depression;	chr6:27831109	chr6:30766825~30792250:+
THCA	trans	rs853679	0.556	rs34706883	ENSG00000228022.4	HCG20	-6.19	1.29e-09	0.00164	-0.7	-0.27	Depression;	chr6:27837477	chr6:30766825~30792250:+
THCA	trans	rs67340775	0.748	rs13212651	ENSG00000228022.4	HCG20	-6.19	1.29e-09	0.00164	-0.7	-0.27	Lung cancer in ever smokers;	chr6:27839207	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs35819751	ENSG00000228022.4	HCG20	-6.19	1.29e-09	0.00164	-0.7	-0.27	Depression;	chr6:27842791	chr6:30766825~30792250:+
THCA	trans	rs7212590	0.748	rs7213697	ENSG00000187870.7	RNFT1P3	6.19	1.29e-09	0.00164	0.55	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59825680	chr17:20743333~20754501:-
THCA	trans	rs9393777	0.92	rs35869525	ENSG00000228022.4	HCG20	-6.19	1.29e-09	0.00164	-0.65	-0.27	Intelligence (multi-trait analysis);	chr6:26978908	chr6:30766825~30792250:+
THCA	trans	rs7945705	0.791	rs6484484	ENSG00000266891.1	RP11-692N5.2	-6.19	1.29e-09	0.00164	-0.34	-0.27	Hemoglobin concentration;	chr11:8795659	chr18:9734882~9735602:-
THCA	trans	rs7826238	0.535	rs2979179	ENSG00000229857.1	RP11-159H20.3	-6.19	1.3e-09	0.00165	-0.33	-0.27	Systolic blood pressure;	chr8:8462519	chr9:76992099~76993108:+
THCA	trans	rs853679	0.607	rs35902873	ENSG00000204338.7	CYP21A1P	-6.19	1.3e-09	0.00166	-0.61	-0.27	Depression;	chr6:28091171	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13197574	ENSG00000204338.7	CYP21A1P	-6.19	1.3e-09	0.00166	-0.61	-0.27	Depression;	chr6:28092461	chr6:32005636~32008451:+
THCA	trans	rs12682352	0.602	rs6993494	ENSG00000256560.1	LINC01486	6.19	1.31e-09	0.00166	0.33	0.27	Neuroticism;	chr8:8809934	chr12:109354083~109359488:-
THCA	trans	rs1707322	0.964	rs7546237	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00167	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211200	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00167	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs7553924	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00167	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4641257	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00167	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs6693336	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00167	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4539075	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00167	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211219	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00167	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211222	ENSG00000255397.1	AC022182.2	-6.19	1.31e-09	0.00167	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr8:60937705~60939871:-
THCA	trans	rs7212590	0.881	rs7216675	ENSG00000187870.7	RNFT1P3	6.19	1.31e-09	0.00167	0.55	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59805313	chr17:20743333~20754501:-
THCA	trans	rs7212590	1	rs73315284	ENSG00000187870.7	RNFT1P3	6.19	1.31e-09	0.00167	0.55	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59807507	chr17:20743333~20754501:-
THCA	trans	rs7212590	1	rs7212590	ENSG00000187870.7	RNFT1P3	6.19	1.31e-09	0.00167	0.55	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808348	chr17:20743333~20754501:-
THCA	trans	rs6087990	0.735	rs2424915	ENSG00000253915.1	MAPRE1P1	6.19	1.31e-09	0.00167	0.35	0.27	Ulcerative colitis;	chr20:32790642	chr8:135625185~135625981:-
THCA	trans	rs9467711	0.79	rs13198716	ENSG00000226314.6	ZNF192P1	6.19	1.32e-09	0.00168	0.59	0.27	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:28161781~28169594:+
THCA	trans	rs7192380	0.825	rs3811348	ENSG00000257513.6	NPIPB1P	-6.19	1.32e-09	0.00168	-0.3	-0.27	Sjögren's syndrome;	chr16:69748952	chr18:11619509~11639699:-
THCA	trans	rs864643	0.773	rs13077475	ENSG00000183298.5	RP11-556K13.1	-6.19	1.32e-09	0.00168	-0.42	-0.27	Attention deficit hyperactivity disorder;	chr3:39546814	chr1:101786340~101787219:-
THCA	trans	rs930395	0.514	rs4866784	ENSG00000231752.4	EMBP1	6.19	1.34e-09	0.0017	0.38	0.27	Breast cancer;	chr5:44901029	chr1:121519112~121571892:+
THCA	trans	rs9314986	0.672	rs2388248	ENSG00000278546.1	RP1-41C23.4	6.19	1.34e-09	0.00171	0.35	0.27	Biliary atresia;	chr13:29891677	chr17:31560132~31560573:+
THCA	trans	rs2736337	0.532	rs6998387	ENSG00000253893.2	FAM85B	-6.19	1.34e-09	0.00171	-0.35	-0.27	Rheumatoid arthritis;	chr8:11435949	chr8:8167819~8226614:-
THCA	trans	rs9425766	0.64	rs3791020	ENSG00000213331.4	RP11-713C19.2	-6.19	1.35e-09	0.00171	-0.39	-0.27	Life satisfaction;	chr1:173844059	chr4:187970273~187971284:+
THCA	trans	rs9649213	0.593	rs2394854	ENSG00000225169.1	BRI3P1	6.19	1.35e-09	0.00171	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr1:100213293~100213670:+
THCA	trans	rs3764796	0.737	rs73200937	ENSG00000250030.2	RP11-584P21.4	6.19	1.35e-09	0.00171	0.56	0.27	Calcium levels;	chr8:17264266	chr4:67446267~67446574:+
THCA	trans	rs902774	0.818	rs73110432	ENSG00000240668.1	KRT8P36	-6.19	1.35e-09	0.00171	-0.54	-0.27	Prostate cancer;	chr12:52894051	chr3:138101478~138102917:-
THCA	trans	rs864643	0.898	rs1631776	ENSG00000183298.5	RP11-556K13.1	6.19	1.35e-09	0.00172	0.44	0.27	Attention deficit hyperactivity disorder;	chr3:39548704	chr1:101786340~101787219:-
THCA	trans	rs9649213	0.574	rs3801251	ENSG00000225169.1	BRI3P1	6.19	1.35e-09	0.00172	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs3779193	ENSG00000225169.1	BRI3P1	6.19	1.35e-09	0.00172	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs12704989	ENSG00000225169.1	BRI3P1	6.19	1.35e-09	0.00172	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr1:100213293~100213670:+
THCA	trans	rs7903456	0.512	rs4460730	ENSG00000232706.3	NUTM2HP	6.18	1.35e-09	0.00172	0.4	0.27	Gout;Renal underexcretion gout;	chr10:87076289	chr10:50676743~50686326:+
THCA	trans	rs10242455	0.717	rs6955424	ENSG00000228834.1	RP11-249L21.4	6.18	1.35e-09	0.00172	0.48	0.27	Blood metabolite levels;	chr7:99751810	chr6:108907615~108907873:-
THCA	trans	rs4415084	0.804	rs9790879	ENSG00000231752.4	EMBP1	-6.18	1.36e-09	0.00172	-0.37	-0.27	Breast cancer;	chr5:44899783	chr1:121519112~121571892:+
THCA	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-6.18	1.36e-09	0.00172	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
THCA	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-6.18	1.36e-09	0.00172	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
THCA	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-6.18	1.36e-09	0.00172	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
THCA	trans	rs7819412	0.818	rs11989439	ENSG00000256560.1	LINC01486	-6.18	1.36e-09	0.00173	-0.34	-0.27	Triglycerides;	chr8:11198088	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.626	rs332040	ENSG00000256560.1	LINC01486	6.18	1.36e-09	0.00173	0.33	0.27	Mood instability;	chr8:8872978	chr12:109354083~109359488:-
THCA	trans	rs8014204	0.869	rs2070599	ENSG00000181227.3	RP4-682C21.2	6.18	1.36e-09	0.00173	0.22	0.27	Caffeine consumption;	chr14:74894474	chr1:75743423~75744776:-
THCA	trans	rs7824557	0.602	rs7833966	ENSG00000253893.2	FAM85B	-6.18	1.37e-09	0.00174	-0.36	-0.27	Retinal vascular caliber;	chr8:11348711	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.568	rs35747588	ENSG00000253893.2	FAM85B	-6.18	1.37e-09	0.00174	-0.36	-0.27	Retinal vascular caliber;	chr8:11349118	chr8:8167819~8226614:-
THCA	trans	rs34546498	1	rs34546498	ENSG00000253570.1	RNF5P1	6.18	1.37e-09	0.00174	0.79	0.27	Breast cancer;	chr6:26993501	chr8:38600661~38601200:-
THCA	trans	rs7824557	0.843	rs2736375	ENSG00000254153.1	CTA-398F10.2	6.18	1.37e-09	0.00174	0.29	0.27	Retinal vascular caliber;	chr8:11258240	chr8:8456909~8461337:-
THCA	trans	rs930395	0.514	rs6868779	ENSG00000231752.4	EMBP1	-6.18	1.37e-09	0.00174	-0.38	-0.27	Breast cancer;	chr5:44885898	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.652	rs10045264	ENSG00000231752.4	EMBP1	-6.18	1.37e-09	0.00174	-0.38	-0.27	Breast cancer;	chr5:44886330	chr1:121519112~121571892:+
THCA	trans	rs9425766	0.64	rs2281486	ENSG00000213331.4	RP11-713C19.2	6.18	1.37e-09	0.00175	0.39	0.27	Life satisfaction;	chr1:173853083	chr4:187970273~187971284:+
THCA	trans	rs9425766	0.64	rs16846439	ENSG00000213331.4	RP11-713C19.2	6.18	1.37e-09	0.00175	0.39	0.27	Life satisfaction;	chr1:173854900	chr4:187970273~187971284:+
THCA	trans	rs7819412	0.522	rs11776603	ENSG00000229857.1	RP11-159H20.3	6.18	1.38e-09	0.00175	0.38	0.27	Triglycerides;	chr8:11162803	chr9:76992099~76993108:+
THCA	trans	rs4879656	0.866	rs10971316	ENSG00000215007.3	DNAJA1P3	6.18	1.38e-09	0.00175	0.32	0.27	Menopause (age at onset);	chr9:33013964	chrX:107351650~107352843:-
THCA	trans	rs2898290	0.5	rs11998678	ENSG00000254153.1	CTA-398F10.2	6.18	1.38e-09	0.00175	0.31	0.27	Systolic blood pressure;	chr8:11972641	chr8:8456909~8461337:-
THCA	trans	rs902774	0.818	rs4919737	ENSG00000250539.1	KRT8P33	-6.18	1.38e-09	0.00176	-0.51	-0.27	Prostate cancer;	chr12:52877011	chr5:123400922~123402344:-
THCA	trans	rs902774	0.818	rs73108429	ENSG00000250539.1	KRT8P33	-6.18	1.38e-09	0.00176	-0.51	-0.27	Prostate cancer;	chr12:52877887	chr5:123400922~123402344:-
THCA	trans	rs9649213	0.574	rs62478236	ENSG00000225169.1	BRI3P1	6.18	1.38e-09	0.00176	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98401065	chr1:100213293~100213670:+
THCA	trans	rs7819412	1	rs2409722	ENSG00000254153.1	CTA-398F10.2	6.18	1.38e-09	0.00176	0.3	0.27	Triglycerides;	chr8:11182307	chr8:8456909~8461337:-
THCA	trans	rs2985684	1	rs11157696	ENSG00000240785.1	RPL36AP21	-6.18	1.39e-09	0.00176	-0.35	-0.27	Carotid intima media thickness;	chr14:49639028	chr5:18049550~18049872:+
THCA	trans	rs3808502	0.525	rs13280813	ENSG00000229857.1	RP11-159H20.3	6.18	1.39e-09	0.00176	0.35	0.27	Neuroticism;	chr8:11567596	chr9:76992099~76993108:+
THCA	trans	rs7769051	1	rs3813347	ENSG00000227615.1	RP11-864N7.2	6.18	1.39e-09	0.00176	0.46	0.27	Type 2 diabetes nephropathy;	chr6:132798639	chr11:74745716~74746114:-
THCA	trans	rs714543	0.811	rs13238404	ENSG00000214975.4	PPIAP29	6.18	1.39e-09	0.00176	0.32	0.27	Plateletcrit;	chr7:44811812	chr6:24976419~24976982:+
THCA	trans	rs7819412	0.805	rs2409710	ENSG00000254153.1	CTA-398F10.2	6.18	1.39e-09	0.00176	0.31	0.27	Triglycerides;	chr8:11122311	chr8:8456909~8461337:-
THCA	trans	rs2950393	0.804	rs898611	ENSG00000228224.3	NACAP1	-6.18	1.39e-09	0.00177	-0.27	-0.27	Platelet distribution width;	chr12:56769532	chr8:101361794~101372707:+
THCA	trans	rs902774	0.818	rs4919763	ENSG00000230716.3	KRT8P7	-6.18	1.39e-09	0.00177	-0.58	-0.27	Prostate cancer;	chr12:52885839	chr11:119602875~119604306:-
THCA	trans	rs902774	0.818	rs55914512	ENSG00000230716.3	KRT8P7	-6.18	1.39e-09	0.00177	-0.58	-0.27	Prostate cancer;	chr12:52888490	chr11:119602875~119604306:-
THCA	trans	rs902774	0.818	rs73108466	ENSG00000230716.3	KRT8P7	-6.18	1.39e-09	0.00177	-0.58	-0.27	Prostate cancer;	chr12:52889857	chr11:119602875~119604306:-
THCA	trans	rs902774	0.818	rs55999178	ENSG00000230716.3	KRT8P7	-6.18	1.39e-09	0.00177	-0.58	-0.27	Prostate cancer;	chr12:52890576	chr11:119602875~119604306:-
THCA	trans	rs9467711	0.659	rs3734542	ENSG00000280107.1	AL022393.9	-6.18	1.39e-09	0.00177	-0.52	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26468098	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.606	rs34104395	ENSG00000280107.1	AL022393.9	-6.18	1.39e-09	0.00177	-0.52	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26478024	chr6:28170845~28172521:+
THCA	trans	rs9650657	0.711	rs10100209	ENSG00000253893.2	FAM85B	6.18	1.4e-09	0.00177	0.34	0.27	Neuroticism;	chr8:10726702	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.905	rs13254263	ENSG00000254153.1	CTA-398F10.2	6.18	1.4e-09	0.00177	0.3	0.27	Neuroticism;	chr8:10397671	chr8:8456909~8461337:-
THCA	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-6.18	1.4e-09	0.00178	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
THCA	trans	rs1707322	1	rs11211243	ENSG00000255397.1	AC022182.2	-6.18	1.41e-09	0.00179	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211244	ENSG00000255397.1	AC022182.2	-6.18	1.41e-09	0.00179	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4660903	ENSG00000255397.1	AC022182.2	-6.18	1.41e-09	0.00179	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4660905	ENSG00000255397.1	AC022182.2	6.18	1.41e-09	0.00179	0.38	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr8:60937705~60939871:-
THCA	trans	rs902774	0.818	rs4919742	ENSG00000250539.1	KRT8P33	-6.18	1.41e-09	0.00179	-0.51	-0.27	Prostate cancer;	chr12:52879180	chr5:123400922~123402344:-
THCA	trans	rs453301	0.653	rs7005133	ENSG00000256560.1	LINC01486	6.18	1.41e-09	0.00179	0.31	0.27	Joint mobility (Beighton score);	chr8:9043712	chr12:109354083~109359488:-
THCA	trans	rs7826238	0.509	rs2948288	ENSG00000229857.1	RP11-159H20.3	-6.18	1.43e-09	0.00181	-0.33	-0.27	Systolic blood pressure;	chr8:8257782	chr9:76992099~76993108:+
THCA	trans	rs902774	0.818	rs73110471	ENSG00000230716.3	KRT8P7	-6.18	1.43e-09	0.00181	-0.56	-0.27	Prostate cancer;	chr12:52923037	chr11:119602875~119604306:-
THCA	trans	rs7829975	0.871	rs777709	ENSG00000256560.1	LINC01486	-6.17	1.44e-09	0.00182	-0.32	-0.27	Mood instability;	chr8:8726362	chr12:109354083~109359488:-
THCA	trans	rs73108077	0.736	rs73104088	ENSG00000279352.1	RP11-411B10.7	6.17	1.44e-09	0.00182	0.62	0.27	Red blood cell density in sickle cell anemia;	chr20:31311110	chr18:14010054~14010917:+
THCA	trans	rs4879656	0.872	rs12375624	ENSG00000215007.3	DNAJA1P3	6.17	1.44e-09	0.00182	0.32	0.27	Menopause (age at onset);	chr9:33017140	chrX:107351650~107352843:-
THCA	trans	rs1580019	0.713	rs2167274	ENSG00000176826.14	FKBP9P1	-6.17	1.44e-09	0.00183	-0.37	-0.27	Cognitive ability;	chr7:32485232	chr7:55681074~55713252:-
THCA	trans	rs76228276	0.737	rs77630923	ENSG00000260318.1	COX6CP1	6.17	1.44e-09	0.00183	0.8	0.27	Childhood ear infection;	chr8:99409997	chr16:11903923~11904137:-
THCA	trans	rs9467711	0.659	rs13220261	ENSG00000280107.1	AL022393.9	-6.17	1.44e-09	0.00183	-0.51	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26498957	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs35555795	ENSG00000280107.1	AL022393.9	-6.17	1.44e-09	0.00183	-0.51	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26509154	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs35433030	ENSG00000280107.1	AL022393.9	-6.17	1.44e-09	0.00183	-0.51	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26529662	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs66941101	ENSG00000280107.1	AL022393.9	-6.17	1.44e-09	0.00183	-0.51	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26530148	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs34246779	ENSG00000280107.1	AL022393.9	-6.17	1.44e-09	0.00183	-0.51	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26548984	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs72845428	ENSG00000280107.1	AL022393.9	-6.17	1.44e-09	0.00183	-0.51	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26549916	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs35277236	ENSG00000280107.1	AL022393.9	-6.17	1.44e-09	0.00183	-0.51	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26562041	chr6:28170845~28172521:+
THCA	trans	rs9467711	0.659	rs72844462	ENSG00000280107.1	AL022393.9	-6.17	1.44e-09	0.00183	-0.51	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26563636	chr6:28170845~28172521:+
THCA	trans	rs853679	0.546	rs13195291	ENSG00000204338.7	CYP21A1P	-6.17	1.45e-09	0.00183	-0.61	-0.27	Depression;	chr6:28201463	chr6:32005636~32008451:+
THCA	trans	rs853679	0.556	rs13197633	ENSG00000204338.7	CYP21A1P	-6.17	1.45e-09	0.00183	-0.61	-0.27	Depression;	chr6:28206979	chr6:32005636~32008451:+
THCA	trans	rs9329221	0.905	rs28507213	ENSG00000254153.1	CTA-398F10.2	6.17	1.45e-09	0.00184	0.3	0.27	Neuroticism;	chr8:10393339	chr8:8456909~8461337:-
THCA	trans	rs9329221	0.905	rs28712068	ENSG00000254153.1	CTA-398F10.2	6.17	1.45e-09	0.00184	0.3	0.27	Neuroticism;	chr8:10393635	chr8:8456909~8461337:-
THCA	trans	rs9649213	0.593	rs6465665	ENSG00000225169.1	BRI3P1	6.17	1.45e-09	0.00184	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr1:100213293~100213670:+
THCA	trans	rs7746199	0.736	rs13212318	ENSG00000228022.4	HCG20	-6.17	1.46e-09	0.00184	-0.69	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs13202291	ENSG00000228022.4	HCG20	-6.17	1.46e-09	0.00184	-0.69	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs17750424	ENSG00000228022.4	HCG20	-6.17	1.46e-09	0.00184	-0.69	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:30766825~30792250:+
THCA	trans	rs34421088	0.56	rs11780851	ENSG00000229857.1	RP11-159H20.3	6.17	1.46e-09	0.00184	0.36	0.27	Neuroticism;	chr8:11543607	chr9:76992099~76993108:+
THCA	trans	rs950169	0.845	rs4106951	ENSG00000259295.5	CSPG4P12	6.17	1.46e-09	0.00185	0.42	0.27	Schizophrenia;	chr15:84164642	chr15:85191438~85213905:+
THCA	trans	rs7819412	0.549	rs28887839	ENSG00000253893.2	FAM85B	6.17	1.46e-09	0.00185	0.38	0.27	Triglycerides;	chr8:11142903	chr8:8167819~8226614:-
THCA	trans	rs1707322	0.963	rs11211202	ENSG00000255397.1	AC022182.2	-6.17	1.46e-09	0.00185	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr8:60937705~60939871:-
THCA	trans	rs864643	0.898	rs635235	ENSG00000183298.5	RP11-556K13.1	6.17	1.46e-09	0.00185	0.45	0.27	Attention deficit hyperactivity disorder;	chr3:39549614	chr1:101786340~101787219:-
THCA	trans	rs4415084	0.652	rs10060645	ENSG00000231752.4	EMBP1	-6.17	1.46e-09	0.00185	-0.38	-0.27	Breast cancer;	chr5:44908097	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs4919742	ENSG00000230716.3	KRT8P7	-6.17	1.47e-09	0.00186	-0.57	-0.27	Prostate cancer;	chr12:52879180	chr11:119602875~119604306:-
THCA	trans	rs930395	0.514	rs34115673	ENSG00000231752.4	EMBP1	-6.17	1.47e-09	0.00186	-0.38	-0.27	Breast cancer;	chr5:44892699	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs10035358	ENSG00000231752.4	EMBP1	-6.17	1.47e-09	0.00186	-0.38	-0.27	Breast cancer;	chr5:44892800	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs13154729	ENSG00000231752.4	EMBP1	-6.17	1.47e-09	0.00186	-0.38	-0.27	Breast cancer;	chr5:44892827	chr1:121519112~121571892:+
THCA	trans	rs3808502	0.509	rs2729940	ENSG00000229857.1	RP11-159H20.3	-6.17	1.47e-09	0.00186	-0.34	-0.27	Neuroticism;	chr8:11524858	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.564	rs1435275	ENSG00000256560.1	LINC01486	-6.17	1.47e-09	0.00186	-0.34	-0.27	Retinal vascular caliber;	chr8:11378226	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs73108469	ENSG00000250539.1	KRT8P33	-6.17	1.47e-09	0.00186	-0.52	-0.27	Prostate cancer;	chr12:52891065	chr5:123400922~123402344:-
THCA	trans	rs6601327	0.606	rs35233861	ENSG00000253893.2	FAM85B	6.17	1.48e-09	0.00187	0.34	0.27	Multiple myeloma (hyperdiploidy);	chr8:9700937	chr8:8167819~8226614:-
THCA	trans	rs950169	0.922	rs4586394	ENSG00000259295.5	CSPG4P12	-6.17	1.48e-09	0.00187	-0.42	-0.27	Schizophrenia;	chr15:84153633	chr15:85191438~85213905:+
THCA	trans	rs9329221	0.525	rs4394398	ENSG00000253893.2	FAM85B	6.17	1.49e-09	0.00188	0.39	0.27	Neuroticism;	chr8:10226884	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.507	rs12678938	ENSG00000253893.2	FAM85B	6.17	1.49e-09	0.00188	0.37	0.27	Neuroticism;	chr8:10159459	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs4660889	ENSG00000255397.1	AC022182.2	-6.17	1.49e-09	0.00189	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs10890355	ENSG00000255397.1	AC022182.2	-6.17	1.49e-09	0.00189	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs11211204	ENSG00000255397.1	AC022182.2	-6.17	1.49e-09	0.00189	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr8:60937705~60939871:-
THCA	trans	rs11098499	0.865	rs10213221	ENSG00000253326.2	RP11-261C10.7	6.17	1.5e-09	0.0019	0.38	0.27	Corneal astigmatism;	chr4:119334771	chr1:243054861~243056394:-
THCA	trans	rs853679	0.607	rs35001169	ENSG00000204338.7	CYP21A1P	-6.17	1.51e-09	0.00191	-0.61	-0.27	Depression;	chr6:28219854	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs35656932	ENSG00000204338.7	CYP21A1P	-6.17	1.51e-09	0.00191	-0.61	-0.27	Depression;	chr6:28223510	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13208096	ENSG00000204338.7	CYP21A1P	-6.17	1.51e-09	0.00191	-0.61	-0.27	Depression;	chr6:28257533	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.673	rs72847313	ENSG00000228022.4	HCG20	-6.16	1.52e-09	0.00192	-0.69	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.611	rs17750747	ENSG00000228022.4	HCG20	-6.16	1.52e-09	0.00192	-0.69	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:30766825~30792250:+
THCA	trans	rs7769051	0.808	rs1467404	ENSG00000227615.1	RP11-864N7.2	-6.16	1.53e-09	0.00193	-0.46	-0.27	Type 2 diabetes nephropathy;	chr6:132769002	chr11:74745716~74746114:-
THCA	trans	rs11951515	0.899	rs6883936	ENSG00000174977.8	AC026271.5	-6.16	1.53e-09	0.00194	-0.32	-0.27	Metabolite levels  (X-11787);	chr5:43399062	chr17:18650195~18651542:+
THCA	trans	rs6087990	0.806	rs4911258	ENSG00000253915.1	MAPRE1P1	6.16	1.54e-09	0.00194	0.35	0.27	Ulcerative colitis;	chr20:32781673	chr8:135625185~135625981:-
THCA	trans	rs9650657	0.524	rs10088408	ENSG00000256560.1	LINC01486	-6.16	1.54e-09	0.00195	-0.33	-0.27	Neuroticism;	chr8:10959687	chr12:109354083~109359488:-
THCA	trans	rs6600671	0.692	rs11249430	ENSG00000270231.3	NBPF8P	6.16	1.55e-09	0.00196	0.25	0.27	Hip geometry;	chr1:121547115	chr1:120436353~120467739:+
THCA	trans	rs7829975	0.782	rs6990746	ENSG00000229857.1	RP11-159H20.3	6.16	1.55e-09	0.00196	0.33	0.27	Mood instability;	chr8:8690301	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.803	rs13276026	ENSG00000229857.1	RP11-159H20.3	6.16	1.57e-09	0.00198	0.33	0.27	Neuroticism;	chr8:10752445	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.652	rs10473376	ENSG00000231752.4	EMBP1	-6.16	1.57e-09	0.00198	-0.38	-0.27	Breast cancer;	chr5:44931126	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs10473377	ENSG00000231752.4	EMBP1	-6.16	1.57e-09	0.00198	-0.38	-0.27	Breast cancer;	chr5:44931144	chr1:121519112~121571892:+
THCA	trans	rs45509595	0.556	rs34409918	ENSG00000228022.4	HCG20	-6.16	1.57e-09	0.00198	-0.7	-0.27	Breast cancer;	chr6:27717569	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs72845070	ENSG00000228022.4	HCG20	-6.16	1.58e-09	0.00199	-0.74	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:30766825~30792250:+
THCA	trans	rs7112043	0.838	rs11032839	ENSG00000225531.1	RP11-196I18.3	6.16	1.58e-09	0.00199	0.35	0.27	Lung disease severity in cystic fibrosis;	chr11:34756178	chr9:107116829~107117557:+
THCA	trans	rs453301	0.686	rs4840389	ENSG00000229857.1	RP11-159H20.3	6.16	1.58e-09	0.00199	0.34	0.27	Joint mobility (Beighton score);	chr8:9026993	chr9:76992099~76993108:+
THCA	trans	rs453301	0.658	rs13271797	ENSG00000229857.1	RP11-159H20.3	6.16	1.58e-09	0.00199	0.34	0.27	Joint mobility (Beighton score);	chr8:9028444	chr9:76992099~76993108:+
THCA	trans	rs4883201	0.518	rs887782	ENSG00000179899.8	PHC1P1	-6.16	1.58e-09	0.00199	-0.28	-0.27	Total cholesterol levels;Cholesterol, total;	chr12:8932082	chr12:55411727~55414787:-
THCA	trans	rs6981523	0.566	rs34162231	ENSG00000256560.1	LINC01486	-6.16	1.58e-09	0.002	-0.35	-0.27	Neuroticism;	chr8:11145578	chr12:109354083~109359488:-
THCA	trans	rs7520050	0.751	rs2991975	ENSG00000255397.1	AC022182.2	6.16	1.58e-09	0.002	0.36	0.27	Reticulocyte count;Red blood cell count;	chr1:45558854	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.679	rs7004362	ENSG00000229857.1	RP11-159H20.3	6.16	1.58e-09	0.002	0.35	0.27	Retinal vascular caliber;	chr8:11278465	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.713	rs9286062	ENSG00000254153.1	CTA-398F10.2	6.16	1.59e-09	0.002	0.29	0.27	Retinal vascular caliber;	chr8:11261018	chr8:8456909~8461337:-
THCA	trans	rs9649213	0.574	rs34830366	ENSG00000225169.1	BRI3P1	6.16	1.59e-09	0.00201	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr1:100213293~100213670:+
THCA	trans	rs9649213	0.593	rs34776142	ENSG00000225169.1	BRI3P1	6.16	1.59e-09	0.00201	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr1:100213293~100213670:+
THCA	trans	rs11172055	1	rs11172055	ENSG00000121089.4	NACA3P	6.16	1.59e-09	0.00201	0.31	0.27	Migraine;	chr12:56914476	chr4:164943290~164943937:+
THCA	trans	rs9467711	0.606	rs2393667	ENSG00000253570.1	RNF5P1	6.16	1.59e-09	0.00201	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:26421117	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.606	rs9366656	ENSG00000253570.1	RNF5P1	6.16	1.59e-09	0.00201	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:26434402	chr8:38600661~38601200:-
THCA	trans	rs12682352	0.602	rs28399241	ENSG00000256560.1	LINC01486	6.16	1.6e-09	0.00201	0.33	0.27	Neuroticism;	chr8:8805705	chr12:109354083~109359488:-
THCA	trans	rs7945705	0.791	rs7944560	ENSG00000266891.1	RP11-692N5.2	-6.16	1.6e-09	0.00202	-0.34	-0.27	Hemoglobin concentration;	chr11:8795729	chr18:9734882~9735602:-
THCA	trans	rs7903456	0.512	rs9420426	ENSG00000232706.3	NUTM2HP	6.16	1.6e-09	0.00202	0.4	0.27	Gout;Renal underexcretion gout;	chr10:87046781	chr10:50676743~50686326:+
THCA	trans	rs930395	0.514	rs10044321	ENSG00000231752.4	EMBP1	-6.16	1.6e-09	0.00202	-0.38	-0.27	Breast cancer;	chr5:44890658	chr1:121519112~121571892:+
THCA	trans	rs2950393	0.804	rs11171951	ENSG00000257210.1	NACAP3	6.16	1.6e-09	0.00202	0.32	0.27	Platelet distribution width;	chr12:56718853	chr12:93124063~93124543:-
THCA	trans	rs7829975	0.714	rs4841040	ENSG00000229857.1	RP11-159H20.3	-6.16	1.6e-09	0.00202	-0.33	-0.27	Mood instability;	chr8:8797017	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.522	rs10088853	ENSG00000229857.1	RP11-159H20.3	6.15	1.61e-09	0.00203	0.36	0.27	Triglycerides;	chr8:11130457	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.807	rs519019	ENSG00000256560.1	LINC01486	-6.15	1.61e-09	0.00203	-0.32	-0.27	Mood instability;	chr8:8737594	chr12:109354083~109359488:-
THCA	trans	rs4720118	0.875	rs3884597	ENSG00000213492.2	NT5C3AP1	-6.15	1.61e-09	0.00204	-0.35	-0.27	Leprosy;	chr7:33345650	chr4:117574512~117576174:-
THCA	trans	rs7819412	0.74	rs7844536	ENSG00000256560.1	LINC01486	-6.15	1.61e-09	0.00204	-0.34	-0.27	Triglycerides;	chr8:11176519	chr12:109354083~109359488:-
THCA	trans	rs11671005	0.736	rs11668201	ENSG00000279267.1	RP11-395L14.18	6.15	1.61e-09	0.00204	0.39	0.27	Mean platelet volume;	chr19:58492265	chr2:113605867~113607908:-
THCA	trans	rs76228276	0.737	rs1021415	ENSG00000260318.1	COX6CP1	6.15	1.62e-09	0.00204	0.81	0.27	Childhood ear infection;	chr8:99377038	chr16:11903923~11904137:-
THCA	trans	rs853679	0.607	rs13204012	ENSG00000204338.7	CYP21A1P	-6.15	1.62e-09	0.00204	-0.61	-0.27	Depression;	chr6:28233753	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13205211	ENSG00000204338.7	CYP21A1P	-6.15	1.62e-09	0.00204	-0.61	-0.27	Depression;	chr6:28235278	chr6:32005636~32008451:+
THCA	trans	rs4720118	0.875	rs9784973	ENSG00000213492.2	NT5C3AP1	-6.15	1.63e-09	0.00205	-0.35	-0.27	Leprosy;	chr7:33350077	chr4:117574512~117576174:-
THCA	trans	rs34421088	0.678	rs35726503	ENSG00000256560.1	LINC01486	-6.15	1.63e-09	0.00205	-0.32	-0.27	Neuroticism;	chr8:11734407	chr12:109354083~109359488:-
THCA	trans	rs6458375	1	rs6458375	ENSG00000205940.8	HSP90AB2P	6.15	1.63e-09	0.00205	0.38	0.27	Interleukin-10 levels;	chr6:44234615	chr4:13333414~13338657:+
THCA	trans	rs7819412	1	rs2409722	ENSG00000256560.1	LINC01486	-6.15	1.63e-09	0.00205	-0.33	-0.27	Triglycerides;	chr8:11182307	chr12:109354083~109359488:-
THCA	trans	rs9329221	0.576	rs1986972	ENSG00000253893.2	FAM85B	-6.15	1.63e-09	0.00206	-0.36	-0.27	Neuroticism;	chr8:10411295	chr8:8167819~8226614:-
THCA	trans	rs12145833	0.569	rs12049318	ENSG00000154608.12	CEP170P1	-6.15	1.63e-09	0.00206	-0.35	-0.27	Obesity (early onset extreme);	chr1:243430358	chr4:118467590~118554204:+
THCA	trans	rs7212590	0.748	rs55794618	ENSG00000187870.7	RNFT1P3	6.15	1.63e-09	0.00206	0.54	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59856976	chr17:20743333~20754501:-
THCA	trans	rs7212590	0.748	rs58681483	ENSG00000187870.7	RNFT1P3	6.15	1.63e-09	0.00206	0.54	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59857293	chr17:20743333~20754501:-
THCA	trans	rs1707322	0.963	rs11211229	ENSG00000255397.1	AC022182.2	-6.15	1.63e-09	0.00206	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.564	rs55758514	ENSG00000254153.1	CTA-398F10.2	6.15	1.64e-09	0.00207	0.31	0.27	Retinal vascular caliber;	chr8:11372750	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.806	rs17723229	ENSG00000256560.1	LINC01486	-6.15	1.64e-09	0.00207	-0.34	-0.27	Triglycerides;	chr8:11072559	chr12:109354083~109359488:-
THCA	trans	rs11250098	0.642	rs4841460	ENSG00000229857.1	RP11-159H20.3	6.15	1.64e-09	0.00207	0.33	0.27	Morning vs. evening chronotype;	chr8:10931983	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs6601564	ENSG00000254153.1	CTA-398F10.2	6.15	1.65e-09	0.00207	0.31	0.27	Triglycerides;	chr8:11124541	chr8:8456909~8461337:-
THCA	trans	rs902774	0.818	rs73108469	ENSG00000254285.3	KRT8P3	-6.15	1.65e-09	0.00208	-0.57	-0.27	Prostate cancer;	chr12:52891065	chr8:61578220~61579668:+
THCA	trans	rs941207	0.756	rs7313074	ENSG00000228224.3	NACAP1	-6.15	1.65e-09	0.00208	-0.31	-0.27	Platelet count;	chr12:56760705	chr8:101361794~101372707:+
THCA	trans	rs2921036	0.505	rs35190619	ENSG00000229857.1	RP11-159H20.3	6.15	1.65e-09	0.00208	0.38	0.27	Neuroticism;	chr8:8504313	chr9:76992099~76993108:+
THCA	trans	rs1190596	0.578	rs12887161	ENSG00000181359.5	HSP90AA6P	-6.15	1.65e-09	0.00208	-0.39	-0.27	Behavioural disinhibition (generation interaction);	chr14:102240581	chr4:170581470~170605450:-
THCA	trans	rs7819412	0.643	rs7829396	ENSG00000256560.1	LINC01486	-6.15	1.65e-09	0.00208	-0.35	-0.27	Triglycerides;	chr8:11142073	chr12:109354083~109359488:-
THCA	trans	rs8014204	1	rs8014204	ENSG00000181227.3	RP4-682C21.2	-6.15	1.66e-09	0.00209	-0.22	-0.27	Caffeine consumption;	chr14:74856091	chr1:75743423~75744776:-
THCA	trans	rs7829975	0.564	rs2976855	ENSG00000256560.1	LINC01486	6.15	1.66e-09	0.00209	0.32	0.27	Mood instability;	chr8:8444284	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.589	rs6985109	ENSG00000229857.1	RP11-159H20.3	-6.15	1.66e-09	0.00209	-0.33	-0.27	Neuroticism;	chr8:10904075	chr9:76992099~76993108:+
THCA	trans	rs7769051	0.614	rs76404165	ENSG00000227615.1	RP11-864N7.2	6.15	1.67e-09	0.0021	0.53	0.27	Type 2 diabetes nephropathy;	chr6:132914797	chr11:74745716~74746114:-
THCA	trans	rs453301	0.624	rs330049	ENSG00000229857.1	RP11-159H20.3	-6.15	1.67e-09	0.00211	-0.33	-0.27	Joint mobility (Beighton score);	chr8:9229789	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.967	rs10108320	ENSG00000229857.1	RP11-159H20.3	6.15	1.68e-09	0.00211	0.35	0.27	Monocyte count;	chr8:11974754	chr9:76992099~76993108:+
THCA	trans	rs62344088	0.59	rs6882234	ENSG00000185986.11	SDHAP3	6.15	1.68e-09	0.00211	0.42	0.27	Asthma (childhood onset);	chr5:177274	chr5:1572222~1594620:-
THCA	trans	rs12472274	1	rs12472274	ENSG00000224699.7	LAMTOR5-AS1	-6.15	1.68e-09	0.00211	-0.24	-0.27	Phospholipid levels (plasma);	chr2:238186781	chr1:110347116~110443817:+
THCA	trans	rs9467711	0.79	rs13195401	ENSG00000253570.1	RNF5P1	6.15	1.68e-09	0.00211	0.77	0.27	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.79	rs13195402	ENSG00000253570.1	RNF5P1	6.15	1.68e-09	0.00211	0.77	0.27	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr8:38600661~38601200:-
THCA	trans	rs8014204	0.935	rs8010840	ENSG00000181227.3	RP4-682C21.2	6.15	1.68e-09	0.00211	0.22	0.27	Caffeine consumption;	chr14:74888500	chr1:75743423~75744776:-
THCA	trans	rs6601327	0.67	rs7004937	ENSG00000253893.2	FAM85B	-6.15	1.68e-09	0.00212	-0.35	-0.27	Multiple myeloma (hyperdiploidy);	chr8:9563451	chr8:8167819~8226614:-
THCA	trans	rs10109025	0.67	rs7825690	ENSG00000253893.2	FAM85B	6.15	1.69e-09	0.00212	0.35	0.27	Joint mobility (Beighton score);	chr8:11000747	chr8:8167819~8226614:-
THCA	trans	rs8014204	0.868	rs2230237	ENSG00000181227.3	RP4-682C21.2	6.15	1.69e-09	0.00213	0.22	0.27	Caffeine consumption;	chr14:74892967	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.935	rs4903267	ENSG00000181227.3	RP4-682C21.2	6.15	1.69e-09	0.00213	0.22	0.27	Caffeine consumption;	chr14:74893716	chr1:75743423~75744776:-
THCA	trans	rs864643	0.898	rs66860744	ENSG00000183298.5	RP11-556K13.1	6.15	1.7e-09	0.00213	0.44	0.27	Attention deficit hyperactivity disorder;	chr3:39548245	chr1:101786340~101787219:-
THCA	trans	rs930395	0.514	rs10063172	ENSG00000231752.4	EMBP1	-6.15	1.7e-09	0.00214	-0.38	-0.27	Breast cancer;	chr5:44930607	chr1:121519112~121571892:+
THCA	trans	rs7260598	0.892	rs67180860	ENSG00000261770.1	CTC-459F4.1	6.14	1.71e-09	0.00215	0.46	0.27	Response to taxane treatment (placlitaxel);	chr19:24023433	chr19:27757184~27760849:-
THCA	trans	rs6087990	0.806	rs6141814	ENSG00000253915.1	MAPRE1P1	6.14	1.71e-09	0.00215	0.35	0.27	Ulcerative colitis;	chr20:32781154	chr8:135625185~135625981:-
THCA	trans	rs12542260	0.871	rs4128469	ENSG00000234369.1	TATDN1P1	6.14	1.72e-09	0.00216	0.38	0.27	Colonoscopy-negative controls vs population controls;	chr8:124467234	chr10:63222155~63223045:+
THCA	trans	rs6601327	0.613	rs33994795	ENSG00000253893.2	FAM85B	6.14	1.72e-09	0.00216	0.34	0.27	Multiple myeloma (hyperdiploidy);	chr8:9615919	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.702	rs7838131	ENSG00000256560.1	LINC01486	-6.14	1.72e-09	0.00216	-0.33	-0.27	Neuroticism;	chr8:11738654	chr12:109354083~109359488:-
THCA	trans	rs2950393	0.929	rs7973157	ENSG00000257210.1	NACAP3	-6.14	1.72e-09	0.00216	-0.33	-0.27	Platelet distribution width;	chr12:56655409	chr12:93124063~93124543:-
THCA	trans	rs3764796	0.867	rs73208578	ENSG00000250030.2	RP11-584P21.4	6.14	1.72e-09	0.00217	0.55	0.27	Calcium levels;	chr8:17282796	chr4:67446267~67446574:+
THCA	trans	rs6885307	1	rs7701679	ENSG00000231752.4	EMBP1	6.14	1.72e-09	0.00217	0.42	0.27	Age at first birth;	chr5:45042692	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.806	rs7007394	ENSG00000253893.2	FAM85B	6.14	1.73e-09	0.00218	0.34	0.27	Retinal vascular caliber;	chr8:11237057	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.806	rs6601573	ENSG00000253893.2	FAM85B	6.14	1.73e-09	0.00218	0.34	0.27	Retinal vascular caliber;	chr8:11237242	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.806	rs6601574	ENSG00000253893.2	FAM85B	6.14	1.73e-09	0.00218	0.34	0.27	Retinal vascular caliber;	chr8:11237376	chr8:8167819~8226614:-
THCA	trans	rs864643	0.898	rs636476	ENSG00000183298.5	RP11-556K13.1	6.14	1.74e-09	0.00218	0.46	0.27	Attention deficit hyperactivity disorder;	chr3:39549841	chr1:101786340~101787219:-
THCA	trans	rs7833986	1	rs61690651	ENSG00000244245.1	RP11-120B7.1	6.14	1.74e-09	0.00218	0.33	0.27	Height;	chr8:56184102	chr5:108593609~108593967:+
THCA	trans	rs7833986	1	rs56699713	ENSG00000244245.1	RP11-120B7.1	6.14	1.74e-09	0.00218	0.33	0.27	Height;	chr8:56184111	chr5:108593609~108593967:+
THCA	trans	rs6885307	1	rs6894974	ENSG00000231752.4	EMBP1	-6.14	1.74e-09	0.00218	-0.41	-0.27	Age at first birth;	chr5:45020429	chr1:121519112~121571892:+
THCA	trans	rs9329221	0.935	rs3750311	ENSG00000254153.1	CTA-398F10.2	6.14	1.74e-09	0.00219	0.3	0.27	Neuroticism;	chr8:10426092	chr8:8456909~8461337:-
THCA	trans	rs616147	0.627	rs816510	ENSG00000239269.1	RPSAP4	-6.14	1.75e-09	0.00219	-0.29	-0.27	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr14:94726288~94727175:+
THCA	trans	rs2985684	1	rs1957977	ENSG00000240785.1	RPL36AP21	6.14	1.75e-09	0.0022	0.35	0.27	Carotid intima media thickness;	chr14:49623885	chr5:18049550~18049872:+
THCA	trans	rs4930561	0.765	rs34493482	ENSG00000155070.8	UNC93B2	-6.14	1.75e-09	0.0022	-0.32	-0.27	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68202041	chr7:6855485~6859830:-
THCA	trans	rs7824557	0.564	rs13268126	ENSG00000254153.1	CTA-398F10.2	6.14	1.75e-09	0.0022	0.31	0.27	Retinal vascular caliber;	chr8:11373065	chr8:8456909~8461337:-
THCA	trans	rs7429990	0.864	rs13085978	ENSG00000235912.1	RP1-159A19.3	-6.14	1.76e-09	0.0022	-0.34	-0.27	Educational attainment (years of education);	chr3:47608585	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.727	rs61675361	ENSG00000235912.1	RP1-159A19.3	-6.14	1.76e-09	0.0022	-0.34	-0.27	Educational attainment (years of education);	chr3:47610630	chr1:27649419~27649610:+
THCA	trans	rs4415084	0.617	rs10039173	ENSG00000231752.4	EMBP1	-6.14	1.76e-09	0.00221	-0.37	-0.27	Breast cancer;	chr5:44903274	chr1:121519112~121571892:+
THCA	trans	rs8014204	0.753	rs6574199	ENSG00000181227.3	RP4-682C21.2	6.14	1.76e-09	0.00221	0.22	0.27	Caffeine consumption;	chr14:74889400	chr1:75743423~75744776:-
THCA	trans	rs9329221	0.537	rs6983332	ENSG00000253893.2	FAM85B	6.14	1.76e-09	0.00221	0.34	0.27	Neuroticism;	chr8:10120408	chr8:8167819~8226614:-
THCA	trans	rs7829975	1	rs7829975	ENSG00000229857.1	RP11-159H20.3	6.14	1.77e-09	0.00222	0.34	0.27	Mood instability;	chr8:8690607	chr9:76992099~76993108:+
THCA	trans	rs7260598	0.892	rs58931976	ENSG00000261770.1	CTC-459F4.1	6.14	1.77e-09	0.00222	0.46	0.27	Response to taxane treatment (placlitaxel);	chr19:24008247	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.892	rs59831281	ENSG00000261770.1	CTC-459F4.1	6.14	1.77e-09	0.00222	0.46	0.27	Response to taxane treatment (placlitaxel);	chr19:24008258	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.786	rs59387271	ENSG00000261770.1	CTC-459F4.1	6.14	1.77e-09	0.00222	0.46	0.27	Response to taxane treatment (placlitaxel);	chr19:24009130	chr19:27757184~27760849:-
THCA	trans	rs941207	0.789	rs2958145	ENSG00000228224.3	NACAP1	-6.14	1.77e-09	0.00222	-0.31	-0.27	Platelet count;	chr12:56662290	chr8:101361794~101372707:+
THCA	trans	rs2985684	1	rs2147712	ENSG00000240785.1	RPL36AP21	6.14	1.77e-09	0.00222	0.35	0.27	Carotid intima media thickness;	chr14:49624966	chr5:18049550~18049872:+
THCA	trans	rs2985684	0.779	rs12160	ENSG00000240785.1	RPL36AP21	6.14	1.77e-09	0.00222	0.35	0.27	Carotid intima media thickness;	chr14:49625214	chr5:18049550~18049872:+
THCA	trans	rs62344088	0.59	rs61710713	ENSG00000185986.11	SDHAP3	6.14	1.77e-09	0.00222	0.48	0.27	Asthma (childhood onset);	chr5:181384	chr5:1572222~1594620:-
THCA	trans	rs8014204	0.901	rs6574200	ENSG00000181227.3	RP4-682C21.2	6.14	1.78e-09	0.00223	0.22	0.27	Caffeine consumption;	chr14:74897748	chr1:75743423~75744776:-
THCA	trans	rs4930561	0.714	rs7950451	ENSG00000155070.8	UNC93B2	-6.14	1.78e-09	0.00223	-0.32	-0.27	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194939	chr7:6855485~6859830:-
THCA	trans	rs4930561	0.714	rs7950452	ENSG00000155070.8	UNC93B2	-6.14	1.78e-09	0.00223	-0.32	-0.27	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194940	chr7:6855485~6859830:-
THCA	trans	rs7824557	0.564	rs34964435	ENSG00000254153.1	CTA-398F10.2	6.14	1.78e-09	0.00224	0.3	0.27	Retinal vascular caliber;	chr8:11372697	chr8:8456909~8461337:-
THCA	trans	rs3096299	0.658	rs12443705	ENSG00000215030.5	RPL13P12	-6.14	1.79e-09	0.00224	-0.27	-0.27	Multiple myeloma (IgH translocation);	chr16:89480646	chr17:17383377~17384012:-
THCA	trans	rs7809615	0.515	rs10254729	ENSG00000228834.1	RP11-249L21.4	6.14	1.79e-09	0.00225	0.44	0.27	Blood metabolite ratios;	chr7:99598805	chr6:108907615~108907873:-
THCA	trans	rs2048656	0.6	rs1976671	ENSG00000253893.2	FAM85B	-6.14	1.8e-09	0.00226	-0.36	-0.27	Schizophrenia;	chr8:9822124	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.742	rs1533059	ENSG00000229857.1	RP11-159H20.3	6.14	1.81e-09	0.00227	0.33	0.27	Mood instability;	chr8:8827443	chr9:76992099~76993108:+
THCA	trans	rs7200543	1	rs16966952	ENSG00000255185.4	PDXDC2P	6.13	1.81e-09	0.00227	0.38	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:70010751~70065945:-
THCA	trans	rs7200543	0.848	rs62039480	ENSG00000255185.4	PDXDC2P	6.13	1.82e-09	0.00228	0.37	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:70010751~70065945:-
THCA	trans	rs2980439	0.818	rs2948300	ENSG00000256560.1	LINC01486	6.13	1.82e-09	0.00228	0.33	0.27	Neuroticism;	chr8:8248986	chr12:109354083~109359488:-
THCA	trans	rs941207	0.756	rs2950388	ENSG00000228224.3	NACAP1	-6.13	1.82e-09	0.00228	-0.32	-0.27	Platelet count;	chr12:56639569	chr8:101361794~101372707:+
THCA	trans	rs2645424	0.639	rs35581201	ENSG00000281304.1	Metazoa_SRP	6.13	1.82e-09	0.00228	0.36	0.27	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11849325	chr6:35911481~35911729:-
THCA	trans	rs1707322	0.638	rs9429095	ENSG00000255397.1	AC022182.2	6.13	1.82e-09	0.00228	0.38	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr8:60937705~60939871:-
THCA	trans	rs6087990	0.806	rs1474738	ENSG00000253915.1	MAPRE1P1	6.13	1.82e-09	0.00228	0.34	0.27	Ulcerative colitis;	chr20:32792503	chr8:135625185~135625981:-
THCA	trans	rs7769051	1	rs6910639	ENSG00000227615.1	RP11-864N7.2	6.13	1.82e-09	0.00228	0.45	0.27	Type 2 diabetes nephropathy;	chr6:132799414	chr11:74745716~74746114:-
THCA	trans	rs73108077	0.92	rs73248560	ENSG00000279352.1	RP11-411B10.7	6.13	1.83e-09	0.0023	0.58	0.27	Red blood cell density in sickle cell anemia;	chr20:31436938	chr18:14010054~14010917:+
THCA	trans	rs2950393	0.804	rs1026565	ENSG00000257210.1	NACAP3	6.13	1.84e-09	0.0023	0.32	0.27	Platelet distribution width;	chr12:56744044	chr12:93124063~93124543:-
THCA	trans	rs9467711	1	rs9467701	ENSG00000176998.4	HCG4	-6.13	1.84e-09	0.0023	-0.48	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26311942	chr6:29791753~29792750:-
THCA	trans	rs9467711	1	rs6923139	ENSG00000176998.4	HCG4	-6.13	1.84e-09	0.0023	-0.48	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26313120	chr6:29791753~29792750:-
THCA	trans	rs9649213	0.593	rs7812180	ENSG00000225169.1	BRI3P1	-6.13	1.84e-09	0.0023	-0.37	-0.27	Prostate cancer (SNP x SNP interaction);	chr7:98339828	chr1:100213293~100213670:+
THCA	trans	rs9467711	0.606	rs9393718	ENSG00000253570.1	RNF5P1	6.13	1.84e-09	0.00231	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:26407254	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.606	rs34273322	ENSG00000253570.1	RNF5P1	6.13	1.84e-09	0.00231	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:26415181	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.606	rs9358939	ENSG00000253570.1	RNF5P1	6.13	1.84e-09	0.00231	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:26416559	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.606	rs2076030	ENSG00000253570.1	RNF5P1	6.13	1.84e-09	0.00231	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:26426628	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.606	rs2235251	ENSG00000253570.1	RNF5P1	6.13	1.84e-09	0.00231	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:26431754	chr8:38600661~38601200:-
THCA	trans	rs73108077	1	rs73108027	ENSG00000279352.1	RP11-411B10.7	6.13	1.85e-09	0.00231	0.6	0.27	Red blood cell density in sickle cell anemia;	chr20:31398778	chr18:14010054~14010917:+
THCA	trans	rs9914988	0.619	rs12451955	ENSG00000267449.1	RP11-264B14.2	6.13	1.85e-09	0.00231	0.42	0.27	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28987206	chr17:61069856~61070356:-
THCA	trans	rs7429990	0.864	rs319693	ENSG00000235912.1	RP1-159A19.3	-6.13	1.85e-09	0.00232	-0.35	-0.27	Educational attainment (years of education);	chr3:47845090	chr1:27649419~27649610:+
THCA	trans	rs804280	0.565	rs2645453	ENSG00000253893.2	FAM85B	-6.13	1.85e-09	0.00232	-0.34	-0.27	Myopia (pathological);	chr8:11764492	chr8:8167819~8226614:-
THCA	trans	rs3947	0.789	rs8005	ENSG00000253893.2	FAM85B	-6.13	1.86e-09	0.00233	-0.38	-0.27	Blood protein levels;	chr8:11843587	chr8:8167819~8226614:-
THCA	trans	rs7833986	0.501	rs2667978	ENSG00000236862.1	RPS20P24	6.13	1.86e-09	0.00233	0.41	0.27	Height;	chr8:55985392	chr9:72655832~72656192:-
THCA	trans	rs1707322	0.963	rs34907901	ENSG00000255397.1	AC022182.2	-6.13	1.86e-09	0.00233	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.527	rs2736296	ENSG00000256560.1	LINC01486	-6.13	1.87e-09	0.00234	-0.33	-0.27	Retinal vascular caliber;	chr8:11377335	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.51	rs2736297	ENSG00000256560.1	LINC01486	-6.13	1.87e-09	0.00234	-0.33	-0.27	Retinal vascular caliber;	chr8:11377376	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs2736298	ENSG00000256560.1	LINC01486	-6.13	1.87e-09	0.00234	-0.33	-0.27	Retinal vascular caliber;	chr8:11377627	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs57629785	ENSG00000256560.1	LINC01486	-6.13	1.87e-09	0.00234	-0.33	-0.27	Retinal vascular caliber;	chr8:11377641	chr12:109354083~109359488:-
THCA	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-6.13	1.88e-09	0.00235	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
THCA	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-6.13	1.88e-09	0.00235	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
THCA	trans	rs10242455	0.867	rs2740565	ENSG00000228834.1	RP11-249L21.4	6.13	1.88e-09	0.00235	0.51	0.27	Blood metabolite levels;	chr7:99695852	chr6:108907615~108907873:-
THCA	trans	rs7200543	0.89	rs4985155	ENSG00000255185.4	PDXDC2P	6.13	1.89e-09	0.00236	0.38	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15035602	chr16:70010751~70065945:-
THCA	trans	rs6601327	0.6	rs7828039	ENSG00000253893.2	FAM85B	6.13	1.89e-09	0.00236	0.36	0.27	Multiple myeloma (hyperdiploidy);	chr8:9797247	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.635	rs10112972	ENSG00000253893.2	FAM85B	6.13	1.89e-09	0.00236	0.36	0.27	Multiple myeloma (hyperdiploidy);	chr8:9797708	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.665	rs10113155	ENSG00000253893.2	FAM85B	6.13	1.89e-09	0.00236	0.36	0.27	Multiple myeloma (hyperdiploidy);	chr8:9797848	chr8:8167819~8226614:-
THCA	trans	rs12542260	0.871	rs7834203	ENSG00000234369.1	TATDN1P1	6.13	1.89e-09	0.00236	0.38	0.27	Colonoscopy-negative controls vs population controls;	chr8:124470655	chr10:63222155~63223045:+
THCA	trans	rs12542260	0.871	rs62527884	ENSG00000234369.1	TATDN1P1	6.13	1.89e-09	0.00236	0.38	0.27	Colonoscopy-negative controls vs population controls;	chr8:124471103	chr10:63222155~63223045:+
THCA	trans	rs12542260	0.871	rs72713049	ENSG00000234369.1	TATDN1P1	6.13	1.89e-09	0.00236	0.38	0.27	Colonoscopy-negative controls vs population controls;	chr8:124471847	chr10:63222155~63223045:+
THCA	trans	rs11172055	0.775	rs10876940	ENSG00000121089.4	NACA3P	6.13	1.89e-09	0.00237	0.3	0.27	Migraine;	chr12:56871233	chr4:164943290~164943937:+
THCA	trans	rs35851103	0.506	rs4841659	ENSG00000254153.1	CTA-398F10.2	-6.13	1.9e-09	0.00238	-0.3	-0.27	Neuroticism;	chr8:11970691	chr8:8456909~8461337:-
THCA	trans	rs4879656	0.835	rs13290323	ENSG00000215007.3	DNAJA1P3	6.13	1.91e-09	0.00238	0.31	0.27	Menopause (age at onset);	chr9:33062293	chrX:107351650~107352843:-
THCA	trans	rs902774	0.818	rs73110471	ENSG00000250539.1	KRT8P33	-6.13	1.91e-09	0.00238	-0.5	-0.27	Prostate cancer;	chr12:52923037	chr5:123400922~123402344:-
THCA	trans	rs902774	0.818	rs73110464	ENSG00000250539.1	KRT8P33	-6.13	1.91e-09	0.00239	-0.49	-0.27	Prostate cancer;	chr12:52918828	chr5:123400922~123402344:-
THCA	trans	rs1190596	0.525	rs8004474	ENSG00000181359.5	HSP90AA6P	-6.13	1.92e-09	0.0024	-0.39	-0.27	Behavioural disinhibition (generation interaction);	chr14:102290161	chr4:170581470~170605450:-
THCA	trans	rs9329221	0.509	rs3088186	ENSG00000253893.2	FAM85B	-6.12	1.92e-09	0.0024	-0.37	-0.27	Neuroticism;	chr8:10368845	chr8:8167819~8226614:-
THCA	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-6.12	1.92e-09	0.0024	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
THCA	trans	rs9650657	0.504	rs2409724	ENSG00000254153.1	CTA-398F10.2	6.12	1.93e-09	0.00241	0.3	0.27	Neuroticism;	chr8:11184133	chr8:8456909~8461337:-
THCA	trans	rs7746199	0.736	rs35848276	ENSG00000228022.4	HCG20	-6.12	1.93e-09	0.00242	-0.69	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:30766825~30792250:+
THCA	trans	rs7824557	0.583	rs2263511	ENSG00000254153.1	CTA-398F10.2	6.12	1.94e-09	0.00242	0.3	0.27	Retinal vascular caliber;	chr8:11375809	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.549	rs28887839	ENSG00000256560.1	LINC01486	-6.12	1.94e-09	0.00242	-0.35	-0.27	Triglycerides;	chr8:11142903	chr12:109354083~109359488:-
THCA	trans	rs4879656	0.843	rs10813918	ENSG00000215007.3	DNAJA1P3	-6.12	1.94e-09	0.00242	-0.32	-0.27	Menopause (age at onset);	chr9:32996372	chrX:107351650~107352843:-
THCA	trans	rs80264589	1	rs80264589	ENSG00000228022.4	HCG20	-6.12	1.94e-09	0.00243	-0.65	-0.27	Intelligence (multi-trait analysis);Lung cancer;	chr6:26959823	chr6:30766825~30792250:+
THCA	trans	rs2288327	0.841	rs2303828	ENSG00000269800.1	PLEKHA3P1	6.12	1.95e-09	0.00243	0.36	0.27	Atrial fibrillation;	chr2:178683133	chr19:41521043~41521989:-
THCA	trans	rs6601327	0.665	rs10113186	ENSG00000253893.2	FAM85B	6.12	1.95e-09	0.00243	0.36	0.27	Multiple myeloma (hyperdiploidy);	chr8:9797916	chr8:8167819~8226614:-
THCA	trans	rs453301	0.631	rs13250781	ENSG00000229857.1	RP11-159H20.3	6.12	1.95e-09	0.00244	0.36	0.27	Joint mobility (Beighton score);	chr8:8935833	chr9:76992099~76993108:+
THCA	trans	rs330048	0.561	rs4840401	ENSG00000229857.1	RP11-159H20.3	6.12	1.96e-09	0.00245	0.36	0.27	Systemic lupus erythematosus;	chr8:9290615	chr9:76992099~76993108:+
THCA	trans	rs3849046	1	rs3849046	ENSG00000226666.1	HSPA9P1	6.12	1.96e-09	0.00245	0.28	0.27	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138515503	chr2:221961737~221963765:+
THCA	trans	rs4415084	0.932	rs2218080	ENSG00000231752.4	EMBP1	6.12	1.97e-09	0.00246	0.36	0.27	Breast cancer;	chr5:44714228	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.804	rs9790896	ENSG00000231752.4	EMBP1	6.12	1.97e-09	0.00246	0.36	0.27	Breast cancer;	chr5:44899989	chr1:121519112~121571892:+
THCA	trans	rs7212590	0.748	rs73315252	ENSG00000187870.7	RNFT1P3	6.12	1.98e-09	0.00247	0.54	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59777494	chr17:20743333~20754501:-
THCA	trans	rs7212590	0.748	rs8073489	ENSG00000187870.7	RNFT1P3	6.12	1.98e-09	0.00247	0.54	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59784433	chr17:20743333~20754501:-
THCA	trans	rs902774	0.818	rs73106451	ENSG00000250539.1	KRT8P33	-6.12	1.98e-09	0.00247	-0.5	-0.27	Prostate cancer;	chr12:52872955	chr5:123400922~123402344:-
THCA	trans	rs7824557	0.933	rs6601576	ENSG00000253893.2	FAM85B	6.12	1.98e-09	0.00247	0.35	0.27	Retinal vascular caliber;	chr8:11242766	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.967	rs4841661	ENSG00000254153.1	CTA-398F10.2	-6.12	1.98e-09	0.00247	-0.31	-0.27	Monocyte count;	chr8:11975260	chr8:8456909~8461337:-
THCA	trans	rs11992162	1	rs11994417	ENSG00000254153.1	CTA-398F10.2	-6.12	1.98e-09	0.00247	-0.31	-0.27	Monocyte count;	chr8:11975753	chr8:8456909~8461337:-
THCA	trans	rs1190596	0.65	rs1190600	ENSG00000181359.5	HSP90AA6P	6.12	1.99e-09	0.00248	0.4	0.27	Behavioural disinhibition (generation interaction);	chr14:102125121	chr4:170581470~170605450:-
THCA	trans	rs1707322	1	rs6675222	ENSG00000255397.1	AC022182.2	-6.12	1.99e-09	0.00248	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4660895	ENSG00000255397.1	AC022182.2	-6.12	1.99e-09	0.00248	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4660318	ENSG00000255397.1	AC022182.2	-6.12	1.99e-09	0.00248	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr8:60937705~60939871:-
THCA	trans	rs76228276	0.737	rs7833870	ENSG00000260318.1	COX6CP1	6.12	2e-09	0.00249	0.72	0.27	Childhood ear infection;	chr8:99778928	chr16:11903923~11904137:-
THCA	trans	rs889398	0.617	rs4985450	ENSG00000196796.5	CTB-134H23.2	-6.12	2e-09	0.00249	-0.3	-0.27	Body mass index;	chr16:69867203	chr16:29038655~29052726:+
THCA	trans	rs7824557	0.583	rs2263512	ENSG00000254153.1	CTA-398F10.2	6.12	2.01e-09	0.0025	0.3	0.27	Retinal vascular caliber;	chr8:11375910	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.583	rs6601585	ENSG00000254153.1	CTA-398F10.2	6.12	2.01e-09	0.0025	0.3	0.27	Retinal vascular caliber;	chr8:11376150	chr8:8456909~8461337:-
THCA	trans	rs2288327	0.915	rs62178972	ENSG00000269800.1	PLEKHA3P1	6.12	2.01e-09	0.0025	0.38	0.27	Atrial fibrillation;	chr2:178676885	chr19:41521043~41521989:-
THCA	trans	rs2736337	0.53	rs11782375	ENSG00000253893.2	FAM85B	-6.12	2.01e-09	0.00251	-0.37	-0.27	Rheumatoid arthritis;	chr8:11437425	chr8:8167819~8226614:-
THCA	trans	rs2950393	0.804	rs3214051	ENSG00000257210.1	NACAP3	6.12	2.02e-09	0.00251	0.32	0.27	Platelet distribution width;	chr12:56725452	chr12:93124063~93124543:-
THCA	trans	rs7200543	0.961	rs1741	ENSG00000250569.1	NTAN1P2	6.12	2.02e-09	0.00252	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr8:86481754~86483002:-
THCA	trans	rs7200543	1	rs6498541	ENSG00000255185.4	PDXDC2P	6.12	2.03e-09	0.00253	0.38	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:70010751~70065945:-
THCA	trans	rs853679	0.769	rs7752608	ENSG00000253570.1	RNF5P1	6.12	2.03e-09	0.00253	0.68	0.27	Depression;	chr6:28333418	chr8:38600661~38601200:-
THCA	trans	rs453301	0.686	rs11787026	ENSG00000229857.1	RP11-159H20.3	-6.12	2.03e-09	0.00253	-0.33	-0.27	Joint mobility (Beighton score);	chr8:9044861	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.774	rs13259216	ENSG00000229857.1	RP11-159H20.3	-6.11	2.04e-09	0.00254	-0.33	-0.27	Mood instability;	chr8:8816091	chr9:76992099~76993108:+
THCA	trans	rs12145833	0.62	rs7538558	ENSG00000154608.12	CEP170P1	-6.11	2.04e-09	0.00254	-0.35	-0.27	Obesity (early onset extreme);	chr1:243426211	chr4:118467590~118554204:+
THCA	trans	rs6885307	0.941	rs10941692	ENSG00000231752.4	EMBP1	6.11	2.04e-09	0.00254	0.43	0.27	Age at first birth;	chr5:45099676	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.8	rs930396	ENSG00000231752.4	EMBP1	-6.11	2.05e-09	0.00255	-0.36	-0.27	Breast cancer;	chr5:44856349	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.936	rs7814499	ENSG00000254153.1	CTA-398F10.2	6.11	2.05e-09	0.00255	0.3	0.27	Triglycerides;	chr8:11183138	chr8:8456909~8461337:-
THCA	trans	rs9329221	0.905	rs4610752	ENSG00000229857.1	RP11-159H20.3	6.11	2.05e-09	0.00256	0.34	0.27	Neuroticism;	chr8:10391452	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.564	rs2572399	ENSG00000256560.1	LINC01486	-6.11	2.05e-09	0.00256	-0.33	-0.27	Retinal vascular caliber;	chr8:11377011	chr12:109354083~109359488:-
THCA	trans	rs2069408	1	rs2069408	ENSG00000204652.6	RPS26P8	-6.11	2.06e-09	0.00257	-0.4	-0.27	Asthma;	chr12:55970537	chr17:45608571~45608918:+
THCA	trans	rs3808502	0.574	rs4841559	ENSG00000256560.1	LINC01486	-6.11	2.07e-09	0.00257	-0.33	-0.27	Neuroticism;	chr8:11559376	chr12:109354083~109359488:-
THCA	trans	rs12157904	1	rs12158264	ENSG00000235954.5	TTC28-AS1	-6.11	2.07e-09	0.00258	-0.4	-0.27	Response to anti-depressant treatment in major depressive disorder;	chr22:37605497	chr22:27919376~28008581:+
THCA	trans	rs902774	0.818	rs4919763	ENSG00000250539.1	KRT8P33	-6.11	2.07e-09	0.00258	-0.52	-0.27	Prostate cancer;	chr12:52885839	chr5:123400922~123402344:-
THCA	trans	rs902774	0.818	rs55914512	ENSG00000250539.1	KRT8P33	-6.11	2.07e-09	0.00258	-0.52	-0.27	Prostate cancer;	chr12:52888490	chr5:123400922~123402344:-
THCA	trans	rs902774	0.818	rs73108466	ENSG00000250539.1	KRT8P33	-6.11	2.07e-09	0.00258	-0.52	-0.27	Prostate cancer;	chr12:52889857	chr5:123400922~123402344:-
THCA	trans	rs902774	0.818	rs55999178	ENSG00000250539.1	KRT8P33	-6.11	2.07e-09	0.00258	-0.52	-0.27	Prostate cancer;	chr12:52890576	chr5:123400922~123402344:-
THCA	trans	rs902774	0.818	rs56207534	ENSG00000230716.3	KRT8P7	-6.11	2.08e-09	0.00259	-0.56	-0.27	Prostate cancer;	chr12:52873525	chr11:119602875~119604306:-
THCA	trans	rs3764796	1	rs73208601	ENSG00000250030.2	RP11-584P21.4	6.11	2.08e-09	0.00259	0.53	0.27	Calcium levels;	chr8:17301980	chr4:67446267~67446574:+
THCA	trans	rs12210905	1	rs9348752	ENSG00000242375.1	RP11-498P14.3	-6.11	2.08e-09	0.00259	-0.63	-0.27	Hip circumference adjusted for BMI;	chr6:27107704	chr9:97195351~97197687:-
THCA	trans	rs6601327	0.67	rs10092751	ENSG00000253893.2	FAM85B	-6.11	2.08e-09	0.00259	-0.35	-0.27	Multiple myeloma (hyperdiploidy);	chr8:9568815	chr8:8167819~8226614:-
THCA	trans	rs7112043	0.868	rs10768093	ENSG00000225531.1	RP11-196I18.3	6.11	2.09e-09	0.0026	0.35	0.27	Lung disease severity in cystic fibrosis;	chr11:34756012	chr9:107116829~107117557:+
THCA	trans	rs4879656	0.8	rs10971379	ENSG00000215007.3	DNAJA1P3	6.11	2.09e-09	0.0026	0.31	0.27	Menopause (age at onset);	chr9:33064932	chrX:107351650~107352843:-
THCA	trans	rs740160	0.614	rs9969217	ENSG00000228834.1	RP11-249L21.4	6.11	2.09e-09	0.0026	0.57	0.27	Dehydroepiandrosterone sulphate levels;	chr7:99293815	chr6:108907615~108907873:-
THCA	trans	rs9393777	0.92	rs72839445	ENSG00000228022.4	HCG20	-6.11	2.09e-09	0.00261	-0.7	-0.27	Intelligence (multi-trait analysis);	chr6:27281907	chr6:30766825~30792250:+
THCA	trans	rs7829975	0.559	rs4841025	ENSG00000256560.1	LINC01486	-6.11	2.09e-09	0.00261	-0.32	-0.27	Mood instability;	chr8:8745650	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.547	rs6601570	ENSG00000254153.1	CTA-398F10.2	6.11	2.1e-09	0.00261	0.31	0.27	Retinal vascular caliber;	chr8:11221858	chr8:8456909~8461337:-
THCA	trans	rs9650657	0.506	rs7823296	ENSG00000229857.1	RP11-159H20.3	6.11	2.1e-09	0.00261	0.33	0.27	Neuroticism;	chr8:10921036	chr9:76992099~76993108:+
THCA	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	6.11	2.12e-09	0.00263	0.39	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
THCA	trans	rs10435719	0.902	rs6601633	ENSG00000254153.1	CTA-398F10.2	6.11	2.12e-09	0.00263	0.31	0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:8456909~8461337:-
THCA	trans	rs3812762	0.871	rs3862352	ENSG00000266891.1	RP11-692N5.2	6.11	2.12e-09	0.00263	0.36	0.27	Hypospadias;	chr11:8796473	chr18:9734882~9735602:-
THCA	trans	rs1908814	0.516	rs13275143	ENSG00000254153.1	CTA-398F10.2	-6.11	2.13e-09	0.00265	-0.31	-0.27	Neuroticism;	chr8:11939481	chr8:8456909~8461337:-
THCA	trans	rs453301	0.624	rs2915251	ENSG00000229857.1	RP11-159H20.3	-6.11	2.13e-09	0.00265	-0.33	-0.27	Joint mobility (Beighton score);	chr8:9009901	chr9:76992099~76993108:+
THCA	trans	rs7429990	0.864	rs11712464	ENSG00000235912.1	RP1-159A19.3	-6.11	2.14e-09	0.00266	-0.34	-0.27	Educational attainment (years of education);	chr3:47724057	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs56376646	ENSG00000235912.1	RP1-159A19.3	-6.11	2.14e-09	0.00266	-0.34	-0.27	Educational attainment (years of education);	chr3:47732588	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs11927129	ENSG00000235912.1	RP1-159A19.3	-6.11	2.14e-09	0.00266	-0.34	-0.27	Educational attainment (years of education);	chr3:47745413	chr1:27649419~27649610:+
THCA	trans	rs930395	0.514	rs10057521	ENSG00000231752.4	EMBP1	-6.11	2.14e-09	0.00266	-0.37	-0.27	Breast cancer;	chr5:44865884	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs11958451	ENSG00000231752.4	EMBP1	-6.11	2.14e-09	0.00266	-0.37	-0.27	Breast cancer;	chr5:44866800	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs4866920	ENSG00000231752.4	EMBP1	-6.11	2.14e-09	0.00266	-0.37	-0.27	Breast cancer;	chr5:44879044	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs10040488	ENSG00000231752.4	EMBP1	-6.11	2.14e-09	0.00266	-0.37	-0.27	Breast cancer;	chr5:44880186	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs13157608	ENSG00000231752.4	EMBP1	-6.11	2.14e-09	0.00266	-0.37	-0.27	Breast cancer;	chr5:44881402	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs13168400	ENSG00000231752.4	EMBP1	-6.11	2.14e-09	0.00266	-0.37	-0.27	Breast cancer;	chr5:44883434	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs4642377	ENSG00000231752.4	EMBP1	-6.11	2.14e-09	0.00266	-0.37	-0.27	Breast cancer;	chr5:44885138	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.589	rs10107145	ENSG00000229857.1	RP11-159H20.3	6.11	2.14e-09	0.00266	0.33	0.27	Neuroticism;	chr8:10900703	chr9:76992099~76993108:+
THCA	trans	rs2069408	1	rs2069408	ENSG00000234354.3	RPS26P47	-6.11	2.14e-09	0.00267	-0.4	-0.27	Asthma;	chr12:55970537	chr13:100539901~100540248:-
THCA	trans	rs9467711	1	rs9467713	ENSG00000176998.4	HCG4	-6.11	2.15e-09	0.00267	-0.48	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26337900	chr6:29791753~29792750:-
THCA	trans	rs4415084	0.834	rs7711136	ENSG00000231752.4	EMBP1	6.11	2.15e-09	0.00267	0.36	0.27	Breast cancer;	chr5:44822977	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.834	rs7730841	ENSG00000231752.4	EMBP1	6.11	2.15e-09	0.00267	0.36	0.27	Breast cancer;	chr5:44823032	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.834	rs10512865	ENSG00000231752.4	EMBP1	6.11	2.15e-09	0.00267	0.36	0.27	Breast cancer;	chr5:44823265	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.834	rs6867533	ENSG00000231752.4	EMBP1	6.11	2.15e-09	0.00267	0.36	0.27	Breast cancer;	chr5:44827190	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.834	rs1048758	ENSG00000231752.4	EMBP1	6.11	2.15e-09	0.00267	0.36	0.27	Breast cancer;	chr5:44828492	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.834	rs7380559	ENSG00000231752.4	EMBP1	-6.11	2.15e-09	0.00267	-0.36	-0.27	Breast cancer;	chr5:44836908	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.744	rs1371023	ENSG00000231752.4	EMBP1	-6.11	2.15e-09	0.00267	-0.36	-0.27	Breast cancer;	chr5:44846473	chr1:121519112~121571892:+
THCA	trans	rs2898290	0.694	rs2248909	ENSG00000229857.1	RP11-159H20.3	6.11	2.15e-09	0.00268	0.34	0.27	Systolic blood pressure;	chr8:11534584	chr9:76992099~76993108:+
THCA	trans	rs9649213	0.593	rs1076272	ENSG00000225169.1	BRI3P1	6.1	2.16e-09	0.00268	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr1:100213293~100213670:+
THCA	trans	rs7200543	1	rs4985124	ENSG00000255185.4	PDXDC2P	6.1	2.17e-09	0.0027	0.38	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:70010751~70065945:-
THCA	trans	rs7746199	0.673	rs35501037	ENSG00000228022.4	HCG20	-6.1	2.17e-09	0.0027	-0.68	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:30766825~30792250:+
THCA	trans	rs7819412	0.54	rs11777355	ENSG00000229857.1	RP11-159H20.3	6.1	2.18e-09	0.0027	0.36	0.27	Triglycerides;	chr8:11187180	chr9:76992099~76993108:+
THCA	trans	rs9393777	0.844	rs72839477	ENSG00000253570.1	RNF5P1	6.1	2.18e-09	0.00271	0.77	0.27	Intelligence (multi-trait analysis);	chr6:27359221	chr8:38600661~38601200:-
THCA	trans	rs3764796	0.737	rs73210203	ENSG00000250030.2	RP11-584P21.4	6.1	2.18e-09	0.00271	0.54	0.27	Calcium levels;	chr8:17303133	chr4:67446267~67446574:+
THCA	trans	rs3764796	0.737	rs73210204	ENSG00000250030.2	RP11-584P21.4	6.1	2.18e-09	0.00271	0.54	0.27	Calcium levels;	chr8:17303550	chr4:67446267~67446574:+
THCA	trans	rs453301	0.624	rs6987558	ENSG00000256560.1	LINC01486	6.1	2.18e-09	0.00271	0.31	0.27	Joint mobility (Beighton score);	chr8:9005011	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs6601584	ENSG00000254153.1	CTA-398F10.2	6.1	2.19e-09	0.00272	0.3	0.27	Retinal vascular caliber;	chr8:11374834	chr8:8456909~8461337:-
THCA	trans	rs76228276	0.737	rs72672316	ENSG00000260318.1	COX6CP1	6.1	2.2e-09	0.00273	0.78	0.27	Childhood ear infection;	chr8:99192534	chr16:11903923~11904137:-
THCA	trans	rs453301	0.719	rs34004903	ENSG00000229857.1	RP11-159H20.3	6.1	2.2e-09	0.00273	0.33	0.27	Joint mobility (Beighton score);	chr8:9035094	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs4841490	ENSG00000256560.1	LINC01486	-6.1	2.2e-09	0.00273	-0.33	-0.27	Triglycerides;	chr8:11079381	chr12:109354083~109359488:-
THCA	trans	rs6981523	0.566	rs34162231	ENSG00000253893.2	FAM85B	6.1	2.2e-09	0.00274	0.37	0.27	Neuroticism;	chr8:11145578	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.967	rs10112888	ENSG00000254153.1	CTA-398F10.2	-6.1	2.21e-09	0.00274	-0.3	-0.27	Monocyte count;	chr8:11972699	chr8:8456909~8461337:-
THCA	trans	rs1707322	0.721	rs11211181	ENSG00000255397.1	AC022182.2	-6.1	2.21e-09	0.00274	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr8:60937705~60939871:-
THCA	trans	rs7709909	0.967	rs7712332	ENSG00000188985.6	DHFRP1	-6.1	2.21e-09	0.00274	-0.36	-0.27	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80662016	chr18:26170726~26171284:-
THCA	trans	rs889398	0.594	rs2133799	ENSG00000196796.5	CTB-134H23.2	6.1	2.22e-09	0.00275	0.3	0.27	Body mass index;	chr16:69879123	chr16:29038655~29052726:+
THCA	trans	rs4879656	0.872	rs7876033	ENSG00000215007.3	DNAJA1P3	6.1	2.23e-09	0.00276	0.31	0.27	Menopause (age at onset);	chr9:33058561	chrX:107351650~107352843:-
THCA	trans	rs4879656	0.8	rs1537041	ENSG00000215007.3	DNAJA1P3	6.1	2.23e-09	0.00276	0.31	0.27	Menopause (age at onset);	chr9:33060418	chrX:107351650~107352843:-
THCA	trans	rs4879656	0.872	rs1537039	ENSG00000215007.3	DNAJA1P3	6.1	2.23e-09	0.00276	0.31	0.27	Menopause (age at onset);	chr9:33061718	chrX:107351650~107352843:-
THCA	trans	rs453301	0.686	rs10217044	ENSG00000229857.1	RP11-159H20.3	6.1	2.23e-09	0.00277	0.33	0.27	Joint mobility (Beighton score);	chr8:9037242	chr9:76992099~76993108:+
THCA	trans	rs2048656	0.598	rs7846399	ENSG00000253893.2	FAM85B	6.1	2.23e-09	0.00277	0.34	0.27	Schizophrenia;	chr8:9635619	chr8:8167819~8226614:-
THCA	trans	rs7112043	0.778	rs1472975	ENSG00000225531.1	RP11-196I18.3	6.1	2.24e-09	0.00277	0.35	0.27	Lung disease severity in cystic fibrosis;	chr11:34755096	chr9:107116829~107117557:+
THCA	trans	rs330048	0.509	rs36111783	ENSG00000253893.2	FAM85B	-6.1	2.24e-09	0.00278	-0.35	-0.27	Systemic lupus erythematosus;	chr8:9288078	chr8:8167819~8226614:-
THCA	trans	rs3812762	0.826	rs2292045	ENSG00000266891.1	RP11-692N5.2	6.1	2.24e-09	0.00278	0.36	0.27	Hypospadias;	chr11:8785162	chr18:9734882~9735602:-
THCA	trans	rs4879677	1	rs7858681	ENSG00000269560.1	CTD-2192J16.21	-6.1	2.25e-09	0.00279	-0.34	-0.27	Gut microbiome composition (summer and winter);	chr9:27659161	chr19:12529768~12532973:-
THCA	trans	rs7945705	0.818	rs4929916	ENSG00000266891.1	RP11-692N5.2	-6.1	2.26e-09	0.0028	-0.34	-0.27	Hemoglobin concentration;	chr11:8803449	chr18:9734882~9735602:-
THCA	trans	rs1707322	1	rs10890360	ENSG00000255397.1	AC022182.2	-6.1	2.27e-09	0.00281	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs6682683	ENSG00000255397.1	AC022182.2	-6.1	2.27e-09	0.00281	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr8:60937705~60939871:-
THCA	trans	rs7829975	0.777	rs6989926	ENSG00000229857.1	RP11-159H20.3	6.1	2.28e-09	0.00282	0.33	0.27	Mood instability;	chr8:8689803	chr9:76992099~76993108:+
THCA	trans	rs7429990	0.803	rs6776963	ENSG00000235912.1	RP1-159A19.3	6.09	2.28e-09	0.00283	0.34	0.27	Educational attainment (years of education);	chr3:47789251	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs4858863	ENSG00000235912.1	RP1-159A19.3	6.09	2.28e-09	0.00283	0.34	0.27	Educational attainment (years of education);	chr3:47814143	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs7629850	ENSG00000235912.1	RP1-159A19.3	6.09	2.28e-09	0.00283	0.34	0.27	Educational attainment (years of education);	chr3:47815592	chr1:27649419~27649610:+
THCA	trans	rs453301	0.598	rs10104303	ENSG00000229857.1	RP11-159H20.3	-6.09	2.28e-09	0.00283	-0.32	-0.27	Joint mobility (Beighton score);	chr8:8977018	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.593	rs2979241	ENSG00000229857.1	RP11-159H20.3	-6.09	2.29e-09	0.00283	-0.33	-0.27	Mood instability;	chr8:8445843	chr9:76992099~76993108:+
THCA	trans	rs2950393	0.804	rs898611	ENSG00000257210.1	NACAP3	-6.09	2.29e-09	0.00284	-0.31	-0.27	Platelet distribution width;	chr12:56769532	chr12:93124063~93124543:-
THCA	trans	rs941207	0.756	rs2926743	ENSG00000228224.3	NACAP1	6.09	2.29e-09	0.00284	0.31	0.27	Platelet count;	chr12:56720316	chr8:101361794~101372707:+
THCA	trans	rs1707322	1	rs7526369	ENSG00000255397.1	AC022182.2	-6.09	2.29e-09	0.00284	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs10890371	ENSG00000255397.1	AC022182.2	-6.09	2.29e-09	0.00284	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr8:60937705~60939871:-
THCA	trans	rs2950393	0.804	rs7295862	ENSG00000228224.3	NACAP1	-6.09	2.3e-09	0.00284	-0.28	-0.27	Platelet distribution width;	chr12:56775374	chr8:101361794~101372707:+
THCA	trans	rs7824557	0.806	rs34171564	ENSG00000253893.2	FAM85B	6.09	2.31e-09	0.00286	0.34	0.27	Retinal vascular caliber;	chr8:11237837	chr8:8167819~8226614:-
THCA	trans	rs12542260	0.871	rs7836802	ENSG00000234369.1	TATDN1P1	6.09	2.31e-09	0.00286	0.38	0.27	Colonoscopy-negative controls vs population controls;	chr8:124461489	chr10:63222155~63223045:+
THCA	trans	rs3808502	0.526	rs36048422	ENSG00000256560.1	LINC01486	-6.09	2.32e-09	0.00287	-0.33	-0.27	Neuroticism;	chr8:11559635	chr12:109354083~109359488:-
THCA	trans	rs3808502	0.526	rs11783065	ENSG00000256560.1	LINC01486	-6.09	2.32e-09	0.00287	-0.33	-0.27	Neuroticism;	chr8:11559748	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.602	rs7817658	ENSG00000253893.2	FAM85B	-6.09	2.32e-09	0.00287	-0.36	-0.27	Retinal vascular caliber;	chr8:11349034	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs10158032	ENSG00000255397.1	AC022182.2	-6.09	2.32e-09	0.00287	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr8:60937705~60939871:-
THCA	trans	rs9393777	0.764	rs35565446	ENSG00000228022.4	HCG20	-6.09	2.33e-09	0.00289	-0.69	-0.27	Intelligence (multi-trait analysis);	chr6:27177562	chr6:30766825~30792250:+
THCA	trans	rs12477438	0.539	rs12999417	ENSG00000276576.1	MRPL30P1	-6.09	2.34e-09	0.00289	-0.35	-0.27	Chronic sinus infection;	chr2:99249085	chr6:57029521~57029988:+
THCA	trans	rs1908814	0.516	rs35391955	ENSG00000254153.1	CTA-398F10.2	-6.09	2.34e-09	0.00289	-0.31	-0.27	Neuroticism;	chr8:11939219	chr8:8456909~8461337:-
THCA	trans	rs4646450	0.891	rs1011024	ENSG00000228834.1	RP11-249L21.4	6.09	2.34e-09	0.0029	0.44	0.27	Blood metabolite levels;	chr7:99599778	chr6:108907615~108907873:-
THCA	trans	rs853679	0.607	rs13211507	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28289600	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34691223	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28290431	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13207345	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28297795	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs72854513	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28298177	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs56189111	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28304196	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34950484	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28310911	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs35072899	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28313764	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34661125	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28314117	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13190888	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28318208	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs56075693	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28322551	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34218844	ENSG00000204338.7	CYP21A1P	-6.09	2.34e-09	0.0029	-0.59	-0.27	Depression;	chr6:28322870	chr6:32005636~32008451:+
THCA	trans	rs453301	0.658	rs3855900	ENSG00000229857.1	RP11-159H20.3	6.09	2.34e-09	0.0029	0.33	0.27	Joint mobility (Beighton score);	chr8:9044411	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.562	rs10090444	ENSG00000229857.1	RP11-159H20.3	-6.09	2.34e-09	0.0029	-0.33	-0.27	Neuroticism;	chr8:10887959	chr9:76992099~76993108:+
THCA	trans	rs1190596	0.525	rs35350456	ENSG00000181359.5	HSP90AA6P	-6.09	2.34e-09	0.0029	-0.39	-0.27	Behavioural disinhibition (generation interaction);	chr14:102238414	chr4:170581470~170605450:-
THCA	trans	rs4784054	0.568	rs11640551	ENSG00000230849.2	GOT2P2	6.09	2.35e-09	0.00291	0.42	0.27	Blood metabolite levels;	chr16:58787994	chr1:173141100~173142350:-
THCA	trans	rs4415084	0.804	rs13177711	ENSG00000231752.4	EMBP1	6.09	2.36e-09	0.00292	0.36	0.27	Breast cancer;	chr5:44796860	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.834	rs6896417	ENSG00000231752.4	EMBP1	6.09	2.36e-09	0.00292	0.36	0.27	Breast cancer;	chr5:44802536	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.834	rs13159598	ENSG00000231752.4	EMBP1	6.09	2.36e-09	0.00292	0.36	0.27	Breast cancer;	chr5:44805824	chr1:121519112~121571892:+
THCA	trans	rs1908814	0.51	rs57655799	ENSG00000254153.1	CTA-398F10.2	-6.09	2.36e-09	0.00292	-0.31	-0.27	Neuroticism;	chr8:11924908	chr8:8456909~8461337:-
THCA	trans	rs7746199	0.736	rs34064842	ENSG00000228022.4	HCG20	-6.09	2.36e-09	0.00292	-0.68	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:30766825~30792250:+
THCA	trans	rs34546498	1	rs34546498	ENSG00000228022.4	HCG20	-6.09	2.37e-09	0.00292	-0.7	-0.27	Breast cancer;	chr6:26993501	chr6:30766825~30792250:+
THCA	trans	rs453301	0.686	rs3989373	ENSG00000229857.1	RP11-159H20.3	6.09	2.37e-09	0.00292	0.33	0.27	Joint mobility (Beighton score);	chr8:9053798	chr9:76992099~76993108:+
THCA	trans	rs76228276	0.737	rs35755686	ENSG00000260318.1	COX6CP1	6.09	2.37e-09	0.00293	0.8	0.27	Childhood ear infection;	chr8:99201697	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11997495	ENSG00000260318.1	COX6CP1	6.09	2.37e-09	0.00293	0.8	0.27	Childhood ear infection;	chr8:99202040	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11986138	ENSG00000260318.1	COX6CP1	6.09	2.37e-09	0.00293	0.8	0.27	Childhood ear infection;	chr8:99210536	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs77745880	ENSG00000260318.1	COX6CP1	6.09	2.37e-09	0.00293	0.8	0.27	Childhood ear infection;	chr8:99245830	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs79132217	ENSG00000260318.1	COX6CP1	6.09	2.37e-09	0.00293	0.8	0.27	Childhood ear infection;	chr8:99252581	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs79013399	ENSG00000260318.1	COX6CP1	6.09	2.37e-09	0.00293	0.8	0.27	Childhood ear infection;	chr8:99254480	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs75079359	ENSG00000260318.1	COX6CP1	6.09	2.37e-09	0.00293	0.8	0.27	Childhood ear infection;	chr8:99265692	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs11984531	ENSG00000260318.1	COX6CP1	6.09	2.37e-09	0.00293	0.8	0.27	Childhood ear infection;	chr8:99269658	chr16:11903923~11904137:-
THCA	trans	rs9649213	0.531	rs35216698	ENSG00000225169.1	BRI3P1	6.09	2.37e-09	0.00293	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr1:100213293~100213670:+
THCA	trans	rs7429990	0.828	rs55823596	ENSG00000235912.1	RP1-159A19.3	-6.09	2.38e-09	0.00294	-0.35	-0.27	Educational attainment (years of education);	chr3:47758541	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs4858853	ENSG00000235912.1	RP1-159A19.3	-6.09	2.38e-09	0.00294	-0.35	-0.27	Educational attainment (years of education);	chr3:47760605	chr1:27649419~27649610:+
THCA	trans	rs902774	0.759	rs4919707	ENSG00000250539.1	KRT8P33	-6.09	2.38e-09	0.00294	-0.51	-0.27	Prostate cancer;	chr12:52895864	chr5:123400922~123402344:-
THCA	trans	rs902774	0.818	rs56095813	ENSG00000250539.1	KRT8P33	-6.09	2.38e-09	0.00294	-0.51	-0.27	Prostate cancer;	chr12:52900963	chr5:123400922~123402344:-
THCA	trans	rs4879677	1	rs12237360	ENSG00000269560.1	CTD-2192J16.21	-6.09	2.38e-09	0.00294	-0.35	-0.27	Gut microbiome composition (summer and winter);	chr9:27660200	chr19:12529768~12532973:-
THCA	trans	rs6601327	0.6	rs4841219	ENSG00000253893.2	FAM85B	6.09	2.38e-09	0.00295	0.36	0.27	Multiple myeloma (hyperdiploidy);	chr8:9796675	chr8:8167819~8226614:-
THCA	trans	rs2060793	0.519	rs7931291	ENSG00000236360.2	RP11-334A14.2	-6.09	2.39e-09	0.00295	-0.36	-0.27	Vitamin D levels;	chr11:14622880	chr1:52993201~52993702:-
THCA	trans	rs4415084	0.768	rs9292915	ENSG00000231752.4	EMBP1	-6.09	2.39e-09	0.00295	-0.36	-0.27	Breast cancer;	chr5:44871555	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.806	rs2898256	ENSG00000256560.1	LINC01486	-6.09	2.39e-09	0.00295	-0.33	-0.27	Triglycerides;	chr8:11075185	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.875	rs11250121	ENSG00000254153.1	CTA-398F10.2	6.09	2.39e-09	0.00296	0.3	0.27	Triglycerides;	chr8:11202802	chr8:8456909~8461337:-
THCA	trans	rs6601327	0.641	rs4840437	ENSG00000253893.2	FAM85B	6.09	2.4e-09	0.00296	0.34	0.27	Multiple myeloma (hyperdiploidy);	chr8:9748754	chr8:8167819~8226614:-
THCA	trans	rs9987353	0.793	rs9329182	ENSG00000253893.2	FAM85B	6.09	2.4e-09	0.00296	0.38	0.27	Recombination measurement;	chr8:9253679	chr8:8167819~8226614:-
THCA	trans	rs853679	0.769	rs7752448	ENSG00000253570.1	RNF5P1	6.09	2.4e-09	0.00297	0.62	0.27	Depression;	chr6:28333322	chr8:38600661~38601200:-
THCA	trans	rs889398	0.594	rs1466863	ENSG00000196796.5	CTB-134H23.2	-6.09	2.4e-09	0.00297	-0.3	-0.27	Body mass index;	chr16:69870235	chr16:29038655~29052726:+
THCA	trans	rs7819412	0.806	rs6980856	ENSG00000256560.1	LINC01486	6.09	2.4e-09	0.00297	0.33	0.27	Triglycerides;	chr8:11080750	chr12:109354083~109359488:-
THCA	trans	rs889398	0.617	rs11648348	ENSG00000196796.5	CTB-134H23.2	6.08	2.42e-09	0.00299	0.3	0.27	Body mass index;	chr16:69856819	chr16:29038655~29052726:+
THCA	trans	rs4415084	0.8	rs2330572	ENSG00000231752.4	EMBP1	-6.08	2.43e-09	0.003	-0.36	-0.27	Breast cancer;	chr5:44740887	chr1:121519112~121571892:+
THCA	trans	rs1079467	1	rs1079467	ENSG00000275945.1	EIF3S5P1	-6.08	2.44e-09	0.00301	-0.42	-0.27	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7948164	chr21:10330732~10331537:+
THCA	trans	rs7200543	1	rs6498540	ENSG00000250569.1	NTAN1P2	6.08	2.44e-09	0.00302	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr8:86481754~86483002:-
THCA	trans	rs6601327	0.67	rs12545250	ENSG00000253893.2	FAM85B	-6.08	2.44e-09	0.00302	-0.35	-0.27	Multiple myeloma (hyperdiploidy);	chr8:9563056	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.525	rs12682349	ENSG00000254153.1	CTA-398F10.2	-6.08	2.46e-09	0.00303	-0.3	-0.27	Retinal vascular caliber;	chr8:11387794	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs60176945	ENSG00000254153.1	CTA-398F10.2	-6.08	2.47e-09	0.00304	-0.31	-0.27	Neuroticism;	chr8:11939165	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs56102998	ENSG00000254153.1	CTA-398F10.2	-6.08	2.47e-09	0.00304	-0.31	-0.27	Neuroticism;	chr8:11939166	chr8:8456909~8461337:-
THCA	trans	rs7826238	0.566	rs2945886	ENSG00000256560.1	LINC01486	6.08	2.47e-09	0.00304	0.32	0.27	Systolic blood pressure;	chr8:8290748	chr12:109354083~109359488:-
THCA	trans	rs11250098	0.51	rs4840525	ENSG00000229857.1	RP11-159H20.3	6.08	2.48e-09	0.00306	0.32	0.27	Morning vs. evening chronotype;	chr8:10908125	chr9:76992099~76993108:+
THCA	trans	rs2985684	1	rs2985697	ENSG00000240785.1	RPL36AP21	6.08	2.48e-09	0.00306	0.35	0.27	Carotid intima media thickness;	chr14:49626184	chr5:18049550~18049872:+
THCA	trans	rs9329221	0.538	rs2272598	ENSG00000253893.2	FAM85B	6.08	2.48e-09	0.00306	0.36	0.27	Neuroticism;	chr8:10243259	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.516	rs4841641	ENSG00000254153.1	CTA-398F10.2	-6.08	2.49e-09	0.00307	-0.31	-0.27	Neuroticism;	chr8:11940718	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.635	rs4841501	ENSG00000256560.1	LINC01486	-6.08	2.5e-09	0.00308	-0.35	-0.27	Triglycerides;	chr8:11143466	chr12:109354083~109359488:-
THCA	trans	rs4415084	0.8	rs1821934	ENSG00000231752.4	EMBP1	6.08	2.52e-09	0.00311	0.36	0.27	Breast cancer;	chr5:44789070	chr1:121519112~121571892:+
THCA	trans	rs6087990	0.806	rs4911257	ENSG00000253915.1	MAPRE1P1	6.08	2.52e-09	0.00311	0.34	0.27	Ulcerative colitis;	chr20:32771768	chr8:135625185~135625981:-
THCA	trans	rs7819412	0.765	rs17783634	ENSG00000254153.1	CTA-398F10.2	6.08	2.52e-09	0.00311	0.31	0.27	Triglycerides;	chr8:11196588	chr8:8456909~8461337:-
THCA	trans	rs2277458	0.925	rs2144530	ENSG00000214249.3	CTAGE11P	6.08	2.53e-09	0.00312	0.43	0.27	Vitamin D levels;	chr14:39083280	chr13:75237944~75240296:-
THCA	trans	rs1580019	0.713	rs2122632	ENSG00000176826.14	FKBP9P1	6.08	2.53e-09	0.00312	0.37	0.27	Cognitive ability;	chr7:32485074	chr7:55681074~55713252:-
THCA	trans	rs34421088	0.678	rs35928010	ENSG00000256560.1	LINC01486	-6.08	2.54e-09	0.00313	-0.32	-0.27	Neuroticism;	chr8:11734367	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.775	rs4841489	ENSG00000256560.1	LINC01486	-6.08	2.55e-09	0.00314	-0.32	-0.27	Triglycerides;	chr8:11079301	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.843	rs2572418	ENSG00000229857.1	RP11-159H20.3	6.08	2.56e-09	0.00315	0.33	0.27	Retinal vascular caliber;	chr8:11255580	chr9:76992099~76993108:+
THCA	trans	rs7113874	0.655	rs67257872	ENSG00000266891.1	RP11-692N5.2	6.08	2.56e-09	0.00315	0.34	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508671	chr18:9734882~9735602:-
THCA	trans	rs7829975	0.902	rs777707	ENSG00000256560.1	LINC01486	6.07	2.56e-09	0.00316	0.32	0.27	Mood instability;	chr8:8726834	chr12:109354083~109359488:-
THCA	trans	rs4646450	0.838	rs10257758	ENSG00000228834.1	RP11-249L21.4	6.07	2.57e-09	0.00317	0.43	0.27	Blood metabolite levels;	chr7:99591365	chr6:108907615~108907873:-
THCA	trans	rs804280	0.509	rs12719915	ENSG00000254153.1	CTA-398F10.2	6.07	2.57e-09	0.00317	0.31	0.27	Myopia (pathological);	chr8:11928746	chr8:8456909~8461337:-
THCA	trans	rs6601327	0.613	rs7835002	ENSG00000253893.2	FAM85B	-6.07	2.57e-09	0.00317	-0.34	-0.27	Multiple myeloma (hyperdiploidy);	chr8:9597535	chr8:8167819~8226614:-
THCA	trans	rs941207	0.756	rs2950394	ENSG00000228224.3	NACAP1	-6.07	2.58e-09	0.00318	-0.31	-0.27	Platelet count;	chr12:56644548	chr8:101361794~101372707:+
THCA	trans	rs7819412	0.56	rs3021497	ENSG00000229857.1	RP11-159H20.3	6.07	2.59e-09	0.00319	0.37	0.27	Triglycerides;	chr8:11138579	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.547	rs11250099	ENSG00000254153.1	CTA-398F10.2	-6.07	2.6e-09	0.0032	-0.29	-0.27	Neuroticism;	chr8:10961147	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.872	rs6601577	ENSG00000253893.2	FAM85B	-6.07	2.6e-09	0.0032	-0.34	-0.27	Retinal vascular caliber;	chr8:11245173	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.569	rs4929942	ENSG00000266891.1	RP11-692N5.2	-6.07	2.6e-09	0.0032	-0.35	-0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8603549	chr18:9734882~9735602:-
THCA	trans	rs9393777	0.92	rs35768595	ENSG00000228022.4	HCG20	-6.07	2.6e-09	0.00321	-0.7	-0.27	Intelligence (multi-trait analysis);	chr6:27174125	chr6:30766825~30792250:+
THCA	trans	rs2980439	0.729	rs2955586	ENSG00000229857.1	RP11-159H20.3	-6.07	2.61e-09	0.00321	-0.32	-0.27	Neuroticism;	chr8:8236445	chr9:76992099~76993108:+
THCA	trans	rs12546962	0.739	rs1461727	ENSG00000253893.2	FAM85B	-6.07	2.61e-09	0.00321	-0.37	-0.27	Body mass index;	chr8:9342840	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.602	rs7815463	ENSG00000253893.2	FAM85B	-6.07	2.61e-09	0.00321	-0.36	-0.27	Retinal vascular caliber;	chr8:11353474	chr8:8167819~8226614:-
THCA	trans	rs8014204	0.935	rs2300596	ENSG00000181227.3	RP4-682C21.2	-6.07	2.62e-09	0.00322	-0.21	-0.27	Caffeine consumption;	chr14:74887152	chr1:75743423~75744776:-
THCA	trans	rs6601327	0.575	rs7001832	ENSG00000253893.2	FAM85B	6.07	2.62e-09	0.00322	0.34	0.27	Multiple myeloma (hyperdiploidy);	chr8:9749725	chr8:8167819~8226614:-
THCA	trans	rs11671005	0.779	rs55875034	ENSG00000279267.1	RP11-395L14.18	6.07	2.62e-09	0.00323	0.4	0.27	Mean platelet volume;	chr19:58472191	chr2:113605867~113607908:-
THCA	trans	rs6928977	0.932	rs4896143	ENSG00000275632.1	RP5-967N21.11	6.07	2.62e-09	0.00323	0.24	0.27	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135313962	chr20:6000418~6000941:+
THCA	trans	rs7819412	0.505	rs67849263	ENSG00000253893.2	FAM85B	6.07	2.64e-09	0.00324	0.37	0.27	Triglycerides;	chr8:11150034	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.522	rs3021495	ENSG00000229857.1	RP11-159H20.3	6.07	2.64e-09	0.00325	0.37	0.27	Triglycerides;	chr8:11137233	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.778	rs6601572	ENSG00000253893.2	FAM85B	6.07	2.64e-09	0.00325	0.33	0.27	Retinal vascular caliber;	chr8:11235828	chr8:8167819~8226614:-
THCA	trans	rs3764796	0.737	rs28502188	ENSG00000250030.2	RP11-584P21.4	6.07	2.65e-09	0.00325	0.54	0.27	Calcium levels;	chr8:17266593	chr4:67446267~67446574:+
THCA	trans	rs3764796	0.737	rs17687363	ENSG00000250030.2	RP11-584P21.4	6.07	2.65e-09	0.00325	0.54	0.27	Calcium levels;	chr8:17266724	chr4:67446267~67446574:+
THCA	trans	rs9650657	0.513	rs4314618	ENSG00000256560.1	LINC01486	-6.07	2.65e-09	0.00326	-0.32	-0.27	Neuroticism;	chr8:10959262	chr12:109354083~109359488:-
THCA	trans	rs3008870	0.651	rs2815376	ENSG00000227992.1	AC108463.2	6.07	2.65e-09	0.00326	0.34	0.27	Lymphocyte percentage of white cells;	chr1:67042848	chr2:111203964~111206215:-
THCA	trans	rs7824557	0.527	rs2572449	ENSG00000256560.1	LINC01486	6.07	2.66e-09	0.00327	0.32	0.27	Retinal vascular caliber;	chr8:11381628	chr12:109354083~109359488:-
THCA	trans	rs34421088	0.56	rs2248699	ENSG00000229857.1	RP11-159H20.3	6.07	2.66e-09	0.00327	0.35	0.27	Neuroticism;	chr8:11536255	chr9:76992099~76993108:+
THCA	trans	rs3812762	0.957	rs10160684	ENSG00000266891.1	RP11-692N5.2	-6.07	2.66e-09	0.00327	-0.35	-0.27	Hypospadias;	chr11:8753872	chr18:9734882~9735602:-
THCA	trans	rs7824557	0.602	rs1435273	ENSG00000253893.2	FAM85B	-6.07	2.66e-09	0.00328	-0.36	-0.27	Retinal vascular caliber;	chr8:11351990	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs4660334	ENSG00000255397.1	AC022182.2	-6.07	2.66e-09	0.00328	-0.38	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr8:60937705~60939871:-
THCA	trans	rs2288327	0.75	rs6750145	ENSG00000269800.1	PLEKHA3P1	6.07	2.67e-09	0.00329	0.37	0.27	Atrial fibrillation;	chr2:178717878	chr19:41521043~41521989:-
THCA	trans	rs7829975	0.626	rs332040	ENSG00000229857.1	RP11-159H20.3	-6.07	2.67e-09	0.00329	-0.34	-0.27	Mood instability;	chr8:8872978	chr9:76992099~76993108:+
THCA	trans	rs7113874	0.531	rs10840094	ENSG00000266891.1	RP11-692N5.2	-6.07	2.68e-09	0.00329	-0.35	-0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8606427	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.569	rs10840095	ENSG00000266891.1	RP11-692N5.2	-6.07	2.68e-09	0.00329	-0.35	-0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8606428	chr18:9734882~9735602:-
THCA	trans	rs12472274	0.817	rs12621791	ENSG00000224699.7	LAMTOR5-AS1	-6.07	2.68e-09	0.0033	-0.24	-0.27	Phospholipid levels (plasma);	chr2:238195420	chr1:110347116~110443817:+
THCA	trans	rs12472274	0.941	rs4663861	ENSG00000224699.7	LAMTOR5-AS1	-6.07	2.68e-09	0.0033	-0.24	-0.27	Phospholipid levels (plasma);	chr2:238196562	chr1:110347116~110443817:+
THCA	trans	rs4415084	0.804	rs9292913	ENSG00000231752.4	EMBP1	-6.07	2.69e-09	0.00331	-0.36	-0.27	Breast cancer;	chr5:44870777	chr1:121519112~121571892:+
THCA	trans	rs6601327	0.67	rs4128198	ENSG00000253893.2	FAM85B	-6.07	2.69e-09	0.00331	-0.34	-0.27	Multiple myeloma (hyperdiploidy);	chr8:9575989	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs73110432	ENSG00000259500.1	KRT8P24	-6.07	2.7e-09	0.00332	-0.54	-0.27	Prostate cancer;	chr12:52894051	chr15:48971803~48973361:+
THCA	trans	rs6087990	0.806	rs6088008	ENSG00000253915.1	MAPRE1P1	6.07	2.71e-09	0.00333	0.34	0.27	Ulcerative colitis;	chr20:32795054	chr8:135625185~135625981:-
THCA	trans	rs7746199	0.736	rs35037868	ENSG00000204338.7	CYP21A1P	-6.06	2.72e-09	0.00334	-0.61	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:32005636~32008451:+
THCA	trans	rs62344088	0.59	rs58563514	ENSG00000185986.11	SDHAP3	6.06	2.72e-09	0.00334	0.42	0.27	Asthma (childhood onset);	chr5:177722	chr5:1572222~1594620:-
THCA	trans	rs853679	0.607	rs66886492	ENSG00000228022.4	HCG20	-6.06	2.72e-09	0.00334	-0.7	-0.27	Depression;	chr6:28121953	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs35345226	ENSG00000228022.4	HCG20	-6.06	2.72e-09	0.00334	-0.7	-0.27	Depression;	chr6:28123802	chr6:30766825~30792250:+
THCA	trans	rs889398	0.617	rs1566456	ENSG00000196796.5	CTB-134H23.2	6.06	2.72e-09	0.00334	0.3	0.27	Body mass index;	chr16:69866323	chr16:29038655~29052726:+
THCA	trans	rs9425766	0.64	rs2295366	ENSG00000213331.4	RP11-713C19.2	6.06	2.72e-09	0.00335	0.37	0.27	Life satisfaction;	chr1:173856554	chr4:187970273~187971284:+
THCA	trans	rs9393777	0.92	rs67859638	ENSG00000228022.4	HCG20	-6.06	2.73e-09	0.00335	-0.7	-0.27	Intelligence (multi-trait analysis);	chr6:27390199	chr6:30766825~30792250:+
THCA	trans	rs4646450	0.735	rs11762273	ENSG00000228834.1	RP11-249L21.4	6.06	2.73e-09	0.00335	0.46	0.27	Blood metabolite levels;	chr7:99379564	chr6:108907615~108907873:-
THCA	trans	rs2277458	0.858	rs8018720	ENSG00000214249.3	CTAGE11P	6.06	2.73e-09	0.00335	0.42	0.27	Vitamin D levels;	chr14:39086981	chr13:75237944~75240296:-
THCA	trans	rs453301	0.686	rs6748	ENSG00000229857.1	RP11-159H20.3	6.06	2.74e-09	0.00336	0.33	0.27	Joint mobility (Beighton score);	chr8:9033292	chr9:76992099~76993108:+
THCA	trans	rs9379945	1	rs9379945	ENSG00000228022.4	HCG20	-6.06	2.74e-09	0.00337	-0.51	-0.27	Intelligence (multi-trait analysis);	chr6:26940052	chr6:30766825~30792250:+
THCA	trans	rs3764796	0.737	rs73208600	ENSG00000250030.2	RP11-584P21.4	6.06	2.74e-09	0.00337	0.53	0.27	Calcium levels;	chr8:17301977	chr4:67446267~67446574:+
THCA	trans	rs9650657	0.538	rs11250093	ENSG00000229857.1	RP11-159H20.3	-6.06	2.75e-09	0.00337	-0.34	-0.27	Neuroticism;	chr8:10941318	chr9:76992099~76993108:+
THCA	trans	rs4929949	0.902	rs61875898	ENSG00000266891.1	RP11-692N5.2	-6.06	2.76e-09	0.00339	-0.35	-0.27	Body mass index;	chr11:8605677	chr18:9734882~9735602:-
THCA	trans	rs453301	0.657	rs36056437	ENSG00000229857.1	RP11-159H20.3	6.06	2.77e-09	0.00339	0.35	0.27	Joint mobility (Beighton score);	chr8:8935355	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.662	rs12109710	ENSG00000231752.4	EMBP1	-6.06	2.77e-09	0.0034	-0.38	-0.27	Breast cancer;	chr5:44929826	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.715	rs35223712	ENSG00000254153.1	CTA-398F10.2	6.06	2.77e-09	0.0034	0.3	0.27	Triglycerides;	chr8:11186417	chr8:8456909~8461337:-
THCA	trans	rs9393777	0.841	rs13207082	ENSG00000228022.4	HCG20	-6.06	2.79e-09	0.00342	-0.59	-0.27	Intelligence (multi-trait analysis);	chr6:27283600	chr6:30766825~30792250:+
THCA	trans	rs7809615	0.515	rs6961634	ENSG00000228834.1	RP11-249L21.4	6.06	2.8e-09	0.00343	0.43	0.27	Blood metabolite ratios;	chr7:99584216	chr6:108907615~108907873:-
THCA	trans	rs34421088	0.623	rs2572433	ENSG00000256560.1	LINC01486	6.06	2.8e-09	0.00344	0.35	0.27	Neuroticism;	chr8:11243532	chr12:109354083~109359488:-
THCA	trans	rs853679	0.607	rs67998226	ENSG00000204338.7	CYP21A1P	-6.06	2.81e-09	0.00344	-0.59	-0.27	Depression;	chr6:28270281	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34878803	ENSG00000204338.7	CYP21A1P	-6.06	2.81e-09	0.00344	-0.59	-0.27	Depression;	chr6:28282402	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs34396849	ENSG00000204338.7	CYP21A1P	-6.06	2.81e-09	0.00344	-0.59	-0.27	Depression;	chr6:28283178	chr6:32005636~32008451:+
THCA	trans	rs889398	0.617	rs3790082	ENSG00000196796.5	CTB-134H23.2	6.06	2.81e-09	0.00344	0.3	0.27	Body mass index;	chr16:69862851	chr16:29038655~29052726:+
THCA	trans	rs1908814	0.516	rs58869268	ENSG00000254153.1	CTA-398F10.2	-6.06	2.81e-09	0.00345	-0.31	-0.27	Neuroticism;	chr8:11939586	chr8:8456909~8461337:-
THCA	trans	rs1045529	0.524	rs34251783	ENSG00000229857.1	RP11-159H20.3	6.06	2.82e-09	0.00345	0.33	0.27	Myopia (pathological);Myopia;	chr8:9033866	chr9:76992099~76993108:+
THCA	trans	rs853679	0.607	rs67340775	ENSG00000204338.7	CYP21A1P	-6.06	2.82e-09	0.00346	-0.59	-0.27	Depression;	chr6:28336607	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs35030260	ENSG00000204338.7	CYP21A1P	-6.06	2.82e-09	0.00346	-0.59	-0.27	Depression;	chr6:28337731	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13217619	ENSG00000204338.7	CYP21A1P	-6.06	2.82e-09	0.00346	-0.59	-0.27	Depression;	chr6:28338894	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs35016036	ENSG00000204338.7	CYP21A1P	-6.06	2.82e-09	0.00346	-0.59	-0.27	Depression;	chr6:28347103	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs35744819	ENSG00000204338.7	CYP21A1P	-6.06	2.82e-09	0.00346	-0.59	-0.27	Depression;	chr6:28350554	chr6:32005636~32008451:+
THCA	trans	rs3096299	0.685	rs4785676	ENSG00000215030.5	RPL13P12	-6.06	2.82e-09	0.00346	-0.27	-0.27	Multiple myeloma (IgH translocation);	chr16:89487216	chr17:17383377~17384012:-
THCA	trans	rs3808502	0.526	rs1042701	ENSG00000256560.1	LINC01486	-6.06	2.83e-09	0.00347	-0.34	-0.27	Neuroticism;	chr8:11564536	chr12:109354083~109359488:-
THCA	trans	rs3808502	0.526	rs7843987	ENSG00000256560.1	LINC01486	-6.06	2.83e-09	0.00347	-0.34	-0.27	Neuroticism;	chr8:11564621	chr12:109354083~109359488:-
THCA	trans	rs941207	0.756	rs9634246	ENSG00000228224.3	NACAP1	-6.06	2.84e-09	0.00348	-0.31	-0.27	Platelet count;	chr12:56640604	chr8:101361794~101372707:+
THCA	trans	rs2985684	0.895	rs3007033	ENSG00000240785.1	RPL36AP21	6.06	2.84e-09	0.00348	0.35	0.27	Carotid intima media thickness;	chr14:49637098	chr5:18049550~18049872:+
THCA	trans	rs67340775	0.834	rs13218875	ENSG00000204338.7	CYP21A1P	-6.06	2.85e-09	0.00349	-0.6	-0.27	Lung cancer in ever smokers;	chr6:27916234	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs67040724	ENSG00000204338.7	CYP21A1P	-6.06	2.85e-09	0.00349	-0.6	-0.27	Depression;	chr6:27937731	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs67662114	ENSG00000204338.7	CYP21A1P	-6.06	2.85e-09	0.00349	-0.6	-0.27	Depression;	chr6:27964523	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13216117	ENSG00000204338.7	CYP21A1P	-6.06	2.85e-09	0.00349	-0.6	-0.27	Depression;	chr6:27970706	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs36101351	ENSG00000204338.7	CYP21A1P	-6.06	2.85e-09	0.00349	-0.6	-0.27	Depression;	chr6:27975591	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs28360499	ENSG00000204338.7	CYP21A1P	-6.06	2.85e-09	0.00349	-0.6	-0.27	Depression;	chr6:27977618	chr6:32005636~32008451:+
THCA	trans	rs3096299	0.685	rs8050512	ENSG00000215030.5	RPL13P12	-6.06	2.86e-09	0.0035	-0.28	-0.27	Multiple myeloma (IgH translocation);	chr16:89485912	chr17:17383377~17384012:-
THCA	trans	rs4929949	0.78	rs4929941	ENSG00000229152.2	ANKRD10-IT1	6.06	2.86e-09	0.0035	0.15	0.27	Body mass index;	chr11:8603404	chr13:110894639~110899172:-
THCA	trans	rs3808502	0.526	rs7822958	ENSG00000256560.1	LINC01486	-6.06	2.86e-09	0.0035	-0.34	-0.27	Neuroticism;	chr8:11564933	chr12:109354083~109359488:-
THCA	trans	rs4415084	0.834	rs1438820	ENSG00000231752.4	EMBP1	6.06	2.86e-09	0.00351	0.36	0.27	Breast cancer;	chr5:44797668	chr1:121519112~121571892:+
THCA	trans	rs7429990	0.864	rs883662	ENSG00000235912.1	RP1-159A19.3	-6.06	2.87e-09	0.00352	-0.34	-0.27	Educational attainment (years of education);	chr3:47619342	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.828	rs11712152	ENSG00000235912.1	RP1-159A19.3	-6.06	2.87e-09	0.00352	-0.34	-0.27	Educational attainment (years of education);	chr3:47655314	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs12635438	ENSG00000235912.1	RP1-159A19.3	-6.06	2.87e-09	0.00352	-0.34	-0.27	Educational attainment (years of education);	chr3:47693210	chr1:27649419~27649610:+
THCA	trans	rs7829975	0.591	rs12677543	ENSG00000229857.1	RP11-159H20.3	-6.06	2.88e-09	0.00352	-0.33	-0.27	Mood instability;	chr8:8786764	chr9:76992099~76993108:+
THCA	trans	rs930395	0.514	rs10041518	ENSG00000231752.4	EMBP1	-6.06	2.88e-09	0.00352	-0.37	-0.27	Breast cancer;	chr5:44927304	chr1:121519112~121571892:+
THCA	trans	rs804280	0.517	rs7815179	ENSG00000254153.1	CTA-398F10.2	-6.05	2.88e-09	0.00352	-0.31	-0.27	Myopia (pathological);	chr8:11934539	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.871	rs7815186	ENSG00000254153.1	CTA-398F10.2	-6.05	2.88e-09	0.00352	-0.31	-0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs7833079	ENSG00000254153.1	CTA-398F10.2	-6.05	2.88e-09	0.00352	-0.31	-0.27	Neuroticism;	chr8:11934620	chr8:8456909~8461337:-
THCA	trans	rs2950393	0.804	rs7295862	ENSG00000257210.1	NACAP3	-6.05	2.89e-09	0.00353	-0.32	-0.27	Platelet distribution width;	chr12:56775374	chr12:93124063~93124543:-
THCA	trans	rs7826238	0.601	rs2979206	ENSG00000229857.1	RP11-159H20.3	-6.05	2.89e-09	0.00354	-0.35	-0.27	Systolic blood pressure;	chr8:8488071	chr9:76992099~76993108:+
THCA	trans	rs11250098	0.583	rs66724331	ENSG00000229857.1	RP11-159H20.3	6.05	2.9e-09	0.00355	0.33	0.27	Morning vs. evening chronotype;	chr8:10931835	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.913	rs67073020	ENSG00000253326.2	RP11-261C10.7	6.05	2.9e-09	0.00355	0.37	0.27	Corneal astigmatism;	chr4:119231402	chr1:243054861~243056394:-
THCA	trans	rs1190596	0.525	rs2236493	ENSG00000181359.5	HSP90AA6P	-6.05	2.9e-09	0.00355	-0.38	-0.27	Behavioural disinhibition (generation interaction);	chr14:102229356	chr4:170581470~170605450:-
THCA	trans	rs7824557	0.564	rs2572395	ENSG00000256560.1	LINC01486	-6.05	2.91e-09	0.00356	-0.33	-0.27	Retinal vascular caliber;	chr8:11377851	chr12:109354083~109359488:-
THCA	trans	rs6601327	0.613	rs12682175	ENSG00000253893.2	FAM85B	6.05	2.91e-09	0.00356	0.34	0.27	Multiple myeloma (hyperdiploidy);	chr8:9621651	chr8:8167819~8226614:-
THCA	trans	rs3849046	0.967	rs2242599	ENSG00000226666.1	HSPA9P1	6.05	2.92e-09	0.00357	0.27	0.27	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138508585	chr2:221961737~221963765:+
THCA	trans	rs453301	0.538	rs7830804	ENSG00000229857.1	RP11-159H20.3	6.05	2.92e-09	0.00357	0.32	0.27	Joint mobility (Beighton score);	chr8:9113252	chr9:76992099~76993108:+
THCA	trans	rs7769051	0.808	rs1467403	ENSG00000227615.1	RP11-864N7.2	6.05	2.92e-09	0.00357	0.47	0.27	Type 2 diabetes nephropathy;	chr6:132768813	chr11:74745716~74746114:-
THCA	trans	rs7824557	0.872	rs2572431	ENSG00000254153.1	CTA-398F10.2	6.05	2.93e-09	0.00358	0.28	0.27	Retinal vascular caliber;	chr8:11247568	chr8:8456909~8461337:-
THCA	trans	rs7200543	0.883	rs4985148	ENSG00000250569.1	NTAN1P2	6.05	2.94e-09	0.00359	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr8:86481754~86483002:-
THCA	trans	rs9650657	0.665	rs7002117	ENSG00000253893.2	FAM85B	-6.05	2.94e-09	0.00359	-0.34	-0.27	Neuroticism;	chr8:10758659	chr8:8167819~8226614:-
THCA	trans	rs2950393	0.794	rs1563897	ENSG00000257210.1	NACAP3	6.05	2.94e-09	0.00359	0.32	0.27	Platelet distribution width;	chr12:56699316	chr12:93124063~93124543:-
THCA	trans	rs1908814	0.516	rs13281315	ENSG00000254153.1	CTA-398F10.2	-6.05	2.95e-09	0.00361	-0.31	-0.27	Neuroticism;	chr8:11937346	chr8:8456909~8461337:-
THCA	trans	rs9467711	0.79	rs13195401	ENSG00000226314.6	ZNF192P1	-6.05	2.96e-09	0.00362	-0.6	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr6:28161781~28169594:+
THCA	trans	rs9467711	0.79	rs13195402	ENSG00000226314.6	ZNF192P1	-6.05	2.96e-09	0.00362	-0.6	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr6:28161781~28169594:+
THCA	trans	rs8014204	0.967	rs4903266	ENSG00000181227.3	RP4-682C21.2	6.05	2.96e-09	0.00362	0.21	0.27	Caffeine consumption;	chr14:74878238	chr1:75743423~75744776:-
THCA	trans	rs804280	0.662	rs804283	ENSG00000253893.2	FAM85B	-6.05	2.97e-09	0.00363	-0.4	-0.27	Myopia (pathological);	chr8:11753534	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.769	rs17123658	ENSG00000253915.1	MAPRE1P1	6.05	2.98e-09	0.00365	0.34	0.27	Ulcerative colitis;	chr20:32803034	chr8:135625185~135625981:-
THCA	trans	rs7746199	0.736	rs13202295	ENSG00000204338.7	CYP21A1P	-6.05	2.99e-09	0.00365	-0.61	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:32005636~32008451:+
THCA	trans	rs9650657	0.593	rs1968401	ENSG00000253893.2	FAM85B	6.05	2.99e-09	0.00365	0.33	0.27	Neuroticism;	chr8:10757873	chr8:8167819~8226614:-
THCA	trans	rs4930561	0.765	rs1894204	ENSG00000155070.8	UNC93B2	-6.05	2.99e-09	0.00365	-0.32	-0.27	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68162204	chr7:6855485~6859830:-
THCA	trans	rs8014204	0.935	rs10141438	ENSG00000181227.3	RP4-682C21.2	6.05	3e-09	0.00367	0.21	0.27	Caffeine consumption;	chr14:74887897	chr1:75743423~75744776:-
THCA	trans	rs7833986	1	rs7833986	ENSG00000244245.1	RP11-120B7.1	6.05	3.01e-09	0.00368	0.33	0.27	Height;	chr8:56187590	chr5:108593609~108593967:+
THCA	trans	rs7824557	0.51	rs1435274	ENSG00000256560.1	LINC01486	-6.05	3.02e-09	0.00368	-0.33	-0.27	Retinal vascular caliber;	chr8:11378401	chr12:109354083~109359488:-
THCA	trans	rs656319	0.586	rs35013996	ENSG00000253893.2	FAM85B	6.05	3.02e-09	0.00368	0.37	0.27	Myopia (pathological);	chr8:10089635	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.935	rs3750310	ENSG00000254153.1	CTA-398F10.2	6.05	3.02e-09	0.00369	0.3	0.27	Neuroticism;	chr8:10425916	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.805	rs4333549	ENSG00000254153.1	CTA-398F10.2	6.05	3.04e-09	0.00371	0.3	0.27	Triglycerides;	chr8:11122051	chr8:8456909~8461337:-
THCA	trans	rs453301	0.686	rs11787026	ENSG00000256560.1	LINC01486	6.04	3.05e-09	0.00372	0.32	0.27	Joint mobility (Beighton score);	chr8:9044861	chr12:109354083~109359488:-
THCA	trans	rs76228276	0.737	rs72672328	ENSG00000260318.1	COX6CP1	6.04	3.05e-09	0.00373	0.73	0.27	Childhood ear infection;	chr8:99228607	chr16:11903923~11904137:-
THCA	trans	rs9329221	0.905	rs17765901	ENSG00000229857.1	RP11-159H20.3	6.04	3.05e-09	0.00373	0.33	0.27	Neuroticism;	chr8:10391970	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.834	rs1061310	ENSG00000231752.4	EMBP1	6.04	3.07e-09	0.00375	0.36	0.27	Breast cancer;	chr5:44820748	chr1:121519112~121571892:+
THCA	trans	rs4929949	0.771	rs4304764	ENSG00000266891.1	RP11-692N5.2	6.04	3.08e-09	0.00375	0.35	0.27	Body mass index;	chr11:8422975	chr18:9734882~9735602:-
THCA	trans	rs9393777	0.841	rs67092078	ENSG00000228022.4	HCG20	-6.04	3.09e-09	0.00377	-0.69	-0.27	Intelligence (multi-trait analysis);	chr6:27086993	chr6:30766825~30792250:+
THCA	trans	rs7824557	0.564	rs2572394	ENSG00000256560.1	LINC01486	-6.04	3.09e-09	0.00377	-0.33	-0.27	Retinal vascular caliber;	chr8:11377884	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs2437152	ENSG00000256560.1	LINC01486	-6.04	3.09e-09	0.00377	-0.33	-0.27	Retinal vascular caliber;	chr8:11377988	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs2736300	ENSG00000256560.1	LINC01486	-6.04	3.09e-09	0.00377	-0.33	-0.27	Retinal vascular caliber;	chr8:11378070	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs2572392	ENSG00000256560.1	LINC01486	-6.04	3.09e-09	0.00377	-0.33	-0.27	Retinal vascular caliber;	chr8:11378096	chr12:109354083~109359488:-
THCA	trans	rs453301	0.624	rs2288671	ENSG00000256560.1	LINC01486	6.04	3.1e-09	0.00378	0.31	0.27	Joint mobility (Beighton score);	chr8:9003384	chr12:109354083~109359488:-
THCA	trans	rs6981523	0.553	rs11783045	ENSG00000229857.1	RP11-159H20.3	6.04	3.11e-09	0.00379	0.36	0.27	Neuroticism;	chr8:11198666	chr9:76992099~76993108:+
THCA	trans	rs6885307	0.941	rs3860741	ENSG00000231752.4	EMBP1	6.04	3.12e-09	0.00381	0.43	0.27	Age at first birth;	chr5:45071050	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.623	rs7833435	ENSG00000229857.1	RP11-159H20.3	6.04	3.12e-09	0.00381	0.34	0.27	Triglycerides;	chr8:10943627	chr9:76992099~76993108:+
THCA	trans	rs7200543	1	rs3803575	ENSG00000255185.4	PDXDC2P	6.04	3.13e-09	0.00381	0.37	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:70010751~70065945:-
THCA	trans	rs7746199	0.736	rs72845070	ENSG00000253570.1	RNF5P1	6.04	3.14e-09	0.00383	0.8	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr8:38600661~38601200:-
THCA	trans	rs4929949	0.688	rs10769905	ENSG00000266891.1	RP11-692N5.2	6.04	3.18e-09	0.00387	0.35	0.27	Body mass index;	chr11:8420169	chr18:9734882~9735602:-
THCA	trans	rs860295	0.529	rs17385065	ENSG00000241627.3	UBQLN4P1	6.04	3.2e-09	0.00389	0.3	0.27	Body mass index;	chr1:156006597	chr3:148985868~148987668:-
THCA	trans	rs9899728	0.706	rs7210092	ENSG00000234925.2	ATP5HP4	6.04	3.2e-09	0.0039	0.57	0.27	Alzheimer's disease or small vessel stroke;	chr17:75025505	chr12:68642519~68642993:-
THCA	trans	rs6600671	1	rs2319969	ENSG00000270392.2	PFN1P2	6.04	3.2e-09	0.0039	0.27	0.27	Hip geometry;	chr1:121465481	chr1:120432204~120434052:-
THCA	trans	rs3808502	0.526	rs7823100	ENSG00000256560.1	LINC01486	-6.04	3.2e-09	0.0039	-0.34	-0.27	Neuroticism;	chr8:11564982	chr12:109354083~109359488:-
THCA	trans	rs3808502	0.526	rs7823101	ENSG00000256560.1	LINC01486	-6.04	3.2e-09	0.0039	-0.34	-0.27	Neuroticism;	chr8:11564983	chr12:109354083~109359488:-
THCA	trans	rs3808502	0.526	rs11985709	ENSG00000256560.1	LINC01486	-6.04	3.2e-09	0.0039	-0.34	-0.27	Neuroticism;	chr8:11565574	chr12:109354083~109359488:-
THCA	trans	rs3812762	0.833	rs10500707	ENSG00000266891.1	RP11-692N5.2	-6.04	3.21e-09	0.00391	-0.36	-0.27	Hypospadias;	chr11:8796033	chr18:9734882~9735602:-
THCA	trans	rs9467711	1	rs6939978	ENSG00000176998.4	HCG4	-6.04	3.21e-09	0.00391	-0.48	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26328234	chr6:29791753~29792750:-
THCA	trans	rs34421088	0.548	rs2618443	ENSG00000256560.1	LINC01486	-6.04	3.22e-09	0.00392	-0.33	-0.27	Neuroticism;	chr8:11527047	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.835	rs4911106	ENSG00000253915.1	MAPRE1P1	6.04	3.22e-09	0.00393	0.34	0.27	Ulcerative colitis;	chr20:32743524	chr8:135625185~135625981:-
THCA	trans	rs34546498	1	rs34546498	ENSG00000204338.7	CYP21A1P	-6.04	3.23e-09	0.00393	-0.61	-0.27	Breast cancer;	chr6:26993501	chr6:32005636~32008451:+
THCA	trans	rs6600671	0.691	rs6600662	ENSG00000270231.3	NBPF8P	6.03	3.23e-09	0.00393	0.25	0.27	Hip geometry;	chr1:121488992	chr1:120436353~120467739:+
THCA	trans	rs6831352	0.819	rs1230158	ENSG00000228407.2	RP4-800M22.1	-6.03	3.24e-09	0.00394	-0.36	-0.27	Alcohol dependence;	chr4:99069035	chr1:52160261~52160600:-
THCA	trans	rs9314986	0.734	rs998751	ENSG00000278546.1	RP1-41C23.4	6.03	3.24e-09	0.00394	0.34	0.27	Biliary atresia;	chr13:29890749	chr17:31560132~31560573:+
THCA	trans	rs7829975	0.564	rs2976855	ENSG00000229857.1	RP11-159H20.3	-6.03	3.24e-09	0.00394	-0.32	-0.27	Mood instability;	chr8:8444284	chr9:76992099~76993108:+
THCA	trans	rs930395	0.514	rs9292914	ENSG00000231752.4	EMBP1	-6.03	3.24e-09	0.00395	-0.37	-0.27	Breast cancer;	chr5:44871279	chr1:121519112~121571892:+
THCA	trans	rs2567519	0.71	rs2714012	ENSG00000236439.4	RP11-175B9.3	6.03	3.24e-09	0.00395	0.31	0.27	Smoking initiation;	chr17:72787618	chr1:202471864~202472117:-
THCA	trans	rs932287	1	rs932287	ENSG00000266891.1	RP11-692N5.2	6.03	3.24e-09	0.00395	0.35	0.27	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr18:9734882~9735602:-
THCA	trans	rs6087990	0.842	rs4911105	ENSG00000253915.1	MAPRE1P1	6.03	3.24e-09	0.00395	0.34	0.27	Ulcerative colitis;	chr20:32742607	chr8:135625185~135625981:-
THCA	trans	rs7824557	0.564	rs2736293	ENSG00000256560.1	LINC01486	-6.03	3.24e-09	0.00395	-0.33	-0.27	Retinal vascular caliber;	chr8:11377104	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs2736294	ENSG00000256560.1	LINC01486	-6.03	3.24e-09	0.00395	-0.33	-0.27	Retinal vascular caliber;	chr8:11377117	chr12:109354083~109359488:-
THCA	trans	rs9393777	0.92	rs35768595	ENSG00000204338.7	CYP21A1P	-6.03	3.25e-09	0.00396	-0.61	-0.27	Intelligence (multi-trait analysis);	chr6:27174125	chr6:32005636~32008451:+
THCA	trans	rs2645424	0.635	rs6980952	ENSG00000260438.1	RP11-405F3.2	-6.03	3.27e-09	0.00398	-0.37	-0.27	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11858964	chr16:57713782~57714957:+
THCA	trans	rs616147	0.548	rs2370965	ENSG00000239269.1	RPSAP4	-6.03	3.28e-09	0.00399	-0.29	-0.27	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr14:94726288~94727175:+
THCA	trans	rs8067354	0.574	rs2526354	ENSG00000187870.7	RNFT1P3	6.03	3.29e-09	0.004	0.44	0.27	Hemoglobin concentration;	chr17:59899297	chr17:20743333~20754501:-
THCA	trans	rs6087990	0.731	rs2424897	ENSG00000253915.1	MAPRE1P1	6.03	3.29e-09	0.004	0.34	0.27	Ulcerative colitis;	chr20:32750292	chr8:135625185~135625981:-
THCA	trans	rs4879677	1	rs10812633	ENSG00000269560.1	CTD-2192J16.21	-6.03	3.3e-09	0.00401	-0.35	-0.27	Gut microbiome composition (summer and winter);	chr9:27656975	chr19:12529768~12532973:-
THCA	trans	rs9987353	1	rs9987353	ENSG00000253893.2	FAM85B	6.03	3.32e-09	0.00404	0.38	0.27	Recombination measurement;	chr8:9258839	chr8:8167819~8226614:-
THCA	trans	rs7662987	0.818	rs35123946	ENSG00000228407.2	RP4-800M22.1	6.03	3.33e-09	0.00405	0.68	0.27	Smoking initiation;	chr4:99079760	chr1:52160261~52160600:-
THCA	trans	rs1707322	1	rs4524994	ENSG00000255397.1	AC022182.2	-6.03	3.33e-09	0.00405	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs9787412	ENSG00000255397.1	AC022182.2	-6.03	3.33e-09	0.00405	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs4660896	ENSG00000255397.1	AC022182.2	-6.03	3.33e-09	0.00405	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.928	rs10732844	ENSG00000255397.1	AC022182.2	-6.03	3.33e-09	0.00405	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs12133129	ENSG00000255397.1	AC022182.2	-6.03	3.33e-09	0.00405	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs4553121	ENSG00000255397.1	AC022182.2	-6.03	3.33e-09	0.00405	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr8:60937705~60939871:-
THCA	trans	rs1707322	0.963	rs6690652	ENSG00000255397.1	AC022182.2	-6.03	3.33e-09	0.00405	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr8:60937705~60939871:-
THCA	trans	rs1707322	1	rs6695421	ENSG00000255397.1	AC022182.2	-6.03	3.33e-09	0.00405	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr8:60937705~60939871:-
THCA	trans	rs6601327	0.641	rs12542457	ENSG00000253893.2	FAM85B	6.03	3.33e-09	0.00405	0.33	0.27	Multiple myeloma (hyperdiploidy);	chr8:9707090	chr8:8167819~8226614:-
THCA	trans	rs6087990	0.871	rs4911252	ENSG00000253915.1	MAPRE1P1	-6.03	3.34e-09	0.00406	-0.34	-0.27	Ulcerative colitis;	chr20:32742309	chr8:135625185~135625981:-
THCA	trans	rs7200543	1	rs35574015	ENSG00000250569.1	NTAN1P2	6.03	3.34e-09	0.00407	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr8:86481754~86483002:-
THCA	trans	rs2980439	0.807	rs2980438	ENSG00000256560.1	LINC01486	6.03	3.37e-09	0.0041	0.31	0.27	Neuroticism;	chr8:8237303	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.775	rs34094119	ENSG00000256560.1	LINC01486	-6.03	3.4e-09	0.00413	-0.32	-0.27	Triglycerides;	chr8:11078388	chr12:109354083~109359488:-
THCA	trans	rs3764796	0.582	rs67526723	ENSG00000250030.2	RP11-584P21.4	6.03	3.4e-09	0.00414	0.52	0.27	Calcium levels;	chr8:17327142	chr4:67446267~67446574:+
THCA	trans	rs7824557	0.527	rs2572369	ENSG00000256560.1	LINC01486	-6.03	3.41e-09	0.00414	-0.33	-0.27	Retinal vascular caliber;	chr8:11381088	chr12:109354083~109359488:-
THCA	trans	rs7113874	0.569	rs9300091	ENSG00000266891.1	RP11-692N5.2	6.02	3.43e-09	0.00416	0.35	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8567276	chr18:9734882~9735602:-
THCA	trans	rs9329221	0.505	rs7840347	ENSG00000253893.2	FAM85B	6.02	3.43e-09	0.00416	0.38	0.27	Neuroticism;	chr8:10214840	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.775	rs11773990	ENSG00000256560.1	LINC01486	-6.02	3.43e-09	0.00416	-0.32	-0.27	Triglycerides;	chr8:11077572	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.775	rs4545055	ENSG00000256560.1	LINC01486	-6.02	3.43e-09	0.00416	-0.32	-0.27	Triglycerides;	chr8:11077856	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.775	rs2898257	ENSG00000256560.1	LINC01486	-6.02	3.43e-09	0.00416	-0.32	-0.27	Triglycerides;	chr8:11077858	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.711	rs4841051	ENSG00000229857.1	RP11-159H20.3	6.02	3.43e-09	0.00416	0.33	0.27	Mood instability;	chr8:8828136	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.68	rs10042455	ENSG00000231752.4	EMBP1	-6.02	3.45e-09	0.00419	-0.37	-0.27	Breast cancer;	chr5:44924916	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs10039866	ENSG00000231752.4	EMBP1	-6.02	3.45e-09	0.00419	-0.37	-0.27	Breast cancer;	chr5:44924959	chr1:121519112~121571892:+
THCA	trans	rs9467711	1	rs6903015	ENSG00000176998.4	HCG4	-6.02	3.45e-09	0.00419	-0.47	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26322298	chr6:29791753~29792750:-
THCA	trans	rs9467711	1	rs6908156	ENSG00000176998.4	HCG4	-6.02	3.45e-09	0.00419	-0.47	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26322633	chr6:29791753~29792750:-
THCA	trans	rs9467711	1	rs9467707	ENSG00000176998.4	HCG4	-6.02	3.45e-09	0.00419	-0.47	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26327677	chr6:29791753~29792750:-
THCA	trans	rs9467711	1	rs9467708	ENSG00000176998.4	HCG4	-6.02	3.45e-09	0.00419	-0.47	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26327728	chr6:29791753~29792750:-
THCA	trans	rs1432133	0.844	rs12899579	ENSG00000225200.2	AB019441.29	-6.02	3.46e-09	0.00421	-0.22	-0.27	Hepatitis;	chr15:26979174	chr14:105978520~105979146:-
THCA	trans	rs7824557	0.527	rs4634600	ENSG00000256560.1	LINC01486	-6.02	3.47e-09	0.00421	-0.32	-0.27	Retinal vascular caliber;	chr8:11381508	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs4631425	ENSG00000256560.1	LINC01486	-6.02	3.47e-09	0.00421	-0.32	-0.27	Retinal vascular caliber;	chr8:11381545	chr12:109354083~109359488:-
THCA	trans	rs3808502	0.585	rs4549730	ENSG00000256560.1	LINC01486	-6.02	3.47e-09	0.00421	-0.32	-0.27	Neuroticism;	chr8:11381569	chr12:109354083~109359488:-
THCA	trans	rs877636	0.847	rs2017445	ENSG00000196933.5	RPS26P11	6.02	3.47e-09	0.00421	0.55	0.27	Cognitive function;	chr12:56013288	chrX:72044545~72044892:+
THCA	trans	rs330048	0.561	rs4840401	ENSG00000256560.1	LINC01486	-6.02	3.48e-09	0.00422	-0.34	-0.27	Systemic lupus erythematosus;	chr8:9290615	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs73106451	ENSG00000220378.3	KRT8P42	-6.02	3.48e-09	0.00422	-0.57	-0.27	Prostate cancer;	chr12:52872955	chr6:134296997~134298695:-
THCA	trans	rs9393777	0.778	rs66841633	ENSG00000204338.7	CYP21A1P	-6.02	3.48e-09	0.00423	-0.54	-0.27	Intelligence (multi-trait analysis);	chr6:27414607	chr6:32005636~32008451:+
THCA	trans	rs6885307	1	rs10434610	ENSG00000231752.4	EMBP1	6.02	3.49e-09	0.00424	0.41	0.27	Age at first birth;	chr5:45083372	chr1:121519112~121571892:+
THCA	trans	rs12682352	0.715	rs332039	ENSG00000256560.1	LINC01486	6.02	3.49e-09	0.00424	0.33	0.27	Neuroticism;	chr8:8866141	chr12:109354083~109359488:-
THCA	trans	rs9616064	0.506	rs6008944	ENSG00000258384.1	AC068831.6	6.02	3.5e-09	0.00425	0.32	0.27	Urate levels in obese individuals;	chr22:46665079	chr15:90952239~90955225:-
THCA	trans	rs1908814	0.516	rs7812563	ENSG00000254153.1	CTA-398F10.2	-6.02	3.51e-09	0.00426	-0.3	-0.27	Neuroticism;	chr8:11936979	chr8:8456909~8461337:-
THCA	trans	rs9329221	0.905	rs17709397	ENSG00000254153.1	CTA-398F10.2	6.02	3.52e-09	0.00426	0.29	0.27	Neuroticism;	chr8:10392351	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.715	rs2409727	ENSG00000254153.1	CTA-398F10.2	6.02	3.52e-09	0.00426	0.3	0.27	Triglycerides;	chr8:11185727	chr8:8456909~8461337:-
THCA	trans	rs889398	0.617	rs55887947	ENSG00000196796.5	CTB-134H23.2	6.02	3.54e-09	0.00429	0.3	0.27	Body mass index;	chr16:69859440	chr16:29038655~29052726:+
THCA	trans	rs9329221	0.905	rs4841329	ENSG00000254153.1	CTA-398F10.2	6.02	3.56e-09	0.00431	0.29	0.27	Neuroticism;	chr8:10395588	chr8:8456909~8461337:-
THCA	trans	rs7200543	1	rs72774845	ENSG00000250569.1	NTAN1P2	6.02	3.56e-09	0.00432	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr8:86481754~86483002:-
THCA	trans	rs8014204	0.935	rs3742786	ENSG00000181227.3	RP4-682C21.2	6.02	3.56e-09	0.00432	0.21	0.27	Caffeine consumption;	chr14:74906308	chr1:75743423~75744776:-
THCA	trans	rs7192380	0.639	rs12448486	ENSG00000196796.5	CTB-134H23.2	-6.02	3.56e-09	0.00432	-0.32	-0.27	Sjögren's syndrome;	chr16:69768975	chr16:29038655~29052726:+
THCA	trans	rs1962073	0.667	rs11250004	ENSG00000253893.2	FAM85B	6.02	3.57e-09	0.00433	0.35	0.27	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10413448	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.698	rs12547997	ENSG00000253893.2	FAM85B	-6.02	3.57e-09	0.00433	-0.36	-0.27	Neuroticism;	chr8:10403327	chr8:8167819~8226614:-
THCA	trans	rs6831352	0.819	rs1230155	ENSG00000228407.2	RP4-800M22.1	-6.02	3.58e-09	0.00434	-0.36	-0.27	Alcohol dependence;	chr4:99068108	chr1:52160261~52160600:-
THCA	trans	rs8014204	0.935	rs1799900	ENSG00000181227.3	RP4-682C21.2	6.02	3.58e-09	0.00434	0.21	0.27	Caffeine consumption;	chr14:74901037	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.935	rs2853779	ENSG00000181227.3	RP4-682C21.2	6.02	3.58e-09	0.00434	0.21	0.27	Caffeine consumption;	chr14:74901805	chr1:75743423~75744776:-
THCA	trans	rs2645424	0.671	rs2294138	ENSG00000269898.1	RP11-568J23.4	-6.02	3.58e-09	0.00434	-0.33	-0.27	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847630	chr16:85743287~85744225:+
THCA	trans	rs7819412	0.538	rs4523214	ENSG00000254153.1	CTA-398F10.2	6.02	3.6e-09	0.00436	0.3	0.27	Triglycerides;	chr8:11113263	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs10113042	ENSG00000254153.1	CTA-398F10.2	-6.02	3.6e-09	0.00436	-0.3	-0.27	Neuroticism;	chr8:11935669	chr8:8456909~8461337:-
THCA	trans	rs804280	0.662	rs810738	ENSG00000253893.2	FAM85B	-6.02	3.61e-09	0.00438	-0.4	-0.27	Myopia (pathological);	chr8:11753697	chr8:8167819~8226614:-
THCA	trans	rs1190596	0.525	rs28607975	ENSG00000181359.5	HSP90AA6P	-6.01	3.63e-09	0.0044	-0.39	-0.27	Behavioural disinhibition (generation interaction);	chr14:102252082	chr4:170581470~170605450:-
THCA	trans	rs1190596	0.525	rs3783372	ENSG00000181359.5	HSP90AA6P	-6.01	3.63e-09	0.0044	-0.39	-0.27	Behavioural disinhibition (generation interaction);	chr14:102253283	chr4:170581470~170605450:-
THCA	trans	rs1190596	0.525	rs10145478	ENSG00000181359.5	HSP90AA6P	-6.01	3.63e-09	0.0044	-0.39	-0.27	Behavioural disinhibition (generation interaction);	chr14:102254559	chr4:170581470~170605450:-
THCA	trans	rs7113874	0.655	rs7945659	ENSG00000266891.1	RP11-692N5.2	6.01	3.63e-09	0.0044	0.33	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508378	chr18:9734882~9735602:-
THCA	trans	rs7192380	0.639	rs7186296	ENSG00000196796.5	CTB-134H23.2	-6.01	3.64e-09	0.00441	-0.32	-0.27	Sjögren's syndrome;	chr16:69775095	chr16:29038655~29052726:+
THCA	trans	rs12472274	0.617	rs7568705	ENSG00000224699.7	LAMTOR5-AS1	-6.01	3.64e-09	0.00441	-0.22	-0.27	Phospholipid levels (plasma);	chr2:238173167	chr1:110347116~110443817:+
THCA	trans	rs889398	0.594	rs7202233	ENSG00000196796.5	CTB-134H23.2	6.01	3.65e-09	0.00443	0.3	0.27	Body mass index;	chr16:69860529	chr16:29038655~29052726:+
THCA	trans	rs7829975	0.6	rs1719381	ENSG00000256560.1	LINC01486	-6.01	3.66e-09	0.00443	-0.32	-0.27	Mood instability;	chr8:8744834	chr12:109354083~109359488:-
THCA	trans	rs853679	0.607	rs35749575	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28147040	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs72846780	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28151277	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13205911	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28156336	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13197176	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28161454	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13201308	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28162311	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34765154	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28162672	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs34505829	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28165461	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs35098436	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28166443	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs72846794	ENSG00000228022.4	HCG20	-6.01	3.66e-09	0.00443	-0.68	-0.27	Depression;	chr6:28169721	chr6:30766825~30792250:+
THCA	trans	rs4415084	0.834	rs11746980	ENSG00000231752.4	EMBP1	6.01	3.69e-09	0.00447	0.36	0.27	Breast cancer;	chr5:44777776	chr1:121519112~121571892:+
THCA	trans	rs335206	0.641	rs335210	ENSG00000256427.1	RP11-118B22.4	-6.01	3.69e-09	0.00447	-0.29	-0.27	QRS duration;	chr5:123166170	chr12:9246497~9257960:+
THCA	trans	rs7833986	0.501	rs2668007	ENSG00000236862.1	RPS20P24	6.01	3.69e-09	0.00447	0.42	0.27	Height;	chr8:56031552	chr9:72655832~72656192:-
THCA	trans	rs2288327	0.591	rs2255167	ENSG00000269800.1	PLEKHA3P1	6.01	3.71e-09	0.00449	0.34	0.27	Atrial fibrillation;	chr2:178693555	chr19:41521043~41521989:-
THCA	trans	rs11992162	0.967	rs10088415	ENSG00000229857.1	RP11-159H20.3	6.01	3.71e-09	0.00449	0.34	0.27	Monocyte count;	chr8:11973316	chr9:76992099~76993108:+
THCA	trans	rs9467711	1	rs6939799	ENSG00000176998.4	HCG4	-6.01	3.71e-09	0.00449	-0.47	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26328138	chr6:29791753~29792750:-
THCA	trans	rs9467711	1	rs34569761	ENSG00000176998.4	HCG4	-6.01	3.71e-09	0.00449	-0.47	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26334078	chr6:29791753~29792750:-
THCA	trans	rs6885307	1	rs6889445	ENSG00000231752.4	EMBP1	6.01	3.72e-09	0.0045	0.42	0.27	Age at first birth;	chr5:44989465	chr1:121519112~121571892:+
THCA	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-6.01	3.72e-09	0.0045	-0.38	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
THCA	trans	rs8014204	0.967	rs1319171	ENSG00000181227.3	RP4-682C21.2	6.01	3.72e-09	0.0045	0.21	0.27	Caffeine consumption;	chr14:74867393	chr1:75743423~75744776:-
THCA	trans	rs8014204	1	rs4553560	ENSG00000181227.3	RP4-682C21.2	6.01	3.72e-09	0.0045	0.21	0.27	Caffeine consumption;	chr14:74867496	chr1:75743423~75744776:-
THCA	trans	rs853679	0.607	rs66886492	ENSG00000204338.7	CYP21A1P	-6.01	3.73e-09	0.00451	-0.61	-0.27	Depression;	chr6:28121953	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs35345226	ENSG00000204338.7	CYP21A1P	-6.01	3.73e-09	0.00451	-0.61	-0.27	Depression;	chr6:28123802	chr6:32005636~32008451:+
THCA	trans	rs616147	0.816	rs1768190	ENSG00000243904.1	RP11-600F24.1	6.01	3.74e-09	0.00453	0.34	0.27	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr14:103374033~103374916:-
THCA	trans	rs7701967	0.697	rs11948761	ENSG00000237714.1	P4HA2-AS1	-6.01	3.75e-09	0.00454	-0.39	-0.27	Itch intensity from mosquito bite;Mosquito bite size;Itch intensity from mosquito bite adjusted by bite size;	chr5:131035277	chr5:132184876~132192808:+
THCA	trans	rs8014204	0.839	rs6574197	ENSG00000181227.3	RP4-682C21.2	6.01	3.76e-09	0.00454	0.21	0.27	Caffeine consumption;	chr14:74864784	chr1:75743423~75744776:-
THCA	trans	rs7520050	0.778	rs3014238	ENSG00000255397.1	AC022182.2	6.01	3.76e-09	0.00455	0.35	0.27	Reticulocyte count;Red blood cell count;	chr1:45624542	chr8:60937705~60939871:-
THCA	trans	rs930395	0.514	rs4360054	ENSG00000231752.4	EMBP1	-6.01	3.78e-09	0.00457	-0.37	-0.27	Breast cancer;	chr5:44928902	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.602	rs7839053	ENSG00000253893.2	FAM85B	-6.01	3.79e-09	0.00458	-0.35	-0.27	Retinal vascular caliber;	chr8:11349922	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.602	rs10110557	ENSG00000253893.2	FAM85B	-6.01	3.79e-09	0.00458	-0.35	-0.27	Retinal vascular caliber;	chr8:11349999	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs11211217	ENSG00000255397.1	AC022182.2	-6.01	3.79e-09	0.00458	-0.37	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr8:60937705~60939871:-
THCA	trans	rs7709909	0.686	rs6151617	ENSG00000188985.6	DHFRP1	6.01	3.79e-09	0.00458	0.31	0.27	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80665824	chr18:26170726~26171284:-
THCA	trans	rs7709909	0.755	rs2081853	ENSG00000188985.6	DHFRP1	6.01	3.79e-09	0.00458	0.31	0.27	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80668530	chr18:26170726~26171284:-
THCA	trans	rs3808502	0.563	rs12549144	ENSG00000229857.1	RP11-159H20.3	-6.01	3.8e-09	0.00459	-0.34	-0.27	Neuroticism;	chr8:11565352	chr9:76992099~76993108:+
THCA	trans	rs1908814	0.516	rs10113062	ENSG00000254153.1	CTA-398F10.2	-6.01	3.81e-09	0.0046	-0.3	-0.27	Neuroticism;	chr8:11935740	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs10113145	ENSG00000254153.1	CTA-398F10.2	-6.01	3.81e-09	0.0046	-0.3	-0.27	Neuroticism;	chr8:11935786	chr8:8456909~8461337:-
THCA	trans	rs902774	0.818	rs56207534	ENSG00000250539.1	KRT8P33	-6.01	3.81e-09	0.00461	-0.5	-0.27	Prostate cancer;	chr12:52873525	chr5:123400922~123402344:-
THCA	trans	rs7212590	0.748	rs8074843	ENSG00000187870.7	RNFT1P3	6.01	3.81e-09	0.00461	0.53	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59858574	chr17:20743333~20754501:-
THCA	trans	rs7212590	0.748	rs7223057	ENSG00000187870.7	RNFT1P3	6.01	3.81e-09	0.00461	0.53	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59859077	chr17:20743333~20754501:-
THCA	trans	rs7824557	0.544	rs1865521	ENSG00000254153.1	CTA-398F10.2	-6.01	3.83e-09	0.00462	-0.3	-0.27	Retinal vascular caliber;	chr8:11373740	chr8:8456909~8461337:-
THCA	trans	rs7826238	0.517	rs35144760	ENSG00000229857.1	RP11-159H20.3	6.01	3.83e-09	0.00463	0.38	0.27	Systolic blood pressure;	chr8:8504213	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.602	rs10096194	ENSG00000253893.2	FAM85B	-6	3.84e-09	0.00463	-0.35	-0.27	Retinal vascular caliber;	chr8:11350163	chr8:8167819~8226614:-
THCA	trans	rs7709909	0.72	rs6151603	ENSG00000188985.6	DHFRP1	6	3.84e-09	0.00464	0.31	0.27	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80664309	chr18:26170726~26171284:-
THCA	trans	rs9899728	0.706	rs9895516	ENSG00000234925.2	ATP5HP4	6	3.85e-09	0.00464	0.56	0.27	Alzheimer's disease or small vessel stroke;	chr17:75024422	chr12:68642519~68642993:-
THCA	trans	rs864643	0.898	rs530080	ENSG00000183298.5	RP11-556K13.1	6	3.85e-09	0.00465	0.45	0.27	Attention deficit hyperactivity disorder;	chr3:39547507	chr1:101786340~101787219:-
THCA	trans	rs7829975	0.711	rs1039916	ENSG00000229857.1	RP11-159H20.3	-6	3.85e-09	0.00465	-0.33	-0.27	Mood instability;	chr8:8828344	chr9:76992099~76993108:+
THCA	trans	rs73110464	0.591	rs11829997	ENSG00000254285.3	KRT8P3	-6	3.85e-09	0.00465	-0.65	-0.27	Cancer (pleiotropy);	chr12:52921875	chr8:61578220~61579668:+
THCA	trans	rs4929949	0.932	rs10840087	ENSG00000266891.1	RP11-692N5.2	-6	3.86e-09	0.00466	-0.35	-0.27	Body mass index;	chr11:8594708	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.55	rs11042002	ENSG00000266891.1	RP11-692N5.2	-6	3.86e-09	0.00466	-0.35	-0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8595099	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.569	rs10769924	ENSG00000266891.1	RP11-692N5.2	-6	3.86e-09	0.00466	-0.35	-0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8601646	chr18:9734882~9735602:-
THCA	trans	rs7769051	1	rs12204027	ENSG00000213303.3	CTC-398G3.2	6	3.86e-09	0.00467	0.48	0.27	Type 2 diabetes nephropathy;	chr6:132801692	chr19:11523436~11523831:+
THCA	trans	rs7769051	1	rs9493444	ENSG00000213303.3	CTC-398G3.2	6	3.86e-09	0.00467	0.48	0.27	Type 2 diabetes nephropathy;	chr6:132804181	chr19:11523436~11523831:+
THCA	trans	rs453301	0.686	rs17702602	ENSG00000229857.1	RP11-159H20.3	6	3.87e-09	0.00467	0.33	0.27	Joint mobility (Beighton score);	chr8:9051086	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.834	rs7716571	ENSG00000231752.4	EMBP1	6	3.87e-09	0.00467	0.36	0.27	Breast cancer;	chr5:44816882	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.707	rs11250076	ENSG00000229857.1	RP11-159H20.3	6	3.89e-09	0.0047	0.33	0.27	Neuroticism;	chr8:10790313	chr9:76992099~76993108:+
THCA	trans	rs6885307	0.941	rs4389695	ENSG00000231752.4	EMBP1	6	3.9e-09	0.0047	0.43	0.27	Age at first birth;	chr5:45071809	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.941	rs62369902	ENSG00000231752.4	EMBP1	6	3.9e-09	0.0047	0.43	0.27	Age at first birth;	chr5:45082798	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.941	rs12514910	ENSG00000231752.4	EMBP1	6	3.9e-09	0.0047	0.43	0.27	Age at first birth;	chr5:45082940	chr1:121519112~121571892:+
THCA	trans	rs6885307	0.941	rs12520150	ENSG00000231752.4	EMBP1	6	3.9e-09	0.0047	0.43	0.27	Age at first birth;	chr5:45083004	chr1:121519112~121571892:+
THCA	trans	rs6601327	0.632	rs6980595	ENSG00000253893.2	FAM85B	6	3.9e-09	0.00471	0.34	0.27	Multiple myeloma (hyperdiploidy);	chr8:9793652	chr8:8167819~8226614:-
THCA	trans	rs4415084	0.834	rs7711697	ENSG00000231752.4	EMBP1	6	3.9e-09	0.00471	0.36	0.27	Breast cancer;	chr5:44780301	chr1:121519112~121571892:+
THCA	trans	rs889398	0.617	rs3790083	ENSG00000196796.5	CTB-134H23.2	-6	3.91e-09	0.00472	-0.3	-0.27	Body mass index;	chr16:69861383	chr16:29038655~29052726:+
THCA	trans	rs7829975	0.714	rs12544992	ENSG00000256560.1	LINC01486	6	3.92e-09	0.00472	0.31	0.27	Mood instability;	chr8:8804171	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.713	rs9286062	ENSG00000229857.1	RP11-159H20.3	6	3.92e-09	0.00473	0.32	0.27	Retinal vascular caliber;	chr8:11261018	chr9:76992099~76993108:+
THCA	trans	rs10435719	0.509	rs13248956	ENSG00000254153.1	CTA-398F10.2	-6	3.92e-09	0.00473	-0.31	-0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932259	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.528	rs13250020	ENSG00000254153.1	CTA-398F10.2	-6	3.92e-09	0.00473	-0.31	-0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932260	chr8:8456909~8461337:-
THCA	trans	rs1707322	0.638	rs1707302	ENSG00000255397.1	AC022182.2	6	3.92e-09	0.00473	0.38	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr8:60937705~60939871:-
THCA	trans	rs9329221	0.935	rs3750311	ENSG00000229857.1	RP11-159H20.3	6	3.94e-09	0.00475	0.34	0.27	Neuroticism;	chr8:10426092	chr9:76992099~76993108:+
THCA	trans	rs8014204	1	rs8014374	ENSG00000181227.3	RP4-682C21.2	6	3.94e-09	0.00475	0.21	0.27	Caffeine consumption;	chr14:74856211	chr1:75743423~75744776:-
THCA	trans	rs34421088	0.576	rs2572437	ENSG00000256560.1	LINC01486	-6	3.95e-09	0.00477	-0.36	-0.27	Neuroticism;	chr8:11240932	chr12:109354083~109359488:-
THCA	trans	rs62344088	0.59	rs7700533	ENSG00000185986.11	SDHAP3	6	3.96e-09	0.00477	0.44	0.27	Asthma (childhood onset);	chr5:180531	chr5:1572222~1594620:-
THCA	trans	rs16957091	0.909	rs9919994	ENSG00000259781.1	RP11-673C5.1	-6	3.97e-09	0.00478	-0.35	-0.27	MGMT methylation in smokers;	chr15:42719339	chr15:71164770~71165415:-
THCA	trans	rs7819412	0.521	rs11777887	ENSG00000229857.1	RP11-159H20.3	-6	3.97e-09	0.00479	-0.36	-0.27	Triglycerides;	chr8:11179290	chr9:76992099~76993108:+
THCA	trans	rs10816533	1	rs12236125	ENSG00000232063.1	RP11-307E17.8	6	3.97e-09	0.00479	0.65	0.27	Height;	chr9:96821186	chr9:94332476~94360948:+
THCA	trans	rs853679	0.769	rs7752448	ENSG00000204338.7	CYP21A1P	-6	3.97e-09	0.00479	-0.48	-0.27	Depression;	chr6:28333322	chr6:32005636~32008451:+
THCA	trans	rs930395	0.514	rs11951760	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.0048	-0.37	-0.27	Breast cancer;	chr5:44872070	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs6874167	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44916572	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs4866921	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44917035	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs6451783	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44918191	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs6871820	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44919455	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs7736092	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44920893	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs10941687	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44921081	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs7708506	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44922602	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs7708686	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44922736	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs13153556	ENSG00000231752.4	EMBP1	-6	3.99e-09	0.00481	-0.37	-0.27	Breast cancer;	chr5:44927999	chr1:121519112~121571892:+
THCA	trans	rs7829975	0.711	rs12682352	ENSG00000229857.1	RP11-159H20.3	-6	3.99e-09	0.00481	-0.33	-0.27	Mood instability;	chr8:8788736	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.668	rs4841507	ENSG00000229857.1	RP11-159H20.3	6	4e-09	0.00482	0.35	0.27	Triglycerides;	chr8:11188885	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.775	rs2001329	ENSG00000254153.1	CTA-398F10.2	6	4e-09	0.00482	0.3	0.27	Triglycerides;	chr8:11129349	chr8:8456909~8461337:-
THCA	trans	rs453301	0.606	rs6601279	ENSG00000229857.1	RP11-159H20.3	6	4.01e-09	0.00482	0.33	0.27	Joint mobility (Beighton score);	chr8:9050721	chr9:76992099~76993108:+
THCA	trans	rs453301	0.606	rs6981060	ENSG00000229857.1	RP11-159H20.3	6	4.01e-09	0.00482	0.33	0.27	Joint mobility (Beighton score);	chr8:9050725	chr9:76992099~76993108:+
THCA	trans	rs9467711	0.659	rs36162392	ENSG00000280107.1	AL022393.9	-6	4.01e-09	0.00483	-0.5	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr6:28170845~28172521:+
THCA	trans	rs4879677	1	rs7859172	ENSG00000269560.1	CTD-2192J16.21	-6	4.02e-09	0.00484	-0.34	-0.27	Gut microbiome composition (summer and winter);	chr9:27659388	chr19:12529768~12532973:-
THCA	trans	rs4295623	0.559	rs4841600	ENSG00000260438.1	RP11-405F3.2	-6	4.02e-09	0.00484	-0.37	-0.27	Morning vs. evening chronotype;	chr8:11830639	chr16:57713782~57714957:+
THCA	trans	rs4879677	0.878	rs12238699	ENSG00000269560.1	CTD-2192J16.21	-6	4.04e-09	0.00487	-0.34	-0.27	Gut microbiome composition (summer and winter);	chr9:27640783	chr19:12529768~12532973:-
THCA	trans	rs9329221	0.521	rs4841294	ENSG00000229857.1	RP11-159H20.3	6	4.05e-09	0.00488	0.34	0.27	Neuroticism;	chr8:10247558	chr9:76992099~76993108:+
THCA	trans	rs453301	0.597	rs7001187	ENSG00000229857.1	RP11-159H20.3	5.99	4.06e-09	0.00489	0.35	0.27	Joint mobility (Beighton score);	chr8:8935272	chr9:76992099~76993108:+
THCA	trans	rs4936894	0.5	rs7107539	ENSG00000196933.5	RPS26P11	5.99	4.06e-09	0.00489	0.34	0.27	Aging (time to death);	chr11:124310386	chrX:72044545~72044892:+
THCA	trans	rs7819412	0.745	rs4841498	ENSG00000254153.1	CTA-398F10.2	5.99	4.07e-09	0.0049	0.3	0.27	Triglycerides;	chr8:11127922	chr8:8456909~8461337:-
THCA	trans	rs616147	1	rs616147	ENSG00000243904.1	RP11-600F24.1	-5.99	4.08e-09	0.00491	-0.34	-0.27	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr14:103374033~103374916:-
THCA	trans	rs12477438	0.501	rs7349217	ENSG00000276576.1	MRPL30P1	5.99	4.08e-09	0.00491	0.35	0.27	Chronic sinus infection;	chr2:99198683	chr6:57029521~57029988:+
THCA	trans	rs9650657	0.617	rs7814795	ENSG00000229857.1	RP11-159H20.3	5.99	4.09e-09	0.00492	0.32	0.27	Neuroticism;	chr8:10661775	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.818	rs11989439	ENSG00000254153.1	CTA-398F10.2	5.99	4.1e-09	0.00493	0.3	0.27	Triglycerides;	chr8:11198088	chr8:8456909~8461337:-
THCA	trans	rs7212590	0.748	rs62081818	ENSG00000187870.7	RNFT1P3	5.99	4.11e-09	0.00494	0.53	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59813268	chr17:20743333~20754501:-
THCA	trans	rs7212590	0.748	rs59685433	ENSG00000187870.7	RNFT1P3	5.99	4.11e-09	0.00494	0.53	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59813846	chr17:20743333~20754501:-
THCA	trans	rs2980439	0.556	rs2921059	ENSG00000229857.1	RP11-159H20.3	-5.99	4.12e-09	0.00496	-0.33	-0.27	Neuroticism;	chr8:8460377	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.967	rs10108320	ENSG00000254153.1	CTA-398F10.2	5.99	4.12e-09	0.00496	0.3	0.27	Monocyte count;	chr8:11974754	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.583	rs2736292	ENSG00000254153.1	CTA-398F10.2	-5.99	4.13e-09	0.00496	-0.3	-0.27	Retinal vascular caliber;	chr8:11376991	chr8:8456909~8461337:-
THCA	trans	rs804280	0.542	rs36100659	ENSG00000254153.1	CTA-398F10.2	-5.99	4.13e-09	0.00496	-0.31	-0.27	Myopia (pathological);	chr8:11934144	chr8:8456909~8461337:-
THCA	trans	rs1432133	0.844	rs12899579	ENSG00000239253.1	RPS4XP23	5.99	4.13e-09	0.00497	0.39	0.27	Hepatitis;	chr15:26979174	chr19:34021659~34021895:+
THCA	trans	rs7212590	0.748	rs7211208	ENSG00000187870.7	RNFT1P3	5.99	4.14e-09	0.00497	0.53	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59879748	chr17:20743333~20754501:-
THCA	trans	rs7212590	0.655	rs8070039	ENSG00000187870.7	RNFT1P3	5.99	4.14e-09	0.00497	0.53	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59896224	chr17:20743333~20754501:-
THCA	trans	rs7212590	0.655	rs56198517	ENSG00000187870.7	RNFT1P3	5.99	4.14e-09	0.00497	0.53	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59899221	chr17:20743333~20754501:-
THCA	trans	rs7824557	0.564	rs2572389	ENSG00000256560.1	LINC01486	-5.99	4.14e-09	0.00498	-0.33	-0.27	Retinal vascular caliber;	chr8:11378883	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs2736301	ENSG00000256560.1	LINC01486	-5.99	4.14e-09	0.00498	-0.33	-0.27	Retinal vascular caliber;	chr8:11378904	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs2736302	ENSG00000256560.1	LINC01486	-5.99	4.14e-09	0.00498	-0.33	-0.27	Retinal vascular caliber;	chr8:11378910	chr12:109354083~109359488:-
THCA	trans	rs3808502	0.647	rs7821302	ENSG00000256560.1	LINC01486	-5.99	4.14e-09	0.00498	-0.33	-0.27	Neuroticism;	chr8:11379063	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs7821459	ENSG00000256560.1	LINC01486	-5.99	4.14e-09	0.00498	-0.33	-0.27	Retinal vascular caliber;	chr8:11379172	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs7834572	ENSG00000256560.1	LINC01486	-5.99	4.14e-09	0.00498	-0.33	-0.27	Retinal vascular caliber;	chr8:11379176	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs4631424	ENSG00000256560.1	LINC01486	-5.99	4.14e-09	0.00498	-0.33	-0.27	Retinal vascular caliber;	chr8:11379300	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.967	rs7461062	ENSG00000254153.1	CTA-398F10.2	-5.99	4.14e-09	0.00498	-0.3	-0.27	Monocyte count;	chr8:11974439	chr8:8456909~8461337:-
THCA	trans	rs877636	0.702	rs773108	ENSG00000233278.1	RPS26P2	5.99	4.15e-09	0.00498	0.33	0.27	Cognitive function;	chr12:55976127	chr9:30831878~30832225:-
THCA	trans	rs9693857	0.553	rs10100760	ENSG00000253893.2	FAM85B	5.99	4.15e-09	0.00499	0.33	0.27	Systolic blood pressure;	chr8:9513049	chr8:8167819~8226614:-
THCA	trans	rs4295623	0.504	rs11250160	ENSG00000256560.1	LINC01486	-5.99	4.16e-09	0.005	-0.31	-0.27	Morning vs. evening chronotype;	chr8:11735208	chr12:109354083~109359488:-
THCA	trans	rs6885307	0.941	rs76631775	ENSG00000231752.4	EMBP1	5.99	4.16e-09	0.005	0.43	0.27	Age at first birth;	chr5:45036903	chr1:121519112~121571892:+
THCA	trans	rs11671005	0.779	rs731259	ENSG00000279267.1	RP11-395L14.18	5.99	4.16e-09	0.005	0.4	0.27	Mean platelet volume;	chr19:58478057	chr2:113605867~113607908:-
THCA	trans	rs7824557	0.569	rs7816601	ENSG00000253893.2	FAM85B	-5.99	4.18e-09	0.00502	-0.35	-0.27	Retinal vascular caliber;	chr8:11348084	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.602	rs7816636	ENSG00000253893.2	FAM85B	-5.99	4.18e-09	0.00502	-0.35	-0.27	Retinal vascular caliber;	chr8:11348145	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.602	rs7828711	ENSG00000253893.2	FAM85B	-5.99	4.18e-09	0.00502	-0.35	-0.27	Retinal vascular caliber;	chr8:11348156	chr8:8167819~8226614:-
THCA	trans	rs4415084	0.834	rs13160259	ENSG00000231752.4	EMBP1	5.99	4.2e-09	0.00504	0.36	0.27	Breast cancer;	chr5:44828862	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs11831919	ENSG00000230716.3	KRT8P7	-5.99	4.2e-09	0.00505	-0.55	-0.27	Prostate cancer;	chr12:52878231	chr11:119602875~119604306:-
THCA	trans	rs6601327	0.665	rs9286060	ENSG00000253893.2	FAM85B	5.99	4.2e-09	0.00505	0.35	0.27	Multiple myeloma (hyperdiploidy);	chr8:9795635	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.665	rs10107992	ENSG00000253893.2	FAM85B	5.99	4.2e-09	0.00505	0.35	0.27	Multiple myeloma (hyperdiploidy);	chr8:9795777	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.665	rs4841218	ENSG00000253893.2	FAM85B	5.99	4.2e-09	0.00505	0.35	0.27	Multiple myeloma (hyperdiploidy);	chr8:9796392	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.933	rs10108075	ENSG00000254153.1	CTA-398F10.2	-5.99	4.22e-09	0.00507	-0.3	-0.27	Monocyte count;	chr8:11974570	chr8:8456909~8461337:-
THCA	trans	rs7809615	0.515	rs11772470	ENSG00000228834.1	RP11-249L21.4	5.99	4.24e-09	0.0051	0.42	0.27	Blood metabolite ratios;	chr7:99583473	chr6:108907615~108907873:-
THCA	trans	rs13016963	0.604	rs12612166	ENSG00000235105.1	RP11-329A14.1	5.99	4.25e-09	0.0051	0.3	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201314035	chr1:48435967~48437223:+
THCA	trans	rs4415084	0.716	rs4395640	ENSG00000231752.4	EMBP1	-5.99	4.26e-09	0.00511	-0.37	-0.27	Breast cancer;	chr5:44868998	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.652	rs10059086	ENSG00000231752.4	EMBP1	-5.99	4.26e-09	0.00511	-0.37	-0.27	Breast cancer;	chr5:44871905	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs4866783	ENSG00000231752.4	EMBP1	-5.99	4.26e-09	0.00511	-0.37	-0.27	Breast cancer;	chr5:44876405	chr1:121519112~121571892:+
THCA	trans	rs7746199	0.736	rs13195636	ENSG00000228022.4	HCG20	-5.99	4.26e-09	0.00511	-0.68	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:30766825~30792250:+
THCA	trans	rs453301	0.686	rs3989373	ENSG00000256560.1	LINC01486	-5.99	4.26e-09	0.00511	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9053798	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.545	rs2572380	ENSG00000256560.1	LINC01486	-5.99	4.26e-09	0.00512	-0.33	-0.27	Retinal vascular caliber;	chr8:11379968	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.51	rs4841524	ENSG00000256560.1	LINC01486	-5.99	4.27e-09	0.00512	-0.33	-0.27	Retinal vascular caliber;	chr8:11385617	chr12:109354083~109359488:-
THCA	trans	rs3812762	0.957	rs7120004	ENSG00000266891.1	RP11-692N5.2	-5.99	4.29e-09	0.00515	-0.35	-0.27	Hypospadias;	chr11:8747550	chr18:9734882~9735602:-
THCA	trans	rs2950393	0.572	rs10783794	ENSG00000257210.1	NACAP3	-5.99	4.29e-09	0.00515	-0.31	-0.27	Platelet distribution width;	chr12:56593395	chr12:93124063~93124543:-
THCA	trans	rs75920871	0.858	rs17120197	ENSG00000279518.1	AC083843.4	5.99	4.29e-09	0.00515	0.23	0.27	Subjective well-being;	chr11:116974388	chr8:134783694~134785879:-
THCA	trans	rs1978968	0.956	rs2017932	ENSG00000258334.1	RP11-161H23.9	5.98	4.3e-09	0.00516	0.38	0.27	Presence of antiphospholipid antibodies;	chr22:17956424	chr12:49292631~49324576:-
THCA	trans	rs1978968	0.913	rs12158823	ENSG00000258334.1	RP11-161H23.9	5.98	4.3e-09	0.00516	0.38	0.27	Presence of antiphospholipid antibodies;	chr22:17956654	chr12:49292631~49324576:-
THCA	trans	rs1978968	1	rs1076539	ENSG00000258334.1	RP11-161H23.9	5.98	4.3e-09	0.00516	0.38	0.27	Presence of antiphospholipid antibodies;	chr22:17956832	chr12:49292631~49324576:-
THCA	trans	rs1978968	1	rs1076540	ENSG00000258334.1	RP11-161H23.9	5.98	4.3e-09	0.00516	0.38	0.27	Presence of antiphospholipid antibodies;	chr22:17957192	chr12:49292631~49324576:-
THCA	trans	rs9329221	0.935	rs3750310	ENSG00000229857.1	RP11-159H20.3	5.98	4.31e-09	0.00517	0.34	0.27	Neuroticism;	chr8:10425916	chr9:76992099~76993108:+
THCA	trans	rs4879656	0.872	rs10813930	ENSG00000215007.3	DNAJA1P3	5.98	4.33e-09	0.00519	0.3	0.27	Menopause (age at onset);	chr9:33064338	chrX:107351650~107352843:-
THCA	trans	rs7819412	0.74	rs28633434	ENSG00000254153.1	CTA-398F10.2	5.98	4.34e-09	0.0052	0.3	0.27	Triglycerides;	chr8:11196413	chr8:8456909~8461337:-
THCA	trans	rs9649213	0.574	rs7789440	ENSG00000225169.1	BRI3P1	5.98	4.34e-09	0.0052	0.35	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98259486	chr1:100213293~100213670:+
THCA	trans	rs7520050	0.778	rs2991985	ENSG00000255397.1	AC022182.2	5.98	4.34e-09	0.0052	0.35	0.27	Reticulocyte count;Red blood cell count;	chr1:45614858	chr8:60937705~60939871:-
THCA	trans	rs4929949	0.653	rs10840040	ENSG00000266891.1	RP11-692N5.2	5.98	4.34e-09	0.00521	0.35	0.27	Body mass index;	chr11:8419724	chr18:9734882~9735602:-
THCA	trans	rs7200543	0.583	rs4985149	ENSG00000250569.1	NTAN1P2	5.98	4.35e-09	0.00522	0.27	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr8:86481754~86483002:-
THCA	trans	rs7824557	0.527	rs2572376	ENSG00000256560.1	LINC01486	-5.98	4.36e-09	0.00523	-0.32	-0.27	Retinal vascular caliber;	chr8:11380247	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs2736305	ENSG00000256560.1	LINC01486	-5.98	4.36e-09	0.00523	-0.32	-0.27	Retinal vascular caliber;	chr8:11380264	chr12:109354083~109359488:-
THCA	trans	rs7429990	0.965	rs35199727	ENSG00000235912.1	RP1-159A19.3	-5.98	4.36e-09	0.00523	-0.35	-0.27	Educational attainment (years of education);	chr3:47905218	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.965	rs11707679	ENSG00000235912.1	RP1-159A19.3	-5.98	4.36e-09	0.00523	-0.35	-0.27	Educational attainment (years of education);	chr3:47915016	chr1:27649419~27649610:+
THCA	trans	rs9292918	0.627	rs13183247	ENSG00000231752.4	EMBP1	5.98	4.4e-09	0.00527	0.5	0.27	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45280462	chr1:121519112~121571892:+
THCA	trans	rs6981523	0.553	rs11783045	ENSG00000254153.1	CTA-398F10.2	5.98	4.41e-09	0.00528	0.31	0.27	Neuroticism;	chr8:11198666	chr8:8456909~8461337:-
THCA	trans	rs4930561	0.765	rs4930229	ENSG00000155070.8	UNC93B2	-5.98	4.41e-09	0.00528	-0.31	-0.27	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68176613	chr7:6855485~6859830:-
THCA	trans	rs7819412	0.608	rs28417109	ENSG00000254153.1	CTA-398F10.2	5.98	4.42e-09	0.00529	0.3	0.27	Triglycerides;	chr8:11117571	chr8:8456909~8461337:-
THCA	trans	rs930395	0.514	rs6880275	ENSG00000231752.4	EMBP1	-5.98	4.42e-09	0.0053	-0.37	-0.27	Breast cancer;	chr5:44908833	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs6870136	ENSG00000231752.4	EMBP1	-5.98	4.42e-09	0.0053	-0.37	-0.27	Breast cancer;	chr5:44910560	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs6881563	ENSG00000231752.4	EMBP1	-5.98	4.42e-09	0.0053	-0.37	-0.27	Breast cancer;	chr5:44912751	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.652	rs6883465	ENSG00000231752.4	EMBP1	-5.98	4.43e-09	0.00531	-0.37	-0.27	Breast cancer;	chr5:44891518	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs7734331	ENSG00000231752.4	EMBP1	-5.98	4.43e-09	0.00531	-0.37	-0.27	Breast cancer;	chr5:44895486	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs79377635	ENSG00000230716.3	KRT8P7	-5.98	4.43e-09	0.00531	-0.55	-0.27	Prostate cancer;	chr12:52883148	chr11:119602875~119604306:-
THCA	trans	rs2336384	0.929	rs2236056	ENSG00000261819.1	RP11-680G24.4	5.98	4.45e-09	0.00533	0.35	0.27	Platelet count;	chr1:11996383	chr16:14988259~14990160:-
THCA	trans	rs7819412	0.745	rs6601569	ENSG00000254153.1	CTA-398F10.2	5.98	4.46e-09	0.00535	0.3	0.27	Triglycerides;	chr8:11216069	chr8:8456909~8461337:-
THCA	trans	rs11992162	1	rs7460395	ENSG00000229857.1	RP11-159H20.3	-5.98	4.47e-09	0.00536	-0.34	-0.27	Monocyte count;	chr8:11977866	chr9:76992099~76993108:+
THCA	trans	rs6921919	0.887	rs7766356	ENSG00000228078.1	HLA-U	-5.98	4.49e-09	0.00538	-0.43	-0.27	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:29934101~29934286:+
THCA	trans	rs9329221	0.655	rs4292737	ENSG00000253893.2	FAM85B	5.98	4.49e-09	0.00538	0.35	0.27	Neuroticism;	chr8:10401605	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2572386	ENSG00000256560.1	LINC01486	-5.98	4.5e-09	0.00538	-0.33	-0.27	Retinal vascular caliber;	chr8:11379466	chr12:109354083~109359488:-
THCA	trans	rs7200543	0.89	rs4985155	ENSG00000250569.1	NTAN1P2	5.98	4.5e-09	0.00539	0.27	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15035602	chr8:86481754~86483002:-
THCA	trans	rs7824557	0.569	rs10106207	ENSG00000254153.1	CTA-398F10.2	5.98	4.5e-09	0.00539	0.3	0.27	Retinal vascular caliber;	chr8:11157828	chr8:8456909~8461337:-
THCA	trans	rs76228276	0.737	rs4735605	ENSG00000260318.1	COX6CP1	5.98	4.5e-09	0.00539	0.8	0.27	Childhood ear infection;	chr8:99195726	chr16:11903923~11904137:-
THCA	trans	rs76228276	0.737	rs79220697	ENSG00000260318.1	COX6CP1	5.98	4.5e-09	0.00539	0.8	0.27	Childhood ear infection;	chr8:99239102	chr16:11903923~11904137:-
THCA	trans	rs11098499	0.675	rs11098534	ENSG00000253326.2	RP11-261C10.7	5.98	4.52e-09	0.00541	0.36	0.27	Corneal astigmatism;	chr4:119635617	chr1:243054861~243056394:-
THCA	trans	rs9329221	0.736	rs12548025	ENSG00000253893.2	FAM85B	-5.98	4.54e-09	0.00543	-0.36	-0.27	Neuroticism;	chr8:10403411	chr8:8167819~8226614:-
THCA	trans	rs2950393	0.929	rs10876916	ENSG00000257210.1	NACAP3	5.98	4.54e-09	0.00543	0.32	0.27	Platelet distribution width;	chr12:56692728	chr12:93124063~93124543:-
THCA	trans	rs4930561	0.739	rs10896303	ENSG00000155070.8	UNC93B2	-5.97	4.56e-09	0.00546	-0.31	-0.27	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68206825	chr7:6855485~6859830:-
THCA	trans	rs4930561	0.739	rs12225316	ENSG00000155070.8	UNC93B2	-5.97	4.56e-09	0.00546	-0.31	-0.27	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68208536	chr7:6855485~6859830:-
THCA	trans	rs7746199	0.736	rs17749927	ENSG00000228022.4	HCG20	-5.97	4.56e-09	0.00546	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs13192965	ENSG00000228022.4	HCG20	-5.97	4.56e-09	0.00546	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:30766825~30792250:+
THCA	trans	rs11992162	1	rs12334769	ENSG00000254153.1	CTA-398F10.2	-5.97	4.57e-09	0.00547	-0.3	-0.27	Monocyte count;	chr8:11975652	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.807	rs10105315	ENSG00000256560.1	LINC01486	-5.97	4.59e-09	0.00549	-0.33	-0.27	Triglycerides;	chr8:11074693	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs2572448	ENSG00000256560.1	LINC01486	-5.97	4.6e-09	0.0055	-0.33	-0.27	Retinal vascular caliber;	chr8:11381843	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs2572447	ENSG00000256560.1	LINC01486	-5.97	4.6e-09	0.0055	-0.33	-0.27	Retinal vascular caliber;	chr8:11382001	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs2572446	ENSG00000256560.1	LINC01486	-5.97	4.6e-09	0.0055	-0.33	-0.27	Retinal vascular caliber;	chr8:11382056	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.527	rs10109537	ENSG00000256560.1	LINC01486	-5.97	4.6e-09	0.0055	-0.33	-0.27	Retinal vascular caliber;	chr8:11382131	chr12:109354083~109359488:-
THCA	trans	rs7200543	1	rs4500751	ENSG00000255185.4	PDXDC2P	5.97	4.6e-09	0.0055	0.37	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:70010751~70065945:-
THCA	trans	rs7829975	0.902	rs485107	ENSG00000256560.1	LINC01486	-5.97	4.61e-09	0.00551	-0.31	-0.27	Mood instability;	chr8:8723898	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.735	rs2889703	ENSG00000253915.1	MAPRE1P1	5.97	4.62e-09	0.00552	0.34	0.27	Ulcerative colitis;	chr20:32791378	chr8:135625185~135625981:-
THCA	trans	rs10435719	0.805	rs13269417	ENSG00000254153.1	CTA-398F10.2	-5.97	4.62e-09	0.00552	-0.31	-0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:8456909~8461337:-
THCA	trans	rs11098499	0.73	rs78971550	ENSG00000253326.2	RP11-261C10.7	5.97	4.63e-09	0.00553	0.36	0.27	Corneal astigmatism;	chr4:119359886	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.645	rs78422072	ENSG00000253326.2	RP11-261C10.7	5.97	4.63e-09	0.00553	0.36	0.27	Corneal astigmatism;	chr4:119359887	chr1:243054861~243056394:-
THCA	trans	rs10107145	0.509	rs4310166	ENSG00000253893.2	FAM85B	5.97	4.64e-09	0.00555	0.35	0.27	Systolic blood pressure;	chr8:10906226	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.627	rs7838897	ENSG00000253893.2	FAM85B	-5.97	4.65e-09	0.00555	-0.35	-0.27	Retinal vascular caliber;	chr8:11349817	chr8:8167819~8226614:-
THCA	trans	rs330048	0.545	rs11774353	ENSG00000229857.1	RP11-159H20.3	-5.97	4.65e-09	0.00556	-0.32	-0.27	Systemic lupus erythematosus;	chr8:9295617	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.522	rs11776603	ENSG00000254153.1	CTA-398F10.2	5.97	4.66e-09	0.00557	0.32	0.27	Triglycerides;	chr8:11162803	chr8:8456909~8461337:-
THCA	trans	rs11992162	1	rs11784499	ENSG00000254153.1	CTA-398F10.2	-5.97	4.67e-09	0.00557	-0.3	-0.27	Monocyte count;	chr8:11977030	chr8:8456909~8461337:-
THCA	trans	rs4415084	0.716	rs9637783	ENSG00000231752.4	EMBP1	5.97	4.67e-09	0.00558	0.36	0.27	Breast cancer;	chr5:44819544	chr1:121519112~121571892:+
THCA	trans	rs11250098	0.574	rs4554431	ENSG00000229857.1	RP11-159H20.3	5.97	4.68e-09	0.00559	0.31	0.27	Morning vs. evening chronotype;	chr8:10914128	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.628	rs11250129	ENSG00000253893.2	FAM85B	-5.97	4.69e-09	0.0056	-0.35	-0.27	Retinal vascular caliber;	chr8:11344645	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.582	rs2409685	ENSG00000256560.1	LINC01486	-5.97	4.7e-09	0.00561	-0.33	-0.27	Triglycerides;	chr8:11051683	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.511	rs2980512	ENSG00000256560.1	LINC01486	5.97	4.71e-09	0.00562	0.32	0.27	Mood instability;	chr8:8283379	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.665	rs1897207	ENSG00000253893.2	FAM85B	5.97	4.73e-09	0.00564	0.33	0.27	Neuroticism;	chr8:10757725	chr8:8167819~8226614:-
THCA	trans	rs4879677	1	rs10435785	ENSG00000269560.1	CTD-2192J16.21	-5.97	4.73e-09	0.00564	-0.34	-0.27	Gut microbiome composition (summer and winter);	chr9:27683815	chr19:12529768~12532973:-
THCA	trans	rs453301	0.658	rs12114954	ENSG00000229857.1	RP11-159H20.3	5.97	4.73e-09	0.00565	0.32	0.27	Joint mobility (Beighton score);	chr8:9047352	chr9:76992099~76993108:+
THCA	trans	rs2980439	0.607	rs2980419	ENSG00000229857.1	RP11-159H20.3	-5.97	4.73e-09	0.00565	-0.33	-0.27	Neuroticism;	chr8:8256619	chr9:76992099~76993108:+
THCA	trans	rs6885307	1	rs59235595	ENSG00000231752.4	EMBP1	5.97	4.73e-09	0.00565	0.41	0.27	Age at first birth;	chr5:44993055	chr1:121519112~121571892:+
THCA	trans	rs1391708	0.834	rs4759040	ENSG00000121089.4	NACA3P	5.97	4.75e-09	0.00567	0.43	0.27	Airway wall thickness;	chr12:56887746	chr4:164943290~164943937:+
THCA	trans	rs1391708	0.764	rs4759265	ENSG00000121089.4	NACA3P	5.97	4.75e-09	0.00567	0.43	0.27	Airway wall thickness;	chr12:56887788	chr4:164943290~164943937:+
THCA	trans	rs6831352	0.819	rs896992	ENSG00000228407.2	RP4-800M22.1	-5.97	4.75e-09	0.00567	-0.36	-0.27	Alcohol dependence;	chr4:99081221	chr1:52160261~52160600:-
THCA	trans	rs7819412	0.807	rs4840542	ENSG00000256560.1	LINC01486	-5.97	4.76e-09	0.00567	-0.33	-0.27	Triglycerides;	chr8:11087299	chr12:109354083~109359488:-
THCA	trans	rs9467773	0.572	rs2076029	ENSG00000242375.1	RP11-498P14.3	-5.97	4.76e-09	0.00568	-0.38	-0.27	Intelligence (multi-trait analysis);	chr6:26390602	chr9:97195351~97197687:-
THCA	trans	rs7746199	0.736	rs13209332	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs34105070	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.673	rs72845046	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs67652222	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs13212093	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs34038546	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:30766825~30792250:+
THCA	trans	rs141342723	1	rs141342723	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs34543938	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs56405707	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs13210634	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs13215275	ENSG00000228022.4	HCG20	-5.97	4.76e-09	0.00568	-0.67	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:30766825~30792250:+
THCA	trans	rs7824557	0.628	rs2572387	ENSG00000253893.2	FAM85B	-5.97	4.77e-09	0.00569	-0.35	-0.27	Retinal vascular caliber;	chr8:11346656	chr8:8167819~8226614:-
THCA	trans	rs7746199	0.736	rs13193542	ENSG00000228022.4	HCG20	-5.97	4.77e-09	0.00569	-0.68	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs13193480	ENSG00000228022.4	HCG20	-5.97	4.77e-09	0.00569	-0.68	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:30766825~30792250:+
THCA	trans	rs930395	0.514	rs34501299	ENSG00000231752.4	EMBP1	-5.97	4.77e-09	0.00569	-0.37	-0.27	Breast cancer;	chr5:44912977	chr1:121519112~121571892:+
THCA	trans	rs7192380	0.893	rs1469908	ENSG00000257513.6	NPIPB1P	-5.97	4.78e-09	0.0057	-0.29	-0.27	Sjögren's syndrome;	chr16:69730509	chr18:11619509~11639699:-
THCA	trans	rs4415084	0.652	rs4591754	ENSG00000231752.4	EMBP1	-5.97	4.78e-09	0.0057	-0.37	-0.27	Breast cancer;	chr5:44894989	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs7356604	ENSG00000231752.4	EMBP1	-5.97	4.78e-09	0.0057	-0.37	-0.27	Breast cancer;	chr5:44895097	chr1:121519112~121571892:+
THCA	trans	rs3808502	0.516	rs6983727	ENSG00000256560.1	LINC01486	5.97	4.78e-09	0.0057	0.33	0.27	Neuroticism;	chr8:11558303	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs73108469	ENSG00000230716.3	KRT8P7	-5.97	4.78e-09	0.0057	-0.55	-0.27	Prostate cancer;	chr12:52891065	chr11:119602875~119604306:-
THCA	trans	rs7819412	0.654	rs34741518	ENSG00000229857.1	RP11-159H20.3	5.97	4.79e-09	0.00571	0.32	0.27	Triglycerides;	chr8:10919350	chr9:76992099~76993108:+
THCA	trans	rs7826238	0.601	rs2976907	ENSG00000229857.1	RP11-159H20.3	-5.97	4.79e-09	0.00571	-0.34	-0.27	Systolic blood pressure;	chr8:8487658	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.537	rs1484640	ENSG00000253893.2	FAM85B	-5.97	4.8e-09	0.00572	-0.34	-0.27	Neuroticism;	chr8:10125733	chr8:8167819~8226614:-
THCA	trans	rs11250097	0.543	rs68164957	ENSG00000253893.2	FAM85B	5.97	4.81e-09	0.00574	0.36	0.27	Neuroticism;	chr8:10941979	chr8:8167819~8226614:-
THCA	trans	rs4295623	0.553	rs34962960	ENSG00000256560.1	LINC01486	-5.97	4.81e-09	0.00574	-0.33	-0.27	Morning vs. evening chronotype;	chr8:11737088	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.623	rs7004066	ENSG00000253893.2	FAM85B	5.96	4.82e-09	0.00575	0.33	0.27	Neuroticism;	chr8:10743233	chr8:8167819~8226614:-
THCA	trans	rs930395	0.514	rs4391175	ENSG00000231752.4	EMBP1	-5.96	4.83e-09	0.00576	-0.37	-0.27	Breast cancer;	chr5:44889954	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs7718354	ENSG00000231752.4	EMBP1	-5.96	4.83e-09	0.00576	-0.37	-0.27	Breast cancer;	chr5:44890912	chr1:121519112~121571892:+
THCA	trans	rs6087990	0.842	rs6119279	ENSG00000253915.1	MAPRE1P1	5.96	4.84e-09	0.00577	0.34	0.27	Ulcerative colitis;	chr20:32742806	chr8:135625185~135625981:-
THCA	trans	rs7819412	0.806	rs10113808	ENSG00000256560.1	LINC01486	-5.96	4.85e-09	0.00578	-0.32	-0.27	Triglycerides;	chr8:11069382	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.509	rs2945269	ENSG00000256560.1	LINC01486	5.96	4.87e-09	0.0058	0.31	0.27	Mood instability;	chr8:8258056	chr12:109354083~109359488:-
THCA	trans	rs9467711	0.72	rs75782365	ENSG00000228022.4	HCG20	-5.96	4.88e-09	0.00581	-0.71	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26408323	chr6:30766825~30792250:+
THCA	trans	rs9467711	0.659	rs3734542	ENSG00000219392.1	RP1-265C24.5	-5.96	4.89e-09	0.00582	-0.56	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26468098	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.606	rs34104395	ENSG00000219392.1	RP1-265C24.5	-5.96	4.89e-09	0.00582	-0.56	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26478024	chr6:28115628~28116551:+
THCA	trans	rs6921919	1	rs6921919	ENSG00000228078.1	HLA-U	-5.96	4.9e-09	0.00584	-0.38	-0.27	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:29934101~29934286:+
THCA	trans	rs7746199	0.736	rs35848276	ENSG00000253570.1	RNF5P1	5.96	4.9e-09	0.00584	0.75	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr8:38600661~38601200:-
THCA	trans	rs7200543	1	rs55727637	ENSG00000250569.1	NTAN1P2	5.96	4.91e-09	0.00584	0.27	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr8:86481754~86483002:-
THCA	trans	rs453301	0.686	rs1045527	ENSG00000256560.1	LINC01486	-5.96	4.92e-09	0.00586	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9032531	chr12:109354083~109359488:-
THCA	trans	rs877636	1	rs2292239	ENSG00000227586.5	RP11-162A23.5	5.96	4.93e-09	0.00586	0.34	0.27	Cognitive function;	chr12:56088396	chr10:123171535~123171875:-
THCA	trans	rs11250098	0.503	rs13270870	ENSG00000229857.1	RP11-159H20.3	5.96	4.93e-09	0.00587	0.32	0.27	Morning vs. evening chronotype;	chr8:10913272	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.538	rs10111950	ENSG00000254153.1	CTA-398F10.2	5.96	4.93e-09	0.00587	0.29	0.27	Neuroticism;	chr8:10958244	chr8:8456909~8461337:-
THCA	trans	rs9616064	0.506	rs737135	ENSG00000258384.1	AC068831.6	5.96	4.94e-09	0.00587	0.32	0.27	Urate levels in obese individuals;	chr22:46665894	chr15:90952239~90955225:-
THCA	trans	rs7769051	0.708	rs9483514	ENSG00000213303.3	CTC-398G3.2	5.96	4.95e-09	0.0059	0.48	0.27	Type 2 diabetes nephropathy;	chr6:132907577	chr19:11523436~11523831:+
THCA	trans	rs7212590	0.748	rs8074176	ENSG00000187870.7	RNFT1P3	5.96	4.95e-09	0.0059	0.53	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59784634	chr17:20743333~20754501:-
THCA	trans	rs9292918	0.671	rs13180087	ENSG00000231752.4	EMBP1	5.96	4.96e-09	0.0059	0.49	0.27	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45265666	chr1:121519112~121571892:+
THCA	trans	rs7769051	1	rs58832890	ENSG00000213303.3	CTC-398G3.2	5.96	4.96e-09	0.0059	0.48	0.27	Type 2 diabetes nephropathy;	chr6:132806000	chr19:11523436~11523831:+
THCA	trans	rs7746199	0.736	rs58616630	ENSG00000228022.4	HCG20	-5.96	4.97e-09	0.00591	-0.66	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs34573979	ENSG00000228022.4	HCG20	-5.96	4.97e-09	0.00591	-0.66	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:30766825~30792250:+
THCA	trans	rs1075232	1	rs12440544	ENSG00000270055.1	CTD-3092A11.2	-5.96	4.97e-09	0.00591	-0.53	-0.27	Survival in colorectal cancer (non-distant metastatic);	chr15:31804301	chr15:30487963~30490313:+
THCA	trans	rs7829975	0.626	rs907183	ENSG00000256560.1	LINC01486	-5.96	4.97e-09	0.00591	-0.32	-0.27	Mood instability;	chr8:8872251	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.754	rs1814813	ENSG00000253326.2	RP11-261C10.7	-5.96	4.97e-09	0.00592	-0.35	-0.27	Corneal astigmatism;	chr4:119337052	chr1:243054861~243056394:-
THCA	trans	rs453301	0.631	rs28572014	ENSG00000229857.1	RP11-159H20.3	5.96	4.98e-09	0.00592	0.35	0.27	Joint mobility (Beighton score);	chr8:8936097	chr9:76992099~76993108:+
THCA	trans	rs616147	0.627	rs816487	ENSG00000239269.1	RPSAP4	-5.96	4.98e-09	0.00592	-0.28	-0.27	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr14:94726288~94727175:+
THCA	trans	rs4930561	0.765	rs4930564	ENSG00000155070.8	UNC93B2	5.96	4.99e-09	0.00594	0.31	0.27	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68215814	chr7:6855485~6859830:-
THCA	trans	rs4415084	0.834	rs7720787	ENSG00000231752.4	EMBP1	5.96	5e-09	0.00595	0.35	0.27	Breast cancer;	chr5:44817207	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.603	rs11250130	ENSG00000254153.1	CTA-398F10.2	5.96	5.01e-09	0.00596	0.29	0.26	Retinal vascular caliber;	chr8:11356946	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.603	rs2250028	ENSG00000254153.1	CTA-398F10.2	-5.96	5.01e-09	0.00596	-0.3	-0.26	Retinal vascular caliber;	chr8:11356080	chr8:8456909~8461337:-
THCA	trans	rs853679	0.607	rs34243448	ENSG00000204338.7	CYP21A1P	-5.96	5.02e-09	0.00597	-0.58	-0.26	Depression;	chr6:28225324	chr6:32005636~32008451:+
THCA	trans	rs7113874	0.531	rs7934396	ENSG00000266891.1	RP11-692N5.2	-5.96	5.03e-09	0.00598	-0.35	-0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8594085	chr18:9734882~9735602:-
THCA	trans	rs5786757	1	rs5786757	ENSG00000232706.3	NUTM2HP	5.96	5.03e-09	0.00598	0.39	0.26	Nose morphology;	chr10:87076396	chr10:50676743~50686326:+
THCA	trans	rs7746199	0.673	rs35501037	ENSG00000204338.7	CYP21A1P	-5.96	5.03e-09	0.00598	-0.59	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.92	rs13195040	ENSG00000204338.7	CYP21A1P	5.96	5.04e-09	0.00599	0.53	0.26	Intelligence (multi-trait analysis);	chr6:27446145	chr6:32005636~32008451:+
THCA	trans	rs7824557	0.628	rs34237267	ENSG00000253893.2	FAM85B	-5.96	5.04e-09	0.006	-0.34	-0.26	Retinal vascular caliber;	chr8:11339792	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.628	rs7008205	ENSG00000253893.2	FAM85B	-5.96	5.04e-09	0.006	-0.34	-0.26	Retinal vascular caliber;	chr8:11339814	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.617	rs483916	ENSG00000254153.1	CTA-398F10.2	5.96	5.08e-09	0.00603	0.3	0.26	Neuroticism;	chr8:9936091	chr8:8456909~8461337:-
THCA	trans	rs9393777	0.92	rs13207689	ENSG00000204338.7	CYP21A1P	-5.96	5.09e-09	0.00604	-0.58	-0.26	Intelligence (multi-trait analysis);	chr6:27401925	chr6:32005636~32008451:+
THCA	trans	rs2985684	0.841	rs2281836	ENSG00000240785.1	RPL36AP21	5.95	5.11e-09	0.00607	0.34	0.26	Carotid intima media thickness;	chr14:49598999	chr5:18049550~18049872:+
THCA	trans	rs7824557	0.602	rs11784544	ENSG00000253893.2	FAM85B	-5.95	5.11e-09	0.00608	-0.35	-0.26	Retinal vascular caliber;	chr8:11346994	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.602	rs11781375	ENSG00000253893.2	FAM85B	-5.95	5.11e-09	0.00608	-0.35	-0.26	Retinal vascular caliber;	chr8:11347023	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.837	rs17724467	ENSG00000254153.1	CTA-398F10.2	5.95	5.12e-09	0.00608	0.3	0.26	Triglycerides;	chr8:11118172	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.539	rs35571782	ENSG00000256560.1	LINC01486	5.95	5.14e-09	0.0061	0.32	0.26	Mood instability;	chr8:8284301	chr12:109354083~109359488:-
THCA	trans	rs7212590	0.655	rs8067568	ENSG00000187870.7	RNFT1P3	5.95	5.14e-09	0.00611	0.52	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59921854	chr17:20743333~20754501:-
THCA	trans	rs11098499	0.874	rs13139045	ENSG00000253326.2	RP11-261C10.7	5.95	5.15e-09	0.00611	0.34	0.26	Corneal astigmatism;	chr4:119247433	chr1:243054861~243056394:-
THCA	trans	rs10435719	0.753	rs9694940	ENSG00000254153.1	CTA-398F10.2	-5.95	5.15e-09	0.00612	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:8456909~8461337:-
THCA	trans	rs7826238	0.509	rs2948288	ENSG00000256560.1	LINC01486	5.95	5.23e-09	0.0062	0.31	0.26	Systolic blood pressure;	chr8:8257782	chr12:109354083~109359488:-
THCA	trans	rs4295623	0.585	rs13259242	ENSG00000256560.1	LINC01486	-5.95	5.23e-09	0.0062	-0.32	-0.26	Morning vs. evening chronotype;	chr8:11735524	chr12:109354083~109359488:-
THCA	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	5.95	5.23e-09	0.00621	0.38	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
THCA	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	5.95	5.23e-09	0.00621	0.38	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
THCA	trans	rs804280	0.509	rs13268030	ENSG00000254153.1	CTA-398F10.2	-5.95	5.24e-09	0.00621	-0.3	-0.26	Myopia (pathological);	chr8:11925564	chr8:8456909~8461337:-
THCA	trans	rs80264589	1	rs80264589	ENSG00000280107.1	AL022393.9	-5.95	5.24e-09	0.00622	-0.5	-0.26	Intelligence (multi-trait analysis);Lung cancer;	chr6:26959823	chr6:28170845~28172521:+
THCA	trans	rs7824557	0.579	rs10098322	ENSG00000253893.2	FAM85B	-5.95	5.25e-09	0.00623	-0.34	-0.26	Retinal vascular caliber;	chr8:11338786	chr8:8167819~8226614:-
THCA	trans	rs4720118	0.508	rs4604335	ENSG00000213492.2	NT5C3AP1	5.95	5.25e-09	0.00623	0.36	0.26	Leprosy;	chr7:33349739	chr4:117574512~117576174:-
THCA	trans	rs7824557	0.602	rs11784458	ENSG00000253893.2	FAM85B	-5.95	5.27e-09	0.00625	-0.35	-0.26	Retinal vascular caliber;	chr8:11346675	chr8:8167819~8226614:-
THCA	trans	rs930395	0.514	rs9791059	ENSG00000231752.4	EMBP1	-5.95	5.28e-09	0.00627	-0.37	-0.26	Breast cancer;	chr5:44900345	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs4457088	ENSG00000231752.4	EMBP1	-5.95	5.28e-09	0.00627	-0.37	-0.26	Breast cancer;	chr5:44900852	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs9791056	ENSG00000231752.4	EMBP1	-5.95	5.28e-09	0.00627	-0.37	-0.26	Breast cancer;	chr5:44903789	chr1:121519112~121571892:+
THCA	trans	rs10435719	0.902	rs7459545	ENSG00000254153.1	CTA-398F10.2	-5.95	5.29e-09	0.00627	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:8456909~8461337:-
THCA	trans	rs2898290	0.617	rs13273172	ENSG00000229857.1	RP11-159H20.3	5.95	5.29e-09	0.00627	0.34	0.26	Systolic blood pressure;	chr8:11603602	chr9:76992099~76993108:+
THCA	trans	rs73108077	1	rs58925751	ENSG00000279352.1	RP11-411B10.7	5.95	5.29e-09	0.00628	0.56	0.26	Red blood cell density in sickle cell anemia;	chr20:31459409	chr18:14010054~14010917:+
THCA	trans	rs930395	0.514	rs4129642	ENSG00000231752.4	EMBP1	-5.95	5.3e-09	0.00628	-0.37	-0.26	Breast cancer;	chr5:44898027	chr1:121519112~121571892:+
THCA	trans	rs12477438	0.52	rs13035311	ENSG00000276576.1	MRPL30P1	5.95	5.3e-09	0.00628	0.34	0.26	Chronic sinus infection;	chr2:99100859	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs34766932	ENSG00000276576.1	MRPL30P1	5.95	5.3e-09	0.00628	0.34	0.26	Chronic sinus infection;	chr2:99120810	chr6:57029521~57029988:+
THCA	trans	rs6087990	0.814	rs2424895	ENSG00000253915.1	MAPRE1P1	-5.95	5.31e-09	0.00629	-0.34	-0.26	Ulcerative colitis;	chr20:32748172	chr8:135625185~135625981:-
THCA	trans	rs9649213	0.574	rs34817002	ENSG00000225169.1	BRI3P1	5.95	5.31e-09	0.0063	0.35	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98257739	chr1:100213293~100213670:+
THCA	trans	rs11250097	0.528	rs36043848	ENSG00000229857.1	RP11-159H20.3	5.95	5.35e-09	0.00634	0.34	0.26	Neuroticism;	chr8:11452024	chr9:76992099~76993108:+
THCA	trans	rs3808502	0.516	rs6983727	ENSG00000229857.1	RP11-159H20.3	-5.95	5.35e-09	0.00634	-0.34	-0.26	Neuroticism;	chr8:11558303	chr9:76992099~76993108:+
THCA	trans	rs6601327	0.571	rs7838571	ENSG00000253893.2	FAM85B	-5.95	5.37e-09	0.00636	-0.33	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9790286	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.634	rs6987767	ENSG00000256560.1	LINC01486	5.95	5.38e-09	0.00637	0.32	0.26	Triglycerides;	chr8:11052556	chr12:109354083~109359488:-
THCA	trans	rs853679	0.607	rs13199649	ENSG00000204338.7	CYP21A1P	-5.95	5.39e-09	0.00638	-0.6	-0.26	Depression;	chr6:27901014	chr6:32005636~32008451:+
THCA	trans	rs7769051	1	rs10484629	ENSG00000227615.1	RP11-864N7.2	5.95	5.39e-09	0.00639	0.45	0.26	Type 2 diabetes nephropathy;	chr6:132796731	chr11:74745716~74746114:-
THCA	trans	rs889398	0.641	rs7200258	ENSG00000196796.5	CTB-134H23.2	5.94	5.4e-09	0.00639	0.3	0.26	Body mass index;	chr16:69863566	chr16:29038655~29052726:+
THCA	trans	rs35851103	0.627	rs58602899	ENSG00000229857.1	RP11-159H20.3	-5.94	5.4e-09	0.0064	-0.33	-0.26	Neuroticism;	chr8:11991324	chr9:76992099~76993108:+
THCA	trans	rs453301	0.686	rs11785634	ENSG00000229857.1	RP11-159H20.3	5.94	5.42e-09	0.00642	0.32	0.26	Joint mobility (Beighton score);	chr8:9035087	chr9:76992099~76993108:+
THCA	trans	rs76228276	0.737	rs72672342	ENSG00000260318.1	COX6CP1	5.94	5.42e-09	0.00642	0.8	0.26	Childhood ear infection;	chr8:99264513	chr16:11903923~11904137:-
THCA	trans	rs9314986	0.548	rs6490433	ENSG00000278546.1	RP1-41C23.4	5.94	5.43e-09	0.00642	0.33	0.26	Biliary atresia;	chr13:29894365	chr17:31560132~31560573:+
THCA	trans	rs9650657	0.537	rs7016385	ENSG00000229857.1	RP11-159H20.3	-5.94	5.43e-09	0.00642	-0.32	-0.26	Neuroticism;	chr8:10921962	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.741	rs10100333	ENSG00000253893.2	FAM85B	5.94	5.43e-09	0.00643	0.33	0.26	Neuroticism;	chr8:10726778	chr8:8167819~8226614:-
THCA	trans	rs12614435	0.512	rs2472751	ENSG00000269800.1	PLEKHA3P1	5.94	5.44e-09	0.00644	0.32	0.26	Atrial fibrillation;	chr2:178675176	chr19:41521043~41521989:-
THCA	trans	rs875971	0.651	rs313829	ENSG00000213640.3	EEF1DP4	5.94	5.47e-09	0.00647	0.34	0.26	Aortic root size;	chr7:66087510	chr7:64862999~64864370:+
THCA	trans	rs7819412	0.505	rs17782536	ENSG00000254153.1	CTA-398F10.2	5.94	5.47e-09	0.00648	0.31	0.26	Triglycerides;	chr8:11164172	chr8:8456909~8461337:-
THCA	trans	rs1190596	0.689	rs2224460	ENSG00000181359.5	HSP90AA6P	5.94	5.47e-09	0.00648	0.38	0.26	Behavioural disinhibition (generation interaction);	chr14:102097460	chr4:170581470~170605450:-
THCA	trans	rs7212590	0.618	rs35806089	ENSG00000187870.7	RNFT1P3	5.94	5.48e-09	0.00648	0.53	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59866545	chr17:20743333~20754501:-
THCA	trans	rs4879677	1	rs642259	ENSG00000269560.1	CTD-2192J16.21	-5.94	5.48e-09	0.00648	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27661755	chr19:12529768~12532973:-
THCA	trans	rs12477438	0.52	rs4402818	ENSG00000276576.1	MRPL30P1	5.94	5.48e-09	0.00649	0.34	0.26	Chronic sinus infection;	chr2:99101145	chr6:57029521~57029988:+
THCA	trans	rs7746199	0.736	rs34064842	ENSG00000204338.7	CYP21A1P	-5.94	5.5e-09	0.00651	-0.59	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs13214023	ENSG00000253570.1	RNF5P1	-5.94	5.52e-09	0.00653	-0.64	-0.26	Depression;	chr6:28364364	chr8:38600661~38601200:-
THCA	trans	rs7824557	0.602	rs35807737	ENSG00000253893.2	FAM85B	-5.94	5.55e-09	0.00656	-0.35	-0.26	Retinal vascular caliber;	chr8:11346902	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.518	rs11250094	ENSG00000256560.1	LINC01486	-5.94	5.56e-09	0.00658	-0.32	-0.26	Retinal vascular caliber;	chr8:10944491	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.518	rs12546366	ENSG00000256560.1	LINC01486	-5.94	5.56e-09	0.00658	-0.32	-0.26	Retinal vascular caliber;	chr8:10944636	chr12:109354083~109359488:-
THCA	trans	rs616147	0.627	rs9871799	ENSG00000239269.1	RPSAP4	5.94	5.56e-09	0.00658	0.28	0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr14:94726288~94727175:+
THCA	trans	rs11098499	0.644	rs28787668	ENSG00000253326.2	RP11-261C10.7	5.94	5.57e-09	0.00658	0.36	0.26	Corneal astigmatism;	chr4:119633532	chr1:243054861~243056394:-
THCA	trans	rs889398	0.594	rs8047194	ENSG00000196796.5	CTB-134H23.2	5.94	5.57e-09	0.00659	0.3	0.26	Body mass index;	chr16:69857607	chr16:29038655~29052726:+
THCA	trans	rs853679	0.607	rs66868086	ENSG00000204338.7	CYP21A1P	-5.94	5.58e-09	0.00659	-0.6	-0.26	Depression;	chr6:27898124	chr6:32005636~32008451:+
THCA	trans	rs7819412	0.837	rs17724467	ENSG00000256560.1	LINC01486	-5.94	5.59e-09	0.0066	-0.33	-0.26	Triglycerides;	chr8:11118172	chr12:109354083~109359488:-
THCA	trans	rs4879677	1	rs10968061	ENSG00000269560.1	CTD-2192J16.21	5.94	5.59e-09	0.00661	0.33	0.26	Gut microbiome composition (summer and winter);	chr9:27688780	chr19:12529768~12532973:-
THCA	trans	rs4879677	1	rs620232	ENSG00000269560.1	CTD-2192J16.21	5.94	5.6e-09	0.00662	0.34	0.26	Gut microbiome composition (summer and winter);	chr9:27656448	chr19:12529768~12532973:-
THCA	trans	rs7824557	0.518	rs11777007	ENSG00000256560.1	LINC01486	-5.94	5.62e-09	0.00664	-0.32	-0.26	Retinal vascular caliber;	chr8:10944347	chr12:109354083~109359488:-
THCA	trans	rs11250098	0.574	rs7015168	ENSG00000229857.1	RP11-159H20.3	5.94	5.65e-09	0.00667	0.31	0.26	Morning vs. evening chronotype;	chr8:10914700	chr9:76992099~76993108:+
THCA	trans	rs3812762	0.871	rs11042068	ENSG00000266891.1	RP11-692N5.2	5.94	5.65e-09	0.00668	0.36	0.26	Hypospadias;	chr11:8794052	chr18:9734882~9735602:-
THCA	trans	rs2645424	0.55	rs28577034	ENSG00000269898.1	RP11-568J23.4	-5.94	5.67e-09	0.00669	-0.32	-0.26	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851206	chr16:85743287~85744225:+
THCA	trans	rs1908814	0.516	rs7825529	ENSG00000254153.1	CTA-398F10.2	-5.94	5.67e-09	0.00669	-0.3	-0.26	Neuroticism;	chr8:11936935	chr8:8456909~8461337:-
THCA	trans	rs4295623	0.559	rs2409836	ENSG00000260438.1	RP11-405F3.2	-5.94	5.68e-09	0.00671	-0.37	-0.26	Morning vs. evening chronotype;	chr8:11831719	chr16:57713782~57714957:+
THCA	trans	rs4415084	0.834	rs2118764	ENSG00000231752.4	EMBP1	5.94	5.68e-09	0.00671	0.35	0.26	Breast cancer;	chr5:44787621	chr1:121519112~121571892:+
THCA	trans	rs7647973	0.667	rs9869256	ENSG00000197582.5	GPX1P1	5.94	5.69e-09	0.00672	0.48	0.26	Menarche (age at onset);	chr3:49586662	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.71	rs6446285	ENSG00000197582.5	GPX1P1	5.94	5.69e-09	0.00672	0.48	0.26	Menarche (age at onset);	chr3:49588873	chrX:13378735~13379340:-
THCA	trans	rs6424115	0.737	rs10917430	ENSG00000228217.1	AL390877.1	5.94	5.69e-09	0.00672	0.37	0.26	Immature fraction of reticulocytes;	chr1:23843968	chr1:117778087~117778506:-
THCA	trans	rs4879677	0.736	rs12379575	ENSG00000269560.1	CTD-2192J16.21	-5.94	5.69e-09	0.00672	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27639812	chr19:12529768~12532973:-
THCA	trans	rs930395	0.514	rs10060878	ENSG00000231752.4	EMBP1	-5.94	5.7e-09	0.00673	-0.36	-0.26	Breast cancer;	chr5:44899322	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.571	rs2409672	ENSG00000253893.2	FAM85B	5.94	5.7e-09	0.00673	0.33	0.26	Neuroticism;	chr8:10741270	chr8:8167819~8226614:-
THCA	trans	rs7945705	0.791	rs12421789	ENSG00000266891.1	RP11-692N5.2	5.94	5.7e-09	0.00673	0.32	0.26	Hemoglobin concentration;	chr11:8792409	chr18:9734882~9735602:-
THCA	trans	rs7945705	0.791	rs10769958	ENSG00000266891.1	RP11-692N5.2	5.94	5.7e-09	0.00673	0.32	0.26	Hemoglobin concentration;	chr11:8793568	chr18:9734882~9735602:-
THCA	trans	rs6601327	0.6	rs10103925	ENSG00000253893.2	FAM85B	5.94	5.71e-09	0.00674	0.34	0.26	Multiple myeloma (hyperdiploidy);	chr8:9794701	chr8:8167819~8226614:-
THCA	trans	rs9393777	0.92	rs72839445	ENSG00000204338.7	CYP21A1P	-5.93	5.71e-09	0.00675	-0.6	-0.26	Intelligence (multi-trait analysis);	chr6:27281907	chr6:32005636~32008451:+
THCA	trans	rs7520050	0.778	rs3014218	ENSG00000255397.1	AC022182.2	5.93	5.71e-09	0.00675	0.35	0.26	Reticulocyte count;Red blood cell count;	chr1:45560656	chr8:60937705~60939871:-
THCA	trans	rs4879656	0.762	rs7868944	ENSG00000215007.3	DNAJA1P3	-5.93	5.72e-09	0.00676	-0.31	-0.26	Menopause (age at onset);	chr9:32938861	chrX:107351650~107352843:-
THCA	trans	rs6601327	0.573	rs13278824	ENSG00000253893.2	FAM85B	-5.93	5.72e-09	0.00676	-0.33	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9788609	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.635	rs7821575	ENSG00000253893.2	FAM85B	5.93	5.73e-09	0.00676	0.35	0.26	Multiple myeloma (hyperdiploidy);	chr8:9808445	chr8:8167819~8226614:-
THCA	trans	rs11992162	0.967	rs11250185	ENSG00000254153.1	CTA-398F10.2	-5.93	5.76e-09	0.0068	-0.3	-0.26	Monocyte count;	chr8:11975614	chr8:8456909~8461337:-
THCA	trans	rs853679	0.607	rs35749575	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28147040	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs72846780	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28151277	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13205911	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28156336	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13197176	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28161454	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13201308	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28162311	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34765154	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28162672	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34505829	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28165461	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs35098436	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28166443	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs72846794	ENSG00000248290.1	TNXA	-5.93	5.77e-09	0.00681	-0.57	-0.26	Depression;	chr6:28169721	chr6:32008614~32012472:-
THCA	trans	rs7824557	0.564	rs2572379	ENSG00000256560.1	LINC01486	-5.93	5.78e-09	0.00682	-0.32	-0.26	Retinal vascular caliber;	chr8:11379971	chr12:109354083~109359488:-
THCA	trans	rs860295	0.529	rs1475766	ENSG00000241627.3	UBQLN4P1	5.93	5.79e-09	0.00683	0.29	0.26	Body mass index;	chr1:156011698	chr3:148985868~148987668:-
THCA	trans	rs7819412	0.74	rs7844536	ENSG00000254153.1	CTA-398F10.2	5.93	5.79e-09	0.00683	0.3	0.26	Triglycerides;	chr8:11176519	chr8:8456909~8461337:-
THCA	trans	rs3812762	0.879	rs10743088	ENSG00000266891.1	RP11-692N5.2	-5.93	5.8e-09	0.00684	-0.34	-0.26	Hypospadias;	chr11:8766073	chr18:9734882~9735602:-
THCA	trans	rs902774	0.818	rs56207534	ENSG00000220378.3	KRT8P42	-5.93	5.8e-09	0.00684	-0.57	-0.26	Prostate cancer;	chr12:52873525	chr6:134296997~134298695:-
THCA	trans	rs9329221	0.905	rs28507213	ENSG00000229857.1	RP11-159H20.3	5.93	5.8e-09	0.00684	0.33	0.26	Neuroticism;	chr8:10393339	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.905	rs28712068	ENSG00000229857.1	RP11-159H20.3	5.93	5.8e-09	0.00684	0.33	0.26	Neuroticism;	chr8:10393635	chr9:76992099~76993108:+
THCA	trans	rs453301	0.686	rs6601281	ENSG00000256560.1	LINC01486	-5.93	5.81e-09	0.00685	-0.31	-0.26	Joint mobility (Beighton score);	chr8:9053494	chr12:109354083~109359488:-
THCA	trans	rs1707322	0.896	rs946528	ENSG00000255397.1	AC022182.2	5.93	5.81e-09	0.00685	0.37	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr8:60937705~60939871:-
THCA	trans	rs616147	0.671	rs674192	ENSG00000239269.1	RPSAP4	-5.93	5.83e-09	0.00688	-0.29	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr14:94726288~94727175:+
THCA	trans	rs80264589	1	rs80264589	ENSG00000253570.1	RNF5P1	5.93	5.84e-09	0.00688	0.7	0.26	Intelligence (multi-trait analysis);Lung cancer;	chr6:26959823	chr8:38600661~38601200:-
THCA	trans	rs864643	1	rs552724	ENSG00000183298.5	RP11-556K13.1	-5.93	5.85e-09	0.00689	-0.44	-0.26	Attention deficit hyperactivity disorder;	chr3:39513455	chr1:101786340~101787219:-
THCA	trans	rs7819412	0.668	rs2409721	ENSG00000254153.1	CTA-398F10.2	5.93	5.85e-09	0.0069	0.3	0.26	Triglycerides;	chr8:11180735	chr8:8456909~8461337:-
THCA	trans	rs3764796	0.867	rs17687453	ENSG00000250030.2	RP11-584P21.4	5.93	5.85e-09	0.0069	0.52	0.26	Calcium levels;	chr8:17301889	chr4:67446267~67446574:+
THCA	trans	rs6600671	0.693	rs1853731	ENSG00000270231.3	NBPF8P	5.93	5.88e-09	0.00692	0.24	0.26	Hip geometry;	chr1:121510262	chr1:120436353~120467739:+
THCA	trans	rs453301	0.686	rs6987107	ENSG00000229857.1	RP11-159H20.3	5.93	5.88e-09	0.00693	0.32	0.26	Joint mobility (Beighton score);	chr8:9036071	chr9:76992099~76993108:+
THCA	trans	rs7945705	0.738	rs11042067	ENSG00000266891.1	RP11-692N5.2	5.93	5.88e-09	0.00693	0.32	0.26	Hemoglobin concentration;	chr11:8793906	chr18:9734882~9735602:-
THCA	trans	rs4879656	0.835	rs1332096	ENSG00000215007.3	DNAJA1P3	5.93	5.88e-09	0.00693	0.31	0.26	Menopause (age at onset);	chr9:32936041	chrX:107351650~107352843:-
THCA	trans	rs6981523	0.553	rs11989369	ENSG00000254153.1	CTA-398F10.2	-5.93	5.89e-09	0.00694	-0.31	-0.26	Neuroticism;	chr8:11197876	chr8:8456909~8461337:-
THCA	trans	rs11250098	0.503	rs7821826	ENSG00000229857.1	RP11-159H20.3	5.93	5.91e-09	0.00697	0.31	0.26	Morning vs. evening chronotype;	chr8:10911929	chr9:76992099~76993108:+
THCA	trans	rs4879656	0.831	rs13289835	ENSG00000215007.3	DNAJA1P3	5.93	5.92e-09	0.00697	0.3	0.26	Menopause (age at onset);	chr9:33069183	chrX:107351650~107352843:-
THCA	trans	rs1908814	0.516	rs13281077	ENSG00000254153.1	CTA-398F10.2	-5.93	5.93e-09	0.00698	-0.3	-0.26	Neuroticism;	chr8:11937305	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.745	rs6601569	ENSG00000256560.1	LINC01486	-5.93	5.94e-09	0.007	-0.32	-0.26	Triglycerides;	chr8:11216069	chr12:109354083~109359488:-
THCA	trans	rs1406428	0.748	rs1919427	ENSG00000229119.3	CTB-63M22.1	5.93	5.95e-09	0.00701	0.29	0.26	Response to tocilizumab in rheumatoid arthritis;	chr2:51508356	chr5:166382305~166382599:+
THCA	trans	rs804280	0.543	rs13261205	ENSG00000254153.1	CTA-398F10.2	-5.93	5.96e-09	0.00701	-0.3	-0.26	Myopia (pathological);	chr8:11933707	chr8:8456909~8461337:-
THCA	trans	rs804280	0.518	rs34266352	ENSG00000254153.1	CTA-398F10.2	-5.93	5.96e-09	0.00701	-0.3	-0.26	Myopia (pathological);	chr8:11933953	chr8:8456909~8461337:-
THCA	trans	rs804280	0.542	rs34117651	ENSG00000254153.1	CTA-398F10.2	-5.93	5.96e-09	0.00701	-0.3	-0.26	Myopia (pathological);	chr8:11934108	chr8:8456909~8461337:-
THCA	trans	rs34421088	0.576	rs2572436	ENSG00000256560.1	LINC01486	-5.93	5.97e-09	0.00703	-0.36	-0.26	Neuroticism;	chr8:11241700	chr12:109354083~109359488:-
THCA	trans	rs9467711	0.79	rs13198716	ENSG00000253570.1	RNF5P1	-5.93	5.98e-09	0.00704	-0.73	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr8:38600661~38601200:-
THCA	trans	rs11250098	0.574	rs4240672	ENSG00000229857.1	RP11-159H20.3	5.93	5.98e-09	0.00704	0.31	0.26	Morning vs. evening chronotype;	chr8:10910407	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.655	rs4316191	ENSG00000253893.2	FAM85B	5.93	5.99e-09	0.00705	0.34	0.26	Neuroticism;	chr8:10401719	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.541	rs7824267	ENSG00000254153.1	CTA-398F10.2	-5.93	6e-09	0.00706	-0.3	-0.26	Neuroticism;	chr8:11936770	chr8:8456909~8461337:-
THCA	trans	rs9650657	0.547	rs11250099	ENSG00000256560.1	LINC01486	5.93	6e-09	0.00706	0.31	0.26	Neuroticism;	chr8:10961147	chr12:109354083~109359488:-
THCA	trans	rs6087990	0.865	rs6058859	ENSG00000253915.1	MAPRE1P1	5.93	6e-09	0.00707	0.34	0.26	Ulcerative colitis;	chr20:32747351	chr8:135625185~135625981:-
THCA	trans	rs8014204	0.773	rs2241275	ENSG00000181227.3	RP4-682C21.2	5.93	6.01e-09	0.00707	0.21	0.26	Caffeine consumption;	chr14:74784737	chr1:75743423~75744776:-
THCA	trans	rs7819412	0.645	rs10156356	ENSG00000229857.1	RP11-159H20.3	5.93	6.01e-09	0.00707	0.35	0.26	Triglycerides;	chr8:11188700	chr9:76992099~76993108:+
THCA	trans	rs2980439	0.846	rs2980437	ENSG00000229857.1	RP11-159H20.3	5.93	6.01e-09	0.00707	0.31	0.26	Neuroticism;	chr8:8237241	chr9:76992099~76993108:+
THCA	trans	rs546131	0.928	rs558967	ENSG00000225531.1	RP11-196I18.3	5.93	6.01e-09	0.00708	0.35	0.26	Lung disease severity in cystic fibrosis;	chr11:34805621	chr9:107116829~107117557:+
THCA	trans	rs77688320	1	rs78053840	ENSG00000235105.1	RP11-329A14.1	-5.93	6.03e-09	0.00709	-0.42	-0.26	Breast cancer;	chr2:201502845	chr1:48435967~48437223:+
THCA	trans	rs77688320	1	rs77688320	ENSG00000235105.1	RP11-329A14.1	-5.93	6.03e-09	0.00709	-0.42	-0.26	Breast cancer;	chr2:201502866	chr1:48435967~48437223:+
THCA	trans	rs7824557	0.564	rs2736290	ENSG00000256560.1	LINC01486	-5.93	6.03e-09	0.00709	-0.32	-0.26	Retinal vascular caliber;	chr8:11376789	chr12:109354083~109359488:-
THCA	trans	rs35851103	0.627	rs6601644	ENSG00000229857.1	RP11-159H20.3	-5.93	6.04e-09	0.00711	-0.33	-0.26	Neuroticism;	chr8:11989569	chr9:76992099~76993108:+
THCA	trans	rs8177876	0.731	rs4889227	ENSG00000224837.1	GCSHP5	-5.93	6.04e-09	0.00711	-0.4	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr1:168055901~168056422:-
THCA	trans	rs9914988	0.576	rs11080075	ENSG00000267449.1	RP11-264B14.2	-5.92	6.04e-09	0.00711	-0.4	-0.26	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28995423	chr17:61069856~61070356:-
THCA	trans	rs7824557	0.505	rs2572440	ENSG00000254153.1	CTA-398F10.2	-5.92	6.05e-09	0.00712	-0.29	-0.26	Retinal vascular caliber;	chr8:11391501	chr8:8456909~8461337:-
THCA	trans	rs4295623	0.585	rs34421088	ENSG00000256560.1	LINC01486	-5.92	6.06e-09	0.00712	-0.32	-0.26	Morning vs. evening chronotype;	chr8:11731533	chr12:109354083~109359488:-
THCA	trans	rs2971100	1	rs2971103	ENSG00000268278.1	RP11-420K14.1	5.92	6.06e-09	0.00713	0.49	0.26	Colonoscopy-negative controls vs population controls;	chr7:9879463	chr19:21637974~21656300:+
THCA	trans	rs7829975	0.5	rs7841082	ENSG00000229857.1	RP11-159H20.3	5.92	6.07e-09	0.00714	0.34	0.26	Mood instability;	chr8:8311465	chr9:76992099~76993108:+
THCA	trans	rs10435719	0.902	rs7006538	ENSG00000254153.1	CTA-398F10.2	-5.92	6.09e-09	0.00716	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.518	rs11250094	ENSG00000229857.1	RP11-159H20.3	5.92	6.1e-09	0.00718	0.33	0.26	Retinal vascular caliber;	chr8:10944491	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.518	rs12546366	ENSG00000229857.1	RP11-159H20.3	5.92	6.1e-09	0.00718	0.33	0.26	Retinal vascular caliber;	chr8:10944636	chr9:76992099~76993108:+
THCA	trans	rs10435719	0.773	rs7842810	ENSG00000254153.1	CTA-398F10.2	-5.92	6.13e-09	0.0072	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:8456909~8461337:-
THCA	trans	rs3812762	0.871	rs3844100	ENSG00000266891.1	RP11-692N5.2	-5.92	6.13e-09	0.00721	-0.35	-0.26	Hypospadias;	chr11:8796261	chr18:9734882~9735602:-
THCA	trans	rs7568458	0.636	rs11126995	ENSG00000223886.3	RP11-251G23.2	5.92	6.14e-09	0.00722	0.37	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85565285	chr7:105530209~105530671:+
THCA	trans	rs10435719	0.744	rs11250175	ENSG00000254153.1	CTA-398F10.2	-5.92	6.14e-09	0.00722	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs13252853	ENSG00000254153.1	CTA-398F10.2	-5.92	6.14e-09	0.00722	-0.3	-0.26	Neuroticism;	chr8:11935465	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs13252854	ENSG00000254153.1	CTA-398F10.2	-5.92	6.14e-09	0.00722	-0.3	-0.26	Neuroticism;	chr8:11935469	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs13279577	ENSG00000254153.1	CTA-398F10.2	-5.92	6.14e-09	0.00722	-0.3	-0.26	Neuroticism;	chr8:11935587	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs10112958	ENSG00000254153.1	CTA-398F10.2	-5.92	6.14e-09	0.00722	-0.3	-0.26	Neuroticism;	chr8:11935631	chr8:8456909~8461337:-
THCA	trans	rs2985684	0.841	rs7158577	ENSG00000240785.1	RPL36AP21	5.92	6.15e-09	0.00722	0.33	0.26	Carotid intima media thickness;	chr14:49591915	chr5:18049550~18049872:+
THCA	trans	rs9584850	1	rs9584850	ENSG00000230079.1	STK24P1	5.92	6.16e-09	0.00724	0.32	0.26	Neuroticism;	chr13:98449172	chrX:136295690~136300298:-
THCA	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	5.92	6.18e-09	0.00727	0.39	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
THCA	trans	rs453301	0.686	rs2409120	ENSG00000256560.1	LINC01486	-5.92	6.22e-09	0.00731	-0.31	-0.26	Joint mobility (Beighton score);	chr8:9025061	chr12:109354083~109359488:-
THCA	trans	rs12472274	0.941	rs6748440	ENSG00000224699.7	LAMTOR5-AS1	-5.92	6.22e-09	0.00731	-0.23	-0.26	Phospholipid levels (plasma);	chr2:238191734	chr1:110347116~110443817:+
THCA	trans	rs6499255	0.638	rs57824734	ENSG00000196796.5	CTB-134H23.2	5.92	6.24e-09	0.00733	0.34	0.26	IgE levels;	chr16:69778092	chr16:29038655~29052726:+
THCA	trans	rs10435719	0.899	rs11250177	ENSG00000254153.1	CTA-398F10.2	-5.92	6.25e-09	0.00734	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.518	rs11777007	ENSG00000229857.1	RP11-159H20.3	5.92	6.25e-09	0.00735	0.33	0.26	Retinal vascular caliber;	chr8:10944347	chr9:76992099~76993108:+
THCA	trans	rs3799378	0.582	rs1796518	ENSG00000242375.1	RP11-498P14.3	-5.92	6.25e-09	0.00735	-0.4	-0.26	Intelligence (multi-trait analysis);	chr6:26388444	chr9:97195351~97197687:-
THCA	trans	rs9650657	0.504	rs10109167	ENSG00000256560.1	LINC01486	-5.92	6.26e-09	0.00735	-0.33	-0.26	Neuroticism;	chr8:11176016	chr12:109354083~109359488:-
THCA	trans	rs4879677	0.881	rs10968058	ENSG00000269560.1	CTD-2192J16.21	-5.92	6.26e-09	0.00735	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27685336	chr19:12529768~12532973:-
THCA	trans	rs4879677	1	rs4879706	ENSG00000269560.1	CTD-2192J16.21	-5.92	6.26e-09	0.00735	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27685777	chr19:12529768~12532973:-
THCA	trans	rs9584850	0.874	rs4584	ENSG00000230079.1	STK24P1	5.92	6.29e-09	0.00739	0.31	0.26	Neuroticism;	chr13:98449615	chrX:136295690~136300298:-
THCA	trans	rs9650657	0.504	rs10108347	ENSG00000256560.1	LINC01486	-5.92	6.3e-09	0.00739	-0.33	-0.26	Neuroticism;	chr8:11176008	chr12:109354083~109359488:-
THCA	trans	rs7429990	0.965	rs1060407	ENSG00000235912.1	RP1-159A19.3	-5.92	6.31e-09	0.00741	-0.34	-0.26	Educational attainment (years of education);	chr3:47916547	chr1:27649419~27649610:+
THCA	trans	rs34421088	0.564	rs6983129	ENSG00000253893.2	FAM85B	-5.92	6.31e-09	0.00741	-0.33	-0.26	Neuroticism;	chr8:11733627	chr8:8167819~8226614:-
THCA	trans	rs7816032	0.617	rs79396901	ENSG00000233393.1	AP000688.29	5.92	6.32e-09	0.00742	0.45	0.26	Hyperactive-impulsive symptoms;	chr8:19890937	chr21:36104881~36109690:+
THCA	trans	rs1475911	0.671	rs12483409	ENSG00000229759.1	MRPS18AP1	-5.92	6.33e-09	0.00743	-0.34	-0.26	IgG glycosylation;	chr21:42101792	chr3:48256350~48256938:-
THCA	trans	rs930395	0.514	rs6871052	ENSG00000231752.4	EMBP1	-5.92	6.34e-09	0.00744	-0.36	-0.26	Breast cancer;	chr5:44863215	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs6893319	ENSG00000231752.4	EMBP1	-5.92	6.34e-09	0.00744	-0.36	-0.26	Breast cancer;	chr5:44863627	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.652	rs10053247	ENSG00000231752.4	EMBP1	-5.92	6.34e-09	0.00744	-0.36	-0.26	Breast cancer;	chr5:44863857	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs10065638	ENSG00000231752.4	EMBP1	-5.92	6.34e-09	0.00744	-0.36	-0.26	Breast cancer;	chr5:44866060	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs6894324	ENSG00000231752.4	EMBP1	-5.92	6.34e-09	0.00744	-0.36	-0.26	Breast cancer;	chr5:44867234	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs10069220	ENSG00000231752.4	EMBP1	-5.92	6.34e-09	0.00744	-0.36	-0.26	Breast cancer;	chr5:44881876	chr1:121519112~121571892:+
THCA	trans	rs930395	0.514	rs13187933	ENSG00000231752.4	EMBP1	-5.92	6.34e-09	0.00744	-0.36	-0.26	Breast cancer;	chr5:44883141	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.652	rs11948387	ENSG00000231752.4	EMBP1	-5.92	6.34e-09	0.00744	-0.36	-0.26	Breast cancer;	chr5:44884139	chr1:121519112~121571892:+
THCA	trans	rs453301	0.686	rs2409120	ENSG00000229857.1	RP11-159H20.3	5.92	6.34e-09	0.00744	0.32	0.26	Joint mobility (Beighton score);	chr8:9025061	chr9:76992099~76993108:+
THCA	trans	rs1475911	0.708	rs56185023	ENSG00000229759.1	MRPS18AP1	-5.92	6.35e-09	0.00745	-0.34	-0.26	IgG glycosylation;	chr21:42101428	chr3:48256350~48256938:-
THCA	trans	rs9467773	0.587	rs9467722	ENSG00000242375.1	RP11-498P14.3	-5.92	6.36e-09	0.00746	-0.38	-0.26	Intelligence (multi-trait analysis);	chr6:26352338	chr9:97195351~97197687:-
THCA	trans	rs9650657	0.615	rs11986845	ENSG00000253893.2	FAM85B	5.92	6.36e-09	0.00746	0.33	0.26	Neuroticism;	chr8:10833808	chr8:8167819~8226614:-
THCA	trans	rs7769051	0.803	rs56148066	ENSG00000227615.1	RP11-864N7.2	5.92	6.39e-09	0.00749	0.45	0.26	Type 2 diabetes nephropathy;	chr6:132908976	chr11:74745716~74746114:-
THCA	trans	rs9467711	0.79	rs13220495	ENSG00000219392.1	RP1-265C24.5	-5.92	6.39e-09	0.00749	-0.61	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr6:28115628~28116551:+
THCA	trans	rs4415084	0.618	rs6872254	ENSG00000231752.4	EMBP1	5.91	6.41e-09	0.00751	0.36	0.26	Breast cancer;	chr5:44803682	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs13174122	ENSG00000231752.4	EMBP1	5.91	6.41e-09	0.00751	0.36	0.26	Breast cancer;	chr5:44810638	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs930394	ENSG00000231752.4	EMBP1	5.91	6.41e-09	0.00751	0.36	0.26	Breast cancer;	chr5:44822515	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs12513749	ENSG00000231752.4	EMBP1	5.91	6.41e-09	0.00751	0.36	0.26	Breast cancer;	chr5:44828101	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs16901989	ENSG00000231752.4	EMBP1	-5.91	6.41e-09	0.00751	-0.36	-0.26	Breast cancer;	chr5:44837027	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.505	rs17782554	ENSG00000229857.1	RP11-159H20.3	5.91	6.41e-09	0.00751	0.35	0.26	Triglycerides;	chr8:11164596	chr9:76992099~76993108:+
THCA	trans	rs9393777	0.841	rs13191474	ENSG00000204338.7	CYP21A1P	-5.91	6.41e-09	0.00752	-0.53	-0.26	Intelligence (multi-trait analysis);	chr6:27445566	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.92	rs41269265	ENSG00000204338.7	CYP21A1P	-5.91	6.41e-09	0.00752	-0.53	-0.26	Intelligence (multi-trait analysis);	chr6:27457570	chr6:32005636~32008451:+
THCA	trans	rs11098499	0.644	rs7676296	ENSG00000253326.2	RP11-261C10.7	5.91	6.41e-09	0.00752	0.36	0.26	Corneal astigmatism;	chr4:119634532	chr1:243054861~243056394:-
THCA	trans	rs941207	0.756	rs2958153	ENSG00000228224.3	NACAP1	5.91	6.42e-09	0.00752	0.3	0.26	Platelet count;	chr12:56687733	chr8:101361794~101372707:+
THCA	trans	rs7824557	0.583	rs4448232	ENSG00000254153.1	CTA-398F10.2	-5.91	6.43e-09	0.00753	-0.29	-0.26	Retinal vascular caliber;	chr8:11373845	chr8:8456909~8461337:-
THCA	trans	rs2645424	0.762	rs2294139	ENSG00000269898.1	RP11-568J23.4	-5.91	6.44e-09	0.00754	-0.33	-0.26	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847933	chr16:85743287~85744225:+
THCA	trans	rs9329221	0.905	rs17709397	ENSG00000229857.1	RP11-159H20.3	5.91	6.44e-09	0.00754	0.33	0.26	Neuroticism;	chr8:10392351	chr9:76992099~76993108:+
THCA	trans	rs9648716	0.577	rs11769042	ENSG00000224775.2	BRAFP1	5.91	6.44e-09	0.00755	0.4	0.26	Type 2 diabetes;	chr7:140760369	chrX:75582676~75585506:+
THCA	trans	rs7032940	0.784	rs10980253	ENSG00000262519.1	TXNP4	5.91	6.44e-09	0.00755	0.37	0.26	Height;	chr9:110205555	chr17:4572206~4572515:+
THCA	trans	rs2164273	0.523	rs1435279	ENSG00000253893.2	FAM85B	-5.91	6.44e-09	0.00755	-0.36	-0.26	Extraversion;	chr8:11300878	chr8:8167819~8226614:-
THCA	trans	rs4415084	0.716	rs6451781	ENSG00000231752.4	EMBP1	-5.91	6.45e-09	0.00756	-0.36	-0.26	Breast cancer;	chr5:44860404	chr1:121519112~121571892:+
THCA	trans	rs7824557	0.628	rs7005469	ENSG00000253893.2	FAM85B	-5.91	6.45e-09	0.00756	-0.34	-0.26	Retinal vascular caliber;	chr8:11336948	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.628	rs6988922	ENSG00000253893.2	FAM85B	-5.91	6.45e-09	0.00756	-0.34	-0.26	Retinal vascular caliber;	chr8:11337402	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2736304	ENSG00000256560.1	LINC01486	-5.91	6.47e-09	0.00758	-0.32	-0.26	Retinal vascular caliber;	chr8:11379455	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.899	rs7815595	ENSG00000254153.1	CTA-398F10.2	-5.91	6.48e-09	0.00759	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.834	rs11250176	ENSG00000254153.1	CTA-398F10.2	-5.91	6.48e-09	0.00759	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs4367597	ENSG00000254153.1	CTA-398F10.2	-5.91	6.48e-09	0.00759	-0.3	-0.26	Neuroticism;	chr8:11936020	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.899	rs9329251	ENSG00000254153.1	CTA-398F10.2	-5.91	6.48e-09	0.00759	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:8456909~8461337:-
THCA	trans	rs73108077	1	rs73108061	ENSG00000279352.1	RP11-411B10.7	5.91	6.48e-09	0.0076	0.58	0.26	Red blood cell density in sickle cell anemia;	chr20:31413650	chr18:14010054~14010917:+
THCA	trans	rs6601327	0.67	rs6990418	ENSG00000253893.2	FAM85B	-5.91	6.49e-09	0.0076	-0.34	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9564496	chr8:8167819~8226614:-
THCA	trans	rs73108077	0.915	rs17328705	ENSG00000279352.1	RP11-411B10.7	5.91	6.49e-09	0.0076	0.59	0.26	Red blood cell density in sickle cell anemia;	chr20:31438570	chr18:14010054~14010917:+
THCA	trans	rs7819412	0.505	rs17726209	ENSG00000254153.1	CTA-398F10.2	-5.91	6.49e-09	0.0076	-0.31	-0.26	Triglycerides;	chr8:11164675	chr8:8456909~8461337:-
THCA	trans	rs3947	0.906	rs1692821	ENSG00000253893.2	FAM85B	5.91	6.5e-09	0.00762	0.38	0.26	Blood protein levels;	chr8:11842479	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.638	rs4413734	ENSG00000253893.2	FAM85B	-5.91	6.51e-09	0.00762	-0.35	-0.26	Retinal vascular caliber;	chr8:11355269	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.578	rs2060458	ENSG00000253893.2	FAM85B	-5.91	6.51e-09	0.00762	-0.35	-0.26	Retinal vascular caliber;	chr8:11355302	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.617	rs28680211	ENSG00000229857.1	RP11-159H20.3	5.91	6.51e-09	0.00763	0.31	0.26	Neuroticism;	chr8:10661935	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.502	rs4840548	ENSG00000229857.1	RP11-159H20.3	5.91	6.52e-09	0.00764	0.36	0.26	Triglycerides;	chr8:11135373	chr9:76992099~76993108:+
THCA	trans	rs2980439	0.783	rs2948305	ENSG00000256560.1	LINC01486	5.91	6.57e-09	0.00769	0.31	0.26	Neuroticism;	chr8:8241055	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.505	rs67849263	ENSG00000256560.1	LINC01486	-5.91	6.58e-09	0.0077	-0.33	-0.26	Triglycerides;	chr8:11150034	chr12:109354083~109359488:-
THCA	trans	rs9329221	0.537	rs1351876	ENSG00000253893.2	FAM85B	5.91	6.58e-09	0.0077	0.33	0.26	Neuroticism;	chr8:10127267	chr8:8167819~8226614:-
THCA	trans	rs7032940	0.784	rs10980253	ENSG00000228236.2	TXNP5	5.91	6.59e-09	0.00771	0.35	0.26	Height;	chr9:110205555	chr2:149068596~149068910:-
THCA	trans	rs6601327	0.665	rs11249949	ENSG00000253893.2	FAM85B	5.91	6.59e-09	0.00771	0.34	0.26	Multiple myeloma (hyperdiploidy);	chr8:9798102	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.663	rs12543346	ENSG00000253893.2	FAM85B	5.91	6.59e-09	0.00771	0.34	0.26	Multiple myeloma (hyperdiploidy);	chr8:9798313	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.632	rs4841220	ENSG00000253893.2	FAM85B	5.91	6.59e-09	0.00771	0.34	0.26	Multiple myeloma (hyperdiploidy);	chr8:9798549	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.867	rs6999030	ENSG00000254153.1	CTA-398F10.2	-5.91	6.6e-09	0.00772	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.834	rs6985792	ENSG00000254153.1	CTA-398F10.2	-5.91	6.6e-09	0.00772	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:8456909~8461337:-
THCA	trans	rs3947	0.789	rs9009	ENSG00000253893.2	FAM85B	-5.91	6.61e-09	0.00774	-0.36	-0.26	Blood protein levels;	chr8:11844497	chr8:8167819~8226614:-
THCA	trans	rs616147	0.671	rs675595	ENSG00000239269.1	RPSAP4	-5.91	6.63e-09	0.00776	-0.29	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr14:94726288~94727175:+
THCA	trans	rs139156	0.908	rs139151	ENSG00000250326.1	RP11-284M14.1	-5.91	6.67e-09	0.00781	-0.48	-0.26	Survival in colon cancer;	chr22:44198596	chr4:142933195~143184861:-
THCA	trans	rs3096299	0.719	rs2353581	ENSG00000215030.5	RPL13P12	-5.91	6.68e-09	0.00781	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89452500	chr17:17383377~17384012:-
THCA	trans	rs7829975	0.511	rs2980423	ENSG00000256560.1	LINC01486	5.91	6.69e-09	0.00782	0.32	0.26	Mood instability;	chr8:8285053	chr12:109354083~109359488:-
THCA	trans	rs9393777	0.92	rs13196692	ENSG00000204338.7	CYP21A1P	-5.91	6.69e-09	0.00782	-0.57	-0.26	Intelligence (multi-trait analysis);	chr6:27411340	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.92	rs34150729	ENSG00000204338.7	CYP21A1P	-5.91	6.69e-09	0.00782	-0.57	-0.26	Intelligence (multi-trait analysis);	chr6:27420975	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.92	rs13191227	ENSG00000204338.7	CYP21A1P	-5.91	6.69e-09	0.00782	-0.57	-0.26	Intelligence (multi-trait analysis);	chr6:27422336	chr6:32005636~32008451:+
THCA	trans	rs902774	0.818	rs4919740	ENSG00000259500.1	KRT8P24	-5.91	6.71e-09	0.00784	-0.52	-0.26	Prostate cancer;	chr12:52877187	chr15:48971803~48973361:+
THCA	trans	rs9467711	0.79	rs13198716	ENSG00000219392.1	RP1-265C24.5	5.91	6.71e-09	0.00784	0.58	0.26	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:28115628~28116551:+
THCA	trans	rs6424115	0.767	rs11591202	ENSG00000228217.1	AL390877.1	5.91	6.73e-09	0.00787	0.37	0.26	Immature fraction of reticulocytes;	chr1:23775590	chr1:117778087~117778506:-
THCA	trans	rs1347297	0.526	rs890579	ENSG00000269800.1	PLEKHA3P1	5.91	6.73e-09	0.00787	0.28	0.26	Alzheimer disease and age of onset;	chr2:178398560	chr19:41521043~41521989:-
THCA	trans	rs4415084	0.8	rs11949847	ENSG00000231752.4	EMBP1	5.91	6.74e-09	0.00787	0.35	0.26	Breast cancer;	chr5:44752067	chr1:121519112~121571892:+
THCA	trans	rs1391708	0.834	rs34263825	ENSG00000121089.4	NACA3P	-5.91	6.75e-09	0.00789	-0.42	-0.26	Airway wall thickness;	chr12:56902465	chr4:164943290~164943937:+
THCA	trans	rs10435719	0.902	rs12681142	ENSG00000254153.1	CTA-398F10.2	-5.91	6.75e-09	0.00789	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:8456909~8461337:-
THCA	trans	rs11098499	0.913	rs12186259	ENSG00000253326.2	RP11-261C10.7	5.91	6.75e-09	0.00789	0.37	0.26	Corneal astigmatism;	chr4:119230884	chr1:243054861~243056394:-
THCA	trans	rs1962073	0.528	rs12544112	ENSG00000253893.2	FAM85B	-5.9	6.79e-09	0.00793	-0.34	-0.26	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10461305	chr8:8167819~8226614:-
THCA	trans	rs2985684	1	rs56098064	ENSG00000240785.1	RPL36AP21	5.9	6.81e-09	0.00796	0.33	0.26	Carotid intima media thickness;	chr14:49639131	chr5:18049550~18049872:+
THCA	trans	rs6683419	0.729	rs10917477	ENSG00000224237.1	MINOS1P3	-5.9	6.82e-09	0.00796	-0.33	-0.26	Serum thyroid-stimulating hormone levels;	chr1:19534612	chr3:27214816~27215018:-
THCA	trans	rs7824557	0.652	rs12677504	ENSG00000229857.1	RP11-159H20.3	5.9	6.82e-09	0.00797	0.33	0.26	Retinal vascular caliber;	chr8:11275666	chr9:76992099~76993108:+
THCA	trans	rs7429990	0.965	rs184388	ENSG00000235912.1	RP1-159A19.3	-5.9	6.83e-09	0.00798	-0.34	-0.26	Educational attainment (years of education);	chr3:47898136	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.965	rs319696	ENSG00000235912.1	RP1-159A19.3	-5.9	6.83e-09	0.00798	-0.34	-0.26	Educational attainment (years of education);	chr3:47902371	chr1:27649419~27649610:+
THCA	trans	rs7829975	0.511	rs2948286	ENSG00000256560.1	LINC01486	5.9	6.85e-09	0.008	0.31	0.26	Mood instability;	chr8:8272638	chr12:109354083~109359488:-
THCA	trans	rs930395	0.533	rs11948636	ENSG00000231752.4	EMBP1	-5.9	6.85e-09	0.008	-0.36	-0.26	Breast cancer;	chr5:44881127	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.8	rs994793	ENSG00000231752.4	EMBP1	5.9	6.86e-09	0.00801	0.35	0.26	Breast cancer;	chr5:44743145	chr1:121519112~121571892:+
THCA	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	5.9	6.88e-09	0.00803	0.39	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
THCA	trans	rs10435719	0.809	rs77601743	ENSG00000254153.1	CTA-398F10.2	-5.9	6.89e-09	0.00804	-0.31	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933060	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.678	rs74724594	ENSG00000254153.1	CTA-398F10.2	-5.9	6.89e-09	0.00804	-0.31	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933067	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.702	rs77055881	ENSG00000254153.1	CTA-398F10.2	-5.9	6.89e-09	0.00804	-0.31	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933072	chr8:8456909~8461337:-
THCA	trans	rs860295	0.529	rs11577179	ENSG00000241627.3	UBQLN4P1	5.9	6.92e-09	0.00807	0.29	0.26	Body mass index;	chr1:156013919	chr3:148985868~148987668:-
THCA	trans	rs7829975	0.714	rs60315134	ENSG00000229857.1	RP11-159H20.3	-5.9	6.95e-09	0.00811	-0.32	-0.26	Mood instability;	chr8:8813089	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.506	rs17689674	ENSG00000253893.2	FAM85B	-5.9	6.95e-09	0.00811	-0.33	-0.26	Neuroticism;	chr8:10124344	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.502	rs4841499	ENSG00000254153.1	CTA-398F10.2	5.9	6.96e-09	0.00812	0.31	0.26	Triglycerides;	chr8:11130628	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.84	rs572366	ENSG00000256560.1	LINC01486	5.9	6.96e-09	0.00812	0.31	0.26	Mood instability;	chr8:8721284	chr12:109354083~109359488:-
THCA	trans	rs4415084	0.716	rs4373287	ENSG00000231752.4	EMBP1	-5.9	6.97e-09	0.00813	-0.36	-0.26	Breast cancer;	chr5:44862782	chr1:121519112~121571892:+
THCA	trans	rs6035126	1	rs13433287	ENSG00000235482.1	RPL21P135	-5.9	6.97e-09	0.00814	-0.61	-0.26	Liver enzyme levels (alanine transaminase);	chr20:1950873	chr3:37748110~37748900:+
THCA	trans	rs9650657	0.615	rs2271355	ENSG00000253893.2	FAM85B	5.9	6.98e-09	0.00815	0.33	0.26	Neuroticism;	chr8:10834648	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.84	rs555617	ENSG00000256560.1	LINC01486	-5.9	7e-09	0.00816	-0.31	-0.26	Mood instability;	chr8:8735335	chr12:109354083~109359488:-
THCA	trans	rs4879677	1	rs4879677	ENSG00000269560.1	CTD-2192J16.21	5.9	7e-09	0.00817	0.34	0.26	Gut microbiome composition (summer and winter);	chr9:27664434	chr19:12529768~12532973:-
THCA	trans	rs9329221	0.592	rs7832708	ENSG00000254153.1	CTA-398F10.2	-5.9	7.02e-09	0.00818	-0.29	-0.26	Neuroticism;	chr8:10332530	chr8:8456909~8461337:-
THCA	trans	rs1190596	0.525	rs10134693	ENSG00000181359.5	HSP90AA6P	-5.9	7.05e-09	0.00822	-0.38	-0.26	Behavioural disinhibition (generation interaction);	chr14:102266987	chr4:170581470~170605450:-
THCA	trans	rs7819412	0.505	rs17726209	ENSG00000229857.1	RP11-159H20.3	-5.9	7.05e-09	0.00822	-0.35	-0.26	Triglycerides;	chr8:11164675	chr9:76992099~76993108:+
THCA	trans	rs10816533	1	rs10124911	ENSG00000232063.1	RP11-307E17.8	-5.9	7.05e-09	0.00822	-0.69	-0.26	Height;	chr9:96805102	chr9:94332476~94360948:+
THCA	trans	rs7819412	0.54	rs2409725	ENSG00000229857.1	RP11-159H20.3	5.9	7.05e-09	0.00822	0.35	0.26	Triglycerides;	chr8:11184152	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.54	rs2409726	ENSG00000229857.1	RP11-159H20.3	5.9	7.05e-09	0.00822	0.35	0.26	Triglycerides;	chr8:11185629	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.502	rs7820738	ENSG00000256560.1	LINC01486	-5.9	7.07e-09	0.00825	-0.31	-0.26	Mood instability;	chr8:8845097	chr12:109354083~109359488:-
THCA	trans	rs4415084	0.716	rs987394	ENSG00000231752.4	EMBP1	5.9	7.1e-09	0.00827	0.36	0.26	Breast cancer;	chr5:44846276	chr1:121519112~121571892:+
THCA	trans	rs2985684	1	rs7142457	ENSG00000240785.1	RPL36AP21	5.9	7.11e-09	0.00828	0.33	0.26	Carotid intima media thickness;	chr14:49631144	chr5:18049550~18049872:+
THCA	trans	rs2985684	0.901	rs2354448	ENSG00000240785.1	RPL36AP21	5.9	7.11e-09	0.00828	0.33	0.26	Carotid intima media thickness;	chr14:49631578	chr5:18049550~18049872:+
THCA	trans	rs2985684	1	rs1952012	ENSG00000240785.1	RPL36AP21	5.9	7.11e-09	0.00828	0.33	0.26	Carotid intima media thickness;	chr14:49632178	chr5:18049550~18049872:+
THCA	trans	rs7829975	0.744	rs2409092	ENSG00000229857.1	RP11-159H20.3	-5.9	7.13e-09	0.00831	-0.32	-0.26	Mood instability;	chr8:8824682	chr9:76992099~76993108:+
THCA	trans	rs2929451	0.566	rs17658270	ENSG00000229857.1	RP11-159H20.3	-5.9	7.13e-09	0.00831	-0.34	-0.26	Nose size;	chr8:9296109	chr9:76992099~76993108:+
THCA	trans	rs4295623	0.531	rs2898295	ENSG00000256560.1	LINC01486	-5.9	7.13e-09	0.00831	-0.31	-0.26	Morning vs. evening chronotype;	chr8:11738460	chr12:109354083~109359488:-
THCA	trans	rs9393777	0.777	rs56114371	ENSG00000228022.4	HCG20	-5.9	7.14e-09	0.00832	-0.66	-0.26	Intelligence (multi-trait analysis);	chr6:27307055	chr6:30766825~30792250:+
THCA	trans	rs9329221	0.905	rs10283145	ENSG00000229857.1	RP11-159H20.3	5.9	7.15e-09	0.00833	0.33	0.26	Neuroticism;	chr8:10383901	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.547	rs4512344	ENSG00000254153.1	CTA-398F10.2	5.89	7.18e-09	0.00836	0.3	0.26	Retinal vascular caliber;	chr8:11221272	chr8:8456909~8461337:-
THCA	trans	rs7113874	0.61	rs11041924	ENSG00000266891.1	RP11-692N5.2	5.89	7.21e-09	0.00839	0.34	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8441560	chr18:9734882~9735602:-
THCA	trans	rs9581094	1	rs73154395	ENSG00000237917.1	PARP4P1	-5.89	7.21e-09	0.0084	-0.49	-0.26	Sudden cardiac arrest;	chr13:24507665	chrY:26594851~26634652:-
THCA	trans	rs7520050	0.778	rs2934857	ENSG00000255397.1	AC022182.2	-5.89	7.25e-09	0.00844	-0.35	-0.26	Reticulocyte count;Red blood cell count;	chr1:45573940	chr8:60937705~60939871:-
THCA	trans	rs7824557	0.547	rs2409749	ENSG00000254153.1	CTA-398F10.2	5.89	7.26e-09	0.00845	0.3	0.26	Retinal vascular caliber;	chr8:11221440	chr8:8456909~8461337:-
THCA	trans	rs9467711	0.72	rs35627490	ENSG00000253570.1	RNF5P1	5.89	7.26e-09	0.00846	0.74	0.26	Autism spectrum disorder or schizophrenia;	chr6:26461876	chr8:38600661~38601200:-
THCA	trans	rs9467773	0.626	rs9379860	ENSG00000242375.1	RP11-498P14.3	-5.89	7.27e-09	0.00846	-0.38	-0.26	Intelligence (multi-trait analysis);	chr6:26370377	chr9:97195351~97197687:-
THCA	trans	rs7113874	0.589	rs7127684	ENSG00000266891.1	RP11-692N5.2	5.89	7.27e-09	0.00846	0.34	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8441172	chr18:9734882~9735602:-
THCA	trans	rs7746199	0.736	rs10484399	ENSG00000228022.4	HCG20	-5.89	7.28e-09	0.00847	-0.64	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:30766825~30792250:+
THCA	trans	rs2985684	1	rs2985687	ENSG00000240785.1	RPL36AP21	5.89	7.29e-09	0.00848	0.33	0.26	Carotid intima media thickness;	chr14:49633668	chr5:18049550~18049872:+
THCA	trans	rs2985684	0.948	rs2985685	ENSG00000240785.1	RPL36AP21	5.89	7.29e-09	0.00848	0.33	0.26	Carotid intima media thickness;	chr14:49634652	chr5:18049550~18049872:+
THCA	trans	rs2985684	1	rs2985684	ENSG00000240785.1	RPL36AP21	5.89	7.29e-09	0.00848	0.33	0.26	Carotid intima media thickness;	chr14:49634964	chr5:18049550~18049872:+
THCA	trans	rs7312770	1	rs7312770	ENSG00000242206.2	RPS26P35	-5.89	7.33e-09	0.00852	-0.29	-0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:118761856~118762201:-
THCA	trans	rs6601327	0.602	rs7820917	ENSG00000253893.2	FAM85B	-5.89	7.34e-09	0.00853	-0.33	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9790358	chr8:8167819~8226614:-
THCA	trans	rs7826238	0.564	rs2921053	ENSG00000229857.1	RP11-159H20.3	-5.89	7.35e-09	0.00855	-0.32	-0.26	Systolic blood pressure;	chr8:8462453	chr9:76992099~76993108:+
THCA	trans	rs1908814	0.516	rs4840597	ENSG00000254153.1	CTA-398F10.2	-5.89	7.37e-09	0.00857	-0.3	-0.26	Neuroticism;	chr8:11938559	chr8:8456909~8461337:-
THCA	trans	rs804280	0.509	rs4841639	ENSG00000254153.1	CTA-398F10.2	-5.89	7.37e-09	0.00857	-0.3	-0.26	Myopia (pathological);	chr8:11938584	chr8:8456909~8461337:-
THCA	trans	rs853679	0.769	rs7752608	ENSG00000204338.7	CYP21A1P	-5.89	7.38e-09	0.00858	-0.53	-0.26	Depression;	chr6:28333418	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.72	rs3857546	ENSG00000280107.1	AL022393.9	-5.89	7.39e-09	0.0086	-0.38	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26157534	chr6:28170845~28172521:+
THCA	trans	rs7429990	0.93	rs71323371	ENSG00000235912.1	RP1-159A19.3	-5.89	7.39e-09	0.0086	-0.34	-0.26	Educational attainment (years of education);	chr3:47904327	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.932	rs34025851	ENSG00000235912.1	RP1-159A19.3	-5.89	7.39e-09	0.0086	-0.34	-0.26	Educational attainment (years of education);	chr3:47912243	chr1:27649419~27649610:+
THCA	trans	rs453301	0.606	rs7462373	ENSG00000229857.1	RP11-159H20.3	5.89	7.39e-09	0.0086	0.32	0.26	Joint mobility (Beighton score);	chr8:9041808	chr9:76992099~76993108:+
THCA	trans	rs9467711	0.606	rs9379873	ENSG00000253570.1	RNF5P1	5.89	7.4e-09	0.0086	0.63	0.26	Autism spectrum disorder or schizophrenia;	chr6:26402489	chr8:38600661~38601200:-
THCA	trans	rs4930561	0.765	rs10896304	ENSG00000155070.8	UNC93B2	-5.89	7.41e-09	0.00861	-0.31	-0.26	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68214247	chr7:6855485~6859830:-
THCA	trans	rs7824557	0.603	rs2246606	ENSG00000254153.1	CTA-398F10.2	-5.89	7.42e-09	0.00863	-0.3	-0.26	Retinal vascular caliber;	chr8:11361825	chr8:8456909~8461337:-
THCA	trans	rs9650657	0.513	rs4314618	ENSG00000254153.1	CTA-398F10.2	5.89	7.43e-09	0.00864	0.29	0.26	Neuroticism;	chr8:10959262	chr8:8456909~8461337:-
THCA	trans	rs902774	0.818	rs4919737	ENSG00000220378.3	KRT8P42	-5.89	7.44e-09	0.00865	-0.57	-0.26	Prostate cancer;	chr12:52877011	chr6:134296997~134298695:-
THCA	trans	rs902774	0.818	rs73108429	ENSG00000220378.3	KRT8P42	-5.89	7.44e-09	0.00865	-0.57	-0.26	Prostate cancer;	chr12:52877887	chr6:134296997~134298695:-
THCA	trans	rs17711722	0.523	rs313812	ENSG00000234585.5	CCT6P3	-5.89	7.45e-09	0.00866	-0.24	-0.26	Calcium levels;	chr7:66040056	chr7:65038354~65074713:+
THCA	trans	rs11098499	0.661	rs10015965	ENSG00000253326.2	RP11-261C10.7	5.89	7.45e-09	0.00866	0.35	0.26	Corneal astigmatism;	chr4:119347082	chr1:243054861~243056394:-
THCA	trans	rs2439831	1	rs1814538	ENSG00000180867.10	PDIA3P1	5.89	7.46e-09	0.00868	0.28	0.26	Lung cancer in ever smokers;	chr15:43467576	chr1:147178113~147179622:+
THCA	trans	rs9581094	1	rs73154401	ENSG00000237917.1	PARP4P1	-5.89	7.48e-09	0.00869	-0.49	-0.26	Sudden cardiac arrest;	chr13:24511529	chrY:26594851~26634652:-
THCA	trans	rs6601450	0.534	rs1133184	ENSG00000253893.2	FAM85B	5.89	7.48e-09	0.0087	0.33	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10369050	chr8:8167819~8226614:-
THCA	trans	rs7200543	1	rs55727637	ENSG00000255185.4	PDXDC2P	5.89	7.49e-09	0.0087	0.37	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:70010751~70065945:-
THCA	trans	rs9329221	0.662	rs9650650	ENSG00000254153.1	CTA-398F10.2	-5.89	7.5e-09	0.00871	-0.3	-0.26	Neuroticism;	chr8:10390466	chr8:8456909~8461337:-
THCA	trans	rs7200543	1	rs7200543	ENSG00000255185.4	PDXDC2P	-5.89	7.51e-09	0.00872	-0.37	-0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:70010751~70065945:-
THCA	trans	rs7824557	0.603	rs6995404	ENSG00000253893.2	FAM85B	-5.89	7.52e-09	0.00873	-0.34	-0.26	Retinal vascular caliber;	chr8:11324639	chr8:8167819~8226614:-
THCA	trans	rs889398	0.741	rs3790076	ENSG00000257513.6	NPIPB1P	-5.89	7.53e-09	0.00875	-0.29	-0.26	Body mass index;	chr16:69873542	chr18:11619509~11639699:-
THCA	trans	rs6601327	0.571	rs7820675	ENSG00000253893.2	FAM85B	-5.89	7.54e-09	0.00875	-0.33	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9790238	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs13260727	ENSG00000254153.1	CTA-398F10.2	-5.89	7.54e-09	0.00876	-0.29	-0.26	Retinal vascular caliber;	chr8:11375351	chr8:8456909~8461337:-
THCA	trans	rs853679	0.567	rs16894091	ENSG00000228078.1	HLA-U	5.89	7.54e-09	0.00876	0.36	0.26	Depression;	chr6:28422360	chr6:29934101~29934286:+
THCA	trans	rs4415084	0.652	rs10070928	ENSG00000231752.4	EMBP1	-5.89	7.55e-09	0.00877	-0.36	-0.26	Breast cancer;	chr5:44888455	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.623	rs7833435	ENSG00000256560.1	LINC01486	-5.89	7.56e-09	0.00878	-0.32	-0.26	Triglycerides;	chr8:10943627	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.711	rs4481596	ENSG00000229857.1	RP11-159H20.3	-5.89	7.57e-09	0.00879	-0.33	-0.26	Mood instability;	chr8:8846820	chr9:76992099~76993108:+
THCA	trans	rs7746199	0.736	rs34965299	ENSG00000228022.4	HCG20	-5.88	7.58e-09	0.0088	-0.66	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:30766825~30792250:+
THCA	trans	rs35491132	1	rs35491132	ENSG00000228022.4	HCG20	-5.88	7.58e-09	0.0088	-0.66	-0.26	Urinary tract infection frequency;	chr6:27559449	chr6:30766825~30792250:+
THCA	trans	rs2665103	0.61	rs56398167	ENSG00000235370.6	DNM1P51	-5.88	7.59e-09	0.00881	-0.32	-0.26	Intelligence (multi-trait analysis);	chr15:82237482	chr15:84398316~84411701:-
THCA	trans	rs853679	0.556	rs45509595	ENSG00000204338.7	CYP21A1P	-5.88	7.63e-09	0.00886	-0.59	-0.26	Depression;	chr6:27873148	chr6:32005636~32008451:+
THCA	trans	rs453301	0.686	rs4840389	ENSG00000256560.1	LINC01486	-5.88	7.65e-09	0.00888	-0.31	-0.26	Joint mobility (Beighton score);	chr8:9026993	chr12:109354083~109359488:-
THCA	trans	rs453301	0.658	rs13271797	ENSG00000256560.1	LINC01486	-5.88	7.65e-09	0.00888	-0.31	-0.26	Joint mobility (Beighton score);	chr8:9028444	chr12:109354083~109359488:-
THCA	trans	rs7647973	0.667	rs6446286	ENSG00000197582.5	GPX1P1	5.88	7.66e-09	0.00889	0.47	0.26	Menarche (age at onset);	chr3:49644271	chrX:13378735~13379340:-
THCA	trans	rs7824557	0.583	rs2736306	ENSG00000254153.1	CTA-398F10.2	-5.88	7.7e-09	0.00893	-0.29	-0.26	Retinal vascular caliber;	chr8:11382253	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.902	rs7459983	ENSG00000254153.1	CTA-398F10.2	-5.88	7.71e-09	0.00894	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.774	rs1039915	ENSG00000229857.1	RP11-159H20.3	-5.88	7.72e-09	0.00895	-0.32	-0.26	Mood instability;	chr8:8822104	chr9:76992099~76993108:+
THCA	trans	rs804280	0.509	rs13276433	ENSG00000254153.1	CTA-398F10.2	-5.88	7.72e-09	0.00895	-0.3	-0.26	Myopia (pathological);	chr8:11925527	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.774	rs35039922	ENSG00000229857.1	RP11-159H20.3	-5.88	7.73e-09	0.00896	-0.32	-0.26	Mood instability;	chr8:8817815	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.691	rs73198970	ENSG00000229857.1	RP11-159H20.3	5.88	7.73e-09	0.00897	0.34	0.26	Triglycerides;	chr8:11182707	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.774	rs57312668	ENSG00000229857.1	RP11-159H20.3	-5.88	7.74e-09	0.00898	-0.32	-0.26	Mood instability;	chr8:8822967	chr9:76992099~76993108:+
THCA	trans	rs7192380	0.737	rs7204433	ENSG00000257513.6	NPIPB1P	5.88	7.77e-09	0.00901	0.3	0.26	Sjögren's syndrome;	chr16:69556021	chr18:11619509~11639699:-
THCA	trans	rs6601327	0.635	rs7844461	ENSG00000253893.2	FAM85B	-5.88	7.79e-09	0.00903	-0.34	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9795545	chr8:8167819~8226614:-
THCA	trans	rs2164273	0.565	rs2736387	ENSG00000253893.2	FAM85B	-5.88	7.8e-09	0.00904	-0.35	-0.26	Extraversion;	chr8:11299862	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.902	rs4840599	ENSG00000254153.1	CTA-398F10.2	5.88	7.8e-09	0.00904	0.3	0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:8456909~8461337:-
THCA	trans	rs9329221	0.537	rs13282106	ENSG00000253893.2	FAM85B	-5.88	7.84e-09	0.00909	-0.33	-0.26	Neuroticism;	chr8:10124390	chr8:8167819~8226614:-
THCA	trans	rs330048	0.545	rs11781008	ENSG00000229857.1	RP11-159H20.3	-5.88	7.85e-09	0.00909	-0.33	-0.26	Systemic lupus erythematosus;	chr8:9295729	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.522	rs6601689	ENSG00000229857.1	RP11-159H20.3	-5.88	7.86e-09	0.0091	-0.33	-0.26	Mood instability;	chr8:8314761	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.505	rs17782536	ENSG00000229857.1	RP11-159H20.3	5.88	7.87e-09	0.00912	0.35	0.26	Triglycerides;	chr8:11164172	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.508	rs6601455	ENSG00000253893.2	FAM85B	-5.88	7.87e-09	0.00912	-0.36	-0.26	Neuroticism;	chr8:10415916	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.665	rs12543369	ENSG00000253893.2	FAM85B	5.88	7.89e-09	0.00915	0.34	0.26	Multiple myeloma (hyperdiploidy);	chr8:9798405	chr8:8167819~8226614:-
THCA	trans	rs6601327	0.665	rs12546411	ENSG00000253893.2	FAM85B	5.88	7.89e-09	0.00915	0.34	0.26	Multiple myeloma (hyperdiploidy);	chr8:9798406	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.562	rs10090444	ENSG00000256560.1	LINC01486	5.88	7.9e-09	0.00915	0.31	0.26	Neuroticism;	chr8:10887959	chr12:109354083~109359488:-
THCA	trans	rs3096299	0.503	rs9925045	ENSG00000215030.5	RPL13P12	-5.88	7.94e-09	0.0092	-0.27	-0.26	Multiple myeloma (IgH translocation);	chr16:89490068	chr17:17383377~17384012:-
THCA	trans	rs4879677	1	rs10757676	ENSG00000269560.1	CTD-2192J16.21	-5.88	7.95e-09	0.0092	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27680309	chr19:12529768~12532973:-
THCA	trans	rs12472274	0.648	rs67102443	ENSG00000224699.7	LAMTOR5-AS1	-5.88	7.97e-09	0.00923	-0.21	-0.26	Phospholipid levels (plasma);	chr2:238175961	chr1:110347116~110443817:+
THCA	trans	rs6035126	1	rs13433286	ENSG00000235482.1	RPL21P135	-5.88	7.99e-09	0.00925	-0.63	-0.26	Liver enzyme levels (alanine transaminase);	chr20:1950854	chr3:37748110~37748900:+
THCA	trans	rs7824557	0.603	rs2736278	ENSG00000254153.1	CTA-398F10.2	-5.88	8.01e-09	0.00928	-0.3	-0.26	Retinal vascular caliber;	chr8:11362272	chr8:8456909~8461337:-
THCA	trans	rs9987353	0.518	rs4841110	ENSG00000229857.1	RP11-159H20.3	-5.87	8.04e-09	0.00931	-0.33	-0.26	Recombination measurement;	chr8:9228513	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.521	rs17693945	ENSG00000229857.1	RP11-159H20.3	5.87	8.05e-09	0.00932	0.34	0.26	Neuroticism;	chr8:10248500	chr9:76992099~76993108:+
THCA	trans	rs930395	0.514	rs9791164	ENSG00000231752.4	EMBP1	5.87	8.06e-09	0.00933	0.35	0.26	Breast cancer;	chr5:44903928	chr1:121519112~121571892:+
THCA	trans	rs11671005	0.779	rs11670125	ENSG00000279267.1	RP11-395L14.18	5.87	8.07e-09	0.00933	0.39	0.26	Mean platelet volume;	chr19:58476023	chr2:113605867~113607908:-
THCA	trans	rs9329221	0.537	rs13254175	ENSG00000253893.2	FAM85B	-5.87	8.07e-09	0.00933	-0.32	-0.26	Neuroticism;	chr8:10121262	chr8:8167819~8226614:-
THCA	trans	rs9914988	0.537	rs28448745	ENSG00000267449.1	RP11-264B14.2	-5.87	8.07e-09	0.00934	-0.39	-0.26	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28861278	chr17:61069856~61070356:-
THCA	trans	rs3096299	0.642	rs12934829	ENSG00000215030.5	RPL13P12	-5.87	8.08e-09	0.00935	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89456941	chr17:17383377~17384012:-
THCA	trans	rs9650657	0.589	rs12542037	ENSG00000256560.1	LINC01486	5.87	8.09e-09	0.00936	0.3	0.26	Neuroticism;	chr8:10900986	chr12:109354083~109359488:-
THCA	trans	rs4879677	1	rs10812642	ENSG00000269560.1	CTD-2192J16.21	-5.87	8.1e-09	0.00937	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27684906	chr19:12529768~12532973:-
THCA	trans	rs7826238	0.594	rs2948285	ENSG00000256560.1	LINC01486	5.87	8.13e-09	0.0094	0.31	0.26	Systolic blood pressure;	chr8:8273016	chr12:109354083~109359488:-
THCA	trans	rs6601327	0.67	rs6601338	ENSG00000253893.2	FAM85B	-5.87	8.13e-09	0.0094	-0.33	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9581418	chr8:8167819~8226614:-
THCA	trans	rs853679	0.546	rs71537572	ENSG00000204338.7	CYP21A1P	-5.87	8.14e-09	0.00942	-0.58	-0.26	Depression;	chr6:28002937	chr6:32005636~32008451:+
THCA	trans	rs7819412	0.56	rs3021497	ENSG00000254153.1	CTA-398F10.2	5.87	8.15e-09	0.00942	0.31	0.26	Triglycerides;	chr8:11138579	chr8:8456909~8461337:-
THCA	trans	rs7746199	0.673	rs72847313	ENSG00000204338.7	CYP21A1P	-5.87	8.15e-09	0.00943	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.611	rs17750747	ENSG00000204338.7	CYP21A1P	-5.87	8.15e-09	0.00943	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:32005636~32008451:+
THCA	trans	rs7824557	0.707	rs3808519	ENSG00000229857.1	RP11-159H20.3	-5.87	8.15e-09	0.00943	-0.33	-0.26	Retinal vascular caliber;	chr8:11285461	chr9:76992099~76993108:+
THCA	trans	rs1045529	0.524	rs34251783	ENSG00000256560.1	LINC01486	-5.87	8.16e-09	0.00943	-0.31	-0.26	Myopia (pathological);Myopia;	chr8:9033866	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.51	rs332037	ENSG00000229857.1	RP11-159H20.3	-5.87	8.17e-09	0.00944	-0.34	-0.26	Mood instability;	chr8:8865165	chr9:76992099~76993108:+
THCA	trans	rs9650657	1	rs9650657	ENSG00000229857.1	RP11-159H20.3	5.87	8.18e-09	0.00945	0.31	0.26	Neuroticism;	chr8:10749890	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.513	rs4841459	ENSG00000229857.1	RP11-159H20.3	5.87	8.18e-09	0.00946	0.32	0.26	Neuroticism;	chr8:10924932	chr9:76992099~76993108:+
THCA	trans	rs7647973	0.626	rs1078341	ENSG00000197582.5	GPX1P1	5.87	8.2e-09	0.00948	0.47	0.26	Menarche (age at onset);	chr3:49648159	chrX:13378735~13379340:-
THCA	trans	rs1962073	0.577	rs11250005	ENSG00000253893.2	FAM85B	5.87	8.22e-09	0.0095	0.35	0.26	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10421168	chr8:8167819~8226614:-
THCA	trans	rs2985684	1	rs17121651	ENSG00000240785.1	RPL36AP21	5.87	8.24e-09	0.00952	0.33	0.26	Carotid intima media thickness;	chr14:49630454	chr5:18049550~18049872:+
THCA	trans	rs11739656	0.831	rs9654464	ENSG00000245532.5	NEAT1	5.87	8.25e-09	0.00954	0.28	0.26	Night sleep phenotypes;	chr5:174774167	chr11:65422774~65445540:+
THCA	trans	rs7824557	0.602	rs7834139	ENSG00000253893.2	FAM85B	-5.87	8.25e-09	0.00954	-0.35	-0.26	Retinal vascular caliber;	chr8:11348854	chr8:8167819~8226614:-
THCA	trans	rs11098499	0.615	rs28551750	ENSG00000253326.2	RP11-261C10.7	5.87	8.27e-09	0.00955	0.35	0.26	Corneal astigmatism;	chr4:119343746	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.691	rs9995716	ENSG00000253326.2	RP11-261C10.7	5.87	8.27e-09	0.00955	0.35	0.26	Corneal astigmatism;	chr4:119343841	chr1:243054861~243056394:-
THCA	trans	rs9649213	0.574	rs7802541	ENSG00000225169.1	BRI3P1	5.87	8.27e-09	0.00956	0.34	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr1:100213293~100213670:+
THCA	trans	rs3096299	0.685	rs3803681	ENSG00000215030.5	RPL13P12	-5.87	8.29e-09	0.00957	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89478348	chr17:17383377~17384012:-
THCA	trans	rs9329221	0.537	rs12678800	ENSG00000253893.2	FAM85B	-5.87	8.29e-09	0.00958	-0.32	-0.26	Neuroticism;	chr8:10121430	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.537	rs13264586	ENSG00000253893.2	FAM85B	-5.87	8.3e-09	0.00959	-0.33	-0.26	Neuroticism;	chr8:10121875	chr8:8167819~8226614:-
THCA	trans	rs9584850	0.915	rs7983438	ENSG00000230079.1	STK24P1	5.87	8.3e-09	0.00959	0.31	0.26	Neuroticism;	chr13:98451063	chrX:136295690~136300298:-
THCA	trans	rs6981523	0.532	rs1987190	ENSG00000229857.1	RP11-159H20.3	5.87	8.3e-09	0.00959	0.36	0.26	Neuroticism;	chr8:11196005	chr9:76992099~76993108:+
THCA	trans	rs1063857	0.656	rs216292	ENSG00000241717.1	VWFP1	5.87	8.35e-09	0.00964	0.3	0.26	vWF levels;Coagulation factor levels;	chr12:6043810	chr22:16690103~16704477:-
THCA	trans	rs7824557	0.614	rs7816606	ENSG00000253893.2	FAM85B	-5.87	8.36e-09	0.00965	-0.35	-0.26	Retinal vascular caliber;	chr8:11348093	chr8:8167819~8226614:-
THCA	trans	rs2048656	0.535	rs2014514	ENSG00000253893.2	FAM85B	-5.87	8.37e-09	0.00967	-0.33	-0.26	Schizophrenia;	chr8:9789686	chr8:8167819~8226614:-
THCA	trans	rs7746199	0.736	rs13212318	ENSG00000204338.7	CYP21A1P	-5.87	8.39e-09	0.00968	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs13202291	ENSG00000204338.7	CYP21A1P	-5.87	8.39e-09	0.00968	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs17750424	ENSG00000204338.7	CYP21A1P	-5.87	8.39e-09	0.00968	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:32005636~32008451:+
THCA	trans	rs6981523	0.553	rs2409730	ENSG00000229857.1	RP11-159H20.3	5.87	8.44e-09	0.00974	0.34	0.26	Neuroticism;	chr8:11203129	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.716	rs6451778	ENSG00000231752.4	EMBP1	-5.87	8.44e-09	0.00974	-0.36	-0.26	Breast cancer;	chr5:44857886	chr1:121519112~121571892:+
THCA	trans	rs9393777	0.92	rs55834529	ENSG00000280107.1	AL022393.9	-5.87	8.44e-09	0.00974	-0.55	-0.26	Intelligence (multi-trait analysis);	chr6:27104763	chr6:28170845~28172521:+
THCA	trans	rs601162	0.516	rs62539461	ENSG00000268278.1	RP11-420K14.1	-5.87	8.44e-09	0.00974	-0.39	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr9:29747927	chr19:21637974~21656300:+
THCA	trans	rs7746199	0.736	rs72845070	ENSG00000204338.7	CYP21A1P	-5.87	8.46e-09	0.00976	-0.62	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:32005636~32008451:+
THCA	trans	rs9650657	0.615	rs11986935	ENSG00000253893.2	FAM85B	5.87	8.48e-09	0.00978	0.33	0.26	Neuroticism;	chr8:10834039	chr8:8167819~8226614:-
THCA	trans	rs4879677	1	rs10812637	ENSG00000269560.1	CTD-2192J16.21	-5.86	8.49e-09	0.00979	-0.34	-0.26	Gut microbiome composition (summer and winter);	chr9:27664832	chr19:12529768~12532973:-
THCA	trans	rs9393777	0.841	rs67092078	ENSG00000204338.7	CYP21A1P	-5.86	8.49e-09	0.0098	-0.59	-0.26	Intelligence (multi-trait analysis);	chr6:27086993	chr6:32005636~32008451:+
THCA	trans	rs7647973	0.626	rs9830730	ENSG00000197582.5	GPX1P1	5.86	8.5e-09	0.00981	0.47	0.26	Menarche (age at onset);	chr3:49638442	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs2329021	ENSG00000197582.5	GPX1P1	5.86	8.5e-09	0.00981	0.47	0.26	Menarche (age at onset);	chr3:49641639	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.587	rs10452032	ENSG00000197582.5	GPX1P1	5.86	8.5e-09	0.00981	0.47	0.26	Menarche (age at onset);	chr3:49643540	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs4855846	ENSG00000197582.5	GPX1P1	5.86	8.5e-09	0.00981	0.47	0.26	Menarche (age at onset);	chr3:49646093	chrX:13378735~13379340:-
THCA	trans	rs2439831	0.681	rs498837	ENSG00000180867.10	PDIA3P1	-5.86	8.52e-09	0.00983	-0.28	-0.26	Lung cancer in ever smokers;	chr15:43315826	chr1:147178113~147179622:+
THCA	trans	rs10028773	0.6	rs4001390	ENSG00000253326.2	RP11-261C10.7	5.86	8.52e-09	0.00983	0.34	0.26	Educational attainment;	chr4:119344628	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.691	rs2136911	ENSG00000253326.2	RP11-261C10.7	5.86	8.52e-09	0.00983	0.34	0.26	Corneal astigmatism;	chr4:119344704	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.779	rs6815934	ENSG00000253326.2	RP11-261C10.7	5.86	8.52e-09	0.00983	0.34	0.26	Corneal astigmatism;	chr4:119346155	chr1:243054861~243056394:-
THCA	trans	rs10028773	0.568	rs6838457	ENSG00000253326.2	RP11-261C10.7	5.86	8.52e-09	0.00983	0.34	0.26	Educational attainment;	chr4:119346212	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.535	rs10005542	ENSG00000253326.2	RP11-261C10.7	5.86	8.52e-09	0.00983	0.34	0.26	Corneal astigmatism;	chr4:119347147	chr1:243054861~243056394:-
THCA	trans	rs9650657	0.615	rs11996727	ENSG00000253893.2	FAM85B	5.86	8.55e-09	0.00986	0.33	0.26	Neuroticism;	chr8:10833979	chr8:8167819~8226614:-
THCA	trans	rs12477438	0.52	rs1044575	ENSG00000276576.1	MRPL30P1	5.86	8.57e-09	0.00988	0.34	0.26	Chronic sinus infection;	chr2:99195607	chr6:57029521~57029988:+
THCA	trans	rs11992162	0.967	rs4840601	ENSG00000254153.1	CTA-398F10.2	-5.86	8.58e-09	0.00989	-0.3	-0.26	Monocyte count;	chr8:11971221	chr8:8456909~8461337:-
THCA	trans	rs7746199	0.736	rs13193542	ENSG00000253570.1	RNF5P1	5.86	8.59e-09	0.0099	0.74	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr8:38600661~38601200:-
THCA	trans	rs7746199	0.736	rs13193480	ENSG00000253570.1	RNF5P1	5.86	8.59e-09	0.0099	0.74	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr8:38600661~38601200:-
THCA	trans	rs7819412	0.595	rs10106914	ENSG00000229857.1	RP11-159H20.3	5.86	8.6e-09	0.00992	0.33	0.26	Triglycerides;	chr8:11130141	chr9:76992099~76993108:+
THCA	trans	rs10774547	0.785	rs2076022	ENSG00000226976.3	COX6A1P2	-5.86	8.63e-09	0.00994	-0.23	-0.26	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy);	chr12:120437987	chr6:37044860~37045189:+
THCA	trans	rs7200543	0.583	rs4985149	ENSG00000255185.4	PDXDC2P	5.86	8.64e-09	0.00995	0.37	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:70010751~70065945:-
THCA	trans	rs11668609	1	rs11668609	ENSG00000261770.1	CTC-459F4.1	5.86	8.64e-09	0.00995	0.36	0.26	Response to taxane treatment (docetaxel);	chr19:24172691	chr19:27757184~27760849:-
THCA	trans	rs889398	0.741	rs6499268	ENSG00000257513.6	NPIPB1P	5.86	8.64e-09	0.00995	0.3	0.26	Body mass index;	chr16:69872626	chr18:11619509~11639699:-
THCA	trans	rs4879656	0.866	rs10971227	ENSG00000215007.3	DNAJA1P3	-5.86	8.65e-09	0.00997	-0.3	-0.26	Menopause (age at onset);	chr9:32934619	chrX:107351650~107352843:-
THCA	trans	rs4646450	0.891	rs10238965	ENSG00000228834.1	RP11-249L21.4	5.86	8.67e-09	0.00999	0.42	0.26	Blood metabolite levels;	chr7:99548222	chr6:108907615~108907873:-
THCA	trans	rs9807841	0.592	rs7250071	ENSG00000226084.5	RP4-706A16.3	5.86	8.67e-09	0.00999	0.28	0.26	Inflammatory skin disease;	chr19:10655143	chr1:77129114~77129668:+
THCA	trans	rs34421088	0.576	rs2736369	ENSG00000256560.1	LINC01486	-5.86	8.67e-09	0.00999	-0.35	-0.26	Neuroticism;	chr8:11243889	chr12:109354083~109359488:-
THCA	trans	rs7694207	0.615	rs13107706	ENSG00000215481.7	BCRP3	5.86	8.68e-09	0.01	0.28	0.26	Response to mTOR inhibitor (everolimus);	chr4:96961868	chr22:24632915~24653356:+
THCA	trans	rs4415084	0.635	rs7736952	ENSG00000231752.4	EMBP1	5.86	8.68e-09	0.01	0.36	0.26	Breast cancer;	chr5:44790277	chr1:121519112~121571892:+
THCA	trans	rs546131	0.82	rs744841	ENSG00000225531.1	RP11-196I18.3	5.86	8.7e-09	0.01	0.34	0.26	Lung disease severity in cystic fibrosis;	chr11:34836120	chr9:107116829~107117557:+
THCA	trans	rs7520050	0.645	rs1768809	ENSG00000255397.1	AC022182.2	5.86	8.72e-09	0.01	0.34	0.26	Reticulocyte count;Red blood cell count;	chr1:46037164	chr8:60937705~60939871:-
THCA	trans	rs9650657	0.572	rs4841465	ENSG00000254153.1	CTA-398F10.2	5.86	8.76e-09	0.0101	0.28	0.26	Neuroticism;	chr8:10962344	chr8:8456909~8461337:-
THCA	trans	rs3096299	0.685	rs3803682	ENSG00000215030.5	RPL13P12	-5.86	8.79e-09	0.0101	-0.27	-0.26	Multiple myeloma (IgH translocation);	chr16:89478228	chr17:17383377~17384012:-
THCA	trans	rs9650657	0.513	rs7005884	ENSG00000256560.1	LINC01486	-5.86	8.8e-09	0.0101	-0.31	-0.26	Neuroticism;	chr8:10938962	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.644	rs10009566	ENSG00000253326.2	RP11-261C10.7	5.86	8.8e-09	0.0101	0.35	0.26	Corneal astigmatism;	chr4:119637453	chr1:243054861~243056394:-
THCA	trans	rs11671005	0.779	rs3794971	ENSG00000279267.1	RP11-395L14.18	5.86	8.81e-09	0.0101	0.39	0.26	Mean platelet volume;	chr19:58474499	chr2:113605867~113607908:-
THCA	trans	rs4415084	0.716	rs16901964	ENSG00000231752.4	EMBP1	5.86	8.82e-09	0.0102	0.36	0.26	Breast cancer;	chr5:44783153	chr1:121519112~121571892:+
THCA	trans	rs45509595	0.841	rs17751184	ENSG00000204338.7	CYP21A1P	-5.86	8.83e-09	0.0102	-0.58	-0.26	Breast cancer;	chr6:27807250	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs67101035	ENSG00000204338.7	CYP21A1P	-5.86	8.83e-09	0.0102	-0.58	-0.26	Depression;	chr6:27831109	chr6:32005636~32008451:+
THCA	trans	rs853679	0.556	rs34706883	ENSG00000204338.7	CYP21A1P	-5.86	8.83e-09	0.0102	-0.58	-0.26	Depression;	chr6:27837477	chr6:32005636~32008451:+
THCA	trans	rs67340775	0.748	rs13212651	ENSG00000204338.7	CYP21A1P	-5.86	8.83e-09	0.0102	-0.58	-0.26	Lung cancer in ever smokers;	chr6:27839207	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs35819751	ENSG00000204338.7	CYP21A1P	-5.86	8.83e-09	0.0102	-0.58	-0.26	Depression;	chr6:27842791	chr6:32005636~32008451:+
THCA	trans	rs7819412	0.634	rs4841485	ENSG00000256560.1	LINC01486	5.86	8.87e-09	0.0102	0.32	0.26	Triglycerides;	chr8:11052426	chr12:109354083~109359488:-
THCA	trans	rs1478897	0.898	rs2249040	ENSG00000253893.2	FAM85B	5.86	8.88e-09	0.0102	0.35	0.26	Systemic lupus erythematosus;	chr8:11533270	chr8:8167819~8226614:-
THCA	trans	rs453301	0.686	rs6748	ENSG00000256560.1	LINC01486	-5.86	8.91e-09	0.0102	-0.31	-0.26	Joint mobility (Beighton score);	chr8:9033292	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.554	rs2175381	ENSG00000253326.2	RP11-261C10.7	5.86	8.94e-09	0.0103	0.34	0.26	Corneal astigmatism;	chr4:119344812	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.599	rs3864142	ENSG00000253326.2	RP11-261C10.7	5.86	8.94e-09	0.0103	0.34	0.26	Corneal astigmatism;	chr4:119345036	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.605	rs6833140	ENSG00000253326.2	RP11-261C10.7	5.86	8.94e-09	0.0103	0.34	0.26	Corneal astigmatism;	chr4:119345667	chr1:243054861~243056394:-
THCA	trans	rs11958034	1	rs11957769	ENSG00000271874.1	CTD-2024P10.2	-5.86	8.95e-09	0.0103	-0.41	-0.26	Mitochondrial DNA levels;	chr5:18912236	chr5:34651457~34651888:-
THCA	trans	rs9650657	0.504	rs6601566	ENSG00000254153.1	CTA-398F10.2	5.86	8.95e-09	0.0103	0.3	0.26	Neuroticism;	chr8:11185465	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.574	rs4841559	ENSG00000254153.1	CTA-398F10.2	5.86	8.96e-09	0.0103	0.29	0.26	Neuroticism;	chr8:11559376	chr8:8456909~8461337:-
THCA	trans	rs1475911	0.708	rs11701371	ENSG00000229759.1	MRPS18AP1	-5.85	8.99e-09	0.0103	-0.34	-0.26	IgG glycosylation;	chr21:42103862	chr3:48256350~48256938:-
THCA	trans	rs7829975	0.871	rs572307	ENSG00000256560.1	LINC01486	-5.85	9.01e-09	0.0104	-0.31	-0.26	Mood instability;	chr8:8721301	chr12:109354083~109359488:-
THCA	trans	rs9584850	0.874	rs3742137	ENSG00000230079.1	STK24P1	5.85	9.01e-09	0.0104	0.31	0.26	Neuroticism;	chr13:98450195	chrX:136295690~136300298:-
THCA	trans	rs12477438	0.52	rs11123764	ENSG00000276576.1	MRPL30P1	5.85	9.03e-09	0.0104	0.33	0.26	Chronic sinus infection;	chr2:99134214	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.501	rs12995473	ENSG00000276576.1	MRPL30P1	5.85	9.03e-09	0.0104	0.33	0.26	Chronic sinus infection;	chr2:99148421	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.501	rs11685756	ENSG00000276576.1	MRPL30P1	5.85	9.03e-09	0.0104	0.33	0.26	Chronic sinus infection;	chr2:99149752	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6708576	ENSG00000276576.1	MRPL30P1	5.85	9.03e-09	0.0104	0.33	0.26	Chronic sinus infection;	chr2:99184845	chr6:57029521~57029988:+
THCA	trans	rs3096299	0.658	rs4785679	ENSG00000215030.5	RPL13P12	-5.85	9.06e-09	0.0104	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89499705	chr17:17383377~17384012:-
THCA	trans	rs6601327	0.736	rs4840426	ENSG00000253893.2	FAM85B	-5.85	9.07e-09	0.0104	-0.33	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9551468	chr8:8167819~8226614:-
THCA	trans	rs9467711	0.72	rs1417998	ENSG00000280107.1	AL022393.9	-5.85	9.1e-09	0.0105	-0.38	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26161791	chr6:28170845~28172521:+
THCA	trans	rs4629607	1	rs4629607	ENSG00000231752.4	EMBP1	-5.85	9.11e-09	0.0105	-0.36	-0.26	Schizophrenia;	chr5:44857365	chr1:121519112~121571892:+
THCA	trans	rs9650657	0.538	rs11250093	ENSG00000256560.1	LINC01486	5.85	9.14e-09	0.0105	0.32	0.26	Neuroticism;	chr8:10941318	chr12:109354083~109359488:-
THCA	trans	rs7429990	0.965	rs34750113	ENSG00000235912.1	RP1-159A19.3	-5.85	9.15e-09	0.0105	-0.34	-0.26	Educational attainment (years of education);	chr3:47944902	chr1:27649419~27649610:+
THCA	trans	rs4415084	0.716	rs1438822	ENSG00000231752.4	EMBP1	-5.85	9.16e-09	0.0105	-0.36	-0.26	Breast cancer;	chr5:44859070	chr1:121519112~121571892:+
THCA	trans	rs853679	0.607	rs34788973	ENSG00000204338.7	CYP21A1P	-5.85	9.16e-09	0.0105	-0.57	-0.26	Depression;	chr6:27911422	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs61742093	ENSG00000204338.7	CYP21A1P	-5.85	9.16e-09	0.0105	-0.57	-0.26	Depression;	chr6:27912204	chr6:32005636~32008451:+
THCA	trans	rs4879677	1	rs10757674	ENSG00000269560.1	CTD-2192J16.21	5.85	9.17e-09	0.0105	0.33	0.26	Gut microbiome composition (summer and winter);	chr9:27671312	chr19:12529768~12532973:-
THCA	trans	rs3947	0.906	rs709822	ENSG00000253893.2	FAM85B	5.85	9.19e-09	0.0105	0.38	0.26	Blood protein levels;	chr8:11844804	chr8:8167819~8226614:-
THCA	trans	rs12477438	0.52	rs2516829	ENSG00000276576.1	MRPL30P1	5.85	9.19e-09	0.0105	0.33	0.26	Chronic sinus infection;	chr2:99156738	chr6:57029521~57029988:+
THCA	trans	rs10037055	0.853	rs10077929	ENSG00000228305.2	AC016734.2	5.85	9.2e-09	0.0106	0.24	0.26	Migraine without aura;	chr5:177270843	chr2:63622178~63622831:-
THCA	trans	rs7769051	0.803	rs59740783	ENSG00000227615.1	RP11-864N7.2	5.85	9.23e-09	0.0106	0.45	0.26	Type 2 diabetes nephropathy;	chr6:132910572	chr11:74745716~74746114:-
THCA	trans	rs7769051	0.803	rs34334052	ENSG00000227615.1	RP11-864N7.2	5.85	9.23e-09	0.0106	0.45	0.26	Type 2 diabetes nephropathy;	chr6:132910690	chr11:74745716~74746114:-
THCA	trans	rs453301	0.686	rs1045527	ENSG00000229857.1	RP11-159H20.3	5.85	9.26e-09	0.0106	0.32	0.26	Joint mobility (Beighton score);	chr8:9032531	chr9:76992099~76993108:+
THCA	trans	rs2048656	0.578	rs7817784	ENSG00000253893.2	FAM85B	5.85	9.26e-09	0.0106	0.34	0.26	Schizophrenia;	chr8:9825043	chr8:8167819~8226614:-
THCA	trans	rs4415084	0.716	rs4605791	ENSG00000231752.4	EMBP1	-5.85	9.32e-09	0.0107	-0.36	-0.26	Breast cancer;	chr5:44855610	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.744	rs4604199	ENSG00000231752.4	EMBP1	-5.85	9.32e-09	0.0107	-0.36	-0.26	Breast cancer;	chr5:44855614	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs4566804	ENSG00000231752.4	EMBP1	-5.85	9.32e-09	0.0107	-0.36	-0.26	Breast cancer;	chr5:44855637	chr1:121519112~121571892:+
THCA	trans	rs4295623	0.504	rs11250160	ENSG00000229857.1	RP11-159H20.3	5.85	9.35e-09	0.0107	0.32	0.26	Morning vs. evening chronotype;	chr8:11735208	chr9:76992099~76993108:+
THCA	trans	rs889398	0.617	rs6499265	ENSG00000196796.5	CTB-134H23.2	5.85	9.36e-09	0.0107	0.29	0.26	Body mass index;	chr16:69864095	chr16:29038655~29052726:+
THCA	trans	rs3764796	1	rs3764796	ENSG00000250030.2	RP11-584P21.4	5.85	9.37e-09	0.0107	0.49	0.26	Calcium levels;	chr8:17300168	chr4:67446267~67446574:+
THCA	trans	rs616147	1	rs1768208	ENSG00000243904.1	RP11-600F24.1	-5.85	9.37e-09	0.0107	-0.33	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr14:103374033~103374916:-
THCA	trans	rs75920871	0.557	rs11216275	ENSG00000279518.1	AC083843.4	-5.85	9.37e-09	0.0107	-0.21	-0.26	Subjective well-being;	chr11:117104988	chr8:134783694~134785879:-
THCA	trans	rs4415084	0.716	rs7708213	ENSG00000231752.4	EMBP1	-5.85	9.39e-09	0.0108	-0.36	-0.26	Breast cancer;	chr5:44848299	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs4440370	ENSG00000231752.4	EMBP1	-5.85	9.39e-09	0.0108	-0.36	-0.26	Breast cancer;	chr5:44853250	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs4492119	ENSG00000231752.4	EMBP1	-5.85	9.39e-09	0.0108	-0.36	-0.26	Breast cancer;	chr5:44855512	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs4919742	ENSG00000220378.3	KRT8P42	-5.85	9.4e-09	0.0108	-0.56	-0.26	Prostate cancer;	chr12:52879180	chr6:134296997~134298695:-
THCA	trans	rs7819412	0.521	rs10110684	ENSG00000229857.1	RP11-159H20.3	5.85	9.41e-09	0.0108	0.35	0.26	Triglycerides;	chr8:11181650	chr9:76992099~76993108:+
THCA	trans	rs9393777	0.778	rs77666565	ENSG00000280107.1	AL022393.9	-5.85	9.45e-09	0.0108	-0.49	-0.26	Intelligence (multi-trait analysis);	chr6:26883636	chr6:28170845~28172521:+
THCA	trans	rs7647973	0.626	rs1352889	ENSG00000197582.5	GPX1P1	5.85	9.45e-09	0.0108	0.46	0.26	Menarche (age at onset);	chr3:49614715	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs4855833	ENSG00000197582.5	GPX1P1	5.85	9.45e-09	0.0108	0.46	0.26	Menarche (age at onset);	chr3:49620008	chrX:13378735~13379340:-
THCA	trans	rs7212590	0.529	rs60283440	ENSG00000187870.7	RNFT1P3	5.85	9.47e-09	0.0109	0.51	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59916887	chr17:20743333~20754501:-
THCA	trans	rs11992162	0.591	rs34123222	ENSG00000229857.1	RP11-159H20.3	5.84	9.5e-09	0.0109	0.34	0.26	Monocyte count;	chr8:11937840	chr9:76992099~76993108:+
THCA	trans	rs3096299	0.685	rs12446145	ENSG00000215030.5	RPL13P12	-5.84	9.51e-09	0.0109	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89476287	chr17:17383377~17384012:-
THCA	trans	rs2799081	1	rs2799081	ENSG00000228078.1	HLA-U	-5.84	9.52e-09	0.0109	-0.34	-0.26	Myopia;	chr6:28302807	chr6:29934101~29934286:+
THCA	trans	rs1962073	0.528	rs9329223	ENSG00000253893.2	FAM85B	5.84	9.53e-09	0.0109	0.34	0.26	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10474244	chr8:8167819~8226614:-
THCA	trans	rs867371	0.502	rs8025964	ENSG00000235370.6	DNM1P51	-5.84	9.53e-09	0.0109	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:84398316~84411701:-
THCA	trans	rs4646450	0.891	rs2240384	ENSG00000228834.1	RP11-249L21.4	-5.84	9.6e-09	0.011	-0.41	-0.26	Blood metabolite levels;	chr7:99429421	chr6:108907615~108907873:-
THCA	trans	rs889398	0.617	rs11075742	ENSG00000196796.5	CTB-134H23.2	5.84	9.6e-09	0.011	0.29	0.26	Body mass index;	chr16:69865031	chr16:29038655~29052726:+
THCA	trans	rs7824557	0.545	rs2572450	ENSG00000254153.1	CTA-398F10.2	5.84	9.65e-09	0.0111	0.29	0.26	Retinal vascular caliber;	chr8:11372129	chr8:8456909~8461337:-
THCA	trans	rs902774	0.818	rs73110464	ENSG00000230716.3	KRT8P7	-5.84	9.66e-09	0.0111	-0.52	-0.26	Prostate cancer;	chr12:52918828	chr11:119602875~119604306:-
THCA	trans	rs1347297	0.526	rs919177	ENSG00000269800.1	PLEKHA3P1	5.84	9.71e-09	0.0111	0.28	0.26	Alzheimer disease and age of onset;	chr2:178394196	chr19:41521043~41521989:-
THCA	trans	rs2950393	0.804	rs1131514	ENSG00000257210.1	NACAP3	-5.84	9.71e-09	0.0111	-0.31	-0.26	Platelet distribution width;	chr12:56739356	chr12:93124063~93124543:-
THCA	trans	rs1908814	0.516	rs11996277	ENSG00000254153.1	CTA-398F10.2	-5.84	9.71e-09	0.0111	-0.3	-0.26	Neuroticism;	chr8:11942522	chr8:8456909~8461337:-
THCA	trans	rs13177918	0.626	rs2748240	ENSG00000226396.1	RP5-1056L3.3	5.84	9.75e-09	0.0112	0.24	0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:19608114~19608568:+
THCA	trans	rs9616064	0.506	rs2542038	ENSG00000258384.1	AC068831.6	5.84	9.78e-09	0.0112	0.31	0.26	Urate levels in obese individuals;	chr22:46663385	chr15:90952239~90955225:-
THCA	trans	rs11098499	0.722	rs17595727	ENSG00000253326.2	RP11-261C10.7	-5.84	9.79e-09	0.0112	-0.34	-0.26	Corneal astigmatism;	chr4:119340919	chr1:243054861~243056394:-
THCA	trans	rs8014204	0.836	rs7154256	ENSG00000181227.3	RP4-682C21.2	-5.84	9.8e-09	0.0112	-0.21	-0.26	Caffeine consumption;	chr14:74785884	chr1:75743423~75744776:-
THCA	trans	rs34546498	1	rs34546498	ENSG00000219392.1	RP1-265C24.5	-5.84	9.81e-09	0.0112	-0.6	-0.26	Breast cancer;	chr6:26993501	chr6:28115628~28116551:+
THCA	trans	rs7819412	0.66	rs7462931	ENSG00000256560.1	LINC01486	-5.84	9.81e-09	0.0112	-0.32	-0.26	Triglycerides;	chr8:11052833	chr12:109354083~109359488:-
THCA	trans	rs656319	0.638	rs670044	ENSG00000253893.2	FAM85B	-5.84	9.82e-09	0.0112	-0.33	-0.26	Myopia (pathological);	chr8:10035019	chr8:8167819~8226614:-
THCA	trans	rs4964805	0.586	rs934846	ENSG00000278725.1	RP11-666O2.5	5.84	9.87e-09	0.0113	0.28	0.26	Attention deficit hyperactivity disorder;	chr12:103791519	chr16:28602340~28604519:+
THCA	trans	rs853679	0.607	rs67998226	ENSG00000248290.1	TNXA	-5.84	9.88e-09	0.0113	-0.55	-0.26	Depression;	chr6:28270281	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34878803	ENSG00000248290.1	TNXA	-5.84	9.88e-09	0.0113	-0.55	-0.26	Depression;	chr6:28282402	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34396849	ENSG00000248290.1	TNXA	-5.84	9.88e-09	0.0113	-0.55	-0.26	Depression;	chr6:28283178	chr6:32008614~32012472:-
THCA	trans	rs4415084	0.688	rs1837286	ENSG00000231752.4	EMBP1	-5.84	9.88e-09	0.0113	-0.36	-0.26	Breast cancer;	chr5:44858639	chr1:121519112~121571892:+
THCA	trans	rs8014204	0.804	rs34956813	ENSG00000181227.3	RP4-682C21.2	-5.84	9.9e-09	0.0113	-0.21	-0.26	Caffeine consumption;	chr14:74787464	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.743	rs35809608	ENSG00000181227.3	RP4-682C21.2	-5.84	9.9e-09	0.0113	-0.21	-0.26	Caffeine consumption;	chr14:74788059	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.804	rs35769520	ENSG00000181227.3	RP4-682C21.2	-5.84	9.9e-09	0.0113	-0.21	-0.26	Caffeine consumption;	chr14:74788412	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.804	rs2287403	ENSG00000181227.3	RP4-682C21.2	-5.84	9.9e-09	0.0113	-0.21	-0.26	Caffeine consumption;	chr14:74792437	chr1:75743423~75744776:-
THCA	trans	rs56116382	0.605	rs12715435	ENSG00000197582.5	GPX1P1	-5.84	9.9e-09	0.0113	-0.48	-0.26	High light scatter reticulocyte count;Intelligence (multi-trait analysis);	chr3:49301559	chrX:13378735~13379340:-
THCA	trans	rs9467773	0.566	rs66972160	ENSG00000242375.1	RP11-498P14.3	-5.84	9.92e-09	0.0113	-0.37	-0.26	Intelligence (multi-trait analysis);	chr6:26359078	chr9:97195351~97197687:-
THCA	trans	rs9467773	0.526	rs9348710	ENSG00000242375.1	RP11-498P14.3	-5.84	9.92e-09	0.0113	-0.37	-0.26	Intelligence (multi-trait analysis);	chr6:26360258	chr9:97195351~97197687:-
THCA	trans	rs7824557	0.547	rs2409745	ENSG00000254153.1	CTA-398F10.2	-5.84	9.94e-09	0.0114	-0.29	-0.26	Retinal vascular caliber;	chr8:11219126	chr8:8456909~8461337:-
THCA	trans	rs860295	0.5	rs34995046	ENSG00000241627.3	UBQLN4P1	5.84	9.95e-09	0.0114	0.29	0.26	Body mass index;	chr1:156018694	chr3:148985868~148987668:-
THCA	trans	rs7746199	0.736	rs13193542	ENSG00000204338.7	CYP21A1P	-5.84	9.96e-09	0.0114	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs13193480	ENSG00000204338.7	CYP21A1P	-5.84	9.96e-09	0.0114	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:32005636~32008451:+
THCA	trans	rs12477438	0.52	rs6542869	ENSG00000276576.1	MRPL30P1	5.84	9.97e-09	0.0114	0.33	0.26	Chronic sinus infection;	chr2:99166940	chr6:57029521~57029988:+
THCA	trans	rs7824557	0.603	rs2249804	ENSG00000256560.1	LINC01486	5.84	9.98e-09	0.0114	0.33	0.26	Retinal vascular caliber;	chr8:11358108	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.967	rs4840601	ENSG00000229857.1	RP11-159H20.3	-5.84	9.99e-09	0.0114	-0.34	-0.26	Monocyte count;	chr8:11971221	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.623	rs11250065	ENSG00000253893.2	FAM85B	5.84	1e-08	0.0114	0.32	0.26	Neuroticism;	chr8:10742871	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.623	rs7004253	ENSG00000253893.2	FAM85B	5.84	1e-08	0.0114	0.32	0.26	Neuroticism;	chr8:10743347	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.589	rs6578969	ENSG00000266891.1	RP11-692N5.2	5.83	1e-08	0.0115	0.34	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8467444	chr18:9734882~9735602:-
THCA	trans	rs801193	0.591	rs9986881	ENSG00000164669.11	INTS4P1	-5.83	1.01e-08	0.0115	-0.33	-0.26	Aortic root size;	chr7:66708053	chr7:65141225~65234216:+
THCA	trans	rs9584850	0.834	rs3783005	ENSG00000230079.1	STK24P1	-5.83	1.01e-08	0.0115	-0.3	-0.26	Neuroticism;	chr13:98459083	chrX:136295690~136300298:-
THCA	trans	rs7819412	0.775	rs4840551	ENSG00000254153.1	CTA-398F10.2	5.83	1.01e-08	0.0115	0.3	0.26	Triglycerides;	chr8:11171530	chr8:8456909~8461337:-
THCA	trans	rs9987353	0.83	rs2126267	ENSG00000253893.2	FAM85B	5.83	1.01e-08	0.0115	0.37	0.26	Recombination measurement;	chr8:9250441	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.718	rs7813935	ENSG00000254153.1	CTA-398F10.2	-5.83	1.01e-08	0.0115	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.504	rs7830734	ENSG00000254153.1	CTA-398F10.2	-5.83	1.01e-08	0.0115	-0.3	-0.26	Neuroticism;	chr8:11938130	chr8:8456909~8461337:-
THCA	trans	rs7647973	0.626	rs4855849	ENSG00000197582.5	GPX1P1	5.83	1.01e-08	0.0115	0.46	0.26	Menarche (age at onset);	chr3:49615945	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.588	rs4855848	ENSG00000197582.5	GPX1P1	5.83	1.01e-08	0.0115	0.46	0.26	Menarche (age at onset);	chr3:49616024	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.554	rs13096480	ENSG00000197582.5	GPX1P1	5.83	1.01e-08	0.0115	0.46	0.26	Menarche (age at onset);	chr3:49620651	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs1586827	ENSG00000197582.5	GPX1P1	5.83	1.01e-08	0.0115	0.46	0.26	Menarche (age at onset);	chr3:49633791	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs12715437	ENSG00000197582.5	GPX1P1	5.83	1.01e-08	0.0115	0.46	0.26	Menarche (age at onset);	chr3:49714423	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs9835157	ENSG00000197582.5	GPX1P1	-5.83	1.01e-08	0.0115	-0.46	-0.26	Menarche (age at onset);	chr3:49760336	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs9829155	ENSG00000197582.5	GPX1P1	-5.83	1.01e-08	0.0115	-0.46	-0.26	Menarche (age at onset);	chr3:49780017	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs7637711	ENSG00000197582.5	GPX1P1	-5.83	1.01e-08	0.0115	-0.46	-0.26	Menarche (age at onset);	chr3:49792220	chrX:13378735~13379340:-
THCA	trans	rs4415084	0.716	rs1371022	ENSG00000231752.4	EMBP1	-5.83	1.01e-08	0.0115	-0.36	-0.26	Breast cancer;	chr5:44847890	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs7726586	ENSG00000231752.4	EMBP1	-5.83	1.01e-08	0.0115	-0.36	-0.26	Breast cancer;	chr5:44848720	chr1:121519112~121571892:+
THCA	trans	rs6601450	0.579	rs11775625	ENSG00000253893.2	FAM85B	-5.83	1.01e-08	0.0116	-0.33	-0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10414929	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs11831919	ENSG00000220378.3	KRT8P42	-5.83	1.01e-08	0.0116	-0.55	-0.26	Prostate cancer;	chr12:52878231	chr6:134296997~134298695:-
THCA	trans	rs34421088	0.576	rs2572432	ENSG00000256560.1	LINC01486	-5.83	1.01e-08	0.0116	-0.35	-0.26	Neuroticism;	chr8:11244214	chr12:109354083~109359488:-
THCA	trans	rs11098499	0.569	rs10023641	ENSG00000253326.2	RP11-261C10.7	5.83	1.02e-08	0.0116	0.34	0.26	Corneal astigmatism;	chr4:119337255	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.644	rs3986377	ENSG00000253326.2	RP11-261C10.7	5.83	1.02e-08	0.0116	0.34	0.26	Corneal astigmatism;	chr4:119339115	chr1:243054861~243056394:-
THCA	trans	rs10028773	0.556	rs4473640	ENSG00000253326.2	RP11-261C10.7	5.83	1.02e-08	0.0116	0.34	0.26	Educational attainment;	chr4:119339282	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.691	rs10010355	ENSG00000253326.2	RP11-261C10.7	5.83	1.02e-08	0.0116	0.34	0.26	Corneal astigmatism;	chr4:119339888	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.691	rs9307471	ENSG00000253326.2	RP11-261C10.7	5.83	1.02e-08	0.0116	0.34	0.26	Corneal astigmatism;	chr4:119340107	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.644	rs17517414	ENSG00000253326.2	RP11-261C10.7	5.83	1.02e-08	0.0116	0.34	0.26	Corneal astigmatism;	chr4:119340946	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.722	rs10006192	ENSG00000253326.2	RP11-261C10.7	5.83	1.02e-08	0.0116	0.34	0.26	Corneal astigmatism;	chr4:119341867	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.505	rs2572440	ENSG00000256560.1	LINC01486	5.83	1.02e-08	0.0116	0.32	0.26	Retinal vascular caliber;	chr8:11391501	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs4919763	ENSG00000220378.3	KRT8P42	-5.83	1.02e-08	0.0117	-0.57	-0.26	Prostate cancer;	chr12:52885839	chr6:134296997~134298695:-
THCA	trans	rs902774	0.818	rs55914512	ENSG00000220378.3	KRT8P42	-5.83	1.02e-08	0.0117	-0.57	-0.26	Prostate cancer;	chr12:52888490	chr6:134296997~134298695:-
THCA	trans	rs902774	0.818	rs73108466	ENSG00000220378.3	KRT8P42	-5.83	1.02e-08	0.0117	-0.57	-0.26	Prostate cancer;	chr12:52889857	chr6:134296997~134298695:-
THCA	trans	rs902774	0.818	rs55999178	ENSG00000220378.3	KRT8P42	-5.83	1.02e-08	0.0117	-0.57	-0.26	Prostate cancer;	chr12:52890576	chr6:134296997~134298695:-
THCA	trans	rs7429990	0.864	rs6442081	ENSG00000235912.1	RP1-159A19.3	5.83	1.02e-08	0.0117	0.32	0.26	Educational attainment (years of education);	chr3:47728890	chr1:27649419~27649610:+
THCA	trans	rs7212590	0.655	rs8072050	ENSG00000187870.7	RNFT1P3	5.83	1.03e-08	0.0117	0.51	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59933611	chr17:20743333~20754501:-
THCA	trans	rs7212590	0.618	rs7217337	ENSG00000187870.7	RNFT1P3	5.83	1.03e-08	0.0117	0.51	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59946056	chr17:20743333~20754501:-
THCA	trans	rs7212590	0.618	rs7219051	ENSG00000187870.7	RNFT1P3	5.83	1.03e-08	0.0117	0.51	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59955349	chr17:20743333~20754501:-
THCA	trans	rs9650657	0.615	rs6601534	ENSG00000253893.2	FAM85B	5.83	1.03e-08	0.0117	0.32	0.26	Neuroticism;	chr8:10834483	chr8:8167819~8226614:-
THCA	trans	rs453301	0.598	rs1025395	ENSG00000256560.1	LINC01486	5.83	1.03e-08	0.0118	0.3	0.26	Joint mobility (Beighton score);	chr8:8979093	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.524	rs10088408	ENSG00000254153.1	CTA-398F10.2	5.83	1.04e-08	0.0118	0.28	0.26	Neuroticism;	chr8:10959687	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.78	rs9692662	ENSG00000254153.1	CTA-398F10.2	-5.83	1.04e-08	0.0118	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.899	rs9693925	ENSG00000254153.1	CTA-398F10.2	-5.83	1.04e-08	0.0118	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:8456909~8461337:-
THCA	trans	rs11992162	0.636	rs11250182	ENSG00000254153.1	CTA-398F10.2	5.83	1.04e-08	0.0118	0.29	0.26	Monocyte count;	chr8:11950067	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.628	rs7831346	ENSG00000253893.2	FAM85B	-5.83	1.04e-08	0.0119	-0.34	-0.26	Retinal vascular caliber;	chr8:11336021	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.628	rs6601580	ENSG00000253893.2	FAM85B	-5.83	1.04e-08	0.0119	-0.34	-0.26	Retinal vascular caliber;	chr8:11336227	chr8:8167819~8226614:-
THCA	trans	rs16976116	0.572	rs16976015	ENSG00000231806.2	PCAT7	5.83	1.04e-08	0.0119	0.4	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55154852	chr9:94555069~94568127:+
THCA	trans	rs1027479	1	rs1909030	ENSG00000214832.5	UPF3AP2	-5.83	1.04e-08	0.0119	-0.33	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr8:108708052	chr17:20375369~20376840:-
THCA	trans	rs11098499	0.532	rs4833624	ENSG00000253326.2	RP11-261C10.7	5.83	1.05e-08	0.0119	0.36	0.26	Corneal astigmatism;	chr4:119664342	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.532	rs12512646	ENSG00000253326.2	RP11-261C10.7	5.83	1.05e-08	0.0119	0.36	0.26	Corneal astigmatism;	chr4:119664578	chr1:243054861~243056394:-
THCA	trans	rs7809615	0.515	rs3843540	ENSG00000228834.1	RP11-249L21.4	5.83	1.05e-08	0.0119	0.41	0.26	Blood metabolite ratios;	chr7:99529017	chr6:108907615~108907873:-
THCA	trans	rs28627593	0.628	rs10033498	ENSG00000274066.1	MIR6514	5.83	1.05e-08	0.0119	0.3	0.26	Pursuit maintenance gain;	chr4:31360317	chr11:62792702~62792771:-
THCA	trans	rs2048656	0.524	rs12543959	ENSG00000253893.2	FAM85B	5.83	1.05e-08	0.012	0.33	0.26	Schizophrenia;	chr8:9681490	chr8:8167819~8226614:-
THCA	trans	rs12545912	0.739	rs12541617	ENSG00000253893.2	FAM85B	5.83	1.05e-08	0.012	0.33	0.26	Multiple myeloma (hyperdiploidy);	chr8:9681589	chr8:8167819~8226614:-
THCA	trans	rs7819412	0.669	rs35499486	ENSG00000254153.1	CTA-398F10.2	5.83	1.05e-08	0.012	0.3	0.26	Triglycerides;	chr8:11216527	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.623	rs7010753	ENSG00000229857.1	RP11-159H20.3	-5.83	1.06e-08	0.012	-0.32	-0.26	Mood instability;	chr8:8516446	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.644	rs34835603	ENSG00000253326.2	RP11-261C10.7	5.83	1.06e-08	0.012	0.35	0.26	Corneal astigmatism;	chr4:119632273	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.615	rs28850368	ENSG00000253326.2	RP11-261C10.7	5.83	1.06e-08	0.012	0.35	0.26	Corneal astigmatism;	chr4:119633158	chr1:243054861~243056394:-
THCA	trans	rs1908814	0.509	rs13282439	ENSG00000229857.1	RP11-159H20.3	-5.83	1.06e-08	0.012	-0.34	-0.26	Neuroticism;	chr8:11937392	chr9:76992099~76993108:+
THCA	trans	rs2048656	0.578	rs4841235	ENSG00000253893.2	FAM85B	5.83	1.06e-08	0.012	0.33	0.26	Schizophrenia;	chr8:9825848	chr8:8167819~8226614:-
THCA	trans	rs853679	0.607	rs68188794	ENSG00000204338.7	CYP21A1P	-5.83	1.06e-08	0.012	-0.58	-0.26	Depression;	chr6:28112999	chr6:32005636~32008451:+
THCA	trans	rs10435719	0.867	rs62493601	ENSG00000254153.1	CTA-398F10.2	-5.83	1.06e-08	0.0121	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:8456909~8461337:-
THCA	trans	rs1347297	0.526	rs6757186	ENSG00000269800.1	PLEKHA3P1	5.83	1.06e-08	0.0121	0.28	0.26	Alzheimer disease and age of onset;	chr2:178394992	chr19:41521043~41521989:-
THCA	trans	rs10435719	0.867	rs34465618	ENSG00000254153.1	CTA-398F10.2	-5.82	1.06e-08	0.0121	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.867	rs34583868	ENSG00000254153.1	CTA-398F10.2	-5.82	1.06e-08	0.0121	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:8456909~8461337:-
THCA	trans	rs4646450	0.891	rs1980307	ENSG00000228834.1	RP11-249L21.4	5.82	1.07e-08	0.0121	0.41	0.26	Blood metabolite levels;	chr7:99462980	chr6:108907615~108907873:-
THCA	trans	rs9393777	0.92	rs66462181	ENSG00000204338.7	CYP21A1P	-5.82	1.07e-08	0.0122	-0.59	-0.26	Intelligence (multi-trait analysis);	chr6:27123882	chr6:32005636~32008451:+
THCA	trans	rs9650657	0.645	rs4841408	ENSG00000229857.1	RP11-159H20.3	5.82	1.07e-08	0.0122	0.31	0.26	Neuroticism;	chr8:10658826	chr9:76992099~76993108:+
THCA	trans	rs12477438	0.52	rs7605843	ENSG00000276576.1	MRPL30P1	5.82	1.07e-08	0.0122	0.34	0.26	Chronic sinus infection;	chr2:99195431	chr6:57029521~57029988:+
THCA	trans	rs7829975	0.511	rs1543238	ENSG00000256560.1	LINC01486	5.82	1.07e-08	0.0122	0.3	0.26	Mood instability;	chr8:8277287	chr12:109354083~109359488:-
THCA	trans	rs8014204	0.901	rs4899536	ENSG00000181227.3	RP4-682C21.2	5.82	1.07e-08	0.0122	0.21	0.26	Caffeine consumption;	chr14:74849911	chr1:75743423~75744776:-
THCA	trans	rs7819412	0.594	rs7460507	ENSG00000254153.1	CTA-398F10.2	5.82	1.07e-08	0.0122	0.29	0.26	Triglycerides;	chr8:11111565	chr8:8456909~8461337:-
THCA	trans	rs73110464	0.591	rs11829997	ENSG00000248568.1	KRT8P48	-5.82	1.08e-08	0.0122	-0.63	-0.26	Cancer (pleiotropy);	chr12:52921875	chr5:146706381~146707600:-
THCA	trans	rs7295246	1	rs7957909	ENSG00000268713.1	CTC-444N24.8	-5.82	1.08e-08	0.0122	-0.18	-0.26	Alzheimer's disease (late onset);	chr12:43567685	chr19:57261354~57262738:+
THCA	trans	rs7200543	1	rs16966947	ENSG00000255185.4	PDXDC2P	5.82	1.08e-08	0.0122	0.37	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:70010751~70065945:-
THCA	trans	rs9329221	0.537	rs2062331	ENSG00000253893.2	FAM85B	5.82	1.08e-08	0.0123	0.32	0.26	Neuroticism;	chr8:10122482	chr8:8167819~8226614:-
THCA	trans	rs9848726	0.963	rs9833094	ENSG00000235499.1	AC073046.25	-5.82	1.08e-08	0.0123	-0.22	-0.26	Skin aging (microtopography measurement);	chr3:100872081	chr2:73985132~73986343:+
THCA	trans	rs7212590	0.655	rs16943969	ENSG00000187870.7	RNFT1P3	5.82	1.08e-08	0.0123	0.51	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59953792	chr17:20743333~20754501:-
THCA	trans	rs4879677	1	rs10968051	ENSG00000269560.1	CTD-2192J16.21	-5.82	1.08e-08	0.0123	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27677646	chr19:12529768~12532973:-
THCA	trans	rs7212590	0.618	rs59767604	ENSG00000187870.7	RNFT1P3	5.82	1.08e-08	0.0123	0.51	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59963978	chr17:20743333~20754501:-
THCA	trans	rs7769051	1	rs3813347	ENSG00000213303.3	CTC-398G3.2	5.82	1.08e-08	0.0123	0.48	0.26	Type 2 diabetes nephropathy;	chr6:132798639	chr19:11523436~11523831:+
THCA	trans	rs9393777	0.72	rs13217285	ENSG00000228022.4	HCG20	-5.82	1.08e-08	0.0123	-0.56	-0.26	Intelligence (multi-trait analysis);	chr6:27032066	chr6:30766825~30792250:+
THCA	trans	rs853679	0.607	rs13211507	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28289600	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34691223	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28290431	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13207345	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28297795	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs72854513	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28298177	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs56189111	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28304196	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34950484	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28310911	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs35072899	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28313764	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34661125	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28314117	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13190888	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28318208	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs56075693	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28322551	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34218844	ENSG00000248290.1	TNXA	-5.82	1.08e-08	0.0123	-0.55	-0.26	Depression;	chr6:28322870	chr6:32008614~32012472:-
THCA	trans	rs11992162	0.636	rs4841645	ENSG00000254153.1	CTA-398F10.2	5.82	1.08e-08	0.0123	0.29	0.26	Monocyte count;	chr8:11941175	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.774	rs34208825	ENSG00000256560.1	LINC01486	-5.82	1.09e-08	0.0123	-0.32	-0.26	Triglycerides;	chr8:11157106	chr12:109354083~109359488:-
THCA	trans	rs7617773	0.823	rs9839446	ENSG00000235912.1	RP1-159A19.3	5.82	1.09e-08	0.0123	0.32	0.26	Coronary artery disease;	chr3:48153176	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.823	rs9839447	ENSG00000235912.1	RP1-159A19.3	5.82	1.09e-08	0.0123	0.32	0.26	Coronary artery disease;	chr3:48153177	chr1:27649419~27649610:+
THCA	trans	rs12477438	0.52	rs13798	ENSG00000276576.1	MRPL30P1	5.82	1.09e-08	0.0124	0.34	0.26	Chronic sinus infection;	chr2:99197151	chr6:57029521~57029988:+
THCA	trans	rs7824557	0.815	rs958648	ENSG00000254153.1	CTA-398F10.2	5.82	1.09e-08	0.0124	0.27	0.26	Retinal vascular caliber;	chr8:11246386	chr8:8456909~8461337:-
THCA	trans	rs6601327	0.613	rs12547642	ENSG00000253893.2	FAM85B	5.82	1.1e-08	0.0125	0.33	0.26	Multiple myeloma (hyperdiploidy);	chr8:9636417	chr8:8167819~8226614:-
THCA	trans	rs2048656	0.561	rs12544371	ENSG00000253893.2	FAM85B	5.82	1.1e-08	0.0125	0.33	0.26	Schizophrenia;	chr8:9684561	chr8:8167819~8226614:-
THCA	trans	rs4879677	1	rs10968045	ENSG00000269560.1	CTD-2192J16.21	-5.82	1.1e-08	0.0125	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27674262	chr19:12529768~12532973:-
THCA	trans	rs4879677	1	rs10968046	ENSG00000269560.1	CTD-2192J16.21	-5.82	1.1e-08	0.0125	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27674369	chr19:12529768~12532973:-
THCA	trans	rs9650657	0.535	rs7011756	ENSG00000254153.1	CTA-398F10.2	5.82	1.11e-08	0.0125	0.29	0.26	Neuroticism;	chr8:11162068	chr8:8456909~8461337:-
THCA	trans	rs6601327	0.586	rs6601340	ENSG00000253893.2	FAM85B	5.82	1.11e-08	0.0126	0.32	0.26	Multiple myeloma (hyperdiploidy);	chr8:9603805	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.628	rs58283816	ENSG00000253893.2	FAM85B	-5.82	1.11e-08	0.0126	-0.34	-0.26	Retinal vascular caliber;	chr8:11335042	chr8:8167819~8226614:-
THCA	trans	rs6600671	0.719	rs9728991	ENSG00000270231.3	NBPF8P	5.82	1.11e-08	0.0126	0.24	0.26	Hip geometry;	chr1:121522281	chr1:120436353~120467739:+
THCA	trans	rs6921919	1	rs6922111	ENSG00000228078.1	HLA-U	-5.82	1.11e-08	0.0126	-0.37	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:29934101~29934286:+
THCA	trans	rs75920871	0.589	rs4938342	ENSG00000279518.1	AC083843.4	-5.82	1.12e-08	0.0127	-0.25	-0.26	Subjective well-being;	chr11:117132704	chr8:134783694~134785879:-
THCA	trans	rs8014204	0.804	rs7154845	ENSG00000181227.3	RP4-682C21.2	-5.81	1.12e-08	0.0127	-0.2	-0.26	Caffeine consumption;	chr14:74781043	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.804	rs2241274	ENSG00000181227.3	RP4-682C21.2	-5.81	1.12e-08	0.0127	-0.2	-0.26	Caffeine consumption;	chr14:74784628	chr1:75743423~75744776:-
THCA	trans	rs902774	0.818	rs55958994	ENSG00000240668.1	KRT8P36	-5.81	1.12e-08	0.0127	-0.53	-0.26	Prostate cancer;	chr12:52907235	chr3:138101478~138102917:-
THCA	trans	rs4879677	0.959	rs10812643	ENSG00000269560.1	CTD-2192J16.21	-5.81	1.12e-08	0.0127	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27690092	chr19:12529768~12532973:-
THCA	trans	rs7200543	1	rs16966947	ENSG00000250569.1	NTAN1P2	5.81	1.12e-08	0.0127	0.27	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr8:86481754~86483002:-
THCA	trans	rs9650657	0.645	rs4841409	ENSG00000229857.1	RP11-159H20.3	-5.81	1.13e-08	0.0128	-0.31	-0.26	Neuroticism;	chr8:10658864	chr9:76992099~76993108:+
THCA	trans	rs10107145	0.509	rs73209953	ENSG00000253893.2	FAM85B	5.81	1.13e-08	0.0128	0.34	0.26	Systolic blood pressure;	chr8:10902602	chr8:8167819~8226614:-
THCA	trans	rs950169	1	rs11638297	ENSG00000259295.5	CSPG4P12	5.81	1.13e-08	0.0128	0.4	0.26	Schizophrenia;	chr15:84113665	chr15:85191438~85213905:+
THCA	trans	rs9650657	0.615	rs1549796	ENSG00000253893.2	FAM85B	5.81	1.13e-08	0.0128	0.32	0.26	Neuroticism;	chr8:10834849	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.902	rs11250179	ENSG00000254153.1	CTA-398F10.2	-5.81	1.13e-08	0.0128	-0.3	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:8456909~8461337:-
THCA	trans	rs2048656	0.524	rs13270518	ENSG00000253893.2	FAM85B	5.81	1.13e-08	0.0128	0.33	0.26	Schizophrenia;	chr8:9679203	chr8:8167819~8226614:-
THCA	trans	rs12545912	0.77	rs12114182	ENSG00000253893.2	FAM85B	5.81	1.13e-08	0.0128	0.33	0.26	Multiple myeloma (hyperdiploidy);	chr8:9680125	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.564	rs2572400	ENSG00000256560.1	LINC01486	-5.81	1.14e-08	0.0129	-0.32	-0.26	Retinal vascular caliber;	chr8:11376858	chr12:109354083~109359488:-
THCA	trans	rs9467711	0.659	rs3823158	ENSG00000253570.1	RNF5P1	5.81	1.14e-08	0.0129	0.71	0.26	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr8:38600661~38601200:-
THCA	trans	rs7617773	1	rs6442108	ENSG00000235912.1	RP1-159A19.3	5.81	1.14e-08	0.0129	0.32	0.26	Coronary artery disease;	chr3:48151469	chr1:27649419~27649610:+
THCA	trans	rs7617773	1	rs6442109	ENSG00000235912.1	RP1-159A19.3	5.81	1.14e-08	0.0129	0.32	0.26	Coronary artery disease;	chr3:48151491	chr1:27649419~27649610:+
THCA	trans	rs4646450	0.945	rs12333760	ENSG00000228834.1	RP11-249L21.4	5.81	1.14e-08	0.0129	0.42	0.26	Blood metabolite levels;	chr7:99587783	chr6:108907615~108907873:-
THCA	trans	rs853679	0.607	rs67340775	ENSG00000248290.1	TNXA	-5.81	1.14e-08	0.0129	-0.55	-0.26	Depression;	chr6:28336607	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs35030260	ENSG00000248290.1	TNXA	-5.81	1.14e-08	0.0129	-0.55	-0.26	Depression;	chr6:28337731	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13217619	ENSG00000248290.1	TNXA	-5.81	1.14e-08	0.0129	-0.55	-0.26	Depression;	chr6:28338894	chr6:32008614~32012472:-
THCA	trans	rs853679	0.546	rs35016036	ENSG00000248290.1	TNXA	-5.81	1.14e-08	0.0129	-0.55	-0.26	Depression;	chr6:28347103	chr6:32008614~32012472:-
THCA	trans	rs853679	0.546	rs35744819	ENSG00000248290.1	TNXA	-5.81	1.14e-08	0.0129	-0.55	-0.26	Depression;	chr6:28350554	chr6:32008614~32012472:-
THCA	trans	rs9467711	0.932	rs11966360	ENSG00000176998.4	HCG4	-5.81	1.14e-08	0.013	-0.41	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26316754	chr6:29791753~29792750:-
THCA	trans	rs2985684	1	rs2224949	ENSG00000240785.1	RPL36AP21	-5.81	1.15e-08	0.013	-0.33	-0.26	Carotid intima media thickness;	chr14:49629842	chr5:18049550~18049872:+
THCA	trans	rs7746199	0.673	rs72847313	ENSG00000253570.1	RNF5P1	5.81	1.15e-08	0.013	0.73	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr8:38600661~38601200:-
THCA	trans	rs7746199	0.611	rs17750747	ENSG00000253570.1	RNF5P1	5.81	1.15e-08	0.013	0.73	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr8:38600661~38601200:-
THCA	trans	rs4879677	1	rs10116400	ENSG00000269560.1	CTD-2192J16.21	-5.81	1.15e-08	0.013	-0.32	-0.26	Gut microbiome composition (summer and winter);	chr9:27686882	chr19:12529768~12532973:-
THCA	trans	rs11172055	0.902	rs12422981	ENSG00000121089.4	NACA3P	5.81	1.15e-08	0.013	0.29	0.26	Migraine;	chr12:56900282	chr4:164943290~164943937:+
THCA	trans	rs11250098	0.6	rs4240671	ENSG00000229857.1	RP11-159H20.3	-5.81	1.15e-08	0.013	-0.3	-0.26	Morning vs. evening chronotype;	chr8:10910238	chr9:76992099~76993108:+
THCA	trans	rs2736345	0.672	rs2618473	ENSG00000253893.2	FAM85B	-5.81	1.15e-08	0.013	-0.37	-0.26	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486618	chr8:8167819~8226614:-
THCA	trans	rs2950393	0.929	rs7980835	ENSG00000257210.1	NACAP3	5.81	1.15e-08	0.013	0.31	0.26	Platelet distribution width;	chr12:56676847	chr12:93124063~93124543:-
THCA	trans	rs2950393	0.929	rs10747769	ENSG00000257210.1	NACAP3	5.81	1.15e-08	0.013	0.31	0.26	Platelet distribution width;	chr12:56677056	chr12:93124063~93124543:-
THCA	trans	rs7200543	1	rs72774845	ENSG00000255185.4	PDXDC2P	5.81	1.15e-08	0.013	0.37	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:70010751~70065945:-
THCA	trans	rs11992162	0.967	rs7836456	ENSG00000229857.1	RP11-159H20.3	-5.81	1.15e-08	0.013	-0.33	-0.26	Monocyte count;	chr8:11971666	chr9:76992099~76993108:+
THCA	trans	rs190945449	1	rs190945449	ENSG00000280107.1	AL022393.9	-5.81	1.15e-08	0.0131	-0.48	-0.26	Urinary tract infection frequency;	chr6:26860580	chr6:28170845~28172521:+
THCA	trans	rs453301	0.719	rs34004903	ENSG00000256560.1	LINC01486	-5.81	1.15e-08	0.0131	-0.31	-0.26	Joint mobility (Beighton score);	chr8:9035094	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs11831919	ENSG00000250539.1	KRT8P33	-5.81	1.16e-08	0.0131	-0.48	-0.26	Prostate cancer;	chr12:52878231	chr5:123400922~123402344:-
THCA	trans	rs3790645	0.958	rs1466286	ENSG00000221817.8	PPP3CB-AS1	-5.81	1.16e-08	0.0131	-0.24	-0.26	Glucose homeostasis traits;	chr1:26544239	chr10:73495525~73520070:+
THCA	trans	rs7647973	0.592	rs6774202	ENSG00000197582.5	GPX1P1	5.81	1.16e-08	0.0131	0.46	0.26	Menarche (age at onset);	chr3:49650346	chrX:13378735~13379340:-
THCA	trans	rs9650657	0.596	rs2409674	ENSG00000253893.2	FAM85B	5.81	1.16e-08	0.0131	0.32	0.26	Neuroticism;	chr8:10738368	chr8:8167819~8226614:-
THCA	trans	rs11671005	0.779	rs3794970	ENSG00000279267.1	RP11-395L14.18	-5.81	1.16e-08	0.0131	-0.38	-0.26	Mean platelet volume;	chr19:58474893	chr2:113605867~113607908:-
THCA	trans	rs453301	0.686	rs7814328	ENSG00000229857.1	RP11-159H20.3	5.81	1.16e-08	0.0131	0.32	0.26	Joint mobility (Beighton score);	chr8:9018719	chr9:76992099~76993108:+
THCA	trans	rs10090774	0.93	rs6982216	ENSG00000230756.1	RHOQP3	5.81	1.16e-08	0.0132	0.32	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140838142	chr2:130212870~130213490:-
THCA	trans	rs7819412	0.502	rs10095003	ENSG00000254153.1	CTA-398F10.2	5.81	1.17e-08	0.0132	0.32	0.26	Triglycerides;	chr8:11184940	chr8:8456909~8461337:-
THCA	trans	rs2736345	0.788	rs998683	ENSG00000256560.1	LINC01486	-5.81	1.17e-08	0.0132	-0.34	-0.26	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr12:109354083~109359488:-
THCA	trans	rs2645424	0.604	rs9644756	ENSG00000269898.1	RP11-568J23.4	-5.81	1.17e-08	0.0132	-0.31	-0.26	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11857591	chr16:85743287~85744225:+
THCA	trans	rs9467711	0.72	rs75782365	ENSG00000253570.1	RNF5P1	5.81	1.17e-08	0.0133	0.77	0.26	Autism spectrum disorder or schizophrenia;	chr6:26408323	chr8:38600661~38601200:-
THCA	trans	rs4646450	0.891	rs917154	ENSG00000228834.1	RP11-249L21.4	5.81	1.18e-08	0.0133	0.41	0.26	Blood metabolite levels;	chr7:99423183	chr6:108907615~108907873:-
THCA	trans	rs3096299	0.503	rs9940093	ENSG00000215030.5	RPL13P12	-5.81	1.18e-08	0.0133	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89492297	chr17:17383377~17384012:-
THCA	trans	rs7819412	0.595	rs4841500	ENSG00000229857.1	RP11-159H20.3	5.81	1.18e-08	0.0134	0.33	0.26	Triglycerides;	chr8:11130765	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.571	rs4240673	ENSG00000256560.1	LINC01486	-5.81	1.18e-08	0.0134	-0.31	-0.26	Neuroticism;	chr8:10930102	chr12:109354083~109359488:-
THCA	trans	rs7945705	0.776	rs11042069	ENSG00000266891.1	RP11-692N5.2	-5.8	1.19e-08	0.0134	-0.33	-0.26	Hemoglobin concentration;	chr11:8795768	chr18:9734882~9735602:-
THCA	trans	rs11958034	1	rs4616898	ENSG00000271874.1	CTD-2024P10.2	-5.8	1.19e-08	0.0134	-0.41	-0.26	Mitochondrial DNA levels;	chr5:18912227	chr5:34651457~34651888:-
THCA	trans	rs7945705	0.846	rs4929912	ENSG00000266891.1	RP11-692N5.2	5.8	1.19e-08	0.0134	0.34	0.26	Hemoglobin concentration;	chr11:8795148	chr18:9734882~9735602:-
THCA	trans	rs9650657	0.596	rs6989370	ENSG00000253893.2	FAM85B	-5.8	1.19e-08	0.0134	-0.32	-0.26	Neuroticism;	chr8:10759070	chr8:8167819~8226614:-
THCA	trans	rs9987353	0.518	rs4841110	ENSG00000253893.2	FAM85B	-5.8	1.19e-08	0.0135	-0.34	-0.26	Recombination measurement;	chr8:9228513	chr8:8167819~8226614:-
THCA	trans	rs1908814	0.503	rs34657250	ENSG00000229857.1	RP11-159H20.3	5.8	1.19e-08	0.0135	0.34	0.26	Neuroticism;	chr8:11937864	chr9:76992099~76993108:+
THCA	trans	rs4646450	0.891	rs13227795	ENSG00000228834.1	RP11-249L21.4	5.8	1.19e-08	0.0135	0.41	0.26	Blood metabolite levels;	chr7:99451780	chr6:108907615~108907873:-
THCA	trans	rs4646450	0.891	rs2280601	ENSG00000228834.1	RP11-249L21.4	5.8	1.19e-08	0.0135	0.41	0.26	Blood metabolite levels;	chr7:99458476	chr6:108907615~108907873:-
THCA	trans	rs9467711	0.79	rs13195401	ENSG00000219392.1	RP1-265C24.5	-5.8	1.19e-08	0.0135	-0.59	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.79	rs13195402	ENSG00000219392.1	RP1-265C24.5	-5.8	1.19e-08	0.0135	-0.59	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr6:28115628~28116551:+
THCA	trans	rs9650657	0.571	rs4840512	ENSG00000253893.2	FAM85B	5.8	1.19e-08	0.0135	0.32	0.26	Neuroticism;	chr8:10739315	chr8:8167819~8226614:-
THCA	trans	rs7192380	0.651	rs34769743	ENSG00000257513.6	NPIPB1P	5.8	1.2e-08	0.0135	0.3	0.26	Sjögren's syndrome;	chr16:69546587	chr18:11619509~11639699:-
THCA	trans	rs4646450	0.891	rs10271049	ENSG00000228834.1	RP11-249L21.4	5.8	1.2e-08	0.0135	0.41	0.26	Blood metabolite levels;	chr7:99428870	chr6:108907615~108907873:-
THCA	trans	rs4646450	0.891	rs7794705	ENSG00000228834.1	RP11-249L21.4	5.8	1.2e-08	0.0135	0.41	0.26	Blood metabolite levels;	chr7:99431761	chr6:108907615~108907873:-
THCA	trans	rs3096299	0.719	rs12934708	ENSG00000215030.5	RPL13P12	-5.8	1.2e-08	0.0135	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89457382	chr17:17383377~17384012:-
THCA	trans	rs12477438	0.52	rs4340581	ENSG00000276576.1	MRPL30P1	5.8	1.2e-08	0.0136	0.33	0.26	Chronic sinus infection;	chr2:99108562	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs36071868	ENSG00000276576.1	MRPL30P1	5.8	1.2e-08	0.0136	0.33	0.26	Chronic sinus infection;	chr2:99120657	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs34252185	ENSG00000276576.1	MRPL30P1	5.8	1.2e-08	0.0136	0.33	0.26	Chronic sinus infection;	chr2:99121183	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs13023744	ENSG00000276576.1	MRPL30P1	5.8	1.2e-08	0.0136	0.33	0.26	Chronic sinus infection;	chr2:99121761	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.501	rs6751927	ENSG00000276576.1	MRPL30P1	5.8	1.2e-08	0.0136	0.33	0.26	Chronic sinus infection;	chr2:99123712	chr6:57029521~57029988:+
THCA	trans	rs34043524	1	rs11730547	ENSG00000260036.1	RP11-178D12.2	5.8	1.21e-08	0.0136	0.49	0.26	Lateral ventricle volume in trauma-exposed individuals;	chr4:116982791	chr15:55442635~55443357:-
THCA	trans	rs11098499	0.566	rs7664440	ENSG00000253326.2	RP11-261C10.7	5.8	1.21e-08	0.0136	0.36	0.26	Corneal astigmatism;	chr4:119657385	chr1:243054861~243056394:-
THCA	trans	rs7824557	0.583	rs4448232	ENSG00000256560.1	LINC01486	5.8	1.21e-08	0.0136	0.32	0.26	Retinal vascular caliber;	chr8:11373845	chr12:109354083~109359488:-
THCA	trans	rs453301	0.658	rs6983877	ENSG00000229857.1	RP11-159H20.3	5.8	1.21e-08	0.0136	0.31	0.26	Joint mobility (Beighton score);	chr8:9047129	chr9:76992099~76993108:+
THCA	trans	rs12477438	0.501	rs9941561	ENSG00000276576.1	MRPL30P1	5.8	1.21e-08	0.0136	0.33	0.26	Chronic sinus infection;	chr2:99137366	chr6:57029521~57029988:+
THCA	trans	rs9650657	0.615	rs4840519	ENSG00000253893.2	FAM85B	5.8	1.21e-08	0.0137	0.32	0.26	Neuroticism;	chr8:10835603	chr8:8167819~8226614:-
THCA	trans	rs3096299	0.685	rs4329923	ENSG00000215030.5	RPL13P12	-5.8	1.22e-08	0.0137	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89493770	chr17:17383377~17384012:-
THCA	trans	rs6885307	1	rs59468706	ENSG00000231752.4	EMBP1	5.8	1.22e-08	0.0137	0.4	0.26	Age at first birth;	chr5:45025021	chr1:121519112~121571892:+
THCA	trans	rs1908814	0.516	rs11250178	ENSG00000254153.1	CTA-398F10.2	-5.8	1.22e-08	0.0137	-0.3	-0.26	Neuroticism;	chr8:11942725	chr8:8456909~8461337:-
THCA	trans	rs3008870	0.536	rs2815383	ENSG00000227992.1	AC108463.2	5.8	1.22e-08	0.0137	0.33	0.26	Lymphocyte percentage of white cells;	chr1:67050633	chr2:111203964~111206215:-
THCA	trans	rs45509595	0.841	rs17751184	ENSG00000253570.1	RNF5P1	5.8	1.22e-08	0.0138	0.72	0.26	Breast cancer;	chr6:27807250	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs67101035	ENSG00000253570.1	RNF5P1	5.8	1.22e-08	0.0138	0.72	0.26	Depression;	chr6:27831109	chr8:38600661~38601200:-
THCA	trans	rs853679	0.556	rs34706883	ENSG00000253570.1	RNF5P1	5.8	1.22e-08	0.0138	0.72	0.26	Depression;	chr6:27837477	chr8:38600661~38601200:-
THCA	trans	rs67340775	0.748	rs13212651	ENSG00000253570.1	RNF5P1	5.8	1.22e-08	0.0138	0.72	0.26	Lung cancer in ever smokers;	chr6:27839207	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs35819751	ENSG00000253570.1	RNF5P1	5.8	1.22e-08	0.0138	0.72	0.26	Depression;	chr6:27842791	chr8:38600661~38601200:-
THCA	trans	rs902774	0.759	rs4919707	ENSG00000220378.3	KRT8P42	-5.8	1.22e-08	0.0138	-0.57	-0.26	Prostate cancer;	chr12:52895864	chr6:134296997~134298695:-
THCA	trans	rs902774	0.818	rs56095813	ENSG00000220378.3	KRT8P42	-5.8	1.22e-08	0.0138	-0.57	-0.26	Prostate cancer;	chr12:52900963	chr6:134296997~134298695:-
THCA	trans	rs7617773	0.746	rs11713476	ENSG00000235912.1	RP1-159A19.3	-5.8	1.22e-08	0.0138	-0.31	-0.26	Coronary artery disease;	chr3:48333944	chr1:27649419~27649610:+
THCA	trans	rs853679	0.607	rs33932084	ENSG00000204338.7	CYP21A1P	-5.8	1.22e-08	0.0138	-0.54	-0.26	Depression;	chr6:28301047	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.764	rs35565446	ENSG00000204338.7	CYP21A1P	-5.8	1.22e-08	0.0138	-0.58	-0.26	Intelligence (multi-trait analysis);	chr6:27177562	chr6:32005636~32008451:+
THCA	trans	rs6601450	0.54	rs7824231	ENSG00000253893.2	FAM85B	5.8	1.23e-08	0.0138	0.33	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10416448	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.61	rs7950870	ENSG00000266891.1	RP11-692N5.2	5.8	1.23e-08	0.0138	0.32	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8523938	chr18:9734882~9735602:-
THCA	trans	rs9329221	0.597	rs17751178	ENSG00000229857.1	RP11-159H20.3	-5.8	1.23e-08	0.0138	-0.34	-0.26	Neuroticism;	chr8:10259220	chr9:76992099~76993108:+
THCA	trans	rs7769051	0.711	rs7770081	ENSG00000227615.1	RP11-864N7.2	5.8	1.23e-08	0.0138	0.44	0.26	Type 2 diabetes nephropathy;	chr6:132768430	chr11:74745716~74746114:-
THCA	trans	rs7520050	0.667	rs11211176	ENSG00000255397.1	AC022182.2	5.8	1.23e-08	0.0138	0.35	0.26	Reticulocyte count;Red blood cell count;	chr1:45757414	chr8:60937705~60939871:-
THCA	trans	rs7647973	0.626	rs4855845	ENSG00000197582.5	GPX1P1	5.8	1.23e-08	0.0139	0.46	0.26	Menarche (age at onset);	chr3:49649610	chrX:13378735~13379340:-
THCA	trans	rs7212590	0.748	rs9904374	ENSG00000187870.7	RNFT1P3	5.8	1.23e-08	0.0139	0.51	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59830735	chr17:20743333~20754501:-
THCA	trans	rs453301	0.686	rs6601281	ENSG00000229857.1	RP11-159H20.3	5.8	1.23e-08	0.0139	0.31	0.26	Joint mobility (Beighton score);	chr8:9053494	chr9:76992099~76993108:+
THCA	trans	rs10090774	0.965	rs13276704	ENSG00000230756.1	RHOQP3	5.8	1.24e-08	0.014	0.32	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140983597	chr2:130212870~130213490:-
THCA	trans	rs7829975	0.871	rs7829826	ENSG00000256560.1	LINC01486	-5.8	1.24e-08	0.014	-0.3	-0.26	Mood instability;	chr8:8720610	chr12:109354083~109359488:-
THCA	trans	rs9393777	0.778	rs74689501	ENSG00000280107.1	AL022393.9	-5.8	1.24e-08	0.014	-0.49	-0.26	Intelligence (multi-trait analysis);	chr6:26920042	chr6:28170845~28172521:+
THCA	trans	rs8177876	0.822	rs7203546	ENSG00000224837.1	GCSHP5	-5.8	1.24e-08	0.014	-0.37	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr1:168055901~168056422:-
THCA	trans	rs7769051	1	rs7761365	ENSG00000213303.3	CTC-398G3.2	5.8	1.25e-08	0.014	0.49	0.26	Type 2 diabetes nephropathy;	chr6:132780422	chr19:11523436~11523831:+
THCA	trans	rs7769051	1	rs7765224	ENSG00000213303.3	CTC-398G3.2	5.8	1.25e-08	0.014	0.49	0.26	Type 2 diabetes nephropathy;	chr6:132780485	chr19:11523436~11523831:+
THCA	trans	rs7769051	0.614	rs6912936	ENSG00000213303.3	CTC-398G3.2	5.8	1.25e-08	0.014	0.49	0.26	Type 2 diabetes nephropathy;	chr6:132781525	chr19:11523436~11523831:+
THCA	trans	rs2665103	0.589	rs2134046	ENSG00000235370.6	DNM1P51	-5.8	1.25e-08	0.0141	-0.32	-0.26	Intelligence (multi-trait analysis);	chr15:82232203	chr15:84398316~84411701:-
THCA	trans	rs17783634	0.509	rs11775489	ENSG00000229857.1	RP11-159H20.3	5.8	1.25e-08	0.0141	0.34	0.26	Subjective well-being;	chr8:11179334	chr9:76992099~76993108:+
THCA	trans	rs10435719	0.746	rs58007588	ENSG00000229857.1	RP11-159H20.3	-5.8	1.25e-08	0.0141	-0.34	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.511	rs2955578	ENSG00000256560.1	LINC01486	5.79	1.26e-08	0.0141	0.3	0.26	Mood instability;	chr8:8279561	chr12:109354083~109359488:-
THCA	trans	rs4646450	0.838	rs2272168	ENSG00000228834.1	RP11-249L21.4	5.79	1.26e-08	0.0142	0.41	0.26	Blood metabolite levels;	chr7:99505154	chr6:108907615~108907873:-
THCA	trans	rs853679	0.769	rs17720293	ENSG00000228022.4	HCG20	-5.79	1.26e-08	0.0142	-0.58	-0.26	Depression;	chr6:28246920	chr6:30766825~30792250:+
THCA	trans	rs11098499	0.698	rs4422403	ENSG00000253326.2	RP11-261C10.7	5.79	1.26e-08	0.0142	0.34	0.26	Corneal astigmatism;	chr4:119337039	chr1:243054861~243056394:-
THCA	trans	rs9649213	0.555	rs7785612	ENSG00000225169.1	BRI3P1	5.79	1.26e-08	0.0142	0.33	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr1:100213293~100213670:+
THCA	trans	rs7113874	0.524	rs11041990	ENSG00000266891.1	RP11-692N5.2	5.79	1.26e-08	0.0142	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8564068	chr18:9734882~9735602:-
THCA	trans	rs7746199	0.736	rs13212318	ENSG00000253570.1	RNF5P1	5.79	1.26e-08	0.0142	0.72	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr8:38600661~38601200:-
THCA	trans	rs7746199	0.736	rs13202291	ENSG00000253570.1	RNF5P1	5.79	1.26e-08	0.0142	0.72	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr8:38600661~38601200:-
THCA	trans	rs7746199	0.736	rs17750424	ENSG00000253570.1	RNF5P1	5.79	1.26e-08	0.0142	0.72	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr8:38600661~38601200:-
THCA	trans	rs7746199	0.736	rs35848276	ENSG00000204338.7	CYP21A1P	-5.79	1.26e-08	0.0142	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:32005636~32008451:+
THCA	trans	rs7829975	0.774	rs11775523	ENSG00000229857.1	RP11-159H20.3	-5.79	1.26e-08	0.0142	-0.32	-0.26	Mood instability;	chr8:8821666	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.899	rs9650656	ENSG00000229857.1	RP11-159H20.3	5.79	1.27e-08	0.0143	0.31	0.26	Neuroticism;	chr8:10749744	chr9:76992099~76993108:+
THCA	trans	rs12477438	0.52	rs6741772	ENSG00000276576.1	MRPL30P1	5.79	1.27e-08	0.0143	0.33	0.26	Chronic sinus infection;	chr2:99122498	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6741773	ENSG00000276576.1	MRPL30P1	5.79	1.27e-08	0.0143	0.33	0.26	Chronic sinus infection;	chr2:99122499	chr6:57029521~57029988:+
THCA	trans	rs804280	0.504	rs2645457	ENSG00000256560.1	LINC01486	-5.79	1.27e-08	0.0143	-0.33	-0.26	Myopia (pathological);	chr8:11756603	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.623	rs10092965	ENSG00000229857.1	RP11-159H20.3	-5.79	1.27e-08	0.0143	-0.32	-0.26	Mood instability;	chr8:8515975	chr9:76992099~76993108:+
THCA	trans	rs6921919	0.562	rs13198809	ENSG00000204338.7	CYP21A1P	-5.79	1.27e-08	0.0143	-0.56	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs35353359	ENSG00000204338.7	CYP21A1P	-5.79	1.27e-08	0.0143	-0.56	-0.26	Depression;	chr6:28356601	chr6:32005636~32008451:+
THCA	trans	rs902774	0.818	rs79377635	ENSG00000220378.3	KRT8P42	-5.79	1.27e-08	0.0143	-0.56	-0.26	Prostate cancer;	chr12:52883148	chr6:134296997~134298695:-
THCA	trans	rs7520050	0.778	rs3014216	ENSG00000255397.1	AC022182.2	-5.79	1.27e-08	0.0143	-0.34	-0.26	Reticulocyte count;Red blood cell count;	chr1:45570088	chr8:60937705~60939871:-
THCA	trans	rs656319	0.669	rs56279061	ENSG00000253893.2	FAM85B	5.79	1.27e-08	0.0143	0.35	0.26	Myopia (pathological);	chr8:10016470	chr8:8167819~8226614:-
THCA	trans	rs6894216	0.627	rs12654296	ENSG00000237714.1	P4HA2-AS1	-5.79	1.27e-08	0.0143	-0.32	-0.26	Response to amphetamines;	chr5:130355167	chr5:132184876~132192808:+
THCA	trans	rs9329221	0.537	rs12678797	ENSG00000253893.2	FAM85B	5.79	1.28e-08	0.0144	0.32	0.26	Neuroticism;	chr8:10121409	chr8:8167819~8226614:-
THCA	trans	rs7694207	0.706	rs10012628	ENSG00000215481.7	BCRP3	5.79	1.28e-08	0.0144	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96960997	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs13131583	ENSG00000215481.7	BCRP3	5.79	1.28e-08	0.0144	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96961492	chr22:24632915~24653356:+
THCA	trans	rs9467711	0.659	rs34605993	ENSG00000253570.1	RNF5P1	5.79	1.28e-08	0.0144	0.74	0.26	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.659	rs66757203	ENSG00000253570.1	RNF5P1	5.79	1.28e-08	0.0144	0.74	0.26	Autism spectrum disorder or schizophrenia;	chr6:26454728	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.659	rs35680819	ENSG00000253570.1	RNF5P1	5.79	1.28e-08	0.0144	0.74	0.26	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.659	rs36033628	ENSG00000253570.1	RNF5P1	5.79	1.28e-08	0.0144	0.74	0.26	Autism spectrum disorder or schizophrenia;	chr6:26455846	chr8:38600661~38601200:-
THCA	trans	rs7819412	0.502	rs11777918	ENSG00000229857.1	RP11-159H20.3	-5.79	1.29e-08	0.0144	-0.35	-0.26	Triglycerides;	chr8:11179410	chr9:76992099~76993108:+
THCA	trans	rs12477438	0.52	rs11678456	ENSG00000276576.1	MRPL30P1	5.79	1.29e-08	0.0144	0.33	0.26	Chronic sinus infection;	chr2:99091774	chr6:57029521~57029988:+
THCA	trans	rs9584850	0.874	rs9168	ENSG00000230079.1	STK24P1	5.79	1.29e-08	0.0145	0.31	0.26	Neuroticism;	chr13:98449329	chrX:136295690~136300298:-
THCA	trans	rs9467711	0.79	rs35400317	ENSG00000226314.6	ZNF192P1	-5.79	1.29e-08	0.0145	-0.58	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr6:28161781~28169594:+
THCA	trans	rs9467711	0.79	rs67777156	ENSG00000226314.6	ZNF192P1	-5.79	1.29e-08	0.0145	-0.58	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr6:28161781~28169594:+
THCA	trans	rs9467711	0.722	rs13201782	ENSG00000226314.6	ZNF192P1	-5.79	1.29e-08	0.0145	-0.58	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr6:28161781~28169594:+
THCA	trans	rs3812762	0.871	rs11603335	ENSG00000266891.1	RP11-692N5.2	-5.79	1.29e-08	0.0145	-0.34	-0.26	Hypospadias;	chr11:8788297	chr18:9734882~9735602:-
THCA	trans	rs5758511	0.573	rs738248	ENSG00000268568.1	AC007228.9	-5.79	1.29e-08	0.0145	-0.3	-0.26	Birth weight;	chr22:41800463	chr19:56672574~56673901:-
THCA	trans	rs5758511	0.573	rs5996069	ENSG00000268568.1	AC007228.9	-5.79	1.29e-08	0.0145	-0.3	-0.26	Birth weight;	chr22:41805181	chr19:56672574~56673901:-
THCA	trans	rs902774	0.818	rs17120257	ENSG00000240668.1	KRT8P36	-5.79	1.29e-08	0.0145	-0.53	-0.26	Prostate cancer;	chr12:52909547	chr3:138101478~138102917:-
THCA	trans	rs330048	0.561	rs330088	ENSG00000256560.1	LINC01486	5.79	1.3e-08	0.0145	0.31	0.26	Systemic lupus erythematosus;	chr8:9292236	chr12:109354083~109359488:-
THCA	trans	rs6831352	0.819	rs1154401	ENSG00000228407.2	RP4-800M22.1	-5.79	1.3e-08	0.0146	-0.35	-0.26	Alcohol dependence;	chr4:99088587	chr1:52160261~52160600:-
THCA	trans	rs867371	0.614	rs7183805	ENSG00000235370.6	DNM1P51	-5.79	1.3e-08	0.0146	-0.35	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:84398316~84411701:-
THCA	trans	rs2048656	0.578	rs925610	ENSG00000253893.2	FAM85B	5.79	1.3e-08	0.0146	0.33	0.26	Schizophrenia;	chr8:9824326	chr8:8167819~8226614:-
THCA	trans	rs7429990	0.901	rs9825114	ENSG00000235912.1	RP1-159A19.3	5.79	1.3e-08	0.0146	0.33	0.26	Educational attainment (years of education);	chr3:48096592	chr1:27649419~27649610:+
THCA	trans	rs7819412	0.807	rs9657519	ENSG00000256560.1	LINC01486	-5.79	1.31e-08	0.0147	-0.32	-0.26	Triglycerides;	chr8:11087929	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs4919740	ENSG00000240668.1	KRT8P36	-5.79	1.31e-08	0.0147	-0.49	-0.26	Prostate cancer;	chr12:52877187	chr3:138101478~138102917:-
THCA	trans	rs2980439	0.818	rs2948300	ENSG00000229857.1	RP11-159H20.3	-5.79	1.31e-08	0.0147	-0.32	-0.26	Neuroticism;	chr8:8248986	chr9:76992099~76993108:+
THCA	trans	rs9329221	0.537	rs6601414	ENSG00000253893.2	FAM85B	-5.79	1.32e-08	0.0148	-0.32	-0.26	Neuroticism;	chr8:10119238	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.537	rs6601415	ENSG00000253893.2	FAM85B	-5.79	1.32e-08	0.0148	-0.32	-0.26	Neuroticism;	chr8:10119295	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.512	rs7843924	ENSG00000253893.2	FAM85B	-5.79	1.32e-08	0.0148	-0.32	-0.26	Neuroticism;	chr8:10119030	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.537	rs2062332	ENSG00000253893.2	FAM85B	-5.79	1.32e-08	0.0148	-0.32	-0.26	Neuroticism;	chr8:10122514	chr8:8167819~8226614:-
THCA	trans	rs7769051	1	rs6934161	ENSG00000213303.3	CTC-398G3.2	-5.79	1.32e-08	0.0148	-0.46	-0.26	Type 2 diabetes nephropathy;	chr6:132802938	chr19:11523436~11523831:+
THCA	trans	rs2665103	0.589	rs3858953	ENSG00000235370.6	DNM1P51	-5.78	1.33e-08	0.0149	-0.32	-0.26	Intelligence (multi-trait analysis);	chr15:82238049	chr15:84398316~84411701:-
THCA	trans	rs11992162	0.967	rs10112888	ENSG00000229857.1	RP11-159H20.3	-5.78	1.33e-08	0.0149	-0.33	-0.26	Monocyte count;	chr8:11972699	chr9:76992099~76993108:+
THCA	trans	rs2645424	0.666	rs2272767	ENSG00000260438.1	RP11-405F3.2	5.78	1.33e-08	0.0149	0.36	0.26	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853550	chr16:57713782~57714957:+
THCA	trans	rs9381040	0.655	rs9394756	ENSG00000232097.1	AC079781.8	5.78	1.33e-08	0.0149	0.31	0.26	Alzheimer's disease (late onset);	chr6:41048444	chr7:97938439~97938794:-
THCA	trans	rs4879677	1	rs2150022	ENSG00000269560.1	CTD-2192J16.21	-5.78	1.33e-08	0.0149	-0.32	-0.26	Gut microbiome composition (summer and winter);	chr9:27688031	chr19:12529768~12532973:-
THCA	trans	rs10090774	0.965	rs4507813	ENSG00000230756.1	RHOQP3	-5.78	1.33e-08	0.0149	-0.32	-0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140786245	chr2:130212870~130213490:-
THCA	trans	rs7617773	0.963	rs6771787	ENSG00000235912.1	RP1-159A19.3	5.78	1.33e-08	0.0149	0.31	0.26	Coronary artery disease;	chr3:48152752	chr1:27649419~27649610:+
THCA	trans	rs7617773	1	rs6771889	ENSG00000235912.1	RP1-159A19.3	5.78	1.33e-08	0.0149	0.31	0.26	Coronary artery disease;	chr3:48152836	chr1:27649419~27649610:+
THCA	trans	rs7829975	0.714	rs7823757	ENSG00000229857.1	RP11-159H20.3	-5.78	1.33e-08	0.0149	-0.31	-0.26	Mood instability;	chr8:8812667	chr9:76992099~76993108:+
THCA	trans	rs7113874	0.589	rs2028882	ENSG00000266891.1	RP11-692N5.2	5.78	1.34e-08	0.015	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483307	chr18:9734882~9735602:-
THCA	trans	rs2288327	0.75	rs62178978	ENSG00000269800.1	PLEKHA3P1	5.78	1.34e-08	0.015	0.35	0.26	Atrial fibrillation;	chr2:178718671	chr19:41521043~41521989:-
THCA	trans	rs9393777	0.92	rs66462181	ENSG00000228022.4	HCG20	-5.78	1.34e-08	0.015	-0.66	-0.26	Intelligence (multi-trait analysis);	chr6:27123882	chr6:30766825~30792250:+
THCA	trans	rs45509595	0.556	rs34409918	ENSG00000204338.7	CYP21A1P	-5.78	1.34e-08	0.015	-0.58	-0.26	Breast cancer;	chr6:27717569	chr6:32005636~32008451:+
THCA	trans	rs12477438	0.501	rs2632284	ENSG00000276576.1	MRPL30P1	5.78	1.34e-08	0.015	0.33	0.26	Chronic sinus infection;	chr2:99159402	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs2969379	ENSG00000276576.1	MRPL30P1	5.78	1.34e-08	0.015	0.33	0.26	Chronic sinus infection;	chr2:99160223	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs12621007	ENSG00000276576.1	MRPL30P1	5.78	1.34e-08	0.015	0.33	0.26	Chronic sinus infection;	chr2:99175483	chr6:57029521~57029988:+
THCA	trans	rs4646450	0.838	rs10229569	ENSG00000228834.1	RP11-249L21.4	5.78	1.34e-08	0.015	0.41	0.26	Blood metabolite levels;	chr7:99586081	chr6:108907615~108907873:-
THCA	trans	rs11098499	0.644	rs10012252	ENSG00000253326.2	RP11-261C10.7	5.78	1.35e-08	0.0151	0.35	0.26	Corneal astigmatism;	chr4:119637984	chr1:243054861~243056394:-
THCA	trans	rs9467711	0.659	rs3823158	ENSG00000226314.6	ZNF192P1	-5.78	1.35e-08	0.0151	-0.55	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr6:28161781~28169594:+
THCA	trans	rs6601327	0.571	rs35874762	ENSG00000253893.2	FAM85B	5.78	1.35e-08	0.0152	0.32	0.26	Multiple myeloma (hyperdiploidy);	chr8:9707882	chr8:8167819~8226614:-
THCA	trans	rs1964356	0.967	rs17701675	ENSG00000256560.1	LINC01486	-5.78	1.36e-08	0.0152	-0.3	-0.26	Mean corpuscular volume;	chr8:8993123	chr12:109354083~109359488:-
THCA	trans	rs11085466	1	rs11085466	ENSG00000239830.1	RPS4XP22	-5.78	1.36e-08	0.0152	-0.33	-0.26	Colorectal or endometrial cancer;	chr19:21569009	chr19:9683294~9684073:-
THCA	trans	rs4646450	0.891	rs11976018	ENSG00000228834.1	RP11-249L21.4	5.78	1.36e-08	0.0152	0.41	0.26	Blood metabolite levels;	chr7:99524814	chr6:108907615~108907873:-
THCA	trans	rs11992162	1	rs7460395	ENSG00000254153.1	CTA-398F10.2	-5.78	1.36e-08	0.0153	-0.29	-0.26	Monocyte count;	chr8:11977866	chr8:8456909~8461337:-
THCA	trans	rs12659622	0.651	rs17602228	ENSG00000236722.1	RP11-359I18.1	5.78	1.36e-08	0.0153	0.42	0.26	Obesity-related traits;	chr5:15695087	chr3:58511310~58511676:+
THCA	trans	rs7819412	0.522	rs3021495	ENSG00000254153.1	CTA-398F10.2	5.78	1.37e-08	0.0153	0.31	0.26	Triglycerides;	chr8:11137233	chr8:8456909~8461337:-
THCA	trans	rs4415084	0.716	rs7703497	ENSG00000231752.4	EMBP1	5.78	1.37e-08	0.0153	0.36	0.26	Breast cancer;	chr5:44856926	chr1:121519112~121571892:+
THCA	trans	rs1190596	0.525	rs34440178	ENSG00000181359.5	HSP90AA6P	-5.78	1.37e-08	0.0153	-0.38	-0.26	Behavioural disinhibition (generation interaction);	chr14:102244864	chr4:170581470~170605450:-
THCA	trans	rs875971	0.545	rs221986	ENSG00000213640.3	EEF1DP4	5.78	1.37e-08	0.0153	0.35	0.26	Aortic root size;	chr7:66105323	chr7:64862999~64864370:+
THCA	trans	rs11098499	0.691	rs12502524	ENSG00000253326.2	RP11-261C10.7	5.78	1.37e-08	0.0154	0.34	0.26	Corneal astigmatism;	chr4:119350259	chr1:243054861~243056394:-
THCA	trans	rs7769051	0.615	rs12209144	ENSG00000227615.1	RP11-864N7.2	5.78	1.37e-08	0.0154	0.44	0.26	Type 2 diabetes nephropathy;	chr6:132869925	chr11:74745716~74746114:-
THCA	trans	rs9329221	0.772	rs7824675	ENSG00000229857.1	RP11-159H20.3	5.78	1.38e-08	0.0154	0.32	0.26	Neuroticism;	chr8:10385908	chr9:76992099~76993108:+
THCA	trans	rs453301	0.686	rs7017868	ENSG00000229857.1	RP11-159H20.3	5.78	1.38e-08	0.0154	0.32	0.26	Joint mobility (Beighton score);	chr8:9015783	chr9:76992099~76993108:+
THCA	trans	rs453301	0.686	rs3895823	ENSG00000229857.1	RP11-159H20.3	5.78	1.38e-08	0.0154	0.32	0.26	Joint mobility (Beighton score);	chr8:9016136	chr9:76992099~76993108:+
THCA	trans	rs453301	0.658	rs6983877	ENSG00000256560.1	LINC01486	-5.78	1.38e-08	0.0154	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9047129	chr12:109354083~109359488:-
THCA	trans	rs12145833	0.679	rs10927010	ENSG00000154608.12	CEP170P1	5.78	1.39e-08	0.0156	0.34	0.26	Obesity (early onset extreme);	chr1:243415510	chr4:118467590~118554204:+
THCA	trans	rs6006893	0.515	rs6007316	ENSG00000228395.1	RP11-216B9.6	5.78	1.39e-08	0.0156	0.45	0.26	Binge eating behaviour in bipolar disorder;	chr22:44842997	chr9:128528901~128552410:-
THCA	trans	rs7829975	0.742	rs882462	ENSG00000229857.1	RP11-159H20.3	-5.78	1.39e-08	0.0156	-0.32	-0.26	Mood instability;	chr8:8821020	chr9:76992099~76993108:+
THCA	trans	rs453301	0.686	rs6987107	ENSG00000256560.1	LINC01486	-5.78	1.39e-08	0.0156	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9036071	chr12:109354083~109359488:-
THCA	trans	rs7617773	1	rs11711766	ENSG00000235912.1	RP1-159A19.3	5.78	1.39e-08	0.0156	0.31	0.26	Coronary artery disease;	chr3:48151680	chr1:27649419~27649610:+
THCA	trans	rs6915893	0.74	rs12194394	ENSG00000267156.1	TPMTP1	-5.78	1.4e-08	0.0156	-0.28	-0.26	Intrinsic epigenetic age acceleration;	chr6:18103050	chr18:47630112~47630848:+
THCA	trans	rs2439831	0.681	rs825740	ENSG00000180867.10	PDIA3P1	-5.78	1.4e-08	0.0157	-0.28	-0.26	Lung cancer in ever smokers;	chr15:43300210	chr1:147178113~147179622:+
THCA	trans	rs1190596	0.525	rs12896377	ENSG00000181359.5	HSP90AA6P	-5.77	1.4e-08	0.0157	-0.37	-0.26	Behavioural disinhibition (generation interaction);	chr14:102247244	chr4:170581470~170605450:-
THCA	trans	rs6424115	0.708	rs2076343	ENSG00000228217.1	AL390877.1	5.77	1.4e-08	0.0157	0.37	0.26	Immature fraction of reticulocytes;	chr1:23802636	chr1:117778087~117778506:-
THCA	trans	rs1347297	0.526	rs10201175	ENSG00000269800.1	PLEKHA3P1	5.77	1.41e-08	0.0157	0.28	0.26	Alzheimer disease and age of onset;	chr2:178400621	chr19:41521043~41521989:-
THCA	trans	rs10783779	0.647	rs705708	ENSG00000225071.1	GS1-184P14.2	5.77	1.41e-08	0.0157	0.33	0.26	Educational attainment;	chr12:56095129	chrX:24429573~24429920:-
THCA	trans	rs17711722	0.523	rs313812	ENSG00000182722.5	SEPHS1P1	5.77	1.41e-08	0.0157	0.31	0.26	Calcium levels;	chr7:66040056	chr7:64852397~64853354:-
THCA	trans	rs853679	0.769	rs7752608	ENSG00000228022.4	HCG20	-5.77	1.41e-08	0.0157	-0.58	-0.26	Depression;	chr6:28333418	chr6:30766825~30792250:+
THCA	trans	rs4879677	1	rs72712238	ENSG00000269560.1	CTD-2192J16.21	-5.77	1.41e-08	0.0158	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27675371	chr19:12529768~12532973:-
THCA	trans	rs7429990	0.833	rs3755638	ENSG00000235912.1	RP1-159A19.3	5.77	1.42e-08	0.0158	0.31	0.26	Educational attainment (years of education);	chr3:47580841	chr1:27649419~27649610:+
THCA	trans	rs9650657	0.623	rs11250066	ENSG00000253893.2	FAM85B	5.77	1.42e-08	0.0158	0.32	0.26	Neuroticism;	chr8:10742957	chr8:8167819~8226614:-
THCA	trans	rs4879677	1	rs10757677	ENSG00000269560.1	CTD-2192J16.21	-5.77	1.42e-08	0.0158	-0.32	-0.26	Gut microbiome composition (summer and winter);	chr9:27684534	chr19:12529768~12532973:-
THCA	trans	rs8177876	0.822	rs7206814	ENSG00000224837.1	GCSHP5	-5.77	1.42e-08	0.0158	-0.36	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr1:168055901~168056422:-
THCA	trans	rs9987353	0.566	rs34491841	ENSG00000229857.1	RP11-159H20.3	5.77	1.42e-08	0.0158	0.34	0.26	Recombination measurement;	chr8:9208000	chr9:76992099~76993108:+
THCA	trans	rs4295623	0.553	rs11250163	ENSG00000229857.1	RP11-159H20.3	-5.77	1.42e-08	0.0159	-0.33	-0.26	Morning vs. evening chronotype;	chr8:11738928	chr9:76992099~76993108:+
THCA	trans	rs10090774	0.965	rs13253989	ENSG00000230756.1	RHOQP3	5.77	1.42e-08	0.0159	0.32	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140922363	chr2:130212870~130213490:-
THCA	trans	rs7694207	0.706	rs10005942	ENSG00000215481.7	BCRP3	5.77	1.42e-08	0.0159	0.28	0.26	Response to mTOR inhibitor (everolimus);	chr4:96958653	chr22:24632915~24653356:+
THCA	trans	rs453301	0.658	rs12114954	ENSG00000256560.1	LINC01486	-5.77	1.42e-08	0.0159	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9047352	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.521	rs10100660	ENSG00000229857.1	RP11-159H20.3	5.77	1.43e-08	0.0159	0.34	0.26	Triglycerides;	chr8:11181376	chr9:76992099~76993108:+
THCA	trans	rs6087990	0.735	rs6119946	ENSG00000253915.1	MAPRE1P1	-5.77	1.43e-08	0.0159	-0.33	-0.26	Ulcerative colitis;	chr20:32741898	chr8:135625185~135625981:-
THCA	trans	rs7829975	0.774	rs35431455	ENSG00000229857.1	RP11-159H20.3	-5.77	1.43e-08	0.016	-0.31	-0.26	Mood instability;	chr8:8816226	chr9:76992099~76993108:+
THCA	trans	rs6087990	0.806	rs4911259	ENSG00000253915.1	MAPRE1P1	5.77	1.43e-08	0.016	0.33	0.26	Ulcerative colitis;	chr20:32788476	chr8:135625185~135625981:-
THCA	trans	rs12542260	0.817	rs117952028	ENSG00000234369.1	TATDN1P1	5.77	1.43e-08	0.016	0.36	0.26	Colonoscopy-negative controls vs population controls;	chr8:124459149	chr10:63222155~63223045:+
THCA	trans	rs889398	0.741	rs6499269	ENSG00000257513.6	NPIPB1P	5.77	1.44e-08	0.016	0.29	0.26	Body mass index;	chr16:69875015	chr18:11619509~11639699:-
THCA	trans	rs2950393	0.929	rs2958155	ENSG00000257210.1	NACAP3	5.77	1.44e-08	0.016	0.31	0.26	Platelet distribution width;	chr12:56670761	chr12:93124063~93124543:-
THCA	trans	rs7824557	0.815	rs2572430	ENSG00000254153.1	CTA-398F10.2	-5.77	1.44e-08	0.016	-0.26	-0.26	Retinal vascular caliber;	chr8:11247795	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.62	rs6996368	ENSG00000253893.2	FAM85B	-5.77	1.44e-08	0.0161	-0.34	-0.26	Retinal vascular caliber;	chr8:11325195	chr8:8167819~8226614:-
THCA	trans	rs8014204	0.836	rs12588415	ENSG00000181227.3	RP4-682C21.2	-5.77	1.44e-08	0.0161	-0.2	-0.26	Caffeine consumption;	chr14:74811508	chr1:75743423~75744776:-
THCA	trans	rs11098499	0.604	rs2389886	ENSG00000253326.2	RP11-261C10.7	5.77	1.44e-08	0.0161	0.36	0.26	Corneal astigmatism;	chr4:119649267	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.604	rs2389887	ENSG00000253326.2	RP11-261C10.7	5.77	1.44e-08	0.0161	0.36	0.26	Corneal astigmatism;	chr4:119649489	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.604	rs34278750	ENSG00000253326.2	RP11-261C10.7	5.77	1.44e-08	0.0161	0.36	0.26	Corneal astigmatism;	chr4:119649981	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.604	rs10022185	ENSG00000253326.2	RP11-261C10.7	5.77	1.44e-08	0.0161	0.36	0.26	Corneal astigmatism;	chr4:119650610	chr1:243054861~243056394:-
THCA	trans	rs4646450	0.891	rs1043466	ENSG00000228834.1	RP11-249L21.4	5.77	1.44e-08	0.0161	0.41	0.26	Blood metabolite levels;	chr7:99456666	chr6:108907615~108907873:-
THCA	trans	rs7192380	0.767	rs8061725	ENSG00000257513.6	NPIPB1P	5.77	1.44e-08	0.0161	0.3	0.26	Sjögren's syndrome;	chr16:69547174	chr18:11619509~11639699:-
THCA	trans	rs12439619	0.774	rs2867649	ENSG00000235370.6	DNM1P51	-5.77	1.45e-08	0.0161	-0.41	-0.26	Intelligence (multi-trait analysis);	chr15:82262331	chr15:84398316~84411701:-
THCA	trans	rs3812762	0.871	rs2173999	ENSG00000266891.1	RP11-692N5.2	-5.77	1.45e-08	0.0162	-0.34	-0.26	Hypospadias;	chr11:8756530	chr18:9734882~9735602:-
THCA	trans	rs9467711	0.659	rs13195509	ENSG00000226314.6	ZNF192P1	-5.77	1.46e-08	0.0162	-0.55	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr6:28161781~28169594:+
THCA	trans	rs9329221	0.539	rs35060302	ENSG00000253893.2	FAM85B	-5.77	1.46e-08	0.0162	-0.34	-0.26	Neuroticism;	chr8:10407261	chr8:8167819~8226614:-
THCA	trans	rs7312770	0.612	rs773114	ENSG00000242206.2	RPS26P35	5.77	1.46e-08	0.0162	0.29	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:118761856~118762201:-
THCA	trans	rs8014204	0.836	rs12888998	ENSG00000181227.3	RP4-682C21.2	-5.77	1.46e-08	0.0163	-0.2	-0.26	Caffeine consumption;	chr14:74825959	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.806	rs11159104	ENSG00000181227.3	RP4-682C21.2	-5.77	1.46e-08	0.0163	-0.2	-0.26	Caffeine consumption;	chr14:74826671	chr1:75743423~75744776:-
THCA	trans	rs7829975	0.714	rs11777085	ENSG00000229857.1	RP11-159H20.3	-5.77	1.46e-08	0.0163	-0.31	-0.26	Mood instability;	chr8:8814919	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.644	rs2389880	ENSG00000253326.2	RP11-261C10.7	5.77	1.46e-08	0.0163	0.35	0.26	Corneal astigmatism;	chr4:119638715	chr1:243054861~243056394:-
THCA	trans	rs7212590	0.581	rs57812342	ENSG00000187870.7	RNFT1P3	5.77	1.46e-08	0.0163	0.52	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59749793	chr17:20743333~20754501:-
THCA	trans	rs7824557	0.872	rs2572417	ENSG00000229857.1	RP11-159H20.3	5.77	1.47e-08	0.0164	0.31	0.26	Retinal vascular caliber;	chr8:11253953	chr9:76992099~76993108:+
THCA	trans	rs2985684	0.841	rs12894785	ENSG00000240785.1	RPL36AP21	5.77	1.47e-08	0.0164	0.32	0.26	Carotid intima media thickness;	chr14:49583037	chr5:18049550~18049872:+
THCA	trans	rs453301	0.658	rs3855900	ENSG00000256560.1	LINC01486	-5.77	1.47e-08	0.0164	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9044411	chr12:109354083~109359488:-
THCA	trans	rs9572786	0.651	rs9318033	ENSG00000228956.7	SATB1-AS1	-5.77	1.48e-08	0.0164	-0.28	-0.26	Plateletcrit;	chr13:71816374	chr3:18445024~18920401:+
THCA	trans	rs12477438	0.52	rs13030961	ENSG00000276576.1	MRPL30P1	5.77	1.48e-08	0.0164	0.33	0.26	Chronic sinus infection;	chr2:99183057	chr6:57029521~57029988:+
THCA	trans	rs902774	0.818	rs79377635	ENSG00000250539.1	KRT8P33	-5.76	1.48e-08	0.0165	-0.48	-0.26	Prostate cancer;	chr12:52883148	chr5:123400922~123402344:-
THCA	trans	rs453301	0.606	rs6601279	ENSG00000256560.1	LINC01486	-5.76	1.49e-08	0.0166	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9050721	chr12:109354083~109359488:-
THCA	trans	rs453301	0.606	rs6981060	ENSG00000256560.1	LINC01486	-5.76	1.49e-08	0.0166	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9050725	chr12:109354083~109359488:-
THCA	trans	rs9584850	0.834	rs12463	ENSG00000230079.1	STK24P1	5.76	1.49e-08	0.0166	0.31	0.26	Neuroticism;	chr13:98453048	chrX:136295690~136300298:-
THCA	trans	rs9584850	0.834	rs8481	ENSG00000230079.1	STK24P1	5.76	1.49e-08	0.0166	0.31	0.26	Neuroticism;	chr13:98453141	chrX:136295690~136300298:-
THCA	trans	rs7694207	0.706	rs10018175	ENSG00000215481.7	BCRP3	5.76	1.49e-08	0.0166	0.28	0.26	Response to mTOR inhibitor (everolimus);	chr4:96962196	chr22:24632915~24653356:+
THCA	trans	rs4295623	0.553	rs11250163	ENSG00000256560.1	LINC01486	5.76	1.5e-08	0.0166	0.32	0.26	Morning vs. evening chronotype;	chr8:11738928	chr12:109354083~109359488:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000242206.2	RPS26P35	5.76	1.5e-08	0.0167	0.29	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:118761856~118762201:-
THCA	trans	rs9987353	0.84	rs41436744	ENSG00000253893.2	FAM85B	5.76	1.51e-08	0.0167	0.36	0.26	Recombination measurement;	chr8:9265814	chr8:8167819~8226614:-
THCA	trans	rs34421088	0.624	rs6986736	ENSG00000253893.2	FAM85B	5.76	1.51e-08	0.0168	0.34	0.26	Neuroticism;	chr8:11726994	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs4919737	ENSG00000223940.1	KRT8P8	-5.76	1.51e-08	0.0168	-0.54	-0.26	Prostate cancer;	chr12:52877011	chrX:152479577~152481024:+
THCA	trans	rs902774	0.818	rs73108429	ENSG00000223940.1	KRT8P8	-5.76	1.51e-08	0.0168	-0.54	-0.26	Prostate cancer;	chr12:52877887	chrX:152479577~152481024:+
THCA	trans	rs4646450	0.891	rs13240600	ENSG00000228834.1	RP11-249L21.4	5.76	1.51e-08	0.0168	0.4	0.26	Blood metabolite levels;	chr7:99466843	chr6:108907615~108907873:-
THCA	trans	rs4646450	0.891	rs10244158	ENSG00000228834.1	RP11-249L21.4	5.76	1.51e-08	0.0168	0.4	0.26	Blood metabolite levels;	chr7:99482621	chr6:108907615~108907873:-
THCA	trans	rs4879677	1	rs10757673	ENSG00000269560.1	CTD-2192J16.21	-5.76	1.51e-08	0.0168	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27670815	chr19:12529768~12532973:-
THCA	trans	rs73108077	1	rs73110016	ENSG00000279352.1	RP11-411B10.7	5.76	1.52e-08	0.0168	0.57	0.26	Red blood cell density in sickle cell anemia;	chr20:31432402	chr18:14010054~14010917:+
THCA	trans	rs7617773	0.962	rs6797587	ENSG00000235912.1	RP1-159A19.3	5.76	1.52e-08	0.0169	0.31	0.26	Coronary artery disease;	chr3:48156124	chr1:27649419~27649610:+
THCA	trans	rs11739656	0.764	rs6873941	ENSG00000245532.5	NEAT1	-5.76	1.52e-08	0.0169	-0.28	-0.26	Night sleep phenotypes;	chr5:174772208	chr11:65422774~65445540:+
THCA	trans	rs9914988	0.887	rs4795456	ENSG00000267449.1	RP11-264B14.2	5.76	1.52e-08	0.0169	0.4	0.26	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28745445	chr17:61069856~61070356:-
THCA	trans	rs2243480	0.901	rs3813708	ENSG00000232546.1	RP11-458F8.1	-5.76	1.52e-08	0.0169	-0.34	-0.26	Diabetic kidney disease;	chr7:65840645	chr7:66848496~66858136:+
THCA	trans	rs11958034	1	rs11954375	ENSG00000271874.1	CTD-2024P10.2	-5.76	1.52e-08	0.0169	-0.4	-0.26	Mitochondrial DNA levels;	chr5:18912217	chr5:34651457~34651888:-
THCA	trans	rs7647973	0.626	rs11130217	ENSG00000197582.5	GPX1P1	5.76	1.52e-08	0.0169	0.46	0.26	Menarche (age at onset);	chr3:49699890	chrX:13378735~13379340:-
THCA	trans	rs3808502	0.509	rs2729940	ENSG00000254153.1	CTA-398F10.2	-5.76	1.52e-08	0.0169	-0.28	-0.26	Neuroticism;	chr8:11524858	chr8:8456909~8461337:-
THCA	trans	rs7809615	0.551	rs3901286	ENSG00000228834.1	RP11-249L21.4	5.76	1.53e-08	0.0169	0.41	0.26	Blood metabolite ratios;	chr7:99510104	chr6:108907615~108907873:-
THCA	trans	rs11098499	0.691	rs28396837	ENSG00000253326.2	RP11-261C10.7	5.76	1.53e-08	0.0169	0.34	0.26	Corneal astigmatism;	chr4:119350386	chr1:243054861~243056394:-
THCA	trans	rs8014204	0.87	rs3742790	ENSG00000181227.3	RP4-682C21.2	5.76	1.53e-08	0.017	0.2	0.26	Caffeine consumption;	chr14:74842055	chr1:75743423~75744776:-
THCA	trans	rs7829975	0.511	rs1401390	ENSG00000256560.1	LINC01486	5.76	1.53e-08	0.017	0.3	0.26	Mood instability;	chr8:8278888	chr12:109354083~109359488:-
THCA	trans	rs9381040	0.61	rs9394758	ENSG00000232097.1	AC079781.8	5.76	1.53e-08	0.017	0.31	0.26	Alzheimer's disease (late onset);	chr6:41050082	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs9367094	ENSG00000232097.1	AC079781.8	5.76	1.53e-08	0.017	0.31	0.26	Alzheimer's disease (late onset);	chr6:41050121	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs742495	ENSG00000232097.1	AC079781.8	5.76	1.53e-08	0.017	0.31	0.26	Alzheimer's disease (late onset);	chr6:41050494	chr7:97938439~97938794:-
THCA	trans	rs7995618	0.616	rs78603082	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89282004	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs77269664	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89285590	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs78808880	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89286025	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.616	rs75321300	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89286522	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs78304741	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89286700	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs74356458	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89296697	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs77576439	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89298837	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs75925780	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89299009	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs75399994	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89299692	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs76579177	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89302423	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs78421246	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89304091	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs74871833	ENSG00000225931.3	RP3-395M20.7	5.76	1.53e-08	0.017	0.44	0.26	Plasma clusterin levels;	chr13:89307203	chr1:2566410~2569888:+
THCA	trans	rs8014204	0.748	rs12889277	ENSG00000181227.3	RP4-682C21.2	-5.76	1.53e-08	0.017	-0.21	-0.26	Caffeine consumption;	chr14:74762673	chr1:75743423~75744776:-
THCA	trans	rs7945705	0.875	rs10769947	ENSG00000266891.1	RP11-692N5.2	-5.76	1.53e-08	0.017	-0.33	-0.26	Hemoglobin concentration;	chr11:8736567	chr18:9734882~9735602:-
THCA	trans	rs7709909	0.653	rs40139	ENSG00000188985.6	DHFRP1	5.76	1.53e-08	0.017	0.31	0.26	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80738016	chr18:26170726~26171284:-
THCA	trans	rs10918270	0.702	rs10917892	ENSG00000279800.1	ABBA01017803.1	-5.76	1.54e-08	0.017	-0.32	-0.26	Parkinson's disease (age of onset);	chr1:161774352	chr16:34266044~34268649:-
THCA	trans	rs4879677	0.959	rs10968039	ENSG00000269560.1	CTD-2192J16.21	-5.76	1.54e-08	0.0171	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27670118	chr19:12529768~12532973:-
THCA	trans	rs4879677	1	rs10968041	ENSG00000269560.1	CTD-2192J16.21	-5.76	1.54e-08	0.0171	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27670205	chr19:12529768~12532973:-
THCA	trans	rs2980439	0.729	rs2955585	ENSG00000229857.1	RP11-159H20.3	-5.76	1.54e-08	0.0171	-0.3	-0.26	Neuroticism;	chr8:8235989	chr9:76992099~76993108:+
THCA	trans	rs2898290	0.617	rs13273172	ENSG00000256560.1	LINC01486	-5.76	1.54e-08	0.0171	-0.32	-0.26	Systolic blood pressure;	chr8:11603602	chr12:109354083~109359488:-
THCA	trans	rs6601327	0.543	rs11249948	ENSG00000253893.2	FAM85B	-5.76	1.54e-08	0.0171	-0.33	-0.26	Multiple myeloma (hyperdiploidy);	chr8:9791176	chr8:8167819~8226614:-
THCA	trans	rs2950393	0.895	rs2958123	ENSG00000257210.1	NACAP3	5.76	1.55e-08	0.0172	0.31	0.26	Platelet distribution width;	chr12:56668441	chr12:93124063~93124543:-
THCA	trans	rs7189233	0.955	rs72801821	ENSG00000277863.1	RP11-282A11.4	5.76	1.55e-08	0.0172	0.35	0.26	Intelligence (multi-trait analysis);	chr16:53445740	chr13:106903150~106904099:-
THCA	trans	rs3947	0.544	rs8191604	ENSG00000253893.2	FAM85B	5.76	1.55e-08	0.0172	0.42	0.26	Blood protein levels;	chr8:11779375	chr8:8167819~8226614:-
THCA	trans	rs2950393	0.857	rs9989034	ENSG00000257210.1	NACAP3	5.76	1.55e-08	0.0172	0.31	0.26	Platelet distribution width;	chr12:56674508	chr12:93124063~93124543:-
THCA	trans	rs7829975	0.511	rs2921028	ENSG00000229857.1	RP11-159H20.3	-5.76	1.56e-08	0.0173	-0.33	-0.26	Mood instability;	chr8:8482967	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.701	rs4568582	ENSG00000229857.1	RP11-159H20.3	-5.76	1.56e-08	0.0173	-0.33	-0.26	Retinal vascular caliber;	chr8:11302986	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.593	rs11778398	ENSG00000254153.1	CTA-398F10.2	5.75	1.57e-08	0.0174	0.3	0.26	Triglycerides;	chr8:11116733	chr8:8456909~8461337:-
THCA	trans	rs2971100	1	rs2971097	ENSG00000268278.1	RP11-420K14.1	5.75	1.57e-08	0.0174	0.47	0.26	Colonoscopy-negative controls vs population controls;	chr7:9885799	chr19:21637974~21656300:+
THCA	trans	rs1190596	0.525	rs10133613	ENSG00000181359.5	HSP90AA6P	-5.75	1.57e-08	0.0174	-0.37	-0.26	Behavioural disinhibition (generation interaction);	chr14:102269846	chr4:170581470~170605450:-
THCA	trans	rs7429990	0.864	rs6777081	ENSG00000235912.1	RP1-159A19.3	5.75	1.57e-08	0.0174	0.32	0.26	Educational attainment (years of education);	chr3:48114079	chr1:27649419~27649610:+
THCA	trans	rs11098499	0.691	rs17009144	ENSG00000253326.2	RP11-261C10.7	-5.75	1.57e-08	0.0174	-0.34	-0.26	Corneal astigmatism;	chr4:119349640	chr1:243054861~243056394:-
THCA	trans	rs6087990	0.806	rs910084	ENSG00000253915.1	MAPRE1P1	5.75	1.57e-08	0.0174	0.32	0.26	Ulcerative colitis;	chr20:32791859	chr8:135625185~135625981:-
THCA	trans	rs9990333	0.622	rs57783901	ENSG00000236833.1	AC024560.2	5.75	1.58e-08	0.0175	0.32	0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:197660565~197665757:-
THCA	trans	rs7824557	0.527	rs2409756	ENSG00000256560.1	LINC01486	-5.75	1.58e-08	0.0175	-0.32	-0.26	Retinal vascular caliber;	chr8:11384516	chr12:109354083~109359488:-
THCA	trans	rs4879677	0.92	rs3861018	ENSG00000269560.1	CTD-2192J16.21	-5.75	1.58e-08	0.0175	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27654018	chr19:12529768~12532973:-
THCA	trans	rs2278331	1	rs2278331	ENSG00000273232.1	RP11-370A5.2	5.75	1.58e-08	0.0175	0.33	0.26	Sleep duration;	chr18:73914271	chr18:22882825~22883357:-
THCA	trans	rs1478897	0.898	rs2248696	ENSG00000253893.2	FAM85B	5.75	1.58e-08	0.0175	0.34	0.26	Systemic lupus erythematosus;	chr8:11536294	chr8:8167819~8226614:-
THCA	trans	rs7945705	0.875	rs10769955	ENSG00000266891.1	RP11-692N5.2	-5.75	1.58e-08	0.0175	-0.33	-0.26	Hemoglobin concentration;	chr11:8763100	chr18:9734882~9735602:-
THCA	trans	rs9467711	0.79	rs35400317	ENSG00000228022.4	HCG20	-5.75	1.58e-08	0.0175	-0.66	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr6:30766825~30792250:+
THCA	trans	rs9467711	0.79	rs67777156	ENSG00000228022.4	HCG20	-5.75	1.58e-08	0.0175	-0.66	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr6:30766825~30792250:+
THCA	trans	rs9467711	0.722	rs13201782	ENSG00000228022.4	HCG20	-5.75	1.58e-08	0.0175	-0.66	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr6:30766825~30792250:+
THCA	trans	rs453301	0.686	rs11785634	ENSG00000256560.1	LINC01486	-5.75	1.58e-08	0.0175	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9035087	chr12:109354083~109359488:-
THCA	trans	rs656319	0.674	rs1484639	ENSG00000253893.2	FAM85B	-5.75	1.59e-08	0.0176	-0.33	-0.26	Myopia (pathological);	chr8:10125714	chr8:8167819~8226614:-
THCA	trans	rs10435719	0.647	rs10092605	ENSG00000254153.1	CTA-398F10.2	-5.75	1.59e-08	0.0176	-0.29	-0.26	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:8456909~8461337:-
THCA	trans	rs75920871	0.589	rs73008568	ENSG00000279518.1	AC083843.4	-5.75	1.59e-08	0.0176	-0.26	-0.26	Subjective well-being;	chr11:117194291	chr8:134783694~134785879:-
THCA	trans	rs2689154	1	rs2689154	ENSG00000251211.1	RP11-889L3.4	-5.75	1.59e-08	0.0177	-0.29	-0.26	Pancreatic cancer;	chr1:238745053	chr5:178165702~178166562:+
THCA	trans	rs12477438	0.52	rs10865029	ENSG00000276576.1	MRPL30P1	5.75	1.6e-08	0.0177	0.33	0.26	Chronic sinus infection;	chr2:99101835	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6712704	ENSG00000276576.1	MRPL30P1	5.75	1.6e-08	0.0177	0.33	0.26	Chronic sinus infection;	chr2:99103224	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6542863	ENSG00000276576.1	MRPL30P1	5.75	1.6e-08	0.0177	0.33	0.26	Chronic sinus infection;	chr2:99108675	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs11123762	ENSG00000276576.1	MRPL30P1	5.75	1.6e-08	0.0177	0.33	0.26	Chronic sinus infection;	chr2:99111326	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs11692699	ENSG00000276576.1	MRPL30P1	5.75	1.6e-08	0.0177	0.33	0.26	Chronic sinus infection;	chr2:99114194	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs13022329	ENSG00000276576.1	MRPL30P1	5.75	1.6e-08	0.0177	0.33	0.26	Chronic sinus infection;	chr2:99114726	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6743355	ENSG00000276576.1	MRPL30P1	5.75	1.6e-08	0.0177	0.33	0.26	Chronic sinus infection;	chr2:99115897	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs13004491	ENSG00000276576.1	MRPL30P1	5.75	1.6e-08	0.0177	0.33	0.26	Chronic sinus infection;	chr2:99121545	chr6:57029521~57029988:+
THCA	trans	rs616147	0.85	rs631312	ENSG00000243904.1	RP11-600F24.1	-5.75	1.6e-08	0.0177	-0.33	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr14:103374033~103374916:-
THCA	trans	rs902774	0.759	rs4919707	ENSG00000223940.1	KRT8P8	-5.75	1.6e-08	0.0177	-0.54	-0.26	Prostate cancer;	chr12:52895864	chrX:152479577~152481024:+
THCA	trans	rs902774	0.818	rs56095813	ENSG00000223940.1	KRT8P8	-5.75	1.6e-08	0.0177	-0.54	-0.26	Prostate cancer;	chr12:52900963	chrX:152479577~152481024:+
THCA	trans	rs2349775	0.961	rs970526	ENSG00000253177.1	RP11-100L22.1	5.75	1.6e-08	0.0177	0.24	0.26	Neuroticism;	chr7:8656177	chr8:92668836~92679594:+
THCA	trans	rs7647973	0.626	rs2131108	ENSG00000197582.5	GPX1P1	5.75	1.6e-08	0.0178	0.45	0.26	Menarche (age at onset);	chr3:49627957	chrX:13378735~13379340:-
THCA	trans	rs9393777	0.92	rs55834529	ENSG00000204338.7	CYP21A1P	-5.75	1.61e-08	0.0178	-0.61	-0.26	Intelligence (multi-trait analysis);	chr6:27104763	chr6:32005636~32008451:+
THCA	trans	rs2439831	0.681	rs540031	ENSG00000180867.10	PDIA3P1	-5.75	1.61e-08	0.0178	-0.28	-0.26	Lung cancer in ever smokers;	chr15:43316657	chr1:147178113~147179622:+
THCA	trans	rs75920871	0.562	rs68137714	ENSG00000279518.1	AC083843.4	-5.75	1.61e-08	0.0178	-0.24	-0.26	Subjective well-being;	chr11:117154641	chr8:134783694~134785879:-
THCA	trans	rs7113874	0.569	rs4418812	ENSG00000266891.1	RP11-692N5.2	-5.75	1.61e-08	0.0178	-0.33	-0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8590453	chr18:9734882~9735602:-
THCA	trans	rs546131	0.928	rs516228	ENSG00000225531.1	RP11-196I18.3	5.75	1.61e-08	0.0178	0.34	0.26	Lung disease severity in cystic fibrosis;	chr11:34817276	chr9:107116829~107117557:+
THCA	trans	rs7824557	0.564	rs11782430	ENSG00000254153.1	CTA-398F10.2	5.75	1.61e-08	0.0178	0.29	0.26	Retinal vascular caliber;	chr8:11368562	chr8:8456909~8461337:-
THCA	trans	rs9650657	0.623	rs6601517	ENSG00000253893.2	FAM85B	5.75	1.61e-08	0.0178	0.32	0.26	Neuroticism;	chr8:10746283	chr8:8167819~8226614:-
THCA	trans	rs902774	0.818	rs56207534	ENSG00000223940.1	KRT8P8	-5.75	1.62e-08	0.018	-0.53	-0.26	Prostate cancer;	chr12:52873525	chrX:152479577~152481024:+
THCA	trans	rs9467711	0.79	rs34107459	ENSG00000228022.4	HCG20	-5.75	1.63e-08	0.018	-0.71	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26328125	chr6:30766825~30792250:+
THCA	trans	rs4646450	0.891	rs7794682	ENSG00000228834.1	RP11-249L21.4	5.75	1.63e-08	0.018	0.4	0.26	Blood metabolite levels;	chr7:99431654	chr6:108907615~108907873:-
THCA	trans	rs7819412	0.56	rs13265553	ENSG00000229857.1	RP11-159H20.3	5.75	1.63e-08	0.018	0.34	0.26	Triglycerides;	chr8:11131547	chr9:76992099~76993108:+
THCA	trans	rs875971	0.545	rs17138156	ENSG00000213640.3	EEF1DP4	-5.75	1.63e-08	0.018	-0.34	-0.26	Aortic root size;	chr7:66249708	chr7:64862999~64864370:+
THCA	trans	rs6885307	0.882	rs72759917	ENSG00000231752.4	EMBP1	5.75	1.63e-08	0.018	0.42	0.26	Age at first birth;	chr5:44990957	chr1:121519112~121571892:+
THCA	trans	rs7113874	0.569	rs11041983	ENSG00000266891.1	RP11-692N5.2	5.75	1.63e-08	0.018	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8559072	chr18:9734882~9735602:-
THCA	trans	rs7769051	1	rs73554431	ENSG00000213303.3	CTC-398G3.2	5.75	1.63e-08	0.018	0.46	0.26	Type 2 diabetes nephropathy;	chr6:132808783	chr19:11523436~11523831:+
THCA	trans	rs902774	0.818	rs55958994	ENSG00000223940.1	KRT8P8	-5.75	1.63e-08	0.0181	-0.53	-0.26	Prostate cancer;	chr12:52907235	chrX:152479577~152481024:+
THCA	trans	rs889398	0.771	rs1500337	ENSG00000257513.6	NPIPB1P	-5.75	1.64e-08	0.0181	-0.29	-0.26	Body mass index;	chr16:69867981	chr18:11619509~11639699:-
THCA	trans	rs7312770	0.612	rs1873914	ENSG00000234192.1	RP11-57C13.5	5.75	1.64e-08	0.0181	0.3	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:87642607~87642954:+
THCA	trans	rs9467711	0.659	rs13195509	ENSG00000253570.1	RNF5P1	5.75	1.64e-08	0.0181	0.7	0.26	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr8:38600661~38601200:-
THCA	trans	rs10028773	0.666	rs12498657	ENSG00000253326.2	RP11-261C10.7	5.75	1.64e-08	0.0182	0.34	0.26	Educational attainment;	chr4:119341711	chr1:243054861~243056394:-
THCA	trans	rs9584850	0.794	rs9630321	ENSG00000230079.1	STK24P1	5.75	1.64e-08	0.0182	0.31	0.26	Neuroticism;	chr13:98454725	chrX:136295690~136300298:-
THCA	trans	rs77688320	1	rs80273648	ENSG00000235105.1	RP11-329A14.1	-5.75	1.65e-08	0.0182	-0.41	-0.26	Breast cancer;	chr2:201446432	chr1:48435967~48437223:+
THCA	trans	rs902774	0.818	rs4919742	ENSG00000223940.1	KRT8P8	-5.75	1.65e-08	0.0182	-0.54	-0.26	Prostate cancer;	chr12:52879180	chrX:152479577~152481024:+
THCA	trans	rs9393777	0.841	rs67092078	ENSG00000219392.1	RP1-265C24.5	-5.75	1.65e-08	0.0182	-0.58	-0.26	Intelligence (multi-trait analysis);	chr6:27086993	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.79	rs13195401	ENSG00000228022.4	HCG20	-5.74	1.65e-08	0.0183	-0.66	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr6:30766825~30792250:+
THCA	trans	rs9467711	0.79	rs13195402	ENSG00000228022.4	HCG20	-5.74	1.65e-08	0.0183	-0.66	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr6:30766825~30792250:+
THCA	trans	rs34546498	1	rs34546498	ENSG00000226314.6	ZNF192P1	-5.74	1.66e-08	0.0183	-0.58	-0.26	Breast cancer;	chr6:26993501	chr6:28161781~28169594:+
THCA	trans	rs7995618	0.669	rs79703267	ENSG00000225931.3	RP3-395M20.7	5.74	1.66e-08	0.0183	0.44	0.26	Plasma clusterin levels;	chr13:89300383	chr1:2566410~2569888:+
THCA	trans	rs9650657	0.648	rs7833945	ENSG00000229857.1	RP11-159H20.3	5.74	1.66e-08	0.0183	0.32	0.26	Neuroticism;	chr8:10842756	chr9:76992099~76993108:+
THCA	trans	rs7826238	0.539	rs2945891	ENSG00000256560.1	LINC01486	5.74	1.66e-08	0.0183	0.3	0.26	Systolic blood pressure;	chr8:8297953	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.623	rs10087493	ENSG00000229857.1	RP11-159H20.3	5.74	1.66e-08	0.0184	0.32	0.26	Mood instability;	chr8:8516047	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.591	rs35657308	ENSG00000229857.1	RP11-159H20.3	5.74	1.67e-08	0.0184	0.33	0.26	Monocyte count;	chr8:11946893	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.603	rs7016671	ENSG00000253893.2	FAM85B	-5.74	1.67e-08	0.0184	-0.34	-0.26	Retinal vascular caliber;	chr8:11324946	chr8:8167819~8226614:-
THCA	trans	rs847577	0.677	rs4729403	ENSG00000225169.1	BRI3P1	-5.74	1.67e-08	0.0184	-0.34	-0.26	Breast cancer;	chr7:98078529	chr1:100213293~100213670:+
THCA	trans	rs9292918	0.616	rs78835966	ENSG00000231752.4	EMBP1	5.74	1.67e-08	0.0185	0.5	0.26	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45139787	chr1:121519112~121571892:+
THCA	trans	rs12477438	0.52	rs6717729	ENSG00000276576.1	MRPL30P1	5.74	1.68e-08	0.0185	0.33	0.26	Chronic sinus infection;	chr2:99140478	chr6:57029521~57029988:+
THCA	trans	rs7709909	0.72	rs6864512	ENSG00000188985.6	DHFRP1	5.74	1.68e-08	0.0186	0.3	0.26	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80690128	chr18:26170726~26171284:-
THCA	trans	rs7709909	0.72	rs6868774	ENSG00000188985.6	DHFRP1	5.74	1.68e-08	0.0186	0.3	0.26	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80690144	chr18:26170726~26171284:-
THCA	trans	rs7617773	0.925	rs6442105	ENSG00000235912.1	RP1-159A19.3	5.74	1.68e-08	0.0186	0.31	0.26	Coronary artery disease;	chr3:48140836	chr1:27649419~27649610:+
THCA	trans	rs453301	0.631	rs7843369	ENSG00000229857.1	RP11-159H20.3	5.74	1.68e-08	0.0186	0.34	0.26	Joint mobility (Beighton score);	chr8:8940276	chr9:76992099~76993108:+
THCA	trans	rs45509595	0.556	rs34409918	ENSG00000253570.1	RNF5P1	5.74	1.69e-08	0.0186	0.72	0.26	Breast cancer;	chr6:27717569	chr8:38600661~38601200:-
THCA	trans	rs6831352	0.734	rs2602856	ENSG00000228407.2	RP4-800M22.1	-5.74	1.69e-08	0.0186	-0.34	-0.26	Alcohol dependence;	chr4:99107994	chr1:52160261~52160600:-
THCA	trans	rs7819412	0.522	rs13276708	ENSG00000229857.1	RP11-159H20.3	5.74	1.7e-08	0.0188	0.34	0.26	Triglycerides;	chr8:11131696	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.522	rs13266785	ENSG00000229857.1	RP11-159H20.3	5.74	1.7e-08	0.0188	0.34	0.26	Triglycerides;	chr8:11132011	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.522	rs4291231	ENSG00000229857.1	RP11-159H20.3	5.74	1.7e-08	0.0188	0.34	0.26	Triglycerides;	chr8:11132654	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.522	rs10101329	ENSG00000229857.1	RP11-159H20.3	5.74	1.7e-08	0.0188	0.34	0.26	Triglycerides;	chr8:11133162	chr9:76992099~76993108:+
THCA	trans	rs7709909	0.755	rs2035256	ENSG00000188985.6	DHFRP1	5.74	1.7e-08	0.0188	0.3	0.26	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80700813	chr18:26170726~26171284:-
THCA	trans	rs616147	0.616	rs1768234	ENSG00000239269.1	RPSAP4	-5.74	1.71e-08	0.0188	-0.28	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr14:94726288~94727175:+
THCA	trans	rs7824557	0.628	rs7841394	ENSG00000253893.2	FAM85B	-5.74	1.71e-08	0.0188	-0.33	-0.26	Retinal vascular caliber;	chr8:11328162	chr8:8167819~8226614:-
THCA	trans	rs12682352	0.652	rs3789843	ENSG00000229857.1	RP11-159H20.3	-5.74	1.71e-08	0.0189	-0.33	-0.26	Neuroticism;	chr8:8866747	chr9:76992099~76993108:+
THCA	trans	rs12682352	0.652	rs3827806	ENSG00000229857.1	RP11-159H20.3	-5.74	1.71e-08	0.0189	-0.33	-0.26	Neuroticism;	chr8:8866766	chr9:76992099~76993108:+
THCA	trans	rs7769051	1	rs6910639	ENSG00000213303.3	CTC-398G3.2	5.74	1.71e-08	0.0189	0.47	0.26	Type 2 diabetes nephropathy;	chr6:132799414	chr19:11523436~11523831:+
THCA	trans	rs4879677	1	rs12235880	ENSG00000269560.1	CTD-2192J16.21	-5.74	1.71e-08	0.0189	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27674779	chr19:12529768~12532973:-
THCA	trans	rs4879677	1	rs12237023	ENSG00000269560.1	CTD-2192J16.21	-5.74	1.71e-08	0.0189	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27674972	chr19:12529768~12532973:-
THCA	trans	rs4879677	0.959	rs10968049	ENSG00000269560.1	CTD-2192J16.21	-5.74	1.71e-08	0.0189	-0.33	-0.26	Gut microbiome composition (summer and winter);	chr9:27676933	chr19:12529768~12532973:-
THCA	trans	rs6885307	1	rs62369865	ENSG00000231752.4	EMBP1	5.74	1.72e-08	0.0189	0.42	0.26	Age at first birth;	chr5:44993657	chr1:121519112~121571892:+
THCA	trans	rs902774	0.818	rs17120257	ENSG00000223940.1	KRT8P8	-5.74	1.72e-08	0.0189	-0.53	-0.26	Prostate cancer;	chr12:52909547	chrX:152479577~152481024:+
THCA	trans	rs3096299	0.632	rs8051537	ENSG00000215030.5	RPL13P12	-5.74	1.72e-08	0.0189	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89477976	chr17:17383377~17384012:-
THCA	trans	rs7819412	0.634	rs6987767	ENSG00000254153.1	CTA-398F10.2	-5.74	1.72e-08	0.0189	-0.28	-0.26	Triglycerides;	chr8:11052556	chr8:8456909~8461337:-
THCA	trans	rs7617773	1	rs9832957	ENSG00000235912.1	RP1-159A19.3	5.74	1.72e-08	0.019	0.31	0.26	Coronary artery disease;	chr3:48143776	chr1:27649419~27649610:+
THCA	trans	rs2980439	0.818	rs2948294	ENSG00000229857.1	RP11-159H20.3	-5.74	1.72e-08	0.019	-0.3	-0.26	Neuroticism;	chr8:8237439	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.544	rs1865521	ENSG00000256560.1	LINC01486	5.74	1.72e-08	0.019	0.32	0.26	Retinal vascular caliber;	chr8:11373740	chr12:109354083~109359488:-
THCA	trans	rs7769051	1	rs10484629	ENSG00000213303.3	CTC-398G3.2	5.74	1.72e-08	0.019	0.48	0.26	Type 2 diabetes nephropathy;	chr6:132796731	chr19:11523436~11523831:+
THCA	trans	rs7709909	0.755	rs6883090	ENSG00000188985.6	DHFRP1	5.74	1.72e-08	0.019	0.3	0.26	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80680569	chr18:26170726~26171284:-
THCA	trans	rs9650657	0.801	rs7018334	ENSG00000229857.1	RP11-159H20.3	5.74	1.72e-08	0.019	0.32	0.26	Neuroticism;	chr8:10754565	chr9:76992099~76993108:+
THCA	trans	rs8014204	0.836	rs7153700	ENSG00000181227.3	RP4-682C21.2	-5.74	1.73e-08	0.019	-0.2	-0.26	Caffeine consumption;	chr14:74801841	chr1:75743423~75744776:-
THCA	trans	rs7520050	0.807	rs4353138	ENSG00000255397.1	AC022182.2	5.74	1.73e-08	0.019	0.34	0.26	Reticulocyte count;Red blood cell count;	chr1:45754131	chr8:60937705~60939871:-
THCA	trans	rs7819412	0.806	rs6980856	ENSG00000254153.1	CTA-398F10.2	-5.74	1.73e-08	0.019	-0.29	-0.26	Triglycerides;	chr8:11080750	chr8:8456909~8461337:-
THCA	trans	rs740160	0.51	rs10267346	ENSG00000228834.1	RP11-249L21.4	5.74	1.73e-08	0.0191	0.44	0.26	Dehydroepiandrosterone sulphate levels;	chr7:99301144	chr6:108907615~108907873:-
THCA	trans	rs7945705	0.791	rs4579928	ENSG00000266891.1	RP11-692N5.2	-5.74	1.73e-08	0.0191	-0.32	-0.26	Hemoglobin concentration;	chr11:8794157	chr18:9734882~9735602:-
THCA	trans	rs616147	0.72	rs2965067	ENSG00000239269.1	RPSAP4	-5.74	1.73e-08	0.0191	-0.28	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr14:94726288~94727175:+
THCA	trans	rs8014204	0.836	rs8021280	ENSG00000181227.3	RP4-682C21.2	-5.74	1.74e-08	0.0191	-0.2	-0.26	Caffeine consumption;	chr14:74823315	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.806	rs11159105	ENSG00000181227.3	RP4-682C21.2	-5.74	1.74e-08	0.0191	-0.2	-0.26	Caffeine consumption;	chr14:74831349	chr1:75743423~75744776:-
THCA	trans	rs8014204	0.836	rs7150254	ENSG00000181227.3	RP4-682C21.2	-5.74	1.74e-08	0.0191	-0.2	-0.26	Caffeine consumption;	chr14:74832398	chr1:75743423~75744776:-
THCA	trans	rs5758511	0.541	rs6002494	ENSG00000268568.1	AC007228.9	-5.74	1.74e-08	0.0191	-0.3	-0.26	Birth weight;	chr22:41803856	chr19:56672574~56673901:-
THCA	trans	rs5758511	0.513	rs7292782	ENSG00000268568.1	AC007228.9	-5.74	1.74e-08	0.0191	-0.3	-0.26	Birth weight;	chr22:41804320	chr19:56672574~56673901:-
THCA	trans	rs7212590	0.581	rs8069418	ENSG00000187870.7	RNFT1P3	5.74	1.74e-08	0.0192	0.52	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59740852	chr17:20743333~20754501:-
THCA	trans	rs6928977	0.932	rs11154799	ENSG00000275632.1	RP5-967N21.11	5.74	1.74e-08	0.0192	0.22	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311511	chr20:6000418~6000941:+
THCA	trans	rs4879677	1	rs10125353	ENSG00000269560.1	CTD-2192J16.21	5.74	1.75e-08	0.0192	0.32	0.26	Gut microbiome composition (summer and winter);	chr9:27677546	chr19:12529768~12532973:-
THCA	trans	rs7824557	0.767	rs17797443	ENSG00000229857.1	RP11-159H20.3	-5.74	1.75e-08	0.0192	-0.32	-0.26	Retinal vascular caliber;	chr8:11306503	chr9:76992099~76993108:+
THCA	trans	rs12439619	0.846	rs28697264	ENSG00000235370.6	DNM1P51	-5.73	1.75e-08	0.0192	-0.41	-0.26	Intelligence (multi-trait analysis);	chr15:82265559	chr15:84398316~84411701:-
THCA	trans	rs4415084	0.745	rs12188871	ENSG00000231752.4	EMBP1	5.73	1.75e-08	0.0192	0.35	0.26	Breast cancer;	chr5:44813902	chr1:121519112~121571892:+
THCA	trans	rs9858542	0.537	rs9873994	ENSG00000197582.5	GPX1P1	-5.73	1.75e-08	0.0192	-0.48	-0.26	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49322510	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.537	rs56038006	ENSG00000197582.5	GPX1P1	-5.73	1.75e-08	0.0192	-0.48	-0.26	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49324936	chrX:13378735~13379340:-
THCA	trans	rs11250098	0.567	rs4326350	ENSG00000229857.1	RP11-159H20.3	-5.73	1.75e-08	0.0192	-0.3	-0.26	Morning vs. evening chronotype;	chr8:10906145	chr9:76992099~76993108:+
THCA	trans	rs7709909	0.782	rs3958547	ENSG00000188985.6	DHFRP1	5.73	1.75e-08	0.0193	0.3	0.26	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80699751	chr18:26170726~26171284:-
THCA	trans	rs11098499	0.629	rs28369518	ENSG00000253326.2	RP11-261C10.7	5.73	1.75e-08	0.0193	0.34	0.26	Corneal astigmatism;	chr4:119350475	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.722	rs10025925	ENSG00000253326.2	RP11-261C10.7	5.73	1.75e-08	0.0193	0.34	0.26	Corneal astigmatism;	chr4:119350589	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.731	rs10015579	ENSG00000253326.2	RP11-261C10.7	5.73	1.75e-08	0.0193	0.34	0.26	Corneal astigmatism;	chr4:119350647	chr1:243054861~243056394:-
THCA	trans	rs4879656	0.966	rs1016674	ENSG00000215007.3	DNAJA1P3	-5.73	1.75e-08	0.0193	-0.31	-0.26	Menopause (age at onset);	chr9:32982689	chrX:107351650~107352843:-
THCA	trans	rs433755	0.669	rs4702627	ENSG00000189014.7	FAM35DP	-5.73	1.76e-08	0.0193	-0.29	-0.26	Obesity-related traits;	chr5:9487231	chr10:47689707~47730436:+
THCA	trans	rs10090774	0.965	rs13258420	ENSG00000230756.1	RHOQP3	5.73	1.76e-08	0.0194	0.32	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140895513	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs11783743	ENSG00000230756.1	RHOQP3	5.73	1.76e-08	0.0194	0.32	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140897118	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs9324537	ENSG00000230756.1	RHOQP3	5.73	1.76e-08	0.0194	0.32	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140964035	chr2:130212870~130213490:-
THCA	trans	rs902774	0.818	rs73106451	ENSG00000230716.3	KRT8P7	-5.73	1.77e-08	0.0195	-0.52	-0.26	Prostate cancer;	chr12:52872955	chr11:119602875~119604306:-
THCA	trans	rs6981523	0.553	rs2409730	ENSG00000254153.1	CTA-398F10.2	5.73	1.77e-08	0.0195	0.29	0.26	Neuroticism;	chr8:11203129	chr8:8456909~8461337:-
THCA	trans	rs2530545	0.851	rs1458549	ENSG00000211974.3	IGHV2-70	5.73	1.77e-08	0.0195	0.24	0.26	IgG glycosylation;	chr7:34647180	chr14:106723574~106724093:-
THCA	trans	rs10107145	0.509	rs73209954	ENSG00000253893.2	FAM85B	5.73	1.77e-08	0.0195	0.34	0.26	Systolic blood pressure;	chr8:10903157	chr8:8167819~8226614:-
THCA	trans	rs867371	0.614	rs1814739	ENSG00000235370.6	DNM1P51	-5.73	1.78e-08	0.0195	-0.35	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:84398316~84411701:-
THCA	trans	rs7694207	0.706	rs6829728	ENSG00000215481.7	BCRP3	5.73	1.78e-08	0.0195	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96968565	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs6830362	ENSG00000215481.7	BCRP3	5.73	1.78e-08	0.0195	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96968822	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs13150786	ENSG00000215481.7	BCRP3	5.73	1.78e-08	0.0195	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96969373	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs28619933	ENSG00000215481.7	BCRP3	5.73	1.78e-08	0.0195	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96970221	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs6850789	ENSG00000215481.7	BCRP3	5.73	1.78e-08	0.0195	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96971781	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs9307192	ENSG00000215481.7	BCRP3	5.73	1.78e-08	0.0195	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96972315	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs10025136	ENSG00000215481.7	BCRP3	5.73	1.78e-08	0.0195	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96974041	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs13149244	ENSG00000215481.7	BCRP3	5.73	1.78e-08	0.0195	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96974847	chr22:24632915~24653356:+
THCA	trans	rs10090774	0.813	rs11166996	ENSG00000230756.1	RHOQP3	5.73	1.78e-08	0.0196	0.31	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140712561	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13280245	ENSG00000230756.1	RHOQP3	5.73	1.78e-08	0.0196	0.31	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140717211	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13276301	ENSG00000230756.1	RHOQP3	5.73	1.78e-08	0.0196	0.31	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140720628	chr2:130212870~130213490:-
THCA	trans	rs73110464	0.591	rs11829997	ENSG00000224520.2	KRT8P45	-5.73	1.78e-08	0.0196	-0.62	-0.26	Cancer (pleiotropy);	chr12:52921875	chr1:157073257~157074703:+
THCA	trans	rs7769051	0.711	rs9493437	ENSG00000227615.1	RP11-864N7.2	5.73	1.78e-08	0.0196	0.44	0.26	Type 2 diabetes nephropathy;	chr6:132767266	chr11:74745716~74746114:-
THCA	trans	rs7833986	0.64	rs72656010	ENSG00000244245.1	RP11-120B7.1	5.73	1.79e-08	0.0196	0.39	0.26	Height;	chr8:56209656	chr5:108593609~108593967:+
THCA	trans	rs7694207	0.706	rs10021594	ENSG00000215481.7	BCRP3	5.73	1.79e-08	0.0196	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96972452	chr22:24632915~24653356:+
THCA	trans	rs9987353	0.589	rs1053036	ENSG00000229857.1	RP11-159H20.3	5.73	1.79e-08	0.0197	0.32	0.26	Recombination measurement;	chr8:9202567	chr9:76992099~76993108:+
THCA	trans	rs80033912	0.64	rs6785832	ENSG00000235912.1	RP1-159A19.3	-5.73	1.79e-08	0.0197	-0.33	-0.26	Intelligence (multi-trait analysis);	chr3:49186883	chr1:27649419~27649610:+
THCA	trans	rs9650657	0.601	rs10903330	ENSG00000253893.2	FAM85B	-5.73	1.79e-08	0.0197	-0.32	-0.26	Neuroticism;	chr8:10815594	chr8:8167819~8226614:-
THCA	trans	rs12682352	0.652	rs1567398	ENSG00000256560.1	LINC01486	-5.73	1.79e-08	0.0197	-0.32	-0.26	Neuroticism;	chr8:8869294	chr12:109354083~109359488:-
THCA	trans	rs2439831	0.681	rs484846	ENSG00000180867.10	PDIA3P1	-5.73	1.8e-08	0.0198	-0.27	-0.26	Lung cancer in ever smokers;	chr15:43308605	chr1:147178113~147179622:+
THCA	trans	rs2288327	0.778	rs6755456	ENSG00000269800.1	PLEKHA3P1	5.73	1.8e-08	0.0198	0.35	0.26	Atrial fibrillation;	chr2:178697413	chr19:41521043~41521989:-
THCA	trans	rs7113874	0.569	rs10840072	ENSG00000266891.1	RP11-692N5.2	5.73	1.81e-08	0.0198	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8547813	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.569	rs10769914	ENSG00000266891.1	RP11-692N5.2	5.73	1.81e-08	0.0198	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8554655	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.569	rs11041978	ENSG00000266891.1	RP11-692N5.2	5.73	1.81e-08	0.0198	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8556603	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.524	rs9704586	ENSG00000266891.1	RP11-692N5.2	5.73	1.81e-08	0.0198	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8556983	chr18:9734882~9735602:-
THCA	trans	rs440932	0.887	rs398801	ENSG00000229857.1	RP11-159H20.3	5.73	1.81e-08	0.0198	0.31	0.26	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr9:76992099~76993108:+
THCA	trans	rs75920871	0.513	rs76904522	ENSG00000279518.1	AC083843.4	-5.73	1.81e-08	0.0198	-0.24	-0.26	Subjective well-being;	chr11:117144147	chr8:134783694~134785879:-
THCA	trans	rs75920871	0.513	rs113560866	ENSG00000279518.1	AC083843.4	-5.73	1.81e-08	0.0198	-0.24	-0.26	Subjective well-being;	chr11:117144473	chr8:134783694~134785879:-
THCA	trans	rs9467711	0.606	rs13190739	ENSG00000219392.1	RP1-265C24.5	-5.73	1.81e-08	0.0199	-0.54	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.606	rs34781270	ENSG00000219392.1	RP1-265C24.5	-5.73	1.81e-08	0.0199	-0.54	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.606	rs35076545	ENSG00000219392.1	RP1-265C24.5	-5.73	1.81e-08	0.0199	-0.54	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.606	rs13212985	ENSG00000219392.1	RP1-265C24.5	-5.73	1.81e-08	0.0199	-0.54	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr6:28115628~28116551:+
THCA	trans	rs3812762	0.871	rs10734637	ENSG00000266891.1	RP11-692N5.2	-5.73	1.81e-08	0.0199	-0.33	-0.26	Hypospadias;	chr11:8766678	chr18:9734882~9735602:-
THCA	trans	rs11992186	0.505	rs7845203	ENSG00000229857.1	RP11-159H20.3	-5.73	1.81e-08	0.0199	-0.31	-0.26	Neuroticism;	chr8:8287918	chr9:76992099~76993108:+
THCA	trans	rs7113874	0.569	rs11041985	ENSG00000266891.1	RP11-692N5.2	5.73	1.81e-08	0.0199	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8561137	chr18:9734882~9735602:-
THCA	trans	rs9393777	0.92	rs35869525	ENSG00000253570.1	RNF5P1	5.73	1.82e-08	0.0199	0.67	0.26	Intelligence (multi-trait analysis);	chr6:26978908	chr8:38600661~38601200:-
THCA	trans	rs11098499	0.722	rs7673476	ENSG00000253326.2	RP11-261C10.7	5.73	1.82e-08	0.02	0.34	0.26	Corneal astigmatism;	chr4:119327528	chr1:243054861~243056394:-
THCA	trans	rs7312770	0.637	rs705700	ENSG00000242206.2	RPS26P35	5.73	1.83e-08	0.02	0.29	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:118761856~118762201:-
THCA	trans	rs860295	0.529	rs10908486	ENSG00000241627.3	UBQLN4P1	5.73	1.83e-08	0.02	0.28	0.26	Body mass index;	chr1:156008753	chr3:148985868~148987668:-
THCA	trans	rs11098499	0.691	rs12510133	ENSG00000253326.2	RP11-261C10.7	5.73	1.83e-08	0.02	0.34	0.26	Corneal astigmatism;	chr4:119350189	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.754	rs12506487	ENSG00000253326.2	RP11-261C10.7	5.73	1.83e-08	0.02	0.34	0.26	Corneal astigmatism;	chr4:119350206	chr1:243054861~243056394:-
THCA	trans	rs12439619	0.846	rs62011975	ENSG00000235370.6	DNM1P51	-5.73	1.83e-08	0.02	-0.41	-0.26	Intelligence (multi-trait analysis);	chr15:82159213	chr15:84398316~84411701:-
THCA	trans	rs4654899	0.895	rs7515590	ENSG00000280120.1	RP11-546D6.3	-5.73	1.83e-08	0.0201	-0.18	-0.26	Superior frontal gyrus grey matter volume;	chr1:20890171	chr12:123152324~123153377:-
THCA	trans	rs1363119	1	rs1363119	ENSG00000258738.1	RP11-73E17.2	5.73	1.84e-08	0.0201	0.3	0.26	Intelligence (multi-trait analysis);	chr19:18333999	chr14:34874343~34876459:+
THCA	trans	rs7617480	0.648	rs6766238	ENSG00000235912.1	RP1-159A19.3	-5.73	1.84e-08	0.0201	-0.4	-0.26	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48764496	chr1:27649419~27649610:+
THCA	trans	rs45509595	0.841	rs370155	ENSG00000228022.4	HCG20	-5.73	1.84e-08	0.0202	-0.49	-0.26	Breast cancer;	chr6:27814253	chr6:30766825~30792250:+
THCA	trans	rs902774	0.818	rs4919763	ENSG00000223940.1	KRT8P8	-5.73	1.84e-08	0.0202	-0.54	-0.26	Prostate cancer;	chr12:52885839	chrX:152479577~152481024:+
THCA	trans	rs902774	0.818	rs55914512	ENSG00000223940.1	KRT8P8	-5.73	1.84e-08	0.0202	-0.54	-0.26	Prostate cancer;	chr12:52888490	chrX:152479577~152481024:+
THCA	trans	rs902774	0.818	rs73108466	ENSG00000223940.1	KRT8P8	-5.73	1.84e-08	0.0202	-0.54	-0.26	Prostate cancer;	chr12:52889857	chrX:152479577~152481024:+
THCA	trans	rs902774	0.818	rs55999178	ENSG00000223940.1	KRT8P8	-5.73	1.84e-08	0.0202	-0.54	-0.26	Prostate cancer;	chr12:52890576	chrX:152479577~152481024:+
THCA	trans	rs1391708	0.834	rs4259865	ENSG00000121089.4	NACA3P	5.73	1.84e-08	0.0202	0.4	0.26	Airway wall thickness;	chr12:56881229	chr4:164943290~164943937:+
THCA	trans	rs1391708	0.834	rs7358569	ENSG00000121089.4	NACA3P	5.73	1.84e-08	0.0202	0.4	0.26	Airway wall thickness;	chr12:56883608	chr4:164943290~164943937:+
THCA	trans	rs7819412	0.66	rs7462931	ENSG00000254153.1	CTA-398F10.2	5.72	1.85e-08	0.0203	0.28	0.26	Triglycerides;	chr8:11052833	chr8:8456909~8461337:-
THCA	trans	rs9393777	0.778	rs77666565	ENSG00000219392.1	RP1-265C24.5	-5.72	1.85e-08	0.0203	-0.54	-0.26	Intelligence (multi-trait analysis);	chr6:26883636	chr6:28115628~28116551:+
THCA	trans	rs7694207	0.706	rs75395436	ENSG00000215481.7	BCRP3	5.72	1.85e-08	0.0203	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96963599	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs72878917	ENSG00000215481.7	BCRP3	5.72	1.85e-08	0.0203	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96963779	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs67893013	ENSG00000215481.7	BCRP3	5.72	1.85e-08	0.0203	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96964804	chr22:24632915~24653356:+
THCA	trans	rs4415084	0.716	rs12518851	ENSG00000231752.4	EMBP1	5.72	1.85e-08	0.0203	0.35	0.26	Breast cancer;	chr5:44828129	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs13155698	ENSG00000231752.4	EMBP1	5.72	1.85e-08	0.0203	0.35	0.26	Breast cancer;	chr5:44828579	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs10038562	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44832124	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs6896350	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44832469	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.68	rs1371025	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44834131	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs2330620	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44839720	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs2083243	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44840045	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs729599	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44842158	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs16901990	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44842638	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.68	rs10072025	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44843392	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs1371024	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44843488	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.68	rs7715731	ENSG00000231752.4	EMBP1	-5.72	1.85e-08	0.0203	-0.35	-0.26	Breast cancer;	chr5:44846742	chr1:121519112~121571892:+
THCA	trans	rs9467711	0.72	rs35627490	ENSG00000219392.1	RP1-265C24.5	-5.72	1.86e-08	0.0203	-0.58	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26461876	chr6:28115628~28116551:+
THCA	trans	rs7995618	0.634	rs314529	ENSG00000225931.3	RP3-395M20.7	5.72	1.86e-08	0.0203	0.42	0.26	Plasma clusterin levels;	chr13:89268952	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.53	rs314534	ENSG00000225931.3	RP3-395M20.7	5.72	1.86e-08	0.0203	0.42	0.26	Plasma clusterin levels;	chr13:89273842	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.634	rs74647267	ENSG00000225931.3	RP3-395M20.7	5.72	1.86e-08	0.0203	0.42	0.26	Plasma clusterin levels;	chr13:89275118	chr1:2566410~2569888:+
THCA	trans	rs12439619	0.846	rs62010071	ENSG00000235370.6	DNM1P51	-5.72	1.87e-08	0.0204	-0.41	-0.26	Intelligence (multi-trait analysis);	chr15:82289442	chr15:84398316~84411701:-
THCA	trans	rs9329221	0.905	rs13254263	ENSG00000256560.1	LINC01486	-5.72	1.87e-08	0.0205	-0.31	-0.26	Neuroticism;	chr8:10397671	chr12:109354083~109359488:-
THCA	trans	rs2985684	1	rs3007031	ENSG00000240785.1	RPL36AP21	5.72	1.87e-08	0.0205	0.33	0.26	Carotid intima media thickness;	chr14:49635551	chr5:18049550~18049872:+
THCA	trans	rs9393777	0.841	rs13207082	ENSG00000253570.1	RNF5P1	5.72	1.87e-08	0.0205	0.62	0.26	Intelligence (multi-trait analysis);	chr6:27283600	chr8:38600661~38601200:-
THCA	trans	rs7694207	0.706	rs10023987	ENSG00000215481.7	BCRP3	5.72	1.87e-08	0.0205	0.27	0.26	Response to mTOR inhibitor (everolimus);	chr4:96969702	chr22:24632915~24653356:+
THCA	trans	rs6831352	0.819	rs2851274	ENSG00000228407.2	RP4-800M22.1	-5.72	1.87e-08	0.0205	-0.34	-0.26	Alcohol dependence;	chr4:99104715	chr1:52160261~52160600:-
THCA	trans	rs4415084	0.68	rs12652026	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44798507	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.661	rs10462080	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44798950	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.646	rs13183209	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44803647	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.646	rs969679	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44803950	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs7717459	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44804423	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.688	rs10462083	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44806635	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs3761648	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44807977	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.662	rs3761649	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44808062	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs3761650	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44808254	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs3747479	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44809060	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs1866406	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44809843	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs11746506	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44812464	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs2165008	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44821577	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs4457089	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44821634	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs13189120	ENSG00000231752.4	EMBP1	5.72	1.88e-08	0.0205	0.35	0.26	Breast cancer;	chr5:44822181	chr1:121519112~121571892:+
THCA	trans	rs9944275	0.932	rs12910872	ENSG00000240463.1	RPS19P3	5.72	1.88e-08	0.0206	0.41	0.26	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);	chr15:96626769	chr14:34568689~34569129:-
THCA	trans	rs4964805	0.526	rs934845	ENSG00000278725.1	RP11-666O2.5	5.72	1.88e-08	0.0206	0.28	0.26	Attention deficit hyperactivity disorder;	chr12:103791479	chr16:28602340~28604519:+
THCA	trans	rs7824557	0.736	rs10107010	ENSG00000229857.1	RP11-159H20.3	5.72	1.89e-08	0.0206	0.32	0.26	Retinal vascular caliber;	chr8:11275203	chr9:76992099~76993108:+
THCA	trans	rs10090774	0.932	rs7816620	ENSG00000230756.1	RHOQP3	5.72	1.89e-08	0.0207	0.31	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994015	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13258775	ENSG00000230756.1	RHOQP3	5.72	1.89e-08	0.0207	0.31	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140984141	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs11786859	ENSG00000230756.1	RHOQP3	5.72	1.89e-08	0.0207	0.31	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140974782	chr2:130212870~130213490:-
THCA	trans	rs2985684	0.789	rs1957979	ENSG00000240785.1	RPL36AP21	5.72	1.89e-08	0.0207	0.32	0.26	Carotid intima media thickness;	chr14:49596614	chr5:18049550~18049872:+
THCA	trans	rs2985684	0.789	rs7161649	ENSG00000240785.1	RPL36AP21	5.72	1.89e-08	0.0207	0.32	0.26	Carotid intima media thickness;	chr14:49597310	chr5:18049550~18049872:+
THCA	trans	rs7824557	0.525	rs12682349	ENSG00000256560.1	LINC01486	5.72	1.9e-08	0.0207	0.32	0.26	Retinal vascular caliber;	chr8:11387794	chr12:109354083~109359488:-
THCA	trans	rs4948102	0.642	rs766333	ENSG00000215006.4	CHCHD2P2	-5.72	1.9e-08	0.0207	-0.36	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr5:69333929~69334249:+
THCA	trans	rs9393777	0.778	rs74689501	ENSG00000219392.1	RP1-265C24.5	-5.72	1.9e-08	0.0208	-0.54	-0.26	Intelligence (multi-trait analysis);	chr6:26920042	chr6:28115628~28116551:+
THCA	trans	rs4646450	0.891	rs3137	ENSG00000228834.1	RP11-249L21.4	5.72	1.91e-08	0.0208	0.4	0.26	Blood metabolite levels;	chr7:99533252	chr6:108907615~108907873:-
THCA	trans	rs16976116	0.572	rs28802062	ENSG00000231806.2	PCAT7	5.72	1.91e-08	0.0208	0.39	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55160110	chr9:94555069~94568127:+
THCA	trans	rs714543	0.61	rs4724320	ENSG00000214975.4	PPIAP29	-5.72	1.91e-08	0.0209	-0.29	-0.26	Plateletcrit;	chr7:44775735	chr6:24976419~24976982:+
THCA	trans	rs2439831	0.85	rs3097773	ENSG00000180867.10	PDIA3P1	5.72	1.92e-08	0.0209	0.28	0.26	Lung cancer in ever smokers;	chr15:43600874	chr1:147178113~147179622:+
THCA	trans	rs7995618	0.634	rs9301545	ENSG00000225931.3	RP3-395M20.7	-5.72	1.92e-08	0.0209	-0.41	-0.26	Plasma clusterin levels;	chr13:89201001	chr1:2566410~2569888:+
THCA	trans	rs12210905	0.764	rs72835248	ENSG00000242375.1	RP11-498P14.3	-5.72	1.92e-08	0.0209	-0.7	-0.26	Hip circumference adjusted for BMI;	chr6:26964038	chr9:97195351~97197687:-
THCA	trans	rs7945705	0.875	rs4929914	ENSG00000266891.1	RP11-692N5.2	5.72	1.92e-08	0.021	0.32	0.26	Hemoglobin concentration;	chr11:8802841	chr18:9734882~9735602:-
THCA	trans	rs3096299	0.632	rs4399533	ENSG00000215030.5	RPL13P12	-5.72	1.93e-08	0.021	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89472974	chr17:17383377~17384012:-
THCA	trans	rs356220	0.642	rs356173	ENSG00000245479.2	LINC01585	5.72	1.93e-08	0.021	0.31	0.25	Parkinson's disease;	chr4:89710565	chr15:90660234~90664967:+
THCA	trans	rs4879677	0.96	rs9695050	ENSG00000269560.1	CTD-2192J16.21	5.72	1.93e-08	0.0211	0.32	0.25	Gut microbiome composition (summer and winter);	chr9:27671900	chr19:12529768~12532973:-
THCA	trans	rs9393777	0.92	rs13196692	ENSG00000253570.1	RNF5P1	5.72	1.93e-08	0.0211	0.7	0.25	Intelligence (multi-trait analysis);	chr6:27411340	chr8:38600661~38601200:-
THCA	trans	rs9393777	0.92	rs34150729	ENSG00000253570.1	RNF5P1	5.72	1.93e-08	0.0211	0.7	0.25	Intelligence (multi-trait analysis);	chr6:27420975	chr8:38600661~38601200:-
THCA	trans	rs9393777	0.92	rs13191227	ENSG00000253570.1	RNF5P1	5.72	1.93e-08	0.0211	0.7	0.25	Intelligence (multi-trait analysis);	chr6:27422336	chr8:38600661~38601200:-
THCA	trans	rs804280	0.509	rs7461273	ENSG00000254153.1	CTA-398F10.2	-5.72	1.93e-08	0.0211	-0.29	-0.25	Myopia (pathological);	chr8:11920468	chr8:8456909~8461337:-
THCA	trans	rs7945705	0.776	rs2316865	ENSG00000266891.1	RP11-692N5.2	-5.72	1.93e-08	0.0211	-0.33	-0.25	Hemoglobin concentration;	chr11:8793923	chr18:9734882~9735602:-
THCA	trans	rs453301	0.631	rs11779804	ENSG00000229857.1	RP11-159H20.3	5.72	1.94e-08	0.0212	0.34	0.25	Joint mobility (Beighton score);	chr8:8940442	chr9:76992099~76993108:+
THCA	trans	rs453301	0.686	rs11785819	ENSG00000229857.1	RP11-159H20.3	5.72	1.94e-08	0.0212	0.32	0.25	Joint mobility (Beighton score);	chr8:9012868	chr9:76992099~76993108:+
THCA	trans	rs2439831	0.681	rs528517	ENSG00000180867.10	PDIA3P1	-5.72	1.94e-08	0.0212	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43320727	chr1:147178113~147179622:+
THCA	trans	rs853679	0.599	rs13193295	ENSG00000204338.7	CYP21A1P	-5.72	1.94e-08	0.0212	-0.56	-0.25	Depression;	chr6:28035450	chr6:32005636~32008451:+
THCA	trans	rs4415084	0.716	rs6868232	ENSG00000231752.4	EMBP1	5.72	1.95e-08	0.0212	0.35	0.25	Breast cancer;	chr5:44827578	chr1:121519112~121571892:+
THCA	trans	rs7694207	0.615	rs13109296	ENSG00000215481.7	BCRP3	5.72	1.95e-08	0.0212	0.29	0.25	Response to mTOR inhibitor (everolimus);	chr4:96986203	chr22:24632915~24653356:+
THCA	trans	rs4415084	0.804	rs57300972	ENSG00000231752.4	EMBP1	-5.71	1.95e-08	0.0213	-0.34	-0.25	Breast cancer;	chr5:44897734	chr1:121519112~121571892:+
THCA	trans	rs2921036	0.545	rs4840975	ENSG00000229857.1	RP11-159H20.3	5.71	1.95e-08	0.0213	0.36	0.25	Neuroticism;	chr8:8505748	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.645	rs56057779	ENSG00000229857.1	RP11-159H20.3	5.71	1.96e-08	0.0214	0.3	0.25	Neuroticism;	chr8:10659370	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.716	rs6451775	ENSG00000231752.4	EMBP1	-5.71	1.96e-08	0.0214	-0.35	-0.25	Breast cancer;	chr5:44836686	chr1:121519112~121571892:+
THCA	trans	rs7945705	0.806	rs12224436	ENSG00000266891.1	RP11-692N5.2	-5.71	1.97e-08	0.0215	-0.33	-0.25	Hemoglobin concentration;	chr11:8794278	chr18:9734882~9735602:-
THCA	trans	rs7824557	0.628	rs11994376	ENSG00000253893.2	FAM85B	-5.71	1.97e-08	0.0215	-0.34	-0.25	Retinal vascular caliber;	chr8:11345451	chr8:8167819~8226614:-
THCA	trans	rs7995618	0.669	rs75263180	ENSG00000225931.3	RP3-395M20.7	5.71	1.97e-08	0.0215	0.44	0.25	Plasma clusterin levels;	chr13:89311082	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.601	rs117514867	ENSG00000225931.3	RP3-395M20.7	5.71	1.97e-08	0.0215	0.44	0.25	Plasma clusterin levels;	chr13:89318189	chr1:2566410~2569888:+
THCA	trans	rs853679	0.546	rs200490	ENSG00000228022.4	HCG20	-5.71	1.98e-08	0.0215	-0.49	-0.25	Depression;	chr6:27829157	chr6:30766825~30792250:+
THCA	trans	rs7824557	0.564	rs12550129	ENSG00000256560.1	LINC01486	-5.71	1.98e-08	0.0216	-0.31	-0.25	Retinal vascular caliber;	chr8:11376408	chr12:109354083~109359488:-
THCA	trans	rs853679	0.607	rs35001169	ENSG00000248290.1	TNXA	-5.71	1.98e-08	0.0216	-0.55	-0.25	Depression;	chr6:28219854	chr6:32008614~32012472:-
THCA	trans	rs853679	0.546	rs35656932	ENSG00000248290.1	TNXA	-5.71	1.98e-08	0.0216	-0.55	-0.25	Depression;	chr6:28223510	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13208096	ENSG00000248290.1	TNXA	-5.71	1.98e-08	0.0216	-0.55	-0.25	Depression;	chr6:28257533	chr6:32008614~32012472:-
THCA	trans	rs9348739	1	rs9348739	ENSG00000228022.4	HCG20	-5.71	1.98e-08	0.0216	-0.48	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26955320	chr6:30766825~30792250:+
THCA	trans	rs9650657	0.596	rs2409675	ENSG00000253893.2	FAM85B	5.71	1.99e-08	0.0216	0.32	0.25	Neuroticism;	chr8:10737749	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.767	rs2060463	ENSG00000229857.1	RP11-159H20.3	-5.71	1.99e-08	0.0216	-0.32	-0.25	Retinal vascular caliber;	chr8:11304101	chr9:76992099~76993108:+
THCA	trans	rs7833986	0.752	rs2316947	ENSG00000244245.1	RP11-120B7.1	5.71	1.99e-08	0.0217	0.3	0.25	Height;	chr8:56151586	chr5:108593609~108593967:+
THCA	trans	rs4415084	0.716	rs6451774	ENSG00000231752.4	EMBP1	5.71	1.99e-08	0.0217	0.35	0.25	Breast cancer;	chr5:44793882	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs727305	ENSG00000231752.4	EMBP1	5.71	1.99e-08	0.0217	0.35	0.25	Breast cancer;	chr5:44795940	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs2330619	ENSG00000231752.4	EMBP1	5.71	1.99e-08	0.0217	0.35	0.25	Breast cancer;	chr5:44795960	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs727304	ENSG00000231752.4	EMBP1	5.71	1.99e-08	0.0217	0.35	0.25	Breast cancer;	chr5:44796188	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs1438819	ENSG00000231752.4	EMBP1	5.71	1.99e-08	0.0217	0.35	0.25	Breast cancer;	chr5:44797744	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.688	rs11741772	ENSG00000231752.4	EMBP1	5.71	1.99e-08	0.0217	0.35	0.25	Breast cancer;	chr5:44814495	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs9637796	ENSG00000231752.4	EMBP1	5.71	1.99e-08	0.0217	0.35	0.25	Breast cancer;	chr5:44817817	chr1:121519112~121571892:+
THCA	trans	rs10090774	0.965	rs7813058	ENSG00000230756.1	RHOQP3	5.71	2e-08	0.0217	0.32	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140994094	chr2:130212870~130213490:-
THCA	trans	rs7192380	0.928	rs12933210	ENSG00000257513.6	NPIPB1P	-5.71	2e-08	0.0218	-0.28	-0.25	Sjögren's syndrome;	chr16:69708145	chr18:11619509~11639699:-
THCA	trans	rs66486766	1	rs66486766	ENSG00000259295.5	CSPG4P12	5.71	2e-08	0.0218	0.41	0.25	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:85191438~85213905:+
THCA	trans	rs1478897	0.898	rs2248932	ENSG00000253893.2	FAM85B	5.71	2.01e-08	0.0218	0.34	0.25	Systemic lupus erythematosus;	chr8:11534141	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.905	rs13252982	ENSG00000256560.1	LINC01486	-5.71	2.01e-08	0.0219	-0.31	-0.25	Neuroticism;	chr8:10397595	chr12:109354083~109359488:-
THCA	trans	rs9329221	0.87	rs11777976	ENSG00000256560.1	LINC01486	-5.71	2.01e-08	0.0219	-0.31	-0.25	Neuroticism;	chr8:10397892	chr12:109354083~109359488:-
THCA	trans	rs453301	0.522	rs1964356	ENSG00000256560.1	LINC01486	5.71	2.01e-08	0.0219	0.3	0.25	Joint mobility (Beighton score);	chr8:8995760	chr12:109354083~109359488:-
THCA	trans	rs10504229	0.679	rs75402323	ENSG00000226986.4	RP11-543B16.2	-5.71	2.02e-08	0.0219	-0.4	-0.25	Developmental language disorder (linguistic errors);	chr8:57223668	chr1:211207239~211207897:+
THCA	trans	rs7824557	0.628	rs11991153	ENSG00000253893.2	FAM85B	-5.71	2.02e-08	0.022	-0.34	-0.25	Retinal vascular caliber;	chr8:11345598	chr8:8167819~8226614:-
THCA	trans	rs6011368	0.84	rs6062361	ENSG00000226210.3	WASH7P	-5.71	2.02e-08	0.022	-0.29	-0.25	Clozapine-induced cytotoxicity;	chr20:64273189	chr12:14522~32015:-
THCA	trans	rs9467711	0.79	rs35400317	ENSG00000204338.7	CYP21A1P	-5.71	2.02e-08	0.022	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.79	rs67777156	ENSG00000204338.7	CYP21A1P	-5.71	2.02e-08	0.022	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.722	rs13201782	ENSG00000204338.7	CYP21A1P	-5.71	2.02e-08	0.022	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr6:32005636~32008451:+
THCA	trans	rs4415084	0.716	rs10462081	ENSG00000231752.4	EMBP1	5.71	2.02e-08	0.022	0.35	0.25	Breast cancer;	chr5:44800563	chr1:121519112~121571892:+
THCA	trans	rs453301	0.624	rs7014430	ENSG00000256560.1	LINC01486	5.71	2.02e-08	0.022	0.3	0.25	Joint mobility (Beighton score);	chr8:8970227	chr12:109354083~109359488:-
THCA	trans	rs941207	0.507	rs73337030	ENSG00000257210.1	NACAP3	-5.71	2.02e-08	0.022	-0.3	-0.25	Platelet count;	chr12:56652410	chr12:93124063~93124543:-
THCA	trans	rs10090774	0.965	rs11775023	ENSG00000230756.1	RHOQP3	5.71	2.02e-08	0.022	0.32	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959246	chr2:130212870~130213490:-
THCA	trans	rs9858542	0.537	rs4410472	ENSG00000197582.5	GPX1P1	-5.71	2.03e-08	0.022	-0.48	-0.25	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49291657	chrX:13378735~13379340:-
THCA	trans	rs853679	0.607	rs13204012	ENSG00000248290.1	TNXA	-5.71	2.03e-08	0.0221	-0.55	-0.25	Depression;	chr6:28233753	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13205211	ENSG00000248290.1	TNXA	-5.71	2.03e-08	0.0221	-0.55	-0.25	Depression;	chr6:28235278	chr6:32008614~32012472:-
THCA	trans	rs9467711	0.79	rs13198716	ENSG00000228022.4	HCG20	5.71	2.03e-08	0.0221	0.63	0.25	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:30766825~30792250:+
THCA	trans	rs4269515	0.764	rs6469084	ENSG00000219891.2	ZSCAN12P1	5.71	2.03e-08	0.0221	0.33	0.25	Dental caries;	chr8:106895804	chr6:28091154~28093664:+
THCA	trans	rs9467711	0.606	rs2072803	ENSG00000253570.1	RNF5P1	5.71	2.03e-08	0.0221	0.6	0.25	Autism spectrum disorder or schizophrenia;	chr6:26392287	chr8:38600661~38601200:-
THCA	trans	rs14057	0.929	rs7549198	ENSG00000215869.3	RP11-364B6.1	5.71	2.04e-08	0.0222	0.34	0.25	Systolic blood pressure;	chr1:6649550	chr1:104073023~104077087:+
THCA	trans	rs2980439	0.558	rs2955584	ENSG00000229857.1	RP11-159H20.3	-5.71	2.04e-08	0.0222	-0.31	-0.25	Neuroticism;	chr8:8234652	chr9:76992099~76993108:+
THCA	trans	rs6710503	1	rs6710503	ENSG00000277406.1	CH17-385C13.2	-5.71	2.04e-08	0.0222	-0.3	-0.25	Lung cancer in ever smokers;Breast cancer;	chr2:24748307	chr1:146321842~146328211:-
THCA	trans	rs3002142	0.908	rs3002139	ENSG00000219201.4	RP11-181C21.4	-5.71	2.04e-08	0.0222	-0.32	-0.25	LDL peak particle diameter (total fat intake interaction);	chr1:222611722	chr1:77810861~77811781:-
THCA	trans	rs9650657	0.631	rs1124010	ENSG00000253893.2	FAM85B	5.71	2.04e-08	0.0222	0.31	0.25	Neuroticism;	chr8:10737992	chr8:8167819~8226614:-
THCA	trans	rs853679	0.607	rs13194781	ENSG00000204338.7	CYP21A1P	-5.71	2.05e-08	0.0222	-0.57	-0.25	Depression;	chr6:27847861	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs36116761	ENSG00000204338.7	CYP21A1P	-5.71	2.05e-08	0.0222	-0.57	-0.25	Depression;	chr6:27850704	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs34194357	ENSG00000204338.7	CYP21A1P	-5.71	2.05e-08	0.0222	-0.57	-0.25	Depression;	chr6:27850757	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13199772	ENSG00000204338.7	CYP21A1P	-5.71	2.05e-08	0.0222	-0.57	-0.25	Depression;	chr6:27866307	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs13199906	ENSG00000204338.7	CYP21A1P	-5.71	2.05e-08	0.0222	-0.57	-0.25	Depression;	chr6:27866361	chr6:32005636~32008451:+
THCA	trans	rs853679	0.607	rs17763089	ENSG00000204338.7	CYP21A1P	-5.71	2.05e-08	0.0222	-0.57	-0.25	Depression;	chr6:27867440	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs17695758	ENSG00000204338.7	CYP21A1P	-5.71	2.05e-08	0.0222	-0.57	-0.25	Depression;	chr6:27869405	chr6:32005636~32008451:+
THCA	trans	rs9650657	0.645	rs9969657	ENSG00000229857.1	RP11-159H20.3	-5.71	2.06e-08	0.0223	-0.3	-0.25	Neuroticism;	chr8:10657768	chr9:76992099~76993108:+
THCA	trans	rs4646450	0.891	rs6962772	ENSG00000228834.1	RP11-249L21.4	5.71	2.06e-08	0.0224	0.4	0.25	Blood metabolite levels;	chr7:99484107	chr6:108907615~108907873:-
THCA	trans	rs9987353	0.84	rs329994	ENSG00000253893.2	FAM85B	5.7	2.06e-08	0.0224	0.32	0.25	Recombination measurement;	chr8:9265723	chr8:8167819~8226614:-
THCA	trans	rs35851103	0.627	rs6601644	ENSG00000254153.1	CTA-398F10.2	-5.7	2.06e-08	0.0224	-0.28	-0.25	Neuroticism;	chr8:11989569	chr8:8456909~8461337:-
THCA	trans	rs9393777	0.92	rs13196692	ENSG00000228022.4	HCG20	-5.7	2.07e-08	0.0224	-0.63	-0.25	Intelligence (multi-trait analysis);	chr6:27411340	chr6:30766825~30792250:+
THCA	trans	rs9393777	0.92	rs34150729	ENSG00000228022.4	HCG20	-5.7	2.07e-08	0.0224	-0.63	-0.25	Intelligence (multi-trait analysis);	chr6:27420975	chr6:30766825~30792250:+
THCA	trans	rs9393777	0.92	rs13191227	ENSG00000228022.4	HCG20	-5.7	2.07e-08	0.0224	-0.63	-0.25	Intelligence (multi-trait analysis);	chr6:27422336	chr6:30766825~30792250:+
THCA	trans	rs9858542	0.543	rs2230929	ENSG00000197582.5	GPX1P1	-5.7	2.07e-08	0.0225	-0.47	-0.25	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49305742	chrX:13378735~13379340:-
THCA	trans	rs9393777	0.92	rs35716472	ENSG00000204338.7	CYP21A1P	-5.7	2.07e-08	0.0225	-0.49	-0.25	Intelligence (multi-trait analysis);	chr6:27438828	chr6:32005636~32008451:+
THCA	trans	rs7819412	0.669	rs6601568	ENSG00000254153.1	CTA-398F10.2	5.7	2.07e-08	0.0225	0.29	0.25	Triglycerides;	chr8:11215893	chr8:8456909~8461337:-
THCA	trans	rs12477438	0.52	rs6542864	ENSG00000276576.1	MRPL30P1	5.7	2.07e-08	0.0225	0.33	0.25	Chronic sinus infection;	chr2:99108760	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6739579	ENSG00000276576.1	MRPL30P1	5.7	2.07e-08	0.0225	0.33	0.25	Chronic sinus infection;	chr2:99115089	chr6:57029521~57029988:+
THCA	trans	rs4879656	0.966	rs1016673	ENSG00000215007.3	DNAJA1P3	-5.7	2.08e-08	0.0225	-0.31	-0.25	Menopause (age at onset);	chr9:32982450	chrX:107351650~107352843:-
THCA	trans	rs7819412	0.521	rs9329238	ENSG00000229857.1	RP11-159H20.3	5.7	2.08e-08	0.0226	0.34	0.25	Triglycerides;	chr8:11176228	chr9:76992099~76993108:+
THCA	trans	rs7746199	0.736	rs13195636	ENSG00000204338.7	CYP21A1P	-5.7	2.08e-08	0.0226	-0.57	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:32005636~32008451:+
THCA	trans	rs11992162	0.636	rs4841644	ENSG00000254153.1	CTA-398F10.2	-5.7	2.08e-08	0.0226	-0.29	-0.25	Monocyte count;	chr8:11940924	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.843	rs2736375	ENSG00000229857.1	RP11-159H20.3	5.7	2.08e-08	0.0226	0.3	0.25	Retinal vascular caliber;	chr8:11258240	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.564	rs13274106	ENSG00000256560.1	LINC01486	-5.7	2.08e-08	0.0226	-0.31	-0.25	Retinal vascular caliber;	chr8:11376449	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.517	rs12542733	ENSG00000256560.1	LINC01486	-5.7	2.08e-08	0.0226	-0.29	-0.25	Mood instability;	chr8:8967348	chr12:109354083~109359488:-
THCA	trans	rs804280	0.509	rs10109241	ENSG00000254153.1	CTA-398F10.2	-5.7	2.09e-08	0.0227	-0.29	-0.25	Myopia (pathological);	chr8:11927476	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.563	rs12541800	ENSG00000229857.1	RP11-159H20.3	-5.7	2.09e-08	0.0227	-0.32	-0.25	Neuroticism;	chr8:11565563	chr9:76992099~76993108:+
THCA	trans	rs4654899	0.931	rs2275468	ENSG00000280120.1	RP11-546D6.3	-5.7	2.1e-08	0.0227	-0.18	-0.25	Superior frontal gyrus grey matter volume;	chr1:20893882	chr12:123152324~123153377:-
THCA	trans	rs9693857	0.52	rs7814570	ENSG00000253893.2	FAM85B	-5.7	2.1e-08	0.0227	-0.35	-0.25	Systolic blood pressure;	chr8:9508802	chr8:8167819~8226614:-
THCA	trans	rs9393777	0.92	rs55834529	ENSG00000248290.1	TNXA	-5.7	2.1e-08	0.0228	-0.58	-0.25	Intelligence (multi-trait analysis);	chr6:27104763	chr6:32008614~32012472:-
THCA	trans	rs4295623	0.789	rs12541318	ENSG00000259972.2	AC009120.6	5.7	2.1e-08	0.0228	0.16	0.25	Morning vs. evening chronotype;	chr8:11737461	chr16:74305127~74335346:-
THCA	trans	rs5758511	0.573	rs2267439	ENSG00000268568.1	AC007228.9	-5.7	2.1e-08	0.0228	-0.3	-0.25	Birth weight;	chr22:41841765	chr19:56672574~56673901:-
THCA	trans	rs7769051	1	rs12203977	ENSG00000213303.3	CTC-398G3.2	5.7	2.1e-08	0.0228	0.45	0.25	Type 2 diabetes nephropathy;	chr6:132801621	chr19:11523436~11523831:+
THCA	trans	rs7769051	1	rs9493445	ENSG00000213303.3	CTC-398G3.2	5.7	2.1e-08	0.0228	0.45	0.25	Type 2 diabetes nephropathy;	chr6:132804270	chr19:11523436~11523831:+
THCA	trans	rs7769051	1	rs9493446	ENSG00000213303.3	CTC-398G3.2	5.7	2.1e-08	0.0228	0.45	0.25	Type 2 diabetes nephropathy;	chr6:132804504	chr19:11523436~11523831:+
THCA	trans	rs7769051	1	rs5006218	ENSG00000213303.3	CTC-398G3.2	5.7	2.1e-08	0.0228	0.45	0.25	Type 2 diabetes nephropathy;	chr6:132805081	chr19:11523436~11523831:+
THCA	trans	rs7694207	0.706	rs13107927	ENSG00000215481.7	BCRP3	5.7	2.11e-08	0.0229	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96961979	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.528	rs76520319	ENSG00000215481.7	BCRP3	5.7	2.11e-08	0.0229	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96963044	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.66	rs10012403	ENSG00000215481.7	BCRP3	5.7	2.11e-08	0.0229	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96969892	chr22:24632915~24653356:+
THCA	trans	rs9329221	0.905	rs10283145	ENSG00000254153.1	CTA-398F10.2	5.7	2.11e-08	0.0229	0.28	0.25	Neuroticism;	chr8:10383901	chr8:8456909~8461337:-
THCA	trans	rs10090774	0.965	rs11780030	ENSG00000230756.1	RHOQP3	5.7	2.11e-08	0.0229	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140997644	chr2:130212870~130213490:-
THCA	trans	rs6921919	0.562	rs13198809	ENSG00000248290.1	TNXA	-5.7	2.11e-08	0.0229	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:32008614~32012472:-
THCA	trans	rs853679	0.546	rs35353359	ENSG00000248290.1	TNXA	-5.7	2.11e-08	0.0229	-0.53	-0.25	Depression;	chr6:28356601	chr6:32008614~32012472:-
THCA	trans	rs10090774	0.87	rs11782305	ENSG00000230756.1	RHOQP3	5.7	2.11e-08	0.0229	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140995572	chr2:130212870~130213490:-
THCA	trans	rs9368481	0.761	rs7775041	ENSG00000242375.1	RP11-498P14.3	-5.7	2.12e-08	0.023	-0.37	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr9:97195351~97197687:-
THCA	trans	rs12477438	0.52	rs7604557	ENSG00000276576.1	MRPL30P1	5.7	2.12e-08	0.023	0.32	0.25	Chronic sinus infection;	chr2:99131366	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs13010904	ENSG00000276576.1	MRPL30P1	5.7	2.12e-08	0.023	0.32	0.25	Chronic sinus infection;	chr2:99137826	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs13012481	ENSG00000276576.1	MRPL30P1	5.7	2.12e-08	0.023	0.32	0.25	Chronic sinus infection;	chr2:99137827	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6717723	ENSG00000276576.1	MRPL30P1	5.7	2.12e-08	0.023	0.32	0.25	Chronic sinus infection;	chr2:99140467	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs11685759	ENSG00000276576.1	MRPL30P1	5.7	2.12e-08	0.023	0.32	0.25	Chronic sinus infection;	chr2:99149754	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs11123765	ENSG00000276576.1	MRPL30P1	5.7	2.12e-08	0.023	0.32	0.25	Chronic sinus infection;	chr2:99151601	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.501	rs2632260	ENSG00000276576.1	MRPL30P1	5.7	2.12e-08	0.023	0.32	0.25	Chronic sinus infection;	chr2:99155127	chr6:57029521~57029988:+
THCA	trans	rs17711722	0.523	rs365896	ENSG00000234585.5	CCT6P3	-5.7	2.12e-08	0.023	-0.23	-0.25	Calcium levels;	chr7:66045710	chr7:65038354~65074713:+
THCA	trans	rs10100465	0.596	rs218009	ENSG00000242951.1	RP11-507E23.1	-5.7	2.13e-08	0.0231	-0.33	-0.25	Leprosy;	chr8:117704036	chr14:75595805~75596206:-
THCA	trans	rs7189233	0.955	rs16952242	ENSG00000277863.1	RP11-282A11.4	5.7	2.13e-08	0.0231	0.34	0.25	Intelligence (multi-trait analysis);	chr16:53440338	chr13:106903150~106904099:-
THCA	trans	rs2985684	0.74	rs2883438	ENSG00000240785.1	RPL36AP21	5.7	2.13e-08	0.0231	0.32	0.25	Carotid intima media thickness;	chr14:49577674	chr5:18049550~18049872:+
THCA	trans	rs10435719	0.867	rs35778860	ENSG00000254153.1	CTA-398F10.2	-5.7	2.13e-08	0.0231	-0.29	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:8456909~8461337:-
THCA	trans	rs453301	0.657	rs36056437	ENSG00000256560.1	LINC01486	-5.7	2.13e-08	0.0231	-0.32	-0.25	Joint mobility (Beighton score);	chr8:8935355	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.564	rs12547100	ENSG00000256560.1	LINC01486	-5.7	2.14e-08	0.0231	-0.32	-0.25	Retinal vascular caliber;	chr8:11385123	chr12:109354083~109359488:-
THCA	trans	rs12477438	0.52	rs11689265	ENSG00000276576.1	MRPL30P1	5.7	2.14e-08	0.0232	0.32	0.25	Chronic sinus infection;	chr2:99182804	chr6:57029521~57029988:+
THCA	trans	rs62045849	0.557	rs4782444	ENSG00000215030.5	RPL13P12	-5.7	2.14e-08	0.0232	-0.41	-0.25	Red blood cell count;	chr16:89117565	chr17:17383377~17384012:-
THCA	trans	rs10090774	0.813	rs10098028	ENSG00000230756.1	RHOQP3	5.7	2.15e-08	0.0233	0.32	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141000954	chr2:130212870~130213490:-
THCA	trans	rs10793968	0.585	rs4740358	ENSG00000231210.2	LINC01510	-5.7	2.15e-08	0.0233	-0.24	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:130692372	chr7:116570960~116614820:-
THCA	trans	rs7819412	0.521	rs2409720	ENSG00000229857.1	RP11-159H20.3	5.7	2.15e-08	0.0233	0.34	0.25	Triglycerides;	chr8:11180394	chr9:76992099~76993108:+
THCA	trans	rs9393777	1	rs9393777	ENSG00000228022.4	HCG20	-5.7	2.16e-08	0.0234	-0.48	-0.25	Intelligence (multi-trait analysis);	chr6:26974248	chr6:30766825~30792250:+
THCA	trans	rs2048656	0.524	rs7840706	ENSG00000253893.2	FAM85B	5.7	2.16e-08	0.0234	0.32	0.25	Schizophrenia;	chr8:9677546	chr8:8167819~8226614:-
THCA	trans	rs10090774	0.901	rs13280609	ENSG00000230756.1	RHOQP3	5.7	2.17e-08	0.0234	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140961641	chr2:130212870~130213490:-
THCA	trans	rs16976116	0.53	rs508482	ENSG00000231806.2	PCAT7	-5.7	2.17e-08	0.0235	-0.39	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55118309	chr9:94555069~94568127:+
THCA	trans	rs11992162	0.636	rs4841642	ENSG00000254153.1	CTA-398F10.2	-5.69	2.18e-08	0.0236	-0.29	-0.25	Monocyte count;	chr8:11940825	chr8:8456909~8461337:-
THCA	trans	rs11992162	0.636	rs4841646	ENSG00000254153.1	CTA-398F10.2	-5.69	2.18e-08	0.0236	-0.29	-0.25	Monocyte count;	chr8:11941198	chr8:8456909~8461337:-
THCA	trans	rs804280	0.703	rs745379	ENSG00000253893.2	FAM85B	5.69	2.18e-08	0.0236	0.33	0.25	Myopia (pathological);	chr8:11758186	chr8:8167819~8226614:-
THCA	trans	rs7192380	0.893	rs12924052	ENSG00000257513.6	NPIPB1P	-5.69	2.18e-08	0.0236	-0.28	-0.25	Sjögren's syndrome;	chr16:69743343	chr18:11619509~11639699:-
THCA	trans	rs7646881	0.544	rs16829273	ENSG00000239393.1	CTD-2301A4.1	-5.69	2.18e-08	0.0236	-0.38	-0.25	Tetralogy of Fallot;	chr3:158664831	chr5:177346073~177346426:+
THCA	trans	rs6981523	0.5	rs4412337	ENSG00000254153.1	CTA-398F10.2	-5.69	2.19e-08	0.0236	-0.3	-0.25	Neuroticism;	chr8:11214511	chr8:8456909~8461337:-
THCA	trans	rs9693857	0.518	rs7005065	ENSG00000253893.2	FAM85B	5.69	2.19e-08	0.0236	0.37	0.25	Systolic blood pressure;	chr8:9418138	chr8:8167819~8226614:-
THCA	trans	rs875971	0.571	rs160641	ENSG00000213640.3	EEF1DP4	5.69	2.19e-08	0.0237	0.34	0.25	Aortic root size;	chr7:66112359	chr7:64862999~64864370:+
THCA	trans	rs11638815	0.668	rs1877242	ENSG00000235370.6	DNM1P51	5.69	2.2e-08	0.0237	0.34	0.25	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82728706	chr15:84398316~84411701:-
THCA	trans	rs3764796	0.618	rs11995192	ENSG00000250030.2	RP11-584P21.4	5.69	2.2e-08	0.0238	0.45	0.25	Calcium levels;	chr8:17214007	chr4:67446267~67446574:+
THCA	trans	rs13183434	0.722	rs13176182	ENSG00000231752.4	EMBP1	5.69	2.2e-08	0.0238	0.48	0.25	Breast cancer;	chr5:45194616	chr1:121519112~121571892:+
THCA	trans	rs875971	0.545	rs313830	ENSG00000213640.3	EEF1DP4	5.69	2.2e-08	0.0238	0.35	0.25	Aortic root size;	chr7:66086944	chr7:64862999~64864370:+
THCA	trans	rs1572299	0.64	rs7871469	ENSG00000273669.1	RP11-405M12.4	-5.69	2.2e-08	0.0238	-0.32	-0.25	Schizophrenia;	chr9:118566645	chr18:75073543~75074205:+
THCA	trans	rs7212590	0.655	rs62081824	ENSG00000187870.7	RNFT1P3	5.69	2.21e-08	0.0239	0.51	0.25	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59830589	chr17:20743333~20754501:-
THCA	trans	rs9393777	0.92	rs34953377	ENSG00000204338.7	CYP21A1P	-5.69	2.21e-08	0.0239	-0.5	-0.25	Intelligence (multi-trait analysis);	chr6:27413881	chr6:32005636~32008451:+
THCA	trans	rs7824557	0.603	rs2736278	ENSG00000256560.1	LINC01486	5.69	2.21e-08	0.0239	0.32	0.25	Retinal vascular caliber;	chr8:11362272	chr12:109354083~109359488:-
THCA	trans	rs1075232	1	rs16956838	ENSG00000270055.1	CTD-3092A11.2	-5.69	2.21e-08	0.0239	-0.45	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31527492	chr15:30487963~30490313:+
THCA	trans	rs7189233	0.955	rs8054299	ENSG00000277863.1	RP11-282A11.4	-5.69	2.22e-08	0.0239	-0.37	-0.25	Intelligence (multi-trait analysis);	chr16:53464743	chr13:106903150~106904099:-
THCA	trans	rs853679	0.607	rs200489	ENSG00000228022.4	HCG20	-5.69	2.22e-08	0.024	-0.49	-0.25	Depression;	chr6:27830479	chr6:30766825~30792250:+
THCA	trans	rs10090774	0.965	rs13270490	ENSG00000230756.1	RHOQP3	5.69	2.22e-08	0.024	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140951080	chr2:130212870~130213490:-
THCA	trans	rs6601327	0.602	rs12678014	ENSG00000253893.2	FAM85B	-5.69	2.23e-08	0.024	-0.32	-0.25	Multiple myeloma (hyperdiploidy);	chr8:9791655	chr8:8167819~8226614:-
THCA	trans	rs2645424	0.53	rs1293303	ENSG00000269898.1	RP11-568J23.4	5.69	2.23e-08	0.0241	0.3	0.25	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11862718	chr16:85743287~85744225:+
THCA	trans	rs7429990	0.833	rs3755637	ENSG00000235912.1	RP1-159A19.3	5.69	2.23e-08	0.0241	0.31	0.25	Educational attainment (years of education);	chr3:47580720	chr1:27649419~27649610:+
THCA	trans	rs10512697	0.685	rs11747698	ENSG00000250222.1	CTC-338M12.5	5.69	2.24e-08	0.0241	0.35	0.25	Immune response to smallpox vaccine (IL-6);	chr5:3576894	chr5:181191924~181194429:+
THCA	trans	rs7829975	0.714	rs4840362	ENSG00000229857.1	RP11-159H20.3	5.69	2.24e-08	0.0242	0.31	0.25	Mood instability;	chr8:8812572	chr9:76992099~76993108:+
THCA	trans	rs4646450	0.891	rs883403	ENSG00000228834.1	RP11-249L21.4	5.69	2.24e-08	0.0242	0.4	0.25	Blood metabolite levels;	chr7:99450355	chr6:108907615~108907873:-
THCA	trans	rs4646450	0.891	rs2280600	ENSG00000228834.1	RP11-249L21.4	5.69	2.24e-08	0.0242	0.4	0.25	Blood metabolite levels;	chr7:99450809	chr6:108907615~108907873:-
THCA	trans	rs7824557	0.583	rs2263511	ENSG00000256560.1	LINC01486	-5.69	2.24e-08	0.0242	-0.31	-0.25	Retinal vascular caliber;	chr8:11375809	chr12:109354083~109359488:-
THCA	trans	rs10090774	0.93	rs4961293	ENSG00000230756.1	RHOQP3	-5.69	2.24e-08	0.0242	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140802275	chr2:130212870~130213490:-
THCA	trans	rs9982086	0.557	rs2829771	ENSG00000277945.1	RP11-677M24.1	5.69	2.24e-08	0.0242	0.33	0.25	Carboplatin disposition in epthelial ovarian cancer;	chr21:25468785	chr12:65830750~65831050:+
THCA	trans	rs2665103	0.61	rs1972460	ENSG00000235370.6	DNM1P51	-5.69	2.25e-08	0.0243	-0.31	-0.25	Intelligence (multi-trait analysis);	chr15:82238289	chr15:84398316~84411701:-
THCA	trans	rs9858542	0.537	rs34514189	ENSG00000197582.5	GPX1P1	-5.69	2.25e-08	0.0243	-0.47	-0.25	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49335612	chrX:13378735~13379340:-
THCA	trans	rs4269515	0.764	rs6992057	ENSG00000219891.2	ZSCAN12P1	5.69	2.25e-08	0.0243	0.33	0.25	Dental caries;	chr8:106883026	chr6:28091154~28093664:+
THCA	trans	rs4269515	0.764	rs28579317	ENSG00000219891.2	ZSCAN12P1	5.69	2.25e-08	0.0243	0.33	0.25	Dental caries;	chr8:106886382	chr6:28091154~28093664:+
THCA	trans	rs4269515	0.764	rs61449471	ENSG00000219891.2	ZSCAN12P1	5.69	2.25e-08	0.0243	0.33	0.25	Dental caries;	chr8:106889260	chr6:28091154~28093664:+
THCA	trans	rs1572299	0.64	rs7040518	ENSG00000273669.1	RP11-405M12.4	-5.69	2.26e-08	0.0243	-0.32	-0.25	Schizophrenia;	chr9:118565948	chr18:75073543~75074205:+
THCA	trans	rs11764116	0.54	rs73080842	ENSG00000235649.2	MXRA5Y	-5.69	2.26e-08	0.0244	-0.4	-0.25	Ulcerative colitis;	chr7:18786695	chrY:11957208~11987386:+
THCA	trans	rs853679	0.546	rs13195291	ENSG00000248290.1	TNXA	-5.69	2.27e-08	0.0244	-0.54	-0.25	Depression;	chr6:28201463	chr6:32008614~32012472:-
THCA	trans	rs853679	0.556	rs13197633	ENSG00000248290.1	TNXA	-5.69	2.27e-08	0.0244	-0.54	-0.25	Depression;	chr6:28206979	chr6:32008614~32012472:-
THCA	trans	rs7824557	0.767	rs2164272	ENSG00000229857.1	RP11-159H20.3	-5.69	2.27e-08	0.0244	-0.32	-0.25	Retinal vascular caliber;	chr8:11304987	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.701	rs2060465	ENSG00000229857.1	RP11-159H20.3	-5.69	2.27e-08	0.0244	-0.32	-0.25	Retinal vascular caliber;	chr8:11305100	chr9:76992099~76993108:+
THCA	trans	rs9982086	0.557	rs2829776	ENSG00000277945.1	RP11-677M24.1	5.69	2.27e-08	0.0245	0.33	0.25	Carboplatin disposition in epthelial ovarian cancer;	chr21:25489747	chr12:65830750~65831050:+
THCA	trans	rs7806994	1	rs7806994	ENSG00000186940.6	CHCHD2P9	5.69	2.28e-08	0.0245	0.46	0.25	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr9:79391304~79391759:+
THCA	trans	rs1964356	0.967	rs2953802	ENSG00000256560.1	LINC01486	5.69	2.28e-08	0.0246	0.3	0.25	Mean corpuscular volume;	chr8:8994371	chr12:109354083~109359488:-
THCA	trans	rs853679	0.607	rs35902873	ENSG00000248290.1	TNXA	-5.69	2.28e-08	0.0246	-0.54	-0.25	Depression;	chr6:28091171	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13197574	ENSG00000248290.1	TNXA	-5.69	2.28e-08	0.0246	-0.54	-0.25	Depression;	chr6:28092461	chr6:32008614~32012472:-
THCA	trans	rs7595950	0.534	rs1465487	ENSG00000234183.1	AC004854.4	-5.69	2.28e-08	0.0246	-0.26	-0.25	Major depression and alcohol dependence;	chr2:59996923	chr7:44848416~44849568:+
THCA	trans	rs7829975	0.742	rs1533059	ENSG00000256560.1	LINC01486	-5.69	2.28e-08	0.0246	-0.3	-0.25	Mood instability;	chr8:8827443	chr12:109354083~109359488:-
THCA	trans	rs7769051	0.711	rs6569847	ENSG00000227615.1	RP11-864N7.2	5.69	2.28e-08	0.0246	0.44	0.25	Type 2 diabetes nephropathy;	chr6:132762048	chr11:74745716~74746114:-
THCA	trans	rs3764796	0.618	rs17124212	ENSG00000250030.2	RP11-584P21.4	5.69	2.29e-08	0.0246	0.45	0.25	Calcium levels;	chr8:17208425	chr4:67446267~67446574:+
THCA	trans	rs7824557	0.628	rs3174048	ENSG00000253893.2	FAM85B	-5.69	2.29e-08	0.0247	-0.33	-0.25	Retinal vascular caliber;	chr8:11327428	chr8:8167819~8226614:-
THCA	trans	rs971891	1	rs971891	ENSG00000224431.1	AC063976.7	5.69	2.29e-08	0.0247	0.23	0.25	Itch intensity from mosquito bite;Itch intensity from mosquito bite adjusted by bite size;	chr5:130237973	chr5:132199456~132203487:+
THCA	trans	rs8141529	0.664	rs5762861	ENSG00000277545.1	RP11-73M11.3	5.69	2.29e-08	0.0247	0.34	0.25	Lymphocyte counts;	chr22:28854517	chr13:112811566~112812158:+
THCA	trans	rs9467711	0.659	rs13220261	ENSG00000219392.1	RP1-265C24.5	-5.69	2.3e-08	0.0247	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26498957	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs35555795	ENSG00000219392.1	RP1-265C24.5	-5.69	2.3e-08	0.0247	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26509154	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs35433030	ENSG00000219392.1	RP1-265C24.5	-5.69	2.3e-08	0.0247	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26529662	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs66941101	ENSG00000219392.1	RP1-265C24.5	-5.69	2.3e-08	0.0247	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26530148	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs34246779	ENSG00000219392.1	RP1-265C24.5	-5.69	2.3e-08	0.0247	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26548984	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs72845428	ENSG00000219392.1	RP1-265C24.5	-5.69	2.3e-08	0.0247	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26549916	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs35277236	ENSG00000219392.1	RP1-265C24.5	-5.69	2.3e-08	0.0247	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26562041	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs72844462	ENSG00000219392.1	RP1-265C24.5	-5.69	2.3e-08	0.0247	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26563636	chr6:28115628~28116551:+
THCA	trans	rs7212590	0.581	rs8081710	ENSG00000187870.7	RNFT1P3	5.69	2.3e-08	0.0247	0.51	0.25	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59760679	chr17:20743333~20754501:-
THCA	trans	rs7189233	0.955	rs72801817	ENSG00000277863.1	RP11-282A11.4	5.69	2.3e-08	0.0248	0.34	0.25	Intelligence (multi-trait analysis);	chr16:53440656	chr13:106903150~106904099:-
THCA	trans	rs950169	0.959	rs12902070	ENSG00000259295.5	CSPG4P12	5.68	2.3e-08	0.0248	0.4	0.25	Schizophrenia;	chr15:84124806	chr15:85191438~85213905:+
THCA	trans	rs4879677	1	rs10968050	ENSG00000269560.1	CTD-2192J16.21	-5.68	2.3e-08	0.0248	-0.32	-0.25	Gut microbiome composition (summer and winter);	chr9:27677633	chr19:12529768~12532973:-
THCA	trans	rs4879677	1	rs10812638	ENSG00000269560.1	CTD-2192J16.21	-5.68	2.3e-08	0.0248	-0.32	-0.25	Gut microbiome composition (summer and winter);	chr9:27668808	chr19:12529768~12532973:-
THCA	trans	rs9467711	0.79	rs72843784	ENSG00000253570.1	RNF5P1	5.68	2.3e-08	0.0248	0.79	0.25	Autism spectrum disorder or schizophrenia;	chr6:26498530	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.79	rs45527431	ENSG00000253570.1	RNF5P1	5.68	2.3e-08	0.0248	0.79	0.25	Autism spectrum disorder or schizophrenia;	chr6:26599281	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.79	rs66488313	ENSG00000253570.1	RNF5P1	5.68	2.3e-08	0.0248	0.79	0.25	Autism spectrum disorder or schizophrenia;	chr6:26631340	chr8:38600661~38601200:-
THCA	trans	rs11992162	0.967	rs7836456	ENSG00000254153.1	CTA-398F10.2	-5.68	2.3e-08	0.0248	-0.29	-0.25	Monocyte count;	chr8:11971666	chr8:8456909~8461337:-
THCA	trans	rs2950393	0.929	rs2290893	ENSG00000257210.1	NACAP3	5.68	2.3e-08	0.0248	0.3	0.25	Platelet distribution width;	chr12:56684836	chr12:93124063~93124543:-
THCA	trans	rs12210905	1	rs1102557	ENSG00000242375.1	RP11-498P14.3	5.68	2.31e-08	0.0249	0.68	0.25	Hip circumference adjusted for BMI;	chr6:27182015	chr9:97195351~97197687:-
THCA	trans	rs4879677	0.959	rs4878536	ENSG00000269560.1	CTD-2192J16.21	-5.68	2.31e-08	0.0249	-0.33	-0.25	Gut microbiome composition (summer and winter);	chr9:27682259	chr19:12529768~12532973:-
THCA	trans	rs7746199	0.736	rs34965299	ENSG00000204338.7	CYP21A1P	-5.68	2.31e-08	0.0249	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:32005636~32008451:+
THCA	trans	rs35491132	1	rs35491132	ENSG00000204338.7	CYP21A1P	-5.68	2.31e-08	0.0249	-0.56	-0.25	Urinary tract infection frequency;	chr6:27559449	chr6:32005636~32008451:+
THCA	trans	rs9329221	0.636	rs6999466	ENSG00000253893.2	FAM85B	-5.68	2.32e-08	0.0249	-0.33	-0.25	Neuroticism;	chr8:10408202	chr8:8167819~8226614:-
THCA	trans	rs2806731	0.577	rs17088493	ENSG00000234192.1	RP11-57C13.5	-5.68	2.32e-08	0.0249	-0.32	-0.25	Obesity-related traits;	chr13:53688229	chr10:87642607~87642954:+
THCA	trans	rs12439619	0.846	rs62013464	ENSG00000235370.6	DNM1P51	-5.68	2.32e-08	0.0249	-0.41	-0.25	Intelligence (multi-trait analysis);	chr15:82288250	chr15:84398316~84411701:-
THCA	trans	rs7819412	0.744	rs4841503	ENSG00000254153.1	CTA-398F10.2	5.68	2.32e-08	0.0249	0.28	0.25	Triglycerides;	chr8:11166817	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.737	rs10481445	ENSG00000254153.1	CTA-398F10.2	5.68	2.32e-08	0.0249	0.28	0.25	Retinal vascular caliber;	chr8:11251760	chr8:8456909~8461337:-
THCA	trans	rs12682352	0.535	rs12677550	ENSG00000256560.1	LINC01486	-5.68	2.32e-08	0.025	-0.31	-0.25	Neuroticism;	chr8:8786812	chr12:109354083~109359488:-
THCA	trans	rs11992162	0.56	rs13256329	ENSG00000229857.1	RP11-159H20.3	5.68	2.32e-08	0.025	0.33	0.25	Monocyte count;	chr8:11924705	chr9:76992099~76993108:+
THCA	trans	rs10435719	0.638	rs67146188	ENSG00000229857.1	RP11-159H20.3	5.68	2.32e-08	0.025	0.33	0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr9:76992099~76993108:+
THCA	trans	rs16957091	0.821	rs58938096	ENSG00000259781.1	RP11-673C5.1	-5.68	2.32e-08	0.025	-0.34	-0.25	MGMT methylation in smokers;	chr15:42713606	chr15:71164770~71165415:-
THCA	trans	rs7769051	0.711	rs9493436	ENSG00000227615.1	RP11-864N7.2	5.68	2.32e-08	0.025	0.44	0.25	Type 2 diabetes nephropathy;	chr6:132767136	chr11:74745716~74746114:-
THCA	trans	rs7824557	0.583	rs2263512	ENSG00000256560.1	LINC01486	-5.68	2.33e-08	0.025	-0.31	-0.25	Retinal vascular caliber;	chr8:11375910	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.583	rs6601585	ENSG00000256560.1	LINC01486	-5.68	2.33e-08	0.025	-0.31	-0.25	Retinal vascular caliber;	chr8:11376150	chr12:109354083~109359488:-
THCA	trans	rs9470794	1	rs35142414	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38023592	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11753388	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38029574	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11755894	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38029606	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11759205	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38034789	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73417996	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38035521	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73417997	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38035709	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs56413211	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38037161	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73419907	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38042865	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73419916	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38046328	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73419919	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38046409	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs75740926	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38052468	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs55825770	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38053903	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs55836194	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38062355	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs55707043	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38064215	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs55990078	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38064850	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.748	rs73419938	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38065757	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.915	rs73419941	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38065771	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.831	rs73419944	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38066051	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73419945	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38069533	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs75484621	ENSG00000279138.1	KB-1742H10.3	5.68	2.33e-08	0.025	0.57	0.25	Type 2 diabetes;	chr6:38069593	chr8:104478539~104480783:-
THCA	trans	rs7617773	0.78	rs13090538	ENSG00000235912.1	RP1-159A19.3	-5.68	2.33e-08	0.0251	-0.31	-0.25	Coronary artery disease;	chr3:48329279	chr1:27649419~27649610:+
THCA	trans	rs2338224	1	rs2338224	ENSG00000251314.2	CTD-2337A12.1	-5.68	2.34e-08	0.0251	-0.46	-0.25	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr5:72432861	chr5:95962001~96631085:+
THCA	trans	rs453301	0.631	rs17700611	ENSG00000229857.1	RP11-159H20.3	5.68	2.34e-08	0.0251	0.34	0.25	Joint mobility (Beighton score);	chr8:8936144	chr9:76992099~76993108:+
THCA	trans	rs7113874	0.589	rs10840065	ENSG00000266891.1	RP11-692N5.2	5.68	2.34e-08	0.0252	0.33	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8505096	chr18:9734882~9735602:-
THCA	trans	rs7429990	0.864	rs4274776	ENSG00000235912.1	RP1-159A19.3	-5.68	2.34e-08	0.0252	-0.31	-0.25	Educational attainment (years of education);	chr3:47605868	chr1:27649419~27649610:+
THCA	trans	rs453301	0.686	rs10217044	ENSG00000256560.1	LINC01486	-5.68	2.35e-08	0.0252	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9037242	chr12:109354083~109359488:-
THCA	trans	rs2439831	0.867	rs2278860	ENSG00000180867.10	PDIA3P1	5.68	2.35e-08	0.0252	0.28	0.25	Lung cancer in ever smokers;	chr15:43366848	chr1:147178113~147179622:+
THCA	trans	rs950169	0.96	rs35159785	ENSG00000259295.5	CSPG4P12	5.68	2.35e-08	0.0253	0.4	0.25	Schizophrenia;	chr15:84135262	chr15:85191438~85213905:+
THCA	trans	rs7945705	0.846	rs4929911	ENSG00000266891.1	RP11-692N5.2	-5.68	2.36e-08	0.0253	-0.32	-0.25	Hemoglobin concentration;	chr11:8794948	chr18:9734882~9735602:-
THCA	trans	rs10090774	1	rs4291312	ENSG00000230756.1	RHOQP3	-5.68	2.36e-08	0.0253	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140816039	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs4445273	ENSG00000230756.1	RHOQP3	-5.68	2.36e-08	0.0253	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140740574	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs4246123	ENSG00000230756.1	RHOQP3	-5.68	2.36e-08	0.0253	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140765069	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs7826800	ENSG00000230756.1	RHOQP3	-5.68	2.36e-08	0.0253	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140828313	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10094003	ENSG00000230756.1	RHOQP3	5.68	2.36e-08	0.0253	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140847055	chr2:130212870~130213490:-
THCA	trans	rs950169	1	rs62026530	ENSG00000259295.5	CSPG4P12	5.68	2.36e-08	0.0254	0.39	0.25	Schizophrenia;	chr15:84107088	chr15:85191438~85213905:+
THCA	trans	rs889398	0.741	rs2362642	ENSG00000257513.6	NPIPB1P	5.68	2.36e-08	0.0254	0.29	0.25	Body mass index;	chr16:69897555	chr18:11619509~11639699:-
THCA	trans	rs1908814	0.503	rs34657250	ENSG00000254153.1	CTA-398F10.2	5.68	2.36e-08	0.0254	0.3	0.25	Neuroticism;	chr8:11937864	chr8:8456909~8461337:-
THCA	trans	rs3096299	0.746	rs9931120	ENSG00000215030.5	RPL13P12	-5.68	2.37e-08	0.0254	-0.26	-0.25	Multiple myeloma (IgH translocation);	chr16:89434949	chr17:17383377~17384012:-
THCA	trans	rs10774547	0.758	rs11065108	ENSG00000226976.3	COX6A1P2	-5.68	2.37e-08	0.0254	-0.23	-0.25	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy);	chr12:120425681	chr6:37044860~37045189:+
THCA	trans	rs7113874	0.569	rs11041962	ENSG00000266891.1	RP11-692N5.2	5.68	2.37e-08	0.0255	0.33	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8528076	chr18:9734882~9735602:-
THCA	trans	rs1167827	1	rs1167827	ENSG00000106133.16	NSUN5P2	-5.68	2.37e-08	0.0255	-0.23	-0.25	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:72947581~72954790:-
THCA	trans	rs12477438	0.52	rs11123761	ENSG00000276576.1	MRPL30P1	5.68	2.37e-08	0.0255	0.33	0.25	Chronic sinus infection;	chr2:99089440	chr6:57029521~57029988:+
THCA	trans	rs10090774	0.93	rs9886378	ENSG00000230756.1	RHOQP3	5.68	2.37e-08	0.0255	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140910738	chr2:130212870~130213490:-
THCA	trans	rs5758511	0.573	rs2267438	ENSG00000268568.1	AC007228.9	-5.68	2.38e-08	0.0256	-0.3	-0.25	Birth weight;	chr22:41841561	chr19:56672574~56673901:-
THCA	trans	rs2242330	0.862	rs7341003	ENSG00000226982.4	CENPCP1	5.68	2.38e-08	0.0256	0.39	0.25	Parkinson's disease;	chr4:67495866	chr12:89500093~89502670:+
THCA	trans	rs34119086	1	rs34119086	ENSG00000204338.7	CYP21A1P	-5.68	2.38e-08	0.0256	-0.57	-0.25	Breast cancer;	chr6:28594471	chr6:32005636~32008451:+
THCA	trans	rs3764796	0.618	rs34234595	ENSG00000250030.2	RP11-584P21.4	5.68	2.38e-08	0.0256	0.45	0.25	Calcium levels;	chr8:17209720	chr4:67446267~67446574:+
THCA	trans	rs2055729	0.813	rs55999429	ENSG00000253893.2	FAM85B	5.68	2.38e-08	0.0256	0.34	0.25	Multiple myeloma (hyperdiploidy);	chr8:9883675	chr8:8167819~8226614:-
THCA	trans	rs932287	0.505	rs2742536	ENSG00000266891.1	RP11-692N5.2	5.68	2.39e-08	0.0257	0.32	0.25	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr18:9734882~9735602:-
THCA	trans	rs10090774	0.965	rs7839697	ENSG00000230756.1	RHOQP3	-5.68	2.39e-08	0.0257	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140804566	chr2:130212870~130213490:-
THCA	trans	rs546131	0.963	rs539044	ENSG00000225531.1	RP11-196I18.3	5.68	2.4e-08	0.0257	0.33	0.25	Lung disease severity in cystic fibrosis;	chr11:34819995	chr9:107116829~107117557:+
THCA	trans	rs453301	0.686	rs28482034	ENSG00000229857.1	RP11-159H20.3	5.68	2.4e-08	0.0257	0.32	0.25	Joint mobility (Beighton score);	chr8:9012154	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.564	rs13260727	ENSG00000256560.1	LINC01486	5.68	2.4e-08	0.0257	0.31	0.25	Retinal vascular caliber;	chr8:11375351	chr12:109354083~109359488:-
THCA	trans	rs28627593	0.628	rs2081665	ENSG00000274066.1	MIR6514	5.68	2.4e-08	0.0258	0.3	0.25	Pursuit maintenance gain;	chr4:31359167	chr11:62792702~62792771:-
THCA	trans	rs28627593	0.628	rs11946035	ENSG00000274066.1	MIR6514	5.68	2.4e-08	0.0258	0.3	0.25	Pursuit maintenance gain;	chr4:31359363	chr11:62792702~62792771:-
THCA	trans	rs9693857	0.501	rs67985496	ENSG00000253893.2	FAM85B	5.68	2.4e-08	0.0258	0.37	0.25	Systolic blood pressure;	chr8:9405618	chr8:8167819~8226614:-
THCA	trans	rs4295623	0.556	rs10903343	ENSG00000253981.4	ALG1L13P	5.68	2.4e-08	0.0258	0.25	0.25	Morning vs. evening chronotype;	chr8:11838363	chr8:8236003~8244667:-
THCA	trans	rs16976116	0.572	rs28704633	ENSG00000231806.2	PCAT7	5.68	2.41e-08	0.0258	0.39	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55154343	chr9:94555069~94568127:+
THCA	trans	rs7824557	0.707	rs3808518	ENSG00000229857.1	RP11-159H20.3	5.68	2.41e-08	0.0258	0.32	0.25	Retinal vascular caliber;	chr8:11285763	chr9:76992099~76993108:+
THCA	trans	rs263156	0.932	rs263172	ENSG00000276182.1	RP11-872J21.5	-5.68	2.41e-08	0.0259	-0.2	-0.25	Lobe size;Ear morphology;Lobe attachment;	chr6:142548273	chr14:96537170~96537904:+
THCA	trans	rs4646450	0.891	rs7804551	ENSG00000228834.1	RP11-249L21.4	5.68	2.41e-08	0.0259	0.4	0.25	Blood metabolite levels;	chr7:99521487	chr6:108907615~108907873:-
THCA	trans	rs4879677	0.92	rs1826742	ENSG00000269560.1	CTD-2192J16.21	-5.68	2.41e-08	0.0259	-0.32	-0.25	Gut microbiome composition (summer and winter);	chr9:27654052	chr19:12529768~12532973:-
THCA	trans	rs11098499	0.691	rs10028773	ENSG00000253326.2	RP11-261C10.7	-5.68	2.41e-08	0.0259	-0.34	-0.25	Corneal astigmatism;	chr4:119344104	chr1:243054861~243056394:-
THCA	trans	rs10504229	0.679	rs111843870	ENSG00000226986.4	RP11-543B16.2	-5.68	2.42e-08	0.0259	-0.4	-0.25	Developmental language disorder (linguistic errors);	chr8:57214239	chr1:211207239~211207897:+
THCA	trans	rs7829975	0.714	rs11784052	ENSG00000229857.1	RP11-159H20.3	-5.68	2.42e-08	0.0259	-0.31	-0.25	Mood instability;	chr8:8814452	chr9:76992099~76993108:+
THCA	trans	rs7692395	0.556	rs17327535	ENSG00000276188.1	RP11-173P15.10	-5.68	2.42e-08	0.026	-0.38	-0.25	Incident myocardial infarction;	chr4:182689328	chr12:120709112~120709523:+
THCA	trans	rs11992162	0.613	rs6998690	ENSG00000254153.1	CTA-398F10.2	-5.68	2.42e-08	0.026	-0.29	-0.25	Monocyte count;	chr8:11941287	chr8:8456909~8461337:-
THCA	trans	rs901683	0.85	rs113722818	ENSG00000228981.3	RP11-364L4.1	5.68	2.42e-08	0.026	0.59	0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45597760	chr4:143349275~143350117:-
THCA	trans	rs901683	0.85	rs112184470	ENSG00000228981.3	RP11-364L4.1	5.68	2.42e-08	0.026	0.59	0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45597854	chr4:143349275~143350117:-
THCA	trans	rs9329221	0.525	rs4394398	ENSG00000229857.1	RP11-159H20.3	5.67	2.43e-08	0.026	0.35	0.25	Neuroticism;	chr8:10226884	chr9:76992099~76993108:+
THCA	trans	rs73384572	1	rs2123421	ENSG00000247595.2	SPTY2D1-AS1	-5.67	2.44e-08	0.0261	-0.49	-0.25	Neuroticism;	chr10:129133180	chr11:18599787~18610255:+
THCA	trans	rs9467711	0.72	rs7749823	ENSG00000280107.1	AL022393.9	-5.67	2.44e-08	0.0261	-0.38	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26157851	chr6:28170845~28172521:+
THCA	trans	rs9470794	1	rs35248010	ENSG00000279138.1	KB-1742H10.3	5.67	2.44e-08	0.0262	0.57	0.25	Type 2 diabetes;	chr6:38026808	chr8:104478539~104480783:-
THCA	trans	rs853679	0.546	rs34676049	ENSG00000204338.7	CYP21A1P	-5.67	2.45e-08	0.0262	-0.59	-0.25	Depression;	chr6:28485841	chr6:32005636~32008451:+
THCA	trans	rs7769051	1	rs9493454	ENSG00000213303.3	CTC-398G3.2	-5.67	2.45e-08	0.0263	-0.45	-0.25	Type 2 diabetes nephropathy;	chr6:132823490	chr19:11523436~11523831:+
THCA	trans	rs2645424	0.635	rs62495697	ENSG00000260438.1	RP11-405F3.2	5.67	2.45e-08	0.0263	0.36	0.25	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11851498	chr16:57713782~57714957:+
THCA	trans	rs11098499	0.644	rs3806808	ENSG00000253326.2	RP11-261C10.7	5.67	2.45e-08	0.0263	0.34	0.25	Corneal astigmatism;	chr4:119629930	chr1:243054861~243056394:-
THCA	trans	rs10804591	0.606	rs2625998	ENSG00000228271.1	RP11-513G11.2	5.67	2.46e-08	0.0263	0.35	0.25	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;	chr3:129584901	chr3:194276682~194287368:+
THCA	trans	rs2941509	1	rs9900541	ENSG00000263011.1	RP11-473M20.11	-5.67	2.46e-08	0.0263	-0.53	-0.25	Systemic lupus erythematosus;	chr17:39839818	chr16:3106764~3109576:+
THCA	trans	rs2941509	1	rs67600807	ENSG00000263011.1	RP11-473M20.11	-5.67	2.46e-08	0.0263	-0.53	-0.25	Systemic lupus erythematosus;	chr17:39845306	chr16:3106764~3109576:+
THCA	trans	rs4879656	1	rs4879656	ENSG00000215007.3	DNAJA1P3	5.67	2.46e-08	0.0264	0.31	0.25	Menopause (age at onset);	chr9:33012384	chrX:107351650~107352843:-
THCA	trans	rs7773004	0.601	rs13210340	ENSG00000253570.1	RNF5P1	5.67	2.46e-08	0.0264	0.75	0.25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;	chr6:26326086	chr8:38600661~38601200:-
THCA	trans	rs11668609	1	rs919813	ENSG00000261770.1	CTC-459F4.1	5.67	2.47e-08	0.0265	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24163431	chr19:27757184~27760849:-
THCA	trans	rs4948102	0.597	rs12669623	ENSG00000215006.4	CHCHD2P2	-5.67	2.47e-08	0.0265	-0.36	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr5:69333929~69334249:+
THCA	trans	rs801193	0.591	rs9986881	ENSG00000213640.3	EEF1DP4	-5.67	2.48e-08	0.0265	-0.3	-0.25	Aortic root size;	chr7:66708053	chr7:64862999~64864370:+
THCA	trans	rs853679	0.556	rs13200214	ENSG00000248290.1	TNXA	-5.67	2.48e-08	0.0266	-0.54	-0.25	Depression;	chr6:28049472	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs71559070	ENSG00000248290.1	TNXA	-5.67	2.48e-08	0.0266	-0.54	-0.25	Depression;	chr6:28071151	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34166054	ENSG00000248290.1	TNXA	-5.67	2.48e-08	0.0266	-0.54	-0.25	Depression;	chr6:28098023	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs34662244	ENSG00000248290.1	TNXA	-5.67	2.48e-08	0.0266	-0.54	-0.25	Depression;	chr6:28106103	chr6:32008614~32012472:-
THCA	trans	rs35952432	1	rs35952432	ENSG00000248290.1	TNXA	-5.67	2.48e-08	0.0266	-0.54	-0.25	Lung cancer;	chr6:28107123	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs13203816	ENSG00000248290.1	TNXA	-5.67	2.48e-08	0.0266	-0.54	-0.25	Depression;	chr6:28111820	chr6:32008614~32012472:-
THCA	trans	rs853679	0.556	rs34588114	ENSG00000248290.1	TNXA	-5.67	2.48e-08	0.0266	-0.54	-0.25	Depression;	chr6:28112850	chr6:32008614~32012472:-
THCA	trans	rs853679	0.546	rs34371502	ENSG00000248290.1	TNXA	-5.67	2.48e-08	0.0266	-0.54	-0.25	Depression;	chr6:28113980	chr6:32008614~32012472:-
THCA	trans	rs7769051	1	rs9399041	ENSG00000213303.3	CTC-398G3.2	5.67	2.48e-08	0.0266	0.48	0.25	Type 2 diabetes nephropathy;	chr6:132775094	chr19:11523436~11523831:+
THCA	trans	rs7769051	1	rs9493438	ENSG00000213303.3	CTC-398G3.2	5.67	2.48e-08	0.0266	0.48	0.25	Type 2 diabetes nephropathy;	chr6:132777210	chr19:11523436~11523831:+
THCA	trans	rs875971	0.545	rs316316	ENSG00000213640.3	EEF1DP4	5.67	2.48e-08	0.0266	0.34	0.25	Aortic root size;	chr7:66149270	chr7:64862999~64864370:+
THCA	trans	rs7746199	0.673	rs35501037	ENSG00000253570.1	RNF5P1	5.67	2.49e-08	0.0266	0.7	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr8:38600661~38601200:-
THCA	trans	rs9329221	0.572	rs4841295	ENSG00000229857.1	RP11-159H20.3	-5.67	2.49e-08	0.0266	-0.32	-0.25	Neuroticism;	chr8:10247605	chr9:76992099~76993108:+
THCA	trans	rs9467711	0.79	rs13220495	ENSG00000228022.4	HCG20	-5.67	2.49e-08	0.0266	-0.66	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr6:30766825~30792250:+
THCA	trans	rs7192380	0.729	rs11648335	ENSG00000257513.6	NPIPB1P	5.67	2.49e-08	0.0266	0.29	0.25	Sjögren's syndrome;	chr16:69563414	chr18:11619509~11639699:-
THCA	trans	rs6782422	0.557	rs6765485	ENSG00000255165.1	CTD-2609K8.3	5.67	2.49e-08	0.0267	0.36	0.25	Parental extreme longevity (95 years and older);	chr3:174195188	chr11:44071462~44072403:+
THCA	trans	rs7192380	0.964	rs55780735	ENSG00000257513.6	NPIPB1P	-5.67	2.49e-08	0.0267	-0.28	-0.25	Sjögren's syndrome;	chr16:69706471	chr18:11619509~11639699:-
THCA	trans	rs7212590	0.655	rs34687426	ENSG00000187870.7	RNFT1P3	5.67	2.49e-08	0.0267	0.49	0.25	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59920496	chr17:20743333~20754501:-
THCA	trans	rs7829975	0.774	rs1703982	ENSG00000229857.1	RP11-159H20.3	5.67	2.5e-08	0.0267	0.31	0.25	Mood instability;	chr8:8740878	chr9:76992099~76993108:+
THCA	trans	rs8014204	0.901	rs2080087	ENSG00000181227.3	RP4-682C21.2	-5.67	2.51e-08	0.0268	-0.2	-0.25	Caffeine consumption;	chr14:74898359	chr1:75743423~75744776:-
THCA	trans	rs73108077	0.92	rs73108088	ENSG00000279352.1	RP11-411B10.7	5.67	2.51e-08	0.0268	0.56	0.25	Red blood cell density in sickle cell anemia;	chr20:31424444	chr18:14010054~14010917:+
THCA	trans	rs4415084	0.716	rs4596389	ENSG00000231752.4	EMBP1	5.67	2.51e-08	0.0269	0.35	0.25	Breast cancer;	chr5:44836454	chr1:121519112~121571892:+
THCA	trans	rs7212590	0.581	rs8064505	ENSG00000187870.7	RNFT1P3	5.67	2.51e-08	0.0269	0.51	0.25	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59761470	chr17:20743333~20754501:-
THCA	trans	rs9470794	1	rs11753122	ENSG00000279138.1	KB-1742H10.3	5.67	2.51e-08	0.0269	0.57	0.25	Type 2 diabetes;	chr6:38011284	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421483	ENSG00000279138.1	KB-1742H10.3	5.67	2.51e-08	0.0269	0.57	0.25	Type 2 diabetes;	chr6:38012140	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73417963	ENSG00000279138.1	KB-1742H10.3	5.67	2.51e-08	0.0269	0.57	0.25	Type 2 diabetes;	chr6:38013403	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73417971	ENSG00000279138.1	KB-1742H10.3	5.67	2.51e-08	0.0269	0.57	0.25	Type 2 diabetes;	chr6:38018623	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.915	rs73417972	ENSG00000279138.1	KB-1742H10.3	5.67	2.51e-08	0.0269	0.57	0.25	Type 2 diabetes;	chr6:38018654	chr8:104478539~104480783:-
THCA	trans	rs902774	1	rs11831942	ENSG00000255815.3	KRT8P11	-5.67	2.52e-08	0.0269	-0.45	-0.25	Prostate cancer;	chr12:52878329	chr9:99305176~99306611:+
THCA	trans	rs853679	0.607	rs13194781	ENSG00000253570.1	RNF5P1	5.67	2.52e-08	0.0269	0.7	0.25	Depression;	chr6:27847861	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs36116761	ENSG00000253570.1	RNF5P1	5.67	2.52e-08	0.0269	0.7	0.25	Depression;	chr6:27850704	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs34194357	ENSG00000253570.1	RNF5P1	5.67	2.52e-08	0.0269	0.7	0.25	Depression;	chr6:27850757	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13199772	ENSG00000253570.1	RNF5P1	5.67	2.52e-08	0.0269	0.7	0.25	Depression;	chr6:27866307	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs13199906	ENSG00000253570.1	RNF5P1	5.67	2.52e-08	0.0269	0.7	0.25	Depression;	chr6:27866361	chr8:38600661~38601200:-
THCA	trans	rs853679	0.607	rs17763089	ENSG00000253570.1	RNF5P1	5.67	2.52e-08	0.0269	0.7	0.25	Depression;	chr6:27867440	chr8:38600661~38601200:-
THCA	trans	rs853679	0.546	rs17695758	ENSG00000253570.1	RNF5P1	5.67	2.52e-08	0.0269	0.7	0.25	Depression;	chr6:27869405	chr8:38600661~38601200:-
THCA	trans	rs7819412	0.668	rs4841507	ENSG00000256560.1	LINC01486	-5.67	2.52e-08	0.0269	-0.32	-0.25	Triglycerides;	chr8:11188885	chr12:109354083~109359488:-
THCA	trans	rs7945705	0.782	rs3763918	ENSG00000266891.1	RP11-692N5.2	-5.67	2.52e-08	0.0269	-0.32	-0.25	Hemoglobin concentration;	chr11:8798136	chr18:9734882~9735602:-
THCA	trans	rs2985684	0.894	rs2354439	ENSG00000240785.1	RPL36AP21	5.67	2.53e-08	0.027	0.31	0.25	Carotid intima media thickness;	chr14:49552699	chr5:18049550~18049872:+
THCA	trans	rs7121616	0.92	rs7109445	ENSG00000229091.2	HSPA8P8	5.67	2.53e-08	0.027	0.3	0.25	Breast cancer;	chr11:123094779	chr7:10451311~10452526:+
THCA	trans	rs10090774	0.87	rs10093977	ENSG00000230756.1	RHOQP3	5.67	2.53e-08	0.027	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141000585	chr2:130212870~130213490:-
THCA	trans	rs7113874	0.55	rs10840084	ENSG00000266891.1	RP11-692N5.2	-5.67	2.53e-08	0.0271	-0.33	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8587727	chr18:9734882~9735602:-
THCA	trans	rs9584850	0.874	rs3742136	ENSG00000230079.1	STK24P1	5.67	2.54e-08	0.0271	0.3	0.25	Neuroticism;	chr13:98450353	chrX:136295690~136300298:-
THCA	trans	rs7829975	0.774	rs11249893	ENSG00000229857.1	RP11-159H20.3	-5.67	2.54e-08	0.0271	-0.32	-0.25	Mood instability;	chr8:8843341	chr9:76992099~76993108:+
THCA	trans	rs875971	0.545	rs75840613	ENSG00000213640.3	EEF1DP4	-5.67	2.54e-08	0.0271	-0.34	-0.25	Aortic root size;	chr7:66376399	chr7:64862999~64864370:+
THCA	trans	rs9467711	0.79	rs35400317	ENSG00000219392.1	RP1-265C24.5	-5.67	2.54e-08	0.0271	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.79	rs67777156	ENSG00000219392.1	RP1-265C24.5	-5.67	2.54e-08	0.0271	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.722	rs13201782	ENSG00000219392.1	RP1-265C24.5	-5.67	2.54e-08	0.0271	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr6:28115628~28116551:+
THCA	trans	rs7113874	0.589	rs11041944	ENSG00000266891.1	RP11-692N5.2	-5.67	2.54e-08	0.0271	-0.33	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8479449	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.55	rs4929949	ENSG00000266891.1	RP11-692N5.2	-5.67	2.54e-08	0.0272	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8583046	chr18:9734882~9735602:-
THCA	trans	rs3096299	0.685	rs4785675	ENSG00000215030.5	RPL13P12	-5.67	2.55e-08	0.0272	-0.26	-0.25	Multiple myeloma (IgH translocation);	chr16:89473566	chr17:17383377~17384012:-
THCA	trans	rs7819412	0.561	rs2001328	ENSG00000254153.1	CTA-398F10.2	5.67	2.55e-08	0.0272	0.29	0.25	Triglycerides;	chr8:11129689	chr8:8456909~8461337:-
THCA	trans	rs2243480	0.901	rs2900904	ENSG00000232546.1	RP11-458F8.1	-5.67	2.55e-08	0.0273	-0.33	-0.25	Diabetic kidney disease;	chr7:65739282	chr7:66848496~66858136:+
THCA	trans	rs2243480	1	rs6460260	ENSG00000232546.1	RP11-458F8.1	5.67	2.55e-08	0.0273	0.33	0.25	Diabetic kidney disease;	chr7:65750468	chr7:66848496~66858136:+
THCA	trans	rs2243480	1	rs6460261	ENSG00000232546.1	RP11-458F8.1	5.67	2.55e-08	0.0273	0.33	0.25	Diabetic kidney disease;	chr7:65750593	chr7:66848496~66858136:+
THCA	trans	rs853679	0.546	rs483143	ENSG00000228022.4	HCG20	-5.67	2.56e-08	0.0273	-0.49	-0.25	Depression;	chr6:27878966	chr6:30766825~30792250:+
THCA	trans	rs10885122	0.85	rs4548554	ENSG00000225338.1	RP11-384C4.3	5.67	2.56e-08	0.0273	0.41	0.25	Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;Fasting blood glucose;	chr10:111269619	chr1:212309051~212309518:-
THCA	trans	rs7819412	0.521	rs4451268	ENSG00000229857.1	RP11-159H20.3	5.67	2.56e-08	0.0273	0.34	0.25	Triglycerides;	chr8:11177350	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.688	rs67274820	ENSG00000231752.4	EMBP1	5.67	2.56e-08	0.0273	0.35	0.25	Breast cancer;	chr5:44782193	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs16901963	ENSG00000231752.4	EMBP1	5.67	2.56e-08	0.0273	0.35	0.25	Breast cancer;	chr5:44783000	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs16901965	ENSG00000231752.4	EMBP1	5.67	2.56e-08	0.0273	0.35	0.25	Breast cancer;	chr5:44783256	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs6875933	ENSG00000231752.4	EMBP1	5.67	2.56e-08	0.0273	0.35	0.25	Breast cancer;	chr5:44786594	chr1:121519112~121571892:+
THCA	trans	rs853679	0.546	rs493161	ENSG00000228022.4	HCG20	-5.67	2.56e-08	0.0273	-0.5	-0.25	Depression;	chr6:27882936	chr6:30766825~30792250:+
THCA	trans	rs7746199	0.736	rs34064842	ENSG00000253570.1	RNF5P1	5.66	2.57e-08	0.0274	0.7	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr8:38600661~38601200:-
THCA	trans	rs7824557	0.593	rs11774673	ENSG00000253893.2	FAM85B	-5.66	2.57e-08	0.0274	-0.33	-0.25	Retinal vascular caliber;	chr8:11334028	chr8:8167819~8226614:-
THCA	trans	rs1707322	1	rs12077974	ENSG00000255397.1	AC022182.2	-5.66	2.58e-08	0.0275	-0.36	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr8:60937705~60939871:-
THCA	trans	rs356220	0.606	rs356175	ENSG00000245479.2	LINC01585	-5.66	2.58e-08	0.0275	-0.31	-0.25	Parkinson's disease;	chr4:89709663	chr15:90660234~90664967:+
THCA	trans	rs356220	0.642	rs356174	ENSG00000245479.2	LINC01585	-5.66	2.58e-08	0.0275	-0.31	-0.25	Parkinson's disease;	chr4:89709750	chr15:90660234~90664967:+
THCA	trans	rs11668609	0.748	rs8112938	ENSG00000261770.1	CTC-459F4.1	5.66	2.58e-08	0.0275	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24169654	chr19:27757184~27760849:-
THCA	trans	rs7113874	0.524	rs10769918	ENSG00000266891.1	RP11-692N5.2	-5.66	2.58e-08	0.0275	-0.33	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8588163	chr18:9734882~9735602:-
THCA	trans	rs34816374	1	rs34816374	ENSG00000228022.4	HCG20	-5.66	2.59e-08	0.0276	-0.61	-0.25	Lung cancer in ever smokers;	chr6:26981893	chr6:30766825~30792250:+
THCA	trans	rs1962073	0.667	rs4521760	ENSG00000253893.2	FAM85B	5.66	2.6e-08	0.0277	0.33	0.25	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10416678	chr8:8167819~8226614:-
THCA	trans	rs1475911	0.708	rs56109792	ENSG00000229759.1	MRPS18AP1	-5.66	2.6e-08	0.0277	-0.33	-0.25	IgG glycosylation;	chr21:42099950	chr3:48256350~48256938:-
THCA	trans	rs9650657	0.501	rs3021500	ENSG00000254153.1	CTA-398F10.2	5.66	2.6e-08	0.0277	0.28	0.25	Neuroticism;	chr8:11166488	chr8:8456909~8461337:-
THCA	trans	rs12546962	0.639	rs56731460	ENSG00000253893.2	FAM85B	-5.66	2.6e-08	0.0277	-0.37	-0.25	Body mass index;	chr8:9337160	chr8:8167819~8226614:-
THCA	trans	rs12477438	0.52	rs4851187	ENSG00000276576.1	MRPL30P1	-5.66	2.62e-08	0.0279	-0.32	-0.25	Chronic sinus infection;	chr2:99129397	chr6:57029521~57029988:+
THCA	trans	rs7903456	0.648	rs7069764	ENSG00000232706.3	NUTM2HP	5.66	2.62e-08	0.0279	0.37	0.25	Gout;Renal underexcretion gout;	chr10:87057507	chr10:50676743~50686326:+
THCA	trans	rs7945705	0.875	rs11042059	ENSG00000266891.1	RP11-692N5.2	-5.66	2.63e-08	0.0279	-0.32	-0.25	Hemoglobin concentration;	chr11:8773533	chr18:9734882~9735602:-
THCA	trans	rs7694207	0.66	rs9307193	ENSG00000215481.7	BCRP3	5.66	2.63e-08	0.028	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96983147	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.66	rs9307194	ENSG00000215481.7	BCRP3	5.66	2.63e-08	0.028	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96983172	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.66	rs9307196	ENSG00000215481.7	BCRP3	5.66	2.63e-08	0.028	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96983299	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.66	rs9307197	ENSG00000215481.7	BCRP3	5.66	2.63e-08	0.028	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96983308	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.66	rs9307198	ENSG00000215481.7	BCRP3	5.66	2.63e-08	0.028	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96983353	chr22:24632915~24653356:+
THCA	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	5.66	2.63e-08	0.028	0.36	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
THCA	trans	rs11992162	0.597	rs7011924	ENSG00000229857.1	RP11-159H20.3	5.66	2.63e-08	0.028	0.33	0.25	Monocyte count;	chr8:11923084	chr9:76992099~76993108:+
THCA	trans	rs16912285	0.748	rs7952223	ENSG00000215190.7	LINC00680	5.66	2.63e-08	0.028	0.36	0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr11:24234897	chr6:57946074~57961501:-
THCA	trans	rs656319	0.647	rs13264668	ENSG00000253893.2	FAM85B	5.66	2.64e-08	0.028	0.34	0.25	Myopia (pathological);	chr8:10027367	chr8:8167819~8226614:-
THCA	trans	rs2349775	0.924	rs765457	ENSG00000253177.1	RP11-100L22.1	5.66	2.64e-08	0.028	0.24	0.25	Neuroticism;	chr7:8645348	chr8:92668836~92679594:+
THCA	trans	rs2349775	0.924	rs11973932	ENSG00000253177.1	RP11-100L22.1	5.66	2.64e-08	0.028	0.24	0.25	Neuroticism;	chr7:8645991	chr8:92668836~92679594:+
THCA	trans	rs2349775	0.813	rs11978224	ENSG00000253177.1	RP11-100L22.1	5.66	2.64e-08	0.028	0.24	0.25	Neuroticism;	chr7:8646423	chr8:92668836~92679594:+
THCA	trans	rs2048656	0.524	rs13263409	ENSG00000253893.2	FAM85B	5.66	2.64e-08	0.0281	0.33	0.25	Schizophrenia;	chr8:9678746	chr8:8167819~8226614:-
THCA	trans	rs10090774	0.965	rs11786709	ENSG00000230756.1	RHOQP3	5.66	2.64e-08	0.0281	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140991849	chr2:130212870~130213490:-
THCA	trans	rs9650657	0.537	rs7016385	ENSG00000256560.1	LINC01486	5.66	2.64e-08	0.0281	0.3	0.25	Neuroticism;	chr8:10921962	chr12:109354083~109359488:-
THCA	trans	rs1232027	0.666	rs13161245	ENSG00000188985.6	DHFRP1	-5.66	2.64e-08	0.0281	-0.33	-0.25	Huntington's disease progression;	chr5:80648914	chr18:26170726~26171284:-
THCA	trans	rs3008870	0.585	rs2815382	ENSG00000227992.1	AC108463.2	5.66	2.64e-08	0.0281	0.32	0.25	Lymphocyte percentage of white cells;	chr1:67049545	chr2:111203964~111206215:-
THCA	trans	rs3008870	0.628	rs2755257	ENSG00000227992.1	AC108463.2	5.66	2.64e-08	0.0281	0.32	0.25	Lymphocyte percentage of white cells;	chr1:67049626	chr2:111203964~111206215:-
THCA	trans	rs453301	0.686	rs28665409	ENSG00000229857.1	RP11-159H20.3	5.66	2.65e-08	0.0282	0.32	0.25	Joint mobility (Beighton score);	chr8:9011767	chr9:76992099~76993108:+
THCA	trans	rs4929949	0.585	rs11041900	ENSG00000266891.1	RP11-692N5.2	5.66	2.65e-08	0.0282	0.33	0.25	Body mass index;	chr11:8382669	chr18:9734882~9735602:-
THCA	trans	rs2985684	0.894	rs7152110	ENSG00000240785.1	RPL36AP21	5.66	2.65e-08	0.0282	0.31	0.25	Carotid intima media thickness;	chr14:49551500	chr5:18049550~18049872:+
THCA	trans	rs9650657	0.623	rs6601514	ENSG00000253893.2	FAM85B	5.66	2.65e-08	0.0282	0.32	0.25	Neuroticism;	chr8:10743771	chr8:8167819~8226614:-
THCA	trans	rs3096299	0.566	rs4129126	ENSG00000215030.5	RPL13P12	5.66	2.66e-08	0.0282	0.29	0.25	Multiple myeloma (IgH translocation);	chr16:89495067	chr17:17383377~17384012:-
THCA	trans	rs7824557	0.736	rs35392635	ENSG00000229857.1	RP11-159H20.3	-5.66	2.66e-08	0.0283	-0.32	-0.25	Retinal vascular caliber;	chr8:11306840	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.767	rs11775635	ENSG00000229857.1	RP11-159H20.3	-5.66	2.66e-08	0.0283	-0.32	-0.25	Retinal vascular caliber;	chr8:11307356	chr9:76992099~76993108:+
THCA	trans	rs7824557	0.767	rs28507159	ENSG00000229857.1	RP11-159H20.3	-5.66	2.66e-08	0.0283	-0.32	-0.25	Retinal vascular caliber;	chr8:11308567	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.566	rs17051356	ENSG00000253326.2	RP11-261C10.7	5.66	2.67e-08	0.0283	0.36	0.25	Corneal astigmatism;	chr4:119664153	chr1:243054861~243056394:-
THCA	trans	rs45509595	0.841	rs9368531	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.49	-0.25	Breast cancer;	chr6:27814094	chr6:30766825~30792250:+
THCA	trans	rs45509595	0.749	rs401763	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.49	-0.25	Breast cancer;	chr6:27814750	chr6:30766825~30792250:+
THCA	trans	rs45509595	0.659	rs390764	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.49	-0.25	Breast cancer;	chr6:27814757	chr6:30766825~30792250:+
THCA	trans	rs45509595	0.841	rs401754	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.49	-0.25	Breast cancer;	chr6:27814760	chr6:30766825~30792250:+
THCA	trans	rs45509595	0.841	rs2747054	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.49	-0.25	Breast cancer;	chr6:27815581	chr6:30766825~30792250:+
THCA	trans	rs45509595	0.841	rs200501	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.49	-0.25	Breast cancer;	chr6:27821164	chr6:30766825~30792250:+
THCA	trans	rs13191038	1	rs13191038	ENSG00000204338.7	CYP21A1P	-5.66	2.67e-08	0.0284	-0.56	-0.25	Urinary tract infection frequency;	chr6:28515140	chr6:32005636~32008451:+
THCA	trans	rs7769051	0.614	rs62426674	ENSG00000227615.1	RP11-864N7.2	5.66	2.67e-08	0.0284	0.55	0.25	Type 2 diabetes nephropathy;	chr6:132906337	chr11:74745716~74746114:-
THCA	trans	rs9368481	0.729	rs9379950	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.32	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:30766825~30792250:+
THCA	trans	rs9368481	1	rs9368481	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.32	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:30766825~30792250:+
THCA	trans	rs9368481	0.554	rs2754603	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.32	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:30766825~30792250:+
THCA	trans	rs9368481	0.761	rs9357028	ENSG00000228022.4	HCG20	-5.66	2.67e-08	0.0284	-0.32	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:30766825~30792250:+
THCA	trans	rs453301	0.686	rs17702602	ENSG00000256560.1	LINC01486	-5.66	2.68e-08	0.0284	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9051086	chr12:109354083~109359488:-
THCA	trans	rs9650657	0.711	rs35091929	ENSG00000229857.1	RP11-159H20.3	5.66	2.68e-08	0.0285	0.31	0.25	Neuroticism;	chr8:10835982	chr9:76992099~76993108:+
THCA	trans	rs4879677	0.959	rs2150021	ENSG00000269560.1	CTD-2192J16.21	5.66	2.68e-08	0.0285	0.32	0.25	Gut microbiome composition (summer and winter);	chr9:27688292	chr19:12529768~12532973:-
THCA	trans	rs7819412	0.634	rs4841485	ENSG00000254153.1	CTA-398F10.2	-5.66	2.68e-08	0.0285	-0.28	-0.25	Triglycerides;	chr8:11052426	chr8:8456909~8461337:-
THCA	trans	rs7113874	0.569	rs10160430	ENSG00000266891.1	RP11-692N5.2	-5.66	2.68e-08	0.0285	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8578329	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.569	rs10840077	ENSG00000266891.1	RP11-692N5.2	-5.66	2.68e-08	0.0285	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8579663	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.569	rs9736791	ENSG00000266891.1	RP11-692N5.2	5.66	2.68e-08	0.0285	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8568101	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.569	rs10769916	ENSG00000266891.1	RP11-692N5.2	5.66	2.68e-08	0.0285	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8576667	chr18:9734882~9735602:-
THCA	trans	rs6948404	0.737	rs7806528	ENSG00000279762.2	RP11-227G15.12	-5.66	2.69e-08	0.0286	-0.46	-0.25	HIV-1 viral setpoint;	chr7:36584438	chr17:32423971~32446038:-
THCA	trans	rs10090774	0.965	rs11778798	ENSG00000230756.1	RHOQP3	-5.66	2.69e-08	0.0286	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140908781	chr2:130212870~130213490:-
THCA	trans	rs546131	0.928	rs552868	ENSG00000225531.1	RP11-196I18.3	5.66	2.69e-08	0.0286	0.33	0.25	Lung disease severity in cystic fibrosis;	chr11:34809147	chr9:107116829~107117557:+
THCA	trans	rs656319	0.702	rs587328	ENSG00000253893.2	FAM85B	5.66	2.69e-08	0.0286	0.34	0.25	Myopia (pathological);	chr8:9952212	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.871	rs7829826	ENSG00000229857.1	RP11-159H20.3	5.66	2.69e-08	0.0286	0.31	0.25	Mood instability;	chr8:8720610	chr9:76992099~76993108:+
THCA	trans	rs901683	0.702	rs113019116	ENSG00000228981.3	RP11-364L4.1	5.66	2.69e-08	0.0286	0.59	0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45598491	chr4:143349275~143350117:-
THCA	trans	rs7200543	0.883	rs4985148	ENSG00000255185.4	PDXDC2P	5.66	2.69e-08	0.0286	0.36	0.25	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:70010751~70065945:-
THCA	trans	rs9393777	0.92	rs35869525	ENSG00000204338.7	CYP21A1P	-5.66	2.7e-08	0.0286	-0.53	-0.25	Intelligence (multi-trait analysis);	chr6:26978908	chr6:32005636~32008451:+
THCA	trans	rs7729723	0.533	rs219279	ENSG00000226666.1	HSPA9P1	-5.66	2.7e-08	0.0286	-0.26	-0.25	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138499544	chr2:221961737~221963765:+
THCA	trans	rs3790645	0.958	rs12723936	ENSG00000221817.8	PPP3CB-AS1	-5.66	2.7e-08	0.0286	-0.23	-0.25	Glucose homeostasis traits;	chr1:26546063	chr10:73495525~73520070:+
THCA	trans	rs62045849	0.557	rs9938463	ENSG00000215030.5	RPL13P12	-5.66	2.7e-08	0.0287	-0.41	-0.25	Red blood cell count;	chr16:89117364	chr17:17383377~17384012:-
THCA	trans	rs9381040	0.61	rs2268196	ENSG00000232097.1	AC079781.8	-5.66	2.71e-08	0.0287	-0.31	-0.25	Alzheimer's disease (late onset);	chr6:41054211	chr7:97938439~97938794:-
THCA	trans	rs7995618	0.603	rs1576679	ENSG00000225931.3	RP3-395M20.7	5.65	2.72e-08	0.0288	0.41	0.25	Plasma clusterin levels;	chr13:89183949	chr1:2566410~2569888:+
THCA	trans	rs7769051	0.711	rs7738071	ENSG00000227615.1	RP11-864N7.2	5.65	2.72e-08	0.0289	0.45	0.25	Type 2 diabetes nephropathy;	chr6:132763977	chr11:74745716~74746114:-
THCA	trans	rs7701967	0.697	rs11948761	ENSG00000233006.5	AC034220.3	-5.65	2.72e-08	0.0289	-0.22	-0.25	Itch intensity from mosquito bite;Mosquito bite size;Itch intensity from mosquito bite adjusted by bite size;	chr5:131035277	chr5:132311285~132369916:-
THCA	trans	rs9581094	1	rs9581094	ENSG00000237917.1	PARP4P1	-5.65	2.73e-08	0.0289	-0.46	-0.25	Sudden cardiac arrest;	chr13:24508492	chrY:26594851~26634652:-
THCA	trans	rs9393777	0.92	rs66462181	ENSG00000226314.6	ZNF192P1	-5.65	2.73e-08	0.029	-0.56	-0.25	Intelligence (multi-trait analysis);	chr6:27123882	chr6:28161781~28169594:+
THCA	trans	rs4415084	0.716	rs6451772	ENSG00000231752.4	EMBP1	5.65	2.73e-08	0.029	0.35	0.25	Breast cancer;	chr5:44785661	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs7710952	ENSG00000231752.4	EMBP1	5.65	2.73e-08	0.029	0.35	0.25	Breast cancer;	chr5:44785689	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs7710978	ENSG00000231752.4	EMBP1	5.65	2.73e-08	0.029	0.35	0.25	Breast cancer;	chr5:44785762	chr1:121519112~121571892:+
THCA	trans	rs11098499	0.874	rs28452522	ENSG00000253326.2	RP11-261C10.7	5.65	2.73e-08	0.029	0.35	0.25	Corneal astigmatism;	chr4:119189629	chr1:243054861~243056394:-
THCA	trans	rs8177876	0.822	rs4889225	ENSG00000224837.1	GCSHP5	-5.65	2.74e-08	0.0291	-0.36	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr1:168055901~168056422:-
THCA	trans	rs9329221	0.525	rs4394398	ENSG00000254153.1	CTA-398F10.2	5.65	2.74e-08	0.0291	0.31	0.25	Neuroticism;	chr8:10226884	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.54	rs2409725	ENSG00000254153.1	CTA-398F10.2	5.65	2.75e-08	0.0291	0.3	0.25	Triglycerides;	chr8:11184152	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.54	rs2409726	ENSG00000254153.1	CTA-398F10.2	5.65	2.75e-08	0.0291	0.3	0.25	Triglycerides;	chr8:11185629	chr8:8456909~8461337:-
THCA	trans	rs356220	0.642	rs356176	ENSG00000245479.2	LINC01585	-5.65	2.75e-08	0.0291	-0.31	-0.25	Parkinson's disease;	chr4:89709650	chr15:90660234~90664967:+
THCA	trans	rs17767392	0.514	rs72726654	ENSG00000280334.1	RP11-361L15.5	-5.65	2.75e-08	0.0292	-0.27	-0.25	Mitral valve prolapse;	chr14:71197705	chr16:67006672~67009481:-
THCA	trans	rs12439619	0.739	rs62012046	ENSG00000235370.6	DNM1P51	-5.65	2.75e-08	0.0292	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82236824	chr15:84398316~84411701:-
THCA	trans	rs12439619	0.81	rs62012049	ENSG00000235370.6	DNM1P51	-5.65	2.75e-08	0.0292	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82237722	chr15:84398316~84411701:-
THCA	trans	rs12439619	0.846	rs62012056	ENSG00000235370.6	DNM1P51	-5.65	2.75e-08	0.0292	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82247278	chr15:84398316~84411701:-
THCA	trans	rs2645424	0.604	rs9644756	ENSG00000260438.1	RP11-405F3.2	5.65	2.76e-08	0.0292	0.35	0.25	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11857591	chr16:57713782~57714957:+
THCA	trans	rs7824557	0.767	rs7837036	ENSG00000254153.1	CTA-398F10.2	-5.65	2.76e-08	0.0292	-0.28	-0.25	Retinal vascular caliber;	chr8:11317980	chr8:8456909~8461337:-
THCA	trans	rs10090774	0.932	rs61307926	ENSG00000230756.1	RHOQP3	5.65	2.76e-08	0.0293	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140932255	chr2:130212870~130213490:-
THCA	trans	rs7113874	0.569	rs9737401	ENSG00000266891.1	RP11-692N5.2	5.65	2.77e-08	0.0293	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8574105	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.589	rs9705253	ENSG00000266891.1	RP11-692N5.2	5.65	2.77e-08	0.0293	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8574936	chr18:9734882~9735602:-
THCA	trans	rs7824557	0.628	rs7815802	ENSG00000253893.2	FAM85B	-5.65	2.77e-08	0.0294	-0.33	-0.25	Retinal vascular caliber;	chr8:11333138	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.524	rs9734055	ENSG00000266891.1	RP11-692N5.2	5.65	2.78e-08	0.0294	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8555689	chr18:9734882~9735602:-
THCA	trans	rs8036358	1	rs77157369	ENSG00000272486.1	RP11-532M24.1	-5.65	2.78e-08	0.0294	-0.48	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:86009702	chr8:124579631~124580648:+
THCA	trans	rs8036358	1	rs72748024	ENSG00000272486.1	RP11-532M24.1	-5.65	2.78e-08	0.0294	-0.48	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:86009777	chr8:124579631~124580648:+
THCA	trans	rs8036358	1	rs77962857	ENSG00000272486.1	RP11-532M24.1	-5.65	2.78e-08	0.0294	-0.48	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:86009797	chr8:124579631~124580648:+
THCA	trans	rs2985684	0.894	rs4900928	ENSG00000240785.1	RPL36AP21	5.65	2.78e-08	0.0295	0.31	0.25	Carotid intima media thickness;	chr14:49554099	chr5:18049550~18049872:+
THCA	trans	rs7595950	0.534	rs6731782	ENSG00000234183.1	AC004854.4	-5.65	2.78e-08	0.0295	-0.26	-0.25	Major depression and alcohol dependence;	chr2:59997194	chr7:44848416~44849568:+
THCA	trans	rs1908814	0.516	rs10113042	ENSG00000229857.1	RP11-159H20.3	-5.65	2.78e-08	0.0295	-0.33	-0.25	Neuroticism;	chr8:11935669	chr9:76992099~76993108:+
THCA	trans	rs9596837	0.514	rs9591528	ENSG00000234192.1	RP11-57C13.5	-5.65	2.78e-08	0.0295	-0.34	-0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53646910	chr10:87642607~87642954:+
THCA	trans	rs2242330	0.862	rs10440481	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67497372	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.862	rs28754895	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67498710	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.822	rs62301094	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67504173	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.862	rs9992020	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67512755	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.862	rs10003115	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67520510	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.815	rs10003368	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67521343	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.815	rs1391110	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67530669	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.906	rs6829533	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67534028	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.906	rs1157087	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67537244	chr12:89500093~89502670:+
THCA	trans	rs2242330	0.862	rs1157088	ENSG00000226982.4	CENPCP1	5.65	2.78e-08	0.0295	0.39	0.25	Parkinson's disease;	chr4:67537256	chr12:89500093~89502670:+
THCA	trans	rs10090774	0.965	rs13255947	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140901346	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10089610	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140911514	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13254151	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140915211	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13273095	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140916839	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11778436	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140920047	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11785722	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140923414	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10103265	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140924839	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.841	rs11781072	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140928040	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs11786423	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140929471	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11784127	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140931408	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.813	rs11774672	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140931433	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13279233	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140936375	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs11775547	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140938349	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs11777476	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140940276	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11774024	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140940435	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11167010	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140944111	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs10102796	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140945576	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10093049	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140947405	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs2166869	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140950479	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13269453	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140951078	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs7843337	ENSG00000230756.1	RHOQP3	-5.65	2.79e-08	0.0295	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140952543	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10088980	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140953591	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10092810	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955055	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11992645	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955298	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs55827446	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959173	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11775885	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140959895	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10089966	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140962443	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13265704	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140963053	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs727944	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140965089	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.901	rs9324538	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140966639	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10104187	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140968361	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.87	rs10087115	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140968731	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13278775	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140971830	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.87	rs10099696	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140980411	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11990541	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140987915	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11167017	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140989972	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10110937	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992419	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs1397380	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140992955	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11167018	ENSG00000230756.1	RHOQP3	5.65	2.79e-08	0.0295	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140993212	chr2:130212870~130213490:-
THCA	trans	rs656319	0.605	rs4840467	ENSG00000229857.1	RP11-159H20.3	-5.65	2.79e-08	0.0295	-0.35	-0.25	Myopia (pathological);	chr8:10222127	chr9:76992099~76993108:+
THCA	trans	rs936332	1	rs936332	ENSG00000259565.2	KRT8P23	5.65	2.79e-08	0.0296	0.33	0.25	Diisocyanate-induced asthma;	chr12:52246493	chr15:76979245~76980451:-
THCA	trans	rs7824557	0.603	rs2246606	ENSG00000256560.1	LINC01486	5.65	2.8e-08	0.0296	0.32	0.25	Retinal vascular caliber;	chr8:11361825	chr12:109354083~109359488:-
THCA	trans	rs10435719	0.58	rs13260712	ENSG00000229857.1	RP11-159H20.3	5.65	2.8e-08	0.0296	0.32	0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.551	rs13268217	ENSG00000229857.1	RP11-159H20.3	5.65	2.8e-08	0.0296	0.32	0.25	Monocyte count;	chr8:11925100	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.573	rs13264994	ENSG00000229857.1	RP11-159H20.3	5.65	2.8e-08	0.0296	0.32	0.25	Monocyte count;	chr8:11925250	chr9:76992099~76993108:+
THCA	trans	rs11992162	0.573	rs13275808	ENSG00000229857.1	RP11-159H20.3	5.65	2.8e-08	0.0296	0.32	0.25	Monocyte count;	chr8:11925306	chr9:76992099~76993108:+
THCA	trans	rs10090774	0.932	rs11998619	ENSG00000230756.1	RHOQP3	5.65	2.8e-08	0.0296	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140885597	chr2:130212870~130213490:-
THCA	trans	rs950169	1	rs35297609	ENSG00000259295.5	CSPG4P12	5.65	2.81e-08	0.0297	0.39	0.25	Schizophrenia;	chr15:84104144	chr15:85191438~85213905:+
THCA	trans	rs4615179	1	rs28494136	ENSG00000231177.4	LINC00852	5.65	2.81e-08	0.0297	0.34	0.25	Obesity-related traits;	chr4:38462881	chr3:10284419~10285746:+
THCA	trans	rs7113874	0.589	rs6578968	ENSG00000266891.1	RP11-692N5.2	5.65	2.81e-08	0.0297	0.33	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8459172	chr18:9734882~9735602:-
THCA	trans	rs10435719	0.764	rs10103485	ENSG00000254153.1	CTA-398F10.2	-5.65	2.81e-08	0.0297	-0.29	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.767	rs3808513	ENSG00000254153.1	CTA-398F10.2	5.65	2.81e-08	0.0297	0.28	0.25	Retinal vascular caliber;	chr8:11299951	chr8:8456909~8461337:-
THCA	trans	rs916888	0.61	rs199529	ENSG00000264070.1	DND1P1	5.65	2.81e-08	0.0297	0.35	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45585871~45586929:+
THCA	trans	rs9393777	0.778	rs4452638	ENSG00000228022.4	HCG20	5.65	2.81e-08	0.0297	0.54	0.25	Intelligence (multi-trait analysis);	chr6:27261486	chr6:30766825~30792250:+
THCA	trans	rs7113874	0.544	rs9704807	ENSG00000266891.1	RP11-692N5.2	5.65	2.81e-08	0.0297	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8557224	chr18:9734882~9735602:-
THCA	trans	rs877636	1	rs705696	ENSG00000233278.1	RPS26P2	5.65	2.82e-08	0.0298	0.31	0.25	Cognitive function;	chr12:56086864	chr9:30831878~30832225:-
THCA	trans	rs875971	0.545	rs73136346	ENSG00000213640.3	EEF1DP4	5.65	2.82e-08	0.0298	0.35	0.25	Aortic root size;	chr7:66101095	chr7:64862999~64864370:+
THCA	trans	rs2268365	0.5	rs17848190	ENSG00000232928.2	DDX3P1	-5.65	2.83e-08	0.0299	-0.34	-0.25	Blood pressure (smoking interaction);	chr2:169173290	chrX:74121012~74131923:+
THCA	trans	rs453301	0.652	rs2043129	ENSG00000256560.1	LINC01486	5.65	2.83e-08	0.0299	0.29	0.25	Joint mobility (Beighton score);	chr8:8967994	chr12:109354083~109359488:-
THCA	trans	rs73108077	0.831	rs73116283	ENSG00000279352.1	RP11-411B10.7	5.65	2.83e-08	0.0299	0.6	0.25	Red blood cell density in sickle cell anemia;	chr20:31485479	chr18:14010054~14010917:+
THCA	trans	rs7694207	0.706	rs35920863	ENSG00000215481.7	BCRP3	5.65	2.83e-08	0.0299	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96977066	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs78581399	ENSG00000215481.7	BCRP3	5.65	2.83e-08	0.0299	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96977420	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs13119789	ENSG00000215481.7	BCRP3	5.65	2.83e-08	0.0299	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96977665	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs13119726	ENSG00000215481.7	BCRP3	5.65	2.83e-08	0.0299	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96977935	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs10035044	ENSG00000215481.7	BCRP3	5.65	2.83e-08	0.0299	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96978185	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs60043138	ENSG00000215481.7	BCRP3	5.65	2.83e-08	0.0299	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96978738	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.706	rs28717677	ENSG00000215481.7	BCRP3	5.65	2.83e-08	0.0299	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96980822	chr22:24632915~24653356:+
THCA	trans	rs12477438	0.52	rs11123763	ENSG00000276576.1	MRPL30P1	5.65	2.84e-08	0.03	0.32	0.25	Chronic sinus infection;	chr2:99134210	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs11677247	ENSG00000276576.1	MRPL30P1	5.65	2.84e-08	0.03	0.32	0.25	Chronic sinus infection;	chr2:99139895	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs11890338	ENSG00000276576.1	MRPL30P1	5.65	2.84e-08	0.03	0.32	0.25	Chronic sinus infection;	chr2:99151405	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.508	rs2516832	ENSG00000276576.1	MRPL30P1	5.65	2.84e-08	0.03	0.32	0.25	Chronic sinus infection;	chr2:99154805	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs2516827	ENSG00000276576.1	MRPL30P1	5.65	2.84e-08	0.03	0.32	0.25	Chronic sinus infection;	chr2:99156102	chr6:57029521~57029988:+
THCA	trans	rs7945705	0.846	rs905290	ENSG00000266891.1	RP11-692N5.2	-5.65	2.84e-08	0.03	-0.33	-0.25	Hemoglobin concentration;	chr11:8732182	chr18:9734882~9735602:-
THCA	trans	rs12477438	0.52	rs2309581	ENSG00000276576.1	MRPL30P1	-5.65	2.85e-08	0.03	-0.33	-0.25	Chronic sinus infection;	chr2:99167829	chr6:57029521~57029988:+
THCA	trans	rs453301	0.682	rs2929308	ENSG00000256560.1	LINC01486	-5.65	2.85e-08	0.0301	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9226611	chr12:109354083~109359488:-
THCA	trans	rs9733	0.65	rs4970923	ENSG00000273254.1	RP1-100J12.1	5.65	2.86e-08	0.0301	0.27	0.25	Tonsillectomy;	chr1:150635824	chr21:29024255~29024890:-
THCA	trans	rs9733	0.65	rs11204684	ENSG00000273254.1	RP1-100J12.1	5.65	2.86e-08	0.0301	0.27	0.25	Tonsillectomy;	chr1:150636418	chr21:29024255~29024890:-
THCA	trans	rs9650657	0.537	rs11250092	ENSG00000256560.1	LINC01486	5.65	2.86e-08	0.0301	0.3	0.25	Neuroticism;	chr8:10929033	chr12:109354083~109359488:-
THCA	trans	rs875971	0.545	rs67775320	ENSG00000213640.3	EEF1DP4	-5.65	2.86e-08	0.0302	-0.34	-0.25	Aortic root size;	chr7:66193792	chr7:64862999~64864370:+
THCA	trans	rs9470794	1	rs11751153	ENSG00000279138.1	KB-1742H10.3	5.64	2.87e-08	0.0302	0.57	0.25	Type 2 diabetes;	chr6:38073337	chr8:104478539~104480783:-
THCA	trans	rs7824557	0.583	rs2736292	ENSG00000256560.1	LINC01486	5.64	2.87e-08	0.0303	0.31	0.25	Retinal vascular caliber;	chr8:11376991	chr12:109354083~109359488:-
THCA	trans	rs7829975	0.742	rs1533058	ENSG00000229857.1	RP11-159H20.3	-5.64	2.89e-08	0.0305	-0.31	-0.25	Mood instability;	chr8:8827680	chr9:76992099~76993108:+
THCA	trans	rs4948102	0.595	rs7793921	ENSG00000186940.6	CHCHD2P9	-5.64	2.9e-08	0.0306	-0.34	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr9:79391304~79391759:+
THCA	trans	rs4948102	0.595	rs10255049	ENSG00000186940.6	CHCHD2P9	-5.64	2.9e-08	0.0306	-0.34	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr9:79391304~79391759:+
THCA	trans	rs12659622	0.651	rs7733676	ENSG00000236722.1	RP11-359I18.1	5.64	2.9e-08	0.0306	0.4	0.25	Obesity-related traits;	chr5:15702360	chr3:58511310~58511676:+
THCA	trans	rs7113874	0.61	rs1446462	ENSG00000266891.1	RP11-692N5.2	5.64	2.9e-08	0.0306	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8544796	chr18:9734882~9735602:-
THCA	trans	rs7429990	0.864	rs7631950	ENSG00000235912.1	RP1-159A19.3	5.64	2.9e-08	0.0306	0.31	0.25	Educational attainment (years of education);	chr3:47591865	chr1:27649419~27649610:+
THCA	trans	rs7995618	0.549	rs389177	ENSG00000225931.3	RP3-395M20.7	5.64	2.9e-08	0.0306	0.41	0.25	Plasma clusterin levels;	chr13:89171822	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.518	rs505914	ENSG00000225931.3	RP3-395M20.7	5.64	2.9e-08	0.0306	0.41	0.25	Plasma clusterin levels;	chr13:89172266	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.549	rs506805	ENSG00000225931.3	RP3-395M20.7	5.64	2.9e-08	0.0306	0.41	0.25	Plasma clusterin levels;	chr13:89172358	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.634	rs404451	ENSG00000225931.3	RP3-395M20.7	5.64	2.9e-08	0.0306	0.41	0.25	Plasma clusterin levels;	chr13:89175181	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.634	rs432913	ENSG00000225931.3	RP3-395M20.7	5.64	2.9e-08	0.0306	0.41	0.25	Plasma clusterin levels;	chr13:89178775	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.634	rs457810	ENSG00000225931.3	RP3-395M20.7	5.64	2.9e-08	0.0306	0.41	0.25	Plasma clusterin levels;	chr13:89190809	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.552	rs465014	ENSG00000225931.3	RP3-395M20.7	5.64	2.9e-08	0.0306	0.41	0.25	Plasma clusterin levels;	chr13:89191077	chr1:2566410~2569888:+
THCA	trans	rs9393777	0.92	rs13207689	ENSG00000253570.1	RNF5P1	5.64	2.9e-08	0.0306	0.69	0.25	Intelligence (multi-trait analysis);	chr6:27401925	chr8:38600661~38601200:-
THCA	trans	rs4936894	0.5	rs11604309	ENSG00000196933.5	RPS26P11	-5.64	2.9e-08	0.0306	-0.32	-0.25	Aging (time to death);	chr11:124297266	chrX:72044545~72044892:+
THCA	trans	rs9856151	1	rs9817730	ENSG00000275120.1	RP11-182J1.17	5.64	2.91e-08	0.0307	0.3	0.25	Body mass index;	chr3:131888811	chr15:84599434~84606463:-
THCA	trans	rs7113874	0.569	rs10444316	ENSG00000266891.1	RP11-692N5.2	5.64	2.91e-08	0.0307	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8513067	chr18:9734882~9735602:-
THCA	trans	rs433755	0.669	rs11134360	ENSG00000189014.7	FAM35DP	-5.64	2.91e-08	0.0307	-0.29	-0.25	Obesity-related traits;	chr5:9476808	chr10:47689707~47730436:+
THCA	trans	rs80018415	0.908	rs77345875	ENSG00000187653.11	TMSB4XP8	5.64	2.92e-08	0.0307	0.32	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr8:132904255	chr4:90838903~90839037:-
THCA	trans	rs80018415	0.908	rs6984038	ENSG00000187653.11	TMSB4XP8	5.64	2.92e-08	0.0307	0.32	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr8:132904259	chr4:90838903~90839037:-
THCA	trans	rs9329221	0.712	rs1962073	ENSG00000254153.1	CTA-398F10.2	5.64	2.92e-08	0.0307	0.27	0.25	Neuroticism;	chr8:10403043	chr8:8456909~8461337:-
THCA	trans	rs7189233	1	rs16952251	ENSG00000277863.1	RP11-282A11.4	5.64	2.92e-08	0.0307	0.34	0.25	Intelligence (multi-trait analysis);	chr16:53449226	chr13:106903150~106904099:-
THCA	trans	rs2412819	0.571	rs28410121	ENSG00000180867.10	PDIA3P1	5.64	2.92e-08	0.0307	0.26	0.25	Lung cancer;	chr15:43777831	chr1:147178113~147179622:+
THCA	trans	rs7113874	0.523	rs7117945	ENSG00000266891.1	RP11-692N5.2	5.64	2.92e-08	0.0308	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8510911	chr18:9734882~9735602:-
THCA	trans	rs162211	0.723	rs161916	ENSG00000226253.1	MRPL35P3	-5.64	2.92e-08	0.0308	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:7781828	chr10:74527584~74527947:+
THCA	trans	rs10090774	0.965	rs11775840	ENSG00000230756.1	RHOQP3	5.64	2.93e-08	0.0308	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140873134	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs4074812	ENSG00000230756.1	RHOQP3	5.64	2.93e-08	0.0308	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140873430	chr2:130212870~130213490:-
THCA	trans	rs9393777	0.72	rs34864993	ENSG00000204338.7	CYP21A1P	-5.64	2.93e-08	0.0308	-0.46	-0.25	Intelligence (multi-trait analysis);	chr6:27003116	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.72	rs56874662	ENSG00000204338.7	CYP21A1P	-5.64	2.93e-08	0.0308	-0.46	-0.25	Intelligence (multi-trait analysis);	chr6:27017828	chr6:32005636~32008451:+
THCA	trans	rs263156	0.899	rs263176	ENSG00000276182.1	RP11-872J21.5	-5.64	2.93e-08	0.0308	-0.2	-0.25	Lobe size;Ear morphology;Lobe attachment;	chr6:142547365	chr14:96537170~96537904:+
THCA	trans	rs7769051	0.711	rs9493435	ENSG00000227615.1	RP11-864N7.2	5.64	2.93e-08	0.0309	0.43	0.25	Type 2 diabetes nephropathy;	chr6:132767066	chr11:74745716~74746114:-
THCA	trans	rs11992162	0.551	rs35010200	ENSG00000229857.1	RP11-159H20.3	5.64	2.93e-08	0.0309	0.33	0.25	Monocyte count;	chr8:11928146	chr9:76992099~76993108:+
THCA	trans	rs7617480	0.648	rs9882443	ENSG00000235912.1	RP1-159A19.3	-5.64	2.93e-08	0.0309	-0.41	-0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48711631	chr1:27649419~27649610:+
THCA	trans	rs2819332	0.639	rs2842192	ENSG00000238181.2	AHCYP2	5.64	2.94e-08	0.0309	0.32	0.25	Amyotrophic lateral sclerosis (age of onset);	chr1:43504626	chr9:120720673~120721972:+
THCA	trans	rs875971	0.545	rs313828	ENSG00000213640.3	EEF1DP4	5.64	2.94e-08	0.0309	0.34	0.25	Aortic root size;	chr7:66087627	chr7:64862999~64864370:+
THCA	trans	rs875971	0.571	rs160647	ENSG00000213640.3	EEF1DP4	5.64	2.94e-08	0.0309	0.34	0.25	Aortic root size;	chr7:66089365	chr7:64862999~64864370:+
THCA	trans	rs11992162	0.56	rs13276386	ENSG00000254153.1	CTA-398F10.2	-5.64	2.94e-08	0.0309	-0.29	-0.25	Monocyte count;	chr8:11939912	chr8:8456909~8461337:-
THCA	trans	rs11992162	0.621	rs13268810	ENSG00000254153.1	CTA-398F10.2	-5.64	2.94e-08	0.0309	-0.29	-0.25	Monocyte count;	chr8:11939921	chr8:8456909~8461337:-
THCA	trans	rs11992162	0.636	rs13265816	ENSG00000254153.1	CTA-398F10.2	-5.64	2.94e-08	0.0309	-0.29	-0.25	Monocyte count;	chr8:11939976	chr8:8456909~8461337:-
THCA	trans	rs875971	0.545	rs6460281	ENSG00000213640.3	EEF1DP4	-5.64	2.94e-08	0.0309	-0.34	-0.25	Aortic root size;	chr7:66216128	chr7:64862999~64864370:+
THCA	trans	rs9650315	0.53	rs61334940	ENSG00000244245.1	RP11-120B7.1	5.64	2.94e-08	0.031	0.29	0.25	Height;	chr8:56160011	chr5:108593609~108593967:+
THCA	trans	rs7824557	0.628	rs7820301	ENSG00000254153.1	CTA-398F10.2	-5.64	2.94e-08	0.031	-0.28	-0.25	Retinal vascular caliber;	chr8:11371163	chr8:8456909~8461337:-
THCA	trans	rs616147	0.655	rs1707981	ENSG00000239269.1	RPSAP4	-5.64	2.94e-08	0.031	-0.28	-0.25	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr14:94726288~94727175:+
THCA	trans	rs7829975	0.511	rs2976906	ENSG00000229857.1	RP11-159H20.3	-5.64	2.96e-08	0.0311	-0.32	-0.25	Mood instability;	chr8:8484905	chr9:76992099~76993108:+
THCA	trans	rs9368481	0.761	rs9348746	ENSG00000228022.4	HCG20	-5.64	2.96e-08	0.0311	-0.33	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:30766825~30792250:+
THCA	trans	rs9368481	0.761	rs9379952	ENSG00000228022.4	HCG20	-5.64	2.96e-08	0.0311	-0.33	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:30766825~30792250:+
THCA	trans	rs9329221	0.683	rs814359	ENSG00000229857.1	RP11-159H20.3	5.64	2.96e-08	0.0311	0.31	0.25	Neuroticism;	chr8:10025622	chr9:76992099~76993108:+
THCA	trans	rs4415084	0.804	rs4329028	ENSG00000231752.4	EMBP1	5.64	2.96e-08	0.0311	0.34	0.25	Breast cancer;	chr5:44872251	chr1:121519112~121571892:+
THCA	trans	rs6782422	0.674	rs6775619	ENSG00000255165.1	CTD-2609K8.3	5.64	2.96e-08	0.0311	0.36	0.25	Parental extreme longevity (95 years and older);	chr3:174198064	chr11:44071462~44072403:+
THCA	trans	rs7995618	0.669	rs77540614	ENSG00000225931.3	RP3-395M20.7	5.64	2.97e-08	0.0312	0.43	0.25	Plasma clusterin levels;	chr13:89300081	chr1:2566410~2569888:+
THCA	trans	rs7995618	0.669	rs75868821	ENSG00000225931.3	RP3-395M20.7	5.64	2.97e-08	0.0312	0.43	0.25	Plasma clusterin levels;	chr13:89300100	chr1:2566410~2569888:+
THCA	trans	rs12477438	0.52	rs11695751	ENSG00000276576.1	MRPL30P1	5.64	2.97e-08	0.0312	0.32	0.25	Chronic sinus infection;	chr2:99091784	chr6:57029521~57029988:+
THCA	trans	rs7819412	0.691	rs73198970	ENSG00000254153.1	CTA-398F10.2	5.64	2.98e-08	0.0313	0.29	0.25	Triglycerides;	chr8:11182707	chr8:8456909~8461337:-
THCA	trans	rs9467711	0.606	rs13190739	ENSG00000204338.7	CYP21A1P	-5.64	2.98e-08	0.0313	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.606	rs34781270	ENSG00000204338.7	CYP21A1P	-5.64	2.98e-08	0.0313	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.606	rs35076545	ENSG00000204338.7	CYP21A1P	-5.64	2.98e-08	0.0313	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.606	rs13212985	ENSG00000204338.7	CYP21A1P	-5.64	2.98e-08	0.0313	-0.53	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr6:32005636~32008451:+
THCA	trans	rs73110464	0.591	rs11829997	ENSG00000255815.3	KRT8P11	-5.64	2.99e-08	0.0314	-0.62	-0.25	Cancer (pleiotropy);	chr12:52921875	chr9:99305176~99306611:+
THCA	trans	rs9982086	0.557	rs2829778	ENSG00000277945.1	RP11-677M24.1	5.64	2.99e-08	0.0314	0.33	0.25	Carboplatin disposition in epthelial ovarian cancer;	chr21:25494354	chr12:65830750~65831050:+
THCA	trans	rs2980439	0.818	rs2945249	ENSG00000229857.1	RP11-159H20.3	-5.64	2.99e-08	0.0314	-0.3	-0.25	Neuroticism;	chr8:8237204	chr9:76992099~76993108:+
THCA	trans	rs263156	0.932	rs263174	ENSG00000276182.1	RP11-872J21.5	5.64	3e-08	0.0315	0.2	0.25	Lobe size;Ear morphology;Lobe attachment;	chr6:142547962	chr14:96537170~96537904:+
THCA	trans	rs2439831	0.681	rs478104	ENSG00000180867.10	PDIA3P1	-5.64	3.01e-08	0.0316	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43302702	chr1:147178113~147179622:+
THCA	trans	rs7829975	0.714	rs59046059	ENSG00000229857.1	RP11-159H20.3	-5.64	3.01e-08	0.0316	-0.31	-0.25	Mood instability;	chr8:8813226	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.513	rs4841459	ENSG00000256560.1	LINC01486	-5.64	3.01e-08	0.0316	-0.3	-0.25	Neuroticism;	chr8:10924932	chr12:109354083~109359488:-
THCA	trans	rs853679	0.546	rs200977	ENSG00000228022.4	HCG20	-5.64	3.01e-08	0.0317	-0.5	-0.25	Depression;	chr6:27886523	chr6:30766825~30792250:+
THCA	trans	rs2439831	0.571	rs689883	ENSG00000180867.10	PDIA3P1	-5.64	3.02e-08	0.0317	-0.28	-0.25	Lung cancer in ever smokers;	chr15:43520398	chr1:147178113~147179622:+
THCA	trans	rs889398	0.715	rs13330951	ENSG00000257513.6	NPIPB1P	5.64	3.02e-08	0.0317	0.28	0.25	Body mass index;	chr16:69529939	chr18:11619509~11639699:-
THCA	trans	rs7617773	1	rs7617773	ENSG00000235912.1	RP1-159A19.3	5.63	3.02e-08	0.0317	0.31	0.25	Coronary artery disease;	chr3:48152025	chr1:27649419~27649610:+
THCA	trans	rs7819412	0.617	rs10087081	ENSG00000254153.1	CTA-398F10.2	5.63	3.02e-08	0.0317	0.29	0.25	Triglycerides;	chr8:11117407	chr8:8456909~8461337:-
THCA	trans	rs12682352	0.602	rs635594	ENSG00000256560.1	LINC01486	-5.63	3.03e-08	0.0318	-0.29	-0.25	Neuroticism;	chr8:8755877	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.505	rs17782554	ENSG00000254153.1	CTA-398F10.2	5.63	3.03e-08	0.0318	0.29	0.25	Triglycerides;	chr8:11164596	chr8:8456909~8461337:-
THCA	trans	rs950880	0.553	rs3755272	ENSG00000277895.1	RP11-114F3.4	5.63	3.03e-08	0.0318	0.4	0.25	Serum protein levels (sST2);	chr2:102417365	chr12:64451591~64452901:-
THCA	trans	rs950880	0.553	rs2293225	ENSG00000277895.1	RP11-114F3.4	5.63	3.03e-08	0.0318	0.4	0.25	Serum protein levels (sST2);	chr2:102419429	chr12:64451591~64452901:-
THCA	trans	rs1572299	0.64	rs10818189	ENSG00000273669.1	RP11-405M12.4	-5.63	3.03e-08	0.0318	-0.32	-0.25	Schizophrenia;	chr9:118566569	chr18:75073543~75074205:+
THCA	trans	rs190945449	1	rs190945449	ENSG00000219392.1	RP1-265C24.5	-5.63	3.03e-08	0.0318	-0.53	-0.25	Urinary tract infection frequency;	chr6:26860580	chr6:28115628~28116551:+
THCA	trans	rs9818758	0.556	rs9872660	ENSG00000197582.5	GPX1P1	-5.63	3.04e-08	0.0319	-0.47	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49341399	chrX:13378735~13379340:-
THCA	trans	rs9818758	0.882	rs74926817	ENSG00000197582.5	GPX1P1	-5.63	3.04e-08	0.0319	-0.47	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49341400	chrX:13378735~13379340:-
THCA	trans	rs9858542	0.537	rs67882627	ENSG00000197582.5	GPX1P1	-5.63	3.04e-08	0.0319	-0.47	-0.25	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49343008	chrX:13378735~13379340:-
THCA	trans	rs7617773	0.78	rs7653152	ENSG00000235912.1	RP1-159A19.3	-5.63	3.04e-08	0.0319	-0.31	-0.25	Coronary artery disease;	chr3:48320607	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs4541431	ENSG00000235912.1	RP1-159A19.3	-5.63	3.04e-08	0.0319	-0.31	-0.25	Coronary artery disease;	chr3:48323728	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.743	rs13071960	ENSG00000235912.1	RP1-159A19.3	-5.63	3.04e-08	0.0319	-0.31	-0.25	Coronary artery disease;	chr3:48326047	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.743	rs4632568	ENSG00000235912.1	RP1-159A19.3	-5.63	3.04e-08	0.0319	-0.31	-0.25	Coronary artery disease;	chr3:48326329	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs11130164	ENSG00000235912.1	RP1-159A19.3	-5.63	3.04e-08	0.0319	-0.31	-0.25	Coronary artery disease;	chr3:48327544	chr1:27649419~27649610:+
THCA	trans	rs10090774	1	rs9650572	ENSG00000230756.1	RHOQP3	-5.63	3.05e-08	0.032	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140821890	chr2:130212870~130213490:-
THCA	trans	rs3002142	0.818	rs3008604	ENSG00000219201.4	RP11-181C21.4	-5.63	3.05e-08	0.032	-0.32	-0.25	LDL peak particle diameter (total fat intake interaction);	chr1:222609854	chr1:77810861~77811781:-
THCA	trans	rs9650657	0.537	rs11250092	ENSG00000229857.1	RP11-159H20.3	-5.63	3.05e-08	0.032	-0.31	-0.25	Neuroticism;	chr8:10929033	chr9:76992099~76993108:+
THCA	trans	rs7945705	0.818	rs2742537	ENSG00000266891.1	RP11-692N5.2	5.63	3.06e-08	0.0321	0.32	0.25	Hemoglobin concentration;	chr11:8886842	chr18:9734882~9735602:-
THCA	trans	rs11992162	0.529	rs6995037	ENSG00000229857.1	RP11-159H20.3	5.63	3.06e-08	0.0321	0.33	0.25	Monocyte count;	chr8:11923378	chr9:76992099~76993108:+
THCA	trans	rs6918777	1	rs6918777	ENSG00000243836.4	WDR86-AS1	-5.63	3.07e-08	0.0322	-0.19	-0.25	Amyotrophic lateral sclerosis;	chr6:92659937	chr7:151409161~151413354:+
THCA	trans	rs2243480	0.706	rs6460257	ENSG00000230295.1	RP11-458F8.2	-5.63	3.07e-08	0.0322	-0.27	-0.25	Diabetic kidney disease;	chr7:65731813	chr7:66880708~66882981:+
THCA	trans	rs9914988	0.943	rs4795465	ENSG00000267449.1	RP11-264B14.2	-5.63	3.07e-08	0.0322	-0.38	-0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28824480	chr17:61069856~61070356:-
THCA	trans	rs902774	0.759	rs4919707	ENSG00000240668.1	KRT8P36	-5.63	3.07e-08	0.0322	-0.52	-0.25	Prostate cancer;	chr12:52895864	chr3:138101478~138102917:-
THCA	trans	rs902774	0.818	rs56095813	ENSG00000240668.1	KRT8P36	-5.63	3.07e-08	0.0322	-0.52	-0.25	Prostate cancer;	chr12:52900963	chr3:138101478~138102917:-
THCA	trans	rs875971	0.545	rs1547529	ENSG00000213640.3	EEF1DP4	-5.63	3.08e-08	0.0323	-0.33	-0.25	Aortic root size;	chr7:66258859	chr7:64862999~64864370:+
THCA	trans	rs875971	0.545	rs7783889	ENSG00000213640.3	EEF1DP4	-5.63	3.08e-08	0.0323	-0.33	-0.25	Aortic root size;	chr7:66283366	chr7:64862999~64864370:+
THCA	trans	rs9987353	0.566	rs34389718	ENSG00000229857.1	RP11-159H20.3	5.63	3.08e-08	0.0323	0.33	0.25	Recombination measurement;	chr8:9208015	chr9:76992099~76993108:+
THCA	trans	rs7617773	0.747	rs34076262	ENSG00000235912.1	RP1-159A19.3	-5.63	3.08e-08	0.0323	-0.31	-0.25	Coronary artery disease;	chr3:48328926	chr1:27649419~27649610:+
THCA	trans	rs1232027	0.666	rs1643637	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80633090	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs2560423	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80633355	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643638	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80634437	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1650717	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80634760	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1650715	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80634922	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1650712	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80639694	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643657	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80640598	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.656	rs966762	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80640980	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1677692	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80641195	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1677691	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80641209	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1650709	ENSG00000188985.6	DHFRP1	-5.63	3.08e-08	0.0323	-0.32	-0.25	Huntington's disease progression;	chr5:80641355	chr18:26170726~26171284:-
THCA	trans	rs11958034	1	rs11957763	ENSG00000271874.1	CTD-2024P10.2	-5.63	3.08e-08	0.0323	-0.39	-0.25	Mitochondrial DNA levels;	chr5:18912215	chr5:34651457~34651888:-
THCA	trans	rs7647973	0.593	rs9870755	ENSG00000197582.5	GPX1P1	5.63	3.09e-08	0.0324	0.45	0.25	Menarche (age at onset);	chr3:49772408	chrX:13378735~13379340:-
THCA	trans	rs56176327	0.583	rs7613603	ENSG00000197582.5	GPX1P1	-5.63	3.09e-08	0.0324	-0.45	-0.25	Intelligence (multi-trait analysis);	chr3:49775433	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.593	rs7620848	ENSG00000197582.5	GPX1P1	-5.63	3.09e-08	0.0324	-0.45	-0.25	Menarche (age at onset);	chr3:49790588	chrX:13378735~13379340:-
THCA	trans	rs9470794	1	rs73419946	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38070827	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73419949	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38072898	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs112825323	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38075305	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs56229452	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38076517	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73419960	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38079593	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73419963	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38081305	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11756626	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38098069	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs55786741	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38102147	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.915	rs57564251	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38102780	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.748	rs55972258	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38103429	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421810	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38103895	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421817	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38106090	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421819	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38106100	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421822	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38106705	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421825	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38109097	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs76766775	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38111706	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421831	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38111870	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11753563	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38112442	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs60109083	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38118538	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.915	rs73421842	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38120248	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.748	rs11757980	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38124319	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11753391	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38124690	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421855	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38126883	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs56178553	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38129772	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11759816	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38132865	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11751094	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38133221	chr8:104478539~104480783:-
THCA	trans	rs9470794	0.831	rs111937094	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38135755	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421866	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38136077	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421874	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38138991	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11757654	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38139444	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs58003999	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38139535	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11755600	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38140089	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs56021282	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38147884	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11755566	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38148893	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs11760121	ENSG00000279138.1	KB-1742H10.3	5.63	3.09e-08	0.0324	0.57	0.25	Type 2 diabetes;	chr6:38148894	chr8:104478539~104480783:-
THCA	trans	rs9650657	0.529	rs10108618	ENSG00000254153.1	CTA-398F10.2	5.63	3.1e-08	0.0325	0.29	0.25	Neuroticism;	chr8:11095582	chr8:8456909~8461337:-
THCA	trans	rs6885307	0.714	rs116806673	ENSG00000231752.4	EMBP1	5.63	3.1e-08	0.0325	0.46	0.25	Age at first birth;	chr5:45034954	chr1:121519112~121571892:+
THCA	trans	rs2055729	0.885	rs13268133	ENSG00000253893.2	FAM85B	-5.63	3.1e-08	0.0325	-0.34	-0.25	Multiple myeloma (hyperdiploidy);	chr8:9873960	chr8:8167819~8226614:-
THCA	trans	rs6894216	0.651	rs6889557	ENSG00000237714.1	P4HA2-AS1	-5.63	3.1e-08	0.0325	-0.32	-0.25	Response to amphetamines;	chr5:130359142	chr5:132184876~132192808:+
THCA	trans	rs875971	0.545	rs11767262	ENSG00000213640.3	EEF1DP4	-5.63	3.11e-08	0.0325	-0.33	-0.25	Aortic root size;	chr7:66302237	chr7:64862999~64864370:+
THCA	trans	rs875971	0.545	rs66594357	ENSG00000213640.3	EEF1DP4	-5.63	3.11e-08	0.0325	-0.33	-0.25	Aortic root size;	chr7:66327797	chr7:64862999~64864370:+
THCA	trans	rs875971	0.545	rs73142233	ENSG00000213640.3	EEF1DP4	-5.63	3.11e-08	0.0326	-0.34	-0.25	Aortic root size;	chr7:66221293	chr7:64862999~64864370:+
THCA	trans	rs5758511	0.573	rs2284082	ENSG00000268568.1	AC007228.9	-5.63	3.11e-08	0.0326	-0.29	-0.25	Birth weight;	chr22:41844793	chr19:56672574~56673901:-
THCA	trans	rs9470794	1	rs55743233	ENSG00000279138.1	KB-1742H10.3	5.63	3.11e-08	0.0326	0.56	0.25	Type 2 diabetes;	chr6:38062271	chr8:104478539~104480783:-
THCA	trans	rs10435719	0.746	rs58007588	ENSG00000254153.1	CTA-398F10.2	-5.63	3.12e-08	0.0327	-0.29	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:8456909~8461337:-
THCA	trans	rs6142102	0.651	rs6119463	ENSG00000269202.1	RP4-614O4.12	5.63	3.12e-08	0.0327	0.23	0.25	Skin pigmentation;	chr20:34149412	chr20:35201747~35203288:-
THCA	trans	rs3808502	0.526	rs7822958	ENSG00000254153.1	CTA-398F10.2	5.63	3.12e-08	0.0327	0.29	0.25	Neuroticism;	chr8:11564933	chr8:8456909~8461337:-
THCA	trans	rs6981523	0.553	rs11783890	ENSG00000229857.1	RP11-159H20.3	5.63	3.13e-08	0.0327	0.34	0.25	Neuroticism;	chr8:11198879	chr9:76992099~76993108:+
THCA	trans	rs7829975	0.533	rs35900578	ENSG00000229857.1	RP11-159H20.3	-5.63	3.13e-08	0.0327	-0.32	-0.25	Mood instability;	chr8:8862003	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.623	rs10091636	ENSG00000253893.2	FAM85B	5.63	3.13e-08	0.0327	0.31	0.25	Neuroticism;	chr8:10745456	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.54	rs10094732	ENSG00000253893.2	FAM85B	5.63	3.13e-08	0.0327	0.31	0.25	Neuroticism;	chr8:10745505	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.514	rs2920983	ENSG00000256560.1	LINC01486	5.63	3.13e-08	0.0328	0.29	0.25	Mood instability;	chr8:8410553	chr12:109354083~109359488:-
THCA	trans	rs902774	0.818	rs73110471	ENSG00000220378.3	KRT8P42	-5.63	3.13e-08	0.0328	-0.54	-0.25	Prostate cancer;	chr12:52923037	chr6:134296997~134298695:-
THCA	trans	rs950169	0.92	rs12915390	ENSG00000259295.5	CSPG4P12	5.63	3.14e-08	0.0328	0.39	0.25	Schizophrenia;	chr15:84123317	chr15:85191438~85213905:+
THCA	trans	rs67311347	0.955	rs11717036	ENSG00000139239.7	RPL14P1	5.63	3.14e-08	0.0328	0.21	0.25	Renal cell carcinoma;	chr3:40338087	chr12:62965325~62965969:+
THCA	trans	rs546131	0.928	rs553789	ENSG00000225531.1	RP11-196I18.3	5.63	3.14e-08	0.0328	0.33	0.25	Lung disease severity in cystic fibrosis;	chr11:34806032	chr9:107116829~107117557:+
THCA	trans	rs7829975	0.508	rs1594437	ENSG00000256560.1	LINC01486	5.63	3.14e-08	0.0328	0.29	0.25	Mood instability;	chr8:8968365	chr12:109354083~109359488:-
THCA	trans	rs9393777	0.622	rs13191326	ENSG00000228022.4	HCG20	-5.63	3.14e-08	0.0329	-0.55	-0.25	Intelligence (multi-trait analysis);	chr6:27063250	chr6:30766825~30792250:+
THCA	trans	rs7694207	0.706	rs13149263	ENSG00000215481.7	BCRP3	5.63	3.15e-08	0.0329	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96981861	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.66	rs13149156	ENSG00000215481.7	BCRP3	5.63	3.15e-08	0.0329	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96982003	chr22:24632915~24653356:+
THCA	trans	rs7694207	0.66	rs13149194	ENSG00000215481.7	BCRP3	5.63	3.15e-08	0.0329	0.27	0.25	Response to mTOR inhibitor (everolimus);	chr4:96982091	chr22:24632915~24653356:+
THCA	trans	rs7189233	1	rs62048520	ENSG00000277863.1	RP11-282A11.4	5.63	3.16e-08	0.033	0.34	0.25	Intelligence (multi-trait analysis);	chr16:53457183	chr13:106903150~106904099:-
THCA	trans	rs2444240	0.669	rs508205	ENSG00000250659.2	RP11-864I4.3	-5.63	3.16e-08	0.033	-0.29	-0.25	Corneal curvature;	chr11:120186635	chr11:62537312~62542018:+
THCA	trans	rs9393777	0.92	rs35768595	ENSG00000248290.1	TNXA	-5.63	3.16e-08	0.0331	-0.55	-0.25	Intelligence (multi-trait analysis);	chr6:27174125	chr6:32008614~32012472:-
THCA	trans	rs7709909	0.755	rs32950	ENSG00000188985.6	DHFRP1	5.63	3.17e-08	0.0331	0.3	0.25	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80722425	chr18:26170726~26171284:-
THCA	trans	rs162211	0.759	rs801275	ENSG00000226253.1	MRPL35P3	-5.63	3.17e-08	0.0331	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:7786079	chr10:74527584~74527947:+
THCA	trans	rs8177876	0.822	rs1563075	ENSG00000224837.1	GCSHP5	5.63	3.17e-08	0.0331	0.38	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr1:168055901~168056422:-
THCA	trans	rs10435719	0.61	rs76311455	ENSG00000254153.1	CTA-398F10.2	-5.63	3.17e-08	0.0331	-0.29	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933017	chr8:8456909~8461337:-
THCA	trans	rs10435719	0.61	rs80269926	ENSG00000254153.1	CTA-398F10.2	-5.63	3.17e-08	0.0331	-0.29	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933018	chr8:8456909~8461337:-
THCA	trans	rs11992162	0.55	rs61426048	ENSG00000229857.1	RP11-159H20.3	5.63	3.17e-08	0.0331	0.33	0.25	Monocyte count;	chr8:11927447	chr9:76992099~76993108:+
THCA	trans	rs427943	0.52	rs2003273	ENSG00000237842.2	RP11-110J1.2	5.63	3.17e-08	0.0331	0.3	0.25	Body mass index;	chr21:45116671	chr1:157059232~157060762:-
THCA	trans	rs7192380	0.895	rs2917670	ENSG00000257513.6	NPIPB1P	-5.63	3.17e-08	0.0331	-0.28	-0.25	Sjögren's syndrome;	chr16:69725060	chr18:11619509~11639699:-
THCA	trans	rs4788439	1	rs72770488	ENSG00000227782.2	CTC-529I10.2	-5.63	3.18e-08	0.0332	-0.33	-0.25	Blood metabolite levels;	chr16:24938765	chr17:16040472~16041273:+
THCA	trans	rs4788439	0.901	rs56342719	ENSG00000227782.2	CTC-529I10.2	-5.63	3.18e-08	0.0332	-0.33	-0.25	Blood metabolite levels;	chr16:24960266	chr17:16040472~16041273:+
THCA	trans	rs4788439	1	rs55968743	ENSG00000227782.2	CTC-529I10.2	-5.63	3.18e-08	0.0332	-0.33	-0.25	Blood metabolite levels;	chr16:24973451	chr17:16040472~16041273:+
THCA	trans	rs4788439	1	rs4787659	ENSG00000227782.2	CTC-529I10.2	-5.63	3.18e-08	0.0332	-0.33	-0.25	Blood metabolite levels;	chr16:24975885	chr17:16040472~16041273:+
THCA	trans	rs9596837	0.514	rs9568884	ENSG00000234192.1	RP11-57C13.5	-5.63	3.18e-08	0.0332	-0.32	-0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53691494	chr10:87642607~87642954:+
THCA	trans	rs9596837	0.514	rs36044722	ENSG00000234192.1	RP11-57C13.5	-5.63	3.18e-08	0.0332	-0.32	-0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53692824	chr10:87642607~87642954:+
THCA	trans	rs9596837	0.514	rs9596840	ENSG00000234192.1	RP11-57C13.5	-5.63	3.18e-08	0.0332	-0.32	-0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53693494	chr10:87642607~87642954:+
THCA	trans	rs758324	0.572	rs247294	ENSG00000123201.13	GUCY1B2	5.63	3.18e-08	0.0332	0.33	0.25	Alzheimer's disease in APOE e4- carriers;	chr5:132121335	chr13:50994511~51080862:-
THCA	trans	rs875971	0.545	rs73142265	ENSG00000213640.3	EEF1DP4	-5.63	3.18e-08	0.0332	-0.34	-0.25	Aortic root size;	chr7:66234510	chr7:64862999~64864370:+
THCA	trans	rs9329221	0.617	rs615632	ENSG00000254153.1	CTA-398F10.2	5.63	3.18e-08	0.0332	0.28	0.25	Neuroticism;	chr8:9938811	chr8:8456909~8461337:-
THCA	trans	rs2439831	0.681	rs825739	ENSG00000180867.10	PDIA3P1	-5.63	3.19e-08	0.0333	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43300230	chr1:147178113~147179622:+
THCA	trans	rs4788439	1	rs72770489	ENSG00000227782.2	CTC-529I10.2	-5.62	3.19e-08	0.0333	-0.33	-0.25	Blood metabolite levels;	chr16:24942206	chr17:16040472~16041273:+
THCA	trans	rs6011368	0.607	rs6062363	ENSG00000226210.3	WASH7P	5.62	3.19e-08	0.0333	0.29	0.25	Clozapine-induced cytotoxicity;	chr20:64281110	chr12:14522~32015:-
THCA	trans	rs10090774	0.965	rs9324540	ENSG00000230756.1	RHOQP3	5.62	3.19e-08	0.0333	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140980322	chr2:130212870~130213490:-
THCA	trans	rs7429990	0.932	rs6766641	ENSG00000235912.1	RP1-159A19.3	5.62	3.2e-08	0.0334	0.32	0.25	Educational attainment (years of education);	chr3:48103734	chr1:27649419~27649610:+
THCA	trans	rs889398	0.771	rs3790080	ENSG00000257513.6	NPIPB1P	5.62	3.2e-08	0.0334	0.28	0.25	Body mass index;	chr16:69868236	chr18:11619509~11639699:-
THCA	trans	rs11081761	0.527	rs58863502	ENSG00000238123.1	MID1IP1-AS1	5.62	3.21e-08	0.0335	0.41	0.25	Resting heart rate;	chr18:32312397	chrX:38801568~38803883:-
THCA	trans	rs11081761	0.527	rs57546420	ENSG00000238123.1	MID1IP1-AS1	5.62	3.21e-08	0.0335	0.41	0.25	Resting heart rate;	chr18:32312620	chrX:38801568~38803883:-
THCA	trans	rs11668609	1	rs66972560	ENSG00000261770.1	CTC-459F4.1	5.62	3.21e-08	0.0335	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24178138	chr19:27757184~27760849:-
THCA	trans	rs4936894	0.5	rs4936918	ENSG00000196933.5	RPS26P11	-5.62	3.21e-08	0.0335	-0.31	-0.25	Aging (time to death);	chr11:124309939	chrX:72044545~72044892:+
THCA	trans	rs7617773	0.78	rs13067450	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48295716	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs4479622	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48296683	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs34946886	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48296997	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs34589064	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48298059	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs2541	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48298128	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs13085251	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48298555	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs35297395	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48301392	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs35190747	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48301800	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.743	rs7621785	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48302218	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs4511915	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48302368	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs13066758	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48302387	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs4392440	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48302430	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs13082859	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48303185	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs35778847	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48305495	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs34749846	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48305678	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs79089926	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48307074	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs4511916	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48308876	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.815	rs7624450	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48308885	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.815	rs6793150	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48310070	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs6793239	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48310128	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs6782166	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48310193	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs4130522	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48310823	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.674	rs13069029	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48313534	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs13081169	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48315307	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs35411187	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48318527	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs11714176	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48319372	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.743	rs11716371	ENSG00000235912.1	RP1-159A19.3	-5.62	3.22e-08	0.0335	-0.31	-0.25	Coronary artery disease;	chr3:48321260	chr1:27649419~27649610:+
THCA	trans	rs7816032	0.617	rs73597688	ENSG00000233393.1	AP000688.29	5.62	3.22e-08	0.0336	0.4	0.25	Hyperactive-impulsive symptoms;	chr8:19897664	chr21:36104881~36109690:+
THCA	trans	rs10090774	0.93	rs9324539	ENSG00000230756.1	RHOQP3	5.62	3.22e-08	0.0336	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140966898	chr2:130212870~130213490:-
THCA	trans	rs9393777	0.778	rs13212921	ENSG00000228022.4	HCG20	-5.62	3.22e-08	0.0336	-0.54	-0.25	Intelligence (multi-trait analysis);	chr6:27237643	chr6:30766825~30792250:+
THCA	trans	rs10504229	0.683	rs6980850	ENSG00000226986.4	RP11-543B16.2	-5.62	3.23e-08	0.0336	-0.39	-0.25	Developmental language disorder (linguistic errors);	chr8:57214645	chr1:211207239~211207897:+
THCA	trans	rs7113874	0.513	rs2015629	ENSG00000266891.1	RP11-692N5.2	5.62	3.23e-08	0.0337	0.33	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8542879	chr18:9734882~9735602:-
THCA	trans	rs2645424	0.639	rs35581201	ENSG00000269898.1	RP11-568J23.4	-5.62	3.24e-08	0.0337	-0.3	-0.25	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11849325	chr16:85743287~85744225:+
THCA	trans	rs7192380	0.767	rs11641686	ENSG00000257513.6	NPIPB1P	5.62	3.25e-08	0.0338	0.29	0.25	Sjögren's syndrome;	chr16:69546496	chr18:11619509~11639699:-
THCA	trans	rs7192380	0.737	rs11641722	ENSG00000257513.6	NPIPB1P	5.62	3.25e-08	0.0338	0.29	0.25	Sjögren's syndrome;	chr16:69546499	chr18:11619509~11639699:-
THCA	trans	rs11992162	0.613	rs56094399	ENSG00000229857.1	RP11-159H20.3	5.62	3.25e-08	0.0338	0.33	0.25	Monocyte count;	chr8:11939961	chr9:76992099~76993108:+
THCA	trans	rs9467711	0.524	rs13216484	ENSG00000228022.4	HCG20	-5.62	3.25e-08	0.0338	-0.63	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26739799	chr6:30766825~30792250:+
THCA	trans	rs9467711	0.584	rs34244947	ENSG00000228022.4	HCG20	-5.62	3.25e-08	0.0338	-0.63	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26740141	chr6:30766825~30792250:+
THCA	trans	rs3808502	0.525	rs13280813	ENSG00000254153.1	CTA-398F10.2	5.62	3.25e-08	0.0338	0.28	0.25	Neuroticism;	chr8:11567596	chr8:8456909~8461337:-
THCA	trans	rs9596837	0.514	rs7990240	ENSG00000234192.1	RP11-57C13.5	-5.62	3.25e-08	0.0339	-0.32	-0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53632883	chr10:87642607~87642954:+
THCA	trans	rs9596837	0.514	rs7989655	ENSG00000234192.1	RP11-57C13.5	-5.62	3.25e-08	0.0339	-0.32	-0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53633160	chr10:87642607~87642954:+
THCA	trans	rs875971	0.545	rs1638735	ENSG00000213640.3	EEF1DP4	-5.62	3.26e-08	0.0339	-0.33	-0.25	Aortic root size;	chr7:66630751	chr7:64862999~64864370:+
THCA	trans	rs546131	0.89	rs496558	ENSG00000225531.1	RP11-196I18.3	5.62	3.26e-08	0.0339	0.33	0.25	Lung disease severity in cystic fibrosis;	chr11:34804878	chr9:107116829~107117557:+
THCA	trans	rs10090774	0.932	rs1448226	ENSG00000230756.1	RHOQP3	5.62	3.26e-08	0.0339	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140894289	chr2:130212870~130213490:-
THCA	trans	rs453301	0.686	rs7814328	ENSG00000256560.1	LINC01486	-5.62	3.26e-08	0.034	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9018719	chr12:109354083~109359488:-
THCA	trans	rs7945404	0.548	rs10750188	ENSG00000230779.1	RP1-140J1.4	-5.62	3.26e-08	0.034	-0.33	-0.25	QT interval;	chr11:121359537	chr1:153225080~153226006:+
THCA	trans	rs853679	0.607	rs66886492	ENSG00000248290.1	TNXA	-5.62	3.26e-08	0.034	-0.55	-0.25	Depression;	chr6:28121953	chr6:32008614~32012472:-
THCA	trans	rs853679	0.607	rs35345226	ENSG00000248290.1	TNXA	-5.62	3.26e-08	0.034	-0.55	-0.25	Depression;	chr6:28123802	chr6:32008614~32012472:-
THCA	trans	rs875971	0.545	rs6460276	ENSG00000213640.3	EEF1DP4	-5.62	3.26e-08	0.034	-0.33	-0.25	Aortic root size;	chr7:66182290	chr7:64862999~64864370:+
THCA	trans	rs9650657	0.515	rs7820860	ENSG00000254153.1	CTA-398F10.2	5.62	3.26e-08	0.034	0.28	0.25	Neuroticism;	chr8:11092886	chr8:8456909~8461337:-
THCA	trans	rs13315469	0.859	rs7615625	ENSG00000271933.1	RP11-338I21.1	5.62	3.27e-08	0.034	0.22	0.25	Lymphocyte counts;	chr3:171150138	chr10:84138420~84140582:-
THCA	trans	rs9368481	0.761	rs9357030	ENSG00000228022.4	HCG20	-5.62	3.28e-08	0.0341	-0.32	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:30766825~30792250:+
THCA	trans	rs35607894	0.948	rs35077074	ENSG00000187686.4	KRT18P59	5.62	3.28e-08	0.0341	0.35	0.25	Schizophrenia;	chr14:71941485	chr11:125113161~125126781:+
THCA	trans	rs7819412	0.522	rs4841497	ENSG00000254153.1	CTA-398F10.2	5.62	3.28e-08	0.0341	0.29	0.25	Triglycerides;	chr8:11127630	chr8:8456909~8461337:-
THCA	trans	rs7746199	0.736	rs58616630	ENSG00000204338.7	CYP21A1P	-5.62	3.28e-08	0.0342	-0.55	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs34573979	ENSG00000204338.7	CYP21A1P	-5.62	3.28e-08	0.0342	-0.55	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:32005636~32008451:+
THCA	trans	rs9470794	1	rs11753759	ENSG00000279138.1	KB-1742H10.3	5.62	3.29e-08	0.0342	0.57	0.25	Type 2 diabetes;	chr6:38140962	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs75847900	ENSG00000279138.1	KB-1742H10.3	5.62	3.29e-08	0.0342	0.57	0.25	Type 2 diabetes;	chr6:38143176	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73421889	ENSG00000279138.1	KB-1742H10.3	5.62	3.29e-08	0.0342	0.57	0.25	Type 2 diabetes;	chr6:38143380	chr8:104478539~104480783:-
THCA	trans	rs9329221	0.935	rs6601450	ENSG00000256560.1	LINC01486	5.62	3.29e-08	0.0342	0.29	0.25	Neuroticism;	chr8:10385591	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.701	rs4568582	ENSG00000254153.1	CTA-398F10.2	-5.62	3.29e-08	0.0342	-0.28	-0.25	Retinal vascular caliber;	chr8:11302986	chr8:8456909~8461337:-
THCA	trans	rs9596837	0.514	rs9596841	ENSG00000234192.1	RP11-57C13.5	-5.62	3.3e-08	0.0343	-0.32	-0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53696332	chr10:87642607~87642954:+
THCA	trans	rs2439831	1	rs565007	ENSG00000180867.10	PDIA3P1	-5.62	3.3e-08	0.0343	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43424443	chr1:147178113~147179622:+
THCA	trans	rs2439831	1	rs550239	ENSG00000180867.10	PDIA3P1	-5.62	3.3e-08	0.0343	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43427999	chr1:147178113~147179622:+
THCA	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	5.62	3.31e-08	0.0344	0.35	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
THCA	trans	rs12477438	0.52	rs4588238	ENSG00000276576.1	MRPL30P1	5.62	3.31e-08	0.0344	0.32	0.25	Chronic sinus infection;	chr2:99132887	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs13018891	ENSG00000276576.1	MRPL30P1	5.62	3.31e-08	0.0344	0.32	0.25	Chronic sinus infection;	chr2:99138636	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6542865	ENSG00000276576.1	MRPL30P1	5.62	3.31e-08	0.0344	0.32	0.25	Chronic sinus infection;	chr2:99148058	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs11883676	ENSG00000276576.1	MRPL30P1	5.62	3.31e-08	0.0344	0.32	0.25	Chronic sinus infection;	chr2:99184351	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.501	rs6753063	ENSG00000276576.1	MRPL30P1	5.62	3.31e-08	0.0344	0.32	0.25	Chronic sinus infection;	chr2:99185006	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6756650	ENSG00000276576.1	MRPL30P1	5.62	3.31e-08	0.0344	0.32	0.25	Chronic sinus infection;	chr2:99185337	chr6:57029521~57029988:+
THCA	trans	rs9467711	0.659	rs34605993	ENSG00000219392.1	RP1-265C24.5	-5.62	3.31e-08	0.0344	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs66757203	ENSG00000219392.1	RP1-265C24.5	-5.62	3.31e-08	0.0344	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26454728	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs35680819	ENSG00000219392.1	RP1-265C24.5	-5.62	3.31e-08	0.0344	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.659	rs36033628	ENSG00000219392.1	RP1-265C24.5	-5.62	3.31e-08	0.0344	-0.58	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26455846	chr6:28115628~28116551:+
THCA	trans	rs7260598	1	rs62117633	ENSG00000261770.1	CTC-459F4.1	5.62	3.31e-08	0.0344	0.4	0.25	Response to taxane treatment (placlitaxel);	chr19:24036672	chr19:27757184~27760849:-
THCA	trans	rs7819412	0.642	rs11250117	ENSG00000254153.1	CTA-398F10.2	5.62	3.32e-08	0.0345	0.29	0.25	Triglycerides;	chr8:11115230	chr8:8456909~8461337:-
THCA	trans	rs875971	0.789	rs28815324	ENSG00000213640.3	EEF1DP4	5.62	3.32e-08	0.0345	0.34	0.25	Aortic root size;	chr7:66100789	chr7:64862999~64864370:+
THCA	trans	rs9467711	0.659	rs36162392	ENSG00000253570.1	RNF5P1	5.62	3.32e-08	0.0345	0.65	0.25	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr8:38600661~38601200:-
THCA	trans	rs7113874	0.569	rs7131358	ENSG00000266891.1	RP11-692N5.2	5.62	3.33e-08	0.0346	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8536786	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.55	rs2044464	ENSG00000266891.1	RP11-692N5.2	5.62	3.33e-08	0.0346	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8538148	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.524	rs10743076	ENSG00000266891.1	RP11-692N5.2	5.62	3.33e-08	0.0346	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8539024	chr18:9734882~9735602:-
THCA	trans	rs7716600	0.501	rs1438827	ENSG00000231752.4	EMBP1	5.62	3.33e-08	0.0346	0.35	0.25	Breast cancer;	chr5:44751854	chr1:121519112~121571892:+
THCA	trans	rs7260598	0.579	rs9676579	ENSG00000261770.1	CTC-459F4.1	5.62	3.34e-08	0.0347	0.4	0.25	Response to taxane treatment (placlitaxel);	chr19:24029180	chr19:27757184~27760849:-
THCA	trans	rs7260598	0.818	rs11666653	ENSG00000261770.1	CTC-459F4.1	5.62	3.34e-08	0.0347	0.4	0.25	Response to taxane treatment (placlitaxel);	chr19:24037440	chr19:27757184~27760849:-
THCA	trans	rs1962073	0.529	rs13258627	ENSG00000253893.2	FAM85B	-5.62	3.34e-08	0.0347	-0.34	-0.25	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10417068	chr8:8167819~8226614:-
THCA	trans	rs3096299	0.719	rs2965817	ENSG00000215030.5	RPL13P12	-5.62	3.34e-08	0.0347	-0.25	-0.25	Multiple myeloma (IgH translocation);	chr16:89446826	chr17:17383377~17384012:-
THCA	trans	rs4879656	0.966	rs10813912	ENSG00000215007.3	DNAJA1P3	5.62	3.34e-08	0.0347	0.31	0.25	Menopause (age at onset);	chr9:32975212	chrX:107351650~107352843:-
THCA	trans	rs56114371	0.777	rs200482	ENSG00000228022.4	HCG20	-5.62	3.34e-08	0.0347	-0.48	-0.25	Breast cancer;	chr6:27806126	chr6:30766825~30792250:+
THCA	trans	rs546131	0.928	rs572690	ENSG00000225531.1	RP11-196I18.3	5.62	3.34e-08	0.0347	0.33	0.25	Lung disease severity in cystic fibrosis;	chr11:34812067	chr9:107116829~107117557:+
THCA	trans	rs6921919	0.848	rs6903823	ENSG00000228078.1	HLA-U	-5.62	3.35e-08	0.0348	-0.35	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:29934101~29934286:+
THCA	trans	rs4936894	0.5	rs4936919	ENSG00000196933.5	RPS26P11	5.62	3.35e-08	0.0348	0.32	0.25	Aging (time to death);	chr11:124310186	chrX:72044545~72044892:+
THCA	trans	rs12989701	1	rs12989701	ENSG00000218208.1	RP11-367G18.2	-5.62	3.36e-08	0.0348	-0.33	-0.25	Alzheimer's disease (late onset);	chr2:127130409	chr6:113581501~113581947:+
THCA	trans	rs11098499	0.604	rs17051352	ENSG00000253326.2	RP11-261C10.7	5.62	3.36e-08	0.0349	0.36	0.25	Corneal astigmatism;	chr4:119660272	chr1:243054861~243056394:-
THCA	trans	rs9650315	0.778	rs71519447	ENSG00000244245.1	RP11-120B7.1	5.62	3.36e-08	0.0349	0.4	0.25	Height;	chr8:56244984	chr5:108593609~108593967:+
THCA	trans	rs9650315	0.778	rs55811836	ENSG00000244245.1	RP11-120B7.1	5.62	3.36e-08	0.0349	0.4	0.25	Height;	chr8:56245781	chr5:108593609~108593967:+
THCA	trans	rs9470794	1	rs57180729	ENSG00000279138.1	KB-1742H10.3	5.62	3.36e-08	0.0349	0.56	0.25	Type 2 diabetes;	chr6:38016088	chr8:104478539~104480783:-
THCA	trans	rs1381660	0.74	rs12676826	ENSG00000260711.2	RP11-747H7.3	-5.62	3.36e-08	0.0349	-0.22	-0.25	Body mass index;Body mass index in physically active individuals;	chr8:75947158	chr14:91752856~91759798:-
THCA	trans	rs61946325	0.938	rs12430881	ENSG00000250412.1	KLHL2P1	5.61	3.37e-08	0.035	0.33	0.25	Monocyte count;	chr13:28020665	chr4:119334329~119378233:+
THCA	trans	rs7824557	1	rs7824557	ENSG00000254153.1	CTA-398F10.2	5.61	3.37e-08	0.035	0.27	0.25	Retinal vascular caliber;	chr8:11246602	chr8:8456909~8461337:-
THCA	trans	rs902774	0.818	rs4919763	ENSG00000240668.1	KRT8P36	-5.61	3.39e-08	0.0352	-0.52	-0.25	Prostate cancer;	chr12:52885839	chr3:138101478~138102917:-
THCA	trans	rs902774	0.818	rs55914512	ENSG00000240668.1	KRT8P36	-5.61	3.39e-08	0.0352	-0.52	-0.25	Prostate cancer;	chr12:52888490	chr3:138101478~138102917:-
THCA	trans	rs902774	0.818	rs73108466	ENSG00000240668.1	KRT8P36	-5.61	3.39e-08	0.0352	-0.52	-0.25	Prostate cancer;	chr12:52889857	chr3:138101478~138102917:-
THCA	trans	rs902774	0.818	rs55999178	ENSG00000240668.1	KRT8P36	-5.61	3.39e-08	0.0352	-0.52	-0.25	Prostate cancer;	chr12:52890576	chr3:138101478~138102917:-
THCA	trans	rs1908814	0.509	rs13282439	ENSG00000254153.1	CTA-398F10.2	-5.61	3.39e-08	0.0352	-0.29	-0.25	Neuroticism;	chr8:11937392	chr8:8456909~8461337:-
THCA	trans	rs11668609	1	rs4452076	ENSG00000261770.1	CTC-459F4.1	5.61	3.4e-08	0.0352	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24143981	chr19:27757184~27760849:-
THCA	trans	rs9393777	0.72	rs36022097	ENSG00000204338.7	CYP21A1P	-5.61	3.4e-08	0.0352	-0.45	-0.25	Intelligence (multi-trait analysis);	chr6:27027389	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.72	rs35212793	ENSG00000204338.7	CYP21A1P	-5.61	3.4e-08	0.0352	-0.45	-0.25	Intelligence (multi-trait analysis);	chr6:27030914	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.72	rs35769282	ENSG00000204338.7	CYP21A1P	-5.61	3.4e-08	0.0352	-0.45	-0.25	Intelligence (multi-trait analysis);	chr6:27032129	chr6:32005636~32008451:+
THCA	trans	rs7929679	0.602	rs10501135	ENSG00000225531.1	RP11-196I18.3	5.61	3.4e-08	0.0352	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34789633	chr9:107116829~107117557:+
THCA	trans	rs2349775	0.824	rs11980578	ENSG00000253177.1	RP11-100L22.1	5.61	3.4e-08	0.0353	0.24	0.25	Neuroticism;	chr7:8646408	chr8:92668836~92679594:+
THCA	trans	rs10918270	0.664	rs7553368	ENSG00000279800.1	ABBA01017803.1	-5.61	3.41e-08	0.0353	-0.31	-0.25	Parkinson's disease (age of onset);	chr1:161770520	chr16:34266044~34268649:-
THCA	trans	rs930395	0.514	rs10070037	ENSG00000231752.4	EMBP1	-5.61	3.41e-08	0.0354	-0.35	-0.25	Breast cancer;	chr5:44870135	chr1:121519112~121571892:+
THCA	trans	rs7829975	0.511	rs2980426	ENSG00000256560.1	LINC01486	5.61	3.41e-08	0.0354	0.3	0.25	Mood instability;	chr8:8288087	chr12:109354083~109359488:-
THCA	trans	rs9393777	0.778	rs35608615	ENSG00000228022.4	HCG20	-5.61	3.41e-08	0.0354	-0.54	-0.25	Intelligence (multi-trait analysis);	chr6:27072623	chr6:30766825~30792250:+
THCA	trans	rs9393777	0.778	rs35526527	ENSG00000228022.4	HCG20	-5.61	3.41e-08	0.0354	-0.54	-0.25	Intelligence (multi-trait analysis);	chr6:27074508	chr6:30766825~30792250:+
THCA	trans	rs12210905	1	rs115268625	ENSG00000242375.1	RP11-498P14.3	-5.61	3.41e-08	0.0354	-0.68	-0.25	Hip circumference adjusted for BMI;	chr6:26980450	chr9:97195351~97197687:-
THCA	trans	rs12210905	1	rs12192446	ENSG00000242375.1	RP11-498P14.3	-5.61	3.41e-08	0.0354	-0.68	-0.25	Hip circumference adjusted for BMI;	chr6:27027859	chr9:97195351~97197687:-
THCA	trans	rs12210905	1	rs76889265	ENSG00000242375.1	RP11-498P14.3	-5.61	3.41e-08	0.0354	-0.68	-0.25	Hip circumference adjusted for BMI;	chr6:27041056	chr9:97195351~97197687:-
THCA	trans	rs7903456	0.648	rs9421573	ENSG00000232706.3	NUTM2HP	5.61	3.42e-08	0.0354	0.37	0.25	Gout;Renal underexcretion gout;	chr10:87061945	chr10:50676743~50686326:+
THCA	trans	rs4269515	0.764	rs7827343	ENSG00000219891.2	ZSCAN12P1	5.61	3.42e-08	0.0354	0.32	0.25	Dental caries;	chr8:106874764	chr6:28091154~28093664:+
THCA	trans	rs4269515	0.764	rs7843994	ENSG00000219891.2	ZSCAN12P1	5.61	3.42e-08	0.0354	0.32	0.25	Dental caries;	chr8:106874946	chr6:28091154~28093664:+
THCA	trans	rs4269515	0.764	rs4734933	ENSG00000219891.2	ZSCAN12P1	5.61	3.42e-08	0.0354	0.32	0.25	Dental caries;	chr8:106875995	chr6:28091154~28093664:+
THCA	trans	rs4269515	0.665	rs4524762	ENSG00000219891.2	ZSCAN12P1	5.61	3.42e-08	0.0354	0.32	0.25	Dental caries;	chr8:106876475	chr6:28091154~28093664:+
THCA	trans	rs7595950	0.51	rs4141842	ENSG00000234183.1	AC004854.4	-5.61	3.42e-08	0.0355	-0.26	-0.25	Major depression and alcohol dependence;	chr2:59996077	chr7:44848416~44849568:+
THCA	trans	rs12989701	1	rs13009551	ENSG00000218208.1	RP11-367G18.2	-5.61	3.42e-08	0.0355	-0.33	-0.25	Alzheimer's disease (late onset);	chr2:127131542	chr6:113581501~113581947:+
THCA	trans	rs6981523	0.553	rs11783890	ENSG00000254153.1	CTA-398F10.2	5.61	3.42e-08	0.0355	0.29	0.25	Neuroticism;	chr8:11198879	chr8:8456909~8461337:-
THCA	trans	rs10090774	0.901	rs11997937	ENSG00000230756.1	RHOQP3	5.61	3.43e-08	0.0355	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140957252	chr2:130212870~130213490:-
THCA	trans	rs9329221	0.682	rs6982308	ENSG00000256560.1	LINC01486	-5.61	3.43e-08	0.0355	-0.3	-0.25	Neuroticism;	chr8:10336262	chr12:109354083~109359488:-
THCA	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	5.61	3.43e-08	0.0355	0.36	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
THCA	trans	rs9368481	0.547	rs2093303	ENSG00000242375.1	RP11-498P14.3	5.61	3.43e-08	0.0355	0.35	0.25	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr9:97195351~97197687:-
THCA	trans	rs7824557	0.767	rs10104728	ENSG00000254153.1	CTA-398F10.2	-5.61	3.44e-08	0.0356	-0.28	-0.25	Retinal vascular caliber;	chr8:11313791	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.836	rs765731	ENSG00000254153.1	CTA-398F10.2	5.61	3.44e-08	0.0357	0.27	0.25	Retinal vascular caliber;	chr8:11263989	chr8:8456909~8461337:-
THCA	trans	rs4140564	0.73	rs10752974	ENSG00000227939.1	RPL3P2	5.61	3.44e-08	0.0357	0.33	0.25	Knee osteoarthritis;	chr1:186775742	chr6:31280317~31281519:+
THCA	trans	rs4140564	0.73	rs2205951	ENSG00000227939.1	RPL3P2	5.61	3.44e-08	0.0357	0.33	0.25	Knee osteoarthritis;	chr1:186777189	chr6:31280317~31281519:+
THCA	trans	rs9650657	0.655	rs1991651	ENSG00000229857.1	RP11-159H20.3	-5.61	3.44e-08	0.0357	-0.31	-0.25	Neuroticism;	chr8:10848901	chr9:76992099~76993108:+
THCA	trans	rs950169	0.96	rs12905475	ENSG00000259295.5	CSPG4P12	5.61	3.45e-08	0.0357	0.4	0.25	Schizophrenia;	chr15:84131743	chr15:85191438~85213905:+
THCA	trans	rs7945705	0.715	rs10840123	ENSG00000266891.1	RP11-692N5.2	-5.61	3.45e-08	0.0357	-0.33	-0.25	Hemoglobin concentration;	chr11:8797468	chr18:9734882~9735602:-
THCA	trans	rs7746199	0.736	rs13195636	ENSG00000253570.1	RNF5P1	5.61	3.45e-08	0.0358	0.7	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr8:38600661~38601200:-
THCA	trans	rs9329221	0.905	rs6601451	ENSG00000254153.1	CTA-398F10.2	5.61	3.45e-08	0.0358	0.27	0.25	Neuroticism;	chr8:10386171	chr8:8456909~8461337:-
THCA	trans	rs7429990	0.833	rs2293226	ENSG00000235912.1	RP1-159A19.3	-5.61	3.46e-08	0.0358	-0.31	-0.25	Educational attainment (years of education);	chr3:47585292	chr1:27649419~27649610:+
THCA	trans	rs11992162	0.548	rs4841631	ENSG00000229857.1	RP11-159H20.3	5.61	3.46e-08	0.0358	0.32	0.25	Monocyte count;	chr8:11924159	chr9:76992099~76993108:+
THCA	trans	rs2898290	0.622	rs978804	ENSG00000254153.1	CTA-398F10.2	5.61	3.46e-08	0.0358	0.29	0.25	Systolic blood pressure;	chr8:11486164	chr8:8456909~8461337:-
THCA	trans	rs1232027	0.7	rs1677694	ENSG00000188985.6	DHFRP1	-5.61	3.46e-08	0.0358	-0.33	-0.25	Huntington's disease progression;	chr5:80640478	chr18:26170726~26171284:-
THCA	trans	rs875971	0.545	rs10950029	ENSG00000213640.3	EEF1DP4	-5.61	3.46e-08	0.0359	-0.33	-0.25	Aortic root size;	chr7:66169334	chr7:64862999~64864370:+
THCA	trans	rs12477438	0.52	rs11695379	ENSG00000276576.1	MRPL30P1	5.61	3.47e-08	0.0359	0.32	0.25	Chronic sinus infection;	chr2:99125698	chr6:57029521~57029988:+
THCA	trans	rs11992162	0.56	rs7846248	ENSG00000254153.1	CTA-398F10.2	-5.61	3.47e-08	0.0359	-0.29	-0.25	Monocyte count;	chr8:11936540	chr8:8456909~8461337:-
THCA	trans	rs4929949	0.618	rs7929500	ENSG00000266891.1	RP11-692N5.2	5.61	3.47e-08	0.0359	0.33	0.25	Body mass index;	chr11:8403043	chr18:9734882~9735602:-
THCA	trans	rs7746199	0.736	rs13209332	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs34105070	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.673	rs72845046	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs67652222	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs13212093	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs34038546	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:32005636~32008451:+
THCA	trans	rs141342723	1	rs141342723	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs34543938	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs56405707	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs13210634	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs13215275	ENSG00000204338.7	CYP21A1P	-5.61	3.48e-08	0.036	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:32005636~32008451:+
THCA	trans	rs889398	0.802	rs9940315	ENSG00000257513.6	NPIPB1P	5.61	3.48e-08	0.036	0.28	0.25	Body mass index;	chr16:69842261	chr18:11619509~11639699:-
THCA	trans	rs3096299	0.685	rs4238830	ENSG00000215030.5	RPL13P12	-5.61	3.48e-08	0.036	-0.25	-0.25	Multiple myeloma (IgH translocation);	chr16:89473833	chr17:17383377~17384012:-
THCA	trans	rs10090774	0.93	rs6578132	ENSG00000230756.1	RHOQP3	-5.61	3.48e-08	0.036	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140752459	chr2:130212870~130213490:-
THCA	trans	rs7617773	0.78	rs3197223	ENSG00000235912.1	RP1-159A19.3	-5.61	3.48e-08	0.036	-0.31	-0.25	Coronary artery disease;	chr3:48294367	chr1:27649419~27649610:+
THCA	trans	rs12210905	1	rs72838266	ENSG00000242375.1	RP11-498P14.3	-5.61	3.49e-08	0.0361	-0.68	-0.25	Hip circumference adjusted for BMI;	chr6:27047273	chr9:97195351~97197687:-
THCA	trans	rs12210905	1	rs12201498	ENSG00000242375.1	RP11-498P14.3	-5.61	3.49e-08	0.0361	-0.68	-0.25	Hip circumference adjusted for BMI;	chr6:27062305	chr9:97195351~97197687:-
THCA	trans	rs12210905	1	rs12203728	ENSG00000242375.1	RP11-498P14.3	-5.61	3.49e-08	0.0361	-0.68	-0.25	Hip circumference adjusted for BMI;	chr6:27083971	chr9:97195351~97197687:-
THCA	trans	rs10090774	0.932	rs13256088	ENSG00000230756.1	RHOQP3	5.61	3.5e-08	0.0362	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844857	chr2:130212870~130213490:-
THCA	trans	rs10090774	1	rs4961296	ENSG00000230756.1	RHOQP3	-5.61	3.5e-08	0.0362	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140815482	chr2:130212870~130213490:-
THCA	trans	rs10090774	1	rs11166999	ENSG00000230756.1	RHOQP3	-5.61	3.5e-08	0.0362	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140819711	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13251663	ENSG00000230756.1	RHOQP3	5.61	3.5e-08	0.0362	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140831478	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11167001	ENSG00000230756.1	RHOQP3	5.61	3.5e-08	0.0362	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844303	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.932	rs11167002	ENSG00000230756.1	RHOQP3	5.61	3.5e-08	0.0362	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844410	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs13256101	ENSG00000230756.1	RHOQP3	5.61	3.5e-08	0.0362	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844865	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.896	rs11787521	ENSG00000230756.1	RHOQP3	5.61	3.5e-08	0.0362	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140844994	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10875458	ENSG00000230756.1	RHOQP3	-5.61	3.5e-08	0.0362	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140769727	chr2:130212870~130213490:-
THCA	trans	rs10090774	1	rs6578140	ENSG00000230756.1	RHOQP3	-5.61	3.5e-08	0.0362	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140824011	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs10088621	ENSG00000230756.1	RHOQP3	-5.61	3.5e-08	0.0362	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140828127	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs4961297	ENSG00000230756.1	RHOQP3	-5.61	3.5e-08	0.0362	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140829135	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs4434666	ENSG00000230756.1	RHOQP3	-5.61	3.5e-08	0.0362	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830069	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs4246128	ENSG00000230756.1	RHOQP3	-5.61	3.5e-08	0.0362	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830640	chr2:130212870~130213490:-
THCA	trans	rs9693857	0.518	rs13279136	ENSG00000253893.2	FAM85B	5.61	3.5e-08	0.0362	0.36	0.25	Systolic blood pressure;	chr8:9421436	chr8:8167819~8226614:-
THCA	trans	rs7429990	0.833	rs11716582	ENSG00000235912.1	RP1-159A19.3	5.61	3.5e-08	0.0362	0.31	0.25	Educational attainment (years of education);	chr3:47592269	chr1:27649419~27649610:+
THCA	trans	rs263156	0.967	rs263107	ENSG00000276182.1	RP11-872J21.5	-5.61	3.51e-08	0.0362	-0.21	-0.25	Lobe size;Ear morphology;Lobe attachment;	chr6:142557343	chr14:96537170~96537904:+
THCA	trans	rs3808502	0.563	rs12549144	ENSG00000254153.1	CTA-398F10.2	-5.61	3.51e-08	0.0362	-0.28	-0.25	Neuroticism;	chr8:11565352	chr8:8456909~8461337:-
THCA	trans	rs10090774	0.965	rs6578135	ENSG00000230756.1	RHOQP3	-5.61	3.51e-08	0.0363	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140768550	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs4554515	ENSG00000230756.1	RHOQP3	-5.61	3.51e-08	0.0363	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140768594	chr2:130212870~130213490:-
THCA	trans	rs356220	0.642	rs356172	ENSG00000245479.2	LINC01585	-5.61	3.51e-08	0.0363	-0.3	-0.25	Parkinson's disease;	chr4:89710835	chr15:90660234~90664967:+
THCA	trans	rs356220	0.642	rs356171	ENSG00000245479.2	LINC01585	-5.61	3.51e-08	0.0363	-0.3	-0.25	Parkinson's disease;	chr4:89710872	chr15:90660234~90664967:+
THCA	trans	rs656319	0.564	rs11776035	ENSG00000253893.2	FAM85B	5.61	3.51e-08	0.0363	0.37	0.25	Myopia (pathological);	chr8:10214017	chr8:8167819~8226614:-
THCA	trans	rs656319	0.625	rs34427895	ENSG00000253893.2	FAM85B	5.61	3.52e-08	0.0363	0.34	0.25	Myopia (pathological);	chr8:10017711	chr8:8167819~8226614:-
THCA	trans	rs12472274	0.536	rs12619455	ENSG00000224699.7	LAMTOR5-AS1	-5.61	3.52e-08	0.0364	-0.25	-0.25	Phospholipid levels (plasma);	chr2:238171508	chr1:110347116~110443817:+
THCA	trans	rs6601450	0.522	rs7837979	ENSG00000254153.1	CTA-398F10.2	-5.61	3.53e-08	0.0365	-0.26	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10341024	chr8:8456909~8461337:-
THCA	trans	rs853679	0.607	rs13217984	ENSG00000228022.4	HCG20	-5.61	3.53e-08	0.0365	-0.65	-0.25	Depression;	chr6:28171932	chr6:30766825~30792250:+
THCA	trans	rs853679	0.556	rs67297533	ENSG00000228022.4	HCG20	-5.61	3.53e-08	0.0365	-0.65	-0.25	Depression;	chr6:28173475	chr6:30766825~30792250:+
THCA	trans	rs853679	0.505	rs35781323	ENSG00000228022.4	HCG20	-5.61	3.53e-08	0.0365	-0.65	-0.25	Depression;	chr6:28177054	chr6:30766825~30792250:+
THCA	trans	rs875971	0.545	rs17138149	ENSG00000213640.3	EEF1DP4	-5.61	3.54e-08	0.0365	-0.33	-0.25	Aortic root size;	chr7:66228193	chr7:64862999~64864370:+
THCA	trans	rs11668609	0.81	rs8105851	ENSG00000261770.1	CTC-459F4.1	5.61	3.54e-08	0.0366	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24080533	chr19:27757184~27760849:-
THCA	trans	rs2736345	0.535	rs4366049	ENSG00000253893.2	FAM85B	-5.61	3.55e-08	0.0366	-0.34	-0.25	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11540995	chr8:8167819~8226614:-
THCA	trans	rs2335704	0.649	rs13397179	ENSG00000262870.1	CYCSP40	-5.61	3.55e-08	0.0366	-0.41	-0.25	Tuberculosis;	chr2:205167392	chr17:77198950~77199543:-
THCA	trans	rs546131	0.928	rs552627	ENSG00000225531.1	RP11-196I18.3	5.61	3.55e-08	0.0367	0.34	0.25	Lung disease severity in cystic fibrosis;	chr11:34805133	chr9:107116829~107117557:+
THCA	trans	rs73108077	1	rs73116268	ENSG00000279352.1	RP11-411B10.7	5.6	3.56e-08	0.0368	0.54	0.25	Red blood cell density in sickle cell anemia;	chr20:31461103	chr18:14010054~14010917:+
THCA	trans	rs73108077	1	rs75774213	ENSG00000279352.1	RP11-411B10.7	5.6	3.56e-08	0.0368	0.54	0.25	Red blood cell density in sickle cell anemia;	chr20:31462439	chr18:14010054~14010917:+
THCA	trans	rs9393777	0.777	rs56114371	ENSG00000204338.7	CYP21A1P	-5.6	3.57e-08	0.0368	-0.56	-0.25	Intelligence (multi-trait analysis);	chr6:27307055	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs17749927	ENSG00000204338.7	CYP21A1P	-5.6	3.57e-08	0.0368	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:32005636~32008451:+
THCA	trans	rs7746199	0.736	rs13192965	ENSG00000204338.7	CYP21A1P	-5.6	3.57e-08	0.0368	-0.56	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:32005636~32008451:+
THCA	trans	rs11098499	0.874	rs12509054	ENSG00000253326.2	RP11-261C10.7	5.6	3.57e-08	0.0369	0.34	0.25	Corneal astigmatism;	chr4:119193920	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.874	rs10022508	ENSG00000253326.2	RP11-261C10.7	5.6	3.57e-08	0.0369	0.34	0.25	Corneal astigmatism;	chr4:119194073	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.874	rs12502503	ENSG00000253326.2	RP11-261C10.7	5.6	3.57e-08	0.0369	0.34	0.25	Corneal astigmatism;	chr4:119195100	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.874	rs6832670	ENSG00000253326.2	RP11-261C10.7	5.6	3.57e-08	0.0369	0.34	0.25	Corneal astigmatism;	chr4:119197637	chr1:243054861~243056394:-
THCA	trans	rs11098499	0.874	rs6822498	ENSG00000253326.2	RP11-261C10.7	5.6	3.57e-08	0.0369	0.34	0.25	Corneal astigmatism;	chr4:119199028	chr1:243054861~243056394:-
THCA	trans	rs11668609	1	rs2099360	ENSG00000261770.1	CTC-459F4.1	5.6	3.57e-08	0.0369	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24147361	chr19:27757184~27760849:-
THCA	trans	rs11668609	1	rs2082493	ENSG00000261770.1	CTC-459F4.1	5.6	3.57e-08	0.0369	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24147554	chr19:27757184~27760849:-
THCA	trans	rs9381040	0.655	rs7775972	ENSG00000232097.1	AC079781.8	5.6	3.58e-08	0.0369	0.3	0.25	Alzheimer's disease (late onset);	chr6:41070377	chr7:97938439~97938794:-
THCA	trans	rs9329221	0.905	rs4841329	ENSG00000256560.1	LINC01486	-5.6	3.58e-08	0.037	-0.3	-0.25	Neuroticism;	chr8:10395588	chr12:109354083~109359488:-
THCA	trans	rs356220	0.656	rs356216	ENSG00000245479.2	LINC01585	-5.6	3.59e-08	0.037	-0.31	-0.25	Parkinson's disease;	chr4:89715557	chr15:90660234~90664967:+
THCA	trans	rs902774	1	rs115756021	ENSG00000224520.2	KRT8P45	-5.6	3.59e-08	0.037	-0.47	-0.25	Prostate cancer;	chr12:52881917	chr1:157073257~157074703:+
THCA	trans	rs902774	1	rs17689987	ENSG00000224520.2	KRT8P45	-5.6	3.59e-08	0.037	-0.47	-0.25	Prostate cancer;	chr12:52881962	chr1:157073257~157074703:+
THCA	trans	rs4615179	1	rs73808729	ENSG00000231177.4	LINC00852	5.6	3.59e-08	0.0371	0.34	0.25	Obesity-related traits;	chr4:38470467	chr3:10284419~10285746:+
THCA	trans	rs4615179	0.881	rs55894917	ENSG00000231177.4	LINC00852	5.6	3.59e-08	0.0371	0.34	0.25	Obesity-related traits;	chr4:38474327	chr3:10284419~10285746:+
THCA	trans	rs9467711	0.79	rs13220495	ENSG00000226314.6	ZNF192P1	-5.6	3.6e-08	0.0371	-0.57	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr6:28161781~28169594:+
THCA	trans	rs9467711	0.606	rs9379875	ENSG00000219392.1	RP1-265C24.5	-5.6	3.6e-08	0.0371	-0.48	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26444504	chr6:28115628~28116551:+
THCA	trans	rs9467711	0.538	rs35942482	ENSG00000219392.1	RP1-265C24.5	-5.6	3.6e-08	0.0371	-0.48	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26444710	chr6:28115628~28116551:+
THCA	trans	rs7429990	0.833	rs4858801	ENSG00000235912.1	RP1-159A19.3	5.6	3.6e-08	0.0371	0.3	0.25	Educational attainment (years of education);	chr3:47599432	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs61620099	ENSG00000235912.1	RP1-159A19.3	5.6	3.6e-08	0.0371	0.3	0.25	Educational attainment (years of education);	chr3:47600755	chr1:27649419~27649610:+
THCA	trans	rs4788439	1	rs56149730	ENSG00000227782.2	CTC-529I10.2	-5.6	3.6e-08	0.0371	-0.33	-0.25	Blood metabolite levels;	chr16:24935075	chr17:16040472~16041273:+
THCA	trans	rs12439619	0.774	rs62012047	ENSG00000235370.6	DNM1P51	-5.6	3.61e-08	0.0372	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82236852	chr15:84398316~84411701:-
THCA	trans	rs7113874	0.569	rs9300093	ENSG00000266891.1	RP11-692N5.2	5.6	3.61e-08	0.0372	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8569278	chr18:9734882~9735602:-
THCA	trans	rs12439619	0.846	rs62012004	ENSG00000235370.6	DNM1P51	-5.6	3.63e-08	0.0374	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82183924	chr15:84398316~84411701:-
THCA	trans	rs4263408	0.755	rs13108552	ENSG00000237550.5	UBE2Q2P6	5.6	3.63e-08	0.0374	0.3	0.25	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39650252	chr15:82372196~82372912:-
THCA	trans	rs12477438	0.52	rs11123766	ENSG00000276576.1	MRPL30P1	5.6	3.63e-08	0.0374	0.32	0.25	Chronic sinus infection;	chr2:99164452	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs2964969	ENSG00000276576.1	MRPL30P1	5.6	3.63e-08	0.0374	0.32	0.25	Chronic sinus infection;	chr2:99166348	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs2171359	ENSG00000276576.1	MRPL30P1	5.6	3.63e-08	0.0374	0.32	0.25	Chronic sinus infection;	chr2:99178897	chr6:57029521~57029988:+
THCA	trans	rs12477438	0.52	rs6542870	ENSG00000276576.1	MRPL30P1	5.6	3.63e-08	0.0374	0.32	0.25	Chronic sinus infection;	chr2:99180175	chr6:57029521~57029988:+
THCA	trans	rs9381040	0.61	rs6940462	ENSG00000232097.1	AC079781.8	5.6	3.63e-08	0.0374	0.3	0.25	Alzheimer's disease (late onset);	chr6:41052484	chr7:97938439~97938794:-
THCA	trans	rs9329221	0.51	rs4841282	ENSG00000253893.2	FAM85B	-5.6	3.63e-08	0.0374	-0.31	-0.25	Neuroticism;	chr8:10118094	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.967	rs7005363	ENSG00000254153.1	CTA-398F10.2	5.6	3.64e-08	0.0374	0.27	0.25	Neuroticism;	chr8:10426238	chr8:8456909~8461337:-
THCA	trans	rs950169	1	rs11638394	ENSG00000259295.5	CSPG4P12	5.6	3.64e-08	0.0375	0.38	0.25	Schizophrenia;	chr15:84110176	chr15:85191438~85213905:+
THCA	trans	rs950169	1	rs35658069	ENSG00000259295.5	CSPG4P12	5.6	3.64e-08	0.0375	0.38	0.25	Schizophrenia;	chr15:84111394	chr15:85191438~85213905:+
THCA	trans	rs73108077	1	rs73116272	ENSG00000279352.1	RP11-411B10.7	5.6	3.64e-08	0.0375	0.53	0.25	Red blood cell density in sickle cell anemia;	chr20:31467430	chr18:14010054~14010917:+
THCA	trans	rs73108077	1	rs117762506	ENSG00000279352.1	RP11-411B10.7	5.6	3.64e-08	0.0375	0.53	0.25	Red blood cell density in sickle cell anemia;	chr20:31467935	chr18:14010054~14010917:+
THCA	trans	rs9467711	0.606	rs13190739	ENSG00000253570.1	RNF5P1	5.6	3.64e-08	0.0375	0.67	0.25	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.606	rs34781270	ENSG00000253570.1	RNF5P1	5.6	3.64e-08	0.0375	0.67	0.25	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.606	rs35076545	ENSG00000253570.1	RNF5P1	5.6	3.64e-08	0.0375	0.67	0.25	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr8:38600661~38601200:-
THCA	trans	rs9467711	0.606	rs13212985	ENSG00000253570.1	RNF5P1	5.6	3.64e-08	0.0375	0.67	0.25	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr8:38600661~38601200:-
THCA	trans	rs11739656	1	rs11739656	ENSG00000245532.5	NEAT1	5.6	3.64e-08	0.0375	0.29	0.25	Night sleep phenotypes;	chr5:174767801	chr11:65422774~65445540:+
THCA	trans	rs4646450	0.891	rs11972285	ENSG00000228834.1	RP11-249L21.4	5.6	3.64e-08	0.0375	0.39	0.25	Blood metabolite levels;	chr7:99427968	chr6:108907615~108907873:-
THCA	trans	rs860295	0.529	rs17381047	ENSG00000241627.3	UBQLN4P1	5.6	3.64e-08	0.0375	0.28	0.25	Body mass index;	chr1:156013857	chr3:148985868~148987668:-
THCA	trans	rs9329221	0.905	rs4433149	ENSG00000256560.1	LINC01486	-5.6	3.64e-08	0.0375	-0.3	-0.25	Neuroticism;	chr8:10391758	chr12:109354083~109359488:-
THCA	trans	rs9393777	0.92	rs35869525	ENSG00000280107.1	AL022393.9	-5.6	3.65e-08	0.0375	-0.47	-0.25	Intelligence (multi-trait analysis);	chr6:26978908	chr6:28170845~28172521:+
THCA	trans	rs9650657	0.615	rs7012199	ENSG00000253893.2	FAM85B	5.6	3.65e-08	0.0376	0.31	0.25	Neuroticism;	chr8:10839487	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.617	rs483916	ENSG00000253981.4	ALG1L13P	-5.6	3.65e-08	0.0376	-0.25	-0.25	Neuroticism;	chr8:9936091	chr8:8236003~8244667:-
THCA	trans	rs6894216	0.651	rs6868888	ENSG00000237714.1	P4HA2-AS1	5.6	3.66e-08	0.0376	0.31	0.25	Response to amphetamines;	chr5:130348857	chr5:132184876~132192808:+
THCA	trans	rs9381040	0.655	rs9381029	ENSG00000232097.1	AC079781.8	5.6	3.66e-08	0.0377	0.3	0.25	Alzheimer's disease (late onset);	chr6:41058714	chr7:97938439~97938794:-
THCA	trans	rs3096299	0.754	rs2965816	ENSG00000215030.5	RPL13P12	5.6	3.66e-08	0.0377	0.25	0.25	Multiple myeloma (IgH translocation);	chr16:89447775	chr17:17383377~17384012:-
THCA	trans	rs804280	0.509	rs9886639	ENSG00000254153.1	CTA-398F10.2	-5.6	3.66e-08	0.0377	-0.29	-0.25	Myopia (pathological);	chr8:11927020	chr8:8456909~8461337:-
THCA	trans	rs1326986	0.826	rs11010359	ENSG00000237396.1	LINC01384	5.6	3.67e-08	0.0377	0.44	0.25	Ankylosing spondylitis;	chr10:19562642	chr20:22587522~22607517:-
THCA	trans	rs875971	0.52	rs160645	ENSG00000213640.3	EEF1DP4	5.6	3.67e-08	0.0378	0.34	0.25	Aortic root size;	chr7:66091320	chr7:64862999~64864370:+
THCA	trans	rs875971	0.545	rs10950036	ENSG00000213640.3	EEF1DP4	-5.6	3.67e-08	0.0378	-0.33	-0.25	Aortic root size;	chr7:66353241	chr7:64862999~64864370:+
THCA	trans	rs875971	0.545	rs73148639	ENSG00000213640.3	EEF1DP4	-5.6	3.67e-08	0.0378	-0.33	-0.25	Aortic root size;	chr7:66390342	chr7:64862999~64864370:+
THCA	trans	rs13177918	0.603	rs2748241	ENSG00000226396.1	RP5-1056L3.3	5.6	3.68e-08	0.0378	0.23	0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:19608114~19608568:+
THCA	trans	rs10090774	0.965	rs11786116	ENSG00000230756.1	RHOQP3	5.6	3.68e-08	0.0378	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140853997	chr2:130212870~130213490:-
THCA	trans	rs875971	0.545	rs2420456	ENSG00000213640.3	EEF1DP4	-5.6	3.68e-08	0.0378	-0.33	-0.25	Aortic root size;	chr7:66280619	chr7:64862999~64864370:+
THCA	trans	rs77688320	0.613	rs80252786	ENSG00000235105.1	RP11-329A14.1	-5.6	3.68e-08	0.0378	-0.41	-0.25	Breast cancer;	chr2:201058759	chr1:48435967~48437223:+
THCA	trans	rs7617480	0.648	rs4858830	ENSG00000235912.1	RP1-159A19.3	-5.6	3.69e-08	0.0379	-0.39	-0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48696569	chr1:27649419~27649610:+
THCA	trans	rs7617480	0.544	rs6442129	ENSG00000235912.1	RP1-159A19.3	-5.6	3.69e-08	0.0379	-0.39	-0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48697823	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.52	rs78838427	ENSG00000235912.1	RP1-159A19.3	5.6	3.69e-08	0.0379	0.3	0.25	Educational attainment (years of education);	chr3:47595561	chr1:27649419~27649610:+
THCA	trans	rs11764116	0.54	rs6951973	ENSG00000235649.2	MXRA5Y	5.6	3.69e-08	0.0379	0.39	0.25	Ulcerative colitis;	chr7:18777644	chrY:11957208~11987386:+
THCA	trans	rs7945705	0.846	rs11042055	ENSG00000266891.1	RP11-692N5.2	-5.6	3.69e-08	0.0379	-0.33	-0.25	Hemoglobin concentration;	chr11:8735309	chr18:9734882~9735602:-
THCA	trans	rs6894216	0.651	rs6869287	ENSG00000237714.1	P4HA2-AS1	-5.6	3.69e-08	0.0379	-0.31	-0.25	Response to amphetamines;	chr5:130348863	chr5:132184876~132192808:+
THCA	trans	rs6894216	0.62	rs6869219	ENSG00000237714.1	P4HA2-AS1	-5.6	3.69e-08	0.0379	-0.31	-0.25	Response to amphetamines;	chr5:130349084	chr5:132184876~132192808:+
THCA	trans	rs9329221	0.537	rs6986911	ENSG00000253893.2	FAM85B	-5.6	3.69e-08	0.0379	-0.31	-0.25	Neuroticism;	chr8:10121013	chr8:8167819~8226614:-
THCA	trans	rs4687717	0.544	rs587871	ENSG00000224820.2	BTF3P4	-5.6	3.7e-08	0.038	-0.27	-0.25	Blood metabolite levels;Blood metabolite ratios;	chr3:53447270	chr9:72107818~72108312:-
THCA	trans	rs7617773	0.78	rs13079728	ENSG00000235912.1	RP1-159A19.3	-5.6	3.7e-08	0.038	-0.31	-0.25	Coronary artery disease;	chr3:48297870	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs77044321	ENSG00000235912.1	RP1-159A19.3	-5.6	3.7e-08	0.038	-0.31	-0.25	Coronary artery disease;	chr3:48307824	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.746	rs4371540	ENSG00000235912.1	RP1-159A19.3	-5.6	3.7e-08	0.038	-0.31	-0.25	Coronary artery disease;	chr3:48312053	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.743	rs13081633	ENSG00000235912.1	RP1-159A19.3	-5.6	3.7e-08	0.038	-0.31	-0.25	Coronary artery disease;	chr3:48315791	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs11718350	ENSG00000235912.1	RP1-159A19.3	-5.6	3.7e-08	0.038	-0.31	-0.25	Coronary artery disease;	chr3:48319502	chr1:27649419~27649610:+
THCA	trans	rs3808502	0.526	rs7823100	ENSG00000254153.1	CTA-398F10.2	5.6	3.7e-08	0.038	0.28	0.25	Neuroticism;	chr8:11564982	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.526	rs7823101	ENSG00000254153.1	CTA-398F10.2	5.6	3.7e-08	0.038	0.28	0.25	Neuroticism;	chr8:11564983	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.526	rs11985709	ENSG00000254153.1	CTA-398F10.2	5.6	3.7e-08	0.038	0.28	0.25	Neuroticism;	chr8:11565574	chr8:8456909~8461337:-
THCA	trans	rs9914988	0.887	rs2070265	ENSG00000267449.1	RP11-264B14.2	-5.6	3.71e-08	0.0381	-0.37	-0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28748405	chr17:61069856~61070356:-
THCA	trans	rs9393777	0.622	rs13191326	ENSG00000204338.7	CYP21A1P	-5.6	3.71e-08	0.0381	-0.48	-0.25	Intelligence (multi-trait analysis);	chr6:27063250	chr6:32005636~32008451:+
THCA	trans	rs6894216	0.532	rs6876137	ENSG00000237714.1	P4HA2-AS1	-5.6	3.72e-08	0.0382	-0.31	-0.25	Response to amphetamines;	chr5:130337513	chr5:132184876~132192808:+
THCA	trans	rs875971	0.502	rs2946580	ENSG00000213640.3	EEF1DP4	5.6	3.72e-08	0.0382	0.34	0.25	Aortic root size;	chr7:66066855	chr7:64862999~64864370:+
THCA	trans	rs9381040	0.61	rs2235679	ENSG00000232097.1	AC079781.8	5.6	3.72e-08	0.0382	0.3	0.25	Alzheimer's disease (late onset);	chr6:41052838	chr7:97938439~97938794:-
THCA	trans	rs4929949	0.618	rs7112477	ENSG00000266891.1	RP11-692N5.2	5.6	3.72e-08	0.0382	0.33	0.25	Body mass index;	chr11:8382152	chr18:9734882~9735602:-
THCA	trans	rs7824557	0.767	rs3808509	ENSG00000229857.1	RP11-159H20.3	-5.6	3.72e-08	0.0382	-0.32	-0.25	Retinal vascular caliber;	chr8:11305747	chr9:76992099~76993108:+
THCA	trans	rs9368481	0.761	rs12661756	ENSG00000228022.4	HCG20	5.6	3.73e-08	0.0383	0.33	0.25	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:30766825~30792250:+
THCA	trans	rs7824557	0.564	rs2736295	ENSG00000256560.1	LINC01486	5.6	3.73e-08	0.0383	0.31	0.25	Retinal vascular caliber;	chr8:11377271	chr12:109354083~109359488:-
THCA	trans	rs7819412	0.521	rs10110684	ENSG00000254153.1	CTA-398F10.2	5.6	3.73e-08	0.0383	0.29	0.25	Triglycerides;	chr8:11181650	chr8:8456909~8461337:-
THCA	trans	rs1962073	0.528	rs4582610	ENSG00000253893.2	FAM85B	5.6	3.74e-08	0.0383	0.33	0.25	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10460833	chr8:8167819~8226614:-
THCA	trans	rs3096299	0.606	rs4785573	ENSG00000215030.5	RPL13P12	5.6	3.74e-08	0.0383	0.29	0.25	Multiple myeloma (IgH translocation);	chr16:89498995	chr17:17383377~17384012:-
THCA	trans	rs9467773	0.526	rs10946817	ENSG00000242375.1	RP11-498P14.3	-5.6	3.74e-08	0.0383	-0.36	-0.25	Intelligence (multi-trait analysis);	chr6:26363828	chr9:97195351~97197687:-
THCA	trans	rs9470794	0.92	rs11755439	ENSG00000279138.1	KB-1742H10.3	5.6	3.74e-08	0.0383	0.52	0.25	Type 2 diabetes;	chr6:38090738	chr8:104478539~104480783:-
THCA	trans	rs11098499	0.874	rs13123591	ENSG00000253326.2	RP11-261C10.7	5.6	3.74e-08	0.0384	0.34	0.25	Corneal astigmatism;	chr4:119184835	chr1:243054861~243056394:-
THCA	trans	rs6928977	0.863	rs2614275	ENSG00000275632.1	RP5-967N21.11	5.6	3.74e-08	0.0384	0.22	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135337376	chr20:6000418~6000941:+
THCA	trans	rs356220	0.617	rs356169	ENSG00000245479.2	LINC01585	-5.6	3.74e-08	0.0384	-0.3	-0.25	Parkinson's disease;	chr4:89711617	chr15:90660234~90664967:+
THCA	trans	rs9292918	0.671	rs12655990	ENSG00000231752.4	EMBP1	-5.6	3.74e-08	0.0384	-0.45	-0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45229290	chr1:121519112~121571892:+
THCA	trans	rs6921919	0.848	rs6903652	ENSG00000228078.1	HLA-U	-5.6	3.75e-08	0.0384	-0.35	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:29934101~29934286:+
THCA	trans	rs7617480	0.648	rs4858800	ENSG00000235912.1	RP1-159A19.3	-5.6	3.75e-08	0.0384	-0.39	-0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48718387	chr1:27649419~27649610:+
THCA	trans	rs3812762	0.868	rs7952335	ENSG00000266891.1	RP11-692N5.2	-5.6	3.75e-08	0.0385	-0.32	-0.25	Hypospadias;	chr11:8732484	chr18:9734882~9735602:-
THCA	trans	rs11992162	0.597	rs7824564	ENSG00000229857.1	RP11-159H20.3	5.59	3.76e-08	0.0385	0.33	0.25	Monocyte count;	chr8:11922671	chr9:76992099~76993108:+
THCA	trans	rs9381040	0.61	rs6940356	ENSG00000232097.1	AC079781.8	5.59	3.76e-08	0.0386	0.3	0.25	Alzheimer's disease (late onset);	chr6:41052621	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs2235678	ENSG00000232097.1	AC079781.8	5.59	3.76e-08	0.0386	0.3	0.25	Alzheimer's disease (late onset);	chr6:41052771	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs2268195	ENSG00000232097.1	AC079781.8	5.59	3.76e-08	0.0386	0.3	0.25	Alzheimer's disease (late onset);	chr6:41056601	chr7:97938439~97938794:-
THCA	trans	rs5758511	0.573	rs1883205	ENSG00000268568.1	AC007228.9	-5.59	3.77e-08	0.0386	-0.29	-0.25	Birth weight;	chr22:41847016	chr19:56672574~56673901:-
THCA	trans	rs9914988	0.943	rs3181215	ENSG00000267449.1	RP11-264B14.2	-5.59	3.77e-08	0.0387	-0.37	-0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28750313	chr17:61069856~61070356:-
THCA	trans	rs12477438	0.501	rs12992218	ENSG00000276576.1	MRPL30P1	5.59	3.77e-08	0.0387	0.32	0.25	Chronic sinus infection;	chr2:99137371	chr6:57029521~57029988:+
THCA	trans	rs73108077	0.92	rs10084487	ENSG00000279352.1	RP11-411B10.7	5.59	3.77e-08	0.0387	0.5	0.25	Red blood cell density in sickle cell anemia;	chr20:31425330	chr18:14010054~14010917:+
THCA	trans	rs73108077	1	rs10084488	ENSG00000279352.1	RP11-411B10.7	5.59	3.77e-08	0.0387	0.5	0.25	Red blood cell density in sickle cell anemia;	chr20:31425366	chr18:14010054~14010917:+
THCA	trans	rs7824557	0.628	rs3779891	ENSG00000253893.2	FAM85B	-5.59	3.77e-08	0.0387	-0.33	-0.25	Retinal vascular caliber;	chr8:11325996	chr8:8167819~8226614:-
THCA	trans	rs7824557	0.628	rs11782706	ENSG00000253893.2	FAM85B	-5.59	3.77e-08	0.0387	-0.33	-0.25	Retinal vascular caliber;	chr8:11328706	chr8:8167819~8226614:-
THCA	trans	rs2439831	1	rs690002	ENSG00000180867.10	PDIA3P1	-5.59	3.77e-08	0.0387	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43437151	chr1:147178113~147179622:+
THCA	trans	rs2439831	1	rs537115	ENSG00000180867.10	PDIA3P1	-5.59	3.77e-08	0.0387	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43437750	chr1:147178113~147179622:+
THCA	trans	rs1572299	0.64	rs7025627	ENSG00000273669.1	RP11-405M12.4	-5.59	3.77e-08	0.0387	-0.31	-0.25	Schizophrenia;	chr9:118565620	chr18:75073543~75074205:+
THCA	trans	rs7232775	0.908	rs17669582	ENSG00000274029.1	RP11-340F14.6	-5.59	3.78e-08	0.0387	-0.29	-0.25	Metabolite levels;	chr18:45610826	chr12:121190868~121191518:+
THCA	trans	rs11668609	1	rs919812	ENSG00000261770.1	CTC-459F4.1	5.59	3.79e-08	0.0388	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24163425	chr19:27757184~27760849:-
THCA	trans	rs34043524	1	rs66557818	ENSG00000260036.1	RP11-178D12.2	5.59	3.79e-08	0.0388	0.48	0.25	Lateral ventricle volume in trauma-exposed individuals;	chr4:117011341	chr15:55442635~55443357:-
THCA	trans	rs34043524	1	rs35607430	ENSG00000260036.1	RP11-178D12.2	5.59	3.79e-08	0.0388	0.48	0.25	Lateral ventricle volume in trauma-exposed individuals;	chr4:117012008	chr15:55442635~55443357:-
THCA	trans	rs11122895	0.509	rs55937046	ENSG00000204745.3	AC083899.3	5.59	3.8e-08	0.0389	0.31	0.25	Allergic sensitization;	chr2:111689719	chr2:87125390~87196647:+
THCA	trans	rs12439619	0.846	rs7496227	ENSG00000235370.6	DNM1P51	-5.59	3.8e-08	0.0389	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82275241	chr15:84398316~84411701:-
THCA	trans	rs7429990	0.864	rs1464614	ENSG00000235912.1	RP1-159A19.3	-5.59	3.81e-08	0.039	-0.3	-0.25	Educational attainment (years of education);	chr3:47612885	chr1:27649419~27649610:+
THCA	trans	rs9650315	0.704	rs67742458	ENSG00000244245.1	RP11-120B7.1	5.59	3.81e-08	0.039	0.38	0.25	Height;	chr8:56258088	chr5:108593609~108593967:+
THCA	trans	rs9393777	0.844	rs72839477	ENSG00000204338.7	CYP21A1P	-5.59	3.81e-08	0.039	-0.57	-0.25	Intelligence (multi-trait analysis);	chr6:27359221	chr6:32005636~32008451:+
THCA	trans	rs9572786	0.617	rs61956390	ENSG00000228956.7	SATB1-AS1	-5.59	3.82e-08	0.0391	-0.27	-0.25	Plateletcrit;	chr13:71816693	chr3:18445024~18920401:+
THCA	trans	rs902774	0.938	rs73108457	ENSG00000224520.2	KRT8P45	-5.59	3.82e-08	0.0391	-0.47	-0.25	Prostate cancer;	chr12:52883583	chr1:157073257~157074703:+
THCA	trans	rs7617773	0.78	rs7645425	ENSG00000235912.1	RP1-159A19.3	-5.59	3.83e-08	0.0392	-0.31	-0.25	Coronary artery disease;	chr3:48320879	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs6793223	ENSG00000235912.1	RP1-159A19.3	-5.59	3.83e-08	0.0392	-0.31	-0.25	Coronary artery disease;	chr3:48322611	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs11714944	ENSG00000235912.1	RP1-159A19.3	-5.59	3.83e-08	0.0392	-0.31	-0.25	Coronary artery disease;	chr3:48325481	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs7653336	ENSG00000235912.1	RP1-159A19.3	-5.59	3.83e-08	0.0392	-0.31	-0.25	Coronary artery disease;	chr3:48327974	chr1:27649419~27649610:+
THCA	trans	rs9393777	0.778	rs35608615	ENSG00000204338.7	CYP21A1P	-5.59	3.83e-08	0.0392	-0.48	-0.25	Intelligence (multi-trait analysis);	chr6:27072623	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.778	rs35526527	ENSG00000204338.7	CYP21A1P	-5.59	3.83e-08	0.0392	-0.48	-0.25	Intelligence (multi-trait analysis);	chr6:27074508	chr6:32005636~32008451:+
THCA	trans	rs853679	0.546	rs34295134	ENSG00000228022.4	HCG20	-5.59	3.84e-08	0.0393	-0.48	-0.25	Depression;	chr6:27860373	chr6:30766825~30792250:+
THCA	trans	rs453301	0.624	rs2915251	ENSG00000256560.1	LINC01486	5.59	3.84e-08	0.0393	0.29	0.25	Joint mobility (Beighton score);	chr8:9009901	chr12:109354083~109359488:-
THCA	trans	rs7520050	0.553	rs2993263	ENSG00000255397.1	AC022182.2	-5.59	3.84e-08	0.0393	-0.33	-0.25	Reticulocyte count;Red blood cell count;	chr1:45555958	chr8:60937705~60939871:-
THCA	trans	rs6499255	0.638	rs57824734	ENSG00000257513.6	NPIPB1P	5.59	3.85e-08	0.0394	0.31	0.25	IgE levels;	chr16:69778092	chr18:11619509~11639699:-
THCA	trans	rs11098499	0.913	rs68128210	ENSG00000253326.2	RP11-261C10.7	5.59	3.85e-08	0.0394	0.34	0.25	Corneal astigmatism;	chr4:119216664	chr1:243054861~243056394:-
THCA	trans	rs11958034	1	rs12652071	ENSG00000271874.1	CTD-2024P10.2	-5.59	3.86e-08	0.0395	-0.39	-0.25	Mitochondrial DNA levels;	chr5:18913028	chr5:34651457~34651888:-
THCA	trans	rs433755	0.647	rs907654	ENSG00000189014.7	FAM35DP	-5.59	3.87e-08	0.0396	-0.28	-0.25	Obesity-related traits;	chr5:9501843	chr10:47689707~47730436:+
THCA	trans	rs9329221	0.621	rs522483	ENSG00000229857.1	RP11-159H20.3	5.59	3.88e-08	0.0397	0.32	0.25	Neuroticism;	chr8:9955459	chr9:76992099~76993108:+
THCA	trans	rs11668609	1	rs7260280	ENSG00000261770.1	CTC-459F4.1	5.59	3.88e-08	0.0397	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24140020	chr19:27757184~27760849:-
THCA	trans	rs1190596	0.525	rs6575901	ENSG00000181359.5	HSP90AA6P	-5.59	3.89e-08	0.0397	-0.36	-0.25	Behavioural disinhibition (generation interaction);	chr14:102225517	chr4:170581470~170605450:-
THCA	trans	rs356220	0.642	rs2572322	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89713395	chr15:90660234~90664967:+
THCA	trans	rs356220	0.642	rs2572323	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89713401	chr15:90660234~90664967:+
THCA	trans	rs356220	0.642	rs6825421	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89713655	chr15:90660234~90664967:+
THCA	trans	rs356220	0.656	rs6848708	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89713677	chr15:90660234~90664967:+
THCA	trans	rs356220	0.656	rs181489	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89713869	chr15:90660234~90664967:+
THCA	trans	rs356220	0.656	rs181490	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89713882	chr15:90660234~90664967:+
THCA	trans	rs356220	0.656	rs356206	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89713898	chr15:90660234~90664967:+
THCA	trans	rs356220	0.656	rs356207	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89714256	chr15:90660234~90664967:+
THCA	trans	rs356220	0.656	rs356208	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89714302	chr15:90660234~90664967:+
THCA	trans	rs356220	0.642	rs356210	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89715042	chr15:90660234~90664967:+
THCA	trans	rs356220	0.509	rs356212	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89715321	chr15:90660234~90664967:+
THCA	trans	rs356220	0.656	rs356217	ENSG00000245479.2	LINC01585	-5.59	3.89e-08	0.0398	-0.31	-0.25	Parkinson's disease;	chr4:89715652	chr15:90660234~90664967:+
THCA	trans	rs7694207	0.706	rs17026134	ENSG00000215481.7	BCRP3	-5.59	3.89e-08	0.0398	-0.26	-0.25	Response to mTOR inhibitor (everolimus);	chr4:96959701	chr22:24632915~24653356:+
THCA	trans	rs804280	0.662	rs11784693	ENSG00000271851.1	RP11-565F19.2	-5.59	3.89e-08	0.0398	-0.29	-0.25	Myopia (pathological);	chr8:11753165	chr17:9553323~9555696:-
THCA	trans	rs2242330	0.859	rs10015022	ENSG00000226982.4	CENPCP1	5.59	3.9e-08	0.0398	0.39	0.25	Parkinson's disease;	chr4:67529489	chr12:89500093~89502670:+
THCA	trans	rs9650657	0.644	rs3808603	ENSG00000253893.2	FAM85B	5.59	3.9e-08	0.0398	0.31	0.25	Neuroticism;	chr8:10840708	chr8:8167819~8226614:-
THCA	trans	rs950169	0.92	rs2135551	ENSG00000259295.5	CSPG4P12	5.59	3.9e-08	0.0399	0.39	0.25	Schizophrenia;	chr15:84039099	chr15:85191438~85213905:+
THCA	trans	rs950169	1	rs12902672	ENSG00000259295.5	CSPG4P12	5.59	3.9e-08	0.0399	0.39	0.25	Schizophrenia;	chr15:84048234	chr15:85191438~85213905:+
THCA	trans	rs950169	1	rs12903820	ENSG00000259295.5	CSPG4P12	5.59	3.9e-08	0.0399	0.39	0.25	Schizophrenia;	chr15:84055068	chr15:85191438~85213905:+
THCA	trans	rs950169	0.919	rs12915589	ENSG00000259295.5	CSPG4P12	5.59	3.9e-08	0.0399	0.39	0.25	Schizophrenia;	chr15:84065712	chr15:85191438~85213905:+
THCA	trans	rs950169	0.959	rs66801143	ENSG00000259295.5	CSPG4P12	5.59	3.9e-08	0.0399	0.39	0.25	Schizophrenia;	chr15:84067905	chr15:85191438~85213905:+
THCA	trans	rs950169	1	rs35648189	ENSG00000259295.5	CSPG4P12	5.59	3.9e-08	0.0399	0.39	0.25	Schizophrenia;	chr15:84071996	chr15:85191438~85213905:+
THCA	trans	rs950169	0.92	rs17300048	ENSG00000259295.5	CSPG4P12	5.59	3.9e-08	0.0399	0.39	0.25	Schizophrenia;	chr15:84080725	chr15:85191438~85213905:+
THCA	trans	rs950169	1	rs1848093	ENSG00000259295.5	CSPG4P12	5.59	3.9e-08	0.0399	0.39	0.25	Schizophrenia;	chr15:84086775	chr15:85191438~85213905:+
THCA	trans	rs2980439	0.783	rs2955587	ENSG00000229857.1	RP11-159H20.3	-5.59	3.9e-08	0.0399	-0.3	-0.25	Neuroticism;	chr8:8240557	chr9:76992099~76993108:+
THCA	trans	rs11098499	0.913	rs13126596	ENSG00000253326.2	RP11-261C10.7	5.59	3.9e-08	0.0399	0.34	0.25	Corneal astigmatism;	chr4:119219574	chr1:243054861~243056394:-
THCA	trans	rs875971	0.545	rs6969224	ENSG00000213640.3	EEF1DP4	-5.59	3.91e-08	0.0399	-0.34	-0.25	Aortic root size;	chr7:66370011	chr7:64862999~64864370:+
THCA	trans	rs7113874	0.589	rs10840060	ENSG00000266891.1	RP11-692N5.2	-5.59	3.91e-08	0.0399	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8478498	chr18:9734882~9735602:-
THCA	trans	rs11992162	0.573	rs61468577	ENSG00000229857.1	RP11-159H20.3	5.59	3.91e-08	0.0399	0.32	0.25	Monocyte count;	chr8:11927416	chr9:76992099~76993108:+
THCA	trans	rs1232027	0.7	rs1677633	ENSG00000188985.6	DHFRP1	-5.59	3.91e-08	0.0399	-0.32	-0.25	Huntington's disease progression;	chr5:80632405	chr18:26170726~26171284:-
THCA	trans	rs2011905	0.818	rs28735683	ENSG00000214770.2	RP11-544I20.2	5.59	3.91e-08	0.04	0.25	0.25	Cytomegalovirus antibody response;	chr15:86534840	chr14:64329431~64338599:-
THCA	trans	rs3096299	0.658	rs3934737	ENSG00000215030.5	RPL13P12	-5.59	3.91e-08	0.04	-0.25	-0.25	Multiple myeloma (IgH translocation);	chr16:89493801	chr17:17383377~17384012:-
THCA	trans	rs1232027	0.666	rs1643634	ENSG00000188985.6	DHFRP1	-5.59	3.91e-08	0.04	-0.32	-0.25	Huntington's disease progression;	chr5:80632080	chr18:26170726~26171284:-
THCA	trans	rs1978968	0.957	rs55865752	ENSG00000258334.1	RP11-161H23.9	5.59	3.93e-08	0.0401	0.36	0.25	Presence of antiphospholipid antibodies;	chr22:17961461	chr12:49292631~49324576:-
THCA	trans	rs12477438	0.52	rs7572660	ENSG00000276576.1	MRPL30P1	5.59	3.93e-08	0.0401	0.32	0.25	Chronic sinus infection;	chr2:99172119	chr6:57029521~57029988:+
THCA	trans	rs1232027	0.7	rs73765838	ENSG00000188985.6	DHFRP1	-5.59	3.93e-08	0.0402	-0.32	-0.25	Huntington's disease progression;	chr5:80652003	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs73765839	ENSG00000188985.6	DHFRP1	-5.59	3.93e-08	0.0402	-0.32	-0.25	Huntington's disease progression;	chr5:80652004	chr18:26170726~26171284:-
THCA	trans	rs7113874	0.569	rs10769915	ENSG00000266891.1	RP11-692N5.2	5.59	3.93e-08	0.0402	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8575902	chr18:9734882~9735602:-
THCA	trans	rs864643	0.735	rs76417541	ENSG00000183298.5	RP11-556K13.1	5.59	3.94e-08	0.0402	0.53	0.25	Attention deficit hyperactivity disorder;	chr3:39519802	chr1:101786340~101787219:-
THCA	trans	rs8014204	0.905	rs8014289	ENSG00000181227.3	RP4-682C21.2	5.59	3.94e-08	0.0402	0.2	0.25	Caffeine consumption;	chr14:74910649	chr1:75743423~75744776:-
THCA	trans	rs7816032	0.617	rs17482310	ENSG00000233393.1	AP000688.29	5.59	3.95e-08	0.0403	0.43	0.25	Hyperactive-impulsive symptoms;	chr8:19889365	chr21:36104881~36109690:+
THCA	trans	rs2985684	0.894	rs4900932	ENSG00000240785.1	RPL36AP21	5.59	3.95e-08	0.0403	0.31	0.25	Carotid intima media thickness;	chr14:49556210	chr5:18049550~18049872:+
THCA	trans	rs2980439	0.783	rs2948305	ENSG00000229857.1	RP11-159H20.3	-5.59	3.95e-08	0.0403	-0.3	-0.25	Neuroticism;	chr8:8241055	chr9:76992099~76993108:+
THCA	trans	rs8014204	0.836	rs11159099	ENSG00000181227.3	RP4-682C21.2	-5.59	3.95e-08	0.0403	-0.2	-0.25	Caffeine consumption;	chr14:74768694	chr1:75743423~75744776:-
THCA	trans	rs546131	0.928	rs546521	ENSG00000225531.1	RP11-196I18.3	5.59	3.96e-08	0.0404	0.33	0.25	Lung disease severity in cystic fibrosis;	chr11:34803226	chr9:107116829~107117557:+
THCA	trans	rs1991651	0.507	rs17778581	ENSG00000229857.1	RP11-159H20.3	5.58	3.96e-08	0.0404	0.3	0.25	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10885911	chr9:76992099~76993108:+
THCA	trans	rs9733	0.715	rs7534124	ENSG00000273254.1	RP1-100J12.1	5.58	3.96e-08	0.0404	0.26	0.25	Tonsillectomy;	chr1:150766597	chr21:29024255~29024890:-
THCA	trans	rs2229774	1	rs11170481	ENSG00000280798.1	LINC00294	5.58	3.97e-08	0.0405	0.35	0.25	Anthracycline-induced cardiotoxicity in childhood cancer;	chr12:53218007	chr11:33076149~33079454:+
THCA	trans	rs9596837	0.514	rs12184586	ENSG00000234192.1	RP11-57C13.5	-5.58	3.98e-08	0.0406	-0.32	-0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr13:53679666	chr10:87642607~87642954:+
THCA	trans	rs4724055	0.793	rs567809	ENSG00000242640.1	RP11-302F12.1	5.58	3.98e-08	0.0406	0.35	0.25	Non-substance related behavioral disinhibition;	chr7:41574563	chr4:25678850~25679020:+
THCA	trans	rs7260598	0.892	rs60186040	ENSG00000261770.1	CTC-459F4.1	5.58	3.99e-08	0.0406	0.4	0.25	Response to taxane treatment (placlitaxel);	chr19:24024068	chr19:27757184~27760849:-
THCA	trans	rs453301	0.658	rs9329175	ENSG00000229857.1	RP11-159H20.3	5.58	3.99e-08	0.0407	0.32	0.25	Joint mobility (Beighton score);	chr8:9009151	chr9:76992099~76993108:+
THCA	trans	rs10504229	0.683	rs11786527	ENSG00000226986.4	RP11-543B16.2	-5.58	4e-08	0.0407	-0.38	-0.25	Developmental language disorder (linguistic errors);	chr8:57218785	chr1:211207239~211207897:+
THCA	trans	rs12439619	0.846	rs62012059	ENSG00000235370.6	DNM1P51	-5.58	4e-08	0.0407	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82251669	chr15:84398316~84411701:-
THCA	trans	rs2439831	0.681	rs1095386	ENSG00000180867.10	PDIA3P1	-5.58	4e-08	0.0408	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43317311	chr1:147178113~147179622:+
THCA	trans	rs902774	1	rs73108453	ENSG00000224520.2	KRT8P45	-5.58	4.01e-08	0.0408	-0.47	-0.25	Prostate cancer;	chr12:52883116	chr1:157073257~157074703:+
THCA	trans	rs902774	1	rs75236700	ENSG00000224520.2	KRT8P45	-5.58	4.01e-08	0.0408	-0.47	-0.25	Prostate cancer;	chr12:52883154	chr1:157073257~157074703:+
THCA	trans	rs3002142	1	rs3002142	ENSG00000219201.4	RP11-181C21.4	-5.58	4.01e-08	0.0409	-0.31	-0.25	LDL peak particle diameter (total fat intake interaction);	chr1:222614720	chr1:77810861~77811781:-
THCA	trans	rs9467711	0.745	rs9467714	ENSG00000176998.4	HCG4	-5.58	4.01e-08	0.0409	-0.4	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26340557	chr6:29791753~29792750:-
THCA	trans	rs853679	0.607	rs13217984	ENSG00000204338.7	CYP21A1P	-5.58	4.01e-08	0.0409	-0.58	-0.25	Depression;	chr6:28171932	chr6:32005636~32008451:+
THCA	trans	rs853679	0.556	rs67297533	ENSG00000204338.7	CYP21A1P	-5.58	4.01e-08	0.0409	-0.58	-0.25	Depression;	chr6:28173475	chr6:32005636~32008451:+
THCA	trans	rs853679	0.505	rs35781323	ENSG00000204338.7	CYP21A1P	-5.58	4.01e-08	0.0409	-0.58	-0.25	Depression;	chr6:28177054	chr6:32005636~32008451:+
THCA	trans	rs7816032	0.617	rs76085257	ENSG00000233393.1	AP000688.29	5.58	4.02e-08	0.0409	0.43	0.25	Hyperactive-impulsive symptoms;	chr8:19897616	chr21:36104881~36109690:+
THCA	trans	rs35851103	0.6	rs4841662	ENSG00000254153.1	CTA-398F10.2	5.58	4.02e-08	0.0409	0.28	0.25	Neuroticism;	chr8:11986249	chr8:8456909~8461337:-
THCA	trans	rs4415084	0.716	rs7712949	ENSG00000231752.4	EMBP1	5.58	4.02e-08	0.0409	0.34	0.25	Breast cancer;	chr5:44770243	chr1:121519112~121571892:+
THCA	trans	rs4415084	0.716	rs13154781	ENSG00000231752.4	EMBP1	5.58	4.02e-08	0.0409	0.34	0.25	Breast cancer;	chr5:44774925	chr1:121519112~121571892:+
THCA	trans	rs7819412	0.594	rs60921132	ENSG00000254153.1	CTA-398F10.2	5.58	4.02e-08	0.041	0.29	0.25	Triglycerides;	chr8:11107459	chr8:8456909~8461337:-
THCA	trans	rs902774	0.818	rs4919743	ENSG00000230716.3	KRT8P7	-5.58	4.03e-08	0.041	-0.47	-0.25	Prostate cancer;	chr12:52915800	chr11:119602875~119604306:-
THCA	trans	rs7113874	0.589	rs10840062	ENSG00000266891.1	RP11-692N5.2	5.58	4.03e-08	0.041	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500600	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.589	rs10840063	ENSG00000266891.1	RP11-692N5.2	5.58	4.03e-08	0.041	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500635	chr18:9734882~9735602:-
THCA	trans	rs9329221	0.51	rs6995837	ENSG00000253893.2	FAM85B	-5.58	4.04e-08	0.0411	-0.31	-0.25	Neuroticism;	chr8:10118165	chr8:8167819~8226614:-
THCA	trans	rs9329221	0.537	rs6995859	ENSG00000253893.2	FAM85B	-5.58	4.04e-08	0.0411	-0.31	-0.25	Neuroticism;	chr8:10118199	chr8:8167819~8226614:-
THCA	trans	rs7647973	0.626	rs11709734	ENSG00000197582.5	GPX1P1	5.58	4.04e-08	0.0411	0.44	0.25	Menarche (age at onset);	chr3:49707802	chrX:13378735~13379340:-
THCA	trans	rs56176327	0.6	rs7628207	ENSG00000197582.5	GPX1P1	5.58	4.04e-08	0.0411	0.44	0.25	Intelligence (multi-trait analysis);	chr3:49717537	chrX:13378735~13379340:-
THCA	trans	rs7647973	0.626	rs9870858	ENSG00000197582.5	GPX1P1	5.58	4.04e-08	0.0411	0.44	0.25	Menarche (age at onset);	chr3:49731638	chrX:13378735~13379340:-
THCA	trans	rs56176327	0.532	rs9849038	ENSG00000197582.5	GPX1P1	5.58	4.04e-08	0.0411	0.44	0.25	Intelligence (multi-trait analysis);	chr3:49734557	chrX:13378735~13379340:-
THCA	trans	rs7113874	0.569	rs7104646	ENSG00000266891.1	RP11-692N5.2	5.58	4.05e-08	0.0412	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8537294	chr18:9734882~9735602:-
THCA	trans	rs7617773	0.78	rs36075665	ENSG00000235912.1	RP1-159A19.3	-5.58	4.05e-08	0.0412	-0.31	-0.25	Coronary artery disease;	chr3:48301597	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs36121690	ENSG00000235912.1	RP1-159A19.3	-5.58	4.05e-08	0.0412	-0.31	-0.25	Coronary artery disease;	chr3:48304021	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs7632297	ENSG00000235912.1	RP1-159A19.3	-5.58	4.05e-08	0.0412	-0.31	-0.25	Coronary artery disease;	chr3:48306673	chr1:27649419~27649610:+
THCA	trans	rs427943	0.52	rs2838787	ENSG00000237842.2	RP11-110J1.2	5.58	4.05e-08	0.0412	0.3	0.25	Body mass index;	chr21:45119810	chr1:157059232~157060762:-
THCA	trans	rs6601327	0.602	rs7829463	ENSG00000253893.2	FAM85B	5.58	4.06e-08	0.0413	0.32	0.25	Multiple myeloma (hyperdiploidy);	chr8:9792181	chr8:8167819~8226614:-
THCA	trans	rs17807624	0.78	rs11250152	ENSG00000256560.1	LINC01486	-5.58	4.07e-08	0.0413	-0.3	-0.25	Systemic lupus erythematosus;	chr8:11596691	chr12:109354083~109359488:-
THCA	trans	rs2209875	0.64	rs7864748	ENSG00000189343.7	RPS2P46	5.58	4.07e-08	0.0414	0.33	0.25	Pelvic organ prolapse (moderate/severe);	chr9:89098472	chr17:19445970~19446852:-
THCA	trans	rs902774	0.818	rs73108469	ENSG00000223940.1	KRT8P8	-5.58	4.07e-08	0.0414	-0.52	-0.25	Prostate cancer;	chr12:52891065	chrX:152479577~152481024:+
THCA	trans	rs12682352	0.602	rs6993494	ENSG00000229857.1	RP11-159H20.3	-5.58	4.07e-08	0.0414	-0.31	-0.25	Neuroticism;	chr8:8809934	chr9:76992099~76993108:+
THCA	trans	rs7746199	0.736	rs6904596	ENSG00000253570.1	RNF5P1	5.58	4.07e-08	0.0414	0.6	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr8:38600661~38601200:-
THCA	trans	rs4879656	0.897	rs1537255	ENSG00000215007.3	DNAJA1P3	5.58	4.07e-08	0.0414	0.31	0.25	Menopause (age at onset);	chr9:33004377	chrX:107351650~107352843:-
THCA	trans	rs3808502	0.563	rs12541800	ENSG00000254153.1	CTA-398F10.2	-5.58	4.08e-08	0.0415	-0.28	-0.25	Neuroticism;	chr8:11565563	chr8:8456909~8461337:-
THCA	trans	rs9816784	0.901	rs56253832	ENSG00000236833.1	AC024560.2	5.58	4.08e-08	0.0415	0.3	0.25	Mean corpuscular hemoglobin;	chr3:196090304	chr3:197660565~197665757:-
THCA	trans	rs2439831	0.681	rs540388	ENSG00000180867.10	PDIA3P1	-5.58	4.08e-08	0.0415	-0.27	-0.25	Lung cancer in ever smokers;	chr15:43314296	chr1:147178113~147179622:+
THCA	trans	rs9863067	0.892	rs73121776	ENSG00000231104.7	RP11-354M20.3	-5.58	4.08e-08	0.0415	-0.38	-0.25	Lead levels in blood;	chr3:84136437	chr10:118017487~118045810:+
THCA	trans	rs9816784	0.901	rs12490036	ENSG00000236833.1	AC024560.2	-5.58	4.08e-08	0.0415	-0.3	-0.25	Mean corpuscular hemoglobin;	chr3:196089324	chr3:197660565~197665757:-
THCA	trans	rs9470794	1	rs73419947	ENSG00000279138.1	KB-1742H10.3	5.58	4.08e-08	0.0415	0.56	0.25	Type 2 diabetes;	chr6:38070863	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs73419959	ENSG00000279138.1	KB-1742H10.3	5.58	4.08e-08	0.0415	0.56	0.25	Type 2 diabetes;	chr6:38078581	chr8:104478539~104480783:-
THCA	trans	rs9470794	1	rs76363145	ENSG00000279138.1	KB-1742H10.3	5.58	4.08e-08	0.0415	0.56	0.25	Type 2 diabetes;	chr6:38114833	chr8:104478539~104480783:-
THCA	trans	rs10090774	0.965	rs10087782	ENSG00000230756.1	RHOQP3	5.58	4.08e-08	0.0415	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140848521	chr2:130212870~130213490:-
THCA	trans	rs7819412	0.669	rs2409743	ENSG00000254153.1	CTA-398F10.2	5.58	4.09e-08	0.0415	0.28	0.25	Triglycerides;	chr8:11212851	chr8:8456909~8461337:-
THCA	trans	rs7829975	0.714	rs12544992	ENSG00000229857.1	RP11-159H20.3	-5.58	4.09e-08	0.0416	-0.3	-0.25	Mood instability;	chr8:8804171	chr9:76992099~76993108:+
THCA	trans	rs4687717	0.544	rs551551	ENSG00000224820.2	BTF3P4	-5.58	4.09e-08	0.0416	-0.27	-0.25	Blood metabolite levels;Blood metabolite ratios;	chr3:53447687	chr9:72107818~72108312:-
THCA	trans	rs9584850	0.874	rs7988959	ENSG00000230079.1	STK24P1	5.58	4.1e-08	0.0416	0.3	0.25	Neuroticism;	chr13:98451750	chrX:136295690~136300298:-
THCA	trans	rs263156	0.967	rs263103	ENSG00000276182.1	RP11-872J21.5	-5.58	4.1e-08	0.0416	-0.2	-0.25	Lobe size;Ear morphology;Lobe attachment;	chr6:142554555	chr14:96537170~96537904:+
THCA	trans	rs875971	0.545	rs73376401	ENSG00000213640.3	EEF1DP4	-5.58	4.1e-08	0.0416	-0.33	-0.25	Aortic root size;	chr7:66174841	chr7:64862999~64864370:+
THCA	trans	rs4788439	1	rs55808472	ENSG00000227782.2	CTC-529I10.2	-5.58	4.11e-08	0.0417	-0.32	-0.25	Blood metabolite levels;	chr16:24920370	chr17:16040472~16041273:+
THCA	trans	rs7113874	0.543	rs10840047	ENSG00000266891.1	RP11-692N5.2	5.58	4.11e-08	0.0418	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8439350	chr18:9734882~9735602:-
THCA	trans	rs9650657	0.572	rs11250098	ENSG00000254153.1	CTA-398F10.2	5.58	4.11e-08	0.0418	0.27	0.25	Neuroticism;	chr8:10961097	chr8:8456909~8461337:-
THCA	trans	rs875971	0.545	rs35459055	ENSG00000213640.3	EEF1DP4	-5.58	4.11e-08	0.0418	-0.33	-0.25	Aortic root size;	chr7:66479399	chr7:64862999~64864370:+
THCA	trans	rs9393777	0.778	rs13219354	ENSG00000228022.4	HCG20	-5.58	4.11e-08	0.0418	-0.54	-0.25	Intelligence (multi-trait analysis);	chr6:27217885	chr6:30766825~30792250:+
THCA	trans	rs9393777	0.778	rs67457459	ENSG00000228022.4	HCG20	-5.58	4.11e-08	0.0418	-0.54	-0.25	Intelligence (multi-trait analysis);	chr6:27230564	chr6:30766825~30792250:+
THCA	trans	rs453301	0.658	rs6986044	ENSG00000229857.1	RP11-159H20.3	5.58	4.11e-08	0.0418	0.31	0.25	Joint mobility (Beighton score);	chr8:9017276	chr9:76992099~76993108:+
THCA	trans	rs1475911	0.708	rs66994219	ENSG00000229759.1	MRPS18AP1	-5.58	4.12e-08	0.0418	-0.33	-0.25	IgG glycosylation;	chr21:42101537	chr3:48256350~48256938:-
THCA	trans	rs1348850	0.632	rs4470372	ENSG00000226038.5	PPIAP21	5.58	4.12e-08	0.0419	0.34	0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177641129	chr20:43230760~43231260:+
THCA	trans	rs7113874	0.569	rs11041980	ENSG00000266891.1	RP11-692N5.2	5.58	4.13e-08	0.0419	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8557534	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.524	rs11041981	ENSG00000266891.1	RP11-692N5.2	5.58	4.13e-08	0.0419	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8557661	chr18:9734882~9735602:-
THCA	trans	rs12545912	0.71	rs10903317	ENSG00000253893.2	FAM85B	5.58	4.13e-08	0.0419	0.32	0.25	Multiple myeloma (hyperdiploidy);	chr8:9698397	chr8:8167819~8226614:-
THCA	trans	rs7113874	0.569	rs10160805	ENSG00000266891.1	RP11-692N5.2	-5.58	4.14e-08	0.042	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8578846	chr18:9734882~9735602:-
THCA	trans	rs10199359	0.945	rs17026588	ENSG00000256393.1	RPL41P5	5.58	4.14e-08	0.042	0.37	0.25	Pre-treatment pain in head and neck squamous cell carcinoma;	chr2:102084033	chr12:93083598~93083675:-
THCA	trans	rs10199359	0.891	rs11123907	ENSG00000256393.1	RPL41P5	5.58	4.14e-08	0.042	0.37	0.25	Pre-treatment pain in head and neck squamous cell carcinoma;	chr2:102090375	chr12:93083598~93083675:-
THCA	trans	rs10199359	0.945	rs13432744	ENSG00000256393.1	RPL41P5	5.58	4.14e-08	0.042	0.37	0.25	Pre-treatment pain in head and neck squamous cell carcinoma;	chr2:102092270	chr12:93083598~93083675:-
THCA	trans	rs2439831	0.681	rs524527	ENSG00000180867.10	PDIA3P1	5.58	4.14e-08	0.042	0.27	0.25	Lung cancer in ever smokers;	chr15:43306918	chr1:147178113~147179622:+
THCA	trans	rs7617773	0.78	rs13084616	ENSG00000235912.1	RP1-159A19.3	5.58	4.14e-08	0.042	0.31	0.25	Coronary artery disease;	chr3:48298209	chr1:27649419~27649610:+
THCA	trans	rs9393777	0.844	rs35909544	ENSG00000228022.4	HCG20	-5.58	4.15e-08	0.0421	-0.54	-0.25	Intelligence (multi-trait analysis);	chr6:27195677	chr6:30766825~30792250:+
THCA	trans	rs7773004	0.601	rs13210340	ENSG00000280107.1	AL022393.9	-5.58	4.15e-08	0.0421	-0.53	-0.25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;	chr6:26326086	chr6:28170845~28172521:+
THCA	trans	rs2645424	0.55	rs12338	ENSG00000269898.1	RP11-568J23.4	-5.58	4.16e-08	0.0422	-0.29	-0.25	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853379	chr16:85743287~85744225:+
THCA	trans	rs7819412	0.608	rs17780806	ENSG00000254153.1	CTA-398F10.2	5.58	4.16e-08	0.0422	0.29	0.25	Triglycerides;	chr8:11118119	chr8:8456909~8461337:-
THCA	trans	rs1908814	0.516	rs10113062	ENSG00000229857.1	RP11-159H20.3	-5.58	4.16e-08	0.0422	-0.32	-0.25	Neuroticism;	chr8:11935740	chr9:76992099~76993108:+
THCA	trans	rs1908814	0.516	rs10113145	ENSG00000229857.1	RP11-159H20.3	-5.58	4.16e-08	0.0422	-0.32	-0.25	Neuroticism;	chr8:11935786	chr9:76992099~76993108:+
THCA	trans	rs7769051	0.711	rs7758531	ENSG00000227615.1	RP11-864N7.2	5.58	4.17e-08	0.0423	0.43	0.25	Type 2 diabetes nephropathy;	chr6:132764163	chr11:74745716~74746114:-
THCA	trans	rs7769051	0.711	rs7758703	ENSG00000227615.1	RP11-864N7.2	5.58	4.17e-08	0.0423	0.43	0.25	Type 2 diabetes nephropathy;	chr6:132764278	chr11:74745716~74746114:-
THCA	trans	rs7617773	0.643	rs78159520	ENSG00000235912.1	RP1-159A19.3	-5.58	4.17e-08	0.0423	-0.31	-0.25	Coronary artery disease;	chr3:48307533	chr1:27649419~27649610:+
THCA	trans	rs12477438	0.539	rs720228	ENSG00000276576.1	MRPL30P1	5.58	4.18e-08	0.0424	0.32	0.25	Chronic sinus infection;	chr2:99088084	chr6:57029521~57029988:+
THCA	trans	rs16912285	0.748	rs58504811	ENSG00000215190.7	LINC00680	5.58	4.18e-08	0.0424	0.35	0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr11:24230474	chr6:57946074~57961501:-
THCA	trans	rs889398	0.77	rs8052225	ENSG00000257513.6	NPIPB1P	5.57	4.18e-08	0.0424	0.28	0.25	Body mass index;	chr16:69849750	chr18:11619509~11639699:-
THCA	trans	rs11098499	0.913	rs56122576	ENSG00000253326.2	RP11-261C10.7	5.57	4.18e-08	0.0424	0.34	0.25	Corneal astigmatism;	chr4:119208181	chr1:243054861~243056394:-
THCA	trans	rs9470794	1	rs1923280	ENSG00000279138.1	KB-1742H10.3	5.57	4.19e-08	0.0425	0.54	0.25	Type 2 diabetes;	chr6:38141117	chr8:104478539~104480783:-
THCA	trans	rs10090774	0.965	rs1375062	ENSG00000230756.1	RHOQP3	5.57	4.2e-08	0.0425	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955682	chr2:130212870~130213490:-
THCA	trans	rs11992162	0.613	rs6601634	ENSG00000229857.1	RP11-159H20.3	5.57	4.2e-08	0.0425	0.33	0.25	Monocyte count;	chr8:11948947	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.615	rs12541110	ENSG00000253893.2	FAM85B	5.57	4.2e-08	0.0426	0.31	0.25	Neuroticism;	chr8:10837615	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.584	rs28613656	ENSG00000253893.2	FAM85B	5.57	4.2e-08	0.0426	0.31	0.25	Neuroticism;	chr8:10837909	chr8:8167819~8226614:-
THCA	trans	rs9650657	0.644	rs6601535	ENSG00000253893.2	FAM85B	5.57	4.2e-08	0.0426	0.31	0.25	Neuroticism;	chr8:10838142	chr8:8167819~8226614:-
THCA	trans	rs875971	0.545	rs4718325	ENSG00000213640.3	EEF1DP4	-5.57	4.2e-08	0.0426	-0.34	-0.25	Aortic root size;	chr7:66215323	chr7:64862999~64864370:+
THCA	trans	rs10504229	0.683	rs949856	ENSG00000226986.4	RP11-543B16.2	-5.57	4.21e-08	0.0426	-0.38	-0.25	Developmental language disorder (linguistic errors);	chr8:57231937	chr1:211207239~211207897:+
THCA	trans	rs1908814	0.516	rs7812563	ENSG00000229857.1	RP11-159H20.3	-5.57	4.21e-08	0.0427	-0.32	-0.25	Neuroticism;	chr8:11936979	chr9:76992099~76993108:+
THCA	trans	rs9381040	0.61	rs9381028	ENSG00000232097.1	AC079781.8	5.57	4.21e-08	0.0427	0.3	0.25	Alzheimer's disease (late onset);	chr6:41057342	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs9357345	ENSG00000232097.1	AC079781.8	5.57	4.21e-08	0.0427	0.3	0.25	Alzheimer's disease (late onset);	chr6:41057379	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs2268191	ENSG00000232097.1	AC079781.8	5.57	4.21e-08	0.0427	0.3	0.25	Alzheimer's disease (late onset);	chr6:41059914	chr7:97938439~97938794:-
THCA	trans	rs9467711	0.79	rs55706012	ENSG00000280107.1	AL022393.9	-5.57	4.22e-08	0.0428	-0.52	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26266083	chr6:28170845~28172521:+
THCA	trans	rs4140564	0.73	rs7532307	ENSG00000227939.1	RPL3P2	-5.57	4.22e-08	0.0428	-0.33	-0.25	Knee osteoarthritis;	chr1:186772404	chr6:31280317~31281519:+
THCA	trans	rs4140564	0.667	rs1158043	ENSG00000227939.1	RPL3P2	5.57	4.22e-08	0.0428	0.33	0.25	Knee osteoarthritis;	chr1:186770299	chr6:31280317~31281519:+
THCA	trans	rs4140564	0.73	rs1158042	ENSG00000227939.1	RPL3P2	5.57	4.22e-08	0.0428	0.33	0.25	Knee osteoarthritis;	chr1:186770518	chr6:31280317~31281519:+
THCA	trans	rs4140564	0.73	rs10752973	ENSG00000227939.1	RPL3P2	5.57	4.22e-08	0.0428	0.33	0.25	Knee osteoarthritis;	chr1:186771377	chr6:31280317~31281519:+
THCA	trans	rs4140564	0.667	rs10911922	ENSG00000227939.1	RPL3P2	5.57	4.22e-08	0.0428	0.33	0.25	Knee osteoarthritis;	chr1:186774771	chr6:31280317~31281519:+
THCA	trans	rs10774547	0.758	rs4766961	ENSG00000226976.3	COX6A1P2	5.57	4.23e-08	0.0428	0.22	0.25	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy);	chr12:120424729	chr6:37044860~37045189:+
THCA	trans	rs9650657	0.538	rs6984496	ENSG00000256560.1	LINC01486	-5.57	4.23e-08	0.0428	-0.29	-0.25	Neuroticism;	chr8:10938583	chr12:109354083~109359488:-
THCA	trans	rs7824557	0.603	rs2250028	ENSG00000256560.1	LINC01486	5.57	4.23e-08	0.0429	0.31	0.25	Retinal vascular caliber;	chr8:11356080	chr12:109354083~109359488:-
THCA	trans	rs7769051	0.522	rs10457596	ENSG00000227615.1	RP11-864N7.2	5.57	4.24e-08	0.0429	0.47	0.25	Type 2 diabetes nephropathy;	chr6:132848835	chr11:74745716~74746114:-
THCA	trans	rs11098499	0.874	rs7661020	ENSG00000253326.2	RP11-261C10.7	5.57	4.24e-08	0.0429	0.34	0.25	Corneal astigmatism;	chr4:119185827	chr1:243054861~243056394:-
THCA	trans	rs7429990	0.965	rs34380889	ENSG00000235912.1	RP1-159A19.3	-5.57	4.24e-08	0.0429	-0.31	-0.25	Educational attainment (years of education);	chr3:47905692	chr1:27649419~27649610:+
THCA	trans	rs7945705	0.875	rs10769957	ENSG00000266891.1	RP11-692N5.2	5.57	4.24e-08	0.043	0.32	0.25	Hemoglobin concentration;	chr11:8787469	chr18:9734882~9735602:-
THCA	trans	rs728478	0.845	rs9747559	ENSG00000187870.7	RNFT1P3	-5.57	4.25e-08	0.043	-0.32	-0.25	QT interval;	chr17:59403334	chr17:20743333~20754501:-
THCA	trans	rs4654899	0.897	rs10799668	ENSG00000280120.1	RP11-546D6.3	-5.57	4.25e-08	0.043	-0.18	-0.25	Superior frontal gyrus grey matter volume;	chr1:20842892	chr12:123152324~123153377:-
THCA	trans	rs3096299	0.719	rs2911262	ENSG00000215030.5	RPL13P12	-5.57	4.25e-08	0.0431	-0.25	-0.25	Multiple myeloma (IgH translocation);	chr16:89448633	chr17:17383377~17384012:-
THCA	trans	rs7113874	0.569	rs2871753	ENSG00000266891.1	RP11-692N5.2	-5.57	4.26e-08	0.0431	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8465103	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.589	rs10840058	ENSG00000266891.1	RP11-692N5.2	-5.57	4.26e-08	0.0431	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8476852	chr18:9734882~9735602:-
THCA	trans	rs2806731	0.6	rs1932866	ENSG00000234192.1	RP11-57C13.5	5.57	4.26e-08	0.0431	0.33	0.25	Obesity-related traits;	chr13:53673027	chr10:87642607~87642954:+
THCA	trans	rs7829975	0.902	rs485107	ENSG00000229857.1	RP11-159H20.3	5.57	4.27e-08	0.0432	0.3	0.25	Mood instability;	chr8:8723898	chr9:76992099~76993108:+
THCA	trans	rs73108077	1	rs6059305	ENSG00000279352.1	RP11-411B10.7	5.57	4.27e-08	0.0432	0.55	0.25	Red blood cell density in sickle cell anemia;	chr20:31432624	chr18:14010054~14010917:+
THCA	trans	rs12439619	0.846	rs62012003	ENSG00000235370.6	DNM1P51	-5.57	4.27e-08	0.0432	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82183236	chr15:84398316~84411701:-
THCA	trans	rs12439619	0.768	rs28694364	ENSG00000235370.6	DNM1P51	-5.57	4.27e-08	0.0432	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82208119	chr15:84398316~84411701:-
THCA	trans	rs12439619	0.81	rs28876157	ENSG00000235370.6	DNM1P51	-5.57	4.27e-08	0.0432	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82216708	chr15:84398316~84411701:-
THCA	trans	rs902774	0.818	rs11831919	ENSG00000223940.1	KRT8P8	-5.57	4.27e-08	0.0432	-0.51	-0.25	Prostate cancer;	chr12:52878231	chrX:152479577~152481024:+
THCA	trans	rs6142102	0.59	rs6059691	ENSG00000269202.1	RP4-614O4.12	5.57	4.28e-08	0.0433	0.23	0.25	Skin pigmentation;	chr20:34149161	chr20:35201747~35203288:-
THCA	trans	rs2985684	0.894	rs2281837	ENSG00000240785.1	RPL36AP21	5.57	4.28e-08	0.0433	0.31	0.25	Carotid intima media thickness;	chr14:49598641	chr5:18049550~18049872:+
THCA	trans	rs9292918	0.502	rs71616284	ENSG00000231752.4	EMBP1	5.57	4.28e-08	0.0433	0.46	0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45190649	chr1:121519112~121571892:+
THCA	trans	rs7260598	1	rs7260598	ENSG00000261770.1	CTC-459F4.1	-5.57	4.28e-08	0.0433	-0.39	-0.25	Response to taxane treatment (placlitaxel);	chr19:24039984	chr19:27757184~27760849:-
THCA	trans	rs7824557	0.767	rs7003241	ENSG00000254153.1	CTA-398F10.2	-5.57	4.28e-08	0.0433	-0.28	-0.25	Retinal vascular caliber;	chr8:11311566	chr8:8456909~8461337:-
THCA	trans	rs10090774	0.965	rs1349081	ENSG00000230756.1	RHOQP3	5.57	4.28e-08	0.0433	0.3	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140933983	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs7831770	ENSG00000230756.1	RHOQP3	5.57	4.29e-08	0.0434	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140990088	chr2:130212870~130213490:-
THCA	trans	rs6831352	0.734	rs1154400	ENSG00000228407.2	RP4-800M22.1	-5.57	4.29e-08	0.0434	-0.35	-0.25	Alcohol dependence;	chr4:99088859	chr1:52160261~52160600:-
THCA	trans	rs4295623	0.531	rs2898295	ENSG00000229857.1	RP11-159H20.3	5.57	4.29e-08	0.0434	0.3	0.25	Morning vs. evening chronotype;	chr8:11738460	chr9:76992099~76993108:+
THCA	trans	rs7819412	0.54	rs11777355	ENSG00000254153.1	CTA-398F10.2	5.57	4.29e-08	0.0434	0.29	0.25	Triglycerides;	chr8:11187180	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.526	rs1042701	ENSG00000254153.1	CTA-398F10.2	5.57	4.29e-08	0.0434	0.28	0.25	Neuroticism;	chr8:11564536	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.526	rs7843987	ENSG00000254153.1	CTA-398F10.2	5.57	4.29e-08	0.0434	0.28	0.25	Neuroticism;	chr8:11564621	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.595	rs10503416	ENSG00000229857.1	RP11-159H20.3	-5.57	4.3e-08	0.0435	-0.32	-0.25	Triglycerides;	chr8:11130043	chr9:76992099~76993108:+
THCA	trans	rs875971	0.545	rs6460298	ENSG00000213640.3	EEF1DP4	-5.57	4.3e-08	0.0435	-0.33	-0.25	Aortic root size;	chr7:66442783	chr7:64862999~64864370:+
THCA	trans	rs10090774	0.965	rs13258028	ENSG00000230756.1	RHOQP3	5.57	4.31e-08	0.0435	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140880414	chr2:130212870~130213490:-
THCA	trans	rs356220	0.656	rs356218	ENSG00000245479.2	LINC01585	-5.57	4.31e-08	0.0436	-0.3	-0.25	Parkinson's disease;	chr4:89715859	chr15:90660234~90664967:+
THCA	trans	rs4140564	0.892	rs10737269	ENSG00000227939.1	RPL3P2	5.57	4.31e-08	0.0436	0.33	0.25	Knee osteoarthritis;	chr1:186781501	chr6:31280317~31281519:+
THCA	trans	rs4140564	0.73	rs7418312	ENSG00000227939.1	RPL3P2	5.57	4.32e-08	0.0436	0.33	0.25	Knee osteoarthritis;	chr1:186792451	chr6:31280317~31281519:+
THCA	trans	rs6921919	0.789	rs6912584	ENSG00000228078.1	HLA-U	-5.57	4.32e-08	0.0437	-0.35	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:29934101~29934286:+
THCA	trans	rs453301	0.597	rs7001187	ENSG00000256560.1	LINC01486	-5.57	4.33e-08	0.0437	-0.32	-0.25	Joint mobility (Beighton score);	chr8:8935272	chr12:109354083~109359488:-
THCA	trans	rs6601327	0.635	rs10099122	ENSG00000253893.2	FAM85B	5.57	4.33e-08	0.0437	0.31	0.25	Multiple myeloma (hyperdiploidy);	chr8:9710493	chr8:8167819~8226614:-
THCA	trans	rs9894429	0.789	rs9747336	ENSG00000278875.1	CTC-439O9.1	-5.57	4.34e-08	0.0438	-0.25	-0.25	Eye color traits;	chr17:81617163	chr19:31364297~31366098:+
THCA	trans	rs9894429	0.789	rs35887231	ENSG00000278875.1	CTC-439O9.1	-5.57	4.34e-08	0.0438	-0.25	-0.25	Eye color traits;	chr17:81620100	chr19:31364297~31366098:+
THCA	trans	rs9894429	0.738	rs8077038	ENSG00000278875.1	CTC-439O9.1	5.57	4.34e-08	0.0438	0.25	0.25	Eye color traits;	chr17:81610101	chr19:31364297~31366098:+
THCA	trans	rs7113874	0.589	rs7949017	ENSG00000266891.1	RP11-692N5.2	-5.57	4.34e-08	0.0438	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8470580	chr18:9734882~9735602:-
THCA	trans	rs453301	0.658	rs9650616	ENSG00000229857.1	RP11-159H20.3	5.57	4.34e-08	0.0438	0.31	0.25	Joint mobility (Beighton score);	chr8:9011689	chr9:76992099~76993108:+
THCA	trans	rs4906172	1	rs1741155	ENSG00000181359.5	HSP90AA6P	-5.57	4.34e-08	0.0439	-0.34	-0.25	Menopause (age at onset);	chr14:101962061	chr4:170581470~170605450:-
THCA	trans	rs67311347	0.955	rs2123999	ENSG00000139239.7	RPL14P1	-5.57	4.35e-08	0.0439	-0.21	-0.25	Renal cell carcinoma;	chr3:40337247	chr12:62965325~62965969:+
THCA	trans	rs12682352	0.602	rs28399241	ENSG00000229857.1	RP11-159H20.3	-5.57	4.35e-08	0.0439	-0.31	-0.25	Neuroticism;	chr8:8805705	chr9:76992099~76993108:+
THCA	trans	rs10090774	0.932	rs13259836	ENSG00000230756.1	RHOQP3	5.57	4.35e-08	0.044	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140955789	chr2:130212870~130213490:-
THCA	trans	rs7429990	0.932	rs11720151	ENSG00000235912.1	RP1-159A19.3	5.57	4.36e-08	0.044	0.31	0.25	Educational attainment (years of education);	chr3:48099144	chr1:27649419~27649610:+
THCA	trans	rs7113874	0.524	rs4929943	ENSG00000266891.1	RP11-692N5.2	-5.57	4.36e-08	0.0441	-0.33	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8603807	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.524	rs4929944	ENSG00000266891.1	RP11-692N5.2	-5.57	4.36e-08	0.0441	-0.33	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8603894	chr18:9734882~9735602:-
THCA	trans	rs7113874	0.524	rs4929945	ENSG00000266891.1	RP11-692N5.2	-5.57	4.36e-08	0.0441	-0.33	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8603904	chr18:9734882~9735602:-
THCA	trans	rs864643	0.838	rs58141864	ENSG00000183298.5	RP11-556K13.1	5.57	4.37e-08	0.0441	0.52	0.25	Attention deficit hyperactivity disorder;	chr3:39505344	chr1:101786340~101787219:-
THCA	trans	rs9329221	1	rs9329221	ENSG00000254153.1	CTA-398F10.2	-5.57	4.37e-08	0.0441	-0.26	-0.25	Neuroticism;	chr8:10382692	chr8:8456909~8461337:-
THCA	trans	rs7192380	0.895	rs2917671	ENSG00000257513.6	NPIPB1P	-5.57	4.38e-08	0.0442	-0.27	-0.25	Sjögren's syndrome;	chr16:69724838	chr18:11619509~11639699:-
THCA	trans	rs9329221	0.683	rs525726	ENSG00000229857.1	RP11-159H20.3	5.57	4.38e-08	0.0442	0.31	0.25	Neuroticism;	chr8:10030287	chr9:76992099~76993108:+
THCA	trans	rs10809457	0.836	rs4560889	ENSG00000244171.4	PBX2P1	-5.57	4.38e-08	0.0442	-0.31	-0.25	Palmitic acid (16:0) levels;	chr9:11402624	chr3:143176327~143177617:+
THCA	trans	rs263156	0.932	rs166401	ENSG00000276182.1	RP11-872J21.5	-5.57	4.39e-08	0.0443	-0.2	-0.25	Lobe size;Ear morphology;Lobe attachment;	chr6:142549241	chr14:96537170~96537904:+
THCA	trans	rs853679	0.546	rs200996	ENSG00000228022.4	HCG20	-5.57	4.39e-08	0.0443	-0.48	-0.25	Depression;	chr6:27844050	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs200990	ENSG00000228022.4	HCG20	-5.57	4.39e-08	0.0443	-0.48	-0.25	Depression;	chr6:27848045	chr6:30766825~30792250:+
THCA	trans	rs9693857	0.518	rs35589912	ENSG00000253893.2	FAM85B	5.57	4.39e-08	0.0443	0.35	0.25	Systolic blood pressure;	chr8:9420478	chr8:8167819~8226614:-
THCA	trans	rs10090774	0.965	rs4961291	ENSG00000230756.1	RHOQP3	-5.57	4.39e-08	0.0443	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140767676	chr2:130212870~130213490:-
THCA	trans	rs10435719	0.744	rs11250175	ENSG00000229857.1	RP11-159H20.3	-5.57	4.39e-08	0.0443	-0.32	-0.25	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr9:76992099~76993108:+
THCA	trans	rs1908814	0.516	rs13252853	ENSG00000229857.1	RP11-159H20.3	-5.57	4.39e-08	0.0443	-0.32	-0.25	Neuroticism;	chr8:11935465	chr9:76992099~76993108:+
THCA	trans	rs1908814	0.516	rs13252854	ENSG00000229857.1	RP11-159H20.3	-5.57	4.39e-08	0.0443	-0.32	-0.25	Neuroticism;	chr8:11935469	chr9:76992099~76993108:+
THCA	trans	rs1908814	0.516	rs13279577	ENSG00000229857.1	RP11-159H20.3	-5.57	4.39e-08	0.0443	-0.32	-0.25	Neuroticism;	chr8:11935587	chr9:76992099~76993108:+
THCA	trans	rs1908814	0.516	rs10112958	ENSG00000229857.1	RP11-159H20.3	-5.57	4.39e-08	0.0443	-0.32	-0.25	Neuroticism;	chr8:11935631	chr9:76992099~76993108:+
THCA	trans	rs9914988	0.943	rs11652272	ENSG00000267449.1	RP11-264B14.2	5.57	4.39e-08	0.0443	0.37	0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28840955	chr17:61069856~61070356:-
THCA	trans	rs11668609	0.938	rs8110507	ENSG00000281468.1	CTC-459F4.9	-5.57	4.4e-08	0.0444	-0.31	-0.25	Response to taxane treatment (docetaxel);	chr19:24099470	chr19:27802838~27803472:+
THCA	trans	rs7189233	0.955	rs7189726	ENSG00000277863.1	RP11-282A11.4	5.57	4.4e-08	0.0444	0.34	0.25	Intelligence (multi-trait analysis);	chr16:53463862	chr13:106903150~106904099:-
THCA	trans	rs8177876	0.749	rs935942	ENSG00000224837.1	GCSHP5	-5.57	4.4e-08	0.0444	-0.35	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr1:168055901~168056422:-
THCA	trans	rs9914988	0.943	rs67327562	ENSG00000267449.1	RP11-264B14.2	5.57	4.41e-08	0.0445	0.37	0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28781810	chr17:61069856~61070356:-
THCA	trans	rs9329221	0.65	rs657913	ENSG00000229857.1	RP11-159H20.3	5.56	4.42e-08	0.0445	0.31	0.25	Neuroticism;	chr8:10025065	chr9:76992099~76993108:+
THCA	trans	rs78587638	1	rs79147465	ENSG00000198580.7	RP11-611L7.2	-5.56	4.42e-08	0.0445	-0.38	-0.25	Mosquito bite size;	chr2:118432653	chr7:6673494~6676366:+
THCA	trans	rs34546498	1	rs34546498	ENSG00000248290.1	TNXA	-5.56	4.43e-08	0.0446	-0.55	-0.25	Breast cancer;	chr6:26993501	chr6:32008614~32012472:-
THCA	trans	rs7824557	0.767	rs1897951	ENSG00000254153.1	CTA-398F10.2	-5.56	4.43e-08	0.0446	-0.28	-0.25	Retinal vascular caliber;	chr8:11312345	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.767	rs11250127	ENSG00000254153.1	CTA-398F10.2	-5.56	4.43e-08	0.0446	-0.28	-0.25	Retinal vascular caliber;	chr8:11312700	chr8:8456909~8461337:-
THCA	trans	rs3812762	0.917	rs905289	ENSG00000266891.1	RP11-692N5.2	-5.56	4.43e-08	0.0446	-0.32	-0.25	Hypospadias;	chr11:8732005	chr18:9734882~9735602:-
THCA	trans	rs950169	1	rs12915234	ENSG00000259295.5	CSPG4P12	5.56	4.43e-08	0.0447	0.38	0.25	Schizophrenia;	chr15:84089549	chr15:85191438~85213905:+
THCA	trans	rs950169	1	rs34751999	ENSG00000259295.5	CSPG4P12	5.56	4.43e-08	0.0447	0.38	0.25	Schizophrenia;	chr15:84089667	chr15:85191438~85213905:+
THCA	trans	rs950169	0.919	rs17300292	ENSG00000259295.5	CSPG4P12	5.56	4.43e-08	0.0447	0.38	0.25	Schizophrenia;	chr15:84093816	chr15:85191438~85213905:+
THCA	trans	rs7824557	0.527	rs11785394	ENSG00000256560.1	LINC01486	-5.56	4.43e-08	0.0447	-0.31	-0.25	Retinal vascular caliber;	chr8:11380520	chr12:109354083~109359488:-
THCA	trans	rs17783634	0.509	rs11775489	ENSG00000254153.1	CTA-398F10.2	5.56	4.44e-08	0.0447	0.29	0.25	Subjective well-being;	chr8:11179334	chr8:8456909~8461337:-
THCA	trans	rs4140564	0.73	rs6660635	ENSG00000227939.1	RPL3P2	5.56	4.44e-08	0.0447	0.32	0.25	Knee osteoarthritis;	chr1:186780101	chr6:31280317~31281519:+
THCA	trans	rs9914988	0.943	rs9303621	ENSG00000267449.1	RP11-264B14.2	5.56	4.44e-08	0.0447	0.37	0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28834120	chr17:61069856~61070356:-
THCA	trans	rs9914988	0.943	rs7211502	ENSG00000267449.1	RP11-264B14.2	5.56	4.44e-08	0.0447	0.37	0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28836277	chr17:61069856~61070356:-
THCA	trans	rs2985684	0.846	rs11157693	ENSG00000240785.1	RPL36AP21	5.56	4.44e-08	0.0447	0.31	0.25	Carotid intima media thickness;	chr14:49581708	chr5:18049550~18049872:+
THCA	trans	rs67311347	1	rs10510708	ENSG00000139239.7	RPL14P1	-5.56	4.44e-08	0.0448	-0.21	-0.25	Renal cell carcinoma;	chr3:40363279	chr12:62965325~62965969:+
THCA	trans	rs670523	0.722	rs4661079	ENSG00000241627.3	UBQLN4P1	5.56	4.44e-08	0.0448	0.28	0.25	Crohn's disease;Inflammatory bowel disease;	chr1:156013507	chr3:148985868~148987668:-
THCA	trans	rs7429990	0.864	rs6806860	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47708218	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs6768699	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47711258	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs6786001	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47718500	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs12495204	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47720540	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs7618758	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47720993	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs7612219	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47739676	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs35148469	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47739873	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.694	rs7645846	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47740829	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs17079785	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47743160	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs6442082	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47743991	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.747	rs6442083	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47744305	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.786	rs13064183	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47745405	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs7637372	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47750385	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs13086149	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47784158	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs3772399	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47826237	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs3915654	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47827132	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.833	rs35582375	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47829639	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs13077230	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47832232	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs11710199	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.3	0.25	Educational attainment (years of education);	chr3:47836588	chr1:27649419~27649610:+
THCA	trans	rs9329221	0.623	rs7825778	ENSG00000254153.1	CTA-398F10.2	5.56	4.45e-08	0.0448	0.26	0.25	Neuroticism;	chr8:10403500	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.736	rs35392635	ENSG00000254153.1	CTA-398F10.2	-5.56	4.45e-08	0.0448	-0.28	-0.25	Retinal vascular caliber;	chr8:11306840	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.767	rs11775635	ENSG00000254153.1	CTA-398F10.2	-5.56	4.45e-08	0.0448	-0.28	-0.25	Retinal vascular caliber;	chr8:11307356	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.767	rs28507159	ENSG00000254153.1	CTA-398F10.2	-5.56	4.45e-08	0.0448	-0.28	-0.25	Retinal vascular caliber;	chr8:11308567	chr8:8456909~8461337:-
THCA	trans	rs7429990	0.833	rs6777632	ENSG00000235912.1	RP1-159A19.3	5.56	4.45e-08	0.0448	0.31	0.25	Educational attainment (years of education);	chr3:47748775	chr1:27649419~27649610:+
THCA	trans	rs453301	0.509	rs7000323	ENSG00000229857.1	RP11-159H20.3	5.56	4.46e-08	0.0448	0.34	0.25	Joint mobility (Beighton score);	chr8:8934763	chr9:76992099~76993108:+
THCA	trans	rs1232027	0.7	rs2560424	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80629486	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs2618372	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80629791	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1623489	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80630296	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.666	rs1677636	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80630307	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.632	rs60244599	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80630608	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1677634	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80632505	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643636	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80632948	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.632	rs1650718	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80634457	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.632	rs1677706	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80634484	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.632	rs1677701	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80635513	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1677700	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80635600	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs67837398	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80636677	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs71578847	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80636685	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643662	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80637416	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643661	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80637757	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643660	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80638208	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643659	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80639017	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1677696	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80639198	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.666	rs1650710	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80640342	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643658	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80640522	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1677687	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80642517	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.666	rs1677686	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80642709	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643647	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80642749	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643648	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80642796	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.666	rs1677685	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80643122	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643649	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80643630	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1643650	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80644324	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs58490646	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80644715	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs865647	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80646457	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.666	rs34965641	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80646557	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs844370	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80647183	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs836822	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80647957	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs865645	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80648285	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.666	rs1650701	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80648612	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.666	rs1650700	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80648613	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs836818	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80652137	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.632	rs863215	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80652186	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs861373	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80652243	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.666	rs1643646	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80652822	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1677670	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80652835	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1478834	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80653756	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1478835	ENSG00000188985.6	DHFRP1	-5.56	4.46e-08	0.0448	-0.32	-0.25	Huntington's disease progression;	chr5:80653781	chr18:26170726~26171284:-
THCA	trans	rs1232027	0.7	rs1677626	ENSG00000188985.6	DHFRP1	5.56	4.46e-08	0.0448	0.32	0.25	Huntington's disease progression;	chr5:80653626	chr18:26170726~26171284:-
THCA	trans	rs3096299	0.692	rs4785565	ENSG00000215030.5	RPL13P12	-5.56	4.46e-08	0.0449	-0.25	-0.25	Multiple myeloma (IgH translocation);	chr16:89449351	chr17:17383377~17384012:-
THCA	trans	rs7819412	0.807	rs4840542	ENSG00000254153.1	CTA-398F10.2	5.56	4.47e-08	0.0449	0.28	0.25	Triglycerides;	chr8:11087299	chr8:8456909~8461337:-
THCA	trans	rs4929949	0.585	rs12289586	ENSG00000266891.1	RP11-692N5.2	5.56	4.47e-08	0.0449	0.33	0.25	Body mass index;	chr11:8405757	chr18:9734882~9735602:-
THCA	trans	rs9914988	0.943	rs7215310	ENSG00000267449.1	RP11-264B14.2	5.56	4.47e-08	0.0449	0.37	0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28761608	chr17:61069856~61070356:-
THCA	trans	rs6574988	0.86	rs2245606	ENSG00000237714.1	P4HA2-AS1	5.56	4.47e-08	0.0449	0.54	0.25	Bipolar disorder;	chr14:88129578	chr5:132184876~132192808:+
THCA	trans	rs7824557	0.724	rs2251473	ENSG00000256560.1	LINC01486	5.56	4.48e-08	0.045	0.31	0.25	Retinal vascular caliber;	chr8:11319617	chr12:109354083~109359488:-
THCA	trans	rs11668609	1	rs66972560	ENSG00000281468.1	CTC-459F4.9	-5.56	4.48e-08	0.045	-0.32	-0.25	Response to taxane treatment (docetaxel);	chr19:24178138	chr19:27802838~27803472:+
THCA	trans	rs3790645	0.874	rs1002488	ENSG00000221817.8	PPP3CB-AS1	-5.56	4.48e-08	0.045	-0.23	-0.25	Glucose homeostasis traits;	chr1:26539431	chr10:73495525~73520070:+
THCA	trans	rs11786541	0.521	rs4841261	ENSG00000253893.2	FAM85B	5.56	4.48e-08	0.045	0.34	0.25	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:9959789	chr8:8167819~8226614:-
THCA	trans	rs11786541	0.521	rs2409619	ENSG00000253893.2	FAM85B	5.56	4.48e-08	0.045	0.34	0.25	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:9959910	chr8:8167819~8226614:-
THCA	trans	rs2985684	0.901	rs57119148	ENSG00000240785.1	RPL36AP21	5.56	4.48e-08	0.0451	0.32	0.25	Carotid intima media thickness;	chr14:49630508	chr5:18049550~18049872:+
THCA	trans	rs1478897	0.575	rs12679960	ENSG00000253893.2	FAM85B	-5.56	4.48e-08	0.0451	-0.35	-0.25	Systemic lupus erythematosus;	chr8:11573481	chr8:8167819~8226614:-
THCA	trans	rs7769051	0.803	rs12193474	ENSG00000227615.1	RP11-864N7.2	5.56	4.49e-08	0.0451	0.44	0.25	Type 2 diabetes nephropathy;	chr6:132865029	chr11:74745716~74746114:-
THCA	trans	rs9650315	0.706	rs36112366	ENSG00000244245.1	RP11-120B7.1	5.56	4.49e-08	0.0451	0.39	0.25	Height;	chr8:56226117	chr5:108593609~108593967:+
THCA	trans	rs12200782	1	rs12200782	ENSG00000242375.1	RP11-498P14.3	-5.56	4.5e-08	0.0452	-0.62	-0.25	Small cell lung carcinoma;	chr6:26402808	chr9:97195351~97197687:-
THCA	trans	rs6743068	0.6	rs1035140	ENSG00000235105.1	RP11-329A14.1	5.56	4.5e-08	0.0452	0.27	0.25	Lymphocyte percentage of white cells;	chr2:201287768	chr1:48435967~48437223:+
THCA	trans	rs1232027	0.7	rs1677688	ENSG00000188985.6	DHFRP1	-5.56	4.5e-08	0.0452	-0.32	-0.25	Huntington's disease progression;	chr5:80642188	chr18:26170726~26171284:-
THCA	trans	rs10090774	0.965	rs4543590	ENSG00000230756.1	RHOQP3	5.56	4.51e-08	0.0453	0.3	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140715735	chr2:130212870~130213490:-
THCA	trans	rs7429990	0.864	rs3888	ENSG00000235912.1	RP1-159A19.3	5.56	4.51e-08	0.0453	0.3	0.25	Educational attainment (years of education);	chr3:47816085	chr1:27649419~27649610:+
THCA	trans	rs7617773	0.78	rs34630841	ENSG00000235912.1	RP1-159A19.3	-5.56	4.52e-08	0.0454	-0.31	-0.25	Coronary artery disease;	chr3:48301771	chr1:27649419~27649610:+
THCA	trans	rs3808502	0.526	rs36048422	ENSG00000254153.1	CTA-398F10.2	5.56	4.53e-08	0.0455	0.28	0.25	Neuroticism;	chr8:11559635	chr8:8456909~8461337:-
THCA	trans	rs3808502	0.526	rs11783065	ENSG00000254153.1	CTA-398F10.2	5.56	4.53e-08	0.0455	0.28	0.25	Neuroticism;	chr8:11559748	chr8:8456909~8461337:-
THCA	trans	rs57583458	1	rs57583458	ENSG00000267449.1	RP11-264B14.2	5.56	4.53e-08	0.0455	0.38	0.25	Mean corpuscular hemoglobin concentration;	chr17:28779794	chr17:61069856~61070356:-
THCA	trans	rs10090774	0.965	rs13250888	ENSG00000230756.1	RHOQP3	5.56	4.54e-08	0.0456	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140888931	chr2:130212870~130213490:-
THCA	trans	rs7429990	0.864	rs11130150	ENSG00000235912.1	RP1-159A19.3	5.56	4.54e-08	0.0456	0.3	0.25	Educational attainment (years of education);	chr3:47832449	chr1:27649419~27649610:+
THCA	trans	rs433755	0.74	rs2387706	ENSG00000189014.7	FAM35DP	-5.56	4.55e-08	0.0456	-0.28	-0.25	Obesity-related traits;	chr5:9492275	chr10:47689707~47730436:+
THCA	trans	rs433755	0.716	rs6865050	ENSG00000189014.7	FAM35DP	-5.56	4.55e-08	0.0456	-0.28	-0.25	Obesity-related traits;	chr5:9493380	chr10:47689707~47730436:+
THCA	trans	rs11992162	0.508	rs7003792	ENSG00000229857.1	RP11-159H20.3	5.56	4.55e-08	0.0456	0.32	0.25	Monocyte count;	chr8:11923955	chr9:76992099~76993108:+
THCA	trans	rs263156	0.967	rs839556	ENSG00000276182.1	RP11-872J21.5	-5.56	4.55e-08	0.0456	-0.2	-0.25	Lobe size;Ear morphology;Lobe attachment;	chr6:142550741	chr14:96537170~96537904:+
THCA	trans	rs4654899	0.931	rs1152998	ENSG00000280120.1	RP11-546D6.3	5.56	4.55e-08	0.0456	0.18	0.25	Superior frontal gyrus grey matter volume;	chr1:20797797	chr12:123152324~123153377:-
THCA	trans	rs10090774	0.965	rs13261338	ENSG00000230756.1	RHOQP3	5.56	4.55e-08	0.0457	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140881722	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs7830394	ENSG00000230756.1	RHOQP3	5.56	4.55e-08	0.0457	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140884642	chr2:130212870~130213490:-
THCA	trans	rs10090774	0.965	rs11167006	ENSG00000230756.1	RHOQP3	5.56	4.55e-08	0.0457	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140885398	chr2:130212870~130213490:-
THCA	trans	rs12200782	1	rs12207181	ENSG00000242375.1	RP11-498P14.3	-5.56	4.57e-08	0.0458	-0.62	-0.25	Small cell lung carcinoma;	chr6:26431057	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs12199239	ENSG00000242375.1	RP11-498P14.3	-5.56	4.57e-08	0.0458	-0.62	-0.25	Small cell lung carcinoma;	chr6:26432342	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs10456330	ENSG00000242375.1	RP11-498P14.3	-5.56	4.57e-08	0.0458	-0.62	-0.25	Small cell lung carcinoma;	chr6:26436464	chr9:97195351~97197687:-
THCA	trans	rs12200782	1	rs12208390	ENSG00000242375.1	RP11-498P14.3	-5.56	4.57e-08	0.0458	-0.62	-0.25	Small cell lung carcinoma;	chr6:26436878	chr9:97195351~97197687:-
THCA	trans	rs12200782	0.929	rs72843734	ENSG00000242375.1	RP11-498P14.3	-5.56	4.57e-08	0.0458	-0.62	-0.25	Small cell lung carcinoma;	chr6:26448116	chr9:97195351~97197687:-
THCA	trans	rs80264589	1	rs80264589	ENSG00000204338.7	CYP21A1P	-5.56	4.57e-08	0.0458	-0.52	-0.25	Intelligence (multi-trait analysis);Lung cancer;	chr6:26959823	chr6:32005636~32008451:+
THCA	trans	rs9393777	0.92	rs34071253	ENSG00000204338.7	CYP21A1P	-5.56	4.57e-08	0.0458	-0.47	-0.25	Intelligence (multi-trait analysis);	chr6:27424023	chr6:32005636~32008451:+
THCA	trans	rs902774	1	rs11831942	ENSG00000248568.1	KRT8P48	-5.56	4.57e-08	0.0459	-0.44	-0.25	Prostate cancer;	chr12:52878329	chr5:146706381~146707600:-
THCA	trans	rs11668609	1	rs8100931	ENSG00000261770.1	CTC-459F4.1	5.56	4.57e-08	0.0459	0.35	0.25	Response to taxane treatment (docetaxel);	chr19:24175770	chr19:27757184~27760849:-
THCA	trans	rs7113874	0.589	rs1374262	ENSG00000266891.1	RP11-692N5.2	-5.56	4.58e-08	0.0459	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8437202	chr18:9734882~9735602:-
THCA	trans	rs10090774	0.965	rs11990900	ENSG00000230756.1	RHOQP3	5.56	4.59e-08	0.046	0.31	0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140967821	chr2:130212870~130213490:-
THCA	trans	rs9381040	0.61	rs2294694	ENSG00000232097.1	AC079781.8	5.56	4.59e-08	0.046	0.31	0.25	Alzheimer's disease (late onset);	chr6:41078438	chr7:97938439~97938794:-
THCA	trans	rs7212590	0.581	rs8070961	ENSG00000187870.7	RNFT1P3	5.56	4.59e-08	0.046	0.5	0.25	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59735807	chr17:20743333~20754501:-
THCA	trans	rs7829975	0.54	rs2976909	ENSG00000229857.1	RP11-159H20.3	5.56	4.6e-08	0.0461	0.32	0.25	Mood instability;	chr8:8489180	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.515	rs6601560	ENSG00000254153.1	CTA-398F10.2	5.56	4.61e-08	0.0462	0.28	0.25	Neuroticism;	chr8:11093356	chr8:8456909~8461337:-
THCA	trans	rs73195822	0.614	rs55680931	ENSG00000232284.6	GNG12-AS1	5.56	4.61e-08	0.0462	0.45	0.25	Itch intensity from mosquito bite;	chr12:110780492	chr1:67832303~68202987:+
THCA	trans	rs2150462	0.508	rs6475737	ENSG00000226084.5	RP4-706A16.3	5.56	4.61e-08	0.0462	0.28	0.25	Neuroticism;	chr9:23353926	chr1:77129114~77129668:+
THCA	trans	rs11122895	0.509	rs10174353	ENSG00000204745.3	AC083899.3	5.56	4.62e-08	0.0463	0.31	0.25	Allergic sensitization;	chr2:111690311	chr2:87125390~87196647:+
THCA	trans	rs7113874	0.55	rs10840085	ENSG00000266891.1	RP11-692N5.2	-5.56	4.62e-08	0.0463	-0.32	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8592402	chr18:9734882~9735602:-
THCA	trans	rs9467711	0.659	rs36162392	ENSG00000219392.1	RP1-265C24.5	-5.56	4.63e-08	0.0463	-0.52	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr6:28115628~28116551:+
THCA	trans	rs7692395	0.556	rs79259858	ENSG00000276188.1	RP11-173P15.10	-5.56	4.63e-08	0.0464	-0.37	-0.25	Incident myocardial infarction;	chr4:182711776	chr12:120709112~120709523:+
THCA	trans	rs1580019	0.844	rs1584615	ENSG00000176826.14	FKBP9P1	-5.56	4.64e-08	0.0464	-0.35	-0.25	Cognitive ability;	chr7:32463646	chr7:55681074~55713252:-
THCA	trans	rs7617773	0.78	rs11710257	ENSG00000235912.1	RP1-159A19.3	-5.56	4.64e-08	0.0464	-0.31	-0.25	Coronary artery disease;	chr3:48331724	chr1:27649419~27649610:+
THCA	trans	rs11098499	0.913	rs10006304	ENSG00000253326.2	RP11-261C10.7	5.56	4.64e-08	0.0465	0.34	0.25	Corneal astigmatism;	chr4:119203150	chr1:243054861~243056394:-
THCA	trans	rs6921919	0.789	rs11970439	ENSG00000228078.1	HLA-U	-5.56	4.64e-08	0.0465	-0.34	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:29934101~29934286:+
THCA	trans	rs12210905	1	rs12209429	ENSG00000242375.1	RP11-498P14.3	-5.56	4.65e-08	0.0465	-0.67	-0.25	Hip circumference adjusted for BMI;	chr6:27087088	chr9:97195351~97197687:-
THCA	trans	rs902774	0.818	rs73108469	ENSG00000240668.1	KRT8P36	-5.56	4.65e-08	0.0465	-0.51	-0.25	Prostate cancer;	chr12:52891065	chr3:138101478~138102917:-
THCA	trans	rs7819412	0.582	rs2409685	ENSG00000254153.1	CTA-398F10.2	5.56	4.65e-08	0.0465	0.28	0.25	Triglycerides;	chr8:11051683	chr8:8456909~8461337:-
THCA	trans	rs7429990	0.864	rs17290490	ENSG00000235912.1	RP1-159A19.3	5.56	4.65e-08	0.0465	0.3	0.25	Educational attainment (years of education);	chr3:47841237	chr1:27649419~27649610:+
THCA	trans	rs2224003	0.759	rs9452695	ENSG00000279611.1	CTD-2619J13.5	5.56	4.65e-08	0.0465	0.28	0.25	Brain connectivity;	chr6:94429414	chr19:58350795~58351720:+
THCA	trans	rs2224003	0.788	rs9452723	ENSG00000279611.1	CTD-2619J13.5	5.56	4.65e-08	0.0465	0.28	0.25	Brain connectivity;	chr6:94435604	chr19:58350795~58351720:+
THCA	trans	rs7113874	0.524	rs4244804	ENSG00000266891.1	RP11-692N5.2	-5.56	4.65e-08	0.0465	-0.33	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8596003	chr18:9734882~9735602:-
THCA	trans	rs10809457	0.869	rs3949548	ENSG00000244171.4	PBX2P1	-5.55	4.65e-08	0.0466	-0.3	-0.25	Palmitic acid (16:0) levels;	chr9:11356167	chr3:143176327~143177617:+
THCA	trans	rs9987353	0.522	rs2929466	ENSG00000229857.1	RP11-159H20.3	5.55	4.67e-08	0.0467	0.31	0.25	Recombination measurement;	chr8:9206389	chr9:76992099~76993108:+
THCA	trans	rs9650657	0.644	rs10091386	ENSG00000253893.2	FAM85B	5.55	4.67e-08	0.0467	0.31	0.25	Neuroticism;	chr8:10839110	chr8:8167819~8226614:-
THCA	trans	rs2226284	0.901	rs1938576	ENSG00000204054.10	LINC00963	-5.55	4.67e-08	0.0467	-0.32	-0.25	Hypertension risk in short sleep duration;	chr1:69893480	chr9:129483451~129513683:+
THCA	trans	rs10504229	0.683	rs56408763	ENSG00000226986.4	RP11-543B16.2	-5.55	4.67e-08	0.0467	-0.38	-0.25	Developmental language disorder (linguistic errors);	chr8:57224717	chr1:211207239~211207897:+
THCA	trans	rs7824557	0.707	rs3808519	ENSG00000254153.1	CTA-398F10.2	-5.55	4.67e-08	0.0467	-0.27	-0.25	Retinal vascular caliber;	chr8:11285461	chr8:8456909~8461337:-
THCA	trans	rs8014204	0.967	rs2359240	ENSG00000181227.3	RP4-682C21.2	5.55	4.69e-08	0.0469	0.2	0.25	Caffeine consumption;	chr14:74861544	chr1:75743423~75744776:-
THCA	trans	rs7819412	0.521	rs10100660	ENSG00000254153.1	CTA-398F10.2	5.55	4.7e-08	0.0469	0.29	0.25	Triglycerides;	chr8:11181376	chr8:8456909~8461337:-
THCA	trans	rs6601327	0.606	rs7006985	ENSG00000253893.2	FAM85B	5.55	4.71e-08	0.0471	0.31	0.25	Multiple myeloma (hyperdiploidy);	chr8:9706927	chr8:8167819~8226614:-
THCA	trans	rs7829975	0.628	rs1109618	ENSG00000256560.1	LINC01486	-5.55	4.72e-08	0.0472	-0.31	-0.25	Mood instability;	chr8:8713854	chr12:109354083~109359488:-
THCA	trans	rs853679	0.546	rs200977	ENSG00000253570.1	RNF5P1	5.55	4.72e-08	0.0472	0.54	0.25	Depression;	chr6:27886523	chr8:38600661~38601200:-
THCA	trans	rs10090774	0.965	rs4246125	ENSG00000230756.1	RHOQP3	-5.55	4.73e-08	0.0472	-0.31	-0.25	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140778430	chr2:130212870~130213490:-
THCA	trans	rs7829975	0.714	rs6994038	ENSG00000229857.1	RP11-159H20.3	-5.55	4.73e-08	0.0473	-0.3	-0.25	Mood instability;	chr8:8803028	chr9:76992099~76993108:+
THCA	trans	rs10809457	0.805	rs4593654	ENSG00000244171.4	PBX2P1	-5.55	4.73e-08	0.0473	-0.3	-0.25	Palmitic acid (16:0) levels;	chr9:11402513	chr3:143176327~143177617:+
THCA	trans	rs7617773	0.78	rs11706277	ENSG00000235912.1	RP1-159A19.3	-5.55	4.73e-08	0.0473	-0.31	-0.25	Coronary artery disease;	chr3:48318943	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs11130143	ENSG00000235912.1	RP1-159A19.3	5.55	4.74e-08	0.0474	0.3	0.25	Educational attainment (years of education);	chr3:47614943	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs6774170	ENSG00000235912.1	RP1-159A19.3	5.55	4.74e-08	0.0474	0.3	0.25	Educational attainment (years of education);	chr3:47615977	chr1:27649419~27649610:+
THCA	trans	rs2279168	1	rs79270762	ENSG00000272275.1	RP11-791G15.2	-5.55	4.75e-08	0.0474	-0.41	-0.25	Response to platinum-based chemotherapy (carboplatin);	chr15:85530945	chr2:10767875~10770058:-
THCA	trans	rs12477438	0.52	rs13009147	ENSG00000276576.1	MRPL30P1	5.55	4.75e-08	0.0475	0.32	0.25	Chronic sinus infection;	chr2:99187535	chr6:57029521~57029988:+
THCA	trans	rs9650657	0.615	rs6601536	ENSG00000253893.2	FAM85B	5.55	4.76e-08	0.0475	0.3	0.25	Neuroticism;	chr8:10838801	chr8:8167819~8226614:-
THCA	trans	rs9650315	0.53	rs35399441	ENSG00000244245.1	RP11-120B7.1	5.55	4.77e-08	0.0476	0.29	0.25	Height;	chr8:56176872	chr5:108593609~108593967:+
THCA	trans	rs2898290	0.622	rs978802	ENSG00000254153.1	CTA-398F10.2	5.55	4.77e-08	0.0476	0.28	0.25	Systolic blood pressure;	chr8:11485769	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.521	rs4451268	ENSG00000254153.1	CTA-398F10.2	5.55	4.77e-08	0.0476	0.29	0.25	Triglycerides;	chr8:11177350	chr8:8456909~8461337:-
THCA	trans	rs7617773	0.709	rs4404473	ENSG00000235912.1	RP1-159A19.3	-5.55	4.77e-08	0.0477	-0.31	-0.25	Coronary artery disease;	chr3:48312136	chr1:27649419~27649610:+
THCA	trans	rs4948102	0.551	rs4275190	ENSG00000215006.4	CHCHD2P2	-5.55	4.79e-08	0.0478	-0.35	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr5:69333929~69334249:+
THCA	trans	rs1475911	1	rs12482477	ENSG00000229759.1	MRPS18AP1	-5.55	4.79e-08	0.0478	-0.35	-0.25	IgG glycosylation;	chr21:42097123	chr3:48256350~48256938:-
THCA	trans	rs6921919	0.848	rs56131013	ENSG00000228078.1	HLA-U	-5.55	4.8e-08	0.0479	-0.35	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:29934101~29934286:+
THCA	trans	rs9329221	0.678	rs560638	ENSG00000229857.1	RP11-159H20.3	5.55	4.8e-08	0.0479	0.31	0.25	Neuroticism;	chr8:10025257	chr9:76992099~76993108:+
THCA	trans	rs4929949	0.644	rs10840042	ENSG00000266891.1	RP11-692N5.2	-5.55	4.81e-08	0.048	-0.32	-0.25	Body mass index;	chr11:8422431	chr18:9734882~9735602:-
THCA	trans	rs12989701	1	rs13004848	ENSG00000218208.1	RP11-367G18.2	5.55	4.81e-08	0.048	0.33	0.25	Alzheimer's disease (late onset);	chr2:127129984	chr6:113581501~113581947:+
THCA	trans	rs2240255	0.522	rs56069843	ENSG00000269481.1	CTD-2521M24.6	-5.55	4.82e-08	0.048	-0.28	-0.25	White matter lesion progression (adjusted for white matter lesion burden at baseline);	chr16:74751888	chr19:17414257~17422324:-
THCA	trans	rs56114371	0.777	rs200483	ENSG00000228022.4	HCG20	-5.55	4.82e-08	0.0481	-0.48	-0.25	Breast cancer;	chr6:27807046	chr6:30766825~30792250:+
THCA	trans	rs6928977	0.932	rs11154798	ENSG00000275632.1	RP5-967N21.11	-5.55	4.82e-08	0.0481	-0.21	-0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135311487	chr20:6000418~6000941:+
THCA	trans	rs7824557	0.767	rs6985460	ENSG00000254153.1	CTA-398F10.2	-5.55	4.83e-08	0.0482	-0.28	-0.25	Retinal vascular caliber;	chr8:11313578	chr8:8456909~8461337:-
THCA	trans	rs7824557	0.767	rs7003241	ENSG00000229857.1	RP11-159H20.3	-5.55	4.83e-08	0.0482	-0.31	-0.25	Retinal vascular caliber;	chr8:11311566	chr9:76992099~76993108:+
THCA	trans	rs7404928	0.522	rs9806904	ENSG00000241431.1	RPL37P6	5.55	4.83e-08	0.0482	0.23	0.25	Rheumatoid arthritis;Primary biliary cholangitis;	chr16:23866021	chr8:56588385~56588787:+
THCA	trans	rs12637928	0.504	rs4682013	ENSG00000144158.4	RP11-395L14.17	5.55	4.85e-08	0.0484	0.31	0.25	Neuroticism;	chr3:110587688	chr2:113657908~113658675:+
THCA	trans	rs12637928	0.504	rs1512511	ENSG00000144158.4	RP11-395L14.17	-5.55	4.85e-08	0.0484	-0.31	-0.25	Neuroticism;	chr3:110584540	chr2:113657908~113658675:+
THCA	trans	rs9693444	0.898	rs4732697	ENSG00000273293.1	RP11-445N20.3	-5.55	4.86e-08	0.0484	-0.25	-0.25	Breast cancer;	chr8:29662345	chr7:149881359~149881580:-
THCA	trans	rs12200782	1	rs41267923	ENSG00000242375.1	RP11-498P14.3	-5.55	4.86e-08	0.0484	-0.63	-0.25	Small cell lung carcinoma;	chr6:26452719	chr9:97195351~97197687:-
THCA	trans	rs7769051	0.522	rs17061975	ENSG00000227615.1	RP11-864N7.2	5.55	4.86e-08	0.0484	0.52	0.25	Type 2 diabetes nephropathy;	chr6:132918880	chr11:74745716~74746114:-
THCA	trans	rs995030	0.571	rs7960514	ENSG00000236494.1	RP11-89N17.4	5.55	4.86e-08	0.0484	0.39	0.25	Testicular germ cell tumor;	chr12:88436558	chr7:33793168~33803156:-
THCA	trans	rs995030	0.571	rs7973853	ENSG00000236494.1	RP11-89N17.4	5.55	4.86e-08	0.0484	0.39	0.25	Testicular germ cell tumor;	chr12:88436731	chr7:33793168~33803156:-
THCA	trans	rs995030	0.571	rs7486285	ENSG00000236494.1	RP11-89N17.4	5.55	4.86e-08	0.0484	0.39	0.25	Testicular germ cell tumor;	chr12:88437195	chr7:33793168~33803156:-
THCA	trans	rs995030	0.528	rs10858731	ENSG00000236494.1	RP11-89N17.4	5.55	4.86e-08	0.0484	0.39	0.25	Testicular germ cell tumor;	chr12:88437902	chr7:33793168~33803156:-
THCA	trans	rs995030	0.528	rs11104874	ENSG00000236494.1	RP11-89N17.4	5.55	4.86e-08	0.0484	0.39	0.25	Testicular germ cell tumor;	chr12:88439041	chr7:33793168~33803156:-
THCA	trans	rs995030	0.528	rs10858733	ENSG00000236494.1	RP11-89N17.4	5.55	4.86e-08	0.0484	0.39	0.25	Testicular germ cell tumor;	chr12:88441860	chr7:33793168~33803156:-
THCA	trans	rs995030	0.528	rs57849625	ENSG00000236494.1	RP11-89N17.4	5.55	4.86e-08	0.0484	0.39	0.25	Testicular germ cell tumor;	chr12:88443454	chr7:33793168~33803156:-
THCA	trans	rs995030	0.528	rs7487564	ENSG00000236494.1	RP11-89N17.4	5.55	4.86e-08	0.0484	0.39	0.25	Testicular germ cell tumor;	chr12:88444186	chr7:33793168~33803156:-
THCA	trans	rs12543645	0.609	rs35112858	ENSG00000253893.2	FAM85B	-5.55	4.86e-08	0.0484	-0.35	-0.25	Schizophrenia;	chr8:10419759	chr8:8167819~8226614:-
THCA	trans	rs9393777	0.778	rs66841633	ENSG00000228022.4	HCG20	-5.55	4.87e-08	0.0485	-0.57	-0.25	Intelligence (multi-trait analysis);	chr6:27414607	chr6:30766825~30792250:+
THCA	trans	rs34119086	1	rs34119086	ENSG00000270604.4	HCG17	-5.55	4.87e-08	0.0485	-0.55	-0.25	Breast cancer;	chr6:28594471	chr6:30234039~30326134:-
THCA	trans	rs11992162	0.507	rs60902764	ENSG00000229857.1	RP11-159H20.3	5.55	4.88e-08	0.0486	0.32	0.25	Monocyte count;	chr8:11927482	chr9:76992099~76993108:+
THCA	trans	rs7617480	0.648	rs6806356	ENSG00000235912.1	RP1-159A19.3	-5.55	4.88e-08	0.0486	-0.39	-0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48690203	chr1:27649419~27649610:+
THCA	trans	rs6928977	1	rs6928977	ENSG00000275632.1	RP5-967N21.11	5.55	4.88e-08	0.0486	0.22	0.25	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135305210	chr20:6000418~6000941:+
THCA	trans	rs2898290	0.593	rs2199690	ENSG00000254153.1	CTA-398F10.2	5.55	4.88e-08	0.0486	0.28	0.25	Systolic blood pressure;	chr8:11482107	chr8:8456909~8461337:-
THCA	trans	rs1024889	0.539	rs6791507	ENSG00000229196.3	RP11-775D22.2	-5.55	4.88e-08	0.0486	-0.39	-0.25	Body mass index;	chr3:70439047	chr7:130141731~130142615:+
THCA	trans	rs7113874	0.569	rs4620720	ENSG00000266891.1	RP11-692N5.2	-5.55	4.89e-08	0.0487	-0.33	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8594392	chr18:9734882~9735602:-
THCA	trans	rs9914988	0.673	rs9890212	ENSG00000267449.1	RP11-264B14.2	5.55	4.89e-08	0.0487	0.37	0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28842872	chr17:61069856~61070356:-
THCA	trans	rs889398	0.771	rs4985448	ENSG00000257513.6	NPIPB1P	5.55	4.9e-08	0.0488	0.28	0.25	Body mass index;	chr16:69865492	chr18:11619509~11639699:-
THCA	trans	rs889398	0.771	rs1566454	ENSG00000257513.6	NPIPB1P	5.55	4.9e-08	0.0488	0.28	0.25	Body mass index;	chr16:69866180	chr18:11619509~11639699:-
THCA	trans	rs889398	0.651	rs1566455	ENSG00000257513.6	NPIPB1P	5.55	4.9e-08	0.0488	0.28	0.25	Body mass index;	chr16:69866261	chr18:11619509~11639699:-
THCA	trans	rs7824557	0.767	rs2164273	ENSG00000229857.1	RP11-159H20.3	-5.55	4.9e-08	0.0488	-0.31	-0.25	Retinal vascular caliber;	chr8:11310990	chr9:76992099~76993108:+
THCA	trans	rs5758511	0.573	rs4501042	ENSG00000268568.1	AC007228.9	-5.55	4.91e-08	0.0489	-0.29	-0.25	Birth weight;	chr22:41849759	chr19:56672574~56673901:-
THCA	trans	rs1381660	0.74	rs7818702	ENSG00000260711.2	RP11-747H7.3	5.55	4.91e-08	0.0489	0.22	0.25	Body mass index;Body mass index in physically active individuals;	chr8:75971738	chr14:91752856~91759798:-
THCA	trans	rs875971	0.545	rs75577046	ENSG00000213640.3	EEF1DP4	-5.54	4.91e-08	0.0489	-0.33	-0.25	Aortic root size;	chr7:66493729	chr7:64862999~64864370:+
THCA	trans	rs875971	0.545	rs3735147	ENSG00000213640.3	EEF1DP4	-5.54	4.91e-08	0.0489	-0.33	-0.25	Aortic root size;	chr7:66505541	chr7:64862999~64864370:+
THCA	trans	rs9467711	0.659	rs34605993	ENSG00000204338.7	CYP21A1P	-5.54	4.91e-08	0.0489	-0.57	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.659	rs66757203	ENSG00000204338.7	CYP21A1P	-5.54	4.91e-08	0.0489	-0.57	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26454728	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.659	rs35680819	ENSG00000204338.7	CYP21A1P	-5.54	4.91e-08	0.0489	-0.57	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr6:32005636~32008451:+
THCA	trans	rs9467711	0.659	rs36033628	ENSG00000204338.7	CYP21A1P	-5.54	4.91e-08	0.0489	-0.57	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26455846	chr6:32005636~32008451:+
THCA	trans	rs7617480	0.616	rs7429596	ENSG00000235912.1	RP1-159A19.3	-5.54	4.92e-08	0.049	-0.4	-0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48771098	chr1:27649419~27649610:+
THCA	trans	rs7013285	0.514	rs7833269	ENSG00000278035.1	RP11-234K24.6	5.54	4.92e-08	0.049	0.35	0.25	Paclitaxel disposition in epithelial ovarian cancer;	chr8:106378168	chr20:36233851~36234297:+
THCA	trans	rs2242330	0.862	rs7684846	ENSG00000226982.4	CENPCP1	5.54	4.93e-08	0.049	0.38	0.25	Parkinson's disease;	chr4:67500827	chr12:89500093~89502670:+
THCA	trans	rs6142102	0.607	rs6088408	ENSG00000269202.1	RP4-614O4.12	5.54	4.93e-08	0.0491	0.24	0.25	Skin pigmentation;	chr20:34146800	chr20:35201747~35203288:-
THCA	trans	rs4724055	0.557	rs533250	ENSG00000242640.1	RP11-302F12.1	5.54	4.94e-08	0.0491	0.34	0.25	Non-substance related behavioral disinhibition;	chr7:41563668	chr4:25678850~25679020:+
THCA	trans	rs2242330	0.862	rs6834849	ENSG00000226982.4	CENPCP1	5.54	4.94e-08	0.0492	0.38	0.25	Parkinson's disease;	chr4:67435727	chr12:89500093~89502670:+
THCA	trans	rs3808502	0.527	rs2736389	ENSG00000229857.1	RP11-159H20.3	-5.54	4.95e-08	0.0492	-0.34	-0.25	Neuroticism;	chr8:11303801	chr9:76992099~76993108:+
THCA	trans	rs9572786	0.617	rs303935	ENSG00000228956.7	SATB1-AS1	5.54	4.95e-08	0.0492	0.27	0.25	Plateletcrit;	chr13:71801590	chr3:18445024~18920401:+
THCA	trans	rs9398764	0.517	rs7768327	ENSG00000216895.7	AC009403.2	5.54	4.95e-08	0.0492	0.21	0.25	Political ideology;	chr6:124725129	chr7:155611231~155645205:-
THCA	trans	rs7833986	0.501	rs2976044	ENSG00000244086.1	RPS20P35	5.54	4.95e-08	0.0493	0.36	0.25	Height;	chr8:56074178	chr17:38855314~38855670:+
THCA	trans	rs9650657	0.644	rs7012206	ENSG00000253893.2	FAM85B	5.54	4.96e-08	0.0493	0.31	0.25	Neuroticism;	chr8:10839505	chr8:8167819~8226614:-
THCA	trans	rs853679	0.546	rs175597	ENSG00000228022.4	HCG20	-5.54	4.96e-08	0.0493	-0.48	-0.25	Depression;	chr6:27842848	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs200989	ENSG00000228022.4	HCG20	-5.54	4.96e-08	0.0493	-0.48	-0.25	Depression;	chr6:27848664	chr6:30766825~30792250:+
THCA	trans	rs453301	0.686	rs13252797	ENSG00000256560.1	LINC01486	5.54	4.97e-08	0.0494	0.29	0.25	Joint mobility (Beighton score);	chr8:9003920	chr12:109354083~109359488:-
THCA	trans	rs45509595	0.841	rs200485	ENSG00000228022.4	HCG20	-5.54	4.97e-08	0.0494	-0.48	-0.25	Breast cancer;	chr6:27807919	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs493161	ENSG00000253570.1	RNF5P1	5.54	4.97e-08	0.0494	0.54	0.25	Depression;	chr6:27882936	chr8:38600661~38601200:-
THCA	trans	rs4936894	0.5	rs11601414	ENSG00000196933.5	RPS26P11	5.54	4.98e-08	0.0495	0.31	0.25	Aging (time to death);	chr11:124206911	chrX:72044545~72044892:+
THCA	trans	rs9987353	0.566	rs6998368	ENSG00000229857.1	RP11-159H20.3	5.54	4.98e-08	0.0495	0.33	0.25	Recombination measurement;	chr8:9212778	chr9:76992099~76993108:+
THCA	trans	rs1265507	0.666	rs1248061	ENSG00000225449.3	RAB6C-AS1	5.54	4.98e-08	0.0495	0.31	0.25	Percent mammographic density;	chr12:114425154	chr2:129966592~129980466:-
THCA	trans	rs356220	0.642	rs4437213	ENSG00000245479.2	LINC01585	-5.54	4.99e-08	0.0496	-0.31	-0.25	Parkinson's disease;	chr4:89715478	chr15:90660234~90664967:+
THCA	trans	rs7232775	0.955	rs1905673	ENSG00000274029.1	RP11-340F14.6	-5.54	4.99e-08	0.0496	-0.29	-0.25	Metabolite levels;	chr18:45612481	chr12:121190868~121191518:+
THCA	trans	rs330048	0.509	rs36111783	ENSG00000229857.1	RP11-159H20.3	-5.54	4.99e-08	0.0496	-0.31	-0.25	Systemic lupus erythematosus;	chr8:9288078	chr9:76992099~76993108:+
THCA	trans	rs7617773	0.78	rs35297486	ENSG00000235912.1	RP1-159A19.3	-5.54	4.99e-08	0.0496	-0.31	-0.25	Coronary artery disease;	chr3:48336657	chr1:27649419~27649610:+
THCA	trans	rs2048656	0.578	rs10095236	ENSG00000253893.2	FAM85B	5.54	4.99e-08	0.0496	0.32	0.25	Schizophrenia;	chr8:9827415	chr8:8167819~8226614:-
THCA	trans	rs950169	1	rs12916348	ENSG00000259295.5	CSPG4P12	5.54	4.99e-08	0.0496	0.38	0.25	Schizophrenia;	chr15:84096775	chr15:85191438~85213905:+
THCA	trans	rs2898290	0.622	rs7829381	ENSG00000254153.1	CTA-398F10.2	5.54	5e-08	0.0497	0.28	0.25	Systolic blood pressure;	chr8:11487064	chr8:8456909~8461337:-
THCA	trans	rs2898290	0.622	rs11250140	ENSG00000254153.1	CTA-398F10.2	5.54	5e-08	0.0497	0.28	0.25	Systolic blood pressure;	chr8:11489083	chr8:8456909~8461337:-
THCA	trans	rs7819412	0.521	rs9329238	ENSG00000254153.1	CTA-398F10.2	5.54	5e-08	0.0497	0.29	0.25	Triglycerides;	chr8:11176228	chr8:8456909~8461337:-
THCA	trans	rs9470794	0.667	rs113604488	ENSG00000279138.1	KB-1742H10.3	5.54	5e-08	0.0497	0.56	0.25	Type 2 diabetes;	chr6:37855228	chr8:104478539~104480783:-
THCA	trans	rs9381040	0.61	rs4140580	ENSG00000232097.1	AC079781.8	5.54	5e-08	0.0497	0.31	0.25	Alzheimer's disease (late onset);	chr6:41074003	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs4140579	ENSG00000232097.1	AC079781.8	5.54	5e-08	0.0497	0.31	0.25	Alzheimer's disease (late onset);	chr6:41074013	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.655	rs2268188	ENSG00000232097.1	AC079781.8	5.54	5e-08	0.0497	0.31	0.25	Alzheimer's disease (late onset);	chr6:41074851	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs6941090	ENSG00000232097.1	AC079781.8	5.54	5e-08	0.0497	0.31	0.25	Alzheimer's disease (late onset);	chr6:41075726	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.655	rs9381031	ENSG00000232097.1	AC079781.8	5.54	5e-08	0.0497	0.31	0.25	Alzheimer's disease (late onset);	chr6:41077218	chr7:97938439~97938794:-
THCA	trans	rs9381040	0.61	rs717883	ENSG00000232097.1	AC079781.8	5.54	5e-08	0.0497	0.31	0.25	Alzheimer's disease (late onset);	chr6:41077531	chr7:97938439~97938794:-
THCA	trans	rs4841097	0.876	rs6601288	ENSG00000256560.1	LINC01486	5.54	5.01e-08	0.0497	0.32	0.25	Platelet distribution width;	chr8:9085920	chr12:109354083~109359488:-
THCA	trans	rs2349775	0.889	rs7780103	ENSG00000253177.1	RP11-100L22.1	5.54	5.01e-08	0.0497	0.24	0.25	Neuroticism;	chr7:8650600	chr8:92668836~92679594:+
THCA	trans	rs7824557	0.836	rs2736378	ENSG00000254153.1	CTA-398F10.2	5.54	5.01e-08	0.0498	0.26	0.25	Retinal vascular caliber;	chr8:11262251	chr8:8456909~8461337:-
THCA	trans	rs7429990	0.864	rs13098128	ENSG00000235912.1	RP1-159A19.3	5.54	5.03e-08	0.05	0.31	0.25	Educational attainment (years of education);	chr3:47756066	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs7637950	ENSG00000235912.1	RP1-159A19.3	5.54	5.03e-08	0.05	0.31	0.25	Educational attainment (years of education);	chr3:47758204	chr1:27649419~27649610:+
THCA	trans	rs7429990	0.864	rs6442085	ENSG00000235912.1	RP1-159A19.3	5.54	5.03e-08	0.05	0.31	0.25	Educational attainment (years of education);	chr3:47760080	chr1:27649419~27649610:+
THCA	trans	rs853679	0.546	rs200981	ENSG00000228022.4	HCG20	-5.54	5.03e-08	0.05	-0.47	-0.25	Depression;	chr6:27865396	chr6:30766825~30792250:+
THCA	trans	rs853679	0.546	rs200953	ENSG00000228022.4	HCG20	-5.54	5.03e-08	0.05	-0.47	-0.25	Depression;	chr6:27869489	chr6:30766825~30792250:+
THCA	trans	rs6810798	0.731	rs1560226	ENSG00000236936.1	RP3-329E20.2	5.54	5.03e-08	0.05	0.35	0.25	Coronary artery disease;	chr4:147344036	chr1:21266082~21267251:+
THCA	trans	rs6894216	0.65	rs1473132	ENSG00000237714.1	P4HA2-AS1	-5.54	5.04e-08	0.05	-0.31	-0.25	Response to amphetamines;	chr5:130333894	chr5:132184876~132192808:+